| Parameters | School A | School B |
| qc, mean [ 95 % CI] | 1.39×10−2 [ 8.10×10−3−2.03×10−2] | 1.96×10−2 [ 1.11×10−2−2.89×10−2] |
| qg, mean [ 95 % CI] | 4.36×10−3 [ 9.61×10−4−8.34×10−3] | 4.61×10−3 [ 2.98×10−4−1.15×10−2] |
| qs, mean [ 95 % CI] | 9.52×10−4 [ 2.87×10−4−1.82×10−3] | 2.96×10−3 [ 1.64×10−3−4.45×10−3] |
| ε, mean [ 95 % CI] | 3.70×10−3 [ 1.95×10−3−5.69×10−3] | 2.65×10−3 [ 1.37×10−3−4.20×10−3] |
| Dependent variable | ANC4 | SBA | IFD | |||
| Density variable | % \"urban\" | score | % \"urban\" | score | % \"urban\" | score |
| Density | 0.003*** | 0.002** | 0.004*** | 0.002** | 0.004*** | 0.002* |
| (0.001) | (0.001) | (0.001) | (0.001) | (0.001) | (0.001) | |
| ln(health expenditure) | 0.07*** | 0.101*** | 0.073*** | 0.115*** | 0.085*** | 0.129*** |
| (0.011) | (0.008) | (0.011) | (0.008) | (0.011) | (0.009) | |
| Hospital beds, per capita | 0.003 | 0.000 | 0.006 | 0.002 | 0.006 | 0.002 |
| (0.006) | (0.006) | (0.006) | (0.006) | (0.006) | (0.006) | |
| Total fertility rate | −0.009 | −0.009 | 0.000 | 0.002 | 0.002 | 0.003 |
| (0.011) | (0.011) | (0.010) | (0.010) | (0.010) | (0.011) | |
| # 4-wheel vehicles, per capita | 0.035 | 0.068 | 0.014 | 0.054 | 0.013 | 0.054 |
| (0.057) | (0.059) | (0.052) | (0.055) | (0.054) | (0.056) | |
| Constant | 0.130 | 0.039 | 0.154** | 0.040 | 0.050 | −0.058 |
| (0.066) | (0.070) | (0.062) | (0.068) | (0.064) | (0.070) |
| Weeks | Daily dose | Niaspan FCT dosage | |
| Initial titration schedule | 0 to 4 | 500 mg | One 500 mg tablet at bedtime |
| 5 to 8 | 1,000 mg | One 1,000 mg tablet or two 500 mg tablets at bedtime | |
| 9 to 12 | 1,500 mg | One 1,000 mg tablet and one 500 mg tablet at bedtime | |
| 13 to 24 | 2,000 mg | Two 1,000 mg tablets at bedtime |
| Combination | TP | FP | TN | FN | sensitivity (HCC = 50) | specificity (LC = 41) | TPP | TPN | LR |
| afp | 28 | 0 | 41 | 22 | 56.00% | 100.00% | 100.0% | 65.10% | - |
| afp+piv | 47 | 8 | 33 | 3 | 94.00% | 80.50% | 85.50% | 91.70% | 4.82 |
| piv | 39 | 8 | 33 | 11 | 78.00% | 80.50% | 83.00% | 75.00% | 4 |
| afp+scca | 36 | 11 | 30 | 14 | 72.00% | 73.20% | 76.60% | 68.20% | 2.68 |
| afp+piv+scca | 45 | 16 | 25 | 5 | 90.00% | 61.00% | 73.80% | 83.30% | 2.31 |
| piv+scca | 42 | 16 | 25 | 8 | 84.00% | 61.00% | 72.40% | 75.80% | 2.15 |
| gcp+scca | 36 | 16 | 25 | 14 | 72.00% | 61.00% | 69.20% | 64.10% | 1.85 |
| afp+gcp | 41 | 22 | 19 | 9 | 82.00% | 46.30% | 65.10% | 67.90% | 1.53 |
| afp+piv+gcp | 48 | 27 | 14 | 2 | 96.00% | 34.10% | 64.00% | 87.50% | 1.46 |
| gcp+piv | 46 | 27 | 14 | 4 | 92.00% | 34.10% | 63.00% | 77.80% | 1.4 |
| all | 48 | 31 | 10 | 2 | 96.00% | 24.40% | 60.80% | 83.30% | 1.27 |
| gcp | 34 | 22 | 19 | 16 | 68.00% | 46.30% | 60.70% | 54.30% | 1.27 |
| gcp+piv+scca | 47 | 31 | 10 | 3 | 94.00% | 24.40% | 60.30% | 76.90% | 1.24 |
| afp+gcp+scca | 36 | 28 | 13 | 14 | 72.00% | 31.70% | 56.30% | 48.10% | 1.05 |
| scca | 9 | 11 | 30 | 41 | 18.00% | 73.20% | 45.00% | 42.30% | 0.67 |
| Variable | ORa (IC95%) | pa value | ORB (IC95%) | pb value | |
| PSVI | Part 1 | ||||
| Low PSVI | 1 | < 0.01 | |||
| Middle PSVI | 1.21 (1.21; 1.21) | < 0.01 | |||
| High PSVI | 2.50 (2.49; 2.51) | < 0.01 | |||
| Part 2 | |||||
| Gender | Female | 2.05 (2.04, 2.05) | < 0.01 | 1.78 (1.59; 2.00) | < 0.01 |
| Male | 1 | < 0.01 | 1 | ||
| Skin Color | White | 1 | < 0.01 | 1 | < 0.01 |
| Black | 1.51 (1.51; 1.52) | < 0.01 | 1.56 (1.25; 1.93) | < 0.01 | |
| Brown | 1.32 (1.32; 1.32) | < 0.01 | 1.66 (1.47; 1.88) | ||
| Age group | 15–19 | 1.09 (1.09; 109) | < 0.01 | 1.04 (1, 1.08) | |
| Part 3 | |||||
| Family income | Household income (R$) | ||||
| Up to 1.500 | 1.28 (1.28; 1.29) | < 0.001 | 1.28 (1.28; 1.29) | < 0.001 | |
| Over 1.500 | 1 | 1 | |||
| Part 4 | |||||
| Clinical factors | Untreated caries lesions | ||||
| None | 1 | < 0.01 | 1 | ||
| At least one decayed tooth | 2.11 (1.89; 2.36) | < 0.01 | 1.42 (1.25; 1.61) | < 0.01 | |
| Tooth loss | |||||
| None | 1 | < 0.01 | 1 | ||
| At least one tooth loss | 1.87 (1.59; 2.19) | < 0.01 | 1.49 (1.25; 1.78) | < 0.01 | |
| Toothache | |||||
| Yes | 5.47 (4.80; 6.24) | < 0.01 | 4.87 (4.25; 5.59) | < 0.01 | |
| No | 1 | < 0.01 | 1 | ||
| Maxillary Overjet | |||||
| Normal | 1 | 1 | |||
| Moderate | 1.25 (1.11; 1.40) | < 0.01 | 1.23 (1.09; 1.40) | 0.01 | |
| Severe | 1.80 (1.28; 2.54) | < 0.01 | 1.68 (1.15; 2.45) | 0.006 | |
| Cross Bite | |||||
| Absence | 1 | < 0.01 | |||
| Presence | 0.94 (0.74; 1.20) | 0.667 | |||
| Open Bite | |||||
| Mild | 1 | 1 | |||
| Moderate | 1.34 (1.07; 1.68) | 0.01 | 1.14 (0.89; 1.47) | 0.275 | |
| Severe | 1.28 (0.84; 1.96) | 0.239 | 1.27 (0.80; 2.03) | 0.302 | |
| Presence of bleeding | |||||
| Yes | 2.09 (1.86; 2.35) | < 0.01 | 1.45 (1.25; 1.68) | < 0.01 | |
| No | 1 | 1 | |||
| Presence of calculus | |||||
| Yes | 2.05 (1.82; 2.31) | < 0.01 | 1.55 (1,34; 1,80) | < 0.01 | |
| No | 1 | 1 |
| Group I(n = 25) | Group P(n = 25) | P value | |
| Desaturation (SpO2 < 90%) | 3 (12%) | 2 (8%) | 1.000 |
| Gastric insufflations | 1 (4%) | 0 (0%) | 1.000 |
| Aspiration | 0 (0%) | 0 (0%) | — |
| Laryngospasm | 1 (4%) | 1 (4%) | 1.000 |
| Bronchospasm | 0 (0%) | 0 (0%) | — |
| Blood stain | 0 (0%) | 2 (8%) | 0.490 |
| Remaining per-base coverage after B-tail removal | Number of positions with this coverage in the ZR reference (Bv-95nt data) | Number of positions with this coverage in the PhiX reference (PhiX-95nt data) |
| 90 to 100% | 41,130 (40.26%) | 4,016 (91.65%) |
| 80 to 90% | 4,056 (3.97%) | 266 (6.07%) |
| 60 to 80% | 1,711 (1.67%) | 100 (2.28%) |
| 40 to 60% | 310 (0.30%) | 0 (0.00%) |
| 20 to 40% | 76 (0.07%) | 0 (0.00%) |
| 0 to 20% | 29 (0.03%) | 0 (0.00%) |
| Parameter | DF | TPC | Antioxidant Capacity | ||||||
| ABTS | DPPH | CUPRAC | |||||||
| F | p > F | F | p > F | F | p > F | F | p > F | ||
| β0 | 1 | 16.90 | <0.01 * | 16.85 | <0.01 * | 8.91 | <0.01 * | 16.34 | <0.01 * |
| β1 | 1 | 0.45 | 0.53 | 7.16 | 0.04 * | 23.92 | 0.00 * | 12.63 | 0.02 * |
| β2 | 1 | 1.78 | 0.24 | 0.62 | 0.47 | 1.46 | 0.28 | 0.32 | 0.59 |
| β3 | 1 | 6.47 | 0.05 * | 1.78 | 0.24 | 2.22 | 0.20 | 2.98 | 0.15 |
| β12 | 1 | 7.24 | 0.04 * | 0.01 | 0.92 | 5.96 | 0.06 | 0.35 | 0.58 |
| β13 | 1 | 0.02 | 0.89 | 1.07 | 0.35 | 0.35 | 0.58 | 0.00 | 0.99 |
| β23 | 1 | 0.02 | 0.90 | 0.31 | 0.60 | 0.86 | 0.40 | 0.26 | 0.63 |
| β11 | 1 | 6.65 | 0.05 * | 7.59 | 0.04 * | 0.85 | 0.40 | 7.26 | 0.04* |
| β22 | 1 | 0.11 | 0.75 | 0.00 | 0.96 | 2.17 | 0.20 | 1.89 | 0.23 |
| β33 | 1 | 2.50 | 0.17 | 7.75 | 0.04 * | 0.10 | 0.77 | 11.59 | 0.02 * |
| Medical categories | Number of species | Citations | Fic |
| Tonic | 5 | 38 | 0.89 |
| Dermatological | 4 | 120 | 0.97 |
| Gastrointestinal | 32 | 433 | 0.92 |
| Galactagogue | 8 | 86 | 0.91 |
| Reproductive | 11 | 155 | 0.93 |
| Miscellaneous | 22 | 201 | 0.89 |
| Respiratory disorders | 4 | 37 | 0.91 |
| Fever | 5 | 41 | 0.90 |
| Wound healing | 7 | 41 | 0.85 |
| Marker | Peripheral stroma | Central stroma | Anterior stroma | Posterior stroma |
| ABCG2 | − | − | − | − |
| ABCG5 | − | − | − | − |
| ALDH1A1 | ++ | ++ | ++ | + |
| α-Actinin | ++ | ++ | ++ | + |
| CD31 | + | + | + | + |
| CD34 | ++ | ++ | ++ | ++ |
| CD73 | − | − | − | − |
| CD90 | − | − | − | − |
| CD105 | − | − | − | − |
| Collagen I | ++ | ++ | ++ | ++ |
| Collagen IV | − | − | − | − |
| CXCR4 | − | − | − | − |
| Fibroblast marker | − | − | − | − |
| Fibronectin | − | − | − | − |
| Ki-67 | − | − | − | − |
| Nestin | − | − | − | − |
| VE-Cadherin | − | − | − | − |
| Vimentin | ++ | ++ | ++ | ++ |
| Ezetimibe plus Fenofibrate | Atorvastatin Monotherapy | |||||||||
| Baseline | 6 Weeks | % Change | p Value | Baseline | 6 Weeks | % Change | p Value | % Difference | p Value | |
| Total Chol (mmol/L) | 5.9 | 4.4 | -25.1 | < 0.001 | 5.8 | 4.4 | -24.6 | < 0.001 | -0.4 | 0.806 |
| LDL-C (mmol/L) | 3.8 | 2.4 | -34.6 | < 0.001 | 3.7 | 2.3 | -36.7 | < 0.001 | 2.1 | 0.46 |
| HDL-C (mmol/L) | 1.4 | 1.5 | 10.0 | 0.002 | 1.3 | 1.5 | 8.9 | 0.006 | 1.1 | 0.778 |
| Triglycerides (mmol/L) | 1.5 | 1.0 | -25.4 | < 0.001 | 1.6 | 1.4 | -14.5 | 0.002 | -11.0 | 0.079 |
| TC:HDL Ratio | 4.3 | 3.0 | -29.0 | < 0.001 | 4.4 | 3.1 | -28.7 | < 0.001 | -0.2 | 0.904 |
| Apo A | 1.27 | 1.32 | 4.5 | 0.041 | 1.29 | 1.30 | 1.5 | 0.493 | 3.04 | 0.295 |
| Apo B | 1.21 | 0.82 | -31.8 | < 0.001 | 1.19 | 0.82 | -29.8 | < 0.001 | -1.99 | 0.392 |
| Axis | CoG Position | Linear Acceleration | ||
| First Version | Second Version | First Version | Second Version | |
| X | 2.4252e−06 | 1.0008e−06 | --* | --* |
| Y | 1.3992e−05 | 1.3390e−05 | 6.3191e−06 | 5.1146e−06 |
| Z | 1.5306e−05 | 4.4980e−06 | 2.7849e−06 | 2.3104e−06 |
| Over-expressed in melan-a v B16 | Under-expressed in melan-a v B16 | Total | |
| Upregulated by RA treatment | 71 | 14 | 85 |
| Downregulated by RA treatment | 16 | 132 | 151 |
| Total | 87 | 149 | 233 |
| Characteristics | n (%) |
| Patient factors | |
| Age (years) | |
| ≥ 50 | 68 (30.9) |
| < 50 | 152 (69.1) |
| Gender | |
| Male | 167 (75.9) |
| Female | 53 (24.1) |
| Tumor factors | |
| Histology | |
| WHO type I | 2 (0.9) |
| WHO type II | 15 (6.8) |
| WHO type III | 203 (92.3) |
| Clinical stage | |
| I | 10 (4.5) |
| II | 46 (20.9) |
| III | 106 (48.2) |
| IV | 58 (26.4) |
| T category | |
| T1 | 39 (17.7) |
| T2 | 33 (15.0) |
| T3 | 103 (46.8) |
| T4 | 45 (20.5) |
| N category | |
| N0 | 30 (13.6) |
| N1 | 132 (60.0) |
| N2 | 40 (18.2) |
| N3 | 18 (8.2) |
| Treatment factors | |
| chemotherapy | |
| Yes | 190 (86.4) |
| No | 30 (13.6) |
| Group | Variable | Lambda | F | DF1 | DF2 | p-value |
| SD-Risk | IFN | 0.4841 | 17.5871 | 2 | 33 | < 0.0001 |
| SD-Risk | IL-2 | 0.3719 | 27.8637 | 2 | 33 | < 0.0001 |
| SD-Risk | IL-10 | 0.6091 | 10.5889 | 2 | 33 | 0.0003 |
| Treatment | IFN | 0.7142 | 5.6031 | 2 | 28 | 0.0090 |
| Treatment | IL-2 | 0.6751 | 6.7385 | 2 | 28 | 0.0041 |
| line | gene copy number |
| WT | 0 |
| Sox23 | 6 (12 homozygous) |
| Sox42 | 1 (2 homozygous) |
| Sox44 | 2 (4 homozygous) |
| Skill 1 | Skill 2 | Skill 3 | Skill 4 | Skill 5 | Total/Avg | Skill 6 | |
| Pre-workshop (n = 12) | 3.5 | 4.3 | 3.8 | 2.8 | 2.3 | 16.7/3.3 | 3.5 |
| Post-workshop (n = 7) | 4.6 | 5.0 | 4.4 | 4.7 | 2.6 | 21.3/4.3 | 2.0 |
| p-value | <0.01 | <0.05 | 0.18 | 0.01 | 0.86 | 0.01 | 0.01 |
| Index | Placebo group | Zaleplon 10 mg group | Zaleplon 15 mg group |
| Scores of SQS | 3.75 ± 1.04 | 5.38 ± 0.92** | 6.00 ± 0.76** |
| Scores of SDS | 3.25 ± 1.04 | 4.62 ± 1.41* | 6.12 ± 0.83**∆ |
| Scores of SSS | 2.38 ± 0.92 | 2.12 ± 0.64 | 2.38 ± 0.92 |
| Characteristic | No. of patients | % |
| Patients evaluable | 40 | 100 |
| Age, years | ||
| Median | 65 | |
| Range | 34–75 | |
| Sex | ||
| Male | 24 | 60 |
| Female | 16 | 40 |
| ECOG PS | ||
| 0 | 6 | 15 |
| 1 | 27 | 67.5 |
| 2 | 7 | 17.5 |
| Disease location | ||
| Gastric | 30 | 75 |
| GEJ | 10 | 25 |
| Histologic type | ||
| Diffuse | 19 | 47.5 |
| Intestinal | 15 | 37.5 |
| Unspecified | 6 | 15 |
| Previous adjuvant chemotherapy | 6 | 15 |
| Status of primary tumor | ||
| Unresected | 28 | 70 |
| Resected | 12 | 30 |
| Predominant site of disease | ||
| Liver | 24 | 60 |
| Peritoneum | 8 | 20 |
| Nodes | 4 | 10 |
| Lung | 2 | 5 |
| Bone | 2 | 5 |
| No. of metastatic sites | ||
| 1 | 11 | 27.5 |
| 2 | 19 | 47.5 |
| ≥ 3 | 10 | 25 |
| Patient | Karyotype/Molecular lesion(s) | FAB subgroup | Age at diagnosis | IDO1 status | CR | Relapse | Alive |
| UPN #1 | Normal | M2 | 13.0 | Negative | Yes | No | Yes |
| UPN #2 | t(8;21) (q22;q22) | M2 | 13.0 | Negative | Yes | No | Yes |
| UPN #3 | Normal | M1 | 10.0 | Negative | Yes | No | Yes |
| UPN #4 | Normal | M2 | 4.9 | Negative | Yes | No | Yes |
| UPN #5 | Normal | M5 | 12.0 | Negative | Yes | No | Yes |
| UPN #6 | Normal | M1 | 3.0 | Negative | Yes | No | Yes |
| UPN #7 | t(8;21) (q22;q22) | M2 | 9.0 | Negative | Yes | No | Yes |
| UPN #8 | Normal | M1/M2 | 1.0 | Negative | Yes | No | Yes |
| UPN #9 | Normal | M2 | 15.0 | Negative | Yes | No | Yes |
| UPN #10 | N.A. | M1 | 15.4 | Negative | No | Yes | No |
| UPN #11 | Normal | N.A. | N.A. | Negative | No | Yes | No |
| UPN #12 | FLT3-ITD | U | 6.0 | Negative | No | Yes | Yes |
| UPN #13 | Normal | M2 | 3.4 | Negative | Yes | Yes | Yes |
| UPN #14 | t(6;9) - FLT3-ITD | M4 | 23.0 | Negative | Yes | Yes | No |
| UPN #15 | Normal | M5 | 15.5 | Negative | Yes | Yes | No |
| UPN #16 | t(8;21) (q22;q22) | M2 | 11.3 | Negative | Yes | Yes | Yes |
| UPN #17 | t(8;21) (q22;q22) | M2 | 9.0 | Negative | Yes | Yes | No |
| UPN #18 | FLT3-ITD | N.A. | 14.0 | Negative | N.A. | Yes | No |
| UPN #19 | t(9;11)(p22;q23) - MLL-AF9 | M5 | 1.0 | Positive | No | No | No |
| UPN #20 | t(10;11) - MLL-AF10 | M5 | 6.0 | Positive | Yes | No | Yes |
| UPN #21 | inv(16)(p13q22) | M4 | 16.0 | Positive | Yes | No | No |
| UPN #22 | t(8;21) (q22;q22) | M4 | 16.0 | Positive | Yes | No | Yes |
| UPN #23 | t(10;11) - MLL-AF10 | M4/M5 | 4.0 | Positive | Yes | No | Yes |
| UPN #24 | FLT3-ITD | M4 | 12.3 | Positive | Yes | No | Yes |
| UPN #25 | inv(16) (p13q22) | M4 | 17.2 | Positive | Yes | No | Yes |
| UPN #26 | t(1;11) - MLL-AF1 | M5 | 0.2 | Positive | Yes | No | Yes |
| UPN #27 | inv(16)(p13q22) | M5 | 9.0 | Positive | Yes | No | Yes |
| UPN #28 | Normal | M5 | 16.5 | Positive | N.A. | No | No |
| UPN #29 | FLT3-ITD | M5 | 7.0 | Positive | No | Yes | No |
| UPN #30 | Normal | M5 | 14.1 | Positive | Yes | Yes | No |
| UPN #31 | FLT3-ITD | M5 | 15.0 | Positive | Yes | Yes | No |
| UPN #32 | Normal | M5 | 0.4 | Positive | Yes | Yes | Yes |
| UPN #33 | FLT3-ITD | M5 | 12.3 | Positive | Yes | Yes | No |
| UPN #34 | inv(16) (p13q22) | M4 | 13.0 | Positive | Yes | Yes | Yes |
| UPN #35 | t(10;11) - MLL-AF10 | M5 | 4.0 | Positive | Yes | Yes | No |
| UPN #36 | inv(16) (p13q22) | M4 | 0.8 | Positive | Yes | Yes | Yes |
| UPN #37 | FLT3-ITD | M4 | 15.7 | Positive | N.A. | Yes | No |
| Sock-only | Shod | |||
| Subject | r | nMAD | r | nMAD |
| 1 | 0.91 | 0.09 | 0.59 | 0.23 |
| 2 | 0.77 | 0.16 | 0.56 | 0.22 |
| 3 | 0.84 | 0.13 | 0.7 | 0.18 |
| 4 | 0.91 | 0.1 | 0.84 | 0.12 |
| 5 | 0.79 | 0.16 | 0.39 | 0.27 |
| 6 | 0.92 | 0.1 | 0.87 | 0.12 |
| 7 | 0.85 | 0.14 | 0.83 | 0.13 |
| 8 | 0.92 | 0.09 | 0.8 | 0.15 |
| 9 | 0.65 | 0.16 | 0.05 | 0.29 |
| 10 | 0.83 | 0.14 | 0.7 | 0.17 |
| 11 | 0.75 | 0.17 | 0.4 | 0.26 |
| 12 | 0.74 | 0.17 | 0.5 | 0.25 |
| 13 | 0.91 | 0.1 | 0.71 | 0.19 |
| 14 | 0.8 | 0.16 | 0.56 | 0.23 |
| 15 | 0.76 | 0.16 | 0.82 | 0.13 |
| 16 | 0.86 | 0.13 | 0.5 | 0.23 |
| 17 | 0.66 | 0.2 | 0.53 | 0.23 |
| 18 | 0.71 | 0.19 | 0.18 | 0.28 |
| 19 | 0.76 | 0.16 | 0.46 | 0.23 |
| 20 | 0.28 | 0.26 | 0.22 | 0.26 |
| Mean | 0.78 | 0.15 | 0.56 | 0.21 |
| Patient | Before | 2 months | 6 months | 1 year | ||||
| Righta | Leftb | Right | Left | Right | Left | Right | Left | |
| Biceps brachii muscle (latency) | ||||||||
| 6 | 0.00c | 0.00 | 0.00 | 0.00 | 14.49 | 14.31 | 15.99 | 17.37 |
| 9 | 0.00 | 0.00 | 13.01 | 13.27 | 14.57 | 14.40 | 14.50 | 14.60 |
| 10 | 0.00 | 0.00 | 0.00 | 0.00 | 12.39 | 0.00 | 12.16 | 0.00 |
| Biceps brachii muscle (amplitude) | ||||||||
| 1 | 0.00d | 0.00 | 0.00 | 0.00 | 0.79 | 0.87 | 0.69 | 0.61 |
| 2 | 0.00 | 0.00 | 0.00 | 0.00 | 0.22 | 0.00 | 0.62 | 0.00 |
| 6 | 0.00 | 0.00 | 0.00 | 0.00 | 0.75 | 1.25 | 0.88 | 0.53 |
| 9 | 0.00 | 0.00 | 0.36 | 0.20 | 0.65 | 0.40 | 0.84 | 0.54 |
| 10 | 0.00 | 0.00 | 0.00 | 0.00 | 1.37 | 0.00 | 1.66 | 0.00 |
| 12 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.51 | 0.42 |
| 14 | 0.55 | 0.00 | 0.62 | 0.38 | 2.14 | 1.39 | 1.07 | 0.66 |
| 16 | 0.00 | 0.00 | 0.85 | 0.76 | 0.91 | 2.49 | 1.57 | 1.00 |
| 17 | 0.00 | 0.00 | 0.82 | 0.84 | 0.93 | 1.24 | 1.21 | 1.58 |
| Abductor pollicis brevis muscle (latency) | ||||||||
| 3 | 0.00 | 0.00 | 24.85 | 0.00 | 25.95 | 0.00 | 28.59 | 0.00 |
| 11e | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 30.06 | 0.00 | 0.00 |
| Abductor pollicis brevis muscle (amplitude) | ||||||||
| 3 | 0.00 | 0.00 | 0.39 | 0.00 | 0.07 | 0.00 | 0.18 | 0.00 |
| 11e | 0.00 | 0.00 | 0.00 | 1.06 | 0.00 | 0.00 | 0.00 | 0.00 |
| Age range | Counta | ERPb | Ratec | Ratiod | 95 % CI | |
| 4 | 7,594 | 72,820 | 10.4 | 0.26 | 0.26 | 0.26 |
| 5–9 | 100,787 | 340,503 | 29.6 | 0.74 | 0.74 | 0.74 |
| 10–14 | 132,965 | 330,448 | 40.2 | 1 | 1 | 1 |
| 15–19 | 81,910 | 355,117 | 23.1 | 0.57 | 0.57 | 0.57 |
| 20–24 | 47,831 | 412,009 | 11.6 | 0.29 | 0.29 | 0.29 |
| 25–29 | 31,965 | 433,533 | 7.4 | 0.18 | 0.18 | 0.18 |
| 30–34 | 20,529 | 406,284 | 5.1 | 0.13 | 0.13 | 0.13 |
| 35–39 | 13,952 | 391,179 | 3.6 | 0.09 | 0.09 | 0.09 |
| 40–44 | 12,831 | 411,667 | 3.1 | 0.08 | 0.08 | 0.08 |
| 45–49 | 7,824 | 378,012 | 2.1 | 0.05 | 0.05 | 0.05 |
| 50–54 | 4,357 | 371,333 | 1.2 | 0.03 | 0.03 | 0.03 |
| 55–59 | 1,570 | 333,160 | 0.5 | 0.01 | 0.01 | 0.01 |
| 60–64 | 789 | 296,984 | 0.3 | 0.01 | 0.01 | 0.01 |
| 65–69 | 288 | 249,830 | 0.1 | <0.01 | <0.01 | <0.01 |
| 70–74 | 144 | 188,531 | 0.1 | <0.01 | <0.01 | <0.01 |
| 75–79 | 33 | 146,349 | <0.1 | <0.01 | <0.01 | <0.01 |
| 80–84 | 12 | 114,990 | <0.1 | <0.01 | <0.01 | <0.01 |
| 85–100 | 22 | 110,096 | <0.1 | <0.01 | <0.01 | <0.01 |
| All | 465,403 | 5,629,122 | 8.3 | 0.21 | 0.21 | 0.21 |
| Patients withAlzheimer's disease (n=21) | Patients withfrontotemporal dementia (n=23) | U | Z | p* | ||||
| M±SD | CI 95% | M±SD | CI 95% | |||||
| Age, y | 73.52±7.94 | 69.90|-|77.14 | 63.95±13.47 | 58.12|-|69.78 | 598 | -1.136 | 0.310† | |
| Dementia duration,y | 2.84±2.21 | 1.83|-|3.85 | 4.41±4.18 | 2.60|-|6.22 | 697 | -0.245 | 0.376† | |
| MMSE score | 13.19±7.41 | 9.81|-|16.56 | 13.82±9.39 | 9.76|-|17.88 | 576 | -1.178 | 0.298† | |
| FAQ | 22.00±10.34 | 17.28|-|26.71 | 20.04±10.45 | 15.52|-|24.56 | 818 | -0.034 | 0.816† | |
| Education, y | 7.00±5.71 | 4.40|-|9.59 | 7.67±5.48 | 5.30|-|10.04 | 688 | -1.29 | 0.358† | |
| BFI | 35.05±5.01 | 32.76 |-| 37.33 | 34.90±5.33 | 32.6 |-|37.21 | 556 | -0.394 | 0.742† |
| Concentration range (pg/g lipid) | Second-order (equivalent to minus change in apparent elimination rate in 2006) | First-order (equivalent to minus apparent elimination rate) | ||
| coefficient | p-value | coefficient | p-value | |
| 0–10 | −0.000596 | 0.599665 | −0.004032 | 0.165814 |
| 10–20 | 0.000464 | 0.463854 | −0.000462 | 0.786707 |
| 20–50 | 0.000643 | 0.182574 | 0.001669 | 0.229181 |
| 50–100 | 0.002124 | 7.99 × 10−5 | −0.005452 | 0.000216 |
| >100 | 0.001436 | 9.68 × 10−7 | −0.008294 | <2 × 10−16 |
| N = 1352 | Non-responders n = 909 | Responders n = 443 | p value |
| Women, n (%) | 520 (57) | 273 (62) | 0.12 A |
| Age, average years (SD) | 41.3 (11.8) | 44.4 (10.8) | 0.05 B |
| Work n (%) | 0.15 A | ||
| Farming, fishery, industry | 150 (17) | 65 (15) | |
| Construction, trading and transport | 231 (25) | 109 (25) | |
| Communication, information, finance, insurance, real estate and consultancy | 103 (11) | 49 (11) | |
| Public administration, teaching, health, culture and leisure | 329 (36) | 189 (43) | |
| Other | 36 (4) | 11 (2) | |
| Missing | 60 (7) | 20 (5) | |
| Self-reported reason for sickness absence n (%) | <0.001 A | ||
| Musculoskeletal disorder (MSD) | 387 (43) | 244 (55) | |
| Common mental disorder (CMD) | 294 (32) | 94 (21) | |
| Stress | 95 (19) | 52 (12) | |
| Functional somatic syndrome/unknown | 19 (2) | 10 (2) | |
| Heart disorder, lung disorder, cancer | 36 (4) | 12 (3) | |
| Other | 78 (9) | 31 (7) | |
| Previous year before inclusion median (iqr) | |||
| Employment or unemployment, weeks | 42 (26-46) | 42 (33-45) | 0.35 C |
| Duration of sickness absence, weeks | 7 (5-12) | 7 (6-11) | 0.43 C |
| Health care utilization | |||
| Visits in general practice | 11 (7-18) | 12 (7-18) | 0.30 C |
| Visits in physiotherapist clinics | 0 (0-0) | 0 (0-1) | 0.30 C |
| Visits in out-patient clinics | 2 (1-6) | 3 (1-6) | 0.58 C |
| Visits in psychiatric out-patient clinics | 0 (0-0) | 0 (0-0) | 0.19 C |
| Admissions in hospitals | 0 (0-0) | 0 (0-0) | 0.45 C |
| Admissions in psychiatric hospitals | 0 (0-0) | 0 (0-0) | 0.02 C |
| One year after inclusion | |||
| Labour market participation n (%) | 0.92 A | ||
| Non-RTW | 309 (34) | 146 (33) | |
| RTW | 548 (60) | 273 (62) | |
| Old age and disability pension | 50 (6) | 22 (5) | |
| Died | 2 (0) | 2 (0) |
| Perianal disease prior to pregnancy n = 27 | No perianal disease prior to pregnancy n = 87 | |||
| Mode of childbirth | Vaginal delivery n (%) | Caesarean section n (%) | Vaginal delivery n (%) | Caesarean section n (%) |
| 11 (41) | 16 (59) | 66 (76) | 21 (24) | |
| Progression perianal disease ≤ 2 years post partum: | 2 (18) | 5 (31) | 3 (5) | 3 (14) |
| - Yes | 9 (82) | 9 (56) | 58(94) | 18 (86) |
| - No | 0 (0) | 2 (13) | 5 (1) | 0 (0) |
| - Not applicable† |
| Peptide | Sequence | Mw | pI1 | Net charge | Mean hydrophobicity2 |
| KHN20 | KHNLGHGHKHERDQGHGHQR | 2365.5 | 9.99 | +2 | −4.91 |
| GHG20 | GHGLGHGHEQQHGLGHGHKF | 2127.2 | 7.21 | 0 | −2.01 |
| GHG21 | GHGHKFKLDDDLEHQGGHVLD | 2354.5 | 5.63 | −3 | −2.32 |
| GGH20 | GGHVLDHGHKHKHGHGHGKH | 2169.3 | 9.70 | +2 | −3.44 |
| HKH20 | HKHGHGHGKHKNKGKKNGKH | 2151.5 | 10.78 | +7 | −5.91 |
| GKH17 | GKHKNKGKKNGKHNGWK | 1946 | 10.78 | +7 | −5.77 |
| GKH17WWW | GKHKNKGKKNGKHNGWKWWW | 2505 | 10.78 | +7 | −3.45 |
| GKH17WWWWW | GKHKNKGKKNGKHNGWKWWWWW | 2287 | 10.78 | +7 | −2.25 |
| LL-37 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | 4492 | 10.61 | +6 | −1.84 |
| Histatin-5 | DSHAKRHHGYKRKFHEKHHSHRGY | 3036 | 10.28 | +5 | −4.67 |
| Matching phase | Type of match | Number linked | % |
| 1 | Child’s first, middle, and last name & dob and mother’s dob | 5282 | 2.6 % |
| 2 | Child’s first, middle initial, and last name & dob and mother’s dob | 32094 | 16.0 % |
| 3 | Child’s first, middle, and last name & dob | 3035 | 1.5 % |
| 4 | Child’s first, middle initial, and last name & dob | 66730 | 33.3 % |
| 5 | Child’s first and last name & dob | 90506 | 45.2 % |
| 6 | Child’s first 3 letters of first name and last name & dob | 2696 | 1.3 % |
| Number | Authors, year | c | Age, sex | Period (years) | symptoms | Preoperative lab | Treatment | Histological diagnosis | Outcomes |
| 1 | Boriani et al, 1978 [8] | S1-3 | 18, M | DNMI | Bone pain, weakness | Hypophosphatemia, elevated ALP | Complete resection, radiotherapy | Osteosarcoma | NOLF |
| 2 | Stone et al, 1992 [9] | T3-4 | 33, F | DNMI | Bone pain, weakness, fractures | Hypophosphatemia | Complete resection, supplementation of vitamin D, phosphate, and calcium | Neuroendocrine tumor | NOLF |
| 3 | Yu et al, 1995 [10] | C2 | 58, F | DNMI | Musculoskeletal pain, weakness | Hypophosphatemia, elevated ALP and PTH | Partial resection, supplementation of vitamin D and phosphate | PMT | PSA |
| 4 | Terek et al, 2001 [11] | S1-2 | 14, M | 1+ | Bone pain, skeletal abnormalities | Hypophosphatemia, hypocalcemia, low level of vitamin D3, elevated ALP | Partial resection, chemotherapy (doxorubicin) | Osteosarcoma | PSA, ALL |
| 5 | Dissanayake et al, 2003 [37] | L2 | 58, M | 3+ | Musculoskeletal pains, fractures | Hypophosphatemia, low level of vit D3, elevated ALP | Complete resection | Haemangiopericytoma | NOLF |
| 6 | Folpe et al, 2004 [5] | C1 | 32, F | 4 | DNMI | DNMI | Partial resection, radiotherapy | Malignant PMTMCT | PSA recurrence |
| 7 | Chua et al, 2008 [12] | T3 | 34, F | 1 | Musculoskeletal pain, fatigue | Hypophosphatemia, hypocalcemia, elevated ALP and PTH | Partial resection, supplementation of phosphate and calcitriol | Plasmacytoma | DNMI |
| 8 | Sciubba et al, 2009 [13] | T8 | 56, F | 5 | Bone pain, weakness, fractures | Hypophosphatemia, low level of vitamin D3, elevated ALP and PTH | Complete resection | PMT | NOLF |
| 9 | Pirola et al, 2009 [14] | T4 | 57, M | DNMI | Fractures, paresthesias | Hypophosphatemia, low level of vitamin D3, elevated ALP and PTH | Complete resection, supplementation of vitamin D and phosphate | PMT | NOLF |
| 10 | Mavrogenis et al, 2010 [15] | S1 | 42, F | 2 | Bone pain, paresthesias | Normal | Complete resection | PMTMCT | NOLF |
| 11 | Marshall et al, 2010 [16] | T12 | 55, F | 6+ | Bone pain; fractures | Hypophosphatemia | Complete resection | PMTMCT | DNMI |
| 12 | Akhter et al, 2011 [17] | C5 | 52, M | 1 | Fracture | Hypophosphatemia | Complete resection, supplementation of vitamin D, and phosphate | PMTMCT | NOLF |
| 13 | Gandhi et al, 2012 [18] | L4 | 66, F | 2, | Bone pain, weakness | Hypophosphatemia, hypocalcemia, low level of vit D3, elevated ALP and PTH | Complete resection | PMTMCT | NOLF |
| 14 | Nakamura et al, 2014 [19] | C5 | 72, M | 2.5 | Weakness | Hypophosphatemia, elevated ALP and PTH | Complete resection, supplementation of phosphate and calcitriol. | PMTMCT | NOLF |
| 15 | Puthenveetil et al [38] | T12 | 61, F | 7 | Musculoskeletal pain, weakness, fractures | Hypophosphatemia, increased ALP | Complete resection, supplementation of calcium and phosphate | PMTMCT | NOLF |
| 16 | Present case | T1 | 60, M | 6 | Bone pain, weakness, paresthesia | Hypophosphatemia, hypocalcemia, elevated PTH | Complete resection, supplementation of calcitriol | PMT | NOLF |
| Antibioticsa | Extracts concentrationb | Bacteria, MIC (μg/mL) and modulating factors (in bracket) | Modulating effect (%)b | ||||||||
| E. coli | E. aerogenes | K. pneumoniae | P. stuartuii | P. aeruginosa | |||||||
| AG100 | AG102 | AG100Tet | CM64 | EA289 | EA298 | K24 | NEA16 | PA124 | |||
| AMP | 0 | - | - | - | - | - | - | - | - | - | |
| MIC/2 | - | - | - | - | - | - | - | - | - | 0 | |
| MIC/4 | - | - | - | - | - | - | - | - | - | 0 | |
| CHL | 0 | 8 | 32 | 64 | 256 | 128 | 64 | 64 | 64 | 64 | |
| MIC/2 | 8 (1) | 16 (2) | 32 (2) | 256 (1) | 128 (1) | 32 (2) | 32 (2) | 32 (2) | 32 (2) | 66.67 | |
| MIC/4 | 8 (1) | 16 (2) | 64 (1) | 256 (1) | 256 (0.5) | 64 (1) | 64 (1) | 32 (2) | 32 (2) | 33.33 | |
| CIP | 0 | ≤0.5 | ≤0.5 | 128 | 64 | 128 | 1 | 128 | 1 | 32 | |
| MIC/2 | ≤0.5 (na) | ≤0.5 (na) | 64(2) | 32 (2) | 128 (1) | 1 (1) | 64 (2) | 1 (1) | 32 (1) | 33.33 | |
| MIC/4 | ≤0.5 (na) | ≤0.5 (na) | 128(1) | 64 (1) | 128 (1) | 1 (1) | 64 (2) | 1 (1) | 32 (1) | 11.11 | |
| KAN | 0 | 64 | 4 | 8 | 2 | 16 | 32 | 4 | 16 | 128 | |
| MIC/2 | 4 (16) | 1 (4) | 2 (4) | 1 (2) | 4 (4) | 32 (1) | 2 (2) | 8 (2) | 64 (2) | 88.89 | |
| MIC/4 | 16 (4) | 4 (1) | 2 (4) | 2 (1) | 8 (2) | 32 (1) | 2 (2) | 8 (2) | 64 (2) | 66.67 | |
| ERY | 0 | 32 | 64 | - | - | 64 | 16 | 128 | 16 | 128 | |
| MIC/2 | 32 (1) | 64 (1) | - | - | 64 (1) | 16 (1) | 128 (1) | 8 (2) | 64 (2) | 22.22 | |
| MIC/4 | 32 (1) | 64 (1) | - | - | 64 (1) | 16 (1) | 128 (1) | 8 (2) | 128 (1) | 11.11 | |
| TET | 0 | 2 | 8 | 32 | 16 | 32 | 4 | 16 | 4 | 16 | |
| MIC/2 | ≤0.5 (≥4) | 4 (2) | 4 (8) | 4 (4) | 4 (8) | 2 (2) | 8 (2) | 2 (2) | 16 (1) | 88.89 | |
| MIC/4 | ≤0.5 (≥4) | 4 (2) | 8 (4) | 16 (1) | 8 (4) | 2 (2) | 8 (2) | 2 (2) | 16 (1) | 77.78 |
| Period | No. of regions | STR-realigner | ReviSTER | IndelRealigner | --realign option | Original BAM |
| 1 | 5345 | 2.695 | 6.017 | 6.009 | 6.009 | |
| 2 | 1160 | 3.740 | 6.948 | 6.885 | 6.899 | |
| 3 | 517 | 3.728 | 6.898 | 6.843 | 6.843 | |
| 4 | 1433 | 3.818 | 7.476 | 7.417 | 7.431 | |
| 5 | 668 | 4.469 | 8.760 | 8.762 | 8.762 | |
| 6 | 472 | 4.319 | 8.232 | 8.217 | 8.233 | |
| Total | 9595 | 3.309 | 6.752 | 6.727 | 6.732 |
| Variables | β | P value | OR (95% CI) |
| Age | 0.428 | <0.001 | 1.53 (1.35–1.75) |
| HR | 0.859 | <0.001 | 2.36 (2.09–2.67) |
| BMI | 0.273 | 0.001 | 1.31 (1.13–1.53) |
| WC | 0.510 | <0.001 | 1.67 (1.3–2.14) |
| SBP | 0.018 | <0.001 | 1.02 (1.01–1.02) |
| DBP | 0.019 | 0.001 | 1.02 (1.01–1.03) |
| FPG | 0.450 | <0.001 | 1.57 (1.39–1.78) |
| PBG | 0.475 | <0.001 | 1.61 (1.41–1.83) |
| IR | 0.279 | <0.001 | 1.32 (1.20–1.46) |
| TG | 0.336 | 0.003 | 1.40 (1.12–1.75) |
| DM | 0.936 | <0.001 | 2.55 (2.00–3.25) |
| DM duration | 0.412 | <0.001 | 1.51 (1.30–1.76) |
| PH | 0.779 | <0.001 | 2.18 (1.74–2.73) |
| PH duration | 0.356 | <0.001 | 1.43 (1.28–1.59) |
| Year | ||||||||
| 1992 (n = 321) | 2000 (n = 433) | 2008 (n = 607) | Trend | |||||
| % | n | % | n | % | n | χ2 (d.f. = 1) | P | |
| No diagnosis specified | 39 | 124 | 24 | 102 | 31 | 189 | ||
| Bad news | 76 | 94 | 73 | 74 | 48 | 91 | 26.653 | < 0.001 |
| Understanding mental illness | 6 | 8 | 14 | 14 | 24 | 45 | 17.096 | < 0.001 |
| Services and advocacy | 18 | 22 | 14 | 14 | 28 | 53 | 5.692 | 0.017 |
| Depression | 28 | 91 | 34 | 149 | 37 | 226 | ||
| Bad news | 38 | 35 | 32 | 47 | 28 | 63 | 3.287 | 0.070 |
| Understanding mental illness | 46 | 42 | 59 | 88 | 63 | 142 | 6.643 | 0.010 |
| Services and advocacy | 15 | 14 | 9 | 14 | 9 | 21 | 1.976 | 0.160 |
| Eating disorders | 14 | 45 | 13 | 58 | 14 | 82 | ||
| Bad news | 58 | 26 | 16 | 9 | 17 | 14 | 20.297 | < 0.001 |
| Understanding mental illness | 42 | 19 | 78 | 45 | 78 | 64 | 14.682 | < 0.001 |
| Services and advocacy | 0 | 0 | 7 | 4 | 5 | 4 | - | - |
| Anxiety disorders | 10 | 32 | 14 | 62 | 11 | 67 | ||
| Bad news | 19 | 6 | 21 | 13 | 18 | 12 | 0.38 | 0.845 |
| Understanding mental illness | 63 | 20 | 69 | 43 | 72 | 48 | 0.760 | 0.383 |
| Services and advocacy | 19 | 6 | 10 | 6 | 10 | 7 | - | - |
| Schizophrenia | 12 | 38 | 14 | 59 | 9 | 57 | ||
| Bad news | 58 | 22 | 49 | 29 | 68 | 39 | 1.535 | 0.215 |
| Understanding mental illness | 16 | 6 | 27 | 16 | 25 | 14 | 0.758 | 0.384 |
| Services and advocacy | 26 | 10 | 24 | 14 | 7 | 4 | 6.443 | 0.011 |
| Bipolar disorder | 4 | 12 | 3 | 11 | 3 | 19 | ||
| Bad news | 50 | 6 | 64 | 7 | 21 | 4 | - | - |
| Understanding mental illness | 33 | 4 | 9 | 1 | 53 | 10 | - | - |
| Services and advocacy | 17 | 2 | 27 | 3 | 26 | 5 | - | - |
| Personality disorders | 2 | 7 | 6 | 26 | 1 | 9 | ||
| Bad news | 86 | 6 | 85 | 22 | 56 | 5 | - | - |
| Understanding mental illness | 0 | 0 | 8 | 2 | 33 | 3 | - | - |
| Services and advocacy | 14 | 1 | 8 | 2 | 11 | 1 | - | - |
| ADHD | 0 | 0 | 4 | 18 | 4 | 24 | ||
| Bad news | 0 | 0 | 22 | 4 | 8 | 2 | - | - |
| Understanding mental illness | 0 | 0 | 72 | 13 | 88 | 21 | - | - |
| Services and advocacy | 0 | 0 | 6 | 1 | 4 | 1 | - | - |
| Other disorders | 1 | 2 | 1 | 5 | 1 | 7 | ||
| Bad news | 50 | 1 | 40 | 2 | 14 | 1 | - | - |
| Understanding mental illness | 0 | 0 | 60 | 3 | 71 | 5 | - | - |
| Services and advocacy | 50 | 1 | 0 | 0 | 14 | 1 | - | - |
| Trait (nm) | Standard diet | Standard diet + ATRA | ||
| SHR | SHR-Lx | SHR | SHR-Lx | |
| (n = 7) | (n = 7) | (n = 7) | (n = 8) | |
| VLDL-TG | 49.51 ± 0.45 | 48.24 ± 0.49 | 48.48 ± 0.68 | 50.27 ± 0.41*,a |
| LDL-C | 21.45 ± 0.25 | 21.54 ± 0.11 | 21.77 ± 0.12 | 22.52 ± 0.18‡,b |
| HDL-C | 12.20 ± 0.04 | 12.10 ± 0.03 | 12.18 ± 0.03 | 11.93 ± 0.05‡,c |
| Method of risk assessment | Definition | Advantages | Limitations |
| Clinical prediction rules | The use of a scoring system based on patient- or procedure-related risk factors to quantify risk | Often cost-neutral | Estimates population risk for patient rather than providing an individualized risk assessment |
| Requires no specialist knowledge[34] | |||
| ASA-PS | Six-point scale used to grade patient according to comorbidities[35] | Validated in a number of settings[36-38] | Inter-observer variability[39] |
| Poor sensitivity and specificity for prediction of morbidity and mortality on an individual patient basis[33,40] | |||
| Lee Revised Cardiac Risk Index (RCRI) | Scores patients according to six variables, including whether the surgery is high risk | Discriminates moderately well between patients at low versus high risk for cardiac events after mixed noncardiac surgery[42] | Designed to identify patients at risk of cardiac complications so may miss patients at risk of other complications who may benefit from PACU care |
| Assesses cardiac risk[41] | Well validated | ||
| POSSUM | A more detailed scoring system with 18 components, 6 operative variables and 12 physiological variables[46] | A revision of POSSUM, the Portsmouth POSSUM[43] has been shown to be a better predictor of outcome in certain surgical settings[33,44,45] | Some variables cannot be ascertained until after surgery, making it of limited use for preoperative identification of patients who may benefit from PACU care |
| Variations in the model have been devised for specific patient groups, such as the Cr-POSSUM (colorectal), which has been shown to be a better predictor of outcome in this type of surgery[47] | |||
| Cardiopulmonary exercise testing | CPET is an integrative and quantitative measure of a patient’s cardiopulmonary reserve | Good evidence that CPET is useful to help predict perioperative morbidity and mortality and may aid triage to an appropriate level of postoperative care[48-50] | In 2008, 17% of Hospital Trusts in England had a CPET service, and a further 7% were in the process of setting one up[52] |
| The assessment requires the patient to exercise (usually on a cycle ergometer) while oxygen consumption, carbon dioxide production, and other cardiorespiratory variables are measured | RCT in progress to further evaluate its use to stratify to appropriate level of postoperative care[51] |
| Polymorphism | Reference allele homozygote | Heterozygote | Variant allele homozygote |
| PAI-2 (SERPINB, rs6095) | |||
| Event Rate (%) | 34.7 | 14.6 | 6.7 |
| Number of patients | 72 | 48 | 15 |
| Number of patients (%) | 53.3 | 35.6 | 11.1 |
| LRP-1 (LRP1, rs1800156) | |||
| Event Rate (%) | 21.1 | 24.5 | 33.3 |
| Number of patients | 57 | 53 | 18 |
| Number of patients (%) | 44.5 | 41.4 | 14.1 |
| p22phox (CYBA, rs4673)* | |||
| Event Rate (%) | 36.9 | 15.1 | 8.0 |
| Number of patients | 65 | 53 | 25 |
| Number of patients (%) | 45.5 | 37.1 | 17.5 |
| TSP-4 (THBS4, rs1866389)* | |||
| Event Rate (%) | 17.9 | 36.6 | 50.0 |
| Number of patients | 95 | 41 | 4 |
| Number of patients (%) | 67.9 | 29.3 | 2.9 |
| CETP (CETP, rs708272)* | |||
| Event Rate (%) | 14.9 | 26.4 | 33.3 |
| Number of patients | 47 | 72 | 24 |
| Number of patients (%) | 32.9 | 50.4 | 16.8 |
| Group | Location | Gender | Age range (years) | Number of participants |
| One | ROI | Female | 20-29 | 8 |
| Two | ROI | Female | 30-40 | 9 |
| Three | ROI | Male | 29-39 | 8 |
| Four | NI | Male | 29-59 | 6 |
| Five* | NI | Male | 20-25 | 7 |
| Six | NI | Female | 21-59 | 4 |
| Seven | NI | Male | 19-24 | 8 |
| Eight† | NI | Female | 39-45 | 4 |
| Nine | NI | Female | 22-63 | 5 |
| Ten‡ | NI | Female | 35-64 | 7 |
| Gene/Gene Cluster Name | Localization within the POC9 Draft Genome Sequence(GenBank acc. no.) | Protein | Best BLAST Hits:[% Identity] Organism(GeneBank acc. no.) | Predicted Antimicrobial Resistance Profile | Tested Antibiotics | Profile |
| gcvA-blaOCH | contig00009 (QGST01000009.1)coordinates: 164,062–165,431 | class Cbeta-lactamase | [98%] Ochrobactrum tritici C8846-N36 (SME85995) | penams, penems,cephalosporins, cephamycins, monobactams | AMPCFMCTXCRO | RRRR |
| transcriptional regulator GcvA | [98%] Ochrobactrum anthropi (WP_061347328) | |||||
| acrAB-TolC | contig00001 (QGST01000001.1)coordinates: 191,438-196,605 | transcriptional regulator TetR | [93%] Ochrobactrum oryzae (WP_104756164) | tetracyclines, cephalosporins penams, phenicols, ryfamycins, fluoroquinolones | AMPCIPCFMCTXCROTEMXFRIF | RSRRRSSR |
| efflux RND transporter periplasmic adaptor subunit | [98%] Ochrobactrum anthropi (WP_061344971) | |||||
| efflux RND transporter permease subunit | [99%] Ochrobactrum anthropi (WP_061344972) | |||||
| acrAB-TolC | contig00010 (QGST01000010.1)coordinates: 49,666–54,163 | efflux RND transporter periplasmic adaptor unit | [98%] Ochrobactrum sp. (WP_024900215) | |||
| efflux RND transporter permease subunit | [99%] Ochrobactrum oryzae (WP_104755654) | |||||
| qacH | contig00007 (QGST01000007.1)coordinates: 192,104–191,772 | efflux SMR transporter | [100%] Ochrobactrum sp. (WP_010661279) | fluoroquinolones | CIPMXF | SS |
| cmlA/floR | contig00016 (QGST01000016.1)coordinates: 56,907–55,714 | CmlA/floR chloramphenicol efflux MFS transporter | [94%] Ochrobactrum anthropi(WP_061345584) | chloramphenicol | C | R |
| acc (6’) | contig00016 (QGST01000016.1)coordinates: 92,931–92,485 | aminoglycoside 6’-acetyl-transferase | [93%] Ochrobactrum anthropi FRAF13(KXO77791) | aminoglycosides | CN | S |
| tetG-tetR | contig00014 (QGST01000014.1)coordinates: 7148–9063 | Tet(A/B/C) family MFS transporter | [87%] Ochrobactrum oryzae(WP_104755825) | tetracyclines | TE | S |
| transcriptional regulator tetR | [89%] Ochrobactrum oryzae(WP_104755986) |
| Fixed effects model | Growth curve model 1 | Growth curve model 2 | |
| Fixed part | |||
| Intercept | 0.820 (0.756 to 0.884) | 0.823 (0.779 to 0.866) | 0.830 (0.791 to 0.87) |
| Age-centred (linear term) | −0.008 (−0.01 to –0.007) | −0.007 (−0.008 to –0.006) | −0.006 (−0.007 to –0.004) |
| Age (quadratic term) | −0.0003 (−0.0004 to –0.0003) | −0.0002 (−0.0002 to –0.0001) | −0.0002 (−0.0002 to –0.0002) |
| p, 2df | <0.001 | <0.001 | <0.001 |
| Frequency of public transport use(ref: every day or nearly every day) | |||
| Two or three times a week | −0.012 (−0.024 to 0.0001) | −0.006 (−0.016 to 0.003) | −0.005 (−0.018 to 0.008) |
| Once a week | −0.020 (−0.034 to –0.005) | −0.011 (−0.022 to –0.0002) | −0.006 (−0.019 to 0.008) |
| No use: no need | −0.018 (−0.032 to –0.003) | −0.011 (−0.022 to –0.001) | −0.005 (−0.018 to 0.008) |
| No use: health problems | −0.058 (−0.075 to –0.040) | −0.090 (−0.104 to –0.077) | −0.115 (−0.135 to –0.095) |
| No use: structural reasons | −0.020 (−0.035 to –0.006) | −0.009 (−0.019 to 0.002) | −0.002 (−0.014 to 0.011) |
| p, 5df | <0.001 | <0.001 | |
| Interaction between age (linear term) and frequency of public transport use | |||
| Age* two or three times a week | −0.0003 (−0.002 to 0.001) | ||
| Age* once a week | −0.001 (−0.002 to 0.0004) | ||
| Age* no use: no need | −0.001 (−0.002 to –0.00002) | ||
| Age* no use: health problems | 0.002 (0.0001 to 0.003) | ||
| Age* no use: structural reasons | −0.001 (−0.003 to –0.0002) | ||
| p, 5df | <0.001 | ||
| Random part | |||
| Level 2 (individual) | |||
| Intercept variance | 0.0238 | 0.0238 | |
| Age-centred (linear term) variance | 0.00002 | 0.00002 | |
| Covariance of intercept and age centred | −0.0004 | −0.0004 | |
| Level 1 (wave) | |||
| Intercept | 0.020 | 0.020 | |
| N observations (level 1) | 27 509 | 27 509 | 27 509 |
| N clusters (level 2) | 9656 | 9656 | 9656 |
| Goodness of fit | Adj R-sq: 0.7273 | Deviance: −13 719.59 | Deviance: −13 746.54 |
| Characteristic | N | % |
| Age | ||
| < = 50 | 22 | 13.3 |
| 51-60 | 42 | 25.3 |
| 61-70 | 57 | 34.3 |
| > 70 | 45 | 27.1 |
| Tumor (T) | ||
| T1 | 68 | 41 |
| T2 | 40 | 24.1 |
| T3 | 34 | 20.5 |
| T4 | 24 | 14.4 |
| Lymph nodes (N) | ||
| N0 | 59 | 35.5 |
| N1 | 107 | 64.5 |
| Metastasis (M) | ||
| M0 | 124 | 74.7 |
| M1 | 42 | 25.3 |
| Grade (G) | ||
| G1 | 57 | 34.4 |
| G2 | 54 | 32.5 |
| G3 | 55 | 33.1 |
| Month 1 | Month 16 | Month 21 | Total samplen = 72 | |
| Decisions to be made, n (%) | ||||
| Medical admission or treatment | 17 (81)a | 12 (44)a | 8 (33)a | 37 (51) |
| Psychiatric admission or treatment | 5 (24) | 13 (48) | 13 (54) | 31 (43) |
| Agreement status, n (%) | ||||
| Agreeing | 5 (24) | 15 (56) | 12 (50) | 32 (44) |
| Not agreeing(or unable to express a choice/not documented) | 16 (76) | 12 (44) | 12 (50) | 40 (56) |
| Food composition of major foods in Uganda (per 100 g of edible portion) | ||||
| Food | Calories | Protein (g) | Iron (Mg) | |
| Finger millet | 346 | 8.7 | 4.0 | |
| Sorghum | 354 | 10.2 | 4.1 | |
| Ground nuts | 577 | 27.1 | 2.5 | |
| Cowpeas | 330 | 22.4 | 5.0 | |
| Bananas | 100 | 1.5 | 0.4 | |
| Cassava | 350 | 1.8 | 2.0 | |
| Maize | 354 | 9.0 | 2.5 | |
| Beans | 330 | 19.5 | 8.0 | |
| Simsim | 593 | 20.1 | 9.8 | |
| Sweet Potato | 166 | 1.3 | 1.2 | |
| Per capita of protein and calories derived from the major foods | ||||
| Food | Protein | Calories | ||
| Teso | Uganda | Teso | Uganda | |
| Finger millet | 53.40 | 8.46 | 2292 | 497 |
| Sorghum | 22.0 | 5.13 | 704 | 164 |
| Ground nuts | 27.20 | 6.03 | 571 | 126 |
| Cowpeas | 38.00 | 3.51 | 570 | 53 |
| Bananas | 0.30 | 3.24 | 26 | 324 |
| Cassava | 3.70 | 3.96 | 814 | 854 |
| Maize | 7.10 | 7.21 | 258 | 261 |
| Beans | 3.90 | 12.25 | 55 | 172 |
| Simsim | 3.30 | 1.53 | 99 | 46 |
| Sweet Potato | 4.80 | 2.70 | 365 | 205 |
| Others | 0 | 1.83 | 708 | 123 |
| Total | 163.70 | 55.85 | 6462 | 2825 |
| Cluster # | Expression level | ||||
| High | Medium high | Medium | Medium low | Low | |
| 1 | Ribosome | Lumen | Lumen | Lumen | DNA repair/Stress response |
| 2 | Oxidative Phosphorylation | Cytoskeleton | Chromosome structure | Zinc finger PHD | Zinc/ion binding |
| 3 | Ubiquitination | Protein catabolism | Protein complexes | Transcriptional regulation | Protein catabolism |
| 4 | Spliceosome | Chromosome structure | Mitochondrial subunits | Mitochondrial matrix | Protein transport |
| 5 | RNA binding | Nucleic acid binding | Nucleic acid binding/Phospho-rylation | Ankyrin repeats | tRNA aminoacylation |
| 6 | Electron transport | Ubiquitination | Endoplasmic reticulum | Protein/nucleotide interactions | Zinc finger CH2 |
| 7 | Protein localization | Protein complex synthesis | Cell cycle | Microtubules | Cell death |
| 8 | Protein biosynthesis | Cell cycle | Cellular membranes | Mitochondrial membranes | DNA repair/Polymerase |
| 9 | Ribosomal subunits | Mitochondrial components | Ankyrin repeats | Phosphorylation | Suppression of differentiation |
| 10 | Protein folding | RNA splicing | tRNA | Zinc finger CH2 | Nucleic acid binding |
| Primary reference, Study, Country (secondary references) | Objectives | Design | Sample size | Patient population | Follow-up |
| Treatment-related observational studies | |||||
| Driessen 2008[68], Radboud University Registry, The Netherlands (Driessen 2009[69]) | Efficacy and tolerability of etenercept and efalizumab | Registry | 118 | Psoriasis | 24 weeks |
| Fortune 2003[6], PUVA Study, UK and Ireland | Role of psychological distress on PUVA treatment outcomes | Cohort | 112 | Plaque psoriasis (chronic) | 2 years |
| Lecha 2005[70], Spanish tacalcitol ointment study | Efficacy and tolerability of tacalcitol | Cohort | 556 | Psoriasis (moderate) | 2 months |
| Naldi 2008[71], Psocare, Italy | Effect of BMI on clinical response to systemic treatment | Cohort | 2368 | Plaque psoriasis | 3 years |
| Paul 2003[72] Cyclosporine study, Europe and Canada | Incidence of malignancies in cyclosporine treated patients | Cohort | 1252 | psoriasis - severe | 5 years |
| Wahl 2005[73], Climate therapy study, Norway | Effectiveness of climate therapy | Cohort | 286 | Psoriasis | 8 months |
| Heiberg 2008[74], Norwegian register of disease modifying anti-rheumatic drugs, (Heiberg 2007[75]) | Comparative effectiveness of TNF inhibitors vs. methotrexate monotherapy | Registry | 526 | Psoriatic arthritis | 1 year |
| Kristensen 2008[76], South Swedish Arthritis Treatment Group register, (Gulfe 2009[77], Geborek 2002[78], Kristensen 2006[79]) | Efficacy, utility and tolerability of TNF-inhibitors (etanercept, infliximab, adalimumab) | Registry | 261 | Psoriatic arthritis | 7 years |
| Sparado 1997[80], Cyclosporin Study, Italy | Probability of continuing to take cyclosporine vs. other DMARDS | Cohort | 172 | Psoriatic arthritis | 10 years |
| Saad 2009[81], British Society for Rheumatology Biologics Register, (Harrison 2009[82], Silman 2003[83]) | Effectiveness and tolerability of TNF-inhibitors (etanercept, infliximab, adalimumab) | Registry | 566 | RA, psoriasis, psoriatic arthritis | 1 year |
| Non-treatment related observational studies | |||||
| Carrascosa 2006[84], EPIDERMA cost of illness, Spain | Direct and indirect cost; relationship between cost and severity | Cohort | 797 | Psoriasis | 1 year |
| Colombo 2008[11], Cost of illness, Italy | Direct and indirect cost; HRQOL; relationship between cost, HRQOL and severity | Cohort | 150 | Moderate to severe plaque psoriasis | 3 months |
| Schmid-ott 2005[85], Bad Bentheim Rehabilitation Hospital, Germany | Relationship between the degree of stigmatisation and gender, skin symptoms, PASI and SPASI | Cohort | 166 | Psoriasis | 1 year |
| Ali 2007[86], Husted 2007[2], Gladman 2009[16], Rohekar 2008[87], Toronto PsA clinic, Canada, (Chandran 2007[88], Gladman 1995[89], Gladman 1998[90], Gladman 1999 [91], Gladman 2001[92], Husted 2005[93], Wong 1997[94]) | (1) Mortality associated with PsA; (2) relationship between physical functioning, disease activity and joint damage; (3) CVD associated with PsA; (4) malignancies associated with PsA | Cohort | 382 to 680 | Psoriatic arthritis | 26 years |
| Kane 2003[95], St. Vincent's University study, Ireland, (Kane 2003a[96]) | Clinical presentation, outcome and prognosis of early PsA | Cohort | 129 | Early psoriatic arthritis | 2 years |
| Lindqvist 2008[97], SwePsA registry, Sweden, (Svensson 2002[98]) | Factors associated with disease progression; outcome of treated and non-treated groups, comparison of outcomes with RA patients | Registry | 135 | Early psoriatic arthritis | 2 years |
| Characteristics | No OSA | Mild-Moderate OSA | Severe OSA | p value |
| n = 10 | n = 33 | n = 34 | ||
| Total sleep time (minutes) | 288.2 ± 88.2 | 268.3 ± 80.7 | 253.8 ± 74.6 | 0.207 |
| Sleep efficiency (%) | 76.1 ± 22.9 | 75.8 ± 16.1 | 72.1 ± 18.0 | 0.506 |
| AHI event. h−1 | 2.4 ± 1.5 | 16.2 ± 6.6 | 61.4 ± 20.0 | 0.001 |
| ODI event. h−1 | 1.7 ± 1.7 | 14.5 ± 6.1 | 52.1 ± 22.8 | 0.001 |
| Average SaO2 (%) | 95.0 ± 1.3 | 93.1 ± 3.0 | 91.4 ± 3.3 | 0.001 |
| Lowest SaO2 (%) | 88.2 ± 6.0 | 82.2 ± 5.5 | 74.7 ± 9.7 | 0.001 |
| SaO2 < 90% (%) | 0 ± 0 | 9.1 ± 18.2 | 20.5 ± 25.9 | 0.001 |
| SaO2 < 80% (%) | 0 ± 0 | 0.2 ± 0.4 | 3.3 ± 5.2 | 0.021 |
| Wake % | 13.9 ± 8.1 | 22.4 ± 13.7 | 22.7 ± 17.8 | 0.226 |
| N1 % | 20.8 ± 11.0 | 16.5 ± 11.0 | 22.3 ± 10.7 | 0.423 |
| N2 % | 27.6 ± 11.5 | 28.8 ± 11.2 | 34.1 ± 14.1 | 0.125 |
| N3 % | 23.6 ± 8.4 | 22.1 ± 10.8 | 13.4 ± 9.8 | 0.001 |
| REM % | 14.1 ± 3.4 | 10.3 ± 8.5 | 7.4 ± 5.9 | 0.013 |
| Animal group | Body weight (g) | Blood glucose (mg/dL) | ||
| Before STZ injection | End experiment | Before drug injection | End experiment | |
| Control (8) | 270 ± 13.9 | 276.25 ± 13.29 | 133 ± 33.41 | 132.87 ± 35.62 |
| Vehicle (8) | 260 ± 21.60 | 237.14 ± 24.97* | 423.71 ± 108.85 | 491.42 ± 87.83 |
| Angipars 5 (8) | 257.1 ± 21.38 | 210 ± 45.82* | 457.1 ± 115.71 | 492.85 ± 137.44 |
| Angipars 10 (8) | 275.5 ± 14.24 | 272.22 ± 22.79 | 391.33 ± 66.64 | 459.22 ± 94.98 |
| Angipars 20 (8) | 266.25 ± 14.07 | 251.87 ± 17.30 | 359.87 ± 65.21 | 471.25 ± 58.66 |
| Symbol | Name | Function | Reference |
| PLK1 | polo-like kinase 1 | cell cycle regulation | [13-19] |
| CDK16 | cyclin-dependent kinase 16 | cell cycle regulation | [20] |
| RYK | receptor-like tyrosine kinase | cellular growth and differentiation Regulation | [21] |
| MTOR | mechanistic target of rapamycin (serine/threonine kinase) | cellular metabolism, growth, and proliferation Regulation | [22-24] |
| STK17B | serine/threonine kinase 17b | positive regulation of apoptosis | [25] |
| PLK4 | polo-like kinase 4 | cell cycle regulation | [17,26] |
| MAST2 | microtubule associated serine/threonine kinase 2 | cellular growth and differentiation Regulation | [27] |
| MAP3K4 | mitogen-activated protein kinase kinase kinase 4 | role in signal transduction cascades | [28] |
| MARK2 | MAP/microtubule affinity-regulating kinase 2 | cell polarity and microtubule dynamics regulation | [29] |
| CDK1 | cyclin-dependent kinase 1 | cell cycle regulation | [13,15-17,30,31] |
| NEK2 | NIMA (never in mitosis gene a)-related kinase 2 | cell cycle regulation | [14-16,30] |
| PRKCSH | protein kinase C substrate 80K-H | roles in inflammation, cell growth, signaling and death | [32] |
| AURKA | aurora kinase A | cell cycle regulation | [33,34] |
| BUB1 | mitotic checkpoint serine/threonine kinase | cell cycle regulation | [35] |
| CDC7 | cell division cycle 7 homolog (S. cerevisiae) | cell cycle regulation | [30] |
| SRPK1 | SRSF protein kinase 1 | cellular growth and differentiation Regulation | [36] |
| TTK | TTK protein kinase | cell cycle regulation | [14-16,37,38] |
| VRK1 | vaccinia related kinase 1 | cell cycle regulation | [39,40] |
| Dietary supplementationa | Statistical significance of variance ratio (P)b, effects of | ||||||
| Control | TTA | FO | TTA + FO | TTA | FO | TTA*FO | |
| CPT-I | 2.79 ± 0.26c | 1.69 ± 0.38 | 2.54 ± 0.12 | 1.75 ± 0.14 | <0.001 | 0.22 | 0.06 |
| CPT-I (with malonyl-CoA) | 1.89 ± 0.21 | 1.23 ± 0.28 | 1.77 ± 0.14 | 1.31 ± 0.13 | <0.001 | 0.73 | 0.14 |
| CPT-II | 10.79 ± 1.03 | 23.55 ± 3.15 | 12.40 ± 2.33 | 22.39 ± 4.32 | <0.001 | 0.82 | 0.15 |
| ACOX | 1.65 ± 0.31 | 4.53 ± 1.16 | 4.61 ± 1.41 | 8.47 ± 1.37 | <0.001 | <0.001 | 0.19 |
| GPAT | 0.25 ± 0.06 | 0.43 ± 0.09 | 0.39 ± 0.09 | 0.64 ± 0.14 | <0.001 | <0.001 | 0.37 |
| FAS | 0.04 ± 0.01 | 0.09 ± 0.01 | 0.06 ± 0.02 | 0.10 ± 0.02 | <0.001 | 0.01 | 0.34 |
| D-dimer ≥10 μg/mL after treatment | |||
| No | Yes | p∗ | |
| (n = 31) | (n = 21) | ||
| Male sex | 18 (58.1%) | 10 (47.6%) | 0.458 |
| Age, years | 63 (55–71) | 63 (55–70) | 0.970 |
| DWI patterns | 0.724 | ||
| Single vascular territory | 6 (19.4%) | 3 (14.3%) | |
| Single lesion | 3 | 2 | |
| Multiple lesions | 3 | 1 | |
| Multiple vascular territories | 25 (80.6%) | 18 (85.7%) | |
| Treatment | 0.002 | ||
| Enoxaparin | 21 (67.7%) | 5 (23.8%) | |
| Warfarin | 10 (32.3%) | 16 (72.6%) | |
| Cancer profiles | |||
| Primary cancer type | 0.586 | ||
| Lung | 15 (48.4%) | 12 (57.1%) | |
| Gastrointestinal | 4 (12.9%) | 3 (14.3%) | |
| Hepatobiliary | 5 (16.1%) | 5 (23.8%) | |
| Breast-gynecologic | 4 (12.9%) | 1 (4.8%) | |
| Other | 3 (9.7%) | 0 (0%) | |
| Systemic metastasis | 23 (74.2%) | 20 (95.2%) | 0.067 |
| Adenocarcinoma | 19 (61.3%) | 17 (85.0%) | 0.070 |
| Generic name | Study drug name (Brand name) | Active ingredient content | Manufacturers/distributors |
| amlodipine besilate | Amlodin® tablets 2.5 | containing 2.5 mg of amlodipine | Sumitomo Pharmaceuticals Co., Ltd. |
| Amlodin® tablets 5 | containing 5 mg of amlodipine | ||
| Norvasc® tablets 2.5 mg | containing 2.5 mg of amlodipine | Pfizer Japan Inc. | |
| Norvasc® tablets 5 mg | containing 5 mg of amlodipine |
| BPG | Patient Eligibility Criteria | Participating Program Units |
| Asthma | Patients who present to the participating units with a primary or secondary diagnosis of asthma | Emergency, in-patient and medical units |
| Breastfeeding | Postpartum women and their infants with a singleton birth, gestational age of 37 or more weeks, hospital length of stay for mother and infant 24 hours or more after birth, infant not delivered by a midwife. Additional infant criteria included: no major congenital anomalies, no galactasemia. Additional postpartum women criteria included: no documented use of street drugs, no major psychiatric illness, baby not up for adoption. | Labour and delivery, postpartum, neonatal intensive care, and public health unit |
| Delirium-Dementia-Depression | Clients admitted to participating units, age 65 years and older. | Surgical, medical and rehabilitation units |
| Smoking Cessation | Clients age 18 years and older admitted to participating unit. For outpatients, admission to out-patient services within the past month and currently attending the clinic. | In-patient and out-patient long-term mental health, in-patient unit for drug and alcohol addition, in-patient unit for acute psychiatric disorders, resource unit for nicotine dependency |
| Venous Leg Ulcers | All clients with new and recurrent venous leg ulcers. Patients with primary lymphedema, vasculitis, and under diabetic management excluded. | Chronic care unit, wound care clinic, and community care agency |
| Diabetes | Adults age 18 and over with a diagnosis of diabetes admitted to one of the participating units. Women with gestational diabetes excluded. | Oncology, medical and diabetes care and education centre and community care agency |
| Organism | Precision | Recall | F-score |
| Mouse | 0.77 | 0.81 | 0.79 |
| Yeast | 0.97 | 0.84 | 0.90 |
| Fly | 0.83 | 0.80 | 0.82 |
| FlyAccept matches of synonyms associated to up to 3 different Entrez Gene entries | 0.74 | 0.83 | 0.79 |
| Human | 0.86 | 0.81 | 0.84 |
| Command | Value | Description |
| ACK | 0×06 | It is sent when a frame has been received and decoded correctly. |
| NACK | 0×15 | It is sent when a frame has not been decoded correctly. |
| RESET | 0×08 | It forces the node to be reset. After this command, the node sends an ACK and resets itself. For the next 2 seconds the node enters a programing mode which allows the central computer to reprogram the device. |
| ALIFE | 0×0C | This command is sent to a specific node to check if it is in working mode. If the board is correctly working, it answers with an ACK command. |
| N | % | % susceptible TMP/SMX | Ciprofloxacin | Nitrofurantoin | |
| E. coli | 73 | 82 | 93 | 100 | 95 |
| P. mirabillis | 5 | 5.6 | 100 | 100 | na |
| K. pneumonia | 4 | 4.4 | 100 | 100 | 50 |
| S. aureus | 3 | 3.3 | 100 | 0 | 100 |
| C. koseri | 2 | 2.2 | 100 | 100 | 100 |
| B-hemolytic Strep | 1 | 1.1 | na | na | na |
| S. saphophyticus | 1 | 1.1 | 0 | 100 | 100 |
| Total | 89 | 100 |
| Dimension | Categories |
| Primary diagnosis | Organic mental health problem (most commonly dementia) |
| Depression or anxiety | |
| Other mental health problem e.g., schizophrenia | |
| Main reason for admission | Risk of deliberate self-harm |
| Other risks i.e., self-neglect, accidental self-harm, abuse/exploitation or falls, or carer stress | |
| Behaviour management related i.e., need for behaviour management, risk of harming others or care breakdown | |
| Need for diagnostic assessment, medication review or treatment | |
| Challenging behaviour | Low (behaviour score 0 or 1) |
| Medium (behaviour score 2–7, typically including agitation, wandering and/or disturbed sleep) | |
| High (behaviour score 8–14, typically including resistance to care and/or aggression) | |
| Living situation | Resident primary carer (including care home residents) |
| No resident carer |
| Adsorbent | qm (mg/g) | Ref. |
| GO sponge | 446 | [38] |
| GO-CS sponge | 468 | [39] |
| GO-Fe3O4 sponge | 526 | [40] |
| RGO sponge | 27 | [38] |
| RGO-MFe2O4 | 34.72 | [41] |
| RL-GO | 529.10 | [42] |
| MCGO | 95.16 | [43] |
| GO-biopolymer gel | 701.78 | [44] |
| GO-COOH sponge | 780 ± 47 | This study |
| Line | Duration in 2013DS | qDTY12.1 | qDTY3.1 | qDTY2.2 | GY (kg ha−1) | |||
| DS2013 | DS2014 | |||||||
| RS | NS | RS | NS | |||||
| IR 99784-156-137-1-1 | Medium | - | √ | - | 1362 | 6200 | 2523 | 10713 |
| IR 99784-255-7-2-5 | Medium | √ | √ | - | 1346 | 7783 | 1591 | 8383 |
| IR 99784-188-202-1-2 | Medium | - | √ | √ | 939 | 9431 | 1562 | 8369 |
| IR 99784-188-202-1-1 | Medium | - | √ | √ | 939 | 9431 | 1478 | 7937 |
| IR 99784-255-68-1-5 | Medium | √ | √ | √ | 1611 | 6905 | 1183 | 7782 |
| IR 99784-188-202-1-3 | Medium | - | √ | √ | 939 | 9431 | 1058 | 6947 |
| IR 99784-255-55-2-5 | Medium | √ | - | √ | 2073 | 8525 | 1049 | 7858 |
| IR 99784-188-201-B-1 | Medium | √ | - | √ | 977 | 8610 | 1042 | 9975 |
| IR 99784-255-7-2-2 | Medium | √ | √ | - | 1346 | 7783 | 983 | 9438 |
| IR 99784-40-1-B-6 | Medium | - | - | √ | 1164 | 8168 | 942 | 8254 |
| IR 99784-11-35-2-2 | Short | - | √ | √ | 1300 | 8633 | - | - |
| IR 99784-255-9-1-3 | Medium | √ | √ | - | 888 | 8174 | 936 | 9014 |
| IR 99784-156-87-1-9 | Medium | √ | √ | √ | 923 | 5808 | 930 | 11672 |
| IR 99784-188-179-1-2 | Medium | √ | √ | - | 1459 | 9107 | 927 | 7419 |
| IR 99784-11-8-1-5 | Short | - | - | √ | 756 | 9573 | - | - |
| IR 99784-255-49-1-1 | Medium | √ | √ | - | 2521 | 5832 | 903 | 8152 |
| MR 219 | - | - | - | 13 | 5917 | 0 | 8322 |
| Pathogen | CSF | Blood | Urine | Aspirates | Pus swabs | Sputum | Stool | Total |
| n = 303 (%) | n = 2238(%) | n = 307(%) | n = 148 (%) | n = 206(%) | n = 86(%) | n = 42(%) | n = 3330(%) | |
| Candida species. | 0 (0) | 0 (0) | 1 (0.33) | 0 (0) | 12 (5.8) | 0 (0) | 0 (0) | 13 |
| Citrobacter species. | 0 (0) | 11 (0.5) | 4 (1.3) | 0 (0) | 9 (4.4) | 3 (3.48) | 0 (0) | 27 |
| Escherichia coli | 1 (0.33) | 9 (0.4) | 22 (7.2) | 0 (0) | 8 (3.9) | 1 (1.16) | 0 (0) | 41 |
| Klebsiella pneumoniae | 1 (0.33) | 42 (1.9) | 15 (4.9) | 0 (0) | 3 (1.45) | 4 (4.65) | 0 (0) | 65 |
| Other gram-positivea | 0 (0) | 4 (0.2) | 3 (0.9) | 0 (0) | 1 (0.5) | 0 (0) | 0 (0) | 8 |
| Other gram-negativeb | 1 (0.33) | 54 (2.4) | 35 (11.4) | 1 (0.67) | 24 (11.65) | 14 (16.3) | 3 (7.14) | 132 |
| Pseudomonas aeruginosa | 0 (0) | 5 (0.22) | 2 (0.7) | 0 (0) | 14 (6.8) | 3 (3.48) | 0 (0) | 24 |
| Staphylococcus aureus | 0 (0) | 80 (3.6) | 1 (0.33) | 0 (0) | 18 (8.7) | 1 (1.16) | 0 (0) | 100 |
| Salmonella species. | 0 (0) | 22 (0.9) | 0 (0) | 0 (0) | 1 (0.48) | 0 (0) | 0 (0) | 23 |
| Streptococcus species. | 1 (0.33) | 4 (0.2) | 1 (0.33) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 6 |
| Total | 4 (1.32) | 231 (10.32) | 84 (27.39) | 1 (0.67) | 90 (43.68) | 26 (30.23) | 3 (7.14) | 439 (13.2) |
| Characteristic, N (%) | Arm AN = 22 | Arm BN = 14 | Arm CN = 14 | P value |
| Age at randomization | ||||
| 18–39 years | 2 (9) | 5 (36) | 1 (7) | |
| 40–49 years | 8 (36) | 0 | 5 (36) | |
| 50–59 years | 5 (23) | 4 (29) | 7 (50) | |
| ≥ 60 years | 7 (32) | 5 (36) | 1 (7) | 0.02 |
| Extent of surgery | ||||
| Breast sparing | 9 (41) | 6 (43) | 6 (43) | |
| Mastectomy | 13 (59) | 8 (57) | 8 (57) | 0.99 |
| Tumor size | ||||
| ≤ 2.0 cm | 9 (41) | 6 (43) | 9 (64) | |
| 2.1–4.9 cm | 13 (59) | 7 (50) | 5 (36) | |
| ≥ 5.0 cm | 0 | 1 (7%) | 0 | 0.33 |
| Axillary lymph node dissection | ||||
| Yes | 20 (91) | 14 (100) | 14 (100) | |
| No | 2 (9) | 0 | 0 | 0.27 |
| Sentinel node biopsy | ||||
| Yes | 8 (36) | 8 (57) | 6 (43) | |
| No | 14 (64) | 6 (43) | 8 (57) | 0.47 |
| Tumor grade | ||||
| Low/Intermediate | 4 (18) | 4 (29) | 6 (43) | |
| High | 18 (82) | 10 (71) | 8 (57) | 0.28 |
| T stage | ||||
| 1 | 9 (41) | 6 (43) | 9 (64) | |
| 2 | 13 (59) | 7 (50) | 5 (36) | |
| 3 | 0 | 1 (7) | 0 | 0.33 |
| N stage | ||||
| 1 | 21 (95) | 13 (93) | 14 (100) | |
| 2 | 1 (5) | 1 (7) | 0 | 0.62 |
| Dataset | Note | Reference |
| Global | 289 isolates; Human and environmental isolates, from six countries (Australia, Indonesia, Laos, Singapore, Vietnam, USA), sampled to maximize diversity and exclude members of a clonal outbreak, metadata includes invasiveness, acquisition type and sample site. Invasiveness status of human isolates consists of three types: carriage (isolates not considered to be the cause of an infection), non-invasive (pneumonia, urinary tract infection, wound infection; with no recorded bacteraemia) and invasive (isolated from normally sterile sites: blood, CSF, intra-ocular, pleural, pericardial, joint fluids, deep-seated tissue abscesses). Acquisition type is either community acquisition (isolated within 48 hours of admission to hospital) or hospital acquisition (isolated after 48 hours after admission) | (Holt et al. 2015) |
| UK Hospital | 162 isolates; Collection from Cambridge University Hospitals NHS Foundation Trust in the UK over a period of seven years, invasive isolates isolated from normally sterile sites. Biased selection for antimicrobial resistance to three or more of six antimicrobial classes (penicillins, amoxacillin-clavulanate, aminoglycosides, fluoroquinolones, trimethoprim and third-generation cephalosporins), metadata includes sample site | (Ellington 2016) |
| Nepal Hospital | 88 isolates; Nepalese hospital outbreak from May to December 2012, consisting mainly of two clonal lineages; randomly selected blood cultures. | (Chung The et al. 2015) |
| Preantibiotic | 34 isolates; Collection of isolates isolated before the widespread use of antibiotics (pre 1949). No additional metadata available. | (Wand et al. 2015) |
| FHS | HRS | |||
| (1) | (2) | (3) | (4) | |
| Female sex | 0.55† (0.14) | 0.53† (0.14) | −0.33† (0.06) | −0.31† (0.06) |
| Age | 0.01 (0.01) | 0.01 (0.01) | 0.00 (0.00) | 0.00 (0.00) |
| Survey year | 0.02 (0.01) | 0.02 (0.01) | ||
| Mother’s highest grade completed | 0.25† (0.04) | 0.24† (0.04) | 0.17† (0.01) | 0.17† (0.01) |
| Respondent’s educational genetic score, standardized | 0.24* (0.11) | 0.32† (0.03) | ||
| Mother’s educational genetic score, standardized | −0.14 (0.11) | |||
| Father’s highest grade completed | 0.13† (0.04) | 0.13† (0.04) | 0.17† (0.01) | 0.17† (0.01) |
| Father’s educational genetic score, standardized | 0.00 (0.09) | |||
| Constant | 8.45 (0.74)† | 8.65† (0.90) | −26.95 (26.80) | −35.35 (26.54) |
| R2 | 0.16 | 0.17 | 0.18 | 0.20 |
| All (n = 713) | Anterolateral (n = 463) | Posterolateral (n = 250) | p-value | |
| Age, mean (SD) | 76.8 (9.0) | 77.2 (8.4) | 76.1 (10.1) | 0.1 |
| Sex a | ||||
| Female | 573 (80) | 374 (81) | 199 (80) | 0.8 |
| Male | 140 (20) | 89 (19) | 51 (20) | |
| Indication a | ||||
| Primary | 311 (44) | 251 (54) | 60 (24) | < 0.001 |
| Secondary | 402 (56) | 212 (46) | 190 (76) | |
| Surgeons’ experience a | ||||
| Registrar | 77 (11) | 64 (14) | 13 (5) | < 0.001 |
| Post-registrar | 636 (89) | 399 (86) | 237 (95) | |
| Femoral head size a | ||||
| 22-mm | 171 (24) | 14 (3) | 157 (63) | < 0.001 |
| 28-mm | 542 (76) | 449 (97) | 93 (37) |
| Cell growth inhibition ratios (%) | |||
| Cell groups | time | ||
| 24 h | 48 h | 72 h | |
| HepG2 | 55.45 ± 1.4 | 68.91 ± 1.8 | 78.83 ± 3.9 |
| DMSO | 1.00 ± 0.9 | 1.53 ± 1.6 | 1.72 ± 0.7 |
| CAV1 | 68.32 ± 2.0* | 80.12 ± 1.7* | 90.02 ± 4.0* |
| CAVM1 | 55.78 ± 1.0 | 74.83 ± 2.8 | 82.46 ± 1.6 |
| CAVM2 | 57.27 ± 1.2 | 76.79 ± 1.6 | 84.35 ± 2.6 |
| CAVRNAi | 41.23 ± 1.5* | 55.39 ± 1.2* | 68.27 ± 1.9* |
| GFP | 54.04 ± 1.6 | 70.06 ± 1.1 | 76.27 ± 1.7 |
| Standard sections | Keywords |
| Introduction | Introduction, Background, Review, Context, Literature |
| Materials and Methods | Methods, Materials, Implementation, Experimental |
| Results | Results, Findings |
| Discussion | Discussion |
| Conclusion | Conclusion(s) |
| Patients | ||
| Characteristic | No. | % |
| Median age at onset (yr) | 4 (0.1-15.7) | |
| Gender | ||
| Female | 74 | 81 |
| Male | 17 | 19 |
| JIA onset subtype | ||
| Oligoarticular | 62 | 68 |
| Polyarticular | 29 | 32 |
| NSAID* | ||
| Naproxen | 87 | 95 |
| Meloxicam | 4 | 4 |
| Tolmetin | 11 | 12 |
| Ibuprofen | 16 | 18 |
| Rofecoxib | 6 | 7 |
| Diclofenac | 8 | 9 |
| Celecoxib | 3 | 3 |
| Nabumetone | 2 | 2 |
| Other Medications† | 6 | 7 |
| Median duration of treatment (yr) | ||
| Oligoarticular | 1.5 (0.14-17.7) | |
| Polyarticular | 0.58 (0.11-9.8) |
| Models | ||||||
| WAG | GTR | |||||
| Observed | Predicted | P | Observed | Predicted | P | |
| Substitutions | 65.4727 ± 1.1915 | 63.8521 ± 1.5705 | 0.04 | 71.4523 ± 1.41065 | 71.5064 ± 1.73156 | 0.51 |
| Homoplasy | 52.4011 ± 1.13881 | 49.5447 ± 1.52248 | 0 | 58.443 ± 1.37283 | 57.4735 ± 1.7008 | 0.15 |
| Characteristic | OCP Users (n = 449) | DMPA Users (n = 181) | P value |
| Age in years, mean [range] | 23 [21, 26] | 24 [22, 27] | 0.04 |
| Race | <0.01 | ||
| White/European American | 347 (77.3) | 103 (56.9) | |
| Black/African American | 19 (4.2) | 38 (21.0) | |
| Latina | 23 (5.1) | 24 (13.3) | |
| Other | 60 (13.4) | 16 (8.8) | |
| Marital Status | <0.01 | ||
| Single | 201 (44.8) | 59 (32.6) | |
| Married | 15 (3.3) | 15 (8.3) | |
| Divorced | 2 (0.5) | 3 (1.7) | |
| In a relationship | 231 (51.5) | 104 (57.5) | |
| Education | <0.01 | ||
| High school or less | 24 (5.4) | 29 (16.0) | |
| Some college | 133 (29.6) | 72 (39.8) | |
| College graduate | 206 (46.0) | 54 (29.8) | |
| Graduate or professional school | 86 (19.2) | 26 (14.4) | |
| Income (personal, annual) | <0.01 | ||
| $9,999 or less | 187 (41.8) | 50 (27.8) | |
| $10,000–34,999 | 162 (36.2) | 80 (44.4) | |
| $35,000 or more | 98 (21.9) | 50 (27.8) | |
| Number of Prior PregnanciesMean [range] | 0 [0, 0] | 1 [0, 2] | <0.01 |
| Any prior Pregnancy | 89 (19.9) | 92 (50.8) | <0.01 |
| No | Pathotype | AGE | N 9-p | N 10-p | N 14-p | Micro | Sexta |
| 1 | EAggEC | P | |||||
| 2 | EAggEC | P | L | L | |||
| 3 | EAggEC | P | L | ||||
| 4 | EAggEC | P | L | L | L | L | L |
| 5 | EAggEC | P | L | L | |||
| 6 | EAggEC | L | L | L | L | ||
| 7 | EAggEC | P | L | L | L | L | |
| 8 | EAggEC | P | L | L | |||
| 9 | EAggEC | P | L | L | L | ||
| 10 | EAggEC | P | L | L | L | L | |
| 11 | EIEC | L | L | L | L | L | |
| 12 | EIEC | L | L | L | L | L | |
| 13 | EIEC | L | L | L | L | L | |
| 14 | EPEC | ||||||
| 15 | EPEC | L | L | ||||
| 16 | EPEC | ||||||
| 17 | EPEC | ||||||
| 18 | EPEC | L | L | L | |||
| 19 | EPEC | P | L | L | L | L | |
| 20 | EPEC | P | |||||
| 21 | EPEC | P | |||||
| 22 | EPEC | P | L | L | L | ||
| 23 | EPEC | P | L | ||||
| 24 | EPEC | L | L | ||||
| 25 | EPEC | L | L | ||||
| 26 | EPEC | L | L | ||||
| 27 | EPEC | P | |||||
| 28 | EPEC | P | L | L | L | ||
| 29 | VTEC | L | L | L | L | L | |
| 30 | VTEC | L | L | L | L | L | |
| 31 | VTEC | L | L | L | L | ||
| 32 | ETEC O114 | P | L | L | L | ||
| 33 | ETEC O167 | P | L | L | |||
| 34 | ETEC O6 | P | L | ||||
| 35 | ETEC O25 | P | L | L | |||
| 36 | ETEC O25 | P | |||||
| 37 | ETEC O78 | P | L | L | L | L | |
| 38 | ETEC O115 | P | L | L | |||
| 39 | ETEC O114 | P | |||||
| 40 | ETEC O115 | P | L | L | |||
| 41 | ETEC O25 | P | L | ||||
| 42 | ETEC O115 | P | |||||
| 43 | ETEC O6 | P | L | L | L | ||
| 44 | ETEC O167 | P | |||||
| 45 | ETEC O114 | P | L | L | L | ||
| 46 | ETEC O8 | P |
| Cox proportional hazard model for independent risk factors of survival | |||
| Hazard ratio | 95% Confidence interval | P‐value | |
| Age groups | |||
| 0–5 | Ref | – | |
| 6–10 | 1.41 | 1.069–1.854 | 0.015 |
| 11–19 | 1.41 | 1.094–1.806 | 0.008 |
| Race | |||
| White | Ref | – | |
| Black | 1.29 | 1.017–1.656 | 0.036 |
| Other | 1.04 | 0.718–1.521 | 0.8181 |
| Income | |||
| <$30,000 | 1.173 | 0.895–1.536 | 0.2471 |
| $30,000–$34,999 | 1.492 | 1.171–1.9 | 0.0012 |
| $35,000–$45,999 | 1.198 | 0.966–1.487 | 0.0996 |
| >$46,000 | Ref | – | – |
| Primary Site | |||
| Hemispheric | Ref | – | |
| Central location | 1.467 | 1.153–1.868 | 0.0018 |
| Others | 0.986 | 0.793–1.227 | 0.9022 |
| Treatment combination | |||
| None | Ref | – | – |
| RT+CT+Surgery | 0.53 | 0.341–0.824 | 0.0048 |
| RT+CT | 0.883 | 0.537–1.454 | 0.6257 |
| RT+Surgery | 0.727 | 0.435–1.215 | 0.2232 |
| Surgery alone | 0.905 | 0.564–1.451 | 0.6773 |
| Other | 0.62 | 0.387–0.995 | 0.0476 |
| Level | Vision | Hearing | Speech | Ambulation | Dexterity | Emotion | Cognition | Pain |
| 1 | 126(100) | 122(97) | 105(83.3) | 126 (100) | 126 (100) | 6(4.8) | 16(12.7) | 125(99) |
| 2 | 0(0.0) | 3(2.4) | 5(4.0) | 0 (0.0) | 0 (0.0) | 16(12.7) | 24(19.0) | 1 (0.8) |
| 3 | 0(0.0) | 0(0.0) | 7(5.6) | 0 (0.0) | 0 (0.0) | 49(38.9) | 24(19.0) | 0 (0.0) |
| 4 | 0(0.0) | 0(0.0) | 6(4.8) | 0 (0.0) | 0 (0.0) | 39(31.0) | 34(27.0) | 0 (0.0) |
| 5 | 0(0.0) | 0(0.0) | 3(2.4) | 0 (0.0) | 0 (0.0) | 16(12.7) | 18(14.3) | 0 (0.0) |
| 6 | 0(0.0) | 1(0.8) | n/a | 0 (0.0) | 0 (0.0) | n/a | 10(7.9) | n/a |
| Total | 126 | 126 | 126 | 126 | 126 | 126 | 126 | 126 |
| 9% | 3% | 1% | Control | |
| Proximates | ||||
| Moisture (g/100 g) | 8.395 | 8.625 | 8.57 | 8.27 |
| Ash (g/100 g) | 7.14 | 6.835 | 6.66 | 6.63 |
| Protein (g/100 g) | 28.155 | 23.545 | 22.185 | 21.21 |
| Fat (g/100 g) | 3.94 | 3.61 | 4.26 | 3.77 |
| Fiber (g/100 g) | 3.16 | 3.14 | 3.39 | 3.43 |
| Carbohydrate (g/100 g) | 52.37 | 57.385 | 58.325 | 60.13 |
| Energy (Kcal/100 g) | 362.02 | 360.75 | 364.79 | 363.81 |
| Amino acids(mg/g) | ||||
| Asp | 15.91 | 14.20 | 13.39 | 12.43 |
| Thr | 6.73 | 6.12 | 5.71 | 5.32 |
| Ser | 8.75 | 8.26 | 7.95 | 7.11 |
| Glu | 39.61 | 36.72 | 35.09 | 32.39 |
| Gly | 15.13 | 10.22 | 7.93 | 6.52 |
| Ala | 10.94 | 9.21 | 7.73 | 7.21 |
| Cys | 2.46 | 3.22 | 2.69 | 2.72 |
| Val | 7.46 | 7.49 | 6.86 | 6.71 |
| Met | 2.64 | 2.66 | 2.31 | 1.79 |
| Ile | 6.24 | 5.74 | 5.49 | 5.21 |
| Leu | 12.98 | 12.29 | 11.45 | 11.11 |
| Tyr | 4.00 | 3.80 | 3.60 | 3.54 |
| Phe | 8.31 | 7.63 | 7.33 | 6.94 |
| Lys | 9.31 | 7.90 | 7.11 | 6.99 |
| His | 4.12 | 3.83 | 3.57 | 3.36 |
| Arg | 11.61 | 9.92 | 9.18 | 8.20 |
| Pro | 14.61 | 12.22 | 10.32 | 9.91 |
| Total amino acids(mg/g) | 180.81 | 161.42 | 147.71 | 137.46 |
| Minerals | ||||
| Calcium (g/100 g) | 1.03 | 1.12 | 1.29 | 1.21 |
| Phosphorus (g/100 g) | 0.79 | 0.98 | 0.315 | 0.65 |
| Gene | TGCT Probands (n=150) | Controls (n=1,609) | OR | P-value | Total no. affected familial cases (n=306) | Rank |
| DNAAF1 | 2 | 1 | 21.3 | 9.9 × 10−3 | 4 | 1 |
| ACSM1 | 2 | 6 | 3.6 | 6.4 × 10−2 | 4 | 2 |
| TSNAXIP1 | 3 | 11 | 2.9 | 6.9 × 10−2 | 6 | 3 |
| C1orf186 | 2 | 8 | 2.7 | 1.3 × 10−1 | 4 | 4 |
| KIAA1586 | 2 | 8 | 2.7 | 1.3 × 10−1 | 4 | 5 |
| ABCA10 | 2 | 8 | 2.7 | 1.6 × 10−1 | 4 | 6 |
| PIK3C2G | 3 | 13 | 2.5 | 2.4 × 10−1 | 6 | 7 |
| C1orf168 | 2 | 9 | 2.4 | 2.5 × 10−1 | 5 | 8 |
| RRP15 | 3 | 18 | 1.8 | 2.8 × 10−1 | 6 | 9 |
| MUC4 | 3 | 22 | 1.5 | 2.9 × 10−1 | 7 | 10 |
| OR6K2 | 2 | 15 | 1.4 | 3.0 × 10−1 | 5 | 11 |
| KRTAP1-1 | 2 | 15 | 1.4 | 3.0 × 10−1 | 4 | 12 |
| ABCC12 | 3 | 23 | 1.4 | 3.3 × 10−1 | 7 | 13 |
| CALML4 | 2 | 16 | 1.3 | 3.4 × 10−1 | 5 | 14 |
| Factor | Level | n | Test +ve | % | OR | 95 % CI | χ2 | P value |
| Farm type | Extensive | 33 | 14 | 42.4 | ||||
| Intensive | 4 | 3 | 75 | 4.07 | 0.38–43.38 | 1.52 | 0.22 |
| Line | Patients by gender identity | Number (a) |
| 20 | Male | |
| 21 | Female | |
| 22 | Transgender male/female-to-male | |
| 23 | Transgender female/male-to-female | |
| 24 | Other | |
| 25 | Choose not to disclose | |
| 26 | Total patients (sum lines 20 to 25) |
| Bird ID | Paired-End Reads | Reads Mapped (%) | Reads Unmapped (%) | Genes (FPKM > 0.5) | |
| HG | 1536 | 64,372,528 | 58,450,255 (91%) | 5,922,272 (9%) | 14,171 |
| 1572 | 72,993,942 | 54,526,474 (75%) | 18,467,467 (25%) | 14,086 | |
| 1759 | 72,258,015 | 54,988,349 (76%) | 17,269,665 (24%) | 14,121 | |
| 1807 | 53,773,174 | 44,524,188 (83%) | 9,248,985 (17%) | 14,251 | |
| LG | 1890 | 51,157,100 | 42,460,393 (83%) | 8,696,707 (17%) | 14,241 |
| 1923 | 71,021,405 | 58,450,616 (82%) | 12,570,788 (18%) | 14,449 | |
| 5629 | 75,046,371 | 62,063,348 (83%) | 12,983,022 (17%) | 14,465 | |
| 5678 | 69,207,601 | 57,027063 (82%) | 12,180,537 (18%) | 14,362 |
| Category | AML | ALL | CML | MDS | MM | LD | SAA | Total |
| Sex | ||||||||
| Male | 33 (55.9%) | 30 (62.5%) | 45 (59.2%) | 6 (37.5%) | 1 (100%) | 12 (44.4%) | 29 (56.9%) | 156 (56.1%) |
| Female | 26 (44.1%) | 18 (37.5%) | 31 (40.8%) | 10 (62.5%) | 0 | 15 (55.6%) | 22 (43.1%) | 122 (43.9%) |
| Source | ||||||||
| BM | 49 (83.1%) | 41 (85.4%) | 63 (82.9%) | 11 (68.8%) | 0 | 7 (25.9%) | 49 (96.1%) | 220 (79.1%) |
| PBSC | 10 (16.9%) | 3 (6.3%) | 13 (17.1%) | 4 (25%) | 1 (100%) | 20 (74.1%) | 1 (2%) | 52 (18.7%) |
| CB | 0 | 4 (8.3%) | 0 | 1 (6.3%) | 0 | 0 | 1 (2%) | 6 (2.2%) |
| Regimen | ||||||||
| Myeloablative | 58 (98.3%) | 48 (100%) | 76 (100%) | 12 (75%) | 0 | 0 | 46 (90.2%) | 241 (86.7%) |
| RIC | 1 (1.7%) | 0 | 0 | 4 (25%) | 1 (100%) | 27 (100%) | 5 (9.8%) | 37 (13.3%) |
| Patient age | ||||||||
| Median | 35 | 15 | 36.5 | 35 | 31 | 43 | 20 | 32 |
| Range | 1–55 | 1–47 | 7–57 | 2–55 | 31 | 18–56 | 5–51 | 1–57 |
| Age | ||||||||
| <20 | 14 (23.7%) | 27 (56.3%) | 6 (7.9%) | 4 (25%) | 0 | 2 (7.4%) | 26 (51%) | 79 (28.4%) |
| 20–40 | 27 (45.8%) | 16 (33.3%) | 40 (52.6%) | 6 (37.5%) | 1 (100%) | 10 (37%) | 19 (37.3%) | 119 (42.8%) |
| >40 | 18 (30.5%) | 5 (10.4%) | 30 (39.5%) | 6 (37.5%) | 0 | 15 (55.6%) | 6 (11.8%) | 80 (28.8%) |
| Disease stage | ||||||||
| Early | 28 (47.5%) | 18 (37.5%) | 60 (78.9%) | 16 (100%) | 0 | 2 (7.4%) | 51 (100%) | 175 (62.9%) |
| Intermediate | 17 (28.8%) | 23 (47.9%) | 12 (15.8%) | 0 | 1 (100%) | 7 (25.9%) | — | 60 (21.6%) |
| Advanced | 14 (23.7%) | 7 (14.6%) | 4 (5.3%) | 0 | 0 | 18 (66.7%) | — | 43 (15.5%) |
| Time interval | ||||||||
| <12 months | 24 (40.7%) | 13 (27.1%) | 13 (17.1%) | 5 (31.3%) | 0 | 1 (3.7%) | 36 (70.6%) | 92 (33.1%) |
| >12 months | 35 (59.3%) | 35 (72.9%) | 63 (82.9%) | 11 (68.7%) | 1 (100%) | 26 (96.3%) | 15 (29.45) | 186 (66.9%) |
| HLA | ||||||||
| HLA IS | 50 (84.7%) | 33 (68.8%) | 69 (90.8%) | 14 (87.5%) | 1 (100%) | 27 (100%) | 44 (86.3%) | 238 (85.6%) |
| Unrelated | 9 (15.35) | 15 (31.3%) | 7 (9.2%) | 2 (12.5%) | 0 | 0 | 7 (13.7%) | 40 (14.4%) |
| Gender com | ||||||||
| Other | 42 (71.2%) | 34 (70.8%) | 58 (76.3%) | 16 (100%) | 0 | 21 (77.8%) | 38 (74.5%) | 209 (75.2%) |
| DF/RM | 17 (28.8%) | 14 (29.2%) | 18 (23.7%) | 0 | 1 (100%) | 6 (22.2%) | 13 (25.5%) | 69 (24.8%) |
| Score | ||||||||
| 0 | 2 (3.4%) | 4 (8.3%) | 1 (1.3%) | 2 (12.5%) | 0 | 0 | 13 (25.5%) | 22 (7.9%) |
| 1 | 10 (16.9%) | 6 (12.5%) | 7 (9.2%) | 4 (25%) | 0 | 0 | 18 (35.3%) | 45 (16.2%) |
| 2 | 17 (28.8%) | 12 (25%) | 20 (26.3%) | 3 (18.8%) | 0 | 1 (3.7%) | 13 (25.5%) | 66 (23.7%) |
| 3 | 9 (15.3%) | 12 (25%) | 35 (46.1%) | 7 (15.3%) | 0 | 3 (11.1%) | 6 (11.8%) | 72 (25.9%) |
| 4 | 10 (16.9%) | 11 (22.9%) | 9 (11.8%) | 0 | 1 (100%) | 11 (40.7%) | 1 (2.0%) | 43 (15.5%) |
| 5 | 8 (13.6%) | 2 (4.2%) | 4 (5.3%) | 0 | 0 | 11 (40.7%) | 0 | 25 (9.0%) |
| 6 | 3 (5.1%) | 1 (2.1%) | 0 | 0 | 0 | 1 (3.7%) | 0 | 5 (1.8%) |
| CMV | ||||||||
| Recipient pos | 52 (91.2%) | 37 (77.1%) | 65 (85.5%) | 14 (87.5%) | 1 (100%) | 23 (88.5%) | 46 (90.2%) | 238 (86.5%) |
| Recipient neg | 5 (8.8%) | 11 (22.9%) | 11 (14.5%) | 2 (12.5%) | 0 | 3 (11.5%) | 5 (9.8%) | 37 (13.5%) |
| IQ | TMT interference | Stroop interference | ZOO MAP | |||||
| B | 95%CI | B | 95%CI | B | 95%CI | B | 95%CI | |
| Distress experience | - 0.04 | -0.06 - -0.12* | -0.05 | -0.16 – 0.05 | 0.79 | -0.23 – 1.82 | 0.75 | -0.08 – 0.23 |
| Perceived control | 0.03 | -0.00 – 0.05 | -0.01 | -0.09 – 0.11 | -0.17 | -1.20 – 0.85 | 0.03 | -0.14 – 0.19 |
| Control group | Pancreatic cancer patients | |
| Age (years) | 58 ± 11 | 61 ± 7 |
| Gender (M-men/W-women) | (10-M/9-W) | (19-M/10-W) |
| BMI (kg/m2) | 25.12 ± 3.43 | 26.18 ± 4.56 |
| RBC (×1012 cells/l) | 4.67 ± 0.73 | 4.38 ± 0.84 |
| Hb (g/dl) | 14.26 ± 1.57 | 12.56 ± 2.63 |
| Platelets count (×109 cells/l) | 209 ± 47 | 253 ± 102 |
| WBC count (×109 cells/l) | 8.01 ± 1.91 | 9.16 ± 4.09 |
| CRP (mg/l) | 3.07 ± 2.88 | 8.57 ± 2.14* |
| CA19.9 (U/ml) | 17.81 ± 4.15 | 194.11 ± 73.01* |
| Subjective pain intensity (n [%]) | ||
| None | 17 [89.5] | 15 [51.7] |
| Delicate | 2 [10.5] | 6 [20.7] |
| Moderate | 0 [0] | 4 [13.8] |
| Intensive | 0 [0] | 4 [13.8] |
| General feeling (n [%]) | ||
| Good | 19 [100] | 15 [51.7] |
| Poor | 0 [0] | 10 [34.5] |
| Terrible/very weak | 0 [0] | 4 [13.8] |
| Patients | n = 13 |
| Mean age years (min – max) | 53 (28–77) |
| Male/female | 7/6 |
| Mean height cm (min-max) | 166 (146–177) |
| Mean weight kg (min-max) | 72 (44–105) |
| Mean BMI (min-max) | 27 (19–38) |
| ASA I/II/III/IV | 2/4/2/5 |
| Mallampati class I/II/III/IV | 6/2/2/3 |
| Orally/nasally awake fiberoptic intubation | 6/7 |
| Reasons for awake fiberoptic intubation | |
| o Cervical spine disease, i.e. rheumatoid arthritis | 5 |
| o Head and neck abnormality, i.e. supraglottic cancer, oral abscess | 2 |
| o Thyroidea abnormality | 3 |
| o Upper airway trauma, i.e. acute pharyngeal bleeding, mandible fracture | 3 |
| Previous experience with anaesthesia, yes/no | 10/3 |
| Genome | Proteome size | Clustered proteins | Core proteome |
| Halobacterium sp. NRC-1 | 2626 | 2174 (82.8%) | 857 (32.6%) |
| Haloarcula marismortui | 4240 | 3464 (81.7%) | 893 (23.1%) |
| Natronomonas pharaonis | 2822 | 2285 (81.0%) | 847 (30.0%) |
| Haloquadratum walsbyi | 2626 | 2108 (80.3%) | 835 (31.8%) |
| Halorubrum lacusprofundi | 3913 | 3166 (80.9%) | 870 (22.2%) |
| Halogeometricum borinquense | 4303 | 3209 (74.6%) | 891 (20.7%) |
| Halomicrobium mukohataei | 3548 | 2902 (81.8%) | 858 (24.2%) |
| Halorhabdus utahensis | 3160 | 2334 (73.9%) | 856 (27.1%) |
| Haloferax volcanii | 4074 | 3240 (79.5%) | 870 (21.4%) |
| Strains | Characteristics | Source/origin |
| J940047 | Wild-type isolate | Clinical, Portugal |
| J940557 | Wild-type isolate | Clinical, Portugal |
| J940915 | Wild-type isolate | Clinical, Portugal |
| 06L3FF02 | Wild-type isolate | Wine cellar; Bairrada Wine Region, Portugal |
| 06L1FF11 | Wild-type isolate | Wine cellar; Bairrada Wine Region, Portugal |
| 06L3FF15 | Wild-type isolate | Wine cellar; Bairrada Wine Region, Portugal |
| 06L6FF20 | Wild-type isolate | Wine cellar; Bairrada Wine Region, Portugal |
| UM218 | Wild-type isolate | Vineyard; Vinho Verde Wine Region, Portugal |
| UM237 | Wild-type isolate | Vineyard; Vinho Verde Wine Region, Portugal |
| BB1235 | Wild-type isolate | Vineyard; Bairrada Wine Region, Portugal |
| BB2453 | Wild-type isolate | Vineyard; Bairrada Wine Region, Portugal |
| Lalvin EC-1118 | Commercial; used in the Vinho Verde Wine Region | Champagne, France |
| Lalvin ICV D254 | Commercial; used in the Bairrada Wine Region | Rhône Valley, France |
| IOC 18–2007 | Commercial; used in the Bairrada Wine Region | Institut Oenologique de Champagne, France |
| AEB Fermol Rouge | Commercial; used in the Bairrada Wine Region | Montpellier University, France |
| Davis Lalvin 522 | Commercial; used in the Bairrada Wine Region | University of California, Davis, USA |
| S288C | MATα SUC2 mal mel gal2 CUP1 flo1 flo8-1 | Mortimer & Johnston, 1986 [87] |
| Gene | Accession number | Forward Primer (5'-3') | Reverse Primer (5'-3') | qPCR primer combination (product length) | Sequencing primer combination (product length) |
| GST mu 1 | AF462190 | F1: GCTATTGGGATCTTCGTGGA | R1:TGCCCAAATACCGGAGAATA | F1/R1 (228 bp) | F1/R2 (628 bp) |
| R2: TGTATTCCATTTCGCCATTG | |||||
| GST mu 2 | AY825933 | F1: GCCCATCAGAATGATGCTTT | R1: TTCTCAAGATAATCTGGCTTTA | F1/R1 (344 bp) | F1/R2 (519 bp) |
| R2: GAATCGATTAACATAGTTGCC | |||||
| GST mu 3 | AY825934 | F1: ATCTGGCGTGCAGATAAAC | R1: CTCGAGCCTTCTCGAAATTG | F1/R1 (241 bp) | F2/R2 (929 bp) |
| F2: ACGCAGTTTTGTTTCGTTGG | R2: GTCTGGATTTGTTCCGTGGT | ||||
| GST delta 1 | AY825935 | F1: TGGACCAACATTAGCCGATA | R1: TTGCATTTGTTGAGCGAATC | F1/R1 (193 bp) | F2/R1 (631 bp) |
| F2: CAGAAAGTGCACCATGTCGT | |||||
| GST delta 2 | AY825936 | F1: AGCTCAAACCGATGAGCCTA | R1:GCGAATGCAATGATGTTAGC | F1/R1 (192 bp) | F2/R1 (652 bp) |
| F2:TGGGTTCTATTCGACCGATAA | |||||
| GST delta 3 | AY825937 | F1: ATGGAGGTGGTTTGAACGAG | R1: TCGTGATCGACAGCATTCAT | F1/R1 (244 bp) | F2/R1 (580 bp) |
| F2: AGAGAGCCCACCATGTCGTA | |||||
| P-glycoprotein | DQ146410 | AGGCAACTTCAGCACTCGAT | ACATTCTGACCGCCATCAAT | 155 bp | |
| SsCl | EF611372 | TGATTTCTATATGTCGGGCCATTTG | CAGGGAACCAAAGATCAACA | 329 bp | |
| β-actin | EU624346 | CAACCATCCTTCTTGGGTATG | CCAGCTTCGTCGTATTCTTGT | 311 bp |
| Characteristics | HR | 95% CI | P-value |
| Health knowledgea | |||
| Low (0) | 1 | ||
| Moderate (1–3) | 0.63 | 0.33–1.19 | 0.15 |
| High (4–15) | 0.43 | 0.22–0.86 | 0.02 |
| Age | 1.04 | 1.00–1.07 | 0.04 |
| Sex | 0.81 | 0.42–1.58 | 0.54 |
| Smoking status | |||
| Never | 1 | ||
| Current | 2.24 | 1.13–4.44 | 0.02 |
| Former | 0.92 | 0.25–3.34 | 0.90 |
| Comorbidities | |||
| Hypertension | |||
| No | 1 | ||
| Yes | 0.96 | 0.50–1.85 | 0.91 |
| Hyperlipidemia | |||
| No | 1 | ||
| Yes | 1.88 | 1.00–3.55 | 0.05 |
| Atrial fibrillation | |||
| No | 1 | ||
| Yes | 3.61 | 1.28–10.20 | 0.02 |
| Coronary artery disease | |||
| No | 1 | ||
| Yes | 1.16 | 0.67–2.01 | 0.60 |
| Congestive heart failure | |||
| No | 1 | ||
| Yes | 1.61 | 0.75–3.45 | 0.22 |
| Different scales | Mean | SD | Score ≥ 3,5 (total) | |
| Images of God (5 point scale) | Personal God | 2,75 | 1,42 | 18 (50) |
| Non-personal God | 2,70 | 0,75 | 24 (49) | |
| Unknowable God | 3,23 | 1,18 | 19 (46) | |
| Attitudes towards death (5 point scale) | Explicitly religious | 2,53 | 1,34 | |
| Agnostic/Atheistic | 3,35 | 0,96 | ||
| Reincarnation | 2,17 | 1,08 | ||
| Community | 2,43 | 1,24 | ||
| Continuation | 2,70 | 1,27 | ||
| Spiritual wellbeing scales (4 point scale) | Existential wellbeing | 2,96 | ,59 | |
| Relation to Self | 3,05 | ,54 | ||
| Relation to Others | 3,30 | ,50 | ||
| Relation to Something Greater | 2,40 | ,73 | ||
| Relation to God (1-item scale for ‘believers’ n = 29 completed this scale) | 2,38 | 1,02 |
| Frequencies of graft cell subsets, (%), mean ± SD | Doses of graft cell subsets infused, 106 cells/kg of body weight, median (min–max) | |||||
| G-BM (n = 49) | G-PBSC (n = 52) | P | G-BM (n = 49) | G-PBSC (n = 52) | P | |
| CD3+ | 60 ± 10 | 68.0 ± 14.0 | 0.007 | 69.6(22–156) | 285.8(68–467) | <0.001 |
| CD3+CD4+ | 29 ± 8.7 | 35.0 ± 10.7 | 0.065 | 33(10–56) | 139.3(45–257) | <0.001 |
| CD4+CD45RA+ | 9.5 ± 5.7 | 13.1 ± 8.1 | 0.220 | 11(3–30) | 51.3(16–121) | <0.001 |
| CD4+CD45RO+ | 13.8 ± 7.7 | 16.2 ± 8.0 | 0.647 | 16(5–39) | 63.6(16–150) | <0.001 |
| CD3+CD8+ | 26.6 ± 7.4 | 27.9 ± 9.2 | 0.297 | 30(25–59) | 111.8(28–265) | <0.001 |
| CD8+CD45RA+ | 19.6 ± 6.6 | 20.5 ± 7.6 | 0.625 | 22(11–60) | 79.0(20–189) | <0.001 |
| CD4+/CD8+ | 1.04 ± 0.5 | 1.12 ± 0.5 | 0.967 | |||
| CD19+ | 12.3 ± 5.0 | 12.7 ± 6.0 | 0.659 | 14(5–42) | 48.5(12–90) | <0.001 |
| CD3−CD56+ | 10.0 ± 7.0 | 7.0 ± 8.9 | 0.144 | 12(6–38) | 27.9(3–76) | <0.010 |
| Treg | 3.1 ± 3.2 | 2.3 ± 2.0 | 0.192 | 3.0(1.5–6.7) | 8.6(3.6–12.6) | <0.010 |
| MDSCs | 0.66 ± 0.23 | 0.40 ± 0.19 | <0.01 | 3.9(1.4–7.3) | 3.5(1.7–6.0) | 0.045 |
| Characteristics | No. (%) |
| Sex | |
| M | 65 (67%) |
| F | 32 (33%) |
| Age (years) | |
| 0-14 | 3 (3%) |
| 15-24 | 23 (24%) |
| 25-34 | 43 (44%) |
| 35-44 | 24 (25%) |
| ≥45 | 4 (4%) |
| Hospitalization | |
| Yes | 90 (93%) |
| No | 7 (7%) |
| Calendar year | Participation | RP & dependents | Office worker | Non-office worker | Public officers | ||||
| N | % | N | % | N | % | N | % | ||
| 2006 | No | 5,110,899 | 64.0 | 437,274 | 28.9 | 945,129 | 20.4 | 152,241 | 16.5 |
| Yes | 2,880,225 | 36.0 | 1,078,249 | 71.1 | 3,677,914 | 79.6 | 771,830 | 83.5 | |
| Total | 7,991,124 | 1,515,523 | 4,623,043 | 924,071 | |||||
| 2007 | No | 4,717,810 | 59.7 | 232,925 | 21.7 | 923,421 | 18.1 | 65,021 | 23.3 |
| Yes | 3,189,796 | 40.3 | 839,517 | 78.3 | 4,176,693 | 81.9 | 213,526 | 76.7 | |
| Total | 7,907,606 | 1,072,442 | 5,100,114 | 278,547 | |||||
| 2008 | No | 4,651,095 | 56.8 | 738,024 | 26.5 | 720,013 | 15.6 | 120,249 | 13.4 |
| Yes | 3,531,109 | 43.2 | 2,044,152 | 73.5 | 3,909,321 | 84.4 | 779,838 | 86.6 | |
| Total | 8,182,204 | 2,782,176 | 4,629,334 | 900,087 | |||||
| 2009 | No | 4,360,434 | 51.8 | 682,419 | 25.0 | 652,252 | 13.3 | 44,268 | 18.4 |
| Yes | 4,051,519 | 48.2 | 2,049,755 | 75.0 | 4,240,682 | 86.7 | 195,910 | 81.6 | |
| Total | 8,411,953 | 2,732,174 | 4,892,934 | 240,178 | |||||
| 2010 | No | 4,172,755 | 48.3 | 728,312 | 25.9 | 563,799 | 11.5 | 83,178 | 12.1 |
| Yes | 4,470,443 | 51.7 | 2,088,031 | 74.1 | 4,326,907 | 88.5 | 606,349 | 87.9 | |
| Total | 8,643,198 | 2,816,343 | 4,890,706 | 689,527 | |||||
| 2011 | No | 3,303,175 | 41.0 | 758,846 | 24.8 | 485,263 | 9.8 | 46,406 | 15.6 |
| Yes | 4,743,687 | 59.0 | 2,302,668 | 75.2 | 4,442,913 | 90.2 | 250,506 | 84.4 | |
| Total | 8,046,862 | 3,061,514 | 4,928,176 | 296,912 | |||||
| 2012 | No | 3,138,510 | 38.9 | 855,579 | 28.8 | 584,841 | 11.6 | 68,834 | 10.8 |
| Yes | 4,935,574 | 61.1 | 2,120,013 | 71.2 | 4,458,500 | 88.4 | 569,189 | 89.2 | |
| Total | 8,074,084 | 2,975,592 | 5,043,341 | 638,023 | |||||
| 2013 | No | 3,302,678 | 40.4 | 950,361 | 31.2 | 505,778 | 9.4 | 43,762 | 13.5 |
| Yes | 4,875,356 | 59.6 | 2,091,641 | 68.8 | 4,860,568 | 90.6 | 281,320 | 86.5 | |
| Total | 8,178,034 | 3,042,002 | 5,366,346 | 325,082 |
| Degradation Time (Week) | Tg (°C) | |||
| nHA 0% | nHA 10% | nHA 30% | nHA 50% | |
| 0 | 51.5 | 50.4 | 52.9 | 51.0 |
| 1 | 52.2 | 52.8 | 51.9 | 51.8 |
| 2 | 51.8 | 52.1 | 51.5 | 53.1 |
| 3 | 52.6 | 52.2 | 51.9 | 52.5 |
| 4 | 52.1 | 52.4 | 51.8 | 52.8 |
| 6 | 52.1 | 52.1 | 51.9 | 52.9 |
| 8 | 51.0 | 51.9 | 52.1 | 52.5 |
| Pt. | Indication for tons. | CP type | Initial cleft repair | Protons. endoscopy | Posttons. endoscopy | Speech intelligibility | VPI Severity | ||||
| Preop. | postop. | Diff. | Preop. | Postop. | Diff. | ||||||
| 4 | VPI | SM | Unk. | Palate 9 lat 4 | Palate 9 lat 4 | 2 | 2 | 0 | 2 | 2 | 0 |
| 5 | VPI | None | None | Palate 7 lat 2 | Palate 9 lat 4 | 2 | 2 | 0 | 3 | 2 | −1 |
| 6 | VPI | UC | 2 flap | Palate 0 lat 0 | Palate 0 lat 1 | 3 | 2 | −1 | 2 | 2 | 0 |
| 7 | VPI | UC | 2 flap | Palate 9 lat 2 | Palate 9 lat 1 | 3 | 2 | −1 | 1 | 2 | 1 |
| 9 | VPI | UC | 2 flap | Palate 1 lat 1 | Palate 2 lat 1 | 3 | 4 | 1 | 4 | 4 | 0 |
| 12 | VPI | UC | 2 flap | Palate 5 lat 1 | Palate 5 lat 3 | 4 | 4 | 0 | 4 | 4 | 0 |
| 15 | Recurrent strep + VPI | I | 2 flap | Palate 8 lat 4 | Palate 9 lat 4 | 2 | 1 | −1 | 1 | 2 | 1 |
| 16 | VPI | None | None | Palate 9 lat 4 | Palate 7/8, lat 1 | 3 | 3 | 0 | 3 | 3 | 0 |
| 17 | OSA | UC | 2 flap | Palate 8 lat 0 | Palate 8 lat 1 | 2 | 2 | 0 | 2 | 2 | 0 |
| 22 | VPI | SM | furlow | Palate 4 lat 0 | Palate 3.5 lat 1 | 4 | 4 | 0 | 3 | 3 | 0 |
| Genes | Primer Sequences (5'-3') | Cycles | Size (bp) | Annealing Temperature (°C) | |
| Pluripotency-associated markers | |||||
| Oct4 | F | TCTCGCCCCCTCCAGGT | 30 | 218 | 53 |
| R | GCCCCACTCCAACCTGG | ||||
| Sox2 | F | GGCAGCTACAGCATGATGCAGGACC | 34 | 130 | 60 |
| R | CTGGTCATGGAGTTGTACTGCAGG | ||||
| Endodermal-associated markers | |||||
| FoxA2 | F | GGGAGCGGTGAAGATGGA | 38 | 89 | 55 |
| R | TCATGTTGCTCACGGAGGAGTA | ||||
| Gata6 | F | GAGTGAGAGAAGATGGAAGGG | 38 | 250 | 55 |
| R | CGCACATGAAATCTGGATGTGG | ||||
| Ectodermal-associated markers | |||||
| Nestin | F | CAGCTGGCGCACCTCAAGATG | 30 | 209 | 55 |
| R | AGGGAAGTTGGGCTCAGGACTGG | ||||
| Pax6 | F | AACAGACACAGCCCTCACAAACA | 30 | 275 | 55 |
| R | CGGGAACTTGAACTGGAACTGAC | ||||
| Mesodermal-associated markers | |||||
| Brachyury | F | GAACCAGCACCCTGTGTCCAC | 38 | 608 | 57 |
| R | GCCACGACAAAAAGTCACTGC | ||||
| Goosecoid | F | CTCAACCAGCTGCACTGTC | 38 | 322 | 55 |
| R | GTCAGCTGTCCGAGTCCAAATC | ||||
| Control-associated markers | |||||
| GAPDH | F | ATGGAGAAGGCTGGGGCTC | 28 | 196 | 55 |
| R | AAGTTGTCATGGATGACCTTG |
| Referrals & Services | Team 1 | Team 2 | Team 3 | Team 4 | Team 5 | |||||
| T1 | A2 | T | A | T | A | T | A | T | A | |
| # of referrals | 1104 | 61 | 0 | 0 | 172 | 10 | 2742 | 152 | 250 | 14 |
| # of new registration | 418 | 23 | 1163 | 65 | 81 | 5 | 488 | 27 | 71 | 4 |
| # of consultation | 1889 | 105 | 7207 | 400 | 107 | 6 | 2682 | 149 | 110 | 6 |
| # of telephone contact with Patient | 328 | 18 | 2296 | 128 | 76 | 4 | 585 | 33 | 50 | 3 |
| # of telephone contact with family members | 0 | - | 0 | - | 33 | 2 | 43 | 2 | 15 | 1 |
| WAT | Continuous grazing | Rotational grazing | Rotational grazing + parasiticide fungi | |||||
| G-1 (n = 6)a | G-2 (n = 8)b | G-3 (n = 8)c | ||||||
| FECR (95% CI) | PHR (95% CI) | Pasture | FECR (95% CI) | PHR (95% CI) | Pasture | FECR (95% CI) | PHR (95% CI) | |
| 2 | 100 | 100 | A | 96 (94–98) | 75 (50–100) | 1 | 99 (98–100) | 88 (65–100) |
| 3 | 99 (97–99) | 83 (46–100) | 96 (94–98) | 75 (50–100) | 98 (97–99) | 88 (65–100) | ||
| 4 | 91 (87–93) | 50 (10–90) | 93 (91–96) | 63 (29–96) | 98 (96–99) | 75 (45–100) | ||
| 5 | 90 (87–93 ) | 50 (10–90) | 92 (90–95) | 63 (29–96) | 96 (95–98) | 75 (45–100) | ||
| 6 | 80 (76–84) | 0 | 92 (89–95) | 50 (15–85) | 96 (94–98) | 75 (45–100) | ||
| 7 | 72 (68–77) | 0 | B | 92 (89–95) | 50 (15–85) | 2 | 95 (94–97) | 75 (45–100) |
| 8 | 54 (49–59) | 0 | 90 (87–93) | 38 (4–71) | 95 (93–97) | 63 (29–96) | ||
| 9 | 52 (47–57) | 0 | 91 (88–93) | 38 (4–71) | 94 (93–96) | 63 (29–96) | ||
| 10 | 51 (46–56) | 0 | 77 (72–81) | 38 (4–71) | 93 (9195) | 63 (29–96) | ||
| 12 | 17 (13–20) | 0 | 69 (65–74) | 38 (4–71) | 93 (9195) | 50 (15–85) | ||
| 14 | 15 (12–19) | 0 | C | 58 (53–63) | 0 | 3 | 91 (8893) | 50 (15–85) |
| 16 | 14 (11–18) | 0 | 39 (34–44) | 0 | 83 (79–86) | 38 (4–71) | ||
| 20 | 3 (1–4) | 0 | D | 24 (20–28) | 0 | 4 | 74 (70–77) | 38 (4–71) |
| 24 | 0 | 0 | 22 (18–26) | 0 | 63 (59–67) | 25 (0–55) | ||
| 26 | 0 | 0 | A | 0 | 0 | 1 | 60 (56–65) | 0 |
| 30 | 0 | 0 | 0 | 0 | 60 (56–65) | 0 | ||
| 32 | 0 | 0 | B | 0 | 0 | 2 | 64 (60–68) | 0 |
| 36 | 0 | 0 | 0 | 0 | 61 (57–66) | 0 | ||
| 38 | 0 | 0 | C | 0 | 0 | 3 | 54 (50–59) | 0 |
| 42 | 0 | 0 | 0 | 0 | 60 (56–65) | 0 | ||
| 44 | 0 | 0 | D | 0 | 0 | 4 | 59 (55–63) | 0 |
| 48 | 0 | 0 | 0 | 0 | 54 (50–58) | 0 |
| Points censoring (days) | All patients (%) | IL-6 rs1800795 polymorphism | ||
| rs1800795GG/CG (%) | rs1800795CC (%) | p value (log-rank test) | ||
| 7 | 86.6 | 88.5 | 68.4 | 0.005 |
| 28 | 60.7 | 63.2 | 32.9 | 0.009 |
| 90 | 14.3 | 15.5 | 0.0 | 0.006 |
| Screening options | |
| Fecal screening tests | These tests search for occult blood in stool, which is nonspecific but can be detected especially in larger polyps and CRC. It is important to collect samples from consecutive bowel movements [39, 40].Guaiac fecal occult blood test (gFOBT) detects qualitatively heme in the stool, using a guaiac material to which hydroperoxidase is added. Heme promotes a process that leads to the guaiac's oxygenation and to a blue discoloration [41, 42]. It has a low sensitivity for the detection of CRC, but when performed every year or two, mortality is reduced [39, 43, 44].Fecal immunochemical tests (FITs) use monoclonal or polyclonal antibodies to detect human haemoglobin. They can give qualitative or quantitative results. FIT is more accurate than gFOBT, because it does not react with nonhuman heme and is less sensitive to upper gastrointestinal tract's bleeding [41, 45]. |
| Endoscopic screening | Flexible Sigmoidoscopy is a screening option that allows examining the rectum and the lower part of the colon. It is an invasive technique that requires simple bowel preparation but cannot detect lesion in the whole colon [41, 45].Colonoscopy is esteemed as the gold standard for CRC screening; it allows exploring the whole colon and removing the suspicious lesions [46, 47]. It is an invasive and expensive exam that must be performed if any other test has a positive result [39]. The most common side effect is postpolypectomy bleeding, but also tearing and perforation may be possible [45]. It is recommended that colonoscopy be practiced every 10 years in average-risk patients that underwent to a complete, negative exam [39, 48, 49]. |
| CT-colonography (CTC) | CTC is a noninvasive test that has become a common method for CRC screening. It requires a bowel preparation, but sedation is not needed. The estimated sensitivity and sensibility in detecting polyps > 1 cm are high, above 90%. Limitation of this technique includes low sensitivity for small lesion and serrated polyps, the exposure to radiation, and the need of follow-up for extra colic incidental findings [39, 49–51]. |
| Effect: | Relevancea | Pointsb | Classc | |||||
| 1 | 2 | 3 | 4 | 5 | ||||
| 1 | Temperature: Heat-related mortality | 6 | 2 | 1 | 41 | IV | ||
| 2 | Temperature: Heat-related cardiovascular problems | 1 | 2 | 11 | III | |||
| 3 | Temperature: Heat-related respiratory problems | 1 | 1 | 1 | 11 | III | ||
| 4 | Temperature: Heat-related stress and sleep disturbance | 1 | 5 | II | ||||
| 5 | Temperature: Cold-related mortality | I | ||||||
| 6 | Temperature: Cold-related diseases | I | ||||||
| 7 | Temperature: Drought-related exposure to contaminants | I | ||||||
| 8 | Temperature: Shortages of drinking water | 1 | 1 | II | ||||
| 9 | Temperature: Dehydration | 2 | 8 | II | ||||
| 10 | Allergies: Asthma | 1 | 1 | 4 | II | |||
| 11 | Allergies: Allergic eczema | I | ||||||
| 12 | Allergies: Hay fever: duration of pollen season | 2 | 1 | 2 | 12 | III | ||
| 13 | Allergies: Hay fever: pollen types, abundance and allergenicity | 2 | 1 | 11 | III | |||
| 14 | Pests: Wasps | I | ||||||
| 15 | Pests: Oak processionary caterpillar | 1 | 4 | II | ||||
| 16 | Vector-borne: Native vector-borne diseases | 1 | 1 | 1 | 10 | II | ||
| 17 | Vector-borne: Incidents of non-native vector-borne diseases | 1 | 2 | 2 | 1 | 21 | IV | |
| 18 | Vector-borne: Epidemics of non-native vector-borne diseases | 2 | 2 | 14 | III | |||
| 19 | Food/water-borne: Food poisoning | 1 | 2 | II | ||||
| 20 | Food/water-borne: Legionnaires Disease | 1 | 1 | II | ||||
| 21 | Food/water-borne: Contamination of swimming/recreation water | 1 | 2 | 4 | II | |||
| 22 | Air quality: Respiratory problems due to ground-level ozone | 1 | 2 | 7 | II | |||
| 23 | Air quality: Respiratory problems due to particulate matter | I | ||||||
| 24 | Air quality: Air quality-related cardiovascular problems | 1 | 1 | 3 | II | |||
| 25 | Flood/storm: Flood-related mortality | 1 | 1 | 1 | 10 | II | ||
| 26 | Flood/storm: Flood-related infectious diseases | I | ||||||
| 27 | Flood/storm: Flood-related exposure to dangerous substances and contaminants | 1 | 3 | II | ||||
| 28 | Flood/storm: Flood-related respiratory problems | I | ||||||
| 29 | Flood/storm: Flood-related mental health problems | 1 | 2 | 6 | II | |||
| 30 | Flood/storm: Storm-related mortality and injury | I | ||||||
| 31 | UV: Cataract | I | ||||||
| 32 | UV: Skin cancer | 2 | 6 | II | ||||
| 33 | UV: Weakening of the immune system | I | ||||||
| 34 | OTHER: societal disruption elsewhere | 1 | 5 | II |
| Catchment Area | Size of catchment area population | Public Corporation | Third Sector | Private Company | Different MTC | |||
| BSIC | Different MTC | BSIC | Different MTC | BSIC | Different MTC | |||
| Länsi-Uusimaa (1) | 35296 | 13 | 11 | 6 | 4 | 4 | 2 | 16 |
| Lohja (2) | 70379 | 17 | 8 | 14 | 7 | 9 | 3 | 16 |
| Hyvinkää (3) | 139734 | 41 | 13 | 37 | 15 | 16 | 2 | 26 |
| Porvoo (4) | 74611 | 17 | 8 | 20 | 7 | 6 | 2 | 13 |
| Helsinki (5) | 501929 | 94 | 16 | 93 | 26 | 5 | 3 | 38 |
| Jorvi (6) | 230005 | 29 | 16 | 29 | 13 | 11 | 5 | 27 |
| Peijas (7) | 187332 | 34 | 15 | 32 | 11 | 11 | 3 | 23 |
| Carea (8) | 143265 | 38 | 13 | 66 | 18 | 12 | 4 | 24 |
| Eksote (9) | 109379 | 34 | 16 | 30 | 8 | 9 | 4 | 23 |
| Turku (10) | 151616 | 34 | 12 | 44 | 19 | 15 | 6 | 32 |
| Turku (10) | 128039 | 52 | 17 | 42 | 15 | 11 | 7 | 21 |
| Vakka-Suomi (12) | 81392 | 25 | 8 | 14 | 5 | 9 | 6 | 19 |
| Turunmaa (13) | 18200 | 8 | 3 | 3 | 1 | 2 | 2 | 6 |
| Total BSICsc | 1871178 | 436 | 430 | 120 | ||||
| % | 44 % | 44 % | 12 % | |||||
| Different MTC | 41 | 52 | 14 | 65 | ||||
| % | 63 % | 80 % | 22 % | 100 % |
| Parameters | Supplemented group (n = 9) | Control group (n = 7) |
| Age (years) | 21.3 ± 0.82 | 21.3 ± 0.71 |
| Body mass (kg) | 93.6 ± 6.02 | 81.6 ± 9.44 |
| Body height (cm) | 192.6 ± 6.53 | 189.0 ± 4.62 |
| Duration of training (years) | 7.5 ± 1.5 | 6.9 ± 1.2 |
| Species | Age (M) | DiseaseStage* | Gene | Expression, HD/Control | SEM | t-value | p-value |
| Mouse | 3 | Casp2 | .704 | .063 | 1.78 | > 0.05 | |
| Mouse | 6 | Casp2 | 1.15 | .11 | 0.56 | > 0.05 | |
| Mouse | 9 | Casp2 | 1.20 | .12 | 0.71 | > 0.05 | |
| Mouse | 12 | Casp2 | 1.01 | .12 | 0.08 | > 0.05 | |
| Human** | 0-2 | Casp2 | 0.996 | -0.14 | > 0.05 | ||
| Human** | 0-2 | HMGCR | 0.739 | -5.04 | < 0.001 |
| Strain | Phenotypeb | Vancomycin MIC (μg/ml) by Etest after various periods of incubation | ||||||||||
| CLSI classification (48 h) | New classification | Without antibiotics | With mupirocin at 0.032 μg/ml | |||||||||
| 48 h | 72 h | 96 h | 120 h | 144 h | 48 h | 72 h | 96 h | 120 h | 144 h | |||
| 209P | VSSA (MSSA) | VSSA (MSSA) | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 |
| N315ΔIP | VSSA (MRSA) | VSSA (MRSA) | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Mu3 | hVISA | hVISA | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Mu50 | VISA | VISA | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 |
| MI (HIP5827) | VISA | VISA | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 |
| Mu3-6R | VISA | Slow VISA | 8 | 8 | 12 | 12 | 16 | 16 | 16 | 16 | 16 | 16 |
| Clinical blood culture isolates from 9 hospitals | ||||||||||||
| MRSA212 | VSSA | VSSA | 1.5 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 3 |
| MRSA84 | VSSA | hVISA | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| MRSA220 | VSSA | hVISA | 1.5 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| MRSA192 | VSSA | hVISA | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| MRSA190 | VISA | Slow VISA | 4 | 8 | 8 | 8 | 8 | 12 | 12 | 12 | 12 | 12 |
| MRSA194 | VISA | Slow VISA | 4 | 6 | 8 | 12 | 12 | 8 | 12 | 12 | 12 | 12 |
| T series clinical blood culture isolatesa | ||||||||||||
| T12 | VISA | Slow VISA | 4 | 4 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 |
| T15 | VISA | Slow VISA | 4 | 6 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 |
| T61 | VISA | Slow VISA | 4 | 6 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 |
| T89 | VISA | Slow VISA | 4 | 8 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
| T122 | VISA | Slow VISA | 4 | 8 | 8 | 8 | 8 | 6 | 6 | 8 | 8 | 8 |
| T123 | VISA | Slow VISA | 4 | 6 | 8 | 8 | 8 | 6 | 8 | 8 | 8 | 8 |
| T12-L | hVISA | hVISA | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| T15-L | hVISA | hVISA | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 |
| T61-L | hVISA | hVISA | 3 | 3 | 3 | 3 | 4 | 6 | 6 | 6 | 6 | 6 |
| T89-L | hVISA | hVISA | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| T122-L | VSSA | VSSA | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 3 |
| T123-L | VSSA | VSSA | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 3 |
| All subjects | Placebo | Donation | ||||||
| Group | Time | Time | Time | |||||
| F value | p value | F value | p value | F value | p value | F value | p value | |
| Pmax | 0.43 | 0.5219 | 9.54 | <0.0001 | 4.13 | <0.0001 | 6.48 | <0.0001 |
| VO2peak | 0.32 | 0.5775 | 4.31 | <0.0001 | 0.81 | 0.6573 | 5.46 | <0.0001 |
| Hb mass | 0.80 | 0.3959 | 3.82 | <0.0001 | 0.51 | 0.9255 | 6.03 | <0.0001 |
| EPO | 0.10 | 0.7631 | 2.88 | 0.0003 | 0.76 | 0.7181 | 2.62 | 0.0019 |
| Lactate 190W | 0.18 | 0.6722 | 9.10 | <0.0001 | 8.34 | 0.0008 | 3.22 | <0.0001 |
| Lactate post | 0.01 | 0.9069 | 4.12 | <0.0001 | 1.62 | 0.0993 | 3.63 | <0.0001 |
| HR max | 0.21 | 0.6510 | 4.44 | <0.0001 | 1.75 | 0.0699 | 3.70 | <0.0001 |
| Oxygen pulse | 0.41 | 0.5325 | 1.61 | 0.0744 | 0.61 | 0.8459 | 3.57 | <0.0001 |
| VE max | 0.09 | 0.7675 | 3.78 | <0.0001 | 1.23 | 0.2807 | 3.15 | 0.0002 |
| Total time | 0.43 | 0.5241 | 9.61 | <0.0001 | 4.12 | <0.0001 | 6.57 | <0.0001 |
| Hematocrit | 12.90 | 0.0021 | 6.51 | <0.0001 | 1.56 | 0.1168 | 12.38 | <0.0001 |
| Hemoglobin | 6.77 | 0.0180 | 8.48 | <0.0001 | 1.25 | 0.2635 | 12.94 | <0.0001 |
| Iron | 0.55 | 0.4670 | 3.30 | 0.0003 | 1.69 | 0.0811 | 2.91 | 0.0006 |
| Ferritin | 8.49 | 0.0093 | 3.48 | <0.0001 | 1.12 | 0.3589 | 6.50 | <0.0001 |
| Transferrin | 1.98 | 0.1769 | 2.97 | 0.0003 | 0.96 | 0.5055 | 3.11 | 0.0003 |
| Transf sat | 1.25 | 0.2785 | 2.98 | 0.0003 | 1.62 | 0.0976 | 3.10 | 0.0003 |
| MCH | 0.03 | 0.8603 | 6.36 | <0.0001 | 1.82 | 0.0551 | 6.61 | <0.0001 |
| MCHC | 0.01 | 0.9105 | 8.10 | <0.0001 | 2.64 | 0.0045 | 6.81 | <0.0001 |
| MCV | 0.03 | 0.8689 | 4.14 | <0.0001 | 1.35 | 0.2047 | 4.26 | <0.0001 |
| MPV | 2.77 | 0.1136 | 2.47 | 0.0028 | 1.11 | 0.3699 | 2.71 | 0.0013 |
| RBC | 6.93 | 0.0169 | 6.31 | <0.0001 | 1.18 | 0.3122 | 11.67 | <0.0001 |
| RDW | 1.05 | 0.3181 | 10.74 | <0.0001 | 2.02 | 0.0303 | 10.70 | <0.0001 |
| WBC | 0.89 | 0.3589 | 0.86 | 0.5990 | 0.46 | 0.9445 | 1.61 | 0.0821 |
| Platelets | 0.09 | 0.7639 | 3.37 | <0.0001 | 1.43 | 0.1670 | 3.14 | 0.0002 |
| Number of resting follicles (%) | Number of primary follicles (%) | Number of secondary follicles (%) | |||||
| Group | Total number of follicles | Total | Intact | Total | Intact | Total | Intact |
| Unfrozen | 249 | 203 (81.5 %) | 203 (100 %) | 39 (15.7 %) | 38 (97.4 %) | 7 (2.8 %) | 7 (100 %) |
| Vitrification | 482 | 467*** (96.9 %) | 392*** (84 %) | 11** (2.3 %) | 9 (81.8 %) | 4* (0.8 %) | 2 (50 %) |
| Slow-freezing | 374 | 365*** (97.6 %) | 293*** (80.3 %) | 9** (2.4 %) | 9 (100 %) | 0* (0 %) | _ |
| Average annual costs | References | |
| Health care costs (per episode/year) | ||
| Myocardial infarction | $18627 | Bergenheim et al., 2012 [12] |
| Heart failure | $14118 | Bergenheim et al., 2012 [12] |
| Stroke | $7939 | Bergenheim et al., 2012 [12] |
| Hypoglycemia events requiring medical assistance | $199 | Bergenheim et al., 2012 [12] |
| Severe hypoglycemia event | $146 | Bergenheim et al., 2012 [12] |
| Weight gain | $289 | Bergenheim et al., 2012 [12] |
| Drug cost (per patient/year) | ||
| Metformin, generic drug | $24 | NADAC (January 2015) [22] |
| Dipeptidyl peptidase-4 inhibitor, brand | $3500 ($3401; $3599) | NADAC (January 2015) [22] |
| Sulfonylurea (glipizide), generic | $16 | NADAC (January 2015) [22] |
| Insulin glargine, brand | $3646 | NADAC (January 2015) [22] |
| Nutrients | Incomes (€) per Person per Month | Primary | Secondary | Undergraduate | Postgraduate | ||||||||||||||||
| Mean | SE 5 | Difference with >2700 € 2 | Relative Difference (%) 3 | p | Mean | SE 5 | Difference with >2700 € 2 | Relative Difference (%) 3 | p | Mean | SE 5 | Difference with >2700 € 2 | Relative Difference (%) 3 | p | Mean | SE 5 | Difference with >2700 € 2 | Relative Difference (%) 3 | p | ||
| Magnesium | <1200 | 350.7 | 13.1 | 51.6 | 12.8% | 0.0003 | 357.7 | 3.3 | 29.8 | 7.7% | <0.0001 | 382.6 | 4.6 | 10.8 | 2.8% | 0.0038 | 388.0 | 5.8 | 16.7 | 4.1% | <0.0001 |
| 1200–1800 | 366.7 | 11.5 | 35.6 | 8.9% | 368.1 | 2.8 | 19.4 | 5.0% | 379.5 | 3.9 | 14.0 | 3.6% | 391.1 | 5.1 | 13.6 | 3.4% | |||||
| 1800–2700 | 363.3 | 12.7 | 38.9 | 9.7% | 383.8 | 3.0 | 3.7 | 0.9% | 389.4 | 4.1 | 4.1 | 1.0% | 390.7 | 4.8 | 14.0 | 3.5% | |||||
| >2700 | 402.3 | 14.4 | 0.0 | 0.0% | 387.5 | 3.6 | 0.0 | 0.0% | 393.5 | 4.3 | 0.0 | 0.0% | 404.7 | 4.6 | 0.0 | 0.0% | |||||
| Potassium | <1200 | 3147.4 | 87.3 | 217.2 | 6.5% | 0.009 | 3239.8 | 22.0 | 175.5 | 5.1% | <0.0001 | 3370.9 | 31.1 | 61.9 | 1.8% | 0.001 | 3358.2 | 19.7 | 113.0 | 3.3% | 0.0005 |
| 1200–1800 | 3173.9 | 76.4 | 190.7 | 5.7% | 3330.5 | 18.3 | 84.9 | 2.5% | 3346.4 | 26.4 | 86.4 | 2.5% | 3396.0 | 18.4 | 75.2 | 2.2% | |||||
| 1800–2700 | 3198.6 | 84.6 | 166.0 | 4.9% | 3381.8 | 20.1 | 33.5 | 1.0% | 3442.0 | 27.5 | −9.2 | −0.3% | 3421.9 | 18.2 | 49.2 | 1.4% | |||||
| >2700 | 3364.6 | 96.1 | 0.0 | 0.0% | 3415.3 | 24.1 | 0.0 | 0.0% | 3432.8 | 28.9 | 0.0 | 0.0% | 3471.2 | 17.6 | 0.0 | 0.0% | |||||
| Folate | <1200 | 339.6 | 14.3 | 11.9 | 3.4% | 0.04 | 341.1 | 3.2 | 29.4 | 7.9% | <0.0001 | 362.7 | 4.9 | 12.7 | 3.4% | 0.009 | 369.0 | 6.4 | 9.0 | 2.4% | 0.006 |
| 1200–1800 | 333.5 | 12.5 | 18.0 | 5.1% | 355.3 | 2.9 | 15.3 | 4.1% | 363.5 | 4.2 | 12.0 | 3.2% | 365.4 | 5.6 | 12.6 | 3.3% | |||||
| 1800–2700 € | 352.9 | 13.8 | −1.3 | −0.4% | 358.7 | 3.2 | 11.8 | 3.2% | 372.7 | 4.3 | 2.7 | 0.7% | 366.8 | 5.3 | 11.2 | 3.0% | |||||
| >2700 | 351.5 | 15.7 | 0.0 | 0.0% | 370.5 | 3.9 | 0.0 | 0.0% | 375.4 | 4.6 | 0.0 | 0.0% | 378.1 | 5.1 | 0.0 | 0.0% | |||||
| Beta-carotene | <1200 | 3207.5 | 335.1 | 261.5 | 7.5% | 0.2 | 3176.0 | 84.9 | 462.4 | 12.7% | 0.002 | 3676.4 | 128.9 | −2.9 | −0.1% | 0.04 | 3621.7 | 156.1 | 128.7 | 3.4% | 0.07 |
| 1200–1800 | 3059.7 | 293.2 | 409.3 | 11.8% | 3407.9 | 70.7 | 230.5 | 6.3% | 3495.7 | 109.6 | 177.9 | 4.8% | 3584.6 | 136.6 | 165.8 | 4.4% | |||||
| 1800–2700 | 3371.1 | 324.4 | 97.9 | 2.8% | 3563.3 | 77.6 | 75.1 | 2.1% | 3705.5 | 114.0 | −32.0 | −0.9% | 3648.8 | 128.9 | 101.6 | 2.7% | |||||
| >2700 | 3469.0 | 368.6 | 0.0 | 0.0% | 3638.4 | 99.8 | 0.0 | 0.0% | 3673.6 | 119.9 | 0.0 | 0.0% | 3750.4 | 123.1 | 0.0 | 0.0% | |||||
| Proteins | <1200 | 95.5 | 2.3 | 2.1 | 2.1% | 0.008 | 94.3 | 0.6 | 0.2 | 0.3% | 0.4 | 94.5 | 0.8 | −0.1 | −0.1% | 0.9 | 91.8 | 1.0 | 1.5 | 1.6% | 0.05 |
| 1200–1800 | 90.0 | 2.0 | 7.6 | 7.8% | 95.5 | 0.5 | −1.0 | −1.0% | 94.4 | 0.7 | 0.0 | 0.0% | 92.2 | 0.8 | 1.1 | 1.2% | |||||
| 1800–2700 | 92.3 | 2.2 | 5.3 | 5.4% | 94.9 | 0.5 | −0.4 | −0.4% | 95.1 | 0.7 | −0.6 | −0.7% | 92.3 | 0.8 | 0.9 | 1.0% | |||||
| >2700 | 97.6 | 2.5 | 0.0 | 0.0% | 94.6 | 0.6 | 0.0 | 0.0% | 94.4 | 0.7 | 0.0 | 0.0% | 93.3 | 0.8 | 0.0 | 0.0% | |||||
| Fibre | <1200 | 21.3 | 0.8 | −0.6 | −2.7% | 0.03 | 20.9 | 0.2 | 1.4 | 6.3% | 0.0001 | 22.8 | 0.3 | −0.3 | −1.5% | 0.2 | 23.8 | 0.4 | −0.6 | −2.5% | 0.5 |
| 1200–1800 | 20.7 | 0.7 | 0.1 | 0.3% | 21.5 | 0.2 | 0.8 | 3.7% | 22.1 | 0.3 | 0.4 | 1.6% | 23.2 | 0.4 | 0.1 | 0.3% | |||||
| 1800–2700 | 21.0 | 0.8 | −0.3 | −1.2% | 22.1 | 0.2 | 0.2 | 0.8% | 22.6 | 0.3 | −0.1 | −0.4% | 23.2 | 0.3 | 0.0 | 0.0% | |||||
| >2700 | 20.7 | 0.9 | 0.0 | 0.0% | 22.3 | 0.3 | 0.0 | 0.0% | 22.5 | 0.3 | 0.0 | 0.0% | 23.2 | 0.3 | 0.0 | 0.0% |
| Items | Mean | SD | Median | Min | Max | Skew | Kurtosis |
| 1 | 0.89 | 0.49 | 1 | 0 | 2 | −0.23 | 0.79 |
| 2 | 0.39 | 0.54 | 0 | 0 | 2 | 0.97 | −0.14 |
| 3 | 0.25 | 0.49 | 0 | 0 | 2 | 1.76 | 2.26 |
| 4 | 0.26 | 0.50 | 0 | 0 | 2 | 1.70 | 2.02 |
| 5 | 0.71 | 0.55 | 1 | 0 | 2 | −0.01 | −0.55 |
| 6 | 0.74 | 0.53 | 1 | 0 | 2 | −0.16 | −0.38 |
| 7 | 0.51 | 0.53 | 0 | 0 | 2 | 0.33 | −1.16 |
| 8 | 0.61 | 0.56 | 1 | 0 | 2 | 0.23 | −0.82 |
| 9 | 0.35 | 0.54 | 0 | 0 | 2 | 1.17 | 0.34 |
| 10 | 0.31 | 0.51 | 0 | 0 | 2 | 1.32 | 0.71 |
| 11 | 0.16 | 0.43 | 0 | 0 | 2 | 2.71 | 6.86 |
| 12 | 0.58 | 0.61 | 1 | 0 | 2 | 0.54 | −0.63 |
| 13 | 0.89 | 0.50 | 1 | 0 | 2 | −0.22 | 0.76 |
| 14 | 0.44 | 0.58 | 0 | 0 | 2 | 0.91 | −0.17 |
| 15 | 0.48 | 0.55 | 0 | 0 | 2 | 0.59 | −0.75 |
| 16 | 0.29 | 0.49 | 0 | 0 | 2 | 1.35 | 0.76 |
| 17 | 0.46 | 0.59 | 0 | 0 | 2 | 0.85 | −0.27 |
| 18 | 0.21 | 0.42 | 0 | 0 | 2 | 1.66 | 1.41 |
| 19 | 0.09 | 0.33 | 0 | 0 | 2 | 4.02 | 16.63 |
| 20 | 0.37 | 0.53 | 0 | 0 | 2 | 0.99 | −0.14 |
| 21 | 1.00 | 0.61 | 1 | 0 | 2 | 0 | −0.32 |
| 22 | 0.34 | 0.53 | 0 | 0 | 2 | 1.22 | 0.47 |
| 23 | 0.52 | 0.62 | 0 | 0 | 2 | 0.79 | −0.39 |
| 24 | 0.73 | 0.57 | 1 | 0 | 2 | 0.08 | −0.51 |
| 25 | 0.26 | 0.50 | 0 | 0 | 2 | 1.71 | 2.06 |
| 26 | 0.54 | 0.61 | 0 | 0 | 2 | 0.66 | −0.52 |
| 27 | 0.16 | 0.40 | 0 | 0 | 2 | 2.44 | 5.43 |
| 28 | 0.35 | 0.53 | 0 | 0 | 2 | 1.18 | 0.38 |
| N=55 | |
| Motor score | |
| Voluntary movement score [0–20] | 6.33 (5.71) |
| Stiffness [0–8] | 2.20 (2.14) |
| Chorea [0–16] | 5.19 (4.51) |
| Precise movement [0–8] | 4.06 (2.46) |
| Behavioural score | |
| Depression anxiety [0–20] | 9.12 (5.01) |
| Temper [0–8] | 2.81 (2.18) |
| Psychotic disorder [0–12] | 1.35 (2.16) |
| Cognition [0–12] | 3.52 (2.97) |
| Functional score | |
| Functional score [0–7] | 3.06 (2.53) |
| Characteristic | N |
| Gender | |
| Male/female | 33/90 |
| Age | |
| 21 to 30 y | 22 |
| 31 to 40 y | 36 |
| 41 to 50 y | 30 |
| >50 y | 35 |
| Years in practice | |
| <5 y | 19 |
| 5 to 10 y | 21 |
| 11 to 20 y | 34 |
| >20 y | 49 |
| Average number of clients with nonsurgicalknee osteoarthritis treated per year | |
| 1 to 20 | 43 |
| 21 to 40 | 42 |
| >40 | 38 |
| Diagnostic miR(s) | Disease Setting | Description | Reference(s) |
| miR-20a, miR-24, miR-25, miR-145, miR-152, miR-199-5p, miR-221, miR-222, miR-223, miR-320 | Lung Cancer | 10 microRNAs were found to have significantly different expression levels in NSCLC serum samples compared with the control serum samples. | [24] |
| miR-10b, miR-155, miR-195, miR34a | Breast Cancer | Increased expression of miR-10b, miR-155, and miR-195 and decreased miR-34a was associated with disease. | [25] |
| miR-221 | Ovarian Cancer, Melanoma, Lymphoma | Increase expression in several different cancers compared to control serum samples. | [27,28,29] |
| miR-141, miR-16, miR-92a, miR-92b, miR-103, miR-107, miR-197, miR-34b, miR-328, miR-485-3p, miR-486-5p, miR-574-3p, miR-636, miR-640, miR-766, and miR-885-5p. | Prostate | Levels of these microRNAs were found to be higher in the serum of patients compared to controls. | [21,26] |
| Rank | GAN | [3] | Rank | Gene description | |
| S2N | SVM-RFE | ||||
| 1 | M27891 | • | 1 | 2 | cystatin C (CST3) |
| 2 | M28130 | • | 25 | 3 | interleukin 8 (IL8) |
| 3 | M84526 | • | 5 | 1 | D component of complement (adipsin) (DF) |
| 4 | M19507 | 131 | 7 | myeloperoxidase (MPO) | |
| 5 | Y00787 | • | 23 | 4 | interleukin-8 precursor |
| 6 | M11722 | 71 | 41 | deoxynucleotidyltransferase, terminal (DNTT) | |
| 7 | X95735 | • | 2 | 11 | zyxin (ZYX) |
| 8 | D88422 | 3 | 8 | cystatin A (CSTA) | |
| 9 | M27783 | 15 | 5 | elastase 2, neutrophil (ELA2) | |
| 10 | M96326 | • | 75 | 10 | azurocidin 1 (AZU1) |
| SLD (n = 20) | HAD (n = 20) | |
| Body weight (g) | ||
| initial | 198 ± 4 | 200 ± 5 |
| 1 week | 257 ± 6 | 247 ± 6 |
| 6 weeks | 450 ± 10 | 438 ± 10 |
| 70 days | 525 ± 12 | 498 ± 12 |
| Food intake (g/kg b.w./day) | ||
| 1st week | 116 ± 4 | 122 ± 4 |
| 6th week | 74 ± 1 | 73 ± 1 |
| last week | 64 ± 2 | 66 ± 1 |
| Expression | MAWBP | |||
| Protein | Positive (%) | Negative (%) | P-value | |
| TGF-beta | Positive | 43/216 (19.9) | 59/216 (27.3) | <0.001 |
| Negative | 13/216 (6.0) | 101/216 (46.8) | ||
| E-cadherin | Positive | 31/208 (14.9 | 58/208 (27.9) | 0.026 |
| Negative | 25/208 (15.7) | 94/208 (45.2) | ||
| PGC | Positive | 28/223 (12.0) | 57/223 (25.6) | 0.112 |
| Negative | 32/223 (14.3) | 106/223 (47.5) |
| Cpd. | % inhibition (at 6.25 μg/mL) | Estimation of MIC90 | LD50ip (mg/kg) |
| 4a | 100 | <6.25 | 800 |
| 4b | 61 | >6.25 | 650 |
| 4c | 91 | <6.25 | 180 |
| 4d | 65 | >6.25 | 710 |
| 4e | 15 | >6.25 | >1000 |
| 4f | 0 | >6.25 | 410 |
| 4g | 92 | <6.25 | >1000 |
| 4h | 96 | <6.25 | 750 |
| 4i | ND | ND | 280 |
| Sex | Progesterone (ng/ml) | Corticosterone (ng/ml) | IGF-I (ng/ml) | Testosterone (ng/ml) | Estradiol (ng/ml) |
| Female | 2.74 ± 0.44 | 67.87 ± 6.26 | 43.33 ± 5.66 | 1.98 ± 0.21 | 6.43 ± 0.31* |
| Male | 2.24 ± 1.61 | 55.95 ± 13.99 | 47.92 ± 12.76 | 2.93 ± 0.32* | 5.21 ± 0.26 |
| Group | Description of the group | Strength |
| TM1 | The total number of skills is 2; number of skills of each employee and task is 2. | The quantum of effort needed in every task is to be equal; each employee has the same contribution of maximum dedication and salary. |
| TM2 | The amount of skills is 10; number of employee skills is 5–7; number of skills required in the task is 3-4. | The functionalities in TM2 and TM3 have the same TPG; the tasks have the same efforts; each employee has maximum dedication and salary. |
| TM3 | The amount of skills is 15; number of employee skills is 6-7; number of skills required in the task is 2-3. | |
| TM4 | The amount of skills is 10; number of employee skills is 2-3; number of skills required in the task is 4-5. | The functionalities in TM4 and TM5 have the same TPG; the tasks have the same effort and each employee has maximum dedication and salary. |
| TM5 | The amount of skills is 5; number of employee skills is 3-4; number of skills required in the task is 2-3. |
| All | Males | Females | |
| Age | |||
| 20 - 29 years | 104 (23.6%) | 41 (21.8%) | 63 (25.0%) |
| 30 - 39 years | 116 (26.4%) | 44 (23.4%) | 72 (28.6%) |
| 40 - 49 years | 129 (29.3%) | 59 (31.4%) | 69 (27.4%) |
| ≥50 years | 91 (20.7%) | 44 (23.4%) | 48 (19.0%) |
| Number of working years in current position | |||
| 1 to 5 years | 132 (30.0%) | 63 (33.5%) | 69 (27.4%) |
| 6 to 10 years | 107 (24.3%) | 47 (25.0%) | 60 (23.8%) |
| 11 to 15 years | 94 (21.4%) | 40 (21.3%) | 54 (21.4%) |
| 15 years and more | 107 (24.3%) | 38 (20.2%) | 69 (27.4%) |
| Number of working hours with computer/day | |||
| 2 to 5 hrs | 107 (24.3%) | 63 (33.5%) | 44 (17.5%) |
| 6 to 9 hrs | 248 (56.4%) | 81 (43.1%) | 167 (66.3%) |
| > 9 hrs | 85 (19.3%) | 44 (23.4%) | 41 (16.3%) |
| Gender | Age (years) | Length of diagnosis of hypothyroidism (years) |
| Female | 93 | 13 |
| Female | 80 | 10 |
| Male | 84 | Approx. 8 |
| Female | 82 | 24 |
| Male | 83 | 15 |
| Female | 88 | 9 |
| Female | 85 | 14 |
| Female | 80 | 3 |
| Female | 83 | 14 |
| Female | 82 | 18 |
| Female | 85 | 16 |
| Abbreviated Trial Name/NCT# | Phase | Agent(s) | Study population | Expected Primary Endpoint |
| NCT01935921 | Ib | Cetuximab, ipilimumab and IMRT | stage III-IVaHPV+ OPSCC | Dose limiting toxicities (DLT) |
| RTOG 3504NCT02764593 | III w/phase I lead in | Nivolumab and cisplatin CRT | stage III-IV, intermediate to high risk HNSCC | DLT for phase I |
| NCT02777385 | II | Concurrent vs sequential pembro, cisplatin and IMRT | stage III-IVbHNSCC | 1 year PFS1 year failure rateAcute toxicity rates |
| HN003NCT02775812 | I | Adjuvant pembro, cisplatin and IMRT | high risk stage III-IV HSNCC | DLT |
| NCT02641093 | II | Adjuvant pembro, cisplatin and IMRT | high risk stage III-IV HSNCC | Treatment related adverse events (TRAE)Disease free survival (DFS) |
| Decay class | |||||||||||
| Quaking aspen | Douglas-fir | ||||||||||
| Component | Comparison | 1 | 2 | 3 | 4 | 5 | 1 | 2 | 3 | 4 | 5 |
| Top and branches | 1 | 0.8 | 6.7 | 11.8 | 8.7 | 8.4 | 9.7 | 16.7 | 37.7 | 4.0 | 33.8 |
| 2 | 1.2 | 17.2 | 23.2 | 21.4 | 21.8 | 10.6 | 59.9 | 82.2 | 9.7 | 59.6 | |
| Bole | 1 | 2.6 | 21.5 | 39.2 | 30.0 | 29.4 | 60.1 | 104.7 | 237.9 | 13.6 | 215.7 |
| 2 | 3.8 | 25.2 | 44.0 | 36.5 | 37.3 | 65.8 | 130.0 | 268.2 | 16.5 | 239.6 | |
| Stump | 1 | 0.1 | 1.1 | 2.0 | 1.5 | 1.5 | 2.2 | 3.6 | 7.6 | 0.7 | 6.4 |
| 2 | 0.2 | 1.3 | 2.3 | 1.8 | 1.8 | 2.4 | 4.5 | 8.6 | 0.8 | 7.1 | |
| Belowground | 1 | 0.7 | 5.7 | 10.3 | 7.8 | 7.6 | 16.2 | 28.0 | 63.4 | 3.5 | 57.1 |
| 2 | 1.0 | 7.5 | 13.7 | 13.2 | 14.7 | 17.7 | 41.4 | 88.1 | 6.0 | 82.1 |
| Intervention | Control | |||
| All costs | USD | % total costs | USD | % total costs |
| Personnel | 87 926 | 58.4 | 56 632 | 60.5 |
| CHWs (salaries and incentives) | 10 332 | 6.9 | 3 982 | 4.3 |
| Field supervision and medical staff | 28 193 | 18.7 | 17 194 | 18.4 |
| Management and technical staff | 45 656 | 30.3 | 32 536 | 34.7 |
| Support staff (logistics, finance, administrative) | 3 746 | 2.5 | 2 921 | 3.1 |
| Programme costs | 35 648 | 23.7 | 20 848 | 22.3 |
| Office and programme materials | 1 756 | 1.2 | 1 324 | 1.4 |
| RUTF (supply) | 17 795 | 11.8 | 5 648 | 6.0 |
| Training costs (trainer, location, supplies) | 9 248 | 6.1 | 7 407 | 7.9 |
| Supervision and monitoring | 6 849 | 4.6 | 6 469 | 6.9 |
| Logistics | 20 732 | 13.8 | 12 953 | 13.8 |
| Rent and utilities | 8 927 | 5.9 | 2 767 | 3.0 |
| Transport (car rental, maintenance and fuel) | 10 025 | 6.7 | 9 621 | 10.3 |
| RUTF transport and storage | 1 780 | 1.2 | 565 | 0.6 |
| Community contributions | 6 218 | 4.1 | 3 208 | 3.4 |
| Costs to households | 4 807 | 3.2 | 3 191 | 3.4 |
| Opportunity costs for community leaders | 35 | 0.0 | 17 | 0.0 |
| Community-level rent | 1 376 | 0.9 | 0 | 0.0 |
| Total | 150 523 | 100.0 | 93 641 | 100.0 |
| Cost to government | 11 881 | 7.9 | 5 341 | 5.7 |
| Cost to partners | 132 425 | 88.0 | 85 093 | 90.9 |
| Cost to community | 6 218 | 4.1 | 3 208 | 3.4 |
| Variables | No. of E. coli tested | C No. (%)a | OT No. (%)a | SXT No. (%)a | PB No. (%)b | N No. (%)c | |||
| S | S | S | S | R | S | I | R | ||
| Food handlers and source | |||||||||
| Meat handlers at butcher | 8 | 8 (100) | 8 (100) | 8 (100) | 7 (87.5) | 1 (12.5) | – | 2 (25) | 6 (75) |
| Milk seller at open market | 9 | 9 (100) | 9 (100) | 9 (100) | 9 (100) | – | 2 (22.2) | – | 7 (77.8) |
| Milk seller at dairy station | 2 | 2 (100) | 2 (100) | 2 (100) | 2 (100) | – | – | – | 2 (100) |
| Bread and the related food handler at cafeteria | 10 | 10 (100) | 10 (100) | 10 (100) | 10 (100) | – | – | – | 10 (100) |
| Fruit and vegetables handlers at supermarket | 14 | 14 (100) | 14 (100) | 14 (100) | 14 (100) | – | – | 3 (21.4) | 11 (78.6) |
| Currency | |||||||||
| Birr 1 | 9 | 9 (100) | 9 (100) | 9 (100) | 9 (100) | – | – | – | 9 (100) |
| Birr 5 | 10 | 10 (100) | 10 (100) | 10 (100) | 9 (90) | 1 (10.0) | 1 (10.0) | 2 (20.0) | 7 (70.0) |
| Birr 10 | 9 | 9 (100) | 9 (100) | 9 (100) | 9 (100) | – | 1 (11.1) | – | 8 (88.9) |
| Birr 50 | 8 | 8 (100) | 8 (100) | 8 (100) | 8 (100) | – | – | 3 (37.5) | 5 (62.5) |
| Birr 100 | 7 | 7 (100) | 7 (100) | 7 (100) | 7 (100) | – | – | – | 7 (100) |
| Total | 43 | 43 (100) | 43 (100) | 43 (100) | 42 (97.7) | 1 (2.3) | 2 (4.7) | 5 (11.6) | 36 (83.7) |
| Kegg pathway | Number of genes | Fold enrichment | p value* | |
| UP | Steroid biosynthesis (cholesterol biosynthesis) | 7 | 23.8 | 1.6E-07 |
| Insulin signaling pathway | 7 | 3.1 | 2.3E-02 | |
| Adipocytokine signaling pathway | 5 | 5 | 1.6E-02 | |
| MAPK signaling pathway | 9 | 2.5 | 2.4E-02 | |
| Glycolysis / Gluconeogenesis | 4 | 4.5 | 5E-02 | |
| DOWN | Steroid biosynthesis (cholesterol biosynthesis) | 4 | 27.8 | 3.3E-04 |
| Tight junction | 6 | 5.3 | 4.6E-03 |
| Details | HR-12 (current study) | 93–11 [2] | IR-64 [3] | Kasalath [4] | Nipponbare [1] |
| Subspecies | indica | indica | indica | aus | japonica |
| Sequence depth | 73x (Illumina) and 20x (PacBio) | 4.2x (Sanger) and 36x (Illumina) | 110x (Illumina) | 6x (Roche 454) and 148X (Illumina) | 6x (Sanger), 62x (Illumina) and 2.57x (Roche 454) |
| Sequencing technologies | Illumina and PacBio | Sanger and Illumina | Illumina | Illumina and Roche 454 | Sanger, Illumina and Roche 454 |
| Genome assembler(s) | MaSuRCA and PBJelly | RePS and SOAPDenovo | ALLPATHS-LG | Celera Assembler and String Graph Assembler | TIGR Assembler |
| Genome size (Mb) | 389.77 (389.60) | 374.55 (359.41) | 345.9 (321.2) | 401.14 (328.25) | 374.47 (374.31) |
| No. of N's (Mb) | 0.17 | 15.14 | 24.7 | 72.89 | 0.17 |
| Total no. of contigs/scaffolds | 59,692 | 50,231 | 26,160 | 51,550 | NA |
| a. Anchored contigs/scaffolds | 43,781 | 35,415 | NA | 36,932 | NA |
| b. Unanchored contigs/scaffolds | 15,911 | 14,816 | NA | 14,618 | NA |
| N50 (Kb) | 28.5 | 6.69 | 22.2 | 13.73 | NA |
| No. of genes | 56,284 | 40,464 | 37,758 | 53,662 | 55,986 |
| CEG mapping (%) | 94.35 | 95.97 | 94.35 | 95.97 | 95.97 |
| Location | Posture | Interpretation |
| None | None | No heat imprint found in frame. Due to the lack of heat imprint in frame, neither location nor posture can be identified. |
| Bed | Sitting Laying | The individual is either sitting up in bed or laying in bed. The heat imprint is within bed boundaries. |
| Bedrail | Sitting Laying | The individual is either sitting on the bed with legs partly outside bed, laying in the bed on the bedrail, or sitting on the floor with parts of the upper body, e.g., arms, in the bed. The latter is interpreted as laying on the bedrail. Laying on bedrail is considered hazardous. |
| Floor | Standing Sitting Laying | The person is either standing on the floor, sitting on the floor, or laying on the floor |
| Groups | Day post-challenge | |||
| 7 | 17 | 21 | 28 | |
| PCV2 in serum | ||||
| Vaccinated group | 3 of 5 | 3 of 5 | 2 of 5 | 0 of 5 |
| Control group | 5 of 5 | 5 of 5 | 5 of 5 | 5 of 5 |
| Viral load in positive pigs | ||||
| Vaccinated group | 7.69 ± 0.11 | 7.67 ± 0.22 | 7.76 ± 0.26 | 0.00 ± 0.00 |
| Control group | 8.31 ± 0.40 | 8.41 ± 0.91 | 8.77 ± 0.55 | 7.72 ± 0.55 |
| Manufacturer | Model | AEC System | Number of Times Tested |
| GE | Discovery 670a | AutomA 3D (AutomA & SmartmA) | 2 |
| GE | Discovery 670 Proa | 1 | |
| GE | Discovery 690a | 8 | |
| GE | Discovery 710a | 1 | |
| GE | LightSpeed Ultra | 5 | |
| GE | VCT | 5 | |
| Philips | Gemini TFa | DoseRight 2.0 | 8 |
| Siemens | Definition (Dual Source) | 6 (12) | |
| Siemens | Definition AS | 8 | |
| Siemens | Definition AS+ | 3 | |
| Siemens | Definition AS+ | 1 | |
| Siemens | Definition Edge | 1 | |
| Siemens | Emotion 16 | 2 | |
| Siemens | Sensation 16 | 7 | |
| Siemens | Sensation 16 | CARE Dose 4D | 5 |
| Siemens | Sensation 64 | 6 | |
| Siemens | Sensation 64 | 7 | |
| Siemens | Sensation 64 | 6 | |
| Siemens | Sensation Openb | 8 | |
| Siemens | Sensation Openb | 6 | |
| Siemens | Sensation Openb | 7 | |
| Siemens | Symbia Ta | 2 | |
| Toshiba | Aquilion CXL | SURE Exposure 3D | 4 |
| Prostatitis | BPH | PIN | PC stage I | PC stage II | PC stage III | PC stage IV | |
| N=342 | N=282 | N=138 | N=332 | N=220 | N=48 | N=16 | |
| Albumin | |||||||
| Mean | 4 | 3.98 | 4.09 | 4.04 | 4 | 3.95 | 3.9 |
| SD | 0.38 | 0.37 | 0.37 | 0.38 | 0.42 | 0.39 | 0.42 |
| HGB * | |||||||
| Mean | 14.27 | 14.24 | 14.3 | 14.17 | 13.7 | 12.59 | 12.84 |
| SD | 1.54 | 1.76 | 1.68 | 1.66 | 1.87 | 2.2 | 14.08 |
| RBC | |||||||
| Mean | 4.67 | 4.65 | 4.76 | 4.69 | 4.63 | 4.58 | 4.5 |
| SD | 0.46 | 0.52 | 0.52 | 0.5 | 0.57 | 0.44 | 0.67 |
| Creatinine | |||||||
| Mean | 1.25 | 1.16 | 1.2 | 1.16 | 1.15 | 1.14 | 1.13 |
| SD | 0.7 | 0.32 | 0.35 | 0.56 | 0.34 | 0.39 | 0.2 |
| PSA* | |||||||
| Mean | 8.06 | 7.99 | 7.67 | 9.7 | 14.12 | 21.85 | 44.03 |
| SD | 6.74 | 11.2 | 4.58 | 11.66 | 29.27 | 30.21 | 48.71 |
| MCV | |||||||
| Mean | 90.78 | 91.13 | 90.09 | 91.17 | 90.98 | 90.23 | 92.24 |
| SD | 4.65 | 5.35 | 5.79 | 5.05 | 6.11 | 4.18 | 4.99 |
| Bilirubin | |||||||
| Mean | 0.66 | 0.65 | 0.6 | 0.66 | 0.67 | 0.65 | 0.6 |
| SD | 0.4 | 0.3 | 0.25 | 0.35 | 0.35 | 0.34 | 0.3 |
| BUN* | |||||||
| Mean | 17.98 | 17.6 | 17.23 | 16.53 | 17.4 | 16 | 15.97 |
| SD | 6.93 | 7.9 | 6.5 | 6.56 | 6.73 | 6.74 | 4.54 |
| Platlet | |||||||
| Mean | 230.45 | 227.63 | 240.81 | 226.54 | 232.5 | 234.3 | 235.44 |
| SD | 59.16 | 61.56 | 84.31 | 62.26 | 69.25 | 68.07 | 50.76 |
| WBC | |||||||
| Mean | 7.24 | 7.11 | 7.42 | 7.19 | 7.13 | 10.41 | 7.37 |
| SD | 2.11 | 2.17 | 3.24 | 2.42 | 2.08 | 17.78 | 1.84 |
| Folate | |||||||
| Mean | 12.93 | 12.56 | 12.31 | 13.37 | 11.92 | 10.71 | 10.03 |
| SD | 5.44 | 5.78 | 5.29 | 5.25 | 5.43 | 5.44 | 4.99 |
| LDH | |||||||
| Mean | 426.91 | 424.78 | 371.84 | 404.6 | 406.41 | 392.11 | 393.33 |
| SD | 375.09 | 144.84 | 185.54 | 155.38 | 158.19 | 170.98 | 73.76 |
| 16-L | 16-O | 32-L | 32-O | 32-LT | 32-OT | |
| (n = 8) | (n = 8) | (n = 8) | (n = 8) | (n = 7) | (n = 8) | |
| Body Weight (g) | 383.8 ± 8.9 | 468.8 ± 10.6 ** | 460.8 ± 7.6 | 563.2 ± 15.2†† | 465.0 ± 14.9 | 521.4 ± 21.5 |
| HbA1c (%) | 3.04 ± 0.07 | 3.18 ± 0.06 | 3.17 ± 0.07 | 4.45 ± 0.26†† | 3.09 ± 0.13 | 3.52 ± 0.07# |
| Serum Insulin (ng/ml) | 1.5 ± 2.3 | 2.4 ± 0.8 | 1.7 ± 0.9 | 3.3 ± 1.1 | 1.6 ± 0.6 | 1.8 ± 0.2 |
| Plasma glucose in OGTT (mg/dl) | ||||||
| pre | 86.6 ± 2.2 | 100.9 ± 4.1* | 106.3 ± 3.7 | 122.3 ± 5.1† | 95.8 ± 2.0 | 98.8 ± 3.9# |
| 60 min | 131.1 ± 4.1 | 157.1 ± 14.4 | 142.5 ± 4.1 | 310.7 ± 5.0†† | 134.9 ± 1.7 | 225.6 ± 6.9## |
| 120 min | 102.6 ± 4.1 | 100.9 ± 1.9 | 101.9 ± 1.9 | 161.5 ± 4.8†† | 95.1 ± 3.1 | 98.9 ± 4.3## |
| Code | Communication items | Inpatient | Outpatient | ||||
| Explaining | Breaking bad news | Discussing with a family | Explaining a diagnosis | Managing time | Managing a difficult consultation | ||
| 1 | Announcing the duration of the consultation | x | |||||
| 2 | Establishing initial rapport | x | x | x | x | x | x |
| 3 | Setting the medical agenda | x | x | x | x | x | x |
| 4 | Introducing each other | x | |||||
| 5 | Negotiating the agenda | x | x | x | x | ||
| 6 | Announcing | x | |||||
| 7 | Exploring patient’s perspectives | x | x | x | x | x | x |
| 8 | Exploring patient’s understanding of what has happened | x | |||||
| 9 | Summarizing the context | x | x | x | x | x | x |
| 10 | Informing | x | x | x | x | x | x |
| 11 | Clarifying roles, rules | x | |||||
| 12 | Using clear language/no jargon | x | x | x | x | x | |
| 13 | Chunking and checking (by open-ended questioning, reflecting, silence) | x | x | x | x | x | x |
| 14 | Empathy/legitimating | x | x | x | x | x | x |
| 15 | Making information circulate between participants | x | |||||
| 16 | Being supportive | x | x | x | x | x | x |
| 17 | Summarizing | x | x | x | x | x | x |
| 18 | Planning the future | x | x | x | x | x | x |
| 19 | Remaining calm | x | x | ||||
| 20 | Checking patient’s understanding at the end | x | x | x | x | ||
| 21 | Non verbal | x | x | x | x | x | x |
| 22 | Defining the limits | x | x | ||||
| 23 | Negotiating a common solution with the patient | x | x | ||||
| 24 | Maintaining the frame | x | x | ||||
| 25 | Acknowledging the problem | x | |||||
| 26 | Apologizing | x |
| Histopathology | Pediatrics | Adults | All patients |
| n (%) | |||
| Pineal region tumors | 4 (10) | 2 (5) | 6 (14) |
| Colloid cyst | - | 6 (14) | 6 (14) |
| Pilocytic astrocytoma | 3 (10) | 2 (5) | 5 (12) |
| Central neurocytoma | 1 (2) | 4 (10) | 5 (12) |
| Glioblastoma | 1 (2) | 3 (7) | 4 (10) |
| Atypical teratoid rhabdoid tumor | 3 (7) | - | 3 (7) |
| Ependymoma | - | 2 (5) | 2 (5) |
| Meningioma | - | 2 (5) | 2 (5) |
| Lymphoma | - | 1 (2) | 1 (2) |
| Choroid plexus papilloma | 1 (2) | - | 1 (2) |
| Anaplastic ependymoma | 1 (2) | - | 1 (2) |
| Anaplastic astrocytoma | 1 (2) | - | 1 (2) |
| Mature teratoma | 1 (2) | - | 1 (2) |
| Anaplastic oligodendroglioma | - | 1 (2) | 1 (2) |
| Craniopharyngioma | - | 1 (2) | 1 (2) |
| Glioneuronal tumor | 1 (2) | - | 1 (2) |
| Langerhans cell histiocytosis | 1 (2) | - | 1 (2) |
| Total | 18 | 24 | 42 |
| Visual area | Raw N PV | Corrected N PV | Raw N dual-labeled | Corrected N dual-labeled | % dually-labeled |
| V1 | 293 | 205 | 235 | 164 | 80 |
| MT | 293 | 205 | 218 | 153 | 75 |
| Variable | Total of patients or mean value |
| Gender | |
| Female | 624 (41,8%) |
| Male | 868 (58,2%) |
| Gestational age (weeks) | |
| 28 | 18 (1,2%) |
| [28–32[ | 85 (5,7%) |
| [32–34[ | 93 (6,2%) |
| [34–37[ | 364 (24,4%) |
| ≥37 | 932 (62,5%) |
| Birth weight (g) | |
| <750 | 12 (0,8%) |
| [750–1000[ | 14 (0,9%) |
| [1000–1500[ | 72 (4,8%) |
| [1500–2500[ | 464 (31,1%) |
| [2500–4000[ | 881 (59,1%) |
| ≥4000 | 49 (3,3%) |
| Mode of delivery | |
| Cesarean section | 721 (48,3%) |
| Vaginal delivery | 771 (51,7%) |
| Mechanical ventilation | |
| Invasive | 52 (3,5%) |
| Noninvasive | 45 (3,0%) |
| Both modalities | 151 (10,1%) |
| Phototherapy | 675 (45,2%) |
| Parenteral nutrition | 221 (14,8%) |
| Total (£) | |
| Trial Website: | |
| Implementation of the consent process and the randomization and group assignment system | 470 |
| Implementation of the primary and secondary outcome questionnaires, including the code | 1,410 |
| Basic e-mail reminders system and follow-up questionnaires system | 1,645 |
| Control Website: | |
| Implementation of the control site (estimated about 15-20 pages of information) | 1,645 |
| Intervention Website: | |
| Implementation of the three modules, based on restructuring some old content and adding more new content provided by research team | 5,875 |
| SUB TOTAL: | 11,045 |
| Technical consultancy & project management | 7,050 |
| AGREED SPEND AT OUTSET: | 18,095 |
| VAT @ 17.5% | 3,167 |
| TOTAL | 21,262 |
| Acinetobacter baumanii (N = 59) | Escherichia coli (N = 92) | Klebsiella pneumoniae (N = 92) | Pseudomonas aeruginosa (N = 26) | Non-typhoidal Salmonella (N = 20) | ||||||
| Antimicrobial | No isolates tested | No (%) Susceptible | No isolates tested | No (%) Susceptible | No isolates tested | N (%) Susceptible | No isolates tested | N (%) Susceptible | No isolates tested | N (%) Susceptible |
| Ampicillin | – | – | 91 | 9 (9.9) | 92 | – | – | – | 20 | 19 (95) |
| Co-amoxyclava | – | – | 89 | 43 (48.3) | 91 | 27 (29.7) | – | – | 1 | 1 (100) |
| Ceftriaxone | – | – | 90 | 59 (65.6) | 88 | 20 (22.7) | – | – | 20 | 20 (100) |
| Ceftazidime | 59 | 24 (40.7) | 91 | 60 (65.9) | 91 | 20 (22) | 26 | 23 (88.5) | 1 | 1 (100) |
| Ciprofloxacin | 59 | 45 (76.3) | 87 | 70 (80.5) | 85 | 52 (61.2) | 26 | 15 (57.7) | 19 | 18 (94.7) |
| Piperacillin-tazobactam | 58 | 10 (17.2) | 6$ | 5 (83.3) | 49$ | 34 (69.4) | 7$ | 1 (14.3) | 1$ | 1 (100) |
| Gentamicin | 59 | 27 (45.8) | 91 | 64 (70.3) | 89 | 25 (28.1) | 25 | 15 (60) | – | – |
| Amikacin | 58 | 26 (44.8) | 92 | 77 (83.7) | 91 | 70 (76.9) | 26 | 16 (61.5) | – | – |
| Meropenem | 56 | 26 (46.4) | 92 | 92 (100) | 92 | 92 (100) | 26 | 22 (84.6) | 20 | 20 (100) |
| Imipenem | 49 | 27 (55.1) | 90 | 90 (100) | 90 | 90 (100) | 26 | 21 (80.8) | 20 | 20 (100) |
| Ertapenem | 92 | 92 (100) | 91 | 91 (100) | – | – | 20 | 20 (100) | ||
| Colistin | 59 | 59 (100) | 90 | 90 (100) | 89 | 89 (100) | 26 | 23 (88.5) | – | – |
| Parameter | HR point estimate | 95% CI | p-value |
| Continuous variables | |||
| Age (years)* | 1.05 | 0.81-1.37 | 0.722 |
| Gleason score | 0.82 | 0.71-0.96 | 0.012 |
| PSA# | 1.00 | 0.89-1.13 | 0.001 |
| Linear interaction term with time° | 1.03 | 1.01-1.06 | |
| ALP# | 1.07 | 0.99-1.16 | 0.074 |
| LDH# | 1.22 | 1.02-1.46 | 0.027 |
| Categorical variables | |||
| Staging at diagnosis | |||
| M0 | 1 | ||
| M1 | 0.92 | 0.59-1.45 | 0.733 |
| Metastatic sites | |||
| Bone only | 1 | ||
| Other | 0.80 | 0.40-1.59 | 0.526 |
| Statement | Online simulator superior | Equivalent | Atlas or lecture superior | Unsure |
| Learning tympanic membrane anatomy | 45.5% | 45.5% | 0.0% | 9.1% |
| Learning external auditory canal anatomy | 63.6% | 36.4% | 0.0% | 0.0% |
| Learning otoscopy technique | 63.6% | 27.3% | 0.0% | 9.1% |
| Availability of training technique | 54.5% | 9.1% | 27.3% | 9.1% |
| LncRNA name | Target | Cell type | Organism/system |
| FAL1 | p21 | Cancer cells | Human/in vitro |
| BANCR | p21 | Colorectal cancer cells | Human/in vitro |
| LINCRNA-p21 | p21 | Mouse embryonic fibroblasts | Mouse/in vivo and in vitro |
| MALAT1 | p53 | Human osteosarcoma cells | Human/in vitro |
| 7SL | p53 | HeLa cells | Human/in vitro |
| VAD | INK4 locus/p16INK4a | hTERT-immortalized WI38 human fibroblasts | Human/in vitro |
| ANRIL | INK4 locus/p16INK4a | WI38 cell line | Human/in vitro |
| MIR31HG | INK4 locus/p16INK4a | Immortalized human diploid fibroblasts, TIG3-hTERT | Human/in vitro |
| UCA1 | p16INK4a mRNA | Mouse primary cells | Mouse/in vitro |
| SAL-RNA | p53 | WI38 cell line (old versus young) | Human/in vitro |
| SALNR | NF-90 localization | Human fibroblast cells | Human/in vitro |
| TERRA | Telomere length | Mammalian cells and medulloblastoma | |
| ASNCMTRNA2 | hsa-miR-4485 | Human endothelial cells | Human/in vitro |
| HOTAIR | E3 ubiquitin ligase and PRC2 | Ovarian cancer cells and HeLa cells | Human/in vitro |
| PANDA | PRC1 and PRC2 recruitment | Primary human diploid fibroblast strains, BJ (neonatal foreskin), and WI38 (fetal lung) | Human/in vitro |
| Proportion of reps. meeting: | |||||||||
| Linkage threshold | Association threshold (avg. no. SNPs analyzed)c | Avg. no. cases analyzed | Overall power | ||||||
| Stringenta | Looseb | Stringent | Loose | Stringent | Loose | Stringent | Loose | ||
| 9 (186) | A | 0 | 0.14 | 0 (n/a) | 0 (144) | 1500 | 1500 | 0 | 0 |
| B | 0 | 0.14 | 0 (n/a) | 0 (144) | 983 | 987 | 0 | 0 | |
| C | 0.13 | 0.64 | 0.23 (48) | 0.25 (145) | 127 | 136 | 0.03 | 0.16 | |
| D | 0.83 | 0.96 | 0.01 (48) | 0 (147) | 1500 | 1500 | 0.01 | 0 | |
| E | 0.2 | 0.65 | 0.30 (48) | 0.20 (148) | 129 | 121 | 0.06 | 0.13 | |
| 11 (389) | A | 0.06 | 0.24 | 1 (52) | 1 (147) | 1500 | 1500 | 0.06 | 0.24 |
| B | 0.06 | 0.24 | 1 (52) | 1 (147) | 988 | 985 | 0.06 | 0.24 | |
| C | 0.11 | 0.62 | 1 (48) | 0.92 (147) | 258 | 273 | 0.11 | 0.57 | |
| D | 0.98 | 1 | 1 (44) | 1 (146) | 1500 | 1500 | 0.98 | 1 | |
| E | 0.23 | 0.56 | 1 (46) | 1 (147) | 281 | 290 | 0.23 | 0.56 | |
| 18 (269) | A | 0.21 | 0.64 | 1 (28) | 1 (97) | 1500 | 1500 | 0.21 | 0.64 |
| B | 0.21 | 0.64 | 1 (28) | 1 (97) | 998 | 988 | 0.21 | 0.64 | |
| C | 0.53 | 0.91 | 1 (28) | 1 (96) | 372 | 390 | 0.53 | 0.91 | |
| D | 0.73 | 0.99 | 1 (27) | 1 (95) | 1500 | 1500 | 0.73 | 0.99 | |
| E | 0.44 | 0.88 | 1 (27) | 1 (95) | 370 | 382 | 0.44 | 0.88 |
| Exp | Dilution of 2-butanone (‘X’), % | N | n | %Response | Mean (±SE) mosquito catches | Exp (B) | |
| Reference (MB5 + CO2) | Test treatment (MB5 + ‘X’) | ||||||
| 1 | 99.5 | 4 | 622 | 77.75 | 122.75 ± 5.54 | 32.75 ± 2.86 | 3.748* |
| 2 | 10 | 4 | 559 | 69.88 | 122.75 ± 5.54 | 17.00 ± 2.06 | 7.221* |
| 3 | 1.0 | 4 | 588 | 73.50 | 118.75 ± 5.45 | 28.25 ± 2.66 | 4.204* |
| 4 | 0.1 | 4 | 526 | 65.75 | 115.00 ± 5.36 | 16.50 ± 2.03 | 6.970* |
| 5 | 0.01 | 4 | 415 | 51.88 | 89.75 ± 4.74 | 14.00 ± 1.87 | 6.411* |
| 6 | 0.004 | 4 | 543 | 67.88 | 118.50 ± 5.44 | 17.25 ± 2.08 | 6.870* |
| 7 | 0.001 | 4 | 535 | 66.88 | 118.00 ± 5.43 | 15.75 ± 1.98 | 7.492* |
| 8 | 0.0004 | 4 | 483 | 60.38 | 106.50 ± 5.16 | 14.25 ± 1.89 | 7.474* |
| CS Diagnostic Kit | Microscopy | PCR | ||||||
| P. falciparum* | P. vivax | P. falciparum* | P.vivax | |||||
| Positive | Negative | Positive | Negative | Positive | Negative | Positive | Negative | |
| Positive | 54 | 2 | 59 | 0 | 56 | 0 | 59 | 0 |
| Negative | 7 | 113 | 6 | 115 | 7 | 113 | 6 | 113 |
| Sensitivity (95% IC)% | 88.52 (78.16, 94.33) | 90.77 (81.29, 95.7) | 88.89 (78.8, 94.51) | 90.77 (81.29, 95.7) | ||||
| Specificity (95% IC)% | 98.26 (93.88, 99.52) | 100 (96.77, 100) | 100 (96.71, 100) | 100 (96.71, 100) | ||||
| Positive Predictive Value (95% IC)% | 96.43 (87.88, 99.02) | 100 (93.89, 100) | 100 (93.58, 100) | 100 (93.89, 100) | ||||
| Negative Predictive Value (95% IC)% | 94.17 (88.45, 97.15) | 95.04 (89.6, 97.71) | 94.17 (88.45, 97.15) | 94.96 (89.44, 97.67) | ||||
| Diagnostic Accuracy (95% IC)% | 94.89 (90.57, 97.29) | 96.67 (92.92, 98.46) | 96.02 (92.02, 98.06) | 96.63 (92.84, 98.45) | ||||
| Cohen’s kappa (Unweighted) | 0.89 (0.74, 1.03) | 0.93 (0.78,1.07) | 0.91 (0.76, 1.06) | 0.93 (0.78, 1.07) |
| Resident | Fellow | Attending | Overall | |
| N = 46 | N = 36 | N = 94 | N = 176 | |
| Mean theory of | ||||
| Intelligence score (SD): | 3.66 (1.22) | 3.40 (1.15) | 3.66 (1.29) | 3.64 (1.22) |
| Fixed (1–3) | 20 | 19 | 45 | 84 |
| Growth (4–6) | 23 | 16 | 47 | 86 |
| Indeterminate (3.1-3.9) | 3 | 1 | 2 | 6 |
| Median errors | ||||
| Reported (IQR) by: | ||||
| Self | 1 (0, 2.75) | 0 (0,1) | 0 (0,0) | 0 (0,1) |
| Others | 3 (0,3) | 3.5 (0,4) | 1 (0,4) | 2 (0,5) |
| SNP density (k/M) | WS | BayesC | BayesD |
| 0.5 | 0.25 | 0.653 (0.223) | 0.639 (0.219) |
| 0.5 | 1.050 (0.275) | 1.047 (0.245) | |
| 1 | 1.779 (0.283) | 1.796 (0.259) | |
| 1 | 0.25 | 0.525 (0.130) | 0.517 (0.095) |
| 0.5 | 0.943 (0.138) | 0.943 (0.152) | |
| 1 | 1.720 (0.215) | 1.744 (0.182) | |
| 2 | 0.25 | 0.506 (0.138) | 0.467 (0.085) |
| 0.5 | 0.930 (0.125) | 0.909 (0.121) | |
| 1 | 1.746 (0.184) | 1.728 (0.157) | |
| 7 | 0.25 | 0.468 (0.042) | 0.449 (0.046) |
| 0.5 | 0.912 (0.074) | 0.906 (0.075) | |
| 1 | 1.798 (0.120)) | 1.802 (0.114) |
| ALL | GIST | Melanoma | |
| global-median | -0.098 | 0.344 | -0.751 |
| popLowess | -0.239 | 0.348 | -0.760 |
| Chen et al. | -0.228 | 0.315 | -0.508 |
| CGHnormaliter | -0.204 | 0.304 | -0.439 |
| Characteristic | |
| Age, years | 69.6 ± 17.0a |
| Male sex, no. (%) | 187 (61.9) |
| Smoking status | |
| Current smoker, no. (%) | 73 (24.2) |
| Pack-years for smokers | 40.1 ± 24.2a |
| Antibiotic pretreatment (%) | 61 (20.2) |
| Coexisting illnesses, no. (%) | |
| Coronary artery disease | 97 (32.1) |
| Hypertensive heart disease | 78 (25.8) |
| Congestive heart failure | 16 (5.3) |
| Peripheral vascular disease | 20 (6.6) |
| Cerebrovascular disease | 16 (5.3) |
| Renal dysfunction | 81 (26.8) |
| Liver disease | 31 (10.3) |
| Diabetes mellitus | 61 (20.2) |
| Chronic obstructive pulmonary disease | 76 (25.2) |
| Neoplastic disease | 48 (15.9) |
| History, no. (%) | |
| Cough | 270 (89.4) |
| Sputum | 221 (73.2) |
| Dyspnea | 229 (75.8) |
| Examination, no. (%) | |
| Rales | 271 (89.7) |
| Laboratory findings | |
| CRP (mg/l), median (IQ range) | 129.7 [65–211] |
| Procalcitonin (μg/l), median (IQ range) | 0.5 [0.2–2.2] |
| Leukocyte count (× 109) | 13.6 ± 6.7a |
| proADM (pmol/l), median (IQ range) | 1.1 [0.6–1.9] |
| Radiographic findings, no. (%) | |
| Pleural effusion | 37 (12.3) |
| Multilobar CAP | 53 (17.5) |
| PSI points | 99.4 ± 35.3a |
| PSI class, no. (%) | |
| I, II and III | 120 (39.7) |
| IV | 130 (43) |
| V | 52 (17) |
| Plants | Root number (mean ± SE)a | Root length (cm) (mean ± SE)b | Dry root biomass (mg) (mean ± SE)b | Shoot height (cm) (mean ± SE)b | Dry shoot biomass (mg) (mean ± SE)b |
| WT | 4.4 ± 0.5 | 28.2 ± 0.7 | 543.6 ± 14.6 | 48.0 ± 0.9 | 3093.4 ± 146.1 |
| iaaM | 13.8 ± 1.1* | 24.5 ± 0.9* | 345.3 ± 23.9* | 46.7 ± 1.5 | 2969.5 ± 73.25 |
| iaaM+CKX | 14.4 ± 1.2* | 33.7 ± 1.0* | 688.3 ± 57.3* | 47.5 ± 1.2 | 3157.7 ± 55.3 |
| Gene Symbol | Gene Name | Entrez Gene ID | Fold difference DA/Cia5a | p-value* |
| Anti-inflammatory and regulators of immune responses | ||||
| Scd1 | stearoyl-Coenzyme A desaturase 1 | 246074 | 54.62 | 0.0001 |
| Timp3 | TIMP metallopeptidase inhibitor 3 | 25358 | 11.48 | 0.000000003 |
| Adipoq | adiponectin, C1Q and collagen domain containing | 246253 | 10.96 | 0.000003 |
| Ptpn11 | protein tyrosine phosphatase, non-receptor type 11 | 25622 | 4.18 | 0.00002 |
| Cyp2j3 | cytochrome P450, family 2, subfamily j, polypeptide 3 | 313375 | 3.38 | 0.002 |
| Ptgis | prostaglandin I2 (prostacyclin) synthase | 25527 | 2.63 | 0.0003 |
| Cat | catalase | 24248 | 1.91 | 0.002 |
| Gss | glutathione synthetase | 25458 | 1.56 | 0.001 |
| Sod1 | superoxide dismutase 1, soluble | 24786 | 1.53 | 0.00002 |
| Nuclear receptors and an interacting protein | ||||
| Rxrg | retinoid X receptor gamma, Nr2b3 | 83574 | 5.39 | 0.0001 |
| Pparg | peroxisome proliferator-activated receptor gamma, Nr1c3 | 25664 | 5.32 | 0.00005 |
| Rev-erba | Nr1d1 | 252917 | 3.41 | 0.004 |
| Arp1 | Nr2f2 | 113984 | 2.45 | 0.0002 |
| Nrip1 | nuclear receptor interacting protein 1 | 304157 | 2.35 | 0.00004 |
| Thrb | thyroid hormone receptor beta, Nr1a2 | 24831 | 2.07 | 0.002 |
| Thra | thyroid hormone receptor alpha, Nr1a1 | 81812 | 1.97 | 0.001 |
| Ncor1 | nuclear receptor co-repressor 1 | 54299 | 1.89 | 0.003 |
| Rora | RAR-related orphan receptor alpha, Nr1f1 | 300807 | 1.88 | 0.0001 |
| Lxra | Liver X receptor alpha, Nr1h3 | 58852 | 1.52 | 0.0006 |
| Variable | Frequency | Median (IQR) or percentage |
| Age in years | 740 | 35 [27–42] |
| Age group | ||
| ≥45 years | 156 | 21.1 |
| <45 years | 584 | 78.9 |
| Sex | ||
| Male | 275 | 37.2 |
| Female | 465 | 62.8 |
| Marital status | ||
| Married | 278 | 37.6 |
| Divorced | 160 | 21.6 |
| Widow | 154 | 20.8 |
| Single | 51 | 6.9 |
| WHO stage | ||
| 3 & 4 | 261 | 35.3 |
| 1 & 2 | 479 | 64.7 |
| Baseline CD4 (cell/μl) | 740 | 256 [132–469] |
| Baseline CD4 group | ||
| ≤200 cell/μl | 258 | 34.9 |
| >200 cell/μl | 482 | 65.1 |
| Hemoglobin (g/dL) | 740 | 11.4 [9.7–13.1] |
| Normal HB | 452 | 61.1 |
| Anemia total | 288 | 38.9 |
| Mild anemia | 147 | 19.9 |
| Moderate anemia | 88 | 11.9 |
| Severe anemia | 53 | 7.2 |
| OI on diagnosis | ||
| Tuberculosis | 197 | 26.6 |
| Others | 543 | 73.4 |
| Outcome on ART | ||
| Median time (Mo) | 740 | 27 [17–37] |
| Dead | 86 | 11.6 |
| Alive | 654 | 88.4 |
| Strain | AltDE | AltDE1 | ||||
| Total genes in the genome | 4389 | 4748 | ||||
| Total core genes in the genome (%)a | 3631 (83) | 3631 (76) | ||||
| Total flexible genes in the genome (%)a | 758 (17) | 1117 (24) | ||||
| Comparison | Temperature (13-25°C) | Media (RM-MMG) | Media (MMG-STR) | Temperature (13-25°C) | Media (RM-MMG) | Media (MMG-STR) |
| Total genes differentially expressed (%)a | 985 (22) | 1037 (24) | 1627 (37) | 1026 (22) | 1362 (29) | 2771 (58) |
| Total core genes differentially expressed (%)b | 763 (21) | 809 (22) | 1286 (35) | 684 (19) | 978 (27) | 2143 (59) |
| Contribution of core genes to total genes differentially expressed | 77% | 78% | 79% | 67% | 72% | 77% |
| Total flexible genes differentially expressed (%)c | 222 (29) | 230 (30) | 342 (45) | 342 (30) | 384 (34) | 629 (56) |
| Contribution of flexible genes to total genes differentially expressed | 23% | 22% | 21% | 33% | 28% | 23% |
| Method | Specificity | Recall | Precision | F1 | ΔF1 |
| Robetta | 0.87 | 0.33 | 0.52 | 0.40 | ** |
| FOLDEF | 0.88 | 0.26 | 0.48 | 0.34 | -0.06 |
| KFC | 0.85 | 0.31 | 0.48 | 0.37 | -0.03 |
| MINERVA | 0.90 | 0.44 | 0.65 | 0.52 | +0.12 |
| APIS (this work) | 0.76 | 0.72 | 0.57 | 0.64 | +0.24 |
| Food (utensil) | Accuracy |
| Meat (fork and knife) | 127% |
| Sides (fork) | 82.6% |
| Soup (spoon) | 60.2% |
| Pizza (hands) | 87.3% |
| Soda (hands) | 81.7% |
| Smoothie (straw) | 57.7% |
| Total | 81.2% |
| Unst. est. | SE | St. est. | CR | |
| Harsh discipline | ||||
| Physical discipline | 1.37 | 0.30 | .82 | 4.63*** |
| Emotional discipline | 1.00 | - | .70 | - |
| Internalizing problems | ||||
| Harsh discipline | 1.45 | 0.33 | .50 | 4.35*** |
| Emotional symptoms (SDQ) | 1.00 | - | .62 | - |
| Peer problems (SDQ) | 0.52 | 0.09 | .45 | 5.64*** |
| Depressive symptoms (CDI) | 1.91 | 0.32 | .61 | 5.99*** |
| Working memory | ||||
| Harsh discipline | −2.23 | 2.19 | -.08 | −1.02 |
| Block-Tapping test forward | 1.00 | - | .83 | - |
| Block-Tapping test backward | 0.92 | 0.20 | .71 | 4.59*** |
| School performance | ||||
| Harsh discipline | −0.01 | 0.09 | -.01 | −0.12 |
| Working memory | 0.01 | 0.03 | .31 | 3.80*** |
| School grades English | 1.22 | 0.11 | .74 | 10.97*** |
| School grades Mathematics | 1.14 | 0.11 | .70 | 10.56*** |
| School grades Swahili | 1.00 | - | .61 | - |
| School grades Science | 1.35 | 0.12 | .83 | 11.51*** |
| Factor | Chi-square | Significance |
| Female sex | 255.97 | p. < 0.01 |
| Family history of osteoporosis | 3.11 | p. < 0.01 |
| Previous fracture | 1.51 | p. < 0.01 |
| Underweight | 20.04 | p. < 0.01 |
| Steroids | 7.21 | p. < 0.05 |
| Rheumatoid Arthritis | 2.86 | ns |
| Nephrolithiasis* | 3.00 | ns |
| Thyroid* | 3.85 | ns |
| Early menopause | 47.36 | p. < 0.01 |
| Amenorrhea > 12 months | 0.15 | ns |
| Ovariectomy by age 50 | 44.61 | p. < 0.01 |
| Alcohol consumption | 0.11 | ns |
| Smoking habit | 6.18 | p. < 0.05 |
| Exercise < 30 min/day | 0.17 | ns |
| Avoiding dairy products | 10.50 | p. < 0.01 |
| Exposure to sunlight | 8.85 | p. < 0.05 |
| Crohn disease* | 0.74 | ns |
| Celiac disease* | 0.31 | ns |
| Rectocolitis ulcerosa* | 0.40 | ns |
| Secondary osteoporosis* | 15.20 | p. < 0.01 |
| Telencephalon | Opctic tecta | Cerebellum | Medulla | Hypothalamus | |
| Olfactory bulbs | 1.06 | 1.02 | 1.23 | 1.15 | 1.04 |
| Telencephalon | 0.96 | 1.16 | 1.08 | 0.98 | |
| Optic tecta | 1.21 | 1.13 | 1.03 | ||
| Cerebellum | 0.93 | 0.85 | |||
| Medulla | 0.91 |
| Hospital characteristic | All hospitals (n = 51) | Score 0 to 6 (n = 17) | Score 7 to 8 (n = 9) | Score 9 to 14 (n = 16) | Score 15 to 19 (n = 9) |
| Number of hospital beds | 107 (44 to 198) | 33 (21 to 69) | 143 (101 to 198) | 122 (96 to 122) | 250 (156 to 315) |
| Number of hospital days 2009 | 31,011 (6,974 to 59,696) | 5,979 (4,061 to 14,265) | 33,964 (19,612 to 54,391) | 34,828 (24,480 to 48,239) | 79,759 (34,446 to 108,542) |
| Number of ICU beds | 16 (6 to 31) | 6 (4 to 9) | 16 (15 to 20) | 20 (10 to 31) | 38 (27 to 80) |
| Number of ICU days 2009 | 3,772 (1,284 to 8,603) | 1,200 (630 to 3,772) | 3,759 (3,224 to 4,784) | 5,678 (2,588 to 9,040) | 18,623 (8,219 to 31,715) |
| Part of a larger hospital network | 25 (49.0) | 4 (23.5) | 2 (22.2) | 10 (62.5) | 9 (100) |
| Critical access hospital | 8 (15.7) | 7 (41.2) | 0 (0) | 1 (6.3) | 0 (0) |
| Private, not-for-profit hospital | 30 (58.8) | 7 (41.2) | 4 (44.4) | 13 (81.2) | 6 (66.7) |
| Public, not-for-profit hospital | 17 (33.3) | 10 (58.8) | 2 (22.2) | 3 (18.8) | 2 (22.2) |
| Private, for-profit hospital | 4 (7.8) | 0 (0) | 3 (33.3) | 0 (0) | 1 (11.1) |
| Number of ICUs | 1 (1 to 1) | 1 (1 to 1) | 1 (1 to 1) | 1 (1 to 1) | 2 (2 to 2) |
| Teaching ICU | 16 (31.4) | 2 (11.8) | 3 (33.3) | 4 (25.0) | 7 (77.8) |
| Open ICU | 46 (90.2) | 17 (100) | 8 (88.9) | 15 (93.8) | 6 (66.7) |
| Computerized provider order entry | 12 (23.5) | 2 (11.8) | 2 (22.2) | 2 (12.5) | 6 (66.7) |
| Variable | Odds ratio | 95% confidence interval |
| Sex | ||
| Male | 1.00 | — |
| Female | 2.93 | 1.29–6.67 |
| Posttest HIV counselling | ||
| No | 1.00 | — |
| Yes | 2.96 | 1.22–7.19 |
| Used contraception to prevent risk of transmission of HIV to partner | ||
| No | 1.00 | — |
| Yes | 2.30 | 1.01–5.20 |
| Used contraception due to partner's preference | ||
| No | 1.00 | — |
| Yes | 2.76 | 1.08–7.06 |
| Last CD4 cell count (per increase of 50 cells/mL) | 0.73 | 0.62–0.87 |
| European Americans | African Americans | Mexican Americans | ||||
| With noise (%) | Denoised (%) | With noise (%) | Denoised (%) | With noise (%) | Denoised (%) | |
| Europe | 100 | 100 | 97 | 94 | 100 | 98 |
| Africa | 1 | 0 | 99 | 99 | 91 | 80 |
| America | 29 | 7 | 32 | 10 | 100 | 100 |
| East Asia | 1 | 0 | 20 | 4 | 76 | 27 |
| Oceania | 6 | 0 | 10 | 3 | 18 | 0 |
| Central Asia | 11 | 1 | 30 | 3 | 38 | 7 |
| MM mean (SD) | PA mean (SD) | Comparison mean (SD) | Statistics | Paired Comparisons* | |
| MANCOVA | Multivariate Test: Wilk's λ (6, 110) = .754; p < 0.015 | ||||
| Composite MCMI | 385.22 (136.66) | 395.68 (123.02) | 243.74 (63.96) | Univariate F = 5.11, df = 2, p < 0.009 | A, B |
| Cluster A | 67.89 (32.27) | 71.41 (33.85) | 39.52 (18.9) | Univariate F = 2.58, df = 2, p = 0.084 | |
| Cluster B | 179.39 (63.7) | 187.78 (55.64) | 116.43 (33.42) | Univariate F = 6.19, df = 2, p = 0.004 | A, B |
| Cluster C | 137.94 (45.94) | 136.50 (40.16) | 87.78 (21.75) | Univariate F = 4.28, df = 2, p = 0.019 | A, B |
| f | 1/2 | 5/8 | 3/4 | 7/8 | 1 |
| model A: simple | 69 | 59 | 47 | 32 | 16 |
| model B: treated class | 62 | 53 | 42 | 31 | 19 |
| model C: day care | 80 | 73 | 62 | 43 | 20 |
| model E: dual transmission | 79 | 71 | 61 | 47 | 29 |
| WT-NFD | Pr2x7−/−-NFD | WT-HFD | Pr2x7−/−-HFD | |
| Body weight, g | 31.8 ± 2.3 | 32.6 ± 1.9 | 41.2 ± 5.5∗ | 40.6 ± 1.5∗ |
| Glucose, mmol·l−1 | 5.56 ± 0.88 | 5.63 ± 0.73 | 9.01 ± 0.71∗ | 8.85 ± 1.08∗ |
| Insulin, pmol·l−1 | 63.9 ± 18.7 | 58.3 ± 11.5 | 158.1 ± 18.1∗ | 151.9 ± 19.1∗ |
| HOMA-IR | 2.21 ± 0.79 | 2.05 ± 0.56 | 8.84 ± 1.32∗ | 8.38 ± 1.86∗ |
| Cholesterol, mmol·l−1 | 2.64 ± 0.31 | 2.62 ± 0.54 | 3.93 ± 0.62∗ | 3.82 ± 0.31∗ |
| Triglycerides, mmol·l−1 | 0.56 ± 0.21 | 0.57 ± 0.17 | 1.78 ± 0.52∗ | 1.42 ± 0.29∗ |
| FFA, mEq·l−1 | 0.33 ± 0.05 | 0.31 ± 0.06 | 0.95 ± 0.11∗ | 0.83 ± 0.09∗ |
| AST, UI·l−1 | 33.6 ± 5.6 | 31.3 ± 4.6 | 87.1 ± 12.3∗ | 55.9 ± 7.1∗† |
| ALT, UI·l−1 | 22.6 ± 7.2 | 18.6 ± 3.6 | 111.4 ± 18.4∗ | 58.3 ± 15.7∗† |
| Treatment | Dose (mg/kg) | Reversibility study | ||||||||
| Liver | Kidney | Lungs | Heart | Testes | Spleen | Pancreas | Brain | Ovaries | ||
| Distilled water | (10 ml/kg) | 2.60 ± 0.11 | 0.57 ± 0.01 | 0.73 ± 0.06 | 0.36 ± 0.02 | 1.39 ± 0.13 | 0.29 ± 0.01 | 0.25 ± 0.03 | 0.78 ± 0.03 | 0.12 ± 0.00 |
| DAS-77 | 80 | 2.53 ± 0.12 | 0.55 ± 0.03 | 0.68 ± 0.03 | 0.35 ± 0.02 | 1.21 ± 0.05 | 0.25 ± 0.01 | 0.24 ± 0.02 | 0.82 ± 0.04 | 0.10 ± 0.01 |
| DAS-77 | 400 | 2.74 ± 0.12 | 0.62 ± 0.01 | 0.88 ± 0.0* | 0.42 ± 0.03 | 0.95 ± 0.27 | 0.25 ± 0.01 | 0.26 ± 0.02 | 0.71 ± 0.04 | 0.12 ± 0.01 |
| DAS-77 | 2000 | 2.79 ± 0.10 | 0.63 ± 0.05 | 0.83 ± 0.02 | 0.38 ± 0.03 | 1.35 ± 0.28 | 0.27 ± 0.02 | 0.34 ± 0.02 | 0.82 ± 0.04 | 0.14 ± 0.01 |
| Baseline | Week 12 | Percentage change (%)# | Baseline vs. week 12 p-value | |
| hsCRP [mg/dL] | ||||
| PTV | 0.17 ± 0.2 | 0.14 ± 0.21 | −28.6 ± 157.4 | 0.08 |
| ATV | 0.33 ± 1.1 | 0.19 ± 0.38 | −10.8 ± 124.9 | 0.38 |
| CPK [U/L] | ||||
| PTV | 125.4 ± 64.6 | 153.2 ± 252.7 | 22.3 ± 140.6 | 0.13 |
| ATV | 130.9 ± 81.1 | 142.7 ± 90.8 | 17.8 ± 45.8 | 0.0001 |
| AST [U/L] | ||||
| PTV | 27.5 ± 10.7 | 28.3 ± 13.6 | 5.9 ± 29.3 | 0.05 |
| ATV | 26.8 ± 7.1 | 27.4 ± 8.5 | 4.5 ± 24.9 | 0.07 |
| ALT [U/L] | ||||
| PTV | 31.5 ± 17.9 | 32.1 ± 19.5 | 6.7 ± 33.8 | 0.06 |
| ATV | 30.6 ± 15.1 | 31.1 ± 14.3 | 10.5 ± 39.9 | 0.008 |
| Gamma GT [U/L] | ||||
| PTV | 37.6 ± 37 | 34.8 ± 25.6 | −5.6 ± 29.9 | 0.07 |
| ATV | 36.8 ± 27.5 | 37. ± 27.1 | 6.2 ± 32.3 | 0.05 |
| Total bilirubin [mg/dL]** | ||||
| PTV | 0.8 ± 0.3 | 0.7 ± 0.3 | −0.9 ± 31.8 | 0.77 |
| ATV | 0.8 ± 0.3 | 0.9 ± 0.4 | 14.0 ± 43.0 | 0.001 |
| BUN [mg/dL] | ||||
| PTV | 15.7 ± 3.6 | 16.4 ± 4.0 | 5.2 ± 22.0 | 0.02 |
| ATV | 15.7 ± 3.9 | 16.1 ± 4.5 | 4.2 ± 19.8 | 0.03 |
| Serum creatinine [mg/dL] | ||||
| PTV | 0.8 ± 0.2 | 0.8 ± 0.2 | −1.2 ± 9.9 | 0.24 |
| ATV | 0.8 ± 0.2 | 0.8 ± 0.2 | −0.7 ± 10.7 | 0.54 |
| LDH [U/L] | ||||
| PTV | 192.0 ± 31.7 | 189.7 ± 33.8 | −0.3 ± 14.6 | 0.84 |
| ATV | 193.8 ± 38.4 | 195.3 ± 47.7 | 1.3 ± 17.9 | 0.45 |
| Variables | PITC acceptance status | ||
| Yes (%) | No (%) | Total (%) | |
| Age | |||
| ≤19 | 85 (81.7) | 19 (18.3) | 104 (26.9) |
| 20–29 | 181 (81.9) | 40 (18.1) | 221 (57.3) |
| 30–45 | 46 (75.4) | 15 (24.6) | 61 (15.8) |
| Residence | |||
| Urban | 235 (78.9) | 63 (21.1) | 298 (74.6) |
| Rural | 77 (87.5) | 11 (12.5) | 88 (25.4) |
| Religion | |||
| Orthodox christians | 130 (78.8) | 35 (21.2) | 165 (42.7) |
| Muslim | 137 (82.0) | 30 (18.0) | 167 (43.3) |
| Protestant | 40 (81.6) | 9 (18.4) | 49 (12.7) |
| Catholic | 5 (100) | 0 (0.0) | 5 (1.3) |
| Ethnicity | |||
| Berta | 78 (87.6) | 11 (12.4) | 89 (23.1) |
| Amhara | 133 (76.0) | 42 (24.0) | 175 (45.3) |
| Oromo | 53 (81.5) | 12 (18.5) | 65 (16.8) |
| Othersa | 48 (84.2) | 9 (15.8) | 57 (14.7) |
| Educational status | |||
| Not able to read and write | 37 (78.7) | 10 (21.3) | 47 (12. 2) |
| Able to read and write | 31 (77.5) | 9 (22.5) | 40 (10.4) |
| Grade 1–8 | 70 (79.5) | 18 (20.5) | 88 (22.8) |
| Grade 9–12 | 72 (76.6) | 22 (23.4) | 94 (24.4) |
| Above 12 | 102 (87.2) | 15 (12.8) | 117 (30.3) |
| Occupation | |||
| Merchant | 29 (90.6) | 3 (9.4) | 32 (8.3) |
| Farmer | 49 (84.5) | 9 (15.5) | 58 (15.0) |
| Employedb | 105 (85.4) | 18 (14.6) | 123 (31.9) |
| Student | 25 (89.3) | 3 (10.7) | 28 (7.3) |
| Housewife | 104 (71.7) | 41 (28.3) | 145 (37.6) |
| Marital status | |||
| Unmarried | 8 (66.7) | 4 (33.3) | 12 (3.1) |
| Married/living together | 303 (83.2) | 68 (16.8) | 364 (96.1) |
| Divorced | 1 (33.3) | 2 (66.7) | 3 (0.8) |
| Household expenditur (Birr/month) | |||
| No response | 78 (81.2) | 18 (18.8) | 96 (24.9) |
| <1000 | 70 (83.7) | 24 (16.3) | 94 (24.4) |
| ≥1000 | 164 (74.5) | 32 (24.4) | 196 (50.8) |
| Week | Direct heritability | Indirect heritability | Total heritability |
| 1 | 0.17 (0.03) | 0.44 (0.13) | 0.19 (0.10) |
| 2 | 0.24 (0.03) | 0.23 (0.07) | 0.09 (0.06) |
| 3 | 0.22 (0.02) | 0.18 (0.06) | 0.05 (0.04) |
| 4 | 0.15 (0.02) | 0.16 (0.06) | 0.06 (0.04) |
| 5 | 0.08 (0.02) | 0.18 (0.11) | 0.12 (0.10) |
| Principle parameter | EACM | EAC | |||||
| Case number | Eradication rate (%) | P value | Case number | Eradication rate (%) | P value | ||
| Age | <60 years | 75/78 | 96.1 | 0.578 | 52/64 | 81.2 | 0.496 |
| ≥60 years | 13/14 | 92.8 | 21/28 | 75.0 | |||
| Sex | Female | 44/47 | 93.6 | 0.328 | 33/46 | 71.1 | 0.071 |
| Male | 44/45 | 97.8 | 40/46 | 86.9 | |||
| Smoking | (−) | 74/78 | 94.9 | 0.386 | 61/78 | 78.2 | 0.523 |
| (+) | 14/14 | 100.0 | 12/14 | 85.7 | |||
| Alcohol consumption | (−) | 69/72 | 95.8 | 0.872 | 61/78 | 78.2 | 0.523 |
| (+) | 19/20 | 95.0 | 12/14 | 85.7 | |||
| Previous history of peptic ulcer | (−) | 74/78 | 94.9 | 0.386 | 57/73 | 78.1 | 0.557 |
| (+) | 14/14 | 100.0 | 16/19 | 84.2 | |||
| Compliance | Good | 92/92 | 100.0 | — | 92/92 | 100.0 | — |
| Poor | 0 | 0 | 0 | 0 | |||
| H. pylori culture (n = 68) | |||||||
| Amoxicillin | Susceptible | 31/34 | 91.2 | — | 15/33 | 45.4 | 0.367 |
| Resistance | 0 | — | 0/1 | 0 | |||
| Clarithromycin | Susceptible | 29/30 | 96.7 | 0.002 | 15/15 | 100 | <0.001 |
| Resistance | 2/4 | 50.0 | 0/19 | 0 | |||
| Metronidazole | Susceptible | 23/23 | 100 | 0.009 | 11/24 | 45.8 | 0.755 |
| Resistance | 8/11 | 72.7 | 4/10 | 40.0 | |||
| Dual resistance | Absent | 30/31 | 96.8 | <0.001 | 15/28 | 53.6 | <0.001 |
| Present | 1/3 | 33.3 | 0/6 | 0 |
| Amino acid | No. residues/100 residues |
| Arginine | 7.12 |
| Histidine | 3.39 |
| Isoleucine | 3.76 |
| Leucine | 7.71 |
| Lysine | 9.18 |
| Methionine | 3.52 |
| Phenylalanine | 4.46 |
| Threonine | 4.67 |
| Tryptophan | 0.19 |
| Valine | 5.17 |
| Indispensable AA (IAA) | 49.16 |
| Alanine | 5.70 |
| Aspartic acid | 10.45 |
| Cystine | 1.05 |
| Glutamic acid | 15.72 |
| Glycine | 6.56 |
| Proline | 3.61 |
| Serine | 4.10 |
| Tyrosine | 3.65 |
| Dispensable AA (DAA) | 50.84 |
| Anatomical region | BA | x | y | z | Z-value | Extent |
| R lingual/paraH gyrus | 19/30 | 18 | −51 | −3 | 5.03 | 109 |
| R lingual gyrus | 19 | 18 | −59 | −5 | 3.54 | |
| L lingual/paraH gyrus | 19/30 | −16 | −47 | −3 | 4.91 | 227 |
| −8 | −62 | 0 | 3.50 | |||
| L post. cingulate gyrus | 23/31 | −12 | −56 | 12 | 3.50 | |
| Lingual gyrus | 19/18 | 4 | −58 | 1 | 3.63 | 16 |
| R posterior insula/TTG | 41 | 38 | −17 | 16 | 4.49 | 45 |
| L superior temporal gyrus | 22 | −50 | −24 | 16 | 4.07 | 38 |
| L MidFG/frontal pole | 10 | −34 | 51 | 16 | 4.00 | 21 |
| L mPFC/ACC | 10 | −8 | 43 | 14 | 3.97 | 17 |
| L anterior cingulate cortex | 32 | −14 | 34 | 19 | 3.87 | 20 |
| −22 | 36 | 15 | 3.18 | |||
| Anterior cingulate cortex | 32/24 | 0 | 47 | 0 | 3.39 | 14 |
| L inferior frontal gyrus | 44/45 | −34 | 11 | 16 | 3.85 | 16 |
| mPFC/frontal pole | 10 | −4 | 65 | 12 | 3.85 | 11 |
| R MidFG/frontal pole | 10 | 40 | 47 | 12 | 3.63 | 15 |
| L precuneus | 7 | −16 | −76 | 42 | 4.42 | 78 |
| L posterior cingulate | 31 | −12 | −33 | 31 | 4.19 | 13 |
| R precuneus | 7 | 12 | −72 | 40 | 3.76 | 44 |
| 14 | −62 | 42 | 3.60 | |||
| 12 | −68 | 48 | 3.35 | |||
| Cuneus | 17/31 | 0 | −71 | 11 | 3.44 | 10 |
| Precuneus/post. cingulate | 31/23 | −2 | −63 | 25 | 3.37 | 41 |
| 31/23 | −2 | −68 | 33 | 3.35 | ||
| R IPL/angular g./TPJ | 40/39 | 40 | −62 | 38 | 3.71 | 25 |
| 34 | −68 | 42 | 3.33 | |||
| L MTG/angular g./TPJ | 39 | −34 | −65 | 29 | 3.71 | 22 |
| L IPL/angular g./TPJ | 40/39 | −51 | −60 | 40 | 3.65 | 17 |
| R hippocampus/ParaH g. | 30/19 | 24 | −39 | −6 | 3.65 | 26 |
| L superior temporal gyrus | 22/42 | −61 | −26 | 16 | 3.59 | 15 |
| Dataset | Number of sequences |
| GATA1 | 14,351 |
| SOX2 | 4526 |
| OCT4 | 3761 |
| STAT3 | 2546 |
| KLF1 | 945 |
| Locations of lesion | Group 1 | Group 2 | p value |
| RIV | (1/1) 100.00% | (2/2) 100.00% | - |
| RSCV | (0/0) 0.00% | (2/2) 100.00% | - |
| SVC | (1/1) 100.00% | (3/3) 100.00% | - |
| IJV+ SVC | (1/1) 100.00% | (0/1) 0.00% | - |
| RIV + SVC | (0/2) 0.00% | (3/4) 75.00% | 0.350 |
| RSCV + RIV | (0/2) 0.00% | (2/3) 66.67% | 0.361 |
| RSCV + RIV + SVC | (1/2) 50.00% | (2/3) 66.67% | 0.709 |
| LIV | (1/2) 50.00% | (2/2) 100.00% | 0.171 |
| LSCV | (1/1) 100.00% | (2/2) 100.00% | - |
| LIV + SVC | (1/2) 50.00% | (3/3) 100.00% | 0.171 |
| LSCV + LIV | (2/3) 66.67% | (2/3) 66.67% | - |
| LSCV + LIV + SVC | (0/1) 0.00% | (1/2) 50.00% | - |
| Total | (9/19) 47.36% | (25/30) 83.33% | 0.012 |
| Variables | Group 1 ISH positiveN = 10 | Group 2 ISH negative N = 15 | P |
| Patient age at LT | 49 ±11 | 52 ±11 | .66 |
| Female gender (patient) | 40% | 13% | .13 |
| Caucasian (patient) | 90% | 87% | .69 |
| Recipient body mass index | 31 ±7 | 29 ±6 | .51 |
| MELD at LT | 14 ±5 | 18 ±9 | .42 |
| Genotype 1 (unknown in 1 patient per group) | 56% | 86% | .11 |
| Donor age | 47 ±13 | 43 ±14 | .82 |
| Female gender (donor) | 40% | 53% | .51 |
| Caucasian (Donor) | 90% | 67% | .34 |
| Cold ischemia time, hours | 7 ±2 | 7 ±2 | .74 |
| Warm ischemia time, minutes | 39 ±9 | 34 ±10 | .28 |
| Tacrolimus as primary immune suppressant | 100% | 83% | .23 |
| Steroid bolus treated ACR | 30% | 40% | .61 |
| LT to ISH biopsy interval, months | 23 ±10 | 24 ±12 | .91 |
| S1 | S2 | S3 | S4 | Id | Neuro-Fuzzy output |
| 6752 | 6664 | 6577 | 6490 | 0 | 0.7655 |
| 6664 | 6577 | 6490 | 6404 | 0 | 0.7383 |
| 6577 | 6490 | 6404 | 6320 | 0 | 0.7004 |
| 6490 | 6404 | 6320 | 6236 | 0 | 0.6653 |
| 6404 | 6320 | 6236 | 6153 | 0 | 0.6348 |
| 6320 | 6236 | 6153 | 6072 | 0 | 0.5904 |
| 6236 | 6153 | 6072 | 5992 | 0 | 0.5428 |
| Experiment | ∆6 | REG19 | TS01 |
| 1 | 0 | 11 | 120 |
| 2 | 0 | 64 | 714 |
| 3 | 4 | 111 | 445 |
| 4 | no data | no data | 599 |
| average | 133 | 6200 | 42,633 |
| Males | Females | |||||||||
| % (n/N) | PRb | 95% CI | PRc | 95% CI | % (n/N) | PRc | 95% CI | PRb | 95% CI | |
| Baseline | ||||||||||
| Overweight/Obese | ||||||||||
| Primary School | ||||||||||
| Low PA School | 14 (51/371) | 1.0 | Ref | 1.0 | Ref | 12 (48/417) | 1.0 | Ref | 1.0 | Ref |
| Med PA School | 10 (48/460) | 0.76 | (0.52–1.11) | 0.80 | (0.57–1.12) | 13 (60/455) | 1.15 | (0.81–1.61) | 1.14 | (0.80–1.62) |
| High PA School | 11 (53/503) | 0.77 | (0.55–1.06) | 0.77 | (0.56–1.07) | 13 (59/472) | 1.09 | (0.80–1.48) | 1.10 | (0.83–1.47) |
| ptrend | 0.13 | 0.14 | 0.62 | 0.51 | ||||||
| Secondary School | ||||||||||
| Low PA School | 9 (40/440) | 1.0 | Ref | 1.0 | Ref | 12 (51/442) | 1.0 | Ref | 1.0 | Ref |
| Med PA School | 11 (55/485) | 1.25 | (0.78–1.99) | 1.27 | (0.86–1.88) | 13 (57/456) | 1.08 | (0.72–1.63) | 1.15 | (0.80–1.65) |
| High PA School | 11 (68/622) | 1.20 | (0.82–1.76) | 1.14 | (0.79–1.64) | 13 (69/532) | 1.12 | (0.80–1.59) | 1.15 | (0.81–1.64) |
| ptrend | 0.39 | 0.59 | 0.50 | 0.44 | ||||||
| Follow-Up | ||||||||||
| Overweight/Obese | ||||||||||
| Low PA School | 59 (123/208) | 1.0 | Ref | 1.0 | Ref | 39 (92/239) | 1.0 | Ref | 1.0 | Ref |
| Med PA School | 66 (169/254) | 1.13 | (0.97–1.30) | 1.10 | (0.97–1.25) | 38 (96/250) | 1.00 | (0.78–1.28) | 0.98 | (0.79–1.22) |
| High PA School | 63 (182/288) | 1.07 | (0.93–1.23) | 1.08 | (0.95–1.23) | 41 (110/270) | 1.06 | (0.83–1.34) | 1.04 | (0.84–1.28) |
| ptrend | 0.46 | 0.33 | 0.63 | 0.63 |
| Pin | I/O Attached | Action | States |
| L0 | Red LED | move | |
| L1 | Green LED | turn | |
| L2 | Orange LED | gripper is open | |
| L4 | Yellow LED | bottle is collected | |
| L3 | Switch A | touching | |
| L5 | Switch B | see drop | |
| L6 | Switch C | see bottle | |
| L7 | Switch D | over drop |
| 12-15 weeks old | Symptomatic | ||
| WT | SOD1a | SOD1b | |
| n (fiber, mice) | 30, 11 | 19, 8 | 20, 10 |
| Males | 17, 5 | 11, 4 | 10, 5 |
| Females | 13, 6 | 8, 4 | 10,5 |
| Age range (days) | 89-108 | 94-107 | 94-102 |
| RMP (mV) | -64.8 ± 2.50 | -64.4 ± 2.05 | -67.1 ± 2.67 |
| EPPs amplitude (mV) | 21.0 ± 2.45 | 11.4 ± 2.00 #WT | 24.9 ± 2.33 #SOD1a |
| EPPs amplitude NOR (mV) | 23.6 ± 2.21 | 12.8 ± 2.06 #WT | 28.1 ± 2.41 |
| Quantal contentNOR | 41.3 ± 3.79 | 32.7 ± 4.40 | 38.8 ± 3.30 |
| MEPPs amplitude (mV) | 0.50 ± 0.03 | 0.32 ± 0.02 #WT | 0.64 ± 0.02 #WT #SOD1a |
| MEPPs rise-time (ms) | 0.98 ± 0.07 | 1.39 ± 0.12 #WT | 0.93 ± 0.06 #SOD1a |
| MEPPs decay-time(ms) | 3.12 ± 0.14 | 3.12 ± 0.17 | 3.28 ± 0.20 |
| MEPPs frequency (s-1) | 0.76 ± 0.11 | 0.61 ± 0.11 | 1.26 ± 0.33 |
| N° of NMJs with GMEPPs | 16 | 3 | 17 |
| GMEPPs frequency (s-1) | 0.44 ± 0.12 | 0.07 ± 0.03 +WT | 0.38 ± 0.12 +SOD1a |
| Fr(GMEPPs)/Fr(MEPPs) | 1.58 ± 0.49 | 0.11 ± 0.07 +WT | 1.40 ± 0.80 |
| age (median, IQR) | Female sex (n) | FEV1 % predicted (median, IQR) | ICS dose, mcg/day (median, IQR) | Current smoker (n) | |
| AKL1 – Placebo (n = 16) | 41.00, 33.50 – 55.75 | 13 | 90.00, 79.75 – 115.50 | 1000, 400 – 2000 | 1 |
| Placebo – AKL1 (n = 16) | 35.50, 29.50 – 55.50 | 12 | 85.50, 56.50 – 110.00 | 800, 400 – 1150 | 1 |
| P value | 0.67 | 0.67 | 0.25 | 0.51 | 1.00 |
| Ancestry | Parent | Count | Mean age | ||||
| Alive | Dead | Total | Alive | Dead | All | ||
| African | Father | 2435 | 6924 | 9359 | 72.4 | 70.4 | 70.9 |
| African | Mother | 4185 | 5889 | 10,074 | 73.1 | 70.7 | 71.7 |
| European | Father | 113,611 | 178,017 | 291,628 | 62.9 | 71.2 | 68 |
| European | Mother | 150,854 | 144,144 | 294,998 | 66.2 | 75.1 | 70.5 |
| ALL | 271,085 | 334,974 | 606,059 |
| Pathway | miRNAs | Genes |
| MAPK signaling pathway | 10 | 95 |
| PI3K-Akt signaling pathway | 9 | 106 |
| Endocytosis | 10 | 72 |
| TGF-β signaling pathway | 6 | 35 |
| Wnt signaling pathway | 9 | 58 |
| Ubiquitin mediated proteolysis | 8 | 49 |
| Regulation of actin cytoskeleton | 8 | 74 |
| Gene | GeneBank accession number | Specific primer sequences (5’ to 3’) | Product size (bp) |
| αA-crystallin (CRYAA) | U05569 | F: CGGGACAAGTTCGTCATCTT | 203 |
| R: GCAGACAGGGAGCAAGAGAG | |||
| Heat-shock protein 70 (Hsp70) | NM05345 | 1F: AAGTACAAAGCGGAGGACG | 249 |
| 1R: GATGGGGTTACACACCTGC | |||
| 2F: TGCTGATCCAGGTGTACGAG | 185 | ||
| 2R: CGTTGGTGATGGTGATCTTG | |||
| Heat-shock protein 90α (Hsp90α)) | NM005348.3 | F: ACCCAGACCCAAGACCAACCG | 141 |
| R: ATTTGAAATGAGCTCTCTCAG | |||
| Superoxide dismutase (SOD) | NM000454.4 | F: AGGGCATCATCAATTTCGAGC | 430 |
| R: CAAGGGAATGTTTATTGGGCG | |||
| αB-crystallin (CRYAB) | NM001885.1 | F: TCACCTAGCCACCATGGACATCGCCA | 541 |
| R: CAAAAGCTTATTACTATTTCTTGGGGG | |||
| Metallothionein 1M (MT) | NM176870.2 | F: GCAAAGAGTGCAAATGCACCTC | 125 |
| R: TCAGGCACAGCAGCTGCACT | |||
| Interleukin-6 (IL-6) | NM000600.2 | F: CTGGTCTTTTGGAGTTTGAGGTATACC | 295 |
| R: CCATGCTACATTTGCCGAAGA | |||
| Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) | BC014085 | F: GAAGGTGAAGGTCGGAGT | 225 |
| R: GAAGATGGTGATGGGATTTC |
| Neuropsychological test | Schizophrenics high SANS-score (S1) | Schizophrenics low SANS-score (S2) | Controls (C) | Post-hoc analyses | ||||||
| Mean | SD | Mean | SD | Mean | SD | F-value1 | S1 vs. S2* | S2 vs. C* | S1 vs. C* | |
| WMS-R, logical memory I | 22,80 | 5,73 | 29,40 | 6,15 | 33,28 | 6,97 | 6,58** | n.s. | n.s. | p ≤0,01 |
| WMS-R, logical memory II | 15,70 | 5,98 | 25,10 | 5,61 | 29,63 | 8,54 | 8,34** | p ≤0,05 | n.s. | p ≤0,01 |
| NAI, wordlist trial I | 6,20 | 1,03 | 7,90 | 1,97 | 8,22 | 2,79 | 1,97 | n.s. | n.s. | n.s. |
| NAI, wordlist trial II | 8,80 | 1,93 | 10,40 | 2,07 | 11,84 | 2,48 | 4,97** | n.s. | n.s. | p ≤0,01 |
| NAI, wordlist trial III | 11,00 | 1,76 | 12,80 | 1,55 | 13,22 | 1,75 | 4,22** | n.s. | n.s. | p ≤0,01 |
| NAI, wordlist delayed | 7,90 | 3,76 | 11,40 | 2,41 | 11,91 | 3,38 | 3,7** | n.s. | n.s. | p ≤0,01 |
| HAWIE-R, information | 14,80 | 4,42 | 16,50 | 3,17 | 18,94 | 3,63 | 5,5** | n.s. | n.s. | p ≤0,01 |
| WMS-R, visual reproduction I | 37,90 | 2,96 | 37,60 | 2,01 | 39,47 | 1,68 | 3,27* | n.s. | p ≤0,05 | n.s. |
| WMS-R, visual reproduction II | 34,60 | 6,29 | 37,50 | 1,90 | 39,13 | 2,20 | 5,36** | n.s. | n.s. | p ≤0,01 |
| HAWIE-R, digit span | 15,60 | 3,17 | 14,50 | 2,80 | 17,25 | 4,53 | 1,89 | n.s. | n.s. | n.s. |
| HAWIE-R, digit span forward | 8,20 | 2,04 | 8,20 | 1,69 | 8,78 | 2,09 | 1,27 | n.s. | n.s. | n.s. |
| HAWIE-R, digit span backward | 7,40 | 1,84 | 6,30 | 1,49 | 8,47 | 2,85 | 2,34 | n.s. | n.s. | n.s. |
| Stroop interference | 84,00 | 23,08 | 90,70 | 24,22 | 63,56 | 11,97 | 7,85** | n.s. | p ≤0,01 | p ≤0,01 |
| Verbal fluency | 30,10 | 9,83 | 30,70 | 7,76 | 41,34 | 15,51 | 2,75 | n.s. | n.s. | n.s. |
| WCST, ntcc1 | 19,60 | 11,65 | 12,13 | 6,36 | 12,26 | 3,82 | 7,07** | n.s. | n.s. | p ≤0,01 |
| WCST, perseverative reactions | 14,40 | 10,16 | 25,88 | 23,01 | 12,39 | 12,60 | 2,46 | n.s. | n.s. | n.s. |
| WCST, perseverative errors | 13,10 | 8,50 | 22,63 | 18,94 | 10,88 | 10,17 | 2,77* | n.s. | p ≤0,05 | n.s. |
| Patients with diabetes | Diabetes-free comparison group | |||||||||
| Person-years | Cases | IR per 1000 person-years | 95% CI | Person-years | Cases | IR per 1000 person-years | 95% CI | IRR | 95% CI | |
| All | 284887.4 | 5802 | 20.4 | 19.8–20.9 | 284953.5 | 3087 | 10.8 | 10.5–11.2 | 1.9 | 1.8–2.0 |
| Men | 153029.5 | 2524 | 16.5 | 15.9–17.1 | 148846.7 | 1267 | 8.5 | 8.0–9.0 | 1.9 | 1.8–2.1 |
| Women | 131857.9 | 3278 | 24.9 | 24.0–25.7 | 136106.8 | 1820 | 13.4 | 12.8–14.0 | 1.9 | 1.8–2.0 |
| Age 40–44 | 9224.9 | 22 | 2.4 | 1.4–3.4 | 8675.2 | 6 | 0.7 | 0.1–1.2 | 3.4 | 1.4–8.5 |
| Age 45–49 | 25840.3 | 70 | 2.7 | 2.1–3.3 | 24085.6 | 10 | 0.4 | 0.2–0.7 | 6.5 | 3.3–12.5 |
| Age 50–54 | 37674.4 | 193 | 5.1 | 4.4–5.8 | 35173.7 | 31 | 0.9 | 0.6–1.2 | 5.8 | 4.0–8.5 |
| Age 55–59 | 44047.4 | 324 | 7.4 | 6.6–8.2 | 42089.5 | 118 | 2.8 | 2.3–3.3 | 2.6 | 2.1–3.2 |
| Age 60–64 | 46713.6 | 526 | 11.3 | 10.3–12.2 | 45310.4 | 199 | 4.4 | 3.8–5.0 | 2.6 | 2.2–3.0 |
| Age 65–69 | 43022.1 | 860 | 20.0 | 18.7–21.3 | 43263.2 | 369 | 8.5 | 7.7–9.4 | 2.3 | 2.1–2.6 |
| Age 70–74 | 34468.6 | 1111 | 32.2 | 30.3–34.1 | 36143.3 | 611 | 16.9 | 15.6–18.2 | 1.9 | 1.7–2.1 |
| Age 75–79 | 24776.3 | 1295 | 52.3 | 49.4–55.1 | 27036.8 | 782 | 28.9 | 26.9–31.0 | 1.8 | 1.7–2.0 |
| Age 80–84 | 12867.7 | 911 | 70.8 | 66.2–75.4 | 15319.3 | 601 | 39.2 | 36.1–42.4 | 1.8 | 1.6–2.0 |
| Age 85–89 | 4836.9 | 403 | 83.3 | 75.2–91.5 | 5989.4 | 290 | 48.4 | 42.8–54.0 | 1.7 | 1.5–2.0 |
| Age ≥90 | 1415.1 | 87 | 61.5 | 48.6–74.4 | 1867.0 | 70 | 37.5 | 28.7–46.3 | 1.6 | 1.2–2.2 |
| Microstructure analysis | Vehicle | SB-742457 | ||
| 3.0 mg/kg | 10 mg/kg | 30 mg/kg | ||
| Number of licks | 1456.7 (199.9) | 992.8* (255.2) | 1130.7 (249.9) | 1238.9 (278.4) |
| Bout duration (s) | 2.7 (0.5) | 1.9 (0.1) | 2.1 (0.3) | 2.0 (0.3) |
| Bout number | 97.2 (12.8) | 73.5* (17.2) | 80.1 (13.9) | 114.5 (27.3) |
| Intra-bout lick rate(licks/s) | 6.4 (0.1) | 6.4 (0.2) | 6.3 (0.2) | 5.9* (0.1) |
| Latency (s) | 84.7 (46.9) | 66.1 (28.0) | 76.1 (20.7) | 62.7 (23.9) |
| Characteristic | Doctors | Nurses |
| Sex | ||
| Female | 7 | 5 |
| Male | 8 | 0 |
| Age (years) | ||
| Mean | 37 | 45 |
| Range | 26–53 | 38–53 |
| Years of practice in total | ||
| Mean | 13 | 24 |
| Range | 1.75–29 | 16–33 |
| Years of practice in nephrology | ||
| Mean | 9 | 20 |
| Range | 0.3–26 | 15–26 |
| Pre-Delphi questionnaire | Round 1 | Round 2 | Round 3 | |
| Consumers | 16 | 13 | 13 | 9 |
| Carers | 3 | 2 | 0 | 0 |
| Professionals | 26 | 21 | 17 | 16 |
| Exposure | Cases (n = 2634) | Controls (n = 5074) | Crude OR (95%CI) | Adjusted OR† (95%CI) |
| Current use, n (%) | ||||
| Conventional NSAIDs − PPIs | 1599 (60.7) | 3013 (59.4) | 1 | 1 |
| Conventional NSAIDs + PPIs | 775 (29.4) | 1356 (26.7) | 1.08 (0.97–1.20) | 0.79 (0.68–0.92)* |
| Selective COX‐2 inhibitors − PPIs | 179 (6.8) | 487 (9.6) | 0.69 (0.58–0.83)* | 0.66 (0.48–0.89)* |
| Selective COX‐2 inhibitors + PPIs | 81 (3.1) | 218 (4.3) | 0.70 (0.54–0.91)* | 0.51 (0.35–0.73)* |
| Time | 50 Units, n = 9 | 100 Units, n = 10 | 200 Units, n = 10 | F Statistic (d.f.) a | p-Value | |||
| Mean, g | (SD) | Mean, g | (SD) | Mean, g | (SD) | |||
| Baseline | 0.54 | (0.419) | 0.58 | (0.305) | 0.53 | (0.703) | 0.58 (4) | 0.687 |
| 2 weeks | 0.27 | (0.185) | 0.28 | (0.098) | 0.34 | (0.502) | ||
| 6 weeks | 0.30 | (0.260) | 0.33 | (0.229) | 0.23 | (0.257) | ||
| 12 weeks | 0.33 | (0.287) | 0.30 | (0.237) | 0.28 | (0.403) | ||
| 24 weeks | 0.34 | (0.231) | 0.34 | (0.271) | 0.22 | (0.237) |
| Compound | Content (mg/g) | |
| Panax ginseng | Rb1 | 2.24 |
| Re | 1.13 | |
| Rg1 | 1.47 | |
| Salvia miltiorrhiza | Salvianolia acid B | 28.2 |
| Tanshinone IIA | 0.6 |
| Age group | Sex | Testosterone concentration (ng/mL) | Sex* group mean | Group mean | Sex mean | |||
| 0.10 | 1 | 10 | 100 | |||||
| Group-I | Male | 1.27 ± 0.06 | 1.04 ± 0.04 | 1.18 ± 0.04 | 1.02 ± 0.04 | 1.13 ± 0.03 | 1.04 ± 0.017 | 1.03 ± 0.01 (Male) |
| Female | 0.97 ± 0.03 | 0.94 ± 0.02 | 0.94 ± 0.02 | 0.98 ± 0.03 | 0.96 ± 0.01 | |||
| Group-II | Male | 0.95 ± 0.03 | 1.05 ± 0.03 | 0.93 ± 0.04 | 0.91 ± 0.03 | 0.96 ± 0.02 | 1.03 ± 0.017 | |
| Female | 1.11 ± 0.05 | 1.140 ± 0.04 | 1.08 ± 0.05 | 1.07 ± 0.03 | 1.10 ± 0.02 | 1.05 ± 0.01 (Female) | ||
| Group-III | Male | 0.94 ± 0.05 | 1.05 ± 0.05 | 1.06 ± 0.03 | 0.90 ± 0.03 | 0.99 ± 0.02 | 1.04 ± 0.017 | |
| Female | 1.06 ± 0.06 | 1.08 ± 0.05 | 1.12 ± 0.05 | 1.14 ± 0.09 | 1.10 ± 0.03 | |||
| Treatment mean | 1.05 ± 0.02 | 1.05 ± 0.02 | 1.05 ± 0.02 | 1.00 ± 0.02 |
| Entire cohort | PODXL neg | PODXL pos | ||
| n (%) | n (%) | n (%) | p-value | |
| 171 (100.0) | 29 (17.0) | 142 (83.0) | ||
| Age | ||||
| ≤70 | 85 (49.7) | 12 (41.4) | 73 (51.4) | 0.416 |
| >70 | 86 (50.3) | 17 (58.6) | 69 (48.6) | |
| Sex | ||||
| Female | 39 (22.8) | 9 (31.0) | 30 (21.1) | 0.330 |
| Male | 132 (77.2) | 20 (69.0) | 112 (78.9) | |
| T stage | ||||
| T1 | 18 (10.5) | 2 (6.9) | 16 (11.3) | 0.637 |
| T2 | 32 (18.7) | 6 (20.7) | 26 (18.3) | |
| T3 | 94 (55.0) | 16 (55.2) | 78 (54.9) | |
| T4 | 27 (15.8) | 5 (17.2) | 22 (15.5) | |
| N stage | ||||
| N0 | 57 (33.3) | 16 (55.2) | 41 (28.9) | 0.006 |
| N1 | 29 (17.0) | 4 (13.8) | 25 (17.6) | |
| N2 | 41 (24.0) | 6 (20.7) | 35 (24.6) | |
| N3 | 44 (25.7) | 3 (10.3) | 41 (28.9) | |
| M stage | ||||
| M0 | 152 (88.9) | 25 (86.2) | 127 (89.4) | 0.535 |
| M1 | 19 (11.1) | 4 (13.8) | 15 (10.6) | |
| R classification | ||||
| R0 | 117 (68.4) | 22 (75.9) | 95 (66.9) | 0.556 |
| R1 | 45 (26.3) | 5 (17.2) | 40 (28.2) | |
| R2 | 9 (5.3) | 2 (6.9) | 7 (4.9) | |
| Differentiation grade | ||||
| Low grade | 8 (4.7) | 4 (13.8) | 4 (2.8) | 0.023 |
| Intermediate grade | 52 (30.4) | 10 (34.5) | 42 (29.6) | |
| High grade | 111 (64.9) | 15 (51.7) | 96 (67.6) | |
| Lauren classification | ||||
| Intestinal | 119 (69.6) | 23 (79.3) | 96 (67.6) | 0.335 |
| Mixed | 9 (5.3) | 0 (0.0) | 9 (6.3) | |
| Diffuse | 43 (25.1) | 6 (20.7) | 37 (26.1) | |
| Location | ||||
| Esophagus + EG junction | 106 (62.0) | 15 (51.7) | 91 (64.1) | 0.217 |
| Stomach | 65 (38.0) | 14 (48.3) | 51 (35.9) |
| Characteristic | Non-IRABC | IRABC | Pa | ORb | 95% CIb | Pb |
| Number | 1060 | 580 | ||||
| Mean age ± SDc | 65.0 ± 20.2 | 70.0 ± 18.8 | <0.001 | |||
| Age 65 and olderc | 629 (61.1) | 401 (71.9) | <0.001 | 1.464 | 1.122-1.912 | 0.005 |
| Specimen types | ||||||
| Respiratory tracts | 481 (45.4) | 341 (58.8) | <0.001 | 2.597 | 1.888-3.570 | <0.001 |
| Blood | 192 (18.1) | 52 (9.0) | <0.001 | Reference | ||
| Pus/discharge | 160 (15.1) | 59 (10.2) | 0.005 | 1.934 | 1.240-3.018 | 0.004 |
| Urine | 140 (13.2) | 76 (13.1) | >0.99 | 2.138 | 1.401-3.263 | <0.001 |
| Healthcare settings | ||||||
| Medical centers | 507 (47.8) | 228 (39.3) | 0.001 | 0.814 | 0.631-1.049 | 0.112 |
| ICU Settings | 328 (30.9) | 272 (46.9) | <0.001 | 1.919 | 1.482-2.486 | <0.001 |
| Geographic regions | ||||||
| Northern | 336 (31.7) | 136 (23.4) | <0.001 | Reference | ||
| Central | 341 (32.2) | 286 (49.3) | <0.001 | 2.43 | 1.791-3.296 | <0.001 |
| Southern | 258 (24.3) | 85 (14.7) | <0.001 | 1.178 | 0.812-1.710 | 0.388 |
| Eastern | 125 (11.8) | 73 (12.6) | 0.635 | 2.24 | 1.489-3.370 | <0.001 |
| TSAR periodd | 2.277 | 2.054-2.523 | <0.001 |
| Group | Mean fluorescence recovery rate(%,x±s) (t=4min) |
| BGC-823Cx43 | 35.6±0.9* |
| BGC-823Cx43T154A | 12.1±0.6 |
| BGC-823v | 13.4±0.7 |
| SGC-7901Cx43 | 39.4±0.8† |
| SGC-7901Cx43T154A | 15.3±0.4 |
| SGC-7901v | 14.7±0.6 |
| b | l-95 % | u-95 % | Neff | |
| Dominance | ||||
| Intercept | −0.30 | −0.75 | 0.16 | 4000.00 |
| SS vs. LL + LS | 0.05 | −0.48 | 0.60 | 4000.00 |
| Sex | 0.70 | −0.05 | 1.45 | 3812.24 |
| SS vs. LL + LS × sex | −0.15 | −0.96 | 0.77 | 4000.00 |
| Conscientiousness | ||||
| Intercept | 0.55 | 0.10 | 1.00 | 4000.00 |
| SS vs. LL + LS | −0.46 | −1.01 | 0.10 | 4000.00 |
| Sex | −0.62 | −1.38 | 0.15 | 4000.00 |
| SS vs. LL + LS × sex | 0.22 | −0.65 | 1.04 | 4000.00 |
| Low alpha | ||||
| Intercept | −0.47 | −0.93 | −0.03 | 4000.00 |
| SS vs. LL + LS | 0.31 | −0.27 | 0.83 | 3822.28 |
| Sex | 0.77 | 0.08 | 1.56 | 4287.68 |
| SS vs. LL + LS × sex | −0.30 | −1.12 | 0.54 | 4090.68 |
| Disinhibition | ||||
| Intercept | −0.47 | −0.90 | −0.00 | 4000.00 |
| SS vs. LL + LS | 0.41 | −0.11 | 0.99 | 4000.00 |
| Sex | 0.65 | −0.07 | 1.43 | 3578.12 |
| SS vs. LL + LS × sex | −0.33 | −1.18 | 0.54 | 3419.31 |
| Negative emotionality/low dominance | ||||
| Intercept | 0.21 | −0.24 | 0.65 | 3945.26 |
| SS vs. LL + LS | 0.03 | −0.49 | 0.58 | 4105.81 |
| Sex | −0.62 | −1.35 | 0.13 | 4000.00 |
| SS vs. LL + LS × sex | 0.12 | −0.72 | 0.98 | 3875.40 |
| Age (Years) | Gender | 0 | 1 | 2 | ≥3 | χ2 | p |
| 60–69 | Male | 30 (2.5) | 1128 (62.1) | 298 (61.6) | 56 (45.5) | 2933.719 | <0.001 |
| Female | 1590 (54.2) | 5 (0.6) | 6 (2.8) | 7 (14.9) | |||
| 70–79 | Male | 819 (68.3) | 475 (26.2) | 118 (24.4) | 48 (39.0) | 5.898 | 0.117 |
| Female | 846 (28.8) | 497 (55.9) | 122 (56.2) | 28 (59.6) | |||
| 80–89 | Male | 321 (26.8) | 192 (10.6) | 63 (13.0) | 13 (10.6) | 10.156 | 0.017 |
| Female | 417 (14.2) | 328 (36.9) | 71 (32.7) | 9 (19.1) | |||
| ≥90 | Male | 30 (2.5) | 21 (1.1) | 5 (1.0) | 6 (4.9) | 1.318 | 0.251 |
| Female | 80 (2.7) | 59 (6.6) | 18 (8.3) | 3 (6.4) |
| Categories of Infant Feeding Index | ptrend | |||
| Poor | Medium | Good | ||
| Acute upper respiratory infection | ||||
| Two weeks prevalence (%) | 31.7 | 25.5 | 20.6 | 0.16 a |
| Unadjusted OR (95% CI) | 1.00 (reference) | 0.74 (0.40–1.36) | 0.56 (0.25–1.28) | 0.16 |
| Adjusted OR (95% CI) b | 1.00 (reference) | 0.78 (0.42–1.47) | 0.46 (0.16–1.28) | 0.16 |
| Prevalence (%) | 65.0 | 71.9 | 36.5 | 0.0007 a |
| Unadjusted OR (95% CI) | 1.00 (reference) | 1.38 (0.76–2.49) | 0.31 (0.15–0.65) | <0.001 |
| Adjusted OR (95% CI) b | 1.00 (reference) | 1.45 (0.79–2.67) | 0.60 (0.24–1.53) | 0.57 |
| Diarrhea | ||||
| Two weeks prevalence (%) | 13.3 | 19.0 | 22.2 | 0.21 a |
| Unadjusted OR (95% CI) | 1.00 (reference) | 1.53 (0.68–3.42) | 1.86 (0.72–4.81) | 0.21 |
| Adjusted OR (95% CI) b | 1.00 (reference) | 1.49 (0.66–3.38) | 1.77 (0.54–5.81) | 0.31 |
| Prevalence (%) | 55.0 | 64.6 | 36.7 | 0.11 a |
| Unadjusted OR (95% CI) | 1.00 (reference) | 1.50 (0.85–2.64) | 0.56 (0.28–1.18) | 0.11 |
| Adjusted OR (95% CI) b | 1.00 (reference) | 1.42 (0.79–2.55) | 1.00 (0.40–2.48) | 0.73 |
| Factor solution OLQ-13 | Factor solution OLQ-11 | ||||||
| item | dim | 1 | 2 | 3 | 1 | 2 | 3 |
| A | Me | - | - | .408 | - | - | .405 |
| B | Co | - | .753 | - | |||
| C | Ma | - | .880 | - | -.150 | .669 | - |
| D | Me | .128 | -.223 | .348 | |||
| E | Ma | .285 | .198 | .102 | .160 | .368 | - |
| F | Co | .512 | - | .163 | .455 | .165 | .120 |
| G | Me | .142 | - | .409 | .117 | .126 | .374 |
| H | Co | .818 | - | - | .850 | - | - |
| I | Co | .787 | - | - | .714 | .101 | - |
| J | Ma | .363 | .299 | - | .139 | .576 | |
| K | Co | .259 | - | .327 | .283 | - | .266 |
| L | Me | .109 | - | .699 | .167 | - | .728 |
| M | Ma | .627 | - | .182 | .624 | - | .206 |
| Explained variance | 32% one factor/42% three factor | 35% one factor/40% three factor |
| Parameter | Total (N = 193) |
| Reason for last admission | |
| Palliative procedure or surgery | 28 (14.5) |
| Gastrointestinal symptoms | 52 (26.9) |
| Cardiovascular or pulmonary symptoms | 39 (20.2) |
| Infectious state | 31 (16.2) |
| Uncontrolled pain | 11 (5.7) |
| Hematologic instability | 12 (6.2) |
| Neurologic symptom | 7 (3.6) |
| Others | 13 (6.7) |
| ICU admission in the last month | 23 (11.9) |
| Imaging examination conducted in the last month | |
| No examination | 56 (29.0) |
| Examination | 137 (71.0) |
| CT | 101 (73.7) |
| MRI | 8 (5.8) |
| PET-CT | 1 (0.7) |
| Combined imaging (>2) | 27 (19.7) |
| Type of treatment administered during the last 6 mo | |
| Chemotherapy alone | 155 (80.3) |
| Chemotherapy with radiation | 26 (13.5) |
| Chemotherapy with surgery | 12 (6.2) |
| Gastrointestinal surgery | 9 |
| Pelvic exenteration | 2 |
| Neuro-surgery | 1 |
| Type of chemotherapy-agent administered during the last 6 mo | |
| IV only | 177 (91.7) |
| IV with PO | 16 (8.3) |
| DFS, P value | OS, P value | |
| [HR (95 % CI)] | [HR (95 % CI)] | |
| Age (years) | ||
| <50 | 0.251 | 0.885 |
| ≥50 | 0.678 (0.349–1.316) | 0.938 (0.395–2.228) |
| Sex | ||
| Female | 0.776 | 0.164 |
| Male | 1.163 (0.411–3.297) | 0.490 (0.179–1.337) |
| Nodal status | ||
| (−) metastasis, (−) ECS | 0.001 | 0.008 |
| (+) metastasis, (−) ECS | 1.193 (0.384–3.705) | 1.858 (0.463–7.447) |
| (+) metastasis, (+) ECS | 3.586 (1.733–7.420) | 4.618 (1.729–12.338) |
| Differentiation | ||
| Well/moderate | 0.027 | 0.041 |
| Poor | 2.437 (1.105–5.372) | 2.868 (1.043–7.886) |
| Pathologic tumor status | ||
| Earlya | 0.023 | 0.096 |
| Advancedb | 2.172 (1.111–4.247) | 2.084 (0.877–4.949) |
| CRP | ||
| <5 mg/mL | 0.016 | 0.027 |
| ≥5 mg/mL | 2.274 (1.163–4.448) | 2.636 (1.118–6.217) |
| Cyfra 21-1 | ||
| <3.3 ng/mL | 0.135 | 0.667 |
| ≥3.3 ng/mL | 1.885 (0.821–4.328) | 0.726 (0.169–3.120) |
| Tumor depth | ||
| <10 mm | 0.030 | 0.052 |
| ≥10 mm | 2.207 (1.080–4.510) | 2.560 (0.991–6.613) |
| Cyfra 21-1 and CRP | 0.019 | 0.235 |
| Cyfra 21-1 < 3.3 ng/mL, CRP < 5 mg/L | 1 | 1 |
| Cyfra 21-1 ≥ 3.3 ng/mL, CRP < 5 mg/L | 0.575 (0.077–4.300) | 0.000 (0.000) |
| Cyfra 21-1 < 3.3 ng/mL, CRP ≥ 5 mg/L | 1.683 (0.761–3.722) | 2.578 (1.036–6.414) |
| Cyfra 21-1 ≥ 3.3 ng/mL, CRP ≥ 5 mg/L | 4.065 (1.610–10.261) | 1.928 (0.426–8.726) |
| Period Prevalence Per 100 000 (95% CI) | Incidence Per 100 000 (95% CI) | |
| Overall | 140.2 (100.1–179.2) | 72.7 (52.5–91.8) |
| Age, y | ||
| 18–24 | 23.3 (16.7–29.8) | 14.8 (10.6–18.8) |
| 25–44 | 59.1 (42.9–74.4) | 34.1 (25.2–42.2) |
| 45–64 | 177.5 (127.2–225.9) | 96.7 (70.2–121.4) |
| ≥65 | 479.6 (338.3–618.9) | 231.9 (164.7–297.6) |
| Sex | ||
| Men | 110.1 (78.1–141.4) | 61.9 (44.3–78.7) |
| Women | 169.1 (121.0–215.4) | 83.1 (60.4–104.3) |
| Race | ||
| White | 192.3 (136.7–246.6) | 99.75 (71.64–126.6) |
| Black | 219.9 (157.7–279.2) | 106.8 (77.72–133.4) |
| Asian/Pacific Islander | 92.7 (66.6–117.9) | 51.48 (37.62–64.45) |
| Chronic kidney disease | ||
| Yes | 573.3 (405.6–736.2) | 266.4 (189.1–341.2) |
| No | 124.9 (89.2–159.5) | 66.5 (48.1–83.8) |
| Diabetes mellitus | ||
| Yes | 373.9 (265.9–478.2) | 183.4 (131.6–232.5) |
| No | 123.6 (88.2–158.0) | 66.4 (48.0–83.9) |
| Hypertension | ||
| Yes | 415.9 (294.2–534.9) | 193.7 (138.6–46.5) |
| No | 94.9 (68.1–120.7) | 53.9 (39.1–67.8) |
| Coronary heart disease | ||
| Yes | 697.0 (494.4–891.5) | 298.7 (212.5–381.3) |
| No | 157.3 (112.2–201.0) | 71.3 (51.5–90.0) |
| Heart failure | ||
| Yes | 825.0 (579.4–1064.7) | 365.9 (256.3–473.6) |
| No | 154.4 (110.3–197.3) | 70.5 (51.0–89.0) |
| Assembler | Species assembled | ||||
| A.hydrophila | B.cereus | B.fragilis | S.aureus | X.axonopodis | |
| ABySS | 237.5 | 48.3 | 146.2 | 73.9 | 89.9 |
| CABOG | 278.4 | 61.6 | 94.2 | 102.8 | 105.8 |
| MIRA | 246.2 | 47.4 | 134.3 | 132.4 | 105.6 |
| MaSuRCA | 828.6 | 103.6 | 158.7 | 221.8 | 117.9 |
| SGA | 68.8 | 23.4 | 41.2 | 38.1 | 47.8 |
| SOAPdenovo | 243.9 | 57.9 | 116.1 | 146.3 | 74.2 |
| SPAdes | 379.7 | 97.2 | 157.7 | 187.1 | 117.5 |
| Velvet | 184.4 | 38.9 | 125.2 | 122.5 | 83.0 |
| Groups | No smoker (n: 6742) | Ex-smoker (n: 976) | Cigarette smoking (n: 864) | Hookah smoking (n: 1067) | Cigarette and hookah (n: 41) | p value |
| FBG1 (mg/dl) | 92.65 ± 38.71 | 96.78 ± 43.26 | 87.59 ± 33.86ab | 93.60 ± 42.43c | 94.85 ± 47.02 | 0.013 |
| TG2 (mg/dl) | 117 (83–170) | 128 (90.5–177.5) | 122 (86–180) | 121 (88–171) | 122 (96–186) | 0.125 |
| Cholesterol1 (mg/dl) | 192.41 ± 39.36 | 191.10 ± 38.76 | 184.18 ± 39.4a | 190.53 ± 37.6a | 189.27 ± 37.25 | 0.045 |
| LDL1 (mg/dl) | 116.77 ± 35.53 | 117.18 ± 35.45 | 112.42 ± 34.93 | 117.48 ± 33.63 | 109.03 ± 35.39 | 0.9 |
| HDL1 (mg/dl) | 43.63 ± 10 | 41.96 ± 10.18 | 38.77 ± 9.22ab | 42.53 ± 9.04ab | 41.11 ± 9.65 | < 0.001 |
| Uric acid1 (mg/dl) | 4.62 ± 1.4 | 4.91 ± 1.45 | 5 ± 1.34ab | 4.36 ± 1.32c | 5.37 ± 1.6c | < 0.001 |
| Serum urea1 (mg/dl) | 12.93 ± 4.28 | 13.54 ± 4.2 | 13.48 ± 4.22 | 12.52 ± 4.05 | 13.8 ± 5.57 | 0.63 |
| Cr1 (mg/dl) | 0.85 ± 0.25 | 0.90 ± 0.24 | 0.93 ± 0.25 | 0.84 ± 0.27 | 0.93 ± 0.21 | 0.65 |
| GFR3 ml/min | ||||||
| < 60 | 119 (2.7%) | 28 (4.4%) | 33 (5.7%) | 10 (1.5%) | 1 (3.3%) | < 0.001 |
| > 60 | 4364 (97.3%) | 605 (95.6%) | 546 (94.3%) | 646 (98.5%) | 29 (96.7%) | |
| hsCRP2 (mg/l) | 1.62 (0.98–3.51) | 1.55 (1–3.35) | 1.71 (1.06–3.89) | 1.63 (1.04–3.46) | 2.02 (1.1–4.65) | < 0.001 |
| Element | Measurement |
| Ulna (NMMNH P-19460), length of semilunar notch | 24.5* |
| Ulna (NMMNH P-19460), depth of semilunar notch | 6.2* |
| Ulna (NMMNH P-19460), maximum mediolateral breadth | 21.5 |
| Radius (NMMNH P-19460), length | 93.0 |
| Radius (NMMNH P-19460), anteroposterior midshaft diameter | 11.0 |
| Radius (NMMNH P-19460), midshaft mediolateral diameter | 11.5 |
| Metacarpal II (NMMNH P-19460), length | 25.0 |
| Metacarpal II (NMMNH P-19460), proximal breadth | 9.8 |
| Metacarpal II (NMMNH P-19460), midshaft mediolateral diameter | 8.7 |
| Metacarpal II (NMMNH P-19460), distal breadth | 12.4 |
| Metacarpal III (NMMNH P-19640), length | 29.3 |
| Metacarpal III (NMMNH P-19640), proximal breadth | 13.9 |
| Metacarpal III (NMMNH P-19640), midshaft mediolateral diameter | 9.8 |
| Metacarpal III (NMMNH P-19640), distal breadth | 13.5 |
| Metacarpal IV (NMMNH P-19640), length | 23.9 |
| Metacarpal IV (NMMNH P-19640), proximal breadth | 10.9 |
| Metacarpal IV (NMMNH P-19640), midshaft mediolateral diameter | 6.8 |
| Metacarpal IV (NMMNH P-19640), distal breadth | 9.9 |
| Ungual (NMMNH P-19640), proximal breadth of most complete | 8.6 |
| Media surveillance | Active surveillance | Total casualties | |
| Jan 08 –Sep 09 | Oct 09 – Dec 11 | N (% total) | |
| N (% total) | N (% total) | ||
| Sex | |||
| Male | 255 (78.0) | 86 (78.2) | 341 (78.0) |
| Female | 60 (18.3) | 24 (21.8) | 84 (19.2) |
| Unknown | 12 (3.7) | 0 (0) | 12 (2.7) |
| Age group | |||
| Child (< 18 years) | 25 (7.6) | 15 (13.6) | 40 (9.2) |
| Adult | 192 (58.7) | 94 (85.5) | 286 (65.4) |
| Unknown | 110 (33.6) | 1 (0.9) | 111 (25.4) |
| Outcome | |||
| Non-fatal injury | 298 (91.1) | 105 (95.5) | 403 (92.2) |
| Fatal injury | 29 (8.9) | 5 (4.5) | 34 (7.8) |
| Type of explosive device | |||
| Socket bomb | 50 (15.3) | 48 (43.6) | 98 (22.4) |
| Sutali bomb | 47 (14.4) | 7 (6.4) | 54 (12.4) |
| Pressure cooker bomb | 16 (4.9) | 6 (5.5) | 22 (5.0) |
| Other improvised explosive device | 87 (26.6) | 41 (37.3) | 128 (29.3) |
| Unknown | 127 (38.8) | 8 (7.3) | 135 (30.9) |
| Place of incident | |||
| Busy street or crossroads | 69 (21.1) | 15 (13.6) | 84 (19.2) |
| Shop or market | 26 (8.0) | 18 (16.4) | 44 (10.1) |
| Place of worship | 26 (8.0) | 0 (0) | 26 (5.9) |
| Near government or police office | 28 (8.6) | 1 (0.9) | 29 (6.6) |
| Near school or hospital | 5 (1.5) | 0 (0) | 5 (1.1) |
| Near stadium | 44 (13.5) | 0 (0) | 44 (10.1) |
| Factory or industry | 7 (2.1) | 2 (1.8) | 9 (2.1) |
| On the bus | 9 (2.8) | 52 (47.3) | 61 (14.0) |
| Near bus station | 18 (5.5) | 0 (0) | 18 (4.1) |
| Home | 43 (13.1) | 16 (14.5) | 59 (13.5) |
| Other | 50 (15.3) | 6 (5.5) | 56 (12.8) |
| Unknown | 2 (0.6) | 0 (0) | 2 (0.5) |
| Total | 327 | 110 | 437 |
| First author | Year | Skin condition |
| Praveenkumar et al. [29] | 2016 | Psoriasis |
| Kokpol et al. [30] | 2014 | Psoriasis |
| Henseler et al. [31] | 1995 | Psoriasis |
| Owczarczyk-Saczonek et al. [34] | 2015 | Psoriasis |
| Gisondi et al. [26] | 2007 | Psoriasis |
| Nagpal et al. [51] | 2016 | Acne |
| Del Prete et al. [52] | 2012 | Acne |
| Akin Belli et al. [54] | 2016 | Rosacea |
| Shlyankevich et al. [56] | 2014 | Hidradenitis suppurativa |
| Banger et al. [61] | 2015 | Androgenic alopecia |
| El Sayed et al. [62] | 2016 | Androgenic alopecia |
| Saleh et al. [66] | 2014 | Lichen planus |
| Arias-Santiago et al. [65] | 2011 | Lichen planus |
| Lee et al. [68] | 2017 | Atopic dermatitis |
| Ambiel et al. [71] | 2014 | Pemphigus |
| Saylam Kurtipek et al. [83] | 2015 | Holoderma |
| Wali et al. [84] | 2016 | Striae |
| Chen et al. [85] | 2016 | Acanthosis nigricans |
| Puttegowda et al. [75] | 2015 | Tendon xanthomas |
| Nagase et al. [76] | 2013 | Skin aging |
| Penington et al. [86] | 2007 | Wound healing |
| MIGS ID | Property | Term | Evidence codea |
| Domain Bacteria | TAS [13] | ||
| Phylum Bacteroidetes | TAS [14,15] | ||
| Class Bacteroidia | TAS [14,16] | ||
| Current classification | Order Bacteroidales | TAS [14,17] | |
| Family Rikenellaceae | TAS [14,18] | ||
| Genus Alistipes | TAS [5,19] | ||
| Species Alistipes timonensis | IDA | ||
| Type strain JC136T | IDA | ||
| Gram stain | Negative | IDA | |
| Cell shape | Bacilli | IDA | |
| Motility | Nonmotile | IDA | |
| Sporulation | Nonsporulating | IDA | |
| Temperature range | Mesophile | IDA | |
| Optimum temperature | 37°C | IDA | |
| MIGS-6.3 | Salinity | Growth in BHI medium + 1% NaCl | IDA |
| MIGS-22 | Oxygen requirement | Anaerobic | IDA |
| Carbon source | Unknown | NAS | |
| Energy source | Unknown | NAS | |
| MIGS-6 | Habitat | Human gut | IDA |
| MIGS-15 | Biotic relationship | Free living | IDA |
| MIGS-14 | PathogenicityBiosafety levelIsolation | Unknown2Human feces | NAS |
| MIGS-4 | Geographic location | Senegal | IDA |
| MIGS-5 | Sample collection time | September 2010 | IDA |
| MIGS-4.1 | Latitude | 13.7167 | IDA |
| MIGS-4.1 | Longitude | 16.4167 | IDA |
| MIGS-4.3 | Depth | Surface | IDA |
| MIGS-4.4 | Altitude | 51 m above sea level | IDA |
| Correct reactions | Correct | |
| (ignoring enzyme) | (including enzyme) | |
| Pantothenate and coenzyme A biosynthesis pathway | ||
| Recall(P) (%) | 78 (7/9) | 56 (5/9) |
| Precision (%) | 59 (24/41) | 41 (17/41) |
| Tetrahydrofolate biosynthesis pathway | ||
| Recall(P) (%) | 90 (9/10) | 70 (7/10) |
| Precision (%) | 60 (39/65) | 38 (25/65) |
| Aerobic fatty acid β-oxidation I pathway | ||
| Recall(P) (%) | 29 (2/7) | 29 (2/7) |
| Precision (%) | 30 (11/37) | 14 (5/37) |
| Prognosis | Wald | P | Exp(B) | 95% CI for Exp(B) | |
| Lower | Upper | ||||
| OS | |||||
| Age(year) ≥50 vs.<50 | 1.577 | 0.215 | 1.643 | 0.788 | 3.319 |
| Gender Female vs. Male | 3.298 | 0.081 | 2.506 | 0.907 | 6.387 |
| Histological type U vs. D | 0.441 | 0.526 | 0.745 | 0.253 | 2.479 |
| T classification T2–4 vs. T1 | 9.309 | 0.003a | 3.568 | 1.521 | 6.517 |
| N classification N1-3vs. N0 | 12.505 | 0.001a | 2.389 | 1.543 | 4.228 |
| Clinical classification II-IVb vs. I | 6.218 | 0.014a | 0.487 | 0.119 | 0.668 |
| CXCL5 expression High vs. Low | 4.885 | 0.027 | 1.960 | 1.079 | 3.560 |
| CXCR2 expression High vs. Low | 1.295 | 0.255 | 0.691 | 0.365 | 1.307 |
| DMFS | |||||
| Age(year) ≥50 vs.<50 | 1.267 | 0.234 | 2.137 | 0.802 | 4.304 |
| Gender Female vs. Male | 3.137 | 0.091 | 3.267 | 0.798 | 13.223 |
| Histological type U vs. D | 0.702 | 0.564 | 0.523 | 0.158 | 2.694 |
| T classification T2–4 vs. T1 | 3.236 | 0.079a | 2.413 | 0.903 | 6.446 |
| N classification N1-3vs. N0 | 6.533 | 0.004a | 2.578 | 1.131 | 6.327 |
| Clinical classification II-IVb vs. I | 2.786 | 0.095a | 0.413 | 0.251 | 1.099 |
| CXCL5 expression High vs. Low | 5.169 | 0.023 | 2.740 | 1.149 | 6.532 |
| CXCR2 expression High vs. Low | 1.700 | 0.192 | 1.879 | 0.728 | 4.849 |
| Year | Zonal Population* | New PTB+ cases Reported (n = 8558) | Case Notification/ 105 persons/year | Proportion of estimated PTB+ incident cases notified, %** |
| 1994 | 1004000 | 512 | 49 | 45.2 |
| 1995 | 1070160 | 1025 | 96 | 87.9 |
| 1996 | 1101195 | 1162 | 106 | 96.8 |
| 1997 | 1133129 | 946 | 84 | 76.6 |
| 1998 | 1165990 | 1277 | 110 | 100.5 |
| 1999 | 1199804 | 1510 | 126 | 115.5 |
| 2000 | 1234598 | 1267 | 103 | 94.2 |
| 2001§ | 1174118 | 858 | 73 | 67.0 |
| Intervention (n=5297) | Control (n=5246) | Incidence rate ratio (95% CI) | p value | |||
| Number of events | Incidence rate (cases per 100 child-years, 95% CI) | Number of events | Incidence rate (cases per 100 child-years, 95% CI) | |||
| Malaria | 175 | 2·19 (1·87–2·52) | 134 | 1·66 (1·38–1·95) | 1·32 (1·03–1·69) | 0·03 |
| Sepsis | 51 | 0·64 (0·46–0·82) | 54 | 0·67 (0·49–0·85) | 0·95 (0·64–1·41) | 0·81 |
| Gastroenteritis | 24 | 0·30 (0·18–0·42) | 28 | 0·35 (0·22–0·48) | 0·86 (0·49–1·53) | 0·62 |
| Burns | 9 | 0·11 (0·04–0·19) | 10 | 0·12 (0·05–0·20) | 0·91 (0·37–2·23) | 0·83 |
| Accidental injury | 12 | 0·15 (0·07–0·24) | 9 | 0·11 (0·04–0·18) | 1·42 (0·58–3·45) | 0·44 |
| Malnutrition | 5 | 0·06 (0·01–0·12) | 5 | 0·06 (0·01–0·12) | 1·01 (0·29–3·48) | 0·99 |
| Asthma | 6 | 0·08 (0·02–0·14) | 2 | 0·02 (0·01–0·06) | 3·03 (0·51–18·11) | 0·22 |
| Other | 36 | 0·45 (0·30–0·60) | 36 | 0·45 (0·30–0·59) | 1·02 (0·62–1·66) | 0·94 |
| Total | 318 | 3·99 (3·55–4·43) | 278 | 3·45 (3·05–3·86) | 1·15 (0·95–1·38) | 0·15 |
| Folates | Methionine cycle | Transsulfuration | Other |
| THF = 4.61 | Met = 49.2 | Cysta = 36.9 | Ser = 563 |
| 510CH = 0.28 | SAM = 81.1 | Cys = 195 | Gly = 924 |
| 510CH2 = 0.51 | SAH = 19.1 | GluCys = 9.8 | Sarc = 9.16 |
| 10fTHF = 3.41 | Hcy = 1.12 | GSH = 6591 | DMG = 0.71 |
| 5mTHF = 4.50 | GSSG = 61.3 | Aicart = 0.94 | |
| DHF = 0.039 | Glut = 3219 | HCOOH = 13.1 |
| Physical symptoms | GSF group | Non-GSF group | |||||||
| Subscale and item | Very much | Quite a bit | A little bit | Not at all | Very much | Quite a bit | A little bit | Not at all | Missing |
| n(%) | n(%) | n(%) | n(%) | n(%) | n(%) | n(%) | n(%) | n(%) | |
| Distressed or bothered by pain | 56 (31.1) | 37 (20.6) | 38 (21.1) | 49 (27.2) | 114 (36.2) | 84 (26.7) | 57 (18.1) | 60 (19) | 19 (3.7) |
| Loss of memory | 25 (13.9) | 17 (9.4) | 45 (25) | 93 (51.3) | 15 (4.9) | 19 (6.2) | 72 (23.4) | 202 (65.6) | 26 (5.1) |
| Headache | 7 (3.9) | 14 (7.8) | 45 (25.1) | 113 (63.1) | 16 (5.2) | 37 (12) | 60 (19.5) | 195 (63.3) | 27 (5.3) |
| Dry mouth | 31 (17.1) | 56 (30.9) | 51 (28.2) | 43 (23.8) | 56 (17.9) | 53 (17) | 88 (28.2) | 115 (36.9) | 21 (4.1) |
| Sore mouth | 9 (5) | 16 (8.8) | 29 (16) | 127 (70.2) | 10 (3.3) | 19 (6.3) | 41 (13.5) | 233 (76.9) | 30 (5.8) |
| Shortness of breath | 42 (23.1) | 41(22.5) | 43 (23.6) | 56 (30.8) | 42 (13.3) | 36 (11.4) | 71 (22.5) | 166 (52.7) | 17 (3.3) |
| Cough | 19 (10.5) | 37 (20.4) | 39 (21.5) | 86 (47.5) | 15 (4.9) | 34 (11.1) | 81 (26.5) | 176 (57.5) | 27 (5.3) |
| Feeling sick (nausea) | 16 (8.8) | 24 (13.3) | 40 (22.1) | 101 (55.8) | 30 (9.6) | 41 (13.2) | 73 (23.5) | 167 (53.7) | 22 (4.3) |
| Being sick (vomiting) | 11 (6.1) | 14 (7.8) | 24 (13.4) | 130 (72.6) | 29 (9.4) | 21 (6.8) | 43 (14) | 214 (69.7) | 28 (5.4) |
| Bowel problems | 35 (19.2) | 35 (19.2) | 32 (17.6) | 80 (44) | 48 (15) | 48 (15) | 66 (20.7) | 157 (49.2) | 13 (2.5) |
| Bladder problems | 24 (13.3) | 21 (11.6) | 25 (13.8) | 111 (61.3) | 31 (10) | 31 (10 | 47 (15.1) | 202 (65) | 22 (4.3) |
| Feeling weak | 53 (28.8) | 54 (29.3) | 40 (21.7) | 37 (20.1) | 40 (12.7) | 85 (27.1) | 86 (27.4) | 103 (32.8) | 16 (3.1) |
| Feeling tired | 63 (34.6) | 57 (31.3) | 43 (23.6) | 19 (10.4) | 85 (26.7) | 92 (28.9) | 76 (23.9) | 65 (20.4) | 14 (2.7) |
| Problems sleeping at night | 34 (18.9) | 31 (17.2) | 33 (18.3) | 82 (45.6) | 73 (23.2) | 70 (22.2) | 51 (16.2) | 121 (38.4) | 19 (3.7) |
| Feeling sleepy during the day | 33 (17.9) | 69 (37.5) | 54 (29.3) | 28 (15.2) | 56 (17.7) | 77 (24.4) | 112 (35.4) | 71 (22.5) | 14 (2.7) |
| Loss of appetite | 33 (18) | 34 (18.6) | 45 (24.6) | 71 (38.8) | 45 (14.2) | 59 (18.6) | 67 (21.1) | 147 (46.2) | 13 (2.5) |
| Changes in your weight | 32 (17.7) | 41(22.7) | 40 (22.1) | 68 (37.6) | 37 (11.9) | 38 (12.2) | 77 (24.7) | 160 (51.3) | 21 (4.1) |
| Swallowing | 12 (6.7) | 6 (3.4) | 25 (13.4) | 135 (75.8) | 12 (3.8) | 12 (3.8) | 29 (9.2) | 261 (83.1) | 22 (4.3) |
| Changes in your appearance | 13 (7.2) | 24 (13.3) | 25 (13.9) | 118 (65.6) | 10 (3.2) | 22 (7) | 41 (13.1) | 240 (76.7) | 21 (4.1) |
| Restless and agitated | 22 (12.2) | 34 (18.9) | 55 (30.6) | 69 (38.3) | 28 (8.8) | 47 (14.8) | 76 (23.9) | 167 (52.5) | 16 (3.1) |
| Symptoms not being under control | 19 (10.4) | 29 (15.8) | 46 (25.1) | 81 (44.3) | 34 (10.8) | 26 (8.2) | 72 (22.8) | 184 (58.2) | 30 (5.8) |
| Experimental phase | Correlation | Brain regions | x | y | z | Cluster size | t value | p value FWE |
| Fear conditioning | Positive | Posterior cingulate cortex | 12 | −34 | 46 | 70 | 3.10 | 0.033 |
| Posterior insular cortex | 44 | −38 | 24 | 116 | 3.22 | 0.034 | ||
| Amygdala | 16 | 2 | 12 | 140 | 3.32 | 0.037 | ||
| Hypothalamus | −12 | 0 | −8 | 33 | 2.71 | 0.039 | ||
| Anterior insular cortex | 36 | 28 | 6 | 138 | 3.09 | 0.051 | ||
| Negative | Orbitofrontal cortex | −16 | 34 | −24 | 21 | 3.21 | 0.038 | |
| Subgenual anterior cingulate cortex | −6 | 18 | −18 | 48 | 3.00 | 0.039 | ||
| Shock delivery (unconditioned responses) | Positive | Hypothalamus | 8 | 4 | −32 | 357 | 4.11 | 0.015 |
| Middle insular cortex | −40 | 2 | 8 | 311 | 3.53 | 0.040 | ||
| Negative | Orbitofrontal cortex | −14 | 34 | −18 | 44 | 3.40 | 0.011 | |
| Late extinction learning | Positive | Subgenual anterior cingulate cortex | −14 | 26 | −14 | 30 | 2.88 | 0.028 |
| Negative | Middle insular cortex | −36 | 4 | 16 | 62 | 3.27 | 0.024 | |
| Early extinction recall | Positive | Parahippocampus | −30 | 2 | −20 | 183 | 5.35 | 0.001 |
| Subgenual anterior cingulate cortex | 10 | 12 | −18 | 64 | 4.39 | 0.002 | ||
| Anterior insular cortex | 32 | 18 | 12 | 82 | 4.35 | 0.003 | ||
| Anterior insular cortex | −62 | 10 | 0 | 1595 | 5.34 | 0.005 | ||
| Dorsal anterior cingulate cortex | 10 | 24 | 40 | 91 | 4.13 | 0.005 | ||
| Ventromedial prefrontal cortex | −14 | 40 | −26 | 572 | 4.37 | 0.014 | ||
| Middle cingulate cortex | −4 | 0 | 36 | 76 | 3.33 | 0.024 | ||
| Orbitofrontal cortex | −16 | 52 | −18 | 572 | 3.94 | 0.034 |
| ANXA1-SER | ANXA1-TYR | |||||
| HPV+ | HPV- | Controls | HPV+ | HPV- | Controls | |
| Cancer | 13.5 ± 1.6 | 14.6 ± 0.4 | - | 15.3 ± 0.6** | 13.6 ± 1.6* | - |
| Epithelium | 23.2 ± 1.7* | 16.0 ± 1.0 | 15.3 ± 0.3 | 22.2 ± 0.7 | 18.5 ± 1.5 | 26.7 ± 0.9 |
| Variations | 1st Day | 2nd Day | 3rd Day | P value | |
| Number of bolusesrequired | Group B | 31.47±24.39 | 24.07±20.25 | 19.20±14.59 | 0.084 |
| Group L | 38.87±28.27 | 21.13±16.82 | 17.77±12.38 | ||
| Number of bolusesdelivered | Group B | 15.87±6.66 | 9.97±4.79 | 8.93±3.95 | 0.348 |
| Group L | 16.37±8.39 | 9.70±5.42 | 8.50±4.20 | ||
| Total Consumption(ml) | Group B | 79.17±33.45 | 49.67±23.81 | 44.67±19.78 | 0.371 |
| Group L | 81.67±41.65 | 48.5±27.13 | 42.5±20.99 |
| Components | Mean IOP (±SD) | P Value | Mean CCT (±SD) | P Value |
| Abdominal Obesity | ||||
| Yes | 26.23±4.17 | 0.126 | 591.12±56.15 | 0.317 |
| No | 25.34±3.76 | 596.34±91.77 | ||
| Elevated Fasting Glucose | ||||
| Yes | 26.12±3.69 | 0.033 | 584.59±76.28 | 0.462 |
| No | 24.59±2.45 | 597.72±92.65 | ||
| High Blood Pressure | ||||
| Yes | 27.24±2.62 | <0.0001 | 601.38±74.67 | 0.002 |
| No | 23.83±4.47 | 576.23±93.79 | ||
| Low HDL | ||||
| Yes | 25.37±3.23 | 0.234 | 585.53±97.28 | 0.538 |
| No | 26.29±2.72 | 598.09±64.92 | ||
| Elevated Triglyceride | ||||
| Yes | 27.51±2.39 | 0.004 | 589.57±46.45 | 0.317 |
| No | 23.74±3.34 | 597.52±73.73 |
| Reference | Measurement of PAH-RPF/true RPF (n/n) | PAH-RPF (ml/min) | True RPF (ml/min) |
| [17] | 6 (0) | - | 690 |
| [18] | 40 (11) | 475 | 1116 |
| [19] | 22 (6) | 474 | 1238 |
| SNP | MAF (% [n/N]) | OR (95% CI) | P |
| rs600144 | |||
| Cases | 25.9 (850/3278) | 0.96 (0.9 to 1.1) | NS |
| Controls | 26.8 (857/3202) | ||
| rs11970361 | |||
| Cases | 5.7 (187/3300) | 0.94 (0.8 to 1.2) | NS |
| Controls | 6.0 (194/3238) | ||
| rs11970411 | |||
| Cases | 10.2 (338/3300) | 1.01 (0.9 to 1.2) | NS |
| Controls | 10.1 (328/3238) | ||
| rs582757 | |||
| Cases | 24.8 (816/3286) | 0.89 (0.8 to 0.99) | 0.041 |
| Controls | 27.0 (871/3220) | ||
| rs17780429 | |||
| Cases | 12.7 (418/3300) | 0.91 (0.8 to 1.0) | NS |
| Controls | 13.8 (446/3236) |
| accepted marine species in WORMS | 18S V9 OTUs in planktona | |
| Acanthocephala | 468 | 0 |
| Annelida | 12 862 | 404 (48) |
| Arthropoda | 57 871 | 9497 (205) |
| Brachiopoda | 396 | 8 (4) |
| Bryozoa | 6167 | 15 (5) |
| Cephalorhyncha | 238 | 13 |
| Chaetognatha | 131 | 531 (7) |
| Chordata | 22 248 | 6972 (32) |
| Cnidaria | 11 407 | 842 (82) |
| Ctenophora | 192 | 33 (9) |
| Cycliophora | 2 | 0 |
| Dicyemida | 122 | 1 |
| Echinodermata | 7252 | 74 (19) |
| Entoprocta | 180 | 12 |
| Gastrotricha | 497 | 2 |
| Gnathostomulida | 98 | 0 |
| Hemichordata | 130 | 12 (3) |
| Mollusca | 45 219 | 560 (89) |
| Nematoda | 7152 | 30 (6) |
| Nemertea | 1359 | 81 (4) |
| Orthonectida | 25 | 0 |
| Phoronida | 19 | 0 |
| Placozoa | 1 | 0 |
| Platyhelminthes | 12 230 | 148 (12) |
| Porifera | 8476 | 25 (4) |
| Rotifera | 187 | 7 (2) |
| Sipuncula | 147 | 0 |
| Tardigrada | 193 | 2 |
| Xenacoelomorpha | 433 | 0 |
| unassigned metazoan | n.a. | 402 |
| total | 195 702 | 19 671 (531) |
| CON | HSD2BKO | |
| Adrenal size: body weight (adult) | 5.9 ± 0.9 × 10−4 (15) | 4.9 ± 0.9 × 10−4 (18) |
| Brain gene expression (n = 5–8) | ||
| Crh (E15.5; PVN)(ROD) | 0.336 ± 0.01 | 0.320 ± 0.026 |
| Crh (E17.5; PVN)(ROD) | 0.274 ± 0.0181 | 0.252 ± 0.016 |
| Nr3c2 (E15.5; HC)(ROD) | ND | ND |
| Nr3c2 (E17.5; HC)(ROD) | 0.26 ± 0.02 | 0.26 ± 0.01 |
| Nr3c2 (Adult; HC) (norm to HPRT) | 0.868 ± 0.077 | 0.818 ± 0.061 |
| Nr3c1 (Adult; HC)(norm to HPRT) | 0.733 ± 0.170 | 0.744 ± 0.055 |
| Hsd11b1 (E12.5; norm to HPRT) | 0.172 ± 0.033 | 0.155 ± 0.021 |
| Hsd11b1 (E17.5; norm to HPRT) | 0.188 ± 0.028 | 0.148 ± 0.022 |
| Plasma corticosterone (nmol/l) | ||
| Fetal (E17.5) | 31.2 ± 2.1 | 28.1 ± 2.0 |
| Adult | (10) | (9) |
| AM | 35.3 ± 4.8 | 34.3 ± 6.7 |
| PM | 196.5 ± 16.6 | 179.9 ± 22.9 |
| Restraint stress corticosterone levels (nmol/l) | (12) | (12) |
| 0 min restraint stress | 33.8 ± 4.7 | 35.9 ± 5.3 |
| 30 min restraint stress | 622.9 ± 87.4 | 661.0 ± 98.1 |
| 1 h post restraint stress | 155.7 ± 27.8 | 181.9 ± 26.8 |
| Level of lesion | Number of patients | Percentage |
| Thoracic | 3 | 3.49 |
| Thoracolumbar | 6 | 6.98 |
| Lumbar | 23 | 26.74 |
| Lumbosacral | 18 | 20.93 |
| Sacral | 16 | 18.60 |
| Sacrococcygeal | 1 | 1.16 |
| Not available | 19 | 22.09 |
| Total | 86 | 100 |
| β | t | p | |
| Maternal age (per year) | −0.008 | −0.45 | 0.65 |
| Maternal weight (per kg) | 0.211 | 11.77 | <0.001 |
| Frozen thawed embryo (versus fresh embryo) | 0.079 | 4.25 | <0.001 |
| ICSI (versus IVF) | 0.009 | 0.48 | 0.63 |
| SAGE (versus Vitrolife) | −0.004 | −0.24 | 0.81 |
| Gestational age | 0.490 | 27.38 | <0.001 |
| Gender (male versus female) | 0.110 | 6.33 | <0.001 |
| Secretory uric acid transporter | ||
| Compound | OAT1 | ABCG2 |
| Lesinurad | 3.90 ± 0.94 | >100 |
| Pathway | Description |
| G protein-coupled receptor (GPCR) signaling | There are more than 800 GPR genes in the genome. These receptors activate adenyl cyclase to produce cAMP from ATP, or in the phosphatidylinositol pathway to produce a cell response, depending on the context. Sixteen of these receptors were deregulated in our tumor series (available upon request). |
| EGFR signaling | This receptor was markedly downregulated. In addition, SOS1 (present in cytosol) was upregulated in this pathway. |
| ErbB2 signaling | The ligand NRG1 and its receptors ErbB2 and ErbB3 were upregulated. The ErbB2 interacting protein (ERBB2IP) was also upregulated. However, the ErbB4 signaling pathway was not deregulated. |
| Integrin cell surface interactions | Integrin αIIb β3 signaling presented four upregulated elements. The amyloid β (A4) precursor protein-binding family B member 1-interacting protein (APBB1IP) and downstream effector Talin-1 (TLN1) were upregulated. This upregulation provoked the activation of integrin αIIb β3 and the subsequent activation of tyrosine-protein kinase SYK (SYK), which was also upregulated, by Src. |
| Characteristic | Case (n = 82) |
| Age in years | |
| > 45 | 21 |
| ≤ 45 | 61 |
| Sex | |
| Male | 33 |
| Female | 49 |
| Tumour size, cm | 5.94 ± 2.65 |
| Location | |
| Left | 31 |
| Right | 51 |
| Symptoms | |
| Asymptomatic | 48 |
| Symptomatic | 34 |
| Fuhrman grade | |
| 1 to 2 | 32 |
| 3 to 4 | 50 |
| TNM stage | |
| I to II | 49 |
| III to IV | 33 |
| pT status | |
| T1 to T2 | 64 |
| T3 to T4 | 18 |
| pN status | |
| N0 | 59 |
| N1 | 23 |
| pM status | |
| M0 | 78 |
| M1 | 4 |
| Surgical treatment | |
| Radical | 55 |
| Partial | 27 |
| Tumour thrombus | |
| Negative | 72 |
| Positive | 10 |
| Annual Report Year | Case Number | Clinical Summary |
| Patients Treated with FabAV | ||
| 2001 | 55 | A 17-year-old girl presented after apparent intravascular envenomation by an unknown snake with features of anaphylaxis to venom. Within minutes, she was hypotensive, profoundly hypoxic, developed pulmonary edema, and had a seizure. Treatment included intubation with ventilator support, dopamine, and FabAV (dose not reported). She never developed local tissue effects or coagulopathy. Despite maximal therapy, she died five days after envenomation. |
| 2002 | 69 | A 43-year-old man presented with severe hypotension after a rattlesnake bite. He remained hypotensive despite fluids, dopamine, epinephrine, diphenhydramine, steroids, and 26 vials of whole-IgG antivenom. Disseminated intravascular coagulopathy developed. He then received six vials of FabAV, after which his blood pressure improved such that vasopressors were discontinued. He developed epistaxis and oral mucosal bleeding that was treated with 7 additional vials of whole-IgG antivenom and transfusions of platelets, fresh frozen plasma, and cryoprecipitate (response not reported). He developed renal failure, and ultimately died of multi-system organ failure. |
| 2003 | 424 | A 33-year-old man received FabAV for an apparently uncomplicated rattlesnake envenomation. He was discharged from the hospital 24 hours later with only minimal symptoms, and was given a prescription for oxycodone with acetaminophen. He died of an apparent overdose of oxycodone that night. |
| 2004 | 52 | A 52-year-old man presented with a forearm compartment syndrome due to a copperhead snakebite. He received FabAV and underwent a dermotomy of his finger and a fasciotomy of his arm. Subsequently, he developed severe alcohol withdrawal, which was treated with diazepam, haloperidol, and fentanyl, which led to respiratory arrest, aspiration, and acute respiratory distress syndrome. Medical care was withdrawn, and the patient died. |
| 2004 | 53 | A 55-year-old man presented with severe hypotension and coma from apparent intravascular envenomation from a rattlesnake. FabAV therapy and aggressive resuscitation were not initiated for several hours. The patient developed renal failure, disseminated intravascular coagulopathy, and circulatory collapse, and died seven hours after envenomation. |
| Patients Treated with Unspecified Antivenom | ||
| 2001 | 56 | A 30-year-old man presented comatose after rattlesnake envenomation. On presentation, he was found to have coagulopathy, thrombocytopenia, and a subarachnoid hemorrhage. He received \"10 to 20 vials\" of unspecified antivenom, but died after withdrawal of life support. |
| 2005 | 57 | A 32-year-old man presented to the emergency department in respiratory arrest due to anaphylaxis from a rattlesnake bite. He received unspecified antivenom, and subsequently died of anoxic encephalopathy. |
| Groups | Dose (mg/Kg bw) | Blood antioxidant enzymes | ||
| SOD (U/g Hb) | GPX (U/g Hb) | CAT (K/g Hb) | ||
| NC | - | 2943 ± 104.4 a | 51.31±4.2a | 1.57 ± 0.6a |
| DC | - | 1945.8 ± 21.6 | 33.11 ± 3.74 | 0.541 ± 0.011 |
| ASE+D | 500 | 3125.4 ± 54.2 a | 42.2 ± 5.21b | 0.882 ± 0.12 c |
| AAE+D | 500 | 3214.3 ± 83.2 a | 47.5 ± 4.2 a | 0.839 ± 0.09 c |
| SOE+D | 250 | 2591 ± 9.13 a | 41.33 ± 2.08 b | 0.598 ± 0.04 e |
| Met+D | 100 | 2118.1 ± 29.7 c | 37.31 ± 5.51 e | 0.551 ± 0.07 e |
| NanoString FROZ vs FFPE | ScriptSeq FROZ vs FFPE | |
| BRB123 | 0.926 (0.950) | 0.790 (0.943) |
| BRB144 | 0.955 (0.965) | 0.807 (0.957) |
| BRB147 | 0.728 (0.917) | 0.802 (0.945) |
| BRB157 | 0.807 (0.930) | 0.793 (0.932) |
| BRB212 | 0.972 (0.962) | 0.830 (0.963) |
| BRB215 | 0.818 (0.976) | 0.598 (0.961) |
| BRB248 | 0.942 (0.976) | 0.830 (0.972) |
| BRB277 | 0.973 (0.970) | 0.825 (0.971) |
| MCJBCR028 | 0.747 (0.941) | 0.773 (0.933) |
| mean | 0.874 (0.954) | 0.783 (0.953) |
| N | Drug | Duration | Subcutaneous adipose tissue | Visceral adipose tissue | Body mass index (kg/m2) | Reference | |
| No change in SAT | 30 | Rosi versus placebo | 24 weeks | MRI: NS | MRI: NS | NS | Sutinen et al. [55] |
| 108 | Rosi versus placebo | 48 weeks | DEXA limb fat: NS CT thigh: NS CT s.c. abdomen: NS | CT: NS | NS | Carr et al. [56] | |
| 14 | Pio versus feno versus pio + feno versus placebo | 12 months | DEXA upper limb fat: NS DEXA lower limb fat: NS CT s.c. abdomen: NS | CT: NS | NS | Gavrila et al. [65] | |
| 96 | Rosi versus placebo | 24 weeks | DEXA limb fat: NSDEXA arm fat: NS DEXA leg fat: NS | ND | NS | Cavalcanti et al. [62] | |
| Increase in SAT | 28 | Rosi versusplacebo | 3 months | CT thigh (cm2): rosi: + 2.3 versus pla −0.9, Δ rosi versus pla, P = .002CT s.c. abdomen: NS DEXA leg: NS (rosi +50 g versus pla −80 g,Δ rosi versus pla P = .08) | CT: NS | NS | Hadigan et al. [57] |
| 105 | Rosi versus metformin versus rosi + met versus placebo | 16 weeks | DEXA leg fat (%): rosi: +4.8,*NS; met: −3.6,*NS; rosi + met: −0.5,*NS; pla: −8.3%,*NS Δ rosi vs pla P = .03, other groups versus pla, NSDEXA arm fat: NS DEXA limb fat: NS CT s.c. abdomen: NS | CT (%): rosi: 0.0,*NS; met: −0.6,*NS; rosi + met:−7.9,*NS; pla: −7.2,*NS Δ rosi versus pla, P = .08, other groups versus pla, NS | Body mass index ND, body weight (kg): rosi: 0.0,*NS; met: −2.0,*P < .001; rosi + met: −1.5,*P < .01; pla:−0.05,*NS Δ met versuspla, P = .03; Δ met + rosi versuspla, P = .06 | Mulligan et al. [60] | |
| 130 | Pio versus placebo | 48 weeks | DEXA limb fat (g): pio: +380 g; pla: +50 gΔ pio versus pla P = .051 CT s.c. abdomen: NS | CT: NS | Pio: +0.9; pla: +0.3Δ pio versus pla P = .07 | Slama et al. [66] | |
| 39 | Rosi versus metformin | 26 weeks | CT s.c. abdomen (cm2) rosi: +16,*P < .05; met: −11,*P < .05 Δ rosi versus met 27cm2 (95% CI, 7 to 46) | CT (cm2)rosi: −1,*NS; met: −25,*P < .05 Δ rosi versus met 24 cm2 (95% CI, 6 to 51) | Rosi: +0.4,*P < .05; met: −0.4,*P < .05 Δ rosi versusmet 0.7 (95% CI, 0.5 to 1.6) | van Wijk et al. [58] |
| Group A (non-GBA) | Group B (GBA) | P value | |
| Neck lymphadenopathy | 26/60 (43%) | 7/14 (50%) | NS |
| Fissured lips | 53/60 (88%) | 12/14 (86%) | NS |
| Strawberry tongue | 47/61 (77%) | 11/14 (79%) | NS |
| Conjunctivitis | 55/60 (92%) | 12/14 (86%) | NS |
| Skin rash | 51/58 (88%) | 15/15 (100%) | NS |
| BCG erythema change | 25/58 (43%) | 6/13 (46%) | NS |
| Induration of extremities | 39/56 (70%) | 3/12 (25%) | NS |
| Heuristic | Network load (No. of groups) | Channel Constraint (ω) | Radio Constraint | Network Size | Communication Radius |
| SPT | (200%, 200%)* | (175%, 150%) | (400%, 350%) | (300%, 142%) | (180%, 175%) |
| GIT | (200%, 125%) | (175%, 100%) | (400%, 250%) | (16%, 96%) | (180%, 83%) |
| CAGIT | (50%, 125%) | (125%, 100%) | (300%, 250%) | (16%, 142%) | (100%, 175%) |
| ICADCR | (31%, 13%) | (17%, 25%) | (50%, 100%) | (7%, 7%) | (61.4%, 92%) |
| AMPLICON | SSCP ANALYSIS | HRMA/SEQUENCING1 | N. OF CASES |
| EXON 1 | WT | WT | 26 |
| EXON 2 | WT | WT | 23 |
| WT | c.[64G > A]+[=] | 1 | |
| c.[64G > A]+[64G > A] | c.[64G > A]+[64G > A] | 2 | |
| EXON 3 | WT | WT | 26 |
| EXON 4 | WT | WT | 26 |
| EXON 5 | WT | WT | 26 |
| EXON 6 | WT | WT | 18 |
| c.[504+35G > A]+[=] | c.[504+35G > A]+[=] | 7 | |
| c.[481G > C]+[=] | c.[481G > C]+[=] | 1 | |
| EXON 7 | WT | WT | 19 |
| c.[536A > G]+[536A > G] | c.[536A > G]+[536A > G] | 2 | |
| c.[536A > G]+[=] | c.[536A > G]+[=] | 5 | |
| EXON 8 | WT | WT | 26 |
| EXON 9 | WT | WT | 26 |
| EXON 10 | WT | WT | 26 |
| EXON 11 | WT | WT | 26 |
| EXON 12 | WT | WT | 16 |
| c.[1014G > C]+[=] | c.[1014G > C]+[=] | 6 | |
| WT | c.[1014G > C]+[1014G > C] | 1 | |
| c.[1147delC]+[=] | c.[1147delC]+[=] | 1 | |
| c.[1023_1024insGA]2+[=] | c.[1023_1024insGA]2+[=] | 1 | |
| c.[1163T > C]+[=] | c.[1163T > C]+[=] | 1 | |
| EXON 13 | WT | WT | 19 |
| c.[1187G > A]+[1187G > A] | c.[1187G > A]+[1187G > A] | 1 | |
| c.[1187G > A]+[=] | c.[1187G > A]+[=] | 4 | |
| c.[1227_1228dupGG]+[1227_1228dupGG] | c.[1227_1228dupGG]+[1227_1228dupGG] | 1 | |
| c.[1187-27C > T(+)1258C > A]3 | c.[1187-27C > T(+)1258C > A]3 | 1 | |
| EXON 14 | WT | WT | 24 |
| c.[1437_1439delGGA]+[=] | c.[1437_1439delGGA]+[=] | 1 | |
| c.[1437_1439delGGA]+[1437_1439delGGA] | c.[1437_1439delGGA]+[1437_1439delGGA] | 1 | |
| EXON 15 | WT | WT | 26 |
| EXON 16 | WT | WT | 26 |
| Essential oil | S. pyogenes | S. pneumoniae | S. mutans | |||
| MIC | MBC | MIC | MBC | MIC | MBC | |
| Cinnamon bark | 0.41 | 0.81 | 0.06 | 0.13 | 0.20 | 0.41 |
| Thyme | 0.43 | 0.87 | 0.11 | 0.22 | 0.04 | 0.09 |
| Clove | 0.10 | 0.20 | 0.25 | 0.50 | 0.41 | 0.81 |
| Peppermint | 0.35 | 0.70 | 0.35 | 0.70 | 0.70 | 1.39 |
| Citronella | 0.17 | 0.34 | 0.09 | 0.17 | 0.17 | 0.34 |
| Eucalyptus | 2.82 | 5.64 | 1.41 | 2.81 | 0.70 | 1.41 |
| Scots pine | 1.35 | 2.71 | 0.68 | 1.35 | 1.35 | 2.71 |
| Stimulus 1 | Stimulus 2 | 95% CI Lower bound | Difference of Means (1–2) | 95% CI Upper bound | P |
| TOTALLY ENGAGED (N = 27) | |||||
| Audio only | Multimodal | –39.72 | –28.33 | –16.95 | <0.001 |
| Music: FAV | Audio only | 27.69 | 39.07 | 50.46 | <0.001 |
| Music: FAV | Multimodal | –0.64 | 10.74 | 22.12 | 0.0682 |
| FRUSTRATED (N = 27) | |||||
| Audio only | Multimodal | –3.81 | 6.19 | 16.18 | 0.3023 |
| Music: FAV | Audio only | –27.47 | –17.48 | –7.49 | <0.001 |
| Music: FAV | Multimodal | –21.29 | –11.30 | –1.31 | 0.0232 |
| Activities Related to HAI Prevention | Professional Groups | N | Average Values in Groups | Median | Standard Deviation | 95% CI |
| Hand-hygiene | Medical student | 28 | 5.6 | 6.0 | 2.71 | 4.649, 6.494 |
| Medical intern | 18 | 6.2 | 7.0 | 2.71 | 4.873, 7.571 | |
| Physician | 54 | 6.0 | 7.0 | 2.78 | 5.241, 6.759 | |
| Use of disposable gloves | Medical student | 28 | 6.6 | 7.0 | 1.52 | 6.016, 7.198 |
| Medical intern | 18 | 5.0 | 5.5 | 2.57 | 3.724, 6.276 | |
| Physician | 54 | 4.9 | 5.0 | 2.41 | 4.229, 5.548 | |
| Adherence to aseptic technique | Medical student | 28 | 5.2 | 5.0 | 1.97 | 4.451, 5.978 |
| Medical intern | 18 | 5.5 | 6.0 | 2.50 | 4.255, 6.745 | |
| Physician | 54 | 5.3 | 6.0 | 2.63 | 4.616, 6.051 |
| urine pH > 5.5 (idRTA) | urine pH < 5.5 | p | |||||||
| Baseline | 3 months | 6 months | 9 months | Baseline | 3 months | 6 months | 9 months | ||
| serum alkaline phosphate (U/L)mean (SD) | 798 (82.84) | 617 (55.67) | 533 (55.02) | 375 (53.21) | 679 (64.60) | 489 (51.40) | 447 (60.00) | 299 (46.82) | P < 0.01 |
| serum calcium (mmol/L)mean (SD) | 1.92 (0.08) | 2.01 (0.06) | 2.12 (0.03) | 2.25 (0.5) | 1.98 (0.07) | 2.13 (0.08) | 2.20 (0.080 | 2.28 (0.08) | P < 0.01 |
| serum phosphate (mmol/L)mean (SD) | 1.13 (0.08) | 1.26 (0.07) | 1.47 (0.06) | 1.50 (0.06) | 1.10 (0.09) | 1.24 (0.08) | 1.54 (0.07) | 1.59 (0.05) | P < 0.01 |
| Mean Height range (cm) | 72.00 to 83.00 | 74.00 to 91.00 | |||||||
| Mean height velocity range (cm) | 4.50 -8.00 | 4.00 - 8.40 |
| Identified Motif Sequence | # Seqs withMotif | Motif E-Value | TRANS FAC Hit ID | TRANS AC Binding Site Sequence | TRANS FAC annotation |
| CATCCAACGGC | 29 | 1.2E-1 | M00227 | TCCAACGGC | Myb |
| CCCGCCACGCGCCAC | 48 | 5.1E-26 | M00187 | GCCACG | Helix Loop Helix |
| TGGCGGGA | 50 | 5.8E-13 | M00024 | TGGCG | Elongation Factor 2 |
| CCAAACCC | 50 | 2.7E-5 | No Hit | ||
| CCACCACCACC | 48 | 3.8E-16 | No Hit | ||
| ACACAACACAC | 45 | 2.2E-10 | No Hit | ||
| AAAATAAAAATAAAA | 9 | 2.27E-7 | No Hit | ||
| AATAAAAAAATAAAA | 8 | 1.51E-7 | No Hit | ||
| AGCTAGCTAGC | 6 | 1.47E-7 | No Hit | ||
| AGCGAGCGAGC | 4 | 6.23E-8 | No Hit | ||
| AGCAAGCTAGC | 3 | 2.47E-7 | No Hit |
| Number | Percentage (%) | |
| 1 year follow up | 66 | 81.5 |
| Lost to follow up | 5 | 6 |
| Deceased at 1 year | 10 | 12.3 |
| Referral done to specialized cardiology center | 37 | 45.6 |
| Underwent Exercise ECG | 22 | 27 |
| Underwent Coronary angiogram | 10 | 12.3 |
| Underwent Revascularization | 7 | 7.3 |
| Re-admitted with Coronary events | 6 | 7.4 |
| Modification | Hypotheses tested |
| Ranking task | Introducing the ranking task prior to the cTTO valuation will reduce the inconsistencies and improves the overall data quality (i.e. more WTD responses). |
| BTD/WTD split | Separating the BTD and WTD cTTO tasks will reduce the inconsistencies of the valuations and improve the overall data quality (i.e. more WTD responses, higher values for mild heath state and fewer spikes). |
| Feedback module | Presenting respondents with the rank ordering implied by their cTTO valuations will reduce the inconsistencies as they will identify and flag problematic valuations for removal from the data. |
| Viroid small RNAs (vd-sRNAs) | Reference |
| vd-sRNAs of peach latent mosaic viroid were used to study the viroid evolution and pathogenesis | Di Serio et al., 2009; Navarro et al., 2012a |
| Gaining further insights into the genesis and role of vd-RNAs of hop stunt viroid and grapevine yellow speckle viroid 1 in plant–viroid interaction | Navarro et al., 2009 |
| vd-sRNAs from PSTVd-infected wild-type and RDR6i Nicotiana benthamiana plants accumulate to levels paralleling their genomic RNA, display similar patterns with prevailing 22- or 21-nt plus-strand species, and adopt strand-specific hot spot profiles | Di Serio et al., 2010 |
| The pathway involved in the biogenesis of vd-sRNAs of hop stunt viroid was studied and revealed | Martinez et al., 2010 |
| Characterization of vd-sRNA of hop stunt viroid, grapevine yellow speckle 1 and grapevine yellow speckle 2 viroids in grapevine | Alabi et al., 2012 |
| vd-sRNAs of peach latent mosaic viroid (PLMVd) were characterized. Similarly to host microRNAs (miRNAs), two PLMVd vd-sRNA derived from the pathogenic determinant of an extreme albinism direct cleavage of a specific host mRNA, strongly suggesting their involvement in symptom expression | Navarro et al., 2012a |
| Based on the observation that viroid-infected plants generate vd-sRNAs 21–24 nt, an approach was developed to utilize several bioinformatic tools for identifying novel and known viroids and viroid-like circular RNAs in sRNA libraries | Wu et al. (2012) |
| vd-sRNAs derived from potato spindle tuber viroid variants inducing different symptoms, may aim at multiple and different host mRNA targets | Wang et al., 2011; Piernikarczyk et al., 2013 |
| Computational algorithms as bioinformatic tools were utilized to identify circular RNAs of viroid or satellite sRNAs | Zhang et al., 2014 |
| Extending the host range of apple dimple fruit viroid to fig | Chiumenti et al., 2014 |
| Inoculation with a single variant of peach latent mosaic viroid generates a highly heterogeneous progeny within a single infected peach seedling. The most distant variants displayed a 17% variation level when compared to the parent sequence | Glouzon et al., 2014 |
| vd-sRNAs of potato spindle tuber viroid (PSTVd) and effects of artificial miRNA derived from PSTVd-mild or -severe infected plants were analyzed. Differences in the distribution of vdsRNAs hot spots were observed. Data suggest involvement of vd-sRNAs in symptom expression | Adkar-Purushothama et al., 2015; Avina-Padilla et al., 2015 |
| Extending the host range of hop stunt viroid to chickpea | Pirovano et al., 2015 |
| Species | Specimen voucher | cox1a | ITS-2b | ||||||
| GenBank accession no. | Length (bp) | G+C content (%) | Pairwise difference (%) | GenBank accession no. | Length (bp) | G+C content (%) | Pairwise difference (%) | ||
| I. auritulus | S63 | KY213767 | 674 | 31.75 | 1.1 | – | – | – | – |
| S64 | KY213768 | 674 | 31.75 | – | – | – | – | ||
| I. anatis | S28 | KY213769 | 674 | 31.90 | 1.2 | KY213757 | 703 | 54.62 | – |
| S29 | KY213770 | 674 | 31.90 | – | – | – | – | ||
| I. holocyclus | S1 | KY213782 | 674 | 32.20 | 0.2–0.9 | KY213766 | 679 | 55.38 | 1.4–8.6 |
| S4 | KY213783 | 674 | 32.05 | KY213765 | 630 | 55.70 | |||
| S37 | KY213781 | 674 | 32.34 | KY213756 | 684 | 55.40 | |||
| S17 | KY213779 | 674 | 32.49 | KY213762 | 638 | 55.80 | |||
| S39 | KY213780 | 674 | 31.90 | KY213755 | 676 | 55.47 | |||
| I. myrmecobii | S26 | KY213784 | 674 | 30.86 | 0.2–1.1 | KY213758 | 649 | 53.80 | 0.8–3.6 |
| S46 | KY213785 | 674 | 31.16 | KY213753 | 656 | 53.70 | |||
| S56 | KY213786 | 674 | 31.00 | KY213752 | 657 | 53.60 | |||
| S44 | KY213787 | 674 | 31.00 | – | – | – | |||
| S25 | KY213788 | 674 | 30.70 | KY213759 | 668 | 53.30 | |||
| S42 | KY213789 | 674 | 30.86 | KY213754 | 647 | 53.80 | |||
| I. cornuatus | S19 | KY213792 | 674 | 30.42 | 0.2–1.2 | – | – | – | – |
| S20 | KY213793 | 674 | 30.12 | – | – | – | – | ||
| S18 | KY213790 | 674 | 30.12 | KY213761 | 654 | 53.36 | – | ||
| S41 | KY213791 | 674 | 30.27 | - | – | – | – | ||
| I. dendrolagi | S14 | KY213776 | 674 | 30.70 | – | KY213763 | 672 | 55.20 | – |
| I. trichosuri | S23 | KY213777 | 674 | 31.90 | 0.3 | – | – | – | – |
| S21 | KY213778 | 674 | 31.90 | KY213760 | 704 | 56.39 | – | ||
| I. hirsti | S10 | KY213773 | 674 | 33.10 | 0.2–0.3 | – | – | – | – |
| S12 | KY213774 | 674 | 33.38 | – | – | – | – | ||
| S9 | KY213775 | 674 | 33.23 | KY213764 | 667 | 56.97 | – | ||
| I. tasmani | S68 | KY213771 | 674 | 32.20 | 10.9 | – | – | – | – |
| S69 | KY213772 | 674 | 32.05 | – | – | – | – |
| Parameter | Value | |
| n = 4068 | ||
| Age (n,%) | ||
| 18-34 | 20 | 0.5 |
| 35-44 | 108 | 2.7 |
| 45-54 | 513 | 12.6 |
| 55-64 | 1,481 | 36.4 |
| > = 65 | 1,946 | 47.8 |
| Geographic region (n,%) | ||
| Northeast | 538 | 13.2 |
| Northcentral | 1,249 | 30.7 |
| South | 2,071 | 50.9 |
| West | 208 | 5.1 |
| Payer type (n,%) | ||
| HMO | 81 | 2.0 |
| Indemnity | 1,814 | 44.6 |
| PPO | 1,210 | 29.7 |
| POS | 941 | 23.1 |
| Other | 21 | 0.5 |
| Comorbidities (n,%) | ||
| Cerebrovascular Disease | 426 | 10.5 |
| Coronay heart disease | 910 | 22.4 |
| Heart failure | 66 | 1.6 |
| Peripheral arterial disease | 165 | 4.1 |
| Diabetes | 808 | 19.9 |
| Kidney Disease | 60 | 1.5 |
| Liver Disease | 272 | 6.7 |
| Respiratory Disease | 2,384 | 58.6 |
| Health care expenditures prior to index date (mean, SD) | ||
| -365 days | 28,562 | 31,136 |
| Combination | Nr of MRSA strains (%) for which combinations gave | ||
| Synergy | No interaction | Antagonism | |
| LVX + VA (n = 50) | 16 (32) | 34 (68) | 0 |
| LVX + TEC (n = 50) | 9 (18) | 41 (82) | 0 |
| CTX + VA (n = 50) | 23 (46) | 27 (54) | 0 |
| CTX + TEC (n = 50) | 43 (86) | 7 (14) | 0 |
| LVX + VA + AMK (n = 25) | 5 (20) | 20 (80) | 0 |
| LVX + TEC + AMK (n = 25) | 10 (40) | 15 (60) | 0 |
| LVX + VA + CAZ (n = 25) | 15 (60) | 10 (40) | 0 |
| LVX + TEC + CAZ (n = 25) | 20 (80) | 5 (20) | 0 |
| LVX + VA + FEP (n = 25) | 10 (40) | 15 (60) | 0 |
| LVX + TEC + FEP (n = 25) | 10 (40) | 15 (60) | 0 |
| LVX + VA + IPM (n = 25) | 5 (20) | 20 (80) | 0 |
| LVX + TEC + IPM (n = 25) | 10 (40) | 15 (60) | 0 |
| LVX + VA + TZP (n = 25) | 5 (20) | 20 (80) | 0 |
| LVX + TEC + TZP (n = 25) | 20 (80) | 5 (20) | 0 |
| Attack-free periods Mean ± S.D. | Control Mean ± S.D. | P | |
| IOP, mmHg | 14,11 ± 2,88 | 15,81 ± 0,81 | 0,07 |
| Range | (11–20) | (11–20) | |
| AL, mm | 23,08 ± 1,2 | 23,3 ± 0,7 | 0,4 |
| Pachymetry | 0,5 | ||
| CCT, μm | 538,13 ± 35,42 | 533,20 ± 31,85 | |
| ACD, mm | 3,48 ± 0,23 | 3,52 ± 0,25 | 0,4 |
| Keratometry readings | |||
| K1, D | 43,11 ± 1,72 | 43,23 ± 1,52 | 0,7 |
| K2, D | 44,23 ± 2,03 | 44,19 ± 1,50 | 0,9 |
| LT, mm | 4,47 ± 3,75 | 3,76 ± 0,31 | 0,3 |
| PD, mm | 5,99 ± 0,92 | 5,81 ± 1,07 | 0,4 |
| WtW, mm | 12,20 ± 0,44 | 0,112 |
| Gene | Number of exons | Number of mutations worldwide** | Number of homopolymer repeats* in CDS | Function in hearing process |
| GJB2 | 2 | > 220 | 0 | ion homeostasis |
| SLC26A4 | 21 | 43 | 7 | ion homeostasis |
| MYO15A | 66 | 28 | 8 | hair bundle, motor protein |
| OTOF | 48 | 26 | 4 | exocytose at auditory ribbon synapse |
| CDH23 | 69 | 21 | 4 | hair bundle, adhesion protein |
| TMC1 | 24 | 20 | 4 | unknown function |
| TMPRSS3 | 13 | 16 | 3 | unknown function |
| TECTA | 23 | 10 | 2 | extracellular matrix protein |
| TRIOBP | 24 | 9 | 7 | hair bundle, cytoskeletal formation |
| TMIE | 4 | 8 | 0 | unknown function |
| PJVK | 7 | 7 | 3 | signaling of hair cells and neurons |
| ESPN | 13 | 6 | 1 | hair bundle, cytoskeletal formation |
| PCDH15 | 33 | 5 | 8 | hair bundle, adhesion protein |
| ESRRB | 12 | 5 | 1 | transcription factor |
| MYO7A | 49 | 5 | 5 | hair bundle, motor proteins |
| Parameter | Mean value for group ± SEa | |||||
| NI | Pretherapy (120 dpi) | Posttherapy (180–200 dpi) | ||||
| Veh | PTX | Bz | Bz+PTX | |||
| Parasitemia level (104 parasites/ml) | 0 | 53 ± 10 | 56 ± 45 | 23 ± 8.5 # | 9.9 ± 9.9 ## | 5.7 ± 3 ### |
| % of mice with arrhythmia | 0 | 100 ± 0 *** | 100 ± 0 *** | 100 ± 0 *** | 100 ± 0 *** | 48 ± 3 #,§,‡,† |
| No. of flutter events/2 min | 0 | 0 | 41.3 ± 2.6 ***,††† | 29.5 ± 0.5 #,††† | 0 ###,§§§ | 0 ###,§§§ |
| % of mice with AVB2 | 0 | 86 ± 6 *** | 78 ± 7 *** | 82 ± 2 | 58 ± 1.5 §,† | 41 ± 2 #,§,‡,†† |
| No. of AVB2 events/2 min | 0 | 212 ± 11 *** | 292 ± 18 ***,†† | 47 ± 1.5 ###,††† | 50 ± 2.8 ###,††† | 51 ± 1.2 ###,††† |
| QRS (ms) | 11 ± 0.14 | 13 ± 0.48 * | 13.4 ± 0.3 *** | 11.8 ± 0.2 ## | 11.9 ± 0.4 # | 10.9 ± 0.3 ###,†† |
| QTc (ms) | 77 ± 2.5 | 89.9 ± 2.4 ** | 94.2 ± 2.7 *** | 88.3 ± 3.4 | 86.9 ± 3.9 | 83.2 ± 3.4# |
| Parameter | Temperature (K) | ||
| 293 | 303 | 313 | |
| −ΔG° (kJ mol−1) | 6.543 | 6.063 | 5.687 |
| −ΔH° (kJ mol−1) | 16.869 | ||
| −ΔS° (kJ mol−1 K−1) | 0.0353 | ||
| Ea (kJ mol−1) | 3.309 |
| Temperature (°C) | −40 | −20 | 0 | +20 | +40 | +60 |
| Resonant frequency of the upper resonator (Hz) | 31,331.12 | 31,379.3 | 31,426.16 | 31,462.37 | 31,496.56 | 31,514.02 |
| Resonant frequency of the lower resonator (Hz) | 31,439.55 | 31,486.05 | 31,531.33 | 31,565.55 | 31,598.49 | 31,615.11 |
| Frequency difference (Hz) | 108.43 | 106.75 | 105.17 | 103.18 | 101.93 | 101.09 |
| Participant code | Sex | Age (yrs) | BMI (kg/m2) | Injury level and AIS score | Years since SCI | Medications | Treatment |
| 1 | M | 46 | 32.9 | C5A | 23.3 | Baclofen, Temazepam | CPAP |
| 2 | M | 68 | 27.7 | C4A | 23.9 | Baclofen | CPAP |
| 3 | F | 28 | 20.3 | C5A | 4.10 | Baclofen, Diazepam | — |
| 4 | M | 42 | 20.8 | C6A | 17.10 | Baclofen, Diazepam | Oral Splint |
| 5 | M | 26 | 18.5 | C6A | 10.10 | Baclofen | — |
| Positive control | |||||||
| 1 | M | 43 | 24.8 | — | — | — | — |
| 2 | F | 31 | 20.7 | — | — | — | — |
| Women | Men | ||||
| N = 214 | N = 154 | ||||
| OR | p | OR | p | ||
| Surgical specialties | Combining work with family | 0.4 (0.3–0.6) | .000 | 0.4 (0.3–0.7) | .000 |
| Good salarya | 1.9 (1.2–3.0) | .004 | 0.8 (0.5–1.3) | NS | |
| In line with technical skills | 1.4 (1.0–1.9) | .034 | 1.9 (1.2–3.0) | .011 | |
| Lots of direct patient contact | 0.9 (0.6–1.3) | NS | 0.6 (0.4–0.9) | .018 | |
| Non-surgical specialties | Research opportunities | 1.4 (1.0–1.9) | .023 | 1.9 (1.3–2.9) | .001 |
| Good salary | 0.4 (0.2–0.6) | .000 | 0.8 (0.5–1.3) | NS | |
| Interesting content | 2.4 (1.0–5.5) | .048 | 1.7 (0.8–3.9) | NS | |
| Family medicine | Lots of direct patient contact | 3.7 (1.8–7.9) | .001 | 2.9 (1.4–6.0) | .005 |
| Career prospectsa | 0.4 (0.2–0.7) | .002 | 0.8 (0.4–1.5) | NS | |
| Combining work with family | 2.3 (1.3–4.2) | .004 | 1.6 (0.9 –2.9) | NS | |
| Good salary | 1.9 (1.1–3.3) | .018 | 1.7 (0.9–3.2) | NS | |
| Interesting content | 0.4 (0.2–0.9) | .024 | 0.8 (0.4–1.9) | NS | |
| In line with technical skills | 0.6 (0.4–1.0) | .045 | 0.7 (0.5–1.2) | NS | |
| Research opportunities | 0.8 (0.6–1.3) | NS | 0.6 (0.4–1.0) | .031 | |
| Uncertain | Combining work with family | 2.1 (1.5–3.1) | .000 | 1.8 (1.2–2.7) | .005 |
| Lots of direct patient contact | 0.6 (0.4–0.8) | .003 | 1.0 (0.7–1.5) | NS |
| Characteristics | THC score mean (SE) | CH score mean (SE) | PH score mean (SE) | P value |
| First contact and continuity | 95.40 (0.39) | 90.93 (0.52) | 85.23 (0.51) | <0.001 |
| Comprehensiveness (medical care) | 80.9 (0.99) | 78.05 (1.03) | 80.45 (0.67) | 0.075 |
| Comprehensiveness (social care) | 90.33 (0.84) | 85.39 (0.73) | 81.91 (0.61) | <0.001 |
| First contact (access) | 80.16 (1.15) | 69.21 (1.40) | 60.04 (0.86) | <0.001 |
| Coordination | 91.65 (0.73) | 84.39 (0.91) | 77.65 (0.75) | <0.001 |
| Family centeredness | 90.34 (0.68) | 87.93 (0.60) | 84.18 (0.53) | <0.001 |
| Community orientation | 87.98 (0.87) | 80.36 (0.85) | 67.36 (0.78) | <0.001 |
| Same doctor | 66.42 (1.54) | 70.95 (1.26) | 74.44 (0.95) | <0.001 |
| Stableness | 45.37 (1.18) | 43.14 (1.04) | 48.75 (0.92) | 0.001 |
| Total | 86.64 (0.49) | 82.01 (0.50) | 77.42 (0.38) | <0.001 |
| Authors | Intervention | Patient Population | Design | No. of Patients | Outcome |
| Pizzocarro et al15 | IFN-α2b v placebo | Robson stages II and III (T3aN0M0 and T3bN0M0 or T2/3N1-3M0) | Multicenter, randomized, controlled trial | 247 | 5-year OS: 0.665 (control) v 0.660 (treatment) (HR 1.040; 95% CI, 0.671 - 1.613, P = 0.861) |
| 5-year DFS: 0.671 (control) v 0.567 (treatment) (HR 1.412; 95% CI, 0.927–2.149, P = .107) | |||||
| Messing et al16 | IFN-α-NL v observation | pT3–4a and/or node-positive) | Multicenter, randomized, controlled trial | 283 | At 10.4 years median follow-up: |
| Median survival: 7.4 years (control) v 5.1 years (treatment) (P = .09). | |||||
| DFS: 3.0 years (control) v 2.2years (treatment) (P = .33) | |||||
| Clark et al17 | IL-2 v observation | T3b-4 or N1–3 (LA) or M1 | Multicenter, randomized, controlled trial | 69 total; 44 LA, 25 M1 disease | 2-year DFS: 48% (control in LA patients) v 53% (treatment in LA patients) (P = 0.73) |
| 2-year OS: 77% (control in LA patients) v 86% (treatment in LA patients) (P = .38) | |||||
| Passalacqua et al18 | IL-2 and IFN-α v observation | pT1, T2, T3 a-b-c; pN0-pN3, M0 | Multicenter, randomized, controlled trial | 310 | 5-year DFS: 0.73 (control) v 0.73 (treatment) |
| 10-year DFS: 0.60 (control) v 0.73 (treatment) (HR 0.84; 95% CI, 0.54–1.33, P = 0.47) | |||||
| Atzpodien et al19 | IL-2 and IFN-α2a and intravenous 5 v fluorouracil | pT3b/c pN0 or pT4pN0), pN, complete resection of tumor relapse or solitary metastasis (R0) | Multicenter, randomized, controlled trial | 203 | At median follow-up of 4.3 years: |
| 2-year OS: 91% (control) v 81% (treatment) | |||||
| 5-year OS: 76% (control) v 58% (treatment) | |||||
| 8-year OS: 66% (control) v 58% (treatment) (P = 0.0278) | |||||
| 2-year DFS: 62% (control) v 54% (treatment) | |||||
| 5-year DFS: 49% (control) v 42% (treatment) | |||||
| 8-year DFS: 49% (control) v 39% (treatment) (P = 0.2398) | |||||
| Aitchison et al22 | IL-2 and IFN-α2a and intravenous 5-fluorouracil | T3b-c,T4 or any pT and pN 1 or pN 2 or positive microscopic margins or microscopic vascular invasion | Multicenter, randomized, controlled trial | 309 | 3-year DFS: 50% (control) v 60% (treatment) (HR 0.87; 95% CI, 0.63-1.20) |
| 5 year OS: 60% (control) v 68% (treatment) (HR 0.91; 95% CI, 0.60–1.38) | |||||
| Galligioni et al24 | Autologous irradiated tumor cells & BCG v observation | Stages I, II, and III | Prospective, randomized, controlled trial | 120 | At 61 months median follow-up: |
| 5-year OS: 78% (control) v 69% (treatment) | |||||
| 5-year DFS: 72% (control) v 63% (treatment) | |||||
| Adler et al25 | Autologous irradiated tumor cells & BCG & hormone v hormone | All stages | Prospective, randomized, controlled trial | 43 | Trend for prolongation of DFS for stage I, II, and III |
| (P<.1) | |||||
| Wood et al26 | Autologous, tumor-derived heat-shock protein (glycoprotein 96)–peptide complex (HSPPC-96; vitespen) v observation | cT1b–T4 N0 M0, or cT any N1-2 M0 | Multicenter, randomized, controlled trial | 819 | At 1.9 years median follow-up: |
| Recurrence: 39.8% (control) v 37.7% (treatment) (HR 0·923; 95% CI, 0·729–1·169, P = .506) | |||||
| OS not mature | |||||
| Jocham et al27 | Autologous renal tumor cells (Reniale) | pT2–3b pN0–3 M0 | Multicenter, randomized, controlled trial | 558 | At 5-year follow-up: |
| DFS: 67.8% (control) v77.4% (treatment) (P = .0204) At 70-month follow-up: | |||||
| DFS: 59.3% (control) v 72% (treatment) | |||||
| HR for tumor progression: 1.58 (95% CI 1.05–2.37) and 1.59 (1.07–2.36) (P = .0204) |
| Species | Fu’s FS | Tajima’s D | SSD | rg |
| H. bovis | −12.795*** | −2.031 ** | 0.001 | 0.035 |
| H. sinense | −19.809*** | −2.320** | 0.001 | 0.033 |
| Primary | Definition |
| Tumor (T) | |
| Tx | Primary tumor cannot be assessed |
| T0 | No evidence of primary tumor |
| Tis | Carcinoma in situ |
| T1 | Tumor 2 cm or less in greatest dimension and no medullary bone invasion |
| T2 | Tumor more than 2 cm but not more than 4 cm in greatest dimension and no bone invasion or tumor 2 cm or less in greatest dimension with medullary bone invasion |
| T3 | Tumor more than 4 cm in greatest dimension and no medullary bone invasion or tumor more than 2 cm but not more than 4 cm with medullary bone invasion |
| T4a | Tumor more than 4 cm in greatest dimension with medullary bone invasion or tumor invades into mandibular canal, deep/extrinsic muscle of tongue (genioglossus, hyoglossus, palatoglossus, and styloglossus), maxillary sinus, or skin of face |
| T4b | Tumor invades masticator space, pterygoid plates, or skull base; or encases internal carotid artery |
| Location of study village | Types of prevention practices reported | Frequency & motivation for bed net use | Influences on preventative health behaviours | Community suggestions for participation in malaria elimination |
| North Tanna | Use of bed netsClean home/personalhygieneProtective clothingTidy village/sourceInsect spray | Some reported seasonal use others reported year round use (varies at household & individual levels)Motivation to nets for both mosquito nuisance and protection from malariaNet rarely used whentravelling | Health officers most influential (VHW, nurse)Church leaders, chiefs &Village eldersTeachersMothers most influentialon health behaviours ofchildrenRisk perceptionAcceptability andPractical issues | Take advice of village leadersSet example for othersTidy village/sourcereducton activitiesUse bed netsMosquito sprayand coilsUse fire/smoke for protection outsideImprove roads to Lenakel/closer clinics for treatment |
| Middle Bush | Use of bed netsClean homeTidy village/sourcereductionDrinking clean waterBlanket for protectionwhen sleeping duringtravel | Mostly seasonal use of bed netsPrimary motivation ismosquito nuiscanceNet rarely used whentravelling | Doctors & health officersCheif & church leadersTeachersHousehold heads influencefamily practicesMothers influence healthpractices of childrenRisk perceptionAcceptability andpractical issues | Village leaders to spread messagesLeaders to set example for othersTidy village/sourcereduction activitiesUse bed netsImprove access to earlyand effectivetreatment |
| South Tanna | Use of bed netsClean home/personalhygieneTidy village/sourcereductionFire/smoke as repellentBlanket for protectionwhen travelling | Some reported seasonal use others year round use (varies at household &individual levels)Motivation to use nets forboth mosquito nuiscanceand protection frommalariaNet rarely used whentravelling | Health officers Church leaders, chief and village eldersHousehold heads influencefamilyMothers influence healthpractices of childrenRisk perceptionAcceptability andpractical issues | Village leaders to encourage participationTidy village/sourcereduction activitiesUse bed netsSupport IRS |
| Homogeneity/ Heterogeneity of responses | Homogeneity in types of protection methods used across the 3 villages | Heterogeneity between the Middle Bush village and other 2 villages due to absence of malaria | Homogeneity in influences on health behaviours across the 3 villages | Homogeneity in ideas for participation in malaria prevention across the 3 villages |
| Sex and variable | Blood pressure category | P for differenceb | |||
| Normal | Pre- | Stage 1 | Stage 2a | ||
| Men | |||||
| No. of participants | 3309 | 5866 | 2874 | 4120 | |
| Age, years | 56.5 ± 8.4 | 58.6 ± 7.9 | 60.1 ± 7.4 | 62.2 ± 6.2 | <0.0001 |
| Blood pressure, mm Hg | |||||
| Systolic | 109.6 ± 6.8 | 127.7 ± 6.5 | 143.5 ± 7.5 | 144.7 ± 16.3 | <0.0001 |
| Diastolic | 67.9 ± 6.2 | 77.4 ± 6.5 | 85.7 ± 7.6 | 85.4 ± 11.0 | <0.0001 |
| Body mass index, kg/m2 | 22.9 ± 2.7 | 23.7 ± 2.8 | 24.3 ± 2.9 | 24.7 ± 2.9 | <0.0001 |
| Total cholesterol, mmol/L | 5.3 ± 0.9 | 5.3 ± 0.9 | 5.3 ± 0.9 | 5.3 ± 0.9 | 0.0168 |
| HDL-cholesterol, mmol/L | 1.4 ± 0.4 | 1.4 ± 0.3 | 1.4 ± 0.4 | 1.4 ± 0.4 | 0.2994 |
| Triglycerides, mmol/L | 1.5 ± 1.0 | 1.8 ± 1.2 | 1.9 ± 1.4 | 1.8 ± 1.2 | <0.0001 |
| History of diabetes, % | 7.1 | 9.3 | 10.9 | 13.6 | <0.0001 |
| Smoking status, % | <0.0001 | ||||
| Never | 21.2 | 22.3 | 21.5 | 23.5 | |
| Former | 27.3 | 32.3 | 36.4 | 39.7 | |
| Current | 51.4 | 45.4 | 42.1 | 36.8 | |
| Drinking habit, % | <0.0001 | ||||
| None | 31.7 | 25.0 | 21.0 | 19.0 | |
| Sometimes | 27.1 | 22.2 | 19.6 | 18.3 | |
| Daily | 41.3 | 52.8 | 59.4 | 62.7 | |
| Women | |||||
| No. of participants | 7480 | 9371 | 3307 | 6099 | |
| Age, years | 56.4 ± 7.8 | 59.4 ± 7.1 | 60.8 ± 6.5 | 62.3 ± 5.6 | <0.0001 |
| Blood pressure, mm Hg | |||||
| Systolic | 108.1 ± 7.4 | 127.9 ± 6.2 | 144.8 ± 6.4 | 142.6 ± 16.5 | <0.0001 |
| Diastolic | 66.0 ± 6.4 | 75.5 ± 6.7 | 83.2 ± 7.7 | 81.8 ± 10.3 | <0.0001 |
| Body mass index, kg/m2 | 22.2 ± 2.8 | 23.2 ± 3.0 | 23.9 ± 3.2 | 24.6 ± 3.4 | <0.0001 |
| Total cholesterol, mmol/L | 5.5 ± 0.9 | 5.7 ± 0.9 | 5.8 ± 0.9 | 5.7 ± 0.8 | <0.0001 |
| HDL-cholesterol, mmol/L | 1.6 ± 0.4 | 1.6 ± 0.4 | 1.6 ± 0.4 | 1.5 ± 0.4 | <0.0001 |
| Triglycerides, mmol/L | 1.2 ± 0.7 | 1.4 ± 0.9 | 1.5 ± 0.9 | 1.5 ± 0.9 | <0.0001 |
| History of diabetes, % | 2.7 | 4.2 | 5.5 | 9.0 | <0.0001 |
| Smoking status, % | <0.0001 | ||||
| Never | 87.9 | 92.3 | 92.6 | 93.1 | |
| Former | 2.3 | 1.7 | 1.5 | 1.7 | |
| Current | 9.8 | 6.0 | 5.9 | 5.2 | |
| Drinking habit, % | <0.0001 | ||||
| None | 74.0 | 76.6 | 77.5 | 79.8 | |
| Sometimes | 20.0 | 17.9 | 16.8 | 14.9 | |
| Daily | 6.0 | 5.5 | 5.7 | 5.3 |
| Exon | Primers (3′-5′) | Annealing temperature (°C) | Buffer pH | MgCl2 (mM) | % DMSO | Fragment (bp) |
| 1 | F: GCAGATTTAAAGCAACACCACC | 60 | 8.4 | 1 | 0 | 242 |
| R: CCCCTTCAAATTATCCTCAGC | ||||||
| 2 | F: CTAGTGATTCATCGATGTAGCTC | 52 | 8.4 | 1 | 10 | 370 |
| R: TTTCCAGCTCCTCTGGTCATTGC | ||||||
| 3 | F: TGATGTCAGTTTTCAAAGTTTTCC | 54 | 8.4 | 1 | 0 | 313 |
| R: TAATTAGCAAAACTGAGAGAGTGG | ||||||
| 4 | F: GCACACATTAAATTTGTTTCTGCA | 54 | 8.4 | 1.5 | 0 | 345 |
| R: TACCACTTTGTCAGATTATAGATG | ||||||
| 5 | F: TAGTAACTCCACATTTTTCTATAC | 50 | 8.4 | 1.5 | 0 | 301 |
| R: TAAGTGCAAAGTAATAGTAACTGT | ||||||
| 6 | F: AATATTTTCAGAGTAAGCACTCAT | 50 | 8.4 | 1.5 | 0 | 288 |
| R: ACACTTTATACAATCCCAATCAAA | ||||||
| 7 | F: GTGATGTTGCTTAAAAGCATCAAAC | 54 | 8.6 | 1.5 | 0 | 325 |
| R: CTTGTAAAGAAGCAACAAGATCAAC | ||||||
| 8 | F: CCATTTTCCTGAAACACTACCCTA | 52 | 8.4 | 1.5 | 0 | 377 |
| R: TTGGGGTACAGTGCAACAGATTAG | ||||||
| 9 | F: AATTATTTGAATTTCCAGACACCT | 50 | 8.4 | 1.5 | 0 | 375 |
| R: GGGTTATTCTATGAAATTAGTCCA | ||||||
| 10 | F: GCAATTTCACTATTCTATGAAAGG | 52 | 8.4 | 1.5 | 0 | 348 |
| R: ACAGAATTGGCTACATAATGGCT |
| r/P | |||||||
| sIL-6 | sVEGF | pVEGF | D-D | Platelets | Fibrinogen | sVEGF/pl | |
| sIL-6 | 0.25/0.03 | 0.33/0.005 | 0.41/0.006 | 0.23/0.06 | 0.22/0.06 | ||
| sVEGF | 0.48/<0.001 | 0.25/0.04 | 0.22/0.06 | 0.88/<0.0001 | |||
| pVEGF | 0.38/0.0019 | 0.23/0.05 | 0.26/0.0339 | 0.38/0.001 | |||
| D-D | 0.26/0.03 | 0.34/0.0061 |
| Variable | CTX only | Trastuzumab + CTX | Total | P-value | ||||
| Number of patients | 45 | 70 | 115 | |||||
| Gender | ||||||||
| Male | 34 | 75.6% | 52 | 74.3% | 86 | 74.8% | 0.878 | |
| Female | 11 | 24.4% | 18 | 25.7% | 29 | 25.2% | ||
| Age | ||||||||
| Median age, years (range) | 58 (37–72) | 59 (30–80) | 58 (30–80) | 0.884* | ||||
| BMI | ||||||||
| Median, kg/m2 (range) | 22.7 (16.7–35.0) | 21.4 (13.8–32.5) | 21.9 (13.8–35.0) | 0.059* | ||||
| Baseline LVEF | ||||||||
| Median, % (range) | 66 (57–75) | 65 (57–75) | 66 (57–75) | 0.307* | ||||
| Maximally decreased LVEF from baseline LVEF | ||||||||
| Median, % (range) | 6 (1–12) | 7 (1–21) | 6 (1–21) | 0.279* | ||||
| Total treatment cycles | ||||||||
| Median, number (range) | 8 (2–92) | 9 (1–62) | 8 (1–92) | 0.827* | ||||
| Hypertension | ||||||||
| Yes | 12 | 26.7% | 18 | 25.7% | 30 | 26.1% | 0.910 | |
| No | 33 | 73.3% | 52 | 74.3% | 85 | 73.9% | ||
| Underlying cardiac disease | ||||||||
| Yes | 1 | 2.2% | 3 | 4.3% | 4 | 3.5% | >0.99† | |
| No | 44 | 97.8% | 67 | 95.7% | 111 | 96.5% | ||
| Diabetes | ||||||||
| Yes | 5 | 11.1% | 8 | 11.4% | 13 | 11.3% | >0.99† | |
| No | 40 | 88.9% | 62 | 88.6% | 102 | 88.7% | ||
| Hyperlipidemia | ||||||||
| Yes | 0 | 0.0% | 2 | 2.8% | 2 | 1.7% | 0.519† | |
| No | 45 | 100% | 68 | 97.2% | 113 | 98.3% | ||
| Cerebrovascular disease | ||||||||
| Yes | 1 | 2.2% | 3 | 4.3% | 4 | 3.5% | >0.99† | |
| No | 44 | 97.8% | 67 | 95.7% | 111 | 96.5% | ||
| Smoking | ||||||||
| Current | 15 | 33.3% | 20 | 28.6% | 35 | 30.4% | 0.862 | |
| Former | 11 | 24.4% | 18 | 25.7% | 29 | 25.2% | ||
| Never | 19 | 42.3% | 32 | 45.7% | 51 | 44.4% |
| Factors | β | S.E. | aOR (95% CI) |
| Residence (rural vs. urban) | 0.79 | 0.36 | 2.03 (1.30–4.25) |
| Parental history of T1DM (positive history vs. negative) | 3.90 | 2.54 | 9.03 (1.02–85.32) |
| Mod Of Delivery (cesarean vs. vaginal) | 0.75 | 0.43 | 2.13 (1.09–5.03) |
| Breast feeding (>6 months vs. <6 months) | −1.46 | 0.39 | 0.23 (0.11–0.50) |
| Introduction of cows milk in first year of life (positive vs. negative) | 2.99 | 0.42 | 19.94 (8.73–45.53) |
| Vitamin D Supplementation in first year of life (positive vs. negative) | −2.16 | 0.37 | 0.11 (0.05–0.24) |
| Physical Activity (high vs. low) | −2.90 | 0.44 | 0.05 (0.02–0.12) |
| Sample sizes | N | Alternative | Power | Correct classif. rate |
| 200/200/200/200 | 800 | .05/.05/.05/.10 | .682 | .935 |
| 540/200/40/20 | 800 | .05/.05/.05/.10 | .251 | .758 |
| 200/200/200/200 | 800 | .05/.05/.10/.10 | .792 | .831 |
| 540/200/40/20 | 800 | .05/.05/.10/.10 | .425 | .687 |
| 200/200/200/200 | 800 | .05/.10/.10/.10 | .603 | .783 |
| 540/200/40/20 | 800 | .05/.10/.10/.10 | .755 | .854 |
| 400/400/400/400 | 1600 | .05/.05/.05/.10 | .915 | .971 |
| 1340/200/40/20 | 1600 | .05/.05/.05/.10 | .266 | .749 |
| 400/400/400/400 | 1600 | .05/.05/.10/.10 | .968 | .916 |
| 1340/200/40/20 | 1600 | .05/.05/.10/.10 | .438 | .667 |
| 400/400/400/400 | 1600 | .05/.10/.10/.10 | .903 | .904 |
| 1340/200/40/20 | 1600 | .05/.10/.10/.10 | .832 | .883 |
| 9740/200/40/20 | 10000 | .05/.05/.05/.10 | .252 | .702 |
| Substance | Reported Usage | Percent of Survey Participants |
| Opioid Pharmaceuticals | 18 | 5.95% |
| Hallucinogens | 11 | 3.63% |
| MDMA/Ecstasy | 10 | 3.30% |
| Cocaine/Crack Cocaine | 7 | 2.31% |
| Benzodiazepine Pharmaceuticals | 6 | 1.98% |
| Other Substances | 5 | 1.65% |
| Stimulant Pharmaceuticals | 3 | 0.99% |
| Methamphetamine | 2 | 0.66% |
| Heroin | 0 | 0.00% |
| Variables | Lean | Overweight | Obese | p for heterogeneity |
| BMI (kg/m2)(mean) | 18.5–24.9922.7 ± 1.7 | 25–29.9927.1 ± 1.6 | ≥3033.5 ± 3.8 | |
| No. of subjects (%) | 246 (51) | 150 (31) | 77 (18) | |
| Sociodemographic variables | ||||
| Age (years) | 48 ± 16 | 57 ± 17 | 61 ± 16 | <0.0001 |
| Female/male | 122/124 | 66/84 | 49/28 | <0.0001 |
| University degree or higher | 180 | 89 | 33 | <0.0001 |
| Household income (above median) | 149 | 84 | 38 | 0.1 |
| Health behaviors | ||||
| Current smoking (%) | 16 | 11 | 6 | 0.9 |
| Physical activity (kJ/d/Kg) | 47 ± 20 | 47 ± 22 | 43 ± 23 | 0.44 |
| Health measures | ||||
| Systolic blood pressure (BP) (mm Hg) | 116 ± 15 | 123 ± 16 | 126 ± 19 | <0.0001 |
| Diastolic BP (mm Hg) | 71 ± 10 | 75 ± 11 | 77 ± 11 | <0.0001 |
| Disease diagnosis | ||||
| Myocardial infarction | 1 | 3 | 1 | 0.3 |
| Cancer | 11 | 6 | 9 | 0.03 |
| Diabetes | 3 | 6 | 9 | <0.0001 |
| Stroke | 4 | 0 | 1 | 0.3 |
| High cholesterol | 21 | 17 | 17 | <0.01 |
| High BP | 19 | 30 | 29 | <0.001 |
| Time since quitting | Beneficial health changes that take place |
| 24 h | Lungs start to clear out mucus and other smoking debris |
| 48 h | Carbon monoxide will be eliminated from the body. Ability to taste and smell is greatly improved |
| 72 h | Breathing becomes easier. Bronchial tubes begin to relax and energy levels increase |
| 2–12 weeks | Circulation improves |
| 3–9 months | Coughs, wheezing and breathing problems improve as lung function is increased by up to 10% |
| 1 year | Risk of a heart attack falls to about half that of a smoker |
| 10 years | Risk of lung cancer falls to half that of a smoker |
| 15 years | Risk of heart attack falls to the same as someone who has never smoked |
| Characteristic | N | % |
| Pre-pregnancy nutritional status (BMI) | ||
| Underweight (<18.5 kg/m2) | 84 | 10.9 |
| Normal weight (18.5 – 24.99 kg/m2) | 494 | 63.8 |
| Overweight (25.0 – 29.99 kg/m2) | 131 | 16.9 |
| Obese (≥30.0 kg/m2) | 65 | 8.4 |
| Total weight gain | ||
| Low | 209 | 26.9 |
| Intermediate | 298 | 38.4 |
| High | 270 | 34.7 |
| Mode of delivery | ||
| Normal | 288 | 49.6 |
| Forceps | 22 | 3.8 |
| Cesarean section | 270 | 46.6 |
| Gestational age at birth | ||
| Preterm (<37 weeks) | 26 | 4.7 |
| Term (≥37 weeks) | 527 | 95.3 |
| Weight at birth | ||
| Low (<2500 g) | 33 | 4.3 |
| Normal (2500 g - 3999 g) | 695 | 91.1 |
| High (≥4000 g) | 35 | 4.6 |
| Pregnancy complications | ||
| None | 455 | 54.9 |
| Other | 347 | 41.9 |
| Gestational diabetes mellitus | 27 | 3.3 |
| Analysis | Number of plants assayed | Number of tolerant plants | Transformation frequency |
| Basta leaf paint | 78 | 70 | 89.73% |
| Kanamycin/paromomycin Leaf bleach | 34 | 32 | 94.12% |
| Plant specie | Aa length | PTS1 | pI | Molecular Mass (kDa) | Accession number |
| Arabidopsis thaliana | 486 | -SKI | 7.02 | 53.6 | AEE73797.1 |
| Cleome spinosa | 485 | -SMI | 5.80 | 53.6 | ABD96861.1 |
| Medicago sativa | 486 | -SRI | 5.33 | 53.7 | AAB41553.1 |
| Oryza sativa | 480 | -AKM | 5.85 | 52.7 | AJB98434.1 |
| Pinus sylvestris | 483 | -SKI | 6.31 | 53.3 | ADP03057.1 |
| Pinus pinaster | 483 | -SKI | 6.74 | 53.2 | ADP03318.1 |
| Spinacia oleracea | 483 | -SKI | 6.04 | 53.2 | AAK51690.1 |
| Vitis vinifera | 438 | -SKI | 8.13 | 48.3 | CAN67602.1 |
| Zea mays | 480 | -SKI | 6.09 | 52.7 | ACN35899.1 |
| Oil | Isothermal T (°C) | t0 (min) | tmax(min) | Regression equationa | R2b | Reported t0 or shelf life at 20 °C (d) |
| Linola | ||||||
| 100 | 170.7 | 287.1 | Log (k) = 0.0211 T-4.3479 | 0.9987 | 5.9 | |
| 110 | 108.3 | 183.7 | ||||
| 120 | 64.6 | 114.5 | ||||
| GT | ||||||
| 100 | 162.5 | 229.9 | Log (k) = 0.0237 T – 4.5500 | 0.9633 | 8.3 | |
| 110 | 78.4 | 128.4 | ||||
| 120 | 54.6 | 88.4 | ||||
| W 92 | ||||||
| 100 | 200.1 | 424.3 | Log (k) = 0.0240 T – 4.7354 | 0.9574 | 12.5 | |
| 110 | 140.8 | 297.9 | ||||
| 120 | 66.1 | 210.5 | ||||
| W 86 | ||||||
| 100 | 118.5 | 270.8 | Log (k) = 0.0277 T – 4.8907 | 0.9346 | 15.1 | |
| 110 | 83.9 | 186.7 | ||||
| 120 | 33.0 | 120.5 |
| Resource | Brief description | Included information |
| Facilitator manual | Comprehensive train-the-trainer manual detailing all information required for the delivery of the program | * Introduction* Successful facilitating* Background to the research* Session guides |
| Manual for Dads | Handbook for fathers that includes a summary of the information from the face-to-face sessions and additional background information | * Session 1: Weight loss fundamentals for men* Session 2: Raising children in an inactive world* Session 3: Ready to rumble with dad* Session 4: Healthy eating for families - dads matter* Session 5: Fun, fitness and fundamental movement skills* Session 6: Sustaining healthy lifestyles* Session 7: Weight loss is a journey not a destination |
| Dad's log book | Handbook that dads use as a working document | * Program activities: Energy calculations; sedentary behaviors; goal setting; eating habits* Homework activities: Children's screen time; family fitness activity; family cooking; children's food intake; cue words; family activity* Monitoring procedures: Pedometer chart; weight loss chart; goal recording |
| Website user guide | Handbook to guide fathers through the setup and use of the dietary and physical activity monitoring website | * Setting up a profile* Food and exercise diary* Check in diary* Charts and reports |
| Kid's Handbook | Includes tasks for children to complete each week with their dads that must be signed off with their dads (space to receive a sticker from facilitators if completed) | * Kids homework activities* Recipes to cook with dad |
| Green slips | Homework activity slips given to fathers at the end of each session | * Activities are designed to align with the principles presented at the intervention session and any activities detailed in the Dad's log book and Kid's handbook (e.g. cooking meals with kids, family fundamental movement skills circuit, rough and tumble games with dad) |
| F0-1 | F2-4 | P value | F0-2 | F3-4 | P value | F0-3 | F4 | P value | |
| HBeAg (+) | 4.60 (4.38-4.78) | 4.12 (3.98-4.30) | <0.001 | 4.51 (4.28-4.74) | 4.03 (3.89-4.25) | <0.001 | 4.48 (4.26-4.71) | 3.95 (3.74-4.10) | <0.001 |
| HBeAg (-) | 3.20 (2.77-3.62) | 3.42 (2.84-3.83) | 0.084 | 3.32 (2.82-3.82) | 3.24 (2.78-3.65) | 0.349 | 3.23 (2.77-3.68) | 3.37 (3.02-3.92) | 0.178 |
| Echium Oil | Fish Oil | Significant Effect | ||||||||
| Fatty Acids | Control | EO-1 | EO-3 | EO-5 | FO-1 | FO-3 | FO-5 | Oil | Dose | Oil × Dose |
| C16:0 | 19.4 ± 0.90 | 20.1 ± 0.91 | 18.77 ± 0.84 | 18.36 ± 0.66 | 19.12 ± 0.43 | 20.24 ± 0.38 | 20.37 ± 0.92 | ns | ns | ns |
| C16:1n-9 | 1.9 ± 0.40 b | 1.1 ± 0.13 a | 1.2 ± 0.28 a | 1.0 ± 0.18 a | 1.4 ± 0.15 a | 1.7 ± 0.14 b | 1.90.13 b | 0.003 | ns | ns |
| C18:0 | 14.8 ± 0.60 b | 12.5 ± 0.57 a | 12.1 ± 1.04 a | 13.3 ± 1.09 a | 14.9 ± 0.71 b | 14.6 ± 0.87 b | 15.1 ± 0.72 b | 0.012 | ns | ns |
| C18:1n-9 | 17.2 ± 0.77 | 18.5 ± 0.29 | 18.0 ± 1.16 | 17.6 ± 0.56 | 18.6 ± 0.44 | 18.6 ± 0.57 | 16.9 ± 0.56 | ns | ns | ns |
| C18:1n-7 | 5.6 ± 0.37 b | 4.2 ± 0.71 a | 3.2 ± 0.43 a | 3.3 ± 0.18 a | 5.3 ± 0.24 a,b | 5.1 ± 0.39 b | 4.7 ± 0.27 a,b | <0.001 | ns | ns |
| C18:2n-6 (LA) | 20.4 ± 0.71 a,b | 21.0 ± 0.14 a,b | 20.0 ± 0.62 a,b | 19.2 ± 1.09 a | 21.7 ± 0.54 b | 19.5 ± 0.48 a,b | 18.3 ± 0.42 a | ns | 0.018 | ns |
| C18:3n-3 (ALA) | 0.0 ± 0.00 a | 1.3 ± 0.29 b | 2.6 ± 0.57 b,c | 3.1 ± 0.41 c | 0.0 ± 0.00 a | 0.0 ± 0.00 a | 0.0 ± 0.00 a | <0.001 | ns | ns |
| C18:4n-3 (SDA) | nd | nd | nd | nd | nd | nd | nd | |||
| C20:0 | 2.5 ± 0.36 | 1.9 ± 0.82 | 2.1 ± 0.64 | 2.7 ± 0.57 | 1.9 ± 0.33 | 2.0 ± 0.40 | 2.5 ± 0.38 | ns | ns | ns |
| C20:2n-6 | nd | nd | nd | nd | nd | nd | nd | |||
| C20:3n-6 | 0.7 ± 0.06 | 0.7 ± 0.02 | 1.0 ± 0.07 | 0.9 ± 0.10 | 0.7 ± 0.08 | 0.8 ± 0.09 | 0.6 ± 0.07 | ns | ns | ns |
| C20:4n-6 (ARA) | 16.2 ± 1.66 a,b | 16.0 ± 2.16 a,b | 17.6 ± 2.66 a,b | 17.3 ± 1.12 b | 13.1 ± 0.84 a,b | 11.1 ± 0.39 a | 11.8 ± 1.20 a,b | 0.027 | ns | ns |
| C20:5n-3 (EPA) | 0.2 ± 0.13 a | 0.7 ± 0.06 a,b | 1.3 ± 0.06 b | 1.3 ± 0.07 b | 0.8 ± 0.03 b | 2.0 ± 0.23 c | 2.7 ± 0.08 d | <0.001 | <0.001 | <0.001 |
| C24:0 | nd | nd | nd | nd | nd | nd | nd | |||
| C22:5n-3 (DPA) | 0.0 ± 0.00 a | 0.5 ± 0.13 b | 0.9 ± 0.13 b | 0.8 ± 0.12 b | 0.0 ± 0.00 a | 0.0 ± 0.00 a | 0.0 ± 0.00 a | <0.001 | ns | ns |
| C22:6n-3 (DHA) | 1.1 ± 0.09 a | 1.4 ± 0.28 a,b | 1.4 ± 0.11 a | 1.1 ± 0.15 a | 2.6 ± 0.28 b | 4.5 ± 0.26 c | 5.2 ± 0.53 c | <0.001 | 0.001 | <0.001 |
| Total n-3 PUFA | 1.3 ± 0.10 a | 2.7 ± 0.60 a,b | 3.6 ± 0.22 b | 3.2 ± 0.30 b | 3.4 ± 0.29 b | 6.5 ± 0.48 c | 7.9 ± 0.52 c | <0.001 | <0.001 | <0.001 |
| Total n-6 PUFA | 37.3 ± 2.02 c | 18.0 ± 1.92 a | 21.2 ± 2.20 a | 21.2 ± 0.95 a | 35.4 ± 0.52 b | 31.4 ± 1.50 b | 30.7 ± 1.36 b | <0.001 | ns | 0.012 |
| EPA + DHA | 1.3 ± 0.10 a | 2.1 ± 0.33 a,b | 2.7 ± 0.09 b | 2.4 ± 0.21 b | 3.4 ± 0.29 b | 6.5 ± 0.48 c | 7.9 ± 0.52 d | <0.001 | <0.001 | <0.001 |
| Total SFA | 36.7 ± 0.64 b | 34.6 ± 1.22 a,b | 32.9 ± 1.25 a | 34.4 ± 1.38 a,b | 35.9 ± 0.60 b | 36.9 ± 1.23 b | 37.9 ± 1.98 b | 0.014 | ns | ns |
| Total MUFA | 24.7 ± 1.48 b | 23.8 ± 1.00 a | 22.4 ± 1.62 a | 22.0 ± 0.78 a | 25.2 ± 0.71 b | 25.3 ± 0.80 b | 23.5 ± 0.27 a,b | 0.027 | ns | ns |
| Total PUFA | 38.7 ± 2.00 a,b | 41.6 ± 2.21 a,b | 44.7 ± 1.91 b | 43.7 ± 1.25 a,b | 38.8 ± 0.58 a,b | 37.9 ± 0.97 a | 38.6 ± 1.86 a,b | 0.001 | ns | ns |
| Stimulus/Cytokine | Model 1 | Model 2 | Model 3 |
| OR (95%CI) | OR (95%CI) | OR (95%CI) | |
| Spontaneous production | |||
| IL-5 (n = 418) | 1.42 (0.93;2.15) | 1.00 (0.52;1.92) | 0.95 (0.48;1.87) |
| IL-13 (n = 418) | 1.54 (1.01;2.37) | 0.67 (0.34;1.32) | 0.53 (0.26;1.07) |
| IFN-γ (n = 417) | 1.88 (1.19;2.98) | 1.67 (0.83;3.37) | 1.50 (0.72;3.10) |
| IL-10 (n = 415) | 1.86 (1.05;3.32) | 2.64 (1.12;6.22) | 2.56 (1.05;6.24) |
| IL-17 (n = 416) | 0.83 (0.37;1.84) | 2.13 (0.66;6.84) | 1.61 (0.48;5.42) |
| Ascaris lumbricoides | |||
| IL-5 (n = 418) | 0.75 (0.48;1.15) | 1.50 (0.75;3.00) | 1.53 (0.74;3.15) |
| IL-13 (n = 418) | 0.66 (0.44;1.01) | 1.14 (0.59;2.22) | 1.29 (0.65;2.57) |
| IFN-γ (n = 417) | 1.35 (0.78;2.33) | 1.73 (0.72;4.12) | 1.67 (0.67;4.14) |
| IL-10 (n = 416) | 1.83 (1.08;3.11) | 2.43 (1.09;5.38) | 2.51 (1.09;5.79) |
| IL-17 (n = 416) | 0.69 (0.33;1.47) | 0.79 (0.27;2.34) | 0.61 (0.19;1.95) |
| House dust mite | |||
| IL-5 (n = 418) | 1.73 (1.06;2.82) | 2.06 (0.98;4.29) | 2.09 (0.97;4.52) |
| IL-13 (n = 418) | 0.89 (0.58;1.35) | 1.54 (0.80;2.99) | 1.48 (0.74;2.94) |
| IFN-γ (n = 417) | 1.45 (0.85;2.46) | 1.63 (0.68;3.92) | 1.57 (0.64;3.87) |
| IL-10 (n = 416) | 2.42 (1.54;3.78) | 1.83 (0.91;3.68) | 2.24 (1.07;4.70) |
| IL-17 (n = 411) | 1.22 (0.57;2.61) | 1.63 (0.61;4.38) | 1.63 (0.57;4.67) |
| Kindergarten | Elementary school | Junior high school | P-valueb | |
| n (%) | n (%) | n (%) | ||
| Feeling upon awakening | ||||
| good | 213 (86.2) | 877 (76.5) | 389 (61.6) | |
| bad | 34 (13.8) | 270 (23.5) | 243 (38.5) | |
| total | 247 | 1147 | 632 | <0.01 |
| Time of awakening | ||||
| <6:30 | 40 (16.2) | 414 (36.3) | 168 (26.6) | |
| ≥6:30 | 207 (83.8) | 726 (63.7) | 464 (73.4) | |
| total | 247 | 1140 | 632 | <0.01 |
| Bedtime | ||||
| <22:00 | 232 (93.9) | 816 (71.1) | 60 (9.5) | |
| ≥22:00 | 15 (6.1) | 331 (28.9) | 572 (90.5) | |
| total | 247 | 1147 | 632 | <0.01 |
| Sleep duration | ||||
| ≥8 h | 244 (98.8) | 432 (76.5) | 177 (28.0) | |
| <8 h | 3 (1.2) | 133 (23.5) | 455 (72.0) | |
| total | 247 | 565 | 632 | <0.01 |
| Television | ||||
| <2 h | 166 (67.2) | 786 (68.6) | 292 (46.2) | |
| ≥2 h | 81 (32.8) | 360 (31.4) | 340 (53.8) | |
| total | 247 | 1146 | 632 | <0.01 |
| Video games | ||||
| <30 min | 221 (89.5) | 731 (64.1) | 411 (65.0) | |
| ≥30 min | 26 (10.5) | 409 (35.9) | 221 (35.0) | |
| total | 247 | 1140 | 632 | <0.01 |
| Personal computera | ||||
| <30 min | — | 1007 (88.0) | 437 (69.2) | |
| ≥30 min | — | 138 (12.1) | 195 (30.9) | |
| total | — | 1145 | 632 | <0.01 |
| Cellular phonea | ||||
| <30 min | — | 1096 (95.6) | 526 (83.2) | |
| ≥30 min | — | 51 (4.5) | 106 (16.8) | |
| total | — | 1147 | 632 | <0.01 |
| Instrument | Countries |
| Supply side regulation: in patent drugs | |
| Price controls: administrative or statutory pricing | All EU Member States except Germany, UK and, to a certain extent, Sweden |
| External reference pricing | All EU Member States except UK, Germany, Sweden |
| Rate of return regulation | UK |
| Negotiations and price-volume agreements | France, Italy, Austria |
| Direct expenditure controls: payback | France, Portugal, Austria |
| Direct expenditure controls: price volume agreements | France |
| Cost-plus pricing | Spain |
| Supply side regulation: off patent drugs | |
| Tendering for generics pharmaceuticals in primary care | Netherlands, Germany |
| Price capping for generics and linking these to the originator price | Italy, Greece, France |
| Supply side regulation: reimbursement methods | |
| Positive and negative formularies | All EU Member States |
| Internal reference pricing | Germany, Netherlands, Czech Republic, Italy, Spain, France, Hungary |
| Health Technology Assessments (HTA) | UK, Sweden, Netherlands, Hungary, Poland, Finland, Estonia, Latvia, Lithuania. In France only assessment of clinical benefit |
| Innovative pricing and reimbursement schemes | Italy, Germany, UK, Finland |
| Demand side regulation: policies towards physicians | |
| Clinical practice guidelines | All EU Member States |
| Compulsory generic prescribing | UK, Denmark, Estonia |
| Financial incentives | France, UK |
| Prescription monitoring and audit | Belgium, UK, Netherlands, France, Denmark, Sweden, Estonia |
| Demand side regulation: policies towards pharmacies | |
| Control of remuneration (e.g. margins, fees) including contractual arrangements | All Member States |
| Generic substitution | France, Italy, Spain, Sweden |
| Demand side regulation: policies towards patients | |
| Cost-sharing | All EU Member States |
| Encouraging use of over-the counter medicines and “de-listing” | UK, Germany, Sweden, Netherlands |
| Baseline | 12 months | 18 months | |||||||
| W | WB | C | W | WB | C | W | WB | C | |
| N | N | N | N | N | N | N | N | N | |
| Variables | Mean±SD | Mean±SD | Mean±SD | Mean±SD | Mean±SD | Mean±SD | Mean±SD | Mean±SD | Mean±SD |
| W.Vs. C(P) | W.Vs. C(P) | W.Vs. W(P) | W.Vs. C(P) | W.Vs. C(P) | W.Vs. W(P) | ||||
| Coping | 79 | 69 | 73 | 44 | 44 | 40 | 44 | 41 | 36 |
| With | 1.069±794 | 1.126±0.775 | 1.013±0.946 | 0.864±0.771 | 1.239±0.730 | 1.192±0.835 | 1.064±0.952 | 1.388±0.856 | 1.342±1.127 |
| Symptoms | (0.091) | (0.858) | (0.057) | (0.190) | (0.793) | (0.286) | |||
| Confidence | 79 | 69 | 73 | 44 | 44 | 39 | 43 | 41 | 36 |
| About | 7.406±1.719 | 7.827±1.488 | 7.858±1.512 | 7.826±1.551 | 7.682±1.785 | 8.064±1.575 | 7.690±1.920 | 7.546±1.848 | 8.015±1.476 |
| Doing Things | (0.433) | (0.297) | (0.060) | (0.235) | (0.422) | *(0.041) |
| Male | Female | ||||||||
| CCU or ICU | Medical ward | CCU or ICU | Medical ward | ||||||
| Age groups | Standard Population | Death rate % | Expected # death | Death rate % | Expected # death | Death rate % | Expected # death | Death rate % | Expected # death |
| All ages | 4859 | ||||||||
| 18–54 | 1223 | 0.53 | 6.5 | 0.97 | 11.9 | 1.10 | 13.5 | 2.70 | 33.0 |
| 55–65 | 1245 | 1.78 | 22.2 | 1.84 | 22.9 | 1.72 | 21.4 | 1.52 | 18.9 |
| 66–78 | 1289 | 2.77 | 35.7 | 3.65 | 47.0 | 2.95 | 38.0 | 3.97 | 51.2 |
| 79 + | 1102 | 5.80 | 63.9 | 6.67 | 73.5 | 7.08 | 78.0 | 12.03 | 132.6 |
| Total number of deaths expected | 128 | 155 | 151 | 236 | |||||
| Crude rates | 2.1 % | 3.5 % | 3.3 % | 7.8 % | |||||
| Age adjusted rates | 128/4859 = 2.6 % | 155/4859 = 3.2 % | 151/4859 = 3.1 % | 236/4859 = 4.9 % |
| ATC Code | Drug classification | No. of visits | % |
| G01A | Anti-infectives | 5402 | 15.1% |
| M01A | Anti-inflammatory, non-steroids | 3754 | 10.5% |
| N02B | Other analgesics and anti-pyretics | 2884 | 8.1% |
| G03D | Progestogens | 2871 | 8.0% |
| A02A | Antacids | 2683 | 7.5% |
| D07C | Corticosteroids, combinations with antibiotics | 2090 | 5.9% |
| R06A | Antihistamines for systemic use | 1932 | 5.4% |
| A03A | Drugs for functional bowel disorders | 1866 | 5.2% |
| J01D | Other beta-lactam anti-bacterials | 1863 | 5.5% |
| G03C | Estrogens | 1837 | 5.1% |
| Variables | Number | Percentage |
| Acute or chronic inflammation | 36 | 30 |
| Rheumatism | 33 | 26.6 |
| Degeneration of valves | 49 | 40.8 |
| Endocarditic | 2 | 1.6 |
| Pairwise correlation at age 7 year | ||||
| Compound | PFAS concentration, ng/mL, median (IQRa) | PFOS | PFOA | PFHxS |
| Age 5 year | ||||
| PFOS | 17.3 (14.2,21.3) | 0.77 | 0.06 | 0.43 |
| PFOA | 4.1 (3.3, 5.0) | 0.34 | 0.61 | 0.39 |
| PFHxS | 0.6 (5.0, 0.9) | 0.40 | 0.27 | 0.85 |
| Age 7 year | ||||
| PFOS | 15.5 (12.8, 19.2) | 1 | ||
| PFOA | 4.4 (3.5, 5.7) | 0.29 | 1 | |
| PFHxS | 0.5 (0.4,0.7) | 0.50 | 0.34 | 1 |
| Analyses | Nanoemulsion | Curcumin-nanoemulsion |
| Size (nm) | 200 ± 9.9 | 199 ± 0.2 |
| Zeta potential (mV) | −40.2 | −46.3 |
| Polydispersity index (PdI) | 0.248 | 0.179 |
| BMD (g/cm2) | BMC (g) | Area (cm2) | |
| Lumbar Vertebra | |||
| Baseline (n = 8) | 0.237 ± 0.018 | 0.502 ± 0.073 | 2.124 ± 0.287 |
| Control (n = 12) | 0.259 ± 0.026 | 0.609 ± 0.107 | 2.343 ± 0.297 |
| 1.5 mg CsA (n = 11) | 0.204 ± 0.030** | 0.473 ± 0.091** | 2.325 ± 0.260 |
| 7.5 mg CsA (n = 9) | 0.201 ± 0.015** | 0.462 ± 0.073 ** | 2.291 ± 0.462 |
| Proximal Femur | |||
| Baseline (n = 8) | 0.245 ± 0.038 | 0.126 ± 0.022 | 0.513 ± 0.028 |
| Control (n = 12) | 0.258 ± 0.046 | 0.139 ± 0.029 | 0.536 ± 0.029 |
| 1.5 mg CsA (n = 11) | 0.181 ± 0.036* | 0.099 ± 0.017** | 0.542 ± 0.037 |
| 7.5 mg CsA (n = 9) | 0.171 ± 0.039** | 0.092 ± 0.025** | 0.530 ± 0.027 |
| Middle Femur | |||
| Baseline (n = 8) | 0.298 ± 0.075 | 0.228 ± 0.058 | 0.762 ± 0.021 |
| Control (n = 12) | 0.323 ± 0.068 | 0.258 ± 0.052 | 0.794 ± 0.058 |
| 1.5 mg CsA (n = 11) | 0.311 ± 0.066 | 0.241 ± 0.058 | 0.771 ± 0.052 |
| 7.5 mg CsA (n = 9) | 0.317 ± 0.058 | 0.243 ± 0.045 | 0.767 ± 0.065 |
| Indicators | Value |
| White blood cell | 5200/μL |
| Hemoglobin | 11.3 g/dL |
| Platelet | 103 × 103/μL |
| Prothrombin time | 96% |
| Activated partial thromboplastin time | 22.6 s |
| Aspartate aminotransferase | 26 U/L |
| Alanine aminotransferase | 20 U/L |
| Lactate dehydrogenase | 244 U/L |
| Alkaline phosphatase | 280 U/L |
| Total bilirubin | 0.7 mg/dL |
| Total protein | 6.9 g/dL |
| Albumin | 3.9 g/dL |
| Blood urea nitrogen | 25.6 mg/dL |
| Creatinine | 1.05 mg/dL |
| Uric acid | 7.3 mg/dL |
| Na | 139 mEq/L |
| K | 6.9 mEq/L |
| Cl | 104 mEq/L |
| Total cholesterol | 169 mg/dL |
| C-reactive protein | 0.11 mg/dL |
| Protein induced by vitamin K absence II | 61 mAU/mL |
| α-Fetoprotein | 384 ng/mL |
| H-reflex parameters | Ankle Positions | Muscle and posture | |||||
| Sol | MG | LG | |||||
| Lying | Standing | Lying | Standing | Lying | Standing | ||
| Amplitude | N | 7.25*†(3.35) | 4.28*§‡(2.03) | 2.06*†(1.20) | 1.38*§‡(0.85) | 1.50*†(0.70) | 1.15*§‡(0.67) |
| DF | 2.47†(2.63) | 1.96§(2.18) | 0.60†(0.39) | 0.53§(0.60) | 0.47†(0.34) | 0.49§(0.51) | |
| PF | 5.95(3.37) | 6.40‡(2.88) | 1.76(1.19) | 2.65‡(1.52) | 1.38(0.89) | 1.81‡(0.97) | |
| H/M | N | 0.51*†(0.17) | 0.38*§‡(0.19) | 0.42*†(0.30) | 0.20*§‡(0.11) | 0.28*†(0.13) | 0.18*§‡(0.08) |
| DF | 0.22†(0.18) | 0.19§(0.18) | 0.17†(0.14) | 0.08§(0.08) | 0.18†(0.04) | 0.11§(0.12) | |
| PF | 0.40(0.24) | 0.60‡(0.27) | 0.32(0.25) | 0.39‡(0.15) | 0.22(0.09) | 0.32‡(0.14) | |
| Latency | N | 30.2(2.3) | 30.6(2.3) | 29.3(2.2) | 29.3(2.3) | 29.1(2.1) | 28.9(2.4) |
| DF | 30.4(2.5) | 30.9(2.3) | 29.3(2.3) | 29.3(2.3) | 29.0(2.3) | 29.0(2.6) | |
| PF | 30.5(2.3) | 30.8(2.3) | 29.1(2.2) | 29.1(2.4) | 28.8(2.4) | 28.7(2.1) |
| Groups | LDH | CK-MB | CK | CTN-I | MB |
| C | 0.92 ± 0.04 | 2.11 ± 0.18 | 11.70 ± 0.46 | 144.61 ± 12.71 | 3.32 ± 0.49 |
| EE | 1.08 ± 0.09∗ | 3.23 ± 0.19∗ | 16.93 ± 0.41∗ | 172.00 ± 12.83∗ | 4.90 ± 0.41∗ |
| LS | 1.04 ± 0.06# | 3.14 ± 0.24 | 14.56 ± 0.53# | 157.18 ± 16.95 | 4.22 ± 0.43# |
| HS | 1.02 ± 0.10# | 2.57 ± 0.21#Δ | 13.19 ± 1.91#Δ | 159.26 ± 8.93 | 3.98 ± 0.54#Δ |
| Genotypes | No. identified proteins | ρ-Valuea/FPRb(%) | No. proteins | ||||
| Rep#1 | Rep#2 | Rep#3 | Rep#1 | Rep#2 | Rep#3 | ||
| Resistantc | 3297 | 3302 | 3602 | 93/0.71 | 92/0.70 | 93/0.70 | 2002 |
| Susceptiblec | 3228 | 3187 | 3153 | 93/0.71 | 93/0.67 | 93/0.70 | 1859 |
| Key actor | Moura-Barrancos | Guadiana | Malcata | Total |
| Land owners (including livestock breeders) | 9 | 9 | 5 | 23 |
| Local council representatives | 8 | 8 | 8 | 24 |
| Local nature conservation technicians (administration, NGOs, fiscalization) | 6 | 7 | 7 | 20 |
| Land and hunting managers | 6 | 8 | 2 | 16 |
| Hunting guards | 8 | 3 | 3 | 14 |
| Nature activity users and promoters (tourism, collectors, leisure) | 6 | 7 | 5 | 18 |
| Lynx observers | 9 | - | 7 | 16 |
| Total | 52 | 42 | 37 | 131 |
| Hunter | 26 | 19 | 15 | 60 |
| Non-hunter | 26 | 23 | 22 | 71 |
| Participants | GPS routes | |||
| N | % | N | % | |
| Total/All | 175 | 1191 | ||
| Sex | ||||
| Girl | 89 | 50.86% | 614 | 51.55% |
| Boy | 86 | 49.14% | 577 | 48.45% |
| How do you usually travel to school? | ||||
| By car | 41 | 23.43% | 262 | 22.00% |
| By bus or train | 68 | 38.86% | 475 | 39.88% |
| By bicycle | 8 | 4.57% | 62 | 5.21% |
| On foot | 58 | 33.14% | 392 | 32.91% |
| Home location | ||||
| Urban | 57 | 32.57% | 367 | 30.81% |
| Town & Fringe | 44 | 25.14% | 300 | 25.19% |
| Village, Hamlet & Isolated Dwelling | 74 | 42.29% | 524 | 44.00% |
| What is your annual household pre-tax income? | ||||
| Up to £10,000 | 17 | 9.71% | 96 | 8.06% |
| Over £10,000 to £30,000 | 40 | 22.86% | 284 | 23.85% |
| Over £30,000 to £50,000 | 49 | 28.00% | 341 | 28.63% |
| Over £50,000 to £70,000 | 30 | 17.14% | 184 | 15.45% |
| Over £70,000 | 10 | 5.71% | 78 | 6.55% |
| I do not wish to share this information | 28 | 16.00% | 203 | 17.04% |
| Measurement day | Dosage | ucOC (ng/mL) | Gla-OC (ng/mL) | UGR | Dietary vitamin K intake (μg/week) | ||||
| Median | Range | Median | Range | Median | Range | Median | Range | ||
| Day 1 | Baseline | 5.03 | (2.20-23.03) | 18.41 | (10.62-26.60) | 0.32 | (0.13-1.70) | - | - |
| Day 8 | 0 μg/day | 5.81 | (2.63-26.65) | 18.71 | (8.62-24.36) | 0.36 | (0.12-1.88) | 40.18 | (0.00-540.27) |
| Day 15 | 300 μg/day | 6.77 | (1.89-14.52) | 21.27 | (10.57-26.91) | 0.35 | (0.18-0.54) | 17.40 | (0.00-638.76) |
| Day 22 | 600 μg/day | 4.82 | (1.84-8.73)* | 25.33 | (12.29-33.04) | 0.22 | (0.14-0.31)** | 31.68 | (0.00-389.40) |
| Day 29 | 900 μg/day | 2.98 | (1.27-6.90)** | 22.75 | (12.38-38.10)* | 0.15 | (0.10-0.23)** | 9.60 | (0.00-196.94) |
| Day 36 | 1500 μg/day | 3.92 | (1.88-7.52)* | 23.33 | (13.97-45.49)** | 0.15 | (0.13-0.21)** | 7.50 | (0.00-167.58) |
| Topic | Reference | Question | Summary of the results |
| Knowledge | (26–42) | Differences in knowledge | Almost all studies found a gradient in knowledge about HPV and cervical cancer with any of the variables used to measure SES or deprivation: educational level, disadvantaged groups, etc |
| (43–48) | Effective tools to improve knowledge and reduce inequalities | Differences tend to diminish after any kind intervention to inform women. Results about written material are inconclusive; short counseling showed to be effective | |
| Coverage | (16, 49–51) | Longer screening intervals can increase the coverage for hard-to-reach population | No data are available |
| (9, 52) | Access to opportunistic HPV testing could be limited by the high cost of the test in private laboratories | No data are available | |
| (49, 53, 54) | Self-sampling device could be used to reduce sampling costs, but could affect coverage | Only one trial conducted in Mexico. A lower coverage was achieved, but it was due to women not found at home and to whom the self-sampling was not mailed | |
| Participation | (9, 13, 16, 17, 21, 26, 32, 50, 52, 53, 55–57) | The proposal of a new test may change the participation | Several observational studies and one trial found a small increase in participation when invited for a HPV test compared to Pap test. No data on how it will impact on inequalities |
| Longer intervals could disrupt the habits, thereby of women reducing participation | No data are available | ||
| (14, 22, 49, 53–55, 58–75) | Self-sampling device could be used to participation in screening program | Nine studies showed a positive effect of self-sampling in under-screened population. Some studies showed that the device is acceptable also among disadvantage women, even in some case to a minor extent | |
| Compliance to screening protocols | (41) | Longer intervals could increase opportunistic over-screening | No data are available |
| (9, 21, 35, 36, 57) | Referral to early rescreen after HPV positive cytology-negative test could increase use of unnecessary ascertainment | No data are available | |
| (17, 21, 76, 77) | Referral to early rescreen after HPV positive cytology-negative test could result in substantial loss to follow up | The compliance to early rescreen in this group of women varied among studies, showing that correct communication can reduce loss to follow up. No data about differences in socio-economic status are available | |
| Communication of positive results | (2, 9, 78–81) | Communication of HPV positivity can induce anxiety | Several studies showed anxiety after the communication of Pap test and/or HPV positivity. Women with higher educational level are advantaged in understanding the gynecologist’s and midwife’s recommendations and explanations |
| (32, 40, 79, 80, 82–84) | Communication of HPV positivity can induce changes in sexual habits | Some studies showed concern about the sexual transmission of the virus. These concerns were stronger in women of lower educational level and disadvantaged ethnic groups | |
| (31, 36, 84–91) | Effective ways to reduce anxiety and other adverse effects | Face-to-face counseling was preferred by women, but cannot be used only for positive results because of the anxiety caused by the understanding that the test was positive and the need to wait for the counseling. Short phone counseling only for positive was also appreciated | |
| Interaction vaccine and screening | (38, 92–98) | Negative effect of vaccine on future screening | Only one studies reported a small proportion of girls referring that vaccination would change their attitude to screening |
| (56, 99–103) | Association between vaccine and screening attitudes | Several studies showed an association between vaccine and screening attitude or between vaccination and screening coverage in mothers. Results are heterogeneous |
| Cytogenetic abnormality | Frequency | ASXL1 mutational frequency | SETBP1 mutational frequency | SRSF2 mutational frequency | U2AF1 mutational frequency | SF3B1 mutational frequency | Spanish cytogenetic risk stratification | Mayo–French cytogenetic risk stratification |
| +8 | ~23% | ~24% | 0% | ~27% | 0% | 0% | High risk | Intermediate risk |
| -Y | ~20% | ~12% (SS) | ~40% | ~16% | 0% | ~9% | Low risk | Low risk |
| -7/7q- | ~14% | ~14% | ~40% | ~11% | 40% | 0% | High risk | Intermediate risk |
| 20q- | ~8% | ~10% | 0% | ~11% | 0% | 0% | Intermediate risk | Intermediate risk |
| der(3q) | ~8% | ~2% (SS) | 0% | ~3% | 20% | 45% (SS) | Intermediate risk | Low risk |
| +21 | ~8% | ~10% | 0% | ~5% | 20% | 0% | Intermediate risk | Intermediate risk |
| Complex and monosomal karyotypes (MK) | ~10% | ~4% | ~20% | ~8% | ~40% (SS) | 0% | Complex high risk. MK not included in stratification | High risk |
| Risk factor | Changes in capillary morphology or blood rheology |
| Aging | Human brain: Pericyte loss. Variable capillary diameters, increased capillary tortuosity, twisting, and looping. Thickened basement membranes with inclusions. Pericapillary fibrosis [29, 30] |
| Hypertension | Animal brain: Pericyte degeneration, swelling of endothelium and surrounding astrocyte end feet. Thickened basement membranes [31, 32]In vitro: Angiotensin II, endothelin-1 constrict retinal pericytes [33, 34] |
| Diabetes | Human: Thickened basement membranes [35, 36]. Hyperviscosity and reduced erythrocyte deformability in proportion to microvascular complications [37]Animal models: Pericyte loss and thickening of capillary basement membrane [31, 38, 39]. Glycocalyx degradation by oxidative stress, oxidized lipoproteins, and hyperglycemia [40–42]In vitro: Hyperglycemia-induced oxidative stress in the pericytic mitochondria causes pericyte apoptosis [43] |
| Alzheimer’s diseaseAPOE ε4 genotype | Human brain: Pericyte degeneration, pericapillary fibrosis [44]In vitro: Cultured human pericytes undergo degeneration when exposed to certain subtypes of Aβ [45]. Pericytes express Aβ receptors involved in amyloid internalization and pericyte death [46] |
| Nicotine use (including smoking) | Nicotine upregulates the expression of adhesion molecules in the capillary endothelium [47] and increases leukocyte rolling [48] |
| Authors | Contrast |
| *Aichorn et al., 2009 | False belief > photo (question) |
| *Abraham et al., 2010 | Belief-questions > control-questions and desire-questions > control-questions |
| *Bahnemann et al., 2010 | ToM judgments minus appearance judgments |
| *Bruneau et al., 2012 | ToM localizer |
| *Dohnel et al., 2012 | Sally Anne task (true and false ToM minus reality) |
| Fletcher et al., 1995 | ToM stories vs. Physical stories |
| Gallagher et al., 2000 | ToM vs. non-ToM stories |
| Gobbini et al., 2007 | False belief stories vs. physical belief stories |
| *Hartwright et al., 2012 | False belief minus false photograph |
| Hynes et al., 2005 | Cognitive PT minus Control |
| *Jenkins and Mitchell, 2010 | Mentalizing scenarios > non-social scenarios |
| *Kobayashi et al., 2008 | ToM > physical (both japanese and english language groups) |
| *Kobayashi et al., 2006 | ToM compared with non-ToM-conjunction among language groups |
| *van der Meer et al., 2011 | ToM high inhibition minus fixation |
| Mitchell, 2007 | Tom minus attention cueing task |
| Perner et al., 2006 | False belief vignettes minus photo vignettes |
| *Rabin et al., 2009 | ToM photo minus autobiographical memory photo |
| Ruby and Decety, 2003 | 3rd person minus 1st person |
| *Samson et al., 2008 | ToM cartoons minus non-ToM cartoons |
| Saxe and Kanwisher, 2003 | ToM inference minus mechanical inference |
| Saxe and Powell, 2006 | False belief minus false photograph |
| Saxe et al., 2006 | ToM reference experiment |
| *Veroude et al., 2012 | Others vs. self (females only) |
| Vollm et al., 2006 | ToM minus physical causality one character |
| *Wolf et al., 2010 | Social minus physical inference (multiple choice and silent) |
| Young et al., 2007 | Belief minus photo |
| *Young et al., 2010 | Mental > physical sentences |
| *Zaitchik et al., 2010 | Belief sentences > control sentences |
| With seizures§ | Without seizures | |||
| Early seizures | Late seizures | pvalue | ||
| n = 13 (%) | n = 15 (%) | n = 152 (%) | ||
| Mean age, years | 47.3 ± 17.3 | 52.1 ± 25.0 | 0.32 | 53.2 ± 17.9 |
| Sex (male/female) | 7/6 | 9/6 | 0.74 | 92/60 |
| Mean GCS on presentation | 11.5 ± 3.9 | 12.1 ± 4.4 | 0.71 | 13.1 ± 3.1 |
| Clinical features | ||||
| Fever/chills | 8 (61.5) | 13 (86.6) | 0.20 | 89 (58.5) |
| Headache | 9 (69.2) | 9 (60) | 0.71 | 69 (45.3) |
| Disturbed consciousness | 8 (61.5) | 8 (53.3) | 0.66 | 61 (40.1) |
| Visual disturbance | 2 (15.3) | 5(33.3) | 0.61 | 26 (17.1) |
| Hearing impairment | 1 (7.6) | 1 (6.6) | 1.0 | 4 (2.6) |
| Hyponatremia | 3 (23.1) | 2 (13.3) | 0.64 | 21 (13.8) |
| Outcome | ||||
| Death | 5 (38.4) | 10 (66.6) | 0.14 | 42 (27.6) |
| Mean length of hospitalization (days) | 58.0 ± 38.9 | 89.3 ± 62.6 | 0.08 | 56.9 ± 49.3 |
| Scale | Whole sample | Gender | Presence of symptoms | ||||
| N = 446 | Boys N = 207 | Girls N = 239 | p-value (ANOVA) | No symptoms N = 197 | At least one symptom once a week N = 199 | p-value (ANOVA) | |
| PsyWB | 69.4 ± 20.6 | 75.4 ± 18.6 | 64.2 ± 0.7 | p < 0.001 | 76.5 ± 18.1 | 62.8 ± 21.3 | p < 0.001 |
| PhyWB | 64.4 ± 18.7 | 69.4 ± 17.9 | 60.0 ± 8.3 | p < 0.001 | 72.0 ± 15.1 | 56.1 ± 18.2 | p < 0.001 |
| VIT | 66.3 ± 22.2 | 70.1 ± 21.0 | 62.9 ± 22.5 | p < 0.001 | 71.5 ± 20 | 61.4 ± 22.9 | p < 0.001 |
| RT | 49.4 ± 24.4 | 48.9 ± 23.3 | 49.9 ± 25.2 | 0.68 | 51.9 ± 2.3 | 47.2 ± 26.0 | p < 0.05 |
| SP | 48.8 ± 26.2 | 48.3 ± 26.4 | 49.1 ± 25.9 | 0.75 | 51.6 ± 24.5 | 47.6 ± 27.1 | 0.12 |
| RF | 61.4 ± 20.7 | 54.9 ± 18.8 | 67.0 ± 20.8 | p < 0.001 | 61.2 ± 20.7 | 62.8 ± 20.9 | 0.4 |
| RP | 53.0 ± 26.2 | 55.4 ± 24.9 | 51.0 ± 27.2 | 0.80 | 55.4 ± 25.1 | 50.7 ± 27.4 | 0.8 |
| BI | 61.6 ± 28.1 | 65.0 ± 25.2 | 58.8 ±30.0 | 0.023 | 66.2 ± 26.9 | 59.2 ± 27.8 | p < 0.05 |
| LA | 53.6 ± 20.8 | 57.7 ± 19.5 | 50.0 ± 1.3 | p < 0.001 | 56.1 ± 19.7 | 50.3 ± 21.9 | p < 0.001 |
| SSL | 59.6 ± 32.4 | 59.3 ± 30.7 | 59.9 ± 4.2 | 0.87 | 57.7 ± 32.1 | 61.8 ± 33.1 | 0.26 |
| Index | 58.6 ± 13.0 | 60.7 ± 12.1 | 56.3 ± 3.5 | p < 0.01 | 62.3 ± 11.7 | 55.3 ± 13.5 | p < 0.001 |
| Maternal health service use indicator | Overall (n = 1457) | District | P value | |
| Jhelum (n = 747) | Layyah (n = 710) | |||
| Sought at least one antenatal care (ANC) visit | 96.6 | 97.8 | 95.3 | 0.01 |
| Type of ANC provider | ||||
| Community Midwife (CMW) | 8.3 | 13.8 | 2.4 | 0.00 |
| Doctor | 57.5 | 57.2 | 57.8 | 0.83 |
| Skilled birth attendant | 27.2 | 24.3 | 30.4 | 0.02 |
| Dai | 4.6 | 2.6 | 6.7 | 0.00 |
| Type of childbirth attendant | ||||
| CMW | 7.9 | 12.4 | 3.2 | 0.00 |
| Doctor | 36.1 | 47.6 | 24 | 0.00 |
| Non-physician skilled birth attendant | 25.5 | 26.3 | 24.6 | 0.49 |
| Dai/traditional birth attendant | 30.5 | 13.7 | 48.2 | 0.00 |
| Place of delivery | ||||
| Home (home and dai home) | 41.2 | 29.3 | 54 | 0.00 |
| CMW clinic/home | 1.1 | 3.1 | 0.7 | 0.01 |
| Government | 21.6 | 27.1 | 15.9 | 0.00 |
| Private | 35.1 | 40.5 | 29.4 | 0.00 |
| Satisfaction with CMW care | ||||
| For ANC (n = 245) | 0.05 | |||
| Very satisfied | 39.5 | 44.2 | 12.9 | |
| Satisfied | 53.7 | 50.0 | 74.2 | |
| Somewhat satisfied | 2.9 | 1.8 | 9.6 | |
| Somewhat dissatisfied/dissatisfied | 4.0 | 4.0 | 3.3 | |
| For delivery (competency) (n = 109) | 0.00 | |||
| Very satisfied | 68.1 | 75.2 | 39.3 | |
| Satisfied | 28.5 | 21.1 | 58.5 | |
| Somewhat satisfied | 1.7 | 1.6 | 2.2 | |
| Somewhat dissatisfied/dissatisfied | 1.7 | 2.2 | 0.0 |
| High-energy probe | Low-energy probe | Units | |
| Source used | 22Na | 99mTc | |
| Photon energy | 511 | 142 | keV |
| Sensitivity | 10 | 12 | cps/kBq |
| Spatial resolution | |||
| @ 1 cm in air | 15 | 10 | mm |
| @ 5 cm in air | 47 | 35 | mm |
| Count rate range | 1–50 | 1–100 | kcps |
| Count rate loss | < 10% | < 10% | |
| Shielding | n.a. | 1 | mmPb |
| Weight | 500 | 650 | g |
| Data | Feature | Vector | Algorithm | F1 | AUC | p-value |
| iDASH | Bag-of-words + UMLS (5SG) | Tf-idf | SVM-Lin | 0.932 | 0.957 | <0.01 |
| Bag-of-words + UMLS (All) | Tf-idf | SVM-Lin | 0.931 | 0.957 | <0.01 | |
| Bag-of-words + UMLS (15ST) | Tf-idf | SVM-Lin | 0.930 | 0.957 | <0.01 | |
| Bag-of-words + UMLS (All) | Tf-idf | SVM-Lin-SGD | 0.928 | 0.955 | <0.01 | |
| Bag-of-words | Tf-idf | SVM-Lin | 0.927 | 0.955 | <0.01 | |
| Bag-of-words | Tf | NB | 0.893 | 0.935 | Baseline | |
| MGH | Bag-of-words + UMLS (5SG) | Tf-idf | SVM-Lin | 0.934 | 0.964 | <0.01 |
| Bag-of-words + UMLS (15ST) | Tf-idf | SVM-Lin | 0.931 | 0.962 | <0.01 | |
| Bag-of-words + UMLS (All) | Tf-idf | SVM-Lin | 0.930 | 0.962 | <0.01 | |
| Bag-of-words | Tf-idf | SVM-Lin | 0.924 | 0.958 | <0.01 | |
| Bag-of-words + UMLS (5SG) | Tf | LR-L1 | 0.915 | 0.953 | <0.01 | |
| Bag-of-words | Tf | NB | 0.755 | 0.867 | Baseline |
| Characteristic | Number (N = 1,568) | Percent (%) |
| Sex | 915 | 58.4 |
| Female | 653 | 41.6 |
| Male | ||
| Age group (in years) | ||
| 15 – 24 | 410 | 26.1 |
| 25 – 34 | 595 | 37.9 |
| 35 – 49 | 563 | 35.9 |
| Educational level | ||
| No formal education | 142 | 9.1 |
| Primary Education | 1,308 | 83.4 |
| Secondary Education and above | 118 | 7.5 |
| Marital status | ||
| Married/cohabiting | 969 | 62.2 |
| Single | 444 | 27.7 |
| Divorced/separated/widowed | 155 | 10.1 |
| Occupation | ||
| Student | 56 | 3.6 |
| Salaried employed | 36 | 2.3 |
| Self-employed | 76 | 4.8 |
| Peasant/farmer | 1,370 | 87.4 |
| Others | 30 | 1.9 |
| Radio ownership | ||
| Yes | 1,211 | 77.2 |
| No | 357 | 22.8 |
| CHF absent (n = 66) | CHF present (n = 29) | p | |
| Age (years) | 54.9 ± 10.2 | 65.8 ± 14.2 | < 0.001 |
| Systemic Hypertension | 32 (49%) | 18 (62%) | 0.22 |
| Diabetes Mellitus | 12 (18%) | 5 (17%) | 0.91 |
| Site of infarction | |||
| Anterior | 35 (53%) | 19 (66%) | 0.26 |
| Inferior | 31 (47%) | 10 (34%) | |
| Treatment | |||
| PTI | 26 (39%) | 10 (35%) | |
| Trombolysis | 30 (46%) | 10 (34.5%) | |
| Conservative | 10 (15%) | 9 (31%) | 0.19 |
| CKMB peak (iu/l) | 205 ± 138 | 346 ± 239 | 0.004 |
| Angiography | |||
| Non obstructive | 5 (8%) | 1 (3%) | |
| One vessel disease | 34 (51%) | 10 (35%) | |
| Multivessel disease | 22 (33%) | 15 (52%) | |
| Not done | 5 (8%) | 3 (10%) | 0.31 |
| No. of children | Cumulative incidence | ||
| Year | Born alive | With clubfoot | per thousand (95% CI) |
| 1991 | 62,189 | 70 | 1.12 (0.9–1.3) |
| 1992 | 68,996 | 64 | 0.93 (0.8–1.2) |
| 1993 | 64,873 | 73 | 1.12 (0.8–1.4) |
| 1994 | 61,000 | 51 | 0.84 (0.6–1.2) |
| 1995 | 58,063 | 55 | 0.95 (0.8–1.2) |
| 1996 | 58,479 | 57 | 0.97 (0.8–1.2) |
| 1997 | 57,629 | 70 | 1.20 (0.9–1.3) |
| 1998 | 55,313 | 59 | 1.07 (1.0–1.3) |
| 1999 | 54,879 | 58 | 1.05 (0.9–1.2) |
| 2000 | 53,152 | 63 | 1.19 (1.0–1.3) |
| 2001 | 51,890 | 51 | 0.98 (0.8–1.2) |
| 2002 | 51,234 | 51 | 1.00 (0.8–1.2) |
| 2003 | 51,899 | 53 | 1.02 (0.8–1.2) |
| 2004 | 51,728 | 52 | 1.01 (0.8–1.3) |
| Total | 801,324 | 827 | 1.03 (0.8–1.2) |
| Group session topics | |||
| Session # | Physical activity | Nutrition | Educational incentive |
| 1 | Overview of healthy nutrition | Overview of exercise | Pedometer |
| 2 | Eating healthy on a budget | Being active at home | Fruit and vegetable guide |
| 3 | Eating out and fast food | Local exercise resources | Water bottle |
| 4 | Portion control and measuring | Hidden times for exercise | Measuring cups |
| 5 | Label reading and breakfast | Injury prevention and treatment | Massage tool |
| 6 | Healthy drinks | Building strong muscles | Healthy drink ingredients |
| 7 | Mindful eating and lunch | Take a deep breath and relax | Muscle relaxation CD |
| 8 | Healthy fast food and dinner | Exercise with friends and family | Whole grain pasta |
| 9 | Eating at social events and holidays | Mini holidays for exercise | Food pamphlet |
| 10 | Healthier traditions and review | Review and social dancing | Recipe with ingredients |
| 11 | Relapse response | Review and relay games | Motivational letter |
| 12-15 | Review relapse response, problem solving, and goal setting | Social support cards and displayable health guides | |
| Beverage inventory, evaluation of milk and water consumption, and goal for healthy beverages | |||
| Evaluation of fat in cooking and goal for cooking with less fat (steaming, baking, etc.) | |||
| Evaluation of fruit and vegetable consumption and goal for consuming more fruits and vegetables | |||
| Evaluation of high calorie foods and goals for reduction of high calorie food or snacking | |||
| Decision-making for shopping and meal planning | |||
| Chart and practice walking route (at first environmental support session) | |||
| Identify support network of friends and family members for exercise | |||
| Identify exercise locations in and around home | |||
| Select physical activity goal | |||
| Identify new physical activities to try | |||
| *Topics may be covered in any order, but must be during the intensive intervention phase. |
| Feature | P. fici |
| Assembly size (Mb) | 52 |
| Scaffold N50 (Mb) | 4 |
| Coverage (fold) | 24.5 |
| GC content (%) | 48.73 |
| GC exon (%) | 53.56 |
| GC intron (%) | 44.18 |
| Repeat content (%) | 2.97 |
| Protein-coding genes | 15,413 |
| Gene density (genes per Mb) | 296.9 |
| Exons per gene | 2.76 |
| tRNA genes | 258 |
| rRNA genes | 52 |
| Pseudogenes | 494 |
| Transposable elements (%) | 1.54 |
| Controls (N = 39) (%) | Cases (N = 123) % | |
| Stage I | 22 (56) | 55 (45) |
| Stage II | 14 (36) | 54 (44) |
| Stage III | 3 (8) | 14 (11) |
| ER or PR positive/HER2 negative | 33 (85) | 104 (85) |
| ER or PR positive/HER2 positive | 6 (15) | 19 (15) |
| Mutation model | Sign test | Standardized differences test | Wilcoxon test |
| IAM | Hee = 20.49 | T2 = 13.196 | P (one tail for H deficiency) 1.000 |
| Hd = 0 | P = 0.000 | P (one tail for H excess) 0.000 | |
| He = 40 | P (two tails for H excess and deficiency) 0.000 | ||
| P = 0.000 | |||
| SMM | Hee = 22.40 | T2 = 11.518 | P (one tail for H deficiency) 1.000 |
| Hd = 0 | P = 0.000 | P (one tail for H excess) 0.000 | |
| He = 40 | P (two tails for H excess and deficiency) 0.000 | ||
| P = 0.000 |
| Substrate | Enzymatic activity(mU/μL) | Specific activity(mU/mg) |
| Laminarin | 0.049 ± 0.002 | 290 ± 30 |
| CMC | 0.010 ± 0.001 | 59 ± 8 |
| Pectin | 0.0008 ± 0.0001 | 5 ± 1 |
| Xylan | 0.034 ± 0.002 | 210 ± 20 |
| pnPβGlu | 0.020 ± 0.001 | 120 ± 10 |
| pnPβXyl | 0.013 ± 0.001 | 81 ± 9 |
| Avicel | 0.015 ± 0.001 | 90 ± 10 |
| CSCB | 0.032 ± 0.002 | 190 ± 21 |
| Parameters | Units | Vinasse | Filter Cake (n = 9) | Bagasse (n = 9) | Straw (n = 12) | Recommendation | |||||||
| Autonomous (n = 6) | Annexed (n = 15) | ||||||||||||
| AV | SD | AV | SD | AV | SD | AV | SD | AV | SD | [13] | [14] | ||
| TS a | % FM d | 1.15 | ±0.12 | 3.44 | ±1.11 | 28.9 | ±3.77 | 55.4 | ±4.19 | 76.7 | ±21.6 | - | - |
| VS b | % TS | 76.0 | ±6.99 | 70.6 | ±3.84 | 74.2 | ±10.8 | 96.0 | ±2.70 | 86.3 | ±11.9 | - | - |
| COD c | g·L−1 | 22.1 | ±0.46 | 32.4 | ±10.0 | - | - | - | - | - | - | - | - |
| C | % TS | 37.0 | ±4.24 | 39.0 | ±8.61 | 42.7 | ±6.95 | 47.6 | ±2.69 | 43.4 | ±4.78 | C:N 20–40:1 | - |
| N | % TS | 2.94 | ±0.35 | 2.31 | ±0.35 | 1.76 | ±0.24 | 0.41 | ±0.04 | 0.52 | ±0.21 | - | |
| P | % TS | 0.16 | ±0.05 | 0.35 | ±0.12 | 0.60 | ±0.25 | 0.04 | ±0.02 | 0.06 | ±0.03 | C:N:P:S 600:15:5:3 | - |
| S | % TS | 0.87 | ±0.49 | 2.12 | ±0.27 | 0.18 | ±0.02 | 0.05 | ±0.03 | 0.21 | ±0.06 | - | |
| Ca | mg·L−1 | 77.4 | ±24.3 | 655 | ±211 | 4139 | ±1667 | 704 | ±215 | 2981 | ±1656 | - | 100–200 |
| Na | mg·L−1 | 16.4 | ±9.39 | 24.5 | ±9.58 | 7.75 | ±5.98 | 11.3 | ±8.83 | 37.1 | ±25.1 | - | 100–200 |
| K | mg·L−1 | 1306 | ±708 | 6021 | ±565 | 740 | ±280 | 1651 | ±1036 | 5002 | ±2344 | - | 200–400 |
| Mg | mg·L−1 | 173.6 | ±72.4 | 771 | ±177 | 971 | ±259 | 409 | ±173 | 1140 | ±404 | - | 75–150 |
| Variables | Rank† | P-value | HR | 95% CI |
| Age | 5 | 0.60 | 0.9 | 0.5-1.6 |
| Male | 3 | 0.10 | 2.5 | 0.8-7.7 |
| Black | 6 | 0.82 | 1.1 | 0.3-3.8 |
| Initial creatinine ≥ 175 μmol /L | 1 | 0.00 | 6.1 | 2.2-17 |
| Uncontrolled hypertension | 2 | 0.01 | 4.3 | 1.4-14 |
| Trombotic microangiopathy | 4 | 0.19 | 1.9 | 0.7-5.2 |
| Gene locus | Control (fructose) | Xylose 1 hour | Xylose 4 hours | Xylose + glucose 1 hour | Xylose + glucose 4 hours |
| An06g00620 | 0.08 ± 0.03 | 0.42 ± 0.07 | 0.38 ± 0.05 | 0.003 ± 0.00 | 0.03 ± 0.01 |
| An15g04270 | 0.05 ± 0.00 | 0.04 ± 0.00 | 0.20 ± 0.00 | 0.04 ± 0.00 | 0.02 ± 0.00 |
| An15g05440 | 0.34 ± 0.04 | 0.24 ± 0.03 | 0.56 ± 0.12 | 0.09 ± 0.05 | 0.19 ± 0.05 |
| An11g03700 | 0.06 ± 0.00 | 0.04 ± 0.01 | 0.17 ± 0.01 | 0.009 ± 0.001 | 0.05 ± 0.01 |
| An12g09270 | 0.29 ± 0.04 | 0.20 ± 0.02 | 0.56 ± 0.03 | 0.010 ± 0.001 | 0.20 ± 0.05 |
| An01g00850 | 0.25 ± 0.01 | 0.16 ± 0.03 | 0.60 ± 0.02 | 0.13 ± 0.01 | 0.45 ± 0.17 |
| An06g00260 | 0.70 ± 0.03 | 2.40 ± 0.22 | 2.30 ± 0.64 | 0.25 ± 0.01 | 0.36 ± 0.07 |
| Diploid, n (%) | Aneuploid, n (%) | p-value* | |
| Age, quartiles | |||
| <58 | 178 (91) | 18 (9) | <0.001 |
| 58 – 66 | 171 (83) | 35 (17) | |
| 66 – 75 | 145 (69) | 66 (31) | |
| ≥ 75 | 144 (68) | 68 (32) | |
| Histologic type and gradea | <0.001 | ||
| Endometrioid, grade 1-2 | 467 (87) | 71 (13) | |
| Endometrioid, grade 3 | 75 (63) | 44 (37) | |
| Non-endometrioid | 76 (51) | 72 (49) | |
| FIGO stage | <0.001 | ||
| Stage I | 502 (81) | 121 (19) | |
| Stage II | 54 (74) | 19 (26) | |
| Stage III | 62 (66) | 32 (34) | |
| Stage IV | 20 (57) | 15 (43) | |
| ER/PR statusb | <0.001 | ||
| ER and/or PR positive | 389 (82) | 84 (18) | |
| ER and PR negative | 72 (61) | 46 (39) |
| Container capacity, L | Number of 2MR disks | Target ppb |
| 10 | 1/5 | 27 |
| 20 | 1⁄2 | 27 |
| 30 | 2/3 | 27 |
| 40 | 1 | 27 |
| 50 | 1 | 27 |
| Variable | B | SE | p | OR |
| Theme B vs all others | 3.260 | .744 | .017 | 4.64 |
| having some TFA questions | 2.816 | .757 | <.001 | 16.71 |
| constant | -5.515 | .841 | <.001 | .004 |
| A | B | C | D | E | F | S | M | Range(where present) | Peak assignments* |
| – | – | – | – | – | 1299 | – | – | 1299 | (CH2)n deformations |
| – | – | – | – | 1356 | – | 1355 | – | 1356 | Tertiary (CH) deformation |
| 1411 | 1415 | 1413 | 1413 | 1413 | 1415 | – | – | 1411–1415 | (CH2) or (CH3) |
| – | 1438 | – | – | – | 1439 | – | – | 1438–1439 | (CH2) |
| 1450 | – | 1443 | 1447 | 1447 | 1449 | – | 1445 | 1443–1450 | (CH2), (CH) |
| 1509 | – | 1509 | 1507 | 1511 | – | 1510 | 1510 | 1507–1511 | Asymmetrical aryl ring stretch |
| 1603 | – | 1603 | 1603 | 1602 | 1605 | – | – | 1602–1605 | Aryl stretching vibration |
| 1716 | 1724 | 1729 | 1724 | 1727 | 1719 | 1727 | 1728 | 1716–1729 | C = O stretch of aldehydes, ketones, esters |
| – | – | – | – | – | – | 2820 | – | 2820 | CH bending |
| – | 2851 | 2845 | 2856 | 2856 | 2850 | – | – | 2845–2856 | CH antisymmetric and symmetric stretch of aliphatic compounds |
| – | 2882 | – | – | – | 2881 | – | – | 2881–2882 | CH antisymmetric and symmetric stretch of aliphatic compounds |
| 2905 | 2907 | 2907 | 2908 | 2907 | – | – | 2909 | 2905–2909 | CH antisymmetric and symmetric stretch of aliphatic compounds |
| – | 2932 | – | – | – | 2932 | – | 2934 | 2932–2934 | CH antisymmetric and symmetric stretch of aliphatic compounds |
| 2939 | – | – | 2941 | 2938 | 2938 | 2939 | – | 2938–2941 | Antisymmetric C–H stretch in –OCH3 symmetric CH stretch |
| 2963 | 2966 | 2966 | 2968 | 2966 | 2967 | – | 2969 | 2963–2969 | CH antisymmetric and symmetric stretch of aliphatic compounds |
| 3074 | – | – | – | 3073 | – | – | – | 3073–3074 | (=C–H) |
| 6-month change score | Difference of two groups (I – C) | ||||
| Intervention Group | Control Group | ||||
| N* | N* | ||||
| Laboratory data | |||||
| HbA1c (% (mmol/l) | 224 | −1.0 (−1.2 to −0.7) | 217 | −0.5 (−0.8 to −0.3) | −0.4 (−0.8 to −0.1) |
| (−10.5 (−13.2 to −8.0)) | (−5.9 (−8.7 to −3.2)) | (−4.6 (−8.4 to −0.9)) | |||
| Social support | |||||
| Social support score from Diabetes Care Profile (points) | 222 | 0.2 (−0.0 to 0.4) | 217 | 0.1 (−0.1 to 0.3) | 0.1 (−0.2 to 0.4) |
| SF-12 Scores | |||||
| PCS-12 (points) | 203 | 0.6 (−0.4 to 1.6) | 196 | 1.6 (0.6 to 2.6) | −1.0 (−2.4 to 0.4) |
| MCS-12 (points) | 203 | 1.4 (0.3 to 2.5) | 196 | −0.2 (−1.3 to 0.9) | 1.6 (0.1 to 3.2) |
| Program evaluation (Post-intervention only) | |||||
| Participants’ perception of empowerment attributable to the program at follow-up (points) † | 226 | 4.4 (4.4 to 4.5) | 216 | 4.3 (4.2 to 4.4) | 0.1 (0.0 to 0.2) |
| Value | ||
| Age (years) | 41 (18–79) | |
| Gender (n) | Male | 64 |
| Female | 73 | |
| Marital status (n) | Single | 26 |
| Married | 111 | |
| Education (n) | Primary school | 69 |
| Secondary school | 17 | |
| High school | 31 | |
| University | 20 |
| Feature | B | W | A | W+A | LLQ (pg/mL) | ULQ (pg/mL) |
| AR | 73 | 27 | 0 | 27 | 48 | 5599 |
| BDNF | 8 | 87 | 5 | 92 | 26 | 3956 |
| Flt3Lig | 2 | 98 | 0 | 98 | 17 | 9835 |
| GCP-2 | 26 | 74 | 0 | 74 | 132 | 13153 |
| HCC4 | 8 | 46 | 46 | 92 | 112 | 7907 |
| I-309 | 30 | 70 | 0 | 70 | 20 | 5142 |
| IL-17 | 95 | 5 | 0 | 5 | 330 | 7921 |
| IL-1a | 69 | 31 | 0 | 31 | 10 | 2943 |
| IL-1b | 46 | 54 | 0 | 54 | 4 | 2932 |
| IL-2 | 89 | 7 | 4 | 11 | 31 | 3671 |
| M-CSF | 55 | 45 | 0 | 45 | 86 | 6761 |
| MCP-1 | 17 | 69 | 14 | 83 | 82 | 2065 |
| MIG | 8 | 87 | 5 | 92 | 13 | 5030 |
| MIP-1b | 29 | 56 | 16 | 71 | 16 | 2399 |
| MIP-1d | 10 | 72 | 18 | 90 | 192 | 6969 |
| NT-3 | 75 | 25 | 0 | 25 | 160 | 22314 |
| NT-4 | 60 | 40 | 0 | 40 | 128 | 19170 |
| PARC | 4 | 25 | 70 | 96 | 12 | 1870 |
| Rantes | 0 | 13 | 87 | 100 | 5 | 1302 |
| SCF | 29 | 71 | 0 | 71 | 69 | 20306 |
| TARC | 15 | 85 | 0 | 85 | 21 | 3134 |
| TNF-R1 | 2 | 97 | 1 | 98 | 108 | 16285 |
| TNF-a | 71 | 29 | 0 | 29 | 56 | 6901 |
| TNF-b | 88 | 12 | 1 | 12 | 221 | 7617 |
| VEGF | 86 | 14 | 0 | 14 | 702 | 79564 |
| sgp130 | 0 | 63 | 37 | 100 | 334 | 38573 |
| Antimicrobial Agent | Number (%) of E. coli Isolates | Test of Independencep-Value * | |
| Adults | Young Children | ||
| n = 296 | n = 86 | ||
| Ampicillin | 113 (38.2) | 27 (31.4) | 0.2506 |
| Amoxicillin/Clavulanic acid | 40 (13.5) | 3 (3.5) | 0.0096 * |
| Piperacillin | 72 (24.3) | 5 (5.8) | 0.0002 * |
| Cephalothin | 86 (29.1) | 24 (27.9) | 0.8362 |
| Cefuroxime | 20 (6.8) | 3 (3.5) | 0.3152 |
| Cefotaxime | 4 (1.4) | 2 (2.7) | 0.6206 |
| Streptomycin | 137 (46.3) | 19 (22.1) | <0.0001 * |
| Gentamicin | 32 (10.8) | 9 (10.5) | 0.9273 |
| Amikacin | 30 (10.1) | 7 (8.1) | 0.5818 |
| Tetracycline | 63 (21.3) | 17 (19.8) | 0.7610 |
| Doxycycline | 46 (15.5) | 11 (12.8) | 0.5287 |
| Trimethoprim/sulfamethoxazole | 33 (11.1) | 12 (14) | 0.4776 |
| Chloramphenicol | 18 (6.1) | 0 | 0.0171 |
| Nalidixic acid | 39 (13.2) | 8 (9.3) | 0.3358 |
| Norfloxacin | 8 (2.7) | 2 (2.3) | 1 |
| Ciprofloxacin | 8 (2.7) | 2 (2.3) | 1 |
| Nitrofurantoin | 12 (4.1) | 3 (3.5) | 1 |
| Antimicrobial susceptibility characteristic | |||
| R | 224 (75.7) | 47 (54.7) | 0.0002 * |
| MDR | 90 (30.4) | 12 (14) | 0.0024 * |
| Qualitative Theme | Exemplar Quotation(s) |
| Less Willing to Honestly Disclose SU/MH with PROs | |
| Harder to disclose to computer | “It takes a lot for a person to express how they feel when you can be face to face with somebody. Emotionally and physically...being face to face with her ... It’s easier.” (Patient 20, Not Retained, MH only) |
| Fear of Provider Judgement | “Other patients see [will start] missing their appointments because they ashamed of what the doctor seen. Especially when you bring it to their attention...They’ll start shying away from the clinic” (Patient, Retained, SU only). |
| More Willing to Honestly Disclose SU/MH with PROs | |
| Easier to disclose to computer | “That would give the doctor herself an extra little something that well, I can read this and maybe they don’t want to open to me, but they’ll open up to this. So I think that’d be real good.” (Patient 19, Retained, SU only) |
| Modification | Role | Species/System | Region/Residue(s) | Enzyme | Reference(s) |
| Ubiquitination | Target for proteasome dependent degradation | Human Mcm10(HeLa, U2OS)in vivo | 440–525783–803843–875(regions that can mediate degradation) | Cul4-DDB1-VprBP | [93,95,97,98] |
| Ubiquitination | Functional regulation during S-phase | Yeast Mcm10(Saccharomyces cerevisiae) | K85, K122, K319, K372, K414, K436 | Not identified | [67,100] |
| Phosphorylation | Unknown function | Human Mcm10 (HeLa) | T85, S93, S150, S155, A182, S203, S204, A210, S212, T217, R286, T296, S488, S548, S555, S559, S577, S593, Y641, S644, T663, S706, S824(* only sites identified in more than 2 datasets are listed) | Not identified, except T85 which is ATR or ATM dependent. | [93,101,102,103,104,105,106,107,108,109,110,111,112] |
| Phosphorylation | Replisome stability | Xenopus extract | S154, S173, S206, S596, S630, S690, S693 | S-CDK | [113] |
| Acetylation | Protein stability and DNA binding | Human Mcm10 | K267, K312 *, K318, K390 *, K657, K664, K668, K674 *, K681 *, K682 *, K683 *, K685 *, K737 *, K739 *, K745 *, K761 *, K768 *, K783, K847 *, K849 *, K853, K868, K874 | p300 (acetylase)SIRT1 * deacetylase)* indicates subset of SIRT1 target residues | [62] |
| Group | n = | Mean | Std dev. | Difference in means MT-AR (95% CI) | p | |
| VAS | AR | 19 | 3.3 | 26.3 | 15.0 (-1.1,31.2) | .067 |
| MT | 20 | 18.3 | 23.5 | |||
| RMQ | AR | 19 | 0.6 | 3.2 | 3.6 (1.1,6.2) | .006 |
| MT | 20 | 4.2 | 4.5 | |||
| PRI | AR | 19 | -0.1 | 7.2 | 7.1 (2.0,12.2) | .007 |
| MT | 20 | 7.0 | 8.5 |
| Risser’s stage | Original method | French method |
| Stage 0 | Micro-ossification (2)1 Gas shadow (1)2 | Micro-ossification (2)1 Gas shadow (1)2 |
| Stage 1 | Skip ossification (2)3 Gas shadow (1)2 | Gas shadow (1)2 Skip ossification (2)3 |
| Stage 2 | Skip ossification (1)3 Miscalculation of excursion (4)4 | Skip ossification (1)3 Miscalculation of excursion (2)4 |
| Stage 3 | Miscalculation of excursion (5)4 | Micro-fusion (4)5 |
| Stage 4 | Miscalculation of excursion (1)4 Micro-fusion (3)5 | Skip ossification (2)3 Pseudo-fusion (10)6Micro-fusion (4)5 |
| Stage 5 | Skip ossification (2)3 Pseudo-fusion (14)6 |
| Skin to calyx distance | |||
| ≤75mm | >75mm | P value | |
| Number | 140 | 130 | |
| Gender | 0.823 | ||
| Male | 88 | 80 | |
| Female | 52 | 50 | |
| Mean age (years) | 43.09±12.5 | 45.4±12.4 | 0.129 |
| Mean body mass index (kg/m2) | 25.7±3.5 | 26.6±5.3 | 0.090 |
| Mean stone size (mm) | 21.7±5.8 | 22.8±6.0 | 0.143 |
| Stone location | 0.077 | ||
| Complex stone | 60 | 57 | |
| Pelvis | 31 | 34 | |
| Lower | 40 | 30 | |
| Middle | 8 | 6 | |
| Upper | 1 | 3 | |
| Operation side | 0.745 | ||
| Left | 76 | 68 | |
| Right | 64 | 62 | |
| Degree of hydronephrosis | 0.682 | ||
| 0 | 6 | 4 | |
| 1 | 72 | 66 | |
| 2 | 54 | 54 | |
| 3 | 6 | 6 | |
| 4 | 2 | 0 | |
| Previous renal stone treatment | 0.853 | ||
| SWL | 22 | 21 | |
| PNL | 14 | 17 | |
| Open renal stone surgery | 11 | 13 |
| Test set | Our representation | Shen's representation | ||||
| SN (%) | SP (%) | AC (%) | SN (%) | SP (%) | AC (%) | |
| 1 | 86.5 | 88.5 | 87.5 | 69.2 | 84.6 | 76.9 |
| 2 | 73.1 | 88.5 | 80.8 | 69.2 | 84.6 | 76.9 |
| 3 | 76.9 | 86.5 | 81.7 | 78.8 | 82.7 | 80.8 |
| Average | 78.8 | 87.8 | 83.3 | 72.4 | 83.9 | 78.2 |
| Characteristic | Improvisation | Composition |
| Context | Public or private | Private |
| Individual/group | Individual or group | Individual or group (less frequent) |
| Development | Continuous, linear, real-time act, extemporaneous creation | Continuous or discontinuous act, mediated creation |
| Experimentation | Extemporaneous experimentation; it can provide suggestions to composition | Reasoned experimentation |
| Abilities | Performing and compositional | Compositional |
| Processes | Anticipation, use of repertoire, emotive communication, feedback, and flow | Planning, translating from the sound to graph, idea generation, organization and construction, revision |
| Reversibility | Irreversible action, it cannot be changed | Reversible action, it can be changed until the final draft |
| Revision | It cannot be reviewed, but only adjusted in real-time during the performance with the feedback | It can be reviewed and improved |
| Control | Control of individual variables but not of group variables | Overall control of the score and of the complexity of the compositional process |
| Feedback | Real-time feedback | Feedback without real-time pressure |
| Process dynamics | Interactive process. It has an adaptable nature, it allows you to answer to context variables, it can be adjusted instantly. Challenge between performers, taking risks | Fix product. The composition can be interpreted but it is not possible to change the notes of the score |
| Communication | The author has a direct communication with the audience. It is more authentic and real than composition | The author has a communication with the audience mediated by the performer(s) who interprets his/her ideas |
| Comorbidities and outcomes | Estimate (mean or proportion) | 95% CI |
| Number of comorbidities | 7.54 | (7.53-7.55) |
| Charlson comorbidity category | ||
| Low (1–2) | 0.29% | (0.26%-0.31%) |
| Medium (3–4) | 17.29% | (17.12%-17.46%) |
| High (5+) | 82.42% | (82.25%-82.60%) |
| Inpatient death | 3.15% | (3.08%-3.23%) |
| Inpatient length of stay (days) | 5.22 | (5.20-5.25) |
| Inpatient cost (2009 $US) | $11,313.28 | ($11,233.77-$11,329.80) |
| Population | L | h | π | K | Ho | He | AR | Fis | M-He | M-Rs |
| JL | 12 | 0.800 | 0.07688 | 20.7564 | 0.600 | 0.780 | 10.275 | 0.255 | 0.73 | 6.27 |
| HY | 15 | 0.891 | 0.09296 | 25.1000 | 0.607 | 0.875 | 11.938 | 0.323 | 0.72 | 6.40 |
| DB | 8 | 0.862 | 0.08600 | 23.2196 | 0.786 | 0.832 | 8.000 | 0.092 | 0.68 | 5.68 |
| XJ | 10 | 0.807 | 0.10219 | 27.5919 | 0.741 | 0.792 | 8.262 | 0.084 | 0.70 | 6.20 |
| HS | 7 | 0.718 | 0.08387 | 22.6441 | 0.833 | 0.706 | 5.733 | −0.164 | 0.67 | 5.27 |
| Conditions | In-the-bag dislocation | Out-of-the-bag dislocation | Overall |
| Group (n = 209) | Group (n = 21) | (n = 230) | |
| Pseudoexfoliation | 90 (43.1 %) | 1 (4.8 %) | 91 (39.6 %) |
| Eye rubbing or tapping* | 30 (14.4 %) | 4 (19.0 %) | 34 (14.8 %) |
| Atopic dermatitis | 16 (7.7 %) | 2 (9.5 %) | 18 (7.8 %) |
| Long axial length | 24 (11.5 %) | 2 (9.5 %) | 26 (11.3 %) |
| Postvitrectomy | 22 (10.5 %) | 2 (9.5 %) | 24 (10.4 %) |
| Postglaucoma surgery | 6 (2.9 %) | 0 (0.0 %) | 6 (2.6 %) |
| Postkeratoplasty | 2 (1.0 %) | 0 (0.0 %) | 2 (0.9 %) |
| Operative complications† | 16 (7.7 %) | 5 (23.8 %) | 21 (9.1 %) |
| Secondary implantation‡ | 0 (0.0 %) | 3 (14.3 %) | 3 (1.3 %) |
| Retinitis pigmentosa | 6 (2.9 %) | 2 (9.5 %) | 8 (3.5 %) |
| Primary angle closure | 2 (1.0 %) | 0 (0.0 %) | 2 (0.9 %) |
| Chronic uveitis | 2 (1.0 %) | 0 (0.0 %) | 2 (0.9 %) |
| Unidentifiable | 33 (15.8 %) | 3 (14.3 %) | 36 (15.7 %) |
| Strains and conditions | Throughput (Mbp) | Absolute counts | Ratios | ||
| Reads aligned on reference genome | Uniquely aligned reads | Ratio considering DB110 HP as reference (all reads) | Ratio considering DB110 HP as reference (unique reads) | ||
| DB110 28 MPa (DB110 HP) | 582 | 16.621.219 | 5.836.186 | 1.00 | 1.00 |
| DB110 0.1 MPa (DB110 LP) | 584 | 16.690.818 | 3.050.616 | 1.00 | 0.52 |
| TW30 28 MPa (TW30 HP) | 611 | 17.466.471 | 5.692.495 | 1.05 | 0.97 |
| TW30 0.1 MPa (TW30 LP) | 479 | 13.699.146 | 4.517.864 | 0.824 | 0.77 |
| Months | 2 (n = 7) | 8 (n = 9) | 15 (n = 9) | 24 (n = 9) |
| Blood Na ± mEq/L | 141.31 ± 1.18 | 145.22 ± 1.56 | 145.81 ± 2.73 | 147.20 ± 1.22* |
| Blood K ± mEq/L | 4.22 ± 0.13 | 5.46 ± 0.37* | 5.42 ± 0.29* | 5.45 ± 0.26* |
| UNaV μEq/min | 0.56 ± 0.13 | 0.71 ± 0.06* | 0.75 ± 0.05* | 1.49 ± 0.14* |
| UKV μEq/min | 1.31 ± 0.11 | 1.68 ± 0.15 | 2.00 ± 0.31* | 3.03 ± 0.02* |
| Blood Aldosterone ng% | 23.6 ± 0.82 | 13.2 ± 1.63* | 15.7 ± 1.43* | 13.7 ± 1.63* |
| Cost category | Cost (USD) | Percentage |
| Project costs of program implementation: | ||
| Support structure | 57,794 | 14.2 |
| Salary | 196,839 | 48.3 |
| Medicine | 144,020 | 35.3 |
| Supplies | 9,301 | 2.3 |
| Total financial cost | 407,954 | 100.0 |
| Estimated unit costs of program implementation: | ||
| Unit annual cost per WAJA | 3,610 | |
| Per capita cost | 1.16 |
| Parameters | Definitions |
| Patient characteristics | Age, weight, height, body mass index (BMI), medical insurance status and performance status |
| Hospitalisation | LOS (length of hospitalisation post-operation), the procedure performed, diagnosis, operating time, name of surgery, intra-operative estimated blood loss |
| Post-operation | Time to full tolerance of free fluids (days), time to full tolerance of solid food (days), time to drain removal (days) hospitalisation expenses |
| Complications | |
| Infection | Wound infection, lung infection, intraperitoneal infection, operation space infection (fever, mild abdominal pain without radiographic abnormalities) |
| Post-operative nausea and vomiting (PONV) | It was recognised that nausea and vomiting are common side effects of surgical recovery |
| Ileus | Is a disruption of the normal propulsive ability of the gastrointestinal tract |
| Post-operative haemorrhage | Evidence of blood loss from drains or based on ultrasonography |
| Post-operative thrombosis | Evidence of blood thrombosis based on ultrasonography |
| APACHE II score | Acute Physiology and Chronic Health Evaluation II |
| Risk-factors | Level | Categorization |
| Herd1 | 1,2,3,4 | |
| Sow-related factors | ||
| Parity | Young | 1st parity |
| Mature | 2nd-7th parity | |
| Litter size | Large2 | Gilts: >15 piglets, Sows: >18 piglets |
| Small | Gilts: <16 piglets, Sows: < 19 piglets | |
| Stillborn | Many | >1 piglet |
| Few | 0-1 piglets | |
| Clinical disease | Yes | Mastitis and/or temp > 39.5°C and/or leg problems and/or vulva discharge3 |
| No | None of the above | |
| Piglet-related factors4 | ||
| Gender | Male | |
| Female | ||
| Birth weight | Continuous scale | |
| Faecal consistency | Liquid | Watery or liquid consistency of rectal contents |
| Normal | Creamy, firm or solid consistency of rectal contents and if no faeces on swab | |
| Flanks | Hollow | Area behind ribs turned inwards |
| Normal | Area behind ribs followed the line of the ribs | |
| Hair coat | Rough | Hair coat appeared dull |
| Normal | Hair coat did not appear dull |
| Site of metastases | PTC-GD | Euthyroid |
| Bone | 2 (6.8%) | 1 (0.4%) |
| Lung | 0 | 2 (0.8%) |
| Bone + lung | 2 (6.8%) | 4 (1.6%) |
| Local recurrence + lung | 0 | 3 (1.3%) |
| Local recurrence + lung + bone | 0 | 3 (1.3%) |
| Local recurrence | 1 (3.4%) | 4 (1.7%) |
| Parameter | Description | Baseline cohort (n = 43) | PD cohort (n = 40) |
| Age at sample draw | Median age (range) | 72 (37–83) | 63 (35–88) |
| Adjuvant endocrine therapy (%) | No | 26 (60) | 26 (65) |
| Yes, tamoxifen only | 10 (23) | 9 (23) | |
| Yes, tamoxifen + AI | 5 (12) | 4 (10) | |
| Yes, AI only | 2 (5) | 1 (2) | |
| Adjuvant chemotherapy (%) | No | 34 (79) | 28 (70) |
| Yes | 9 (21) | 12 (30) | |
| Neoadjuvant therapies (%) | No | 43 (100) | 40 (100) |
| Number of previous lines endocrine therapy lines for MBC (%) | 0 | 43 (100) | |
| 1 | 22 (55) | ||
| 2 | 12 (30) | ||
| ≥3 | 6 (15) | ||
| Endocrine therapy after start (BL cohort) or before PD (PD cohort) (%) | AI | 30 (70) | 25 (63) |
| Tamoxifen | 13 (30) | 7 (17) | |
| Fulvestrant | 8 (20) | ||
| Previous endocrine therapy lines for MBC (in case of inclusion at PD on ≥second‐line endocrine therapy) (%) | Yes, AI only | 9 (23) | |
| Yes, AI + tamoxifen | 6 (15) | ||
| Yes, tamoxifen only | 3 (7) | ||
| Progression on the current line (%) | Yes | 35 (81) | 40 (100) |
| CTC count | Median count (range) | 81 (6–32492) | 21 (5–2837) |
| Variable | Cycling (%Wmax) (n = 22) | Knee extension (%MVC) (n = 23) | ||||
| Baseline | 30% | 60% | Baseline | 40% | 75% | |
| Systole | ||||||
| Apical rot. (°) | 9.40 ± 3.02 | 14.29 ± 4.20† | 15.85 ± 5.04† | 9.22 (5.55) | 11.53 (6.30)* | 13.58 (7.11)* |
| Basal rot. (°) | −4.32 ± 2.85 | −6.40 ± 2.77* | −6.90 ± 2.57† | −4.56 ± 2.68 | −3.26 ± 2.32 | −4.73 ± 3.06 |
| Twist (°) | 13.21 ± 4.63 | 20.04 ± 4.76† | 22.50 ± 4.93† | 13.40 ± 4.80 | 14.72 ± 4.38 | 16.77 ± 5.54 |
| Apical rot. velocity (° s−1) | 62.12 (30.77) | 123.32 (53.39) † | 182.55 (42.82)†‡ | 59.65 (31.23) | 100.95 (48.71)† | 105.09 (70.98)† |
| Basal rot. velocity (° s−1) | −46.18 ± 15.28 | −79.83 ± 25.51† | −114.63 ± 30.21†‡ | −46.42 ± 14.95 | −55.13 ± 15.34 | −64.68 ± 19.84† |
| Twisting velocity (° s−1) | 88.21 ± 20.51 | 145.11 ± 27.08† | 209.05 ± 34.56†‡ | 89.15 ± 21.77 | 106.66 ± 21.00* | 124.32 ± 34.89†** |
| Diastole | ||||||
| Apical rot. velocity (° s−1) | −63.59 ± 17.05 | −146.60 ± 31.52† | −204.35 ± 68.77†‡ | −63.21 (25.81) | −80.15 (47.50)* | −119.03 (66.78)†‡ |
| Basal rot. velocity (° s−1) | 41.47 (25.94) | 73.17 (48.76)† | 109.41 (53.36)†‡ | 42.37 (26.22) | 46.17 (16.68) | 62.72 (28.00) |
| Untwisting velocity (° s−1) | −93.90 (29.62) | −193.19 (64.32)† | −267.31 (104.30)†‡ | −90.60 (27.19) | −98.44 (43.54) | −138.42 (73.29)†‡ |
| Time-to-peak (ms) | 59.50 (28.50) | 57.50 (27.00) | 53.50 (28.00) | 62.00 (31.00) | 99.00 (64.00) | 75.00 (75.00) |
| PUV % of diastole | 7.00 (4.31) | 15.45 (10.12)† | 21.78 (12.53)†‡ | 8.33 (4.66) | 19.11 (19.56)† | 20.33 (30.11)† |
| Walk Well | Control | Main between group comparison | |||||
| Outcomes | N | Mean (SD) | N | Mean (SD) | Mean difference at 12-weeks (95 % CI)a | p | ICC |
| Primary outcome | |||||||
| Step count per day | 42 | 4823 (2059) | 40 | 4784 (2613) | 69.5 (-1054 , 1193.3) | 0.90 | 0.51 |
| Secondary outcomes | |||||||
| Percentage time per day MVPA | 42 | 3.0 (2.6) | 40 | 3.1 (2.1) | 0.3 (-0.7 , 1.3) | 0.55 | 0.42 |
| Percentage time per day sedentary | 42 | 66.4 (10.0) | 40 | 65.9 (12.0) | 1.6 (-3.0 , 6.1) | 0.49 | 0.22 |
| Total MET minutes per week | 37 | 1311.9 (1293.2) | 37 | 1154.8 (1103.7) | 56.0 (-428.8,540.9) | 0.82 | 0.02 |
| Body Mass Index (kg/m2) | 43 | 32.1 (7.7) | 43 | 32.9 (7.5) | −0.2 (-0.83,0.41) | 0.49 | 0.00 |
| Waist circumference (cm) | 45 | 104.9 (16.9) | 42 | 107.8 (17.8) | −1.6 (-3.93,0.64) | 0.15 | 0.00 |
| Subjective vitality (mean score) | 39 | 14.6 (2.5) | 35 | 14.3 (2.8) | 0.3 (-0.85, 1.52) | 0.57 | 0.00 |
| Self-efficacy (mean score) | 43 | 14.4 (3.0) | 42 | 13.7 (3.7) | 0.8 (-0.68, 2.22) | 0.29 | 0.08 |
| EQ-5D (mean health utility score) | 44 | 0.8 (0.27) | 43 | 0.7 (0.30) | 0.0 (-0.09, 0.14) | 0.70 | 0.00 |
| Measures to stockpile | Total | ||||
| Yes | No | Don't know | |||
| Hospital size | <100 | 1 (12.5 %) | 5 (62.5 %) | 2 (25.0 %) | 8 (100.0 %) |
| 100-199 | 13 (72.2 %) | 5 (27.8 %) | 0 (0.0 %) | 18 (100.0 %) | |
| >199 | 9 (47.4 %) | 9 (47.4 %) | 1 (5.3 %) | 19 (100.0 %) | |
| Total | 23 (51.1 %) | 19 (42.2 %) | 3 (6.7 %) | 45 (100.0 %) |
| Area | |||||||
| Khagrachari | Cox’s Bazar | Bandarban | Rangamati | Netrokona | Total | Frequency | |
| A (1,900 bp) | 10 | 56 | 6 | 1 | 2 | 75 | 0.735 |
| B (1,400 bp) | 1 | 2 | 1 | 0 | 1 | 5 | 0.049 |
| C (1,100 bp) | 2 | 5 | 2 | 0 | 0 | 9 | 0.088 |
| Mixed | 2 | 10 | 0 | 0 | 1 | 13 | 0.127 |
| No. | Abbreviated item | Factor 1 | Factor 2 | Factor 3 | Factor 4 | h2 |
| 1 | Abdominal bloating | 0.78 | 0.22 | 0.10 | 0.14 | 0.69 |
| 2 | Tenesmus | 0.74 | 0.21 | –0.00 | 0.12 | 0.61 |
| 3 | Changed stool form | 0.68 | 0.16 | 0.37 | 0.12 | 0.65 |
| 4 | Changed stool frequency | 0.69 | 0.03 | 0.39 | 0.15 | 0.65 |
| 5 | Flatulence | 0.73 | 0.22 | 0.16 | 0.22 | 0.66 |
| 6 | Depression | 0.24 | 0.77 | 0.12 | 0.27 | 0.73 |
| 7 | Irritation | 0.34 | 0.69 | 0.25 | 0.27 | 0.73 |
| 8 | Angry | 0.09 | 0.81 | 0.18 | 0.14 | 0.71 |
| 9 | Nervousness | 0.26 | 0.77 | 0.20 | 0.26 | 0.76 |
| 10 | Finding a toilet | 0.20 | 0.32 | 0.77 | 0.25 | 0.70 |
| 11 | Holding back defecation | 0.20 | 0.10 | 0.89 | 0.18 | 0.75 |
| 12 | Unpredictability | 0.21 | 0.26 | 0.80 | 0.21 | 0.84 |
| 13 | Eating before going out | 0.24 | 0.22 | 0.46 | 0.63 | 0.74 |
| 14 | Consideration of foods | 0.20 | 0.23 | 0.15 | 0.80 | 0.80 |
| 15 | Favorite foods | 0.16 | 0.21 | 0.09 | 0.87 | 0.86 |
| 16 | Eating out | 0.15 | 0.28 | 0.35 | 0.72 | 0.79 |
| Mean | 95% HPD | Posterior probability | |
| PB2 | August 2016 | June – October 2016 | 0.9992 |
| PB1 | August 2016 | July – October 2016 | 0.9993 |
| PA | July 2016 | May – October 2016 | 0.9995 |
| HA | September 2016 | July – October 2016 | 0.9997 |
| NP | May 2016 | October 2015 – October 2016 | 0.9997 |
| NA | May 2016 | June – October 2016 | 0.9689 |
| M | August 2016 | June – October 2016 | 0.4849 |
| NS | September 2016 | June – October 2016 | 0.9995 |
| Accession | Runs | 0A | 5A | 10A | 15A | 20A | 25A |
| SRX016359 | SRR035678 | 4,373,013 | 4,373,128 | 4,373,220 | 4,373,338 | 4,374,306 | 4,840,614 |
| SRR037439 | 2,028,240 | 2,028,376 | 2,028,503 | 2,028,622 | 2,028,900 | 2,069,175 | |
| SRR037440 | 4,385,598 | 4,385,761 | 4,385,880 | 4,386,034 | 4,386,793 | 4,794,397 | |
| SRR037441 | 2,161,858 | 2,162,012 | 2,162,156 | 2,162,303 | 2,162,646 | 2,205,932 | |
| SRR037442 | 4,840,368 | 4,840,534 | 4,840,669 | 4,840,802 | 4,841,777 | 5,319,375 | |
| SRR037443 | 2,043,229 | 2,043,370 | 2,043,531 | 2,043,665 | 2,043,916 | 2,070,547 | |
| SRR037444 | 1,939,846 | 1,939,970 | 1,940,096 | 1,940,204 | 1,940,597 | 1,988,929 |
| Conceptual definition | Operational definition |
| Prostate cancer knowledge—Participants’ understanding of CaP disease, prevention and detection. | Ten questions assessed participants’ prostate cancer knowledge using a True/False/Don’t Know scale. Each correct response had 1 point and incorrect response or ‘I don’t know’ response had 0 point. Higher score indicated high knowledge of prostate cancer information. |
| Prostate cancer early detection behaviour—CaP information seeking behaviour and CaP screening. | An index of Prostate Cancer Detection Behaviour was created by combining (sum) the responses of participants on prostate cancer screening by DRE in the last year (5 if Yes, and 0 if No); prostate cancer screening by PSA in the last year (5 if Yes, and 0 if No); prostate cancer information seeking behaviour (measured on a 5-point Strongly Agree–Strongly Disagree scale); prostate cancer discussion with a physician (measured on a 5-point Strongly Agree–Strongly Disagree scale); and paying attention to prostate cancer information (measured on a 5-point Strongly Agree–Strongly Disagree scale). The index score ranged from 0 to 25. |
| Prostate cancer screening intention—Participants’ expressed likelihood of screening for CaP in the future | Three questions were used to measure intention. For example, participants responded to the question: ‘Within the next year, I will get tested for prostate cancer with the Digital Rectal Examination (DRE)’ on a strongly disagree (1)–strongly agree (5) scale, with higher score indicating high intention. |
| Decisional conflict—Participants’ state of uncertainty about the course of action to take relative to CaP screening [34]. | O’Connor’s scale [34] provided the items for decisional conflict. The scale used for this study assessed CaP screening uncertainty (3 items) and factors contributing to uncertainty (7 items) on a strongly disagree (1)–strongly agree (5) scale. An example of the screening uncertainty measure is ‘I’m unsure what to do when it comes to prostate cancer screening’. Lower score on this scale indicates high uncertainty. An example of the factors contributing to uncertainty measure is ‘I feel I know the risks and side effects of prostate cancer screening’. Higher score on this scale indicates greater number of factors contributing to uncertainty. |
| Satisfaction with the W.O.R.D video | Participants’ satisfaction was assessed by three questions. For example, participants responded to the statement, ‘The information I received from the Prostate Cancer Education video can best be described as’ using a Very Unsatisfactory (1)–Very Satisfactory scale (5) with higher score indicating high satisfaction. |
| Quality of the W.O.R.D video | Participants’ perceived quality was assessed by three questions. For example, participants responded to the statement, ‘The Prostate Cancer Education video can best be described as superior’ using a strongly disagree (1) strongly agree (5) scale, with higher score indicating high quality rating. |
| General assessment of the W.O.R.D video | Using a ‘Yes’, ‘No’ and ‘I can’t say’ scale, participants responded to ten questions focused on general assessment of the video. Examples were: Was the information provided by the video useful to you? Did you experience any difficulty with the video? In your opinion, would you say that the video is credible? |
| Input | Processing | Output |
| Alignment | Export to a different format | Alignment |
| Alignment | Remove sequences >80 % identical and columns with conservation <0.9 | Alignment |
| Alignment | Construct neighbour-joining tree using Kimura distance correction | Distance matrix |
| Distance matrix | Reconstruct tree | Tree |
| Alignment | Apply bootstrap analysis | Bootstrap trees |
| Source | Country | Filling (Years) | Remarks |
| R Franceys, et al. [15] | Various | 15–25 | Design recommendations for household properties |
| J Pickford [17] | East Africa | Over 30 | Reported at a house hold level |
| P Morgan [53] | Zimbabwe | Over 30 | Household latrine |
| DA Still and K Foxon [107] | South Africa | 20 | Design recommendation |
| South Africa | 5–9 | Empting time for most (85 %) pit latrines. Lower and higher filling rates were also noted | |
| I Günther, et al. [56] | Uganda | 5 | Study in low income areas of Kampala, Uganda (Slums) |
| RN Kulabako, et al. [108] | Uganda | <1 | Low laying areas of peri-urban settlements in Kampala |
| K Adubofour, et al. [109] | Ghana (slums in Kusami metroplis) | 4.2 | Average filling time |
| >10 | High income areas | ||
| 0.25 | Low income areas | ||
| E Appiah-Effah, et al. [57] | Ghana (Ashanti region) | 6–10 | Low income area in Ashanti region |
| MONITORING LAYER | INFORMATION LAYER | INTERCHANGE LAYER | |||
| Capture Subsystem | Analysis Subsystem | Visualization & Control Subsystem | |||
| MDP | Probes | ||||
| Communication events: | Composite probe: | Merging traces | Web-based visualization | XML records with TimeStamp, Metadata and Radio packet | Ethernet based platform |
| Transmission_Error | |||||
| Routing_Error | Attached monitor node (Traps) | ||||
| Transmission_success | Trace Analysis on the merged trace, based on several analysis tools | SQL database | |||
| Captured_Frame | Single probe: Sniffers | ||||
| Mote_state |
| Locus | Locus reference | Number of individuals genotyped in study population | Predicted allele size | Observed allele size range | Number of alleles obs. | He | Ho | Est. null allele freq. (CERVUS v3.0) | Mean estimated error rate (CERVUS v3.0) | Multiplex set |
| ZF01-020 | This study | 320 | 178 | 160-261 | 15 | 0.69 | 0.59 | 0.075 | 0.007 | 3 |
| ZF01-025 | This study | 334 | 211 | 188-217 | 11 | 0.78 | 0.77 | 0.005 | 0 | 2, 3 |
| TG01-040 | This study | 307 | 286 | 286-294 | 7 | 0.69 | 0.70 | -0.011 | 0 | 2 |
| ZF01-054a | This study | 308 | 185 | 157-188 | 13 | 0.89 | 0.75 | 0.083 | 0.002 | 2 |
| ZF01-139b | This study | 330 | 188 | 156-209 | 4 | 0.53 | 0.55 | -0.007 | 0.040 | 4 |
| ZF01-136 | This study | 299 | 367 | 333-373 | 10 | 0.73 | 0.55 | 0.138$ | 0 | 2 |
| ZF01-170c | [47] | 21 | 316 | 257-305 | 9 | 0.83 | 0.86 | -0.032 | - | 4 |
| ZF01-161 | This study | 333 | 159 | 125-168 | 8 | 0.70 | 0.74 | -0.036 | 0 | 4 |
| ZF01-190 | This study | 329 | 342 | 308-366 | 12 | 0.83 | 0.87 | -0.026 | 0 | 3 |
| ZF01-196 | This study | 334 | 292 | 270-304 | 7 | 0.74 | 0.77 | -0.014 | 0 | 2, 3, 4 |
| Tgu12 | This study | 331 | 282 | 248-273 | 10 | 0.79 | 0.75 | 0.026 | 0.016 | 3 |
| ZF01-180b | [43] | 331 | 213 | 166-218 | 8 | 0.76 | 0.66 | 0.071 | 0.060 | 4 |
| ZF01-081b | This study | 337 | 233 | 130-154 | 5 | 0.55 | 0.51 | 0.031 | 0.077 | 4 |
| ZF02-068 | This study | 292 | 185 | 121-152 | 7 | 0.70 | 0.50 | 0.157$ | 0.010 | 2 |
| ZF02-038b | This study | 301 | 233 | 211-245 | 11 | 0.77 | 0.66 | 0.074 | 0.085 | 2 |
| TG02-078 | [43] | 314 | 309 | 308-321 | 6 | 0.73 | 0.76 | -0.024 | 0 | 1 |
| TG02-088 | [43] | 310 | 268 | 263-269 | 5 | 0.73 | 0.77 | -0.034 | 0 | 1 |
| Ase44 | [64] | 303 | 268 | 308-329 | 8 | 0.81 | 0.79 | 0.010 | 0.006 | 2 |
| ZF02-128 | This study | 301 | 374 | 365-435 | 9 | 0.83 | 0.79 | 0.022 | 0.005 | 2 |
| ZF02-129 | This study | 329 | 169 | 124-172 | 11 | 0.83 | 0.82 | 0.004 | 0.005 | 3 |
| ZEST09-005 | Dawson et al. unpublished | 316 | 168 | 155-165 | 5 | 0.74 | 0.67 | 0.047 | 0 | 1 |
| Smm4 | [65] | 313 | 332 | 332-341 | 6 | 0.57 | 0.50 | 0.049$ | 0.018 | 1 |
| Cpi7 | [66] | 308 | 128 | 119-131 | 5 | 0.54 | 0.55 | -0.016 | 0 | 1 |
| ZEST09-018 | Dawson et al. unpublished | 289 | 285 | 282-293 | 8 | 0.70 | 0.75 | -0.039 | 0 | 1 |
| ZEST09-021 | Dawson et al. unpublished | 311 | 119 | 114-121 | 5 | 0.47 | 0.41 | 0.096 | 0 | 1 |
| ZEST09-025 | Dawson et al. unpublished | 281 | 167 | 164-170 | 6 | 0.71 | 0.69 | 0.014 | 0 | 1 |
| Poroscientific Model 740 | Relative uncertainty (k = 1) | Absolute uncertainty | Percent contribution | Comments |
| LP CFV stagnation pres., P0 = 570.03 kPa | (× 10−6) | (Pa) | (%) | |
| Calibration transfer standard for static pres. | 17 | 9.7 | 2.1 | Traceable to NIST Pres. and Vacuum Group |
| Drift limit | 60 | 34.2 | 25.6 | < 0.01 % in 6 months, assume rect. distrib. |
| Residuals, hysteresis, thermal effects | 100 | 57.0 | 71.3 | From cal. records, experiments |
| Dynamic pres. Unc. | 12 | 6.7 | 1 | Est. based on unc. of 10 % u(M) and 5 % |
| RSS | 118 | 67.5 | 100 |
| Quartiles of DDS | ||||
| 1st (n = 37) | 2nd (n = 34) | 3rd (n = 46) | 4th (n = 43) | |
| FSG (mg/dl) | 93.73 ± 12.40 | 88.00 ± 12.11 | 87.83 ± 13.90 | 90.55 ± 16.51 |
| TG (mg/dl) | 200.47 ± 104.85 a | 197.87 ± 141.02 | 194.76 ± 119.80 | 168.50 ± 71.25 |
| TC (mg/dl) | 189.29 ± 52.61 | 191.61 ± 38.11 | 187.34 ± 33.62 | 191.17 ± 37.63 |
| LDL (mg/dl) | 122.23 ± 4.56 | 123.12 ± 34.65 | 122.56 ± 45.98 | 122.18 ± 54.65 |
| HDL (mg/dl) | 40.05 ± 11.05 | 40.85 ± 9.36 | 41.30 ± 9.22 | 42.32 ± 10.78 |
| SBP (mmHg) | 133.05 ± 9.70a | 132.08 ± 8.70 | 128.70 ± 8.56 | 128.69 ± 3.12 |
| DBP (mmHg) | 88.08 ± 5.07 | 87.74 ± 3.37 | 89.39 ± 6.65 | 87.62 ± 9.19 |
| Adiponectin (ng/ml) | 11.82 ± 4.35 a | 14.50 ± 4.12 | 14.27 ± 3.70 | 15.27 ± 5.72 |
| Bacteria | Total (N = 221) |
| Gram-negative organisms | |
| Klebsiella species | 83 (38%) |
| Escherichia coli | 72 (33%) |
| Pseudomonas aeruginosa | 10 (5%) |
| Enterobacter species | 8 (4%) |
| Proteus species | 3 (1%) |
| Citrobacter species | 3 (1%) |
| Serratia species | 1 (1%) |
| Acinetobacter species | 1 (1%) |
| Gram-positive organisms | |
| Enterococcus species | 18 (8%) |
| Streptococcus species | 17 (8%) |
| Staphylococcus species | 2 (1%) |
| Anaerobes | |
| Bacteroides species | 3 (1%) |
| Level | 2005–2007 | 2002–2004 | ||||
| Total deaths | HT deaths | % | Total deaths | HT deaths | % | |
| Level 1 | 1429 | 162 | 11.3 | 1103 | 149 | 13.5 |
| Level 2 | 1527 | 232 | 15.2 | 1241 | 234 | 18.9 |
| Level 3 | 850 | 202 | 23.8 | 941 | 233 | 24.8 |
| APPLE Schoolsa | Alberta Schoolsb | Intervention Effect: Change in APPLE Schools over time relative to the coinciding change in Alberta schools (95% CI)b | ||||
| Fruits and vegetables consumption per day (β and 95% CI) | 0.39 | (0.00, 0.78) | -0.12 | (-0.29, 0.06) | 0.55 | (-0.02, 1.13) |
| Dietary energy intake (kcal) per day (β and 95% CI) | -236.51 | (-366.22, -106.81) | -25.89 | (-78.34, 26.56) | -212.11 | (-315.07, -109.16) |
| DQI score (β and 95% CI) | 0.96 | (-0.28, 2.19) | -0.23 | (-0.77, 0.31) | 1.14 | (-0.55, 2.83) |
| PAQ-C score (β and 95% CI) | 0.13 | (0.03,0.23) | 0.02 | (-0.01, 0.06) | 0.10 | (0.01, 0.20) |
| Obesity (Odds Ratio and 95% CI) | 0.84 | (0.52, 1.36) | 1.37 | (1.11, 1.70) | 0.61 | (0.35, 1.06) |
| Samplea | HW Categoryb | Witness® HW | SNAP® RT | DiroChek® | Sample OD(+ control OD) Initial Test | Sample OD(+ control OD)Post-Heat Treatment |
| 1 | BL | + (+) | − (vol.b) | + (+) | 0.038 (0.352) | 0.049 (0.309) |
| 23 | BL | + (+) | − (+) | + (+) | 0.013 (0.363) | 0.070 (0.309) |
| 26 | BL | − (−) | − (−) | + (−) | 0.015 (0.363) | 0.000 (0.309) |
| 52 | BL | + (+) | − (+) | + (+) | 0.027 (0.470) | 0.124 (0.309) |
| 62 | BL | + (+) | − (+) | + (+) | 0.020 (0.470) | 0.077 (0.309) |
| 68 | BL | − (+) | − (+) | + (+) | 0.019 (0.380) | 0.050 (0.309) |
| 92 | Neg. | + (−) | − (−) | − (−) | 0.000 (0.380) | 0.000 (0.309) |
| 98 | BL | + (+) | − (+) | − (+) | 0.004 (0.380) | 0.025 (0.309) |
| 116 | BL | − (−) | + (−) | − (−) | 0.001 (0.337) | 0.000 (0.309) |
| 121 | BL | + (+) | − (vol.c) | − (+) | 0.009 (0.337) | 0.126 (0.309) |
| Subscale | Experimental group (n = 25) | Control group (n = 23) |
| Anxiety | ||
| Week 0 | 6.3 ± 3.2 | 6.5 ± 3.4 |
| Week 4 | 4.1 ± 2.9∗# | 6.1 ± 3.2 |
| Depression | ||
| Week 0 | 4.9 ± 3.8 | 4.8 ± 3.1 |
| Week 4 | 3.1 ± 2.8∗∗## | 4.6 ± 2.9 |
| Total | ||
| Week 0 | 10.9 ± 4.1 | 10.8 ± 3.9 |
| Week 4 | 7.1 ± 3.1∗∗## | 9.8 ± 3.4 |
| Acceptance Number | Drug | Date | Company | Progress |
| JXSL1600007 | Nivolumab | 17 February 2016 | Bristol-Myers Squibb | In Assessing |
| JXSL1500068 | 7 December 2015 | |||
| JXSL1300032 | 20 May 2013 | In Clinic | ||
| JXSL1600009 | Pembrolizumab | 29 February 2016 | Merck | In Assessing |
| JXSL1600005 | 16 February 2016 | |||
| JXSL1500074 | 31 December 2015 | |||
| JXSL1500058 | 30 September 2015 | |||
| JXSL1500040 | 28 July 2015 | |||
| JXSL1500020 | 25 May 2015 | |||
| CXSL1400138 | JS001-PD-1 | 21 January 2015 | ShangHai JunShi | In Clinic |
| CXSL1400153 | SHR-1210 | 19 January 2015 | ShangHai HengRui | |
| CXSL1500096 | BGB-317 | 11 December 2015 | BeiGene | In Assessing |
| CXSL1600016 | Genor PD-1 Antibody | 7 April 2016 | Genorbio |
| PDB code of the receptor | AutoDock binding energy (kcal/mol) | PDB code of the receptor | AutoDock binding energy (kcal/mol) |
| 1A8G | -7.28 | 3EKX | -7.95 |
| 1A9M | -8.30 | 3EM3 | -8.90 |
| 1AJV | -7.77 | 3MXD | -7.86 |
| 1AJX | -7.24 | 3MXE | -7.66 |
| 1BV9 | -7.38 | 3NLS | -8.24 |
| 1BWA | -9.25 | 3O9F | -8.42 |
| 1BWB | -8.67 | 3O9H | -7.81 |
| 1CPI | -7.41 | 3O9I | -7.59 |
| 1DIF | -6.64 | 3O9G | -7.37 |
| 1GNO | -8.60 | 3SA3 | -7.90 |
| 1HPV | -7.83 | 3SA4 | -7.92 |
| 1IDB | -6.90 | 3SA5 | -7.97 |
| 1MUI | -7.09 | 3SA6 | -7.72 |
| 1T3R | -8.11 | 3SA7 | -7.51 |
| 1T7J | -7.45 | 3SA8 | -8.11 |
| 1XL2 | -6.73 | 3SA9 | -7.87 |
| 1XL5 | -7.60 | 3SAA | -9.15 |
| 2I0A | -7.88 | 3SAB | -8.16 |
| 2I0D | -7.37 | 3SAC | -8.06 |
| 2PQZ | -7.32 | 4DJO | -7.85 |
| 2PSU | -7.66 | 4DJP | -7.46 |
| 2PSV | -8.12 | 4DJQ | -7.79 |
| 2Q5K | -8.00 | 4DJR | -7.67 |
| 2Q54 | -8.19 | 4DQB | -7.85 |
| 2Q55 | -7.33 | 3IXO | -4.94 |
| 3EKV | -8.10 |
| Inputs | Outputs |
| Solar irradiance spectra | Radiance spectrum |
| Gas absorption and scattering cross sections | Jacobians (partial derivatives of the radiance spectrum with respect to each of the state vector elements) |
| Atmospheric state | - |
| Surface state | - |
| Instrument line shape function | - |
| Aerosol optical properties | - |
| Imaging direction | Treatment | Sheep (n = 5) | Pigs (n = 3) |
| Dorsal/Ventral | Baseline | 14 | 15 |
| Hypertonic | 1 | 7 | |
| Isotonic | 0 | 6 | |
| Mannitol | 0 | 3 | |
| Lateral | Baseline | 14 | 10 |
| Hypertonic | 3 | 2 | |
| Isotonic | 4 | 3 | |
| Mannitol | 0 | 4 | |
| Other | Upside down | 2 | 0 |
| At 24 h | 1 | 0 | |
| Lung | 0 | 4 | |
| 39 | 51 |
| Volume (ml) | Protein concentration (mg/l) | Specific activity (AU *10000/ml) | Total activity (AU*100000) | Recovery (%) | |
| Culture supernatant | 1000 | 1213.64 ± 42.68 | 15.36 ± 0.43 | 1536 | 100 |
| Sephadex G-25 | 2600 | 357.31 ± 17.14 | 5.37 ± 0.08 | 1397 | 90.95 |
| SP FF | |||||
| Sepharose | 820 | 376.89 ± 15.83 | 15.52 ± 0.36 | 1273 | 82.93 |
| Median of Means (Range) | |||||
| All available data | No. of comparisons | TEA group | GA group | WMD (95 % CI) | P value |
| During two-lung ventilation | |||||
| PaO2 (mmHg) | 13 | 382.42(205.00 to 85.00) | 377.92(191.0 to 453.00) | 6.29 [0.04 to 12.17] | 0.35 |
| PaCO2 (mmHg) | 10 | 39.67 (32.50 to 37.6) | 40.23 (35.60 to 37.40) | −0.21 [−1.11 to 0.68] | 0.64 |
| PvO2 (mmHg) | 7 | 51.50(48.00 to 55.0) | 51.62(48.0 to 53.30) | 0.27 [−1.51 to 2.06] | 0.76 |
| Qs/Qt (%) | 13 | 14.80 (4.90 to 22.50) | 15.50 (3.95 to 21.60) | 0.02[−0.47 to 0.50] | 0.95 |
| SvO2 (%) | 4 | 85.37(83.30 to 87.10) | 86.68(84.90 to 88.20) | −1.22[−2.36 to −0.07] | 0.58 |
| SaO2 (%) | 4 | 99.75(99.70 to 99.90) | 99.45(99.00 to 99.90) | −0.06[−0.08 to −0.04] | 0.30 |
| PH | 4 | 7.43 (7.42 to 7.43) | 7.44 (7.43 to 7.44) | −0.01 [−0.02 to 0.00] | 0.21 |
| Paw (cmH2O) | 4 | 18.63 (17.00 to 20.00) | 19.03 (17.00 to 21.40) | −0.24 [−1.14 to 0.66] | 0.60 |
| During one-lung ventilation within 30 min | |||||
| PaO2 (mmHg) | 10 | 166.90(118.00 to 211.00) | 171.2(122.00 to 201.00) | −16.52[−21.98 to -11.05] | <0.01 |
| PaCO2 (mmHg) | 10 | 37.12 (36.10 to 44.20) | 36.85(34.20 to 42.20) | 0.29 [−0.53 to 1.10] | 0.49 |
| PvO2 (mmHg) | 7 | 47.78(44.90 to 54.00) | 46.14(44.50 to 51.00) | 1.13 [−0.50 to 2.76] | 0.17 |
| Qs/Qt (%) | 10 | 33.32 (27.30 to 39.50) | 32.77 (26.70 to 40.60) | 2.53 [1.35 to 3.72] | <0.01 |
| SvO2 (%) | 4 | 80.53(78.30 to 82.60) | 81.58(78.40 to 84.20) | −1.13[−2.74 to 0.48] | 0.17 |
| SaO2 (%) | 4 | 97.98(96.80 to 99.30) | 97.65(97.30 to 98.00) | 0.74[0.33 to 1.15] | <0.01 |
| PH | 4 | 7.43 (7.42 to 7.44) | 7.44 (7.42 to 7.46) | −0.01 [−0.02 to 0.001] | 0.41 |
| Paw (cmH2O) | 4 | 28.00 (23.00 to 32.50) | 27.00 (24.00 to 30.90) | 1.95 [1.61 to 2.28] | <0.01 |
| One-lung ventilation more than 30 min | |||||
| PaO2 (mmHg) | 11 | 162.27(117.00 to 203.00) | 168.72(148.00 to 221.00) | −14.23[−20.81 to -7.65] | <0.01 |
| PaCO2 (mmHg) | 11 | 36.61 (33.90 to 44.60) | 36.78 (35.00 to 44.20) | −0.22 [−0.96 to 0.53] | 0.57 |
| PvO2 (mmHg) | 6 | 44.70(42.60 to 46.10) | 44.98(43.40 to 46.60) | −0.61[−2.23 to 1.02] | 0.46 |
| Qs/Qt (%) | 12 | 34.40 (33.60 to 42.70) | 32.67 (32.10 to 40.90) | 2.77 [1.81 to 3.74] | <0.01 |
| SvO2 (%) | 6 | 79.33(77.40 to 81.10) | 81.97(78.50 to 83.90) | −2.39[−3.73 to −0.99] | <0.01 |
| SaO2 (%) | 6 | 97.68(96.60 to 98.10) | 98.20(97.20 to 99.00) | −0.63[−1.23 to −0.04] | 0.04 |
| PH | 6 | 7.43 (7.43 to 7.44) | 7.44 (7.41 to 7.46) | 0.00 [−0.01 to 0.01] | 0.50 |
| Paw (cmH2O) | 6 | 26.80 (24.00 to 32.50) | 26.72 (24.00 to 31.40) | 0.87 [0.54 to 1.20] | <0.01 |
| Re-two ventilation | |||||
| PaO2 (mmHg) | 7 | 322.28(173.00 to 482.00) | 307.28(168.00 to 407.00) | 11.54[−4.25 to 27.34] | 0.15 |
| PaCO2 (mmHg) | 3 | 37.8 (34.00 to 46.10) | 35.6 (34.90 to 36.90) | −0.60 [−3.03 to 1.83] | 0.63 |
| PvO2 (mmHg) | 5 | 47.82(43.00 to 50.00) | 48.68(46.20 to 51.00) | 0.06[−2.24 to 2.36] | 0.96 |
| Qs/Qt (%) | 6 | 18.55(15.30 to 24.50) | 20.15(15.50 to 24.80) | −1.27 [−2.73 to 0.20] | 0.09 |
| SvO2 (%) | 2 | 81.90(81.50 to 82.30) | 85.30(85.30 to 85.30) | −3.62[−6.28 to −0.95] | 0.80 |
| SaO2 (%) | 2 | 99.75(99.70 to 99.80) | 99.00 (99.00 to 99.00) | 0.75[0.52 to 0.98] | 0.67 |
| PH | 2 | 7.42 (7.41 to 7.42) | 7.42 (7.42 to 7.42) | 0.00 [−0.03 to 0.02] | 0.77 |
| Paw (cmH2O) | 2 | 19.00 (18.00 to 20.00) | 18.00 (18.00 to 18.00) | 0.95 [−0.81 to 2.71] | 0.29 |
| Quintiles of Dietary Intake | No. Cases | Person-Years | Multivariate Adjusted HR (95% CI) 1 |
| Total fiber (g/day) | |||
| <10.3 | 420 | 302,828 | 1.00 (Reference) |
| 10.3–13.6 | 426 | 312,546 | 1.00 (0.87, 1.15) |
| 13.6–17.0 | 354 | 316,244 | 0.83 (0.71, 0.97) |
| 17.0–21.5 | 372 | 318,893 | 0.87 (0.74, 1.03) |
| >21.5 | 380 | 318,844 | 0.90 (0.73, 1.10) |
| p-trend | 0.09 | ||
| Soluble fiber (g/day) | |||
| <2.8 | 408 | 304,051 | 1.00 (Reference) |
| 2.8–3.7 | 409 | 312,599 | 0.97 (0.84, 1.12) |
| 3.7–4.6 | 361 | 316,928 | 0.85 (0.73, 1.00) |
| 4.6–5.8 | 410 | 318,628 | 0.96 (0.81, 1.13) |
| >5.8 | 364 | 317,148 | 0.84 (0.69, 1.03) |
| p-trend | 0.14 | ||
| Insoluble fiber (g/day) | |||
| <7.4 | 433 | 302,242 | 1.00 (Reference) |
| 7.4–9.8 | 413 | 312,804 | 0.93 (0.81, 1.07) |
| 9.8–12.3 | 357 | 316,721 | 0.81 (0.69, 0.94) |
| 12.3–15.7 | 370 | 318,704 | 0.84 (0.72, 1.00) |
| >15.7 | 379 | 318,884 | 0.87 (0.72, 1.06) |
| p-trend | 0.08 | ||
| Pectin (g/day) | |||
| <1.4 | 399 | 303,832 | 1.00 (Reference) |
| 1.4–2.0 | 397 | 313,746 | 0.97 (0.84, 1.12) |
| 2.0–2.6 | 379 | 316,302 | 0.92 (0.79, 1.06) |
| 2.6–3.5 | 396 | 318,847 | 0.97 (0.83, 1.13) |
| >3.5 | 381 | 316,626 | 0.94 (0.80, 1.11) |
| p-trend | 0.56 |
| Mycotoxins | Positives (N) | Occurrence (%) | Mean (μg kg−1) | Median (μg kg−1) | Range (μg kg−1) |
| Raisins | |||||
| TeA | 20 | 35.1 | 104.8 | 29.4 | 6.9~594.4 |
| AOH | 3 | 5.3 | 8.9 | 7.5 | 3.5~15.6 |
| AME | 11 | 19.3 | 3.1 | 0.4 | 0.3~13.5 |
| OTA | 11 | 19.3 | 1.9 | 0.4 | 0.2~8.8 |
| OTB | 2 | 3.5 | 0.2 | 0.2 | 0.1~0.3 |
| MPA | 27 | 47.4 | 130.7 | 9.4 | 0.3~2647.3 |
| Dried apricots | |||||
| TeA | 21 | 37.5 | 237.1 | 71.8 | 10.4~1231.8 |
| TEN | 4 | 7.1 | 14.0 | 12.6 | 2.7~28.0 |
| AME | 3 | 5.4 | 1.3 | 1.2 | 0.5~2.1 |
| PAT | 1 | 1.8 | 30.6 | 30.6 | 30.6 |
| MPA | 15 | 26.8 | 26.7 | 3.9 | 1.0~119.7 |
| Dried dates | |||||
| TeA | 18 | 34.0 | 873.2 | 555.0 | 9.6~4411.4 |
| TEN | 7 | 13.2 | 6.2 | 5.2 | 1.4~11.2 |
| PA | 14 | 26.4 | 39.1 | 35.2 | 20.4~85.6 |
| MPA | 1 | 1.9 | 7.5 | 7.5 | 7.5 |
| Dried wolfberries | |||||
| TeA | 35 | 64.8 | 574.8 | 93.4 | 23.8~5665.3 |
| TEN | 34 | 63.0 | 156.5 | 75.9 | 11.7~1032.6 |
| AOH | 2 | 3.7 | 16.6 | 16.6 | 5.9~27.4 |
| AME | 4 | 7.4 | 3.9 | 0.3 | 0.2~15.0 |
| Subject terms | Titles |
| synuclein | alpha-synuclein |
| alpha synuclein | |
| alpha | |
| protein | |
| aggregation | |
| deep brain | deep brain stimulation |
| deep | |
| stimulation | |
| brain stimulation | |
| subthalamic | |
| lewy | lewy bodies |
| lewy bodies | |
| bodies | |
| lewy body | |
| dementia | |
| monoamine oxidase | monoamine oxidase |
| oxidase | |
| monoamine | |
| mao | |
| b | |
| mitochondrial | oxidative stress |
| oxidative | |
| complex i | |
| oxidative stress | |
| stress |
| Score | Criteria |
| 0 | Active and positive engagement with the assessor or a positive response to the stimuli introduced |
| 1 | Relaxed or passive response |
| 2 | Acceptance after a few attempts and eventual tolerance |
| 3 | Overexcitement |
| 4 | Dog was attempting to avoid the assessor or the stimuli or used mouthing |
| 5 | Exhibition of fear, tonic immobility, or escape from the arena |
| Organisms | Patients |
| Coagulase-negative Staph. | 14 (35%) |
| Staph. Aureus` | 7 (17.5%) |
| Gram-negative rods | 5 (12.5%) |
| Enterococcus | 2 (5%) |
| Coliform Bacilli | 3 (7.5%) |
| Diphteroid Bacilli | 1 (2.5%) |
| No Pathogens identified | 8 (20%) |
| Adverse effect | Outcome | Upper risk limit (%) | |
| Low-dose methylprednisolone | High-dose methylprednisolone | ||
| Acute severe allergy | Lethal | 0.24 | 0.00a |
| Life-threatening | 2.65 | 1.18 | |
| Cardio-pulmonary distress | Lethal | 0.33 | 0.79 |
| Persistent | 0.02 | 0.39 | |
| Life-threatening | 0.86 | 1.71 | |
| Diabetes | Lethal | 0.02 | 0.53 |
| Persistent | 0.86 | 1.05 | |
| Life-threatening | 0.07 | 0.13 | |
| Gastrointestinal haemorrhage | Lethal | 0.26 | 0.39 |
| Persistent | 0.13 | 0.13 | |
| Life-threatening | 0.37 | 0.79 | |
| Hepatotoxicity | Lethal | 0.11 | 0.13 |
| Persistent | 0.11 | 0.53 | |
| Life-threatening | 0.29 | 0.66 | |
| Myopathy | Persistent | 0.46 | 0.79 |
| Life-threatening | 0.07 | 0.13 | |
| Osteonecrosisb | Persistent | 0.57 | 1.58 |
| Pancreatitis | Lethal | 0.04 | 0.13 |
| Psychosis | Persistent | 0.04 | 0.13 |
| Life-threatening | 0.07 | 0.13 | |
| Seizure | Lethal | 0.09 | 0.39 |
| Persistent | 0.13 | 0.00a | |
| Life-threatening | 0.13 | 0.13 | |
| Ventricular arrhythmia/cardiac arrest | Lethal | 0.55 | 1.05 |
| Persistent | 0.09 | 0.13 | |
| Life-threatening | 0.86 | 1.18 | |
| Totalc | Lethal | 1.65 | 3.42 |
| Persistent | 2.43 | 4.73 | |
| Life-threatening | 5.36 | 6.04 |
| Location | Year | N | Genotype frequency | HWEa | |||
| Phe/Phe | Phe/Cys | Cys/Cys | χ2 | P | |||
| Porto Velho (RO) | 2010 | 37 | 0.95 | 0.05 | 0 | 0.002 | 0.821 |
| Rondonópolis (MT) | 2012 | 11 | 1 | 0 | 0 | – | – |
| Cianorte (PR) | 2009 | 16 | 1 | 0 | 0 | – | – |
| Foz do Iguaçu (PR) | 2009 | 24 | 0.79 | 0.21 | 0 | 0.324 | 0.875 |
| Maringá (PR) | 2012 | 24 | 0.87 | 0.13 | 0 | 0.107 | 0.753 |
| Marilena (PR) | 2014 | 16 | 0.94 | 0.06 | 0 | 0.017 | 0.874 |
| Nova Londrina (PR) | 2014 | 21 | 1 | 0 | 0 | – | – |
| Alvorada do Sul (PR) | 2014 | 17 | 1 | 0 | 0 | – | – |
| PR | 2009–2014 | 118 | 0.92 | 0.08 | 0 | 0.185 | 0.768 |
| MIGS ID | Property | Term | Evidence codea |
| Classification | Domain Bacteria | TAS [7] | |
| Phylum Firmicutes | TAS [8–10] | ||
| Class Firmibacteria | TAS [8, 9, 11] | ||
| Order Bacillales | TAS [8, 9, 12, 13] | ||
| Family Bacillaceae | TAS [8, 9, 13, 14] | ||
| Genus Bacillus | TAS [8, 9, 13, 15] | ||
| Species Bacillus cereus | TAS [8, 9, 13, 16] | ||
| Strain FORC_005 | |||
| Gram stain | Positive | TAS [17, 18] | |
| Cell shape | Rod | TAS [17, 18] | |
| Motility | Motile with peritrichous flagella | TAS [17, 18] | |
| Sporulation | Endospore-forming | TAS [8] | |
| Temperature range | 10 °C–50 °C | TAS [8, 17] | |
| Optimum temperature | 28–35 °C | TAS [8] | |
| pH range; Optimum | 4.9–9.3; 6.0–7.0 | TAS [17] | |
| Carbon source | Glucose, Aesculin | TAS [19] | |
| MIGS-6 | Habitat | Ubiquitous; especially in soil | TAS [17, 18] |
| MIGS-6.3 | Salinity | 0–7.5 % NaCl (w/v) | TAS [17] |
| MIGS-22 | Oxygen requirement | Facultative anaerobes | TAS [17, 18] |
| MIGS-15 | Biotic relationship | free-living | NAS |
| MIGS-14 | Pathogenicity | Diarrhea, emesis in human | NAS |
| MIGS-4 | Geographic location | Incheon, South Korea | IDA |
| MIGS-23 | Isolation | Korean soy sauce braised fish-cake with quail-egg | IDA |
| MIGS-5 | Sample collection | March 2014 | IDA |
| MIGS-4.1 | Latitude | 37.27 N | IDA |
| MIGS-4.2 | Longitude | 126.42 E | IDA |
| MIGS-4.4 | Altitude | Not reported |
| RAFK, RAF-RAFK |
| RAFPH, RAFPH-RAF~{p1} |
| RAF, MEK-RAF~{p1}, RAF-RAFK, RAFPH-RAF~{p1}, MEK~{p1}-RAF~{p1}, RAF~{p1} |
| MEKPH, MEKPH-MEK~{p1}, MEKPH-MEK~{p1, p2} |
| MEK, MAPK-MEK~{p1, p2}, MEK-RAF~{p1}, MEKPH-MEK~{p1}, MEKPH-MEK~{p1, p2}, MAPK~{p1}-MEK~{p1, p2}, MEK~{p1}-RAF~{p1}, MEK~{p1}, MEK~{p1, p2} |
| MAPKPH, MAPKPH-MAPK~{p1}, MAPKPH-MAPK~{p1, p2} |
| MAPK, MAPK-MEK~{p1, p2}, MAPKPH-MAPK~{p1}, MAPK~{p1, p2} MAPK~{p1}-MEK~{p1, p2}, MAPK~{p1}, MAPKPH-MAPK ~{p1, p2}, |
| Comparison | χ2 statistics | p-value | |
| IPI vs. NCCN-IPI | IPI | 6.46 | 0.0110 |
| NCCN-IPI | 1.69 | 0.1941 | |
| IPI vs. GELTAMO-IPI | IPI | 10.32 | 0.0013 |
| GELTAMO-IPI | 3.25 | 0.0712 | |
| NCCN-IPI vs. GELTAMO-IPI | NCCN-IPI | 0.06 | -* |
| GELTAMO-IPI | 1.60 | -* |
| Animals | Saline | TNBS alone | TNBS + RTP |
| SD rats | 31.5 ± 2.16 | 41.8 ± 3.22 | 31.9 ± 1.18 |
| BALB/c mice | 33.7 ± 1.13 | 42.9 ± 2.20 | 35.1 ± 3.24 |
| Impact point | PC (kPa) | PCC (kPa) | σVM (kPa) | τ (kPa) |
| A1 | 755 | −297 | 34.7 | 18.8 |
| A2 | 767 | −558 | 36.3 | 19.4 |
| A3 | 721.7 | −407.7 | 36.5 | 19.7 |
| A4 | 772 | −355 | 37.6 | 20.7 |
| A5 | 737 | −426.5 | 37.17 | 20.6 |
| B1 | 711 | −550 | 33.5 | 18 |
| B2 | 691.9 | −546.6 | 36.4 | 19.5 |
| B3 | 1066 | −428 | 36.8 | 19.9 |
| B4 | 786 | −374 | 37.4 | 20.6 |
| B5 | 782 | 424.6 | 37.4 | 20.9 |
| C1 | 700 | −338 | 34.7 | 18.6 |
| C2 | 731 | −362 | 35.3 | 18.9 |
| C3 | 723.7 | −399 | 37 | 20.1 |
| C4 | 761 | −428.8 | 37.1 | 20.5 |
| C5 | 881 | −459 | 37.9 | 21.1 |
| Fourier Descriptor-Based | GEI-Based | Convexity Defect-Based | ||||||||||
| Behavior | TPR | PPV | ACC | F_Score | TPR | PPV | ACC | F_Score | TPR | PPV | ACC | F_Score |
| Walking | 0 | 0 | 1.6 | - | 83.9 | 97.7 | 82.4 | 90.3 | 17.4 | 98.4 | 18.4 | 29.6 |
| Running | 13.0 | 97.2 | 16.0 | 22.9 | 0 | 0 | 3.5 | - | 23.4 | 98.4 | 27.6 | 37.8 |
| Standing | 85.9 | 100 | 85.9 | 92.4 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Sitting | 59.7 | 100 | 59.7 | 74.8 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Waving with two hands | 81.4 | 13.7 | 47.8 | 23.5 | 96.5 | 19.1 | 59.6 | 31.9 | 89.0 | 68.6 | 94.9 | 77.4 |
| Waving with one hand | 78.2 | 13.8 | 50.3 | 23.5 | 21.2 | 10.1 | 73.8 | 13.7 | 34.9 | 73.4 | 92.4 | 47.3 |
| Punching | 27.1 | 20.3 | 74.6 | 23.2 | 62.2 | 16.5 | 50.1 | 26.1 | 39.7 | 55.7 | 86.9 | 46.4 |
| Lying down | 12.9 | 72.0 | 38.6 | 21.9 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Kicking | 61.1 | 42.0 | 78.7 | 49.8 | 24.7 | 80.7 | 86.0 | 37.8 | 29.3 | 47.6 | 82.2 | 36.3 |
| Average | 46.6 | 51.0 | 50.4 | 48.7 | 55.5 | 46.3 | 65.1 | 50.5 | 47.7 | 77.4 | 71.8 | 59.0 |
| IOFB location | Number of cases (%) |
| In the vitreous | 11 (52.38 %) |
| In the retina | 7 (33.33 %) |
| Perforating | 3 (14.28 %) |
| Groups | Time points | p-value1 | p-value2 | |||
| Baseline n = 87 | 4 months n = 76 | 8 months n = 74 | 12 months* n = 69 | |||
| MMSE ± SD** | ||||||
| Stimulation therapy | 22.9 ± 4.5 | 22.2 ± 5.1 | 23.0 ± 4.0 | 22.7 ± 4.8 | 0.040 | 0.0016 |
| Donepezil | 23.7 ± 3.7 | 23.8 ± 3.8 | 25.1 ± 3.0 | 23.6 ± 3.8 | ||
| Clock Drawing Test ± SD** | ||||||
| Stimulation therapy | 2.8 ± 1.3 | 2.9 ± 1.2 | 2.8 ± 1.0 | 2.9 ± 1.1 | 0.940 | 0.713 |
| Donepezil | 2.8 ± 1.3 | 2.7 ± 1.3 | 2.8 ± 1.2 | 2.9 ± 1.1 | ||
| ADAS-cog ± SD** | ||||||
| Stimulation therapy | 18.5 ± 8.7 | 17.9 ± 8.6 | 16.7 ± 8.8 | 17.6 ± 8.6 | 0.225 | 0.060 |
| Donepezil | 17.6 ± 5.8 | 15.8 ± 6.9 | 15.1 ± 7.9 | 16.7 ± 8.1 |
| Type of interview | In-depth interviews | Focus group discussions |
| Members of HIV serodiscordant couples | ||
| N | 42 | 25 (total participants – 4FGDs) |
| Age, Median (IQR) | 31 (28–38) | 32(28–35) |
| % Female | 21 (50%) | 14 (56%) |
| % HIV positive | 21 (50%) | 20 (80%) |
| Children, Median (IQR) | 1 (1–2) | 1 (0–1) |
| Providers (participating in key informant interviews) | ||
| N | 20 | |
| Gynaecologist | 11 (55%) | |
| Fertility clinics | 5 | |
| Jointly public and private clinics | 4 | |
| Safer conception research sites | 2 | |
| Nurse counsellors | 5 (25%) | |
| Safer conception research sites | 3 | |
| Public health hospitals | 2 | |
| Clinical Officers | 2 (10%) | |
| Safer conception research sites | 1 | |
| Public health hospitals | 1 | |
| Counsellors | 2 (10%) |
| Sampling sites | Functional type | Vehicle and personnel | Greenbelt coverage rate | Air pollution |
| SSC | Shed used to stay chicken waiting for slaughtering | A few transport vehicles with chickens about 10 times h−1 | ~50% | Serious air pollution |
| EPV | Entrances to personnel and transport vehicles with products | Flow of transport vehicles, and some flow of personnel at commuting time | <5% | A little air pollution |
| GB | Green belt | Little flow of vehicles and personnel | >95% | Little air pollution |
| COL4A3 polymorphism | PolyPhen prediction (score) | SIFT prediction (score) |
| G43R | possibly damaging (1.800) | not tolerated (0.00) |
| P141L | probably damaging (2.250) | tolerated (0.40) |
| E162G | benign(0.024) | tolerated (0.64) |
| D326Y | probably damaging (2.025) | tolerated (0.08) |
| H451R | benign (1.426) | tolerated (0.54) |
| P574L | probably damaging (2.250) | tolerated (0.19) |
| COL4A4 polymorphism | PolyPhen prediction (score) | SIFT prediction (score) |
| P482S | benign (1.125) | tolerated (0.71) |
| G545A | benign (1.350) | not tolerated (0.01) |
| M1327V | benign(0.017) | tolerated (0.13) |
| Site | Amino acid replacements | Aminoacid change | PAML | |||||
| SLAC | REL | FEL | MEME | FUBAR | Branch-sites | |||
| COX1 | 3 | Y; S (2, 12, 14, 21, 22, 23, 24); P (15) | x | – | x | – | – | – |
| 177 | T, A (19) | – | – | – | – | – | E. mitis | |
| 199 | G; L (2, 6, 7, 14, 15); V (1); A (5, 10) | – | – | – | x | x | – | |
| 363 | T; S (5, 9, 13, 25) | – | – | – | x | – | – | |
| 365 | V; L (2, 6, 7, 14, 18, 21, 23, 24) | – | – | x | x | – | – | |
| 415 | S; I (12) | – | x | – | – | – | – | |
| 457 | V; I (9, 12) | – | x | – | – | – | – | |
| COX3 | 82 | S; C (3, 17, 18, 19, 20, 21); A (16) | – | – | x | – | – | – |
| 135 | I; V (17, 18, 19, 20) | – | – | – | – | – | E. mitis | |
| 145 | A; S (16, 22, 24, 25) | – | – | x | – | – | – | |
| 208 | T; V (2, 6, 7, 14, 24, 25), P (1, 5, 9, 10, 11, 13, 14); A (4, 8); L (12) | x | – | x | – | – | – | |
| 218 | S; N (3) | – | – | – | – | – | E. brunetti | |
| CYTB | 131 | F, Y (12) | – | x | – | – | – | – |
| 185 | F, Y (10) | – | x | – | – | – | – | |
| 264 | Y; N (10) | – | – | – | x | x | E. mitis | |
| 347 | V; L (9, 11, 13, 25); A (1, 12, 21); I (3); G (10), T (15) | x | – | x | – | x | – |
| CpG | A | B | V | Total |
| CpG_2 | 0.94 (0.93,0.96) | 0.95 (0.93,0.96) | 0.94 (0.92,0.95) | 0.94 (0.93,0.96) |
| CpG_3 | 0.81 (0.79,0.84) | 0.89 (0.85,0.95) | 0.85 (0.81,0.89) | 0.84 (0.81,0.89) |
| CpG_4 | 0.33 (0.06,0.63) | 0.39 (0.18,0.63) | 0.36 (0.25,0.75) | 0.35 (0.04,0.63) |
| Model a | ||||
| Cr in blood (N = 300) | Cr in hair (ln) (N = 299) | |||
| R2 = 0.135, (p < 0.001) | R2 = 0.184, (p < 0.001) | |||
| Parameter | SRC b | p value | SRC | p value |
| Exposure dose (ln) | 0.134 | 0.023 | 0.226 | <0.001 |
| Age | −0.025 | 0.687 | −0.102 | 0.078 |
| Sex (women) | 0.023 | 0.714 | −0.091 | 0.124 |
| S/N | Communities | Number of health facilities | Population size (2010 projection) | Major source of water supply | Means of waste disposal | Means of faecal disposal | |||
| Public | Private | Mission | Other | ||||||
| 1 | Moniya | 6 | 4 | 0 | 0 | 28,990 | • Well water is the major source | • Indiscriminate dumping at dump sites and drainages | • Most use latrine at home |
| 2 | Ojoo | 2 | 13 | 0 | 0 | 35,737 | • Well water is the major source | • Indiscriminate dumping at dump sites and drainages in some areas | • Most use latrine at home |
| • Private refuse collector are engaged by some areas | |||||||||
| 3 | Alagbafo | 1 | 1 | 0 | 1 | 22,635 | • Well water and spring are the major sources of water although water pipe runs through but disconnected | • Refuse containers provided by the government | • Most use latrine at home |
| 4 | Foko | 1 | 3 | 0 | 0 | 29,279 | • Well water is the major source of water although water pipe runs through the community but irregular | • Indiscriminate dumping at dump sites and drainages in some areas | • Indiscriminate disposal of fecal matter through the drainage or dumping site |
| 5 | Inalende | 0 | 3 | 0 | 1 | 24,279 | • Well water is the major source of water although water pipe runs through the community but irregular | • Indiscriminate dumping at dump sites and drainages in some areas | • Most dispose their fecal matter through the drainage or dump site |
| 6 | Odo-Ona/Apata | 4 | 7 | 2 | 0 | 55,429 | • Pipe borne water irregular | • Indiscriminate dumping at dump sites and drainages in some areas | • Most use latrine at home |
| • Well water is the major source | |||||||||
| 7 | Olorunsogo | 1 | 6 | 0 | 2 | 38,475 | • Well water is the major source | • Indiscriminate dumping at dump sites and drainages in some areas | • Most use latrine at home |
| 8 | Olunloyo | 1 | 2 | 0 | 0 | 25,531 | • Well water is the major source and some have borehole | • Indiscriminate dumping at dump sites and drainages in some areas | • Most use latrine at home |
| Assays | Nominal concentration (ng/ml) | |||||
| 250 | 500 | 1000 | 2000 | 3000 | ||
| Microbiological Intra-assay | Mean concentration obtained (ng/ml) (n=3) | 345.06 | 600.59 | 873.98 | 1651.43 | 3261.38 |
| Precision (SD) | 44.36 | 138.60 | 112.37 | 404.46 | 452.97 | |
| Precision (RSD, %) | 12.86 | 23.08 | 12.86 | 24.49 | 13.89 | |
| Accuracy | 138.02 | 120.11 | 87.39 | 82.57 | 108.71 | |
| Microbiological Inter-assay | Mean concentration obtained (ng/ml) (n=3) | 327.99 | 464.32 | 870.53 | 1570.46 | 2944.52 |
| Precision (SD) | 14.79 | 124.32 | 151.93 | 395.31 | 786.25 | |
| Precision (RSD, %) | 4.51 | 26.78 | 17.45 | 25.17 | 26.70 | |
| Accuracy | 131.19 | 92.86 | 87.05 | 78.52 | 98.15 | |
| HPLC Intra-assay | Mean concentration obtained (ng/ml) (n=3) | 248.57 | 492.14 | 990.74 | 1994.82 | 2712.25 |
| Precision (SD) | 10.59 | 4.33 | 17.08 | 10.95 | 538.64 | |
| Precision (RSD, %) | 4.26 | 0.88 | 1.72 | 0.55 | 19.86 | |
| Accuracy | 99.43 | 98.43 | 99.07 | 99.74 | 90.41 | |
| HPLC Inter-assay | Mean concentration obtained (ng/ml) (n=3) | 258.56 | 496.34 | 1002.85 | 2002.43 | 3011.78 |
| Precision (SD) | 13.15 | 9.03 | 16.17 | 15.11 | 7.80 | |
| Precision (RSD, %) | 5.08 | 1.82 | 1.61 | 0.75 | 0.26 | |
| Accuracy | 103.42 | 99.27 | 100.28 | 100.12 | 100.39 |
| Predictors of HSCL | Drop-outs at one- year follow-up N = 155 | Participants at one- year follow-up N = 758 | Drop-outs at 15-year follow-up N = 514 | Participants at 15- year follow-up N = 399 |
| Women: | ||||
| Age | -.12 | -.17** | -.14** | -.18** |
| Alone with child | .19* | .12** | .16** | .09 |
| Family finances | -.33** | -.28** | -.29** | -.28** |
| Education | -.15 | -.18** | -.20** | -.13** |
| Not working | .16 | .14** | .14** | .14** |
| Emotionality | .65** | .55** | .53** | .62** |
| Sociability | -.16* | -.19** | -.22** | -.13* |
| Activity | .00 | -.01 | -.01 | -.01 |
| Partner support | -.46** | -.37** | -.38** | -.40** |
| Emotional support from friends and family | -.28** | -.34** | -.33** | -.32** |
| Chronic stressors | .55** | .54** | .52** | .56** |
| Children: | ||||
| Activity | -.04 | -.05 | -.04 | -.05 |
| Sociability | -.04 | .03 | .05 | -.02 |
| Emotionality | .33** | .22** | .26** | .20** |
| Shyness | .11 | .07* | .07 | .09 |
| Reference | n | Subjects/methods | Exposure Measurement (PC; CC, CS) | Intervention (RCT) | Cancer type | Gene/s | Locus | Effect |
| Al-Hilal et al., 2013 [14] | 367 | 6-month RCT/M + F, 45–70 year | EPA + DHA; 0.45, 0.9 or 1.9 g/day | FADS1 + FADS2 | rs174537 | ↓D5D activity associated with T variant allele; ↑D5D activity in TG, TT with increasing doses; no association for D6D | ||
| Fradet et al., 2009 [12] | Control 478; case 466 | CC/M, mean age 65 year | FFQ | Prostate | COX2 | rs4648310 | G allele correlated with aggressive PCa when n-3 FA intake was low, and low risk with high intake | |
| Gago-Dominguez et al., 2004 [49] | Control 670; case 258 | CC/F, 45–74 year | SQ FFQ | Breast | GSTM1, GSTT1, GSTP1 | multiple | Lower activity genotypes associated with higher BCa protection with ↑ intake of marine n-3 FA | |
| Habermann et al., 2013 [11] | Control 912; case 712 | CC/M + F, 30–79 year | CARDIA questionnaire | Rectal | ALOX12 | rs11571339 | G allele associated with↓rectal cancer risk in those with low n-3 PUFA intake (NS) | |
| Habermann et al., 2013 [11] | Control 1900; case 1543 | CC/M + F, 30–79 year | CARDIA questionnaire | Colon | ALOX15 | rs11568131 | AA genotype have ↓risk of colon cancer with↑ intakes of n-3 PUFA (NS) | |
| Habermann et al., 2013 [11] | Control 1900; case 1543 | CC/M + F, 30–79 year | CARDIA questionnaire | Colon | COX1 | rs10306110 | Low EPA/DHA intake associated with higher colon cancer risk in variant allele carriers only | |
| Hedelin et al., 2006 [50] | Control 1130; case1499 | CC/M, 35–79 year | FFQ | Prostate | COX2 | rs5275 | C allele at locus rs5275 correlated with ↓risk of PCa with high intake of fatty fish | |
| Hester et al., 2014 [13] | 30 | CS/Caucasian F, 21–65 year | Serum FA | FADS1 | rs174537 | T variant correlated with lower AA; GG genotype associated with ↑LTB4 + 5-HETE | ||
| Hog et al., 2013 [37] | 122 | 3 year PC/M, 35–59 year | Blood serum | FADS1, FADS2 + FADS3 | rs174537 (FADS1); rs174575, rs2727270 (FADS2), rs1000778 (FADS3) | rs174537GG had ↑AA, AA/DGLA, DPA, LDL, oxLDL + ↓ETA. Rs17453 had↓AA, AA/DGLA, EPA, DPA, EPA/ALA + urinary PGF2a | ||
| Poole et al., 2007 [51] | Control 626; case 716 | CC/M + F, 30–74 year | FFQ | Colorectal | COX1 | Phe17Leu | Modest↓risk of CRC for carriers of P17 with higher fish intake; L17 carriers have ↓risk of CRC with lower intake | |
| Poole et al., 2010 [52] | Control 582; case 483 | CC/M + F, 30–74 year | FFQ | Colorectal | PGES | rs7873087 | Carriers of T allele have ↓risk of CRC with ↑fish intake | |
| Poole et al., 2010 [52] | Control 582; case 483 | CC/M + F, 30–74 year | FFQ | Colorectal | EP4 | Val294Ile | Carriers of Ile variant showed correlation between ↑fish intake and ↑CRC risk | |
| Porenta et al., 2013 [53] | 108 | 6-month RCT/CRC at risk M + F | 2 day FR + 24 h recall | Healthy People 2010 diet or Mediterranean diet | Colon | FADS cluster | rs174556 and rs174561 in FADS1, rs383445 in FADS2 and rs174537 of the FADS1/2 intragenic region | Wild-type alleles associated with lower AA in colonic mucosa in persons on Mediterranean Diet |
| Instrument A | Time 1 | Time 2 | Intervention | Time 3 | Difference score | Exercise test Result |
| Subject 1 | 8 | 9 | Verum | 15 | +6 | Much improved |
| Subject 2 | 9 | 8 | “” | 15 | +7 | Much improved |
| Subject 3 | 8 | 9 | “” | 15 | +6 | Much improved |
| Subject 4 | 9 | 8 | “” | 15 | +7 | Much improved |
| Subject 5 | 8 | 9 | Placebo | 8 | -1 | Unchanged |
| Subject 6 | 9 | 8 | “” | 9 | +1 | Unchanged |
| Subject 7 | 8 | 9 | “” | 8 | -1 | Unchanged |
| Subject 8 | 9 | 8 | “” | 9 | +1 | Unchanged |
| Instrument B | Time 1 | Time 2 | Time 3 | Difference score | Exercise test Result | |
| Subject 1 | 5 | 5 | Verum | 5 | 0 | Much improved |
| Subject 2 | 9 | 9 | “” | 9 | 0 | Much improved |
| Subject 3 | 13 | 13 | “” | 13 | 0 | Much improved |
| Subject 4 | 17 | 17 | “” | 17 | 0 | Much improved |
| Subject 5 | 5 | 5 | Placebo | 5 | 0 | Unchanged |
| Subject 6 | 9 | 9 | “” | 9 | 0 | Unchanged |
| Subject 7 | 13 | 13 | “” | 13 | 0 | Unchanged |
| Subject 8 | 17 | 17 | “” | 17 | 0 |
| Reference | Population | N | RRT | Mortality | Prognostic factors for hospital mortality |
| Mixed population (solid and hematological tumors, including bone marrow transplantation) | |||||
| Berghmans et al. (15) | Solid: 50% | 32 | CVVHDF | ICU: 50% | Number of organ failure |
| Hemato: 50% | Hospital: 53% | ||||
| BMT: 28% | |||||
| Salahudeen et al. (5) | Solid: 38% | 199 | C-SLED | Day 30: 65% | SOFA score, pH, mean blood pressure |
| Hemato: 62% | |||||
| BMT: 18% | |||||
| Mixed population (solid and hematological tumors, excluding bone marrow transplantation) | |||||
| Maccariello et al. (13) | Solid: 73% | 118 | IRRT daily conventional | ICU: 70% | Number of organ failure |
| Hemato: 27% | IRRT daily extended | Hospital: 78% | |||
| CRRT | |||||
| Darmon et al. (7) | Solid: 7% | 94 | CRRT | ICU: 43.6% | LOD score, late RRT (>24 h after ICU admission) |
| Hemato: 78% | IRRT | Hospital: 51.1% | |||
| Other: 15% | 6 months: 65.4% | ||||
| Soares et al. (14) | Solid: 75% | 98 | IRRT conventional | Hospital: 64–86% | – |
| Hemato: 25% | IRRT extended | ||||
| CRRT | |||||
| Hematological tumors | |||||
| Letourneau et al. (12) | BMT: 100% | 14 | CVVHDF | – | – |
| IRRT | |||||
| Lanore et al. (11) | BMT: 11% | 43 | ICU: 72% | ARF secondary to sepsis, SAPS score, mechanical ventilation support | |
| Benoit et al. (9) | BMT: 22.4% | 50 | IRRT | ICU: 79.6% | – |
| CRRT | Hospital: 83.7% | ||||
| 6 months: 86% |
| OCT (μm) Mean ± SD | Chloroquine group | Control group | p value∗ |
| CFT | 238.15 ± 22.5 | 248.2 ± 19.05 | 0.034 |
| Parafoveal thickness | |||
| Superior | 310.7 ± 21.64 | 322.35 ± 12.02 | 0.004 |
| Inferior | 309.05 ± 18.75 | 319.025 ± 11.3 | 0.005 |
| Nasal | 311.45 ± 14.9 | 320.05 ± 11.39 | 0.005 |
| Temporal | 299.025 ± 21.67 | 320.05 ± 11.39 | 0.013 |
| Perifoveal thickness | |||
| Superior | 287.675 ± 19.9 | 286.7 ± 11.85 | 0.791 |
| Inferior | 279.1 ± 17.75 | 282.75 ± 10.34 | 0.264 |
| Nasal | 287.38 ± 15.82 | 302 ± 11.4 | 0.107 |
| Temporal | 278.15 ± 20.6 | 282.6 ± 12.144 | 0.243 |
| RNFL thickness | 111.4458 ± 14.6969 | 107.6425 ± 11.5335 | 0.202 |
| GCC thickness | 95.61 ± 6.385 | 96.1217 ± 6.1347 | 0.716 |
| FLV | 0.86 ± 1.04 | 0.60 ± 0.53 | 0.167 |
| GLV | 4.28 ± 3.87 | 3.56 ± 3.05 | 0.358 |
| Metal | PFP soluble metals (μg metal/g PM) | Fresno soluble metals (μg metal/g PM)b |
| Co | < 3.2 | n/a |
| Cr | < 0.84 | n/a |
| Cu | < 1.0 | 344 ± 137 |
| Fe | < 25 | 262 ± 32 |
| Mn | < 1.8 | 397 ± 56 |
| Ni | < 3.4 | n/a |
| V | < 0.68 | 17 ± 3 |
| Zn | 7.8 ± 4.9 | n/a |
| Before SVA onset (n = 30) | After SVA onset (n = 30) | p | |
| Systolic arterial pressure, mmHg | 114 [97–127] | 97 [86–118] | 0.076 |
| Diastolic arterial pressure, mmHg | 58 [51–63] | 58 [47–64] | 0.513 |
| Mean arterial pressure, mmHg | 77.0 [70.0–87.0] | 73.0 [58.5–80.5] | 0.056 |
| Arterial pulse pressure, mmHg | 54 [39–70] | 42 [31–57] | 0.081 |
| Heart rate, beats/min | 99 [87–118] | 140 [123–165] | <0.001 |
| Dobutamine dose, μg/kg/mina | 7.5 [5.0–10.0] | 7.5 [5.0–10.0] | >0.99 |
| Norepinephrine dose, mg/ha | 1.7 [0.3–3.0] | 1.8 [0.5–4.5] | 0.010 |
| Epinephrine dose, mg/ha | 1.3 [0.5–2.0] | 1.5 [0.0–3.0] | 0.655 |
| Nest (%) | Environment (%) | Chi-square | P | |
| Egg stage | ||||
| String | 55 | 76 | 3.366 | 0.07 |
| Foil | 10 | 13 | 0.391 | 0.53 |
| Paper | 0 | 2 | – | – |
| Other | 35 | 9 | 15.364 | < 0.001 |
| Chick stage | ||||
| String | 30 | 83 | 24.858 | < 0.001 |
| Foil | 21 | 8 | 5.828 | 0.02 |
| Paper | 11 | 2 | 6.231 | 0.01 |
| Other | 38 | 7 | 21.356 | < 0.001 |
| Number of clones | Number of heteroinsertion | Number of homoinsertion | Efficiency of heteroinsertion | Efficiency of homoinsertion | ||
| Eed | LNL insertion | 88 | 17 | 4 | 19.3% | 4.5% |
| FNFL insertion | 190 | 33 | 5 | 17.4% | 2.6% | |
| SRCAP | LNL insertion | 94 | 65 | 3 | 69.1% | 3.2% |
| FNFL insertion | 96 | 70 | 2 | 72.9% | 2.1% |
| Donor | Population | Expansionday | EGA sample accessionnumber |
| 1 | IgM+ IgD+ | 0 | EGAN00001588556 |
| 1 | IgM+ IgD- | 0 | EGAN00001588558 |
| 1 | IgM- IgD- | 0 | EGAN00001588559 |
| 1 | IgM+ IgD+ | 5 | EGAN00001588560 |
| 1 | IgM+ IgD- | 5 | EGAN00001588561 |
| 1 | IgM- IgD- | 5 | EGAN00001588562 |
| 1 | IgM+ IgD+ | 10 | EGAN00001588563 |
| 1 | IgM+ IgD- | 10 | EGAN00001588564 |
| 1 | IgM- IgD- | 10 | EGAN00001588565 |
| 2 | IgM+ IgD+ | 0 | EGAN00001588549 |
| 2 | IgM+ IgD- | 0 | EGAN00001588541 |
| 2 | IgM- IgD- | 0 | EGAN00001588542;EGAN00001588543 |
| 2 | IgM+ IgD+ | 5 | EGAN00001588575 |
| 2 | IgM+ IgD- | 5 | EGAN00001588550 |
| 2 | IgM- IgD- | 5 | EGAN00001588551 |
| 2 | IgM+ IgD+ | 10 | EGAN00001588552 |
| 2 | IgM+ IgD- | 10 | EGAN00001588554 |
| 2 | IgM- IgD- | 10 | EGAN00001588555 |
| Total (n = 116) | Covered (n = 42) | Uncovered (n = 74) | p value¶ | |
| Complication rate | ||||
| Stent migration, n(%) | 8(6.9) | 4(9.5) | 4(5.4) | 0.458 |
| Granulation tissue formation, n(%) | 22(19.0) | 7 (16.7) | 15(20.3) | 0.634 |
| Stent fracture, n(%) | 19(16.4) | 5(11.9) | 14(18.9) | 0.44 |
| Resolution of symptoms, n(%) | 89(76.7) | 30 (71.4) | 59 (79.7) | 0.363 |
| Hazard ratio | 95% CI | p | |
| Model 1* | |||
| Age | 1.02 | 1.01-1.03 | 0.01 |
| Heart failure | 1.83 | 1.18-2.83 | 0.007 |
| Hemoglobin on admission | 0.91 | 0.85-0.98 | 0.01 |
| Model 2** | |||
| Age | 1.02 | 1.00-1.04 | 0.004 |
| Peripheral artery disease | 0.56 | 0.32-0.98 | 0.04 |
| Hemoglobin at admission | 0.92 | 0.85-0.99 | 0.02 |
| CKD | 1.62 | 1.09-2.40 | 0.02 |
| Model 1 + SAPS II | |||
| Heart failure | 2.25 | 1.29-3.93 | 0.005 |
| Coronary artery disease | 0.40 | 0.21-0.77 | 0.006 |
| Hemoglobin on admission | 0.91 | 0.84-0.98 | 0.009 |
| SAPS II | 1.04 | 1.03-1.05 | 0.001 |
| Model 2 + SAPS II | |||
| Heart failure | 1.70 | 0.99-2.88 | 0.05 |
| Peripheral artery disease | 0.51 | 0.28-0.95 | 0.03 |
| Coronary artery disease | 0.49 | 0.26-0.93 | 0.03 |
| Hemoglobin on admission | 0.91 | 0.84-0.98 | 0.01 |
| CKD | 1.67 | 1.08-2.57 | 0.02 |
| SAPS II | 1.04 | 1.03-1.05 | 0.001 |
| Indexes | Biological Rope Unit | Myriophyllum verticillatum Unit | Iris wilsonii Unit | Activated Carbon Unit |
| TN | 16.07% | 28.10% | 30.33% | 19.55% |
| NO3−-N | 28.64% | 37.02% | 33.78% | 25.03% |
| NH4+-N | 17.68% | 25.12% | 29.22% | 28.04% |
| TP | 21.19% | 3.96% | 6.05% | 4.17% |
| PO43−-P | 15.05% | 16.51% | 14.23% | 25.52% |
| Characteristics | |||
| Characteristics of the children | N | % | |
| Age (n = 1067) | - 2 or 3 years old | 227 | 21% |
| - 4 years old | 335 | 31% | |
| - 5 years old | 328 | 31% | |
| - 6 years old | 177 | 17% | |
| Girls (n = 1068) | 537 | 50% | |
| First in birth order (n = 1039) | 498 | 48% | |
| Medical conditions (n = 1068) | - Preterm infant | 96 | 9% |
| - Hospitalisation after birth | 81 | 8% | |
| - Asthma | 156 | 15% | |
| - Wearing of glasses | 146 | 14% | |
| - Auditory disorders | 63 | 6% | |
| - Allergy | 214 | 20% | |
| - Behavioural disorder | 44 | 4% | |
| - At least one surgical intervention | 225 | 21% | |
| - Other medical conditions | 70 | 7% | |
| Long term medication use (n = 1068) | 73 | 7% | |
| Frequency of administrating over the counter drugs without medical advice (n = 1062) | - Never | 168 | 16% |
| - Rarely | 311 | 29% | |
| - Often | 509 | 48% | |
| - Almost every time my child is ill | 74 | 7% | |
| Under homeopathic treatment (n = 1043) | 549 | 53% | |
| Advice from a pharmacist within the last 12 months (n = 1051) | 445 | 42% | |
| Mean | SD | ||
| N. of primary care consultations within the last 12 months (n = 1029) | 5.9 | 4.6 | |
| Parental characteristics | N | % | |
| Single parent family (n = 1066) | 136 | 13% | |
| Rural place of residence (n = 1064) | 217 | 20% | |
| Occupation (n = 1056) | - Disadvantaged (workers, unemployed) | 151 | 14% |
| - Moderately advantaged (self-employed, employees) | 563 | 53% | |
| - Advantaged (managers and executives) | 342 | 33% | |
| Education level (n = 1037) | - Elementary and secondary | 285 | 27% |
| - High school diploma (\"Baccalauréat\") | 238 | 23% | |
| - Lower tertiary | 235 | 23% | |
| - Higher tertiary | 279 | 27% | |
| Annual family income (n = 949) | - < 14 000 € | 168 | 18% |
| - 14 000 to 19 999 € | 203 | 21% | |
| - 20 000 to 29 999 € | 286 | 30% | |
| - 30 000 to 39 999 € | 170 | 18% | |
| - ≥ 40 000 € | 122 | 13% | |
| Mean | SD | ||
| Age of the respondent in year (n = 1058) | 34.0 | 5.0 | |
| Parental stress level (n = 1040) | 4.9 | 2.3 |
| Procedure | Total volume (mL) | Total protein (mg) | Total activity (UI)a | Specific activityb (UI mg−1) | Purificationc (fold) |
| Crude extract | 300 | 1302.3 | 215220 | 165.3 | 1 |
| Ammonium Sulphate ppt. | 22 | 43.9 | 13501.4 | 307.5 | 1.86 |
| Dialysis | 21 | 39.2 | 12559.9 | 320.4 | 1.94 |
| DEAE-cellulose | 12 | 6.37 | 6811.2 | 1069.3 | 6.47 |
| Sephadex G-100 | 9 | 2.9 | 4599.1 | 1585.9 | 9.6 |
| Gene name | Gene symbol | Comments | Statistics | |
| Log2 fold change | q value | |||
| Spermidine synthetase | Srm | Synthesizes polyamines important in granule biogenesis and homeostasis, including storage of histamine and proteases (Garcia-Faroldi, 2010 [47]) | 3.68 | 0.00016 |
| Ornithine decarboxylase 1 | Odc1 | Synthesizes polyamines important in granule biogenesis and homeostasis, including storage of histamine and proteases (Garcia-Faroldi, 2010 [47]) | 2.52 | 0.00016 |
| Spermine synthetase | Sms | Synthesizes polyamines important in granule biogenesis and homesostasis, including storage of histamine and proteases (Garcia-Faroldi, 2010 [47]) | 0.54 | 0.0045 |
| Basic helix-loop-helix family, member A15 | Bhlha15 | Important transcription factor in forming mature secretory granules in a variety of specialized secretory cells (Tian 2010 [72]) | 3.42 | 0.00016 |
| Rab5c, member of Ras oncogene family | Rab5c | Key regulator of mast cell granule fusion during biogenesis (Azouz 2014 [48]) | 0.62 | 0.00032 |
| Mannose-6-phosphate receptor | M6pr | Transports glycosylated proteins, such as lysosomal hydrolases and TNF, into vesicles (Coutinho 2012 [50], Olszewski 2006 [73]) | 0.43 | 0.00016 |
| Adaptor protein 1A complex | Ap1m1 | Protein necessary for the sorting of proteins into vesicles and secretory granule maturation (Bonnemaison 2014 [49]) | 0.36 | 0.0033 |
| ATPase, H+ transporting, lysosomal 16 kDa, V0 subunit c | Atp6v0c | Component of a vacuolar type H+ ATPase that acidifies granule lumen for condensation of granule contents (Borges 2011) | 0.69 | 0.00016 |
| ATPase, H+ transporting, lysosomal 50/57 kDa, V1 subunit H | Atp6v1h | Component of a vacuolar type H+ ATPase that acidifies granule lumen for condensation of granule contents (Borges 2011) | 0.52 | 0.00016 |
| ATPase, H+ transporting, lysosomal V0 subunit a2 | Atp6v0a2 | Component of a vacuolar type H+ ATPase that acidifies granule lumen for condensation of granule contents (Borges 2011) | 0.46 | 0.00016 |
| ATPase, H+ transporting, lysosomal 50/57 kDa, V1 subunit H | Atp6v1a | Component of a vacuolar type H+ ATPase that acidifies granule lumen for condensation of granule contents (Borges 2011) | 0.42 | 0.020 |
| ATPase, H+ transporting, lysosomal 9 kDa, V0 subunit e1 | Atp6v0e | Component of a vacuolar type H+ ATPase that acidifies granule lumen for condensation of granule contents (Borges 2011) | 0.32 | 0.0044 |
| ATPase, H+ transporting, lysosomal 34 kDa, V1 subunit D | Atp6v1d | Component of a vacuolar type H+ ATPase that acidifies granule lumen for condensation of granule contents (Borges 2011) | −0.24 | 0.038 |
| ATPase, H+ transporting, lysosomal 13 kDa, V1 subunit G2 | Atp6v1g2 | Component of a vacuolar type H+ ATPase that acidifies granule lumen for condensation of granule contents (Borges 2011) | −1.84 | 0.00016 |
| Lysosomal trafficking regulator | Lyst | Important regulator of granule formation (Durchfort 2012 [95], Hammel 2010 [52]) | −1.29 | 0.00016 |
| Solute carrier family 18, member 2 | Slc18a2 | Transports histamine and serotonin into granules (Merickel 1995 [96]) | −0.92 | 0.00016 |
| Factor | B | p-value | OR | 95% CI for OR | |
| Lower | Upper | ||||
| Age | .061 | .436 | 1.063 | .912 | 1.239 |
| Sex (Female) | .407 | .488 | 1.502 | .476 | 4.743 |
| BMI | .019 | .755 | 1.019 | .904 | 1.150 |
| Medications | -.118 | .425 | .889 | .665 | 1.188 |
| Comorbidities | .388 | .093 | 1.474 | .938 | 2.318 |
| ASA class | 1.667 | .003* | 5.297 | 1.774 | 15.817 |
| Complications | .918 | .013* | 2.505 | 1.210 | 5.187 |
| Diabetic footpatients | Diabetics withoutfoot complications | p | |
| HbA1c | 8 (7.28-9.40) | 6.85 (6.10-8.00) | 0.018 |
| CRP | 4 (2.25-5.15) | 2.25 (1.90-3.08) | 0.041 |
| Total cholesterol (mg/dl) | 215.50 (166,50-243,00) | 204.00 (185,50-210,00) | 0.054 |
| LDL cholesterol (mg/dl) | 121.70 (98,75-148,75) | 104.50 (78,00-123,00) | 0.032 |
| Tryglicerids (mg/dl) | 160.50 (119,50-209,25) | 180.50 (144,50-199,00) | 0.012 |
| Globuli bianchi | 12.675 (10775,00-14140,00) | 10.700 (8850,00-12027,50) | 0.032 |
| Adiponectin (μg/ml) | 7.1450 (4.47-12.17) | 8.480 (5.15-12.87) | 0.022 |
| Resistin (ng/ml) | 5.160 (2.96-6.29) | 3.290 (2.37-6.5) | 0.021 |
| IL-6 (pg/ml) | 3.21 (1.23-5.34) | 2.13 (1.24-3.97) | 0.033 |
| Histone | Modification 1 | Modification 2 | Modification 3 | Modification 4 | Intensity average 6xHIS-Ibd1 (4 repetitions) | Intensity average 6xHIS-G9a (2 repetitions) |
| H3 | K9ac | K14ac | 0.95 | 0.02 | ||
| H2a | K5ac | K9ac | K13ac | 0.92 | 0.01 | |
| H4 | R3me2s | K5ac | K8ac | K12ac | 0.90 | 0.00 |
| H4 | K5ac | K8ac | K12ac | K16ac | 0.89 | 0.03 |
| H3 | K9me3 | K14ac | 0.88 | 0.01 | ||
| H3 | S10P | K14ac | 0.88 | 0.04 | ||
| H4 | K5ac | K8ac | K12ac | 0.84 | 0.01 | |
| H3 | T11P | K14ac | 0.82 | 0.01 | ||
| H2a | S1P | K5ac | K9ac | K13ac | 0.82 | 0.01 |
| H2a | S1P | K9ac | K13ac | 0.81 | 0.01 | |
| H3 | R2me2s | K4me2 | R8me2a | K9me2 | 0.19 | 0.96 |
| H3 | R2me2a | K4me1 | R8me2a | K9me2 | 0.18 | 0.94 |
| H3 | R2me2a | K4me2 | R8me2a | K9me2 | 0.18 | 0.90 |
| H3 | K4ac | R8me2s | K9me1 | 0.21 | 0.84 | |
| H3 | R2me2a | K4me2 | R8me2a | K9me1 | 0.19 | 0.83 |
| H3 | R2me2a | K4me3 | R8me2a | K9me2 | 0.18 | 0.80 |
| H3 | R2me2a | K4ac | R8me2a | K9me2 | 0.28 | 0.79 |
| H3 | R2me2a | K4me3 | R8me2a | K9me1 | 0.19 | 0.79 |
| H3 | R2me2s | K4ac | R8me2a | K9me1 | 0.16 | 0.76 |
| H3 | R2me2s | K4me2 | R8me2s | K9me1 | 0.17 | 0.76 |
| Characteristic | n | % |
| Area of practice | ||
| GP/FP | 117 | 27 |
| GP/FP with enhanced area | 72 | 17 |
| Specialist | 219 | 51 |
| Other1: | 6 | 1 |
| Not specified | 12 | 3 |
| Number of years in practice | ||
| 0 to 5 | 40 | 9 |
| 6 to 10 | 39 | 9 |
| 11 to 15 | 45 | 11 |
| 16 to 20 | 59 | 14 |
| 21 or more | 230 | 54 |
| Not specified | 13 | 3 |
| Region of practice | ||
| Atlantic | 38 | 9 |
| Quebec | 100 | 23 |
| Ontario | 128 | 30 |
| Prairies | 70 | 16 |
| BC | 64 | 15 |
| Territories | 6 | 1 |
| Not specified | 20 | 5 |
| Community where practicing | ||
| Urban | 226 | 53 |
| Rural | 92 | 22 |
| Both | 96 | 23 |
| Not specified | 12 | 3 |
| Language of survey completion | ||
| English | 388 | 91 |
| French | 38 | 9 |
| Bacteria | MIC (mg/mL) | |||
| IxPE | IxCE | IxME | IxWE | |
| Bacillus subtilis (MTCC111) | 2 | >2 | 0.125 | 1 |
| Staphylococcus aureus (MTCC3160) | >2 | >2 | 1 | >2 |
| Streptococcus mutant (MTCC890) | >2 | 1 | 2 | 2 |
| Escherichia coli (MTCC443) | 2 | 1 | 2 | >2 |
| Klebsiella pneumoniae (MTCC109) | >2 | >2 | 0.25 | >2 |
| Pseudomonas aeruginosa (MTCC741) | 2 | 2 | 0.5 | 2 |
| Current wheeze | Ever had wheeze | Wheeze disturb sleep | Wheeze limiting speech | Exercise wheeze | Night cough | Ever had asthma | Any asthma symptoms | |
| Boys | 29 (9.0%) | 75 (25.3%) | 3 (3.8%) | 4 (4.8%) | 14 (4.8%) | 44 (14.9%) | 43 (13.3%) | 89 (27.6%) |
| Girls | 22 (5.8%) | 65 (18.5%) | 8 (11.6%) | 4 (5.48%) | 15 (4.3%) | 38 (11.0%) | 31 (8.2%) | 77 (20.4%) |
| Overall | 51 (7.3%) | 140 (21.6%) | 11 (7.4%) | 8 (5.1%) | 29 (4.5%) | 82 (12.8%) | 74 (10.6%) | 166 (23.7%) |
| Units | CN | MCI | AD | P-value | |
| n | — | 91 | 144 | 67 | NA |
| Age | Years (s.d.) | 75.74 (5.43) | 74.85 (7.2) | 74.57 (7.61) | 0.502 |
| Female | n (%) | 46 (50.55) | 47 (32.64) | 29 (43.28) | 0.021 |
| Education | Years (s.d.) | 15.67 (2.94) | 15.91 (2.95) | 15.01 (2.96) | 0.123 |
| APOE-ɛ4 +ve | n (%) | 22 (24.18) | 75 (52.08) | 46 (68.66) | 6.50 × 10−8 |
| ADAS-Cog13 | Units (s.d.) | 9.51 (4.16) | 19.19 (5.94) | 29.22 (8.21) | 2.75 × 10−56 |
| CSF Ferritin | ng ml−1 (s.d.) | 6.4 (2.07) | 6.95 (2.72) | 6.94 (2.99) | 0.591 |
| CSF ApoE | μg ml−1 (s.d.) | 7.3 (2.21) | 7.1 (2.22) | 6.35 (2.27) | 0.012 |
| CSF tau | pg ml−1 (s.d.) | 69.78 (28.01) | 104.3 (52.41) | 122.63 (57.47) | 4.57 × 10−7 |
| CSF ptau | pg ml−1 (s.d.) | 24.77 (13.34) | 36.39 (16.09) | 41.39 (20.76) | 1.13 × 10−6 |
| CSF Aβ1-42 | pg ml−1 (s.d.) | 205.31 (56.38) | 161.06 (52.06) | 142.16 (36.84) | 2.29 × 10−6 |
| CSF tau/Aβ1–42 | Units (s.d.) | 0.39 (0.26) | 0.75 (0.5) | 0.94 (0.52) | 7.80 × 10−9 |
| Hippocampus | mm3 (s.d.) | 7,219.6 (848.6) | 6,230.9 (1,047.8) | 5.766.6 (1,283.2) | 6.71 × 10−20 |
| Lateral ventricle | mm3 (s.d.) | 34,052.62 (16,528.1) | 44,842.52 (23,574.05) | 49,902.53 (26,896.68) | 3.35 × 10−5 |
| Subject | Age enrollment(years) | GMFCS level at enrollment | GMFM-66 change over 2 years | Abnormalmovements | Typography |
| 1 | 1.7 | IV | 4 | Spasticity with dystonia | Q |
| 2 | 2.4 | II | 8 | Spasticity | D |
| 3 | 5.1 | I | 19 | Spasticity with dystonia | H (Lh) |
| 4 | 1.2 | IV | 4 | Spasticity with dystonia | Q |
| 5 | 4.0 | II | 2 | Spasticity with dystonia | H (Lh) |
| 6 | 4.4 | III | 4 | Spasticity | D |
| 7 | 2.3 | II | 11 | Spasticity | H (Rh) |
| 8 | 1.4 | II | 17 | Spasticity | H (Lh) |
| 9 | 1.1 | I | 16 | Spasticity with dystonia | H (Rh) |
| 10 | 3.7 | II | 11 | Spasticity | H (Rh) |
| 11 | 1.5 | IV | 2 | Spasticity with dystonia | Q |
| 12 | 3.8 | IV | 5 | Spasticity with dystonia | Q |
| 13 | 2.1 | II | 15 | Spasticity | D |
| 14 | 2.8 | II | 13 | Spasticity with dystonia | H (Lh) |
| 15 | 2.8 | II | 5 | Spasticity | D |
| 16 | 1.4 | IV | 6 | Spasticity predominant, mixed with dystonia | Q |
| 17 | 3.0 | III | 22 | Spasticity predominant, mixed with spasticity | T (LUE) |
| Compound | Class | PIM inhibition selectivity | Development | Disease |
| SGI-1776 | imadizaopyridazine | IC50: 7 nM PIM1, 363 nM PIM2, 69 nM PIM3, 44 nM FLT-3 and 34 nM Haspin [107]. | Failure in phase I clinical trials by cardiotoxicity | Non-Hodgkin lymphoma |
| SMI4a | benzylidene-thiazolidene-2,4-dione | IC50: 21 nM PIM1, 100 nM PIM2 [113]. | Preclinical | Acute myeloid leukemia |
| Selective vs. 56 kinases [114]. | ||||
| LGB321 | 3-(S)-amino-piperidine pyridyl carboxamide | IC50: 0.001 nM PIM1, 0.0021 nM PIM2, and 0.0008 nM PIM3 [106]. | Recruiting patients for clinical trials | Multiple myeloma |
| AZD1897 | IC50: 3 nM PIM1,2 and 3 [115]. | Preclinical | Acute myeloid leukemia | |
| SEL24-B58 | Benzoimidazol | IC50: 31 nM PIM1, 154 nM PIM2, 152 nM PIM3. Selective in a panel of 299 kinases with the exception of haspin, HIPK and CLK kinases [117]. | Preclinical | Leukemic monocyte lymphoma |
| AZD1208 | thiazolidene | IC50: Pim-1 0.4 nM, Pim-2 5.0 nM and Pim-3 1.9 nM [115]. | Recruiting patients for clinical trials | Acute myeloid leukemia |
| Upper Asymptote | Lower Asymptote | Sig Diff | Point of Inflection | Slope | Fit |
| 0.99 | 0.48 | < 0.05 | 3.36 | −1.75 | 0.15 |
| Age stratum | (%) |
| 39 years or younger | 41 |
| 40–49 years | 42 |
| 50 years or older | 15 |
| Missing data | 2 |
| Sex | |
| Female | 15 |
| male | 85 |
| Fields of practice | |
| Pediatrics | 2 |
| Family practice | 11 |
| General internal medicine | 44 |
| Specialty internal medicine | 21 |
| Surgery-related | 7 |
| Emergency medicine | 9 |
| The other fields | 7 |
| Size of employing facilities | |
| Office-based clinic | 24 |
| 1–100 beds | 13 |
| 101–250 beds | 17 |
| 251–500 beds | 17 |
| 501 or more beds | 28 |
| Characteristics | PTCL-NOS | NKT | AITL | ALCL | Total | |
| ALK+ | ALK− | |||||
| Age > 60 | 20/60 (33.3) | 2/18 (11.1) | 6/11 (54.5) | 0/4 (0.0) | 1/4 (25.0) | 29/109 (26.6) |
| Gender, male | 38/60 (63.3) | 13/18 (72.2) | 9/11 (81.8) | 3/4 (75.0) | 3/4 (75.0) | 75/109 (68.8) |
| B symptoms | 47/58 (81.0) | 16/18 (88.9) | 11/11 (100.0) | 4/4 (100.0) | 2/4 (50.0) | 90/107 (84.1) |
| LDH > normal | 36/58 (62.1) | 10/17 (58.8) | 10/11 (90.9) | 4/4 (100.0) | 2/4 (50.0) | 68/105 (64.8) |
| Ann Arbor stage III/IV | 52/58 (89.7) | 15/16 (93.8) | 11/11 (100.0) | 4/4 (100.0) | 3/4 (75.0) | 80/109 (73.4) |
| ECOG > 1 | 30/58 (51.7) | 4/17 (23.5) | 5/11 (45.5) | 3/4 (75.0) | 1/4 (25.0) | 50/106 (47.2) |
| > 1 extranodal site | 29/57 (50.9) | 11/17 (64.7) | 4/11 (36.4) | 4/4 (100.0) | 2/4 (50.0) | 57/104 (54.8) |
| BM involvement | 16/55 (29.1) | 3/17 (17.6) | 1/11 (9.1) | 1/4 (25.0) | 1/4 (25.0) | 25/101 (24.8) |
| IPI > 2 | 35/57 (61.4) | 10/18 (55.6) | 7/11 (63.6) | 4/4 (100.0) | 3/4 (75.0) | 65/105 (61.9) |
| Treatment with CHOP | 26/60 (43.3) | 3/18 (16.7) | 5/11 (45.5) | 3/4 (75.0) | 1/4 (25.0) | 42/109 (38.5) |
| Genotypesa | Number of seedlings tested | Average resistance score | Significanceb |
| Reaction to BPH biotype 4 (2009–2014) | |||
| CR2711–76 | 201 | 2.33 | a |
| Jaya | 207 | 7.99 | b |
| F1 (Jaya/CR2711–76) | 52 | 1.33 | a |
| PTB-33 | 206 | 4.03 | a |
| Reaction to Laguna BPH colony (2013–2015) | |||
| CR2711–76 | 199 | 3.87 | b |
| Jaya | 176 | 8.91 | a |
| F1 (Jaya/CR2711–76) | 24 | 2.88 | b |
| Rathu Heenati | 210 | 3.11 | b |
| TN-1 | 272 | 9.01 | a |
| Chromosomal region | Fragile site (FS) | FS typea | BAC-probe | Co-localization of FA breakpoints and FS |
| 1p13.3 | FRA1N | Aphidicolinb | RP11-242D10 | + |
| 1q21.2 | FRA1F | Aphidicolin | RP11-301 M17 | + |
| 1q42.2 | Near FRA1H | Azacytidin | RP11-109G24 | − |
| 2q35 | FRA2U | Aphidicolin | RP11-316O14 | + |
| 3p14.2 | FRA3B | Aphidicolin | RP11-129 K20 | + |
| 3p21.31 | FRA3H | New nomenclaturec | RP11-787O14RP11-159A17 | + |
| 3q27.1 | FRA3C | Aphidicolin | RP11-110C15 | + |
| 5q13.2 | FRA5K | New nomenclatured | RP11-497H16 | + |
| 5q33.2 | FRA5O | New nomenclatured | RP11-265I24RP11-494C5 | + |
| 7q22.3 | FRA7F | Aphidicolin | CTB-20D2 | + |
| 7q32.3 | FRA7H | Aphidicolin | RP11-138A9RP11-36B6 | + |
| 11q13 | FRA11H | Aphidicolin | RP11-449G14 | + |
| 14q24.3 | FRA14G | Aphidicolinb | RP3-414A15 | + |
| 16q22.1 | FRA16C, FRA16B | Aphidicolin | RP11-106 J23 | + |
| 16q23 | FRA16D | Aphidicolin | RP11-358 L22 | + |
| 18q21.3 | FRA18B | Aphidicolin | RP11-15C15 | + |
| Stage of prostate cancer | Hormonal agent | Function | Year of FDA approval | Reference |
| Advanced, hormone naïve | Goserelin acetate | GnRH agonist | 1989 | [27, 28] |
| Leuprolide acetate | GnRH agonist | 1989 | [27, 29] | |
| Histrelin acetate | GnRH agonist | 1991 | [27, 30] | |
| Triptorelin pamoate | GnRH agonist | 2000 | [27, 31] | |
| Abarelix | GnRH antagonist | 2003 | [27, 48] | |
| Degarelix | GnRH antagonist | 2008 | [27, 49] | |
| Bicalutamide | AR antagonist | 1995 | [27, 126] | |
| Flutamide | AR antagonist | 1989 | [27, 127] | |
| Castrate-resistant | Abiraterone acetate | CYP17 inhibitor | 2011b | [27, 94] |
| 2012a | [96, 99] | |||
| Enzalutamide | AR antagonist | 2012b | [27, 101] | |
| 2014a | [102, 128] |
| MIGS ID | Property | Term | Evidence codea |
| Classification | Domain Bacteria | TAS [38] | |
| Phylum “Nitrospirae” | TAS [38] | ||
| Class “Nitrospira” | TAS [38] | ||
| Order “Nitrospirales” | TAS [38] | ||
| Family “Nitrospiraceae” | TAS [1, 38] | ||
| Genus Leptospirillum | TAS [39] | ||
| Species Leptospirillum ferriphilum | TAS [5] | ||
| Strain Sp-Cl | TAS [5] | ||
| Gram stain | Negative | TAS [5] | |
| Cell shape | Curved rod | IDA | |
| Motility | Motile | TAS [5] | |
| Sporulation | Non-spore forming | TAS [5] | |
| Temperature range | 25° to 45 °C | NAS | |
| Optimum temperature | 30° to 37 °C | NAS | |
| pH range, optimum | 1.3 to 2.0; NA | IDA | |
| Carbon source | CO2 | IDA | |
| MIGS-6 | Habitat | chloride, metal-rich and acidic environment | IDA |
| MIGS-6.3 | Salinity | 0-12 g/L Cl- | IDA |
| MIGS-22 | Oxygen requirement | Aerobic | TAS [5] |
| MIGS-15 | Biotic relationship | Free-living | IDA |
| MIGS-14 | Pathogenicity | None | TAS [5, 22] |
| MIGS-4 | Geographic location | Spence mine, Atacama Desert, Chile | IDA |
| MIGS-5 | Sample collection | 2007 | IDA |
| MIGS-4.1 | Latitude | 22°.81 S | IDA |
| MIGS-4.2 | Longitude | 69°.26 W | IDA |
| MIGS-4.4 | Altitude | 1700 | IDA |
| Dataset | Oct 2006 | Oct 2008 | 2008–2006 | 2008–2006[%] | Filtration2008 |
| GVKBIO | 1488288 | 2054151 | 565863 | 38% | -8% |
| GVKBIO Journals | 542858 | 658198 | 115340 | 21% | -8% |
| GVKBIO patents | 1034548 | 1484218 | 449670 | 43% | -7% |
| GVKBIO DD | 1933 | 3675 | 1742 | 90% | -4% |
| GVKBIO CCD | n/a | 8864 | n/a | n/a | -1% |
| GVKBIO BACE1 | n/a | 5228 | n/a | n/a | -11% |
| GVKBIO BACE1 journals | n/a | 389 | n/a | n/a | -6% |
| GVKBIO BACE1 patents | n/a | 4901 | n/a | n/a | -11% |
| WOMBAT | 128120 | 180856 | 52736 | 41% | -18% |
| PubChem | 7268193 | 14965539 | 7697346 | 106% | -23% |
| PubChem Prous | 3318 | 4652 | 1334 | 40% | -2% |
| PubChem PDB | 5626 | 5706 | n/a | n/a | -8% |
| PubChem actives | 35671 | 7472 | n/a | n/a | -3% |
| PubChem pharmacol | 6070 | 5311 | n/a | n/a | -63% |
| PubChem MLSMR | n/a | 233284 | n/a | n/a | -1% |
| PubChem BindingDB | n/a | 24203 | n/a | n/a | -4% |
| PubChem ChEBI | n/a | 7428 | n/a | n/a | -31% |
| DrugBank | 3723 | 4545 | 822 | 22% | -7% |
| DrugBank approved | 1018 | 1341 | 323 | 32% | -3% |
| DrugBank experimental | 1737 | 2999 | 1262 | 73% | -6% |
| DNP | 131831 | 144383 | 12552 | 10% | -26% |
| MDDR | 159867 | 176600 | 16733 | 10% | -4% |
| MDDR launched | 1118 | 1435 | 317 | 28% | -5% |
| SNPs | Allele | α-helix | Extended strand | β-turn | Random coil |
| c.271C > T | C | 32.92 | 13.04 | 4.35 | 49.69 |
| T | 32.3 | 13.04 | 5.59 | 49.07 |
| Health Behaviour | Total number | No. aimed at general population | No. aimed at community, school or work places | No. aimed at targeted populations or individuals |
| Smoking | 48 | 5 | 6 | Young people (11)Smokers (26) |
| Physical Activity | 24 | 4 | 1 | Young people (6)Older people (2)Adults over 18 years(8) |
| Alcohol | 15 | 4 | 0 | Young people (2)Pregnant women (1)Drink drivers (3)Problem drinkers (4) |
| Healthy eating | 13 | 0 | 3 | Young people (4)Older people (1)Pregnant women (1)Non specific (6) |
| Illicit drug use in young people | 4 | 0 | 4 | 0 |
| Sexual risk taking in young people | 8 | 0 | 8 | 0 |
| Alfalfa | High nitrate-containing barley | Low nitrate-containing barley | NPA-containing milkvetch | NPOH-containing milkvetch | |
| Crude protein (%) | 17.3 | 13.8 | 6.4 | 10.0 | 9.6 |
| Digestible crude protein (%) | 12.6 | 9.4 | 2.5 | 5.8 | 5.4 |
| Acid detergent fiber (%) | 35.5 | 35.4 | 31.4 | 32.4 | 34.8 |
| Neutral detergent fiber (%) | 38.8 | 45.0 | 46.9 | 38.3 | 37.8 |
| Total digestible nutrients (%) | 60.2 | 59.1 | 59.5 | 60.0 | 58.1 |
| Net energy lactation (Mcal/kg) | 1.36 | 1.32 | 1.34 | 1.34 | 1.30 |
| Net energy maintenance (Mcal/kg) | 1.45 | 1.43 | 1.43 | 1.45 | 1.39 |
| Net energy gain (Mcal/kg) | 0.73 | 0.70 | 0.70 | 0.73 | 0.68 |
| In vitro true digestibility (%) | 75.7 | 80.4 | 68.5 | 85.3 | 82.3 |
| Ash (%) | 10.2 | 9.3 | 5.4 | 7.4 | 7.9 |
| Relative feed value | 146.7 | 126.8 | 127.7 | 154.7 | 152.0 |
| Nitratea (%) | 0.16 | 1.69 | 0.23 | 0.15 | 0.03 |
| Mineral analysis (NIR) | |||||
| Calcium | 1.22 | 0.69 | 0.48 | 0.72 | 0.77 |
| Magnesium | 0.29 | 0.15 | 0.04 | 0.11 | 0.11 |
| Phosphorus | 0.39 | 0.29 | 0.16 | 0.25 | 0.23 |
| Potassium | 2.92 | 2.23 | 1.52 | 1.64 | 1.50 |
| Strain | |
| Bifidobacterium adolescentis DSM 20083T | |
| Bifidobacterium adolescentis DSM 20086 | |
| Bifidobacterium adolescentis DSM 20087 | |
| Bifidobacterium animalissubsp. lactis NRRL B-41405 | |
| Bifidobacterium animalissubps. animalis NRRL B-41406T | |
| Bifidobacterium bifidum DSM 20456T | |
| Bifidobacterium breve DSM 20091 | |
| Bifidobacterium breve NRRL B-41408T | |
| Bifidobacterium catenulatum DSM 20224 | |
| Bifidobacterium longumsubsp. infantis ATCC 15697T | |
| Bifidobacterium longumsubsp. longum NRRL B-41409T | |
| Bifidobacterium longumsubsp. suis NRRL B-41407T | |
| Bifidobacterium pseudocatenulatum DSM 20439 | |
| Bifidobacterium pseudolongumsubsp. globosum DSM 20092T | |
| Bifidobacterium pseudolongumsubsp. pseudolongum DSM 20094 | |
| Bifidobacterium pseudolongumsubsp. pseudolongum DSM 20095 | |
| Bifidobacterium pseudolongumsubsp. pseudolongum DSM 20099T |
| University & Library | Responded to phase 2 |
| 1. Charles Drew University of Medicine & Science, Health Sciences Library | ✓ |
| 2. Loma Linda University Medical Center, Jesse Medical Library & Information Center | |
| 3. Oregon Health and Science University, Library | ✓ |
| 4. Stanford University Medical Center, Lane Medical Library | |
| 5. University of Arizona (Tucson Campus), Arizona Health Sciences Library | ✓ |
| (University of Arizona (Phoenix Campus) Partnership of U of A & ASU medical school dissolved mid-project. ASU counted as part of U of A) | |
| 6. University of California, Davis, Carlson Health Sciences Library | |
| 7. University of California, Irvine, Science Library | ✓ |
| 8. University of California, Los Angeles, Biomedical Library | ✓ |
| (University of California, Riverside program is developing, with most services provided by UCLA and therefore, counted under UCLA) | |
| 9. University of California San Diego, Biomedical Library | ✓ |
| 10. University of California, San Francisco, Library | ✓ |
| 11. University of Colorado, Health Sciences Library | ✓ |
| 12. University of Hawaii at Manoa, Health Sciences Library | |
| 13. University of Nevada Reno, Savitt Medical Library | ✓ |
| 14. University of New Mexico School of Medicine, Health Sciences Library and Informatics | ✓ |
| 15. University of Southern California, Norris Medical Library | ✓ |
| 16. University of Utah, Eccles Health Sciences Library | ✓ |
| 17. University of Washington, Health Sciences Library | ✓ |
| Distribution between categories | Assumed hospitalization rate | |
| No-test scenario | 44.6% | |
| Test scenario | ||
| sFlt-1/PlGF ratio ≥ 85 at weeks 20 + 0–33 + 6, or ≥ 110 from week 34 onwards | 19.60% | 70.0% |
| sFlt-1/PlGF ratio > 38 − < 85 at weeks 20 + 0–33 + 6, or > 38 − < 110 from week 34 onwards | 16.20% | 57.6% |
| sFlt-1/PlGF ratio ≤ 38 | 64.20% | 1.5% |
| Fish or krill Oil: 1.3 g/d | ||||||
| Parameter | Overall (N = 66) | Treatment A Ethyl Ester (N = 22) | Treatment B Triglycerides (N = 22) | Treatment C krill Oil (N = 22) | p-value* | |
| Gender | Female | 48 (72.7 %) | 17 (77.3 %) | 13 (59.1 %) | 18 (81.8 %) | 0.2011 |
| Male | 18 (27.3 %) | 5 (22.7 %) | 9 (40.9 %) | 4 (18.2 %) | ||
| Age (years) | N | 66 | 22 | 22 | 22 | 0.4523 |
| Mean (SEM) | 35.45 (1.44) | 37.41 (2.69) | 35.95 (2.39) | 33.00 (2.42) | ||
| Std Dev | 11.72 | 12.64 | 11.21 | 11.37 | ||
| Min, Max | 19.00, 57.00 | 19.00, 57.00 | 19.00, 52.00 | 19.00, 55.00 | ||
| Ethnicity | Not Hispanic or Latino | 27 (40.9 %) | 10 (45.5 %) | 9 (40.9 %) | 8 (36.4 %) | 0.8286 |
| Hispanic or Latino | 39 (59.1 %) | 12 (54.5 %) | 13 (59.1 %) | 14 (63.6 %) | ||
| Race | Asian | 1 (1.5 %) | 1 (4.5 %) | 0 (0.0 %) | 0 (0.0 %) | 0.6239 |
| Black or African American | 7 (10.6 %) | 2 (9.1 %) | 3 (13.6 %) | 2 (9.1 %) | ||
| White | 57 (86.4 %) | 19 (86.4 %) | 18 (81.8 %) | 20 (90.9 %) | ||
| Mixed: White, Black or African American | 1 (1.5 %) | 0 (0.0 %) | 1 (4.5 %) | 0 (0.0 %) | ||
| Weight (kg) | N | 66 | 22 | 22 | 22 | 0.3480 |
| Mean (SEM) | 68.72 (1.43) | 69.06 (2.83) | 71.10 (2.55) | 66.01 (1.96) | ||
| Std Dev | 11.59 | 13.25 | 11.94 | 9.17 | ||
| Min, Max | 50.90, 111.20 | 50.90, 111.20 | 51.00, 89.00 | 52.80, 84.60 | ||
| Height (cm) | N | 66 | 22 | 22 | 22 | 0.2408 |
| Mean (SEM) | 164.35 (1.16) | 164.98 (2.47) | 166.39 (1.80) | 161.68 (1.63) | ||
| Std Dev | 9.45 | 11.59 | 8.44 | 7.66 | ||
| Min, Max | 149.50, 194.00 | 149.50, 194.00 | 153.00, 179.50 | 149.50, 181.00 | ||
| BMI (kg/m^2) | N | 66 | 22 | 22 | 22 | 0.9056 |
| Mean (SEM) | 25.32 (0.32) | 25.22 (0.56) | 25.53 (0.54) | 25.22 (0.59) | ||
| Std Dev | 2.60 | 2.62 | 2.54 | 2.75 | ||
| Min, Max | 19.80, 29.50 | 20.90, 29.50 | 20.80, 29.50 | 19.80, 29.20 |
| Preterm | Term | Preterm & term compared | ||||||
| Fat (g/dL)♦ | ||||||||
| Time frame: | mean | SD | n | mean | SD | n | % difference | p-value |
| d 1-3 | 2.2 | 0.9 | 76 | 1.8 | 0.7 | 74 | 23 | 0.002 |
| d 4-7 | 3.0 | 1.2 | 111 | 2.6 | 0.8 | 136 | 16 | 0.002 |
| week 2 | 3.5 | 1.1 | 158 | 3.0 | 0.9 | 48 | 15 | 0.01 |
| week 3-4 | 3.5 | 1.0 | 180 | 3.4 | 0.8 | 127 | 5 | 0.12 |
| week 5-6 | 3.2 | 0.8 | 95 | 3.6 | 1.1 | 20 | −11 | 0.07 |
| week 7-9 | 3.3 | 0.9 | 120 | 3.4 | 0.8 | 83 | −3 | 0.38 |
| week 10-12 | 3.7 | 1.5 | 22 | 3.4 | 0.9 | 95 | 7 | 0.31 |
| Fat meta-analysis was limited to 24 hour collections. | ||||||||
| ♦ References: [6,11,12,18,19,22,121-123,125,127,142,144,146] | ||||||||
| Lactose (kcal/dL)♦♦ | ||||||||
| Time frame: | mean | SD | n | mean | SD | n | % difference | p-value |
| d 1-3 | 5.1 | 0.7 | 95 | 5.6 | 0.6 | 59 | −9 | < 0.00001* |
| d 4-7 | 6.3 | 1.1 | 114 | 6.0 | 1.0 | 281 | 4 | 0.009 |
| week 2 | 5.7 | 0.8 | 231 | 6.2 | 0.6 | 100 | −8 | < 0.00001* |
| week 3-4 | 6.0 | 0.5 | 225 | 6.7 | 0.7 | 193 | −10 | < 0.00001* |
| week 5-6 | 5.8 | 0.6 | 104 | 6.1 | 1.0 | 22 | −6 | 0.06 |
| week 7-9 | 6.3 | 0.4 | 123 | 6.5 | 0.5 | 646 | −2 | < 0.00001* |
| week 10-12 | 6.8 | 0.3 | 28 | 6.7 | 0.7 | 58 | 2 | 0.47 |
| ♦♦References: [6,11,12,19,21-23,121,123,129-131,135,140,143,146,147] | ||||||||
| Oligosaccharides (g/dL) ♦♦♦ | ||||||||
| Time frame: | mean | SD | n | mean | SD | n | % difference | p-value |
| d 1-3 | - | - | - | 1.6 | 0.2 | 9 | - | - |
| days 4-7 | 2.1 | 0.4 | 89 | 1.9 | 0.4 | 93 | 12 | 0.0009 |
| week 2 (days 7–14) | 2.1 | 0.5 | 89 | 1.9 | 0.4 | 54 | 7 | 0.004 |
| week 3–4 (days 15–30) | 1.7 | 0.3 | 152 | 1.6 | 0.3 | 46 | 12 | 0.27 |
| week 5-6 | - | - | - | 1.4 | 0.3 | 46 | - | - |
| week 7-9 | - | - | - | 1.3 | 0.3 | 46 | - | - |
| week 10-12 | - | - | - | - | - | - | - | - |
| ♦♦♦References: [140,141,143,147]. |
| Library | Restriction enzyme | BAC vector | No. clones | Average insert size (kb) | Insert range (kb) | Genome coverage* | HICF fragments (avg) | Control clones | Successful fingerprints |
| TC_Bba | HindIII | pIndigoBAC536 | 36864 | 145 | 90-185 | 10× | 120.2 | 768 | 31864 |
| TC_BBb | EcoRI | pIndigoBAC536 | 36864 | 120 | 40-160 | 10× | 102.1 | 768 | 32218 |
| TC_BBc | MboI | pIndigoBAC536 | 36864 | 140 | 80-180 | 10× | 120.4 | 768 | 31304 |
| Parameter | Value |
| Self-inductance | L = 6 [mH] |
| Rated current | I = 8 [A] (AC, 50/60 Hz, sinus wave) |
| Current density | J < 3 [A/mm2] |
| Ambient temperature | θa = +40 [°C] |
| Self-resonance frequency range | fcrit = 80 ÷ 140 [kHz] |
| Variable | OR | 95 % CI | P-value |
| Clinical history | |||
| No recent history of UTI | 3.8 | 1.3–11.4 | 0.02 |
| Clinical symptoms | |||
| Nausea/vomiting | 0.4 | 0.1–1.4 | 0.14 |
| Type of UTI, symptoms | |||
| Cystitis, no other non-urinary symptoms | 1 | ||
| Cystitis, with back or adnominal pain symptoms only | 11.4 | 2.1–63.0 | 0.01 |
| Cystitis, with vaginal discharge | 12.1 | 1.1–137.5 | 0.05 |
| Cystitis, with other combinations of non-urinary symptoms | 0.1 | 0.0–1.1 | 0.06 |
| Pyelonephritis (fever or flank pain present) | 2.7 | 0.8–9.3 | 0.12 |
| Characteristics | n (%) |
| Knowledge of modifiable risk factors | |
| Don't know any risk factor | 27 (3.8) |
| Only one risk factor | 89 (12.4) |
| A total of two risk factors | 302 (41.9) |
| Good level of knowledge* | 302 (41.9) |
| Knowledge of symptoms of heart attack | |
| Don't Know | 586 (81.4) |
| List 1 symptom | 93 (12.9) |
| List at least 2 symptoms | 41 (5.7) |
| λ | 0.0 | 0.1 | 0.2 | 0.3 | 0.4 | 0.5 |
| AUC | 0.916 | 0.919 | 0.920 | 0.922 | 0.919 | 0.918 |
| Univariate analysis | Multivariate analysis | |||||
| Variable | Threshold | Unadjusted OR | CI | Adjusted OR | CI | P value |
| Glucose variability (SD) | NA | 5.9 | 0.9 to 37 | 10.4 | 1.3 to 86 | .03 |
| GCS | Every 1 point | 1.1 | 0.8 to 1.4 | 0.5 | 0.2 to 0.99 | .04 |
| Group | n | Clinical pregnancy (case), % | Abortion (case) | Multiple pregnancy (case) | Average treatment cycle |
| LE group | 52 | 16 (30.8%) | 2 | 2 | 4.1±0.5 |
| CC group | 52 | 17 (32.1%) | 3 | 3 | 3.9±0.2 |
| LE + HMG group | 52 | 29 (55.7%)a | 2 | 5 | 2.9 ± 0.3b |
| χ2/F | - | - | - | - | 17.241 |
| P | - | - | - | - | <0.001 |
| Data sources | Health care organization characteristics | |||
| Country | Revenue/income | Practice costs | Remuneration system | Gate-keeping |
| Belgium | Interest group | Interest group | Fee-for-service | No |
| Denmark | Interest group and government agency | Interest group and government agency | Fee-for-service | Yes |
| Finland | WHO (2000) and independent organization | - | Mainly salary, some additional fee-for-service and capitation fee | Yes |
| France | Government agency | Tax office | Fee-for-service | No |
| Germany | Independent organization | Independent organization | Fee-for-service | No |
| Netherlands | Interest group | National statistics office (based on tax data) | Capitation and fee-for-service1) | Yes |
| Sweden | Interest group | - | Salary | No |
| U.K. | Independent organization (1995, 2000), government agency (2005) | Independent organization (1995, 2000), government agency (2005) | Capitation, since 2004 additional quality related payments | Yes |
| PatID | MWRT (sec; average + std) | Percentage of 6-s time windows with difference in MWRT: | ||
| Signal 1 | Signal 2 | |||
| Category A | ||||
| 1 | 0.27 + 0.04 | 0.27 + 0.04 | - | - |
| 2 | 0.21 + 0.02 | 0.21 + 0.02 | - | - |
| 3 | 0.14 + 0.04 | 0.14 + 0.03 | 1 | - |
| 4 | 0.18 + 0.05 | 0.18 + 0.05 | - | - |
| 5 | 0.28 + 0.06 | 0.28 + 0.05 | - | - |
| Category B | ||||
| 6 | 0.29 + 0.04 | 0.24 + 0.04 | 13 | - |
| 7 | 0.25 + 0.02 | 0.25 + 0.04 | 2 | - |
| 8 | 0.23 + 0.02 | 0.21 + 0.03 | 2 | - |
| 9 | 0.14 + 0.04 | 0.14 + 0.04 | 3 | 1 |
| 10 | 0.28 + 0.03 | 0.24 + 0.06 | 14 | - |
| Category C | ||||
| 11 | 0.26 + 0.05 | 0.28 + 0.02 | 9 | - |
| 12 | 0.33 + 0.13 | 0.23 + 0.09 | 45 | 17 |
| 13 | 0.36 + 0.06 | 0.45 + 0.12 | 50 | 20 |
| 14 | 0.33 + 0.09 | 0.39 + 0.10 | 25 | 7 |
| 15 | 0.22 + 14.3 | 0.22 + 14.3 | 8 | 1 |
| 16 | 0.12 + 0.01 | 0.12 + 0.01 | - | - |
| 17 | 0.24 + 0.05 | 0.25 + 0.03 | 7 | - |
| COPD | Non-COPD | |||||
| Variable | Effect | CI 95 % | p | Effect | CI 95 % | p |
| Time trends (years) | ||||||
| 2000–2005 | 0.56 | −0.11; 1.23 | 0.102 | 0.35 | 0.25; 0.46 | <0.001 |
| 2005–2010 | 0.62 | −0.22; 1.26 | 0.059 | 0.39 | 0.29; 0.49 | <0.001 |
| 2000–2010 | 1.18 | 0.52; 1.84 | <0.001 | 0.74 | 0.63; 0.86 | <0.001 |
| Age (years) | −0.06 | −0.08; −0.04 | <0.001 | 0.01 | 0.004; 0.01 | <0.001 |
| Current smoker | −1.87 | −2.42; −1.32 | <0.001 | −0.98 | −1.08; −0.88 | <0.001 |
| Exceeding alcohol limits | 0.04 | −0.69; 0.77 | 0.919 | 0.00 | −0.13; 0.14 | 0.969 |
| Physical activity | 0.93 | 0.34;1.53 | 0.002 | 0.98 | 0.85;1.11 | <0.001 |
| Married/living with a partner | 0.13 | −0.44; 0.69 | 0.661 | 0.34 | 0,23; 0.44 | <0.001 |
| Gender (male) | 1.68 | 1.13; 2.23 | <0.001 | 1.38 | 1.29; 1.47 | <0.001 |
| Education (years) | ||||||
| < 10 vs. 10-12 | 0.72 | 0.14; 1.31 | 0.015 | 0.72 | 0.60; 0.84 | <0.001 |
| < 10 vs. +13 | 0.99 | 0.09; 1.88 | 0.030 | 1.63 | 1.49; 1.77 | <0.001 |
| 10-12 vs. +13 | 0.27 | −0.58; 1.11 | 0.536 | 0.92 | 0.81; 1.02 | <0.001 |
| WOMEN | MEN | |||
| Core | Boost | Core | Boost | |
| % | % | % | % | |
| Self-assessed general health | ||||
| Very good | 33 | 21 | 36 | 24 |
| Good | 45 | 51 | 44 | 48 |
| Fair | 14 | 23 | 14 | 24 |
| Bad | 6 | 4 | 5 | 3 |
| Very bad | 2 | 1 | 1 | 1 |
| P-value | ||||
| Very good/good | 78 | 72 | 79 | 72 |
| Fair/bad/very bad | 22 | 28 | 21 | 28 |
| P-value | ||||
| N | 833 | 2701 | 736 | 2181 |
| Portions of fruit and vegetables | ||||
| Less than 1 | 5 | 4 | 8 | 6 |
| 1 to 2 | 26 | 15 | 26 | 17 |
| 3 to 4 | 27 | 27 | 28 | 24 |
| 5 or more | 42 | 55 | 38 | 54 |
| P-value | ||||
| N | 833 | 2647 | 735 | 2133 |
| Tissue | RNA expression | Tissue | RNA expression |
| Whole brain | • | Lung | • |
| Cerebral cortex | ••• | Placenta | • |
| Frontal lobe | •• | Bladder | •• |
| Parietal lobe | •• | Uterus | •• |
| Occipital lobe | • | Prostate | • |
| Temporal lobe | • | Testis | • |
| Postcentral gyrus | • | Ovary | • |
| of cerebral cortex | Liver | • | |
| Pons | • | Pancreas | ••• |
| Cerebellum left | • | Adrenal gland | ••• |
| Cerebellum right | •• | Thyroid gland | •• |
| Corpus callosum | ••• | Salivary gland | •••• |
| Amygdala | •• | Mammary gland | • |
| Caudate nucleus | • | Esophagus | • |
| Hippocampus | • | Stomach | • |
| Medulla | • | Duodenum | •• |
| oblongata | Jejunum | ••• | |
| Putamen | • | Ileum | •• |
| Substantia nigra | • | Ileocecum | • |
| Accumbens | •• | Appendix | - |
| nucleus | Colon, ascending | • | |
| Thalamus | •• | Colon, transverse | • |
| Pituary gland | • | Colon, descending | • |
| Spinal cord | • | Rectum | • |
| Heart | •• | Fetal brain | • |
| Aorta | • | Fetal heart | •• |
| Artrium left | •• | Fetal kidney | ••• |
| Artrium right | •• | Fetal liver | ••• |
| Ventricle left | •••• | Fetal spleen | • |
| Ventricle right | •• | Fetal thymus | • |
| Interventricular | •• | Fetal lung | • |
| septum | Promyelocytic leukaemia, | • | |
| Apex of the heart | •••• | HL-60 | |
| Kidney | • | Hela S3 | • |
| Skeletal muscle | • | Chronic myelogenous | •• |
| Spleen | • | leukaemia, K-562 | |
| Thymus | •• | Lymphoblastic leukaemia, | •• |
| Peripheral blood | • | MOLT-4 | |
| leukocyte | Burkitt's lymphoma, Raji | • | |
| Lymph node | • | Burkitt's lymphoma, Daudi | • |
| Trachea | • |
| Rank of correct class | ||||
| 1 | 2 | 3 | 4 | |
| Single-localized only | 88.8a | 92.2 | 94.5 | 96.3 |
| CYT-NUC: 1 correct | 88.2a | 96.1 | 99.5 | 100.0 |
| CYT-NUC: both correct | 66.5a | 82.9 | 96.3 | |
| All multi-localized: 1 correct | 81.9a | 92.0 | 96.1 | 97.4 |
| All multi-localized: both correct | 59.7a | 73.8 | 83.2 |
| Group | Patient number | Age | Sex | CRP (mg/dl) | ESR (mm) | Medicine | ||
| PSL (mg/day) | DMARDs other than biologics | Biologics | ||||||
| RA | #1 | 62 | F | 0.05 | 46 | MTX | ADA | |
| #2 | 67 | F | 0.49 | 29 | MTX | |||
| #3 | 43 | F | 0.2 | 26 | 2 | MTX | ||
| #4 | 48 | F | 0.06 | 39 | ||||
| #5 | 42 | F | 0.3 | 15 | 16 | MTX | GLM | |
| #6 | 80 | F | 4.2 | 71 | TCR, SASP, BUC | |||
| #7 | 76 | M | 5.9 | 111 | MTX | |||
| #8 | 62 | F | 0.5 | 38 | ||||
| OA | #9 | 66 | F | 0.02 | 10 | |||
| #10 | 72 | F | 0.42 | 28 | ||||
| #11 | 75 | F | 0.07 | 14 | ||||
| #12 | 74 | F | 0.1 | 40 | ||||
| #13 | 74 | F | 0.03 | 9 | ||||
| #14 | 71 | F | 0.02 | 14 | ||||
| #15 | 78 | F | 0.12 | 18 | ||||
| #16 | 81 | F | 0.03 | 18 |
| Characteristics | Matrilineal | Patrilineal | ||
| Age (years) | M | F | M | F |
| Mean | 41 | 31 | 40 | 29 |
| 20–29 | 0 | 2 | 0 | 3 |
| 30–39 | 3 | 5 | 3 | 4 |
| 40–49 | 4 | 0 | 4 | 0 |
| Years living with HIV | ||||
| 1–5 | 2 | 2 | 7 | 7 |
| 6–10 | 5 | 5 | 0 | 0 |
| Average number of children couples had after an HIV diagnosis | 2 | 1 | ||
| Average number of children couples have in their households | 4 | 4 | ||
| Couples with HIV+ children | 2 | 0 |
| Category | |
| Total number of reads | 1,366,749 |
| Total length of reads (bp) | 625,825,203 |
| Total number of reads cleaned | 1,361,424 |
| Total length of reads cleaned (bp) | 598,655,879 |
| Number of reads placed | 1,302,023 |
| Number of singletons | 10,992 |
| Total length of singletons (bp) | 3,714,066 |
| Average length of singletons (bp) | 337 |
| Largest singleton (bp) | 692 |
| Number of contigs | 39,088 |
| Total length of contigs (bp) | 22,806,009 |
| Average length of contigs (bp) | 583 |
| Largest contig (bp) | 6,401 |
| Average read coverage of contigs | 24 |
| control | condition | YKOaux | BCprot | PBprot |
| SC | control | 3 | 3 | 3 |
| SC | ADE– | 3 | 3 | 3 |
| SC | ARG– | 3 | 3 | 3 |
| SC | HIS– | 0 | 3 | 3 |
| SC | LEU– | 0 | 3 | 3 |
| SC | LYS– | 3 | 2 | 3 |
| SC | MET– | 3 | 3 | 3 |
| SC | SER– | 3 | 2 | 3 |
| SC | THR– | 3 | 2 | 3 |
| SC | TRP– | 3 | 3 | 3 |
| SC | URA– | 0 | 3 | 3 |
| SC | MM* | 3 | 4 | 5 |
| SC | MM + URA | 0 | 1 | 1 |
| YPD | control | 11 | 14 | 12 |
| YPD | cisplatin, DNA cross-linking agent | 3 | 4 | 3 |
| YPD | CCCP, protonophore inhibitor of oxidative phosphorylation | 3 | 3 | 3 |
| YPD | FCCP, protonophore inhibitor of oxidative phosphorylation | 3 | 3 | 3 |
| YPD | PYRQ, novel quinolone compound, PCID 16001701 | 4 | 4 | 4 |
| YPD | YPG, obligate respiratory | 2 | 4 | 4 |
| Healthy non-smoker | Smokers without COPD | Smokers with COPD | ||
| IL-8 (pg/ml) | 307 (225-558) | 262 (208-407) | 360 (165-474) | P = 0.512 |
| MMP-9 (ng/ml) | 338 (105-679) | 170 (62-465) | 217 (101-351) | P = 0.437 |
| TIMP-1 (ng/ml) | 449 (225-814) | 354 (221-535) | 360 (241-469) | P = 0.556 |
| MMP-9/TIMP-1 | 0.54 (0.29-1.16) | 0.37 (0.23-1.10) | 0.38 (0.27-0.96) | P = 0.789 |
| TNF-α (pg/ml) | 2.04 (1.19-3.82) | 0.529*** (<0.5-1.25) | 0.704*** (<0.5-1.23) | P < 0.001 |
| Evaluation method: strict | Evaluation method: average | |||||
| Entity type | OG | OG+NN | OG+CRF | OG | OG+NN | OG+CRF |
| All | 0.62 | 0.70 | 0.58 | 0.65 | 0.72 | 0.67 |
| Chemicals | 0.55 | 0.77 | 0.34 | 0.56 | 0.77 | 0.35 |
| Cells | 0.80 | 0.76 | 0.91 | 0.84 | 0.81 | 0.92 |
| Biological processes/molecular functions | 0.30 | 0.35 | 0.54 | 0.35 | 0.39 | 0.58 |
| Cellular components | 0.55 | 0.70 | 0.75 | 0.56 | 0.71 | 0.78 |
| Organisms | 0.44 | 0.94 | 0.87 | 0.45 | 0.94 | 0.88 |
| Proteins | 0.62 | 0.80 | 0.70 | 0.63 | 0.80 | 0.76 |
| Sequences | 0.54 | 0.75 | 0.12 | 0.57 | 0.76 | 0.13 |
| uORF homology group | uORF length (amino acids) | Conserved sequence features | ||||
| Length conserved at N- and C-Termini | N-terminus (amino acids) | Middle (amino acids) | C-terminus (amino acids) | Overall | ||
| uORF features conserved between Arabidopsis and rice | ||||||
| 1 | 25–43 | C-terminus | SY-rich: 5/14 | 20–39% STY | ||
| 2 | 34–39 | C-terminus | KR-rich: 5–6/20 | 18–24% KR | ||
| 3 | 50–54 | N- and C-termini | K-rich: 4/9 | S-rich: 5–6/6 | KR-rich: 4–5/16, SY-rich: 4–5/12 | 17–23% KR. 22–29% SY |
| 4 | 52–55 | N- and C-termini | SY-rich: 7/30 | 21–23% STY | ||
| 5 | 38–41 | N- and C-termini | ||||
| 6 | 55–68 | N-terminus | ||||
| 7 | 57–105 | N-terminus | STY-rich: 6–7/22 | KR-rich: 4/5–8 | ||
| 8 | 61–62 | N- and C-termini | CHCH domain, 17% KR | |||
| 9 | 17–33 | N-terminus | ||||
| 10.1 | 41 | N- and C-termini | ||||
| 11 | 24–44 | C-terminus | KR-rich: 5–6/15 | 25% KR | ||
| 12 | 39–51 | N- and C-termini | ||||
| 13 | 25 | N- and C-termini | RS-rich: 10–12/18 | 40–48% RS | ||
| 14 | 29 | N-terminus | ST-rich: 4–6/10 | 14–32% STY | ||
| 15.1 | 18–27 | N- and C-termini | 8/9 hydrophobic | |||
| 15.3 | 43–54 | N- and C-termini | 13/14 completely conserved | |||
| 16 | 40–62 | C-terminus | ||||
| 17 | 36–45 | C-terminus | ||||
| 18 | 36–38 | Neither | ||||
| 19 | 30–34 | N-terminus | 29% ST | |||
| uORF features conserved between Arabidopsis paralogs | ||||||
| 20 | 41–43 | N- and C-termini | STY-rich: 8–9/27 | 23% STY | ||
| 21 | 87–90 | N- and C-termini | ST-rich: 11–12/17–22 | 22–25% ST | ||
| 22 | 25 | N- and C-termini | ||||
| 23 | 69–71 | Neither | ||||
| 24 | 31–34 | N- and C-termini | ||||
| 25 | 25 | N- and C-termini | ||||
| 26 | 22 | N-terminus |
| Assay | Cyclohexane extract | Ethanolic extract | Water extract |
| ORAC-PYR (mTE/g) | 1.5 ± 0.4 | 28.1 ± 2.5 | 13.7 ± 1.3 |
| DPPH (mTE/g) | 0.20 ± 0.03 | 2.25 ± 0.07 | 1.01 ± 0.07 |
| DPPH (IC50 μg/mL) | 95.0 ± 0.2 | 24.2 ± 0.5 | 24.5 ± 0.8 |
| TEAC (mTE/g) | 0.64 ± 0.09 | 7.22 ± 0.08 | 5.32 ± 0.02 |
| TEAC (IC50 mg/mL) | 0.800 ± 0.132 | 0.071 ± 0.009 | 0.089 ± 0.002 |
| FRAP (mTE/g) | 0.27 ± 0.01 | 6.70 ± 0.03 | 6.69 ± 0.09 |
| FRAP (mmol FeII/g) | 1.20 ± 0.01 | 22.5 ± 0.1 | 20.9 ± 0.1 |
| Total phenolics (mGAE/g) | 1.22 ± 0.12 | 7.82 ± 0.01 | 4.32 ± 0.05 |
| Total flavonoids (mCE/g) | 0.18 ± 0.01 | 0.63 ± 0.01 | 0.69 ± 0.02 |
| Total anthocyanin (mg cyanidin 3-O-glucoside/g) | n.d. | n.d. | n.d. |
| Population | mu (empirical) | C.I. for mu (empirical) | C.I. for simulations | C.I. bootstrapped data |
| BKL | 5.6178e-05 | −1.1812e-04 to 2.3048e-04 | −1.2157e-07 to 1.1975e-07 | −1.0721e-05 to 1.2234e-04 |
| MHX | 4.1704e-04 | 1.5234e-05 to 8.1885e-04 | −3.9497e-06 to 3.9043e-06 | 1.3536e-04 to 5.3538e-04 |
| Baseline | 6-month | ||
| Mean (SD) | Mean (SD) | P value | |
| Knowledge | |||
| General knowledge on health and tobacco use (range: 0–7) | 4.5 ± 1.0 | 5.2 ± 0.7 | 0.02 |
| Specific knowledge on smoking-related diseases (range: 0–10) | 7.6 ± 2 | 7.7 ± 1.6 | 0.8 |
| Attitudes a | |||
| Banning all tobacco advertisement | 3.4 ± 0.5 | 3.3 ± 0.6 | 0.14 |
| Recognition of own & professional role in smoking cessation counseling | 3.3 ± 0.4 | 3.2 ± 0.3 | 0.17 |
| Bad image of woman smokers | 2.97 ± 0.3 | 3.2 ± 0.3 | 0.001 |
| Practice in smoking cessation counseling | n (%) | n (%) | |
| Had practiced | 15 (62.5) | 12 (55.0) | - |
| Among those who had practiced b | |||
| Ask | 0.83 (1.0) | 0.92 (0.9) | |
| Advise | 1.38 (1.1) | 1.38 (0.8) | |
| Assess | 0.92 (1.0) | 0.92 (0.9) | |
| Assist | 1.00 (1.1) | 1.15 (0.9) | |
| Arrange | 0.42 (0.9) | 0.17 (0.4) |
| Parameter | Step size α | Nr. epochs | Decay constant λ |
| 0.3 | 10 | N/4 |
| Research procedure | Responder | Definitely Yes (%) | Probably Yes (%) | Probably No (%) | Definitely No (%) | |
| “Drawing 1 extra vial of blood for research purposes when other blood is being obtained for clinical purposes. (Would not require an extra blood draw.)” | Parent by Infant Status | NICU ≤ 31 wks | 50 | 22 | 15 | 13 |
| NICU 34-36 wks | 45 | 38 | 3 | 13 | ||
| NICU Term with hypoglycemia | 45 | 45 | 8 | 3 | ||
| Well-Baby Nursery/Mother-Baby Unit (37-42 weeks) | 45 | 43 | 10 | 3 | ||
| Healthcare Provider | 66 | 32 | 2 | 0 | ||
| “Drawing 1 extra vial of blood for research purposes only. (Would require an extra blood draw.)” | Parent by Infant Status | NICU ≤ 31 wks | 12 | 32 | 37 | 20 |
| NICU 34-36 wks | 28 | 42 | 15 | 15 | ||
| NICU Term with hypoglycemia | 18 | 33 | 33 | 15 | ||
| Well-Baby Nursery/Mother-Baby Unit (37-42 weeks) | 32 | 33 | 33 | 15 | ||
| Healthcare Provider | 22 | 41 | 28 | 10 | ||
| “2 Echocardiograms (heart ultrasound). These are not associated with any pain, but occasionally some infants can feel slight discomfort” | Parent by Infant Status | NICU ≤ 31 wks | 33 | 55 | 12 | 5 |
| NICU 34-36 wks | 22 | 52 | 12 | 14 | ||
| NICU Term with hypoglycemia | 18 | 56 | 25 | 0 | ||
| Well-Baby Nursery/Mother-Baby Unit (37-42 weeks) | 30 | 43 | 23 | 3 | ||
| Healthcare Provider | 50 | 48 | 2 | 0 | ||
| “MRI brain without sedation” | Parent by Infant Status | NICU ≤ 31 wks | 20 | 40 | 20 | 20 |
| NICU 34-36 wks | 20 | 25 | 27 | 28 | ||
| NICU Term with hypoglycemia | 7 | 27 | 40 | 20 | ||
| Well-Baby Nursery/Mother-Baby Unit (37-42 weeks) | 12 | 22 | 42 | 23 | ||
| Healthcare Provider | 28 | 38 | 24 | 11 | ||
| “MRI brain with sedation” | Parent by Infant Status | NICU ≤ 31 wks | 15 | 38 | 27 | 30 |
| NICU 34-36 wks | 12 | 18 | 37 | 33 | ||
| NICU Term with hypoglycemia | 5 | 21 | 20 | 54 | ||
| Well-Baby Nursery/Mother-Baby Unit (37-42 weeks) | 5 | 20 | 39 | 36 | ||
| Healthcare Provider | 3 | 16 | 48 | 33 |
| Ethical view | Emic view (relative frequency) n = 65 | Possibilities |
| Finning[100] | “Fishing that only takes shark fins (63,4%) | “Best monitor”; “Give high fine” |
| Immature Capture [101] | Fish small sharks (61,9%) | “drop the baby sharks”, put closure, “increase the mesh of the nets” |
| Bycatch Capture [102] | “Fishing with trawlnet”, “fishnet excess”, “stuck with longline hook in steel” (46,8%) | “forbid trawling”, “control gillnets use”, “forbid longline hooks stuck with Spiral wire Rope use” |
| Females Capture [70] | “female fishing”; “fish a female carrying a baby shark in the belly” (15,1%) | “Drop females”; “make closure” |
| Measures | MBCT, n (%) | Self-help, n (%) | ||||||
| Recovered | Improved | Same | Deteriorated | Recovered | Improved | Same | Deteriorated | |
| Post-treatment | ||||||||
| (MBCT = 28; Self-help = 32) | ||||||||
| Concern over mistakes* | 6 (21) | 12 (43) | 10 (36) | 0 (0) | 4 (13) | 8 (25) | 20 (63) | 0 (0) |
| Clinical perfectionism | 8 (29) | 0 (0) | 20 (71) | 0 (0) | 4 (13) | 0 (0) | 28 (88) | 0 (0) |
| DASS depression* | 10 (36) | 4 (14) | 11 (39) | 3 (11) | 3 (9) | 5 (16) | 22 (69) | 2 (6) |
| DASS anxiety | 3 (11) | 3 (11) | 22 (79) | 0 (0) | 3 (9) | 2 (6) | 26 (81) | 1 (3) |
| DASS stress* | 5 (18) | 10 (36) | 10 (36) | 3 (11) | 3 (9) | 3 (9) | 24 (75) | 2 (6) |
| 10-week follow-up | ||||||||
| Concern over mistakes | 5 (18) | 11 (39) | 12 (43) | 0 (0) | 1 (3) | 0 (0) | 18 (56) | 4 (13) |
| Clinical perfectionism* | 10 (36) | 0 (0) | 18 (64) | 0 (0) | 4 (13) | 0 (0) | 27 (84) | 1 (3) |
| DASS depression | 7 (25) | 5 (18) | 12 (43) | 4 (14) | 6 (19) | 3 (9) | 18 (56) | 5 (16) |
| DASS anxiety | 3 (11) | 5 (18) | 18 (64) | 2 (7) | 3 (9) | 4 (13) | 22 (69) | 3 (9) |
| DASS stress* | 3 (11) | 9 (32) | 14 (50) | 2 (7) | 0 (0) | 6 (19) | 22 (69) | 4 (13) |
| Dietary Group 2 | ||||
| Index | C | LP | R | SEM |
| Day 3 | ||||
| Initial body weight (g/mouse) | 8.5 | 8.4 | 8.6 | 0.10 |
| Final body weight (g/mouse) | 10.4 X | 7.2 Y | 7.4 Y | 0.10 |
| Food intake (g/mouse · 3d) 3 | 7.8 X | 4.5 Y | 3.6 Y | 0.20 |
| Food intake (g/g body weight · d)3 | 0.19 X | 0.13 Y | 0.09 Z | 0.001 |
| Carcass dry matter (g/100g wet weight) | 30.3 X | 28.3 Y | 27.9 Y | 0.30 |
| Carcass lipid (g/100g wet weight)4 | 9.2 X | 5.9 Y | 3.4 Z | 0.03 |
| Day 14 | ||||
| Initial body weight (g/mouse) | 8.3 | 8.5 | 8.6 | 0.08 |
| Final body weight (g/mouse) 4 | 17.5 X | 6.1 Y | 6.0 Y | 0.02 |
| Food intake (g/mouse · 14d) 5 | 60.6 X | 18.2 Y | 12.6 Z | 0.01 |
| Food intake (g/g body weight · d) | 0.20 X | 0.11 Y | 0.08 Z | 0.002 |
| Carcass dry matter (g/100g wet weight) | 32.1 X | 28.1 Y | 26.5 Z | 0.26 |
| Carcass lipid (g/100g wet weight) | 10.4 X | 4.5 Y | 2.7 Z | 0.34 |
| rs3782886 | p for trend | Minor allele frequencies | |||
| Non-minor homo | Minor homo | ||||
| Major homo (A/A) | Hetero (A/G) | (G/G) | |||
| Short stature | |||||
| Total participants (BMI < 25 kg/m2) | |||||
| No. at risk | 232 | 123 | 17 | ||
| No. of cases (percentage) | 56 (24.1) | 30 (24.4) | 9 (52.9) | ||
| Model 1 | 1.00 | 0.96 (0.55, 1.68) | 4.18 (1.37, 12.75) | 0.127 | 1.39 (0.91, 2.13) |
| 1.00 | 4.23 (1.41, 12.72) | 0.010 | |||
| Model 2 | 1.00 | 1.03 (0.57, 1.86) | 4.25 (1.35, 13.39) | 0.092 | 1.47 (0.94, 2.31) |
| 1.00 | 4.21 (1.36, 12.98) | 0.012 | |||
| Reduced maximum voluntary tongue pressure against the palate (MTP) | |||||
| Total participants (BMI < 25 kg/m2) | |||||
| No. at risk | 232 | 123 | 17 | ||
| No. of cases (percentage) | 82 (35.3) | 44 (35.8) | 11 (64.7) | ||
| Model 1 | 1.00 | 1.00 (0.62, 1.61) | 3.56 (1.21, 10.53) | 0.149 | 1.32 (0.91, 1.92) |
| 1.00 | 3.57 (1.22, 10.43) | 0.020 | |||
| Model 2 | 1.00 | 1.11 (0.66, 1.86) | 4.49 (1.45, 13.92) | 0.054 | 1.49 (0.99, 2.24) |
| 1.00 | 4.31 (1.41, 13.11) | 0.010 |
| Case | Fusion | mit. | CD34 | CD99 | EMA | SMA | S100 | BCL2 | STAT6 | EGR1 | Others |
| 1 | Ex4-Ex3 | 8/10 | + | + | - | - | - | + | + | 1 | desmine - |
| 2 | Positive | 3/10 | + | + | + | + | + | + | 3 | desmine -, CK-pan - | |
| 3 | Ex4-Ex3 | 3/10 | + | - | + | + | 1 | desmine - | |||
| 4 | Negative | 0/10 | - | + | - | + | - | + | + | 1 | desmine - |
| 5 | Ex4-Ex3 | 0/10 | + | + | - | - | + | + | 1 | desmine -, CK-pan - | |
| 6 | Ex4-Ex3 | 4/10 | + | w+ | - | + | + | 2 | CK-pan + | ||
| 7 | Negative | 1/10 | + | + | - | - | - | + | + | 5 | CK-pan - |
| 8 | Positive | 0/10 | + | + | - | + | + | 2 | CK-pan - | ||
| 9 | Ex7-Ex3 | 0/10 | + | + | + | + | 2 | CK-pan - | |||
| 10 | Negative | 1/10 | + | + | - | - | - | + | + | 3 | desmine -, CK-pan - |
| 11 | Negative | 0/10 | + | + | - | - | + | + | 2 | desmine -, CK-pan - | |
| 12 | Ex4-Ex3 | 1/10 | + | + | + | 4 | desmine - | ||||
| 13 | Negative | 0/10 | + | + | f+ | - | - | + | + | 3 | desmine - |
| 14 | Ex4-Ex3 | 0/10 | + | + | + | + | 1 | ||||
| 15 | Ex4-Ex3 | 0/10 | + | + | - | - | w+ | + | NA | ||
| 16 | Ex6-Ex17 | 30/10 | + | + | + | + | 3 | desmine - | |||
| 17 | Ex6-Ex18 | 13/10 | + | + | - | - | + | + | 1 | desmine -, CK-pan - | |
| 18 | Ex4-Ex3 | 0/10 | + | - | - | + | + | 2 | desmine f+, CK-pan - | ||
| 19 | Ex4-Ex3 | 0/10 | + | - | - | + | 1 | desmine - | |||
| 20 | Negative | 1/10 | + | - | - | + | 1 | desmine -, CK-pan - | |||
| 21 | Ex6-Ex18 | 0/10 | + | + | + | 1 | |||||
| 22 | Ex6-Ex3 | 0/10 | + | w+ | - | + | 1 | desmine - | |||
| 23 | Ex4-Ex3 | 8/10 | + | + | - | - | + | + | 1 | desmine - | |
| 24 | Negative | 1/10 | + | + | + | + | 3 | desmine -, CK-pan - | |||
| 25 | Ex4-Ex3 | 1/10 | + | + | 1 | ||||||
| 26 | NA | 0/10 | + | + | 5 | ||||||
| 27 | Ex6-Ex18 | 0/10 | + | + | 2 | ||||||
| 28 | NA | 6/10 | + | - | - | + | 5 | desmine -, CK-pan - |
| Study (Year)LocationReview article cited | Nature of Practice | Amount of Practice | Study Results, Attributes and Limitations |
| IWAO et al. (1999) [51]Japan/Kyotouncontrolled observational study | Qigong walking = mild and slow walking using all muscles in body Conventional walking = normal walking | Evaluated 90 min post lunch on 3 different days Qigong walking (30–40 min)Conventional walking (30 min) | Plasma glucose decreased in both exercise groups Conventional = 228 to 205 mg/dL; Qigong = 223 to 216 mg/dLCompared with no exercise, 229 mg/dL (p < 0.025)Very short-duration study where subjects served as their own controls. Little information known about subjects. |
| LIU et al. (2010) [52]Australia/QueenslandPre-post feasibility trial uncontrolled observational study | Kai/Mai Tai Chi/Qigong style - defines qigong as \"mind-body movement therapy...most involve combined training of movement, breathing, and mind, with a strong focus on the mind“ | 12 weeks1–1.5 h 3×/wk with Tai Chi/Qigong instructor; also encouraged to practice at home | Good adherence and high acceptability; Significant reductions with BMI, HbA1c and IRNo subjects were taking medications. Combination of group and individual practice. |
| HUANG et al. (2012) [53]Taiwan/Kaohsiungquasi-experimental | Defines qigong as breathing training. Qi meaning breath and gong meaning to train. Five Element Gymnastics (FEG) consolidates Qigong, Xiang Gong & Martial Arts with Gymnastics. | 16 weeksFEG practiced following DVD 2 ×/day for 20 min each session for 16 weeks with 2 sessions in first week taught by certified fitness instructor and group education sessions at weeks 3, 7, 11 and 14; Control group maintained usual activities | HbA1C change -6.77 (p < 0.01)Included insulin-dependent subjects; however, medications remained same. Combination of instructor led group practice and DVD led at home individual practice. |
| Categories of Alcohol Consumption | |||||||
| Never(n = 248) | Former(n = 208) | 0.1-10.0 g/d(n = 638) | 10.1-20.0 g/d(n = 152) | 20.1-40.0g/d (n = 114) | > 40.0 g/d(n = 132) | p¶ | |
| CCA-IMT, mm | |||||||
| Age-adjusted | 0.805 ± 0.009 | 0.778 ± 0.010* | 0.775 ± 0.006** | 0.773 ± 0.012* | 0.770 ± 0.014* | 0.769 ± 0.013* | 0.028 |
| Multivariate-adjusted† | 0.814 ± 0.009 | 0.782 ± 0.010* | 0.776 ± 0.006** | 0.767 ± 0.012** | 0.756 ± 0.013** | 0.758 ± 0.013** | < 0.001 |
| Multivariate-adjusted+HDL‡ | 0.811 ± 0.009 | 0.778 ± 0.010* | 0.775 ± 0.006** | 0.769 ± 0.012** | 0.762 ± 0.013** | 0.769 ± 0.013** | 0.009 |
| CB-IMT, mm | |||||||
| Age-adjusted | 0.868 ± 0.008 | 0.848 ± 0.009 | 0.843 ± 0.005** | 0.842 ± 0.011* | 0.850 ± 0.012 | 0.827 ± 0.011** | 0.018 |
| Multivariate-adjusted† | 0.874 ± 0.008 | 0.852 ± 0.009 | 0.843 ± 0.005** | 0.839 ± 0.010** | 0.841 ± 0.012* | 0.821 ± 0.011** | 0.001 |
| Multivariate-adjusted+HDL‡ | 0.871 ± 0.008 | 0.848 ± 0.009 | 0.842 ± 0.005** | 0.841 ± 0.010* | 0.847 ± 0.012 | 0.832 ± 0.012** | 0.038 |
| Higher CCA-IMT§ | |||||||
| Prevalence, % | 27.8 | 24.5 | 19.1 | 17.1 | 16.7 | 12.1 | < 0.001 |
| Age-adjusted | 1 | 0.83 (0.54-1.28) | 0.72 (0.51-1.03) | 0.64 (0.38-1.08) | 0.64 (0.36-1.14) | 0.47 (0.26-0.85)* | 0.007 |
| Multivariate-adjusted† | 1 | 0.78 (0.50-1.22) | 0.68 (0.47-0.98)* | 0.56 (0.32-0.95)* | 0.50 (0.28-0.92)* | 0.38 (0.20-0.71)* | 0.001 |
| Multivariate-adjusted+HDL‡ | 1 | 0.78 (0.49-1.22) | 0.68 (0.47-0.99)* | 0.57 (0.33-0.98)* | 0.53 (0.29-0.98)* | 0.41 (0.21-0.78)* | 0.004 |
| Name | Expression plasmids | Properties |
| YJ0 | pBS01A | Empty vector |
| YJ-G01 | pYJ-G01 | TcGPAT1 expression |
| YJ-G02 | pYJ-G02 | TcGPAT2 expression |
| YJ-L01 | pYJ-L01 | TcLPAT1 expression |
| YJ-L02 | pYJ-L02 | TcLPAT2 expression |
| YJ-D01 | pYJ-D01 | TcDGAT1 expression |
| YJ-D02 | pYJ-D02 | TcDGAT2 expression |
| YJ-111 | pYJ-111 | TcGPAT1, TcLPAT1 and TcDGAT1 gene combination expression |
| YJ-112 | pYJ-112 | TcGPAT1, TcLPAT1 and TcDGAT2 gene combination expression |
| YJ-121 | pYJ-121 | TcGPAT1, TcLPAT2 and TcDGAT1 gene combination expression |
| YJ-122 | pYJ-122 | TcGPAT1, TcLPAT2 and TcDGAT2 gene combination expression |
| YJ-211 | pYJ-211 | TcGPAT2, TcLPAT1 and TcDGAT1 gene combination expression |
| YJ-212 | pYJ-212 | TcGPAT2, TcLPAT1 and TcDGAT2 gene combination expression |
| YJ-221 | pYJ-221 | TcGPAT2, TcLPAT2 and TcDGAT1 gene combination expression |
| YJ-222 | pYJ-222 | TcGPAT2, TcLPAT2 and TcDGAT2 gene combination expression |
| Variable | Sensitivity | Specificity | Positive predictive value | Negative predictive value |
| B3 criterion | 0.44 | 0.91 | 0.13 | 0.87 |
| MSI histology | 0.79 | 0.85 | 0.20 | 0.80 |
| MsPath score* | 0.86 | 0.85 | 0.18 | 0.82 |
| Tumor infiltrating lymphocytes | 0.52 | 0.65 | 0.37 | 0.63 |
| Any mucinous differentiation | 0.63 | 0.69 | 0.34 | 0.65 |
| Poor differentiation | 0.27 | 0.89 | 0.13 | 0.88 |
| Family history of cancers (B4.B5) | 0.64 | 0.92 | 0.13 | 0.87 |
| Revised Bethesda guidelines | 0.78 | 0.77 | 0.3 | 0.7 |
| Revised Bethesda guidelines (modified B1, age limit <45 y) | 0.78 | 0.89 | 0.19 | 0.80 |
| Men | Women | |||||||
| Household income | P | Household income | P | |||||
| Low | Middle | High | Low | Middle | High | |||
| Total energy intake, kcal/day | ||||||||
| Model 1 | 1,968 (39) | 2,061 (21) | 1,958 (36) | 0.012 | 1,701 (27) | 1,710 (16) | 1,757 (27) | 0.259 |
| Model 2 | 1,969 (39) | 2,062 (21) | 1,953 (36) | 0.009 | 1,703 (27) | 1,710 (16) | 1,754 (27) | 0.336 |
| Model 3 | 1,978 (40) | 2,061 (21) | 1,948 (37) | 0.010 | 1,711 (28) | 1,710 (16) | 1,748 (28) | 0.474 |
| Protein, % energy | ||||||||
| Model 1 | 15.3 (0.2) | 15.3 (0.1) | 15.5 (0.2) | 0.718 | 15.1 (0.2) | 15.5 (0.1) | 15.8 (0.2) | 0.037 |
| Model 2 | 15.3 (0.2) | 15.3 (0.1) | 15.5 (0.2) | 0.748 | 15.0 (0.2) | 15.5 (0.1) | 15.9 (0.2) | 0.016 |
| Model 3 | 15.5 (0.3) | 15.3 (0.1) | 15.4 (0.2) | 0.742 | 15.2 (0.2) | 15.5 (0.1) | 15.7 (0.2) | 0.378 |
| Fat, % energy | ||||||||
| Model 1 | 22.3 (0.5) | 25.0 (0.3) | 26.1 (0.5) | <0.001 | 24.6 (0.4) | 26.2 (0.3) | 27.6 (0.4) | <0.001 |
| Model 2 | 23.2 (0.5) | 25.0 (0.3) | 25.9 (0.5) | 0.001 | 24.7 (0.4) | 26.2 (0.3) | 27.5 (0.4) | <0.001 |
| Model 3 | 23.2 (0.5) | 25.0 (0.3) | 25.9 (0.5) | 0.001 | 24.9 (0.5) | 26.1 (0.3) | 27.3 (0.5) | 0.003 |
| Carbohydrate, % energy | ||||||||
| Model 1 | 61.5 (0.6) | 59.5 (0.3) | 58.2 (0.6) | 0.001 | 60.2 (0.5) | 58.2 (0.3) | 56.5 (0.5) | <0.001 |
| Model 2 | 61.3 (0.6) | 59.5 (0.3) | 58.4 (0.6) | 0.003 | 60.1 (0.5) | 58.2 (0.3) | 56.5 (0.5) | <0.001 |
| Model 3 | 61.1 (0.6) | 59.5 (0.3) | 58.6 (0.6) | 0.015 | 59.7 (0.5) | 58.3 (0.3) | 56.8 (0.5) | 0.002 |
| Words | Mean | SD |
| Arousal | ||
| Negative | 5.24 | 1.49 |
| Positive | 4.68 | 1.47 |
| Neutral | 2.77 | 1.32 |
| Valence | ||
| Negative | 2.58 | 0.79 |
| Positive | 7.62 | 0.55 |
| Neutral | 5.00 | 0.34 |
| Characteristics | Survivors (n = 64) | Non-survivors (n = 46) | P |
| At ICU admission | |||
| Age (years old) | 60 [45–69] | 63 [57–73] | 0.03 |
| Male sex | 49 (76.6) | 29 (63) | 0.12 |
| Weight (kg) | 70 [60–80] | 70 [58–79] | 0.84 |
| Body mass index (kg/m2) | 24.6 [20.7–27.8] | 24.4 [20.7–28] | 0.58 |
| APACHE II | 21 [17–25] | 26 [22–29] | 0.0007 |
| Simplified Acute Physiology Score 2 | 52 [41–60] | 57 [45–73] | 0.05 |
| History of congestive heart failure | 6 (9.4) | 6 (13) | 0.54 |
| Liver cirrhosis | 0 | 4 (8.7) | 0.03 |
| Chronic obstructive pulmonary disease | 15 (23.4) | 11 (23.9) | 0.96 |
| Chronic kidney disease requiring dialysis | 4 (6.3) | 5 (10.9) | 0.38 |
| Cancer (<3 months) | 11 (17.2) | 5 (10.9) | 0.35 |
| Diabetes mellitus | 15 (23.4) | 24 (52.2) | 0.002 |
| Immunodepression | 16 (25) | 8 (17.4) | 0.34 |
| At the day of aminoglycoside administration | |||
| Day since admission | 1 [0–5] | 2 [0–7] | 0.32 |
| Emergent surgery | 17 (26.6) | 8 (17.4) | 0.26 |
| Sequential Organ Failure Assessment score | 9 [7–10] | 10 [9–13] | 0.004 |
| Weight (kg) | 70 [60–81] | 70.5 [60–80] | 0.92 |
| Weight gain since ICU admission (kg) | 0 [0–2] | 0 [0–3] | 0.62 |
| Extracorporeal membrane oxygenation | 7 (10.9) | 8 (17.4) | 0.33 |
| Catecholamines | 49 (76.6) | 40 (87) | 0.17 |
| Norepinephrine (μg/kg/min) | 0.26 [0.04–0.61] | 0.83 [0.41–1.65] | 0.0002 |
| PaO2/FiO2 ratio | 200 [140–280] | 147 [103–259] | 0.06 |
| Renal replacement therapy | 19 (29.7) | 21 (45.7) | 0.09 |
| Glomerular filtration rate (mL/min) | 53.5 [29.7–90.4] | 29.8 [0–65.9] | 0.008 |
| Lactate level (mmol/L) | 1.7 [1.2–3.1] | 3.2 [1.4–7] | 0.01 |
| Platelet count (G/L) | 205 [105–339] | 201 [86–270] | 0.47 |
| Hematocrit level (%) | 29.2 [26–31.3] | 29.7 [26–32.4] | 0.54 |
| Leucocyte count (G/L) | 15.6 [9.4–22.3] | 13.4 [7.8–18.7] | 0.22 |
| Glasgow Coma Scale score | 15 [14, 15] | 15 [12–15] | 0.23 |
| Bilirubin level (mg/dL) | 12 [8–17] | 145 [9–26] | 0.22 |
| Prothrombin time (%) | 72 [57–81] | 60 [47–75] | 0.01 |
| Proteinemia (g/L) | 58 [49–64] | 52 [46–62] | 0.1 |
| Amikacin Cmax between 60 and 80 mg/L | 34 (53.1) | 13 (28.3) | 0.009 |
| Dependent variables | Adjusted R2 | Independent variables (partial regression coefficient) b |
| Tension | 0.214*** | SOC (−0.408***) |
| Job demand (quantity) (−0.193**) | ||
| Fatigue | 0.306** | SOC (−0.390***) |
| Job demand (quantity) (−0.357***) | ||
| Anxiety | 0.313*** | SOC (−0.352***) |
| Job demand (quality) (−0.349***) | ||
| Low support from supervisor (0.187*) | ||
| Depression | 0.335*** | SOC (−0.411***) |
| Low support from supervisor (0.197**) | ||
| Married (−0.195**) | ||
| Job demand (quantity) (−0.158*) | ||
| Subjective symptoms | 0.092*** | SOC (−0.314***) |
| Vigor | 0.395*** | SOC (0.275**) |
| Low job aptitude (−0.206**) | ||
| Low support from supervisor (−0.254***) | ||
| Self-rated health | 0.018* | Physical job load (−0.183**) |
| Work duration (0.182*) | ||
| Low support from colleagues (−0.157*) |
| Signs and symptoms of Flammer syndrome | Patient 1 | Patient 2 | Patient 3 | Patient 4 | |
| 1 | Do you suffer from cold hands or feet even in summer time? | + | + | + | + |
| 2 | Do you have a low blood pressure? | + | – | + | – |
| 3 | Are you less thirsty than others? | + | + | – | – |
| 4 | If you have to take medications, do you have the feeling that you react strongly to them? | + | Not known | Not known | + |
| 5 | Do you suffer from migraines? | + | Not reported | – | Not reported |
| 6 | Do you suffer from tinnitus (ringing in your ears)? | Not reported | + | + | + |
| 7 | Do you often feel cold when you are not moving for sometime? | + | + | + | + |
| 8 | Do you need a relatively long time to fall asleep, especially when you are cold? | + | + | + | + |
| 9 | Do you identify smells better than others? | + | Not reported | + | Not known |
| 10 | Have you noticed reversible skin blotches (white or red) when you were excited or angry? | + | + | + | + |
| Group | Type | Model | AUC | Specificity | Sensitivity |
| Early | Parenclitic | -7.44 (Alpha-centrality) | 0.624 | 1 | 0.189 ± 0.124 |
| -0.16 (Pill use) | |||||
| RDLG | -2.09 (GPC1) | 0.663 | 1 | 0.163 ± 0.087 | |
| Late | Parenclitic | 0.07 (Connections to MUC16) | 0.904 | 1 | 0.803 ± 0.077 |
| RDLG | 2.14 (MUC16) | 0.904 | 1 | 0.767 ± 0.082 |
| N = 90 | |
| None | |
| No contraceptive use (includes abstinence, withdrawal, celibacy) | 49 |
| Pregnant or trying to get pregnant | 5 |
| Permanent methods | |
| Tubal ligation, partner vasectomy | 6 |
| Long-acting methods | |
| Implanon | 6 |
| Depo | 5 |
| IUD | 1 |
| Reversible methods | |
| The pill | 4 |
| Condoms | 17* |
| Diaphragm | 0 |
| Brain region | Group | Content (ng/mg protein) | ||||
| DA | DOPAC | HVA | NA | 5-HT | ||
| Striatum | 6-OHDA | 1364 ± 337.2 | 1266 ± 223 | 777.2 ± 107.8 | 131 ± 19.5 | 227.9 ± 15.7 |
| 6-OHDA + SR | 2099 ± 759.9 | 1190 ± 61.8 | 828.4 ± 74.4 | 125.7 ± 6.5 | 248.1 ± 32.2 | |
| Prefrontal cortex | 6-OHDA | 16.8 ± 4.1 | 20.2 ± 11.7 | 35.1 ± 7.5 | 104.9 ± 29 | 198.4 ± 107.1 |
| 6-OHDA + SR | 17.1 ± 4.7 | 12.3 ± 5.4 | 42.5 ± 5.3 | 208.7 ± 16.6* | 467.3 ± 24.9* | |
| Hippocampus | 6-OHDA | 23.4 ± 7.8 | 17.6 ± 2.8 | 53.9 ± 14.2 | 195.9 ± 44.4 | 116.4 ± 59.6 |
| 6-OHDA + SR | 28 ± 4.4 | 20.3 ± 2.5 | 32.8 ± 8.5 | 297.5 ± 28.2 | 165.6 ± 41.6 |
| Bone densities (HU) | ||||
| Number of implant sites | Inside (SD) | Outside (SD) | Combination of inside and outside (SD) | |
| Jaw section | ||||
| Maxilla | 31 | 523.8 (267.5) | 558.1 (202.2)a | 540.9 (201.9)b |
| Mandible | 73 | 567.6 (228.7) | 712.4 (222.3)a | 640.0 (214.9)b |
| Region | ||||
| Anterior | 15 | 659.6 (270.1) | 730.4 (279.1) | 695.0 (206.0) |
| Posterior | 89 | 536.9 (232.1) | 655.6 (216.9) | 596.2 (214.3) |
| Procedure | ||||
| 1-stage | 66 | 571.5 (233.8) | 690.1 (235.6) | 630.8 (223.1) |
| 2-stage | 38 | 525.1 (251.9) | 625.2 (207.6) | 575.2 (198.1) |
| Total patients | NLR <3 | NLR ≥3 | p-value | |
| (n =632) | (n =376) | (n =256) | ||
| Age, years | 55.18 (13 – 91) | 53.48 (17 – 91) | 57.68 (13 – 89) | 0.001 |
| Sex | 0.001 | |||
| Men | 297 (47.0) | 156 (41.5) | 141 (55.1) | |
| Women | 335 (53.0) | 220 (58.5) | 115 (44.9) | |
| Body-mass index | 24.51 ± 3.81 | 24.59 ± 3.86 | 24.35 ± 3.72 | 0.445 |
| Previous abdominal surgery (%) | 140 (22.2) | 89 (23.7) | 51 (19.9) | 0.284 |
| Severity of cholecystitis | < 0.001 | |||
| Simple cholecystitis | 503 (79.6) | 342 (91.0) | 161 (62.9) | |
| Severe cholecystitis* | 129 (20.4) | 34 (9.0) | 95 (37.1) | |
| Content in the gallbladder | 0.122 | |||
| No | 121 (19.1) | 64 (17.0) | 57 (22.3) | |
| Stone(s) | 511 (80.9) | 312 (83.0) | 199 (77.7) | |
| Serum leukocyte count | 7700 | 6200 | 11300 | < 0.001 |
| (1500 – 39300) | (2700 – 16500) | (1500 – 39300) | ||
| Presence of symptom | 0.038 | |||
| Abdominal pain | 586 (92.7) | 342 (91.0) | 244 (95.3) | |
| Indigestion (discomfort) | 25 (4.0) | 19 (5.1) | 6 (2.3) | |
| Fever/Chill | 7 (1.1) | 3 (0.8) | 4 (1.6) | |
| Others | 14 (2.2) | 12 (3.2) | 2 (0.8) | |
| Admission route | < 0.001 | |||
| ED | 280 (44.3) | 120 (31.9) | 160 (62.5) | |
| Outpatient clinic | 352 (55.7) | 256 (68.1) | 96 (37.5) | |
| Time to incision | 0.497 | |||
| Mean ± SD | 35.1 ± 27.0 | 34.5 ± 26.9 | 36.0 ± 27.2 | |
| Median (range) | 23.0 (1 – 120) | 22.0 (1 – 120) | 24.0 (2 – 119) |
| Layer | Type | Input | Kernel | Output |
| 1 | Convolution | 28 × 28 × 1 | 5 × 5 | 24 × 24 × 32 |
| 2 | Max pooling | 24 × 24 × 32 | 2 × 2 | 12 × 12 × 64 |
| 3 | Convolution | 12 × 12 × 64 | 5 × 5 | 8 × 8 × 64 |
| 4 | Max pooling | 8 × 8 × 64 | 2 × 2 | 4 × 4 × 64 |
| 5 | Fully connected | 4 × 4 × 64 | 4 × 4 | 512 × 1 |
| 6 | Fully connected | 512 × 1 | 1 × 1 | 2 × 1 |
| 7 | Softmax | 2 × 1 | N/A | Result |
| Group | Age | Optical density | Standard deviation |
| A | <10 | 0.7840 | 0.0044 |
| B | 11-20 | 0.6974 | 0.0435 |
| C | 21-30 | 0.7028 | 0.0300 |
| D | 31-40 | 0.7730 | 0.0375 |
| E | 41-50 | 0.7270 | 0.0347 |
| F | 51-60 | 0.8272 | 0.0379 |
| G | 61-70 | 0.7953 | 0.0253 |
| H | 71-80 | 0.8435 | 0.0264 |
| I | 80> | 0.8166 | 0.0409 |
| Home visits to recipients of programme ITNs | N = 13 | 95% Conf. Int. |
| # of household ITNs found matched self-report | 13/13 (100%) | - |
| Total # of ITNs found in all visited households | 32 | - |
| Mean ITNs per household | 32/13 = 2.5 | - |
| ITNs in working order and mounted | 28/32 (88%) | (72 – 95) |
| ITNs torn and not mounted | 1/32 (3%) | - |
| ITNs torn and still mounted | 3/32 (9%) | - |
| Households in which none of ITNs were mounted | 3/13 (33%) | (8 – 50) |
| Variables | Food-Secure Household (n = 5413) | Food-Insecure Household without Hunger (n = 381) | Food-Insecure Household with Hunger (n = 68) | p-Value |
| Energy 1 | 28.1 ± 0.8 | 31.7 ± 3.1 | 43.7 ± 6.1 | 0.029 |
| Protein 2 | 9.60 ± 0.5 | 8.70 ± 1.8 | 8.40 ± 4.5 | 0.868 |
| Protein 3 | 18.3 ± 0.7 | 23.1 ± 2.7 | 34.7 ± 6.6 | 0.003 |
| Fiber 3 | 97.6 ± 0.3 | 98.3 ± 0.7 | 98.9 ± 1.1 | 0.567 |
| Calcium 3 | 66.1 ± 0.8 | 70.7 ± 2.9 | 86.4 ± 3.4 | 0.002 |
| Phosphorous 3 | 7.80 ± 0.4 | 13.1 ± 2.1 | 24.5 ± 6.6 | <0.001 |
| Iron 3 | 19.6 ± 0.7 | 24.9 ± 2.7 | 29.9 ± 6.1 | 0.018 |
| Sodium 4 | 6.5 ± 0.4 | 8.60 ± 1.8 | 13.0 ± 4.2 | 0.072 |
| Potassium 4 | 66.0 ± 0.8 | 67.9 ± 2.9 | 84.7 ± 4.6 | 0.017 |
| Vitamin A 3 | 39.6 ± 0.8 | 46.7 ± 3.2 | 55.9 ± 7.1 | 0.006 |
| Vitamin B1 3 | 17.1 ± 0.7 | 25.4 ± 3.2 | 23.8 ± 5.5 | 0.003 |
| Vitamin B2 3 | 41.3 ± 0.8 | 45.7 ± 3.3 | 60.2 ± 7.3 | 0.023 |
| Niacin 3 | 24.5 ± 0.7 | 37.2 ± 3.4 | 46.1 ± 7.7 | <0.001 |
| Vitamin C 3 | 47.5 ± 1.0 | 59.8 ± 2.9 | 68.6 ± 6.4 | <0.001 |
| Step | covariate removed | no. of variables | log-l | AIC | cvlog-l |
| 0 | all (null model) | 0 | -675.7 | -675.7 | -846.8 |
| 1 | none (final model) | 6 | -502.1 | -509.1 | -743.1 |
| 2 | β2M | 5 | -504.6 | -510.6 | -738.8 |
| 3 | β2M and sex | 4 | -618.9 | -623.9 | -738.8 |
| Centrality measures (Mi) | |PeC ∩ Mi| | |Mi - PeC| | Non-essential proteins in {Mi - PeC} | Percentage of non-essential proteins in {Mi - PeC} with low PeC |
| Degree Centrality (DC) | 18 | 82 | 44 | 54.5% |
| Betweenness Centrality (BC) | 16 | 84 | 47 | 51.1% |
| Closeness Centrality (CC) | 16 | 84 | 51 | 56.9% |
| Subgraph Centrality(SC) | 11 | 89 | 59 | 64.4% |
| Eigenvector Centrality(EC) | 11 | 89 | 59 | 64.4% |
| Information Centrality(IC) | 17 | 83 | 47 | 55.3% |
| Bottle Neck (BN) | 16 | 84 | 53 | 45.3% |
| Density of Maximum Neighborhood Component (DMNC) | 12 | 88 | 42 | 42.9% |
| Local Average Connectivity-based method (LAC) | 34 | 66 | 37 | 59.5% |
| Sum of ECC (SoECC) | 37 | 63 | 31 | 54.8% |
| Range-Limited Centrality (RL) | 17 | 83 | 42 | 54.8% |
| L-index (LI) | 13 | 87 | 55 | 58.2% |
| Leader Rank(LR) | 16 | 84 | 46 | 52.2% |
| Normalized α-Centrality (NC) | 11 | 89 | 59 | 64.4% |
| Moduland-Centrality(MC) | 11 | 89 | 57 | 66.7% |
| Target of deletion | Animal model | Results of immunization | Reference |
| Biopterin transporter, LdBT1−/− | Balb/C | Protective immunity, antigen-specific IFN-γ secretion | Papadopoulou et al. (53) |
| Centrin 1, LdCen−/− | Balb/C mice, hamsters, dogs | Protective immunity against L. donovani and L. braziliensis challenge. Increased IFNγ, IL-2, and TNF producing cells and IFNγ/IL-10 ratio, presence of multifunctional cells | Selvapandiyan et al. (48), Fiuza et al. (58) |
| Silent information regulatory two single allele deletion, LiSIR2± | Balb/C | Protective immunity, increased antigen-specific IFNγ/IL-10 ratio | Silvestre et al. (55) |
| Cytochrome c oxidase complex component p27, Ldp27−/− | Balb/C | 12-Week survival in host, protective immunity against L. donovani, L. braziliensis, and L. major challenge. Increased IFNγ, IL-2, and TNF producing cells and IFNγ/IL-10 ratio | Dey et al. (49) |
| Heat shock protein 70, LiHsp70−/− | Balb/C | Cross protection against L. major, high IgG2a relative to IgG1 | Carrion et al. (56) |
| Metric variables | Virginity status | Gender | |
| Femalesa | Malesb | ||
| Age at death (wk) | Virgin | 99.2 ± 2.4c (7, 141)d | 85.2 ± 3.4e (1, 133) |
| Age at death (wk) | Mated | 88.3 ± 5.2 (35, 138) | 104.0 ± 3.8 (61, 149) |
| Total number of litters produced by a dam/stud | 8.9 ± 0.7 (2, 16) | 10.5 ± 1.1 (1, 19) | |
| Total number of pups at birth produced by a dam/stud | 56.8 ± 5.2 (4, 92) | 97.2 ± 10.7f (1, 169) | |
| Total number of pups at weaning produced by a dam/stud | 52.4 ± 5.0 (3, 88) | 92.2 ± 10.1f (1, 162) | |
| Age at last litter (wk) | 51.9 ± 2.8 (31, 80) | 92.2 ± 4.3g (54, 130) | |
| Time interval between mating & last litter (wk) | 34.1 ± 2.8 (6, 55) | 40.2 ± 4.3 (2, 78) | |
| Time interval between litters (wk) | 3.8 ± 0.1 (3, 5.4) | 3.7 ± 0.2 (2, 5.6) | |
| Time interval between last litter & death (wk) | 29.2 ± 4.7 (0, 88) | 11.8 ± 4.2h (0, 94) |
| Survival to hospital discharge | Good neurological recovery | |||
| OR (95% CI) | p Value | OR (95% CI) | p Value | |
| Male sex | 1.536 (1.121–2.104) | 0.008 | ||
| Age, years | 0.990 (0.982–0.999) | 0.032 | 0.961 (0.946–0.977) | < 0.001 |
| Call-to-hospital arrival time | 0.979 (0.965–0.993) | 0.003 | 0.950 (0.921–0.980) | 0.001 |
| ACLS time | 0.952 (0.938–0.966) | < 0.001 | 0.956 (0.929–0.982) | 0.001 |
| Witnessed arrest | 2.814 (1.406–5.632) | 0.003 | ||
| Shockable rhythm in ED | 1.829 (1.194–2.802) | 0.006 | 8.111 (4.632–14.203) | < 0.001 |
| TTM | 5.860 (4.332–7.928) | < 0.0001 | 7.546 (4.406–12.924) | < 0.001 |
| E-PCI | 4.442 (1.940–10.170) | < 0.001 | ||
| E-CAG | 2.316 (1.345–3.988) | 0.002 | ||
| pH | 6.287 (2.601–15.197) | < 0.001 | 15.395 (3.439–68.911) | < 0.001 |
| Potassium | 0.888 (0.821–0.962) | 0.003 |
| Wealth quintiles | ||||||
| State | Lowest | Lower | Middle | Higher | Highest | N |
| Yobe | 65.9 | 24.9 | 3.9 | 3.2 | 2.2 | 539 |
| Zamfara | 56.3 | 31.0 | 7.4 | 3.3 | 1.9 | 931 |
| Sokoto | 49.9 | 20.8 | 12.7 | 9.4 | 7.1 | 897 |
| Borno | 49.3 | 34.2 | 11.2 | 4.2 | 1.2 | 816 |
| Kebbi | 48.8 | 26.5 | 11.0 | 6.8 | 6.8 | 952 |
| Jigawa | 46.8 | 31.2 | 12.6 | 6.4 | 3.0 | 897 |
| Taraba | 45.9 | 28.6 | 12.0 | 6.2 | 7.3 | 936 |
| Katsina | 40.8 | 30.8 | 16.3 | 7.0 | 5.2 | 892 |
| Gombe | 36.7 | 27.9 | 15.6 | 11.2 | 8.6 | 795 |
| Bauchi | 34.6 | 26.9 | 18.9 | 11.9 | 7.6 | 866 |
| Kano | 31.3 | 23.2 | 18.3 | 12.5 | 14.7 | 672 |
| Ebonyi | 28.2 | 34.7 | 24.1 | 8.1 | 5.0 | 877 |
| Benue | 27.1 | 23.8 | 19.0 | 16.9 | 13.3 | 728 |
| Adamawa | 23.7 | 32.2 | 18.2 | 13.2 | 12.8 | 721 |
| Nasarawa | 23.4 | 37.0 | 25.8 | 8.2 | 5.6 | 765 |
| Plateau | 22.9 | 33.0 | 19.1 | 8.6 | 16.4 | 864 |
| Niger | 21.3 | 27.7 | 21.4 | 15.4 | 14.2 | 855 |
| Kwara | 12.3 | 10.2 | 18.8 | 31.1 | 27.5 | 861 |
| Oyo | 11.1 | 19.7 | 18.8 | 25.1 | 25.2 | 903 |
| Kaduna | 10.4 | 29.0 | 24.7 | 17.7 | 18.1 | 938 |
| Bayelsa | 8.4 | 19.5 | 26.2 | 25.1 | 20.8 | 821 |
| Cross River | 7.8 | 19.2 | 29.7 | 22.2 | 21.1 | 871 |
| AkwaIbom | 6.0 | 16.0 | 30.8 | 26.7 | 20.6 | 938 |
| Rivers | 5.9 | 8.7 | 19.7 | 29.0 | 36.7 | 645 |
| Ondo | 5.8 | 16.8 | 22.6 | 27.9 | 26.8 | 619 |
| Kogi | 4.2 | 15.0 | 30.3 | 27.2 | 23.3 | 838 |
| Delta | 4.0 | 7.4 | 24.2 | 28.0 | 36.3 | 900 |
| Ogun | 3.8 | 14.6 | 21.4 | 32.8 | 27.5 | 899 |
| Ekiti | 3.5 | 17.6 | 25.4 | 29.1 | 24.3 | 879 |
| Enugu | 3.3 | 16.4 | 29.9 | 22.7 | 27.7 | 669 |
| Osun | 2.4 | 4.3 | 21.2 | 42.1 | 30.0 | 921 |
| Anambra | 1.6 | 7.1 | 23.5 | 33.1 | 34.6 | 910 |
| Edo | 1.3 | 7.7 | 23.0 | 34.6 | 33.5 | 819 |
| Abia | .8 | 6.9 | 26.7 | 31.6 | 34.2 | 919 |
| FCT | .7 | 4.8 | 14.1 | 25.3 | 55.1 | 724 |
| Imo | .4 | 3.5 | 27.6 | 40.5 | 28.0 | 926 |
| Lagos | .0 | 1.6 | 10.0 | 30.3 | 58.1 | 852 |
| Declaration of minimodel | Explanation |
| <SimulaDerivative name=“rootGrowthRate” function=“usePath” unit=“cm/day”> | Declaration of a minimodel named rootGrowthRate which uses the plugin “usePath” to simulate a growth rate with the unit cm d−1 |
| <SimulaConstant name=“path” type=“string”> rootGrowth </SimulaConstant> | Declaration of a minimodel named “path” which contains a string of the path to which “rootGrowthRate” needs to be coupled |
| <SimulaConstant name=“multiplier”> 0.1 < /SimulaConstant> | Declaration of a minimodel named “multiplier” which is a simple constant with which the result of minimodel named by “path” should be multiplied |
| </SimulaDerivative> | Closing of the declaration of minimodel “rootGrowthRate”, so it is clear that “path” and “multiplier” are owned by it |
| <SimulaVariable name=“rootGrowth” function=“useName+Rate” integrationFunction=“RungeKutta4” unit=“cm” > 1. </SimulaVariable> | Declaration of a minimodel named rootGrowth, which will use function “useName+Rate” to retrieve data and will integrate that data with the default integration function, RungeKutta4. Start value is 1 |
| Variables | Univariate analysis | Multivariate analysis |
| pvalue | pvalue [OR] | |
| Chemotherapy | 0.443 | 0.752 |
| Hypertension | 0.805 | 0.782 |
| Age | 0.200 | 0.373 |
| Breast volume | 0.696 | = 0.01504 [OR 1.00612 (0.99659 – 1.01588)] |
| Diabetes | 0.149 | 0.568 |
| Surgical deficits | 0.107 | = 0.00383 [OR 3.4577 (1.4914 – 8.0161)] |
| Boost administration | = 0.0001156 | = 0.00543 [OR 0.9909 (0.98363 – 0.9982)] |
| V > 100% | - | 0.608 |
| V > 104% | - | 0.323 |
| V > 107% | - | 0.279 |
| Boost V > 100% | - | 0.997 |
| Boost V > 104% | - | 0.997 |
| Boost V > 107% | - | 0.546 |
| Variable | TST + N (%) | TST − N (%) | P |
| Gender | |||
| Male | 102 (50) | 102 (50) | 0.006 |
| Female | 16 (29.1) | 39 (70.9) | |
| Age (years) | |||
| <60 | 99 (43.8) | 127 (56.2) | 0.135 |
| ≥60 | 18 (58.1) | 13 (41.9) | |
| Marital status | |||
| Single | 49 (40.2%) | 73 (59.8%) | |
| Married | 38 (55.9%) | 30 (44.1%) | 0.158 |
| Divorced or separated | 22 (43.1%) | 29 (56.9%) | |
| Widowers | 9 (56.2%) | 7 (43.8%) | |
| Immigrant | |||
| Yes | 85 (49.7%) | 86 (50.3%) | 0.062 |
| No | 33 (37.5%) | 55 (62.5%) | |
| Italian National Health Service | |||
| No | 59 (46.5%) | 68 (53.5%) | |
| Yes | 47 (43.5%) | 61 (56.5%) | 0.831 |
| Unknown | 1 (33.3%) | 2 (66.7%) | |
| Temporary Present Foreigners | |||
| No | 31 (49.2) | 32 (50.8) | |
| Yes | 7 (41.2) | 10 (58.8) | 0.473 |
| Not Known | 3 (75) | 1 (25) | |
| Educational level | |||
| No instruction title | 5 (38.5) | 8 (61.5) | |
| Primary school | 54 (43.5) | 70 (56.5) | 0.585 |
| Secondary school | 51 (50) | 51 (50) | |
| Degree | 5 (33.3) | 7 (66.7) | |
| Employment | |||
| No | 86 (44.6) | 107 (55.4) | 0.661 |
| Yes | 31 (47.7) | 34 (52.3) | |
| Previous TBC diagnosis | |||
| No | 114 (46.2) | 133 (53.8) | 0.115 |
| Yes | 3 (75) | 1 (25) | |
| Smoking habit | |||
| No smoker | 42 (42.4) | 57 (57.6) | |
| Smoker | 72 (49) | 75 (51) | 0.328 |
| Former smoker | 4 (30.8) | 9 (69.2) | |
| Alcohol abuse | |||
| No | 98 (44.3) | 123 (55.7) | |
| Yes | 11 (52.4) | 10 (47.6) | 0.743 |
| Exalcohol abuser | 5 (50) | 5 (50) | |
| Illicit drug use | |||
| No | 105 (45.5) | 126 (54.5) | |
| Yes | 1 (33.3) | 2 (66.7) | 0.833 |
| Former drug user | 3 (37.5) | 5 (62.5) | |
| Obesity | |||
| No | 87 (42.9) | 116 (57.1) | 0.096 |
| Yes | 30 (55.6) | 24 (44.4) |
| Variable | Intervention | Sham | p* |
| N | 24 | 10 | – |
| Age [years] | 57 (12) | 65 (12) | 0.079 |
| Gender M/F (%) | 67/33% | 70/30% | 0.999 |
| Education [years] | 10 (4) | 10 (4) | 0.869 |
| Affected hemisphere R/L (%) | 50/50% | 40/60% | 0.715 |
| Etiopathogenesis (%) | 0.999 | ||
| Ischemic | 71% | 70% | |
| Hemorrhagic | 29% | 30% | |
| Previous stroke events (%) | 21% | 30% | 0.666 |
| Lesion localization (%) | 0.735 | ||
| Cortical | 25% | 10% | |
| Subcortical | 62% | 80% | |
| Both | 13% | 10% | |
| Time from stroke [mos] | 41 (39) | 37 (32) | 0.797 |
| Smoke (%) | 25% | 10% | 0.644 |
| Hypertension (%) | 72% | 70% | 0.999 |
| Diabetes (%) | 8% | 30% | 0.138 |
| Dyslipidemia (%) | 38% | 40% | 0.999 |
| Stroke familiar history (%) | 21% | 30% | 0.666 |
| THERAPY | |||
| Antidepressant | 71% | 40% | 0.130 |
| Antihypertensive | 58% | 60% | 0.999 |
| Antiplatelet | 79% | 70% | 0.666 |
| NIBS SEQUENCE | |||
| TMS-tDCS | 8 | – | – |
| tDCS-TMS | 16 | ||
| SIDE EFFECTS IN 10 SESSIONS** | |||
| TMS | 4 | – | |
| tDCS | 6 | 3 | |
| Drop outs (%) | 24% | 0% | – |
| Total cohort | Matched cohort | |||||
| LAP (n = 85) | OP (n = 195) | P | LAP (n = 71) | OP (n = 71) | P | |
| Age (years) | ||||||
| Median (IQR) | 82.0 (80–84) | 82.0 (81–85) | 0.055 | 82.0 (81–84) | 82.0 (81–84) | 0.711 |
| Sex | 0.552 | 1.000 | ||||
| Male | 46 (54.1) | 98 (50.3) | 40 (56.3) | 40 (56.3) | ||
| Female | 39 (45.9) | 97 (49.7) | 31 (43.7) | 31 (43.7) | ||
| BMI (kg/m2) | ||||||
| Median (IQR) | 22.2 (20.6–24.1) | 21.6 (19.5–23.6) | 0.093 | 21.9 (20.4–24.2) | 22.0 (20.6–24.5) | 0.901 |
| ASA score | 0.882 | 0.396 | ||||
| 1 | 13 (15.3) | 35 (17.9) | 12 (16.9) | 16 (22.5) | ||
| 2 | 56 (65.9) | 120 (61.5) | 45 (63.4) | 37 (52.1) | ||
| 3 | 16 (18.8) | 38 (19.5) | 14 (19.7) | 18 (25.4) | ||
| 4 | 0 (0.0) | 2 (1.0) | ||||
| Comorbidity | 55 (64.7) | 108 (55.4) | 0.146 | 44 (62.0) | 40 (56.3) | 0.495 |
| Hypertension | 49 (57.6) | 90 (46.2) | 40 (56.3) | 34 (47.9) | ||
| Diabetes mellitus | 10 (11.8) | 26 (13.3) | 10 (14.1) | 10 (14.1) | ||
| Cardiovascular disease | 8 (9.4) | 10 (5.1) | 4 (5.6) | 3 (4.2) | ||
| Cerebrovascular disease | 4 (4.7) | 7 (3.6) | 2 (2.8) | 5 (7.0) | ||
| Pulmonary disease | 3 (3.5) | 4 (2.1) | 2 (2.8) | 0 (0.0) | ||
| TNM Stage | 0.002 | 0.978 | ||||
| I | 26 (30.6) | 25 (12.8) | 19 (26.8) | 18 (25.4) | ||
| II | 28 (32.9) | 77 (39.5) | 24 (33.8) | 24 (33.8) | ||
| III | 31 (36.5) | 93 (47.7) | 28 (39.4) | 29 (40.8) | ||
| Tumor location | 0.007 | 0.913 | ||||
| Right colon | 19 (22.4) | 61 (31.3) | 17 (23.9) | 15 (21.1) | ||
| Left colon | 44 (51.8) | 62 (31.8) | 34 (47.9) | 36 (50.7) | ||
| Rectum | 22 (25.9) | 72 (36.9) | 20 (28.2) | 20 (28.2) | ||
| Preoperative CEA (ng/mL) | 0.179 | 0.579 | ||||
| ≤5 | 59 (75.6) | 117 (67.2) | 52 (73.2) | 49 (69.0) | ||
| >5 | 19 (24.4) | 57 (32.8) | 19 (26.8) | 22 (31.0) |
| Interaction | Notes | Reference |
| IL-1α and IL-1β induce autophagy | Induction of autophagy by IL-1 family cytokines suggests a potential negative feedback loop for the control of inflammation by autophagy, as well as a possible anti-microbial response mediated by inflammatory cytokines | Shi and Kehrl (2010) |
| Inhibition of autophagy increases IL-1α, IL-1β, and IL-18 secretion | Inhibition of (or deficiency in) autophagy leads to increased secretion of IL-1 family cytokines in response to TLR ligands and Mycobacterium tuberculosis. This is dependent on TRIF (in mice), reactive oxygen species, and mitochondrial DNA. These results suggest that autophagy normally regulates endogenous factors that would otherwise induce inflammasome assembly, caspase-1 activation, and subsequent processing and secretion of IL-1β and IL-18. In humans, regulation of IL-1β by autophagy occurs at the transcriptional level | Saitoh et al. (2008), Crisan et al. (2011), Harris et al. (2011), Kleinnijenhuis et al. (2011), Nakahira et al. (2011), Zhou et al. (2011a) |
| Induction of autophagy reduces IL-1β secretion in vitro and in vivo | Induction of autophagy with drugs (e.g., rapamycin) or starvation reduces secretion of IL-1β by macrophages and dendritic cells in response to LPS with alum or ATP or in response to Mycobacterium tuberculosis. Induction of autophagy also decreases intracellular levels of pro-IL-1β. In a mouse model of LPS-induced sepsis, rapamycin decreases serum levels of IL-1β. | Crisan et al. (2011), Harris et al. (2011), Shi et al. (2012) |
| Autophagosomes sequester and degrade IL-1β and inflammasome components | In macrophages stimulated with TLR ligands, autophagosomes sequester IL-1β. The inflammasome component ASC is ubiquitinated in response to inflammasome activation and delivered to autophagosomes. NLRP3 and AIM2 are also sequestered by autophagosomes | Harris et al. (2011), Shi et al. (2012) |
| Activation of the NLRP3 and AIM2 inflammasomes induces autophagosome formation | Induction of the AIM2 inflammasome by transfection of macrophages with poly(dA:dT) or the NLRP3 inflammasome with uric acid crystals or nigericin leads to an increase in autophagosome formation | Shi et al. (2012) |
| Autophagy can act as secretory pathway for the release of IL-1β | Induction of inflammasome activation in parallel with autophagy induction can lead to an increase in IL-1β secretion. This novel secretory pathway is dependent on inflammasome assembly, Atg5, Rab8a, and GRASP55 (GORASP2; a mammalian Golgi reassembly stacking protein paralog) | Dupont et al. (2011) |
| First Author Year (Ref) | Study Years | AA, n | Caucasian, n | Age, yrs | Population | Study design | Enrollment states |
| Marcus et al. 2010 [7] | 1989-1999 | 804 | 4,543 | >65 | Older population | Cohort | 15 U.S. states**, Washington D.C. |
| Go et al. 2001 [16] | 1996-1997 | 39,579 | 519,714 | >50* | General population | Cross-sectional | California |
| Alonso et al. 2009 [17] | 1987–2004 | 4,115 | 11,292 | >55* | General population | Cohort | Maryland, |
| Minnesota, | |||||||
| Mississippi, | |||||||
| N. Carolina | |||||||
| Afzal et al. 1999 [18] | 1996 | 113 | 50 | >35* | Heart failure | Cohort | Michigan |
| Ruo et al. 2004 [19] | 1999-2000 | 223 | 1,150 | >35* | Heart failure | Cohort | California |
| Winkelmayer et al. 2011 [20] | 1992–2006 | 90,217 | 121,698 | >30* | Hemodialysis | Cohort | United States |
| Upshaw Jr. 2002 [21] | 1996–1998 | 922 | 1,201 | >20 | Hospitalized patients | Cohort | Georgia |
| Shen et al. 2010 [22] | 2008 | 40,293 | 191,860 | >60 | Older population | Cross-sectional | California |
| Smith et al. 2006 [23] | 1993–2005 | 644 | 1,932 | >25* | Post-CABG | Case control | Ohio |
| Lahiri et al. 2011 [24] | 2004–2008 | 270 | 731 | >25* | Post-CABG | Cohort | Michigan |
| Characteristic | % | Crude 1 | OR (95% CI) | Adj.2 | OR (95% CI) | Adj.3 | OR (95% CI) |
| Model 1 | Model 2 | ||||||
| Age-Race/ethnicity | |||||||
| Interaction4 | |||||||
| <60, Non-Black | 1.00 | (referent) | 1.00 | (referent) | |||
| <60, NH Black | 2.98 | (1.77 - 4.96) | 2.62 | (1.50 - 4.52) | |||
| 60-64, Non-Black | 2.01 | (1.42 - 2.88) | 1.95 | (1.36 - 2.83) | |||
| 60-64, NH Black | 2.80 | (1.52 - 5.03) | 2.53 | (1.32 - 4.72) | |||
| 65-74, Non-Black | 7.20 | (5.38 - 9.79) | 7.55 | (5.57 - 10.40) | |||
| 65-74, NH Black | 5.14 | (3.24 - 8.18) | 5.19 | (3.15 - 8.59) | |||
| >= 75, Non-Black | 68.08 | (41.57 - 116.45) | 69.73 | (41.94 - 120.93) | |||
| >= 75, NH Black | 41.09 | (13.58 - 178.13) | 43.31 | (13.28 - 196.39) | |||
| Age at diagnosis | |||||||
| <60 | 17.20 | 1.00 | (referent) | 1.00 | (referent) | ||
| 60-64 | 25.54 | 1.65 | (1.22 - 2.25) | 1.63 | (1.18 - 2.26) | ||
| 65-69 | 39.76 | 3.18 | (2.41 - 4.22) | 3.37 | (2.52 - 4.54) | ||
| 70-74 | 69.25 | 10.84 | (8.08 - 14.66) | 12.22 | (8.94 - 16.86) | ||
| >= 75 | 91.32 | 50.63 | (32.27 - 82.56) | 54.47 | (34.11 - 90.27) | ||
| Marital status | |||||||
| Married | 42.30 | 1.00 | (referent) | 1.00 | (referent) | 1.00 | (referent) |
| Not Married | 49.18 | 1.32 | (1.05 - 1.65) | 1.44 | (1.10 - 1.88) | 1.51 | (1.15 - 1.98) |
| Unknown | 60.58 | 2.10 | (1.41 - 3.16) | 2.20 | (1.36 - 3.58) | 2.22 | (1.36 - 3.65) |
| Registry | |||||||
| California | 36.60 | 1.00 | (referent) | 1.00 | (referent) | 1.00 | (referent) |
| Colorado | 39.30 | 1.12 | (0.83 - 1.52) | 1.57 | (1.10 - 2.25) | 1.60 | (1.11 - 2.31) |
| Illinois | 46.46 | 1.50 | (1.11 - 2.04) | 1.57 | (1.09 - 2.27) | 1.71 | (1.17 - 2.49) |
| Louisiana | 38.36 | 1.08 | (0.80 - 1.46) | 1.06 | (0.73 - 1.53) | 1.07 | (0.74 - 1.56) |
| New York | 53.80 | 2.02 | (1.49 - 2.75) | 2.40 | (1.66 - 3.49) | 2.78 | (1.91 - 4.06) |
| Rhode Island | 49.39 | 1.69 | (1.24 - 2.30) | 2.00 | (1.39 - 2.90) | 1.98 | (1.36 - 2.89) |
| South Carolina | 47.66 | 1.58 | (1.14 - 2.19) | 2.12 | (1.43 - 3.14) | 2.35 | (1.58 - 3.51) |
| DRE results | |||||||
| Normal | 40.28 | 1.00 | (referent) | 1.00 | (referent) | 1.00 | (referent) |
| Abnormal | 50.67 | 1.52 | (1.26 - 1.84) | 1.19 | (0.95 - 1.50) | 1.17 | (0.93 - 1.48) |
| Equivocal/unknown | 41.33 | 1.05 | (0.85 - 1.29) | 0.78 | (0.60 - 1.02) | 0.77 | (0.59 - 1.00) |
| PSA value | |||||||
| 0-4 | 39.52 | 1.00 | (referent) | 1.00 | (referent) | 1.00 | (referent) |
| >4-10 | 41.56 | 1.09 | (0.81 - 1.47) | 1.01 | (0.71 - 1.44) | 1.06 | (0.74 - 1.53) |
| >10-20 | 53.88 | 1.79 | (1.28 - 2.50) | 1.57 | (1.06 - 2.34) | 1.64 | (1.09 - 2.46) |
| 20+ | 61.00 | 2.40 | (1.61 - 3.58) | 2.14 | (1.34 - 3.45) | 2.17 | (1.35 - 3.52) |
| Unknown | 29.91 | 0.65 | (0.44 - 0.97) | 0.45 | (0.27 - 0.73) | 0.46 | (0.28 - 0.75) |
| Gleason score | |||||||
| 2-4 | 43.01 | 1.00 | (referent) | 1.00 | (referent) | 1.00 | (referent) |
| 5-7 | 40.92 | 0.92 | (0.68 - 1.24) | 0.76 | (0.54 - 1.09) | 0.76 | (0.53 - 1.09) |
| 8-10 | 61.05 | 2.08 | (1.39 - 3.13) | 1.53 | (0.94 - 2.48) | 1.59 | (0.97 - 2.62) |
| Unknown | 72.48 | 3.49 | (2.12 - 5.86) | 5.59 | (3.09 - 10.34) | 5.64 | (3.08 - 10.52) |
| Indicators | Prevalence per 10,000 (n/N)* | 95 % CI |
| Prevalence of congenital defects | 52.0 (142/27201) | 44.0–61.0 |
| Prevalence of selected NTDs only | 4.0 (11/27201) | 2.0–7.0 |
| Prevalence of other congenital defects except NTDs | 48.0 (131/27201) | 40.0–57.0 |
| Prevalence of congenital defects in Mountain | 16.0 (5/3079) | 7.0–38.0 |
| Prevalence of congenital defects in Hill | 56.0 (85/15156) | 45.0–69.0 |
| Prevalence of congenital defects in Terai | 58.0 (52/8966) | 44.0–76.0 |
| Variable | Frequency | % |
| Age (mean = 36.8 ± 14.0 yrs) | ||
| < 50 years | 554 | 80 |
| ≥ 50 years | 139 | 20 |
| Gender | ||
| Male | 374 | 54 |
| Female | 319 | 46 |
| Religion | ||
| Christian | 554 | 80 |
| Moslem | 111 | 16 |
| Traditional religion | 21 | 3 |
| Other | 7 | 1 |
| Marital status | ||
| Married | 267 | 38 |
| Single | 281 | 41 |
| Widowed | 68 | 10 |
| Separated | 50 | 7 |
| Divorced | 27 | 4 |
| Highest education attained | ||
| Illiterate | 97 | 14 |
| Primary | 104 | 15 |
| Secondary | 360 | 52 |
| Tertiary | 132 | 19 |
| Monthly income (Cedis) | ||
| < 100 | 180 | 26 |
| 100-999 | 270 | 39 |
| 1000-1999 | 21 | 3 |
| 2000-2999 | 14 | 2 |
| ≥ 3000 | 14 | 2 |
| Unemployed | 194 | 28 |
| Stroke risk factors | ||
| Alcohol intake | 118 | 17 |
| Hypertension | 76 | 11 |
| Smoking | 47 | 7 |
| Previous stroke | 43 | 6 |
| High cholesterol | 25 | 4 |
| Heart disease | 19 | 3 |
| Diabetes | 17 | 2 |
| At least one stroke risk factor | 274 | 40 |
| Method | Detection range | Reference |
| Colorimetric | 0.05–50 ng/mL | Luan et al., 2015 |
| Surface plasmon resonance | 0–10 ng/mL | Zhu et al., 2015 |
| Colorimetric | 0.5–100 ng/mL | Wang et al., 2016a |
| Colorimetric | 0.0316–316 ng/mL | Our work |
| Variable | De Hoogte(n = 90) | Corpus-Noord(n = 133) | F | p | ηp2 |
| Neighborhood Satisfaction (1–5) | 3.39 (0.07) | 3.88 (0.07) | 26.12 | <0.001 | 0.11 |
| Well-Being (Happiness; 0–10) | 7.24 (0.14) | 7.34 (0.11) | 0.34 | 0.563 | 0.00 |
| Green Space Quality (1–5; average score) | 3.21 (0.07) | 3.61 (0.06) | 20.04 | <0.001 | 0.08 |
| Green spaces in my neighborhood | |||||
| 1. contain enough recreational facilities (e.g., play equipment, hard court, grass pitches for football). | 3.10 (0.11) | 3.39 (0.09) | 4.13 | 0.043 | 0.02 |
| 2. provide amenities for sitting, picnic table, litter bins, signs and lighting in the night. | 2.74 (0.11) | 3.37 (0.09) | 18.16 | <0.001 | 0.08 |
| 3. have good natural features such as grass, trees and flower beds. | 3.37 (0.09) | 3.87 (0.07) | 17.71 | <0.001 | 0.08 |
| 4. are absent of incivilities (e.g., general litter, graffiti, dog mess, evidence of alcohol, drug use, broken glass and noise). | 2.95 (0.11) | 3.40 (0.09) | 10.15 | 0.002 | 0.04 |
| 5. are easily accessed, there are many access points and enough walking paths, and roads around are not busy. | 3.64 (0.08) | 3.91 (0.06) | 7.36 | 0.007 | 0.03 |
| 6. are well maintained. | 3.47 (0.11) | 3.73 (0.09) | 3.46 | 0.06 | 0.02 |
| Beneficial Affordances of Green Space (1–5; average score) | 4.00 (0.08) | 3.98 (0.06) | 0.05 | 0.824 | 0.00 |
| Green spaces in my neighborhood | |||||
| 1. promote the quality of life. | 4.12 (0.08) | 4.16 (0.07) | 0.08 | 0.779 | 0.00 |
| 2. promote health. | 4.12 (0.08) | 4.06 (0.07) | 0.37 | 0.544 | 0.00 |
| 3. promote recreational use. | 3.90 (0.10) | 4.01 (0.08) | 0.68 | 0.411 | 0.00 |
| 4. promote social interaction. | 3.86 (0.10) | 3.69 (0.08) | 1.55 | 0.214 | 0.01 |
| TLD placement | Cumulative mSv | mSv per screw | % Reduction | ||
| Robot-Guided (154 screws) | Fluoro-Guided (140 screws) | Robot-guided | Fluoro-guided | ||
| Outside of thyroid protector | 1.24 | 3.15 | 0.0082 | 0.0225 | 63.7% |
| Inside of thyroid protector | 0.91 | 1.95 | 0.0060 | 0.0139 | 56.9% |
| Outside of trunk protector | 1.37 | 3.35 | 0.0090 | 0.0239 | 62.3% |
| Inside of trunk protector | 0.84 | 1.84 | 0.0055 | 0.0131 | 57.8% |
| Eye dosimeter | 0.71 | 2.31 | 0.0047 | 0.0165 | 71.6% |
| Identification criteria | |
| Cardiovascular dysfunction | • Shock |
| • Use of continuous vasoactive drugs | |
| • Cardiac arrest | |
| • Cardio-pulmonary resuscitation | |
| • Severe hypoperfusion (lactate > 5 mmol/L or > 45 mg/dL) | |
| • Severe acidosis (pH < 7.1) | |
| Respiratory dysfunction | • Acute cyanosis |
| • Gasping | |
| • Severe tachypnea (respiratory rate > 40 bpm) | |
| • Severe bradypnea (respiratory rate < 6 bpm) | |
| • Severe hypoxemia (PAO2/FiO2 < 200 or O2 saturation < 90 % for ≥60 min) | |
| • Intubation and ventilation not related to anesthesia | |
| Renal dysfunction | • Oliguria non responsive to fluids/diuretics |
| • Dialysis for acute renal failure | |
| • Severe acute azotemia (creatinine ≥ 300 umol/ml or ≥ 3.5 mg/dL) | |
| Coagulation/hematologic dysfunction | • Failure to form clots |
| • Massive transfusion of blood or red cells (≥5 units) | |
| • Severe acute thrombocytopenia (<50,000 platelets/ml) | |
| Hepatic dysfunction | • Jaundice in the presence of pre-eclampsia |
| • Severe acute hyperbilirubinemia (bilirubin > 100 umol/L or > 6.0 mg/dL) | |
| Neurologic dysfunction | • Prolonged unconsciousness (lasting ≥ 12 hours)/coma (including metabolic coma) |
| • Stroke | |
| • Status epilepticus/uncontrollable fits | |
| • Total paralysis | |
| Uterine dysfunction | • Hemorrhage or infection leading to hysterectomy |
| Duration | ARBs | ACEi | CCBs | BBs | Diuretics | |
| Bloom [15] | 12 | 64% | 58%*** | 50% | 43% | 38% |
| Conlin [18] | 48 | 50.9% | 46.5% | 40.7%** | 34.7%** | 16.4%** |
| Hasford [36] | 12 | 51.3% | 42.0% | 43.6% | 49.7% | 34.4% |
| Degli-Esposti [23] | 12 | 41.7% | 32.2% | 26.7% | 36.9% | 25.9% |
| Erkens [37] | 12 | 62.0% | 59.7% | 34.7% | 35.0% | 33.0% |
| Veronesi [19] | 24 | 68.5% | 64.5% | 51.6%** | 44.8%** | 34.4%* |
| Hasford [17] | 12 | 26.4% | 28.2% | 25.9% | 25.8% | 21.9% |
| Patel [16] | 12 | 51.9% | 48.0% | 38.3% | 40.3% | 29.9% |
| Main Geographic Region | Populations (ID) | Individuals | HWE | (%) allele frequencies LCE3 C_LCE3B-del | SNP genotype frequencies (%) | LD | ||||
| x2 | p-value | + | − | AA | AG | GG | r2 | |||
| Sub-Saharan Africans | Pygmies* (PYG) | 44 | 0.93 | 0.33 | 64.77 | 35.23 | 0 | 13.64 | 86.36 | 0.013 |
| Mandenka (MAN) | 17 | 0.78 | 0.56 | 58.82 | 41.18 | 4.55 | 22.73 | 72.73 | 0.121 | |
| Yoruba (YRI) | 22 | 2.18 | 0.14 | 65.91 | 34.09 | 0 | 28.57 | 71.43 | 0.089 | |
| Bantu (BAN) | 18 | 2.66 | 0.10 | 72.22 | 27.78 | 0 | 50.00 | 50.00 | 0 | |
| North-African/Middle East | Mozabite* (ALG) | 26 | 0.04 | 0.84 | 32.69 | 67.31 | 0 | 21.43 | 78.57 | 0.256 |
| Bedouin* (BED) | 36 | 0.47 | 0.49 | 47.22 | 52.78 | 14.63 | 53.66 | 31.71 | 0.772 | |
| Druze* (DRU) | 37 | 1.87 | 0.17 | 36.49 | 63.51 | 9.09 | 56.82 | 34.09 | 1 | |
| Palestinian (PAL) | 40 | 0.44 | 0.50 | 31.25 | 68.75 | 4.44 | 44.44 | 51.11 | 0.936 | |
| European | French (FRA) | 27 | 1.47 | 0.23 | 40.74 | 59.26 | 16.67 | 41.67 | 41.67 | 1 |
| French Basque* (BASQ) | 21 | 1.70 | 0.19 | 40.48 | 59.52 | 9.09 | 54.55 | 36.36 | 0.91 | |
| Sardinian* (SARD) | 24 | 0 | 0.97 | 29.17 | 70.83 | 13.04 | 47.83 | 39.13 | 1 | |
| Italian (ITL) | 17 | 0.28 | 0.60 | 31.76 | 38.24 | 35.00 | 40.00 | 25.00 | 1 | |
| Orcadian* (ORC) | 16 | 2.80 | 0.09 | 31.25 | 68.75 | 23.08 | 23.08 | 53.85 | 1 | |
| Russian (RUS) | 23 | 0.18 | 0.68 | 39.13 | 60.87 | 14.29 | 42.86 | 42.86 | 0.897 | |
| Central-South Asians | Brahui (BRA) | 22 | 0.61 | 0.44 | 43.18 | 56.82 | 21.74 | 43.48 | 34.78 | 1 |
| Balochi (BAL) | 18 | 0.21 | 0.65 | 27.78 | 72.22 | 5.00 | 40.00 | 55.00 | 0.852 | |
| Makrani (MAK) | 24 | 0.67 | 0.41 | 50.00 | 50.00 | 23.81 | 42.86 | 33.33 | 0.55 | |
| Sindhi (SIN) | 21 | 1.71 | 0.19 | 33.33 | 66.67 | 0 | 50.00 | 50.00 | 0.905 | |
| Kalash* (KAL) | 24 | 1.53 | 0.22 | 47.92 | 52.08 | 16.67 | 55.56 | 27.78 | 0.861 | |
| Burusho (BUR) | 23 | 3.19 | 0.07 | 41.30 | 58.70 | 27.27 | 31.82 | 40.91 | 1 | |
| Hazara ( HAZ) | 17 | 1.14 | 0.29 | 79.41 | 20.59 | 43.75 | 56.25 | 0 | 0.904 | |
| Eastern Asians | Han (CHB) | 34 | 0 | 0.98 | 38.24 | 61.76 | 0 | 52.17 | 47.83 | 0.468 |
| Japanese (JPN) | 26 | 2.45 | 0.12 | 48.08 | 51.92 | 50.00 | 37.93 | 37.93 | 0.837 | |
| Yaut* (YAK) | 11 | 0.55 | 0.46 | 77.27 | 22.73 | 50.00 | 31.82 | 18.18 | 1 | |
| NEA | 34 | 0.54 | 0.46 | 45.59 | 54.41 | 20.59 | 52.94 | 26.47 | 0.852 | |
| SEA | 36 | 0.73 | 0.40 | 29.17 | 70.83 | 5.88 | 50.00 | 44.12 | 0.537 | |
| Oceania | Papuan-Melasian (OCE) | 35 | 2.31 | 0.13 | 50.00 | 50.00 | 26.47 | 41.18 | 32.35 | 0.935 |
| Americans | PIMA | 22 | 0.51 | 0.48 | 25.00 | 75.00 | 9.09 | 36.36 | 54.55 | 0.804 |
| MAYA | 21 | 0.94 | 0.33 | 38.10 | 61.90 | 7.14 | 57.14 | 35.71 | 1 | |
| Karitiana (KAR) | 17 | 0.02 | 0.90 | 97.06 | 2.94 | 90.48 | 4.76 | 4.76 | 1 | |
| Surui* (SUR) | 15 | 1.52 | 0.22 | 26.67 | 73.33 | 10.53 | 26.31 | 63.16 | 1 |
| OR or β*† (95% CI) | ||||
| Iron score | Ferritin score | Transferrin score | Transferrin saturation score | |
| Atopy (n=2208) | ||||
| Per SD increase | 1.08 (0.97 to 1.19) | 1.06 (0.95 to 1.17) | 0.97 (0.88 to 1.07) | 1.05 (0.95 to 1.17) |
| P for trend | 0.15 | 0.28 | 0.56 | 0.31 |
| Asthma (n=2787) | ||||
| Per SD increase | 1.09 (0.97 to 1.22) | 0.98 (0.88 to 1.10) | 1.00 (0.90 to 1.12) | 1.08 (0.96 to 1.21) |
| P for trend | 0.15 | 0.75 | 0.95 | 0.20 |
| FEV1 (n=2300) | ||||
| Per SD increase | −0.04 (−0.08 to 0.00) | −0.02 (−0.06 to 0.02) | −0.03 (−0.07 to 0.01) | −0.05 (−0.09 to −0.01) |
| P for trend | 0.07 | 0.38 | 0.13 | 0.03 |
| FVC (n=2336) | ||||
| Per SD increase | −0.03 (−0.07 to 0.01) | −0.01 (−0.05 to 0.03) | −0.03 (−0.07 to 0.01) | −0.04 (−0.08 to 0.00) |
| P for trend | 0.12 | 0.72 | 0.14 | 0.04 |
| FEF25-75 (n=2336) | ||||
| Per SD increase | −0.02 (−0.06 to 0.02) | −0.02 (−0.06 to 0.02) | −0.02 (−0.06 to 0.02) | −0.02 (−0.06 to 0.02) |
| P for trend | 0.35 | 0.39 | 0.36 | 0.28 |
| Patient | Sex | Age (years) | Time from implantation until removal (months) | Implant Material | Location | Reason for removal | Broken Screws? |
| 1 | Female | 48 | 11 | Ti | PU | Nonunion | No |
| 2 | Female | 27 | 23 | Ti | DH | Symptoms | Yes |
| 3 | Female | 34 | 5 | Ti | PU | Infection | No |
| 4 | Male | 40 | 48 | SS | DH | Contracture | No |
| 5 | Male | 30 | 74 | SS | PU | Infection | No |
| 6 | Female | 25 | 38 | Ti | Both | Nonunion | No |
| 7 | Male | 44 | 2 | Ti | Both | Infection | No |
| 8 | Female | 43 | 5 | SS | PU | Symptoms | No |
| 9 | Female | 30 | 12 | Ti | PU | Symptoms | No |
| 10 | Female | 57 | 9 | Ti | PU | Symptoms | No |
| 11 | Female | 46 | 33 | SS | Both | Nonunion | No |
| 12 | Male | 24 | 8 | SS | PU | Infection | No |
| 13 | Male | 47 | 4 | Ti | DH | Infection | No |
| 14 | Female | 40 | 9 | SS | Both* | Symptoms | Yes |
| 15 | Male | 17 | 53 | Ti | Both* | Nonunion | Yes |
| 16 | Male | 56 | 25 | Ti | DH | Symptoms | Yes |
| 17 | Female | 35 | 64 | Ti | DH | Infection | Yes |
| 18 | Female | 48 | 12 | Ti | PU | Symptoms | No |
| 19 | Male | 27 | 8 | SS | DH | Infection | No |
| 20 | Male | 66 | 16 | Ti | PU | Nonunion | Yes |
| 21 | Male | 28 | 7 | Ti | Both | Nonunion | No |
| Genotype | Control | RPC* | UC* | Total UTUC | ||||||
| N (%) | N (%) | Odds ratio (95% CI*) | P | N (%) | Odds ratio (95% CI*) | P | N (%) | Odds ratio (95% CI*) | P | |
| rs2736100 (N/%) | 289 | 92 | 120 | 212 | ||||||
| AA | 86 (29.8) | 34 (37.0) | 1.0 (ref.) | 49 (40.8) | 1.0 (ref.) | 83 (39.2) | 1.0 (ref.) | |||
| AC | 144 (49.8) | 32 (34.8) | 0.562 (0.324 - 0.976) | 0.055 | 49 (40.8) | 0.597 (0.370 - 0.963) | 0.045 | 81 (38.2) | 0.583 (0.388 - 0.875) | 0.012 |
| CC | 59 (20.4) | 26 (28.2) | 1.115 (0.606 - 2.049) | 0.846 | 22 (18.4) | 0.714 (0.396 - 1.288) | 0.330 | 48 (22.6) | 0.878 (0.542 - 1.423) | 0.685 |
| AA + CC | 145 (50) | 60 (65) | 1.0 (ref.*) | 71 (59.2) | 1.0 (ref.) | 133(62.1) | 1.0 (ref.) | |||
| AC | 144 (49.8) | 32 (35) | 0.537 (0.330 - 0.874) | 0.016 | 49 (40.8) | 0.695 (0.452 - 1.069) | 0.121 | 81 (37.9) | 0.613 (0.428 - 0.879) | 0.010 |
| Isolate no. | A600 | Residual Cr(VI)a (mM) | % Cr(VI) reduced | Cr(VI) transformed per A600 of growth |
| TSB-1 | 0.56 | 0 | 100 | 1.79 |
| TSB-2 | 0.65 | 0 | 100 | 1.54 |
| TSB-3 | 0.3 | 0.4 | 60 | 2.00 |
| TSB-4 | 0.251 | 0.6 | 40 | 1.59 |
| TSB-5 | 0.690 | 0 | 100 | 1.45 |
| TSB-7 | 0.325 | 0.65 | 35 | 1.08 |
| TSB-8 | 0.202 | 0.68 | 32 | 1.58 |
| TSB-9 | 0.0.596 | 0 | 100 | 1.68 |
| TSB-10 | 0.42 | 0.66 | 34 | 0.81 |
| TSB-11 | 0.695 | 0 | 100 | 1.44 |
| Lesion [sources] | HPV prevalence | HPV 6/11/16/18 attributable fraction among HPV+ cases | HPV 6/11/16/18/31/33/45/52/58 attributable fraction among HPV+ cases | HPV 31/33/45/52/58 absolute (relative) attributable fraction among HPV+ cases |
| Genital warts [2] | 100% | 90% | 90% | 0% (0%) |
| CIN 2/3 [2] | 100% | 45.5% | 82.3% | 36.8% (80.9%) |
| VIN2/3 [8] | 86.9% | 80.9% | 93.9% | 13.0% (16.1%) |
| VaIN 2/3 [9] | 98.0% | 65.7% | 79.0% | 13.3% (20.2%) |
| AIN 2/3 [22] | 95.7% | 80.5% | 87.8% | 7.3% (9.1%) |
| PIN 2/3 [10] | 89.1% | 81.0% | 91.9% | 10.9% (13.4%) |
| Cervical cancer [21] | 100% | 72.4%(a) | 88.3%(a) | 15.9% (21.9%)(a) |
| Vulvar cancer [8] | 18.3% (b) | 78.0% | 91.6% | 13.6% (17.4%) |
| Vaginal cancer [9] | 71.0% | 64.0%(a) | 84.2%(a) | 20.2% (31.6%)(a) |
| Anal cancer [22] | 87.6% | 84.3%(a) | 92.3%(a) | 8.0% (9.5%)(a) |
| Penile cancer [10] | 32.2% | 70.2%(a) | 79.4%(a) | 9.2% (13.1%)(a) |
| Oral cavity [23] | 7.4% | 72.0%(a) | 80.6%(a) | 8.6% (11.9%)(a) |
| Nasopharynx [23] | 7,9% | 75.0%(a) | 87.5%(a) | 12.5% (16.7%)(a) |
| Oropharynx cancer [23] | 24.9% | 85.2%(a) | 89.7%(a) | 4.5% (5.3%)(a) |
| Hypopharynx cancer [23] | 3.9% | 80.0%(a) | 100%(a) | 20.0% (25.0%)(a) |
| Pharynx cancer [23] | 21.4% | 66.7%(a) | 66.7%(a) | 0% (0%)(a) |
| Larynx cancer [23] | 5.7% | 57.6%(a) | 74.6%(a) | 17.0% (29.5%)(a) |
| Concrete resistivity ρ (kΩcm) | Probable corrosion rate |
| >20 | Despicable |
| Between 10 and 20 | Low |
| Between 5 and 10 | High |
| <5 | Very high |
| Target virusesa | Target genesb | Primer sequence, 5′–3′c | Size (bp) | Source or reference |
| PToV | S | F: ACCCCTGCCTGAGGTTTCYTTR: AGCACGACGTTGTCTRCGTGT | 451 | Established by our own laboratory |
| PEDV | S | F: TTCTGAGTCACGAACAGCCAR: CATATGCAGCCTGCTCTGAA | 651 | Kim et al. (2001) [11] |
| PKBV | 3D | F: TGGATTACAAGTGTTTTGATGCR: TGTCGTAGAACTCCTTGATGAA | 313 | Established by our own laboratory |
| PRV A | VP6 | F: AAAGATGCTAGGGACAAAATTGR: TTCAGATTGTGGAGCTATTCCA | 308 | Elschner et al. (2002) [12] |
| nF: GACAAAATTGTCGAAGGCACATTATAnR: TCGGTAGATTACCAATTCCTCCAG | 121 | |||
| PRV B | NSP2 | F: CTATTCAGTGTGTCGTGAGAGG R: GCAGACAAGCTAGCCCGCTTCG | 434 | Gouvea et al. (1991) [13] |
| PRV C | VP6 | F: CTCGATGCTACTACAGAATCAGR: AGCCACATAGTTCACATTTCATCC | 366 | Gouvea et al. (1991) [13] |
| nF: CTCGATGCTACTACAGAATCAGnR: GGGATCATCCACGTCATGCGT | 328 | |||
| TGEV | ORF1b | F: GGGTAAGTTGCTCATTAGAAATAATGGR: CTTCTTCAAAGCTAGGGACTG | 1006 | Kim et al. (2010) [14] |
| S | ||||
| AV | RdRp | F11: GARTTYGATTGGRCKCGKTAYGAF12: GARTTYGATTGGRCKAGGTAYGAF21: CGKTAYGATGGKACKATHCF22: AGGTAYGATGGKACKATHCR1: GGYTTKACCCACATICCRAA | 422 | Chu et al. (2008) [15] |
| MRV | L1 | F: GCATCCATTGTAAATGACGAGTCTGR: CTTGAGATTAGCTCTAGCATCTTCTG | 416 | Decaro et al. (2005) [16] |
| nF: GCTAGGCCGATATCGGGAATGCAGnR: GTCTCACTATTCACCTTACCAGCAG | 344 | |||
| PSaV and PNoV | RdRp | F: GATTACTCCAAGTGGGACTCCACR: TGACAATGTAATATCACCATA | 319 | Kim et al. (2010) [14] |
| Correlation between IGF-I/IGFBP-3 molar ratio and: | Total group (GHD and controls) | GHD group |
| Height SDS | +0.01 | +0.16 |
| BMI SDS for HA | +0.26 | +0.24 |
| Ghrelin | −0.35∗ | −0.34∗ |
| Leptin | +0.29 | +0.34 |
| Adiponectin | −0.15 | −0.41∗ |
| Resistin | −0.24 | 0.0 |
| Triglycerides | +0.4∗ | +0.59∗ |
| Cholesterol | +0.22 | +0.05 |
| LDL-cholesterol | +0.16 | +0.08 |
| HDL-cholesterol | −0.04 | −0.59∗ |
| Glucose | +0.18 | +0.2 |
| Insulin | +0.41∗ | +0.48∗ |
| IRI HOMA | +0.36∗ | +0.41∗ |
| A2780 | A2780/CDDP | SKOV3 | ||||
| control | BRCA1 si | control | BRCA1 si | control | BRCA1 si | |
| G1 | 52.57±5.11% | 50.03±4.88% | 48.87±4.76% | 44.77±5.71% | 45.07±4.1% | 43.03±2.71% |
| S | 16.43±3.18% | 19.33±2.81% | 10.89±2.18% | 10.40±3.23% | 9.43±5.18% | 9.39±1.86% |
| G2/M | 19.73±2.50% | 21.37±2.76% | 28.83±2.44% | 29.39±3.50% | 23.03±1.50% | 23.99±2.90% |
| Epidemiological strata | Study sites | Age (months) | Total | ||||
| < 60 | 60–119 | 120+ | |||||
| HWP | Bamenda | Gender | F | 70 (40.5) | 29 (16.8) | 74 (42.8) | 173 (54.4) |
| M | 58 (40.0) | 38 (26.2) | 49 (33.8) | 145 (45.6) | |||
| Total | 128 (40.3) | 67 (21.1) | 123 (38.7) | 318 | |||
| C | Limbe | Gender | F | 75 (50.3) | 39 (26.2) | 35 (23.5) | 149 (46.9) |
| M | 103 (61.0) | 39 (23.1) | 27 (15.9) | 169 (53.1) | |||
| Total | 178 (56.0) | 78 (24.5) | 62 (19.5) | 318 | |||
| SCEF | Yaounde | Gender | F | 61 (40.7) | 32 (21.3) | 57 (38.0) | 150 (44.0) |
| M | 100 (52.4) | 46 (24.1) | 45 (23.6) | 191 (56.0) | |||
| Total | 161 (47.2) | 78 (22.9) | 102 (29.9) | 341 | |||
| SS | Maroua | Gender | F | 122 (74.4) | 27 (16.5) | 15 (9.1) | 164 (52.1) |
| M | 111 (73.5) | 27 (17.9) | 13 (8.6) | 151 (47.9) | |||
| Total | 233 (74.0) | 54 (17.1) | 28 (8.9) | 315 | |||
| HIP | Ngaoundere | Gender | F | 94 (65.7) | 32 (22.4) | 17 (11.9) | 143 (45.1) |
| M | 116 (66.7) | 34 (19.5) | 24 (13.8) | 174 (54.9) | |||
| Total | 210 (66.3) | 66 (20.8) | 41 (12.9) | 317 | |||
| Total | Gender | F | 422 (54.2) | 159 (20.4) | 198 (25.4) | 779 (48.4) | |
| M | 488 (58.8) | 184 (22.2) | 158 (19.0) | 830 (51.6) | |||
| Total | 910 (56.6) | 343 (21.3) | 356 (22.1) | 1609 |
| Animal ID | Total tRFs | tRFs/cow | ||||||||
| tRF3 | 1141 | 1143 | 2919 | 2927 | 2931 | 2938 | 2939 | 2942 | ||
| tRF3-Ala | 1 | 0 | 1 | 2 | 1 | 0 | 0 | 0 | 5 | 0.625 |
| tRF3-Arg | 1 | 4 | 4 | 10 | 1 | 7 | 2 | 4 | 33 | 4.125 |
| tRF3-Asn | 13 | 6 | 18 | 8 | 3 | 6 | 14 | 6 | 74 | 9.250 |
| tRF3-Asp | 6 | 3 | 9 | 6 | 3 | 3 | 6 | 4 | 40 | 5 |
| tRF3-Cys | 0 | 1 | 0 | 3 | 0 | 0 | 0 | 0 | 4 | 0.500 |
| tRF3-Gln | 2 | 1 | 1 | 2 | 1 | 1 | 0 | 1 | 9 | 1.125 |
| tRF3-Glu | 34 | 16 | 41 | 43 | 25 | 26 | 24 | 46 | 255 | 31.875 |
| tRF3-Gly | 0 | 0 | 1 | 4 | 0 | 1 | 2 | 0 | 8 | 1 |
| tRF3-His | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| tRF3-Ile | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0.125 |
| tRF3-Leu | 1 | 0 | 0 | 0 | 1 | 0 | 2 | 2 | 6 | 0.750 |
| tRF3-Lys | 4 | 2 | 7 | 2 | 0 | 5 | 4 | 12 | 36 | 4.500 |
| tRF3-Met | 3 | 2 | 1 | 1 | 1 | 1 | 0 | 0 | 9 | 1.125 |
| tRF3-Phe | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 0.25 |
| tRF3-Pro | 0 | 1 | 1 | 3 | 0 | 0 | 0 | 0 | 5 | 0.625 |
| tRF3-Ser | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| tRF3-Stop | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| tRF3-Thr | 1 | 0 | 3 | 7 | 1 | 3 | 2 | 1 | 18 | 2.250 |
| tRF3-Trp | 2 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 5 | 0.625 |
| tRF3-Tyr | 0 | 1 | 2 | 0 | 0 | 1 | 1 | 0 | 5 | 0.625 |
| tRF3-Val | 6 | 2 | 5 | 16 | 3 | 7 | 2 | 6 | 47 | 5.875 |
| Total tRF3 | 47 | 41 | 95 | 107 | 41 | 61 | 61 | 82 | 562 |
| Characteristics | Value | |
| No. | % | |
| Material surrounding the base | ||
| Mud | 10 | 40 |
| Brick | 2 | 8 |
| Small amount of cement | 2 | 8 |
| Large cement platform | 11 | 44 |
| Tubewell colour | ||
| Natural | 21 | 84 |
| Green | 3 | 12 |
| Red | 1 | 4 |
| Sediment in water | ||
| Iron | 0 | 0 |
| Sand | 1 | 4 |
| Iron and sand | 3 | 13 |
| None | 21 | 84 |
| Arsenic present∗ | ||
| No (<50 μg/L) | 2 | 8 |
| Yes (≥50 μg/L) | 2 | 8 |
| Never tested | 21 | 84 |
| Mean (SD) and range | ||
| Temperature (°C) | 26.8 (0.5) | |
| 25.8-28.6 | ||
| pH | 7.3 (0.3) | |
| 6.5-7.8 | ||
| Median (IQR) and range | ||
| Total iron concentration (mg/L) | ||
| AAS | 11.4 (8.4-15.8) | |
| 0.2-28.0 | ||
| Test-kit | 12.8 (10.8-18.8) | |
| 0.6-32.0 | ||
| Colorimeter | 13.60 (9.60-17.60) | |
| 0.50-49.20 | ||
| Ferrous iron by colorimeter (mg/L) | 6.32 (3.10-10.50) | |
| 0.02-28.60 |
| Organism | Fe' (Free Inorganic Iron) | FOB | FeAB | |
| Not Limited | Fe-Limited | Fe-Limited | Fe-Limited | |
| Synechococcus WH8102 | Yes (+) | Yes (+++) | Yes (++) | n/a |
| Synechococcus WH7803 | Yes (+++) | Yes (+++) | Yes (++) | n/a |
| Synechococcus CCMP1183 | Yes (++) | - | - | - |
| Synechococcus PCC7002 | Yes (++) | Yes (+++) | Yes (+) | No |
| Prochlorococcus MED4 | Yes (++) | Yes (+++) | Yes (+) | n/a |
| Synechocystis PCC6803 | Yes (+++)a | Yes (+++)a | Yes (++)a | Yes (++) |
| Trichodesmium IMS101 | - | Yes (+) | - | - |
| Anabaena UTEX2576 | Yes (+++) | Yes (+++) | No* | No |
| Parameter | Insufficient Sleep | Excessive Duration | ||||
| OR | 95% CI | p-Value | OR | 95% CI | p-Value | |
| Hospital capacity/quality | ||||||
| High vs. Low | 0.99 | (0.72, 1.38) | 0.979 | 1.05 | (0.72, 1.52) | 0.812 |
| Medium vs. Low | 0.33 | (0.21, 0.54) | <0.000 | 2.57 | (1.69, 3.90) | <0.000 |
| Residence | ||||||
| Urban vs. Rural | - | - | - | 0.64 | (0.50, 0.83) | 0.001 |
| Nationality | ||||||
| Minority vs. Han nationality | 0.45 | (0.24, 0.84) | 0.012 | - | - | - |
| Without sibling | ||||||
| Yes vs. No | 0.8 | (0.65, 0.97) | 0.024 | - | - | - |
| Education level | ||||||
| Secondary education vs. Basic education | 1.32 | (0.93, 1.86) | 0.117 | - | - | - |
| Higher education vs. Basic education | 0.96 | (0.73, 1.27) | 0.797 | - | - | - |
| Trimester of pregnancy | ||||||
| Second trimester of pregnancy vs. First trimester of pregnancy | 0.66 | (0.49, 0.90) | 0.009 | 1.08 | (0.74, 1.57) | 0.705 |
| Third trimester of pregnancy vs. First trimester of pregnancy | 0.65 | (0.49, 0.86) | 0.003 | 1.51 | (1.07, 2.13) | 0.020 |
| Job | ||||||
| Manual vs. Non-manual | - | - | - | 1.19 | (0.86, 1.64) | 0.289 |
| Unemployed vs. Non-manual | - | - | - | 1.46 | (1.13, 1.88) | 0.003 |
| Others vs. Non-manual | - | - | - | 1.19 | (0.86, 1.66) | 0.296 |
| Secondhand smoke exposure frequency per week | ||||||
| Every day vs. None | 1.43 | (1.10, 1.86) | 0.008 | - | - | - |
| 4–6 days per week vs. None | 1.1 | (0.73, 1.66) | 0.637 | - | - | - |
| 1–3 days per week vs. None | 1.44 | (1.14, 1.80) | 0.002 | - | - | - |
| Gestational diabetes mellitus | ||||||
| Yes vs. No | 1.51 | (0.94, 2.43) | 0.085 | - | - | - |
| Coded value | Glasgow coma scale score | Systolic blood pressure (mmHg) | Respiratory rate (/min) | Age (years) | Injury Severity Score |
| 4 | 13-15 | > 89 | 10-29 | < 16 | |
| 3 | 9-12 | 76-89 | > 29 | 16-24 | |
| 2 | 6-8 | 50-75 | 6-9 | 25-40 | |
| 1 | 4-5 | 1-49 | 1-5 | ≥ 55 | 41-65 |
| 0 | < 4 | No pulse | 0 | 0-54 | > 65 |
| Grade | Points | Symptoms of neurological behavior |
| Normal (no neurological deficit) | 0 | Rats behave normally, can fully outstretch forelimbs toward the ground when lifting tails and dangling. |
| Mild neurological deficit | 1 | Rats cannot fully stretch their left forelimbs when lifting tails and dangling. |
| Moderate neurological deficit | 2 | Rats have decreased resistance to lateral push and mild neurological behavior. |
| Severe neurological deficit | 3 | Rats turn around into a circle, and have mild and moderate neurological behavior. |
| 4 | Rats do not walk spontaneously and have a depressed level of consciousness. |
| LD 14:10 No Wheels | LDLD 7:5:7:5 Wheels (1) | LDLD 7:5:7:5 Wheels (2) | LDLD 7:5:7:5 No Wheels | LDLD 9:3:9:3 No Wheels (1) | LDLD 9:3:9:3 No Wheels (2) | |
| General Locomotion (GL) | 0 | 1/17 | 13/18 | 6/18 | 8/17 | 10/14 |
| Body Temperature (Tb) | 0 | 1/17 | 13/18 | 6/18 | 7/16 | 10/14 |
| Group | Resistive Index before sildenafil | Resistive Index after sildenafil | ||||
| Control | Breath hold | Hyperventilation | Control | Breath hold | Hyperventilation | |
| Normal | 0.56 ± 0.02 | 0.51 ± 0.02* | 0.7 ± 0.03* | 0.58 ± 0.02 | 0.49 ± 0.02* | 0.7 ± 0.02* |
| DM | 0.6 ± 0.02 | 0.53 ± .02* | 0.71 ± 0.02* | 0.6 ± .015 | 0.53 ± .02* | 0.72 ± .018* |
| TSS | Turbidity | Discharge | Daily Water Temp | ||||||||||
| % Average annual | mg L-1 | ntu | (m3 sec-1) | (°C) | |||||||||
| Treatment | Year | n= | precipitationa | Stationb | Mean | Max | Mean | Max | Max | Mean | Min | Meanc | Maxd |
| Pre | 2003 | 6 | 107 | BR6 | 4.3 | 6.9 | 0.41 | 0.67 | 59 | 29 | 8 | 8 | 10 |
| BR1 | 5.3 | 10.0 | 0.60 | 0.99 | 92 | 46 | 17 | 9 | 12 | ||||
| Pre | 2004 | 8 | 93 | BR6 | 2.5 | 7.7 | 1.02 | 3.10 | 58 | 24 | 5 | 8 | 11 |
| BR1 | 3.0 | 6.5 | 1.22 | 3.88 | 71 | 31 | 8 | 9 | 12 | ||||
| Pre | 2006 | 7 | 117 | BR6 | 2.7 | 6.5 | 0.21 | 0.62 | 54 | 24 | 7 | 7 | 10 |
| September | BR1 | 3.2 | 5.3 | 0.18 | 0.28 | 65 | 29 | 7 | 8 | 11 | |||
| Post | 2007 | 8 | 51 | BR6 | 1.6 | 3.5 | 0.25 | 0.53 | 19 | 8 | 3 | 10 | 13 |
| BR1 | 1.5 | 3.5 | 0.33 | 0.79 | 20 | 8 | 3 | 11 | 15 | ||||
| Post | 2008 | 9 | 55 | BR6 | 3.3 | 14.1 | 0.37 | 1.27 | 42 | 12 | 3 | 10 | 13 |
| BR1 | 1.7 | 5.9 | 0.52 | 1.08 | 46 | 15 | 3 | 11 | 15 | ||||
| Post | 2009 | 8 | 69 | BR6 | 3.7 | 5.3 | 0.56 | 1.95 | 34 | 17 | 3 | 9 | 12 |
| BR1 | 4.5 | 7.1 | 0.43 | 0.71 | 41 | 22 | 10 | 10 | 14 | ||||
| Post | 2010 | 7 | 78 | BR6 | 5.3 | 13.5 | 0.82 | 3.01 | 78 | 37 | 7 | 7 | 10 |
| BR1 | 6.5 | 8.8 | 0.83 | 1.54 | 134 | 53 | 19 | 8 | 11 |
| Number of term births | Total number | % |
| 0 | 42 | 21 |
| 1–2 | 82 | 41 |
| 3–4 | 37 | 19 |
| 5–6 | 26 | 13 |
| 7–8 | 4 | 2 |
| > 9 | 1 | 0.5 |
| Not captured | 6 | 3 |
| Mother's age | ||
| 19 & younger | 43 | 22 |
| 20–30 | 72 | 36 |
| 31–40 | 61 | 31 |
| 41 & older | 3 | 1.5 |
| Not captured | 19 | |
| Birthweight (mean=3,444 g) | ||
| 1,000–2,000 g | 4 | 4 |
| 2,100–3,000 g | 37 | 18 |
| 3,100–4,000 g | 125 | 63 |
| > 4,000 g | 32 | 15 |
| Apgar scores | ||
| 1 minute 8–10 | 162 | 82 |
| 1 minute 6–7 | 19 | 10 |
| 1 minute 4–5 | 6 | 3 |
| Score 3 or lessa | 9 | 5 |
| Sr. no. | Retention time (min) | Area (AUC) | Height (mAU) | Area % |
| 1 | 1.67 | 8031 | 337 | 5.1381 |
| 2 | 2.148 | 54,114 | 9762 | 34.6226 |
| 3 | 2.395 | 35,061 | 4229 | 22.4327 |
| 4 | 2.589 | 8605 | 1540 | 5.5057 |
| Brunnstrom Stage | Samples in Testing Set | Predictive Accuracy | |
| Raw Model | Compressed Sensing Model | ||
| II | 2 | 100 (2/2) | 100 (2/2) |
| III | 14 | 85.7 (12/14) | 78.6 (11/14) |
| IV | 9 | 88.8 (8/9) | 100 (9/9) |
| V | 9 | 100 (9/9) | 88.8 (8/9) |
| VI | 4 | 100 (4/4) | 100 (4/4) |
| Total | 38 | 92.1 (35/38) | 89.5 (34/38) |
| max ATP | max NADH | max NADPH | |
| Dissimilation processes | in mol.mol(methanol)-1 | ||
| MeOH - > CO2 (cytoplasmic FDH) | 5 | 2 | 2 |
| MeOH - > CO2 (periplasmic FDH) | 3 | 0 | 0 |
| MeOH + CO2 (Ser cycle) - > Acetyl-CoA - > TCA cycle - > 2 CO2 | 1 | 0.5 | 0.5 |
| MeOH + n CO2 (Ser cycle + EMCP) - > other C2s, C3s, etc - > central pathways - > n+1 CO2 | 1 | 0.5 | 0.5 |
| n | Diabetic (N = 57) | Control (N = 54) |
| Heart rate (bpm) | 73.36 (8.30) | 68.94 (9.77)† |
| SDNN (ms) | 30.10 (15.43) | 40.28 (17.06)† |
| RMSSD (ms) | 21.83 (21.20) | 31.70 (21.78)* |
| LFnorm (ms2) | 55.74 (19.36) | 61.98 (20.26)‡ |
| HFnorm (ms2) | 34.01 (20.26) | 48.25 (19.36)* |
| LF : HF ratio | 2.19 (2.43) | 1.93 (1.77)‡ |
| Total power (ms2) | 1718.34 (337.58) | 1156.31 (279.38)† |
| Timed deep breathing | 14.6 (8.05) | 19.3 (7.26)* |
| Valsalva ratio | 1.24 (0.30) | 1.58 (0.28)* |
| Standing ratio | 1.24 (0.20) | 1.46 (0.13)‡ |
| Element | n | No. of scored sites | Sexuals | Asexuals | t | P |
| Losses | ||||||
| Dpul_D16 | 93 | 4 | 0 | 0 | n/a | n.s. |
| Dpul_D5 | 92 | 7 | 0.0028(± 0.0004) | 0.00031(± 0.0001) | 5.44 | < 0.000001 |
| Putative Somatic Gains | ||||||
| Dpul_D16 | 93 | 4 | 0.0036(± 0.0003) | 0.0016(± 0.0001) | 2.26 | 0.013 |
| Dpul_D5 | 91 | 7 | 0.0020(± 0.0005) | 0.0022(± 0.0004) | -0.23 | 0.41 |
| Mean (SD) | n | t-value | ||
| Pretest | Posttest | |||
| 1. Teamwork and collaboration** | 3.89 (0.52) | 4.02 (0.56) | 676 | 7.687 |
| 2. Negative professional identity* | 2.33 (0.79) | 2.27 (0.86) | 691 | −2.178 |
| 3. Positive professional identity** | 3.74 (0.57) | 3.87 (0.60) | 692 | 6.409 |
| 4. Roles and responsibilities** | 3.24 (0.49) | 3.31 (0.69) | 695 | 3.503 |
| Factors | Subgroup | N | % |
| Median age at baseline | 69.9 y (45–70) | ||
| Sex | Male | 6 | 60 |
| Female | 4 | 40 | |
| Smoker | Yes | 5 | 50 |
| No | 2 | 20 | |
| Unknown | 3 | 30 | |
| ECOG PS | 0-1 | 10 | 100 |
| 2 | 0 | 0 | |
| Histopathology | Adenocarcinoma | 9 | 90 |
| Squamous cell | 1 | 10 | |
| Mutational status | EGFR mutation | 0 | 0 |
| ALK translocation | 1 | 10 | |
| ROS1 translocation | 1 | 10 | |
| None | 8 | 80 | |
| Metastasis location | Bone | 1 | 10 |
| Liver | 1 | 10 | |
| Contralateral lung | 4 | 40 | |
| Adrenal gland | 1 | 10 | |
| Brain | 3 | 30 | |
| Chemotherapy | CDDP-pemetrexed | 7 | 70 |
| CDDP-gemcitabine | 2 | 20 | |
| CDDP-taxotere | 1 | 10 |
| Culture | Strain | growth rate/h-1 | rel. growth | lag phase/h | OD600 max |
| LB, 0% NaCl | NhaD | 0.36 ± 0.05 | 1.4 | 2 | 0.85 ± 0.1 |
| Control | 0.26 ± 0.05 | 1 | 2 | 0.65 ± 0.1 | |
| LB, 3% NaCl | NhaD | 0.23 ± 0.05 | 1.5 | 4 | 0.65 ± 0.1 |
| Control | 0.15 ± 0.05 | 1 | 6 | 0.65 ± 0.1 | |
| MM63, 0% NaCl | NhaD | 0.22 ± 0.05 | 2.2 | 6 | 3.1 ± 0.2 |
| Control | 0.10 ± 0.05 | 1 | 13 | 2.1 ± 0.2 | |
| MM63, 3% NaCl | NhaD | 0.16 ± 0.05 | 2.2 | 10 | 3.2 ± 0.2 |
| Control | 0.07 ± 0.05 | 1 | 31 | 2.0 ± 0.2 |
| Screening strategya | B-coefficient | β-coefficient | P-value | Adjusted R2 | |
| Death reduction, %b | |||||
| Japan | initiating agesc | −0.696 | −0.771 | 0.000*** | 0.93 |
| terminating agesd | 0.598 | 0.497 | 0.000*** | ||
| United States | initiating ages | −0.401 | −0.473 | 0.000*** | 0.95 |
| terminating ages | 0.900 | 0.797 | 0.000*** | ||
| Average life expectency extension, %b | |||||
| Japan | initiating ages | −1.078 | −0.932 | 0.000*** | 0.93 |
| terminating ages | 0.287 | 0.186 | 0.052 | ||
| United States | initiating ages | −0.829 | −0.835 | 0.000*** | 0.93 |
| terminating ages | 0.526 | 0.398 | 0.002** |
| Location | Number of samples | Standardized mean (μg/m3) | 95% Confidence interval | |
| Bedroom | Urban cement roof | 30 | 116 | 87.8 to 144 |
| Urban tiled roof | 12 | 233 | 133 to 333 | |
| Urban straw roof | 4 | 134 | 109 to 159 | |
| Rural cement roof | 19 | 175 | 134 to 217 | |
| Rural tiled roof | 22 | 125 | 50.6 to 199 | |
| Rural straw roof | 9 | 236 | 120 to 351 | |
| Combined roof urban | 47 | 166 | 117 to 215 | |
| Combined roof rural | 50 | 192 | 135 to 249 | |
| Veranda | Urban | 15 | 592 | 281 to 902 |
| Rural | 16 | 445 | 264 to 627 | |
| School | Urban | 14 | 121 | 82.4 to 160 |
| Rural | 8 | 123 | 37.5 to 209 | |
| Outdoors | Urban | 19 | 131 | 80.7 to 181 |
| Rural | 19 | 202 | 128 to 276 | |
| Kitchen cooking | Biomass together | 21 | 908 | 614 to 1203 |
| Non-biomass | 10 | 175 | 63.2 to 286 | |
| Kitchen no cooking | Biomass | 21 | 438 | − 138 to 1010 |
| Non-biomass | 8 | 213 | − 15.8 to 442 |
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | |
| (1) DAST total | 1 | |||||||
| (2) SMAST total | 0.538** | 1 | ||||||
| (3) DERS total | 0.245** | 0.186** | 1 | |||||
| (4) Victimization | 0.349** | 0.311** | 0.279** | 1 | ||||
| (5) Family rejection | 0.147* | 0.170** | 0.118* | 0.380** | 1 | |||
| (6) Gender | -0.080 | -0.182** | 0.170** | -0.154** | -0.077 | 1 | ||
| (7) Sexual orientation | 0.100 | 0.030 | 0.038 | -0.136* | -0.163** | 0.387** | 1 | |
| (8) Age | -0.021 | 0.088 | -0.254** | 0.022 | 0.094 | -0.325** | -0.208** | 1 |
| Admin1/state | Population | PfPR % 2–9 years | ITN coverage % | Probability of IRS | People pro-tected by IRS | IRS coverage % |
| Abia | 3,680,378 | 37 | 27 | 73% | ||
| Adamawa | 3,914,499 | 31 | 18 | 82% | ||
| Akwa Ibom | 4,859,492 | 40 | 33 | 67% | ||
| Anambra | 5,642,911 | 14 | 24 | 76% | ||
| Bauchi | 5,816,387 | 30 | 19 | 81% | ||
| Bayelsa | 1,938,009 | 19 | 35 | 65% | ||
| Benue | 5,545,269 | 28 | 31 | 69% | ||
| Borno | 5,409,746 | 19 | 17 | 83% | ||
| Cross River | 3,696,053 | 28 | 39 | 61% | ||
| Delta | 5,109,252 | 13 | 25 | 75% | ||
| Ebonyi | 2,673,883 | 26 | 38 | 62% | ||
| Edo | 4,583,326 | 20 | 23 | 77% | ||
| Ekiti | 3,056,399 | 43 | 30 | 70% | ||
| Enugu | 4,238,001 | 14 | 28 | 72% | ||
| FCT - Abuja | 1,569,832 | 33 | 27 | 73% | ||
| Gombe | 2,996,780 | 29 | 19 | 81% | ||
| Imo | 5,025,285 | 34 | 27 | 73% | ||
| Jigawa | 5,648,410 | 19 | 26 | 74% | ||
| Kaduna | 7,933,232 | 46 | 21 | 79% | ||
| Kano | 12,733,799 | 23 | 16 | 84% | 316,255 | 2.5 |
| Katsina | 7,692,509 | 25 | 25 | 75% | ||
| Kebbi | 4,196,653 | 41 | 30 | 70% | ||
| Kogi | 4,107,085 | 28 | 30 | 70% | ||
| Kwara | 3,223,696 | 42 | 30 | 70% | ||
| Lagos | 14,316,546 | 5 | 22 | 78% | ||
| Nassarawa | 2,332,988 | 32 | 26 | 74% | ||
| Niger | 5,207,649 | 41 | 26 | 74% | ||
| Ogun | 4,248,558 | 21 | 36 | 64% | ||
| Ondo | 4,551,442 | 35 | 32 | 68% | ||
| Osun | 4,830,341 | 40 | 26 | 74% | ||
| Oyo | 7,588,162 | 33 | 31 | 69% | ||
| Plateau | 4,071,155 | 27 | 25 | 75% | ||
| Rivers | 6,195,103 | 19 | 30 | 70% | ||
| Sokoto | 4,607,886 | 22 | 19 | 81% | ||
| Taraba | 2,761,408 | 33 | 21 | 79% | ||
| Yobe | 3,067,612 | 20 | 21 | 79% | ||
| Zamfara | 4,501,061 | 32 | 18 | 82% | ||
| Nigeria national | 183,570,791 | 27 | 25 | 316,255 | 0.17 |
| Cultivation | Size distribution after batch [%] | Size distribution after non-induced fed-batch [%] | Size distribution after induced fed-batch [%] | |||
| <15 μm | >15 μm | < 15 μm | > 15 μm | < 15 μm | > 15 μm | |
| DoE1 | 53.0 | 47.0 | 41.5 | 58.5 | 79.8 | 20.2 |
| DoE2 | 56.8 | 43.2 | 64.8 | 35.2 | 79.9 | 20.1 |
| DoE3 | 54.7 | 45.3 | 60.5 | 39.5 | 64.7 | 35.3 |
| DoE4 | 38.3 | 61.7 | 57.1 | 42.9 | 80.6 | 19.4 |
| DoE5 | 53.8 | 46.2 | 74.8 | 25.2 | 73.3 | 26.7 |
| DoE6 | 55.7 | 44.3 | 70.9 | 29.1 | 81.0 | 19.0 |
| DoE7 | 36.3 | 63.7 | 42.5 | 57.5 | 75.8 | 24.2 |
| DoE8 | 40.8 | 59.2 | 47.0 | 53.0 | 71.0 | 29.0 |
| DoE9 | 49.9 | 50.1 | 69.5 | 30.5 | 90.4 | 9.6 |
| DoE10 | 48.2 | 51.8 | 69.4 | 30.6 | 89.1 | 10.9 |
| average | 48.8 ± 7.6 | 51.3 ± 7.6 | 59.8 ± 12.3 | 40.2 ± 12.3 | 78.6 ± 7.8 | 21.4 ± 7.8 |
| wildtype OCH1 strain | 87.5 | 12.5 | 87.3 | 12.7 | 86.5 | 13.5 |
| Weather | ASF (ns) | Error Correction (m) | Statistical Probability of the Error Correction Interval (%) | Error Correction Average (m) | |||
| 0–100 (m) | 100–200 (m) | 200–300 (m) | 300–400 (m) | ||||
| Partly cloudy | 1.93–138 | 0.58–41.54 | 100 | 0 | 0 | 0 | 10.4741 |
| Cloudy | 610–930 | 183.11–279.05 | 0 | 3.33 | 96.67 | 0 | 232.9513 |
| Foggy | 673–1050 | 201.83–316.49 | 0 | 0 | 96.06 | 3.94 | 258.2011 |
| sunny | 583–872 | 174.92–261.5 | 0 | 12.39 | 87.61 | 0 | 218.2041 |
| Abbreviation | Corresponding pathological diagnosis |
| NILM | normal, infection, inflammation, lichen planus, leukoplakia, benign epithelial lesion, etc. |
| LSIL | mild and moderate dysplasia, and SIN1 and SIN2; mentioned in WHO 2005 |
| HSIL | severe dysplasia, carcinoma in situ, and SIN3; mentioned in WHO 2005 |
| SCC | squamous cell carcinoma |
| Other malig. | other malignancy |
| IFN | indefinite for neoplasia or non-neoplasia |
| β | SE | OR | 95% CI for OR | P | ||
| WIM | 0.012 | 0.006 | 1.012 | 1.000, 1.024 | 0.07 | |
| MY | 0.023 | 0.013 | 1.024 | 0.998, 1.050 | 0.04 | |
| Parity | 1st parity1 | - | - | - | - | - |
| 2nd parity | 0.023 | 0.196 | 1.023 | 0.697, 1.501 | 0.91 | |
| > 2nd parity | 0.534 | 0.203 | 1.707 | 1.146, 2.540 | < 0.01 | |
| Intercept | - 1.435 | 0.355 | - | - | < 0.01 |
| Plasmids | β-Galactosidase Activity in units/mg bacteria | Protein Functions |
| Negative Control | ||
| pT18 + pT25 | 412.0 ± 82.4 | pT18: Empty vector |
| Positive Control: | pT25: Empty vector | |
| pT18-PknD + pT25-CdsD-FHA-2 | 996.3 ± 50.0 | FliI: Putative flagellar ATPase |
| Negative Interactions: | FliF: Putative flagellar MS ring protein | |
| pT18-FliI + pT25-FliF | 396.4 ± 32.1 | FlhA: Putative flagellar integral membrane |
| pT18-FliF + pT25-Cpn0859 | 421.1 ± 25.9 | protein |
| pT18-FliI + pT25-Cpn0706 | 404.4 ± 19.5 | Cpn0859: Hypothetical C. pneumoniae |
| pT18-Cpn0706 + pT25-FlhA | 443.0 ± 32.3 | protein |
| Positive Interactions: | Cpn0706: Putative T3S chaperone | |
| pT18-FliF + pT25-FlhA | 847.2 ± 21.2 | CdsL: Putative T3S ATPase tethering |
| pT18-FliI + pT25-FlhA | 942.9 ± 123.1 | protein |
| pT18-FliI + pT25-CdsL | 874.3 ± 59.3 | CopN: Putative T3S plug protein |
| pT18-FliI + pT25-CopN | 943.2 ± 74.2 | Cpn0322: Putative CdsU ortholog |
| pT18-Cpn0322 + pT25-FlhA | 779.9 ± 32.7 | |
| pT18-CdsL + pT25-FlhA | 832.1 ± 23.3 |
| Variables | Univariate analysis | Multivariate analysis | ||||
| HR | 95 % CI | P value | HR | 95 % CI | P value | |
| Age (<50 vs. 50<) | 1.85 | 0.877–3.944 | 0.1055 | |||
| Residual tumor size (>2.0 cm vs. <2.0 cm) | 2.89 | 1.354–6.520 | 0.0059* | 1.37 | 0.593–3.332 | 0.4637 |
| Nodal status after NAC (positive vs. negative) | 4.83 | 2.144–12.29 | <0.0001* | 3.76 | 1.574–10.02 | 0.0024* |
| Grade (III vs. I, II) | 1.45 | 0.460–2.173 | 0.4014 | |||
| Basal-like vs. non basal-like | 1.56 | 0.721–3.635 | 0.2634 | |||
| Ki-67 LI (high vs. low) | 1.78 | 0.839–3.935 | 0.1329 | |||
| Unstained TILs (low vs. high) | 2.38 | 0.709–14.77 | 0.1815 | |||
| CD8 (low vs. high) | 4.75 | 2.106–12.12 | 0.0001* | 3.59 | 1.499–9.581 | 0.0036* |
| CD8 (as a continuous variable)a | 1.01b | 1.004–1.016 | 0.0007* | 1.01b | 1.001–1.015 | 0.0152* |
| FOXP3 (low vs. high) | 1.68 | 0.795–3.699 | 0.1751 | |||
| FOXP3 (as a continuous variable)a | 1.00b | 0.998–1.013 | 0.1412 | |||
| CD8/FOXP3 (low vs. high) | 2.53 | 1.128–6.436 | 0.0233* | 1.28 | 0.526–3.453 | 0.5932 |
| CD8/FOXP3 (as a continuous variable)a | 1.25b | 1.048–1.649 | 0.0077* | 1.11b | 0.953–1.397 | 0.2115 |
| Data set 1 | Data set 2 | Data set 3 | Data set 4 | |||||
| Selection method: | Back | For | Back | For | Back | For | Back | For |
| Slope | ||||||||
| Temperature | + | + | + | + | + | + | + | + |
| Precipitation | ||||||||
| Market influence | + | + | + | + | + | + | + | + |
| Population density | + | |||||||
| Built-up area | + | + | + | + | + | |||
| Distance to roads | ||||||||
| Wetland area | - | - | - | - | - | - | - | - |
| Cropland area | + | + | + | + | ||||
| Organic content | ||||||||
| Regulatory Quality | ||||||||
| ROC | 0.908 | 0.908 | 0.884 | 0.880 | 0.905 | 0.905 | 0.908 | 0.887 |
| Study | Omeprazole 20 mg Events/Treated | Placebo Events/Treated | Log OR | 95% CI | P Value |
| Bond | 93/219 (42.5%) | 57/219 (26.0%) | 0.74 | (0.32 to 1.15), | <.001 |
| Opera | 68/202 (33.7%) | 62/203 (30.5%) | 0.14 | (−0.27 to 0.55) | .252 |
| Anopheline status | Window | Village | |||
| Absent | Present | Low | Mid | High | |
| Fresh fed | |||||
| Mean | 2.49 | 0.89 | 2.58 | 0.84 | 0.55 |
| p | 0.005 | 0.001 | |||
| Half gravid | |||||
| Mean | 0.87 | 0.40 | 0.89 | 0.29 | 0.27 |
| p | 0.053 | 0.013 | |||
| Gravid | |||||
| Mean | 0.68 | 0.38 | 0.72 | 0.25 | 0.18 |
| p | 0.196 | 0.051 | |||
| Unfed | |||||
| Mean | 0.74 | 0.29 | 0.75 | 0.29 | 0.27 |
| p | 0.032 | 0.034 | |||
| Bovine fed | |||||
| Mean | 1.34 | 0.44 | 1.31 | 0.56 | 0.14 |
| p | 0.018 | 0.039 | |||
| Human fed | |||||
| Mean | 1.15 | 0.61 | 1.07 | 0.72 | 0.57 |
| p | 0.036 | 0.234 | |||
| Human and bovine fed | |||||
| Mean | 0.46 | 0.08 | 0.46 | 0.21 | 0 |
| p | 0.008 | 0.065 | |||
| P. vivax positive | |||||
| Mean | 0.09 | 0.03 | 0.09 | 0.03 | 0 |
| p | 0.299 | 0.512 | |||
| P. falciparum positive | |||||
| Mean | 0.01 | 0 | 0.01 | 0 | 0 |
| p | 0.346 | 0.847 |
| Patient no. | 1 | 2 | 3 | 4 | 5 | 6 | 7 |
| Isolated organism | Pseudomonas aeruginosa | Pseudomonas aeruginosa | Pseudomonas aeruginosa | Klebsiella pneumoniae | Klebsiella pneumoniae | Pseudomonas aeruginosa | Pseudomonas aeruginosa |
| Site of isolation | Bronchial secretions | Cerebrospinal fluid | Bronchial secretions | Tip of central venous catheter | Bronchial secretions | Urine | Blood |
| Date of isolation (mo/dd/year) | 08/07/2001 | 07/17/2002 | 07/29/2003 | 01/16/2004 | 01/30/ 2004 | 04/16/ 2004 | |
| Days in the ICU until the isolation of the pandrug-resistant strain | 40 | 62 | 34 | 33 | 52 | 32 | 0 |
| Prior colistin use (days) | 0 | 23 | 11 | 33 | 31 | 6 | 0 |
| Antibiotic combination used after isolation | Colistin + imipenem/ cilastatin, Colistin + meropenem, Colistin + ofloxacin | Two days prior to the isolation, all antibiotics had been stopped | Colistin + meropenem + ofloxacin + gentamicin | Colistin + meropenem | Colistin + ampicillin/sulbactam + trimethoprim/sulfamethoxazole | Colistin + ceftazidime | Piperacillin/tazobactam |
| Dosage/Duration of colistin | 2 million IU q8h iv for 35 days, 1 million IU q8h iv for 17 days | 1 million IU q8h iv for 23 days | 3 million IU q8h iv for 37 days, 1 million IU q8h nebulized for 11 days | 2 million IU q8h iv for 16 days, 1 million IU q8h iv for 12 days, 1 million IU q12h iv for 19 days | 1 million IU q8h iv for 34 days | 2 million IU q8h in for 35 days, 1 million IU q8h iv for 17 days | 2.25 gr q8h iv for 10 days |
| Outcome of the infection | Cure (clinical + microbiological). | No response.Patient died due to meningitis. | Cure (clinical + microbiological). | Clinical cure (microbiological persistence for 1 month). | Deterioration.Superinfection of the respiratory tract by an Acinetobacter baumannii strain. Patient died due to sepsis. | Cure (clinical + microbiological). | Cure (clinical + microbiological). |
| Gene | Chr | Start | Stop | Nb SNP | Fat | Fat % | Milk | Protein | Prot % |
| AKT2 | 18 | 49804012 | 50050072 | 55 | 0.38 | 0.31 | 0.13 | 0.20 | 0.11 |
| CSN1S1 | 6 | 87041556 | 87259096 | 98 | 0.07 | 0.18 | 0.05 | 0.09 | 0.22 |
| CSN2 | 6 | 87079502 | 87288025 | 58 | 0.40 | 0.59 | 0.83 | 0.78 | 0.90 |
| CISH | 22 | 50220205 | 50425617 | 38 | 0.21 | 0.00 | 0.21 | 0.24 | 0.32 |
| RAF1 | 22 | 57022412 | 57304951 | 115 | 0.34 | 0.06 | 0.47 | 0.52 | 0.01 |
| ELF5 | 15 | 65724442 | 65954386 | 80 | 0.25 | 0.40 | 0.30 | 0.34 | 0.18 |
| ERBB4 | 2 | 99560620 | 100097642 | 71 | 0.35 | 0.20 | 0.37 | 0.42 | 0.14 |
| ESR1 | 9 | 89869586 | 90355801 | 103 | 0.21 | 0.19 | 0.33 | 0.38 | 0.13 |
| GAL | 29 | 46659818 | 46865617 | 59 | 0.15 | 0.29 | 0.07 | 0.31 | 0.37 |
| GATA3 | 13 | 15884602 | 16102940 | 29 | 0.21 | 0.14 | 0.24 | 0.24 | 0.17 |
| IGF2 | 29 | 49946626 | 50165230 | 27 | 0.37 | 0.04 | 0.30 | 0.22 | 0.15 |
| IL6 | 4 | 31478311 | 31682667 | 25 | 0.40 | 0.00 | 0.24 | 0.36 | 0.00 |
| IRS1 | 2 | 115690540 | 115894253 | 22 | 0.18 | 0.32 | 0.14 | 0.41 | 0.09 |
| JAK2 | 8 | 39531342 | 39850796 | 32 | 0.28 | 0.47 | 0.63 | 0.56 | 0.44 |
| NR3C1 | 7 | 56131970 | 56450496 | 65 | 0.63 | 0.37 | 0.28 | 0.52 | 0.43 |
| PRL | 23 | 35005135 | 35213759 | 53 | 0.19 | 0.04 | 0.11 | 0.19 | 0.36 |
| PRLR | 20 | 38973246 | 39237480 | 56 | 0.48 | 0.61 | 0.50 | 0.25 | 0.82 |
| PTH | 15 | 39628332 | 39830868 | 31 | 0.23 | 0.06 | 0.58 | 0.19 | 0.26 |
| SOCS1 | 25 | 9875299 | 10075970 | 56 | 0.30 | 0.00 | 0.16 | 0.32 | 0.00 |
| SOCS2 | 5 | 23423981 | 23628860 | 46 | 0.28 | 0.67 | 0.59 | 0.52 | 0.67 |
| SOCS3 | 19 | 54358856 | 54559555 | 62 | 0.44 | 0.21 | 0.18 | 0.40 | 0.50 |
| GH1 | 19 | 48668618 | 48872014 | 73 | 0.08 | 0.16 | 0.32 | 0.26 | 0.34 |
| STAT3 | 19 | 42956660 | 43232624 | 58 | 0.43 | 0.84 | 0.53 | 0.78 | 0.84 |
| STAT5A | 19 | 42933597 | 43154075 | 59 | 0.36 | 0.85 | 0.61 | 0.75 | 0.80 |
| STAT5B | 19 | 42860226 | 43096671 | 60 | 0.10 | 0.83 | 0.78 | 0.55 | 0.80 |
| TNFRSF11A | 24 | 61139109 | 61375194 | 65 | 0.15 | 0.08 | 0.03 | 0.02 | 0.18 |
| TNFSF11 | 12 | 12641069 | 12882474 | 73 | 0.33 | 0.56 | 0.05 | 0.08 | 0.51 |
| N = 27 | 1569 | 458 | 519 | 571 | 636 | 628 |
| Parameter | ST-21 complex | ST-45 complex | ST-828 complex |
| Substitution rate (10−3 per site per τ) | 2.815 (1.950, 3.560) | 3.715 (2.315, 5.158) | 9.582 (8.019, 11.534) |
| TMRCA | |||
| Coalescent time, τ | 1.022 (0.442, 3.068) | 0.709 (0.288, 2.583) | 0.159 (0.110, 0.232) |
| Yearsa | 89.069 (38.521, 267.381) | 81.545 (33.124, 297.085) | 47.168 (32.632, 68.824) |
| Host switching rate | |||
| Per τ | 54.078 (10.089,97.519) | 61.634 (14.540, 98.069) | 23.491 (6.802, 85.357) |
| Per yeara | 0.621 (0.116, 1.119) | 0.536 (0.126, 0.853) | 0.079 (0.023, 0.287) |
| Number of migrations | 588.89 (109.80, 1325.90) | 468.67 (105.70, 1264.48) | 117.691 (36.558, 456.318) |
| Estimated host frequencies | |||
| Chicken | 0.614 (0.388, 0.809) | 0.498 (0.311, 0.685) | 0.425 (0.136, 0.691) |
| Cattle | 0.386 (0.191, 0.612) | 0.348 (0.185, 0.540) | 0.282 (0.095, 0.562) |
| Wild bird | — | 0.140 (0.0429, 0.313) | — |
| Pig | — | — | 0.270 (0.103, 0.545) |
| Relative migration rates between host species | |||
| Chicken–cattle | 0.695 (0.023, 3.705) | 0.820 (0.051, 3.779) | 0.303 (0.010, 2.139) |
| Chicken–wild bird | — | 0.592 (0.021, 3.282) | — |
| Chicken–pig | — | — | 0.581 (0.024, 3.129) |
| Cattle–wild bird | — | 0.728 (0.031, 3.643) | — |
| Cattle–pig | — | — | 1.367 (0.192, 4.783) |
| Coeff | Std Err | p-value | 95 % Confidence interval | |
| Frailty score | ||||
| Age | 0.04 | 0.06 | 0.49 | −0.07–0.16 |
| Gender | 1.28 | 0.55 | 0.02 | 0.21–2.36 |
| Smoking | 0.07 | 0.78 | 0.94 | −1.50–1.62 |
| iADL | −0.10 | 0.08 | 0.22 | −0.26–0.06 |
| Fish intake | 0.04 | 0.53 | 0.94 | −0.99–1.08 |
| HDL | −0.05 | 0.30 | 0.86 | −0.63–0.53 |
| TG | 0.33 | 0.54 | 0.55 | −0.74–1.39 |
| CDR-SB | −0.31 | 0.39 | 0.43 | −1.08–0.46 |
| Population | Location | Insecticide | N | % Mortality [Cl95] | Resistance status |
| Sites | |||||
| Banikoara | West-North | DDT | 100 | 4 [−3.68-11.68] | R |
| Permethrin | 100 | 4 [−3.68-11.68] | R | ||
| Deltamethrin | 100 | 28 [10.40- 45.60] | R | ||
| Bendiocarb | 100 | 52 [32.42- 71.58] | R | ||
| Kandi | West-North | DDT | 100 | 12 [− 0.74-24.74] | R |
| Permethrin | 100 | 20 [4.32- 35.68] | R | ||
| Deltamethrin | 100 | 24 [24.54- 63.46] | R | ||
| Bendiocarb | 100 | 72 [54.40- 89.60] | R | ||
| Natitingou | East-North | DDT | 100 | 12 [− 0.74-24.74] | R |
| Permethrin | 100 | 24 [7.26- 40.74] | S | ||
| Deltamethrin | 100 | 48 [28.42- 67.58] | R | ||
| Bendiocarb | 100 | 76 [59.26- 92.74] | R | ||
| Houeyiho | South | DDT | 100 | 8 [−2.63 -18.63] | R |
| Permethrin | 100 | 8 [−2.63 -18.63] | R | ||
| Deltamethrin | 100 | 32 [13.71- 50.29] | R | ||
| Bendiocarb | 100 | 60 [40.80- 79.20] | R | ||
| Cx. SLAB | DDT | 100 | 100 | S | |
| Permethrin | 100 | 100 | S | ||
| Deltamethrin | 100 | 99 | S | ||
| Bendiocarb | 100 | 99 | S |
| Year | Campus | |||
| Maraki N (%) | CMHS N (%) | Atse Theodros N (%) | Total N (%) | |
| 2007 | 28 (84.8) | 5 (15.2) | 0 (0) | 33 (100) |
| 2008 | 18 (56.2) | 13 (40.6) | 1 (3.1) | 32 (100) |
| 2009 | 11 (35.5) | 11 (35.5) | 9 (29) | 31 (100) |
| 2010 | 10 (25.6) | 21 (53.8) | 8 (20.5) | 39 (100) |
| 2011 | 16 (34.8) | 18 (39.1) | 12 (26.1) | 46 (100) |
| Total | 83 (45.9) | 68 (37.6) | 30 (16.6) | 181 (100) |
| Category | n | Concentration (Mean (Range)) | ||||
| Pb (ug·L−1) | Cd (ug·L−1) | Zn (mg·L−1) | As (ug·L−1) | Hg (ug·L−1) | ||
| Water source | ||||||
| Open wells | 2 | 0.06 (BDL–0.18) | 0.029 (BDL–0.054) | 0.115 (0.018–0.306) | 0.568 (0.034–1.247) | 0.081 (0.048–0.13) |
| Hand-pressed wells | ||||||
| Depth < 3m | 4 | 3.51 (BDL–10.53 *) | 0.227 (BDL–0.53) | 0.026 (0.004–0.056) | 3.209 (0.262–4.683) | 0.070 (0.060–0.076) |
| Depth = 3~6 m | 4 | BDL | 0.02 (BDL–0.076) | 0.027 (0.022–0.039) | 1.824 (BDL–5.802) | 0.074 (0.030–0.106) |
| Depth > 6 m | 4 | BDL | 0.126 (BDL–0.35) | 0.0195 (0.006–0.033) | 2.582 (0.059–6.428) | 0.047 (BDL–0.106) |
| Spring water | 1 | BDL | BDL | 0.027 | 0.000 | 0.051 |
| Tap water | 1 | BDL | BDL | 0.025 | BDL | BDL |
| Barreled water | 1 | BDL | BDL | 0.030 | BDL | BDL |
| Villages | ||||||
| MaTian | 9 | 0.824(BDL~10.53 *) | 0.098(BDL–0.53) | 0.045 (0.004–0.306) | 2.227 (0.034–6.428) ** | 0.069 (BDL–0.13) |
| ZhuDui | 6 | BDL | 0.0860(BDL–0.18) | 0.026 (0.02–0.03) | 0.316 (BDL–0.947) | 0.0520 |
| Chinese drinking water standard (GB5749-2006) | 10 (ug·L−1) | 5 (ug·L−1) | 1(mg·L−1) | 50 (ug·L−1) | 1 (ug·L−1) |
| Author | Year | Study location | Patient(male/female) | Age | Antibody source | Dilution | Method | Definition of abnormal β-catenin expression | Hazard ratio source | HR(95% CI) |
| Qiao et al. | 2001 | Germany | 43(23/20) | 61.1(42–83) | Transduction Laboratories | 1:100 | IHC | Cytoplasma | Calculated | 6.26(1.52–25.76) |
| Watanabe et al. | 2003 | Japan | 23(14/9) | 58.1(25–85) | Transduction Laboratories | 1:100 | IHC | Membranous reduced | Primary article | 1.71(0.44–6.69) |
| Wang et al. | 2013 | China | 36(25/11) | 58.5(34–76) | Santa Cruz | 1:200 | IHC | Positive cell | Primary article | 2.10(0.77–5.72) |
| Arensman et al. | 2014 | USA | 41(NR) | NR | NR | NR | IHC | Cytoplasma or nuclea | Primary article | 3.16(1.19–8.40) |
| Wu et al. | 2015 | China | 58(37/21) | 65(21–80) | Santa Cruz | 1:100 | IHC | Nuclear expression | Calculated | 6.89(2.96–16.03) |
| Variable | n (%) responders* |
| Risk behaviour (multiple responses allowed), referenced to time and location as below | |
| Unprotected anal intercourse | |
| Without ejaculation | |
| insertive | 48 (11.9) |
| receptive | 26 (6.5) |
| With ejaculation | |
| insertive | 35 (8.7) |
| receptive | 23 (5.7) |
| Condom failure | |
| insertive | 21 (5.2) |
| receptive | 14 (3.5) |
| Unprotected vaginal intercourse | |
| Without ejaculation | 30 (7.5) |
| With ejaculation | 43 (10.7) |
| Condom failure | 19 (4.7) |
| Oral uptake of body fluids (blood, sperm) | 75 (18.7) |
| Other risk behaviour | 39 (9.7) |
| Risk situations | |
| Partners involved in the risk situation (multiple responses allowed) | |
| Steady partner | 79 (19.7) |
| Casual partner | 100 (24.9) |
| Anonymous partner | 148 (36.8) |
| HIV serostatus of involved partners | |
| Positive serostatus | 28 (7.0) |
| Negative serostatus | 107 (26.6) |
| Serostatus unknown | 190 (47.3) |
| Location of risk situation | |
| Privat location (at home) | 172 (42.8) |
| Bathhouse/Darkroom | 52 (12.9) |
| Park/cruising area | 19 (4.7) |
| Private party | 10 (2.5) |
| Other location | 42 (10.4) |
| Time of risk situation | |
| 0 – 3 days ago | 21 (5.2) |
| 4 – 14 days ago | 30 (7.5) |
| 15 days – 3 months ago | 109 (27.1) |
| 3 – 6 months ago | 93 (23.1) |
| > 6 months ago | 52 (12.9) |
| Model type | Volume [mL] |
| Analytical model | 6.51 |
| Model reconstructed from CT imagining | 6.65 |
| Model reconstructed from 3D scanning | 6.65 |
| Value of the measurement error | 0.14 |
| Physical functioning | Physical role | Bodily pain | General health | Vitality | Social functioning | Emotional role | Mental health | |
| Persistence of disability | ||||||||
| Educational attainment | 0.88*(0.77 to 0.98) | 0.96(0.85 to 1.08) | 0.89(0.79 to 1.01) | 0.82**(0.72 to 0.93) | 1.00(0.88 to 1.13) | 1.05(0.93 to 1.17) | 0.99(0.89 to 1.11) | 0.93(0.82 to 1.06) |
| Family income | 0.92**(0.87 to 0.98) | 0.95(0.90 to 1.01) | 0.97(0.92 to 1.03) | 0.94*(0.89 to 0.99) | 0.92**(0.87 to 0.98) | 0.91**(0.86 to 0.96) | 0.92**(0.87 to 0.98) | 0.90**(0.84 to 0.95) |
| Unemployment | 1.39(0.68 to 2.82) | 1.96*(1.04 to 3.68) | 1.42(0.66 to 3.05) | 1.33(0.79 to 2.23) | 2.57*(1.06 to 6.24) | 1.48(0.64 to 3.40) | 1.02(0.44 to 2.34) | 1.68(0.57 to 4.93) |
| Physical health conditions | 4.00***(2.29 to 6.97) | 5.11***(2.96 to 8.80) | 4.87***(2.71 to 8.73) | 2.25**(1.35 to 3.75) | 3.34***(1.75 to 6.38) | 1.77*(1.06 to 2.98) | 2.29*(1.20 to 4.37) | 1.58(0.86 to 2.88) |
| Mental health conditions | 1.10(0.69 to 1.75) | 0.84(0.53 to 1.33) | 1.12(0.74 to 1.69) | 1.20(0.84 to 1.72) | 0.63(0.36 to 1.08) | 1.19(0.75 to 1.87) | 1.17(0.73 to 1.88) | 1.04(0.62 to 1.75) |
| Severity of depression | 1.03(0.86 to 1.23) | 1.09(0.93 to 1.27) | 1.11(0.93 to 1.32) | 1.32**(1.12 to 1.55) | 1.20(0.99 to 1.46) | 1.40***(1.18 to 1.66) | 1.28*(1.03 to 1.58) | 1.25*(1.03 to 1.52) |
| Seeking help for major depression | 2.01**(1.19 to 3.38) | 1.73**(1.16 to 2.58) | 1.52(0.96 to 2.42) | 1.57*(1.05 to 2.36) | 1.71(0.96 to 3.03) | 1.43(0.88 to 2.32) | 1.80*(1.04 to 3.10) | 1.48(0.82 to 2.65) |
| Incidence of disability | ||||||||
| Educational attainment | 0.78*(0.64 to 0.96) | 0.92(0.73 to 1.17) | 0.91(0.73 to 1.14) | 0.70*(0.54 to 0.92) | 0.83(0.62 to 1.11) | 0.82(0.64 to 1.05) | 0.78(0.57 to 1.07) | 0.65*(0.45 to 0.95) |
| Family income | 0.98(0.89 to 1.07) | 0.94(0.84 to 1.06) | 0.98(0.88 to 1.10) | 1.01(0.87 to 1.16) | 1.03(0.89 to 1.19) | 0.86*(0.74 to 0.98) | 1.08(0.92 to 1.25) | 1.03(0.87 to 1.21) |
| Unemployment | 3.98*(1.05 to 15.07) | 1.24(0.25 to 6.26) | 0.95(0.14 to 6.26) | 1.55(0.17 to 14.17) | 12.87*(1.15 to 144.69) | 0.40(0.08 to 1.98) | 0.11(0.01 to 1.58) | 0.15(0.01 to 4.42) |
| Physical health conditions | 3.13*(1.01 to 9.78) | 0.92(0.14 to 5.99) | 2.54(0.58 to 11.10) | 4.80*(1.30 to 17.71) | 14.66*(1.12 to 192.35) | 6.38*(1.42 to 28.67) | 4.19(0.68 to 25.93) | 1.19(0.26 to 5.50) |
| Mental health conditions | 1.51(0.55 to 4.14) | 0.80(0.29 to 2.20) | 1.15(0.45 to 2.97) | 1.21(0.40 to 3.71) | 2.09(0.62 to 7.04) | 1.13(0.31 to 4.08) | 0.51(0.15 to 1.67) | 1.60(0.33 to 7.67) |
| Severity of depression | 0.74(0.50 to 1.09) | 0.97(0.62 to 1.51) | 0.89(0.63 to 1.27) | 0.79(0.54 to 1.15) | 1.30(0.80 to 2.10) | 1.07(0.63 to 1.80) | 1.20(0.84 to 1.73) | 0.69(0.43 to 1.12) |
| Seeking help for major depression | 0.60(0.20 to 1.75) | 0.73(0.21 to 2.50) | 1.54(0.51 to 4.69) | 0.98(0.26 to 3.71) | 0.58(0.11 to 3.05) | 1.73(0.49 to 6.07) | 4.85(0.70 to 33.60) | 6.81**(1.83 to 25.43) |
| Outcome | Dhaka (%) | Raipur (%) | Nabiganj (%) | |||
| Base n = 5,477 | End n = 5,670 | Base n = 6,433 | End n = 6,211 | Base n = 6,288 | End n = 6,419 | |
| Received ANC | 82.5 | 80.8 | 77.9 | 80.6* | 43.9 | 57.1* |
| Received PNC | 37.1 | 89.8* | 39.7 | 89.0* | 33.7 | 87.3* |
| Variable | Model | OR | CI 95% | LRT | DF | p-value | AIC | |
| No additional variables (weight + habitat) | 567.9 | |||||||
| Bioclimat | Subarid | 1 | 5.5 | 3 | 0.14 | 568.4 | ||
| Dry | 7.15 | 1–51.26 | ||||||
| Humid | 8.34 | 1.22–56.83 | ||||||
| Subhumid | 6.24 | 1–38.79 | ||||||
| Season | 1.24 | 0.39–3.88 | 0.13 | 1 | 0.72 | 569.8 | ||
| Rural/Urban | 1.03 | 0.35–2.97 | 0.002 | 1 | 0.96 | 570.2 | ||
| Rattus rattus (Rr) abundance | Rr caught within houses | Linear | 0.83 | 0.51–1.36 | 0.53 | 1 | 0.47 | 569.4 |
| Non-linear | 1.22 | 0.78–1.93 | 0.72 | 1 | 0.4 | 570.7 | ||
| Rr caught outside trap lines | Linear | 1.18 | 0.7–1.99 | 0.39 | 1 | 0.53 | 569.5 | |
| Non-linear | 1.08 | 0.62–1.9 | 0.08 | 1 | 0.73 | 571.5 | ||
| Shannon diversity index | Linear | 1 | 0.63–1.59 | 0.00 | 1 | 1 | 569.9 | |
| Non-linear | 1.08 | 0.62–1.9 | 0.21 | 1 | 0.65 | 571.7 | ||
| Evenness diversity index | Linear | 0.84 | 0.49–1.41 | 0.45 | 1 | 0.5 | 569.5 | |
| Non-linear | 0.92 | 0.58–1.47 | 0.12 | 1 | 0.73 | 571.45 | ||
| Mean annual temperature | Linear | 1.11 | 0.66–1.87 | 0.15 | 1 | 0.7 | 569.8 | |
| Non-linear | 1.09 | 0.61–1.95 | 0.09 | 1 | 0.76 | 571.7 | ||
| Mean diurnal range in temperature | Linear | 0.56 | 0.33–0.96 | 4.53 | 1 | 0.03 | 565.4 | |
| Non-linear | 0.58 | 0.31–1.09 | 3.19 | 1 | 0.07 | 564.2 | ||
| Temperature seasonality | Linear | 0.6 | 0.36–1.01 | 3.67 | 1 | 0.06 | 566.3 | |
| Non-linear | 0.6 | 0.28–1.26 | 1.79 | 1 | 0.18 | 566.5 | ||
| Annual precipitation | Linear | 2 | 1.28–3.12 | 8.67 | 1 | 0.003 | 561.3 | |
| Non-linear | 0.75 | 0.54–1.04 | 3.22 | 1 | 0.07 | 560.0 | ||
| Precipitation seasonality | Linear | 0.8 | 0.47–1.36 | 0.67 | 1 | 0.41 | 569.3 | |
| Non-linear | 1.02 | 0.53–1.97 | 0.004 | 1 | 0.95 | 571.3 | ||
| Precipitation of driest quarter | Linear | 1.45 | 0.89–2.37 | 2.16 | 1 | 0.14 | 567.8 | |
| Non-linear | 1.05 | 0.49–2.23 | 0.02 | 1 | 0.9 | 569.7 | ||
| PCA Axis 1 (F1) | Linear | 1.31 | 1.02–1.68 | 4.36 | 1 | 0.04 | 565.6 | |
| Non-linear | 0.82 | 0.69–0.98 | 5.21 | 1 | 0.02 | 562.4 | ||
| PCA Axis 2 (F2) | Linear | 1.08 | 0.71–1.66 | 0.13 | 1 | 0.72 | 569.8 | |
| Non-linear | 1.16 | 0.8–1.68 | 0.61 | 1 | 0.43 | 571.2 |
| Treatment | Dose | No. of writhing (10 min) |
| Saline | 10 ml/kg | 64.80 ± 1.77 |
| Diclofenac sodium | 10 mg/kg | 10.40 ± 0.98** |
| Au-EM | 10 mg/kg | 29.57 ± 2.97** |
| 20 mg/kg | 19.89 ± 3.98** |
| Variable | Level | Number of observations |
| Lame leg position | 1=Right front | 2 |
| 2=Right hind | 22 | |
| 3=Left front | 3 | |
| 4=Left hind | 16 | |
| Locomotion score | 0=Negative (<2) | 10 |
| 1=Positive (≥2) | 33 | |
| CMT score | 0=Negative (<3) | 19 |
| 1=Positive (≥3) | 24 | |
| Body condition score | 0=Negative (<3) | 12 |
| 1=Positive (≥3) | 31 |
| child's weight status | |||||
| Variables | Obese(n = 140) | Normal wt (n = 140) | p-value (χ2-test) | OR | 95%CI for OR |
| Percentage | Percentage | ||||
| Parental nutritional status | |||||
| Father | |||||
| Normal wt | 22.9 | 40.0 | <0.05 | 1.0 | |
| Obese | 77.1 | 60.0 | 2.2 | 1.1-3.3 | |
| Mother | |||||
| Normal wt | 45.7 | 65.7 | <0.05 | 1.0 | |
| Obese | 54.3 | 34.3 | 2.0 | 1.2-3.3 | |
| Home environment | |||||
| Good | 8.6 | 18.6 | 0.03 | 1.0 | |
| Moderate | 42.9 | 44.3 | 2.1 | 1.0-4.5 | |
| Poor | 48.6 | 37.1 | 2.8 | 1.3-6.1 | |
| Television viewing time | |||||
| <2 hours/day | 25.7 | 48.6 | <0.05 | 1.0 | |
| ≥2 hours/day | 74.3 | 51.4 | 2.7 | 1.7-4.5 | |
| Eating habits | <0.05 | ||||
| High | 34.3 | 50.7 | 1.0 | ||
| Moderate | 60.7 | 46.4 | 1.9 | 1.2-3.12 | |
| Low | 5.0 | 2.9 | 2.5 | 0.7-9.3 | |
| Managing expenses | <0.05 | ||||
| High | 17.1 | 27.1 | 1.0 | ||
| Moderate | 65.0 | 64.3 | 1.6 | 0.9-2.9 | |
| Low | 17.9 | 8.6 | 3.3 | 1.4-7.8 | |
| Time management | <0.05 | ||||
| High | 8.6 | 42.9 | 1.0 | ||
| Moderate | 65.0 | 47.1 | 3.8 | 2.2-6.6 | |
| Low | 17.9 | 10.0 | 1.8 | 0.8-4.7 |
| Patient No. | Diagnosis | Reason |
| 1 | cerebral hemorrhage | coma, LTMV |
| 2 | high paraplegia | LTMV |
| 3 | high paraplegia | LTMV |
| 4 | HIE | coma, LTMV |
| 5 | cerebral hemorrhage | coma, cerebral hernia |
| 6 | Guillain-Barre | LTMV |
| 7 | cerebral infarction | coma, LTMV |
| 8 | severe thoracic wound | sedation, LTMV |
| 9 | cerebral hemorrhage | coma, dyspnea |
| 10 | pulmonary heart disease | LTMV |
| 11 | refractory heart failure | LTMV |
| 12 | refractory heart failure | LTMV |
| 13 | tetanus | NMBAs, LTMV |
| 14 | cerebral infarction | LTMV |
| 15 | cardiogenic shock | LTMV |
| 16 | cerebral hemorrhage | coma, dyspnea |
| 17 | AMI | LTMV |
| 18 | high paraplegia | LTMV |
| 19 | HIE | coma, LTMV |
| 20 | cerebral infarction | LTMV |
| 21 | tetanus | NMBAs, LTMV |
| 22 | cerebral hemorrhage | coma, dyspnea |
| 23 | cardiogenic shock | LTMV |
| 24 | pulmonary heart disease | LTMV |
| 25 | HIE | coma, LTMV |
| 26 | HIE | sedation, LTMV |
| 27 | cerebral hemorrhage | glossocoma, coma, LTMV |
| 28 | Guillain-Barre | LTMV |
| 29 | severe thoracic wound | sedation, LTMV |
| 30 | refractory heart failure | LTMV |
| 31 | cerebral infarction | glossocoma, LTMV |
| 32 | severe thoracic wound | sedation, LTMV |
| 33 | traumatic brain injury | sedation, LTMV |
| 34 | cerebral hemorrhage | coma, dyspnea |
| 35 | high paraplegia | LTMV |
| 36 | respiratory failure | LTMV |
| 37 | tetanus | NMBAs, LTMV |
| 38 | cerebral infarction | LTMV |
| Number | Frequency (Hz) | Amplitude (mm) | Measuring Distance (m) | Operating Mode |
| V-1 | 8 | ±4 | 1.0 | Sine-wave |
| V-2 | 8 | ±4 | 2.0 | Sine-wave |
| V-3 | 8 | ±4 | 3.0 | Sine-wave |
| V-4 | 8 | ±4 | 4.0 | Sine-wave |
| V-5 | 8 | ±4 | 5.0 | Sine-wave |
| V-6 | 8 | ±4 | 6.0 | Sine-wave |
| V-7 | 8 | ±4 | 7.0 | Sine-wave |
| V-8 | 8 | ±4 | 8.0 | Sine-wave |
| V-9 | 8 | ±4 | 9.0 | Sine-wave |
| V-10 | 8 | ±4 | 10.0 | Sine-wave |
| V-11 | 8 | ±4 | 11.0 | Sine-wave |
| V-12 | 8 | ±4 | 12.0 | Sine-wave |
| Response | After IC 2 cycles (%)(n=30) | After IC 4 cycles (%)(n= 19) | After CCRT (%)(n=19) |
| CR | 1 (3) | 1 (5) | 3 (16) |
| PR | 18 (60) | 18 (95) | 14 (74) |
| SD | 8 (27) | - | 2 (10) |
| PD | 3 (10) | - | - |
| Slow waves | ||||||
| Frequency cycles/min | Amplitude mV | Conduction velocity cm/s | ||||
| Mean | Range | Mean | Range | Mean | Range | |
| Healthy volunteers | 1.6 ± 0.5 | 1.3–2.1 | 0.12 ± 0.01 | 0–0.2 | 1.6 ± 0.3 | 1.2–2.1 |
| ED group | 1.4 ± 0.3 | 1.1–1.7 | 0.15 ± 0.02 | 0.11–0.21 | 1.3 ± 0.06 | 1.1–1.6 |
| Subcategory | Exposed | Non-exposed | Total | P value | OR (95% CI) | |||
| n | Percent | n | Percent | n | Percent | |||
| Demographics (N = 92) | ||||||||
| Santa Marta | 61 | 83.6 | 7 | 36.8 | 68 | 73.9 | < 0.001* | 8.71 (2.85–26.68) |
| Age less than or equal to 25 years† | 41 | 56.2 | 5 | 26.3 | 46 | 50.0 | 0.038* | 3.59 (1.17–11.01) |
| Male | 43 | 58.9 | 8 | 42.1 | 51 | 55.4 | 0.207 | 1.97 (0.71–5.48) |
| Household characteristics | ||||||||
| More than five people living in household (N = 92) | 52 | 71.2 | 8 | 42.1 | 60 | 65.2 | 0.029* | 3.41 (1.20–9.65) |
| Own pets/livestock (N = 91) | 63 | 87.5 | 17 | 89.5 | 80 | 87.9 | 1 | 0.82 (0.16–4.17) |
| Own dogs (N = 91) | 24 | 33.3 | 11 | 57.9 | 35 | 38.5 | 0.065 | 0.36 (0.13–1.02) |
| Any pets/livestock bitten by bats (N = 79) | 53 | 84.1 | 6 | 37.5 | 59 | 74.7 | < 0.001* | 8.83 (2.62–29.83) |
| Activities | ||||||||
| Lived in this house less than 1 year (N = 73) | 7 | 13.0 | 8 | 42.1 | 15 | 20.5 | 0.017* | 0.20 (0.06–0.69) |
| More than 5 years living/working with bats (N = 53) | 12 | 32.4 | 2 | 12.5 | 14 | 26.4 | 0.183 | 3.36 (0.66–17.21) |
| Reported hunting bats (N = 70) | 6 | 11.8 | 1 | 5.3 | 7 | 10.0 | 0.665 | 2.40 (0.27–21.37) |
| Reported agriculture (N = 70) | 43 | 84.3 | 17 | 89.5 | 60 | 85.7 | 0.717 | 0.63 (0.12–3.29) |
| Reported using a mosquito net (N = 70) | 37 | 72.5 | 14 | 73.7 | 51 | 72.9 | 1 | 0.94 (0.29–3.11) |
| Education (N = 76) | ||||||||
| Secondary or above | 11 | 19.3 | 3 | 15.8 | 14 | 18.4 | 1 | 1.28 (0.32–5.16) |
| Knowledge (N = 70) | ||||||||
| Reported having basic or no rabies knowledge | 51 | 100.0 | 19 | 100.0 | 70 | 100.0 | NA‡ | NA |
| Indicated animal bites as mechanism of transmission | 11 | 21.6 | 5 | 26.3 | 16 | 22.9 | 0.752 | 0.77 (0.23–2.61) |
| Described rabies as severe | 19 | 37.3 | 8 | 42.1 | 27 | 38.6 | 0.785 | 0.82 (0.28–2.39) |
| Identified bats as a rabies source | 8 | 15.7 | 4 | 21.1 | 12 | 17.1 | 0.723 | 0.70 (0.18–2.65) |
| Identified dogs as a rabies source | 16 | 31.4 | 9 | 47.4 | 25 | 35.7 | 0.266 | 0.51 (0.17–1.49) |
| If bitten by a bat (N = 70) | ||||||||
| Wash with soap and water | 5 | 9.8 | 0 | 0.0 | 5 | 7.1 | 0.314 | NA |
| Seek medical care | 10 | 19.6 | 6 | 31.6 | 16 | 22.9 | 0.343 | 0.53 (0.16–1.74) |
| Do not know or do nothing | 30 | 58.8 | 7 | 36.8 | 37 | 52.9 | 0.116 | 2.45 (0.83–7.26) |
| Other | 6 | 11.8 | 6 | 31.6 | 12 | 17.1 | 0.074 | 0.29 (0.08–1.05) |
| If bitten by a rabid animal (N = 70) | ||||||||
| Wash with soap and water | 2 | 3.9 | 0 | 0.0 | 2 | 2.9 | 1 | NA |
| Seek medical care | 16 | 31.4 | 10 | 52.6 | 26 | 37.1 | 0.163 | 0.41 (0.14–1.21) |
| Do not know or do nothing | 33 | 64.7 | 7 | 36.8 | 40 | 57.1 | 0.056 | 3.14 (1.05–9.39) |
| Other | 0 | 0.0 | 1 | 5.3 | 1 | 1.4 | 0.195 | 0.18 (0.09–0.34) |
| Vaccinated against rabies (N = 92) | ||||||||
| Post-exposure prophylaxis (bat exposure) | 1 | 1.4 | 1 | 5.3 | 2 | 2.2 | 0.372 | 0.25 (0.015–4.19) |
| Pre-exposure prophylaxis (military service) | 1 | 1.4 | 0 | 0.0 | 1 | 1.1 | 1 | NA |
| Both sexes (95% CI) | Male (95% CI) | Female (95% CI) | |
| All ages | |||
| 1990 | 0.092 (0.091, 0.094) | 0.087 (0.086, 0.088) | 0.097 (0.096, 0.099) |
| 1995 | 0.097 (0.096, 0.099) | 0.092 (0.090, 0.095) | 0.101 (0.100, 0.103) |
| 0–14 years | |||
| 1990 | 0.048 (0.047, 0.049) | 0.049 (0.048, 0.051) | 0.046 (0.044, 0.048) |
| 1995 | 0.049 (0.048, 0.050) | 0.052 (0.050, 0.054) | 0.046 (0.044, 0.048) |
| 15–24 years | |||
| 1990 | 0.056 (0.054, 0.059) | 0.053 (0.050, 0.056) | 0.059 (0.056, 0.062) |
| 1995 | 0.060 (0.058, 0.062) | 0.056 (0.053, 0.059) | 0.063 (0.060, 0.066) |
| 25–44 years | |||
| 1990 | 0.072 (0.071, 0.074) | 0.069 (0.067, 0.071) | 0.075 (0.073, 0.077) |
| 1995 | 0.079 (0.077, 0.081) | 0.076 (0.074, 0.079) | 0.082 (0.079, 0.084) |
| 45–64 years | |||
| 1990 | 0.127 (0.124, 0.130) | 0.126 (0.122, 0.131) | 0.127 (0.124, 0.131) |
| 1995 | 0.132 (0.128, 0.138) | 0.130 (0.123, 0.137) | 0.134 (0.130, 0.140) |
| 65+ years | |||
| 1990 | 0.183 (0.178, 0.188) | 0.172 (0.166, 0.178) | 0.190 (0.184, 0.196) |
| 1995 | 0.183 (0.174, 0.188) | 0.174 (0.166, 0.183) | 0.189 (0.177, 0.197) |
| Characteristic | Description | N (%) |
| Gender | ||
| Male | 17 (44.7) | |
| Female | 21 (55.3) | |
| Age (years) | ||
| 30–39 | 7 (18.4) | |
| 40–49 | 6 (15.8) | |
| 50–59 | 16 (42.1) | |
| 60–69 | 7 (18.4) | |
| 70 and over | 2 (5.3) | |
| Employment | ||
| Employed | 35 (92.1) | |
| Unemployeda | 3 (7.9) | |
| Education | ||
| Higher education | 19 (50.0) | |
| Secondary education | 12 (31.6) | |
| Other qualification | 4 (10.5) | |
| None | 3 (7.9) | |
| Area of residence | ||
| Notional intervention area | 19 (50.0) | |
| Notional control area | 19 (50.0) | |
| Recruitment group | ||
| Intercept | 15 (39.5) | |
| Cohort | 23 (60.5) | |
| Behaviour change | ||
| None | 11 (28.9) | |
| More active (away from car) | 13 (34.2) | |
| Less active (towards car) | 10 (26.3) | |
| Change which does not affect activity levels | 4 (10.5) | |
| Interviewed previously | ||
| Yes | 3 (7.9) | |
| No | 35 (92.1) | |
| Total | 38 |
| Stage 34 | Stage 37 | Stage 40 | Stage 45 | |||||||||
| Protein | C | N | M | C | N | M | C | N | M | C | N | M |
| HDAC1 | − | + | +++ | − | +++ | + | − | +++ | + | − | +++ | − |
| HDAC2 | − | ++ | + | − | ++ | + | − | +++ | + | − | +++ | − |
| HDAC3 | + | ++ | + | + | ++ | + | + | ++ | + | − | +++ | − |
| HDAC8 | ++ | + | + | ++ | + | + | ++ | + | + | ++ | + | + |
| COMPASS-31 domains | Expanded Disability Status Scale | |
| Correlation coefficient (ρ) | P | |
| orthostatic intolerance | 0.079 | 0.303 |
| vasomotor | 0.073 | 0.341 |
| secretomotor | 0.179 | 0.019 |
| gastrointestinal | 0.333 | <0.001 |
| bladder | 0.563 | <0.001 |
| pupillomotor | 0.095 | 0.214 |
| Total score | 0.266 | <0.001 |
| Response Variable | Comparison | Test | Litters 1–5 (n = 45) | Litters 1–4 (n = 35) |
| Survival | Across P and 3 dosages of T | Chi-Square | 0.0327 | 0.1362 |
| Survival | P versus pooled T | Chi-Square | 0.0039 | 0.0210 |
| Survival curve (survival over time) | P versus pooled T | Kaplan-Meier | 0.0165 | 0.0658 |
| Weight change | P versus pooled T | t test | 0.0014 | 0.0038 |
| Weight change/h | P versus pooled T | t test | 0.0073 | 0.0132 |
| Brain lesions and neurological signs | Relationship | Fisher’s exact test | <0.0001 | <0.0001 |
| Brain lesions and death | Relationship | Fisher’s exact test | <0.0001 | <0.0001 |
| Total brain lesion score | S versus D | t test | <0.0001 | <0.0001 |
| Total brain lesion score | P versus T | t test | 0.0010 | 0.0440 |
| % Efficacy against death † | P versus T | 1-Relative Risk | <0.0004 | <0.001 |
| % Efficacy against brain lesions ‡ | P versus T | 1-Relative Risk | <0.0004 | <0.0086 |
| Demographics | N | % |
| Gender | ||
| Female | 362 | 59.9 |
| Male | 209 | 34.6 |
| not reported | 33 | 5.5 |
| Racial/Ethnic Group | ||
| Asian/Hawaiian/Pacific Islander | 9 | 1.5 |
| Black | 17 | 2.8 |
| Hispanic | 13 | 2.2 |
| White | 523 | 86.6 |
| Other | 9 | 1.5 |
| not reported | 33 | 5.5 |
| University Affiliation | ||
| Student | 401 | 66.4 |
| Faculty | 65 | 10.8 |
| Staff | 90 | 14.9 |
| Both student & staff/faculty | 24 | 4.0 |
| Neither Student nor staff/faculty | 24 | 4.0 |
| Pre-test ST Stage | ||
| Precontemplation | 478 | 79.1 |
| Contemplation | 126 | 20.9 |
| Access to Car | ||
| I own my own vehicle | 535 | 88.6 |
| I share a Vehicle | 27 | 4.5 |
| Neither own nor share | 40 | 6.6 |
| not reported | 2 | 0.3 |
| Own a Bicycle | ||
| Yes | 119 | 19.7 |
| No | 443 | 73.3 |
| not reported | 42 | 7.0 |
| Mean | SD | |
| Age | 28.3 | 13.9 |
| Diabetic Nephropathy | Diabetic Neuropathy | Retinopathy | ||||
| OR | P value | OR | P value | OR | P value | |
| Gender | ||||||
| Females | 0.23 | 0.00 | 0.17 | 0.00 | −0.09 | 0.00 |
| Age bands | ||||||
| Range 40–44 | 0.32 | 0.00 | 0.55 | 0.00 | 0.33 | 0.00 |
| Range 44–49 | 0.42 | 0.00 | 0.87 | 0.00 | 0.52 | 0.00 |
| Range 50–54 | 0.39 | 0.00 | 1.00 | 0.00 | 0.59 | 0.00 |
| Range 55–59 | 0.54 | 0.00 | 1.05 | 0.00 | 0.69 | 0.00 |
| Range 60–64 | 0.57 | 0.00 | 1.16 | 0.00 | 0.80 | 0.00 |
| Range 65–69 | 0.76 | 0.00 | 1.21 | 0.00 | 0.91 | 0.00 |
| Range 70–74 | 0.91 | 0.00 | 1.27 | 0.00 | 0.91 | 0.00 |
| Range 74–79 | 1.01 | 0.00 | 1.47 | 0.00 | 0.90 | 0.00 |
| Range 80–84 | 1.18 | 0.00 | 1.47 | 0.00 | 0.80 | 0.00 |
| Range 85 and over | 1.17 | 0.00 | 1.38 | 0.00 | 0.61 | 0.00 |
| Reference (Male <40) | −4.22 | 0.00 | −4.75 | 0.00 | −3.27 | 0.00 |
| Diagnosis | N° of cases | N° of images |
| Melanoma | 94 | 288 |
| Atypical nevi | 1785 | 2677 |
| Benign nevi | 18160 | 21155 |
| Congenital nevi | 189 | 331 |
| Blue nevi | 60 | 105 |
| Combined nevi | 18 | 21 |
| Ungueal nevi | 5 | 7 |
| Lentigo | 45 | 53 |
| Melanosis | 80 | 107 |
| Basal cell carcinomas | 55 | 60 |
| Total | 20491 | 24804 |
| Chinese name | Full scientific name | Parts of plant use | Dose of dry plant (grams) | Dose after extraction (grams) |
| Xian Ling Pi | Epimedium brevicornum Maxim | Overground part | 30 | 1.5 |
| Tu Si Zi | Cuscuta chinensis Lam. | Mature seed | 10 | 0.5 |
| Du Zhong | Eucommia ulmoides Oliver | Plant bark | 15 | 0.75 |
| Huai Niu Xi | Achyranthes bidentata Bl. | Root | 15 | 6 |
| Ye Xia Zhu | Phyllanthus urinaria Linn. | Whole plant | 15 | 6 |
| Huang Qi | Astragalus membranaceus (Fisch.) Bge. | Root | 15 | 1.5 |
| Bai Shu | Atractylodes macrocephala koidz | Rhizome | 15 | 2.55 |
| Fu Ling | Poria cocos (Schw.) Wolf | Sclerotium | 15 | 1.5 |
| Zhu Ling | Polyporus umbellatus (Pers.) Fries | Sclerotium | 10 | 1.0 |
| Zhi Ke | Fructus Aurantii | Immature fruits (pulp removed) | 15 | 2.55 |
| Dan Shen | Salvia miltiorrhiza Bge. | Root and rhizome | 20 | 3 |
| San Qi | Panax notoginseng (Burk.) F. H. Chen | Root | 5 | 5 |
| Yu Jin | Radix curcumae | Tuberous root | 15 | 0.75 |
| Gou Qi Zi | Lycium barbarum L. | Mature fruit | 15 | 6 |
| Total | 210 | 38.6 |
| Results | Frequency | Percentage |
| Sputum with one smear positive | 20 | 50 |
| Sputum with two smear positive | 4 | 10 |
| Sputum with three sputum smear positive | 13 | 32.5 |
| Sputum with smear negative | 3 | 7.5 |
| 2005–2007 | 2002–2004 | |||
| Sub-categories | n | % | n | % |
| chronic hypertension | 38 | 6.1 | 37 | 5.9 |
| proteinuric hypertension | 173 | 27.8 | 171 | 27.2 |
| eclampsia | 344 | 55.3 | 347 | 55.3 |
| HELLP syndrome | 54 | 8.7 | 70 | 11.1 |
| rupture of the liver | 10 | 1.6 | 3 | 0.5 |
| acute fatty liver | 3 | 0.48 | 0 | 0.0 |
| Total | 622 | 628 |
| Sampling method | ||
| Location | Fluorescent marker | Adenosine triphosphate and microbiologic sampling |
| Bed rail | Between raised control buttons on the outer surface of the railing closest to room door | Adjacent to fluorescent marker |
| Overbed tray table | On the upper surface of the table, adjacent to and centered on the edge of the table closest to the hand-operated height adjustment mechanism | Adjacent to fluorescent marker |
| Call button | On the hand-held device, centered between the emergency button and speaker | Adjacent to fluorescent marker, including raised control buttons |
| Bedside telephone | Top center of the surface of the receiver, on the obverse side of the earpiece | Adjacent to the fluorescent marker including lateral dial surfaces |
| Bedside table | Corner closest to the patient bed on the drawer-side (front) top surface [if more than one table is present in the room, the table located to the patient’s right] | Adjacent to fluorescent marker |
| Chair | On the surface of the seat, in the rear corner closest to the patient bed [if more than one chair present in the room, the chair located closest to the patient bed] | Adjacent to fluorescent marker |
| Room sink | Corner of the surface adjacent to the basin, closest to the wall and room door | Adjacent to fluorescent marker |
| Room light switch | Upper left corner of the wall plate | Surface of the light switch plate, over a 2×2-inch surface around but not touching the switch itself |
| Room door knob, inner | Upper middle of the door plate behind the handle | Surface of the door plate, over a 2×2-inch surface around but not touching the handle |
| Bathroom light switch | Upper left corner of the wall plate [if electrical sockets are present in upper left, then the upper right corner] | Surface of the light switch pad, over a 2×2-inch surface around but not touching the switch itself |
| Bathroom hand rail (adjacent to toilet) | Lateral surface of the portion of the handrail farthest from the toilet | Adjacent to the fluorescent mark, with a circumferential sampling of a 2-inch length of railing |
| Bathroom sink | Corner of the surface adjacent to the basin, to the left and rear of the sink surface | Adjacent to fluorescent marker |
| Toilet seat | Rear left corner of the seat on the upper surface | Adjacent to fluorescent marker |
| Toilet flush handle | Superior surface of the handle closest to the plumbing connection | Adjacent to the fluorescent marker, with a circumferential sampling of 1/2 of the handle length |
| Bedpan cleaner | Surface of the cleaning mechanism behind the spray head (excluding the handle) | Adjacent to fluorescent marker, sampling all surfaces of a lateral half of the cleaning mechanism for a 2-inch length |
| Responders | Non-responders | |
| Gender | 13 female, 24 male | 4 female, 14 male |
| Race | 50 caucasian, 11 AA | 23 caucasian, 8 AA |
| Log-viral load | 14 ± 3.7 | 15.6 ± 1.6 |
| Metavir | 1.6 ± 1.7 | 1.7 ± 2.3 |
| Primers | Sequence | Enzyme |
| FLT3-ITD | GCAATTTAGGTATGAAAGCCAGC | - |
| CTTTCAGCATTTTGACGGCAACC | ||
| FLT3-TKD | CCGCCAGGAACGTGCTTG | EcoRV |
| GCAGCCTCACATTGCCCC |
| Variables | TUBA1C-Low | TUBA1C-High | pvalue |
| Reccurence | 0.031 | ||
| No | 18 | 11 | |
| Yes | 2 | 8 | |
| differentiate | 0.103 | ||
| 1-2 | 9 | 3 | |
| 3-4 | 20 | 25 | |
| Primary Tumor stage | 0.056 | ||
| 1-2 | 26 | 19 | |
| 3-4 | 3 | 9 | |
| Membrane | 0.171 | ||
| No | 19 | 11 | |
| Yes | 6 | 8 | |
| daughter_nodule | 0.079 | ||
| No | 27 | 21 | |
| Yes | 2 | 7 | |
| embolus | 0.029 | ||
| No | 26 | 18 | |
| Yes | 3 | 10 | |
| AFP | 0.014 | ||
| Low(<20) | 16 | 7 | |
| High(>20) | 11 | 22 |
| Measurement at: | Measurement at: | ||
| Hemodynamics | Acid Base Balance | ||
| Noradrenalin requirement (mg/h) | BL – T120 | Anion Gap (mmol/L) | BL – T120 |
| Heart rate (min-1) | BL – T120 | HCO3- (mmol/L) | BL – T120 |
| ABP systolic (mmHg) | BL – T120 | BE (mmol/L) | BL – T120 |
| ABP diastolic (mmHg) | BL – T120 | pH | BL – T120 |
| Central venous pressure (mmHg) | BL – T120 | paCO2 (mmHg) | BL – T120 |
| Blood loss (mL) | BL – T120 | ||
| Hemoglobin (g/dL) | BL – T120 | Stewart Acid Base Approach [A-] (mmol/L) | BL – T120 |
| Hematocrit (%) | BL – T120 | Effective Strong Ion Difference (mmol/L) | BL – T120 |
| Urine quantity (mL) | BL – T120 | Strong Ion Gap (mmol/L) | BL – T120 |
| Administered amount of RL/ABIS (mL) | BL – T120 | [Albumin] (g/L) | BL – T120 |
| [Serum-Lactate] (mmol/L) | BL – T120 | ||
| Serum-Electrolytes([Na+][Cl-] [K+] [Mg++] [Ca++]) | BL – T120 | [A-]: = Serum-concentration of week acids | BL – T120 |
| Parameter | AT BASELINE | AT 24-WeeksPost E-Cigarette | p value‡ |
| Sustained 50% (excluding quitters) reduction in cigarette smoking (n = 13) | |||
| Age | 40.1 (± 7.7)† | 6 (5, 6)* | < 0.001 |
| Sex | 8M; 5F | 8 (6, 11)* | 0.001 |
| Smoking Years | 24.5 (± 8.7)† | ||
| Cigarettes/day | 25 (20, 30)* | ||
| eCO | 18 (14, 33)* | ||
| Sustained 80% (excluding quitters) reduction in cigarette smoking (n = 5) | |||
| Age | 40.6 (± 10.4)† | 3 (3, 6)* | 0.043 |
| Sex | 4M; 1F | 6 (4, 10)* | 0.042 |
| Smoking Years | 25.4 (± 11.8)† | ||
| Cigarettes/day | 30(25, 35)* | ||
| eCO | 15 (14, 44)* | ||
| Sustained 100% (quitters) reduction in cigarette smoking (n = 9) | |||
| Age | 44.7 (± 9.3)† | 0 (0, 0)* | 0.008 |
| Sex | 8M; 1F | 3 (2, 3)* | 0.008 |
| Smoking Years | 29 (± 9.6)† | ||
| Cigarettes/day | 25 (23, 30)* | ||
| eCO | 31 (23, 41)* | ||
| Sustained > 50% (including quitters) reduction in cigarette smoking (n = 22) | |||
| Age | 42 (± 8.5)† | 3 (0, 6)* | < 0.001 |
| Sex | 16M; 6F | 5.5 (3, 9.5)* | < 0.001 |
| Smoking Years | 26.3 (± 9.1)† | ||
| Cigarettes/day | 25 (20, 30)* | ||
| eCO | 27 (15.5, 37.5)* | ||
| Smoking Failure (< 50% smoking reduction) (n = 5) | |||
| Age | 45.6 (± 7.9)† | 20 (20, 20)* | 0.157 |
| Sex | 2M; 3F | 28 (17, 31)* | 0.892 |
| Smoking Years | 31.2 (± 7)† | ||
| Cigarettes/day | 25 (20, 25)* | ||
| eCO | 18 (16, 32)* |
| Risk factors for invasive candidiasis | Unadjusted odds ratio | 95% Confidence interval |
| Malignancy | 3.22 | 1.36-7.6 |
| Presence of a central venous catheter | 13.4 | 4.8-37.42 |
| Presence of a arterial catheter | 1.77 | 1.02-3.06 |
| Receipt of total parenteral nutrition | 5.3 | 2.8-10.05 |
| Neutropenia within 15 days | 5.58 | 1.12-27.79 |
| Non-candidal blood stream infection within 15 days | 2.47 | 1.35-4.52 |
| Receipt of antifungal agents within 15 days | 2.86 | 1.44-5.66 |
| Receipt of antibiotics within 15 days | 5.44 | 1.87-15.77 |
| Parenteral or oral vancomycin during 1-3 days | 2.56 | 1.27-5.16 |
| Parenteral or oral vancomycin ≥4 days | 3.17 | 1.73-5.82 |
| Extended-spectrum cephalosporins ≥4 days | 2.31 | 1.26-4.22 |
| Carbapenems ≥4 days | 3.29 | 1.1-9.89 |
| Aminoglycosides | 2.09 | 1.17-3.74 |
| Agents covering anaerobic organisms ≥4 daysa | 2.3 | 1.29-4.11 |
| SPPC (n = 39) | Conventional (n = 38) | p-value | |
| LFC, mean (SD) | 85° (4) | 84° (3) | 0.1 |
| LFC, range | 74–94° | 79–89° | |
| LFC, number of outliers > 3° | 16/39 | 33/38 | < 0.001 |
| LFC, ICC | 0.99 | 0.99 | |
| LTC, mean (SD) | 94° (4) | 87° (3) | < 0.001 |
| LTC, range | 87–102° | 75–92° | |
| LTC, number of outliers > 3° | 14 | 21 | 0.02 |
| LTC, ICC | 0.99 | 0.99 |
| OCA2 c.808-3C>G | OCA2 c.2080-2A>G | |
| Wild type score | 5.2 | 11.5 |
| Mutant score | -5.3 | 0.6 |
| Dataset | Dissimilarity | Linkage | Data permutation method |
| Simulated6 | Euclidean | complete | Independently for each coordinate (column) |
| (1 - Pearson correlation) | average | ||
| Leukemia | Euclidean | Ward | Independently for each gene (column) |
| (1 - Pearson correlation) | average | ||
| T10 | Euclidean | Ward | Independently for each chromosome; identically for all cores (columns) in a chromosome |
| (1 - Pearson correlation) | average | ||
| Organelles | (1 - Pearson correlation) | Ward | Independently for each protein (column) |
| (1 - Pearson correlation) | average | ||
| Chondrosarcoma | (1 - Spearman correlation) | Ward | Independently for each surface marker (column) |
| (1 - Kendall correlation) | average | ||
| Manhattan | Ward |
| Predictor | P-value | Sub-hazard Ratio | 95% CI |
| EHD >1 site / 1 site outside the lung | 0.001 | 3.0 | 1.6 - 5.9 |
| Kras mutant | 0.009 | 2.0 | 1.2 - 3.3 |
| CEA >30 ng/ml | 0.056 | 1.9 | 0.98 - 3.7 |
| Dose Diff‐DTA | Head and Neck | Prostate | |||
| Criteria | QA Method | Mean | SD | Mean | SD |
| C1 | PGAC | 56.1 | 8.6 | 58.7 | 8.5 |
| (1%‐1 mm) | SGAC | 70.9 | 8.3 | 68.3 | 8.1 |
| FBF | 71.1 | 6.6 | 66.5 | 7.2 | |
| PGAC‐WOC | 75.1 | 7.8 | 69.7 | 12.2 | |
| PG‐FBF | 51.5 | 4.8 | 49.1 | 2.4 | |
| C2 | PGAC | 90.7 | 4.8 | 91.0 | 3.7 |
| (2%‐2 mm) | SGAC | 94.7 | 3.0 | 97.9 | 3.5 |
| FBF | 95.0 | 1.9 | 97.2 | 1.9 | |
| PGAC‐WOC | 96.9 | 2.4 | 95.9 | 3.1 | |
| PG‐FBF | 82.0 | 3.8 | 75.8 | 3.5 | |
| C3 | PGAC | 98.8 | 1.1 | 98.9 | 0.6 |
| (3%‐3 mm) | SGAC | 99.6 | 0.4 | 100.0 | 0.0 |
| FBF | 99.5 | 0.3 | 100.0 | 0.1 | |
| PGAC‐WOC | 99.6 | 0.6 | 99.7 | 0.5 | |
| PG‐FBF | 93.3 | 2.3 | 87.5 | 3.9 |
| DTS | NCS | NCW | PWB | SoWB | |
| Direct Exposure Victims | |||||
| DTS | .71** [.56 .82] | .63** [.45 .76] | −.41** [−.61–.16] | −.40** [−.59–.17] | |
| NCS | .73** [.60 .82] | −.66** [−.79–.48] | −.43** [−.61–.21] | ||
| NCW | −.56** [−.72–.35] | −.42** [−.60–.20] | |||
| PWB | .63*[.44 .76] | ||||
| SoWB | |||||
| Indirect Exposure Victims | |||||
| DTS | .34** [.21 .46] | .15* [.01 .28] | −.49** [−.59–.38] | −.25** [−.38–.12] | |
| NCS | .49** [.38 .59] | −.46** [−.57–.34] | −.32** [−.44–.19] | ||
| NCW | −.20** [−.32–.05] | −.39** [−.50–.26] | |||
| PWB | .49** [−.59–.38] | ||||
| SWB |
| Clinical parameter | Diabetic subjects | Controls | P (ANOVA) | ||
| PCO (n = 64) | Non-PCO (n = 41) | PCO (n = 22) | Non-PCO (n = 38) | ||
| Fasting glucose (mg/dl) | 123.8 ± 36.28 | 115.55 ± 32.0 | 92.14 ± 12.7 | 85.71 ± 14.6 | 0.000 |
| Total cholesterol (mg/dl) | 189.4 ± 40.9 | 199.8 ± 57.0 | 183.27 ± 37.6 | 183.87 ± 41.3 | 0.375 |
| Triglycerides (mg/dl) | 194.4 ± 69.9 | 192.4 ± 67.8 | 182.27 ± 52.1 | 187.65 ± 80.2 | 0.895 |
| HDL cholesterol (mg/dl) | 42.0 ± 6.6 | 43.3 ± 8.8 | 44.00 ± 11.0 | 43.99 ± 7.6 | 0.593 |
| LDL cholesterol (mg/dl) | 127.5 ± 55.2 | 131.1 ± 71.9 | 97.74 ± 40.7 | 105.76 ± 40.0 | 0.033 |
| VLDL cholesterol (mg/dl) | 38.8 ± 13.9 | 38.4 ± 13.5 | 36.45+10.4 | 37.53+16.0 | 0.895 |
| LH (IU/L) | 7.51+6.65 | 3.42 +2.21a | 7.93 ± 9.52 | 2.77 ± 2.17b | 0.000 |
| FSH (IU/L) | 5.82+2.80 | 7.23+4.86 | 5.50 ± 2.3 | 5.11 ± 2.9 | 0.039 |
| LH/FSH ratio | 1.31 ± 0.78 | 0.55 ± 0.26a | 1.3 ± 0.85 | 0.5 ± 0.26b | 0.000 |
| Testosterone (ng/ml) | 37.4 ± 23.0 | 16.9 ± 7.3a | 39.6 ± 13.3 | 18.8 ± 7.5b | 0.000 |
| Androstendione (ng/ml) | 2.40 ± 1.9 | 1.04 ± 0.36a | 2.10 ± 0.6 | 1.21 ± 0.40b | 0.000 |
| ID | Short description | T | AP | AS | AR |
| X1 | partOfSpeech(token) | ✓ | ✓ | ||
| X2 | syntCat(token) | ✓ | ✓ | ||
| X3 | partOfSpeech(L3) | ✓ | ✓ | ||
| X4 | syntCat(L3) | ✓ | ✓ | ||
| X5 | syntCatPathFromRoot(token) | ✓ | |||
| X6 | syntCatCollapsedPathFromRoot(token) | ✓ | |||
| X7 | syntCatPositionPathFromRoot(token) | ✓ | |||
| X8 | ancestor (token,[1..3]) | ✓ | |||
| X9 | lowestCommonAncestor (token,neighbourOf (token,left,1)) | ✓ | |||
| X10 | distanceBetween(token, X9) | ✓ | |||
| X11 | posString (trigger) | ✓ | ✓ | ||
| X12 | syntCatString (trigger) | ✓ | ✓ | ||
| X13 | posStringDupl (trigger) | ✓ | ✓ | ||
| X14 | syntCatStringDupl (sent) | ✓ | ✓ | ||
| X15 | containsMainVerb(trigger) | ✓ | ✓ | ||
| X16 | mainVerb(sent) | ✓ | |||
| X17 | voiceOfVerb(trigger) | ✓ |
| Components | Content (mg/g) | |||||||||
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | |
| Danshensu | 9.8 | 10.0 | 9.8 | 10.0 | 10.0 | 9.8 | 10.1 | 10.2 | 10.0 | 9.7 |
| Paeoniflorin | 582.6 | 591.2 | 612.4 | 579.8 | 617.3 | 591.4 | 609.3 | 582.4 | 582.0 | 601.4 |
| Acteoside | 3.4 | 3.4 | 3.3 | 3.4 | 3.3 | 3.3 | 3.5 | 3.2 | 3.4 | 3.4 |
| Lithospermic acid | 4.5 | 4.7 | 4.6 | 4.4 | 4.5 | 4.6 | 4.6 | 4.5 | 4.6 | 4.6 |
| Salvianolic acid B | 265.9 | 266.4 | 260.5 | 260.7 | 263.4 | 262.6 | 272.8 | 263.5 | 264.8 | 270.7 |
| Salvianolic acid C | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 |
| Mean (SD) | Min. | Max. | P value | |
| Supine position | ||||
| Rest | ||||
| PVDF | 1.05 (±0.37) | 0.55 | 2.05 | 0.27 |
| PP | 0.89 (±0.23) | 0.45 | 1.6 | |
| Contraction | ||||
| PVDF | 0.99 (±0.31) | 0.61 | 1.6 | 0.14 |
| PP | 0.82 (±0.21) | 0.32 | 1.27 | |
| Valsalva | ||||
| PVDF | 1.04 (±0.43) | 0.55 | 2.29 | 0.22 |
| PP | 0.86 (±0.25) | 0.4 | 1.44 | |
| Upright position | ||||
| Rest | ||||
| PVDF | 0.94 (±0.25) | 0.63 | 1.4 | 0.21 |
| PP | 0.83 (±0.19) | 0.48 | 1.31 | |
| Contraction | ||||
| PVDF | 0.89 (±0.26) | 0.55 | 1.67 | 0.13 |
| PP | 0.79 (±0.21) | 0.45 | 1.39 | |
| Valsalva | ||||
| PVDF | 0.89 (±0.26) | 0.35 | 1.35 | 0.12 |
| PP | 0.78 (±0.23) | 0.4 | 1.36 |
| SITE | Baseline assessment | Training | Post-test assessment | 8 week follow-up assessment | All 4 steps |
| N | N | n | n (%) | n | |
| MKT | 15 | 26 | 22 | 14/22 (63.6%) | 5 |
| MLA | 20 | 26 | 21 | 20/21 (95.2%) | 10 |
| WPA | 14 | 19 | 16 | 13/16 (81.3%) | 9 |
| ALL SITES | 49 | 71 | 59 | 47/59 (79.7%) | 24 |
| EQ-5D-5L | |||||
| EQ-5D-3L | No problems 1 | Slight problems 2 | Moderate problems 3 | Severe problems 4 | Unable/extreme 5 |
| Mobility | |||||
| No problems in walking about (n = 6390) | 6287 (98.6%) [77.4] | 86 (1.2%) [58.5] | 16 (0.2%) [53.5] | 1 (0.0%) [15.0] | 0 (0.0%) - |
| Some problems in walking about (n = 1104) | 36 (3.2%) [60.7] | 392 (34.8%) [57.0] | 436 (41.1%) [48.9] | 221 (19.8%)[38.2] | 19 (1.1%)[52.2] |
| Confined to bed (n = 60) | 3 (4.4%) [74.5] | 1 (0.2%) [40.0] | 3 (7.9%) [37.3] | 15 (26.5%) [35.2] | 38 (60.9%) [35.5] |
| Self-care | |||||
| No problems with self-care (n = 7057) | 6956 (98.6%) [75.4] | 88 (1.2%) [46.8] | 12 (0.2%) [32.5] | 1 (0.0%) [40.0] | (0.0%) - |
| Some problems washing or dressing myself (n = 345) | 27 (6.3%) [61.8] | 109 (29.1%) [49.9] | 154 (48.9%) [43.7] | 51 (14.9%) [30.6] | 4 (0.8%) [24.9] |
| Unable to wash or dress myself (n = 152) | 2 (1.5%) [76.9] | 3 (1.7%) [52.3] | 5 (3.6%) [55.4] | 29 (18.4%) [44.7] | 113 (74.9%) [36.5] |
| Usual activities | |||||
| No problems with performing my usual activities (n = 6677) | 6526 (97.8%) [77.0] | 105 (1.6%) [58.2] | 37 (0.5%) [56.5] | 8 (0.1%) [36.3] | 1 (0.0%) [70.0] |
| Some problems with performing my usual activities (n = 600) | 31 (4.3%) [59.0] | 197 (31.3%) [53.8] | 269 (46.3%) [46.0] | 92 (16.3%) [40.0] | 11 (1.7%) [47.1] |
| Unable to perform my usual activities (n = 277) | 1 (0.6%) [70.0] | 2 (0.5%) [69.1] | 20 (7.7%) [48.8] | 81 (30.0%) [42.2] | 173 (61.3%) [35.0] |
| Pain/discomfort | |||||
| No pain or discomfort (n = 5275) | 5124 (97.3%) [79.7] | 113 (2.0%) [68.1] | 34 (0.6%) [65.5] | 4 (0.1%) [65.9] | 0 (0%) - |
| Moderate pain of discomfort (n = 1846) | 73 (3.7%) [68.7] | 790 (41.9%) [67.6] | 875 (47.9%) [59.4] | 107 (6.6%) [49.4] | 1 (0.0%) [40.0] |
| Extreme pain or discomfort (n = 433) | 0 (0%) - | 7 (1.8%) [55.8] | 70 (15.7%) [47.9] | 324 (75.5%) [40.1] | 32 (7.0%) [34.2] |
| Anxiety/depression | |||||
| Not anxious or depressed (n = 6226) | 6098 (98.1%) [77.4] | 100 (1.5%) [61.0] | 21 (0.3%) [65.8] | 6 (0.0%) [43.9] | 1 (0.0%) [50.0] |
| Moderately anxious or depressed (n = 1111) | 52 (4.5%) [58.0] | 526 (47.0%) [62.1] | 474 (43.6%) [54.8] | 56 (4.6%) [46.1] | 3 (0.3%) [22.3] |
| Extremely anxious or depressed (n = 217) | 3 (1.5%) [49.6] | 6 (2.4%) [51.5] | 37 (18.2%) [46.5] | 147 (66.4%) [41.7] | 24 (11.5%) [29.5] |
| Pollen type | Location (log mean) | Location (log mean) | Log mean difference | p value | 95% Confidence interval | |
| Lower bound | Upper bound | |||||
| Acer (Maple) | A (0.110) | D (0.210) | − 0.099 | 0.015 | − 0.179 | − 0.020 |
| A (0.110) | E (0.230) | − 0.116 | 0.005 | − 0.196 | − 0.037 | |
| C (0.150) | D (0.210) | − 0.083 | 0.042 | − 0.163 | − 0.003 | |
| Fraxinus (Ash) | No significant difference among locations | |||||
| Morus (Mulberry) | D (0.540) | E (0.170) | 0.360 | 0.051 | − 0.001 | 0.722 |
| Olea europea (Olive) | A (0.076) | B (0.156) | − 0.080 | 0.012 | − 0.143 | − 0.018 |
| A (0.076) | D (0.162) | − 0.086 | 0.007 | − 0.148 | − 0.024 | |
| B (0.156) | C (0.088) | 0.067 | 0.035 | 0.005 | 0.130 | |
| C (0.088) | D (0.162) | − 0.073 | 0.021 | − 0.135 | − 0.011 | |
| Pinaceae (Pine) | No significant difference among locations | |||||
| Platanus (Sycamore) | B (0.044) | D (0.156) | − 0.112 | 0.017 | − 0.204 | − 0.021 |
| C (0.057) | D (0.156) | − 0.099 | 0.034 | − 0.191 | − 0.008 | |
| Ulmus (Elm) | No significant difference among locations |
| CNAs DETECTED IN 37 CC | TCGA | ||||||||||
| Gene symbol | Chromosomeband | Number ofsamples showing CNA | Percentage of samples showing CNA | Log2(CNA)* | Mean CN ratio ** | Range of CN ratio | Type of CNA | Percentage of samples showing CN GAIN | Number ofsamples showing CN GAIN | Percentage of samples showing CN LOSS | Number ofsamples showing CN LOSS |
| MLL3 | 7q36.1 | 16 | 43.24 | 0.41 | 1.34 | 1.14–1.49 | GAIN | 47.21 | 169 | 1.96 | 7 |
| AKAP9 | 7q21.2 | 15 | 40.54 | 0.47 | 1.4 | 1.21–1.52 | GAIN | 47.49 | 170 | 1.12 | 4 |
| ASXL1 | 20q11.21 | 14 | 37.84 | 0.72 | 1.66 | 1.40–2.10 | GAIN | 70.95 | 254 | 0 | 0 |
| UBR5 | 8q22.3 | 13 | 35.14 | 0.54 | 1.47 | 1.23–1.72 | GAIN | 55.87 | 200 | 1.96 | 7 |
| PLCG1 | 20q12 | 13 | 35.14 | 0.89 | 1.88 | 1.39–2.55 | GAIN | 71.23 | 255 | 0.56 | 2 |
| KAT6A | 8p11.21 | 9 | 24.32 | 0.79 | 1.79 | 1.43–3.22 | GAIN | 42.74 | 153 | 9.5 | 34 |
| DST | 6p12.1 | 8 | 21.62 | 0.36 | 1.29 | 1.17–1.42 | GAIN | 19.27 | 69 | 8.38 | 30 |
| ATR | 3q23 | 7 | 18.92 | 0.49 | 1.41 | 1.19–1.54 | GAIN | 14.53 | 52 | 7.82 | 28 |
| BRAF | 7q34 | 7 | 18.92 | 0.66 | 1.58 | 1.41–1.67 | GAIN | 47.77 | 171 | 1.12 | 4 |
| CSMD3 | 8q23.3 | 7 | 18.92 | 0.53 | 1.47 | 1.29–1.92 | GAIN | 55.87 | 200 | 2.51 | 9 |
| DCC | 18q21.2 | 13 | 35.14 | -0.61 | 0.66 | 0.54–0.81 | LOSS | 2.23 | 8 | 61.17 | 219 |
| WHSC1 | 4p16.3 | 12 | 32.43 | -0.50 | 0.71 | 0.63–0.75 | LOSS | 2.23 | 8 | 27.65 | 99 |
| NLRP1 | 17p13.2 | 10 | 27.03 | -0.60 | 0.66 | 0.55–0.76 | LOSS | 3.63 | 13 | 53.07 | 190 |
| MBD1 | 18q21.1 | 10 | 27.03 | -0.67 | 0.63 | 0.54–0.72 | LOSS | 2.79 | 10 | 59.22 | 212 |
| EP400 | 12q24.33 | 9 | 24.32 | -0.51 | 0.7 | 0.56–0.76 | LOSS | 18.99 | 68 | 12.01 | 43 |
| TGM7 | 15q15.2 | 9 | 24.32 | -0.71 | 0.61 | 0.50–0.72 | LOSS | 2.79 | 10 | 37.43 | 134 |
| RNF213 | 17q25.3 | 9 | 24.32 | -0.36 | 0.78 | 0.71–0.86 | LOSS | 23.46 | 84 | 12.01 | 43 |
| ERG | 21q22.2 | 9 | 24.32 | -0.67 | 0.63 | 0.48–0.78 | LOSS | 4.75 | 17 | 27.93 | 100 |
| GATA2 | 3q21.3 | 8 | 21.62 | -0.85 | 0.56 | 0.45–0.65 | LOSS | 13.97 | 50 | 7.54 | 27 |
| LTK | 15q15.1 | 8 | 21.62 | -0.64 | 0.64 | 0.55–0.72 | LOSS | 2.79 | 10 | 37.43 | 134 |
| Forward | Reverse | |
| G6Pase | ATGACTTTGGGATCCAGTCG | TGGAACCAGATGGGAAAGAG |
| PEPCK | CTGGCACCTCAGTGAAGACA | TCGATGCCTTCCCAGTAAAC |
| LGP | CCAGAGTGCTCTACCCCAAT | CCACAAAGTACTCCTGTTTCAGC |
| GS | GACACTGAGCAGGGCTTTT | GGGCCTGGGATACTTAAAGC |
| CPT1α | ACCCTGAGGCATCTATTGACAG | ATGACATACTCCCACAGATGGC |
| MCAD | GGCAAATGCCTGTGATTCTT | CCATTGCGATCTTGAAACCT |
| GK | TCCCTGTAAGGCACGAAGACAT | ATTGCCACCACATCCATCTCA |
| CS | TGCCCACACAAGCCATTTG | CTGACACGTCTTTGCCAACTT |
| SIRT4 | CGCTGCTCAAGATCCCTAAG | GCGACACAGCTACTCCATCA |
| SIRT6 | GGCTACGTGGATGAGGTGAT | GGCTCAGCCTTGAGTGCTAC |
| GLUT2 | CTGCTCTTCTGTCCAGAAAGC | TGGTGACATCCTCAGTTCCTC |
| GLUT4 | TCGTCATTGGCATTCTGGTTG | AGCTCGTTCTACTAAGAGCAC |
| miRNA name | Reference genome | Location | Annotation | Strand | Mature sequence |
| HPV16-miR-H1 | NC_001526.2 | 2635–2716 | E1 | + | AGUGUAUGAGCUUAAUGAUAA |
| HPV16-miR-H2 | FJ610147.1 | 56-1/7906–7851 | LCR | − | AUGUGUAACCCAAAACGGUUUG |
| HPV16-miR-H3 | NC_001526.2 | 518–642 | LCR | + | CAACUGAUCUCUACUGUUA |
| HPV16-miR-H5 | NC_001526.2 | 2471–2556 | E1 | + | GUAAAGCAUAGACCAUUG |
| HPV16-miR-H6 | NC_001526.2 | 6684–6584 | L1 | – | AUCAACAACAGUAACAAA |
| ID | Observation | Year | Quarter | Employment | Tenure | Age | FirmID | MassLayoff | Included IntoOur Sample | Pregnancy |
| 1 | 1 | 1981 | 1 | Other | –– | 24 | –– | –– | Not included | No |
| 1 | 2 | 1981 | 2 | Work | 0.25 | 24 | 12 | No | Not included | No |
| 1 | 3 | 1981 | 3 | Work | 0.50 | 24 | 12 | No | Not included | No |
| 1 | 4 | 1981 | 4 | Work | 0.75 | 24 | 12 | No | Not included | No |
| 1 | 5 | 1982 | 1 | Work | 1.00 | 25 | 12 | No | Not included | No |
| 1 | 6 | 1982 | 2 | Work | 1.25 | 25 | 12 | No | Not included | No |
| 1 | 7 | 1982 | 3 | Work | 1.50 | 25 | 12 | No | Not included | No |
| 1 | 8 | 1982 | 4 | Work | 1.75 | 25 | 12 | No | Control | No |
| 1 | 9 | 1983 | 1 | Work | 2.00 | 26 | 12 | No | Control | No |
| 1 | 10 | 1983 | 2 | Work | 2.25 | 26 | 12 | No | Control | No |
| 1 | 11 | 1983 | 3 | Work | 2.50 | 26 | 12 | Yes | Control | No |
| 1 | 12 | 1983 | 4 | Work | 2.75 | 26 | 12 | Yes | Control | No |
| 1 | 13 | 1984 | 1 | Work | 3.00 | 27 | 12 | Yes | Treated | No |
| 1 | 14 | 1984 | 2 | Other | –– | 27 | –– | Yes | Not included | No |
| 1 | 15 | 1984 | 3 | Other | –– | 27 | –– | –– | Not included | No |
| 1 | 16 | 1984 | 4 | Other | –– | 27 | –– | –– | Not included | No |
| 1 | 17 | 1985 | 1 | Other | –– | 28 | –– | –– | Not included | Yes |
| University hospital | Non-university hospital | ||
| (n = 87) | (n = 111) | p value | |
| Age (years) | 59.0 (16.2); 63 (47–72) | 62.8 (15.9); 65 (52–74) | 0.10 |
| Sex, male/female | 62 (71.3)/25 (28.7) | 80 (72.1)/31 (27.9) | 0.9 |
| BMI (kg/m2) | 26.0 (4.9); 25.7 (23.2–27.7) | 26.9 (6.2); 26.0 (23.1–29.4) | 0.34 |
| BMI categories | |||
| < 18.5/<25.5/<30.0/≥30.0 kg/m2 | 3 (4.5)/28 (41.8)/28 (41.8)/8 (11.9) | 5 (4.7)/39 (36.8)/41 (38.7)/21(19.8) | 0.6 |
| SAPS II at ICU admission | 45.2 (17.2); 42 (32–58) | 48.7 (20.4); 48 (37–62) | 0.21 |
| Main problem, medical/surgical | 48 (55.2)/39 (44.8) | 69 (62.2)/42 (37.8) | 0.32 |
| ARDS origin, pulmonary/ extrapulmonary | 65 (78.3)/18 (21.7) | 79 (72.5)/30 (27.5) | 0.36 |
| Late onset of ARDSa | 35 (40.2) | 28 (25.2) | 0.02 |
| Onset of ARDS: day after initiation of mechanical ventilation | 1 (0-5) | 0 (0-2) | 0.02 |
| PaO2/FiO2 (mmHg) | 157 (124-186) | 149 (114-179) | 0.29 |
| Dynamic complianceb (ml/mbar; ml/mbar/kg PBW) | 39 (29–55); 0.58 (0.44–0.79) | 33 (24–43); 0.52 (0.39–0.67) | 0.006; 0.04 |
| Reason for initiation of mechanical ventilation (only presented when different between groups)c | |||
| Postoperative acute respiratory failure | 19 (21.8) | 12 (10.8) | 0.03 |
| Acute respiratory failure after aspiration | 2 (2.3) | 12 (10.8) | 0.02 |
| Complications until the onset of ARDS | |||
| Sepsisc | 41 (47.1) | 38 (34.2) | 0.07 |
| Pneumoniac | 43 (49.4) | 44 (39.6) | 0.17 |
| Cardiovascular failure | 63 (72.4) | 71 (64.0) | 0.21 |
| Renal failure | 26 (29.9) | 32 (28.8) | 0.87 |
| Coagulopathy | 23 (26.4) | 8 (7.2) | <0.001 |
| Liver failure | 11 (12.6) | 2 (1.8) | 0.002 |
| Metabolic acidosis | 8 (9.2) | 13 (11.7) | 0.57 |
| Respiratory acidosis | 18 (20.7) | 23 (20.7) | 1.0 |
| Barotrauma | 14 (16.1) | 13 (11.7) | 0.37 |
| Group | Material | Code | Manufacturer | Shade | Organic Matrix | Filler | Filler Loading | LOT Number |
| Bulk-fill composite | SureFil SDR Flow | SDR | Dentsply Caulk, Milford, DE, USA | U | Modified UDMA, EBPADMA, TEGDMA | Ba-Al-F-B silicate glass, Sr-Al-F silicate glass | 68 wt % | 1202174 |
| x-tra base | XB | Voco, Cuxhaven, Germany | U | UDMA, BisEMA | no information | 75 wt % | 1305261 | |
| Filtek Bulk Fill | FBF | 3M ESPE, St Paul, MN, USA | U | BisGMA, UDMA, BisEMA(6), TEGDMA, substituated dimethacrylate, Procrylat resin | silane treated zirconia/silica, ytterbium trifluoride | 64.5 wt % | N414680 | |
| Conventional flowable composite | Filtek Ultimate Flow | FUF | 3M ESPE, St Paul, MN, USA | A2 | BisGMA, TEGDMA, substituated dimethacrylate, Procrylat resin | silane treated zirconia/silica, ytterbium trifluoride | 65 wt % | N652740 |
| Diagnostic test | Number (%) |
| Any laboratory test | 73 (22.5) |
| Urinalysis | 71 (21.9) |
| Bloodwork | 30 (9.2) |
| Any Imaging | 96 (29.5) |
| Plain radiograph | 89 (27.4) |
| CT | 15 (4.6) |
| MRI | 2 (0.6) |
| Plain radiograph and CT | 11 (3.4) |
| CT and MRI | 1 (0.3) |
| Only MRI | 1 (0.3) |
| Selection methods | No. selected SNPs | Selected SNPs |
| Stepwise/AIC | 9 | 2823 3301 3379 3384 3394 3437a 3439 3474 3477 |
| Lasso/AIC | 29 | 2823 2826 2827 2848 2859 3286 3301 3310 3352 3366 3379 3384 3387 3394 3396 3426 3429 3430 3437 3439 3440 3447 3459 3474 3478 3481 3580 3581 3599 |
| Lasso/CV | 17 | 2823 2826 2827 2848 3301 3310 3379 3387 3394 3426 3429 3430 3437 3439 3440 3474 3599 |
| Bayesian | 2 | 3437 3439 |
| Trait locus DR/C* | 3437 |
| NS1-2 gene counts | NS1-2 dis gene counts | NS1-2 aadjusted p-values | NS1-2 disaadjusted p-values | |
| Upregulated gene pathways | ||||
| Proteasome | 25 | 15 | 1.80E−15 | 2.30E−06 |
| Aminoacyl-tRNA biosynthesis | 14 | 9 | 4.80E−05 | 2.30E−02 |
| Focal adhesion | 27 | 22 | 6.90E−03 | 2.60E−02 |
| RIG-I-like receptor signaling | 14 | 10 | 5.60E−03 | 6.20E−02 |
| Toll-like receptor signaling | 16 | 13 | 2.10E−02 | 5.30E−02 |
| Pathways in cancer | 33 | 28 | 7.80E−02 | 4.80E−02 |
| NOD-like receptor signaling | 11 | 8 | 7.20E−02 | 1.90E−01 |
| Apoptosis | 12 | 11 | 1.90E−01 | 9.50E−02 |
| Regulation of actin cytoskeleton | 22 | 16 | 1.80E−01 | 3.80E−01 |
| Antigen processing and presentation | 11 | 9 | 3.00E−01 | 3.50E−01 |
| MAPK signaling | 24 | 22 | 3.00E−01 | 1.50E−01 |
| Gap junction | 10 | 10 | 3.60E−01 | 1.90E−01 |
| VEGF signaling | 9 | 9 | 3.80E−01 | 1.90E−01 |
| Cytokine-cytokine receptor interaction | - | 20 | - | 1.80E−01 |
| Downregulated gene pathways | ||||
| Lysosome | 28 | 17 | 1.50E−11 | 4.30E−05 |
| Leukocyte transendothelial migration | 13 | 8 | 2.00E−01 | 6.30E−01 |
| Phosphatidylinositol signaling system | 9 | 9 | 3.30E−01 | 1.00E−01 |
| Toll-like receptor signaling | 10 | 7 | 3.70E−01 | 5.80E−01 |
| Regulation of actin cytoskeleton | 16 | 12 | 4.30E−01 | 7.30E−01 |
| Glycosaminoglycan degradation | 4 | 4 | 6.60E−01 | 7.50E−01 |
| Cell adhesion molecules | 11 | - | 7.10E−01 | - |
| p53 signaling | - | 6 | - | 8.50E−01 |
| Cytokine-cytokine receptor interaction | - | 13 | - | 6.80E−01 |
| Focal adhesion | - | 11 | - | 5.90E−01 |
| mTOR signaling | - | 5 | - | 5.40E−01 |
| Patients with a NRAS negative FN (N = 90) | Patients with a NRAS positive FN (N = 33) | P-value | |
| Average FN size (cm) | 2.2 ± 1.5 | 1.4 ± 0.8 | <0.001 |
| Age | |||
| ≤45 years | 31 (65%) | 17 (35%) | 0.086 |
| >45 years | 59 (79%) | 16 (21%) | |
| Gender | |||
| Female | 71 (74%) | 25 (26%) | 0.710 |
| Male | 19 (70%) | 8 (30%) | |
| Final results of FNs | |||
| Benign | 52 (83%) | 11 (17%) | 0.016 |
| Malignancy | 38 (63%) | 22 (37%) | |
| Final results of coexisting nodules∗ | |||
| Benign | 26 (83%) | 10 (28%) | 0.080 |
| Malignancy | 12 (63%) | 12 (50%) | |
| Total risk of malignancy | 53% (47/90) | 79% (26/33) | 0.008 |
| Predicted syndromes | Recorded syndromes | |
| Qi deficiency of spleen and kidney (n = 80) | Deficiency of both qi and yin (n = 14) | |
| Qi deficiency of spleen and kidney | 70 (87.5) | 13 (92.9) |
| Deficiency of both qi and yin | 4 (5.0) | 1 (7.1) |
| Other types | 6 (7.5) | 0 |
| Type of publication | Average citation per paper |
| All papers | 12.2 |
| Case reports | 6.24 |
| Comparative studies | 16.9 |
| Reviews | 10.89 |
| Multicenter | 23.94 |
| RCT# | 25.57 |
| Evaluation | 9.92 |
| Top ten | 22.75 |
| Collaboration between 2 AL countries | 11.2 |
| Collaboration between 3 AL countries | 19.2 |
| Date | Test | Results | |
| Case 1 | Apr. 17, 2013 | NMDAR antibodies | Serum: positive (+) |
| CSF: Strong positive (++) | |||
| Apr. 18, 2013 | Pelvic CT | Left ovarian cystic lesions | |
| Apr. 22, 2013 | Pelvic Ultrasound | Left ovarian cyst | |
| May 9, 2013 | NMDAR antibodies | Serum: Weakly positive | |
| CSF: positive (+) | |||
| May 14, 2013 | Anatomopathology | Ovarian mature cystic teratoma | |
| May 22, 2013 | NMDAR antibodies | Serum: Negative (−) | |
| CSF: Weakly positive | |||
| Case 2 | June 16, 2014 | NMDAR antibodies | Serum: positive (+) |
| June 23, 2014 | NMDAR antibodies | Serum: Weakly positive | |
| CSF: positive (+) | |||
| June 26, 2014 | Pelvic Ultrasound | Right ovarian cyst | |
| June 26, 2014 | Pelvic MRI | Right ovarian cystic lesions | |
| July 1, 2014 | Anatomopathology | Ovarian mature cystic teratoma | |
| July 7, 2014 | NMDAR antibodies | Serum: Negative (−) | |
| CSF: positive (+) |
| N = 1129 Lesions in 964 Subjects | |
| Navigation Success (per lesion)a | 91.8% (1036/1129) |
| Navigation Success (per subject)a | 94.4% (910/964) |
| Number of Lesions Biopsied (per subject) | 1.2 ± 0.5 (964) [1.0] (1.0–5.0) |
| Biopsy Tools Used During ENB Index Procedureb | |
| Aspiration Needle | 52.2% (503/964) |
| Biopsy Forceps | 81.2% (783/964) |
| Cytology Brush | 47.0% (453/964) |
| Needle-Tipped Cytology Brush | 20.2% (195/964) |
| Triple Needle-Tipped Cytology Brush | 23.4% (226/964) |
| GenCutTM Core Biopsy Tool | 18.9% (182/964) |
| Bronchoalveolar Lavage or Washing | 37.8% (364/964) |
| Rapid on-site evaluation (ROSE) usedc | 66.1% (601/909) |
| Molecular/genetic testing attemptedd | 28.3% (70/247) |
| Molecular/genetic testing successful | 80.0% (56/70) |
| Inadequate Sample | 20.0% (14/70) |
| Molecular/genetic testing not attemptedd | 71.7% (177/247) |
| Not Necessary | 49.2% (87/177) |
| Not Standard Practice | 41.2% (73/177) |
| Other | 9.6% (17/177) |
| Bacteria | Antibiotics (100 mg ml-1) | Larval Extracts (200 mg ml-1) | ||
| L. cuprina | S. peregrina | M. domestica | ||
| S. aureus | Chloramphenicol 1.56 | 100.0 | - | - |
| MRSA | Chloramphenicol 25.0 | 100.0 | 100.0 | 100.0 |
| P. aeruginosa | Gentamicin 1.56 | 100.0 | - | - |
| E. coli | Gentamicin 0.78 | 100.0 | - | - |
| Infection parameters | Distributions | |||
| Gonorrhoea | Reference | Chlamydia | Reference | |
| Probability of infection being symptomatic | ||||
| Male | β (0.9, 0.05) | [12-15] | β (0.30, 0.15) | [12,13] |
| Female | β (0.4, 0.15) | [12-15] | β (0.15, 0.08) | [12,13] |
| Duration of latent period (days) | U (3, 5) | [13,16-18] | U (12, 28) | [13,17,19] |
| Duration of asymptomatic infection in the absence of treatment (days) | Γ (105, 35) | [12,13,20] | Γ (220, 188) | [12,19,21-24]* |
| Duration of symptomatic infection in the absence of treatment (days) | Γ (105, 35) | [12,13,20] | Γ (112, 35) | [12,25] |
| Duration of immunity following recovery (days) | Γ (7, 3.5) | - | Γ (45, 15) | - |
| Transmission probability per sex act | ||||
| Male to Female | β (0.2, 0.05) | [12,21,26,27] | β (0.16, 0.10) | [12,19,28,29] |
| Female to Male | β (0.4, 0.10) | [12,21,26,30,31] | β (0.12, 0.06) | [12,19,28,29] |
| Urban | Rural | |||||||||||
| Characteristics | Total | Children who received PLF | Total | Children who received PLF | ||||||||
| N † | % ¶ | n § | % ‡ | 95%CI | P value | N † | % ¶ | n§ | % ‡ | 95%CI | P value | |
| Maternal socio demographic,characteristics | ||||||||||||
| Mother's age at birth | ||||||||||||
| <=19 | 317 | 8.2 | 217 | 63.5 | (58.4–68.6) | <0.001 | 1336 | 16.9 | 1019 | 73.7 | (71.4–76.0) | <0.001 |
| 20–24 | 931 | 24.0 | 507 | 51.6 | (48.5–54.7) | 1998 | 25.3 | 1248 | 64.7 | (62.5–66.8) | ||
| 25–29 | 1181 | 30.4 | 630 | 48.4 | (45.7–51.1) | 2035 | 25.8 | 1256 | 64.2 | (62.1–66.4) | ||
| 30–34 | 820 | 21.1 | 387 | 44.2 | (41.0–47.5) | 1282 | 16.3 | 761 | 63.0 | (60.3–65.7) | ||
| >=35 | 630 | 16.2 | 334 | 49.9 | (46.1–53.7) | 1237 | 15.7 | 788 | 67.8 | (65.1–70.5) | ||
| Mother's education | ||||||||||||
| No education | 774 | 20.0 | 553 | 64.3 | (61.1–67.5) | <0.001 | 4557 | 57.8 | 3596 | 75.7 | (74.5–76.9) | <0.001 |
| Primary | 774 | 20.0 | 427 | 52.6 | (49.2–56.0) | 1502 | 19.0 | 731 | 55.8 | (53.1–58.4) | ||
| Secondary and above | 2331 | 60.0 | 1096 | 43.8 | (41.9–45.8) | 1829 | 23.2 | 745 | 47.3 | (44.8–49.8) | ||
| Mother's occupation | ||||||||||||
| Non-working | 1042 | 27.0 | 638 | 56.3 | (53.4–59.1) | <0.001 | 2645 | 33.7 | 1780 | 68.9 | (67.1–70.7) | 0.001 |
| Working | 2820 | 73.0 | 1427 | 47.3 | (45.5–49.0) | 5200 | 66.3 | 3272 | 65.1 | (63.8–66.4) | ||
| Wealth index | ||||||||||||
| Lowest | 144 | 3.7 | 93 | 64.6 | (56.9–72.6) | <0.001 | 2455 | 31.1 | 1995 | 77.0 | (75.3–78.6) | <0.001 |
| Second | 269 | 6.9 | 167 | 56.2 | (50.6–61.9) | 2463 | 31.2 | 1583 | 66.2 | (64.2–68.0) | ||
| Middle | 677 | 17.5 | 389 | 58.3 | (54.5–62.0) | 1675 | 21.2 | 911 | 58.3 | (55.9–60.8) | ||
| Fourth | 1216 | 31.3 | 686 | 52.3 | (49.6–55.0) | 975 | 12.4 | 467 | 57.7 | (54.3–61.1) | ||
| Highest | 1573 | 40.6 | 741 | 42.3 | (40.0–44.6) | 320 | 4.1 | 116 | 41.3 | (35.6–47.1) | ||
| Zones | ||||||||||||
| North Central | 530 | 13.7 | 146 | 37.6 | (32.8–42.4) | <0.001 | 1204 | 15.3 | 673 | 54.3 | (51.5–57.1) | <0.001 |
| North East | 505 | 13.0 | 321 | 63.6 | (59.4–67.8) | 1905 | 24.2 | 1217 | 79.6 | (77.6–81.6) | ||
| North West | 684 | 17.6 | 629 | 67.6 | (64.6–70.6) | 2963 | 37.6 | 2428 | 72.3 | (70.8–73.8) | ||
| South East | 688 | 17.7 | 405 | 55.0 | (51.4–58.6) | 382 | 4.8 | 193 | 56.8 | (51.5–62.0) | ||
| South South | 437 | 11.3 | 161 | 41.4 | (36.5–46.3) | 989 | 12.5 | 375 | 51.6 | (48.0–55.2) | ||
| South West | 1035 | 26.7 | 414 | 33.9 | (31.2–36.5) | 445 | 5.6 | 185 | 41.8 | (37.2–46.4) | ||
| Antenatal and postnatal factors | ||||||||||||
| Combined birth interval and rank | ||||||||||||
| 1st birth rank | 869 | 22.4 | 485 | 51.7 | (48.4–54.9) | <0.001 | 1447 | 18.4 | 947 | 66.5 | (64.1–67.0) | 0.052 |
| 2nd–3rd birth rank,<=23 monthsinterval | 324 | 8.4 | 177 | 50.3 | (45.1–55.5) | 445 | 5.8 | 263 | 63.2 | (58.6–67.9) | ||
| 2nd–3rd birth rank, 24 monthsand above interval | 1079 | 27.9 | 498 | 43.8 | (40.9–46.7) | 1904 | 24.2 | 1222 | 64.7 | (62.5–66.8) | ||
| 4th and above birth rank,<=23months interval | 253 | 6.5 | 149 | 56.9 | (50.7–62.7) | 618 | 7.9 | 380 | 64.5 | (60.7–68.4) | ||
| 4th and above birth rank, 24months and above interval | 1346 | 34.8 | 757 | 51.4 | (48.9–60.0) | 3445 | 43.8 | 2246 | 68.0 | (66.4–69.6) | ||
| Antenatal care visit | ||||||||||||
| 0 | 384 | 10.3 | 268 | 63.1 | (58.4–67.6) | <0.001 | 3421 | 44.2 | 2539 | 73.2 | (71.8–74.7) | <0.001 |
| 1–3 | 432 | 11.6 | 276 | 57.4 | (52.9–61.7) | 1130 | 14.6 | 727 | 67.4 | (64.6–70.2) | ||
| 4 and above | 2917 | 78.1 | 1477 | 47.3 | (45.6–49.1) | 3187 | 41.2 | 1737 | 59.0 | (57.2–60.7) | ||
| Place of delivery | ||||||||||||
| Home | 1337 | 34.5 | 930 | 61.6 | (59.1–64.0) | <0.001 | 5937 | 75.4 | 4245 | 72.5 | (71.3–73.6) | <0.001 |
| Health facility | 2535 | 65.5 | 1145 | 43.1 | (41.2–45.0) | 1934 | 24.6 | 821 | 46.5 | (44.1–48.8) | ||
| Mode of delivery | ||||||||||||
| Spontaneous vaginal delivery | 3637 | 95.4 | 1964 | 50.0 | (48.5–51.6) | 0.238 | 7789 | 98.9 | 5025 | 66.6 | (65.5–67.7) | 0.009 |
| Caesarean section | 175 | 4.6 | 92 | 54.8 | (47.2–62.3) | 87 | 1.1 | 43 | 52.4 | (41.4–63.2) | ||
| Type of birth | ||||||||||||
| Single | 3814 | 98.3 | 2027 | 49.4 | (47.9–51.0) | <0.001 | 7759 | 98.4 | 4981 | 66.4 | (65.3–67.4) | 0.782 |
| Multiple | 65 | 1.7 | 49 | 73.1 | (61.8–83.4) | 129 | 1.6 | 91 | 67.9 | (59.8–75.7) | ||
| Sex of child | ||||||||||||
| Male | 1963 | 50.6 | 1027 | 49.4 | (47.2–51.5) | 0.642 | 4010 | 50.8 | 2566 | 66.9 | (65.4–68.4) | 0.370 |
| Female | 1916 | 49.4 | 1048 | 50.1 | (48.0–52.3) | 3878 | 49.2 | 2506 | 65.9 | (64.4–67.4) | ||
| Size of child at birth | ||||||||||||
| Small | 478 | 12.4 | 303 | 58.3 | (53.9–62.4) | <0.001 | 1321 | 16.8 | 964 | 75.1 | (72.7–77.4) | <0.001 |
| Average | 1604 | 41.5 | 939 | 53.3 | (51.0–55.7) | 3141 | 40.1 | 2133 | 70.7 | (69.0–72.3) | ||
| Large | 1784 | 46.1 | 828 | 44.1 | (41.8–46.3) | 3379 | 43.1 | 1952 | 59.2 | (57.5–60.9) |
| Evaluated parameters | DF group (n = 104)* | C group (n = 48)** | P value | |
| Education level | Basic education/training (% of patients) | 30.4 | 8.4 | P < 0.001 |
| Secondary without leaving exam (% of patients) | 25.5 | 16.7 | NS | |
| Secondary with leaving exam (% of patients) | 30.4 | 33.3 | NS | |
| University (% of patients) | 13.7 | 41.7 | P < 0.001 | |
| Employment status | Full-time job (% of patients) | 11.7 | 29.2 | P < 0.001† |
| Part-time job (% of patients) | 4.9 | 2.1 | NS | |
| Business (% of patients) | 4.9 | 18.8 | P < 0.001† | |
| Old age pension (% of patients) | 34 | 39.6 | NS | |
| Disability pension (% of patients) | 41.7 | 6.2 | P < 0.001† | |
| Others (% of patients) | 2.9 | 4.2 | NS | |
| Self-support | Fully self-support (% of patients) | 38.1 | 87.2 | P < 0.001†† |
| Partially self-support (% of patients) | 55.7 | 12.8 | P < 0.001†† | |
| Fully dependent on the assistance of other persons (% of patients) | 6.2 | 0 | NS |
| Subjects | -1,026 bp | -277 bp | Haplotype | |||||||
| G/G | G/T | T/T | A/A | A/G | G/G | GA | TA | GG | TG | |
| SSc with PAH (n = 20) | 20 (100) | 0 | 0 | 20 (100) | 0 | 0 | 40 | 0 | 0 | 0 |
| SSc without PAH (n = 58) | 43 (74) | 11 (19) | 4 (7) | 43 (74) | 10 (17) | 5 (9) | 96 | 0 | 1 | 19 |
| Healthy controls (n = 95) | 69 (73) | 23 (24) | 3 (3) | 73 (77) | 19 (20) | 3 (3) | 161 | 0 | 4 | 25 |
| Group | Number of subjects | M/F | Age |
| Low SES | 25 | 14/11 | 24.4 ± 1.2 |
| Mid SES | 27 | 14/13 | 23.1 ± 1.2 |
| MCHC Physicians | Non-MCHC Physicians | Nurses | Parents | |||||
| N | % | N | % | N | % | N | % | |
| Physical Examination | 86/94 | 91.5 | 129/146 | 88.4 | 137/148 | 92.6 | 923/1050 | 87.9 |
| Detection of Abnormal Health Conditions | 77/93 | 82.8 | 124/147 | 84.4 | 130/148 | 87.8 | 981/1049 | 93.5* |
| Developmental Screening | 79/94 | 84 | 126/145 | 86.9 | 94/148 | 63.5** | 876/1050 | 83.4 |
| Anticipatory Guidance | 73/94 | 77.7 | 104/145 | 71.7 | 68/146 | 46.6** | 312/1050 | 29.7** |
| Parent-child interaction counseling | 70/93 | 75.3 | 95/145 | 65.5 | 60/144 | 41.7** | 235/1050 | 22.4** |
| Consultant for MCHC Staff | 70/94 | 74.5 | 125/147 | 85 | 110/147 | 74.8 | 602/1048 | 57.4** |
| Detection of Children at Risk | 71/92 | 77.2 | 121/143 | 84.6* | 104/148 | 70.3 | 749/1050 | 71.3 |
| Growth Surveillance | 69/93 | 74.2 | 121/146 | 82.9 | 61/146 | 41.8** | 426/1050 | 40.6** |
| Vaccination Counseling | 57/93 | 61.3 | 123/145 | 84.8 | 50/145 | 34.5** | 358/1050 | 34.1** |
| Primary Care Physician Communication | 36/90 | 40** | 108/146 | 74 | 92/148 | 62.2 | 737/1050 | 70.2 |
| Proposal ingredient | Key question | Review criteria | Check (yes/no) |
| 1. The care gap or quality gap | The proposal has clear evidence that a gap in quality exists? | Significance Impact | |
| 2. The evidence-based treatment to be implemented | Is the evidence for the program, treatment, or set of services to be implemented demonstrated? | Significance Innovation | |
| 3. Conceptual model and theoretical justification | The proposal delineates a clear conceptual framework/theory/model that informs the design and variables being tested? | Approach Innovation | |
| 4. Stakeholder priorities, engagement in change | Is there a clear engagement process of the stakeholders in place? | Significance Impact Approach Environment | |
| 5. Setting’s readiness to adopt new services/treatments/programs | Is there clear information that reflects the setting’s readiness, capacity, or appetite for change, specifically around adoption of the proposed evidence-based treatment? | Impact Approach Environment | |
| 6. Implementation strategy/process | Are the strategies to implement the intervention clearly defined, and justified conceptually? | Significance Impact Innovation | |
| 7. Team experience with the setting, treatment, implementation process | Does the proposal detail the team’s experience with the study setting, the treatment whose implementation is being studied, and implementation processes? | Approach Investigator team | |
| 8. Feasibility of proposed research design and methods | Does the methods section contain as much detail as possible, as well as lay out possible choice junctures and contingencies, should methods not work as planned? | Approach Investigator team | |
| 9. Measurement and analysis section | Does the proposal clarify the key constructs to be measured, corresponding to the overarching conceptual model or theory? | Approach Investigator team | |
| Is a measurement plan clear for each construct? | |||
| Does the analysis section demonstrate how relationships between constructs will be tested? | |||
| 10. Policy/funding environment; leverage or support for sustaining change | Does the proposal address how the implementation initiative aligns with policy trends? | Impact Significance |
| WCST Error Score | ||
| Component 1 | Component 2 | |
| (7.4% Variance) | (6.5% Variance) | |
| Age | 0.391 | |
| Education | −0.538 | |
| Income | −0.295 | |
| Proficiency L1 | −0.283 | |
| Open to experiences | −0.258 | |
| QoL | 0.437 | |
| Attitude L3 | 0.436 | |
| Emotional stability | 0.280 |
| Independent variables | Non-working | Irregular employees | Regular employees |
| Age and Marital status | |||
| Age | 0.0187 | 0.0269** | −0.006 |
| (0.0129) | (0.0126) | (0.0169) | |
| Married | −0.349*** | 0.0361 | −0.0957 |
| (0.101) | (0.104) | (0.148) | |
| Educational attainment | |||
| Junior high school | −0.00893 | −0.101 | 0.0893 |
| (0.106) | (0.108) | (0.151) | |
| Vocational school | −0.0298 | 0.190* | −0.0753 |
| (0.111) | (0.114) | (0.150) | |
| Junior college or technical college | 0.121 | 0.0536 | −0.120 |
| (0.0921) | (0.107) | (0.156) | |
| University | −0.0657 | −0.0973 | −0.157 |
| (0.106) | (0.0986) | (0.105) | |
| Graduate school | −0.145 | 0.000837 | 0.284 |
| (0.513) | (0.388) | (0.302) | |
| Residence | |||
| Rental housing | 0.0491 | 0.227* | 0.197 |
| (0.137) | (0.121) | (0.163) | |
| Company residence | −0.371 | 0.560 | 0.254 |
| (0.522) | (0.425) | (0.450) | |
| Other residences | −0.169 | 0.357 | 0.510 |
| (0.263) | (0.225) | (0.335) | |
| Health status and Medical care use | |||
| Diabetes | −0.0372 | −0.151 | −0.0755 |
| (0.122) | (0.125) | (0.148) | |
| Heart disease | 0.0851 | 0.0306 | 0.320* |
| (0.166) | (0.167) | (0.187) | |
| Cerebral stroke | 0.0890 | 0.203 | −0.681 |
| (0.222) | (0.259) | (0.545) | |
| Cancer | −0.0948 | −0.00433 | 0.435 |
| (0.212) | (0.238) | (0.300) | |
| Having friend/acquaintances | −0.0823 | 0.0586 | 0.121 |
| (0.0867) | (0.103) | (0.122) |
| GO biological process terms | p-value | GO biological process terms | p-value |
| Genes up-regulated in erythroblasts | |||
| heme biosynthesis | 8.3593E-09 | tRNA metabolism | 4.7686E-04 |
| heme metabolism | 4.1178E-08 | nitrogen compound metabolism | 0.0011 |
| pigment biosynthesis | 7.8243E-08 | cholesterol biosynthesis | 0.0021 |
| porphyrin biosynthesis | 8.0158E-08 | amino acid activation | 0.0022 |
| pigment metabolism | 1.8805E-07 | tRNA aminoacylation for protein translation | 0.0022 |
| porphyrin metabolism | 2.5313E-07 | tRNA aminoacylation | 0.0022 |
| carboxylic acid metabolism | 3.5431E-07 | electron transport | 0.0023 |
| organic acid metabolism | 4.0819E-07 | amino acid and derivative metabolism | 0.0025 |
| secondary metabolism | 5.8601E-07 | amine metabolism | 0.0037 |
| heterocycle metabolism | 4.7133E-06 | lipid metabolism | 0.0037 |
| cellular biosynthesis | 6.9372E-06 | steroid biosynthesis | 0.0041 |
| cofactor metabolism | 1.0534E-05 | cholesterol metabolism | 0.0041 |
| cofactor biosynthesis | 1.9914E-05 | iron ion homeostasis | 0.0042 |
| generation of precursor metabolites and energy | 3.9831E-05 | sterol biosynthesis | 0.0045 |
| cellular metabolism | 5.6290E-05 | mitotic cell cycle | 0.0059 |
| lipid biosynthesis | 1.6546E-04 | alcohol metabolism | 0.0060 |
| cellular lipid metabolism | 2.3765E-04 | sterol metabolism | 0.0061 |
| amino acid metabolism | 4.3568E-04 | ||
| Genes up-regulated in megakaryoblasts | |||
| hemostasis | 0.0010 | positive regulation of cell proliferation | 0.0024 |
| endocytosis | 0.0011 | steroid metabolism | 0.0024 |
| cellular lipid metabolism | 0.0012 | lipid biosynthesis | 0.0026 |
| wound healing | 0.0014 | regulation of receptor mediated endocytosis | 0.0034 |
| lipid metabolism | 0.0020 | localization of cell | 0.0049 |
| alcohol metabolism | 0.0020 | cell motility | 0.0049 |
| regulation of body fluids | 0.0024 | cytoskeleton organization and biogenesis | 0.0081 |
| transport | 0.0024 | cholesterol biosynthesis | 0.0089 |
| Genes up-regulated in monoblasts | |||
| response to biotic stimulus | 6.3071E-15 | antimicrobial humoral response | 3.1669E-04 |
| immune response | 2.8466E-13 | detection of stimulus | 6.8750E-04 |
| defense response | 7.3698E-13 | protein kinase cascade | 0.0010 |
| response to pest, pathogen or parasite | 1.2074E-12 | wound healing | 0.0014 |
| response to other organism | 2.4524E-12 | intracellular signaling cascade | 0.0017 |
| response to external stimulus | 1.0443E-10 | positive regulation of cellular process | 0.0017 |
| response to stimulus | 8.1038E-10 | endocytosis | 0.0019 |
| response to wounding | 1.3630E-09 | I-kappaB kinase/NF-kappaB cascade | 0.0025 |
| response to stress | 2.1560E-08 | lymphocyte activation | 0.0031 |
| inflammatory response | 3.0602E-08 | blood coagulation | 0.0034 |
| cell communication | 5.0323E-07 | taxis | 0.0035 |
| signal transduction | 7.7480E-07 | chemotaxis | 0.0035 |
| organismal physiological process | 8.0044E-07 | innate immune response | 0.0037 |
| response to pathogen | 3.1842E-06 | coagulation | 0.0038 |
| humoral immune response | 3.4723E-05 | locomotory behavior | 0.0044 |
| detection of biotic stimulus | 4.6946E-05 | hemostasis | 0.0045 |
| response to bacteria | 6.7200E-05 | carbohydrate metabolism | 0.0048 |
| response to pathogenic bacteria | 9.7266E-05 | cell surface receptor linked signal transduction | 0.0059 |
| immune cell activation | 1.0815E-04 | positive regulation of biological process | 0.0064 |
| cell activation | 1.2116E-04 | macrophage activation | 0.0093 |
| humoral defense mechanism (sensu Vertebrata) | 1.4837E-04 | regulation of body fluids | 0.0097 |
| antimicrobial humoral response (sensu Vertebrata) | 2.8361E-04 | ||
| Genes up-regulated in myeloblasts | |||
| carboxylic acid metabolism | 2.2728E-05 | defense response | 0.0018 |
| organic acid metabolism | 2.3815E-05 | response to biotic stimulus | 0.0025 |
| cellular biosynthesis | 7.1605E-04 | immune response | 0.0048 |
| biosynthesis | 0.0016 | positive regulation of cell proliferation | 0.0069 |
| Peaks | Human | Yeast | Random |
| 1 | 0.246 | 0.218 | 0.402 |
| 2 | 0.213 | 0.168 | 0.320 |
| 3 | 0.188 | 0.151 | 0.269 |
| Gene3D | Pfam | Panther | SeqF_95 | SeqF_99 | SeqF_100 | |
| True positive sensitivity | 0.998 | 0.937 | 0.919 | 0.862 | 0.821 | 0.492 |
| False negative sensitivity | 0.907 | 0.704 | 0.532 | 0.831 | 0.775 | 0.282 |
| Overall (TP + FN) sensitivity | 0.983 | 0.898 | 0.831 | 0.857 | 0.814 | 0.457 |
| (False positive) specificity | 0.854 | 1.000 | - | 0.452 | 0.603 | 0.973 |
| Positive predictive value | 0.990 | 1.000 | - | 0.948 | 0.960 | 0.995 |
| Sensitivity at <35% seq-ID | 0.925 | 0.761 | 0.639 | 0.769 | 0.699 | 0.316 |
| Sensitivity at <30% seq-ID | 0.869 | 0.738 | 0.618 | 0.869 | 0.783 | 0.400 |
| Sensitivity at <25% seq-ID | 0.600 | 0.467 | 0.250 | 0.933 | 0.786 | 0.429 |
| Variables | SD | SD + Chol (0.25 %) | HF + Chol (0.25 %) | |||
| Sham | Ovx | Sham | Ovx | Sham | Ovx | |
| Final body weight (g) | 353.9 ± 11.3 | 439.6 ± 14.5*** | 347.5 ± 8.7 | 431.6 ± 25.7*** | 391.6 ± 13.7 | 467.4 ± 15.6*** |
| Intra-abdominal fat pad weights (g) | 29.2 ± 4.4 | 39.3 ± 3.7** | 26.6 ± 2.6 | 40.2 ± 4.9** | 38.7 ± 3.8 | 43.8 ± 2.6** |
| Food intake (kcal/day) | 82.7 ± 4.3 | 99.8 ± 4.2*** | 81 ± 2.5 | 95.7 ± 7.0*** | 94.9 ± 4.7†δ | 110.1 ± 4.2***†δ |
| Uterus (g) | 0.50 ± 0.03 | 0.10 ± 0.01*** | 0.51 ± 0.07 | 0.10 ± 0.01*** | 0.47 ± 0.05 | 0.11 ± 0.01*** |
| AGRF ID | GenBank Accession | UniGene Cluster | Gene | Fold Change | P Value |
| H3084H06 | BG070211 | Mm.25335 | EST: Cdc14b: CDC14 cell division cycle 14 homolog B (S. cerevisiae) | + 3.1 | 0.044 |
| H3137G08 | BG074662 | Mm.197274 | EST: Moderately similar to GNMSLL retrovirus-related reverse transcriptase homolog – mouse retrotransposon (M. musculus) | + 3.0 | 0.046 |
| H3123E03 | BG073512 | Mm.197252 | EST: Weakly similar to TLM MOUSE TLM PROTEIN (M. musculus) | + 2.9 | 0.047 |
| H3073G12 | BG069200 | Mm.328026 | EST: Transcribed sequence with moderate similarity to protein ref:NP_083358.1 (M. musculus); RIKEN cDNA 5830411J07 | + 2.5 | 0.038 |
| H3082G05 | AU014577 | Not assigned | EST | + 2.1 | 0.032 |
| Mean (SD) | |
| Age | 43.7 (9.9) years |
| Gender | 11 males, 12 females |
| Center-edge angle | 33.7 (7.8)° |
| Alpha angle | 73 (9.6)° (all alpha angles were 55° or greater) |
| Loose bodies visible on radiographs | 5 (23.8%) |
| Loose bodies visible on MRI | 14 (66.6%) |
| Tonnis grade | Grade 0 in 14 patients (66.6%) |
| Grade 1 in 7 patients (28.5%) | |
| Grade 2 in one (4%) |
| Without allergy | With allergy | P-value | |
| (n = 387) | (n = 18) | ||
| Boys | |||
| Age | 12.44 ± 2.62 | 12.25 ± 3.33 | 0.056* |
| Height | 141.76 ± 16.24 | 147.59 ± 16.44 | 0.229 |
| Weight | 35.54 ± 10.25 | 37.53 ± 12.46 | 0.519 |
| HAZ | −1.43 ± 1.21 | −0.52 ± 0.96 | 0.011* |
| WAZ | −1.26 ± 1.03 | −0.85 ± 0.82 | 0.176 |
| BMIZ | −0.61 ± 1.27 | −0.88 ± 0.87 | 0.460 |
| Parasitic infection | 0.21 ± 0.41 | 0.42 ± 0.51 | 0.102 |
| Total IgE (IU/ml) | 1809.59 ± 3037.425 | 1257.00 ± 1212.94 | 0.690 |
| Girls | |||
| Age | 11.72 ± 2.25 | 14.00 ± 4.00 | 0.019* |
| Height | 138.83 ± 13.28 | 142.67 ± 15.11 | 0.490 |
| Weight | 34.96 ± 9.15 | 40.58 ± 17.37 | 0.154 |
| HAZ | −1.35 ± 1.40 | −1.63 ± 0.58 | 0.637 |
| WAZ | −0.89 ± 1.00 | −1.06 ± 1.21 | 0.676 |
| BMIZ | −0.27 ± 1.43 | −0.32 ± 1.01 | 0.941 |
| Parasitic infection | 0.23 ± 0.42 | 0.33 ± 0.52 | 0.543 |
| Total IgE (IU/ml) | 2000.98 ± 3127.71 | 1267.67 ± 1793.02 | 0.692 |
| Group | At surgery | At 8 weeks | ISQ change |
| Control | 46.83 ± 3.97 | 60.17 ± 3.25 | 13.33 ± 5.43 |
| 0.1 | 48.00 ± 4.00 | 64.83 ± 3.19 | 16.83 ± 4.67 |
| 0.5 | 49.83 ± 5.95 | 71.67 ± 6.15 | 19.83 ± 9.56 |
| 1.0 | 52.67 ± 7.61 | 72.00 ± 2.68 | 18.17 ± 6.94 |
| Period | Activity | Who involved |
| Month 1 | Consultation and sensitisation of Kilifi District stakeholders | 1. MoH structure: District Medical Officer of Health and District Health Management Team at Kilifi District Hospital. All health facility in-charges working in Kilifi District |
| 2. Provincial administration structures: District Commissioner, Senior District Officer, all chiefs working in Kilifi District | ||
| Months 2 to 6 | Community entry and sensitisation of stakeholders in sites A, B and C respectively | 1. MoH Structure: Dispensary health committees, dispensary staff (facility in-charges, nurses, public health officers, community health extension workers), and community health workers (CHWs) |
| 2. Local administration: District officers, local (assistant) chiefs and village elders | ||
| 3. Others: primary school head teachers, religious leaders, a local District Stakeholders Forum | ||
| Months 8 to 13 | Identification and recruitment of 5 to 17 month-old children (n = 600) | CHWs and fieldworkers |
| Months 15 to 27 | Identification and recruitment of 6 to 12 week-old children (n = 304) | CHWs and fieldworkers |
| From month 8 to date | Follow-up of research participants | Fieldworkers |
| Continuous feedback to and from community | Fieldworkers and other key gatekeepers | |
| Feedback of results | Involves all of the above, for example, preliminary study results disseminated |
| Item | N | Change + | No change | Change - | p | |||
| n | % | n | % | n | % | |||
| Habit: days’ sunbathing on the beach | 228 | 73 | 32.0 | 112 | 49.1 | 43 | 18.9 | 0.108 |
| Habit: hours per day | 224 | 75 | 33.5 | 101 | 45.1 | 48 | 21.4 | 0.068 |
| Habit: mid-day sun exposure | 222 | 73 | 32.9 | 100 | 45.0 | 49 | 22.1 | 0.049 |
| Sunburn experienced during the previous summer | 227 | 60 | 26.4 | 131 | 57.7 | 36 | 15.9 | 0.051 |
| Practice: sunshade | 225 | 44 | 19.6 | 99 | 44.0 | 82 | 36.4 | 0.006 |
| Practice: sunglasses | 227 | 62 | 27.3 | 101 | 44.5 | 64 | 28.2 | 0.167 |
| Practice: sunhat | 215 | 45 | 20.9 | 118 | 54.9 | 52 | 24.2 | 0.529 |
| Practice: long-sleeves, long trousers | 221 | 11 | 5.0 | 193 | 87.3 | 17 | 7.7 | 0.690 |
| Practice: avoid mid-day exposure | 225 | 78 | 34.7 | 97 | 43.1 | 50 | 22.2 | 0.052 |
| Practice: use suncream | 227 | 69 | 30.4 | 102 | 44.9 | 56 | 24.7 | 0.547 |
| Overlap size | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 |
| Frequency | 151 | 22 | 9 | 13 | 4 | 1 | 10 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 |
| Sample | Rapprent (U/mg) | KM (mM) | kcat (min−1) |
| GOD + HRP | 165 | 112 ± 8.9 | 5.0 ± 0.2 |
| GNC-HNC-HMS | 162 | 119 ± 8.1 | 4.8 ± 0.3 |
| GOD-HRP-HMS | 136 | 136 ± 9.8 | 3.3 ± 0.1 |
| GOD + HNC-HMS | 145 | 127 ± 8.5 | 3.8 ± 0.2 |
| HRP + GNC-HMS | 149 | 131 ± 9.1 | 3.6 ± 0.1 |
| GNC-HNC-HMS[b] | 151 | 132 ± 9.3 | 3.7 ± 0.2 |
| Academic year | Number of students | Verbally noted by student during simulation* N(%) | Written in note after simulation N(%) | ||||
| Student discovered that acetaminophen was administered n(%) | Student established the dosage of acetaminophen | Student stated that the dose was too high | Student identified medication error in write up | Male | Female | ||
| 2010-11 | 114 | 88 (77) | 44 (39) | 12 (11) | 12 (11) | 4 (4) | 8 (7) |
| 2011-12 | 108 | 44 (41) | 49 (45) | 9 (8) | 9 (8) | 8 (7) | 1 (1) |
| 2012-13 | 118 | 102 (86) | 68 (58) | 16 (14) | 13 (11) | 7 (6) | 6 (5) |
| Total | 340 | 234 (69) | 161 (47) | 37 (11) | 34 (10) | 19 (6) | 15 (4) |
| Loci | Ref | Var | Gene | Variant type | Novel | Frequency of Mutation | |
| Mismatch Repair | |||||||
| 80149981 | A | G | MSH3 | nonsynonymous SNV | 0 | 0.60 | |
| 80168937 | G | A | MSH3 | nonsynonymous SNV | 0 | 0.51 | |
| 79950724 | G | C | MSH3 | nonsynonymous SNV | 0 | 0.02 | |
| 48023115 | T | C | MSH6 | synonymous SNV | 0 | 0.14 | |
| 48030588 | C | T | MSH6 | stopgain | 0 | 0.06 | |
| Tumor Suppressor | |||||||
| 63410110 | T | C | AMER1 | synonymous SNV | 0 | 0.08 | |
| 63412690 | A | C | AMER1 | nonsynonymous SNV | 0 | 0.06 | |
| 63411276 | G | A | AMER1 | stopgain | 0 | 0.06 | |
| 63411684 | G | T | AMER1 | nonsynonymous SNV | 1 | 0.06 | |
| 112162854 | T | C | APC | synonymous SNV | 0 | 0.52 | |
| 112164561 | G | A | APC | synonymous SNV | 0 | 0.49 | |
| 112176325 | G | A | APC | synonymous SNV | 0 | 0.49 | |
| 112176559 | T | G | APC | synonymous SNV | 0 | 0.54 | |
| 112177171 | G | A | APC | synonymous SNV | 0 | 0.59 | |
| 112176756 | T | A | APC | nonsynonymous SNV | 0 | 0.57 | |
| 112175770 | G | A | APC | synonymous SNV | 0 | 0.49 | |
| 112164586 | C | T | APC | stopgain | 0 | 0.06 | |
| 7579472 | G | C | TP53 | nonsynonymous SNV | 0 | 0.40 | |
| 48604664 | C | T | SMAD4 | nonsynonymous SNV | 1 | 0.08 | |
| Oncogenes | |||||||
| 70118935 | C | T | SOX9 | synonymous SNV | 0 | 0.13 | |
| 114912121 | G | A | TCF7L2 | synonymous SNV | 0 | 0.08 | |
| 114910829 | A | G | TCF7L2 | synonymous SNV | 0 | 0.05 | |
| 30732970 | G | A | TGFBR2 | nonsynonymous SNV | 0 | 0.06 | |
| 30713842 | C | T | TGFBR2 | synonymous SNV | 0 | 0.02 | |
| 178916890 | C | T | PIK3CA | nonsynonymous SNV | 0 | 0.06 | |
| 178952085 | A | G | PIK3CA | nonsynonymous SNV | 0 | 0.06 | |
| 25368462 | C | T | KRAS | synonymous SNV | 0 | 0.67 |
| P. falciparum ortholog | P. vivax ortholog | |||||
| Protein description | Ortholog group | PlasmoDB Gene ID | SP prediction | Predicted localization | PlasmoDB Gene ID | SP prediction* |
| Proline tRNA synthetase | OG4_11662 | PFI1240c | + | Apicoplast | PVX_099680 ® | + |
| OG4_10599 | PFL0670c | - | Cytosol | PVX_123380 | - | |
| Asparagine tRNA synthetase | OG4_44547 | PFE0475w | + | Apicoplast | PVX_098040 ® | + |
| OG4_10251 | PFB0525w | - | Cytosol | PVX_002940 | - | |
| Methionine tRNA synthetase | OG4_47490 | PF10_0053 | + | Apicoplast | PVX_094445 ® | + |
| OG4_10161 | PF10_0340 | - | Cytosol | PVX_110980 | - | |
| Leucine tRNA synthetase | OG4_11105 | PF08_0011 | + | Apicoplast | PVX_088945 ® | + |
| OG4_10828 | PFF1095w | - | Cytosol | PVX_114255 | - | |
| Glutamate tRNA amidotransferase subunit A | OG4_10803 | PFD0780w | + | Apicoplast | PVX_089895 ® | + |
| Initiation Factor-1 | OG4_12019 | MAL8P1.27 | + | Apicoplast | PVX_089095 ® | + |
| Initiation Factor-3 | OG4_14117 | PF14_0658 | + | Apicoplast | PVX_117015 ® | + |
| DNA gyrase subunit A | OG4_12828 | PFL1120c | + | Apicoplast | PVX_123795 ® | + |
| OG4_10491 | PF14_0316 | - | Nucleus | PVX_084855 | - | |
| DNA gyrase subunit B | OG4_12159 | PFL1915w | + | Apicoplast | PVX_100925 ® | + |
| OG4_10746 | PF10_0412 | - | Nucleus | PVX_111340 | - | |
| Ferredoxin | OG4_14702 | MAL13P1.95 | + | Apicoplast | PVX_122725 ® | + |
| Mass Range (Daltons) | WPH-P % Protein | WPH-AT % Protein |
| >20,000 | 44 | 13 |
| 5000–20,000 | 17 | 20 |
| 1500–5000 | 16 | 23 |
| 1000–1500 | 6 | 8 |
| 500–1000 | 8 | 12 |
| <500 | 9 | 23 |
| Number of patients | Total |
| n = 2,270 | |
| Age, years (SD) | 61.7 (17.0) |
| Sex, male (%) | 1,277 (56.3) |
| Height, metres (SD) | 1.68 (0.11) |
| Weight, kg (SD) | 78.1 (26.0) |
| BMI, mean (SD) | 27.6 (8.3) |
| BMI, n (%) | |
| <24 | 1,039 (45.9) |
| 25-29 | 594 (26.2) |
| 30-40 | 463 (20.4) |
| >40 | 169 (7.5) |
| Admission type | |
| Medical, n (%) | 2,270 (100) |
| Surgical | 0 |
| ICU admission diagnosis, n (%) | |
| Aspiration pneumonia | 330 (14.5) |
| Bacterial/viral pneumonia | 911 (40.1) |
| Sepsis (other than urinary tract) | 859 (37.8) |
| Sepsis of urinary tract origin | 170 (7.5) |
| APACHE II score, mean (SD) | 23.9 (7.9) |
| Days from hospital admission to ICU admission (hours), median [IQR] | 6.55 [0.08, 65.08] |
| Days from hospital admission to ICU admission, n (%) | |
| [0–1] day | 1,437 (63.4) |
| [1-3] days | 303 (13.4) |
| >3 days | 527 (23.3) |
| Length of ICU stay (days), median [IQR] | 11.5 [6.9-21.4] |
| Length of hospital stay (days), median [IQR] | 23.8 [13.8-48.5] |
| Length of mechanical ventilation (days), median [IQR] | 8.4 [4.6-19.2] |
| Ventilator-free days, median [IQR] | 46.4 [4.0-55.0] |
| Mortality (60 day),% | 30.5 |
| HIV Uninfected | HIV Infected | |||||
| Race/ethnicity, Region | N (%) | Crude OR (95% CI)* | Adj. OR (95% CI)* | N (%) | Crude OR (95% CI)* | Adj. OR (95% CI)* |
| United States White | 696 (17.7) | Referent | Referent | 43 (1.1) | 2.36 (1.17, 4.76) | 1.04 (0.38, 2.79) |
| United States Black | 1,638 (41.7) | 1.67 (1.31, 2.13) | 1.84 (1.42, 2.39) | 419 (10.7) | 1.89 (1.38, 2.58) | 2.60 (1.83, 3.71) |
| United States Hispanic | 65 (1.7) | 1.24 (0.63, 2.46) | 1.18 (0.56, 2.48) | 7 (0.2) | 4.58 (1.01, 20.76) | 3.30 (0.54, 20.19) |
| United States Other | 40 (1.0) | 1.08 (0.44, 2.63) | 1.13 (0.45, 2.83) | 2 (0.1) | n/a | n/a |
| Africa | 123 (3.1) | 3.28 (2.14, 5.03) | 2.28 (1.45, 3.59) | 21 (0.5) | 1.44 (0.47, 4.36) | 0.97 (0.32, 3.00) |
| Americas | 482 (12.3) | 1.72 (1.27, 2.33) | 1.36 (0.97, 1.91) | 64 (1.6) | 5.73 (3.36, 9.79) | 5.12 (2.84, 9.23) |
| East Asia | 79 (2.0) | 2.36 (1.38, 4.03) | 1.62 (0.93, 2.80) | 0 (0.0) | n/a | n/a |
| Europe/Middle East | 28 (0.7) | 4.58 (2.10, 9.97) | 3.38 (1.47, 7.76) | 0 (0.0) | n/a | n/a |
| India | 75 (1.9) | 7.77 (4.69, 12.85) | 5.09 (3.01, 8.60) | 0 (0.0) | n/a | n/a |
| Southeast Asia | 147 (3.7) | 3.98 (2.68, 5.90) | 2.88 (1.90, 4.37) | 2 (0.1) | 6.10 (0.38, 98.36) | n/a |
| Group A (n = 45) | Group B (n = 31) | Group C (n = 18) | ||||||
| Stool | Duodenal fluid | Stool | ||||||
| Kato-Katz | Filtration | Kato-Katz | Kato-Katz | |||||
| Helminth species | Positive/examined (%) | Intensity (epg) | Positive/examined (%) | Intensityb | Positive/examined (%) | Intensity (epg) | Positive/examined (%) | Intensity (epg) |
| Median (range) | Median (range) | Median (range) | Median (range) | |||||
| Opisthorchis viverrini | 45/45 (100) | 900 (60–13,710) | 19/32 (59.4) | 24 (1–7140) | 15/29 (52.7) | 40 (24–56) | 9/18 (50.0) | 24 (24–40) |
| Hookworma | 18/45 (40.0) | 180 (30–2940) | 4/32 (12.5) | 13 (5–27) | 6/29 (20.7) | 24 (24–72) | 0/18 (0) | n.a. |
| T. trichiura | 4/45 (8.9) | n.d. | 0/32 (0) | n.a. | 0/29 (0) | n.d. | 0/18 (0) | n.a. |
| Taenia spp.a | 7/45 (15.6) | n.d. | 0/32 (0) | n.a. | 0/29/0) | n.a. | 0/18 (0) | n.a. |
| Trichostrongylus spp.b | 0/45 (0) | n.a. | 0/32 (0) | n.a. | 3/29 (10.3) | n.d. | 2/18 (11.1) | n.d. |
| OPEN APPENDECTOMY | Nr. UNITS | TOTAL |
| 2/0 silk suture | 3 | 0.4 € |
| 2/0 braided absorbable suture | 2 | 4.3 € |
| Suction device | 1 | 2.3 € |
| TOTAL | 7 € | |
| LAPAROSCOPIC APPENDECTOMY | ||
| Hasson Trocar | 1 | 37 € |
| 5 mm Trocar | 2 | 70 € |
| Endoclinch | 1 | 75 € |
| Lap. Irrigation/suction device | 1s | 70 € |
| Biosyn® 3/0 | 2 | 4.3 € |
| 1-Ti-Cron® suture | 1 | 3 € |
| TOTAL | 259.3 € | |
| DIFFERENTIAL | + 252.3 € |
| HIV Knowledge Score | Chi square | p value | |||
| High Score | Medium Score | Low Score | |||
| Age | |||||
| 15–19 years | 5.2 % | 1.9 % | 4.4 % | 17.549 | 0.130 |
| 20–24 years | 10.1 % | 3.7 % | 8.1 % | ||
| 25–29 years | 9.7 % | 3.6 % | 7.3 % | ||
| 30–34 years | 7.6 % | 2.7 % | 5.0 % | ||
| 35–39 years | 6.0 % | 2.0 % | 4.2 % | ||
| 40–44 years | 4.9 % | 1.8 % | 3.6 % | ||
| 45–49 years | 3.7 % | 1.4 % | 2.9 % | ||
| Wealth Index | |||||
| Poorest | 4.5 % | 2.0 % | 4.1 % | 72.757 | <0.0001* |
| Poor | 6.1 % | 2.3 % | 6.0 % | ||
| Middle | 8.9 % | 3.5 % | 6.8 % | ||
| Rich | 11.8 % | 4.0 % | 8.7 % | ||
| Richest | 15.9 % | 5.3 % | 10.0 % | ||
| Highest Education | |||||
| No Education | 5.7 % | 2.8 % | 6.5 % | 159.963 | <0.0001* |
| Primary | 12.1 % | 4.8 % | 10.4 % | ||
| Secondary | 22.7 % | 7.8 % | 15.5 % | ||
| Higher | 6.8 % | 1.6 % | 3.3 % | ||
| Region | |||||
| Barisal | 6.8 % | 1.8 % | 3.5 % | 85.210 | <0.0001* |
| Chittagong | 7.2 % | 2.7 % | 6.2 % | ||
| Dhaka | 8.4 % | 3.5 % | 6.8 % | ||
| Khulna | 8.0 % | 3.1 % | 6.1 % | ||
| Rajshahi | 6.3 % | 2.5 % | 5.0 % | ||
| Rangpur | 5.9 % | 1.7 % | 4.0 % | ||
| Sylhet | 4.6 % | 1.7 % | 4.1 % | ||
| Type of Residence | |||||
| Urban | 20.3 % | 6.9 % | 14.1 % | 13.359 | 0.001* |
| Rural | 26.9 % | 10.2 % | 21.5 % | ||
| Sex of Household Head | |||||
| Male | 41.9 % | 15.6 % | 32.1 % | 12.201 | 0.002* |
| Female | 5.4 % | 1.5 % | 3.6 % |
| Social variable | Nonpregnant women | Pregnant women |
| Age (years) | 29.250 ± 2.314 | 28.333 ± 1.971 |
| Ethnicity | Han | Han |
| Occupation | ||
| Housewife | 0 | 3 |
| Employee | 20 | 27 |
| Level of education | ||
| <Technical | 6 | 10 |
| Bachelor | 9 | 13 |
| Master | 5 | 7 |
| Economic status | Regular | Regular |
| Diet ingredients, % (DM basis) | Ratio |
| Corn stalk pellets | 60.0 |
| Corn | 24.8 |
| Soybean meal | 10.4 |
| Wheat bran | 3.2 |
| Sodium chloride | 0.4 |
| Calcium hydrophosphate | 0.8 |
| Premixa | 0.4 |
| Nutrient composition (DM basis) | |
| Dry matter, % | 93.56 |
| Digestible energy, MJ/kg | 8.13 |
| Crude protein, % | 10.39 |
| Ether extract, % | 8.15 |
| Neutral detergent fiber, % | 22.79 |
| Acid detergent fiber, % | 16.0 |
| Vitamin E, IU/kg | 5.08 |
| Comp-ound | Docking Score | Residue involv-ed in hydrogen bonds | Residues involv-ed in π-π intera-ctions |
| 9 | -6.76 | Asp-168 | Lys 53, Arg 67 |
| 10 | -6.70 | Asp-168 | Arg 67 |
| 11 | -4.30 | Asp-168 | His 148, Arg 67 |
| 12 | -5.29 | Asp-168 | - |
| 13 | -4.52 | Asp-168 | His 174, Arg 67 |
| 14 | -4.69 | Met-109 | Phe 169 |
| 15 | -5.19 | Asp-168 | Arg 67 |
| Positive influenza A | Positive influenza B | Negative samples | ||||
| Seasonal H1N1 | 2009 pandemic H1N1 | H3N2 | H5N1 | |||
| RT-qPCR | 14 | 39 | 29 | 2 | 69 | 80 |
| Multiplex DPO PCR | 13 | 25 | 16 | 2 | 43 | 134 |
| Positive Concordant Percentage | 56 (66.67%, 56/84) | 43(62.32%, 43/69) | ____ |
| Animal name | Genotype | Sex | Age (m) | Brain weight (g) | CA1 thickness (μm) | Cortex thickness (μm) | Nf | Nn |
| AN1 | WT | M | 8–9 | NA | 56 | 800 | 7 | 3 |
| AN4 | WT | M | 8–9 | 0.350 | 51 | 790 | 16 | 0 |
| AN18 | WT | M | 7–8 | 0.334 | 55 | 760 | 8 | 10 |
| AN19 | WT | F | 7–8 | 0.324 | 51 | 690 | 41 | 30 |
| AN20 | WT | F | 7–8 | 0.392 | 51 | 690 | 16 | 37 |
| AN21 | WT | F | 8–9 | 0.328 | 51 | 690 | 31 | 34 |
| AN10 | +/− | M | 8–9 | 0.364 | NA | NA | 42 | 33 |
| AN11 | +/− | M | 7–8 | 0.356 | 53 | 760 | 10 | 15 |
| AN12 | −/+ | F | 7–8 | 0.310 | 50 | 800 | 12 | 18 |
| AN16 | −/+ | M | 8–9 | 0.332 | 60 | 800 | 15 | 18 |
| AN5 | Tau | F | 8–9 | 0.192 | 26 | 580 | 17 | 15 |
| AN13 | Tau | F | 8–9 | 0.226 | 22 | 580 | 14 | 10 |
| AN14 | Tau | F | 8–9 | 0.236 | 27 | 580 | 24 | 25 |
| AN15 | Tau | M | 8–9 | 0.214 | 26 | 580 | 10 | 18 |
| AN22 | Tau | M | 7–8 | NA | 28 | 550 | 20 | 10 |
| AN23 | Tau | M | 7–8 | 0.198 | 24 | 550 | 7 | 10 |
| AN24 | Tau | F | 7–8 | 0.232 | 27 | 550 | 14 | 14 |
| AN25 | Tau | M | 7–8 | 0.226 | 26 | NA | 29 | 27 |
| Total | 333 | 327 |
| Wealth variable | Response options | Crude score | Rescaled crude score | Assigned weight | Weighted score |
| Main roof material | Cement/concrete | 4 | 1.00 | 5 | 5.00 |
| Corrugated iron | 3 | 0.67 | 3.35 | ||
| Wood planks/wood | 2 | 0.33 | 1.65 | ||
| Thatch / leaf/reed/bamboo | 1 | 0.00 | 0.00 | ||
| Type of toilet facility | Flush to septic tank/sewer system/pit latrine | 6 | 1.00 | 4 | 4.00 |
| Ventilated improved pit latrine (VIP) | 5 | 0.80 | 3.20 | ||
| Pit latrine with slab | 4 | 0.60 | 2.40 | ||
| Pit latrine without slab / open pit | 3 | 0.40 | 1.60 | ||
| Composting toilet | 2 | 0.20 | 0.80 | ||
| No facility / bush / field | 1 | 0.00 | 0.00 | ||
| Educational attainment | Higher | 6 | 1.00 | 3 | 3.00 |
| Complete secondary | 5 | 0.80 | 2.40 | ||
| Incomplete secondary | 4 | 0.60 | 1.80 | ||
| Complete primary | 3 | 0.40 | 1.20 | ||
| Incomplete primary | 2 | 0.20 | 0.60 | ||
| No education | 1 | 0.00 | 0.00 | ||
| Household owns table | Yes | 2 | 1.00 | 2 | 2.00 |
| No | 1 | 0.00 | 0.00 | ||
| Household has radio | Yes | 2 | 1.00 | 1 | 1.00 |
| No | 1 | 0.00 | 0.00 |
| Number | Raw CW (g) | Water Added (mL) | Mixing Condition | Final Liquid Volume (mL) | Recovery (g sugars/kg raw CW) |
| 1 | 250 | 250 | Mixer | 170 | 19.7 |
| 2 | 150 | 250 | Mixer | 250 | 29.7 |
| 3 | 250 | 250 | Shaking at 120 rpm (15 min) | 250 | 24.8 |
| 4 | 150 | 250 | Shaking at 120 rpm (15 min) | 250 | 30.3 |
| Correct | Under-triage | Over-triage | Total | |
| All missions | 67.5 (8589) | 9.2 (1166) | 23.4 (2974) | 100.0 (12729) |
| A priority | 23.1 (142) | - | 76.9 (474)a | 100.0 (616) |
| B priority | 13.9 (445) | 7.8 (248)b | 78.3 (2500)b | 100.0 (3193) |
| C priority | 87.5 (4933) | 12.5 (704)c | - | 100.0 (5637) |
| D priority | 93.5 (3069 | 6.5 (214)d | - | 100.0 (3283) |
| Male | 65.2 (4090) | 10.0 (627) | 24.8 (1558) | 100.0 (6275) |
| Female | 69.7 (4461) | 8.4 (537) | 21.9 (1399) | 100.0 (6397) |
| 16–64 years | 66.0 (3615) | 7.0 (383) | 27.0 (1477) | 100.0 (5475) |
| 65–74 years | 67.7 (1313) | 11.2 (218) | 21.1 (409) | 100.0 (1940) |
| 75–84 years | 69.6 (2160) | 10.3 (319) | 20.1 (623) | 100.0 (3102) |
| 85+ years | 67.9 (1501) | 11.1 (246) | 21.0 (465) | 100.0 (2212) |
| 00:00–08:00 | 67.7 (1933) | 8.8 (250) | 23.5 (671) | 100.0 (2854) |
| 08:00–16:00 | 67.4 (3567) | 9.5 (501) | 23.1 (1223) | 100.0 (5291) |
| 16:00–24:00 | 67.5 (3081) | 9.1 (414) | 23.5 (1072) | 100.0 (4567) |
| Operation | Duration (ms) |
| Conceptual preparation (from picture onset to selecting the target concept) | 175 |
| Lemma retrievalForm encoding: | 75 |
| Phonological code retrieval | 80 |
| Syllabification | 125 |
| Phonetic encoding (till initiation of articulation) | 145 |
| Total | 600 |
| Excluded species | Reasons for exclusion |
| Baissopsyche pura | Forewing venation not complete, key characters missing |
| Mesopsyche ordinata | Forewing width/length ratio at 0.48 much higher than that of all others (with typical ratio between 0.30 and 0.35 and two outliers at 0.27 and 0.38) |
| Mesopsyche justa | Base of forewing missing for holotype; inconsistent venation among holotype and paratypes. |
| Mesopsyche gentica | Base of forewing missing |
| Mesopsyche tortiva | Incomplete forewing and base of hind wing missing |
| Mesopsyche incompleta | Incomplete fore- and hind wings |
| Mesopsyche javorskii | Hind wing only |
| Mesopsyche tongchuanensis | Incomplete forewing only |
| Mesopanorpodes wianamattensis | Anal area of forewing missing |
| Permopsyche robustus | Incomplete forewing only |
| Mesoses optata | Incomplete forewing only |
| Mesoses magna | Incomplete forewing only |
| Mesoses gayndah | Incomplete forewing only |
| Ptychopteropsis mirabilis | Incomplete forewing only |
| Turanopsyche venosa | Incomplete hind wing only |
| Ferghanopsyche rotundata | Incomplete forewing only |
| Cryptography authentication | Biometrics recognition | |
| Authentication method | Digital | Analog |
| Authentication rule | Without error tolerance | With error tolerance |
| Data processing | Data is disordered | Data is processed but not disordered |
| Adoption of cryptography technique | Data can be encrypted and signed | Data cannot be encrypted or signed |
| Case | Removal of catheter | Antifungal treatment | Outcome | References |
| 1 | Yes | AmB (cumulative dose, 0.3 g) | Switching to permanent hemodialysis | [18] |
| 2 | Yes | AmB (cumulative dose, 2 g) | Cured | [20] |
| 3 | Yes | AmB + 5-FC | Died | [20] |
| 4 | Yes | AmB (cumulative dose, 1.4 g) + 5-FC (cumulative dose, 55 g) | Switching to permanent hemodialysis | [19] |
| 5 | Yes | MCZ × 3 days + AmB (cumulative dose, 0.5 g) | Cured | [16] |
| 6 | Yes | KCZ 400 mg/day × 2 days + FCZ 400 mg/day × 5 days | Cured | [21] |
| 7 | Yes | AmB 0.5 mg/kg/day × 6 weeks +5-FC × 4 weeks | Switching to permanent hemodialysis | [22] |
| 8 | Yes | (FCZ 200 mg/day + CPF 50 mg/day) × 5 days + AmB liposomal 400 mg/day × 7 days | Switching to permanent hemodialysis | [14] |
| 9 | Yes | FCZ200 mg/day × 6 days + AmB 0.5 mg/kg/day × 4 weeks | Switching to permanent hemodialysis | [15] |
| 10 | Yes | VCZ 500 mg × 8 days | Cured | [13] |
| 11 | No | AmB (cumulative dose, 2.5 g) + 5-FC 50 mg/kg × 6 weeks | Cured | [23] |
| 12 | No | AmB (cumulative dose, 1.9 g) | Cured | [17] |
| 13 | Yes | AmB 0.5 mg/kg/day × 6 weeks | Died | [24] |
| 14 | ND | ND | Died | [27] |
| 15 | No | (AmB + 5-FC) × 9 days + FCZ × 24 weeks | Cured | [26] |
| 16 | No | VCZ 400 mg/d × 10 days + AmB 100 mg/day × 4 days + | Cured | [25] |
| 17 | No | (VCZ 0.4 g/day + 5-FC 4 g/day) × 2 weeks | Cured | This study |
| 18 | No | (AmB 30 mg/days + 5-FC 4.5 g/day) × 4 weeks | Cured | This study |
| CESD-10 score category | n | Total tremor score | ETEA score | Number (%) who had been prescribed medication for tremor |
| 0–9 (no or minimal depressive symptoms) | 47 | 19.6 ± 6.2 | 19.9 ± 16.4 | 28 (59.6) |
| 10–19 (moderate depressive symptoms) | 37 | 22.1 ± 5.8 | 28.4 ± 16.4 | 24 (64.9) |
| ≥20 (severe depressive symptoms) | 7 | 19.0 ± 2.0 | 31.4 ± 17.6 | 7 (100) |
| p = 0.36a | p = 0.01b |
| Groupsa | Immunization time | |||
| 1st | 2nd | 3rd | 4th | |
| PBS | 100 μl | 100 μl | 100 μl | 100 μl |
| pEGFPb | 100 μg | 100 μg | 100 μg | 100 μg |
| pGRA4c | 100 μg | 100 μg | 100 μg | 100 μg |
| peptided | 100 μg | 100 μg | 100 μg | 100 μg |
| peptide/DNA | 100 μg peptide | 100 μg peptide | 100 μg pGRA4 | 100 μg pGRA4 |
| DNA/peptide | 100 μg pGRA4 | 100 μg pGRA4 | 100 μg peptide | 100 μg peptide |
| Variables | Knowledge | Value | Opinion | Practice | ||||
| Mean ± SD | P value | Mean ± SD | P value | Mean ± SD | P value | Mean ± SD | P value | |
| Sex | ||||||||
| Male | 41.6 ± 3.7 | 0.47 | 17.4 ± 2.2 | 0.88 | 18.3 ± 2.3 | 0.07 | 12.9 ± 2.2 | 0.76 |
| Female | 41.1 ± 3.6 | 18.3 ± 1.9 | 18.1 ± 1.9 | 12.9 ± 2.5 | ||||
| Age (in years) | ||||||||
| 25–34 | 40.9 ± 3.7 | 0.06 | 17.6 ± 2.1 | 0.96 | 18.1 ± 2.1 | 0.11 | 12.8 ± 2.5 | 0.42 |
| 35–44 | 42.3 ± 3.5 | 17.7 ± 2.0 | 18.7 ± 2.0 | 13.3 ± 1.9 | ||||
| ≥45 | 42.4 ± 3.8 | 17.7 ± 2.3 | 19.1 ± 2.9 | 13.3 ± 2.0 | ||||
| Qualification | ||||||||
| MDS | 44.5 ± 2.9 | 0.00* | 18.2 ± 1.9 | 0.07 | 20.2 ± 1.8 | 0.08 | 13.7 ± 0.4 | 0.01* |
| BDS | 39.7 ± 2.9 | 17.7 ± 2.0 | 19.3 ± 1.6 | 12.5 ± 2.7 | ||||
| Work experience (in years) | ||||||||
| <5 | 42.3 ± 4.2a | 0.04* | 17.7 ± 2.0 | 0.82 | 18.9 ± 2.0 | 0.78 | 12.8 ± 2.5 | 0.37 |
| 5–10 | 42.1 ± 3.3 | 17.8 ± 2.2 | 18.4 ± 1.9 | 12.9 ± 2.5 | ||||
| >10 | 40.7 ± 3.5a | 17.5 ± 2.1 | 17.8 ± 2.6 | 13.4 ± 1.7 | ||||
| Total | 41.8 ± 3.7 | 18.7 ± 2.8 | 18.1 ± 1.4 | 12.9 ± 2.3 |
| Variables | Frequency | Percent |
| Number of pregnancies | ||
| 1 | 161 | 29.7 |
| 2-3 | 276 | 50.9 |
| 4+ | 105 | 19.4 |
| Gestational age | ||
| ≤16 | 10 | 1.9 |
| 17–24 | 134 | 24.7 |
| 25–35 | 333 | 61.4 |
| ≥36 | 65 | 12.0 |
| Antenatal visit | ||
| Yes | 312 | 57.6 |
| No | 230 | 42.4 |
| Number of ANC visit (n = 312) | ||
| 1 | 122 | 39.1 |
| 2-3 | 176 | 56.4 |
| 4+ | 14 | 4.5 |
| Received information from health care providers | ||
| On HIV | ||
| Yes | 346 | 63.8 |
| No | 196 | 36.2 |
| On antenatal care | ||
| Yes | 304 | 56.1 |
| No | 238 | 43.9 |
| On MTCT | ||
| Yes | 284 | 52.4 |
| No | 258 | 47.6 |
| On infant feeding | ||
| Yes | 181 | 33.4 |
| No | 361 | 66.6 |
| Comprehensive knowledge of HIV/AIDS | ||
| Yes | 346 | 63.8 |
| No | 196 | 36.2 |
| Heard of PITC | ||
| Yes | 345 | 63.7 |
| No | 197 | 36.3 |
| Heard about MTCT | ||
| Yes | 458 | 84.5 |
| No | 84 | 15.5 |
| Know the means of transmission on MTCT (n = 458) | ||
| During pregnancy | 309 | 67.5 |
| During labor/delivery | 324 | 70.7 |
| During breast feeding | 251 | 54.8 |
| Exact timing of MTCT answered by women | ||
| None | 84 | 15.5 |
| One | 130 | 24.0 |
| Two | 225 | 41.5 |
| Three | 103 | 19.0 |
| No. of contigs with hits | No. of unique accessions | No. of unique protein hits | |
| Zebrafish RefSeq | 87,931 | 19,711 | 19,711 |
| Uniprot/Swiss-Prot | 80,012 | 26,396 | 17,669 |
| Total | 94,476 | - | 25,144 |
| Model 1 | Model 2 | Model 3 | Model 4 | Model 5 | |
| Segregation | |||||
| D <0.6 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| D >0.6 | 1.16 (1.13 to 1.19) | 1.19 (1.16 to 1.22) | 1.18 (1.15 to 1.20) | 1.02 (1.00 to 1.05) | 1.03 (1.00 to 1.05) |
| Gender | |||||
| Male | 1.00 | 1.00 | 1.00 | 1.00 | |
| Female | 1.91 (1.87 to 1.94) | 1.90 (1.87 to 1.94) | 1.91 (1.88 to 1.95) | 1.91 (1.88 to 1.95) | |
| Age (years) | |||||
| 18–24 | 1.00 | 1.00 | 1.00 | 1.00 | |
| 25–34 | 2.29 (2.18 to 2.41) | 2.29 (2.18 to 2.41) | 2.28 (2.17 to 2.39) | 2.28 (2.16 to 2.39) | |
| 35–44 | 4.11 (3.92 to 4.31) | 4.12 (3.93 to 4.32) | 4.26 (4.06 to 4.46) | 4.26 (4.06 to 4.47) | |
| 45–54 | 5.50 (5.25 to 5.76) | 5.51 (5.26 to 5.78) | 5.74 (5.48 to 6.02) | 5.75 (5.49 to 6.02) | |
| 55–64 | 6.70 (6.39 to 7.02) | 6.72 (6.41 to 7.04) | 7.00 (6.68 to 7.34) | 7.00 (6.68 to 7.34) | |
| 65–74 | 7.72 (7.36 to 8.10) | 7.73 (7.37 to 8.11) | 7.96 (7.59 to 8.35) | 7.96 (7.58 to 8.35) | |
| Conurbation | |||||
| Rural | 1.00 | 1.00 | 1.00 | ||
| Urban | 1.48 (1.41 to 1.55) | 1.20 (1.14 to 1.25) | 1.18 (1.12 to 1.24) | ||
| Deprivation | |||||
| 1—most affluent | 1.00 | 1.00 | |||
| 2 | 1.32 (1.28 to 1.36) | 1.27 (1.23 to 1.32) | |||
| 3 | 1.62 (1.60 to 1.68) | 1.55 (1.49 to 1.60) | |||
| 4 | 2.10 (2.03 to 2.17) | 1.94 (1.87 to 2.02) | |||
| 5—most deprived | 2.91 (2.82 to 3.01) | 2.67 (2.57 to 2.78) | |||
| Crime | |||||
| 1—low crime | 1.00 | ||||
| 2 | 1.12 (1.08 to 1.16) | ||||
| 3 | 1.16 (1.12 to 1.20) | ||||
| 4 | 1.17 (1.13 to 1.22) | ||||
| 5—high crime | 1.22 (1.17 to 1.26) |
| Parameters | Results |
| Weight (g) | 24.9±3.1 |
| Peak CSA [ mm2] | |
| Cartesian Measurement | 0.75±0.05 |
| Radial Triggered Measurement | 0.75±0.04 |
| Retrospective Measurement | 0.73±0.04 |
| Peak volume flow [ cm3/s] | |
| Cartesian Measurement | 0.27±0.04 |
| Radial Triggered Measurement | 0.28±0.03 |
| Retrospective Measurement | 0.28±0.04 |
| PWV [m/s] | |
| Cartesian Measurement | 2.4±0.2 |
| Radial Triggered Measurement | 2.3±0.2 |
| Retrospective Measurement | 2.3±0.2 |
| Chiropractor ID | Number of diagnoses coded | Agreement on *rubric level(%) | Agreement on **term level(%) |
| 1 | 9 | 89 | 67 |
| 2 | 20 | 15 | 10 |
| 3 | 12 | 92 | 50 |
| 4 | 15 | 60 | 0 |
| 5 | 14 | 29 | 29 |
| 6 | 9 | 67 | 56 |
| 7 | 14 | 29 | 7 |
| 8 | 10 | 100 | 100 |
| 9 | 16 | 44 | 31 |
| 10 | 11 | 82 | 73 |
| 11 | 10 | 100 | 10 |
| 12 | 11 | 27 | 18 |
| 13 | 12 | 0 | 0 |
| 14 | 4 | 75 | 0 |
| Overall agreement % | 52 | 35 | |
| Agreement expected by chance | 17 | 6 | |
| Overall agreement (Cohen’s Kappa) | Total number of codes: 167 | 0.4 (95% CI 0.3-0.7)*** | 0.3 (95% CI 0.2-0.5)*** |
| Measure | Sample size | Mean score (SD) |
| Adverse childhood experience (ACE) score | n = 67 | 1.93 (2.45) |
| ACE z-score | n = 67 | 0.053 (0.94) |
| ACE (range) | n = 67 | 0.00–10.00 |
| Cyanotoxins | Water | Fish | Plant | Percent of detections | |||
| 2009 | 2010 | 2009 | 2010 | 2009 | 2010 | 2009–2010 | |
| BMAA | 13 | 12 | 22 | 9 | 5 | 5 | 18% |
| DABA | 13 | 12 | 19 | 7 | 5 | 5 | 17% |
| Anatoxin-a | 13 | 18 | 0 | 0 | 5 | 5 | 12% |
| Total samples | 31 | 36 | 115 | 133 | 36 | 36 | 387 |
| Prevalence (%) | Men | Women | Total |
| Diabetes | 14.0 | 10.0 | 11.6 |
| Dyslipidemia | 27.4 | 34.8 | 31.8 |
| Hypertension | 30.2 | 36.2 | 33.7 |
| Smoking | 12.6 | 7.9 | 9.8 |
| Obesity | 17.3 | 21.5 | 19.8 |
| Demographics | Baseline | Follow-up |
| Male, n | 19 (61%) | |
| Mean age + −SD, years 70.2 (SD 11.7) | ||
| < 9 years of education | 5 (16%) | |
| Stroke subtype | ||
| Cerebral infarction | 29 (94%) | |
| TIA | 2 (6%) | |
| Risk factors, n | ||
| Hypertension | 20 (65%) | |
| Hyperlipideamia | 23 (74%) | |
| Diabetes | 6 (19%) | |
| Current smoking | 7 (23%) | |
| Atrial fibrillation | 3 (10%) | |
| BMI | 18 (58%) | |
| TOAST classification, n | ||
| Large-vessel disease | 2 (7%) | |
| Cardio-embolic disease | 2 (6%) | |
| Small vessel disease | 17 (55%) | |
| Stroke of undetermined aetiology | 10 (32%) | |
| OCSP classification, n | ||
| TACI | 0 | |
| PACI | 13 (42%) | |
| LACI | 15 (48%) | |
| POCI | 3 (10%) | |
| Assessments | ||
| NIHSS, day 1, mean (IQR) | 3.06 (1.0-4.0) | 0.58 (0.0-1.0) |
| BI, mean(IQR) | 18.5 (19.5-20.0) | 19.48 (20.0-20.0) |
| mRS, mean (IQR) | 1.35 (0.0-3.0) | 1.06 (1.0-1.0) |
| Total TAU, mean (IQR) | 363 (227–382) | |
| Apoɛ4 | 9 (29%) | |
| TMT A (seconds) (SD) | 86.0 (±97.0) | 61.6 (±48.4) |
| MMSE (points) (SD) | 26.0 (±3.8) | 26.7 (±3.9) |
| 10 word test (words) | 20.1 (±6.8) | 24.5 (±6.1) |
| Ventricular volume (mm^3)(SD) | 60,796 (±17,339) | 60,334 (±25,118) |
| Global brain volume(mm^3) (SD) | 1,404,660 (±63,160) | 1,368,194 (±142,856) |
| Dimension | F | BMS | WMS | ICC1 | ICC2 | η2 | ω2 | PROB |
| UNIT LEVEL AGGREGATION | ||||||||
| Leadership | 2.1733 | 0.7596 | 0.3495 | 0.0768 | 0.5399 | 0.1417 | 0.0765 | 0.0000 |
| Culture | 2.9261 | 0.7410 | 0.2533 | 0.1201 | 0.6582 | 0.1814 | 0.1193 | 0.0000 |
| Evaluation | 2.3907 | 0.7391 | 0.3092 | 0.0897 | 0.5817 | 0.1540 | 0.0895 | 0.0000 |
| Social Capital | 1.7570 | 0.4074 | 0.2319 | 0.0509 | 0.4308 | 0.1181 | 0.0508 | 0.0000 |
| Formal Interactions | 1.5716 | 0.8838 | 0.5624 | 0.0389 | 0.3637 | 0.1064 | 0.0387 | 0.0009 |
| Informal Interactions | 1.3070 | 3.3072 | 2.5304 | 0.0213 | 0.2349 | 0.0906 | 0.0213 | 0.0342 |
| Structural and Electronic Resources | 2.5201 | 6.8517 | 2.7189 | 0.0972 | 0.6032 | 0.1612 | 0.0972 | 0.0000 |
| OS-staff | 7.8907 | 7.3179 | 0.9274 | 0.3281 | 0.8733 | 0.3728 | 0.3254 | 0.0000 |
| OS-space | 7.7267 | 5.4560 | 0.7061 | 0.3228 | 0.8706 | 0.3685 | 0.3207 | 0.0000 |
| OS-time | 4.9345 | 2.8298 | 0.5735 | 0.2180 | 0.7973 | 0.2724 | 0.2170 | 0.0000 |
| NURSING HOME LEVEL AGGREGATION | ||||||||
| Leadership | 3.7238 | 1.3391 | 0.3596 | 0.0521 | 0.7315 | 0.0682 | 0.0498 | 0.0000 |
| Culture | 7.0012 | 1.8055 | 0.2579 | 0.1079 | 0.8572 | 0.1205 | 0.1032 | 0.0000 |
| Evaluation | 4.5091 | 1.4341 | 0.3181 | 0.0661 | 0.7782 | 0.0815 | 0.0634 | 0.0000 |
| Social Capital | 3.2422 | 0.7592 | 0.2342 | 0.0432 | 0.6916 | 0.0600 | 0.0415 | 0.0000 |
| Formal Interactions | 2.6004 | 1.4760 | 0.5676 | 0.0313 | 0.6154 | 0.0485 | 0.0298 | 0.0000 |
| Informal Interactions | 2.0836 | 5.2765 | 2.5324 | 0.0214 | 0.5201 | 0.0394 | 0.0205 | 0.0017 |
| Structural and Electronic Resources | 5.8401 | 16.0841 | 2.7541 | 0.0889 | 0.8288 | 0.1032 | 0.0855 | 0.0000 |
| OS-staff | 23.9814 | 22.9152 | 0.9555 | 0.3166 | 0.9583 | 0.3184 | 0.3050 | 0.0000 |
| OS-space | 22.1040 | 16.3660 | 0.7404 | 0.2985 | 0.9548 | 0.3015 | 0.2877 | 0.0000 |
| OS-time | 14.6247 | 8.4892 | 0.5805 | 0.2155 | 0.9316 | 0.2229 | 0.2075 | 0.0000 |
| Sample | N (mmol/g) | C (mmol/g) | Molar ratio of C/N | CO2 adsorption capacity (mmol/g) | Amine efficiency | ||||||
| 25 °C | 30 °C | 50 °C | 75 °C | 25 °C | 30 °C | 50 °C | 75 °C | ||||
| APS/LDHs | 3.89 | 25.62 | 6.58 | 1.55 | 2.05 | 2.09 | 1.86 | 0.40 | 0.53 | 0.54 | 0.48 |
| Gene | ENSEMBL ID | ENSEMBL description |
| Acot7 | ENSMUSG00000028937 | acyl-CoA thioesterase 7 [Acc:MGI:1917275] |
| Ankrd13d | ENSMUSG00000005986 | ankyrin repeat domain 13 family, member D [Acc:MGI:1915673] |
| Aplp1 | ENSMUSG00000006651 | amyloid beta (A4) precursor-like protein 1 [Acc:MGI:88046] |
| Atp1a3 | ENSMUSG00000040907 | ATPase, Na+/K+ transporting, alpha 3 polypeptide [Acc:MGI:88107] |
| Atp6v1a | ENSMUSG00000052459 | ATPase, H+ transporting, lysosomal V1 subunit A [Acc:MGI:1201780] |
| Atp6v1d | ENSMUSG00000021114 | ATPase, H+ transporting, lysosomal V1 subunit D [Acc:MGI:1921084] |
| Calm3 | ENSMUSG00000019370 | calmodulin 3 [Acc:MGI:103249] |
| Cdh13 | ENSMUSG00000031841 | cadherin 13 [Acc:MGI:99551] |
| Cyfip2 | ENSMUSG00000020340 | cytoplasmic FMR1 interacting protein 2 [Acc:MGI:1924134] |
| Dos | ENSMUSG00000035640 | downstream of Stk11 [Acc:MGI:1354170] |
| Dusp26 | ENSMUSG00000039661 | dual specificity phosphatase 26 (putative) [Acc:MGI:1914209] |
| Gprasp1 | ENSMUSG00000043384 | G protein-coupled receptor associated sorting protein 1 [Acc:MGI:1917418] |
| Gria1 | ENSMUSG00000020524 | glutamate receptor, ionotropic, AMPA1 (alpha 1) [Acc:MGI:95808] |
| Grina | ENSMUSG00000022564 | glutamate receptor, ionotropic, N-methyl D-asparate-associated protein 1 [Acc:MGI:1913418] |
| Hdac11 | ENSMUSG00000034245 | histone deacetylase 11 [Acc:MGI:2385252] |
| Kifap3 | ENSMUSG00000026585 | kinesin-associated protein 3 [Acc:MGI:107566] |
| Kns2 | ENSMUSG00000021288 | kinesin 2 [Acc:MGI:107978] |
| Ndrg4 | ENSMUSG00000036564 | N-myc downstream regulated gene 4 [Acc:MGI:2384590] |
| Pcdh17 | ENSMUSG00000035566 | protocadherin 17 [Acc:MGI:2684924] |
| Pfkm | ENSMUSG00000033065 | phosphofructokinase, muscle [Acc:MGI:97548] |
| Phactr1 | ENSMUSG00000054728 | phosphatase and actin regulator 1 [Acc:MGI:2659021] |
| Pja2 | ENSMUSG00000024083 | praja 2, RING-H2 motif containing [Acc:MGI:2159342] |
| Ppp2r2c | ENSMUSG00000029120 | protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), gamma isoform [Acc:MGI:2442660] |
| Prkacb | ENSMUSG00000005034 | protein kinase, cAMP dependent, catalytic, beta [Acc:MGI:97594] |
| Rogdi | ENSMUSG00000022540 | rogdi homolog (Drosophila) [Acc:MGI:1913299] |
| Rusc1 | ENSMUSG00000041263 | RUN and SH3 domain containing 1 [Acc:MGI:1919546] |
| Scamp5 | ENSMUSG00000040722 | secretory carrier membrane protein 5 [Acc:MGI:1928948] |
| Slc25a4 | ENSMUSG00000031633 | solute carrier family 25 (mitochondrial carrier, adenine nucleotide translocator), member 4 [Acc:MGI:1353495] |
| Stx1b2 | ENSMUSG00000030806 | syntaxin 1B2 [Acc:MGI:1930705] |
| Sult4a1 | ENSMUSG00000018865 | sulfotransferase family 4A, member 1 [Acc:MGI:1888971] |
| Sv2a | ENSMUSG00000038486 | synaptic vesicle glycoprotein 2 a [Acc:MGI:1927139] |
| Syngr3 | ENSMUSG00000007021 | synaptogyrin 3 [Acc:MGI:1341881] |
| Tspyl4 | ENSMUSG00000039485 | TSPY-like 4 [Acc:MGI:106393] |
| Vamp2 | ENSMUSG00000020894 | vesicle-associated membrane protein 2 [Acc:MGI:1313277] |
| Wbp2 | ENSMUSG00000034341 | WW domain binding protein 2 [Acc:MGI:104709] |
| Wsb2 | ENSMUSG00000029364 | WD repeat and SOCS box-containing 2 [Acc:MGI:2144041] |
| 0710005I19Rik | ENSMUSG00000041141 | RIKEN cDNA 0710005I19 gene [Acc:MGI:1918941] |
| 2900002G04Rik | ENSMUSG00000041020 | RIKEN cDNA 2900002G04 gene [Acc:MGI:1917474] |
| 2900011O08Rik | ENSMUSG00000044117 | RIKEN cDNA 2900011O08 gene [Acc:MGI:1914504] |
| 5330410G16Rik | ENSMUSG00000035964 | RIKEN cDNA 5330410G16 gene [Acc:MGI:1915187] |
| A030009H04Rik | ENSMUSG00000043419 | RIKEN cDNA A030009H04 gene [Acc:MGI:1915359] |
| Week | Multivariate 1* | Multivariate 2** | ||||||
| BMI <18.5 | BMI ≥18.5 | BMI <18.5 | BMI ≥18.5 | |||||
| β | P value | β | P value | β | P value | β | P value | |
| 8 | −4.076 | 0.347 | −0.693 | 0.802 | −6.761 | 0.192 | −3.012 | 0.388 |
| 12 | 6.357 | 0.197 | 5.915 | 0.090 | 5.190 | 0.324 | 8.878 | 0.020 |
| 17 | 8.626 | 0.024 | 2.501 | 0.358 | 7.279 | 0.053 | 3.844 | 0.148 |
| 19 | 5.466 | 0.127 | 2.119 | 0.393 | 6.971 | 0.067 | 4.345 | 0.101 |
| 24 | 2.414 | 0.450 | −0.904 | 0.665 | 9.649 | 0.078 | −0.772 | 0.835 |
| 28 | 1.344 | 0.675 | −1.755 | 0.381 | 7.352 | 0.173 | −5.336 | 0.115 |
| 30 | 3.224 | 0.311 | −2.228 | 0.257 | 8.083 | 0.072 | −4.482 | 0.111 |
| Before birth | ||||||||
| 6 | 6.484 | 0.053 | −3.556 | 0.082 | 7.263 | 0.041 | −5.047 | 0.024 |
| 4 | 8.100 | 0.025 | −2.021 | 0.353 | 7.916 | 0.026 | −1.380 | 0.533 |
| 2 | 8.891 | 0.022 | 0.334 | 0.889 | 9.270 | 0.014 | 1.003 | 0.675 |
| At birth | 7.219 | 0.075 | 1.659 | 0.507 | 7.455 | 0.061 | 2.614 | 0.291 |
| Contribution of need and non-need factors to the concentration indices for access to MCH care | ||||||||
| Medical treatment for Diarrhea | Skilled birth attendance | Measles immunization | Modern Contraceptive | |||||
| Absolute | % | Absolute | % | Absolute | % | Absolute | % | |
| Need factors | ||||||||
| Demographic | 0.0002 | 0.1 | −0.0079 | −1.1 | 0.0012 | 1.4 | −0.0038 | −1.4 |
| Health status | 0a | 0.0 | −0.0072 | −1.0 | - | - | 0.0000 | 0.0 |
| Subtotal | 0.0002 | 0.1 | −0.0151 | −2.1 | 0.0012 | 1.4 | −0.0038 | −1.4 |
| Non-need factors | ||||||||
| Wealth index | 0.0510 | 33.5 | 0.1162 | 15.9 | 0.0578 | 68.2 | 0.1605 | 58.4 |
| Educational attainment (women) | 0.0294 | 19.3 | 0.1779 | 24.4 | 0.0175 | 20.7 | 0.0449 | 16.4 |
| Educational attainment (men) | 0.0205 | 13.4 | 0.0510 | 7.0 | −0.0033 | −3.8 | 0.0021 | 0.8 |
| Area of residence (rural) | 0.0158 | 10.4 | 0.2984 | 40.9 | −0.0019 | −2.3 | 0.0265 | 9.7 |
| Subtotal | 0.1097 | 77.0 | 0.6434 | 88.2 | 0.0702 | 82.8 | 0.2341 | 85.2 |
| Residual | 0.0355 | 22.8 | 0.1015 | 13.9 | 0.0134 | 15.8 | 0.0443 | 16.1 |
| Total | 0.1523 | 0.7299 | 0.0847 | 0.2747 | ||||
| Horizontal inequity index | 0.1521 | 0.7450 | 0.0835 | 0.2784 | ||||
| Adjusted R2 | 0.05 | 0.35 | 0.13 | 0.21 |
| Rank | IF range | China (%) | USA (%) | UK (%) | Germany (%) | Japan (%) | South Korea (%) |
| Top 25% | 11.089-4.046 | 809(27.67) | 16901(51.63) | 2973(54.52) | 3583(47.91) | 2170(34.19) | 426(30.15) |
| Top 25%-50% | 3.693-2.462 | 942(32.22) | 10815(33.04) | 1383(25.36) | 1951(26.09) | 1486(23.41) | 415(29.37) |
| Bottom25%-50% | 2.427-1.679 | 770(26.33) | 3204(9.79) | 598(10.97) | 1310(17.52) | 1726(27.19) | 376(26.61) |
| Bottom 25% | 1.590-0.101 | 403(13.78) | 1812(5.54) | 499(9.15) | 635(8.49) | 965(15.20) | 196(13.87) |
| PDGFαR | GalC | MBP | |
| Control | 0.43 ± 0.07 | 0.40 ± 0.09 | 0.49 ± 0.07 |
| NSCs | 0.90 ± 0.11∗ | 0.74 ± 0.09∗ | 1.10 ± 0.14∗ |
| T3/NSCs | 1.42 ± 0.10∗# | 1.50 ± 0.09∗# | 1.43 ± 0.10∗# |
| GDNF-T3/NSCs | 1.52 ± 0.09∗# | 1.69 ± 0.08∗#ψ | 1.62 ± 0.10∗#ψ |
| Generic name | Score | Information from DrugBankb | Information from other sources |
| Dexamethasone | 22.1 | An anti-inflammatory 9-fluoro-glucocorticoid. | Dexamethasone was reported to have a dramatic life-saving effect on people with cerebral malaria[44]. However, two subsequent placebo-controlled clinical trials failed to demonstrate clinical benefit[45,46]. |
| Verapamil | 21.5 | A calcium channel blocker for hypertension, angina, and cluster headache prophylaxis. | A 1995 study[48] reported that verapamil reverses chloroquine resistance in the malaria parasite. |
| Quercetin | 18.9 | A flavonol found in plants, antioxidant. | A 2012 study[47] reported that quercetin had antiplasmodial activity. |
| Miconazole | 16.5 | An imidazole antifungal agent. | Many studies[39-43] have reported antimalarial activities of antifungal azole compounds. |
| Clotrimazole | 15.9 | An imidazole derivative with a broad spectrum of antimycotic activity. | Many studies[39-43] have reported antimalarial activities of azoles, including clotrimazole[43]. |
| Cimetidine | 15.5 | For acid-reflux disorders (GERD), peptic ulcer disease, heartburn, and acid indigestion. | A 1997 study[49] reported synergism of cimetidine with antimalarial agents. It is ineffective when used alone. |
| Ketoconazole | 15.2 | For systemic fungal infections. | Many studies[39-43] have reported antimalarial activities of azoles, including ketoconazole[41]. |
| Nifedipine | 14.9 | A calcium channel blocker for angina, hypertension, and Raynaud's phenomenon. | |
| Tamoxifen | 14.4 | For breast cancer. | |
| Clobetasol | 14.4 | For corticosteroid-responsive dermatoses of the scalp. |
| Ethanol (g/L) | Yield (g/g) | Xylose (g/L/h) | Ethanol (g/L/h) | Time (h) | ||
| ScF2 | Pre-G | 52.25 ± 1.48 | 0.40 ± 0.01 | 1.10 ± 0.00 | 0.44 ± 0.01 | 120 |
| Pre-X | 50.20 ± 1.78 | 0.37 ± 0.01 | 1.28 ± 0.01 | 0.52 ± 0.02 | 96 | |
| P stipitis | Pre-G | 52.15 ± 0.28 | 0.38 ± 0.00 | 0.95 ± 0.01 | 0.36 ± 0.00 | 144 |
| Pre-X | 49.94 ± 0.62 | 0.37 ± 0.01 | 0.93 ± 0.01 | 0.35 ± 0.00 | 144 |
| Miracidia1 | Mean2 | Std. Error | 95% CI | |
| Lower | Upper | |||
| MweaB. pfeifferix MweaS. mansoni | ||||
| 1 miracidium | 7.66 | 0.80 | 6.09 | 9.23 |
| 5 miracidia | 6.18 | 0.80 | 4.61 | 7.75 |
| 10 miracidia | 4.04 | 0.43 | 3.20 | 4.88 |
| 25 miracidia | 4.14 | 0.55 | 3.05 | 5.23 |
| Overall | 5.51 | 0.35 | 4.83 | 6.18 |
| MweaB. pfeifferix AsaoS. mansoni | ||||
| 1 miracidium | 5.10 | 0.58 | 3.96 | 6.24 |
| 5 miracidia | 5.34 | 0.38 | 4.59 | 6.09 |
| 10 miracidia | 3.94 | 0.26 | 3.43 | 4.45 |
| 25 miracidia | 4.40 | 0.37 | 3.68 | 5.12 |
| Overall | 4.70 | 0.21 | 4.28 | 5.11 |
| AsaoB. pfeifferix MweaS. mansoni | ||||
| 1 miracidium | 14.42 | 1.34 | 11.80 | 17.04 |
| 5 miracidia | 13.52 | 0.88 | 11.80 | 15.24 |
| 10 miracidia | 12.44 | 1.18 | 10.13 | 14.75 |
| 25 miracidia | 10.30 | 0.69 | 8.95 | 11.65 |
| Overall | 12.68 | 0.54 | 11.63 | 13.73 |
| AsaoB. pfeifferix AsaoS. mansoni | ||||
| 1 miracidium | 12.70 | 1.35 | 10.05 | 15.35 |
| 5 miracidia | 14.18 | 1.26 | 11.71 | 16.65 |
| 10 miracidia | 9.62 | 1.25 | 7.17 | 12.07 |
| 25 miracidia | 10.98 | 1.49 | 8.06 | 13.90 |
| Overall | 12.06 | 0.70 | 10.68 | 13.44 |
| Overall analysis | ||||
| Negative control | 18.34 | 0.86 | 16.65 | 20.03 |
| 1 miracidium | 9.97 | 0.60 | 8.80 | 11.14 |
| 5 miracidium | 9.81 | 0.53 | 8.78 | 10.84 |
| 10 miracidia | 7.51 | 0.52 | 6.50 | 8.52 |
| 25 miracidia | 7.46 | 0.50 | 6.48 | 8.43 |
| X2 | p Value | Odds Ratio 95% CI | Genotype/Allele |
| TT Vs TC + CC | 3.31 | 0.06 | 0.71(0.5015-1.026) |
| TC Vs TT+CC | 0.28 | 0.59 | 1.10(0.7752-1.563) |
| CCVs TC + TT | 4.51 | 0.03 | 1.94(1.044-3.605) |
| C Vs T | 5.12 | 0.02 | 1.35(1.041-1.758) |
| T Vs C | 5.12 | 0.02 | 0.73(0.56-0.960) |
| Variables | ||
| During the next 3 months | Measured Scale | Reliability coefficient |
| Self-efficacy | Very unlikely/very likely | .35a |
| I would be able to participate regularly in one or more physical activities even if... | ||
| 1-I have little free time | ||
| 2-I am not carrying excess body weight | ||
| Anticipated Regret | Very unlikely/very likely | .80b |
| During the next 3 months, if I do not participate in one or more physical activities... | ||
| 1-This will bother me | ||
| 2-I will regret it | ||
| 3-I will worry about it | ||
| Positive Feeling | Very unlikely/very likely | .52a |
| If I participate in one or more physical activities... | ||
| 1-I will be proud | ||
| 2-I would be satisfied | ||
| Moral Norm | Strongly disagree/strongly agree | .80b |
| 1-It is in my principles to participate in one or more physical activities | ||
| 2-To participate in one or more physical activities would be acting in accordance with my personal values | ||
| 3-It would be against my principles not to participate in one or more physical activities | ||
| Descriptive Norm | ||
| 1-A lot of people I know participate in one or more physical activities | Strongly disagree/strongly agree | .55a |
| 2-Among the 5 persons you know best, how many of them participate in one or more physical activities? | 0 person to 5 people |
| Region of location | Upper East (Talensi- Nabdam and Kassena-Nankana West Districts) | Form of involvement (initiation, contribution of partners and management of the collaboration) | Advantages | Disadvantages |
| Interviews conducted | 2 NGO2GHS | - Dubbed “CIMACS”- Initiated by GHS with CRS as an expert partner/and funder.- An MOU signed.- GHS supported with health facilities and personnel.- CRS trained Traditional Birth Attendants (TBAs) and community volunteers in social mobilization skills, provided logistics/incentives to attract pregnant women to deliver in health centres.- Program officers of CRS and focal persons of GHS shared equally in program management and regularly exchanged project progress information.- GHS held review meetings at sub-district, district and regional; quarterly, half yearly and annual basis, to evaluate progress with CRS/stakeholders.- CRS maintained monitoring and evaluation systems e.g. conduct of baseline studies; mid- term and end-of-project evaluations.- Quarterly and annual reports generated and shared with GHS/ donors as a requirement for continued support.- GHS required to keep records of CRS support (material and cash) and to render accounts periodically. | Improvement in maternal and child health indicators-e.g. antenatal registration (25 %); antenatal clinic attendance (22 %); exclusive breastfeeding (25 %); institutional deliveries (55 %); [35] and increased drug and immunization uptake. | - Occasional tendency for some GHS staff to provide somewhat unreliable data not useful for effective programming;- Occasional non-disclosure of full budget lines by GHS- Lack of synchronization of each other’s timetables;- CRS’ eagerness about timelines to demonstrate program performance to donors. |
| Driver of Collaboration | High under-five and maternal mortality recognized by GHS;- Need to attract pregnant women to deliver in government health centres rather than with TBAs. | |||
| Time Frame | 2009–2011 |
| Nuevo Laredo | Matamoros | Veracruz | |
| Iowa | Train: 1686 km | Train: 1800 km | Train: 220 kmWater: 2300 km |
| Ilinois | Train: 1637 km | Train: 1700 km | Train: 405 kmWater: 2300 km |
| Indiana | Train: 1833 km | Train: 1885 km | Train: 677 kmWater: 2300 km |
| Total | 1718 km + 650 km to the middle of the country | 1795 km + 650 km to the middle of the country | 434 km, train + 650 km to the middle of the country, Water: 2300 km |
| Model | LnL | AIC | AICc | ΔAICc | AICcWt |
| Legacy calibrated phylogeny | |||||
| Brownian motion single rate | 123.77 | −229.54 | −203.82 | 221 | 0.00 |
| Brownian motion multiple rate | 130.51 | −219.03 | −403.83 | 20.99 | 0.00 |
| Ornstein-Uhlbeck single rate | 134.9 | −239.91 | 240.09 | 664.91 | 0.00 |
| Ornstein-Uhlbeck multiple rate | 141.01 | −240.02 | −424.82 | 0.00 | 0.99 |
| Ecological release | 125.02 | −220.04 | 259.96 | 684.78 | 0.00 |
| Release and radiate | 135.67 | −229.34 | −414.14 | 10.68 | 0.00 |
| Ecological constraint | 119.64 | −209.28 | 270.72 | 695.54 | 0.00 |
| Radiation & ecological constraint | 126.43 | −210.86 | −395.66 | 30.16 | 0.00 |
| Brownian motion/early burst | 122.50 | −225.01 | −188.34 | 236.48 | 0.00 |
| Early burst/Brownian motion | 53.24 | −86.49 | −49.83 | 374.99 | 0.00 |
| Isthmus calibrated phylogeny | |||||
| Brownian motion single rate | 123.94 | −229.89 | −204.17 | 223.12 | 0.00 |
| Brownian motion multiple rate | 131.21 | −220.42 | −405.22 | 22.07 | 0.00 |
| Ornstein-Uhlbeck single rate | 135.1 | −240.19 | 239.81 | 667.10 | 0.00 |
| Ornstein-Uhlbeck multiple rate | 142.24 | −242.49 | −427.29 | 0.00 | 0.99 |
| Ecological release | 129.60 | −229.20 | 250.80 | 678.09 | 0.00 |
| Release and radiate | 135.48 | −228.97 | −413.77 | 13.52 | 0.00 |
| Ecological constraint | 123.47 | −216.94 | 263.05 | 690.34 | 0.00 |
| Radiation & ecological constraint | 125.51 | −209.02 | −393.82 | 33.47 | 0.00 |
| Brownian motion/early burst | 121.06 | −222.13 | −185.47 | 241.82 | 0.00 |
| Early burst/Brownian motion | 121.78 | −223.55 | −186.89 | 240.40 | 0.00 |
| Gene | Target sequence | ShRNA sequences |
| CXCR4-1 | TCCTGGCCTTCATCAGTCT (6) | 5′-GAT CCT CCT GGC CTT CAT CAG TCT TTC AAG AGA AGA CTG ATG AAG GCC AGG ATT TTT GGA AGC TAG GA-3′ |
| CXCR4-2 | TGCCCACCATCTACTCCAT (7) | 5′-GAT CCT GCC CAC CAT CTA CTC CAT TTC AAG AGA ATG GAG TAG ATG GTG GGC ATT TTT GGA AGC TAG CA-3′ |
| Negative control | AATCGCATAGCGTATGCCGTT (8) | 5′-GAT CCA ATC GCA TAG CGT ATG CCG TTT TCA AGA GAA ACG GCA TAC GCT ATG CGA TTT TTT TGG AAG CTA GCA-3′ |
| human | mouse | rat | ||
| miRanda | 34 838 559 | 16 164 311 | 1 372 897 | |
| Pita | 773 112 | 313 113 | 52 281 | |
| RNAHybrid | 36 832 689 | 10 390 354 | 536 248 | |
| microtar | 6 049 837 | 1 750 058 | 3 348 100 | |
| Targetscan | 7 270 936 | 5 186 036 | 417 501 | |
| TarBase | 36 853 | 20 513 | 7 | |
| miRTarbase | 39 118 | 9 314 | 307 | |
| miRecords | 1 198 | 227 | — | |
| OncomirDB | 2 368 | 1 917 | — | |
| miRGate | 85 844 670 | 33 835 843 | 5 727 341 | 125 407 854 |
| Background characteristics | Number (%) |
| Sex | |
| Male | 86 (7.6) |
| Female | 975 (86.3) |
| Missing | 69 (6.1) |
| Age [mean, (SD)] years | 28.8 (SD = 7.5) |
| Current marital status | |
| Never married | 51 (4.6) |
| Married (monogamous) | 827 (73.9) |
| Married (polygamous) | 139 (12.4) |
| Othera | 102 (9.1) |
| Education status | |
| Never in school | 166 (14.7) |
| Some primary | 803 (71.1) |
| Above primary | 151 (13.3) |
| Missing | 10 (0.9) |
| Employment status | |
| Salaried | 778 (68.8) |
| Unemployed | 213 (18.9) |
| Subsistence farmer | 70 (6.2) |
| Self-employed/wage earners | 58 (5.1) |
| Missing | 11 (1.0) |
| Relationship to the child | |
| Parent | 1043 (92.3) |
| Kin or other | 47 (4.2) |
| Missing | 40 (3.5) |
| VP1 NTa position | NTs in Sabin 2 and cVDPV2 sequences | iVDPV2 sequences | # sequences (iVDPV2) that exhibit variations |
| 32 | A | A or C | 7 |
| 116 | A | A or G | 1 |
| 208 | C | A or C | 1 |
| 218 | C | C or T | 1 |
| 223 | T | A or T | 12 |
| 302 | C | A or C | 1 |
| 307 | A | Deletionb | 1 |
| 358 | C | C or T | 1 |
| 433 | G | G or T | 12 |
| 496 | A | A or G | 1 |
| 502 | G | A or G | 1 |
| 506 | A | A or C | 1 |
| 604 | G | A or G | 1 |
| 740 | A | A or G | 1 |
| 761 | C | C or T | 1 |
| 781 | A | A or C or T | 11C; 1 T |
| Description | E7 Clusters* | E14 Clusters* |
| Affected only by serum | 13, 39 | 13, 39 |
| Affected only by rcSF3 | None | None |
| Serum and rcSF3 oppose one another | 7, 14, 18, 34, 35, 38 | 14, 18, 34, 38 |
| Serum and rcSF3 reinforce one another | 0, 8, 49 | 0, 8, 10, 49 |
| Serum and rcSF3 modulate one another | 2, 5, 42 | 2, 5, 10, 47 |
| Serum and rcSF3 substitute for one another | None | 12 |
| Gene expression increases with increasing TER | 42 | None |
| Gene expression decreases with increasing TER | None | None |
| L/min | ||||
| 2.5 | 5 | 7.5 | 10 | |
| Aysis | 15.41 | 4.25 | 2.14 | 2.15 |
| FLOW-i | 10.73 | 4.45 | 2.49 | 2.48 |
| Activity monitor group (n = 14) | Pedometer group (n = 14) | p value | |
| Age (years) | 65.8 ± 6.7 | 62.4 ± 9.9 | 0.58 |
| Male | 78.6% | 71.4% | 0.66 |
| Height (m) | 1.61 ± 0.08 | 1.63 ± 0.09 | 0.46 |
| Weight (kg) | 62.4 ± 12.7 | 68.3 ± 9.5 | 0.08 |
| BMI | 24.1 ± 4.0 | 25.9 ± 4.3 | 0.24 |
| HbA1c (%) | 6.6 ± 0.6 | 6.4 ± 0.9 | 0.27 |
| Systolic BP (mmHg) | 121.1 ± 10.8 | 121.6 ± 6.8 | 0.89 |
| Diastolic BP (mmHg) | 67.8 ± 8.1 | 73.5 ± 9.0 | 0.09 |
| UA (mg/dL) | 5.5 ± 1.6 | 5.6 ± 1.6 | 0.80 |
| HDL cholesterol (mg/dL) | 66.6 ± 18.7 | 60.3 ± 11.6 | 0.72 |
| LDL cholesterol (mg/dL) | 111.4 ± 34.9 | 103 ± 10.8 | 0.09 |
| Triglycerides (mg/dL) | 107.6 ± 59.7 | 127.1 ± 90.8 | 0.68 |
| Version | Parameter | Separation index | Reliability | Average infit mean square | Average outfit mean square | |
| Malay | 9-items | Person ability | 2.84 | 0.89 | 1.00 | 1.01 |
| Item difficulty | 4.81 | 0.96 | 1.00 | 1.00 | ||
| 7-itemsa | Person ability | 2.59 | 0.87 | 1.00 | 0.99 | |
| Item difficulty | 4.97 | 0.96 | 1.00 | 0.98 | ||
| Chinese | 9-items | Person ability | 2.59 | 0.87 | 1.00 | 1.01 |
| Item difficulty | 6.96 | 0.98 | 1.00 | 1.02 | ||
| 7-itemsa | Person ability | 2.30 | 0.84 | 1.01 | 0.98 | |
| Item difficulty | 5.28 | 0.97 | 1.00 | 0.98 |
| Target | Forward primer | Reverse primer | Product length [bp] | Reference |
| HPRT | GAGAGCGTTGGGCTTACCTC | ATCGCTAATCACGACGCTGG | 136 | Rohm et al., 2015 |
| PPARG | GTGCCAGTTTCGATCCGTAGA | GGCCAGCATCGTGTAGATGA | 142 | Rohm et al., 2015 |
| FAS | CACAGATGATGACAGGAGATGG | TCGGAGTGAGGCTGGGTTGAT | 205 | Hewitt et al., 2004 |
| LRP2 | TGTACCAGAAAATGTGGAAAACC | GTGTCTTCTGTGGCAGTGTAGC | 288 | Lyons et al., 2003 |
| IGF1R | GGAGTGTCCCTCAGGCTTCA | CATCGCCGCAGACTTTGG | 89 | Nef et al., 2003 |
| Study | No. randomized | Characteristics of patients | BMI (SD) | Mean APACHE II score (SD) | |||
| LE | HE | LE | HE | LE | HE | ||
| Arabi et al. [21] | 120 | 120 | >18 years old | 28.5 (7.4) | 28.5 (8.4) | 25.2 (7.5) | 25.3 (8.2) |
| ICU >48 hours | |||||||
| Braunschweig et al. [22] | 38 | 40 | >18 years old | 30.1 (8.9) | 29.8 (9.3) | 27.7 (7.9) | 23.4 (9.3) |
| Medical or surgical ICU | |||||||
| ALI <24 hours | |||||||
| Charles et al. [23] | 41 | 42 | >18 years old | 32.9 (2.0) | 28.1 (0.9) | 16.6 (0.9) | 17.3 (0.8) |
| Artificial nutrition >48 hours | |||||||
| ICU >48 hours | |||||||
| Desachy et al. [24] | 50 | 50 | >18 years old | 27 (5) | 25 (3) | 40 (11)1 | 42 (17)1 |
| Medical or surgical ICU | |||||||
| Mechanical ventilation >72 hours | |||||||
| Peake et al. [25] | 55 | 57 | ≥18 years old | 26.2 (6.4) | 27.8 (7.9) | 22 (8.9) | 23 (9.1) |
| Enteral nutrition ≥2 days | |||||||
| Mechanical ventilation | |||||||
| Rice et al. [26] | 98 | 102 | ICU admission | 29.2 (10.2) | 28.2 (9.4) | 26.9 (8.1) | 26.9 (6.6) |
| Mechanical ventilation >72 hours | |||||||
| Rice et al. [27] | 508 | 492 | ICU admission | 29.9 (7.8) | 30.4 (8.2) | 92 (28)2 | 90 (27)2 |
| ALI <48 hours | |||||||
| Mechanical ventilation >72 hours | |||||||
| Taylor et al. [28] | 41 | 41 | Head injury necessitating mechanical ventilation | N/A | N/A | 143 | 143 |
| Glasgow Coma Scale >3 |
| Learning rate η | The number of hidden neurons | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90 | 100 |
| 0.0005 | Training time (seconds) | 4092.19 | 4213.25 | 4276.55 | 4424.77 | 4455.69 | 4589.70 | 4553.02 | 4640.63 | 4745.16 | 4884.30 |
| Testing accuracy (%) | 94.77 | 94.00 | 94.16 | 95.32 | 94.74 | 92.62 | 92.52 | 90.28 | 88.77 | 89.91 | |
| 0.001 | Training time (seconds) | 4058.33 | 4157.41 | 4218.09 | 4354.41 | 4408.23 | 4500.06 | 5.75* | 1532.38* | 2.38* | 32.61* |
| Testing accuracy (%) | 95.02 | 94.45 | 95.83 | 95.51 | 93.56 | 91.30 | 78.17 | 78.17 | 78.17 | 78.17 | |
| 0.002 | Training time (seconds) | 4054.50 | 4212.85 | 4213.71 | 4385.40 | 1.11* | 1.12* | 1.12* | 3.44* | 1.17* | 144.12* |
| Testing accuracy (%) | 96.42 | 95.72 | 89.37 | 86.15 | 78.17 | 78.17 | 78.17 | 78.17 | 78.17 | 78.17 |
| Gene name | Primer sequence (5' to 3') | Position in ORF | |
| APN1 | 3'Race | TGCGCTTCGAAGATTGGCTCACGATA | 2018–2044 |
| 5'Race | CTTCGATGAATGCCGAGACGCTGGAC | 2122–2097 | |
| APN2 | 3'Race | CTTTGCTGCTGGTGCTATGGAGAACTGG | 906–932 |
| 5'Race | ACAGGGCTGACTTCATTTCCGAACCATT | 1067–1040 | |
| APN3 | 3'Race | ATGCGTGAYGAYATGTACGGTAT | 496–518 |
| 5'Race | GCCAGGAGATAAGTTGACATTTTTGGGG | 779–752 | |
| APN4 | 3'Race | TGGCTTTCCATGTGAGCGATTTTGTGC | 728–754 |
| 5'Race | CACACCGATTTCTGCAGCATACGAGTGC | 849–822 |
| Symbol | Definition | |Fold Change|(TM/TM-MSC) | Padj |
| MYOC | Myocilin, trabecular meshwork inducible glucocorticoid response | 1374 | 6.97E-04 |
| ANGPTL7 | Angiopoietin-like 7 | 1189 | 1.48E-03 |
| PCP4 | Purkinje cell protein 4 | 656 | 2.33E-03 |
| KRT13 | Keratin 13 | 459 | 1.08E-03 |
| SERPINA3 | Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3 | 447 | 3.75E-03 |
| MYH11 | Myosin, heavy chain 11, smooth muscle | 429 | 1.00E-02 |
| CDH23 | Cadherin-like 23 | 420 | 6.97E-04 |
| HLA-DRA | Major histocompatibility complex, class II, DR alpha | 354 | 9.27E-04 |
| PTGDS | Prostaglandin D2 synthase 21 kDa (Brain) | 300 | 2.05E-02 |
| FAM107A | Family with sequence similarity 107, member A | 275 | 6.97E-04 |
| HBB | Hemoglobin, beta | 264 | 4.13E-03 |
| C2orf40 | Chromosome 2 open reading frame 40 | 239 | 8.31E-04 |
| FCGBP | Fc fragment of IgG binding protein | 231 | 9.27E-04 |
| APOD | Apolipoprotein D | 230 | 2.40E-02 |
| CXADR | Coxsackie virus and adenovirus receptor | 218 | 7.76E-04 |
| TACSTD2 | Tumor-associated calcium signal transducer 2 | 215 | 9.45E-04 |
| H19 | H19, imprinted maternally expressed transcript (non-protein coding) | 210 | 1.38E-03 |
| KRT5 | Keratin 5 | 209 | 7.76E-04 |
| CCL3L3 | Chemokine (C-C motif) ligand 3-like 3 | 209 | 1.27E-03 |
| VCAM1 | Vascular cell adhesion molecule 1 | 199 | 2.49E-03 |
| Session Topic | Protective Factor Targeted |
| Introduction and Program OverviewREADY resilience model, protective factors, warning signs of low resilience. | |
| Activity Promotion (group 2 only)Activity benefits, national activity guidelines, step counting & pedometers, identifying preferences, goal setting, barriers & problem solving. | Physical activity |
| MindfulnessMindfulness vs mindlessness, mindfulness strategies. | Cognitive flexibilityPositive emotions |
| Defusion 1Thought fusion, identifying unhelpful thoughts, defusion strategies. | Cognitive flexibility |
| Defusion 2Observer self, defusion strategies. | Cognitive flexibility |
| AcceptanceAbout emotions, responding to emotions, about acceptance, acceptance strategies. | Positive emotions |
| Mid Program ReviewResilient and non resilient characteristics, activating and trouble shooting coping strategies. | Active coping |
| Life Values and Meaningful ActionAbout values, value identification, meaningful action. | Life meaning |
| Social ConnectednessTypes of support, support responses, active and reflective listening, barriers to social connectedness. | Social support |
| Relaxation and Pleasant ActivitiesActive relaxation exercises, progressive muscle relaxation exercises, pleasurable activities. | Positive emotions |
| Review and Planning for the FutureResilient and non resilient characteristics, activating and trouble shooting coping strategies. | Active coping |
| Three-dimensional scapular attitudes (in degrees) | |||||||
| Healthy subjects | SIS subjects | ||||||
| Impaired shoulder | Non-impaired shoulder | ||||||
| Arm Positions | Scapular Rotations | n = 30 shoulders | n = 8 shoulders | n = 8 shoulders | |||
| Mean | SD | Mean | SD | Mean | SD | ||
| Rest | A(-) P(+) T | -9.2 | 4.3 | -7.4 | 3.7 | -6.6 | 4.2 |
| L(-) M(+) R | -1.1 | 4.7 | -7.6 | 3.7 | -5.3 | 4.0 | |
| PRO(+) RET(-) | -31.8 | 5.6 | -33.3 | 6.8 | -32.1 | 5.5 | |
| Flexion 70° | A(-) P(+) T | -3.8 | 4.5 | -3.2 | 3.9 | -1.9 | 5.2 |
| L(-) M(+) R | -9.3 | 3.7 | -14.5 | 4.5 | -12.4 | 4.2 | |
| PRO(+) RET(-) | -39.8 | 7.5 | -40.7 | 8.2 | -39.5 | 6.7 | |
| Abduction 90° | A(-) P(+) T | -1.6 | 5.6 | -1.7 | 5.2 | -1.4 | 7.1 |
| L(-) M(+) R | -27.5 | 4.2 | -30.4 | 4.7 | -31.6 | 9.0 | |
| PRO(+) RET(-) | -19.1 | 6.1 | -18.6 | 8.7 | -20.1 | 6.6 |
| SF-36 Domains | Total Patients (n=308) | Thalassemia Major (n=209) | Thalassemia Intermedia (n=99) | Healthy Individuals† (n=4804) |
| Physical Functioning* | 67.95 (22.68) | 72.11 (21.19) | 59.19 (23.34) | 85.2 (20.8) |
| Role Limitation-Physical | 53.24 (18.58) | 54.31 (17.88) | 50.96 (19.89) | 70.0 (38.0) |
| General Health | 53.05 (16.96) | 52.69 (17.42) | 53.84 (15.99) | 67.5 (20.4) |
| Vitality | 55.02 (14.93) | 54.31 (15.05) | 56.57 (14.61) | 65.8 (17.3) |
| Social Functioning | 60.11 (20.89) | 60.11 (20.84) | 60.10 (21.10) | 76.0 (24.4) |
| Role Limitation-Emotional* | 55.13 (21.09) | 57.89 (19.64) | 49.32 (22.91) | 65.6 (41.1) |
| Mental Health | 56.91 (16.40) | 56.22 (15.54) | 58.40 (18.11) | 67.0 (18.0) |
| Bodily Pain* | 55.47 (20.96) | 53.40 (20.48) | 59.88 (21.38) | 79.4 (25.1) |
| Characteristic | Control Group | OC Group | T-Test | |
| Age | 20.3 (2.56) | 20.5 (1.79) | n.s. | |
| Education (yrs) | 14.8 (1.68) | 15.4 (1.93) | n.s. | |
| BMI | 23.3 (3.85) | 24.3 (4.50) | n.s. | |
| Cycle length | 30.5 (4.12) | 27.6 (1.29) | t = 2.99, p < 0.01 | |
| Test Day | ||||
| Follicular | 5.6 (2.24) | 6.0 (1.97) | n.s. | |
| Mid-Cycle | 14.5 (2.21) | 14.0 (1.17) | n.s. | |
| Luteal | 22.8 (3.00) | 22.2 (1.44) | n.s. | |
| Race/Ethnicity | ||||
| Caucasian/NHW | 8 (40%) | 11 (55%) | ||
| African American/Black | 1 (5%) | 1 (5%) | ||
| Hispanic/Latino | 5 (25%) | 5 (25%) | ||
| Asian/Pacific Islander | 6 (30%) | 3 (15%) |
| Median score | U | Z | p | r | ||
| AN-R | ASRSTS | 7 | ||||
| AN-BP (vs. AN-R) | ASRSTS | 11 | 910 | −2.34 | 0.019 | 0.23 |
| BN (vs. AN-R) | ASRSTS | 12 | 8942 | −4.98 | 0.000* | 0.23 |
| EDNOS-BP (vs. AN-R) | ASRSTS | 10 | 7922 | −3.80 | 0.000* | 0.19 |
| BED (vs. AN-R) | ASRSTS | 10 | 2187 | −3.17 | 0.002* | 0.25 |
| AN-R | ITS | 5 | ||||
| AN-BP (vs. AN-R) | ITS | 7 | 855 | −2.72 | 0.007* | 0.26 |
| BN (vs. AN-R) | ITS | 8 | 8480 | −5.41 | 0.000* | 0.24 |
| EDNOS-BP (vs. AN-R) | ITS | 6 | 7982 | −3.73 | 0.000* | 0.19 |
| BED (vs. AN-R) | ITS | 7 | 1930 | −4.07 | 0.000* | 0.32 |
| AN-R | HTS | 3 | ||||
| AN-BP (vs. AN-R) | HTS | 5 | 1033 | −1.53 | 0.127 | 0.15 |
| BN (vs. AN-R) | HTS | 4 | 11801 | −2.34 | 0.019 | 0.11 |
| EDNOS-BP (vs. AN-R) | HTS | 4 | 8995 | −2.57 | 0.010* | 0.13 |
| BED (vs. AN-R) | HTS | 3 | 2959 | −0.47 | 0.635 | 0.04 |
| AN-R | CPRS-dep | 9.5 | ||||
| AN-BP (vs. AN-R) | CPRS-dep | 11.5 | 955 | −2.03 | 0.042 | 0.06 |
| BN (vs. AN-R) | CPRS-dep | 11.0 | 11901 | −2.23 | 0.026 | 0.07 |
| EDNOS-BP (vs. AN-R) | CPRS-dep | 10.0 | 9947 | −1.44 | 0.150 | 0.04 |
| BED (vs. AN-R) | CPRS-dep | 10.0 | 2763 | −1.16 | 0.248 | 0.04 |
| No. | JAT | COP | BER | EPI | PAL | Inhibiting ratio (%) |
| 1 | 1 | 1 | 1 | 1 | 1 | 90.6 |
| 2 | 1 | 1 | 1 | −1 | −1 | 70.0 |
| 3 | 1 | 1 | −1 | 1 | −1 | 50.7 |
| 4 | 1 | 1 | −1 | −1 | 1 | 44.1 |
| 5 | 1 | −1 | 1 | 1 | −1 | 66.3 |
| 6 | 1 | −1 | 1 | −1 | 1 | 72.9 |
| 7 | 1 | −1 | −1 | 1 | 1 | 30.0 |
| 8 | 1 | −1 | −1 | −1 | −1 | 32.5 |
| 9 | −1 | 1 | 1 | 1 | −1 | 43.0 |
| 10 | −1 | 1 | 1 | −1 | 1 | 70.4 |
| 11 | −1 | 1 | −1 | 1 | 1 | 52.3 |
| 12 | −1 | 1 | −1 | −1 | −1 | 30.4 |
| 13 | −1 | −1 | 1 | 1 | 1 | 61.9 |
| 14 | −1 | −1 | 1 | −1 | −1 | 26.3 |
| 15 | −1 | −1 | −1 | 1 | −1 | 37.3 |
| 16 | −1 | −1 | −1 | −1 | 1 | 16.2 |
| 17 | −2 | 0 | 0 | 0 | 0 | 20.9 |
| 18 | 2 | 0 | 0 | 0 | 0 | 40.4 |
| 19 | 0 | −2 | 0 | 0 | 0 | 29.3 |
| 20 | 0 | 2 | 0 | 0 | 0 | 71.0 |
| 21 | 0 | 0 | −2 | 0 | 0 | 23.9 |
| 22 | 0 | 0 | 2 | 0 | 0 | 40.4 |
| 23 | 0 | 0 | 0 | −2 | 0 | 17.8 |
| 24 | 0 | 0 | 0 | 2 | 0 | 39.2 |
| 25 | 0 | 0 | 0 | 0 | −2 | 9.5 |
| 26 | 0 | 0 | 0 | 0 | 2 | 30.8 |
| 27 | 0 | 0 | 0 | 0 | 0 | 23.8 |
| 28 | 0 | 0 | 0 | 0 | 0 | 41.8 |
| 29 | 0 | 0 | 0 | 0 | 0 | 42.8 |
| 30 | 0 | 0 | 0 | 0 | 0 | 28.6 |
| 31 | 0 | 0 | 0 | 0 | 0 | 39.5 |
| 32 | 0 | 0 | 0 | 0 | 0 | 44.9 |
| 33 | 0 | 0 | 0 | 0 | 0 | 39.0 |
| 34 | 0 | 0 | 0 | 0 | 0 | 30.3 |
| 35 | 0 | 0 | 0 | 0 | 0 | 41.5 |
| 36 | 0 | 0 | 0 | 0 | 0 | 36.7 |
| Types | Relative | Personal | DNP | All |
| EL | 6 | 0 | 0 | 6 |
| FL | 5 | 19 | 6 | 30 |
| BMB | 0 | 8 | 0 | 8 |
| Sum | 11 | 27 | 6 | 44 |
| MMSE score | SIB-L | SIB[lang] | ||
| Donepezil 23 mg/day | Donepezil 10 mg/day | Donepezil 23 mg/day | Donepezil 10 mg/day | |
| 0 to 20b | 32.4 ± 8.2(n = 907) | 32.9 ± 7.7(n = 462) | 31.4 ± 8.3(n = 907) | 31.9 ± 7.7(n = 462) |
| 0 to 16 | 30.5 ± 8.9(n = 641) | 31.2 ± 8.3(n = 331 ) | 29.5 ± 9.0(n = 641) | 30.3 ± 8.4(n = 331) |
| First author [Reference] | Bjerregaard [[28]] | Pelletier [[29]] | Elo [[31]] | Berger [[30]] |
| Country | Denmark | Canada | Finland | Israel |
| Year | 1991 | 1998 | 1979 | 1990 |
| WB income group | High | High | High | High |
| Comparators | 1. Vaccinate 15-month and 12-yr-olds | 1. 1-dose child vaccination campaign | 1. Vaccinate 13-yr-olds & post-partum women | 1. Vaccinate children from 1 – 12 years |
| 2. Vaccinate only 15-month-olds | 2. 2-dose child vaccination campaign | 2. Vaccinate 13-yr-olds & 1-yr-olds | 2. Vaccinate only 12-yr-olds (routine) | |
| 3. 1-dose child vaccination | 3. Vaccinate only 1-yr-olds over 20 years | |||
| 4. 2-dose child vaccination | ||||
| Perspective | Societal* | Societal* | Societal* | NR |
| Cost components measured | OP visits; prescriptions; hospitalizations; vaccines | OP visits; hospitalizations; laboratory tests; nursing home care; special education; indirect costs (lost productivity for illness, disability and premature death) | Fetal loss; fetal damage; annual costs; long-term costs | Vaccine; vaccination side effects; serology; OP visits; hospitalizations; hearing aids; mothers’ work loss; |
| Method of cost estimation | Micro-costing | Micro-costing; Lifetime earnings (for indirect costs) | Top-down costing based on Delphi panel | Micro-costing |
| Method of benefits estimation | Averted costs | Averted costs | Averted costs | Averted costs |
| Time period for costs and benefits | 20 years | Lifetime | 30 years | 13 years |
| Discounting (Rate) | NR | Yes (5%) | Yes (6%) | Yes (5 and 10%) |
| Results—Benefit-cost ratio | 1. 3 | 1. 2.6 | 1. 10 | 1. 1.1 |
| 2. 2 | 2. 2.9 | 2. 3 | 2. 1.8 | |
| 3. 3.6 | 3. 6 | |||
| 4. 4.3 | ||||
| Stated conclusion | Vaccinating both age groups is preferable | The benefits of a second dose outweigh the costs | Vaccinating 13-yr-old girls and postpartum women was preferable | Vaccinating infants and adolescent girls is preferable |
| Sponsor | NR | LCDC | NR | NR |
| Organ | OA |
| Fifth leaf | −0.16 ± 0.07 |
| Awn | 0.36 ± 0.07 |
| Lemma | 0.42 ± 0.05 |
| Palea | 0.30 ± 0.04 |
| WT 4dpp | KO 4dpp | WT 9dpp | KO 9dpp | WT adult | KO adult | |
| ≥2 apoptotic cells per tubule | 1.4 | 3.4 | 17.6 | 36.4 | 28.0 | 30.5 |
| Total number of tubules counted | 300 | 300 | 300 | 300 | 201 | 201 |
| Number of testes used | 4 | 4 | 4 | 4 | 2 | 4 |
| P (Fisher's exact test | 0.17 | 0.0006 | 0.8 |
| S. No. | Name | Description |
| 1. | Circular Fingerprint | Circular fingerprint is based on CDK’s [31] circular fingerprinter and is functionally equivalent to ECFP-2 [43] |
| 2. | Extended Fingerprint | Functionally equivalent to ExtendedFingerprinter of CDK [31]. This fingerprint is unique from the standard form since it accounts for ring systems. Default length size is 1024 bits. |
| 3. | Substructure Fingerprint | This is a structural key type fingerprint which considers assessment of 307 different substructures and is based on KlekotaRothFingerprinter [44] in CDK. |
| 4. | Enhanced Fingerprint | An in-house developed improvised extended fingerprint which accounts for stereochemistryand charges on molecules. |
| Elution methods | Elution liquid-solid ratio (mL/g) | Elution time (h) | Elution capacity (Q, mg/g) |
| Soxhlet extraction | 100 | 24 | 547 |
| Ultrasonic extraction | 40 | 1 | 815 |
| Microwave-assisted extraction | 40 | 5 | 326 |
| Node | Description | Degree |
| UBC | ubiquitin C | 739 |
| EGFR | epidermal growth factor receptor | 157 |
| MDM2 | MDM2 proto-oncogene | 153 |
| TP53 | tumor protein p53 | 152 |
| APP | amyloid beta precursor protein | 149 |
| HSP90AA1 | heat shock protein 90 alpha family class A member 1 | 149 |
| EP300 | E1A binding protein p300 | 135 |
| SUMO1 | small ubiquitin-like modifier 1 | 130 |
| GRB2 | growth factor receptor bound protein 2 | 128 |
| SRC | SRC proto-oncogene, non-receptor tyrosine kinase | 126 |
| CTNNB1 | catenin beta 1 | 125 |
| FN1 | fibronectin 1 | 123 |
| YWHAZ | tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta | 122 |
| ESR1 | estrogen receptor 1 | 110 |
| HSP90AB1 | heat shock protein 90 alpha family class B member 1 | 107 |
| HDAC1 | histone deacetylase 1 | 100 |
| AKT1 | AKT serine/threonine kinase 1 | 96 |
| AR | androgen receptor | 92 |
| MAPK1 | mitogen-activated protein kinase 1 | 88 |
| CUL7 | cullin 7 | 87 |
| MYC† | v-myc avian myelocytomatosis viral oncogene homolog | 87 |
| Parameters | Con. (μg/mL) | Duodenum | Jejunum | Ileum | Colon |
| Peff × 10−3 | 3 | 7.11 ± 3.68 | 8.72 ± 3.47 | 9.48 ± 2.91 | 10.3 ± 1.56 |
| 6 | 6.93 ± 3.01 | 9.52 ± 3.28 | 8.15 ± 3.82 | 10.8 ± 1.79 | |
| 9 | 9.03 ± 1.35 | 10.5 ± 1.67 | 9.13 ± 2.63 | 8.57 ± 3.75 | |
| 10 cm%ABS | 3 | 4.76 ± 1.27 | 4.98 ± 2.46 | 5.62 ± 1.81 | 6.34 ± 1.63 |
| 6 | 4.69 ± 1.46 | 5.19 ± 1.44 | 5.34 ± 2.57 | 5.59 ± 2.34 | |
| 9 | 4.75 ± 0.98 | 5.09 ± 1.45 | 5.46 ± 2.24 | 5.75 ± 1.86 | |
| Ka × 10−2 | 3 | 1.52 ± 0.41 | 2.08 ± 0.33 | 2.62 ± 0.17 | 1.27 ± 0.19 |
| 6 | 1.66 ± 0.23 | 2.12 ± 0.23 | 2.48 ± 0.45 | 1.03 ± 0.37 | |
| 9 | 1.44 ± 0.58 | 2.03 ± 0.45 | 2.43 ± 0.74 | 1.19 ± 0.24 |
| Parameter | Body weight (g) | Food Intake (Kcal) | Glucose (mM) | Ketones (mM) | Seizure Susceptibility |
| Body weight (g) | 1.000 | ||||
| Food Intake (Kcal) | 0.488* | 1.000 | |||
| Glucose (mM) | 0.509* | 0.382* | 1.000 | ||
| Ketones (mM) | -0.379* | -0.379* | -0.429* | 1.000 | |
| Seizure Susceptibility | 0.512* | 0.464* | 0.616* | -0.510* | 1.000 |
| Application | (n) Total | Dead larvae % | |||||
| (Days) | (Larvae) | CXa (5.5 mg/L) | CX (5.5 mg/L) | CXa (11 mg/L) | CX (11 mg/L) | CXa (22 mg/L) | Control |
| 0 | 625 | – | – | – | – | – | – |
| 3 | 625 | 100 ± 0 | 100 ± 0 | 100 ± 0 | 100 ± 0 | 100 ± 0 | 24 ± 31,749 |
| 6 | 625 | 100 ± 0 | 100 ± 0 | 100 ± 0 | 100 ± 0 | 100 ± 0 | 9,3 ± 6,110 |
| 9 | 625 | 99,2 ± 1,789 | 99,2 ± 1,789 | 99,2 ± 1,789 | 100 ± 0 | 100 ± 0 | 0 ± 0 |
| 12 | 675 | 95,1 ± 1,789 | 96,6 ± 3,578 | 98,3 ± 2,191 | 100 ± 0 | 100 ± 0 | 3,2 ± 9,237 |
| 15 | 625 | 95,1 ± 2,191 | 94,2 ± 6,066 | 98,3 ± 3,578 | 100 ± 0 | 98 ± 2,828 | 2,6 ± 2,309 |
| 18 | 625 | 93,6 ± 4,561 | 95,2 ± 3,347 | 95,2 ± 4,382 | 99,2 ± 1,789 | 100 ± 0 | 0 ± 0 |
| 21 | 625 | 83,2 ± 7,155 | 87,2 ± 7,694 | 89,6 ± 2,109 | 96,8 ± 3,347 | 96 ± 0 | 0 ± 0 |
| 24 | 625 | 80 ± 4 | 89,6 ± 3,578 | 88 ± 2,828 | 96,8 ± 3,346 | 98 ± 2,828 | 0 ± 0 |
| Comorbidity | Prevalence | ||
| N = 14,005 | (n) | (%) | 95% CI |
| Mental health condition | 5,401 | 38.6% | (37.8% to 39.4%) |
| Physical conditions: | |||
| Myocardial infarction | 174 | 1.2% | (1.1% to 1.4%) |
| Congestive heart disease | 233 | 1.7% | (1.5% to 1.9%) |
| Chronic obstructive pulmonary disease | 1,106 | 7.9% | (7.5% to 8.3%) |
| End stage renal disease | 223 | 1.6% | (1.4% to 1.8%) |
| Peripheral vascular disease | 72 | 0.5% | (0.4% to 0.6%) |
| Asthma | 1,780 | 12.7% | (12.2% to 13.3%) |
| Diabetes | 1,167 | 8.3% | (7.9% to 8.8%) |
| Hypertension | 2,093 | 14.9% | (14.4% to 15.5%) |
| Stroke | 173 | 1.2% | (1.1% to 1.4%) |
| At least one physical condition | 4820 | 34.4% | (33.6% to 35.2%) |
| Physical-mental health multimorbidity | 2,174 | 15.5% | (14.9% to16.1%) |
| Multimorbidity (at least two physical conditions) | 1,508 | 10.8% | (10.3% to 11.3%) |
| Items | ||
| Variables | Glucose | HbA1c |
| PATIENT INFORMATION | ||
| Number of subjects | 485 | 155 |
| Sex | ||
| Female | 187 (38.6) | 54 (34.8) |
| Male | 298 (61.4) | 101 (65.2) |
| Age, years | ||
| 20–49 | 67 (13.8) | 20 (12.9) |
| 50–59 | 103 (21.2) | 33 (21.3) |
| 60–69 | 150 (31.0) | 47 (30.3) |
| 70< | 165 (34.0) | 55 (35.5) |
| Medication | ||
| candesartan cilexetil | 177 (36.5) | 51 (32.9) |
| losartan potassium | 78 (16.1) | 35 (22.6) |
| olmesartan medoxomil | 56 (11.5) | 21 (13.5) |
| telmisartan | 56 (11.5) | 18 (11.6) |
| valsartan | 118 (24.3) | 30 (19.4) |
| DATA INFORMATION | ||
| Number of examinations | 2464 | 457 |
| Treatment duration | ||
| 0 = \"Baseline\" | 733 (29.8) | 150 (32.8) |
| 1 = \"~3 M\" | 1068 (43.3) | 132 (28.9) |
| 2 = \"3~6 M\" | 377 (15.3) | 89 (19.5) |
| 3 = \"6~12 M\" | 286 (11.6) | 86 (18.8) |
| Phytochemical | Detection system | Observation | Result |
| Coumarin | 365 nm | Blue spot | + |
| Flavonoids | 5% AlCl3 | Yellow spot | + |
| Tannin | 2% FeCl3 | Greenish Black spot | + |
| Saponin | 10% Vanillin (Ethanol) | Violet and yellow | + |
| Monoterpene alcohol, Bitter principle saponin | Vanillin-H2SO4 | Blue | + |
| Triterpene and steroid | Lieberman-Buchard’s reagent | Brown and yellow spots | + |
| Classification result | ||
| Actual result | Forecast result | |
| P | N | |
| P | TP | FN |
| N | FP | TN |
| Time | Predicted value | 95% prediction intervals | |
| Lower prediction limit | Upper prediction limit | ||
| 2013m1 | 24.68 | 17.4 | 31.96 |
| 2013m2 | 22.05 | 14.60 | 29.49 |
| 2013m3 | 23.69 | 16.08 | 31.29 |
| 2013m4 | 23.35 | 15.59 | 31.12 |
| 2013m5 | 23.89 | 15.97 | 31.81 |
| 2013m6 | 23.43 | 15.35 | 31.50 |
| ASD | Control | |
| Saccade error (absolute value in degree of visual angle) | ||
| 10 deg | 1.46 (0.43)* | 1.27 (0.07) |
| 20 deg | 2.40 (0.72)*** | 1.86 (0.11) |
| 30 deg | 3.33 (1.12)** | 2.60 (0.17) |
| Trial-wise variability (SD) of saccade error (absolute value in degrees) | ||
| 10 deg | 1.11 (0.37) | 1.03 (0.37) |
| 20 deg | 1.90 (0.58)*** | 1.31 (0.58) |
| 30 deg | 2.79 (0.58)** | 2.07 (0.29) |
| Saccade amplitude in degrees | ||
| 10 deg | 9.78 (0.82) | 9.69 (0.82) |
| 20 deg | 19.11 (1.28) | 19.20 (1.28) |
| 30 deg | 27.71 (1.68) | 28.14 (1.68) |
| Trial-wise variability (SD) of saccade amplitude in degrees | ||
| 10 deg | 1.91 (0.64) | 1.86 (0.65) |
| 20 deg | 2.75 (0.83)* | 2.30 (0.83) |
| 30 deg | 3.86 (1.19)*** | 2.10 (1.19) |
| Saccade latency in ms | ||
| 10 deg | 255 (52) | 248 (52) |
| 20 deg | 275 (58) | 273 (58) |
| 30 deg | 313 (55) | 300 (55) |
| Trial-wise variability (SD) of saccade latency in ms | ||
| 10 deg | 80 (30)** | 64 (21) |
| 20 deg | 90 (37)** | 66 (37) |
| 30 deg | 90 (32)* | 75 (32) |
| Model | Genotype | Controls (%) | Asthma Patients (%) | OR (95% CI) | P-value |
| rs2280090 | C/C | 166 (83) | 331 (83) | 1 | 0.33 |
| C/T | 34 (17) | 65 (16.3) | 1.03 (0.61–1.71) | ||
| T/T | 0 (0) | 3 (0.8) | NA (0.00-NA) | ||
| rs487377 | G/G | 82 (41) | 142 (35.6) | 1 | 0.79 |
| G/A | 90 (45) | 197 (49.4) | 1.15 (0.76–1.75) | ||
| A/A | 28 (14) | 60 (15) | 1.03 (0.57–1.88) | ||
| rs511898 | G/G | 97 (48.5) | 185 (46.2) | 1 | 0.94 |
| G/A | 87 (43.5) | 179 (44.8) | 1.04 (0.70–1.55) | ||
| A/A | 16 (8) | 36 (9) | 1.13 (0.55–2.31) | ||
| rs2787094 | C/C | 90 (45) | 143 (35.8) | 1 | 0.049 |
| C/G | 89 (44.5) | 189 (47.2) | 1.21 (0.80–1.82) | ||
| G/G | 21 (10.5) | 68 (17) | 1.91 (1.02–3.60) | ||
| rs528557 | G/G | 124 (62) | 248 (62) | 1 | 0.56 |
| G/C | 66 (33) | 133 (33.2) | 0.96 (0.63–1.44) | ||
| C/C | 10 (5) | 19 (4.8) | 1.61 (0.63–4.14) | ||
| rs678881 | C/C | 166 (83) | 298 (74.7) | 1 | 0.0083 |
| G/C | 30 (15) | 97 (24.3) | 1.92 (1.16–3.18) | ||
| G/G | 4 (2) | 4 (1) | 0.68 (0.14–3.38) | ||
| rs2853215 | C/C | 128 (64) | 250 (62.5) | 1 | 0.39 |
| C/T | 64 (32) | 127 (31.8) | 1.02 (0.67–1.54) | ||
| T/T | 8 (4) | 23 (5.8) | 1.91 (0.73–5.01) | ||
| rs554743 | A/A | 64 (32.3) | 122 (30.5) | 1 | 0.51 |
| G/A | 100 (50.5) | 193 (48.2) | 0.84 (0.54–1.30) | ||
| G/G | 34 (17.2) | 85 (21.2) | 1.10 (0.63–1.94) | ||
| rs2853209 | A/A | 43 (21.5) | 108 (27.2) | 1 | 0.37 |
| A/T | 102 (51) | 201 (50.6) | 0.82 (0.51–1.33) | ||
| T/T | 55 (27.5) | 88 (22.2) | 0.67 (0.39–1.17) | ||
| rs570269 | G/G | 66 (33) | 140 (35) | 1 | 0.49 |
| G/C | 93 (46.5) | 199 (49.8) | 1.01 (0.66–1.55) | ||
| C/C | 41 (20.5) | 61 (15.2) | 0.74 (0.43–1.29) | ||
| rs44707 | C/C | 66 (33) | 172 (43) | 1 | 0.0084 |
| C/A | 90 (45) | 178 (44.5) | 0.73 (0.47–1.12) | ||
| A/A | 44 (22) | 50 (12.5) | 0.47 (0.27–0.83) | ||
| rs512625 | C/C | 94 (47) | 142 (35.5) | 1 | 0.033 |
| C/T | 75 (37.5) | 193(48.2) | 1.60 (1.06–2.43) | ||
| T/T | 31 (15.5) | 65 (16.2) | 1.32 (0.74–2.34) | ||
| rs677044 | T/T | 120 (60) | 193 (48.6) | 1 | 0.0033 |
| C/T | 69 (34.5) | 167 (42.1) | 1.51 (1.00–2.28) | ||
| C/C | 11 (5.5) | 37 (9.3) | 2.77 (1.23–6.24) |
| Annotation Clusters | Official Symbol |
| Vascular development | Eph2, Chd7, Ereg, Foxc1, Gja1, Itgav, Lepr, Nus1, Pdpn,Prox1, S1pr1, Socs3, Zfp36l1 |
| Embryonic morphogenesis | Eph2, Chd7, Chst11, Foxc1, Hes1, Il10, Mmp13, Pbx1,Prox1, Socs3, Spry2, Jag2 |
| Sexual reproduction | Bcl6, Bcl2l11, Crem, Calca, Cadm1, Ereg, Fst, Foxc1,Jag2, Lepr, Pvrl3, Rgs2, Stat3 |
| Response to wounding, Inflammatory and Defense responses | Bmp6, Cd14, Calca, Ddah2, Entpd1, Gja1, Hdac5, Il1f6,Il10, Saa1, Saa2, Stat3, Thbd, Thbs1 |
| Growth factors, GF activity | Areg, Bmp6, Chst11, Csf3, Ereg, Foxc1, Gja1, Hgf, Inhbb,Jag2 |
| DNA binding, Transcription regulation | Arid3b, Bcl6, Bach2, Gata2, Lhx8, Mxd1, Mxi1, Setbp1,Thap2, Crem, Chd7, Dedd2, Foxc1, Hes1, Hdac5, Lrrfip1,Nr4a2, Pbx1, Prox1, Runx2, Stat3, Fosl2, Sbno2, Tshz3, Tle1,Mafb, Zfp36, Zfp36l1 |
| Disulfide bond | Nt53, Abca1, Cd14, Cd80, Edil3, Eph2, Gpr35, Areg,Antxr2, Bmp6, Calca, Cacna1d, Cadm1, Cbln3, CxCr7, Csf3,Entpd1, Ereg, Fst, Gja1, Havcr2, Hgf, Inhbb, Itgav, Il10,Jag2, Lepr, Lifr, Man1a, Mmp13, Mmp3, Mpzl1, Niacr1, Pla1a,Pvrl3, Ptger2, Lpar6, Ramp3, Sema6d, Tnfaip6, Thbd, Thbs1,Trem1, Tnfrsf9 |
| Gene | Ensembl ID | Reference | Sites found by RNA-seq for | Sites found by HTA for | Concordant | ||
| exons | junctions | exons | junctions | ||||
| TP63 | ENSG00000073282 | Lo Iacono et al. [57] | 6 | 10 | 2 | 27 | No |
| TP73 | ENSG00000078900 | Lo Iacono et al. [57] | 0 | 2 | 2 | 6 | No |
| CD44 | ENSG00000026508 | Wang et al. [58] | 34 | 32 | 19 | 43 | No |
| HLA-G | ENSG00000204632 | Yan et al. [59] | 2 | 0 | 0 | 0 | No |
| POSTN | ENSG00000133110 | Morra et al. [60] | 3 | 5 | 1 | 7 | No |
| RUNX1 | ENSG00000159216 | Ito et al. [61] | 8 | 2 | 18 | 13 | Yes |
| Flock size | 2000 | 2010 | |||
| n | % | n | % | ||
| Flocks enrolled | <26 | 1009 | 20.4 | 547 | 15.0 |
| 26–125 | 3651 | 73.9 | 2602 | 71.2 | |
| 126–250 | 268 | 5.4 | 451 | 12.3 | |
| >250 | 13 | 0.3 | 54 | 1.5 | |
| Ewes enrolled in flocks | <26 | 17,044 | 6.2 | 8355 | 3.1 |
| 26–125 | 214,086 | 77.4 | 170,358 | 63.1 | |
| 126–250 | 41,542 | 15.0 | 73,551 | 27.2 | |
| >250 | 3959 | 1.4 | 17,847 | 6.6 |
| Gene | Location | The length of protein(aa) | ||
| SNU8067 | KM91 | SNU8067 | KM91 | |
| 1a | 529–12390 | 529–12387 | 3953 | 3952 |
| 1b | 12465–20423 | 12357–20420 | 2652 | 2688 |
| S | 20374–23883 | 20371–23862 | 1169 | 1163 |
| 3a | 23883–24056 | 23862–24008 | 57 | 48 |
| 3b | 24056–24250 | 23995–24183 | 64 | 62 |
| E | 24234–24560 | 24167–24496 | 108 | 109 |
| M | 24532–25209 | 24465–25145 | 225 | 226 |
| 5a | 25569–25766 | 25505–25702 | 65 | 65 |
| 5b | 25763–26011 | 25699–25947 | 82 | 82 |
| N | 25954–27183 | 25890–27119 | 409 | 409 |
| Field | Code | Character | Item amount | Scores (R) | Calculation method |
| Physical function | PF | Function | 5 | 3 | (Q1 + Q2 + Q3 + Q4 + Q5)/5 |
| Role function | RF | Function | 2 | 3 | (Q6 + Q7)/2 |
| Emotional function | EF | Function | 4 | 3 | (Q21 + Q22 + Q23 + Q24)/4 |
| Cognitive function | CF | Function | 2 | 3 | (Q20+ Q25)/2 |
| Social function | SF | Function | 2 | 3 | (Q26 + Q27)/2 |
| Global QOL | QL | 2 | 6 | (Q29 + Q30)/2 | |
| Fatigue | FA | Symptom | 3 | 3 | (Q10 + Q12 + Q26)/3 |
| Nausea and vomiting | NV | Symptom | 2 | 3 | (Q14 + Q15)/2 |
| Pain | PA | Symptom | 2 | 3 | (Q9 + Q19)/2 |
| Dyspnea | DY | Symptom | 1 | 3 | Q8 |
| Sleep disturbance | SL | Symptom | 1 | 3 | Q11 |
| Appetite loss | AP | Symptom | 1 | 3 | Q13 |
| Constipation | CO | Symptom | 1 | 3 | Q16 |
| Diarrhea | DI | Symptom | 1 | 3 | Q17 |
| Financial difficulties | FI | Symptom | 1 | 3 | Q28 |
| PMPs mean (SD) counts/μl | EMPs-CD31 mean (SD) counts/μl | EMPs-CD62 mean (SD) counts/μl | PMPs p vs.Ct | EMPs-CD31 p vs.Ct | EMPs-CD62 p vs.Ct | |
| Control | 15,646 (11,901) | 2,202 (2,784) | 418 (289) | |||
| CIS | 30,936 (22,550) | 7,964 (6,888) | 646 (195) | n.s. | <0.05 | <0.05 |
| RRMS | 28,929 (18,247) | 7,136 (6,088) | 511 (231) | <0.001 | <0.001 | n.s. |
| SPMS | 34,188 (29,511) | 7,512 (5,962) | 629 (644) | <0.01 | <0.001 | n.s. |
| PPMMS | 26,422 (9,865) | 6,460 (3,610) | 699 (621) | <0.05 | <0.001 | n.s. |
| Patient | CA (years) | BA (years) | GH peak (ng/mL) | FT3 (pmol/L) | FT4 (pmol/L) | TSH (mIU/L) | TPOAb (IU/mL) | TgAb (IU/mL) | IGF-1 (ng/mL) | PRL (μg/L) | Pituitary height (mm) |
| 1 M | 6.2 | 1.0 | 8.0 | 1.6 | 3.4 | >150 | 42.1 | 23.9 | 145.0 | 49.1 | 11.0 |
| 2 M | 9.8 | 6.0 | 2.7 | 0.1 | 3.0 | >150 | >500 | >1300 | 78.0 | 32.2 | 14.0 |
| 3 M | 11.2 | 8.0 | 5.1 | 1.2 | 4.3 | >150 | >500 | >1300 | 97.7 | 12.5 | 16.0 |
| 4 M | 10.7 | 6.0 | 7.5 | 2.0 | 3.3 | >150 | 73.8 | >1300 | 68.61 | 52.6 | 18.0 |
| 5 M | 10.8 | 7.0 | 2.6 | 2.6 | 4.3 | 75.0 | >500 | >1300 | 56.7 | 27.5 | 20.3 |
| 6 M | 7.9 | 4.0 | 1.5 | 3.0 | 6.6 | >150 | >500 | 404.5 | 106.98 | 52.4 | 19.0 |
| 7 M | 15.0 | 13.0 | 6.7 | 4.9 | 6.7 | 65.5 | >500 | >1300 | 147.42 | 28.5 | 14.0 |
| 8 M | 15.8 | 10.0 | 8.0 | 1.0 | 1.2 | >150 | 627.3 | 36.9 | 148.3 | 41.5 | 14.0 |
| 9 F | 5.0 | 3.0 | 7.1 | 0.2 | 3.6 | >150 | >500 | >1300 | 75.26 | 75.4 | 13.0 |
| 10 F | 9.3 | 8.5 | 5.2 | 6.5 | 7.3 | 78.0 | >500 | 600.9 | 63.0 | 33.2 | 8.8 |
| 11 F | 11.5 | 9.0 | 1.0 | 0.8 | 1.4 | >150 | >500 | >1300 | 123.0 | 41.4 | 9.0 |
| Primer name | Assay | Sequence (5′-3′) | Exon position | Target gene | Amplicon sizes (bp) |
| GHRL-1 F | RT-PCR | TTTCTGAGCCCTGAACATCAG | 1 | GHRL | 305 canonical (wild-type) preproghrelin |
| GHRL-4R | GAGAACAGACAGGTGGTTGG | 4 | |||
| GHRL-5OF | RACE | ATGAATGAACACTGCGTTTGCT | N/A | GHRL | 174 |
| GHRL-5OR | CAGTTTCTGATGTTCAGGGCTC | 1 | |||
| GHRL-5IF | RACE | GAACACTGCGTTTGCTGGCT | N/A | GHRL | 130 |
| GHRL-5IR | GGCCAAGTCCATCCAGAGCA | 1 | |||
| GHRL-2F | qRT-PCR | CTAAGAAGCCGTCAGGCAGACT | 2 | GHRL (preproghrelin) | 153 |
| GHRL-2R | GGGACTGAGCCCCTGACA | 3 | |||
| GHRL1_3F | qRT-PCR | CAGAAACTGCAGTTCAATGC | 1 / 3 | GHRL (Δex2 preproghrelin) | 224 |
| GHRL-4R | CACGTGGTCTCGGAAGTGT | 4 | |||
| GHRL1_4F | qRT-PCR | CTGCAGAAACCCTGGCTGA | 1 / 4 | GHRL (Δex2,3 preproghrelin) | 109 |
| GHRL-4R | CACGTGGTCTCGGAAGTGT | 4 | |||
| GOAT-mF | qRT-PCR | GGTTTCAAGCTCGAGTTGAAGG | N/A | MBOAT4 (GOAT) | 212 |
| GOAT-mR | AGTAGGTGAGTTTGAAGAGCCC | ||||
| GAPDH-F | qRT-PCR | CCTGGAGAAACCTGCCAAGT | N/A | GAPDH | 209 |
| GAPDH-R | GCCAAATTCATTGTCGTACCA |
| Case (N = 43) | Control (N = 179) | p | |
| Primipara | 24 (55.8%) | 75 (41.9%) | 0.14 |
| Maternal transfer | 28 (65.1%) | 109 (60.9) | 0.742 |
| Preeclampsia/eclampsia or chronic hypertension | 16 (37.2%) | 42 (23.5%) | 0.104 |
| Vaginal bleeding | 21 (48.8%) | 98 (54.8%) | 0.596 |
| Abdominal pain | 20 (46.5%) | 57 (31.8%) | 0.104 |
| Abnormal ultrasonographic finding | 35 (81.4%) | 128 (71.5%) | 0.257 |
| Abnormal FHR patterns | 42 (97.7%) | 98 (54.7%) | <0.0001 |
| Bradycardia | 32 (74.4%) | 42 (23.5%) | <0.0001 |
| Persistent late decelerations | 9(20.9%) | 34 (19.0%) | 0.919 |
| Cesarean section | 41 (95.3%) | 171 (95.5%) | 0.993 |
| Gestational age at delivery (weeks) | 34(24–39)* | 35 (24–41)* | 0.07 |
| Gestational age at delivery <35 wks | 19 (44.2%) | 99 (55.3%) | 0.253 |
| Birth weight (g) | 1997 (517–3504)* | 2062 (774–3450)* | 0.107 |
| Male | 22 (51.2%) | 108 (60.3%) | 0.568 |
| Apgar score (1 min) | 2(0–6)* | 6 (0–9)* | <0.0001 |
| Apgar score (5 min) | 5 (0–9)* | 8 (0–10)* | <0.0001 |
| Blood transfusion | 21 (48.8%) | 37 (20.7%) | 0.006 |
| Health Variable | Coefficient (Standard Error) | |||
| NR Score | NR Self | NR Perspective | NR Experience | |
| Depression | −0.11(0.07) | −0.02(0.06) | −0.04(0.06) | −0.17(0.06) ** |
| Anxiety | −0.08(0.08) | 0.05(0.06) | −0.04(0.07) | −0.17(0.06) ** |
| Stress | −0.03(0.07) | 0.00(0.00) | 0.07(0.06) | −0.12(0.06) * |
| Self-reported health | 0.26(0.08) *** | −0.15(0.06) * | −0.03(0.07) | 0.38(0.06) *** |
| Altitudinal band (m) | Bryophyte | Fern | Seed plants | Overall plants |
| 800 | 20 | 24 | 14 | 58 |
| 900 | 28 | 29 | 80 | 137 |
| 1000 | 39 | 43 | 254 | 336 |
| 1100 | 52 | 42 | 319 | 413 |
| 1200 | 64 | 54 | 766 | 884 |
| 1300 | 81 | 61 | 767 | 909 |
| 1400 | 92 | 66 | 692 | 850 |
| 1500 | 111 | 73 | 656 | 840 |
| 1600 | 112 | 61 | 637 | 810 |
| 1700 | 122 | 61 | 611 | 794 |
| 1800 | 138 | 57 | 607 | 802 |
| 1900 | 139 | 51 | 593 | 783 |
| 2000 | 141 | 52 | 625 | 818 |
| 2100 | 132 | 43 | 501 | 676 |
| 2200 | 134 | 40 | 510 | 684 |
| 2300 | 132 | 40 | 504 | 676 |
| 2400 | 114 | 36 | 421 | 571 |
| 2500 | 120 | 38 | 415 | 573 |
| 2600 | 112 | 28 | 337 | 477 |
| 2700 | 115 | 29 | 304 | 448 |
| 2800 | 99 | 28 | 316 | 443 |
| 2900 | 93 | 22 | 222 | 337 |
| 3000 | 94 | 21 | 236 | 351 |
| 3100 | 91 | 9 | 178 | 278 |
| 3200 | 70 | 8 | 170 | 248 |
| 3300 | 56 | 4 | 127 | 187 |
| 3400 | 44 | 4 | 120 | 168 |
| 3500 | 40 | 4 | 145 | 189 |
| 3600 | 29 | 1 | 84 | 114 |
| 3700 | 1 | 1 | 64 | 66 |
| All bands pooled | 257 | 110 | 1491 | 1858 |
| Sub-group | Overall sample | Bicycle ridership |
| n=26 078 | n1=19 410 (row % 74.4) | |
| Sub-group totals in n (% of n) | Sub-group totals in n1 (% of n1) | |
| Sex: | ||
| Boys | 12 815 (49.2) | 10 085 (52.0) (row % 78.7) |
| Girls | 13 254 (50.8) | 9322 (48.0) (row % 70.3) |
| Age: | ||
| Mean (SD) | 13.3 (1.6) | 13.3 (1.6) |
| Range in years | 9 to 19 | 10 to 19 |
| Grade level: | ||
| < 8 | 10 370 (39.8) | 8180 (42.2) (row % 78.9) |
| 8-9 | 10 661 (40.9) | 7708 (39.8) (row % 72.3) |
| ≥ 10 | 5047 (19.3) | 3521 (18.1) (row % 69.8) |
| Socio-Economic status: | ||
| Above average | 13 998 (56.9) | 10 817 (58.0) (row % 77.3) |
| Average | 8276 (33.6) | 6176 (33.1) (row % 74.6) |
| Below average | 2339 (9.5) | 1652 (8.9) (row % 70.6) |
| Urban–rural Location: | ||
| Large Urban Centre | 8589 (32.9) | 6161 (31.7) (row % 71.7) |
| Medium Urban Centre | 5739 (22.0) | 4174 (21.5) (row % 72.7) |
| Small Town | 10 767 (41.3) | 8329 (42.9) (row % 77.4) |
| Rural | 983 (3.8) | 746 (3.8) (row % 75.9) |
| Years in Canada: | ||
| Lifetime (born in Can.) | 18 466 (71.5) | 13 855 (72.0) (row % 75.0) |
| Immigrant > 5 yrs | 6143 (23.8) | 4642 (24.1) (row % 75.6) |
| Immigrant ≤ 5 yrs | 1212 (4.7) | 750 (3.9) (row 61.9) |
| How did you know when to take your child for his/her most recent immunization? | ChoseResponsec % (95% CI)d | UTD4:3:1:3:3 Chose Response % (95% CI) | UTD4:3:1:3:3 Did Not Chose Response % (95% CI) | UTD 4:3:1:3:3 Difference % points (95% CI) |
| Doctor/Nurse at Previous Immunization Visit e | 70.3 (68.3, 72.3) | 77.2 (74.9, 79.5) | 70.1 (66.0, 74.1) | 7.1 (2.5, 11.8) |
| Shot Card/Record | 19.5 (17.6, 21.3) | 70.6 (65.2, 76.0) | 76.2 (74.0, 78.3) | -5.6 (-11.3, 0.2) |
| Reminder/Recallf | 8.6 (7.4, 9.8) | 71.0 (63.8, 78.1) | 75.5 (73.4, 77.6) | -4.5 (-11.9, 2.9) |
| Otherg | 18.3 (16.7, 19.9) | 75.4 (71.4, 79.5) | 75.0 (72.7, 77.3) | 0.4 (-4.3, 5.1) |
| CD8+T cells | CD4+T cells | References | |
| Characteristics | Decreased HBV-specific CD8+ T cells; impaired cytotoxicity (IL-2, IFN-γ and TNF-α); increased inhibitory receptors including PD-1, TIM-3, CTLA-4 and 2B4 | Impaired proliferation without obvious defect in Th-1-type cytokines; high PD-1 and low expression of CTLA-4, TIM-3, KLRG1 and 2B4 | 1, 9, 11, 25, 26, 27, 28, 106, 107 |
| Evidence for immunotherapy | Blockade of the PD-1/PD-L1 pathway restored proliferation and function of HBV-specific CD8+ T cells; blockade of CD244 or its ligand CD48 may recover proliferation, cytokine production and cytotoxicity of exhausted HBV-specific CD8+ T cells; blockade of CTLA-4 was able to increase the proliferation of IFN-γ-producing HBV-specific CD8+ T cells; by blocking Tim-3/galectin-9 interactions, expansion of HBV-specific CD8+ T cells was enhanced, which were able to produce cytokines and mediate cytotoxicity | PDGF-BB inhibited CD4+ T-cell proliferation; antibody specific for the PDGF-B chain was able to reduce the development of liver fibrosis; neutralization of PD-L1/2 was able to improve the ability of CD4+ T cells to produce Th-1 cytokines | 11, 26, 35, 47, 49, 51, 61, 62, 63, 106, 107 |
| Mucosal Biopsy | Surgical Resection | |
| Actin | Positive | Positive |
| Vimentin | Positive | Positive |
| Bcl-2 | Positive | Positive |
| CD138 | Positive | Not done |
| Calponin | Not done | Positive |
| Collagen type IV | Not done | Pericellular net-like pattern |
| EMA | Not done | Focal Positive |
| AE1/3 | Negative | Focal Positive |
| Cam5.2 | Negative | Negative |
| CK20 | Negative | Not done |
| CD56 | Negative | Negative |
| Desmin | Negative | Negative |
| S100 | Negative | Negative |
| MPO | Negative | Not done |
| CD20 | Negative | Not done |
| CD21 | Negative | Not done |
| CD99 | Negative | Not done |
| CD30 | Negative | Not done |
| C-Kit | Negative | Negative |
| DOG1 | Negative | Negative |
| PLAP | Negative | Not done |
| WT1 | Not done | Negative |
| CD10 | Not done | Negative |
| Chromogranin | Not done | Negative |
| Synaptophysin | Not done | Patchy Positive |
| NSE | Not done | Focal Positive |
| Myogenin | Not done | Negative |
| EWS translocation | Not done | Negative |
| SYT translocation | Not done | Negative |
| CIC-DUX4 translocation | Not done | Negative |
| Area | Median | Range | Inter Quartile Range (IQR) | Z* | P value |
| Shenzhen (N = 1,826) | 6 | 0-8 | 4-7 | -12.547 | <0.001 |
| Xiuning (N = 2,572) | 5 | 0-8 | 3-6 |
| Young group | Middle-aged and elderly group | |||
| Men | Women | Men | Women | |
| Number | 310 | 357 | 273 | 861 |
| Age (years) | 29 ± 7 | 29 ± 7 | 60 ± 12 | 60 ± 11 |
| Height (cm) | 173.2 ± 5.6 | 160.4 ± 5.9 | 168.7 ± 6.3 | 155.7 ± 5.8 |
| Weight (kg) | 68.6 ± 8.8 | 53.9 ± 7.2 | 63.9 ± 6.7 | 52.0 ± 5.8 |
| BMI (kg/m2) | 22.9 ± 2.8 | 20.9 ± 2.5 | 22.4 ± 1.5 | 21.4 ± 1.9 |
| WC (cm) | 79.2 ± 7.9 | 73.0 ± 8.4 | 82.1 ± 5.6 | 79.6 ± 7.2 |
| Percent body fat (%) | 16.7 ± 4.8 | 24.4 ± 5.7 | 20.0 ± 3.9 | 28.0 ± 5.2 |
| Handgrip strength (kg) | 44.5 ± 7.1 | 29.3 ± 5.3 | 38.6 ± 7.3 | 25.1 ± 4.5 |
| ASM/Ht2 (kg/m2) | 8.66 ± 0.89 | 6.80 ± 0.75 | 8.05 ± 0.68 | 6.47 ± 0.58 |
| ASM/Wt × 100 (%) | 38.1 ± 3.0 | 32.7 ± 3.2 | 35.9 ± 2.6 | 30.3 ± 2.9 |
| Cell Line | MTT Assay | CellTiter-Glo Assay |
| MCF10a | ND | ND |
| MCF-7 | 24±2 | 27±2 |
| T47D | 26±2 | 28±3 |
| MDA-MB-231 | 30±3 | 30±3 |
| Sno | Sub-District | Health Facility | ANC Attendance | % of Total Attendance | Quota Sampled |
| Wa Municipality | |||||
| 1 | Kambale Sub | Kambale HC | 697 | 5.64 | 14 |
| 2 | Bamahu Sub | Bamahu HC | 407 | 3.30 | 8 |
| 3 | Charingu Sub | Charingu HC | 282 | 2.28 | 6 |
| 4 | Busa Sub | Busa HC | 279 | 2.26 | 5 |
| 5 | Wa Sub | Wa Reg. Hospital | 8942 | 10.87 | 180 |
| 6 | Wa sub | Wa Central HC | 1341 | 72.50 | 27 |
| 7 | Charia Sub | Dobile CHPS | 392 | 3.18 | 8 |
| Total | 12,340 | 100.00 | 248 | ||
| Lawra District | |||||
| 8 | Eremon Sub | Eremon HC | 107 | 8.89 | 19 |
| 9 | Lawra Sub | Lawra Dist. Hosp | 715 | 59.43 | 125 |
| 10 | Lawra Sub | Lawra Sub HC | 28 | 2.33 | 5 |
| 11 | Babile Sub | Babile Polyclinic | 194 | 16.13 | 34 |
| 12 | Domwini Sub | Domwini HC | 42 | 3.49 | 7 |
| 13 | Zambo Sub | Zambo HC | 117 | 9.73 | 20 |
| Total | 1203 | 100.00 | 210 |
| Biomarker | Abbreviation | Biological Sample Type | Marker Characteristics |
| Ethanol | EtOH | BloodUrineBreath | Restricted to conditions where ethanol is still present in circulation. |
| Ethyl glucuronide /Ethyl sulfate | EtG/EtS | UrineSerumCerebrospinal fluidVitreous humourHairNails | Ethanol metabolite, which remains positive in urine samples 2–5 days after stopping ethanol use. Window of detection dependent on sample type. |
| Phosphatidylethanol | PEth | BloodDry blood spots | Ethanol metabolite, which remains detectable 1–2 weeks after alcohol use. Measured by LC-MS or immunological techniques. |
| Fatty acid ethyl esters | FAEE | PlasmaHairMeconium | Ethanol metabolite derived from a combination of fatty acid with alcohol. |
| Acetaldehyde adducts and associated immune responses | AA-Ab | BloodTissue specimens | IgA response towards acetaldehyde adducts most specific for alcohol-related disorders. |
| Carbohydrate-deficient transferrin | CDT | SerumCerebrospinal fluid | Specific marker of chronic alcohol consumption. Lacks sensitivity for screening purposes. |
| Gamma-glutamyltransferase | GGT | Serum/plasma | Sensitive marker of alcohol use, liver dysfunction and oxidative stress. Several sources of unspecificity. Normalization time 2–3 weeks. |
| GGT-CDT combination | GGT-CDT | Serum/plasma | Improves sensitivity and specificity of detecting alcohol abuse. Relies on a mathematical model. |
| Blood cell counts | Blood | Mean corpuscular volume (MCV) of erythrocytes typically elevated in alcoholics. Normalization time 2–4 months. Mean corpuscular haemoglobin (MCH) and thrombocytes (platelet counts) are also frequently altered in alcohol abusers. Several sources of unspecificity. | |
| Transaminase enzymes | ALT, AST | Serum/plasma | Suitable for screening for liver dysfunction in alcohol users. Sensitive to effects of excess body weight. AST/ALT ratio increases in alcoholic liver disease. |
| n | 5-year survival rate (%) | P value | |
| Gender | 0.759 | ||
| Male | 1102 | 52 | |
| Female | 479 | 53 | |
| Age (yr) | < 0.001 | ||
| ≤ 60 | 891 | 58 | |
| >60 | 690 | 45 | |
| Tumor size (cm) | < 0.001 | ||
| ≤ 5 | 1136 | 59 | |
| >5 | 445 | 36 | |
| Tumor location | < 0.001 | ||
| Upper third | 563 | 39 | |
| Middle third | 275 | 49 | |
| Lower third | 702 | 65 | |
| Two-third or more | 41 | 32 | |
| TNM stage | < 0.001 | ||
| Stage I | 403 | 94 | |
| Stage II | 382 | 61 | |
| Stage III | 796 | 27 | |
| Type of Gastrectomy | < 0.001 | ||
| Subtotal | 1342 | 56 | |
| Total | 239 | 34 | |
| Operation time (min) | < 0.001 | ||
| < 180 | 1025 | 58 | |
| ≥ 180 | 556 | 43 | |
| Albumin level at admission (g/dl) | 0.006 | ||
| < 3.5 | 379 | 47 | |
| ≥ 3.5 | 1202 | 54 | |
| Hemoglobin level at admission (g/dl) | < 0.001 | ||
| < 12 | 575 | 46 | |
| ≥ 12 | 1006 | 56 | |
| Perioperative blood transfusion | < 0.001 | ||
| Yes | 298 | 40 | |
| No | 1283 | 55 |
| Unstandardized coefficients | Standardized coefficients | |||
| Herbs (g/day) | Estimate | Std. error | Estimate | P value |
| Garlic | 0.21 | 0.03 | 0.08 | 0.01 |
| Cinnamon | 1.24 | 0.19 | 0.08 | 0.01 |
| Black pepper | 0.57 | 0.15 | 0.05 | 0.01 |
| Dried rosemary | 3.43 | 1.17 | 0.03 | 0.01 |
| Fresh dill | 4.83 | 2.00 | 0.03 | 0.02 |
| Fresh peppermint | −6.77 | 2.80 | −0.03 | 0.02 |
| Chinese | Non-Chinese | P | |
| Case-fatality rate, % | |||
| n, all patients | 1,339 | 97,939 | |
| At 30 days | |||
| Crude, % | 12.3 | 10.9 | 0.10 |
| Risk-adjusted, % (95% CI) | 12.3 (10.7-13.9) | 10.9 (10.7-11.0) | - |
| At 1 year | |||
| Crude, % | 31.7 | 30.2 | 0.24 |
| Risk-adjusted, % (95% CI) | 31.3 (29.1-33.6) | 30.2 (29.9-30.5) | - |
| Readmission rate, % | |||
| n, discharged alive | 1,211 | 89,022 | |
| For HF | |||
| At 30 days | |||
| Crude, % | 5.2 | 6.0 | 0.23 |
| Risk-adjusted, % (95% CI) | 5.1 (3.8-6.4) | 6.0 (5.9-6.2) | - |
| At 1 year | |||
| Crude, % | 16.6 | 19.4 | 0.014 |
| Risk-adjusted, % (95% CI) | 16.4 (14.2-18.6)† | 19.4 (19.2-19.7) | - |
| For any reason | |||
| At 30 days | |||
| Crude, % | 16.2 | 16.5 | 0.80 |
| Risk-adjusted, % (95% CI) | 16.1 (14.1-18.2) | 16.5 (16.2-16.7) | - |
| At 1 year | |||
| Crude, % | 50.0 | 51.5 | 0.28 |
| Risk-adjusted, % (95% CI) | 49.8 (47.0-52.5) | 51.5 (51.2-51.9) | - |
| Composite rate, %* | |||
| n, all patients | 1339 | 97,939 | |
| At 30 days | |||
| Crude, % | 16.6 | 16.0 | 0.58 |
| Risk-adjusted, % (95% CI) | 16.2 (14.3-18.1) | 16.0 (15.8-16.2) | - |
| At 1 year | |||
| Crude, % | 41.4 | 42.0 | 0.65 |
| Risk-adjusted, % (95% CI) | 41.0 (38.5-43.5) | 42.0 (41.7-42.3) | - |
| Group | Age (years) | Gender | Iris Color* | BMI (kg/m2) | Carotenoid Intake Score | Smoking Status | Years Smoking |
| StatinUsers | 58.05 ± 11.08 | n = 13 malesn = 7 females | 2.1 ± 0.9 | 27.51 ± 5.19 | 14.1 ± 5.25 | n = 13 nonsmokersn = 7 past smokersn = 0 current smokers | 5.3 ± 9.18 |
| Non-Users | 57.95 ± 11.03 | n = 14 malesn = 6 females | 1.9 ± 0.8 | 26.34 ± 2.73 | 13.93 ± 3.63 | n = 12 nonsmokersn = 4 past smokersn = 4 current smokers | 9.10 ± 12.47 |
| Forecast period | GMT | SST |
| 1 year: 2018 | 58% | 75% |
| 2 years: 2018–2019 | 64% | 74% |
| 3 years: 2018–2020 | 70% | 71% |
| 4 years: 2018–2021 | 72% | 69% |
| 5 years: 2018–2022 | 58% | 69% |
| 6 years: 2018–2023 | 55% | 65% |
| 7 years: 2018–2024 | 45% | 58% |
| 8 years: 2018–2025 | 50% | 59% |
| 9 years: 2018–2026 | 49% | 60% |
| 10 years: 2018–2027 | 50% | 62% |
| Items | Test-retest reliability ICC (Confident interval) | Kappa | Weighted kappa | Cronbach’s alpha (Dialysis group) |
| Symptom/problem | 0.997 (0.991-0.999) | 0.826-1 | 0.851-1 | 0.833 |
| Effects of kidney disease | 0.983 (0.951-0.994) | 0.75-1 | 0.828-1 | 0.794 |
| Burden of kidney disease | 1 | 1-1 | 1-1 | 0.651 |
| PCS | 0.993 (0.981-0.998) | 0.688-1 | 0.737-1 | 0.322 |
| MCS | 0.996 (0.989-0.999) | 0.537 |
| GI transit study (n = 11) | %GE | GC |
| Nonseptic animals | 88.96 ± 8.13 | 4.86 ± 0.45 |
| Sham + vehicle + CLP | 53.27 ± 10.32 | 2.53 ± 0.42 |
| Sham + GTS-21 8 mg/kg + CLP | 83.62 ± 5.91* | 4.26 ± 0.35* |
| SPLX + vehicle + CLP | 79.49 ± 8.98* | 3.86 ± 0.44* |
| SPLX + GTS-21 8 mg/kg + CLP | 77.64 ± 11.81* | 3.55 ± 0.52 |
| Cytokine level in serum (n = 8 to 11) | IL-6 | TNFα |
| Nonseptic animals | 2.57 ± 0.48 | 4.95 ± 0.29 |
| Sham + vehicle + CLP | 243.56 ± 54.89 | 63.72 ± 21.25 |
| Sham + GTS-21 8 mg/kg + CLP | 90.26 ± 31.31* | 54.23 ± 25.14 |
| SPLX + vehicle + CLP | 74.31 ± 17.45* | 11.52 ± 1.99# |
| SPLX + GTS-21 8 mg/kg + CLP | 64.98 ± 7.15* | 12.81 ± 3.91# |
| Cytokine levels in colonic tissue (n = 5 to 11) | IL-6 | TNFα |
| Nonseptic animals | 20.43 ± 4.87 | 41.30 ± 4.47 |
| Sham + vehicle + CLP | 1281.85 ± 932.10 | 137.15 ± 61.36 |
| Sham + GTS-21 8 mg/kg + CLP | 134.88 ± 36.15 | 46.46 ± 5.03* |
| SPLX + vehicle + CLP | 214.22 ± 75.88 | 29.97 ± 8.60* |
| SPLX + GTS-21 8 mg/kg + CLP | 487.49 ± 343.87 | 46.03 ± 17.22* |
| Pairs of raters | ||||||||
| PDs | Rater TW | % Agreement | Rater NW | % Agreement | ||||
| Rater SR | No (N) | Yes (Y) | Rater SR | No (N) | Yes (Y) | |||
| Avoidant | No (N) | 9 | 0 | 100 | No (N) | 7 | 1 | 88 |
| Yes (Y) | 0 | 1 | Yes (Y) | 0 | 0 | |||
| Dependent | N | 9 | 1 | 90 | N | 7 | 0 | 100 |
| Y | 0 | 0 | Y | 0 | 1 | |||
| Obsessive-Compulsive | N | 8 | 0 | 100 | N | 6 | 0 | 100 |
| Y | 0 | 2 | Y | 0 | 2 | |||
| Passive-aggressive | N | 9 | 0 | 90 | N | 6 | 1 | 88 |
| Y | 1 | 0 | Y | 0 | 1 | |||
| Depressive | N | 10 | 0 | 100 | N | 7 | 0 | 100 |
| Y | 0 | 0 | Y | 0 | 1 | |||
| Paranoid | N | 9 | 0 | 90 | N | 8 | 0 | 100 |
| Y | 1 | 0 | Y | 0 | 0 | |||
| Schizotypal | N | 9 | 0 | 100 | N | 8 | 0 | 100 |
| Y | 0 | 1 | Y | 0 | 0 | |||
| Schizoid | N | 7 | 1 | 90 | N | 6 | 0 | 88 |
| Y | 0 | 2 | Y | 1 | 1 | |||
| Histrionic | N | 10 | 0 | 100 | N | 8 | 0 | 100 |
| Y | 0 | 0 | Y | 0 | 0 | |||
| Narcissistic | N | 9 | 0 | 100 | N | 8 | 0 | 100 |
| Y | 0 | 1 | Y | 0 | 0 | |||
| Borderline | N | 8 | 1 | 90 | N | 7 | 0 | 100 |
| Y | 0 | 1 | Y | 0 | 1 | |||
| Total Antisocial | N | 10 | 0 | 100 | N | 7 | 0 | 100 |
| Y | 0 | 0 | Y | 0 | 1 |
| Rank | Journal | # citations |
| 1 | Journal of the American Chemical Society | 351 |
| 2 | Journal of Organic Chemistry | 65 |
| 3 | Journal of Physical Chemistry A | 64 |
| 4 | Journal of Chemical Physics | 58 |
| 5 | Angewandte Chemie | 38 |
| 6 | Chemical Physics Letters | 25 |
| 7 | Organic Letters | 24 |
| 8 | Tetrahedron Letters | 22 |
| 8 | Journal of Physical Chemistry | 22 |
| 10 | Journal of Computational Chemistry | 17 |
| Study (Author-Date) | Representativeness | Demonstration that outcome not present at outset | Assessment of outcome (proven infection vs suspected infection based on other criteria) | Adequacy of follow-up (<5% loss) |
| Alleyne 2000 [31] | * | * | * | * |
| Arabi 2005 [36] | * | * | ||
| Bota 2005 [35] | * | * | * | * |
| Camacho 2011 [8] | * | * | * | |
| Chi 2009 [24] | * | * | * | * |
| Dasic 2006 [10] | * | * | * | |
| Fichtner 2010 [28] | * | * | ||
| Hader 2000 [17] | * | * | * | * |
| Hoefnagel 2008 [2] | * | * | * | |
| Holloway 1996 [25] | * | |||
| Khalil 2005 [9] | * | * | * | * |
| Kim 2012 [34] | * | * | * | * |
| Kitchen 2011 [6] | * | * | ||
| Lemcke 2012 [20] | * | * | * | * |
| Leverstein Van-Dall 2010 [21] | * | * | ||
| Lo 2007 [18] | * | * | * | |
| Lundberg 2000 [16] | * | * | ||
| Lwin 2012 [27] | * | * | * | |
| Lyke 2001 [13] | * | * | * | * |
| Mahe 1995 [7] | * | * | ||
| McLaughlin 2012 [19] | * | |||
| Moon 2007 [12] | * | * | * | |
| Park 2004 [29] | * | * | * | * |
| Rafiq 2011 [15] | * | * | * | * |
| Rivero-Garvia 2011 [26] | * | * | ||
| Roitberg 2001 [30] | * | |||
| Scheithauer 2009 [23] | * | * | * | |
| Scheithauer 2010 [22] | * | * | * | |
| Schodel 2012 [32] | * | * | * | |
| Schultz 1993 [11] | * | * | * | |
| Sloffer 2005 [33] | * | * | * | |
| Smigoc 2012 [5] | * | * | * | |
| Smith 1976 [4] | * | * | ||
| Williams 2011 [14] | * | * | * | * |
| Wyler 1972 [3] | * | * | * |
| EU Rarotonga | EU southern group | EU northern group | ||||||
| Village surveyed | No. of people surveyed | % Ag positive | Island surveyed | No. of people surveyed | % Ag positive | Island surveyed | No. of people surveyed | % Ag positive |
| Tupapa/Maraerenga | 200 | 0.00 | Atiu | 150 | 0.00 | Pukapuka | 200 | 3.50 |
| Takuvaine/Tutakimoa | 200 | 0.50 | Aitutaki | 300 | 7.33 | Penrhyn | 100 | 0.00 |
| Ruatonga/A Vaitu | 200 | 0.50 | Mauke | 150 | 0.00 | Manihiki | 100 | 0.00 |
| Pokoinu/Nikao | 200 | 0.00 | Mangaia | 200 | 0.50 | Rakahanga | 100 | 2.00 |
| Takitumu | 200 | 0.00 | Mitiaro | 100 | 0.00 | Suwarrow | 2 | 0.00 |
| Puaikura | 200 | 0.00 | – | – | – | – | – | – |
| Total | 1000 | 0.20 | – | 900 | 2.56 | – | 502 | 1.79 |
| HIV-2 infected | HIV-uninfected | ||||
| Number died/total per category (%) | Mortality rate per 100 person-years (95% CI) | Number died/total per category (%) | Mortality rate per 100 person-years (95% CI) | Rate ratio (95% CI) | |
| Age groupa, b | |||||
| <40 | 15/37 (41) | 3.4 (2.0, 5.6) | 7/56 (13) | 0.8 (0.4, 1.7) | 4.2 (1.7, 10.2) |
| 40-59 | 23/59 (39) | 3.4 (2.3, 5.1) | 15/63 (24) | 1.6 (1.0, 2.7) | 2.1 (1.1, 4.1) |
| ≥ 60 | 28/36 (78) | 8.5 (5.9, 12.3) | 27/39 (69) | 5.8 (4.0, 8.5) | 1.5 (0.9, 2.5) |
| Sex | |||||
| Male | 27/42 (64) | 6.1 (4.2, 8.8) | 20/43 (46) | 3.7 (2.4, 5.8) | 1.6 (0.9, 2.9) |
| Female | 39/91 (43) | 3.9 (2.8, 5.3) | 29/115 (25) | 1.7 (1.2, 2.4) | 2.3 (1.4, 3.7) |
| Calendar time | |||||
| 1991-1998 | 37/133 (28) | 4.3 (3.1, 6.0) | 24/158 (15) | 1.9 (1.3, 2.8) | 2.3 (1.4, 3.8) |
| 1999-2009 | 29/84 (35) | 4.8 (3.4, 7.0) | 25/120 (21) | 2.5 (1.7, 3.7) | 1.9 (1.1, 3.3) |
| Overall | 66/133 (50) | 4.5 (3.6, 5.8) | 49/158 (31) | 2.2 (1.6, 2.9) | 2.1 (1.5, 3.0) |
| Group | Null model | Full model (OR < 95 % CI) |
| Individual | ||
| Gender | ||
| Male | 1.00 | |
| Female | 0.45 (0.23, 0.88)** | |
| Education | ||
| Elementary school or less | 1.00 | |
| Junior high school | 1.14 (0.64,2.04) | |
| High school | 0.60 (0.31,1.14) | |
| Junior college or more | 0.35 (0.18, 0.69)** | |
| Occupation | ||
| Managers and clerks | 1.00 | |
| Professionals | 0.95 (0.53,1.70) | |
| Commerce and service | 1.20 (0.63,2.30) | |
| Operations | 0.79 (0.42,1.51) | |
| Students | 0.32 (0.16, 0.65)** | |
| Retired | 0.28 (0.11, 0.73)** | |
| Other | 0.25 (0.08, 0.72)** | |
| Per capita income (Yuan) | ||
| <10,000 | 1.00 | |
| 10,000–19,999 | 0.80 (0.54,1.27) | |
| 20,000–29,999 | 0.55 (0.35, 0.87)** | |
| 30,000–39,999 | 0.24 (0.09, 0.64)** | |
| 40,000–49,999 | 0.23 (0.10, 0.55)** | |
| 50,000+ | 0.34 (0.14, 0.79)** | |
| Exposure to tobacco advertising | ||
| No | 1.00 | |
| Yes | 2.83 (1.23, 6.48)** | |
| City-level | ||
| GDP per capita | ||
| <40,000 | 1.00 | |
| 40,000–49,999 | 1.02 (0.39,3.17) | |
| 50,000+ | 0.39 (0.16, 0.92)* | |
| Anti-smoking media news coverage | ||
| <20 | 1.00 | |
| 20–29 | 1.33 (0.42,4.24) | |
| 30 and over | 0.26 (0.09, 0.79)** | |
| Random parameters between regions | 3.12 | 2.25* |
| Fixed parameters | 2.92** | 2.43* |
| Genea | Oedogonium | Stigeoclonium | Scenedesmus | Chlamydomonas |
| infA | + | - | + | - |
| petA | - | - | + | + |
| psaM | + | + | - | - |
| rpl12 | - | - | + | - |
| rpl32 | + | + | - | - |
| trnL(caa) | + | + | - | - |
| trnR(ccu) | + | - | - | - |
| trnR(ucg) | + | - | - | - |
| trnS(gga) | - | + | - | - |
| Set A | Set B | |||
| CV | AoA | CV | AoA | |
| CHAT | 3.80 | PIED | 3.60 | Children + Adults |
| OEIL | 4.10 | RUE | 5.20 | Children + Adults |
| OEUF | 4.50 | BOUE | 5.80 | Children + Adults |
| BEAU | 4.50 | PLUIE | 4.40 | Children + Adults |
| DOUX | 5.10 | OIE | 5.60 | Children + Adults |
| TRAIN | 5.10 | JOUR | 4.70 | Children + Adults |
| MAIN | 3.60 | NUIT | 4.10 | Children + Adults |
| BRAS | 4.20 | LOUP | 4.70 | Children + Adults |
| DOIGT | 3.70 | FEU | 4.90 | Adults |
| Relapse group (n=30) | Remission group (n=35) | P | |
| Withdrawal MPV (fL) | 8.0±1.2 | 8.0±1.0 | 0.81 |
| Withdrawal TSH (uIU/ml) | 1.5±1.0 | 2.0±1.0 | 0.03 |
| Withdrawal fT3 (pmol/L) | 4.8±1.2 | 4.7±0.5 | 0.46 |
| Withdrawal fT4 (pmol/L) | 14.8±2.9 | 13.6±1.6 | 0.04 |
| Isolates | Identification by API system (% similarity) | Identification by rep-PCR (% identity) |
| 1S | Lactobacillus plantarum (99.9%) | Lactobacillus plantarum (72.5%) |
| 2S | Lactobacillus plantarum (99.9%) | Lactobacillus plantarum (80.0%) |
| 3S | Lactobacillus plantarum (99.9%) | Lactobacillus plantarum (75.8%) |
| 4S | Lactobacillus plantarum (75.9%) | Lactobacillus plantarum (74.6%) |
| 5S | Lactobacillus plantarum (99.9%) | Lactobacillus plantarum (74.9%) |
| 6S | Lactobacillus plantarum (99.9%) | Lactobacillus plantarum (74.5%) |
| 7S | Lactobacillus plantarum (99.9%) | Lactobacillus plantarum (72.6%) |
| 8S | Lactobacillus plantarum (99.9%) | Lactobacillus plantarum (73.0%) |
| 9S | Lactobacillus plantarum (72.0%) | Lactobacillus plantarum (72.9%) |
| 10S | Lactobacillus plantarum (79.0%) | Lactobacillus plantarum (73.9%) |
| 11S | Lactobacillus plantarum (77.0%) | Lactobacillus plantarum (73.6%) |
| 15S | Lactobacillus plantarum (85.9%) | Lactobacillus plantarum (65.8%) |
| 16S | Lactobacillus plantarum (89.9%) | Lactobacillus plantarum (65.7%) |
| 18S | Lactobacillus rhamnosus (97.5%) | Unidentified |
| 19S | Lactobacillus rhamnosus (86.0%) | Unidentified |
| 1K | Lactobacillus rhamnosus (86.0%) | Lactobacillus rhamnosus (73.1%) |
| 3K | Lactobacillus rhamnosus (88.5%) | Lactobacillus rhamnosus (65.0%) |
| 1K1 | Lactobacillus rhamnosus (96.5%) | Lactobacillus rhamnosus (70.4%) |
| 2K | Lactobacillus fermentum (74.1%) | Lactobacillus fermentum (69.2%) |
| 13S* | Lactobacillus coprophilus (77.0%) | Lactobacillus fermentum (68.4%) |
| 1SB1 | Lactobacillus coprophilus (97.0%) | unidentified |
| Risk of T2D | Prediabetes | HOMA-IR | |
| Highest ρE | Cer(d18:0/24:1),0.3177, p = 2.7 × 10−8 | PS(40:5),0.2917, p = 1.0000 | Cer(d18:0/22:0), 0.4234, p = 2.3 × 10−24 |
| Lowest ρE | LPC(26:0),−0.3588 p = 0.0001 | PC(39:6),−0.2076, p = 0.1501 | PC(P-34:1),−0.2972, p = 7.8 × 10−17 |
| N (significant) | 114 | 59 | 172 |
| Gene symbol | Forward primer (5′ to 3′) | Reverse primer (5′ to 3′) |
| Oct-4 | CTTGGGCTACACAGGC | CTCAATACTCGTTCGCTTTC |
| Nanog | TTTGGAAGCTGCTGGGGAAG | GATGGGAGGAGGGGAGAGGA |
| CDX2 | CCGAACAGGGACTTGTTTAGAG | CTCTGGCTTGGATGTTACACAG |
| TF | ACGCTCCTGCTCGGCTGGGT | CGTCTGCTTCACATCCTTCA |
| GAPDH | GGAGCCAAAAGGGTCATC | CCAGTGAGTTTCCCGTTC |
| Mouse strain | Methods | PV cells with PNNs (%) | |
| Visual cortex | |||
| Pizzo et al., 2016 | C57BL/6J | PV: (1) monoclonal mouse α-PV (SWANT, 1:500); (2) polyclonal guinea pig α-PV PNN: biotin-conjugated WFA (Sigma, 1:200) | |
| Morishita et al., 2015 | C57BL/6J | PV: monoclonal rabbit α-PV (SWANT, 1:500) PNN: biotin-conjugated WFA (Vector, 1:400) | |
| Lensjø et al., 2017 | C57BL/6J | PV: polycolonal rabbit α-PV (SWANT, 1:2000) PNN: biotin-conjugated WFA (Sigma, 1:200) | |
| Ueno et al., 2017c | C57BL/6J | PV: monoclonal mouse α-PV (Sigma, 1:1000) PNN: biotin-conjugated WFA (Vector, 1:200) | |
| Somatosensory cortex | |||
| Nowicka et al., 2009 | Swiss albino mice | PV: (1) rabbit α-PV (1:1000); (2) monoclonal mouse α-PV (Sigma, 1:1000) PNN: biotin-conjugated WFA (Vector, 1:1000) | |
| Ueno et al., 2017b | C57BL/6J | PV: monoclonal mouse α-PV (Sigma, 1:1000) PNN: biotin-conjugated WFA (Vector, 1:200) | |
| Karetko-Sysa et al., 2014 | C57BL/6J | PV: polyclonal goat α-PV (Affinity BioReagents, 1:1000) PNN: biotin-conjugated WFA (Vector, 1:1000) | ∗Most PV cells colocalized with PNNs in layer 4 |
| Auditory cortex | |||
| Brewton et al., 2016 | C57BL/6J CBA/CaJ | PV: rabbit α-PV (SWANT, 1:10,000) PNN: FITC-conjugated WFA (Vector, 1:750) | |
| Nguyen et al., 2017 | CBA/CaJ | PV: rabbit α-PV (SWANT, 1:5000) PNN: FITC-conjugated WFA (Vector, 1:500) | |
| Wen et al., 2017 | FVB WT | PV: (1) rabbit α-PV (SWANT, 1:5000), (2) mouse α-PV (Sigma, 1:1000) PNN: FITC-conjugated WFA (Vector, 1:500) | |
| Ueno et al., 2017c | C57BL/6J | PV: monoclonal mouse α-PV (Sigma, 1:1000) PNN: biotin-conjugated WFA (Vector, 1:200) |
| Normal weight mice | DIO mice | |||||||
| PBS | NS1 | Vaccine | Sig. | PBS | NS1 | Vaccine | Sig. | |
| Ghrelin (pg/ml) | 114.1 ± 27.9 | 186.9 ± 14.8 | 361.3 ± 79.9 | p=0.009 | 105.9 ± 27.8 | 147.3 ± 53.2 | 429.6 ± 179.3 | NS |
| Leptin (ng/ml) | 1.32 ± 0.23 | 0.98 ± 0.21 | 1.50 ± 0.61 | NS | 5.85 ± 0.93 | 5.15 ± 0.75 | 7.11 ± 0.39 | NS |
| Insulin (ng/ml) | 0.35 ± 0.08 | 1.08 ± 0.63 | 0.41 ± 0.07 | NS | 1.31 ± 0.09 | 1.01 ± 0.13 | 1.27 ± 0.11 | NS |
| Growth hormone (ng/ml) | 2.65 ± 0.69 | 5.50 ± 2.44 | 2.57 ± 0.41 | NS | 2.36 ± 0.74 | 5.28 ± 1.95 | 4.13 ± 1.31 | NS |
| IGF-1 (ng/ml) | 473.8 ± 68.6 | 561.7 ± 35.3 | 499.8 ± 62.1 | NS | 347.7 ± 17.9 | 387.4 ± 34.5 | 394.8 ± 21.1 | NS |
| Glucose (mg/dl) | 86.5 ± 6.3 | 82.3 ± 8.2 | 76.3 ± 2.9 | NS | 156.3 ± 31.8 | 128.2 ± 15.0 | 121.8 ± 11.3 | NS |
| TNF-α | 0.30 ± 0.30 | 8.42 ± 4.22 | 1.65 ± 1.31 | NS | 45.59 ± 24.72 | 5.76 ± 4.44 | 21.34 ± 15.29 | NS |
| Authors | Novel prognostic marker | Conclusion |
| Li et al. 2015 [39] | The expression patterns of miR-15a/16-1 | miR-15a seems to be linked with disease progression and prognosis while miR-16-1 acts as a valuable diagnostic marker |
| Wang et al. 2015 [40] | Immune checkpoint signaling | The overall response rate to treatment was higher in low sPD-L1 patients than in high sPD-L1 patients |
| Jung et al. 2016 [41] | Inverse platelet to lymphocyte ratio (iPLR) | Staging by iPLR group had predictive value for PFS and OS |
| Zhou et al. 2015 [42] | Dysregulated long noncoding RNAs (lncRNAs) | Four lncRNAs were identified to be significantly associated with OS |
| Lee et al. 2015 [43] | Bone marrow (BM) microvessel density (MVD) | PFS was significantly lower in the high MVD group than in the low MVD group |
| Ma et al. 2015 [44] | N-Cadherin | OS is worse with high expression of N-Cadherin which may be related to 1q21 amplification. |
| Lullo et al. 2015 [45] | Th22 cells | Increased frequency of IL-22(+)IL-17(−)IL-13(+) T cells correlates with poor prognosis |
| Li et al. 2015 [46] | Downregulated miR-33b | miR-33b low expression had significantly shortened PFS and OS |
| Bolomsky et al. 2015 [47] | Insulin-like growth factor binding protein 7 (IGFBP7) expression | IGFBP7 expression is linked to translocation t(4;14) showing clinical features of adverse prognosis |
| Jung et al. 2015 [48] | Autophagic markers beclin 1 and LC3 | Higher immunoreactivity for autophagic markers in MM is associated with superior patient survival |
| Trotter et al. 2015 [49] | Myeloma cell-derived Runx2 | Runx2 expression is a major regulator of MM progression in bone and myeloma bone disease |
| SYMBOL | RefSeq | logFC | adj.P.Val | Sens. | Spec. | KEGGID |
| SERPINA1 | NM_000295, NM_001002235, NM_001002236 | 3.30 | 7.81e-39 | 0.98 | 1.00 | 04610 |
| PROS1 | NM_000313 | 2.12 | 8.89e-34 | 0.98 | 1.00 | 04610 |
| LRP4 | NM_002334 | 2.80 | 8.89e-34 | 1.00 | 0.96 | NA |
| NPC2 | NM_006432 | 1.29 | 5.83e-33 | 1.00 | 0.94 | 04142 |
| LAMB3 | NM_000228, NM_001017402 | 2.46 | 5.11e-31 | 0.96 | 1.00 | 04510, 04512, 05200, 05222 |
| DPP4 | NM_001935 | 2.86 | 6.96e-31 | 0.98 | 0.98 | NA |
| SDC4 | NM_002999 | 1.68 | 5.50e-30 | 0.96 | 0.96 | 04512, 04514 |
| IPCEF1 | NM_015553 | -2.10 | 2.88e-29 | 1.00 | 0.00 | NA |
| QPCT | NM_012413 | 2.09 | 3.00e-29 | 0.98 | 1.00 | NA |
| MPPED2 | NM_001584 | -2.28 | 7.73e-29 | 1.00 | 0.00 | NA |
| TIMP1 | NM_003254 | 1.85 | 1.48e-27 | 0.96 | 0.94 | NA |
| TFF3 | NM_003226 | -3.42 | 2.07e-27 | 1.00 | 0.00 | NA |
| PRSS23 | NM_007173 | 1.48 | 2.32e-27 | 0.98 | 0.98 | NA |
| MET | NM_000245 | 1.64 | 2.37e-27 | 0.94 | 0.98 | 04060, 04144, 04360, 04510, 04520, 05120, 05200, 05210, 05211, 05218 |
| CDH3 | NM_001793 | 2.72 | 3.45e-27 | 0.96 | 0.94 | 04514 |
| GGCT | NM_024051 | 1.21 | 2.74e-26 | 0.98 | 0.92 | 00480 |
| PDLIM4 | NM_003687 | 2.21 | 3.37e-26 | 0.96 | 0.98 | NA |
| KRT19 | NM_002276 | 2.33 | 3.40e-25 | 0.98 | 0.98 | NA |
| CITED1 | NM_004143 | 3.17 | 4.42e-25 | 0.94 | 0.96 | NA |
| CHI3L1 | NM_001276 | 3.50 | 4.42e-25 | 0.96 | 0.90 | NA |
| Subjects | ||
| Number | Percentage | |
| Supplements use | ||
| No | 145 | 69.9% |
| Yes | 62 | 30.1% |
| Users of supplement by gender | ||
| Male | 43 | 34.1% |
| Female | 19 | 23.8% |
| Frequency of use | ||
| 1 time per wk | 8 | 12.9% |
| 2 times per wk | 5 | 8.1% |
| 3 times per wk | 13 | 21.0% |
| 4 times per wk | 11 | 17.7% |
| 5 times per wk | 9 | 14.5% |
| 6 times per wk | 1 | 1.6% |
| 7 times per wk | 15 | 24.2% |
| Protein supplements | ||
| Whey protein shakes | 31 | 50.0% |
| Egg protein shakes | 15 | 24.1% |
| Protein bars | 12 | 19.3% |
| Protein Gel | 1 | 1.6% |
| Protein shake blends | 3 | 4.8% |
| Other supplements* | ||
| Multivitamin/mineral | 3 | 4.8% |
| Creatine - Amino acids | 30 | 48.3% |
| Amino acids | 16 | 25.9% |
| Multivitamin/mineral - Creatine - Amino acids | 8 | 12.9% |
| Multivitamin/mineral - Amino acids | 1 | 1.6% |
| Creatine | 4 | 6.4% |
| Characteristic | Number | Percent |
| Age (in years) | ||
| 15–24 | 5 | 33.3 |
| 25–34 | 6 | 40 |
| 35 or above | 4 | 26.7 |
| Education | ||
| Elementary & secondary school | 2 | 13.3 |
| Diploma | 4 | 26.7 |
| University | 9 | 60 |
| Marital status | ||
| Single | 10 | 66.7 |
| Married | 5 | 33.3 |
| Occupation | ||
| Housewife | 6 | 40 |
| Employed | 4 | 26.7 |
| Student | 5 | 33.3 |
| Total | 15 | 100 |
| First yearTotalN = 298n (%) | Last yearTotalN = 209n (%) | P value | Men | P value | Women | P value | |||||||||
| First yearN = 125n (%) | Last yearN = 77n (%) | First yearN = 173n (%) | Last yearN = 132n (%) | ||||||||||||
| Work | 290 | (97) | 195 | (93) | < .05 | 122 | (98) | 65 | (84) | < .001 | 168 | (97) | 130 | (98) | NS |
| I like my job* | 158 | (53) | 89 | (43) | < .05 | 55 | (44) | 26 | (34) | NS | 103 | (60) | 63 | (48) | < .05 |
| I know whatI want to be | 70 | (23) | 82 | (39) | < .001 | 28 | (22) | 26 | (34) | NS | 42 | (24) | 56 | (42) | < .01 |
| The world is my workplace | 56 | (19) | 13 | (6) | < .001 | 21 | (17) | 3 | (4) | < .01 | 35 | (20) | 10 | (8) | < .01 |
| I am a good doctor | 30 | (10) | 32 | (15) | NS | 12 | (10) | 8 | (10) | NS | 18 | (10) | 24 | (18) | NS |
| Full-time or more | 27 | (9) | 15 | (7) | NS | 9 | (7) | 3 | (4) | NS | 18 | (10) | 12 | (9) | NS |
| Part-time | 11 | (4) | 28 | (13) | < .001 | 2 | (2) | 12 | (16) | < .001 | 9 | (5) | 16 | (12) | < .05 |
| Work– not specified* | 42 | (14) | 28 | (13) | NS | 25 | (20) | 11 | (14) | NS | 17 | (10) | 17 | (13) | NS |
| Family | 228 | (77) | 160 | (77) | NS | 89 | (71) | 53 | (69) | NS | 139 | (80) | 107 | (81) | NS |
| Children* | 136 | (46) | 119 | (57) | < .05 | 51 | (41) | 35 | (45) | NS | 85 | (49) | 84 | (64) | < .05 |
| Partner | 107 | (36) | 100 | (48) | < .01 | 49 | (39) | 33 | (43) | NS | 58 | (34) | 67 | (51) | < .01 |
| Family– not specified | 72 | (24) | 28 | (13) | < .01 | 27 | (22) | 10 | (13) | NS | 45 | (26) | 18 | (14) | < .01 |
| Leisure | 93 | (31) | 98 | (47) | < .001 | 36 | (29) | 33 | (43) | < .05 | 57 | (33) | 65 | (49) | < .01 |
| Travel and hobbies* | 37 | (12) | 50 | (24) | < .01 | 14 | (11) | 11 | (14) | NS | 23 | (13) | 39 | (30) | < .001 |
| Friends and relatives | 35 | (12) | 42 | (20) | < .05 | 8 | (6) | 18 | (23) | < .001 | 27 | (16) | 24 | (18) | NS |
| Physical activity | 20 | (7) | 26 | (12) | < .05 | 6 | (8) | 9 | (12) | NS | 12 | (7) | 17 | (13) | NS |
| Leisure– not specified | 17 | (6) | 16 | (8) | NS | 9 | (7) | 4 | (5) | NS | 8 | (5) | 12 | (9) | NS |
| Quality ofpersonal life | 131 | (44) | 127 | (61) | < .001 | 48 | (38) | 51 | (66) | < .001 | 83 | (48) | 76 | (58) | NS |
| Work-life balance | 81 | (27) | 67 | (32) | NS | 24 | (19) | 26 | (34) | < .05 | 57 | (33) | 41 | (31) | NS |
| Happiness | 31 | (10) | 50 | (24) | < .001 | 13 | (10) | 21 | (27) | < .01 | 18 | (10) | 29 | (22) | < .01 |
| Health | 15 | (5) | 20 | (10) | < .05 | 3 | (2) | 9 | (12) | < .01 | 12 | (7) | 11 | (8) | NS |
| Wealth | 39 | (13) | 39 | (19) | NS | 20 | (16) | 15 | (19) | NS | 19 | (11) | 24 | (18) | NS |
| VT IPD | NVT IPD | Total | ||
| Baseline | 0 | 3765 | 3765 | |
| V, vaccine coverage | 0.89 | |||
| 0.5 | 757 | 3594 | 4351 | |
| 0.95 | 0 | 3765 | 3765 | |
| 1/w, Duration of vaccine protection | 8.3 years | |||
| 5 Years | 788 | 3570 | 4358 | |
| 20 Years | 0 | 3765 | 3765 | |
| Degree | 0.76 | |||
| 0.3 | 1599 | 3338 | 4937 | |
| 0.9 | 0 | 3765 | 3765 | |
| cV | 0.5 | |||
| 0 | 0 | 3836 | 3836 | |
| 1 | 2 | 3710 | 3712 | |
| cN | 0.85 | |||
| 0 | 0 | 9533 | 9533 | |
| 1 | 0 | 2921 | 2921 | |
| ε | 0.88 | |||
| 0 | 0 | 3765 | 3765 | |
| 0.95 | 438 | 3702 | 4140 |
| Pathway | Number of Proteins in Pathway | Proteins from Gene List | P-value | FDR | Genes |
| Pathways in cancer (K) | 327 | 7 | 0.0004 | 1.40E-02 | E2F1,PTEN,AKT2,MSH6,HSP90AA1,JUN,VEGFA |
| Direct p53 effectors (N) | 133 | 5 | 0.0002 | 1.40E-02 | E2F1,PTEN,SP1,JUN,SMARCA4 |
| Hepatitis B (K) | 146 | 5 | 0.0004 | 1.38E-02 | E2F1,PTEN,AKT2,JUN,YWHAQ |
| Nonsense-mediated decay (R) | 106 | 5 | 0.0001 | 1.55E-02 | RPL30,UPF1,SMG7,RNPS1,RPL18A |
| RNA transport (K) | 164 | 5 | 0.0006 | 1.50E-02 | EEF1A1,UPF1,RNPS1,EIF4G2,NUP205 |
| E2F transcription factor network (N) | 68 | 4 | 0.0002 | 1.44E-02 | E2F1,KAT2B,SP1,RRM2 |
| Estrogen signaling pathway (K) | 100 | 4 | 0.0009 | 1.69E-02 | AKT2,HSP90AA1,SP1,JUN |
| Glucocorticoid receptor regulatory network (N) | 77 | 4 | 0.0003 | 1.34E-02 | SMARCD1,HSP90AA1,JUN,SMARCA4 |
| HIF-1-alpha transcription factor network (N) | 66 | 4 | 0.0002 | 2.03E-02 | NPM1,SP1,JUN,VEGFA |
| Huntington disease (P) | 121 | 4 | 0.0017 | 2.79E-02 | GAPDH,AKT2,AP2A2,JUN |
| Processing of capped intron-containing pre-mRNA (R) | 138 | 4 | 0.0028 | 3.33E-02 | DDX23,PCBP1,RNPS1,NUP205 |
| Prostate cancer (K) | 89 | 4 | 0.0006 | 1.56E-02 | E2F1,PTEN,AKT2,HSP90AA1 |
| Regulation of androgen receptor activity (N) | 49 | 4 | 0.0001 | 1.70E-02 | KAT7,HSP90AA1,KAT2B,JUN |
| Regulation of telomerase (N) | 68 | 4 | 0.0002 | 1.44E-02 | E2F1,HSP90AA1,SP1,JUN |
| Mean difference | SD (±) | P | ||
| Flat SimK (D) | IOL Master-Galilei | 0.155 | 0.156 | <0.001 |
| IOL Master-WAM 5500 | 0.007 | 0.187 | 0.302 | |
| Galilei-WAM 5500 | −0.148 | 0.195 | <0.001 | |
| Steep SimK (D) | IOL Master-Galilei | 0.171 | 0.168 | <0.001 |
| IOL Master-WAM 5500 | −0.055 | 0.227 | 0.172 | |
| Galilei-WAM 5500 | −0.226 | 0.236 | <0.001 | |
| Corneal astigmatism (D) | IOL Master-Galilei | 0.016 | 0.249 | 0.662 |
| IOL Master-WAM 5500 | −0.061 | 0.265 | 0.055 | |
| Galilei-WAM 5500 | −0.078 | 0.292 | 0.022 | |
| ACD (mm) | IOL Master-Galilei | −0.269 | 0.158 | <0.001 |
| WTW (mm) | IOL Master-Galilei | −0.080 | 0.274 | 0.009 |
| Programs | Species | Algorithms | Advantages | Disadvantages |
| Diana-microT | Human | Seed match, thermodynamics | Prefers target structure before seed pairing. | Absence of cooperativity and multiplicity of miRNAbinding sites.Conservation filter. |
| miRDB | Human, mouse, rat, dog, chicken | SVM classifier | Editable Wikipedia based interface for functionalannotation. | Feature selection procedure ismissing. |
| miRWalk | Human, mouse, rat | Seed match, statistical model | Provides binding sites within promoter, 5’-UTR, CDS,and 3’-UTR regions.Amalgamates 10 prediction datasets and other uniquefeatures such as validated information on miRNAs associated with genes,diseases, cell lines, pathways, etc. | Free energy of the duplex is missing,however; it integrates other algorithms which consider free energy. |
| miRanda | Human, mouse, rat, fly, worm | Complementarity, free energy, conservation | Offers tissue-based miRNA expression profile. | Low precision.Conservation filter. |
| miTarget | Any | Seed match, free energy, SVM classifier | Validated miRNA targets information collected fromliterature search is used as training dataset. | A simple filtering for feature selection method. |
| PicTar | Vertebrates, flies, worms | Seed match, free energy, conservation, HMM | Considers cross-species conservation to reduce falsepositives. | Non-conservative sites prediction. |
| PITA | Human, mouse, fly, worm | Seed match, free energy | Considers secondary structure for prediction. | Low efficiency to existing algorithms. |
| RNA22 | Human, mouse, fly, worm | Pattern recognition | Serves interactive exploration.It does not consider cross-species conservationfilter. | Low efficiency to existing algorithms. |
| RNAhybrid | Any | Seed match, free energy, statistical model | Extension of classical RNA secondary structureprograms. | Unable to distinguish functional and non-functionalsites. |
| TargetScan | Mammals, flies, worms, fish | Seed match, free energy, conservation | Broadly scans for conserved 8nt and 7nt sites. | Restricts to seed matching and conservation. |
| Non-surgical n = 261 | Bariatric surgery n = 301 | Adjusted for gender/ age/BMI | |||||
| Range | α | Mean (SD) | Mean (SD) | F | p | ηp2 | |
| Self-esteem | 1–4 | 0.81 | 2.7 (0.7) | 2.7 (0.7) | 0.54 | 0.46 | |
| Body satisfaction | 1–5 | 0.74 | 2.4 (0.5) | 2.6 (0.5) | 1.76 | 0.18 | |
| Appearance importance | 1–5 | 0.82 | 3.4 (0.7) | 3.4 (0.8) | 2.68 | 0.10 | |
| Mental health | |||||||
| - Anxiety | 0–20 | 7.2 (4.1) | 7.0 (4.2) | 0.78 | 0.38 | ||
| - Depression | 0–20 | 4.8 (3.2) | 5.4 (3.8) | 4.45 | <0.05 | 0.008 | |
| Binge eating | 1–3 | 1.8 (0.9) | 1.7 (0.8) | 7.69 | <0.01 | 0.015 | |
| Stressful life events | |||||||
| -frequency | 0–13 | 3.3 (2.2) | 3.8 (2.8) | 3.25 | 0.07 | ||
| -impact | 1–4 | 3.2 (0.7) | 3.3 (0.7) | 0.59 | 0.44 | ||
| -coping | 1–3 | 1.9 (0.6) | 2.0 (0.6) | 1.41 | 0.24 | ||
| Emotion regulation | |||||||
| - reappraisal | 1–7 | 0.77 | 4.1 (0.9) | 4.0 (0.9) | 1.48 | 0.22 | |
| - suppression | 1–7 | 79 | 3.8 (1.1) | 3.8 (1.1) | 0.34 | 0.56 | |
| Resilience factors | |||||||
| - Total | 1–5 | 0.91 | 3.6 (0.6) | 3.7 (0.6) | 3.00 | 0.08 | |
| - Personal strength | 1–5 | 0.87 | 3.4 (0.8) | 3.5 (0.8) | 8.40 | <0.01 | 0.015 |
| - Structural style | 1–5 | 0.49 | 3.2 (0.8) | 3.4 (0.8) | 10.45 | <0.001 | 0.019 |
| - Social competence | 1–5 | 0.74 | 3.6 (0.7) | 3.7 (0.8) | 0.99 | 0.32 | |
| - Family cohesion | 1–5 | 0.84 | 3.7 (0.8) | 3.6 (1.0) | 0.18 | 0.67 | |
| - Social resources | 1–5 | 0.80 | 4.1 (0.7) | 4.1 (0.8) | 0.01 | 0.95 | |
| Relationship satisfactiona | 1–7 | 0.85 | 5.6 (1.1) | 5.6 (1.1) | 0.07 | 0.79 |
| Parameter | Description |
| L | ORF length in codons |
| x | average number of transcripts per cell |
| g | ribosome density in number of ribosomes per 100 codons |
| w | number of ribosomes attached to a single transcript |
| m | transcript mean lifetime |
| I | mean translation initiation time |
| E | mean translation elongation time |
| e | mean time required for elongation of one codon of a transcript |
| b | number of proteins produced from a single transcript during its lifespan |
| B | total number of protein molecules produced from all transcripts of a gene |
| A | number of protein molecules per cell taken from high-throughput studies |
| R | average number of proteins produced from a gene per second |
| Tissue/Organ | Weighting factor |
| Breast, colon, lungs, red marrow, remainder, stomach | 0.12 |
| Gonads | 0.08 |
| Bladder, liver, esophagus, thyroid | 0.04 |
| Bone surfaces, brain, salivary glands, skin | 0.01 |
| Criteria | O157 | O26 | O103 | O111 | O145 | O45 | O91 | O113 | O121 | O128 |
| (6) | (27) | (8) | (17) | (8) | (8) | (12) | (4) | (11) | (6) | |
| Spring (32) | - | 9 | - | 3 | 5 | 6 | 2 | - | 5 | 2 |
| Summer (40) | 4 | 10 | 3 | 5 | 2 | 1 | 7 | 2 | 3 | 3 |
| (Autumn) (17) | - | 2 | 3 | 9 | - | 1 | - | - | 1 | 1 |
| Winter (18) | 2 | 6 | 2 | - | 1 | - | 3 | 2 | 2 | - |
| Nausea (42) | - | 7 | 1 | 6 | 5 | 5 | 5 | 3 | 7 | 3 |
| Fever (34) | 2 | 17 | 1 | 8 | - | 1 | 3 | 1 | 1 | - |
| Dysentery (14) | 4 | 3 | 1 | - | 2 | - | 2 | - | 1 | 1 |
| Other clinical signs (17) | - | - | 5 | 3 | 1 | 2 | 2 | - | 2 | 2 |
| Load Cases | No. of Locations | Load Cases | No. of Locations |
| Load Case 3-1 | 3 | Load Case 3-7 | 4 |
| Load Case 3-2 | 5 | Load Case 3-8 | 6 |
| Load Case 3-3 | 7 | Load Case 3-9 | 8 |
| Load Case 3-4 | 9 | Load Case 3-10 | 10 |
| Load Case 3-5 | 11 | Load Case 3-11 | 12 |
| Load Case 3-6 | 2 | Load Case 3-12 | 13 |
| Bipolar I disorder (N = 14) N (%) | Bipolar spectrum disorder (N = 26) N (%) | Bipolar disorder total (N = 40) N (%) | Significance Fisher exact test | |
| Recognized past depressive episodes | 11 (78.6) | 22 (84.6) | 33 (82.5) | ns |
| Recognized past (hypo)manic episodes | 3 (21.4) | 6 (23.1) | 9 (22.5) | ns |
| Consulted health professional for depressive episodes | 11 (78.6) | 19 (73.1) | 30 (75.0) | ns |
| Consulted health professional for (hypo)manic episodes | 5 (35.7) | 2 (7.7) | 7 (17.5) | P = 0.039 |
| Hospitalization for a manic episode | 7 (50) | 0 (0) | 7 (17.5) | P = 0.000 |
| Indicated a past diagnosis of bipolar disorder | 4 (28.6) | 1 (3.8) | 5 (12.5) | P = 0.043 |
| Treatment for bipolar disorder | 4 (28.6) | 1 (3.8) | 5 (12.5) | P = 0.043 |
| Ethnicity | MKT | WPA | MLA | Total | ||||
| Sgaw Karen | 1,081 | 26.3% | 1,470 | 32.0% | 3,443 | 71.3% | 5,994 | 44.3% |
| Poe Karen | 456 | 11.1% | 774 | 16.9% | 441 | 9.1% | 1,671 | 12.4% |
| Burman | 1,954 | 47.6% | 1,822 | 39.7% | 77 | 1.6% | 3,853 | 28.5% |
| “Muslim” | 15 | 0.4% | 11 | 0.2% | 573 | 11.9% | 599 | 4.4% |
| Mon | 72 | 1.8% | 56 | 1.2% | 14 | 0.3% | 142 | 1.1% |
| Kachin | 2 | 0.0% | 0 | 0.0% | 12 | 0.2% | 14 | 0.1% |
| Pa Oh | 46 | 1.1% | 501 | 1.1% | 10 | 0.2% | 106 | 0.8% |
| Rakhine | 55 | 1.3% | 14 | 0.3% | 1 | 0.0% | 70 | 0.5% |
| Shan | 9 | 0.2% | 10 | 0.2% | 6 | 0.1% | 25 | 0.2% |
| “Mixed” | 348 | 8.5% | 334 | 7.3% | 234 | 4.8% | 916 | 6.8% |
| Other | 66 | 1.6% | 48 | 1.0% | 16 | 0.3% | 130 | 1.0% |
| Total | 4,104 | 100.0% | 4,585 | 100.0% | 4,827 | 100.0% | 13,520 | 100.0% |
| Y | J | P | I | |
| ABNER(B) | 54.2 | 60.8 | 62.0 | 54.0 |
| BANNER | 62.0 | 61.0 | 68.7 | 53.9 |
| Extend_thres | P | R | F | Sn | PPV | Acc |
| 0.05 | 0.506 | 0.314 | 0.387 | 0.569 | 0.389 | 0.471 |
| 0.1 | 0.589 | 0.36 | 0.447 | 0.521 | 0.541 | 0.531 |
| 0.2 | 0.55 | 0.341 | 0.421 | 0.451 | 0.611 | 0.525 |
| 0.3 | 0.524 | 0.321 | 0.398 | 0.39 | 0.653 | 0.505 |
| 0.4 | 0.515 | 0.311 | 0.388 | 0.349 | 0.677 | 0.486 |
| 0.5 | 0.506 | 0.314 | 0.387 | 0.332 | 0.699 | 0.482 |
| 0.6 | 0.502 | 0.314 | 0.386 | 0.331 | 0.701 | 0.482 |
| 0.7 | 0.502 | 0.314 | 0.386 | 0.331 | 0.701 | 0.482 |
| 0.8 | 0.502 | 0.314 | 0.386 | 0.331 | 0.701 | 0.482 |
| 0.9 | 0.502 | 0.314 | 0.386 | 0.331 | 0.701 | 0.482 |
| 1.0 | 0.502 | 0.314 | 0.386 | 0.331 | 0.701 | 0.482 |
| Control | PaDRw-25 (t48) | PaDRw-25 (t72) |
| Peak (cm−1) | Peak (cm−1) | Peak (cm−1) |
| 3306 (p, c) | 3308 (+2) | 3308 (+2) |
| 2957 (p, l) | 2958 (+1) | 2958 (+1) |
| 2922 (l) | 2921 (−1) | 2922 |
| 2869 (p, l) | 2874 (+5) | 2875 (+6) |
| 2850 (l) | 2850 | 2851 (+1) |
| 1651 (p) | 1646 (−5) | 1648 (−3) |
| 1544 (p) | 1538 (−6) | 1538 (−6) |
| 1453 (p, l) | 1450 (−3) | 1449 (−4) |
| 1393 (p, l) | 1399 (+6) | 1398 (+5) |
| 1296 (p) | 1305 (+9) | 1304 (+8) |
| 1248 (DNA) | 1231 (+17) | 1230 (+18) |
| 1146 (DNA, c) | 1150 (+4) | - |
| 1082 (DNA) | 1084 (+2) | 1096 (+14) |
| 1037 (DNA, c) | 1057 (+20) | 1067 (+30) |
| XX18 | YY18 | XY18 | 1818 | Total Disomy | |
| 3PBA | |||||
| ≤LOD (n = 33) | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| >LOD (n = 42) | 1.00 (0.90, 1.10) | 1.28 (1.15, 1.42) | 0.82 (0.77, 0.87) | 0.89 (0.65, 1.23) | 0.93 (0.87, 0.97) |
| CDCCA | |||||
| ≤LOD (n = 53) | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| >LOD (n = 22) | 1.22 (1.09, 1.36) | 1.18 (1.05, 1.31) | 1.07 (1.00, 1.14) | 0.89 (0.65, 1.21) | 1.12 (1.06, 1.17) |
| TDCCA | |||||
| ≤LOD (n = 56) | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| >LOD (n = 19) | 1.30 (1.17, 1.46) | 1.19 (1.06, 1.34) | 1.01 (0.93, 1.08) | 1.10 (0.84, 1.44) | 1.09 (1.04, 1.15) |
| Genetic model | OR (95% CI) | P heterogeneity | |
| Co-dominant model | CC | 1 | |
| CT | 1.072 (0.843, 1.362)b | 0.025 | |
| TT | 1.666 (1.127, 2.461)a | 0.991 | |
| Dominant model | CT+TT vs. CC | 1.119 (0.899, 1.392)b | 0.050 |
| Recessive model | CC+CT vs. TT | 1.663 (1.148, 2.408)a | 0.967 |
| Allele | C vs. T | 1.150 (1.014, 1.304)a | 0.231 |
| Chromosome | Start | End | Length | Score |
| 1 | 82955709 | 82956371 | 663 | 306.0 |
| 7 | 1194442 | 1195252 | 811 | 286.97 |
| 1 | 76438827 | 76439515 | 689 | 251.83 |
| 5 | 4911834 | 4912728 | 895 | 236.06 |
| 5 | 4907997 | 4908831 | 835 | 235.12 |
| 9 | 4315702 | 4316286 | 585 | 230.55 |
| 1 | 89187456 | 89187990 | 535 | 214.65 |
| 8 | 61869092 | 61869619 | 528 | 201.54 |
| 3 | 59054967 | 59055546 | 580 | 188.78 |
| 9 | 58915814 | 58916418 | 605 | 184.69 |
| 6 | 41195995 | 41196596 | 602 | 173.86 |
| 2 | 46987902 | 46988604 | 703 | 173.8 |
| 2 | 48205156 | 48205766 | 611 | 173.8 |
| 12 | 6609432 | 6610083 | 652 | 173.8 |
| 12 | 64009107 | 64009667 | 561 | 173.51 |
| Number of SNPs | Haplotype combination | Chromosomal position | Pvalue | FWER corrected Pvalue |
| 2 | rs2268493-rs2254298 | 8800840-8802228 | 0.00086 | 0.00468 |
| 3 | rs2268490-rs2268493-rs2254298 | 8797085-8802228 | 0.000365 | 0.0018 |
| 3 | rs2268493-rs2254298-rs53576 | 8800840-8804371 | 0.00208 | 0.01268 |
| 4 | rs237885-rs2268490-rs2268493-rs2254298 | 8795543-8802228 | 0.0012 | 0.00712 |
| 4 | rs2268490- rs2268493-rs2254298-rs53576 | 8797085-8804371 | 0.00132 | 0.0079 |
| Gene | Wt | Het | Null |
| IL-17A | 7.62 ± 4.70∗ | 1.10 ± 0.32‡ | 0.31 ± 0.01‡ |
| IL-17F | 12.95 ± 3.71∗ | 5.46 ± 1.07‡ | 4.19 ± 0.98‡ |
| IL-21 | 1.53 ± 0.80 | 0.70 ± 0.18 | 0.47 ± 0.14 |
| IL-22 | 1.48 ± 1.05 | 0.44 ± 0.33 | 0.10 ± 0.10 |
| IL-23 | 3.88 ± 0.43∗ | 3.58 ± 0.57∗‡ | 2.19 ± 0.39‡ |
| IL-23R | 0.73 ± 0.16 | 0.40 ± 0.05 | 0.65 ± 0.21 |
| IL-27 | 2.75 ± 0.67 | 1.86 ± 0.42 | 1.80 ± 0.46 |
| CCL20 | 1.42 ± 0.49 | 1.36 ± 0.57 | 1.13 ± 0.30 |
| CCR6 | 1.22 ± 0.38 | 0.82 ± 0.24 | 0.91 ± 0.44 |
| RORγτ | 11.07 ± 2.04∗ | 8.75 ± 1.34∗ | 5.28 ± 0.17‡ |
| Tbet | 8.35 ± 1.32∗ | 3.30 ± 0.66‡ | 4.12 ± 0.69‡ |
| Foxp3 | 2.95 ± 0.65 | 2.52 ± 0.23 | 1.81 ± 0.27 |
| IL-10 | 13.57 ± 3.91∗ | 9.08 ± 2.77∗ | 3.95 ± 1.38‡ |
| TGFβ1 | 1.80 ± 0.27 | 1.68 ± 0.26 | 1.31 ± 0.13 |
| MCP-1 | 25.57 ± 8.37∗ | 32.41 ± 14.00∗ | 8.86 ± 3.49‡ |
| IL-1β | 44.13 ± 12.57 | 31.30 ± 13.19 | 24.51 ± 12.95 |
| TNFα | 9.85 ± 1.81 | 9.89 ± 3.82 | 5.65 ± 1.72 |
| IL-6 | 11.54 ± 4.07∗ | 7.11 ± 3.34∗‡ | 2.10 ± 0.73‡ |
| IFNγ | 1.89 ± 1.01 | 0.52 ± 0.16 | 0.62 ± 0.21 |
| IL-4 | 0.64 ± 0.36 | nd | 0.38 ± 0.73 |
| Efficacy measures | Baseline | Week 12 | Week 24 |
| 6MWD, meters (LOCF) | |||
| N | 133 | 133 | 133 |
| Mean (SD) | 377.1 (61.30) | +53.6 (64.50) | +64.4 (91.17) |
| *P value (95 % CI) | <0.001 (42.5; 64.7) | <0.001 (48.7; 80.0) | |
| BDI scores (LOCF) | |||
| N | 133 | 133 | 133 |
| Mean (SD) | 2.5 (1.37) | −0.3 (1.52) | −0.2 (1.95) |
| P value (95 % CI) | <0.001 | 0.003 | |
| WHO functional classification, n (%) (LOCF) | |||
| N | - | 133 | 133 |
| Improved by class 1/2 | 44 (33.1)/0 | 51 (38.3)/0 | |
| No change | 84 (63.2) | 77 (57.9) | |
| Worsened by class 1/2 | 4 (3.0)/1 (0.8) | 3 (2.3)/2 (1.5) | |
| NT-proBNP levels, ng/L (Observed data) | |||
| N | 132 | 123 | 122 |
| Mean (SD) | 1600.7 (1832.84) | −861.4 (1452.96) | −806.0 (1384.00) |
| P values (95 % CI) | P < 0.001 | P < 0.001 |
| Direction of the Acceleration Loaded | Maximum Differential Stress of x-Component (MPa) | Maximum Differential Stress of y-Component (MPa) | Maximum Differential Stress of z-Component (MPa) |
| x-axis | 0.00048 | 14.7 | 0.00036 |
| y-axis | 0.0009 | 0.00025 | 0.00065 |
| z-axis | 0.00014 | 0.000172 | 0.000354 |
| Participant | No motor constant load VOL | No motor constant load FES | No motor incremental load VOL | No motor incremental load FES | Motor constant load VOL | Motor constant load FES | Motor incremental load VOL | Other cycling trials completed |
| 1 | × | × | No motor constant load with FES alternating on:off in 1 minute increments | |||||
| 2 | × | × | ||||||
| 3 | × | × | × | |||||
| 4 | × | × | × | No motor-Brief trial without FES assistance |
| Event sequence | WBC (×109) | Eosinophils in PB (%, AEC) | Eosinophils in BM (%) | Blasts in BM (%) | Diagnosis | Intervention | Disease status |
| Initial presentation | 44.6 | 1, 0.45 | 1 | 7 | CMML-1 | SGI-110 | Refractory |
| After 2 months | 65.1 | 9, 5.8 | 5 | 4 | CMML-1 | SGI-110 | Progression |
| After 1 month | 126 | 11, 13.8 | 16 | 12 | Myelodysplastic/myeloproliferative neoplasm with eosinophilia, and PDGFRA rearrangement | Fludarabine + Cytarabine | Progression |
| After 1 month | 6.4 | 1, 0.06 | 1 | 26 | AML with PDGFRA rearrangement | Imatinib (with Idarubicin + Cutarabine) | Remission |
| Gene name | Forward primer | Reverse primer |
| IL-6 | 5′-ATCTGCCCTTCAGGAACAGC-3′ | 5′-AGCCTCCGACTTGTGAAGTG-3′ |
| STAT3 | 5′-CAAAGAAAACATGGCCGGCA-3′ | 5′-GGGGGCTTTGTGCTTAGGAT-3′ |
| JAK-1 | 5′-ATGGAGTTTCTGCCTTCGGG-3′ | 5′-TTCTTGCTGCTAAGTCCCGG-3′ |
| MEK5 | 5′-TCGTGCCATGGAGAACCA-3′ | 5′-CGCGCCACTATTTGGAATCT-3′ |
| FADD | 5′-CCAAACAAGTGCAAGAGCCC-3′ | 5′-AGGATTGCAGAGTGAGCCAC-3′ |
| Bcl2 | 5′-CTTCTCTCGTCGCTACCGTC-3′ | 5′-CATGACCCCACCGAACTCAA-3′ |
| BCL-XL | 5′-CTTCTCTCGTCGCTACCGTC-3′ | 5′-GTGAGGTGGAAGGGACCATG-3′ |
| EGF | 5′-TGTGGGCTGAGAAGAAGCTG-3′ | 5′-GAGTACCAGATCTGCCGCTC-3′ |
| GAPDH | 5′-AACTCCCATTCCTCCACCTT-3′ | 5′-GAGGGCCTCTCTCTTGCTCT-3′ |
| Total | FOBT | Colonoscopy/sigmoidoscopy | |
| % Ordered | 48 | 33 | 26 |
| % Completed | 43 | 23 | 26 |
| Method | FPS | |
| Ours | K-SVD & Lasso | 482 |
| K-SVD & Ridge | 34 | |
| K-SVD & Elastic Net | 27 | |
| DMM & SVM | 87 | |
| DMM & RF | 215 | |
| LBP & SVM | 62 | |
| LBP & RF | 159 | |
| MEMM [12] | 10 | |
| Orderlet [24] | 25 | |
| DNBC [36] | 7 |
| Lymphoma type | Mean MFI relative to normal B cells (SEM) | |||
| IgM | IgG | CD79a | CD79b | |
| MZL | 0.23 (0.62) | −0.21 (0.28) | 0.19 (0.33) | −1.29 (0.43) |
| SLL/CLL | −1.38 (0.38) | −0.38 (0.24) | −0.15 (0.18) | −2.04 (0.32) |
| GOJ subtypes | Type I (Adenocarcinoma of distal oesophagus) | Type II (True cardia carcinoma) | Type III (Sub-cardial carcinoma) |
| Endoscopic criteria | Tumour mass arises 1 to 5 cm above the endoscopic cardia | Tumour mass arises 1 cm above to 2 cm below the endoscopic cardia | Tumour mass arises 2 to 5 cm below the area of the endoscopic cardia |
| Differing Characteristics | • Male predominance• Arise in association with Barrett's oesophagus (80%)• More likely to have hiatus hernia or history of GORD | • More similarities to Type III tumours than Type I• Barrett's mucosa identified in 10% | • Barrett's mucosa identified in only 2%• 60% have a diffuse growth pattern and 70% undifferentiated |
| Lymph node metastases | To mediastinal and abdominal lymph node stations | Mainly to abdominal lymph node stations | Mainly to abdominal lymph node stations |
| Precursor lesions | Barrett's oesophagus | Possible short segment Barrett's oesophagus or IM at the gastric cardia | Helicobacter pylori and IM of the subcardia region |
| Optimal surgical treatment | Transthoracic or transhiatal oesophagectomy | Controversial; may include either extended total gastrectomy or transthoracic or transhiatal oesophagogastrectomy | Extended total gastrectomy |
| Adherence to ≥ 4 recommendation items(n = 385) | Adherence to < 4 recommendation items(n = 325) | p value | Overall cohort (n = 710) | |
| Age, years, mean, (SD) | 57.9 (8.77) | 57.2 (9.64) | 0.268 | 57.6 (9.18) |
| Males, n (%) | 306 (79) | 276 (85) | 0.060 | 582 (82) |
| Education, years, mean (SD) | 11.8 (3.64) | 10.8 (3.19) | < 0.001 | 11.4 (3.48) |
| Ethnicity, n (%) | 0.100 | |||
| European | 241 (63) | 232 (71) | 473 (67) | |
| South Asian | 49 (13) | 27 (8) | 76 (11) | |
| Other Asian | 44 (11) | 28 (9) | 72 (10) | |
| Middle Eastern | 39 (10) | 32 (10) | 71 (10) | |
| Other | 12 (3) | 6 (2) | 18 (3) | |
| Hypertension, n (%) | 242 (63) | 198 (61) | 0.597 | 440 (62) |
| Diabetes, n (%) | 124 (32) | 105 (32) | 0.977 | 229 (32) |
| Depression, n (%) | 57 (15) | 52 (16) | 0.660 | 109 (15) |
| Current smoker, n (%) | 174 (45) | 203 (62) | < 0.001 | 377 (53) |
| BMI, mean (SD) | 29.2 (5.52) | 30.1 (6.37) | 0.044 | 29.7 (5.93) |
| Cardiac rehabilitation attendance, n (%) | 162 (43) | 132 (42) | 0.683 | 294 (43) |
| CAM preparation | % (n) |
| Homeopathy | |
| Schuessler Salts | 3.1 (11) |
| Dietary supplements | |
| Minerals | |
| Magnesium | 13.5 (48) |
| Calcium | 9.0 (32) |
| Zinc | 2.5 (9) |
| Iron | 2.0 (7) |
| Single vitamins | |
| Vitamin C | 2.3 (8) |
| Vitamin B | 1.4 (5) |
| Vitamin D | 0.8 (3) |
| Combination (mineral/vitamin/other) | 4.5 (16) |
| Herbs | |
| Without specific indication | |
| Chamomile (Matricaria recutita) tea | 6.5 (23) |
| Unspecified “herbal” tea | 5.1 (18) |
| Fennel, anise, caraway (Foeniculum vulgare, Pimpinella anisum, Carum carvi) tea | 4.8 (17) |
| Peppermint (Mentha piperita) tea | 3.7 (13) |
| Medicinal formulation | |
| Bronchial tea | 2.8 (10) |
| Kidney-Bladder tea | 2.5 (9) |
| Gastrointestinal tea | 2.3 (8) |
| Ginkgo (Ginkgo biloba) | 3.9 (14) |
| Valerian (Valeriana officinalis) | 2.8 (10) |
| St. John’s wort (Hypericum perforatum) | 1.4 (5) |
| External applications | |
| Ointments | |
| Arnica (Arnica montana) | 5.6 (20) |
| Calendula (Calendula officinalis) | 3.1 (11) |
| Mountain pine (Pinus Montana) foot cream/balm/footbath | 3.1 (11) |
| Rubbing alcohol | 3.1 (11) |
| Juices | |
| Unspecified “vegetable” juice | 0.6 (2) |
| Grapefruit (Citrus paradisi) juice | 0.3 (1) |
| Target genea | Forward primer, reverse primer and probe sequences (5'-3') | Location within sequences | Gene Bank accession no. |
| nleG6-2 (Z2150) | ATATGCTCTCTATATGATAAGGATG | 1928877-1928901 | AE005174 |
| AAAGTGACATTCGTCTTTTCTCATA | 1928996-1928872 | ||
| [6FAM]CGTTAGTGCAACTTGTTGAAACTGGTGGAA[BHQ1] | 1928902-1928931 | ||
| nleG5-2 (Z2151) | AGACTATTCGTGGAGAAGCTCAAG | 1929199-1929222 | AE005174 |
| TATTGAAGGCCAATCTGGATG | 1929337-1929317 | ||
| [6FAM]TGGATATTTTATGGGAAGTCTTAACCAGGATGG[BHQ1] | 1929269-1929301 | ||
| espK | ATTGTAACTGATGTTATTTCGTTTGG | 1673295-1673320 | AE005174 |
| GRCATCAAAAGCGAAATCACACC | 1673419-1673397 | ||
| [6FAM]CAGATACTCAATATCACAATCTTTGATATATAAACGACC[BHQ1] | 1673330-1673368 | ||
| bfpA | CCAGTCTGCGTCTGATTCCA | 2756-2775 | FM180569 |
| CGTTGCGCTCATTACTTCTGAA | 2816-2795 | ||
| TAAGTCGCAGAATGC-MGB | 2777-2791 |
| Capital cost ($MM) | Additional chemical cost ($MM/year) | Description | |
| Preprocessing unit | $10.17 | $1.90 | Preprocessing unit includes tanks for preprocessing and belt transfer conveyors, where the preprocessed biomass may be additionally washed |
| Wastewater treatment unita | $21.70 | $3.00 | Additional cost account for the increase of the wastewater treatment capacity and treatment chemicals |
| Parameters | B | Wald | Sig. | Exp (B) | 95% CI |
| Age (≥60y) | 0.913 | 0.996 | 0.318 | 2.491 | 0.415-14.957 |
| Histological type | 0.457 | 0.110 | 0.740 | 1.579 | 0.107-23.390 |
| Grade | -1.369 | 3.599 | 0.058 | 0.254 | 0.062-1.046 |
| Stage | -0.234 | 0.051 | 0.821 | 0.791 | 0.103-6.051 |
| Tumor size | 1.006 | 0.996 | 0.318 | 2.734 | 0.379-19.708 |
| LN metastasis (+) | -0.061 | 0.004 | 0.948 | 0.941 | 0.154-5.735 |
| Family history (+) | 0.656 | 0.957 | 0.328 | 1.927 | 0.518-7.177 |
| Menopause (+) | 0.248 | 0.137 | 0.712 | 1.282 | 0.344-4.778 |
| Her2 (+) | 0.364 | 0.364 | 0.546 | 1.438 | 0.442-4.685 |
| PR (+) | -0.17 | 0.000 | 0.984 | 0.983 | 0.185-5.220 |
| ER (+) | 0.024 | 0.001 | 0.978 | 1.024 | 0.188-5.578 |
| Ki-67 (≥ 14%) | 1.673 | 7.992 | 0.005 | 5.326 | 1.670-16.983 |
| Jab1/COPS5 | 0.036 | 5.181 | 0.023 | 1.037 | 1.005-1.069 |
| Antibiotics | S. aureus (n = 30)Resistant frequency (%) | MRSA (n = 8)Resistant frequency (%) |
| Penicillin G | 22 (73) | 8 (100) |
| Ciprofloxacin | 11 (36.7) | 6 (75.0) |
| Gentamicin | 10 (33.3) | 5 (62.5) |
| Amikacin | 3 (10) | 1 (12.5) |
| Erythromycin | 10 (33.3) | 5 (62.5) |
| Cotrimoxazole | 6 (20) | 4 (50.0) |
| Tetracycline | 6 (20) | 3 (37.5) |
| Rifampicin | 6 (20) | 3 (37.5) |
| Vancomycin | 0 | 0 |
| Teicoplanin | 0 | 0 |
| Cefoxitin | 8 (26.7) | 8 (100) |
| Oxacillin | 8 (26.7) | 8 (100) |
| Clindamycin | 8 (26.7) | 3 (37.5) |
| Index | Target group | Number of drugs | ||
| Training dataset | Test dataset | Total | ||
| 1 | G Protein-coupled Receptors | 272 | 35 | 307 |
| 2 | Nuclear Receptors | 82 | 13 | 95 |
| 3 | Ion Channels | 109 | 9 | 118 |
| 4 | Enzymes | 325 | 31 | 356 |
| — | Total | 788 | 88 | 876 |
| Variable | CAP due to other definite bacterial pathogensn = 621 | p1 | MPP n = 307 | p2 | CAP with no known bacterial etiology n = 3604 |
| Age (∅ ± SD) | 61 ± 17 years | .000 | 41 ± 16 years | .000 | 61 ± 18 years |
| Male gender | 58% | .000 | 41% | .000 | 56% |
| Outpatient/hospitalized | 22%/78% | .000 | 56%/44% | .000 | 36%/64% |
| CRB 65 Score0-1-2-3-4 (%) | 33-46-16-4-1 | .000 | 72-25-3-0.4-0 | .000 | 39-43-15-2-0.4 |
| Packyears(∅ ± SD) | 32 ± 25 | .000 | 15 ± 14 | .000 | 29 ± 23 |
| Pleural effusion | 17% | .000 | 6% | .001 | 13% |
| Dyspnoea | 80% | .000 | 69% | ns | 72% |
| Pleural pain | 47% | .000 | 34% | ns | 42% |
| Confusion | 11% | .000 | 2% | .001 | 8% |
| Oxygen requirement | 57% | .000 | 25% | .000 | 41% |
| Malignancy | 9% | .000 | 2% | .000 | 10% |
| Chronic respiratory disease | 38% | .000 | 20% | .000 | 36% |
| Renal insufficiency | 8% | .001 | 2% | .000 | 8% |
| Congestive heart failure | 19% | .000 | 4% | .000 | 19% |
| Diabetes | 20% | .000 | 3% | .000 | 16% |
| Respiratory sample obtained* | 42% | .000 | 58% | .000 | 30% |
| Leucocytes (median)/μl | 13 200 | .000 | 8850 | .000 | 11 000 |
| CRP (median) mg/l | 173 | .000 | 60 | .001 | 73 |
| Duration of antibiotic therapy(∅ ± SD) | 13 ± 6 days | .000 | 11 ± 4 days | ns | 11 ± 5 days |
| LOS in hospitalized patients(∅ ± SD) | 14 ± 11 days | .000 | 9 ± 5 days | .000 | 12 ± 9 days |
| Deaths within 30 days | 54 (8.7%) | .000 | 2 (0.7%) | .000 | 234 (6.5%) |
| Gene name | Control Fold change Peak to Trough | Alcohol Fold change Peak to Trough | Ratio (Alcohol fed/control) |
| clock | 3.1 | 3.5 | 1.1 |
| Bmal1 | 14.9 | 10.7 | 0.7 |
| Npas2 | 38.5 | 8.0 | 0.2 |
| per1 | 5.9 | 6.2 | 1.1 |
| per2 | 6.2 | 3.3 | 0.5 |
| per3 | 23.5 | 9.6 | 0.4 |
| cry1 | 4.8 | 8.9 | 1.9 |
| cry2 | 9.9 | 4.0 | 0.4 |
| Rev-erbα | 17.0 | 11.0 | 0.6 |
| Rev-erbβ | 6.9 | 2.1 | 0.3 |
| AUC | Cut-off value | Sensitivity, % (95 % CI) | Specificity, % (95 % CI) | Likelihood ratio | |
| BAFF | 0.823 | 1.7 ng · mL−1 | 67.6 (49.4 to 82.6) | 94.7 (73.9 to 99.8) | 12.85 |
| KL-6 | 0.566 | 1562 U · mL−1 | 79.4 (62.1 to 91.3) | 52.6 (28.8 to 75.5) | 1.67 |
| SP-D | 0.643 | 158 ng · mL−1 | 47.1 (29.7 to 64.8) | 77.7 (52.3 to 93.5) | 2.11 |
| Parameters | df | F-Value | p-value |
| Drug | 1 | 2.288 | 0.138 |
| Timepoint | 6.932 | 2.163 | 0.038* |
| Stimulation | 3 | 11.423 | 0.001* |
| Drug × stimulation | 3 | 8.673 | 0.001* |
| Timepoint × stimulation | 30 | 2.056 | 0.001* |
| Drug × timepoint | 5.446 | 1.478 | 0.192 |
| Drug × timepoint × stimulation | 30 | 1.831 | 0.027* |
| Pathway2 | Sex | Diet | PAPOLG genotype | Sex × diet | Sex × gene | Diet × gene |
| Amino acids (85) | 1123 | 3 | 8 | 1 | 2 | 4 |
| Carbohydrates (23) | 9 | 0 | 3 | 2 | 1 | 0 |
| Cofactors and vitamins (15) | 3 | 1 | 4 | 0 | 1 | 0 |
| Energy (9) | 1 | 0 | 1 | 1 | 0 | 1 |
| Lipids (141) | 15 | 7 | 29 | 6 | 6 | 31 |
| Nucleotides (14) | 1 | 2 | 3 | 0 | 0 | 2 |
| Peptides (14) | 0 | 1 | 0 | 0 | 0 | 0 |
| Xenobiotics (46) | 4 | 3 | 1 | 6 | 0 | 1 |
| Total (347) | 44 | 17 | 50 | 16 | 10 | 39 |
| Median number after Y scrambling3 | 20 | 17 | 20 | 20 | 20 | 20 |
| 4 | <0.001 | NS | <0.001 | NS | <0.001 | <0.001 |
| Hexanoyl-carnitine | Octenoyl-carnitine | Octanoyl-carnitine | Decenoyl-carnitine | Decanoyl-carnitine | Dodecenoyl-carnitine | Tetradecenoyl-carnitine | Linoleyl-carnitine | Stearoyl-carnitine | |
| Hexanoylcarnitine | 1 | 0.26 | 0.94 | 0.82 | 0.94 | 0.73 | 0.58 | 0.16 | 0.19 |
| Octenoylcarnitine | 0.26 | 1 | 0.18 | 0.50 | 0.19 | 0.35 | 0.27 | 0.28 | 0.10 |
| Octanoylcarnitine | 0.94 | 0.18 | 1 | 0.81 | 0.99 | 0.69 | 0.57 | 0.12 | 0.14 |
| Decenoylcarnitine | 0.82 | 0.50 | 0.81 | 1 | 0.83 | 0.82 | 0.60 | 0.28 | 0.16 |
| Decanoylcarnitine | 0.94 | 0.19 | 0.99 | 0.83 | 1 | 0.75 | 0.61 | 0.11 | 0.15 |
| Dodecenoylcarnitine | 0.73 | 0.35 | 0.69 | 0.82 | 0.75 | 1 | 0.72 | 0.22 | 0.21 |
| Tetradecenoylcarnitine | 0.58 | 0.27 | 0.57 | 0.60 | 0.61 | 0.72 | 1 | 0.20 | 0.18 |
| Linoleylcarnitine | 0.16 | 0.28 | 0.12 | 0.28 | 0.11 | 0.22 | 0.20 | 1 | 0.59 |
| Stearoylcarnitine | 0.19 | 0.10 | 0.14 | 0.16 | 0.15 | 0.21 | 0.18 | 0.59 | 1 |
| Coefficient (Standard Error) | ||||
| Independent Variable | Initial Family Lifestyle | Family LifestyleAge 3 | Family LifestyleAge 5 | Family LifestyleAge 7 |
| α (Eq. 4) | ||||
| Previous Latent Family Lifestyle, α | – | 1.094*** (0.007) | 1.094*** (0.007) | 1.094*** (0.007) |
| β(Eqs. 3 and 4) | ||||
| Currently High SES | 0.028*** (0.008) | – | – | – |
| Currently Low SES | −0.072*** (0.008) | – | – | – |
| Maternal Education at Birth | 0.013*** (0.003) | – | – | – |
| Single Parent | −0.044*** (0.010) | −0.002 (0.007) | − 0.003 (0.005) | −0.012** (0.005) |
| Patient | Age (years) | Gender | Location | Primary malignancy | Metastases type | Treatment for primary malignancy |
| 1 | 69 | M | Right | Kidney cancer | S | Surgery, chemotherapy |
| 2 | 65 | F | Left | Lung cancer | M | Surgery, chemotherapy |
| 3 | 46 | M | Right | Melanoma | M | Surgery, chemotherapy |
| 4 | 70 | F | Left | Kidney cancer | M | Surgery |
| 5 | 80 | M | Right | Colon cancer | S | Surgery, chemotherapy |
| 6 | 81 | F | Right | Colon cancer | M | Surgery, chemotherapy |
| 7 | 60 | M | Left | Kidney cancer | S | Surgery |
| 8 | 68 | F | Left | Kidney cancer | S | Surgery |
| 9 | 59 | M | Left | Stomach cancer | S | Surgery, chemotherapy |
| Hip bearing surface | Femoral head size (mm) | Number of hips implanted | Number of hips revised for ARMD | Risk of ARMD revision surgery (%) (95% CI) | Relative risk (95% CI) of ARMD revision with 36 mm head size (vs. 28/32 mm) | p-value (36 mm vs. 28/32 mm for same bearing surface) |
| MoP | 28 & 32 | 407,412 | 85 | 0.021 (0.017–0.026) | 2.80 (1.74–4.36) | <0.001 |
| MoP | 36 | 46,258 | 27 | 0.058 (0.038–0.085) | ||
| CoC | 28 & 32 | 61,937 | 35 | 0.057 (0.039–0.079) | 0.92 (0.56–1.51) | 0.725 |
| CoC | 36 | 67,373 | 35 | 0.052 (0.036–0.072) | ||
| CoP | 28 & 32 | 96,286 | 24 | 0.025 (0.016–0.037) | 0.82 (0.24–2.19) | 0.683 |
| CoP | 36 | 24,513 | 5 | 0.020 (0.007–0.048) |
| Model I* | Model II** | |||
| Variable names | HR (95% CI) | P | HR (95% CI) | P |
| Care recipient's gender | ||||
| Female | 1.00 | 1.00 | ||
| Male | 3.97 (1.17 - 13.42) | 0.027 | 5.13 (2.25 - 11.69) | < 0.0001 |
| Informal care-giving arrangement | ||||
| Spousal care | 1.00 | 1.00 | ||
| Daughter-in-law care | 4.09 (1.23 - 13.58) | 0.022 | 4.40 (1.60 - 12.10) | 0.004 |
| Other categories (biological daughter care/other relative care/living alone) | 1.55 (0.45 - 5.39) | 0.491 | 1.26 (0.55 - 2.90) | 0.580 |
| Interaction | ||||
| Male gender * Daughter-in-law care | 0.09 (0.01 - 0.57) | 0.011 | 0.08 (0.02 - 0.46) | 0.004 |
| Male gender * Other categories | 0.66 (0.14 - 3.11) | 0.601 |
| Characteristics | Adjusting for age and gender | Simple logistic regression | Multiple logistic regression | |||
| OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P | |
| Age (years) | 1.001 (0.978–1.024) | 0.961 | 1.010 (0.989–1.031) | 0.373 | — | — |
| Gender (M/F) | 1.167 (0.673–2.024) | 0.583 | 1.036 (0.626–1.715) | 0.891 | — | — |
| BMI (kg/m2) | — | — | 1.029 (0.960–1.103) | 0.414 | — | — |
| SBP (mmHg) | — | — | 1.024 (1.012–1.035) | <0.001 | 1.024 (1.006–1.041) | 0.008 |
| DBP (mmHg) | — | — | 1.030 (1.011–1.048) | 0.001 | 1.007 (0.980–1.035) | 0.618 |
| HbA1c (%) | — | — | 1.093 (0.911–1.311) | 0.340 | — | — |
| TG (mmol/L) | — | — | 1.126 (0.931–1.362) | 0.221 | — | — |
| TC (mmol/L) | — | — | 1.298 (1.027–1.641) | 0.029 | 1.888 (0.710–5.020) | 0.203 |
| HDL-C (mmol/L) | — | — | 1.419 (0.494–4.071) | 0.515 | — | — |
| LDL-C (mmol/L) | — | — | 1.339 (1.010–1.775) | 0.043 | 0.665 (0.203–2.176) | 0.500 |
| BUN (nmol/L) | — | — | 1.346 (1.165–1.555) | <0.001 | 1.380 (1.111–1.714) | 0.004 |
| Cr (μmol/L) | — | — | 1.016 (1.005–1.028) | 0.004 | 1.003 (0.982–1.024) | 0.802 |
| GFR (mL/min/1.73 m2) | — | — | 0.991 (0.984–0.999) | 0.019 | 1.010 (0.998–1.021) | 0.095 |
| Adropin (ng/mL) | 0.285 (0.180–0.452) | <0.001 | 0.288 (0.183–0.453) | <0.001 | 0.270 (0.160–0.455) | <0.001 |
| MetS | — | — | 1.506 (0.865–2.621) | 0.148 | — | — |
| Condition | Femoral Taper Mean + Standard Deviation (Newtons) | Acetabular Taper Mean + Standard Deviation (Newtons) |
| 10 million cycles dynamic fatigue | 12,957 + 1797 | 3429 + 347 |
| 50 million cycles dynamic fatigue | 12,506 + 774 | 4329 + 443 |
| Characteristics | No of patients | % | TIMP-1 negativeN (%) | TIMP-1 positiveN (%) | P |
| Age | 0.34 | ||||
| <50 | 47 | 28.8 | 44 (93.6) | 3 (6.4) | |
| 51-65 | 94 | 57.7 | 80 (85.1) | 14 (14.9) | |
| > 65 | 22 | 13.5 | 19 (86.4) | 3 (12.3) | |
| Median 55.2 | |||||
| Range 29-70 | |||||
| FIGO stage | 0.36 | ||||
| I | 0 | 0 | |||
| II | 26 | 15.9 | 25 (96.2) | 1 (3.8) | |
| III | 123 | 75.5 | 106 (86.2) | 17 (13.8) | |
| IV | 14 | 8.6 | 12 (85.7) | 2 (14.3) | |
| Tumour grade | 0.32 | ||||
| 1 | 34 | 20.9 | 28 (82.4) | 6 (17.6) | |
| 2 | 49 | 30.1 | 43 (87.8) | 6 (12.2) | |
| 3 | 66 | 40.5 | 61 (92.4) | 5 (7.6) | |
| Not graded (clear cell or metastatic biopsy/cytology only) | 14 | 8.6 | |||
| Histopathologic cell type | 0.00004 | ||||
| Serous | 129 | 79.1 | 119 (92.2) | 10 (7.8) | |
| Endometrioid | 11 | 6.8 | 9 (81.8) | 2 (18.2) | |
| Clear cell | 5 | 3.1 | 4 (80.0) | 1 (20.0) | |
| Mucinous | 9 | 5.5 | 4 (44.4) | 5 (55.6) | |
| Undifferentiated | 6 | 3.7 | 6 (100) | 0 (0.0) | |
| Carcinosarcoma | 3 | 1.8 | 1 (33.3) | 2 (66.7) | |
| Residual postoperative tumour | 0.95 | ||||
| ≤ 1 cm | 60 | 44.4 | 53 (88.3) | 7 (11.7) | |
| > 1 cm(Unknown: 28) | 75 | 55.6 | 66 (88.0) | 9 (12.0) | |
| TIMP immunostaining | |||||
| Negative | 143 | 87.7 | NA | NA | NA |
| Positive | 20 | 12.3 | |||
| (<0.1%: 26) | |||||
| (0.1-10%: 80) | |||||
| (>10-25%: 30) | |||||
| (>25-50%:17) | |||||
| (>50%: 10) |
| Lctg (n = 7) | Fccg (n = 9) | |||||
| Pre | Post | Difference | Pre | Post | Difference | |
| ONE LEG PRESS (1 RM* IN kg) | ||||||
| Right | 151 ± 31 | 152 ± 34 | 1 ± 4 | 128 ± 14 | 130 ± 18 | 2 ± 8 |
| Left | 150 ± 38 | 148 ± 37 | −1 ± 5 | 122 ± 12 | 123 ± 14 | 1 ± 7 |
| ONE LEG EXTENSION (1 RM* IN kg) | ||||||
| Right | 47 ± 8 | 46 ± 7 | −1 ± 2 | 44 ± 6 | 45 ± 8 | 1 ± 3 |
| Left | 45 ± 8 | 44 ± 9 | 0 ± 3 | 41 ± 7 | 43 ± 8 | 2 ± 3 |
| Specimen No. | Tensile Strength (MPa) | Modulus of Elasticity (GPa) | Strain to Failure (%) |
| 1 | 42.65 | 0.68 | 6.27 |
| 2 | 38.24 | 0.67 | 5.71 |
| 3 | 48.04 | 0.68 | 7.11 |
| 4 | 44.44 | 0.68 | 6.51 |
| 5 | 44.22 | 0.64 | 6.88 |
| 6 | 46.43 | 0.72 | 6.41 |
| 7 | 45.70 | 0.71 | 6.40 |
| 8 | 37.39 | 0.65 | 5.78 |
| 9 | 39.20 | 0.73 | 5.37 |
| 10 | 33.87 | 0.67 | 5.03 |
| 11 | 42.13 | 0.62 | 6.74 |
| 12 | 44.94 | 0.61 | 7.37 |
| 13 | 41.00 | 0.72 | 5.70 |
| 14 | 37.46 | 0.64 | 5.82 |
| 15 | 39.48 | 0.73 | 5.38 |
| Genotype | α+/β+/γ+ | α−/β+/γ+ | α+/β−/γ+ | α+/β+/γ− | α−/β+/γ− | α+/β−/γ− | α−/β−/γ+ | α−/β−/γ− |
| DOPAC:DA | ||||||||
| Average | 0.1019 | 0.1044 | 0.0940 | 0.0981 | 0.1150 | 0.0893 | 0.0807∗ | 0.1608∗∗ |
| SEM | 0.0062 | 0.0046 | 0.0047 | 0.0072 | 0.0043 | 0.0051 | 0.0053 | 0.0091 |
| HVA:DA | ||||||||
| Average | 0.0827 | 0.0814 | 0.0908 | 0.0832 | 0.0969 | 0.0911 | 0.0980 | 0.1090∗ |
| SEM | 0.0136 | 0.0059 | 0.0033 | 0.0059 | 0.0058 | 0.0080 | 0.0060 | 0.0026 |
| Variables | All PTB cases | PTB cases with smear resultsa | PTB cases without smear resultsa | ||||
| n | % | n | % | n | % | p value | |
| Age, years, mean (SD) | 36 ± 12.8 | - | 35 ± 13.1 | - | 37 ± 12.3 | p < 0.0001 | |
| Gender | p < 0.0001 | ||||||
| Female | 7556 | 39.35 | 5130 | 40.26 | 2424 | 37.56 | |
| Male | 11,641 | 60.65 | 7612 | 59.74 | 4029 | 62.44 | |
| HIV status | p < 0.0001 | ||||||
| Negative | 13,086 | 68.17 | 9047 | 71.00 | 4039 | 62.59 | |
| Positive | 4256 | 22.17 | 2720 | 21.35 | 1536 | 23.80 | |
| Unknown | 1853 | 9.65 | 975 | 7.65 | 878 | 13.61 | |
| Disease classification | p = 0.061 | ||||||
| PTB | 19,024 | 99.11 | 12,640 | 99.20 | 6384 | 98.93 | |
| PTB and EPTB | 171 | 0.89 | 102 | 0.80 | 69 | 1.07 | |
| TB classification | p < 0.0001 | ||||||
| New | 12,833 | 66.86 | 10,574 | 82.99 | 2259 | 35.01 | |
| Re-treatment | 6362 | 33.14 | 2168 | 17.01 | 4194 | 64.99 | |
| Smear conversion statusa | |||||||
| Negative | 11,115 | 87.23 | 11,115 | 87.23 | - | - | |
| Positive | 1627 | 12.77 | 1627 | 12.77 | - | - | |
| Pre-treatment smear grading | p = 0.053 | ||||||
| Scanty | 1670 | 8.70 | 1101 | 8.64 | 569 | 8.82 | |
| AFB+ | 3991 | 20.79 | 2665 | 20.92 | 1326 | 20.55 | |
| AFB++ | 3983 | 20.75 | 2659 | 20.87 | 1324 | 20.52 | |
| AFB+++ | 8575 | 44.67 | 5712 | 44.83 | 2863 | 44.37 | |
| Not recorded | 976 | 5.08 | 605 | 4.75 | 371 | 5.75 | |
| Sub-district | p = 0.887 | ||||||
| Bitou | 1662 | 8.66 | 1119 | 8.78 | 543 | 8.41 | |
| George | 7101 | 36.99 | 4731 | 37.13 | 2370 | 36.73 | |
| Hessequa | 1245 | 6.49 | 818 | 6.42 | 427 | 6.62 | |
| Kannaland | 940 | 4.90 | 615 | 4.83 | 325 | 5.04 | |
| Knysna | 2088 | 10.88 | 1388 | 10.89 | 700 | 10.85 | |
| Mossel Bay | 3090 | 16.10 | 2028 | 15.92 | 1062 | 16.46 | |
| Oudtshoorn | 3069 | 15,99 | 2043 | 16.03 | 1026 | 15.90 |
| Criterion | Data extracted |
| Country research conducted | Country |
| Study design | Between-subjects, within-subject, laboratory, field. |
| Participant characteristics | Total sample size; number of male and female participants; mean, median, standard deviation and range for age and BMI and BMI assessment method if assessed (self-report or objectively measured). |
| Moderating variables | Individual differences in eating behaviour traits [dieting status; restrained eating (scale used) or any other psychometric scales]; any other moderators examined. |
| Cue type and level of engagement | Type of cue: Specific item (e.g. slim models, foods); level of engagement: explicit, incidental, sub-conscious; cue validation |
| Test food | Interval between cue exposure and assessment of food intake; Test foods used: snack, meal, sweet, savoury, food name. |
| Mechanism for effects tested? | Yes, no; type of assessment used. |
| Main outcome | Food intake in ounces, piece count, grams and energy intake; assessment method for food intake (weighed, piece count) |
| Risk of bias | Random allocation to conditions, randomisation methods, allocation concealment, blinding (use of a cover story and participants' beliefs about the study aims; whether the researcher was aware of the study aims or condition that had been administered), completion of outcome reporting (excluded participants), procedures used to control for appetite, individual or social setting, administration of psychometric scales. |
| Intervention Group (n = 39) | Control Group (n = 40) | |||
| Baseline | Week 12 | Baseline | Week 12 | |
| Work-related PA | ||||
| Vigorous PA | 0 (1080) | 0 (1800) | 0 (720) | 0 (540) |
| Moderate PA | 0 (1500) | 0 (900) | 0 (1500) | 0 (600) |
| Walking | 0 (1620) | 0 (2520) | 0 (1350) | 0 (1650) |
| Total | 0 (3000) | 30 (4680) | 0 (2550) | 0 (2730) |
| Transportation PA | ||||
| Bicycling | 0 (0) | 0 (0) | 0 (40) | 0 (40) |
| Walking | 105 (1680) | 140 (900) | 80 (1680) | 70 (1680) |
| Total | 105 (1680) | 140 (900) | 80 (1720) | 70 (1720) |
| Housework PA | ||||
| Vigorous outside home | 0 (840) | 0 (840) | 0 (750) | 0 (360) |
| Moderate outside home | 0 (2100) | 0 (1680) | 0 (1260) | 0 (840) |
| Moderate inside home | 210 (2100) | 150 (840) | 180 (1680) | 120 (1680) |
| Total | 360 (4200) | 300 (2520) | 255 (2640) | 202.5 (2520) |
| Leisure-time PA | ||||
| Walking | 40 (840) | 100 (840) | 35 (600) | 16.25 (840) |
| Vigorous PA | 0 (180) | 0 (120) | 0 (120) | 0 (600) |
| Moderate PA | 0 (360) | 0 (60) | 0 (180) | 0 (180) |
| Total | 60 (840) | 120 (840) | 60 (600) | 60 (840) |
| Combined Domains | ||||
| Total Walking | 225 (3360) | 290 (2850) | 167.5 (1740) | 155 (1925) |
| Total Moderate PA | 420 (4380) | 405 (2760) | 360 (2640) | 262.5 (2590) |
| Total Vigorous PA | 0 (1080) | 0 (1800) | 0 (720) | 0 (600) |
| Total PA | 690 (6300) | 840 (5415) | 640 (4300) | 577.5 (4270) |
| Time Spent Sitting | ||||
| Weekday | 1500 (3750) | 1200 (3900) | 1500 (3450) | 1500 (2850) |
| Weekend | 480 (1320) | 360 (1200) | 600 (1200) | 600 (1320) |
| Total | 1980 (4650) | 1680 (5100) | 2130 (4170) | 2100 (3630) |
| Coefficientsa | |||||||||
| Model | Unstandardized Coefficients | Standardized Coefficients | t | Sig. | Correlations | ||||
| B | Std. Error | Beta | Zero-order | Partial | Part | ||||
| 1 | (Constant) | 1.556 | 0.344 | 4.519 | 0.000 | ||||
| Age | -0.003 | 0.003 | -0.113 | -1.212 | 0.227 | -0.141 | -0.087 | -0.076 | |
| Diabetes Mellitus | 0.365 | 0.052 | 0.453 | 7.079 | 0.000 | 0.475 | 0.454 | 0.442 | |
| GFR | 0.001 | 0.003 | 0.022 | 0.191 | 0.849 | 0.169 | 0.014 | 0.012 | |
| Serum Creatinine | -0.099 | 0.132 | -0.075 | -0.753 | 0.452 | -0.134 | -0.054 | -0.047 | |
| Weight | -0.001 | 0.003 | -0.039 | -0.427 | 0.670 | -0.035 | -0.031 | -0.027 | |
| Proteinuria | 7.064E-5 | 0.000 | 0.027 | 0.425 | 0.671 | 0.006 | 0.031 | 0.027 |
| CoW structure | Computation | Measurement [43] | ||||
| L. ICA | R. ICA | BA | L. ICA | R. ICA | BA | |
| Type 1 | 4.81 | 4.85 | 2.36 | 5.07 | 5.18 | 2.75 |
| Type 2 | 6.14 | 3.50 | 2.36 | 6.12 | 3.93 | 2.35 |
| Type 3 | 4.80 | 5.70 | 1.49 | 5.28 | 5.91 | 1.50 |
| Demographics and clinical characteristics | n (%) |
| Age (mean ± SD) | 55.4 ± 17.3 |
| Male | 131 (76.6) |
| Medical use before admission | |
| NSAIDs | 43 (25.1) |
| PPIs ≤ 2 weeks | 28 (16.4) |
| Antibiotics ≤ 4 weeks | 13 (7.6) |
| Prior history of peptic ulcers | 42 (24.6) |
| Prior history of H. pylori eradication | 12 (7.0) |
| Presenting symptoms | |
| Hematemesis | 88 (51.5) |
| Melena | 77 (45) |
| Hematochezia | 6 (3.5) |
| Preendoscopic PPIs use | |
| High-dose, intravenous | 133 (77.8) |
| Low-dose, intravenous | 8 (4.6) |
| Oral | 3 (1.8) |
| None | 27 (15.8) |
| Hemodynamic instability at admission (heart rate > 100 beats per minute and/or systemic blood pressure < 100 mmHg) | 47 (27.5) |
| Transfusion requirement | 47 (27.5) |
| Cerebral structure | Embryonic day | Genotype/normalised volume (mm3 × 10−2) | |||
| Gldc+/+ | GldcGT1/+ | GldcGT2/+ | GldcGT1/GT2 | ||
| Mesencephalic vesicle | 16.518.5 | 30 ± 515 ± 2* | 34 ± 413 ± 1* | 35 ± 316 ± 2* | 30 ± 314 ± 2* |
| Body of the LVs | 16.518.5 | 15 ± 27 ± 1* | 13 ± 28 ± 1** | 11 ± 17 ± 1** | 13 ± 323 ± 9*** |
| Base of the posterior horn of LVs | 16.518.5 | 10 ± 511 ± 5 | 10 ± 29 ± 1 | 13 ± 512 ± 3 | 13 ± 79 ± 6 |
| Fourth ventricle | 16.518.5 | 14 ± 27 ± 1* | 12 ± 15 ± 1* | 14 ± 24 ± 1* | 10 ± 16 ± 1* |
| Fourth ventricle choroid plexus | 16.518.5 | 95 ± 110 ± 1 | 10 ± 18 ± 1 | 11 ± 19 ± 4 | 80 ± 110 ± 1 |
| Cerebellum | 16.518.5 | 11 ± 0.0122 ± 2* | 13 ± 121 ± 3* | 15 ± 119 ± 1* | 12 ± 121 ± 2* |
| With Hashimoto’s | Without Hashimoto’s | P value | |
| Number of patients | 653 | 5456 | |
| Age (years) | 44.4±11.9 | 46.3±12.3 | 0.077 |
| Gender | |||
| Male | 56 | 1482 | 0.001 |
| Female | 597 | 3974 | |
| Nodule Size (cm) | 1.75±1.23 | 2.26±1.48 | 0.001 |
| PTC | 381(58.3%) | 2440(44.3%) | 0.001 |
| PTC cancer with serum TSH | 358(54.8%) | 2262(41.6%) | 0.001 |
| Entry | PA (n = 30) | Non-PA (n = 18) | ||||
| U-PA (n = 13) | B-PA (n = 17) | |||||
| Combined | Single | Combined | Single | Combined | Single | |
| PAC 30 min/PAC 0 min | 3.3 | 1.8 | 2.5 | 2.3 | 2.7 | 2.5 |
| (2.4–4.4) | (1.5–3.0) | (1.9–2.9) | (2.1–2.7) | (2.4–3.0) | (2.1–3.4) | |
| p-Value c | 0.05 | 0.49 | 0.78 | |||
| PAC 60 min/PAC 0 min | 2.9 | 1.9 | 2.3 | 2.3 | 2.9 | 2.8 |
| (2.5–5.0) | (1.7–3.0) | (2.1–2.9) | (2.0–2.9) | (2.7–3.6) | (2.5–3.5) | |
| p-Value | 0.09 | 0.52 | 0.71 | |||
| PAC/F, 0 min | 14.8 | 3.5 | 11.8 | 2.2 | 7.7 | 1.3 |
| (11.5–26.0) | (1.3–5.7) | (6.1–15.7) | (1.5–2.9) | (4.2–11.9) | (1.0–1.5) | |
| p-Value | <0.01 | <0.01 | <0.01 | |||
| PAC/F, 30 min | 4.5 | 3.8 | 1.7 | 1.6 | 1.3 | 1.4 |
| (1.7–8.5) | (1.5–5.3) | (1.4–1.9) | (1.4–2.0) | (1.0–1.8) | (0.9–1.7) | |
| p-Value | <0.01 | 0.94 | 0.68 | |||
| PAC/F, 60 min | 4.1 | 3.3 | 1.4 | 1.5 | 1.3 | 1.1 |
| (1.5–6.8) | (1.6–4.9) | (1.0–1.6) | (1.1–1.9) | (0.9–1.5) | (0.7–1.6) | |
| p-Value | 0.05 | 0.23 | 0.85 |
| β coefficient | 95% CI | p | ||
| EBM score | −0.33 | −0.53 | −0.12 | <0.01 |
| % admissions in urgency | 0.02 | −0.07 | 0.10 | 0.95 |
| ward (surgical/medical) | 0.64 | −4.71 | 5.99 | 0.81 |
| % appropriateness in admissions | −0.66 | −0.77 | −0.55 | <0.01 |
| constant | 85.27 | 73.33 | 97.20 | <0.01 |
| Peri-centenarian Female | Controls Female | Peri-centenarian Male | ControlMale | |||||||
| Genotype | N = 180 | N = 156 | p | N = 181 | N = 186 | p | ||||
| 5/5 | 1 | 0.56% | 6 | 3.85% | 0.053 | 8 | 4.42% | 4 | 2.15% | 0.253 |
| 5/6 | 1 | 0.56% | 3 | 1.92% | 0.341 | 2 | 1.10% | 2 | 1.08% | 1.000 |
| 5/7 | 29 | 16.11% | 32 | 20.51% | 0.322 | 41 | 22.65% | 41 | 22.04% | 0.901 |
| 5/9 | 8 | 4.44% | 3 | 1.92% | 0.232 | 7 | 3.87% | 11 | 5.91% | 0.470 |
| 6/6 | 2 | 1.11% | 0 | 0.00% | 0.501 | 0 | 0.00% | 0 | 0.00% | nc |
| 6/7 | 10 | 5.56% | 2 | 1.28% | 0.041 | 5 | 2.76% | 13 | 6.99% | 0.089 |
| 6/9 | 2 | 1.11% | 3 | 1.92% | 0.666 | 1 | 0.55% | 3 | 1.61% | 0.623 |
| 7/7 | 83 | 46.11% | 74 | 47.44% | 0.827 | 82 | 45.30% | 77 | 41.40% | 0.463 |
| 7/8 | 0 | 0.0% | 1 | 0.64% | 0.464 | 0 | 0.00% | 0 | 0.00% | nc |
| 7/9 | 41 | 22.78% | 29 | 18.59% | 0.419 | 29 | 19.02% | 32 | 17.20% | 0.781 |
| 9/9 | 3 | 1.67% | 3 | 1.92% | 1.000 | 6 | 3.31% | 3 | 1.61% | 0.332 |
| homozygotes | 89 | 49.45% | 83 | 53.21% | 0.513 | 96 | 53.04% | 84 | 45.16% | 0.144 |
| Heterozygotes | 91 | 50.55% | 73 | 46.79% | 0.513 | 85 | 46.96% | 102 | 54.84% | 0.144 |
| Alleles | ||||||||||
| 5 | 40 | 11.11% | 50 | 16.03% | 0.069 | 66 | 18.23% | 62 | 16.67% | 0.627 |
| 6 | 17 | 4.72% | 8 | 2.56% | 0.157 | 8 | 2.21% | 18 | 4.84% | 0.071 |
| 7 | 246 | 68.33% | 212 | 67.95% | 0.934 | 239 | 66.02% | 240 | 64.52% | 0.699 |
| 8 | 0 | 0.00% | 1 | 0.32% | 0.464 | 0 | 0.00% | 0 | 0.00% | nc |
| 9 | 57 | 15.83% | 41 | 13.14% | 0.381 | 49 | 13.54% | 52 | 13.98% | 0.915 |
| Outcome measures | AT | TAU | Unpaired t test | P | ||
| (n = 57) | (n = 57) | |||||
| M | SD | M | SD | |||
| ITAQ (0–22)a | 9.12 | 6.14 | 9.33 | 3.31 | 1.52 | 0.20 |
| PANSS | ||||||
| Total score (30–210)a | 80.19 | 11.10 | 81.13 | 12.01 | 1.71 | 0.18 |
| Positive symptoms (7–49)a | 15.39 | 5.12 | 15.11 | 5.01 | ||
| Negative symptoms (7–49)a | 16.31 | 5.87 | 16.45 | 6.87 | ||
| General psychopathology (16–112)a | 48.49 | 9.12 | 49.57 | 9.88 | ||
| SLOF | ||||||
| Total score (43–215)a | 140.01 | 18.22 | 138.34 | 17.18 | 1.49 | 0.20 |
| Self-maintenance(12–60)a | 42.11 | 5.52 | 40.18 | 7.08 | ||
| Social functioning (14–70)a | 42.00 | 5.88 | 43.01 | 6.91 | ||
| Community living skills (17–85)a | 55.90 | 8.01 | 55.15 | 8.33 | ||
| Adherence rating scale (1–5)a | 1.48 | 0.98 | 1.39 | 1.01 | 1.92 | 0.12 |
| Total non-adherence (f, %) | (22, 38.80) | (20, 35.09) | χ2 = 1.48 | 0.13 | ||
| Poor to inadequate adherence (f, %) | (28, 49.12) | (29, 50.88) | ||||
| Fair to good adherence (f, %) | (7, 12.28) | (8, 14.04) | ||||
| Re-hospitalization | ||||||
| Numberb | 1.41 | 0.98 | 1.50 | 0.92 | 1.83 | 0.12 |
| Durationc | 9.12 | 3.98 | 10.01 | 4.02 | 2.33 | 0.10 |
| DAI (0–22)a | 8.82 | 3.03 | 9.01 | 3.71 | 1.51 | 0.13 |
| IORT, n = 267a | EB-APBI, n = 206 | p value | |||
| N, median | %,range | N, median | %, range | ||
| Age | |||||
| Years | 68 | 59–90 | 67 | 59–86 | 0.683 |
| pT stage | |||||
| pTis | 18 | 7% | 26 | 13% | 0.068 |
| pT1a | 12 | 5% | 14 | 7% | |
| pT1b | 80 | 30% | 50 | 24% | |
| pT1c | 130 | 49% | 89 | 43% | |
| pT2 | 26 | 10% | 27 | 13% | |
| pN stage (invasive) | |||||
| pN0 | 227 | 92% | 172 | 96% | 0.045 |
| pN1mi/pN1a | 20 | 8% | 6 | 3% | |
| unknown | 1 | 0% | 2 | 1% | |
| BR stage (invasive) | |||||
| Grade 1 | 81 | 33% | 61 | 34% | 0.075 |
| Grade 2 | 109 | 44% | 91 | 51% | |
| Grade 3 | 56 | 23% | 25 | 14% | |
| unknown | 2 | 1% | 3 | 2% | |
| ER (invasive) | |||||
| Positive | 232 | 94% | 169 | 94% | 0.712 |
| PR (invasive) | |||||
| Positive | 187 | 75% | 138 | 78% | 0.611 |
| Her2neu (invasive) | |||||
| Positive | 15 | 6% | 10 | 6% | 0.893 |
| Systemic therapy | |||||
| No | 157 | 59% | 127 | 62% | 0.538 |
| HT | 91 | 34% | 60 | 29% | |
| CT ± HT | 19 | 7% | 17 | 8% |
| Hospitalisations withAKI diagnosis (N = 230)(%) | Hospitalisations without AKI diagnosis (N = 7574)(%) | P Value | |
| Age (years) | < 0.001 | ||
| < 65 | 10.9 | 31.4 | |
| 65-74 | 22.2 | 29.2 | |
| 75-84 | 41.7 | 27.9 | |
| ≥ 85 | 25.2 | 11.5 | |
| Sex (Male) | 53.0 | 36.3 | < 0.001 |
| Smoking history | 0.037 | ||
| Non-smoker | 28.7 | 37.7 | |
| Ex-smoker | 59.6 | 53.4 | |
| Current smoker | 11.3 | 8.6 | |
| Missing | 0.4 | 0.3 | |
| Co-diagnosis of COPD | 60.4 | 50.0 | 0.002 |
| Outpatient eGFR (mL/min/1.73 m2) | <0.001 | ||
| > 60 | 33.0 | 53.8 | |
| 45-60 | 17.4 | 11.0 | |
| 30-45 | 21.3 | 4.2 | |
| 15-30 | 10.0 | 1.3 | |
| No measurement | 18.3 | 29.8 | |
| History of AKI | 20.4 | 4.4 | < 0.001 |
| Chronic conditions | |||
| Heart failure | 19.6 | 9.0 | < 0.001 |
| Cirrhosis | 0.9 | 0.6 | 0.638 |
| Diabetes | 26.1 | 13.1 | < 0.001 |
| Dementia | 4.8 | 2.9 | 0.107 |
| Prostatic hypertrophy | 17.0 | 7.5 | < 0.001 |
| Drugs with nephrotoxic potential | |||
| NSAIDs | 28.3 | 22.5 | 0.038 |
| Aminoglycoside nebuliser | 1.3 | 0.1 | 0.001 |
| Aminoglycoside injection | 1.3 | 0.7 | 0.227 |
| ACEI or ARBs | 35.2 | 21.9 | < 0.001 |
| Diuretics | 44.8 | 29.5 | < 0.001 |
| Sepsis diagnosis | 12.2 | 1.0 | < 0.001 |
| Among plants in population | Among populations | |||
| Population | Range of length | Average length | Population pair | Length |
| Uss | 8-41 | 17.33 | Uss - Spa | 24 |
| Spa | 9-30 | 22.57 | Uss - Dgor | 22 |
| Dgor | 15-38 | 23.0 | Uss - Part | 33 |
| Pozh | 14-43 | 28.0 | Part - Drech | 50 |
| Nad | 21-36 | 29.07 | Drech - Chu | 25 |
| Part | 12-30 | 22.06 | Part - Yak | 19 |
| Yak | 22-57 | 35.13 | Yak - Olg | 35 |
| Chu | 15-44 | 25.0 | Pozh -Nad | 24 |
| Drech | 12-51 | 24.88 | Pozh - Part | 27 |
| Olg | 14-52 | 36.5 | ||
| Average | 26.35 | 28.78 |
| Normal range | ED admission | ICU admission | |
| HR, bpm | — | 143 | 117 |
| MAP, mmHg | — | 65 | 77 |
| PaO2/FiO2 | — | 72,7 | 120 |
| Body temperature, °C | — | 38.1 | 37.9 |
| Lactate, mmol/L | 0.5–1.6 | 3.4 | 1.4 |
| Creatinine, mg/dl | <1.2 | 1.95 | 1.41 |
| GOT, U/L | <35 | 202 | 290 |
| GPT, U/L | <45 | 248 | 320 |
| gGT, U/L | <55 | 316 | 238 |
| CK, U/L | <190 | 1014 | 1553 |
| Troponin T, ng/ml | 0–0.03 | 0.274 | Na |
| CRP, mg/dl | <1 | 5.51 | 9.27 |
| WBC, G/L | 4.0–10.0 | 10.35 | 8.77 |
| Factor | Odds ratio (95 % confidence interval) | p-value | |
| Time period | Pre-intervention | Reference | |
| Post-intervention | 1.543 (0.956–2.491) | 0.074 | |
| Monthly trend | Pre-intervention | 1.009 (0.983–1.036) | 0.487 |
| Post-intervention | 1.048 (1.007–1.091) | 0.023 | |
| Season | Dry | Reference | |
| Wet | 0.974 (0.845–1.123) | 0.708 | |
| Total outpatient attendance | Per 1,000 | 0.919 (0.883–0.956) | <0.001 |
| % G2/M cells | |||||
| Time (hr) | ABZ (nM) | A2058 | A375 | H1530 | H446 |
| 0 | 0 | 10.6 | 4.7 | 4.3 | 0.9 |
| 12 | 100 | 10.0 | 13.1 | 3.0 | 5.2 |
| 12 | 500 | 29.3 | 65.2 | 38.6 | 47.7 |
| 12 | 1000 | 32.3 | 87.1 | 46.3 | 71.4 |
| Year | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
| Number of police road stops | 26 | 26 | 26 | 26 | 24 | 20 |
| Median number of drivers | 425 | 294.5 | 300 | 323.1 | 236.9 | 648.1 |
| Body mass index (> 25 Kg/m2)(%) | 64.5 | 63.8 | 64.9 | 65.5 | 55.2 | 58.5 |
| Neck circumference (≥ 40 cm)(%) | 13.9 | 11.1 | 12.5 | 7.5 | 13.9 | 11.1 |
| Abdominal circumference (≥ 102 cm) (%) | 52.8 | 50.3 | 49.8 | 43.8 | 19.8 | 52.8 |
| Diabetes (%) | 11 | 11.9 | 10.1 | 11.8 | 14.9 | 14.4 |
| Hypertension (%) | 25.9 | 24 | 27.7 | 36.3 | 39.6 | 36.3* |
| Overtime hours (> 8h) (%) | 42.8 | 43.4 | 20.9 | 28.7 | 52.2 | 49.9* |
| Illicit drug use (% yes) | 8.1 | 8.5 | 5.8 | 4.8 | 5.5 | 4.1 |
| Alcohol (% yes) | 23 | 30.9 | 24.2 | 30.3 | 32 | 36.6* |
| Smoking (% yes) | 17.7 | 19.6 | 18.4 | 20.5 | 20.3 | 19.1 |
| Hypercholesterolemia (%) | 13.7 | 12.5 | 8.8 | 8.5 | 13.9 | 4.4* |
| Sleepiness (%) | 14.7 | 14.8 | 13.6 | 10 | 6.9 | 4.9* |
| Waist circumference (> 109 cm) (%) | 52.8 | 50.3 | 49.8 | 43.8 | 19.8 | NA |
| Body fat (%) | 62.4 | 60.6 | 63.8 | 56.1 | NA | NA |
| Hypertriglyceridemia (%) | 39.1 | 39.6 | 33.4 | 25.8* | NA | NA |
| Cargo vehicles accidents (%) | 15.1 | 16.1 | 16.6 | 17.4 | 12.9 | NA |
| Microorganism Isolated | Total No. 241 (100) |
| Pseudomonas aeruginosa | 51 (21.16) |
| aMDR Pseudomonas aeruginosa | 16 (6.64) |
| Methicillin susceptible Staphylococcus aureus | 11 (4.56) |
| Methicillin resistant Staphylococcus aureus | 6 (2.49) |
| Acinetobacter sp | 3 (1.24) |
| Moraxella catarrhalis | 7 (2.9) |
| Stenotrophomonas maltophilia | 4 (1.66) |
| Enterobacteriaceae | 12 (4.98) |
| Escherichia coli | 5 (2.07) |
| Proteus spp | 3 (1.24) |
| Klebsiella pneumonia | 3 (1.24) |
| Serratia spp | 1 (0.41) |
| Haemophilus influenzae | 27 (11.2) |
| Streptococcus pneumoniae | 25 (10.37) |
| Achromobacter xylosoxidans | 5 (2.07) |
| Mycoplasma pneumoniae | 6 (2.49) |
| Chlamydia pneumoniae | 1 (0.41) |
| Atypical mycobacteria | 4 (1.66) |
| Aspergillus spp | 12 (4.98) |
| Candida spp | 15 (6.22) |
| Virus | 25 (10.37) |
| Coronavirus | 1 (0.41) |
| Metapneumovirus | 4 (1.65) |
| Rhinovirus | 10 (4.14) |
| Influenza A | 3 (1.24) |
| Influenza B | 2 (0.82) |
| Parainfluenza 3 | 2 (0.82) |
| Respiratory Syncytial virus | 3 (1.24) |
| Others | 11 (4.56) |
| Maintenance Time (ms) | Rise Time (ms) | |
| Doped LC | VA LC | |
| 3 | 4.72 | 193 |
| 5 | 6.96 | 115 |
| 10 | – | 108 |
| # | Misincorporation | Untemplated | Sequence 5′-GCAUGGGCCC ... -3′ |
| 24 | +C | AUGC | |
| 20 | +CC | AUGC | |
| 2 | G→C | +C | AU |
| 38 | G→C | AU | |
| 14 | (U/G)→C | A | |
| 4 | +A(C/U)C | AUGC | |
| 1 | AUGC AUGC UUGC | ||
| 1 | ΔG | AUC AUGC UUGC |
| Site | Eligible visits | BMD testing | Initiation of any osteoporosis medication | Initiation of any nutritional supplements (calcium, vitamin D) | |||||||
| Median (IQR) | Total | Median (IQR) | Total | Rate‡(95% CI) | Median (IQR) | Total | Rate (95% CI) | Median (IQR) | Total | Rate (95% CI) | |
| Combined† | |||||||||||
| Overall | 240.0 (51.75) | 12,445 | 10.00 (7.00) | 550 | 4.42 (4.07-4.80) | 1.00 (2.00) | 82 | 0.66 (0.53-0.82) | 3.00 (3.75) | 191 | 1.53 (1.32-1.77) |
| Pre-Intervention | 238.0 (49.75) | 6,139 | 7.00 (5.25) | 180 | 2.93 (2.53-3.39) | 1.00 (1.00) | 25 | 0.41 (0.27-0.61) | 2.00 (2.25) | 60 | 0.98 (0.75-1.27) |
| Post-Intervention | 247.0 (60.50) | 6,306 | 14.00 (16.25) | 370 | 5.87 (5.31-6.48) | 2.00 (2.25) | 57 | 0.90 (0.69-1.17) | 4.50 (4.25) | 131 | 2.08 (1.75-2.47) |
| Site One | |||||||||||
| Overall | 72.50 (25.50) | 3,683 | 3.00 (3.00) | 189 | 5.13 (4.45-5.91) | 0.00 (1.00) | 21 | 0.57 (0.36-0.89) | 0.00 (0.00) | 14 | 0.38 (0.21-0.65) |
| Pre-Intervention | 69.0 (23.50) | 1,852 | 2.00 (3.00) | 68 | 3.67 (2.88-4.66) | 0.00 (1.00) | 9 | 0.49 (0.24-0.96) | 0.00 (0.00) | 4 | 0.22 (0.07-0.59) |
| Post-Intervention | 76.50 (30.75) | 1,831 | 4.50 (3.25) | 121 | 6.61 (5.53-7.87) | 0.00 (1.00) | 12 | 0.66 (0.36-1.18) | 0.00 (1.00) | 10 | 0.55 (0.28-1.04) |
| Site Two | |||||||||||
| Overall | 53.50 (15.75) | 2,618 | 1.50 (2.00) | 123 | 4.70 (3.93-5.60) | 0.00 (1.00) | 20 | 0.76 (0.48-1.20) | 2.00 (2.00) | 94 | 3.59 (2.93-4.39) |
| Pre-Intervention | 52.50 (19.25) | 1,219 | 1.00 (2.00) | 40 | 3.28 (2.38-4.48) | 0.00 (1.00) | 8 | 0.66 (0.31-1.34) | 1.00 (2.00) | 38 | 3.12 (2.24-4.30) |
| Post-Intervention | 57.00 (19.50) | 1,399 | 2.50 (3.00) | 83 | 5.93 (4.78-7.33) | 0.00 (1.00) | 12 | 0.86 (0.47-1.54) | 2.00 (3.00) | 56 | 4.00 (3.06-5.20) |
| Site Three | |||||||||||
| Overall | 114.50 (28.00) | 6,144 | 4.00 (4.25) | 238 | 3.87 (3.41-4.39) | 0.00 (1.00) | 41 | 0.67 (0.49-0.91) | 1.00 (3.00) | 83 | 1.35 (1.08-1.68) |
| Pre-Intervention | 114.00 (31.00) | 3,068 | 2.00 (3.00) | 72 | 2.34 (1.85-2.96) | 0.00 (1.00) | 8 | 0.26 (0.12-0.54) | 0.00 (1.00) | 18 | 0.59 (0.36-0.95) |
| Post-Intervention | 117.50 (31.75) | 3,076 | 5.50 (5.00) | 166 | 5.40 (4.64-6.27) | 1.00 (1.25) | 33 | 1.07 (0.75-1.52) | 2.00 (3.00) | 65 | 2.11 (1.65-2.70) |
| Model | BC (0.94 × 10−5/m)a | PM2.5 (1.58 μg/m3)a | NO2 (8.4 μg/m3)a | NO (13.2 μg/m3)a |
| Hospitalization | ||||
| Model 1: unadjusted single pollutant | 1.04 (1.03–1.06) | 1.03 (1.01–1.05) | 1.02 (1.00–1.04) | 0.99 (0.97–1.02) |
| Model 2: + sex, age, comorbidity, SES | 1.01 (1.00–1.03) | 1.00 (0.98–1.02) | 0.97 (0.95–0.99) | 0.96 (0.94–0.98) |
| Model 3: + two other pollutantsb | 1.03 (1.01–1.05) | 1.02 (1.00–1.05) | 0.96 (0.94–0.98) | 0.95 (0.92–0.97) |
| Mortality | ||||
| Model 1: unadjusted single pollutant | 1.14 (1.11–1.17) | 1.13 (1.09–1.16) | 1.19 (1.15–1.23) | 1.13 (1.09–1.17) |
| Model 2: + sex, age, comorbidity, SES | 1.06 (1.03–1.09) | 1.01 (0.98–1.05) | 1.04 (1.01–1.08) | 1.06 (1.02–1.10) |
| Model 3: + two other pollutantsb | 1.06 (1.03–1.09) | 1.00 (0.96–1.03) | 1.03 (0.99–1.07) | 1.03 (0.99–1.08) |
| Chi-square tests | |||
| Value | df | Asymp. Sig. (2-sided) | |
| Pearson chi-square | .036a | 3 | .998 |
| Likelihood ratio | .036 | 3 | .998 |
| Fisher's exact test | .074 | ||
| Linear-by-linear | .004c | 1 | .952 |
| Association | |||
| N of valid cases | 288 |
| 3 months | 6 months | ||||||||||
| Intervention n = 152–155 | Control n = 157–159 | Intervention n = 124–127 | Control n = 133–141 | ||||||||
| Median | IQR | Median | IQR | p-value* | Median | IQR | Median | IQR | p-value* | ||
| Psychological symptoms | Somatisation | 0.7 | 0.3–1.1 | 0.8 | 0.3–1.3 | 0.09 | 0.6 | 0.3–1.0 | 0.7 | 0.3–1.3 | 0.20 |
| Anxiety | 0.6 | 0.2–1.1 | 0.8 | 0.3–1.3 | 0.04 | 0.4 | 0.2–0.9 | 0.6 | 0.2–1.2 | 0.09 | |
| Interpersonal sensitivity | 0.7 | 0.4–1.2 | 0.9 | 0.4–1.6 | 0.08 | 0.7 | 0.2–1.2 | 1.0 | 0.3–1.4 | 0.10 | |
| Depression | 1.0 | 0.5–1.7 | 1.3 | 0.7–2.3 | 0.02 | 0.8 | 0.5–1.5 | 1.1 | 0.5–1.9 | 0.19 | |
| Phobic anxiety | 0.1 | 0.0–0.6 | 0.1 | 0.0–0.6 | 0.29 | 0.1 | 0.0–0.4 | 0.1 | 0.0–0.4 | 0.27 | |
| Obsessive-compulsive | 1.0 | 0.5–1.8 | 1.2 | 0.7–2.0 | 0.12 | 0.8 | 0.4–1.5 | 1.0 | 0.6–1.7 | 0.05 | |
| Locus of control | Internal LOC | 23.0 | 19.0–28.0 | 20.0 | 16.0–25.0 | <0.001 | 24.0 | 19.5–28.0 | 21.0 | 16.0–25.0 | <0.001 |
| Chance | 14.0 | 11.0–18.0 | 14.5 | 11.0–18.0 | 0.23 | 14.0 | 9.0–18.0 | 14.0 | 10.0–18.0 | 0.43 | |
| Doctors | 12.0 | 10.0–14.0 | 12.0 | 10.0–14.0 | 0.50 | 12.0 | 9.0–13.0 | 12.0 | 10.0–13.0 | 0.76 | |
| Other people | 11.0 | 9.0–13.0 | 11.0 | 8.0–13.0 | 0.39 | 10.0 | 8.0–12.0 | 10.0 | 8.0–12.0 | 0.88 | |
| Mental health related QoL | Vitality | 45.0 | 30.0–60.0 | 45.0 | 25.0–60.0 | 0.32 | 50.0 | 30.0–65.0 | 50.0 | 25.0–65.0 | 0.54 |
| Social functioning | 75.0 | 62.5–100.0 | 87.5 | 62.5–100.0 | 0.98 | 87.5 | 75.0–100.0 | 87.5 | 62.5–100.0 | 0.58 | |
| Role limitations due to emotional problems | 66.7 | 33.3–100.0 | 66.7 | 0.0–100.0 | 0.33 | 66.7 | 33.3–100.0 | 66.7 | 33.3–100.0 | 0.71 | |
| Mental health | 64.0 | 52.0–76.0 | 60.0 | 44.0–76.0 | 0.04 | 68.0 | 56.0–80.0 | 68.0 | 52.0–78.0 | 0.41 |
| State | Description | Probability* |
| Normal | No abnormality | 0.78 |
| Adenoma <10 mm | Individual has adenoma that is <10 mm in diameter | 0.1668 |
| Adenoma ≥10 mm | Individual has adenoma that is ≥10 mm in diameter | 0.0464 |
| Surveillance | Individuals are in the surveillance state once they have had an adenoma ≥ 10 mm removed | 0 |
| CRC Dukes’ A | Individual has developed CRC and is at Dukes stage A | 0.0036 |
| Treatment Dukes’ A | Individual with Dukes stage A has been diagnosed and will not take part in any further screening | 0 |
| CRC Dukes’ B | Individual has developed CRC and is at Dukes stage B | 0.0016 |
| Treatment Dukes’ B | Individual with Dukes stage B has been diagnosed and will not take part in any further screening | 0 |
| CRC Dukes’ C | Individual has developed CRC and is at Dukes stage C | 0.0012 |
| Treatment Dukes’ C | Individual with Dukes stage C has been diagnosed and will not take part in any further screening | 0 |
| CRC Dukes’ D | Individual has developed CRC and is at Dukes stage D | 0.0004 |
| Treatment Dukes’ D | Individual with Dukes stage D has been diagnosed and will not take part in any further screening | 0 |
| Dead CRC | Death from CRC | 0 |
| Dead other causes | Death from colonoscopy | 0 |
| Factors (Number) | Univariate model | Multivariate model #1 | Multivariate model #2 | ||||||
| HR | 95% CI | P | HR | 95% CI | P | HR | 95% CI | P | |
| Age (years) | 1.008 | 0.980–1.036 | 0.584 | ||||||
| Gender (Male/Female) (83/20) | 2.070 | 0.808–5.303 | 0.130 | ||||||
| Primary site | |||||||||
| Parotid gland (69) | 1 (Ref.) | ||||||||
| Non-parotid gland (34) | 1.718 | 0.912–3.237 | 0.094 | ||||||
| TN categories | |||||||||
| T3–4/T1–2 (45/58) | 1.986 | 1.048–3.761 | 0.035 | 0.984 | 0.460–2.103 | 0.967 | |||
| N1–3/N0 (48/55) | 4.489 | 2.241–8.994 | < 0.001 | 4.693 | 1.990–11.069 | < 0.001 | 4.650 | 1.967–10.994 | < 0.001 |
| Pathological diagnosis | |||||||||
| Salivary duct carcinoma (67) | 1 (Ref.) | ||||||||
| Squamous cell carcinoma, primary (9) | 0.226 | 0.031–1.661 | 0.114 | ||||||
| Adenoid cystic carcinoma, solid type (8) | 1.289 | 0.451–3.685 | 0.635 | ||||||
| Mucoepidermoid carcinoma, high-grade (7) | 0.851 | 0.258–2.806 | 0.791 | ||||||
| Adenocarcinoma, high-grade (6) | 0.283 | 0.040–2.162 | 0.229 | ||||||
| Others (6) | 1.847 | 0.556–6.138 | 0.317 | ||||||
| Treatment modalities | |||||||||
| Surgery (13) | 1 (Ref) | 1 (Ref) | 1 (Ref) | ||||||
| Surgery + radiation (62) | 1.294 | 0.450–3.719 | 0.632 | 0.917 | 0.303–2.778 | 0.879 | 0.912 | 0.301–2.758 | 0.870 |
| Surgery + radiation + chemotherapy (28) | 1.068 | 0.339–3.359 | 0.911 | 0.421 | 0.125–1.425 | 0.164 | 0.421 | 0.125–1.424 | 0.164 |
| Surgery of primary tumor (R1/R0) (6/97) | 1.126 | 0.347–3.660 | 0.843 | ||||||
| Neck dissection/no neck dissection (72/31) | 1.489 | 0.739–3.000 | 0.266 | ||||||
| Pathological risk factors | |||||||||
| Perineural invasion (Y/N) (13/90) | 1.111 | 0.434–2.846 | 0.827 | ||||||
| Lymphovascular invasion (Y/N) (16/87) | 1.132 | 0.440–2.915 | 0.797 | ||||||
| Extra-parenchymal extension (Y/N) (45/58) | 2.045 | 1.077–3.886 | 0.029 | 1.006 | 0.469–2.157 | 0.988 | |||
| Extra-capsular spread (Y/N) (26/77) | 3.236 | 1.665–6.290 | 0.001 | 1.799 | 0.850–3.811 | 0.125 | 1.792 | 0.846–3.795 | 0.128 |
| Peak (1999) | Crash (2000) | Peak (2002) | Crash (2003) | Peak (2005) | Crash (2006) | |
| Peak (1999) | 0.07000 | 0.02667* | 0.01333* | 0.00333* | 0.00333* | |
| Crash (2000) | 0.0002 | 0.87000 | 0.08667 | 0.19333 | 0.00667* | |
| Peak (2002) | 0.0032 | −0.0010 | 0.24000 | 0.06667 | 0.01000* | |
| Crash (2003) | 0.0019 | 0.0013 | −0.0012 | 0.12000 | 0.01667 | |
| Peak (2005) | 0.0040 | 0.0009 | 0.0053 | 0.0033 | 0.00333* | |
| Crash (2006) | 0.0104 | 0.0090 | 0.0083 | 0.0049 | 0.0102 |
| Characteristic | Intervention arm | Control arm |
| N = 609 | N = 667 | |
| Children’s characteristics | ||
| Female sex, n (%) | 329 (54.0) | 336 (50.4) |
| Mean age, months (SD) | 30.4 (15.9) | 31.5 (16.4) |
| Caregivers’ characteristics | ||
| Female sex, n (%) | 562 (92.3) | 625 (93.7) |
| Age in years, mean (SD) | 30.9 (9.4) | 30.5 (8.7) |
| Education level, n (%)* | ||
| None | 59 (9.7) | 62 (10.4) |
| Primary | 381 (62.7) | 450 (67.7) |
| Post primary | 168 (27.6) | 146 (22.0) |
| Religion, n (%)*# | ||
| Catholic | 30 (4.9) | 65 (9.8) |
| Protestant | 244 (40.1) | 223 (33.5) |
| Muslim | 310 (51.0) | 335 (50.4) |
| Other | 24 (4.0) | 42 (6.3) |
| Marital status, n (%)** | ||
| Married | 559 (92.1) | 592 (88.8) |
| Single | 23 (3.8) | 27 (4.1) |
| Divorced | 19 (3.1) | 37 (5.6) |
| Widowed | 6 (1.0) | 11 (1.7) |
| Rural residence, n (%) | 499 (81.9) | 600 (90.0) |
| Outcome and instrument | Method | Data collection time | ||
| T0 | T1 | T2 | ||
| Degree of integration | ||||
| Self-constructed questionnaire | Mailed questionnaire | x | x | |
| Satisfaction health professionals | ||||
| Self-constructed questionnaire | Mailed questionnaire | x | x | |
| Relational coordination Survey | Mailed questionnaire | x | x | |
| Self-reported satisfaction | Diaries | x | x | |
| Interviews | x | |||
| Focus groups | x | x | x | |
| Satisfaction frail elderly | ||||
| CQ-index | Interview elderly | x | x | x |
| Self-constructed questionnaire | Interview elderly | x | x | x |
| Satisfaction caregiver | ||||
| CQ-index | Interview caregiver or mailed questionnaire | x | x | x |
| Self-constructed questionnaire | Interview caregiver or mailed questionnaire | x | x | x |
| Fetal cotyledonary tissue | Maternal caruncular tissue | |||||
| fdPAG (mg) and [PAG/TP ratio (%)] | fdPAG (mg) and [PAG/TP ratio (%)] | |||||
| Purification step | TP (mg) | RIA-438 | RIA-706 | TP (mg) | RIA-438 | RIA-706 |
| 20-40% A.S. | 1,401.6 | 3.16 [0.23] | 0.12 [0.01] | 1,956.5 | 1.23 [0.06] | 0.06 [0] |
| 40-80% A.S. | 2,014.9 | 10.59 [0.53] | 0.44 [0.02] | 815.2 | 3.95 [0.48] | 0.31 [0.04] |
| Factor | Bup | Bup+Dex(3) | Bup+Dex(5) | F | P value |
| Apgar score | |||||
| 1min | 9.0(8.0,9.0) | 9.0(8.0,9.0) | 9.0(8.0,9.0) | 0.59 | 0.7450 |
| 5min | 10.0(9.0,10.0) | 10.0(9.0,10.0) | 10.0(9.5,10.0) | 0.31 | 0.8556 |
| Umbilical oxygen partial pressure(mmHg) | 24.8±10.3 | 25.7±8.4 | 27.6±9.0 | 0.48 | 0.6217 |
| Umbilical dioxide partial pressure(mmHg) | 41.9±5.1 | 43.1±5.4 | 43.6±5.9 | 0.49 | 0.6162 |
| Umbilical glucose(mmol/L) | 3.5±0.6 | 3.6±0.4 | 3.6±0.6 | 0.12 | 0.8838 |
| Umbilical lactate(mmol/L) | 1.5(1.4,1.6) | 1.5(1.3,1.7) | 1.4(1.2,1.6) | 1.33 | 0.5136 |
| Umbilical blood PH | 7.4±0.0 | 7.3±0.0 | 7.3±0.0 | 1.99 | 0.1460 |
| Red light | |
| GO term | P value |
| MF: structural constituent of ribosome | 3.95E–29 |
| CC: ribosome | 9.50E–25 |
| BP: translation | 1.22E–22 |
| CC: integral to membrane | 1.19E–06 |
| BP: cell redox homeostasis | 1.96E–06 |
| CC: mitochondrion | 8.95E–05 |
| MF: glycerone kinase activity | 9.31E–05 |
| A total of 1,000 genes were submitted to the GOBU functional enrichment tool, which resulted in 689 unique genes with annotations. Terms are ranked by P value of over–representation and are included in list if P <1E–04. BP: Biological process; CC: Cellular component; MF: Molecular function. | |
| Blue light | |
| GO term | P value |
| CC: chloroplast | 4.67E–33 |
| MF: structural constituent of ribosome | 1.66E–29 |
| CC: ribosome | 5.14E–27 |
| BP: translation | 1.63E–20 |
| BP: reductive pentose–phosphate cycle | 1.47E–16 |
| CC: photosystem II | 2.36E–10 |
| BP: photosynthesis, light harvesting | 6.62E–10 |
| CC: photosystem I | 8.56E–10 |
| CC: stromule | 2.32E–09 |
| MF: chlorophyll binding | 2.53E–08 |
| CC: thylakoid | 6.47E–08 |
| BP: photorespiration | 1.00E–07 |
| CC: chloroplast envelope | 1.12E–07 |
| BP: photosynthesis | 3.92E–07 |
| CC: oxygen evolving complex | 5.16E–07 |
| CC: cytosolic ribosome | 3.22E–06 |
| MF: rRNA binding | 1.68E–05 |
| BP: cell redox homeostasis | 2.21E–05 |
| BP: translational elongation | 2.26E–05 |
| MF: ribulose–bisphosphate carboxylase activity | 2.86E–05 |
| BP: nitrate assimilation | 5.10E–05 |
| MF: glycerone kinase activity | 7.63E–05 |
| INNO-LIA | p31 | LAg-Avidity EIA | BED CEIA | Decision tree | |||||||
| n | Seroconversion | Very early | Early | Recent | Long term | Advanced | |||||
| Negative/ID | Recent | Recent | Recent | 24 | Congruent | 24 | |||||
| Positive | Recent | Recent | Recent | 81 | 81 | ||||||
| Positive | Long-term | Recent | Recent | 56 | 56 | ||||||
| Positive | Long-term | Long-term | Recent | 74 | 71 | 3 | |||||
| Positive | Long-term | Long-term | Long-term | 313 | 313 | ||||||
| Positive | Recent | Long-term | Recent | 8 | Incongruent | 8 | |||||
| Positive | Long-term | Recent | Long-term | 1 | 1 | ||||||
| Positive | Recent | Long-term | Long-term | 9 | 9 | ||||||
| 566 |
| Type of health services | % use | CHEa | Impoverismenta |
| Dental care | 7.0 | 1.88 [1.78-1.99]*** | 1.88 [1.78-1.99]*** |
| Inpatient care | 4.2 | 3.93 [3.70-4.17]*** | 3.24 [2.99-3.53]*** |
| Outpatient care | 14.1 | 3.11 [3.01-3.31]*** | 2.57 [2.47-2.73]*** |
| Traditional medicine | 6.1 | 1.82 [1.72-1.92]*** | 1.81 [1.67-1.96]*** |
| Medications or drugs | 42.7 | 4.13 [3.97-4.28]*** | 3.49 [3.29-3.70]*** |
| Health care products | 3.5 | 1.88 [1.75-2.02]*** | 1.76 [1.56-1.95]*** |
| Medical tests | 6.3 | 3.80 [3.62-3.99]*** | 2.88 [2.68-3.09]*** |
| Other health services | 4.1 | 1.92 [1.80-2.05]*** | 1.53 [1.38-1.69]*** |
| ECLS strategy | Possible indication(s) |
| VV ECMO + atrial septostomy | Refractory hypoxia and/or pulmonary hypertension on VV ECMO avoiding sternotomy |
| VV ECMO + transeptal return to left atrium | Refractory hypoxia and/or pulmonary hypertension on VV ECMO avoiding sternotomy |
| Venoarterial ECMO + transeptal access from left atrium and right atrium | Refractory left ventricular distension on venoarterial ECMO |
| VHV | Health center | ||
| MEAN | |||
| Direct cost (Kina; Kina 1 = USD 0.48) | −1.2977*** (0.408) | ||
| Walking distance (km) | −0.6843*** (0.198) | ||
| Antimalarial drug availability (no = 0/yes = 1) | 2.0290*** (0.742) | ||
| Gender of patient (female = 0/male = 1) | −1.0621** (0.514) | −1.8564** (0.862) | |
| Age of patient (year) | −0.2646 (0.178) | −0.7626** (0.311) | |
| Illness severity (mild = 0/moderate or severe = 1) | 1.4926** (0.602) | 3.4261*** (1.191) | |
| Education of caretaker (year) | −0.2177** (0.102) | −0.1925 (0.214) | |
| Economic status (low = base) | Middle | 0.835 (0.672) | 0.1147 (0.779) |
| High | 0.6924 (0.594) | −3.9198 (2.586) | |
| Constant | 0.9367 (0.981) | 6.6108*** (2.508) | |
| SD | |||
| Direct cost | 0.0039 (0.291) | ||
| Walking distance | 0.0039 (0.181) | ||
| Antimalarial drug availability | 1.1833 (1.358) | ||
| Economic status | Middle | 2.5479* (1.543) | 0.0603 (1.964) |
| High | 0.0170 (2.680) | 4.2573 (2.903) | |
| Sample size | 210 | ||
| Log likelihood | −148.98 | ||
| Pseudo R2 | 0.3280 |
| Assemblers | Repeat | Contigs (kb) | E-size | Assembly size (kb) | Genome coverage (%) | |||||||
| TRC | NNC | Rep-size | Rep-acc | Num.C | N90 | Mean | N50 | Max | ||||
| SWA | 13 | 1774 | 7.8 kb | 44.5% | 1787 | 1.3 | 2.6 | 4.2 | 29.4 | 5812 | 4600.3 | 99.94 |
| ABySS | 13 | 1910 | 8.3 kb | 44.5% | 1915 | 1.1 | 2.5 | 4.2 | 54.7 | 6877 | 4969.5 | 108 |
| Allpaths-LG | 2 | 202 | 1.4 kb | 6.7% | 204 | 11.5 | 22.5 | 34.4 | 106 | 35973 | 4587.8 | 99.6 |
| Bambus2 | 2 | 175 | 1.3 kb | 9.2% | 177 | 6.1 | 8.5 | 12.8 | 279 | 16281 | 4371.6 | 94.9 |
| CABOG | 1 | 312 | 0.3 kb | 8.9% | 322 | 6.5 | 13 | 17.9 | 88.5 | 21539 | 4238 | 92 |
| MSR-CA | 7 | 388 | 4.1 kb | 25.4% | 395 | 5.7 | 11.3 | 19 | 83.7 | 21579 | 4465 | 97 |
| SGA | 9 | 3053 | 3.9 kb | 64.3% | 3067 | 0.66 | 1.4 | 2.9 | 29.5 | 4067 | 4502.7 | 97 |
| SOAPdenovo | 9 | 195 | 3.7 kb | 84.5% | 204 | 7.8 | 11.8 | 14.3 | 376 | 18553 | 4596 | 99.8 |
| Velvet | 5 | 578 | 2.2 kb | 24.5% | 583 | 4.6 | 7.7 | 14.5 | 60.7 | 16711 | 4503 | 97.8 |
| Regular Menus | Carbohydrate-Controlled Menus | 3000 mg Menus | 2000 mg Menus | |||||
| Standard (n = 21) | Standard Range | Standard (n = 21) | Standard Range | Standard (n = 21) | Standard Range | Standard (n = 21) | Standard Range | |
| Calories (kcal) | 1673 ± 362 | 1296–3007 | 1808 ± 175 | 1516–2067 | 1600 ± 210 | 1281–2168 | 1687 ± 228 | 1342–2091 |
| Protein (g) | 63 ± 9 b | 49–86 | 77 ± 10 a | 61–96 | 66 ± 22 | 52–159 | 67 ± 14 | 51–102 |
| % Total Energy from Protein | 18 ± 5 | 12–31 | 22 ± 9 | 14–38 | 19 ± 5 | 13–29 | 18 ± 4 | 13–28 |
| <10% of kcal [5] | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | ||||
| Protein (g/kg) e | 0.9 ± 0.1 b | 0.7–1.2 | 1.1 ± 0.1 a | 0.9–1.4 | 1.0 ± 0.3 | 0.7–2.3 | 1.0 ± 0.2 | 0.7–1.5 |
| Fat (g) | 52 ± 13 | 30–83 | 61 ± 8 c,d | 48–76 | 48 ± 13b | 28–73 | 50 ± 14b | 33–74 |
| % Total Energy from Fat | 28 ± 3 | 21–34 | 30 ± 3 c,d | 25–35 | 26 ± 5b | 18–34 | 26 ± 4b | 20–32 |
| >35% of kcal [5] | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | ||||
| Carbohydrate (g) | 240 ± 60 | 193–483 | 242 ± 24 | 206–295 | 226 ± 23 | 191–278 | 246 ± 26 | 202–288 |
| % Total Energy from Carbohydrate | 57 ± 3 b | 52–64 | 54 ± 3 a,d | 47–58 | 57 ± 6 | 38–68 | 59 ± 5b | 50–68 |
| <45% of kcal [5] | 0 (0%) | 0 (%) | 1 (5%) | 0 (0%) | ||||
| Sodium (mg) | 2896 ± 606 b,c,d | 1746–4531 | 3406 ± 544 a,c,d | 2532–4425 | 2401 ± 389 a,b,d | 1755–3487 | 1504 ± 296 a,b,c | 1114–2149 |
| Fiber (g) | 17.6 ± 4.2 | 10.6–24.0 | 25.1 ± 4.9 | 18.0–33.3 | 17.0 ± 4.4 | 10.6–27.1 | 19.2 ± 6.6 | 10.0–34.1 |
| <30g | 14 (100) | 10 (71) | 14 (100%) | 13 (93%) | ||||
| Cholesterol (mg) | 282 ± 133 | 131–496 | 333 ± 136 | 136–498 | 295 ± 185 | 111–641 | 148 ± 80 | 58–359 |
| Vitamin C (mg) | 106 ± 75 | 11–248 | 114 ± 60 | 27–236 | 106 ± 74 | 7–214 | 107 ± 75 | 21–215 |
| <75 mg | 6 (43%) | 2 (14%) | 6 (43%) | 7 (50%) | ||||
| Iron (mg) | 11.9 ± 4.2 | 6.3–22.3 | 12.7 ± 2.9 | 8.2–17.2 | 11.7 ± 3.0 | 7.9–17.7 | 11.7 ± 2.9 | 7.6–16.2 |
| <6 mg | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | ||||
| Calcium (mg) | 682 ± 148 | 469–1002 | 1086 ±174 | 845–1375 | 658 ± 121 | 512–917 | 547 ± 145 | 367–920 |
| <1000 mg | 13 (93%) | 6 (43%) | 14 (100%) | 14 (100%) |
| Groups | Standard error | Mean difference | Significance (P ≤ 0.05) | 95% Confidence interval for mean | |
| Lower bound | Upper bound | ||||
| Dentistry versus medicine | 0.775 | −0.536 | 0.489 | −2.06 | 0.99 |
| Dentistry versus arts | 0.632 | −1.784 | 0.005 | −3.02 | −0.54 |
| Dentistry versus computer science | 0.727 | −1.766 | 0.015 | −3.19 | −0.34 |
| Unique region ID | VFDB ID | GIs | Gene | Putative functions | Organisms | % Identity | E-value |
| C8R1 | VFG1693 | GI 1 | int | Prophage P4 integrase | Escherichia coli CFT073 | 33 | 1.1E-45 |
| C10R1 | VFG0893 | - | papA_2 | PapA protein | Escherichia coli CFT073 | 33 | 2.1E-16 |
| C10R1 | VFG0075 | - | InlA | Internalin A | Listeria monocytogenes (serovar 1/2a) EGD-e | 30 | 1.4E-16 |
| C13R2 | VFG0783 | - | intL | Putative integrase for prophage 933L and the LEE pathogenicity island | Escherichia coli O157:H7 EDL933 | 27 | 1.3E-16 |
| C15R4 | VFG0038 | GI 2 | bplA | probable oxidoreductase | Bordetella pertussis Tohama I | 28 | 2.3E-19 |
| C15R4 | VFG0344 | GI 2 | hitC | iron(III) ABC transporter, ATP | Haemophilus influenzae Rd | 33 | 6.7E-23 |
| C15R5 | VFG0082 | - | aldA | aldehyde dehydrogenase | Vibrio cholerae N16961 | 31 | 1.2E-47 |
| C15R6 | VFG0598 | - | intC | Sai integrase | Shigella flexneri (serotype 2a) 301 | 47 | 4.9E-93 |
| C18R3 | VFG0672 | GI 6 | int | integrase | Shigella flexneri (serotype 2a) | 66 | 5E-162 |
| C20R4 | VFG1124 | - | VC1791 | conserved hypothetical protein | Vibrio cholerae N16961 | 41 | 4.2E-39 |
| C20R7 | VFG0925 | - | fepC | Ferric enterobactin transport ATP | Escherichia coli CFT073 | 33 | 2.3E-23 |
| C20R7 | VFG0922 | - | chuU | Putative permease of iron compound ABC transport system | Escherichia coli CFT073 | 39 | 3.8E-29 |
| C20R8 | VFG0358 | - | fyuA/psn | yersiniabactin receptor protein | Yersinia pestis CO92 | 26 | 1.4E-34 |
| C20R8 | VFG0167 | - | pchR | transcriptional regulator PchR | Pseudomonas aeruginosa PAO1 | 41 | 1.1E-26 |
| C26R1 | VFG1102 | GI 12 | hsdM | DNA methylase HsdM | Vibrio cholerae N16961 | 25 | 4.6E-17 |
| C26R1 | VFG1098 | GI 12 | hsdR | type I restriction enzyme HsdR | Vibrio cholerae N16961 | 24 | 1.3E-21 |
| C26R2 | VFG2417 | - | ecpE | hypothetical protein | Escherichia coli O157:H7 EDL933 | 47 | 5.7E-41 |
| C26R2 | VFG2416 | - | ecpD | putative receptor | Escherichia coli O157:H7 EDL933 | 56 | 1.2E-108 |
| C26R2 | VFG2415 | - | ecpC | putative enzyme | Escherichia coli O157:H7 EDL933 | 55 | 8.5E-142 |
| C26R2 | VFG2412 | - | ecpB | hypothetical protein | Escherichia coli O157:H7 EDL933 | 48 | 1.1E-50 |
| C26R2 | VFG2414 | - | ecpA | hypothetical protein | Escherichia coli O157:H7 EDL933 | 57 | 7.2E-44 |
| C26R2 | VFG2044 | - | bvgA | Virulence factors transcription regulator | Bordetella pertussis Tohama I | 47 | 7.7E-53 |
| C27R1 | VFG1433 | GI 13 | csvA | CS7 fimbria major subunit CsvA precursor | Escherichia coli | 39 | 6.8E-22 |
| C27R1 | VFG0584 | GI 13 | yjcC | putative diguanylate cyclase | Salmonella enterica (serovar typhimurium) LT2 | 29 | 4.8E-28 |
| C32R1 | VFG1584 | GI 14 | orf50 | hypothetical protein | Escherichia coli 536 | 26 | 1.9E-13 |
| C32R1 | VFG1584 | GI 14 | orf50 | hypothetical protein | Escherichia coli 536 | 26 | 4.7E-18 |
| C32R2 | VFG1888 | - | letS | sensory box histidine kinase | Legionella pneumophila Philadelphia 1 | 39 | 1.1E-41 |
| C32R2 | VFG0584 | - | yjcC | putative diguanylate cyclase | Salmonella enterica (serovar typhimurium) LT2 | 32 | 6.9E-32 |
| C36R3 | VFG1092 | GI 16 | int3 | integrase, phage family | Vibrio cholerae N16961 | 26 | 9.3E-15 |
| C36R3 | VFG1443 | GI 16 | ompA | outer membrane protein A | Escherichia coli | 38 | 1.8E-54 |
| C36R3 | VFG1548 | GI 16 | prfC | PrfC protein | Escherichia coli 536 | 39 | 1E-164 |
| C36R3 | VFG1547 | GI 16 | prfD | PrfD protein | Escherichia coli 536 | 51 | 2.7E-61 |
| C39R1 | VFG0266 | - | hmbR | hemoglobin receptor | Neisseria meningitidis MC58 (serogroup B) | 31 | 1.4E-45 |
| C39R1 | VFG0266 | - | hmbR | hemoglobin receptor | Neisseria meningitidis MC58 (serogroup B) | 36 | 6.5E-34 |
| HAART years | Mean and standard deviation | Significance |
| 1–3 | 43.4 ± 23.5 | 0.000♣ |
| 4–6 | 29.9 ± 20.1 | |
| 7–10 | 30.8 ± 15.9 | |
| >11 | 23.4 ± 15.5 | |
| Mean and standard deviation | Significance | |
| 1–3 | ||
| 4–6 | 13.5 ± 4.0 | 0.006◆ |
| 7–10 | 12.6 ± 4.5 | 0.048◆ |
| >11 | 20.0 ± 4.5 | 0.000◆ |
| 4–6 | ||
| 1–3 | −13.5 ± 4.0 | 0.006◆ |
| 7–10 | −0.9 ± 4.7 | 1.000◆ |
| >11 | 6.5 ± 4.7 | 0.673◆ |
| 7–10 | ||
| 1–3 | −12.6 ± 5.4 | 0.048◆ |
| 4–6 | 0.9 ± 4.7 | 1.000◆ |
| >11 | 7.4 ± 5.1 | 0.634◆ |
| >11 | ||
| 1–3 | −20.6 ± 4.5 | 0.000◆ |
| 4–6 | −6.4 ± 4.7 | 0.673◆ |
| 7–10 | −7.4 ± 5.1 | 0.634◆ |
| Photoelectric | Detector with CO Sensor | |||
| CO Concentration (ppm) | CO Dose (ppm minute) | CO Concentration (ppm) | CO Dose (ppm minute) | |
| Shortest time of alarm | 576 | 30,859 | 25 | 587 |
| 733 | 31,384 | 38 | 425 | |
| 502 | 17,855 | 53 | 1121 | |
| 639 | 22,690 | 52 | 802 | |
| 643 | 18,985 | 35 | 276 | |
| 993 | 57,893 | 36 | 515 | |
| - | - | 44 | 965 | |
| - | - | 30 | 437 | |
| - | - | 47 | 902 | |
| Mean time of alarm | 664 | 37,593 | 35 | 875 |
| 1453 | 63,957 | 42 | 766 | |
| 638 | 24,371 | 62 | 1236 | |
| 907 | 39,325 | 61 | 965 | |
| 933 | 32,547 | 35 | 315 | |
| 1075 | 64,184 | 37 | 554 | |
| - | - | 46 | 1019 | |
| - | - | 36 | 489 | |
| - | - | 46 | 960 |
| Factors | Weight | Parameters | Weight |
| 1. Environmental background | 0.10 | 1.1 elevation | 0.25 |
| 1.2 Slope | 0.07 | ||
| 1.3 geomorphological types | 0.36 | ||
| 1.4 accumulated temperature (> 0 °C) | 0.11 | ||
| 1.5 wetness index | 0.21 | ||
| 2. Water/land resources | 0.37 | 2.1 precipitation | 0.22 |
| 2.2 river density | 0.11 | ||
| 2.3 land-use types | 0.67 | ||
| 3. Socio-economic development | 0.53 | 3.1 railway density | 0.25 |
| 3.2 road density | 0.13 | ||
| 3.3 population density | 0.62 |
| Hypothesis | Cyt b | 16S | Concatenated |
| Monophyly of “Mixed Genera” and “Parougia” | n.a.1 | 0.501 | n.a.1 |
| Monophyly of “Mixed Genera” and “Ophryotrocha” | 0.097 | n.a.1 | 0.227 |
| Monophyly of Ophryotrocha | 0.003 | 0.010 | 0.001 |
| Monophyly of Ophryotrocha Seep 1 and 2 | n.a.2 | <0.001 | n.a.2 |
| Monophyly of Ophryotrocha Seep 3–5 | 0.229 | n.a.1 | n.a.1 |
| Monophyly of Ophryotrocha Seep 1–5 | n.a.3 | <0.001 | n.a.3 |
| Control (n=10) | MSG (n=10) | P value | ||
| Urine Volume (ml/day) | 26.9 ± 7.2 | 51.5 ± 23.6 | < 0.01 | |
| Urine pH | 6.6 ± 0.6 | 8.7 ± 0.4 | < 0.001 | |
| Sodium (mEq/day) | 1.0 ± 0.5 | 6.1 ± 2.9 | < 0.001 | |
| Potassium (mEq/day) | 4.1 ± 1.2 | 4.8 ± 1.5 | NS | |
| Chloride (mEq/day) | 1.3 ± 0.6 | 1.8 ± 0.7 | NS | |
| Calcium (mg/day) | 3.9 ± 1.2 | 4.1 ± 1.2 | NS | |
| Phosphate (mg/day) | 36 ± 15 | 39 ± 5 | NS | |
| Citrate (mmol/day) | 0.43 ± 13 | 0.77 ± 0.16 | < 0.001 | |
| Ammonium (mmol/day) | 1.41 ± 0.39 | 0.38 ± 0.19 | < 0.001 | |
| Magnesium (mg/day) | 4.1 ± 0.9 | 2.0 ± 1.1 | < 0.001 |
| n | Males | n | Females | |
| Height (cm) | ||||
| Birth | 981 | 48.4(2.7) | 897 | 47.9(2.8) |
| 3 mo | 834 | 58.4(3.1) | 779 | 57.4(3.0) |
| 6.5 y | 874 | 107.0(5.4) | 806 | 106.3(5.5) |
| 15 y | 558 | 150.5(9.0) | 550 | 148.8(6.1) |
| Adult | 981 | 166.4(6.6) | 897 | 153.9(5.9) |
| Weight(kg) | ||||
| Birth | 981 | 2.84(0.49) | 897 | 2.75(0.49) |
| 3 mo | 834 | 4.99(0.82) | 779 | 4.68(0.72) |
| 6.5 y | 874 | 16.0(2.0) | 806 | 15.8(2.0) |
| 15 y | 558 | 35.7(6.7) | 550 | 37.3(6.0) |
| Adult | 981 | 57.2(11.2) | 897 | 49.1(10.4) |
| BMI(kg/m2) | ||||
| Birth | 981 | 12.1(1.8) | 897 | 12.0(1.8) |
| 3 mo | 834 | 14.7(2.1) | 779 | 14.2(1.9) |
| 6.5 y | 874 | 13.9(1.4) | 806 | 14.0(1.4) |
| 15 y | 558 | 15.6(1.5) | 550 | 16.8(2.0) |
| Adult | 981 | 20.6(3.4) | 897 | 20.7(4.0) |
| Adult variables | ||||
| Age (y) | 981 | 28.0(1.0) | 897 | 28.2(0.9) |
| WC (cm) | 981 | 77.3(10.5) | 897 | 70.8(9.4) |
| Hip circumference(cm) | 981 | 86.8(7.3) | 897 | 88.7(8.7) |
| SBP (mm Hg) | 981 | 112.2(11.2) | 897 | 101.4(10.8) |
| DBP (mm Hg) | 981 | 72.7(9.3) | 897 | 72.4(8.6) |
| Total cholesterol (mmol/L) | 981 | 4.0(0.9) | 897 | 3.9(0.8) |
| HDL cholesterol (mmol/L) | 970 | 0.98(0.24) | 893 | 1.09(0.24) |
| LDL cholesterol (mmol/L) | 968 | 2.5(0.7) | 893 | 2.4(0.7) |
| Triglyceride (mmol/L)* | 980 | 1.0(0.8,1.5) | 897 | 0.8(0.6,1.1) |
| Fasting glucose (mg/dL)* | 981 | 98(92,104) | 897 | 96(90,102) |
| 2-h glucose(mg/dL)* | 981 | 110(94,131) | 897 | 115(99,134) |
| Fasting insulin (mIU/mL)* | 981 | 5.7(2.6,9.7) | 897 | 3.2(1.2,6.2) |
| 2-h insulin (mIU/mL)* | 981 | 21.7(11.9,39.1) | 897 | 20.8(10.7,37.3) |
| HOMA-IR* | 981 | 1.35(0.60,2.41) | 897 | 0.77(0.28,1.49) |
| Urban at birth(%) | 981 | 29.7 | 897 | 26.1 |
| Urban as adult(%) | 981 | 45.7 | 897 | 41.8 |
| Education: ≤ primary (%) | 981 | 18 | 897 | 36.7 |
| Education: middle and high (%) | 981 | 57.1 | 897 | 48.9 |
| Education: > high (%) | 981 | 24.9 | 897 | 14.3 |
| Material possessions score | 981 | 5(3.8) | 897 | 5(2.7) |
| Current smoker (%) | 981 | 42.9 | 897 | 2.7 |
| Alcohol consumption: any (%) | 981 | 54 | 897 | 0.8 |
| Physical activity score | 981 | 1407(832,1890) | 897 | 1854(1427,2409) |
| Strategy | Country | Cases | Tests | Prevalence (per 10,000) | CI 95% |
| Intensified monitoring in AS positive flocks | Finland | 0 | 36 | 0 | 0 - 973.9 |
| France | 11 | 14965 | 7.4 | 3.7 - 13.1 | |
| Greece | 0 | 67 | 0 | 0 - 535.7 | |
| Norway | 0 | 75 | 0 | 0 - 480.0 | |
| Portugal | 3 | 4612 | 6.5 | 1.3 - 19.0 | |
| Sweden | 0 | 47 | 0 | 0.0 - 754.9 | |
| Intensified monitoring in CS positive flocks | France | 7 | 31113 | 2.2 | 0.9 - 4.6 |
| Selective culling in AS positive flocks | Belgium | 0 | 223 | 0 | 0 - 164.1 |
| Denmark | 0 | 168 | 0 | 0 - 217.2 | |
| France | 5 | 10462 | 4.8 | 1.6 - 11.1 | |
| Italy | 1 | 2260 | 4.4 | 0.1 - 24.6 | |
| The Netherlands | 0 | 60 | 0 | 0 - 596.3 | |
| Norway | 0 | 1033 | 0 | 0 - 35.6 | |
| Portugal | 2 | 1763 | 11.3 | 1.4 - 40.9 | |
| Selective culling in CS positive flocks | Belgium | 0 | 295 | 0 | 0 - 124.3 |
| France | 4 | 12087 | 3.3 | 0.9 - 8.5 | |
| Greece | 3 | 10310 | 2.9 | 0.6 - 8.5 | |
| Italy | 2 | 8565 | 2.3 | 0.3 - 8.4 | |
| Special genetic selection in AS positive flocks | Italy | 0 | 351 | 0 | 0 - 104.5 |
| Stamping out in AS positive flocks | Denmark | 0 | 17 | 0 | 0 - 1950.6 |
| Finland | 0 | 173 | 0 | 0 - 211.0 | |
| Iceland | 1 | 467 | 21.4 | 0.5 - 118.7 | |
| Italy | 1 | 1309 | 7.6 | 0.2 - 42.5 | |
| Norway | 0 | 1156 | 0 | 0 - 31.9 | |
| Sweden | 0 | 195 | 0 | 0 - 187.4 | |
| Stamping out in CS positive flocks | Iceland | 0 | 367 | 0 | 0 - 100.0 |
| Italy | 0 | 3231 | 0 | 0 - 11.4 | |
| Norway | 0 | 343 | 0 | 0 - 107.0 |
| Attended predictable | Attended unpredictable | Unattended predictable | Unattended unpredictable | |
| Mean | 175.38 | 171.38 | 171.81 | 173.50 |
| Range | 165–182 | 141–187 | 142–188 | 161–181 |
| Texture analysis parameter | Main effects (P value) | Effect interactions (P value) | |||||
| (1) Exp. day | (2) Potency | (3) Replicate | 1-2 | 1-3 | 2-3 | 1-2-3 | |
| Cluster_prominence | <0.0001* | 0.0436 | 0.2143 | 0.0005 | 0.1135 | 0.3126 | 0.1706 |
| Cluster_shade | <0.0001* | 0.0004* | 0.1296 | 0.3264 | 0.2145 | 0.4365 | 0.5069 |
| Correlation | <0.0001* | 0.0039 | 0.5376 | 0.0001* | 0.1567 | 0.0918 | 0.1896 |
| Diagonal_moment | <0.0001* | 0.0002* | 0.0508 | 0.2998 | 0.0943 | 0.6176 | 0.3498 |
| Difference_energy | <0.0001* | 0.0076 | 0.3948 | 0.0040 | 0.2444 | 0.1625 | 0.1077 |
| Difference_entropy | <0.0001* | 0.0059 | 0.5062 | 0.0009 | 0.2248 | 0.1288 | 0.1592 |
| Energy | <0.0001* | 0.0055 | 0.4246 | 0.0143 | 0.3051 | 0.1684 | 0.1437 |
| Entropy | <0.0001* | 0.0150 | 0.2997 | 0.0006 | 0.1970 | 0.1947 | 0.1318 |
| Inertia | <0.0001* | 0.0041 | 0.5262 | 0.0001* | 0.1567 | 0.0978 | 0.1934 |
| Inverse_different_moment | <0.0001* | 0.0024 | 0.0166 | 0.0001* | 0.0893 | 0.2193 | 0.0138 |
| Kappa | <0.0001* | 0.0023 | 0.0112 | <0.0001* | 0.0923 | 0.2521 | 0.0124 |
| Maximum_probability | <0.0001* | 0.0022 | 0.0528 | 0.2930 | 0.1958 | 0.1342 | 0.0886 |
| Sum_energy | <0.0001* | 0.0002* | 0.4163 | 0.0046 | 0.0902 | 0.0397 | 0.3965 |
| Sum_entropy | <0.0001* | 0.0013 | 0.7932 | 0.0001* | 0.1380 | 0.0387 | 0.1780 |
| Sum_variance | <0.0001* | 0.0030 | 0.6470 | <0.0001* | 0.1622 | 0.0507 | 0.1598 |
| nr | Item description | loading | α1 | α2 | ITC |
| Factor 1: Communication with ophthalmologist | 0.89 | ||||
| Q7 | Ophthalmologist treated me with respect | 0.88 | 0.88 | 0.66 | |
| Q8 | Ophthalmologist listened carefully | 0.90 | 0.87 | 0.73 | |
| Q9 | Ophthalmologist explained things clearly | 0.75 | 0.88 | 0.67 | |
| Q10 | Ophthalmologist spent enough time | 0.85 | 0.87 | 0.74 | |
| Q11 | Ophthalmologist went seriously into merits of my questions | 0.81 | 0.87 | 0.78 | |
| Q12 | Ophthalmologist shared decision making | 0.68 | 0.87 | 0.74 | |
| Q13 | Ophthalmologist took specific wishes into account | 0.68 | 0.87 | 0.74 | |
| Q16 | Ophthalmologist talked about things that went wrong | 0.40 | 0.91 | 0.49 | |
| Factor 2: Communication with nurses | 0.72 | ||||
| Q30 | Nurses treat me with respect | 0.84 | 0.66 | 0.56 | |
| Q31 | Nurses listened carefully | 0.84 | 0.59 | 0.63 | |
| Q32 | Nurses explained things clearly | 0.80 | 0.62 | 0.56 | |
| Q38 | Information was adequately coordinated* | 0.41 | 0.76 | 0.41 | |
| Factor 3: Communication about medication | 0.79 | ||||
| Q50 | Questions asked about allergic iodine | 0.91 | 0.69 | 0.65 | |
| Q51 | Questions asked about allergic medication | 0.92 | 0.58 | 0.74 | |
| Q52 | Clear information about side-effects medication | 0.61 | 0.83 | 0.51 | |
| Factor 4: Rest items | 0.52 | ||||
| Q16 | Ophthalmologist talked about things that went wrong | 0.41 | 0.43 | 0.33 | |
| Q38 | Information was adequately coordinated | 0.53 | 0.36 | 0.44 | |
| Q39 | Care was adequately coordinated | 0.57 | 0.36 | 0.40 | |
| Q63 | How often did insurers compensate for costs medication | 0.46 | 0.61 | 0.12 |
| GRADING | ADC | fp | Dp | Dt | |||
| Spearman Correlation Coefficient | GRADING | Correlation Coefficient | 1,000 | ,687* | ,737* | −,326 | ,674* |
| P value | ,000 | ,000 | ,090 | ,000 | |||
| ADC | Correlation Coefficient | ,687* | 1,000 | ,483* | −,128 | ,835* | |
| P value | ,000 | ,006 | ,518 | ,000 | |||
| fp | Correlation Coefficient | ,737* | ,483* | 1,000 | −,615* | ,245 | |
| P value | ,000 | ,006 | ,001 | ,183 | |||
| Dp | Correlation Coefficient | −,326 | −,128 | −,615* | 1,000 | ,290 | |
| P value | ,090 | ,518 | ,001 | ,135 | |||
| Dt | Correlation Coefficient | ,674* | ,835* | ,245 | ,290 | 1,000 | |
| P value | ,000 | ,000 | ,183 | ,135 |
| n | Gender female | Age (years)* | Height (cm)* | Weight (kg)* | BMI (kg/m2)* | |
| Residents | 64 | n = 53 (82.8%) | 83.2 ± 8.1 | 161.9 ± 9.3 | 72.1 ± 16.1 | 27.4 ± 5.4 |
| Caregivers | 29 | n = 29 (100%) | 42.0 ± 11.7 | 166.7 ± 6.2 | 76.3 ± 16.6 | 27.3 ± 5.9 |
| Material | Q4 (%Area) | Q3 (%Area) | Q2 (%Area) |
| FDU-12-H100 | 61.75 | 30.82 | 7.43 |
| FDU-12-H130 | 67.1 | 29.46 | 3.44 |
| FDU-12-H150 | 70.86 | 26.50 | 2.64 |
| FDU-12-H180 | 73.86 | 23.91 | 2.23 |
| FDU-12-H200 | 75.42 | 22.94 | 1.64 |
| CT(A, B) | McTwo | CFS | PAM | RRF |
| McTwo | 0/17/0 | 1/2/14 | 12/1/4 | 15/0/2 |
| CFS | 14/2/1 | 0/17/0 | 16/1/0 | 17/0/0 |
| PAM | 4/1/12 | 0/1/16 | 0/17/0 | 13/0/4 |
| RRF | 2/0/15 | 0/0/17 | 4/0/13 | 0/17/0 |
| Factors analyzed | RAI (−) patients | |
| Risk ratio (CI) | p value | |
| Age (years) | 0.034 (0.000–48.227) | 0.362 |
| Male gender | 1.170 (0.279–4.911) | 0.830 |
| Microscopic ETE | 0.794 (0.096–6.551) | 0.830 |
| Diameter of largest tumor | 0.621 (0.148–2.609) | 0.515 |
| Sum diameter of all tumors | 1.624 (0.388–6.802) | 0.507 |
| LLND bilaterality | 2.070 (0.254–16.892) | 0.497 |
| Multifocality | 1.051 (0.211–5.239) | 0.952 |
| Bilaterality | 0.443 (0.106–1.855) | 0.265 |
| With chronic thyroiditis | 0.895 (0.109–7.360) | 0.918 |
| BRAF mutation | 1.443 (0.177–11.780) | 0.732 |
| Variants of PTMC | 0.595 (0.073–4.842) | 0.628 |
| CLNM Ratio | 12.948 (2.610–64.229) | 0.002 |
| LLNM Ratio | 8.321 (1.234–32.321) | 0.031 |
| Measure | Inclusion (n = 165) | 18 months (n = 156) | 30 months (n = 149) |
| Mean M-HAQ score (median) | 0.93 ± 0.64 (0.875) | 0.42 ± 0.50 (0.25) | 0.35 ± 0.41 (0.25) |
| No. with M-HAQ ≥ 1.0 (%) | 76 (46.1) | 18 (11.6%) | 17 (11.5%) |
| Mean DAS28-3 score (median) | 5.01 ± 1.27 (4.94) | 2.94 ± 1.26 (2.66) | 2.81 ± 1.06 (2.46) |
| No. with DAS28-3 < 2.6 (%) | 5 (3.0) | 76 (48.7) | 82 (55.0) |
| Mean swollen joint count (median) | 12.55 ± 9.57 (10) | 2.83 ± 5.51 (0) | 2.04 ± 3.64 (0) |
| Number without synovitis (%) | n.a. | 72 (46.2) | 82 (55.0) |
| Number with persistent arthritis (%) | n.a. | 137 (87.8) | 125 (83.9) |
| No. fulfilling criteria for RA (%) | 133 (80.6) | 36 (23.1) | 28 (18.8) |
| No. with severe arthritis (%) | 106 (64.2) | 65 (41.7) | 56 (37.8) |
| Mean total SvH score (median) | 6.05 ± 8.38 (4) | 11.34 ± 13.82 (7) | 15.76 ± 18.38 (10) |
| Mean erosion SvH score (median) | 3.02 ± 4.99 (1) | 6.94 ± 9.37 (4) | 10.31 ± 13.14 (7) |
| Upper third of the total SvH score | >5 | >10 | >15 |
| No. on DMARDs (%) | |||
| Total | 31 (18.8) | 120 (76.9) | 116 (77.9) |
| RF-positive | 13/68 (19.1) | 60/63 (95.2) | 60/61 (98.4) |
| Anti-CCP-positive | 10/53 (18.9) | 49/52 (94.2) | 50/51 (98.0) |
| Anti-Sa-positive | 6/46 (13.0) | 43/45 (95.6) | 44/44 (100.0) |
| Groups | I | N | Total |
| H | 5 | 7 | 12 |
| L | 7 | 4 | 11 |
| Total | 12 | 11 | 23 |
| Effect Type | City | |||
| Washington | New York | Chicago | Atlanta | |
| Combined Fallout and Thermal | 188,430 | 1,649,587 | 614,535 | 182,717 |
| Combined Fallout and Blast | 223,570 | 1,733,983 | 637,033 | 207,025 |
| All Thermal categories | 39,641 | 140,701 | 79,451 | 36,256 |
| All Fallout categories | 172,819 | 1,592,968 | 554,048 | 160,224 |
| All Blast categories | 92,040 | 286,587 | 104,988 | 63,814 |
| All Thermal categories | 39,641 | 140,701 | 79,451 | 36,256 |
| > 25 cal cm2 Zone | 1,024 | 12,336 | 11,574 | 1,431 |
| > 13–25 cal cm2 Zone | 963 | 15,303 | 14,685 | 1,810 |
| 3rd Degree Burn Zone* | 3,132 | 20,660 | 12,456 | 5,001 |
| 2nd Degree Burn Zone** | 9,876 | 22,993 | 10,381 | 8,593 |
| 1st Degree Burn Zone | 24,646 | 69,409 | 30355 | 19,421 |
| All Fallout Categories where mortality > 0.5% | 172,819 | 1,592,968 | 554,048 | 160,224 |
| Mortality > 90% | 80,386 | 429,172 | 252,538 | 46,579 |
| > 50–90% | 14,851 | 145,123 | 52,182 | 11,632 |
| > 10–50% | 28,335 | 358,922 | 85,807 | 43,970 |
| > 0.5–10% | 49,247 | 661,177 | 163,521 | 58,043 |
| All Blast categories over 1psi | 92,040 | 286,587 | 104,988 | 63,814 |
| > 20psi | 902 | 8,616 | 4,222 | 961 |
| 10–20psi | 658 | 10,056 | 9,799 | 1,342 |
| 3–10psi | 9,194 | 46,515 | 33,410 | 12,949 |
| 2–3psi *** | 22,532 | 55,126 | 23,360 | 15,278 |
| 1–2psi | 58,754 | 166,274 | 34,197 | 33,284 |
| Cluster | Observed cases | Expected Cases | RR | LLR | P value |
| (a) Without covariate adjustment | |||||
| Most likely cluster | 3388 | 2754.18 | 1.27 | 78.04 | <0.001 |
| Secondary cluster 1 | 496 | 319.35 | 1.57 | 42.43 | <0.001 |
| Secondary cluster 3 | 525 | 382.84 | 1.38 | 24.08 | <0.001 |
| Secondary cluster 4 | 1992 | 1775.27 | 1.13 | 13.84 | <0.001 |
| Secondary cluster 5 | 119 | 71.95 | 1.66 | 12.88 | <0.001 |
| Not significant cluster | 52 | 33.23 | 1.57 | 4.52 | 0.654 |
| (b) With adjustment of race/ethnic status of population | |||||
| Most likely cluster | 4550 | 3843.34 | 1.23 | 74.66 | <0.001 |
| Secondary cluster 1 | 476 | 363.25 | 1.32 | 16.21 | <0.001 |
| Not significant cluster | 119 | 85.39 | 1.40 | 5.91 | 0.26 |
| Not significant cluster | 1209 | 1111.12 | 1.09 | 4.41 | 0.68 |
| Not significant cluster | 713 | 640.85 | 1.12 | 4.04 | 0.80 |
| Not significant cluster | 413 | 370.87 | 1.12 | 2.35 | 1.00 |
| NIHSS | MMSE | ||
| Man, 84 years | He fell when he put his glasses on the small table beside his bed | 5 | 27 |
| Man, 86 years | He fell on his way from the bedroom to the kitchen | 2 | 23 |
| Woman, 73 years | She fell when the door of the elevator hit her | 6 | 29 |
| Man, 77 years | The staff at his nursing home found him on the floor in the bathroom | 2 | 20 |
| Woman, 84 years | She lost the grip and fell when she tried to draw herself up from the wheelchair | 6 | 21 |
| Woman, 94 years | She fell backwards into the wheelchair but it turned over and she fell on the floor | 12 | 15 |
| Man, 89 years | He fell on his way from the bedroom to the kitchen | 0 | 13 |
| Man, 58 years | On his way from the bedroom to the front door, he stumbled on a carpet and fell | 2 | 24 |
| Man, 87 years | He was going to sit down but missed the chair and fell on the floor | 8 | 12 |
| Man, 69 years | He was going to sit down in his wheelchair but missed it and fell on the floor | 4 | — |
| Woman, 87 years | During the night she fell in her home | 2 | — |
| Man, 81 years | He arrived at the hospital after fall in her home | 5 | — |
| Woman, 76 years | She fell in her home and hit her hip | 8 | — |
| Woman, 86 years | She fell from a chair | 3 | — |
| Woman, 83 years | She fell during the evening and hit her hip | 2 | — |
| Woman, 86 years | Unspecified fall. She complained from pain in the right leg | 7 | — |
| Class | Subclass | Pathway |
| Biosynthesis | Polyamines | Betaine biosynthesis |
| Polyamine biosynthesis | ||
| Fatty acids and lipids | Phospholipid biosynthesis | |
| Fatty acid biosynthesis - initial steps | ||
| Fatty acid elongation - saturated | ||
| Cofactors, prosthetic groups, electron carriers | Pyridine nucleotide biosynthesis | |
| Thioredoxin pathway | ||
| Glutathione biosynthesis | ||
| Pantothenate and coenzyme A biosynthesis | ||
| Pyridoxal 5'-phosphate salvage pathway | ||
| Polyisoprenoid biosynthesis | ||
| FormylTHF biosynthesis | ||
| Cell structures | Colanic acid building blocks biosynthesis | |
| GDP-mannose metabolism | ||
| Carbohydrates | Gluconeogenesis | |
| Trehalose degradation - low osmolarity | ||
| Aminoacyl-tRNAs | tRNA charging pathway | |
| Amino acid biosynthesis | Proline biosynthesis I | |
| Glycine biosynthesis I | ||
| Serine biosynthesis | ||
| Degradation | Sugars and polysaccharides | Glucose 1-phosphate metabolism |
| Galactose metabolism | ||
| Trehalose degradation - low osmolarity | ||
| Glycogen degradation | ||
| Ribose degradation | ||
| Other degradation | Removal of superoxide radicals | |
| Nucleosides and nucleotides | (Deoxy)ribose phosphate metabolism | |
| Fatty acids | Fatty acid oxidation pathway | |
| Carboxylates, other | Acetate degradation | |
| Amino acids, amines | L-serine degradation | |
| Alcohols | Glycerol metabolism | |
| Energy metabolism | Pyruvate dehydrogenase | |
| TCA cycle - aerobic respiration | ||
| Glycolysis | ||
| Oxidative branch of the pentose phosphate pathway | ||
| Nonoxidative branch of the pentose phosphate pathway |
| Multiple sclerosis | Normal controls | |
| Number | N = 31 | N = 18 |
| Age (years) (mean ± SD) | 43.3 ± 8.7 | 43.6 ± 8.1 |
| Women, number (%) | 21 (68 %) | 14 (78 %) |
| Disease category, number (%) | ||
| Relapsing-remitting | 26 (84 %) | - |
| Secondary progressive | 4 (13 %) | - |
| Primary progressive | 1 (3 %) | - |
| Disease durationa (years) (mean ± SD) | 9.0 ± 8.3 | - |
| Expanded Disability Status Scale score (mean ± SD) | 2.1 ± 2.1 | - |
| Timed 25-foot walk (mean ± SD) | 6.0 ± 5.2 | - |
| T1 normalized cord area (mm2) (mean ± SD) | 77.7 ± 10.6 | 81.4 ± 7.0 |
| T2 normalized cord area (mm2) (mean ± SD) | 70.2 ± 10.5 | 75.1 ± 9.0 |
| All | Non-C9/GRN | C9orf72 | GRN | |||||
| pTDP-43 | NeuN | pTDP-43 | NeuN | pTDP-43 | NeuN | pTDP-43 | NeuN | |
| Range | 0-308.8 | 0-777.9 | 0.3-195.1 | 0-777.9 | 0-194.2 | 0.1-740.2 | 0.3-308.8 | 0.6-640.7 |
| Median | 14.0 | 118.6 | 16.3 | 149.8 | 15.1 | 99.4 | 10.1 | 39.6 |
| Mean | 28.9 | 148.6 | 30.2 | 190.8 | 25.0 | 126.6 | 39.5 | 110.6 |
| SD | 41.6 | 145.7 | 38.4 | 155.1 | 31.1 | 130.7 | 72.4 | 145.9 |
| PWM | GATA-3 bound sequences | GATA-3 not bound sequences | |||||
| Total hits | TP sequences | FN | Sensitivity | Total hits | Total sequences with hits | TN | |
| New-mono | 45095 | 21289 | 7040 | 75% | 39276 | 19760 | 8569 |
| New-di | 58409 | 23378 | 4951 | 83% | 52897 | 22450 | 5879 |
| Match_minFN | 102257 | 27158 | 1171 | 96% | 97461 | 27071 | 1258 |
| Match_minFP | 673 | 663 | 27666 | 2.38% | 639 | 630 | 27699 |
| Match_minSUM | 14988 | 11436 | 16893 | 43% | 12330 | 9846 | 18483 |
| Study | Conduit | Number of patients | Skeletonized Group | Key Findings | Adverse Events | |||
| Ref | Type | RA/GEA | Skel | Control | Age (Yrs ± S.D.) | Gender M/F | ||
| Kamiya et al [13] | A | GEA | 70 | 98 | 60 ± 9.2 | 51/80 | Significantly increases luminal diameter Composite grafts effective for multiple grafting | No deaths 15 Atrial Fibrillation |
| Rukosujew et al [21] | A | RA | 20 | 20 | n/a | N/a | Significantly increases harvesting time Length significantly increased by skeletonization with scissors Endothelial damage seen in all groups | Not recorded |
| Amano et al [12] | B | RA | 131 | 112 | 65.8 ± 8.9 | 102/80 | Proximal diameter of RA significantly larger in skeletonized conduits Significant increase in sequential RA grafting | 2 MI, 2 Respiratory Failures, 4 CVA, 2 Mediastinitis, 2 Deaths |
| Li et al [20] | C | GEA | 59 | 21 | 66.7 ± 8.8 | 46/19 | No significant difference in harvest time or number of distal anastomoses | 1 CVA, 1 Respiratory Failure, 1 Death |
| Kamiya et al [23] | C | GEA | 168 | 60 | 65 ± 11.5 | 131/47 | Functional patency significantly better in skeletonized group | 20 Atrial Fibrillation, 1 MI, 2 Re-exploration for bleeding |
| Trial Characteristics | Percent (number) of Trials |
| Study Type | |
| Individual patient RCT | 76.25% (61/80) |
| Factorial RCT | 6.25% (5/80) |
| Cluster RCT | 17.5% (14/80) |
| Number of study arms | |
| Two | 83.75% (67/80) |
| Three | 7.5% (6/80) |
| Four | 8.75% (7/80) |
| Patient Population | |
| Adults | 91.25% (73/80) |
| Children | 6.25% (5/80) |
| Infants | 1.25% (1/80) |
| Mixed (Adults & Children) | 1.25% (1/80) |
| Study Intervention | |
| Drug | 46.25% (37/80) |
| Surgery | 8.75% (7/80) |
| Education | 10.0% (8/80) |
| Other | 27.5% (22/80) |
| Procedure | 3.75% (3/80) |
| Weight loss | 3.75% (3/80) |
| Funding Source | |
| Academic | 73.75% (59/80) |
| Industry | 26.25% (21/80) |
| Trial start-up meeting described | 8.75% YES (7/80) |
| Trial run-in phase described | 8.75% YES (7/80) |
| GCP adherence reported | 6.25% YES (5/80) |
| Lead Investigator reports previous research experience | 62.5% YES (50/80) |
| Trial results | |
| Harm | 2.5% (2/80) |
| Neutral | 32.5% (26/80) |
| Positive | 65.0% (52/80) |
| Management structure | |
| MC, SC & others (explicit structure) | 26.25% (21/80) |
| MC or SC only (basic structure) | 21.25% (17/80) |
| Not reported | 52.8% (42/80) |
| Primary cultures | ||||
| Gene | oJIA (n = 12) | pJIA (n = 4) | ||
| Day 14 | Day 21 | Day 14 | Day 21 | |
| Runx2 | 0.02 (0.01-0.07) | 0.05 (0.02-0.11) | 0.00 (0.00-0.01) | 0.02 (0.00-0.05) |
| P (vs. pJIA) | 0.02 | 0.18 | ||
| P (vs. day 21) | 0.20 | 0.34 | ||
| OPG | 1.63 (0.39-5.65) | 13.99 (8.22-21.82) | 0.68 (0.40-1.48) | 1.52 (0.50-5.68) |
| P (vs. pJIA) | 0.47 | 0.03 | ||
| P (vs. day 21) | 0.001 | 0.49 | ||
| RANKL | 0.08 (0.00-0.16) | 0.18 (0.04-0.50) | 0.12 (0.03-0.20) | 0.16 (0.06-0.20) |
| P (vs. pJIA) | 0.54 | 0.90 | ||
| P (vs. day 21) | 0.42 | 0.89 | ||
| P4 cultures | ||||
| oJIA (n = 7) | pJIA (n = 4) | |||
| Day 10 | Day 14 | Day 10 | Day 14 | |
| Runx2 | 0.04 (0.02-0.08) | 0.03 (0.02-0.05) | 0.02 (0.01-0.02) | 0.02 (0.01-0.03) |
| P (vs. pJIA) | 0.02 | 0.32 | ||
| P (vs. day14) | 0.46 | 0.20 | ||
| OPG | 0.07 (0.04-0.08) | 0.12 (0.08-0.20) | 0.04 (0.01-0.06) | 0.04 (0.01-0.06) |
| P (vs. pJIA) | 0.23 | 0.01 | ||
| P (vs. day14) | 0.04 | 0.89 | ||
| RANKL | 0.01 (0.01-0.03) | 0.01 (0.01-0.04) | 0.00 (0.00-0.00) | 0.01 (0.00-0.01) |
| P (vs. pJIA) | 0.04 | 0.23 | ||
| P (vs. day14) | 0.53 | 0.06 |
| Transmission route | Cases (n = 30) | Controls(n = 50) | Odds ratio | 95% Confidence intervals | P value |
| Blood transfusion (without proper screening) | |||||
| • Yes | 11 | 7 | 3.56 | 1.061–12.220 | 0.038 |
| • No | 19 | 43 | 1.00 | (Reference) | |
| Mutual sharing of house hold contents | |||||
| • Yes | 25 | 42 | 7.50 | 2.217–26.946 | 0.0001 |
| • No | 05 | 08 | 1.00 | (Reference) | |
| Surgery history | |||||
| • Positive | 9 | 5 | 3.86 | 1.009–15.374 | 0.048 |
| • Negative | 21 | 45 | 1.00 | (Reference) | |
| Dental treatment | |||||
| • Yes | 12 | 11 | 3.87 | 1.192–12.827 | 0.021 |
| • No | 18 | 39 | 1.00 | (Reference) |
| Targeted protein | Peptide number | Sequence | Specificity Tm.I/Tm.II# | Global proteomics 2007 study (Bertin et al., 2011) | Cell cultures | 2007 COWG | 2009 COWG | 2009 COWG | 2011 COWG | 2012 COWG |
| AioA | 1 | ACVVNQGLSSTR | Tm.I/Tm.II | X | CB1, CB2, CB3, CB6 | X | – | – | – | – |
| 2 | IQIFPAK | Tm.II (Carn2_0821 only)* | X | – | – | – | – | – | – | |
| 3 | DFIANHTEGFDAAVK | Tm.II (Carn2_1469 only)* | – | – | – | – | – | – | – | |
| 4 | DFIANHTEGFEAAVK | Tm.II (Carn2_0821, Carn2_1330) | – | – | – | – | – | – | – | |
| 5 | FWINNGR | Tm.I/Tm.II | X | CB1, CB2, CB6 | X | – | – | – | – | |
| 6 | YPAADFPIPR | Tm.I/Tm.II | X | CB1, CB2, CB3, CB6 | X | X | X | X | X | |
| 7 | YPASSVPIPR | T. intermedia K12 (Tm.I) | – | – | – | – | – | – | – | |
| 8 | DFIAQHTEGFEAAVK | Tm.I | – | – | – | – | – | – | – | |
| 9 | IQVFPAK | Tm.I/Tm.II | – | CB1, CB2, CB3, CB6 | X | – | – | – | – | |
| 10 | ITGVPVAQIK | Tm.I/Tm.II | X | CB1, CB2, CB3, CB6 | X | X | X | X | X | |
| 11 | LIFTGIQTPTVR | Tm.I/Tm.II | X | CB2, CB3, CB6 | X | X | X | X | X | |
| AioB | 12 | AVAVTGLIYGR | Tm.I/Tm.II | X | CB1, CB6 | X | X | X | X | X |
| RpoA | 13 | SETELLK | Tm.I/Tm.II | – | CB1, CB2, CB3, CB6 | X | – | – | – | – |
| 14 | SIGHIVLDASFSPVR | Tm.I | – | – | – | – | – | – | – | |
| 15 | SIQVEALGPLR | Tm.II | X | – | – | X | X | X | X | |
| 16 | SIQVESLGHNR | Tm.I | – | – | – | – | – | – | – |
| No type 2 diabetes (n = 609) | Type 2 diabetes (n = 253) | p-value | |
| Age, years | 58 ± 8.6 | 64 ± 7.0 | < 0.001 |
| Male sex, n (%) | 296 (49 %) | 176 (70 %) | < 0.001 |
| Partner, n (%) | 515 (85 %) | 208 (85 %) | 0.98 |
| Educational level, % low/middle/high | 12/39/49 | 28/47/25 | <0.001 |
| HbA1c, % | 5.65 ± 0.37 | 6.91 ± 0.88 | < 0.001 |
| Diabetes duration, years | - | 7 [3–11] | |
| Diabetes medication, % no/oral/insulin | - | 22/57/21 | |
| Smoking, % never/former/current | 34/49/17 | 22/64/14 | |
| Pack years | 4 [0–18] | 15 [0–33] | < 0.001 |
| Body mass index, kg/m2 | 26.3 ± 4.0 | 29.8 ± 4.7 | < 0.001 |
| Systolic blood pressure, mmHg | 133 ± 18 | 146 ± 19 | < 0.001 |
| Diastolic blood pressure, mmHg | 76 ± 10 | 78 ± 10 | 0.004 |
| Total cholesterol, mmol/l | 5.5 ± 1.1 | 4.4 ± 1.0 | < 0.001 |
| HDL cholesterol, mmol/l | 1.40 ± 0.41 | 1.12 ± 0.40 | < 0.001 |
| LDL cholesterol, mmol/l | 3.5 ± 1.0 | 2.6 ± 0.9 | < 0.001 |
| Triglycerides, mmol/l | 1.3 ± 0.9 | 1.8 ± 1.0 | < 0.001 |
| Primary clinical diagnostic category | All diagnoses included in primary clinical diagnostic categories |
| I. Non-Proliferative* | Non-Proliferative only |
| Fibroadenoma | |
| II. Proliferative changes without atypia | Usual ductal hyperplasia |
| Columnar cell hyperplasia/columnar cell changes | |
| Sclerosing adenosis | |
| Radial Scar/complex sclerosing lesion | |
| Flat epithelial atypia | |
| Intraductal papilloma w/o atypia | |
| III. Atypical ductal hyperplasia (ADH) | Atypical ductal hyperplasia |
| Intraductal papilloma with atypia | |
| IV. Ductal carcinoma in situ (DCIS) | Ductal carcinoma in situ |
| V. Invasive breast cancer | Invasive (ductal or lobular or other special type) |
| Genotype | Case Number | Percentage (%) |
| CYP2D6*2 | 74 | 100 |
| CC | 59 | 79.7 |
| CT | 9 | 12.1 |
| TT | 6 | 8.1 |
| CYP2D6*10 | 83 | 100 |
| CC | 16 | 19.3 |
| CT | 8 | 9.6 |
| TT | 59 | 71.1 |
| CYP1A2*1C | 66 | 100 |
| GG | 38 | 59.6 |
| GA | 21 | 31.8 |
| AA | 7 | 10.6 |
| CYP1A2*1 F | 77 | 100 |
| CC | 33 | 42.9 |
| CA | 11 | 14.3 |
| AA | 33 | 42.9 |
| Univariate analysis | Multivariate analysis | |||
| HR (95 % CI) | P-value | HR (95 % CI) | P-value | |
| Control | Reference | |||
| HBV | 1.291 (0.635-2.624) | 0.481 | 1.321 (0.612-2.850) | 0.479 |
| HCV | 3.425 (1.752-6.697) | <0.001 | 2.623 (1.289-5.338) | 0.008 |
| HBV+HCV | 9.273 (2.793-30.788) | <0.001 | 9.401 (2.691-32.841) | <0.001 |
| Age, per year | 1.025 (1.007-1.043) | 0.005 | 1.034 (1.013-1.054) | 0.001 |
| HCC | 3.361 (1.212-9.322) | 0.020 | 1.790 0.598-5.356) | 0.298 |
| Baseline LFTAbnormalitya | 2.702 (1.526-4.784) | 0.001 | 2.331 (1.238-4.390) | 0.009 |
| Feature | FluxTransgenics | Phytotracker | QTreds |
| Operational system | Web Application, can be accessed from any OS. | Mac OS or Microsoft Windows. | Web Application, can be accessed from any OS. |
| Data storage | MySQL Relational Database. | FileMaker Pro. | MySQL Relational Database. |
| Process support | Most laboratory processes. Adaptable to any workflow. | Pre-defined workflow. | Adaptable to any workflow. |
| Access control | Permissions are granted to user or roles. Roles, or groups, can be created by administrator user. | Permissions are granted only to users. The concept of roles is non existent. | Permissions are granted to user or roles. But the roles are fixed (cannot be created). |
| Genetic characteristic | Frequency,% |
| VKORC1 (N = 96) | |
| Gene | |
| GG (wild type) | 84 (87.5) |
| GA | 12 (12.5) |
| AA | – |
| Allele | |
| G | 180 (93.8) |
| A | 12 (6.2) |
| CYP4F2 (N = 116) | |
| Gene | |
| CC (wild type) | 28 (24.1) |
| CT | 80 (69.0) |
| TT | 8 (6.9) |
| Allele | |
| C | 136 (58.6) |
| T | 96 (41.4) |
| CYP2C9*2 (N = 86) | |
| Gene | |
| CC (wild type) | 86 (100) |
| CT | – |
| TT | – |
| Allele | |
| C | 172 (100) |
| T | – |
| CYP2C9*3 (N = 84) | |
| Gene | |
| AA (wild type) | 84 (100) |
| AC | – |
| CC | – |
| Allele | |
| A | 168 (100) |
| C | – |
| Variable | PC1 | PC2 | PC3 |
| Feeding score in glass-house (Day 7) | 0.278 | –0.245 | 0.065 |
| Feeding score in glass-house (Day 13) | 0.239 | –0.305 | 0.014 |
| In vitro M-C feeding damage (12 h) | 0.175 | 0.003 | –0.304 |
| In vitro T-C feeding damage (12 h) | 0.235 | –0.018 | 0.237 |
| Glucoiberin | –0.265 | 0.194 | 0.221 |
| Progoitrin | 0.247 | 0.372 | –0.070 |
| Glucoraphanin | 0.286 | –0.019 | 0.328 |
| Sinigrin | –0.172 | 0.318 | 0.342 |
| Gluconapin | 0.227 | –0.201 | 0.411 |
| Glucoiberverin | –0.233 | 0.242 | 0.264 |
| Glucoerucin | 0.295 | 0.274 | –0.046 |
| 4-Hydroxyglucobrassicin | 0.296 | 0.266 | 0.027 |
| Glucobrassicin | –0.288 | 0.145 | 0.092 |
| 4-Methoxyglucobrassicin | –0.087 | –0.097 | 0.494 |
| Neoglucobrassicin | 0.177 | –0.228 | 0.250 |
| Total glucosinolate | 0.257 | 0.352 | 0.099 |
| % Variation explained | 48.2 | 20.3 | 13.0 |
| P-value | <0.001 | <0.001 | <0.001 |
| Cabbage lines | Mean PC scores (±SD) | ||
| Rubra | 1.71 ± 0.51 b | –2.23 ± 0.18 e | 1.67 ± 0.42 a |
| YR gold | 3.61 ± 0.60 a | 2.29 ± 0.37 a | –0.34 ± 0.65 b |
| Ohgane | –1.30 ± 0.14 cd | –1.17 ± 0.03 d | –1.87 ± 0.23 c |
| BN3383 | –0.34 ± 0.28 c | –1.35 ± 0.05 d | –2.05 ± 0.63 c |
| BN4059 | –4.66 ± 0.38 g | 2.57 ± 0.23 a | 2.15 ± 0.16 a |
| BN4072 | –2.33 ± 0.11 de | 0.09 ± 0.06 c | –0.25 ± 0.31 b |
| BN4098 | –2.97 ± 0.15 ef | 0.05 ± 0.13 c | 0.33 ± 0.04 b |
| BN4303 | –4.00 ± 0.04 fg | 0.96 ± 0.03 b | –0.25 ± 0.36 b |
| ASAQ | AL | |
| No. of included patients (intention-to-treat) | 62 | 61 |
| PCR-uncorrected responses on day 28 | ||
| Withdrawn or lost to follow up: N; % (95 % CI) | 7; 11.3 (4.7–21.9) | 9; 14.8 (7.0–26.2) |
| Per protocol population: N; % (95 % CI) | 55; 88.7 (78.1–95.3) | 52; 85.2 (73.8–93.0) |
| Failures: N; % (95 % CI) | 4; 7.3 (2.0–17.6) | 4; 7.7 (2.1–18.5) |
| ETF: N; % (95 % CI) | 0; 0 (0–5.8) | 1; 1.9 (0–10.3) |
| LCF: N; % (95 % CI) | 1; 1.8 (0–9.7) | 1; 1.9 (0–10.3) |
| LPF : N; % (95 % CI) | 3; 5.5 (1.1–15.1) | 2; 3.8 (0.5–13.2) |
| ACPR: N; % (95 % CI) | 51; 92.7 (82.4–98.0) | 48; 92.3 (81.5–97.9) |
| PCR-corrected responses on day 28 | ||
| Withdrawn + lost-to-follow-up + censured due to new infections: N; % (95 % CI) | 11; 17.7 (9.2–29.5) | 12; 19.7 (10.6–31.8) |
| Per protocol population: N; % (95 % CI) | 51; 82.3 (70.5–90.8) | 49; 80.3 (68.2–89.4) |
| ETF: N; % (95 % CI) | 0; 0 (0–7.0) | 1; 2.0 (0.1–10.9) |
| Recrudescence: N; % (95 % CI) | 0; 0 (0–7.0) | 0; 0 (0–7.2) |
| ACPR: N; % (95 % CI) | 51; 100 (93.0–100) | 48; 98.0 (89.1–99.9) |
| New infections: n/N (%) | 4/4 (100) | 3/3 (100) |
| <1 y | 1-4 y | 5-9 y | 10-14 y | 15-19 y | 20-29 y | ||
| n=62 (%) | n=75 (%) | n=10 (%) | n=9 (%) | n=35 | n=41 | n=52 | |
| Bronchopneumonia (n=227) | 46 (74.2%) | 61 (81.3%) | 9 (90.0%) | 7 (77.8%) | 29 (82.9%) | 35 (85.4%) | 40 (76.9%) |
| Diarrhea (n=111) | 33 (53.2%) | 32 (42.7%) | 3 (30.0%) | 3 (33.3%) | 8 (22.9%) | 12 (29.3%) | 20 (38.5%) |
| Cough with expectoration (n=32) | 1 (1.6%) | 6 (17.1%) | 12 (29.3%) | 13 (25.0%) | |||
| Otitis (n=8) | 4 (6.4%) | 3 (4.0%) | 1 (1.9%) | ||||
| Laringitis (n=8) | 1 (1.6%) | 1 (1.3%) | 1 (2.9%) | 3 (7.3%) | 2 (3.8%) | ||
| Febrile convulsions (n=4) | 4 (5.3%) | ||||||
| Epistaxis (n=2) | 2 (4.9%) | ||||||
| Chronic bronchitis (n=5) | 3 (4.8%) | 2 (2.7%) | |||||
| Asthma (n=4) | 1 (1.6%) | 1 (1.3%) | 2 (3.8%) | ||||
| Epilepsy (n=2) | 1 (1.3%) | 1 (11.1%) | |||||
| Psychomotor retardation (n=2) | 1 (1.3%) | 1 (2.4%) | |||||
| Pregnancy (n=9) | 6 (14.6%) | 3 (5.8%) |
| SKO | ||
| WASI matrix reasoning | 18/32 (T = 49) | |
| Digit span forwards | 3 digits | |
| Repetition | 63/90 | |
| Reading [from Brown and Ure (1969)] | 11/72 | |
| Graded non-word reading test | 0/20 | |
| Spoken non-word–written non-word match | ||
| Level I (e.g., bep-civ) | 7/10 | |
| Level II (e.g., bem-bav) | 5/10 | |
| British picture vocabulary scale (short) | 26/32 | |
| Pyramid and palm trees test | ||
| 3 pictures | 45/52 | |
| 3 written words | 34/52 | |
| McKenna and Warrington (1978) | ||
| Naming | Animals | 3/10 (30%) |
| Man-made artifacts | 3/10 (30%) | |
| Colors | 2/10 (20%) | |
| Body part | 3/10 (30%) | |
| Countries | 9/10 (90%) | |
| TOTAL | 20/50 (40%) | |
| Comprehension | Animals | 10/10 (100%) |
| Man-made artifacts | 10/10 (100%) | |
| Colors | 7/10 (70%) | |
| Body part | 6/10 (60%) | |
| Countries | 10/10 (100%) | |
| TOTAL | 43/50 (86%) |
| Flow type | The flow is fast and in vasculitis direction and velocity are important for diagnosis |
| PRF and wall filters | Different PRF for different vessels: |
| Temporal and facial arteries, PRF range = 2–3.5 kHz | |
| Carotis, subclavian and axillary arteries, PRF range = 3–4 kHz | |
| Vertebral and occipital arteries, PRF range = 0.7–1.5 kHz | |
| High PRF ensures display of correct flow direction and velocity | |
| Wall filters are linked controls and with a high PRF, the wall filter will also be high to eliminate motion artefacts from moving arterial walls | |
| Choice of Doppler | CD as it displays the mean blood velocity |
| Spectral Doppler for indicating correct insonation angle and for calculating the correct velocity of the flow | |
| Doppler frequency | Optimal frequency varies according to the location of the vessel |
| Higher for temporal arteries lower for the larger arteries because of penetration | |
| Gain | Gain should be adjusted according to noise level for both CD and spectral Doppler but with a minimum of blooming |
| Colour priority | If adjustable, then it should be kept high to ensure Doppler filling in the vessel |
| Focus | At the level of region of interest to ensure optimal Doppler sensitivity |
| Parameter | Logistic Regression | ||
| Odds Ratio | 95% CI | P-value | |
| Women's age (years) | 0.96 | 0.87 to 1.06 | 0.44 |
| Men's age (years) | 0.98 | 0.91 to 1.05 | 0.61 |
| Duration of infertility (years) | 0.81 | 0.63 to 1.03 | 0.10 |
| MSOME (%)-Normal spermatozoa | 1.28 | 1.08 to 1.51 | 0.003 |
| Follicles ≥17 mm (n) | 1.40 | 0.53 to 3.68 | 0.49 |
| DNA fragmentation (%) | 0.97 | 0.97 to 1.02 | 0.26 |
| Total sperm count (x106/ml) | 1.00 | 0.99 to 1.01 | 0.59 |
| Motility (% spermatozoa)(rapid + slow progression) | 0.98 | 0.96 to 1.01 | 0.13 |
| Leukocytes (x106) (mean ± SD) | 1.77 | 0.46 to 6.70 | 0.39 |
| Facilitators | N | Barriers | N |
| Concern over impacts of smoking on children’s health | 22 | Light smoking | 10 |
| Economic concern | 20 | Refusal of use of smoking cessation aids | 9 |
| Different smoking environment between China and Canada | 22 | Having friends or colleagues who smoke | 7 |
| Smoking cessation supports from wives and other people | 14 | Difficulty in getting rid of the habit | 6 |
| Smoking cessation supports from health professionals | 8 | The need for coping stress, and killing time | 8 |
| Concern over impacts of smoking on own health | 11 |
| Position and academic responsibility | All (n = 993) | Community-based (n = 294) | DGH-based (n = 412) | Tertiary (n = 279) |
| Consultants | 84% | 60% | 96% | 96% |
| Non-consultant career grades | 12% | 34% | 4% | 1% |
| Other positions | 4% | 6% | 1% | 4% |
| With academic responsibility | 18% | 9% | 10% | 36% |
| Parameter | n (%) |
| Operational procedure | |
| TEA | 22 (40.7) |
| Thrombectomy/embolectomy | 14 (25.9) |
| Bypass | 13 (24.1) |
| Resection of the dissection membrane | 11 (20.3) |
| SMA-transposition | 7 (13.0) |
| Visceral surgery | 8 (14.8) |
| Explorative laparotomy | 3 (5.6) |
| Cause of occlusion | |
| Arterial embolism | 16 (29.6) |
| Arteriosclerosis combined with local thrombosis | 13 (24.0) |
| Arterial thrombosis | 12 (22.2) |
| Arterial dissection | 9 (16.7) |
| Local dissection | 2 (3.7) |
| Unclear cause of occlusion | 2 (3.7) |
| DNA Source | Position in MYD88 Exon 5 Amplicon | |||||||
| 19t | +58g | +1245a | +1524t | |||||
| SMRT | Illumina | SMRT | Illumina | SMRT | Illumina | SMRT | Illumina | |
| Tumor DLBCL773 | 8t + 65C | 8t + 22C | 73g | All g | 3a + 70G | 1G | 73t | No reads |
| Tumor DLBCL778 | 17t + 73C | 5t + 44C | 90g | All g | 90a | No reads | 90t | No reads |
| Tumor DLBCL799 | 26t + 29C | 16t + 21C | 37g + 18T | 5g + 4T | 55a | No reads | 55t | No reads |
| Tumor DLBCL816 | 88t + 19C | 8t + 3C | 107g | All g | 53a + 54G | No reads | 107t | No reads |
| Tumor DLBCL894 | 165t + 50C | 27t + 14C | 215g | All g | 315a | No reads | 315t | No reads |
| Tumor DLBCL832 | 75t | All t | 75g | All g | 75a | No reads | 75t | No reads |
| Cell line Ly3 | 79C | 2t + 10C | 79g | All g | 79G | No reads | 63t + 16A | No reads |
| Cell line Ly10 | 16t + 28C | 7t + 5C | 44g | All g | 16a + 28G | No reads | 44t | No reads |
| Cell line SKI | 310t | All t | 310g | All g | 151a + 159G | No reads | 310t | No reads |
| Cell line Karpas422 | 11t | All t | 11g | All g | 11a | No reads | 11t | 2t |
| Cell line Ly1 | 121t | All t | 121g | All g | 121a | No reads | 121t | No reads |
| Placebo | Rapid CORT | Slow CORT | |
| Reaction times neutral, in ms | 674(17) | 702(23) | 650(20) |
| Reaction times aversive, in ms | 687(17) | 709(23) | 664(20) |
| Emotional interference on reaction times, in Δms | 12(7) | 7(7) | 14(6) |
| Correct responses neutral, in % | 95.03(1.03) | 95.29(0.64) | 96.63(0.64) |
| Correct responses aversive, in % | 95.24(0.90) | 93.96(0.77) | 96.80(0.63) |
| Emotional interference on correct responses, in Δ% | 0.21(0.44) | −1.33(0.50)* | 0.17(0.77) |
| – | – | – | – |
| Factor | ||||
| Items | 1 | 2 | 3 | |
| 5. | Did you understand the method for border molding at the buccal side? | .957 | .029 | −.087 |
| 7. | Did you understand the method for border molding at the lingual side? | .953 | −.095 | .010 |
| 4. | Did you understand the method for border molding at the retromolar pad? | .821 | .077 | −.053 |
| 3. | Did you understand how to adjust the custom trays? | .649 | .113 | −.039 |
| 9. | Did you understand the mobility of mucosa? | .643 | −.292 | .134 |
| 1. | Did you understand how to use the impression material? | .588 | .061 | −.080 |
| 8. | Did you understand the image of the denture shapes? | .449 | .058 | .231 |
| 2. | Did you understand how to use the alcohol torch? | .446 | .129 | .117 |
| 19. | Is practical training well organized? | −.113 | .794 | −.052 |
| 13. | Did you understand the instructions of the teacher? | .083 | .738 | −.094 |
| 21. | Do you value practical training overall? | .161 | .645 | .046 |
| 20. | Is practical training easily comprehensible? | −.004 | .606 | .106 |
| 12. | Was the level of practical training appropriate for students? | −.059 | .538 | .140 |
| 15. | Did you find proper literature and references? | .061 | −.081 | .840 |
| 14. | Did you prepare for or review practical training? | −.027 | .032 | .785 |
| 16. | Are you satisfied with what you have learned? | −.046 | .168 | .652 |
| Interfactor correlation | ||||
| 1 | – | .339 | .459 | |
| 2 | – | .449 | ||
| 3 | – | |||
| Percent of variance explained | 33.309 | 13.669 | 6.813 | |
| Cronbach’s alpha | .893 | .800 | .818 | |
| Mean | 3.700 | 4.390 | 3.380 | |
| SD | .991 | .748 | 1.040 |
| Characteristic | % |
| Males | 67.3 |
| Age, median (range) | 40 (21–79) |
| Education level* | |
| Less than high school | 31.4 |
| High school | 39.2 |
| College | 29.4 |
| Employment status* | |
| Employed | 25.0 |
| Unemployed | 75.0 |
| Alcohol use* | 51.5 |
| Intravenous drug use* | 34.4 |
| Clinical AIDS | 9.5 |
| CD4 count <200 cells/μL* | 41.8 |
| Received antiretroviral treatment | 64.4 |
| Anemia: Hb < 12 g/dL women, < 13 g/dL men | 41.5 |
| Variable | No | ΔCt (Mean ± SD) | |
| SAA1 | SAA4 | ||
| NNL tissues | 10 | 7.64 ± 2.02 | 13.63 ± 3.11 |
| CC tissues | 21 | 2.85 ± 3.02 | 9.12 ± 3.05 |
| ΔΔCt | 4.79 (P < 0.000) | 4.51 (P = 0.001) | |
| 2ΔΔCt | 27.67 | 22.78 |
| Gene Set | Number of Genes in Original Set | Number of Genes Present in GWAS Data | Number of SNPs Present in GWAS Data | Self-Contained p-Value (α = 2.8 × 10−3) | Competitive p-Value (α = 0.05) |
| All synaptic genes | 1028 | 956 | 61413 | 0.0393 * | 0.1733 |
| Ion balance/transport | 43 | 40 | 1454 | 0.0118 | NA |
| Cell metabolism | 57 | 51 | 1059 | 0.0429 | NA |
| Endocytosis | 26 | 26 | 1075 | 0.0554 | NA |
| Cell adhesion and trans-synaptic signaling | 81 | 76 | 13550 | 0.0709 | NA |
| Exocytosis | 87 | 83 | 4855 | 0.0962 | NA |
| Protein cluster | 47 | 42 | 4182 | 0.1491 | NA |
| Peptide/neurotrophin signals | 28 | 25 | 1742 | 0.1659 | NA |
| Structural plasticity | 98 | 90 | 4655 | 0.1764 | NA |
| Tyrosine kinase signaling | 7 | 7 | 1281 | 0.2030 | NA |
| Neurotransmitter metabolism | 29 | 27 | 1059 | 0.2959 | NA |
| RNA and protein synthesis, folding and breakdown | 71 | 64 | 1152 | 0.4994 | NA |
| Ligand-gated ion channel signaling | 36 | 32 | 2935 | 0.6500 | NA |
| G-protein-coupled receptor signaling | 41 | 40 | 3129 | 0.6578 | NA |
| Unassigned | 61 | 53 | 2258 | 0.6644 | NA |
| Intracellular signal transduction | 150 | 145 | 9563 | 0.7001 | NA |
| G-protein relay | 27 | 25 | 946 | 0.7047 | NA |
| Intracellular trafficking | 80 | 75 | 2024 | 0.7334 | NA |
| Excitability | 59 | 56 | 4508 | 0.7914 | NA |
| Perdriolle degree difference | JIS (R2 = 0.40) | AIS (R2 = 0.29) | ||||
| Independent variables | B coefficient | Standard error | p | B coefficient | Standard error | p |
| Complete (reference) | - | - | - | - | - | |
| Adherence | Incomplete A | 1.92 | 1.19 | 0.109 | 1.35 | 0.78 |
| Incomplete B | 4.23 | 0.89 | 0.000 | 3.97 | 0.56 | |
| Incomplete C | 3.35 | 1.22 | 0.007 | 1.94 | 0.44 | |
| Incomplete D | 4.65 | 1.27 | 0.000 | 2.46 | 0.54 | |
| Gender | 2.15 | 1.29 | 0.099 | 0.18 | 0.58 | |
| Age baseline | 0.18 | 0.31 | 0.558 | 0.09 | 0.13 | |
| Length of treatment | 0.05 | 0.01 | 0.001 | 0.05 | 0.01 | |
| Perdriolle at baseline | −0.04 | 0.08 | 0.633 | -0.02 | 0.04 | |
| Type of brace | Lyon (Reference) | - | - | - | - | - |
| Milwaukee | −0.18 | 1.08 | 0.865 | 0.21 | 0.52 | |
| Pasb | −0.47 | 1.09 | 0.669 | −0.93 | 0.34 |
| Disease | Underlying Disease(s) | Incidence/Prevalence Used to Estimate Burden | Comments | Reference |
| Oesophageal candidiasis | HIV/AIDS | 22% of patients with CD4 counts <200 × 106/mL and 5% of ARV-treated patients | [17] | |
| Candidaemia | Multiple hospitalized patients | 5/100,000 population, 33% occurring in intensive care | Few patients managed in ICU currently. | [18] |
| Candida peritonitis | Major abdominal surgery, pancreatitis | 50% of the ICU population with candidaemia | [19] | |
| Recurrent vaginal candidiasis ( | Pre-menopausal women | 6% prevalence | Based on mean self-reported disease in Europe and US, reduced by 33% because of incorrect diagnosis. | [20] |
| Allergic bronchopulmonary aspergillosis | Asthma | 2.5% of adults with asthma | Rare in children | [21] |
| Severe asthma with fungal sensitisation | Severe asthma | 33% of the 10% of the most severe adult asthmatics | Uncommon in children. Fungal sensitization prevalence not known for Cameroon. | [22] |
| Chronic pulmonary aspergillosis | Tuberculosis (TB), COPD, prior pneumothorax, asthma, lung surgery | 22% of patients with a cavity of pulmonary TB survivors (22%), 2% of those without a cavity. Patients with other pulmonary conditions contribute an additional 25% of cases | [23,24,25] | |
| Invasive aspergillosis | Leukaemia, lymphoma, COPD | 10% of acute myeloid leukaemia, an equal number of cases in all other haematological conditions + 1.3% of patients with COPD admitted to hospital | Patients with other conditions not included, including HIV/AIDS. | [26] |
| Cryptococcal meningitis | HIV/AIDS | 11% over 2 years in patients with CD4 counts <200 × 106/mL | The annual incidence rises as the CD4 count falls | [8,9,10] |
| Pneumocystis pneumonia | HIV/AIDS | 15% over 2 years in patients with CD4 counts <200 × 106/mL | Common in children but not estimated separately. Cases in non-AIDS cases not estimated. | [27,28] |
| Histoplasmosis | HIV/AIDS | 1.5% over 2 years in patients with CD4 counts <200 × 106/mL | [29] | |
| Tinea capitis | Children 1–15 years | 8.1% | The most conservative estimate is 8.1% in school aged children. There will be a slight over-estimate by including babies under 2 years. | [2] |
| Subject number | Age | Gender | BCVA | IOP (mmHg) | C/D | VF | ||||||
| RE | LE | RE | LE | RE | LE | RE | LE | |||||
| V | H | V | H | |||||||||
| II2 | 74 | F | 0.3 | NLP | 17.1 | 17.5 | 0.8 | 0.8 | 0.9 | 0.9 | N/A | N/A |
| II4 | 65 | F | 0.3 | 0.5 | 7 | 22.6 | 0.6 | 0.7 | 0.9 | 0.8 | PC | IZD |
| II6 | 58 | F | 1.0 | 1.2 | 15.6 | 12.1 | 0.4 | 0.5 | 0.6 | 0.7 | N/A | N/A |
| III1 | 59 | F | 0.4 | 0.7 | 16.3 | 13.7 | 0.9 | 0.8 | 0.9 | 0.8 | N/A | N/A |
| III4 | 48 | F | 1.5 | 1.2 | 27.3 | 23 | 0.5 | 0.5 | 0.7 | 0.7 | N | N |
| III5 | 44 | M | LP | 1.2 | 19 | 18 | 1.0 | 1.0 | 0.8 | 0.7 | N/A | N/A |
| III7 | 38 | F | 1.5 | 0.1 | 14 | 15.4 | 0.4 | 0.4 | 1.0 | 0.9 | N/A | N/A |
| III8 | 55 | F | 1.0 | 0.6 | 13 | 16 | 0.5 | 0.6 | 0.95 | 0.85 | N/A | N/A |
| III19 | 35 | M | 1.5 | 1.2 | 15.2 | 17.9 | 0.2 | 0.2 | 0.2 | 0.2 | N/A | N/A |
| IV1 | 37 | M | 0.1 | LP | 16 | 19 | 0.9 | 1.0 | 1.0 | 1.0 | N/A | N/A |
| IV2 | 36 | M | 1.5 | 1.5 | 14 | 19 | 0.2 | 0.2 | 0.4 | 0.5 | N/A | N/A |
| IV8 | 26 | F | 1.0 | 1.2 | 11 | 19 | 1.0 | 1.0 | 0.9 | 0.9 | IZD | IZD |
| IV9 | 21 | F | 1.5 | 1.5 | 28 | 26 | 0.3 | 0.4 | 0.5 | 0.5 | N | N |
| IV10 | 19 | M | 1.5 | 1.2 | 36 | 37 | 0.9 | 0.8 | 0.55 | 0.6 | IZD | N |
| IV11 | 18 | M | 1.5 | HM | 8 | 7 | 0.5 | 0.4 | 0.3 | 0.3 | N/A | N/A |
| IV16 | 31 | F | 1.0 | 0.9 | 10 | 16 | 0.5 | 0.5 | 1.0 | 1.0 | N/A | N/A |
| IV17 | 32 | M | 0.5 | 0.6 | 8 | 8 | 0.8 | 0.8 | 0.8 | 0.8 | N/A | N/A |
| Tissue | Concentration (μg g–1 fresh weight of tissue) | |||
| (–)-Kolavenol | Hardwickiic acid | Salvinorin B | Salvinorin A | |
| Leaf | 0.200 ± 0.031 | 2.00 ± 0.27 | 31.0 ± 1.6 | 30.0 ± 2.3 |
| Gland | 1100 ± 170 | 15 000 ± 1100 | 150 000 ± 24 000 | 250 000 ± 13 000 |
| Ideas for better cooperation | examples |
| Mutual accessibility | • use of faxes: obligatory processes, standardised forms, notation on urgency• establish telephone consulting hours for the GP• acute telephone calls: availability of mobile number of GP• contact nurse in the nursing home: competent, informed, skilled, cross-shift, one mobile phone per living area (residential unit) |
| Fix date for GP’s visit | • fixed date: nursing home sets date, fixed weekday, timing of a 30 min period of time• announcements and arrangements: via fax, timely cancellation of date by GP• central telephone number in nursing home for information transfer |
| PreparationCompany during GPs’visits Postprocessing | • prior to visit: communication via fax, nurse compiles and prepares records, (standardised) prioritisation of inquiries• preparation: chart round by GP and nurse• resident visit: preferably with nurse, standardised documentation• postprocessing: realisation in the responsibility of the nurse• soft skills: reliability, trust, openness, agreements, sufficient time |
| TransparencyDefinition of tasks | • regular exchange of medical information• periodical assessment of diagnosis and therapy (GP)• reliable/competent reporting (nurse)• name badges• clarification of responsibilities and expectations• information about processes in the nursing home and GP practice |
| Appreciation and respect | • mutual respect, trust, tolerance of mistakes• establishment of a communication culture• acknowledgement of nurse /GP competencies (feedback, enough time, listening, GP asks for suggestions from nurses)• to be on equal level, provision of patient care in partnership |
| Mean mitocondrial area (μm2) | |||
| Genotype | Treatment | Myelinated | Unmyelinated |
| WT | Naive | 0.102 ± 0.002 | 0.135 ± 0.016# |
| Vehicle | 0.117 ± 0.008 | 0.164 ± 0.006## | |
| Paclitaxel | 0.134 ± 0.007** | 0.161 ± 0.009# | |
| σ1R-KO | Naive | 0.107 ± 0.005 | 0.134 ± 0.010# |
| Vehicle | 0.116 ± 0.005 | 0.164 ± 0.021## | |
| Paclitaxel | 0.115 ± 0.006 | 0.170 ± 0.007## |
| Pregnant women (weeks' gestation) | Postpartum women (months postpartum) | |
| Questionnaires for the participants | ||
| Background, physical activity, diet, psychosocial wellbeing | 8–9 | 2 |
| Physical activity, feedback for physical activity counselling | 16–18 | 5 |
| Diet, feedback for dietary counselling | 22–24 | 5 |
| Background, physical activity, diet, psychosocial wellbeing | 36–37 | 10 |
| Feedback for the physical activity and dietary counselling and the study as a whole | 36–37 | 10 |
| Other data collection | ||
| Adverse events form | 16–18, 22–24, 32–34 and 36–37 | 3, 5, 6 and 10 |
| A copy of the maternity card (weight development and other data on pregnancy) | after delivery | 2 |
| Weight and waist circumference measurement form | - | 2, 3, 5, 6 and 10 |
| Blood sample | 9–11 and 36–37 | 2–2.5 and 8 |
| A 3-day food record prior to the blood sample | 9–11 and 36–37 | - |
| Nipple aspirate fluid (NAF) sample | - | 8–12 |
| MSigDB pathway | C26 (Fold change) | |||||||
| 1 | 2 | 3 | 4 | 5 | Gene description | Gene symbol | AAV9-ev | AAV9-dnFoxO* |
| x | x | x | x | x | collagen, type I, alpha 2 | Col1a2 | −4.26 | −2.31 |
| x | x | x | x | x | collagen, type I, alpha 1 | Col1a1 | −5.20 | −2.44 |
| x | x | x | x | x | collagen, type VI, alpha 1 | Col6a1 | −2.64 | −1.70 |
| x | x | x | x | x | collagen, type VI, alpha 2 | Col6a2 | −2.69 | −1.71 |
| x | x | x | x | x | collagen, type VI, alpha 3 | Col6a3 | −3.55 | −1.75 |
| x | x | x | thrombospondin 2 | Thbs2 | −1.62 | −1.07 | ||
| x | x | x | tenascin C (hexabrachion) | Tnc | −2.43 | −1.45 | ||
| x | x | integrin, beta 6 | Itgb6 | −10.24 | −2.20 | |||
| x | x | cartilage oligomeric matrix protein | Comp | −2.48 | −1.05 | |||
| x | x | chondroadherin | Chad | −16.34 | −2.40 | |||
| x | fibrillin 1 | Fbn1 | −2.86 | −1.71 | ||||
| x | Rho-associated, coiled-coil protein kinase2 | Rock2 | −1.98 | −1.16 | ||||
| x | x | collagen, type XIV, alpha 1 (undulin) | Col14a1 | −2.08 | −1.26 | |||
| x | x | procollagen C-endopeptidase enhancer | Pcolce | −1.81 | −1.10 | |||
| x | matrix metallopeptidase 15 | Mmp15 | −3.12 | −2.06 | ||||
| DAVID annotation | ||||||||
| 1 | 2 | 3 | 4 | 5 | ||||
| x | x | x | myozenin 3 | Myoz3 | −5.53 | −1.99 | ||
| x | x | x | integrin beta 1 binding protein 2 (melusin) | Itgb1bp2 | −4.25 | −2.07 | ||
| x | x | x | junctophilin 2 | Jph2 | −3.95 | −2.10 | ||
| x | x | x | synemin, intermediate filament protein | Synm | −2.61 | −1.47 | ||
| x | x | x | homer homologue 1 | Homer1 | −2.26 | −1.45 | ||
| x | x | x | LIM domain binding 3/Zasp/Cypher | Ldb3 | −1.84 | −1.14 | ||
| x | x | fibromodulin | Fmod | −3.29 | −1.29 | |||
| x | x | keratocan | Kera | −14.38 | −3.30 | |||
| x | x | lumican | Lum | −2.47 | −1.43 |
| Project | Number of participants interviewed |
| Total non-Indigenous participants | 28 (19 F, 9 M) |
| Total Indigenous research participants | 8 (6 F, 2 M) |
| TOTAL research participants | 36 (24 F, 11 M) |
| Peak number | Mass | Composition of ion |
| 1 | 357.13 | B ion: CHR |
| 2 | 458.24 | B ion: CHR_K |
| 3 | 616.28 | B ion: CHR_K_OH-D |
| 4 | 718.32 | B ion: CHR_K_OH-D_T |
| 5 | 818.39 | B ion: CHR_K_OH-D_T_T |
| 6 | 905.42 | B ion: CHR_K_OH-D_T_T_S |
| 7 | 1036.41 | B ion: CHR_K_OH-D_T_T_S_OH-D |
| Y1 | 1067.48 | Y ion resulting from loss of chromophore acyl group |
| Groups | Dose (mg/kg) | Water (ml) | Food (g) | Weight gain (day 7) | Weight gain (day 14) |
| Control | — | 6.190 ± 0.31 | 4.697 ± 0.14 | 1.100 ± 0.46 | 1.100 ± 0.46 |
| Treated | 300 | 7.673 ± 0.31∗ | 5.536 ± 0.19∗ | 2.397 ± 0.64∗ | 0.772 ± 0.10 |
| Treated | 2000 | 6.884 ± 0.35 | 4.306 ± 0.25 | −1.093 ± 0.38∗ | 0.375 ± 0.28 |
| ABSOLUTE LATENCIES | ||||||
| GA/P | I | III | V | |||
| Mean | SD | Mean | SD | Mean | SD | |
| Preterm/P1 | 1.80 | 0.35 | 4.47 | 0.75 | 6.66 | 0.55 |
| Preterm/P2 | 1.60 | 0.20 | 4.26 | 0.18 | 6.32 | 0.24 |
| Preterm/P3 | 1.62 | 0.20 | 4.09 | 0.27 | 6.23 | 0.29 |
| Full term/P1 | 1.67 | 0.28 | 4.49 | 0.47 | 6.77 | 0.54 |
| Full term/P2 | 1.71 | 0.30 | 4.32 | 0.33 | 6.50 | 0.33 |
| Full term/P3 | 1.71 | 0.20 | 3.97 | 0.28 | 6.23 | 0.30 |
| Variable | Odds ratio | 95% CI |
| Joint family | 4.03 | 2.41-6.18 |
| > 2 birth order | 3.09 | 2.16-4.19 |
| Mother's education ≤ 6th standard | 3.81 | 2.37-5.96 |
| Mother working | 4.47 | 3.04-6.98 |
| 1997–2004 | 2005–2010 | Increased % | |
| AA + White | 75.37% | 87.62% | 12.25% |
| AA | 74.53% | 87.15% | 12.62% |
| White | 78.70% | 89.99% | 11.29% |
| AA-Whitedifference | 4.17% | 2.84% | 1.33% |
| Final identification (no of isolates) | Number of isolates | ||||||
| Conventional identification method (Vitek 2) | VITEK MS identification | Bruker MS identification | 16S rRNA sequence results (number of discrepant organisms sequenced) | ||||
| No ID | Mis - ID | No ID | Mis - ID | No ID | Mis - ID | ||
| Haemophilus influenzae (8) | 0 | 0 | 0 | 0 | 0 | 2 (score <1.7) | H. influenzae (2) |
| Neisseria cinerea (1) | 0 | 0 | 0 | 1 (Neisseria subflava) | 0 | 1 (Neisseria sicca) | N. cinerea (1) |
| Neisseria subflava (5) | NA | NA | 0 | 0 | 0 | Neisseria flava (5) | N. subflava (5) |
| Neisseria meningitidis (1) | 0 | 0 | 0 | 0 | 0 | 0 | |
| Moraxella catarrhalis (1) | 0 | 0 | 0 | 0 | 0 | 0 |
| Total expressed features | Overlapping features | EM | PL | ES | TS |
| 13,718 | EM | 9,840 | 9,212 | 9,314 | |
| 10,559 | PL | 8,508 | 8,881 | ||
| 9,667 | ES | 8,816 | |||
| 9,840 | TS | ||||
| Total expressed U-clusters | Overlapping U-clusters | EM | PL | ES | TS |
| 11,360 | EM | 8,271 | 7,749 | 7,853 | |
| 8,828 | PL | 7,181 | 7,492 | ||
| 8,101 | ES | 7,435 | |||
| 8,271 | TS | ||||
| Total expressed transcripts | Overlapping transcripts | EM | PL | ES | TS |
| 11,762 | EM | 8,516 | 7,980 | 8,090 | |
| 9,108 | PL | 7,386 | 7,718 | ||
| 8,357 | ES | 7,657 | |||
| 8,534 | TS |
| Year of point prevalence study | MRSA | VRE | ESBL-EC (2012)3MRGN-EC (2014) | ESBL-KS (2012)3MRGN-KP* (2014) | CD | |||||
| Mean prevalence[95 % CI] | Mean prevalence[95 % CI] | Mean prevalence[95 % CI] | Mean prevalence[95 % CI] | Mean prevalence[95 % CI] | ||||||
| 2012 [12] | 1.53 | [1.32 – 1.75] | 0.27 | [0.18 – 0.36] | 0.97 | [0.80 – 1.14] | 0.33 | [0.19 – 0.48] | 1.30 | [1.11 – 1.50] |
| 2014 | 1.64 | [1.46 – 1.82] | 0.25 | [0.13 – 0.37] | 0.75 | [0.60 – 0.89] | 0.22 | [0.15 – 0.29] | 0.74 | [0.60 – 0.88] |
| Primers and probes | Nucleic acid sequences of primers and probes |
| qPCR Zika virus (ZIKV) | |
| ZIKV forward | 5-nt9271AARTACACATACCARAACAAAgTggT9297–3’ |
| ZIKV reverse | 5′ nt9352-TCCRCTCCCYCTYTggTCTTg-9373 -3’ |
| ZIKV probe | nt 9304-FAM-CTYAgACCAgCTgAAR-BBQ-9320 |
| qPCR Dengue total (DENV 1–4 system) | |
| DENT forward | 5′- AGGACYAGAGGTTAGAGGAGA - 3’ |
| DENT reverse | 5′- CGYTCTGTGCCTGGAWTGAT −3’ |
| DENT probe | FAM-ACAGCATATTGACGCTGGGARAGACC-TAMRA |
| qPCR Dengue subtypes (DENV1, DENV2, DENV3) | |
| DEN1 forward | 5′ ATACCYCCAACAGCAGGAATT - 3’ |
| DEN1 reverse | 5′ AGCATRAGGAGCATGGTCAC −3’ |
| DEN1 probe | FAM-TTGGCTAGATGGRGCTCATTCAAGAAGAAT-TAMRA |
| DEN2 forward | 5′ TGGACCGACAAAGACAGATTCTT 3’ |
| DEN2 reverse | 5′ CGYCCYTGCAGCATTCCAA 3’ |
| DEN2 probe | FAM-CGCGAGAGAAACCGCGTGTCRACTGT-TAMRA |
| DEN3 forward | 5′ AAGACGGGAAAACCGTCTATCAA 3’ |
| DEN3 reverse | 5′ TTGAGAATCTCTTCGCCAACTG 3’ |
| DEN3 probe | FAM-ATGCTGAAACGCGTGAGAAACCGTGT-TAMRA |
| qPCR Chikungunya (CHIK) | |
| CHIK forward | 5′- AAGCTYCGCGTCCTTTACCAAG - 3’ |
| CHIK reverse | 5′- CCAAATTGTCCYGGTCTTCCT −3’ |
| CHIK probe | FAM-CCAATGTCYTCMGCCTGGACACCTTT-TAMRA |
| qPCR Rift Valley fever virus (RVFV) | |
| RVFV forward | 5′- AAA ggA ACA ATg gAC TCT ggT CA - 3’ |
| RVFV reverse | 5′- CAC TTC TTA CTA CCA TTC CTC CAA T − 3’ |
| RVFV probe | FAM-AAA gCT TTg ATA TCT CTC AgT gCC CCA A -TAMRA |
| qPCR West Nile virus (WNV) | |
| WNV3p forward | 5′ Agg TTA gWg gAg ACC CCg T - 3’ |
| WNV3p reverse | 5′ ggT TgT gCA gAg CAg AAg ATC −3’ |
| WNV3p probe | FAM-CGGTTCCGGCGGTGGTTTCT-TAMRA |
| Conventional PCR Crimean-Congo haemorrhagic fever virus (CCHFV) | |
| CCHFV forward | 5′ – TGGACACCTTCACAAACTC - 3’ |
| CCHFV reverse | 5′ – GACAAATTCCCTGCACCA - 3’ |
| qPCR Hepatitis E virus (HEV) | |
| HEV forward | 5′ GCCCGGTCAGCCGTCTGG −3’ |
| HEV reverse | 5′-CTGAGAATCAACCCGGTCAC −3’ |
| HEV probe | FAM-CGGTTCCGGCGGTGGTTTCT-TAMRA |
| Item number | Question description | Expert raters | I-CVIa | |||
| 1 | 2 | 3 | 4 | |||
| Q1 | Lifetime prevalence | 4 | 4 | 4 | 4 | 1.00 |
| Q2 | Age of onset | 4 | 4 | 4 | 4 | 1.00 |
| Q3 | Recurrent NSLBPc | 4 | 4 | 4 | 2 | 0.75 |
| Q4 | Frequency of recurrent NSLBP | 4 | 4 | 4 | 3 | 1.00 |
| Q5 | Duration of recurrent NSLBP | 2 | 4 | 4 | 4 | 0.75 |
| Q6 | Intensity of recurrent NSLBP | 4 | 4 | 4 | 4 | 1.00 |
| Q7 | Sciatica | 4 | 4 | 4 | 4 | 1.00 |
| Q8 | Point prevalence | 4 | 4 | 4 | 4 | 1.00 |
| Q9 | Point pain intensity | 4 | 4 | 4 | 4 | 1.00 |
| Q10 | Medical treatment | 4 | 4 | 4 | 4 | 1.00 |
| Q11a | Sitting on a chair | 4 | 4 | 4 | 4 | 1.00 |
| b) | Reaching up | 4 | 4 | 4 | 4 | 1.00 |
| c) | Standing | 4 | 4 | 4 | 4 | 1.00 |
| d) | Walking | 4 | 4 | 4 | 4 | 1.00 |
| e) | Sporting activity | 4 | 4 | 4 | 4 | 1.00 |
| f) | Bending | 4 | 4 | 4 | 4 | 1.00 |
| g) | School-bag carrying | 4 | 4 | 4 | 4 | 1.00 |
| h) | Sitting up in bed | 4 | 4 | 4 | 4 | 1.00 |
| i) | Running | 4 | 4 | 4 | 4 | 1.00 |
| Q12 | Absenteeism | 3 | 4 | 4 | 4 | 1.00 |
| Q13 | Bag carriage | 4 | 4 | 4 | 4 | 1.00 |
| Q14 | Perception school-bag weight | 4 | 4 | 4 | 3 | 1.00 |
| Q15 | Duration of carrying school-bag | 3 | 4 | 4 | 4 | 1.00 |
| Q16 | Method of carrying school-bag | 4 | 4 | 4 | 4 | 1.00 |
| Q17 | Sports participation | 4 | 4 | 4 | 4 | 1.00 |
| Q18 | Type of sport | 4 | 4 | 4 | 4 | 1.00 |
| Q19 | Sports duration | 4 | 4 | 4 | 4 | 1.00 |
| Q20 | Sedentary time | 3 | 4 | 4 | 4 | 1.00 |
| Q21 | Smoking | 4 | 4 | 4 | 1 | 0.75 |
| Q22 | Past week smoking | 4 | 4 | 4 | 1 | 0.75 |
| dTotal agreement=0.86 bS-CVI/Ave = 0.97 |
| Symptomatic Group (n = 30) | Asymptomatic Group (n = 30) | Overall (n = 60) | |||
| GSRS-IBS Subdomains | Score ≥ 2 (Any Discomfort), n | Score ≥ 4 (Moderate to Severe Discomfort), n | Score ≥ 2 (Any Discomfort), n | Score ≥ 4 (Moderate to Severe Discomfort), n | Score ≥ 2 (Any Discomfort), n |
| Pain (Q1 or 2) | 15 (50%) | 11 (37%) | 1 (3%) | 0 | 16 (27%) |
| Bloating (Q3, 4 or 13) | 24 (80%) | 3 (10%) | 7 (23%) | 1 (3%) | 31 (52%) |
| Constipation (Q5 or 8) | 17 (57%) | 8 (27%) | 8 (27%) | 3 (10%) | 25 (42%) |
| Diarrhoea (Q6, 7, 9 or 10) | 24 (80%) | 10 (33%) | 6 (20%) | 0 | 30 (50%) |
| Satiety (Q11 or 12) | 15 (50%) | 3 (10%) | 5 (17%) | 2 (7%) | 20 (33%) |
| Time | Monday | Tuesday | Wednesday | Thursday | Friday |
| 8 am – 10 am | Lecture (C1) / Morning session (C2) | Lecture (C1) / Morning session (C2) | Social and Population Health | Lecture (C1)/ Morning session (C2) | Primary Health / Community attachment |
| 10 am-12:30 pm | Bedside teaching | Inpatient/ outpatient care | Inpatient/ outpatient care | Bedside teaching | |
| 12:30 pm- 2 pm | Lunch | Lunch | Lunch | Lunch | Lunch |
| 2 pm–4 pm | Inpatient/ outpatient care | PCD | Inpatient/ outpatient care | Inpatient/ outpatient care | Whole group session seminar/journal club/grand round |
| 4 pm-5:30 pm | Inpatient/ outpatient care |
| Adverse events | Placebo (n = 23) | 100 mg/day 5-Loxin® (n = 24) | 250 mg/day 5-Loxin® (n = 23) |
| Diarrhoea | 3 | 2 | 2 |
| Nausea | 1 | 3 | 2 |
| Vomiting | 1 | 1 | 1 |
| Abdominal pain | 4 | 2 | 2 |
| Pedal edema | 0 | 1 | 0 |
| Itching | 2 | 1 | 4 |
| General weakness | 2 | 4 | 2 |
| Constipation | 0 | 0 | 1 |
| Mild fever (up to 37.5°C) | 1 | 2 | 2 |
| Stomach burn | 4 | 0 | 3 |
| Allergya | 3 | 0 | 1 |
| Headache | 0 | 0 | 1 |
| Miscellaneousb | 9 | 2 | 6 |
| Sum of events | 30 | 18 | 27 |
| Femoral offset (mm) | |||||
| Operated | Contralateral | Average diff | < 4.62 mm diff | P value | |
| Hip Resurfacing | 50.71 | 50.63 | -0.08 | 50% | 0.9 |
| Large-head metal on metal | 51 | 56.56 | +5.56 | 35% | 0.0002 |
| Total hip replacement | 47.61 | 56.23 | +8.62 | 30% | 0.0003 |
| Author | Country | Patients for score derivation (n) | Outcome | Patients with outcome n (%) | Maximum time between assessment and outcome measure | Variables | Performance |
| Soxa 1990 [35] | USA | 1074 | MIAnginaCoronary insufficiency | 424 (39.5) | 1 year | AgeGenderExertional painPatient stops activities when pain occursPMH of MISmokingPain relived by NTG | For score > 4S:0.99Sp:0.18PPV:0.45NPV:0.98 |
| Gencer 2010 [36] | Switzerland Germany | 661 | CAD | 85 (12.9) | 1 year | AgeGenderCV Risk KnownPain locationPain duration Exertional painPain on palpationPMH of CVD | AUC: 0.95 (0.92-0.97) |
| For scores < 5(Lowest 5 % for patients with CAD):S:0.98Sp:0.71NPV:0.99 | |||||||
| Bösner 2010 [30] | Germany Switzerland | 1199 | CAD | 180 (15.0) | 6 months | AgeGenderExertional painPMH of CVDPatient assumes pain of cardiac originPain on palpation | AUC: 0.90 (0.87-0.93) |
| For a cut-off value of 3 (risk of CAD > 35 %): S:0.86(0.79-0.92)Sp:0.75(0.72-0.78)PPV:0.35(0.29-0.41)NPV:0.97(0.96-0.98) |
| SCOP superfamily | PFAM name | Accession number |
| Ig | V-set | PF07686 |
| I-set | PF07679 | |
| C2-set | PF05790 | |
| C1-set | PF07654 | |
| Ig | PF00047 | |
| Ig_2 | PF13895 | |
| ICAM_N | PF03921 | |
| E-SET | Alpha_amylase_N | PF02903 |
| arrestin_N | PF00339 | |
| arrestin_C | PF02752 | |
| CelD_N | PF02927 | |
| peptidaseC25 | PF03785 | |
| TIG | PF01833 | |
| RHD | PF00554 | |
| DUF291 | PF03442 | |
| Filamin | PF00630 | |
| He_Pig | PF05345 | |
| Fibronectin type 3 | FN3 | PF00041 |
| tissue_fac | PF01108 | |
| lep_receptor_Ig | PF06328 | |
| PKD | PKD | PF00801 |
| PPC | PF04151 | |
| HYR | PF02494 | |
| β-Galactosidase/β-Glucuronidase | Glycol_hydro_2 | PF00703 |
| Cu, Zn Superoxide dismutase-like | Sod_Cu | PF00080 |
| PapD-like | Pili_assembly_C | PF02753 |
| pili_assembly_N | PF00345 | |
| Invasin/intimin cell-adhesion fragments | Big_1 | PF02369 |
| Big_2 | PF02368 | |
| Big_3 | PF07523 | |
| Big_4 | PF07532 | |
| Clathirin adaptor appendage domain | Alpha_adaptin_C2 | PF02883 |
| Transglutaminase N-terminal domain | Transglut_N | PF00868 |
| Cadherin-Like | Cadherin domain | PF00028 |
| Actinoxanthin-like | Neocarzinostatin family | PF00960 |
| CBD9-like | Domain of unknown function | PF06452 |
| laminA/C globular tail domain | Intermediate filament tail domain | PF00932 |
| Other Ig-like | C type Lectin | PF00059 |
| BACON | PF13004 | |
| MucBP | PF06458 |
| Condition | Peak moment [(N·m)/kg] | Peak power (W/kg) |
| Unpowered | 1.81 (0.25) | 4.35 (1.10) |
| 80% extension | 1.65 (0.27) | 3.96 (1.11) |
| 90% extension | 1.58 (0.52) | 3.94 (1.83) |
| 0% extension | 1.64 (0.25) | 3.34 (1.29) |
| 10% extension | 1.65 (0.35) | 3.92 (1.26) |
| 30% flexion | 1.73 (0.33) | 4.54 (1.01) |
| 40% flexion | 1.61 (0.27) | 3.68 (1.11) |
| 50% flexion | 1.71 (0.22) | 3.36 (0.63) |
| 60% flexion | 1.56 (0.26) | 3.83 (0.87) |
| Access to PC dimension | Number of patients (share) | Mean(sd) | |
| Communicational (N=1,943) | 0 = bad access | 3 (0.2%) | 5.548 (0.888) |
| 1 | 18 (0.9%) | ||
| 2 | 17 (0.9%) | ||
| 3 | 29 (1.5%) | ||
| 4 | 111 (5.7%) | ||
| 5 | 393 (20.2%) | ||
| 6 = good access* | 1,372 (70.6%) | ||
| Cultural (N=1,593) | 0 = bad access | 3 (0.2%) | 3.930 (0.356) |
| 1 | 4 (0.3%) | ||
| 2 | 19 (1.2%) | ||
| 3 | 49 (3.1%) | ||
| 4 = good access* | 1,518 (95.3%) | ||
| Financial (N=1,928) | 0 = bad access | 1 (0.1%) | 1.992 (0.094) |
| 1 | 13 (0.7%) | ||
| 2 = good access* | 1,914 (99.3%) | ||
| Geographical (N=1,874) | 0 = bad access | 50 (2.7%) | 1.860 (0.417) |
| 1 | 163 (8.7%) | ||
| 2 = good access* | 1,661 (88.6%) | ||
| Organizational (N=1,292) | 0 = bad access | 5 (0.4%) | 3.543 (0.732) |
| 1 | 21 (1.6%) | ||
| 2 | 93 (7.2%) | ||
| 3 | 322 (24.9%) | ||
| 4 = good access* | 851 (65.9%) |
| Variable | Men | Women | ||
| r | p | r | p | |
| Weight (kg) | 0.45 | <0.01 | 0.36 | <0.01 |
| Waist circumference (cm) | 0.40 | <0.01 | 0.40 | <0.01 |
| Hip circumference (cm) | 0.37 | <0.01 | 0.33 | <0.01 |
| Waist to hip ratio | 0.05 | 0.18 | 0.22 | <0.01 |
| BMI (kg/m2) | 0.41 | <0.01 | 0.30 | <0.01 |
| SBP (mmHg) | 0.18 | <0.01 | 0.08 | <0.01 |
| DBP (mmHg) | 0.09 | <0.01 | 0.06 | <0.01 |
| FBG (mmol/L) | 0.06 | 0.09 | 0.10 | <0.01 |
| Fasting insulin (pmol/L) | 0.11 | <0.01 | 0.09 | <0.01 |
| HbA1c (%) | 0.11 | <0.01 | 0.06 | <0.01 |
| HOMA-IR | 0.12 | <0.01 | 0.17 | <0.01 |
| Total cholerterol (mmol/L) | 0.10 | <0.01 | 0.02 | 0.51 |
| LDL-cholesterol (mmol/L) | 0.16 | <0.01 | 0.01 | 0.57 |
| HDL-cholesterol (mmol/L) | −0.13 | <0.01 | −0.18 | <0.01 |
| Triglycerides (mmol/L) | 0.14 | <0.01 | 0.14 | <0.01 |
| Creatinine (umol/L) | 0.11 | <0.01 | 0.05 | 0.05 |
| eGFR (ml/min/1.732) | −0.13 | <0.01 | 0.07 | <0.01 |
| ALT (U/L) | 0.07 | 0.05 | 0.07 | <0.01 |
| Total weight change over 17 days compared to control/% change | Daily weight change (per day over 17 days) compared to control (kg) | |
| Treatment 1 - Control | ||
| Treatment 2–0.5× | 0.633 kg/11.1% | 0.037 kg |
| Treatment 3 - lx | −0.325 kg/−5.7% | −0.019 kg |
| Treatment 4 - 2× | 0.807 kg/14.1% | 0.047 kg |
| Key obstetric danger signs | Place of delivery | P-values* | |
| Cases (n = 118) | Controls (n = 238) | ||
| Frequency (%) | Frequency (%) | ||
| Key danger sign during pregnancy | |||
| Vaginal bleeding | 86(72.9) | 117(49.2) | <0.001 |
| Swelling of the face and hands | 56(47.5) | 35(14.7) | <0.001 |
| Blurring (difficult) vision | 26(22.0) | 26(10.9) | 0.005 |
| Key danger sign during Labour and delivery | |||
| Excess vaginal bleeding | 93(78.8) | 89(37.4) | <0.001 |
| Prolonged labour (>12 hours) | 76(64.4) | 113(47.5) | 0.003 |
| Retained placenta(>30minuts) | 54(45.8) | 74(31.1) | 0.007 |
| Convulsions | 13(11.0) | 2(0.8) | <0.001 |
| Key danger sign during postpartum period | |||
| Vaginal bleeding | 71(60.2) | 76(31.9) | <0.001 |
| Increased body temp (fever) | 8(6.8) | 11(4.6) | 0.454 |
| Offensive vaginal bleeding | 21(17.8) | 13(5.5) | <0.001 |
| Bipolar disorder | Depression | Non-mood disorder | |||
| (n = 572) | (n = 5,464) | (n = 53,905) | |||
| Total U.S. Population(18-64) | 1,647,408 | 16,874,994 | 165,702,423 | ||
| 0.9% | 9.2% | 90.0% | |||
| Gender | |||||
| Male | 35.2% | 33.3% | 51.1% | * | |
| Female | 64.8% | 66.7% | 48.9% | * | |
| Age | |||||
| 18-24 | 11.4% | 9.7% | 16.1% | * | |
| 25-34 | 20.7% | 16.2% | 22.0% | ||
| 35-44 | 30.3% | 23.0% | * | 23.1% | * |
| 45-54 | 25.1% | 28.8% | 22.3% | ||
| 55-64 | 12.5% | 22.3% | * | 16.6% | * |
| Race/Ethnicity | |||||
| Hispanic | 8.1% | 9.4% | 14.8% | * | |
| NH White | 74.3% | 77.9% | 65.8% | * | |
| NH Black | 9.2% | 7.8% | 12.3% | ||
| NH Multiple | 4.7% | 2.4% | 1.2% | * | |
| NH Other | 3.8% | 2.5% | 6.0% | ||
| Marital status | |||||
| Married | 35.8% | 48.1% | * | 56.3% | * |
| Other | 64.2% | 51.9% | * | 43.8% | * |
| Income (% Federal Poverty Level) | |||||
| < 200% | 39.0% | 21.3% | * | 13.5% | * |
| 200-399% | 39.3% | 43.4% | 43.4% | ||
| > = 400% | 21.7% | 35.4% | * | 43.1% | * |
| Educational Attainment (24 and older) | |||||
| Less than High School grad | 16.6% | 15.9% | 14.3% | ||
| High School grad | 35.7% | 31.9% | 30.9% | ||
| Some College | 27.1% | 24.7% | 23.3% | ||
| College degree or more | 20.7% | 27.4% | * | 31.5% | * |
| Living Arrangement | |||||
| Living Alone | 37.6% | 25.6% | * | 17.1% | * |
| Living with child and adult | 24.5% | 29.0% | 40.3% | * | |
| Living with adult only | 29.4% | 38.2% | * | 38.4% | * |
| Living with child only | 8.5% | 7.2% | 4.2% | * | |
| Comorbid conditions | |||||
| 0 | 78.8% | 74.9% | 88.3% | * | |
| 1 | 16.9% | 19.5% | 10.3% | * | |
| 2 | 2.9% | 4.6% | 1.2% | ||
| 3 or more | 1.4% | 1.1% | 0.2% | ||
| Geography | |||||
| Metropolitan Statistical Area (MSA) | 19.9% | 17.5% | 16.1% | ||
| Non-MSA | 80.1% | 82.5% | 83.9% | ||
| Region | |||||
| Northeast | 18.8% | 16.6% | 18.7% | ||
| Midwest | 25.3% | 25.6% | 21.9% | ||
| South | 32.1% | 33.9% | 36.3% | ||
| West | 23.8% | 23.9% | 23.1% |
| Trait category | Traits from GWAS consortia | rg | s.e. | P |
| Physical health | Blood pressure: diastolic | 0.0332 | 0.0502 | 0.5083 |
| Blood pressure: systolic | −0.0698 | 0.0478 | 0.1444 | |
| BMI | 0.2024 | 0.0322 | 3.18 × 10−10 | |
| Cholesterol: HDL | −0.1087 | 0.0373 | 0.0036 | |
| Cholesterol: LDL | 0.0829 | 0.0413 | 0.0449 | |
| Coronary artery disease | 0.1338 | 0.067 | 0.0459 | |
| C-reactive protein | 0.0165 | 0.054 | 0.0021 | |
| Grip strengtha | −0.1596 | 0.0482 | 0.0009 | |
| HbA1c | 0.2536 | 0.0857 | 0.0031 | |
| Height | −0.0201 | 0.0297 | 0.4980 | |
| Longevity | −0.3943 | 0.1096 | 0.0003 | |
| Forced expiratory volume 1sa | −0.1181 | 0.0538 | 0.0281 | |
| Obesity | 0.2063 | 0.0381 | 6.31 × 10−8 | |
| Rheumatoid arthritis | −0.0181 | 0.0674 | 0.7885 | |
| Self-rated healtha | −0.7780 | 0.0349 | 7.30 × 10−110 | |
| Smoking status | 0.2009 | 0.0603 | 0.0009 | |
| Triglycerides | 0.1324 | 0.0332 | 6.62 × 10−5 | |
| Type 2 diabetes | 0.1784 | 0.0689 | 0.0097 | |
| Waist–hip ratio | 0.2834 | 0.0417 | 1.09 × 10−11 | |
| Mental health | ADHD | 0.2694 | 0.1116 | 0.0158 |
| Alzheimer’s disease | 0.0762 | 0.1079 | 0.4801 | |
| Alzheimer’s disease (500 kb) | 0.0613 | 0.0872 | 0.4816 | |
| Anorexia nervosa | 0.0192 | 0.0492 | 0.6967 | |
| Autism | 0.0129 | 0.0695 | 0.8522 | |
| Bipolar disorder | 0.1382 | 0.0605 | 0.0223 | |
| Childhood cognitive ability | −0.1528 | 0.0891 | 0.0864 | |
| Major depressive disorder | 0.5902 | 0.1015 | 6.03 × 10−9 | |
| Neuroticism | 0.6150 | 0.038 | 7.34 × 10−59 | |
| Schizophrenia | 0.2490 | 0.0386 | 1.14 × 10−10 | |
| Verbal-numerical reasoninga | −0.1379 | 0.0596 | 0.0206 |
| Average number of antenatal visits | Average number in intervention arm | Difference | Power | Sample sizeper arm |
| 8.9 | 10.9 | 2 | 90% | 190 |
| 9.4 | 10.9 | 1.5 | 90% | 337 |
| 2001 NCEP ATP III definition | AHA/NHLBI definition | IDF definition |
| (any three of five) | (any three of five) | (requiredaand any two of four criteria left) |
| BMI ≥30 kg/m2 | BMI ≥ 30 kg/m2 | BMI ≥30 kg/m2 a |
| TG ≥150 mg/dl | TG ≥150 mg/dl or treatment for elevated TG | TG ≥150 mg/dl or treatment for elevated TG |
| C-HDL <40 mg/dl in men | C-HDL <40 mg/dl in men | C-HDL <40 mg/dl in men |
| C-HDL <50 mg/dl in women | C-HDL <50 mg/dl in women | C-HDL <50 mg/dl in women |
| Blood pressure ≥130/85 mmHg or previous hypertension diagnosis | Blood pressure ≥130/85 mmHg or previous hypertension diagnosis | Blood pressure ≥130/85 mmHg or previous hypertension diagnosis |
| Fasting glucose ≥110 mg/dl or previous type 2 DM | Fasting glucose ≥100 mg/dl or previous type 2 DM | Fasting glucose ≥100 mg/dl or previous type 2 DM |
| Metastasis location | Upper thoracic section (174) | Middle thoracic section (132) | Lower thoracic section (80) | Total | P |
| CTG zone | 117(67.2%) | 50(37.9%) | 15(18.8%) | 182(47.2%) | 0.000 |
| MSC zone | 55(31.6%) | 25(18.9%) | 9(11.3%) | 89(23.1%) | 0.001 |
| LSC zone | 11(6.3%) | 4(3.0%) | 1(1.3%) | 16(4.1%) | 0.124 |
| No toxicity | Grade 1 | Grade 2 | Grade 3 | Grade 4 | |
| Dyesthesia | 12.8% | 70.9% | 11.6% | 4.7% | 0% |
| Paresthesia | 5.7% | 66.3% | 19.8% | 7% | 1.2% |
| Categories | Number (%) | |
| Age range (years) | 2–4 | 2 (3%) |
| 4–12 | 19 (28%) | |
| 12–19 | 22 (33%) | |
| 19–40 | 18 (27%) | |
| 40–50 | 3 (4.5%) | |
| >50 | 3 (4.5%) | |
| Type of abnormal foot position | Equinus | 18 (27%) |
| Flatfoot (flexible) | 15 (22%) | |
| Flatfoot (rigid) | 12 (18%) | |
| Other | 7 (10.5%) | |
| No problems | 10 (15%) | |
| Nil response | 5 (7.5%) | |
| Type of foot support | Semi-orthopedic footwear | 14 (21%) |
| Orthopedic footwear | 17 (25.5%) | |
| Ankle-foot orthosis (AFO) | 15 (22%) | |
| Other | 4 (6%) | |
| Not required | 10 (15%) | |
| Nil response | 7 (10.5%) | |
| Full foot on the floor (when standing with bare feet) | Yes | 24 (36%) |
| Partial | 4 (6%) | |
| No | 30 (45%) | |
| Nil response | 9 (13%) | |
| Symmetrical weight bearing through both legs (when standing) | Yes | 12 (18%) |
| No | 46 (69%) | |
| Nil response | 9 (13%) |
| Subj. | Resp. | Resp. Ad. | Heart | Heart Ad. | |
| [min−1] | [min−1] | [bpm] | [bpm] | ||
| SE | 1 | 0.0 (0.3) | 0.0 (0.3) | -0.3 (2.1) | -0.2 (1.4) |
| SE | 2 | -0.3 (0.5) | -0.2 (0.3) | -0.8 (2.3) | -0.7 (1.7) |
| DS | 1 | -0.1 (0.3) | 0.0 (0.3) | -1.2 (2.3) | -0.2 (1.5) |
| DS | 2 | -0.3 (0.4) | -0.2 (0.3) | -0.3 (2.2) | -0.8 (1.7) |
| BS | 1 | -0.1 (0.2) | 0.0 (0.3) | 11.2 (5.7) | -0.2 (1.5) |
| BS | 2 | -0.2 (0.4) | -0.2 (0.3) | 42.0 (6.1) | -0.7 (1.7) |
| Cell line | HPV DNA | Cisplatin IC50 (μmol/L) |
| UPCI-SCC-003 | (−) | 1.7 |
| UPCI-SCC-036 | (−) | 3.0 |
| UPCI-SCC-089 | (−) | 1.2 |
| UPCI-SCC-090 | (+) | 5.7 |
| UPCI-SCC-152 | (+) | 4.6 |
| UPCI-SCC-154 | (+) | 2.0 |
| Patient | Pre-operative cretinine | Post-operative creatinine | Voiding | Incontience | Dialysis |
| 1 | Normal | Normal | Spontaneous | − | − |
| 2 | Elevated | Normal | Spontaneous | − | − |
| 3 | Elevated | Elevated | Vesicostomy | − | + |
| 4 | Normal | Normal | Spontaneous | − | − |
| 5 | Normal | Normal | Spontaneous | − | − |
| 6 | Elevated | Elevated | CIC | − | + |
| 7 | Normal | Normal | Spontaneous | − | − |
| 8 | Normal | Normal | Spontaneous | − | − |
| 9 | Normal | Normal | Spontaneous | Frequency/urgency | − |
| 10 | Normal | Normal | Spontaneous | − | − |
| 11 | Normal | Normal | Spontaneous | − | − |
| Cell line | HEK 293T | HeLa | ||||
| Replicate number | 1 | 2 | 3 | 1 | 2 | 3 |
| Telomerase activity ratio (flow through/input) | 0.65 | 0.48 | 0.44 | 0.56 | 0.37 | 0.33 |
| hTR ratio (flow through/input) | 0.94 | 0.84 | 0.77 | 0.91 | 0.88 | 0.88 |
| Estimated number of assembled telomerase monomer per cella | 146 | 245 | 332 | 255 | 255 | 222 |
| Million hTR per μl elutionb | 9.2 | 8.2 | 1.2 | 1.3 | 1.4 | |
| Million hTERT per μl elution | 15 | 11 | 1.7 | 3.1 | 3.3 | |
| Estimated number of hTERT protein per cellc | 237 | 322 | 382 | 608 | 534 |
| Authors | Number of patients/centres included | Epoetin isoform | Variables explored (inputs) | Predictions (outputs) |
| Gabutti et al (present study) | 432/29 | Beta | Sex; age; weight, presence or absence of a diabetes mellitus and/or a cardiomyopathy with EF<50%; haemoglobin; creatinine; BUN; pH; ionized calcium; albumin; CRP; ferritin; PTH; epoetin and iron dose; epoetin administration route sc vs. iv; Kt/V | Epoetin dose and follow-up haemoglobin |
| Bellazzi [24] | 10/1 | n.s. | Sex; age; haemoglobin; calcium; PTH; epoetin dose and others non specified | Follow-up haemoglobin |
| Martin Guerriero et al [20] | 110/1 | Alpha and beta | Age; weight; haemoglobin; ferritin; epoetin dose; isoform and number of administrations weekly; iron dose | Epoetin dose |
| Gaweda et al [25] | 209/1 | n.s. | Haematocrit; albumin; ferritin; iron saturation; PTH; epoetin and iron dose; Kt/V | Follow-up haematocrit |
| Jacobs et al [26] | 166/n.s. | n.s. | Haematocrit; albumin; ferritin; iron saturation; PTH; epoetin and iron dose; Kt/V | Follow-up haematocrit |
| Maryland score | Mean ± SD | Excellent (%) (90–100) | Good (%) (75–89) | Fair (%) (50–74) | Poor (<50) |
| Total | 88.1 ± 8.8 | 11 (61.1) | 4 (22.2) | 3 (16.7) | 0 (0) |
| Sanders II | 88.1 ± 8.8 | 8 (57.1) | 4 (28.6) | 2 (14.3) | 0 (0) |
| Sanders III | 87.8 ± 10.1 | 3 (75.0) | 0 (0) | 1 (25.0) | 0 (0) |
| IORNS SRI r | IORNS DRI r | IORNS PSI r | IORNS TOT r | |
| LASC severity | .22 | .40** | −.16 | .33 |
| LASC global | .25 | .56** | −.34* | .52** |
| LASC B “re-experiencing” | .09 | .29 | −.18 | .21 |
| LASC C “avoidance” | .25 | .46** | −.11 | .43** |
| LASC D “hyperarousal” | .15 | .28 | −.11 | .23 |
| Urban Area | Type of Mobile Source Pollution | EC | NOx | CO |
| Atlanta, GA | Diesel | 0.64 | 0.36 | * |
| Gasoline | * | 0.38 | 0.62 | |
| Combined | 0.32 | 0.36 | 0.32 | |
| Denver, CO | Diesel | 0.70 | 0.30 | * |
| Gasoline | * | 0.32 | 0.68 | |
| Combined | 0.33 | 0.29 | 0.37 | |
| Houston, TX | Diesel | 0.55 | 0.44 | * |
| Gasoline | * | 0.35 | 0.65 | |
| Combined | 0.22 | 0.38 | 0.40 |
| Parameter | Ethnic group | Rest of the sample | P value |
| Age (years± standard deviation) | 39.5±14 | 39.1±13 | NS |
| Gender | |||
| % Female | 51.5 | 58 | NS |
| % Male | 48.5 | 42 | NS |
| Education level | |||
| % Without studies or elementary school | 48.9 | 44.8 | <0.05 |
| % High-school | 43.4 | 46.7 | <0.05 |
| % College | 7.7 | 8.5 | NS |
| % Self-reported gingival bleeding | 5.1 | 3.4 | <0.05 |
| GDP | 0.63 | 0.70 | <0.05 |
| HDI | 0.75 | 0.78 | <0.05 |
| UBNI | 32 | 20.7 | <0.05 |
| ZMP | Fore-aft | Lateral |
| Std. | Std. | |
| Open-loop | 21.1 mm | 14.9 mm |
| Closed-loop | 12.1 mm | 14.1 mm |
| GO Term | Annotation | Abbreviation |
| GO:0006281 | DNA repair | DNA repair |
| GO:0006284 | base-excision repair | BER |
| GO:0006289 | nucleotide-excision repair | NER |
| GO:0006298 | mismatch repair | MMR |
| GO:0000724 | double-strand break repair via homologous recombination | HR |
| GO:0006303 | double-strand break repair via non-homologous end joining | NHEJ |
| Patient characteristics: | N | % | Median | Range | |
| All MPS I | 61 | ||||
| Gender (male/female) | 38/23 | 62/38 | |||
| Phenotype (Hurler/Attenuated) | 44/17 | 69/31 | |||
| Age @ Start of treatment (mths) | 18 | 3-364 | |||
| Age @ final assessment (mths) | 82 | 0.3-420 | |||
| HSCT treated Hurler patient characteristics | |||||
| Gender (male/female) | 30/14 | ||||
| Age @ Start of treatment (mths) | 14 | 3-30 | |||
| Age @ final assessment (mths) | 66 | 11-203 | |||
| Interventions | |||||
| Therapeutic airway intervention post-HSCT | 3 | 7% | Adenotonsillar surgery: 2 pts (1 had revision). Longterm O2: 1 | ||
| Treatments and metabolic characteristics | |||||
| No HSCT (1/2/3) | 32/8/1 | 78/20/2 | |||
| Source (CB/BM/PBSC/Unknown) | 17/15/7/2 | 41/37/17/5 | |||
| Donor (Related/MUD) | 15/26 | 37/63 | |||
| IDUA @ 1 year post HSCT | 36 | 30.0 | 6.3-87.0 | ||
| Heterozygote Donors | 12 | 19.7 | 6.7-49.4 | ||
| Matched Unrelated Donors | 24 | 34.6 | 17.7-87.0 | ||
| Pre HSCT DS:CS ratio | 20 | 1.6 | 0.7-3.4 | ||
| DS:CS ratio @ 1 year | 32 | 0.5 | 0.2-0.8 | ||
| ERT treated Hurler Patients | |||||
| Gender (male/female) | 2/1 | ||||
| Age @ Start of treatment (mths) | 85 | 74-144 | |||
| Age @ final assessment (mths) | 123 | 98-148 | |||
| ERT Treated attenuated patients | |||||
| Gender (male/female) | 9/8 | ||||
| Age @ Start of treatment (mths) | 60 | 24-364 | |||
| Age @ final assessment (mths) | 131 | 72-420 | |||
| Interventions | |||||
| Therapeutic airway intervention on ERT | 7 | 41% | CPAP: 5 pts | ||
| Adenotonsillar Surgery: 2 pts (1 had revision) | |||||
| Metabolic characteristics | |||||
| Pre ERT DS:CS ratio | 5 | 1.9 | 1.1-2.7 | ||
| DS:CS ratio @ 1 year | 13 | 0.8 | 0.4-2.2 |
| Position | Residue (number of independent origins) |
| 97 | *C (1), F (2), I (4), L (A), V (5), *Y (1) |
| 100 | A (1), *F (1), *G (1), I (A), *L (1), *T (1), V (4) |
| 117 | H (1), I (4), L (A), V (1) |
| 125 | A (A), *C (1), *F (1), I (3), L (2), T (1), V (3) |
| 135 | I (4), L (A), *T (1), V (2) |
| 154 | A (1), *C (1), *F (1), I (A), L (2), *M (1), V (5) |
| CLOCK genotypes | Non-T2D subjects at baseline (n = 3671) | ||||||||
| Cases | Person-y | Incidence ratea | Model 1 | Model 2 | |||||
| HR | 95 % CI | P value | HR | 95 % CI | P value | ||||
| Dominant model | |||||||||
| CC | 130 | 6088.5 | 21.4 | 1.00 | (Reference) | 1.00 | (Reference) | ||
| CG + GG | 156 | 10727.7 | 14.5 | 0.68 | (0.54–0.86) | 0.001 | 0.69 | (0.54–0.87) | 0.002 |
| Variables | AA (n = 17) | SS (n = 55) |
| TNF-α (pg/mL) | 0(0); 0 7.2 | 0.63 (3.90); 0, 15.25* |
| IL-1β (pg/mL) | 0 (0.05); 0, 3.3 | 0 (0.91); 0, 6.33 |
| ICAM-1 (ng/mL) | 150.05 (89.91); 0, 249.01 | 93.81 (209.28); 0, 445.01 |
| IL-10 (ng/mL) | 6.36 (3.06); 0, 11.09 | 9.12 (12.76); 0, 33.56 |
| Holistic Affect | Worry | Afraid | Helpless | Interested | Angry | Sad | Hopeful | Depressed | Guilty | |
| Worry | 0.65** | |||||||||
| Afraid | 0.43** | 0.67** | ||||||||
| Helpless | 0.37** | 0.50** | 0.64** | |||||||
| Interested | 0.32** | 0.50** | 0.57** | 0.54** | ||||||
| Angry | 0.24** | 0.41** | 0.57** | 0.48** | 0.53** | |||||
| Sad | 0.44** | 0.59** | 0.70** | 0.58** | 0.57** | 0.68** | ||||
| Hopeful | 0.24** | 0.35** | 0.36** | 0.43** | 0.64** | 0.32** | 0.38** | |||
| Depressed | 0.37** | 0.55** | 0.68** | 0.57** | 0.47** | 0.57** | 0.66** | 0.27** | ||
| Guilty | 0.34** | 0.54** | 0.65** | 0.51** | 0.43** | 0.41** | 0.56** | 0.35** | 0.59** | |
| Disgusted | 0.21** | 0.40** | 0.54** | 0.52** | 0.52** | 0.78** | 0.64** | 0.26** | 0.57** | 0.40** |
| χ2 | P value | ||
| N0 | N1 | 5.701 | 0.017 |
| N2 | 6.164 | 0.013 | |
| N3 | 0.316 | 0.574 | |
| N1 | N2 | 0.379 | 0.538 |
| N3 | 0.613 | 0.434 | |
| N2 | N3 | 1.306 | 0.253 |
| Case | Treatment period (course) | Reason for cessation of therapy |
| 1 | 4 | Originally scheduled |
| 2 | 8 | |
| 3 | 8 | |
| 4 | 8 | |
| 5 | 4 | Changing the treatment |
| 6 | 2 | Severe watering eyes and fatigue |
| 7 | 8 | |
| 8 | 2 | Changing the hospital |
| 9 | 8 | |
| 10 | 7 | Repeated extension of drug holidays |
| 11 | 6 | Repeated extension of drug holidays |
| Variable | OR | SE | 95% CI | p value |
| Model 1. Knowledge about the modes of transmission and the main preventative measures of HIV (Sample size=244) | ||||
| Log likelihood=−118.4, χ2=37.67 (6 df), p<0.0001 | ||||
| Physician as source of information about HIV/AIDS | 4.34 | 1.71 | 2.01-9.42 | <0.001 |
| Having had more than one sexual partner and no consistent condom use in the last year | 0.33 | 0.13 | 0.16-0.7 | 0.004 |
| Educational level | ||||
| Middle school or lower | 0.34 | 0.16 | 0.14-0.84 | 0.019 |
| Baccalaureate degree/graduate degree* | 1.0 | |||
| Employment status | 0.63 | 0.2 | 0.33-1.19 | 0.15 |
| Need of additional information about HIV/AIDS | 0.63 | 0.21 | 0.33-1.21 | 0.17 |
| Number of other persons in the household | 0.69 | 0.27 | 0.32-1.47 | 0.34 |
| Model 3. Having received the HIV test (Sample size=244) | ||||
| Log likelihood=−114.71, χ2=20.76 (5 df), p<0.0001 | ||||
| Having visited a physician or having participated in preventive activities about HIV/AIDS | 2.67 | 0.93 | 1.35-5.29 | 0.005 |
| Gender | 0.42 | 1.66 | 0.19-0.91 | 0.028 |
| Knowledge about the modes of transmission and the main preventative measures of HIV | 1.73 | 0.62 | 0.85-3.52 | 0.13 |
| Educational level | ||||
| Middle school or lower | 0.54 | 0.23 | 0.23-1.26 | 0.15 |
| Baccalaureate degree/graduate degree* | 1.0 | |||
| Injecting drugs use in the last year | 1.85 | 0.8 | 0.79-4.33 | 0.16 |
| Variable | Coeff | SE | t | p value |
| Model 2. Fear of contracting HIV/AIDS (Sample size=244) | ||||
| F(6,237)=6.96, p<0.0001, R2=15%, adjusted R2=12.8% | ||||
| Perception of personal health status | 0.25 | 0.08 | 2.94 | 0.004 |
| Age | −0.04 | 0.02 | −2.48 | 0.014 |
| Marital status | −0.84 | 0.41 | −2.07 | 0.04 |
| Need of additional information about HIV/AIDS | 0.5 | 0.33 | 1.5 | 0.13 |
| Gender | 0.51 | 0.34 | 1.5 | 0.13 |
| Having received the HIV test | 0.39 | 0.39 | 1.01 | 0.31 |
| Constant | 5.87 |
| Variable | n | % |
| Official graduation | ||
| Soldier | 99 | 60 |
| Corporal | 38 | 23 |
| Sargent | 17 | 10.3 |
| Sublieutenant | 2 | 1.2 |
| Lieutenant | 5 | 3 |
| Capitan | 2 | 1.2 |
| Major | 2 | 1.2 |
| Total | 165 | 100 |
| Operation | ||
| Predominantly administrative | 28 | 17 |
| Predominantly operational | 137 | 83 |
| Total | 165 | 100 |
| Years of service | ||
| 1-10 | 67 | 40.6 |
| 11-20 | 34 | 20.6 |
| 21-30 | 62 | 37.6 |
| Above 31 | 2 | 1.2 |
| Total | 165 | 100 |
| Leisure physical activity level | ||
| Low | 86 | 52.1 |
| Moderate | 37 | 22.4 |
| High | 24 | 14.52 |
| Very high | 18 | 10.9 |
| Total | 165 | 100 |
| Coronary risk rating | ||
| Risk much lower than average | 10 | 6.1 |
| Risk lower than average | 58 | 35.2 |
| Medium risk | 70 | 42.4 |
| Moderate risk | 25 | 15.2 |
| High risk | 2 | 1.2 |
| Total | 165 | 100 |
| Age (years, mean ± SD (median and range)) | 67.8 ± 13.5 (68, 35-94) |
| Gender (male/female) | 35/26 |
| Eastern Cooperative Oncology Group Performance Status (0/1/2/3) | 33/13/12/3 |
| Location (colon/rectum) | 32/29 |
| Primary tumor-related obstruction (yes/no) | 36/25 |
| Metastasis (n) | |
| Liver only | 20 |
| Liver and lung | 10 |
| Liver and peritoneum | 5 |
| Extended lymph node only | 4 |
| Peritoneum only | 4 |
| Lung only | 1 |
| Bone only | 1 |
| Lung and bone | 1 |
| Treatment (n) | |
| Chemotherapy only | 16 |
| Surgical intervention + chemotherapy | 25 |
| Surgical intervention only | 13 |
| Best supportive care | 7 |
| Test | k-mer size | Promoter Set | Error (Ave ± S.D.) |
| (g, k)-table | 6 | small | 3.53e-5 ± 1.87e-4 |
| large | 2.65e-5 ± 1.04e-4 | ||
| 8 | small | 1.84e-5 ± 6.57e-5 | |
| large | 1.16e-5 ± 4.35e-5 | ||
| ESAsearch | small | 1.23e-4 ± 5.96e-4 | |
| large | 1.61e-4 ± 7.68e-4 |
| CRB-65 class (risk class) | 2005, n deaths (% of risk class) | 2006, n deaths (% of risk class) | Total, n deaths (% of risk class) |
| RC 1 (CRB-65 = 0) | 532 (1.76) | 1009 (2.97) | 1541 (2.40) |
| RC 2 (CRB-65 = 1 or 2) | 15 439 (12.09) | 21 871 (14.56) | 37 310 (13.43) |
| RC 3 (CRB-65 = 3 or 4 or requirement for mechanical ventilation at admission) | 9651 (33.56) | 6252 (35.76) | 15 903 (34.39) |
| Total deaths | 25 622 (13.72) | 29 132 (14.44) | 54 757 (14.10) |
| Characters | V. alcesa | V. alcesb | V. capreolic | V.cf.capreolia |
| Total length | 16.3–21.5 (18.3 ± 2.3) | 11.1–11.5 | 9.41–15 | 17.93* |
| Maximum width | 73–102 (86.0 ± 9.9) | 75–95 | 38–95 | 48.9–52.2 (50.5 ± 2.31) |
| Esophagus§ | 270–310 (289 ± 14.71) | – | 122–290 | 196–242.9 (225.0 ± 20.21) |
| Esophagus base width | 30–42 (36.7 ± 4.32) | – | – | 21.9–27.7 (23.8 ± 2.60) |
| Body width at esophagus base | 57–67 (61.1 ± 4.56) | – | – | 31–40.8 (35.3 ± 5.06) |
| Nerve-ring§ | 86–97 (91.6 ± 4.33) | – | 72–90 | 55.4–65.2 (60.7 ± 4.49) |
| Cervical papillae§ | 150–180 (163.3 ± 15.28) | – | – | 185.82* |
| Excretory pore§ | 159–220 (190.4 ± 29.11) | – | 86–186 | 171.5–190.8 (183.4 ± 10.37) |
| Tail | 34.2–50.5 (44.5 ± 4.65) | – | 34–78 | 31–40.8 (37.2 ± 3.47) |
| Vulva-anus | 70.1–104 (87.3 ± 10.1) | – | – | 57.1–73.4 (64.3 ± 6.62) |
| Vulva-tail | 107.6–146 (131.9 ± 12.77) | 122 | 90–144 | 91–114.1 (101.6 ± 8.42) |
| Width at vulva | 45.6–69 (56 ± 7.31) | – | – | 32.2–35.9 (33.4 ± 1.42) |
| Vagina | 702.2–961.42 (846.41 ± 94.94) | – | – | 467* |
| Vagina Vera | 63.3–71.7 (66.8 ± 2.70) | – | – | 73.4–91.3 (77.4 ± 6.90) |
| Vagina Uterina | 637–889.7 (779.2 ± 93.82) | – | – | 391.2* |
| Sphincter | 21.2–35.9 (31.8 ± 3.96) | – | – | 24.45* |
| Eggs Length† | 55.2–66.5 (61.9 ± 3.51) | 78 | 56–78 | NA |
| Eggs Width† | 46.2–63.0 (55.6 ± 6.14) | – | 37–45 | NA |
| CONV (N = 2575) | CAM (N = 6595) | ||||||
| # | % | 95% CI | # | % | 95% CI | ||
| Physicians | N | 78 | 30 | 184 | 70 | ||
| Patients | Children (N = 1291) | 118 | 9 | 1173 | 91 | ||
| Adults* (N = 7879) | 2457 | 31 | 5422 | 69 | |||
| All | 2575 | 28 | 6595 | 72 | |||
| Proportion of female, patients | Children** | 72 | 61 | 52–70 | 537 | 46 | 43–48 |
| Adults** | 1405 | 57 | 54–60 | 3866 | 71 | 70–73 | |
| All* | 1477 | 57 | 54–61 | 4403 | 67 | 65–68 | |
| Mean age, patients | Children | 11 years | 7 years | ||||
| Adults | 51 years | 49 years | |||||
| All | 49 years | 41 years |
| ISG (95% CI) | ICBD (95% CI) | |
| Sensitivity | 77.9% (71.3 to 83.6) | 97.9% (94.7 to 99.4) |
| Specificity | 69.1% (58.0 to 78.7) | 19.1% (11.3 to 29.1) |
| Positive Likelihood ratio | 2.52 (1.85 to 3.53) | 1.21 (1.10 to 1.28) |
| Negative Likelihood ratio | 0.32 (0.24 to 0.43) | 0.11 (0.03 to 0.34) |
| Disease prevalence | 69.3% (63.5 to 74.8) | 69.3% (63.5 to 74.8) |
| Positive Predictive Value | 85.1% (78.9 to 90.0) | 73.2 (67.3 to 78.6) |
| Negative Predictive Value | 58.0 (47.7 to 67.8) | 80.0 (56.3 to 94.3) |
| Position | Orientation | Distance/Å | Ea (NH3)/meV | ∆Q |
| B | U | 3.40 | 31.44 | 0.02 e |
| C | U | 3.49 | 45.53 | 0.02 e |
| T | U | 3.66 | 38.04 | 0.02 e |
| B | D | 3.46 | 39.45 | −0.01 e |
| C | D | 3.45 | 48.87 | −0.01 e |
| T | D | 3.45 | 39.42 | −0.01 e |
| Characteristics | Patients (Percentages) |
| Gender: | |
| Male | 49 (57) |
| Female | 37 (43) |
| Median Age: | 63 |
| Surgery: | |
| Biopsy | 7 (8) |
| STR | 32 (37) |
| GTR | 47 (55) |
| Adjuvant treatment: | |
| Long course adjuvant RT/TMZ | 65 (75) |
| Hypofractionated RT/TMZ | 4 (5) |
| Hypofractionated RT | 17 (20) |
| TMZ alone | 0 (0) |
| Radiotherapy dose: | |
| 60Gy | 65 (76) |
| 40Gy | 21 (24) |
| Re-resection rates: | |
| No further craniotomy | 70 (81) |
| Re-resection | 16 (19) |
| Attribute | LMG 727 | % | LMG 728 | % | LMG 730 | % |
| Genome size (bp) | 4,754,971 | 100.00 | 4,610,480 | 100.00 | 4,399,523 | 100.00 |
| DNA coding (bp) | 4,132,338 | 86.90 | 3,961,227 | 85.91 | 3,805,731 | 86.50 |
| DNA G+C (bp) | 3,250,022 | 68.35 | 3,149,419 | 68.31 | 3,007,954 | 68.37 |
| DNA scaffolds | 58 | 100.00 | 129 | 100.00 | 84 | 100.00 |
| Total genes | 3,933 | 100.00 | 3,906 | 100.00 | 3,803 | 100.00 |
| Protein coding genes | 3,878 | 98.6 | 3,851 | 98.6 | 3,749 | 98.6 |
| RNA genes | 55 | 1.40 | 55 | 1.40 | 54 | 1.40 |
| Pseudo genes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Genes in internal clusters | 978 | 24.86 | 924 | 23.65 | 876 | 23.03 |
| Genes with function prediction | 2,781 | 70.7 | 2,759 | 70.63 | 2,697 | 70.91 |
| Genes assigned to COGs | 2,987 | 75.94 | 2,935 | 75.14 | 2,928 | 76.99 |
| Genes with Pfam domains | 3,045 | 77.42 | 2,984 | 76.39 | 2,968 | 78.04 |
| Genes with signal peptides | 585 | 14.87 | 586 | 15 | 553 | 14.54 |
| Genes with transmembrane helices | 954 | 24.25 | 935 | 23.93 | 918 | 24.13 |
| CRISPR repeats | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Parameter | Mean ± SD | Range |
| Urinary sTNF-R55 (ng/μmol creatinine) | 29.2 ± 20.1 | 1.94–117 |
| Urinary sTNF-R55 (pg/ml) | 277 ± 183 | 52.0–861 |
| Urinary sTNF-R55 (ng/h) | 16.7 ± 11.5 | 0.94–81.1 |
| Urinary protein (mg/μmol creatinine) | 3.20 ± 2.25 | 0.08–14.5 |
| Urinary protein (mg/dl) | 3.48 ± 2.58 | 0.10–10.0 |
| Urinary protein (mg/h) | 1.76 ± 1.09 | 0.07–6.38 |
| Oral ulceration (%) | 0.59 ± 2.79 | 0.00–19.9 |
| Facial rash (%) | 2.67 ± 5.60 | 0.00–22.0 |
| Body temperature (°C) | 36.7 ± 0.25 | 36.1–37.4 |
| Weakness (%) | 7.77 ± 5.86 | 0.00–38.0 |
| Fatigue (%) | 35.2 ± 17.2 | 6.00–77.0 |
| Joint pain (%) | 20.2 ± 11.5 | 5.00–54.0 |
| Medium Cell\\Threshold | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| 1 | 641 | 557 | 481 | 418 | 359 | 295 | 228 | 182 | 147 | 118 |
| 2 | 787 | 710 | 641 | 583 | 545 | 502 | 458 | 424 | 399 | 354 |
| 3 | 568 | 517 | 456 | 419 | 397 | 361 | 330 | 308 | 286 | 263 |
| 4 | 433 | 370 | 326 | 281 | 242 | 211 | 175 | 138 | 117 | 98 |
| 5 | 469 | 428 | 376 | 336 | 316 | 286 | 272 | 251 | 236 | 214 |
| 6 | 649 | 510 | 466 | 433 | 388 | 369 | 338 | 313 | 291 | 273 |
| 7 | 509 | 489 | 402 | 359 | 325 | 298 | 265 | 237 | 214 | 195 |
| 8 | 459 | 409 | 374 | 339 | 304 | 285 | 263 | 243 | 227 | 212 |
| 9 | 658 | 583 | 536 | 489 | 453 | 416 | 384 | 356 | 326 | 302 |
| 10 | 642 | 582 | 527 | 473 | 431 | 395 | 364 | 324 | 298 | 272 |
| Mean CAV (μm3) | 582 | 516 | 458 | 413 | 376 | 342 | 308 | 278 | 254 | 230 |
| SD CAV (μm3) | 113 | 100 | 94 | 88 | 87 | 83 | 83 | 84 | 84 | 80 |
| Number of Cells | 86 | 85 | 84 | 83 | 80 | 81 | 81 | 81 | 80 | 81 |
| TAV (μm3 * 10E6) | 0.05 | 0.04 | 0.04 | 0.03 | 0.03 | 0.03 | 0.03 | 0.02 | 0.02 | 0.02 |
| Gene | size | Sense primer | Antisense primer |
| Ehvps2 | 741 | 5′-GCGGATCCATGTCAAGGTTATTC-3′ | 5′-CCGTCGACTTAAAGATTGGCTATTCT |
| TGAAACAATATCATCTTCATCTTC-3′ | |||
| Ehvps20 | 621 | 5′-GCGGATCCATGTTAAATCGATTCA-3′ | 5′-CCGTCGACTTTAAATTGCAAATTTTTT |
| GCTATCTGGTT-3′ | |||
| Ehvps20 (1-173) | 522 | 5′-CCGGATCCATGTTAAATCGATTCA-3′ | 5′-CGTCGACTTAAATATCTCCTTCAAACA |
| TTGAAT-3′ | |||
| Ehvps24 | 618 | 5′-GCGGATCCATGGGCAACCTTAAT | 5′-CCGTCGACTTAAAAGGTTTCTATTACA |
| AGCCAAACAGTAGATAATAG-3′ | ATATTTTGTTTAGATATTAACATTCACTT-3′ | ||
| Ehvps32 (1-165) | 495 | 5′-CCCCGGATCCATGTCTTGGTTCA | 5′-CCCCGTCGACTTATTCTTGTTCATCA |
| GAAGAAATACTAC-3′ | AGAACTTGATCTTCTAAT-3′ |
| Process mode | Sugar | Strain | Time | CDW | Sugar consumed | 3HB | HAc | mean qS total | mean q3HB | Y3HB/HAc | Y3HB/CDW | Y3HB/Sugar |
| (h) | (g L−1) | (g L−1) | (g L−1) | (g L−1) | (g g−1 h−1) | (mg g−1 h−1) | (g g−1) | (g g−1) | (g g−1) | |||
| Batch | Glc | AF1000 | 5.5 | 4.18 | 8.90 | 0.51 | 0.96 | 1.0 | 68 | 0.54 | 0.12 | 0.06 |
| Batch | Glc + Xyl + Ara | PPA652ara | 7.3 | 4.88 | 9.65 | 0.31 | 0.00 | 0.7 | 25 | → ∞ | 0.06 | 0.03 |
| N-depletion | Glc + Xyl + Ara | AF1000 | 16.0 | 0.27 | 2.73 | 0.64 | 0.48 | 0.2 | 29 | 1.33 | 2.37 | 0.23 |
| N-depletion | Glc + Xyl + Ara | PPA652ara | 15.0 | 0.39 | 3.79 | 0.54 | 0.54 | 0.3 | 31 | 1.00 | 1.38 | 0.14 |
| N-fedbatch | Glc + Xyl + Ara | AF1000 | 11.0 | 10.37 | 37.05 | 1.84 | 2.66 | 0.6 | 45 | 0.69 | 0.18 | 0.05 |
| N-fedbatch | Glc + Xyl + Ara | PPA652ara | 11.0 | 11.82 | 36.75 | 1.87 | 0.77 | 0.6 | 38 | 2.43 | 0.16 | 0.05 |
| Probe set | Microarray | Probe subset | T0 | T1 | T2 | T4 | T8 | T12 |
| PrV | SLA/PrV | Probes homologous to a single transcript | 0 | 3 | 7 | 18 | 26 | 30 |
| Total | 0 | 3 | 13 | 34 | 52 | 58 | ||
| Pig | SLA/PrV | up-regulated SLA/Immune probes | 0 | 0 | 0 | 1 | 4 | 3 |
| down regulated SLA/Immune probes | 0 | 0 | 0 | 11 | 18 | 13 | ||
| up-regulated random probes | 1 | 0 | 2 | 4 | 15 | 11 | ||
| down-regulated random probes | 0 | 0 | 0 | 20 | 70 | 80 | ||
| Total | 1 | 0 | 2 | 36 | 107 | 107 | ||
| Qiagen- NRSP8 | up-regulated probes | ND* | 27 | 134 | 1262 | 3184 | ND* | |
| down-regulated probes | ND* | 4 | 47 | 1494 | 3509 | ND* | ||
| Total | ND* | 31 | 181 | 2756 | 6693 | ND* |
| Morphed | Non-morphed | |
| Same identity | Not associated during training | Associated during training |
| Different identity | Associated during training | Not associated during training |
| MOTHERS | INFANTS | ||||||
| N | θw | θc | θw | θc | |||
| Mother B | 12 | 0.015 | 0.038 | Infant B | 12 | 0.014 | 0.033 |
| Mother C | 12 | 0.025 | 0.058 | Infant C | 13 | 0.021 | 0.060 |
| Mother D | 11 | 0.017 | 0.042 | Infant D | 10 | 0.019 | 0.040 |
| Mother F | 14 | 0.012 | 0.029 | Infant F | 12 | 0.018 | 0.053 |
| Mother H | 14 | 0.020 | 0.020 | Infant H1 | 11 | 0.009 | 0.016 |
| Infant H2 | 11 | 0.015 | 0.044 | ||||
| Totals | 63 | 0.018 | 0.037 | 69 | 0.016 | 0.041 |
| Phe/protein goals | Formula goals | Healthy food choices | |
| Precontemplation | 1 | – | – |
| Contemplation | 6 | – | 5 |
| Preparation | 5 | 5 | 5 |
| Action | 5 | 6 | 10 |
| Maintenance | 14 | 20 | 11 |
| Variable | n | % |
| Gender | ||
| Female | 1371 | 62.1 |
| Male | 836 | 37.9 |
| Age | ||
| ≤16 years | 1259 | 57.3 |
| ≥17 years | 940 | 42.7 |
| Socioeconomic status | ||
| High (A1, A2, B1, B2) | 517 | 23.7 |
| Intermediate (C1, C2) | 1383 | 63.4 |
| Low (“D” and “E”) | 280 | 12.8 |
| Violent behavior | ||
| Yes | 363 | 16.5 |
| No | 1842 | 83.5 |
| Cigarette smoking | ||
| Yes | 146 | 6.6 |
| No | 2051 | 93.4 |
| Alcohol consumption | ||
| Yes | 844 | 38.5 |
| No | 1350 | 61.5 |
| Marijuana consumption | ||
| Yes | 53 | 2.4 |
| No | 2140 | 97.6 |
| Body shape satisfaction | ||
| Satisfied | 1314 | 59.9 |
| Dissatisfied | 879 | 40.1 |
| Physical activity | ||
| Low levels | 1945 | 89.2 |
| Active | 236 | 10.8 |
| Suicide ideation | ||
| Yes | 307 | 14.0 |
| No | 1889 | 86.0 |
| Suicide plan | ||
| Yes | 208 | 9.5 |
| No | 1992 | 90.5 |
| Suicide attempt | ||
| Yes | 131 | 5.9 |
| No | 94.1 | 94.1 |
| Baseline characteristic variables | Intervention group (n = 70) | Control group (n = 72) | Meaningful level (P value) |
| Age (mean ± SD) | 32.04 ± 5.901 | 29.77 ± 5.21 | 0.017 |
| Number of previous pregnancies (mean ± SD) | 3.04 ± 1.13 | 2.92 ± .900 | 0.463 |
| Weeks of pregnancy(mean ± SD) | 14.39 ± 3.12 | 14.39 ± 2.69 | 0.997 |
| Systolic blood pressure(mm Hg; mean ± SD) | 115.87 ± 14.52 | 114.51 ± 7.27 | 0.028 |
| Diastolic blood pressure(mm Hg; mean ± SD) | 74.28 ± 4.95 | 74.31 ± 6.40 | 0.975 |
| Uterine ↓ cm(mean ± SD) | 14.58 ± 3.50 | 14.28 ± 3.26 | 0.597 |
| 24 h proteinuria (mg/cc;mean ± SD) | 132.22/1844.91 ± 61.447 | 154.94/1958.53 ± 53.376 | 0.023 |
| BMI < 18.5 kg/m2 (n (%)) | 1 (1.4%) | 1 (1.4%) | 0.267 |
| BMI, 18.5–24.9 kg/m2 (n (%)) | 23 (32.9%) | 14 (19.4%) | 0.267 |
| BMI, 25.0–29.9 kg/m2 (n (%)) | 32 (45.7%) | 35 (49.3%) | 0.267 |
| BMI ≥ 30.0 kg/m2 (n (%)) | 13 (18.6%) | 21 (29.6%) | 0.267 |
| Mean± SD | Poor collateral | Good collateral | P value |
| Number (%) | (n = 122) | (n = 80) | |
| Number of diseased vessels | 2.1 ± 0.9 | 2.6 ± 0.6 | <0.001 |
| Significant CAD, n (%) | |||
| 1 vessel disease (%) | 47 (38.5) | 12 (15.0) | |
| 2 vessel disease (%) | 41 (33.6) | 21 (26.3) | <0.001 |
| 3 vessel disease (%) | 34 (27.9) | 47 (58.8) | |
| Diffuse score of CAD | 3.01 ± 1.75 | 4.03 ± 1.83 | <0.001 |
| 1 vessel disease | 1.25 ± 0.67 | 1.42 ± 0.66 | |
| 2 vessel disease | 2.72 ± 0.86 | 2.84 ± 0.99 | |
| 3 vessel disease | 4.41 ± 1.43 | 4.84 ± 1.63 |
| Gene ID | Gene | Regulation | Computational matching of regulatory consensus | Position of DNA fragment used § | |||
| Position§ | Sequence | Score | LacZ | Footprinting | |||
| YPO1222 | ompC | + | R-191...-169 | AAACAGTGAGTTATAGCACATAT | 12.3 | -379...+130 | -281...-26 |
| YPO1411 | ompF | + | D-131...-109 | ACTTTGTGACTTAGATCGAATTT | 10.73 | -328...+143 | -237...-4 |
| YPO2506 | ompX | - | D-156...-134 | AGTATGTGACCTCCATCACCCAA | 11.68 | -374...+123 | -321...+4 |
| YPO0136 | ompR | NO | - | - | 0 | -409...+83 | -409...+83 |
| YPO0175 | crp | NO | R+235...+257 | GAACTCTGAGCCCTGTTAAGTTA | 1.44 | -147...+344 | -147...+344 |
| Target radius [px] | 15 | 20 | 25 | 30 | |
| Feedback factor | 0.3 | 7.0 (10.0) | 6.1 (8.2) | 13.2 (13.7) | 16.6 (21.0) |
| 0.8 | 28.2 (21.6) | 34.8 (25.7) | 52.7 (33.2) | 56.8 (35.1) | |
| 1.3 | 48.5 (28.1) | 64.4 (29.2) | 69.5 (28.9) | 82.4 (27.5) | |
| 1.8 | 67.3 (29.7) | 77.1 (25.4) | 90.0 (14.3) | 93.0 (14.4) |
| Exon | Name | Target | Amplicon size | Sequence (5’–3’) |
| 18 | 18 FP | G719A/S/C | 112 bp | CAGGAAACAGCTATGACCTGGAGCCTCTTACACCCAGT |
| 18 RP | ACCGTGCCGAACGCACCGGA | |||
| 18 LNA | GAGCCCAGC | |||
| 19 | 19 FP | Deletions | 176 bp | GTTAAAATTCCCGTCGCTATCA |
| 19 RP | TGTAAAACGACGGCCAGTTGTGGAGATGAGCAGGGTCT | |||
| 19 LNA | CAAGGAATTAAGA | |||
| 20 | 20 FP | Insertions | 161 bp | GAAGCCTACGTGATGGCCA |
| 20 RP | CAGGAAACAGCTATGACCAGCAGGTACTGGGAGCCAAT | |||
| 20 LNA | CAGCGTGGACA | |||
| - | M13-tag 1 | For Sanger sequencing | - | TGTAAAACGACGGCCAGT |
| - | M13-tag 2 | For Sanger sequencing | - | CAGGAAACAGCTATGACC |
| Covariates | dfAIC | dfAICc | dfBIC | dfREML |
| DI | 14.99 | 14.99 | 5.10 | 6.39 |
| Size | 10.98 | 10.63 | 1.78 | 2.78 |
| LNI | 2.01 | 1.50 | 1.50 | 2.18 |
| Number of helminth infections | All asthma | Non-atopic asthma | Atopic asthma | ||||
| n (%) | *OR (95% CI) | n (%) | **Non-atopic/non-asthmatic | n (%) | **Non-atopic/non-asthmatic | **Atopic/non-asthmatic | |
| 0 | |||||||
| (n = 580; 45.6%) | 164 (28.3) | 1 | 59 (10.2) | 1 | 60 (10.3) | 1 | 1 |
| 1 | 1.02 | 1.40 | 1.24 | 1.01 | |||
| (n = 463; 36.4%) | 133 (28.7) | (0.78; 1.34) | 60 (13.0) | (0.92; 2.11) | 51 (11.0) | (0.81; 1.90) | (0.69; 1.74) |
| 2 | 1.20 | 1.33 | 1.23 | 1.01 | |||
| (n = 162; 12.8%) | 52 (32.1) | (0.82; 1.75) | 21 (13.0) | (0.74; 2.38) | 19 (11.7) | (0.68; 2.23) | (0.53; 1.92) |
| 3 | 1.55 | 1.84 | 0.91 | 1.02 | |||
| (n = 66; 5.2%) | 25 (37.9) | (0.91; 2.63) | 12 (18.2) | (0.87; 3.89) | 6 (9.1) | (0.36; 2.34) | (0.37; 2.84) |
| P value of the Wilcoxon signed-rank test | |||||||
| DSSs | PRM (Degree) | LPDS | BRDS | FUDS | LBDS | LFDS | BFDS |
| LPDS | 4.02 ± 1.84 | ||||||
| BRDS | 39.70 ± 4.60 | <0.001 | |||||
| FUDS | 0.93 ± 1.06 | <0.001 | <0.001 | ||||
| LBDS | 31.44 ± 5.10 | <0.001 | <0.001 | <0.001 | |||
| LFDS | 4.22 ± 2.26 | 0.823 | <0.001 | <0.001 | <0.001 | ||
| BFDS | 37.67 ± 8.68 | <0.001 | 0.723 | <0.001 | 0.003 | <0.001 | |
| LBFDS | 31.31 ± 6.11 | <0.001 | <0.001 | <0.001 | 0.852 | <0.001 | 0.004 |
| P value of the Friedman test | <0.001 |
| Key inclusion criteria | Key exclusion criteria |
| - Male or female patients ≥18 years old. | - Patients with a history of acute rejection classified > BANFF II, chronic active antibody-mediated rejection or chronic T-cell-mediated rejection. |
| - Recipients of deceased or living kidney transplants. | - Patients with an EC-MPS dose of <720 mg/d (MMF <1000 mg/d) and MPA-AUC <30 mg*h/L. |
| - Time after the last renal transplantation at least six months. | - Patients with symptoms of significant somatic or mental illness. Inability to cooperate or communicate with the investigator, who are unlikely to comply with the study requirements, or who are unable to give informed consent. |
| - Stable renal allograft function, defined as S-creatinine ≤3.5 mg/dL and Δ S-creatinine ≤30% during the last three months. | - Females of childbearing potential who are planning to become pregnant, who are pregnant or lactating, and/or who are unwilling to use effective means of contraception, unless |
| - Patients who are willing and able to participate in the study and from whom written informed consent has been obtained. | a. their career, lifestyle, or sexual orientation precludes intercourse with a male partner,orb. their partners have been sterilised by vasectomy or other means |
| - Evidence of drug or alcohol abuse | |
| - Patients actively taking part in an interventional trial |
| ORF | Gene Symbol | EC | Enzyme | Evidence |
| a) Intersection of our predictions with the experimental screen | ||||
| STM0123 | murE | 6.3.2.13 | UDP-N-acetylmuramoylalanyl-D-glutamate-2,6-diaminopimelate ligase | ** |
| STM0128 | murG | 2.4.1.227 | N-acetylglucosaminyl transferase | * |
| STM0129 | murC | 6.3.2.8 | UDP-N-acetylmuramate-L-alanine ligase | ** |
| STM0154 | lpdA | 1.8.1.4 | Dihydrolipoamide dehydrogenase | |
| STM0218 | pyrH | 2.7.4.22 | Uridylate kinase | * |
| STM0221 | uppS | 2.5.1.31 | Undecaprenyl pyrophosphate synthase | ** |
| STM0222 | cdsA | 2.7.7.41 | CDP-diglyceride synthase | |
| STM0228 | lpxA | 2.3.1.129 | UDP-N-acetylglucosamine acyltransferase | |
| STM0232 | accA | 6.4.1.2 | Acetyl-CoA carboxylase | ** |
| STM0489 | hemH | 4.99.1.1 | Ferrochelatase | * |
| STM0535 | lpxH | UDP-2,3-diacylglucosamine hydrolase | ||
| STM0542 | folD | 1.5.1.5, 3.5.4.9 | Bifunctional 5,10-methylene-tetrahydrofolate dehydrogenase | |
| STM0988 | kdsB | 2.7.7.38 | CTP:CMP-KDO cytidylyltransferase | * |
| STM1194 | fabD | 2.3.1.39 | Acyl carrier protein S-malonyltransferase | * |
| STM1195 | fabG | 1.1.1.100 | 3-ketoacyl-(acyl-carrier-protein) reductase | ** |
| STM1200 | tmk | 2.7.4.9 | Thymidylate kinase | |
| STM1700 | fabI | 1.3.1.10 | Enoyl-(acyl carrier protein) reductase | |
| STM2483 | dapE | 3.5.1.18 | Succinyl-diaminopimelate desuccinylase | |
| STM2652 | pssA | 2.7.8.8 | Phosphatidylserine synthase | * |
| STM3090 | metK | 2.5.1.6 | ||
| STM3415 | rpoA | 2.7.7.6 | DNA-directed RNA polymerase subunit alpha | |
| STM3724 | kdtA | 3-deoxy-D-manno-octulosonic-acid transferase | * | |
| STM3730 | dfp | 4.1.1.36 | Pantothenate kinase | ** |
| STM3912 | rep | 3.6.1.- | ATP-dependent DNA helicase Rep | * |
| STM3978 | yigC | 3-octaprenyl-4-hydroxybenzoate decarboxylase | ||
| STM4153 | rpoB | 2.7.7.6 | DNA-directed RNA polymerase subunit beta | * |
| STM4154 | rpoC | 2.7.7.6 | DNA-directed RNA polymerase subunit beta' | |
| b) Predictions for the non-mevalonate pathway | ||||
| STM0049 | ispH, lytB | 1.17.1.2 | 4-hydroxy-3-methylbut-2-enyl diphosphate reductase | * |
| STM0220 | dxr | 1.1.1.267 | 1-deoxy-D-xylulose 5-phosphate reductoisomerase | * |
| STM0422 | dxs | 2.2.1.7 | 1-deoxy-D-xylulose-5-phosphate synthase | ** |
| STM0423 | ispA | 2.5.1.10 | geranyltranstransferase | * |
| STM1779 | ispE, ipk | 2.7.1.149 | 4-diphosphocytidyl-2-C-methyl-D-erythritol kinase | ** |
| STM2523 | ispG, gcpE | 1.17.7.1 | 4-hydroxy-3-methylbut-2-en-1-yl diphosphate synthase | * |
| STM2929 | ispF | 4.6.1.12 | 2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase | * |
| STM2930 | ispD | 2.7.7.60 | 2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase | * |
| Species | FTa | FTb | FTc | MFT | TFL1 | BFT | Total |
| A. duranensis | 3 | 4 | 1 | 2 | 2 | 1 | 13 |
| A. ipaensis | 4 | 4 | 1 | 2 | 3 | 1 | 15 |
| C. cajan | 2 | 2 | 0 | 1 | 3 | 1 | 9 |
| C. arietinum | 3 | 1 | 1 | 1 | 5 | 1 | 12 |
| G. max | 4 | 4 | 2 | 1 | 5 | 2 | 18 |
| L. japonicus | 1 | 2 | 0 | 1 | 2 | 0 | 6 |
| L. angustifolius | 2 | 0 | 2 | 3 | 4 | 1 | 12 |
| M. truncatula | 3 | 2 | 1 | 1 | 3 | 1 | 11 |
| P. vulgaris | 2 | 2 | 1 | 1 | 3 | 1 | 10 |
| V. radiata | 2 | 4 | 1 | 1 | 3 | 1 | 12 |
| Total | 26 | 25 | 10 | 14 | 33 | 10 | 118 |
| n* | Discomfort | Lack of motivation | Lack of time | Lack of social support | Poor environment | |
| Median (25%–75%)† | Median (25%–75%)† | Median (25%–75%)† | Median (25%–75%)† | Median (25%–75%)† | ||
| Overall | 1.8 (1.3–2.4) | 2.9 (2.1–3.7) | 3.0 (2.3–3.8) | 1.6 (1.1–2.3) | 2.2 (1.4–3.0) | |
| Sex | ||||||
| Male | 403 | 2.0 (1.4–2.5) | 2.9 (2.1–3.7) | 3.0 (2.3–3.8) | 1.8 (1.1–2.4) | 2.3 (1.5–3.0) |
| Female | 462 | 1.7 (1.3–2.4) | 3.0 (2.2–3.6) | 3.1 (2.3–3.8) | 1.6 (1.1–2.2) | 2.2 (1.4–3.0) |
| P value‡ | 0.028 | 0.944 | 0.952 | 0.102 | 0.282 | |
| Age, years | ||||||
| 20–39 | 275 | 1.8 (1.3–2.5) | 3.1 (2.3–3.9) | 3.3 (2.6–3.9) | 1.6 (1.1–2.3) | 2.3 (1.4–3.1) |
| 40–59 | 373 | 1.9 (1.4–2.5) | 3.0 (2.2–3.7) | 3.2 (2.5–3.9) | 1.6 (1.1–2.3) | 2.1 (1.4–2.9) |
| 60–69 | 217 | 1.8 (1.3–2.4) | 2.6 (1.8–3.3) | 2.4 (1.7–3.2) | 1.6 (1.1–2.3) | 2.4 (1.5–3.0) |
| P value§ | 0.320 | <0.001 | <0.001 | 0.706 | 0.155 | |
| Location of residence | ||||||
| Tsukuba | 207 | 1.8 (1.3–2.5) | 2.9 (2.1–3.7) | 3.0 (2.3–3.9) | 1.6 (1.1–2.3) | 2.2 (1.4–3.0) |
| Koganei | 248 | 1.8 (1.4–2.4) | 3.0 (2.3–3.8) | 3.1 (2.5–3.7) | 1.6 (1.1–2.2) | 2.3 (1.6–3.0) |
| Shizuoka | 222 | 1.9 (1.3–2.5) | 3.0 (2.2–3.6) | 3.0 (2.2–3.9) | 1.7 (1.1–2.4) | 2.3 (1.5–3.0) |
| Kagoshima | 188 | 1.8 (1.3–2.3) | 2.8 (2.0–3.5) | 2.9 (2.1–3.6) | 1.7 (1.1–2.3) | 2.1 (1.3–2.9) |
| P value§ | 0.501 | 0.203 | 0.149 | 0.603 | 0.215 | |
| Education, years | ||||||
| <13 | 332 | 1.8 (1.4–2.5) | 2.7 (1.9–3.4) | 2.8 (2.1–3.6) | 1.7 (1.1–2.3) | 2.2 (1.4–3.0) |
| ≥13 | 529 | 1.8 (1.3–2.4) | 3.1 (2.3–3.8) | 3.2 (2.4–3.8) | 1.6 (1.1–2.3) | 2.2 (1.5–3.0) |
| P value‡ | 0.751 | <0.001 | 0.001 | 0.193 | 0.979 | |
| Marital status | ||||||
| Married | 650 | 1.9 (1.3–2.4) | 2.9 (2.1–3.6) | 3.0 (2.3–3.7) | 1.6 (1.1–2.2) | 2.2 (1.4–3.0) |
| Not married | 211 | 1.8 (1.3–2.6) | 3.0 (2.2–3.8) | 3.2 (2.4–4.0) | 1.7 (1.1–2.5) | 2.3 (1.4–3.1) |
| P value‡ | 0.515 | 0.491 | 0.020 | 0.344 | 0.594 | |
| Employment status | ||||||
| Employed | 644 | 1.8 (1.3–2.5) | 3.0 (2.2–3.7) | 3.2 (2.5–3.9) | 1.6 (1.1–2.3) | 2.2 (1.5–3.0) |
| Not employed | 220 | 1.8 (1.3–2.4) | 2.9 (2.0–3.5) | 2.5 (1.7–3.2) | 1.6 (1.1–2.3) | 2.2 (1.4–3.0) |
| P value‡ | 0.600 | 0.317 | <0.001 | 0.832 | 0.740 | |
| Living with a child or person in need of care | ||||||
| Yes | 313 | 1.7 (1.3–2.5) | 2.9 (2.0–3.7) | 3.2 (2.4–3.9) | 1.6 (1.1–2.3) | 2.2 (1.4–3.0) |
| No | 551 | 1.9 (1.4–2.4) | 3.0 (2.2–3.7) | 3.0 (2.2–3.6) | 1.6 (1.1–2.3) | 2.2 (1.5–3.0) |
| P value‡ | 0.301 | 0.473 | 0.010 | 0.941 | 0.944 | |
| Self-rated health | ||||||
| Fair or poor | 407 | 2.1 (1.5–2.6) | 3.1 (2.3–3.8) | 3.0 (2.3–3.8) | 1.8 (1.1–2.4) | 2.3 (1.6–3.0) |
| Good | 456 | 1.7 (1.2–2.3) | 2.8 (2.0–3.5) | 3.1 (2.3–3.8) | 1.5 (1.1–2.2) | 2.1 (1.3–3.0) |
| P value‡ | <0.001 | <0.001 | 0.849 | 0.008 | 0.037 | |
| BMI, kg/m2 | ||||||
| <25 | 689 | 1.8 (1.3–2.4) | 2.9 (2.1–3.7) | 3.0 (2.3–3.7) | 1.5 (1.1–2.3) | 2.2 (1.4–2.9) |
| ≥25 | 173 | 2.1 (1.4–2.6) | 3.1 (2.4–3.7) | 3.1 (2.2–3.9) | 1.9 (1.2–2.4) | 2.5 (1.7–3.3) |
| P value‡ | 0.010 | 0.169 | 0.732 | 0.028 | 0.001 | |
| Exercise, days/week | ||||||
| <3 | 684 | 1.9 (1.4–2.5) | 3.0 (2.2–3.7) | 3.1 (2.4–3.9) | 1.7 (1.1–2.3) | 2.3 (1.5–3.0) |
| ≥3 | 181 | 1.5 (1.1–2.3) | 2.7 (1.7–3.4) | 2.8 (1.9–3.5) | 1.3 (1.0–2.1) | 2.2 (1.3–3.0) |
| P value‡ | <0.001 | <0.001 | 0.001 | 0.001 | 0.519 |
| Non-smoker, non ETS exposed | Non-smoker ETS exposed | Active smoker | |
| Birth weight (in Kg) | N = 8091 | N = 2256 | N = 6395 |
| Mean Birthweight (SE)† | 3.448 (0.007) | 3.389 (0.014) | 3.279 (0.009) |
| Crude mean difference compared to Non-Smoker, Non ETS exposed (95% CI) | - | -0.059 (-0.090 to -0.027)p < 0.001 | -0.168 (-0.191 to -0.146)p < 0.001 |
| Adjusted Mean difference* (95% CI) | - | -0.036 (-0.067 to -0.005)p = 0.025 | -0.146 (-0.171 to -0.122)p < 0.001 |
| SGA z score | N = 8024 | N = 2228 | N = 6338 |
| Mean Z score (SD)† | 0.077 (0.014) | 0.006 (0.026) | -0.237 (0.016) |
| Crude mean difference compared to Non-Smoker, Non ETS exposed (95% CI) | - | -0.070 (-0.128 to -0.013)p = 0.016 | -0.314 (-0.354 to -0.273)p < 0.001 |
| Adjusted Mean difference* (95% CI) | -0.038 (-0.093 to 0.018)p = 0.18 | -0.275 (-0.319 to -0.231)p < 0.001 |
| Defecation: all records | ||||
| Variable | Pooled | Pooled | Means (n > 5) | Means (n > 5) |
| Data type | angular | axial | angular | axial |
| Number of observations | 1,893 | 1,893 | 49 | 49 |
| Mean vector (μ) | 133° | 157°/337° | 80° | 148°/328° |
| Length of mean vector (r) | 0.013 | 0.052 | 0.043 | 0.209 |
| Circular standard deviation | 169° | 70° | 144° | 51° |
| 95% Confidence interval (-/+) for μ | - | - | - | 121°-174° |
| 99% Confidence interval (-/+) for μ | - | - | - | 112°-183° |
| Rayleigh test (Z) | 0.307 | 5.203 | 0.091 | 2.143 |
| Rayleigh test (p) | 0.736 | 0.006 | 0.914 | 0.117 |
| NO. | Lesion size (cm) | GTV volume (cc) | Seed activity (mCi)/D90 (Gy) | GTV:V100/V90 | Seeds numbers | Post-seed implant therapies | PS:NRS | ASIA | Ambulatory function score | RR | LR (m) | Follow-up (m) | Cause of death |
| 1 | 1.5×1.5×1.0 | 9.9 | 0.5/90 | 92.4/95.2 | 7 | Palliative Surgery | 2-3 | E | PR | 13 | 69 | MM | |
| 2 | 8.5×7.5×7.0 | 110.2 | 0.5/100 | 93.2/96 | 80 | Seed implant | 0-1 | C | PR | 8 | 11 | MM | |
| 3 | 5.5×4.5×11 | 104.1 | 0.8/100 | 90.1/94.2 | 79 | No | 5-6 | C | SD | 39 | 41 | MM | |
| 4 | 2.7×1.5×5.0 | 102.8 | 0.8/140 | 93.2/96.7 | 92 | No | 1-2 | D | PR | 32 | 32 | MM | |
| 5 | 2.5×2.0×1.6 | 32.6 | 0.7/121 | 92.8/94.5 | 45 | Seed implant | 0-1 | E | CR | 34 | 36 | MM | |
| 6 | 5.5×4.1×1.7 | 103.8 | 0.72/108 | 89.2/93.2 | 109 | No | 1-2 | D | PR | 19 | 19 | MM | |
| 7 | 6.2×10.7×8.3 | 100.3 | 0.75/148 | 96.8/99.2 | 100 | CTx | 0-1 | D | CR | 36 | 36 | S | |
| 8 | 8.1×6.3×6.8 | 99.6 | 0.73/143 | 97.5/99 | 103 | No | 2 | E | PR | 35 | 35 | S | |
| 9 | 11.5×3.1×3.5 | 39.6 | 0.7/102 | 87.8/90.7 | 44 | No | 0-1 | E | PR | 21 | 21 | S | |
| 10 | 6.0×3.2×4.1 | 73.1 | 0.6/150 | 99/99.7 | 122 | No | 1-2 | E | PR | 4 | 4 | MM | |
| 11 | 1.4×4.8×3.9 | 50.5 | 0.64/164 | 95.2/95.9 | 98 | No | 2 | E | PR | 17 | 17 | S | |
| 12 | 4.6×3.5×7.7 | 46.2 | 0.68/152 | 98.6/99.3 | 74 | No | 0 | E | PR | 3 | 3 | S | |
| 13 | 4.5×6.4×4.3 | 27.4 | 0.7/152 | 95.1/96.4 | 47 | No | 0 | E | SD | 3 | 3 | S | |
| 14 | 6.0×5.0×4.0 | 27.8 | 0.65/133 | 98.1/99.3 | 48 | No | 1 | E | PR | 12 | 12 | S | |
| 15 | 6.0×3.5×4.5 | 60.5 | 0.74/122 | 93.5/96.2 | 85 | No | 3 | D | PR | 11 | 11 | S | |
| 16 | 2.3×1.8×1.2 | 22.9 | 0.75/137 | 96.3/98.2 | 31 | No | 2 | D | SD | 2 | 2 | S | |
| 17 | 4.8×4.1×5.0 | 28.2 | 0.74/183 | 93.2/96.3 | 55 | Seed implant | 0-1 | E | SD | 14 | 20 | LR |
| Phase | Activity | Setting | Duration |
| 1. Open focus group discussion | Firstly, informal conversation and ice-breaking activities were used to create a relaxing environment. Then a discussion was conducted to identify barriers that influence children’s recess play. Questions used were: | Classroom/meeting room at the school | 30 minutes |
| • What are your experiences around recess? | |||
| • What do you do during recess? | |||
| • Who are you playing with? | |||
| • Who initiates play? | |||
| • Is there something you want to do in recess that you cannot or may not do? What was this? | |||
| • What do you think about your schoolyard? | |||
| • Can you explain what physical activity is? | |||
| • Do you like being physically active? Why/why not? | |||
| • What influences your physical activity during recess? | |||
| 2. Go-along interview | The children pointed out where they usually played during recess, the activity they played and who they played with. A Google Earth aeria photograph of the schoolyard was used as a tool (by the moderator), to indicate where different activities took place. | Shared indoor and outdoor areas at the school | 20 minutes |
| 3. Post-it note activity | An open brainstorm to identify significant barriers to engaging in physical activity during recess. The groups were told to write down all the barriers that they could think of on post-it notes. | Classroom/meeting room. Gender separated groups | 10 minutes |
| Response | Fraction | Acid/alkali | pH | T | t | pH·T | pH·pH | T·t |
| Glucose | Solid | Acidic | x | x | x | - | ||
| Liquid | Acidic | - | - | |||||
| Xylose | Solid | Acidic | x | x | x | x | ||
| Liquid | Acidic | x | ||||||
| Lignin | Solid | Acidic | x | |||||
| Glucose | Solid | Alkaline | x | x | x | |||
| Liquid | Alkaline | x | x | x | ||||
| Xylose | Solid | Alkaline | x | - | x | |||
| Liquid | Alkaline | x | x | x | x | |||
| Lignin | Solid | Alkaline | x | x | x |
| Case no. | Sex | Age (y) | Profession | Eye | Risk Factor | Disease course | Initial diagnosis |
| P1 | Female | 55 | Actress | Left | Eye exposure to cosmetics | 4 m | AK |
| P2 | Male | 44 | Fisherman | Left | Eye exposure to fish pond water | 20d | AK |
| P3 | Male | 60 | Farmer | Right | Mosquito entering into the eye | 2 m | FK |
| P4 | Female | 23 | Clerk | Right | Wearing contact lenses | 1 m | HSK |
| P5 | Male | 52 | Farmer | Left | Hit with an iron wire | 2 m | FK |
| P6 | Male | 49 | Farmer | Left | Eye exposed to paddy field water | 45d | AK |
| P7 | Female | 59 | Farmer | Right | Winged insect in the eye | 1 m | AK |
| P8 | Male | 39 | Upfitter | Right | Eye exposed to cement | 2 m | FK |
| P9 | Male | 28 | Fisherman | Left | Unclear | 40d | HSK |
| P10 | Male | 37 | Farmer | Right | Unclear | 1 m | BK |
| P11 | Male | 19 | Worker | Right | Eye exposed to foul water | 1 m | AK |
| P12 | Male | 63 | Farmer | Left | Injured by a stick | 2 m | FK |
| P13 | Male | 37 | Farmer | Right | Injured by a stick | 1.5 m | FK |
| P14 | Female | 39 | Farmer | Left | Injured by a stick | 3 m | FK |
| P15 | Female | 30 | Worker | Right | Injured by a pencil | 2 m | FK |
| Statistics | PIS_3 | PIS_4 | ||
| Fluidigm2PURC | reduce_amplicons | Fluidigm2PURC | reduce_amplicons | |
| Consensus | ||||
| Alignment length (bp) | 395 | 415 | 403 | 418 |
| Percent gaps | 27.9 | 30.0 | 1.9 | 4.4 |
| Parsimony informative sites | 19 | 19 | 11 | 10 |
| Unknown ploidy/occurrence | ||||
| No. of haplotypes | 18 | 5 | 14 | 6 |
| Alignment length (bp) | 395 | 403 | 403 | 424 |
| Percent gaps | 16.2 | 48.9 | 2.7 | 7.1 |
| Parsimony informative sites | 48 | 11 | 43 | 10 |
| Known ploidy | ||||
| No. of haplotypes | 57 | — | 43 | — |
| Alignment length (bp) | 395 | — | 403 | — |
| Percent gaps | 10.3 | — | 2.6 | — |
| Parsimony informative sites | 81 | — | 62 | — |
| BVS (n = 26) | EES (n = 34) | P-value | |
| MACE, n (%) | 1 (4) | 2 (6) | 1.000 |
| Death, n (%) | 0 | 0 | |
| MI, n (%) | 0 | 0 | |
| TV-Revasc., n (%) | 1 (4) | 2 (6) | 1.000 |
| Non-TV-Revasc. n (%) | 0 | 0 |
| Would more or better testing have produced a more effective intervention? | ||||
| Was the intervention tested?1 | Yes | No | Unclear | Totals |
| Yes – extensively | 4 | 11 | 1 | 16 |
| Yes – to some degree | 5 | 11 | 2 | 18 |
| No | 4 | 4 | 0 | 8 |
| Totals | 13 | 26 | 3 | 42 |
| Was the test phase mentioned in the published article?2 | ||||
| Was the intervention tested?1 | Yes | No | Totals | |
| Yes – extensively | 10 | 6 | 16 | |
| Yes – to some degree | 7 | 11 | 18 | |
| No | - | 8 | 8 | |
| Totals | 17 | 25 | 42 |
| Knowledge items | Mean current knowledge score (1–5) | Mean desired knowledge score (1–5) | Gapa |
| Dosing and creating effective treatment plans for patients using CTP | 1.63 | 4.10 | 2.60 |
| Health Canada's MMPR | 1.88 | 4.20 | 2.43 |
| Similarities and differences between dried cannabis, other forms of cannabis products, and prescription cannabinoid medications | 1.83 | 4.14 | 2.41 |
| Laws and regulations surrounding CTP | 2.06 | 4.21 | 2.29 |
| Mechanism of action of cannabis/endocannabinoid system | 2.15 | 4.16 | 2.24 |
| Safety, warning signs and precautions for patients using CTP | 2.21 | 4.22 | 2.18 |
| Alternative routes of administration of CTP | 2.10 | 4.13 | 2.11 |
| Potential risks of using CTP | 2.39 | 4.20 | 1.96 |
| Potential uses of CTP | 2.57 | 4.13 | 1.79 |
| Tracheostomy | No tracheostomy | Standardized differences of mean | |
| Number (%) or mean ± sd | Number (%) or mean ± sd | ||
| Number | 267 | 267 | |
| Age | 58.4 ± 16.6 | 58.9 ± 17.9 | 0.03 |
| Sex (male) | 171 (64.0) | 171 (64.0) | 0.00 |
| BMI | 27.9 ± 7.8 | 27.9 ± 15.0 | 0.00 |
| Geographic area | |||
| European countries with high income | 174 (64.2) | 172 (64.4) | 0.02 |
| Non-European countries with high income | 49 (18.4) | 48 (18.0) | 0.01 |
| Countries with middle income | 44 (16.5) | 47 (17.6) | 0.03 |
| Type of admission | |||
| Medical | 178 (66.7) | 183 (68.5) | 0.04 |
| Surgical | 52 (19.5) | 48 (18.0) | 0.04 |
| Elective | 19 (7.1) | 21 (7.9) | 0.03 |
| Trauma | 18 (6.7) | 15 (5.6) | 0.05 |
| Comorbidities | |||
| COPD or home ventilation | 60 (22.5) | 65 (24.3) | 0.04 |
| Diabetes mellitus | 64 (23.9) | 64 (23.9) | 0.00 |
| Chronic renal failure | 27 (10.1) | 23 (8.6) | 0.05 |
| Immunosuppression or active or hematologic neoplasm | 66 (24.7) | 62 (23.3) | 0.04 |
| Heart failure (NYHA classes III-IV) | 19 (7.1) | 22 (8.2) | 0.04 |
| Chronic liver failure (Child-Pugh Class C) | 2 (0.7) | 2 (0.7) | 0.00 |
| Cause of AHRF - pneumonia | 186 (69.7) | 195 (73.0) | 0.07 |
| ARDS risk factor | |||
| No risk factor | 17 (6.4) | 17 (6.4) | 0.00 |
| Only indirect risks factor | 45 (16.9) | 39 (14.6) | 0.06 |
| Only direct risk factors | 168 (62.9) | 173 (65.0) | 0.04 |
| Both risk factors | 37 (13.9) | 38 (14.2) | 0.01 |
| ECMO use | 19 (7.1) | 16 (6.0) | 0.05 |
| Arterial gas | |||
| pH | 7.4 ± 0.1 | 7.4 ± 0.1 | 0.07 |
| P/F ratio (mmHg) | 204.1 ± 86.5 | 199.1 ± 63.7 | 0.07 |
| PaCO2 (mmHg) | 44.4 ± 13.9 | 44.2 ± 14.1 | 0.01 |
| Non-respiratory SOFA score adjusted for missing values, | 5.1 ± 3.4 | 5.1 ± 3.6 | 0.00 |
| Study | Diagnostic variable | Comparison | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) |
| Casellini (34) | DPN | NIS-LL | 78 | 92 | 74 | 93 |
| Smith (9) | Distal symmetric polyneuropathy | UENS | 77 | 67 | 59 | 83 |
| Yajnik (37) | DPN | VPT | 73 | 62 | N/A | N/A |
| Eranki (41) | DPN | VPT | 82 | 55 | N/A | N/A |
| Calvet (39) | CAN – diabetes | CARTs | 83 | 63 | N/A | N/A |
| Ozaki (42) | Diabetic kidney disease | eGFR, ACR | 94 | 78 | 81 | 93 |
| Beat Type | Total Number | TP | TN | FP | FN | Sensitivity(%) | Specificity(%) |
| N | 800 | 800 | 2943 | 3 | 0 | 100.00 | 99.90 |
| PVC | 289 | 272 | 3450 | 7 | 17 | 94.12 | 99.80 |
| APC | 1175 | 1166 | 2559 | 12 | 9 | 99.23 | 99.53 |
| RBBB | 900 | 896 | 2835 | 11 | 4 | 99.55 | 99.61 |
| LBBB | 582 | 574 | 3159 | 5 | 8 | 98.62 | 99.84 |
| Average | 98.98 | 99.75 |
| Anatomical region | Coordinates x, y, and z (mm) | Brodmann area | Cluster equiv. | Voxel Z score |
| Activation | ||||
| Broca's area | −34, 6, 28 | 44 | 110 | 5.84 |
| ACC | 2, 8, 40 | 32 | 228 | 5.72 |
| SSAC | 16, −26, 48 | 5 | 114 | 5.65 |
| Wernicke's area | 46, −48, 20 | 22 | 30 | 5.52 |
| VAC | −6, −88, 38 | 19 | 31 | 5.32 |
| CV | 6, −62, −4 | — | 14 | 5.28 |
| VC (V2) | 24, −80, 6 | 18 | 17 | 5.24 |
| Deactivation | ||||
| IPL | −40, −40, 34 | 39/40 | 286 | 6.74 |
| FP | −2, 68, −8 | 10 | 160 | 6.66 |
| IFG PT | 40, 28, 16 | 45 | 117 | 6.53 |
| PSMA | 30, 14, 44 | 6 | 348 | 6.34 |
| PMC (M1) | −28, −18, 56 | 4 | 45 | 6.12 |
| FEF/dl-PFC | −30, 12, 44 | 8/9 | 157 | 5.93 |
| dl-PFC | −38, 26, 24 | 46 | 309 | 5.70 |
| AG/FG | −40, −60, 8 | 39/37 | 177 | 5.58 |
| ITG | −70, −22, −20 | 20 | 20 | 5.66 |
| TP | 40, 22, −44 | 38 | 12 | 5.64 |
| CV (V1) | −14, −66, 24 | 17 | 46 | 5.29 |
| Meeting days | Non-meeting days | P | |
| Whole arrests | |||
| 1-month survival, % (n/N) | 3.8 (774/20 143) | 3.8 (1477/38 859) | |
| Crude OR (95% CI) | 1.01 (0.93–1.11) | Reference | 0.802 |
| Adjusted OR (95% CI) | 1.01 (0.92–1.11) | Reference | 0.799 |
| Favorable neurologic outcome, % (n/N) | 1.6 (324/20 142) | 1.5 (596/38 855) | |
| Crude OR (95% CI) | 1.05 (0.92–1.08) | Reference | 0.488 |
| Adjusted OR (95% CI) | 1.02 (0.88–1.19) | Reference | 0.757 |
| Bystander-witnessed VF arrests with cardiac origin | |||
| 1-month survival, % (n/N) | 28.9 (275/951) | 26.5 (481/1814) | |
| Crude OR (95% CI) | 1.12 (0.94–1.35) | Reference | 0.179 |
| Adjusted OR (95% CI) | 1.10 (0.92–1.33) | Reference | 0.297 |
| Favorable neurologic outcome, % (n/N) | 19.1 (182/951) | 17.9 (324/1813) | |
| Crude OR (95% CI) | 1.09 (0.89–1.33) | Reference | 0.413 |
| Adjusted OR (95% CI) | 1.04 (0.83–1.29) | Reference | 0.750 |
| Point estimate | SE (boot) | Bootstrapping BC 95 % CI | ||
| Lower | Upper | |||
| Visiting STI services regularly | ||||
| Subjective norms | −0.00 | 0.02 | −0.04 | 0.04 |
| Perceived behavioral control | 0.08 | 0.03 | 0.04 | 0.15a |
| Adherence to STI treatment | ||||
| Subjective norms | 0.13 | 0.11 | 0.01 | 0.46a |
| Perceived behavioral control | 0.29 | 0.17 | 0.10 | 0.63a |
| Taking an HIV test | ||||
| Subjective norms | 0.03 | 0.03 | −0.01 | 0.09 |
| Perceived behavioral control | 0.03 | 0.02 | 0.01 | 0.07a |
| Picking up the result of HIV test | ||||
| Subjective norms | −0.01 | 0.02 | −0.05 | 0.02 |
| Perceived behavioral control | 0.13 | 0.04 | 0.06 | 0.22a |
| Children (n = 168), M (SD) | Parents (n = 172), M (SD) | |
| Total anxiety | 29.03 (18.47) | 29.07 (14.61) |
| Separation anxiety | 4.37 (3.90) | 5.18 (3.62) |
| Social phobia | 5.76 (3.92) | 6.79 (3.74) |
| Panic disorder/agoraphobia | 4.37 (4.55) | 4.05 (3.42) |
| Specific phobia | 4.20 (2.88) | 4.63 (2.94) |
| Generalized anxiety | 5.39 (3.65) | 4.65 (2.61) |
| STEMI (n = 22) | NSTEMI (n = 11) | Total (n = 33) | |
| Age in years, median | 62.6 | 62.4 | 62.5 |
| Age ≥ 70 | 9 (40.9%) | 2 (18.2%) | 9 (27.3%) |
| Female | 5 (22.7%) | 2 (18.2%) | 7 (21.2%) |
| Hypertension | 7 (31.8%) | 8 (72.7%) | 15 (45.5%) |
| Diabetes mellitus | 5 (22.7%) | 2 (18.2%) | 7 (21.2%) |
| Dyslipidemia | 19 (86.4%) | 8 (72.7%) | 27 (81.8%) |
| Current smoker | 9 (40.9%) | 6 (54.5%) | 15 (45.5%) |
| Prior MI | 1 (4.5%) | 3 (27.3%) | 4 (12.2%) |
| Prior PCI | 1 (4.5%) | 5 (45.5%) | 6 (18.2%) |
| Prior CABG | 0 | 0 | 0 |
| BMI in kg/m2 | 28.4 | 27.4 | 28.1 |
| Control | Social Media | |||||
| T0 (n) | T1 (n) | p-value | T0 (n) | T1 (n) | p-value | |
| MPR (mean) | 0.79 ± 0.07 (12) | 0.81 ± 0.05 (12) | 0.56 | 0.75 ± 0.06 (12) | 0.92 ± 0.03 (12) | < 0.001* |
| MPR < 1 | 0.64 ± 0.07 (7) | 0.76 ± 0.07 (7) | 0.08 | 0.72 ± 0.05 (11) | 0.93 ± 0.05 (11) | < 0.001* |
| MPR ≥ 0.8 | 58% (7/12) | 67% (8/12) | 0.67 | 50% (6/12) | 92% (11/12) | 0.03 |
| MASRI (mean) | 87.8 ± 4.0 (12) | 90.4 ± 2.4 (12) | 0.76 | 85.4 ± 6.7 (11) | 84.2 ± 7.7 (11) | 0.44* |
| MASRI ≥0.8 | 79% (11/14) | 93% (13/14) | 0.28 | 75% (9/12) | 75% (9/12) | 1.0 |
| Traitsa | SNPs | Chr. | Position (bp) | Allele | MAF | -Log10(P) | Allele's effect |
| RCC | TM57102 | D5 | 8,908,622 | A/G | 0.36(G) | 5.23 | 0.06 |
| TM57104 | D5 | 8,918,010 | A/C | 0.14(C) | 5.23 | 0.06 | |
| RMDA | TM5633 | A2 | 80,274,022 | A/G | 0.18(A) | 5.00 | −0.28 |
| TM70162 | D9 | 3,595,148 | A/G | 0.47(A) | 6.53 | −0.13 | |
| TM70169 | D9 | 3,793,378 | A/C | 0.48(A) | 6.53 | −0.13 | |
| TM70170 | D9 | 3,801,945 | A/G | 0.47(A) | 6.53 | −0.13 | |
| TM70171 | D9 | 3,812,331 | A/T | 0.47(T) | 6.53 | −0.13 | |
| RGR | TM43002 | A12 | 84,233,507 | A/G | 0.17(G) | 5.34 | 0.13 |
| Unadjusted odds ratio | p value | Adjusted odds ratio | p value | |
| [95% confidence interval] | [95% confidence interval] | |||
| Adequate sleep | <.0001 | .9812 | ||
| 7 hours or more | Reference | Reference | ||
| Less than 7 hours | 1.34 [1.18, 1.52] | 1.00 [0.83, 1.21] | ||
| Age group | <.0001 | |||
| 30 to less than 45 years | Reference | |||
| 45 to less than 55 years | 2.77 [2.04, 3.76] | |||
| 55 years and above | 5.49 [3.77, 8.01] | |||
| Sex | <.0001 | |||
| Female | Reference | |||
| Male | 2.60 [2.17, 3.12] | |||
| Race/ethnicity | ||||
| Non-Hispanic white | Reference | |||
| Non-Hispanic black | 1.88 [1.20, 2.96] | .0060 | ||
| Hispanic | 2.94 [2.18, 3.97] | <.0001 | ||
| Other | 1.65 [1.13, 2.41] | .0092 | ||
| Education | <.0001 | |||
| HS graduate/less | 1.34 [1.09, 1.65] | |||
| Some coll/tech/more | Reference | |||
| Smoking | ||||
| Current | 2.74 [1.98, 3.80] | <.0001 | ||
| Former | 1.43 [1.15, 1.79] | .0016 | ||
| Never | Reference | |||
| Number of missing teeth | ||||
| 0–5 | Reference | |||
| 6–9 | 1.44 [1.14, 1.82] | .0024 | ||
| 10–20 | 2.64 [2.02, 3.44] | <.0001 | ||
| More than 20 | 2.18 [1.02, 4.65] | .0445 | ||
| Federal Poverty Level Index | ||||
| 0 to less than 1.25 | 1.82 [1.23, 2.71] | .0028 | ||
| 1.25 to less than 2.00 | 1.62 [1.15, 2.26] | .0053 | ||
| 2.00 to less than 4.00 | 1.60 [1.07, 2.39] | .0213 | ||
| 4.00 and above | Reference | |||
| Insurance coverage | <.0001 | |||
| Yes | Reference | |||
| No | 1.73 [1.43, 2.10] | |||
| Diabetes | .1567 | |||
| Yes | 1.41 [0.88, 2.26] | |||
| No | reference |
| Primers | Sequence (5′–3′) |
| pmirGLO-HA-F | CTAGCTAGCAGCAAAAGCAGGGGAAAAC |
| pmirGLO-HA-R | CCGCTCGAGTAGTAGAAACAAGGGTGTTTTTTTC |
| pmirGLO-HA-mut-F | ATTAATGATATTCCGAAAGAAGTCC |
| pmirGLO-HA-mut-R | GGACTTCTTTCGGAATATCATTAAT |
| pmirGLO-NS-F | TACGAGCTCGCAAAAGCAGGGTGACAA |
| pmirGLO-NS-R | TGCTCTAGATAGTAGAAACAAGGGTGTTTTTTAT |
| pmirGLO-NS-mut-F | GATATCGAAACTCGGACTCTTGTTG |
| pmirGLO-NS-mut-R | CAACAAGAGTCCGAGTTTCGATATC |
| pmirGLO-PB1-F | TACGAGCTCAGCAAAAGCAGGCAAACC |
| pmirGLO-PB1-R | CCGCTCGAGTAGTAGAAACAAGGCATTTTTTCA |
| pmirGLO-PB2-F | CCGCTCGAGAGCAAAAGCAGGTCAAATATATT |
| pmirGLO-PB2-R | TGCTCTAGATAGTAGAAACAAGGTCGTTTTAAAC |
| pmirGLO-PA-F | TACGAGCTCAGCAAAAGCAGGTACTGATCC |
| pmirGLO-PA -R | CCGCTCGAGTAGTAGAAACAAGGTACTTTTTTGG |
| pmirGLO-NA-F | TACGAGCTCAGCAAAAGCAGGAGTTTAAAAT |
| pmirGLO-NA-R | CCGCTCGAGTAGTAGAAACAAGGAGTTTTTTGAAC |
| pmirGLO-NP-F | CCGCTCGAGAGCAAAAGCAGGGTAGATAATC |
| pmirGLO-NP-R | TGCTCTAGATAGTAGAAACAAGGGTATTTTTCCT |
| Variables | No. of study (n = 28) | Coefficient (95% CI) | P value |
| Univariate meta-regression | |||
| Year of publication | 28 | 0.03 (−0.03–0.08) | 0.288 |
| Male% in sample | 28 | 0.001 (−0.01–0.02) | 0.862 |
| Sample size | 28 | 0.00 (−0.00–0.00) | 0.435 |
| Study location | |||
| Inland | 19 | Reference | |
| Coastal | 9 | −0.35 (−0.84–0.14) | 0.153 |
| Study region | 0.054 | ||
| South | 5 | Reference | |
| Central | 6 | 0.54 (−0.15–1.22) | 0.119 |
| North | 17 | 0.71 (0.14–1.30) | 0.017 |
| Study period | |||
| 2006–2012 | 18 | Reference | |
| 1990–2005 | 10 | −0.11 (−0.60–0.38) | 0.656 |
| Study setting | 0.451 | ||
| Rural and urban | 4 | Reference | |
| Urban | 21 | 0.39 (−0.29–1.06) | 0.251 |
| Rural | 3 | 0.51 (−0.44–1.47) | 0.278 |
| Diagnostic criteria | |||
| 15 μmol/L | 25 | Reference | |
| Others | 3 | 0.16 (−0.60–0.92) | 0.671 |
| Methods of Hcy measurement | 0.798 | ||
| FPIA | 5 | Reference | |
| ECA | 9 | −0.10 (−0.81–0.62) | 0.783 |
| HPLC | 8 | 0.07 (−0.66–0.80) | 0.846 |
| Others | 6 | 0.22 (−0.55–1.00) | 0.555 |
| Multivariate meta-regression | 0.0511 | ||
| Year of publication | 28 | 0.04 (−0.01–0.09) | 0.242 |
| Study location | |||
| Inland | 19 | Reference | |
| Coastal | 9 | −0.16 (−0.70–0.38) | 0.614 |
| Study region | 0.294 | ||
| South | 5 | Reference | |
| Central | 6 | 0.48 (−0.25–1.21) | 0.185 |
| North | 17 | 0.66 (−0.01–1.33) | 0.052 |
| Al | Cd | Cu | Fe | Pb | Zn | Na | Ca | K | Mg | DOC | PH = | Temp. | |
| P1 | NS | *(0.89) | NS | NS | NS | NS | NS | NS | NS | NS | *(0.80) | *(0.85) | NS |
| P1.1 | NS | *(0.82) | NS | NS | NS | NS | NS | NS | NS | NS | NS | NS | NS |
| P2 | NS | *(0.82) | NS | NS | NS | NS | NS | NS | NS | NS | *(0.80) | *(0.86) | NS |
| P3 | NS | NS | NS | NS | NS | NS | NS | *(0.90) | NS | NS | NS | NS | NS |
| P4 | NS | NS | NS | NS | NS | NS | NS | *(0.90) | NS | NS | NS | NS | NS |
| P5 | NS | NS | NS | NS | NS | NS | *(0.88) | NS | NS | NS | NS | NS | NS |
| P6 | NS | NS | NS | NS | NS | NS | *(0.84) | NS | NS | NS | NS | NS | NS |
| G1 | *(0.86) | NS | *(0.83) | ‡(0.99) | ‡(1.00) | *(0.80) | NS | NS | NS | NS | NS | NS | *(0.87) |
| G2 | *(0.88) | NS | *(0.85) | ‡(1.00) | ‡ (1.00) | *(0.82) | NS | NS | NS | NS | NS | NS | *(0.89) |
| G3 | NS | NS | NS | NS | NS | NS | *(0.91) | NS | NS | *(0.81) | NS | NS | NS |
| G4 | NS | NS | NS | NS | NS | NS | †(0.94) | NS | NS | NS | NS | NS | NS |
| G5 | NS | *(0.87) | NS | NS | NS | NS | NS | NS | NS | NS | NS | †(0.92) | NS |
| G6 | NS | NS | NS | NS | NS | NS | †(0.94) | NS | NS | NS | NS | NS | NS |
| G7 | NS | NS | NS | NS | NS | NS | NS | *(0.90) | NS | †(0.77) | NS | NS | NS |
| G8 | NS | NS | NS | NS | NS | NS | †(0.94) | NS | NS | NS | NS | NS | NS |
| G9 | NS | NS | NS | NS | NS | NS | NS | *(0.90) | NS | NS | NS | NS | NS |
| G10 | NS | NS | NS | NS | NS | NS | †(0.93) | NS | NS | NS | NS | NS | NS |
| G11 | *(0.85) | NS | *(0.82) | ‡(0.98) | ‡ (1.00) | †(0.79) | NS | NS | NS | NS | NS | NS | *(0.86) |
| G12 | NS | NS | NS | NS | NS | NS | *(0.90) | NS | NS | NS | NS | NS | NS |
| G13 | NS | NS | NS | NS | NS | NS | *(0.91) | NS | *(0.77) | NS | NS | NS | NS |
| G14 | NS | NS | NS | NS | NS | NS | †(0.92) | NS | NS | NS | NS | NS | NS |
| G15 | NS | *(0.89) | NS | NS | NS | NS | NS | NS | NS | NS | *(0.84) | †(0.93) | NS |
| G16 | NS | NS | NS | NS | NS | NS | NS | *(0.90) | NS | *(0.78) | NS | NS | NS |
| G17 | NS | NS | NS | NS | NS | NS | †(0.94) | NS | NS | NS | NS | NS | NS |
| G18 | NS | NS | NS | NS | NS | NS | NS | *(0.87) | NS | NS | NS | NS | NS |
| G19 | *(0.86) | NS | *(0.83) | ‡(0.99) | ‡(1.00) | *(0.80) | NS | NS | NS | NS | NS | NS | *(0.88) |
| G20 | NS | NS | NS | NS | NS | NS | NS | †(0.93) | NS | *(0.82) | NS | NS | NS |
| G21 | NS | NS | NS | NS | NS | NS | NS | *(0.91) | NS | *(0.78) | NS | NS | NS |
| G22 | NS | NS | NS | NS | NS | NS | NS | *(0.85) | NS | NS | NS | NS | NS |
| G23 | NS | NS | NS | NS | NS | NS | NS | *(0.90) | NS | NS | NS | NS | NS |
| G24 | NS | NS | NS | NS | NS | NS | NS | *(0.90) | NS | *(0.77) | NS | NS | NS |
| G25 | NS | *(0.86) | NS | NS | NS | NS | NS | NS | NS | NS | *(0.83) | †(0.93) | NS |
| 3 hours | 24 hours | 7 days | |
| Pulpdent | 6.3-7.2 | 7.1-8.2 | 7.4-7.9 |
| Dycal | 5.8-7.6 | 7.2-7.8 | 7.4-7.8 |
| ProRoot MTA | 6.2-7.3 | 7.1-7.5 | 7.5-7.8 |
| Negative control | 5.7-7.2 | 6.0-7.6 | 6.8-7.7 |
| Positive control | 6.4-7.0 | 6.8-7.5 | 6.7-7.4 |
| Deionized water | 6.4-7.4 | 6.9-7.2 | 6.8-7.5 |
| BMI | Macrosomia (n =700) | Control (n =5137) | OR (95%CI) | P | |
| Male | Normal | 259(60.66%) | 1,838(69.99%) | - | - |
| Overweight | 99(23.19%) | 459(17.52%) | 1.53(1.19-1.97) | 0.001 | |
| Obesity | 69(16.15%) | 328(12.49%) | 1.49(1.14-1.99) | 0.007 | |
| Female | Normal | 183(67.03%) | 1,873(74.56%) | - | - |
| Overweight | 58(21.24%) | 408(16.24%) | 1.45(1.06-1.99) | 0.019 | |
| Obesity | 32(11.73%) | 231(9.20%) | 1.42(0.95-2.11) | 0.087 | |
| Total | Normal | 442(63.14%) | 3,711(72.24%) | - | - |
| Overweight | 157(22.43%) | 867(16.88%) | 1.52(1.24-1.86) | 0.001 | |
| Obesity | 101(14.43%) | 559(10.88%) | 1.50(1.19-1.92) | < 0.001 |
| Group | Material | Contrast | Region of main effect | Comparison with controls (increased/decreased, location) | Correlation with memory performance (location, correlating measure) |
| Controls | Words | Remembered > forgotten | Left HC | ||
| Pictures | Bilateral PHG | ||||
| Faces | Right HC, A | ||||
| Words | Viewing > fixate | Left PHG | |||
| Pictures | Left PHG | ||||
| Faces | Bilateral FG | ||||
| Left TLE | Words | Remembered > forgotten | – | Increased, Right PHG | Right HC, 1/verbal recall |
| Pictures | – | – | – | ||
| Faces | Right HC, ERC | Increased, Right ERC | - | ||
| Words | Viewing > fixate | Right PHG | Reduced, Left HC | Left HC, verbal recall | |
| Increased, Right PHG | Right HC, 1/verbal recall | ||||
| Pictures | Right PHG | Reduced, Left HC | Left HC, verbal learning | ||
| Right HC, 1/verbal learning | |||||
| Faces | Right PHG, FG | Increased, Right FG | - | ||
| Right TLE | Words | Remembered > forgotten | Left HC | Increased, Left HC | - |
| Pictures | Left PHG | - | Right HC, figure recall | ||
| Faces | - | - | Left HC, 1/figure recall | ||
| - | |||||
| Words | Viewing > fixate | - | Increased, Left HC | - | |
| Pictures | Left HC | Increased, Left HC | Right HC, figure recall | ||
| Faces | Right HC | - | - |
| Bivariate associations (n = 3438) | Adjusted odds ratios (n = 3293) | |||||||
| Increased = No | Increased = Yes | OR | 95% CI1 | AORa | 95% CI1 | |||
| n | (%) | n | (%) | |||||
| Site Characteristics | ||||||||
| Site level | ||||||||
| Primary | 1932 | 78% | 552 | 22% | Ref | Ref | ||
| Secondary | 594 | 73% | 218 | 27% | 1.28 | (1.07, 1.54)** | 1.20 | (0.95, 1.51) |
| Tertiary | 94 | 66% | 48 | 34% | 1.78 | (1.25, 2.56)** | 1.78 | (0.99, 3.19) |
| Community outreach with abortion information | ||||||||
| Yes | 763 | 75% | 256 | 25% | 1.10 | (0.92, 1.90) | 1.26 | (1.03, 1.55)* |
| No | 1756 | 77% | 538 | 23% | Ref | Ref | ||
| Provider Characteristics | ||||||||
| Fiscal year trained | ||||||||
| FY 2012 | 747 | 77% | 220 | 23% | Ref | Ref | ||
| FY 2013 | 650 | 71% | 271 | 29% | 1.44 | (1.17, 1.77)** | 1.56 | (1.24, 1.96)*** |
| FY 2014 | 555 | 77% | 162 | 23% | 1.01 | (0.80, 1.27) | 0.97 | (0.75, 1.26) |
| FY 2015 | 654 | 80% | 165 | 20% | 0.87 | (0.70, 1.10) | 0.81 | (0.63, 1.04) |
| Any prior uterine evacuation experience | ||||||||
| Yes | 803 | 75% | 273 | 25% | 1.13 | (0.95, 1.33) | 0.95 | (0.77, 1.17) |
| No | 1788 | 77% | 540 | 23% | Ref | Ref | ||
| Any other Ipas-trained providers at site | ||||||||
| Yes | 803 | 77% | 239 | 23% | 0.93 | (0.79, 1.11) | 0.95 | (0.76, 1.19) |
| No | 1817 | 76% | 579 | 24% | Ref | Ref | ||
| Provider Support | ||||||||
| Total in-person, post-training contacts (Mean, SD) | (3.3, 2.2) | (3.8, 2.4) | 1.11 | (1.07, 1.15)*** | 1.17 | (1.11, 1.22)*** | ||
| Total non-in-person, post-training contacts (Mean, SD) | (2.3, 2.0) | (2.3, 1.8) | 1.01 | (0.97, 1.05) | 0.95 | (0.91, 1.00) |
| Culture | MIC mode (μg/ml)a | ||||||||
| Carb | Cpz | Gentb | Kanb | Levo | Nor | Rif | Tet | Vanc | |
| M. smegmatis | |||||||||
| pH 5.6 | 50 | 2.0 | 4.0 | 6.3 | |||||
| pH 6.6 | 50 | 2.0 | 2.0 | 25 | |||||
| pH 7.6 | 50 | 1.0 | 2.0 | 25 | |||||
| pH 6.6 + DNP | 50 | 2.0 | 2.0 | 13 | |||||
| S. aureus | |||||||||
| pH 6 | 50 | 3.1 | 13 | ||||||
| pH 7 | 13 | 1.6 | 13 | ||||||
| pH 8 | 3.1 | 1.6 | 13 | ||||||
| pH 7 + DNP | 200 | 0.4 | 13 | ||||||
| E. coli | |||||||||
| pH 6 | 6.3 | 13 | 125 | ||||||
| pH 7 | 6.3 | 6.3 | 63 | ||||||
| pH 8 | 6.3 | 1.6 | 31 | ||||||
| pH 7 + DNP | 13 | 6.3 | 125 | ||||||
| P. aeruginosa | |||||||||
| pH 6 | 3.1 | 0.2 | 13 | ||||||
| pH 7 | 1.6 | 0.2 | 13 | ||||||
| pH 8 | 0.4 | 0.1 | 13 | ||||||
| pH 7 + DNP | 1.6 | 0.2 | 13 |
| Solution Set | Health Status Level | Health Description | Maintenance Level |
| A1 | Health (HS) | healthy condition | No maintenance |
| A2 | Subhealth (SHS) | normal range | Preventive maintenance |
| A3 | failure edge (FES) | fault edge | Corrective maintenance |
| A4 | Failure (FS) | fault condition | Immediate maintenance |
| Reference | Study | # Cases | # Controls | Outcomes | Comment |
| [214] | Nurses' Health Study | 3,483 | ↓folate intake + alcohol = ↑risk of breast cancer (OR = 0.55, P-trend = 0.001) | Folate intake not associated with overall risk of breast cancer | |
| [215] | Canadian National Breast Screening Study | 1,336 | 5,382 | ↓folate intake + alcohol = ↑risk of breast cancer (OR = 0.34, P-trend = 0.004) | Folate intake not associated with overall risk of breast cancer |
| [216] | Prospective study in USA with postmenopausal women | 1,586 | Among drinkers, ↓folate intake = ↑breast cancer risk (OR = 1.59) | No association in overall cohort | |
| [125] | Shanghai Breast Cancer Study, China | 1,321 | 1,382 | ↑folate intake = ↓ risk (OR = 0.71, P-trend = 0.05); ↑folate, ↑methionine, ↑B6, ↑B12 = ↓risk (OR = 0.47, P-trend = 0.01) | No alcohol, no supplements, unprocessed, unfortified foods |
| [217] | Nurses' Health Study II, study of premenopausal women | 714 | Vitamin A protective (OR = 0.28); Vitamins C, E, and folate not associated with risk. | ||
| [118] | Nurses' Health Study | 712 | 712 matched | ↑plasma folate = ↓risk (OR = 0.73, P-trend = 0.06). For women who drank alcohol, ↑plasma folate even more protective, OR = 0.11. | ↑plasma B6 and plasma B12 were also protective |
| [218] | Prospective study in USA with postmenopausal women | 1,823, 308 with family history (FH) | FH- +Alcohol = ↑risk (OR = 1.40) FH- + Alcohol + ↑folate = normal risk; FH+ ↓folate = ↑risk for drinkers (OR = 2.21) and non-drinkers (OR = 2.39); FH+ +Alcohol + ↑folate = ↑risk (OR = 1.67); FH+ + ↑folate = normal risk | Women with family history of breast cancer can reduce risk by increasing folate intake and not drinking. |
| Formulations | Crystalline Phase (wt%) | Amorphous Phase (wt%) | |
| Pure Ca/Mg-rich glass | 66 | 34 | |
| 1 | H62C + fillers | 88 | 12 |
| 2 | H62C + fillers + 10 wt% glass | 98 | 2 |
| 3 | MK + fillers | 92 | 8 |
| 4 | MK + fillers + 10 wt% glass | 96 | 4 |
| Number of HIV-negative people and people living in sub-national areas with incidence ≥3% | Number of HIV-negative people and people living in sub-national areas with incidence ≥1.5% | ||
| Characteristics | Estimates | Characteristics | Estimates |
| Women:• 15–19 years old• 20–24 years old | 140,000770,000 | Women: • 15–19 years old • 20–24 years old | 2.2 million2.4 million |
| Men:• 15–19 years old• 20–24 years old | 040,000 | Men: • 15–19 years old • 20–24 years old | 01.2 million |
| Countries: Kenya, Lesotho, Mozambique, South Africa, Swaziland. | Countries: Kenya, Lesotho, Mozambique, South Africa, Swaziland, Zimbabwe and Uganda. |
| Groups | Specific Diseases (ICD-10 Coding) [Number of GPs Mentioning It] |
| ICD-10 E86 Volume depletion/ E87 Other disorders of fluid, electrolyte and acid-base balance [22/24] | E86 Volume depletion OR T67.3 Heat exhaustion due to water depletion [18] |
| E87 Other disorders of fluid, electrolyte and acid-base balance OR T67.4 Heat exhaustion due to salt depletion [4] | |
| Circulatory diseases, ICD10-I00-I99 [15/24] | I99 Other and unspecified disorders of circulatory system [9]: usually naming circulatory collapse and circulatory dysregulation |
| I95 Hypotension [4] | |
| Other [3]: I74 Arterial embolism and thrombosis [1], I64 Stroke, not specified as hemorrhage or infarction [1], I49.9 Cardiac arrhythmia, unspecified [1] | |
| T67 Effects of heat and light [8/24] | T67.6 Heat fatigue, transient [5]; T67.0 Heatstroke and sunstroke [3]; T67.5 Heat exhaustion, unspecified [2], T67.1 Heat syncope [2]; T76.7 Heat edema [1] |
| Infectious diseases, ICD10-A00-B99 [7/24] | A00–A09 Intestinal infectious diseases [6] |
| Other [3]: B37.2 Candidiasis of skin and nail [1], L00–L08 Infections of the skin and subcutaneous tissue [2], N39.0 Urinary tract infection, site not specified [1] | |
| Organic mental disorders, ICD-F00-F09 [5/24] | Disorientation, cognitive or emotional impairment [4] (in line with F05–F07 *) |
| Aggravation of dementia [2] (F00–F003) | |
| Others [5/24] | N17 Acute renal failure [2]; J98.9 Respiratory disorder, unspecified [1]; L55 Sunburn [1]; Injuries from fall [3] |
| Question | n (%) |
| Do customers talk about experiences of trying to quit smoking? | |
| Yes many do | 30 (73) |
| Yes some do | 9 (22) |
| No | 1 (2) |
| No response | 1 (2) |
| Do customers ask for advice about quitting? | |
| Yes | 37 (90) |
| No | 3 (7) |
| No response | 1 (2) |
| What kind of information do you give to customers? (multiple responses permitted) | |
| Product information | 38 (93) |
| Smoking cessation advice | 17 (41) |
| Information how to cut down regular cigarettes | 36 (88) |
| Other | 9 (22) |
| Where do you access this information? (Open question) | |
| Online | 22 (54) |
| In-house training | 6 (15) |
| Personal experience | 10 (24) |
| Manufacturers' guidelines | 3 (7) |
| How confident are you about offering smoking cessation advice to customers that ask for it? | |
| Not at all | 0 (0) |
| Not too confident | 2 (5) |
| Quite confident | 15 (37) |
| Very confident | 16 (39) |
| No response | 8 (20) |
| Do you think it would be a good idea to deliver smoking cessation advice with training in your shop? | |
| Yes | 19 (46) |
| No | 4 (10) |
| Not sure | 17 (41) |
| No response | 1 (2) |
| Do you think customers would be interested in accessing this in-store smoking cessation service? | |
| Yes | 17 (41) |
| No | 9 (22) |
| Not sure | 15 (37) |
| Which type of in-store cessation service do you think might work best? (n = 19 - staff who think service is a good idea) | |
| Support from a training member of staff | 14 (74) |
| Face-to-face support from an external advisor | 1 (5) |
| A text or email-based support service | 0 (0) |
| No response | 4 (21) |
| Characteristics of patients | 100 |
| Phototype | |
| I | 0 (0%) |
| II | 72 (72%) |
| III | 28 (28%) |
| IV | 0 (0%) |
| V | 0 (0%) |
| Skin hydration | |
| dry skin | 56 (56%) |
| normal skin | 10 (10%) |
| sensible skin | 34 (34%) |
| Rate ratio (95% CIa) | Intervention effect ratiob | ||
| (intervention period relative to baseline) | (95% CIa) | ||
| Outcome variable | Intervention | Control | |
| ISH presentations and self-inflicted death events | 0.91 (0.81–1.02) | 0.85 (0.76–0.95) | 1.07 (0.82–1.40) |
| ISH presentations only | 0.91 (0.80–1.02) | 0.85 (0.75–0.95) | 1.07 (0.82–1.40) |
| Self-inflicted death events only | 1.17 (0.84–1.65) | 1.01 (0.77–1.31) | 1.18 (0.51–2.70) |
| Sample | Conc.(μg/ml) | No of brine shrimps taken | No of brine shrimps killed | LC50 (μg/ml) |
| 1000 | 10 | 10 ± 0 | ||
| 100 | 10 | 10 ± 0 | ||
| 10 | 10 | 10 ± 0 | ||
| CSA | 7.5 | 10 | 10 ± 0 | 2.3 ± 0.16 |
| 5 | 10 | 9.67 ± 0.58 | ||
| 2.5 | 10 | 06 ± 1 | ||
| 1.25 | 10 | 03 ± 1 | ||
| 1000 | 10 | 10 ± 0 | ||
| 100 | 10 | 10 ± 0 | ||
| 10 | 10 | 9.8 ± 0.76 | ||
| CST | 7.5 | 10 | 7 ± 0.5 | 5.23 ± 0.34 |
| 5 | 10 | 5 ± 0.5 | ||
| 2.5 | 10 | 2.9 ± 0.36 | ||
| 1.25 | 10 | 1 ± 0.14 |
| Responses (verbatim) | Number of health workers (n=10) | Percentage (%) |
| We usually ask if they had finished the treatment | 1 | 10 |
| When they come we check the container, most have finishedbut others did not finish due to nausea and vomiting. Thosewho did not finish we educate them | 1 | 10 |
| We repeat Hb test | 1 | 10 |
| Through statistics records | 1 | 10 |
| We interview, the questions are like how is the progress, ifthey are complying; and if they have problems they usuallytell us | 1 | 10 |
| We ask mothers to accompany teenagers and ask the motherabout compliance | 1 | 10 |
| We give them 28 day supply, if after 4 weeks they still havesupplements we know they are not complying | 1 | 10 |
| You give them health education, if they understand you aresure they are going to comply | 1 | 10 |
| We only hear from them if they complain with side effects, ifno complain they are complying | 1 | 10 |
| Usually ask questions and check Hb levels | 1 | 10 |
| Phantom configuration | True sphere/background ratio | SPECT alone | SPECT-CT | |||||
| Isocontour (%) | Measured volume (cm3) | Error (%) | Isocontour (%) | Measured volume (cm3) | Error (%) | |||
| 18,5 MBq/sphere | Cylinder 1 | — | 1% | 7087 | 5,52 | 2% | 6521 | −2,90 |
| Sphere 1 | 2.8 | 31% | 207 | 276,36 | 48% | 57,2 | 4,00 | |
| Sphere 2 | 7.6 | 13% | 104,5 | 397,62 | 28% | 24,4 | 16,19 | |
| Sphere 3 | 9.6 | 19% | 27,4 | 71,25 | 29% | 16,9 | 5,62 | |
| Sphere 4 | 19.6 | 8% | 29,2 | 265,00 | 19% | 10,9 | 36,25 | |
| 37 MBq/sphere | Cylinder 1 | — | 2% | 6180 | −7,98 | 1% | 6700 | −0,24 |
| Sphere 1 | 6 | 7% | 169,7 | 208,55 | 34% | 53,56 | −2,62 | |
| Sphere 2 | 17 | 3% | 113,7 | 441,43 | 23% | 24,34 | 15,90 | |
| Sphere 3 | 23.4 | 3% | 119,78 | 648,63 | 27% | 14,9 | −6,88 | |
| Sphere 4 | 43.8 | 4% | 53,48 | 568,50 | 33% | 9,8 | 22,50 | |
| 55,5 MBq/sphere | Cylinder 1 | — | 1% | 6737 | 0,31 | 1% | 6737 | 0,31 |
| Sphere 1 | 9.9 | 10% | 159,3 | 189,64 | 35% | 55,7 | 1,27 | |
| Sphere 2 | 29.6 | 4% | 85 | 304,76 | 25% | 22,7 | 8,10 | |
| Sphere 3 | 38.6 | 7% | 51,5 | 221,88 | 36% | 15,5 | −3,13 | |
| Sphere 4 | 73.1 | 6% | 44,1 | 451,25 | 36% | 12 | 50,00 | |
| 74 MBq/sphere | Cylinder 1 | — | 1% | 6565 | −2,10 | 1 | 6565 | −2,10 |
| Sphere 1 | 16 | 15% | 99,5 | 80,91 | 32% | 56 | 1,82 | |
| Sphere 2 | 45 | 6% | 54,1 | 157,62 | 23% | 23,7 | 12,86 | |
| Sphere 3 | 57 | 5% | 42,8 | 167,50 | 25% | 17,4 | 8,75 | |
| Sphere 4 | 114 | 2% | 35,8 | 347,50 | 20% | 8,7 | 8,75 | |
| 55 MBq | Cylinder 2 | — | 17% | 887 | 14,60 | 27% | 801 | 3,49 |
| 116 MBq | Cylinder 2 | — | 19% | 855 | 10,47 | 29% | 775 | 0,13 |
| 72 MBq | Cylinder 3 | — | 21% | 520 | 9,94 | 27% | 481 | 1,69 |
| Clinical parameters | Total | Male patients | Female patients | p-value |
| Median(25th–75th) | Median(25th–75th) | Median(25th–75th) | ||
| Age(years) | 47.5 ± 11.94 | 50.19 ± 12.43 | 45.04 ± 11.17 | 0.15 |
| BMI(Kg/m2) | 28.94 ± 4.21 | 28.65 ± 4.90 | 29.2 ± 3.56 | 0.67 |
| Lab data | ||||
| OPG(pmol/l) | 3.5(2.9–4) | 3.4(2.9–4.3) | 3.6(2.8–3.9) | 0.61 |
| sRANKL(pmol/l) | 0.2(0.1–0.3) | 0.2(0.1–0.3) | 0.2(0.1–0.3) | 0.85 |
| BUN(mg/dl) | 15.2(12.98–17.38) | 15.8(14.15–18.45) | 14(11.8–16.3) | 0.02 |
| Creatinie (mg/dl) | 0.9(0.8–1.1) | 1.1(1–1.25) | 0.8(0.8–0.9) | ≤ 0.001 |
| Uric acid (mg/dl) | 5.45(4.03–6.3) | 6.3(5.65–7.25) | 4.4(3.3–5.3) | ≤ 0.001 |
| Ca(mg/dl) | 9.6(8.9–9.98) | 9.7(8.95–10.05) | 9.5(8.9–9.9) | 0.2 |
| P(mg/dl) | 3.4(3.13–4.18) | 3.3(3–4) | 3.6(3.3–4.2) | 0.19 |
| Urine volume(ml/24 h) | 1350(900–2237.5) | 1650(950–2237.5) | 1150(825–2250) | 0.39 |
| Urine creatinine(mg/24 h) | 1227(949.5–1624) | 1538(1150–1789.5) | 1011(725–1273.5) | 0.003 |
| Urine uric acid(mg/24 h) | 593(405–804.5) | 786(436–865.25) | 547(390–760.5) | 0.14 |
| Urine calcium (mg/24 h) | 209.5(150–327) | 193.5(152.5–285) | 232(105–340.5) | 0.9 |
| Urine phosphorus (mg/24 h) | 741.5(592.5–958) | 832(663.75–1163.5) | 671(484.5–814.5) | 0.04 |
| PTH(pg/ml) | 32.9(24.65–42.83) | 36.1(27.1–41.8) | 31.1(20.7–61.4) | 0.5 |
| Vitamin D(nmol/l) | 36.8(25.45–61.10) | 40(27.1–56.7) | 31.55(20.5–64.45) | 0.41 |
| Urine citrate (mg/24 h) | 493(267–740) | 427(277–674) | 592(225–756.25) | 0.3 |
| Na(mEq/l) | 137.4(136.8–138.35) | 137.3(136.75–138) | 137.5(136.8–139) | 0.5 |
| eGFR (ml/minute) | 102.48(82.27–119.33) | 101.98(79.14–117.83) | 103.62(82.43–125.85) | 0.71 |
| kidney stone disease duration (year) | 3.5(1, 11) | 3.25(1–8.88) | 4.5(1–11.5) | 0.66 |
| Instruments | Categories | Variables |
| Baseline questionnaire | Demographic characteristics | Age; Sex; Nationality; Education; Occupation; Marriage; Family income of last year; Health insurance, etc. |
| Family history | Liver, renal and other disease history of family members. | |
| Medical history and concurrent disease | Previous hepatitis history; Previous hepatitis virus tests results. Diagnosis and duration of past renal, visional, auditive and other chronic disease history; Allergic history; Concurrent chronic diseases. | |
| TB diagnosis and previous treatment | Definitive diagnosis of TB; Diagnosis time; Diagnosis agency; Anti-TB treatment history; Anti-tuberculosis induced ADEs occurrence history. | |
| Current drug usage information | Product name; Production NO; Dose; Method and cost of anti-tuberculosis drugs and other concurrent using drugs. | |
| Physical, laboratory examination | Physical examinations | Height; Weight. |
| Blood routine test | Erythrocyte count (1012/L); Leukocyte count (109/L); Hemoglobin concentration (g/L); Platelet count (109/L). | |
| Urine routine test | PH value; Urine protein; Erythrocyte count; Leukocyte count; Urinary cylinder count. | |
| Liver and renal function test | Alanine aminotransferase (ALT, U/L); Aspartate aminotransferase (AST, U/L); Total bilirubin (TBIL, μmol/L); Blood urea nitrogen (BUN, mmol/L). | |
| Hepatitis B virus marker | HBsAg test. | |
| Medication record | Anti-TB drugs | Name, commercial name, manufacturer, production number, usage, dosage, starting and ending time of anti-TB drugs, including RHZES and other supplementary anti-TB drugs. |
| Liver protective drugs | Name, commercial name, manufacturer, production number, usage, dosage, starting and ending time of drugs used for preventing ATLI. | |
| Other drugs | Name, commercial name, manufacturer, production number, usage, dosage, starting and ending time of other drugs used during the anti-TB therapy, for example, antihypertensive drugs, hypoglycaemic drugs, etc. |
| model | traditional method | |||
| Sensitivity (%) | Specificity (%) | Sensitivity (%) | Specificity (%) | |
| ≤ T2 | 84.1 | 96.1 | 41.3 | 96.3 |
| T3 | 81.8 | 89.7 | 27.3 | 69 |
| T4 | 95.2 | 94.6 | 85.7 | 61.2 |
| Within population a | Between populations b | ||||||
| Chr | Site | Pop. c | π | Tajima’s D | MAF | FU | FW |
| A | 0-fold | RG | 0.0012 | −0.8397 | 0.1222 | 0.1516 | 0.1709 |
| FR | 0.0010 | −0.2586 | |||||
| 4-fold | RG | 0.0154 | −0.1069 | 0.1653 | 0.1684 | 0.1743 | |
| FR | 0.0119 | 0.1116 | |||||
| SI d | RG | 0.0145 | −0.1380 | 0.1630 | 0.1677 | 0.1766 | |
| FR | 0.0113 | 0.1413 | |||||
| X | 0-fold | RG | 0.0012 | −1.1907 | 0.1073 | 0.1653 | 0.2924 |
| FR | 0.0005 | −0.2293 | |||||
| 4-fold | RG | 0.0166 | −0.4679 | 0.1367 | 0.1903 | 0.2879 | |
| FR | 0.0068 | 0.1412 | |||||
| SI d | RG | 0.0160 | −0.4561 | 0.1379 | 0.2033 | 0.3173 | |
| FR | 0.0061 | 0.3414 |
| Age | Sex | Start [g] | Final eu [g] | Final hyper [g] | Final hypo [g] |
| Adult | Males | 40.2 ± 5.0 | 45.8 ± 3.7 ** | 40.1 ± 4.1 | 35.6 ± 2.0 * |
| Females | 28.0 ± 1.4†††† | 30.5 ± 3.1†† | 34.3 ± 2.2 *** | 27.0 ± 1.6 | |
| Old | Males | 39.0 ± 5.2 | 41.3 ± 3.7 | 36.9 ± 5.3 | 34.0 ± 3.1 * |
| Females | 30.3 ± 3.5†††† | 32.8 ± 3.2†††† | 33.7 ± 4.4† | 28.7 ± 1.7†††† |
| Variables | Frequency (%) |
| Sex | |
| Male | 363 (58.8) |
| Female | 254 (41.2) |
| Age (years, n = 569) | |
| 15–19 | 75 (13.2) |
| 20–24 | 451 (79.3) |
| ≥ 25 | 43 (7.3) |
| Religion | |
| Orthodox | 540 (87.5) |
| Muslim | 29 (4.7) |
| Protestant | 44 (7.1) |
| Other | 4 (0.7) |
| Region | |
| Tigray | 37 (6.0) |
| Amhara | 274 (44.4) |
| Oromia | 59 (9.6) |
| SNNP | 31 (5.0) |
| Addis Ababa | 136 (22.0) |
| Othera | 8 (1.34) |
| Income Category (in birr) | |
| ≤ 500 | 306 (68.8) |
| 501–1000 | 92 (20.7) |
| ≥ 1001 | 47 (10.6) |
| Mother’s Educational Status | |
| Not Educated | 277 (44.9) |
| Primary school | 134 (21.7) |
| Diploma | 55 (8.9) |
| Degree and above | 67 (10.9) |
| Father’s Educational Status | |
| Not Educated | 213 (34.5) |
| Secondary school | 71 (11.5) |
| Diploma | 56 (9.1) |
| Degree and above | 126 (20.4) |
| Preparatory School | |
| Public | 547(88.7) |
| Private | 63 (10.2) |
| NGO | 7 (1.1) |
| Group | N | Pain intensity | Facial Swelling | Mouth Opening | |||
| D1 | D2 | D1 | D2 | D1 | D2 | ||
| Group I | 50 | 0.62 ± 0.6* | 0.5 ± 0.51* | 30.9 ± 1.6* | 31.0 ± 1.58* | 36.0 ± 11.2 | 38.1 ± 10.05 |
| Group II | 50 | 1.64 ± 0.9* | 1.3 ± 0.62* | 31.7 ± 1.6* | 32.04 ± 1.5* | 39.2 ± 11.3 | 36.0 ± 10.02 |
| Population(CT n = 327, HPV n = 324) | Vaccinees(CT n = 248, HPV n = 245) | Non vaccinees(CT n = 77, HPV n = 77) | p-value | |||||||
| n | pr | sd | n | pr | sd | n | pr | sd | ||
| CT | 15 | 4.6 | 1.2 | 10 | 4.0 | 1.3 | 5 | 6.5 | 2.8 | 0.360 |
| HPV global | 95a | 29.5 | 2.5 | 70 | 28.6 | 2.9 | 25 | 32.5 | 5.4 | 0.567 |
| HPV vaccine | 9b | 2.8 | 0.9 | 6 | 2.4 | 1.0 | 3 | 3.9 | 2.2 | 0.451 |
| SIMD quintile & domain | Mean score out of 10 & (SD) | Developmentally vulnerable | Developmentally at risk | On track | |
| In the lowest 10% | Between the 10th and the 25th percentile | Between the 25th and 50th percentile | Above the 50% percentile | ||
| % | % | % | % | ||
| 1: Most deprived | |||||
| PHWB | 8.45 (1.67) | 25.6 | 12.8 | 28.2 | 33.3 |
| SC | 8.18 (1.97) | 20.6 | 8.8 | 35.3 | 35.3 |
| EM | 7.94 (1.52) | 15.8 | 21.1 | 28.9 | 34.2 |
| L&CD | 8.36 (1.70) | 18.9 | 18.9 | 45.9 | 16.2 |
| C&GK | 7.77 (2.66) | 17.9 | 17.9 | 64.1 | 0 |
| 2: Deprived | |||||
| PHWB | 8.55 (1.38) | 22.4 | 18.1 | 25.4 | 34.1 |
| SC | 8.27 (1.91) | 14.4 | 19.1 | 29.8 | 36.7 |
| EM | 8.21 (1.44) | 13.9 | 16.5 | 25.1 | 44.6 |
| L&C | 8.46 (1.93) | 19.0 | 11.1 | 43.5 | 26.4 |
| C&GK | 7.97 (2.47) | 18.1 | 16.8 | 65.1 | 0 |
| 3: Average | |||||
| PHWB | 8.86 (1.31) | 14.6 | 14.6 | 26.5 | 44.2 |
| SC | 8.65 (1.73) | 11.9 | 12.4 | 23.3 | 52.4 |
| EM | 8.27 (1.36) | 11.9 | 19.0 | 17.3 | 51.8 |
| L&C | 8.90 (1.61) | 10.5 | 14.3 | 34.3 | 41.0 |
| C&GK | 8.26 (2.33) | 15.9 | 14.2 | 69.9 | 0 |
| 4: Affluent | |||||
| PHWB | 9.04 (1.28) | 12.8 | 8.6 | 25.6 | 53.0 |
| SC | 8.77 (1.63) | 8.6 | 12.6 | 25.7 | 53.1 |
| EM | 8.36 (1.26) | 9.7 | 18.1 | 20.8 | 51.4 |
| L&C | 8.99 (1.51) | 8.8 | 8.3 | 53.5 | 29.5 |
| C&GK | 8.58 (2.11) | 9.4 | 12.1 | 78.6 | 0 |
| 5: Most affluent | |||||
| PHWB | 9.09 (1.05) | 6.7 | 17.9 | 25.1 | 50.3 |
| SC | 8.89 (1.42) | 6.3 | 15.0 | 26.3 | 52.5 |
| EM | 8.45 (1.17) | 7.3 | 14.6 | 23.0 | 55.1 |
| L&C | 9.34 (0.93) | 1.8 | 10.7 | 42.6 | 45.0 |
| C&GK | 8.78 (1.93) | 5.6 | 15.0 | 79.4 | 0 |
| Age group | |||||||||
| Label reason for encounter | Total N (%) | 0–4 N (%) | 5–14 N (%) | 15–24 N (%) | 25–44 N (%) | 45–64 N (%) | 65–74 N (%) | 75+ N (%) | |
| 1 | Symptoms or complaints of sinus (including pain)a | 2001 (24.5) | 7 (4.6) | 60 (11.8) | 196 (21.8) | 1131 (29.7) | 417 (22.7) | 133 (20.9) | 57 (18.3) |
| 2 | Upper respiratory infection (common cold) | 1000 (12.3) | 16 (10.5) | 60 (11.8) | 126 (14.0) | 464 (12.2) | 243 (13.3) | 54 (8.5) | 37 (11.9) |
| 3 | Headacheb | 994 (12.2) | 6 (3.9) | 84 (16.5) | 148 (16.4) | 457 (12.0) | 192 (10.5) | 66 (10.4) | 41 (13.2) |
| 4 | Cough | 947 (11.6) | 38 (24.8) | 100 (19.6) | 90 (10.0) | 333 (8.7) | 211 (11.5) | 121 (19.1) | 54 (17.4) |
| 5 | Sinusitis, acute or chronicc | 784 (9.6) | 3 (2.0) | 9 (1.8) | 69 (7.7) | 429 (11.3) | 218 (11.9) | 43 (6.8) | 13 (4.2) |
| 6 | Fever | 386 (4.7) | 35 (22.9) | 60 (11.8) | 31 (3.4) | 141 (3.7) | 70 (3.8) | 30 (4.7) | 19 (6.1) |
| 7 | Symptoms or complaints of throat | 237 (2.9) | 2 (1.3) | 13 (2.5) | 43 (4.8) | 88 (2.3) | 64 (3.5) | 20 (3.1) | 7 (2.3) |
| 8 | Medication/prescription/injection | 218 (2.7) | 1 (0.7) | 4 (0.8) | 10 (1.1) | 115 (3.0) | 71 (3.9) | 13 (2.0) | 4 (1.3) |
| 9 | Sneezing/nasal congestion | 211 (2.6) | 4 (2.6) | 17 (3.3) | 36 (4.0) | 81 (2.1) | 37 (2.0) | 26 (4.1) | 10 (3.2) |
| 10 | General weakness/tiredness | 181 (2.2) | 8 (5.2) | 20 (3.9) | 21 (2.3) | 73 (1.9) | 29 (1.6) | 17 (2.7) | 13 (4.2) |
| Fixed effects | Coefficient value | Standard error | Degrees of freedom | P-valuea |
| Intercept | 44.917 | 0.776 | 57 | <.0001 |
| D530c vs. D-SPECT | −26.300 | 1.049 | 12 | <.0001 |
| A-SPECT vs. D-SPECT | −37.779 | 1.021 | 12 | <.0001 |
| Slope for the D-SPECT | −1.747 | 0.072 | 57 | <.0001 |
| Slope for the D530c | 0.277 | 0.043 | 57 | <.0001 |
| Slope for the A-SPECT | −0.022 | 0.007 | 57 | 0.0016 |
| Random effects | Standard deviation | Standard deviation adjustment per camera | ||
| Intercept | 1.42 | D-SPECT | D530c | A-SPECT |
| Residual | 0.497 | 1 | 0.706 | 0.108 |
| Combination* | Patients | Controls | P | OR; 95% CI; P | OR; 95% CI; P** |
| Men | |||||
| T-A-G-C | 45.03% | 44.23% | 0.807 | Reference group | |
| G-G-G-C | 24.38% | 27.06% | 0.394 | 0.90; 0.74–1.11; 0.345 | 0.90; 0.74–1.11; 0.344 |
| T-A-A-T | 13.98% | 13.46% | 0.815 | 1.05; 0.75–1.46; 0.787 | 1.05; 0.75–1.46; 0.785 |
| G-G-A-T | 7.92% | 6.18% | 0.254 | 1.29; 0.85–1.96; 0.227 | 1.29; 0.85–1.96; 0.225 |
| G-A-G-C | 4.50% | 5.63% | 0.509 | 0.84; 0.57–1.25; 0.391 | 0.84; 0.57–1.25; 0.397 |
| Women | |||||
| T-A-G-C | 48.44% | 49.20% | 0.888 | Reference group | |
| G-G-G-C | 22.75% | 25.00% | 0.251 | 0.91; 0.66–1.25; 0.560 | 0.91; 0.66–1.25; 0.549 |
| T-A-A-T | 18.30% | 10.53% | < 0.001 | 1.83; 1.20–2.80; 0.005 | 1.84; 1.20–2.81; 0.005 |
| G-G-A-T | 6.96% | 5.73% | 0.124 | 1.39; 0.74–2.58; 0.304 | 1.40; 0.75–2.62; 0.288 |
| T-A-G-T | 1.24% | 5.21% | 0.001 | 0.34; 0.15–0.77; 0.010 | 0.33; 0.15–0.76; 0.010 |
| Continuous level (1/day) | p-value | Level of soy consumptionb | ||||
| Quartile 1 | Quartile 2 | Quartile 3 | Quartile 4 | |||
| Total soy | ||||||
| Median intake, svg/wk | 0.0 | 4.5 | 13.5 | 24.2 | ||
| Median AOM, yrc | 12.6 | 12.4 | 12.5 | 12.6 | ||
| Relative risk | 0.99 (0.91, 1.07) | 0.770 | 1.00 Ref | 0.96 (0.66, 1.40) | 0.95 (0.64, 1.41) | 1.19 (0.79, 1.80) |
| Meat alternatives | ||||||
| Median intake, svg/wk | 0.0 | 2.5 | 8.0 | 14.5 | ||
| Median AOM, yrc | 12.5 | 12.5 (12.5) | 12.8 (12.7) | 12.5 | ||
| Relative risk | 1.01 (0.90, 1.13) | 0.838 | 1.00 Ref | 0.92 (0.62, 1.36) | 1.02 (0.70, 1.48) | 1.07 (0.70, 1.65) |
| Non-consumers | Low-moderate | High | ||||
| Tofu/Traditional soy | ||||||
| Median intake, svg/wk | 0.0 | 1.0 | 4.8 | |||
| Median AOM, yrc | 12.5 | 12.6 | 12.4 | |||
| Relative Risk | 0.90 (0.70, 1.16) | 0.401 | 1.00 Ref | 0.93 (0.68, 1.26) | 1.00 (0.72, 1.40) | |
| Soy beverages | ||||||
| Median intake, svg/wk | 0.0 | 1.5 | 8.5 | |||
| Median AOM, yrc | 12.6 | 12.4 | 12.6 | |||
| Relative Risk | 0.98 (0.84, 1.14) | 0.759 | 1.00 Ref | 1.07 (0.79, 1.46) | 1.12 (0.82, 1.54) |
| No PORT N (%) | PORT N (%) | P value | |||
| Number of patients | 3211 | 2093 | |||
| Year of diagnosis, median (range) | 2007 (1988–2012) | 2006 (1988–2012) | |||
| Age, median (interquartile range) | 67 (59–75) | 63 (56–70) | < 0.05 (χ2 test) | ||
| Sex | 0.312 | ||||
| Male | 1599 | (49.8) | 1072 | (51.2) | |
| Female | 1612 | (50.2) | 1021 | (48.8) | |
| Race or ethnicity | 0.038 | ||||
| White | 2638 | (82.2) | 1679 | (80.2) | |
| Black | 286 | (8.9) | 231 | (11.0) | |
| Others | 287 | (8.9) | 183 | (8.7) | |
| Cancer stage | < 0.001 | ||||
| Localized | 451 | (14.0) | 210 | (10.0) | |
| Regional | 2167 | (67.5) | 1695 | (81.0) | |
| Distant | 581 | (18.1) | 181 | (8.6) | |
| Unstaged | 12 | (0.4) | 7 | (0.3) | |
| Tumor location | < 0.001 | ||||
| Head of pancreas | 2239 | (69.7) | 1559 | (74.5) | |
| Body or tail of pancreas | 561 | (17.5) | 330 | (15.8) | |
| Other | 411 | (12.8) | 204 | (9.7) | |
| Tumor differentiation | |||||
| Poorly differentiated or undifferentiated | 1111 | (34.6) | 652 | (31.2) | 0.001 |
| Well or moderately differentiated | 1828 | (56.9) | 1294 | (61.8) | |
| Unknown | 272 | (8.5) | 147 | (7.0) | |
| Total number of LN, median (range) | 12 | (0–69) | 12 | (0–72) | |
| Number of PLN, median (range) | 1 | (0–32) | 1 | (0–34) | |
| LNR (mean ± SD) | 0.18 ± 0.23 | 0.17 ± 0.22 | |||
| Lymph node status | < 0.001 | ||||
| Not examined | 231 | (7.2) | 74 | (3.5) | |
| pN0 | 1118 | (34.8) | 699 | (33.4) | |
| pN1 | 1862 | (58.0) | 1320 | (63.1) | |
| Median overall survival, months 95% CI | 14.0 (13.3–14.7) | 19.0 (18.2–19.8) | < 0.001 | ||
| Cancer-specific survival, months 95% CI | 15.0 (14.2–15.8) | 20.0 (19.1–20.9) | < 0.001 | ||
| Other-cause survival, months 95% CI | 163.0 (129.5–196.5) | 196.0 (160.2–231.8) | < 0.001 |
| Workpiece | Upper Punch | Die | Lower Punch | |
| Properties | Elastic-plastic | Rigid | ||
| Material | C1010 | SKH55 | WC | SKH9 |
| Mesh number | 35,000 | 30,000 | ||
| Hardness | HRC38 | HRC66 | HRC77 | HRC61 |
| ID | No-Attr BE | Sex BE | Age BE | Ped BE | All-Attr BE | All-Attr BE+CE | SSABE | SSABEG |
| rs6442089 | 74 | 72 | 74 | 66 | 35 | 55 | 57 | 24 |
| rs1060407 | 76 | 66 | 58 | 50 | 18 | 41 | 46 | 13 |
| 13rs3772219 | 2 | 2 | 6 | 20 | 52 | 44 | 9 | 13 |
| rs1131356 | 20 | 28 | 13 | 25 | 60 | 67 | 41 | 29 |
| rs4679394 | 22 | 21 | 6 | 4 | 0 | 0 | 6 | 2 |
| rs4683602 | 10 | 7 | 28 | 7 | 0 | 0 | 16 | 16 |
| rs16851435 | 34 | 34 | 44 | 0 | 0 | 0 | 19 | 14 |
| rs304079 | 4 | 6 | 8 | 16 | 38 | 32 | 19 | 21 |
| rs373572 | 7 | 4 | 14 | 17 | 16 | 24 | 19 | 28 |
| rs2322142 | 21 | 24 | 33 | 55 | 70 | 34 | 36 | 33 |
| LogMAR BCVA | Phacotrab group | Phaco group | P Value |
| Mean preoperative ± SD | 1.21 ± 0.49 | 1.23 ± 0.43 | 0.93* |
| Mean postoperative ± SD (6 mos) | 0.82 ± 0.44 | 0.80 ± 0.38 | 0.91* |
| Mean postoperative ± SD (12 mos) | 0.82 ± 0.41 | 0.80 ± 0.39 | 0.85* |
| P Value | 0.003* | <0.001* |
| ROI | BMD ratios in the bisphosphonates group | BMD ratios in the control group | WMD | [95 % CI] | P of chi-square | I2 | Selected model | P for overall effect | |
| 1 | 97.556 | 90.840 | 6.364 | 2.122 | 10.606 | 0 | 92 % | Random-effect model | 0.003 |
| 2 | 96.275 | 93.488 | 2.479 | 1.886 | 3.072 | 0.564 | 0 % | Fixed-effect model | <0.001 |
| 3 | 97.041 | 95.413 | 1.309 | 0.824 | 1.794 | 0.673 | 0 % | Fixed-effect model | <0.001 |
| 4 | 100.207 | 98.036 | 2.349 | 0.505 | 4.193 | 0.003 | 78 % | Random-effect model | 0.013 |
| 5 | 97.528 | 97.172 | −0.619 | −1.120 | −0.119 | 0.138 | 46 % | Fixed-effect model | 0.015 |
| 6 | 95.641 | 92.724 | 2.177 | 1.598 | 2.756 | 0.552 | 0 % | Fixed-effect model | <0.001 |
| 7 | 91.099 | 84.457 | 6.634 | 0.655 | 12.612 | 0.001 | 95 % | Random-effect model | 0.030 |
| Normal | 1 | 2 | 3 | 4 | 5 | 6 | |
| Motor | |||||||
| Median nerve | |||||||
| DML (ms) | ≤ 3,9 | 2,8 | 3 | 3,8 | 5 | ||
| NCV (m/s) | ≥ 50 | 53 | 50 | n.d. | 46,2 | 56 | n.d. |
| Amplitude (mV) | ≥ 6 | 11,4 | 14,2 | n.d. | 11 | ||
| Peroneal nerve | |||||||
| DML (ms) | ≤ 4,8 | 7,6 | 4 | 5,3 | |||
| NCV (m/s) | ≥ 42 | 37 | 45 | not recordable | 47,8 | not recordable | not recordable |
| Amplitude (mV) | ≥ 4 | 0,8 | 8,4 | 2 | |||
| Tibial nerve | |||||||
| DML (ms) | ≤ 5,1 | 6,2 | 4,2 | 7,1 | |||
| NCV (m/s) | ≥ 41 | 31 | 36 | 38 | n.d. | not recordable | not recordable |
| Amplitude (mV) | ≥ 5 | 0,6 | 0,4 | 0,4 | |||
| Sensory | |||||||
| Median nerve | |||||||
| NCV (m/s) | ≥ 47 | 60 | 54 | n.d. | 57,7 | 45 | n.d. |
| Amplitude (mV) | ≥ 7 | 13,4 | 11 | n.d. | 20 | ||
| Sural nerve | |||||||
| NCV (m/s) | ≥ 41 | 34 | not recordable | 30 | 56,5 | 32 | not recordable |
| Amplitude (mV) | ≥ 10 | 7,2 | 1 | n.d. | 6 |
| Males | P | Females | P | |
| (n = 24) | (n = 20) | |||
| Model R | 0.28 | 0.80 | 0.79 | 0.004 |
| Standardised coefficients (Beta) | ||||
| BMI | −0.06 | 0.88 | 1.06 | 0.008 |
| Diet (1.5 g/d ALA vs. 9.5 g/d ALA) | 0.02 | 0.94 | 0.63 | 0.003 |
| Age | −0.15 | 0.56 | −0.47 | 0.029 |
| Weight | −0.15 | 0.68 | −0.70 | 0.055 |
| Variable | β | p | OR | 95% CI |
| Marital status | ||||
| Single | 0.859 | 0.031 | 2.36 | 1.081 – 5.150 |
| All others | 1 | |||
| Migrant | ||||
| Yes | 0.403 | 0.002 | 1.497 | 1.156 – 1.937 |
| No | 1 | |||
| Religion | ||||
| Catholic | 0.312 | 0.034 | 1.366 | 1.024 – 1.823 |
| All others | 1 | |||
| Income (n° of minimal wages) | 0.054 | 0.026 | 1.056 | 1.007 – 1.107 |
| Factor | OR (95% CI)b | P valuec |
| Ultrasound examination | 53.7 (28.6 to 83.5) | < 0.001 |
| NT-proBNP | 14.3 (8.1 to 29.4) | < 0.001 |
| Orthopnea | 6.9 (1.9 to 18.39 | < 0.001 |
| Rales | 5.1 (1.5 to 12.8) | 0.014 |
| Troponin T | 2.1 (1.3 to 4.6) | 0.018 |
| petCO2 | 7.6 (2.9 to 19.6) | < 0.001 |
| HF medications | 2.7 (1.3 to 5.1) | 0.031 |
| Asthma/COPD medications | 0.12 (0.03 to 0.42) | 0.028 |
| Previous HF | 7.4 (2.3 to 20.4) | < 0.001 |
| Fever | 0.17 (0.06 to 0.49) | 0.017 |
| Expression | Gene | Meningioma (%) | Schwannoma (%) |
| Downregulation | FOS | 90 | 65 |
| ICAM1 | 71 | 61 | |
| FLY1 | 78 | 48 | |
| Upregulation | ITCAV | 66 | 61 |
| Cluster number | x, y, za | Peak intensity | Cluster sizeb | Regionc | Brodmann's area |
| Taking the Declive as ROI | |||||
| 1 | −30, 3, −18 | 3.649 | 142 | L Superior Temporal Gyrus/Inferior Parietal Lobe | 41, 42, 44, 45 |
| 2 | 12, −72, 27 | −3.462 | 125 | R Medial Frontal Gyrus | 7 |
| 3 | −21, −27, 60 | 3.764 | 189 | L Precentral Gyrus | 4, 6 |
| Taking the Precentral Gyrus as ROI | |||||
| 1 | 0, 27, −21 | −5.278 | 136 | Orbital Frontal Gyrus | 8, 9 |
| 2 | 3, 27, 39 | 4.077 | 497 | Superior Frontal Gyrus/Medial Frontal Gyrus | 4, 6, 8, 9 |
| Taking the Striatum as ROI | |||||
| 1 | 9, 0, 54 | 3.632 | 151 | R Anterior Cingulate Cortex | 6, 23, 24 |
| 2 | 39, −24, 48 | 3.884 | 185 | R Middle Frontal Gyrus | 4 |
| R Inferior Frontal Gyrus | |||||
| 3 | −24, 6, 51 | 3.749 | 197 | L Postcentral Gyrus | 1, 2, 3 |
| Time of assessment | n | Mean | Median | Minimum | Maximum | SD | P-value* |
| Preoperative | 30 | 4.1 | 4.0 | 2.0 | 8.3 | 1.4 | |
| 3-5 days | 30 | 3.3 | 3.1 | 1.8 | 4.9 | 0.8 | |
| 1 month | 30 | 3.0 | 2.9 | 2.0 | 4.6 | 0.7 | 0.019 |
| 6 months | 30 | 3.0 | 3.1 | 1.1 | 5.0 | 0.8 | |
| 1 year | 30 | 3.1 | 3.2 | 1.5 | 5.4 | 0.8 |
| Time Light | Morning | Mid-day | Evening | Total | ||||
| Bright | Dim | Bright | Dim | Bright | Dim | Bright | Dim | |
| Baseline start | 21.23 (6.08) 13 | 21.00 (4.47) 15 | 18.73 (2.91) 15 | 19.50 (4.43) 16 | 18.54 (5.63) 13 | 17.00 (4.27) 16 | 19.46 (5.01) 41 | 19.50 (4.56) 40 |
| End of baseline week | 21.77 (5.85) 13 | 20.33 (4.53) 15 | 18.93 (3.41) 15 | 19.63 (4.83) 16 | 18.62 (5.61) 13 | 17.89 (5.09) 9 | 19.73 (5.07) 41 | 19.50 (4.74) 40 |
| After wake therapy | 21.67 (5.68) 9 | 19.43 (6.73) 14 | 18.00 (5.31) 12 | 18.00 (5.85) 13 | 16.60 (5.97) 10 | 17.14 (4.14) 7 | 18.61 (5.82) 31 | 18.41 (5.85) 34 |
| Treatment Week 1 | 20.00 (5.55) 13 | 19.33 (7.69) 15 | 18.20 (4.06) 15 | 16.94 (3.99) 16 | 15.08 (8.41) 13 | 15.11 (5.11) 9 | 17.78 (6.35) 41 | 17.43 (5.95) 40 |
| Treatment Week 2 | 20.08 (6.22) 13 | 18.60 (7.60) 15 | 16.21 (5.69) 14 | 14.38 (5.30) 16 | 14.75 (8.07) 12 | 12.33 (5.45) 9 | 17.05 (6.87) 39 | 15.50 (6.65) 40 |
| Treatment Week 3 | 18.85 (6.50) 13 | 18.50 (6.44) 14 | 15.00 (5.41) 15 | 14.81 (5.97) 16 | 13.23 (6.66) 13 | 13.00 (7.05) 9 | 15.66 (6.45) 41 | 15.72 (6.61) 39 |
| Treatment Week 4 | 17.38 (6.96) 13 | 18.67 (7.79) 15 | 14.07 (6.06) 15 | 13.81 (5.60) 16 | 11.77 (7.00) 13 | 12.22 (6.53) 9 | 14.39 (6.88) 41 | 15.28 (7.07) 40 |
| Two-Week follow-up | 16.25 (7.96) 12 | 16.00 (7.72) 11 | 13.69 (5.41) 13 | 11.85 (5.80) 14 | 11.80 (6.66) 10 | 12.13 (8.41) 8 | 14.03 (6.77) 35 | 13.30 (7.18) 33 |
| Four-Week follow-up | 17.25 (6.54) 8 | 14.00 (9.03) 9 | 12.77 (5.69) 13 | 13.08 (5.27) 13 | 13.55 (6.25) 11 | 10.25 (8.40) 8 | 14.16 (6.18) 32 | 12.60 (7.29) 30 |
| 3-Month follow-up | 14.00 (9.47) 8 | 18.14 (9.58) 7 | 15.91 (5.26) 11 | 11.21 (5.74) 14 | 16.29 (6.97) 7 | 11.60 (9.63) 5 | 15.42 (6.99) 26 | 13.15 (7.97) 26 |
| Typer | Overall | HLA-A | HLA-B | HLA-C |
| Optitype (4-digit) | 0.09 | 0.08 | 0.08 | 0.11 |
| Polysolver (8-digit) | 0.08 | 0.08 | 0.02 | 0.14 |
| Polysolver (4-digit) | 0.12 | 0.12 | 0.09 | 0.15 |
| Characteristics | New-onset CAE (n = 35) | Control (n = 33) | P value |
| Age (years), mean ± SD (range) | 7.3 ± 1.3 (5–10) | 6.8 ± 1.1 (5–9) | 0.14 |
| Gender (boys/girls) | 14/21 | 18/15 | 0.23 |
| Age at onset, years (SD) | 6.7 (1.3) | N/A | N/A |
| Duration of epilepsy (time to diagnosis), months (SD) | 7 (7) | N/A | N/A |
| 2007 | 2008 | 2009 | 2010 | |
| Total number of insured persons | 4 048 709 | 3 931 988 | 3 906 411 | 3 954 172 |
| Age in years (mean) | 43.0 | 43.5 | 43.7 | 43.7 |
| Sex (men & women) | 47.1 % & 52.9 % | 47.0 % & 53.0 % | 47.1 % & 52.9 % | 47.2 % & 52.8 % |
| Number of persons insured permanently over the respective year (study population) | 3 538 793 | 3 483 739 | 3 459 461 | 3 492 326 |
| Proportion of the included study population compared to total number of insured persons (%) | 87.4 % | 88.6 % | 88.6 % | 88.3 % |
| Age in years (mean) | 44.4 | 44.8 | 40.0 | 45.0 |
| Sex (men & women) | 46.2 % & 53.8 % | 46.3 % & 53.7 % | 46.4 % & 53.6 % | 46.4 % & 53.6 % |
| Age group (years) | Haemophilus influenzae type b (invasive) | Measles | Meningococcal disease(invasive) | Mumps | Pertussis | Pneumococcal disease(invasive) | Rubella | Tetanus | ||||||||
| n | Rate | n | Rate | n | Rate | n | Rate | n | Rate | n | Rate | n | Rate | n | Rate | |
| 0–4 | 3 | 0.6 | 12 | 2.4 | 14 | 2.8 | 7 | 1.4 | 400 | 80.8 | 69 | 13.9 | 0 | 0 | 0 | 0 |
| 5–9 | 0 | 0.0 | 4 | 0.9 | 0 | 0 | 8 | 1.7 | 636 | 134.6 | 11 | 2.3 | 1 | 0.2 | 0 | 0 |
| 10–14 | 0 | 0.0 | 6 | 1.3 | 3 | 0.7 | 3 | 0.7 | 518 | 115.2 | 5 | 1.1 | 0 | 0 | 0 | 0 |
| 15–19 | 0 | 0.0 | 15 | 3.2 | 3 | 0.7 | 9 | 1.9 | 122 | 26.3 | 9 | 1.9 | 0 | 0 | 0 | 0 |
| 20–24 | 0 | 0.0 | 11 | 2.2 | 1 | 0.2 | 7 | 1.4 | 86 | 17.0 | 6 | 1.2 | 1 | 0.2 | 0 | 0 |
| 25–29 | 0 | 0.0 | 8 | 1.5 | 0 | 0.0 | 1 | 0.2 | 82 | 15.2 | 12 | 2.2 | 3 | 0.6 | 0 | 0 |
| 30–34 | 1 | 0.2 | 6 | 1.1 | 2 | 0.4 | 10 | 1.8 | 128 | 23.6 | 11 | 2.0 | 0 | 0 | 1 | 0.2 |
| 35–39 | 0 | 0.0 | 4 | 0.8 | 0 | 0.0 | 9 | 1.8 | 128 | 25.6 | 20 | 4.0 | 2 | 0.4 | 0 | 0 |
| 40–44 | 0 | 0.0 | 1 | 0.2 | 1 | 0.2 | 2 | 0.4 | 175 | 33.3 | 18 | 3.4 | 1 | 0.2 | 0 | 0 |
| 45–49 | 0 | 0.0 | 0 | 0 | 0 | 0 | 3 | 0.6 | 145 | 29.9 | 38 | 7.8 | 2 | 0.4 | 0 | 0 |
| 50–54 | 0 | 0.0 | 0 | 0 | 1 | 0.2 | 4 | 0.8 | 125 | 25.0 | 30 | 6.0 | 0 | 0 | 0 | 0 |
| 55–59 | 0 | 0.0 | 0 | 0 | 1 | 0.2 | 4 | 0.9 | 122 | 26.4 | 41 | 8.9 | 0 | 0 | 0 | 0 |
| 60–64 | 1 | 0.2 | 0 | 0 | 1 | 0.2 | 4 | 1.0 | 127 | 31.0 | 46 | 11.2 | 0 | 0 | 0 | 0 |
| 65–69 | 1 | 0.3 | 0 | 0 | 3 | 0.8 | 3 | 0.8 | 103 | 27.9 | 49 | 13.3 | 0 | 0 | 0 | 0 |
| 70–74 | 0 | 0.0 | 0 | 0 | 1 | 0.4 | 2 | 0.7 | 80 | 29.5 | 34 | 12.5 | 0 | 0 | 0 | 0 |
| 75–79 | 0 | 0.0 | 0 | 0 | 2 | 1.0 | 2 | 1.0 | 68 | 33.0 | 31 | 15.0 | 0 | 0 | 0 | 0 |
| 80–84 | 0 | 0.0 | 0 | 0 | 0 | 0 | 1 | 0.7 | 48 | 31.2 | 32 | 20.8 | 0 | 0 | 0 | 0 |
| 85+ | 0 | 0.0 | 0 | 0 | 3 | 1.9 | 0 | 0 | 37 | 23.1 | 54 | 33.8 | 0 | 0 | 0 | 0 |
| Outcome | ID | GH | PE | HEELP | FGR | PL | Abruptio | Previa | DIC |
| Cases with single mutation Pearson correlation 2-tailed significance | |||||||||
| AT III deficiency | 0 | 2 | 6 | 0 | 2 | 0 | 0 | 0 | 2 |
| -0.035 | -0.034 | 0.131 | 0.002 | 0.012 | -0.042 | 0.052 | -0.050 | 0.138 | |
| 0.541 | 0.551 | 0.022 | 0.972 | 0.837 | 0.468 | 0.366 | 0.383 | 0.016 | |
| Protein S deficiency | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| -0.024 | -0.055 | -0.028 | -0.041 | -0.016 | -0.028 | -0.043 | -0.034 | -0.015 | |
| 0.679 | 0.337 | 0.623 | 0.481 | 0.786 | 0.623 | 0.450 | 0.555 | 0.794 | |
| APCR | 1 | 4 | 0 | 3 | 12 | 3 | 11 | 4 | 0 |
| -0.028 | -0.066 | -0.034 | -0.048 | 0.010 | -0.034 | 0.159 | -0.041 | -0.018 | |
| 0.622 | 0.253 | 0.558 | 0.402 | 0.868 | 0.558 | 0.005 | 0.481 | 0.756 | |
| Hyper-HCY | 0 | 3 | 0 | 2 | 6 | 0 | 2 | 2 | 0 |
| 0.046 | -0.016 | -0.050 | 0.089 | 0.110 | -0.050 | -0.026 | -0.060 | -0.026 | |
| 0.424 | 0.785 | 0.386 | 0.122 | 0.056 | 0.386 | 0.647 | 0.298 | 0.122 | |
| C677T MTHFR (+/+) | 1 | 4 | 1 | 2 | 9 | 2 | 3 | 4 | 0 |
| -0.061 | 0.039 | -0.084 | -0.041 | 0.131 | -0.084 | -0.023 | -0.041 | 0.044 | |
| 0.286 | 0.493 | 0.144 | 0.478 | 0.022 | 0.144 | 0.695 | 0.477 | 0.448 | |
| A1298C MTHFR (+/+) | 0 | 2 | 0 | 0 | 3 | 0 | 0 | 0 | 0 |
| -0.032 | -0.041 | -0.038 | 0.033 | 0.070 | 0.146 | -0.017 | -0.046 | -0.020 | |
| 0.576 | 0.476 | 0.506 | 0.563 | 0.224 | 0.011 | 0.762 | 0.425 | 0.725 | |
| G20210A PTR (+/+) | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| -0.027 | -0.063 | -0.032 | 0.016 | -0.002 | -0.032 | 0.009 | 0.108 | -0.017 | |
| 0.638 | 0.275 | 0.576 | 0.775 | 0.971 | 0.576 | 0.872 | 0.059 | 0.767 | |
| G1691A factor V (+/+) | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| -0.038 | -0.089 | -0.046 | -0.065 | 0.029 | -0.046 | 0.102 | -0.001 | -0.024 | |
| 0.505 | 0.122 | 0.428 | 0.257 | 0.611 | 0.428 | 0.077 | 0.985 | 0.675 | |
| PAI-1 (5G/5G) (+/+) | 1 | 3 | 0 | 1 | 2 | 0 | 0 | 0 | 0 |
| 0.005 | -0.035 | -0.054 | -0.016 | 0.018 | -0.054 | -0.054 | 0.007 | -0.029 | |
| 0.934 | 0.54 | 0.350 | 0.779 | 0.755 | 0.350 | 0.348 | 0.906 | 0.620 |
| BehaviouralCorrelate | Brain region | Cerebral hemisphere | Cluster size (voxels) | p value |
| Combined groups | Anterior TL, OFC | R | 107,453 | 0.02 |
| bvFTD only | Anterior TL, OFC | Bilateral | 318,805 | 0.01 |
| bvFTD > svPPA | Parahippocampal, fusiform gyri | L | 61,222 | 0.03 |
| Baseline | Day 1 | Day 3 | Day 7 | |||||
| PHARLAP | Control | PHARLAP | Control | PHARLAP | Control | PHARLAP | Control | |
| VT, mls | 519 ± 56 | 501 ± 30 | 463 ± 42 | 563 ± 65 | 586 ± 58 | 511 ± 55 | 528 ± 76 | 579 ± 78 |
| RR, bpm | 21 ± 2 | 21 ± 1 | 22 ± 2 | 20 ± 2 | 19 ± 2 | 24 ± 2 | 22 ± 2 | 22 ± 2 |
| FiO2 | 0.48 ± 0.06 | 0.57 ± 0.06 | 0.4 ± 0.04 | 0.5 ± 0.04 | 0.5 ± 0.07 | 0.55 ± 0.06 | 0.5 ± 0.07 | 0.5 ± 0.09 |
| PEEP,cm H2O | 11.8 ± 0.7 | 14.2 ± 1.2 | 15 ± 1* | 10 ± 0.5 | 12.1 ± 1.5 | 9.3 ± 1.4 | 8.5 ± 1.8 | 7.8 ± 2.0 |
| Pplateau, cmH2O | 28.4 ± 1.5 | 29 ± 1.5 | 27.6 ± 1.5 | 26.9 ± 1.4 | 24.2 ± 2.4 | 24 ± 2.1 | 21 ± 2.9 | 20. ± 3.4 |
| Arterial pH | 7.34 ± 0.02 | 7.36 ± 0.02 | 7.36 ± 0.01 | 7.35 ± 0.01 | 7.38 ± 0.03 | 7.44 ± 0.03 | 7.42 ± 0.03 | 7.42 ± 0.04 |
| PaCO2, mmHg | 49 ± 5 | 46 ± 5 | 45 ± 3 | 46 ± 3 | 47.6 ± 3.7 | 44 ± 3.5 | 43.3 ± 4 | 56.5 ± 5 |
| Variable | C | F |
| Glucose (mg/dl) | 83.6 ± 4.5 | 98.5 ± 10.5* |
| Triglycerides (mg/dl) | 123.4 ± 49.0 | 268.3 ± 35.1* |
| Total cholesterol (mg/dl) | 91.7 ± 9.6 | 96.3 ± 15.5 |
| HDL cholesterol (mg/dl) | 42.7 ± 5.3 | 43.5 ± 6.9 |
| LDL cholesterol (mg/dl) | 62.8 ± 3.9 | 65.4 ± 1.3 |
| AST/ALT ratio | 1.08 ± 0.4 | 2.8 ± 0.8* |
| SOD (U/ml) | 1.7 ± 0.4 | 1.5 ± 0.6 |
| Catalase (U/ml) | 42.2 ± 10.4 | 68.4 ± 6.8* |
| TBARS (μM) | 16.5 ± 2.0 | 22.2 ± 4.4* |
| Normal versus normal-tension glaucoma | ||
| AUROC (SE) | Sn/Sp (Sp > 90%) | |
| OCT-A whole image vessel density | 0.950 (0.027) | 82.14/92.00 |
| OCT-A inside disc vessel density | 0.931 (0.034) | 78.57/92.00 |
| OCT-A peripapillary vessel density | 0.830 (0.056)∗ | 60.71/92.00 |
| LSFG MBRA | 0.793 (0.065)∗† | 60.71/92.00 |
| LSFG MBRV | 0.601 (0.079)∗†‡ | 21.43/92.00 |
| LSFG MBRT | 0.601 (0.079)∗†‡ | 28.57/92.00 |
| GCC thickness | 0.970 (0.021)‡ | 92.86/92.00 |
| RNFL thickness | 0.906 (0.039) | 75.00/96.00 |
| Variables | Overall | Somalian | Ethiopian | Eritrean | Gambian | P-value |
| N | 36,366 | 24,253 | 5631 | 4483 | 1999 | |
| Age distribution, % | ||||||
| 0–14 | 38.1 | 41.2 | 34.1 | 28.5 | 33.7 | <0.001 |
| 15–44 | 52.2 | 50.8 | 56.0 | 56.1 | 49.9 | <0.001 |
| 45–64 | 8.8 | 7.0 | 9.6 | 14.5 | 16.2 | <0.001 |
| ≥ 64 | 0.8 | 0.9 | 0.4 | 0.9 | 0.2 | <0.001 |
| Age, mean (SD) | 22.8 (16.0) | 21.5 (15.8) | 24.0 (15.5) | 27.3 (16.7) | 25.0 (16.5) | |
| Women, % | 47.0 | 47.0 | 46.5 | 48.7 | 44.4 | 0.11 |
| Urban settlement, % | 83.3 | 81.9 | 86.6 | 82.6 | 92.0 | <0.001 |
| Marital status, %: | ||||||
| Unmarried | 64.4 | 65.0 | 63.1 | 63.7 | 61.4 | <0.001 |
| Married | 24.5 | 23.8 | 27.7 | 27.0 | 19.2 | <0.001 |
| Others (divorced, separated or widow) | 11.1 | 11.2 | 9.2 | 9.3 | 19.4 | <0.001 |
| Income, mean [Norwegian crownes] | 75,827 | 53,731 | 126,980 | 118,213 | 104,721 | <0.001 |
| Employment status, % | ||||||
| Outside work force | 67.9 | 73.3 | 55.3 | 58.7 | 58.5 | <0.001 |
| Employed | 26.0 | 19.9 | 40.9 | 38.0 | 35.8 | <0.001 |
| Self-employed | 0.7 | 0.6 | 0.8 | 0.7 | 1.9 | <0.001 |
| Unemployed | 3.3 | 4.0 | 1.9 | 1.7 | 2.4 | <0.001 |
| Social welfare beneficiaries | 1.8 | 2.2 | 1.0 | 0.9 | 1.4 | <0.001 |
| Immigrants, reasons of migration, %: | ||||||
| Labour | 0.1 | 0.1 | 0.4 | 0.1 | 0.4 | <0.001 |
| Refugee | 35.3 | 37.9 | 29.7 | 43.4 | 1.0 | <0.001 |
| Family reunification | 25.1 | 28.8 | 19.7 | 11.5 | 25.6 | <0.001 |
| Others | 2.2 | 0.9 | 7.5 | 1.5 | 3.4 | <0.001 |
| Reason not specified | 37.3 | 32.3 | 42.7 | 43.5 | 69.6 | <0.001 |
| Length of stay in Norway, mean (SD) | 7.63 (7.15) | 6.61 (5.39) | 8.51 (9.07) | 9.33 (9.71) | 13.74 (8.77) | <0.001 |
| Immigrants background, % | ||||||
| Immigrant | 69.0 | 71.2 | 64.4 | 71.8 | 48.6 | <0.001 |
| Born in Norway with immigrant parent | 23.3 | 26.3 | 14.2 | 20.4 | 18.7 | <0.001 |
| Born out of Norway with one parent a Norwegian | 0.3 | 0.0 | 1.5 | 0.4 | 0.3 | <0.001 |
| Born in Norway with one parent a Norwegian | 5.1 | 2.4 | 7.1 | 5.0 | 32.4 | <0.001 |
| Born out of Norway with both parent Norwegian | 2.3 | 0.0 | 12.8 | 2.4 | 0.0 | <0.001 |
| Norwegian nationality, % | 56.5 | 54.2 | 58.2 | 55.4 | 81.5 | <0.001 |
| Use of health care services, mean (SD) | ||||||
| Number of consultations with GP in 2008 | 2.42 (3.38) | 2.48 (3.41) | 2.29 (3.30) | 2.33 (3.45) | 2.14 (3.01) | <0.001 |
| Number of consultations at ER in 2008 | 0.24 (0.67) | 0.27 (0.72) | 0.22 (0.61) | 0.14 (0.48) | 0.19 (0.53) | <0.001 |
| Private Hospital | National Data | ||||
| YEAR | No. of Malaria cases | Plasmodium falciparum | YEAR | No. of Malaria Cases | Plasmodium falciparum |
| 2006July -December | 60 | 31 | 2006 | 928 | 36 |
| 2007 | 35 | 15 | 2007 | 182 | 2 |
| 2008Jan - July | 18 | 10 | 2008 | 248 | 0 |
| Group I (Harvesting) | Group II (Preserving) | p value* | |
| Patients | 61 (10 M & 51 F) | 43 (1 M & 42 F) | |
| Age (years) | 14.0 (11 ~ 19) | 13.8 (10 ~ 18) | 0.71 |
| Median f/u length (months) | 60 (24 ~ 128) | 73 (24 ~ 107) | |
| Level fused | 10.6 ± 1.7 | 10.0 ± 1.9 | 0.06 |
| Duration of surgery (minutes) | 216 ± 47 | 224 ± 50 | 0.40 |
| Implants inserted (numbers) | 13.3 ± 2.2 | 13.3 ± 2.0 | 0.97 |
| Blood loss (ml) | 983 ± 446 | 824 ± 361 | 0.048 |
| Peri-OP blood transfusion (units) | 6.0 ± 3.3 | 5.1 ± 3.0 | 0.13 |
| Hospitalization length (days) | 7.4 ± 1.0 | 6.8 ± 0.8 | 0.003 |
| Station | Sampling date | Water depth (m) | Water temperature (°C) | Salinity (psu) | Flow velocity (mm s-1) |
| H1 | Oct 25, 2012 | 3.8 | 16.0 | 25.0 | 129 ± 70 |
| A3 | Apr 3, 2013 | 3.4 | 19.1 | 19.4 | 818 ± 172 |
| A5 | Apr 4, 2013 | 7.3 | 19.2 | 30.1 | 713 ± 498 |
| Health education mode | Medical and health information from friends’ moments, group chats, public account sharing (open to all) | Normal health education information from the doctor in charge of you | Personalized health education information from the doctor in charge of you | Personalized health education information from the doctor in charge of you, and reminders for you (for example, referred to you, @ you, private letter to you) |
| Score | 61.40 | 70.15 | 74.15 | 76.42 |
| CMs modalities | Level of need | ||||
| No % | Low % | Moderate % | High % | Some % | |
| Herbal medicines | 10 | 31 | 47 | 13 | 90 |
| Vitamins, minerals, trace elements | 7 | 35 | 46 | 13 | 93 |
| Nutritional supplements | 10 | 34 | 46 | 11 | 90 |
| Homeopathic preparations | 45 | 36 | 15 | 4 | 55 |
| Aromatherapy products | 50 | 37 | 10 | 4 | 50 |
| Dietary interventions | 12 | 27 | 43 | 18 | 88 |
| Factor | mean± SD | Min | Max |
| Age (years) | 53.04±4.53 | 42 | 60 |
| Axial length (mm) | 24.60±0.68 | 23.2 | 26.1 |
| Operation time (min) | 6.35±0.86 | 5 | 9 |
| EFT (sec) | 6.36±1.66 | 3 | 10 |
| Central ECD (cells/mm2) | 2542.9±194.03 | 2004 | 2897 |
| ECD (temporal) | 2547.7±248.03 | 2145 | 3238 |
| ECD (superior) | 2748.9±206.9 | 2245 | 3254 |
| ECD (superotemporal) | 2751.3±231.01 | 2321 | 3345 |
| 1st Line | Maintenance | |||||||
| Mean | 95% CI | Mean | 95% CI | Diff. | 95% CI | F-value | p-value | |
| Dyspnoea | 23.0 | 19.9-26.0 | 21.2 | 0.0-45.4 | 1.73 | −22.6-26.1 | 0.230 | 0.632 |
| Coughing | 31.1 | 27.8-34.4 | 26.7 | 21.4-32.0 | 4.4 | −1.8-10.6 | 1.943 | 0.165 |
| Haemoptysis | 2.8 | 1.1-4.5 | <0.1 | 0.0-10.5 | 2.8 | −7.8-13.4 | 0.273 | 0.603 |
| Sore mouth | 8.0 | 5.5-10.4 | 7.0 | 2.9-11.1 | 1.0 | −3.7-5.8 | 0.183 | 0.670 |
| Dysphagia | 9.1 | 6.8-11.4 | 6.1 | 1.7-10.6 | 3.0 | −2.0-8.0 | 1.408 | 0.237 |
| Peripheral neuropathy | 14.9 | 11.8-18.0 | 18.8 | 13.7-23.9 | −3.9 | −9.9-2.0 | 1.711 | 0.192 |
| Alopecia | 10.2 | 7.3-13.0 | 21.7 | 16.6-26.8 | −11.5 | −17.4- -5.7 | 15.116 | <0.001 |
| Pain in chest | 13.2 | 10.8-15.7 | 8.0 | 4.3-11.7 | 5.3 | 0.8-9.7 | 5.437 | 0.022 |
| Pain in arm or shoulder | 18.1 | 14.8-21.3 | 19.6 | 14.6-24.7 | −1.6 | −7.6-4.4 | 0.266 | 0.607 |
| Pain in other parts | 24.9 | 21.0-28.9 | 25.2 | 18.3-32.0 | −0.2 | −8.1-7.6 | 0.004 | 0.951 |
| Taste Alterationsa | 19.7 | 16.1-23.2 | 31.4 | 24.3-38.4 | −11.7 | −19.6- -3.7 | 8.442 | 0.004 |
| Skin Toxicitya | 18.1 | 15.0-21.3 | 16.9 | 12.0-21.8 | 1.2 | −4.6-7.0 | 0.179 | 0.673 |
| Group 1 | Group 2 | Group 3 | P* | |
| Healthy children | Ambulant sick children | Non ambulant sick children | ||
| n = 126 | n = 99 | n = 36 | ||
| (%1) | (%1) | (%1) | ||
| Direct benefits to the parent’s own child of participating in the study | 85.7 | 100.0 | 100.0 | 0.88 |
| Benefits to the general population | 93.6 | 87.2 | 27.6 | 0.001 |
| Low risk to the child of participating in the study | 100.0 | 60.8 | 70.2 | 0.04 |
| Understanding the study and its regulation | 66.7 | 57.4 | 13.8 | 0.001 |
| Type of histopathology | n (%) |
| Metaplastic carcinoma, spindle cells component | 10 (25.0) |
| Metaplastic carcinoma, producing mucin | 3 (7.5) |
| Metaplastic carcinoma, liposarcoma component | 2 (5.0) |
| Metaplastic carcinoma, squamous cell | 1 (2.5) |
| Metaplastic carcinoma, matrix hyaline | 1 (2.5) |
| Medullary carcinoma | 13 (32.5) |
| Micropapillary carcinoma | 1 (2.5) |
| Invasive ductal carcinoma grade 3 | 6 (15.0) |
| Invasive lobular carcinoma grade 3 | 2 (5.0) |
| Invasive ductal carcinoma + invasive lobularcarcinoma (mixed) | 1 (2.5) |
| Nucleotide no. | Exon | Original* | Mutant | Amino acid change | Frequency in Japanese |
| 590 | IV | A | C | Asn to Thr | 15% |
| 800 | V | T | C | Leu to Pro | 40% |
| Head resection volume groups* | Number of head resections performed | Non-head resection volume groups | Number of non-head resections performed |
| High volume years | High volume years | ||
| 2002 | 42 | 2000 | 28 |
| 2000 | 38 | 2002 | 22 |
| 1998 | 33 | 1999 | 20 |
| 2001 | 31 | 2001 | 19 |
| 1999 | 28 | 2004 | 16 |
| Medium volume years | Medium volume years | ||
| 1997 | 23 | 2005 | 14 |
| 1995 | 19 | 1991 | 14 |
| 2003 | 17 | 1994 | 10 |
| 1993 | 14 | 1995 | 10 |
| 1994 | 13 | 2003 | 11 |
| Low volume years | Low volume years | ||
| 1996 | 12 | 1996 | 9 |
| 2004 | 11 | 1992 | 8 |
| 2005 | 8 | 1990 | 6 |
| 1992 | 7 | 1993 | 6 |
| 1991 | 5 | 1997 | 6 |
| 1990 | 5 | 1998 | 6 |
| PlasmoDB ID | PlasmoDB annotation | Motifs | Key | Refs |
| PPP group | ||||
| PF14_0630 | protein serine/threonine phosphatase | A | 42 | |
| PF14_0142 | serine/threonine protein phosphatase, putative | B | 45, 46 | |
| PF14_0224 | PP1-like protein serine/threonine phosphatase | C | 47, 48 | |
| PFC0595c | serine/threonine protein phosphatase, putative | D | 49 | |
| PF10_0177 | erythrocyte membrane-associated antigen | HT; SP; API | E | |
| PF08_0129 | protein phosphatase, putative | F | 48 | |
| PFI1245c | Protein phosphatase-beta | G | 52 | |
| PFI1360c | serine/threonine protein phosphatase, putative | H | ||
| MAL13P1.274 | serine/threonine protein phosphatase pfPp5 | I | 55, 56 | |
| PF13_0222 | RNA lariat debranching enzyme, putative | K | ||
| PFA0390w | DNA repair exonuclease, putative | L | ||
| PF14_0064 | vacuolar protein sorting 29, putative | M | ||
| PF14_0036 | acid phosphatase, putative | J | ||
| PF14_0660 | hypothetical protein | SP; API | O | |
| PFL0300c | phosphoesterase, putative | SP | P | |
| PF14_0614 | hypothetical protein | SP | N | |
| PPM group | ||||
| MAL13P1.44 | protein phosphatase 2c-like protein, putative | A | ||
| PFL2365w | hypothetical protein, conserved | B | ||
| PF14_0523 | Protein phosphatase 2C, putative | C | ||
| PFD0505c | protein phosphatase 2C | D | ||
| PFE1010w | protein phosphatase 2c, putative | E | ||
| PF11_0362 | protein phosphatase, putative | F | ||
| PF11_0396 | Protein phosphatase 2C | G | 59 | |
| MAL8P1.109 | Protein phosphatase 2C, putative | H | ||
| MAL8P1.108 | protein phosphatase, putative | I | ||
| PF10_0093 | hypothetical protein | J | ||
| PTP group | ||||
| PF14_0524 | protein phosphatase 7 homolog, putative | API | A | |
| PFC0380w | dual-specificity protein phosphatase, putative | B | 67 | |
| PF11_0139 | protein tyrosine phosphatase, putative | C | 68 | |
| PF11_0281 | hypothetical protein | D | ||
| NIF group | ||||
| PFE0795c | nif-like protein, putative | A | ||
| PF07_0110 | hypothetical protein, conserved | B | ||
| PF10_0124 | hypothetical protein | C | ||
| MAL13P1.275 | NLI interacting factor-like phosphatase, putative | D |
| Sample | Thickness, mm | Fiber Weight Fraction, % | Fiber Volume Fraction, % |
| PLA | 0.740 ± 0.020 | - | - |
| PLA-Flax | 0.698 ± 0.016 | 38.2 ± 1.6 | 30.6 ± 0.4 |
| PLA-Jute | 0.750 ± 0.021 | 44.4 ± 0.9 | 41.1 ± 1.2 |
| Preoperative signs | Frequency |
| Reflexes | |
| Normal upper extremity reflex | 30, 44.1 |
| Hyperreflexia of upper extremity | 25, 36.8 |
| Hyporeflexia of upper extremity | 13, 19.1 |
| Normal lower extremity reflex | 43, 63.2 |
| Hyperreflexia in lower extremity | 22, 32.4 |
| Hyporeflexia in lower extremity | 3, 4.4 |
| Upper extremity muscle power (in one or two dermatomal groups) | |
| 3/5 | 2, 2.9 |
| 4/5 | 48, 70.6 |
| 5/5 | 18, 26.5 |
| Lower extremity muscle power | |
| 3/5 | 1, 1.5 |
| 4/5 | 14, 20.6 |
| 5/5 | 53, 77.9 |
| Hoffmann's sign | |
| Positive | 25, 36.8 |
| Negative | 43, 63.2 |
| Babinski sign | |
| Upward | 18, 26.5 |
| Downward | 50, 73.5 |
| Upper extremity hypoesthesia | |
| Positive | 40, 58.8 |
| Negative | 28, 41.2 |
| Gender | Expert diagnosis | SCAT-B diagnosis (N, %) | Predictability (%) | Kappa | |||
| TE | SE | SY | Total | ||||
| Males | TE | 287 (80.2) | 18 (5) | 53 (14.8) | 358 (100) | 489 (61.3) | .387 |
| SE | 33 (17.6) | 107 (56.9) | 48 (25.5) | 188 (100) | |||
| SY | 102 (40.5) | 55 (21.8) | 95 (37.7) | 252 (100) | |||
| Females | TE | 361 (69.3) | 21 (4) | 139 (26.7) | 521 (100) | 767 (54.2) | .298 |
| SE | 52 (13.9) | 146 (38.9) | 177 (47.2) | 375 (100) | |||
| SY | 149 (28.7) | 111 (21.3) | 260 (50) | 520 (100) |
| Characteristic | Placebo | Desvenlafaxine | Desvenlafaxine |
| (n = 223) | 10 mg/d (n = 226) | 50 mg/d (n = 224) | |
| Age, y | 42 ± 13 | 41 ± 14 | 43 ± 14 |
| Age group, n (%) | |||
| 18-64 y | 215 (96) | 212 (94) | 213 (95) |
| >64 y | 8 (4) | 14 (6) | 11 (5) |
| Female, n (%) | 139 (62) | 135 (60) | 135 (60) |
| Race, n (%) | |||
| White | 176 (79) | 199 (88) | 177 (79) |
| Black | 38 (17) | 20 (9) | 37 (17) |
| Asian | 4 (2) | 3 (1) | 2 (1) |
| Other | 5 (2) | 4 (2) | 8 (4) |
| Weight, kg | 87 ± 24 | 88 ± 27 | 91 ± 26 |
| Body mass index, kg/m2 | 30 ± 7 | 31 ± 9 | 32 ± 8 |
| Baseline HAM-D17 score | 23 ± 3 | 23 ± 2 | 23 ± 3 |
| Duration of current depressive episode, mo | 34 ± 81 | 26 ± 48 | 31 ± 76 |
| Age <65 years (n = 1052) | ||||||
| Points | Events | Hazard ratio | 95% CI | p* | 10-year survival | 95% CI |
| 0 | 12/137 | 1 | 91.5% | 84.7-95.4% | ||
| 1 | 47/450 | 1.44 | 0.81-2.56 | 0.2133 | 90.5% | 86.7-93.3% |
| 2 | 23/253 | 1.30 | 0.65-2.57 | 0.4582 | 90.9% | 85.4-94.4% |
| 3 | 22/125 | 2.70 | 1.35-5.39 | 0.0049 | 80.3% | 69.6-87.6% |
| 4 | 11/61 | 2.68 | 1.07-6.70 | 0.0346 | 82.5% | 69.8-90.2% |
| 5 | 6/26 | 7.11 | 1.73-29.24 | 0.0066 | 74.2% | 47.2-88.8% |
| Age 65+ years (n = 1079) | ||||||
| Points | Events | Hazard ratio | 95% CI | p* | 10-year survival | 95% CI |
| 0 | 3/53 | 1 | 98.1% | 87.4-99.7% | ||
| 1 | 56/469 | 2.24 | 1.08-4.64 | 0.0300 | 88.0% | 83.6-91.2% |
| 2 | 46/259 | 2.60 | 1.32-5.13 | 0.0058 | 80.5% | 73.5-85.8% |
| 3 | 30/157 | 3.14 | 1.48-6.69 | 0.0030 | 78.2% | 69.0-84.9% |
| 4 | 29/106 | 4.07 | 1.98-8.37 | 0.0001 | 67.0% | 54.7-76.6% |
| 5 | 16/35 | 21.12 | 7.45-59.90 | <0.0001 | 48.9% | 26.2-68.3% |
| All patients (n = 2131) | ||||||
| Points | Events | Hazard ratio | 95% CI | p* | 10-year survival | 95% CI |
| 0 | 15/190 | 1 | 93.4% | 88.3-96.3% | ||
| 1 | 103/919 | 1.73 | 1.11-2.69 | 0.0149 | 89.3% | 86.5-91.5% |
| 2 | 69/512 | 2.00 | 1.26-3.18 | 0.0032 | 85.7% | 81.4-89.0% |
| 3 | 52/282 | 2.89 | 1.77-4.71 | <0.0001 | 78.9% | 72.2-84.2% |
| 4 | 40/167 | 3.88 | 2.25-6.70 | <0.0001 | 73.0% | 64.2-80.0% |
| 5 | 22/61 | 21.30 | 8.95-50.72 | <0.0001 | 60.3% | 43.2-73.7% |
| Onset < 20 y.o. | Onset >40 y.o. | Abdominal | C1q < 50% | |
| % pts. | % pts. | % pts. | %pts | |
| Acquired angioedema | 0 | 94 | 48 | 70 |
| Hereditary angioedema | 12 | 3 | 87 | < 5 |
| BudesonideNanodispersion | BudesonideMicrosuspension | |
| Inhalation Filter (percent of the nominal dose) | 14.24 (2.51) | 14.97 (4.3) |
| Exhalation Filter (percent of the nominal dose) | 14.92 (3.21) | 15.27 (4.48) |
| Chamber (percent of the nominal dose) | 69.33 (5.08) | 68.36 (8.95) |
| Connector (percent of the nominal dose) | 1.49 (0.33) | 1.39 (0.20) |
| Nebulization time (min) | 12.30 (0.37) | 14.85 (0.36) |
| Factor | p in univariate regression* | p in multivariate regression ° | Odds ratio in multivariate regression [95% CI] |
| Predictive of complaint specificity | |||
| Age | 0.171 | ||
| Gender | 0.466 | ||
| Previous medical contact | 0.001 | 0.001 | 1.828 [1.268–2.636] |
| Consequences of complaint specificity | |||
| Triage | 0.101 | ||
| Resuscitation bay | 0.241 | ||
| Length of ED stay | 0.748 | ||
| Vague diagnosis at ED discharge | 0.012 | 0.001 | 1.822 [1.159–2.899] |
| Length of hospital stay | 0.029 | 0.025 | 1.001 [1–1.002] |
| Vague diagnosis at ED discharge | 0.923 | ||
| Mortality | 0.054 | 0.087 | 1.922 [0.909–4.065] |
| MEN | WOMEN | ||||
| FOOD ITEM | ASSOCIATION | VIP | FOOD ITEM | ASSOCIATION | VIP |
| Influential for high SOC | Influential for high SOC | ||||
| Bread | + | 2.18 | Fruits | + | 1.83 |
| Bread and cereals | + | 1.96 | Vegetables | + | 1.83 |
| Rye crisp bread (whole meal) | + | 1.89 | Liver paste | + | 1.64 |
| Fish | + | 1.76 | Boiled potato | + | 1.47 |
| Boiled potato | + | 1.71 | Rye crisp bread (whole meal) | + | 1.43 |
| Berries | + | 1.51 | Blood foods | + | 1.32 |
| Wine | + | 1.49 | Cereals | + | 1.29 |
| Light beer | + | 1.32 | Oat flake porridge | + | 1.24 |
| Vegetables | + | 1.23 | |||
| Influential for low SOC | Influential for low SOC | ||||
| Pizza | - | 2.41 | Mashed potato | - | 2.98 |
| Soft drinks | - | 2.25 | Sausage as main course | - | 2.11 |
| Pasta | - | 2.14 | Potato salad | - | 1.98 |
| Candies | - | 2.02 | Soft drinks | - | 1.94 |
| Sausage as main course | - | 1.97 | French fries | - | 1.89 |
| Hamburgers | - | 1.94 | Hamburgers | - | 1.82 |
| Mashed potato | - | 1.87 | Beer (high alcohol) | - | 1.71 |
| Fried potato | - | 1.65 | Pizza | - | 1.68 |
| Butter for cooking | - | 1.63 | Sweets | - | 1.67 |
| Chips, cheese doodles, nuts | - | 1.57 | Candies | - | 1.60 |
| Potato salad | - | 1.48 | Rice | - | 1.50 |
| Banana | - | 1.37 | Pancakes | - | 1.43 |
| French fries | - | 1.22 | Syrups | - | 1.42 |
| Traditional broth soaked bread | - | 1.21 | Cookies | - | 1.39 |
| Fruit soup | - | 1.21 | Traditional broth soaked bread | - | 1.29 |
| Traditional potato dumpling | - | 1.20 | Chips, cheese doodles, nuts | - | 1.29 |
| Anthropometric | p | FFQ Intake | p | Model R-squared | FFQ—Plasma Correlation | Correlation 95% CI |
| Plasma α-carotene | ||||||
| α-carotene | <0.001 | 0.26 | 0.52 | 0.35, 0.69 | ||
| BMI | 0.004 | α-carotene | <0.001 | 0.34 | 0.49 | 0.33, 0.64 |
| BMI | 0.001 | 0.11 | ||||
| Plasma β-carotene | ||||||
| β-carotene | 0.003 | 0.21 | 0.47 | 0.18, 0.75 | ||
| Veg Serves | 0.007 | 0.17 | 0.42 | 0.12, 0.71 | ||
| BMI | 0.016 | β-carotene | 0.004 | 0.31 | 0.41 | 0.15, 0.68 |
| Fat mass | 0.013 | Veg Serves | 0.013 | 0.25 | 0.34 | 0.08, 0.61 |
| BMI | 0.004 | 0.14 | ||||
| Fat mass | 0.003 | 0.14 | ||||
| Plasma Lycopene | ||||||
| Lycopene | 0.756 | 0.00 | ||||
| Plasma Lutein/zeaxanthin | ||||||
| Lutein/zeax | 0.041 | 0.09 | 0.26 | 0.01, 0.51 | ||
| BMI | <0.001 | Lutein/zeax | 0.095 | 0.20 | ||
| BMI | <0.001 | 0.14 | ||||
| Plasma Cryptoxanthin | ||||||
| Cryptoxant | 0.236 | 0.08 | ||||
| Fat mass | 0.005 | Supplements | 0.003 | 0.35 | ||
| Fat mass | <0.001 | 0.22 |
| Marker name | Region | Chr | Position | SNP quality | Alleles (A/B) | EAF (B allele) | Effect size for B allele (95% CI) | P | Gene context |
| rs377070 | 4q27 | 4 | 123629002 | 0.99 | C/G | 0.388 | −0.070 (−0.081, −0.060) | 1.2 × 10−36 | IL21--[]--BBS12 |
| rs3134995 | 6p21.32 | 6 | 32672089 | 0.99 | C/T | 0.242 | −0.065 (−0.077, −0.052) | 1.9 × 10−24 | HLA-DQB1--[]--HLA-DQA2 |
| rs5750339 | 22q12.3 | 22 | 37319589 | 0.96 | C/G | 0.457 | −0.052 (−0.062, −0.041) | 9.2 × 10−21 | [CSF2RB] |
| rs55722650 | 5q31.1 | 5 | 131607300 | >0.99 | C/T | 0.41 | −0.049 (−0.060, −0.038) | 4.8 × 10−19 | [PDLIM4] |
| rs2906856 | 12q15 | 12 | 68390201 | 0.99 | C/T | 0.353 | 0.039 (0.028, 0.050) | 7.9 × 10−12 | DYRK2---[]---IFNG |
| rs11751172 | 6p21.1 | 6 | 45552731 | 0.99 | C/T | 0.244 | −0.040 (−0.053, −0.028) | 1.1 × 10−10 | RUNX2--[]---CLIC5 |
| rs6754311 | 2q21.3 | 2 | 136707982 | 0.97 | C/T | 0.609 | 0.039 (0.027, 0.051) | 1.6 × 10−10 | [DARS] |
| rs143626010 | 16p11.2 | 16 | 28539398 | 0.91 | D/I | 0.611 | 0.033 (0.021, 0.044) | 1.5 × 10−8 | [NPIPL1] |
| rs7793919 | 7p22.1 | 7 | 4769030 | 0.94 | C/T | 0.435 | 0.031 (0.020, 0.042) | 2.8 × 10−8 | [FOXK1] |
| rs62447171 | 7p12.2 | 7 | 50309890 | >0.99 | A/G | 0.736 | 0.034 (0.022, 0.046) | 3.5 × 10−8 | C7orf72---[]--IKZF1 |
| rs3024971 | 12q13.3 | 12 | 57493727 | >0.99 | G/T | 0.896 | 0.047 (0.030, 0.065) | 5.9 × 10−8 | [STAT6] |
| rs3102960 | 2p25.1 | 2 | 8452497 | 0.98 | C/T | 0.793 | −0.036 (−0.049, −0.023) | 7.6 × 10−8 | []---ID2 |
| rs2230624 | 1p36.22 | 1 | 12175658 | 0.80 | A/G | 0.988 | 0.162 (0.102, 0.222) | 1.1 × 10−7 | [TNFRSF8] |
| rs9815073 | 3q28 | 3 | 188115682 | 0.80 | A/C | 0.657 | −0.033 (−0.046, −0.021) | 1.1 × 10−7 | [LPP] |
| rs112637405 | 4q28.2 | 4 | 130258336 | 0.63 | A/T | 0 | 1.946 (1.228, 2.664) | 1.1 × 10−7 | C4orf33---[] |
| rs6841258 | 4p14 | 4 | 40565426 | 0.85 | C/T | 0.179 | 0.039 (0.024, 0.054) | 3.6 × 10−7 | [RBM47] |
| rs78587638 | 2q14.2 | 2 | 119187509 | 0.98 | A/G | 0.842 | −0.037 (−0.051, −0.023) | 4.2 × 10−7 | INSIG2---[]---EN1 |
| rs12133641 | 1q21.3 | 1 | 154428283 | >0.99 | A/G | 0.395 | 0.028 (0.017, 0.038) | 4.3 × 10−7 | [IL6R] |
| rs2075533 | 9q32 | 9 | 117693631 | >0.99 | A/G | 0.572 | 0.027 (0.017, 0.038) | 4.7 × 10−7 | TNFSF8[]--TNC |
| rs921533 | 2q31.1 | 2 | 174551931 | 0.98 | A/T | 0.658 | 0.029 (0.018, 0.040) | 5.2 × 10−7 | CDCA7---[]---SP3 |
| rs2963854 | 5q35.2 | 5 | 175083754 | 0.84 | A/G | 0.196 | −0.034 (−0.047, −0.021) | 5.3 × 10−7 | SFXN1---[]-HRH2 |
| rs112724722 | 7q21.3 | 7 | 93546386 | >0.99 | A/G | 0.998 | −0.384 (−0.534, −0.234) | 5.3 × 10−7 | GNGT1-[]-GNG11 |
| rs969584 | 8q24.13 | 8 | 126620429 | 0.99 | C/G | 0.351 | −0.028 (−0.040, −0.017) | 5.4 × 10−7 | TRIB1---[]---FAM84B |
| rs71872522 | 1p31.1 | 1 | 77050728 | 0.73 | D/I | 1 | −1.797 (−2.505, −1.089) | 6.6 × 10−7 | [ST6GALNAC3] |
| rs200872239 | 1p36.11 | 1 | 25250916 | 0.77 | D/I | 0.313 | 0.032 (0.020, 0.045) | 6.8 × 10−7 | [RUNX3] |
| Phase I - 2011 (n = 1054) % | Phase II - 2012 (n = 1105) % | Phase III - 2013 (n = 1854) % | P** | |
| Location: | p < 0.001 | |||
| • Operating room | 1.2 | 1.8 | 1.5 | |
| • Medical surgical unit | 73.1 | 71.7 | 62.0 | |
| • Pharmacy | 0.0 | 0.1 | 4.6 | |
| • Step Down Unit | 10.9 | 8.3 | 20.7 | |
| • Emergency Department | 0.0 | 2.6 | 0.0 | |
| • Intensive Care Unit | 14.7 | 15.5 | 11.2 | |
| Time: | p < 0.001 | |||
| • Morning (7 am to 1 pm) | 33.0 | 38.4 | 30.9 | |
| • Not identified | 13.4 | 0.2 | 0.8 | |
| • Night (7 pm to 7 am) | 23.5 | 31.0 | 47.1 | |
| • Afternoon (1 pm to 7 pm) | 30.1 | 30.4 | 21.3 | |
| Order entry type: | p < 0.001 | |||
| • Electronic | 38.4 | 40.4 | 73.7 | |
| • Manual | 61.6 | 51.4 | 26.3 | |
| • Not Prescribed | 0.0 | 8.2 | 0.0 | |
| Error class: | p < 0.001 | |||
| • A | 29.2 | 14.1 | 2.2 | |
| • B | 25.8 | 34.8 | 65.1 | |
| • C | 35.7 | 35.2 | 27.5 | |
| • D | 8.0 | 13.8 | 4.6 | |
| • E, F, H, G or I | 1.3 | 2.1 | 0.5 | |
| Error accountability: | p < 0.001 | |||
| • Nursing | 46.4 | 48.5 | 58.7 | |
| • Pharmacy | 19.4 | 20.1 | 26.9 | |
| • Physician | 32.4 | 22.9 | 10.8 | |
| • Other | 1.7 | 8.5 | 3.6 | |
| Phase of medication use where error occurred: | p < 0.001 | |||
| • Administering | 35.5 | 43.1 | 55.6 | |
| • Dispensing | 19.6 | 24.3 | 22.7 | |
| • Monitoring | 3.4 | 0.9 | 0.2 | |
| • Prescribing | 34.5 | 23.8 | 11.7 | |
| • Transcribing | 6.9 | 8.0 | 9.9 |
| Variables | No. of cases. | Univariate analysis | Multivariate analysis | ||||
| HR ratio | 95%CI | P-value | HR ratio | 95%CI | P-value | ||
| Age(years) | 1.009 | 0.991-1.027 | 0.349 | ||||
| <60 | 76 | ||||||
| ≥60 | 49 | ||||||
| Gender | 0.911 | 0.554-1.498 | 0.713 | ||||
| Female | 59 | ||||||
| Male | 66 | ||||||
| Tumor diameter(cm) | 0.566 | 0.3629-0.8826 | 0.012* | 1.719 | 1.049-2.816 | 0.019* | |
| ≤5 | 71 | ||||||
| >5 | 54 | ||||||
| Tumor location | 0.996 | 0.609-1.628 | 0.987 | ||||
| Colon | 69 | ||||||
| Rectum | 56 | ||||||
| Depth of infiltration | 1.055 | 0.749-1.485 | 0.761 | ||||
| Submucosa, musculeris propria | 28 | ||||||
| Subserosa | 66 | ||||||
| To the surrounding tissue | 31 | ||||||
| Histologic type | 1.61 | 1.155-2.245 | 0.005** | 1.615 | 1.138-2.293 | 0.007** | |
| Well differentiated | 56 | ||||||
| Morderately differentiated | 49 | ||||||
| Poorly differentiated | 20 | ||||||
| TNM staging | 1.716 | 1.055-2.791 | 0.029* | 1.849 | 1.119-3.057 | 0.007** | |
| I/II | 81 | ||||||
| III/IV | 44 | ||||||
| Lymph node metastasis | 1.811 | 1.099-2.983 | 0.02* | ||||
| NO | 85 | ||||||
| YES | 40 | ||||||
| CHRDL2 expression | 1.956 | 1.188-3.221 | 0.008** | 1.956 | 1.188-3.221 | 0.008* | |
| Low | 63 | ||||||
| High | 62 |
| MBA | LEBA | |
| Deep squat | 2.20 ± 0.79 | 2.50 ± 0.71 |
| Hurdle step | 1.80 ± 0.63 | 1.80 ± 0.79 |
| Inline lunge | 2.10 ± 0.74 | 2.70 ± 0.48 * |
| Shoulder mobility | 1.40 ± 0.52 | 1.90 ± 0.57 ‡ |
| Active straight leg raise | 1.80 ± 0.79 | 2.30 ± 0.67 |
| Trunk stability pushup | 2.30 ± 0.82 | 2.60 ± 0.52 |
| Rotary stability | 1.80 ± 0.79 | 1.60 ± 0.84 |
| Total | 13.40 ± 2.17 | 15.40 ± 1.90 * |
| Survey/Questionnaire | Scheduled at | Contents | Conducted by * | Consent/Reconsent |
| Women's Enrollment Survey | Beginning of trial | Baseline census of all women of reproductive age, enrollment into surveillance | FD | Y |
| Newly Married Woman Survey | Ongoing, 5- weekly | Allows enrollment of eligible, newly married women | FD | Y |
| Pregnancy Surveillance Survey | Ongoing, 5- weekly | Urinary hCG-based identification of new pregnancies | FD | Y, for urine test |
| Women's ConsentInterview | Pregnancy identification | Informing women about the trial, obtaining consent for interviews and supplementation | TL | Y |
| Pregnancy Dosing Visits | Weekly | Weekly supplementation of enrolled pregnant women | FD | N |
| Pregnancy Enrollment Questionnaire | First week after consent | Baseline characteristics, pregnancy history, 7 d diet, 7 d/30 d morbidity, exposures | FI | N |
| Socioeconomic Status Questionnaire | First week after consent | Education, employment of self and husband, household assets | FI | N |
| Family History Questionnaire | First week after consent | Parental vital status, cause of death, chronic morbidity | FI | N |
| Late Pregnancy Questionnaire | At 28 weeks gestation | 7 d diet, 7 d/30 d morbidity, exposures | FI | N |
| Three-Month Postpartum Questionnaire | At 12 weeks postpartum | Complications of labor and delivery, 7 d diet, 7 d/30 d morbidity, exposures | FI | N |
| Six-Month Postpartum Questionnaire | At 24 weeks postpartum | 7 d diet, 7 d/30 d morbidity, exposures | FI | N |
| Miscarriage/Stillbirth Questionnaire | 4 weeks after event | Complications of labor and delivery, care-seeking | FI | Y |
| Verbal Autopsy - Infant | 4 weeks after event | Enhanced from WHO standard instrument | FI | Y |
| Verbal Autopsy - Mother | 4 weeks after event | Enhanced from WHO standard instrument | RP | Y |
| 70 OR patients(n, %) | 49 EVAR patients (n, %) | p | |
| In-hospital | |||
| Reintervention | 1, 1.4 | 2, 4 | 0.36 |
| Mortality | 0, 0 | 0, 0 | NA |
| 30-day | |||
| Reintervention | 0, 0 | 2, 4 | 0.16 |
| Mortality | 0, 0 | 0, 0 | NA |
| 1-year | |||
| Reintervention | 1, 1.4 | 2, 4 | 0.36 |
| Mortality | 0, 0 | 0, 0 | NA |
| Long-term | |||
| Reintervention | 8, 11.4 | 4, 8.1 | 0.39 |
| Mortality | 3, 4.2 | 4, 8.1 | 0.38 |
| Characteristics | Number (%) |
| Number of patients | 112 |
| Tissue samples analyzed | 224 |
| Sex | |
| male | 27 |
| female | 85 |
| Age | |
| < 45y | 49 |
| ≥ 45y | 63 |
| Tumor size* | |
| T1 | 63 |
| T2 | 36 |
| T3 | 8 |
| Multifocality | 34 (30%) |
| Lymph node metastasis | 41 (38%) |
| Distant metastasis | 0 |
| Tumor mutation status | |
| BRAF V600E | 69 (63%) |
| Outcome | Controls: no transfusion in ED group (n = 204) | Cases: transfusion group (n = 204) | Odds ratio or between-group difference (95% CI) | P value* |
| Primary composite outcome, n (%) | 26 (12.7) | 28 (13.7) | 0.91 (0.48–1.72) | 0.77 |
| • Respiratory failure | 17 (8.3) | 19 (9.3) | 1.13 (0.57–2.24) | 0.73 |
| • ICU admission | 8 (3.9) | 7 (3.4) | 0.87 (0.31–2.45) | 0.79 |
| • ARDS | 9 (4.4) | 14 (6.9) | 1.60 (0.68–3.78) | 0.28 |
| Secondary outcomes (days) | ||||
| Ventilator-free | 24.7 (9.4) | 23.7 (10.3) | 1.0 (−0.9–2.9) | 0.30 |
| ICU-free | 24.7 (8.3) | 23.7 (9.0) | 0.9 (−0.8–2.6) | 0.30 |
| Hospital-free | 20.0 (8.5) | 18.6 (9.1) | 1.4 (−0.3–3.1) | 0.11 |
| RRT, n (%) | 18 (8.8) | 7 (3.4) | 0.37 (0.15–0.90) | 0.02 |
| Mortality, n (%) | 18 (8.8) | 22 (10.8) | 1.25 (0.65–2.41) | 0.51 |
| Training | Development | Test | ||||
| Year | Tit./Abs. | Full | Tit./Abs. | Full | Tit./Abs. | Full |
| 2009 | 800 | 0 | 150 | 0 | 260 | 0 |
| 2011 | 800 | 108 | 150 | 109 | 260 | 87 |
| 2013 | 0 | 222 | 0 | 249 | 0 | 305 |
| All PCa | Sign PCa | Insig PCa | |
| Sensitivity | 96 | 98 | 91 |
| Specificity | 32 | 22 | 13 |
| NPV | 75 | 92 | 83 |
| PPV | 78 | 56 | 23 |
| Trait | Transgene (T) | Genotype (G) | Planting (C) | T * B | T * C | G * C | T * G * C | |||||||
| df | F | df | F | df | F | df | F | df | F | df | F | df | F | |
| Number of tillers per plant | 1 | 4.4* | 4 | 19.1** | 1 | 0.1 | 4 | 1.2 | 1 | 1.2 | 4 | 1.2 | 4 | 2.0 |
| Number of panicles per plant | 1 | 27.3** | 4 | 17.3** | 1 | 28.8** | 4 | 0.4 | 1 | 0.1 | 4 | 1.8 | 4 | 1.0 |
| Number of filled seeds per plant | 1 | 112.5** | 4 | 6.1** | 1 | 0.2 | 4 | 1.5 | 1 | 0.0 | 4 | 1.3 | 4 | 0.9 |
| Ratio of seed set | 1 | 14.8** | 4 | 3.8* | 1 | 1.9 | 4 | 1.3 | 1 | 0.3 | 4 | 1.3 | 4 | 1.3 |
| 1000‐seed weight | 1 | 8.3* | 4 | 12.5** | 1 | 1.4 | 4 | 1.2 | 1 | 0.1 | 4 | 2.2 | 4 | 0.2 |
| All | African American Female | African American Male | Caribbean Black Female | Caribbean Black Male | ||||||
| B | 95% CI | B | 95% CI | B | 95% CI | B | 95% CI | B | 95% CI | |
| Ethnicity (Caribbean Black) | −0.01 * | −0.03–0.00 | - | - | - | - | - | - | - | - |
| Gender (Female) | 0.00 | 0.00–0.01 | - | - | - | - | - | - | - | - |
| Age (Years) | 0.01 # | 0.00–0.02 | 0.13 | −0.23–0.48 | 0.61 *** | 0.38–0.83 | 0.27 | −0.13–0.66 | −0.09 | −0.66–0.48 |
| SES (Income to needs ratio) | 0.00 | −0.01–0.01 | 0.12 | −0.06–0.31 | 0.20 * | 0.02–0.37 | 0.35 *** | 0.17–0.53 | 0.35 | −0.25–0.95 |
| Intercept | −0.06 | −0.14–0.02 | 2.43 | −2.91–7.76 | −4.53 ** | −7.82–−1.25 | −1.11 | −7.29–5.07 | 5.89 | −2.17–13.96 |
| Free State Department of Health ART course (Standard training) | PALSA PLUS training (Standard training) | STRETCH Training (Additional training in intervention clinics) | |
| Description | Two- week training course comprising one week of lectures and one week of practical training | One- to two-hour sessions weekly or fortnightly of case scenario-based interactive training in use of PALSA PLUS guidelines (six to eight sessions in total) | One- to two-hour sessions weekly or fortnightly of case scenario-based interactive training in use of PALSA PLUS STRETCH guidelines (four sessions in total) |
| Trainers | Senior doctors, pharmacists dieticians and social workers working in ART programme | Middle level nurse managers trained as PALSA PLUS trainers | Middle level nurse managers trained as PALSA PLUS and STRETCH trainers |
| Trainees | Doctors, professional nurses enrolled nurses pharmacists and social workers involved in providing primary care services at hospitals and clinics across the province | Professional and enrolled nurses and ancillary staff at all intervention and control clinics and primary care clinics throughout the province. | All professional nurses (whether appointed to ART or primary care posts) at 16 intervention sites only |
| Setting | Local classrooms located throughout the province to which lectures are broadcast.Local ART sites during practical training | Training sessions held at the clinic | Training sessions held at the clinic |
| Mode of delivery | Lectures broadcast live from central studio with limited telephone interaction.Face-to-face with staff at ART sites during practical training | Face-to-face small group facilitative work | Face-to-face small group facilitative work |
| Intensity and duration | Full day training for one week of lectures and one week of practical training | One to two hours once every week or two weeks for two to three months | One to two hours once every week for four weeks |
| Variable | Serum zinc μg/dl (mean+/-sd) | ZD+ | ZD- | Crude OR (95% CI) |
| One-way walking distance from nearby health facility (n = 700) | ||||
| 0-30 min | 52.5 (9.9) | 311 | 287 | 0.76 (0.50-1.16) |
| Longer than 30 min | 51.6 (10.2) | 60 | 42 | 1r |
| Frequency of ANC follow up (n = 700) | ||||
| 0 | 53.4 (9.9) | 184 | 180 | 1r |
| 1-2 | 51.3 (9.8) | 171 | 136 | 1.23 (0.48-2.20) |
| ≥ 3 | 50.6 (9.5) | 16 | 13 | 1.20 (0.56-2.58) |
| Received nutrition education during the pregnancy (n = 700) | ||||
| Yes | 51.4 (10.2) | 99 | 76 | 1.21 (0.86-1.71) |
| No | 52.7 (9.8) | 272 | 253 | 1r |
| Men (n = 74) | Women (n = 199) | ||
| Age (years) | 46.2 ± 14.2 | 46 ± 13.5 | |
| BMI (kg/m2) | 40.4 ± 8.3 | 34.8 ± 6.2 | |
| Obesity-related diseases (%) | Type 2 Diabetes | 14.9 | 12.6 |
| Thyroid diseases | 6.8 | 35.2 | |
| Gastrointestinal diseases | 23 | 19.6 | |
| Cardiovascular diseases | 16.2 | 5.0 | |
| Hypertension | 45.9 | 36.2 | |
| Osteaorticular diseases | 25.7 | 22.1 | |
| Respiratory diseases | 21.6 | 16.6 | |
| Psychiatric diseases | 14.9 | 12.1 | |
| Dyslipidemia | 16.2 | 12.6 | |
| Insulin resistance | 10.8 | 15.1 | |
| Level of education (%) | Primary school | 2.7 | 5 |
| Middle school | 20.3 | 25.3 | |
| High school | 60.8 | 55.1 | |
| University degree | 16.2 | 14.6 | |
| Occupation (%) | Housewife | 1.4 | 32,7 |
| Employee | 21.9 | 29.6 | |
| Freelance worker | 17.6 | 10.1 | |
| Factory worker | 14.9 | 8.5 | |
| Retiree | 12.2 | 9.5 | |
| Unemployed | 6.8 | 5.5 | |
| Student | 5.4 | 4 |
| γ-rays | # | X-rays | # | UV-A | # | UV-B | # | UV-C | # |
| RAD54 | 30 | ATLIG4 | 28 | AT2G21970.1 | 2 | UVH3 | 32 | TED4 | 3 |
| AT4G14970 | 30 | MIM | 7 | RPA70B | 7 | MC4 | 2 | ||
| RPA1A | 27 | SMC6A | 6 | RPA70D | 5 | MC7 | 2 | ||
| MSH5 | 23 | XPB1 | 4 | MC5 | 2 | ||||
| RAD51 | 18 | XPB2 | 4 | MC6 | 2 | ||||
| AT3G48900 | 1 | MC8 | 2 | ||||||
| HO4 | 1 | ||||||||
| HO3 | 1 | ||||||||
| ETL1 | 1 | ||||||||
| PCC1 | 1 | ||||||||
| PAD4 | 1 |
| ROI | cluster size | peak t-value | MNI coordinates | p-value | ||
| x | y | z | ||||
| temporal pole R | 12091 | 7.27 | 56 | 8 | -38 | <0.001 |
| paracentral lobule | 7873 | 5.84 | -2 | -34 | 44 | <0.001 |
| orbitofrontal cortex L | 1825 | 4.76 | -20 | 52 | -22 | 0.004 |
| Treatment -seeking behavior for malaria | VMW village | HC village | |||
| n | % | n | % | p | |
| Patients who sought treatment outside home* | n=110 | n=126 | 0.101 | ||
| Yes | 104 | 94.6 | 124 | 98.4 | |
| No | 6 | 5.5 | 2 | 1.6 | |
| Treatment source* | n=104 | n=124 | <.0001 | ||
| VMW | 42 | 40.4 | 0 | 0 | |
| HC | 29 | 27.9 | 117 | 94.4 | |
| Private clinic | 21 | 20.2 | 4 | 3.2 | |
| Drug seller | 5 | 4.8 | 1 | 0.8 | |
| Other | 7 | 6.7 | 2 | 1.6 | |
| Blood test for malaria* | n=104 | n=124 | 0.570 | ||
| Yes, Dipstick/Sldie | 88 | 84.6 | 98 | 79.0 | |
| Not tested | 15 | 14.4 | 24 | 19.4 | |
| Don’t know | 1 | 1.0 | 2 | 1.6 | |
| Place to get the blood test* | n=88 | n=98 | <.0001 | ||
| VMW | 38 | 43.2 | 0 | 0 | |
| HC | 28 | 31.8 | 93 | 94.9 | |
| Private clinic | 18 | 20.5 | 3 | 3.1 | |
| Other | 4 | 4.6 | 2 | 2.0 | |
| Result of the blood test* | n=88 | n=98 | 1.000 | ||
| Positive | 70 | 79.6 | 78 | 79.6 | |
| Negative | 17 | 19.3 | 19 | 19.4 | |
| Don’t know/don’t remember | 1 | 1.1 | 1 | 1.0 | |
| Time to receive first treatment† | n=104 | n=124 | <.0001 | ||
| Same day | 24 | 23.1 | 13 | 10.5 | |
| Next day | 35 | 33.7 | 80 | 64.5 | |
| 2 days after the illness started | 31 | 29.8 | 23 | 18.6 | |
| 3 or more days after the illness started | 14 | 13.5 | 8 | 6.5 | |
| Antimalarial drugs† | n=104 | n=124 | 0.032 | ||
| Yes | 98 | 94.2 | 106 | 85.5 | |
| No | 6 | 5.8 | 18 | 14.5 | |
| Type of antimalarial taken* | n=98 | n=106 | 0.555 | ||
| A+M | 25 | 25.5 | 26 | 24.5 | |
| Malarine | 14 | 14.3 | 14 | 13.2 | |
| Antimalalrial drugs not recommended | 8 | 8.2 | 4 | 3.8 | |
| Paracetamol | 7 | 7.1 | 5 | 4.7 | |
| Don’t know/don’t remember | 44 | 44.9 | 57 | 53.8 |
| Controlsubjects | Type 2 diabetic patients staged by neuropathy severity | |||
| Stage I | Stage II | Stage III | ||
| Corneal nerve fiber density (no/mm2) | 30.6–34.1 | 25.6–29.4∗ | 24.9–28.1† | 21.6–25.7† |
| Corneal nerve fiber length (mm/mm2) | 12.1–13.3 | 10.6–12.0 | 10.1–11.5∗ | 8.95–10.4†,‡ |
| Corneal nerve branch density (no/mm2) | 12.0–15.6 | 10.7–13.0 | 8.7–11.2∗ | 8.4–11.0∗ |
| Corneal nerve branch length (mm/mm2) | 2.43–3.08 | 2.31–2.78 | 2.03–2.64 | 2.01–2.75 |
| Tortuosity grade | 1.86–2.04 | 2.40–2.64† | 2.39–2.58† | 2.47–2.68† |
| Beading frequency (no/0.1 mm) | 23.5–24.6 | 19.3–20.7† | 19.2–20.4† | 19.5–20.8† |
| Bead size (μm2) | 7.89–8.25 | 9.80–10.2† | 9.90–10.3† | 10.0–10.4† |
| Sugar | MIC |
| l-fucose | 0.586 mM |
| Methyl-α,l-fucoside | 0.293 mM |
| Fuc(1,2)Gal (2-O-(l-fucosyl)-d-galactose) | 0.293 mM |
| Fuc(1-3)GlcNAc (3-O-(l-fucosyl)-2-N-acetyl-d-glucosamine) | 0.147 mM |
| Fuc(1-4)GlcNAc (4-O-(l-fucosyl)-2-N-acetyl-d-glucosamine) | 0.147 mM |
| Fuc(1-6)GlcNAc (6-O-(l-fucosyl)-2-N-acetyl-d-glucosamine) | 0.293 mM |
| l-galactose | 4.69 mM |
| d-arabinose | 9.375 mM |
| d-fructose | 75 mM |
| d-mannose | 150 mM |
| methyl-α,d-mannoside, d-glucose, d-galactose, l-arabinose, d-xylose, d-lyxose, d-tagatose, l-rhamnose | NI* |
| Range | N | Mean | SD | Response rates | Floor effects | Ceiling effects | |
| EQ-5D-3 L (Utility) | −0.594 to 1 | 234 | 0.60 | 0.36 | 95.29 % | 0.00 % | 19.73 % |
| SF-6D (Utility) | 0.345 to 1 | 218 | 0.66 | 0.16 | 93.16 % | 0.92 % | 0.92 % |
| SF-12 PCS | 0 to 100 | 209 | 36.88 | 12.32 | 89.32 % | 0.00 % | 0.00 % |
| SF-12 MCS | 0 to 100 | 209 | 43.43 | 13.30 | 89.32 % | 0.00 % | 0.00 % |
| SGRQ Symptoms Score | 0 to 100 | 221 | 33.71 | 27.89 | 94.44 % | 1.36 % | 1.36 % |
| SGRQ Activity Score | 0 to 100 | 193 | 46.04 | 31.80 | 82.47 % | 7.77 % | 7.77 % |
| SGRQ Impact Score | 0 to 100 | 194 | 22.13 | 22.42 | 82.90 % | 0.00 % | 0.00 % |
| SGRQ Total Score | 0 to 100 | 175 | 32.08 | 24.18 | 74.79 % | 0.00 % | 0.00 % |
| Comparison | Studies | Overall effect | Heterogeneity | Publication bias | ||||
| OR | Z-score | p-value | I2 | P-value | Begg's test | Egger's test | ||
| tt vs TT | 36 | 0.86 [0.73–1.01] | 1.82 | 0.069 | 44.10% | 0.004 | 0.382 | 0.363 |
| Tt vs TT | 36 | 0.92 [0.81–1.04] | 1.35 | 0.176 | 60% | 0.000 | 0.955 | 0.891 |
| tt/Tt vs TT | 36 | 0.89 [0.80–1.00] | 1.96 | 0.05 | 56.20% | 0.000 | 0.808 | 0.914 |
| tt vs TT/Tt | 36 | 0.90 [0.76–1.06] | 1.29 | 0.197 | 54.20% | 0.000 | 0.318 | 0.496 |
| t vs T | 36 | 0.91 [0.84–0.99] | 2.18 | 0.03 | 56.90% | 0.000 | 0.465 | 0.472 |
| HILP Group | G-A n (%) | G-B n (%) | G-C n (%) |
| Lymphocele | 4 (6.6) | 7 (9.4) | 19 (17.5) |
| Bleeding necessitating surgery | - | 1(1.3) | 3(2.7) |
| Deep venous thrombosis | - | 2(2.6) | 3(2.7) |
| Pain | 1(1.6) | 1(1.3) | 1(0.9) |
| Peripheral nerve palsy | - | 1(1.3) | 1(0.9) |
| ARDS | 1(1.6) | - | 1(0.9) |
| Pleural effusion | - | 1(1.3) | - |
| Pulmonary microembolism | - | 1(1.3) | - |
| Death (MOF or ARDS) | - | 1(1.3) | 2(1,8) |
| Schematic Name | Arabidopsis homologue CloneID | Normalized Expression Levels | Description | KEGGID |
| Glycolysis - KEGG PATHWAY | ||||
| contig 763 | At3g04120 | 4.1 | Glyceraldehyde 3-phosphate dehydrogenase, cytosolic | Ac763 |
| contig 251 | At4g33070 | 3.4 | Pyruvate decarboxylase 1 | Ac251 |
| contig 30 | At2g36530 | 2.3 | Enolase | Ac30 |
| contig 1110 | At1g77120 | 2.1 | Alcohol dehydrogenase | Ac1110 |
| contig 3191 | At3g55440 | 2.1 | Triose-phosphate isomerase | Ac3191 |
| contig 441 | At1g09780 | 1.6 | Phosphoglycerate mutase | Ac441 |
| Cysteine and Methionine Metabolism | ||||
| contig 3189 | At4g14880 | 2.3 | Cysteine synthase | Ac3189 |
| contig 117 | At4g14710 | 1.7 | ATARD2 acireductone dioxygenase2 | Ac117 |
| contig 113 | At3g25570 | 1.6 | S-adenosylmethionine decarboxylase | Ac113 |
| contig 1009 | At5g11520 | 1.5 | Aspartate aminotransferase | Ac1009 |
| contig 3350 | At4g19710 | 1.5 | Bifunctional aspartokinase/homoserine dehydrogenase | Ac3350 |
| Ubiquitin-Mediated Proteolysis - KEGG Pathway | ||||
| contig 1299 | At2g02760 | 3.1 | Ubiquitin conjugating protein | UBE2A |
| contig 154 | At1g16890 | 1.6 | Ubiquitin carrier protein E2 36 | UBE2N |
| contig 861 | At5g22920 | 1.6 | Putative PGPD14 protein (pollen germination related protein) | PIRH2 |
| contig 1793 | At5g42190 | 1.5 | SKP1-like protein 1B | SKP1 |
| contig 1433 | At1g64230 | −2.0 | Ubiquitin carrier protein E2 28 | UBE2D_E |
| contig 153 | At3g57870 | −2.2 | Ubiquitin carrier protein | UBE2I |
| Commitment | Promoting teamwork | RoleB | T&D | Information sharing | |
| willing to put in a great deal of effort | 0.74 | 0.51 | 0.67 | 0.52 | 0.53 |
| talk up this coach to my friends as a great coach | 0.86 | 0.56 | 0.52 | 0.51 | 0.58 |
| would accept assignments in order to keep playing for my coach | 0.79 | 0.47 | 0.38 | 0.45 | 0.50 |
| my personal values and the coach’s values are similar | 0.90 | 0.59 | 0.57 | 0.48 | 0.66 |
| proud to tell others that I play for my coach | 0.91 | 0.60 | 0.54 | 0.53 | 0.62 |
| My coach really inspires the very best in me | 0.91 | 0.56 | 0.54 | 0.48 | 0.60 |
| glad that I chose to be athlete under the direction of my coach | 0.92 | 0.63 | 0.52 | 0.56 | 0.62 |
| really care about the future of my role under my coach | 0.88 | 0.59 | 0.58 | 0.51 | 0.59 |
| generally feel informed by my coach about changes in my role | 0.63 | 0.59 | 0.44 | 0.41 | 0.89 |
| My coach keeps me informed and up-to-date | 0.61 | 0.58 | 0.42 | 0.41 | 0.87 |
| I know what is expected of me | 0.52 | 0.50 | 0.45 | 0.45 | 0.82 |
| I get adequate feedback from my coach | 0.64 | 0.61 | 0.48 | 0.60 | 0.86 |
| My coach communicates to me frequently and honestly | 0.62 | 0.53 | 0.46 | 0.55 | 0.90 |
| get the information I need to do well | 0.49 | 0.55 | 0.49 | 0.41 | 0.82 |
| adequately complete assigned tasks that my coach gives me | 0.53 | 0.40 | 0.83 | 0.34 | 0.43 |
| fulfill responsibilities specified by my coach | 0.60 | 0.42 | 0.89 | 0.38 | 0.48 |
| perform tasks that are expected of me, by my coach | 0.57 | 0.45 | 0.87 | 0.39 | 0.44 |
| meet formal performance expectations | 0.56 | 0.47 | 0.87 | 0.36 | 0.49 |
| engage in activities assigned by my coach, | 0.53 | 0.35 | 0.79 | 0.39 | 0.43 |
| don’t neglect aspects of a student-athlete that I am obligated to | 0.40 | 0.39 | 0.78 | 0.32 | 0.38 |
| I don’t fail to perform essential duties of a student-athlete | 0.40 | 0.34 | 0.73 | 0.26 | 0.39 |
| My coach systematically trains and develops my student-athletic abilities | 0.48 | 0.47 | 0.38 | 0.89 | 0.45 |
| My coach trains me to gain many skills and abilities | 0.50 | 0.46 | 0.39 | 0.90 | 0.47 |
| I receive from my coach the training I need to do well as a student-athlete | 0.51 | 0.46 | 0.36 | 0.89 | 0.48 |
| I receive the training and support from my coach that I need to perform well as a student-athlete | 0.59 | 0.54 | 0.39 | 0.90 | 0.58 |
| My coach encourages decentralized decision making | 0.48 | 0.79 | 0.41 | 0.39 | 0.51 |
| My coach encourages my team members to decide about sports specific performances and operational problems | 0.58 | 0.82 | 0.37 | 0.42 | 0.52 |
| We (team members) regularly work as a team to perform various tasks | 0.48 | 0.83 | 0.31 | 0.42 | 0.48 |
| My coach promotes teamwork | 0.56 | 0.80 | 0.48 | 0.52 | 0.58 |
| miRNA Family | miRNA name | PMA | MA | SCP | BCP |
| miR2118 | osa-miR2118d | up | up | ||
| osa-miR2118p | up | ||||
| osa-miR2118o | up | down | |||
| osa-miR2118i | up | ||||
| osa-MIR2118i-p5 | up | ||||
| osa-MIR2118e-p5 | up | ||||
| miR2275 | osa-miR2275d | down | down | down | up |
| mes-miR2275 | down | down | down | ||
| osa-MIR2275c-p3 | down | down | up | ||
| zma-miR2275b-3p_1ss10CT | down | down | up | ||
| zma-miR2275b-3p_1ss22AG | down | down | up | ||
| zma-miR2275a-3p_L-1 | down | down |
| Age (years) | ≤45 | >45 |
| Total = 510 | ||
| n = 101 | n = 409 | |
| Sex | 53.1± | 53.7± |
| Men | 38.1 | 30.6 |
| Women | 61.9 | 69.4 |
| Waist circumference n (%) | 75 (74.3) | 293 (71.6) |
| Men ≥102 cm, women ≥88 cm | ||
| Reduced HDL-C n (%) | 98 (97.0) | 382 (93.4) |
| Men <40 mg/dL | ||
| Women <50 mg/dL | ||
| Triglycerides ≥150 mg/dL or medical treatment of elevated TG n (%) | 87 (86.1) | 307 (75.0) |
| Blood pressure ≥130/≥85 mmHg or previous diagnosis of hypertension n (%) | 29 (28.7) | 250 (61.1) |
| Elevated fasting glucose ≥100 mg/dL or previous diagnosis of T2DM | 68 (67.3) | 296 (72.4) |
| Holeboard task measures and their definition | |
| Measure | Definition |
| Working memory (WM) | A ratio defined by the number of visits that yield a food reward divided by the number of visits and re-visits to the rewarded set of holes |
| Reference memory (RM) | A ratio that is defined by the number of visits and re-visits to the rewarded set of holes divided by the number of visits and re-visits to all holes |
| Trial duration (TD) | The time between entering the holeboard and finding all four rewards (when not all rewards were found the maximum trial duration of 450 s was recorded) |
| Inter-visit interval (IVI) | The average time between two hole visits during a trial |
| Latency to the first visit (LFV) | The latency until the first visit during a trial |
| Latency to the first reward (LFR) | The latency until the first rewarded visit during a trial |
| Total visits (TV) | The total number of hole visits made during a trial |
| Unrewarded visits (URV) | The total number of unrewarded hole visits made during a trial |
| Rewarded visits (RV) | The total number of rewarded hole visits made during a trial |
| Number of visits until 1st reward (Vfirst) | The number of hole visits until the first reward was found |
| Number of visits until 2nd reward (Vsecond) | The number of hole visits between the first and second reward were found |
| Number of visits until 3rd reward (Vthird) | The number of hole visits between the second and third reward were found |
| Number of visits until 4th reward (Vfourth) | The number of hole visits between the third and fourth reward were found |
| Type of bacterial isolate | Total number of isolates | MDRa isolates, N (%) |
| S. aureus | 40 | 18 (45) |
| K. pneumoniae | 7 | 4 (57.1) |
| Other Klebsiella spp. | 5 | 2 (40) |
| E. coli | 15 | 7 (46.7) |
| Enterobacter spp. | 10 | 2 (20) |
| Citrobacter freundii | 4 | 1 (25) |
| Serratia marcescens | 5 | 1 (20) |
| P. shigelloides | 1 | 0 |
| Proteus spp. | 3 | 0 |
| Acinetobacter spp. | 5 | 1 (20) |
| Total | 95 | 36 (37.9) |
| All | White British | Pakistani | p value | |
| 8850 | 4119 | 4731 | ||
| Mother variables | ||||
| Mother age at delivery | 27.5 (5.61) | 27.0 (6.05) | 27.9 (5.16) | <0.001 |
| Mother education higher than A level | 2540 (28.7%) | 1162 (28.2%) | 1372 (29.0%) | = 0.420 |
| Housing tenure (Owner occupied) | 5487 (62.0%) | 2175 (52.8%) | 3312 (70.0%) | <0.001 |
| Household in receipt of means tested benefits | 3797 (42.9%) | 1557 (37.8%) | 2242 (47.4%) | <0.001 |
| Mother height (cm) | 161.8 (6.35) | 164.1 (6.23) | 159.7 (5.72) | <0.001 |
| Mother weight (kg) | 74.3 (15.6) | 77.9 (16.5) | 71.1 (14.0) | <0.001 |
| Mother BMI (at recruitment) | 28.3 (5.47) | 28.9 (5.72) | 27.8 (5.19) | <0.001 |
| Parity 0 | 3513 (39.7%) | 4283 (48.4%) | 2841 (32.1%) | <0.001 |
| Parity 1 | 2558 (28.9%) | 2788 (31.5%) | 2354 (26.6%) | |
| Parity 2+ | 2779 (31.4%) | 1779 (20.1%) | 3655 (41.3%) | |
| Mother never smoked | 6071 (68.6%) | 3690 (41.7%) | 8151 (92.1%) | <0.001 |
| Mother smoked before pregnancy | 1478 (16.7%) | 2673 (30.2%) | 434 (4.9%) | |
| Mother smoked during pregnancy | 1301 (14.7%) | 2496 (28.2%) | 266 (3.0%) | |
| Child Variables | ||||
| Birth-weight (g) | 3238 (541) | 3371 (547) | 3147 (518) | <0.001 |
| Low birthweight (< 2500 g) | 620 (7.0%) | 443 (5.0%) | 770 (8.7%) | <0.001 |
| Small For Gestational Age (GROW – 10th Decile) | 902 (15.8%) | 257 (6.24%) | 645 (15.3%) | <0.001 |
| Gestation (weeks) | 39.2 (1.72) | 39.3 (1.76) | 39.2 (1.68) | = 0.006 |
| Pre-term birth (< 37 weeks) | 439 (5.0%) | 220 (5.3%) | 219 (4.6%) | = 0.124 |
| Gender (female) | 4319 (48.8%) | 4283 (48.4%) | 4345 (49.1%) | = 0.542 |
| GP appointments | 20.0 (13.3) | 16.0 (11.6) | 23.5 (13.8) | <0.001 |
| Analgesic prescriptions | 4.65 (4.97) | 2.82 (3.10) | 6.24 (5.68) | <0.001 |
| Antibiotic prescriptions | 3.24 (3.90) | 2.64 (3.26) | 3.77 (4.32) | <0.001 |
| Bronchodilator prescriptions | 1.44 (3.18) | 1.49 (3.04) | 1.40 (3.29) | = 0.184 |
| Emergency hospital episodes | 0.42 (1.00) | 0.38 (0.83) | 0.45 (1.12) | = 0.001 |
| Elective hospital episodes | 0.08 (0.61) | 0.07 (0.36) | 0.10 (0.77) | = 0.022 |
| GammaGap < 3.65 (g/dL) | GammaGap ≥ 3.65 (g/dL) | ||||||
| Models a | Tertiles of MAMC | Hazard Ratio (95% CI) | P -value | Models a | Tertiles of MAMC | Hazard Ratio (95% CI) | P -value |
| Aged 20–39 years | Aged 20–39 years | ||||||
| Model 1 | T2 v.s. T1T3 v.s. T1 | 0.86 (0.39–1.92)0.60 (0.25–1.41) | 0.7210.241 | Model 1 | T2 v.s. T1T3 v.s. T1 | 1.45 (0.36–5.81)1.31 (0.29–5.86) | 0.5980.726 |
| Model 2 | T2 v.s. T1T3 v.s. T1 | 1.16 (0.49–2.74)1.11 (0.31–3.95) | 0.7400.869 | Model 2 | T2 v.s. T1T3 v.s. T1 | 1.27 (0.30–5.40)1.06 (0.14–7.88) | 0.7460.954 |
| Model 3 | T2 v.s. T1T3 v.s. T1 | 1.28 (0.53–3.10)1.39 (0.38–5.12) | 0.5870.622 | Model 3 | T2 v.s. T1T3 v.s. T1 | 1.27 (0.29–5.48)1.09 (0.15–8.09) | 0.7520.935 |
| Model 4 | T2 v.s. T1T3 v.s. T1 | 1.28 (0.53–3.10)1.39 (0.38–5.14) | 0.5860.621 | Model 4 | T2 v.s. T1T3 v.s. T1 | 1.37 (0.32–5.94)1.14 (0.16–8.16) | 0.6730.897 |
| Aged 40–59 years | Aged 40–59 years | ||||||
| Model 1 | T2 v.s. T1T3 v.s. T1 | 1.52 (1.02–2.28)1.04 (0.69–1.55) | 0.0400.863 | Model 1 | T2 v.s. T1T3 v.s. T1 | 1.08 (0.47–2.45)0.90 (0.38–2.12) | 0.8630.812 |
| Model 2 | T2 v.s. T1T3 v.s. T1 | 1.14 (0.72–1.80)0.72 (0.41–1.25) | 0.5690.240 | Model 2 | T2 v.s. T1T3 v.s. T1 | 0.86 (0.35–2.11)0.53 (0.18–1.58) | 0.7420.255 |
| Model 3 | T2 v.s. T1T3 v.s. T1 | 1.16 (0.74–1.84)0.75 (0.43–1.32) | 0.5190.320 | Model 3 | T2 v.s. T1T3 v.s. T1 | 0.98 (0.39–2.47)0.67 (0.22–2.00) | 0.9600.468 |
| Model 4 | T2 v.s. T1T3 v.s. T1 | 1.17 (0.74–1.85)0.76 (0.44–1.34) | 0.4950.346 | Model 4 | T2 v.s. T1T3 v.s. T1 | 1.08 (0.42–2.79)0.67 (0.22–2.05) | 0.8730.482 |
| Aged 60–90 years | Aged 60–90 years | ||||||
| Model 1 | T2 v.s. T1T3 v.s. T1 | 1.54 (1.20–1.96)1.34 (1.03–1.73) | 0.0010.028 | Model 1 | T2 v.s. T1T3 v.s. T1 | 1.09 (0.73–1.64)1.17 (0.76–1.78) | 0.6780.472 |
| Model 2 | T2 v.s. T1T3 v.s. T1 | 1.11 (0.85–1.46)0.90 (0.65–1.25) | 0.4480.521 | Model 2 | T2 v.s. T1T3 v.s. T1 | 0.60 (0.38–0.95)0.49 (0.29–0.83) | 0.0280.008 |
| Model 3 | T2 v.s. T1T3 v.s. T1 | 1.11 (0.84–1.46)0.90 (0.64–1.25) | 0.4570.517 | Model 3 | T2 v.s. T1T3 v.s. T1 | 0.66 (0.42–1.04)0.53 (0.31–0.88) | 0.0730.015 |
| Model 4 | T2 v.s. T1T3 v.s. T1 | 1.11 (0.84–1.47)0.87 (0.62–1.21) | 0.4460.404 | Model 4 | T2 v.s. T1T3 v.s. T1 | 0.66 (0.42–1.04)0.57 (0.33–0.96) | 0.0760.036 |
| All | All | |||
| Boys | Girls | Black | White | |
| Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD | |
| Sleep/Sedentary PA < 1.5 METs | 1178.0 ± 88.9a | 1070.0 ± 108.4a | 1091.0 ± 103.1 | 1174.0 ± 122.3b |
| Light 1.5 – 3.0 METs | 234.1 ± 81.7a | 306.9 ± 85.5a | 296.0 ± 80.47 | 225.0 ± 99.5b |
| Moderate PA >3 – 6 METs | 33.2 ± 32.5a | 58.6 ± 39.0a | 46.2 ± 37.6 | 55.6 ± 40.8 |
| Vigorous PA >6 METs | 1.8 ± 2.7 | 2.5 ± 4.9 | 1.7 ± 3.2 | 3.9 ± 5.8b |
| MVPA >3 METSs | 35.0 ± 32.9a | 61.1 ± 52.2a | 47.9 ± 39.6 | 59.5 ± 41.8 |
| Boys | Girls | |||
| Black | White | Black | White | |
| Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD | |
| Sleep/Sedentary PA < 1.5 METs | 1154.0 ± 85.1 | 1224.0 ± 78.6 | 1058.0 ± 96.48 | 1118.0 ± 139.5 |
| Light 1.5 – 3.0 METs | 259.0 ± 78.54 | 187.0 ± 65.5 | 316.3 ± 74.6 | 269.0 ± 114.1 |
| Moderate PA >3 – 6 METs | 25.9 ± 24.6 | 46.7 ± 40.7 | 56.9 ± 38.9 | 65.8 ± 39.1 |
| Vigorous PA >6 METs | 1.2 ± 1.7 | 2.8 ± 3.8 | 1.8 ± 3.9 | 5.1 ± 7.5 |
| MVPA >3 METSs | 27.2 ± 25.3 | 49.6 ± 40.5 | 58.8 ± 41.4 | 70.9 ± 41.1 |
| Household experiences in last 12 months | Adjusted Odds Ratio | 95% Confidence Interval | p-value |
| Household members falling sick | 1.3 | (0.9, 2.0) | 0.182 |
| Lifestyle related illness (major illness e.g., heart, kidney, liver) | 1.6 | (1.0,2.4) | 0.043 |
| Relationship problems between partners (arguing, not talking) | 2.2 | (1.1, 4.4) | 0.022 |
| Strained relationships within household | 2.1 | (1.1, 4.1) | 0.032 |
| Separation between spouses or partners | 1.9 | (0.5, 7.2) | 0.367 |
| Infidelity or cheating between spouses or partners | 4.1 | (1.2, 13.9) | 0.023 |
| Behavioral problems in children at home | 3.1 | (1.0, 9.6) | 0.048 |
| Antisocial problems of children at home/school | 2.3 | (0.9, 6.1) | 0.101 |
| Violent behavior | 1.7 | (0.6, 4.9) | 0.312 |
| Verbal abuse | 1.8 | (0.9, 3.7) | 0.101 |
| Police Intervention in household dispute | 1.6 | (0.5, 5.3) | 0.406 |
| Receiving a traffic ticket | 2.7 | (1.2, 5.9) | 0.015 |
| Group | Baseline | 3 hours | 5 hours | ANOVA (P) | |
| Sublingual mucosa | |||||
| MFI s | Sepsis | 2.73 ± 0.24 | 1.56 ± 0.30a | 1.54 ± 0.34a | 0.001 |
| Sham | 2.89 ± 0.19 | 3.00 ± 0.00 | 3.00 ± 0.00 | 0.368 | |
| MFI l | Sepsis | 3.00 ± 0.00 | 2.94 ± 0.19 | 3.00 ± 0.00 | 0.368 |
| Sham | 3.00 ± 0.00 | 3.00 ± 0.00 | 3.00 ± 0.00 | 0.999 | |
| PPV s, % | Sepsis | 91.4 ± 3.3 | 71.0 ± 8.1a | 70.2 ± 8.4a | 0.011 |
| Sham | 95.0 ± 0.3 | 93.8 ± 1.9 | 94.3 ± 2.0 | 0.264 | |
| PVD s, 1/mm | Sepsis | 14.5 ± 3.2 | 11.6 ± 2.7 | 12.4 ± 1.9 | 0.197 |
| Sham | 15.3 ± 1.8 | 15.4 ± 2.3 | 16.5 ± 2.0 | 0.100 | |
| TVD s, mm/mm2 | Sepsis | 27.9 ± 2.4 | 27.8 ± 2.8 | 30.0 ± 3.6 | 0.197 |
| Sham | 29.9 ± 3.9 | 30.7 ± 2.8 | 32.6 ± 5.0 | 0.529 | |
| TVD l, mm/mm2 | Sepsis | 6.0 ± 1.3 | 7.1 ± 1.1 | 7.3 ± 2.0 | 0.197 |
| Sham | 8.4 ± 1.4 | 8.2 ± 1.3 | 8.1 ± 3.3 | 0.761 | |
| Het MFI | Sepsis | 0.17 ± 0.14 | 0.44 ± 0.40 | 0.37 ± 0.24 | 0.250 |
| Sham | 0.06 ± 0.11 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.368 | |
| Ocular conjunctiva | |||||
| MFI s | Sepsis | 2.74 ± 0.21 | 2.14 ± 0.33a | 2.00 ± 0.52a | 0.004 |
| Sham | 2.94 ± 0.10 | 2.83 ± 0.17 | 2.83 ± 0.29 | 0.867 | |
| MFI l | Sepsis | 3.00 ± 0.00 | 2.98 ± 0.04 | 3.00 ± 0.00 | 0.135 |
| Sham | 2.94 ± 0.10 | 2.94 ± 0.10 | 3.00 ± 0.00 | 0.368 | |
| PPV s, % | Sepsis | 93.4 ± 3.1 | 84.4 ± 4.2a | 78.4 ± 8.7a | 0.009 |
| Sham | 95.5 ± 0.3 | 94.4 ± 1.6 | 94.5 ± 1.2 | 0.441 | |
| PVD s, 1/mm | Sepsis | 15.7 ± 3.0 | 12.7 ± 1.8a | 11.7 ± 3.6 | 0.042 |
| Sham | 16.9 ± 3.0 | 16.3 ± 3.6 | 15.2 ± 3.8 | 0.160 | |
| TVD s, mm/mm2 | Sepsis | 29.5 ± 4.8 | 26.6 ± 3.9 | 25.9 ± 8.4 | 0.135 |
| Sham | 29.4 ± 6.3 | 29.1 ± 6.6 | 28.1 ± 7.8 | 0.761 | |
| TVD l, mm/mm2 | Sepsis | 7.9 ± 2.0 | 7.4 ± 2.3 | 8.0 ± 1.5 | 0.846 |
| Sham | 8.6 ± 3.4 | 6.8 ± 1.8 | 8.5 ± 4.8 | 0.529 | |
| Het MFI | Sepsis | 0.13 ± 0.12 | 0.38 ± 0.32 | 0.36 ± 0.31 | 0.113 |
| Sham | 0.06 ± 0.10 | 0.09 ± 0.09 | 0.10 ± 0.17 | 0.867 | |
| Jejunal mucosa | |||||
| MFI s | Sepsis | 2.89 ± 0.13 | 1.90 ± 0.32a | 2.10 ± 0.43a | < 0.0001 |
| Sham | 3.00 ± 0.00 | 2.67 ± 0.14 | 2.64 ± 0.32 | 0.124 | |
| PPV v, % | Sepsis | 95.2 ± 2.8 | 82.6 ± 6.4a | 84.3 ± 8.8a | 0.022 |
| Sham | 99.2 ± 1.4 | 92.0 ± 7.1 | 92.6 ± 1.7 | 0.368 | |
| MFI Het | Sepsis | 0.11 ± 0.11 | 0.37 ± 0.19a | 0.50 ± 0.27a | < 0.0001 |
| Sham | 0.00 ± 0.00 | 0.09 ± 0.01 | 0.10 ± 0.10 | 0.178 | |
| Rectal mucosa | |||||
| MFI s | Sepsis | 2.74 ± 0.15 | 1.95 ± 0.28a | 1.83 ± 0.19a | < 0.0001 |
| Sham | 3.00 ± 0.00 | 2.92 ± 0.12 | 2.67 ± 0.12 | 0.156 | |
| PPV c | Sepsis | 93.0 ± 1.5 | 78.6 ± 6.9a | 80.6 ± 6.3a | 0.018 |
| Sham | 97.1 ± 1.0 | 95.4 ± 1.6 | 93.1 ± 0.4 | 0.156 | |
| Het MFI | Sepsis | 0.05 ± 0.08 | 0.36 ± 0.20a | 0.21 ± 0.14a | 0.015 |
| Sham | 0.00 ± 0.00 | 0.09 ± 0.12 | 0.28 ± 0.01 | 0.156 |
| Components of SPs | Level of compliance | ||
| Always | Sometimes | Seldom | |
| Wash hands before touching a patient | 74 (18.2%) | 82 (20.1%) | 251 (61.7%) |
| Wash hands before clean or aseptic procedures | 161 (39.6%) | 144 (35.4%) | 102 (25.1%) |
| Wash hands after body fluid exposure | 375 (92.2%) | 28 (6.8%) | 4 (1%) |
| Wash hands after touching a patient | 113 (27.8%) | 124 (30.5%) | 170 (41.8%) |
| Wash hands immediately after removal of gloves | 328 (80.6%) | 49 (12%) | 30 (7.4%) |
| Wash hands between patient contact | 79 (19.4%) | 104 (25.6%) | 224 (55%) |
| Wash hands after touching patient surroundings | 91 (22.4%) | 129 (31.7%) | 187 (45.9%) |
| I provide nursing care considering all patients as potentially infectious | 110 (27%) | 132 (32.4%) | 165 (40.5%) |
| I protect myself against body fluids of all patients regardless of their diagnosis | 132 (32.4%) | 151 (37.1%) | 122 (30%) |
| I wear clean gloves whenever there is a possibility of exposure to any body fluids | 361 (88.7%) | 32 (7.9%) | 14 (3.4%) |
| I change gloves between contacts with different patients | 362 (88.9%) | 39 (9.5%) | 6 (1.5%) |
| I avoid wearing my gown out of hospital compounds | 153 (37.6%) | 232 (57%) | 22 (5.4%) |
| I wear a waterproof apron whenever there is a possibility of body fluid splashing in my body | 153 (37.6) | 211 (51.8%) | 43 (10.6%) |
| I wear eye goggles whenever there is a possibility of body fluid splashing in my face | 88 (21.6%) | 80 (19.7%) | 238 (58.5%) |
| I sterilize all reusable equipment before being used on another patient | 300 (73.7%) | 88 (21.6%) | 19 (4.7%) |
| I clean and disinfect equipment and environmental surfaces | 156 (38.3%) | 148 (36.4%) | 103 (25.3%) |
| I segregate noninfectious wastes in black colour coded dust bin | 123 (30.2%) | 192 (47.2%) | 92 (22.6%) |
| I segregate infectious medical wastes in yellow coloured coded dust bin | 140 (34.4%) | 177 (43.5%) | 90 (22.1%) |
| I never bend needles with my hands | 311 (76.4%)∗ | 68 (16.7%) | 28 (6.9%) |
| I avoid removing used needles from disposable syringes | 221 (54.3%) | 132 (32.4%) | 54 (13.3%) |
| I place used sharps in puncture-resistant container at point of use | 355 (87.2%) | 41 (10%) | 11 (2.8%) |
| I never recap needles | 239 (58.7%)∗ | 100 (24.6%) | 68 (16.7%) |
| Description | Yes | No |
| n = 10 | n = 10 | |
| Separate containers for hazardous and non hazardous waste | 5 | 5 |
| Formal or informal HCW separation guideline | 5 | 5 |
| Labeling of the container | 3 | 7 |
| Personal protective equipment usage by HCW handlers | 7 | 3 |
| HCW transportation container with lid | 0 | 10 |
| Presence of interim HCW storage container | 9 | 1 |
| Treatment of infectious waste before disposing off | 0 | 9 |
| Ash remain disposal within close damping | 8 | 2 |
| Fencing the incinerator | 7 | 3 |
| Placental pit constructed with concrete | 7 | 3 |
| Focal person for HCW in Health center | 10 | 0 |
| Presence of SOP FOR HCW | 6 | 4 |
| Presence of HCW management committee | 3 | 7 |
| Registration book for any HCW injury or contamination | 6 | 4 |
| Managers concern on HCW | 6 | 4 |
| Needle stick injury in the past 12 months | 8 | 2 |
| Any risk to HCW handlers | 7 | 3 |
| Levela | Variable | n (%) | Crude PRb (95%CI) | pc | Adjusted PRd (95%CI) | pc |
| Demographic and socioeconomic variables | ||||||
| 1 | Sex | 0.004 | 0.003 | |||
| Female | 703 (60.3) | 1 | 1 | |||
| Male | 1,101 (65.1) | 1.08 (1.02–1.14) | 1.08 (1.03–1.14) | |||
| 1 | Age (years) | < 0.001 | 0.021 | |||
| 20–39 | 760 (67.1) | 1.15 (1.06–1.24) | 1.10 (1.02–1.20) | |||
| 40–59 | 675 (61.7) | 1.05 (0.96–1.15) | 1.03 (0.94–1.12) | |||
| 60 or more | 369 (58.6) | 1 | 1 | |||
| 1 | Skin color/Race | 0.565 | - | |||
| White | 1,436 (62.7) | 1 | - | |||
| Black | 222 (64.4) | 1.02 (0.93–1.13) | - | |||
| Othere | 146 (65.8) | 1.05 (0.95–1.15) | - | |||
| 1 | Education (years) | 0.005 | 0.008 | |||
| 0–4 | 284 (57.4) | 1 | 1 | |||
| 5–8 | 529 (66.5) | 1.15 (1.06–1.26) | 1.16 (1.05–1.27) | |||
| 9 or more | 988 (63.3) | 1.10 (1.01–1.20) | 1.13 (1.03–1.25) | |||
| 1 | Asset index (quintiles) | 0.058 | 0.033 | |||
| 1st (20% poorest) | 371 (66.9) | 1.15 (1.03–1.27) | 1.18 (1.06–1.33) | |||
| 2nd | 360 (66.9) | 1.15 (1.03–1.28) | 1.15 (1.02–1.30) | |||
| 3rd | 367 (63.0) | 1.08 ( 0.96–1.21) | 1.07 ( 0.95–1.21) | |||
| 4th | 365 (62.1) | 1.06 (0.95–1.20) | 1.06 (0.94–1.19) | |||
| 5th (20% wealthiest) | 332 (58.3) | 1 | 1 | |||
| Health status | ||||||
| 2 | Use of drugs for chronic or eventual diseases | |||||
| Chronic | 1,005 (63.8) | 1 | 0.590 | - | ||
| Eventual | 570 (36.2) | 0.98 (0.91–1.05) | - | |||
| 2 | Self-reported health status | |||||
| Excellent/Very good | 555 (62.4) | 1 | 0.071 | 1 | 0.026 | |
| Good/Fair | 1,157 (62.9) | 1.00 (0.95–1.07) | 1.01 (0.95–1.08) | |||
| Poor | 92 (72.4) | 1.16 (1.02–1.32) | 1.20 (1.05–1.38) | |||
| Incorrect visual identification of similar medicines as generic drugs | ||||||
| 3 | No | 1,325 (64.4) | 1.07 (1.00–1.16) | 0.052 | 0.98 (0.92–1.05) | 0.608 |
| Yes | 479 (60.0) | 1 | 1 | |||
| Score of knowledge about generic drugsf | ||||||
| 3 | 0 | 14 (18.4) | 1 | < 0.001g | 1 | < 0.001g |
| 1 | 120 (34.3) | 1.86 (1.14–3.03) | 2.01 (1.20–3.37) | |||
| 2 | 514 (54.6) | 2.96 (1.90–4.62) | 3.27 (2.04–5.27) | |||
| 3 | 1,156 (77.7) | 4.22 (2.70–6.58) | 4.66 (2.89–7.52) | |||
| Total | 1,804 (63.2) |
| EPCAM | KRT8 | KRT18 | KRT5 | KRT7 | HER2 | MUC1 | EGFR | |
| EpCAM | 1 | |||||||
| KRT8 | 0.370** | |||||||
| KRT18 | 0.654** | 0.760** | ||||||
| KRT5 | - | 0.335** | 0.204* | |||||
| KRT7 | - | 0.635** | 0.279** | 0.353** | ||||
| HER2 | 0.441** | - | 0.351** | - | - | |||
| MUC1 | 0.372** | –0.240* | - | - | –0.510** | 0.468** | ||
| EGFR | - | –0.284** | - | - | –0.286** | 0.314** | 0.355** | 1 |
| Mean baseline level [mg/dL (mmol/L)] | Difference between treatment groups | |||
| End-of-study | ||||
| PROACTIVE [40] | ||||
| HbA1c | 7.9% | −6% | ||
| LDL | 112 (2.9) | 2% | ||
| HDL | 42 (1.1) | 9% | ||
| Triglycerides | 159 (1.8) | −13% | ||
| DREAM [50] | HbA1c and lipids not reported | |||
| ADOPT [49] | Median baseline level [mg/dL (mmol/L)] | Rosiglitazone versus Metformin | Rosiglitazone versus Glyburide | |
| Glycated Hgb | 7.4% | −2% | −6% | |
| Total cholesterol | 204 (5.28) | NR | NR | |
| LDL | 120 (3.11) | 8% | 5% | |
| HDL | 47 (1.22) | 3% | 6% | |
| Triglycerides | 161 (1.82) | −2% | −5% | |
| RECORD [51, 77] | Mean baseline level [mg/dL (mmol/L)] | |||
| Glycated Hgb | 7.9% | NR | ||
| LDL | 127 (3.29) | NR | ||
| HDL | 46 (1.20) | NR | ||
| Triglycerides | 202 (2.28) | NR |
| Themes | Statement | Agree/ disagree with the statement | Univariate estimate | Multivariate model | ||
| OR | 95 % Cl | OR | 95 % Cl | |||
| Physical and mental health | I feel physically worn out. | Disagree | Ref. | Ref. | ||
| Partly agree | 2.3 | 1.7–2.9 | 1.7 | 1.3–2.3 | ||
| Agree | 3.6 | 2.7–4.7 | 2.3 | 1.7–3.2 | ||
| Physical work environment | I can usually manage physical working demands of my daily work. | Agree | Ref. | Ref. | ||
| Partly agree | 2.1 | 1.9–4.6 | 2.3 | 1.5–3.7 | ||
| Disagree | 3.1 | 2.2–4.4 | 2.4 | 1.7–3.5 | ||
| Working pace and working time | The pace of work in my daily work is too rapid. | Disagree | Ref. | Ref. | ||
| Partly agree | 0.8 | 0.7–1.1 | 0.6 | 0.5–0.8 | ||
| Agree | 1.3 | 1.0–1.6 | 0.8 | 0.7–1.1 | ||
| I feel that I get enough rest/relaxation between my working days. | Agree | Ref. | Ref. | |||
| Partly agree | 2.4 | 1.9–3.0 | 1.7 | 1.3–2.2 | ||
| Disagree | 2.1 | 1.7–2.7 | 1.8 | 1.4–2.4 |
| Aspect of treatment | No preference | Expressed a preference | |
| Given adequate choice | Not given adequate choice | ||
| n % (95 % CI) | n % (95 % CI) | n % (95 % CI) | |
| Choice of venue | 6855 47.7 (46.9-48.5) | 5282 36.7 (35.9-37.5) | 2242 15.6 (15.0-16.2) |
| Time of day of appointments | 3950 27.4 (26.7-28.1) | 8639 59.9 (59.1-60.7) | 1837 12.7 (12.2-13.2) |
| Gender of therapist | 10027 70.2 (69.5-71.0) | 1769 11.9 (11.4-12.4) | 2483 17.9 (16.8-18.0) |
| Language/ interpreter | 11743 92.0 (91.5-92.5) | 643 4.9 (4.5-5.3) | 382 3.1 (2.8-3.4) |
| Type of treatment | 6844 48.0 (47.2-48.8) | 4981 34.9 (34.1-35.7) | 2441 17.1 (16.5-17.7) |
| 100% of training data | 50% of training data | |||||||||
| Dimension | D5 | D6 | D7 | D8 | D9 | D4 | D5 | D6 | D7 | D8 |
| Classification accuracy | 91.28% | 91.52% | 91.79% | 90.01% | 90.54% | 89.50% | 88.43% | 88.60% | 88.68% | 87.60% |
| Training iterations | 553 | 97 | 167 | 33 | 41 | 141 | 68 | 44 | 27 | 11 |
| Learning parameter | 0.45 | 0.42 | 0.54 | 0.75 | 0.63 | 0.51 | 0.54 | 0.72 | 0.72 | 0.84 |
| Amplicon | Age limit | Values considered | p_values |
| IGF2_shore | 60 | Correlation | 0.00047*** |
| IGF2AS | 60 | Correlation | 0.022* |
| H19 | 60 | Correlation | 0.27 |
| IGF2_island | 60 | Correlation | 0.77 |
| IGF2_shore | 60 | Euclidean distance | 0.0075** |
| IGF2AS | 60 | Euclidean distance | 0.023* |
| H19 | 60 | Euclidean distance | 0.48 |
| IGF2_island | 60 | Euclidean distance | 0.57 |
| Crop | Cultural practice | Seeding rate (million seeds ha−1) | N fertilization at planting | N fertilization rate(kg N ha−1) | Planting date | Stubble height (cm) |
| Spring wheat | Traditional | 2.23 | Broadcast | 101 | Early April | 20 |
| Improved | 2.98 | Banded | 101 | Early May | 30 | |
| Pea | Traditional | 0.60 | Broadcast | 6 | Early April | 5 |
| Improved | 0.92 | Banded | 6 | Early April | 5 | |
| Barley hay | Traditional | 2.23 | Broadcast | 67 | Late April | 5 |
| Improved | 2.98 | Banded | 67 | Late April | 5 | |
| Corn | Traditional | 0.04 | Broadcast | 78 | Early May | 5 |
| Improved | 0.05 | Broadcast | 78 | Early May | 5 |
| Gene | Exon vs | Tag-seq vs | Exon vs |
| RT-qPCR | RT-qPCR | tag-seq | |
| CD74 | 0.964 | 0.964 | 0.927 |
| HLA-DRA | 1.000 | 0.952 | 0.952 |
| BCL6 | 0.976 | 0.873 | 0.846 |
| Hypothesis | Total cost | Cost differencea | RMSD | Correlation | Features |
| Hypo1 | 106.849 | 98.098 | 0.53586 | 0.963930 | HBA, HBA, HY, RA |
| Hypo2 | 110.479 | 94.468 | 0.58484 | 0.957944 | HBA, HBA, HY |
| Hypo3 | 111.652 | 93.295 | 0.59607 | 0.952531 | HBA, HBA, HBA |
| Hypo4 | 112.733 | 92.214 | 0.63861 | 0.949526 | HBD, HY, HY |
| Hypo5 | 115.391 | 89.556 | 0.66088 | 0.946132 | HBA, HBA, HBA |
| Hypo6 | 116.238 | 88.709 | 0.69439 | 0.938954 | HBA, HBA, HBA |
| Hypo7 | 117.641 | 87.306 | 0.72386 | 0.931788 | HBA, HBD, HY |
| Hypo8 | 118.967 | 85.980 | 0.78047 | 0.929203 | HBA, HBD, HY |
| Hypo9 | 119.145 | 85.802 | 0.85013 | 0.924316 | HBD, HY, HY |
| Hypo10 | 120.562 | 84.385 | 0.89086 | 0.917282 | HBA, HBA, HY |
| Study sample (n=308) | Weekend all children (n=284) | Weekday non-daycare children (n=121) | Weekday daycare children (n=202) | |
| Age [months, mean (SD)] | 41.7 (10.3) | 41.6 (10.0) | 41.3 (11.3) | 41.9 (9.6) |
| Sex (% girls) | 48.4 | 48.2 | 48.8 | 45.5 |
| Weight [kg, mean (SD)] | 16.1 (3.0) | 16.1 (3.0) | 15.9 (2.7) | 16.3 (3.2) |
| Height [cm, mean (SD)] | 98.8 (7.8) | 98.8 (7.7) | 98.8 (8.0) | 99.0 (7.8) |
| BMI [kg/m2, mean (SD)] | 16.3 (1.5) | 16.4 (1.5) | 16.2 (1.4) | 16.5 (1.5) |
| BMI percentile [mean (SD)] | 60.7 (28.2) | 60.8 (28.4) | 58.8 (29.4) | 62.8 (26.8) |
| Hispanic (%) | 5.8 | 6.0 | 3.3 | 7.4 |
| Race (%) | ||||
| African-American | 37.7 | 37.3 | 38.0 | 38.6 |
| Caucasian | 50.7 | 51.4 | 50.4 | 50.5 |
| Others/missing | 11.7 | 11.3 | 11.6 | 10.9 |
| Protein profiling using LPITM FlowCells and LC-MS/MS | Hybridoma-based phenotypic antibody screening | Phage display-based phenotypic antibody screening | |||
| Advantages | Disadvantages | Advantages | Disadvantages | Advantages | Disadvantages |
| Direct comparison with normal matched tissue can be performed | Extremely reliant on quality of membrane preparation and extraction of membrane proteins | Screening antibodies can assign a potential mechanism of action | High cell requirement | Reduced cell requirement compared to hybridoma approach | Isolation of relatively low affinity antibodies and poor target identification success rate- requirement for complementary techniques for success of target identification |
| Sample fractionation possible and total survey of the membranome | Reliant on database annotations | Isolation of high affinity antibodies | Dominance of single targets and antibodies | Ability to perform initial screen against multiple cell types with relative ease | |
| No function or mechanism of action associated with antigens identified | Functional in phenotypic screens | No ability to deselect against abundant antigens or comparator cell types | Screening can assign a potential mechanism of action | ||
| High target identification success rate | Ability to avoid dominance – can deselect against abundant antigens and comparator cell types | ||||
| Isolation of antibodies that can be used for target validation or as a therapeutic candidates | Isolation of antibodies that can be used for target validation | ||||
| Potential to identify target and therapeutic candidate |
| High confidence only | High or low confidence | HECTARa | |
| Sensitivity | 0.80 | 0.93 | 0.71 |
| Specificity | 0.99 | 0.82 | 0.94 |
| MCC | 0.82 | 0.74 | 0.67 |
| PHC1 | PHC2 | PHC3 | PHC4 | PHC5 | PHC6 | PHC7 | PHC8 | PHC9 | PHC10 | PHC11 | PHC12 | PHC13 | |
| Efficiency indices | |||||||||||||
| Expected costs/patient, € | 733.65 | 752.71 | 728.61 | 686.39 | 707.07 | 691.07 | 721.16 | 757.56 | 695.46 | 637.15 | 711.20 | 638.55 | 664.07 |
| Observed costs/patient, € | 775.79 | 600.87 | 752.10 | 772.50 | 807.85 | 693.66 | 694.88 | 757.02 | 693.06 | 678.34 | 666.05 | 648.02 | 527.16 |
| Cost efficiency index | 1.06 | 0.80 | 1.03 | 1.13 | 1.14 | 1.00 | 0.96 | 1.00 | 1.00 | 1.06 | 0.94 | 1.01 | 0.79 |
| Number expected episodes/patient | 4.73 | 4.80 | 4.93 | 4.57 | 4.66 | 4.59 | 4.46 | 4.61 | 4.56 | 3.98 | 4.46 | 4.23 | 4.49 |
| Number observed episodes/patient | 4.61 | 4.88 | 5.09 | 4.59 | 4.93 | 4.72 | 4.42 | 4.94 | 4.31 | 3.76 | 4.30 | 4.14 | 4.60 |
| Episodes efficiency index | 0.98 | 1.02 | 1.03 | 1.00 | 1.06 | 1.03 | 0.99 | 1.07 | 0.94 | 0.95 | 0.96 | 0.98 | 1.02 |
| Number expected visits/patient | 8.17 | 8.33 | 8.49 | 7.85 | 8.02 | 7.90 | 7.80 | 8.09 | 7.87 | 6.93 | 7.76 | 7.29 | 7.71 |
| Number observed visits/patient | 8.93 | 8.56 | 9.04 | 9.05 | 9.87 | 9.31 | 7.17 | 7.90 | 7.94 | 5.40 | 6.39 | 6.85 | 8.72 |
| Visits efficiency index | 1.09 | 1.03 | 1.07 | 1.15 | 1.23 | 1.18 | 0.92 | 0.98 | 1.01 | 0.89 | 0.99 | 0.93 | 1.13 |
| Risk index | 1.05 | 1.07 | 1.09 | 1.00 | 1.03 | 1.01 | 1.00 | 1.03 | 1.01 | 0.89 | 0.99 | 0.93 | 0.99 |
| Effectiveness index | |||||||||||||
| Synthetic index | 50.67 | 59.19 | 54.93 | 55.53 | 56.62 | 56.72 | 46.18 | 55.56 | 50.09 | 53.25 | 59.42 | 56.57 | 64.09 |
| Probe sets | 1 | 2 | 3 | 4 |
| 1 | - | 0.955 | 0962 | 0.942 |
| 2 | - | - | 0.946 | 0.927 |
| 3 | - | - | - | 0.983 |
| 4 | - | - | - | - |
| Criterion | Inclusion | Exclusion |
| Time period | January 1990 and February 2012 | Any study outside these dates |
| Language | English | Non-English |
| Type of article | Original research article published in a peer reviewed journal | Any article that was not original research and/or unpublished |
| Study focus | Community participation | No reference to community participation, i.e. individual consultation between health professional and client |
| Health service | Rural | No reference to rural health care services |
| Geographical place of study | International, developed countries | Developing countries |
| Population and sample | Mixed population sociodemographic | Reference to only a single sociodemographic factor i.e. gender, cultural group |
| Name | Microalgae | Specificities |
| f/2 medium [148,149] | Coastal microalgae, diatoms | Enriched medium |
| K medium [146,150] | Oceanic microalgae | Trace metals |
| Pro99 [151] | Prochlorococcus spp. and some picoeukaryotes | High ammonia concentrations, No vitamin requirement |
| MNK medium [152] | Oceanic coccolithophores | Enriched medium |
| Variables | Standardized coefficient (β) | P | Adjusted R2 |
| Men | |||
| Lipoprotein(a), mg/dL | 0.190 | < 0.001 | 0.039 |
| LDLR g.3131C > T, yes/no | -0.179 | < 0.001 | 0.070 |
| Age, years | 0.177 | < 0.001 | 0.100 |
| All study subjects | |||
| Age, years | 0.236 | < 0.001 | 0.054 |
| Lipoprotein(a), mg/dL | 0.172 | < 0.001 | 0.083 |
| LDLR g.3131C > T, yes/no | -0.146 | < 0.001 | 0.103 |
| Delta-RF | Delta-RF | ||
| Data | RAxML | FastTree-2 | |
| Indelible M2 | 0.021 | 0.014 | |
| RNAsim | 0.677 | 0.660 | |
| Rose L1 | 0.036 | 0.054 | |
| Rose M1 | 0.136 | 0.030 | |
| Rose S1 | 0.010 | 0.007 |
| Cluster 1 (n = 94, 17 families) | Cluster 2 (n = 50, 12 families) | Cluster 3 (n = 115, 25 families) | ||||
| Mean | SD | Mean | SD | Mean | SD | |
| Sex (F/M) | 48/46 | 24/26 | 50/65 | |||
| Age | 48.8 | 9.4 | 52.3 | 12.6 | 48.5 | 11.3 |
| Education years | 11.3a,b | 3.0 | 9.3 | 2.4 | 9.9 | 2.3 |
| Total | Condylar alterations | No condylar alterations | P | |
| Total, n (% girls) | 158 (73) | 68 (78) | 90 (70) | 0.26 |
| Duration, yrs, median (25/75th percentile) | 2.5 (0.5/3.9) | 2.8 (0.6/4.7) | 2.3 (0.4/3.2) | 0.21 |
| “EU 1 any time”, n (%) | 15 (9) | 9 (13) | 6 (7) | 0.11 |
| Number of “active disease periods”, median (25/75th percentile) | 2.49 (1.0/3.0) | 2.87 (1.0/4.0) | 2.28 (1.0/3.0) | 0.06 |
| “Potent medication” any time, n (%) | 75 (47) | 41 (60) | 34 (38) | 0.01 |
| Number of “medication periods”, median (25/75th percentile) | 2.69 (1.0/4.0) | 3.06 (1.0/4.0) | 2.41 (1.0/3.0) | 0.02 |
| Both “MTX and TNF-alpha inhibitor” any time, n (%) | 43 (27) | 23 (34) | 20 (22) | 0.09 |
| “EU 1 or potent medication” any time, n (%) | 82 (52) | 43 (63) | 39 (43) | 0.01 |
| “EU 1 and potent medication” any time, n (%) | 15 (10) | 11 (16) | 4 (4) | 0.02 |
| Spot No. | Protein name | Expression volume* | p-value | |
| Healthy | Ascites | |||
| 1 | similar to keratin 10 isoform 2 | 0.141 | 0.150 | 0.081 |
| 2 | chain A, crystal structures of chicken annexin v in complex with Ca2+ | 0.042 | 0.057 | 0.076 |
| 3 | similar to proteasome subunit alpha type 3 | 0.053 | 0.063 | 0.120 |
| 4 | keratin, type II cytoskeletal 1 | 0.085 | 0.077 | 0.041 |
| 5 | N-ethylmaleimide-sensitive factor | 0.051 | 0.071 | 0.045 |
| 6 | ring finger protein 170, isoform CRA_b | 0.088 | 0.049 | 0.004 |
| 7 | Rho GDP dissociation inhibitor (GDI) alpha | 0.120 | 0.156 | 0.002 |
| 8 | dihydropteridinereductase | 0.122 | 0.128 | 0.053 |
| 9 | ryncolin-1 | 0.080 | 0.121 | 0.004 |
| 10 | translationally-controlled tumor protein homolog | 0.131 | 0.160 | 0.014 |
| 11 | similar to natural killer cell enhancing factor isoform 4 | 0.126 | 0.074 | 0.027 |
| 12 | unnamed protein product | 0.214 | 0.228 | 0.109 |
| 13 | neutrophil cytosol factor 2 variant | 0.129 | 0.150 | 0.216 |
| 14 | glia maturation factor beta | 0.046 | 0.046 | 0.039 |
| 15 | keratin, type II cytoskeletal 1 | 0.193 | 0.387 | 0.177 |
| 16 | serpin B3 | 0.171 | 0.231 | 0.057 |
| 17 | chain A, the structure of chicken mitochondrial PEPCK. | 0.084 | 0.130 | 0.006 |
| 18 | hypothetical protein LOC100446659 | 0.432 | 0.894 | 0.114 |
| Level of agreement | ||||||
| Agree strongly | Agree a little | Neither agree nor disagree | Disagree a little | Disagree strongly | Mean value | |
| (5) | (4) | (3) | (2) | (1) | ||
| Tolerance of risk and uncertainty – all patients out-of-hours (OOH)* | ||||||
| 1. When it comes to OOH-medicine I’m quite cautious | 13 | 51 | 12 | 22 | 2 | 3.5 |
| 2. As an OOH-physician you think that you can deal with most things most of the time | 18 | 63 | 6 | 11 | 2 | 3.8 |
| 3. I think my risk assessment is reasonably good, and I’m reasonably safe | 27 | 67 | 4 | 2 | 0 | 4.2 |
| 4. All OOH-physicians take risks; it’s risk assessment OOH all the time (n = 99) | 17 | 29 | 21 | 31 | 1 | 3.3 |
| 5. OOH-physicians are good at living with uncertainty and risk | 9 | 48 | 31 | 11 | 1 | 3.5 |
| 6. I don’t worry about my decisions after I’ve made them | 8 | 42 | 4 | 41 | 5 | 3.1 |
| 7. I sometimes go back and check on the patient’s outcome after a shift has finished | 10 | 41 | 12 | 26 | 11 | 3.1 |
| Experiment group (n = 36) | Control group (n = 33) | P values | |
| Female/Male | 22/14 | 19/14 | 0.821 |
| Age (years) | 36.36 ± 14.75 | 38.73 ± 12.18 | 0.945 |
| BMI | 23.92 ± 14.45 | 23.62 ± 13.25 | 0.921 |
| Side: Left/Right | 23/12 | 18/15 | 0.644 |
| Cause: Strain/traffic injury (case) | 20/16 | 18/15 | 0.876 |
| Incidence of concomitant posterior dislocation of talus (%) | 55.56% (20/36) | 51.52% (17/33) | 0.932 |
| Posterior ankle fracture block accounts for the area of the articular surface (%) | 42.16 ± 18.42 | 38.23 ± 20.73 | 0.522 |
| Lauge-hansen system: supination-eversion type/ supination-external rotation type (case) | 21/15 | 18/15 | 0.822 |
| Danis-Weber system: B type/C type (case) | 23/13 | 19/14 | 0.912 |
| Time from injury to surgery (day) | 7.62 ± 2.37 | 6.87 ± 3.18 | 0.774 |
| Follow-up time (month) | 17.69 ± 12.26 | 15.94 ± 10.66 | 0.681 |
| Author; year | Specimen: lesser MTPJs | Age;Gender | PP dimensions |
| Johnston, Smith [15] | 20 FF of 5 cadavers | NR | L: mean 19 mm;2nd MTPJ 16–23 mmW: mean 11 mm proximally, to 9 mm distally;2nd MTPJ 8–13 mmT: 2–5 mm |
| Deland, Lee [8] | 30 FF of 6 cadavers | Median age 64 y;gender NR | L: mean 18.8 mm2nd, 3rd MTPJ: 20 mm mean4th, 5th MTPJ: 17 mm meanW: NRT: 2–4 mm |
| Deland and Sung [17] | 8 FF of 1 cadaver (†, ‡) | 68 y, F | NR |
| Gregg, Marks [14] | 8 FF of 1 cadaver | 19 y, F | Referring to Johnston et al. |
| 8 soft-embalmed of 3 cadavers | Age NR;2x M, 1x F | ||
| Coughlin, Schutt [22] | 16 FF cadavericspecimens, ‡ | Age NR;10x F2x M4x NR | NR |
| Median survival (days) | P-value | HR (95% CI) | ||
| “Good” (n = 25) | “Poor” (n = 7) | |||
| PFS | 62 | 48 | 0.0011 | 0.18 (0.06–0.57) |
| OS | 128 | 47 | 0.0078 | 0.31 (0.13–0.77) |
| Accession | Predicted protein function | Signal peptides | Family | Ratio AX/A | P-value | Ratio AX/X | P-value |
| 525580909 | Swollenin | Y | nd | nd | nd | nd | nd |
| 525584244 | Cellobiohydrolase | Y | GH7 | nd | nd | nd | nd |
| 525581542 | Beta-glucosidase | Y | GH3 | 1.05 | 9.90E-20 | 82.65 | 2.29E-06 |
| 525581794 | Beta-1,3-1,4-glucanase | Y | GH16 | 4.46 | 2.95E-08 | 0.65 | 0.9994203 |
| 525584431 | Cellulose monooxygenase | Y | GH61 | 2.13 | 7.40E-07 | 1.14 | 0.8792061 |
| 525585914 | Cellobiohydrolase | Y | GH6 | 7.15 | 8.39E-14 | 166.96 | 4.00E-11 |
| 525586734 | Cellobiohydrolase | Y | GH7 | 0.80 | 9.90E-20 | 607.47 | 9.90E-20 |
| 525588012 | Endo-beta-1,4-glucanase | Y | GH5 | 1.50 | 0.0002096 | 358.05 | 6.20E-12 |
| 525588754 | Endo-beta-1,4-glucanase | Y | GH5 | 1.33 | 0.0011941 | 147.03 | 3.54E-08 |
| Domain | Theme | Responses |
| Space Qualities | Nature | 246 |
| Park Features | 285 | |
| “Sense of Place” 1 | 68 | |
| Physical | Physical Pursuits | 1085 |
| Physical Restoration | 61 |
| Homocysteine (Fluorescence) (μM) | Homocysteine (LCMS) (μM) | Methylmalonic Acid (LCMS) (μM) | |
| Group 1 | |||
| Average | 70.24 | 38.48 | 2.46 |
| Standard deviation | 20.68 | 19.40 | 1.29 |
| Median | 69.58 | 33.66 | 2.33 |
| Max. | 101.38 | 83.16 | 4.83 |
| Min. | 36.12 | 14.29 | 0.85 |
| Group 2 | |||
| Average | 58.74 | 41.01 | 4.11 |
| Standard deviation | 12.76 | 20.65 | 2.01 |
| Median | 53.79 | 40.36 | 3.60 |
| Max. | 86.52 | 68.28 | 7.71 |
| Min. | 44.33 | 12.44 | 2.03 |
| Group 3 | |||
| Average | 54.63 | 19.06 | 2.75 |
| Standard deviation | 12.76 | 11.10 | 0.98 |
| Median | 58.12 | 19.26 | 2.46 |
| Max. | 67.87 | 34.51 | 4.32 |
| Min. | 30.28 | 3.18 | 1.78 |
| Trait | PB performance | CB performance | ||||||
| PB offspring | Sires | PB offspring | Sires | |||||
| Mean | Mean difference | Mean | Mean difference | Mean | Mean difference | Mean | Mean difference | |
| ADG | 0.577 (0.026) | 0.050 (0.021) | 0.660 (0.040) | 0.039 (0.016) | 0.514 (0.033) | 0.042 (0.027) | 0.697 (0.047) | 0.022 (0.012) |
| FCR | 0.660 (0.020) | 0.044 (0.015) | 0.732 (0.036) | 0.034 (0.012) | 0.615 (0.023) | 0.041 (0.018) | 0.745 (0.040) | 0.024 (0.010) |
| LM | 0.699 (0.016) | 0.039 (0.013) | 0.716 (0.040) | 0.047 (0.016) | 0.540 (0.030) | 0.032 (0.024) | 0.724 (0.044) | 0.019 (0.010) |
| pH | 0.639 (0.024) | 0.046 (0.018) | 0.745 (0.039) | 0.027 (0.011) | 0.624 (0.025) | 0.045 (0.018) | 0.750 (0.040) | 0.025 (0.011) |
| DL | 0.768 (0.020) | 0.030 (0.012) | 0.768 (0.040) | 0.044 (0.015) | 0.680 (0.020) | 0.026 (0.015) | 0.741 (0.039) | 0.030 (0.012) |
| IMF | 0.626 (0.029) | 0.042 (0.018) | 0.688 (0.047) | 0.034 (0.015) | 0.548 (0.031) | 0.038 (0.023) | 0.730 (0.052) | 0.018 (0.010) |
| Cases/controls (n) | Case-ratio | OR (95 % Cl)b | p-value | AUC (95 % Cl)b | |
| BI-RADS | 0.63 (0.57–0.69) | ||||
| D1 | 30/107 | 21.9 | 1 (reference) | - | |
| D2 | 31/73 | 29.8 | 1.53 (0.85–2.75) | NS | |
| D3 | 37/57 | 39.4 | 2.37 (1.32–4.25) | 0.004 | |
| D4 | 23/22 | 51.1 | 3.93 (1.88–8.20) | <0.001 | |
| Tabár | 0.65 (0.59–0.71) | ||||
| PI | 38/96 | 28.4 | 1.81 (0.96–3.42) | NS | |
| PII | 18/83 | 17.8 | 1 (reference) | - | |
| PIII | 9/13 | 40.9 | 3.23 (1.20–8.75) | 0.021 | |
| PIV | 49/51 | 49.0 | 4.40 (2.31–8.38) | <0.001 | |
| PV | 7/16 | 30.4 | 1.97 (0.70–5.57) | NS | |
| Automated texture (MTR)c | 0.63 (0.57–0.69) cont. | ||||
| 0.63 (0.56–0.69) cat. | |||||
| Q1 | 19/65 | 22.6 | 1 (reference) | - | |
| Q2 | 24/65 | 27.0 | 1.27 (0.63–2.54) | NS | |
| Q3 | 21/65 | 24.4 | 1.11 (0.54–2.25) | NS | |
| Q4 | 57/64 | 47.1 | 3.04 (1.63–5.67) | <0.001 | |
| BI-RADS + MTR | 0.66 (0.60–0.72) | ||||
| Q1 | 11/64 | 14.7 | 1 (reference) | - | |
| Q2 | 23/65 | 26.1 | 2.06 (0.93–4.57) | NS | |
| Q3 | 33/66 | 33.3 | 2.91 (1.36–6.25) | 0.006 | |
| Q4 | 54/64 | 45.8 | 4.91 (2.35–10.24) | <0.001 | |
| BI-RADS + Tabár | 0.67 (0.61–0.72) | ||||
| Q1 | 13/64 | 16.9 | 1 (reference) | - | |
| Q2 | 19/64 | 22.9 | 1.46 (0.67–3.21) | NS | |
| Q3 | 30/66 | 31.3 | 2.24 (1.07–4.67) | 0.032 | |
| Q4 | 59/65 | 47.6 | 4.47 (2.24–8.94) | <0.001 | |
| Tabár + MTR | 0.68 (0.62–0.73) | ||||
| Q1 | 13/65 | 16.7 | 1 (reference) | - | |
| Q2 | 22/65 | 25.3 | 1.69 (0.79–3.64) | NS | |
| Q3 | 24/65 | 27.0 | 1.85 (0.87–3.94) | NS | |
| Q4 | 62/64 | 49.2 | 4.84 (2.43–9.66) | <0.001 | |
| BI-RADS + MTR + Tabár | 0.69 (0.63–0.74) | ||||
| Q1 | 12/64 | 15.8 | 1 (reference) | - | |
| Q2 | 16/66 | 19.5 | 1.29 (0.57–2.95) | NS | |
| Q3 | 28/65 | 30.1 | 2.30 (1.08–4.91) | 0.032 | |
| Q4 | 65/64 | 50.4 | 5.42 (2.67–10.98) | <0.001 |
| Metric | SparseAssembler | Gossamer | Minia | SGA | Diginorm-Velvet | DiMA | ZeMA | Original Velvet |
| Total # of resultant contigs | 2,218 | 6,927 | 2,887 | 2,652 | 2,143 | 3,582 | 5,580 | 2,164 |
| N50 size in bp | 3,211 | 607 | 2,246 | 2,275 | 3,369 | 1,822 | 989 | 3,245 |
| Assembly Size in bp | 4,985,042 | 4,372,958 | 4,502,157 | 4,386,839 | 4,580,783 | 4,581,634 | 4,676,725 | 4,603,060 |
| Chaff bases in bp | 490,566 | 370,300 | 51,725 | 110,663 | 67,933 | 129,282 | 307,705 | 69,147 |
| Missing Reference Bases | 34,461 (0.76%) | 236,516 (5.14%) | 119,552 (2.60%) | 303,703 (6.60%) | 22,572 (0.49%) | 49,767 (1.08%) | 47,324 (1.03%) | 88,863 (1.93%) |
| Bad Trim | 2,716 | 3,609 | 3,125 | 1,288 | 6,850 | 6,486 | 3,508 | 11,233 |
| Translocation | 1 | 1 | 1 | 1 | 5 | 1 | 5 | 2 |
| Total Units Corrected | 2,224 | 6,923 | 2,890 | 2,658 | 2,147 | 3,579 | 5,579 | 2,169 |
| N50 size Corrected | 3,201 | 607 | 2,239 | 2,267 | 3,326 | 1,812 | 988 | 3,232 |
| Time (min:sec) | 3:15 | 7:37 | 1:23 | 55:37 | 5:12 | 5:15 | 6:04 | 2:33 |
| Memory Peak (GBs) | 0.36 | 3 | 0.17 | 2.01 | 0.96 | 0.96 | 0.96 | 2.2 |
| Total (N = 824) | ||
| N | % | |
| Age, year | ||
| Median (Range) | 61 (21–97) | |
| < 65 | 461 | 56.0. |
| ≥ 65 | 344 | 41.7 |
| missing | 19 | 2.3 |
| Gender | ||
| Female | 344 | 41.7 |
| Male | 480 | 58.3 |
| Primary diagnosis | ||
| Lung cancer | 150 | 18.2 |
| Gastrointestinal cancera | 267 | 32.4 |
| Breast cancer | 55 | 6.7 |
| Genitourinary cancerb | 108 | 13.1 |
| Head, neck, and oral cancer | 185 | 22.4 |
| Other cancersc | 59 | 7.2 |
| Length of time in care | ||
| Median (Range) | 20 (7–118) | |
| ≤ 14 days | 231 | 28.0 |
| 15–30 days | 361 | 43.8 |
| 31–60 days | 180 | 21.8 |
| > 60 days | 36 | 4.4 |
| Missing | 16 |
| Vitrectomized group | Control group | P∗ | |
| Number of eyes | 8 | 15 | |
| Sex (male/female) | 5/3 | 3/12 | 0.051∗ |
| Age | 72.8 ± 10.5 | 74.1 ± 5.1 | 0.906† |
| Eye (R/L) | 3/5 | 7/8 | 0.632∗ |
| BSCVA (LogMAR) | 1.15 ± 0.60 | 0.98 ± 0.52 | 0.795† |
| CCT (μm) | 765 ± 63 | 722 ± 88 | 0.194† |
| Frequency of previous surgeries | 3.11 ± 0.78 | 1 | <0.001 |
| Unmodified wildtype | Symmetric mutant | Left lobe cut | Right lobe cut | |
| Unmodified wildtype | − | |||
| Symmetric mutant | 0.0041* | − | ||
| Left lobe cut | 0.0003* | >0.5 | − | |
| Right lobe cut | 0.0592 | >0.5 | >0.5 | − |
| Right lobe shaved | 0.0212* | >0.5 | >0.5 | >0.5 |
| Parameters | SLNB | PALND | ALND | Statistics | P |
| (n = 72) | (n = 158) | (n = 59) | (F or X2) | ||
| Overall Survival | 97.2 % | 98.1 % | 96.6 % | 0.445 | 0.796 |
| Deaths (n) | 2 | 3 | 2 | ||
| Median Survival Time (mo) | 30.0 | 30.0 | 30.0 | 0.251 | 0.882 |
| Disease-Free Survival | 95.8 % | 96.8 % | 94.9 % | 9.033 | 0.340 |
| Event (n) | 3 | 5 | 3 | ||
| Local Recurrence | 0 | 0 | 0 | ||
| Contralateral breast cancer | 0 | 2 | 0 | ||
| Bone Metastasis | 1 | 0 | 0 | ||
| Lung Metastasis | 0 | 0 | 1 | ||
| Multi-Organ | 2 | 3 | 2 | ||
| Disease-Free Survival (mo) | 30.0 | 30.0 | 30.0 | 0.303 | 0.860 |
| Follow-Up Time | 1.633 | 0.197 | |||
| Median (mo) | 24.0 | 20.5 | 22.0 | ||
| Range (mo) | 12-33 | 12-33 | 12-33 |
| Compounds | Conc. (μg/mL) | Percent inhibition (mean ± SEM) | IC50 (μg/mL) |
| 1 | 1000 | 72.41 ± 0.45*** | 440 |
| 500 | 52.49 ± 0.78*** | ||
| 250 | 35.60 ± 0.75*** | ||
| 2 | 1000 | 70.32 ± 0.61*** | 460 |
| 500 | 52.48 ± 0.56*** | ||
| 250 | 33.61 ± 0.66*** | ||
| 3 | 1000 | 60.40 ± 0.49*** | 535 |
| 500 | 54.64 ± 0.70*** | ||
| 250 | 30.59 ± 0.67*** | ||
| 4 | 1000 | 45.80 ± 0.61*** | >1000 |
| 500 | 24.75 ± 0.64*** | ||
| 250 | 20.34 ± 0.58*** | ||
| Ascorbic | 1000 | 93.56 ± 0.37 | 20 |
| acid | 500 | 81.71 ± 0.54 | |
| 250 | 78.61 ± 0.23 |
| Triple genotype | Carriers (n) % | Non-carriers (n) % |
| Offs (n = 153) | (71) 46.4 | (82) 53.6 |
| CTR (n = 301) | (52) 17.3 | (248) 82.7 |
| AMI (n = 239) | (76) 31.8 | (163) 68.2 |
| OffsvsCTR | χ2 = 43.295, p = 0.0001 | |
| AMIvsCTR | χ2 = 15.372, p = 0.0001; OR = 2.224 (CI: 1.484-3.332) |
| Indicator | Baby kits n (%) | Transport vouchers n (%) | ||||||
| Control (Agulurude HC III) | Intervention (Ngai HC III) | Control (Amwa HC II) | Intervention (Atipe + Alao HC IIs) | |||||
| 2013 | 2014 | 2013 | 2014 | 2013 | 2014 | 2013 | 2014 | |
| Catchment population | 21,832 | 29,375 | 24,959 | 33,582 | 8649 | 11,637 | 25,878 | 26,235 |
| No. of expected deliveries | 950 | 1263 | 1086 | 1444 | 376 | 500 | 1126 | 1128 |
| Four ANC visits | ||||||||
| n (%) from catchment area | 284 (77.0) | 525 (72.6) | 235 (78.3) | 519 (90.4) | 152 (70.7) | 220 (75.6) | 125 (92.6) | 738 (89.5) |
| n (%) bypassing | 85 (23.0) | 198 (27.4) | 65 (21.7) | 55 (9.6) | 63 (29.3) | 71 (24.4) | 10 (7.4) | 87 (10.5) |
| Total four ANC visits | 369 | 723 | 300 | 574 | 215 | 291 | 135 | 825 |
| Institutional delivery | ||||||||
| n (%) from catchment area | 675 (79.4) | 646 (72.2) | 407 (80.4) | 734 (87.6) | 130 (77.8) | 249 (81.4) | 224 (98.2) | 811 (89.9) |
| n (%) bypassing | 175 (20.6) | 249 (27.8) | 99 (19.6) | 104 (12.4) | 37 (22.2) | 57 (18.6) | 4 (1.8) | 91 (10.1) |
| Total deliveries | 850 | 895 | 506 | 838 | 167 | 306 | 228 | 902 |
| PNC visits | ||||||||
| n (%) from catchment area | 61 (83.6) | 307 (74.7) | 29 (100) | 348 (94.3) | 33 (68.8) | 43 (69.4) | 7 (100) | 520 (93.4) |
| n (%) bypassing | 12 (16.4) | 104 (25.3) | 0 (0) | 21 (5.7) | 15 (31.2) | 19 (30.6) | 0 (0) | 37 (6.6) |
| Total PNC | 73 | 411 | 29 | 369 | 48 | 62 | 7 | 557 |
| Total OPD attendancea | 20,751 | 18,607 | 20,809 | 17,976 | 6834 | 6203 | 17,169 | 14,483 |
| Characteristics (missing data) | N (%) | Mean OSP1 (SD) | |
| Sex (0) | |||
| Male | 6,460 (53) | 505 (481)a | t = 15.91, p < .001 |
| Female | 5,728 (47) | 373 (423)b | |
| Age (0) | |||
| 12 | 370 (3) | 425 (472) | F = 1.90, p = .091 |
| 13 | 2,726 (22) | 442 (451) | |
| 14 | 3,348 (28) | 451 (460) | |
| 15 | 2,928 (24) | 457 (466) | |
| 16 | 2,151 (18) | 422 (460) | |
| 17 | 665 (6) | 431 (452) | |
| SEP (0) | |||
| Low | 3,932 (32) | 447 (473) | F = 0.33, p = .718 |
| Medium | 5,062 (42) | 439 (459) | |
| High | 3,194 (26) | 443 (441) | |
| Location (0) | |||
| Rural/Remote | 4,347 (36) | 487 (447)a | t = 7.76, p < .001 |
| Metropolitan | 7,841 (64) | 420 (446)b | |
| Cultural Background (148) | |||
| English | 11,052 (91) | 451 (459)c | F = 17.96, p < .001 |
| European | 208 (2) | 508 (482)d | |
| Asian | 703 (6) | 312 (426)a | |
| Middle-Eastern | 110 (1) | 381 (503)b | |
| Other | 97 (1) | 544 (554)d | |
| BMI Category (0) | |||
| Underweight | 587 (5) | 322 (404)a | F = 15.36, p < .001 |
| Healthy Weight | 8,831 (72) | 447 (456)b | |
| Overweight | 2,219 (18) | 464 (484)b | |
| Obese | 551 (5) | 432 (460)b | |
| PA Guidelines (0) | |||
| Meeting | 1,872 (15) | 769 (568)a | t = 34.98, p < .001 |
| Not Meeting | 10,316 (85) | 435 (462)b | |
| Screen-Based Entertainment Guidelines (38) | |||
| Meeting | 2,395 (20) | 476 (449)a | t = 3.85, p < .001 |
| Not Meeting | 9,755 (80) | 435 (462)b | |
| Fruit and Vegetable Guidelines (79) | |||
| Meeting | 1,762 (15) | 613 (528)a | t = 17.09, p < .001 |
| Not Meeting | 10,341 (85) | 413 (440)b | |
| Sugar-Sweetened Beverages (116) | |||
| Daily or more often | 1,629 (13) | 481 (507)a | t = 3.65, p < .001 |
| Less than daily | 10,443 (87) | 436 (450)b | |
| High-Fat Food (153) | |||
| Weekly or more often | 5,173 (43) | 456 (475)a | t = 2.80, p = .005 |
| Less than weekly | 6,863 (57) | 432 (445)b |
| Source organism | Gene/Protein | Target rice cultivar | Reference |
| Oryza sativa | Glutamine synthetase | Kinuhikari | Hoshida et al. (2000) |
| Avena sativa | Arginine decarboxylase | TNG-67 | Roy and Wu (2001) |
| Arthrobacter globiformis | Choline oxidase | Pusa Basmati-1 | Mohanty et al. (2002) |
| Hordeum vulgare | LEA protein | Pusa Basmati 1 | Rohila et al. (2002) |
| Atriplex gmelini | Vacuolar Na+/H+ antiporter | Kinuhikari | Ohta et al. (2002) |
| O. sativa | MAP kinase | Nipponbare | Xiong and Yang (2003) |
| Escherichia coli | Trehalose -6- phosphate synthase and Trehalose -6- phosphate phosphatase | Nakdong | Jang et al. (2003) |
| Vigna aconitifolia | Δ1-pyrroline-5-carboxylate synthetase | Kenfong | Su and Wu (2004) |
| O. sativa | Vacuolar Na+/H+ antiporter | Nipponbare | Fukuda et al. (2004) |
| Mouse | Calcineurin | Xiushui 04 | Ma et al. (2005) |
| Arabidopsis thaliana | MYB transcription factor | TNG-67 | Malik and Wu (2005) |
| Suaeda salsa | Catalase | Zhonghua No. 11 | Zhao and Zhang (2006) |
| A. thaliana and O. sativa | DREB transcription factor | Kita-ake | Ito et al. (2006) |
| O. sativa | NAC transcription factor | Nipponbare | Hu et al. (2006) |
| Suaeda salsa | Vacuolar Na+/H+ antiporter | Zhonghua-11 | Zhao et al. (2006b) |
| Schizosaccharo- myces pombe | Plasma membrane Na+/H+ antiporter | Zhonghua-11 | Zhao et al. (2006a) |
| Arthrobacter pascens | Choline oxidase | TNG-67 | Su et al. (2006) |
| Avicennia marina | SOD | Pusa Basmati-1 | Prashanth et al. (2008) |
| E. coli | Catalase | Nipponbare | Nagamiya et al. (2007) |
| O. sativa | Glyoxalase II | Pusa Basmati-1 | Singla-Pareek et al. (2008) |
| Pennisetum glaucum | Vacuolar Na+/H+ antiporter | Pusa Basmati-1 | Verma et al. (2007) |
| O. sativa | Shaker potassium channel | Nipponbare | Obata et al. (2007) |
| E. coli | Catalase | Nipponbare | Motohashi et al. (2010) |
| O. sativa | Ribosome-inactivating protein gene 18 | Nipponbare | Jiang et al. (2012) |
| O. sativa | Calmodulin-like gene | Pei’ai 64S | Xu et al. (2013) |
| O. sativa | Heat shock transcription factor A7 | Nipponbare | Liu et al. (2013) |
| O. sativa | Vesicle trafficking gene | Zhonghua 11 | Peng et al. (2014) |
| O. sativa | bZIP transcription factor | Zhonghua 11 | Liu et al. (2014b) |
| Bermudagrass | DREB transcription factor | Jonghua 11 | Chen et al. (2015) |
| Citrus tristeza virus | Heat shock protein 70 | Nipponbare | Hoang et al. (2015) |
| A. thaliana | Bcl-2 associated gene product | Nipponbare | Hoang et al. (2015) |
| Baculovirus | p35 | Nipponbare | Hoang et al. (2015) |
| Herbal medicine | Method 1 | Method 2 | Method 3 |
| 1 (Dwarf Lilyturf Tuber) | 0.7737 | 0.8861 | 0.9617 |
| 2 (Radix Glehniae) | 0.6281 | 0.8254 | 0.9382 |
| 3 (Barbary Wolfberry) | 0.8886 | 0.8151 | 0.9172 |
| 4 (Chinese Angelica) | 0.5452 | 0.8493 | 0.9464 |
| 5 (Dried Rehmannia Root) | 0.8382 | 0.8481 | 0.9490 |
| 6 (Szechwan Chinaberry) | 0.8316 | 0.9065 | 0.9417 |
| Samples | Activation energy, Ea (eV) | Coherent length, C (Å) |
| EMIm 0 | 1.055 | 0.099 |
| EMIm 10 | 0.967 | 0.087 |
| EMIm 25 | 0.928 | 0.017 |
| COPD | Non standardized coefficients | Standardized coefficient | t | Sig. | |
| B | SD Error | β | |||
| CVD | |||||
| Constant | .542 | .464 | 1.169 | .247 | |
| Age | .018 | .006 | .373 | 3.259 | .002 |
| BMI | .011 | .006 | .200 | 1.748 | .085 |
| VC,% predicted | −.003 | .002 | −.198 | −1.724 | .090 |
| Pressure overload | |||||
| Constant | 1.110 | .330 | 3.366 | .001 | |
| BMI | .025 | .012 | .263 | 2.060 | .044 |
| Volume overload | |||||
| Constant | .928 | .480 | 1.932 | .058 | |
| Sex | .384 | .148 | .341 | 2.598 | .012 |
| Smoking | .289 | .112 | .339 | 2.576 | .013 |
| VC, % predicted | −.006 | .004 | −.212 | −1.763 | .083 |
| 95% confidence | |||
| Odds ratio | Interval | P | |
| Dai-kenchu-to | |||
| Nonusers | Reference | ||
| Users | 1.60 | 0.86–2.95 | .137 |
| Age (10-yr age increase) | 1.09 | 0.79–1.51 | .592 |
| Sex (Female) | 0.52 | 0.27–1.01 | .054 |
| Diabetes | 0.73 | 0.33–1.60 | .428 |
| Hypertension | 1.07 | 0.47–2.42 | .873 |
| Cardiac diseases | 0.45 | 0.15–1.40 | .169 |
| Chronic lung diseases | 0.84 | 0.09–7.74 | .879 |
| Hospital volume (per month) | 0.99 | 0.94–1.05 | .820 |
| Type of surgery | |||
| Colectomy | Reference | ||
| Rectal of the resection | 0.95 | 0.47–1.94 | .893 |
| Abdominoperineal resection | 0.62 | 0.28–1.41 | .254 |
| Open or laparoscopic surgery | |||
| Open | Reference | ||
| Laparoscopic | 0.85 | 0.26–2.72 | .779 |
| 0° (Baseline) | −6° | −12° | −18° | −12° and CO2 | −12° and LBNP | |
| MD | 0.775± 0.253 | 0.840 ± 0.346 | 0.757 ± 0.207 | 0.748 ± 0.254 | 0.797 ± 0.237 | 0.877 ± 0.343 |
| FA | 0.493± 0.146 | 0.511 *± 0.153 | 0.592 ± 0.116 | 0.578 ± 0.143 | 0.533 ± 0.122 | 0.443 ** ± 0.174 |
| AD | 1.165± 0.256 | 1.276 ± 0.366 | 1.261 ± 0.222 | 1.244 ± 0.248 | 1.264 ± 0.284 | 1.232 ± 0.313 |
| RD | 0.580 ± 0.264 | 0.621 ± 0.342 | 0.505 ± 0.213 | 0.500 ± 0.271 | 0.563 ± 0.225 | 0.699 ± 0.365 |
| Group 1b | Group 2b | |||||
| Day 20 | Day 23 | Day 10 | Day 13 | Day 20 | Day 23 | |
| ODV + SMV | ODV + SMV + AL‐335 | ODV alone | ODV + AL‐335 | ODV + SMV | ODV + SMV + AL‐335 | |
| Cmax (ng/mL) | 649 (183) | 717 (192) | 582 (221) | 669 (349) | 770 (346) | 780 (321) |
| N | 14 | 14 | 16 | 15 | 15 | 15 |
| LSM ratioc | – | – | – | 1.06 (0.95‐1.17) | 1.25 (1.11‐1.41) | 1.28 (1.17‐1.40) |
| Tmax (h) | 6.51 (5.0‐8.0) | 6.00 (5.0‐8.0) | 5.00 (5.0‐7.0) | 5.05 (5.0‐8.0) | 7.00 (3.0‐9.0) | 6.00 (5.0‐16.0) |
| N | 14 | 14 | 16 | 15 | 15 | 15 |
| Cmin (ng/mL) | 313 (89) | 398 (116) | 235 (132) | 314 (166) | 471 (263) | 508 (270) |
| N | 14 | 14 | 16 | 15 | 15 | 15 |
| LSM ratioc | – | – | – | 1.30 (1.11‐1.52) | 1.91 (1.63‐2.24) | 2.09 (1.78‐2.45) |
| Clast (ng/mL) | 368 (116) | 55 (21) | 287 (150) | 331 (180) | 507 (268) | 90 (53) |
| N | 14 | 14 | 16 | 15 | 15 | 15 |
| Tlast (h) | 23.9 (23.9‐24.0) | 696.0 (696.0‐696.0) | 23.9 (23.9‐24.0) | 23.9 (23.9‐23.9) | 23.9 (23.8‐24.1) | 696.0 (696.0‐815.0) |
| N | 14 | 14 | 16 | 15 | 15 | 15 |
| AUC0‐24 h (ng.h/mL) | 10 734 (3124) | 12 376 (3407) | 8694 (3956) | 10 210 (5252) | 13 908 (6911) | 14 771 (7090) |
| N | 14 | 14 | 16 | 15 | 15 | 15 |
| LSM ratioc | – | – | – | 1.10 (1.01‐1.20) | 1.50 (1.36‐1.67) | 1.61 (1.46‐1.77) |
| t1/2 (h)c | NA | 213.13 (15.9) | NA | NA | NA | 233.9 (35.5) |
| N | NA | 11 | NA | NA | NA | 9 |
| All respondents reporting valid travel time data | |||
| Mode | |||
| Mean (sd) | Median (IQR) (range) | Proportion of total | |
| Car | 24.4 (40.8) | 0.0 (40.0) (0–510) | 39.7% |
| Walking | 19.2 (27.8) | 10.0 (30.0) (0–205) | 31.2% |
| Bus | 14.6 (30.8) | 0.0 (20.0) (0–210) | 23.7% |
| Rail | 1.8 (10.0) | 0.0 (0.0) (0–165) | 2.9% |
| Cycling | 0.7 (7.3) | 0.0 (0.0) (0–130) | 1.1% |
| Motorcycle | 0.1 (2.0) | 0.0 (0.0) (0–50) | 0.2% |
| Other | 0.6 (9.4) | 0.0 (0.0) (0–240) | 1.0% |
| Active modes* | 20.0 (28.5) | 10.0 (30.0) (0–205) | 32.4% |
| All modes combined | 61.5 (53.2) | 50.0 (63.0) (0–510) | 100.0% |
| OCa patient | Stage | Age | Late menopause | Previous pregnancy | Early puberty | Blood creatinine |
| 1 | I | 48 | No | Yes | No | Normal |
| 2 | I | 56 | No | Yes | No | Normal |
| 3 | I | 62 | No | Yes | No | Normal |
| 4 | I | 70 | No | Yes | No | Normal |
| 5 | I | 81 | No | Yes | No | Normal |
| 6 | II | 46 | No | Yes | No | Normal |
| 7 | II | 54 | No | Yes | No | Normal |
| 8 | II | 68 | No | Yes | No | Normal |
| 9 | II | 47 | No | Yes | No | Normal |
| Figure | l, σ | ↓D | SNER | μ × μ unit images | M × N | ↑L | LM×LN | α | # of Iterations |
| Fig. 12 | 7, 4 | 4 | - | 4 × 4 | 64 × 64 | 4 | 256×256 | 0.01 | 30 |
| HPV | |||
| Normal | Overexpression | P | |
| PCNA | |||
| Normal | 25 | 8 | 0.002 |
| Overexpression | 15 | 23 |
| ISS > 26 | ISS 15-26 | ISS < 15 | p-value | |||
| Demography, injury severity, transfusion and mortality | ||||||
| N | 23 | 26 | 30 | |||
| Age | yrs | 45 (25-71) | 57 (43-65) | 42 (28-49) | 0.034 | c |
| Gender | m% (n) | 74% (17) | 62% (16) | 67% (20) | NS | |
| Blunt trauma | % (n) | 96% (22) | 96% (25) | 83% (25) | 0.142 | |
| ISS | score | 34 (29-36) | 22 (17-25) | 9 (5-10) | NA | |
| sTBI | % (n) | 17% (4) | 46% (12) | 29% (6) | 0.091 | |
| GCS (PH) | score | 7 (3-13) | 11 (6-15) | 15 (12-15) | 0.002 | a |
| Crystalloids (PH) | ml | 900 (250-1250) | 275 (0-500) | 250 (25-750) | 0.013 | a, b |
| RBC 0-24 h | units | 2 (0-12) | 1 (0-3) | 0 (0-1) | 0.007 | a |
| FFP 0-24 h | units | 2 (0-9) | 0 (0-1) | 0 (0-0) | 0.003 | a |
| PLT 0-24 h | units | 0 (0-4) | 0 (0-0) | 0 (0-0) | 0.006 | a |
| MT (> 10 RBC in 24 h) | % (n) | 35% (8) | 4% (1) | 3% (1) | 0.001 | a, b |
| Mortality | % (n) | 39% (9) | 15% (4) | 3% (1) | 0.003 | a |
| Shock, sympathoadrenal activation, cell damage, biochemistry and hemostasis | ||||||
| SBP (PH) | mmHg | 150 (108-156) | 136 (125-152) | 130 (123-143) | NS | |
| pH | 7.31 (7.25-7.33) | 7.40 (7.307.40) | 7.37 (7.33-7.41) | 0.001 | a, b | |
| Lactate | mmol/l | 1.7 (1.2-2.2) | 2.5 (1.3-3.1) | 1.5 (0.9-2.1) | 0.049 | c |
| SBE | mmol/l | -3.6 (-5.7- -1.9) | -2.7 (-4.6- -0.5) | -1.0 (-1.8-0.7) | 0.005 | a |
| Adrenaline | pg/ml | 1,062 (328-1,549) | 292 (126-1,077) | 247 (86-354) | 0.002 | a |
| Noradrenaline | pg/ml | 1,235 (434-1,511) | 652 (210-1,288) | 332 (217-1,036) | 0.040 | a |
| hcDNA | % | 16.9 (5.6-27.0) | 5.6 (2.4-10.3) | 0.4 (0.0-9.3) | <0.001 | a |
| Hemoglobin | mmol/l | 8.0 (6.3-9.2) | 8.6 (7.2-9.1) | 8.4 (7.7-8.9) | NS | |
| Platelet count | 109/l | 217 (165-252) | 193 (173-260) | 211 (191-240) | NS | |
| Fibrinogen | g/l | 2.0 (1.4-2.2) | 2.4 (2.1-2.9) | 2.6 (2.3-2.9) | 0.002 | a, b |
| FXIII | microg/ml | 25 (20-30) | 30 (22-40) | 32 (28-41) | 0.001 | a |
| vWF | % | 190 (110-218) | 200 (132-223) | 204 (146-230) | NS | |
| APTT > 35 sec | % | 22% (5) | 4% (1) | 0% | 0.009 | a |
| INR > 1.2 | % | 43% (10) | 0% | 0% | <0.001 | a, b |
| Thrombelastography | ||||||
| R | min | 5.1 (4.8-5.9) | 5.9 (5.1-6.7) | 6.0 (5.3-6.4) | 0.046 | |
| Angle | degrees | 65 (62-68) | 67 (62-7) | 66 (62-70) | NS | |
| MA | mm | 63 (58-67) | 64 (62-68) | 63 (61-67) | NS | |
| Ly30 | % | 0.2 (0.0-0.7) | 0.0 (0.0-0.2) | 0.3 (0.0-1.0) | 0.040 | |
| Platelet activation and thrombin generation | ||||||
| sCD40L | pg/ml | 394 (281-551) | 327 (251-406) | 250 (195-305) | 0.006 | a |
| PF1.2 | nmol/l | 4.1 (1.1-13.0) | 15.1 (4.1-45.3) | 4.2 (1.6-9.5) | 0.026 | b, c |
| TAT | ng/ml | 36 (32-41) | 39 (33-44) | 35 (29-40) | 0.181 | |
| Natural anticoagulation | ||||||
| AT | 103 U/l | 0.89 (0.69-0.96) | 0.9 (0.8-1.00) | 0.98 (0.90-1.07) | 0.002 | a |
| PC | % | 92 (75-116) | 107 (96-123) | 117 (100-129) | 0.031 | a |
| APC | ng/ml | 10.4 (9.4-12.1) | 10.5 (8.7-13.5) | 8.0 (6.8-10.5) | 0.005 | a, c |
| TFPI | ng/ml | 64 (48-86) | 67 (52-80) | 54 (41-74) | NS | |
| Fibrinolysis | ||||||
| D-dimer | ng/ml | 173 (172-176) | 170 (144-175) | 128 (36-148) | <0.001 | a, c |
| tPA | ng/ml | 7.3 (5.5-15.4) | 7.8 (4.7-13.7) | 5.2 (2.0-9.9) | 0.063 | |
| PAI-1 | ng/ml | 24 (11-37) | 31 (14-68) | 20 (13-27) | 0.145 | |
| PAP | ng/ml | 316 (22-599) | 475 (83-1152) | 225 (54-393) | 0.159 |
| Clinical presentation | Key chunking propositions |
| Dysphagia | - Oropharyngeal vs. esophageal- Mechanical vs. motility |
| Elevated liver enzymes | - Hepatocellular vs. cholestatic- Intra vs. extrahepatic cholestasis |
| Nausea and vomiting | - GI vs. non-GI causes- GI vs. metabolic vs. CNS vs. drugs |
| Diarrhea | - Small bowel vs. large bowel- Steatorrhea (malabsorption) vs. non-steatorrhea- Osmotic vs. secretory vs. inflammatory vs. motility |
| Protein Accession | Protein Description | 101-35 °C/101-27 °C | 101-37 °C/101-27 °C | Functional Category |
| Up-regulated | ||||
| A2WMG6 | Salt stress root protein RS1 | 1.65 ± 0.24 | 1.51 ± 0.34 | Stress response |
| A2XCH7 | Tonoplast intrinsic protein (Tonoplast water channel) | 1.62 ± 0.16 | 1.58 ± 0.20 | transporter |
| A2Y1Q8 | Similar to TCH2 (TOUCH 2); calcium ion binding | 1.62 ± 0.15 | 1.78 ± 0.20 | Signaling |
| A2Y8H4 | Aldo/keto reductase domain containing protein | 1.54 ± 0.06 | 1.59 ± 0.13 | Metabolic |
| A2YCB4 | Thioredoxin fold domain containing protein | 1.57 ± 0.09 | 1.78 ± 0.19 | Redox |
| A2YI28 | Reticulon-like protein | 1.59 ± 0.26 | 2.02 ± 0.20 | Endoplasmic reticulum, ER |
| A2YM28 | Thiamine thiazole synthase, chloroplastic | 1.55 ± 0.12 | 1.8 ± 0.31 | Starch metabolic |
| A2YQ88 | Similar to PWWP domain containing protein | 1.51 ± 0.22 | 1.51 ± 0.29 | DNA binding |
| A2Z0W7 | Mannose-6-phosphate isomerase | 1.81 ± 0.07 | 1.89 ± 0.20 | Metabolic |
| B8B8G2 | Tubulin alpha chain | 1.54 ± 0.24 | 1.52 ± 0.23 | Cell structure |
| B8BF32 | HAD superfamily hydrolase-like, type 3 domain containing protein | 2.03 ± 0.59 | 3.15 ± 0.60 | Metabolic |
| Down-regulated | ||||
| A2X3J5 | 40S ribosomal protein S3a | 0.66 ± 0.17 | 0.63 ± 0.12 | Ribosome |
| A2X6N1 | 60S ribosomal protein L6 | 0.6 ± 0.02 | 0.61 ± 0.05 | Ribosome |
| A2XCC4 | Similar to 60S ribosomal protein L21 | 0.46 ± 0.07 | 0.56 ± 0.07 | Ribosome |
| A2XM46 | Similar to 60S ribosomal protein L13a-4 | 0.65 ± 0.05 | 0.62 ± 0.04 | Ribosome |
| A2YIS2 | Similar to 60S ribosomal protein L4 | 0.65 ± 0.07 | 0.66 ± 0.06 | Ribosome |
| A2YNM6 | Similar to 60S ribosomal protein L27a-3 | 0.59 ± 0.07 | 0.66 ± 0.05 | Ribosome |
| A2YVK0 | Similar to 60S ribosomal protein L34 | 0.6 ± 0.14 | 0.55 ± 0.10 | Ribosome |
| A2ZLS7 | Similar to 60S ribosomal protein L2 (fragment) | 0.61 ± 0.05 | 0.59 ± 0.05 | Ribosome |
| B8AHZ6 | 40S ribosomal protein S8 | 0.62 ± 0.03 | 0.63 ± 0.03 | Ribosome |
| B8B6Q3 | Similar to Pleiotropic drug resistance protein 3 | 0.66 ± 0.01 | 0.56 ± 0.01 | Transporter |
| Variable | Frequency | Percentage (%) |
| Healthcare decision-making autonomy | ||
| Autonomous | 1,117 | 21.9 |
| Not autonomous | 3,990 | 78.1 |
| Large household purchases decision-making | ||
| Autonomous | 948 | 18.6 |
| Not autonomous | 4,159 | 81.4 |
| Visit to family members decision-making | ||
| Autonomous | 1,097 | 21.5 |
| Not autonomous | 4,008 | 78.5 |
| WT | kua1-1 | OX-1 | 35S:Prx57 | |
| Cel | 98.44±14.5 | 109.48±14.7 | 105.20±3.3 | 96.14±3.7 |
| UAs | 45.14±7.8 | 49.86±4.4 | 48.04±3.4 | 43.91±6.3 |
| Rha | 6.82±1.0 | 5.80±1.6 | 5.70±1.4 | 5.79±1.7 |
| Fuc | 1.15±0.1 | 0.93±0.2 | 1.05±0.2 | 1.02±0.3 |
| Ara | 7.89±1.0 | 6.88±1.2 | 7.34±1.5 | 7.94±2.0 |
| Xyl | 7.35±0.8 | 5.89±1.3 | 6.28±1.6 | 6.13±1.8 |
| Man | 2.55±0.4 | 1.83±0.5 | 2.18±1.0 | 1.97±0.5 |
| Gal | 16.51±1.9 | 16.88±3.0 | 16.62±2.8 | 15.70±3.4 |
| Glc | 8.46±1.3 | 11.40±4.1 | 13.98±2.8 | 8.56±2.2 |
| Female | Male | |||
| Measure | White | African-American | White | African-American |
| Adjusted mean (SE) BMD (g/cm2)a | ||||
| Lowest | 0.789 (0.006) | 0.898 (0.010) | 0.961 (0.007) | 1.036 (0.011) |
| Middle | 0.776b (0.006) | 0.882 (0.009) | 0.944c (0.006) | 1.023 (0.010) |
| Highest | 0.771b (0.007) | 0.873 (0.012) | 0.934c (0.009) | 1.011 (0.013) |
| Unadjusted proportion with back pain (%)a | ||||
| Lowest | 29.5 | 22.3 | 30.5 | 24.8 |
| Middle | 28.7 | 25.4 | 26.8 | 20.4 |
| Highest | 27.5 | 23.8 | 29.8 | 30.8 |
| Unadjusted proportion with osteoporotic (%) fracturesa,d | ||||
| Lowest | 5.7 | 3.0 | 1.1 | 0.2 |
| Middle | 6.2 | 1.0 | 0.4 | 0.4 |
| Highest | 8.2 | 1.8 | 1.0 | 0.4 |
| Plan | Diameter (cm) | Mean Hippocampal Dose (Gy) | Mean Hippocampal dose (Gy2) | HI-PTV whole brain | TC-PTV metastases | TC-PTV whole brain |
| DS 1 | 1 | 12.55 | 8.90 | 0.34 | 0.52 | 0.82 |
| F 1 | 1 | 13.95 | 10.22 | 0.36 | 0.51 | 0.92 |
| O 1 | 1 | 12.82 | 9.15 | 0.64 | 0.54 | 0.99 |
| P 1 | 1 | 13.25 | 9.55 | 0.47 | 0.54 | 0.91 |
| T 1 | 1 | 36.10 | 33.9 | 0.55 | 0.53 | 0.96 |
| DS 2 | 2 | 13.46 | 9.75 | 0.78 | 0.55 | 0.92 |
| F 2 | 2 | 13.49 | 9.78 | 0.78 | 0.72 | 0.90 |
| O 2 | 2 | 13.68 | 9.96 | 0.53 | 0.52 | 0.92 |
| P 2 | 2 | 14.87 | 11.12 | 0.57 | 0.54 | 0.93 |
| T 2 | 2 | 42.00 | 40.27 | 0.68 | 0.48 | 0.90 |
| DS 3 | 3 | 17.80 | 14.18 | 0.77 | 0.49 | 0.93 |
| F 3 | 3 | 15.45 | 11.70 | 0.90 | 0.42 | 0.91 |
| O 3 | 3 | 13.66 | 9.94 | 0.60 | 0.51 | 0.93 |
| P 3 | 3 | 14.76 | 11.01 | 0.84 | 0.46 | 0.93 |
| T 3 | 3 | 50.4 | 47.16 | 0.85 | 0.52 | 0.80 |
| Rewarming technique | Rewarming rate | Notes & controversies | Rewarming complications |
| PASSIVE REWARMING [79] | |||
| Passive rewarming | 0.5–4 °C hr-1 (dependent upon patient’s thermoregulatory function and metabolic reserves) [79, 242]. | Protect from further heat loss and allow patient to self-rewarm. Minimal controversy for mild hypothermia if the patient is able to self-rewarm. | Negligible in isolated mild hypothermia. For colder patients and those with secondary hypothermia or comorbid illness, there may be morbidity associated with a prolonged rewarming process if the patient has poor tolerance for the hypothermia-induced organ dysfunction (i.e. hypotension, coagulopathy, arrhythmias, impaired cellular function etc.). |
| Passive rewarming with active movement | 1–5 °C hr-1 | Exercise has been shown to increase afterdrop in physiology studies from ~0.3 °C in controls to ~1 °C in exercised subjects, however the exercised subjects rewarmed more quickly [243]. | No reported complications. Some authors highlight the theoretical risk that the slightly increased afterdrop could contribute to morbidity and mortality. No adverse events were noted [243]. |
| ACTIVE EXTERNAL REWARMING | |||
| Active rewarming e.g. forced air surface [244] Arctic Sun® [245–247] | 0.5-4 °C hr-1 | Protect from further heat loss, deliver external heat and (if required) warmed IV fluids. Minimal controversies. | Similar to passive rewarming. |
| ACTIVE INTERNAL REWARMING | |||
| Bladder lavage | Variable. Adds ~0.5–1 °C hr-1 | Helpful if rewarming rate is slow. Minimal controversies. Rewarming is intermittent & slow because of small surface area. Poor control of infusate temperature [242, 248, 249]. | Negligible unless difficult catheterization. |
| Gastric lavage | Adds ~0.5–1 °C hr-1 | Not commonly used due to risk vs. benefit ratio [249]. | Potential for aspiration, fluid & electrolyte shifts. |
| Intravascular catheter rewarming e.g. Icy® catheter (CoolGuard®) [76, 250–252]Quattro® [253] Cool Line® [254] Innercool® [255] | Device specific (adds ~0.5–2.5 °C hr-1) | Uncertain indication for use, potential for benefit exists in colder and sicker co-morbid patients with stable circulation. | Potential for haemorrhage or thrombosis, potentially worsening hypotension in unstable patients. |
| Thoracic [79, 256, 257] or Peritoneal lavage [79, 258] | Adds ~1–2 °C hr-1 | Not commonly used unless patient is unstable and ECLS rewarming is not available. | Potential for haemorrhage, lung or bowel trauma, fluid & electrolyte shifts. Thoracic lavage has the potential to impair CPR quality. |
| Continuous venovenous haemofiltration [190, 242, 259–261] | Adds ~1.5–3 °C hr-1 | Not commonly used unless ECLS rewarming not available. Requires adequate blood pressure. Heparinisation required. | Problems rare. Local vascular complications. Air embolism. Hypotension. |
| Haemodialysis [242, 262–266] | Adds ~2–3 °C hr-1 | Not commonly used, patient must be able to increase cardiac output to perfuse the external circuit. Heparinisation required. | Potential for hypotension, haemorrhage, thrombosis, haemolysis, etc. |
| Veno-venous rewarming (usually with an ECMO circuit) [248] | ~4–10 °C hr-1 | Not commonly used. Provides no circulatory or ventilatory support in case of cardiac arrest. Patient must be able to increase cardiac output to provide circuit perfusion. | Potential for hypotension, haemorrhage, thrombosis, haemolysis, etc. |
| Extra-corporeal life support (VA-ECMO or CPB) | ~4–10 °C hr-1 | Preferred rewarming method for patients in cardiac arrest. CPB can use femoral route avoiding need for sternotomy [1, 42] | Potential for haemorrhage, thrombosis, haemolysis, etc. (as with all intravascular devices). |
| Foot Length | Ball Length | Ball Width | MIdfoot Width | Heel Width | Dorsal Arch Hgt | AHR | |
| FEMALES(N = 97) | |||||||
| Left | 24.4(1.2) | 17.8(0.9) | 9.1(0.5) | 8.0(0.6) | 6.1(0.4) | 6.2(0.4) | 0.349(0.026) |
| Right | 24.4(1.2) | 17.9(0.9) | 9.2(0.5) | 8.1(0.6) | 6.1(0.4) | 6.1(0.4) | 0.342(0.030) |
| MALES(N = 58) | |||||||
| Left | 26.7(1.3) | 19.5(0.9) | 10.2(0.5) | 9.1(0.6) | 6.8(0.4) | 6.9(0.5) | 0.354(0.03) |
| Right | 26.7(1.2) | 19.6(0.9) | 10.2(0.6) | 9.2(0.6) | 6.8(0.4) | 6.8(0.5) | 0.348(0.030) |
| Description of main review characteristics and the data extracted from reviews for each characteristic | |
| Aim | Adapted from review objectives. |
| Scope – Study design, Participants, Interventions, Comparison arms, Outcomes | Adapted from review selection criteria; the number and type of studies and participant numbers included were also extracted. |
| Number and types of studies | |
| Number of participants | |
| Analysis | Indicates whether meta-analysis and/or narrative data analysis was performed. |
| Setting | Country and predominant settings in which included studies were conducted and interventions delivered. |
| Recipient | Adapted from the Consumers and Communication Review Group scope, which groups reviews via direction of the communication processes (e.g. to the consumer; from the consumer; between provider and consumer; between consumers), so describing both the primary intervention recipient and the major direction of communication processes. |
| Provider | Who delivered the intervention to the recipient. Also describes important characteristics such as experience or training required to deliver the intervention. |
| Format | The predominant delivery format(s) of the intervention. May also include important characteristics such as frequency, intensity or delivery to individuals or groups. |
| Quality | Quality of included studies: summary based on review authors' criteria used to rate included study quality and authors' assessment of included study quality. |
| Quality of the review: based on AMSTAR; includes the overall quality score and summary of criteria that review methods failed to meet. | |
| Authors' conclusions | Authors' conclusions added as a composite of points raised in the Discussion and Implications (for practice, for research) sections of the Cochrane review. |
| Risk of Bias Summary Analysis | |||||||
| Risk of Bias Severity | Bias due to confounding | Bias in selection of participants into study | Bias in measurement of interventions | Bias due to departures from intended interventions | Bias due to missing data | Bias in measurement of outcomes | Bias in selection of reported result |
| Low | N=8; 6% | N=136; 95% | N=136; 95% | N=139; 97% | N=135; 94% | N=143; 100% | N=127; 89% |
| Moderate | N=112; 78% | N=7; 5% | N=7; 5% | N=3; 2% | N=8; 6% | N=0; 0% | N=16; 11% |
| Serious | N=21; 15% | N=0; 0% | N=0; 0% | N=1; 1% | N=0; 0% | N=0; 0% | N=0; 0% |
| Critical | N=2; 1% | N=0; 0% | N=0; 0% | N=0; 0% | N=0; 0% | N=0; 0% | N=0; 0% |
| Genotype | rs11245007 (C/T) | |||
| CC | CT | TT | CT + TT | |
| All subjects | ||||
| Cases (n = 1532) | 432 (28.20) | 738 (48.17) | 362 (23.63) | 1100 (71.80) |
| Controls (n = 1573) | 443 (28.16) | 768 (48.82) | 362 (23.01) | 1130 (71.84) |
| Crude OR (95 % CI) | 1.00 | 0.985 (0.834,1.164) | 1.025 (0.842, 1.249) | 0.998 (0.854, 1.167) |
| P | 0.863 | 0.802 | 0.982 | |
| Adjusted OR (95 % CI)a | 1.00 | 0.796 (0.638,0.992) | 0.952 (0.735,1.235) | 0.844 (0.687,1.037) |
| P | 0.0420 | 0.7124 | 0.1069 | |
| Parity <3b | ||||
| Cases (n = 1293) | 347 (26.84) | 636 (49.19) | 310 (23.98) | 946 (73.16) |
| Controls (n = 1122) | 314 (27.99) | 564 (50.27) | 244 (21.75) | 808 (72.01) |
| Adjusted OR (95 % CI)a | 1.00 | 0.962 (0.751,1.232) | 1.324 (0.987,1775) | 1.066 (0.846,1.345) |
| P | 0.7605 | 0.0607 | 0.5865 | |
| Parity ≥3b | ||||
| Cases (n = 188) | 67(35.64) | 81 (43.09) | 40 (21.28) | 121 (64.36) |
| Controls (n = 426) | 119 (27.93) | 194 (45.54) | 113 (26.53) | 307 (72.07) |
| Adjusted OR (95 % CI)a | 1.00 | 0.517 (0.304,0.879) | 0.469 (0.251,0.876) | 0.499 (0.307,0.813) |
| P | 0.0148 | 0.0175 | 0.0053 | |
| Family history of cancerc | ||||
| Cases (n = 474) | 126 (26.58) | 238 (50.21) | 110 (23.21) | 348 (73.42) |
| Controls (n = 169) | 31 (18.34) | 95 (56.21) | 43 (25.44) | 138 (81.66) |
| Adjusted OR (95 % CI)a | 1.00 | 0.530 (0.299,0.937) | 0.592 (0.304,1.151) | 0.548 (0.317,0.946) |
| P | 0.0289 | 0.1223 | 0.0308 | |
| No family history of cancerc | ||||
| Cases (n = 1057) | 306 (28.95) | 500 (47.30) | 251 (23.75) | 751 (71.05) |
| Controls (n = 1401) | 411 (29.34) | 672 (47.97) | 318 (22.70) | 990 (70.66) |
| Adjusted OR (95 % CI)a | 1.00 | 0.919 (0.723,1.166) | 1.130 (0.854,1.494) | 0.985 (0.788,1.230) |
| P | 0.4860 | 0.3933 | 0.8908 |
| BD type | Description |
| BD-0 | Schizophrenia |
| BD-1/2 | Schizobipolar disorder |
| BD-I | 'Classic' bipolar disorder |
| BD-I1/2 | Depression with protracted hypomania |
| BD-II | Hypomania plus major depression |
| BD-II1/2 | Depression superimposed on cyclothymic temperament |
| BD-III | Recurrent depression, plus hypomania occurring solely in association with antidepressant or other somatotherapy |
| BD-III1/2 | Mood swings that persist beyond stimulant and/or alcohol abuse |
| BD-IV | Depression superimposed on a hyperthymic temperament |
| BD-V | Recurrent depressions without discrete hypomania, but mixed hypomanic episodes (irritability/agitation/racing thoughts) during depression |
| BD-VI | Bipolarity in the frame of dementia |
| Lipid | Genotype/allele | Unstandardized coefficient | Std. error | Standardized coefficient | t | P |
| TC | ACAT-1 rs1044925 genotype | −0.099 | 0.043 | −0.053 | −2.287 | 0.022 |
| LIPC -250G>A allele | 0.101 | 0.046 | 0.050 | 2.170 | 0.030 | |
| LIPG 584C>T genotype | 0.149 | 0.043 | 0.079 | 3.503 | 0.000 | |
| LIPG 584C>T allele | 0.169 | 0.049 | 0.077 | 3.425 | 0.001 | |
| MTHFR 677C>T genotype | 0.218 | 0.037 | 0.133 | 5.854 | 0.000 | |
| MTHFR 677C>T allele | 0.269 | 0.046 | 0.133 | 5.841 | 0.000 | |
| PPARD +294T>C allele | 0.147 | 0.050 | 0.068 | 2.963 | 0.003 | |
| TG | MTHFR 677C>T genotype | 0.146 | 0.054 | 0.062 | 2.701 | 0.007 |
| MYLIP rs3757354 genotype | −0.102 | 0.042 | −0.057 | −2.456 | 0.014 | |
| PPARD +294T>C allele | 0.321 | 0.086 | 0.087 | 3.732 | 0.000 | |
| SCARB1 rs5888 genotype | −0.041 | 0.023 | −0.049 | −2.039 | 0.042 | |
| HDL-C | ACAT-1 rs1044925 genotype | −0.057 | 0.022 | −0.062 | −2.643 | 0.008 |
| ACAT-1 rs1044925 allele | −0.051 | 0.025 | −0.048 | −2.024 | 0.043 | |
| LIPC -250G>A genotype | 0.038 | 0.016 | 0.055 | 2.366 | 0.018 | |
| LIPG 584C>T genotype | 0.086 | 0.018 | 0.108 | 4.667 | 0.000 | |
| LIPG 584C>T allele | 0.080 | 0.021 | 0.087 | 3.762 | 0.000 | |
| MTHFR 677C>T genotype | 0.097 | 0.017 | 0.132 | 5.718 | 0.000 | |
| MTHFR 677C>T allele | 0.123 | 0.021 | 0.136 | 5.868 | 0.000 | |
| MYLIP rs3757354 genotype | 0.036 | 0.015 | 0.058 | 2.465 | 0.014 | |
| LDL-C | ABCA-1 V825I genotype | 0.075 | 0.025 | 0.068 | 2.954 | 0.003 |
| MTHFR 677C>T genotype | 0.075 | 0.029 | 0.059 | 2.562 | 0.010 | |
| MTHFR 677C>T allele | 0.120 | 0.036 | 0.077 | 3.334 | 0.001 | |
| ApoA1 | ACAT-1 rs1044925 genotype | −0.042 | 0.013 | −0.074 | −3.143 | 0.002 |
| ACAT-1 rs1044925 allele | −0.042 | 0.016 | −0.063 | −2.672 | 0.008 | |
| LIPC -250G>A genotype | 0.036 | 0.012 | 0.068 | 3.020 | 0.003 | |
| LIPG 584C>T genotype | 0.040 | 0.012 | 0.076 | 3.303 | 0.001 | |
| LIPG 584C>T allele | 0.039 | 0.014 | 0.064 | 2.781 | 0.005 | |
| MTHFR 677C>T genotype | 0.053 | 0.010 | 0.118 | 5.130 | 0.000 | |
| MTHFR 677C>T allele | 0.068 | 0.013 | 0.123 | 5.338 | 0.000 | |
| ApoB | MTHFR 677C>T genotype | 0.032 | 0.008 | 0.086 | 3.781 | 0.000 |
| MTHFR 677C>T allele | 0.042 | 0.010 | 0.092 | 4.049 | 0.000 | |
| ApoA1/ApoB | LIPC -250G>A genotype | 0.070 | 0.026 | 0.063 | 2.649 | 0.008 |
| Characteristics | Local Lab (n=734), n (%) | |
| Age | Median±SD | 60.4±11.50 |
| <60 | 337(46.0) | |
| ≥60 | 395(54.0) | |
| NA | 2 | |
| Gender | Male | 525(71.8) |
| Female | 206(28.2) | |
| NA | 3 | |
| Tissue type | Resection | 693(94.4) |
| Biopsy | 41(5.6) | |
| Stage* | I-IIIa | 428(58.3) |
| IIIb/IIIc | 187(25.5) | |
| IV | 82(11.2) | |
| NA | 37(5.0) | |
| Tumor location | Stomach | 535(72.9) |
| GE junction | 199(27.1) | |
| Intestinal | 292(39.8) | |
| Lauren | Diffuse | 254(34.6) |
| Mixed | 188(25.6) |
| Variables | Category | Cases | Controls | Crude OR | P-value |
| No (%) | No (%) | (95 % CI) | |||
| Knew about immunization | Yes | 101 (55.5) | 263 (72.6) | 1 | |
| No | 81 (44.5) | 99 (27.3) | 2.13 (1.46, 3.09) | <0.001* | |
| Knew the schedule of vaccines | Yes | 50 (49.5) | 134 (51) | 1 | |
| No | 51 (50.5) | 129 (49) | 1.06 (0.67, 1.67) | 0.8 | |
| Knew the benefits of immunization | Yes | 88 (87.9) | 256 (97.7) | 1 | |
| No | 13 (12.1) | 6 (2.3) | 6.30 (2.32, 17.08) | <0.001* | |
| Knew about vaccine side effects | Yes | 25 (24.8) | 47 (18) | 1.49 (0.85, 2.56) | 0.16 |
| No | 76 (75.2) | 214 (82) | 1 | ||
| Attitude towards benefits of immunization | Positive | 165 (94.8) | 339 (96.6) | 1 | |
| Negative | 9 (5.2) | 12 (3.4) | 1.54 (0.63, 3.73) | 0.33 | |
| Perception about vaccine side effects | Positive | 104 (60.1) | 236 (65.9) | 1 | |
| Negative | 69 (39.8) | 122 (34.1) | 1.28 (0.86, 1.88) | 0.21 | |
| Attitude towards the last received child immunization | Positive | 90 (49.7) | 176 (49) | 1 | |
| Negative | 91 (50.3) | 183 (51) | 0.97 (0.68, 1.39) | 0.8 |
| Food Groups | Men (n = 968) | Women (n = 1078) | ||||||
| Rice Staple | Wheat Staple | Snacks | Prudent | Rice Staple | Wheat Staple | Snacks | Prudent | |
| Rice | 0.413 | −0.503 | −0.462 | 0.415 | −0.565 | |||
| Wheat | 0.619 | 0.575 | ||||||
| Deep fried wheat | 0.213 | |||||||
| Instant noodles | −0.221 | 0.213 | ||||||
| Coarse grains | 0.966 | 0.278 | 0.929 | |||||
| Starchy roots and tubers | 0.295 | −0.439 | 0.352 | 0.428 | ||||
| Vegetables | 0.580 | −0.370 | 0.684 | |||||
| Fruits | 0.277 | 0.966 | 0.280 | 0.464 | 0.928 | |||
| Pork | 0.244 | −0.216 | −0.202 | 0.267 | −0.279 | |||
| Poultry | 0.571 | 0.319 | ||||||
| Other livestock meats | - | |||||||
| Organ meats | 0.226 | |||||||
| Processed meats | 0.466 | −0.355 | 0.274 | |||||
| Fresh water fish and seafood | −0.447 | 0.286 | 0.203 | |||||
| Dairy | 0.383 | 0.317 | 0.591 | |||||
| Legumes | 0.370 | 0.264 | ||||||
| Eggs | −0.446 | 0.464 | ||||||
| Seeds and nuts | 0.288 | 0.201 | 0.669 | |||||
| Fungi and algae | 0.312 | 0.474 | 0.200 | |||||
| Western fast food | ||||||||
| Cakes and pastries | 0.433 | 0.541 | ||||||
| Candy and chocolates | ||||||||
| Soft drinks | 0.407 | 0.363 | ||||||
| Alcoholic beverages | 0.306 | |||||||
| Tea | 0.344 | 0.201 | 0.220 | 0.236 |
| Characteristic | Greenland (n = 513) | Warsaw, Poland (n = 180) | Kharkiv, Ukraine (n = 557) |
| Maternal age at delivery (years) | |||
| 18–24 | 235 (45.8) | 12 (6.7) | 299 (53.7) |
| 25–29 | 119 (23.2) | 110 (61.1) | 164 (29.4) |
| 30–34 | 82 (16.0) | 55 (27.8) | 76 (13.6) |
| 35–45 | 77 (15.0) | 8 (4.4) | 18 (3.2) |
| Prepregnancy BMI (kg/m2) | |||
| < 18.5 | 14 (2.7) | 11 (6.1) | 79 (14.2) |
| 18.5–24.9 | 306 (59.6) | 154 (85.6) | 410 (73.6) |
| 25.0–29.9 | 136 (26.5) | 13 (7.2) | 56 (10.1) |
| ≥ 30 | 57 (11.1) | 2 (1.1) | 12 (2.2) |
| Maternal height (cm) | 162.0 ± 6.8 | 166.3 ± 5.2 | 165.28 ± 6.0 |
| Parity | |||
| 0 | 161 (31.4) | 153 (85.0) | 440 (79.0) |
| 1 | 153 (29.8) | 24 (13.3) | 95 (17.1) |
| 2 | 104 (20.3) | 2 (1.1) | 12 (2.2) |
| ≥ 3 | 95 (18.5) | 1 (0.6) | 10 (1.8) |
| Serum cotinine (ng/mL) | |||
| < 5.0 | 208 (40.5) | 178 (98.9) | 465 (83.5) |
| 5.0–49.9 | 87 (17.0) | 2 (1.1) | 54 (9.7) |
| ≥ 50.0 | 218 (42.5) | 0 (0.0) | 38 (6.8) |
| Maternal education | |||
| No postsecondary | 244 (50.9) | 8 (4.4) | 221 (39.7) |
| Some postsecondary | 235 (49.1) | 172 (95.6) | 335 (60.3) |
| Missing | 34 | 0 | 1 |
| Alcohol intake (drinks/week)a | |||
| < 7 | 450 (87.7) | 169 (93.9) | 553 (99.3) |
| ≥ 7 | 63 (12.3) | 11 (6.1) | 4 (0.7) |
| Fish or seafood (days/week) | 1.87 ± 1.53 | 1.28 ± 1.06 | 1.08 ± 1.53 |
| Missing | 12 | 10 | 60 |
| Serum vitamin D (ng/mL) | 17.56 ± 9.51 | 28.34 ± 11.73 | 22.46 ± 10.73 |
| Timing of blood sampling (gestational weeks) | |||
| 1–13 | 66 (13.3) | 1 (0.6) | 157 (28.9) |
| 14–26 | 229 (46.1) | 11 (6.2) | 156 (28.7) |
| ≥ 27 | 202 (40.6) | 166 (93.3) | 231 (42.5) |
| Missing | 16 | 2 | 13 |
| Season of blood sampling | |||
| October–March | 274 (53.5) | 135 (75.8) | 353 (64.5) |
| April–September | 238 (46.5) | 43 (24.2) | 194 (35.5) |
| Missing | 1 | 2 | 10 |
| Infant sex | |||
| Female | 237 (46.2) | 92 (51.1) | 264 (47.4) |
| Male | 276 (53.8) | 88 (48.9) | 293 (52.6) |
| Term birth weight (g) | |||
| < 2,500 | 11 (2.1) | 1 (0.6) | 7 (1.3) |
| 2,500–2,999 | 44 (8.6) | 18 (10.0) | 98 (17.6) |
| 3,000–3,499 | 142 (27.7) | 71 (39.4) | 269 (48.3) |
| 3,500–3,999 | 175 (34.1) | 66 (36.7) | 158 (28.4) |
| ≥ 4,000 | 141 (27.5) | 24 (13.3) | 25 (4.5) |
| Gestational age (weeks) | 39.85 ± 1.34 | 39.53 ± 1.25 | 39.21 ± 1.00 |
| aDuring the period around conception. |
| Girls (n = 603) | Boys (n = 509) | p | |||
| Age | 10 – 16 years | 11 – 16 year | .003 | ||
| M = 13.32, SD = 0.79 | M = 13.46, SD = 0.83 | ||||
| Grade | 36.7% | grade 7 | 33.8% | grade 7 | n.s. |
| 36.3% | grade 8 | 36.9% | grade 8 | ||
| 27.0% | grade 9 | 29.3% | grade 9 | ||
| BMI | M = 18.63, SD = 2.57 | M = 18.70, SD = 2.73 | n.s. |
| Gene ID | log2 Ratio | P-value | Annotation | Stress response∗ |
| LOC_Os07g44499 | 8.19 | 8.60E-07 | Peroxidase | D, S |
| LOC_Os08gl4860 | 6.67 | 1.25E-29 | Hydroxyacid oxidase 1 | D |
| LOC_Os01g52240 | 6.05 | 7.61E-36 | Type I chlorophyll a/b-binding protein | D |
| LOC_Os08gl5080 | 5.58 | 1.93E-26 | Proline rich protein 3 | D, S |
| LOC_Os02g39620 | 4.95 | 1.72E-08 | Stress-induced protein OZI1 | D, S |
| LOC_Osllg24140 | 4.53 | 2.59E-22 | Uclacyanin-like protein 35 | |
| LOC_Os07g44480 | 4.47 | 2.67E-06 | Peroxidase | D, A |
| LOC_Os01g02010 | 4.19 | 4.75E-05 | Arabinogalactan protein 12 | S, C |
| LOC_Os08g27850 | 3.76 | 7.07E-74 | MBF1 transcription factor | |
| LOC_Os08g28670 | 3.61 | 2.19E-15 | Bet v I allergen family protein | |
| LOC_Os01g41710 | 2.95 | 5.55E-37 | Chlorophyll a-b binding protein 2 | D |
| LOC_Os08g16070 | 2.91 | 5.16E-06 | Stress response | |
| LOC_Os07g41350 | 2.83 | 6.63E-21 | B12D-like protein 1 | S, C |
| LOC_Os06gl6170 | 2.82 | 1.10E-06 | Protein of unknown DUF231 | D |
| LOC_Os01g58970 | 2.75 | 2.57E-10 | Cytochrome P450 protein | D, C |
| LOC_Os06g45940 | 2.67 | 5.15E-30 | OsHAKB13 | D, S,C |
| LOC_Os05gl2280 | 2.58 | 9.65E-09 | Clumping factor A precursor | |
| LOC_Osl0g41430 | 2.46 | 2.87E-09 | Cyclin-U 4;3 | D, S,C |
| LOC_Os01g07700 | 2.32 | 2.57E-09 | Conserved hypothetical protein | C |
| LOC_Os07g37240 | 2.21 | 1.74E-11 | Chlorophyll A-B binding protein | D, S,C |
| LOC_Os02g44080 | 2.20 | 2.57E-09 | OsTIP2 | S, C |
| LOC_Osl0g31740 | 2.19 | 1.60E-06 | Glycine-rich cell wall structural protein 2 | |
| LOC_Os06g01210 | 2.14 | 1.24E-07 | OsPLAS | |
| LOC_Osllg20790 | 2.12 | 4.79E-06 | Adenylate kinase B | D, S |
| LOC_Os05g01680 | 2.09 | 2.91E-05 | LEA related protein | |
| LOC_Osl0g40700 | 2.07 | 1.23E-06 | Beta-expansin 6 | D, S, C |
| LOC_Os06g40818 | 2.07 | 2.80E-05 | Aspartic proteinase | D, S, C |
| LOC_Os08g01380 | 2.02 | 4.79E-05 | Ferredoxin I | D, S, C |
| LOC_Os02g03620 | 2.00 | 2.39E-05 | RING-HC protein 9 | D, S, C |
| LOC_Os03gl2290 | 1.99 | 2.36E-37 | OsGSl;2 | D, S |
| LOC_Os04g38600 | 1.94 | 6.85E-19 | GADPH | D, S, C |
| LOC_Os05g47700 | 1.89 | 1.94E-11 | Lipid transfer protein 2;4 | D, S, C |
| LOC_Os01g73200 | 1.80 | 1.26E-39 | Peroxidase BP 1 | D |
| LOC_Osl2g36210 | 1.78 | 9.13E-19 | Similar to MPI. | |
| LOC_Os07gl5370 | 1.74 | 1.59E-09 | OsNRAMPS | D, S, C |
| LOC_Os09g25490 | 1.73 | 1.17E-12 | Cellulose synthase catalytic subunit genes 9 | D, S, C |
| LOC_Os02g07410 | 1.71 | 1.05E-09 | Glycine cleavage H-protein | D, S |
| LOC_Os08g05960 | 1.69 | 3.48E-10 | Defense-responsive gene 10 | D, S, C |
| LOC_Os01gl3690 | 1.69 | 4.96E-07 | ligA | D, S, C |
| LOC_Os03g59210 | 1.68 | 2.68E-09 | Conserved hypothetical protein | D, S |
| LOC_Os02g51080 | 1.65 | 6.26E-06 | LYL1 | D, S, C |
| LOC_Os08g38170 | 1.63 | 2.21E-09 | Methyladenine glycosylase | D, S, C |
| LOC_Os07g36090 | 1.62 | 1.01E-06 | Ribosomal protein L28 | D |
| LOC_Os05g09440 | 1.61 | 4.21E-34 | 0sNADP-ME3 | D, S, C |
| LOC_Os03g08710 | 1.59 | 5.25E-08 | Thionin 26 | |
| LOC_Os08g01350 | 1.59 | 1.57E-05 | Transmembrane protein 18 | D |
| LOC_Os03g01700 | 1.59 | 1.40E-16 | LSI2 | D, S |
| All | IFX | TCZ | ABT | p Valuea | |
| Number of patients | 209 | 140 | 38 | 31 | – |
| Female sex, n (%) | 172 (82.3 %) | 113 (80.7 %) | 34 (89.5 %) | 25 (80.6 %) | 0.46626 |
| Age, yr, median (IQR) | 59.0 (47.0–66.0) | 57.5 (46.0–64.3) | 56.0 (44.8–64.0) | 67.0 (62.0–74.0) | 0.00003 |
| Disease duration, yr, median (IQR) | 3.3 (1.1–10.5) | 3.3 (1.1–10.3) | 4.2 (1.5–9.4) | 2.4 (0.5–14.5) | 0.86013 |
| Concomitant drug use | |||||
| Steroid use, n (%) | 80 (38.3 %) | 56 (40.0 %) | 14 (36.8 %) | 10 (32.3 %) | 0.75247 |
| Steroid dose, mg/day, median (IQR) | 0 (0–5.0) | 0 (0–5.0) | 0 (0–3.0) | 0 (0–2.5) | 0.34861 |
| MTX dose, mg/week, median (IQR) | 8.0 (8.0–8.0) | 8.0 (8.0–10.0) | 8.0 (6.0–8.0) | 8.0 (6.0–8.0) | 0.00271 |
| csDMARD useb (except MTX), n (%) | 29 (13.9 %) | 20 (14.3 %) | 5 (13.2 %) | 4 (12.9 %) | 1.00000 |
| Serological markers | |||||
| RF positivity, n (%) | 154 (74.8 %)c | 103 (74.1 %)d | 28 (73.7 %) | 23 (79.3 %)e | 0.88544 |
| RF titer, median (IQR) | 55 (15–115)c | 53 (14–115)d | 54 (17–115) | 77 (22–106)e | 0.94307 |
| ACPA positivity, n (%) | 85 (85.9 %)f | 51 (85.0 %)g | 13 (100 %)h | 21 (80.8 %)i | 0.31205 |
| ACPA titer, median (IQR) | 85.6 (12.8–100)f | 100 (13.3–100)g | 83 (42.9–100)h | 62.1 (9.8–100)i | 0.89773 |
| TJC28, median (IQR) | 6.0 (2.0–8.0) | 6.0 (2.0–8.3) | 6.0 (3.0–8.8) | 6.0 (3.0–8.0) | 0.68798 |
| SJC28, median (IQR) | 6.0 (3.0–11.0) | 7.0 (3.8–11.0) | 6.0 (4.0–8.0) | 5.0 (3.0–8.0) | 0.46376 |
| PtGA, mm, median (IQR) | 53 (28–72) | 52 (27–72) | 52 (31–67) | 63 (41–73) | 0.34811 |
| PhGA, mm, median (IQR) | 43 (30–60) | 43 (29–63) | 43 (33–60) | 45 (31–56) | 0.91700 |
| CRP, mg/dl, median (IQR) | 0.9 (0.4–2.4) | 1.0 (0.4–2.6) | 0.6 (0.2–2.0) | 0.8 (0.4–2.0) | 0.19092 |
| ESR, mm/h, median (IQR) | 42 (25–69) | 45 (28–69) | 37 (22–60) | 37 (23–74) | 0.27517 |
| DAS28-ESR, median (IQR) | 5.3 (4.4–6.1) | 5.3 (4.4–6.2) | 5.1 (4.5–5.8) | 5.5 (4.7–6.1) | 0.65899 |
| SDAI score, median (IQR) | 22.5 (16.2–31.3) | 23.2 (15.6–32.2) | 22.1 (16.8–28.5) | 23.3 (16.8–31.5) | 0.96973 |
| CDAI score, median (IQR) | 21.7 (14.9–28.9) | 21.9 (14.6–29.6) | 20.6 (16.4–26.0) | 22.8 (15.1–28.5) | 0.99430 |
| Analysate | |
| Red blood cells | Haemoglobin |
| Red corpuscle count | |
| Haematocrit | |
| Mean corpuscular volume | |
| Mean corpuscular | |
| Haemoglobin concentration | |
| Red blood cell distribution width | |
| White blood cells | White cell count Total count |
| Differential count | |
| Platelets | Platelets Count |
| Mean platelet volume | |
| Urea | Urine specific gravity |
| Ery | |
| Urea nitrogen | |
| Uric acid (UA) | |
| Creatinine (Cr) | |
| Urine protein | |
| Liver function tests (plasma) | Alkaline phosphatise |
| Alanine transaminase (ALT) | |
| Aspartate aminotransferase (AST) | |
| Phosphatise Transglutaminase (TG) | |
| Liver function tests (serum) | HBsAg |
| Anti-HBs | |
| HBeAg | |
| Anti-HBe | |
| Anti-HBc | |
| Lipids (plasma) | Total cholesterol (TC) |
| Total bilirubin (TBIL) | |
| Triglycerides (TG) | |
| Low density lipoprotein (LDL) | |
| Very Low density lipoprotein (VLDL) | |
| General chemistry (plasma) | C-reactive protein |
| Homocysteine | |
| Steroids | |
| Glucose | |
| Insulin | |
| Glycosylated hemoglobin | |
| Bio-specimen banking | |
| White blood cells | DNA, RNA extraction and analyses |
| Serum | Pedtidome profiling |
| Plasma | Glycome |
| Gene | Direction | Primer sequence | Product size | Reference |
| CYP2E1 | Forward | TCCAGGTTTGCACCAGACTCT | 76 bp | [26] |
| Reverse | TCCTCGCTCCTCCTGAGAAG | |||
| TP53 Exon 7 | Forward | GTG GTA CCG TAT GAG CCA CC | 157 bp | [27] |
| Reverse | CAA CCT GGC ACA CAG CTT CC | |||
| COX2 | Forward | AAA GCC TCGTCCAGATGCTA | 249 bp | [26] |
| Reverse | ATGGTGGCTGTCTTGGTAGG | |||
| GAPDH | Forward | ACCACAGTCCATGCCATCAC | 460 bp | [28] |
| Reverse | TCCACCACCCTGTTG CTGTA |
| Year 2000 vs Year 2008 | |||||
| URBAN RESIDENCE | RURAL RESIDENCE | ||||
| OR(CI)P-ValueUnadjusted | OR(CI)P-ValueAdjusted* | OR(CI)P-ValueUnadjusted | OR(CI)P-ValueAdjusted* | Effect modification§ | |
| Ever Wheeze | 1.40(1.21-1.62)P <0.01 | 1.33(1.13-1.55)P <0.01 | 1.55(1.25-1.94)P <0.01 | 1.66(1.30-2.13)P <0.01 | P = 0.35 |
| Current Wheeze | 1.11(0.89-1.39)P = 0.37 | 1.08(0.84-1.37)P = 0.56 | 1.84(1.30-2.59)P <0.01 | 1.81(1.24-2.64)P <0.01 | P = 0.04 |
| Diagnosis AsthmaEver | 1.50(1.26-1.78)P <0.01 | 1.39(1.15-1.68)P <0.01 | 2.04(1.57-2.65)P <0.01 | 2.20(1.64-2.94)P <0.01 | P = 0.02 |
| Severity of Asthma | 1.41(0.89-2.22)P = 0.14 | 1.30(0.80-2.11)P = 0.29 | 2.67(1.48-4.82)p < 0.01 | 2.99(1.54-5.58)p < 0.01 | P = 0.05 |
| Current Eczema | 1.45(1.08-1.95)P = 0.01 | 1.46(1.07-2.00)P = 0.02 | 1.06(0.66-1.70)P = 0.80 | 1.14(0.68-1.89)P = 0.62 | P = 0.32 |
| Diagnosis EczemaEver | 2.33(1.91-2.84)P <0.01 | 2.05(1.66-2.54)P <0.01 | 1.79(1.31-2.44)P <0.01 | 1.58(1.12-2.22)P = 0.01 | P = 0.14 |
| Current AllergicRhinoconjuctivitis | 1.01(0.67-1.52)P = 0.96 | 0.84(0.54-1.29)P = 0.42 | 1.93(1.05-3.57)P = 0.04 | 2.25(1.16-4.37)P = 0.02 | P = 0.04 |
| Diagnosis RhinitisEver | 1.66(1.21-2.26)P <0.01 | 1.54(1.10-2.14)P = 0.01 | 3.10(1.88-5.11)P <0.01 | 2.79(1.64-4.75)P <0.01 | P = 0.07 |
| Pt. | Sex/age at dgn (years) | Symptoms | Primary site | Tumor extension | Tumor size | TNM | Kadishstage |
| 1 | M/4 | Seizures | Rhinopharynx | Intracranial, bone erosion, cervical lymph nodes | > 5 cm | T2b, N1, M0 | C |
| 2 | M/2 | Exophthalmos | Nasal cavity, rhinopharynx and ethmoid sinuses | Orbital cavity, submandibular lymph node, bone erosion | > 5 cm | T2b, N1, M0 | C |
| 3 | F/16 | Recurrent epistaxis | Paranasal sinuses | - | > 5 cm | T1b, N0, M0 | B |
| 4 | M/10 | None | Nasal cavity, rhinopharynx and maxillary sinuses | Bone erosion | < 5 cm | T2a, N0, M0 | B |
| 5 | M/1 | Recurrent epistaxis | Nasal cavity, ethmoid sinuses | Intracranial, bone erosion | > 5 cm | T2b, N0, M0 | C |
| 6 | M/11 | Nasal obstruction | Nasal cavity, maxillary and ethmoid sinuses | - | > 5 cm | T2b, N0, M0 | B |
| 7 | M/5 | Cranial nerve palsy | Nasal cavity pterygomandibular, infratemporal fossae | Intracranial, orbital cavity, bone erosion | > 5 cm | T2b, N0, M0 | C |
| 8 | F/18 | Proptosis | Nasal cavity | Intracranial, orbital cavity, retromandibular and laterocervical lymph nodes, bone erosion | > 5 cm | T2b, N1, M0 | C |
| 9 | F/17 | Headache | Maxillary and ethmoid sinuses | Orbital cavity, bone erosion | > 5 cm | T2b, N0, M0 | C |
| Variables | Univariate | Multivariate | ||||
| HR (95 % CI) | χ2 | P | HR (95 % CI) | χ2 | P | |
| Age (years) | 0.669 (0.282-1.586) | 0.835 | 0.361 | - | - | - |
| <65 | ||||||
| ≥65 | ||||||
| Histotype | 1.458 (0.720-2.950) | 1.099 | 0.295 | - | - | - |
| Serous | ||||||
| Others | ||||||
| Grade | 1.244 (0.759-2.041) | 0.750 | 0.386 | - | - | - |
| G1-2 | ||||||
| G3 | ||||||
| Ascites (mL) | 0.990 (0.552-1.774) | 0.001 | 0.973 | - | - | - |
| <1000 | ||||||
| >1000 | ||||||
| Residual tumor (cm) | 3.333 (1.650-6.732) | 11.266 | 0.001* | 3.050 (1.499-6.205) | 9.471 | 0.002* |
| <1 | ||||||
| ≥1 | ||||||
| Class III β-tubulin | 1.870 (1.022-3.423) | 4.121 | 0.042* | 1.915 (1.036-3.538) | 4.301 | 0.038* |
| Positive | ||||||
| Negative | ||||||
| Sox2 | 2.623 (1.273-5.407) | 6.829 | 0.009* | 2.100 (1.009-4.373) | 3.935 | 0.047* |
| Positive | ||||||
| Negative | ||||||
| Nuclear Survivin | 1.838 (1.009-3.349) | 3.959 | 0.047* | - | - | - |
| Positive | ||||||
| Negative | ||||||
| Cytoplasmic Survivin | 0.958 (0.495-1.852) | 0.016 | 0.898 | - | - | - |
| Positive | ||||||
| Negative |
| Simultaneous mixed | Sequential mixed | Online | |
| Total costs | |||
| AMPCo rental of list | $15,830 | $15,830 | $15,830 |
| Monetary incentives | $60,000 | $60,000 | $60,000 |
| Web survey costs | $4,000 | $4,000 | $4,000 |
| AMPCO handling and postage | $97,157 | $72,024 | $65,361 |
| Printing of letters, further info, fax sheet, envelopes | $17,981 | $18,470 | $18,458 |
| Printing of surveys | $21,284 | $19,794 | $10,995 |
| Data entry | $33,684 | $16,630 | $6,636 |
| Total | $249,936 | $206,748 | $181,280 |
| Incremental cost effectiveness ratios (compared to online mode) | |||
| Response rate | 19.71% | 20.69% | 12.95% |
| Estimated number of responses | 10,677 | 11,208 | 7,015 |
| Change in response rate compared to online | 6.76% | 7.74% | - |
| Change in number of responses compared to online | 3,662 | 4,193 | - |
| Change in total cost compared to online | $68,656 | $25,468 | - |
| Additional cost per 1% increase in response rate1 | $10,156 | $3,290 | - |
| Additional cost per additional response2 | $18.75 | $6.07 | - |
| Measurement | Hill | Linear | Polynomial | Power |
| Admission SBP | ||||
| BMD | 1.50 | 2.57 | 0.22 | 1.46 |
| BMDL | 1.42 | 1.57 | 0.07 | 1.42 |
| AIC | 1,840 | 1,838 | 1,840 | 1,838 |
| Admission DBP | ||||
| BMD | NC | 2.71 | NC | 1.91 |
| BMDL | NC | 1.62 | NC | 1.43 |
| AIC | NC | 1,698 | NC | 1,699 |
| Maximum SBP | ||||
| BMD | 1.46 | 2.50 | 0.15 | 1.45 |
| BMDL | 1.41 | 1.55 | 0.06 | 1.41 |
| AIC | 1,895 | 1,897 | 1,895 | 1,893 |
| Maximum DBP | ||||
| BMD | 1.50 | 2.95 | 0.15 | 1.47 |
| BMDL | 1.43 | 1.71 | 0.06 | 1.43 |
| AIC | 2,009 | 2,009 | 2,009 | 2,007 |
| Characteristics | Total | LZAP low | LZAP high | P-value |
| Number of cases | 178 | 81 (45.5%) | 97(55.5%) | |
| Gender | 0.88 | |||
| Male | 86 (48.3%) | 38 (46.9%) | 48 (49.5%) | |
| Female | 91 (51.1%) | 42 (51.9%) | 49 (50.5%) | |
| NA | 1 (0.56%) | 0 | 1 (1.2%) | |
| Age at Dx | 0.34 | |||
| Median | 63 | 66 | 64 | |
| Range | 35–89 | 42–89 | 35–83 | |
| Mean | 62.4 | 65.8 | 64.3 | |
| Staging | ||||
| T | ||||
| T1–T2 | 53 (29.8%) | 26 (32.1%) | 27 (27.8%) | 1.00 |
| T3–T4 | 19 (10.7%) | 10 (12.3%) | 9 (9.3%) | |
| NA | 106 (59.6%) | 45 (55.6%) | 61 (62.9%) | |
| N | ||||
| N0 | 34 (19.1%) | 18 (22.2%) | 16 (16.5%) | 0.25 |
| N1–3 | 42 (23.6%) | 16 (19.8%) | 26 (26.8%) | |
| NA | 102 (57.3%) | 47 (58.0%) | 55 (56.7%) | |
| Stage | ||||
| I–II | 124 (69.7%) | 62 (76.5%) | 62 (63.9%) | 0.10 |
| III–IV | 53 (29.8%) | 19 (23.5%) | 34 (35.1%) | |
| NA | 1 (0.56%) | 0 | 1 (1.2%) |
| Diseases | PAF |
| Preterm [20] | 0.0679 |
| Lung Cancer [21] | male 0.6837/female 0.2057 |
| Chronic Obstructive Pulmonary Disease [22] | 0.3024 |
| Asthma [23] | 0.1319 |
| Ischemic Heart Disease [22] | 0.3265 |
| Pneumonia [24] | 0.1340 |
| Target relationship orientation | 1 | 2 |
| Monogamous | ||
| (1) Social distance | – | |
| (2) Promiscuity rating | 0.07 | – |
| (3) STI ratings | 0.07 | 0.52∗∗ |
| Open relationships | ||
| (1) Social distance | – | – |
| (2) Promiscuity rating | 0.13∗∗ | 0.45∗∗ |
| (3) STI ratings | 0.19∗∗ | |
| Polyamorous | ||
| (1) Social distance | – | – |
| (2) Promiscuity rating | 0.22∗∗ | 0.59∗∗ |
| (3) STI ratings | 0.33∗∗ | |
| Swingers | ||
| (1) Social distance | – | – |
| (2) Promiscuity rating | 0.08 | 0.51∗∗ |
| (3) STI rating | 0.27∗∗ |
| Normal-weight n = 165 | Overweight n = 54 | Obese n = 163 | normal-weight versus overweight P | normal-weight versus obese P | overweight versus obese P | |
| Walking | 0.2 ± 0.7 | 0.5 ± 1.1 | 0.9 ± 1.2 | 0.014 | 0.000 | 0.025 |
| Running | 0.3 ± 0.7 | 0.7 ± 1.1 | 1.3 ± 1.3 | 0.001 | 0.000 | 0.001 |
| Hopping | 0.1 ± 0.5 | 0.3 ± 0.9 | 0.9 ± 1.3 | 0.200 | 0.000 | 0.001 |
| Bending | 0.1 ± 0.3 | 0.4 ± 0.9 | 0.6 ± 1.2 | 0.003 | 0.000 | 0.171 |
| Climbing stairs | 0.1 ± 0.5 | 0.5 ± 1.0 | 1.4 ± 1.4 | 0.014 | 0.000 | 0.000 |
| Feeling clumsy or awkward | 0.4 ± 0.7 | 0.6 ± 1.1 | 1.1 ± 1.3 | 0.353 | 0.000 | 0.008 |
| Getting up from chairs | 0.0 ± 0.3 | 0.0 ± 0 | 0.0 ± 0.3 | 0.410 | 0.163 | 0.154 |
| Characteristics | Value |
| Number of patients | 38 |
| Age (years) | 35.9 ± 9.0 (range 17–58) |
| Male to female ratio | 29:16 |
| Fracture locations | |
| T11 | 5 patients |
| T12 | 12 patients |
| L1 | 17 patients |
| L2 | 4 patients |
| Surgical duration (minutes) | 90.7 ± 21.9 |
| Blood loss (milliliters) | 89.2 ± 31.9 |
| Postoperative stay (days) | 3.2 ± 0.9 |
| Hospital stay (days) | 4.8 ± 1.0 |
| Variables | Value |
| Age, years | |
| median years (IQR) | 25 (23-28) |
| ≤ 20 y (%) | 23/375 (6.1) |
| 20-35 y (%) | 331/375 (88.3) |
| > 35 y (%) | 21/375 (5.6) |
| Han Chinese (%) | 371/393 (94.4) |
| Job | |
| Farmer (%) | 200/389 (51.4) |
| Unemployed (%) | 84/389 (21.6) |
| Others (%)† | 105/389 (27.0) |
| BMI, median (IQR) | 26.0 (23.4-29.3) |
| ≤ 25.0 (%) | 99/243 (40.7) |
| 25-30 (%) | 99/243 (40.7) |
| 30-35 (%) | 35/243 (14.4) |
| > 35 (%) | 10/243 (4.1) |
| Gestational age§ | |
| 1st trimester (0-14 week) (%) | 20/394 (5.1) |
| 2nd trimester (15-27 week) (%) | 88/394 (22.3) |
| 3rd trimester (≥ 28 week) (%) | 286/394 (72.6) |
| Chronic pre-existing disease | |
| Respiratory diseases** (%) | 11/388 (2.8) |
| Cardiovascular diseases*** (%) | 13/393 (3.3) |
| Diabetes mellitus (%) | 4/394 (1.0) |
| Cancer or hematological diseases (%) | 3/394 (0.8) |
| Immune suppressed (%) | 1/390 (0.3) |
| Pneumonia (%) | 351/390 (90.0) |
| Symptoms and Lab findings | |
| T ≥ 38°C (%) | 340/374 (90.9) |
| Cough (%) | 372/393 (94.7) |
| Dyspnoea (%) | 199/393 (50.6) |
| Hemoptysis (%) | 55/392 (14.0) |
| Pleural effusion (%) | 44/226 (19.5) |
| CNS symptom ※ (%) | 48/392 (12.2) |
| WBC (×109/L) | 7.4 ± 3.7 |
| Platelet (×109/L) | 169.0 ± 65.7 |
| CK > 200 u/L (%) | 77/306 (19.5) |
| CRP (mg/L) | 42 (16-101) |
| ESR (mm/h) | 35 (23-50) |
| PaO2/FiO2, median (IQR) | 154.7 (89.5-320.5) |
| APACHE II scores, median (IQR) | 7 (4-11) |
| Item-test correlation | |||
| N∘ | Item | Cognitive scale | Affective scale |
| 1 | Her/his parents’ or siblings’ emotions don’t affect her/him much | 0.20 | |
| 2 | After being with a relative who is sad about something, s/he usually feels sad | 0.40 | |
| 4 | S/he gets frightened when s/he watches characters in a good scary movie | 0.32 | |
| 5 | S/he gets caught up in other people’s feelings easily | 0.52 | |
| 7 | S/he doesn’t become sad when he/she sees other people crying | 0.42 | |
| 8 | Other people’s feelings don’t bother her/him at all | 0.47 | |
| 11 | S/he often becomes sad when watching sad things on TV or in films | 0.50 | |
| 13 | Seeing a person who has been angered has no effect on her/his feelings | 0.40 | |
| 15 | S/he tends to feel scared when s/he is with friends or relatives who are afraid | 0.23 | |
| 17 | S/he often gets swept up in her/his siblings’ or friend’s feelings | 0.39 | |
| 18 | Her/his relatives or friend’s unhappiness doesn’t make her/him feels anything | 0.48 | |
| 3 | S/he can understand her/his friend’ or relative’s happiness when that person does well at something | 0.38 | |
| 6 | S/he finds it hard to know when other children are frightened | 0.18 | |
| 9 | When someone is feeling ‘down’ s/he can usually understand how that person feels | 0.56 | |
| 10 | S/he can usually work out when other children are scared | 0.50 | |
| 12 | S/he can often understand how people are feeling even before they tell her/him | 0.46 | |
| 14 | S/he can usually work out when people are cheerful | 0.48 | |
| 16 | S/he can usually realize quickly when either of her/his parents is angry | 0.37 | |
| 19 | S/he is not usually aware of her/his loved ones’ feelings | 0.47 | |
| 20 | S/he has trouble figuring out when other members of the family are happy | 0.42 |
| Diagnosis category | Number of missions |
| Cardiac arresta | 2 |
| Acute coronary syndrome | 6 |
| Circulatory emergencyb | 6 |
| Respiratory emergency | 2 |
| Trauma | 8 |
| Neurological emergency | 3 |
| Gastrointestinal emergency | 5 |
| Other emergency | 3 |
| Trait | Variance (%) |
| α-Amylase | 52.2 |
| Diastatic power | 74.1 |
| Malt extract | 54.0 |
| Heading date | 70.4 |
| Plant height | 64.2 |
| Lodging | 40.3 |
| Grain protein content | 45.6 |
| Yield | 22.4 |
| Project and Timeline | General Objective | Study Sites | Consortium partners |
| CERCA1/03/10 –29/02/14 | To contribute to global knowledge about how health systems can be more responsive to the sexual and reproductive health needs of adolescents and, by extension, to other health needs of Latin American populations. | City of Cuenca (Ecuador)City of Managua (Nicaragua)City of Cochabamba (Bolivia) | South Group (Bolivia), University of Cuenca (Ecuador), Lithuanian University of Health Sciences (Lithuania), Amsterdam University (The Netherlands), Centro de Investigaciones y Estudios de Salud (Nicaragua), Instituto Centro Americano de Salud (Nicaragua) |
| DIFFER1/10/11 –30/09/16 | To improve sexual and reproductive health for all women by expanding and strengthening sexual and reproductive health services, and providing and testing targeted interventions for female sex workers in the context of existing health systems. | Mombasa County, Coastal Province (Kenya)Cities of Tete and Moatize, Tete Province (Mozambique)City of Durban (eThekwini District), KwaZulu-Natal Province (South Africa)City of Mysore, Karnataka State (India) | Ashodaya Samithi (India), International Centre for Reproductive Health Association (Kenya), International Centre for Reproductive Health Association (Mozambique), University of the Witwatersrand – MatCH (South Africa), University College London – Institute for Global Health (United Kingdom) |
| INPAC1/08/12 –31/07/16 | To evaluate the effectiveness of introducing integrated post-abortion family planning services into existing hospital-based abortion services in China in order to reduce unintended pregnancies and repeated abortions. | 30 of 31 provinces, municipalities and autonomous regions of mainland China | Chinese Society of Family Planning – Chinese Medical Association (China), Fudan University (China), National Research Institute for Family Planning (China), West China Second University Hospital of Sichuan University (China), University of Aarhus – Danish Epidemiology Science Centre (Denmark), Liverpool School of Tropical Medicine (United Kingdom) |
| MOMI1/02/11 –31/01/16 | To improve maternal and newborn health through a focus on the postpartum period, adopting context-specific strategies to strengthen health care delivery and services at both facility and community level in four sub-Saharan countries. | Kaya District (Burkina Faso)Kwale District (Kenya)Ntchisi District (Malawi)Chiuta District (Mozambique) | Institut de Recherche en Sciences de la Santé (Burkina Faso), International Centre for Reproductive Health Association (Kenya), Faculdade de Medicina – Eduardo Mondlane University (Mozambique), International Centre for Reproductive Health Association (Mozambique), Parent and Child Health Initiative (Malawi), Faculdade de Medicina da Universidade do Porto – Department of Hygiene and Epidemiology (Portugal), University College London – Institute for Global Health (United Kingdom) |
| Characteristics | Number of patients (%) |
| Sex | |
| Male | 107 (81.7) |
| Female | 24 (18.3) |
| Age | |
| ≤64 | 57 (43.5) |
| >64 | 74 (56.5) |
| Smoking | |
| Smoking index >400 | 41 (31.3) |
| Smoking index ≤400 | 36 (27.5) |
| No | 54 (41.2) |
| Grade | |
| Low | 60 (45.8) |
| High | 71 (54.2) |
| Invasiveness | |
| Muscle-invasive | 72 (55.0) |
| Non-muscle-invasive | 59 (45.0) |
| Relapse | |
| Yes | 90 (68.7) |
| No | 41 (31.3) |
| Metastasis | |
| Yes | 20 (15.3) |
| No | 111 (84.7) |
| Characteristics | All patients(n = 188) | Nafcillin group(n = 91) | Glycopeptide group(n = 97) | P value |
| Age, years, mean ± SD | 62.37 ± 15.14 | 64.38 ± 14.53 | 60.46 ± 15.54 | 0.076 a |
| Male, (%) | 129 (69.0) | 61 (67.0) | 68 (70.8) | 0.636 b |
| Underlying comorbidities, yes (%) | ||||
| Cardiovascular disease | 55 (29.3) | 29 (31.9) | 26 (26.8) | 0.522 b |
| Cerebral vascular accident | 19 (10.1) | 12 (13.2) | 7 (7.2) | 0.227 b |
| Dementia | 5 (2.7) | 1 (1.1) | 4 (4.1) | 0.370 c |
| Lung disease | 14 (7.4) | 8 (8.8) | 6 (6.2) | 0.584 b |
| Autoimmune disease | 10 (5.3) | 4 (4.4) | 6 (6.2) | 0.749 c |
| Peptic ulcer disease | 10 (5.3) | 6 (6.6) | 4 (4.1) | 0.527 c |
| Chronic kidney disease | 39 (20.7) | 23 (25.3) | 16 (16.5) | 0.153 b |
| Diabetes | 62 (33.0) | 35 (38.5) | 27 (27.8) | 0.162 b |
| Liver disease | 23 (12.2) | 8 (8.8) | 15 (15.5) | 0.187 b |
| Malignancy | 85 (45.2) | 26 (28.6) | 59 (60.8) | <0.001 b |
| CA vs. HCA, HCA (%) | 113 (60.1) | 43 (47.3) | 70 (72.2) | <0.001 b |
| Pit bacteremia score, mean ± SD | 1.56 ± 2.55 | 1.42 ± 2.39 | 1.69 ± 2.71 | 0.465 a |
| Infection focus, yes (%) | ||||
| Catheter-related infection | 22 (11.8) | 12 (13.3) | 10 (10.4) | 0.651 b |
| Pneumonia | 8 (4.3) | 1 (1.1) | 7 (7.3) | 0.066 c |
| Urinary tract infection | 7 (3.8) | 9 (6.7) | 1 (1.0) | 0.058 c |
| Skin and Soft tissue infection | 43 (23.1) | 27 (30.0) | 16 (16.7) | 0.037 b |
| Bone and Joint infection | 22 (11.8) | 16 (17.8) | 6 (6.3) | 0.022 b |
| Intra-abdominal infection | 13 (7.0) | 3 (3.3) | 10 (10.4) | 0.083 c |
| Primary bacteremia | 74 (39.8) | 27 (30.0) | 47 (49.0) | 0.011 b |
| Laboratory tests | ||||
| WBC, /mm3, median (IQR) | 10,150 (7,635–14,770) | 10,450 (8,120–15,280) | 9,860 (5,485–14,615) | 0.064 d |
| Leukocytosis or Leukopenia, yes (%) | 116 (61.7) | 50 (54.9) | 66 (68.0) | 0.073 b |
| Platelet counts, ×103/mm3, median (IQR) | 169 (95–250) | 182 (115–257) | 164 (83–250) | 0.190 d |
| Thrombocytopenia, yes (%) | 82 (43.6) | 36 (39.6) | 46 (47.4) | 0.305 b |
| eGFR, mL/min/mm3, mean ± SD | 62.88 ± 28.60 | 62.38 ± 28.27 | 63.35 ± 29.06 | 0.818 a |
| Total bilirubin, mg/dL, median (IQR) | 0.8 (0.5–1.4) | 0.8 (0.5–1.3) | 0.8 (0.5–1.4) | 0.452 d |
| Prothrombin time (INR), median (IQR) | 1.12 (1.01–1.29) | 1.13 (1.02–1.28) | 1.11 (1.01–1.32) | 0.895 d |
| CRP, mg/dL, median (IQR) | 121.01 (56.34–200.85) | 139.60 (79.68–219.00) | 107.61 (42.19–192.90) | 0.022 d |
| Gene | Alteration | RsID | COSMIC | |
| Sample 1 | ARID1A | Gln1614* | NR | NR |
| Sample 1 | NOTCH1 | N280S | rs367825691 | NR |
| Sample 1 | PIK3CA | EDLLNPI453del | NR | NR |
| Sample 1 | ROS1 | V1881_splice | rs772648589 | NR |
| Sample 2 | ARID1A | P476* | NR | NR |
| Sample 2 | ARID1A | Leu1054Phe | NR | NR |
| Sample 2 | KMT2D | Gln3745dup | rs775492040 | NR |
| Sample 3 | CDKN2Aa | Glu69* | rs121913383 | COSM13281 |
| Sample 3 | TP53a | Asn268* | NR | COSM6583 |
| Sample 4 | TP53 | Arg181Cys | rs587782596 | COSM11090 |
| Sample 5 | KRAS | Gly12Val | rs121913529 | COSM520 |
| Sample 5 | PIK3CA | His1047Arg | rs121913279 | COSM775 |
| Sample 6 | ALK | Gly926Arg | NR | NR |
| Sample 6 | ERBB2 | Ile989Met | NR | NR |
| Sample 7 | ARID1Aa | Tyr1055* | NR | NR |
| Sample 7 | PIK3CAa | Lys111Glu | NR | COSM13570 |
| Sample 8 | SPOP | Lys115Glu | NR | NR |
| Sample 9 | ARID1A | Gln537* | NR | NR |
| Sample 9 | ARID1A | Gln2176* | NR | COSM1582021 |
| Sample 9 | PIK3CA | His1047Arg | rs121913279 | COSM775 |
| Native | Derivative | |
| Data collection | ||
| Beamline | ESRF ID14-4 | SLS X06DA (PXIII) |
| Spacegroup | P3 | P3 |
| Unit cell parameters (Å, °) | a = b = 104.50, c = 33.59 | a = b = 104.03, c = 33.56 |
| α = β = 90, γ = 120 | α = β = 90, γ = 120 | |
| Wavelength (Å) | 0.91970 | 0.97942 |
| Resolution limits (Å) | 52.25–1.49 (1.54–1.49)* | 31.45–2.00 (2.06–2.00)* |
| Reflections observed/unique | 607786/64606 | 419456/27271 |
| Completeness (%) | 98.3 (96.3)* | 99.9 (98.9)* |
| Rsym†(%) | 5.6 (36.1)* | 9.4 (75.2)* |
| <I>/<σI> | 26.3 (6.4)* | 24.1 (3.9)* |
| Redundancy | 9.4 (8.8)* | 15.4 (13.9)* |
| SAD phasing | ||
| BAYES-CC | 49.1 ± 18.5 | |
| Se sites found/expected | 5/6 | |
| FOM before solvent flattening and density modification | 0.35 | |
| FOM after solvent flattening and density modification | 0.69 | |
| Refinement | ||
| Resolution limits (Å) | 52.25–1.49 (1.52–1.49)* | |
| Reflections for Rcryst/for Rfree | 59806/4800 | |
| Rcryst‡(%) | 12.4 (20.6)* | |
| Rfree‡(%) | 16.4 (23.0)* | |
| No. of protein atoms/water atoms | 2307/297 | |
| Average B factor protein atoms/water atoms (Å2) | 21.67/35.34 | |
| RMSD bond lengths (Å) | 0.005 | |
| RMSD bond angles (°) | 0.854 | |
| Twin fraction (operator −h, −k, l) | 0.49 | |
| Ramachandran Plot Statistics§ | ||
| Favoured region (%) | 99.3 | |
| Outliers (%) | 0.0 |
| Genetics | Mechanism | Incidence | Reference |
| Ptch+/− | Conventional KO | 14%–19% by 10 months | (23, 44, 98) |
| Ptch+/− | Conventional KO; irradiation | 100% by 10 months | (54, 55) |
| Ptch+/−; p53−/− | Conventional KO | 100% by 2–3 months | (89) |
| Ptch+/−; Ptch2±/− | Conventional KO | 17% by 10 months | (44) |
| Ptch+/− | Conditional KO (GFAP-Cre, Math1-Cre) | 100% by 1–3 months | (95) |
| ND2-SmoA1 | TG | 94% by 2 months | (26, 28) |
| SmoM2 | Conditional TG (GFAP-Cre, Math1-Cre, Olig2-Cre, Tlx-Cre) | 100% by 2–4 months* | (69) |
| Sufu+/−; p53−/− | Conventional KO | 58% by 10 months | (42) |
| Shh | RCAS | 9%–34% by 3 months | (7, 49, 60, 61) |
| Shh; c-myc/Akt/IGF2 | RCAS | 23%–48% by 3 months | (60, 61) |
| Shh; n-myc | RCAS | 78% by 3 months | (7) |
| Shh; Bcl-2 | RCAS | 78% by 3 months | (49) |
| Rb±/−; p53−/− | Conditional KO (GFAP-Cre) | 25%–100% by 2–7 months | (48) |
| Ink4c±/−; p53±/− | Conventional and conditional KO (Nestin-Cre); irradiation | 20%–100% by 5 months | (81) |
| Ptch+/−; Ink4c±/− | Conventional KO | 40%–50% by 9 months | (81) |
| Lig4−/−; p53−/− | Conventional KO | 100% by 2 months | (43) |
| Brca2−/−; p53±/− | Conventional and conditional KO (Nestin-Cre) | 72%–83% by 4–8 months | (17) |
| Xrcc4−/−; p53−/− | Conventional and conditional KO (Nestin-Cre) | 100% by 6 months | (94) |
| Input variables | Unit cost (£) | Source | Details |
| Interventions | |||
| Lens extraction implemented as day case | 866 | National schedule of reference costs year 2012–2013 | Phacoemulsification cataract extraction and lens implant implemented as day case (BZ02) |
| Lens extraction implemented as inpatient | 2157 | National schedule of reference costs year 2012–2013 | Phacoemulsification cataract extraction and lens implant implemented as inpatient (BZ02) |
| Laser iridotomy implemented as outpatient | 118 | National schedule of reference costs year 2012–2013 | Laser iridotomy (minor glaucoma procedures implemented as outpatient (BZ19)) |
| Subsequent procedures | |||
| Lens capsulotomy | 121 | National schedule of reference costs year 2012–2013 | Lens capsulotomy (BZ04) implemented as outpatient |
| Iridoplasty | 172 | National schedule of reference costs year 2012–2013 | Major glaucoma procedures implemented as outpatient (BZ17) |
| Trabeculectomy | 1140 | National schedule of reference costs year 2012–2013 | Intermediate glaucoma procedures implemented as day case (BZ18) |
| Cataract surgery | 866 | National schedule of reference costs year 2012–2013 | Phacoemulsification cataract extraction and lens implant implemented as day case (BZ02) |
| Primary healthcare | |||
| General practitioner visit | 43 | PSSRU 2013 | Community-based healthcare staff |
| General practitioner visit at home | 53.58 | PSSRU 2013 | Community-based healthcare staff |
| General practitioner telephone conversation | 26 | PSSRU 2013 | Community-based healthcare staff |
| Community optician and optometrist | 62 | National schedule of reference costs year 2012–2013 | Follow-up attendance—non-consultant led outpatient attendances |
| District nurse | 12.40 | PSSRU 2013 | Community-based healthcare staff |
| Practice nurse | 10.59 | PSSRU 2013 | Community-based healthcare staff |
| Clinical support worker nursing (community) | 31 | PSSRU 2013 | Community-based healthcare staff |
| Secondary healthcare | |||
| Ophthalmologist visit | 80 | National schedule of reference costs year 2012–2013 | Consultant-led outpatient attendances, follow-up |
| Variable | Beta | Standard error | Significance (p value) |
| toeC | −0.197 | 0.058 | 0.001 |
| lead + 1 | 0.060 | 0.018 | 0.001 |
| toeP-maxE | −0.010 | 0.004 | 0.014 |
| kneeF | −0.349 | 0.107 | 0.001 |
| heelC | 0.123 | 0.047 | 0.009 |
| Total (n = 149) | |
| Mean age ± SD, range | 38.95 ± 11.48, 20-77 |
| Years in the US ± SD | 10.24 ± 10.12 |
| Years in Baltimore ± SD | 7.56 ± 9.09 |
| Gender | |
| Female | (98) 65.7% |
| Male | (51) 34.3% |
| Latin American Region | |
| Mexican | (38) 25.5% |
| Central American | (87) 58.4% |
| South American | (24) 16.1% |
| Education (n = 146) | |
| None | (8) 5.48% |
| Less than 8 years | (80) 54.79% |
| Some High School | (19) 13.01% |
| High School Graduate | (15) 10.27% |
| Some College | (16) 10.96% |
| Completed college or | |
| higher | (8) 5.48% |
| Food security | |
| No food insecurity | (74) 49.66% |
| Some risk for food | |
| insecurity | (15) 10.07% |
| Moderate food insecurity at the household level | (31) 20.81% |
| Food insecure with some hunger at the household level | (29) 19.46% |
| BMI <30 kg/m2 | (89) 59.73% |
| BMI >30 kg/m2 | (60) 40.27% |
| Substance | No. of cases | Percentage |
| Hydrofluoric acid | 135 | 27.44 |
| Sulfuric acid | 115 | 23.37 |
| Mixed acid | 41 | 8.33 |
| Sodium (potassium) hydroxide | 33 | 6.71 |
| Nitric acid | 31 | 6.30 |
| Hydrochloric acid | 27 | 5.49 |
| Lye | 18 | 3.66 |
| Phenol | 14 | 2.85 |
| Calcium oxide | 11 | 2.24 |
| Bromine | 10 | 2.03 |
| Bitumen | 8 | 1.63 |
| Acetic acid | 7 | 1.42 |
| Liquid ammonia | 7 | 1.42 |
| Aromatic amino and nitro compounds | 6 | 1.22 |
| Dimethyl sulfate | 5 | 1.02 |
| m-cresol | 4 | 0.81 |
| Yellow phosphorous | 4 | 0.81 |
| Others | 16 | 3.25 |
| Total Group (n = 1526) 1 | 10–11 Months (n = 31) | 1 Year (n = 411) | 2 Years (n = 497) | 3 Years (n = 410) | ||||||
| Food Group | Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD |
| Potatoes | 29 | 27 | 25 | 25 | 31 | 28 | 28 | 27 | 28 | 26 |
| Vegetables | 58 | 39 | 48 | 45 | 60 | 41 | 58 | 39 | 61 | 38 |
| Fruit | 128 | 59 | 129 | 66 | 127 | 58 | 129 | 59 | 130 | 61 |
| Legumes | 1 | 7 | 1 | 4 | 2 | 9 | 1 | 6 | 1 | 6 |
| Bread | 100 | 35 | 57 | 29 | 86 | 33 | 103 | 33 | 114 | 33 |
| Cereals (including rice and pasta) | 29 | 29 | 21 | 26 | 30 | 30 | 28 | 28 | 30 | 28 |
| Cakes and biscuits | 13 | 12 | 6 | 8 | 11 | 10 | 14 | 12 | 16 | 13 |
| Nuts, seeds, savory snacks | 1 | 5 | 0 | 0 | 1 | 3 | 1 | 5 | 2 | 6 |
| Milk and milk products | 358 | 158 | 176 | 217 | 333 | 162 | 363 | 143 | 383 | 147 |
| Follow-on and young children’s formula | 63 | 135 | 411 | 226 | 111 | 162 | 35 | 87 | 15 | 61 |
| Cheese | 14 | 11 | 14 | 10 | 15 | 11 | 14 | 11 | 15 | 12 |
| Eggs | 3 | 8 | 1 | 4 | 2 | 7 | 3 | 8 | 3 | 8 |
| Fish | 5 | 12 | 2 | 7 | 5 | 12 | 5 | 12 | 6 | 13 |
| Meat, meat products, poultry | 44 | 25 | 24 | 23 | 40 | 24 | 44 | 22 | 49 | 26 |
| Soy and vegetarian products | 8 | 49 | 0 | 2 | 8 | 54 | 8 | 47 | 10 | 55 |
| Savory spreads | 4 | 6 | 0 | 0 | 3 | 6 | 4 | 6 | 4 | 7 |
| Mixed dishes | 20 | 45 | 52 | 78 | 28 | 53 | 15 | 39 | 14 | 35 |
| Soups | 10 | 33 | 0 | 1 | 6 | 23 | 12 | 37 | 13 | 39 |
| Sugar, confectionary, sweet spreads | 18 | 13 | 6 | 7 | 13 | 10 | 20 | 12 | 23 | 14 |
| Fat spreads, oils, savory sauces | 24 | 11 | 11 | 8 | 20 | 10 | 24 | 11 | 27 | 12 |
| Non-alcoholic beverages (excluding milk products) | 427 | 222 | 182 | 145 | 367 | 204 | 446 | 209 | 508 | 220 |
| Variable | |
| Sex [no. (%)] n = 634 | |
| Female | 388 (61.2) |
| Age [mean: years (SD)] n = 634 | 56.30 (13.95) |
| Nationality [no. (%)] n = 619 | |
| German | 610 (98.5) |
| Other | 9 (1.5) |
| Marital status [no. (%)] n = 634 | |
| Single | 82 (12.9) |
| Married | 415 (65.5) |
| Divorced | 80 (12.6) |
| Widowed | 57 (9.0) |
| Living with a partner [no. (%)] n = 611 | 477 (78.1) |
| Persons at household [no. (%)] n = 605 | |
| 1 person | 87 (14.4) |
| 2 persons | 297 (49.1) |
| 3 persons | 114 (18.8) |
| 4 persons | 74 (12.2) |
| > 4 persons | 33 (5.4) |
| Level and years of education [no. (%)] n = 632 | |
| 13/12 years | 100 (15.8) |
| 10 years | 191 (30.2) |
| 9 years | 322 (50.9) |
| Other graduation | 15 (2.4) |
| No qualification | 4 (0.6) |
| Employment status [no. (%)] n = 631 | |
| Working (full or part-time) | 322 (51.0) |
| Reasons for not working [no. (%)] n = 306 | |
| Keeping house | 48 (15.7) |
| Retired | 228 (74.6) |
| Unemployed | 27 (8.8) |
| Other | 3 (1.0) |
| First time of back pain [no (%)] n = 634 | |
| Since < 1 year | 77 (12.2) |
| Since 1-2 years | 47 (7.4) |
| Since 2-5 years | 86 (13.6) |
| Since 5-10 years | 92 (14.5) |
| Since > 10 years | 332 (52.4) |
| Group | No of casesa(Females) | Age (years) median; 80% CRb | Marsh grade span | Anti-TG2 (U/mL)cmedian; 80% CR | Anti-DGP (U/mL)dmedian; 80% CR | Anti-GL (U/mL)emedian; 80% CR |
| Not CD | 14 (8) | 8.8; 2.2-16 | Marsh 0-1 | 0.25; 0.05-11 | 0.95; 0.20-20 | 0.60; 0.10-2.4 |
| Normalized CDf | 15 (13) | 12; 7.3-17 | Marsh 0-1 | 3.4; 0.40-28 | 2.6; 1.2-9.3 | 0.80; 0.20-4.1 |
| Active CDg | 20 (12) | 5.9; 1.5-14 | Marsh 2-3C | 201; 4.4-1997 | 64; 5.6-392 | 16; 2.4-167 |
| Under investigationh | 3 (3) | 15; 12-16 | Marsh 0-1 | 15; 10-16 | 7.1; 2.1-22 | 1.9; 0.50-6.5 |
| Sample Name | N-Call stretch lengths (bp) | Mutation found by conventional sequencing | |
| *GSEQ | *sPROFILER | ||
| mtDNA1 | 5, 6, 9, 13 | 4, 5 | 1 point mutation (in 5 base stretch) |
| mtDNA2 | 5, 6, 12 | 4, 5, 6 | 1 point mutation (in 6 base stretch) |
| mtDNA3 | 5, 6, 7, 11 | 4, 10 | 1 point mutation, 1 insertion (in 10 base stretch) |
| mtDNA4 | 5, 6, 11 | 4, 5 | 1 insertion (in 5 base stretch) |
| mtDNA5 | 5, 13 | 4, 5 | 1 insertion (in 5 base stretch) |
| mtDNA6 | 5, 7, 11 | 4, 5, 11 | 1 point mutation, 1 insertion (in 11 base stretch) |
| mtDNA7 | 5, 10 | 4 | Entire mtDNA sequenced: 1 point mutation(in 4 N-call stretch) |
| mtDNA8 | 5, 6, 8, 9, 10, 11, 14, 18, 20 | 4, 5, 6, 8, 10,18, 20 | 1 point mutation (in 20 base stretch)2 point mutations (in 18 base stretch)1 point mutation (in 10 base stretch) |
| mtDNA9 | 5, 6, 9, 11, 12 | 4, 5, 8 | 2 insertions (in 8 base stretch) |
| mtDNA10 | 5, 7, 8, 9, 10 | 4, 5, 7, 9 | 1 point mutation (in 9 base stretch) |
| mtDNA11 | 5, 6, 8, 9, 12 | 4, 5, 8 | 1 point mutation (in 8 base stretch) |
| mtDNA12 | 5, 9, 10 | 4, 9 | 1 insertion (in 9 base stretch) |
| mtDNA13 | 5, 7, 8, 9, 10 | 4, 5, 9 | 1 point mutation (in 9 base stretch) |
| mtDNA14 | 5, 8, 10 | 4, 5 | No point mutation or indel (in 5 base stretch) |
| mtDNA15 | 5, 6, 7, 11 | 4, 5 | No point mutation or indel (in 5 base stretch) |
| mtDNA16 | 5, 7, 8, 10, 11 | 4, 6 | No point mutation or indel (in 6 base stretch) |
| Country | VTE patients % | General healthy population % | References |
| Lebanon | 19.2 | 1.3–3.6 | 94–99 |
| Palestine | --- | 6.5–11.7 | 74,100 |
| Egypt | 23.75 | 3.33 | 101 |
| Tunisia | 3.2 | 0–7.4 | 74,79–99,102–105 |
| Libya | --- | 2.2 | 74 |
| Algeria | 6.0 | 1.8 | 106 |
| Morocco | --- | 2.4–5.5 | 74,107–109 |
| Spain | 2.7–17.2 | 2.9–6.5 | 31–35 |
| France | 4.6 | 1.0–3.1 | 36–39 |
| Italy | 4.3–15.9 | 2.3–5.7 | 40–47 |
| Slovenia | 5.8–11.3 | 3.1–4.8 | 48,49 |
| Croatia | 8.0–8.3 | 2.5–4.0 | 50–53 |
| Serbia | 11.4 | 2.3–6.0 | 54–56 |
| Greece | 6.8–10.1 | 2.0–2.7 | 57–61 |
| Turkey | 4.0–10.5 | 0.7–8.0 | 62–65 |
| Cyprus | --- | 2.0–7.8 | 66,67 |
| Serum resistin level (ng/ml) | ||||||
| 1.5-6.7 | 6.8-8.7 | 8.8-11.5 | 11.6-16.2 | 16.3-90.2 | P value for trend | |
| No cardiovascular disease, n | 628 | 610 | 604 | 595 | 589 | |
| Cardiovascular disease, n | 20 | 23 | 37 | 41 | 54 | |
| Model 1-adjusted OR (95% CI) | 1(referent) | 0.95(0.51-1.76) | 1.55(0.88-2.74) | 1.51(0.86-2.64) | 1.64(0.95-2.84) | 0.02 |
| Model 2-adjusted OR (95% CI) | 1(referent) | 0.88(0.47-1.66) | 1.56(0.88-2.77) | 1.39(0.79-2.45) | 1.52(0.87-2.66) | 0.04 |
| Model 3-adjusted OR (95% CI) | 1(referent) | 0.87(0.46-1.63) | 1.53(0.86-2.72) | 1.36(0.77-2.41) | 1.47(0.84-2.58) | 0.06 |
| Ischemic stroke, n | 4 | 11 | 17 | 25 | 33 | |
| Model 1-adjusted OR (95% CI) | 1(referent) | 2.21(0.70-7.05) | 3.54(1.17-10.67) | 4.48(1.53-13.09) | 4.70(1.62-13.61) | < 0.001 |
| Model 2-adjusted OR (95% CI) | 1(referent) | 1.94(0.60-6.23) | 3.36(1.11-10.22) | 3.87(1.31-11.39) | 3.97(1.36-11.61) | 0.002 |
| Model 3-adjusted OR (95% CI) | 1(referent) | 1.84(0.57-5.96) | 3.26(1.07-9.92) | 3.66(1.24-10.79) | 3.59(1.22-10.55) | 0.006 |
| Hemorrhagic stroke, n | 9 | 7 | 9 | 7 | 11 | |
| Model 1-adjusted OR (95% CI) | 1(referent) | 0.70(0.26-1.92) | 0.93(0.36-2.37) | 0.66(0.24-1.80) | 0.89(0.36-2.23) | 0.83 |
| Model 2-adjusted OR (95% CI) | 1(referent) | 0.70(0.26-1.92) | 1.02(0.39-2.64) | 0.70(0.25-1.93) | 0.98(0.38-2.50) | 0.99 |
| Model 3-adjusted OR (95% CI) | 1(referent) | 0.69(0.25-1.90) | 1.00(0.39-2.60) | 0.69(0.25-1.90) | 0.96(0.37-2.46) | 0.97 |
| Coronary heart disease, n | 9 | 6 | 12 | 11 | 17 | |
| Model 1-adjusted OR (95% CI) | 1(referent) | 0.55(0.19-1.57) | 1.13(0.47-2.73) | 0.88(0.36-2.18) | 1.11(0.48-2.59) | 0.48 |
| Model 2-adjusted OR (95% CI) | 1(referent) | 0.48(0.16-1.41) | 1.20(0.49-2.95) | 0.79(0.31-1.99) | 1.05(0.44-2.50) | 0.53 |
| Model 3-adjusted OR (95% CI) | 1(referent) | 0.49(0.17-1.42) | 1.21(0.49-2.97) | 0.80(0.32-2.02) | 1.09(0.45-2.59) | 0.49 |
| Spot No. | Protein Identity | Symbol | MW (kDa) |
| 1 | Aldehyde dehydrogenase,mitochondrial precursor | Aldh2 | 56 |
| 2 | Protein disulfide-isomerase A3precursor | Pdia3/ERP57 | 57 |
| 3 | Proteasome subunit alpha type 6 | Psma6 | 27 |
| 4 | Peptidyl-prolyl cis-transisomerase A | Ppia/CYPA | 17 |
| DMC | DMR | CG | |||||||
| CN | SPE | MNE | CN | SPE | MNE | CN | SPE | MNE | |
| Proposed | 5,593.9 | 0.958 | 0.039 | 5,305.3 | 0.939 | 0.055 | 4,893.2 | 0.942 | 0.054 |
| SMETANA | 5,164.5 | 0.926 | 0.068 | 4,900.6 | 0.916 | 0.078 | 4,846.2 | 0.949 | 0.048 |
| BEAMS | 5,076.5 | 0.826 | 0.150 | 5,176.7 | 0.840 | 0.138 | 5,441.2 | 0.870 | 0.112 |
| PINALOG | 3,779 | 0.726 | 0.274 | 3,533.4 | 0.683 | 0.317 | 4,325 | 0.788 | 0.212 |
| IsoRankN | 3,816.5 | 0.827 | 0.163 | 3,905.2 | 0.836 | 0.155 | 3,863.2 | 0.832 | 0.159 |
| Line | Wt (g) | Temperature measures | Observation measures | SqX | Rise | SG | TIS | D/U | ||
| Preax (°C) | Postax (°C) | Preamb (°C) | Postamb (°C) | |||||||
| High | 19.6 | 35.2 | 33.8 | 21.3 | 21.5 | 1.1 | 0.1 | 0.2 | 0.5 | 0.1 |
| SEM | 0.83 | 0.35 | 0.16 | 0.22 | 0.25 | 0.29 | 0.05 | 0.08 | 0.14 | 0.07 |
| Rand | 22.1 | 36.1 | 33.6 | 21.3 | 21.3 | 3.4 | 0.6 | 0.9 | 0.64 | 0.4 |
| SEM | 0.9 | 0.13 | 0.19 | 0.11 | 0.31 | 1.6 | 0.29 | 0.36 | 0.34 | 0.16 |
| Low | 18.8 | 35.5 | 34.0 | 21.3 | 21.5 | 1.1 | 0.1 | 0.2 | 0.3 | 0.0 |
| SEM | 0.99 | 0.19 | 0.26 | 0.22 | 0.28 | 0.36 | 0.08 | 0.11 | 0.14 | 0.00 |
| F | 3.06 | 2.77 | 0.88 | 0.04 | 0.10 | 2.64 | 4.20 | 4.54 | 0.55 | 5.43 |
| P | 0.066 | 0.083 | ns | ns | ns | 0.092 | 0.027 | 0.021 | ns | 0.011 |
| Bonf results | R > H* | R > H* | R > Ht | |||||||
| R > Lt | R > Lt | R > L** |
| Criteria | Conventional | Sutureless |
| Operation duration | Longer | Shorter |
| Blood less during operation | More probable | Less probable |
| Safe and reliable | Less probable | More probable |
| Resistance of anastomosis (mechanical and pressure testing) | Less probable | More probable |
| Operative and post-operative complications | More probable | Less probable |
| Stress of surgeon and patient | More | Less |
| Reduce the cost of treatment | More | Less |
| Institution | Checklists | ||||||
| Step 1 | Step 2 | Step 3 | Step 4 | Step 5 | Step 6 | Step 7 | |
| A | 4 | 1 | 2 | 2 | |||
| B | 3 | 1 | 2 | 5 | |||
| C | 1 | 2 | 1 | ||||
| D | 1 | 1 | 2 | 1 | 2 | 2 | 4 |
| E | 3 | 4 | 3 | 3 | |||
| F | 3 | ||||||
| G | 2 | 2 | 2 | 2 | 4 | 4 | 5 |
| Total number of failure cases at each checklist | 3 | 3 | 15 | 6 | 11 | 13 | 23 |
| No | Preparation | Dosage from | Trade name / Manufacturer | Dissolution time (mins, n=3) | |
| pH 1.2 | pH 5.8 | ||||
| 1 | Ferrous sulphate | Tablet | NAAlmus | 48 ± 4 | 362 ± 16 |
| 2 | Ferrous fumarate | Tablet | FersamalGoldshield | 57 ± 6 | 85 ± 9 |
| 3 | Ferrous gluconate | Tablet | NAZanza | 64 ± 4 | 208 ± 12 |
| 4 | Ferrous sulphate plus ascorbic acid | Controlled release tablet | Ferrograd CTeopharma | 256 ± 8 | – |
| 5 | Ferrous fumarate plus minerals and vitamins | Sustained release capsule | Ferroglobin B12Vitabiotics | 274 ± 8 | 388 ± 11 |
| Multiple Sexual Partners | Paying Sex | |||
| n | % | n | % | |
| Used condom | 384 | 33.9 | 469 | 58.5 |
| Did not use condom | 748 | 66.1 | 333 | 41.5 |
| miRNA | Fold change (cytokine versus normal group) | p value |
| hsa-miR-665 | 4.64 | 0.01 |
| hsa-miR-146b-5p | 4.13 | 0.04 |
| hsa-miR-155-5p | 4.00 | <0.01 |
| hsa-miR-19b-3p | 2.10 | 0.01 |
| hsa-miR-543 | 2.02 | 0.01 |
| hsa-miR-4430 | 0.49 | 0.03 |
| hsa-mir-4530 | 0.47 | 0.01 |
| hsa-miR-6847-5p | 0.44 | 0.02 |
| hsa-miR-4497 | 0.42 | 0.02 |
| hsa-miR-4732-5p | 0.40 | 0.02 |
| hsa-miR-4640-5p | 0.34 | 0.02 |
| hsa-miR-6886-5p | 0.33 | 0.02 |
| hsa-miR-3177-3p | 0.32 | <0.01 |
| hsa-miR-601 | 0.27 | 0.02 |
| hsa-miR-4271 | 0.18 | <0.01 |
| Items | 1) Basic science content objectives were made clear to students | 2) Basic science content was sufficiently integrated across basic science courses | 3) Basic science content objectives and examination content matched closely | 4) Basic science content had sufficient illustrations of clinical relevance | 5) Basic science content provided relevant preparation for clerkships | |
| % of agree | TC | 57.9 | 37.9 | 56.6 | 43.4 | 65.5 |
| RC | 78.8 | 72.7 | 81.8 | 69.7 | 72.7 | |
| TC | Mean | 3.48 | 3.20 | 3.46 | 3.26 | 3.64 |
| SD | 0.973 | 0.925 | 0.936 | 0.993 | 0.926 | |
| RC | Mean | 4.03 | 3.91 | 4.03 | 3.85 | 3.91 |
| SD | 0.770 | 0.843 | 0.728 | 0.906 | 0.843 | |
| U (p) | *1,657.5 (0.003) | *1,401.5 (<0.0001) | *1,587.5(0.001) | *1,616.5(0.002) | 2,041.0(0.153) | |
| Cohen’s d | −0.627 | −0.802 | −0.680 | −0.621 | −0.305 |
| Reported Adverse event | No of related AEs (no. of patients) | CTCAE-grade (range) |
| Fever | 8 (5) | 1–2 |
| Chills | 2 (2) | 1 |
| Rash | 1 (1) | 1 |
| Hypotension | 1 (1) | 2 |
| +20% Fat group (N = 14) | −20% Fat group (N = 17) | |||||
| Pre | Post | P value | Pre | Post | P value | |
| Height (m) | 1.76 ± 0.01 | 1.76 ± 0.01 | — | 1.74 ± 0.02 | 1.74 ± 0.02 | — |
| Mass (kg) | 78.1 ± 2.7 | 78.0 ± 3.0 | .665 | 65.8 ± 2.4 | 66.7 ± 2.4 | .007* |
| BMI (m/kg) | 25.4 ± 0.9 | 25.3 ± 1.0 | .664 | 21.3 ± 0.8 | 21.6 ± 0.9 | .007* |
| LTM (kg) | 56.4 ± 1.7 | 57.1 ± 1.7 | .027* | 56.3 ± 1.5 | 57.1 ± 1.5 | .014* |
| FM (kg) | 23.4 ± 2.4 | 22.71 ± 2.4 | .02* | 6.7 ± 0.9 | 7.0 ± 1.0 | .143 |
| % Total Body Fat | 28.6 ± 1.5 | 27.7 ± 1.6 | .009* | 10.1 ± 1.1 | 10.4 ± 1.1 | .269 |
| % Fat Trunk | 33.7 ± 1.3 | 32.2 ± 1.4 | .001* | 11.8 ± 1.5 | 12.1 ± 1.5 | .299 |
| % Fat ARM | 22.3 ± 2.4 | 22.0 ± 2.4 | .619 | 6.6 ± 0.8 | 6.8 ± 1.1 | .757 |
| % FatLEG | 24.3 ± 2.7 | 24.0 ± 2.8 | .269 | 9.7 ± 1.2 | 9.3 ± 0.9 | .578 |
| LTM ARM (kg) | 6.9 ± 0.3 | 6.9 ± 0.3 | .746 | 6.8 ± 0.3 | 6.9 ± 0.3 | .189 |
| LTM LEG (kg) | 18.4±.0.6 | 18.6 ± 0.6 | .660 | 18.5 ± 0.7 | 19.1 ± 0.8 | .014* |
| LTM TRK (kg) | 27.3 ± 1.1 | 27.8 ± 0.9 | .268 | 27.0 ± 0.8 | 27.0 ± 0.7 | .898 |
| No. | Gene ID | P-value | Fold difference (sensitive vs resistant) | Fold difference (description) |
| 1 | SLC1A4 | 0.00004 | 2.695 | Sensitive up vs resistant |
| 2 | NEK3 | 0.00006 | −2.544 | Sensitive down vs resistant |
| 3 | GLA | 0.00007 | 2.073 | Sensitive up vs resistant |
| 4 | AKNA | 0.00020 | 4.043 | Sensitive up vs resistant |
| 5 | ARHGAP27 | 0.00035 | 3.599 | Sensitive up vs resistant |
| 6 | LY96 | 0.00045 | 3.796 | Sensitive up vs resistant |
| 7 | DLST | 0.00070 | −2.001 | Sensitive down vs resistant |
| 8 | MSL3 | 0.00132 | 2.237 | Sensitive up vs resistant |
| 9 | SQRDL | 0.00134 | 3.906 | Sensitive up vs resistant |
| 10 | NCAPH2 | 0.00206 | 2.129 | Sensitive up vs resistant |
| 11 | PLK1S1 | 0.00262 | −2.035 | Sensitive down vs resistant |
| 12 | MRI1 | 0.00284 | 2.448 | Sensitive up vs resistant |
| 13 | TARS2 | 0.00294 | −2.083 | Sensitive down vs resistant |
| 14 | OBFC2A | 0.00307 | 3.756 | Sensitive up vs resistant |
| 15 | RAB8A | 0.00319 | 2.097 | Sensitive up vs resistant |
| 16 | ABHD2 | 0.00363 | 2.475 | Sensitive up vs resistant |
| 17 | LMF2 | 0.00364 | 2.558 | Sensitive up vs resistant |
| 18 | C6orf48 | 0.00367 | −2.462 | Sensitive down vs resistant |
| 19 | TUBA4A | 0.00400 | 2.189 | Sensitive up vs resistant |
| 20 | HSPA1B | 0.00467 | −2.335 | Sensitive down vs resistant |
| 21 | TFEB | 0.00471 | −2.302 | Sensitive down vs resistant |
| 22 | RNF170 | 0.00504 | −2.34 | Sensitive down vs resistant |
| 23 | SOX12 | 0.00569 | −2.281 | Sensitive down vs resistant |
| 24 | ZNFX1-AS1 | 0.00604 | −2.482 | Sensitive down vs resistant |
| 25 | C2orf69 | 0.00622 | 2.038 | Sensitive up vs resistant |
| 26 | PTPN18 | 0.00634 | 2.635 | Sensitive up vs resistant |
| 27 | PRKD2 | 0.00641 | 3.5 | Sensitive up vs resistant |
| 28 | KHK | 0.00662 | 2.484 | Sensitive up vs resistant |
| 29 | PAQR6 | 0.00710 | −3.645 | Sensitive down vs resistant |
| 30 | HIST1H2BD | 0.00763 | −4.514 | Sensitive down vs resistant |
| 31 | CERK | 0.00776 | 2.481 | Sensitive up vs resistant |
| 32 | UBE2K | 0.00806 | −2.048 | Sensitive down vs resistant |
| 33 | LYSMD1 | 0.00814 | −2.379 | Sensitive down vs resistant |
| 34 | GPSM3 | 0.00832 | 5.309 | Sensitive up vs resistant |
| 35 | MNAT1 | 0.00906 | −2.144 | Sensitive down vs resistant |
| 36 | WFS1 | 0.00911 | 2.397 | Sensitive up vs resistant |
| 37 | MYH9 | 0.00923 | 2.011 | Sensitive up vs resistant |
| 38 | CYTIP | 0.00925 | 2.855 | Sensitive up vs resistant |
| 39 | SVIP | 0.00928 | 2.148 | Sensitive up vs resistant |
| 40 | ARSA | 0.00931 | 3.3 | Sensitive up vs resistant |
| 41 | SFMBT2 | 0.00947 | 2.111 | Sensitive up vs resistant |
| 42 | POLR3GL | 0.00958 | −2.251 | Sensitive down vs resistant |
| Sample no. | Number of subjects | RhD | RhCcEe | RHD zygosity* | RHD allele | ||
| Micro-plate | IAT | Adsorption/elute | |||||
| 13001-13030 | 30 | – | – | + | Ccee | RHD+/RHD- | RHD1227A |
| 13031-13033 | 3 | – | – | + | CCee | RHD+/RHD- | RHD1227A |
| 13034-13035 | 2 | – | – | + | Ccee | RHD+/RHD+ | RHD1227A |
| 13036 | 1 | – | – | + | CCEe | RHD+/RHD- | RHD1227A |
| 13037 | 1 | – | – | + | CcEe | RHD+/RHD- | RHD1227A |
| 13038 | 1 | – | – | + | Ccee | RHD+/RHD- | RHD-CE (2-5)-D |
| 13039 | 1 | – | – | + | Ccee | RHD+/RHD- | RHD-CE (4-7)-D |
| 13040 | 1 | – | – | + | Ccee | RHD+/RHD+ | RHD93T>A |
| 13041 | 1 | – | – | + | Ccee | RHD+/RHD- | RHD838G>A |
| Trial number andaverage error | User 1 | User 2 | User 3 | User 4 | User 5 | User 6 | User 7 | User 8 | User 9 | User 10 |
| 1st trial | 0.59 | 0.46 | 0.76 | 0.51 | 0.82 | 0.78 | 0.56 | 0.84 | 0.93 | 0.72 |
| 2nd trial | 0.66 | 0.65 | 0.47 | 0.60 | 0.79 | 0.77 | 0.68 | 0.85 | 0.90 | 0.90 |
| 3rd trial | 0.84 | 0.55 | 0.53 | 0.74 | 0.58 | 0.66 | 0.74 | 0.32 | 0.67 | 0.84 |
| 4th trial | 0.64 | 0.87 | 0.69 | 0.57 | 0.82 | 0.75 | 0.74 | 0.87 | 0.76 | 1.00 |
| 5th trial | 0.66 | 0.53 | 0.61 | 0.59 | 0.92 | 0.52 | 0.98 | 0.86 | 0.43 | 0.51 |
| Average | 0.68 | 0.61 | 0.61 | 0.60 | 0.79 | 0.70 | 0.74 | 0.75 | 0.74 | 0.79 |
| Total average error of 10 users | 0.70 |
| Method | Week 4 | Week 5 | ||||
| Positive/total | Specificity (%) | Sensitivity (%) | Positive/total | Specificity (%) | Sensitivity (%) | |
| FIU | 18/53 | 72.3 | 83.3 | 12/53 | 83.3 | 80 |
| CM | 13/53 | 81 | 66.6 | 7/53 | 91.7 | 60 |
| FIU+CM | 8/53 | 91.5 | 66.6 | 6/53 | 93.8 | 60 |
| Incremental # sub-types | P-valuesa | |
| mRNA | Methylation | |
| 3 vs 2 | 0.02 | <0.01 |
| 4 vs 3 | 0.06 | 0.04 |
| 5 vs 4 | 0.41 | <0.01 |
| Proteins | Bonds determined by different methods | |||
| Known Linkages | MS2DB+ | SVM | CSP | |
| ST8Sia IV | 142-292 | 142-292 | 142-292 | 142-292 |
| 156-356 | 156-356 | 156-356 | 156-356 | |
| Beta-LG | 82-176 | 82-176 | - | - |
| 122-135 | - | 122-135 | 122-135 | |
| - | 137-176 | 137-176 | ||
| FucT VII | 68-76 | 68-76 | 68-76 | 68-76 |
| 211-214 | 211-214 | 211-214 | 211-214 | |
| 318-321 | 318-321 | 318-321 | 318-321 | |
| Β1,4-GalT | 134-176 | 134-176 | - | 134-176 |
| 247-266 | 247-266 | - | 247-266 | |
| - | 134-247 | - | ||
| C2GnT-I | 59-413 | 59-413 | - | - |
| 372-381 | 372-381 | 372-381 | - | |
| 100-172 | - | 100-172 | - | |
| 151-199 | 151-199 | - | - | |
| - | 199-235 | - | ||
| - | - | 151-217 | ||
| - | - | 172-199 | ||
| - | - | 59-100 | ||
| Lysozyme | 24-145 | 24-145 | 24-145 | - |
| 48-133 | 48-133 | - | - | |
| - | - | 82-98 | ||
| - | - | 94-112 | ||
| FT III | 81-338 | 81-338 | - | - |
| 91-341 | - | - | - | |
| - | 81-91 | 81-91 | ||
| - | 338-341 | 338-341 |
| Variable | All NEETs Included | Economically Inactive NEETs Excluded |
| OR (95% CI) | OR (95% CI) | |
| UNIVARIATEc | ||
| NEET | ||
| No | 1.00* | 1.00 |
| Yes | 0.73 (0.59–0.90) | 0.90 (0.69–1.19) |
| FULLY ADJUSTEDc | ||
| NEET | ||
| No | 1.00* | 1.00 |
| Yes | 0.71 (0.56–0.91) | 0.91 (0.68–1.22) |
| Sex | ||
| Male | 0.71 (0.60–0.85) | 0.69 (0.58–0.82) |
| Female | 1.00** | 1.00** |
| Ethnicity | ||
| White UK & Irish | 1.00** | 1.00** |
| Other (incl. gypsy/traveller) | 0.43 (0.33–0.56) | 0.41 (0.31–0.54) |
| Access to car/van | ||
| Yes | 1.00* | 1.00* |
| No | 1.24 (1.03–1.49) | 1.29 (1.06–1.56) |
| Marital status | ||
| Married/cohabiting | 0.65 (0.53–0.80) | 0.67 (0.54–0.83) |
| Other (incl. single/separated/divorced) | 1.00** | 1.00** |
| Receipt of means-tested benefits | ||
| No | 1.00* | 1.00* |
| Yes | 0.80 (0.67–0.95) | 0.80 (0.67–0.96) |
| NSSEC | ||
| Managerial & professional | 1.00* | 1.00* |
| Intermediate | 1.06 (0.78–1.45) | 1.07 (0.78–1.46) |
| Routine & manual | 1.40 (1.08–1.83) | 1.40 (1.07–1.84) |
| Other or never worked/long-term unemployed | 1.13 (0.80–1.61) | 1.18 (0.82–1.70) |
| Group | Dose (mg/kg) | AST (IU/l) | ALT (IU/l) |
| Vehicle | – | 48.65 ± 6.78** | 28.59 ± 3.15** |
| Model | – | 124.37 ± 10.35 | 75.16 ± 5.79 |
| Silibinin | 100 | 85.94 ± 5.63* | 50.19 ± 4.29* |
| LAE | 50 | 65.38 ± 4.59** | 45.31 ± 6.12* |
| 100 | 60.79 ± 6.96** | 38.33 ± 5.11** | |
| 200 | 56.88 ± 5.61** | 36.99 ± 4.77** |
| Parameters | 5-year PFS | P value b | 5-year OS | P value b |
| SUVmax a | 0.494 | 0.282 | ||
| Low | 73% | 90% | ||
| High | 57% | 72% | ||
| MTV a | <0.001 | <0.001 | ||
| Low | 88% | 98% | ||
| High | 37% | 60% | ||
| TLG a | <0.001 | <0.001 | ||
| Low | 83% | 92% | ||
| High | 34% | 67% | ||
| NCCN-IPI score | 0.039 | 0.036 | ||
| 0-3 | 76% | 92% | ||
| 4-8 | 51% | 71% | ||
| Ann Arbor stage | 0.02 | 0.046 | ||
| I/II | 82% | 94% | ||
| III/IV | 56% | 76% | ||
| B symptoms | <0.001 | 0.027 | ||
| No | 86% | 93% | ||
| Yes | 46% | 70% | ||
| LDH level | 0.013 | 0.015 | ||
| normal | 77% | 88% | ||
| elevated | 48% | 73% | ||
| Subtype | 0.761 | 0.762 | ||
| GCB | 74% | 88% | ||
| non-GCB | 65% | 80% |
| All (N = 104) | PST (n = 55) | WL (n = 49) | Statistic | |
| Age in years (SD) | 37.6 (10.8) | 33.7 (10.7) | 42.1 (9.2) | t(102) = −4.81, p < .001 |
| Female | 73 (70.2) | 48 (87.3) | 25 (51.0) | χ2(1) = 16.27, p < .001 |
| Education* | ||||
| -lower | 7 (6.7) | 4 (7.3) | 3 (6.1) | χ2(2) = 8,62, p = .01 |
| -middle | 51 (49.0) | 34 (61.8) | 17 (34.7) | |
| -higher | 46 (44.2) | 17 (30.9) | 29 (59.2) |
| Grouping variable | Variance | F-value | P-value |
| Year | 0.73 | 37.86 | <0.001 |
| Farmland type | 0.08 | 4.27 | 0.001 |
| Year: Farmland type | 0.13 | 6.48 | <0.001 |
| Health facility indicators | DRH | HFSUH | KGH | Over all |
| Percentage in stock of key drugs | 12(80.0%)a | 6(40.0%)a | 11(73.3%)a | 20(66.7%) |
| % of drugs with adequate recording | 11(73.3%) a | 0a | 12(80.0%)a | 19(63.3) |
| Average number of stock out days during the year for adequately recorded drugs | 9.78 | __ | 35a | 30 |
| Percentage of Expired drug | 0 | 7(46.7%)a | 6(40.0%)a | 8(26.7%)a |
| Sociodemographic and clinical variablesa | Patients with TRD (n=12) | Comparison participants (n=10) | Statisticb | P-value |
| Age, years: mean (s.d.) | 59.17 (8.02) | 54.4 (8.37) | −1.454 | 0.159 |
| Gender, male: n (%) | 6 (50) | 5 (50) | 0 | 1 |
| Education, years: mean (s.d.) | 9.75 (5.91) | 12.44 (3.39) | −1.253 | 0.219 |
| Psychotic symptoms: n (%) | 5 (41.7) | |||
| Comorbid anxiety disorder: n (%) | 3 (25) | |||
| Age at onset, years: mean (s.d.) | 40.58 (19.00) | |||
| Duration of current episode, weeks: mean (s.d.) | 61.75 (134.46) | |||
| Number episodes: mean (s.d.) | 4.08 (2.71) | |||
| HRSD1c: mean (s.d.) | 31.25 (9.21) | |||
| HRSD2: mean (s.d.) | 28.50 (9.52) | |||
| HRSD3: mean (s.d.) | 6.75 (5.17) | |||
| HRSD4: mean (s.d.) | 2.92 (2.54) | |||
| MSM: mean (s.d.) | 9.33 (1.15) | |||
| Drugs: % | ||||
| Antidepressant | 100 | |||
| Antipsychotics | 75 | |||
| Lithium | 16.7 | |||
| Anxiolytics | 50 | |||
| Previous ECT: % | 16.7 |
| Projections | ZF-IDFT | k-t FOCUSS | k-t SLR | k-t RPCA | k-t NCRPCA |
| 8 | 0.3281/7.3112 | 0.7041/16.1893 | 0.8328/16.9640 | 0.7948/17.5719 | 0.8268/17.8084 |
| 12 | 0.4306/8.7548 | 0.8099/17.9173 | 0.8894/18.8529 | 0.8682/20.2187 | 0.8937/20.6879 |
| 16 | 0.4974/9.9446 | 0.8618/19.6515 | 0.9300/20.8879 | 0.9134/21.9271 | 0.9384/22.6999 |
| 24 | 0.5929/11.9903 | 0.9064/21.9681 | 0.9546/23.1806 | 0.9383/23.5353 | 0.9768/25.1972 |
| 32 | 0.6753/13.9492 | 0.9489/24.2931 | 0.9757/25.7613 | 0.9674/25.4710 | 0.9887/27.2034 |
| Clinical characteristics | Total | Minimal ETE | Widely ETE | P value* |
| Patient number | 269 | 175 (65.1) | 94 (34.9) | |
| Gender (female) | 204 (75.8) | 144 (82.3) | 60 (63.8) | 0.0007 |
| Age at diagnosis (year) | 46.8 ± 15.1 | 45.8 ± 13.7 | 48.6 ± 17.2 | 0.1506 |
| Mean tumor size (cm) | 3.0 ± 1.5 | 2.6 ± 1.0 | 3.7 ± 1.9 | 0.0001 |
| Post-operative serum Tg level after 1 month (ng/mL) | 96.2 ± 515.5 | 56.0 ± 187.0 | 172.3 ± 832.3 | 0.0842 |
| Multifocality | 65 (24.2) | 39 (22.3) | 26 (27.6) | 0.3262 |
| Histology variant | 0.1834 | |||
| Follicular variant of papillary | 10 (3.5) | 7 (4.0) | 3 (3.2) | |
| Poorly differentiation | 4 (1.5) | 1 (0.6) | 3 (3.2) | |
| Tall cell | 1 (0.4) | – | 1 (1.1) | |
| Thyroid operative method | 0.1171 | |||
| Total thyroidectomy | 137 (50.9) | 83 (47.4) | 54 (57.4) | |
| Total thyroidectomy with LN dissection | 132 (49.1) | 92 (52.6) | 40 (42.5) | |
| Lymph node metastases | 80 (29.7) | 43 (24.6) | 37 (39.4) | 0.0114 |
| Non-remission | 44 (16.4) | 12 (6.9) | 32 (34.0) | 0.0001 |
| Follow-up period (year) | 13.3 ± 5.5 | 13.5 ± 4.7 | 13.0 ± 6.8 | 0.4733 |
| Post-operative 131I accumulative dose (mCi) | 209.5 ± 253.2 | 157.6 ± 180.5 | 305.9 ± 329.4 | 0.0001 |
| Cancer mortality | 28 (10.4) | 6 (3.4) | 22 (23.4) | 0.0001 |
| Total mortality | 63 (23.4) | 22 (12.6) | 41 (43.6) | 0.0001 |
| Disease free | 89 (33.1) | 71 (40.6) | 18 (19.1) | 0.0004 |
| Second primary cancer | 29 (10.8) | 15 (8.6) | 14 (14.9) | 0.1109 |
| Mortality | 15 (51.7) | 5 (33.3) | 10 (71.4) | 0.0402 |
| Diabetes mellitus | 21 (7.8) | 14 (8.0) | 7 (7.4) | 0.8719 |
| Variable category | Total | EBMT | MEA | p-value* |
| (N = 175) | (N = 59) | (N = 116) | ||
| Gender | (N = 175) | (n = 59) | (n = 116) | |
| Male | (104, 59.4%) | (35, 59.3%) | (69, 59.5%) | 0.98 |
| Female | (71, 40.6%) | (24, 40.7%) | (47, 40.5%) | |
| Age (years) (mean ± SD) | (N = 175) | (n = 59) | (n = 116) | 0.67 |
| (56.6 ± 9.4) | (56.1 ± 9.3) | (56.8 ± 9.5) | ||
| Clinical diagnosis | (N = 175) | (n = 59) | (n = 116) | |
| Early gastric cancer | (40, 22.9%) | (11, 18.6%) | (29, 25.0%) | 0.06 |
| Dysplasia | (19, 10.9%) | (3, 5.1%) | (16, 13.8%) | |
| Peptic ulcer disease | (34, 19.4%) | (17, 28.8%) | (17, 14.7%) | |
| Chronic gastritis | (82, 46.9%) | (28, 47.5%) | (54, 46.6%) | |
| Histological AG in either antrum or body | (N = 116) | (n = 37) | (n = 79) | |
| Yes | (67, 57.8%) | (21, 56.8%) | (46, 68.7%) | 0.88 |
| No | (49, 42.2%) | (16, 43.2%) | (33, 41.8%) | |
| Histological IM in either antrum or body | (N = 144) | (n = 47) | (n = 97) | |
| Yes | (84, 58.3%) | (23, 48.9%) | (61, 62.9%) | 0.11 |
| No | (60, 41.7%) | (24, 51.1%) | (36, 37.1%) |
| Design theory | Definition | Example |
| Accessible design [46] | Provides separate design features for user groups with disabilities Usually permanent and noticeableFulfills code requirements for use by individuals with disabilities | Provide the minimum level of accessibility required by the local building code. This can vary by region (e.g., province or state), and with different building types within the same region. For example, Ontario Building Code requires power door operators (e.g., push button, automatic sensor, etc.) on entrances to hotels, but not on entrances to stand-alone office spaces of less than 300 m2 [47]. |
| Adaptable design [46] | Provides design features that are usable by groups with disabilities, however remain concealed or omitted until neededFeatures are either adjustable or easily and quickly added or removed in order to “adapt” the environment for specific individuals | An electronic push button is provided to open the door, but the use of the push button is optional (i.e., door will open manually). |
| Transgenerational design [48] | Develops products and environments that are compatible with the natural physical and sensory declines experienced during the aging process | Provide a power assist door, which augments the force applied by the user to fully open the door [49]. |
| dissector | sampling | ||||||||||
| base | height | Grid | UGZ | BA | t | ||||||
| Structure quantified (antibody) | OBJ | ssf | (μm × μm) | (μm) | (μm × μm) | (μm) | (μm) | (μm) | ∑OD | ∑Q- | CE |
| Neurofibrillar tangles (AT8) | 60 × | 1/13 | 100 × 100 | 15 | 370 × 370 | 1.5 | 40 | 21.85 | 3296.70 | 394.80 | 0.060 |
| Microglia (Iba1) | 60 × | 1/13 | 70 × 70 | 15 | 860 × 860 | 1.5 | 40 | 24.41 | 767.20 | 1115.40 | 0.030 |
| Macrophage-like structures (Iba1) | 60 × | 1/13 | 70 × 70 | 15 | 860 × 860 | 1.5 | 40 | 24.41 | 767.20 | 96.00 | 0.260 |
| MHCII-positive microglia - frequent (MHCII) | 60 × | 1/13 | 100 × 100 | 15 | 500 × 500 | 1.5 | 40 | 25.60 | 2645.40 | 1861.40 | 0.041 |
| MHCII-positive microglia - sparse (MHCII) | 60 × | 1/13 | 100 × 100 | 15 | 370 × 370 | 1.5 | 40 | 26.54 | 4029.20 | 252.20 | 0.085 |
| Astrocytes (GFAP) | 60 × | 1/13 | 70 × 70 | 15 | 860 × 860 | 1.5 | 40 | 24.66 | 680.19 | 1696.05 | 0.024 |
| Neurons (NeuN) | 60 × | 1/13 | 70 × 70 | 15 | 650 × 650 | 1.5 | 40 | 20.70 | 1243.76 | 1655.81 | 0.047 |
| Group | Survivors of intimate partner violence (n =8) | Women who have not experienced violence (n = 5) | General practitioners (n = 3) |
| Age group | 18-25: 3 | 18-25: 1 | 18-25: 0 |
| 26-50: 4 | 26-50: 4 | 26-50: 2 | |
| 51-74: 1 | 51-74: 0 | 51-74: 1 | |
| Mean age | 36 | 36.6 | 50.6 |
| Number of children | None: 3 | None: 3 | No data |
| One: 2 | One: 0 | ||
| Two: 3 | Two: 2 | ||
| Employment status | Employed 1 | Employed 4 | Employed 3 |
| Unemployed 6 | Unemployed 1 | ||
| Retired 1 | |||
| Ethnicity | Danish 3 | Danish 5 | Danish 3 |
| Other Scandinavian 1 | |||
| Other ethnicity 4 |
| Patient Characteristic | First Line | Supporting Reference |
| Elderly | Lamotrigine or Levetiracetam | [26, 27] |
| Female of reproductive age | Lamotrigine | [25-27] |
| Pregnant | Lamotrigine | [26, 27] |
| Liver failure | Levetiracetam or Lamotrigine or Gabapentina | [26, 27] |
| Renal failure | Lamotrigine or Valproic acidb | [26, 27] |
| Depression | Lamotrigine or Valproic acidb or Oxcarbazepinec | [26, 27] |
| Characteristic | Number (n) or Median (Range) |
| Median age (years) | 22.5 (18–26) |
| Ethnicity (n) | |
| White British | 8 |
| Pakistani British | 1 |
| Indian British | 2 |
| Canadian (various ethnicities) | 4 |
| Gender (n) | |
| Female | 15 |
| Male | 3 |
| Median number of lifetime sexual partners | 3.5 (1–8) |
| Median number of new sexual partners (in last 12 months) | 0 (0–4) |
| Previous self-test use (n) | |
| Had self-tested | 11 |
| Had not self-tested | 7 |
| Previous self-test location (n) | |
| Home | 3 |
| University Students’ Union | 5 |
| Clinic | 3 |
| Data set | P systems | GA | PSO | ACO | k-means |
| AD_5_2 | 326.44 ± 0.0105 | 332.31 ± 0.4792 | 326.44 ± 0.0128 | 326.45 ± 0.0344 | 332.47 ± 3.1286 |
| Data_9_2 | 591.06 ± 0.0280 | 593.72 ± 0.2635 | 591.14 ± 0.0303 | 591.42 ± 0.0372 | 623.57 ± 3.1326 |
| Square_4 | 2379.74 ± 0.0189 | 2380.33 ± 0.6319 | 2379.74 ± 0.0226 | 2379.79 ± 0.0428 | 2386.00 ± 4.5217 |
| Sym_3_22 | 1247.72 ± 0.0105 | 1249.36 ± 1.2163 | 1247.72 ± 0.0149 | 1247.75 ± 0.0315 | 1255.45 ± 3.8725 |
| Iris | 96.75 ± 0.0428 | 99.83 ± 5.5239 | 97.23 ± 0.3513 | 97.25 ± 0.4152 | 104.11 ± 12.4563 |
| BreastCancer | 2970.24 ± 1.1225 | 3249.26 ± 229.734 | 3050.04 ± 110.801 | 3046.06 ± 90.500 | 3251.21 ± 251.143 |
| Newthyroid | 1869.29 ± 0.9215 | 1875.11 ± 13.5834 | 1872.51 ± 11.0923 | 1872.56 ± 11.1045 | 1886.25 ± 16.2189 |
| LungCancer | 124.69 ± 0.0011 | 129.52 ± 4.4961 | 127.23 ± 1.1528 | 127.31 ± 1.2936 | 139.40 ± 7.3136 |
| Wine | 16292.25 ± 0.1529 | 16298.42 ± 2.1523 | 16292.25 ± 0.1531 | 16292.25 ± 0.1672 | 16312.43 ± 9.4269 |
| LiveDisorder | 9851.73 ± 0.0347 | 9856.14 ± 1.9523 | 9851.73 ± 0.0356 | 9851.74 ± 0.0692 | 9868.32 ± 7.9274 |
| Characteristic | Focus groups (N = 5) | Interviews (N = 10) |
| No. participants | n = 20 | n = 10 |
| Mean age (years) | 88.4 (SD ± 5.20) | 88.9 (SD ± 3.60) |
| Gender | ||
| Male | 20 % (n = 4) | - |
| Female | 80 % (n = 16) | 100 % (n = 10) |
| Marital status | ||
| Single | 5 % (n = 1) | 10 % (n = 1) |
| Widowed | 85 % (n=17) | 80 % (n = 8) |
| Married | 5 % (n = 1) | - |
| Separated | - | - |
| Divorced | 5 % (n = 1) | - |
| Common-law | - | - |
| Education | ||
| Public school | 30 % (n = 6) | 10 % (n = 1) |
| High school | 45 % (n = 9) | 30 % (n = 3) |
| College (diploma) | 10 % (n = 2) | 30 % (n = 3) |
| University (Bachelors) | 5 % (n = 1) | 10 % (n = 1) |
| University (Masters) | 5 % (n = 1) | - |
| University (PhD/MD) | - | - |
| Other education | 5 % (n = 1) | 20 % (n = 2) |
| Perceived Healtha | ||
| Excellent | 5 % (n = 1) | 10 % (n = 1) |
| Very good | 20 % (n = 4) | 30 % (n = 3) |
| Good | 50 % (n = 10) | 40 % (n = 4) |
| Fair | 25 % (n = 5) | 20 % (n = 2) |
| Poor | - | - |
| Mean Self-Rated Independenceb | ||
| Completely independent | 10 % (n = 2) | 20 % (n = 2) |
| Very independent | 25 % (n = 5) | 70 % (n = 7) |
| Somewhat independent | 25 % (n = 5) | 10 % (n = 1) |
| Very little independence | 5 % (n = 1) | - |
| Not at all independent | - | - |
| Age (yr) | Gender | Total | |
| Male | Female | ||
| 12 | 146 (51.6) | 137 (48.4) | 283 (34.9) |
| 13 | 121 (62.7) | 72 (37.3) | 193 (23.8) |
| 14 | 105 (61.8) | 65 (38.2) | 170 (21.0) |
| 15 | 87 (53.0) | 77 (47.0) | 164 (20.2) |
| Total | 459 (56.7) | 351 (43.3) | 810 (100) |
| Variable | Cases(n = 175) | Controls(n = 175) |
| Mean age ± SD | 58.15 ± 20.56 | 57.76 ± 20.09 |
| Classification score of disease conditions | ||
| 1 | 40(22.9%) | 40(22.9%) |
| 2 | 63(36.0%) | 63(36.0%) |
| 3 | 42(24.0%) | 42(24.0%) |
| 4 | 26(14.9%) | 26(14.9%) |
| 5 | 4(2.3%) | 4(2.3%) |
| Gender | ||
| Male | 99(56.6%) | 99(56.6%) |
| Female | 76(43.4%) | 76(43.4%) |
| Community infections | 39(22.3%) | 39(22.3%) |
| Repeated hospitalization | 41(23.4%) | 41(23.4%) |
| Low immune function | 29(16.6%) | 29(16.6%) |
| Element type of membrane | Pressure driving force bar | |
| NF90-4040 | 6.96 bar | |
| Parameters mg/L | Internal (Feed water) mg/L | Output Permeable (NF Process) mg/L |
| TDS | 3902.78 | 212.58 |
| Cl ̄1 | 1223.4 | 101.31 |
| Na+1 | 812.41 | 67.53 |
| Dependent variables | |||||
| HH CI | HH ACI | HH SCI | HH SACI | N | |
| Public expenditure on health care (% of GDP) | 0.0036* | 0.0108** | 0.0004 | 0.0035 | 22 |
| Gini index | −0.0003 | −0.0015 | 0.0005 | 0.0004 | 26 |
| Public expenditure on education (% of GDP) | −0.0048 | −0.0038 | −0.0050** | −0.0058 | 25 |
| GDP PPS per capita (in millions) | 0.0770 | 0.8780 | −0.2560 | 0.0403 | 26 |
| GDP euros per capita (in millions) | 0.0515 | 0.6600* | −0.1910 | 0.0438 | 26 |
| Nordic countries | 0.0015 | 0.0142 | −0.0040 | 0.0010 | 26 |
| Eastern Europe | 0.0045 | −0.0143 | 0.0087* | −0.0002 | 26 |
| Southern Europe | −0.0036 | −0.0037 | 0.0001 | 0.0024 | 26 |
| North-Western Europe | −0.0028 | 0.0076 | −0.0064 | −0.0027 | 26 |
| Dependent variables | |||||
| CI | ACI | SCI | SACI | N | |
| Public expenditure on health care (% of GDP) | −0.0012 | 0.0032 | −0.0017 | 0.0001 | 22 |
| Gini index | 0.0015** | 0.0020 | 0.0015* | 0.0025* | 26 |
| Public expenditure on education (% of GDP) | −0.0088*** | −0.0095** | −0.0116*** | −0.0184*** | 25 |
| GDP PPS per capita (in millions) | −0.0675 | 0.8760* | −0.2340 | 0.1310 | 26 |
| GDP euros per capita (in millions) | −0.1630 | 0.4530 | −0.3400* | −0.2120 | 26 |
| Nordic countries | −0.0225*** | −0.0286** | −0.0323*** | −0.0549*** | 26 |
| Eastern Europe | 0.0047 | −0.0235** | 0.0075 | −0.0053 | 26 |
| Southern Europe | 0.0039 | 0.0129 | 0.0110 | 0.0259* | 26 |
| North-Western Europe | 0.0092 | 0.0365*** | 0.0074 | 0.0257* | 26 |
| Gene symbol | Description | Gene function | Gene expression in IBS | Psychiatric diseases | Reference |
| NGF | Nerve growth factor | Pro-inflammatory mediator; psychoneuroendocrine modulator | Overexpression (in rat model) | Anxiety, chronic alcohol consumption, depression | [71, 72] |
| BDNF | Brain-Derived Neurotrophic Factor | Regulation of stress response and in the biology of mood disorders | SNP | Psychiatric IBS, schizophrenia, mood disorders, PTSD | [73, 74] |
| COMT | Catechol | Degradative pathways of the catecholamine transmitters; metabolism of catechol drugs | SNP | Anxiety, panic disorder, and cognitive performance | [75, 76] |
| O-Methyltransferase | |||||
| OPRM1 | Mu Opiate Receptor | Principal target of endogenous opioid peptides | SNP | Pain sensitivity, opioid dependence, and social sensitivity | [77, 78] |
| 5-HTTLPR | 5-hydroxytryptamine transporter gene-linked polymorphic region | Serotonin transporter | SNP | Depression, anxiety, rectal pain ratings | [79, 80] |
| Recombinant strain | Transfer medium | Resistant colonies (%) |
| RQ7/pDH10 | SVO | 104.92 ± 9.57 |
| SVO + Kan | 106.66 ± 3.56 | |
| Tm/pDH10 | SVO | 100.96 ± 23.72 |
| SVO + Kan | 108.59 ± 7.54 |
| Improvement (N = 57)Mean ± SD/n (%) | Nonimprovement (N = 52)Mean ± SD/n (%) | t/χ2 | P value | |
| Age (years) | 47.14 ± 11.79 | 47.82 ± 11.11 | −0.30 | 0.763 |
| Gender | 0.22 | 0.637 | ||
| Male | 15 (35.71) | 21 (31.34) | ||
| Female | 27 (64.29) | 46 (68.66) | ||
| BMI | 2.07 | 0.355 | ||
| <18.5 | 5 (11.90) | 12 (17.91) | ||
| 18.5–25 | 35 (83.33) | 48 (71.64) | ||
| >25 | 2 (4.76) | 7 (10.45) | ||
| Marriage status | 8.00 | 0.005 | ||
| Good marriage | 39 (92.86) | 47 (70.15) | ||
| Others | 3 (7.14) | 20 (29.85) | ||
| Occupation | 0.35 | 0.553 | ||
| Employed | 25 (59.52) | 36 (53.73) | ||
| Others | 17 (40.48) | 31 (46.27) | ||
| Education level | 0.02 | 0.883 | ||
| Lower than high school | 27 (64.29) | 44 (65.67) | ||
| High school and above | 15 (35.71) | 23 (34.33) |
| Nucleotide (genomic) | Nucleotide (cDNA) | Amino Acid | Type | Age at Onset | Number of affected | TCGA_ID | Previous Reported |
| 11:108098418C>T | c.G67T | p.R23X | Nonsense | 71 | 1 | TCGA-RD-A8MV* | NA |
| 11:108106511delTTCT | c.446_449del | p.I149fs | Frameshift deletion | 46 | 1 | TCGA-BR-6564 | NA |
| 11:108121753delAG | c.1561_1562del | p.R521fs | Frameshift deletion | NA | 1 | TCGA-HF-7133 | NA |
| 11:108183151G>T | c.G5932T | p.E1978X | Nonsense | 41,64 | 2 | TCGA-BR-6710TCGA-BR-8077 | Li and Swift et al., 2000 |
| 11:108214065delTTTCAGTGCC | c.8385_8395del | p.D2795fs | Frameshift deletion | 57 | 1 | TCGA-VQ-AA6F | NA |
| 11:108216616T>G | c.8565T>G | p.S2855R | Missense | 64 | 1 | TCGA-BR-7196 | Castellvi-Bel et al., 1999 |
| 11:108186638G>A | c.6095G>A | p.R2032K | Missense | 70 | 1 | TCGA-BR-8365 | Li and Swift et al., 2000 |
| 11:108199929T>G | c.7271T>G | p.V2424G | Missense | 71 | 1 | TCGA-RD-A7BW | Stankovic et al., 1998 |
| Sector | N | pH | Tot C% | Tot N% | P (Al) mg/100 g | P (HCl) mg/100 g | K (Al) mg/100 g | K (HCl) mg/100 g | Mg (Al) mg/100 g | K (Al)/Mg (Al) | Ca (Al) mg/100 g | Cu (HCl) mg/1000 g |
| A1 | 6 | 5.9 ± 0.1 cd | 2.05 ± 0.1 d | 0.25 ± 0.02 ab | 2.0 ± 0.3 bc | 47.8 ± 2 b | 13.2 ± 1 d | 230 ± 12 cd | 22.1 ± 3 e | 0.60 ± 0.09 bc | 197 ± 13 e | 17.2 ± 2 bc |
| A2 | 6 | 5.8 ± 0.1 d | 2.35 ± 0.2 abc | 0.27 ± 0.02 ab | 2.3 ± 0.4 abc | 52.3 ± 3 a | 14.6 ± 1 cd | 254 ± 14 b | 26.6 ± 1 cd | 0.54 ± 0.02 c | 213 ± 6 d | 20.2 ± 1 a |
| B1 | 6 | 6.0 ± 0.1 c | 2.43 ± 0.2 ab | 0.28 ± 0.03 a | 2.1 ± 0.4 abc | 54.7 ± 2 a | 14.6 ± 1 cd | 285 ± 11 a | 29.9 ± 2 ab | 0.49 ± 0.02 d | 236 ± 8 c | 20.2 ± 1 a |
| B2 | 6 | 6.3 ± 0.2 a | 2.15 ± 021 cd | 0.28 ± 0.06 a | 2.4 ± 0.6 a | 47.1 ± 2 b | 16.1 ± 1 bc | 301 ± 16 a | 29.3 ± 1 abc | 0.55 ± 0.03 bc | 289 ± 14 a | 18.4 ± 3 abc |
| C1 | 6 | 5.9 ± 0.1 cd | 2.33 ± 0.1 bc | 0.25 ± 0.03 ab | 2.2 ± 0.2 abc | 55.3 ± 4 a | 14.5 ± 2 cd | 227 ± 11 cd | 19.3 ± 2 e | 0.75 ± 0.07 a | 193 ± 11 e | 17.8 ± 1 bc |
| C2 | 6 | 5.8 ± 0.1 d | 2.55 ± 0.2 ab | 0.28 ± 0.02 a | 2.5 ± 0.4 abc | 53.5 ± 4 a | 14.8 ± 3 cd | 219 ± 16 d | 25.6 ± 4 d | 0.58 ± 0.06 bc | 214 ± 13 d | 18.9 ± 2 ab |
| D1 | 6 | 6.0 ± 0.1 c | 2.57 ± 0.3 a | 0.27 ± 0.03 ab | 2.7 ± 0.7 ab | 51.5 ± 5 ab | 18.4 ± 2 a | 246 ± 24 bc | 31.3 ± 4 a | 0.59 ± 0.04 bc | 242 ± 17 c | 19.1 ± 2 ab |
| D2 | 6 | 6.1 ± 0.1 b | 2.05 ± 0.1 d | 0.24 ± 0.02 b | 1.7 ± 0.3 c | 42.0 ± 5 c | 17.2 ± 1 ab | 264 ± 23 b | 27.9 ± 1 bcd | 0.62 ± 0.04 b | 267 ± 11 b | 16.7 ± 1 c |
| Total | 48 | 6.0 ± 0.2 | 2.3 ± 0.3 | 0.27 ± 0.03 | 2.3 ± 0.6 | 50.5 ± 5 | 15.4 ± 2 | 253 ± 31 | 26.5 ± 4 | 0.59 ± 0.09 | 253 ± 31 | 18.6 ± 2 |
| Component | Low-N Plot | Net Change (g N m–2) | High-N Plot | Net Change (g N m−2) | ||
| Before | After | Before | After | |||
| N input–output (g N m−2 year−1) | ||||||
| N input | 0 | 5 | 5 | 0 | 15 | 15 |
| N leaching | 0.66 | 0.77 | 0.11 | 0.42 | 2.67 | 2.25 |
| N retention | 4.89 | 12.75 | ||||
| N storage (g N m−2) | ||||||
| Aboveground biomass N | 15.68 | 9.26 | −6.42 | 13.36 | 19.12 | 5.76 |
| Belowground biomass N | 4.59 | 7.29 | 2.71 | 5.54 | 8.12 | 2.58 |
| N mass remaining in litter | 0.85 | 1.18 | 0.33 | 1.37 | 1.73 | 0.36 |
| Soil inorganic N | 4.10 | 3.92 | −0.18 | 3.50 | 3.94 | 0.44 |
| Estimated N storage | 8.11 | 2.72 |
| Categories at 6 (±1) months | |||||||||
| Baseline category | Num. of patients1 | A | B | C | D | E | Missing at 6 months2 | Category improved2 | Category worsened2 |
| A | 162 (14%) | 86 | 26 | 7 | 0 | 0 | 43 (27%) | N.A. | 33 (20%) |
| B | 434 (37%) | 61 | 210 | 9 | 12 | 1 | 141 (33%) | 61 (14%) | 13 (3%) |
| C | 208 (18%) | 68 | 16 | 61 | 8 | 1 | 54 (26%) | 68 (33%) | 9 (4%) |
| D | 303 (26%) | 14 | 80 | 18 | 62 | 2 | 127 (42%) | 112 (37%) | N.A. |
| E | 72 (6%) | 3 | 14 | 3 | 18 | 7 | 27 (38%) | 20 (28%) | N.A. |
| Missing | 3 (0.3%) | 0 | 0 | 0 | 0 | 0 | 3 | ||
| Total | 1182 (100%) | 232 (20%) | 346 (29%) | 98 (8%) | 100 (8%) | 11 (1%) | 395 (33%) | 261 (26%) | 55 (7%) |
| Categories at 12 (±3) months | |||||||||
| Baseline category | Num. of patients1 | A | B | C | D | E | Missing at 1 year2 | Category improved2 | Category worsened2 |
| A | 162 (14%) | 83 | 22 | 7 | 1 | 0 | 49 (30%) | N.A. | 30 (19%) |
| B | 434 (37%) | 58 | 169 | 7 | 11 | 4 | 185 (43%) | 58 (13%) | 15 (3%) |
| C | 208 (18%) | 62 | 21 | 36 | 3 | 0 | 86 (41%) | 62 (30%) | 3 (1%) |
| D | 303 (26%) | 20 | 60 | 16 | 43 | 1 | 163 (54%) | 96 (32%) | N.A. |
| E | 72 (6%) | 7 | 12 | 4 | 8 | 4 | 37 (51%) | 23 (32%) | N.A. |
| Missing | 3 (0.3%) | 0 | 0 | 0 | 0 | 0 | 3 | ||
| Total | 1182 (100%) | 230 (19%) | 284 (24%) | 70 (6%) | 66 (6%) | 9 (1%) | 523 (44%) | 239 (24%) | 48 (6%) |
| Delayed Effect | Genetic Effect | |||||||
| Traumatic reaction (ref: 17–49 on PCL-S) | ||||||||
| FY2011 | OR | 95% CI | OR | 95% CI | ||||
| ≥50 | 2.05 | 1.82 | 2.31 | 2.18 | 1.92 | 2.48 | ||
| FY2012 | ||||||||
| ≥50 | 1.86 | 1.61 | 2.15 | 2.05 | 1.75 | 2.40 | ||
| FY2013 | ||||||||
| ≥50 | 1.88 | 1.62 | 2.17 | 1.82 | 1.55 | 2.15 | ||
| Basic characteristics (FY2011) | ||||||||
| Gender (ref: Men) | ||||||||
| Women | 1.27 | 1.18 | 1.36 | 1.30 | 1.22 | 1.40 | ||
| Age (Ref: 50–64) | ||||||||
| 15–49 | 1.52 | 1.40 | 1.65 | 1.12 | 1.03 | 1.21 | ||
| ≥65 | 0.97 | 0.88 | 1.06 | 1.08 | 0.99 | 1.18 | ||
| Education (ref: High school) | ||||||||
| Junior high school | 1.11 | 1.00 | 1.23 | 1.11 | 1.01 | 1.23 | ||
| College or higher | 0.88 | 0.81 | 0.95 | 0.82 | 0.76 | 0.89 | ||
| Exposure to the disaster (FY2011) | ||||||||
| Tsunami (ref: No) | ||||||||
| Yes | 0.99 | 0.91 | 1.08 | 1.03 | 0.95 | 1.12 | ||
| NPP accident (ref: No) | ||||||||
| Yes | 1.30 | 1.21 | 1.40 | 1.35 | 1.26 | 1.45 | ||
| Bereavement (ref: No) | ||||||||
| Yes | 1.26 | 1.16 | 1.37 | 1.24 | 1.14 | 1.35 | ||
| Secondary stressors (FY2013) | ||||||||
| Living in other prefecture (ref: No) | ||||||||
| Yes | 1.03 | 0.94 | 1.13 | 0.92 | 0.84 | 1.01 | ||
| Family separation (ref: No) | ||||||||
| FY2012 or FY2013 | 1.21 | 1.08 | 1.35 | 1.21 | 1.08 | 1.36 | ||
| FY2012 & FY2013 | 1.11 | 1.03 | 1.20 | 1.16 | 1.08 | 1.26 | ||
| Number of relocations (ref: 0–2) | ||||||||
| 3–4 | 1.07 | 0.98 | 1.17 | 1.08 | 0.99 | 1.17 | ||
| ≥5 | 1.19 | 1.09 | 1.30 | 1.20 | 1.10 | 1.31 | ||
| Living circumstances | ||||||||
| (ref: well off/relatively well-off/normal) | ||||||||
| Poor/relatively poor | 1.85 | 1.72 | 1.98 | 1.84 | 1.71 | 1.97 |
| M5:M5 | M5:G1F | M5:M3G1F | M5:G0F | M5:M3G0F | G0F:G0F | |
| Calculated relative | 0.62% | 1.12% | 0.11% | 5.29% | 0.18% | 45.43% |
| Calculated relative to the most abundant G0F:G0F | 1.36% | 2.46% | 0.24% | 11.64% | 0.40% | 100% |
| Observed relative to the most abundant G0F:G0F | 5.13% | ND | ND | 12.73% | ND | 100% |
| Variable | Normal BMD group (N = 17) | Low BMD group (N = 17) | MannWhitney p-value |
| Trunk | |||
| Tilt ROM | 4.05 ± 1.31 | 4.34 ± 1.79 | 0.53 |
| Rotation ROM | 16.06 ± 4.46 | 12.60 ± 4.96 | 0.02* |
| Obliquity ROM | 9.49 ± 2.59 | 8.52 ± 3.03 | 0.32 |
| Hip | |||
| Sagittal ROM | 41.24 ± 7.36 | 38.39 ± 5.57 | 0.17 |
| Coronal ROM | 11.50 ± 3.68 | 11.42 ± 3.17 | 0.86 |
| Transverse ROM | 14.28 ± 2.36 | 12.54 ± 3.25 | 0.08 |
| Socio-demographic characteristics | |
| Mean age (range) years | 21 (17 – 30) |
| Occupation (n) | |
| Farmer | 3 |
| Factory worker | 2 |
| Student | 1 |
| Education level (n) | |
| Completed secondary school | 5 |
| Vocational high school training | 1 |
| Marital status (n) | |
| Married | 6 |
| Perception of economic status (n) | |
| Similar to other households in this area | 6 |
| Parity (n) | |
| Nulliparous | 4 |
| Multiparous | 2 |
| Number of household members over prior six months, median (range) | 5 (4 – 6) |
| Persons participant living with in the same household (n) | |
| Husband | 6 |
| Mother-in-law | 6 |
| Father-in-law | 6 |
| Husband’s brother/sister | 2 |
| Husband’s grandmother | 1 |
| Mother | 2 |
| Reproductive health | |
| Median gestation (range) weeks | 32.5 (28 – 35) |
| Current pregnancy (n) | |
| Very welcome | 6 |
| Coincidental adverse events | |
| No current worrying or distressing coincidental life events | 6 |
| Relationship with partner | |
| Ever experienced fear of husband over the past year (n) | |
| Never | 4 |
| Sometimes or often | 2 |
| Ever physically hurt by husband over last year (n) | |
| Never | 6 |
| Sociodemographic characteristics | Health-related characteristics | ||
| Males N (%) | 119 (41.8) | Smokers N (%) | 81 (28.4) |
| Mean Age in years (SD) | 50.18 (10.1) | Mean Pack-years for smokers (SD) | 24.82 (21.8) |
| Married N (%) | 188 (66) | Mean BMI in Kg/m2 (SD) | 26.34 (5.34) |
| Living alone N (%) | 55 (19.3) | Diagnosis of Disease N (%) | 130 (45.6) |
| Having children N (%) | 209 (73.3) | Mean PSS score (SD) | 26.35 (7.99) |
| Tertiary education N (%) | 165 (57.9) | Mean Internal HLC score (SD) | 26.12 (4.96) |
| Employed N (%) | 214 (75.1) | Mean External HLC score (SD) | 22.23 (6.04) |
| Working shifts N (%) | 64 (22.5) | Mean Chance HLC score (SD) | 16.75 (6.04) |
| Caregivers N (%) | 22 (7.7) | SRRS score N (%) | |
| ≤150 | 164 (57.5) | ||
| 151-299 | 80 (28.1) | ||
| ≥300 | 41 (14.4) | ||
| Mean Sleep Quality (SD) | 6.16 (2.13) | ||
| Mean Health Assessment (in a scale from 1 to 10) (SD) | 7.48 (1.4) |
| Prevalence % | Step 1: Multivariable β (95% CI) Adjusted for age, sex and BMIf | Step 2: Multivariable β (95% CI)§ Further adjusted for all variables significant in Step 1 | |
| Diagnosed OA of: | |||
| Neck | 168 (15) | 2.72 (1.80 to 3.64) | −0.32 (−0.96 to 0.32) |
| Shoulders | 193 (18) | 3.58 (2.34 to 4.81) | 0.23 (−0.64 to 1.10) |
| Back | 167 (15) | 3.41 (2.54 to 4.28) | 0.71 (0.02 to 1.41) |
| Hips | 97 (9) | 3.05 (1.93 to 4.17) | 0.04 (−0.74 to 0.82) |
| Hands | 113 (10) | 2.32 (1.41 to 3.23) | 0.09 (−0.55 to 0.72) |
| Knees | 152 (14) | 2.48 (1.52 to 3.43) | 0.15 (−0.55 to 0.85) |
| Feet | 103 (9) | 3.40 (2.21 to 4.59) | 0.30 (−0.49 to 1.09) |
| Hip JSN (yes/no) | 377 (37) | 0.34 (−0.31 to 0.99) | - |
| Knee JSN (yes/no) | 688 (67) | 0.06 (−0.60 to 0.72) | - |
| Hip osteophyte (yes/no) | 190 (19) | −0.10 (−0.89 to 0.69) | - |
| Knee osteophyte (yes/no) | 143 (14) | −0.31 (−1.21 to 0.59) | - |
| Pain in the: | |||
| Neck (yes/no) | 514 (47) | 3.14 (2.58 to 3.71) | 0.65 (0.16 to 1.15) |
| Shoulder (yes/no) | 674 (62) | 3.35 (2.77 to 3.93) | 1.03 (0.52 to 1.54) |
| Back (yes/no) | 481 (44) | 2.94 (2.39 to 3.50) | 0.58 (0.12 to 1.05) |
| Hip (yes/no) | 481 (44) | 2.44 (1.83 to 3.04) | 0.26 (−0.18 to 0.70) |
| Hand (yes/no) | 505 (46) | 2.63 (2.05 to 3.22) | 0.50 (0.04 to 0.96) |
| Knee (yes/no) | 451 (41) | 2.72 (2.13 to 3.31) | 0.41 (−0.04 to 0.86) |
| Foot (yes/no) | 412 (38) | 3.27 (2.64 to 3.89) | 1.13 (0.62 to 1.63) |
| GGT | Vitamin C | ||||
| Sample (n) | β-Coefficient | p-Value for trend | β-Coefficient | p-Value for trend | |
| Race | |||||
| Non-Hispanic white | 4,485 | 0.073 | < 0.01 | −0.147 | < 0.01 |
| Non-Hispanic black | 2,820 | 0.098 | < 0.01 | −0.153 | < 0.01 |
| Others | 2,793 | 0.009 | 0.43 | −0.082 | < 0.01 |
| p-Value for interaction | < 0.01 | 0.70 | |||
| Sex | |||||
| Men | 4,799 | 0.058 | < 0.01 | −0.140 | < 0.01 |
| Women | 5,299 | 0.046 | < 0.01 | −0.118 | < 0.01 |
| p-Value for interaction | 0.03 | < 0.01 | |||
| Age (years) | |||||
| 20–39 | 4,178 | 0.097 | < 0.01 | −0.223 | < 0.01 |
| 40–59 | 2,831 | 0.048 | < 0.01 | −0.145 | < 0.01 |
| ≥60 | 3,089 | 0.014 | 0.10 | −0.081 | < 0.01 |
| p-Value for interaction | < 0.01 | < 0.01 | |||
| Smoking | |||||
| Never | 5,016 | 0.029 | 0.01 | −0.048 | < 0.01 |
| Ex | 2,550 | 0.051 | < 0.01 | −0.069 | < 0.01 |
| Current | 2,532 | 0.056 | < 0.01 | −0.103 | < 0.01 |
| p-Value for interaction | 0.62 | < 0.01 | |||
| Drinking | |||||
| No | 7,707 | 0.036 | < 0.01 | −0.102 | < 0.01 |
| Yes | 2,391 | 0.133 | < 0.01 | −0.247 | < 0.01 |
| p-Value for interaction | < 0.01 | < 0.01 | |||
| BMI | |||||
| < 25 | 3,900 | 0.105 | < 0.01 | −0.188 | < 0.01 |
| 25–29.9 | 3,567 | 0.045 | < 0.01 | −0.090 | < 0.01 |
| ≥30 | 2,631 | 0.032 | 0.02 | −0.107 | < 0.01 |
| p-Value for interaction | < 0.01 | < 0.01 |
| Men (N = 1206) | Women (N = 1681) | |||
| Numbers of deformities | % (N) | 95% CI (%) | % (N) | 95% CI (%) |
| At least 1 deformity | 9.7 (117) | 8.0, 11. | 7.8 (131) | 46.5, 9.1 |
| 2 deformities | 3.0 (36) | 2.0, 4.0 | 2.5 (42) | 1.8, 3.2 |
| 3 deformities or more | 1.0 (13) | 0.4, 1.6 | 1.4 (26) | 0.8, 2.0 |
| All | 13.8 (166) | 11.9, 15.8 | 11.8 (199) | 10.4, 13.5 |
| Types | n | Age (yr) (%) | Menstrual status (%) | |||
| ≤ 40 | 41 to 60 | >60 | Postmenopausal | Premenopausal | ||
| Type I | 55 | 12 (21.8) | 39 (70.9) | 4 (7.3) | 22 (20.0) | 33 (80.0) |
| Type II | 30 | 4 (13.3) | 24 (80.0) | 2 (6.7) | 17 (56.7) | 13 (43.3) |
| Type III | 5 | 1 (20.0) | 3 (60.0) | 1 (20.0) | 1 (20.0) | 4 (80.0) |
| χ2 | 3.465 | |||||
| P valuea | 0.393 | 0.177 |
| marker | # of markers | detectable strains | data quality |
| Minimal set of SNPs | 2 | known | perfect |
| All SNPs + VNTRs | 150+15 | some unknown | moderate |
| CDSs | ~10,000 | many unknown | poor |
| Sequence alignment | ~5,300,000 | arbitrary | arbitrary |
| Factor | Patients no | P Value | |
| CR | PR | ||
| Sex | 0.889 | ||
| Male | 45 (64.2%) | 7 (10.2%) | |
| Female | 15 (21.4%) | 3 (4.2%) | |
| Pathological subtype | 0.133 | ||
| Non keratinizing | 9 (12.9%) | 4 (5.7%) | |
| Undifferentiated | 45 (64.3%) | 5 (7.1%) | |
| Basaloid | 5 (7.1%) | 2 (2.9 %) | |
| Baseline T stage | <0 .001 | ||
| T1 | 7 (10.1%) | ||
| T2 | 26 (37.1%) | ||
| T3 | 25 (35.7%) | 4 (5.7%) | |
| T4 | 3 (4.3%) | 5 (7.1%) | |
| Baseline N stage | 0.002 | ||
| N0 | 18 (25.7%) | ||
| N1 | 34 (48.6%) | 5 (7.1%) | |
| N2 | 9 (12.9%) | 1 (1.4%) | |
| N3 | 3 (4.3%) | ||
| Radiation Technique | 0.412 | ||
| 3DCRT | 48 (68.6%) | 3 (4.2%) | |
| IMRT | 15 (21.4%) | 4 (5.8%) | |
| Concurrent Chemo-radiationBreak | <0 .001 | ||
| <7 Days | 56 (80%) | 4 (5.7%) | |
| >7 Days | 3 (4.3%) | 7 (10 %) | |
| Pretreatment Pet- CTSUVmaxprimary | 041 | ||
| <8 | 32 (45.7%) | 6 (8.6%) | |
| ≥ 8 | 28 (40%) | 4 (5.7%) |
| ELISA | PCR | ||||||||||
| B. bigemina | B. bovis | B. bigemina and B. bovis | B. bigemina | B. bovis | |||||||
| Governorate | No. tested animals | No. of positive animals | Infection (%) | No. of positive animals | Infection (%) | No. of positive animals | Co-infection (%) | No. of positive animals | Infection (%) | No. of infected animals | Infection (%) |
| Kafr El-Sheikh | 7 | 5 | 71.4 | 3 | 42.9 | 2 | 28.6 | 0 | 0 | 2 | 28.6 |
| El-Beheira | 74 | 13 | 17.6 | 15 | 20.3 | 3 | 4.1 | 0 | 0 | 1 | 1.4 |
| Total | 81 | 18 | 22.2 | 18 | 22.2 | 5 | 6.2 | 0 | 0 | 3 | 3.7 |
| Author | Aims scope | Ethical dimension | Study design | Rigour | Analysis procedure | Depth/detail | Credibility | Relevance transferability | Contribution to knowledge | Overall quality |
| Andersen et al. (a) and (b) | VG | VG | VG | G | VG | G | VG | VG | VG | VG |
| Apps et al. | VG | VG | VG | VG | VG | VG | G | VG | VG | VG |
| Boeckxstaens et al. | VG | VG | VG | VG | VG | G | VG | VG | VG | VG |
| Brandt | G | VG | VG | VG | VG | L | L | G | G | G |
| Brien et al. | VG | VG | G | G | G | G | G | G | G | G |
| Chang et al. | VG | G | G | G | VG | G | G | G | G | G |
| Chen et al. (a) and (b) | VG | VG | G | VG | VG | VG | L | VG | VG | VG |
| Cicutto et al. | VG | VG | VG | VG | VG | VG | VG | VG | VG | VG |
| Duangpaeng et al. | VG | G | G | G | G | G | L | G | G | G |
| Ehrlich et al. | VG | VG | VG | VG | VG | VG | G | VG | VG | VG |
| Fotokain et al. | G | VG | G | VG | VG | G | G | G | G | G |
| Gysels and Higginson | VG | VG | VG | VG | VG | VG | VG | VG | VG | VG |
| Harris et al. | VG | G | VG | VG | VG | VG | VG | VG | VG | VG |
| Harrison et al. | VG | VG | VG | VG | VG | VG | VG | VG | VG | VG |
| Hillebregt et al. | G | VG | VG | VG | VG | G | G | VG | VG | VG |
| Hyde et al. | VG | G | VG | VG | VG | VG | G | VG | VG | VG |
| Johnston et al. (a) | VG | VG | VG | VG | VG | G | G | VG | VG | VG |
| Johnston et al. (b) | VG | G | VG | VG | G | VG | VG | VG | VG | VG |
| Kayyali et al. | VG | G | G | G | G | G | L | G | G | G |
| McCabe et al. | VG | G | VG | G | G | G | G | VG | VG | G |
| Ogunbayo et al. | VG | VG | G | VG | VG | G | VG | VG | VG | VG |
| Panos et al. | VG | G | VG | VG | VG | VG | G | VG | VG | VG |
| Robinson et al. | VG | VG | G | VG | VG | G | VG | VG | VG | VG |
| Sheridan et al. | VG | VG | VG | G | L | VG | VG | VG | VG | VG |
| Stellefson et al. | VG | VG | VG | VG | VG | VG | VG | G | G | VG |
| Summers et al. | VG | VG | G | VG | VG | G | VG | VG | VG | VG |
| Verbrugge et al. | VG | G | VG | VG | VG | VG | VG | VG | VG | VG |
| Wong et al. | VG | VG | VG | G | G | VG | G | VG | VG | VG |
| Wortz et al. | VG | VG | G | G | G | VG | VG | VG | VG | VG |
| Young et al. | VG | VG | VG | G | G | VG | G | VG | VG | VG |
| Zakrisson and Hagglund | VG | G | G | G | G | VG | G | VG | VG | G |
| Sample | Peel | Pulp | ||||||
| K. pneumoniae | Activity | S. aureus | Activity | K. pneumoniae | Activity | S. aureus | Activity | |
| Jeruk Nipis | 4.2 ± 1.8a | Bactericide | 3.5 ±1.4a,b | Bacteriostatic | 4.1 ± 0.4a,b | Bactericide | 3.1 ± 0.6a,b | Bactericide |
| Jeruk Purut | 4.6 ± 1.2a | Bacteriostatic | 4.8 ± 1.7a,b | Bactericide | 5.5 ± 1.1a,b | Bactericide | 3.4 ± 0.9a,b | Bactericide |
| Calung | 5.6 ± 0.7a | Bacteriostatic | 7.0 ± 1.9b | Bacteriostatic | 7.5 ± 1.1b | Bactericide | 6.2 ± 2.0b | Bacteriostatic |
| Makin | 4.1 ± 0.9a | Bacteriostatic | 2.5 ± 0.5a | Bactericide | 3.3 ± 0.3a | Bactericide | 2.6 ± 0.6a | Bactericide |
| Kruet Mameh | 4.3 ± 0.9a | Bactericide | 4.1 ± 1.0a,b | Bactericide | 6.8 ± 2.5a,b | Bacteriostatic | 4.7 ± 1.5a,b | Bacteriostatic |
| Mentui | 11.6 ± 3.5b | Bacteriostatic | 4.8 ± 1.8a,b | Bacteriostatic | 6.3 ± 1.0a,b | Bacteriostatic | 4.1 ± 0.5a,b | Bacteriostatic |
| Gene symbol | Gene title | log2 fold change | P-value |
| VTRNA1-2 | vault RNA 1-2 | 2.28 | 0.026 |
| PGF | Placenta growth factor | 0.70 | 0.013 |
| RNH1 | ribonuclease/angiogenin inhibitor 1 | 0.57 | 0.036 |
| ITPK1 | inositol 1,3,4-triphosphate 5/6 kinase | 0.55 | 0.037 |
| Mir-503 | microRNA 503 | 0.52 | 0.047 |
| RAD23A | RAD23 homolog A (S. cerevisiae) | 0.52 | 0.013 |
| APOC1 | apolipoprotein C-I | 0.50 | 0.037 |
| USP15 | ubiquitin specific peptidase 15 | −0.87 | 0.026 |
| PPP1R12A | protein phosphatase 1. regulatory (inhibitor) subunit 12A | −0.88 | 0.021 |
| FNBP1L | formin binding protein 1-like | −0.89 | 0.046 |
| SMC6 | structural maintenance of chromosomes 6 | −0.92 | 0.026 |
| SMC4 | structural maintenance of chromosomes 4 | −0.92 | 0.024 |
| ROCK2 | Rho-associated. coiled-coil containing protein kinase 2 | −0.92 | 0.021 |
| AKAP9 | A kinase (PRKA) anchor protein (yotiao) 9 | −0.94 | 0.028 |
| COPS2 | COP9 constitutive photomorphogenic homolog subunit 2 (Arabidopsis) | −0.98 | 0.008 |
| GCC2 | GRIP and coiled-coil domain containing 2 | −1.02 | 0.019 |
| ROCK1 | Rho-associated. coiled-coil containing protein kinase 1 | −1.07 | 0.028 |
| Assembly | Dz (nm) | ζ (mV) | P | References |
| DODAB BF | 59 ± 1 | 43 ± 2 | 0.215 ± 0.006 | [24] |
| DODAB BF | 55 ± 1 | 36 ± 2 | 0.248 ± 0.004 | This work |
| DODAB BF/Gr | 54 ± 1 | 72 ± 4 | 0.277 ± 0.004 | [24] |
| DODAB BF/Gr | 71 ± 1 | 58 ± 2 | 0.261 ± 0.003 | This work |
| PSS | 137 ± 2 * | - | - | - |
| PSS | 140 ± 2 | -43 ± 3 | 0.038 ± 0.013 | This work |
| PSS/DODAB | 149 ± 1 | 30 ± 2 | 0.049 ± 0.014 | [11] |
| PSS/DODAB/Gr | 150 ± 1 | 42 ± 2 | 0.039 ± 0.015 | This work |
| Study sample | All first-time fathers in Norway* | ||||
| n | % | n | % | p-value** | |
| Age groups | <0.001 | ||||
| 25-34 years | 11 363 | 76.6 | 163 063 | 77.0 | |
| 35-39 years | 2 693 | 18.2 | 34 291 | 16.2 | |
| ≥40 years | 776 | 5.2 | 14 408 | 6.8 | |
| Mother tongue other than Norwegian | 1 016 | 6.9 | 46 293 | 21.9 | <0.001 |
| Education | <0.001 | ||||
| Primary school | 288 | 2.0 | 29 511 | 13.9 | |
| Secondary school | 4 862 | 33.7 | 87 850 | 41.5 | |
| Higher education ≤4 years | 4 301 | 29.8 | 53 193 | 25.1 | |
| Higher education >4 years | 4 984 | 34.5 | 27 635 | 13.1 | |
| Unknown | 397 | 2.7 | 13 573 | 6.4 |
| p-value+ | ||||
| CONV | UTR | UCR | Overall | |
| N participants with dry weight reduction | 12 | 17 | 14 | |
| DBP-pre: BCM Measurement [mmHg] | 74 ± 15 | 67 ± 13 | 76 ± 20 | 0.23 |
| DBP-pre: Start Intervention Phase [mmHg] | 73 ± 14 | 70 ± 15 | 85 ± 26 | 0.09 |
| DBP-post: Start Intervention Phase [mmHg] | 70 ± 13 | 66 ± 13 | 75 ± 14 | 0.17 |
| DBP-pre: End Intervention Phase [mmHg] | 66 ± 11 | 64 ± 11 | 76 ± 13 | 0.02 |
| DBP-post: End Intervention Phase [mmHg] | 57 ± 15 | 63 ± 12 | 69 ± 14 | 0.10 |
| Delta DBP-pre: Start-to-End In Ph. [mmHg] | −7 ± 11 | −5 ± 12 | −8 ± 31 | 0.10 |
| Delta DBP-post: Start-to-End In Ph. [mmHg] | −12 ± 14 | −3 ± 9 | −6 ± 14 | 0.14 |
| 1-factor solution* | 2-factor solution* | 3-factor solution* | |||||||
| loading | (residual variance) | loading | (residual variance) | loading | (residual variance) | ||||
| 1 | 1 | 2 | 1 | 2 | 3 | ||||
| Items | |||||||||
| Distance tohealth services | 0.896 | (0.197) | -0.017 | 0.967 | (0.083) | 0.987 | -0.025 | -0.002 | (0.044) |
| Having to taketransportation | 0.876 | (0.233) | 0.027 | 0.883 | (0.194) | 0.859 | 0.039 | 0.022 | (0.214) |
| Gettingpermission to go | 0.797 | (0.364) | 0.973 | -0.011 | (0.064) | -0.011 | 0.778 | 0.453 | (0.059) |
| Getting moneyfor treatment | 0.626 | (0.608) | 0.531 | 0.21 | (0.553) | 0.346 | 0.592 | -0.006 | (0.396) |
| Having afemale health worker | 0.59 | (0.652) | 0.315 | 0.371 | (0.637) | -0.013 | -0.122 | 0.840 | (0.332) |
| Going alone | 0.672 | (0.548) | 0.379 | 0.403 | (0.528) | 0.063 | 0.006 | 0.798 | (0.297) |
| Knowing where to go | 0.784 | (0.386) | 0.688 | 0.203 | (0.335) | 0.090 | 0.471 | 0.509 | (0.329) |
| Interfactor correlations | |||||||||
| 2 with 1 | 0.543 | 0.339 | |||||||
| 3 with 1 | 0.609 | ||||||||
| 3 with 2 | 0.202 | ||||||||
| Model fitindices | |||||||||
| Chi-squaremodel (df) | 732.428 (14) | 370.129 (8) | 4.899 (3) | ||||||
| p-value | < 0.001 | < 0.001 | 0.179 | ||||||
| CFI | 0.939 | 0.969 | 1.000 | ||||||
| TLI | 0.909 | 0.920 | 0.999 | ||||||
| RMSEA | 0.119 | 0.112 | 0.013 |
| Health Care Organisation Chart |
| Processes Maps |
| Procedures for risk classification and reduction |
| Procedures and Formal Documents (i.e. budgeting, meeting minutes, etc.) |
| Documents of Reform Projects |
| Periodic Education Plan |
| Clinical Care Pathways |
| Clinical Records |
| Operating Theatres Registries |
| Performance Measurement or Appraisal Tools and Procedures |
| Health Care Professionals Evaluation Forms |
| HTA Tools and Procedures |
| Procedures for Privacy Management |
| Brochures and Booklets for Patients |
| Customer Satisfaction Questionnaires |
| Power Level | TXCTRL Register | Output Power | Current Consumption |
| 31 | 0xA0FF | 0 dBm | 17.4 mA |
| 27 | 0xA0FB | −1 dBm | 16.5 mA |
| 23 | 0xA0F7 | −3 dBm | 15.2 mA |
| 19 | 0xA0F3 | −5 dBm | 13.9 mA |
| 15 | 0xA0EF | −7 dBm | 12.5 mA |
| 11 | 0xA0EB | −10 dBm | 11.2 mA |
| 7 | 0xA0E7 | −15 dBm | 9.9 mA |
| 3 | 0xA0E3 | −25 dBm | 8.5 mA |
| Weeks of training (n) | Sessions/week (n) | MCT/session (min) | MCT/week (min) | |
| ES | 3 | 2 | 6 | 36 |
| 6 | 3 | 6 | 108 | |
| Total MCT | 144 | |||
| LP | 3 | 2 | 2 | 12 |
| 6 | 3 | 2 | 36 | |
| Total MCT | 48 |
| Algorithm | Average CPU Estimation Time (ms) |
| ML-RL-DR | 631.9 |
| ML-RL-SDR | 235.6 |
| MM-RL-DR | 368.8 |
| MM-RL-SDR | 243.9 |
| WLS | 6.8 |
| ML-JE-Wang | 245.0 |
| MM-JE-Wang | 295.9 |
| GEnt | Evolutionary tracea | Jensen–Shannon divergence | Property entropy | VN entropy | Relative entropy | Shannon entropy | Sum of pairs |
| 142 | 142 | 184 | 173 | 125 | 168 | 171 | 184 |
| 168 | 173 | 185 | 184 | 171 | 169 | 184 | 185 |
| 169 | 179 | 222 | 185 | 184 | 224 | 185 | 218 |
| 183 | 184 | 224 | 187 | 185 | 263 | 186 | 263 |
| 184 | 211 | 263 | 206 | 186 | 265 | 187 | 282 |
| 185 | 236 | 265 | 218 | 206 | 351 | 218 | 350 |
| 229 | 247 | 282 | 220 | 218 | 354 | 219 | 351 |
| 265 | 276 | 326 | 255 | 255 | 365 | 222 | 353 |
| 268 | 277 | 328 | 264 | 263 | 454 | 224 | 354 |
| 365 | 324 | 329 | 265 | 265 | 455 | 263 | 365 |
| 328 | 331 | 267 | 282 | 460 | 282 | 457 | |
| 331 | 332 | 282 | 285 | 285 | 459 | ||
| 332 | 350 | 285 | 328 | 326 | 460 | ||
| 346 | 351 | 319 | 329 | 328 | 504 | ||
| 351 | 354 | 325 | 330 | 329 | 521 | ||
| 458 | 365 | 326 | 331 | 331 | 526 | ||
| 460 | 328 | 332 | 332 | 527 | |||
| 461 | 330 | 333 | 334 | 529 | |||
| 331 | 350 | 349 | 603 | ||||
| 350 | 351 | 350 | |||||
| 351 | 353 | 351 | |||||
| 353 | 354 | 353 | |||||
| 354 | 365 | 354 | |||||
| 365 | 409 | 365 | |||||
| 431 | 431 | 411 |
| Species (Classification) No. of genomes analyzed | Genome size (mb) | Habitat niche | Disease | References |
| Neisseria meningitidis (Betaproteobacteria) 5 | 2.2 | Upper airway colonizer | Meningitis, septicemia, Waterhouse–Friderichsen syndrome | Parkhill et al. (2000a), Tettelin et al. (2000) |
| Neisseria gonorrhoeae (Betaproteobacteria) 1 | 2.1 | Urethra | Gonorrhea | Oklahoma University Website |
| Haemophilus influenzae (Gammaproteobacteria) 6 | 1.9 | Upper airway colonizer | Pneumonia, meningitis, bacteremia, otitis media and more | Fleischmann et al. (1995) |
| Streptococcus pneumoniae (Bacilli) 3 | 2.0 | Upper airway colonizer | Pneumonia, septicemia, otitis media, peritonitis, pericarditis, meningitis, brain abscess and more | Tettelin et al. (2001) |
| Helicobacter pylori (Epsilonproteobacteria) 3 | 1.6 | Stomach and duodenum | Peptic ulcer and gastric cancer | Alm et al. (1999) |
| Campylobacter jejuni (Epsilonproteobacteria) 6 | 1.6 | Gastrointestinal | Main cause of diarrhea in Europe, inducer of the Guillain Barre syndrome | Parkhill et al. (2000b) |
| Staphylococcus aureus/MRSA (Bacilli) 14 | 2.8+ | Nose and skin | Pneumonia, meningitis, toxic shock syndrome, septicemia and skin infections | Herron-Olson et al. (2007) |
| Streptococcus pyogenes (Bacilli) 14 | 1.9 | Throat and skin | Diverse pathogenic outcomes/diseases – flesh-eating bacteria | Ferretti et al. (2001) |
| M. tuberculosis (Actinobacteria) 5 | 4.2+ | Lungs, extrapulmonary locations | Tuberculosis | Cole et al. (1998) |
| Bacillus subtilis (Bacilli) 1 | 4.2 | Soil | Reference bacterium | Kunst et al. (1997) |
| Escherichia coli (Gammaproteobacteria) 18 | 4.6+ | Intestine, sewer | Reference bacterium | Blattner et al. (1997) |
| Session | Module/Topic | Content example |
| 1. Baseline | Blood Pressure and Hypertension Definitions | \"Hypertension\" is the medical term for high blood pressure. A person with high blood pressure is sometimes described as \"hypertensive.\" |
| Essential vs. Secondary Hypertension | Normal blood pressure is a systolic pressure of 120 or less. \"Systolic\" is the top number in a blood pressure reading. | |
| Systolic and Diastolic Normal Readings | ||
| 2. Seven Day | Hypertension Risk Factors | High blood pressure has many risk factors. Some you can't control. Family history - High blood pressure tends to run in families. |
| Other risk factors for high blood pressure are within your control: Too much sodium (salt) in your diet which can cause your body to retain fluid, which increases blood pressure. | ||
| 3. Thirty Day | Tobacco and Alcohol Use | If you drink more than moderate amounts of it, alcohol can actually raise blood pressure by several points. It can also reduce the effectiveness of high blood pressure medications. |
| Caffeine Use | ||
| Cut back on caffeine. The role caffeine plays in blood pressure is still debatable. Drinking caffeinated beverages can temporarily cause a spike in your blood pressure, but it's unclear whether the effect is temporary or long lasting. | ||
| 4. Ninety Day | BP Complications | Hypertension is frequently called the \"silent killer\" because it rarely causes symptoms. This is dangerous because untreated hypertension can lead to strokes, heart attacks, kidney disease, and vision loss. |
| Complications of Uncontrolled Blood Pressure | ||
| Very high blood pressure is dangerous. You should call your Healthcare Provider anytime day or night, if your resting systolic blood pressure is over 180 or your resting diastolic blood pressure is over 110. |
| BMI | 20 > | 20-24.9 | 25 - 29.9 | 30 - 34.9 | 35 < | P-value of chi-square test |
| Preeclampsia | 5 | 19 | 31 | 12 | 2 | 0.001** |
| 3.9% | 4.6% | 8.7% | 12.2% | 3.33% | ||
| Induction of labour | 26 | 98 | 103 | 39 | 3 | 0.003** |
| 20.3% | 23.8% | 28.9% | 40.9% | 50% | ||
| Caesarean section | 11 | 59 | 71 | 25 | 4 | 0.001** |
| 8.6% | 14.3% | 19.9% | 25.5% | 7.66% | ||
| Preterm delivery | 2 | 9 | 16 | 6 | 1 | 0.037* |
| 1.6% | 22.2% | 4.7% | 6.1% | 0% | ||
| Post date delivery | 4 | 14 | 12 | 3 | 0 | 0.99 |
| 3.1% | 3.4% | 2.4% | 3% | 0% | ||
| Wound Infection | 0 | 10 | 8 | 6 | 1 | 0.009** |
| 44% | 32% | 24% | 4% |
| Type of allergy | No. of studies | Overall accuracy (%) | Application | ANN | SVM | BN | FL |
| Asthma | 18 | 82.44 ± 23.71 | To classify exacerbations [10–14] | 1 | 1 | 2 | 1 |
| To classify severity [6, 15, 16] | – | – | 1 | 2 | |||
| To classify pathologic vs control [4, 17–19] | 2 | 1 | – | 1 | |||
| To classify asthma control level [8, 20] | 1 | – | – | 1 | |||
| To classify how manage their pathology [21] | 1 | – | – | – | |||
| To predict the clinical effect of salbutamol [22, 23] | 2 | – | – | – | |||
| To classify health state[24] | – | – | 1 | – | |||
| ADR | 6 | 94.5 ± 2.12 | To predict the posterior probability of a drug (BARDI tool) [28–30] | – | – | 3 | – |
| To predict hypersensitivity reaction (AERS database) [25–27] | – | – | 3 | – | |||
| Allergic rhinitis | 1 | 88.31 | To classify pathologic vs control [31] | 1 | – | – | – |
| Allergic conjunctivitis | 1 | 100 | To classify pathologic vs control [32] | 1 | – | – | – |
| Atopic dermatitis | 1 | 96.4 | To classify pathologic vs control [33] | 1 | – | – | – |
| Immediately pre coronary angiography | 6 months after coronary angiogrpahy | P | |
| Global EF (%) | 43 ± 10 | 44 ± 8 | p = NS |
| The size of infarct area (%) | 32 ± 10 | 30 ± 10 | p = NS |
| Infarct wall movement velocity (cm/s) | 1.76 ± 0.76 | 1.80 ± 0.76 | p = NS |
| End-diastolic volume (LVEDV) (ml) | 132 ± 35 | 136 ± 48 | p = NS |
| End-systolic volume (LVESV) (ml) | 75 ± 29 | 76 ± 29 | p = NS |
| Stroke volume index (SVI) (ml/m2) | 29 ± 11 | 33 ± 15 | p = NS |
| BNP (pg/ml) | 155 ± 71 | 141 ± 69 | p = NS |
| NYHA classification | II-III | II-III | p = NS |
| Rotated Component Matrix(a) | |||||
| Verbal Learning & Memory | Processing Speed | Attention and Working Memory | Verbal Fluency and Naming | Concept Formation | |
| Alpha | 0.883 | 0.731 | 0.555 | 0.457 | 0.179 |
| Word List Trial 1 | 0.592 | ||||
| Word List Trial 2 | 0.767 | ||||
| Word Recognition | 0.774 | ||||
| Word List Trial 3 | 0.792 | ||||
| Word List Cued Recall (Total) | 0.829 | ||||
| Word List Delayed Free Recall | 0.834 | ||||
| Choice RT Score Decile | 0.559 | ||||
| Simple RT Right Score Decile | 0.865 | ||||
| Simple RT Left Score Decile | 0.893 | ||||
| DATE Score | 0.373 | ||||
| Digit Span Backward (Span) | 0.784 | ||||
| Digit Span Forward (Span) | 0.804 | ||||
| President/VP Naming | 0.799 | ||||
| F Words (30 Seconds) | 0.504 | ||||
| Animal Naming (30 seconds) | 0.456 | ||||
| Serial 7's | 0.496 | ||||
| 4 Word Naming | 0.745 | ||||
| Similarities | 0.732 |
| Worry about infection of A/H1N1 | Take up preventive measures in daily life | |||||
| Variables | Row% | ORu (95% CI) | ORm(95% CI) | Row% | ORu (95% CI) | ORm(95% CI) |
| Know the main modes of transmission | ||||||
| No | 21.8 | 1.00 | 1.00 | 71.9 | 1.00 | 1.00 |
| Yes | 31.8 | 1.68(1.53-1.83) † | 1.69(1.54-1.86) † | 82.5 | 1.84(1.68-2.02) † | 1.57(1.42-1.73) † |
| Know the state's initial vaccination strategy | ||||||
| No | 24.9 | 1.00 | 1.00 | 68.3 | 1.00 | 1.00 |
| Yes | 28.9 | 1.22(1.12-1.34) † | 1.12(1.01-1.24)* | 82.7 | 2.21(2.02-2.43) † | 1.61(1.43-1.81) † |
| Know the free vaccination policy | ||||||
| No | 26.5 | 1.00 | NU | 69.4 | 1.00 | 1.00 |
| Yes | 28.1 | 1.08(0.98-1.19) | 81.6 | 1.96(1.78-2.16) † | 1.40(1.24-1.58) † | |
| Worry about infection of A/H1N1 | ||||||
| No | - | - | - | 74.4 | 1.00 | 1.00 |
| Yes | 87.9 | 2.51(2.22-2.84) † | 2.09(1.84-2.37) † | |||
| Has your daily life been disturbed by A/H1N1 | ||||||
| No | - | - | - | 73.4 | 1.00 | NS |
| Yes | 87.2 | 2.47(2.22-2.76) † |
| Predictor | B | SE B | β | R2 |
| Step 1 | .05*** | |||
| SES | .14 | .03 | .14*** | |
| City | .15 | .04 | .13*** | |
| 5th grade | .08 | .04 | .08* | |
| 6th grade | .11 | .04 | .11*** | |
| Step 2 | .08*** | |||
| Gender | -.07 | .03 | -.08* | |
| Ethnic status | -.15 | .03 | -.16*** | |
| Step 3a | .08* | |||
| Gender * ethnic status | -.60 | .30 | -.12* | |
| Mediator: School Hassles | ||||
| Step 3b | .20*** | |||
| Gender * ethnic status | -.30 | .28 | -.06 | |
| School hassles | .35 | .03 | .35*** |
| Subtype | Location |
| A | Pancreatic duct into parenchyma∗ |
| B | Pancreatic duct through parenchyma∗ |
| C | Intrahepatic bile ducts into parenchyma∗∗ |
| D | Intrahepatic bile ducts through parenchyma∗∗∗ |
| Group | TAV (mm3) |
| BMP group | 4.27 (3.08–18.23) |
| with pins (n = 2) | 20.87 (19.55–22.20) |
| without pins (n = 3) | 3.08 (1.68–3.68) |
| nonBMP group | 6.24 (5.71–7.52) |
| with pins (n = 2) | 12.25 (9.88–14.62) |
| without pins (n = 3) | 5.71 (3.15–5.98) |
| Control group | 2.75 (1.98–4.80) |
| Group | Pretest | Posttest | Adjusted mean |
| Chess | 1.75 (1.34) | 1.81 (1.69) | 1.64 |
| Checkers | 1.28 (0.96) | 1.60 (1.14) | 1.75 |
| Control | 1.41 (1.20) | 1.87 (1.36) | 1.83 |
| Haplotype | Frequencies | Patients/Deaths | HR (95% CI) a |
| TTGG | 0.415 | 379/184 | 1.00 |
| CTGA | 0.408 | 373/170 | 0.90 (0.73–1.10) |
| CCAA | 0.079 | 72/30 | 0.79 (0.54–1.17) |
| TTGA | 0.036 | 33//11 | 0.54 (0.30–1.00) |
| CTAA | 0.024 | 22//6 | 0.47 (0.21–1.07) |
| CTGG | 0.015 | 14//10 | 1.55 (0.81–2.94) |
| Characteristic | MetS present N = 73 | MetS absent N = 93 | P-value adjusted for age and sex |
| age (years) | 42.2 ± 1.6 | 34.8 ± 1.6 | 0.0019 |
| male (%) | 35.6 | 43.0 | NS (0.33) |
| current smokers (%) | 13.9* | 16.3† | NS (0.86) |
| BMI (kg/m2) | 31.3 ± 0.5 | 27.4 ± 0.5 | <0.0001 |
| waist (cm) | 104 ± 1 | 92.9 ± 1.2 | <0.0001 |
| hypertensive (%) | 54.8 | 18.3 | <0.0001 |
| antihypertensive treatment (%) | 19.2 | 5.4 | 0.017 |
| total cholesterol (mmol/L) | 5.21 ± 0.10 | 4.38 ± 0.08 | <0.0001 |
| HDL cholesterol (mmol/L) | 1.09 ± 0.03 | 1.27 ± 0.02 | <0.0001 |
| triglycerides (mmol/L) | 2.36 ± 0.11 | 1.24 ± 0.05 | <0.0001 |
| TC:HDL ratio | 4.99 ± 0.15 | 3.54 ± 0.09 | <0.0001 |
| fasting glucose (mmol/L) | 9.48 ± 0.54 | 6.34 ± 0.30 | <0.0001 |
| diabetes (%) | 67.1 | 17.2 | <0.0001 |
| IGT (%) | 8.2 | 14.0 | NS (0.72) |
| Cross-sectional | Longitudinal | |||
| Overweight T1 | School Sample | Overweight T1 | Overweight T2 | |
| n | 125 | 172 | 80 | 80 |
| Age | 6–16 | 7–17 | 6–16 | 7–18 |
| 11.02 (SD = 2.41) | 11.88 (SD = 2.45) | 11.29 (SD = 2.29) | 12.58 (SD = 2.26) | |
| Sex | 61 female | 88 female | 42 female | 42 female |
| 64 male | 84 male | 38 male | 38 male |
| Wild type | CD4−/− | |
| Eosinophilia(cells/mg of lung tissue) (as % of total white cells) | 684 ± 132 (6.3 %) | 648 ± 161 (4.3 %) |
| Neutrophilia(cells/mg of lung tissue) (as % of total white cells) | 6443 ± 1048 (45.3 %) | 7361 ± 2260 (49.1 %) |
| Tissue mono/macs(cells/mg of lung tissue) (as % of total white cells) | 639 ± 132 (4.5 %) | 686 ± 179 (9.4 %) |
| Alveolar macs(cells/mg of lung tissue) (as % of total white cells) | 292 ± 48 (2.1 %) | 241 ± 25 (1.6 %) |
| Mast cells (cells/slide) | 66 ± 12 | 77 ± 10 |
| Line item category | Uganda per district (US$) | Kenya per district (US$) | % Uganda | % Kenya |
| Equipment | 3,947 | 4,015 | 27.3 | 25.9 |
| Consumables | 502 | 91 | 3.5 | 0.6 |
| Salaries | 5,860 | 8,753 | 40.6 | 56.4 |
| Per diems | 20 | 84 | 0.1 | 0.5 |
| Total personnel | 5,880 | 8,837 | 40.7 | 57.0 |
| Fuel | 1,426 | 316 | 9.9 | 2.0 |
| Maintenance | 274 | 155 | 1.9 | 1.0 |
| Total transport (excl. training) | 1,700 | 472 | 11.8 | 3.0 |
| Travel & accommodation (for training) | 590 | 64 | 4.1 | 0.4 |
| Utilities | 623 | 797 | 4.3 | 5.1 |
| Room rental | 521 | 816 | 3.6 | 5.3 |
| Fees | 93 | 19 | 0.6 | 0.1 |
| Other | 585 | 401 | 4.1 | 2.6 |
| TOTAL | 14,439 | 15,512 | 100.0 | 100.0 |
| Ref. | Age | Sex | Implementation period | Admission to hospital | Location | Type of plant | Approach to lesions | Healing time |
| 2 | 64 | M | 12 h | Immediately | Left distal thigh | R. arvensis | Debridement, topical nitrofurantoin | 3 weeks |
| 3 | 17 | M | 48 h | 2 days | Back, scrotum, penis, chest | R. arvensis | Wet dressing, silver sulfadiazine, collogenase | 4 weeks |
| 4 | 42 | M | 8 h | 1 week | Left foot dorsum and ankle | C. testiculatus | Clorhexidine scrub + split thickness skin graft | 7 days |
| 40 | F | 4 h | 3 weeks | Right foot dorsum and ankle | C. testiculatus | Clorhexidine scrub + paraffin gauze | 10 days | |
| 60 | F | 2 h | 10 days | Right foot dosrum and left knee | C. testiculatus | Clorhexidine scrub + paraffin gauze | 7 days | |
| 65 | F | 2 h | 1 week | Left knee | C. testiculatus | Clorhexidine scrub+ paraffin gauze | 15 days | |
| 48 | F | 4 h | 14 days | Right leg | C. falcatus | Clorhexidine scrub + paraffin gauze | 2 weeks | |
| 5 | 52-76 | F:6 M:3 | 12 h | NA | Both knees: 7 One knee: 2 | R. constantinopolitanus | Topical antibacterial treatment | 10 d |
| 6 | 55 | F | 1 day | 2 days | Right knee | R. illyricus | Wet dressing and topical antibiotics | 4 days |
| 7 | 58 | F | 2 days | 5 days | Left knee | R. illyricus | Topical antibacterial cream | A few days |
| 54 | F | 1 days | 3 days | Right knee | R. illyricus | Wet dressing and topical antibiotic | 1 week | |
| 8 | 69 | M | 2.5 h | 2 days | Left knee | C. falcatus | Wet dressing and topical fusidic acid | 2 weeks |
| 33 | F | 1.5 h | 2 days | Right distal leg, ankle, dorsal foot | C. falcatus | Wet dressing and topical antibiotic | 3 weeks | |
| 18 | F | 1 h | 1 week | Left ankle, dorsal foot | C. falcatus | Wet dressing and topical antibiotic | 2 weeks | |
| 9 | 47 | F | 25 min | NA | Right knee | C. falcatus | Wet dressing and topical mometasone cream | 10 days |
| 10 | 45 | F | Overnight | 2 days | Abdomen, right leg | R. damascenus | Wet dressing and topical fusidic acid | 10 days |
| 11 | NA | F | NA | NA | Right ankle | C. falcatus | Wet dressing | 2 weeks |
| Current | 48 | M | 1 h | 1 days | Right thumb | R. arvensis | Dressing with fusidic acid | 3 weeks |
| 59 | F | Overnight | 3 days | Bilateral knee | R. arvensis | Clorhexidine scrub + silver sulfadiazine cream | 2 weeks | |
| 70 | F | 2 days | Immediately | Bilateral knee | R. arvensis | Clorhexidine scrub + silver sulfadiazine cream | 10 days |
| Baseline characteristics | Overall no. of patients (%) | Arm A (%) | Arm B (%) | Arm C (%) |
| Total | 19 | 5 | 8 | 6 |
| Age | ||||
| Median | 60 | 51 | 57.5 | 61.5 |
| Range | 27–86 | 27–71 | 50–86 | 47–77 |
| Sex | ||||
| Male | 6 (32) | 1 (20) | 4 (50) | 1 (17) |
| Female | 13 (68) | 4 (80) | 4 (50) | 5 (83) |
| ECOG Performance Status | ||||
| 0 | 10 | 2 | 4 | 4 |
| 1 | 9 | 3 | 4 | 2 |
| Stage at Trial Entry | ||||
| No evidence of disease | 4 (21) | 2 (40) | 0 (0) | 2 (33) |
| Locally advanced | 1 (5) | 0 (0) | 0 (0) | 1 (17) |
| Metastatic* | 14 (74) | 3 (60) | 8 (100) | 3 (50) |
| Prior Therapy | ||||
| Chemotherapy alone | 5 | 1 | 3 | 1 |
| Chemotherapy/RT alone | 2 | 0 | 1 | 1 |
| Surgery total | 12 | 4 | 4 | 4 |
| Surgery followed by chemotherapy | 7 | 3 | 2 | 2 |
| 5 | 1 | 2 | 2 | |
| Surgery followed by chemo/RT | ||||
| Prior surgical resection | ||||
| Yes | 12 (63) | 4 (80) | 4 (50) | 4 (67) |
| No | 7 (37) | 1 (20) | 4 (50) | 2 (33) |
| Serum CEA at trial initiation (ng/mL) | ||||
| Median | 4.8 | 5.3 | 4.65 | 7.95 |
| Range | 1–246.7 | 1.1–34.2 | 2.1–246.7 | 1–18.1 |
| Serum CA-19-9 at trial initiation (ng/mL) | ||||
| Median | 532 | 22 | 1067 | 27 |
| Range | 3–96,900 | 3–2,710 | 3–96,900 | 3–30,300 |
| Method | Precision | Recall | F1 |
| SVM only | 0.6 | 0.12 | 0.2 |
| With del+WkNN | 0.7879 | 0.26 | 0.391 |
| With add+WkNN | 0.66 | 0.33 | 0.44 |
| With del+SoftSL | 0.2140 | 0.64 | 0.3208 |
| With add+SoftSL | 0.4653 | 0.47 | 0.4677 |
| without hot compress | with hot compress | |
| ICG-half-life [min] | 5.88 ± 0.49 | 5.35 ± 0.5 |
| k-value (%/min) | 11.8 ± 1.0 | 13.0 ± 1.2 |
| Room temperature [°C] | 21.2 ± 0.8 | 22.1 ± 0.6 |
| Skin temperature right upper abdomen [°C] | 32.8 ± 0.9 | 40.6 ± 1.6 |
| Heart rate [1/min] | 68.0 ± 8.4 | 68.0 ± 11.0 |
| Systolic blood pressure [mmHg] | 132 ± 18 | 132 ± 21 |
| Diastolic blood pressure [mmHg] | 86 ± 11 | 87 ± 16 |
| Management | All patients(n = 1,903) | Age ≥ 65 years(n = 975) | Age < 65 years(n = 928) |
| Initial method (%) | |||
| Sedation without paralysis | 682 (36) | 360 (37) | 322 (35) |
| Oral without medication | 546 (29) | 298 (31) | 248 (27) |
| Rapid sequence intubation | 542 (28) | 269 (28) | 273 (29) |
| Other* | 133 (7) | 48 (5) | 85 (9) |
| Initial device (%) | |||
| Direct laryngoscope | 1,810 (95) | 933 (96) | 877 (95) |
| Video laryngoscope | 44 (2) | 17 (2) | 27 (3) |
| Other† | 49 (3) | 25 (3) | 24 (2) |
| Sedative (%) | |||
| No sedatives | 724 (38) | 372 (38) | 352 (38) |
| Benzodiazepine | 630 (22) | 343 (35) | 287 (31) |
| Propofol | 447 (23) | 205 (21) | 242 (26) |
| Ketamine | 66 (3) | 42 (4) | 24 (3) |
| Other‡ | 36 (2) | 13 (1) | 23 (2) |
| Paralytic (%) | |||
| No paralytics | 1,291 (68) | 689 (71) | 602 (65) |
| Rocuronium | 402 (21) | 177 (18) | 225 (24) |
| Vecuronium | 150 (8) | 75 (8) | 75 (8) |
| Succinylcholine | 60 (3) | 34 (3) | 26 (3) |
| Specialty of first intubator (%) | |||
| Transitional year resident§ | 703 (37) | 384 (39) | 319 (34) |
| Emergency medicine resident | 648 (34) | 298 (31) | 350 (39) |
| Emergency physician | 348 (18) | 180 (18) | 168 (18) |
| Other specialties¶ | 202 (11) | 113 (12) | 89 (10) |
| Number of intubation attempts, median (IQR) | 1(1–2) | 1(1–2) | 1 (1–2) |
| > 3 intubation attempts (%) | 255 (13) | 128 (13) | 127 (14) |
| Ultimate intubation success (%) | 5 (< 1) | 3 (< 1) | 2 (< 1) |
| siRNA name | sequence |
| A2-3UTR 1 | 5′-UUAAUUCUCUCCGUAGCUCCCCC-3′ |
| A2-3UTR 2 | 5′-UCUUACUGUUCCAUUGGCCCCC-3′ |
| A2-3UTR 3 | 5′-AUUAUCCUUAAGAACCUAGCCCCC-3′ |
| A2-3UTR 4 | 5′-UUCUUACUGUUCCAUUGGCCCCC-3′ |
| scrambled siRNA | 5′-UAAGCACGAAGCUCAGAGUCCCCC-3′ |
| Number of patients (%) | Return of spontaneous circulation (n) | P value | Initial survival | Final survival | |||
| n | P value | n | P value | ||||
| Age | 0.027 | 0.149 | 0.390 | ||||
| <1 month | 2 (4.5%) | 1 | 0 | 0 | |||
| 1–12 months | 9 (20.4%) | 2 | 2 | 0 | |||
| 1–8 years | 13 (29.5%) | 10 | 5 | 0 | |||
| >8 years | 20 (45.4%) | 15 | 12 | 3 | |||
| Gender | 1 | 0.753 | 0.290 | ||||
| Female | 16 (36.3%) | 18 | 6 | 0 | |||
| Male | 28 (63.6%) | 10 | 13 | 3 | |||
| Site of arrest | 0.827 | 1 | 0.693 | ||||
| Home | 6 (13.6%) | 5 | 3 | 0 | |||
| Public place | 13 (29.5%) | 7 | 5 | 1 | |||
| Emergency Department | 3 (6.8%) | 2 | 1 | 0 | |||
| Pediatric intensive care unit | 18 (40.9%) | 11 | 8 | 1 | |||
| Other hospital areas | 4 (9%) | 3 | 2 | 1 | |||
| Inhospital versus out-of hospital | 1 | 1 | 1 | ||||
| Inhospital | 22 (50%) | 14 | 10 | 2 | |||
| Out-of-hospital | 22 (50%) | 14 | 9 | 1 | |||
| Diagnosis | 0.256 | 0.484 | .06 | ||||
| Heart disease or arrhythmia | 18 (40.9%) | 13 | 9 | 2 | |||
| Respiratory disease | 1 (2.2%) | 1 | 1 | 1 | |||
| Neurological disease | 8 (18.1%) | 5 | 3 | 0 | |||
| Infectious disease | 3 (6.8%) | 2 | 1 | 0 | |||
| Drowning | 4 (9%) | 3 | 2 | 0 | |||
| Sudden infant death syndrome | 4 (9%) | 0 | 0 | 0 | |||
| Traumaa | 1 (2.2%) | 1 | 0 | 0 | |||
| Other | 2 (4.5%) | 1 | 1 | 0 | |||
| Unknown | 3 (6.8%) | 2 | 2 | 0 |
| Comorbidity | Classification by severity | PCs | ||
| n | n (%) | p | ||
| Heart disease | surgical or interventional | 19 | 5 (26) | 0.26 |
| only medication | 31 | 13 (42) | ||
| COPD | stage 3 or 4* | 8 | 0 (0) | 0.60 |
| stage 1 or 2 | 104 | 17 (16) | ||
| CNS disease | paralysis | 8 | 2 (25) | 0.69 |
| no paralysis | 31 | 11 (35) | ||
| Liver disease | cirrhosis | 8 | 5 (63) | 0.16 |
| hepatitis | 13 | 3 (23) | ||
| Renal dysfunction | dialysis | 5 | 2 (40) | 0.65 |
| no dialysis | 49 | 15 (31) | ||
| Diabetes mellitus | regular use of insulin | 16 | 4 (25) | 0.46 |
| oral medication | 51 | 8 (16) |
| 1. Of three influenza reference strains provided to WHO (A/California/7/2009, A/California/4/2009 and A/Texas/5/2009) by NHRC and USAFSAM, the A/California/7/2009 was selected as the seed strain. |
| 2. Two biosafety-level 3 (BSL-3) laboratories were commissioned in 2009 at NHRC in San Diego, Calif., and AFRIMS in Bangkok, Thailand; and two BSL-2 laboratories were commissioned, one at the University of Buea, Cameroon, and one on the campus of the Cameroonian Army installation in Yaoundé, Cameroon, under supervision of the Global Viral Forecasting Initiative. |
| 3. NAMRU-3 partners reported the first definitive evidence of human cutaneous leishmaniasis from Leishmania major infections in Ghana. |
| 4. AFRIMS published the first report of clinically significant Plasmodium falciparum malaria resistance to the potent artemisinin antimalarial drug class, spurring WHO, Bill & Melinda Gates Foundation and host national malaria control officials to institute aggressive measures to contain and eliminate artemisinin-resistant malaria in Southeast Asia. |
| 5. The first documented cases of Venezuelan equine encephalitis, brucellosis, dengue and Q fever in Ecuador were reported by NMRCD-Lima, and the first laboratory-confirmed cases of leptospirosis in the border areas of Thailand and Myanmar were reported by AFRIMS. |
| 6. AFRIMS provided timely outbreak response services to the Nepali National Public Health laboratory, ultimately characterizing (by pulse-field gel electrophoresis) nearly 6,000 cases of multidrug-resistant typhoid fever originating from a single point source, and uniformly quinolone-resistant. |
| 7. NAMRU-3 worked closely with WHO to conduct novel A/H1N1 laboratory diagnostic training for 73 participants representing 32 different countries in a strategic and timely two-week period in May 2009. |
| 8. NEPMU-2, NAMRU-3, and AFHSC collaboratively supported CENTCOM efforts in establishing in-theatre novel A/H1N1 testing and isolation of servicemembers deployed or deploying to sites around the world. |
| 9. The WRAIR/USAMRU-K Malaria Diagnostics and Control Center of Excellence, established in 2003, having trained more than 600 malaria microscopists, established new malaria diagnostics training capabilities in Nigeria and Tanzania, leading to a visit by the president of Tanzania to WRAIR to establish new collaborations between the U.S. Army and Tanzania. |
| 10. NMRCD, as part of its expansive febrile-disease surveillance network in the Amazon basin, published the first comprehensive study of the etiologies of undifferentiated febrile illness in Ecuador, documenting the first laboratory-confirmed cases of Venezualan equine encephalitis, brucellosis, dengue and Q fever in Ecuador. |
| Protein | Description | Other Aliases |
| BOD1 | biorientation of chromosomes in cell division 1 | FAM44B |
| CENPW | centromere protein W | CUG2 |
| CENPN | centromere protein N | CENP-N |
| CCNB2 | cyclin B2 | HsT17299 |
| CDKN3 | cyclin-dependent kinase inhibitor 3 | KAP |
| CKS1B | CDC28 protein kinase regulatory subunit 1B | CKS1 |
| CKS2 | CDC28 protein kinase regulatory subunit 2 | CKSHS2 |
| ERH | enhancer of rudimentary homolog (Drosophila) | DROER |
| GMNN | geminin, DNA replication inhibitor | Gem |
| HAUS1 | HAUS augmin-like complex, subunit 1 | CCDC5 |
| ITGB3BP | integrin beta 3 binding protein (beta3-endonexin) | CENPR |
| MAD2L1 | MAD2 mitotic arrest deficient-like 1 (yeast) | MAD2 |
| MAD2L2 | MAD2 mitotic arrest deficient-like 2 (yeast) | MAD2B |
| MITD1 | microtubule interacting and trafficking domain containing 1 | _ |
| NUP37 | nucleoporin 37 kDa | p37 |
| RAN | RAN, member RAS oncogene family | Gsp1 |
| SPC25 | SPC25, NDC80 kinetochore complex component, homolog (S. cerevisiae) | SPBC25 |
| OIP5 | Opa interacting protein 5 | MIS18B |
| Tool | Method | Symbol | Ref. | Time/Gbase |
| FragGeneScan | Hidden Markov Model | FGS3,FGS5 | [11] | 6 hours |
| MetaGeneAnnotator | Codon usage + start site heuristics | MGA | [9] | 15 min |
| MetaGeneMark | Codon usage + gc-content heuristics | MGM | [8] | 20 min |
| Orphelia | Neural network | OPH | [10] | 13 hours |
| Prodigal | Codon usage + dynamic programming | PRD | [12] | 30 min |
| Parameters | AM | PM | ABS Diff | % Error | |
| Mean ± SD (max) | Mean ± SD (max) | Mean ± SD (max) | Mean ± SD (max) | P Value | |
| SS Angle | 38.26 ± 9.16(53.8) | 37.82 ± 10.15(56.3) | 37.82 ± 10.15(56.3) | 16.17 ± 20.28(99.02) | 0.72 |
| AOD 500 | 0.42 ± 0.14(0.69) | 0.41 ± 0.15(0.75) | 0.07 ± 0.06(0.27) | 20.39 ± 22.07(105.7) | 0.68 |
| AOD 750 | 0.59 ± 0.18(0.94) | 0.6 ± 0.22(1.15) | 0.09 ± 0.09(0.4) | 15.39 ± 14.35(51.32) | 0.68 |
| TISA 500 | 0.18 ± 0.12(0.62) | 0.14 ± 0.06(0.25) | 0.06 ± 0.11(0.46) | 26.5 ± 33.69(123.03) | 0.13 |
| TISA 750 | 0.27 ± 0.09(0.46) | 0.27 ± 0.1(0.46) | 0.05 ± 0.04(0.18) | 17.56 ± 18.75(71.61) | 0.93 |
| N =236 | MV1 | Validation Sample S-QoL 18 matched by age and gender N=236 | ||
| 1. Sociodemographics | N (%) | % | N (%) | |
| Gender | Men | 205 (86.9) | 0.0 | 205 (86.9) |
| Age (years) | M (SD)2 | 37.9 (10.8) | 0.0 | 37.9 (10.7) |
| Marital status | Single | 218 (94.0) | 1.7 | NA6 |
| 2. Clinical characteristics | M(SD)2 | % | ||
| MCSI3 | Total score | 21.6 (12.4) | 18.6 | NA |
| RAS4 | Personal confidence and hope | 31.7 (6.5) | 20.8 | NA |
| Willingness to ask for help | 10.0 (2.7) | 8.9 | ||
| Goal and success orientation | 19.4 (3.8) | 7.2 | ||
| Reliance on others | 13.6 (4.1) | 12.3 | ||
| No domination by symptoms | 8.9 (3.2) | 11.0 | ||
| SF-365 | Physical Functioning | 82.7 (26.4) | 0.04 | 79.1 (22.1) |
| Social Functioning | 52.7 (33.5) | 0.12 | 54.4 (29.0) | |
| Role—Physical Problems | 74.6 (30.2) | 0.12 | 43.9 (35.6) | |
| Role—Emotional Problems | 55.8 (33.4) | 0.12 | 39.6 (41.7) | |
| Mental Health | 48.2 (22.0) | 0.12 | 57.2 (20.1) | |
| Vitality | 44.0 (20.1) | 0.12 | 48.4 (19.0) | |
| Bodily Pain | 65.6 (32.6) | 0.12 | 64.7 (27.0) | |
| General Health | 54.4 (21.0) | 0.12 | 54.8 (20.1) | |
| Mental composite score | 34.7 (12.5) | 0.12 | 37.3 (11.1) | |
| Physical composite score | 51.4 (11.1) | 0.12 | 46.9 (7.9) |
| Medium/Organism | Staphylococcus aureus | Staphylococcus epidermidis | Escherichia coli | Candida albicans |
| Mueller-Hinton agar | x | x | x | x |
| Blood agar | x | x | x | |
| Blood agar-NaCl | x | x | ||
| CHROMagar Candida | x | |||
| Roosvelt-Park Institute Medium 1640 with L-glutamine | x | x | x | x |
| Sabouraud agar | x | |||
| Endo agar | x |
| Proposed legislation changes | |||||||
| Community supervision | |||||||
| Broad definition of mental disorder | |||||||
| Detention of DSPD | |||||||
| More general tribunal members | |||||||
| Communication amongst services | |||||||
| Overall assessment |
| Variable | Percent (%) |
| Fitzpatrick skin score grades 4 and 5 | 79 |
| Using sunscreen | 24.2 |
| Exposure to direct sunlight <15 min/day | 71 |
| Milk and milk product (servings/day) | |
| None | 23 |
| 1 to 2 | 64 |
| 3 to 4 | 9 |
| >4 | 4 |
| Fortified breakfast cereal (servings/week) | |
| None | 73.6 |
| 1 to 2 | 12.8 |
| 3 to 4 | 12 |
| >4 | 1.6 |
| Fish (servings/week) | |
| None | 23 |
| 1 to 2 | 46.2 |
| 3 to 4 | 25.3 |
| >4 | 5.5 |
| Cod liver oil | 17.6 |
| Vitamin D supplement | 24.2 |
| Patient | Age | Clinical signs | Metal ions in peripheral blood | CRP (>5 mg/L) | White cell count (>10/nl) | Duration of implantation (years) | Articulating material |
| a) Chrome (>7 μg/L) | |||||||
| b) Cobalt (>7 μg/L) | |||||||
| Metallosis | |||||||
| 1 | 62 | Pain, osteolysis around cup on x-ray | a) 21.3 μg/L | 2.3 mg/L | 4.55/nl | 8 | Metal on metal |
| b) 37.6 μg/L | |||||||
| 2 | 47 | Pain | a) 17.7 μg/L | 16.6 mg/L | 8.96/nl | 5 | Metal on metal |
| b) 38.90 μg/L | |||||||
| 3 | 42 | Pain | a) 4.06 μg/L | 3.6 mg/L | 9.39/nl | 6 | Metal on metal |
| b) 5.49 μg/L | |||||||
| 4 | 71 | Pain | a) 15.0ug/L | 6.9 mg/L | 5.89/nl | 6 | Metal on metal |
| b) 30.0ug/L | |||||||
| 5 | 60 | Non | a) 43.0 μg/L | 2.0 mg/L | 5.70/nl | 8 | Metal on metal |
| b) 64.0 μg/L | |||||||
| Patient | Age | Clinical signs | CRP (>5 mg/l) | White cell count (>10/nl) | Duration of implantation (years) | Articulating material | |
| Aseptic loosening | |||||||
| 1 | 70 | Pain, osteolysis around cup and stem on x-ray | 17.3 mg/l | 4.91/nl | 19 | Ceramic on polyethylene | |
| 2 | 71 | Pain, osteolysis around stem on x-ray | 10.0 mg/l | 8.17/nl | 3 | Ceramic on polyethylene | |
| 3 | 75 | Pain, osteolysis around cup on x-ray | 2.0 mg/l | 5.74/nl | 15 | Metal on polyethylene | |
| 4 | 59 | Pain, osteolysis around stem on x-ray | 2.0 mg/l | 3.53/nl | 2 | Ceramic on polyethylene | |
| 5 | 81 | Pain, osteolysis around stem on x-ray | 2.0 mg/l | 6.92/nl | 12 | Metal on polyethylene | |
| 6 | 84 | Pain, osteolysis around stem on x-ray | 2.0 mg/l | 6.1/nl | 6 | Metal on polyethylene |
| Antigen | Species | Source | Number | Dilution (Western) | Dilution (IHC) | Pepsin (IHC) |
| γ-2 | Guinea pig | M. Watanabe | — | 1:500 | — | — |
| γ-2b | Rabbit | Cell Signaling Technology | 8511 | — | 1:200 | Yesc |
| γ-3 | Guinea pig | M. Watanabe | — | 1:500 | — | — |
| γ-4 | Rabbit | Abcam | ab81107 | 1:500 | — | — |
| γ-5 | Rabbit | M. Watanabe | — | 1:500 | — | — |
| γ-7 | Rabbit | Frontiers Institute | Af720 | 1:500 | 1:500 | No |
| γ-8 | Rabbit | Frontiers Institute | Af1000 | 1:2000 | 1:1000 | No |
| GluA1 | Rabbit | Abcam | ab31232 | — | 1:500 | Yes |
| GluA2 | Mouse | Millipore | MAB397 | 1:500 | 1:500 | Yes |
| c-Fos | Goat | Santa Cruz Biotechnology | sc-52-G | — | 1:100 | No |
| Actin | Mouse | Abcam | ab3280 | 1:5000 | — | — |
| GFP | Chicken | Abcam | Ab13970 | — | 1:500 | No |
| CGRPb | Mouse | Sigma | C7113 | — | 1:400 | No |
| vGluT1b | Guinea pig | Synaptic Systems | 135 304 | — | 1:400 | No |
| vGluT2b | Guinea pig | Millipore | AB2251 | — | 1:4000 | No |
| PEmb-QoL questions | Number of items | Cronbach’s alpha | Average inter-item correlation (r) | |
| Frequency of complaints | Q1 | 8 | 0.90 | 0.52 |
| Activities of daily living limitations | Q4 | 13 | 0.95 | 0.60 |
| Work-related problems | Q5 | 4 | 0.91 | 0.72 |
| Social limitations | Q6 | 1 | - | - |
| Intensity of complaints | Q7, Q8 | 2 | 0.70 | 0.54 |
| Emotional complaints | Q9 | 10 | 0.92 | 0.52 |
| PEmb-QoL summary score | Q1, Q4, Q5, Q6, Q7, Q8, Q9 | 38 | 0.92 | 0.44 |
| Patient no. | Diagnosis | Source | PB-blast% | BM-blast% | WBC | FAB | Cytogenetics | Status |
| 1 | AML | PB | 92 | M1 | OD | New | ||
| 2 | AML | PB | 331.08 | M1 | CD34-ANLL | New | ||
| 3 | AML | PB | 82 | 4.8 | 81.5 | M2b | FLT-ITD | New |
| 4 | AML | PB | 88 | 29.5 | M1 | CEBPA mutation; BCR-ABL(9;22)(+) | New | |
| 5 | AML | PB | 87.5 | 43.36 | M5a | CBFβ/MYH11(+);BCR/ABL(-) | New | |
| 6 | AML | PB | 219.79 | M1 | BCR-ABL(9;22)(+), Ph (+) | New | ||
| 7 | AML | PB | 52 | 4.64 | M1 | OD | New | |
| 8 | AML | PB | 92 | 53.48 | M1 | 46XX[20] CD34-ANLL | Relapsed | |
| 9 | AML | PB | 98 | 156.9 | M1 | OD | New | |
| 10 | AML | PB | 96 | 143 | M1 | BCR/ABL | New | |
| 11 | AML | PB | 12.68 | M2 | OD | New | ||
| 12 | AML | PB | 229 | M1 | OD | New | ||
| 13 | AML | PB | 55 | 15.3 | 14.3 | M1 | OD | Relapsed |
| 14 | AML | PB | 96 | 102.5 | M1 | OD | New | |
| 15 | AML | PB | 31.0 | M1 | OD | New | ||
| 16 | AML | PB | 63.5 | 181.2 | M0 | TEL/AML1(+);C-Kit, NPM1, CEBPA, FLT3/ITD(-) | New | |
| 17 | AML | PB | 3.88 | M3 | PML-RARa(+) | Relapsed | ||
| 18 | AML | PB | >20 | 1.94 | M6 | OD | New | |
| 19 | AML | PB | 8 | 19.1 | M5b | WT1(+) | New | |
| 20 | AML | PB | <10 | 14.7 | M5 | FISH-t (15;17) PML-RARa (bcr3) | New | |
| 21 | AML | PB | 28 | 51.2 | M2a | t(9;22) Bcr/abl (+); JAK2V617F(+) MLL/EVI1; MLL+ | New | |
| 22 | AML | PB | 42 | 116.3 | M4a | WT1 (+); FLT3-ILD (+) | Relapsed | |
| 23 | AML | PB | 24.5 | 77.4 | M2b | FISH-AML/ETO (-); FLT3-ILD (+) | New |
| Statement regarding condition | |||||
| With a typical asthmatic patient, how often do you actually talk about exercise? | Never or rarely: 12 (4.4) | Sometimes: 85 (31.1) | Usually or always: 176 (64.5) | ||
| How relevant do you think talking to asthmatic patients about exercise will be in your intended practice? | Not at all: 8 (3.0) | Somewhat: 95 (35.3) | Highly: 166 (61.7) | ||
| How much training have you had on talking to asthmatic patients about exercise? | None: 90 (33.2) | Some: 116 (42.8) | Extensive: 65 (24.0) | ||
| Data presented as n (%) | |||||
| Statement regarding condition | Strongly agree | Agree | Neither agree nor disagree | Disagree | Strongly disagree |
| n (%) | n (%) | n (%) | n (%) | n (%) | |
| Doctors need more training in preventive care | 151 (55.1) | 111 (39.6) | 9 (3.2) | 2 (0.7) | 1 (0.4) |
| I will be able to provide more credible and effective counseling if I eat a healthy diet | 103 (36.8) | 128 (45.7) | 29 (10.4) | 13 (4.6) | 3 (1.1) |
| I will be able to provide more credible and effective counseling if I exercise and stay fit | 116 (42.2) | 129 (46.9) | 21 (7.6) | 8 (2.9) | 1 (0.4) |
| I will be able to provide more credible and effective counseling if I maintain a healthy weight | 117 (42.4) | 135 (48.9) | 19 (6.9) | 5 (1.8) | 0 (0) |
| Locus | P Value | ||||
| All HSR | SJS/TEN | DILI | NIR | HSS | |
| HLA-A | 894 | .015 | .429 | .672 | .135 |
| HLA-B | 111 | .160 | .068 | .478 | .066 |
| HLA-C | 036 | .014 | .179 | .489 | .564 |
| HLA-DQB1 | 002* | .003* | .006 | .148 | .030 |
| HLA-DRB1 | 137 | .123 | .018 | .455 | .477 |
| Damage Case | I | D1 | D2 | D3 | D4 | D5 | D6 | D7 | D8 |
| Damage quantity of E3 (%) | 0 | 3 | 5 | 15 | 18 | 18 | 18 | 18 | 18 |
| Damage quantity of E7 (%) | 0 | 0 | 0 | 0 | 0 | 3 | 5 | 15 | 18 |
| Steps | Selected questions and issues raised by the example case study “Maria Morales” |
| 1. Identify and frame in own words: What is the underlying moral conflict? | Can a parents’ right to not have an intervention done with their child be overridden by the state (for someone else’s good)? Furthermore: Can parents exercise their will on behalf of their children? |
| 2. Identify and frame in ethical words: Which ethical principles are relevant, how can they be specified and might they be in conflict to each other? | Overall, the principles respect for autonomy and health maximisation seem to be affected and seem to mutually exclude each other. But one also has to ask whose autonomy is at stake. Parents’ autonomy – but what about the future autonomy of children? Furthermore, the immunising doctor might be indecisive whether to advocate for autonomy, health maximisation or non-maleficence. |
| 3. Zoom further in: Do I have all relevant information? Can I get more background information to understand all particularities? | What are the potential side effects of measles immunisation? How severe are measles for children? About how many persons (to be vaccinated against their parents’ will) can be protected, which effect would such an immunisation programme have on the incidence of measles and which side-effects could actually be prevented? |
| 4. Are alternative solutions feasible with less moral issues/costs? | Can there be alternative approaches to mandatory measles immunisation? Can one raise immunisation rates by informing, advertising, setting incentives for parents? |
| 5. Further Specification: Do the specifications change with more information? | If there are alternative ways that are less infringing on the respect for autonomy but rather support the health maximisation and the protection of those who cannot be immunised (ensuring non-maleficence), then these alternatives have a higher moral value. |
| 6. Weighing: Are all conflicting principles and their specifications still of equal value? | If other measures (incentive setting, education campaigns for immunisation) can be successfully implemented elsewhere, mandatory immunisation seems less necessary. Yet, autonomy of the parents (who are safeguarding the autonomy of their children) attains even more weight. |
| 7. What do I conclude from the specification and weighing? What would be my solution to the problem? | Mandatory measles immunisation would – in this very particular situation – not be necessary in order to achieve best health and given that it would infringe autonomy of parents (and allegedly of children), it should not be applied. |
| 8. Integrity: Can I personally accept the conclusion drawn? | It seems to be a suitable solution to – at least first – try other measures, rather than being in charge of forcing parents and children to have children’s bodies ‘invaded’ against their ‘guards’ will. |
| 9. Act and convince: I act according to my judgment and convince colleagues and others also based on ethical reasoning. | I try to find resources within my professional budget and start action to promote immunisation with other means. |
| GenBank Accession Number | Previous name | New name |
| CAA78718 | X. laevis Apx | xShroom1 |
| NP_597713 | H. sapiens APXL2 | hShroom1 |
| CAA58534 | H. sapiens APXL | hShroom2 |
| ABD19518 | M. musculus Apxl | mShroom2 |
| AAF13269 | M. musculus ShroomL | mShroom3a |
| AAF13270 | M. musculus ShroomS | mShroom3b |
| NP_065910 | H. sapiens Shroom | hShroom3 |
| ABD59319 | X. laevis Shroom-like | xShroom3 |
| NP_065768 | H. sapiens KIAA1202 | hShroom4a |
| AAK95579 | H. sapiens SHAP-A | hShroom4b |
| DQ435686 | M. musculus KIAA1202 | mShroom4 |
| ABA81834 | D. melanogaster Shroom | dmShroom |
| EAA12598 | A. gambiae Shroom | agShroom |
| XP_392427 | A. mellifera Shroom | amShroom |
| XP_783573 | S. purpuratus Shroom | spShroom |
| Family | Plant species | Plant part | Extraction | Repellency% | ||
| (minutes post application) | ||||||
| 60 | 120 | 180 | ||||
| Asteraceae | Litogyne gariepina | Roots | DCM | 75 | 52 | 57 |
| Buddlejaceae | Nuxia floribunda | Leaves | DCM/MeOH(1:1) | 43 | 42 | 35 |
| Chenopodiaceae | Chenopodium opulifolium | Roots | Water | 97 | 17 | 30 |
| Lamiaceae | Leucas martinicensis | Leaves | DCM | 60 | 57 | 49 |
| Malvaceae | Sida cordifolia | Whole Plant | DCM/MeOH(1:1) | 40 | 23 | 10 |
| Negative control | Distilled water | 10 | 20 | 20 | ||
| Negative control | Acetone | 17 | 20 | 33 | ||
| Positive control | DEET | 100 | 100 | 100 |
| Gender | Age range (percentage) | Total | |||||
| 0-6 | 7-13 | 14-21 | 22-29 | 30-40 | > 40 | ||
| Female | 56 (24.1) | 82 (35.3) | 35 (15.1) | 34 (14.7) | 19 (8.2) | 6 (2.6) | 232 (100) |
| Male | 62 (14.9) | 121 (29.2) | 118 (28.4) | 62 (14.9) | 37 (8.9) | 15 (3.6) | 415 (100) |
| Total | 118 (18.2) | 203 (31.4) | 153 (23.6) | 96 (14.8) | 56 (8.7) | 21 (3.2) | 647 (100) |
| Area | Layer | Area * Layer | |
| Squirrel monkey | F(3, 6) = 34.15, p < 0.01* | F(1, 6) = 21.43, p = 0.04* | F(3, 6) = 3.59, p = 0.09 |
| Capuchin | F(3, 9) = 5.58, p = 0.02* | F(1, 9) = 20.01, p = 0.02* | F(3, 9) = 14.17, p < 0.01* |
| Moor macaque | F(3, 9) = 6.29, p = 0.01* | F(1, 9) = 79.83, p < 0.01* | F(3, 9) = 6.40, p = 0.01* |
| Pigtailed macaque | F(3, 12) = 4.01, p = 0.03* | F(1, 12) = 66.76, p < 0.01* | F(3, 12) = 0.54, p = 0.66 |
| Baboon | F(3, 9) = 7.43, p = 0.01* | F(1, 9) = 23.98, p = 0.02* | F(3, 9) = 2.26, p = 0.15 |
| Gorilla | F(3, 6) = 0.34, p = 0.80 | F(1, 6) = 23.38, p = 0.04* | F(3, 6) = 0.95, p = 0.47 |
| Chimpanzee | F(3, 9) = 0.10, p = 0.96 | F(1, 9) = 1.52, p = 0.31 | F(3, 9) = 1.58, p = 0.26 |
| Human | F(3, 9) = 3.98, p = 0.07 | F(1, 9) = 0.71, p = 0.49 | F(3, 9) = 0.68, p = 0.60 |
| HD score grade | Breed | Total | ||||||||
| Boxer | Doberman | Great Dane | Golden Retriever | German Shepherd | Hungarian Vizla | Labrador Retriever | Rottweiler | Rhodesian Ridgeback | ||
| >18 | - | 1 | - | - | 77 | 10 | 10 | - | 98 | |
| 13-18 | - | - | 1 | 1 | 139 | 1 | 26 | 22 | 3 | 193 |
| 9-12 | 3 | 5 | 2 | - | 147 | - | 30 | 30 | 6 | 223 |
| 7-8 | - | 1 | - | - | 20 | - | 5 | 14 | 1 | 41 |
| 4-6 | - | 2 | - | - | 13 | - | 1 | 15 | 4 | 35 |
| 1-3 | - | - | - | - | - | - | - | 1 | - | 1 |
| Total | 3 | 9 | 3 | 1 | 396 | 1 | 72 | 92 | 14 | 591 |
| Pain increase at 6-weeks. | Pain increase at 6-months. | |||
| NRS Points (95% confidence interval) | P value | NRS Points (95% confidence interval) | P value | |
| Preoperative anxiety (yes/no) | −.30 (−1.22–.63) | .52 | .42 (−.63–1.46) | .43 |
| Age (years) | −.02 (−.04–.01) | .31 | .00 (−.03–.03) | .98 |
| BMI (points) | −.06 (−.16–.05) | .29 | .13 (.01–.25) | .04* |
| Sex (male) | −.22 (− 1.15–.71) | .64 | −.46 (− 1.51–.59) | .39 |
| Preoperative pain (points) | .36 (.18–.54) | .00* | .36 (.16–.56) | .00* |
| Chronic pain (yes/no a) | .88 (−.08–1.85) | .07 | .55 (−.54–1.63) | .32 |
| Intercept | 3.04 (−.56–6.64) | .10 | − 1.96 (−6.02–2.10) | .34 |
| Antibodies | Species | Dilution | Source | Code no. |
| P2X2 | Rabbit | 1:100 | Alomone | APR-003 |
| IP3R3 | Mouse | 1:100 | Transduction Lab. | 610313 |
| Syntaxin-1 | Mouse | 1:100 | Sigma | S0664 |
| Serotonin | Mouse | 1:100 | Abcam | ab16007 |
| No. | Statement | Rank | Z-score |
| Defining statements | |||
| Agrees strongly with the following statements | |||
| 12 | I value more time for my personal life | 3 | 1.59 |
| 16 | I want to be in a large city | 3 | 1.53 |
| 32 | The fact that subspecialists can also be general internists is important to me | 2 | 1.20 |
| 20 | I want something that pays well given how long we’ve trained | 2 | 1.13 |
| 25 | I’d like to do a combination of inpatient and outpatient | 2 | 1.12 |
| 13 | Lifestyle and more control over my practice are important | 2 | 1.10 |
| 31 | A two-year GIM fellowship is a deterrent | 1 | 1.04 |
| 35 | I want to be valued in what I’m doing | 1 | 1.02 |
| 14 | I want to be in a field that is in demand | 1 | 1.01 |
| Disagrees strongly with the following statements | |||
| 36 | GIM is a dumping ground for patients nobody wants | -2 | -1.13 |
| 9 | The negative interactions with attendings were important | -2 | -1.21 |
| 7 | GIM patients are too complex | -2 | -1.33 |
| 23 | I prefer an outpatient-based practice | -2 | -1.33 |
| 29 | I am willing to do as many years as it takes to get the job and subspecialty I want | -3 | -1.94 |
| 17 | I want to work in a smaller community | -3 | -2.33 |
| Distinguishing statements | |||
| Agrees with the following statements more than other factors | |||
| 16 | I want to be in a large city | 3 | 1.53* |
| 32 | The fact that subspecialists can also be general internists is important to me. | 2 | 1.20* |
| 31 | A two-year GIM fellowship is a deterrent | 1 | 1.04* |
| 22 | Some specialties are not fairly remunerated and this is an important consideration | 1 | 0.76* |
| Disagrees with the following statements more than other factors | |||
| 18 | The resources of a fellowship program are important | -1 | -0.51 |
| 11 | My decision was predominantly based on experiences as a resident | -1 | -0.90* |
| 29 | I am willing to do as many years as it takes to get the job and subspecialty I want | -3 | -1.93* |
| Culture days | Control explants | Explants+MNF | ||
| Cultured | Lost | Cultured | Lost | |
| 3 | 25 | 1 | 13 | 0 |
| 6 | 25 | 3 | 13 | 1 |
| 9 | 25 | 4 | 13 | 1 |
| 75 | 8 | 39 | 2 | |
| Total: 114 explants |
| 3rd level ATC Code Prediction using different initializations and comparison to STP | ||||||||
| Initialization method | Supervised learning | SuperPred | ChEMBL (Perfect 1st level) | STP | ||||
| Prediction method | A(3) | CA(3)(N(3)) | A(3) | CA(3)(N(3)) | A(3) | CA(3)(N(3)) | A(3) | CA(3)(N(3)) |
| MLP | 63.62% | 68.82%(57.16%) | 63.26% | 70.67%(58.24%) | 72.40% | 83.81%(66.67%) | 72.40% | 73.42%(59.14%) |
| Naive Bayes | 56.99% | 50.96%(31.00%) | 66.49% | 68.22%(46.59%) | 69.00% | 78.14%(52.51%) | 57.53% | 60.81%(30.47%) |
| Random Forest | 57.35% | 62.60%(48.03%) | 60.93% | 69.06%(54.84%) | 69.00% | 82.20%(62.37%) | 65.23% | 68.46%(50.18%) |
| SVM | 64.16% | 67.98%(56.99%) | 67.56% | 72.64%(63.44%) | 76.88% | 86.26%(71.68%) | 64.52% | 70.31%(58.60%) |
| Multivariate | |||
| Odds ratio | 95% CI | p | |
| Sm | 0.391 | 0.145-1.056 | 0.064 |
| Global longitudinal strain | 1.457 | 1.002-2.119 | 0.049 |
| Global circumferential strain | 1.560 | 0.912-2.669 | 0.105 |
| Global radial strain | 0.952 | 0.818-1.107 | 0.533 |
| Body site | Number of pain sites | ||
| 1 | 2–3 | >4 | |
| % | % | % | |
| Neck | 9.5 | 46.9 | 43.6 |
| Shoulder | 16.8 | 38.2 | 45.0 |
| Upper back | 16.6 | 39.8 | 43.6 |
| Upper limbs | 23.7 | 42.4 | 33.9 |
| Low back | 27.8 | 42.0 | 30.2 |
| Upper leg/ knee | 21.2 | 39.7 | 39.1 |
| Lower Leg | 16.2 | 42.2 | 41.6 |
| Ankle/Feet | 14.4 | 34.2 | 51.4 |
| Average computation times [sec] | Fully automatic | Semi-automatic | ||
| CPU | GPU | CPU | GPU | |
| Linear registration | 112 | 109 | 140 | 130 |
| Nonlinear registration | 172 | 145 | 176 | 173 |
| Combining transformations | 42 | 42 | 42 | 42 |
| Warping of image channels | 79 | 78 | 76 | 75 |
| Automatic quality assessment | 35 | 35 | 36 | 36 |
| Sum [sec] | 440 | 409 | 470 | 456 |
| Sum [min] | 7 | 7 | 8 | 8 |
| 1a/2a/STAB ratio (mmol/mmol/mmol) | Solvent (mL) | Catalyst | Reaction time (h) | Yielda (%) |
| 1/1/1 | THF | – | 50 | 42 |
| 1/1/1.45 | THF | – | 50 | 61 |
| 1/1/1 | DCE | – | 50 | 91 |
| 1/1.5/1.5 | DCE | – | 50 | 98 |
| 1/1/1.5 | DCE | – | 4 | 59 |
| 1/1/1.5 | DCE | – | 24 | 86 |
| 1/1/1.5 | DCE | Amberlyst-15 | 4 | 89 |
| 1/1/1.5 | DCE | AcOH | 4 | 98 |
| Characteristic | Healthy weight | Overweight | Obese | |||
| n | Mean (s.d.) | n | Mean (s.d.) | n | Mean (s.d.) | |
| Age in months at weight status measurement | 4259 | 140.94 (2.80) | 792 | 140.98 (3.04) | 914 | 141.03 (2.89) |
| Birth weight (g) | 3987 | 3387.61 (526.66) | 740 | 3475.29 (545.34) | 842 | 3494.75 (570.38) |
| Gestation (weeks) | 4043 | 39.45 (1.80) | 746 | 39.49 (1.86) | 850 | 39.45 (1.75) |
| Age of mother in years at delivery | 4043 | 29.12 (4.54) | 746 | 28.76 (4.54) | 850 | 28.82 (4.63) |
| Average daily minutes of MVPA | 3611 | 24 (16) | 669 | 20 (14) | 740 | 19 (13) |
| Depressive symptoms at 11 years | 3569 | 1.99 (2.76) | 651 | 2.11 (2.84) | 715 | 2.49 (3.36) |
| Full-scale IQ at 8 years | 3643 | 107.02 (15.34) | 657 | 106.36 (15.64) | 746 | 103.42 (16.39) |
| BMI Z-score at 11 years | 4259 | −0.25 (0.81) | 792 | 1.32 (0.19) | 914 | 2.19 (0.42) |
| BMI Z-score at 13 years | 1827 | −0.21 (0.96) | 333 | 1.07 (0.56) | 313 | 1.89 (0.64) |
| BMI Z-score at 16 years | 2533 | −0.07 (0.84) | 443 | 1.00 (0.68) | 463 | 1.82 (0.77) |
| Percentage | Percentage | Percentage | ||||
| Proportion of sample | ||||||
| Female | 4260 | 71.4 | 792 | 13.3 | 914 | 15.3 |
| Ethnicity | 2325 | 54.6 | 420 | 53.0 | 466 | 51.0 |
| White | 3716 | 96.4 | 672 | 95.6 | 753 | 94.6 |
| Non-white | 137 | 3.6 | 31 | 4.4 | 43 | 5.4 |
| Mother's oily fish intake | ||||||
| Never/rarely | 1362 | 35.6 | 299 | 42.1 | 347 | 44.1 |
| Once in 2 weeks | 1373 | 35.9 | 243 | 34.2 | 253 | 32.2 |
| 1–3 times a week | 1044 | 27.3 | 161 | 22.7 | 181 | 23.0 |
| 4–7 times a week | 47 | 1.2 | 7 | 1.0 | 4 | 0.5 |
| More than once a day | 1 | 0.0 | 0 | 0.0 | 1 | 0.1 |
| Mother smoked during pregnancy | ||||||
| Yes | 602 | 15.2 | 133 | 18.2 | 177 | 21.3 |
| No | 3369 | 84.8 | 599 | 81.8 | 654 | 78.7 |
| Mothers education | ||||||
| CBSE | 462 | 11.8 | 103 | 14.3 | 142 | 17.7 |
| Vocational | 313 | 8.0 | 64 | 8.9 | 81 | 10.1 |
| O level | 1381 | 35.3 | 270 | 37.5 | 304 | 37.8 |
| A level | 1051 | 26.9 | 186 | 25.8 | 208 | 25.9 |
| Degree | 703 | 18.0 | 97 | 13.5 | 69 | 8.6 |
| Occupational social class | ||||||
| I (professional) | 280 | 8.2 | 29 | 4.6 | 29 | 4.4 |
| II | 1192 | 34.9 | 207 | 33.2 | 225 | 34.3 |
| III (non-manual) | 1431 | 41.8 | 280 | 44.9 | 293 | 44.7 |
| III (manual) | 214 | 6.3 | 47 | 7.5 | 44 | 6.7 |
| IV | 265 | 7.7 | 53 | 8.5 | 53 | 8.1 |
| V (unskilled) | 37 | 1.1 | 8 | 1.3 | 12 | 1.8 |
| Armed forces | 1 | 0.0 | 0 | 0 | 0 | 0 |
| Pubertal status at 11 years | ||||||
| Experienced menarche | 201 | 11.3 | 78 | 25.08 | 101 | 29.79 |
| Tanner stage I | 508 | 40.7 | 69 | 30.0 | 88 | 31.5 |
| Tanner stage II | 485 | 38.9 | 100 | 43.5 | 108 | 38.7 |
| Tanner stage III | 158 | 12.7 | 40 | 17.4 | 55 | 19.7 |
| Tanner stage IV | 42 | 3.4 | 13 | 5.7 | 13 | 4.7 |
| Tanner stage V | 2 | 0.2 | 13 | 5.7 | 1 | 0.4 |
| Characteristics | Number | Percentage (%) |
| Gender | ||
| Male | 60 | 70.6 |
| Female | 25 | 29.4 |
| Age | ||
| ≤ 60 | 53 | 62.4 |
| > 60 | 32 | 37.6 |
| Nationality | ||
| The Han | 60 | 70.6 |
| The Zhuang | 25 | 29.4 |
| Histology | ||
| Squamous carcinoma | 25 | 29.4 |
| Adenocarcinoma | 60 | 70.6 |
| Differentiation | ||
| Well and moderate | 58 | 68.2 |
| Poor | 27 | 31.8 |
| Metastasis lymphatics | ||
| Yes | 28 | 32.9 |
| No | 57 | 67.1 |
| TNM stage | ||
| I + II | 48 | 56.5 |
| III + IV | 37 | 43.5 |
| Surgery status | ||
| Lobectomy | 79 | 92.9 |
| Pneumonectomy | 6 | 7.1 |
| Chemotherapy status(74 cases) | ||
| GP regimens | 34 | 45.9 |
| NP regimens | 29 | 39.2 |
| TP regimens | 11 | 14.9 |
| ECOG Performance status | ||
| 0 | 22 | 25.9 |
| 1 | 63 | 74.1 |
| All studies | Level of methodological quality | ||||||||
| Poor | Fair to good | ||||||||
| Acceptable | Total | % Acceptable | Acceptable | Total | % Acceptable | Acceptable | Total | % Acceptable | |
| Inter-rater reliability | |||||||||
| Weight-handling and strength | |||||||||
| ICC | 6 | 6 | 100.0% | 6 | 6 | 100.0% | |||
| κ | 3 | 6 | 50.0% | 3 | 6 | 50.0% | |||
| POA | 16 | 16 | 100.0% | 12 | 12 | 100.0% | 4 | 4 | 100.0% |
| Total | 25 | 28 | 89.3% | 18 | 18 | 100.0% | 7 | 10 | 70.0% |
| Intra-rater reliability | |||||||||
| Weight-handling and strength | |||||||||
| κ | 1 | 1 | 100.0% | 1 | 1 | 100.0% | |||
| POA | 7 | 7 | 100.0% | 7 | 7 | 100.0% | |||
| Total | 8 | 8 | 100.0% | 8 | 8 | 100.0% | |||
| Test-retest reliability | |||||||||
| Weight-handling and strength | |||||||||
| ICC | 42 | 44 | 95.5% | 33 | 34 | 97.1% | 9 | 10 | 90.0% |
| POA | 4 | 4 | 100.0% | 4 | 4 | 100.0% | |||
| Total | 46 | 48 | 95.8% | 37 | 38 | 97.4% | 9 | 10 | 90.0% |
| Posture and mobility | |||||||||
| ICC | 5 | 17 | 29.4% | 3 | 15 | 20.0% | 2 | 2 | 100.0% |
| κ | 10 | 14 | 71.4% | 10 | 14 | 71.4% | |||
| POA | 22 | 24 | 91.7% | 22 | 24 | 91.7% | |||
| Total | 37 | 55 | 67.3% | 35 | 53 | 66.0% | 2 | 2 | 100.0% |
| Locomotion | |||||||||
| ICC | 1 | 2 | 50.0% | 1 | 2 | 50.0% | |||
| κ | 1 | 3 | 33.3% | 1 | 3 | 33.3% | |||
| POA | 3 | 4 | 75.0% | 3 | 4 | 75.0% | |||
| Total | 5 | 9 | 55.6% | 5 | 9 | 55.6% | |||
| Balance | |||||||||
| POA | 2 | 2 | 100.0% | 2 | 2 | 100.0% | |||
| Total | 2 | 2 | 100.0% | 2 | 2 | 100.0% | |||
| Total test-retest reliability | 90 | 114 | 78.9% | 79 | 102 | 77.5% | 11 | 12 | 91.7% |
| Overall reliability statistics | 123 | 150 | 82.0% | 105 | 128 | 82.0% | 18 | 22 | 81.8% |
| BMI <18.5 | BMI 18.5–24.9 | BMI 25–29.9 | BMI ≥ 30 | ||||||
| Underweight | Normal | Overweight | Obesity | ||||||
| n = 40 (3.3%) | n = 662 (55.3%) | n = 428 (35.7%) | n = 68 (5.7%) | ||||||
| Single complications | No. | % | No. | % | No. | % | No. | % | P |
| Pleural effusion | 2 | 5.0 | 50 | 7.6 | 28 | 6.5 | 9 | 13.2 | 0.243 |
| Arrhythmia | 3 | 7.5 | 35 | 5.3 | 18 | 4.2 | 5 | 7.4 | 0.735 |
| Pneumonia | 6* | 15.0 | 28 | 4.2 | 14 | 3.3 | 2 | 2.9 | 0.029 |
| Prolonged air leaks | 40 | 10.0 | 19 | 2.9 | 3** | 1.5 | 1 | 2.3 | 0.001 |
| Cardiac insufficiency | 1 | 2.5 | 11 | 1.7 | 5 | 1.2 | 1 | 1.5 | 0.496 |
| Heart failure | 0 | 0.0 | 7 | 1.1 | 0 | 0.0 | 0 | 0.0 | 0.076 |
| Chylothorax | 10 | 2.5 | 7 | 1.1 | 6 | 1.4 | 4 | 5.9 | 0.062 |
| Atelectasis | 00 | 0.0 | 7 | 1.1 | 6 | 1.4 | 2 | 2.9 | 0.481 |
| Experiment | Climatea | Land coverb | Managed grassland areac | Atmospheric CO2 concentration | Management strategy |
| Ehistd | Varied for 1901–2010 | Varied for 1901–2010 | Varied for 1901–2010 | Varied for 1901–2010 | Adaptive management change algorithm simulating potential livestock density |
| Econtrol | Varied for 2011–2100 | Constant as in 2010 | Constant as in 2010 | Varied for 2011–2100 (A1B scenario) | Adaptive management change algorithm simulating potential livestock density |
| Enoco2 | Varied for 2011–2100 | Constant as in 2010 | Constant as in 2010 | Constant as in 2010 | Adaptive management change algorithm simulating potential livestock density |
| EfixD | Varied for 2011–2100 | Constant as in 2010 | Constant as in 2010 | Varied for 2011–2100 (A1B scenario) | Adaptive management change algorithm with constant livestock density |
| Log2(ratio) | |||||
| Accession number | Gene description | Localisation | Treatment comparison | ||
| S/M | MA/M | SA/M | |||
| At1g57770 | Amine oxidase family | Chloroplast | nde | 1.59 | 0.80 |
| At3g14420 | (S)-2-hydroxy-acid oxidase, peroxisomal, putative/glycolate oxidase, putative/short chain alpha-hydroxy acid oxidase, putative Proline oxidase, mitochondrial/osmotic stress- | Peroxisome | -1.08 | 1.33 | nde |
| At3g30775 | responsive proline dehydrogenase (POX) (PRO1) (ERD5) | Mitochondrion | nde | 2.51 | 1.22 |
| At3g53950 | Glyoxal oxidase-related | Endomembrane system | nde | 1.00 | nde |
| At4g16760 | Acyl-CoA oxidase (ACX1) | Peroxisome | 0,87 | nde | 1.48 |
| At5g65110 | Acyl-CoA oxidase (ACX2) | Peroxisome | 0.91 | nde | 1.83 |
| Reference | No. of case reports | Patient case conditions | Prophylaxis used | Treatment that cleared infection | Isolate(s) cultured | Geographic location | Year published |
| Wang et al., 2011 | 1 | Mandibulectomy with planned tissue flap reconstruction, infection and necrosis of the flap | Ciprofloxacin | Cefepime | A. hydrophila | Missouri, USA | 2011 |
| Sartor et al., 2013 | 1 | Infection of skin flap of hand crush injury | Ciprofloxacin | Cotrimoxazole | A. hydrophila | Marseille, France | 2013 |
| Giltner et al., 2013 | 1 | Mandibular osteotomy, necrosis of mandibular flap and wound surrounding the distraction arm device | Ciprofloxacin | Vancomycin | A. hydrophila, Morganella morganii | California, USA | 2013 |
| Wilmer et al., 2013 | 1 | Amputation of three digits and necrosis of amputation sites | Ciprofloxacin | Co-trimoxazole | A. hydrophila | British Columbia, Canada | 2013 |
| Patel et al., 2013 | 1 | Breast reconstruction, infection of the implant | Ciprofloxacin, vancomycin | Aztreonam | A. hydrophila | Washington D.C., USA | 2013 |
| van Alphen et al., 2014 | 2 | Replantation of four fingers resulting in flap necrosis after leech therapy, followed by amputation | Ertapenem | Ceftriaxone and co-trimoxazole | A. hydrophila | Minnesota, USA | 2014 |
| Replantation of two fingers failed following leech therapy, amputation | Ciprofloxacin | Cefepime, metronidazole, vancomycin; followed by ceftriaxone | A. hydrophila, Proteus vulgaris, Morganella morganii |
| Subscale | Group | Baseline score | One month after the onset of intervention | Two months after the onset of intervention | Between groups difference |
| Irritability | N-Acetylcysteine + risperidone | 13.2(5.3) | 10.0(4.1) | 9.7(4.1) | F1,29= 4.9, P<0.035 |
| Placebo+Risperidone | 16.7(7.8) | 15.5(7.9) | 15.1(7.8) | ||
| Hyperactivity and Noncompliance | N-Acetylcysteine + risperidone | 29.3(6.4) | 21.4(7.7) | 18.3(6.9) | F1,29= 2.4, P=0.12 |
| Placebo+Risperidone | 31.9(8.9) | 26.8(11.0) | 24.3(12.1) | ||
| Lethargy and Social Withdrawal | N-Acetylcysteine + risperidone | 11.9(6.5) | 9.0(5.7) | 8.5(6.5) | F1,28= 0.4, P=0.53 |
| Placebo+Risperidone | 12.2(8.3) | 11.0(7.8) | 10.9(7.5)6 | ||
| Stereotypic Behavior | N-Acetylcysteine + risperidone | 6.6(4.5) | 4.5(3.6) | 3.9(2.7) | F1,28= 2.8, P=0.1 |
| Placebo+Risperidone | 8.5(6.3) | 7.7(6.2) | 7.8(6.6) | ||
| Inappropriate Speech | N-Acetylcysteine + risperidone | 3.9(3.7) | 3.8(3.7) | 3.2(3.4) | F1,29= 1.8, P=0.1 |
| Placebo+Risperidone | 5.7(3.8) | 5.3(3.7) | 5.2(4.0) |
| Weaned pigs | Growing pigs | Gilts | |
| Number of animals | 9 (6 to 11) | 23 (20 to 25) | 24 (18 to 29) |
| Degree | |||
| Binary | 7a (0 to 16) | 5b (1 to 18) | 5b (0 to 22) |
| Weighted | 12a (0 to 96) | 5b (1 to 27) | 5b (0 to 36) |
| In-degree | |||
| Binary | 4a (0 to 8) | 3b (0 to 11) | 3b (0 to 11) |
| Weighted | 7a (0 to 51) | 3b (0 to 16) | 3b (0 to 17) |
| Out-degree | |||
| Binary | 3a (0 to 9) | 2b (0 to 10) | 2b (0 to 16) |
| Weighted | 5a (0 to 73) | 3b (0 to 17) | 2b (0 to 29) |
| Betweenness | |||
| Binary | 0.03a (0 to 0.50) | 0.02a (0 to 0.26) | 0.02a (0 to 0.32) |
| Weighted | 0.04a (0 to 0.63) | 0.03a (0 to 0.32) | 0.02a (0 to 0.37) |
| Closeness | |||
| Binary | 0.73a (0 to 1.00) | 0.43b (0.04 to 0.73) | 0.43b (0 to 0.94) |
| Weighted | 1.15a (0 to 6.19) | 0.51b (0.04 to 0.93) | 0.49b (0 to 1.22) |
| Ingoing closeness | |||
| Binary | 0.61a (0 to 1.00) | 0.29b (0 to 0.55) | 0.32b (0 to 0.60) |
| Weighted | 0.84a (0 to 5.22) | 0.31b (0 to 0.66) | 0.32b (0 to 0.79) |
| Outgoing closeness | |||
| Binary | 0.62a (0 to 1.00) | 0.30b (0 to 0.60) | 0.32b (0 to 0.94) |
| Weighted | 0.83a (0 to 6.80) | 0.34b (0 to 0.89) | 0.32b (0 to 1.33) |
| Region | Side | MNI coordinates | T value | ||
| Pre-cuneus | R | 4 | -70 | 36 | 32.78 |
| L | -7 | -74 | 42 | 32.12 | |
| Cuneus | R | 10 | 76 | 38 | 32.62 |
| L | -10 | -68 | 42 | 31.25 | |
| Inferior temporal gyrus area (includes fusiform gyrus) | R | 54 | -34 | -26 | 11.18 |
| L | -48 | -56 | -14 | 18.78 | |
| Pre-central gyrus | R | 42 | -14 | 48 | 15.81 |
| Post-central gyrus | R | 44 | -26 | 46 | 13.96 |
| Superior temporal gyrus | R | 50 | -44 | 16 | 11.18 |
| L | -50 | -44 | 18 | 16.92 | |
| Basal forebrain | R | 22 | 10 | -18 | 12.87 |
| L | -24 | 8 | -18 | 12.87 | |
| Inferior frontal gyrus | R | 42 | 28 | 16 | 12.18 |
| L | -42 | 24 | 18 | 12.24 | |
| Inferior frontal orbital | L | -34 | 40 | -14 | 9.71 |
| Lobe occipital Superior | R | 22 | -80 | 40 | 26.90 |
| L | -18 | -80 | 34 | 25.88 | |
| Superior frontal gyrus | R | 20 | -8 | 64 | 6.69 |
| L | -20 | -6 | 66 | 6.70 |
| Characteristics | No. of cases | miR-140 expression | P value | |
| Low (median ≤0.278) | High (median >0.278) | |||
| Age | 0.667 | |||
| < 60 years | 22 | 10 | 12 | |
| ≥ 60 years | 38 | 18 | 20 | |
| Gender | 0.778 | |||
| Male | 33 | 16 | 17 | |
| Female | 27 | 12 | 15 | |
| Tumor size | 0.602 | |||
| < 5 cm | 23 | 12 | 11 | |
| ≥ 5 cm | 37 | 16 | 21 | |
| Stage | 0.045* | |||
| I/II | 28 | 1 | 27 | |
| III/IV | 32 | 27 | 5 | |
| Differentiation | 0.076 | |||
| Well/moderate | 24 | 13 | 11 | |
| Poor | 36 | 15 | 21 | |
| Metastasis | 0.031* | |||
| No | 31 | 7 | 24 | |
| Yes | 29 | 21 | 8 |
| Absolute Contraindications | Relative Contraindications |
| Clinical instability or significant pain suggestive of ruptured EP | Presence of fetal cardiac activity |
| Heterotopic pregnancy with viable and desired IUP | β-hCG level over 5000 mIU/mL |
| Liver function tests more than 2 times the upper limit of normal | An ectopic mass size greater than 4 cm in largest dimension |
| White blood cell count of <1500/uL | Patient refusal of blood transfusion |
| Platelet count <100,000/uL | Patient inability to follow up |
| Creatinine ≥1.5 mg/dL | |
| Current breastfeeding | |
| Active pulmonary disease | |
| Active peptic ulcer disease | |
| Moderate to severe anemia | |
| Sensitivity to methotrexate |
| Item | Details | Intervention |
| 1. Acupuncture rationale | 1a) Style of acupuncture | Traditional needle acupuncture and intradermal acupuncture |
| 1b) Reasoning for treatment provided based on historical context, literature sources, and/or consensus methods, with references where appropriate | Selected traditional acupuncture points on the 12 meridian system based on the systematic review by Yeung and clinical experiences | |
| 1c) Extent to which treatment was varied | No variation | |
| 2. Details of needling | 2a) Number of needle insertions per subject per session (mean and range where relevant) | Five needle insertions per 1 session |
| 2b) Names (or location if no standard name) of points used (uni/bilateral) | Neiguan (PC6), Sanyinjiao (SP6), Shenmen (HT7), Zhaohai (KI6), Shenmai (BL62), all unilateral. | |
| 2c) Depth of insertion, based on a specified unit of measurement or on a particular tissue level | Depth of needle insertion was at least 5 to10 mm and intradermal acupunctured was 1 to 2 mm | |
| 2d) Response sought | De-qi sensation felt by practitioner and subject | |
| 2e) Needle stimulation | No stimulation and just retention without movement Intradermal acupuncture fixed with skin tape and subjects educated to self finger-press on them at nighttime | |
| 2f) Needle retention time | Twenty-minute retention for needles, intradermal acupuncture patched 48 to 72 hours until next session | |
| 2 g) Needle type (diameter, length, and manufacturer or material) | Needles: 0.25 × 40 mm, stainless steel (Dong Bang Medical Co. Ltd, Korea) | |
| Intradermal acupuncture: 0.18 × 1.3 × 1.5 mm, stainless steel (Dong Bang Medical Co. Ltd, Korea) | ||
| 3. Treatment regimen | 3a) Number of treatment sessions | Three sessions |
| 3b) Frequency and duration of treatment sessions | Three times per week, interval of 1 to 4 days between sessions | |
| 4. Other components of treatment | 4a) Details of other interventions administered to the acupuncture group | Sleep hygiene education |
| 4b) Setting and context of treatment, including instructions to practitioners, and information and explanations to patients | Same practitioner treats every subject at every session in the same outpatient clinic | |
| 5. Practitioner background | 5) Description of participating acupuncturists (qualification or professional affiliation, years in acupuncture practice, other relevant experience) | Licensed traditional Korean medicine doctor at the Kyung Hee East-West Neo Medical Center at Gangdong with more than 10 years of acupuncture treatment experience |
| 6. Control or comparator interventions | 6a) Rationale for the control or comparator in the context of the research question, with sources that justify this choice | Sham acupuncture points |
| 6b) Precise description of the control or comparison group. If sham acupuncture or any other type of acupuncture-like control is used, provide details as for items 1 to 3 above | Same as intervention group except 2b) and 2d) | |
| 2b) No acupuncture points located away from acupuncture points at least 10 mm | ||
| 2d) Without De-qi sensation |
| Date | Flight Time | τ (95% Confidence Bounds) | Lu (95% Confidence Bounds) W/m2/μm/sr | r2 | RMSE W/m2/μm/sr | Used Pixels |
| 8/9/2014 | Early Morning | 0.40 (0.51 0.33) | −5.54 (−9.38–3.03) | 0.65 | 0.37 | 48 |
| Landsat Overpass | 0.69 (0.88 0.57) | −2.94 (−6.75–0.45) | 0.58 | 0.84 | 63 | |
| 6/2/2015 | Early Morning | 0.35 (0.38 0.33) | −4.28 (−5.10–3.56) | 0.71 | 0.26 | 336 |
| Landsat Overpass | 0.57 (0.62 0.53) | −3.61 (−4.88–2.53) | 0.62 | 0.88 | 330 | |
| Mid Afternoon | 0.53 (0.58 0.50) | −5.17 (−6.49–4.04) | 0.68 | 0.97 | 330 | |
| 7/11/2015 | Early Morning | 0.81 (0.88 0.76) | −0.94 (−1.58–0.39) | 0.73 | 0.12 | 283 |
| Landsat Overpass | 0.49 (0.52 0.47) | −5.08 (−5.86–4.38) | 0.83 | 0.77 | 352 | |
| Mid Afternoon | 0.47 (0.48 0.45) | −5.21 (−5.71–4.74) | 0.94 | 0.47 | 278 | |
| 5/2/2016 | Early Morning | 0.29 (0.33 0.27) | −5.23 (−6.66–4.05) | 0.53 | 0.21 | 343 |
| Landsat Overpass | 0.62 (0.63 0.60) | −2.21 (−2.49–1.94) | 0.95 | 0.46 | 299 | |
| Mid Afternoon | 0.65 (0.69 0.62) | −2.25 (−2.94–1.62) | 0.79 | 0.55 | 299 | |
| 5/3/2016 | Early Morning | 0.43 (0.45 0.41) | −4.74 (−5.49–4.07) | 0.8 | 0.13 | 326 |
| Mid Afternoon | 0.52 (0.55 0.50) | −3.38 (−4.01–2.82) | 0.83 | 0.43 | 349 |
| SNP | Model/Allele | Genotype | Control | ASD | OR (95% CI) | p |
| n (%) | n (%) | |||||
| rs1801123 | Additive | AA | 73 (49.7) | 114 (63.3) | 1 | |
| Ala804Ala | AG | 63 (42.9) | 56 (31.1) | |||
| IRS1 | GG | 11 (7.5) | 10 (5.6) | 0.66 (0.46–0.95) | 0.022 | |
| Dominant | AA | 73 (49.7) | 114 (63.3) | 1 | ||
| AG/GG | 74 (50.3) | 66 (36.7) | 0.57 (0.37–0.89) | 0.013 | ||
| Recessive | AA/AG | 136 (92.5) | 170 (94.4) | 1 | ||
| GG | 11 (7.5) | 10 (5.6) | 0.73 (0.30–1.76) | 0.48 | ||
| Allele | A | 209 (71.1) | 284 (78.9) | 1 | ||
| G | 85 (28.9) | 76 (21.1) | 0.66 (0.46–0.94) | 0.022 | ||
| rs4773092 | Additive | AA | 41 (27.9) | 51 (28.3) | 1 | |
| Cys816Cys | AG | 76 (51.7) | 95 (52.8) | |||
| IRS2 | GG | 30 (20.4) | 34 (18.9) | 0.96 (0.70–1.32) | 0.8 | |
| Dominant | AA | 41 (27.9) | 51 (28.3) | 1 | ||
| AG/GG | 106 (72.1) | 129 (71.7) | 0.98 (0.60–1.59) | 0.93 | ||
| Recessive | AA/AG | 117 (79.6) | 146 (81.1) | 1 | ||
| GG | 30 (20.4) | 34 (18.9) | 0.91 (0.53–1.57) | 0.73 | ||
| Allele | A | 158 (53.7) | 197 (54.7) | 1 | ||
| G | 136 (46.3) | 163 (45.3) | 0.96 (0.70–1.31) | 0.8 |
| Content of Hg2+ added to various samples (n = 7) | ||||||
| PEI-AuNP probe | DMA | |||||
| Sample | Added amount (μM) | Detected amount (μM) | Coefficient of variation (%) | Recovery (%) | LOD (nM) | Detected amount (μM) |
| Tap water | 0.150 | 0.149 ± 1.53 × 10−4 | 0.102 | 99.9 ± 0.102 | 1.72 | 0.153 |
| 0.500 | 0.499 ± 0.0101 | 2.03 | 99.9 ± 2.03 | 0.505 | ||
| Pond water | 0.150 | 0.150 ± 6.92 × 10−4 | 0.460 | 100.2 ± 0.461 | 1.80 | 0.156 |
| 0.500 | 0.500 ± 3.41 × 10−3 | 0.682 | 100.1 ± 0.683 | 0.504 | ||
| Tuna fish | 0.150 | 0.149 ± 7.09 × 10−4 | 0.473 | 99.8 ± 0.473 | 2.00 | 0.152 |
| 0.500 | 0.503 ± 0.0155 | 3.08 | 100.6 ± 3.10 | 0.504 | ||
| Bovine serum | 0.150 | 0.150 ± 6.43 × 10−4 | 0.427 | 100.1 ± 0.428 | 1.95 | 0.155 |
| 0.500 | 0.503 ± 7.68 × 10−3 | 1.52 | 100.7 ± 1.53 | 0.507 |
| Reasons of unwillingness or hesitation | Will not be vaccinated | Indecisive | Total |
| Possible side effects | 267 (74.8) | 251 (82.0) | 518 (78.1) |
| Lack of comprehensive field evaluation before marketing | 266 (74.5) | 241 (78.8) | 507 (76.5) |
| Implementation in our country before wide implementation in other countries | 199 (55.9) | 184 (60.1) | 383 (57.9) |
| Vaccines which will be administered here are different than the vaccines in the US | 153 (42.9) | 137 (44.9) | 290 (43.8) |
| Do not have trust in the effectiveness of the vaccine | 157 (44.0) | 114 (37.3) | 271 (40.9) |
| Do not trust Ministry of Health's practices | 147 (41.2) | 104 (34.0) | 251 (37.9) |
| Due to the risk of acquiring H1N1 following vaccination | 71 (19.9) | 66 (21.6) | 137 (20.7) |
| The disease is mild | 59 (16.5) | 34 (11.1) | 93 (14.0) |
| Contracting the disease is safer | 34 (9.5) | 13 (4.2) | 47 (7.1) |
| Other | 30 (8.4) | 15 (4.9) | 45 (6.8) |
| Basal | 3 H | 5 H | 24 H | |
| PT, % | ||||
| Control | 62.7±7.3 | 62.7±3.6 | 56.3±3.6 | 62.7±3.6 |
| CM352 | 62.7±5.1 | 62.0±2.6 | 63.7±4.0 | 65.1±7.6 |
| aPTT, s | ||||
| Control | 19.0±1.0 | 19.7±1.5 | 19.0±3.5 | 19.0±2.6 |
| CM352 | 21.0±4.0 | 21.7±4.5 | 21.7±4.0 | 21.7±2.5 |
| Ionphore of mercury(II) electrodes in FIA system | LR (M) | DL (M) |
| 4,7,13,16-tetrathenoyl-1,10-dioxa-4,7,13, 16-tetraazacyclooctadecane [23] | 3.16 × 10−6–1 × 10−3 | 3.16 × 10−6 |
| 7,16-dithenyl-l,4,10,13-tetraoxa-7, 16-diazacyclooctadecane [28] | 3.16 × 10−6–1 × 10−3 | 3.16 × 10−6 |
| [This study] | 5 × 10−6–1 × 10−1 | 5 × 10−6 |
| Magnesium group(n = 30) | Control group(n = 30) | P-value* | |
| Age (y) | 25 ± 3 | 26 ± 3 | 0.41 |
| Height (cm) | 162 ± 3 | 162 ± 3 | 0.42 |
| Weight (kg) | 72 ± 4 | 72 ± 4 | 0.84 |
| Gestational age (week) | 39 ± 1 | 39 ± 1 | 0.60 |
| Duration of surgery (min) | 45 ± 7 | 47 ± 7 | 0.41 |
| Diagnostic characteristics | Two parameters | Three parameters | Four parameters |
| Sensitivity | 96.5% | 89.5% | 63.2% |
| Specificity | 66.0% | 87.2% | 95.7% |
| Positive predictive value | 77.5% | 89.5% | 94.7% |
| Negative predictive value | 93.9% | 87.2% | 68.2% |
| Diagnostic accuracy | 82.7% | 88.5% | 77.9% |
| Youden index | 62.5% | 76.7% | 58.9% |
| Kappa value | 0.641 | 0.767 | 0.569 |
| Outcome variables | Total% | Gender (%) | ||
| n = 775 | Boys(n = 354) | Girls(n = 421) | ||
| Physical activity | *** | |||
| ≤ 2 hours MVPA/day (low) | 49.4 | 37.3 | 59.6 | |
| ≥ 2 hours MVPA/day (high) | 50.6 | 62.7 | 40.4 | |
| Fruit and vegetable consumption | ** | |||
| ≤ 5 portions/day (low) | 47.6 | 53.1 | 43.0 | |
| ≥ 5 portions/day (high) | 52.4 | 46.9 | 57.0 | |
| Groups | ||||
| High PA/High FV | 25.8 | 28.2 | 23.8 | |
| High PA/Low FV | 24.8 | 34.5 | 16.6 | *** |
| Low PA/High FV | 26.6 | 18.6 | 33.3 | *** |
| Low PA/Low FV | 22.8 | 18.6 | 26.4 | *** |
| Leptin | Insulin | |||||
| Fat adj. height | Height adj. fat | Height adj. BMI | Fat adj. height | Height adj. fat | Height adj. BMI | |
| Boys | ||||||
| Visit | ||||||
| 7 | 0.68** | −0.20** | 0.05 | 0.28** | −0.02 | 0.05 |
| 8 | 0.61** | −0.07 | 0.12 | 0.41** | −0.10 | 0.07 |
| 9 | 0.53** | −0.02 | 0.09 | 0.32** | 0.12 | 0.21* |
| 10 | 0.66** | −0.04 | 0.12 | 0.41** | 0.13 | 0.23* |
| 11 | 0.82** | −0.36** | −0.04 | 0.40** | −0.07 | 0.04 |
| 12 | 0.84** | −0.29** | 0.03 | 0.41** | 0.04 | 0.16 |
| All adj. age | 0.68** | −0.12** | 0.09* | 0.37** | 0.01 | 0.11** |
| Girls | ||||||
| Visit | ||||||
| 7 | 0.70** | −0.02 | 0.21* | 0.47** | −0.00 | 0.14 |
| 8 | 0.79** | −0.19 ** | 0.10 | 0.38** | 0.15 | 0.25* |
| 9 | 0.74** | −0.27 | 0.08 | 0.38** | 0.02 | 0.15 |
| 10 | 0.76** | −0.06 | 0.20* | 0.43** | 0.20* | 0.32** |
| 11 | 0.88** | −0.34** | 0.04 | 0.55** | 0.13 | 0.22* |
| 12 | 0.88** | −0.07 | 0.19 | 0.41** | 0.22 * | 0.28** |
| All adj. age | 0.78** | −0.13** | 0.12* | 0.52** | 0.11* | 0.20** |
| Treatment | Dose(p.o.) | Time (sec) spent in | No. of entry in | % of total time (sec) spent in | % of entries in | ||||
| Openarm | Closearm | Openarm | Closearm | Openarm | Closearm | Openarm | Closearm | ||
| Control | 0.5 ml/mice | 7.6±0.51 | 215±1.52 | 1.2±0.49 | 9.4±0.51 | 3.41±0.05 | 96.59±0.14 | 11.32±0.49 | 88.68±0.51 |
| Diazepama | 1 mg/kg | 6.8±0.58 | 260±1.87*** | 1.6±0.81 | 12.0±0.55* | 2.55±0.04* | 97.45±0.14 | 11.76±0.81 | 88.24±0.55 |
| SSL200 | 200 mg/kg | 2.8±0.20*** | 209±1.44 | 0.8±0.37 | 15.4±0.75*** | 1.32±0.02*** | 98.68±0.14 | 4.94±0.37 | 95.06±0.75 |
| SSL400 | 400 mg/kg | 16.6±0.51*** | 237±1.95*** | 0.8±0.37 | 9.0±0.45 | 6.55±0.04*** | 93.45±0.15 | 8.16±0.37 | 91.84±0.45 |
| Items | Inpatients | Outpatients | Cost per patient (€), mean (SD) | ||
| One-day stay | One visit | Inpatientsa | Outpatientsb | P value | |
| Staff salaryc | 228.17d | 80.52 | 2806.49 (174.00) | 262.50 (22.92) | <.001 |
| QDU (1) and (2) visitse | na | 127.24 | na | 414.80 (0.11) | |
| Diagnostic testsf | 83.48 | 218.77 | 1026.80 (76.00) | 713.19 (38.85) | <.001 |
| Therapeutic proceduresg | 1.67 | 0.54 | 20.54 (3.53) | 1.76 (0.23) | <.001 |
| Pharmaceuticals and consumables | 9.95 | 0.87 | 122.39 (20.44) | 2.84 (0.59) | <.001 |
| Consultationsh | 2.47 | 0.32 | 30.38 (9.57) | 1.04 (0.37) | <.001 |
| Adverse events | 0.50 | 0.09 | 6.15 (2.37) | 0.29 (0.10) | <.001 |
| Depreciation | 2.18 | 3.70 | 26.81 (2.44) | 12.06 (0.90) | <.001 |
| Total costs | 328.42 | 432.05 | 4039.56 (513.02) | 1408.48 (197.32) | <.001 |
| Haplogroup | n | Frequency (%) |
| B4* | 4 | 1.2 |
| B4a1* | 18 | 5.6 |
| B4a1a1 | 16 | 4.9 |
| B4a1a3a | 5 | 1.5 |
| B4b1 | 8 | 2.5 |
| B4c1b2a2 | 9 | 2.8 |
| B4c2 | 2 | 0.6 |
| B5b* | 4 | 1.2 |
| B5b1c | 8 | 2.5 |
| D5b1c1 | 5 | 1.5 |
| D6a | 1# | 0.3 |
| E1a1a | 39 | 12.0 |
| E1a2 | 5 | 1.5 |
| E1b | 7 | 2.2 |
| E2 | 7 | 2.2 |
| F1a1a | 1 | 0.3 |
| F1a2 | 1 | 0.3 |
| F1a3a | 16 | 4.9 |
| F1a4a1 | 29 | 9.0 |
| F3b1a | 1 | 0.3 |
| M* | 2 | 0.6 |
| M7c1 | 45 | 13.9 |
| M10 | 1 | 0.3 |
| M21b | 1# | 0.3 |
| M71a2 | 1 | 0.3 |
| M73a | 2 | 0.6 |
| N21a | 2 | 0.6 |
| P1* | 2 | 0.6 |
| P1d | 7# | 2.2 |
| “P1e”§ | 5# | 1.5 |
| Q1 | 46 | 14.2 |
| Q3 | 1# | 0.3 |
| R* | 2 | 0.6 |
| R9c1* | 3 | 0.9 |
| R9c1a | 15 | 4.6 |
| R9c1b2 | 1 | 0.3 |
| R14 | 2 | 0.6 |
| Total | 324 | 100 |
| Characteristics | Sweden (%) | Italy (%) | p* | |
| Number of respondents | 272 | 149 | ||
| Gender | Male | 166 (61.0) | 113 (75.8) | |
| Female | 106 (39.0) | 36 (24.2) | .002 | |
| Missing data | 0 | 0 | ||
| Age | <40 y | 28 (10.3) | 18 (12.2) | ns |
| 40- < 54 y | 170 (62.7) | 87 (58.8) | ||
| ≥55 y | 73 (26.9) | 43 (29.1) | ||
| Missing data | 0 | 0 | ||
| Living with partner | Yes | 235 (88.8) | 121 (81.2) | ns |
| No | 37 (11.2) | 28 (18.8) | ||
| Missing data | 0 | 0 | ||
| Number of children | 0 | 39 (14.6) | 40 (27.2) | .000 |
| 1-2 | 131 (49.1) | 86 (58.5) | ||
| 3 or more | 97 (36.3) | 21 (14.3) | ||
| Missing data | 5 | 2 | ||
| Work-related factors | ||||
| Recent degrading experiences/harassment at work | Yes | 49 (18.0) | 45 (30.2) | ns |
| No | 212 (77.9) | 102 (68.5) | ||
| Missing data | 11 | 2 | ||
| Perpetrator, superior | Yes | 27 (9.9) | 38 (25.5) | .000 |
| No | 245 (90.1) | 111 (74.5) | ||
| Missing data | 0 | 0 | ||
| Perpetrator, colleague | Yes | 23 (8.5) | 17 (11.4) | ns |
| No | 249 (91.5) | 132 (88.6) | ||
| Missing data | 0 | 0 | ||
| Hours on night call, mean (SD) | 8.82 (13.1) | 5.93 (4.57) | .028 | |
| Taken care of in the organisation, mean (SD) | 2.49 (1.03) | 1.60 (0.93) | .000 | |
| Regular meetings to discuss situations at work, mean (SD) | 2.92 (0.88) | 2.66 (0.90) | .005 | |
| Role conflict, mean (SD) | 2.93 (0.88) | 3.04 (0.95) | ns | |
| Empowering leadership, mean (SD) | 2.92 (1.13) | 2.57 (1.23) | .004 | |
| Work/home interface and behavioural factors | ||||
| Work demands interfere with family life, mean (SD) | 3.71 (0.95) | 3.77 (1.01) | ns | |
| Family life interferes with work, mean (SD) | 2.66 (1.13) | 2.50 (1.03) | ns | |
| Sickness presenteeism, mean (SD) | 3.19 (1.16) | 3.34 (1.09) | ns | |
| Compensatory leave, mean (SD) | 1.33 (0.77) | 1.25 (0.68) | ns | |
| Psychological distress | ||||
| Suicidal ideation in last 12 months, number (%) | Yes | 32 (11.8) | 26 (17.4) | ns |
| No | 235 (86.4) | 120 (80.5) | ||
| Missing data | 5 | 3 | ||
| Depression, mean (SD) | 2.09 (0.47) | 2.01 (0.44) | ns | |
| Burnout exhaustion, mean (SD) | 2.57 (0.51) | 2.49 (0.58) | ns | |
| Burnout disengagement, mean (SD) | 2.28 (0.52) | 2.17 (0.57) | ns |
| Question | Domain | Unadjusted odds ratios | Adjusted odds ratios on age and sex | Adjusted odds ratios on age, sex and number of years of residence in France | |||
| Value | CI | Value | CI | Value | CI | ||
| 1* | I | 1.41 | 1.01 1.97 | 1.43 | 1.02 2.00 | 1.43 | 1.02–2.00 |
| 2* | I | 1.58 | 1.15– 2.18 | 1.61 | 1.17– 2.23 | 1.61 | 1.17–2.23 |
| 3 | I | 1.11 | 0.82– 1.51 | 1.13 | 0.83 – 1.54 | 1.13 | 0.83–1.54 |
| 4 | I | 1.23 | 0.90– 1.66 | 1.25 | 0.91– 1.71 | 1.26 | 0.92–1.72 |
| 5* | I | 1.48 | 1.08– 2.02 | 1.49 | 1.09– 2.04 | 1.50 | 1.09–2.05 |
| 6* | I | 1.45 | 1.03– 2.04 | 1.48 | 1.05 – 2.08 | 1.48 | 1.05 – 2.09 |
| 7 | II | 1.27 | 0.93– 1.74 | 1.28 | 0.93– 1.75 | 1.27 | 0.93–1.75 |
| 8 | II | 1.27 | 0.93– 1.73 | 1.28 | 0.93– 1.75 | 1.28 | 0.93–1.75 |
| 9 | II | 1.26 | 0.93– 1.71 | 1.28 | 0.94– 1.74 | 1.28 | 0.94 – 1.75 |
| 10* | II | 1.37 | 1.00– 1.88 | 1.39 | 1.02 – 1.90 | 1.39 | 1.02–1.91 |
| 11* | II | 1.46 | 1.06– 2.02 | 1.47 | 1.06– 2.03 | 1.47 | 1.06–2.03 |
| 12* | III | 1.43 | 1.04– 1.96 | 1.43 | 1.05– 1.96 | 1.44 | 1.05– 1.97 |
| 13 | III | 1.35 | 0.99– 1.85 | 1.36 | 1.00– 1.86 | 1.37 | 1.01–1.88 |
| 14* | III | 1.51 | 1.05– 2.17 | 1.52 | 1.06– 2.19 | 1.53 | 1.06–2.20 |
| 15 | III | 1.29 | 0.93– 1.79 | 1.30 | 0.93– 1.81 | 1.31 | 0.94–1.82 |
| 16* | IV | 1.39 | 1.00– 1.93 | 1.41 | 1.02– 1.97 | 1.42 | 1.02–1.98 |
| 17 | IV | 1.13 | 0.79– 1.60 | 1.14 | 0.80 – 1.62 | 1.14 | 0.80–1.62 |
| 18 | IV | 1.30 | 0.91 – 1.86 | 1.29 | 0.90– 1.86 | 1.29 | 0.90–1.85 |
| 19 | IV | 1.30 | 0.95 – 1.77 | 1.33 | 0.98– 1.8 | 1.33 | 0.98–1.82 |
| 20 | IV | 1.1 | 0.80– 1.51 | 1.10 | 0.80– 1.51 | 1.10 | 0.80–1.51 |
| 21 | IV | 1.39 | 0.96– 2.00 | 1.38 | 0.95– 1.99 | 1.38 | 0.95–1.99 |
| 22* | IV | 1.53 | 1.03– 2.26 | 1.59 | 1.07– 2.36 | 1.60 | 1.08–2.38 |
| 23* | IV | 1.53 | 1.08– 2.15 | 1.51 | 1.07– 2.13 | 1.52 | 1.07–2.14 |
| Study population | Survey no. | Time of survey | Survey population | No. examined (%) | No. positive for mf (%) | Mf GMI* for all examined | Mf GMI* for positives |
| Kirare | 1 | Sep-04 | 530 | 471 (88.9) | 123 (26.1) | 4.83 | 851.1 |
| 2 | Jan-06 | 530 | 461 (87.0) | 96 (20.8) | 2.46 | 385.7 | |
| 3 | Jan-07 | 530 | 438 (82.6) | 69 (15.8) | 1.08 | 101.5 | |
| 4 | Oct-07 | 530 | 351 (66.2) | 35 (10.0) | 0.70 | 200.3 | |
| 5 | Oct-08 | 530 | 302 (57.0) | 39 (12.9) | 0.90 | 142.4 | |
| 6 | Oct-09 | 512 | 259 (53.5) | 13 (5.0) | 0.30 | 194.7 | |
| 7 | Nov-10 | 690 | 400 (58.0)# | 17§ (4.4) | 0.25¤ | 178.9 | |
| 8 | Nov-11 | 690 | 393 (57.0)# | 11§ (2.7) | 0.15¤ | 180.8 | |
| Kiomoni | 7 | Nov-10 | 504 | 386 (76.6)# | 18§ (4.7) | 0.34¤ | 423.1 |
| 8 | Nov-11 | 504 | 312 (61.9)# | 7§ (2.2) | 0.16¤ | 487.3 | |
| Kisimatui | 7 | Nov-10 | 651 | 389 (59.8)# | 34§ (8.7) | 0.55¤ | 159.1 |
| 8 | Nov-11 | 651 | 367 (56.4)# | 24§ (6.5) | 0.33¤ | 77.2 |
| Composite SES measure | Adults in poverty measure | ||||
| Individual | Group | Multilevel | Group | Multilevel | |
| Individual-level education | |||||
| Low | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | ||
| Medium | 1.30 (0.82–2.07) | 1.32 (0.84–2.06) | 1.28 (0.83–1.98) | ||
| High | 1.19 (0.76–1.88) | 1.19 (0.74–1.94) | 1.17 (0.75–1.83) | ||
| Community-level SESb | |||||
| 1 (low) | 1.00 (reference) | 1.00 (reference) | |||
| 2 | 1.34 (0.83–2.15) | 1.34 (0.80–2.24) | |||
| 3 | 1.21 (0.78–1.88) | 1.22 (0.82–1.81) | |||
| 4 | 1.14 (0.72–1.82) | 1.13 (0.72–1.77) | |||
| 5 (high) | 1.31 (0.86–2.00) | 1.30 (0.86–1.96) | |||
| Community-level poverty | |||||
| High | 1.00 (reference) | 1.00 (reference) | |||
| Medium | 1.16 (0.81–1.66) | 1.13 (0.83–1.54) | |||
| Low | 1.30 (0.85–1.99) | 1.27 (0.85–1.92) |
| Gene | Gene position (chromosome - bp)* | SNP location (chromosome - bp) | NCBI SNP number | Variation (5’orientation) | Position in CDS | Position in protein | Aminoacid substitution |
| TEKT4 | 25: 871,130..877,122 | 874,677 | rs109315777 | T/A | 584 | 195 | M/K |
| LOC100138021 | X:49,737,023..49,737,868 | 49,737,296 | rs461402021 | G/C | 573 | 191 | I/M |
| CENPI | X:54,969,324..55,038,297 | 54,971,267 | rs134782295 | G/A | 143 | 48 | S/N |
| TAF7L** | X:55,127,019..55,144,665 | 55,133,975 | rs445729496 | C/T | 829/535 | 277/179 | A/T |
| NXF2 | X:55,592,336..55,604,610 | 55,602,546 | ss1026566625 | T/C | 661 | 221 | N/D |
| CYLC1 | X:69,903,617..69,933,552 | 69,914,225 | rs477320469 | T/A | 818 | 273 | Y/F |
| UXT | X:91,468,065..91,474,474 | 91,472,521 | rs132821996 | C/T | 344 | 115 | S/N |
| SPACA5 | X:92,799,368..92,801,705 | 92,801,539 | rs211186307 | C/T | 109 | 37 | G/S |
| Global | Septal | Regional | ||||
| MBF | PN | MBF | PN | MBF | PN | |
| Reference method | 1.20 ± 0.44 | 0.20 ± 0.08 | 1.23 ± 0.56* | 0.28 ± 0.11* | 1.22 ± 0.68 | 0.34 ± 0.21 |
| Accelerated method | 1.24 ± 0.25 | 0.08 ± 0.05 | 1.28 ± 0.44 | 0.17 ± 0.06 | 1.28 ± 0.46 | 0.21 ± 0.11 |
| p-value | 0.7297 | 0.0059 | 0.6806 | 0.0002 | 0.5353 | 0.0001 |
| Scenario | Intervention | Baseline | 2020 coverage targets | 2025 coverage targets | 2030 coverage targets |
| 1. Sustain | All | Maintain coverage of all interventions at 2011–2013 levels | |||
| 2. Accelerate | Vector controlLLINIRS | Means of 2011–2013 country-specific coverage | 80% with LLIN replaced every 3 years | 90% with LLIN replaced every 2 years | Maintain coverage |
| Other measures | 10% additional coverage with complementary control measures for resistance management | ||||
| SMC | 0% | 80% | 95% | Maintain | |
| IPTp | 0% | 80% | 90% | Maintain | |
| Blood tests, using RDTs or microscopy | 20% | 90% | |||
| 10% G6PD testing | 90% | ||||
| Treatment of uncomplicated cases | 2013 country-specific coverage | 90% at public facilities, 50% in communities | . | 75% community based treatment | |
| Treatment of severe cases | 100% hospitalised cases treated with quinine | 100% hospitalised cases treated with injectable artesunate | 50% severe cases with rectal artesunate in communities | 75% severe cases with rectal artesunate in communities |
| Dataset | # Total genes (T) | # Instances (n) | # Classes (C) |
| Colon tumor | 2000 | 62 | 2 |
| Central nervous system | 7129 | 60 | 2 |
| Leukaemia | 6817 | 72 | 2 |
| Breast cancer | 24481 | 97 | 2 |
| Ovarian cancer | 15154 | 253 | 2 |
| MLL | 12582 | 72 | 3 |
| SRBCT | 2308 | 83 | 4 |
| Lung cancer | 12533 | 181 | 5 |
| Regression coefficient | S.E | Odds ratio | 95% C.I | P value | |
| Retrovirus status | |||||
| (positive vs negative) | 1.67 | 0.70 | 5.68 | 1.35 - 21.20 | 0.02 |
| Gender (male vs female) | 0.85 | 0.47 | 2.30 | 0.96 - 6.00 | 0.07 |
| Age (years) | 0.12 | 0.05 | 1.10 1 | 1.01 - 1.25 | 0.02 |
| Constant | −1.34 | 0.40 | <0.02 |
| Number | pAkt | P value | ||
| Median | Range | |||
| Total | 141 | 36.0 | 0–255.0 | |
| Ethnicity | ||||
| African-American | 72 | 35.7 | 0–174.0 | |
| Latina | 69 | 36.6 | 0–255.0 | 0.992 |
| Age at diagnosis | ||||
| <50 years | 73 | 31.0 | 0–255.0 | |
| ≥ 50 years | 68 | 39.0 | 0–174.0 | 0.678 |
| Tumor size | ||||
| <5 cm | 90 | 32.2 | 0–174.0 | |
| ≥ 5 cm | 51 | 36.6 | 0–255.0 | 0.117 |
| Lymph node status | ||||
| Positive | 89 | 45.0 | 0–255.0 | |
| Negative | 52 | 27.5 | 0–135.0 | 0.001 |
| AJCC stage | ||||
| 0–II | 88 | 33.3 | 0–174.0 | |
| III–IV | 53 | 42.0 | 0–255.0 | 0.160 |
| Histological grade | ||||
| Well to moderately differentiated | 44 | 30.0 | 0–174.0 | |
| Poorly differentiated | 97 | 40.8 | 0–255.0 | 0.094 |
| ER/PR status | ||||
| ER/PR+ | 81 | 30.0 | 0–255.0 | |
| ER/PR- | 60 | 47.3 | 0–170.0 | 0.164 |
| HER2/neu status (IHC) | ||||
| Positive | 46 | 44.5 | 0–255.0 | |
| Negative | 95 | 30.0 | 0–168.9 | 0.009 |
| Plant | Tissue | InsP6 (μM) | Ins(1,2,4,5,6)P5 (μM) |
| Zea mays | leaves | 101–198 (3) | nd |
| Oryza sativa | leaves | 9–49 (6) | nd |
| Arabidopsis thaliana | leaves | 29–89 (9) | 2–22 (5) |
| Arabidopsis thaliana | seedlings | 47–110 (4) | nd |
| Nicotiana tabacum | leaves | 11–24 (3) | nd |
| Solanum lycopersicum | leaves | 39–65 (3) | nd |
| Trifolium repens | leaves | 21 (1) | 6 (1) |
| Acer rubrum | leaves | 35 (1) | 2 (1) |
| Ginkgo biloba | leaves | 61 (1) | nd |
| Camelina sativa | leaves | 70 (1) | 6 (1) |
| Glycine max | leaves | nd (1) | nd |
| Pueraria labata | leaves | nd (1) | nd |
| Gene Symbol | Gene name |
| MBD2 | Methyl-CpG binding domain protein 2 |
| FMO3 | Flavin containing monooxygenase 3 |
| RORC | RAR-related orphan receptor C |
| SGCG | Sarcoglycan, gamma (35kDa dystrophin-associated glycoprotein) |
| PNKD | Paroxysmal nonkinesigenic dyskinesia |
| RNASE1 | Ribonuclease, RNase A family, 1 (pancreatic) |
| NKRF | NFKB repressing factor |
| PFKM | Phosphofructokinase, muscle |
| MOCS1 | Molybdenum cofactor synthesis 1 |
| TRA2A | Transformer 2 alpha homolog |
| Genetic effect | Genotype-by-age effect | Genetic + genotype-by-age effects | ||||||||
| SNPa | Chrb | Position | Alleles | MAF | LRT1 | -log(p) | LRT2 | -log(p) | LRT3 | -log(p) |
| rs17631940 | 17 | 30842243 | A/G | 0.49 | 23.99 | 6.01 | 1.02 | 0.50 | 25.00 | 5.43 |
| rs1476112 | 18 | 170690 | T/G | 0.08 | 14.40 | 3.83 | 13.43 | 3.61 | 27.83 | 6.04 |
| rs8102150 | 19 | 922139 | G/C | 0.03 | 7.05 | 2.10 | 23.09 | 5.81 | 30.14 | 6.55 |
| Variable | Normal (n = 2,537) | VSD (n = 124) | P value | ||
| Mean ± SD | 10 to 90% | Mean ± SD | 10 to 90% | ||
| NBL (mm) | 6.74 ± 0.87 | 5.60 to 7.90 | 6.40 ± 0.79 | 5.30 to 7.40 | <0.0001 |
| BPD (mm) | 54.33 ± 9.10 | 48.00 to 60.00 | 52.65 ± 4.87 | 47.12 to 59.70 | 0.041 |
| HC (mm) | 197.34 ± 15.57 | 177.00 to 218.00 | 193.94 ± 14.66 | 175.00 to 213.40 | 0.017 |
| AC (mm) | 177.08 ± 16.15 | 156.00 to 198.00 | 171.36 ± 16.12 | 150.82 to 194.45 | <0.0001 |
| Femur length (mm) | 37.33 ± 3.86 | 32.50 to 42.40 | 35.93 ± 3.78 | 30.72 to 41.10 | <0.0001 |
| Tibia length (mm) | 32.92 ± 3.42 | 28.30 to 37.30 | 31.90 ± 3.53 | 27.12 to 36.92 | 0.001 |
| Fibula length (mm) | 32.76 ± 3.33 | 28.35 to 37.00 | 31.71 ± 3.27 | 26.88 to 36.00 | 0.001 |
| Humerus length (mm) | 35.39 ± 3.34 | 31.00 to 39.70 | 34.40 ± 3.24 | 29.94 to 38.70 | 0.001 |
| Radius length (mm) | 30.34 ± 2.94 | 26.70 to 34.00 | 29.38 ± 2.70 | 25.70 to 32.46 | <0.0001 |
| Ulna length (mm) | 32.92 ± 3.21 | 28.80 to 37.00 | 32.07 ± 3.14 | 28.00 to 36.30 | 0.004 |
| Estimated FBW (g) | 508.75 ± 116.48 | 364.00 to 666.00 | 470.74 ± 107.31 | 343.60 to 608.20 | <0.0001 |
| CTAR | 0.22 ± 0.12 | 0.18 to 0.25 | 0.21 ± 0.03 | 0.18 to 0.25 | 0.753 |
| CTCR | 0.46 ± 0.06 | 0.42 to 0.50 | 0.46 ± 0.03 | 0.43 to 0.50 | 0.131 |
| UA PI | 1.16 ± 0.22 | 0.93 to 1.40 | 1.33 ± 0.34 | 0.99 to 1.91 | <0.0001 |
| UA RI | 0.69 ± 0.08 | 0.60 to 0.78 | 0.74 ± 0.09 | 0.64 to 0.86 | <0.0001 |
| MCA PI | 1.59 ± 0.27 | 1.26 to 1.90 | 1.48 ± 0.24 | 1.18 to 1.82 | <0.0001 |
| MCA RI | 0.81 ± 0.08 | 0.72 to 0.91 | 0.79 ± 0.65 | 0.71 to 0.87 | 0.008 |
| MCA/UA PI ratio | 1.41 ± 0.34 | 1.02 to 1.79 | 1.19 ± 0.38 | 0.66 to 1.67 | <0.0001 |
| MCA/UA RI ratio | 1.19 ± 0.18 | 0.99 to 1.40 | 1.09 ± 0.18 | 0.85 to 1.30 | <0.0001 |
| Variables | Cases(n=73) | Controls(n=146) |
| Having ANC visit | ||
| Yes | 56(76.7%) | 121(82.9%) |
| No | 17(23.3%) | 25(17.1%) |
| Gestational Age at first ANC | ||
| First trimester | 11(24.4%) | 18(17.1%) |
| Second trimester | 23(51.1%) | 59(56.2%) |
| Third trimester | 11(24.4%) | 28(26.7%) |
| TT vaccination | ||
| Yes | 47(64.4%) | 105(71.9%) |
| No | 26(35.6%) | 41(28.1%) |
| Dose of TT vaccination | ||
| Single dose | 6(12.8%) | 20(19.0%) |
| Two to Three doses | 35(74.5%) | 73(69.5%) |
| Four to Five doses | 6(12.8%) | 12(11.4%) |
| Postnatal visit within 7 days | ||
| Yes | 34(46.6%) | 72(49.3%) |
| No | 39(53.4%) | 74(50.7%) |
| Previous birth intervals | ||
| Less than two years | 15(20.5%) | 18(12.3%) |
| Two years | 7(9.6%) | 9(6.2%) |
| More than two years | 51(69.9%) | 119(81.5%) |
| Walking distance from the nearest health facility | ||
| < 1 hour | 24(32.9%) | 51(34.9%) |
| 1-2 hours | 42(57.5%) | 91(62.3%) |
| > 2 hours | 7(9.6%) | 4(2.7%) |
| Place of delivery | ||
| Home | 56(76.7%) | 136(93.2%) |
| Health Facility | 17(23.3%) | 10(6.8%) |
| First author | Year | Country | Patient (M/F) | Age (year) | Technology | Lgr5 positive threshold | HR (95 % CI) of OS | HR (95 % CI) of DFS | Quality score |
| Liu | 2014 | China | 363 (200/166) | 59mean | IHC | NA | 2.604 (1.894–3.584) | NA | 7 |
| He | 2014 | China | 53 (29/24) | NA | IHC | NA | 2.482 (1.52–4.283) | NA | 7 |
| Gao | 2014 | China | 44 (22/20) | 59median | IHC | The percentage of stained cells ≥ 10 % | 2.299 (0.922–5.714) | NA | 6 |
| Wu | 2012 | China | 192 (120/72) | 62median | IHC | Multiplying the intensity and the quantity score > 5 | 2.768 (1.619–4.732) | NA | 8 |
| Hsu | 2013 | China | 296 (169/127) | 63.5mean | IHC | The percentage of stained cells multiplied by the intensity scores ≥180 | NA | 2.21 (1.11–4.37) | 7 |
| Saiqusa | 2012 | Japan | 52 (41/11) | 64.5median | IHC | The percentage of stained cells ≥ 50 % | 1.061 (0.299–3.771) | 4.942 (1.39–17.577) | 6 |
| Ziskin | 2012 | America | 891 (467/424) | 71.4mean | ISH | Intensity score >1 | 1.15 (0.95–1.4) | NA | 7 |
| Valladares-Ayerbes | 2012 | Spain | 54 (33/21) | 62.7mean | QRT-PCR | 11.6 | 2.517 (0.924–6.858) | 2.995 (1.192–7.527) | 8 |
| Takahashi | 2011 | Japan | 180 (105/75) | NA | QRT-PCR | Median value | 0.909 (0.535–1.543) | 3.3 (1.49–7.33) | 6 |
| Bao | 2012 | China | 246 (131/115) | 63mean | IHC | The percentage of stained cells ≥ 5 % | 1.122 (0.866–1.448) | NA | 4 |
| Peng | 2010 | China | 169 (101/68) | 57mean | IHC | The percentage of stained cells ≥ 10 % | 2.16 (1.35–3.45) | NA | 7 |
| Takeda | 2010 | Japan | 60 (32/28) | 65.7mean | IHC | The percentage of stained cells ≥ 5 % | NA | NA | 7 |
| Probe set | Gene symbol | Locus | Description | Fold difference | q-value |
| 209735_at | ABCG2 | 4q22 | ATP-binding cassette, sub-family G (WHITE), member 2 | −1.29 | 0.031 |
| 208868_s_at | GABARAPL1 | 12p13.2 | GABA(A) receptor-associated protein like 1 | −1.17 | 0.043 |
| 208813_at | GOT1 | 19q24.1-q25.1 | glutamic-oxaloacetic transaminase 1, soluble (aspartate aminotransferase 1) | −1.17 | 0.043 |
| 212878_s_at | KLC1 | 14q32.3 | kinesin light chain 1 | −1.14 | 0.044 |
| 208002_s_at | ACOT7 | 1p36 | acyl-CoA thioesterase 7 | −1.14 | 0.033 |
| 213897_s_at | MRPL23 | 11p15.5 | mitochondrial ribosomal protein L23 | −1.10 | 0.043 |
| 211382_s_at | TACC2 | 10q26 | transforming, acidic coiled-coil containing protein 2 | −1.10 | 0.033 |
| 214365_at | TPM3 | 1q21.2 | tropomyosin 3 | −1.10 | 0.037 |
| 213738_s_at | ATP5A1 | 18q21 | ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit 1, cardiac muscle | −1.10 | 0.031 |
| 221909_at | RNFT2 | 12q24.22 | ring finger protein, transmembrane 2 | −1.10 | 0.033 |
| 201322_at | ATP5B | 12q13.13 | ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide | −1.10 | 0.049 |
| 203272_s_at | TUSC2 | 3p21.3 | tumor suppressor candidate 2 | −1.09 | 0.049 |
| 218332_at | BEX1 | Xq22.1 | brain expressed, X-linked 1 | −1.09 | 0.033 |
| 201077_s_at | NHP2L1 | NA | NHP2 non-histone chromosome protein 2-like 1 (S. cerevisiae) | −1.09 | 0.041 |
| 201410_at | PLEKHB2 | 2q21.1 | pleckstrin homology domain containing, family B (evectins) member 2 | −1.08 | 0.033 |
| 219760_at | LIN7B | 19q13.3 | lin-7 homolog B (C. elegans) | −1.08 | 0.049 |
| 221315_s_at | FGF22 | 19p13.3 | fibroblast growth factor 22 | −1.08 | 0.042 |
| 221706_s_at | USE1 | 19p13.11 | unconventional SNARE in the ER 1 homolog (S. cerevisiae) | −1.07 | 0.042 |
| 202967_at | GSTA4 | 6p12.1 | glutathione S-transferase alpha 4 | −1.07 | 0.049 |
| 207839_s_at | TMEM8B | 9p13.3 | transmembrane protein 8B | −1.07 | 0.042 |
| 221746_at | UBL4A | Xq28 | ubiquitin-like 4A | −1.07 | 0.033 |
| 208971_at | UROD | 1p34 | uroporphyrinogen decarboxylase | −1.07 | 0.043 |
| 202486_at | AFG3L2 | 18p11 | AFG3 ATPase family gene 3-like 2 (S. cerevisiae) | −1.06 | 0.044 |
| Characteristics | Hospitalized | % | Non-Hospitalized | % | |
| N=8681 | N=8681 | ||||
| Sex | |||||
| Male | 3588 | 41.3 | 3588 | 41.3 | |
| Female | 5093 | 58.7 | 5093 | 58.7 | |
| Age (years at index date) | |||||
| 0 - ≥ 18 | 574 | 6.6 | 574 | 6.6 | |
| >18 - ≥ 45 | 2737 | 31.5 | 2737 | 31.5 | |
| > 45 - ≥ 65 | 2246 | 25.9 | 2246 | 25.9 | |
| > 65 - ≥ 79 | 2218 | 25.6 | 2218 | 25.6 | |
| > 79 | 906 | 10.4 | 906 | 10.4 | |
| Number of medications | |||||
| 0 | 3416 | 39.4 | 4534 | 52.2 | |
| 1 | 1794 | 20.7 | 2121 | 24.4 | |
| 2 | 985 | 11.3 | 872 | 10.0 | |
| 3 | 767 | 8.8 | 535 | 6.2 | |
| 4 | 544 | 6.3 | 302 | 3.5 | |
| ≥5 | 1175 | 13.5 | 317 | 3.7 | |
| CDS category | |||||
| CDS score 0 | 3671 | 42.3 | 5206 | 60.0 | |
| CDS score 1-2 | 1331 | 15.3 | 1287 | 14.3 | |
| CDS score 3-4 | 1731 | 19.9 | 1415 | 16.3 | |
| CDS score ≥5 | 1948 | 22.4 | 773 | 8.9 | |
| Duration of hospitalization | |||||
| 1 day | 417 | 4.8 | |||
| 2-5 days | 4374 | 50.4 | |||
| > 5days | 3890 | 44.8 | |||
| Admission type | |||||
| Emergency | 3966 | 45.7 | |||
| Planned | 4715 | 54.3 | |||
| Admission for surgery | |||||
| Yes | 4360 | 50.2 | |||
| No | 4321 | 49.8 |
| No antibody | Erbitux ® (anti-ErB1) | Herceptin ® (anti-ErB2) | |
| U87Ctrl | 130.1±4.4 | 98.3±8.6(*) | 125.6±7.9 (ns) |
| U87dn | 144.3±3.3 | 104.3±3.9(*) | 131.6±8.8 (ns) |
| (1) | (2) | (3) | (4) | (5) | (6) | |
| Outcome variable: | Distance (km) from nearest clinic | At least 2 km from nearest clinic | ||||
| Black African | 0.735** | −0.180 | −0.185 | 0.041 | −0.108 | −0.115 |
| (0.310) | (0.311) | (0.323) | (0.087) | (0.072) | (0.074) | |
| Coloured | −0.078 | −0.613* | −0.601* | −0.206** | −0.284*** | −0.292*** |
| (0.360) | (0.337) | (0.356) | (0.085) | (0.072) | (0.073) | |
| Primary schooling | −0.161*** | −0.156*** | −0.026*** | −0.024*** | ||
| (0.033) | (0.034) | (0.004) | (0.004) | |||
| Secondary schooling | −0.158*** | −0.195*** | −0.020*** | −0.024*** | ||
| (0.051) | (0.056) | (0.007) | (0.007) | |||
| Completed high school | −0.028 | −0.071 | 0.029 | 0.021 | ||
| (0.158) | (0.180) | (0.021) | (0.021) | |||
| Tertiary schooling | 0.565** | 0.630*** | 0.147* | 0.171* | ||
| (0.219) | (0.243) | (0.078) | (0.087) | |||
| 2nd per capita income quintile | −0.484** | −0.376* | −0.085*** | −0.065** | ||
| (0.217) | (0.223) | (0.032) | (0.031) | |||
| 3rd per capita income quintile | −0.582** | −0.480 | −0.141*** | −0.129*** | ||
| (0.295) | (0.315) | (0.039) | (0.040) | |||
| 4th per capita income quintile | −0.755** | −0.710** | −0.193*** | −0.193*** | ||
| (0.326) | (0.350) | (0.042) | (0.042) | |||
| 5th per capita income quintile | −0.497 | −0.499 | −0.138*** | −0.147*** | ||
| (0.341) | (0.370) | (0.050) | (0.051) | |||
| Number of children (<15) in household | 0.186*** | 0.192*** | 0.030*** | 0.029*** | ||
| (0.052) | (0.057) | (0.008) | (0.008) | |||
| Number of individuals age 15 and older in household | −0.125** | −0.121** | −0.005 | −0.005 | ||
| (0.056) | (0.054) | (0.011) | (0.010) | |||
| Number of pensioners in household | 0.389** | 0.408** | 0.043 | 0.058** | ||
| (0.164) | (0.177) | (0.028) | (0.029) | |||
| Self-reports poor or fair health | −0.441*** | −0.055*** | ||||
| (0.163) | (0.020) | |||||
| Observations | 14,968 | 14,843 | 12,400 | 14,968 | 14,843 | 12,400 |
| Purchase status | Condition | |
| Loss | Near-miss | |
| Non-purchasers | 20.18 (20.41) | 34.74 (25.15) |
| Purchasers | 19.43 (9.64) | 61.00 (17.94)* |
| HSFD | HUFD | HDSD | HRSD | ||
| g/Kg | g/Kg | g/Kg | g/Kg | ||
| Protein | |||||
| Casein | 254.1 | 254.1 | 212.9 | 212.9 | |
| Lipid | |||||
| Corn oil | 11.1 | 11.1 | |||
| Olive oil | 364.5 | ||||
| Lard | 364.5 | ||||
| Carbohydrates | |||||
| Corn starch | 305 | 305 | 675 | ||
| Banana starch | 675 | ||||
| Sucrose | 33.8 | 33.8 | 67 | 67 | |
| Vit. & Min. | 15 | 15 | 15 | 15 | |
| Caloric value (Kcal/g) | 5.6 | 5.6 | 3.9 | 3.9 |
| Normal endothelial cells | Vasculogenic mimicry cells |
| Similarities | |
| VE-cadherin positive | |
| E-selectin positive | |
| CD34 positive | |
| Differences | |
| TIE-2 positive | TIE-2 negative |
| VEGFR-1, 2 positive | VEGFR-1, 2 negative |
| P-selectin positive | P-selectin negative |
| VCAM-1/CD106 positive | VCAM-1/CD106 negative |
| CD31/PECAM-1 positive | CD31/PECAM-1 negative *13 (Subpopulations PECAM-1 positive melanoma cells) |
| TIE-1 negative | TIE-1 positive |
| VEGF-C negative | VEGF-C positive |
| Neuropilin 1 negative | Neuropilin 1 positive |
| Endoglin negative | Endoglin positive |
| Tissue factor pathway inhibitor 1 (TFPI1) negative | Tissue factor pathway inhibitor 1 (TFPI1) positive |
| Laminin 5 gamma 2 chain (LAMC2) negative | Laminin 5 gamma 2 chain (LAMC2) positive |
| EphA-2 negative | EphA-2 positive |
| Agent | Normal dose | Estimated GFR (creatinine clearance: CrCl) |
| Zidovudine | 300 mg twice a day orally | 100 mg thrice a day orally |
| Lamivudine | 150 mg twice a day orally | 30–49 mL/min = 150 mg once a day orally15–29 mL/min = 100 mg once a day orally5–14 mL/min = 50 mg once a day orally<5 mL/min = 25 mg once a day orally |
| Stavudine | 30 mg twice a day orally | 26–50 mL/min = 15 mg twice a day orally<26 mL/min = 15 mg once a day orally |
| Didanosine | >60 kg: 200 mg twice a day orally <60 kg, 125 mg twice a day orally | 30–59 mL/min = 200 mg once a day orally10–29 mL/min = 150 mg once a day orally<10 mL/min = 100 mg once a day orally30–59 mL/min = 150 mg once a day orally10–29 mL/min = 100 mg once a day orally<10 mL/min = 75 mg once a day orally |
| Tenofovir | 300 mg once a day orally | 30–49 mL/min = 300 mg every second day10–29 mL/min = 300 mg every third day<10 mL/min = 300 mg once weekly |
| ASIC channel type | pH sensitivity (pH50) [21] | Predominant localization | Likely cellular localization | Potential function | References |
| ASIC1A | 5.8–6.8 | Central and peripheral nervous systems | Axons, cell bodies, dendrites | Cell death following injury, epilepsy, pain signaling, neuroinflammation, neurodegeneration, fear behavior | [21–35] |
| ASIC1B | 6.1–6.2 | Peripheral nervous system | Axons, cell bodies | [21, 36] | |
| ASIC2A | 4.5–4.9 | Central and peripheral nervous systems | Axons, cell bodies, dendrites | Modulate ASIC1, ASIC2b, and ASIC3 function, autonomic circulatory control | [21, 37–40] |
| ASIC2B | Associates with other channels to have pH sensitivity | Central and peripheral nervous systems | Axons, axons terminals, cell bodies | Modulate ASIC1 function, autonomic circulatory control, acidosis-induced neuronal death | [37, 38, 41] |
| ASIC3 | 6.4–6.6 | Peripheral and central nervous systems | Axons, axons terminals, cell bodies | Pain signaling, fear conditioning with exogenous expression, anxiety and aggression | [21, 42–50] |
| ASIC4 | Not pH sensitive | Central nervous system | Fear and anxiety through ASIC1a antagonism | [51] |
| Total female participants n(%) | Female with DNA methylation data, n(%) | P value | |
| Factors | n = 750 | n = 245 | |
| Maternal history of asthma | |||
| Yes | 80 (10.8) | 30 (12.3) | 0.50 |
| No | 662 (89.2) | 213 (87.7) | |
| Missing | 8 | 2 | |
| Maternal smoking during pregnancy | |||
| Yes | 188 (25.3) | 47 (19.3) | 0.05 |
| No | 555 (74.7) | 197 (80.7) | |
| Missing | 7 | 1 | |
| Maternal body mass index (kg/m2) | |||
| Underweight (<18.5) | 10 (1.7) | 4 (2.2) | 0.82 |
| Normal (18.5- <25) | 355 (61.5) | 109 (59.2) | |
| Overweight (≥25.00) | 212 (36.7) | 71 (38.6) | |
| Missing | 173 | 61 | |
| Low birth weight | |||
| Yes | 35 (4.8) | 9 (3.8) | 0.53 |
| No | 699 (95.2) | 228 (96.2) | |
| Missing | 16 | 8 | |
| Asthma at age 18 years | |||
| Yes | 128 (19.4) | 35 (14.3) | 0.07 |
| No | 531 (80.6) | 210 (85.7) | |
| Missing | 91 | 0 | |
| Median (5%, 95% value); n | |||
| Breastfeeding duration (weeks) | 8.0 (0, 40); 664 | 10.5 (0, 40); 222 | 0.16 |
| Missing | 86 | 20 | |
| Body mass index at age 18 (kg/m2) | 22.2 (18, 32); 499 | 22.9 (19.05, 32.93); 240 | 0.56 |
| Missing | 251 | 5 |
| Patient No. | Age | Gender | FEV1 (% pred.) | COPD | DP (cmH2O) | PIF (L/min) | IV (L) | IT (s) | ||||
| GD | TD | GD | TD | GD | TD | GD | TD | |||||
| 1 | 74 | Male | 69 | Mod. | 24 | 31 | 80 | 34 | 2.2 | 1.9 | 2.5 | 6.3 |
| 2 | 69 | Male | 39 | Sev. | 35 | 58 | 97 | 47 | 2.1 | 1.6 | 1.9 | 3.0 |
| 3 | 79 | Male | 58 | Mod. | 8 | 14 | 47 | 23 | 1.3 | 1.5 | 3.0 | 6.1 |
| 4 | 70 | Female | 74 | Mod. | 9 | 15 | 48 | 24 | 1.7 | 1.4 | 3.2 | 5.0 |
| 5 | 52 | Female | 68 | Mod. | 37 | 44 | 99 | 41 | 2.0 | 1.8 | 1.7 | 3.8 |
| 6 | 76 | Female | 66 | Mod. | 15 | 34 | 64 | 36 | 1.0 | 1.3 | 1.3 | 3.1 |
| 7 | 71 | Female | 49 | Sev. | 19 | 61 | 72 | 48 | 1.8 | 1.5 | 2.0 | 2.3 |
| Average | 70 | 60 | 21 | 37 | 72 | 36 | 1.7 | 1.6 | 2.2 | 4.2 |
| Component | Slices | LUTs | FFs | Freq. |
| Network stack | 1788 | 1380 | 2790 | 127.6 MHz |
| Adapters | 624 | 643 | 981 | 186.4 MHz |
| Bus | 284 | 210 | 335 | 220 MHz |
| Gene name | Protein description | Cellular component | Biological process | Predominant normal tissue expression | Spectral counts | Position in B596 NAS fraction (sorted by spectral counts) |
| CCDC86 | Cytokine-induced protein with coiled-coil domain | Nucleus | Unknown | Testis | 106 | 22/236 |
| H2AFY | Core histone macro-H2A.1 | Nucleus | Chromatine Structure | Lung | 42 | 44/236 |
| MECP2 | Methyl-CpG-binding protein 2 | Nucleus | Chromatine Structure | Brain | 16 | 85/236 |
| NUMA1 | Nuclear mitotic apparatus protein 1 | Nucleus | Cell cycle | Lung | 14 | 90/236 |
| LYAR | Cell growth-regulating nucleolar protein | Nucleus | Cell cycle | Testis | 10 | 106/236 |
| STMN2 | Stathmin-2 | Cytoskeleton | Microtubule polymerization | Brain | 1 | 219/236 |
| Sequence | Length (aa) | Position(s) in HXB2 (aa) | Positions in HIVconsv (aa) | Presence of exact match in LANL-HSD | NetMHC binding affinity (nM) | HLA allele | PEAKS score (−10logP) | Sample collection time(s) (h) |
| YKRWIILGLNK | 11 | Gag 262–272 | 58–68 | No | 11,608 | A*03:01 | 15.30 | 1.5 |
| KRWIILGLNK | 10 | Gag 263–272 | 59–68 | Yes | 6,379 | A*03:01 | 16.35 | 2.5 |
| IYKRWIILGLNK | 12 | Gag 261–272 | 57–68 | No | 1,472 | A*03:01 | 15.32 | 3.5 |
| IILGLNK | 7 | Gag 266–272 | 62–68 | No | NA | A*03:01 | 14.82 | 2.5, 3.5 |
| FPISPIETVPVKL | 13 | Pol 155–167 | 194–206 | No | 163 (WB) | B*07:02 | 56.52 | 3.5, 6 |
| SPIETVPVKL | 10 | Pol 158–167 | 197–206 | Yes | 191 (WB) | B*07:02 | 41.33 | 2.5, 3.5, 6 |
| AIFQSSMTK | 9 | Pol 313–321 | 351–360 | Yes | 20 (SB) | A*03:01 | 47.95 | 2.5, 3.5, 6 |
| RKGGIGGYSAG | 11 | Pol 902–912 | 663–673 | Yes | 20,750 | B*07:02 | 14.82 | 6 |
| RTWKSLVK | 8 | Vif 19–26 | 412–419 | No | 39 (SB) | A*03:01 | 28.89 | 6 |
| KIWPS-RWKPKa | 10 | Gag/Pol | 131–140 | NA | 71 (WB) | A*03:01 | 19.25 | 6 |
| KLTP-WVPAHKa | 10 | Env/Pol | 518–527 | NA | 19 (SB) | A*03:01 | 40.52 | 6 |
| No. of embryos (repeat) | Cleavage (%) | Blastocyst (%) | No. of cells in blastocysts |
| 1356 (6) | 846 (76.3 ± 4.0) | 367 (26.7 ± 3.9) | 54.6 ± 13.6 |
| RHY+ORD+ | RHY−ORD+ | RHY+ORD- | RHY−ORD− | ||
| Region 1 | GD | 365 (8.38) | 304 (7.19) | 391 (8.69) | 410 (9.41) |
| RPD | 412 (9.20) | 333 (7.90) | 462 (10.18) | 448 (10.35) | |
| REG | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |
| Region 2 | GD | 394 (8.49) | 439 (10.01) | 360 (8.44) | 333 (7.85) |
| RPD | 476 (13.31) | 709 (23.13) | 429 (11.68) | 443 (14.86) | |
| REG | 0.10 (0.01) | 0.24 (0.02) | 0.12 (0.01) | 0.21 (0.02) | |
| Region 3 | GD | 331 (7.21) | 353 (8.48) | 337 (6.87) | 397 (8.97) |
| RPD | 400 (12.97) | 527 (21.01) | 412 (13.59) | 627 (21.41) | |
| REG | 0.10 (0.01) | 0.18 (0.02) | 0.11 (0.01) | 0.24 (0.02) | |
| Region 4 | GD | 396 (9.43) | 403 (11.07) | 400 (10.32) | 401 (10.57) |
| RPD | 537 (20.22) | 581 (22.34) | 574 (20.99) | 642 (24.91) | |
| REG | 0.11 (0.01) | 0.14 (0.02) | 0.17 (0.02) | 0.19 (0.02) | |
| Region 5 | GD | 548 (17.03) | 531 (17.39) | 537 (19.09) | 517 (18.01) |
| RPD | 1113 (36.11) | 1056 (34.84) | 1155 (36.50) | 1062 (37.47) | |
| REG | 0.49 (0.02) | 0.46 (0.02) | 0.51 (0.02) | 0.43 (0.02) |
| Males | Females | |||||||
| Adjusted Odds Ratio(95%CI): reference time, 1995 | §MH χ2 for Linear trend, 1995–2003: | Adjusted Odds Ratio(95%CI): reference time, 1995 | §MH χ2 for Linear trend, 1995–2003: | |||||
| 1999 | 2003 | P value | 1999 | 2003 | P value | |||
| R | Education (~age)‡ | |||||||
| 0–7 years | 0.93(0.62–1.34) | 0.72(0.47–1.09) | 0.227 | 1.07(0.57–2.01) | 1.03(0.62–1.72) | 0.838 | ||
| U | 8–9 years | 0.74(0.29–1.88) | 0.84(0.28–2.46) | 0.731 | 0.52(0.24–1.13) | 0.50(0.22–1.14) | 0.104 | |
| ≥10 years | 0.38(0.15–0.98) | 0.44(0.22–0.87) | 0.223 | 0.33(0.17–0.65) | 0.29(0.08–0.96) | 0.043 | ||
| R | Marital status | Single | 1.48(0.76–2.86) | 0.50(0.22–1.12) | 0.188 | 0.74(0.23–2.4) | 0.31(0.06–1.49) | 0.021 |
| Married | 0.66(0.38–1.15) | 0.63(0.42–0.96) | 0.096 | 0.91(0.53–1.57) | 0.82(0.49–1.37) | 0.112 | ||
| A | Employed | Yes | 0.66(0.42–1.03 | 0.76(0.48–1.21 | 0.914 | 0.81(0.21–3.15) | 0.73(0.22–2.42) | 0.479 |
| No | 1.03(0.57–1.84) | 0.55(0.34–0.89) | 0.026 | 0.82(0.48–1.38) | 0.78(0.47–1.31) | 0.055 | ||
| Travels | Never | 0.99(0.52–1.91) | 1.36(0.86–2.16) | 0.180 | 0.93(0.54–1.60 | 1.09(0.70–1.71) | 0.644 | |
| L | Sometimes | 0.66(0.44–0.98) | 0.43(0.27–0.70) | 0.019 | 0.76(0.33–1.71) | 0.59(0.31–1.10) | 0.024 | |
| Often | 0.76(0.21–2.75) | 0.62(0.19–1.94) | 0.563 | 0.92(0.23–3.67) | 0.44(0.07–2.89) | 0.051 | ||
| Duration lived | <1 year | 0.25(.10–0.63) | 0.63(0.22–1.81 | 0.733 | 0.57(0.33–0.99) | 0.79(0.35–1.82) | 0.199 | |
| (In current residence) | 1–5 yrs | 0.74(0.36–1.52) | 0.57(0.26–1.28) | 0.069 | 1.79(0.88–3.62) | 1.41(0.74–2.69) | 0.234 | |
| ≥6 yrs | 1.24(0.76–2.03) | 0.95(0.60–1.51) | 0.937 | 0.45(0.23–0.89) | 0.48(0.26–0.88) | 0.011 | ||
| Migration | Village | 0.72(0.43–1.22) | 0.99(0.51–1.94) | 0.922 | 1.12(0.58–2.16) | 1.04(0.55–1.97) | 0.840 | |
| (origin 5 years) | Town | 0.48(0.22–0.98) | 0.30(0.13–0.72) | 0.041 | 1.75(0.99–3.01) | 1.31(0.75–2.32) | 0.586 | |
| Given birth | Yes | -- | -- | 0.75(0.42–1.34) | 0.58(0.30–1.11) | 0.019 | ||
| (ever): age, 15–29 | No | -- | -- | 0.56(0.23–1.33) | 0.27(0.07–0.99) | 0.012 | ||
| U | Education (~age)‡ | |||||||
| 0–7 years | 1.66(0.80–3.42) | 1.34(0.72–2.49) | 0.398 | 0.83(0.59–1.16) | 1.11(0.71–1.76) | 0.498 | ||
| R | 8–9 years | 0.42(0.14–1.26) | 0.52(0.26–1.06) | 0.305 | 1.10(0.76–1.61) | 0.66(0.39–1.08) | 0.179 | |
| ≥10 years | 1.03(0.72–1.49) | 0.55(0.40–0.74) | 0.001* | 0.91(0.61–1.34) | 0.53(0.39–0.72) | 0.001* | ||
| B | Marital status | Single | 0.95(0.62–1.46) | 0.51(0.33–0.79) | 0.001* | 1.05(0.69–1.58) | 0.49(0.35–0.69) | 0.001* |
| Married | 1.04(0.72–1.52) | 0.71(0.47–0.98) | 0.035 | 0.92(0.74–1.14) | 0.73(0.57–0.94) | 0.002 | ||
| A | Employed | Yes | 0.97(0.69–1.36) | 0.64(0.44–0.95) | 0.001 | 0.98(0.67–1.41) | 0.69(0.51–0.95) | 0.018 |
| No | 0.99(0.60–1.64) | 0.52(0.37–0.74) | 0.001* | 0.93(0.76–1.15) | 0.63(0.47–0.85) | 0.001* | ||
| N | Travels | Never | 0.81(0.57–1.16) | 0.57(0.32–1.02) | 0.001 | 0.88(0.70–1.11) | 0.64(0.49–0.83) | 0.003 |
| Sometimes | 1.14(0.86–1.49) | 0.52(0.34–0.81) | 0.001* | 1.06(0.84–1.35) | 0.71(0.52–0.97) | 0.008 | ||
| Often | 1.11(0.55–2.21) | 0.80(0.38–1.70) | 0.189 | 0.77(0.23–2.59) | 0.44(0.23–0.82) | 0.002 | ||
| Duration lived | <1 year | 1.62(0.83–3.19) | 0.47(0.28–0.76) | 0.052 | 0.83(0.54–1.27) | 0.66(0.45–0.97) | 0.196 | |
| (In current residence) | 1–5 yrs | 0.85(0.54–1.35) | 0.71(0.47–1.09) | 0.007 | 0.83(0.59–1.16) | 0.56(0.40–0.79) | 0.001* | |
| ≥6 yrs | 0.90(0.56–1.46) | 0.53(0.29–0.99) | 0.001* | 1.31(0.95–1.81) | 0.86(0.57–1.33) | 0.129 | ||
| Migration | Village | 1.01(0.39–2.59) | 0.39(0.09–1.54) | 0.314 | 0.98(0.42–2.32) | 0.93(0.42–2.09) | 0.651 | |
| (origin 5 years) | Town | 1.03(0.63–1.68) | 0.69(0.49–0.96) | 0.001 | 0.83(0.64–1.06) | 0.58(0.45–0.74) | 0.001* | |
| Given birth | Yes | -- | -- | 0.73(0.63–0.35) | 0.51(0.38–0.67) | 0.001* | ||
| (ever): age, 15–29 | No | -- | -- | 0.87(0.64–1.19) | 0.52(0.35–0.75) | 0.042 |
| Serum biochemical factors | Malignant cholestasis | Stone induced cholestasis | P value |
| AST(IU/L) | 87.00±23.06 | 167.67±36.15 | 0.169 |
| ALT(IU/L) | 91.87±32.23 | 242.00±46.01 | 0.050 |
| AlkPhos (IU/L) | 1269.88±335.91 | 852.50±204.53 | 0.282 |
| T Bili (mg/dl) | 11.60±2.72 | 5.47±1.63 | 0.054 |
| D Bili (mg/dl) | 5.91±1.58 | 2.27±0.85 | 0.006 |
| Cycle Rate(Hz) | AveragePhase 0%Displacement(mm) | SD ofPhase 0%Displacement(mm) | AveragePhase 50%Displacement(mm) | SD ofPhase 50%Displacement(mm) |
| 0.2 | 20.01 | 0.04 | −19.65 | 0.08 |
| 0.33 | 19.96 | 0.05 | −19.64 | 0.11 |
| 1 | 20.73 | .08 | −18.87 | 0.59 |
| Serum parameter | Case | Control | Between groups comparison (P-value)a | ||||
| N | Baseline (mean ± SD | Follow-up (mean ± SD) | N | Baseline (mean ± SD) | Follow-up (mean ± SD) | ||
| FT3 (pmol/L) | 103 | 4.34 ± 0.6 | 4.57 ± 0.2b | 412 | 4.85 ± 0.7 | 4.30 ± 0.5b | <0.001 |
| FT4 (pmol/L) | 103 | 9.06 ± 1.1 | 13.4 ± 1.0b | 412 | 14.7 ± 2.8 | 13.5 ± 1.0b | <0.001 |
| Anti-TPO (kU/L) | 103 | 162.8 ± 120 | 43.4 ± 116b | 412 | 21.5 ± 54.8 | 18.8 ± 26.7 | <0.001 |
| Anti-TG (kU/L) | 103 | 51.8 ± 33.7 | 17.6 ± 27.2b | 412 | 32.0 ± 61.3 | 14.5 ± 30.7b | 0.05 |
| TSH (mlU/L) | 103 | 5.97 ± 4.2 | 2.50 ± 1.1b | 412 | 1.78 ± 0.7 | 1.98 ± 0.6b | <0.001 |
| TG (μg/L) | 31 | 43.1 ± 39.4 | 25.6 ± 4.0b | 244 | 28.2 ± 26.3 | 25.4 ± 5.9 | 0.003 |
| hs-CRP (mg/L) | 103 | 2.05 ± 2.2 | 2.52 ± 1.4 | 412 | 2.35 ± 3.1 | 2.41 ± 1.9 | 0.2 |
| 25(OH)D (nmol/L) | 103 | 68 ± 32 | 110 ± 14b | 412 | 82 ± 34 | 110 ± 27b | 0.001 |
| Vitamin D dose (IU/day) | 103 | 1243 ± 2606 | 3517 ± 2620b | 412 | 1824 ± 2770 | 4150 ± 3321b | 0.9 |
| Food Ingestion Rate (FIR) Limitation (g/day) | As | Cd | Cr | Cu | Pb | Zn | |
| Based on target hazard quotients (THQ) | |||||||
| Cultured fish | Muscle | / | / | 339,296 | 3027 | 1253 | 1018 |
| Mixed tissues | / | 5162 | 526,225 | 1057 | 2227 | 452 | |
| Wild fish | Muscle | / | 10,707 | 49,497 | 6168 | 4894 | 1183 |
| Mixed tissues | 1529 | 1352 | 135,527 | 1506 | 1420 | 396 | |
| Based on carcinogenic risk (CR) | |||||||
| Cultured fish | Muscle | / | / | / | / | 3684 | / |
| Mixed tissues | / | / | / | / | 6550 | / | |
| Wild fish | Muscle | / | / | / | / | 14,396 | / |
| Mixed tissues | 340 | / | / | / | 4178 | / | |
| Based on estimated weekly intake (EWI) | |||||||
| Cultured fish | Muscle | / | / | 465 | 36,284 | 1072 | 3253 |
| Mixed tissues | / | 4950 | 721 | 12,673 | 1907 | 1445 | |
| Wild fish | Muscle | / | 10,267 | 68 | 73,932 | 4190 | 3780 |
| Mixed tissues | 10,475 | 1297 | 186 | 18,052 | 1216 | 1265 |
| Strategy in small animal models | Advantages | Disadvantages |
| Knockout mice | Susceptible to a wide range of clinical isolates of viruses | Cannot study immune responses properly due to abnormal innate immunity |
| Can study pathogenesis of a new pathogen rapidly | Some viruses may not cause disease in knockout mice | |
| Cannot test drugs and vaccines effectively | ||
| Can be age-sensitive: older mice may lose their susceptibility to the pathogen | ||
| Virus adaptation to host via sequential passaging | Can cause uniform lethality | Not always successful in creating a lethal variant |
| Good for screening drugs and vaccines | Can be time consuming to create a lethal variant | |
| Wild-type mice are widely available | Not clinical isolate of virus and thus may harbour important differences in pathogenesis | |
| Transduction with adenoviral vectors encoding the entry receptor to confer sensitivity | Useful when no other known small animal models exist (i.e., MERS) | Need to know the identity of the receptor |
| Can test with clinical isolate of virus | Time consuming to create the recombinant adenovirus |
| Patient nr | Gender | Age of onset | PMD (hours) | Disease duration (years) | ALS type |
| 1 | F | 66 | 6 | 4.5 | Sporadic ALS |
| 2 | F | 61 | Unknown | 1 | Sporadic ALS |
| 3 | M | 56 | 10 | 3.5 | Sporadic ALS |
| 4 | F | 80 | Unknown | 2 | Sporadic ALS |
| 5 | M | 68 | Unknown | 3.5 | Familial ALSa |
| 6 | F | 57 | 9.5 | 3.5 | Sporadic ALS |
| 7 | M | 62 | Unknown | 4 | Sporadic ALS |
| 8 | M | 72 | Unknown | X | Sporadic ALS |
| 9 | M | 68 | Unknown | 3.5 | Sporadic ALS |
| 10 | M | 54 | Unknown | 1.5 | Familial ALSa |
| 11 | F | 58 | 10–11 | 2 | Sporadic ALS |
| Characteristic | LTFU | Viral rebounda | ||
| Univariate HR (95% CI) | aHR (95% CI) (n = 3106) | Univariate HR (95% CI) | aHR (95% CI) (n = 3106) | |
| Age at AC enrolment (years) | ||||
| 16-24 | 2.16 (1.06-4.40) | 2.41 (1.10-5.23) | 1.60 (0.68-3.76) | 1.52 (0.59-3.95) |
| 25-34 | 1.37 (0.93-2.00) | 1.55 (1.03-2.33) | 1.64 (1.11-2.41) | 1.74 (1.17-2.59) |
| 35-44 | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) |
| ≥ 45 | 0.99 (0.58-1.69) | 1.04 (0.60-1.82) | 0.70 (0.37-1.32) | 0.69 (0.36-1.31) |
| Sex | ||||
| Male | 0.99 (0.68-1.44) | 1.13 (0.77-1.68) | 0.77 (0.51-1.15) | 0.94 (0.62-1.43) |
| Duration on ART at AC | ||||
| enrolment (years) | 0.97 (0.88-1.07) | 0.98 (0.89-1.09) | 1.07 (0.98-1.17) | 1.12 (1.03-1.23) |
| Ever sent a buddy | ||||
| Yes | 0.75 (0.52-1.07) | 0.79 (0.55-1.14) | 0.63 (0.43-0.92) | 0.63 (0.43-0.93) |
| Number of clubs at facility/1000 patients | 1.01 (0.93-1.09) | 1.02 (0.93-1.11) | 0.96 (0.89-1.03) | 0.94 (0.87-1.02) |
| Number of patients on ART in facility/1000 | 1.34 (1.13-1.59) | 1.32 (1.11-1.58) | 0.99 (0.81-1.20) | 0.97 (0.79-1.18) |
| Protein | # Unique peptides | % Coverage |
| CUL4A | 6 | 10.2 |
| DDB1 | 4 | 7.9 |
| TOP2A | 14 | 10.1 |
| MCM6 | 1 | 1.8 |
| MCM7 | 1 | 1.2 |
| Type I error | Power | Coverage probability | ||||||||
| IF = 0 | IF = 0.3 | IF = 0.45 | IF = 0.6 | IF = 1 | IF = 0 | IF = 0.3 | IF = 0.45 | IF = 0.6 | IF = 1 | |
| All-cause mortality outcome (median (τ2) = 0.02) | ||||||||||
| IVDL | 0.05 | 0.14 | 0.23 | 0.38 | 0.75 | 0.95 | 0.97 | 0.99 | 0.98 | 0.95 |
| KHDL | 0.11 | 0.21 | 0.32 | 0.46 | 0.78 | 0.89 | 0.94 | 0.93 | 0.92 | 0.90 |
| Subjective outcome (median (τ2) = 0.11) | ||||||||||
| IVDL | 0.07 | 0.14 | 0.23 | 0.34 | 0.63 | 0.94 | 0.96 | 0.96 | 0.97 | 0.95 |
| KHDL | 0.12 | 0.20 | 0.29 | 0.41 | 0.65 | 0.88 | 0.93 | 0.93 | 0.92 | 0.91 |
| Pollutant | Lag | All months | Warm months | Cold months |
| CO | 0 | 0.99 (0.96–1.02) | 1.07 (0.97–1.17) | 0.98 (0.95–1.01) |
| 1 | 0.99 (0.96–1.01) | 1.13 (1.02–1.25)* | 0.97 (0.94–1.00) | |
| 2 | 1.02 (0.99–1.04) | 1.17 (1.06–1.29)* | 1.00 (0.97–1.03) | |
| 3 | 1.00 (0.97–1.03) | 1.08 (0.97–1.19) | 0.99 (0.96–1.02) | |
| 4 | 1.01 (0.98–1.04) | 1.11 (1.01–1.23)* | 1.00 (0.97–1.03) | |
| NO2 | 0 | 0.99 (0.94–1.03) | 0.97 (0.88–1.08) | 0.99 (0.94–1.04) |
| 1 | 0.97 (0.93–1.01) | 0.99 (0.89–1.10) | 0.96 (0.92–1.01) | |
| 2 | 1.03 (0.99–1.08) | 1.04 (0.94–1.15) | 1.03 (0.98–1.08) | |
| 3 | 1.00 (0.96–1.04) | 1.04 (0.94–1.16) | 0.99 (0.94–1.04) | |
| 4 | 1.00 (0.95–1.04) | 1.04 (0.94–1.16) | 0.99 (0.94–1.04) | |
| SO2 | 0 | 0.98 (0.95–1.02) | 0.97 (0.91–1.03) | 0.99 (0.94–1.03) |
| 1 | 0.98 (0.95–1.02) | 0.99 (0.93–1.05) | 0.98 (0.94–1.02) | |
| 2 | 0.98 (0.95–1.01) | 0.97 (0.91–1.03) | 0.98 (0.94–1.02) | |
| 3 | 0.98 (0.95–1.02) | 1.04 (0.98–1.11) | 0.95 (0.92–0.99)* | |
| 4 | 1.01 (0.97–1.04) | 1.04 (0.98–1.11) | 0.99 (0.95–1.03) | |
| O3 | 0 | 1.09 (1.03–1.16)* | 1.11 (1.00–1.24)* | 1.09 (1.01–1.18)* |
| 1 | 1.06 (0.99–1.12) | 0.97 (0.87–1.08) | 1.12 (1.03–1.21)* | |
| 2 | 0.99 (0.93–1.05) | 0.97 (0.87–1.08) | 1.02 (0.94–1.10) | |
| 3 | 1.05 (0.99–1.12) | 1.05 (0.94–1.17) | 1.07 (0.99–1.15) | |
| 4 | 1.02 (0.96–1.09) | 0.98 (0.88–1.09) | 1.06 (0.98–1.14) | |
| PM10 | 0 | 1.02 (0.97–1.06) | 1.04 (0.97–1.10) | 1.00 (0.95–1.06) |
| 1 | 0.98 (0.95–1.03) | 1.04 (0.97–1.11) | 0.95 (0.90–1.01) | |
| 2 | 1.01 (0.97–1.05) | 1.05 (0.98–1.12) | 1.00 (0.95–1.05) | |
| 3 | 0.98 (0.95–1.02) | 1.04 (0.97–1.11) | 0.97 (0.92–1.02) | |
| 4 | 1.00 (0.96–1.04) | 1.03 (0.97–1.10) | 1.00 (0.95–1.05) | |
| PM2.5 | 0 | 1.03 (0.98–1.08) | 1.04 (0.97–1.12) | 1.04 (0.97–1.11) |
| 1 | 1.00 (0.95–1.05) | 1.07 (0.99–1.15) | 0.98 (0.91–1.04) | |
| 2 | 0.97 (0.93–1.02) | 1.01 (0.93–1.10) | 0.97 (0.91–1.03) | |
| 3 | 0.95 (0.90–0.99)* | 0.96 (0.88–1.05) | 0.95 (0.89–1.01) | |
| 4 | 0.98 (0.93–1.02) | 1.00 (0.93–1.08) | 0.96 (0.90–1.03) |
| Parameters | 0 days (mean ± SD) | 30 days (mean ± SD) | 60 days (mean ± SD) | F value | P value |
| Malondialdehyde (MDA) (nmoL/mL) | 3.78 ± 0.24 | 3.11 ± 0.25 | 2.43 ± 0.28 | 216.404 | 0.000* |
| Lipid hydroperoxide (nmoL/mL) | 3.63 ± 0.19 | 3.10 ± 0.23 | 2.44 ± .21 | 240.034 | 0.000* |
| Catalase (kU/L) | 31.53 ± 8.41 | 36.12 ± 8.21 | 42.25 ± 7.59 | 13.314 | 0.000* |
| Superoxide dismutase (SOD) (U/mL) | 67.25 ± 6.43 | 74.76 ± 5.64 | 80.83 ± 4.89 | 42.864 | 0.000* |
| Glutathione-S-transferase (GST) (U/mL) | 28.41 ± 4.02 | 31.61 ± 3.75 | 32.88 ± 3.42 | 11.350 | 0.000* |
| Glutathione (GSH) (nmoL/mL) | 279.3 ± 23.26 | 316.76 ± 16.68 | 356.57 ± 11.71 | 140.565 | 0.000* |
| Vitamin C (mg/dL) | 0.76 ± 0.07 | 0.85 ± .06 | 0.98 ± .05 | 114.403 | 0.000* |
| Cholesterol (mg/dL) | 167.22 ± 10.33 | 155.28 ± 7.45 | 140.72 ± 14.90 | 41.244 | 0.000* |
| Triglyceride (TG) (mg/dL) | 172.10 ± 14.44 | 166.50 ± 13.25 | 161.34 ± 11.68 | 5.011 | 0.000* |
| High density lipoprotein (HDL) (mg/dL) | 42.21 ± 5.17 | 43.16 ± 5.15 | 44.69 ± 4.79 | 1.853 | 0.163 |
| Weight management services and products | Perceived availability of services and products (‘Are the following services or products available at the community pharmacy that you go to?’) | Utilization of services and products obtained (‘Have you ever used the following services or bought the following products at the community pharmacy that you go to?’) | ||||
| Yes n (%) | No n (%) | Not sure n (%) | Yes n (%) | No n (%) | Not sure n (%) | |
| Pharmacy services | ||||||
| Measurement of weight | 409 (56.0) | 276 (37.8) | 45 (6.2) | 234 (32.1) | 396 (54.2) | 100 (13.7) |
| Measurement of height | 367 (50.3) | 313 (42.9) | 50 (6.8) | 194 (26.6) | 453 (62.1) | 81 (11.1) |
| Calculation of body mass index | 337 (46.2) | 337 (46.2) | 56 (7.7) | 157 (21.5) | 494 (67.7) | 79 (10.8) |
| Measurement of waist/hip circumference | 261 (35.8) | 401 (54.9) | 68 (9.3) | 118 (16.2) | 560 (76.7) | 52 (7.1) |
| Measurement of body fat percentage | 250 (34.2) | 395 (54.1) | 83 (11.4) | 89 (12.2) | 586 (80.3) | 55 (7.5) |
| Measurement of blood pressure | 591 (81.0) | 127 (17.4) | 12 (1.6) | 260 (35.6) | 306 (41.9) | 164 (22.5) |
| Measurement of blood glucose | 581 (79.6) | 133 (18.2) | 16 (2.2) | 234 (32.1) | 338 (46.3) | 158 (21.6) |
| Measurement of blood cholesterol | 532 (72.9) | 166 (22.7) | 32 (4.4) | 194 (26.6) | 394 (54.0) | 141 (19.3) |
| Advice on physical activity to achieve weight loss | 353 (48.4) | 312 (42.7) | 64 (8.8) | 211 (28.9) | 402 (55.1) | 117 (16.0) |
| Advice on healthy eating to achieve weight loss | 337 (46.2) | 324 (44.4) | 68 (9.3) | 206 (28.2) | 429 (58.8) | 95 (13.0) |
| Referral to doctors and/or dieticians for weight loss | 189 (25.9) | 439 (60.1) | 102 (14.0) | 43 (5.9) | 645 (88.4) | 42 (5.8) |
| Referral to slimming centers for weight loss | 141 (19.3) | 477 (65.3) | 109 (14.9) | 35 (4.8) | 653 (89.5) | 41 (5.6) |
| Referral to other programs | 25 (3.4) | 479 (65.6) | 85 (11.6) | 9 (1.2) | 505 (69.2) | 99 (13.6) |
| Weight management products and resources | ||||||
| Supplements (e.g. powdered drinks, herbal products and other non-drug products) | 553 (75.8) | 151 (20.7) | 26 (3.6) | 181 (24.8) | 385 (52.7) | 164 (22.5) |
| Creams | 323 (44.2) | 270 (37.0) | 137 (18.8) | 55 (7.5) | 648 (88.8) | 27 (3.7) |
| Oral medications | 388 (53.2) | 238 (32.6) | 104 (14.2) | 76 (10.4) | 553 (75.8) | 100 (13.7) |
| Information materials (e.g. brochures, leaflets, popular diet books and video CDs) | 283 (38.8) | 308 (42.2) | 139 (19.0) | 80 (11.0) | 589 (80.7) | 61 (8.4) |
| Therapeutictarget | Treatment | Route ofadministration | Result |
| Indeterminate | Hypothermia | IV | − |
| Hypothermia | Peritoneal | − | |
| MMTP | Delcasetrib | IV before reperfusion | − |
| TR040303 | IV before reperfusion | − | |
| Bendavia | IV before reperfusion | − | |
| Ciclosporin A | IV before reperfusion | + − | |
| Nitric oxidesignaling | Nitrite sodium | IV | − |
| Nitrite sodium | Intracoronary | − | |
| Nitric oxide | Inhaled | − | |
| Pro-survivalkinase | Copertide | IV | + |
| Exenatide | IV | + | |
| Indeterminate | Metoprolol | IV | + |
| Indeterminate | Post-conditioning | IC balloon inflations | + + − − |
| Indeterminate | RIC | Limb ischemia | + + + ++ + + − |
| 95% CI | ||||
| Variable | Coefficient (SE) | Wald | Lower | Upper |
| Low and medium treatments | ||||
| Castle | 4.536 (1.844) | 6.11* | 1.39 | 15.03 |
| Nine Mile | 12.936 (1.694) | 18.27*** | 4.06 | 16.50 |
| Length (spline 1.9 df) | 1.57a | |||
| High treatment | ||||
| Castle | 3.525 (1.618) | 6.83** | 1.38 | 9.03 |
| Nine Mile | 9.679 (1.655) | 20.36*** | 3.60 | 26.05 |
| Length (spline 2.24 df) | 19.38*** |
| DFTD | CTVT |
| ∼ 16 years old | ∼ 10 000 years old |
| Passed by biting | Passed during coitus |
| Close to 100% mortality | Not fatal (Progression, Stationary and Regression phases) |
| No significant infiltration of lymphocytes | Significant infiltration of lymphocytes during regression |
| Schwann cell origin | Haematopoietic origin (perhaps a macrophage cell) |
| MHC class I and class II negative | MHC class I and class II negative during progression |
| Epigenetic regulation of MHC genes | Epigenetic regulation of MHC genes |
| Sensitive to interferon-γ | Sensitive to interferon-γ |
| Unknown role of immunosuppressive cytokines | Cytokine regulation of immune response by transforming growth factor-β and interleukin-6 |
| Low genetic diversity of host | Host is outbred |
| Cytokine | Luminex | Affymetrix |
| IL-1α | 2.1 | 5.4 |
| IL-1β | 5.4 | 2.6 |
| IL-2 | Spore only, low expressed | Spore only, low expressed |
| IL-3 | Spore only, low expressed | Not expressed |
| IL-4 | Spore only, low expressed | Not expressed |
| IL-5 | Not expressed | Mock only, low expressed |
| IL-6 | 23.7 | 27.2 |
| IL-7 | 1.4 | 0.7 |
| IL-8 | 0.9 | 1.5 |
| IL-10 | 4.6 | 2.5 |
| IL-12p40 | 1.4 | 3.1 |
| IL-12p70 | 2.0 | Not available |
| IL-13 | Spore only, low expressed | 1.4 |
| IL-15 | Not expressed | 1.5 |
| GM-CSF | 3.6 | 1.6 |
| IFN-γ | 5.8 | 3.8 |
| TNF-α | 51.6 | 10.6 |
| Eotaxin | Spore only, low expressed | 1.1 |
| MCP-1 | 2.0 | 1.7 |
| RANTES | 4.7 | 3.3 |
| MIP-1α | 1.7 | 3.0 |
| IP-10 | 1.7 | Not available |
| IFN-α | 0.8 | 2.0 |
| Interventions | Mean difference | Standard error | p-value | 95% confidence interval | |
| FISA&DM | FIS | −6.80 | 3.60 | 0.59 | −16.93 to 3.34 |
| Promotion of the survey | −11.11* | 3.57 | 0.02 | −21.21 to −1.01 | |
| Multiple letters | −16.65* | 3.63 | <0.001 | −26.89 to −6.40 | |
| Control | −10.02 | 3.60 | 0.06 | −20.19 to 0.15 | |
| FIS | Promotion of the survey | −4.32 | 3.47 | 1.00 | −14.13 to 5.50 |
| Multiple letters | −9.65 | 3.53 | 0.06 | −19.82 to 0.12 | |
| Control | −3.22 | 3.50 | 1.00 | −13.11 to 6.67 | |
| Promotion of the survey | Multiple letters | −5.53 | 3.51 | 1.00 | −15.46 to 4.40 |
| Control | 1.10 | 3.50 | 1.00 | −8.76 to 10.95 | |
| Multiple letters | Control | 6.63 | 3.54 | 0.62 | −3.38 to 16.63 |
| BaselineUsual Activities | Specific \"usually enjoyed activity\" identified | |||
| No | Yes | |||
| n (%) | n (%) | Importance(IQR) | Total | |
| No problems | 46 (48.9) | 142 (45.7) | 76 (30) | 188 |
| Some problems | 45 (47.9) | 142 (45.7) | 88 (30) | 187 |
| Unable | 3 (3.2) | 27 (8.7) | 93 (21) | 30 |
| Total | 94 | 311 | 405 | |
| 12 monthsUsual Activities | 12 months \"able to take part in usually enjoyed activity\" | |||
| no | yes | Total | ||
| No problems | 21 (42.0) | 120 (63.5) | 141 | |
| Some problems | 24 (48.0) | 66 (34.9) | 90 | |
| Unable | 5 (10.0) | 3 (1.6) | 8 | |
| Total | 50 | 189 | 239 |
| Cohort N = 151 | |
| Age (mean years ± SD) | 30 ± 11 |
| <18 years of age | 43 (28) |
| Range (years) | 13–61 |
| Race | |
| African-American | 57 (38) |
| Caucasian | 57 (38) |
| Hispanic | 37 (24) |
| County of residence | |
| Dallas | 130 (86) |
| Out of county (TX) | 18 (12) |
| Out of state | 3 (2) |
| Mode of transport to the hospital | |
| Emergency medical services | 16 (11) |
| Police | 69 (46) |
| Self | 64 (42) |
| Unknown | 2 (1) |
| Trauma service evaluation | 15 (10) |
| Estimate | Standard Error | Z Value | P(>|Z|) | |
| Clean and Income | −0.00 | 0.00 | − 0.75 | 0.45 |
| Clean and White | −0.95 | 1.52 | −0.63 | 0.53 |
| Clogged and Income | 0.00 | 0.00 | 0.85 | 0.40 |
| Clogged and White | 0.64 | 1.70 | 0.38 | 0.70 |
| Bottle and Income | −0.00 | 0.00 | −0.89 | 0.37 |
| Bottle and White | −0.31 | 1.47 | −0.21 | 0.83 |
| Handicap and Income | −0.00 | 0.00 | −2.09 | 0.04 |
| Handicap and White | 1.42 | 1.65 | 0.86 | 0.39 |
| Factors | ReactivationN = 97 | No ReactivationN = 189 | UnivariateP value | MultivariateP Value | Odds ratio(95% CI) |
| Hematological malignancy | 0.332 | NA | |||
| AML | 29 | 46 | |||
| ALL | 3 | 10 | |||
| Lymphoma | 46 | 96 | |||
| CML/MPN | 1 | 5 | |||
| CLL | 2 | 3 | |||
| Myeloma | 10 | 21 | |||
| MDS/AA | 6 | 8 | |||
| Age > 65 year | 0.052 | 0.198 | |||
| Yes | 11 | 57 | |||
| No | 86 | 132 | |||
| Gender | 0.781 | NA | |||
| Man | 55 | 106 | |||
| Woman | 42 | 83 | |||
| Hepatitis C | 0.180 | 0.453 | |||
| Yes | 4 | 4 | |||
| No | 93 | 185 | |||
| Liver cirrhosis | 0.906 | NA | |||
| Yes | 4 | 7 | |||
| No | 93 | 182 | |||
| Hepatocellular carcinoma | 0.032 | <0.001 | 0.101(0.029–0.355) | ||
| Yes | 3 | 1 | |||
| No | 94 | 188 | |||
| Diabetes mellitus | 0.388 | NA | |||
| Yes | 10 | 20 | |||
| No | 87 | 169 | |||
| Allogeneic transplantation | 0.113 | 0.269 | |||
| Yes | 28 | 31 | |||
| No | 69 | 158 | |||
| Antiviral prophylaxis | <0.001 | <0.001 | 4.631(2.902–7.390) | ||
| Yes | 26 | 145 | |||
| No | 71 | 44 |
| D-dimer | Plasminogen | PAI-1 | |
| (ng/mL) | (%) | (ng/mL) | |
| Idiopathic ON | |||
| mean (SD) | 241 (132) | 115 (18) b | 4.6 (2.6) |
| median | 173 | 118 | 4.7 |
| range | 86–553 | 72–149 | 1.2–10.5 |
| Corticosteroid-associated ON | |||
| mean (SD) | 384 (274) a | 104 (15) | 3.6 (1.9) |
| median | 333 | 101 | 2.9 |
| range | 85–1000 | 84–129 | 1.5–7.1 |
| Healthy controls | |||
| mean (SD) | 173 (72) | 104 (16) | 3.4 (1.8) |
| median | 164 | 101 | 3.2 |
| range | 65–338 | 65–129 | 0.6–8 |
| Pooled raw data | Means per dog (n > 5) | |||||
| Declination rate | 0% | 0.1-2% | >2% | 0% | 0.1-2% | >2% |
| Number of observations | 607 | 542 | 744 | 43 | 36 | 39 |
| Mean vector (μ) | 176°/356° | 111°/291° | 109°/289° | 173°/353° | 104°/184° | 96°/276° |
| Length of mean vector (r) | 0.216 | 0.106 | 0.03 | 0.598 | 0.283 | 0.194 |
| Circular standard deviation | 50° | 61° | 76° | 29° | 45° | 52° |
| 95% Confidence interval (-/+) for μ | 168°-183° | - | - | 164°-182° | 81°-127° | - |
| 99% Confidence interval (-/+) for μ | 166°-185° | - | - | 161°-185° | 74°-134° | - |
| Rayleigh test (Z) | 28.248 | 6.133 | 0.672 | 15.353 | 2.891 | 1.464 |
| Rayleigh test (p) | <10-12 | 0.002 | 0.511 | 6.20⋅10-8 | 0.055 | 0.233 |
| Author | Design | Subjects | Most common sport | Cardiovascular disease found |
| Corrado et al. [1] | Prospective | 23/300 athletes, ages 12–35 | (1) Soccer(2) Swimming | (1) CADa(2) ARVC |
| de Noronha et al. [6] | Prospective | 118 cases, mean age 28 | (1) Soccer(2) Running | (1) Isolated LVHb(2) Normal heart(3) ARVC |
| Maron et al. [3] | Retrospective | 60 international athletes (ages 19 ± 3) and 213 US Athletes (ages 14 ± 9 years) | Soccer | Commotio Cordis |
| Maron et al. [2] | Retrospective | 1866 athletes (ages 16 ± 4) | (1) Basketball(2) Football(3) Soccer | (1) HCMb (2) CCA |
| Bille et al. [4] | Retrospective | 388 athletes | (1) Soccer(2) Running(3) Basketball | (1) HCMb (2) CCA |
| Allouche et al. [7] | Retrospective | 32 athletes | (1) Running(2) Soccer | (1) HCMb (2) ARVC |
| Suárez-Mier and Aguilera [8] | Retrospective | 61 athletes, mean ages 31.9 ± 14 | (1) Cycling(2) Soccer | (1) ARVCc (2) Isolated LVH |
| McConnell and Collins [9] | Case study | 24 y.o. female | Soccer | Hypoplastic left coronary artery |
| Chen and Sheppard [10] | Case study | 22 y.o. male | Soccer | Ebstein anomaly due to hemangioma |
| Zeller et al. [11] | Case study | 26 y.o. male | Soccer | Marked early repolarization on ECG two weeks prior to SCD; autopsy was normal |
| Pellissier et al. [12] | Case study | 15 y.o. male | Soccer | Left coronary artery arising from the right anterior sinus with an oblique course between the aorta and the pulmonary artery trunk |
| Pacchioni et al. [13] | Case study | 18 y.o. male | Soccer | ARVC |
| Ronneberger et al. [14] | Case study | 8 y.o. male | Soccer | Myxomatous mitral valve with lacerations of the posterior cusp and the left vestibular endocardium and left ventricular hypertrophy |
| Ottaviani et al. [15] | Case study | 13 y.o. male | Soccer | Abnormal origin of left coronary artery from the right aortic sinus of Valsalva |
| Iskandar and Thompson [16] | Case study | 14 y.o male | Soccer | Acute angle takeoff of the left main coronary artery and a transverse slit-like opening with a fibrous cushion, which created a kink near its origin |
| Meel [17] | Case study | 22 y.o. male | Soccer | Abnormal origin of the left coronary artery from the right sinus of Valsalva |
| Participanta | Classifications for sensory profile quadrantsb | Number of quadrants affected | |||
| Low registration | Sensation seeking | Sensory sensitivity | Sensation avoiding | ||
| 1 | More than most | Less than most | More than most | More than most | 4 |
| 2 | More than most | Similar to most | More than most | More than most | 3 |
| 3 | More than most | Less than most | Much more than most | More than most | 4 |
| 4 | More than most | Similar to most | More than most | More than most | 3 |
| 5 | More than most | Similar to most | More than most | More than most | 3 |
| 6 | More than most | Similar to most | More than most | Similar to most | 2 |
| 7 | Similar to most | Similar to most | Less than most | Similar to most | 1 |
| 8 | More than most | Less than most | Similar to most | Similar to most | 2 |
| 9 | Similar to most | Less than most | Similar to most | Similar to most | 1 |
| 10 | Similar to most | Less than most | Much more than most | Similar to most | 2 |
| 11 | More than most | Less than most | More than most | Similar to most | 3 |
| 12 | More than most | Similar to most | More than most | More than most | 3 |
| 13 | Much more most | Similar to most | Much more than most | More than most | 3 |
| 14 | Much more most | Similar to most | More than most | Similar to most | 2 |
| Percentage of participants scoring outside the normal range | 79 | 43 | 93 | 50 | |
| Average quadrant scores, ranges and standard deviations | M = 43 (26–57) | M = 44 (35–54) | M = 42 (22–55) | M = 43 (28–55) | |
| SD = 7.48 | SD = 6.22 | SD = 8.84 | SD = 8.57 |
| Fixed effects | Liking | Representational | Evoked | ||||||
| Estimate | SE | t | Estimate | SE | t | Estimate | SE | t | |
| Condition 1 (neutral) | 1.985 | 0.108 | 18.389∗∗ | 134.830 | 6.712 | 20.088∗∗ | 194.665 | 10.789 | 18.042∗∗ |
| Condition 2 (crying) | -1.261 | 0.089 | -14.093∗∗ | -83.055 | 6.004 | -13.834∗∗ | -133.280 | 10.002 | -13.325∗∗ |
| Condition 3 (laughing) | -0.433 | 0.084 | -5.163∗∗ | -27.716 | 6.799 | -4.076∗∗ | 6.908 | 11.505 | 0.600 |
| SAS | 0.042 | 0.015 | 2.838∗∗ | 3.017 | 0.810 | 3.723∗∗ | 3.538 | 1.357 | 2.607∗∗ |
| Condition 2 × SAS | -0.010 | 0.013 | -0.796 | -0.735 | 0.749 | -0.982 | -0.956 | 1.251 | -0.764 |
| Condition 3 × SAS | -0.028 | 0.010 | -2.761∗∗ | -2.635 | 0.839 | -3.141∗∗ | 0.212 | 1.491 | 0.142 |
| Fieldl | Field3 | Field4 | Field6 | Field7 | |
| Dose 1a | 35.4 | 35.5 | 34.3 | 39.5 | 36.3 |
| Dose 2b | 30.6 | 34.1 | 35.3 | 30.8 | 34.3 |
| Dose 3c | 30.6 | 33.8 | 34.3 | 30.8 | 34.8 |
| Arthrosis grade on MRI | Preoperatively | Postoperatively |
| 0 | 8 | 7 |
| 1 | 17 | 13 |
| 2 | 23 | 25 |
| 3 | 7 | 8 |
| 4 | 6 | 8 |
| P Value | Z = − 0.911 | P = 0.36 |
| Illumina | qPCR | |||||
| Name | Component, accession | Log FC | Log CPM | FDR | Log FC | Range FC |
| FABP | comp254629_c0 ES387222 | −2.24 | 8.57 | 4.55E-09 | −3.45 | 15.6 |
| ELOV | comp267151_c1 ES387246 | −4.72 | 9.31 | 4.36E-16 | −4.74 | 30.0 |
| HR78 | comp265637_c0 KJ026941 | −2.06 | 0.79 | 1.02E-04 | −1.26 | 12.8 |
| ERR | comp273411_c0 KJ026943 | −2.17 | 4.89 | 1.14E-08 | −1.84 | 5.3 |
| HR3 | comp264460_c0 KJ026938 | 3.21 | 4.48 | 2.59E-14 | 3.84 | 64.2 |
| HR38a | comp270260_c0 KJ026939 | 2.65 | 3.63 | 8.58E-12 | 2.25 | 5.9 |
| Vtg | comp274635_c1 KJ026944 | 3.20 | 8.14 | 3.45E-10 | 1.15 | 597.9 |
| Torso-like | comp266966_c0 KJ026945 | 9.26 | 7.40 | 1.19e-84 | 8.24 | 1024.2 |
| FTZ-F1 | comp268775_c0 KJ026942 | 3.25 | 5.97 | 3.05E-16 | 4.25 | 32.0 |
| HR38b | comp267178_c0 KJ026940 | 2.26 | 4.27 | 6.58E-10 | 1.07 | 7.8 |
| EcR | comp263662_c0 EF583877 | 1.10 | 3.13 | 0.39 | 1.06 | 3.4 |
| Fem1 | comp269877_c0 KJ026947 | 4.43 | 7.08 | 1.67E-17 | 1.33 | 7.6 |
| True | Healthy Control | sALS Patient | ALS Mutation Carrier | fALS Patient | |
| Prediction | |||||
| healthy Control | 14(16) | 6(-) | 0(1) | 0(0) | |
| sALS Patient | 3(-) | 8(-) | 2(-) | 0(-) | |
| ALS Mutation Carrier | 0(1) | 2(-) | 8(7) | 1(2) | |
| fALS Patient | 0(0) | 2(-) | 2(4) | 5(4) |
| Nr. | Effect | Effect type | Estimate | Std-Error | P-value | N |
| a | Age class (mother = 0) | Fixed | −0.1 | 0.25 | 0.672 | 2 |
| Site (Tuanan = 0) | Fixed | −0.52 | 0.25 | 0.035 | 2 | |
| Individual | Random | - | - | - | 15 (32) | |
| b | Age | Fixed | 0.02 | 0.1 | 0.863 | cont. |
| Site (Tuanan = 0) | Fixed | −0.69 | 0.3 | 0.021 | 2 | |
| Individual | Random | - | - | - | 8 (17) |
| Total number of participating residents (% of total) | Number of residents with burnout (% of total) | p-value of difference in burnout rate per characteristic | |
| Gender | |||
| Male | 96 (40.7) | 45 (46.9) | |
| Female | 140 (59,3) | 53 (37.9) | |
| 0.17 | |||
| Years in training | |||
| 1 | 52 (22.2) | 22 (42.3) | |
| 2 | 23 (9.7) | 11 (47.8) | |
| 3 | 31 (13.1) | 8 (25.8) | |
| 4 | 50 (21.2) | 24 (48.0) | |
| 5 | 45 (19.1) | 18 (40.0) | |
| 6 | 25 (10.6) | 11 (44.0) | |
| 7 | 8 (3.4) | 2 (25.0) | |
| 0.49 | |||
| Type of specialty | |||
| Surgical | 57 (24.2) | 26 (45.6) | |
| Medical | 144 (61.0) | 59 (41.0) | |
| Supportive | 34 (14.4) | 12 (35.3) | |
| missing | 1 (0.4) | ||
| 0.62 | |||
| Satisfaction with work/life balance | |||
| Very dissatisfied | 31 (13.1) | 21 (67.7) | |
| Dissatisfied | 4 (1.7) | 2 (50.0) | |
| Neutral | 69 (29.2) | 14 (20.3) | |
| Satisfied | 130 (55.1) | 61 (46.9) | |
| Very satisfied | 2 (0.8) | 0 (0.0) | |
| < 0.001 | |||
| Quality of life | |||
| As bad as it can be | 12 (5.1) | 10 (83.3) | |
| Bad | 59 (25.0) | 37 (62.7) | |
| Neutral | 79 (33.5) | 37 (46.8) | |
| Good | 77 (32.6) | 14 (18.2) | |
| As good as it can be | 9 (3.8) | 0 (0.0) | |
| < 0.001 | |||
| Burned outa | 98 (41.5) | ||
| Emotionally exhaustedb | 125 (53.0) | ||
| Depersonalizedb | 125 (53.0) | ||
| Reduced personal accomplishmentb | 60 (23.4) |
| Prevention level | Goal | Child-protective examples |
| Zero-order | Prevent the development of a hazard | Urban planning to reduce GHGs from vehicular traffic and increase pedestrian access, resulting in improved air quality and increased physical activity (Sheffield and Galvez 2009) |
| Primary | Block interaction between hazard and human | Relocation of low-lying island populations facing increased risk of flooding, or distribution of mosquito nets |
| Secondary | Prevent effects after exposure to the hazard | Activation of early warning systems before heat waves |
| Tertiary | Reduce morbidity and mortality, avoid complications, and restore function | Postdisaster restoration of chronic care services |
| Mode | Controlled/Known Parameters | Parameters to Estimate |
| Calibration | Main measurement parameters | System calibration parameters |
| Normal estimation | System calibration parameters | Main measurement parameters |
| Mean (SD) | 95%-CI | Minimum | Maximum | |
| Etanercept (n = 233) | ||||
| Outpatient care | 1,113 (998) | 984-1,241 | 0 | 5,775 |
| Medications | 17,751 (10,024) | 16,457-19,045 | 1,058 | 102,156 |
| Laboratory tests | 585 (531) | 517-654 | 0 | 4,114 |
| Outpatient care in hospitals | 453 (1,206) | 297-609 | 0 | 12,382 |
| Devices and aids | 60 (220) | 32-89 | 0 | 1,827 |
| Other claims | 593 (1,801) | 360-825 | 0 | 19,749 |
| Total direct cost (etanercept) | 20,555 (10,740) | 19,169-21,942 | 1,589 | 111,994 |
| Adalimumab (n = 201) | ||||
| Outpatient care | 1,276 (965) | 1,142-1,410 | 0 | 5,798 |
| Medications | 21,315 (9,008) | 20,062-22,568 | 1,169 | 58,129 |
| Laboratory tests | 634 (521) | 561-706 | 0 | 4,840 |
| Outpatient care in hospitals | 418 (891) | 294-542 | 0 | 5,913 |
| Devices and aids | 90 (358) | 40-140 | 0 | 4,004 |
| Other claims | 419 (810) | 306-531 | 0 | 7,241 |
| Total direct cost (adalimumab) | 24,152 (9,403) | 22,844-25,460 | 1,994 | 61,613 |
| Infliximab (n = 121) | ||||
| Outpatient care | 1,087 (1,243) | 863-1,310 | 0 | 6,358 |
| Medications | 22,666 (10,625) | 20,754-24,579 | 4,247 | 68,590 |
| Laboratory tests | 1,024 (751) | 889-1,159 | 0 | 4,176 |
| Outpatient care in hospitals | 2,363 (2,817) | 1,856-2,871 | 0 | 23,271 |
| Devices and aids | 151 (258) | 104-197 | 0 | 1,722 |
| Other claims | 323 (703) | 196-449 | 0 | 4,304 |
| Total direct cost (infliximab) | 27,614 (11,860) | 25,479-29,748 | 5,733 | 72,233 |
| Abbreviation | Description, Definition |
| Tissue mapping in specific compartments | |
| ABM | Adipose bone marrow |
| TV | Total volume of the body (from ankle to wrist), without INF |
| TVV | Total visceral volume: includes intrathoracic and intraabdominal volume. |
| TSV | Total somatic volume (TV without TVV). |
| TLT | Total lean tissue |
| VLT | Visceral lean tissue: includes lean tissue of intrathoracic and intraabdominal organs. |
| SLT | Somatic lean tissue: mostly muscles |
| TAT | Total adipose tissue (without INF) |
| SAT | Somatic adipose tissue (TAT without VAT) |
| TAST | Total adipose soft tissue (TAT without ABM) |
| SAST | Somatic adipose soft tissue (TAT without ABM and VAT) |
| SCAT | Subcutaneous adipose tissue (SAST without IMAT) |
| IMAT | Intermuscular adipose tissue (SAST without SCAT) |
| VAT | Visceral adipose tissue (IAAT + MAT without INF) |
| IAAT | Intraabdominal adipose tissue: retroperitoneal and intraperitoneal (mesenteric, omental) fat depots (without INF) |
| MAT | Intrathoracic, mainly mediastinal adipose tissue |
| INF | (Undigested) intraluminal nutrition fat in the gastrointestinal tract |
| Tissue mapping of body segments | |
| TV-LE | Total volume of lower extremities (apex trochanter major to ankle joint) |
| TV-TR | Total volume of trunk (acromion to apex of trochanter major) |
| TV-UE | Total volume of upper extremities (wrist to acromion level) |
| LT-LE | Lean tissue volume of lower extremities (apex trochanter major to ankle joint) |
| LT-TR | Lean soft tissue volume of trunk (acromion to apex of trochanter major) |
| LT-UE | Lean soft tissue volume of upper extremities (wrist to acromion level) |
| SAST-LE | Adipose soft tissue volume of lower extremities (apex trochanter major to ankle joint) |
| SAST-TR | Adipose soft tissue volume of trunk (acromion to apex of trochanter major) |
| SAST-UE | Adipose soft tissue volume of upper extremities (wrist to acromion level) |
| PSQI components score | Casesn = 314 | Controlsn = 102 | P value |
| Subjective sleep quality | 1.01 ± 0.77 | 0.89 ± 0.79 | 0.127 |
| Sleep latency | 0.98 ± 0.89 | 0.69 ± 0.88 | 0.001 |
| Sleep duration | 0.68 ± 0.79 | 1.29 ± 0.86 | 0.000 |
| Habitual sleep efficiency | 0.95 ± 1.03 | 0.25 ± 0.64 | 0.000 |
| Sleep disorders | 1.21 ± 0.69 | 0.74 ± 0.63 | 0.000 |
| Use of sleep medications | 0.10 ± 0.46 | 0.01 ± 0.09 | 0.055 |
| Daytime dysfunction | 1.69 ± 0.95 | 1.63 ± 1.00 | 0.635 |
| Total | 6.62 ± 3.62 | 5.50 ± 2.51 | 0.020 |
| Cd | As | Sb | Pb | Mn | ||
| LY(n = 6) | Mean ± SD | 0.050 ± 0.001 | 26.495 ± 3 .2326 | 16.362 ± 1.458 | 30.337 ± 0.845 | 332.604 ± 3.662 |
| Range | 0.006–0.107 | 17.690–34.102 | 10.110–22.300 | 17.345–41.450 | 241.030–401.260 | |
| HY(n = 28) | Mean ± SD | 0.865 ± 0.052 | 142.714 ± 2.210 | 20.393 ± 1.577 | 356.161 ± 1.905 | 420.316 ± 8.631 |
| Range | 0.345–1.451 | 26.870–562.340 | 9.620–36.400 | 124.360–756.200 | 215.630–666.310 | |
| LSJ(n = 20) | Mean ± SD | 0.049 ± 0.001 | 32.628 ± 1.242 | 65.737 ± 5.340 | 13.732 ± 1.616 | 229.395 ± 7.921 |
| Range | 0.010–0.130 | 12.540–70.230 | 37.100–111.240 | 0.555–33.405 | 102.650–412.860 | |
| Total | Mean ± SD | 0.472 ± 0.194 | 89.029 ± 1.461 | 36.739 ± 7.223 | 193.133 ± 3.855 | 339.996 ± 15.924 |
| Range | 0.006–1.451 | 12.540–562.340 | 9.620–111.240 | 0.555–756.200 | 102.650–666.310 | |
| Background valuea | 0.098 | 14 | 27 | 459 | ||
| MACb | 0.3 | 25 | 36d | 300 | NVc |
| Dataset | SparseAssembler | Gossamer | Minia | SGA | Diginorm-Velvet | DiMA | ZeMA | |
| S. aureus | Amazon Instance/Cost ($) | M1/0 | M2/0.015 | M1/0 | M2/0.17 | M2/0.008 | M2/0.006 | M1/0 |
| Amazon Time(min:sec) | 24:20 | 7:45 | 5:46 | 82:23 | 3:50 | 3:8 | 20:30 | |
| Local Time (min:sec) | 2:32 | 4:52 | 0:52 | 33:29 | 3:14 | 3:10 | 3:20 | |
| R. sphaeroides | Amazon Instance / Cost ($) | M1/0 | M2/0.027 | M1/0 | M2/0.22 | M2/0.011 | M2/0.011 | M1/0 |
| Amazon Time (min:sec) | 29:29 | 13:41 | 10:23 | 109:16 | 5:28 | 5:33 | 28:27 | |
| Local Time (min:sec) | 3:15 | 7:37 | 1:24 | 55:37 | 5:12 | 5:15 | 6:4 | |
| Human chr 14 | Amazon Instance/Cost ($) | M2/0.21 | M2/0.59 | M2/0.41 | M2/0.16 | M3/1.1 | M2/0.17 | |
| Amazon Time (h:m:s) | 1:45:32 | 4:57:12 | 3:22:27 | Failed | 1:18:21 | 1:23:23 | 1:23:22 | |
| Local Time (h:m:s) | 1:1:37 | 3:6:50 | 1:33:13 | 1:18:16 | 1:21:8 | 1:15:09 | ||
| B. impatiens | Amazon Instance / Cost ($) | M3/10.9 | M2/7.24 | M3/6.14 | M3/6.04 | M2/0.93 | ||
| Amazon Time (h:m:s) | 13:38:23 | Failed | 60:20:16 | Failed | 7:40:16 | 7:33:15 | 7:47:42 | |
| Local Time (h:m:s) | 13:30:22 | 48:42:50 | 7:40:31 | 7:32:41 | 7:13:36 |
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | ||
| 1 | PCS | |||||||
| 2 | MCS | -.051 | ||||||
| 3 | Gender | -.147 | -.075 | |||||
| 4 | Relationship with advisor | .135 | .390** | -.084 | ||||
| 5 | Marital Status | .149 | -.17 | -.070 | -.005 | |||
| 6 | Perceived Stress | -.189* | -.642** | .169 | -.315** | .073 | ||
| 7 | Acculturative Stress | -.362** | -.442** | .054 | -.333** | -.109 | .463** |
| Item | Case group (n = 30) | Control group (n = 90) | Iranian general population (n = 1997) | ||
| Mean ± SD | Mean ± SD | P value* | Mean ± SD | P value* | |
| Physical functioning (PF) | 42.20 ± 23.11 | 42.83 ± 22.31 | 0.949 | 85.3 ± 20.8 | < 0.001 |
| Role physical (RP) | 15.83 ± 23.20 | 25.00 ± 33.10 | 0.292 | 70.0 ± 38.0 | < 0.001 |
| Bodily pain (BP) | 24.42 ± 23.83 | 24.08 ± 18.80 | 0.874 | 79.4 ± 25.1 | < 0.001 |
| General health (GH) | 34.00 ± 20.53 | 33.50 ± 19.24 | 0.362 | 67.5 ± 20.4 | < 0.001 |
| Vitality (VT) | 44.67 ± 21.99 | 49.83 ± 20.21 | 0.261 | 65.8 ± 17.3 | < 0.001 |
| Social functioning (SF) | 41.25 ± 27.49 | 47.36 ± 26.20 | 0.244 | 76.0 ± 24.4 | < 0.001 |
| Role emotional (RE) | 18.89 ± 32.38 | 36.67 ± 43.00 | 0.050 | 65.6 ± 41.4 | < 0.001 |
| Mental health (MH) | 46.53 ± 25.59 | 50.93 ± 19.71 | 0.362 | 67.0 ± 18.0 | < 0.001 |
| PCS | 29.10 ± 15.77 | 31.35 ± 16.00 | 0.503 | – | – |
| MCS | 37.83 ± 21.50 | 46.20 ± 20.40 | 0.025 | – | – |
| Method | X1 (mm) | X2 (mm) | X3 (mm) | M (kg) |
| Original | 4 | 20 | 7 | 39.8140 |
| GA | 4.8182 | 14.0024 | 3.0029 | 31.9826 |
| BMPSO | 4.8185 | 14.0001 | 3.0017 | 31.3458 |
| Gene/exon | Sequences | Tann |
| β-globin | Forward primer: 5'-GTGCACCTGACTCCTGAGGAGA-3'Reverse primer: 5'-CCTTGATACCAACCTGCCCAG-3'Probe: 5'-FAM-AAGGTGAACGTGGATGAAGTTGGTGG-RTQ1-3' | 60°C |
| PARK2\\ex1 | Forward primer: 5'-CAGCGGCTCTCCTGGGTTAAA-3'Reverse primer: 5'-TACGACTCCCAGCAGGCCCT-3'Probe: 5'-ROX-CCTAGGAATGCGCACGCGCGGAG-RTQ1-3' | 60°C |
| PARK2\\ex2 | Forward primer: 5'-ATCTCAGGCATGAATGTCAGATT-3'Reverse primer: 5'-TGACCAGTTGCGTGTGATTT-3'Probe: 5'-ROX-ATGAGCAATGGAGCTGGCGGCATCC-RTQ1-3' | 60°C |
| PARK2\\ex3 | Forward primer: 5'-CATTGTGCAGAGACCGTGGAGAA-3'Reverse primer: 5'-GCTGAGGTCCACCCGAGTCAA-3'Probe: 5'-ROX-AAATGAATGCAACTGGAGGCGACGACCC-RTQ1-3' | 60°C |
| PARK2\\ex4 | Forward primer: 5'-TAGCCACTTCTTCTGCTTTT-3'Reverse primer: 5'-TGCACTGTACCCTGAGTTTT-3'Probe: 5'-ROX-ATTGCAAAGGCCCCTGTCAAAGAGTGCA-RTQ1-3' | 60°C |
| PARK2\\ex5 | Forward primer: 5'-TCTTGCTGGGATGATGTTTTAATTCCAAA-3'Reverse primer: 5'-TTGCAATAAGAGGAATGAAT-3'Probe: 5'-ROX-AATGCCAATCCCCACACTGCCCTGG-RTQ1-3' | 60°C |
| PARK2\\ex6 | Forward primer: 5'-CCGTGGAGGGAAGTGACACTAT-3'Reverse primer: 5'-TGCACCTGATCGCAACAAAT-3'Probe: 5'-ROX-TGTGCGCGTAATGCAAGTGATGTTCCG-RTQ1-3' | 60°C |
| PARK2\\ex7 | Forward primer: 5'-GGGTCGTGAACAAACTGCCGATCATT-3'Reverse primer: 5'-AGGAGCCCCGTCCTGGTTTT-3'Probe: 5'-ROX-AAGCAAATCACGTGGCGGGAGTTGCAC-RTQ1-3' | 60°C |
| PARK2\\ex8 | Forward primer: 5'-TCACTCACCTGCTCTTCTCCCAGAAT-3'Reverse primer: 5'-CAGAGTGAAAGTGACGTTTT-3'Probe: 5'-ROX-TCAAGGAGTTGGGACAGCCAGCTGTTGG-RTQ1-3' | 60°C |
| PARK2\\ex9 | Forward primer: 5'-ACCCCACAGCCCAGGCCATT-3'Reverse primer: 5'-TGCAGATGGGGGGCGTGTTA-3'Probe: 5'-ROX-TTCGCAGGTGACTTTCCTCTGGTCAGGC-RTQ1-3' | 60°C |
| PARK2\\ex10 | Forward primer: 5'-GCTTGGAGGAATGAGTAGGGCATT-3'Reverse primer: 5'-GTTTGCCTTCTGCCGGGAAT-3'Probe: 5'-ROX-AGGCTTCAAATACGGCACTGCACTCCCC-RTQ1-3' | 60°C |
| PARK2\\ex11 | Forward primer: 5'-TGGTGGTTTTCTTGATGGTTT-3'Reverse primer: 5'-AACGCCTTTCCTCTTTGTTT-3'Probe: 5'-ROX-TCGGCGGCTCTTTCATCGACTCTGTAGG-RTQ1-3' | 60°C |
| PARK2\\ex12 | Forward primer: 5'-CACGATCTTCCTGAGAAGTCAGACAAT-3'Reverse primer: 5'-ACAACACTGCATGCGGCAAA-3'Probe: 5'-ROX-TCTGCGTAGTGTGGGTAAGAGCATGCGG-RTQ1-3' | 60°C |
| SCS | CCS | TCS | |
| Log evidence | 14084 | 14072 | 14058 |
| Cell line | EGFR mutation status | Sulforaphane |
| IC50 (μM) a | ||
| A549 | Wild-type | 10.2 ± 0.15 |
| CL1-5 | Wild-type | 9.7 ± 0.33 |
| H3255 | L858R b | 14.5 ± 0.21 |
| PC9/gef c | Exon 19 del. | 7.3 ± 0.25 |
| H1975 | L858R/T790M d | 5.9 ± 0.18 |
| HFB | Wild-type | 65.4 ± 0.29 |
| Gene | Length | Forward Sequence (5′>3′) | Reverse Sequence (5′>3′) |
| Runx2 | 250 bp | CCACCACTCACTACCACACG | TCAGCGTCAACACCATCATT |
| Osterix | 373 bp | ACCAGGTCCAGGCAACACACCTAC | GCAGTCGCAGGTAGAACGCCCTGC |
| BMP2 | 154 bp | GGGACCCGCTGTCTTCTAGT | TCAACTCAAATTCGCTGAGGAC |
| Osteocalcin | 302 bp | AGACAAGTCCCACACAGCAG | GGCGGTCTTCAAGCCATACT |
| Bone sialoproiten | 312 bp | CTGAAGCAGGTGCAGAAGGA | TCTGACCCTCGTAGCCTTCA |
| Osteopontin | 354 bp | CTGGCAGCTCAGAGGAGAAG | GGACATCGACTGTAGGGACG |
| ALP | 211 bp | TAACACCAACGCTCAGGTCC | GTGGTTCACCCGAGTGGTAG |
| Smad1 | 97 bp | ACCTGTGGCTTCCGTCTC | ATCGTGGCTCCTTCGTC |
| Smad4 | 145 bp | CAGCACTACCACCTGGACTGGA | CTGGAATGCAAGCTCATTGTGAA |
| Smad5 | 197 bp | AAGTAGATTCTGCCTGGGATT | AGACGGTGGTGGGATGG |
| Smad8 | 169 bp | ATCCCTGGCAATCTGTA | CCCTGGCTGTCCTGTAA |
| PARP-1 | 72 bp | GGAAAGGGATCTACTTTGCCG | TCGGGTCTCCCTGAGATGTG |
| GAPDH | 240 bp | TGATGACATCAAGAAGGTGGTGAAG | TCCTTGGAGGCCATGTAGGCCAT |
| Characteristics | Number | Percentage |
| Socio-demographic characteristics | ||
| Gender (n = 674) | ||
| Male | 278 | 41% |
| Female | 396 | 59% |
| Marital status (n = 679) | ||
| Married | 232 | 34% |
| Single | 447 | 65% |
| Race (n = 685) | ||
| Black | 160 | 23% |
| Indian | 143 | 21% |
| White | 319 | 47% |
| Coloured | 53 | 8% |
| Medical school characteristics | ||
| Profession (n = 654) | ||
| Medical doctor | 544 | 79% |
| Dental practitioner | 110 | 16% |
| Tertiary institution (n = 677) | ||
| University of Cape Town | 73 | 11% |
| University of the Witwatersrand | 84 | 12% |
| University of KwaZulu-Natal | 101 | 15% |
| University of Limpopo | 55 | 8% |
| University of the Free State | 64 | 9% |
| University of Pretoria | 101 | 15% |
| University of the Western Cape | 64 | 9% |
| Stellenbosch University | 101 | 15% |
| Walter Sisulu University | 34 | 5% |
| Provincial bursary obligation (versus not) (n = 670) | 142 | 21% |
| Student loans (versus not) (n = 678) | 142 | 35% |
| Number of donors | Europe | North America | Australasia and South Africa | Total |
| <50 | 7 | 2 | 5 | 14 |
| 51–100 | 2 | 1 | 2 | 5 |
| 101–1000 | 2 | 0 | 0 | 2 |
| >1000 | 0 | 2 | 0 | 2 |
| Model description | RMSEA | CFI | χ2 | df | Δχ2 | Δdf | Statistical significance |
| 1. Configural model: no constraints imposed | 0.02 | 0.99 | 8.06 | 6 | - | - | - |
| 2. Factor loadings: constrained equally across groups | 0.03 | 0.97 | 45.44 | 19 | 37.38 | 13 | p < 0.0005 |
| Before treatment compared to first treatment (PET 1–PET 2) | |
| ACC | Midbrain (+0.45), pallidum (+0.61), putamen (+0.34) |
| Hippocampus | Amygdala (+0.20), insula (+0.37), pallidum (+0.47) |
| Insula | Pallidum (+0.56) |
| Group OP vs. Group 0T | Group NT vs. Group NP | |||
| T = 4 weeks | T = 8 weeks | T = 4 weeks | T = 8 weeks | |
| Weight | p < 0.01 | p < 0.001 | p < 0.05 | p < 0.01 |
| BMI | NS | NS | NS | NS |
| Cholesterol | p < 0.001 | NS | NS | NS |
| HDL | NS | p < 0.001 | p < 0.05 | p < 0.05 |
| LDL | NS | p < 0.01 | NS | p < 0.01 |
| Triglycerides | NS | p < 0.001 | p < 0.01 | p < 0.01 |
| Systolic BP | NS | p < 0.05 | p < 0.05 | NS |
| Diastolic BP | p < 0.05 | p < 0.001 | p < 0.05 | p < 0.001 |
| Glucose | p < 0.001 | p < 0.001 | NS | NS |
| Derivation cohort | All cohorts | |||||
| PEARL indices | B | p Value | OR (95% CI) | Weighting | B | Updated weighting |
| Previous admissions (2+) | 1.04 | <0.001 | 2.84 (1.98 to 4.07) | 2 | 1.14 | 3 |
| eMRCD score 4 | 0.67 | 0.002 | 1.96 (1.29 to 2.98) | 1 | 0.37 | 1 |
| eMRCD score 5a | 1.13 | <0.001 | 3.10 (1.89 to 5.10) | 2 | 0.85 | 2 |
| eMRCD score 5b | 2.02 | <0.001 | 7.51 (4.17 to 13.52) | 3 | 1.09 | 3 |
| Age 80 or more | 0.38 | 0.032 | 1.47 (1.03 to 2.08) | 1 | 0.38 | 1 |
| Right ventricular failure | 0.50 | 0.050 | 1.66 (1.00 to 2.74) | 1 | 0.63 | 1 |
| Left ventricular failure | 0.52 | 0.080 | 1.68 (0.94 to 3.00) | 1 | 0.52 | 1 |
| Constant | −0.78 | <0.001 | 0.46 (0.36 to 0.58) | −0.95 | ||
| Maximum PEARL score | 9 |
| Migration of stem | Rotation of stem | |
| (mm) | (degrees) | |
| x-axis | 0.09 | 0.36 |
| y-axis | 0.13 | 0.76 |
| z-axis | 0.23 | 0.13 |
| IC50 (μM) | ||||||||
| Tumor type Cell lines | Rhabdoid | Glioma | Breast | |||||
| MON | G401 | A204 | SF268 | U87 | U251 | MCF7 | MDAMB231 | |
| ATRA | > 50 | > 50 | > 50 | > 50 | > 50 | > 50 | > 50 | > 50 |
| 4-HPR | 2.2 | 0.1 | 2.0 | 6.9 | 5.0 | 1.4 | 2.2 | 0.4 |
| 5h | 3.6 | 0.3 | 1.7 | 18.9 | 16.3 | 5.8 | 6.3 | N/A* |
| 5j | 1.2 | 3.0 | 8.2 | 12.0 | 13.7 | 9.1 | 11.8 | 23 |
| 11a | 1.9 | 0.2 | 4.4 | 10.4 | 5.0 | 2.4 | 8.3 | 2.3 |
| 11c | 5.2 | 0.3 | 5.6 | 15.7 | 9.3 | 5.9 | 12.1 | 5.3 |
| 11d | 1.3 | 3.2 | 7.5 | 3.8 | 9.4 | 7.8 | 8.2 | 12.0 |
| Stratum | LD | Special education | ADHD | |||
| Study population | 1.51 (1.14, 2.00) | 1.44 (1.03, 2.01) | 0.84 (0.61, 1.16) | |||
| Below median lead | 1.67 (1.09, 2.56) | 1.74 (0.91, 3.30) | 1.11 (0.65, 1.91) | |||
| Above median lead | 1.39 (0.98, 1.95) | 1.29 (0.83, 2.01) | 0.73 (0.52, 1.03) | |||
| Female | 1.24 (0.75, 2.04) | 1.31 (0.81, 2.13) | 0.91 (0.50, 1.69) | |||
| Male | 1.75 (1.24, 2.46) | 1.73 (1.02, 2.92) | 0.79 (0.56, 1.11) |
| Protein name | Accession | Score | Coverage | Peptide | Fold change |
| Upregulated proteins | |||||
| Sarcoplasmic calcium-binding protein 1 | comp40442_c0_seq1_No.1 | 83 | 16.1 | 3 | 8.40 |
| Troponin C isoform 2b | comp22592_c0_seq1_No.1 | 69 | 26.3 | 3 | 2.78 |
| Clip domain serine proteinase 3 | comp19522_c0_seq1_No.1 | 520 | 33.8 | 9 | 2.40 |
| Copine-8 | comp20718_c0_seq2_No.1 | 841 | 30.9 | 14 | 2.19 |
| Slow muscle myosin S1 heavy chain | comp20546_c0_seq16_No.1 | 2,058 | 43.7 | 26 | 2.13 |
| Putative secreted salivary gland peptide | comp12272_c1_seq1_No.1 | 83 | 22 | 3 | 2.23 |
| Chloride intracellular Channel isoform 1 | comp20820_c0_seq1_No.1 | 100 | 25.7 | 5 | 2.11 |
| Myophilin | comp18304_c1_seq2_No.1 | 1,662 | 62.4 | 8 | 2.03 |
| Spermine synthase | comp18763_c0_seq1_No.1 | 200 | 16.1 | 4 | 2.02 |
| Putative phosphoglycerate kinase | comp12041_c0_seq1_No.1 | 897 | 33.5 | 13 | 2.02 |
| Downregulated proteins | |||||
| Sacsin | comp19443_c0_seq1_No.1 | 42 | 0.2 | 1 | 31.39 |
| Phospholipase D1 | comp1157_c0_seq1_No.1 | 211 | 17.4 | 5 | 6.97 |
| Low-density lipoprotein receptor | comp20609_c0_seq1_No.1 | 283 | 10.2 | 6 | 5.77 |
| Pseudomonas aeruginosa pathogenicity island I | comp20408_c0_seq1_No.1 | 54 | 7.6 | 1 | 3.02 |
| pacifastin-like serine protease inhibitor | comp3991_c0_seq1_No.1 | 82 | 15.1 | 2 | 2.99 |
| Anti-lipopolysaccharide factor 4 | comp12264_c0_seq1_No.1 | 179 | 27.6 | 2 | 2.82 |
| Anti-lipopolysaccharide factor isoform 4 | comp20686_c1_seq1_No.1 | 126 | 47.7 | 4 | 2.12 |
| Gene | % Nucleotide identity | % Amino-acid identity |
| NP | 98.9 | 99.3 |
| P | 98.8 | 98.4 |
| M | 98.5 | 98.7 |
| G | 98.2 | 98.4 |
| L | 99.0 | 99.8 |
| Test | Method description |
| Polyacrylamide gel electrophoresis (reducing and non-reducing) | Polyacrylamide gel electrophoresis performed in the presence of sodium dodecyl sulphate (SDS PAGE) under both reducing and non-reducing conditions. Gels were stained using Colloidal Coomassie Blue staining |
| Size exclusion chromatography | Resolution of aggregated forms from the monomeric form of rFIXFc using high performance liquid chromatography (TSKgelG3000SWXL column) |
| Coagulation activity | One-stage aPTT method performed in accordance with Pharmacopeia guidelines (USP<32> and Ph.Eur. 2.7.11) with respect to WHO International Standard for Factor IX concentrate |
| FcRn binding | FcRn competitive binding measured using an amplified luminescent proximity homogenous assay |
| Activated rFIXFc | Enzyme-linked immunosorbent assay (ELISA) based on the binding of hATIII to activated factor IX for the detection of the activated form of rFIXFc |
| Bioburden | Microbial enumeration test performed in accordance with Pharmacopeia guidelines (USP<61> and Ph.Eur. 2.6.12) |
| Endotoxin | Kinetic turbidimetric method in accordance with Pharmacopeia guidelines (USP<85> and Ph. Eur. 2.6.14) |
| Haplotype * | CAD | BD | χ2 | OR (95% CI) Univariate Analysis | p | |||
| + (%) | − (%) | + (%) | − (%) | |||||
| H1 | CT | 1.2 | 98.8 | 0 | 100 | 5.18 | 2.04 (1.90–2.19) a | 0.014 |
| H2 | TT | 28.8 | 71.2 | 32.7 | 67.3 | 1.50 | 0.83 (0.62–1.12) | 0.22 |
| H3 | CC | 41.5 | 58.5 | 41.0 | 59.0 | 0.02 | 1.02 (0.77–1.34) | 0.89 |
| H4 | TC | 28.5 | 71.5 | 26.3 | 73.7 | 0.52 | 1.12 (0.82–1.52) | 0.47 |
| Membrane | C 1s (%) | O 1s (%) | Al 2p (%) | P 2s (%) | (O/Al) |
| Al-Ox | 23.9 | 48.7 | 25.4 | 2.0 | 1.9 |
| Mercury measure available | No mercury measure | |
| 4+ DAs at start of pregnancy | 69.6% (1823) | 69.9% (4200) |
| Visited dentist in pregnancy | 86.3% (2464) | 86.0% (5765) |
| Had a new DA in pregnancy | 22.4% (633) | 25.0% (1632) |
| Had old DA removed in pregnancy | 14.8% (420) | 15.7% (1021) |
| Tooth extraction in pregnancy | 3.8% (108) | 3.9% (251) |
| Objectives/Social Values | Option which maximises likelihood of success |
| Equalise access, outcome | Universal (monopoly) Public Insurance/Financing |
| Maximise choice; diversity + safety netOptimise the max of these 2 objectives | Pure private (competitive) scheme |
| Both of the above | Mixed public-private scheme |
| Condition | Major reported impairments of postural responses | Cortical function during impaired standing postural responses |
| Stroke involving cortex | Feet-in-place responses: change in the distal-to-proximal muscle pattern and delayed muscle onset as well as delayed and slowed rates of force development in the more severely involved limb (Di Fabio et al., 1986; Ikai et al., 2003) | Unaware of studies utilizing measures of cortical neurophysiology during standing postural responses post-stroke |
| Stepping responses: paretic limb exhibits delayed foot-lift, low clearance, need for multiple steps, or an inability to initiate a step (Lakhani et al., 2011; Martinez et al., 2013). Steps are non-paretic limb dominant, even when obstacles block the limb (Lakhani et al., 2011; Mansfield et al., 2012). Impairments associate with increased fall risk and, in contrast, greater use of the paretic limb associates with better recovery (Mansfield et al., 2012, 2013) | ||
| Advanced age | Age associates with delays and antagonistic co-contraction of muscles, as well as greater displacement and instability (Halicka et al., 2012) | Electroencephalographic (EEG) PEP delayed, bifid (double-peaked), and decreased with age—effects larger in balance impaired elders (Duckrow et al., 1999) |
| Dual task costs greater for elderly only in late-phase in-place and stepping responses, more so for stepping and more so if balance impaired elder (Brown et al., 1999; Rankin et al., 2000; Brauer et al., 2001, 2002; Zettel et al., 2008) | ||
| Parkinson's disease | Falls, instability, antagonistic co-contraction and lack of modulation based on knowledge of perturbation. Stepping responses may exhibit freezing or have decreased velocity and step length (Jacobs et al., 2005, 2009b; Jacobs and Horak, 2006; Smith et al., 2012) | Increased desynchronization of EEG beta signal, and this increase associates with decreased response adaptation to perturbation magnitude (Smith et al., 2012) |
| With dual tasking, in-place responses are not modulated, and falls increase during stepping responses, but postural preparation or freezing unchanged (de Lima-Pardini et al., 2012; Jacobs et al., 2014a) | ||
| Low back pain | Increased pre-perturbation muscle activation, increased activation amplitude at distal muscle, but decreased or delayed trunk muscle activation (Jacobs et al., 2011) | Late positive peak PEP larger with LBP; larger PEP correlates with less postural instability, disability, and fear of activity (Jacobs et al., 2014b) |
| PRE TTS implementation | POST TTS implementation | |||||
| Missed injuries | Study population (N) | Missed injury rate (%) | Patients with Missed injuries (N) | Study population (N) | Missed injury rate (%) | |
| Enderson, 1990 | N/A | 2.0 | 37 | 399 | 9.27 | |
| Vles, 2003 | 49 | 3,879 | 1.26 | |||
| Hoff, 2004 | 42 | 432 | 9.72 | |||
| Soundappan, 2004 | 12 | 76 | 15.8 | |||
| Howard, 2006 | 12 | 90 | 13.3 | |||
| Okello, 2007 | 78 | 403 | 19.4 | |||
| Janjua, 2008 | 134 | 206 | 65.0 | |||
| Ursic, 2009 | 35 | 981 | 3.57 | 62 | 1,006 | 6.16 |
| Huynh, 2010 | 80 | 5,143 | 1.56 | |||
| Overall | 35 | 981 | 3.57 | 506 | 11,634 | 4.35 |
| Stress-associated and virulence genes | Protein encoded/function |
| Oxidative stress | |
| oxyR | DNA-binding transcriptional regulator OxyR |
| sodA | Manganese-containing superoxide dismutase |
| soxR | Redox-sensitive transcriptional activator of oxidative stress regulon |
| General stress | |
| uspA | Universal stress global response regulator |
| rpoS | Regulator of the general stress response (σS) |
| Starvation | |
| phoA | Alkaline phosphatase |
| dps | DNA-binding protein from starved cells |
| Cold shock | |
| cspA | Cold shock protein A |
| cspC | Cold shock protein C |
| cspE | Cold shock protein E |
| UV | |
| mutS | DNA mismatch repair protein—Mutator S |
| Acid resistance | |
| gadA | Glutamate decarboxylase A |
| gadB | Glutamate decarboxylase B |
| gadW | DNA-binding transcriptional activator GadW |
| Intimin | |
| eae | Intimin (adherence protein) |
| Toxin | |
| stx1A | Shiga-like toxin 1 A subunit |
| stx2A | Shiga-like toxin 2 A subunit |
| Motility | |
| fliC | Flagellin |
| * TPS | 0.5% | 1% | 1.5% | 2% | |
| Tβ | −46.71 | −40.53 | −36.52 | −38.27 | −39.40 |
| Tα | 64.38 | 64.61 | 69.87 | 62.65 | 64.02 |
| Gene | Sequence 5’to 3 | |
| MAPK | Forward | CAGTGGGATGGAATTGAAAG |
| Reverse | AGCAGAAGGAATGAGTGTGC | |
| NOS1 | Forward | GACTGTTGAGATGGAAGAAC |
| Reverse | ATCTTCCTGTCTCCGAGGCG | |
| NOS3 | Forward | GTGATGGCGAAGCGAGTGAAG |
| Reverse | CCGAGCCCGAACACACAGAAC | |
| PIK3CA | Forward | CTCCACGACCATCATCAGG |
| Reverse | GATTACGAAGGTATTGGTT |
| low fCP | high fCP | P values | |||||
| low fCHO | high fCHO | low fCHO | high fCHO | fCP | fCHO | fCP x fCHO | |
| Gene expression1 | |||||||
| DAO | 0.97 ± 0.1 | 1.05 ± 0.1 | 1.19 ± 0.3 | 1.02 ± 0.2 | 0.55 | 0.77 | 0.42 |
| HMT | 0.88 ± 0.1 | 0.84 ± 0.1 | 1.05 ± 0.1 | 0.96 ± 0.1 | 0.033 | 0.35 | 0.70 |
| C-Kit | 0.46 ± 0.1 | 0.37 ± 0.1 | 0.63 ± 0.1 | 0.56 ± 0.1 | 0.005 | 0.22 | 0.82 |
| FcεRI | 0.43 ± 0.2 | 0.71 ± 0.1 | 0.99 ± 0.3 | 0.95 ± 0.1 | 0.049 | 0.30 | 0.58 |
| CFTR | 0.63 ± 0.06 | 0.69 ± 0.07 | 0.44 ± 0.03 | 0.49 ± 0.03 | <0.001 | 0.22 | 0.96 |
| Enzyme activity2 | |||||||
| DAO | 40.8 ± 5.3 | 43.4 ± 5.1 | 77.6 ± 14 | 64.4 ± 13 | 0.001 | 0.55 | 0.37 |
| HMT | 290 ± 32 | 286 ± 38 | 376 ± 56 | 394 ± 33 | 0.006 | 0.84 | 0.77 |
| Species | Erroneous sequences | Corrected sequences | Apparent rate of correction (%) |
| H. sapiens | 941 | 331 | 35.2 |
| M. musculus | 455 | 106 | 23.3 |
| R. norvegicus | 704 | 178 | 25.3 |
| M. domestica | 434 | 93 | 21.4 |
| G. gallus | 458 | 118 | 25.8 |
| X. tropicalis | 547 | 176 | 32.2 |
| D. rerio | 1376 | 180 | 13.1 |
| F. rubripes | 507 | 97 | 19.1 |
| B. floridae | 1753 | 46 | 2.6 |
| C. intestinalis | 391 | 28 | 7.2 |
| C. elegans | 215 | 49 | 22.8 |
| D. melanogaster | 337 | 60 | 17.8 |
| Service | MD | NP | PA | TOTAL |
| N | N = 125 | N = 23 | N = 21 | 169 |
| Multidisciplinary Pain Management | ||||
| Any | 106/123 (86%) | 16/23 (70%) | 19/21 (90%) | 141/167(84%) |
| 9 or more times | 52/123 (42%) | 7/23 (30%) | 10/21 (48%) | 69/167 (41%) |
| Comprehensive Nutritional Assessment and Advice | ||||
| Any | 99/116 (85%) | 18/22 (88%) | 16/20 (80%) | 133/158 (84%) |
| 9 or more times | 43 (37%) | 9/22 (41%) | 8/20 (40%) | 60/158(37%) |
| Obesity Healthy Lifestyle Promotion | ||||
| Any | 99/119 (83%) | 15/23 (65%) | 18/21 (86%) | 132/163 (80%) |
| 9 or more times | 53/119 (45%) | 7/23 (30%) | 8/21 (38%) | 68/163 (41%) |
| Fit for Life (Exercise/Fitness Program) | ||||
| Any | 90/116(77%) | 15/23 (65%) | 17/21 (81%) | 122/160(76%) |
| 9 or more times | 43 (37%) | 6/23 (26%) | 10/21 (48%) | 59/160(36%) |
| Diabetes Healthy Lifestyle Promotion | ||||
| Any | 86/118 (73%) | 16/23 (70%) | 17/21 (81%) | 119/162 (73%) |
| 9 or more times | 38/118 (32%) | 6/23 (26%) | 7/21 (33%) | 51/162 (31%) |
| Psychology support for biofeedback, hypnosis, Mindfulness-based Stress Reduction, other stress management | ||||
| Any | 92/119 (77%) | 13/22 (60%) | 14/21 (67%) | 119/162 (73%) |
| 9 or more times | 31 (26%) | 2/22 (9%) | 7/21 (33%) | 40/162 (24%) |
| Heart Healthy Lifestyle Promotion | ||||
| Any | 81/116 (70%) | 16/23(70%) | 18/21 (86%) | 115/160 (71%) |
| 9 or more times | 39/116 (34%) | 7/23(30%) | 6/21 (29%) | 52/160 (32%) |
| Pharmacy Support for questions about herbs and supplements | ||||
| Any | 80/119 (67%) | 16/23 (70%) | 16/21 (76%) | 112/163 (68%) |
| 9 or more times | 23 (19%) | 6/23 (26%) | 8/21 (38%) | 37/163 (22%) |
| Comprehensive Back Pain | ||||
| Any | 84/123 (68) | 12/23 (52%) | 15/21 (71%) | 111/167 (66%) |
| 9 or more times | 32/123 (26%) | 2/23 (9%) | 9/21 (43%) | 43/167 (25%) |
| Integrative Headache management | ||||
| Any | 80/121 (66%) | 12/23 (52%) | 13/21 (62%) | 105/165 (63%) |
| 9 or more times | 23/121 (19%) | 1/23(4%) | 6/21 (29%) | 30/165(18%) |
| Cancer Patient Support Program | ||||
| Any | 76/117 (65%) | 10/23 (44%) | 15/21 (71%) | 101/161(62%) |
| 9 or more times | 25/117 (21%) | 3/23 (13%) | 5/21 (24%) | 33/161(20%) |
| Stroke Recovery Program | ||||
| Any | 60/120 (50%) | 12/23 (52%) | 12/20 (60%) | 84/163(51%) |
| 9 or more times | 10/120 (8%) | 2/23 (9%) | 2/20 (10%) | 14/163(8%) |
| characteristics | C/G/BMSCs-dECM scaffolds | C/G scaffolds |
| Pore diameter (μm) | 289.17 ± 80.28 | 227.17 ± 44.37 |
| Porosity (%) | 89.25 ± 3.75 | 88.48 ± 2.28 |
| Water uptake ratio | 13.81 ± 1.00 | 11.07 ± 0.87 |
| Compressive modulus (MPa) | 0.82 ± 0.07 | 1.10 ± 0.11 |
| Group 1 | Group 2 | Group 3 | Group 4 | ANOVA | |
| n = 15 | n = 15 | n = 15 | n = 15 | p-value | |
| CLD at 36 weeks | 3 (20 %) | 4 (27 %) | 7 (47 %) | 2 (13 %) | 0.2 |
| Days respiratory support | 21 (9, 33) | 26 (20, 38) | 30 (24, 33) | 24 (10, 35) | 0.4 |
| Days hospital stay | 50 (39, 58) | 53 (41, 71) | 64 (50, 78) | 53 (48, 66) | 0.2 |
| Days to full suck feeds | 40 (35, 54) | 51 (36, 66) | 57 (41, 73) | 51 (37, 64) | 0.5 |
| Days NCPAP | 1 (0, 12) | 24 (9, 28) | 15 (11, 21) | 24 (10, 35) | 0.002 |
| Gestational age off NCPAP | 31.6 | 33.9 | 35.7 | 34.6 | 0.04 |
| (30.0, 34.1) | (32.1, 35.9) | (31.0, 37.6) | (31.9, 35.3) | ||
| Days HFNC from start of treatment | 15 (7, 24) | 30 (20, 34) | 0.004 | ||
| Days pressure support | 15 (9, 29) | 24 (9, 28) | 30 (24, 33) | 24 (10, 35) | 0.1 |
| Gestational age off pressure support | 34.0 | 33.9 | 35.9 | 34.6 | 0.07 |
| (32.7, 35.3) | (32.1, 35.9) | (33.9, 38.9) | (31.9, 35.3) | ||
| Gestational age off respiratory support | 34.7 | 34.1 | 35.9 | 34.6 | 0.1 |
| (33.4, 35.3) | (33.1, 36.0) | (33.9, 38.9) | (31.9, 35.3) | ||
| Gestational age at full suck feeds | 36.9 | 37.1 | 39.6 | 37.3 | 0.1 |
| (36.4, 38.0) | (36.1, 40.6) | (37.1, 44.0) | (36.6, 39.1) | ||
| Gestation at discharge | 37.7 | 37.9 | 39.9 | 38.3 | 0.1 |
| (36.9, 39.1) | (37.1, 40.1) | (37.9, 45.0) | (36.9, 39.7) | ||
| Postnatal growth failure | 9 (60 %) | 9 (60 %) | 7 (47 %) | 7 (47 %) | 0.8 |
| Weight at 36 weeks - g (sd) | 2158 (411) | 2044 (390) | 2042 (338) | 2128 (532) | 0.4 |
| Days caffeine | 24 (24) | 34 (30) | 40 (22) | 39 (33) | 0.2 |
| Grade 2 apnea (required IPPV) | 0 | 1 (7 %) | 0 | 0 | 0.4 |
| Necrotising enterocolitis | 0 | 1 (7 %) | 0 | 0 | 0.4 |
| Treated ductus arteriosus | 2 (13 %) | 5 (33 %) | 4 (27 %) | 1 (7 %) | 0.2 |
| Retinopathy of prematurity | 7 (47 %) | 6 (40 %) | 6 (40 %) | 6 (40 %) | 0.6 |
| Laser therapy | 1 (7 %) | 0 | 0 | 1 (7 %) | 0.6 |
| Nasal injury | 0 | 0 | 1 (7 %) | 1 (7 %) | 0.4 |
| Withdrawn | 0 | 6 (40 %) | 1 (7 %) | 0 | 0.01 |
| Defense related transcripts Leaf | Stress related transcripts Leaf | ||||
| EST/mRNA | Fold | Description | EST/mRNA | Fold | Description |
| EH615198 | 6.4 | Nicotiana tabacum nictaba mRNA (NT1) | TA14956_4097 | 3.8 | Tamarix Putative stress-responsive protein |
| FG636567 | 3.8 | Nicotiana tabacum mRNA for P-rich protein NtEIG-C29 | FG156808 | 3.6 | Nicotiana tabacum 1-D-deoxyxylulose 5-phosphate synthase mRNA (DXS1) |
| EB433973 | 2.8 | Parsley PcPR1-3 mRNA for pathogenesis-related protein type B | CV016057 | 2.9 | Arabidopsis thaliana cold-regulated 413-plasma membrane 2 mRNA COR413-PM2 |
| S44869 | 2.4 | Nicotiana tabacum Endochitinase A precursor | EB441160 | 2.9 | Solanum lycopersicum dxs2 gene for 1-deoxy-D-xylulose 5-phosphate synthase |
| X12739 | 2.1 | Nicotiana tabacum Pathogenesis-related protein R major form precursor | EB435759 | 2.8 | Ipomoea nil In04 mRNA for caffeoyl-CoA O-methyltransferase |
| TA14009_4097 | 0.5 | Nicotiana tabacum Chitinase 134 | TA12600_4097 | 2.8 | Solanum tuberosum Low temperature and salt responsive protein |
| EB425556 | 0.5 | Arabidopsis thaliana beta-1,3-glucanase-related mRNA | EB451519 | 2.8 | Solanum lycopersicum geranylgeranyl pyrophosphate synthase 1 (GGPS1) |
| EH624302 | 0.5 | Arabidopsis thaliana callose synthase 1 mRNA CALS1 | EB445705 | 2.7 | Vitis vinifera RD22-like protein mRNA |
| Defense related transcripts Flower | DV161729 | 2.1 | Arabidopsis thaliana snf1-related protein kinase 2.2, SNRK2.2 | ||
| FG167555 | 3.8 | Nicotiana tabacum Avr9/Cf-9 rapidly elicited protein 111B (ACRE111B) AP2-DOMAIN | FG633784 | 2.0 | Solanum lycopersicum anthocyanin acyltransferase mRNA, Jasmonic acid inducible |
| AB041516 | 3.5 | Nicotiana tabacum P-rich protein EIG-I30 | EB680165 | 0.3 | Arabidopsis thaliana SIP3 (SOS3-INTERACTING PROTEIN 3) |
| TA14524_4097 | 3.0 | Nicotiana tabacum Avr9/Cf-9 rapidly elicited protein 65 (ACRE65) mRNA, | EB433693 | 0.4 | Arabidopsis thaliana AFP1 (ABI FIVE BINDING PROTEIN) |
| FG640154 | 2.6 | Nicotiana tabacum mRNA for basic pathogenesis-related protein Thaumatin | TA14058_4097 | 0.4 | Ipomoea nil CHS-D mRNA for chalcone synthase |
| FG635113 | 2.5 | Nicotiana tabacum Avr9/Cf-9 rapidly elicited protein 20 (ACRE20) mRNA; EF-hand calcium binding protein | EB439278 | 0.4 | Nicotiana tabacum NtERD10B mRNA for dehydrin |
| TA13004_4097 | 2.2 | Nicotiana tabacum mRNA for hin1 gene: Harpin inducing protein | EB437158 | 0.5 | Ricinus communis leuco-anthocyanidin dioxygenase mRNA |
| TA15227_4097 | 2.1 | Nicotiana tabacum Avr9/Cf-9 rapidly elicited protein 76; NDR1/HIN1 | DW003496 | 0.5 | Ricinus communis Salt-tolerance protein |
| AB127582 | 2.1 | Nicotiana tabacum Harpin inducing protein 1-like 18 DOMAIN: LEA_2 | EB438355 | 0.5 | Arabidopsis thaliana ATHK1 (histidine kinase 1/ osmosensor) |
| EB438355 | 0.5 | Catharanthus roseus cold inducible histidine kinase 1 (iK1) mRNA |
| n = 136 | Total | Possible or specific OA diagnosis on GP request | |
| n (%) | ORa (95% CI) | ||
| Male | 62 | 20 (32%) | 1.00 |
| Female | 74 | 30 (41%) | 1.51 (0.73, 3.11) |
| Age | |||
| under 60 | 69 | 19 (28%) | 1.00 |
| 60 & over | 67 | 31 (46%) | 2.32 (1.13, 4.77) |
| Province | City | PCR-confirmedP. falciparum(N) |
| Khyber Pakhtunkhwa | Bannu | 39 |
| Hangu | 19 | |
| Peshawar | 4 | |
| Thal | 29 | |
| Punjab | Bhakkar | 1 |
| Lahore | 1 | |
| Mianwali | 28 | |
| Muzaffarghar | 13 | |
| Rawalpindi | 0 | |
| Balochistan | Quetta | 26 |
| Zhob | 7 | |
| Sindh | Hyderabad | 0 |
| Karachi | 2 | |
| Capital | Islamabad | 2 |
| Total | 171 |
| Animal group | Number ofhemispheres used | MaxPs of activation evoked byF and revF stimulation | Comparison between sound types | ||
| F | revF | Type of test | p values | ||
| Trained | 12 | 0.212 ± 0.063 | 0.116 ± 0.029 | t test | 8.74E-05 |
| Naïve | 12 | 0.199 ± 0.060 | 0.114 ±0.026 | t test | 1.97E-04 |
| Control group(n = 128) | ConventionalIVF group(n = 114) | ICSI group(n = 140) | p-value | |
| Maternal age (yr) | 34.52 ± 4.13 | 35.70 ± 3.97 | 35.49 ± 4.23 | 0.055 |
| Paternal age (yr) | 36.05 ± 4.34a | 37.43 ± 4.39a,b | 38.07 ± 5.40b | 0.002 |
| Maternal BMI | 21.13 ± 2.49 | 21.16 ± 3.04 | 21.73 ± 2.93 | 0.162 |
| Semen analysis | ||||
| Volume (ml) | 2.91 ± 1.59 | 2.83 ± 1.18 | 2.57 ± 1.42 | 0.167 |
| Count (x106/ml) | 91.85 ± 43.72 a | 93.62 ± 58.41 a | 66.48 ± 66.50 b | < 0.001 |
| Morphology, strict | 6.14 ± 2.36 a | 6.68 ± 2.86 a | 4.25 ± 3.57 b | < 0.001 |
| Motility | 47.90 ± 15.46 a | 48.56 ± 16.75 a | 37.99 ± 21.11 b | < 0.001 |
| Hormonal profile | ||||
| Basal FSH (u/ml) | 7.17 ± 2.76 | 7.49 ± 5.08 | 7.28 ± 3.58 | 0.886 |
| Basal LH (u/ml) | 4.18 ± 4.01 | 3.06 ± 1.71 | 3.83 ± 3.08 | 0.127 |
| Basal E2 (pg/ml) | 28.25 ± 14.29 | 28.41 ± 21.74 | 30.44 ± 24.19 | 0.729 |
| Fetal gestational age at D&E (days) | 59.66 ± 8.23 | 61.00 ± 7.51 | 60.98 ± 7.77 | 0.300 |
| Previous pregnancy status (n) | ||||
| Parity | 1.63 ± 1.47a | 1.32 ± 1.51a,b | 0.99 ± 1.18b | 0.001 |
| Abortion | 1.11 ± 1.21a | 0.61 ± 0.98b | 0.49 ± 0.66b | < 0.001 |
| Rank | Tissues | Different developing flowers | Total | ||||||
| Gene name | Coefficient of correlation (r) | p-value | Gene name | Coefficient of correlation (r) | p-value | Gene name | Coefficient of correlation (r) | p-value | |
| 1 | EF1-α | 0.91 | 0.004 | FAD | 0.99 | 0.001 | EF1-α | 0.94 | 0.001 |
| 2 | RPL3 | 0.90 | 0.005 | EF1-α | 0.99 | 0.001 | FAD | 0.92 | 0.001 |
| 3 | 18S | 0.84 | 0.017 | EF1-γ | 0.95 | 0.003 | RPL3 | 0.91 | 0.001 |
| 4 | ACT5 | 0.80 | 0.031 | ACT5 | 0.95 | 0.004 | EF1-γ | 0.85 | 0.001 |
| 5 | FAD | 0.79 | 0.034 | NAC | 0.94 | 0.006 | 18S | 0.81 | 0.001 |
| 6 | NAC | 0.62 | 0.139 | ACT7 | 0.93 | 0.007 | ACT7 | 0.79 | 0.001 |
| 7 | EF1-γ | 0.62 | 0.141 | RPL3 | 0.92 | 0.010 | NAC | 0.76 | 0.003 |
| 8 | GAPDH | 0.59 | 0.168 | GAPDH | 0.88 | 0.021 | ACT5 | 0.73 | 0.005 |
| 9 | UBC | 0.51 | 0.241 | 18S | 0.83 | 0.040 | GAPDH | 0.66 | 0.013 |
| 10 | ACT7 | 0.42 | 0.350 | UBC | 0.33 | 0.523 | UBC | 0.35 | 0.241 |
| Location | X | Y | Z | Extent | Z-value |
| Univariate effect of degradation [((NV + SW)/2) > CL] | |||||
| Left inferior frontal gyrus (p. Opercularis) | −54 | 10 | 20 | 555 | 3.92 |
| Left precentral gyrus | −52 | 8 | 30 | 3.86 | |
| Left precentral gyrus | −46 | 2 | 28 | 3.80 | |
| Multivariate acoustic form coding | |||||
| Left posterior STG | −63 | −33 | 15 | 392 | 4.94 |
| Left mid-STG | −57 | −12 | 4 | 4.62 | |
| Left mid-anterior STG | −54 | −6 | −4 | 4.37 | |
| Right posterior STG | 54 | −42 | 15 | 254 | 4.13 |
| Right anterior STG | 57 | 12 | −8 | 3.99 | |
| Right supramarginal Gyrus | 54 | −36 | 26 | 3.83 | |
| Multivariate syllable identity coding | |||||
| Left mid-posterior left STG | −63 | −24 | 8 | 303 | 4.59 |
| Left mid-STG | −48 | −15 | 0 | 4.38 | |
| Left posterior STS | −57 | −39 | 8 | 4.21 | |
| Right posterior STG | 69 | −30 | 11 | 172 | 4.44 |
| Right posterior STG | 57 | −27 | 8 | 4.19 | |
| Right mid-STG | 63 | −18 | 0 | 3.99 | |
| Left precentral gyrus | −51 | 0 | 41 | 83 | 4.39 |
| Left postcentral gyrus | −60 | −3 | 38 | 3.97 |
| Lineage | ρ (no. of crossovers/Mbp/generation) on chromosomea | % homoplastic SNPs | phi test P value | |||||||
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | Mean | |||
| 1 | 8.6* | 3.8* | 15.1* | 1.4 | 8.5* | 10.6* | 13.5* | 10.57 | 34.56 | 0.0000 |
| 2 | 0.0 | 0.2 | 0.2* | 0.3 | 0.6 | 0.5 | 0.3 | 0.28 | 0.09 | 0.0944 |
| 3 | 0.4* | 0.2* | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.01 | 0.47 | 0.0535 |
| 4 | 0.2 | 0.2* | 0.3 | 0.4 | 0.4 | 0.4 | 0.4 | 0.33 | 0.40 | 0.0014 |
| Author | Age and sex | Mechanism | Fielding type | Associated injuries | Duration to diagnosis | Reduction method and treatment | Results |
| Castel et al., 2001 [4] | 41 M | Rugby injury | I | (—) | 1 month | Reduction and Minerva jacket | Good |
| Fuentes et al., 2001 [5] | 24 M | Suicidal jump | IV | Initial odontoid fracture only | 1 month | C1-C2 fusion | Unknown |
| Kim et al., 2007 [8] | 34 M | Fall down from high place | II | Lt superior facet fracture of C2 | 1 day | C1-C2 fusion | Good |
| Sinigaglia et al., 2008 [11] | 26 F | Road traffic accident | I | (—) | 45 days | Reduction and halo vest | Fair; because of cervical stiffness and headache |
| 21 F | Road traffic accident | I | (—) | 1 day | Reduction and halo vest | Good | |
| 29 M | Road traffic accident | I | (—) | 1 day | Reduction and rigid collar | Good | |
| Wang et al., 2008 [14] | 44 F | Not described | I | (—) | 6 months | Immobilization with halo vest | Poor; because of bilateral hand numbness |
| Goel et al., 2010 [6] | 28 M | Fall down from high place | Not described | Odontoid fracture | 1 day | Intraoperative facet manipulation | Good |
| Singh et al., 2009 [10] | 25 F | Road traffic accident | I | (—) | 0 day | Skull traction and halo brace | Good |
| Jeon et al., 2009 [7] | 25 F | Road traffic accident | I | Thoracic fractures, alar ligament injury | 5 days | Immobilization with Philadelphia brace | Good |
| Stenson, 2011 [12] | 31 F | Falling backward | I | (—) | 0 day | Immobilization with hard collar | Good |
| Marti et al., 2011 [9] | 24 F | Stretching neck herself | I | (—) | 1 day | Reduction and halo vest | Good |
| Venkatesan et al., 2012 [13] | 20 F | Road traffic accident | I | (—) | 0 day | Skull traction and hard collar | Fair; because of occipital pain |
| 52 F | Road traffic accident | I | (—) | 0 day | Halo traction and hard collar | Fair; because of occipital pain |
| DDI, min. | Blood Loss (mls) | Hospital Stay (days) | ||||||
| <1000 | >1000 | COR(95% CI) | AOR(95% CI) | ≤4 | >4 | COR(95% CI) | AOR(95% CI) | |
| DDI | ||||||||
| < 30 | 72(98.6) | 1(1.4) | 1 | 1 | 59(12.6) | 14(10.9) | 1 | |
| 30–75 | 288(99.7) | 1(0.3) | 0.25[0.02–4.05] | 0.55[0.03–10.3] | 231(49.3) | 58(44.9) | 1.06[0.55–2.03] | 0.76[0.36–1.61] |
| > 75 | 235(99.6) | 1(0.4) | 0.31[0.0–4.96] | 3.21[0.02–653.9] | 179(38.1) | 57(44.2) | 1.34[0.7–2.58] | 0.78[0.32–1.81] |
| 30 min | ||||||||
| ≤ 30 | 72(98.6) | 1(1.4) | 1 | 1 | 59(12.6) | 14(10.9) | 1 | 1 |
| > 30 | 523(99.6) | 2(0.4) | 0.28[0.02–3.07] | 0.55[0.03–10.3] | 410(87.4) | 115(89.1) | 1.18[0.64–2.19] | 0.76[0.36–1.62] |
| 75 min | ||||||||
| ≤ 75 | 360(99.4) | 2(0.6) | 1 | 1 | 290(61.8) | 72(55.8) | 1 | 1 |
| > 75 | 235(99.6) | 1(0.4) | 0.77[0.07–8.49] | 5.79[0.05–7.18] | 179(38.2) | 57(44.2) | 1.28[0.86–1.9] | 1.02[0.63–1.64] |
| Filter type | Central Frequency,f0 | Rotation Variation Parameter,c | Half Central Bandwidth, bw | Number of Comb Teeth,n |
| Comblet filter: BSF | 127.178 Hz | 2% | 1.272 Hz | 100 |
| Comblet filter: BPFI | 308.242 Hz | 2% | 3.082 Hz | 41 |
| Comblet filter: BPFO | 171.758 Hz | 2% | 1.718 Hz | 74 |
| Comblet filter: FTF | 28.626 Hz | 2% | 0.286 Hz | 447 |
| SNP | Group | WT/HT/MT | Genotypes OR (95%CI)* | P-HWE | ||
| Additive | Dominant | Recessive | ||||
| rs1065780 | Control | 661/1091/455 | 0.974(0.89-1.065) | 0.984(0.857-1.129) | 0.942(0.806-1.102) | 0.901 |
| (A>G) | Case | 607/1001/404 | P=0.562 | P=0.814 | P=0.457 | |
| rs2854843 | Control | 964/991/254 | 1.058(0.963-1.163) | 1.105(0.972-1.255) | 1.007(0.827-1.226) | 0.977 |
| (T>C) | Case | 829/949/234 | P=0.243 | P=0.126 | P=0.942 | |
| rs1874479 | Control | 1461/666/80 | 1.057(0.944-1.184) | 1.063(0.931-1.214) | 1.094(0.782-1.53) | 0.704 |
| (A>G) | Case | 1290/646/76 | P=0.339 | P=0.363 | P=0.599 | |
| rs3110697 | Control | 1299/771/133 | 1.099(0.99-1.22) | 1.176(1.035-1.336) | 0.908(0.691-1.192) | 0.194 |
| (G>A) | Case | 1115/785/110 | P=0.076 | P=0.013 | P=0.486 | |
| rs13223993 | Control | 939/1007/259 | 1.052(0.957-1.156) | 1.093(0.962-1.243) | 1.011(0.832-1.228) | 0.66 |
| (G>A) | Case | 810/960/240 | P=0.291 | P=0.173 | P=0.915 | |
| rs2132572 | Control | 1505/622/77 | 1.167(1.041-1.309) | 1.235(1.081-1.411) | 0.992(0.703-1.399) | 0.202 |
| (C>T) | Case | 1283/654/72 | P=0.008 | P=0.002 | P=0.962 | |
| rs2453839 | Control | 1363/738/105 | 1.105(0.993-1.23) | 1.117(0.982-1.271) | 1.192(0.895-1.587) | 0.691 |
| (T>C) | Case | 1196/703/112 | P=0.066 | P=0.093 | P=0.23 |
| Program participation rate (%) | Projected number of participants | Total DME program costs | Total medical care cost savings | Medical cost savings net of program cost in 26 counties |
| 5 | 9,365 | $6,087,250 | $18,486,510 | $12,399,459 |
| 10 | 18,730 | $12,174,500 | $36,973,020 | $24,798,917 |
| 15 | 28,095 | $18,261,750 | $55,459,530 | $37,198,376 |
| 20 | 37,461 | $24,349,650 | $73,948,014 | $49,597,834 |
| 50 | 93,652 | $60,873,800 | $184,869,048 | $123,994,586 |
| 75 | 140,477 | $91,310,050 | $277,301,598 | $185,991,879 |
| S/N | Demographic characteristics | No of cases | Percentage | Chi square test | P Value |
| 1 | Age:a. up to 20 yearsb. 21-40 yearsc. 41 years and above | 3417 | 5.8880.3913.75 | 79.411737.686253.6862 | |
| 2 | Parity:a. Para 0-1b. 2-4c. 5 and above | 61629 | 11.7631.3756.86 | 59.647014.15681.9215 | 0.050.5 |
| 3 | Booking Status:a. Bookedb. unbooked | 1338 | 25.4974.50 | 24.5101 | 0.001 |
| 4 | Referral status:a. Referred from other placesb. within hospital | 3912 | 76.4723.52 | 28.5882 | 0.001 |
| 5 | Level of medical person dealing:a. Paramedics LHV/Nursesb. medical officerc. resident doctord. senior resident | 211893 | 41.1735.2917.645.88 | 3.17648.823542.705879.4111 | 0.5 0.5 |
| Feature | CD163p | CD163i | |||||
| Freq N (%) | P-value | Freq N (%) | P-value | ||||
| Low | High | Low | High | ||||
| Gender | Female | 28 (47.5) | 23 (46.0) | 1.0 | 24 (44.4) | 25 (48.1) | 0.7121 |
| Male | 31 (52.5) | 27 (54.0) | 30 (55.6) | 27 (51.9) | |||
| Grade | G1-2 | 6 (10.0) | 6 (12.2) | 0.7179 | 4 (7.3) | 8 (15.1) | 0.4874 |
| G3 | 54 (90.0) | 33 (87.8) | 51 (92.7) | 45 (84.9) | |||
| pT | pT1-2 | 8 (13.3) | 7 (14.0) | 1.0 | 1 (1.8) | 12 (23.1) | 0.0069 |
| pT3 | 52 (86.7) | 43 (86.0) | 54 (98.2) | 40 (76.9) | |||
| pN | pN0 | 13 (21.7) | 5 (10.0) | 0.2041 | 10 (18.2) | 9 (17.0) | 0.8366 |
| pN1 | 47 (78.3) | 25 (90.0) | 45 (81.8) | 44 (83.3) | |||
| pM | pM0 | 36 (61.1) | 29 (58.0) | 1.0 | 30 (54.5) | 29 (54.7) | 0.7179 |
| pM1 | 23 (38.9) | 21 (42.0) | 25 (45.5) | 24 (45.3) | |||
| L | L0 | 12 (19.7) | 3 (6.1) | 0.1942 | 7 (12.7) | 9 (16.9) | 0.6607 |
| L1 | 49 (80.3) | 46 (93.9) | 48 (87.3) | 44 (83.1) | |||
| V | V0 | 47 (78.3) | 48 (96.0) | 0.0291 | 49 (89.1) | 43 (81.1) | 0.3567 |
| V1 | 13 (21.7) | 2 (4.0) | 6 (10.9) | 10 (19.9) | |||
| R | R0 | 43 (71.6) | 37 (75.5) | 0.7955 | 39 (70.9) | 41 (77.3) | 0.5523 |
| R1 | 17 (28.4) | 12 (24.5) | 16 (29.1) | 12 (22.7) | |||
| Chemotherapy | None | 1 (1.7) | 0 (0.0) | 1.0 | 0 (0.0) | 1 (1.9) | 1.0 |
| Yes | 59 (98.3) | 50 (100.0) | 55 (100.0) | 52 (98.1) | |||
| Radiotherapy | None | 32 (86.5) | 15 (83.3) | 1.0 | 23 (92.0) | 24 (80.0) | 0.2689 |
| Yes | 5 (13.5) | 3 (16.7) | 2 (8.0) | 6 (20.0) | |||
| Budding 10-in-10 | Low | 13 (21.6) | 24 (48.0) | 0.0155 | 17 (30.9) | 17 (32.1) | 1.0 |
| High | 47 (78.4) | 26 (52.0) | 38 (69.1) | 36 (67.9) | |||
| ITB (per punch) | Low | 19 (31.6) | 27 (57.1) | 0.0253 | 19 (34.5) | 25 (47.1) | 0.365 |
| High | 41 (68.4) | 22 (42.9) | 36 (65.5) | 28 (52.9) | |||
| PTB (per punch) | Low | 24 (40.0) | 27 (56.0) | 0.0200 | 32 (58.1) | 18 (33.9) | 0.0349 |
| High | 36 (60.0) | 23 (44.0) | 23 (41.9) | 35 (66.1) | |||
| OS | Median (95%CI) | 10 (9–12) | 13 (10–15) | 0.0823 | 12 (9–15) | 11 (9–13) | 0.562 |
| DFI | Median (95%CI) | 5 (4–6) | 6 (4–8) | 0.3054 | 5 (4–6) | 6 (4–6) | 0.7789 |
| Adjusted odds ratio (95% CI) of new-onset depression | ||||
| Women (N = 10,178) | Men (N = 30,041) | |||
| Complete case analysis | Weighted for non- response | Complete case analysis | Weighted for non- response | |
| Deployment experience | ||||
| Nondeployed | 1.00 | 1.00 | 1.00 | 1.00 |
| Deployed without combat exposures | 0.65 (0.47, 0.89) | 0.61 (0.44, 0.84) | 0.66 (0.53, 0.83) | 0.65 (0.52, 0.83) |
| Deployed with combat exposures | 2.13 (1.70, 2.65) | 1.99 (1.58, 2.50) | 1.32 (1.13, 1.54) | 1.31 (1.12, 1.55) |
| Smoking status | ||||
| Never smoker | 1.00 | 1.00 | 1.00 | 1.00 |
| Past smoker | 1.30 (1.09, 1.55) | 1.34 (1.11, 1.62) | 1.18 (1.02, 1.36) | 1.23 (1.06, 1.43) |
| Current smoker | 1.35 (1.10, 1.66) | 1.42 (1.14, 1.78) | 1.52 (1.31, 1.77) | 1.57 (1.33, 1.85) |
| Problem drinking | ||||
| No | 1.00 | 1.00 | 1.00 | 1.00 |
| Yes | 1.27 (1.03, 1.57) | 1.31 (1.04, 1.63) | 1.19 (1.04, 1.37) | 1.23 (1.06, 1.43) |
| Posttraumatic stress at baseline | ||||
| No | 1.00 | 1.00 | 1.00 | 1.00 |
| Yes | 2.98 (2.07, 4.28) | 3.04 (2.09, 4.43) | 4.29 (3.34, 5.50) | 3.91 (2.98, 5.13) |
| Active sites of catalytic triad | HRV-C2 | HRV2 | EV71 | PV | CVB4 | CVB3 | CVA16 |
| Cys | 105 | 106 | 110 | 109 | 110 | 110 | 110 |
| His | 34 | 18 | 21 | 20 | 21 | 18 | 21 |
| Asp | 18 | 35 | 39 | 38 | 39 | 35 | 39 |
| Accession numbers | Gene symbols | Fold change | ||
| LEC | Limbus | Cornea | ||
| WNT signalling pathway | ||||
| NM_016269 | LEF1 | (1.2) | - | - |
| NM_006261 | CDH1 | (5.3) | - | (-5.8) |
| NM_013263 | BRD7 | (-4.0) | (1.8) | (4.0) |
| NM_001892 | CSNK1A1 | - | (4.6) | - |
| AF267864 | TBL1XR1 | - | - | (1.9) |
| NM_003507 | FZD7 | - | - | (2.0) |
| NM_022825 | PORCN | - | - | (2.0) |
| NM_018890 | RAC1 | (-3.0) | - | (3.0) |
| NM_001320 | CSNK2B | (-2.6) | - | (2.6) |
| NM_014248 | RBX1 | (5.6) | (-5.6) | |
| Notch Signalling pathway | ||||
| NM_014276 | RBPJL | (-3.9) | - | (3.9) |
| NM_005524 | HES1 | (-1.5) | - | (2.1) |
| NM_203283 | RBPJ | - | - | (4.6) |
| NM_033632 | FBXW7 | (-6.1) | - | (6.1) |
| JAK/STAT Signalling pathway | ||||
| NM_004232 | SOCS6 | - | - | (3.9) |
| U52912 | LEPR | (-3.4) | (-2.2) | (3.4) |
| U52914 | LEPR | - | - | (2.3) |
| AJ271736 | IL9R | - | (-4.2) | (4.2) |
| NM_000565 | IL6R | - | (-8.7) | (8.7) |
| NM_003150 | STAT3 | - | - | (1.7) |
| NM_000297 | PKD2 | (-2.8) | - | (2.8) |
| NM_014432 | IL20RA | (-4.2) | - | (4.2) |
| TGF-Beta Signalling pathways | ||||
| NM_002165 | ID1 | (-3.6) | (1.5) | (3.6) |
| NM_006350 | FST | - | - | (2.4) |
| NM_014248 | RBX1 | (5.6) | - | (-5.6) |
| NM_002165 | ID1 | (-3.6) | (1.5) | (3.6) |
| BMP Signalling pathway | ||||
| AL096865 | RUNX2 | (-2.4) | - | (2.4) |
| NM_006350 | FST | - | - | (2.4) |
| Hedgehog signalling pathway (HH) | ||||
| NM_001892 | CSNK1A1 | - | (4.5) | - |
| NM_016004 | IFT52 | - | (2.5) | - |
| NM_005870 | SAP18 | (-5.3) | (-3.7) | (6.2) |
| β | SE | OR | CI | P | |
| Age (>1–7 Years) | 0.489 | 0.294 | 1.63 | 0.916–2.903 | 0.097 |
| Cats per household (>1) | −0.714 | 0.292 | 0.49 | 0.276–0.869 | 0.015 |
| Body condition (Regular-bad) | 0.928 | 0.338 | 2.53 | 1.306–4.904 | 0.006 |
| Patient Group | P53 expression | χ2 | P value | |
| (No. of cases) | (+) | (-) | ||
| Grade I (14) | 0 | 14 | 6.568 | 0.037 |
| Grade II (10) | 2 | 8 | ||
| Grade III (16) | 6 | 10 |
| Arlee | Clearwater | Skamania | Swanson | Whale rock | |
| Arlee | - | 2292 | 1460 | 1180 | 1628 |
| Clearwater | (3300) | - | 1425 | 1283 | 2412 |
| Skamania | (2109) | (2156) | - | 792 | 1486 |
| Swanson | (1722) | (1846) | (1197) | - | 1182 |
| Whale Rock | (2359) | (3451) | (2191) | (1716) | - |
| Molecule | FICa |
| Caspofungin | 0.27 (0.10) |
| CP29 | 0.54 (0.07) |
| DmAMP1 | 0.19 (0.00) |
| Fluconazole | 1.00 (0.00) |
| HbD2 | 0.71 (0.31) |
| HST5 | 0.67 (0.07) |
| LL37 | 0.49 (0.16) |
| NaD2 | 0.69 (0.11) |
| Strain (No. of Strains) | a FOX | a E | a DA | a T | a C | a CIP | a CN | a RIF | a LNZ | a SXT |
| S. epidermidis (32) | 25/78.1 | 18/56.3 | 26/81.3 | 25/78.1 | 32/100 | 32/100 | 31/96.9 | 32/100 | 31/96.9 | 23/71.9 |
| S. haemolyticus (31) | 26/83.9 | 14/45.2 | 19/61.3 | 26/83.9 | 25/80.6 | 27/87.1 | 28/90.3 | 31/100 | 31/100 | 18/58.1 |
| S. capitis subsp. capitis (21) | 17/81 | 9/42.9 | 15/71.4 | 19/90.5 | 21/100 | 10/47.6 | 10/41.6 | 19/90.5 | 21/100 | 17/81 |
| S. hominis (11) | 10/90.9 | 4/36.4 | 9/81.8 | 6/54.5 | 9/81.8 | 11/100 | 11/100 | 11/100 | 11/100 | 8/72.7 |
| S. cohnii subsp. cohnii (9) | 7/77.8 | 5/55.6 | 5/55.6 | 5/55.6 | 9/100 | 9/100 | 9/100 | 9/100 | 9/100 | 5/55.6 |
| S. saprophyticus (5) | 5/100 | 1/20 | 4/80 | 5/100 | 5/100 | 5/100 | 5/100 | 5/100 | 5/100 | 3/60 |
| S. kloosii (4) | 4/100 | 2/50 | 3/75 | 1/25 | 3/75 | 4/100 | 4/100 | 4/100 | 4/100 | 4/100 |
| S. warneri (4) | 3/75 | 1/25 | 1/25 | 3/75 | 3/75 | 4/100 | 4/100 | 4/100 | 4/100 | 3/75 |
| S. cohnii subsp. urealyticum (2) | 2/100 | 0/0 | 1/50 | 1/50 | 2/100 | 2/100 | 2/100 | 2/100 | 2/100 | 1/50 |
| S. lugdunensis (1) | 1/100 | 1/100 | 1/100 | 1/100 | 1/100 | 1/100 | 1/100 | 1/100 | 1/100 | 1/100 |
| S. hyicus (1) | 1/100 | 1/100 | 1/100 | 1/100 | 1/100 | 1/100 | 1/100 | 1/100 | 1/100 | 0/0 |
| S. chromogenes (1) | 1/100 | 0/0 | 1/100 | 0/0 | 1/100 | 1/100 | 1/100 | 1/100 | 1/100 | 1/100 |
| Total (122)/% | 10/83.6 | 56/45.9 | 86/70.5 | 93/76.2 | 112/91.8 | 107/87.7 | 107/87.7 | 120/98.4 | 121/99.2 | 84/68.9 |
| OR (95% CI) | ||||
| Exposure | n (cases/total) | Unadjusted model 1 | Adjusted model 2b | Adjusted model 3c |
| Periconceptional CO | ||||
| Categorized by quartiles (ppm) | ||||
| 0.09–0.59 | 21/878 | 1.00 (Referent) | 1.00 (Referent) | 1.00 (Referent) |
| 0.60–0.80 | 27/877 | 1.30 (0.73–2.31) | 1.44 (0.79–2.62) | 1.04 (0.55–1.96) |
| 0.81–1.02 | 30/877 | 1.45 (0.82–2.54) | 1.65 (0.91–3.00) | 0.86 (0.42–1.75) |
| 1.03–3.73 | 39/877 | 1.90 (1.11–3.26) | 2.08 (1.16–3.72) | 0.75 (0.42–1.64) |
| Per 0.1-ppm increase | 1.07 (1.02–1.12) | 1.07 (1.02–1.13) | 0.98 (0.91–1.06) | |
| Periconceptional PM2.5 | ||||
| Categorized by quartiles (μg/m3) | ||||
| 5.9–8.7 | 31/878 | 1.00 (Referent) | 1.00 (Referent) | 1.00 (Referent) |
| 8.8–10.1 | 24/877 | 0.77 (0.45–1.32) | 0.79 (0.45–1.39) | 0.78 (0.43–1.41) |
| 10.2–11.4 | 32/882 | 1.03 (0.62–1.70) | 1.50 (0.80–2.81) | 1.38 (0.71–2.70) |
| 11.5–15.1 | 30/872 | 0.97 (0.58–1.62) | 1.63 (0.79–3.38) | 1.41 (0.63–3.18) |
| Per 0.5-μg/m3 increase | 1.00 (0.94–1.05) | 1.04 (0.95–1.12) | 1.02 (0.93–1.12) |
| Plant Age (Weeks) | Free PAA pmol (g FW)−1 | Free IAA pmol (g FW)−1 |
| Two weeks | 98 ± 6.4 | 35 ± 2.7 |
| Six weeks | 23 ± 2 | 15 ± 1 |
| Misclassification cost setting 5:1, post-pruning confidence 1% | ||
| Classified as | ||
| Observed | SN | Non-SN |
| SN | 0 | 34 |
| Non-SN | 0 | 815 |
| Misclassification cost setting 10:1, post-pruning confidence 1% | ||
| Classified as | ||
| Observed | SN | Non-SN |
| SN | 8 | 26 |
| Non-SN | 66 | 749 |
| Misclassification cost setting 25:1, post-pruning confidence 50% | ||
| Classified as | ||
| Observed | SN | Non-SN |
| SN | 31 | 3 |
| Non-SN | 18 | 797 |
| Reference | Type of study | Subjects/number of studies | Results |
| Knutson et al. (72) | Cohort study and longitudinal, blood pressure and actigraphic sleep measured at 5-year intervals | 578 AA and White | Reduced sleep predicted higher BP and adverse change in BP; sleep duration appeared to mediate racial differences in diastolic BP |
| Knutson (54) | National surveys, self-report | 8 surveys conducted over 31 years | AAs consistently more likely to report short sleep duration than any other racial group |
| Vishnu et al. (73) | Cross-sectional survey, self-report | 369,217 multi-ethnic US subjects | Strongest correlation between insufficient sleep and CHD found in AAs |
| Ruiters et al. (66) | Meta-analysis, variable methods including subjective and objective measures of sleep | 14 studies | AAs had poorer sleep continuity and duration, less slow wave sleep, and a greater proportion of stage 2 sleep |
| Jean-Louis et al. (74) | National Health Interview Survey, 1977–2009, cross-sectional, face to face interviews | All ethnicities surveyed but restricted to Black and White participants | Among Black, very short sleepers 76% increased risk of overweight and 81% increased risk of obese |
| Halder et al. (68) | Cohort study using PSQI and in home polysomnography, correlation with % African genetic ancestry | 70 AA and 101 European-American | % African ancestry correlated with lower percentage slow wave sleep but not sleep duration or efficiency |
| Curtis et al. (63) | Cross-sectional, actigraphic sleep | 426 Midwestern US adults with oversampling of AAs | AA obtained less sleep and had lower sleep efficiency. Sleep duration predicted 41% of cardiometabolic risk factor variance |
| Johnson et al. (67) | Cross-sectional analysis, self-report | 5,301 AAs in the Jackson Heart Study | 54% reported <6 h sleep, 5% >9 h sleep. Social and environmental characteristics associated with sleep duration |
| Riestra et al. (70) | Cross-sectional analysis | 2,962 AA participants | A SNP in the CLOCK gene associated with sleep duration after multifactorial adjustments |
| Interest learning MBP (%) | Interest in participating in study of MBP during MHD (%) | |
| Total (n = 89) | 70 | 74 |
| Age (years) | ||
| 18–34 | 100 | 100 |
| 35–49 | 54 | 69 |
| 50–64 | 71 | 74 |
| 65–79 | 78 | 78 |
| ≥80 | 46 | 46 |
| Gender | ||
| Female | 74 | 74 |
| Males | 66 | 75 |
| Race | ||
| White | 54 | 65 |
| Black | 76 | 74 |
| Other | 71 | 100 |
| Dialysis Vintage (years) | ||
| <1 | 75 | 79 |
| 1–4 | 68 | 74 |
| 5–9 | 78 | 89 |
| ≥10 | 50 | 50 |
| Ever used CAM use | ||
| No | 62 | 54 |
| Yes | 74 | 87 |
| Processing procedure | P(%) | R(%) | F(%) |
| (1): only candidate drugs replaced | 75.9 | 68.7 | 71.5 |
| (2): basic processing | 77.5 | 72.3 | 74.8 |
| (3): (2) + Following anaphora | 76.9 | 76.5 | 76.7 |
| (4): (3) + Pruned Sentences | 78.4 | 76.2 | 77.3 |
| ASA Respondents (n = 209) | ESA Respondents (n = 165) | |
| Answer Options | Response Percent | Response Percent |
| Blood pressure | 88.5% | 77.6% |
| Urine output | 83.3% | 77.0% |
| Clinical experience | 77.5% | 64.8% |
| Central venous pressure | 70.8% | 64.2% |
| Cardiac output | 49.3% | 53.3% |
| Pulse Pressure Variation or Systolic Pressure Variation | 45.0% | 55.8% |
| Transesophageal echocardiography | 43.5% | 28.5% |
| Pulmonary capillary wedge pressure | 38.8% | 24.2% |
| Plethysmographic Waveform Variation | 25.4% | 25.5% |
| Stroke Volume Variation | 19.1% | 36.4% |
| Mixed venous saturation (ScvO2) | 18.7% | 21.8% |
| Global end diastolic volume | 10.5% | 17.0% |
| Central venous saturation (SvO2) | 10.0% | 34.5% |
| A MSC | BM MSC | COMMON | |
| INHIBITION OF MMP | A2M, MMP2, TIMP1, TIMP2 | A2M, MMP2, TIMP2 | A2M, MMP2, TIMP2 |
| EPITHELIAL ADHERENS JUNCTION | ACTN1, ACTN4, ACTR2, MYH9, TUBA1C, TUBB, VCL | ACTN1, ACTN4, ACTR2, ARPC3, IQGAP1, MYH9, TUBB, VCL | ACTN1, ACTN4, ACTR2, MYH9, TUBB, VCL |
| REMODELING OF EPITHELIAL ADHERENS JUNCTION | ACTN1, ACTN4, ACTR2, TUBA1C, TUBB, VCL | ACTN1, ACTN4, ACTR2, IQGAP1, NME1, TUBB, VCL | ACTNI, ACTN4, ACTR2, TUBB, VCL |
| GERM CELL SERTOLI JUNCTION | A2M, ACTN1, ACTN4, TUB1AC, TUBB, VCL | A2M, ACTN1, ACTN4, CFL1, IQGAP1, TUBB, VCL | A2M, ACTN1, ACTN4, TUBB, VCL |
| ACTIN CYTOSKELETON | ACTN1, ACTN4, ACTR2, EZR, MSN, MYH9, PFN1, TLN1, VCL | ACTN1, ACTN4, ARPC3, CFL1, FN1, IQGAP1, MSN, PFN1, RDX, VCL | ACTN1, ACTN4, MSN, PFN1, VCL |
| HEPATIC FIBROSIS | A2M, COL1A1, COL1A2, COL3A1, COL6A2, FN1, IGFBP3, MMP2, MYH9, SERPINE1, TIMP1, TIMP2 | A2M, COL1A1, COL1A2, COL3A1, FN1, IGFBP3, MMP2, MYH9, SERPINE1, TIMP2 | A2M, COL1A1, COL1A2, COL3A1, FN1, IGFBP3, MMP2, MYH9, SERPINE1, TIMP2 |
| PROTEIN UBIQUITINATION | HSP90AA1, HSP90AB1, HSP90B1, HSPA5, HSPA8, HSPB1, HSPD1, PSMA1, PSMA3, PSMA5, PSMA6 | HSP90AA1, HSP90AB1, HSP90B1, HSPA4, HSPA5, HSPA8, HSPB1, HSPD1, PSMA5, PSMB1, PSMB4, PSMB5, PSMB6 | HSP90AA1, HSP90AB1, HSP90B1, HSPA8, HSPD1, PSMA5 |
| RHOA SIGNALING | ACTR2, EZR, MSN, PFN1 | ACRT2, ARPC3, CFL1, MSN, PFN1 | ACTR2, MSN, PFN1 |
| LEUCOCYTE EXTRAVASATION | ACTN1, ACTN4, EZR, GNAI2, MMP2, MSN, TIMP1, TIMP2, VCL | ACTN1, ACTN4, MMP2, MSN, RDX, TIMP2, VCL | ACTN1, ACTN4, MMP2, MSN, TIMP2, VCL |
| Parameters | Case report [2] | Case report [3] | Our case report |
| Age | 76 years | 55 years | 55 years |
| Circumcision | Uncircumcised | Delayed circumcision | Infantile circumcision |
| Site of stricture | Bulbar urethral stricture | Bulbar urethral stricture | Penile and bulbar urethral strictures |
| Time to develop malignancy | 4 months | 3 months | 5 years |
| Presentation | Ulcerative lesion at glans penis | Penile periurethral mass | Ventral penile masses involving glans and whole exteriorised urethra, with associated scrotal wall changes |
| Treatment | Partial penectomy | Total penectomy | Total penectomy |
| O/E ratios | |||||
| hospital | n. deliveries | Model 1 | Model 2 | Model 3 | Model 4 |
| 1 | 3000 | 1.23 | 1.22 | 1.25 | 1.25 |
| 2 | 1710 | 1.22 | 1.22 | 1.25 | 1.24 |
| 3 | 1513 | 0.98 | 0.98 | 1.01 | 1.00 |
| 4 | 473 | 1.30 | 1.30 | 1.40 | 1.40 |
| 5 | 1869 | 0.98 | 0.98 | 1.09 | 1.07 |
| 6 | 1914 | 0.97 | 0.97 | 1.02 | 1.02 |
| 7 | 1558 | 1.18 | 1.18 | 1.25 | 1.24 |
| 8 | 510 | 1.39 | 1.38 | 1.44 | 1.43 |
| 9 | 3735 | 0.68 | 0.68 | 0.71 | 0.71 |
| 10 | 1364 | 0.83 | 0.83 | 0.84 | 0.82 |
| 11 | 1085 | 0.66 | 0.66 | 0.74 | 0.73 |
| 12 | 2501 | 1.09 | 1.08 | 1.09 | 1.08 |
| 13 | 6408 | 0.92 | 0.92 | 0.89 | 0.89 |
| 14 | 2315 | 1.16 | 1.16 | 1.15 | 1.15 |
| 15 | 1289 | 0.98 | 0.99 | 0.99 | 1.05 |
| 16 | 1687 | 0.69 | 0.69 | 0.74 | 0.79 |
| 17 | 3271 | 1.05 | 1.05 | 1.02 | 1.02 |
| 18 | 2337 | 0.76 | 0.76 | 0.78 | 0.78 |
| 19 | 2033 | 0.77 | 0.77 | 0.79 | 0.79 |
| 20 | 3456 | 1.04 | 1.04 | 1.05 | 1.04 |
| 21 | 4837 | 0.75 | 0.75 | 0.76 | 0.76 |
| 22 | 6195 | 1.04 | 1.04 | 0.98 | 0.98 |
| 23 | 2370 | 0.98 | 0.98 | 1.05 | 1.05 |
| 24 | 781 | 1.41 | 1.40 | 1.35 | 1.34 |
| 25 | 5520 | 1.17 | 1.17 | 1.17 | 1.17 |
| 26 | 5402 | 0.89 | 0.89 | 0.89 | 0.88 |
| 27 | 7240 | 1.03 | 1.03 | 1.06 | 1.06 |
| 28 | 7916 | 1.18 | 1.18 | 1.12 | 1.13 |
| 29 | 3285 | 0.91 | 0.92 | 0.87 | 0.87 |
| Tree | CT | CLADHC | HT | SbST |
| 1 | 89.1 (3.5) | 91.2 (5.6) | 89.5 (3.9) | |
| 2 | 94.0 (3.8) | 92.7 (4.1) | 87.6 (5.6) | |
| 3 | 79.3 (3.2) | 88.9 (4.7) | 86.2 (4.7) | |
| 4 | 88.7 (2.3) | 85.7 (3.1) | 87.8 (4.6) | |
| 5 | 85.6 (4.3) | 90.5 (4.5) | 94.0 (4.1) | |
| 6 | 78.6 (3.0) | 81.6 (3.3) | 67.0 (4.2) | |
| 7 | 92.4 (3.8) | 90.5 (3.7) | 87.8 (5.2) | |
| 8 | 98.6 (2.8) | 91.2 (4.7) | 99.6 (4.5) | |
| 9 | 89.2 (4.5) | 91.2 (4.8) | 89.1 (4.1) | |
| 10 | 82.8 (3.0) | 81.3 (4.1) | 79.1 (3.5) | |
| Average | 89,38 (3.4) | 89.35 (3.7) | 88,28 (4.8) | |
| Std dev.a | 6.71 (0.6) | 5.2 (0.6) | 3.06 (0.5) | 9.81 (0.5) |
| Area | Bjørndalen | Sverdrup | |||
| Samples | Bd1 | Bd2 | Bd3 | Bd4 | Sv1, Sv2 |
| Type | Spring water | Thaw water | Mix upstream | Mix downstream | Mat and sediment |
| pH | 2.8 | 6.2 | 3.5 | 3.8 | 2.3 |
| °C (water) | 9 | 7 | 7 | 7 | 4 |
| °C (air) | 6 | 6 | 6 | 6 | 4 |
| Na | 3.1 | 2.5 | 3 | 2.8 | 42 |
| K | 1.1 | 0.5 | 1.6 | 1.3 | 0.2 |
| Zn | 0.3 | Na | 0.1 | 0.07 | 5.1 |
| Ni | 0.1 | Na | 0.03 | 0.02 | 1.3 |
| Mg | 5.4 | 1.3 | 2.6 | 2.3 | 145 |
| Ca | Na | Na | Na | Na | 10 |
| Mn | 0.4 | Na | 0.2 | 0.1 | 9.7 |
| Cu | 0.03 | Na | Na | Na | 0.8 |
| Al | 3.4 | Na | 1.8 | 0.9 | 76 |
| Fe total | 15 | Na | 2 | 2 | 883 |
| Fe2+ | 9 | Na | 1 | 1 | 183 |
| Fe3+ | 6 | Na | 1 | 1 | 700 |
| SO42− | 110 | 10 | 54 | 32 | 1543 |
| Samplelabel | Addedeuropium(%wt) | Ca content(at%) | P content(at%) | Eu content(at%) | Ca+Eu/Pratio |
| HAP | 0 | 6.96 | 5.14 | 0 | 1.35 |
| HAPEu3% | 3 | 9.96 | 8.11 | 0.16 | 1.25 |
| HAPEu5% | 5 | 13.67 | 10.61 | 0.69 | 1.35 |
| HAPEu10% | 10 | 14.44 | 11.03 | 1.43 | 1.44 |
| HAPEu20% | 20 | 10.38 | 7.32 | 2.60 | 1.78 |
| Total types | Total tokens | TTR | |
| Proper nouns (Sem1) | 699 | 9,516 | 0.073 |
| Basic level count nouns (Sem2) | 2,675 | 25,369 | 0.105 |
| Basic level mass nouns (Sem3) | 288 | 2,655 | 0.108 |
| Action words (Sem4a) | 228 | 1,419 | 0.161 |
| Non-basic level words (Sem4b) | 1,507 | 12,618 | 0.119 |
| N | % | |
| Mean Age = 37.5 (S.D.11) | ||
| Citizenship | ||
| Greek | 77 | 76.2 |
| Other | 24 | 23.8 |
| Marital status | ||
| Unmarried | 53 | 52.5 |
| Married | 19 | 18.8 |
| Divorced | 21 | 20.8 |
| Widow | 8 | 7.9 |
| Children | ||
| Yes | 62 | 61.4 |
| No | 39 | 38.6 |
| Occupation before detention | ||
| Employee | 59 | 58.4 |
| Student | 2 | 2.0 |
| Unemployed | 26 | 25.7 |
| Pensioner | 3 | 3.0 |
| Housework | 9 | 8.9 |
| Other | 2 | 2.0 |
| Education level | ||
| Compulsory | 36 | 35.6 |
| Secondary | 32 | 31.7 |
| Tertiary | 24 | 23.8 |
| Postgraduate | 9 | 8.9 |
| Category | Clinical attachment level (CAL) | Probing pocket depth (PD) |
| Severe periodontitis | ≥ 2 interdental sites with CAL ≥ 6 mm (not on same tooth) and | ≥ 1 interdental site with PD ≥ 5 mm |
| Moderate periodontitis | ≥ 2 interdental sites with CAL ≥ 4 mm (not on same tooth) or | ≥ 2 interdental sites with PD ≥ 5 mm (not on same tooth) |
| No-or-mild periodontitis | Neither “moderate” nor “severe” periodontitis |
| Rural(N = 2, 799) | Urban(1, 925) | |||
| Socioeconomic variables | Women(1333) % | Men(1466) % | Women(1 044) % | Men(881) % |
| Mean age in years(95 % CI) | 64.9(64.4, 65.5) | 64.1(63.6, 64.7) | 64.7(64.0, 65.4) | 62.65(62.0, 63.3) |
| Age group (years) | ||||
| 50–59 | 36.2 | 39.0 | 39.5 | 47.2 |
| 60–69 | 26.3 | 29.8 | 26.0 | 28.4 |
| 70–79 | 27.2 | 21.1 | 23.4 | 17.4 |
| 80+ | 10.3 | 10.2 | 11.2 | 7.0 |
| Educational level | ||||
| No formal education | 78.8 | 53.7 | 60.4 | 35.0 |
| Primary Education | 14.5 | 22.1 | 19.4 | 19.8 |
| Secondary education | 5.9 | 20.7 | 16.8 | 36.4 |
| University/postgraduate | 0.5 | 2.7 | 3.1 | 8.2 |
| Missing | 0.3 | 0.8 | 0.3 | 0.6 |
| Marital Status | ||||
| Never Married | 0.9 | 1.2 | 1.8 | 1.1 |
| Currently married/Cohabiting | 36.0 | 84.0 | 29.2 | 82.1 |
| Separated/Divorced | 16.4 | 7.4 | 20.5 | 9.3 |
| Widowed | 46.0 | 7.0 | 47.8 | 6.8 |
| Missing | 0.6 | 0.4 | 0.7 | 0.7 |
| Type of Worka | ||||
| Professional | 0.2 | 1.2 | 1.3 | 5.2 |
| Skilled agricultural and fishery workers | 67.4 | 82.5 | 42.4 | 61.0 |
| Technical | 4.6 | 5.1 | 10.3 | 13.5 |
| Elementary occupation | 10.2 | 2.2 | 29.1 | 10.1 |
| Missing | 17.7 | 9.1 | 16.9 | 10.2 |
| Socio-economic status | ||||
| Poorest | 27.5 | 27.0 | 11.8 | 6.0 |
| Poor | 27.2 | 22.9 | 14.0 | 10.8 |
| Middle | 23.3 | 22.4 | 17.1 | 15.0 |
| Upper fifth | 15.3 | 17.5 | 24.6 | 24.4 |
| Wealthiest | 6.6 | 10.2 | 32.2 | 43.6 |
| Missing | 0.1 | 0.0 | 0.4 | 0.2 |
| Type 45° | Type 60° | Type 75° | Type 90° | p-value | |
| KVPA,° | 5.1 (0.7) | 5.1 (0.9) | 5.1 (0.9) | 4.4 (1.0) | p1* = 0.017 |
| p2* = 0.004 | |||||
| p3* = 0.001 | |||||
| mMDFA,° | 94.0 (1.2) | 93.3 (2.1) | 94.3 (2.0) | 95.0 (1.6) | p4* = 0.031 |
| p5* = 0.008 | |||||
| p6* = 0.001 | |||||
| HKA,° | 179.8 (2.3) | 179.3 (2.1) | 179.6 (2.5) | 181.3 (2.5) | p7* = 0.049 |
| p8* = 0.001 | |||||
| p9* = 0.004 |
| Target | Accession Number | Forward Primer | Reverse Primer |
| Cyp2a4 | NM_009997 | GGAAGACGAACGGTGCTTTC | CCCGAAGACGATTGAGCTAATG |
| Cyp3a11 | NM_007818 | CGCCTCTCCTTGCTGTCACA | CTTTGCCTTCTGCCTCAAGT |
| Cyp2c37 | NM_010001 | ATACTCTATATTTGGGCAGG | GTTCCTCCACAAGGCAAC |
| Cyp2c39 | NM_010003 | GGAGACAGAGCTGTGGC | TAAAAACAATGCCAAGGCCG |
| Cyp2d22 | NM_019823 | GGGCCTTTGTTACCATGTTGG | TACTCGGCGCTGCACATCTG |
| β-actin | NM_007393 | TGTTACCAACTGGGACGACA | GGGGTGTTGAAGGTCTCAAA |
| Surveillance site | Diarrhoea cases | Total | |||||||
| Non-diarrhoea cases | Rotavirusdiarrhoea | Cholera | Non-rotavirus and non-cholera diarrhoea | ||||||
| No. | % | No. | % | No. | % | No. | % | ||
| Bakerganj | 163 | 63.7 | 31 | 12.1 | 27 | 10.5 | 35 | 13.7 | 256 |
| Mathbaria | 163 | 60.0 | 38 | 14.0 | 23 | 8.5 | 48 | 17.7 | 272 |
| Total | 326 | 61.7 | 69 | 13.1 | 50 | 9.5 | 83 | 15.7 | 528 |
| Variables | OR | 95% CI | p-value |
| Age: ≤28 | 1.277 | 0.489-3.333 | 0.617 |
| Gender: male | 1.237 | 0.366-4.183 | 0.732 |
| Smoking: no | 2.717 | 1.017-7.257 | 0.046 |
| Lesion: top | 1.531 | 0.484-4.844 | 0.469 |
| Comorbidities: yes | 3.413 | 1.236-9.433 | 0.018 |
| ISP: yes | 0.862 | 0.3615-2.364 | 0.773 |
| CSP: yes | 0.428 | 0.129-1.420 | 0.166 |
| Operation for ISP: yes | 4.695 | 1.486-14.925 | 0.008 |
| Approach: VATS | 1.802 | 0.464-6.999 | 0.395 |
| Buttress stapling: no | 0.724 | 0.232-2.262 | 0.578 |
| Covering: no | 0.594 | 0.193-1.825 | 0.363 |
| Surgeon: trainee | 0.787 | 0.332-1.867 | 0.587 |
| Pleurodesis: yes | 1.420 | 0.238-8.475 | 0.700 |
| Complication: yes | 1.763 | 0.133-23.255 | 0.667 |
| 12-pNCA | 2PE | PROP | 11PA | 2A5C | MDOB | ALL | |
| Correlation | 0.32 (0.06) | 0.27 (0.11) | 0.06 (0.71) | 0.12 (0.48) | 0.20 (0.24) | 0.36 (0.04) | 0.22(10-3) |
| Total | Male sex | Female sex | ||||
| Normouricemia (n = 1749) | Hyperuricemia (n = 393) | Normouricemia (n = 954) | Hyperuricemia (n = 238) | Normouricemia (n = 795) | Hyperuricemia (n = 155) | |
| At 1-year | ||||||
| CAD | 15 | 5 | 10 | 3 | 5 | 2 |
| Congestive heart failure | 4 | 2 | 2 | 1 | 2 | 1 |
| Stroke | 6 | 2 | 3 | 1 | 3 | 1 |
| Peripheral vascular disease | 0 | 1 | 0 | 0 | 0 | 1 |
| At 2-year | ||||||
| CAD | 25 | 8 | 16 | 5 | 9 | 3 |
| Congestive heart failure | 6 | 3 | 3 | 2 | 3 | 1 |
| Stroke | 11 | 2 | 6 | 1 | 5 | 1 |
| Peripheral vascular disease | 2 | 2 | 1 | 1 | 1 | 1 |
| At 3-year | ||||||
| CAD | 31 | 13 | 18 | 8 | 13 | 5 |
| Congestive heart failure | 15 | 5 | 9 | 3 | 6 | 2 |
| Stroke | 13 | 6 | 8 | 4 | 5 | 2 |
| peripheral vascular disease | 8 | 3 | 5 | 2 | 3 | 1 |
| At 4-year | ||||||
| CAD | 39 | 16 | 22 | 9 | 17 | 6 |
| Congestive heart failure | 16 | 6 | 10 | 4 | 6 | 2 |
| Stroke | 18 | 9 | 11 | 6 | 7 | 3 |
| Peripheral vascular disease | 11 | 5 | 7 | 4 | 4 | 1 |
| At 5-year | ||||||
| CAD | 44 | 17 | 26 | 11 | 18 | 7 |
| Congestive heart failure | 21 | 7 | 13 | 5 | 8 | 2 |
| Stroke | 23 | 13 | 13 | 8 | 10 | 5 |
| Peripheral vascular disease | 12 | 6 | 7 | 4 | 5 | 2 |
| Cumulative Numbers of major CVD events over 5 years | ||||||
| CAD | 154 (8.8%) | 59 (15.0%) | 92 (9.7 %) | 36 (15.1%) | 62 (7.8%) | 23 (14.8%) |
| Congestive heart failure | 62 (3.6%) | 23 (5.9%) | 37 (3.9%) | 15 (6.1%) | 25 (3.2%) | 8 (5.2%) |
| Stroke | 73 (4.2%) | 32 (8.1%) | 41 (4.3%) | 20 (8.2%) | 30 (3.8%) | 12 (7.7%) |
| Peripheral vascular disease | 33 (1.9%) | 17 (4.6%) | 20 (2.1%) | 11 (4.6%) | 13 (1.6%) | 6 (3.7%) |
| ASD (n = 24) | Controls (n = 18) | Statistics | |
| Age | 40.54 ± 10.279 | 37.17 ± 10.983 | p = 0.313 |
| Intelligence quotient | 114.29 ± 15.213 | 113.00 ± 13.920 | p = 0.779 |
| Gender | 12 m:12 f | 8 m:10 f | p = 0.721 |
| Nicotine | 2.292 ± 5.894 | 2.222 ± 6.691 | p = 0.972 |
| Autism-spectrum quotient | 39.08 ± 6.386 | 12.94 ± 5.504 | p < 0.001 |
| Empathy quotient | 17.38 ± 9.523 | 47.94 ± 9.710 | p < 0.001 |
| Wender Utah Rating Scale | 33.75 ± 16.690 | 8.72 ± 7.954 | p < 0.001 |
| Beck Depression Inventory score | 17.25 ± 12.365 | 3.22 ± 4.236 | p < 0.001 |
| Level of education | Low school degree, 1 (4.2%) | Low school degree, 0 (0%) | |
| Medium school degree, 3 (12.5%) | Medium school degree, 3 (16.7%) | ||
| High school degree, 9 (37.5%) | High school degree, 6 (33.3%) | ||
| University degree, 9 (37.5%) | University degree, 9 (50%) | ||
| Other, 2 (8.3%) | Other, 0 (0%) | ||
| Occupational situation | Full-time employed, 13 (54.2%) | Full-time employed, 7 (38.9%) | |
| Part-time employment, 4 (16.7%) | Part-time employment, 4 (22.2%) | ||
| In vocational training/studying, 1 (4.2%) | In vocational training/studying, 7 (38.9%) | ||
| Pension, 1 (4.2%) | Pension, 0 (0%) | ||
| Unemployed, 4 (16.7%) | Unemployed, 0 (0%) | ||
| Other, 1 (4.2%) | Other, 0 (0%) | ||
| Psychiatric medication (in the last 3 months) | No, 11 | No, 18 | |
| AD, 6 | AD, 0 | ||
| NL, 1 | NL, 0 | ||
| AD + NL, 5 | AD + NL, 0 | ||
| AD + MPH, 1 | AD + MPH, 0 |
| Cytological diagnosis | Frequency (n) | Percentage (%) |
| Chronic granulomatous inflammation | 20 | 27.0% |
| Chronic sialadenitis | 25 | 33.7% |
| Acute on chronic sialdenitis | 22 | 29.7% |
| Benign cystic lesion | 7 | 9.4% |
| Total | 74 | 39.5% |
| Plasmid | Properties | Source/Reference |
| pRS316 | Yeast centromeric plasmid. URA3 marker. | [52] |
| pRS316[PPHO84-GFP-TPHO84] (pRUL1336) | pRS316 containing the PHO84 promoter (600 bp), GFP and the PHO84 terminator (436 bp) | This study |
| pRS316[PCYC1-GFP-TCYC1] (pRUL1339) | pRS316 containing the CYC1 promoter (300 bp), GFP and the CYC1 terminator (220 bp) | This study |
| pRS316[PSPL2-GFP-TSPL2] (pRUL1354) | pRS316 containing the SPL2 promoter (647 bp), GFP and the SPL2 terminator (324 bp) | This study |
| pUG6 | Plasmid containing the KAN.MX casette for gene disruptions | [53] |
| pUG36 | Centromeric plasmid to make N-terminal GFP fusions. | Güldener and Hegemann, unpublished |
| pRS305 | Yeast integration plasmid. LEU2 marker. | [52] |
| pRS305[PPHO84-GFP-TPHO84] (pRUL1359) | pRS305 containing the PHO84 promoter (600 bp), GFP and the PHO84 terminator (436 bp) | This study |
| pRS305[PCYC1-GFP-TCYC1] (pRUL1360) | pRS305 containing the CYC1 promoter (300 bp), GFP and the CYC1 terminator (220 bp) | This study |
| pRS313 | Yeast centromeric plasmid. HIS3 selection marker. | [52] |
| pRS313[PHO4](pRUL1334) | pRS313 containing PHO4 | [7] |
| pRS313[BMH1] (pRUL1330) | pRS313 containing a 3.2 kb genomic DNA fragment with BMH1 | I.G. Anemaet, unpublished results |
| pRS305[PHO4] (pRUL1358) | pRS305 containing PHO4 | This study |
| YCplac33 | Yeast centromeric plasmid. URA3 marker | [54] |
| YCplac33[BMH1] | YCplac33 with a 3.2 kb genomic DNA fragment with BMH1 | [55] |
| Down-regulated genes | ||||||||
| mst1ts | ||||||||
| Gene | Log2 change | p-value | ||||||
| SPAC1039.02 | -2.66 | 0.000635869 | ||||||
| SPBC29A3.05 | -2.18 | 5.55E-05 | ||||||
| SPCC757.06 | -2.08 | 1.87E-07 | ||||||
| Up-regulated genes | ||||||||
| mst1ts | mst1ts | mst1ts | ||||||
| Gene | Log 2 change | p-value | Gene | Log 2 change | p-value | Gene | Log2 change | p-value |
| SPBC1348.09 | 1.89 | 3.69E-11 | SPAC977.17 | 2.40 | 1.80E-08 | map2 | 3.52 | 2.50E-12 |
| SPAC22F8.05 | 1.90 | 0.001560473 | SPBC1348.14c | 2.41 | 2.14E-15 | SPAPJ695.01c | 3.52 | 2.00E-09 |
| SPAC3C7.13c | 1.92 | 3.23E-10 | SPAC5H10.02c | 2.46 | 3.89E-11 | SPBC1198.01 | 3.55 | 7.19E-16 |
| SPBPB2B2.06c | 1.93 | 0.000987078 | SPCC663.08c | 2.54 | 0.009807792 | SPAC22A12.17c | 3.57 | 1.96E-11 |
| SPBPB2B2.07c | 1.93 | 9.41E-10 | SPBC725.10 | 2.57 | 9.52E-05 | SPAPB1A11.03 | 3.59 | 1.50E-13 |
| nta1 | 1.94 | 3.20E-06 | SPBC83.19c | 2.58 | 3.49E-12 | SPAC1F8.04c | 3.59 | 5.41E-07 |
| SPCC191.01 | 1.94 | 5.61E-06 | SPCC1393.12 | 2.58 | 4.35E-11 | SPAC11D3.01c | 3.61 | 1.72E-07 |
| SPCC70.04c | 1.95 | 2.09E-06 | SPBPB2B2.08 | 2.60 | 0.007868315 | SPBPB8B6.03 | 3.64 | 2.07E-12 |
| meu7 | 1.96 | 2.81E-05 | SPCC777.04 | 2.63 | 3.77E-05 | SPBP4G3.03 | 3.65 | 2.74E-13 |
| SPAC9.10 | 1.98 | 8.57E-09 | SPAC26F1.05 | 2.64 | 1.00E-07 | SPCC663.06c | 3.66 | 3.28E-05 |
| map1 | 1.98 | 0.000618909 | pma2 | 2.64 | 6.19E-07 | SPBPB21E7.04c | 3.67 | 3.08E-06 |
| SPBC8E4.05c | 1.99 | 1.54E-08 | SPAC32A11.02c | 2.65 | 4.69E-09 | frp1 | 3.69 | 3.37E-05 |
| SPAC637.03 | 2.03 | 0.000132799 | SPBC2G2.17c | 2.66 | 2.11E-07 | SPCC737.04 | 3.85 | 3.10E-07 |
| SPBC4C3.08 | 2.04 | 6.23E-08 | SPAC56F8.15 | 2.68 | 0.001276426 | SPBC359.06 | 3.91 | 0.000499938 |
| meu10 | 2.05 | 4.69E-07 | SPAPJ691.02 | 2.72 | 1.52E-05 | apc10 | 3.96 | 4.49E-12 |
| SPCC1840.12 | 2.05 | 4.17E-06 | SPBC1773.06c | 2.76 | 0.000469242 | SPAPB8E5.10 | 3.98 | 1.31E-12 |
| SPBPB2B2.02 | 2.06 | 0.000305555 | SPBC1685.05 | 2.86 | 1.62E-11 | SPBC16E9.16c | 4.00 | 6.07E-13 |
| SPBC19C7.04c | 2.09 | 0.001283597 | SPAC4F10.17 | 2.88 | 6.57E-09 | SPAC29A4.12c | 4.06 | 1.45E-09 |
| SPAC5H10.04 | 2.10 | 1.33E-06 | SPCC16A11.15c | 2.94 | 5.09E-11 | SPAC869.08 | 4.08 | 1.01E-15 |
| SPBC947.05c | 2.11 | 5.62E-08 | SPCC1739.08c | 2.96 | 0.021512753 | SPBC3H7.08c | 4.09 | 9.33E-14 |
| SPAC3H8.09c | 2.11 | 1.77E-10 | SPAC23C11.06c | 2.99 | 1.15E-07 | SPBCPT2R1.08c | 4.16 | 0.000258571 |
| ish1 | 2.11 | 9.95E-06 | SPAC15E1.02c | 3.00 | 8.68E-09 | fbp1 | 4.32 | 3.57E-14 |
| SPAC513.02 | 2.12 | 1.94E-06 | SPBC1105.13c | 3.02 | 1.10E-07 | SPBC56F2.06 | 4.36 | 2.99E-07 |
| SPAC4H3.03c | 2.14 | 0.000486057 | grt1 | 3.04 | 7.61E-08 | mel1 | 4.43 | 2.62E-15 |
| SPAPB15E9.02c | 2.17 | 3.00E-08 | SPCC338.18 | 3.04 | 7.26E-07 | SPAC139.05 | 4.49 | 1.53E-09 |
| SPCC794.01c | 2.18 | 0.042343035 | SPBPB2B2.18 | 3.05 | 1.46E-05 | SPCPB16A4.06c | 4.53 | 1.21E-11 |
| SPAC1F8.02c | 2.18 | 3.57E-07 | SPCC1322.07c | 3.10 | 9.51E-09 | SPBC1289.14 | 4.61 | 8.12E-16 |
| SPBC4.01 | 2.20 | 9.35E-05 | SPCC757.03c | 3.11 | 2.10E-09 | ght3 | 4.72 | 0.001973142 |
| SPBPB8B6.02c | 2.23 | 1.43E-12 | SPAC4H3.08 | 3.16 | 4.98E-12 | zym1 | 4.85 | 1.83E-08 |
| SPBC36.02c | 2.23 | 0.000135759 | SPBPB2B2.12c | 3.16 | 0.00706426 | SPBC24C6.09c | 4.94 | 1.55E-13 |
| SPCC1393.07c | 2.23 | 4.88E-10 | spk1 | 3.17 | 0.000216514 | dak2 | 5.02 | 4.45E-12 |
| SPAC513.06c | 2.24 | 1.52E-09 | mei2 | 3.25 | 0.000888516 | SPAC186.02c | 5.11 | 6.43E-15 |
| SPCPB1C11.02 | 2.25 | 7.04E-07 | SPAC977.05c | 3.29 | 2.46E-05 | eno102 | 5.11 | 3.01E-13 |
| ste11 | 2.27 | 0.000335259 | SPAC1F8.08 | 3.32 | 2.20E-09 | SPAC3G9.11c | 5.13 | 5.88E-11 |
| wtf20 | 2.28 | 4.37E-06 | SPAC3G6.07 | 3.33 | 1.53E-05 | SPAC22G7.11c | 5.22 | 4.34E-14 |
| ppk33 | 2.28 | 0.000119009 | SPACUNK4.17 | 3.33 | 3.64E-07 | SPBC23G7.10c | 5.25 | 4.94E-06 |
| SPAC1F7.06 | 2.33 | 5.44E-12 | SPAC23H3.15c | 3.42 | 1.03E-05 | isp3 | 5.36 | 1.87E-11 |
| ssa1 | 2.34 | 0.000834021 | caf5 | 3.44 | 4.99E-07 | SPAC869.06c | 6.61 | 2.79E-13 |
| cta3 | 2.36 | 6.88E-11 | str3 | 3.48 | 2.47E-05 | SPAC869.09 | 6.68 | 2.91E-12 |
| agl1 | 2.37 | 0.026304809 |
| N | % | |
| Clinic location | ||
| Rural | 18 | 60 |
| Urban | 5 | 17 |
| Peri-urban | 7 | 23 |
| Clinic type | ||
| Quaternary/tertiary | 1 | 3 |
| Secondary | 1 | 3 |
| Primary | 28 | 93 |
| Public/private | ||
| Public | 27 | 90 |
| Private | 0 | 0 |
| Mixed | 3 | 10 |
| NGO support | ||
| None | 17 | 57 |
| One | 5 | 17 |
| Multiple | 8 | 26 |
| Year of pMTCT initiation | ||
| Before 2005 | 5 | 17 |
| Between 2006 and 2008 | 21 | 70 |
| After 2008 | 4 | 13 |
| Other characteristics | Mean | Median |
| Distance to reference laboratory (km) | 22 | 16 |
| Catchment population (people) | 27,774 | 19,644 |
| No. 1st ANC visits in the last 6 months | 674 | 468 |
| No. institutional births in the last 6 months | 482 | 257 |
| No. post-partum visits in the last 6 months | 418 | 189 |
| Exposure | Study groups | ||
| Serumb | Infections | White blood cells | Lymphocyte subsets |
| CB 28+52+101 | 4 (3–427) | 4 (3–427) | 4 (3–19) |
| CB-153 | 60 (23–179) | 57 (23–158) | 59 (23–158) |
| Di-ortho PCB | 131 (44–362) | 127 (44–342) | 129 (44–342) |
| Mono-ortho PCB TEQ | 4 (1–20) | 4 (1–11) | 4 (1–9) |
| p,p'-DDE | 88 (21–622) | 85 (24–622) | 83 (29–622) |
| Mother's milk exposurec | |||
| CB 28+52+101 | 8 (0–155) | 8 (0–76) | 9 (0–39) |
| CB-153 | 187 (0–853) | 174 (0–396) | 186 (0–396) |
| Di-ortho PCB | 364 (0–1666) | 351 (0–830) | 372 (0–830) |
| Mono-ortho PCB TEQ | 11 (0–54) | 11 (0–26) | 11 (0–26) |
| p,p'-DDE | 311 (0–2199) | 289 (0–2199) | 306 (0–2199) |
| Variable | Category | Cm | Cc | Ci | Ca | TFR |
| Religion | Catholic | 0.756688 | 0.81124 | 0.72359 | 1.0 | 6.8 |
| Protestant | 0.688570 | 0.76740 | 0.74156 | 1.0 | 6.0 | |
| Moslem | 0.723129 | 0.71102 | 0.75700 | 1.0 | 6.0 | |
| Other | 0.677555 | 0.78402 | 0.73206 | 1.0 | 5.9 | |
| Region | Kampala | 0.532694 | 0.52907 | 0.81400 | 1.0 | 3.5 |
| Central | 0.680401 | 0.66009 | 0.76805 | 1.0 | 5.3 | |
| Eastern | 0.776696 | 0.79588 | 0.74267 | 1.0 | 7.0 | |
| Northern | 0.773491 | 0.90037 | 0.69493 | 1.0 | 7.4 | |
| Western | 0.749218 | 0.77022 | 0.73475 | 1.0 | 6.5 | |
| Residence | Rural | 0.761407 | 0.81240 | 0.72966 | 1.0 | 6.9 |
| Urban | 0.562910 | 0.56882 | 0.79239 | 1.0 | 3.9 | |
| Wealth Index | Poorest | 0.815166 | 0.92263 | 0.71200 | 1.0 | 8.2 |
| Poor | 0.767808 | 0.85478 | 0.71023 | 1.0 | 7.1 | |
| Middle | 0.739220 | 0.81104 | 0.71968 | 1.0 | 6.6 | |
| Richer | 0.759015 | 0.73921 | 0.75614 | 1.0 | 6.5 | |
| Richest | 0.577128 | 0.53849 | 0.79618 | 1.0 | 3.8 | |
| Education | None | 0.830933 | 0.89279 | 0.70547 | 1.0 | 8.0 |
| Primary | 0.748226 | 0.78791 | 0.73233 | 1.0 | 6.6 | |
| Secondary + | 0.611473 | 0.56484 | 0.79904 | 1.0 | 4.2 | |
| TOTAL | UGANDA | 0.722717 | 0.78179 | 0.73502 | 1.0 | 6.4 |
| Profession | Round 1 | Round 2 | Round 3 |
| P-HEMS doctors | 21 | 16 | 15 |
| P-HEMS nurses | 14 | 12 | 12 |
| EMS nurses | 28 | 27 | 26 |
| Dispatch centre operators | 14 | 12 | 11 |
| Trauma surgeons | 22 | 24 | 21 |
| Total respondents | 83 | 79 | 71 |
| Hierarchical clustering | CCA | TribeMCL | Spectral clustering | ||
| Cluster count | Significant | 243 | 243 | 245 | 235 |
| All | 293 | 307 | 332 | 308 | |
| Ratio | 0.829 | 0.792 | 0.738 | 0.763 | |
| Total cluster size | Significant | 1,166 | 1,858 | 3,600 | 4,863 |
| All | 1,396 | 2,144 | 4,047 | 5,380 | |
| Ratio | 0.835 | 0.866 | 0.889 | 0.903 |
| missing rate(%) | KNN | SKNN | EM-SKNN | MI | MLE |
| 10 | 0.2171 | 0.2247 | 0.2239 | 0.1573 | 0.2112 |
| 20 | 0.2233 | 0.2223 | 0.2175 | 0.2171 | 0.2602 |
| 30 | 0.2422 | 0.2285 | 0.2224 | 0.2277 | 0.2907 |
| 40 | 0.2778 | 0.2369 | 0.2288 | 0.2380 | 0.3079 |
| 50 | 0.3155 | 0.2450 | 0.2349 | 0.2495 | 0.3237 |
| 60 | 0.3210 | 0.2487 | 0.2476 | 0.2627 | 0.3381 |
| Primer name | Primer sequence (5′–3′) |
| Block-E1 | CTACAAATCTTGTTACGCGGTATTA |
| argX-hisR 5′ intergenic region | CAGCTCAAGCGCCGGGACTA |
| argX-hisR centre intergenic region | TATTACTACCACCGCAGC |
| Block-E2 | TTGTCACAACTTCTAATAA |
| Block-E3 | TTTTAGTTCAATTCTTTAAAGTCG |
| Block-E4 | AATACTGCTTTTTGAATTTTTAG |
| Sample | Average Coverage after 1 s of SP | Coverage Standard Deviation after 1 s of SP | AR Coeff. | t (98%) [s] |
| CD | 65 | 3.0 | 1.05 | 3.71 |
| A36 | 89 | 3.7 | 2.18 | 1.79 |
| A72 | 67 | 2.9 | 1.10 | 3.57 |
| A210 | 83 | 3.9 | 1.75 | 2.24 |
| A360 | 77 | 4.1 | 1.45 | 2.69 |
| S1300 | 60 | 3.3 | 0.92 | 4.28 |
| S1400 | 73 | 2.6 | 1.31 | 2.98 |
| Characteristic | All women (n = 543) | Subset (n = 147) | p value | ||
| Variables | n | Mean ± SD | n | Mean ± SD | |
| Age (years) | 542 | 34.9 ± 11.3 | 147 | 25.5 ± 5.0 | <0.001 |
| Median ± IQR | Median ± IQR | ||||
| Water As (μg/L) | 526 | 32.9 ± 269.4 | 146 | 17.2 ± 120.4 | 0.02 |
| Toenail As (μg/g) | 540 | 2.70 ± 6.97 | 145 | 2.12 ± 3.65 | 0.10 |
| % | % | ||||
| Skin Lesions | 0.80 | ||||
| No | 272 | 50.18 | 72 | 48.98 | |
| Yes | 270 | 49.82 | 75 | 51.02 | |
| Body Mass Index (kg/m2) | 0.70 | ||||
| <18.5 | 158 | 29.10 | 44 | 29.93 | |
| 18.5–24.9 | 332 | 61.14 | 92 | 62.59 | |
| ≥25 | 53 | 9.76 | 11 | 7.48 | |
| Marital Status | <0.001 | ||||
| Not married | 72 | 13.33 | 37 | 25.17 | |
| Ever married | 468 | 86.67 | 110 | 74.83 | |
| Education | <0.001 | ||||
| No formal education | 318 | 58.56 | 53 | 36.1 | |
| Primary | 74 | 13.63 | 17 | 11.56 | |
| Secondary and above | 150 | 27.62 | 77 | 52.38 | |
| Chews betel nut | <0.001 | ||||
| No | 385 | 71.2 | 131 | 89.7 | |
| Yes | 156 | 28.8 | 15 | 10.3 | |
| Water Arsenic | 0.16 | ||||
| ≤10 ug/L | 196 | 36.10 | 65 | 44.22 | |
| 10–50 ug/L | 130 | 23.94 | 34 | 23.13 | |
| >50 ug/L | 217 | 39.96 | 48 | 32.65 | |
| Hemoglobin (g/L) | 0.99 | ||||
| Normal (Hb ≥120 g/L) | 443 | 81.58 | 120 | 81.63 | |
| Anemia (Hb <120 g/L) | 100 | 18.42 | 27 | 18.37 |
| Year Post Op | Glenoid Loosening | Bearing failure | Infection | Dislocation |
| 1 | 0 | 0 | 0 | 0 |
| 2 | 0 | 1 | 0 | 0 |
| 3 | 0 | 0 | 0 | 1 |
| 4 | 0 | 0 | 0 | 0 |
| Total | 0 | 1 | 0 | 1 |
| WHO region | ILO LABORSTA (farm worker average wage) | World Bank (average value per agricultural worker) | ILO (minimum wage) | US State Department (minimum wage) | Overall average – maximum of sourcesa | Overall average – minimum of sourcesa |
| AMRO | $6.90 | $27.36 | $5.27 | $5.17 | $27.36 | $5.11 |
| AFRO | $1.92 | $8.18 | $2.06 | $2.16 | $9.05 | $1.01 |
| EMRO | $4.84 | $18.26 | $3.19 | $5.00 | $18.26 | $3.00 |
| WPRO | $5.36 | $9.06 | $6.81 | $6.74 | $10.70 | $4.98 |
| SEARO | $1.80 | $3.47 | $1.77 | $3.75 | $4.04 | $1.47 |
| Average | $2.02 | $5.10 | $2.10 | $3.42 | $5.84 | $1.50 |
| Subject | Gender | Age (yrs) | Etiology | Deafness (yrs) | CI side | CI experience (mos) | CVC (Ph%) | Implant |
| S1 | Male | 60 | Familial | 46 | Left | 160 | 93 | Clarion CII |
| S2 | Male | 51 | Progressive | 25 | Right | 124 | 76 | HiRes 90K |
| S3 | Female | 74 | Familial | 22 | Left | 114 | 93 | HiRes 90K |
| S4 | Male | 58 | Unknown | 11 | Right | 31 | 93 | HiRes 90K |
| S5 | Male | 67 | Familial | 67 | Right | 96 | 86 | HiRes 90K |
| S6 | Male | 57 | Familial | 45 | Right | 174 | 96 | Clarion CII |
| S7 | Female | 67 | Meningitis | 6 | Left + right | 73 | 88 | HiRes 90K |
| S8 | Female | 43 | Meningitis | 5 | Left + right | 59 | 95 | HiRes 90K |
| S9 | Female | 66 | Unknown | 35 | Right | 105 | 84 | HiRes 90K |
| S10 | Female | 59 | Type II Usher | 4 | Right | 46 | 89 | HiRes 90K |
| S11 | Female | 65 | Meniere | 25 | Right | 149 | 92 | Clarion CII |
| Item | Strongly Agree/Agree | QPCCC Subscale | |
| n | % 1 (95% CIs) | ||
| The staff at the hospital showed respect for me | 191 | 91.0 (87.1–94.8) | Respectful communication |
| The staff at the hospital talked to me in a way I could understand | 188 | 90.8 (86.9–94.8) | Respectful communication |
| The staff at the hospital showed respect for my family or friends | 183 | 87.6 (83.1–92.0) | Respectful communication |
| The staff at the hospital gave me information about cancer that was easy to understand | 183 | 87.1 (82.6–91.7) | Cancer information |
| The staff at the hospital gave me information about cancer and treatments to take home (e.g., booklets, websites) | 180 | 86.1 (81.4–90.8) | Cancer information |
| During my treatment, staff at the hospital made sure I received the treatment I was meant to have | 182 | 85.8 (81.2–90.5) | Treatment delivery |
| The doctors at the hospital explained to me the short-term side effects of each treatment option | 175 | 84.5 (79.6–89.5) | Treatment decision-making |
| The doctors at the hospital explained to me all of the treatments I could have | 175 | 83.7 (78.7–88.7) | Treatment decision-making |
| During my treatment, staff at the hospital had up-to-date information about my cancer care | 173 | 83.2 (78.1–88.3) | Treatment delivery |
| During my treatment, staff at the hospital made sure I received treatment that was based on scientific knowledge | 169 | 82.0 (76.8–87.3) | Treatment delivery |
| During my treatment, staff at the hospital gave me consistent information about my treatment | 169 | 80.9 (75.5–86.2) | Treatment delivery |
| During my treatment, staff at the hospital co-ordinated my appointments so that I did not have to go to hospital more than necessary | 168 | 80.0 (74.6–85.4) | Treatment delivery |
| Place | Age (years) | Level of education (years of study) | Income (R$) | |||
| Average | 95%CI | Average | 95%CI | Average | 95%CI | |
| Supermarket | 29.8 | 29.2–30.3 | 8.2 | 7.9–8.5 | 871.58 | 797.09–946.07 |
| Bakery | 35.0 | 34.3–35.8 | 9.3 | 9.1–9.6 | 1459.60 | 1320.05–1599.16 |
| Street food | 31.4 | 30.9–32.0 | 8.5 | 8.2–8.8 | 829.99 | 765.29–894.69 |
| Snack bar | 32.0 | 31.7–32.3 | 9.5 | 9.3–9.6 | 1193.18 | 1146.81–1239.55 |
| Restaurant | 38.2 | 37.8–38.5 | 9.9 | 9.8–10.0 | 1656.98 | 1582.48–1731.48 |
| Fruit shop | 32.4 | 31.1–33.7 | 7.5 | 7.1–7.9 | 678.39 | 620.34–736.45 |
| Other places | 36.2 | 35.7–36.7 | 8.3 | 8.1–8.6 | 1035.99 | 972.49–1099.49 |
| Name | Screening | Intervention | Follow-up | |||||||||
| Duration | 12 months | 6 months | 6 months | |||||||||
| Visits | Time | Surgery | Days 1–3 | Wk 2 | Wk 4 | Wk 8 | Wk 12 | Wk 16 | Wk 20 | Wk 24 | Wk 48 | |
| Anamnesis | Anamnesis | X | X | X | ||||||||
| Body weight | X | X | X | X | X | X | X | X | X | |||
| Anthropometry | X | X | X | X | X | X | X | X | ||||
| Dietary assessment, BDI | X | X | X | X | X | |||||||
| Bone density | DEXA | X | X | X | ||||||||
| Liver and microbiota | FibroScan and CAPTM | X | X | X | X | X | ||||||
| Stool samples | X | X | X | X | X | |||||||
| Biopsies | Liver, SAT, VAT | X | ||||||||||
| Supplementation | Loading dose | X | X | X | ||||||||
| Maintenance dose | X | X | X | X | X | X | X | |||||
| Blood parameter | Vitamin D | X | X | X | X | X | X | X | X | X | ||
| Biochemical | X | X | X | X | X | X | X | X | X | |||
| Liver | X | X | X | X | X | |||||||
| Inflammation | X | X | X | X | X | X | X | X | X | |||
| Insulin resistance | X | X | X | X | X | X | X | X | X | |||
| Bone turnover | X | X | X | X | X |
| Drug category | Drug name | Prescribed acutely | Prescribed on discharge | ||
| No. | % | No. | % | ||
| Antiplatelet drugs | Aspirin | 521 | 37.0 | 670 | 47.7 |
| Clopidogrel | 50 | 3.6 | 66 | 4.7 | |
| Dipyridamole | < 10 | < 1 | 13 | 0.9 | |
| Aggrenox | < 10 | < 1 | 12 | 0.9 | |
| Fibrinolytic | Alteplase | < 10 | < 1 | n/a | |
| Anticoagulants | Warfarin | 16 | 1.1 | 49 | 3.5 |
| Heparin (subcutaneous) | 333 | 23.7 | n/a | ||
| Heparin (low molecular weight) | 44 | 3.1 | 32 | 2.3 | |
| Statins | Simvastatin, Atorvastatin | 304 | 21.6 | 681 | 48.4 |
| Boys | |||||||
| Special | New | Fashionable | Natural | Local | T city | T countryside | |
| Biscuits and ice creams | 65.3 | 18.7 | 44.6 | 28.7 | 11.2 | 35.1 | 11.2 |
| Bread and pasta | 80.0 | 8.3 | 31.7 | 73.3 | 16.7 | 23.3 | 10.0 |
| Chocolate and snacks | 64.3 | 22.6 | 49.0 | 31.5 | 11.1 | 38.2 | 4.5 |
| Cold cuts | 60.6 | 9.1 | 19.7 | 74.2 | 27.3 | 6.1 | 36.4 |
| Dairy products | 55.0 | 10.0 | 25.0 | 85.0 | 30.0 | 20.0 | 35.0 |
| Eggs | 80.0 | 10.0 | 20.0 | 70.0 | 0.0 | 10.0 | 20.0 |
| Fat Meat | 68.9 | 30.4 | 54.1 | 38.5 | 15.5 | 41.2 | 11.5 |
| Filled cakes and sweets | 72.2 | 14.8 | 50.9 | 31.5 | 21.3 | 35.2 | 6.5 |
| Fish | 75.0 | 0.0 | 50.0 | 75.0 | 25.0 | 50.0 | 25.0 |
| Fried fish | 50.0 | 37.5 | 12.5 | 50.0 | 0.0 | 37.5 | 37.5 |
| Fried potatoes | 80.2 | 33.7 | 60.4 | 24.8 | 9.9 | 48.5 | 6.9 |
| Juices and drinks | 56.3 | 34.4 | 46.9 | 18.8 | 15.6 | 37.5 | 9.4 |
| Lean meet | 58.0 | 4.3 | 26.1 | 84.1 | 11.6 | 15.9 | 18.8 |
| Non-sweet fruits and cereals | 69.2 | 23.1 | 30.8 | 69.2 | 15.4 | 23.1 | 30.8 |
| Oils and condiments | 32.9 | 9.2 | 26.3 | 69.7 | 3.9 | 22.4 | 23.7 |
| Pizza | 85.5 | 21.8 | 58.2 | 43.6 | 30.9 | 40.0 | 9.1 |
| Sweet fruit | 100.0 | 0.0 | 0.0 | 100.0 | 0.0 | 0.0 | 0.0 |
| Vegetables | 50.0 | 11.1 | 22.2 | 88.9 | 22.2 | 5.6 | 22.2 |
| OVERALL | 65.8 | 19.8 | 44.1 | 42.7 | 14.2 | 33.2 | 12.0 |
| Girls | |||||||
| Special | New | Fashionable | Natural | Local | T city | T countryside | |
| Biscuits and ice creams | 61.1 | 13.7 | 35.8 | 30.5 | 15.0 | 24.8 | 8.0 |
| Bread and pasta | 55.5 | 7.8 | 15.6 | 55.5 | 18.8 | 14.1 | 14.8 |
| Chocolate and snacks | 64.1 | 26.4 | 47.3 | 28.8 | 12.0 | 30.7 | 4.6 |
| Cold cuts | 58.1 | 13.5 | 28.4 | 66.2 | 35.1 | 5.4 | 20.3 |
| Dairy products | 56.0 | 12.0 | 20.0 | 76.0 | 8.0 | 16.0 | 40.0 |
| Eggs | 57.1 | 14.3 | 28.6 | 85.7 | 14.3 | 42.9 | 14.3 |
| Fat Meat | 44.0 | 48.0 | 46.7 | 29.3 | 14.7 | 48.0 | 8.0 |
| Filled cakes and sweets | 67.0 | 24.7 | 37.1 | 32.0 | 16.5 | 30.9 | 9.3 |
| Fish | 20.0 | 0.0 | 0.0 | 80.0 | 40.0 | 20.0 | 40.0 |
| Fried fish | 25.0 | 100.0 | 25.0 | 50.0 | 50.0 | 75.0 | 0.0 |
| Fried potatoes | 68.6 | 34.3 | 50.5 | 27.6 | 11.4 | 41.9 | 4.8 |
| Juices and drinks | 60.0 | 42.9 | 60.0 | 17.1 | 17.1 | 37.1 | 2.9 |
| Lean meet | 67.8 | 11.9 | 30.5 | 76.3 | 22.0 | 8.5 | 13.6 |
| Non-sweet fruits and cereals | 35.7 | 7.1 | 35.7 | 71.4 | 42.9 | 14.3 | 35.7 |
| Oils and condiments | 41.4 | 8.1 | 25.2 | 66.7 | 16.2 | 7.2 | 18.0 |
| Pizza | 74.3 | 11.4 | 37.1 | 40.0 | 34.3 | 22.9 | 11.4 |
| Sweet fruit | 77.8 | 22.2 | 11.1 | 77.8 | 55.6 | 0.0 | 44.4 |
| Vegetables | 69.2 | 23.1 | 15.4 | 100.0 | 7.7 | 15.4 | 0.0 |
| OVERALL | 59.9 | 21.1 | 37.1 | 41.5 | 16.9 | 25.2 | 10.4 |
| 599C>T GPX1 (rs1050450) | ||||||
| Interaction | ||||||
| CC (n = 36) | CT + TT (n = 56) | p1 | F | p2 | ||
| BMI (kg/m2) | Before | 33 ± 5 31 | 35 ± 5 33 | 0.001 | 0.68 | 0.412 |
| After | 30 ± 3 30a** | 33 ± 4 32a** | 0.003 | |||
| SBP (mgHg) | Before | 120 ± 9120 | 124 ± 10,120 | 0.117 | 0.17 | 0.684 |
| After | 114 ± 13120a** | 119 ± 13120a** | 0.049 | |||
| DBP (mgHg) | Before | 85 ± 14 79 | 88 ± 8.9 88 | 0.375 | 21.19 | < 0.001 |
| After | 77 ± 8.4 75 | 79 ± 7.1 79a** | 0.011 | |||
| TBARS (mg/dl) | Before | 1.61 ± 0.61 1.40 | 1.34 ± 0.61 1.32 | 0.031 | 2.71 | 0.103 |
| After | 1.08 ± 0.42 1.06a** | 1.01 ± 0.45 1.02a* | 0.611 | |||
| Glucose (mg/dl) | Before | 127 ± 73,104 | 126 ± 68,105 | 0.600 | 0.79 | 0.374 |
| After | 102 ± 29 99a** | 105 ± 25 99a** | 0.990 | |||
| Total cholesterol (mg/dl) | Before | 176 ± 57,161 | 169 ± 34,169 | 0.489 | 1.11 | 0.295 |
| After | 159 ± 43,152 | 150 ± 27 150b** | 0.384 | |||
| LDL-C (mg/dl) | Before | 117.9 ± 52.1107 | 126.5 ± 50.4125 | 0.174 | 0.01 | 0.914 |
| After | 93.7 ± 35.8 89a** | 102.6 ± 38.9 95.5a** | 0.347 | |||
| Triglycerides (mg/dl) | Before | 163.1 ± 32.3157 | 154.8 ± 39.2147 | 0.153 | 0.05 | 0.822 |
| After | 161 ± 73.5 156a* | 149 ± 48.7138 | 0.660 | |||
| Atherogenic index | Before | 4.5 ± 3.3 4 | 4.1 ± 1.1 4.3 | 0.955 | 2.52 | 0.116 |
| After | 3.8 ± 1.5 3.5 | 3.6 ± 1.4 3.3a* | 0.033 |
| EtOH volume (ml) | Equation (1) diameter (nm) | DLS | SEM | ||
| Diameter (nm) | PDI | Diameter (nm) | SD | ||
| 41 | 390 | 397 | 0.041 | 391 | 54 |
| 45 | 360 | 400 | 0.036 | 393 | 48 |
| 47 | 346 | 350 | 0.111 | 320 | 47 |
| 50 | 326 | 369 | 0.028 | 343 | 27 |
| 53 | 307 | 282 | 0.028 | 300 | 28 |
| 55 | 295 | 278 | 0.002 | 291 | 27 |
| 57 | 283 | 288 | 0.040 | 307 | 28 |
| 60 | 267 | 270 | 0.087 | 267 | 22 |
| 62 | 256 | 259 | 0.050 | 252 | 22 |
| 64 | 246 | 242 | 0.007 | 254 | 35 |
| 67 | 232 | 249 | 0.025 | 260 | 27 |
| 73 | 206 | 207 | 0.036 | 210 | 20 |
| 78 | 186 | 181 | 0.016 | 187 | 24 |
| 83 | 168 | 159 | 0.024 | 173 | 37 |
| Phenotype | Frequency (n (%)) | Genotype concordance (%) | ||||
| HLA-B27-positiveα | rs4349859-positiveb | rs116488202-positive | rs4349859 | rs116488202 | ||
| Controls | Caucasian | 9/117 (7.7) | 9/117 (7.7) | 9/117 (7.7) | 100.0 | 100.0 |
| New Zealand Māori | 7/107 (6.5) | 6/107 (5.6) | 6/107 (5.6) | 85.7 | 85.7 | |
| AS | Overall | 164/176 (93.2) | 159/176 (90.3) | 159/176 (90.3) | 96.9 | 97.6 |
| Caucasian | 151/162 (93.2) | 149/162 (91.9)c | 150/162 (92.6)d | 98.7 | 99.3 | |
| New Zealand Māori | 13/14 (92.9) | 10/14 (71.4) | 10/14 (71.4) | 76.9 | 76.9 |
| Plant extracts | IC50 values (μg/mL) ± SD | Vitamin C equivalents for a 200 mg capsule (in g) |
| (1) Rosmarinus officinalis (McConnell's Blue) | 3.48 ± 0.22 | 0.351 |
| (2) Rosmarinus officinalis (Tuscan Blue) | 10.84 ± 0.12 | 1.09 |
| (3) Lavandula-x-intermedia (Margaret Roberts) | 138.5 ± 4.0 | 14.0 |
| (4) Lavandula spica | 125.5 ± 1.8 | 12.67 |
| (5) Origanum vulgare | 26.43 ± 1.58 | 2.67 |
| (6) Petroselinum crispum | 53.3 ± 2.63 | 5.38 |
| (7) Laurus nobilis | 30.85 ± 0.48 | 3.12 |
| (8) Thymus vulgaris | 36.13 ± 0.85 | 3.65 |
| (9) Foeniculum vulgaris | 38.36 ± 0.76 | 3.88 |
| (10) Capsicum annuum (Paprika) | 63.06 ± 1.91 | 6.27 |
| (11) Vitamin Ca | 1.98 ± 0.01 | — |
| Standard low-fat diet | DHA low-fat diet | High saturated fat diet | |
| N | 18 | 20 | 19 |
| Initial body mass (g) | 318 ± 7 | 323 ± 4 | 323 ± 5 |
| Final body mass (g) | 488 ± 10 | 494 ± 8 | 554 ± 111,2 |
| Change in body mass (g) | 170 ± 9 | 171 ± 6 | 242 ± 151,2 |
| LV mass (g) | 0.98 ± 0.02 | 0.97 ± 0.02 | 1.02 ± 0.02 |
| LV/tibia length (mg/mm) | 23.85 ± 0.90 | 22.93 ± 0.51 | 24.52 ± 0.68 |
| LV+RV/body weight (mg/g) | 2.45 ± 0.03 | 2.39 ± 0.03 | 2.24 ± 0.031,2 |
| LV/body weight (mg/g) | 2.01 ± 0.03 | 1.96 ± 0.03 | 1.85 ± 0.021,2 |
| Epididymal fat mass (g) | 9.24 ± 0.85 | 7.27 ± 0.42 | 14.12 ± 1.001,2 |
| Retroperitoneal fat mass (g) | 9.66 ± 1.23 | 7.79 ± 0.48 | 14.08 ± 1.021,2 |
| Echocardiography data | |||
| EDD (mm) | 7.5 ± 0.3 | 7.3 ± 0.2 | 7.2 ± 0.2 |
| ESD (mm) | 3.7 ± 0.2 | 3.7 ± 0.2 | 3.6 ± 0.2 |
| End diastolic volume (mL) | 0.47 ± 0.05 | 0.43 ± 0.03 | 0.41 ± 0.04 |
| End systolic volume (mL) | 0.06 ± 0.01 | 0.06 ± 0.01 | 0.06 ± 0.01 |
| EF (%) | 88.1 ± 1.2 | 86.3 ± 1.7 | 86.9 ± 1.5 |
| Absolute wall thickness (mm) | 4.5 ± 0.2 | 4.4 ± 0.2 | 4.3 ± 0.2 |
| Relative wall thickness (mm) | 0.6 ± 0.1 | 0.6 ± 0.0 | 0.6 ± 0.0 |
| Patient | Gender | Basal CD4+(cells/mm3) | HCV VL range (log10 UI/mL)† | Fibrosis grade (METAVIR score) | Response to IFN-based therapy | Sampling times∗ |
| A | F | U | <2.78–6.5 | 0 | R | 0, 24 h, 4 wk, 12 wk, 24 wk, 48 wk, 72 wk |
| B | F | 644 | 4.5–6.7 | 4 | NR | 0, 24 h, 4 wk, 12 wk, 24 wk |
| C | M | 304 | 5.3–6.8 | 2 | NR | 0, 24 h, 4 wk, 12 wk, 24 wk |
| E | M | 957 | <2.78–6.1 | 3 | NR | 0, 24 h, 3 wk, 12 wk, 24 wk |
| G | M | 376 | <2.78–6.8 | 2 | NR | 0, 24 h, 4 wk, 12 wk, 24 wk, 48 wk, 72 wk |
| H | M | 130 | 5.3–7.1 | 0 | NR | 0, 24 h, 4 wk, 24 wk |
| J | M | 817 | 3.6–7.1 | 1 | NR | 0, 24 h, 4 wk, 12 wk, 24 wk |
| K | M | 400 | 6.4–6.7 | 4 | NR | 0, 24 h, 4 wk, 12 wk |
| L | M | 625 | 5.9–7.4 | 3 | NR | 0, 24 h, 4 wk, 12 wk |
| M | M | 414 | 4.2–6.3 | 3 | NR | 0, 24 h, 4 wk, 12 wk, 24 wk |
| N | M | 303 | 6.0–6.6 | 2 | NR | 0, 24 h, 4 wk, 12 wk, 24 wk |
| P | M | 622 | <2.78–7.0 | 1 | NR | 0, 24 h, 4 wk, 12 wk, 24 wk |
| Q | M | 468 | <2.78–6.2 | 4 | NR | 0, 24 h, 4 wk, 12 wk, 24 wk, 48 wk, 72 wk |
| R | M | U | <2.78–7.5 | 0.5 | R | 0, 24 h, 4 wk, 12 wk, 24 wk, 48 wk, 72 wk |
| S | M | 262 | 5.8–7.2 | 1 | NR | 0, 24 h, 4 wk, 12 wk, 24 wk |
| U | M | 842 | <2.78–6.7 | 4 | R | 0, 24 h, 4 wk, 12 wk, 24 wk, 48 wk |
| X | M | 483 | <2.78–6.1 | 1 | NR | 0, 24 h, 4 wk, 12 wk, 24 wk |
| Z | M | U | <2.78 | 4 | R | 0, 24 h, 4 wk, 12 wk, 24 wk, 48 wk, 72 wk |
| Disease location | Cases(n = 94) | Sensitivity(%) | Specificity(%) | PPV(%) | NPV(%) | Accuracy(%) |
| Endometriomas | 57 (60.6%) | 100 | 100 | 100 | 100 | 100 |
| Bladder nodules | 11 (11.7%) | 90.9 | 100 | 100 | 98.8 | 98.9 |
| Vaginal nodules | 39 (41.5%) | 92.3 | 98.2 | 97.3 | 94.7 | 95.7 |
| Pouch of Douglas obliteration | 48 (51.1%) | 93.8 | 91.3 | 91.8 | 93.3 | 92.5 |
| Bowel lesions (rectum, sigma, POD) | 20 (21.3%) | 80 | 98.6 | 94.1 | 94.8 | 94.7 |
| Uterosacral ligaments | 50 (53.2%) | 60 | 70.5 | 69.8 | 60.8 | 64.9 |
| Phenolic Acid Intake | p | ||||
| Q1 (Median = 120.36) | Q2 (Median = 205.39) | Q3 (Median = 307.70) | Q4 (Median = 522.26) | ||
| Sex, n (%) | 0.919 | ||||
| Male | 186 (41.1) | 197 (40.5) | 215 (42.3) | 206 (42.2) | |
| Female | 267 (58.9) | 290 (59.5) | 293 (57.7) | 282 (57.8) | |
| Educational level, n (%) | <0.001 | ||||
| Low | 150 (33.1) | 161 (33.1) | 198 (39.0) | 188 (38.5) | |
| Medium | 141 (31.1) | 218 (44.8) | 177 (34.8) | 184 (37.7) | |
| High | 162 (35.8) | 108 (22.2) | 133 (26.2) | 116 (23.8) | |
| Occupational level, n (%) | 0.046 | ||||
| Unemployed | 94 (22.8) | 110 (27.0) | 134 (29.7) | 123 (31.9) | |
| Low | 69 (16.7) | 75 (18.4) | 67 (14.9) | 55 (14.2) | |
| Medium | 111 (26.9) | 95 (23.3) | 131 (29.0) | 103 (26.7) | |
| High | 139 (33.7) | 128 (31.4) | 119 (26.4) | 105 (27.2) | |
| Smoking status, n (%) | 0.034 | ||||
| Non smoker | 298 (65.8) | 289 (59.3) | 316 (62.2) | 292 (59.8) | |
| Ex-smoker | 85 (18.8) | 131 (26.9) | 132 (26.0) | 117 (24.0) | |
| Current smoker | 70 (15.5) | 67 (13.8) | 60 (11.8) | 79 (16.2) | |
| Physical activity, n (%) | 0.585 | ||||
| Low | 85 (21.5) | 87 (19.1) | 75 (16.4) | 82 (19.5) | |
| Medium | 190 (48.0) | 218 (47.9) | 234 (51.3) | 214 (50.8) | |
| High | 121 (30.6) | 150 (33.0) | 147 (32.2) | 125 (29.7) | |
| Alcohol intake, n (%) | <0.001 | ||||
| No | 110 (24.2) | 108 (22.2) | 97 (19.1) | 60 (12.3) | |
| Moderate | 324 (71.4) | 319 (65.5) | 290 (57.1) | 273 (55.9) | |
| Regular | 20 (4.4) | 60 (12.3) | 121 (23.8) | 155 (31.8) | |
| Age (years), mean (SD) | 47.4 (19.3) | 48.7 (18.2) | 48.0 (16.0) | 49.5 (16.9) | 0.296 |
| Sodium (mg/day), mean (SD) | 2669 (864.2) | 2868 (1074.2) | 2793.2 (1174.3) | 3093.8 (1224.1) | <0.001 |
| Potassium(mg/day), mean (SD) | 2892 (848.8) | 3471 (1027.1) | 3892.1(1306.1) | 4392.4 (1713.6) | <0.001 |
| Magnesium (mg/day), mean (SD) | 311.1 (87.9) | 382.5 (109.5) | 416.2 (128.6) | 467.5 (172.7) | <0.001 |
| Calcium (mg/day), mean (SD) | 690.5 (258.3) | 755.6 (264.7) | 808.3 (331.0) | 951.6 (400.5) | <0.001 |
| High adherence to the Mediterranean diet (high) | 40 (14.5) | 102 (37.1) | 82 (29.8) | 51 (18.5) | <0.001 |
| Item | Number of Patients | Percentage (%) | |
| Gender | Male | 127 | 59.1 |
| Female | 88 | 40.9 | |
| Age | <60 | 108 | 50.2 |
| ≥60 | 107 | 49.8 | |
| Smoking history | Yes | 95 | 44.2 |
| No | 120 | 55.8 | |
| Disease staging | Stage IIIB | 36 | 16.7 |
| Stage IV | 179 | 83.3 | |
| Therapy received | Chemotherapy | 181 | 84.2 |
| EGFR-TKI treatment | 114 | 53.0 |
| Namea | Age | Regular medication prior to trial | Trial completion | Result of trial | Treatment decision |
| Standard vs heat retaining knee support – trials commencing December 2001 to February 2002 | |||||
| Ann | 67 | solpadol, meloxicam, amitryptiline | Completed | Heat retaining support beneficial | Continued use of heat retaining support |
| Mel | 54 | dihydrocodeine, co-dydramol, amitryptiline | Withdrew after 6 weeks – intolerance to supports | No further use of supports | |
| Amber | 49 | no regular medication, occasional paracetamol | Completed | Heat retaining support beneficial | Continued use of heat retaining support |
| Lyn | 54 | rofecoxib, dihydrocodeine, paracetamol | Completed | No benefit from either support | No further use of supports |
| Pansyb | 51 | rofecoxib | Completed | No benefit from either support | No further use of supports |
| Diclofenac vs paracetamol – trials commencing September 2003 to October 2003 | |||||
| Pansyb | 53 | Rofecoxib | Withdrew after 6 weeks – diclofenac side-effect (stomach pains) | Returned to previous treatment | |
| Rosie | 31 | Paracetamol | Withdrew after 2 weeks – diclofenac side-effect (mouth ulcers) | Returned to previous treatment | |
| Jack | 59 | no regular medication | Completed | No benefit from either drug | No regular medication (paracetamol when necessary) |
| George | 61 | cod liver oil only | Completed | Diclofenac superior | Continued with diclofenac |
| Skin cancer | TGF-β | uPA/uPAR |
| BCC | −/+ | ? |
| SCC | ++ | ++ |
| Melanoma | −/+ | ++ |
| Motif family | Heart | Sperm |
| E2F1 | Hypo-methylated | Hypo-methylated |
| NFY1 | Hypo-methylated | Hypo-methylated |
| YY11 | Hypo-methylated | Hypo-methylated |
| MYCMAX1 | Hypo-methylated | Hyper-methylated |
| NFKB1 | Hypo-methylated | Hyper-methylated |
| AP1 | Hypo-methylated | Hyper-methylated |
| NRSF2 | Hypo-methylated | Neutral |
| SREBP3 | Hypo-methylated | Neutral |
| SRF2 | Hypo-methylated | Neutral |
| STAT4 | Hypo-methylated | Neutral |
| TCF1 | Hypo-methylated | Neutral |
| GATA1 | Neutral | Hyper-methylated |
| NFE21 | Neutral | Neutral |
| OCT5 | Neutral | Neutral |
| SOX5 | Neutral | Neutral |
| EP3005 | Neutral | Neutral |
| TP536 | Neutral | Neutral |
| Features or characteristics | Total | |
| Diagnosed with infection in pregnancy | Infant with CRI but no CRS features at birth | 3 |
| Infant with CRI resulting in CRS | 5 | |
| Diagnosed after birth | Infant with CRI resulting in CRS | 7 |
| Acquisition of rubella infection | Maternal infection acquired abroad | 8 |
| Maternal infection UK acquired | 6 | |
| Place of infection not known | 1 | |
| Maternal place of birth | Mother born abroad | 14 |
| Maternal place of birth not known | 1 | |
| Reported features of 11 of 12 CRS casesb (more than one feature may be reported for each infant) | Thrombocytopaenia at birth | 2 |
| Sensorineural hearing loss | 10 | |
| Eye defects | 8 | |
| Failure to thrive | 3 | |
| Heart defects | 10 | |
| Developmental problems | 3 | |
| Microcephaly | 5 |
| Extraction methods | Abbreviation | Crude extract (mg/g herb) |
| Heat reflux extraction using water | HRE-W | 297.4 ± 28.4 |
| Microwave-assisted extraction using water | MAE-W | 390.8 ± 16.6*** |
| Ultrasonic extraction using ethanol (70 % vol/vol) | UE-E | 327.4 ± 19.4 |
| Ultrasonic extraction using water | UE-W | 275.0 ± 9.0 |
| Treatment | S. aureus NCTC 13297 | P. aeruginosa NCTC 10781 | Co-culture | ||||||
| Concentration | Mean OD | Biofilm | Concentration | Mean OD | Biofilm | Concentration | Mean OD | Biofilm | |
| Bacteria | 0.1 | Moderate | 0.54 | Strong | 0.14 | Moderate | |||
| BgAg | 0.625% | 0.04 | Non-adherent | 0.625% | 0.08 | Weak | 0.625% | 0.06 | Weak |
| 0.15% | 0.1 | Moderate | 0.15% | 0.23 | Strong | 0.15% | 0.09 | Moderate | |
| Bg | 0.625% | 0.11 | Moderate | 0.625% | 0.07 | Weak | 0.625% | 0.09 | Moderate |
| 0.15% | 0.1 | Moderate | 0.15% | 0.5 | Strong | 0.15% | 0.11 | Moderate |
| Source of variations | Degree of freedom | Mean square | ||||
| pH | Exchangeable acidity | Exchangeable Al | Exchangeable Fe | Exchangeable Ca | ||
| Treatments | 4 | 3.71∗ | 0.23∗ | 0.08∗ | 9.03∗ | 70.70∗ |
| Time | 2 | 0.65∗ | 0.15∗ | 0.01∗ | 0.37∗ | 0.52∗ |
| Treatments ∗ time | 8 | 0.76∗ | 0.34∗ | 0.01∗ | 0.14∗ | 0.24∗ |
| Error | 30 |
| EC identifier | Enzyme name | Pathway | Reference |
| 2.1.3.3 | Ornithine carbamoyltransferase | Arginine/Proline | Cook et al (2007) |
| 2.3.1.57 | Diamine N-acetyltransferase | Polyamines | Cook et al (2007) |
| 2.6.99.2 | Pyridoxine 5-phosphate synthase | Misc | Muller and Kappes (2007) |
| 2.7.2.2 | Carbamate kinase | Pyrimidine | Cook et al (2007) |
| 3.5.3.6 | Arginine deaminase | Arginine/Proline | Cook et al (2007) |
| 3.5.4.2 | Adenine deaminase | Purine | Chaudhary et al (2004) |
| 4.2.1.60 | 3-Hydroxydecanoyl-[acp] dehydratase | Fatty-acid synthesis | Dautu et al (2008) |
| 4.2.1.61 | 3-Hydroxydecanoyl-[acp] dehydratase | Fatty-acid synthesis | Dautu et al (2008) |
| 4.2.1.75 | Uroporphyrinogen-III synthase | Porphyrin | Seeber et al (2008) |
| 4.2.1.99 | 2-Methylisocitrate dehydratase | MC cycle | Seeber et al (2008) |
| 5.5.1.4 | Inositol-3-phosphate synthase | Phospholipid | Smith et al (2007) |
| Meeting/ Event (Date) | Alcohol industry | Tobacco industry |
| Informal Discussion meeting for Chairmen & Directors of Large Organisations held at BAT offices (1966) | Courage, Barclay Simmonds | BAT, Gallaher |
| Practical Skills of Managing People (1981) | Allied, Bass, Charrington, S&N | BAT |
| Practical Skills of Managing Event (1981) | Allied, Bass-Charrington, Scottish & Newcastle | BAT |
| Fermenters Symposium (1982) | Allied, Watney, Grand Met | BAT |
| CBI Conference, Seminar: Employee Involvement (1983) | Allied, Bass, Brewers’ Society, Grand Met, Lyons Tetley, Truman, Whitbread | BAT |
| Institute of Chemical Engineers (ICHEME) Meeting (1985) | Guinness, Watney, Nabisco | BAT |
| Minerva Public Relations Group UK Meeting (1988) | The Alcohol Duty Group | The Tobacco Duty Free Group |
| Statistics for Industry Ltd., Statistical Workshops (1991) | Allied, Bass, Guinness | Imperial, Rothmans |
| Advertising Association- Performance Monitoring Seminar (1994) | Carlsberg-Tetley, Allied-Lyons, Hiram Walker Group, United Distillers | BAT |
| Monitoring Advertising Performance Event (1998) | Guinness, Scottish Courage, IDV | BAT |
| Matrix | GlcNAc | GalNAc | ||||||
| ECa | FCb | Recovery (%) | RSDc | ECa | FCb | Recovery (%) | RSDc | |
| Raw milk | 152.3 ± 3.4 | 30.0 | 102.06 | 1.94 | 189.3 ± 12.1 | 12.5 | 100.50 | 2.46 |
| 60.0 | 101.41 | 1.18 | 25.0 | 99.92 | 1.37 | |||
| 120.0 | 95.12 | 0.59 | 50.0 | 103.30 | 2.08 | |||
| UHT milk | 150.2 ± 5.4 | 30.0 | 102.39 | 3.21 | 115.0 ± 1.1 | 12.5 | 103.34 | 1.81 |
| 60.0 | 97.02 | 0.42 | 25.0 | 105.88 | 0.84 | |||
| 120.0 | 101.06 | 2.99 | 50.0 | 102.70 | 0.57 | |||
| Yoghurt | 151.2 ± 11.1 | 30.0 | 101.20 | 0.66 | 157.0 ± 5.5 | 12.5 | 99.39 | 0.91 |
| 60.0 | 100.20 | 0.79 | 25.0 | 100.58 | 0.92 | |||
| 120.0 | 100.81 | 1.03 | 50.0 | 99.79 | 0.62 | |||
| Infant formula | 720.0 ± 1.6 | 30.0 | 105.45 | 0.68 | 1118.4 ± 12.3 | 12.5 | 100.56 | 1.38 |
| 60.0 | 103.95 | 2.90 | 25.0 | 102.17 | 0.81 | |||
| 120.0 | 103.26 | 1.25 | 50.0 | 99.51 | 1.10 |
| Determinants | Odds ratio | Changeabilitya | Category | Target groupb |
| Demographic | ||||
| Age >40 years | 2.65 | - | Not applicable | Not applicable |
| Chronic illness | 3.37 | - | Not applicable | Not applicable |
| Behavioural | ||||
| Aware of personal risk for influenza infection | 2.80 | + | Knowledge | 2 |
| Aware of risk of infecting patients | 2.54 | + | Knowledge | 2 |
| ‘Vaccination reduces risk of infecting patients’ | 3.68 | + | Knowledge | 2 |
| ‘Vaccination is useful despite the constant flow of visitors’ | 1.88 | + | Knowledge | 2 |
| Aware of the contents of the Health Council’s Advice | 2.41 | + | Knowledge | 2 |
| ‘HCWsc should get vaccinated to ensure continuity of care’ | 2.15 | + | Common interest | 3 |
| ‘HCWs should get vaccinated because of their duty to do no harm’ | 2.22 | + | Common interest | 3 |
| ‘People around me think it is important for me to get vaccinated’ | 1.74 | +/- | Social impact | 3 |
| ‘I would definitively get vaccinated if it was available at a convenient time’ | 28.91 | + | Organizational | 1,2,3 |
| Rank | rs ID | pval | Gene Sym | Gene Name | SNP Function |
| 1.0 | rs10018625 | 0.001536 | TAG ERROR | TAG ERROR | unknown, TAG ERROR |
| 2.0 | rs1047643 | 0.001603 | FDFT1 | Farnesyl-diphosphate farnesyltransferase 1 | coding-synon |
| 3.0 | rs20541 | 0.001644 | IL13 | Interleukin 13 | coding-nonsynon |
| 4.0 | rs2108622 | 0.0020374 | CYP4F2 | Cytochrom P450, family 4, subfamily F, polypeptide 2 | coding-nonsynon |
| 5.0 | rs3759259 | 0.002362 | STYK1 | Protein kinase STYK1 | coding-nonsynon |
| 6.0 | rs1801133 | 0.003251 | MTHFR | 5, 10-methylenetetrahydrofolate reductase (NADPH) | coding-nonsynon |
| 7.0 | rs2069456 | 0.003375 | CDK5 | Cyclin-dependent kinase 5 | intron |
| 8.0 | rs1131532 | 0.005650 | TNFSF10 | Tumor necrosis factor (ligand) superfamily, member 10 | coding-synon |
| 9.0 | rs882709 | 0.005965 | SETX | senataxin | coding-nonsynon |
| 10.0 | rs4646421 | 0.007847 | CYP1A1 | Cytochrome P450, family 1, subfamily A, polypeptide 1 | intron |
| 11.0 | rs1799969 | 0.008221 | ICAM1 | Intercellular adhesion molecule 1 (CD54), human rhinovirus receptor | coding-nonsynon |
| 12.0 | rs3822430 | 0.009157 | SRD5A1 | Steroid-5-alpha-reductase, alpha polypeptide 1 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 1) | coding-synon |
| 13.0 | rs7903344 | 0.009471 | CHUK | Conserved helix-loop-helix ubiquitous kinase | coding-nonsynon |
| 14.0 | rs13926 | 0.011531 | TRAP1 | TNF receptor-associated protein 1 | coding-nonsynon |
| 15.0 | rs3172469 | 0.012006 | BCL6 | B-cell CCL/lymphoma 6 (zinc finger protein 51) | intron |
| 16.0 | rs215101 | 0.012028 | ABCC1 | ATP-binding cassette, sub-family C (CFTR/MRP), member 1 | intron, TagSNP:ABCC1 |
| 17.0 | rs2227564 | 0.012246 | PLAU | Plasminogen activator, urokinase | coding-nonsynon |
| 18.0 | rs3096057 | 0.012484 | CSF1 | Colony stimulating factor 1 (macrophage) | Promoter |
| 19.0 | rs6474491 | 0.013935 | STAR | Steriodogenic acute regulator | Promoter |
| 20.0 | rs2066471 | 0.015231 | MTHRF | 5, 10-methlyenetetrahydrofolate reductase (NADPH) | intron |
| Variable | All participantsa | Group 1 (N=21) | Group 2 (N=21) | p valueb |
| Women N | 39 | 19 (90%) | 20 (95%) | 0.55 |
| College degree or higher N | 40 | 20 (95%) | 20 (95%) | 0.32 |
| White race N | 35 | 18 (86%) | 17 (81%) | 0.68 |
| Hispanic N | 4 | 3 (14%) | 1 (5%) | 0.29 |
| Nonvegetarian N | 37 | 18 (86%) | 19 (90%) | 0.63 |
| Mean (SD) | Mean (SD) | Mean (SD) | p valuec | |
| Age (y) | 45.7 (12.7) | 49 (13.5) | 42.4 (11.1) | 0.09 |
| Weight (kg) | 76.9 (19.8) | 78.0 (22.6) | 75.7 (17.1) | 0.71 |
| BMI | 27.6 (6.0) | 27.7 (6.4) | 27.5 (5.8) | 0.90 |
| Illness duration (y) (N=26) | 23.7 (12.6) | 24.7 (13.8) | 22.7 (11.7) | 0.69 |
| Total cholesterol (mg/dl) | 191.1 (36.9) | 195.6 (42.5) | 186.9 (31.1) | 0.46 |
| VAS (cm) (N=41) | 6.4 (2.1) | 6.1 (2.4) | 6.7 (1.9) | 0.38 |
| Headache number (per wk) (N=40) | 2.3 (1.8) | 2.1 (1.6) | 2.6 (2.1) | 0.50 |
| Headache intensity, scale 0–10 (N=37) | 4.2 (1.4) | 3.9 (1.1) | 4.5 (1.7) | 0.20 |
| Headache duration, hrs (N=38) | 5.8 (3.4) | 6.5 (3.3) | 5.1 (3.5) | 0.19 |
| Headache days (per wk) (N=40) | 2.2 (1.4) | 2.1 (1.6) | 2.3 (1.2) | 0.64 |
| Total | Male | Female | |||||||
| CAD patients | Control subjects | P Value | CAD patients | Control subjects | P Value | CAD patients | Control subjects | P Value | |
| Number(n) | 506 | 351 | 369 | 213 | 137 | 138 | |||
| Age(years) | 54.44 ± 0.407 | 53.37 ± 0.508 | 0.120 | 53.94 ± 0.502 | 53.17 ± 0.617 | 0.336 | 53.52 ± 0.710 | 53.21 ± 0.770 | 0.220 |
| BMI(kg/m2) | 27.99 ± 0.183 | 26.96 ± 0.273 | 0.001* | 27.39 ± 0.189 | 25.39 ± 0.321 | 0.000* | 26.63 ± 0.413 | 25.38 ± 0.406 | 0.000* |
| Glu(mmol/L) | 6.81 ± 0.108 | 6.35 ± 0.147 | 0.001* | 6.73 ± 0.124 | 6.45 ± 0.159 | 0.000* | 6.89 ± 0.218 | 6.16 ± 0.206 | 0.004* |
| BUN(mmol/L) | 5.68 ± 0.137 | 6.28 ± 0.281 | 0.030* | 5.76 ± 0.171 | 6.36 ± 0.242 | 0.030* | 5.48 ± 0.185 | 6.14 ± 0.339 | 0.100 |
| TG(mmol/L) | 2.47 ± 0.060 | 2.19 ± 0.093 | 0.009* | 2.46 ± 0.097 | 2.43 ± 0.080 | 0.000* | 2.49 ± 0.133 | 1.85 ± 0.094 | 0.000* |
| TC(mmol/L) | 4.57 ± 0.101 | 3.82 ± 0.088 | 0.000* | 4.61 ± 0.111 | 3.84 ± 0.110 | 0.109 | 4.51 ± 0.191 | 3.78 ± 0.126 | 0.003* |
| LDL-C(mmol/L) | 2.77 ± 0.043 | 2.62 ± 0.050 | 0.010* | 2.81 ± 0.048 | 2.70 ± 0.059 | 0.000* | 2.69 ± 0.076 | 2.50 ± 0.071 | 0.040* |
| HDL-C(mmol/L) | 0.92 ± 0.019 | 1.22 ± 0.062 | 0.001* | 0.91 ± 0.021 | 1.24 ± 0.045 | 0.000* | 0.94 ± 0.033 | 1.20 ± 0.043 | 0.010* |
| VLDL (mmol/L) | 0.49 ± 0.012 | 0.44 ± 0.019 | 0.009* | 0.49 ± 0.012 | 0.48 ± 0.027 | 0.000* | 0.50 ± 0.027 | 0.37 ± 0.020 | 0.000* |
| DM(%) | 174(64.2 %) | 97(35.8 %) | 0.030* | 119(65.0 %) | 64(35.0 %) | 0.000* | 55(62.5 %) | 33(37.5 %) | 0.000* |
| EH(%) | 250(54.1 %) | 212(45.9 %) | 0.002* | 162(55.7 %) | 129(44.3 %) | 0.000* | 88(51.5 %) | 83(48.5 %) | 0.535 |
| Hyperlipidemia(%) | 262(67.9 %) | 212(45.9 %) | 0.000* | 187(68.8 %) | 85(35.0 %) | 0.000* | 75(65.8 %) | 39(34.2 %) | 0.000* |
| Smoking(%) | 385(66.7 %) | 192(33.2 %) | 0.000* | 309(68.2 %) | 144(31.8 %) | 0.000* | 76(61.3 %) | 48(38.7 %) | 0.001* |
| AA-MF | GMP-MF | p | |
| Energy | |||
| kcal/d | 2,266 ± 263 | 2,566 ± 204 | 0.26 |
| kcal from MF/d | 544 ± 100 | 763 ± 118 | 0.049 |
| kcal from NF/d | 1,722 ± 229 | 1,802 ± 127 | 0.77 |
| Protein | |||
| g protein/d | 79 ± 4 | 81 ± 6 | 0.70 |
| g protein from MF/d | 57 ± 5 | 55 ± 7 | 0.72 |
| g protein from NF/d | 21 ± 2 | 26 ± 4 | 0.32 |
| Calcium : phosphorus ratio3 | |||
| Ca : P ratio/d | 1.06 ± 0.14 | 1.19 ± 0.17 | 0.13 |
| Ca : P ratio from MF/d | 0.96 ± 0.14 | 1.22 ± 0.04 | 0.03 |
| Ca : P ratio from NF/d | 0.90 ± 0.27 | 1.38 ± 0.66 | 0.28 |
| Vitamin D2 | |||
| IU vitamin D/d | 630 ± 230 | 680 ± 167 | 0.75 |
| IU vitamin D from MF/d | 623 ± 182 | 593 ± 131 | 0.82 |
| IU vitamin D from NF/d | 54 ± 30 | 60 ± 26 | 0.81 |
| Calcium2 | |||
| mg calcium/d | 1,745 ± 274 | 1,898 ± 270 | 0.69 |
| mg calcium from MF/d | 1,282 ± 240 | 1,408 ± 264 | 0.58 |
| mg calcium from NF/d3 | 416 ± 78 | 484 ± 76 | 0.39 |
| Magnesium | |||
| mg magnesium/d | 568 ± 62 | 684 ± 113 | 0.27 |
| mg magnesium from MF/d | 362 ± 68 | 400 ± 68 | 0.43 |
| mg magnesium from NF/d | 206 ± 30 | 284 ± 77 | 0.37 |
| Phosphorus | |||
| mg phosphorus/d | 1,836 ± 228 | 1,749 ± 161 | 0.62 |
| mg phosphorus from MF/d | 1,183 ± 229 | 1,131 ± 195 | 0.80 |
| mg phosphorus from NF/d | 653 ± 58 | 618 ± 69 | 0.70 |
| Potassium | |||
| mg potassium/d | 3,249 ± 403 | 3,699 ± 383 | 0.40 |
| mg potassium from MF/d | 1,100 ± 307 | 1,388 ± 175 | 0.39 |
| mg potassium from NF/d | 2,149 ± 324 | 2,311 ± 302 | 0.70 |
| Sodium | |||
| mg sodium/d2 | 2,559 ± 298 | 3,487 ± 334 | 0.006 |
| mg sodium from MF/d | 499 ± 123 | 1,251 ± 176 | 0.017 |
| mg sodium from NF/d2 | 2,060 ± 271 | 2,236 ± 270 | 0.48 |
| Category | Male (n = 129) | Female (n = 108) | P-value |
| Mean (sd) | Mean (sd) | ||
| Confidence to undertake endodontic treatment | 11.34 (2.65) | 09.87 (2.83) | 0.001* |
| Training/Support for undertaking more endodontic treatment in NHS primary dental care | 11.33 (2.48) | 11.12 (2.41) | 0.51 |
| Dissatisfaction with endodontic service access | 11.72 (2.25) | 12.05 (2.19) | 0.051 |
| Acceptability/Support for DwSI services | 15.09 (2.05) | 15.58 (1.68) | 0.047 |
| Interest in training as an endodontic DwSI | 3.48 (1.36) | 3.51 (1.41) | 0.82 |
| Characteristic | Full Cohort(n = 309) † | Excluded(n = 199) † | One Month Analysis Sample(n = 110) ‡ | P-value†† |
| Mean (SD) or n (%) | Mean (SD) or n (%) | Mean (SD) or n (%) | ||
| Age in years | 74.7 (8.5) | 75.9 (8.3) | 72.5 (8.3) | 0.001 |
| Male | 145 (47) | 96 (48) | 49 (45) | 0.53 |
| Education in years | 12.5 (2.8) | 12.4 (2.9) | 12.5 (2.6) | 0.75 |
| Non-white race | 51 (16) | 35 (18) | 16 (14) | 0.49 |
| APACHE II score | 23.5 (6.4) | 24.6 (6.3) | 21.4 (6.1) | <0.0001 |
| Charlson Co-Morbidity Index | 1.8 (1.9) | 1.9 (2.0) | 1.7 (1.6) | 0.99 |
| Admitted from home* | 241 (78) | 143 (72) | 98 (89) | 0.0005 |
| Baseline Medical Status | ||||
| Evidence of depression** | 85 (28) | 63 (32) | 22 (20) | 0.03 |
| Dementia | 95 (31) | 75 (38) | 20 (18) | 0.0004 |
| Any Impairment in Activities of Daily Living | 115 (37) | 94 (47) | 21 (19) | <0.0001 |
| Bathing impairment | 104 (34) | 88 (44) | 16 (14) | <0.0001 |
| Grooming impairment | 42 (14) | 37 (19) | 5 (5) | 0.0005 |
| Transfer bed to chair impairment | 54 (17) | 48 (24) | 6 (5) | <0.0001 |
| Walk across room impairment | 56 (18) | 49 (25) | 7 (7) | <0.0001 |
| Ability to dress impairment | 44 (14) | 34 (17) | 10 (9) | 0.05 |
| Ability to eat impairment | 10 (3) | 10 (5) | 0 (0) | 0.02 |
| Ability to toilet impairment | 41 (13) | 38 (19) | 3 (3) | <0.0001 |
| Admitting Diagnosis | ||||
| Sepsis | 51 (16) | 39 (20) | 12 (11) | 0.049 |
| Respiratory | 156 (51) | 104 (52) | 52 (47) | 0.40 |
| Neurologic | 5 (2) | 5 (3) | 0 (0) | 0.16 |
| Gastrointestinal hemorrhage | 52 (17) | 24 (12) | 28 (25) | 0.003 |
| Other | 45 (15) | 27 (14) | 18 (16) | 0.50 |
| ICU Factors | ||||
| Delirium during ICU Stay*** | 239 (79) | 177 (92) | 61 (55) | <0.0001 |
| Intubated | 167 (54) | 126 (63) | 41 (37) | <0.0001 |
| Days of ventilation, Median (IQR)**** | 6 (8) | 6 (10) | 4 (3) | 0.006 |
| Length of stay, Median (IQR)**** | 5 (6) | 6 (9) | 3 (3) | <0.0001 |
| Total days of delirium (IQR)**** | 5 (6) | 6 (9) | 1 (3) | <0.0001 |
| PM/DM-ILD (n = 116) | Infection (n = 38) | Non-infection (n = 78) | P value | |
| Women (n (%)) | 24/38 (63.2%) | 59/78 (75.6%) | 0.16 | |
| Type (n) | PM 7, DM 24, CADM 7 | PM 15, DM 27, CADM 36 | 0.007** | |
| Age (years) | 58.9 ± 13.9c | 54.7 ± 15.2c | 0.15 | |
| Baseline data | LDH (U/l) | 420 (335–574)d | 343 (258–486)d | 0.005** |
| KL-6 (U/ml) | 848 (605–1231)d | 572 (405–978)d | 0.014* | |
| CRP (mg/dl) | 0.9 (0.34–1.99)d | 0.30 (0.10–1.51)d | 0.032* | |
| Lymphocyte (/μl) | 848 (552–1177)d | 1,008 (735–1435)d | 0.040* | |
| Albumin (g/dl) | 3.18 ± 0.52c | 3.53 ± 0.55c | 0.003** | |
| PaCO2 (mmHg) | 36.0 (31.5–38.8)d | 38.0 (35.5–41.5)d | 0.016* | |
| HRCT | Zone A | 1.0 (0–2.0)d | 1.0 (0–1.0)d | 0.054 |
| Zone B | 1.0 (1.0–2.0)d | 1.0 (0–1.0)d | 0.049* | |
| Zone C | 2.0 (1.0–3.0)d | 1.0 (1.0–2.0)d | 0.036* | |
| Zone D | 3.0 (2.0–4.0)d | 3.0 (2.0–4.0)d | 0.068 | |
| Zone total | 7.0 (4.0–11.0)d | 6.0 (4.0–8.0)d | 0.031* | |
| Treatment (n (%)) | Initial PSL dose (mg/kg/day) | 0.94 ± 0.30c | 0.76 ± 0.29c | 0.005** |
| mPSL pulse (n (%)) | 31/38 (81.6%) | 46/78 (59.0%) | 0.016* | |
| IVCY (n (%)) | 25/38 (65.8%) | 23/78 (29.5%) | <0.001** | |
| Calcineurin inhibitor | 34/38 (89.5%) | 47/77 (61.0%) | 0.002** | |
| Combination therapye | 23/38 (60.5%) | 17/78 (21.8%) | <0.001** | |
| Outcome (n (%)) | Death | 11/38 (28.9%) | 3/78 (3.8%) | <0.001** |
| MF (ε = 10) | PHIA (ε = 14) | |||||
| PDB code | Name | length | low energy | high score | low energy | high scoring |
| 1gcq(B) | Grb2 | 57 | 37.2 | 49.5 | 36.1 | 47.0 |
| 1gcq(C) | Vav | 69 | 45.6 | 55.0 | 45.1 | 52.4 |
| 1cka | c-Crk | 56 | 39.8 | 52.1 | 35.9 | 49.9 |
| 1shg | alpha-spec. | 57 | 26.9 | 37.6 | 26.5 | 39.5 |
| 1abo | Abl kinase | 58 | 37.7 | 48.5 | 34.7 | 45.8 |
| 1ad5 | Hck kinase | 58 | 22.6 | 38.4 | 23.6 | 36.1 |
| 1csk | Csk | 56 | 37.3 | 48.5 | 27.0 | 38.5 |
| 1fmk | c-Src | 60 | 32.4 | 43.5 | 33.8 | 45.9 |
| average | 34.9 | 46.6 | 32.8 | 44.4 |
| Developmental stage | Water (n) | Zinc chloride (n) | Soybean root exudate (n) |
| 3 cell | 2.67 ± 1.15 (3) | 3.24 ± 1.25 (4) | 3.20 ± 1.3 (6) |
| 4 cell | 4.67 ± 2.08 (3) | 5.33 ± 1.53 (3) | 5.25 ± 0.96 (7) |
| Gastrula | 75.71 ± 9.25 (6) | 72.60 ± 1.51 (5) | 70.60 ± 4.35 (7) |
| Tadpole | 100.50 ± 8.31 (6) | 97.25 ± 4.57 (4) | 93.80 ± 5.77 (5) |
| J1 stage | 112 ± 7.66 (7) | 113.80 ± 9.49 (5) | 107.72 ± 10.12 (10) |
| J2 stage | 168.29 ± 7.16 (7) | 165.20 ± 9.76 (5) | 166.14 ± 10.16 (11) |
| Citation | Mosquito Species | Diet Components | Success Rate |
| 1955. Lea et al. [57] | Aedes aegypti, Ae. quadrimaculatus | Skimmed milk with 10% honey. | The authors state that skimmed milk can be a substitute for blood to produce eggs. An. quadrimaculatus was also fed proteose-peptone, liver concentrate, and casein hydrolysate. |
| 1955. Dimond et al. [58] | Aedes aegypti | Mixture of 18 amino acids in 10% honey water. | A low egg number of 5.2 eggs/female is reported |
| 1990. Kogan [56] | Aedes aegypti | Porcine albumin (102 mg/mL), γ-globulin (15 mg/mL), hemoglobin (8 mg/mL), ATP (1 mM), NaCl (5–10 mM), and NaHCO3 (120 mM) in water. | 101 ± 6.8 eggs/female |
| 1996. Cosgrove and Wood [59] | Aedes aegypti | Porcine albumin (100 mg/mL), γ-globulin (15 mg/mL), hemoglobin (8 mg/mL), isoleucine (2.5 mg/mL), ATP (1 mM), NaCl (5–10 mM), and NaHCO3 (120 mM) in water. | 55.32 ± 4.1 eggs/female. 61.9% hatch rate |
| 1996. Cosgrove and Wood [59] | Aedes aegypti | Bovine serum albumin (100 mg/mL), γ-globulin (30 mg/mL), hemoglobin (8 mg/mL), and ATP (1 mM) in Ringer‘s solution. | 64.56 ± 5.1 eggs/female. 54.1% hatch rate. A colony of Ae. aegypti was raised on this diet for more than 25 generations |
| 1996. Griffith and Turner [60] | Culex quinquefasciatus | Soy milk formula (33 mg/mL), γ-globulin (11.5 mg/mL), ovalbumin (76.5 mg/mL), ATP (1 mM), NaCl (150 mM), and NaHCO3 (100 mM) in water. | 116 eggs/female. Colonies were maintained for 6 and 15 generations |
| 2014. Pitts [61] | Aedes albopictus | Bovine serum albumin (200 mg/mL) and ATP (1 mM) in phosphate buffered saline. | 92.2 ± 4.4 eggs/female. 71.8% ± 6.1% hatch rate. Colonies were maintained for 6 generations |
| 2015. Gonzales et al. [32] | Aedes aegypti | Bovine serum albumin (200 mg/mL), ATP (1 mM), and iron (III) chloride (0.5 mg/mL) in Aedes physiological saline. | 66 ± 10.8 eggs/female. 33.06% ± 12.34% hatch rate |
| Indicator a,b | Overall Diet | Quintiles of the Contribution of Ultra-Processed Foods to Total Energy Intake | Standardized Regression Coefficient | ||||||
| Mean | SE | Q1 | Q2 | Q3 | Q4 | Q5 | Crude | Adjusted c | |
| Energy intake (kcal/d) | 1764.71 | 8.55 | 1732.00 | 1766.35 | 1784.89 | 1776.38 | 1763.96 | 0.02 | 0.03 |
| Percentage of energy intake from: | |||||||||
| Proteins | 15.77 | 0.06 | 17.24 | 16.57 | 16.00 | 15.19 | 13.84 | -0.32 * | -0.30 * |
| Carbohydrates | 48.65 | 0.12 | 45.45 | 47.27 | 48.61 | 50.07 | 51.84 | 0.30 * | 0.26 * |
| Free sugars | 12.44 | 0.10 | 9.94 | 11.34 | 12.16 | 13.38 | 15.41 | 0.29 * | 0.23 * |
| Fats | 32.18 | 0.09 | 31.37 | 31.93 | 32.12 | 32.47 | 33.04 | 0.09 * | 0.11 * |
| Saturated fats | 12.10 | 0.05 | 11.67 | 12.19 | 12.24 | 12.18 | 12.19 | 0.04 * | 0.03 |
| Dietary fibre density (g/1000 kcal) | 7.70 | 0.04 | 8.36 | 8.04 | 7.81 | 7.46 | 6.86 | -0.20 * | -0.13 * |
| Sodium density (g/1000 kcal) | 1213.91 | 5.11 | 1072.57 | 1204.21 | 1228.75 | 1245.29 | 1318.85 | 0.23 * | 0.22 * |
| Potassium density (mg/1000 kcal) | 1547.86 | 5.94 | 1735.20 | 1635.79 | 1571.38 | 1470.65 | 1326.19 | -0.37 * | -0.31 * |
| Type of services | Quantitative indicators (Survey of female workers) | Qualitative indicators |
| Hotline | • Frequency of services• Ranking frequent topic of call• Number of calls over time• % of women ever heard about the services• % of women ever used services• Ranking about quality/importance of services | • In-depth information about issues when implementing services from service provider (hotline expert)• In-depth information about relevance, quality and usefulness of services from female workers |
| Map of health care services providers | • Number of health services provided surveyed and presented in map• % of women ever received map• % of women ever used map to find health care providers• Ranking about quality/importance of services | • In-depth information about relevance, quality and usefulness of services from female workers |
| SMS | • Frequency of services• Number of SMS developed• Number of SMS sent over time• Major topic of SMS sent• % of women ever heard about the services• % of women ever used services• Ranking about quality/importance of services | • In-depth information about relevance, quality and usefulness of services from female workers |
| Author (Year) | Number of patients with seminoma | Residual disease | Necrosis/scar |
| Chong et al (1986) [8] | 5 | 1 (20%) | 4 (80%) |
| Greist et al (1984) [7]a | 1 | NA | NA |
| Ng (1997) [12] | 1b | 0 | 1b |
| Geldart et al (2002) [13] | 18 | 3 (16.7%) | 15 (83.3%) |
| Ramani et al (2008) [16] | 13 | 0 | 13 (100%) |
| Miller et al (2012) [17]c | 6 | 4 | 2 (33.3%) |
| Total | 43(44)d | 8 (18.6%) | 35 (81.3%) |
| All tumors | TC | AC | LCNEC | |
| Clinical status at last f/u | ||||
| Alive without recurrence | 35 | 30 | 5 | 0 |
| Alive with recurrence | 2 | 0 | 1 | 1 |
| Alive, unknown | 7 | 6 | 0 | 1 |
| Died with disease | 8 | 0 | 1 | 7 |
| Died of other causes | 2 | 2 | 0 | 0 |
| Died, unknown cause | 1 | 1 | 0 | 0 |
| Median disease free survival (months)† | NR | NR | 35.5 | 10.1 |
| Hazard ratio | <0.01 | 0.10 | 1.00 | |
| Confidence interval (95%) | - | 0.01-0.57 | - | |
| P-value | - | <0.0001 | 0.0063 | - |
| Mean DFS follow-up (months) | 20.2 | 21.9 | 21.9 | 12.0 |
| Median survival (months) | NR | NR | NR | 19.7 |
| Hazard ratio | 0.06 | 0.08 | 1.00 | |
| Confidence interval (95%) | 0.01-0.24 | 0.00-0.54 | - | |
| P-value | - | <0.0001 | 0.0070 | - |
| Mean OS follow-up (months) | 29.6 | 31.4 | 34.3 | 18.3 |
| CO initial liquid conc. (mM) (headspace, atm) | tmax (d)* | CO specific activity (mmol CO/g VSS.d) | Relative CO conversion rate (%)§ | CH4 specific activity (mmol CO/g VSS.d) | Relative CH4 conversion rate (%)§ | Products formed (% of the stoichiometric yield)‡ | H2 at maximum (atm.10−3) | ||
| CH4 | Acetate | Propionate | |||||||
| VANCOMYCIN | |||||||||
| 0.09 (0.1) | ** | 0.26 ± 0.03 | 15 ± 2 | 0.15 ± 0.03 | 13 ± 3 | 154 ± 6 | 13 ± 3 | 30 ± 10 | 0.4 ± 0.01 |
| 0.17 (0.2) | ** | 0.36 ± 0.05 | 7 ± 1 | 0.14 ± 0.01 | 14 ± 1 | 130 ± 4 | 21 ± 15 | 17 ± 0.0 | 0.3 ± 0.01 |
| 0.26 (0.3) | 20 | 0.53 ± 0.08 | 7 ± 1 | 0.17 ± 0.0 | 31 | 113 ± 3 | 3 ± 1 | 12 ± 0 | 0.4 ± 0.005 |
| 0.44 (0.5) | 44 | 0.99 ± 0.06 | 11 ± 1 | 0.26 ± 0.04 | 58 ± 18 | 89 ± 8 | 8 | 7 | 1.2 ± 0.2 |
| 0.87 (1.0) | 40 | 2.11 ± 0.32 | 30 ± 5 | 0.74 ± 0.06 | 1480 ± 60 | 89 ± 0.2 | 2.6 | 3.5 | 85 |
| 1.31 (1.5) | 55 | 1.38 ± 0.05 | 19 ± 1 | 0.31 ± 0.06 | ∞ | 66 ± 22 | 7 ± 0.1 | 5.4 ± 1.9 | 72 ± 1.2 |
| BES | |||||||||
| 0.09 (0.1) | 5 | 2.10 ± 0.14 | 119 ± 8 | 0.05 ± 0.0 | 4 | 28 ± 0.2 | 67 ± 2 | 18 ± 3 | 3.3 ± 0.01 |
| 0.17 (0.2) | 4 | 2.39 ± 0.46 | 45 ± 9 | 0.01 ± 0.0 | 1 | 9 ± 0.3 | 51 ± 8 | 7 ± 0.4 | 5.6 ± 2.3 |
| 0.26 (0.3) | 5 | 2.14 ± 0.11 | 30 ± 2 | 0.03 ± 0.01 | 6 ± 2 | 12 ± 3 | 82 ± 4 | 17 ± 1 | 28 ± 14 |
| 0.44 (0.5) | 8 | 4.64 ± 0.30 | 54 ± 3 | 0.00 ± 0.0 | 0 | 2 ± 0 | 54 ± 3 | 10 ± 1 | 22 ± 5 |
| 0.87 (1.0) | 21 | 6.30 ± 0.28 | 82 ± 12 | 0.001 ± 0.00 | 2 | 0.4 ± 0.0 | 57 ± 14 | 16 ± 8 | 37 ± 5 |
| 1.31 (1.5) | 31 | 2.92 ± 0.61 | 41 ± 9 | 0.000 ± 0.00 | 0 | 0.1 ± 0.1 | 45 ± 7 | 11 ± 1 | 37 ± 12 |
| SEQUENCE | ENERGY | SEQUENCE | ENERGY |
| AAA | -0.65821 | AAAAA | -2.84828 |
| AAB | 0.03223 | AAAAB | -1.58944 |
| ABA | -0.65821 | AAABA | -2.44493 |
| ABB | 0.03223 | AAABB | -0.54688 |
| BAB | -0.03027 | AABAA | -2.53170 |
| BBB | -0.03027 | AABAB | -1.34774 |
| AABBA | -0.92662 | ||
| AAAA | -1.67633 | AABBB | 0.04017 |
| AAAB | -0.58527 | ABAAB | -1.37647 |
| AABA | -1.45098 | ABABA | -2.22020 |
| AABB | 0.06720 | ABABB | -0.61680 |
| ABAB | 0.64938 | ABBAB | -0.00565 |
| ABBA | -0.03617 | ABBBA | -0.39804 |
| ABBB | 0.00470 | ABBBB | -0.06596 |
| BAAB | 0.06172 | BAAAB | -0.52108 |
| BABB | -0.00078 | BAABB | 0.09621 |
| BBBB | 0.13974 | BABAB | -0.64803 |
| BABBB | -0.18266 | ||
| BBABB | -0.24020 | ||
| BBBBB | -0.45266 |
| Drug | Route | IC50(μM) | Max serum level (μM) | Elimination half life | Efficacy | Mode of action |
| Aclarubicin | IV | 0.94 | 0.34 | 13.3 hrs | -122.30 | Topoisomerase I and II inhibitor |
| Actinomycin D | IV | 0.38 | 0.02-0.08 | 36 hrs | -112.51 | Inhibitors of DNA synthesis |
| Bortezomib | IV | 0.34 | 0.16-0.31 | 9-15 hrs | -77.11 | Proteasome inhibitor; |
| Carboquone | PO/IV | 0.75 | 0.62-0.74 (200-240 ng/mL) | 0.5 hrs | -119.79 | Alkylating agents |
| Ciclopirox | Topical | 0.64 | N/A - topical only | 2.2 hrs in rabbits | -61.11 | Chelation of polyvalent metal cations |
| Deslanoside | 0.34 | 0.16 | 51 hrs | -110.35 | Na+/K + ATPase inhibition; | |
| Digitoxin | IV | 0.08 | 0.05-0.2 | 4-9 days | -109.13 | Na+/K + ATPase inhibition; |
| Digoxin | PO/IV | 0.19 | 0.003 | 36-48 hrs | -111.40 | Na+/K + ATPase inhibition; |
| Ecteinascidin | IV | 0.01 | Up to 0.05 | 50-180 hrs | -116.82 | Disruption of DNA strand |
| Homoharringtonine | SQ | 0.21 | 0.176 | 9.3 hrs | -125.33 | Protein synthesis inhibitor |
| Lanatoside A | IV/PO | 0.19 | N/A | N/A | -114.10 | Na+/K + ATPase inhibition; |
| Lanatoside C | IV/PO | 0.3 | N/A | N/A | -117.82 | Na+/K + ATPase inhibition; |
| Methotrexate | PO/IV | 0.02 | 10-100 | 8-15 hrs | -74.91 | DHFR inhibitor |
| Metildigoxin | PO/IV | 0.24 | N/A | N/A | -110.90 | Na+/K + ATPase inhibition; |
| Niclosamide | PO/IV | 0.27 | N/A | N/A | -94.29 | Uncouple oxidative phosphorylation |
| Ouabain | IV | 0.08 | 0.128 | 18 hrs | -110.64 | Na+/K + ATPase inhibition; |
| Plicamycin | IV | 0.94 | 0.6 μM | 10.5 hrs | -117.62 | RNA synthesis inhibitor; |
| Proscillaridin A | IV/PO | 0.01 | 0.019 (IV); 0.0019 (PO) | 23-33 hrs | -110.55 | Na+/K + ATPase inhibition; |
| Pyrimethamine | PO/IV | 0.75 | 8.04 | 140-190 hrs | -81.43 | DHFR inhibitor |
| Rotenone | N/A | 0.75 | N/A | N/A | -69.22 | Electron transport chain in mitochondria interference |
| Trimetrexate glucuronate | IV | 0.01 | N/A | 11-16 hrs | -80.39 | DHFR inhibitor |
| Results | Data Frequency (Hz) | |||||||
| 10 | 4 | 2 | 1 | 0.5 | 0.33 | 0.25 | 0.2 | |
| Training instances | 729,097 | 364,588 | 184,297 | 98,301 | 50,805 | 34,291 | 25,527 | 20,566 |
| Test instances | 6,561,871 | 3,281,290 | 1,658,673 | 884,709 | 457,244 | 308,623 | 229,746 | 185,092 |
| Overall accuracy (%) | 99.963 | 99.883 | 99.690 | 99.131 | 98.012 | 96.731 | 95.415 | 94.477 |
| Time (s) | 304.86 | 102.09 | 42.05 | 19.37 | 9.45 | 6.02 | 5.35 | 3.53 |
| Dataset | Description | Updated | Genes | Reference |
| hg18rpa | Protein-coding genes on autosomal chromosomes (based on human genome hg18 and RefSeq genes) | 2011 | 18,166 | [35] |
| HI | Recombination hotspots intersected genes | 2010 | 1,156 | - |
| MI | Recombination middle spots intersected genes | 2010 | 1,481 | - |
| CI | Recombination cold spots intersected genes | 2010 | 1,594 | - |
| HK | Housekeeping genes | 2011 | 1,974 | [36] |
| SPD | Genes encoding secreted proteins | 2010 | 1,667 | [37] |
| TiGER | Tissue-specific genes | 2008 | 4,710 | [38] |
| DGD | Duplicated genes | 2012 | 4,393 | [16] |
| AGE | Genes classified by different evolutionary age | 2011 | 16,418 | [17] |
| OMIM | Mendelian disorder associated genes in human | 2012 | 2,624 | [39] |
| MD | Mendelian Disease Genes (at least one mutation in the particular gene is causative of the disease) | 2011 | 1,629 | [21] |
| CGC | Genes with mutations have been causally implicated in cancer | 2011 | 424 | [23] |
| TICdb | Reciprocal translocation associated genes in human tumours | 2008 | 240 | [40] |
| dbCRID | Chromosomal rearrangement associated genes in human diseases | 2010 | 401 | [22] |
| InteCR | Integrated chromosomal rearrangement associated genes in human diseases (Combined of dbCRID, TICdb and CGC genes) | 2012 | 614 | - |
| Inoculated andContacts vs.Controls | Inoculated vs.Contacts | Carriers vs.Non-Carriers | |
| SAA | <0.0001*** | 0.61 | 0.49 |
| IFN | <0.0001*** | 0.43 | 0.27 |
| Haptoglobin | <0.0001*** | 0.04* | 0.015* |
| Gene name | Sequence (5’–3’) |
| β-actin | Sense: TCTTGGGTATGGAGTCCTGAntisense: TAGAAGCATTTGCGGTGG |
| FGA | Sense: GCAGAACAGCATCCAGGAGCAGGAntisense: TCCACCTGGTAATCAAAACTTCTAGCAC |
| CA2 | Sense: CACTGGCACGAGCACTTCAntisense: ACTTCACGCCATCCACAGT |
| KRT7 | Sense: CTGGACGGGTTGTTAAATAntisense: TCCGCTTCGTAGAGAGAT |
| GRTP1 | Sense: GGCTGCTCCAACGCCCACTTAntisense: CGCAACGCCTTCTGCTCTTT |
| MnSOD | Sense: CTGACCTGCCCTACGACTAntisense: TGGTATGATTGATATGACCC |
| LOC429524 | Sense: GGAGGAAATGCGGCGCTTAGAntisense: GGCTGGACGAGACGCTGTTGA |
| ATP5A1 | Sense: CAGTTTGGGTCTGATTTGGAntisense: AGCTTAGCTTCCGTCTGG |
| FKBP4 | Sense: TACCTCCCAATGCTACGCAntisense: CCTTCGCCTTTCTTACGG |
| GOT1 | Sense: GCACAGACCCTACTCCAGACAntisense: AAGCCCTCGGAGACAAAG |
| LMNA | Sense: GGGGAACTGGCAGGTGAAGCAntisense: CCTCGTCGTCGTCGTTGATG |
| PTGDS | Sense: CCGAGGTCTTTTGTTTGAntisense: AGGAGGGGGACTTTGATG |
| HSPβ1 | Sense: CAAACACGAGGAGAAACAAntisense: CGTTTATTCAAGGCACTG |
| Apo A-I | Sense: TCCGCTTCGTAGAGAGATGTGAntisense: TCAGCGTGTCCAGGTTGTC |
| Independently (N = 372) | Long-term care facility (N = 107) | |||||
| N | HR (95%CI) | P-value | N | HR (95%CI) | P-value | |
| Socio-demographic factors | ||||||
| Female | 242 | 1.4 (0.9, 2.3) | 0.127 | 80 | 2.1 (0.9, 4.9) | 0.098 |
| Low income | 170 | 1.0 (0.7, 1.5) | 0.914 | 68 | 0.9 (0.5, 1.6) | 0.650 |
| Primary school only | 221 | 1.2 (0.8, 1.9) | 0.452 | 75 | 2.3 (1.1, 4.9) | 0.036 |
| Smoking (current) | 55 | 1.1 (0.6, 1.9) | 0.817 | 15 | 1.4 (0.6, 3.1) | 0.443 |
| Body Mass Index ≥27 | 171 | 1.2 (0.8, 1.8) | 0.329 | 41 | 0.9 (0.4, 1.7) | 0.655 |
| Functioning | ||||||
| Severe cognitive impairment(MMSE < 19) | 36 | 1.9 (1.1, 3.4) | 0.030 | 54 | 2.3 (1.2, 4.4) | 0.009 |
| Depressive symptoms (GDS-15 > 4) | 46 | 1.2 (0.6, 2.2) | 0.578 | 12 | 0.2 (0.0, 1.7) | 0.146 |
| Disability in daily living † | 191 | 1.9 (1.3, 2.9) | 0.002 | 92 | 3.6 (1.1, 11.7) | 0.033 |
| Co-morbidities | ||||||
| Diabetes mellitus | 53 | 0.8 (0.4, 1.5) | 0.536 | 23 | 1.1 (0.5, 2.6) | 0.759 |
| Stroke | 31 | 1.4 (0.8, 2.8) | 0.269 | 29 | 1.6 (0.9, 3.1) | 0.143 |
| Cancer | 80 | 1.1 (0.6, 1.8) | 0.845 | 17 | 1.0 (0.4, 2.4) | 0.963 |
| Benign Prostatic Hyperplasia(IPSS score ≥8) | 49 | 1.3 (0.6, 2.9) | 0.521 | 4 | NA | NA |
| UTI between the ages of 85 and 86 years | 41 | 3.3 (2.1, 5.3) | < 0.001 | 31 | 4.1 (2.2, 7.5) | < 0.001 |
| Unintentional loss of faeces | 35 | 2.7 (1.6, 4.8) | < 0.001 | 30 | 2.5 (1.3, 4.6) | 0.004 |
| Self-reported urine incontinence | 143 | 1.7 (1.2, 2.6) | 0.007 | 69 | 1.9 (0.9, 4.0) | 0.071 |
| Medical diagnosis incontinence | 69 | 1.3 (0.8, 2.2) | 0.260 | 26 | 1.7 (0.9, 3.4) | 0.110 |
| PRAFAB score ≥11 | 76 | 0.7 (0.3, 1.7) | 0.462 | 24 | NA | NA |
| PRAFAB: Pad use | 69 | 1.0 (0.4, 2.2) | 0.949 | 22 | 1.9 (0.3, 15.1) | 0.530 |
| Creatinine clearance < 30 mL/minute | 29 | 0.8 (0.4, 1.6) | 0.487 | 14 | 1.8 (0.5, 5.8) | 0.337 |
| CRP > 5 mg/L | 116 | 1.2 (0.8, 1.8) | 0.425 | 43 | 1.1 (0.6, 2.1) | 0.664 |
| Variable | Unadjusted | Adjusted | ||||
| OR | 95%CI | p | OR | 95%CI | p | |
| Level 1a – Demographic characteristics | ||||||
| Education level | < 0.001 | 0.024 | ||||
| High school and university (C/I) | 1.00 | 1.00 | ||||
| Basic education (C) | 1.71 | 1.09–2.67 | 1.27 | 0.73–2.19 | ||
| Basic education (I)/Illiterate | 3.10 | 1.99–4.82 | 2.02 | 1.17–3.47 | ||
| Access to telephone | 0.001 | 0.006 | ||||
| Yes | 1.00 | 1.00 | ||||
| No | 2.95 | 1.58–5.52 | 2.45 | 1.28–4.70 | ||
| Level 2b – Behavioral characteristics | ||||||
| Religion | 0.044 | 0.012 | ||||
| No religion | 1.00 | 1.00 | ||||
| Catholic | 1.16 | 0.77–1.74 | 1.70 | 1.07–2.68 | ||
| Evangelical | 0.68 | 0.45–1.03 | 0.86 | 0.53–1.39 | ||
| Number of pregnancies including current one | 0.002 | 0.008 | ||||
| 1 | 1.00 | 1.00 | ||||
| 2–3 | 1.64 | 1.11–2.43 | 1.77 | 1.12–2.79 | ||
| ≥ 4 | 2.23 | 1.39–3.58 | 2.27 | 1.30–3.95 | ||
| Number of sex partners in the last 12 months | < 0.001 | 0.004 | ||||
| 1 | 1.00 | 1.00 | ||||
| 2 | 1.93 | 1.18–3.17 | 1.66 | 0.93–2.97 | ||
| ≥ 3 | 4.60 | 2.42–8.75 | 3.15 | 1.51–6.53 | ||
| Age at which started using drugs (years) | < 0.001 | 0.003 | ||||
| Does not use | 1.00 | 1.00 | ||||
| ≥ 18 | 1.83 | 0.73–4.60 | 0.50 | 0.16–1.53 | ||
| ≤ 17 | 5.66 | 3.03–10.56 | 3.04 | 1.45– 6.40 | ||
| Current partner uses drugs | <0.001 | 0.026 | ||||
| No | 1.00 | 1.00 | ||||
| Yes | 2.26 | 1.47–3.47 | 1.78 | 1.07–2.98 | ||
| Level 3c – Clinical, obstetric, and health care history in prenatal care and maternity hospital | ||||||
| Number of appointments in the prenatal care | < 0.001 | < 0.001 | ||||
| ≥ 7 | 1.00 | 1.00 | ||||
| 6–4 | 1.31 | 0.86–2.00 | 1.48 | 0.88–2.49 | ||
| 3–1 | 3.60 | 2.17–5.98 | 3.53 | 1.86–6.69 | ||
| No prenatal care | 4.47 | 2.53–7.90 | 3.20 | 1.36–7.54 | ||
| History of previous STI | < 0.001 | < 0.001 | ||||
| No | 1.00 | 1.00 | ||||
| Yes | 10.68 | 6.46–17.66 | 9.70 | 5.46–17.24 |
| Setting | Number of hours | Number of days | Time period |
| 999 | 170 | 41 | Nov 2008 – Jul 2010 |
| SPA | 172 | 33 | Oct 2009 – July 2010 |
| OOH | 149 | 27 | Sept 2009 – Aug 2010 |
| Total | 491 | 101 | Nov 2008 – Aug 2010 |
| Control | Cold | Fold increase | |
| Col-0 | 2.1 , 0.7 | 6.0 , 1.1 | 2.9 |
| dgk1-1 | 2.2 , 0.5 | 5.1 , 0.4 | 2.3 |
| dgk2-1 | 2.2 , 0.6 | 6.7 , 1.7 | 3.1 |
| dgk2-2 | 1.9 , 0.3 | 6.5 , 1.8 | 3.3 |
| dgk4-1 | 1.9 , 0.4 | 5.9 , 0.9 | 3.2 |
| dgk4-2 | 2.0 , 0.3 | 7.2 , 1.0 | 3.7 |
| dgk5-1 | 3.3 , 0.3 | 8.4 , 0.4 | 2.6 |
| dgk6-1 | 2.6 , 0.2 | 9.7 , 0.6* | 3.7 |
| dgk7-1 | 2.0 , 0.4 | 9.4 , 1.4* | 4.6 |
| dgk7-2 | 2.3 , 0.5 | 10.3 , 1.0** | 4.5 |
| dgk7-3 | 1.8 , 0.2 | 8.7 , 0.5 | 4.9 |
| Substance | Mechanism | Cancer Type | Reference |
| β-asarone | p53/Bcl-2/Bclin-1 and p53/AMPK/mTOR pathways | Glioma cell line (U251) | [161] |
| Walsuronoid B | ROS-formation and activation of p53/PI3K/Akt/mTOR signaling pathway | Liver cancer (HepG2 and Bel-7402) | [166] |
| Sulforaphane | Reduction of phosphorylation of Akt and mTOR | Malignant mesothelioma (H-28) | [167] |
| Physapubescin B | (ROS)-mediated suppression of mTORC1 | Colon cancer (HCT116) and cervical cancer (HeLa) | [168] |
| Fluvastatin | p53/AMPK/mTOR pathway | Lung adenocarcinoma (A549 and SPC-A-1) | [169] |
| Trichostatin A and Valproic Acid | ROS formation | Pancreatic cancer (Panc1 and PaCa44) | [170] |
| Cobalt chloride | p53/Bcl-2/Beclin-1 pathway | Malignant glioma (U87-MG) | [162] |
| Oridonin | AMPK deactivation-mediated GLUT1 downregulation in p53-mutated cells | p53-mutated colorectal cancer cells (HCT-15, COLO205, HCT116, RKO, SW480, and SW620) | [171] |
| Astemizole-Histamine | ROS formation and p53 phosphorylation, which increased p53-p62 interactions to enhance Beclin-1-independent autophagy | breast cancer (MCF-7) | [172] |
| Polygonatum odoratum lectin | Up-regulation of miR-15a-3p, which mediated ROS-p53 pathway | human lung adenocarcinoma (A549) | [173] |
| Trichosanthin | ROS-formation and activation of p53/PI3K/Akt/mTOR signaling pathway, | gastric cancer (MKN-45) | [174] |
| Honokiol | ROS-formation and activation of p53/PI3K/Akt/mTOR signaling pathway | Glioma (U87 MG) | [175] |
| Practice (n=number of participating GPs at commencement) | ||||||
| Organisational Characteristics | Eastvale (n = 5) | Gibson (n = 1) | Frank (n = 4) | Southville (n = 7) | Coopers (n = 7) | West Sanders (n = 9) |
| Funding Structure | ||||||
| Privately owned primary care sites | Y | Y | Y | Y | ||
| Corporatised primary care site | Y | |||||
| Publicly funded community health centre | Y | |||||
| Location | ||||||
| Urban | Y | Y | Y | Y | ||
| Outer Urban | Y | |||||
| Regional | Y | |||||
| Personnel employed in the practice (in total) | ||||||
| GP(s) | 6 | 2 | 4 | 8 | 8 | 14 |
| Practice nurse(s) | 2 | 3 | 2 | 4 | 2 | 3 |
| Registrar(s) | 1 | 0 | 0 | 0 | 0 | 1 |
| Psychologist(s) | 1 | 1 | 0 | 2 | 1 | 1 |
| Practice manager(s) | 1 | 0 | 1 | 1 | 1 | 1 |
| Receptionist(s) | 6 | 2 | 3 | 10 | 5 | 7 |
| Other | 2 | 0 | 2 | 7 | 10 | 0 |
| Variables | Adjusted odds ratio | 95% confidence interval | p-value |
| Therapeutic Self-Care | 0.74 | 0.56, 0.96 | 0.03 |
| Over age 75 | 1.01 | 0.77, 1.34 | 0.93 |
| Female | 0.77 | 0.63, 0.96 | 0.02 |
| Polypharmacy | 1.11 | 0.87, 1.44 | 0.40 |
| Polypharmacy*Therapeutic Self-Care | 1.48 | 1.10, 2.02 | 0.01 |
| CHESS Scores | 1.42 | 1.14, 1.76 | <0.01 |
| Congestive Heart Failure | 1.66 | 1.20, 2.30 | <0.01 |
| Alzheimer’s Disease | 1.31 | 1.01, 1.70 | 0.02 |
| Model Fit Assessment | Chi-Square | DF | p-value |
| Likelihood Ratio | 68.28 | 10 | <0.01 |
| Model Fit Assessment | Association of Predicted Probabilities and Observed Responses | ||
| C-index | 0.62 |
| Methods | EdgeC ount | TP | FP | TN | FN | FP to TP | TN to FN | AURO C | AUPR |
| Gold | 2194 | 2194 | 0 | 400396 | 0 | 0 | 0 | 1 | 1 |
| ALL | 5440 | 94 | 5346 | 395050 | 2100 | 4623 | 2150 | 0.7530 | 0.4614 |
| SAMBA | 1611 | 46 | 1565 | 398831 | 2148 | 1340 | 2501 | 0.6958 | 0.3644 |
| ISA | 2558 | 56 | 2502 | 397894 | 2138 | 2141 | 1151 | 0.8451 | 0.6306 |
| OPSM | 220 | 12 | 208 | 400188 | 2182 | 190 | 2453 | 0.5423 | 0.089 |
| Friedman | 947 | 22 | 925 | 399471 | 2172 | 794 | 2700 | 0.6364 | 0.2491 |
| CMSBE | 735 | 20 | 715 | 399681 | 2174 | 653 | 2750 | 0.6181 | 0.2333 |
| K-means | 380 | 13 | 367 | 400029 | 2181 | 323 | 3100 | 0.5667 | 0.1307 |
| Bivisu | 1515 | 13 | 1502 | 398894 | 2181 | 1265 | 2610 | 0.6845 | 0.3326 |
| CC | 590 | 3 | 587 | 399809 | 2191 | 507 | 2800 | 0.5943 | 0.1788 |
| microRNA | p-value | Fold change (NB vs CB) |
| hsa-miR-222 | 0.001 | 2.24 |
| hsa-miR-1292 | 0.020 | 1.27 |
| hsa-miR-23a-star | 0.022 | 1.27 |
| hsa-miR-140-5p | 0.009 | 1.21 |
| hsa-miR-1273d | 0.022 | 1.16 |
| hsa-miR-539 | 0.044 | 1.14 |
| hsa-miR-145-star | 0.049 | 1.14 |
| hsa-miR-30c-1-star | 0.039 | 1.14 |
| hsa-miR-3194 | 0.039 | 1.13 |
| hsa-miR-545-star | 0.004 | 1.13 |
| hsa-miR-593-star | 0.041 | 1.12 |
| hsa-miR-2114 | 0.010 | 1.12 |
| hsa-miR-27b-star | 0.038 | 1.11 |
| hsa-miR-215 | 0.020 | 1.10 |
| hsa-miR-129-3p | 0.029 | 1.10 |
| hsa-miR-549 | 0.011 | 1.09 |
| hsa-miR-23b-star | 0.004 | 1.08 |
| hsa-miR-92a-2-star | 0.044 | 1.07 |
| hsa-miR-2117 | 0.042 | –1.08 |
| hsa-miR-146b-3p | 0.017 | –1.08 |
| hsa-miR-4330 | 0.036 | –1.09 |
| hsa-miR-454 | 0.020 | –1.09 |
| hsa-miR-338-5p | 0.049 | –1.10 |
| hsa-miR-1303 | 0.044 | –1.10 |
| hsa-miR-548a-5p | 0.036 | –1.10 |
| hsa-miR-326 | 0.025 | –1.11 |
| hsa-miR-369-3p | 0.020 | –1.12 |
| hsa-miR-4325 | 0.007 | –1.12 |
| hsa-miR-519e | 0.023 | –1.13 |
| hsa-miR-1244 | 0.041 | –1.13 |
| hsa-miR-586 | 0.024 | –1.14 |
| hsa-miR-562 | 0.016 | –1.15 |
| hsa-miR-590-5p | 0.016 | –1.17 |
| Whole SAMPLE | 8 year–old group | 9 year–old group | 10 year–old group | 11–12 year–old group | ||||||
| Prevalencen. (%) | M | Prevalencen. (%) | M | Prevalencen. (%) | M | Prevalencen. (%) | M | Prevalence n. (%) | M | |
| F | F | F | F | F | ||||||
| DMC | 352 (7.5%) | M = 173 | 116 (6.3%) | M = 62 | 89 (7.8%) | M = 46 | 79 (8.8%) | M = 35 | 68 (8.3%) | M = 30 |
| F = 179 | F = 54 | F = 43 | F = 44 | F = 38 | ||||||
| H | 335 (7.1%) | M = 168 | 118 (6.4%) | M = 59 | 96 (8.4%) | M = 51 | 54 (6,0%) | M = 28 | 67 (8.2%) | M = 30 |
| F = 167 | F = 59 | F = 45 | F = 26 | F = 37 | ||||||
| IT | 185 (3.9%) | M = 87 | 72 (3.9%) | M = 35 | 40 (3.5%) | M = 19 | 39 (4.4%) | M = 17 | 34 (4.2%) | M = 16 |
| F = 98 | F = 37 | F = 21 | F = 22 | F = 18 | ||||||
| TA | 131 (2.8%) | M = 79 | 49 (2.6%) | M = 32 | 31 (2.7%) | M = 19 | 24 (2.7%) | M = 12 | 27 (3.3%) | M = 16 |
| F = 52 | F = 17 | F = 12 | F = 12 | F = 11 | ||||||
| TT | 67 (1.4%) | M = 39 | 34 (1.8%) | M = 19 | 12 (1.1%) | M = 7 | 8 (0.9%) | M = 4 | 13 (1.6%) | M = 9 |
| F = 28 | F = 15 | F = 5 | F = 4 | F = 4 | ||||||
| ST | 43 (0.9%) | M = 25 | 13 (0.7%) | M = 6 | 13 (1.1%) | M = 8 | 8 (0.9%) | M = 4 | 9 (1.1%) | M = 7 |
| F = 18 | F = 7 | F = 5 | F = 4 | F = 2 | ||||||
| O | 30 (0.6%) | M = 13 | 13 (0.7%) | M = 7 | 7 (0.6%) | M = 2 | 5 (0.6%) | M = 2 | 5 (0.6%) | M = 2 |
| F = 17 | F = 6 | F = 5 | F = 3 | F = 3 | ||||||
| T | 2 (0.04%) | M = 1 | 1 (0.1%) | M = 1 | 0 | M = 0 | 0 | M = 0 | 1 (0.1%) | M = 0 |
| F = 1 | F = 0 | F = 0 | F = 0 | F = 1 |
| Fold change | ||||
| SAGE tag | RefSeq accession | Gene ID | Caudal/rostral (SAGE) | Caudal/rostral (RT-qPCR) |
| gttgttcttccagtcgg | NM_016916 | bladder cancer associated protein homolog (human), Blcap | 2.68 | 1.43 |
| gtcatagctgttctgtg | BC025816 | EST sequence BC025816 | Cs | 1.31 (NS) |
| aagcttgacatttggaa | NM_026187 | ankyrin repeat and zinc finger domain containing 1, Ankzf1 | Rs | 1.17† (NS) |
| gatacttggaatgacta | NM_007393 | actin, beta, cytoplasmic, Actb | -2.63 | -1.32 |
| ttggtgaaggaaaaaac | NM_021278 | thymosin, beta 4, X chromosome, Tmsb4x | -2.33 | -2.13 (NS) |
| Prescription | Market | Patient | Physician | |
| TotalVPC (in %) | 42.3[39.0; 45.6] | 50.3[46.4; 54.2] | 4.9[4.5; 5.3] | 2.1[1.9; 2.3] |
| Residualvariance (in %) | 34.8[34.7 34.9] | 38.7[33.2; 45.3] | 2.6[2.6; 2.7] | 1.2[1.2; 1.3] |
| OHIP-14 Subscales Characteristics | DMFT category | Statistics Spearman Ranks (rs) correlationa | |||
| Acceptable DMFT <3 N = 341% = 48.7Mean subscale (S.D) | Average DMFT 4–10N = 220% = 31.4Mean subscale (S.D) | Poor DMFT > 10N = 139% = 19.9Mean subscale (S.D) | |||
| 1. | Functional Limitation | 2.1056 (1.95252) | 2.8545 (1.93660) | 3.1871 (2.05563) | 0.234 |
| 2. | Physical pain | 0.5073 (.96289) | 0.7545 (0.99484) | 0.8489 (1.10934) | 0.160 |
| 3. | Psychological discomfort | 3.3842 (2.39034) | 4.1136 (1.95633) | 4.6403 (1.89968) | 0.221 |
| 4. | Physical disability | 3.8358 (2.87525) | 4.7273 (2.70771) | 5.5540 (2.73775) | 0.230 |
| 5. | Psychological disability | 3.1554 (2.73042) | 3.6591 (1.85973) | 4.1727 (1.84520) | 0.220 |
| 6. | Social disability | 5.6452 (3.33611) | 6.3545 (2.82224) | 7.3165 (2.63487) | 0.194 |
| 7. | Handicap | 1.2669 (1.41496) | 1.4727 (1.32216) | 1.7914 (1.24222) | 0.172 |
| Target gene | Primer name | Nucleotide sequence (5'–3') | Product size (bp) | PCR profile (°C/s) | Reference | |||
| Denaturation | Annealing | Extension | Cycles | |||||
| 17 kDa | Rr17k. 1p | TTTACAAAATTCTAAAAACCAT | 539 | 95/30 | 57/60 | 72/120 | 35 | [23] |
| Rr17k. 539n | TCAATTCACAACTTGCCATT | |||||||
| Rr17k. 90p | GCTCTTGCAACTTCTATGTT | 450 | 95/30 | 57/60 | 72/120 | 35 | ||
| Rr17k. 539n | TCAATTCACAACTTGCCATT | |||||||
| ompA | Rr190k. 71p | TGGCGAATATTTCTCCAAAA | 650 | 95/30 | 42/35 | 60/120 | 35 | [23] |
| Rr190k. 720n | TGCATTTGTATTACCTATTGT | |||||||
| Rr190k. 71p | TGGCGAATATTTCTCCAAAA | 532 | 95/30 | 48/60 | 65/120 | 35 | ||
| Rr190k. 602n | AGTGCAGCATTCGCTCCCCCT |
| Type | Number of cases | |||
| Detected | Misreported | Under-reported | Total | |
| Probe | 226 | 4 | 7 | 233 |
| DoS | 131 | 14 | 23 | 155 |
| R2L | 77 | 12 | 12 | 89 |
| U2R | 29 | 12 | 8 | 36 |
| N (Percentage) | ||||||
| Characteristic | Quintile 1 | Quintile 2 | Quintile 3 | Quintile 4 | Quintile 5 | p value |
| Median z score | -6.11 | -3.21 | -0.55 | 2.58 | 7.67 | |
| Age (mean, SD) | 64.5 ± 9.5 | 64.1 ± 9.3 | 64.4 ± 9.4 | 64.8 ± 9.4 | 64.9 ± 9.4 | .004 |
| Black | 2706 (72) | 1904 (51) | 1397 (37) | 1022 (27) | 438 (12) | <.001 |
| Female | 2309 (62) | 2191 (58) | 2036 (54 | 1961 (52) | 1838 (49) | <.001 |
| Residing in Southeast | 2631 (70) | 2591 (69) | 2404 (64) | 2074 (55) | 1928 (51) | <.001 |
| aHistory of cardiovascular disease | 898 (24) | 832 (22) | 790 (21) | 723 (19) | 698 (19) | <.001 |
| Obese (BMI > =30) | 1749 (47) | 1642 (44) | 1449 (39) | 1292 (34) | 1052 (28) | <.001 |
| High waist circumference (>102 cm (>40 in) for men; > 88 cm (>35 in) for women | 2116 (56) | 2023 (54) | 1875 (50) | 1700 (45) | 1396 (37) | <.001 |
| High triglycerides (>150 mg/dL) | 875 (23) | 1025 (28) | 1118 (30) | 1066 (28) | 1021 (27) | <.001 |
| Low HDL cholesterol (for men <40 mg/dL, for women < 50 mg/dL or on lipid lowering medication) | 1413 (38) | 1433 (38) | 1415 (38) | 1354 (36) | 1112 (30) | <.001 |
| Blood pressure > 130/> 85 mm Hg or on antihypertensive medications | 2574 (69) | 2410 (64) | 2210 (59) | 2069 (55) | 1724 (46) | <.001 |
| Fasting glucose > 110 mg/dL or on antidiabetic medications | 1070 (29) | 912 (24) | 772 (21) | 585 (16) | 444 (12) | <.001 |
| Metabolic syndrome | 992 (26) | 958 (25) | 911 (24) | 785 (21) | 598 (16) | <.001 |
| Inflammation (CRP ≥ 3 mg/L) | 1853 (49) | 1701 (45) | 1505 (40) | 1392 (37) | 1115 (30) | <.001 |
| Metabolic syndrome + inflammation | 1722 (24) | 1615 (23) | 1482 (21) | 1323 (19) | 1003 (14) | <.0001 |
| Current smoking | 751 (20) | 676 (18) | 534 (14) | 445 (12) | 316 (8.5) | <.001 |
| Income | ||||||
| less than $20 K | 1281 (34) | 874 (23) | 579 (16) | 344 (9.2) | 145 (3.9) | |
| $20 K–$34 K | 1079 (29) | 1064 (28) | 1001 (27) | 853 (23) | 514 (14) | |
| $35 K–74 K | 710 (19) | 1039 (28) | 1224 (33) | 1422 (38) | 1317 (35) | |
| $75+ | 171 (4.6) | 340 (9.1) | 487 (13) | 722 (19) | 1337 (36) | |
| Refused to report | 510 (14) | 451 (12) | 455 (12) | 417 (11) | 443 (12) | <.001 |
| Education | ||||||
| <High school | 946 (25) | 597 (16) | 374 (10) | 189 (5.0) | 79 (2.1) | |
| High school | 1287 (34) | 1192 (32) | 1061 (29) | 826 (22) | 489 (13) | |
| Some college | 869 (23) | 1073 (28) | 1132 (30) | 1140 (30) | 900 (24) | |
| College | 649 (17) | 906 (24) | 1179 (31) | 1603 (43) | 2288 (61) | <.001 |
| Feature of presenting complaint | Study participants (n = 30) |
| Trauma (%) | |
| Yes | 16 (53.3) |
| No | 14 (46.7) |
| Weight-bearing (%) | |
| Yes | 17 (56.7) |
| No | 13 (43.3) |
| Side affected (%) | |
| Right | 11 (36.7) |
| Left | 18 (60.0) |
| Both | 1 (3.3) |
| Region affected (%) | |
| Hip | 5 (16.7) |
| Thigh | 8 (26.7) |
| Knee | 6 (20.0) |
| Lower leg | 8 (26.7) |
| Ankle | 3 (10.0) |
| Diagnosis (%) | |
| Soft tissue injury | 13 (43.3) |
| Irritable hip | 9 (30.0) |
| Toddler’s fracture | 3 (10.0) |
| Other | 4 (13.3) |
| Unknown diagnosis | 1 (3.3) |
| Evaluation | Any Difference(Mack Skillings Test) | Paired Comparisons*(Signed Rank Test) | ||
| Raw P Value | Adjusted P Value | P Value of Cycle 1 Comparisons | P Value of Cycle 2 Comparisons | |
| CD4+ | 0.0203 | 0.1827 | - | - |
| CD8+ | 0.0207 | 0.1827 | - | - |
| CD56+ | - | - | 0.1250 | - |
| CD16+/CD56+ | - | - | 1.0 | - |
| CD25+ | 0.3192 | 1.0 | - | - |
| CD27+ | 0.0709 | 0.4254 | - | - |
| NK+ granzyme B+ | 0.2623 | 1.0 | - | - |
| CD8+ granzyme B+ | 0.0948 | 0.4740 | - | - |
| NK activity | 0.0207 | 0.1827 | - | - |
| ADCC w/IL2 | 0.2818 | 1.0 | - | - |
| ADCC | 0.5095 | 1.0 | - | - |
| S100 | - | - | 0.3621 | - |
| IL6 | 0.0366 | 0.0732 | - | - |
| sIL2R | <0.0001 | <0.0001 | 0.0156 | 0.0156 |
| TNF | 0.1948 | 0.1948 | - | - |
| IL10 | 0.0115 | 0.0345 | 0.0769 | 0.250 |
| Neopterin | <0.0001 | <0.0003 | 0.0156 | 0.0222 |
| Month(s) | NT-proBNP (fmol/ml) | IL-6 (pg/ml) | Adiponectin (ng/ml) |
| 1 | 172.79±4.32 | 13.24±1.25 | 15.19±0.86 |
| 3 | 292.43±7.59** | 116.09±8.78** | 12.54±1.61* |
| 6 | 339.43±12.59** | 181.29±16.45** | 12.25±0.29* |
| 9 | 348.53±15.85 ** | 223.61±12.43** | 11.64±0.95* |
| 12 | 379.18±19.37 ** | 236.15±6.05 ** | 9.64±0.85** |
| 15 | 386.52±19.69 ** | 260.05±9.90** † | 10.45±1.52*† |
| 18 | 407.97±18.23 **†† | 421.45±19.49** †† | 11.01±1.81*† |
| p-value | Pearson correlations | |
| Infant age (month) | 0.002 | -0.270 |
| Height at birth (cm) | 0.010 | 0.237 |
| Weight at birth (kg) | 0.940 | -0.007 |
| Head circumference at birth (cm) | 0.251 | 0.157 |
| Annotation category | Number of annotations |
| Natural antisense lncRNA | 64 |
| Pseudogene | 75 |
| Transposable element gene | 10 |
| Transposase | 46 |
| miRNA primary transcript | 4 |
| Hypothetical protein | 5 |
| Protein | 8 |
| Other | 8 |
| Sharing platform | Current users, n = 200n (%) | |
| Do not share data | 130 | (65.0%) |
| Tracker support software | 70 | (35.0%) |
| Strava | 9 | (4.5%) |
| 7 | (3.5%) | |
| 2 | (1.0%) | |
| In person | 2 | (1.0%) |
| 1 | (0.5%) | |
| Other | 3 | (1.5%) |
| Reasons for sharing on social media | ||
| Do not share data on social media | 154 | (77.0%) |
| To compete with friends | 33 | (16.5%) |
| To share progress | 18 | (9.0%) |
| To motivate others | 17 | (8.5%) |
| To get encouragement from others | 13 | (6.5%) |
| Other | 4 | (2.0%) |
| Clinicopathological features | n | BICD1 expression, n (%) | P | |
| 523 | Low, n=262 (50.1) | High, n=261 (49.9) | ||
| Age | 0.089722 | |||
| <65 | 347 | 183 (52.7) | 164 (47.3) | |
| ≥65 | 176 | 79 (44.9) | 97 (55.1) | |
| Gender | 0.136863 | |||
| Female | 205 | 111 (54.1) | 94 (45.9) | |
| Male | 318 | 151 (47.5) | 167 (52.5) | |
| MGMT expression | 0.204737 | |||
| Low | 262 | 124 (47.3) | 138 (52.7) | |
| High | 261 | 138 (52.9) | 123 (47.1) | |
| Overall survival indicator | 0.712211 | |||
| 0 (censor) | 89 | 43 (48.3) | 46 (51.7) | |
| 1 (death) | 434 | 219 (50.5) | 215 (49.5) | |
| Molecular Subclassification | ||||
| Neural | 87 | 70 (80.5) | 17 (19.5) | <0.00001 |
| Proneural | 138 | 91 (65.9) | 47 (34.1) | |
| Mesenchymal | 156 | 71 (45.5) | 85 (54.5) | |
| Classical | 142 | 30 (21.1) | 112 (78.9) |
| Variable | Opium addicted N=50 | Non addicted N=50 | P value |
| Age Mean±SD | 36.00±6.54 | 35.38±6.7 | 0.64 |
| BMI Mean±sD | 21.96±3.46 | 24.27±3.85 | 0.002 |
| Cigarrette smoking No. (%) | 37 (77.1) | 34 (61) | 0.31 |
| Vertebral BMD frequency (%) | |||
| Normal | 22 (44) | 37 (74) | 0.002 |
| Osteopenia | 28 (56) | 13 (26) | |
| Lumbar measurement Mean±SD | 0.92±0.12 | 1.01±0.12 | 0.001 |
| National policies and guidelines |
| Recording and Reporting tools |
| Collaboration and communication between TB and HIV control programmes |
| Leadership and commitment |
| Target setting at all levels of the health care system |
| Human resources: recruitment, training, support, task shifting |
| Financing |
| National Partnerships for results |
| Providing TB and HIV services under one roof |
| Gene | Primers |
| ABCG2 | Primer1: 5′-TGGCTTAGACTCAAGCACAGC-3′ |
| Primer2: 5′- TGGTCCCTGCTTAGACATCC-3′ | |
| MRP1 | Primer1: 5′-TGTGGGAAAACACATCTTTGA-3′ |
| Primer2: 5′-CTGTGCGTGACCAAGATCC-3′ | |
| MRP2 | Primer1: 5′-AGTGAATGACATCTTCACGTTTG-3′ |
| Primer2: 5′-CTTGCAAAGGAGATCAGCAA-3′ | |
| MDR1 | Primer1: 5′-ACAGAAAGCGAAGCAGTGGT-3′ |
| Primer2: 5′-ATGGTGGTCCGACCT TTTC-3′ | |
| CD44 | Primer1: 5′-GCCTTGGCTTTGATTCTTGC-3′ |
| Primer2: 5′-TCCACTTGGCTTTCTGTCCTC-3′ | |
| HES1 | Primer1: 5′-GAAAGATAGCTCGCGGCAT-3′ |
| Primer2: 5′'-GAAGCGGGTCACCTCGTT-3′ | |
| Krt15 | Primer1: 5′-GCTGCTTGACATAAAGACACG-3′ |
| Primer2: 5′'-ATTGCTGCTGCTACCACCA-3′ | |
| Oct-4 | Primer1: 5′-GGAAGGTATTCAGCCAAACGACCA-3′ |
| Primer2: 5′'-CTCACTCGGTTCTCGATACTGGTT-3′ | |
| Sox2 | Primer1: 5′-TTCGATCCCAACTTTCCAT-3′ |
| Primer2: 5′'-ACATGGATTCTCGGCAGAC-3′ | |
| GAPDH | Primer1: 5′-GCCGGTGCTGAATATGTC-3′ |
| Primer2: 5′-CTTCTGGGTGGCAGTGAT-3′ |
| Age | Number of Pupils (%) |
| 16–17 | 214 (24.2) |
| 18–19 | 397 (44.9) |
| 20–22 | 272 (30.8) |
| Total | 883 |
| Study | Running distance | Running period | OA induced | Method | Effect |
| Sekiya et al. [5] 2009 | 30 km | 6 weeks | No | Harmful | |
| Siebelt et al. [24] 2011 | 31.8 km | 6 weeks | No | Harmful | |
| Beckett et al. [17] 2012 | 30 km / 55 km | 3 / 6 weeks | No | Harmful | |
| Pap et al. [20] 1998 | 30 km | 12 weeks | Yes | Intracranial self stimulation | Harmful |
| Siebelt et al. [21] 2014 | 15 km | 6 weeks | Yes | Papain injection | Harmful |
| Saito et al. 2015 | 15 km | 3 weeks | Yes | MIA 0.1 mg injection | Harmful |
| Galois et al. [22] 2004 | 15 km | 4 weeks | Yes | ACLT | Beneficial |
| Cifuentes et al. [23] 2010 | 15 km | 8 weeks | Yes | MIA 1.2 mg injection | Beneficial |
| Baseline Value | Source(s) | |
| Input variables | ||
| Chest pain is caused by ACS | 0.1 | [19-22] |
| GP Sensitivity with ECG | 0.818 | Unpublished data from [8,11-16] |
| GP Sensitivity without ECG | 0.667 | Unpublished data from [8] |
| GP Specificity with ECG | 0.5 | [12-16] |
| GP Specificity without ECG | 0.3 | [17] |
| Correctly referred STEMI patients receiving thrombolysis (%) | 58.5 | [6] |
| Relative risk reduction of thrombolytics | 0.750 | [23,24] |
| Costs (2007 US$) | ||
| GP visit | 1.76 | [37] |
| ECG | 1.93 | [39,40,42-44] |
| Emergency department visit | 3.48 | [37] |
| Streptokinase | 117.00 | [38,45] |
| Admission | 157.55 | [37] |
| Blood transfusion | 107.67 | [37] |
| Stroke | 211.37 | [37] |
| Annual secondary prevention | 16.56 | [37,38] |
| # | Author | Year | Compound | Strain | Dose | Rote | Test | (Model) |
| 1 | Nagase et al. | 2002 | TAN-67 | SD | 1-10 mg/kg | s.c. | FSS | |
| 2 | Broom et al. | 2002 | SNC80 | SD | 10-100 mg/kg | s.c. | FSS | |
| 3 | Broom et al. | 2002 | (+) BW373U86 | SD | 1-10 mg/kg | s.c. | FSS | |
| 4 | Saitoh et al. | 2004 | SNC80 | ICR | 0.3-3 mg/kg | s.c. | FSS/CSM | |
| 5 | Torregrossa et al. | 2005 | (+) BW373U86 | SD | 10 mg/kg X 1, 8, 21 days | s.c. | FSS | |
| 6 | Naidu et al. | 2007 | (-) NIH11082 | C57BL6 | 8-32 mg/kg | i.p. | TST | |
| 7 | Saitoh et al. | 2008 | SNC80 | Wistar | 1-10 mg/kg X 7 days | s.c. | HE | OB rat model |
| 8 | Vergra et al. | 2008 | UFP-512 | Swiss | 0.001-0.1 nmol/0.01-1 mg/kg | i.c.v./i.p. | FSS | |
| 9 | UFP-512 | SD | 0.1-1 mg/kg | i.p. | FSS | |||
| 10 | Le Bourdonnec et al. | 2008 | ADL5859 | - | 0.3-3 mg/kg | p.o. | FSS | |
| 11 | Saitoh et al. | 2011 | KNT-127 | ICR | 0.1-1 mg/kg | s.c. | FSS | |
| 12 | Hudzik et al. | 2011 | AZD2327 | SD | 1-10 mg/kg X 4 days | p.o. | LH |
| Predictability of Spherical Equivalent* | ||||||
| undercorrection <1.0 | 1.0 to 0.51 | ±0.5 | 0.51 to 1.0 | overcorrection >1.0 | Total | |
| WTR | ||||||
| Number | 1 | 9 | 34 | 6 | 0 | 50 |
| % | 2 | 18 | 68 | 12 | 0 | 100 |
| Oblique | ||||||
| Number | 3 | 8 | 38 | 9 | 0 | 58 |
| % | 5 | 14 | 66 | 16 | 0 | 100 |
| ATR | ||||||
| Number | 1 | 6 | 30 | 7 | 1 | 45 |
| % | 2 | 13 | 67 | 16 | 2 | 100 |
| Y-Intercept (#/cm3) | Weekday | Weekend | ||
| Day | Night | Day | Night | |
| Ultrafine | 50 (5) | 101 (8) | 43 (11) | 143 (7) |
| Fine | 48 (2) | 62 (2) | 46 (5) | 90 (3) |
| QUICKI | tertile 1 | tertile 2 | tertile 3 | ||||
| Model | # events | HR (95%CI) | # events | HR (95%CI) | # events | HR (95%CI) | |
| All vascular events | 1 | 48 | 1.70 (1.05-2.74) | 52 | 1.86 (1.16-2.98) | 26 | 1 (reference) |
| 2 | 1.78 (1.10-2.89) | 1.92 (1.20-3.08) | 1 (reference) | ||||
| 3 | 1.79 (1.10-2.90) | 1.86 (1.16-3.00) | 1 (reference) | ||||
| 4 | 1.50 (0.85-2.68) | 1.80 (1.10-2.96) | 1 (reference) | ||||
| Myocardial infarction | 1 | 27 | 1.42 (0.77-2.61) | 30 | 1.63 (0.90-2.96) | 17 | 1 (reference) |
| 2 | 1.41 (0.76-2.61) | 1.61 (0.89-2.93) | 1 (reference) | ||||
| 3 | 1.39 (0.75-2.59) | 1.57 (0.86-2.85) | 1 (reference) | ||||
| 4 | 0.95 (0.46-1.98) | 1.34 (0.72-2.51) | 1 (reference) | ||||
| All cause mortality | 1 | 32 | 1.43 (0.82-2.51) | 39 | 1.69 (0.99-2.91) | 20 | 1 (reference) |
| 2 | 1.56 (0.88-2.75) | 1.80 (1.05-3.10) | 1 (reference) | ||||
| 3 | 1.63 (0.92-2.88) | 1.76 (1.02-3.03) | 1 (reference) | ||||
| 4 | 1.56 (0.78-3.09) | 1.83 (1.04-3.24) | 1 (reference) | ||||
| Vascular mortality | 1 | 15 | 1.50 (0.66-3.43) | 23 | 2.26 (1.04-4.88) | 9 | 1 (reference) |
| 2 | 1.72 (0.74-3.98) | 2.42 (1.12-5.25) | 1 (reference) | ||||
| 3 | 1.74 (0.75-4.04) | 2.24 (1.03-4.88) | 1 (reference) | ||||
| 4 | 1.85 (0.73-4.73) | 2.56 (1.15-5.70) | 1 (reference) |
| TBIC practice | ||||
| Variables | Proper | Improper | COR 95 % CI | AOR 95 % CI |
| Site of health facility | ||||
| Urban | 82 | 139 | 0.94 (0.67,1.32) | |
| Rural | 158 | 252 | 1 | |
| Sex | ||||
| Male | 148 | 237 | 1.05 (0.75,1.45) | |
| Female | 92 | 154 | 1 | |
| Educational level | ||||
| Degree | 79 | 78 | 1.97 (1.37,2.84) | 1.20 (0.77,1.89) |
| Diploma | 161 | 313 | 1 | |
| Age category | ||||
| 25–34 years | 132 | 210 | 1.21 (0.86,1.70) | 0.84 (0.56,1.26) |
| > 34 years | 22 | 15 | 2.83 (1.40,5.74) | 1.20(0.54,2.67) |
| 18–24 years | 86 | 166 | 1 | 1 |
| Experience category | ||||
| 3–5 years | 65 | 80 | 1.76 (1.19,2.61) | 1.11 (0.68,1.79) |
| 5–10 years | 29 | 26 | 2.42 (1.37,4.29) | 1.73 (0.85,3.52) |
| > 10 years | 23 | 18 | 2.77 (1.44,5.33) | 1.05 (0.35,3.13) |
| 1–3 years | 123 | 267 | 1 | |
| Profession | ||||
| Health officer | 44 | 37 | 6.34(2.98,13.51) | 3.00(0.20,45.6) |
| Laboratory technologist | 24 | 46 | 2.78(1.26,6.13) | 1.56(0.13,19.36) |
| Midwifery | 13 | 56 | 1.24(0.52,2.93) | 2.29(0.15,35.58) |
| Nurse | 147 | 188 | 4.17(2.17,8.01) | 3.48(0.25,49.35) |
| pharmacy | 12 | 64 | 1 | 1 |
| Working department | ||||
| TB clinic | 42 | 10 | 22.40(8.88,56.49) | 10.17(3.81,27.17)* |
| Adult OPD | 82 | 105 | 4.17(2.11,8.23) | 3.23(1.54,6.79)* |
| Under 5 OPD | 27 | 48 | 3.00(1.38,6.52) | 2.02(0.87,4.69) |
| Laboratory | 24 | 46 | 2.78(1.26,6.13) | 1.71(0.73,4.00) |
| ART Clinic and IPD | 24 | 34 | 3.77(1.68,8.45) | 2.74(1.13,6.63)* |
| MCH room | 29 | 84 | 1.84(0.87,3.89) | 1.63(0.72,3.67) |
| Pharmacy | 12 | 64 | 1 | 1 |
| Training on TBIC | ||||
| Yes | 122 | 96 | 3.18 (2.26,4.47) | 1.30 (0.83,2.04) |
| No | 118 | 295 | 1 | 1 |
| Knowledge presence of TBIC plan | ||||
| Yes | 221 | 239 | 7.40 (4.44,12.32) | 4.25 (2.46,7.35)* |
| No | 19 | 152 | 1 | 1 |
| Know presence of national guideline for TBIC | ||||
| Yes | 231 | 247 | 14.96 (7.45,30.04) | 8.95 (4.35,18.40)* |
| No | 9 | 144 | 1 | 1 |
| Haddadi et al. | Huang et al. | Lu &Zoubir | Ours | |
| E(lq) | Lawley | Lawley | Lawley | Lawley |
| Var(lq) | Multivariate Statistics | Random Matrix | Random Matrix | Lawley |
| E(Aq) | Lawley | Lawley | Lawley | Lawley |
| Var(Aq) | - * | - | Random Matrix | Random Matrix |
| Disability | No or Other Resistance (n = 220) | INH Resistant (n = 86) | RIF Resistant or MDR (n = 16) | Cumulative Odds Ratioa(95% CI) | P Value |
| Good | 91 (41.4) | 31 (36.0) | 2 (12.5) | INH: 1.44 | |
| Intermediate | 53 (24.1) | 17 (19.8) | 0 (0) | (.90–2.32) | .13 |
| Severe | 20 (9.1) | 11 (12.8) | 3 (18.8) | RIF MDR: 10.31 | |
| Death | 52 (23.6) | 27 (31.4) | 11 (68.8) | (3.39–31.36) | <.001 |
| N | M ± SD | |
| Outcome: Teaching qualitya | ||
| Didactics | 499 | 7.9 ± 1.3 |
| Learning climate | 500 | 8.4 ± 1.1 |
| Motivation and enthusiasm | 500 | 8.1 ± 1.3 |
| Behavior towards patients | 488 | 8.1 ± 1.2 |
| Motivational categoriesb | 55 for all | |
| Intrinsic TM | 2.7 ± 0.9 | |
| Identified TM | 3.2 ± 0.7 | |
| Introjected TM | 0.7 ± 0.8 | |
| External TM | 1.5 ± 1.0 | |
| T Amotivation | 0.9 ± 0.9 | |
| Teaching self-efficacyb | 55 | 2.5 ± 0.5 |
| Situational variablesb | 94 for all | |
| Enough time to prepare lesson | 2.1 ± 1.2 | |
| Stress before lesson | 2.2 ± 1.1 | |
| Perceived students’ motivation | 3.1 ± 0.7 | |
| Perceived students’ competences | 2.9 ± 0.8 | |
| Perceived students’ respect | 3.6 ± 0.6 |
| Variant | Minor/major allele | Minor allele frequency |
| Genotyped and imputed | ||
| rs2206593 | T/C | 0.074 |
| rs5275 | C/T | 0.317 |
| rs10911905 | G/T | 0.084 |
| rs2143417 | T/G | 0.100 |
| Imputed | ||
| rs4648304 | T/C | 0.009 |
| rs689470 | T/C | 0.016 |
| rs2066826 | A/G | 0.077 |
| rs5277 | C/G | 0.174 |
| rs4648262 | T/G | 0.0001 |
| rs4648261 | A/G | 0.069 |
| rs2745557 | T/C | 0.174 |
| rs20417 | C/G | 0.100 |
| rs689466 | G/A | 0.205 |
| rs689462 | C/A | 0.016 |
| rs12042763 | A/C | 0.287 |
| rs2745559 | T/G | 0.174 |
| rs11583191 | T/C | 0.081 |
| rs2143416 | G/T | 0.111 |
| rs2179555 | G/A | 0.088 |
| Medical | Nursing |
| Enhanced scopes of practice | |
| • Physicians are allowed to private practice with specific fees during off hours | • Nurses also are allowed to work in the private sector before and after office hours |
| Producing new types of health workers | |
| • The programmes for production of other paramedics such as medical assistants, laboratory assistants, pharmacists, and physiotherapy assistants are already in place | • Currently, there are a number of nursing and related programmes, such as BSc nursing, postbasic nursing, diploma in nursing, family welfare assistant, community skilled birth assistants, and community health-care providers |
| Compulsory service in rural area | |
| • Provision of minimum 2 years of services at Union Health Sub-Centre | • The Nursing Personnel Recruitment Rules were developed in 1985, without any provision of compulsory rural services |
| • Preference to fill vacancies for remote and hard-to-reach areas/health facilities | • Recently, efforts are underway to introduce provision of compulsory services in rural health facilities |
| • Provision of non-practicing allowance is given to encourage physicians to purely focus on public services | |
| Subsidized education for return of service | |
| • Provision of scholarships, bursaries, and other training and education subsidies are available, but not particularly focused on rural retention | • Provision of scholarships, bursaries, and other training and education subsidies are available, but not particularly focused on rural retention |
| Hyphal size (μm) | |
| Strain | Abscence of CE** vs. Presence of CE** |
| ATCC 90028 | 24.68 (24.68 ± 1.79) vs. 13.35 (13.35 ± 0.92)* |
| SC5314 | 30 (30 ± 2.47) vs. 16 (16 ± 1.16)* |
| Strain 01 | 21.67 (21.67 ± 1.39) vs. 15.02 (15.02 ± 1. 28)* |
| Strain 05 | 22.84 (22.84 ± 1.68) vs. 18.17 (18.17 ± 2.12) |
| Strain 06 | 19.3 (19.3 ± 1.23) vs. 11.24 (11.24 ± 1.79)* |
| Strain 12 | 10.16 (10.3 ± 1.89) vs. 16.62 (16.62 ± 1.34) |
| Strain 23 | 16.81 (16.81 ± 2.12) vs. 11.08 (11.08 ± 0,76) |
| Strain 30 | 10.06 (10.06 ± 0.86) vs. 14.32 (14.32 ± 0.97) |
| Strain 37 | 23.21 (23.21 ± 1.83) vs. 18.55 (18.55 ± 1. 48)* |
| Strain 40 | 23.28 (23.28 ± 1.94) vs. 13.6 (13.6 ± 0.91)* |
| Strain 54 | 15.35 (15.35 ± 1.41) vs. 3 (3 ± 0.32)* |
| Strain 10Li | 21.25 (21.25 ± 1.87) vs. 11.73 (11.73 ± 0.92)* |
| Strain 111R | 36.15 (36.15 ± 2.56) vs. 25.06 (25.06 ± 1.34)* |
| W | AS | Vigilance state effect | Period effect | |||||
| Period | control | prior | during | control | prior | during | P | |
| Total V, s2 | 0.069±0.069 | 0.055±0.058 | 0.074±0.068 | 0.054±0.061 | 0.050±0.052 | 0.056±0.059 | 0.008 | 0.060 |
| LF, s2 | 0.026±0.024 | 0.021±0.020 | 0.027±0.023 | 0.021±0.021 | 0.020±0.020 | 0.022±0.022 | 0.016 | NS |
| HF, s2 | 0.028±0.038 | 0.018±0.031 | 0.028±0.037 | 0019±0.031 | 0014±0.023 | 0016±0.026 | <0.001 | 0.025 |
| LFnu | 62 ±19 | 68 ±21 | 63 ±20 | 65±20 | 70±19 | 68 ±20 | 0.030 | 0.024 |
| HFnu | 38 ±19 | 32 ±21 | 37 ±20 | 35±20 | 30±19 | 32 ±20 | 0.030 | 0.024 |
| LF/HF | 3.2±3.5 | 4.2±4.3 | 3.3±3.5 | 3.7±4.4 | 4.9±5.3 | 4.9±6.5 | 0.007 | 0.045 |
| Objection | Primer | Sequences |
| Murine variable regions of the heavy chain (VH) | VHF | 5'-GCTGCCCAACCAGCCATGGCCGAGGTGCAGCTGGTGGAATCGGG-3' |
| VHR | 5'-CGATGGGCCCTTGGTGGAGGCTGCAGAGACAGTGACCAGAGT-3' | |
| Murine variable regions of the light chain (VL) | VkF | 5'-GGGCCCAGGCGGCCGAGCTCGATATTTTGCTCACTCAG-3' |
| VkR | 5'-GAAGACAGATGGTGCAGCCACAGTTCGTTTCATTTCCAGTTTGGTCCC-3' | |
| Human constant regions of the heavy chain domain 1 (CH1) | CH1-F | 5'-GCCTCCACCAAGGGCCCATCGGTC-3' |
| dpseq | 5'-GATATCAGAAGCGTAGTCCGGAACGTC-3' | |
| Human constant regions of the light chain domain (CL) | HKC-F | 5'-CGAACTGTGGCTGCACCATCTGTC-3' |
| Lead B | 5'-AAGCTTGGCCATGGCTGGTTGGGCAGC-3' | |
| Chimeric heavy chain (Fd) | Lead H | 5'-CATATGGCTGCCCAACCAGCCATGGCC-3' |
| dpseq | Ditto | |
| Chimeric light chain | RSF-F | 5'-GGATCCGGAGGAGGAGGAGGAGGAGGCGGGGCCCAGGCGGCCGAGCTC-3' |
| Lead B | Ditto |
| Number of participants (% within category) | ||
| Country of graduation and current workplace | Rwanda | 13 (76%) |
| Democratic Republic of the Congo | 4 (24%) | |
| Completed whole years since graduation | 1 year | 6 (35%) |
| 2–3 years | 6 (35%) | |
| ≥ 4 years | 5 (29%) | |
| Gender | Male | 15 (88%) |
| Female | 2 (12%) | |
| Desired future specialty | General surgery | 12 (71%) |
| Neurosurgery | 2 (12%) | |
| Orthopaedics | 1 (6%) | |
| Urology | 2 (12%) |
| Characteristics | N | Total (%) | Boys (%) | Girls (%) | χ2 | p-value |
| Sexually active | ||||||
| Yes | 113 | 27.2 | 33.8 | 21.3 | 8.29 | 0.004 |
| No | 303 | 72.8 | 66.2 | 78.7 | ||
| Early sex debut * | ||||||
| Before 15 years | 55 | 48.7 | 60.6 | 31.9 | 9.05 | 0.003 |
| After 15 years | 58 | 51.3 | 39.4 | 68.1 | ||
| Multiple partner * | ||||||
| One | 59 | 57.8 | 50 | 68.2 | 3.39 | 0.07 |
| More than one | 43 | 42.2 | 50 | 31.8 | ||
| Condom use for last sexual intercourse * | ||||||
| Yes | 57 | 53.3 | 50.8 | 41.3 | 0.95 | 0.33 |
| No | 50 | 46.7 | 49.2 | 58.7 | ||
| Regular condom use * | ||||||
| Irregular | 53 | 55.2 | 52.8 | 58.1 | 0.27 | 0.60 |
| Always | 43 | 44.8 | 47.2 | 41.9 | ||
| HIV testing * | ||||||
| Yes | 54 | 13 | 13.4 | 12.7 | 0.04 | 0.84 |
| No | 360 | 87 | 86.6 | 87.3 |
| Parameters | Patients with T1DM(n = 162) | controls(n = 80) | P- value |
| Age (years) | 19.35 ± 2.6 | 19.76 ± 2.76 | 0.3 |
| Females (%) | 55.5% (90/162) | 55% (44/80) | 0.93 |
| Gastrointestinal symptoms | 4.3% (7/162) | 3.7% (3/80) | 0.83 |
| Duration of diabetes (years) | 7.29 ± 7.9 | _ | |
| HbA1c (%) | 8.2 ± 1.75 | _ |
| CME activity | Activity 2 | Activity 3 |
| Sample size | n=1237 | n=611 |
| Responses to: Practitioners are asked to report drug adverse events: | ||
| A. To MedWatch | ||
| B. Only when the adverse event is not specified on the drug label | ||
| C. Within 30 days of occurrence, as required by law. | ||
| D. Voluntarily, if observed within 30 days of the first dose | ||
| Correct (A) | 698 (56%) | 237 (39%) |
| Incorrect (B) | 85 (7%) | 53 (9%) |
| Incorrect (C) | 203 (10%) | 174 (29%) |
| Incorrect (D) | 243 (20%) | 146 (24%) |
| Correct vs. Predicted | −14% | −31% |
| Presyn | Postsyn | Type | Conv | Div | # Synapses |
| MF | Glom | Excitatory | 1 | 20 | 5000 |
| Glom | GR | Excitatory | 4 | 53 | 262,400 |
| Glom | GO | Excitatory | 40 | 0.77 | 4000 |
| GO | GR | Inhibitory | 3.23 | 2120 | 212,000 |
| GR | GO | Excitatory | 2000 | 3 | 200,000 |
| GR | PC | Excitatory | 65,600 | 400 | 26,240,000 |
| IO | PC | Teaching | 1 | 10 | 400 |
| PC | DCN | Inhibitory | 40 | 5 | 2,000 |
| DCN (30%) | IO | Inhibitory | 0.34 | 1 | 14 |
| IO | DCN | Excitatory | 1 | 1,41 | 50 |
| MF | DCN | Excitatory | 12 | 2.4 | 600 |
| Total number of synapses | 26,926,464 |
| Transporters | Organism | Cells/Tissue | Cargo (proteins) specific to each importin or exportin | Reference |
| Importin α1 | Human | ROS 17/2.8, UMR-106, MC3T3-E1, and SaOS-2 | Type 1 parathyroid hormone receptor | [62] |
| Importin α2 | Human | HuT-78 cells | GATA-3 | [63] |
| Importin α3 | Human | A5A9 lung cells, human Bronchial smooth muscle cells | NF-κB p50/p65 | [25, 50] |
| Importin α3 | Mouse | Mouse lung tissue | NF-κB p65 | [11] |
| Importin α4 | Human | A5A9 lung cells | NF-κB p50/p65 | [25] |
| Importin α5 | Human | COS-1HepG2HuH7 hepatoma cells | STAT3 STAT1-STAT2 | [45] [43] |
| Importin β1 | Human | HEK293HUVECC58CO57HeLa | PRPF31NF-κBCREBPTHrPSRY/SOX-9Cyclin B1NFAT | [64–69][33][68] |
| Importin β1 | Mouse | Sf9 | NFAT | [69] |
| Importin β2 | Human | HeLa | HPV16E6 oncoprotein | [70] |
| Importin β3 | Human | HeLa | c-JunRibosomal proteins | [71, 72] |
| Importin 4 | Human | HeLa | Vitamin D receptorHIF1-α | [73, 74] |
| Importin 5 | Human | HeLa | c-Jun | [70] |
| Importin 7 | Human | HeLa | c-JunHistone H1CREBSMAD3Glucocorticoid receptor | [71][75, 76][33][48][55] |
| Importin 8 | Human | HaCaTCOS-1 | SMADsSignal recognition particle protein 19 | [76, 77] |
| Importin 9 | Human | HeLa | c-JunPP2A (PR65) | [71][78] |
| Importin 11 | Human | BHK | L12UbcM2 | [79, 80] |
| Importin 13 | Human | HeLaAirway epithelial cells | c-JunGlucocorticoid receptor | [71] [57] |
| Importin α/β | Human | HTCMCF-7 | HIV-1 integraseP53 | [81, 82] |
| Exportin 1 | Human | NIH-3H3HeLa | Cyclin D1IκBNFAT | [14, 26, 83, 84] |
| Exportin 4 | Mouse | HeLa | elF-5A | [15] |
| Exportin 5 | Human | BHK | Staufen2 | [85] |
| Exportin 6 | Human | Actin | [86] | |
| Exportin 7 | Human | HeLaBHK | P50RhoGAP | [87] |
| Exportin t | Human | HeLa | tRNA | [72, 88] |
| Total (N = 2,984) | Healthcare care utilization in the past 12 months (n = 1,978) | Any marital violence in the past 12 months (n = 834) | ||||||
| %a | Prevalence %b | Χ2 (DF) | p value | Prevalence %b | Χ2 (DF) | p value | ||
| Health care | Utilized | 66.3 | 29.3 | 5.10 (1) | 0.024* | |||
| Not utilized | 33.7 | 25.4 | ||||||
| Marital violence | Any | 28.0 | 69.4 | 5.10 (1) | 0.024* | |||
| None | 72.1 | 65.1 | ||||||
| Education | Jr. high/high | 27.0 | 62.4 | 13.56 (2) | 0.001* | 29.7 | 2.34 (2) | 0.310 |
| College | 31.3 | 64.7 | 28.6 | |||||
| University | 41.7 | 69.9 | 26.7 | |||||
| Household income | Low | 26.5 | 60.7 | 23.73 (2) | <0.001* | 30.8 | 5.36 (2) | 0.068 |
| Average | 36.9 | 66.5 | 29.5 | |||||
| High | 36.6 | 72.4 | 25.8 | |||||
| Employment | Employed | 77.9 | 66.8 | 1.38 (1) | 0.239 | 27.1 | 3.18 (1) | 0.075 |
| Not-employed | 22.1 | 64.3 | 30.7 | |||||
| Gender | Men | 44.0 | 64.3 | 4.54 (1) | 0.033* | 28.3 | 0.05 (1) | 0.818 |
| Women | 56.0 | 68.0 | 27.9 |
| Characteristics (n) | DR5 | DR4 | ||||
| + (%) | −(%) | P-value | + (%) | −(%) | P-value | |
| Age (yr) | ||||||
| ≤40 (n=59) | 21(35.6) | 38(64.4) | 17(28.8) | 42(71.2) | ||
| >40 (n=115) | 42(36.5) | 73(63.5) | 0.904 | 35(30.4) | 80(69.6) | 0.825 |
| Gender | ||||||
| Female (n=38) | 13 (34.2) | 25(65.8) | 13(34.2) | 25(65.8) | ||
| Male (n=136) | 50 (36.8) | 86 (63.2) | 0.772 | 39(28.7) | 97(71.3) | 0.510 |
| Histological type | ||||||
| DNC (n=14) | 5(35.7) | 9(64.3) | 4(28.6) | 10(71.4) | ||
| UDNC (n=160) | 58(36.3) | 102(63.8) | 0.968 | 48(30.0) | 112(70.0) | 0.911 |
| Clinical stages | ||||||
| Stages I-II (n=72) | 34(47.2) | 38(52.8) | 21(29.2) | 51(70.8) | ||
| Stages III-IV (n=102) | 29(28.4) | 73(71.6) | 0.011 | 31(30.4) | 71(69.6) | 0.862 |
| LN status | ||||||
| LNM (n=124) | 36(29.0) | 88(71.0) | 37(29.8) | 87(70.2) | ||
| No LNM (n=50) | 27(54.0) | 23(46.0) | 0.002 | 15(30.0) | 35(70.0) | 0.983 |
| Survival status | ||||||
| Alive (n=111) | 49(44.1) | 62(55.9) | 36(32.4) | 75(67.6) | ||
| Dead (n=63) | 14(22.2) | 49(77.8) | 0.004 | 16(25.4) | 47(74.6) | 0.330 |
| Viruses | F1140O2-5 VP3 | F11VP2O-2 VP2 | F12VP1O-2 Site 1b | F21-48 Site 1a,5 | F21-64 Site 1a,5 | F21-34 Site 2 | F21-58 Site 2 | F21-41 Site 3 | F21-18 Near site 4 |
| ECU/4/2010 | 0.10 | 1.07 | 0.49 | 1.42 | 0.45 | -0.004 | 0.014 | 1.76 | 0.014 |
| HKN/2/2011 | 1.21 | -0.02 | 1.12 | 0.25 | 0.98 | 0.05 | 0.02 | 1.36 | 0.05 |
| VIT/32/11 | 1.22 | 1.02 | 0.56 | 1.51 | 1.52 | 0.15 | 0.04 | 1.44 | 1.39 |
| AFG/41/11 | 1.13 | 1.03 | 0.65 | 1.17 | 1.20 | 1.11 | 1.19 | 0.28 | 0.12 |
| ETH/39/2009 | 1.20 | 1.05 | 0.39 | 1.2 | 1.2 | 1.15 | 1.19 | 1.10 | 1.05 |
| UAE/9/2009 | 1.30 | 1.03 | 0.83 | 1.39 | 1.41 | 0.95 | 1.36 | 1.33 | 0.76 |
| IRN/11/2006 | 1.07 | 1.02 | 0.49 | 1.13 | 1.10 | 0.99 | 1.10 | 1.08 | 1.06 |
| TAW/12/98 | 1.58 | 0.80 | 0.06 | 1.57 | 1.63 | 1.55 | 1.61 | 0.07 | -0.02 |
| KUW/1/11 | 1.26 | 1.08 | 0.33 | 1.30 | 1.31 | 1.25 | 1.25 | 0.90 | 0.73 |
| Maternal Infection Status | Incidence rate per 100 pyrs (95% CI) | Cox HR (95% CI) | Adjusted HRa (95% CI) | P Value | Adjusted HRb (95% CI) | P Value |
| No malaria | ||||||
| No hookworm | 28.81 (27.33,30.38) | 1 | 1 | 1 | ||
| Hookworm | 37.93 (35.95,40.01) | 1.31 (1.15–1.50) | 1.20 (1.05–1.38) | .01 | 1.17 (1.03–1.34) | .02 |
| Had malaria | ||||||
| No hookworm | 35.09 (29.96,41.09) | 1 | 1 | 1 | ||
| Hookworm | 52.46 (46.48,59.21) | 1.48 (1.03–2.14) | 1.63 (1.15–2.32) | .01 | 1.60 (1.13–2.26) | .01 |
| Pinteraction = .23c | ||||||
| No malaria | ||||||
| No Mansonella perstans | 30.79 (29.49,32.15) | 1 | 1 | 1 | ||
| M. perstans | 40.05 (37.13,43.21) | 1.30 (1.12–1.51) | 1.26 (1.08–1.46) | .003 | 1.21 (1.03–1.40) | .02 |
| Had malaria | ||||||
| No M. perstans | 44.33 (39.35,49.93) | 1 | 1 | 1 | ||
| M. perstans | 44.34 (37.68,52.18) | 0.99 (.70–1.40) | 1.25 (.87–1.79) | .23 | 1.22 (.85–1.76) | .28 |
| Pinteraction = .32c | ||||||
| No malaria | ||||||
| No Schistosoma mansoni | 31.85 (30.53,33.22) | 1 | 1 | 1 | ||
| S. mansoni | 36.41 (33.52,39,54) | 1.14 (.96–1.36) | 1.10 (.92–1.31) | .29 | 1.09 (.92–1.29) | .33 |
| Had malaria | ||||||
| No S. mansoni | 43.91 (39.49,48.83) | 1 | 1 | 1 | ||
| S. mansoni | 46.36 (36.97,58.14) | 1.06 (.61–1.86) | 0.86 (.53–1.41) | .56 | 0.88 (.53–1.44) | .60 |
| Pinteraction = .50c |
| Video | CT | DFT | ORIA | MTT | ASLA | L1APG | SCM | MIL | MCT |
| Basketball | 0.278 | 0.604 | 0.072 | 0.223 | 0.398 | 0.256 | 0.475 | 0.247 | 0.526 |
| Boy | 0.587 | 0.418 | 0.189 | 0.502 | 0.389 | 0.725 | 0.397 | 0.491 | 0.818 |
| Football | 0.607 | 0.651 | 0.513 | 0.575 | 0.533 | 0.553 | 0.489 | 0.585 | 0.580 |
| Jogging-1 | 0.212 | 0.218 | 0.221 | 0.211 | 0.213 | 0.208 | 0.212 | 0.214 | 0.717 |
| Skating1 | 0.123 | 0.172 | 0.242 | 0.144 | 0.501 | 0.143 | 0.471 | 0.161 | 0.487 |
| Girl | 0.318 | 0.293 | 0.263 | 0.657 | 0.701 | 0.719 | 0.673 | 0.403 | 0.880 |
| Coke | 0.241 | 0.142 | 0.215 | 0.449 | 0.192 | 0.203 | 0.342 | 0.224 | 0.539 |
| Sylvester | 0.658 | 0.391 | 0.642 | 0.641 | 0.590 | 0.413 | 0.677 | 0.528 | 0.659 |
| Average | 0.378 | 0.361 | 0.295 | 0.425 | 0.440 | 0.403 | 0.467 | 0.357 | 0.650 |
| Metric | Target Performance |
| HC | Communication latency and energy consumption reduction (indirectly) |
| ETX | Reduction of required frame retransmissions |
| RE | Expansion of network lifetime |
| PFI | Reduction of network-layer losses |
| ETT | Assignment of weights to the individual links |
| WCETT | Focus on fixed nodes of local networks |
| Variable | Perc. difference (with - without OB) | Difference (with - without OB) | t-stats |
| Hourly Revenue (Eur) | 15.4 | 6.9 | 2.76 |
| Waiting time (Min) | 3.66 | 6.2 | 0.34 |
| Idle time (Min) | −1.42 | −9.1 | −1.33 |
| Overtime (Min) | 4.05 | 10 | 0.3 |
| Number of days with OB | 112 | ||
| of days without OB | 62 |
| Task | Search | Share | Read | Repeat | Comp man | Comp auto | Query | Analyse | Browse | Populate |
| Importance | Low | Med | Med | High | Low | High | Low | Low | Low | Med |
| Proteinuria negative (n = 13) | Proteinuria positive (n = 67) | p value | |||||
| Median | (min–max) | IQR | Median | (min–max) | IQR | ||
| *Systolic blood pressure | 117 | 103–136 | 20 | 126 | 95–184 | 16 | 0,11 |
| *Diastolic blood pressure | 77 | 64–94 | 10 | 74 | 57–98 | 10 | 0,13 |
| *Pulse pressure | 41 | 26–51 | 9 | 52 | 32–78 | 13 | 0,01 |
| *Mean aortic pressure | 100 | 73–120 | 13,5 | 100 | 70–133 | 17 | 0,24 |
| Aortic distensibility | 2,93 | 1,56–14,40 | 3,70 | 2,44 | 0,32–11,20 | 1,98 | 0,14 |
| Aortic systolic diameter (mm) | 30,61 | 26,55–38,31 | 5,60 | 33,11 | 25,81–48,16 | 6,30 | 0,01 |
| Aortic diastolic diameter (mm) | 29,18 | 26,10–37,71 | 5,84 | 32,78 | 25,46–47,06 | 6,62 | 0,008 |
| Feeding model* | Time of measurement | Reference | ||
| 2 h | 4, 5, or 6 h | 24 h | ||
| MCH-INDUCED HYPERPHAGIA IN RAT | ||||
| Male Sprague-Dawley | −90% | Takekawa et al. (2002) | ||
| Male Sprague-Dawley | −72% | Moriya et al. (2009) | ||
| Male Sprague-Dawley | −75% | −75% | Nagasaki et al. (2009) | |
| Male Wistar | −70% | Borowsky et al. (2002) | ||
| FASTING-INDUCED FEEDING | ||||
| Male Wistar rats | −35% | −30% | −25% | Huang et al. (2005) |
| Mice (strain and gender unknown) | −80% | −40% | Balavoine et al. (2007) | |
| DIO male C57BL/6NCrl:BR mice | −35% | −32% | −22% | McBriar et al. (2006) |
| DIO mice (strain and gender unknown) | −17% | −14% | Palani et al. (2005) | |
| DIO mice (strain and gender unknown) | −12% | −20% | −9% | Sasikumar et al. (2006) |
| SPONTANEOUS FEEDING | ||||
| Male Sprague-Dawley rats | −30% | Kamata et al. (2011) | ||
| Female KKAy mice | −63% | Kamata et al. (2011) | ||
| DIO C57BL/6J mice (gender unknown) | −19% | Haga et al. (2011) | ||
| DIO mice (strain and gender unknown) | −21% | Xu et al. (2006) | ||
| DIO male F344/Jcl rats | −30% | Kasai et al. (2012) | ||
| DIO male F344/Jcl rats | −28% | Kasai et al. (2011) | ||
| DIO male Sprague-Dawley rats | −31% | Kowalski and Sasikumar (2007) | ||
| Male Sprague-Dawley rats, ingestion of condensed milk# | −45% | Borowsky et al. (2002) |
| 50–59 yrs | 60-69 yrs | ≥70 yrs | |
| Patients | 1310 | 1180 | 726 |
| Cases of vertebral fracture | |||
| n, (%) | 31(2.37%)#△ | 105(8.90%)*△ | 159(21.90%)*# |
| Number of ACT | % first-line treatment | |
| Benin | 95 | 83.2 |
| DRC | 131 | 67.9 |
| Madagascar | 83 | 76.9 |
| Nigeria | 171 | 88.1 |
| Uganda | 360 | 100.0 |
| Zambia | 380 | 99.5 |
| Bone 1 | Bone 2 | Bone 3 | Bone 4 | Bone 5 | Bone 6 | Bone 7 | |
| Bone 1 | - | NS | NS | NS | S | NS | NS |
| Bone 2 | NS | - | NS | NS | S | NS | NS |
| Bone 3 | NS | NS | - | NS | S | NS | NS |
| Bone 4 | NS | NS | NS | - | NS | NS | NS |
| Bone 5 | S | S | S | NS | - | S | NS |
| Bone 6 | NS | NS | NS | NS | S | - | NS |
| Bone 7 | NS | NS | NS | NS | NS | NS | - |
| All patients (n = 146) | QoL group (n = 81) | |
| Age [years] | 44 (13 - 74) | 46 (16-74) |
| Gender ratio (male : female) | 37 (25.3%) : 109 (74.7%) | 16 (19.8%) : 65 (80.2%) |
| Tumor size [mm] | 65 (10 - 230) | 70 (8 - 230) |
| Preoperative bilirubine level [mg/dl] | 0.5 (0.2 - 6.2) | 0.5 (0.2 - 3.0) |
| Preoperative AST [U/l] | 24 (6 - 259) | 24 (8 - 259) |
| Preoperative ALT [U/l] | 26 (4 - 775) | 25 (5 - 775) |
| Preoperative Quick value [%] | 97 (27 - 130) | 98 (27 - 130) |
| Variables | UC (N = 181) |
| Sex | |
| Male | 107 (59.1%) |
| Age at UC diagnosis (years), median (IQR) | 35.8 (26.1–47.8) |
| Age at FC level measurement (years), median (IQR) | 40.5 (29.2–53.8) |
| Disease duration before FC level measurement (months), median (IQR) | 18.4 (1.9–59.5) |
| Maximum extent of UC | |
| Proctitis | 33 (18.2%) |
| Left-sided colitis | 47 (26.0%) |
| Extensive colitis | 101 (55.8%) |
| Disease severity of UC | |
| Clinical remission (Mayo score 0-2) | 17 (9.4%) |
| Mild activity (Mayo score 3-5) | 48 (26.5%) |
| Moderate activity (Mayo score 6-10) | 98 (54.1%) |
| Severe activity (Mayo score 11-12) | 18 (10.0%) |
| Smoking status at UC diagnosis | |
| Never smoker | 100 (55.2%) |
| Former smoker | 47 (26.0%) |
| Current smoker | 34 (18.8%) |
| Family history of IBD | |
| No family history | 171 (94.5%) |
| First-degree relative | 9 (5.0%) |
| Second-degree relative | 1 (0.5%) |
| History of medication use at FC level measurement | |
| Oral 5-ASA | 154 (85.1%) |
| Topical 5-ASA | 116 (64.1%) |
| Topical steroids | 32 (17.7%) |
| Systemic corticosteroids | 124 (68.5%) |
| Thiopurines | 58 (32.0%) |
| Cyclosporine | 4 (2.2%) |
| Anti-TNF agents | 30 (16.6%) |
| FC level (mg/kg), median (IQR) | 1518.0 (360.0–4205.0) |
| Hematocrit value (%), median (IQR) | 37.7 (32.8–42.0) |
| Serum albumin level (g/dL), median (IQR) | 3.7 (2.9–4.0) |
| Erythrocyte sedimentation rate (mm/h), median (IQR) | 26.0 (11.5–44.5) |
| White blood cell count (×103 /uL), median (IQR) | 7.1 (5.6–9.5) |
| Platelet count (×103 /uL), median (IQR) | 300.0 (242.0–379.0) |
| C-reactive protein level (mg/L), median (IQR) | 0.41 (0.10–2.37) |
| Partial Mayo score, median (IQR) | 5 (2–6.5) |
| Mayo endoscopic subscore, median (IQR) | 3 (2–3) |
| Mayo score, median (IQR) | 6 (3–8) |
| UCEIS, median (IQR) | 4 (3–6) |
| Authors (year), country | Participants | Tool (cut-off if provided) | Results |
| Burch et al. (2008) [63], South AfricaRisk of bias: High | 790 | MEWS | Hospital admissionMEWS 0–2 (ref)MEWS 3–4: RR 1.3 (95% CI 1.1 to 1.6)MEWS ≥5: RR 1.7 (95% CI 1.5 to 2.0)In-hospital mortalityMEWS 0–2 (ref)MEWS 3–4: RR 2.8 (95% CI 1.7 to 4.8)MEWS ≥5: RR 4.6 (95% CI 2.7 to 7.8) |
| Correia et al. (2014) [55], PortugalRisk of bias: Unclear | 65 | EWS | Length of hospital stay & MortalityScore at 24 h and 12 h seemed to predict both length of stay and mortality (p < 0.05). The EWS would have increased early medical attention by 40% if a threshold of ≥3 was used. |
| Dundar et al. (2015) [41], TurkeyRisk of bias: Low | 671 | MEWSVIEWS | HospitalisationMEWS (≥3): AUROC 0.73 (95% CI 0.69–0.77)VIEWS (≥6): AUROC 0.76 (95% CI 0.72–0.79)In-hospital mortalityMEWS (≥4): AUROC 0.89 (95% CI 0.84–0.94)VIEWS (≥8): AUROC 0.90 (95% CI 0.86–0.94) |
| Eick et al. (2015) [42], GermanyRisk of bias: Low | 5730 | MEWS | In-hospital mortalityAUROC: 0.71 (0.67–0.75; p < 0.001) |
| Graham et al. (2007) [56], Hong KongRisk of bias: Unclear (Conference abstract) | 413 | MEWS (>4) | In-hospital mortalityOR 8.3 (95% CI 1.1–60.4), p = 0.013ED re-attendance within 48 hOR 45.2 (95% CI 3.4–568.9), p < 0.0001 |
| Heitz et al. (2010) [43], USARisk of bias: Low | 280 | MEWS Max (≥4)MEWS plus | Need for higher level of care or mortality within 24 hMEWS Max: AUROC 0.73 (95% CI, 0.66–0.79)MEWS Plus: AUROC 0.76 (95% CI, 0.69–0.82) |
| Junhasavasdiku et al. (2012) [58], ThailandRisk of bias: Unclear | 381 | MEWS | MortalityMEWS at ED was associated with mortality (p < 0.001) |
| Naidoo et al. (2014) [62], South AfricaRisk of bias: High | 265 | TEWS | Discharge within 24 h of admission, admission to a ward, admission to an intensive care unit (ICU), and death in hospital.TEWS <7: 53.7% discharged; no admitted to ICU; none died.TEWS ≥7: 18.7% discharged; 3 admitted to ICU; 4 died |
| Olsson et al. (2003) [33], SwedenRisk of bias: Low | 1027 | APACHE IIRAPSREMS | MortalityREMS: AUROC: 0.91 ± 0.02RAPS: AUROC: 0.87 ± 0.02APACHE II: AUROC: 0.90 ± 0.02 |
| Olsson et al. (2004) [34], SwedenRisk of bias: Low | 11,751 | RAPSREMS | MortalityRAPS: AUROC: 0.65 ± 0.02REMS: AUROC: 0.85 ± 0.01 |
| Subbe et al. (2006) [50], UKRisk of bias: Low | (a) 53 unselected; (b): 49 ICU admission; (c): 49 ED admission, transferred to ward then ICU | MEWS (>2)ASSIST (>3)MET (=1)MTS (orange or red) | Patients identified as critically ill (at risk of deterioration)MTS: Sensitivity: (a) 15%; (b) 96%; (c) 65%MEWS: Sensitivity (a): 8%; (b) 77%; (c) 55%ASSIST: Sensitivity (a): 0%; (b) 22%; (c) 16%MET: Sensitivity (a) 0%; (b) 2%; (c) 7% |
| Wang et al. (2016) [60], TaiwanRisk of bias: Unclear | 99 | CCIMEWS | Survival to dischargeCCI: Adjusted OR 0.57 (95% CI 0.38–0.84); p = 0.005Peri-arrest MEWS: Adjusted OR 0.77 (95% CI 0.60–0.97); p = 0.028 |
| Models (Prevent/Treatment) | Antioxidant/Plants | Effects | Dose (Dose-Effect) | Bioactive Compounds | References |
| Diabetic rats fed on a high fat thermolyzed diet (Prevent) | Omega 3-polyunsaturated fatty acids | ↑ SOD, CAT; ↓ triglycerides, non-esterified fatty acid, lipoperoxidation | 3.0% in diet | Omega 3-polyunsaturated fatty acids | [108] |
| Mice fed with high-fat diet (Prevent and treatment) | Moringa oleifera leaves; haw pectic oligosaccharide; Thymbra spicata | ↑ GSH; ↓ ALT, AST, ALP, lipid peroxidation | 50, 150 and 300 mg/kg b.w. (No dose–effect) | Haw pectic oligosaccharide | [109,110,111] |
| Liver damage in diet-induced atherosclerotic rats (Prevent) | Tulbaghia violacea rhizomes | ↓ LDH, AST, ALT, ALP, bilirubin antioxidation | 100 mg/kg b.w. | [112] | |
| Rabbits with high-fat diet (Prevent) | Apolipoprotein A–I | ↑ SOD, GSH-Px; ↓ iNOS, MDA | 15 mg/kg b.w. | [113] | |
| WeRats fed a high-fat diet (Prevent) | Black cabbage sprout | ↑ SOD, CAT, NADPH, GSH-Px, GRD GST | 250 and 500 mg/kg b.w. (Dose–effect) | [114] |
| Before The Establishment of Trauma Team | After The Establishment of Trauma Team | |||||||
| n | Average | SD | n | Average | SD | t | p | |
| ICU stay | 47 | 7.81 | 7.96 | 76 | 8.74 | 8.98 | −.581 | 0.562 |
| LOS | 63 | 22.16 | 14.80 | 131 | 19.63 | 15.58 | 1.074 | 0.284 |
| Operation waiting time | 17 | 37.47 | 19.71 | 16 | 33.75 | 58.20 | .249 | 0.805 |
| Duration stay in ER | 17 | 290.65 | 353.06 | 16 | 180.75 | 141.35 | 1.160 | 0.255 |
| Clinical Charge | 63 | 9976.56 | 7433.79 | 131 | 8627.64 | 7289.05 | 1.199 | 0.232 |
| Ward Charge | 63 | 52,786.79 | 54,062.83 | 131 | 43,025.78 | 51,620.02 | 1.214 | 0.226 |
| Examination Charge | 62 | 15,666.29 | 21,999.81 | 124 | 10,545.89 | 13,254.21 | 1.975 | 0.05* |
| Radiology Charge | 62 | 8864.85 | 9071.37 | 124 | 5638.11 | 8396.92 | 2.398 | 0.018* |
| Procedure Charge | 63 | 23,629.67 | 27,658.80 | 131 | 21,331.63 | 33,887.60 | .468 | 0.640 |
| Operation Charge | 42 | 54,561.48 | 41,418.76 | 88 | 41,394.32 | 34,149.59 | 1.916 | 0.05* |
| Total Medical Charge | 63 | 224,411.86 | 227,087.79 | 131 | 172,125.21 | 192,091.67 | 1.671 | 0.096 |
| Questions for nurse practitioners | Questions for senior doctors and nurses |
| 1. How would you describe your role? | 1. What is your understanding of the role of the NP? |
| 2. How is the role of a Nurse Practitioner (NP) different from that of doctors and other nurses? | 2. What do you perceive is the impact of the NP role on the delivery of care? |
| − What is the impact of the NP on the delivery of care? | 3. How do you think the role of the NP influences the roles of doctors and nurses? |
| 3. Do you think that the roles of existing Emergency Department (ED) clinicians have changed as a result of the NP role? | 4. What are the mechanisms that determine the role of the NP? |
| 4. Do you think the roles of NPs would differ at other sites? | 5. What is your view on the overlap between NP roles and those of doctors? |
| − Why do you think they would differ? (e.g. due to ICT, casemix, culture etc.) | |
| − What are the mechanisms which determine the role of the NP? For example, what factors lead to these differences across sites? | |
| 5. What is your view on the overlap between NP roles and those of doctors? |
| Variables (mm) | Δ(T2 − T1) | |||
| Mean | SD | p value | ||
| UP(y) (mm) | −1.24 | 1.84 | 0.049* | |
| Stm(y) (mm) | 0.63 | 1.17 | 0.103 | |
| Stm(z) (mm) | −1.79 | 2.48 | 0.003** | |
| LP(y (mm)) | −2.1 | 1.54 | 0.001** | |
| LP(z) (mm) | −2.7 | 3.44 | 0.025* | |
| Li(z) (mm) | −4.32 | 2.49 | 0.000** | |
| 1 | Sn-Ls-UP (°) | −3.16 | 11.21 | 0.371 |
| 2 | Ls-UP-Stm (°) | −9.36 | 10.75 | 0.016* |
| 3 | Stm-LP-Li (°) | 6.43 | 10.29 | 0.065* |
| 4 | LP-Li-Ln (°) | 5.19 | 12.59 | 0.201 |
| Demographic characteristics | Consented to biobanking (n = 2,100) | Refused or withdrew (n = 75) | p-Value |
| Father’s age; mean (SD) | 39.1 (38.8–39.5) | 41.3 (39.6–42.9) | 0.034 |
| Mother’s age; mean (SD) | 33.1 (32.9–33.5) | 34.8 (33.1–36.5) | 0.056 |
| Mother’s level of education | |||
| Before or finished primary school | 468 (22.3%) | 7 (9.3%) | 0.0001 |
| Finished preparatory, secondary, or technical school | 912 (43.4%) | 23 (30.7%) | |
| Education higher than high school | 720 (34.3%) | 45 (60%) | |
| Father’s level of education | |||
| Before or finished primary school | 411 (19.6%) | 5 (6.8%) | 0.001 |
| Finished preparatory, secondary, or technical school | 948 (4.1%) | 24 (32.9%) | |
| Education higher than high school | 741 (35.3%) | 44 (60.3%) | |
| Residency | |||
| Metropolitan Cairo | 818 (39%) | 35 (46.7%) | 0.5 |
| Lower Egypt and Delta (except coastal governorates) | 598 (28.5%) | 18 (24%) | |
| Coastal governorates | 289 (13.8%) | 11 (14.7%) | |
| Upper Egypt | 255 (12.1%) | 5 (6.7%) | |
| Suez Canal | 78 (3.7%) | 4 (5.3%) | |
| Outside Egypt | 62 (3%) | 2 (4.3%) | |
| Population distribution | |||
| Rural | 817 (38.9%) | 22 (27.7%) | 0.077 |
| Urban | 1,283 (61.1%) | 53 (70.7%) |
| Splenic aspirate parasitologic result | Total | ||
| Negative | Positive | ||
| rK39 ICT strip test | |||
| Negative | 5 | 7 | 12 |
| Positive | 13 | 37 | 50 |
| Total | 18 | 44 | 62 |
| # of Patients (%) | |||
| Characteristic | Female | Male | P Value |
| Age (yrs) (n = 86) | 0.26 | ||
| <60 | 37 (88.1%) | 42 (95.5%) | |
| >/=60 | 5 (11.9%) | 2 (4.5%) | |
| Ethnicity (n = 87) | 0.19 | ||
| Hispanic | 23 (53.5%) | 30 (68.2%) | |
| Non-Hispanic | 20 (46.5%) | 14 (31.8%) | |
| Hemoglobin (g/dL) (n = 83) | 0.019 | ||
| <12 | 34 (80.9%) | 23 (56.1%) | |
| >/=12 | 8 (19.1%) | 18(43.9%) | |
| Leukocyte count (× 109/L) (n = 85) | 0.46 | ||
| <50 | 13 (30.2%) | 9 (21.4%) | |
| >/=50 | 30 (69.8%) | 33 (78.6%) | |
| Platelets (× 109/L) (n = 82) | 0.041 | ||
| <450 | 20 (48.8%) | 30 (73.2%) | |
| >/=450 | 21 (51.2%) | 11 (26.8%) | |
| Hasford Score (n = 64) | 1 | ||
| </=780 low-risk | 19 (52.8%) | 16 (57.1%) | |
| >780 and </=1480 intermediate | 12 (33.3%) | 9 (32.1%) | |
| >1480 high-risk | 5 (13.9%) | 3 (10.7%) | |
| Sokal Score (n = 65) | 0.39 | ||
| <0.8 good prognosis | 12 (33.3%) | 13 (44.8%) | |
| 0.8–1.2 moderate prognosis | 16 (44.4%) | 8 (27.6%) | |
| >1.2 poor prognosis | 8 (22.2%) | 8 (27.6%) | |
| CHR at 3 months, all treatments (n = 47) | 0.23 | ||
| Yes | 13 (50%) | 15 (71.4%) | |
| No | 13 (50%) | 6 (28.6%) | |
| CHR at 3 months, imatinib only (n = 36) | 0.13 | ||
| Yes | 12 (63.2%) | 15 (88.2%) | |
| No | 7 (38.4%) | 2 (11.8%) |
| Category | No. of cases | Meandensity of TFPI-2 Mean± SD | Statistics value | p value | |
| Age | ≤55 | 74 | 0.324±0.061 | t=0.302 | 0.764 |
| >55 | 47 | 0.327±0.052 | |||
| Tumor size | ≤2 cm | 56 | 0.351±0.061 | t=4.948 | 0.001 |
| >2 cm | 65 | 0.303±0.044 | |||
| Skin involvementa | No | 96 | 0.336±0.057 | t=4.252 | 0.001 |
| Yes | 25 | 0.284±0.038 | |||
| LN metastasis | 0 | 70 | 0.348±0.055 | F=12.896b | 0.001 |
| 1-3 | 22 | 0.292±0.043 | |||
| 4-9 | 15 | 0.316±0.048 | |||
| 10- | 13 | 0.272±0.038 | |||
| Unknown | 1 | ||||
| Histologic grade | ≤II | 71 | 0.339±0.057 | t=3.389 | 0.001 |
| >II | 50 | 0.305±0.052 | |||
| Vessel invasion | Absence | 109 | 0.333±0.054 | t=5.172 | 0.001 |
| Presence | 12 | 0.251±0.030 | |||
| Clinical stagec | I | 35 | 0.375±0.053 | Chi-Square=43.867c | 0.001 |
| II | 52 | 0.317±0.048 | |||
| III | 34 | 0.286±0.034 | |||
| ER | (-) | 43 | 0.327±0.055 | t=0.253 | 0.801 |
| (+) | 77 | 0.324±0.059 | |||
| Unknown | 1 | ||||
| PR | (-) | 63 | 0.319±0.055 | t=-1.211 | 0.228 |
| (+) | 57 | 0.332±0.060 | |||
| Unknown | 1 | ||||
| HER-2 | (-) | 62 | 0.333±0.059 | t=1.361 | 0.176 |
| (+) | 55 | 0.318±0.056 | |||
| Unknown | 4 | ||||
| Tumor type | IDCd | 98 | 0.324±0.057 | t=0.488 | 0.626 |
| Non-IDCe | 23 | 0.330±0.059 |
| var gene typea | Genome | Geographic origin | Binding phenotype | No. of potential thrombin cleavage sites byb: | No. of potential thrombin cleavage sites with sequenceb: | Presence ofc: | Thrombin cleavage | |||||
| CIDR1 | Other | Prosper | Peptide Cutter | PR | PRXXR | DBLδ1 | KPRGPA | GLGRSL | ||||
| IT4var06 (DC8) | IT4/FCR3 | Southeast Asia | EPCR | ? | 0 | 11 | 7 | 1d | Yes | No | No | NDe |
| IT4var19 (DC8) | IT4/FCR3 | Southeast Asia | EPCR | ? | 0 | 0 | 7 | 1d | Yes | Yes | Yes | Yes |
| IT4var20 (DC8) | IT4/FCR3 | Southeast Asia | EPCR | ? | 0 | 1 | 7 | 0 | Yes | No | No | ND |
| IT4var32b (DC8) | IT4/FCR3 | Southeast Asia | EPCR | ? | 0 | 0 | 7 | 1d | Yes | Yes | Yes | ND |
| DD2var47 (DC8) | DD2 | Southeast Asia | EPCR | ? | 0 | 1 | 6 | 0 | Yes | No | No | ND |
| IGHvar19 (DC8) | IGH | India | EPCR | ? | 0 | 0 | 6 | 1d | Yes | No | No | ND |
| RAJ116var08 (DC8) | RAJ116 | India | EPCR | ? | 0 | 0 | 4 | 0 | No | No | No | ND |
| PFCLINvar30 (DC8) | PFCLIN | Africa | EPCR | ? | 0 | 0 | 4 | 0 | No | No | No | ND |
| PFD0020c (DC8) | 3D7 | Unknown | EPCR | ? | 0 | 2 | 10 | 2 (1d) | Yes | No | No | ND |
| PF08_0140 (DC8) | 3D7 | Unknown | EPCR | ? | 1 | 1 | 7 | 0 | Yes | No | No | ND |
| RAJ116var11 (DC8) | RAJ116 | India | EPCR | ? | 0 | 0 | 6 | 1d | Yes | No | No | ND |
| PFCLINvar31 (DC8) | PFCLIN | Africa | EPCR | ? | 2 | 1 | 6 | 1 | No | No | No | ND |
| MAL6P1.316 (DC8) | 3D7 | Unknown | EPCR | ? | 0 | 1 | 6 | 0 | No | No | No | ND |
| IT4var01 | IT4/FCR3 | Southeast Asia | CD36 | ICAM-1 | 0 | 1 | 3 | 0 | No | No | No | No |
| IT4var11 | IT4/FCR3 | Southeast Asia | CD36 | ? | 0 | 0 | 3 | 1d | Yes | No | No | Yes |
| IT4var14 | IT4/FCR3 | Southeast Asia | CD36 | ICAM-1 | 0 | 0 | 7 | 1d | Yes | No | No | ND |
| IT4var16 | IT4/FCR3 | Southeast Asia | CD36 | ICAM-1 | 1 | 2 | 4 | 1d | Yes | No | No | ND |
| IT4var31 | IT4/FCR3 | Southeast Asia | CD36 | ICAM-1 | 0 | 0 | 3 | 1 | No | No | No | ND |
| IT4var33 | IT4/FCR3 | Southeast Asia | CD36 | ? | 1 | 1 | 2 | 1d | Yes | No | No | ND |
| IT4var39 | IT4/FCR3 | Southeast Asia | CD36 | ? | 0 | 0 | 3 | 1d | Yes | No | No | ND |
| IT4var44 | IT4/FCR3 | Southeast Asia | CD36 | ? | 0 | 0 | 4 | 1d | Yes | No | No | ND |
| IT4var07 | IT4/FCR3 | Southeast Asia | EPCR | ICAM-1 | 0 | 3 | 3 | 1d | Yes | No | Yes | Yes |
| HB3var03 | HB3 | Central America | EPCR | ICAM-1 | 0 | 0 | 5 | 1 | No | No | No | No |
| PFD1235wD4 | 3D7 | Unknown | EPCR | ICAM-1 | 1 | 1 | 8 | 2 (1d) | Yes | No | No | ND |
| IT4var02 | IT4/FCR3 | Southeast Asia | ? | PECAM-1 | 0 | 0 | 8 | 1 | No | No | No | ND |
| PF11_0008 | 3D7 | Unknown | ? | PECAM-1 | 0 | 0 | 8 | 1 | No | No | No | ND |
| PF13_0003 | 3D7 | Unknown | ? | Rosette | 1 | 0 | 10 | 1 | No | No | No | ND |
| HB3var06 | HB3 | Central America | ? | Rosette | 0 | 0 | 6 | 0 | No | No | No | ND |
| IT4var09 | IT4/FCR3 | Southeast Asia | EPCR | Rosette | 0 | 0 | 4 | 1d | Yes | No | No | ND |
| IT4var60 | IT4/FCR3 | Southeast Asia | ? | Rosette | 1 | 0 | 6 | 0 | No | No | No | ND |
| Total (n = 30) | 8 | 26 | 170 | 23 | 18 | 2 | 3 | 3/5 |
| Reference material (Certified or recommended values) | Matrix | Recovery rate |
| NIST 1643e (60.45±0.72 ppb) | Water | 93 to 102% |
| NIST 1568a (290±30 ppb) | Poultry feed/Excreta | 91 to 99% |
| Arsenic standard (20 ppb) | Egg | 89 to 97% |
| Conventional group | Cocktail group | P | |
| Mean dosage (mg) a | N/A | ||
| - Meperidine | 58.33 ± 24.46 | 25 | |
| - Midazolam | 6.81 ± 2.12 | 2.5 | |
| - Propofol | 0 | 172.08 ± 92.15 | |
| Dosage (mg/kg/hr) a | N/A | ||
| - Meperidine | 2.42 ± 2.58 | 1.06 ± 0.60 | |
| - Midazolam | 0.29 ± 0.36 | 0.11 ± 0.06 | |
| - Propofol | 0 | 6.18 ± 3.0 | |
| Indications for ERCP | 0.621 | ||
| - CBD stone | 51 (50.0%) | 53 (51.5%) | |
| - Benign biliary stricture | 7 (6.9%) | 10 (9.7%) | |
| - Malignant biliary stricture | 28 (27.4%) | 20 (19.4%) | |
| - Pancreatic therapy | 5 (4.9%) | 8 (7.8%) | |
| - Others | 11 (10.8%) | 12 (11.6) | |
| Time to intubation (min) a | 3.10 ± 1.86 | 3.68 ± 2.38 | 0.053 |
| Duration (min) a | 31.60 ± 17.56 | 27.88 ±14.38 | 0.099 |
| Construct | [NaCl] | Kd |
| mm | nm | |
| N-domain | 0 | 47.80 ± 4.94 |
| 20 | 4.61 ± 0.63 | |
| C-domain | 0 | 45.50 ± 4.24 |
| 20 | 13.50 ± 2.06 | |
| R186H | 0 | 132.00 ± 6.72 |
| 20 | 4.42 ± 0.50 | |
| E403R | 0 | 2.67 ± 0.31 |
| 20 | 6.76 ± 0.65 | |
| R522Q | 0 | 22.00 ± 3.31 |
| 20 | 15.90 ± 2.09 | |
| R522K | 0 | 35.30 ± 2.85 |
| 20 | 26.30 ± 1.86 |
| Characteristics | Whole cohort (n = 5685) |
| Women (%) | 2782 (50.6) |
| Age (years) | 43.7 ± 0.4 |
| Race/ethnicity (%) | |
| Non-Hispanic whites | 2898 (73.5) |
| Non-Hispanic blacks | 1085 (9.4) |
| Mexican Americans | 1021 (7.8) |
| Others | 681 (9.3) |
| Education categories (%) | |
| Below high school | 1409 (16.1) |
| High school | 1391 (24.3) |
| Above high school | 2885 (59.5) |
| Smoking (%) | |
| Never smoker | 3045 (52.9) |
| Former smoker | 1284 (22.9) |
| Current smoker | 1356 (24.2) |
| Current drinker (%) | 4056 (76.3) |
| Moderate physical activity (%) | 2741 (54.9) |
| Body mass index (%) | |
| Normal weight | 1869 (35.2) |
| Overweight | 2036 (34.6) |
| Obese | 1780 (30.1) |
| Depression (%) | 348 (5.0) |
| Systolic blood pressure (mm Hg) | 119.7 ± 0.3 |
| C-reactive protein (mg/dL) | 0.358 ± 0.011 |
| Total cholesterol (mg/dL) | 200.74 ± 0.78 |
| Prediabetes (%) | 2058 (31.3) |
| In vitro | Percentage of CD4+IL-10+ (%) | MFI CD4+IL-10+ | iMFI CD4+IL-10+ |
| BALB/c | 14·2 ± 1·2 | 125·0 ± 11·2 | 1775·0 ± 121·9 |
| CBA | 3·3 ± 0·2 | 82·1 ± 4·6 | 270·9 ± 15·6 |
| Name | Forward and Revers Primers | Product Size | Comment |
| Bo 5S IGS | F: ACTAGGATGGGTGACCTCCCG; | 484 | 5S-IGS product size |
| R: CGCTTAACTGCGGAGTTCTGA | |||
| Bo ITS1 and 2 | F: CGCGAGAAGTCCACTAAACC; | 823 | Identify sequence differences |
| R: ACGTCCGATTTTCAAGCTGG | |||
| Bo 45S IGS | F: ATTCAGCCCTTTGTCGCTAA; | variable | 45S-IGS product size |
| R: ATGACTACTGGCAGGATCAACCAG | |||
| IGS inter-D | ATCGTGTAGGACCGAGAAGT | D type intergenic | |
| IGS inter-CEF | GGTAGGCACAAAAGGAATGC | C, E and F type intergenic |
| Variable of Interest | n | Mean | Standard Deviation | Notes | |
| Age (years) | 344 | 61.8 | 7.6 | ||
| Age of menarche (years) | 335 | 13.3 | 1.7 | 9 could not recall the age of menarche | |
| Age of menopause (years) | 327 | 49.9 | 5.8 | 17 had not reached menopause | |
| Years since menopause (years) | 327 | 11.9 | 9.4 | ||
| Weight (kg) | 344 | 60.5 | 11.3 | ||
| Height (cm) | 344 | 153.7 | 5.7 | ||
| BMI (kg/m2) | 344 | 25.7 | 4.7 | ||
| Body fat percentage (%) | 344 | 36.2 | 7.0 | ||
| Speed of sound (m/s) | 344 | 1536.0 | 28.6 | ||
| Broadband attenuation of sound (dB/MHz) | 344 | 112.4 | 11.7 | ||
| Stiffness index | 344 | 84.8 | 14.5 | ||
| T-score | 344 | −0.7 | 1.4 | ||
| Total MET | 344 | 2922.0 | 2046.8 | ||
| Number of children (n) | 344 | 2.9 | 1.8 | ||
| n | % | ||||
| Ethnicity | Chinese | 119 | 34.6 | ||
| Malay | 197 | 57.3 | |||
| Indian | 28 | 8.1 | |||
| Menopause status | Natural menopause | 274 | 79.7 | ||
| Menopause due to surgery | 41 | 11.9 | |||
| Menopause due to drugs | 12 | 3.5 | |||
| Perimenopausal | 17 | 5 | |||
| Education level | No formal education | 17 | 4.9 | ||
| Primary school | 60 | 17.4 | |||
| Secondary school | 168 | 48.8 | |||
| Certificate | 31 | 9 | |||
| Diploma | 37 | 10.8 | |||
| Degree | 23 | 6.7 | |||
| Postgraduate | 8 | 2.3 | |||
| Cigarette smoking status | Non-smoker | 335 | 97.4 | ||
| Current smoker | 8 | 2.3 | |||
| Ex-smoker | 1 | 0.3 | |||
| Alcohol drinking | Non-drinker | 336 | 97.7 | ||
| Current drinker | 7 | 2.0 | |||
| Ex-drinker | 1 | 0.3 | |||
| Milk drinking | Non-drinker | 173 | 50.3 | ||
| Drinker | 171 | 49.7 | |||
| Coffee drinking | Non-drinker | 146 | 42.4 | ||
| Current drinker | 197 | 57.3 | |||
| Ex-drinker | 1 | 0.3 | |||
| Physical activity status | Inactive | 15 | 4.4 | ||
| Minimally active | 193 | 56.1 | |||
| HEPA active | 136 | 39.5 |
| SPARQL Query | Note |
| SELECT DISTINCT ?label ?definitionContent ?ontologyId ?termId | To extract the definition and its metadata for a specific ICD category, A19 – Miliary tuberculosis |
| { GRAPH <http://who.int/icd> | |
| { <http://who.int/icd#A19> <http://who.int/icd#definitionPrefilled> ?prefilledDefinition . | |
| <http://who.int/icd#A19> rdfs:label ?label . | |
| ?prefilledDefinition <http://who.int/icd#label> ?definitionContent; | |
| <http://who.int/icd#ontologyId> ?ontologyId; | |
| <http://who.int/icd#termId> ?termId; | |
| }} |
| Disease | Protein Defect | iNKT Cells | Type II NKT Cells | iNKT Cell Subsets |
| Gaucher | β-glucosidase (Glucocerebrosidase) | = [13] | ↑ (glucosylsphingosine-specific) [13] | ND |
| Fabry | α-galactosidase A | = [71] | ND | ↓ CD4+ iNKT cells [71] |
| NPC | NPC1 | = [70] | ND | No alterations in CD4+ iNKT cells [70] |
| Collection Round | eHSR Trap Nights 1 | Culex spp. Ehsr 1 | Culex spp. Abundance Trap Nights 2 | Culex spp. Abundance 2 | Nestlings | Culex: Nestlings | IR 3 |
| 1–15 June | 43 | 0.4 ± 0.26 | 161 | 9.9 ± 1.09 | 107.2 ± 2.06 | 0.09 | 1.9 |
| 16–30 June | 88 | 1.4 ± 1.13 | 172 | 10.2 ± 1.35 | 102.3 ± 3.75 | 0.1 | 0 |
| 1–13 July | 34 | 0.1 ± 0.08 | 137 | 7.5 ± 1.21 | 33.9 ± 2.59 | 0.22 | 0 |
| 14–28 July | 39 | 0.2 ± 0.08 | 187 | 9.7 ± 1.26 | 36.1 ± 1.27 | 0.27 | 1.7 |
| 29 July–11 August | 24 | 0.1 ± 0.10 | 171 | 9.0 ± 1.95 | 19.4 ± 3.35 | 0.47 | 7.9 |
| 12–26 August | 2 | 0 ± 0 | 206 | 5.9 ± 0.83 | 1.4 ± 0.53 | 4.15 | 2.1 |
| Covariate | P value | Hazard radio | 95% Confidence interval | |||
| Univariate | Added SBEM | Univariate | Added SBEM | Univariate | Added SBEM | |
| SBEM (3+ vs. <3+) | 0.000 | 0.000 | 4.113 | 4.113 | 2.004-8.440 | 2.004-8.440 |
| Lymph Node (Pos. vs. Neg.) | 0.000 | 0.000 | 2.972 | 2.734 | 1.777-4.970 | 1.617-4.623 |
| Age (>35Y vs. ≤35Y) | 0.646 | 0.942 | 1.140 | 0.979 | 0.652-1.992 | 0.551-1.738 |
| Tumor size (>20 mm vs. ≤20 mm) | 0.308 | 0.367 | 0.771 | 0.794 | 0.468-1.271 | 0.481-1.311 |
| Grade (>1 vs. =1) | 0.066 | 0.085 | 0.563 | 1.720 | 0.305-1.040 | 0.928-3.188 |
| Grade (=3 vs. ≤2) | 0.001 | 0.004 | 3.036 | 2.688 | 1.572-5.864 | 1.371-5.273 |
| TNM (>1 vs. =1) | 0.000 | 0.000 | 3.164 | 2.769 | 1.918-5.218 | 1.705-4.498 |
| TNM (=3 vs. ≤2) | 0.000 | 0.001 | 4.000 | 3.565 | 1.987-8.055 | 1.734-7.332 |
| Ki67 (≤35 vs. > 35) | 0.001 | 0.004 | 2.956 | 2.597 | 1.585-5.512 | 1.362-4.950 |
| Properties | Rejuvenator A | Rejuvenator B | Test Method |
| Form | Liquid | Liquid | |
| Color | pink | Brown | |
| pH | 4.8 | 5.6 | pH test paper |
| Viscosity (25 °C), SFS | 40 | 15 | ASTM D-244 |
| Solute component [wt %] | 65 | 60 | ASTM D-244 |
| Regeneration component [wt %] | 8 | 8 | ASTM D-2006-70 |
| Asphaltene component [wt %] | 0.4 | 0.75 |
| CT and MRI Metrics | ILD | Non ILD | ||
| AUC | p value | AUC | p value | |
| CT | ||||
| Main PA Diameter | 0.873 | <0.001 | 0.835 | <0.001 |
| PA/AA | 0.799 | 0.003 | 0.794 | <0.001 |
| PA Index | 0.595 | 0.347 | 0.836 | <0.001 |
| Right PA Diameter | 0.753 | 0.012 | 0.757 | <0.001 |
| Left PA Diameter | 0.729 | 0.023 | 0.754 | <0.001 |
| MRI | ||||
| Systolic PA area | 0.887 | <0.001 | 0.824 | <0.001 |
| Diastolic PA area | 0.897 | <0.001 | 0.857 | <0.001 |
| PA relative area change | 0.388 | 0.266 | 0.365 | <0.001 |
| ME II | NFE II | P Value | RR (95% confidence interval) | |
| Prior admissions | 19/23 (83%) | 22/25 (88%) | NS | |
| Prior intubation | 9/30 (30%) | 16/27 (59%) | 0.03 | 1.97 (1–3.7) |
| B2 agonist Use | 23/25 (92%) | 30/33 (91%) | NS | |
| Inhaled corticosteroids | 6/36 (17%) | 16/33 (48%) | 0.008 | 2.9 (1.2–6.5) |
| Systemic corticosteroids | 11/36 (30%) | 10/33 (30%) | NS | |
| Cough | 10/12 (83%) | 15/20 (75%) | NS | |
| Wheezing | 10/12 (83%) | 22/23 (96%) | NS | |
| Sputum | 6/10 (60%) | 13/17 (76%) | NS | |
| Chest tightness | 3/6 (50%) | 6/10 (60%) | NS | |
| URTI | 6/16 (37%) | 7/15 (47%) | NS | |
| Heart rate (beats/min) | 102 ± 21(38) | 124 ± 20(35) | 0.0001 | |
| Respiratory rate (breaths/min) | 25 ± 6(38) | 32 ± 7(25) | <0.0001 | |
| Systolic BP (mmHg) | 136 ± 19(38) | 147 ± 39(36) | NS | |
| Diastolic BP (mmHg) | 75 ± 18(37) | 93 ± 25(34) | 0.002 | |
| PO2 (mmHg) | 85 ± 33(25) | 209 ± 170(34) | 0.003 | |
| PCO2 (mmHg) | 41 ± 10(25) | 57 ± 18(34) | 0.001 | |
| pH | 7.38 ± 0.06(24) | 7.27 ± 0.12(34) | 0.0001 | |
| FiO2 (%) | 40 ± 21(19) | 71 ± 32(26) | 0.001 | |
| A-aO2 (mmHg) | 136 ± 128(19) | 188 ± 142(26) | 0.09 | |
| WBC (mm3) | 11,500 ± 4,000(29) | 15,600 ± 6,200(25) | 0.01 | |
| Eos (%) | 1 ± 1.4(19) | 2.75 ± 1.5(4) | 0.03 | |
| Eos absolute (/mm3) | 125 ± 198(19) | 445 ± 324(4) | 0.03 | |
| Hospitalization days | 3.8 ± 2.6(27) | 9.8 ± 5(7) | 0.001 |
| Phage density | Bacterial density | Implication |
| High | High | Low adsorption rate or partial bacterial refuge, poor control of bacteria. Gives insight to failure |
| High | Low | Not sustainable – a possible transitory step following successful control of bacteria, before phage densities have equilibrated |
| Low | High | Phage unable to replicate adequately; possible genetic resistance of bacteria or inaccessible refuge |
| Low | Low | Treatment success |
| Sango and Daiya | |||
| Within reach | Out of reach | χ2(1) | |
| Robin and Daiya | |||
| Within reach | 32 | 62 | 0.92 |
| Out of reach | 114 | 174 | |
| Koyuki and Daiya | |||
| Within reach | 32 | 30 | 6.12* |
| Out of reach | 101 | 189 | |
| Cherry and Daiya | |||
| Within reach | 9 | 26 | 2.84 |
| Out of reach | 120 | 177 | |
| Chelsea and Daiya | |||
| Within reach | 7 | 45 | 16.39** |
| Out of reach | 107 | 139 | |
| Judy and Daiya | |||
| Within reach | 13 | 19 | 0.16 |
| Out of reach | 117 | 199 |
| Proportion of recurrence | Proportion of death | |||||||
| Group 1 | Group 2 | Group 3 | Group 4 | Group 1 | Group 2 | Group 3 | Group 4 | |
| Group 1 | - | 0.175 | <0.0001 | <0.0001 | - | 0.031 | <0.0001 | <0.0001 |
| Group 2 | - | - | <0.0001 | <0.0001 | - | - | 0.013 | <0.0001 |
| Group 3 | - | - | - | 0.080 | - | - | - | 0.057 |
| Group 4 | - | - | - | - | - | - | - | - |
| Scale | Cronbach’s alpha | |||
| Male | Female | Single | Married | |
| Energy | 0.87 | 0.87 | 0.76 | 0.81 |
| Family role | 0.77 | 0.72 | 0.39 | 0.79 |
| Language | 0.94 | 0.93 | 0.93 | 0.93 |
| Self-care | 0.93 | 0.92 | 0.94 | 0.92 |
| Social role | 0.90 | 0.84 | 0.85 | 0.89 |
| Thinking | 0.80 | 0.83 | 0.90 | 0.79 |
| Mood | 0.82 | 0.76 | 0.70 | 0.82 |
| Personality | 0.86 | 0.85 | 0.94 | 0.84 |
| Upper extremity function | 0.93 | 0.91 | 0.95 | 0.91 |
| Vision | 0.76 | 0.90 | 0.75 | 0.87 |
| Work (productivity) | 0.92 | 0.79 | 0.86 | 0.87 |
| Mobility | 0.95 | 0.92 | 0.95 | 0.93 |
| Bands analyzed | Proteins detected | Database accession number | MOWSE score | Number of unique peptide identified | Sequence coverage, % | emPAI value |
| 1 | HoxF NAD-reducing hydrogenase diaphorase moiety large subunit [R. eutropha H16] | gi|38637753 | 4562 | 142 | 81 | 61.43 |
| 2 | HoxH NAD-reducing hydrogenase moiety large subunit [R. eutropha H16] | gi|38637756 | 3401 | 112 | 71 | 48.36 |
| 3 | HoxU NAD-reducing hydrogenase diaphorase moiety small subunit [R. eutropha H16] | gi|38637754 | 1692 | 61 | 87 | 194.61 |
| 4 | HoxY NAD-reducing hydrogenase moiety small subunit [R. eutropha H16] | gi|32527093 | 474 | 18 | 61 | 7.91 |
| 5 | HoxI [R. eutropha H16] | gi|38637758 | 2876 | 96 | 73 | 346.06 |
| Study Outcome and Factors | 2 Years n (%) | 3.5 Years n (%) | p |
| Child outdoor playtime | 0.126 | ||
| <2 h/day | 181 (37) | 135 (33) | |
| ≥2 h/day | 305 (63) | 379 (67) | |
| Good neighbourhood to bring up child | 0.418 | ||
| No | 99 (20) | 74 (18) | |
| Yes | 395 (80) | 339 (82) | |
| Safe neighbourhood | 0.875 | ||
| No | 48 (10) | 39 (9) | |
| Yes | 443 (90) | 373 (91) | |
| Safe outdoor play | <0.0001 | ||
| No | 125 (26) | 174 (42) | |
| Yes | 358 (74) | 236 (58) | |
| Good parks or playgrounds | 0.939 | ||
| No | 83 (17) | 68 (17) | |
| Yes | 413 (83) | 343 (83) | |
| Traffic in neighbourhood | 0.014 | ||
| Heavy traffic | 95 (19) | 108 (26) | |
| Not heavy traffic | 398 (81) | 306 (74) | |
| Walk score | 0.563 | ||
| ≤49 (car-dependent) | 237 (55) | 197 (57) | |
| >50 (walkable) | 195 (45) | 149 (43) | |
| Population density | 0.135 | ||
| <18/hatch (mean) | 232 (50) | 204 (55) | |
| ≥18/hatch (mean) | 234 (50) | 167 (45) | |
| Accommodation type | 0.083 | ||
| Unit/townhouse | 118 (24) | 79 (19) | |
| Free standing house | 377 (76) | 335 (81) | |
| Number of vehicles in use | 0.0002 | ||
| 0 to 1 car | 228 (47) | 142 (35) | |
| ≥2 cars | 260 (53) | 269 (65) |
| Subcategories of DRPs | Number of DRPs | % | resolved |
| Doctors (N = 272) | |||
| Unnecessary therapy/No clinical indication | 13 | 92.3% | (12/13) |
| Untreated indication | 162 | 71.6% | (116/162) |
| Non reconciled medications | 146 | 72.6% | (106/146) |
| Inappropriate duration | 4 | 75.0% | (3/4) |
| Inappropriate dose schedule | 11 | 54.5% | (6/11) |
| Dose too high | 3 | 33.3% | (1/3) |
| Dose too low | 1 | 0.0% | (0/1) |
| Drug-drug interactions | 3 | 100.0% | (3/3) |
| Inappropriate/inadequate monitoring | 1 | 0.0% | (0/1) |
| Prescription error | 18 | 100.0% | (18/18) |
| Manifest side effect, no other cause | 7 | 85.7% | (6/7) |
| More cost-effective drug available | 3 | 66.7% | (2/3) |
| Deterioration/improvement of disease state | 3 | 66.7% | (2/3) |
| Synergistic/preventive drug required and not given | 19 | 63.2% | (12/19) |
| Duplication of therapy | 10 | 90.0% | (9/10) |
| Prescribed drug not available | 4 | 75.0% | (3/4) |
| Avoid contraindications | 10 | 70.0% | (7/10) |
| Nurses (N = 2) | |||
| Charting error | 2 | 100.0% | (2/2) |
| Group V | Group I | |||||||
| UAI | Univariate | Multivariate OR | UAI | Univariate | Multivariate OR | |||
| Row% | (n) | OR | (95%CI) | Row% | (n) | OR | (95%CI) | |
| Age groups | ||||||||
| 18-29 | 37.5 | (72) | 1.00 | 1.00 | 54.3 | (69) | 1.00 | --- |
| ≥30 | 25.0 | (20) | 0.56* | 0.54(0.29,0.98)* | 50.9 | (28) | 0.87 | |
| Number of items showing perceived discrimination against MSM (to the above 3 items) | ||||||||
| 0 - 2 discrimination responses | 30.1 | (63) | 1.00 | 1.00 | 60.8 | (45) | 1.00 | --- |
| 3 discrimination responses | 46.0 | (29) | 1.98* | 2.33(1.28,4.26)** | 48.1 | (52) | 0.60 | |
| Best friends supporting their sexual orientation | ||||||||
| No/unaware of one's sexual orientation | 25.0 | (20) | 1.00 | 1.00 | 42.5 | (34) | 1.00 | 1.00 |
| Yes | 37.5 | (72) | 1.80* | 1.97 (1.07, 3.62)* | 61.8 | (63) | 2.19* | 1.94(1.05,3.57)* |
| Number of friends having MSM behaviors | ||||||||
| A few or none | 34.7 | (43) | 1.00 | --- | 47.9 | (67) | 1.00 | 1.00 |
| All or most of them | 33.3 | (49) | 0.94 | 71.4 | (30) | 2.72** | 2.38(1.11,5.11)* |
| Features | 1pSS Abs− | 2pSS Abs+ | P* |
| (n = 29) | (n = 23) | I-II | |
| Age, mean ± SD years | 56 ± 12 | 56 ± 13 | 0.873 |
| Schirmer's I test (mm/5 min), mean ± SD | 3.17 ± 1.20 | 1.25 ± 1.12 | <0.0001 |
| Unstimulated salivary flow (mL/15 min), mean ± SD | 1.22 ± 0.20 | 0.83 ± 0.39 | 0.002 |
| Biopsy focus score | 1.17 (1/2) | 2.40 (1/3) | <0.0001 |
| (number of lymphocytic foci/4 mm2), mean (min/max) | |||
| Anti-SSA+, n (%) | 0 (0) | 6 (26) | |
| Anti-SSB+, n (%) | 0 (0) | 2 (9) | |
| BAFF, mean ± SD, ng/mL | 4230 (1748) | 5014 (2518) | 0.187 |
| Anti-SSA/SSB+, n (%) | 0 (0) | 15 (65) | |
| ESSPRI, mean (min/max) | 8.39 (6/10) | 9.1 (7/10) | 0.075 |
| ESSDAI, mean (min/max) | 24.83 (21/30) | 33.50 (27/39) | <0.0001 |
| Compared organisms | CCMP1545 | CCMP1545 | RCC299 | CCMP1545 | O. lucimarinus |
| (pairs) | RCC299 | CCMP2099 | CCMP2099 | O. lucimarinus | O. RCC809 |
| ID (%) | 60 | 57 | 57 | 54 | 73 |
| Coverage (%) | 78 | 74 | 77 | 83 | 93 |
| Gene fraction (%) | 83 | 62 | 65 | 76 | 88 |
| Ortholog count | 8141 | 5859 | 6160 | 5534 | 6449 |
| Hbase and Phoenix | Cassandra and Presto | |||||||
| Query 1 | Query 2 | Query 3 | Query 4 | Query 1 | Query 2 | Query 3 | Query 4 | |
| 3 nodes processing speed (s) | 48.5 | 2.32 | 80.2 | 78.5 | 40.1 | 2 | 25 | 13 |
| 5 nodes processing speed (s) | 27.9 | 1.79 | 58 | 50.5 | 34.3 | 1.85 | 20 | 10 |
| EDAD | ♂ | ♀ | ♀♂ | ||||
| N | % | N | % | ♀/♂ | N | % | |
| < 20 | 3 | 50.00 | 3 | 50.00 | 1.00 | 6 | 2.46 |
| 20.1 - 30 | 4 | 33.33 | 8 | 66.67 | 2.00 | 12 | 4.92 |
| 30.1 - 40 | 9 | 32.14 | 19 | 67.86 | 2.10 | 28 | 11.48 |
| 40.1 - 50 | 20 | 28.17 | 51 | 71.83 | 2.55 | 71 | 29.10 |
| 50.1 - 60 | 20 | 29.41 | 48 | 70.59 | 2.40 | 68 | 27.87 |
| 60.1 - 70 | 6 | 13.64 | 38 | 86.36 | 6.33 | 44 | 18.03 |
| 70.1 - 80 | 4 | 26.67 | 11 | 73.33 | 2.75 | 15 | 6.15 |
| TOTAL | 66 | 27 | 178 | 73 | 2.70 | 244 | 100 |
| Pellet | kVp | mAs | Filter | iDose4 level | No MoM THA baseline | MoM THA O-MAR off | MoM THA O-MAR on |
| CNR | CNR | CNR | |||||
| L0 | 120 | 150 | A | 5 | 33.06 | 13.02 | 12.99 |
| L5 | 120 | 150 | A | 5 | 22.74 | 13.01 | 19.24 |
| L6 | 120 | 150 | A | 5 | 16.75 | 1.37 | 18.16 |
| L8 | 120 | 150 | A | 5 | 23.12 | 5.18 | 4.19 |
| L0 | 120 | 600 | A | 5 | 46.52 | 23.07 | 23.07 |
| L5 | 120 | 600 | A | 5 | 41.18 | 26.31 | 37.11 |
| L6 | 120 | 600 | A | 5 | 41.65 | 5.84 | 24.72 |
| L8 | 120 | 600 | A | 5 | 29.71 | 7.32 | 5.74 |
| L0 | 140 | 101 | A | 5 | 20.27 | 17.51 | 17.51 |
| L5 | 140 | 101 | A | 5 | 18.60 | 8.98 | 14.02 |
| L6 | 140 | 101 | A | 5 | 19.77 | 0.77 | 23.69 |
| L8 | 140 | 101 | A | 5 | 22.94 | 6.61 | 4.64 |
| L0 | 140 | 405 | A | 5 | 43.88 | 30.64 | 30.65 |
| L5 | 140 | 405 | A | 5 | 27.55 | 19.98 | 30.69 |
| L6 | 140 | 405 | A | 5 | 53.21 | 0.85 | 28.91 |
| L8 | 140 | 405 | A | 5 | 40.34 | 8.51 | 6.13 |
| Comparison | Pearson’s Correlation coefficient | R-squared value |
| NBME (raw) version V1 EM M4 | 0.51 | 0.26 |
| NBME (scaled) version V1 EM M4 | 0.42 | 0.18 |
| NBME (raw) version V2 EM M4 | 0.58 | 0.30 |
| NBME (scaled) version V2 EM M4 | 0.41 | 0.13 |
| Temperature (°C) | SRa (%) | Yields of hydrolyzed sugars from | Total yield (%) | CrIb (%) | |||
| Soluble fraction | Residue | ||||||
| Glucose (%) | Xylose (%) | Glucose (%) | Xylose (%) | ||||
| 120 | 99.1 | 0.1 | 0.0 | 3.8 | 0.0 | 3.1 | 60.4 |
| 140 | 96.1 | 0.3 | 0.7 | 5.9 | 5.3 | 6.1 | 62.0 |
| 160 | 85.1 | 0.3 | 29.9 | 23.3 | 21.5 | 29.3 | 67.4 |
| 180 | 70.0 | 1.1 | 65.1 | 50.5 | 9.8 | 56.4 | 69.4 |
| 200 | 66.7 | 2.3 | 15.7 | 74.7 | 4.1 | 65.2 | 74.7 |
| 220 | 62.7 | 1.2 | 0.0 | 72.6 | 1.3 | 58.8 | NDc |
| 240 | 51.8 | 1.1 | 0.0 | 42.5 | 0.0 | 34.6 | 65.6 |
| Cluster name | Voxels | p | Z-MAX | MNI coordinates (mm) | Anatomical regions |
| rIPS | 2163 | 1.19E-06 | 3.82 | 32, − 72, 40 | Right lateral occipital cortex |
| lIPS | 1149 | 0.0011 | 3.53 | -33, − 42, 41 | Left superior parietal lobule, left angular gyrus |
| rFEF | 1117 | 0.00141 | 3.52 | 30, − 2, 62 | Right superior frontal gyrus |
| rSPL | 735 | 0.031 | 3.28 | 14, − 71, 55 | Right precuneus cortex, right superior parietal lobule |
| Total | Participators | Non-participators | P | |
| (n = 172) | (n = 114) | (n = 58) | ||
| Medical care | ||||
| Advice by a physician to undergo screening | 65 (40.4) | 58 (53.7) | 7 (13.2) | < 10-4 |
| Score for perceived accessibility of colonoscopy centres (1 to 5) | 3.8 (1.2) | 4.0 (1.2) | 3.3 (1.1) | 0.0011 |
| Family | ||||
| Index patient sex: female | 84 (48.8) | 58 (50.9) | 26 (44.8) | 0.45 |
| Index patient age at time of diagnosis | 0.49 | |||
| ≤ 45 years old | 22 (12.8) | 16 (14.0) | 6 (10.3) | |
| > 45 years old | 150 (87.2) | 98 (86.0) | 52 (89.7) | |
| Number of cases of colorectal cancer declared in first-degree relatives | 0.1 | |||
| 0 | 45 (26.2) | 26 (22.8) | 19 (32.8) | |
| 1 | 116 (67.4) | 79 (69.3) | 37 (63.8) | |
| ≥ 2 * | 11 (6.4) | 9 (7.9) | 2 (3.4) | |
| Discussion about screening with all brothers and sisters | 84 (49.7) | 73 (65.2) | 11 (19.3) | < 10-4 |
| Social network | ||||
| Belonging to a social group | 54 (32.0) | 41 (36.9) | 13 (22.4) | 0.055 |
| Number of contacts with friends or relatives per month | 0.24 | |||
| ≤ 2 | 19 (12.6) | 13 (12.6) | 6 (12.5) | |
| 3 to 11 | 98 (64.9) | 63 (61.2) | 35 (72.9) | |
| ≥ 12 | 34 (22.5) | 27 (26.2) | 7 (14.6) | |
| Structural support score (0 to 4) | 2.3 (1.1) | 2.4 (1.1) | 2.1 (0.9) | 0.13 |
| Emotional support score (0 to 4) | 3.4 (1.0) | 3.5 (0.9) | 3.2 (1.2) | 0.039 |
| Material support | 153 (91.6) | 103 (93.6) | 50 (87.7) | 0.24 |
| Exercise | CTR | SR | WR |
| AS | 9.6/10.6 | 10.2/7.0* | 7.07/10.1* |
| OHS | 16.2/14.6 | 9.8/7.8* | 8.7/7.8 |
| FS | 11.9/9.6 | 9.2/14.8* | 5.0/11.5* |
| DL | 8.2/7.7 | 4.8/7.9* | 4.1/7.8* |
| Treatment or procedure | Number of patients | Proportion of patients |
| Laboratory examinations such as blood samples, urine stick test and cultivation | 96 | 67.6% |
| Electrocardiography | 64 | 45.1% |
| Diagnostic radiology procedures | 42 | 29.6% |
| Medicine administered per orally, suppository or as an ointment | 41 | 28.9% |
| Intravenous medicine or liquid | 38 | 26.8% |
| Urinary catheterization | 16 | 11.3% |
| Telemetry | 11 | 7.7% |
| None | 10 | 7.1% |
| Oxygen supplement | 6 | 4.2% |
| Medicine administered subcutaneously, intramuscular or as an inhalation | 6 | 4.2% |
| Other | 5 | 3.5% |
| Invasive procedures | 4 | 2.8% |
| Surgeon pair | Kappa values | ||
| Trial 1 | Trial 2 | Mean | |
| Right hip | |||
| 1–2 | 0.48 (M) | 0.48 (M) | 0.48 (M) |
| 1–3 | 0.74 (G) | 0.63 (G) | 0.69 (G) |
| 1–4 | 0.84 (V) | 0.82 (V) | 0.83 (V) |
| 2–3 | 0.5 (M) | 0.47 (M) | 0.49 (M) |
| 2–4 | 0.37 (F) | 0.48 (M) | 0.43 (M) |
| 3–4 | 0.72 (G) | 0.63 (G) | 0.67 (G) |
| Left hip | |||
| 1–2 | 0.44 (M) | 0.59 (M) | 0.52 (M) |
| 1–3 | 0.53 (M) | 0.83 (V) | 0.68 (G) |
| 1–4 | 0.72 (G) | 0.57 (M) | 0.65 (G) |
| 2–3 | 0.49 (M) | 0.45 (M) | 0.47 (M) |
| 2–4 | 0.54 (M) | 0.36 (F) | 0.45 (M) |
| 3–4 | 0.53 (M) | 0.43 (M) | 0.48 (M) |
| Strains | Functional Predictions | Total SNP(%) | Genes Affected(%) | |
| C57BL/6J vs. DBA/2J | PolyPhen | Deleterious | 1,755 (19.4%) | 954 (26.1%) |
| Benign | 6,757 (74.5%) | 2,343 (64%) | ||
| Unknown | 567 (6.3%) | 367 (10.1%) | ||
| Total | 9,079 | 3,664 | ||
| PANTHER | Deleterious | 1,285 (14.2%) | 632(17.1%) | |
| non-deleterious | 4,678 (51.6%) | 1,736 (47%) | ||
| Unknown | 3,116 (34.4%) | 1,329 (36%) | ||
| Total | 9,079 | 3,697 | ||
| C57BL/6J vs. 129S1/SvImJ | PolyPhen | Deleterious | 796 (19.5%) | 480 (24.9%) |
| Benign | 2,995 (73.4%) | 1,270(65.7%) | ||
| Unknown | 293 (7.2%) | 185 (9.6%) | ||
| Total | 4,084 | 1,935 | ||
| PANTHER | Deleterious | 568 (14%) | 327(16.9%) | |
| non-deleterious | 2,049 (50.2%) | 913 (47.1%) | ||
| Unknown | 1,467 (36%) | 701 (36.2%) | ||
| Total | 4,084 | 1,941 | ||
| C57BL/6J vs. A/J | PolyPhen | Deleterious | 2,350 (18.9%) | 1,197(26.1%) |
| Benign | 9,220 (74.2%) | 2,889 (63%) | ||
| Unknown | 865 (7%) | 504 (11%) | ||
| Total | 12,435 | 4,590 | ||
| PANTHER | Deleterious | 1,785 (14.4%) | 798(17.1%) | |
| non-deleterious | 6,443 (51.9%) | 2,154(46.1%) | ||
| Unknown | 4,207 (33.9%) | 1,724 (36.9%) | ||
| Total | 12,435 | 4,676 |
| Step | |
| 1. | X μL 125I is added to wobbling reaction vial |
| 2. | 250 μL phosphate buffer (0.5 M, pH 7.4) is added |
| 3. | 50 μL BoNT-A/ phosphate buffer (=50 μg BoNT-A) is addeda |
| 4. | 115-X μL phosphate buffer (0.1 M, pH 6.8) is added to adjust the reaction volume to 215 μL |
| 5. | 17.5 μL freshly prepared IODOGEN/acetonitrile solution (2.5 μg/35 μL) is added into the reaction mixture (start of reaction, t = 0) |
| 6. | At t = 45 s, another 17.5 μL IODOGEN/acetonitrile solution (2.5 μg/35 μL) is added |
| 7. | At t = 90 s, 100 μL ascorbic acid solution (25 mg/mL, pH 5.0) is added to stop the reaction and to reduce any formed S-Cl bonds |
| 8. | At t = 4.30 min, 10 μL BSA (50 mg/mL) is addedb |
| 9. | At t = 5.30 min, samples are taken for ITLC for determination of the labelling efficiency |
| 10. | At t = 10 min, 360 μL reaction mixture is transferred to a syringe connected to a filterc |
| 11. | The reaction vial is rinsed by 640 μL phosphate buffer (0.1M, pH 6.8) and also transferred to the syringe connected to the filterc |
| 12. | The combined solution in the syringe is filtered and purified on a PD10 column with ascorbic acid solution (5 mg/mL, pH 5.0) as eluent, collected fractions were 0.5 mL |
| 13. | Fractions with highest amount of 125I-BoNT-A and the highest radiochemical purity are pooled |
| 14. | Samples of the pooled 125I-BoNT-A (fractions 6, 7, 8) are taken for ITLC |
| 15. | Final product is diluted by BSA (1 mg/mL) till a concentration of 1 μg/100 μL and stored at 20°C |
| Patient | Sex/Age of onset | Mutations (exon) | Phenotype | Kayser-Freicher rings | Serum ceruloplasmin | Serum free copper | 24 h urinary copper | AST | ALT | PT |
| Normal | – | 20–35 mg/dL | <15 μg/dL | <60–100 μg | <40 IU/L | <40 IU/L | >70% | |||
| Patient 1 | Male/8 | p.Phe1026Tyr (exon 14),c.2866-2A > G(intron 12) | Hepatic, Neurologic | + | 0.0032 mg/dL | 49 μg/dL | 580 μg | 26.82 IU/L | 20.1 IU/L | 49% |
| Patient 2 | Female/8 | p.His251Alafs*19(exon 2),p.Ser105*(exon 2) | Hepatic | + | 0.0190 mg/dL | low | 150 μg | 139.1 IU/L | 116.9 IU/L | 22% |
| Patient 3 | Male/10 | p.Pro868Profs*5(exon 11),p.Ser105*(exon 2) | Hepatic | + | 0.0920 mg/dL | low | 3639 μg | 129.0 IU/L | 55.7 IU/L | 17% |
| Variables | Number | Percent | |
| Gravida (number of pregnancies) | 1 | 78 | 24.4 |
| 2–4 | 183 | 57.2 | |
| > = 5 | 59 | 18.4 | |
| Parity (number of deliveries) | 0 | 78 | 24.4 |
| 1 | 171 | 31.5 | |
| 2–4 | 116 | 53.4 | |
| > = 5 | 25 | 7.8 | |
| Birth order | 1 | 179 | 55.9 |
| 2–4 | 116 | 36.3 | |
| > = 5 | 25 | 7.8 | |
| Pregnancy Trimester during interview | Second trimester | 115 | 35.9 |
| Third trimester | 205 | 64.1 | |
| Gestational Age where ANC started | Before 16 weeks | 154 | 48.1 |
| At or After 16 weeks | 166 | 51.9 | |
| Number of ANC visits | 2–3 | 232 | 72.5 |
| ≥ 4 | 88 | 27.5 | |
| Receiving information about the importance of IFA supplementation | No | 139 | 43.4 |
| Yes | 181 | 56.6 | |
| Medical illness | No | 288 | 90.0 |
| Yes | 32 | 10.0 | |
| Morning sickness | No | 255 | 79.7 |
| Yes | 65 | 20.3 | |
| Side effects | No | 234 | 83.1 |
| Yes | 86 | 26.9 |
| System | Complications |
| Neurologic | Cord compression syndrome |
| Intracranial hypertension/hydrocephalus | |
| Thoracic | Superior vena cava syndrome |
| Pericardial effusion/cardiac tamponade | |
| Pleural effusion | |
| Pulmonary thromboembolism | |
| Massive hemoptysis | |
| Abdominal | Intenstinal obstruction |
| Inflammatory intestinal changes | |
| Biliary obstruction | |
| Urinary tract obstruction | |
| Bleeding complications |
| Category | No. (%) |
| Infection | 331 (59.1) |
| Respiratory tract | 166 (51.2) |
| Urinary tract | 99 (30.6) |
| Intra-abdominal | 39 (12.1) |
| Skin and soft tissue | 18 (3.2) |
| Primary bacteremia/fungemia | 10 (3.1) |
| Central nervous system | 2 (0.6) |
| Bone & joint | 2 (0.6) |
| Other | 2 (0.6) |
| Non-infection | 179 (32.0) |
| Drug fever | 101 (56.4) |
| Post-procedure | 24 (13.4) |
| Cancer fever | 23 (12.8) |
| Transfusion related | 7 (3.9) |
| Dehydration related | 3 (1.7) |
| ICH related central fevera | 2 (1.1) |
| Other | 19 (10.6) |
| Unknown | 50 (8.9) |
| Parameters | Mutants | Salt concentrations | |
| R | P-value | ||
| Early PCD | Col-0 | 0.869** | 0.00 |
| ein2-5 | 0.972** | 0.00 | |
| ein3-1 | 0.913** | 0.00 | |
| ctr1-1 | 0.766* | 0.02 | |
| Total | 0.556** | 0.00 | |
| Late PCD | Col-0 | −0.18 | 0.65 |
| ein2-5 | 0.809** | 0.01 | |
| ein3-1 | 0.51 | 0.16 | |
| ctr1-1 | 0.09 | 0.83 | |
| Total | 0.380* | 0.02 |
| Audio | Visual | Sim. dual | Seq. dual | |
| Mean accuracy rate ± s.e.m. (%) | 95.2 ± 1.6 | 97.3 ± 1.2 | 89.9 ± 1.9 | 94.9 ± 1.1 |
| Histomorphometry1 | Sham control | Vehicle control | CAPT | P 31.25 | P 62.5 | P125 | LOSA |
| Degenerative regions | 1.73 ± 1.60 | 78.92 ± 8.56* | 56.76 ± 10.36∗,# | 54.79 ± 10.93∗,# | 40.50 ± 12.92∗,# | 33.73 ± 5.77∗,# | 63.80 ± 10.24∗,## |
| Dataset | No.of Training(class1/class2) | No.of Testing(class1/class2) |
| Leukaemia | 50(32 ALL/18 AML) | 22 (15 ALL/7 AML) |
| Prostate | 71(35 ALL/36 AML) | 31(15 ALL/16 AML) |
| Colon | 42(14 Normal/28 Tumor) | 20(8 Normal/12 Tumor) |
| DLBCL | 60(45 DLBCL/15FL) | 17(13 DLBCL/4 FL) |
| Disinfectants | Neutralizing agents | |||||
| Classification | Active ingredients | Recommended concentration | Recommended contact time | Optimal application | Active ingredients | Concentration |
| Aldehydes | Glutaraldehyde | 4% | 20 min | Equipment, goods | Glycine | 2% |
| Halogens | Sodium hypochlorite | 2 g/L | 20 min | Biological material, smooth surface | Sodium thiosulfate | 0.2% |
| Trichloroisocyanuric acid | 4 g/L | 30 min | Lab environment, Medical supplies | Sodium thiosulfate | 0.4% | |
| Quaternary ammonium compound | Benzalkonium chloride | 0.2 g/L | / | Skin, mucous membranes | Tween-80 + Phosphatidylcholine | 0.5% + 1% |
| Phenolic | Lysol | 10 g/L | 30 min | Object surface | Tween-80 | 1% |
| Alkaline | Sodium hydroxide | 10 g/L | / | Field, animal housing | Hydrochloric acid | 10% |
| Code | Features | Preparation room use |
| A | No Intubation | NO |
| B | General Anesthesia and Intubation | NO |
| C | B + One Procedure | NO / YES |
| D | B + More Than One Procedure | NO / YES |
| Categorical variables | N* (n = 199) | % | Crude | p value** |
| Continuous variables# | Mean(SD) | OR | ||
| Home ownership | ||||
| Own home (fully owned or mortgaged) | 162 | 4.9% | 1 | 0.027 |
| Rented, gifted or invaded | 37 | 16.2% | 3.726 | |
| Electric power supply | ||||
| Lacking | 22 | 22.7% | 1 | 0.011 ' |
| Present | 177 | 5.1% | 0.182 | |
| Wealth index | ||||
| Richer half | 104 | 1.9% | 1 | 0.004 ' |
| Poorer half | 95 | 12.6% | 7.373 | |
| Mother schooling (years) | ||||
| Did not go to school | 8 | 37.5% | 1 | < 0.001 |
| 1 to 4 years | 27 | 7.4% | 0.013 | |
| Above 4 years | 81 | 1.2% | 0.002 | |
| p linear tendency | 0.003 | |||
| Maternal height (cm)# | 186 | 158.5 (5.29) | 0.855 | 0.01 |
| Number of pregnancies# | 113 | 2.63 (2.21) | 1.35 | 0.018 |
| Anaemia diagnosis | ||||
| No | 69 | 49.64% | 1 | 0.176 |
| Yes | 70 | 50.36% | 3.09 |
| Country | Maize | Other major crops |
| Bangladesh | No | Eggplant |
| India | No | Cotton, soybean |
| Iran | No | Rice |
| Myanmar | No | Cotton |
| Pakistan | No | Cotton |
| Australia | Yes | Alfalfa, canola, cotton, potato, rice, soybean, wheat |
| China | Yes | Canola, cotton, maize, rice, soybean |
| Indonesia | Yes | Soybean, sugarcane |
| Japan | Yes | Alfalfa, canola, cotton, potato, soybean |
| Malaysia | Yes | Soybean |
| New Zealand | Yes | Alfalfa, canola, cotton, potato, rice, soybean, wheat |
| Philippines | Yes | Alfalfa, canola, cotton, potato, rice, soybean |
| Singapore | Yes | Alfalfa, canola, cotton, maize, soybean |
| South Korea | Yes | Alfalfa, canola, cotton, potato, soybean |
| Thailand | Yes | Soybean |
| Turkey | Yes | Soybean |
| Vietnam | Yes | None |
| Strain | 24 hours | 48 hours | ||||||
| Product(mg/L) | Intermediates(mg/L) | Product(mg/L) | Intermediates(mg/L) | |||||
| caffeic acid | tyrosine | p-coumaric acid | L-dopa | caffeicacid | tyrosine | p-coumaric acid | L-dopa | |
| YL-2 | 11.1 ± 1.1 | < 0.2 | < 0.2 | < 0.2 | 12.1 ± 0.3 | < 0.2 | < 0.2 | 7.4 ± 0.2 |
| YL-2* | 20.2 ± 1.8 | < 0.2 | < 0.2 | 2.1 ± 0.3 | 21.5 ± 4.0 | < 0.2 | < 0.2 | 14.2 ± 1.7 |
| YL-3 | - | 188.9 ± 5.7 | - | - | - | 296.6 ± 1.0 | - | - |
| YL-4 | - | 218.6 ± 8.2 | - | - | - | 426.7 ± 4.9 | - | - |
| YL-5 | 30.5 ± 1.9 | 17.1 ± 1.8 | 2.9 ± 0.3 | 15.4 ± 1.7 | 50.2 ± 10.1 | 25.1 ± 2.5 | < 0.2 | 75.3 ± 13.6 |
| Activities | V1 | V2 | V3 | V4 | V5 | V6 | Recall (%) |
| V1 | 92 | 4 | 2 | 3 | 0 | 1 | 90.20 |
| V2 | 1 | 27 | 0 | 0 | 0 | 0 | 96.43 |
| V3 | 5 | 0 | 15 | 0 | 0 | 0 | 75.00 |
| V4 | 5 | 0 | 0 | 105 | 2 | 2 | 95.45 |
| V5 | 0 | 0 | 3 | 3 | 36 | 0 | 85.71 |
| V6 | 0 | 0 | 1 | 1 | 0 | 16 | 88.89 |
| Precision (%) | 92.93 | 87.10 | 71.43 | 93.75 | 94.74 | 84.21 | |
| Accuracy (%) | 90.94 |
| Chromosome (potato) | Tomato | Citation1 |
| 2 | 2 L inversion | a |
| 3 | Translocation | b |
| 5 | 5S inversion | a, c, d, e, f |
| 6 | 6S inversion | a, g |
| 9 | 9S inversion | a, c, d, f |
| 10 | 10 L inversion | a, c, d, f |
| 11 | 11S inversion | a, c, f |
| 12 | 12S inversion | a, c, f |
| Age group | |||||||
| Variables | G50-54 n = 32 | G55-59 n = 56 | G60-64 n = 112 | G65-69 n = 151 | G70-74 n = 126 | G75-79 n = 57 | G80+ n = 22 |
| Age, years | 52.8 (1.3) | 57.6 (1.6) | 62.8 (1.5) | 67.4 (1.4) | 72.4 (1.4) | 77.1 (1.4) | 86.0 (4.3) |
| Height, m | 1.537 (0.048) | 1.542 (0.048) | 1.515 (0.049) | 1.502 (0.050) | 1.495 (0.055) | 1.471 (0.059) | 1.429 (0.062) |
| Thigh length, m | 0.350 (0.015) | 0.351 (0.017) | 0.343 (0.017) | 0.341 (0.018) | 0.342 (0.020) | 0.336 (0.017) | 0.332 (0.017) |
| Lower leg length, m | 0.339 (0.018) | 0.341 (0.017) | 0.335 (0.017) | 0.333 (0.017) | 0.334 (0.018) | 0.328 (0.016) | 0.328 (0.015) |
| Body mass, kg | 53.8 (6.1) | 55.7 (7.2) | 54.2 (6.5) | 53.4 (6.9) | 52.3 (6.9) | 50.5 (6.7) | 48.1 (6.6) |
| BMI, kg/m2 | 22.8 (2.3) | 23.5 (3.2) | 23.7 (3.0) | 23.7 (3.0) | 23.4 (2.7) | 23.3 (2.7) | 23.6 (3.0) |
| Buffer Radius (m) | Number of children within buffer zone | Comparison measures | |||||||
| Parcels | Street | Parcels yes/Street yes | Parcels yes/Street no | Parcel no/Street yes | Parcel no/Street no | Sensitivity (%)1 | Specificity (%)2 | Odds Ratio (95% CI)3 | |
| 50 meters | 391 | 1413 | 151 | 240 | 1262 | 103212 | 39 | 99 | 0.28 (0.25 – 0.31) |
| 100 meters | 2090 | 2851 | 1392 | 698 | 1459 | 101316 | 67 | 99 | 0.73 (0.69 – 0.77) |
| 150 meters | 4717 | 5276 | 3899 | 818 | 1377 | 98771 | 83 | 99 | 0.89 (0.85 – 0.93) |
| 250 meters | 10729 | 10945 | 9704 | 1025 | 1241 | 92895 | 90 | 99 | 0.98 (0.95 – 1.01) |
| 500 meters | 26347 | 26597 | 25201 | 1146 | 1396 | 77122 | 96 | 98 | 0.99 (0.97 – 1.01) |
| 1000 meters | 54500 | 54614 | 53838 | 662 | 776 | 49589 | 99 | 98 | 01.00 (0.980 – 1.01) |
| Model I | Model II | ||||
| Variable | Category | OR | 95% CI | OR | 95% CI |
| Fixed effects | |||||
| Rate of change | |||||
| Agec (Int) | Centred at 67 years | 0.93 | 0.90-0.97 | 0.98 | 0.96-1.012 |
| Agec*cohortc | 1.017 | 1.011-1.024 | 1.009 | 1.006-1.011 | |
| Agec-squared | 1.005 | 1.001-1.010 | 1.005 | 1.001-1.010 | |
| Initial status | |||||
| Cohortc | Centred at 1924 | 0.98 | 0.95-1.02 | 1.02 | 1.00-1.05 |
| Cohortc-squared | 1.008 | 1.005-1.012 | 1.005 | 1.003-1.006 | |
| Educational level | Low-middle | 1 | |||
| High | 1.23 | 0.96-1.58 | |||
| BMI (kg/m2) | Centred at 23 | 0.93 | 0.91-0.96 | ||
| Smoking | Never | 1 | |||
| Former | 1.01 | 0.78-1.30 | |||
| Daily | 0.48 | 0.35-0.65 | |||
| Self-reported health status | Good | 2.57 | 2.08-3.19 | ||
| Poor | 1 | ||||
| Random effects (unstructured) | |||||
| Var (constant) | 1.51 | 1.01-2.23 | 1.05 | 0.66-1.69 |
| Assay 1(Quantitect, 2 min A&E) | Assay 2(Quantifast, 1 min A&E) | |||||
| Tree number (genotype) | T1-C2 | G1-A2 | G1-C2 | T1-C2 | G1-A2 | G1-C2 |
| Tree-14 (G-T/G-G) | 1100 | 16000 | 18000 | 17000 | 53000 | 47000 |
| Tree-17 (G-T/G-G) | 1400 | 23000 | 29000 | 22000 | 54000 | 31000 |
| Tree -20 (G-T/G-G) | 1500 | 32000 | 21000 | 30000 | 81000 | 74000 |
| Mean ± SD | 1400 ± 200 | 24000 ± 8000 | 23000 ± 6000 | 23000 ± 7000 | 63000 ± 16000 | 51000 ± 22000 |
| Tree-2 (G-T/G-T) | 18 | 24000 | 380 | 11000 | 27000 | 20000 |
| Tree-4 (G-T/G-T) | 67 | 51000 | 1100 | 15000 | 35000 | 25000 |
| Tree-6 (G-T/G-T) | 69 | 54000 | 630 | 23000 | 60000 | 47000 |
| Mean ± SD | 51 ± 29 | 43000 ± 16000 | 690 ± 30 | 17000 ± 6000 | 41000 ± 17000 | 31000 ± 14000 |
| Exon | Mutation | Base change | Amino acid change | Mutated samples | % |
| BRAF | |||||
| 15 | V600E | 1799 | Val to Glu | 347 | 92.3 |
| T > A | |||||
| 15 | V600K | 1798-99 GT > AA | Val to Lys | 20 | 5.3 |
| 15 | V600D | 1799-1800 | Val to Asp | 6 | 1.6 |
| TG > AT | |||||
| 15 | V600R | 1798-99 | Val to Arg | 2 | 0.5 |
| GT > AG | |||||
| 15 | L597R | 1790 | Leu to Arg | 1 | 0.3 |
| T > G | |||||
| NRAS | |||||
| 3 | Q61R | 182 | Gln to Arg | 47 | 58.8 |
| A > G | |||||
| 3 | Q61L | 182 | Gln to Leu | 23 | 28.7 |
| A > T | |||||
| 3 | Q61K | 181 | Gln to Lys | 10 | 12.5 |
| C > A |
| January | February | March | April | May | June | July | August | September | October | November | December | |
| Number of sirocco days | 0 | 0 | 0 | 3 | 26 | 59 | 111 | 53 | 11 | 0 | 0 | 0 |
| Biochemical parameters | Control groups | Treated groups | |||
| absolute | relative | Day 1 | Day 7 | Day 14 | |
| Glucose (mg dl-1) | 125.0 ± 11.4 | 119.0 ± 19.5 | 122.0 ± 20.9 | 121.0 ± 18.0 | 118.0 ± 18.0 |
| Urea (mg dl-1) | 29.6 ± 3.5 | 30.8 ± 4.2 | 29.2 ± 1.8 | 30.7 ± 4.1 | 32.3 ± 3.6 |
| Creatinine (mg dl-1) | 0.33 ± 0.06 | 0.38 ± 0.15 | 0.38 ± 0.06 | 0.35 ± 0.13 | 0.39 ± 0.05 |
| Triglyceride (mg dl-1) | 76.0 ± 6.2 | 74.0 ± 5.8 | 73.0 ± 5.7 | 74.0 ± 5.6 | 74.0 ± 5.9 |
| Total cholesterol (mg dl-1) | 60.8 ± 6.3 | 57.2 ± 8.2 | 56.9 ± 5.6 | 57.9 ± 8.1 | 56.5 ± 6.5 |
| Uric acid (mg dl-1) | 0.53 ± 0.10 | 0.53 ± 0.08 | 0.49 ± 0.10 | 0.53 ± 0.10 | 0.52 ± 0.07 |
| Albumin (g dl-1) | 2.8 ± 0.3 | 2.7 ± 0.4 | 2.6 ± 0.3 | 2.9 ± 0.3 | 2.8 ± 0.3 |
| Alkaline phosphatase (Units) | 50.6 ± 8.3 | 51.9 ± 8.0 | 52.8 ± 8.6 | 49.5 ± 7.6 | 47.4 ± 7.5 |
| ALT (Units) | 130 ± 10.3 | 122 ± 9.6 | 123 ± 8.7 | 128 ± 8.9 | 123 ± 6.1 |
| AST (Units) | 74 ± 6.0 | 73 ± 5.9 | 76 ± 6.8 | 73 ± 5.9 | 75 ± 6.9 |
| Movement of Households | Wealth index (PCA) | Consumption Expenditure |
| Proportion of households ranked in the same tercile | 60.99 | 42.64 |
| Proportion of households moving by one tercile | 32.18 | 34.93 |
| Proportion of households moving by two terciles | 6.83 | 22.43 |
| Kappa statistic | 0.373*** | 0.122*** |
| InterPro entry | Signatures | Analysis method |
| IPR000043 (Family) | TIGR00936 (ahcY) | HMMTigr |
| PF05221 (AdoHcyase) | HMMPfam | |
| PTHR23420 (Ad_hcy_hydrolase) | HMMPanther | |
| PIRSF001109 (Ad_hcy_hydrolase) | HMMPIR | |
| IPR015878 (Domain) | PF00670 (AdoHcyase_NAD) | HMMPfam |
| IPR020082 (Site) | PS00738 (ADOHCYASE_1) | PatternScan |
| PS00739 (ADOHCYASE_2) | PatternScan |
| Exposure | Mean difference in gestational age acceleration (days) | ||
| Mean difference | 95% CI | p | |
| Female | − 0.8 | − 1.4, − 0.1 | 0.024 |
| High/non-manual parental social class | 0.1 | − 0.9, 1.0 | 0.91 |
| Maternal education | |||
| Degree | (Ref) | 0.72 | |
| A level | 0.8 | − 0.1, 1.8 | |
| O level | − 0.1 | − 1.0, 0.8 | |
| Less than O level | − 0.3 | − 1.4, 0.8 | |
| Paternal education | |||
| Degree | (Ref) | 0.51 | |
| A level | − 0.8 | − 1.6, 0.1 | |
| O level | − 0.2 | − 1.2, 0.7 | |
| Less than O level | 0.3 | − 0.7, 1.2 | |
| Housing tenure | |||
| Owned/mortgaged | (Ref) | 0.42 | |
| Rented (private) | 0.7 | − 1.1, 2.5 | |
| Rented (council/HA) | 0.2 | − 1.1, 1.5 | |
| Financial difficulties | |||
| None | (Ref) | 0.55 | |
| Some | − 0.1 | − 0.8, 0.6 | |
| Many | − 0.4 | − 1.3, 0.6 |
| Component Label | Component | Subsystem function | Enjoyment of negative emotion example |
| 1. Appraisal | Cognitive component | Evaluation of objects and events | Context detection/knowledge (music, aesthetic) |
| 2. Bodily symptoms | Neurophysiological component | System regulation | Bodily symptoms of the negative emotion |
| 3. Action tendencies | Motivational component | Preparation and direction of action | Inhibition of aversion/hostility tendencies |
| 4. Facial and vocal expression | Motor expression component | Communication of reaction and behavioral intention | Facial symptoms of the negative emotion |
| 5. Emotional experience | Subjective feeling component | Monitoring or internal state and organism-environment interaction | Subjective feeling of the negative emotion (fully fledged, real negative emotion) |
| Domains | Average (± standard deviation) | |
| HAT-QoL (n= 201) | ||
| Overall function | 79.39 (20.9) | |
| Life satisfaction | 71.9 (24.4) | |
| Health worries | 83.2 (22.9) | |
| Financial worries | 55.6 (37.5) | |
| Medication worries | 88.7 (17.3) | |
| HIV mastery | 77.8 (33.6) | |
| Disclosure worries | 39.0 (27.3) | |
| Provider trust | 72.2 (30.7) | |
| Sexual function | 45.9 (43.5) | |
| ASKAS | ||
| Knowledge | 31.7 (6.7) | |
| Attitude | 14.8 (6.8) |
| Sha_w | Sha_15 | BF_18 | BF_22 | ADGw_14 | ADG14_22 | |
| Sha_w | 0.04 ± 0.04 | – | 0.05 ± 0.03 | 0.06 ± 0.03 | 0.04 ± 0.03 | 0.07 ± 0.03 |
| Sha_15 | – | 0.18 ± 0.08 | − 0.10 ± 0.03 | − 0.08 ± 0.03 | − 0.09 ± 0.03 | − 0.09 ± 0.03 |
| BF_18 | 0.42 ± 0.50 | − 0.53 ± 0.23 | 0.30 ± 0.11 | – | 0.43 ± 0.03 | 0.31 ± 0.03 |
| BF_22 | 0.52 ± 0.49 | − 0.45 ± 0.25 | – | 0.28 ± 0.10 | – | 0.45 ± 0.03 |
| ADGw_14 | − 0.73 ± 0.51 | − 0.53 ± 0.32 | 0.29 ± 0.32 | – | 0.09 ± 0.06 | – |
| ADG14_22 | 0.44 ± 0.48 | − 0.53 ± 0.29 | 0.10 ± 0.29 | 0.24 ± 0.28 | – | 0.17 ± 0.08 |
| Gene | GenBank | Forward primer | Reverse primer | Amplicon |
| Name | Accession | 5′ → 3′ | 5′ → 3′ | Size (bp) |
| CD25 | NM_174358 | AGATGTCCTGGCTTGAAC | TGGATATAGACCTGCTAATACC | 134 |
| CCNA1 | XM_005687507 | CGCCACATTTACAGGCTATTCATT | GTACTTCTCCCTGATTGCTTGCTG | 112 |
| CCNB1 | XM_005694606 | TTGATGGAACTGACTATGCTGGACT | CAGGTAATGCTGTAGAGTTGGTGTC | 132 |
| CCND1 | XM_005700049 | AGGAGGTGAGGGTGGAAGTGTG | GAAGTCATCGGTAGCAGCGAATAA | 100 |
| GAPDH | DQ152956 | CCTGGAGAAACCTGCCAAGT | GCCAAATTCATTGTCGTACCA | 200 |
| Software | Normal | Truncated | Solo-LTR | Complex | Nested | Total |
| LTRtype | 59 | 200 | 172 | 7 | 182 | 438 |
| REannotate | 64 | 401 | 115 | 0 | 230 | 580 |
| TEnest | 49 | 281 | 119 | 0 | 427 | 449 |
| Diagnostic Group | Number (men/women) | Age at Symptom Onset* | Age at PET Scan* | MMSE Score (max = 30)+ | Disease Duration (years)* |
| Cohort | 102 (55/47) | 60.06 (4.28) | 64.04 (8.90) | 25 (5–30) | 5.74 (2.75) |
| AD | 49 (24/25) | 61.75 (9.73) | 65.65 (9.41) | 20.97 (5.10) | 5.34 (2.08) |
| FTD | 17 (10/7) | 59.87 (6.72) | 63.42 (7.80) | 25.44 (3.32) | 5.19 (2.27) |
| DLB | 6 (6/0) | 64.47 (5.13) | 69.19 (4.65) | 27.40 (1.82) | 6.68 (2.85) |
| PPA | 6 (3/3) | 61.18 (8.66) | 67.54 (7.59) | 21.00 (10.65) | 7.28 (3.37) |
| Depress | 11 (6/5) | 53.02 (8.28) | 56.29 (7.92) | 27.11 (2.89) | 5.34 (1.85) |
| Serotype | All | Fatal outcome | Any risk factor | Pneumonia | Meningitis | ||||
| No | No (%) | P-value | No (%) | P-value | No (%) | P-value | No (%) | P-value | |
| Children | (all = 95) | (all = 95) | (all = 93) | (all = 93) | |||||
| 1 | 10 | 0 (0%) | ns | 2 (22%) | ns | 7 (88%) | 0.007 | 0 (0%) | ns |
| 5 | 6 | 0 (0%) | ns | 0 (0%) | ns (0.059) | 2 (40%) | ns | 3 (60%) | ns (0.084) |
| 19 F | 11 | 2 (18%) | ns | 5 (46%) | ns | 5 (46%) | ns | 2 (18%) | ns |
| 6B | 8 | 2 (25%) | ns | 4 (50%) | ns | 2 (25%) | ns | 3 (38%) | ns |
| 14 | 14 | 0 (0%) | ns | 5 (36%) | ns | 4 (31%) | ns | 3 (23%) | ns |
| All serotypes | 12 (13%) | 44 (46%) | 38 (41%) | 22 (24%) | |||||
| Adults | (all = 138) | (all = 138) | (all = 136) | (all = 136) | |||||
| 1 | 24 | 3 (13.0%) | ns | 10 (43.5%) | <0.001 | 20 (87.0%) | <0.001 | 2 (8.7%) | 0.038 |
| 5 | 16 | 4 (25.0%) | ns | 11 (68.8%) | ns | 9 (64.3%) | ns | 2 (14.3%) | ns |
| 19 F | 7 | 2 (40.0%) | ns | 6 (100%) | ns | 3 (60.0%) | ns | 2 (40.0%) | ns |
| 6B | 10 | 3 (30.0%) | ns | 10 (100.0%) | ns | 2 (20.0%) | ns | 6 (60.0%) | 0.022 |
| 14 | 3 | 1 (33.3%) | ns | 2 (66.7%) | ns | 3 (100.0%) | ns | 0 (0%) | ns |
| All serotypes | 37 (26.8%) | 107 (77.5%) | 64 (47.1%) | 36 (26.5%) |
| Age | n | Total number ofCPECs counted | PP+ve CPECs | BrdU+ve CPECs | PP/BrdUdouble-labelled CPECs(n = 4) |
| P3 | 6 | 1855 ± 260 | 131 ± 36 | 44 ± 3 | 0 |
| P4 | 6 | 2060 ± 125 | 175 ± 12 | 59 ± 7 | 2 ± 1 |
| P5 | 6 | 2675 ± 205 | 216 ± 33 | 76 ± 12 | 6 ± 2 |
| P10 | 6 | 3254 ± 106 | 230 ± 45 | 65 ± 17 | 11 ± 2 |
| P30 | 6 | 7790 ± 928 | 695 ± 113 | 71 ± 10 | - |
| P45 | 6 | 11104 ± 874 | 512 ± 84 | 80 ± 16 | 24 ± 4 |
| P65 | 6 | 12175 ± 954 | 502 ± 54 | 63 ± 7 | 39 ± 2 |
| p value * | < 0.05 | < 0.05 | < 0.05 | < 0.05 |
| Operational challenge | Description |
| High workload | - One of the major concerns was that the increased utilisation has put so much pressure on the limited medical staff in the facilities. There is large health worker-patient ratio and this affects the provision of responsive care. |
| - Inadequate numbers of health staff was mentioned as a key cause of long waiting hours. | |
| - The absence of people with professional knowledge of claims processing and management. | |
| Logistics/equipment | - Lack of ambulance for referrals especially on emergency cases. |
| - Lack of sophisticated surgical equipments to reduce referrals of cases to the regional hospitals. | |
| - Inadequate medical equipments. | |
| - The absence of operating theatres in the facilities to cope with new and emerging diseases. | |
| Medication | - Many of the complaints related to the fact that the Essential Drug List (EDL) does not adequately cover a wide range of drugs. It is therefore difficult for patients to comprehend why they are not entitled to unlimited drugs under the scheme. |
| Networking | - Networking is a problem. As a result, some patients present expired ID cards with valid dates on them for treatment. |
| - The absence of effective networking system makes activities of hospitals more difficult. | |
| - Because the system is not properly networked, there were instances when unregistered members scan their passport size pictures on ID cards of active members in order to receive medical care. |
| Wound dressing material | Mean value ± standard error of the mean | |
| (number of vessels per high-power field) | ||
| The 7th postoperative day | The 10th postoperative day | |
| Human amniotic membrane | 0.90 ± 0.18 | 1.05 ± 0.14 |
| Polyurethane foil | 1.80 ± 0.16 | 4.70 ± 0.47 |
| Group | Articles, n | Studies, n | Sensitivity (95% ci),% | Specificity (95% ci),% |
| All data | 103 | 132 | 70.8 (68.3-73.2) | 95.8 (94.9-96.6) |
| Effect of STARD score | ||||
| High quality score | 53 | 73 | 70.9 (67.5-74.1) | 95.7 (94.4-96.7) |
| Low quality score | 50 | 59 | 70.7 (67.0-74.1) | 96.0 (94.8-97.0) |
| Effect of STARD item 2 | ||||
| Yes | 101 | 129 | 70.8 (68.3-73.2) | 95.8 (94.9-96.6) |
| No¥ | 2 | 3 | NA | NA |
| Effect of STARD item 5 | ||||
| Yes | 77 | 99 | 71.8 (69.0-74.5) | 95.6 (94.5-96.5) |
| No | 26 | 33 | 67.7 (62.6-72.4) | 96.3 (94.9-97.4) |
| Effect of STARD item 7 | ||||
| Yes | 80 | 103 | 71.0 (68.2-73.7) | 95.9 (94.9-96.7) |
| No | 23 | 29 | 70.0 (64.7-74.9) | 95.6 (93.2-97.2) |
| Effect of STARD item 10 | ||||
| Yes | 93 | 121 | 70.2 (67.5-72.7)* | 95.9 (95.0-96.7) |
| No | 10 | 11 | 77.5 (71.7-82.3) | 94.5 (91.7-96.4) |
| Effect of STARD item 13 | ||||
| Yes | 90 | 116 | 71.5 (68.9-74.1)** | 95.6 (94.6-96.4)* |
| No | 13 | 16 | 65.7 (59.7-71.2) | 97.2 (96.2-97.9) |
| Effect of STARD item 16 | ||||
| Yes | 55 | 66 | 73.3 (69.8-76.6) | 94.6 (93.2-95.8)* |
| No | 48 | 66 | 68.3 (64.9-71.5) | 96.8 (95.7-97.7) |
| Effect of STARD item 19 | ||||
| Yes | 77 | 105 | 70.5 (67.8-73.1) | 95.8 (94.8-96.5) |
| No | 26 | 27 | 72.3 (66.1-77.8) | 96.4 (93.8-97.9) |
| Property | Description | Encoding |
| TF_Class | Encoded 2–3 top levels of five digit code based on TFClass classification; i.e. superclass followed by class (see text) | A 47-dimensional vector where ith position (superclass) and jth position (class) are 1, other positions are 0 |
| PD | TF has a frequent Pfam domain (yes/no) | 1/0 |
| DBD | TF has a DNA-binding domain (DBD) (yes/no) | 1/0 |
| N_DBD | Number of DBDs (see text) | 11/10/00 |
| PPI | TF has a protein-protein interaction (PPI) (yes/no) | 1/0 |
| N_PPI | Number of PPIs (see text) | 11/10/00 |
| N_PhS | Number of Phosphorylation sites (see text) | 11/10/00 |
| PTM | TF has a post-translational modification (PTM) (yes/no) | 1/0 |
| Ind_PTM | TF has a specific PTM (yes/no) | An ordered 6-dimensional vector where position i corresponding to PTM i is 1/0 |
| N_ZFD | Number of the zinc finger domains (see text) | 11/10/00 |
| Gender | n (%) | |
| Female | 20 (43.5) | |
| Male | 26 (56.5) | |
| Age | Years (range) | |
| Mean | 32 (18–37) | |
| HSCT | n (%) | |
| Allogeneic | 31 (67.4) | |
| Autologous | 15 (32.6) | |
| Underlying disease | n (%) | |
| Chronic myelogenous leukemia | 26 (56.5) | |
| Acute myelogenous leukemia | 8 (17.4) | |
| Multiple myeloma | 6 (13.1) | |
| Hodgkin’s lymphoma | 3 (6.5) | |
| Severe aplastic anemia | 3 (6.5) | |
| Immunosuppressive conditioning regimen | n (%) | |
| Busulfan and melphalan | 30 (65.2) | |
| Busulfan and cyclophosphamide | 4 (8.7) | |
| Total body irradiation and melphalan | 3 (6.5) | |
| Total body irradiation and cyclophosphamide | 3 (6.5) | |
| Other | 6 (13.1) |
| Modality | Figurativeness | |||||||
| Motion metaphor/Auditory metaphor | Motion literal/Auditory literal | Motion literal/Motion metaphor | Auditory literal/Auditory metaphor | |||||
| t | Sig. | t | Sig. | t | Sig. | t | Sig. | |
| Sentence | ||||||||
| Cloze probability | ns | ns | ns | ns | ||||
| Familiarity | ns | ns | 5.66 | <0.001 | 6.91 | <0.001 | ||
| Imageability | ns | 4.74 | <0.001 | 10.13 | <0.001 | 5.63 | <0.001 | |
| Figurativeness | ns | ns | −20.95 | <0.001 | −21.98 | <0.001 | ||
| Valence | ns | 2.4 | 0.02 | ns | ns | |||
| Valence RT | ns | 3.1 | 0.003 | ns | 1.99 | 0.05 | ||
| Pilot accuracy | 1.95 | 0.055 | ns | 2.92 | 0.004 | 4.59 | <0.001 | |
| Pilot RT | ns | ns | −3.14 | 0.002 | −2.81 | 0.006 | ||
| # characters | ns | ns | ns | ns | ||||
| # words | ns | ns | ns | ns | ||||
| # content words | ns | ns | ns | ns | ||||
| KF frequency | ns | ns | ns | ns | ||||
| BN frequency | ns | ns | ns | ns | ||||
| Concreteness | ns | ns | ns | ns | ||||
| Target word | ||||||||
| #characters | ns | ns | n/a | n/a | ||||
| KF frequency | ns | ns | n/a | n/a | ||||
| BN frequency | ns | ns | n/a | n/a | ||||
| Concreteness | ns | ns | n/a | n/a |
| Drainage | No drain | ||||
| Median (25th – 75th percentile) | Mean (± SD) | Median (25th – 75th percentile) | Mean (± SD) | p-value | |
| Volume drained (ml) | 500.00 (233.50 – 864.00) | 581.80 (442.60) | 0.00 (0.00 – 0.00) | 21.50 (107.90) | <0.01 |
| Volume aspirated (ml) | 0.00 (0.00 – 270.00) | 176.60 (298.20) | 522.50 (130.00 – 1148.80) | 858.40 (1434.50) | <0.01 |
| Number of aspirations | 0.50 (0.00 – 4.00) | 2.10 (3.10) | 5.00 (3.00 – 7.00) | 5.90 (6.20) | <0.01 |
| Total drained (ml) | 720.00 (395.00 – 1145.00) | 779.30 (451.90) | 540.00 (215.00 – 1152.50) | 890.60 (1434.30) | 0.19 |
| Cluster I | Cluster II | Cluster III | |
| Cluster I | 0 | 1.76 | 1.72 |
| Cluster II | 0.14230 | 0 | 2.80 |
| Cluster III | 0.14540 | 0.08917 | 0 |
| Sample sources | TYLCV positive No./tomato sample No. | TYLCV positive No./whiltefly No. |
| Henan Province | 6,6,6/9a | 7,7 /22 b |
| Shandong Province | 30,30,30/56 | 11,11/20 |
| Zhejiang Province | 195,195,197 /422 | 21,21/68 |
| Total | 231, 231,233 /487 | 39,39/110 |
| GBB-24 scale and sub-scales | m / Me(95%CI) | P-valuesa | |||
| Financial problems | The problems disappeared | ||||
| Yes | No | Yes | No | ||
| (n=98) | (n=106) | (n=83) | (n=121) | ||
| Exhaustion | 8.16 / 8 | 6.98 / 7 | 6.96 / 7 | 7.95 / 7 | 1 P=0.108 |
| (7.18–9.15) | (6.14–7.82) | (6.04–7.89) | (7.06–8.84) | 2 P=0.225 | |
| Gastrointestinal | 4.19 / 4 | 2.72 / 2 | 2.55 / 2 | 4.03 / 4 | 1 P=0.001 |
| (3.46–4.93) | (2.07–3.37) | (1.86–3.25) | (3.36–4.69) | 2 P=0.003 | |
| Cardiovascular | 6.61 / 7 | 4.77 / 4 | 5.10 / 5 | 6.04 / 5 | 1 P=0.002 |
| (5.72–7.51) | (3.96–5.59) | (4.22–5.98) | (5.20–6.88) | 2 P=0.219 | |
| Musculoskeletal | 8.84 / 8.5 | 7.59 / 7 | 6.80 / 7 | 9.14 / 9 | 1 P=0.082 |
| (7.83–9.85) | (6.65–8.52) | (5.96–7.63) | (8.16–10.12) | 2 P=0.002 | |
| Total GBB-24 | 27.81 / 26.5 | 22.06 / 20.5 | 21.41 / 20 | 27.16 / 26 | 1 P=0.005 |
| (24.81–30.81) | (19.50–24.61) | (18.81–24.00) | (24.38–29.94) | 2 P=0.013 |
| No. of teeth | Oral impacts | Sn | Sp | PPV | NPV | ||
| Cutoff | With | Without | Total | ||||
| ≤24 | 73 | 93 | 166 | 0.69 | 0.70 | 0.87 | 0.44 |
| ≥25 | 31 | 208 | 239 | ||||
| Total | 104 | 301 | 405 |
| Outcome | Aligner | Bracket | P* |
| Mean (SD) | Mean (SD) | ||
| s-PlI T0 (transformed) | |||
| T0 | 5.34 (0.87) | 5.55 (1.08) | 0.56 |
| T1 | 3.97 (1.29) | 5.72 (1.24) | 0.001 |
| T2 | 4.80 (1.48) | 6.15 (1.79) | 0.03 |
| s-GI T0 (transformed) | |||
| T0 | 4.35 (0.82) | 5.77 (1.56) | 0.004 |
| T1 | 4.23 (1.29) | 5.71 (1.80) | 0.01 |
| T2 | 5.03 (1.66) | 5.81 (1.69) | 0.21 |
| Treatment | Superfused bath | Static bath | Significance (Student’s t test) | ||
| n | Released ATP* | n | Released ATP* | ||
| Control (Ringer’s) | 89 puncta, 3 slices | 65 ± 1% | 80 puncta, 3 slices | 66 ± 2% | p = 0.61 |
| PPADS | 75 puncta, 2 slices | 62 ± 3% | 82 puncta, 2 slices | 64 ± 1% | p = 0.41 |
| αβMeATP | 144 puncta, 4 slices | 73 ± 1% | 29 puncta, 1 slice | 70 ± 1% | p = 0.09 |
| Media Volume (mL) | Biomass (mg) | RGR 1(mg·mg−1·d−1) | Dry Weight per mL(mg·mL−1) | CA Content 2(μg·gDW−1) | CA Production 3(μg·mL−1) |
| 15 | 23.60 ± 0.60 c | 0.378 ± 0.002 c | 1.580 ± 0.05 a | 898.2 ± 101 a | 1.421 ± 0.228 a |
| 30 | 38.00 ± 1.14 b | 0.395 ± 0.002 b | 1.260 ± 0.04 b | 576.8 ± 96 b | 0.735 ± 0.174 b |
| 60 | 61.60 ± 1.81 a | 0.412 ± 0.002 a | 1.040 ± 0.02 c | 335.3 ± 64 c | 0.348 ± 0.065 c |
| Cluster size | Hemisphere | Brain region | BA | MNI coordinates | Peak T-value |
| POSITIVE RSFCs: PRE > POST | |||||
| 117 | Right | Insula/inferior frontal gyrus | 13/45/44 | 63, 18, 3 | 6.60 |
| 74 | Right | Middle frontal gyrus/superior frontal gyrus | 6 | 33, −3, 66 | 5.14 |
| 64 | Left | Insula | 13 | −39, 6, 3 | 5.74 |
| NEGATIVE RSFCs: POST > PRE | |||||
| 119 | Bilateral | Medial frontal gyrus/superior frontal gyrus | 8 | 12, 51, 48 | 5.38 |
| Aim | Average-measure reliability G(q,k) | |||||||||
| Domain | Searching for research | Research obtained | Relevance appraisal | Quality appraisal | Generating new research | Interacting with researchers | Conceptual research use | Instrumental research use | Tactical research use | Imposed research use |
| (A) Reliability between the two independent coders; q = 0, k = 2 | 0.85 | 0.88 | 0.74 | 0.88 | 0.93 | 0.84 | 0.76 | 0.77 | 0.85 | 0.87 |
| (B) Reliability between the nine experts; q = 0.23, k = 3 | 0.77 | 0.83 | 0.46 | 0.74 | 0.66 | 0.65 | 0.58 | 0.49 | 0.71 | 0.89 |
| Corrected item-total correlation | Cronbach’s α if an item deleted | |
| Item 1 | 0.734 | 0.876 |
| Item 2 | 0.667 | 0.881 |
| Item 3 | 0.563 | 0.892 |
| Item 4 | 0.727 | 0.876 |
| Item 5 | 0.713 | 0.878 |
| Item 6 | 0.716 | 0.878 |
| Item 7 | 0.607 | 0.886 |
| Item 8 | 0.607 | 0.887 |
| Item 9 | 0.641 | 0.885 |
| Items | Days to flowering | Days to maturity | Plant height | Branch per plant | Pods per plant | Seeds per pod | 100-seed wt (gm) | Yield perplant |
| Days to flowering | −0.646 | 1.102 | −0.170 | −0.141 | 0.253 | 0.405 | −0.157 | 0.646∗∗ |
| Days to maturity | −0.601 | 1.184 | −0.161 | −0.111 | 0.188 | 0.173 | −0.005 | 0.667∗∗ |
| Plant height (cm) | −0.425 | 0.736 | −0.258 | −0.221 | 0.543 | 1.050 | −0.836 | 0.589∗∗ |
| Branches per plant (number) | −0.318 | 0.459 | −0.201 | −0.285 | 0.528 | 1.150 | −0.949 | 0.387∗ |
| Pods per plant (number) | −0.248 | 0.338 | −0.213 | −0.228 | 0.659 | 1.250 | −1.040 | 0.518∗∗ |
| Seeds per pod (number) | −0.180 | 0.141 | −0.187 | −0.227 | 0.569 | 1.450 | −1.168 | 0.398∗ |
| 100-seed weight (g) | 0.076 | −0.0086 | 0.161 | 0.201 | −0.510 | −1.258 | 1.350 | 0.012 |
| Male | Female | |||
| n (%) | n (%) | n (%) | ||
| Total | 3450 (100) | 1413 (42.0) | 2037 (58.0) | |
| Age (n=3450) | 15-24 | 1100 (28) | 506 (27.9) | 594 (28.0) |
| 25-34 | 721 (24.3) | 280 (25.8) | 441 (23.1) | |
| 35-44 | 630 (23.0) | 234 (22.2) | 396 (23.6) | |
| 45-54 | 507 (19.2) | 196 (18.7) | 311 (19.7) | |
| 55-64 | 492 (5.5) | 197 (5.4) | 295 (5.6) | |
| Location (n=3450) | Urban | 1737 (50.3) | 702 (49.6) | 1035 (50.2) |
| Rural | 1713 (49.7) | 711 (50.4) | 1002 (49.8) | |
| Education (n= 3450) | Primary or less | 219 (6.4) | 107 (7.5) | 112 (5.4) |
| Secondary School | 2088 (60.5) | 919 (65.0) | 1169 (57.5) | |
| Tertiary Schooling | 1143 (33.1) | 387 (27.4) | 756 (37.1) | |
| Employment (n=3425) | Student | 717 (20.8) | 330 (23.7) | 387 (18.8) |
| Employed | 1503 (43.6) | 696 (49.9) | 807 (39.5) | |
| Unemployed | 508 (14.7) | 204 (14.6) | 304 (14.8) | |
| Retired/Home | 697 (20.2) | 167 (11.8) | 530 (25.9) |
| Question – Recommender’s method | Automation | Fast enough | Accuracy |
| Which ontologies offer the maximum coverage for my data? – (CR – score) | Yes | Yes | Yes |
| Which ontologies are reference ontologies for my data? – (CR+M – score) | Yes | No | Yes |
| Which small ontologies are specialized for my data? – (CR – normalized score) | Yes | Yes | Not enough |
| Complication | Number of patients (n) | Treatment |
| Reflux +/− heartburn | 21 | Medical +/− endoscopy +/− pH 24 h esophageal pH monitoring |
| Vomiting | 5 | Diet modifications |
| Hemorrhage | 7 | 4 surgical, 3 transfusion |
| Fistula | 4 | 2 surgical, 1 prosthesis 1 surgical + endoscopic |
| Fistula + PE | 1 | Surgical |
| Abscess | 3 | ATB |
| Tachycardia | 1 | CT scan within normal findings |
| Dysphagia to meat | 1 | Diet modification |
| Dehydration | 1 | Rehospitalisation |
| LL sensory disorder | 1 | — |
| Cholelithiasis | 1 | Cholecystectomy |
| Failure to lose weight | 2 | — |
| Hypotension ± malaise ± hypoglycemia | 2 | Rest + NS IV infusion |
| Swelling of left internal jugular vein | 1 | — |
| Total | 51 |
| Maternal | Neonatal | Process/intervention |
| Gestational weight gain | Body composition, anthropometry | Visit attendance |
| Preeclampsia* | Preterm delivery | Adherence to probiotic/placebo regimen |
| Induction of labor | Shoulder dystocia | |
| Cesarean delivery | Hypoglycemia | |
| Elective | Treatment with supplementary fluids/feeds | |
| Emergency | ||
| Change in prevalence of L. rhamnosus and B. lactis in gut microbiome | Nerve palsy | |
| Change in lipids and inflammatory profile | Admission to neonatal intensive care unit | |
| Change in dietary indices and physical activity levels between baseline and 28 weeks gestation | Jaundice requiring phototherapy | |
| Bone fracture | ||
| Death: stillbirth or neonatal death |
| Sample | Total Polyphenol Contents (μg Gallic Acid/mL) |
| LJ | 2.084 ± 0.01 (1) |
| HF | 3.215 ± 0.08 |
| CAPEA | RABBIT | NDB | Reference (DEAS) | |
| N | 1033 | 12,230 | 3424 | 6202 |
| Age (years), mean (SD) | 56.6 (14.2) | 56.2 (9.7) | 61.5 (13.7) | 61.5 (12.1) |
| Sex (female), n (%) | 660 (63.9) | 9328 (76.3) | 2611 (76.3) | 3072 (49.5) |
| Disease duration (weeks or years), mean (SD) | 12.6 w (7.2) | 9.9 y (9.1) | 13.5 y (10.6) | NA |
| CRP (mg/l), mean (SD) | 19.7 (30.3) | 18.2 (26.6) | 11.0 (5.2) | NA |
| DAS28, mean (SD) | 5.1 (1.3) | 5.2 (1.3) | 3.1 (1.2) | NA |
| BMI (kg/m2), mean (SD) | 27.0 (5.0) | 26.7 (5.3) | 26.5 (4.9) | 26.6 (4.2) |
| < 18.5, n (%) | 11 (1.1) | 263 (2.2) | 56 (1.6) | 45 (0.8) |
| 18.5 to <25, n (%) | 372 (36.4) | 4810 (39.3) | 1416 (41.4) | 2264 (37.5) |
| 25 to <30, n (%) | 396 (38.8) | 4294 (35.1) | 1219 (35.6) | 2624 (43.5) |
| ≥ 30, n (%) | 243 (23.8) | 2863 (23.4) | 733 (21.4) | 1099 (18.2) |
| Histology parameters | IBA-1 | GFAP | MBP | APP | ||||||||
| t(8) | p | Adj p | t(8) | p | Adj p | t(8) | p | Adj p | t(8) | p | Adj p | |
| Anterior Commissure | 1.27 | 0.24 | 0.56 | 0.42 | 0.68 | 0.94 | 4.14 | <0.01 | 0.06 | 0.84 | 0.43 | 0.67 |
| Brachium_Left | 7.7 | <0.01 | <0.01 | 6.27 | <0.01 | <0.01 | 3.11 | 0.01 | 0.14 | 1.78 | 0.11 | 0.62 |
| Brachium_Right | 4.34 | <0.01 | 0.04 | 8.4 | <0.01 | <0.01 | 3.23 | 0.01 | 0.13 | 2.9 | 0.02 | 0.27 |
| Cingulum Bundle_Left | 1.52 | 0.17 | 0.55 | 2.29 | 0.05 | 0.45 | 2.43 | 0.04 | 0.16 | 2.8 | 0.02 | 0.3 |
| Cingulum Bundle_Right | 1.21 | 0.26 | 0.56 | 1.2 | 0.26 | 0.84 | 2.29 | 0.05 | 0.12 | 3.19 | 0.01 | 0.2 |
| Corpus Callosum_Anterior | 4.15 | <0.01 | 0.05 | 3.46 | 0.01 | 0.12 | 3.45 | 0.01 | 0.15 | 1.91 | 0.09 | 0.59 |
| sCorpus Callosum_Posterior | 4.78 | <0.01 | 0.02 | 2.54 | 0.03 | 0.39 | 2.71 | 0.03 | 0.12 | 1.41 | 0.2 | 0.67 |
| Cortex_Left | 3.01 | 0.02 | 0.17 | 2.33 | 0.05 | 0.45 | 3.45 | 0.01 | 0.02 | 1.28 | 0.24 | 0.67 |
| Cortex_Right | 2.34 | 0.05 | 0.36 | 1.85 | 0.1 | 0.66 | 5.04 | <0.01 | 0.14 | 2.3 | 0.05 | 0.44 |
| External Capsule_Left | 3.77 | 0.01 | 0.07 | 1.55 | 0.16 | 0.79 | 2.99 | 0.02 | 0.15 | 1.23 | 0.25 | 0.67 |
| External Capsule_Right | 3.27 | 0.01 | 0.13 | 1.15 | 0.28 | 0.84 | 2.62 | 0.03 | 0.78 | 1.75 | 0.12 | 0.62 |
| Hippocampus_Left | 2.24 | 0.06 | 0.37 | 1.4 | 0.2 | 0.79 | 0.6 | 0.57 | 0.78 | 2.34 | 0.05 | 0.44 |
| Hippocampus_Right | 2.2 | 0.06 | 0.37 | 1.04 | 0.33 | 0.84 | 0.66 | 0.53 | 0.14 | 2.2 | 0.06 | 0.45 |
| Internal Capsule_Left | 1.6 | 0.15 | 0.55 | 0.54 | 0.6 | 0.94 | 3.16 | 0.01 | 0.12 | 2.49 | 0.04 | 0.41 |
| Internal Capsule_Right | 0.67 | 0.52 | 0.56 | 0.31 | 0.76 | 0.94 | 3.51 | 0.01 | 0.12 | 3.64 | 0.01 | 0.11 |
| Optic Tract_Left | 4.02 | <0.01 | 0.06 | 4.42 | <0.01 | 0.03 | 3.38 | 0.01 | 0.12 | 1.7 | 0.13 | 0.62 |
| Optic Tract_Right | 3.52 | 0.01 | 0.1 | 6.45 | <0.01 | <0.01 | 3.16 | 0.01 | 0.14 | 0.97 | 0.36 | 0.67 |
| Thalamus_Left | 2.69 | 0.03 | 0.24 | 2.38 | 0.04 | 0.45 | 3.87 | <0.01 | 0.08 | 2.4 | 0.04 | 0.44 |
| Thalamus_Right | 1.84 | 0.1 | 0.48 | 1.49 | 0.17 | 0.79 | 3.03 | 0.02 | 0.14 | 3.91 | <0.01 | 0.08 |
| Variables | All cases | miRNA-506 expression | χ2 | p* | |
| High (n = 60) | Low (n = 60) | ||||
| Age (years) | |||||
| ≥60 | 88 | 42 | 46 | ||
| <60 | 32 | 18 | 14 | 0.289 | 0.409 |
| Gendar | |||||
| Male | 81 | 36 | 45 | ||
| Female | 39 | 24 | 15 | 0.010 | 0.079 |
| Tumor size (cm) | |||||
| <5 | 35 | 23 | 12 | ||
| ≥5 | 85 | 37 | 48 | 0.001 | 0.027 |
| Depth of invasiona | |||||
| m/sm/mp | 49 | 29 | 20 | ||
| ss/se/si | 71 | 31 | 40 | 0.014 | 0.095 |
| Tumor differentiation | |||||
| Well | 21 | 12 | 9 | ||
| Moderate | 30 | 18 | 12 | ||
| Poor and others | 69 | 30 | 39 | 0.565 | 0.246 |
| Lymph node invasion | |||||
| Absent | 37 | 25 | 12 | ||
| Present | 83 | 35 | 48 | 0.000 | 0.010 |
| TNM stage | |||||
| I–II | 41 | 26 | 15 | ||
| III–IV | 79 | 34 | 45 | 0.002 | 0.034 |
| Metastasis | |||||
| Yes | 45 | 16 | 29 | ||
| No | 75 | 44 | 31 | 0.000 | 0.014 |
| Participant | Theme | Quote |
| Female, age 22 | Mitigation | “Been getting more hypermobile in the last few days, which shows in the results” |
| Male, age 41 | Response | “Feedback is good, I push harder” |
| Mitigation/pain | “I changed how I was bracing myself and used a cushion on the scales for the glute exercise so it hurts less” | |
| Female, age 21 | Mitigation | “Get a cold, feeling weak but the exercises are fine” |
| Male, age 42 | Mitigation | “A bit weaker over the last couple of days because of flu” |
| Male, age 29 | Pain | “I had an injury while climbing...it’s painful” |
| Variables | High-Sensitivity (n = 23) | Others (n = 34) | |||
| Female, 78.2% | Female, 50.0% | ||||
| Mean | SD | Mean | SD | p | |
| Age (y) | 56.35 | 15.83 | 41.94 | 16.35 | 0.00** |
| Pain Duration (m) | 40.61 | 76.48 | 73.23 | 81.90 | 0.10 |
| 250 Hz PTT (mA) | 0.99 | 0.56 | 6.36 | 2.66 | 0.00** |
| 5 Hz PTT (mA) | 1.59 | 0.54 | 6.01 | 2.51 | 0.00** |
| SF-MPQ sensory score | 13.91 | 7.98 | 16.29 | 7.61 | 0.27 |
| SF-MPQ affective score | 6.42 | 3.76 | 5.71 | 3.53 | 0.51 |
| SF-MPQ Visual Analog Scale | 7.12 | 2.36 | 6.43 | 2.60 | 0.32 |
| SF-MPQ Present Pain Intensity | 3.55 | 1.26 | 3.26 | 1.18 | 0.40 |
| Variable | Dengue Hemorrhagic Fever (n = 280) | Dengue Shock Syndrome (n = 11) |
| P-value OR (95% CI) | ||
| Presence of bleeding | 0.00070.7 (38.4–129.9) | 0.000608.2 (33.9–1008.9) |
| Alanine aminotranferase level | 0.0011.9 (0.97–2.99) | 0.0041.04 (1.015–1.080) |
| Aspartate aminotransferase level | NS | 0.0101.05 (1.012–1.088) |
| Urinary Proteins | 0.0431.1 (0.191–1.974) | NS |
| Urinary Red blood cells | 0.0271.4 (0.179–1.900) | NS |
| Platelet count on admsission less than 50,000 × 109/L | NS | 0.0140.16 (0.13–0.19) |
| Study day | Date | Physical examination | Collar | Blood | Skin | Bone marrow |
| Preliminary Screening | March-April 2012 | + | - | + | - | - |
| Inclusion (D0) | April-May 2012 | + | Application | + | + | + |
| I Follow-up (D90 ± 10) | July-August 2012 | + | - | + | - | - |
| II Follow-up (D180 ± 10) | October-November 2012 | + | - | + | - | - |
| III Follow-up (D210 ± 10) | November-December 2012 | + | Removal | + | + | - |
| IV Follow-up (D300 ± 10) | February-March 2013 | + | - | + | + | + |
| Model 3 | ||||
| Tree | CT | CLADHC | HT | SbST |
| 1 | 40.7 (4.7) | 42.0 (5.9) | 47.5 (4.7) | |
| 2 | 31.7 (3.4) | 32.7 (3.9) | 43.0 (5.9) | |
| 3 | 26.8 (4.2) | 40.7 (6.4) | 45.2 (3.5) | |
| 4 | 34.8 (4.8) | 39.2 (4.7) | 38.9 (7.0) | |
| 5 | 41.5 (5.6) | 44.2 (6.6) | 37.2 (4.6) | |
| 6 | 42.0 (3.6) | 34.8 (4.7) | 41.3 (5.3) | |
| 7 | 28.6 (5.2) | 32.1 (4.7) | 39.9 (4.3) | |
| 8 | 33.2 (4.3) | 42.9 (6.1) | 37.7 (4.0) | |
| 9 | 33.5 (4.4) | 39.1 (4.1) | 41.2 (7.0) | |
| 10 | 48.1 (4.1) | 42.1 (7.8) | 56.9 (4.2) | |
| Average | 37.84 (4.7) | 42.48 (4.4) | 41.9 (6.5) | |
| Std dev.a | 11.07 (0.9) | 7.84 (0.3) | 1.45 (0.7) | 5.94 (0.6) |
| No. | Age (years) | Sex | Employment | Period of Residence (years) | Health Status | Health Effects |
| 1 | 31 | F | unemployed | > 15 | A | not declared |
| 2 | 39 | F | commerce | > 5 | D | gastrointestinal disease, skin hyperpigmentation |
| 3 | 40 | F | unemployed | > 5 | R | gastrointestinal and respiratory diseases |
| 4 | 41 | F | commerce | > 15 | R | skin hyperpigmentation |
| 5 | 41 | F | services | > 5 | R | gastrointestinal disease |
| 6 | 47 | F | unemployed | < 5 | R | gastrointestinal disease |
| 7 | 49 | F | unemployed | > 15 | D | gastrointestinal disease, skin hyperpigmentation |
| 8 | 51 | F | unemployed | > 15 | R | gastrointestinal and vascular diseases |
| 9 | 54 | F | farming/commerce | > 15 | R | gastrointestinal disease |
| 10 | 56 | F | farming | > 15 | A | not declared |
| 11 | 57 | F | commerce | > 15 | R | gastrointestinal disease |
| 12 | 62 | F | unemployed | > 5 | R | nutritionaldisease (obesity) |
| 13 | 64 | F | unemployed | > 15 | D | vascular disease |
| 14 | 73 | F | farming | > 15 | D | skin hyperpigmentation, tumor |
| 15 | 76 | F | unemployed | > 15 | A | not declared |
| 16 | 46 | M | mining | > 15 | R | respiratory and vascular diseases |
| 17 | 52 | M | commerce | > 5 | A | not declared |
| 18 | 52 | M | commerce | > 5 | A | not declared |
| 19 | 58 | M | farming | > 15 | D | gastrointestinal disease, skin hyperpigmentation |
| 20 | 68 | M | mining | > 15 | A | not declared |
| Newborn service | Coverage of service (%) | ||
| Indonesia | Lao PDR | Philippines | |
| Skilled birth attendance* | 83 | 42 | 72 |
| Hep B (first dose) | 85 | 37 (given at birth) | 87 |
| Hep B (fourth dose) | 41 | 56 | 67 (third dose) |
| BCG vaccination | 89 | 78 | 92 |
| Postpartum care for newborn within two days | 48 | 47 | not available |
| Newborns that have a reported birth weight (based on either a written record or the mother’s recall) | 89 | 43 | 73 |
| Newborns that received breastfeeding within 1 hour of birth | 49 | 39 | 54 |
| Experimental (n = 12) | Comparison (n = 8) | p-Value b | |||
| Baseline | 10 Weeks | Baseline | 10 Weeks | ||
| Daily MVPA | 30.7 ± 13.2 | 34.2 ± 18.7 | 30.2 ± 16.2 | 37.8 ± 20.4 | 0.49 |
| Daily LPA | 91.4 ± 28.8 | 98.9 ± 29.5 | 100.4 ± 31.6 | 108.5 ± 47.9 | 0.76 |
| Daily SB | 464.4 ± 50.7 | 466.8 ± 34.7 | 449.2 ± 54.9 | 449.6 ± 53.2 | 0.82 |
| Daily EE | 333.1 ± 113.3 | 359.9 ± 147.4 | 395.5 ± 229.9 | 418.0 ± 188.9 | 0.44 |
| Daily steps | 4832.4 ± 1816.4 | 5175.1 ± 2308.2 | 4411.6 ± 1624.7 | 4746.0 ± 2044.9 | 0.76 |
| Quartile of serum calcium level (mg/dL) | ||||
| Q1 | Q2 | Q3 | Q4 | |
| HR (95% CI) | (<9.0) | (9.0 - 9.4) | (9.4 - 9.8) | (>9.8) |
| Renal replacement therapy | ||||
| Unadjusted | 2.12 (1.55-2.91)* | 1.26 (0.90-1.76) | 1.15 (0.79-1.68) | 1 (reference) |
| Model 1 | 1.52 (1.10-2.10)* | 1.32 (0.94-1.86) | 0.97 (0.67-1.42) | 1 (reference) |
| Model 2 | 1.64 (1.19-2.26)* | 1.32 (0.94-1.86) | 1.05 (0.72-1.54) | 1 (reference) |
| Model 3 | 2.34 (1.65-3.31)* | 1.58 (1.11-2.25)* | 1.51 (1.01-2.25)* | 1 (reference) |
| Model 4 | 2.12 (1.49-3.02)* | 1.50 (1.05-2.15)* | 1.42 (0.95-2.12) | 1 (reference) |
| Rapid renal function progression | ||||
| Unadjusted | 1.44 (1.11-1.88)* | 1.18 (0.90-1.54) | 0.94 (0.70-1.26) | 1 (reference) |
| Model 1 | 1.42 (1.06-1.91)* | 1.28 (0.95-1.71) | 0.93 (0.67-1.28) | 1 (reference) |
| Model 2 | 1.56 (1.15-2.10)* | 1.30 (0.97-1.75) | 0.98 (0.71-1.36) | 1 (reference) |
| Model 3 | 1.72 (1.25-2.35)* | 1.40 (1.03-1.91)* | 1.15 (0.82-1.61) | 1 (reference) |
| Model 4 | 1.65 (1.19-2.27)* | 1.35 (0.99-1.84) | 1.11 (0.79-1.56) | 1 (reference) |
| Cell Viability | ||||
| Compound | Dose | Human Non-small Cell Lung Cancer | Normal Diploid Fibroblasts | |
| X. | Cyc-[AAAGGGPRGPRPGGGAAA] | 200 μM | + + + | + + + |
| XI. | Cyc-[GGGGGGPRGPRPGGGGGG] | 200 μM | + + + | + + + |
| XII. | Cyc-GGGGGGPRGPRPGGGGGG] | 200 μM | + + + | + + + |
| XIII. | Cyc-[AAGPGGPRGPRPGGPGAA] | 200 μM | + + + | + + + |
| XIV. | Linear FPPRGPRPVKLALKLALK | 200 μM | + + + | + + + |
| XV | Linear PRGPRPVALKLALKLAL | 200 μM | + + + | + + + |
| Reference | Primary outcomes | Secondary outcomes |
| Huang (moderate)1[34] | Higher sales of healthier food options were observed in the intervention group compared to the control group. |
| Work productivity assessment | No. of patients | Response, n (%) or mean ± SD |
| Employed at baseline | 575 | Yes: 262 (45.6) |
| Employed when CD symptoms began | 313 | Yes: 161 (51.4) |
| Stopped working due to CD | 161 | Yes: 59 (36.6) |
| Employment status affected by CD | 262 | • Different job with less responsibility or pay: 14 (5.3) |
| • Same job, reduced hours or responsibility: 50 (19.1) | ||
| • No change: 198 (75.6) | ||
| Missed work in past month due to CD | 261 | Yes: 74 (28.4) |
| Number of missed work days in past month | 74 | 5.7 ± 11.6 |
| Decreased productivity due to CD | 261 | Yes: 150 (57.5) |
| Estimated decrease in work productivity (%) | 150 | 72.1 ± 20.5 |
| Have received disability benefits due to CD | 262 | Yes: 12 (4.6) |
| Duration of disability benefits (months) | 12 | 33.2 ± 60.8 |
| Species | Riparian area | Forest | Orchards | High fallows | Market gardens | Village |
| An. braziliensis | 2 | - | - | - | 1 | 2 |
| An. darlingi | 81 | - | 6 | 10 | 78 | 97 |
| An. ininii | - | 1 | - | 1 | - | - |
| An. intermedius | 4 | - | - | 1 | 5 | - |
| An. mediopunctatus | 1 | 3 | 1 | 3 | 1 | - |
| An. nuneztovari | 14 | - | 4 | 15 | 14 | 1 |
| An. oswaldoi | - | 1 | - | - | - | - |
| An. peryassui | 1 | - | - | - | - | - |
| An. strodei | 1 | - | - | - | 1 | - |
| An. triannulatus | 25 | 30 | 16 | 404 | 4 | - |
| Total | 129 | 35 | 27 | 434 | 104 | 100 |
| Species number | 8 | 4 | 4 | 6 | 7 | 3 |
| Group | n | Age (years) | Height (cm) | Body mass (kg) |
| AerG | 12 | 25 ± 5.6 | 176.8 ± 3.8 | 74.7 ± 8.2 |
| ResG | 13 | 25 ± 3.5 | 175.5 ± 5.6 | 69.1 ± 8.5 |
| ConG | 13 | 26 ± 3.1 | 178.7 ± 7.0 | 85.0 ± 12.8 |
| NonG | 12 | 25 ± 2.4 | 179.3 ± 11.9 | 80.3 ± 12.8 |
| Feature | Bee | Fly | Mosquito | Moth | Chafer | Fruit Fly | Average Accuracy |
| Shape feature | 91.42 | 97.67 | 98.43 | 75.92 | 60 | 97.05 | 86.75 |
| Texture feature | 78.57 | 88.37 | 96.87 | 79.62 | 76 | 77.94 | 82.90 |
| Color feature | 41.42 | 72.09 | 78.12 | 85.18 | 68 | 86.76 | 71.93 |
| HOG feature | 97.46 | 91.83 | 91.66 | 81.66 | 84.84 | 97.36 | 90.80 |
| Global feature | 97.46 | 91.83 | 94.44 | 98.68 | 90 | 98.68 | 95.18 |
| Global and local feature | 97.46 | 93.87 | 97.22 | 88.33 | 93.93 | 98.68 | 94.92 |
| Specimen | Culture | Our Taqman PCR Assay | ||
| Positive | Negative | Positive | Negative | |
| Lung (n = 40) | 17 | 23 | 39 | 1 |
| Milk(n = 18) | 4 | 14 | 4 | 14 |
| Swabs(n = 10) | 4 | 6 | 6 | 4 |
| Joint Fluid (n = 3) | 0 | 3 | 1 | 2 |
| Total (n = 71) | 25 | 46 | 50 | 21 |
| Hose Code | Shift |
| H-1;C(*C*C/*CC,*CO/*CO,CCC,*&C,H)H*&,H,HHH,HHH,HHH,CCC/,HHH,HHH,HHH/ | 6.89 |
| H-1;C(*C*C/*CC,*CO/*CO,H=C,*&C,C)H*&,C,CC,H=C,HHC/,HHC,*C*C,%N,CC,HHC/ | 7.88 |
| H-1;C(*C*C/*CC,*CO/*CO,H=C,*&C,C)H*&,C,CC,H=C,HHC/,HHC,*C*C,%N,HC,HHC/ | 7.88 |
| H-1;C(*C*C/*CC,*CO/*CO,H=C,*&C,C)H*&,C,HC,CCC,HHC/,HHC,*C*C,HHH,HHH,HHH,HHC/ | 7.19 |
| H-1;C(*C*C/*CC,*CO/*CO,H=C,*&C,C)H*&,C,HC,H=C,=OC/,=OC,*C*N,HC,,HHH/ | 7.18 |
| H-1;C(*C*C/*CC,*CO/*CO,H=C,*&C,C)H*&,C,HC,H=C,HHC/,HHC,*C*C,CC,HHC/ | 7.14 |
| H-1;C(*C*C/*CC,*CO/*CO,H=C,*&C,C)H*&,C,HC,H=C,HHC/,HHC,*C*C,HC,HCC/ | 7.14 |
| H-1;C(*C*C/*CC,*CO/*CO,H=C,*&C,C)H*&,C,HC,H=C,HHC/,HHC,*C*C,HC,HHC/ | 7.13 |
| H-1;C(*C*C/*CC,*CO/*CO,H=C,*&C,C)H*&,C,HC,H=C,HHC/,HHC,*N*N,HC,HHC/ | 7.13 |
| H-1;C(*C*C/*CC,*CO/*CO,H=C,*&C,C)H*&,C,HC,H=C,HHC/,HHC,=OO,HC,HHC/ | 6.99 |
| H-1;C(*C*C/*CC,*CO/*CO,H=C,*&C,C)H*&,C,HC,H=C,HHH/,HHH,*C*C,HC/ | 7.10 |
| H-1;C(*C*C/*CC,*CO/*CO,H=C,*&C,C)H*&,C,HC,H=O,HHC/,HHC,*C*C,,HCC/ | 7.20 |
| H-1;C(*C*C/*CC,*CO/*CO,H=C,*&C,C)H*&,C,HC,H=O,HHC/,HHC,*C*C,,HHC/ | 7.16 |
| H-1;C(*C*C/*CC,*CO/*CO,H=C,*&C,C)H*&,C,HC,H=O,HHC/,HHC,=OC,,HHC/ | 7.35 |
| H-1;C(*C*C/*CC,*CO/*CO,H=C,*&C,C)H*&,C,HC,HHH,HHC/,HHC,*C*C,HCC/ | 7.19 |
| H-1;C(*C*C/*CC,*CO/*CO,H=C,*&Y,C)H*&,C,HC,,HHC/,HHC,*C*C,HHC/ | 6.89 |
| H-1;C(*C*C/*CC,*CO/*CO,H=C,H*&,C)H*&,C,CC,HHC/,HHC,*C*C,%N,HHC/ | 7.10 |
| H-1;C(*C*C/*CC,*CO/*CO,H=C,H*&,C)H*&,C,CC,HHH/,HHH,*C*C,%N/ | 7.20 |
| H-1;C(*C*C/*CC,*CO/*CO,H=C,H*&,C)H*&,C,HC,HHC/,HHC,*C*C,HHC/ | 7.13 |
| Factor | B | SE | Wald | df | p value | Odds ratio | 95% CI |
| Disturbance to studies: yes | 0.740 | 0.366 | 4.083 | 1 | 0.043 | 2.1 | 1.1–4.3 |
| Facilities of the classroom: satisfactory | − 2.151 | 0.327 | 43.156 | 1 | < 0.001 | 0.1 | 0.1–0.2 |
| Library facilities: satisfactory | − 0.691 | 0.332 | 4.338 | 1 | 0.037 | 0.5 | 0.3–0.9 |
| School health services: satisfactory | − 0.578 | 0.328 | 3.080 | 1 | 0.079 | 0.6 | 0.3–1.1 |
| Scope of subject content: satisfactory | − 1.464 | 0. 357 | 16.818 | 1 | < 0.001 | 0.2 | 0.1–0.5 |
| Relevance of subject area: satisfactory | − 1.900 | 0.421 | 20.333 | 1 | < 0.001 | 0.2 | 0.1–0.3 |
| Difficulty in understanding: easily understood | − 1.380 | 0.340 | 16.444 | 1 | < 0.001 | 0.3 | 0.1–0.5 |
| Duration of study: less than 2 h per day | 0.574 | 0.325 | 3.127 | 1 | 0.077 | 1.8 | 0.9–3.4 |
| Support from parents: satisfactory | − 1.800 | 0.488 | 13.612 | 1 | < 0.001 | 0.2 | 0.1–0.4 |
| Support from teachers: satisfactory | − 1.084 | 0.449 | 5.832 | 1 | 0.016 | 0.3 | 0.1–0.8 |
| Preference of subject stream: own preference | − 1.995 | 0.486 | 16.825 | 1 | < 0.001 | 0.1 | 0.1–0.4 |
| Personal expectations: encouraging | − 1.251 | 0.576 | 4.716 | 1 | 0.030 | 0.3 | 0.1–0.9 |
| Expectations of parents: encouraging | − 1.002 | 0.346 | 8.375 | 1 | 0.004 | 0.4 | 0.2–0.7 |
| Subjected to bullying at school: yes | 0.981 | 0.302 | 10.557 | 1 | 0.001 | 2.7 | 1.5–4.8 |
| n (%) | Median survival (months) | 95% CI1 | |
| Died during follow-up | 38 (74.5) | ||
| Overall survival (months) | 10.2 | 7.5–13.0 | |
| Gender | 51 (100) | P = .64 | |
| M | 35 (68.6) | 10.6 | 3.4–17.8 |
| F | 16 (31.4) | 10.2 | 0.0–22.0 |
| Age | 51 (100) | P = .18 | |
| <50 | 10 (20) | 5.3 | 0.8–9.8 |
| >50 | 41 (80) | 8.2 | 1.8–19.4 |
| FUDR given with 90Y | P = .72 | ||
| Yes | 17 (33.3) | 17.0 | 6.7–27.3 |
| No | 34 (66.7) | 8.2 | 4.2–12.3 |
| Extrahepatic disease present | 48 (100) | P = .07 | |
| Yes | 28 (58.3) | 6.7 | 2.7–10.6 |
| No | 20 (41.7) | 17.0 | 6.4–27.6 |
| CEA response2 | 41 (100) | P = .36 | |
| Yes | 17 (41.5) | 19.1 | 6.3–31.9 |
| No | 24 (42.9) | 9.3 | 6.0–12.7 |
| Radiographic Response3 | 31 (100) | P = .21 | |
| Progressive Disease | 7 (22.6) | 13.6 | 7.4–19.8 |
| Stable Disease | 20 (64.5) | 9.3 | 6.9–11.8 |
| Partial Response | 4 (12.9) | 21.5 | 13.7–29.1 |
| Method | Advantages | Disadvantages |
| Cobb | ▪ Simple procedure | ▪ No means to quantify rotation from gradation scheme |
| ▪ Little patient exposure to radiation (one anteroposterior radiograph) | ▪ Distortion of spinous process tip in scoliotic vertebrae may decrease accuracy | |
| ▪ Limited visibility of spinous process on radiographs of vertebrae with large rotation | ||
| Nash-Moe | ▪ Position of pedicles are less affected by intravertebral rotation; more reliable landmark for measuring rotation | ▪ Provides over-estimation of rotation (can be adjusted by 10° as suggested by Drerup) |
| ▪ Pedicles are poorly visible on vertebrae rotated severely or on spines with surgical instrumentation | ||
| Perdriolle | ▪ Affordable | ▪ Difficulty in making precise markings on radiographs – a 2 mm error corresponds to 5° rotation |
| ▪ Non-invasive | ||
| ▪ Simple procedure | ||
| ▪ Little patient exposure to radiation (one anteroposterior radiograph) | ▪ Reduced accuracy when measuring large degrees of rotation | |
| ▪ General findings report accurate measurements to within ± 5° | ||
| Stokes | ▪ Accounts for three-dimensionality of vertebra; similar accuracy to stereoradiograph | ▪ Greater random error in comparison to methods involving marking of vertebral edges |
| ▪ Little exposure to radiation | ||
| ▪ Simple measuring procedure | ||
| Aaro-Dahlborn | ▪ Better measurement accuracy even when measuring vertebrae tilted in the coronal and saggital planes | ▪ More difficult to use for inexperienced observers due to less obvious landmark definitions |
| Ho | ▪ Clearly defined reference points; simple procedure | ▪ Less correlation to actual rotation value when measuring distorted and |
| ▪ Better interobserver reliability in comparison to Aaro-Dahlborn method when assessing normal vertebrae | tilted vertebrae; less applicable in realistic conditions |
| Type | Male | Female | Total |
| CO | 26 (61.9%) | 16 (38.1%) | 42 |
| PP | 16 (80%) | 4 (20%) | 20 |
| Pl | 10 (55.6%) | 8 (44.4%) | 18 |
| F/D | 4 (100%) | — | 4 |
| Mo | 2 (33.3%) | 4 (66.7%) | 6 |
| Ge | 8 (80%) | 2 (20%) | 10 |
| Total | 66 | 34 | 100 |
| Up-regulated | Down-regulated | Total | |
| Rep1 | 90 | 86 | 176 |
| Rep2 | 77 | 89 | 166 |
| Rep1& Rep2 | 15 | 15 | 30 |
| Group | Habituation | Day 1 | Day 2 | Day 2 - 4 | Day 5 - 8 | Day 9 | Day 9 - 13 | Day 14 | Day 14 - 19 | Day 20 |
| Stress 1 × 15 min | Decap | Stress 2 × 10 min | Stress 3 × 10 min | Decap | Stress 3 × 10 min | Decap | No stress | Decap | ||
| Stress 1 | V | V | V | |||||||
| Control 1 | V | V | V | |||||||
| Stress 2 | V | V | V | V | V | |||||
| Control 2 | V | V | V | V | V | |||||
| Stress 3 | V | V | V | V | V | V | ||||
| Control 3 | V | V | V | V | V | V | ||||
| Stress 4 | V | V | V | V | V | V | V | |||
| Control 4 | V | V | V | V | V | V | V |
| Milestone | Date |
| Review of lower risk drinking guidelines announced | March 2012 |
| Expert group assessment of the need to update the guidelines | 2013–2014 |
| Guidelines development group considered the evidence and produced advice on revisions to the guidelines | 2014–2015 |
| Publication of proposed revisions | January 2016 |
| Public consultation on the clarity of the guidelines concluded | April 2016 |
| Final guidelines released | August 2016 |
| Drug Name | Drug Function | Reference |
| Trimetazidine | Cytoprotective, anti-ischemic | [78,79] |
| Isoflurane | Cytoprotective | [80] |
| Erythropoietin | Anti-apoptotic | [77] |
| Deferoxamine: | HIF-1α stabilizer | [81,82] |
| Dimethyloxalylglycine | HIF-1α stabilizer | [83] |
| Antimycin | Mitochondrial inhibitor | [75] |
| Oxytocin | Anti-oxidant | [84] |
| Celastrol | Anti-oxidant | [85] |
| Melatonin | Anti-oxidant | [86,87] |
| Nicorandil | K+ channel activator | [88] |
| Diazoxide | K+ channel activator | [76] |
| Lipopolysaccharide | TRL4 agonist | [89] |
| Pioglitazone | PPAR-γ agonists | [90] |
| NaHS | H2S donor | [91] |
| Study* | 30-day major complications | 30-day minor complications | Pulmonary embolism | Deep venous thrombosis | Readmissions in the first 30 postoperative days |
| Abdalla [15] | 1 | 5 | 0 | 0 | NR1 |
| Buchs [16] | 24 (not classified) | 7 | 2 | 2 | |
| Hagen [7] | 23 (not classified) | NR | NR | NR | |
| Tieu [17] | 45 | 102 | 2 | 3 | 67 |
| Vilallonga [18] | 1 case | NR | NR | NR | NR |
| Ayloo [19] | NR | NR | NR | 0 | |
| Diamantis [20] | 0 (not classified) | 0 | 0 | 0 | |
| Edelson [21] | NR | NR | NR | NR | |
| Park [22] | 10 (not classified) | 0 | 0 | 0 | |
| Scozzari [8] | 4 | 14 | 1 | NR | NR |
| Curet [23] | 3 (not classified) | NR | NR | NR | |
| Deng [24] | 4 | 7 | NR | NR | 3 |
| Hubens [25] | NR | NR | NR | NR | NR |
| Sudan [26] | NR | NR | NR | NR | NR |
| Parini [27] | 0 | 0 | 0 | 0 | 0 |
| Mohr [28] | 6 | 7 | NR | NR | NR |
| Yu [29] | NR | NR | 1 | NR | NR |
| Ali [30] | NR | NR | NR | NR | NR |
| Artuso [31] | NR | NR | NR | NR | NR |
| Galvani [32] | NR | NR | NR | NR | NR |
| Sanchez [33] | NR | NR | NR | NR | NR |
| Muhlmann [34] | NR | NR | NR | NR | NR |
| Step | Predictor variable | ΔF | R2 | ΔR2 | ß | p |
| OVERALL | ||||||
| 1 | Age | 19.065 | 0.238 | – | −0.413 | 0.001 |
| Sex | – | – | – | 0.220 | 0.007 | |
| 2 | BDI score | 9.249 | 0.292 | 0.054 | −0.236 | 0.003 |
| FEMALES | ||||||
| 1 | Age | 16.228 | 0.167 | – | −0.409 | 0.001 |
| 2 | BDI score | 0.522 | 0.172 | 0.005 | −0.077 | 0.472 |
| MALES | ||||||
| 1 | Age | 10.376 | 0.206 | – | −0.454 | 0.003 |
| 2 | BDI score | 25.059 | 0.517 | 0.311 | −0.560 | 0.001 |
| Variable | N(%) = 604(100%) |
| Gender (male) | 417(69%) |
| Age (yrs) | 60.2(± 12.5) |
| BMI (kg/m2) | 26.5(24.3-29.4) |
| Race (Caucasian) | 560(92.7) |
| Cause of CKD | |
| Diabetic nephropathy | 65(10.8%) |
| Renovascular | 188(31.1%) |
| Glomerular disease | 109(18%) |
| Interstitial disease | 57(9.4%) |
| Congenital (incl PKD) | 62(10.3%) |
| Unknown | 123(20.4%) |
| History of CVD | 178(29.5%) |
| Diabetes Mellitus | 144(23.8%) |
| Hypertension | 433(71.7%) |
| Smoking | 145(24%) |
| Systolic BP (mmHg) | 136(± 21) |
| Diastolic BP (mmHg) | 78(± 11) |
| Creatinine (μmol/l) | 184(± 71) |
| eGFR (MDRD, ml/min/1.73 m2) | 36.8(± 13.9) |
| Total cholesterol (mmol/l) | 4.8(± 1.0) |
| Proteinuria (g/24 hours) | 0.3(0.1-0.9) |
| Phosphate (mmol/l) | 1.12(± 0.26) |
| Calcium (mmol/l) | 2.38(± 0.14) |
| PTH (pmol/l) | 8.3(5.6-14.4) |
| cFGF23 (RU/ml) | 116(67-203) |
| Medication | |
| Active vitamin D (any) | 135(22.4) |
| Phosphate binders (any) | 56(9.3) |
| IFN-γ-1616 T/C Genotypes | OR‡(95% CI) | Pvalue |
| TT | 5.53 (2.30- 13.27) | <0.001 |
| TC | 1.00 | |
| CC | 0.65 (0.15- 2.80) | 0.56 |
| Alleles frequency | ||
| T | 0.28 (0.10- 0.76) | 0.008 |
| C |
| Time (years) | Transformation rate | Standard error | 95% confidence interval |
| 1 | 0.0119 | 0.0015 | 0.0093-0.0154 |
| 2 | 0.0232 | 0.0022 | 0.0192-0.0279 |
| 3 | 0.0290 | 0.0025 | 0.0244-0.0343 |
| 4 | 0.0385 | 0.0030 | 0.0329-0.0449 |
| 5 | 0.0461 | 0.0034 | 0.0398-0.0534 |
| 6 | 0.0543 | 0.0039 | 0.0471-0.0624 |
| 7 | 0.0594 | 0.0042 | 0.0517-0.0681 |
| 8 | 0.0615 | 0.0044 | 0.0535-0.0706 |
| 9 | 0.0669 | 0.0050 | 0.0578-0.0773 |
| 10 | 0.0689 | 0.0053 | 0.0592-0.0802 |
| Receptor | Ligand 7 | Ligand 11 | Ligand 15 |
| CA-II | 6 | 0 | 5 |
| Cat B | 8 | 1 | 3 |
| DNA-1 | 5 | 2 | 7 |
| DNA-2 | 2 | 2 | 5 |
| Gyrase | 3 | 1 | 6 |
| HDAC7 | 3 | 0 | 3 |
| HIS | 4 | 1 | 4 |
| Kinase | 5 | 0 | 4 |
| rHA | 4 | 2 | 2 |
| RNR | 6 | 1 | 7 |
| Top II | 9 | 4 | 7 |
| TrxR | 6 | 4 | 3 |
| TS | 7 | 4 | 7 |
| Number of | Number of | ||||
| Condition | Trials | Patients | Drug treaments | Trial arms | Contributing patients |
| Arthritis | 16 | 2990 | Opioid | 24 | 2173 |
| Placebo | 7 | 445 | |||
| Other comparator | 2 | 447 | |||
| Musculoskeletal | 10 | 1648 | Opioid | 18 | 1561 |
| Placebo | 4 | 302 | |||
| Other comparator | 0 | 0 | |||
| Neuropathic | 5 | 302 | Opioid | 5 | 219 |
| Placebo | 4 | 178 | |||
| Other comparator | 1 | 46 | |||
| Mixed conditions | 3 | 606 | Opioid | 6 | 606 |
| Placebo | 1 | 49 | |||
| Other comparator | 0 | 0 |
| Sub-groups | T1DM patients (N = 216) | Controls (N = 204) | p-value | ORa | CIb |
| Deficient | 182 (84 %) | 158 (77 %) | 0.046 | 1.66 | 1.02–2.701 |
| Insufficient | 31 (15 %) | 29 (14 %) | 0.93 | 0.977 | 0.565–1.689 |
| Sufficient | 3 (1 %) | 11 (5 %) | 0.027 | 0.239 | 0.0658–0.872 |
| Defficient + Insufficient | 213 (99 %) | 187 (92 %) | 0.027 | 4.176 | 1.147–15.202 |
| Participants | Gender | Years of implant | Etiology | Implantation site |
| F.R. | M | 9 | Neurofibratosis type 2 | Brainstem |
| D.M. | M | 13 | Trauma with bilateral cochlear fracture | Brainstem |
| M.A. | F | 16 | Congenital hearing loss | Cochlea |
| P.S. | M | 15 | Congenital hearing loss | Cochlea |
| M.G. | M | 12 | Congenital hearing loss | Cochlea |
| G.A. | F | 16 | Congenital hearing loss | Cochlea |
| Boys | Girls | |||||||||
| <11 years | ≥11 years | <10 years | ≥10 years | |||||||
| N | Mean (SD) | N | Mean (SD) | P value | N | Mean (SD) | N | Mean (SD) | P value | |
| Y1 | 32 | 0.53 (0.36) | 22 | 0.24 (0.34) | 0.0046 | 12 | 0.42 (0.51) | 10 | 0.29 (0.38) | 0.5159 |
| Y2 | 25 | 0.94 (0.65) | 13 | 0.47 (0.50) | 0.0284 | 6 | 0.77 (0.55) | 5 | 0.49 (0.67) | 0.4726 |
| Y3 | 16 | 0.92 (0.65) | 10 | 1.01 (0.65) | 0.7168 | 2 | 1.24 (0.33) | 3 | 1.24 (0.45) | 0.9968 |
| Y4 | 6 | 1.15 (0.93) | 8 | 0.90 (0.88) | 0.6082 | 2 | 1.34 (0.78) | 1 | 1.52 (—) | — |
| Variables | b (SE) | Beta | p-value |
| Intercept | 14.71 | ||
| Pain (VAS) | 0.77 (0.35) | 0.31 | 0.03 |
| Gender (female vs male) | 6.48 (2.00) | 0.39 | 0.00 |
| Age (years) | -0.27 (0.11) | -0.32 | 0.02 |
| Stiffness (WOMAC) | 1.05 (0.43) | 0.30 | 0.02 |
| Maximum walking speed (m/s) | 9.59 (3.54) | 0.41 | 0.01 |
| R2 = 0.47 p < 0.001 |
| Gene symbol | Description | Log2FC | Padjusted |
| FLAI-K-feline | Feline class I antigen-alpha chain-like class I antigen | 1.7066 | 4.95E−06* |
| LOC101084108 | HLA class II histocompatibility antigen, DM alpha chain | 0.24295 | 0.50201 |
| LOC101082906 | HLA class II histocompatibility antigen DO beta chain | 0.06259 | 0.8714 |
| LOC101090265 | HLA class II histocompatibility antigen, DM beta chain | −0.52204 | 0.24494 |
| LOC101098301 | DLA class II histocompatibility antigen, DR-1 beta chain | −0.61283 | 0.2607 |
| LOC101088734 | HLA class II histocompatibility antigen DR alpha chain-like | −0.63486 | 0.24216 |
| HMHA1 | Minor human histocompatibility protein HA-1 | −0.67421 | 0.0512 |
| Immunophenotypic marker | MLL rearrangement (n = 11) | Hyperdiploidy (n = 34) | t (12;21) (n = 21) | t (1;19) (n = 5) | Rare (n = 8) | Normal karyotype (n = 28) | Total (n = 107)* | p-Value |
| CD10 | 27%(3/11§) | 53%(18/34) | 67%(14/21) | 80%(4/5) | 63%(5/8) | 50%(14/28) | 58%(62/107) | ns |
| CD33 | 9.1%(1/11§) | 31%(9/29) | 45%(9/20) | 20%(1/5) | 25%(2/8) | 42%(10/24) | 33%(32/97) | ns |
| CD13 | 18%(2/11) | 19%(6/31) | 15%(3/20) | 20%(1/5) | 38%(3/8) | 7%(2/27) | 17%(17/102) | ns |
| CD123 | 9.1%(1/11) | 6%(2/32) | 17%(3/18) | 20%(1/5) | 25%(2/8) | 7%(2/28) | 8.8%(10/114) | ns |
| CD15/CD65 | 18%(2/11) | 9%(3/32) | 16%(3/19) | 20%(1/5) | 13%(1/8) | 4%(1/26) | 11%(11/101) | ns |
| ≥ 1 altered phenotypic marker | 73%(8/11) | 77%(24/31) | 85%(17/20) | 100%(5/5) | 75%(6/8) | 76%(19/25) | 79%(79/100) | ns |
| Clinicopathological features | N | STK31 methylation | p | |
| + | - | |||
| Age | 148 | |||
| <45 | 49 | 13 | 0.741 | |
| ≥45 | 66 | 20 | ||
| Histology | 102 | |||
| Squamous cell carcinoma | 67 | 13 | 1.000 | |
| Adenocarcinoma | 18 | 4 | ||
| Differentiation | 146 | |||
| Well + Moderate | 75 | 17 | 0.584 | |
| Poor | 42 | 12 | ||
| Lymph node metastasis | 100 | |||
| Positive | 23 | 7 | 0.708 | |
| Negative | 56 | 14 | ||
| FIGO stage | 119 | |||
| IA1 ~ IIA2 | 50 | 14 | 0.617 | |
| IIB ~ IIIA | 45 | 10 | ||
| Tumor size (cm) | 148 | |||
| <1 | 40 | 11 | 0.877 | |
| ≥1 | 75 | 22 | ||
| HPV16/18 | 134 | |||
| No(HPV-negative) | 18 | 0 | 0.037 | |
| Yes | 87 | 29 | ||
| HPV genotyping | 123 | |||
| HPV16 | 81 | 19 | 0.711 | |
| HPV18 | 20 | 3 | ||
| Squamous cell carcinoma-Ag(SCC-Ag) | 80 | |||
| Normal | 24 | 4 | 1.000 | |
| High | 45 | 7 | ||
| Neoajuvant Chemotherapy | 55 | |||
| No | 23 | 7 | 0.029 | |
| Yes | 25 | 0 | ||
| Neoajuvant Chemotherapy resistance | 55 | |||
| No | 44 | 9 | 0.037 | |
| Yes | 0 | 2 |
| Recommendation | Quality of evidence | Strength of recommendation | Rationale (Benefits, harms and the preferences of patients and clinicians) | |
| 1 | Victims with potential spinal injury should have spinal stabilisation. | Very low | Strong | Paucity of literature supporting spinal stabilisation. Very little literature documenting serious harm. Spinal cord injury can have devastating consequences. Potential benefits outweigh harms |
| 2 | A minimal handling strategy should be observed. | Very low | Strong | Paucity of literature supporting spinal stabilisation. Very little literature documenting serious harm. Spinal cord injury can have devastating consequences. Potential benefits outweigh possible harms |
| 3 | Spinal stabilisation should never delay or preclude life-saving intervention in the critically injured trauma victim. | Very low | Good clinical practice | Literature supporting this recommendation was considered too heterogenous for synthesis. The faculty finds that it is logical that spinal stabilisation in the critically injured patient may cause serious harm |
| 4 | Victims of isolated penetrating injury should not be immobilised. | Moderate | Strong | One large study of moderate quality directly supports this recommendation. Spinal injury in patients with isolated penetrating injury is rare |
| 5 | Triaging tools based on clinical findings should be implemented. | Moderate | Strong | Consistent evidence supporting triaging tools based on clinical findings rather than mechanism. No harmful effects documented |
| 6 | Cervical stabilisation may be achieved using manual in-line stabilisation, head-blocks, a rigid collar or combinations thereof. | Very low | Conditional | Consistent experimental evidence demonstrating how rigid collars can stabilise the cervical spine. However, there is also evidence suggesting harm from rigid collars. No evidence proving superiority of any one method |
| 7 | Transfer from the ground or between stretchers should be achieved using a scoop stretcher. | Very low | Conditional | General paucity of evidence. Some evidence for significant spinal motion during log-roll. Some evidence documenting improved stability with scoop stretcher transfers. Safety of scoop stretcher systems is good. No harmful effects documented |
| 8 | Patients with potential spinal injury should be transported strapped supine on a vacuum mattress or on an ambulance stretcher system. | Very low | Conditional | Evidence supporting harm from hard surface stretcher systems. No consistent evidence demonstrating increased stability with any one method. Increased comfort associated with soft surface systems. No evidence exploring spinal stability of common stretcher systems |
| 9 | Hard surface stretcher systems may be used for transports of shorter duration only. | Very low | Conditional | Evidence supporting harm from hard surface stretcher systems. No consistent evidence demonstrating increased stability with any one method. Increased comfort associated with soft surface systems |
| 10 | Patients should under some circumstances be invited to self-extricate from vehicles. | Very low | Conditional | Two experimental studies demonstrating improved stability with self-extrication from vehicles. Reasonable and practical alternative as long as used cautiously |
| x1 | x2 | x3 | x4 | x5 | x6 |
| .688 | .352 | −.083 | .096 | −.301 | −.105 |
| .733 | .352 | .104 | −.176 | .087 | −.411 |
| .856 | −.167 | −.204 | .208 | .006 | −.123 |
| .709 | −.405 | −.357 | −.210 | −.085 | .019 |
| .479 | −.478 | −.376 | −.468 | −.025 | .254 |
| .721 | .101 | −.470 | .200 | .318 | −.100 |
| .562 | .302 | −.362 | .543 | −.259 | −.054 |
| .530 | .365 | .566 | −.072 | −.109 | .410 |
| .545 | .574 | .130 | −.027 | .253 | .204 |
| −.043 | .528 | .660 | .227 | −.017 | −.173 |
| −.039 | .145 | .182 | .358 | .799 | .283 |
| .445 | −.638 | .352 | .448 | .033 | −.124 |
| .464 | −.662 | .260 | .479 | −.028 | −.092 |
| .877 | −.369 | −.011 | .015 | .002 | −.096 |
| .919 | −.239 | −.094 | .040 | −.017 | .079 |
| .767 | .142 | −.093 | .267 | −.132 | .050 |
| .853 | .282 | .085 | −.019 | .203 | −.097 |
| .476 | −.442 | .662 | −.246 | −.124 | −.070 |
| .664 | −.374 | .577 | −.255 | −.021 | −.007 |
| .802 | .388 | .147 | −.092 | −.079 | .054 |
| .623 | .237 | .052 | −.517 | −.025 | .047 |
| .634 | −.269 | −.143 | −.157 | .559 | .179 |
| .374 | .072 | −.051 | .299 | −.427 | .671 |
| .672 | .547 | −.187 | −.154 | −.037 | −.187 |
| Target | Efficiency LNA primers | Efficiency DNA primers | Difference |
| let-7a | 82% | 89% | 6.9% |
| miR-101a | 85% | 90% | 4.9% |
| miR-103 | 93% | 94% | 1.6% |
| miR-122 | 95% | 95% | -0.1% |
| miR-125b | 89% | 94% | 4.5% |
| miR-139b-5p | 79% | 86% | 6.4% |
| miR-150 | 84% | 97% | 12.6% |
| miR-199b-3p | 80% | 87% | 7.1% |
| miR-20a | 88% | 86% | -2.0% |
| miR-200b | 80% | 94% | 13.6% |
| miR-200c | 83% | 84% | 0.2% |
| miR-21 | 91% | 92% | 1.1% |
| miR-23a | 79% | 93% | 14.1% |
| miR-23b | 81% | 87% | 6.2% |
| miR-25 | 84% | 91% | 6.7% |
| miR-26a | 88% | 96% | 8.3% |
| miR-27a | 86% | 85% | -1.1% |
| let-7d | not specific | 102% | |
| Average | 85% | 90% | 5.4% |
| P1 | N1 | P2 | ||||
| Control | Patient | Control | Patient | Control | Patient | |
| AVERAGE AMPLITUDE | ||||||
| Standard | 0.281 | 0.463 | 0.290 | 0.031 | 0.552 | 0.635 |
| Low deviant | 0.324 | 0.337 | −0.941 | −0.468 | 0.705 | 0.812 |
| High deviant | −0.080 | 0.219 | −1.614 | −0.95 | 0.357 | 0.299 |
| PEAK LATENCY | ||||||
| Standard | 77 | 84 | 135 | 135 | 187 | 197 |
| Low deviant | 68 | 73 | 150 | 152 | 242 | 240 |
| High deviant | 65 | 75 | 133 | 139 | 246 | 232 |
| Nutrient | Oxygen (kJ/l) | Carbon dioxide (kJ/l) |
| Carbohydrate | 21.1 | 21.1 |
| Protein | 18.7 | 23.4 |
| Fat | 19.6 | 27.8 |
| Activities | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| 1 | 0.000 | 0.039 | 0.007 | 0.154 | 0.357 | 0.405 | 0.194 | 0.090 |
| 2 | 0.039 | 0.000 | 0.032 | 0.115 | 0.396 | 0.444 | 0.233 | 0.129 |
| 3 | 0.007 | 0.032 | 0.000 | 0.147 | 0.364 | 0.412 | 0.200 | 0.097 |
| 4 | 0.154 | 0.115 | 0.147 | 0.000 | 0.511 | 0.559 | 0.347 | 0.244 |
| 5 | 0.357 | 0.396 | 0.364 | 0.511 | 0.000 | 0.048 | 0.163 | 0.267 |
| 6 | 0.405 | 0.444 | 0.412 | 0.559 | 0.048 | 0.000 | 0.212 | 0.315 |
| 7 | 0.194 | 0.233 | 0.200 | 0.347 | 0.163 | 0.212 | 0.000 | 0.103 |
| 8 | 0.090 | 0.129 | 0.097 | 0.244 | 0.267 | 0.315 | 0.103 | 0.000 |
| Spiked conc.(μg/ml) | Between-day assay (n=6) | Within-day assay (n=6) | ||||
| Mean | SD | RSD (%) | Mean | SD | RSD (%) | |
| 5 | 5.9 | 0.5 | 8.5 | 5.4 | 0.9 | 16.7 |
| 50 | 49.8 | 4.5 | 11 | 52.4 | 5.6 | 10.7 |
| 200 | 217.2 | 21.7 | 10.0 | 217.2 | 26.6 | 12.2 |
| PM (n = 11) | DM (n = 38) | Total (n = 49) | |
| Age at diagnosis (years)† | 51.1 ± 15.8 | 43.7 ± 13.9 | 45.4 ± 14.6 |
| Gender (F:M) | 7:4 | 23:15 | 30:19 |
| Disease duration (months)† | 44.2 ± 46.9 | 62.9 ± 53.0 | 59.1 ± 51.9 |
| Clinical manifestation, n (%) | |||
| Fever | 3 (27.3) | 11 (28.9) | 14 (28.6) |
| Raynaud's phenomenon | 2 (18.2) | 6 (15.8) | 8 (16.3) |
| Arthralgia | 2 (18.2) | 14 (36.8) | 16 (32.7) |
| Dysphagia | 0 (0) | 9 (23.7) | 9 (18.4) |
| Cardiac involvement | 2 (18.2) | 0 (0) | 2 (4.1) |
| ILD | 2 (18.2) | 12 (31.6) | 14 (28.6) |
| Malignancy | 3 (27.3) | 9 (23.7) | 12 (24.5) |
| Myositis overlap | 1 (9.1) | 2 (5.3) | 3 (6.1) |
| Total particles (by optical particle counter) | Viral particles (by RT-PCR analysis) | ||||
| Particle size range (μm) | Average removal efficiency (%) | Particle size range (μm) | Average removal efficiency (%) | ||
| IAV | PRRSV | PEDV | |||
| 0.3–0.5 | 51.6 | 0.4–0.7 | 77.1 | 98.4 | 89.9 |
| 0.5–1.0 | 56.1 | 0.7–1.1 | 52 | –a | 95.5 |
| 1.0–3.0 | 76.2 | 1.1–2.1 | 77.7 | – | 58.8 |
| 3.0–5.0 | 82.2 | 2.1–3.3 | 77.5 | 97.8 | 89.8 |
| 5.0–10.0 | 79.8 | 3.3–4.7 | 98.2 | 99.7 | 96.4 |
| >10 | 76.2 | 4.7–5.8 | 96.5 | 98.8 | 89.7 |
| 5.8–9.0 | 97 | 98.2 | 85.1 | ||
| >9.0 | 98.2 | 99.9 | 84.3 |
| Training | Tuning | Testing | |
| French | |||
| Titles | 458,543 | 57,317 | 57,317 |
| Abstracts (hr=0.0) | 28,882 | 28,882 | 28,881 |
| Abstracts (hr=0.29) | 17,351 | 17,365 | 28,881 |
| Spanish | |||
| Titles | 198,512 | 24,814 | 24,814 |
| Abstracts (hr=0.0) | 7,772 | 7,772 | 7,772 |
| Abstracts (hr=0.29) | 5,403 | 5,418 | 7,772 |
| Demographic variable | Pre (N = 88) | Post (N = 69) | |||
| n (%) | n (%) | Test statistics | |||
| Gender | Female | 63(72) | 53(77) | x2 = 0.546, df = 1, p = 0.46 | |
| Male | 25(28) | 16(23) | |||
| Scenario version | CT ICU scenario | 48(55) | 45(65) | x2 = 1.824, df = 1, p = 0.177 | |
| Gen ICU scenario | 40(45) | 24(35) | |||
| Age | 20 - 29 | 21(24) | 21(30) | x2 = 2.566, df = 4, p = 0.63 | |
| 30 - 39 | 43(49) | 29(42) | |||
| 40 - 49 | 20(23) | 18(26) | |||
| 50 - 59 | 3(3) | 1(1) | |||
| 60 - 69 | 1(1) | ||||
| Current unit* | [n = 76] | [n = 58] | x2 = 3.469, df = 2, p = 0.176 | ||
| Private ICU | 25(33) | 17(29) | |||
| General ICU | 32(42) | 18(31) | |||
| Cardiothoracic ICU | 19(25) | 23(40) | |||
| Current designation | RN | 56(64) | 39(567) | x2 = 5.331, df = 6, p = 0.502 | |
| CNS | 20(23) | 19(27) | |||
| RMO | 3(3) | 1(1) | |||
| Registrar/Senior Registrar | 5(6)) | 7(10) | |||
| Consultant | 4(4) | 2(3) | |||
| Role | Nurse | 76(86) | 58(84) | x2 = 0.164, df = 1, p = 0.69 | |
| Doctor | 12(14) | 11(16) | |||
| Current employment type | Full Time | 64(73) | 47(69) | x2 = 1.154, df = 3, p = 0.76 | |
| Part Time | 22(25) | 20(29) | |||
| Casual/Other | 2(2) | 1(1) | |||
| Highest level of education | Hospital Certificate | 3(4) | x2 = 7.35, df = 8, p = 0.499 | ||
| Associate Diploma/Diploma | 8(9) | 2(3) | |||
| Bachelors Degree | 39(44) | 28(41) | |||
| Graduate Certificate | 21(24) | 20(29) | |||
| Graduate Diploma | 6(7) | 9(13) | |||
| Masters Degree | 8(9) | 8(12) | |||
| PhD | 1(1) | 1(1) | |||
| Other | 2(2) | 1(1) | |||
| Enrolled in higher degree study^ | Yes | 25(29) | 13(20) | x2 = 1.642, df = 1, p = 0.20 | |
| Level of higher degree study enrolled in^ | [n = 25] | [n = 13] | x2 = 3.562, df = 4, p = 0.47 | ||
| Graduate Certificate/Diploma | 14(56) | 6(50) | |||
| Masters Degree by coursework | 5(20) | 4(33) | |||
| PhD | 2(8) | 2(17) | |||
| Other | 4(16) | ||||
| mean(SD) | range | mean(SD) | range | ||
| Years employed in current unit^ | 5.09(6.09) | 3 weeks to 38 yrs | 4.61(4.57) | 1 month to 18 yrs | t = 0.561, df = 151.63, p = 0.576 |
| Years of ICU experience | 7.03(6.55) | 3 weeks to 38 yrs | 6.58(5.70) | 1 month to 21 yrs | t = 0.457, df = 153.24, p = 0.649 |
| Wheeze | Asthma | Eczema | Rhinoconjunctivitis | ||||||
| N | n | % | n | % | n | % | n | % | |
| Smoking status | |||||||||
| Never | 1182 | 105 | 8.9% | 58 | 4.9% | 146 | 12.4% | 302 | 25.6% |
| Former | 503 | 65 | 12.9% | 31 | 6.2% | 72 | 14.3% | 133 | 26.4% |
| Current | 58 | 12 | 20.7% | 7 | 12.1% | 8 | 13.8% | 17 | 29.3% |
| Pack-years of smoking | |||||||||
| None | 1182 | 105 | 8.9% | 58 | 4.9% | 146 | 12.4% | 302 | 25.6% |
| 0.05-3.9 | 262 | 27 | 10.3% | 11 | 4.2% | 36 | 13.7% | 68 | 26.0% |
| ≥ 4.0 | 299 | 50 | 16.7% | 27 | 9.0% | 44 | 14.7% | 82 | 27.4% |
| Growth Variable | Exclusively Breastfed (n = 62) | Exclusively Formula Fed (n = 12) | Solid Foods with Partial Breastfeeding (n = 57) | Solid Foods with Formula Feeding (n = 23) |
| Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD | |
| Weight (kg) | ||||
| At birth | 3.8 ± 0.4 | 3.8 ± 0.4 | 3.7 ± 0.4 | 3.7 ± 0.3 |
| 2 months | 5.6 ± 0.6 | 5.5 ± 0.7 | 5.8 ± 0.5 | 5.4 ± 0.4 |
| 6 months | 7.8 ± 0.8 | 8.2 ± 1.0 | 8.2 ± 1.0 | 8.5 ± 0.8 * |
| 2 months | 9.6 ± 0.9 | 10.3 ± 1.4 | 10.1 ± 1.2 * | 10.6 ± 1.0 * |
| 18 months | 11.3 ± 1.0 | 11.5 ± 1.2 | 11.6 ± 1.3 | 11.9 ± 1.2 * |
| Length (cm) | ||||
| At birth | 51.9 ± 1.5 | 52.0 ± 1.7 | 51.8 ± 1.6 | 51.7 ± 1.9 |
| 2 months | 59.7 ± 1.5 | 59.4 ± 1.8 | 59.8 ± 2.0 | 58.9 ± 1.5 |
| 6 months | 68.3 ± 2.0 | 69.4 ± 2.7 | 69.1 ± 2.3 * | 68.4 ± 1.7 |
| 12 months | 76.2 ± 2.5 | 77.4 ± 2.9 | 77.1 ± 2.7 | 77.6 ± 2.5 * |
| 18 months | 83.0 ± 2.5 | 83.8 ± 3.2 | 83.9 ± 2.7 | 83.1 ± 2.5 |
| NSCLC cases (n = 34) | Controls (n = 30) | P-value | |
| Age | 67.56 (SD 11.12) | 64.48 (SD 11.25) | 0.33 |
| Sex | 0.35 | ||
| Female | 10 | 9 | |
| Male | 24 | 21 | |
| Race | 0.39 | ||
| White | 22 | 20 | |
| African American | 11 | 10 | |
| Pack-years (median) | 34.28 | 31.36 | 0.32 |
| Stage | |||
| Stage I | 10 | ||
| Stage II | 9 | ||
| Stage III-IV | 15 | ||
| Histological type | |||
| Adenocarcinoma | 21 | ||
| Squamous cell carcinoma | 13 |
| Percentile threshold | Number of ET SNPs | Number of ET genes | Number of diseases appropriately distributed among ET populations | Number of ET genes associated with appropriately distributed diseases | Permutation P value |
| 95th/5th | 22 | 33 | 6 | 4 | 0.0237 |
| 90th/10th | 168 | 230 | 27 | 15 | 0.0111 |
| 85th/15th | 733 | 971 | 42 | 49 | 0.0023 |
| Feature | Univariate | Multivariate | ||
| Hazard ratio (95% CI) | P | Hazard ratio (95% CI) | P | |
| Age (y) ≥ 45 vs < 45 | 1.213 (0.782–1.883) | 0.388 | ||
| Gender F VSM | 0.781 (0.109–5.613) | 0.806 | ||
| Smoking status Present vs Absent | 0.967 (0.498–1.876) | 0.921 | ||
| Drinking status Present vs Absent | 0.760 (0.478–1.208) | 0.245 | ||
| Pathological differentiation | 0.023 | |||
| Highly | 1.000 | |||
| Moderately | 1.767 (1.071–2.914) | 0.026 | ||
| Poorly | 2.253 (1.187–4.276) | 0.013 | ||
| Site Non-glottic va Glottic | 0.641 (0.412–0.995) | 0.047 | ||
| T stage | < 0.001 | |||
| T1+T2 | 1.000 | |||
| T3 | 2.415 (1.427–4.087) | 0.001 | ||
| T4 | 2.989 (1.744–5.125) | < 0.001 | ||
| N stage | < 0.001 | < 0.001 | ||
| N0 | 1.000 | 1.000 | ||
| N1 | 2.044 (1.163–3.592) | 0.013 | 1.961 (1.115–3.451) | < 0.001 |
| N2 | 3.862 (2.129–7.007) | < 0.001 | 3.027 (1.659–5.522) | 0.019 |
| CISd2 High vs Low | 3.761 (2.280–6.203) | < 0.001 | 3.318 (2.030–5.425) | < 0.001 |
| Item | 1. Understood | 2. Sufficient information | 3. Active management | 4. Social support | 5. Appraisal | 6. Active engagement | 7. Navigate | 8. Good information | 9. Understand information |
| P1Q2 | 0.83 | ||||||||
| P1Q8 | 0.93 | ||||||||
| P1Q17 | 0.53 | 0.17 | −0.10 | ||||||
| P1Q22 | 0.86 | ||||||||
| P1Q1 | 0.39 | ||||||||
| P1Q10 | 0.65 | ||||||||
| P1Q14 | 0.92 | ||||||||
| P1Q23 | 0.88 | ||||||||
| P1Q6 | 0.72 | ||||||||
| P1Q9 | 0.78 | ||||||||
| P1Q13 | 0.92 | ||||||||
| P1Q18 | 0.81 | ||||||||
| P1Q21 | 0.96 | ||||||||
| P1Q3 | 0.18 | 0.55 | |||||||
| P1Q5 | 0.68 | ||||||||
| P1Q11 | 0.93 | ||||||||
| P1Q15 | 0.70 | ||||||||
| P1Q19 | 1.02 | ||||||||
| P1Q4 | 0.76 | ||||||||
| P1Q7 | 0.78 | ||||||||
| P1Q12 | 0.86 | ||||||||
| P1Q16 | 0.19 | 0.47 | 0.09 | 0.09 | 0.09 | ||||
| P1Q20 | 0.15 | 0.48 | |||||||
| P2Q2 | 0.71 | ||||||||
| P2Q4 | 0.78 | ||||||||
| P2Q7 | 0.75 | ||||||||
| P2Q15 | 0.77 | ||||||||
| P2Q20 | 0.83 | ||||||||
| P2Q1 | 0.68 | ||||||||
| P2Q8 | 0.88 | −0.13 | |||||||
| P2Q11 | 0.89 | ||||||||
| P2Q13 | 0.78 | ||||||||
| P2Q16 | 0.57 | ||||||||
| P2Q19 | −0.16 | 0.62 | |||||||
| P2Q3 | 0.86 | ||||||||
| P2Q6 | 0.14 | 0.84 | |||||||
| P2Q10 | 0.92 | ||||||||
| P2Q14 | 0.22 | 0.40 | 0.29 | ||||||
| P2Q18 | −0.16 | 0.22 | 0.41 | 0.20 | |||||
| P2Q5 | 0.14 | 0.14 | 0.63 | ||||||
| P2Q9 | 0.15 | 0.17 | 0.15 | 0.22 | |||||
| P2Q12 | 0.08 | 0.83 | |||||||
| P2Q17 | 0.76 | ||||||||
| P2Q21 | 0.25 | 0.25 | 0.36 |
| Characteristic | n = 15 |
| GENDER | |
| Male | 14 |
| Female | 1 |
| AGE (YEARS) | |
| Mean | 60 ± 6.8 |
| Range | 52–74 |
| BASELINE MEDICINE USE | |
| Mean duration (years) | 2.2 ± 1.4 |
| Mean l-DOPA equivalents (mg/day) | 451 ± 304 |
| BASELINE UPDRS SCORE | |
| Mean total | 39 ± 14 |
| Mean UPDRS-III | 15 ± 8.5 |
| Fear | Attraction | ||
| Call | No call | Total | |
| Suspension bridge | 9 | 9 | 18 |
| Solid bridge | 2 | 14 | 16 |
| Total | 11 | 23 | 34 |
| Vaccine | Sample time-point | SCR/booster SCR† | SPR | ||
| n/N; % (95% CI) | n/N; % (95% CI) | ||||
| Primary strain | Booster strain | Primary strain | Booster strain | ||
| AS03A-H5N1 | Day 0 | – | – | 15/933; 1.6 | 1/933; 0.1 |
| (0.9, 2.6) | (0.0, 0.6) | ||||
| Day 21 | 393/925; 42.5 | 24/925; 2.6 | 412/925; 44.5 | 27/925; 2.9 | |
| (39.3, 45.7) | (1.7, 3.8) | (41.3, 47.8) | (1.9, 4.2) | ||
| Day 42 | 866/924; 93.7 | 464/924; 50.2 | 871/924; 94.3 | 464/924; 50.2 | |
| (92.0, 95.2) | (46.9, 53.5) | (92.6, 95.7) | (46.9, 53.5) | ||
| Heterologous booster | Month 6 | – | – | 103/251; 41.0 | 9/251; 3.6 |
| (34.9, 47.4) | (1.7, 6.7) | ||||
| Month 6 + 21 | 233/256; 91.0† | 241/256; 94.1† | 242/251; 96.4 | 238/251; 94.8 | |
| (86.8, 94.2) | (90.5, 96.7) | (93.3, 98.3) | (91.3, 97.2) | ||
| Non-adjuvanted-H5N1 | Day 0 | – | – | 5/236; 2.1 | 0/236; 0.0 |
| (0.7, 4.9) | (0.0, 1.6) | ||||
| Day 21 | 8/234; 3.4 | 0/234; 0.0 | 16/234; 6.8 | 0/234; 0.0 | |
| (1.5, 6.6) | (0.0, 1.6) | (4.0, 10.9) | (0.0, 1.6) | ||
| Day 42 | 13/234; 5.6 | 1/234; 0.4 | 24/234; 10.3 | 1/234; 0.4 | |
| (3.0, 9.3) | (0.0, 2.4) | (6.7, 14.9) | (0.0, 2.4) | ||
| Heterologous booster | Month 6 | – | – | 4/224; 1.8 | 0/224; 0.0 |
| (0.5, 4.5) | (0.0, 1.6) | ||||
| Month 6 + 21 | 112/228; 49.1† | 106/228; 46.5† | 120/223; 53.8 | 105/223; 47.1 | |
| (42.5, 55.8) | (39.9, 53.2) | (47.0, 60.5) | (40.4, 53.9) | ||
| Month 6 + 42 | 173/228; 75.9† | 189/228; 82.9† | 180/228; 78.9 | 189/228; 82.9 | |
| (69.8, 81.3) | (77.4, 87.5) | (73.1, 84.1) | (77.4, 87.5) |
| Bacteria spp. | Specimen | Total | ||||
| Aspirate | Blood | Pus swab | Sputum | Urine | ||
| K. pneumoniae | 1 | 23 | 28 | 0 | 24 | 76 |
| E. coli | 1 | 8 | 31 | 1 | 15 | 56 |
| P. aeruginosa | 1 | 16 | 22 | 0 | 2 | 41 |
| C. freundii | 0 | 1 | 8 | 0 | 6 | 15 |
| A. baumannii | 0 | 2 | 8 | 0 | 0 | 10 |
| P. vulgaris | 0 | 0 | 7 | 0 | 0 | 7 |
| E. cloacae | 0 | 3 | 0 | 0 | 2 | 5 |
| M. morganii | 0 | 0 | 2 | 0 | 1 | 3 |
| P. mirabilis | 0 | 0 | 1 | 0 | 1 | 2 |
| S. marcescens | 0 | 2 | 4 | 0 | 3 | 9 |
| Salmonella typhi | 0 | 0 | 0 | 0 | 1 | 1 |
| Salmonella spp. | 0 | 0 | 1 | 0 | 1 | 2 |
| Total | 3 | 55 | 112 | 1 | 56 | 227 |
| SUV 2.0 | SUV 2.5 | r | P | |||
| Range | Mean ± SD | Range | Mean ± SD | |||
| SUVmax | 3.85-43.1 | 13.2 ± 6.74 | 3.85-43.1 | 13.2 ± 6.74 | 1 | .000 |
| SUVmean | 2.44-11.0 | 5.06 ± 1.66 | 3.00-12.4 | 5.71 ± 1.79 | .997 | <.001 |
| MTV | 5.77-204 | 42.1 ± 46.8 | 1.74-178 | 33.9 ± 39.5 | .989 | <.001 |
| COV | .188-.933 | .513 ± .144 | .132-.839 | .438 ± .138 | .996 | <.001 |
| Entropy | 4.58-7.52 | 6.53 ± .76 | 4.10-7.56 | 6.38 ± .84 | .996 | <.001 |
| Correlation | .032-.555 | .255 ± .159 | -.126-.515 | .189 ± .152 | .963 | <.001 |
| Contrast | 13.3-411 | 234 ± 110 | 12.2-395 | 226 ± 105 | .990 | <.001 |
| Busyness | .432-.708 | .557 ± .071 | .370-.692 | .544 ± .072 | .933 | <.001 |
| Coarseness | .007-.104 | .044 ± .025 | .009-.158 | .050 ± .029 | .813 | <.001 |
| 8 Gy × 1N patients (%) | 4 Gy × 5N patients (%) | |
| Age | ||
| ≤65 years (N = 78) | 39 (50) | 39 (50) |
| ≥66 years (N = 78) | 39 (50) | 39 (50) |
| Gender | ||
| Female (N = 36) | 18 (23) | 18 (23) |
| Male (N = 120) | 60 (77) | 60 (77) |
| ECOG Performance status | ||
| 1–2 (N = 26) | 13 (17) | 13 (17) |
| 3–4 (N = 130) | 65 (83) | 65 (83) |
| Type of primary tumor | ||
| Breast cancer (N = 12) | 6 (8) | 6 (8) |
| Prostate cancer (N = 36) | 18 (23) | 18 (23) |
| Myeloma/lymphoma (N = 0) | 0 (0) | 0 (0) |
| Lung cancer (N = 46) | 23 (29) | 23 (29) |
| Unknown primary (N = 32) | 16 (21) | 16 (21) |
| Other tumors (N = 30) | 15 (19) | 15 (19) |
| Involved vertebrae (n) | ||
| 1–2 (N = 34) | 17 (22) | 17 (22) |
| ≥3 (N = 122) | 61 (78) | 61 (78) |
| Other bone metastases | ||
| No (N = 34) | 17 (22) | 17 (22) |
| Yes (N = 122) | 61 (78) | 61 (78) |
| Visceral metastases | ||
| No (N = 36) | 18 (23) | 18 (23) |
| Yes (N = 120) | 60 (77) | 60 (77) |
| Interval from tumor diagnosis to MESCC | ||
| ≤ 15 months (N = 136) | 68 (87) | 68 (87) |
| > 15 months (N = 20) | 10 (13) | 10 (13) |
| Pre-RT ambulatory status | ||
| Not ambulatory (N = 110) | 55 (71) | 55 (71) |
| Ambulatory (N = 46) | 23 (29) | 23 (29) |
| Time developing motor deficits | ||
| 1–7 days (N = 110) | 55 (71) | 55 (71) |
| 8–14 days (N = 30) | 15 (19) | 15 (19) |
| > 14 days (N = 16) | 8 (10) | 8 (10) |
| Characteristics | Placebo (n = 59) | NAC (n = 55) |
| Age (years) | 78.2 ±11.8 | 78.1 ± 12.0 |
| Sex (M/F) | 29/30 | 28/27 |
| BMI (kg/m2) | 24.4 ± 4.6 | 25.0 ± 4.8 |
| Diabetes | 11 (19%) | 15 (27%) |
| Blood pressure (mmHg) | ||
| Diastolic | 69.1 ± 11.7 | 67.0 ± 17.2 |
| Systolic | 129.5 ± 20.8 | 132.9 ± 22.5 |
| Contrast medium (mL) | 117.7 ± 3.2 | 117.4 ± 1.8 |
| Creatinine (μmol/L) | 133.5 ± 34.8 | 132.4 ± 34.8 |
| Cystatin C (mg/L) | 1.9 ± 0.5 | 1.9 ± 0.6 |
| eGFR (MDRD) (ml/min/1.73) | 41.7 ± 1.2 | 42.7 ± 1.2 |
| Antibiotics | 16 (27%) | 16 (29%) |
| Angiotensin-converting enzyme inhibitor (ACE-1 inhibitor) | 28 (48%) | 25 (45%) |
| Non-steroidal antiinflammatory drugs (NSAIDS) | 1 (2%) | 5 (9%) |
| Diuretics | 27 (46%) | 25 (45%) |
| Sample type | Herd A | Herd B |
| Peat | na | 20 |
| Water | 1 | 1 |
| Sawdust | 20 | 20 |
| Faeces from sows | 15 | 17 |
| Faeces at 6 weeks of age | 95 | 146 |
| Faeces at 8 weeks of age | 95 | 164 |
| Mandibular lymph nodes | 95 | 123 |
| Jejunal lymph nodes | nd | 127 |
| Knowledge | Lecture method | Blended method | ||||
| Low (<10) | Average (11-15) | High (16-20) | Low (<10) | Average (11-15) | High (16-20) | |
| Pre-test (%) | 2 (4.5) | 43 (95.5) | 0 | 1 (2.1) | 47 (97.9) | 0 |
| Post-test (%) | 0 | 5 (11.1) | 40 (88.9) | 0 | 4 (8.3) | 44 (91.7) |
| n | % | |
| Prevention of postpartum hemorrhage | ||
| Target population: women giving birth in health facilities | 132 | 100.00% |
| Oxytocin | 114 | 86.36% |
| Any uterotonic (including oxytocin) | 115 | 87.12% |
| Treatment of severe postpartum hemorrhage | ||
| Target population: women with severe PPH | 84 | 100.00% |
| Oxytocin | 57 | 67.86% |
| Ergometrine | 52 | 61.90% |
| Misoprostol | 35 | 41.67% |
| Other uterotonics | 3. | 3.57% |
| Any of the above uterotonics | 57 | 67.86% |
| Tranexamic acid | 6 | 7.14% |
| Removal of retained products | 16 | 19.05% |
| Balloon or condom tamponade | 1. | 1.19% |
| Artery ligation | 4 | 4.76% |
| Hysterectomy | 50 | 59.52% |
| Abdominal packing | 4 | 4.76% |
| Proportion of cases with SMO | 80 | 95.24% |
| Mortality | 6. | 7.14% |
| Anticonvulsants for Eclampsia | ||
| Target population: women with eclampsia | 43 | 100.00% |
| Magnesium sulfate | 29 | 67.44% |
| Other anticonvulsant | 22 | 51.16% |
| Any anticonvulsant | 40 | 93.02% |
| Proportion of cases with SMO | 26 | 60.47% |
| Mortality | 4 | 9.30% |
| Prevention of caesarean section related infection | ||
| Target population: women undergoing caesarean section | 107 | 100.00% |
| Prophylactic antibiotic during caesarean section | 65 | 60.75% |
| Treatment for sepsis | ||
| Target population: women with sepsis | 10 | 100.00% |
| Parenteral therapeutic antibiotics | 10 | 100.00% |
| Proportion of cases with SMO | 6 | 60.00% |
| Mortality | 2 | 20.00% |
| Ruptured uterus | ||
| Target population: women with ruptured uterus | 29 | 100.00% |
| Laparotomy | 28 | 96.55% |
| Laparotomy after 3 hours of hospital stay | 5 | 17.24% |
| Proportion of cases with SMO | 24 | 82.76% |
| Mortality | 3 | 10.34% |
| Preterm birth | ||
| Target population: women having a preterm delivery after 3 hours of hospital stay | 18 | 100.00% |
| Corticosteroids for fetal lung maturation | 10 | 55.56% |
| Year | Centro Hospitalar Tondela-Viseu | National data (NationalTransplantation Coordination)(9) | ||||||
| Effective donorsn (%) | Mean age (years) | Harvested organsn (%) | Number of organs per donor | Effective donorsn | Mean age (years) | Harvested organsn | Number of organs per donor | |
| 2015 | 19 (6.0)* | 58.6 | 59 (6.6)† | 3.1 | 318 | 54.2 | 894 | 2.8 |
| 2014 | 20 (6.9)* | 58.8 | 59 (7.1)† | 3.0 | 289 | 51.4 | 0.83 | 2.9 |
| 2013 | 12 (4.1)* | 61.2 | 31 (3.6)† | 2.6 | 295 | 53.7 | 859 | 2.9 |
| 2012 | 12 (4.8)* | 66.2 | 30 (4.0)† | 2.5 | 252 | 53.3 | 749 | 3.0 |
| 2011 | 16 (5.3)* | 56.6 | 46 (5.0)† | 2.9 | 301 | 48.7 | 928 | 3.1 |
| 2010 | 5 (1.5)* | 57.4 | 11 (1.2)† | 2.2 | 323 | 51.3 | 0.83 | 2.9 |
| Total | 84 (4.7)* | 59.7 | 236 (4.5)† | 2.8 | 1,778 | 52.1 | 5,187 | 2.9 |
| Characteristic | Control mean (SD) or n (%) | Intervention mean (SD) or n (%) | Total mean (SD) or n (%) |
| Female | 128 (76 %) | 123 (72 %) | 251 (74 %) |
| Male | 41 (24 %) | 48 (38 %) | 89 (26 %) |
| Age, years | 81 (8) | 82 (8) | 81 (8) |
| Weight loss ≥ 5 % body weight | 23 (14 %) | 16 (9 %) | 39 (12 %) |
| Co-morbidities, number | 6.9 (2.7) | 7.2 (2.9) | 7.1 (2.8) |
| History of falls | 52 (31 %) | 48 (28 %) | 100 (29 %) |
| Falls as the presenting problem to hospital | 67 (40 %) | 76 (44 %) | 143 (42 %) |
| Length of original hospital stay* | 9 (12) | 11 (15) | 10 (13) |
| Living in low-care residential facility | 12 (7 %) | 8 (5 %) | 20 (6 %) |
| ** MMSE score, mean (SD)/30 | 28.0 (1.8) | 27.9 (2.0) | 28.0 (1.9) |
| Characteristic | HSF | AAF | BF |
| Number | 26 | 20 | 11 |
| Sex: | |||
| Female, n (%) | 9 (36) | 11 (52) | 5 (45) |
| Male, n (%) | 17 (64) | 9 (48) | 6 (55) |
| Mean age at T0 (months) | 8.0 ± 0.8 | 5.6 ± 0.6 | - |
| (range) | 2–17 | 2–13 | |
| Mean age at T1 (months) | 12.0 ± 0.8 | 9.4 ± 0.6 | 12.5 ± 1.8 |
| (range) | 6–21 | 6–17 | 8–25 |
| Mode of birth: | |||
| Cesarean, n (%) | 23 (89) ** | 19 (97) ** | 3 (27) |
| Vaginal, n (%) | 3 (11) ** | 1 (3) ** | 8 (73) |
| Birth weight (g) | 3122 ± 56 | 3115 ± 41 | 3158 ± 88 |
| Length at birth (cm) | 47.9 ± 0.4 | 47.9 ± 0.9 | 47.8 ± 0.6 |
| Exclusive breastfeeding (months) | 2.7 ± 0.5 * | 2.4 ± 0.4 * | 4.9 ± 0.3 |
| Maternal age (years) | 29.3 ± 1.5 | 30.5 ± 1.7 | 26.3 ± 0.9 |
| Maternal education: | |||
| High school, n (%) | 8 (30) ** | 8 (40) ** | 100 (11) |
| College, n (%) | 19 (70) ** | 12 (60) ** | 0 (0) |
| Sheep | Pig | ||||
| thickness | 10 mm | 6 mm | 5 mm | 7.5 mm | 5 mm |
| n = | 35 | 12 | 121 | 38 | 17 |
| Vtotal (ml) | 16.0 (-60.7 to 92.8) | 25.1 (48.0 to 98.2) | 18.4 (-57.5 to 94.4) | 3.0 (-57.0 to 63.0) | 9.6 (-52.2 to 71.4) |
| Vnon (%) | -0.1 (-0.9 to 0.8) | -0.1 (-0.4 to 0.3) | 0.0 (-0.4 to 0.4) | 0.0 (-1.2 to 1.2) | 0.0 (-0.4 to 0.5) |
| Vpoor (%) | -0.5 (-2.6 to 1.6) | -0.2 (-0.8 to 0.3) | -0.1 (-0.9 to 0.7) | 0.2 (-1.6 to 2.0) | -0.2 (-1.5 to 1.2) |
| Vnormal (%) | 0.6 (-1.8 to 3.0) | 0.3 (-0.4 to 1.0) | 0.1 (-0.9 to 1.1) | -0.2 (2.0 to 1.7) | -0.2 (1.2 to 1.5) |
| Vhyper (%) | 0.0 (-0.2 to 0.3) | 0.0 (-0.1 to 0.1) | 0.0 (-0.6 to 0.6) | 0.0 (-0.1 to 0.1) | -0.1 (-0.7 to 0.6) |
| Mtotal (g) | 3.9 (-23.4 to 31.2) | 4.7 (-19.3 to 28.8) | 4.2 (-21.8 to 30.3) | 1.9 (-32.7 to 36.5) | 1.0 (-34.4 to 36.5) |
| Mnon (%) | -0.1 (-1.5 to 1.4) | -0.2 (1.1 to 0.7) | 0.1 (1.0 to 1.1) | -0.1 (-1.3 to 1.2) | 0.1 (-1.2 to 1.4) |
| Mpoor (%) | -0.5 (-2.5 to 1.6) | -0.4 (-1.4 to 0.6) | 0.1 (-1.5 to 1.2) | 0.2 (-1.7 to 2.2) | -0.1 (-1.8 to 1.7) |
| Mnormal (%) | 0.5 (-1.5 to 2.5) | -0.6 (-0.8 to 1.9) | 0.1 (-1.5 to 1.7) | -0.2 (-2.0 to 1.7) | 0.0 (-1.6 to 1.5) |
| Mhyper (%) | 0.0 (-0.1 to 0.1) | 0.0 (0.0 to 0.0) | 0.0 (-0.2 to 0.2) | 0.0 (-0.1 to 0.1) | 0.0 (-0.3 to 0.3) |
| Vgas (ml) | 12.1 (-42.8 to 67.0) | 20.4 (-32.6 to 73.4) | 14.2 (-46.3 to 74.7) | 1.2 (-37.3 to 39.6) | 8.5 (-30.2 to 47.2) |
| Variables | B. tabaci B (p Value) 1 | B. tabaci Q (p Value) | ||||
| Sex | Virus | Sex * Virus | Sex | Virus | Sex * Virus | |
| Non-phloem variables | ||||||
| A, duration of 1st probe (min) | 0.522 | 0.776 | 0.511 | 0.447 | 0.153 | 0.111 |
| B, total number of C 3 (#) | 0.267 | 0.057 | 0.533 | 0.730 | 0.373 | 0.237 |
| C, total duration of C (min) | 0.237 | 0.764 | 0.262 | 0.024 | 0.127 | 0.983 |
| D, total duration of np (min) | 0.016 | 0.591 | 0.006 | 0.003 | 0.166 | 0.111 |
| E, total number of pd (#) | 0.024 | <0.001 | 0.004 | 0.45 | 0.043 | 0.802 |
| F, time to 1st E from 1st probe (min) | 0.550 | 0.014 | 0.036 | 0.085 | <0.001 | 0.906 |
| G, total number of probes before 1st E (#) | 0.747 | 0.060 | 0.580 | 0.160 | 0.082 | 0.396 |
| H, Time to 1st E (min) | 0.453 | 0.005 | 0.041 | 0.202 | <0.001 | 0.657 |
| Phloem variables | ||||||
| I, total duration of 1st E1 (min) | 0.721 | 0.558 | 0.135 | 0.978 | 0.347 | 0.580 |
| J, total number of E1 (#) | 0.558 | 0.110 | 0.335 | 0.006 | 0.001 | 0.084 |
| K, total duration of E1 (min) | 0.950 | 0.762 | 0.488 | 0.484 | 0.001 | 0.146 |
| L, total number of E2 (#) | 0.361 | 0.026 | 0.246 | 0.019 | <0.001 | 0.006 |
| M, total duration of E2 (min) | 0.006 | 0.061 | 0.005 | 0.989 | <0.001 | 0.003 |
| N, total number of E1 after 1st E2 (#) | 0.655 | 0.049 | 0.279 | 0.031 | 0.001 | 0.094 |
| O, total duration of E1 after 1st E2 (min) | 0.493 | 0.575 | 0.351 | 0.116 | 0.007 | 0.049 |
| P, percentage of E (%) 2 | 0.235 | 0.302 | 0.319 | 0.189 | <0.001 | 0.231 |
| Body Point | Body Side | Localization |
| Foot | bilaterally | Basis Metatarsales V |
| Ankle | bilaterally | Malleolus lateralis |
| Knee | bilaterally | Epicondylus lateralis femoris |
| Hip | bilaterally | Trochanter major |
| Elbow | bilaterally | Epicondylus lateralis humeri |
| Shoulder | bilaterally | Acromio-clavicular join |
| Wrist | bilaterally | Os capitatum |
| Type of surgery | Number of cases(n = 128) | Surgeons’ experience in years | |
| ≤5(n = 44) | >5(n = 84) | ||
| Level 1* | 27 (21.1%) | 11 (25.0%) | 16 (19.0%) |
| Level 2† | 60 (46.9%) | 20 (45.5%) | 40 (47.6%) |
| Level 3‡ | 41 (32.0%) | 13 (29.5%) | 28 (33.3%) |
| Patient medication and outcome | ||||||||
| Type | n | LEV | VPA(−/+) | Na+ channel(−/+) | mTOR(−/+) | GABAR(−/+) | other AEDs(−/+) | post OP outcomeWieser (1a/1/2/3/4/5) |
| TSC | 8 | 1:7 | 4:4 | 2:6 | 6:2 | 2:6 | 1:7 | 3/1/1/2/1/0 |
| MMCD | 6 | 0:6 | 0:6 | 0:6 | 6:0 | 2:4 | 1.5 | 1/1/0/0/1/3 |
| FCD IIA | 6 | 4:2 | 5:1 | 0:6 | 6:0 | 5:1 | 3:3 | 2/1/0/0/1/2 |
| FCD IIB | 22 | 6:13* | 7:12* | 2:17* | 19:0* | 8:11* | 7:12* | 13/4/0/1/0/1* |
| Total | 42 | 13:28 | 16:23 | 4:35 | 37:2 | 17:22 | 12:27 | 19/8/1/3/3/6 |
| pilE | No. isolates | No. countries | Years | No. ccs | No. alleles |
| Class I | 219 | 5 | 1963-2011 | 21 + n/a | 219 |
| Class II | 77 | 29 | 1937-2011 | 6 | 15 |
| Characteristic | Baseline value |
| Age (years) | 48.63 (± 13.5) |
| Ethnicity | |
| White | 125 (46.99%) |
| Hispanic | 77 (28.95%) |
| African American | 54 (20.3%) |
| Other | 10 (3.76%) |
| Female sex | 221 (83.08%) |
| Current smoker | 49 (18.42%) |
| Ever smoker | 134 (50.38%) |
| Disease duration (years)a | 2.53 (± 1.63) |
| Limited skin involvement | 110 (41.35%) |
| Autoantibodies | |
| Antinuclear antibodies | 254 (95.49%) |
| Anti-centromere antibodies | 32 (12.03%) |
| Anti-topoisomerase antibodies | 49 (18.42%) |
| Anti-RNA polymerase III | 61 (22.93%) |
| Anti-U1-ribonucleoprotein | 30 (11.28%) |
| Anti-Ro | 10 (3.8%) |
| Anti-fibrillarin | 28 (10.69%) |
| Percentage predicted forced vital capacity | |
| > 80% | 132 (58.15%) |
| 50 to 80% | 81 (35.68%) |
| < 50% | 14 (6.17%) |
| Group 2 | Group 4 | P value | |
| Number | 59 | 154 | |
| Age | 63 ± 5 | 58 ± 3 | 0.08 |
| Sex (m:f) | 35:24 | 87:67 | |
| Weight | 79 ± 7 | 76. ± 6 | 0.16 |
| Hb | 121 ± 3 | 120 ± 3 | 0.57 |
| PT | 10.8 ± 4 | 10.7 ± 1 | 0.56 |
| INR | 1 ± 3 | 1 ± 3 | 0.53 |
| Creatinine | 140 ± 3 | 129 ± 3 | 0.97 |
| Distal tibia | Talus | |||||||
| Left | Right | Left | Right | |||||
| OARSI | n | % | n | % | n | % | n | % |
| 0 | 9 | 11.3 | 12 | 15.0 | 18 | 22.5 | 12 | 15.0 |
| 1 | 37 | 46.3 | 33 | 41.3 | 35 | 43.8 | 32 | 40.0 |
| 2 | 26 | 32.5 | 26 | 32.5 | 17 | 21.3 | 21 | 26.3 |
| 3 | 5 | 6.3 | 7 | 8.8 | 6 | 7.5 | 11 | 13.8 |
| 4 | 1 | 1.3 | 1 | 1.3 | 3 | 3.8 | 3 | 3.8 |
| 5 | 2 | 2.5 | 0 | 0.0 | 0 | 0.0 | 1 | 1.3 |
| 6 | 0 | 0.0 | 1 | 1.3 | 1 | 1.3 | 0 | 0.0 |
| Characteristic | n = 432 | (%) |
| Age group (years) | ||
| 6–9 | 93 | 21.5 |
| 10–14 | 339 | 78.5 |
| Sex | ||
| Female | 224 | 51.9 |
| Male | 208 | 48.1 |
| Location of school | ||
| Rural | 203 | 47.0 |
| Urban slums | 229 | 53.0 |
| Ownership of school | ||
| Public | 217 | 50.2 |
| Private | 215 | 49.8 |
| Cardiac enzymes | Case1 | Case2 | ||||
| 1st set | 2nd set | 3rd set | 1st set | 2nd set | 3rd set | |
| CPK (35–230 IU/L) | 2176 | 2174 | 4895 | 271 | 481 | 365 |
| CK-MB (0.0–5.0 ng/mL) | 55.5 | 40 | 9.7 | 29.4 | 56.5 | 23.8 |
| Troponin (0.00–0.03 ng/mL) | 2.22 | 1.3 | 0.31 | 1.73 | 9.57 | 6.74 |
| Myoglobin (0–450 pg/mL) | 467 | 139 | 287 | 79 | 55 | 19 |
| Odds ratio estimates (95% confidence interval) | |||
| CRM | N-CPAP | MV | |
| Gest. age, weeks 39–40–41 | 1 | 1 | 1 |
| Gest. age, week 38 | 1.5 (0.9– 2.4) | 2.0 (0.9–4.5) | 0.96 (0.3–3.1) |
| Gest. age, week 37 | 3.3 (2.0–5.5) | 5.1 (2.3–11.4) | 3.4 (1.2–10.0) |
| Gest. age, week 36 | 9.1 (5.1–16.2) | 13.3 (5.5–32.2) | 11.1 (3.2–38.8) |
| Gest. age, week 35 | 21.8 (11.5–41.5) | 34.9 (13.5–90.0) | 18.0 (4.2–77.5) |
| Gest. age, week 34 | 40.8 (19.7 –84.9) | 55.9 (19.3–162.0) | 34.4 (6.7–180.6) |
| Spontaneous delivery | 1 | 1 | 1 |
| CS without labor | 3.0 (2.1–4.2) | 3.7 (2.3–6.0) | 2.9 (1.3–6.3) |
| CS with labor | 2.2 (1.4–3.4) | 2.5 (1.4–4.8) | 2.1 (0.8–5.6) |
| Maternal medical disorders no | 1 | 1 | 1 |
| Maternal medical disorders yes | 1.3 (0.9–1.8) | 1.3 (0.7–1.6) | 1.7 (0.8–3.4) |
| Twins birth no | 1 | 1 | 1 |
| Twins birth yes | 0.9 (0.5–1.4) | 1.0 (0.6–1.7) | 0.3 (0.1–1.3) |
| Birth weight, g | 1.0 (0.98–1.1) | 1.0 (0.9–1.05) | 1.1 (0.98–1.2) |
| Female | 1 | 1 | 1 |
| Male | 1.4 (1.1–1.9) | 1.5 (1.0–2.3) | 1.8 (0.9–3.6) |
| Malformation no | 1 | 1 | 1 |
| Malformation yes | 8.9 (5.3–15.1) | 2.4 (0.9–6.2) | 26.0 (12.5–54.1) |
| Small for gestational age no | 1 | 1 | 1 |
| Small for gestational age yes | 1.0 (0.6–1.8) | 0.6 (0.3–1.3) | 2.6 (0.9–7.9) |
| Alternative therapyModerate protein C deficiency24 μg/kg/hr | Standard therapyModerate protein C deficiency24 μg/kg/hr | |||||
| Duration of study drug infusion | Number of patients | Number of deaths | Percent deaths | Number of patients | Number of deaths | Percent deaths |
| Total | 172 | 43 | 25.0 | 173 | 20 | 11.6 |
| ≥97 hours*† | 71 | 17a | 23.9 | 70 | 8b | 11.4 |
| < 97 hours† | 71 | 20c | 28.2 | 65 | 9d | 13.8 |
| Patients with shorter infusions of DAA ‡ | 30 | 6e | 20.0 | 38 | 3f | 7.9 |
| Factor | ≤ 3visits | ≥ 4visits | *Significance level (χ 2; p-value) | #OR (95% CI) | †OR (95% CI) | P-value | ||
| % (n) | 95% CI | % (n) | 95% CI | |||||
| Age (years) | 7.670; 0.022 | |||||||
| ≤20 | 40.7 (35) | 30.9 – 51.3 | 25.8 (51) | 20.2 – 32.3 | 2.0 (1.2 – 3.4) | 2.0 (1.0 – 4.4) | 0.069 | |
| 21-25 | 34.9 (30) | 25.7 – 45.4 | 36.4 (72) | 30.0 – 43.2 | 0.9 (0.6 – 1.2) | 1.5 (0.7– 3.2) | 0.254 | |
| >25 | 24.4 (21) | 16.6 – 34.5 | 37.9 (75) | 31.4 – 44.8 | REF | |||
| Parity | 0.765;0.682 | |||||||
| Primiparous | 34.1 (30) | 25.0 – 44.4 | 29.2 (58) | 23.3 – 35.8 | 1.3 (0.7 – 2.2) | 1.2 (0.6 – 2.6) | 0.671 | |
| Secundiparous | 28.4 (25) | 20.0 – 38.6 | 29.2 (58) | 23.3 – 35.8 | 1.0 (0.6 – 1.7) | 1.4 (0.7 – 2.8) | 0.327 | |
| Multiparous | 37.5 (33) | 28.1 – 47.9 | 41.7 (83) | 35.1 – 48.7 | REF | |||
| Marital status | 7.693; 0.006 | |||||||
| Unmarried | 35.6 (31) | 26.4 – 46.1 | 20.2 (40) | 15.2 – 26.3 | 2.2 (1.3 – 3.8) | 2.5 (1.3 – 4.6) | 0.006 | |
| Married | 64.4 (56) | 53.9 –73.6 | 79.8 (158) | 73.7 – 84.8 | REF | |||
| Educational level | 3.740; 0.291 | |||||||
| None | 3.8 (3) | 1.2 –10.5 | 7.6 (14) | 4.6 – 12.3 | 0.5 (0.1 – 1.7) | 0.8 (0.1 – 5.1) | 0.827 | |
| Primary | 70.0 (56) | 59.2 – 78.9 | 58.9 (109) | 51.7 – 65.8 | 1.6 (0.9 – 2.9) | 1.4 (0.4 – 5.5) | 0.594 | |
| Secondary | 21.3 (17) | 13.7 – 31.4 | 29.2 (54) | 23.1 – 36.1 | 0.7 (0.4 – 1.2) | 0.8 (0.2 – 3.3) | 0.780 | |
| Tertiary | 5.0 (4) | 2.0 – 12.0 | 4.3 (8) | 2.2 – 8.3 | REF | |||
| Fever history | ||||||||
| Yes | 32.5 (26) | 23.2 – 43.4 | 48.4 (93) | 41.5 – 55.5 | 5.829; 0.016 | 0.5 (0.3 – 0.9) | 0.5 (0.3 – 0.8) | 0.009 |
| No | 67.5 (54) | 56.6 – 76.8 | 51.6 (99) | 44.5 – 58.5 | REF | |||
| IPTp-SP dosage | ||||||||
| one | 70.3 (45) | 58.2 – 80.1 | 39.1 (75) | 32.4 – 46.1 | 18.824; 0.001 | 3.7 (2.0 – 6.8) | NA | |
| Two or more | 29.7 (19) | 19.9 – 41.8 | 60.9 (117) | 53.9 – 67.6 |
| Type | Description | Example |
| Change in environment | The Plan structure, that is the totality of means for satisfying basic needs, does not fit to changes in the environment or to a new environment | An individual with first-episode psychosis is not able to satisfy his need for autonomy within the restricted setting of a secure ward with his usual Plan “Decide on appointments for yourself,” due to a predefined weekly schedule |
| Loss of individual abilities | The means for a purpose (e.g., skills) are no longer available | Neuropsychological deficits accompanying schizophrenia impede studying and block the Plan “graduate” |
| Rigid Plan structure | An important Plan has only a single (or too few) means for its realization | The Plan “Heighten self-esteem” is exclusively realized with the means “Stick to conviction of being loved by Jodie Foster” (erotomanic delusion) |
| Conflicting Plans | The means of a Plan endangers another important Plan | The Plan “Conceal hearing voices” endangers the Plan “Seek help when distressed” |
| Dominance of avoidance Plans | A high number of avoidance Plans reduce the degrees of freedom for realizing approach plans | The Plans “Avoid stress” and “Avoid a new psychotic episode” hinder the approach Plan “Try to make new friends” |
| Function | Direct interaction | |||
| R2TP complex target | Target complex | R2TP complex | R2TP component | Target complex component |
| Confirmed | ||||
| RNA polymerase II | Transcription | Assembly | ? | ? |
| snoRNPs | Biogenesis of ribosomes, spliceosomes, and telomerase | |||
| boxC/D snoRNPs | 2′-O-methylation of preRNA | Assembly | PIH1D1? | NOP58? |
| H/ACA snoRNPs | Pseudouridylation of prerRNA | Assembly | PIH1D1? | NAP57? |
| SMG1 | Nonsense mediated mRNA decay | Assembly | PIH1D1 | TEL2 |
| mTORC1 | Central regulator of cell metabolism | Assembly | PIH1D1 | TEL2 |
| ATM/ATR/DNA-PK | Kinases involved in DNA damage signaling | Possibly assembly | PIH1D1 | TEL2 |
| Potential | ||||
| ECD/p53 | Transcription factor involved in DNA damage response | possibly assembly | PIH1D1 | ECD |
| UBR5 | E3 ubiquitin ligase involved in DNA damage signaling | ? | PIH1D1 | UBR5 |
| INO80 | Chromatin remodeling complex, involved in repair of DNA double strand breaks | Possibly loading RUVBL1/2 | ? | ?, RUVBL1/2 |
| TIP 60 | Chromatin remodeling complex, acetyl-transferase activity important for DNA damage response | Possibly loading RUVBL1/2 | ? | ?, RUVBL1/2 |
| SWI/SCRAP | Chromatin remodeling complex, DNA damage signaling | Possibly loading RUVBL1/2 | ? | ?, RUVBL1/2 |
| Fanconi anemia core complex | Recognition and repair of DNA crosslinks | Possibly loading RUVBL1/2 | ? | ?, RUVBL1/2 |
| Albino | Pigmented | ||||
| m-dRGCs | m-oRGCs | m-dRGCs | m-oRGCs | ||
| A: Total | Melanopsin (n = 6/strain) | 54 ± 12 | 2329 ± 198 | 212 ± 21 | 2216 ± 154 |
| mRGC population (displaced + orthotopic) | 2383 ± 178 | 2428 ± 172 | |||
| B: Ipsilateral | FG+ and melanopsin+ (n = 3–5/strain) | 0.2 ± 0.4 | 64 ± 14 | 12 ± 4 | 89 ± 8 |
| Total ipsilateral m-RGCs (displaced + orthotopic) | 65 ± 14 | 101 ± 8 |
| Group | Number of mice | Wt/Wt(% of total) | Wt/KO(% of total) | KO/KO(% of total) |
| Fetus† | ||||
| Conventional | 28 | 7 (25) | 12 (43) | 9 (32) |
| Cre-loxP | 14 | 2(14) | 8 (57) | 4 (29) |
| Adult§ | ||||
| Conventional | 127 | 40 (32) | 66 (52) | 21 (16)** |
| Cre-loxP | 251 | 126 (50)§§ | 97 (39)‡‡ | 28 (11)§§ |
| Dead§ | ||||
| Conventional | 14 | 0** | 4 (29)‡‡ | 10 (71)§§ |
| Intervention received | ||||
| A | B | C | ||
| n | n | n | ||
| Formal responsibility for doing or managing research in CCG? | Yes, doing and managing | 5 | 2 | 2 |
| Yes, managing | 3 | 3 | 7 | |
| Yes, doing | 1 | 2 | 0 | |
| Neither | 28 | 35 | 17 | |
| Highest educational achievement? | School level | 2 | 0 | 0 |
| Undergraduate | 17 | 27 | 12 | |
| Master’s degree | 14 | 13 | 8 | |
| Higher degree | 3 | 2 | 6 | |
| Clinical qualifications? | No | 16 | 8 | 6 |
| Yes | 21 | 34 | 20 | |
| Worked as a researcher in an academic context | No | 34 | 42 | 24 |
| Yes | 5 | 11 | 13 | |
| Commissioned research | No | 29 | 47 | 32 |
| Yes | 10 | 6 | 5 | |
| Been a co-applicant or advisor on a research project | No | 30 | 44 | 30 |
| Yes | 9 | 9 | 7 | |
| Been employed as a researcher | No | 35 | 49 | 32 |
| Yes | 4 | 4 | 5 |
| Features | Thoughts about using a contraceptive method | χ2 | p | ||
| Yes | No | ||||
| Age | 1.712 | 0.310 | |||
| 17-25 | 60 (33%) | 22 (12.1%) | |||
| 26-34 | 65 (35.7%) | 24 (13.2%) | |||
| 35+ | 6 (3.3%) | 5 (2.7%) | |||
| Level of education | 2.747 | 0.109 | |||
| Primary and below | 63 (34.6%) | 24 (13.2%) | |||
| Secondary | 30 (16.5%) | 14 (7.7%) | |||
| High school/ university | 42 (23.1%) | 9 (4.9%) | |||
| Husband education level | 5.526 | 0.457 | |||
| Primary and below | 43 (23.6%) | 13 (7.2%) | |||
| Secondary | 30 (16.5%) | 17 (9.3%) | |||
| High school/ university | 62 (34.1%) | 17 (9.3%) | 0.097 | ||
| Duration of marriage | 7.897 | ||||
| 0-5 year | 63 (34.6%) | 31 (17.1%) | |||
| 6-10 year | 41 (22.5%) | 14 (7.7%) | |||
| 11 years and over | 28 (15.3%) | 5 (2.8%) | |||
| Number of births | 6.306 | 0.184 | |||
| 0 | 38 (20.9%) | 19 (10.4%) | |||
| 1 | 54 (29.7%) | 15 (8.2%) | |||
| 2 | 27 (14.8%) | 12 (6.6%) | |||
| 3+ | 16 (8.8%) | 1 (0.6%) | |||
| Status of contraceptive use before | 6.514 | 0.004 | |||
| Used | 78 (42.9%) | 14 (7.7%) | |||
| Not-used | 53 (29.1%) | 37 (20.3%) | |||
| Receiving contraception counseling | 7.984 | 0.035 | |||
| Yes | 39 (21.4%) | 5 (2.7%) | |||
| No | 92 (50.5%) | 46 (25.3%) |
| All | Male | Female | |||||||
| Coefficient (β) | t-statistic | P | Coefficient (β) | t-statistic | P | Coefficient (β) | t-statistic | P | |
| Arm circumference (cm) | 0.222 | 2.564 | 0.011 | 0.200 | 2.446 | 0.017 | -0.230 | -2.214 | 0.029 |
| Waist circumference (cm) | 0.183 | 1.605 | 0.110 | -0.227 | -1.656 | 0.102 | 0.100 | 0.876 | 0.383 |
| Hip circumference (cm) | -0.154 | -1.298 | 0.196 | 0.627 | 4.405 | 0.000 | 2.451 | 2.451 | 0.016 |
| Thigh circumference (cm) | -0.149 | -1.352 | 0.178 | 0.056 | 0.465 | 0.643 | -0.029 | -0.248 | 0.805 |
| Calf circumference (cm) | 0.718 | 6.736 | 0.000 | 0.306 | 2.874 | 0.005 | 0.714 | 5.778 | 0.000 |
| Multiple linear regression was used for the analysis, adjusted with each other. |
| Data Source | Total N | Mean # days | Median # days | Max # days | P-value for χ2 |
| Provider | 1878 | 10.5 | 5 | 375 | Reference |
| Faxed-LR | 1142 | 3.6 | 2 | 367 | <0.0001 |
| HIE-ELR | 7393 | 2.0 | 1 | 320 | <0.0001 |
| Any Laboratorya | 8535 | 2.2 | 1 | 367 | <0.0001 |
| RF | MSNODmax | NAR | |
| Training | 171 | 171 | 171 |
| Evaluation | 16 + 2 parents | 15 + 2 parents | 9 + 2 parents |
| SNP | Gene | Alleles* | PV MAF (n=38) | ET MAF (n=74†) | MF MAF (n=9) | PV vs. ET | PV vs. MF | ET vs. MF | PV vs. ET vs. MF | |||
| P value | OR (95% CI) | P value | OR (95% CI) | P value | OR (95% CI) | P value | ||||||
| rs12343867 | JAK2 46/1 | C/T | 0.72 | 0.45 | 0.50 | <0.001 | 3.18 (1.75-5.80) | 0.067 | 2.62 (0.91-7.50) | 0.696 | 0.82 (0.31-2.19) | <0.001 |
| rs12339666 | JAK2 intron 8 | T/G | 0.76 | 0.46 | 0.50 | 1.437 × 10-5 | 3.79 (2.04-7.05) | 0.027 | 3.22 (1.11-9.34) | 0.745 | 0.85 (0.32-2.26) | 7.334 × 10-5 |
| rs2201862 | -MECOM | T/C | 0.14 | 0.22 | 0.33 | 0.206 | 0.62 (0.29-1.31) | 0.087 | 0.34 (0.11-1.09) | 0.250 | 0.55 (0.19-1.58) | 0.161 |
| rs9376092 | HBS1L-MYB | A/C | 0.22 | 0.31 | 0.22 | 0.170 | 0.64 (0.34-1.21) | 1.000 | 1.01 (0.29-3.47) | 0.439 | 1.58 (0.49-5.06) | 0.363 |
| rs2736100 | TERT | C/A | 0.59 | 0.56 | 0.44 | 0.654 | 1.14 (0.65-1.99) | 0.256 | 1.81 (0.64-5.11) | 0.349 | 1.60 (0.60-4.27) | 0.524 |
| MZ | DZ | |
| Age (years) | 22.9 ± 2.8 | 23.7 ± 3.7 |
| Weight(kg) | 56.3 ± 6.5 | 59.2 ± 10.3 |
| Height (cm) | 165.5 ± 4.8 | 167.1 ± 6.1 |
| Instrument playing (h/week) | 1.0 ± 0.5 | 1.5 ± 0.2 |
| Keyboard writing (h/week) | 3.9 ± 1.0 | 4.1 ± 2.3 |
| Oldfield handedness score | 0.9 ± 0.0 | 0.8 ± 0.0 |
| Physical activity score | 8.5 ± 2.1 | 8.3 ± 2.9 |
| One-year survival | t | P value | ||
| Alive (n = 135) | Dead (n = 59) | |||
| mean ± SD | mean ± SD | |||
| Child score | 7.54 ± 1.79 | 10.17 ± 2.28 | 7.85 | < 0.001 |
| MELD score | 10.42 ± 5.44 | 16.42 ± 8.40 | 5.05 | < 0.001 |
| Clichy PI | 4.64 ± 0.94 | 5.89 ± 1.09 | 8.12 | < 0.001 |
| New clichy PI | 3.24 ± 1.18 | 4.82 ± 1.37 | 8.11 | < 0.001 |
| Rotterdam index | 1.78 ± 0.88 | 3.41 ± 2.15 | 5.64 | < 0.001 |
| BCS-TIPS score1 | 3.61 ± 0.83 | 4.33 ± 0.97 | 2.99 | 0.003 |
| Chronic lead-exposed group n = 52 | Control group n = 22 | ||||
| Mean | SD | Mean | SD | p | |
| Age (years) | 39 | 8 | 41 | 8 | 0.224 |
| Years of work | 13 | 10 | 17 | 9 | 0.128 |
| Height (cm) | 177 | 5.58 | 179 | 8.03 | 0.112 |
| Weight (kg) | 84.2 | 14.1 | 88.9 | 12.2 | 0.176 |
| Smokers (%) | 37 % | – | 32 % | – | 0.702* |
| PbB (μg/dl) | 36.6 | 8.60 | 2.22 | 1.42 | <0.001 |
| ZPP (μg/g Hb) | 4.24 | 1.82 | 2.38 | 0.61 | <0.001 |
| Gene | Nb. Seq. | Nb. SiLiXfamilies | Nb. Seq. 1st fam. (%) | Nb. Seq. 2nd fam. (%) | Nb. Seq. 3rd fam. (%) | Nb. Singletons (%) |
| ATP8 | 1815 | 26 | 959 (52.8) | 294 (16.2) | 144 (7.9) | 258 (14.2) |
| ATP6 | 1821 | 2 | 1814 (99.6) | 2 (0.1) | - | 5 (0.3) |
| COX1 | 1821 | 1 | 1820 (99.9) | - | - | 1 (0.1) |
| COX2 | 1821 | 1 | 1818 (99.8) | - | - | 3 (0.2) |
| COX3 | 1821 | 1 | 1821 (100) | - | - | - |
| CYTB | 1821 | 1 | 1820 (99.9) | - | - | 1 (0.1) |
| ND1 | 1821 | 1 | 1821 (100) | - | - | - |
| ND2 | 1821 | 11 | 1714 (94.1) | 53 (2.9) | 3 (0.2) | 34 (1.9) |
| ND3 | 1821 | 2 | 1813 (99.6) | 2 (0.1) | - | 6 (0.3) |
| ND4 | 1821 | 2 | 1812 (99.5) | 2 (0.1) | - | 7 (0.4) |
| ND4L | 1821 | 7 | 1758 (96.5) | 4 (0.2) | 3 (0.2) | 47 (2.6) |
| ND5 | 1821 | 2 | 1815 (99.7) | 2 (0.1) | - | 4 (0.2) |
| ND6 | 1821 | 16 | 1366 (75.0) | 313 (17.2) | 55 (3.0) | 45 (2.5) |
| time | mTERF | LSP1 | ND1 | COX2 | ATP6/8 | ND4 | ND6 | CYTB | ||||||||||||
| Frog1 | mod | exp | dev | mod | exp | dev | mod | exp | dev | mod | exp | dev | mod | exp | dev | mod | exp | dev | ||
| Egg | 0.0157 | 0.0034 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | ||||||
| +5 h | 0.0448 | 0.0089 | 1.0 | 1.1 | −12 | 0.9 | 0.8 | +14 | 0.9 | 0.9 | +1 | 0.9 | 2.1 | −59 | 2.4 | 2.4 | −1 | 0.8 | 0.7 | +19 |
| +10 h | 0.0872 | 0.0157 | 1.2 | 1.3 | −5 | 1.1 | 1.1 | +1 | 1.1 | 0.7 | +56 | 1.0 | 2.3 | −57 | 4.1 | 4.0 | +2 | 0.9 | 0.6 | +50 |
| +14 h | 0.0793 | 0.0173 | 1.7 | 2.3 | −26 | 1.6 | 1.6 | −3 | 1.5 | 1.3 | +18 | 1.4 | 3.0 | −53 | 4.4 | 4.4 | 0 | 1.2 | 1.2 | +3 |
| +16 h | 0.0960 | 0.0209 | 2.0 | 2.9 | −31 | 1.7 | 1.4 | +24 | 1.7 | 1.3 | +31 | 1.5 | 4.3 | −65 | 5.6 | 5.8 | −4 | 1.3 | 1.3 | +2 |
| +18 h | 0.0542 | 0.0157 | 2.1 | 3.2 | −34 | 1.9 | 1.7 | +14 | 1.9 | 1.9 | +1 | 1.8 | 4.5 | −60 | 4.4 | 4.2 | +4 | 1.6 | 1.3 | +25 |
| +20 h | 0.0655 | 0.0157 | 1.8 | 3.0 | −41 | 1.6 | 1.4 | +13 | 1.6 | 1.8 | −12 | 1.5 | 4.6 | −68 | 4.2 | 4.2 | 0 | 1.3 | 1.2 | +8 |
| +23 h | 0.0721 | 0.0492 | 9.4 | 9.7 | −4 | 7.6 | 5.1 | +49 | 7.4 | 6.5 | +14 | 6.4 | 16.1 | −60 | 12.9 | 12.2 | +5 | 5.3 | 5.2 | +2 |
| +48 h | 0.0542 | 0.0872 | 29.3 | 26.6 | +10 | 26.2 | 13.4 | +96 | 26.0 | 26.1 | 0 | 23.8 | 60.3 | −61 | 18.6 | 18.6 | 0 | 20.2 | 23.4 | −14 |
| +96 h | 0.0407 | 0.0960 | 48.1 | 48.7 | −1 | 45.3 | 20.9 | +117 | 45.4 | 48.3 | −6 | 43.3 | 104.2 | −58 | 16.7 | 17.4 | −4 | 38.8 | 39.3 | −1 |
| time | mTERF | LSP1 | ND1 | COX2 | ATP6/8 | ND4 | ND6 | CYTB | ||||||||||||
| Frog2 | mod | exp | dev | mod | exp | dev | mod | exp | dev | mod | exp | dev | mod | exp | dev | mod | exp | dev | ||
| Egg | 0.0089 | 0.0041 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | ||||||
| +6 h | 0.0045 | 0.0023 | 1.2 | 1.3 | −8 | 1.2 | 1.0 | +22 | 1.2 | 1.3 | −5 | 1.2 | 1.4 | −12 | 0.7 | 0.7 | +6 | 1.2 | 1.2 | +3 |
| +9 h | 0.0073 | 0.0045 | 1.3 | 1.5 | −14 | 1.3 | 1.3 | −1 | 1.3 | 1.2 | +8 | 1.3 | 1.6 | −19 | 1.1 | 1.1 | +1 | 1.3 | 1.3 | −1 |
| +20 h | 0.0157 | 0.0157 | 3.8 | 4.6 | −17 | 3.7 | 3.7 | +1 | 3.7 | 3.7 | +1 | 3.7 | 3.7 | 0 | 2.8 | 2.8 | −2 | 3.6 | 4.0 | −11 |
| +30 h | 0.0157 | 0.0230 | 7.2 | 7.2 | 0 | 7.1 | 6.8 | +4 | 7.1 | 8.1 | −13 | 7.0 | 6.2 | +14 | 3.7 | 3.7 | 0 | 6.8 | 8.1 | −17 |
| +48 h | 0.0407 | 0.1056 | 20.5 | 19.5 | +5 | 19.7 | 19.7 | 0 | 19.6 | 28.7 | −32 | 19.1 | 17.7 | +8 | 8.6 | 8.4 | +2 | 17.3 | 23.1 | −25 |
| +7 days | 0.0041 | 0.0073 | 6.5 | 6.1 | +7 | 6.6 | 8.0 | −18 | 6.6 | 8.5 | −22 | 6.7 | 4.9 | +36 | 2.4 | 2.3 | +3 | 6.6 | 6.6 | +1 |
| time | mTERF | LSP1 | 16 S | ND6 | ||||||||||||||||
| Frog3 | mod | exp | dev | mod | exp | dev | ||||||||||||||
| Egg | 0.0960 | 0.0026 | 1.0 | 1.0 | 1.0 | 1.0 | ||||||||||||||
| +5 h | 0.0407 | 0.0050 | 2.2 | 2.2 | +0.9 | 2.2 | 2.2 | 0.0 | ||||||||||||
| +14 h | 0.0230 | 0.0081 | 5.0 | 5.0 | 0.0 | 4.5 | 4.5 | −0.2 | ||||||||||||
| +20 h | 0.0038 | 0.0028 | 5.9 | 6.0 | −1.3 | 4.0 | 4.0 | +0.5 | ||||||||||||
| +28 h | 0.0336 | 0.1056 | 92.2 | 92.0 | +0.2 | 25.1 | 25.0 | +0.4 | ||||||||||||
| +48 h | 0.0143 | 0.0306 | 44.1 | 44.0 | +0.2 | 15.0 | 15.0 | +0.3 |
| Chromosome Region | Rectal adenoma | Rectal adenocarcinoma | ||||||
| Start | End | No. of probes | No. of cases | Start | End | No. of probes | No. of cases | |
| 1p36.23-p36.22 | 7804415 | 11633739 | 82 | 3 | ||||
| 1p36.22-p36.13 | 12600054 | 16167534 | 41 | 3 | ||||
| 1p36.12-p35.3 | 21802142 | 29525663 | 226 | 3 | ||||
| 1q21.2-q21.3 | 148163183 | 149505863 | 60 | 2 | ||||
| 1q21.3-q23.1 | 151880217 | 155031244 | 154 | 2 | ||||
| 4q12 | 55913547 | 57653302 | 38 | 2 | ||||
| 5p15.33-p12 | 260981 | 45865412 | 433 | 2 | ||||
| 5q13.2 | 68434643 | 68900029 | 18 | 3 | ||||
| 7p22.2-p22.1 | 4298590 | 6547570 | 42 | 2 | ||||
| 7q11.23 | 72003839 | 75977276 | 77 | 3 | ||||
| 7q22.1 | 99538250 | 101895994 | 79 | 2 | ||||
| 8q22.2-q24.3 | 100781187 | 143914353 | 448 | 2 | ||||
| 8q24.3 | 143914353 | 146250824 | 75 | 2 | ||||
| 9q34.11 | 130111425 | 132321365 | 64 | 2 | ||||
| 10p14-p11.21 | 11825924 | 35645512 | 315 | 3 | ||||
| 11p15.2-p11.12 | 14750051 | 50638829 | 468 | 2 | ||||
| 11q13.1-q14.1 | 63802950 | 80046693 | 442 | 4 | ||||
| 12q24.23-q24.33 | 116956235 | 132193660 | 257 | 2 | ||||
| 14q12-q21.1 | 30209271 | 38927323 | 130 | 3 | ||||
| 14q22.1-q24.3 | 48874529 | 77750644 | 544 | 3 | ||||
| 14q31.3-q32.1 | 87763614 | 93260389 | 110 | 3 | ||||
| 14q32.2-q32.32 | 99254905 | 102592287 | 70 | 3 | ||||
| 15q15.1-q21.1 | 38653893 | 42843706 | 119 | 3 | ||||
| 15q22.31 | 61519869 | 64628895 | 74 | 3 | ||||
| 15q25.1-q25.2 | 76206143 | 79967204 | 77 | 3 | ||||
| 17p13.1-p11.2 | 84287 | 21386319 | 606 | 2 | 8327645 | 20974722 | 266 | 4 |
| 17q25.1 | 70528777 | 71603516 | 61 | 3 | ||||
| 18p11.32-p11.21 | 170229 | 13875315 | 173 | 2 | 2580000 | 13752309 | 137 | 5 |
| 18q11.1-q11.2 | 16904187 | 76018409 | 684 | 2 | 16976046 | 20313378 | 51 | 4 |
| 19p13.3-p13.11 | 1432408 | 19699544 | 795 | 4 | ||||
| 19q13.11-q13.43 | 37554715 | 63672832 | 1114 | 2 | ||||
| 20q13.33 | 60039825 | 62320720 | 85 | 2 | ||||
| 22q13.1 | 37689058 | 37715431 | 3 | 2 |
| Possible IA | Probable and proven IA | |
| n=12 | n=11 | |
| Antifungal treatment-n a | ||
| Liposomal amphotericin B | 6 | 3 |
| Caspofungin | 3 | 1 |
| Voriconazole | 11 | 10 |
| Duration of treatment (days)-Mean (range) | ||
| Liposomal amphotericin B | 7 (1;12) | 8 (2;20) |
| Caspofungin | 6 (3;9) | 11 (3;25) |
| Voriconazole | 100 (2;235) | 130 (42;261) |
| Causes of Voriconazole discontinuation-n b | ||
| Complete response | 10 | 5 |
| Failure | 0 | 1 |
| Death | 1 | 4 |
| Clinical Response (days)-Mean (range) | ||
| Time to apyrexia | 6 (1;14) | 11 (1;19) |
| TDM evaluation-n | 7 | 9 |
| Aggravation | 0 | 2 |
| Number of instances | Reasons | |
| Number of ‘potential’ PI instances in the notes (within 500 notes) | 89 | 70.9% due to misspellings; 20.9% due to PIs being un-entered in source |
| Type of Potential PIs | ||
| Patient Nickname | 20 | Un-entered PI |
| Patient First Name | 18 | Un-entered PI or misspellings |
| Old Address Post Code | 14 | Un-entered PI or misspellings |
| Patient Date of Birth | 13 | Un-entered PI or misspellings |
| Patient Contact Number | 2 | Un-entered PI |
| Patient Last Name | 10 | Un-entered PI or misspellings |
| Old Address Line 1 | 5 | Un-entered PI or misspellings |
| Patient Middle Name | 4 | Un-entered PI |
| Old Address Line 2 | 2 | Un-entered PI or misspellings |
| Old Address Line 3 | 1 | Un-entered PI or misspellings |
| Features | Clinical data | Cases (%) |
| Age (yrs) | <60 | 32 (29.0%) |
| ≥60 | 78 (70.9%) | |
| Sex | Male | 70 (63.6%) |
| Female | 40 (36.3%) | |
| Child-pugh | A | 95 (86.3%) |
| B | 15 (13.6%) | |
| AFP*(μg/L) | <400 | 80 (72.7%) |
| ≥400 | 30 (27.3%) | |
| Tumour size | <2 cm | 97 (88.1%) |
| 2 cm ≤ tumour < 4 cm | 13 (11.8%) | |
| Number of tumours | Single | 87 (79.1%) |
| Multiple | 23 (20.9%) | |
| HBsAg | Positive | 93 (84.5%) |
| Negative | 17 (15.4%) | |
| BCLC stage** | 0 | 86 (78.1%) |
| A | 19 (17.2%) | |
| B | 5 (4.5%) |
| Operative data: | |
| Operation time min (± SD) | 203.96 (±58.51) |
| Cardiopulmonary bypass times min (± SD) | 88.71 (±39.97) |
| Clamp times min (± SD) | 45.95 (±22.63) |
| Of-pump procedures | 1 (1) |
| Venous bypass grafts (exclusivly) | 15 (12) |
| Total arterial revascularization | 66 (52) |
| Arterial and venous revascularization | 43 (34) |
| Number of performed bypass grafts n (± SD) | 2.87 (±0.92) |
| Concomittant procedures | |
| Mitral valve repair | 3 |
| Mitral valve replacement | 3 |
| Aortic valve replacement | 1 |
| DOR Plasty | 3 |
| Carotid TEA | 1 |
| Argentina | Guatemala | Kenya | Zambia | Belgaum, India | Nagpur, India | Pakistan | |
| Number of live births | 7,888 | 26,022 | 33,724 | 26,272 | 77,440 | 38,303 | 38,890 |
| Six-week vital status, n (%) | |||||||
| Survived | 7,744 (98.2) | 25,184 (96.8) | 33,239 (98.6) | 25,571 (97.3) | 75,515 (97.5) | 37,218 (97.2) | 37,152 (95.5) |
| Died | 96 (1.2) | 662 (2.5) | 427 (1.3) | 463 (1.8) | 1,922 (2.5) | 935 (2.4) | 1,174 (3.0) |
| Missing | 48 (0.6) | 176 (0.7) | 58 (0.2) | 238 (0.9) | 3 (0.0) | 150 (0.4) | 564 (1.5) |
| Age at death for infants who died | |||||||
| Median day (p25, p75) | 3 (1, 8) | 5 (2, 16) | 3 (1, 12) | 2 (1, 7) | 3 (1, 7) | 3 (1, 8) | 5 (2, 15) |
| Characteristic | Participant n (%) | Serum Selenium Mean (SD) | p value* | |
| Sex | ||||
| Male | 158 (54) | 85.3 | (25.6) | 0.94 |
| Female | 136 (46) | 85.6 | (31.2) | |
| Age | ||||
| < 50 | 157 (53) | 83.8 | (29.0) | 0.29 |
| ≥ 50 | 137 (47) | 87.3 | (27.5) | |
| Residence | ||||
| Location A | 91 (31) | 70.6 | (19.6) | p < 0.0001 |
| Location B | 58 (20) | 118.8 | (25.8) | |
| Location C | 144 (49) | 81.5 | (22.9) | |
| Education | ||||
| Primary or greater | 100 (34) | 84.6 | (25.8) | 0.70 |
| Less than primary | 194 (66) | 85.9 | (29.5) | |
| Family history of cancer | ||||
| Yes | 33 (11) | 89.8 | (30.0) | 0.35 |
| No | 261 (69) | 84.9 | (28.1) | |
| Family history of esophageal cancer | ||||
| Yes | 18 (6) | 84.5 | (27.4) | 0.88 |
| No | 275 (94) | 85.5 | (28.5) | |
| Tobacco | ||||
| Regular Usea | 56 (19) | 85.8 | (25.7) | 0.91 |
| No regular use | 238 (81) | 85.4 | (28.9) | |
| Alcohol | ||||
| Regular Drinkingb | 92 (31) | 83.0 | (24.4) | 0.31 |
| No regular drinking | 201 (69) | 86.7 | (30.0) | |
| Esophageal Squamous Dysplasia (ESD) | ||||
| Dysplasia | 42 (14) | 94.9 | (29.0) | 0.02 |
| No Dysplasia | 252 (86) | 83.9 | (28.0) |
| Predicted | Percentage Correct (%) | |||
| RRMS | HC | |||
| Observed | RRMS | 22 | 3 | 88.0 |
| HC | 5 | 17 | 77.3 | |
| Overall percentage | 83.0 |
| General characteristic | Control (%) | Case (%) | χ2 value | OR | 95 % CI |
| Number of subjects | 350 | 320 | |||
| Age group: | |||||
| ≤60 years | 170 (48.6) | 152 (47.5) | 1 | – | – |
| >60 years | 180 (51.4) | 168 (52.5) | 0.077 | 1.04 | 0.77–1.41 |
| Gender | |||||
| Female | 153 (43.7) | 129 (40.3) | 1 | – | – |
| Male | 197 (56.3) | 191 (59.7) | 0.794 | 1.15 | 0.85–1.56 |
| Family history of tumors: | |||||
| No | 328 (93.7) | 267 (83.4) | 1 | – | – |
| Yes | 22 (6.30) | 53 (16.6) | 17.76 | 2.96 | 1.76–4.99 |
| Smoking history: | |||||
| No | 215 (61.4) | 178 (55.6) | 1 | – | – |
| Yes | 135 (38.6) | 142 (44.4) | 2.322 | 1.27 | 0.93–1.73 |
| Total smoking amount: | |||||
| Never smoking | 215 (61.4) | 178 (55.6) | 1 | – | – |
| Slight smoking | 84 (24.0) | 62 (19.4) | 0.344 | 0.89 | 0.61–1.31 |
| Heavy smoking | 51 (14.6) | 80 (25.0) | 9.783 | 1.89 | 1.27–2.84 |
| Alcohol drinking: | |||||
| No | 290 (82.9) | 247 (77.2) | 1 | – | – |
| Yes | 60 (17.1) | 73 (22.8) | 3.377 | 1.43 | 0.97–2.09 |
| TOR120 (n = 43) | EXE (n = 45) | |||
| Grade1,2 | Grade3,4 | Grade1,2 | Grade3,4 | |
| Nausea | 4* | 0 | 1 | 0 |
| Fatigue | 3* | 0 | 1 | 0 |
| Hot flush | 3* | - | 1 | - |
| Night sweating | 3* | - | 0 | - |
| Vaginal bleeding, discharge | 2 | - | 0 | - |
| Joint pain, disorder | 1 | - | 2 | - |
| Liver dysfunction | 1 | 0 | 1 | 0 |
| Exanthema | 1 | 0 | 0 | 0 |
| Normal hearing | Abnormal hearing | |
| n | 55 | 15 |
| Mean age (years) | 5.06 (range 3–9) | 5.81 (range 3–13) |
| Duration of tablet assessment (secs)* | 109±65 | 317±113 |
| Number of objects* | 23.8±9.45 | 67.1±19.1 |
| Reliability (%) | 90.4±22.4 | 92.0±10.8 |
| Quartiles of neck circumference | |||||
| Q1 (low) | Q2 | Q3 | Q4 (high) | The overall tendency | |
| AHI < 5# | |||||
| Subjects, n | 805 | 655 | 491 | 283 | |
| Events, n (%) | 10 (1.2) | 17 (2.6) | 17 (3.5) | 14 (4.9) | |
| Univariate Model | 1 (Ref) | 2.120 (0.971–4.631) | 2.951 (1.351–6.445) | 4.164 (1.849–9.374) | 1.117 (1.049–1.189) |
| Multivariate Model 1 | 1 (Ref) | 1.622 (0.710–3.705) | 2.760 (0.977–7.798) | 5.480 (1.574–19.075) | 1.141 (1.014–1.282) |
| Multivariate Model 2 | 1 (Ref) | 1.629 (0.714–3.717) | 2.782 (0.992–7.807) | 5.486 (1.624–18.527) | 1.139 (1.019–1.274) |
| Multivariate Model 3 | 1 (Ref) | 1.914 (0.762–4.807) | 3.427 (1.806–10.814) | 5.477 (1.422–21.090) | 1.134 (1.001–1.284) |
| AHI ≥ 5* | |||||
| Subjects, n | 304 | 455 | 681 | 759 | |
| Events, n (%) | 8 (2.6) | 18 (4.0) | 34 (5.0) | 26 (3.4) | |
| Univariate Model | 1 (Ref) | 1.479 (0.643–3.402) | 1.886 (0.873–4.074) | 1.291 (0.584–2.851) | 1.013 (0.962–1.068) |
| Multivariate Model 1 | 1 (Ref) | 1.773 (0.749–4.194) | 2.115 (0.858–5.215) | 1.972 (0.663–5.868) | 1.061 (0.979–1.150) |
| Multivariate Model 2 | 1 (Ref) | 1.643 (0.690–3.914) | 1.891 (0.762–4.690) | 1.735 (0.586–5.135) | 1.050 (0.968–1.139) |
| Multivariate Model 3 | 1 (Ref) | 1.292 (0.504–3.309) | 1.538 (0.579–4.087) | 1.393 (0.472–4.538) | 1.033 (0.944–1.130) |
| Findings | Eyes/patients (%) |
| Anterior segment | |
| normal | 90/45(96) |
| corneal opacity | 1/1(2) |
| bleb | 1/1(2) |
| Posterior segment | |
| normal | 81/38(76) |
| tubercles | 5/5(10) |
| scars | 3/3(6) |
| chorioretinitis | 1/1(2) |
| CMV retinitis | 1/1(2) |
| HIV retinopathy | 2/1(2) |
| Secondary open-angle glaucoma | 1/1(2) |
| False Positive Rate | ||||||
| Target | Mann-Whitney U | Spearman Correlation | Binomial test | |||
| GC Corrected | GC Corrected | GC Corrected | ||||
| WNV | 0% | 0% | 0% | 0% | 0% | 0% |
| HCoV-SARS | 7% | 0% | 100% | 0% | 0% | 0% |
| EV18 | 63% | 15% | 100% | 12% | 14% | 0% |
| LASV | 11% | 0% | 100% | 0% | 0% | 0% |
| ZEBOV | 0% | 0% | 0% | 0% | 0% | 0% |
| VSV | 0% | 0% | 0% | 0% | 0% | 0% |
| HAdV-4 | 100% | 30% | 100% | 5% | 18% | 0% |
| FLUA H1N1 | 20% | 1% | 100% | 0% | 0% | 0% |
| HSV-1 | 8% | 0% | 0% | 1% | 2% | 0% |
| Negative Control (200 ng HuDNA) | 100% | 0% | 1% | 0% | 1% | 0% † |
| Negative Control (200 ng HuDNA) | 100% | 0% | 100% | 1% | 1% | 0% |
| Negative Control (200 ng HuDNA) | 100% | 0% | 100% | 1% | 1% | 0% |
| Negative Control (200 ng HuDNA) | 100% | 0% | 100% | 0% | 1% | 0% |
| Negative Control (10 ng HuDNA) | 100% | 0% | 88% | 0% | 2% | 0% |
| Negative Control | 100% | 0% | 100% | 0% | 0% | 0% † |
| Negative Control | 0% | 0% | 0% | 0% | 0% | 0% |
| Negative Control | 4% | 0% | 2% | 0% | 0% | 0% |
| Average | 48% | 3% | 58% | 1% | 2% | 0% |
| 1 | 2 | 3 | 4 | 5 | ||
| Euglena | Daisy | Blackberry | Parasite(s) | Sea cucumber | Fish(es) | Frog |
| Bacterium | Plant(s) | Lotus | Earthworm | Tick | Shark | |
| Amoeba | Tree(s) | Jasmine | Spider | Snail | Stingray | |
| Mushroom | Rose | Mistletoe | Beetle(s) | Hydra | ||
| Algae | Flower(s) | Purslane | Butterfly | Invertebrate | ||
| Paramecium | Cactus | Daffodil | Bee | Jellyfish | ||
| Monera | Grass | Kiwi | Grasshopper | Calamari | ||
| Protists | Fern | Snowdrop | Scorpion | Mussel | ||
| Plasmodium | Tulip | Willow | Fly | Mantis | ||
| Plankton | Chrysanthemum | Geranium | Ant | Sponge | ||
| Planaria | Sunflower | Begonia | Caterpillar | Cockroach | ||
| Hyacinth | Violet | Cancer | Ladybug | |||
| Millipede | Octopus | |||||
| 6 | 7 | 8 | 9 | 10 | ||
| Snake | Bird(s) | Lion | Squirrel | Dog | Human, human names | |
| Crocodile | Eagle | Bear | Panda | Cat | ||
| Lizard | Bat | Tiger | Monk seal | Mouse | ||
| Turtle | Penguin | Monkey | Leopard | Rabbit | ||
| Reptile | Parrot | Giraffe | Weasel | Cow | ||
| Chameleon | Falcon | Elephant | Panther | Horse | ||
| Iguana | Pigeon | Whale | Vertebrate | Donkey | ||
| Dragon | Duck | Wolf | Tapir | Sheep | ||
| Cock, Rooster | Fox | Gazelle | Ox | |||
| Chicken, Chick | Gorilla | Cougar | Camel | |||
| Owl | Dolphin | Skunk | Goat | |||
| Partridge | Kangaroo | Cheetah | Mammal(s) | |||
| Sparrow | Koala | Rhinoceros | Calf | |||
| Hawk | Hippopotamus | Otter | Lamb | |||
| Canary | Zebra | Anteater | Buffalo | |||
| Ostrich | Hedgehog | Hyena | Lama | |||
| Vulture | Animal(s) | Pork | Mule | |||
| Lynx | Bull |
| BOLTa, sonidegib 200 mg | ERIVANCEa, vismodegib 150 mg (n = 63) | ||
| Prematched (n = 66) | Postmatched (n = 66) | ||
| Matched baseline characteristics | |||
| Prior BCC radiotherapy, nb (%) | 5 (7.6%) | (20.6%) | 13 (20.6%) |
| Prior BCC surgery, nb (%) | 48 (72.7%) | (89.0%) | 56 (88.9%) |
| Unmatched baseline characteristics | |||
| Age in years | |||
| Mean | 64.6 | 64.6 | 61.4 |
| Median | 67.0 | 67.0 | 62.0 |
| Standard deviation | 15.9 | 15.5 | 16.9 |
| Age range in years, nb (%) | |||
| 18–40 | 6 (9.1%) | (8.6%) | 7 (11.1%) |
| 41–64 | 22 (33.3%) | (31.6%) | 26 (41.3%) |
| ≥65 | 38 (57.6%) | (59.8%) | 30 (47.6%) |
| Race, nb (%) | |||
| White | 59 (89.4%) | (90.8%) | (100.0%) |
| Other | 7 (10.6%) | (9.2%) | (0.0%) |
| ECOG status, nb,c (%) | |||
| 0 | 44 (66.7%) | (69.3%) | 48 (76.2%) |
| 1 | 16 (24.2%) | (21.5%) | 13 (20.6%) |
| 2 | 4 (6.1%) | (6.0%) | 2 (3.2%) |
| Sex, nb (%) | |||
| Male | 38 (57.6%) | (60.8%) | 35 (55.6%) |
| Female | 28 (42.4%) | (39.2%) | 28 (44.4%) |
| Prior systemic therapy for BCC, nb (%) | 4 (6.1%) | (5.4%) | 7 (11.1%)d |
| Early menopause(< 46 years) (n = 25)a | Normal/late menopause(≥ 46 years) (n = 102)a | |
| Mean age at diagnosis; years (SD) | 65.2 (6.94) | 62.8 (8.48) |
| Mean follow-up time; years (SD) | 10.5 (3.0) | 10.1 (3.6) |
| > 3 DMARDs used (%) | 5/25 (20.0) | 23/101 (22.8) |
| DMARDs in combination (%) | 8/25 (32.0) | 45/101 (44.6) |
| Biological treatment ever (%) | 3/25 (12.0) | 33/101 (32.7) |
| Documented radiographic erosions (ever) (%) | 14/23 (60.9) | 52/96 (54.2) |
| RF positive (%) | 11/25 (44.0) | 78/100 (78.0) |
| Mean HAQ at diagnosis (CI)b | 0.58 (0.22-0.93) (n = 12) | 0.96 (0.79-1.12) (n = 55) |
| Mean HAQ 1 year after diagnosis (CI)b | 0.45 (0.08-0.83) (n = 12) | 0.86 (0.70-1.02) (n = 65) |
| Mean HAQ 5 years after diagnosis (CI)b | 0.88 (0.60-1.15) (n = 19) | 0.90 (0.76-1.05) (n = 68) |
| Mean HAQ 10 years after diagnosis (CI)b | 0.67 (0.34-1.00) (n = 12) | 0.98 (0.82-1.14) (n = 49) |
| Cluster distribution (P = 0.005) | ||
| Severe RA (%) | 3 (15.8%) | 23 (34.8%) |
| Mild/moderate seropos RA (%) | 5 (26.3%) | 30 (45.5%) |
| Mild/moderate seroneg RA (%) | 11 (57.9%) | 13 (19.7%) |
| Children (N = 4636) | Adults (N = 4738) | ||||
| % N a | 95% CI | % N a | 95% CI | ||
| Gender | Male | 51 | (49, 53) | 49 | (47, 50) |
| Female | 49 | (47, 51) | 51 | (50, 53) | |
| Age group | 1–5 years | 27 | (25, 28) | ||
| 6–10 years | 27 | (25, 28) | |||
| 11–18 years | 47 | (45, 49) | |||
| 19–64 years | 79 | (77, 80) | |||
| >65 years | 21 | (20, 23) | |||
| Occupation b | Managerial & professional occupations | 43 | (40, 45) | 44 | (42, 46) |
| Intermediate occupations | 20 | (19, 22) | 21 | (19, 22) | |
| Routine & manual occupations | 37 | (35, 39) | 34 | (32, 36) | |
| Household income c (£) | <23,000 | 57 | (54, 59) | 46 | (44, 48) |
| ≥23,000 | 43 | (41, 46) | 54 | (52, 56) | |
| Survey year | 2008–2010 | 38 | (34, 42) | 37 | (33, 41) |
| 2011–2012 | 35 | (32, 39) | 36 | (32, 40) | |
| 2013–2014 | 27 | (24, 31) | 27 | (24, 31) | |
| BMI d | Normal weight | 76 | (74, 77) | 37 | (35, 39) |
| Overweight | 17 | (16, 19) | 37 | (35, 39) | |
| Obese | 7 | (6, 8) | 27 | (25, 29) | |
| Media time e | ≤3 h/day | 47 | (44, 49) | ||
| >3 h/day | 53 | (51, 56) | |||
| Computer time e | ≤1 h/day | 40 | (38, 43) | ||
| >1 h/day | 60 | (58, 62) | |||
| MVPA f | ≤36 min/day | 46 | (43, 48) | ||
| >36 min/day | 54 | (52, 57) | |||
| Misreporting of energy intake | Under-reporters | 9 | (8, 10) | 19 | (17, 20) |
| Plausible reporters | 79 | (77, 80) | 71 | (70, 73) | |
| Over reporters | 12 | (11, 13) | 10 | (9, 11) |
| id | baseMean | baseMean | baseMean | log2Fold | Padj | log2Fold | Padj | Putative annotation |
| (Wild) | (Cultiviar) | (Landrace) | Change(C/W) | (C/W) | Change(L/W) | (L/W) | ||
| Ta7alLoc001275.1 | 1093.35 | 416.13 | 388.49 | −1.39 | 7.96E-03 | −1.49 | 3.19E-03 | 4-coumarate:CoA ligase |
| Ta1blLoc007155.1 | 5137.83 | 1403.42 | 2048.36 | −1.87 | 1.00E-05 | −1.33 | 6.17E-03 | Cellulose synthase |
| Ta5alLoc000723.1 | 1933.05 | 441.04 | 647.98 | −2.13 | 7.97E-07 | −1.58 | 6.55E-04 | Cellulose synthase |
| Ta3bLoc028980.1 | 4678.25 | 1223.81 | 1929.83 | −1.93 | 3.84E-04 | −1.28 | 8.50E-02 | Cellulose synthase |
| Ta4alLoc006547.1 | 177.41 | 0.00 | 0.00 | -Inf | 2.47E-15 | -Inf | 1.30E-17 | CER1 protein |
| Ta4alLoc026069.1 | 550.15 | 0.00 | 0.00 | -Inf | 8.29E-26 | -Inf | 4.65E-29 | CER1 protein |
| Ta1alLoc003924.2 | 40.98 | 1.82 | 0.39 | −4.49 | 5.99E-02 | −6.71 | 1.80E-03 | Cinnamoyl CoA reductase |
| Ta3bLoc003710.1 | 5610.65 | 1515.59 | 1849.21 | −1.89 | 0.0001 | −1.60 | 0.0016 | Fasciclin-like arabinogalactan protein 7 |
| Ta3bLoc056384.1 | 25.40 | 0.00 | 0.00 | -Inf | 6.75E-02 | -Inf | 3.53E-02 | Flavonol 4-sulfotransferase |
| Ta4alLoc006913.1 | 299.00 | 4.85 | 7.32 | −5.95 | 1.64E-16 | −5.35 | 1.08E-16 | Flavonol 4-sulfotransferase |
| Ta5blLoc013288.1 | 944.48 | 181.67 | 269.42 | −2.38 | 1.04E-07 | −1.81 | 1.66E-04 | NAC domain-containing protein 18 |
| Ta6blLoc001596.1 | 1507.23 | 377.78 | 671.34 | −2.00 | 8.20E-06 | −1.17 | 5.04E-02 | Pectin lyase-like protein |
| Ta3bLoc036242.1 | 251.80 | 34.64 | 32.65 | −2.86 | 1.16E-03 | −2.95 | 1.53E-04 | Pectinacetylesterase family protein |
| Ta3bLoc019897.1 | 219.61 | 36.13 | 30.72 | −2.60 | 1.40E-02 | −2.84 | 4.83E-03 | Pectinacetylesterase family protein |
| Ta2blLoc014498.1 | 719.00 | 118.04 | 306.22 | −2.61 | 4.62E-08 | −1.23 | 6.04E-02 | Phenylalanine ammonia-lyase |
| Ta3bLoc024051.1 | 342.10 | 34.22 | 106.23 | −3.32 | 4.41E-09 | −1.69 | 1.19E-02 | Phenylalanine ammonia-lyase |
| Ta7asLoc021287.1 | 3214.99 | 932.09 | 1145.19 | −1.79 | 3.10E-02 | −1.49 | 8.21E-02 | Sucrose synthase 2, putative, expressed |
| Ta6bsLoc005412.1 | 839.45 | 149.96 | 376.09 | −2.48 | 3.87E-07 | −1.16 | 8.73E-02 | Sucrose:fructan-6-fructosyltransferase |
| Ta4alLoc019947.1 | 168.96 | 45.07 | 38.20 | −1.91 | 1.72E-02 | −2.14 | 5.10E-03 | Fiber protein Fb34 |
| Ta7bsLoc005648.1 | 161.29 | 39.24 | 43.95 | −2.04 | 2.28E-02 | −1.88 | 3.37E-02 | TRICHOME BIREFRIGENE like 22 |
| Ta4blLoc021918.2 | 235.61 | 19.18 | 49.36 | −3.62 | 4.92E-08 | −2.26 | 8.61E-04 | Laccase |
| Ta4asLoc013789.1 | 939.60 | 192.99 | 304.20 | −2.28 | 5.70E-07 | −1.63 | 1.16E-03 | laccase 16 LENGTH=523 |
| Total visits | No. referred (%) | No. of nonsevere referrals (%)* | No. of severe referrals (%)* | |
| Trial arm | ||||
| Control (presumptive arm) | 2,404 | 314 (13.1) | 180 (67.7) | 86 (32.3) |
| Intervention (mRDT arm) | 1,097 | 782 (71.3) | 444 (58.3) | 317 (41.7) |
| Within intervention arm | ||||
| mRDT negative | 1,064 | 770 (72.4) | 439 (58.4) | 313 (41.6) |
| mRDT positive | 34 | 13 (38.2) | 5 (50.0) | 5 (50.0) |
| ACT prescription† | ||||
| ACT not prescribed | 1,053 | 782 (74.3) | 454 (59.8) | 305 (40.2) |
| ACT prescribed | 2,328 | 209 (9.0) | 138 (79.8) | 35 (20.2) |
| Rectal artesunate prescribed | 59 | 58 (98.3) | 12 (23.5) | 39 (76.5) |
| TIMI 0 | TIMI 1 | TIMI 2 | TIMI 3 | Sig. | |
| Group (1) (N = 18) | (3) 16.7% | (3) 16.7% | (3) 16.7% | (9) 50% | |
| Group (2) (N = 17) | (1) 5.9% | (2) 11.8% | (6) 35.5% | (8) 47.1% | 0.04 |
| Group (3) (N = 10) | (1) 10% | (6) 60% | (1) 10% | (2) 20% |
| Factors | Expert | Non-expert | ||
| LCI | BLI-BRT | LCI | BLI-BRT | |
| Improved | 73.1% (60/82)a | 19.5% (16/82)b | 76.8% (63/82)c | 24.3% (20/82)d |
| Unchanged | 26.8% (22/82) | 67.0% (55/82) | 23.2% (19/82) | 59.8% (49/82) |
| Worsened | 0% (0/82) | 13.4% (11/82) | 0% (0/82) | 15.9% (13/82) |
| Total | Percentage | |
| Gender | ||
| Male | 50 | 41.5 |
| Female | 70 | 58.5 |
| Age groups | ||
| 21–29 | 2 | 1.6 |
| 30–39 | 8 | 6 |
| 40–49 | 22 | 18.3 |
| 50–59 | 21 | 18 |
| 60–69 | 23 | 19.1 |
| 70–79 | 27 | 22.5 |
| 80–89 | 17 | 14.1 |
| Educational attainment | ||
| Illiterate | 63 | 52.5 |
| Primary | 31 | 25.8 |
| Middle | 16 | 13.3 |
| Secondary | 7 | 5.8 |
| University | 3 | 2.5 |
| Occupation | ||
| Females | ||
| Housewives | 63 | 90 |
| Primary teacher | 7 | 10 |
| Males | ||
| Shopkeepers | 12 | 24 |
| Farmers | 22 | 44 |
| Labour | 8 | 16 |
| Primary teachers | 8 | 16 |
| Region of | Number | % | Population | Regions |
| residence | of cases | of cases | (%) | sending ALS |
| data | ||||
| Abruzzo | 9 | 0.50% | 2,22% | - |
| Basilicata | 16 | 0.89% | 0,98% | * |
| Calabria | 24 | 1.33% | 3,33% | * |
| Campania | 22 | 1.22% | 9,65% | - |
| Estera | 2 | 0.11% | - | - |
| Emilia Romagna | 246 | 13.67% | 7,28% | * |
| FVG | 5 | 0.28% | 2,05% | * |
| Lazio | 195 | 10.84% | 9,42% | * |
| Liguria | 15 | 0.83% | 2,68% | - |
| Lombardia | 95 | 5.28% | 16,28% | * |
| Marche | 33 | 1.83% | 2,58% | * |
| Molise | 3 | 0.17% | 0,53% | - |
| Piemonte | 390 | 21.68% | 7,37% | * |
| Puglia | 148 | 8.23% | 6,77% | * |
| Sardegna | 3 | 0.17% | 2,77% | * |
| Sicilia | 5 | 0.28% | 8,36% | - |
| Toscana | 405 | 22.51% | 6,18% | * |
| TAA | 23 | 1.28% | 1,70% | * |
| Umbria | 18 | 1.00% | 1,49% | - |
| ValledAosta | 3 | 0.17% | 0,21% | - |
| Veneto | 139 | 7.73% | 8,14% | * |
| Italy | - | 100% | 100% |
| Medicinal plant species | Ailments treated in current study | Previous reports of ethnomedical uses | Country of previous use |
| Vernonia amygdalina | Malaria | Malaria | Uganda [63, 101], Ghana [98], Cameroon [102], Democratic Republic of Congo(DRC) [103], Rwanda [104] |
| Wounds | Nigeria [105] | ||
| Skin rashes, diarrhoea, herpes zoster, cryptococcal meningitis | Tanzania [106] | ||
| Infertility, amenorrhea | South Africa [107] | ||
| Tonsolitis | Ethiopia [108] | ||
| Ageratum conyzoides | Uterine pains, helminth infections | Splenomegaly, colic pains, wounds | Uganda [1] |
| Vernonia lasiopus | Malaria, stomachaches | Skin allergy, constipation | Uganda [1] |
| Cleome gynandra | Prolonged labour | Convulsions, diphtheria, toothaches, peptic ulcers, vomiting | Uganda [1, 19] |
| Aloe vera | Malaria | Wounds | Kenya [96] |
| Prunus africana | Enlarged prostate | Prostate and breast cancers, Hypertension | Kenya [96, 109] |
| Capscum frutescens | Prostate cancer | Throat, breast and squamous cell carcinoma | Kenya [109] |
| Amaranthus spinosus | Scalp fungal infections | Haemorrhoids | Nigeria [57] |
| Mangifera indica | Cough, infertility, convulsions | Haemorrhoids | Nigeria [57] |
| Sensory disturbance group(N = 26) | Non-sensory disturbance group(N = 94) | p value | ||
| Gender | Male | 12 | 49 | 0.38 |
| Female | 14 | 45 | ||
| Age (years) | 24.7 ± 10.1 | 24.3 ± 11.9 | 0.87 | |
| BMI | 24.6 ± 3.1 | 23.3 ± 3.7 | 0.40 | |
| Tendon grafta | 3 patients (11.5%) | 10 patients (10.6%) | 0.57 |
| SLE | Control | P | |
| Comfort | 21 (95%) | 20 (100%) | 0.34 |
| Fit | 21 (95%) | 20 (100%) | 0.34 |
| Style | 19 (86%) | 18 (90%) | 0.72 |
| Ease to put on/off | 18 (82%) | 10 (50%) | 0.029 |
| Heel height | 17 (77%) | 15 (75%) | 0.86 |
| Support | 16 (73%) | 15 (75%) | 0.87 |
| Non-slip | 16 (73%) | 11 (55%) | 0.23 |
| Colour | 15 (68%) | 13 (65%) | 0.83 |
| Material | 14 (64%) | 15 (75%) | 0.43 |
| Cost | 12 (55%) | 10 (50%) | 0.77 |
| Weight | 10 (45%) | 10 (50%) | 0.77 |
| Fastening | 9 (41%) | 7 (35%) | 0.69 |
| Annotation Category | Male | Female |
| Behaviour | 16 | 11 |
| Cell Cycle | 21 | 27 |
| Defence Response | 29 | 34 |
| Development | 56 | 87 |
| Metabolism | 273 | 192 |
| Mitochondrial | 39 | 3 |
| Proteolysis | 34 | 25 |
| Response to Toxin | 7 | 8 |
| Signal Transduction | 59 | 66 |
| Structural | 32 | 31 |
| Synaptic Transmission | 11 | 13 |
| Transcription | 17 | 34 |
| Translation | 19 | 14 |
| Transport | 110 | 81 |
| Unknown | 203 | 178 |
| Total No. of Genes | 563 | 481 |
| Primary Breast Tissue | Cases | Promoter Methylation (%) | Statistical Test | |||
| RASSF1A | RASSF10 | |||||
| Normal | n = 25 | 2/25 (8%) | p < 0.005 | 1/25 (4%) | p < 0.005 | Fishers Exact two tailed |
| Tumours | n = 27 | 15/27 (56%) | 17/27 (63%) |
| Variable | Patients |
| (N = 828) | |
| Gender (M/F)* | 687 / 141 |
| Age (y) | 67 (9) |
| Pack-years | 56 (28) |
| Active smoking* | 29% |
| BMI (kg/m2) | 28.1 (5.5) |
| FEV1L | 1.65 (0.65) |
| FEV1% | 56 (28) |
| PaO2 (mmHg) | 67.4 (9.6) |
| FVC L | 3.130 (0.94) |
| FVC% | 88 (19) |
| FEV1/FVC | 53 (11) |
| 6MWD (m) | 438 (104) |
| Dyspnea (mMRC)† | 1 (0-4) |
| BODE index† | 4 (0-6) |
| IC/TLC | 0.35 (0.10) |
| KCO | 74 (24) |
| Charlson index† | 1 (0-5) |
| Exacerbations ≥2 per patient-years‡ | 0.15 (0.01) |
| Hospitalization ≥1 per patient-years‡ | 0.12 (0.01) |
| Inhaled anticholinergic* | 75% |
| Inhaled β2-agonist* | 74% |
| Inhaled corticosteroid* | 65% |
| CAT† | 11 (2-27) |
| CCQ† | 1,3 (0-3.7) |
| Map Type | Count |
| ESTs mapping to the human transcriptome (p ≤ 9 × 10-7) | 140,906 |
| ESTs mapping to the human genome and overlapping with a processed transcript | 1261 |
| ESTs which map to a transcribed region | 8,221 |
| ESTs which map to the human Genome alone | 9,482 |
| ESTs not correlating with the human genome (p ≤ 9 × 10-5) | 20,981 |
| Total | 181,279 |
| Proteins | Functions |
| Ionized calcium-binding adaptor molecule (Iba)1 | Cytoplasmic protein constitutively expressed by microglia, upregulated in inflammation. Iba1 is involved in cytoskeletal reorganization, membrane ruffling of the microglial processes and actin cross-linking needed for cell migration [23], thus reflecting microglial motility and migration properties. |
| CD68 | CD68 labels lysosomal and endosomal transmembrane glycoprotein of microglia, indicating phagocytic activity [33]. |
| Human leukocyte antigen (HLA)-DR | HLA-DR is a Major Histocompatibility Class (MHC) II cell surface receptor which presents antigens to cells of the immune system eliciting an immune response, involved in the non-self recognition and upregulated in inflammation [34]. |
| Macrophage scavenger receptor (MSR)-A | MSR-A is a lipoprotein receptor involved in direct ligand recognition and scavenging activity. Its mouse homolog, scavenger receptor A (SR-A), is associated with plaques and release of reactive oxygen species and neurotoxic substances by microglia upon stimulation with fibrillar Aβ [35]. We previously showed a clustering pattern of MSR-A-positive microglia round plaques in Alzheimer's disease [16] suggesting expression of MSR-A may cause immobilization of the microglia when they encounter plaques [16, 26]. |
| CD64 (Fcγ receptor I) | CD64 is a cell surface receptor with high affinity for the Fc portion of immunoglobulin (IgG), triggering a monocyte/macrophage response [30]. Expression of CD64 reflects the presence of immunoglobulins in the brain and thus the involvement of systemic immunity [36]. Overall FcγRs are important for antibody-dependent cytotoxicity, antigen presentation via MHC, clearance of antibodies and phagocytosis [37]. |
| Setting 1 | Setting 2 | Setting 3 | ||||
| Fitness | Sensitivity | Fitness | Sensitivity | Fitness | Sensitivity | |
| Dataset 1 | 0.0117 | 0.7885 | 0.0054 | 0.7363 | 0.0144 | 0.7678 |
| Dataset 2 | 0.0598 | 0.8249 | 0.0192 | 0.7581 | 0.0769 | 0.7867 |
| Dataset 3 | 0.3586 | 0.8432 | 0.1404 | 0.7502 | 0.2973 | 0.7856 |
| Dataset 4 | 0.1661 | 0.8084 | 0.1128 | 0.7691 | 0.2280 | 0.7802 |
| Total cases (%) 111,495 | PTA (n = 41,987, 37.6%) | Bypass (n = 12,334, 11.1%) | Amputation (n = 57,174, 51.3%) | p-value (χ2 test) | Crude OR (95% CI) | ||||
| No. | (%) | No. | (%) | No. | (%) | ||||
| Gender | |||||||||
| Male | 60,187 (59.5%) | 25,372 | 60.4 | 7,772 | 63.0 | 33,366 | 58.4 | <0.001 | |
| Female | 40,936 (40.5%) | 16,615 | 39.6 | 4,562 | 37.0 | 23,808 | 41.6a | 1.12a (1.09-1.14) | |
| Age Stratum | |||||||||
| 30–49.9 y/o | 7,063 (7.0%) | 2,594 | 6.2 | 748 | 6.1 | 4,182 | 7.3a | <0.001 | 1.30a (1. 24–1.37) |
| 50–64.9 y/o | 26,138 (25.8%) | 10,405 | 24.8 | 2,704 | 21.9 | 15,317 | 26.8a | 1. 22a (1.18-1.25) | |
| 65–74.9 y/o | 31,070 (30.7%) | 12,820 | 30.5 | 4,107 | 33.3b | 17,537 | 30.7 | 1.03b (0.98-1.08) | |
| > = 75y/o | 36,866 (36.5%) | 16,169 | 38.5 | 4,775 | 38.7 | 20,138 | 35.2 | ||
| Diabetes | |||||||||
| Yes | 69,026 (68.2%) | 20,282 | 48.3 | 6,978 | 56.6 | 48,318 | 84.5a | <0.001 | 6.12a (5.95-6.31) |
| Hypertension | |||||||||
| Yes | 45,961 (45.4%) | 25,844 | 61.5c | 5,918 | 48.0 | 18,635 | 32.6 | <0.001 | 3.11c (3.03-3.19) |
| ESRD | |||||||||
| Yes | 11,318 (11.2%) | 4,094 | 9.7 | 1,741 | 14.1b | 6,313 | 11.0 | <0.001 | 1.36b (1.29-1.44) |
| CAD | |||||||||
| Yes | 16,072 (15.9%) | 10,727 | 25.5c | 2,254 | 18.3 | 4,635 | 8.1 | <0.001 | 3.45c (3.33-3.58) |
| Dyslipidemia | |||||||||
| Yes | 4,803 (4.7%) | 3,960 | 9.4c | 438 | 3.6 | 690 | 1.2 | <0.001 | 7.20c (6.68-7.77) |
| Group identified | |||||||||
| Normal | 72,520 (71.7%) | 27,500 | 65.5 | 9,530 | 77.3 | 43,391 | 75.9 | <0.001 | |
| Low-income | 2,704 (2.7%) | 875 | 2.1 | 249 | 2.0 | 1,831 | 3.2a | 1.41a (1.30-1.53) | |
| CIR | 25,913 (25.6%) | 13,620 | 32.4c | 2,557 | 20.7 | 11,957 | 20.9 | 1.81c (1.76-1.87) |
| Type | Symbol | Theme | Relevant figure | Supporting cluster(s) |
| Chemical-gene | A+ | Agonism, activation | 3a | 6+ |
| A− | Antagonism, blocking | 6– | ||
| B | Binding, ligand (esp. receptors) | 14–16 | ||
| E+ | Increases expression/production | 8+, 9+ | ||
| E− | Decreases expression/production | 8–, 9–, 10 | ||
| E | Affects expression/production (neutral) | 8, 9, 11a | ||
| N | Inhibits | 3 | ||
| Gene-chemical | O | Transport, channels | 3a | 19, 21 |
| K | Metabolism, pharmacokinetics | 11c | ||
| Z | Enzyme activity | 20 | ||
| Chemical-disease | T | Treatment/therapy (incl. investigatory) | 3b | 8g, 8h, 9 |
| C | Inhibits cell growth (esp. cancers) | 2, 3 | ||
| Sa | Side effect/adverse event | 6, 15, 16 | ||
| Pr | Prevents, suppresses | 1, 9, 21, 24, 28 | ||
| Pa | Alleviates, reduces | 26, 30 | ||
| J | Role in pathogenesis | 20 | ||
| Disease-chemical | Mp | Biomarkers (progression) | 3b | 18, 19 |
| gene-disease | U | Causal mutations | 3c | 14 |
| Ud | Mutations affect disease course | 13 | ||
| D | Drug targets | 10, 12 | ||
| J | Role in pathogenesis | 2h, 4, 6, 8, 9 | ||
| Te | Possible therapeutic effect | 2j, 3 | ||
| Y | Polymorphisms alter risk | 22, 26, 27 | ||
| G | Promotes progression | 29 | ||
| Disease-gene | Md | Biomarkers (diagnostic) | 3c | 5, 7 |
| X | Overexpression in disease | 15, 17, 30 | ||
| L | Improper regulation linked to disease | 18, 19, 21 | ||
| Gene–gene | B | Binding, ligand (esp. receptors) | 3d | 10 |
| W | Enhances response | 13 | ||
| V+ | Activates, stimulates | 14, 16 | ||
| E+ | Increases expression/production | 21, 22 | ||
| E | Affects expression/production (neutral) | 7, 17 | ||
| I | Signaling pathway | 24 | ||
| H | Same protein or complex | 25 | ||
| Rg | Regulation | 28, 30 | ||
| Q | Production by cell population | 1, 2, 6 |
| Variables | p values - Left | p values - Right |
| LPFX LAF | 0.995 | 0.999 |
| LPFX OAF | 0.969 | 0.246 |
| LPFX OPF | 0.089 | 0.104 |
| LAFX OAF | 0.996 | 0.248 |
| LAFX OPF | 0.050 | 0.106 |
| OAFX OPF | 0.027* | 0.976 |
| Variable | Odds Ratio | 95% CI | P value |
| Cataract surgery | |||
| Before first eye surgery | 1.0 | ||
| After first eye surgery | 0.3 | 0.1–0.7 | 0.004 |
| After second eye surgery | 0.1 | 0.1–0.4 | < 0.001 |
| Gender | |||
| Female | 1.0 | ||
| Male | 0.4 | 0.1–1.3 | 0.122 |
| Age group (years) | |||
| 55–64 | 1.0 | ||
| 65–74 | 0.1 | 0.1–1.2 | 0.072 |
| 75+ | 0.7 | 0.6–8.0 | 0.737 |
| Marital status | |||
| Single | 1.0 | ||
| Married/de facto | 0.3 | 0.1–1.2 | 0.096 |
| Retirement status | |||
| Not retired | 1.0 | ||
| Retired | 5.6 | 1.1–27.7 | 0.036 |
| Number of comorbidities | 1.1 | 0.9–1.4 | 0.257 |
| MMSE score | 1.0 | 0.9–1.2 | 0.803 |
| Variable | Measurement Items | Reference |
| BI | 1. If the hospital decides to develop MEMR in the future, I shall frequently use it. | Hu et al. 1999 [9] |
| 2. If the hospital decides to develop MEMR in the future, I will use it to assist my healthcare work. | ||
| 3. I think I will recommend other physicians (from this hospital or not) to use MEMR. | ||
| 4. If the hospital decides to develop MEMR in the future, it will become one of my favorite assistance tools for my work. | ||
| PU | 1. Using MEMR will speed up my work (e.g. going on rounds and consulting medical records). | Davis et al. 1989 [5]; Davis 1989 [52] |
| 2. Using MEMR will improve my work quality (such as enhancing the immediacy of prescribing physician orders). | ||
| 3. Using MEMR will make it easier to conduct my work. | ||
| 4. Using MEMR will improve my working performance. | ||
| 5. Using MEMR will help me to control my work better. | ||
| PEOU | 1. It is easy to understand the operations of MEMR.] | Davis et al. 1989 [5]; Davis 1989 [52] |
| 2. It is easy to use MEMR to finish my work. | ||
| 3. On the whole, MEME is easy to use. | ||
| PT | 1. Using MEMR may decrease my control over clinical decisions. | Walter & Lopez 2008 [15] |
| 2. Using MEMR may decrease my professional discretion over patient care decisions. | ||
| 3. Using MEMR can decrease my control over each step of the patient care process. | ||
| 4. Using MEMR may increase the monitoring of my diagnostic and therapeutic decisions by non-providers. | ||
| 5. Using MEMR may decrease my control over the allocation of scarce resources. | ||
| 6. I would find MEMR advantageous for the medical profession as a whole. | ||
| PM | 1. I can access the MEMR at any time for the necessary information or service for my patient care | Lee 2005 [53] |
| 2. I can access the MEMR anywhere for the necessaryzinformation or service for my patient care | ||
| 3. I can use the MEMR “anywhere,” and “anytime” at the point of patient care. |
| Parameters | Traditional Technology [35] | Author’s Technology [36] |
| Wear intensity I∙10−7, mm3/N∙m | 8.2 | 4.9 |
| Breaking strength σb, MPa | 18.0 | 24.0 |
| Ratio of CF and PTFE powder (volume) in filler preparation | - | 1:1 |
| Transcription | Meaning unit | ICF category | |
| Moderator: | If you think about your body, what functional problems do you have? | ||
| Patient A: | I used to go to sports very often. Now I can't anymore. I even had to quit swimming | Restriction of sports Quit swimming | d9201 sports d4554 swimming |
| Patient B: | Exactly! I also had to quit swimming. | ||
| Patient C: | I can no longer cycle. (...) | Quit cycling | d4750 driving human-powered transportation |
| Moderator: | If you think about your body, where are your biggest problems? | ||
| Patient C: | Toes, ankle joints, knee joints, fingers | ToesAnkle joints | s7502 structure of ankle & foots75021 ankle joint & joints of foot and toes |
| Knee joints | s75011 knee joint | ||
| Fingers | s7302 structure of hand | ||
| Patient A: | What bothers me are my wrists. (...) | Wrists | s73021 joints of hand and fingers |
| Lake Number | Lake Volume (m3) | Pre-Dam |
| 1 | 5,700,000 | + |
| 2 | 204,000 | + |
| 3 | 1,335,000 | |
| 4 | 5,000,000 | |
| 5 | 14,700,000 | |
| 6 | 1,100,000 | |
| 7 | 4,400,000 | + |
| 8 | 5,800,000 | + |
| 9 | 10,000,000 | + |
| 10 | 8,000,000 |
| Outcome (n) | % or mean (± SD) | OR or β (95 % CI or SE) | P-value |
| Hypertension, baseline (n = 6,422) | 56 % | 1.20 (0.90 – 1.59) | 0.21 |
| Hypertension, lifetime (n = 8,691) | 78 % | 1.23 (0.82 – 1.86) | 0.32 |
| Type 2 diabetes (n = 1,356) | 12 % | 1.32 (0.91 – 1.91) | 0.15 |
| Albumin (g/dL), serum (n = 8,094) | 4.05 (0.51) | −0.001 (0.04) | 0.88 |
| Albumin creatinine ratio (mg/mmol) (n = 1,210) | 14.0 (861.10) | −123.82 (176.60) | 0.48 |
| Albumin (mg/dL), urinary (n = 1,199) | 16.7 (640.2) | −36.35(131.80) | 0.78 |
| Blood urea nitrogen (mg/dL) (n = 10,111) | 11.00 (13.55) | −0.23 (0.93) | 0.80 |
| Body mass index (kg/m2) (n = 9,247) | 27.25 (7.21) | 0.74 (0.51) | 0.15 |
| Creatinine (mg/dL), serum (n = 10,288) | 0.88 (1.99) | 0.07 (0.13) | 0.59 |
| Creatinine (g/kg/day), urinary (n = 172) | 70.00 (73.89) | 23.05 (38.86) | 0.55 |
| Diastolic blood pressure (mm Hg), baseline (n = 10,025) | 76.00 (15.68) | 0.48 (1.07) | 0.66 |
| Diastolic blood pressure (mm Hg), post-medication (n = 5,653) | 79.00 (10.06) | 0.29 (0.90) | 0.75 |
| Diastolic blood pressure (mm Hg), pre-medication (n = 7,009) | 75.00 (11.28) | 0.38 (0.92) | 0.68 |
| Glucose (mg/dL) (n = 9,918) | 96.00 (34.33) | 0.04 (2.37) | 0.99 |
| Glycated hemoglobin (mg/dL) (n = 2,925) | 6.30 (1.80) | 0.07 (0.23) | 0.75 |
| HDL-C (mg/dL) (n = 5,096) | 50.00 (16.99) | −1.02 (1.65) | 0.54 |
| HDL-c (mg/dL) post-medication (n = 2,097) | 47.75 (16.56) | −2.95 (2.48) | 0.23 |
| HDL-C (mg/dL), pre-medication (n = 4,273) | 51.00 (17.09) | −0.91 (1.81) | 0.61 |
| Heart rate (beats per minute) (n = 783) | 76.00 (11.14) | −3.28 (2.67) | 0.22 |
| Insulin (IU/mL) (n = 343) | 16.90 (74.36) | −11.15 (24.38) | 0.65 |
| LDL-C (mg/dL), regardless of medication status | 99.00 (35.18) | −1.17 (3.42) | 0.73 |
| LDL-C (mg/dL), post-medication | 96.00 (38.90) | 4.95 (5.78) | 0.39 |
| LDL-C (mg/dL), pre-medication | 105.00 (39.70) | −3.20 (4.26) | 0.45 |
| PR Interval (msec) (n = 781) | 159.00 (17.92) | −0.12 (4.30) | 0.98 |
| QRS duration (msec) (n = 837) | 82.00 (8.65) | 7.98 (1.99) | 6.7x10-5 |
| QT interval (msec) (n = 783) | 376.00 (27.84) | 11.62 (6.66) | 0.08 |
| Systolic blood pressure (mm Hg), baseline (n = 10,025) | 125.00 (22.54) | −1.43 (1.54) | 0.35 |
| Systolic blood pressure (mm Hg), post-medication (n = 5,653) | 132.00 (16.03) | 0.78 (1.43) | 0.58 |
| Systolic blood pressure (mm Hg), pre-medication (n = 7,009) | 123.00 (16.38) | −0.0003 (1.34) | 0.99 |
| Total cholesterol (mg/dL), regardless of medication status (n = 5,439) | 175.00 (39.48) | −1.65 (3.70) | 0.65 |
| Total cholesterol (mg/dL), post-medication (n = 2,150) | 173.50 (44.22) | 3.48 (6.58) | 0.60 |
| Total cholesterol (mg/dL), pre-medication (n = 4,642) | 181.00 (44.86) | −3.57 (4.55) | 0.43 |
| Triglycerides (mg/dL), regardless of medication status (n = 5,269) | 98.00 (69.46) | 3.34 (6.61) | 0.61 |
| Triglycerides (mg/dL), post-medication (n = 2,115) | 110.00 (74.07) | 10.63 (11.07) | 0.34 |
| Triglycerides (mg/dL), pre-medication (n = 4,445) | 97.00 (79.25) | 2.00 (8.20) | 0.81 |
| Uric acid (mg/dL) (n = 2,465) | 5.40 (2.18) | 0.06 (0.29) | 0.84 |
| HI titers | NT titers | |||
| Strain | Median titer | Proportion titers ≥40 (%) | Median titer | Proportion titer ≥20 (%) |
| A/Hong Kong/1/1968 | 40 | 55.00 | 20 | 59.60 |
| A/Victoria/3/1975 | 40 | 31.10 | 10 | 36.40 |
| A/Bangkok/1/1979 | 40 | 56.30 | 40 | 67.50 |
| A/Beijing/353/1989 | 20 | 35.80 | 10 | 47.70 |
| A/Wuhan/359/1995 | 40 | 69.50 | 80 | 84.80 |
| A/Fujian/411/2002 | 80 | 80.80 | 80 | 83.40 |
| A/Shantou/90/2003 | 40 | 62.30 | 40 | 75.50 |
| A/Shantou/806/2005 | 40 | 57.00 | 40 | 60.30 |
| A/Shantou/904/2008 | 10 | 28.50 | 10 | 45.00 |
| A/Shantou/104/2005 | 20 | 42.40 | 20 | 55.00 |
| A/Shantou/92/2009 | <10 | 9.30 | <10 | 11.30 |
| A/California/07/2009 | <10 | 0.70 | <10 | 1.30 |
| Total | — | 44.00 | — | 52.30 |
| Spot No | Accession No | Protein name | Gene name | Mean ± SD(pSS) | Mean ± SD(healthy) | Mean ± SD(sicca non-SS) | Fold of variationpSS vs healthy | Fold of variationpSS vs sicca non-SS |
| 2261 | P04745 | α-amylases precursor | AMY1A | 2.58 ± 0.44 | 4.77 ± 0.39 | 4.24 ± 0.67 | -1.8** | -1.6** |
| 2572 | Q5FC00 | Carbonic anhydrase VI | CA6 | 0.65 ± 0.11 | 1.50 ± 0.47 | 1.07 ± 0.26 | -2.3* | -1.6* |
| 2642 | P04406 | G3PDH | GAPDH | 0.07 ± 0.03 | 0.31 ± 0.03 | 0.23 ± 0.85 | -4.4*** | -3.2* |
| 2543 | P06733 | α-enolase | ENO1 | 0.08 ± 0.02 | 0.04 ± 0.01 | 0.05 ± 0.03 | +2** | +1.6 |
| 2842 | Q6GMW1 | IGKC | IGKC | 1.33 ± 0.49 | 0.17 ± 0.30 | 0.54 ± 0.42 | +7.8* | +2.5 |
| 3018 | P31151 | Protein S100-A7 (Psoriasin) | S100A7 | 0.47 ± 0.21 | 0.09 ± 0.04 | 0.32 ± 0.15 | +5.2* | +1.5 |
| 3000 | P06702 | Protein S100-A9 (Calgranulin B) | S100A9 | 2.98 ± 0.10 | 2.00 ± 0.42 | 2.75 ± 0.54 | +1.5* | ns |
| 2986 | P01037 | Cystatin SN precursor | CST1 | 0.91 ± 0.36 | 2.37 ± 0.01 | 0.84 ± 0.44 | -2.6** | ns |
| 2938 | P12273 | PIP | PIP | 0.05 ± 0.08 | 0.33 ± 0.01 | 0.09 ± 0.17 | -6.6** | -1.8 |
| 2655 | Q96DR5 | SPLUNC-2 | SPLUNC2 | 0.04 ± 0.07 | 0.40 ± 0.17 | 0.40 ± 0.18 | -10* | -10* |
| 3003 | Q01469 | E-FABP | FABP5 | 0.17 ± 0.07 | 0.02 ± 0.03 | 0.06 ± 0.05 | +8.5* | +2.8* |
| 3036 | P61769 | β-2 microglobulin | B2M | 0.39 ± 0.04 | 0.17 ± 0.04 | 0.23 ± 0.05 | +2.3** | +1.7 |
| Covariate* | QI Strategies and Practices | Composite HQA Process of Care | Observed to Expected Mortality Rate | ||||||
| Beta | 95% CI | P | Beta | 95% CI | P | Beta | 95% CI | P | |
| bed-size category | 0.285 | 0.022 | 0.972 | ||||||
| 25-99 beds | −0.177 | −0.398, 0.045 | 0.119 | −0.04 | −0.07, -0.010 | 0.009 | 0.007 | −0.123, 0.137 | 0.916 |
| 100-399 beds | −0.057 | −0.205, 0.091 | 0.453 | −0.011 | −0.032, 0.010 | 0.308 | −0.004 | −0.103, 0.095 | 0.940 |
| ownership type | 0.438 | 0.001 | 0.626 | ||||||
| government | −0.159 | −0.404, 0.086 | 0.204 | −0.003 | −0.046, 0.039 | 0.881 | −0.017 | −0.205, 0.170 | 0.856 |
| not-for-profit | −0.122 | −0.334, 0.090 | 0.260 | 0.034 | −0.006, 0.073 | 0.093 | −0.053 | −0.229, 0.124 | 0.557 |
| urban | 0.079 | −0.078, 0.236 | 0.323 | −0.009 | −0.029, 0.010 | 0.353 | −0.098 | −0.181, -0.014 | 0.022 |
| non-teaching | 0.046 | −0.113, 0.205 | 0.569 | 0.006 | −0.017, 0.029 | 0.607 | 0.050 | −0.056, 0.156 | 0.350 |
| HIT category | 0.003 | 0.257 | 0.005 | ||||||
| low | −0.378 | −0.610, -0.146 | 0.001 | −0.021 | −0.049, 0.008 | 0.157 | 0.065 | −0.061, 0.191 | 0.312 |
| medium | −0.084 | −0.236, 0.068 | 0.277 | −0.016 | −0.037, 0.004 | 0.122 | −0.076 | −0.172, 0.020 | 0.121 |
| commitment | 0.123 | −0.091, 0.336 | 0.261 | 0.03 | 0.002, 0.058 | 0.037 | −0.029 | −0.155, 0.096 | 0.646 |
| resources | 0.090 | −0.085, 0.265 | 0.312 | 0.007 | −0.015, 0.029 | 0.545 | −0.010 | −0.109, 0.089 | 0.842 |
| R2 | 0.109 | 0.136 | 0.072 | ||||||
| HCAHPS Patient Satisfaction | Quality Manager Assessment of Patient Care Quality | Front-line Clinicians’ Assessment of Patient Care Quality | |||||||
| Covariate* | Beta | 95% CI | P | Beta | 95% CI | P | Beta | 95% CI | P |
| bed-size category | 0.002 | 0.153 | 0.006 | ||||||
| 25-99 beds | 2.390 | −1.493, 6.273 | 0.227 | 0.119 | −0.186, 0.424 | 0.443 | 0.112 | 0.004, 0.220 | 0.042 |
| 100-399 beds | −2.256 | −4.977, 0.466 | 0.104 | −0.082 | −0.316, 0.153 | 0.493 | −0.011 | −0.094, 0.072 | 0.797 |
| ownership type | 0.001 | 0.613 | 0.094 | ||||||
| government | 8.952 | 3.467, 14.437 | 0.001 | 0.207 | −0.221, 0.634 | 0.343 | 0.168 | 0.015, 0.320 | 0.031 |
| not-for-profit | 9.373 | 4.400, 14.347 | 0.000 | 0.199 | −0.203, 0.601 | 0.331 | 0.130 | −0.013, 0.274 | 0.075 |
| urban | −0.149 | −2.569, 2.271 | 0.903 | 0.056 | −0.137, 0.249 | 0.570 | −0.021 | −0.089, 0.048 | 0.557 |
| non-teaching | −1.220 | −4.030, 1.590 | 0.393 | −0.030 | −0.280, 0.220 | 0.813 | −0.097 | −0.186, -0.008 | 0.032 |
| HIT category | 0.000 | 0.006 | 0.392 | ||||||
| low | −7.208 | −11.047, -3.680 | 0.000 | −0.439 | −0.730, -0.147 | 0.003 | −0.067 | −0.170, 0.036 | 0.202 |
| medium | −1.177 | −3.776, 1.421 | 0.370 | −0.342 | −0.567, -0.117 | 0.003 | −0.022 | −0.102, 0.058 | 0.586 |
| commitment | 2.686 | −0.889, 6.261 | 0.140 | 0.337 | 0.050, 0.623 | 0.021 | 0.370 | 0.268, 0.473 | 0.000 |
| resources | 2.814 | 0.029, 5.599 | 0.048 | 0.022 | −0.209, 0.253 | 0.851 | 0.354 | 0.271, 0.436 | 0.000 |
| R2 | 0.228 | 0.078 | 0.579+ |
| VariablesAt the follow-up visit | Higher IR group(n = 71) | Lower IR group (n = 213) | p value |
| BMI | 27.69 ± 4.17 | 24.13 ± 2.65 | <0.001 |
| Prevalence of hypertension | 60 (84.5%) | 148 (70.0%) | 0.013 |
| Prevalence of diabetes | 44 (62.0%) | 72 (33.8%) | <0.001 |
| Fasting glucose | 7.84 ± 1.80 | 5.30 ± 1.22 | 0.005 |
| OGTT | 10.51 ± 3.98 | 8.73 ± 3.43 | 0.002 |
| Fasting insulin | 39.36 ± 96.93 | 10.36 ± 9.56 | 0.002 |
| Postrandial insulin | 135.52 ± 148.57 | 68.41 ± 60.23 | <0.001 |
| Bonnet index | 0.95 ± 0.84 | 0.67 ± 0.95 | <0.001 |
| HbA1c | 6.79 ± 1.53 | 6.07 ± 0.78 | <0.001 |
| GFR | 79.46 ± 28.19 | 70.38 ± 21.72 | 0.016 |
| Triglycerides | 2.09 ± 1.75 | 1.52 ± 1.01 | 0.002 |
| hsCRP | 8.54 ± 13.78 | 3.87 ± 7.45 | 0.005 |
| Control | Mild periodontitis | Moderate periodontitis | Severe periodontitis | Implant | |
| (I) | (II) | (III) | (IV) | (V) | |
| MMP-8 (ng/mL) | |||||
| Range | 0.21–20.70 | 0.20–31.50 | 0.34–54.90 | 0.20–48.51 | 0.30–347.00 |
| Mean ± SD | 5.61 ± 6.55 | 7.40 ± 9.07 | 12.43 ± 16.01 | 13.17 ± 16.43 | 40.46 ± 80.29 |
| I versus II, P = 0.0020I versus III, P = 0.0003I versus IV, P = 0.020I versus V, P = 0.0099 | II versus III, P = 0.0313II versus IV, P = 0.13II versus V, P = 0.0321 | III versus IV, P = 0.357III versus V, P = 0.0489IV versus V, P = 0.0255 |
| Variables | Milk drinking | Non-milk drinking | ||
| Cases/Controls | OR(95%CI)a | Cases/Controls | OR(95%CI)a | |
| Tea consumption | ||||
| No | 139/534 | 1.00 | 206/533 | 1.00 |
| Yes | 28/179 | 0.62(0.39-0.98) | 48/152 | 0.81(0.55-1.19) |
| Duration of tea consumption (years) | ||||
| No | 139/534 | 1.00 | 206/533 | 1.00 |
| <20 | 10/100 | 0.42(0.21-0.84) | 21/69 | 0.72(0.42-1.24) |
| ≥20 | 18/79 | 0.84(0.48-1.48) | 27/83 | 0.89(0.55-1.44) |
| Quantity of tea consumed (ml/day) | ||||
| No | 139/534 | 1.00 | 206/533 | 1.00 |
| <500 | 13/104 | 0.49(0.27-0.92) | 26/77 | 0.85(0.52-1.38) |
| ≥500 | 15/75 | 0.79(0.43-1.46) | 22/75 | 0.77(0.46-1.31) |
| Concentration of tea consumed | ||||
| No | 139/534 | 1.00 | 206/533 | 1.00 |
| Weak | 10/75 | 0.48(0.24-0.98) | 17/54 | 0.78(0.44-1.40) |
| Moderate | 15/88 | 0.68(0.38-1.23) | 21/75 | 0.77(0.46-1.29) |
| Strong | 3/16 | 0.73(0.21-2.56) | 10/23 | 1.15(0.54-2.48) |
| Types of tea | ||||
| No | 139/535 | 1.00 | 206/534 | 1.00 |
| Green tea | 14/100 | 0.55(0.30-0.99) | 26/76 | 0.91(0.56-1.48) |
| Oolong tea | 9/41 | 0.90(0.42-1.96) | 13/43 | 0.76(0.40-1.47) |
| Others | 5/37 | 0.47(0.18-1.25) | 9/32 | 0.77(0.36-1.66) |
| Year | ||||||
| Days of follow up | Sex ratio | 2000 | 2004 | 2006 | 2000–2006 | P value |
| 0 | Mean | 0.004 (12) | 0.048 (38) | 0.2 (16) | 0.076 (66) | < 0.0001 |
| SE | 0.004 | 0.019 | 0.05 | 0.019 | ||
| 1 | Mean | 0.0 (4) | 0.076 (37) | 0.32 (8) | 0.11 (49) | 0.003 |
| SE | 0.0 | 0.025 | 0.12 | 0.03 | ||
| 2 | Mean | 0.13 (7) | 0.1 (34) | 0.25 (6) | 0.13 (47) | 0.3 |
| SE | 0.08 | 0.03 | 0.08 | 0.03 | ||
| 3 | Mean | 0.29 (11) | 0.15 (38) | 0.4 (21) | 0.25 (70) | 0.006 |
| SE | 0.1 | 0.03 | 0.08 | 0.04 | ||
| 7 | Mean | 0.25 (12) | 0.25 (22) | 0.37 (16) | 0.29 (50) | 0.48 |
| SE | 0.11 | 0.05 | 0.1 | 0.05 | ||
| 14 | Mean | 0.13 (5) | 0.28 (18) | 0.51 (6) | 0.3 (29) | 0.14 |
| SE | 0.08 | 0.08 | 0.14 | 0.06 | ||
| 21 | Mean | - | 0.25 (4) | 0.3 (1) | 0.26 (5) | - |
| SE | - | 0.25 | - | 0.19 | ||
| 28 | Mean | - | 0.0 (2) | 0.52 (2) | 0.26 (4) | 0.46 |
| SE | - | 0.0 | 0.19 | 0.17 |
| All(n = 137)a | Exercise(n = 61) | Control(n = 62) | p value | |||
| Baseline | Baseline | 12 months | Baseline | 12 months | ||
| cIMT (mm) | 0.855 ± 0.172 | 0.876 ± 0.187 | 0.858 ± 0.175 | 0.853 ± 0.141 | 0.849 ± 0.131 | 0.57 |
| SBP (mmHg) | 139 ± 17 | 139 ± 17 | 140 ± 17 | 139 ± 16 | 139 ± 16 | 0.75 |
| DBP (mmHg) | 79 ± 9 | 78 ± 9 | 79 ± 9 | 80 ± 9 | 80 ± 10 | 0.51 |
| TC (mmol/L)b | 3.9 (3.4, 4.5) | 3.8 (3.4, 4.3) | 3.9 (3.3, 4.6) | 4.0 (3.3, 4.7) | 3.7 (3.2, 4.5)* | 0.014 |
| LDL (mmol/L)b | 2.0 (1.6, 2.6) | 1.9 (1.6, 2.5) | 2.0 (1.7, 2.7)* | 2.1 (1.6, 2.7) | 1.9 (1.5, 2.7)* | 0.020 |
| HDL (mmol/L)b | 1.12 (0.94, 1.40) | 1.12 (0.96, 1.32) | 1.11 (0.93, 1.41) | 1.13 (0.93, 1.40) | 1.09 (0.94, 1.34) | 0.080 |
| TG (mmol/L)b | 1.40 (1.07, 1.88) | 1.43 (1.09, 1.91) | 1.53 (1.10, 1.99) | 1.38 (0.98, 1.89) | 1.38 (0.87, 2.01) | 0.20 |
| CRP (mg/L)b | 2.41 (1.15, 4.99) | 2.04 (0.95, 4.40) | 1.99 (1.00, 4.21) | 2.40 (1.19, 4.98) | 1.77 (0.96, 3.86) | 0.91 |
| Test | 4CA | Cd | DDT | MeHg | TCDD | VA | AA | As | Pb | PCB | tBHQ |
| Pb | 6.15 | 6.78 | 8.66 | 6.76 | 10.91 | 7.96 | 7.62 | 6.32 | 5.01 | 10.66 | 6.81 |
| DDT | 6.74 | 9.86 | 4.51 | 8.79 | 7.79 | 8.01 | 5.39 | 10.38 | 8.96 | 10.05 | 9.13 |
| 4CA | 6.87* | 10.96 | 6.69* | 9.47 | 8.82 | 8.87 | 6.99* | 11.21 | 8.42 | 10.75 | 9.42 |
| TCDD | 8.55 | 12.43 | 6.78 | 11.01 | 5.42 | 10.37 | 7.61 | 10.76 | 12.61 | 15.63 | 10.62 |
| As | 9.14 | 9.56 | 10.93 | 9.74 | 12.46 | 9.89 | 10.18 | 6.88 | 7.51 | 11.32 | 7.51 |
| Pb | 7.25 | 7.95 | 10.05 | 7.38 | 12.06 | 8.62 | 8.65 | 9.58 | 4.22 | 9.91 | 7.70 |
| PCB | 9.84 | 9.30 | 13.17 | 10.23 | 15.01 | 10.01 | 11.78 | 12.77 | 10.62 | 3.93 | 10.40 |
| As | 9.18 | 9.99 | 9.92 | 10.20 | 11.53 | 10.16 | 9.43 | 5.48 | 7.84 | 12.40 | 7.67 |
| TBHQ | 8.79 | 7.49 | 11.32 | 9.24 | 11.52 | 10.29 | 10.98 | 8.93 | 9.77 | 11.31 | 6.33 |
| PCB | 8.37 | 7.74 | 12.06 | 8.88 | 13.65 | 8.54 | 10.63 | 11.79 | 10.22 | 5.71 | 9.08 |
| AA | 7.18 | 10.79 | 4.29 | 9.28 | 7.21 | 8.63 | 3.56 | 7.67 | 8.12 | 13.04 | 8.86 |
| TBHQ | 7.49 | 7.26 | 11.22 | 8.30 | 11.66 | 9.00 | 10.40 | 9.57 | 9.58 | 10.47 | 5.41 |
| Cd | 8.32 | 6.67 | 10.76 | 8.39 | 12.79 | 8.90 | 10.16 | 10.89 | 6.96 | 8.05 | 8.15 |
| VA | 6.43 | 8.25 | 6.47 | 7.57 | 9.04 | 4.57 | 6.15 | 9.56 | 8.02 | 10.24 | 8.33 |
| AA | 10.26 | 14.38 | 7.09 | 12.23 | 9.61 | 11.59 | 6.25 | 11.26 | 10.54 | 13.89 | 11.84 |
| Cognitive impairment | Controls | Z | p | |
| (n = 377) | (n = 66) | |||
| Age (year) | 63.10 ± 9.70 | 55.09 ± 10.77 | −5.295 | 0.000 |
| Gender (male) | 178(47.2%) | 38(57.6%) | −1.256 | 0.209 |
| Education (year) | 9.01 ± 4.01 | 12.94 ± 3.0 | −6.455 | 0.000 |
| CRP (mg/L) | 2.08(1.07,3.36) | 0.21(0.18,0.42) | −6.488 | 0.001 |
| RAGE (ng/mL) | 4.01(2.49,5.71) | 2.28(1.84,3.03) | −3.271 | 0.004 |
| Hypertension | 60.5% | 54.5% | −0.761 | 0.447 |
| Diabetes | 28.8% | 38.7% | −1.348 | 0.178 |
| Triglycerides (mmol/L) | 1.38(0.89, 1.87) | 1.49(0.99,2.06) | −0.831 | 0.406 |
| LDL (mmol/L) | 2.93(2.41,3.68) | 3.22(2.67,4.18) | −1.651 | 0.099 |
| Smoking | 34.1% | 34.8% | −0.151 | 0.880 |
| BMI (Kg/m2) | 23.58 ± 3.39 | 23.12 ± 2.63 | −0.189 | 0.850 |
| Union group (n = 74) | Non-union group (n = 12) | P value | |
| Age (years) | 81.4 ± 10.4 (54–99) | 85.3 ± 9.7 (62–96) | 0.1606 |
| Sex (male/female) | 17 (23.0%)/57 (77.0%) | 1 (8.3%)/11 (91.7%) | 0.2475 |
| Waiting time (days) | 5.0 ± 3.6 (1–17) | 4.4 ± 3.3 (1–12) | 0.5339 |
| Intraoperative blood loss (g) | 21.0 ± 14.2 (0–100) | 17.9 ± 9.9 (5–40) | 0.5756 |
| Duration of follow-up (m) | 13.0 ± 11.0 (6–48) | 9.0 ± 6.2 (6–26) | 0.1826 |
| Garden classification | |||
| Stage I: 8 (10.8%) | Stage I: 0 (0%) | 0.0008a | |
| Stage II: 44 (59.5%) | Stage II: 1 (8.3%) | ||
| Stage III: 18 (24.3%) | Stage III: 9 (75.0%) | ||
| Stage IV: 4 (5.4%) | Stage IV: 2 (16.7%) | ||
| Garden alignment index | |||
| AP view | 168.0 ± 6.2 | 164.5 ± 8.6 | 0.168 |
| Lateral view | 173.4 ± 5.3 | 169.7 ± 10.2 | 0.159 |
| Preoperative ADL | |||
| Gait alone | 31(41.9%) | 4(33.3%) | 0.4917 |
| With aid | 18(24.3%) | 2(16.7%) | |
| With helper/walker | 21(28.4%) | 4(33.3%) | |
| Wheel chair | 4(5.4%) | 2(16.7%) | |
| Postoperative ADL | |||
| Gait alone | 5(6.8%) | 0(0%) | 0.0493a |
| With aid | 33(44.6%) | 1(8.3%) | |
| With helper/walker | 18(24.3%) | 5(41.7%) | |
| Wheel chair | 18(24.3%) | 6(50.0%) |
| Characteristics | PCV-7 group (n = 811) | Control group (n = 744) | P |
| Males (%) | 476 (58.7) | 413 (55.5) | 0.22 |
| Age at vaccination, median days (range) | |||
| First dose | 82 (75–104) | 82 (76–103) | 0.96 |
| Second dose | 140 (128–155) | 143 (130–158) | 0.93 |
| Third dose | 340 (328–361) | 343 (331–364) | 0.92 |
| Breast-feeding for at least three months, No. (%) | 551 (67.9) | 476 (64.1) | 0.11 |
| Living in urban area, No. (%) | 527 (65.0) | 498 (66.9) | 0.44 |
| Mother's age, median years (range) | 33 (24–49) | 33 (20–46) | 0.96 |
| Father's age, median years (range) | 35 (21–50) | 35 (21–51) | 0.99 |
| No. of persons in household, median (range) | 3 (2–4) | 3 (2–4) | 1.00 |
| No. of siblings, median (range) | 1 (0–2) | 1 (0–2) | 1.00 |
| Children with a smoker in the family, No. (%) | 194 (23.9) | 182 (24.5) | 0.84 |
| Children attending day-care, No. (%) | 284 (35.0) | 231 (31.0) | 0.10 |
| Duration of day care attendance, No. (%) | |||
| 0–6 months | 79 (9.7) | 65 (8.7) | 0.55 |
| 7–12 months | 33 (4.1) | 44 (5.9) | 0.11 |
| 13–18 months | 111 (13.7) | 94 (12.6) | 0.59 |
| 19–24 months | 78 (9.6) | 58 (7.8) | 0.23 |
| Vaccinated against influenza, No. (%) | 12 (1.5) | 10 (1.3) | 0.99 |
| Completed (n = 107) | On treatment (n = 55) | Discontinued (n = 45) | |
| Female | 53 (50%) | 32 (58%) | 20 (44%) |
| Age (years) | 41 ± 11 | 37 ± 12 | 35 ± 9 |
| Other allergies | 77 (73%) | 38 (72%) | 30 (68%) |
| Asthma | 47 (44%) | 28 (53%) | 20 (44%) |
| Year treatment starteda | |||
| 2016 | – | 20 (39%) | 9 (23%) |
| 2015 | – | 18 (35%) | 5 (13%) |
| 2014 | 8 (8%) | 13 (25%) | 6 (15%) |
| 2013 | 29 (30%) | 4 (10%) | |
| 2012 | 14 (14%) | 7 (18%) | |
| 2011 | 12 (12%) | 3 (8%) | |
| 2010 | 7 (7%) | 2 (5%) | |
| 2009 | 12 (12%) | 1 (3%) | |
| 2008 | 8 (8%) | 0 | |
| 2007 | – | – | – |
| 2006 | 7 (7%) | 2 (5%) |
| Control | Reduced | Restricted | |
| Males | |||
| Food intake (g/24 h/kg) | 42 ± 1 | 39 ± 1 | 46 ± 2† |
| Water intake (mL/24 h/kg) | 72 ± 4 | 66 ± 4 | 79 ± 2† |
| Urine production (L/24 h/kg) | 0.036 ± 0.002 | 0.031 ± 0.002 | 0.039 ± 0.004 |
| Glucose (mmol/L/24 h/kg) | 0.043 ± 0.005 | 0.044 ± 0.006 | 0.029 ± 0.008 |
| Creatinine (mmol/L/24 h/kg) | 0.090 ± 0.013 | 0.099 ± 0.011 | 0.104 ± 0.021 |
| Total protein (mg/L/24 h/kg) | 16.924 ± 3.105 | 20.547 ± 2.596 | 23.148 ± 5.152 |
| Albumin (mg/L/24 h/kg) | 0.879 ± 0.175 | 1.031 ± 0.177 | 0.831 ± 0.199 |
| Sodium (mmol/L/(24 h)/kg) | 0.648 ± 0.051 | 0.844 ± 0.081 | 0.693 ± 0.081 |
| Potassium (mmol/L/(24 h)/kg) | 1.766 ± 0.152 | 1.784 ± 0.140 | 1.568 ± 0.185 |
| Chloride (mmol/L/(24 h)/kg) | 2.118 ± 0.137 | 2.220 ± 0.161 | 2.050 ± 0.185 |
| Females | |||
| Food intake (g/24 h/kg) | 64 ± 2 | 65 ± 3 | 65 ± 4 |
| Water intake (mL/24 h/kg) | 141 ± 7 | 134 ± 6 | 159 ± 11 |
| Urine production (L/24 h/kg) | 0.064 ± 0.005 | 0.075 ± 0.004 | 0.091 ± 0.009* |
| Glucose (mmol/L/24 h/kg) | 0.023 ± 0.003 | 0.032 ± 0.006 | 0.012 ± 0.003† |
| Creatinine (mmol/L/24 h/kg) | 0.081 ± 0.012 | 0.125 ± 0.016* | 0.066 ± 0.012† |
| Total protein (mg/L/24 h/kg) | 6.570 ± 0.857 | 8.906 ± 2.024 | 6.029 ± 1.096 |
| Albumin (mg/L/24 h/kg) | 0.443 ± 0.090 | 0.448 ± 0.051 | 0.621 ± 0.090 |
| Sodium (mmol/L/(24 h)/kg) | 1.389 ± 0.179 | 1.891 ± 0.119 | 1.508 ± 0.314 |
| Potassium (mmol/L/(24 h)/kg) | 2.975 ± 0.307 | 4.296 ± 0.356* | 2.982 ± 0.345† |
| Chloride (mmol/L/(24 h)/kg) | 3.743 ± 0.312 | 5.352 ± 0.381* | 4.239 ± 0.500 |
| MBL2 | SCA N = 126 (%) | FVOE ≥ 1 N = 68 (%) | FVOE < 1 N = 58 (%) | p | OR | 95%CI |
| Promoter SNP −550 | ||||||
| LL | 76 (0.60) | 47 (0.69) | 29 (0.50) | Reference | ||
| HL | 42 (0.33) | 17 (0.25) | 25 (0.43) | 0.0129* | 2.38 | 1.10–5.15 |
| HH | 08 (0.07) | 04 (0.06) | 04 (0.07) | 0.3856 | 1.62 | 0.37-6.98 |
| L | 194 (0.77) | 111 (0.82) | 83 (0.72) | Reference | ||
| H | 58 (0.33) | 25 (0.18) | 33 (0.28) | 0.0292* | 1.76 | 0.97-3.19 |
| Promoter SNP −221 | ||||||
| YY | 86 (0.68) | 42 (0.62) | 44 (0.76) | Reference | ||
| YX | 37 (0.29) | 25 (0.37) | 12 (0.21) | 0.0279* | 0.46 | 0.20-1.03 |
| XX | 03 (0.03) | 01 (0.01) | 02 (0.03) | 0.5256 | 1.90 | 0.16-21.86 |
| Y | 209 (0.83) | 109 (0.80) | 100 (0.86) | Reference | ||
| X | 43 (0.17) | 27 (0.20) | 16 (0.14) | 0.1012 | 0.64 | 0.32-1.13 |
| Exon 1 | ||||||
| AA | 87 (0.69) | 44 (0.65) | 43 (0.74) | Reference | ||
| AO | 37 (0.29) | 23 (0.34) | 14 (0.24) | 0.1181 | 0.62 | 0.28-1.36 |
| OO | 02 (0.02) | 01 (0.01) | 01 (0.02) | 0.7472 | 1.02 | 0.06-16.90 |
| A | 211 (0.84) | 111 (0.82) | 100 (0.86) | Reference | ||
| O | 41 (0.16) | 25 (0.18) | 16 (0.14) | 0.1626 | 0.71 | 0.36-1.14 |
| Haplotypes of MBL2 | ||||||
| High (HYA + LYA) | 168 (0.67) | 84 (0.62) | 84 (0.72) | Reference | ||
| Intermediate (LXA) | 43 (0.17) | 27 (0.20) | 16 (0.14) | 0.0670 | 0.59 | 0.29-1.18 |
| Low (HYO + LYO) | 41 (0.16) | 25 (0.18) | 16 (0.14) | 0.1036 | 1.56 | 0.77-3.13 |
| Combined genotypes (diplotypes) of MBL2 | ||||||
| High | 57 (0.45) | 27 (0.40) | 30 (0.52) | Reference | ||
| Intermediate | 57 (0.45) | 31 (0.46) | 26 (0.45) | 0.2268 | 1.31 | 0.61–2.82 |
| Low | 12 (0.10) | 10 (0.14) | 02 (0.03) | 0.0229** | 5.55 | 1.11–27.66 |
| Mineral intake per day | RDA [11] | Fast finishers | Slow finishers |
| Calcium (mg.day−1) | 1,000 mg (M, F) | 848.7 ± 137.6 | 872.4 ± 260.5 |
| Phosphorus (mg.day−1) | 700 mg (M, F) | 1,859.3 ± 781.4* | 717.9 ± 200.2 |
| Iron (mg.day−1) | 8 mg (M), 18 mg (F) | 8.1 ± 3.6 | 5.8 ± 2.0 |
| Sodium (mg.day−1) | 1,500 mg (M, F) | 343.2 ± 38.4 | 3,769.4 ± 1,764.1* |
| Potassium (mg.day−1) | 4,700 mg (M, F) | 1,747.2 ± 845.4* | 531.5 ± 152.3 |
| Magnesium (mg.day−1) | 420 mg (M), 320 mg (F) | 852.6 ± 407.7* | 215.2 ± 73.9 |
| Copper (mg.day−1) | 0.9 mg (M, F) | 3.8 ± 1.8* | 0.9 ± 0.3 |
| Manganese (mg.day−1) | 2.3 mg (M), 1.8 mg (F) | 3.3 ± 1.5 | 4.8 ± 1.6 |
| INVERSION | SIZE (Mb) | GENOMIC DISORDER/REARRANGEMENT | REFERENCE |
| inv(3)(q29) | 1.9 | 3q29 microdeletion syndrome | [29] |
| inv(5)(q35) | 1.3 | Sotos syndrome | [30] |
| inv(7)(q11.23) | 1.8 | Williams-Beuren syndrome | [31] |
| inv(8)(p23) | 4.7 | 8p23 microdeletion syndrome | [32] |
| inv(15)(q11q13) | 4 | Angelman syndrome | [12] |
| inv(15)(q13.3) | 2 | 15q13.3 deletion syndrome | [33] |
| inv(17)(q12) | 1.5 | RCAD syndrome | [29] |
| inv(17)(q21.31) | 0.9 | 17q21.21 deletion syndrome | [34] |
| Type of Nasal-Spray Container (group) | Positive Cultures (No.) | Negative Cultures (No.) | Total |
| 1 (Cap-off) | 3 | 63 | 66 |
| 2 (Cap-on) | 1 | 65 | 66 |
| 3 (Control) | 0 | 66 | 66 |
| Total | 4 | 194 | 198 |
| Smoking cohort | All clients/comparisons | |||||
| Characteristics | Comparisons (n = 7701) | Clients (n = 2595) | p-value | Controls (n = 33,384) | Clients (n = 8986) | p-value |
| % | % | % | % | |||
| Age, less than 18 years | 28.9 | 24.2 | <0.01 | 18.6 | 22.1 | <0.01 |
| Race/ethnicity | ||||||
| White | 75.3 | 75.2 | 50.9 | 50.3 | ||
| Black | 12.9 | 13.8 | 25.3 | 25.9 | ||
| Hispanic | 10.5 | 10.2 | 20.9 | 21.3 | ||
| Other | 1.4 | 0.8 | 0.08 | 2.9 | 2.6 | 0.22 |
| Unmarried | 93.8 | 92.5 | 0.03 | 89.8 | 88.9 | 0.01 |
| Education, less than high school | 36.7 | 38.2 | 0.19 | 30.5 | 31.2 | 0.20 |
| TANF Receipt | 57.1 | 54.0 | 0.01 | 49.6 | 50.4 | 0.18 |
| Foodstamp Receipt | 59.8 | 60.1 | 0.76 | 48.9 | 47.2 | <0.01 |
| Test A versus B | Test B versus C | |||
| Medially loaded | Laterally loaded | Medially loaded | Laterally loaded | |
| Proximal migration | 0.04 | 0.04 | 0.04 | 0.04 |
| Varus rotation | 0.2 | 0.3 | 0.04 | 0.04 |
| Flexion tilt | 0.9 | 0.1 | 0.04 | 0.04 |
| Macronutrient | Source | Content at 20 kcal/fl oz (g/L) | Content at 30 kcal/fl oz (g/L) |
| Protein equivalent | 100% free L-amino acids | 20.3 | 30.1 |
| Carbohydrate | 100% corn syrup solids | 72.3 | 107.0 |
| Fat | 38% high-oleic safflower oil, 33% medium chain triglycerides, 29% soy oil | 32.2 | 47.6 |
| Concordance | Coder 1(YS) | Coder 2 (AV) | ||
| 0 (non found) | 16 (1.7%) | 4 (0.4%) | ||
| 1 (partly concordant) | 127 (13%) | 114 (11.7%) | ||
| 1a. target (SNOMED CT) more specific than source (KSH97-P) | 77 (60%) | 75 (65%) | ||
| 1b. target less specific than source | 25 (20%) | 20 (18%) | ||
| 1c. imprecise but neither more nor less specific' | 25 (20%) | 19 (17%) | ||
| 2 (completely concordant) | 829 (85.3%) | 854 (87.9%) | ||
| Total | 972 (100%) | 127 (100%) | 972 (100%) | 114 (100%) |
| The maximum level of non-compliance, with the seasonality adjustment | The maximum level of non-compliance, without the seasonality adjustment | Total (with seasonal adjustments) | ||||
| Always compliant | At least one first warning | At least one second warning | At least one third warning | Liable for suspension | ||
| Calculation method 1 | ||||||
| Always compliant | 13426 | 524 | 60 | 0 | 0 | 14010 |
| At least one first warning | 0 | 607 | 101 | 13 | 0 | 721 |
| At least one second warning | 0 | 0 | 496 | 95 | 11 | 602 |
| At least one third warning | 0 | 0 | 0 | 444 | 103 | 547 |
| Liable for suspension | 0 | 0 | 0 | 0 | 860 | 860 |
| Total (without seasonal adjustments) | 13426 | 1131 | 657 | 552 | 974 | 16740 |
| Calculation method 2 | ||||||
| Always compliant | 13616 | 393 | 48 | 0 | 0 | 14057 |
| At least one first warning | 0 | 542 | 87 | 14 | 0 | 643 |
| At least one second warning | 0 | 0 | 513 | 84 | 9 | 606 |
| At least one third warning | 0 | 0 | 0 | 479 | 101 | 580 |
| Liable for suspension | 0 | 0 | 0 | 0 | 854 | 854 |
| Total (without seasonal adjustments) | 13616 | 935 | 648 | 577 | 964 | 16740 |
| RPKM interval | Expression level | D1 | D4 | D6 |
| 0-0.1 | no | 17,765 (27.08 %) | 22,483 (34.28 %) | 22,843 (34.83 %) |
| 0.1-3.57 | low | 29, 146 (44.44 %) | 29,935 (45.64 %) | 28,720 (43.79 %) |
| 3.57-15 | medium | 10,459 (15.95 %) | 8,031 (12.24 %) | 8,273 (12.61 %) |
| 15-60 | high | 6, 176 (9.42 %) | 3,822 (5.83 %) | 4,182 (6.38 %) |
| >60 | very high | 2,045 (3.12 %) | 1,320 (2.01 %) | 1,573 (2.40 %) |
| Groups | ALT (U/L) | AST (U/L) | LDH (U/L) | T-BIL (mg/L) |
| Sham (Control) | 292.43 ± 32.41 | 428.39 ± 34.66 | 859.34 ± 94.36 | 75.39 ± 8.12 |
| Model | 580.52 ± 51.96# | 738.11 ± 75.63# | 1404.65 ± 168.74# | 83.94 ± 9.53 |
| LV-NC | 577.21 ± 61.14 | 784.7 ± 47.85 | 1553.19 ± 125.83 | 84.38 ± 10.46 |
| LV-sh4-1BB1 | 333.26 ± 39.92* | 457.7 ± 43.61* | 942.81 ± 83.17* | 76.84 ± 8.43 |
| Subsystem | Instrument | Signal | Task | Measurements |
| Respiratory | Phonatory Aerodynamic System (PAS), KAYPentax | Aerodynamic | /pa/, /pi/ | Maximum subglottal pressure |
| Bamboo passage | Speech duration, pausing pattern (e.g., number of pauses, pause duration, pausing frequency) | |||
| Phonatory | Compact flash recorder, professional quality microphone, Countryman E6, Phonatory Aerodynamic System, KAYPentax | Acoustic, aerodynamic | “Normal” and “high pitch” phonation of /a/ | Phonation duration, maximum F0, jitter, shimmer, NHR, SPL, laryngeal airway resistance |
| Articulatory | Eagle Digital System, Motion Analysis Corp. | Kinematic | “Buy Bobby a puppy”“Say /aCa/ again” | Maximum/minimum velocities of lips and jaw |
| Microphone | Acoustic | Repeat /ba/ as clear and as fast as possible on one breath | Number, duration, and rate of syllable repetitions | |
| Resonatory | Nasometer, Model 6400, KAYPentax | Acoustic | “Mama made a lemon jam” “Buy Bobby a puppy” | Nasalance |
| Phonatory Aerodynamic System, KAYPentax | Aerodynamic | /pa/, /pi/, /ma/, /mi/, “hamper” | Intraoral air pressure and nasal airflow in syllables, time lag between /m/ and /p/ in “hamper” |
| Ocular manifestation first group (n = 18) | Extraocular manifestation first group (n = 21) | P value | |
| Mean age | 57.4 ± 15.3 | 54.1 ± 12.0 | 0.45 |
| Female/male ratio | 17/1 (94.4%) | 18/3 (85.7%) | 0.61 |
| BHLa in radiography | 15 (83.3%) | 19 (90.5%) | 0.65 |
| Increased ACEb | 13 (72.2%) | 16 (76.2%) | 0.78 |
| ACEb level | 82.4 ± 46.5 | 72.6 ± 36.0 | 0.47 |
| Ocular complications | 4 (22.2%) | 5 (23.8%) | 0.61 |
| Visual acuity at last visit | 0.83 ± 0.19 | 0.90 ± 0.14 | 0.15 |
| Ocular involvement | |||
| Mutton-fat KPc | 16 (88.9%) | 14 (66.7%) | 0.10 |
| Angle change | 2 (11.1%) | 3 (14.3%) | 0.58 |
| Vitreous opacity | 5 (27.8%) | 5 (23.8%) | 0.53 |
| Nodular phlebitis | 13 (72.2%) | 13 (61.9%) | 0.37 |
| Multiple choroidal lesions | 7 (38.9%) | 6 (28.6%) | 0.36 |
| Optic disc lesion | 3 (16.7%) | 5 (23.8%) | 0.44 |
| Bilaterality | 16 (88.9%) | 13 (61.9%) | 0.07 |
| Systemic treatment | 16 (88.9%) | 12 (57.1%) | 0.037 |
| Immunosuppression | 10 (55.6%) | 4 (19.0%) | 0.018 |
| ALL | Egypt | Germany | |||||||
| n | Positive LR | Negative LR | n | Positive LR | Negative LR | n | Positive LR | Negative LR | |
| Visual detection | |||||||||
| advanced occlusal | 94 | 7.09 (5.6–8.9) | 0.39 (0.3–0.5) | 55 | 5.0 (4.3–5.8) | 0.29 (0.2–0.4) | 50 | 12.5 (9.2–16.9) | 0.58 (0.5–0.7) |
| all occlusal | 67 | 3.46 (2.8–4.3) | 0.19 (0.15–0.25) | 51 | 3.73 (3.1–4.4) | 0.18 (0.14–0.24) | 12 | 5.56 (3.7–8.5) | 0.56 (0.46–0.68) |
| Radiographic detection | |||||||||
| advanced occlusal | 44 | 4.90 (3.7–6.5) | 0.53 (0.46–0.62) | 38 | 5.96 (3.7–6.6) | 0.51 (0.44–0.60) | 36 | 5.87 (4.3–8.0) | 0.54 (0.46–0.63) |
| all occlusal | 14 | 1.74 (1.3–2.4) | 0.79 (0.65–0.96) | 11 | 2.02 (1.4–2.9) | 0.75 (0.60–0.94) | 9 | 2.36 (1.4–4.1) | 0.76 (0.58–0.99) |
| advanced proximal | 22 | 9.82 (7.3–13.3) | 0.58 (0.52–0.65) | 22 | 9.82 (7.3–13.3) | 0.58 (0.52–0.65) | 22 | 9.82 (7.3–13.3) | 0.58 (0.52–0.65) |
| all proximal | 38 | 4.30 (3.4–5.5) | 0.63 (0.56–0.72) | 31 | 5.34 (4.2–6.8) | 0.65 (0.57–0.74) | 34 | 4.89 (3.9–6.2) | 0.65 (0.57–0.73) |
| Variable | Sub-category | n | GWG up to 28 Weeks (n = 105) Mean (SD) | 95% CI | p-Value | Total GWG (n = 119) Mean (SD) | 95% CI | p-Value |
| All | - | 6.33 (2.85) | 5.78–6.89 | - | 9.30 (3.72) | 8.63–9.98 | - | |
| Education level | None/primary | 16 | 5.72 (2.80) | 4.20–7.24 | 0.519 | 7.34 (3.72) | 5.51–9.17 | 0.072 |
| Secondary | 99 | 6.46 (2.92) | 5.85–7.07 | 9.64 (3.71) | 8.90–10.37 | |||
| Higher | 2 | 5.13 (0.11) | 1.84–8.42 | 8.60 (0.57) | 3.42–13.78 | |||
| Income level (LKR (Sri Lankan rupee)) | <9000 | 5 | 6.67 (2.57) | 3.33–10.00 | 0.978 | 9.08 (4.91) | 5.75–12.41 | 0.474 |
| 9000–13,999 | 20 | 6.09 (2.62) | 4.73–7.46 | 8.30 (3.44) | 6.64–9.96 | |||
| 14,000–19,999 | 32 | 6.27 (3.35) | 5.26–7.27 | 9.42 (3.23) | 8.11–10.74 | |||
| 20,000–31,999 | 45 | 6.52 (2.77) | 5.60–7.45 | 9.23 (4.21) | 8.12–10.34 | |||
| ≥32,000 | 16 | 6.04 (2.44) | 4.30–7.79 | 10.70 (3.31) | 8.77–12.61 | |||
| Area of residence | Urban | 9 | 4.53 (3.49) | 2.40–6.66 | 0.167 | 7.44 (3.93) | 4.97–9.92 | 0.306 |
| Sub-urban | 52 | 6.68 (3.33) | 5.86–7.50 | 9.28 (3.99) | 8.25–10.31 | |||
| Rural | 55 | 6.18 (2.15) | 5.37–7.00 | 9.52 (3.46) | 8.52–10.52 | |||
| History of LBW deliveries | Yes | 22 | 5.33 (3.03) | 4.14–6.52 | 0.062 | 8.04 (3.36) | 6.48–9.59 | 0.077 |
| No | 97 | 6.60 (2.76) | 5.99–7.21 | 9.60 (3.76) | 8.85–10.33 | |||
| History of miscarriage or abortion | Yes | 32 | 6.47 (2.75) | 5.43–7.51 | 0.759 | 8.87 (3.75) | 7.56–10.17 | 0.442 |
| No | 87 | 6.28 (2.91) | 5.62–6.94 | 9.46 (3.77) | 8.67–10.25 | |||
| Hyperemesis gravidarum a | Yes | 20 | 6.34 (3.21) | 5.03–7.65 | 0.978 | 9.04 (4.20) | 7.37–10.70 | 0.730 |
| No | 97 | 6.32 (2.80) | 5.70–6.93 | 9.36 (3.67) | 8.60–10.12 | |||
| Parity | Primiparous | 40 | 6.89 (2.39) | 5.86–7.92 | 0.208 | 10.00(4.00) | 8.84–11.16 | 0.146 |
| Multiparous | 79 | 6.11 (3.00) | 5.46–6.76 | 8.95 (3.54) | 8.12–9.77 | |||
| Pre-pregnancy BMI category b | Underweight | 23 | 8.43 (2.94) 1 | 7.24–9.62 | <0.001 * | 12.00(4.07) 1 | 10.58–13.43 | <0.001 * |
| Normal | 69 | 6.18 (2.26) 2 | 5.51–6.85 | 9.10 (3.12) 2 | 8.27–9.92 | |||
| Overweight | 20 | 5.73 (3.38) 2,3 | 4.60–6.86 | 7.89 (3.81) 2 | 6.37–9.42 | |||
| Obese | 7 | 2.76 (0.97) 3 | 0.44–5.08 | 6.50 (3.30) 2 | 3.92–9.08 | |||
| Energy intake c | <EER | 21 | 5.57 (3.04) | 4.32–6.82 | 0.188 | 8.05 (3.44) | 6.44–9.67 | 0.083 |
| ≥EER | 93 | 6.51 (2.85) | 5.87–7.16 | 9.62 (3.80) | 8.86–10.39 | |||
| Carbohydrate intake (g/day) | 229–429 | 25 | 5.97 (3.08) | 4.78–7.15 | 0.798 | 8.03 (3.60) | 6.56–9.50 | 0.089 |
| 430–629 | 58 | 6.41 (2.99) | 5.60–7.23 | 10.00 (3.68) | 9.03–10.96 | |||
| 630–829 | 31 | 6.45 (2.63) | 5.29–7.61 | 9.16 (3.88) | 7.84–10.49 | |||
| Protein intake d | <RDA | 21 | 5.49 (3.21) | 4.24–6.74 | 0.141 | 7.81 (3.56) | 6.20–9.41 | 0.039 * |
| ≥RDA | 93 | 6.53 (2.80) | 5.89–7.18 | 9.68 (3.74) | 8.92–10.44 | |||
| Sex of the newborn | Male | 53 | 6.44 (2.78) | 5.63–7.25 | 0.552 | 9.23 (3.31) | 8.25–10.21 | 0.976 |
| Female | 53 | 6.10 (2.75) | 5.28–6.91 | 9.21 (3.86) | 8.23–10.19 |
| Outcomes | Transferred (n = 82) | Non-transferred (n = 288) | Pvalue |
| Mortality, n (%) | 35 (42.7) | 150 (52.1) | 0.13 |
| Kidney status among survivors, n (%) | |||
| Full recovery | 6 (12.8) | 46 (33.3) | 0.02 |
| Partial recovery | 20 (42.6) | 42 (30.4) | |
| Renal replacement therapy-dependent | 21 (44.7) | 50 (36.2) |
| Univariate | Multivariate | |||||
| Variable | HR | 95% CI | P | HR | 95% CI | P |
| Gender F/M | 1.35 | 0.80-2.25 | 0.26 | – | – | – |
| Age < 60/≥60 yr | 1.59 | 0.95-2.67 | 0.08 | – | – | – |
| Tumor site | – | – | 0.17 | – | – | – |
| body/fundus | 0.47 | 0.20-1.09 | 0.078 | – | – | – |
| antrum/fundus, body | 0.57 | 0.29 -1.13 | 0.11 | – | – | – |
| Tumor size < 5/ ≥5 cm | 1.72 | 1.02-2.90 | 0.043 | – | – | 0.57 |
| grade Well/Poorly | 0.57 | 0.26-1.27 | 0.17 | – | – | – |
| T stage | – | – | 0.004 | – | – | 0.019 |
| T3/T2 | 1.60 | 0.66-3.89 | 0.30 | 0.83 | 0.33–2.12 | 0.70 |
| T4/T2,T3 | 3.36 | 1.38–8.15 | 0.007 | 1.86 | 0.73–4.70 | 0.19 |
| N stage N0,N1/N2,N3 | 2.87 | 1.57–5.21 | 0.001 | – | – | 0.12 |
| Vascular−/+ | 1.23 | 0.65-2.34 | 0.52 | – | – | – |
| Perineural−/+ | 1.32 | 0.71-2.43 | 0.38 | – | – | – |
| Margin−/+ | 1.29 | 0.72-2.31 | 0.40 | – | – | – |
| TNM stage I,II/III,IV | 4.05 | 2.04– 8.03 | <0.001 | 2.99 | 1.45–6.16 | 0.003 |
| hK6−/+ | 2.88 | 1.40-5.92 | 0.004 | 2.66 | 1.25–5.63 | 0.011 |
| Drowning | No of cases | Testing rates | |
| Alcohol(%) | Medicinal drugs(%) | ||
| Unintentional (V90, V92, W65-W74) | 1746 | 100% | 91.5% |
| Boating-related (V90, V92) | 303 | 100% | 91.1% |
| Non-boating (W65-W74) | 1443 | 100% | 91.6% |
| Variable | Mean (SD) |
| Total energy (kJ) | 7709.0 (2320.4) |
| Total soy product (g) | 45.0 (33.8) |
| Tofu (g) | 20.8 (22.0) |
| Tofu products (g) | 3.0 (5.8) |
| Fermented soybeans (g) | 10.2 (13.3) |
| Boiled soybeans (g) | 4.1 (9.4) |
| Miso (g) | 1.7 (5.3) |
| Miso soup (g) | 5.2 (4.6) |
| Soy protein (g) | 4.6 (3.5) |
| Isoflavone (mg) | 26.8 (21.7) |
| Daidzein (mg) | 10.1 (8.2) |
| Genistein (mg) | 16.7 (13.5) |
| Perceived stress (PS) owing to the following items in Indistinct organisation and conflicts | High stress perception | No/Low stress perception | ||
| % (95% CI) | n | % (95% CI) | n | |
| PS owing to increased work-load | 38 (33 – 43) | 160 | 62 (57 – 67) | 264 |
| PS owing to unclear goals at workplace | 14 (11 – 18) | 60 | 86 (82 – 89) | 364 |
| PS owing to unclear work assignments | 7 (4 – 9) | 28 | 93 (91 – 95) | 396 |
| PS owing to unclear leadership | 3 (1 – 5) | 12 | 97 (95 – 99) | 412 |
| PS owing to conflicts at work | 23 (19 – 27) | 98 | 77 (73 – 81) | 326 |
| PS owing to involved in conflicts at work | 12 (9 – 15) | 49 | 88 (85 – 91) | 375 |
| PS owing to supervisor not solved the conflicts | 17 (13 – 21) | 71 | 83 (79 – 87) | 353 |
| Perceived stress (PS) owing to the following items in Individual demands and commitment | ||||
| PS owing to high demands on oneself at work | 29 (25 – 34) | 125 | 71 (66 – 75) | 299 |
| PS owing to engaged in one's work | 17 (14 – 21) | 72 | 83 (79 – 86) | 352 |
| PS owing to think about work after working-day | 25 (21 – 29) | 106 | 75 (71 – 79) | 318 |
| PS owing to hard to set limits | 44 (39 – 49) | 187 | 56 (51 – 61) | 237 |
| PS owing to high responsibility for one's work | 29 (25 – 34) | 123 | 71 (66 – 75) | 301 |
| PS owing to work over-time/stress | 24 (20 – 28) | 102 | 76 (72 – 80) | 322 |
| PS owing to sleep disturbance on account of work | 26 (22 – 31) | 112 | 74 (69 – 78) | 312 |
| At-genome | Dt-genome | |||
| A | T | C | G | |
| A | 0 | 190,935 | 132,443 | 409,059 |
| T | 190,468 | 0 | 407,605 | 132,678 |
| C | 117,349 | 363,240 | 0 | 86,903 |
| G | 363,609 | 117,194 | 87,509 | 0 |
| CWH43 | YDR056C | ROT2 | ADP1 | SCT1 | PEP1 | |
| CWH43 | No Data | 1.43 | -1.29 | No Data | 0.08 | 1.31 |
| YDR056C | 1.43 | No Data | 1.39 | 1.23 | 0.81 | 0.23 |
| ROT2 | -1.29 | 1.39 | No Data | 0.74 | 0.31 | -0.87 |
| ADP1 | No Data | 1.23 | 0.74 | No Data | 0.25 | -0.64 |
| SCT1 | 0.08 | 0.81 | 0.31 | 0.25 | No Data | No Data |
| PEP1 | 1.31 | 0.23 | -0.87 | -0.64 | No Data | No Data |
| MHPA | PKU | |
| Number patients | 41 | 100 |
| Gender – Male | 20 | 47 |
| Gender – Female | 21 | 53 |
| Average Age | 9y 7 m | 17y 10 m |
| Under 18 years | 35 | 57 |
| zBMI – obese + overweight | 3 | 34 |
| zBMI – normal | 33 | 61 |
| zBMI – underweight | 5 | 5 |
| WC - obese + overweight | 7 | 45 |
| WC - normal | 30 | 50 |
| WC - underweight | 4 | 5 |
| AC - obese + overweight | 5 | 21 |
| AC - normal | 21 | 27 |
| AC - underweight | 4 | 15 |
| Early Diagnostic | 40 | 85 |
| BH4 treatment | 0 | 17 |
| Adequated Diet adherence | 40 | 80 |
| Phe Tol (mg/day) | 1889.6 ± 831.9 | 481.1 ± 376.3 |
| Phe median (μmol/L) | 238.6 ± 93.2 | 397.3 ± 281.9 |
| Total Cholesterol (mg/dL) | 164.2 ± 21.9 | 149.9 ± 31.5 |
| HDL (mg/dL) | 55.8 ± 12.6 | 49.8 ± 11.9 |
| LDL (mg/dL) | 92.1 ± 17.2 | 82.1 ± 24.7 |
| ApoA (mg/dL) | 160.7 ± 26.4 | 144.1 ± 25.9 |
| ApoB (mg/dL) | 75.5 ± 17.6 | 65.9 ± 19.1 |
| LDL/ApoB | 1.26 ± 0.16 | 1.22 ± 0.19 |
| Triglycerids (mg/dL) | 79.2 ± 36.2 | 91.7 ± 45.7 |
| Homocystein (μmol/L) | 5.9 ± 2.4 | 5.9 ± 3.3 |
| Systolic BP (mmHg) | 105.5 ± 12 | 114.9 ± 14.4 |
| Diastolic BP (mmHg) | 65.7 ± 10.5 | 69.3 ± 13.7 |
| B12 (pg/mL) | 584.9 ± 205.6 | 664.5 ± 333.6 |
| Zinc (μg/dL) | 82.4 ± 33.1 | 81.2 ± 21.5 |
| Copper (μg/dL) | 86 ± 22.5 | 78.4 ± 21.3 |
| Zinc/Copper | 1.01 ± 0.46 | 1.11 ± 0.45 |
| Trait | Average heterozygosity | Rotation 1 | Rotation 2 | Rotation 3 | Rotation 4 |
| Age | 0.02 | 0.14 | 0.16 | 0.07 | 0.06 |
| Smoke | −0.01 | −0.04 | −0.05 | 0.04 | 0.01 |
| Q1 | 0.16 | −0.15 | −0.07 | 0.05 | −0.19 |
| Q2 | 0.05 | −0.01 | 0.01 | −0.04 | −0.05 |
| Q4 | −0.06 | −0.09 | −0.12 | −0.07 | −0.03 |
| Q1A | 0.17 | −0.21 | −0.12 | 0.02 | −0.24 |
| Q1B | 0.02 | 0.00 | −0.01 | −0.01 | 0.00 |
| Q4A | −0.10 | 0.06 | 0.02 | −0.02 | 0.06 |
| Affected | 0.14 | 0.02 | 0.09 | 0.07 | −0.05 |
| Non-musicians | Musicians | Pianists | String players | |
| n | 16 | 15 | 7 | 8 |
| Male/Female | 6/10 | 9/6 | 4/3 | 5/3 |
| Age (years) | 23.81 (2.14) | 24.13 (2.35) | 24.29 (3.40) | 24.00 (1.60) |
| AGE OF ONSET (YEARS) | ||||
| Mean (SD) | – | 5.47 (1.25) | 5.57 (1.62) | 5.38 (0.92) |
| Range | – | 4–8 | 4–8 | 4–6 |
| FORMAL TRAINING (YEARS) | ||||
| Mean (SD) | – | 11.40 (3.33) | 10.00 (3.00) | 12.63 (3.29) |
| Range | – | 6–16 | 6–14 | 6–16 |
| CURRENT PRACTICE (H/WEEK) | ||||
| Mean (SD) | – | 6.60 (7.21) | 4.00 (5.69) | 8.88 (7.97) |
| Range | – | 0–25 | 0–15 | 2–25 |
| ELECTROPHYSIOLOGY | ||||
| 1mV L (%) | 45.38 (7.36) | 46.67 (6.38) | 49.00 (6.71) | 44.63 (5.71) |
| 1mV R (%) | 47.50 (7.47) | 47.07 (5.46) | 49.14 (4.14) | 45.25 (6.07) |
| IHI LR (%) | 38.34 (24.57)*+ | 54.37 (15.49) | 48.53 (16.34) | 59.47 (13.67) |
| IHI RL (%) | 45.22 (20.66) | 43.82 (19.80) | 42.56 (18.81) | 44.93 (21.86) |
| Variables | Adnexal Torsion (n = 17) | Control (n = 34) | p |
| Acute onset pain (<8 h) | 11 (64.7%) | 16 (47.1%) | 0.23 |
| Cyst diameter > 5cm | 14 (82.4%) | 14 (41.2%) | <0.001 |
| Peritoneal signs | 9 (52.9%) | 13 (38.2%) | 0.32 |
| Nausea and vomiting | 6 (35.3%) | 3 (8.8%) | 0.04 |
| Negative flow in Doppler | 8 (47.1%) | 2 (5.8%) | 0.001 |
| Leukocytosis (WBC ≥ 12 × 103) (cells/mm3) 10 (71.4%) | 8 (47.1%) | 6 (17.6%) | 0.04 |
| Elevated CRP (≥8 mg/L) | 5 (29.4%) | 4 (11.7%) | 0.14 |
| * Elevated D-dimer | 13 (76.5%) | 3 (8.8%) | 0.001 |
| Drug class | Ovarian cancer indication | Black box warnings | Warnings and precautions | |
| Bevacizumab [33] | VEGF inhibitor; anti-angiogenesis | Platinum-resistant recurrent disease• In combination with paclitaxel, PLD, or topotecan with no more than 2 prior lines of chemotherapyPlatinum-sensitive recurrent disease• In combination with carboplatin and paclitaxel, or carboplatin and gemcitabine; followed by single-agent bevacizumab | • Gastrointestinal perforations• Surgery and wound healing complications• Hemorrhage | • Perforation or fistula• Arterial and venous thromboembolic events• Hypertension• Posterior reversible encephalopathy syndrome• Proteinuria• Infusion reactions• Embryo-fetal toxicity• Ovarian failure |
| Niraparib [36] | PARP inhibitor | Maintenance treatment of recurrent disease in complete or partial response to platinum-based chemotherapy | None | • Myelodysplastic syndrome/acute myeloid leukemia• Bone marrow suppression• Cardiovascular effects (blood pressure and heart rate)• Embryo-fetal toxicity |
| Olaparib [35] | PARP inhibitor | Maintenance treatment of recurrent disease in complete or partial response to platinum-based chemotherapyTreatment of deleterious or suspected deleterious germline BRCA-mutated disease with ≥3 prior lines of chemotherapy; requires FDA-approved companion diagnostic test | None | • Myelodysplastic syndrome/acute myeloid leukemia• Pneumonitis• Embryo-fetal toxicity |
| Rucaparib [34] | PARP inhibitor | Monotherapy in patients with deleterious BRCA mutations treated with two or more prior chemotherapies; requires companion diagnostic test | None | • Myelodysplastic syndrome/acute myeloid leukemia• Embryo-fetal toxicity |
| Inhibited Temperament | Uninhibited Temperament | p value | |||
| Mean | SD | Mean | SD | ||
| Temperament | |||||
| Retrospective | 3.0 | .32 | 1.5 | .22 | .0001 |
| Current | 3.1 | .55 | 1.7 | .14 | .0001 |
| Demographics | |||||
| Age | 22.20 | 3.62 | 21.30 | 2.45 | NS |
| Gender (% Male) | 40% | 40% | NS | ||
| Handedness (% Right) | 80% | 100% | NS | ||
| Ethnicity | .07 | ||||
| % Caucasian | 50% | 70% | |||
| % African-American | 10% | 30% | |||
| % Asian | 40% | 0% |
| SF-36 domains | ASA | Scheduled surgery | Magnitude | ||||||
| I/II | III/IV | pa | Yes | No | P | Major | Mediun/minor | pa | |
| Physical function | 65 | 45 | <0.001 | 55 | 55 | 0.842 | 55 | 50 | 0.626 |
| Role physical | 50 | 25 | <0.001 | 44 | 38 | 0.534 | 44 | 38 | 0.350 |
| Bodily pain | 62 | 52 | 0.118 | 52 | 52 | 0.180 | 52 | 52 | 0.286 |
| General health | 50 | 40 | 0.001 | 45 | 55 | 0.533 | 45 | 45 | 0.330 |
| Vitality | 42 | 27 | <0.001 | 33 | 29 | 0.204 | 33 | 33 | 0.408 |
| Social function | 63 | 50 | 0.006 | 63 | 63 | 0.999 | 63 | 50 | 0.121 |
| Role emotional | 67 | 42 | <0.001 | 50 | 50 | 0.733 | 50 | 50 | 0.313 |
| Mental health | 56 | 44 | 0.001 | 48 | 48 | 0.837 | 48 | 48 | 0.939 |
| Authors | Specimen bone | Yield strength (Re)[MPa] | Ult. tensile strength (σult)[MPa] | Elongation at break (εult)[%] |
| (Yamada 1970) | Femur | 109 | 1.35 | |
| (Reilly and Burstein 1975) | Femur | 114 | 135 | 3.1 |
| (Vinz 1975) | Femur for adults (avg. 30 years) | 106 | 0.26 | |
| (Evans 1976) | Tibia (avg. 41.5 years) | 106 | 1.76 | |
| (Evans 1976) | Tibia (avg. 72 years) | 84 | 1.56 | |
| (McCalden et al. 1993)(Ott 2007, Ott et al. 2010) | Femur (avg. between [20–102] years) | 71 | 98 | 2.4 |
| (MatWeb, 2016) | Femur | 135 | 3.1 |
| Subgroups | No. of studies | HR (95% CI) | I2 (P value) |
| Population | |||
| Children | 6 | 5.62 (3.75–8.42) | 3.2% (0.40) |
| Mixed adult and children | 2 | 3.60 (1.72–7.51) | 65.2% (0.09) |
| Design | |||
| Prospective | 5 | 5.33 (2.88–9.86) | 57.6% (0.05) |
| Retrospective | 3 | 4.59 (2.89–7.27) | 0 (0.73) |
| Detection method | |||
| PCR | 6 | 4.97 (2.93–8.44) | 49.2% (0.08) |
| FC | 2 | 4.77 (3.31–6.87) | 0 (0.70) |
| Adjustment | |||
| Adjusted | 4 | 4.56 (2.64–7.88) | 48.9% (0.12) |
| Crude | 4 | 5.18 (2.94–9.11) | 24.4% (0.27) |
| Factor | Responsive | Unresponsive | p-Value | OR | 95% CI of OR | |
| Lower | Upper | |||||
| Gender, males | 21 (40.4%) | 11 (28.9%) | 0.265 | 1.663 | 0.680 | 4.063 |
| Age, years | 46.75 ± 12.95 | 41.68 ± 17.3 | 0.117 | 1.023 | 0.994 | 1.053 |
| Duration of eye symptoms, months | 8.75 [4–12]a | 24 [12–75] | 0.011 | 0.984 | 0.971 | 0.996 |
| Smoking history | 28 (53.8%) | 19 (50%) | 0.718 | 1.167 | 0.505 | 2.696 |
| Family history of TAO | 9 (17.3%) | 12 (31.6%) | 0.118 | 0.453 | 0.168 | 1.223 |
| History of impaired thyroid function | 44 (84.6%) | 36 (94.7%) | 0.149 | 0.306 | 0.061 | 1.530 |
| Pretreatment CAS | 4 [3–4] | 2 [1–3] | 0.001 | 1.653 | 1.214 | 2.250 |
| Restoration of euthyroidism | 19 (36.5%) | 6 (15.8%) | 0.026 | 3.272 | 1.150 | 9.315 |
| Parameters | Seminal leukocytes (X 106 WBC/mL) | ||
| No leukocytes | 0.1 – 1 WBC | > 1 WBC | |
| Concentration (X 106/mL) | 53.04 ± 56.76 | 69.04 ± 80.72 | 39.35 ± 39.98 |
| Motility (%) | 48.37 ± 17.42 | 47.33 ± 25.74 | 49.23 ± 19.56 |
| Normal morphology (%) | 3.42 ± 3.12 | 3.56 ± 3.16 | 4.14 ± 3.79 |
| ROS (RLU/ sec) | 116.7 (49; 550.3) | 944.8 (127; 3315.4)a | 61286.8 (6905; 234876)a,b |
| DNA damage (%) | 19.89 ± 17.31 | 26.47 ± 19.64a | 24.60 ± 17.47 |
| Percentile GroupsGlobal Improved (%) | ||||
| Variable | Lowest tertile | Middle tertile | Highest tertile | Fisher's Exact Test |
| Patellar Length Ratio (PLR) | 3(25) | 5(38.5) | 4(30.8) | p = 0.907 |
| Bisect Offset (BO) | 8(66.7) | 1(7.7) | 3(23.1) | p = 0.007 |
| Patellar Tilt Angle (PTA) | 5(41.7) | 5(38.5) | 2(15.4) | p = 0.323 |
| Trochlear Inclination (TI) (Lateral) | 4(33.3) | 3(23.1) | 5(38.5) | p = 0.757 |
| Trochlear Inclination (TI) (Medial) | 2(16.7) | 6(46.2) | 4(30.8) | p = 0.383 |
| Trochlear Angle (TA) | 3(25) | 5(38.5) | 4(30.8) | p = 0.907 |
| Sulcus Angle (SA) | 4(33.3) | 4(30.8) | 4(30.8) | p = 1 |
| Lateral Patellofemoral Angle (LPFA) | 2(16.7) | 6(46.2) | 4(30.8) | p = 0.383 |
| Congruence Angle (CA) | 5(41.7) | 5(38.5) | 2(15.4) | p = 0.323 |
| Patellar Lateral Subluxation Distance (PSD) | 7(63.6) | 4(33.3) | 1(8.3) | p = 0.023 |
| Lateral Patellar Displacement (LPD) | 3(27.3) | 5(41.7) | 4(33.3) | p = 0.903 |
| Characteristic | Total (n:12) |
| Demographic characteristics | |
| Age, median (range) | 32 (21–56) |
| Men, number | 9 |
| Epidemiological characteristics and risk factors | |
| Foreigners, numbera | 1 |
| MSM/men, ratio | 9/9 |
| High-risk sexual behaviourb, number | 9 |
| Contact with infected individuals, numberc | 3 |
| Travelled in the 2 months before symptom onset, number | 0 |
| Cases who used drugsd, number | 5 |
| Cases with severe hepatitise, number | 2 |
| Cases which were hospitalised, number | 4 |
| Sexually transmitted co-infections | |
| HIV, number | 5 |
| HBV, number | 1 |
| HCV, number | 0 |
| Syphilis, number | 2 |
| Liver function tests | |
| ALT, median (range) | 3,609 (1,615–5,904) |
| Total bilirubin, median (range) | 8.6 (4–21) |
| INR, median (range) | 1.4 (1.2–2.0) |
| Speciation Mode | Synopsis | References |
| Point mutation | Speciation whereby each individual in the metacommunity has an equal probability of producing an offspring of a new species. Produces many rare species with lifetimes unrealistically short | Hubbell (2001) |
| Random fission | Speciation occurs through a population randomly dividing into two distinct species. Produces species with lifetimes unrealistically long | Hubbell and Lake (2003), Hubbell (2005), Etienne and Haegeman (2011) |
| Peripheral isolate | Divergence follows the isolation of populations. Newly arisen species have abundances drawn from a normal distribution | Hubbell and Lake (2003), Hubbell (2005) |
| Generalized speciation | A generalized neutral community model incorporating numerous modes | Haegeman and Etienne (2009) |
| Protracted speciation | Speciation is a gradual, drawn out process. Results in a new predicted metacommunity SAD (termed the “difference logseries”) | Rosindell et al. (2010) |
| a) AUC for “highly suspected drugs“ | b) AUC for “highly suspected drugs“ or “suspected drugs“ | |
| Univariable CLR | 0.836 | 0.871 |
| Multivariable CLR | 0.741 | 0.775 |
| Lasso | 0.862 | 0.861 |
| Elastic net | 0.868 | 0.909 |
| Bolasso | 0.804 | 0.813 |
| Sublasso | 0.815 | 0.823 |
| Random lasso | 0.820 | 0.847 |
| Firth correction | 0.852 | 0.928 |
| Case-controla | 0.947 | 0.809 |
| Integrins | OS | RFS | ||
| Log-rank P | Cox P* | Log-rank P | Cox P* | |
| ITGA1 | 0.861 | 0.438 | 0.793 | 0.471 |
| ITGA2 | 0.241 | 0.762 | 0.305 | 0.727 |
| ITGA2B | 0.230 | 0.064 | 0.172 | 0.032 |
| ITGA3 | 0.209 | 0.217 | 0.721 | 0.997 |
| ITGA4 | 0.138 | 0.327 | 0.069 | 0.095 |
| ITGA5 | 0.013 | 0.041 | 0.003 | 0.006 |
| ITGA6 | 0.885 | 0.337 | 0.377 | 0.089 |
| ITGA7 | 0.126 | 0.169 | 0.438 | 0.407 |
| ITGA8 | 0.579 | 0.826 | 0.877 | 0.784 |
| ITGA9 | 0.481 | 0.813 | 0.094 | 0.072 |
| ITGA10 | 0.509 | 0.567 | 0.308 | 0.510 |
| ITGAE | 0.528 | 0.464 | 0.906 | 0.913 |
| ITGAL | 0.803 | 0.913 | 0.562 | 0.672 |
| ITGAM | 0.463 | 0.677 | 0.439 | 0.777 |
| ITGAV | 0.411 | 0.172 | 0.825 | 0.692 |
| ITGAX | 0.877 | 0.079 | 0.517 | 0.879 |
| ITGB1 | 0.403 | 0.822 | 0.340 | 0.846 |
| ITGB2 | 0.902 | 0.654 | 0.514 | 0.298 |
| ITGB3 | 0.614 | 0.154 | 0.042 | 0.064 |
| ITGB4 | 0.716 | 0.983 | 0.735 | 0.407 |
| ITGB5 | 0.016 | 0.048 | 0.069 | 0.042 |
| ITGB6 | 0.434 | 0.928 | 0.625 | 0.768 |
| ITGB7 | 0.451 | 0.635 | 0.523 | 0.591 |
| ITGB8 | 0.945 | 0.919 | 0.615 | 0.760 |
| Stunting n = 3886 | Wasting n = 3886 | Underweight n = 3886 | Overweight n = 4302 | Anemia n = 3798 | ||||||
| p-Value | OR ** (95% CI) | p-Value | OR ** (95% CI) | p-Value | OR ** (95% CI) | p-Value | OR ** (95% CI) | p-Value | OR ** (95% CI) | |
| Age in months * | <0.001 | 1.22 (1.16–1.28) | Ns. | - | <0.001 | 1.23 (1.16–1.29) | <0.001 | 0.77 (0.69–0.86) | <0.001 | 0.66 (0.63–0.70) |
| Gender (ref = female) * | Ns. | - | Ns. | - | Ns. | - | 0.031 | 1.76 (1.05–2.94) | Ns. | - |
| Wealth index | <0.001 | 0.83 (0.78–0.89) | 0.015 | 0.89 (0.82–0.98) | <0.001 | 0.84 (0.7–0.90) | 0.038 | 1.22 (1.01–1.47) | <0.001 | 0.85 (0.79–0.91) |
| Living area (ref = rural) | - | - | - | - | - | - | - | - | 0.034 | 0.77 (0.60–0.98) |
| BMI of mother | <0.001 | 0.63 (0.52–0.78) | <0.001 | 0.56 (0.41–0.76) | <0.001 | 0.49 (0.40–0.60) | - | - | 0.017 | 0.81 (0.6–0.96) |
| Low birth weight (ref = normal birth weight) | <0.001 | 2.12 (1.51–2.98) | <0.001 | 2.30 (1.49–3.55) | <0.001 | 2.59 (1.83–3.66) | - | - | - | - |
| Wasting | 0.039 | 1.35 (1.02–1.78) | ||||||||
| Stunting | <0.001 | 1.46 (1.22–1.75) |
| Category | Previous Methods [12] | Proposed Method |
| Number of classes | 24 | 64 |
| Number of USD images | 15,000 | 61,240 |
| False recognition rate (%) | 0.12 | 0.114 |
| Reject rate (%) | 0.58 | 0 |
| Z‐score | G/G | A/C | C/A | U/U | U/C | C/U | A/A | C/C | G/A | A/G |
| G/G | 0.00 | 1.26 | 1.47 | 1.56 | 4.67 | 5.70 | 8.46 | 9.42 | 9.42 | 10.43 |
| A/C | −1.26 | 0.00 | 0.22 | 0.30 | 3.42 | 4.46 | 7.25 | 8.23 | 8.23 | 9.26 |
| C/A | −1.47 | −0.22 | 0.00 | 0.09 | 3.21 | 4.25 | 7.04 | 8.03 | 8.03 | 9.06 |
| U/U | 1.56 | −0.30 | −0.09 | 0.00 | 3.12 | 4.17 | 6.96 | 7.95 | 7.95 | 8.98 |
| U/C | −4.67 | −3.42 | −3.21 | −3.12 | 0.00 | 1.05 | 3.90 | 4.92 | 4.92 | 5.99 |
| C/U | 5.70 | −4.46 | −4.25 | −4.17 | −1.05 | 0.00 | 2.86 | 3.89 | 3.89 | 4.97 |
| A/A | −8.46 | −7.25 | −7.04 | −6.96 | −3.90 | −2.86 | 0.00 | 1.04 | 1.04 | 2.15 |
| C/C | −9.42 | −8.23 | −8.03 | −7.95 | −4.92 | −3.89 | −1.04 | 0.00 | 0.00 | 1.11 |
| G/A | −9.42 | −8.23 | −8.03 | −7.95 | −4.92 | −3.89 | −1.04 | 0.00 | 0.00 | 1.11 |
| A/G | −10.43 | −9.26 | −9.06 | −8.98 | −5.99 | −4.97 | −2.15 | −1.11 | −1.11 | 0.00 |
| Surf | Type | Radius (mm) | Thickness (mm) | Glass | Semidiameter (mm) | Conic |
| OBJ | Standard | 15 | 10 | 10.143393 | 0 | |
| 1 | Standard | 75.638249 | 0.228611 | E48R | 1.467268 | 0 |
| 2 | Even Asphere | 0.730586 | 0.375833 | 0.998383 | −0.7580 | |
| 3 | Even Asphere | 0.677934 | 1.181807 | CAF2 | 0.908234 | −1.5743 |
| 4 | Standard | −1.704216 | 0.173513 | 0.692586 | 0 | |
| STO | Standard | Infinity | 0.055548 | 0.380945 | 0 | |
| 6 | Standard | 15.517551 | 0.530639 | CAF2 | 0.441318 | 0 |
| 7 | Standard | −1.085120 | 0.367124 | 0.619864 | 0 | |
| 8 | Even Asphere | −3.065604 | 0.285170 | COC | 0.714128 | 14.9694 |
| 9 | Even Asphere | 1.970309 | 1.236203 | 1.097346 | −43.1582 | |
| IMA | Infinity | — | 2.328690 | 0 |
| Mean (SD) or N | Mean (SD) or N | P value | |
| Methylphenidate slow release (N = 28) | Placebo (N = 28) | ||
| Age (years) | 35.6(10.8) | 34.7(11.5) | ns |
| Gender, n | 8 | 7 | ns |
| • Female | 20 | 21 | |
| • Male | |||
| Marital status, n | ns | ||
| • Single | 18 | 19 | |
| • Married | 6 | 5 | |
| • Divorced | 4 | 4 | |
| Level of education, n | ns | ||
| • Illiterate | 2 | 1 | |
| • Primary school | 16 | 17 | |
| • High school diploma | 8 | 9 | |
| • University degree | 2 | 1 | |
| Smoking, n | 25 | 26 | ns |
| Use of methadone | 12 | 11 | ns |
| Employed, n | 5 | 7 | ns |
| Years of methamphetamine use | 13.3(8.5) | 12.8(9.1) | ns |
| Days of methamphetamine use (past month) | 10.2(8.7) | 10.4(8.8) | ns |
| Route of methamphetamine use, n | ns | ||
| • Smoking | 23 | 22 | |
| • Nasal | 3 | 2 | |
| • Injection | 1 | 1 | |
| • Oral | 1 | 3 | |
| Addiction severity index composite score | ns | ||
| • Medical | 0.25(0.31) | 0.28(0.26) | |
| • Employment | 0.22(017) | 0.24(0.19) | |
| • Alcohol | 0.15(0.10) | 0.14(0.13) | |
| • Drug | 0.28(0.1) | 0.29(0.12) | |
| • Legal | 0.08(0.17) | 0.07(0.16) | |
| • Family/Social | 0.22(0.23) | 0.19(0.20) | |
| • Psychiatric | 0.24(0.25) | 0.22(0.23 |
| City | Number of Stations | 2008 | 2009 | 2010 | 2011 |
| Kochi | 7 | 43 | 42 | 36 | 38 |
| Kozhikode | 2 | 34 | 32 | 42 | 46 |
| Thrissur | 1 | – | – | 31 | 33 |
| Mallapuram | 1 | – | – | 39 | 30 |
| Trivandrum | 4 | 67 | 61 | 56 | 58 |
| Kollam | 2 | – | – | 47 | 53 |
| MRI | Surgical pathology | Sensitivitya, % (n) | Specificityb, % (n) | POS predictionc value, % (n) | NEG predictiond value, % (n) | Accuracye, % (n) | κ | P-value | |
| POS | NEG | ||||||||
| T1 | 60 (3/5) | 96 (24/25) | 75 (3/4) | 92.33 (24/26) | 90 (27/30) | 0.61 | <0.001 | ||
| POS | 3 | 1 | |||||||
| NEG | 2 | 24 | |||||||
| T2 | 83.3 (5/6) | 87.5 (21/24) | 62.5 (5/8) | 95.4 (21/22) | 86.7 (26/30) | 0.71 | <0.001 | ||
| POS | 5 | 3 | |||||||
| NEG | 1 | 21 | |||||||
| T3 | 90 (9/10) | 90 (18/20) | 81.8 (9/11) | 94.7 (18/19) | 90 (27/30) | 0.78 | <0.001 | ||
| POS | 9 | 2 | |||||||
| NEG | 1 | 18 | |||||||
| T4 | 87.5 (7/8) | 100 (22/22) | 100 (7/7) | 95.7 (22/23) | 96.7 (29/30) | 0.91 | <0.001 | ||
| POS | 7 | 0 | |||||||
| NEG | 1 | 22 |
| Clinicopathologicalcharacteristics | KRAS/BRAF gene | P-value | |
| Mutation(n = 11) | Wild-type(n = 21) | ||
| Age (years) | 0.106 | ||
| < 45 | 1 (9.10%) | 9 (42.86%) | |
| ≥ 45 | 10 (90.90%) | 12 (57.14%) | |
| FIGO stage | 1.000 | ||
| I/II | 3 (27.27%) | 7 (33.33%) | |
| III/IV | 8 (72.73%) | 14 (66.67%) | |
| CA125 (U/ml) | 1.000 | ||
| ≤ 35 U/mL | 0 (0.00%) | 1 (4.76%) | |
| > 35 U/mL | 11 (100.00%) | 20 (95.24%) | |
| Tumor size(cm) | 0.442 | ||
| < 10 | 5 (45.45%) | 6 (28.57%) | |
| ≥ 10 | 6 (54.55%) | 15 (71.43%) | |
| Laterality | 0.053 | ||
| Unilateral | 7 (63.64%) | 5 (23.81%) | |
| Bilateral | 4 (36.36%) | 16 (76.19%) | |
| Cytology | 0.703 | ||
| Negative | 8 (72.73%) | 13 (61.90%) | |
| Positive | 3 (27.27%) | 8 (38.10%) | |
| Ascites | 0.441 | ||
| Absent | 2 (18.18%) | 7 (33.33%) | |
| Present | 9 (81.82%) | 14 (66.67%) | |
| Ovarian surface involvement | 0.815 | ||
| No | 3 (27.27%) | 8 (38.10%) | |
| Yes | 7 (63.64%) | 11 (52.38%) | |
| Unknown | 1 (9.10%) | 2 (9.52%) | |
| Metastases | 1.000 | ||
| No | 3 (27.27%) | 7 (33.33%) | |
| Yes | 8 (72.73%) | 14 (66.67%) | |
| Lymph node involvement | 0.392 | ||
| No | 1 (9.10%) | 1 (4.76%) | |
| Yes | 2 (18.18%) | 1 (4.76%) | |
| Unknown | 8 (72.73%) | 19 (90.48%) |
| Authors | Date | Conditionaand sample size | Exploration-insight gain | Experiential gain | Action gain |
| Current study | Ullman dream group. (n = 11) | 8.17 (0.54) | 7.28 (1.94) | 5.78 (1.04) | |
| Heaton et al. | 1998 | Therapist-facilitated, following Hill (1996). (n = 25) | 8.03 (0.73) | 7.06 (1.50) | 6.98 (1.07)** |
| Self-guided, following Hill (1996) as adapted by Hill et al. (1996). (n = 25) | 6.61 (1.35)** | 6.76 (1.74) | 5.99 (1.11) | ||
| Hill et al. | 1998 | Participants elaborate on image details in dream, following only the Exploration Stage of the Hill (1996) model. (n = 17) | 4.61 (1.71)** | Not reported | Not reported |
| Participants provide associations to images, following only the Exploration Stage of the Hill (1996) model. (n = 17) | 6.48 (1.35)** | Not reported | Not reported | ||
| Participants elaborate on image details and provide associations. Following only the Exploration Stage of the Hill (1996) model. (n = 17) | 5.84 (1.76)** | Not reported | Not reported | ||
| Zack and Hill | 1998 | Used Hill (1996) model. (n = 38) | 7.67 (1.10) | 7.09 (1.42) | 6.34 (1.74) |
| Rochlen et al. | 1999 | Pre-study discussion of benefits of dream contemplation. Participants encouraged to use strategies to boost dream recall prior to study following Hill (1996). (n = 14) | 7.48 (1.48) | 7.00 (1.70) | 6.03 (1.41) |
| Involved an introduction to Hill model and participation in two sessions of the group procedure prior to study following Hill (1996). (n = 14) | 8.04 (0.96) | 6.79 (1.97) | 7.01 (1.34)* | ||
| Pre-study discussion of theoretical perspectives regarding counseling prior to study following Hill (1996). (n = 14) | 7.92 (0.82) | 7.32 (1.48) | 6.79 (1.22)* | ||
| Hill et al. | 2000 | Dream condition, following Hill (1996). (n = 7) | 8.08 (0.52) | 7.43 (0.97) | 7.54 (0.49)** |
| Control condition: Recent loss focussed on, not a dream (n = 7)b | 6.63 (0.76)** | 6.59 (0.99) | 6.12 (0.82) | ||
| Wonnell and Hill | 2000 | Hill (1996) followed, action stage omitted (n = 23) | 7.88 (1.06) | Not reported | 6.10 (1.24) |
| Hill (1996) followed, including Action stage (n = 20) | 7.99 (1.00) | Not reported | 6.98 (1.45)* | ||
| Hill et al. | 2001 | Followed Hill (1996). (n = 105) | 7.77 (1.20) | Not reported | Not reported |
| Hill et al. | 2003 | Participants type dream and computer-generated voice asks questions, following Hill (1996). (n = 39) | 6.72 (1.27)** | Not reported | 6.12 (1.73) |
| Therapist empathy: Followed Hill (1996) but therapists did not offer interpretations or provide action suggestions. (n = 26) | 7.75 (0.85) | Not reported | 6.60 (1.16) | ||
| Therapist empathy + input: Followed Hill (1996), at least one therapist interpretation and one action idea offered to participants. (n = 29) | 7.93 (0.93) | Not reported | 6.81 (1.05)** | ||
| All Hill studies | Weighted mean (SD) of all Hill dream conditionsc | 7.40 (1.15) | 7.03 (1.56) | 6.51 (1.34) |
| Study intervention | N | Darunavir Ctrough,ss, ng/mL | Elvitegravir Ctrough,ss, ng/mL | Refs. | ||
| Median/mean | Range | Median/mean | Range | |||
| DRV/rtv, pre-switch | 5 | 981 (median)932 (mean) | 667–1150 | –– | – | |
| E/C/F/TDF + DRV | 9 | 482 (median)490 (mean) | 96–848 | 184 (median)200 (mean) | <80–435 | |
| DRV/rtv 800/100 mg | 335a | 2041 (median) | 368–7242 | – | – | [22] |
| 119 | 1820 (mean) | IQR 1470–2460 | – | – | [23] | |
| DRV/cobi 800/150 mg | 298a | 2150 (mean) | SD 1320 | – | – | [25] |
| 59 | 1311 (mean) | SD 969 | – | – | [25] | |
| 32 | 1319 (mean) | 288–3641 | – | – | [24] | |
| E/C/F/TDF (no DRV) | 419a | – | – | 451 (mean) | 58–2341 | [26] |
| 32 | – | – | 250 (mean) | 30–762 | [24] | |
| E/C/F/TDF + DRV | 24 | 1294 (mean) | 163–3641 | 234 (mean) | 92–432 | [24] |
| 8 | 273 (median)b | 164–501 (IQR)b | – | – | [12] | |
| E/C/F/TAF + DRV | 15 | 1250 (mean) | NA | 464 (mean) | NA | [36] |
| Characteristics | Serum fibrinogen levels, g/l | p-value | |||
| Q1 (1.7–2.8) | Q2 (2.8–3.3) | Q3 (3.3–3.9) | Q4 (3.9–8.2) | ||
| Patients (n) | 171 | 167 | 167 | 165 | |
| At time of biopsy | |||||
| Female (n [%]) | 95 (55.6) | 100 (59.9) | 99 (59.3) | 87 (52.7) | 0.515 |
| Age (mean [SD], years) | 32.3 (8.3) | 36.4 (11.2) | 38.4 (11.4) | 41.9 (13.9) | < 0.001 |
| BMI (mean [SD], kg/m2) | 22.0 (2.9) | 23.00 (3.2) | 23.12 (3.3) | 24.0 (3.8) | < 0.001 |
| TC (mean [SD], g/l) | 4.4 (0.9) | 4.9 (1.1) | 5.1 (1.1) | 5.7 (1.7) | < 0.001 |
| TG (median [IQR], g/l) | 1.2 [0.9, 1.6] | 1.5 [1.1, 2.3] | 1.6 [1.1, 2.2] | 1.9 [1.3, 2.5] | < 0.001 |
| HDL-C (mean [SD], g/l) | 1.2 (0.3) | 1.2(0.3) | 1.1 (0.3) | 1.1 (0.3) | 0.521 |
| LDL-C (mean [SD], g/l) | 2.6 (0.7) | 2.9 (0.9) | 3.0 (0.8) | 3.4 (1.3) | < 0.001 |
| Scr (median [IQR], mmol/l) | 73 [59, 90] | 73 [59, 96] | 83 [63, 113] | 98 [75, 138] | < 0.001 |
| Upro (median [IQR], g/24 h) | 0.8 [0.4, 1.2] | 1.0 [0.6, 1.6] | 1.4 [0.9, 2.9] | 2.7 [1.5, 4.8] | < 0.001 |
| eGFR (mean [SD], ml/min/1.73 m2) | 105 (25.2) | 99 (25.5) | 86 (30.8) | 71 (31.9) | < 0.001 |
| ALB (mean [SD], g/l) | 40.3 (6.7) | 40.0 (6.7) | 38.1 (7.3) | 34.2 (8.3) | < 0.001 |
| UA (median [IQR], mmol/l) | 342 [274, 404] | 355 [289, 414] | 355 [305, 440] | 382 [327, 446] | < 0.001 |
| Hb (mean [SD], g/l) | 125.1 (19.3) | 130.3 (17.0) | 125.5 (18.5) | 121.6 (19.5) | < 0.001 |
| SBP (mean [SD], mmHg) | 124.96 (15.8) | 130.41 (21.3) | 132.29 (16.9) | 137.98 (19.8) | < 0.001 |
| DBP (mean [SD], mmHg) | 77.25 (10.3) | 81.34 (12.1) | 81.58 (12.4) | 84.61 (12.0) | < 0.001 |
| Oxford classification | |||||
| M1 (n [%]) | 60 (35.9) | 72 (43.4) | 75 (45.7) | 94 (57.7) | 0.001 |
| E1 (n [%]) | 55 (32.9) | 38 (22.9) | 51 (30.9) | 48 (29.4) | 0.206 |
| S1 (n [%]) | 129 (77.2) | 124 (75.2) | 134 (81.2) | 119 (73.0) | 0.338 |
| T (n [%]) | < 0.001 | ||||
| T0 | 130 (77.8) | 119 (71.3) | 89 (53.9) | 81 (49.7) | |
| T1 | 30 (18.0) | 38 (22.8) | 54 (32.7) | 39 (23.9) | |
| T2 | 7 (4.2) | 10 (6.0) | 22 (13.3) | 43 (26.4) | |
| C1 (n [%]) | 79 (46.5) | 65 (38.9) | 82 (49.1) | 86 (52.8) | 0.077 |
| Follow-up | |||||
| Follow-up time (median [IQR], months) | 41.0 [20.0, 66.5] | 34.0 [19.5, 55.5] | 34.0 [16.0, 57.5] | 35.0 [20.0, 64.0] | 0.034 |
| Primary endpoint (n [%]) | 3 (1.8) | 9 (5.4) | 29 (17.4) | 49 (29.7) | < 0.001 |
| ESRD (n [%]) | 2 (1.2) | 1 (0.6) | 10 (6.0) | 17 (10.3) | < 0.001 |
| Treated with ACEIs (n [%]) | 65 (38.0) | 54 (32.3) | 66 (39.5) | 57 (34.5) | 0.509 |
| Treated with ARBs (n [%]) | 148 (86.5) | 148 (88.6) | 147 (88.0) | 133 (80.6) | 0.136 |
| Immunosuppressant therapy | |||||
| Glucocorticoids (n [%]) | 65 (38.0) | 79 (47.3) | 95 (56.9) | 98 (59.4) | < 0.001 |
| Cyclophosphamide (n [%]) | 6 (3.5) | 3 (1.8) | 14 (8.4) | 25 (15.2) | < 0.001 |
| OtherIM (n [%]) | 36 (21.1) | 44 (26.3) | 48 (28.7) | 61 (37.0) | 0.012 |
| Uveoscleral outflow (μL min−1) | |
| Bimatoprost | 1.37* ± 0.27 |
| Vehicle | 0.96 ± 0.20 |
| Immunohistochemistry stains | Esophageal tumor | Liver biopsy (neoplastic cells) | Bladder biopsy (neoplastic cells) | Primary bladder cancer |
| CK7 | + | + | + | + |
| CK20 | + | + | + | + |
| CDX-2 | + | + | + | − |
| GATA-3 | − | − | − | + |
| Uroplakin | − | − | − | + |
| Sequence | Dialysate Potassium | ||
| 1st tertile | 2nd tertile | 3th tertile | |
| 1 | K-1 | K | K+1 |
| 2 | K-1 | K+1 | K |
| 3 | K | K-1 | K+1 |
| 4 | K | K+1 | K-1 |
| 5 | K+1 | K | K-1 |
| 6 | K+1 | K-1 | K |
| Comparison groups | averages | df | t | P |
| TE-genes vs non TE-genes | 0.82 vs 0.76 | 14800 | 7.4 | 1.2e-13 |
| TE-exons vs non TE-genes | 0.96 vs 0.76 | 14386 | 9.4 | 6.8e-21 |
| Alu-exons vs other TE-exons | 1.01 vs 0.95 | 345 | 1.9 | 6.2e-2 |
| Alu-exons vs non TE-genes | 1.01 vs 0.76 | 14106 | 8.2 | 3.9e-16 |
| LncRNA | Expression | Mechanism | Target | Reference |
| AK058003 | Upregulation | Hypoxia;Methylation in the CpG islands | SNCG | [59] |
| AK123072 | Upregulation | Hypoxia;Methylation in the CpG islands | EGFR | [60] |
| HOTTIP | Upregulation | Methylation in the CpG islands;H3K4 methylation | HoxA13 | [61, 62] |
| HOXA11-AS | Upregulation | DNA methylation;Histone modification; miR-1297 | E2F1; P21; E-cadherin; EZH2 | [63, 64] |
| HOTAIR | Upregulation | H3K27 trimethylation; miR-34a | C-Met; Snail | [68–70] |
| MALAT1 | Upregulation | H3 histone acetylation | EGFL7 | [36, 71] |
| GClnc1 | Upregulation | Histone modification | SOD2 | [72] |
| LINC00673 | Upregulation | SP1; Histone modification | KLF2; LATS2 | [73] |
| AGAP2-AS1 | Upregulation | SP1; Histone modification | P21; E-cadherin | [74] |
| ZFAS1 | Upregulation | Histone modification | NDK2; KLF2 | [75] |
| PVT1 | Upregulation | Histone modification | p15; p16 | [70] |
| LINC00668 | Upregulation | E2F1; Histone methylation | p15; p16; p21; p27; p57 | [76, 77] |
| TUG1 | Upregulation | Histone methylation | P57 | [78] |
| LINC00152 | Upregulation | Histone methylation | p15; p21 | [79] |
| FEZF1-AS1 | Upregulation | H3K4 methylation | p21 | [80] |
| ANRIL | Upregulation | Histone modification;miR-99a/miR-449a | p15INK4B; p16INK4A; mTOR; CDK6 | [83–85] |
| SPRY4-IT1 | Downregulation | DNA methylation | SPRY4-IT1 | [87] |
| LOC100130476 | Downregulation | Methylation in the CpG islands | LOC100130476 | [88] |
| GAS5 | Downregulation | Promoter methylation | GAS5 | [89, 90] |
| FENDRR | Downregulation | Histone deacetylation | FENDRR | [90, 91, 92] |
| MEG3 | Downregulation | Promoter methylation; miR-148a | MEG3; RUNX3 | [93, 94,95–97] |
| ROI | hemisphere | x | y | z | t-statistic |
| HF | left | −30 | −36 | −6 | 3.64 |
| right | 33 | −36 | −9 | 3.73 | |
| PHC | left | −21 | −42 | 9 | 4.87 |
| right | 30 | −39 | 6 | 6.81 | |
| Rsp | left | −9 | −48 | 12 | 3.97 |
| right | 9 | −51 | 12 | 3.89 | |
| PCC | left | −12 | −54 | 24 | 5.12 |
| right | 12 | −51 | 24 | 5.16 | |
| AMPFC | left | −9 | 51 | −6 | 3.24 |
| right | 9 | 48 | −3 | 3.72 | |
| pIPL | left | −39 | −75 | 33 | 3.58 |
| Variable | Spearman’s rho | p | |
| Age | -0.08 | <0.05 | |
| Hours of self-regulated learning | |||
| Term time | -0.10 | <0.05 | |
| Revision period | -0.10 | <0.01 | |
| Research activity | -0.17 | <0.01 | |
| Teaching activity | -0.13 | <0.01 | |
| Employment | 0.10 | <0.05 | |
| Care for family | 0.10 | <0.05 |
| K-Cd (μg/g ww) | Age | Sex | Weight | Menopause | S-Ca, ionized (mmol/l) | 24-h urinary flow rate (ml/h) | Overnight urinary flow rate (ml/h) | S-25(OH)D3 (ng/ml) | 24-h U-Ca (mmol/h) | 24-h U-Ca (mmol/mmol creatinine) | ON U-Ca (mmol/h) | ON U-Ca (mmol/mmol creatinine) | |
| K-Cd, μg/g ww | 0.28** | 0.24* | -0.27** | 0.33** | 0.06 | -0.09 | 0.09 | 0.14 | -0.06 | 0.27* | 0.05 | 0.27** | |
| Age | 0.33** | -0.10 | -0.009 | 0.44** | -0.22* | -0.29** | 0.08 | 0.13 | 0.006 | 0.25* | 0.14 | 0.23* | |
| Sex | -0.57** | 0.49** | 0.06 | 0.07 | -0.12 | 0.09 | -0.41** | 0.16 | -0.27** | 0.15 | |||
| Weight | -0.10 | 0.04 | -0.32** | 0.15 | -0.09 | 0.06 | -0.22* | 0.23* | -0.30** | 0.17 | -0.25* | ||
| Menopause | 0.31* | 0.77** | -0.08 | -0.13 | -0.13 | -0.03 | 0.08 | -0.14 | 0.29** | 0.05 | 0.34** | ||
| S-Ca, ionized, mmol/l | 0.17 | -0.15 | 0.21 | -0.22 | 0.05 | 0.12 | -0.06 | 0.21 | 0.30** | 0.22* | 0.26** | ||
| 24-h urinary flow rate, ml/h | -0.02 | -0.25 | -0.01 | -0.23 | 0.06 | 0.43** | 0.13 | -0.01 | -0.06 | -0.06 | -0.07 | ||
| Overnight urinary flow rate, ml/h | 0.25 | -0.04 | -0.11 | 0.05 | 0.15 | 0.52** | 0.02 | 0.005 | 0.06 | 0.30** | 0.16 | ||
| S-25(OH)D3, ng/ml | 0.07 | 0.05 | -0.08 | 0.05 | -0.003 | 0.19 | 0.08 | -0.22 | -0.11 | -0.01 | 0.08 | ||
| 24-h U-Ca, mmol/h | 0.29* | 0.19 | -0.10 | 0.17 | 0.24 | 0.11 | 0.08 | -0.07 | 0.62** | 0.63** | 0.46** | ||
| 24-h U-Ca, mmol/mmol creatinine | 0.35* | 0.36* | -0.26 | 0.28 | 0.31* | -0.03 | 0.14 | -0.07 | 0.82** | 0.47** | 0.72** | ||
| ON U-Ca, mmol/h | 0.37** | 0.25 | -0.19 | 0.33* | 0.19 | 0.04 | 0.31* | 0.25 | 0.56** | 0.57** | 0.77** | ||
| ON U-Ca, mmol/mmol creatinine | 0.37** | 0.29* | -0.27* | 0.36** | 0.25 | -0.03 | 0.21 | 0.22 | 0.57** | 0.70** | 0.91** |
| Genotype frequency (%) | ||||||
| Year | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 |
| Clear | 70.6 | 48.1 | 61.6 | 68.8 | 65.1 | 71.6 |
| Carrier | 23.5 | 41.5 | 31.5 | 25.4 | 29.5 | 25.7 |
| Homozygous | 5.9 | 10.4 | 6.8 | 5.8 | 5.4 | 2.7 |
| Total no. of dogs | 34 | 212 | 146 | 138 | 129 | 74 |
| Disease for which steroids were prescribed | Number of patients | Steroids used | Use of Cyclosporin | Oral or topical therapy | Time period for which the steroid therapy lasted | Prescribed dosage of steroid | Time since PSC developed |
| Renal transplantation | 21 | WY/CY | 5 mg/day | Oral | >2–4 years | 5–10 mg/day | Not recorded |
| Asthma | 08 | WY/DE/DP | - | Oral | >2–4 years | 10 mg/day | Not recorded |
| Lung disease | 02 | WY/DE | - | Oral | >2 years | 7–10 mg/day | Not recorded |
| Arthritis | 03 | OP/DP | - | Oral | >2–3 years | 10 mg/day | Not recorded |
| Allergy | 16 | WY/DE/DP/OP | - | Oral/topical | >2–3 years | 10 mg/day | Not recorded |
| Preoperatively | After ICRS implantation | After IOL implantation | P value | |
| M | −5.35 ± 5.09∗ | −3.45 ± 3.88∗∗ | −0.59 ± 0.80 | <0.0001 |
| J0 | −0.40 ± 0.92∗ | −0.32 ± 0.63∗∗ | −0.07 ± 0.40 | P = 0.009 |
| J45 | 0.17 ± 1.13 | 0.23 ± 0.40∗∗ | −0.09 ± 0.57 | P = 0.02 |
| B | 6.28 ± 4.08∗ | 4.17 ± 3.15∗∗ | 0.94 ± 0.74 | <0.0001 |
| Cellular component | |||
| GOid | Function | Type | Level |
| GO:0030176 | integral to endoplasmic reticulum membrane | component | 7 |
| GO:0001518 | voltage-gated sodium channel complex | component | 6 |
| GO:0005891 | voltage-gated calcium channel complex | component | 6 |
| GO:0008023 | transcription elongation factor complex | component | 6 |
| GO:0005667 | transcription factor complex | component | 6 |
| Molecular Function | |||
| GO:0008332 | low voltage-gated calcium channel activity | function | 9 |
| GO:0005248 | voltage-gated sodium channel activity | function | 8 |
| GO:0005245 | voltage-gated calcium channel activity | function | 8 |
| GO:0005262 | calcium channel activity | function | 7 |
| GO:0005272 | sodium channel activity | function | 7 |
| Biological Process | |||
| GO:0006814 | sodium ion transport | process | 9 |
| GO:0006816 | calcium ion transport | process | 9 |
| GO:0030029 | actin filament-based process | process | 9 |
| n | % | |
| Males | 19 | 95 |
| Female | 1 | 5 |
| Stable angina | 9 | 45 |
| Non-STEMI or unstable angina | 5 | 25 |
| STEMI | 6 | 30 |
| Median age | 50 | |
| Mean age | 51 | |
| White | 12 | 60 |
| Indian/coloured | 7 | 35 |
| Black | 1 | 5 |
| Family history of CAD | 7 | 35 |
| Diabetes mellitus | 4 | 20 |
| Hypertension | 8 | 40 |
| Dyslipidiamia | 7 | 35 |
| Co-existent obstructive CAD | 11 | 55 |
| ICD-10 Code | Cause | Number | Percentage of deaths |
| Natural causes - total | 155 | 80.3 | |
| O00-O99 | Obstetric death | 61 | 31.6 |
| C00-C97 | Cancer | 40 | 20.7 |
| R96-R99 | Unknown/ill-defined | 18 | 9.3 |
| I00-I09,I11,I13,I20-I51 | Heart disease | 5 | 2.6 |
| I60-I69 | Cerebrovascular disease | 4 | 2.1 |
| J00-J99 | Respiratory | 4 | 2.1 |
| B20-B24 | HIV | 2 | 1.0 |
| Remaining natural causes | Other natural | 21 | 10.9 |
| External causes - total | 38 | 19.7 | |
| V01-V99, Y85 | Accidental transport deaths | 14 | 7.3 |
| X85-Y09, Y87.1 | Assault | 9 | 4.7 |
| X60-X84, Y87.0 | Suicide | 7 | 3.6 |
| Y37 | War and terror | 3 | 1.6 |
| W00-W19 | Accidental falls | 2 | 1.0 |
| Y10-Y34 | Undetermined intent | 2 | 1.0 |
| W20-X59, Y86 | Other accidents | 1 | 0.5 |
| Terma | GO Gene Count | GO Slim | GO Slim Gene Count |
| cellular ion homeostasis | 9 | cellular process | 9 |
| regulation of biological quality | 27 | regulation of biological quality | 27 |
| defense response | 22 | ||
| response to stimulus | 48 | ||
| response to chemical stimulus | 22 | ||
| immune system process | 19 | ||
| response to stress | 34 | ||
| immune response | 14 | ||
| regulation of response to stimulus | 12 | ||
| response to external stimulus | 26 | ||
| response to bacterium | 7 | ||
| response to wounding | 20 | response to stimulus | 49 |
| regulation of immune response | 9 | ||
| regulation of defense response | 7 | ||
| inflammatory response | 16 | ||
| blood coagulation | 6 | ||
| innate immune response | 10 | ||
| positive regulation of defense | 5 | ||
| response | 9 | ||
| humoral immune response | 6 | ||
| complement activation, classical pathway | |||
| transition metal ion transport | 5 | transport | 5 |
| Elderly MD subjects (n = 30) | Younger MD subjects (n = 32) | P value | |
| Years since first vertigo | 2.7 ± 2.3 | 3.4 ± 1.8 | 0.08 |
| Hearing loss affected ear | 64.7 ± 8.1 db | 48.2 ± 10.9 db | 0.001 |
| Hearing loss unaffected ear | 18.2 ± 4.5 db | 16.3 ± 3.3 db | 0.04 |
| N° of crises in the last 6 months | 6.5 ± 3.7 | 10.4 ± 5.5 | 0.002 |
| Clinical group | Genotype | Pre-S2 S tart codon | Deletions | ||||||
| Region | Nucleotides | Amino acids | Region and functions affected | ||||||
| ID | Size | Position | Size | position | |||||
| SDAC024 | CR | D | ATG | Pre-S2 | 21 | 35-55a | 7 | 16-22a | |
| SDAC048 | CR | D | ATG | Pre-S1 | 72 | 2998-3069 | 24 | 51-74 | S promoter, Transactivator domain |
| SDAC083 | CR | D | ATG | Pre-S2 | 21 | 35-55 | 7 | 16-22 | |
| SDAC097 | CR | D | GTGb | Pre-S 2 | 9 | 45- 53 | 3 | 19-21 | |
| SDAC098 | CH | D | ATG | Pre-S1 | 18 | 3129-3146 | 6 | 94-99 | Hsc70 binding site, CCAAT binding factor (CBF) binding site, Cytosolic anchorage determinant (CAD) |
| SDAC112 | ASC | D | ATG | Pre-S2 | 6 | 49-54 | 2 | 20-21 | |
| SDAC118 | CR | D | ATG | Pre-S2 | 54 | 4-57 | 18 | 5 to 22 | pHSA binding site, Viral secretion |
| SDAC107 | CR | D | ATA | - | - | - | - | - | - |
| SDAC090 | CR | D | ATA | - | - | - | - | - | - |
| SDAC058 | CR | E | ATG | Pre-S2 | 9 | 58-66c | 3 | 20-22c | Transactivator domain |
| SDAC059 | HCC | E | GTG | Pre-S2 | 12 | 52-63 | 4 | 18-21 | Transactivator domain |
| SDAC088 | HCC | E | ATG | Pre-S2 | 12 | 52-63 | 4 | 18-21 | Transactivator domain |
| SDAC095 | HCC | E | ATG | Pre-S2 | 15 | 52-66 | 5 | 18-22 | Transactivator domain |
| SDAC067 | ASC | E | GTG | - | - | - | - | - | - |
| SDAC113 | ASC | A | ACA | - | - | - | - | - | - |
| Category | Blue LED | UV LED | White light |
| Bark, Bract, | Lint has higher | - | Lint has higher red, green, |
| Brown leaf, | red and green | - | and blue reflectance |
| Green leaf, | fl. emission | - | |
| Stem | - | ||
| Hull | Lint has higher | - | Lint has higher red, green, |
| green fl. | - | and blue reflectance | |
| emission | - | ||
| Paper | - | Lint has lower red, green | Lint has lower red, green |
| - | and blue fl. emission | and blue reflectance | |
| Plastic bag | - | Lint has higher green and | Lint has higher red and |
| - | blue fl. emission | green reflectance | |
| Plastic bale | - | Lint has higher green and | Lint has higher blue |
| Packaging | - | blue fl. emission | reflectance |
| Seed coat (Inner), | - | Lint has higher green and | Lint has higher red, green, |
| Seed coat (Outer), | - | blue fl. emission | and blue reflectance |
| Seed, Twine | - |
| Target species | MIC (μg mL−1) | |||
| 1 | 2 | Polymyxin B | Colistin | |
| Escherichia coli ATCC 25922 | 2 | 2 | 1 | 2 |
| Colistin-resistant E. colia | 2 | 2 | 16 | 16 |
| E. coli ATCC 25922 + 10% serum | 2–4 | 2–4 | 1–2 | 2–4 |
| E. coli ATCC 25922 + Mg2+ (21 mM) | >64 | >64 | >64 | >64 |
| E. coli ATCC 25922 + LPS (1.0 mg mL−1) | >64 | >64 | >64 | >64 |
| E. coli TOP10 | 2 | 2 | 2 | 2 |
| Pseudomonas aeruginosa PAO1 | 1 | 2 | 1 | 1 |
| Acinetobacter baumannii | 16 | 4 | 4 | |
| Klebsiella pneumoniae NRRL-B-408 | 2 | 4 | 16 | |
| K. pneumoniae NRRL-B-3521 | 4 | 4 | 2 | |
| Enterobacter cloacae NRRL-B-413 | 2 | 2 | 8 | |
| E. cloacae NRRL-B-425 | 2 | 2 | 64 | |
| Bacillus subtilis 168 | 32 | 32 | 4 | |
| Candida albicans | >64 | >64 | >64 | |
| Saccharomyces cerevisiae | >64 | >64 | >64 | |
| Staphylococcus aureus (MRSA) | >64 | >64 | 32 |
| Studies (Author) | Year | Chemotherapy regimena | Number (T/C) | Type of Assessable Outcomes | Jadad Scoresb | |
| treatment | control | |||||
| Hao XL[20] | 2008 | NP+SFI | NP | 60/68 | WBC/HB/PLT/nausea and vomiting toxicity, KPS | 3 |
| Wang K[21] | 2007 | NP+SFI | NP | 18/18 | tumor response, WBC/PLT toxicity, KPS | 3 |
| Kang GY[22] | 2006 | NP+SFI | NP | 36/36 | tumor response, WBC/PLT/HB/nausea and vomiting toxicity, KPS | 2 |
| Gong ZM[23] | 2008 | NP+SFI | NP | 33/32 | tumor response, WBC/PLT/HB/nausea and vomiting toxicity, KPS | 2 |
| Wang XY[24] | 2007 | NP+SFI | NP | 35/34 | tumor response, WBC/PLT/HB/nausea and vomiting toxicity, | 4 |
| Wang YZ[25] | 2007 | NP+SFI | NP | 28/27 | tumor response, KPS, WBC/PLT/HB toxicity | 3 |
| Li TW[26] | 2009 | NP+SFI | NP | 36/33 | tumor response, the KPS | 4 |
| Li Y[27] | 2007 | NP+SFI | NP | 44/43 | tumor response, WBC/PLT/nausea and vomiting toxicity, | 4 |
| Lv J[28] | 2008 | NP+SFI | NP | 40/40 | tumor response, WBC/PLT/HB/nausea and vomiting toxicity, KPS | 4 |
| Zhao ZY[29] | 2007 | NP+SFI | NP | 35/34 | tumor response, WBC/PLT/HB nausea and vomiting toxicity, | 4 |
| Geng L[30] | 2004 | NP+SFI | NP | 25/15 | tumor response, KPS | 2 |
| Yu QZ[31] | 2007 | NP+SFI | NP | 30/32 | tumor response, KPS | 4 |
| Liu CL[32] | 2004 | NP+SFI | NP | 60/60 | tumor response, WBC/PLT/HB toxicity | 2 |
| Liu PH[33] | 2007 | NP+SFI | NP | 30/30 | tumor response, KPS | 1 |
| Pan YK[34] | 2008 | NP+SFI | NP | 45/45 | tumor response, WBC/PLT/HB toxicity | 2 |
| Zheng JH[35] | 2009 | NP+SFI | NP | 42/42 | tumor response, WBC/PLT/HB/nausea and vomiting toxicity | 4 |
| Miao SR[36] | 2010 | NP+SFI | NP | 38/41 | tumor response, the KPS, WBC/PLT/nausea and vomiting toxicity | 3 |
| Li YQ[37] | 2010 | NP+SFI | NP | 43/42 | KPS | 5 |
| Geng D[38] | 2007 | NP+SFI | NP | 42/26 | tumor response, WBC/the nausea and vomiting toxicity | 2 |
| Zou Y[39] | 2005 | TP+SFI | TP | 24/24 | tumor response, KPS | 3 |
| Luo SZ[40] | 2006 | TP+SFI | TP | 25/25 | tumor response, KPS, WBC/PLT/nausea and vomiting toxicity | 2 |
| Luo SW[41] | 2007 | TP+SFI | TP | 30/30 | tumor response, WBC/PLT/HB/nausea and vomiting toxicity, KPS | 2 |
| Zhang FL[42] | 2008 | TP+SFI | TP | 30/30 | tumor response, WBC/PLT/HB/nausea and vomiting toxicity, KPS | 3 |
| Zhao YX[43] | 2009 | TP+SFI | TP | 40/40 | tumor response, KPS | 2 |
| Yu F[44] | 2007 | DC+SFI | DC | 30/30 | tumor response, WBC/PLT/HB toxicity | 4 |
| He WJ[45] | 2008 | GP+SFI | GP | 35/35 | tumor response, WBC/PLT/HB/nausea and vomiting toxicity, KPS | 3 |
| Liang K[46] | 2010 | GP+SFI | GP | 39/37 | tumor response, KPS, | 2 |
| Chen J[47] | 2007 | TP/NP+SFI | TP/NP | 41/39 | tumor response, KPS | 2 |
| Wu L[48] | 2004 | TP/NP+SFI | TP/NP | 30/30 | tumor response, WBC toxicity | 5 |
| Percentile (95% CI) | ||||||||
| GM (95% CI) | 10th | 25th | 50th | 75th | 90th | 95th | n | |
| Overall population | ||||||||
| μg/L | 2.73 (2.50–2.98) | < LOD | 1.40 (1.20–1.50) | 2.70 (2.40–3.00) | 5.30 (4.80–5.90) | 10.2 (8.80–11.9) | 17.5 (14.0–21.4) | 2,548 |
| μg/g creatinine | 2.66 (2.43–2.91) | < LOD | 1.47 (1.32–1.61) | 2.48 (2.29–2.71) | 4.48 (4.05–4.85) | 8.67 (7.17–9.71) | 13.2 (10.8–17.5) | 2,548 |
| Age group | ||||||||
| 6–11 years | ||||||||
| μg/L | 4.54 (3.94–5.24) | 1.50 (0.90–2.00) | 2.50 (2.20–3.10) | 4.70 (4.00–5.60) | 8.10 (6.80–9.60) | 14.6 (10.8–19.1) | 22.8 (16.7–35.3) | 356 |
| μg/g creatinine | 5.00 (4.45–5.63) | 1.67 (1.22–2.26) | 3.01 (2.57–3.33) | 5.06 (4.18–5.76) | 7.48 (6.71–8.84) | 16.1 (12.5–18.9) | 23.5 (16.1–31.7) | 356 |
| 12–19 years | ||||||||
| μg/L | 3.18 (2.74–3.68) | 0.700 (< LOD–1.10) | 1.80 (1.50–2.10) | 3.30 (2.90–3.80) | 6.00 (4.70–7.20) | 10.3 (7.60–13.7) | 16.5 (11.5–21.5) | 702 |
| μg/g creatinine | 2.37 (2.04–2.75) | 0.894 (< LOD–1.09) | 1.51 (1.23–1.72) | 2.18 (1.91–2.52) | 3.64 (2.94–4.55) | 6.26 (5.15–8.70) | 10.7 (7.57–14.1) | 702 |
| 20–59 years | ||||||||
| μg/L | 2.52 (2.22–2.85) | < LOD | 1.20 (1.10–1.40) | 2.50 (2.20–2.80) | 4.90 (4.20–5.70) | 9.40 (7.60–12.6) | 17.0 (12.6–24.2) | 1,040 |
| μg/g creatinine | 2.42 (2.17–2.69) | < LOD | 1.34 (1.20–1.50) | 2.21 (2.05–2.48) | 3.95 (3.59–4.53) | 7.46 (6.00–9.41) | 11.2 (9.26–19.0) | 1,040 |
| ≥ 60 years | ||||||||
| μg/L | 2.51 (2.15–2.92) | 0.700 (< LOD–0.80) | 1.10 (0.90–1.40) | 2.40 (1.90–2.70) | 4.70 (3.90–5.80) | 10.1 (7.40–12.5) | 14.7 (12.1–26.3) | 450 |
| μg/g creatinine | 2.92 (2.46–3.46) | 0.913 (< LOD–1.11) | 1.58 (1.35–1.88) | 2.72 (2.41–3.03) | 4.60 (3.72–5.22) | 9.40 (6.43–12.5) | 14.6 (11.2–19.2) | 450 |
| Sex | ||||||||
| Male | ||||||||
| μg/L | 3.16 (2.82–3.54) | 0.800 (< LOD–1.00) | 1.70 (1.40–1.90) | 3.00 (2.70–3.50) | 5.90 (5.10–6.90) | 11.0 (8.80–14.0) | 19.5 (14.0–28.0) | 1,270 |
| μg/g creatinine | 2.53 (2.28–2.82) | 0.894 (< LOD–1.02) | 1.40 (1.27–1.54) | 2.36 (2.14–2.56) | 4.38 (3.74–5.04) | 7.42 (6.47–8.88) | 13.0 (9.40–19.5) | 1,270 |
| Female | ||||||||
| μg/L | 2.37 (2.13–2.65) | < LOD | 1.10 (1.00–1.30) | 2.30 (2.00–2.70) | 4.80 (4.30–5.30) | 9.30 (7.60–11.5) | 14.7 (13.1–18.2) | 1,278 |
| μg/g creatinine | 2.79 (2.47–3.15) | < LOD | 1.52 (1.30–1.77) | 2.65 (2.34–2.96) | 4.51 (4.03–5.16) | 9.41 (6.82–11.6) | 13.5 (10.7–19.7) | 1,278 |
| Race/ethnicity | ||||||||
| Non-Hispanic white | ||||||||
| μg/L | 2.67 (2.39–2.98) | < LOD | 1.30 (1.10–1.50) | 2.60 (2.30–2.90) | 5.30 (4.70–6.10) | 10.1 (8.20–12.6) | 17.6 (12.6–24.3) | 1,038 |
| μg/g creatinine | 2.81 (2.51–3.14) | < LOD | 1.55 (1.36–1.75) | 2.57 (2.34–2.85) | 4.62 (4.10–5.19) | 9.26 (7.00–10.8) | 13.5 (10.3–23.5) | 1,038 |
| Mexican American | ||||||||
| μg/L | 2.72 (2.40–3.08) | 0.700 (< LOD–0.90) | 1.50 (1.20–1.80) | 2.70 (2.40–3.20) | 4.90 (4.30–5.70) | 9.00 (7.00–12.4) | 14.4 (9.00–26.8) | 637 |
| μg/g creatinine | 2.45 (2.13–2.81) | 0.824 (< LOD–1.12) | 1.38 (1.26–1.53) | 2.32 (2.14–2.60) | 4.04 (3.64–4.58) | 6.97 (5.73–8.14) | 11.0 (7.89–19.1) | 637 |
| Non-Hispanic black | ||||||||
| μg/L | 3.18 (2.75–3.67) | 0.700 (< LOD–1.10) | 1.60 (1.30–2.00) | 3.20 (2.70–3.80) | 5.90 (4.90–7.30) | 13.0 (9.50–14.6) | 19.2 (14.6–30.5) | 678 |
| μg/g creatinine | 2.24 (1.96–2.55) | 0.752 (< LOD–0.925) | 1.26 (1.06–1.41) | 1.97 (1.78–2.37) | 3.60 (3.25–4.24) | 7.82 (6.38–10.4) | 12.0 (10.1–17.4) | 678 |
| S. No | Reference | Gender | Lip Pits | Cleft lip (CL) | Cleft palate (CP) | CL & CP | Hypodontia | Ankyloglossia |
| 1 | Arangannal et al., (2002) [3] | M | ✓ | ✓ | ✓ | |||
| 2 | Surasak et al., (2003) [6] | F | ✓ | ✓ | ✓ | ✓ | ||
| 3 | Moore and McCord (2004) [23] | M | ✓ | ✓ | ✓ | ✓ | ||
| 4 | Souissi et al., (2004) [7] | M | ✓ | ✓ | ||||
| 5 | Rizos and Spyropoulos (2004) [5] | F | ✓ | ✓ | ||||
| 6 | Stanier and Moore (2004) [24] | F | ✓ | ✓ | ||||
| 7 | King et al., (2004) [25] | M | ✓ | ✓ | ||||
| 8 | Karande and Patil (2005) [16] | M | ✓ | ✓ | ✓ | |||
| 9 | Tokat et al., (2005) [14] | M | ✓ | ✓ | ||||
| 10 | Newman et al., (2005) [11] | F | ✓ | ✓ | ✓ | |||
| 11 | Ziai et al., (2005) [26] | M | ✓ | |||||
| 12 | Kirzioglu and Ertürk (2006) [27] | M | ✓ | ✓ | ||||
| 13 | King et al., (2004) [25] | F | ✓ | ✓ | ✓ | |||
| 14 | Klinische Padiatrie (2008) [28] | F | ✓ | ✓ | ✓ | ✓ | ||
| 15 | Etöz O. A. and Etöz A. (2009) [29] | M | ✓ | |||||
| 16 | Nakano et al., (2010) [9] | M | ✓ (UL) | ✓ | ||||
| 17 | Lam et al., (2010) [30] | M | ✓ | ✓ | ✓ | ✓ | ✓ | |
| 18 | Baghestani et al., (2010) [31] | M | ✓ | |||||
| 19 | Moghe et al., (2010) [8] | F | ✓ | ✓ | ✓ | ✓ | ||
| 20 | Jobling et al., (2011) [15] | M | ✓ | ✓ | ✓ | ✓ | ||
| 21 | Manoharan et al., (2013) [10] | M | ✓ | ✓ | ||||
| 22 | Shweta et al., (2012) [2] | M | ✓ | ✓ |
| Variables | Group 1 | Group 2 | Group 3 | Group 4 | F/χ2 value | P |
| Cases | 40 | 52 | 21 | 19 | — | — |
| Age (year) | 54.32 ± 10.14 | 58.31 ± 9.24 | 59.10 ± 7.55 | 60.37 ± 8.05 | 2.587 | 0.056 |
| Sex (M/F) | 24/16 | 31/21 | 12/9 | 11/8 | 0.064 | 0.996 |
| Educational years | 9.55 ± 3.37 | 10.37 ± 3.33 | 9.19 ± 2.87 | 8.63 ± 2.75 | 1.662 | 0.178 |
| Etiology | 7.148 | 0.711 | ||||
| B viral hepatitis cirrhosis | — | 21 | 11 | 8 | ||
| C viral hepatitis cirrhosis | — | 1 | 1 | 1 | ||
| Primary biliary cirrhosis | — | 3 | 3 | 1 | ||
| Autoimmune hepatitis cirrhosis | — | 5 | 0 | 3 | ||
| Schistosomiasis cirrhosis | — | 6 | 1 | 1 | ||
| Cryptogenic cirrhosis | — | 16 | 5 | 5 | ||
| Child-Pugh grading | 7.229 | 0.124 | ||||
| Grade A | — | 18 | 4 | 2 | ||
| Grade B | — | 21 | 8 | 7 | ||
| Grade C | — | 13 | 9 | 10 | ||
| Child-Pugh scores | — | 8.27 ± 2.36 | 9.19 ± 2.16 | 10.16 ± 2.27 | 4.965 | 0.009 |
| Ammonia (μmol/L) | — | 37.12 ± 15.28 | 63.81 ± 19.22 | 106.21 ± 46.14 | 52.154 | <0.001 |
| Cr (μmol/L) | — | 86.01 ± 22.80 | 83.35 ± 40.11 | 79.14 ± 43.92 | 0.318 | 0.728 |
| TBil (μmol/L) | — | 45.78 ± 16.76 | 45.57 ± 14.51 | 42.81 ± 14.83 | 0.254 | 0.776 |
| ALB (g/L) | — | 29.62 ± 7.92 | 28.38 ± 5.36 | 31.05 ± 6.71 | 0.691 | 0.504 |
| PT (sec) | — | 3.14 ± 1.76 | 2.87 ± 1.74 | 3.25 ± 1.76 | 0.263 | 0.769 |
| NCT-A (sec) | 46.92 ± 11.80 | 51.31 ± 10.93 | 88.29 ± 9.38 | — | 108.840 | <0.001 |
| DST (scores) | 52.35 ± 10.69 | 49.98 ± 9.98 | 23.57 ± 4.04 | — | 72.476 | <0.001 |
| Species | Origin | N | PCR + blood | Sensitivity of microscopy |
| M. nemestrina | West Java | 4 | 4 (100 %) | NA |
| M. fascicularis | Lampung | 30 | 6 (20 %) | 3 (50 %) |
| M. fascicularis | Palembang | 30 | 24 (80 %) | 14 (58.3 %) |
| Inventory year | Stock changea (MgC yr-1) |
| 1910 | 104,116 |
| 1920 | 97,021 |
| 1930 | 75,712 |
| 1940 | 16,051 |
| 1950 | 298,029 |
| 1960 | 591,785 |
| 1970 | 966,125 |
| 1980 | 437,628 |
| 1990 | 481,517 |
| 1995 | 59,764 |
| 2000 | -184,812 |
| 2005 | -151,437 |
| 2006 | -135,679 |
| 2007 | -200,187 |
| 2008 | -198,821 |
| 2009 | -191,391 |
| 2010 | -173,214 |
| Pelvic obliquity (r) | Lumbar Cobb angle (r) | Thoracic curve Cobb angle (r) | |
| Functional LLD | 0.69* | 0.44* | 0.09 |
| Structural LLD | 0.51* | 0.17 | − 0.05 |
| Gene family | Gene | Description | References |
| MHC class I | ENSGALT00000028239, ENSGALT00000004115 | Deletion of MHC class I antigen-presenting proteins in chicken was associated with Marek’s disease resistance | Luo et al. (2012) |
| MHC class II | CIITA | CIITA, a trans-activator of MHC II, was duplicated in cattle with nematode resistance | Liu et al. (2011) |
| Antimicrobial peptides | LAP, TAP, BSP30A | Cattle-specific, β-defensin family, antimicrobial peptides (AMPs) with high copy number | Bickhart et al. (2012) |
| PGN3, CATHL4 | Cathelicidin family AMPs from pig and cattle, respectively, with high degrees of copy number variation | Paudel et al. (2013), Bickhart et al. (2012) | |
| Endogenous retroviruses | enJSRV | A variant of the endogenous Jaagsiekte sheep retrovirus that is highly duplicated, protects individuals from the exogenous virus, which causes pulmonary adenocarcinoma | Viginier et al. (2012) |
| T cell receptors | WC1 | CNVs of the cattle-specific WC1 gene have been identified | Liu et al. (2010), Chen et al. (2012) |
| RL | RL + 1 | RL + 2 | RL + 3 | RL + 4 | RL + 5 | RL + 6 | RL + 7 | |
| Galaxy S6 | 84.11 | 87.11 | 90.11 | 94.09 | 97.99 | 101.89 | 105.72 | – |
| Galaxy Note 3 | 89.68 | 93.13 | 95.47 | 99.52 | 103.26 | 107.04 | – | – |
| I-phone 5S | 91.97 | 96.02 | 96.69 | 100.06 | 104.18 | 107.17 | 110.08 | 112.44 |
| I-phone 6 | 88.25 | 92.05 | 98.32 | 101.44 | 104.49 | 107.76 | 110.21 | 113.11 |
| LG G2 | 92.35 | 94.90 | 97.91 | 100.73 | 103.34 | 106.45 | 109.42 | – |
| LG G3 | 89.60 | 92.62 | 95.60 | 98.43 | 101.16 | 104.27 | 107.25 | – |
| GeNormPLUS | NormFinder | BestKeeper | Comparative delta-Ct | RefFinder | |||||
| Gene | Stability Coeff. | Gene | Stability Coeff. | Gene | Stability Coeff. | Gene | Stability Coeff. | Gene | Stability Coeff. |
| Histone3 | 1.22 | Histone3 | 0.812 | Histone3 | 1.58 | Histone3 | 1.678 | Histone3 | 12 |
| EF2 | 1.135 | EF2 | 0.743 | RAN | 1.085 | EF2 | 1.549 | EF2 | 10.462 |
| Actin | 1.061 | Tubulin | 0.579 | Tubulin | 1.059 | Actin | 1.343 | Actin | 8.409 |
| Cyclo | 1.028 | Cyclo | 0.523 | EF2 | 0.926 | GAPDH | 1.335 | Cyclo | 6.701 |
| GAPDH | 0.959 | Actin | 0.518 | Clathrin | 0.926 | Clathrin | 1.33 | Clathrin | 6.447 |
| eTIF4E | 0.857 | Clathrin | 0.504 | eTIF4E | 0.888 | Cyclo | 1.319 | Tubulin | 5.948 |
| TIP41 | 0.798 | TIP41 | 0.502 | F-box | 0.885 | RAN | 1.302 | GAPDH | 5.635 |
| Tubulin | 0.703 | GAPDH | 0.462 | Actin | 0.87 | Tubulin | 1.299 | RAN | 4.461 |
| CDPK | 0.599 | RAN | 0.453 | Cyclo | 0.718 | TIP41 | 1.241 | eTIF4E | 3.742 |
| RAN | 0.503 | Fbox | 0.452 | CDPK | 0.699 | F-box | 1.234 | TIP41 | 2.913 |
| Clathrin | 0.47 | CDPK | 0.272 | GAPDH | 0.681 | eTIF4E | 1.155 | F-box | 2.913 |
| F-box | 0.45 | eTIF4E | 0.257 | TIP41 | 0.601 | CDPK | 1.091 | CDPK | 1.861 |
| SOAPsnp | Atlas-SNP2 | SAMtools | GATK-UGT | |
| Quality score | Recalibrated | Raw | Recalibrated | Recalibrated |
| Machine cycle | Yes | Yes | No | Yes |
| Allele type | Yes | No | No | Yes |
| Duplication level | Penalty in quality score | No | No | No |
| Swap-base | No | Yes | No | No |
| MNP events | No | Yes | No | No |
| NQS | No | Yes | No | No |
| Coverage variation | No | Yes | No | No |
| Base dependency | Yes | No | Yes | No |
| Strand independency | No | NO | Yes | No |
| Individual Items | Dimensions | |||||||
| LTC | PROM | N | % missing baseline | % missing follow-up | N | % missing baseline | % missing follow-up | % missing change score |
| Asthma | Mini-AQLQ | 15 | 0-3.8 | 0.8-6.8 | 5 | 1.1-7.1 | 3.4-11.7 | 4.1-15.0 |
| EQ-5D | 5 | 0.4-0.8 | 0.8-1.9 | 1 | 1.1 | 3.0 | 4.1 | |
| EQ-5D VAS | 1 | 3.4 | 3.8 | N/A | N/A | N/A | 6.8 | |
| COPD | CCQ | 10 | 1.6-3.7 | 0-3.7 | 4 | 4.3-9.1 | 2.1-8.6 | 5.9-14.4 |
| EQ-5D | 5 | 0-1.1 | 1.1-2.1 | 1 | 2.1 | 4.8 | 5.3 | |
| EQ-5D VAS | 1 | 5.0 | 4.4 | N/A | N/A | N/A | 7.8 | |
| Diabetes | DHP | 18 | 0-2.8 | 1.2-3.1 | 3 | 1.6-6.2 | 2.8-7.5 | 4.4-12.1 |
| EQ-5D | 5 | 0.9-2.5 | 1.6-2.2 | 1 | 3.4 | 3.7 | 6.2 | |
| EQ-5D VAS | 1 | 5.0 | 4.4 | N/A | N/A | N/A | 7.8 | |
| Epilepsy | QOLIE | 31 | 0-27.9 | 1.0-30.8 | 8 | 0-42.3 | 2.9-50.0 | 2.9-61.5 |
| EQ-5D | 5 | 0-1.9 | 1.0-4.8 | 1 | 1.9 | 6.7 | 8.7 | |
| EQ-5D VAS | 1 | 9.6 | 5.8 | N/A | N/A | N/A | 12.5 | |
| Heart failure | MLHFQ | 21 | 0.6-11.0 | 3.2-21.3 | 3 | 5.8-28.4 | 9.0-36.1 | 14.8-48.4 |
| EQ-5D | 5 | 0-3.9 | 1.9-4.5 | 1 | 4.5 | 7.7 | 11.6 | |
| EQ-5D VAS | 1 | 2.6 | 5.2 | N/A | N/A | N/A | 6.5 | |
| Stroke | SIS | 60 | 2.9-23.5 | 2.0-22.5 | 10 | 5.9-36.3 | 5.9-38.2 | 9.8-52.9 |
| EQ-5D | 5 | 1.0-3.9 | 2.0-4.9 | 1 | 3.9 | 5.8 | 8.8 | |
| EQ-5D VAS | 1 | 11.8 | 10.8 | N/A | N/A | N/A | 19.6 |
| Characteristic | n = 52 |
| Age, year (mean ± SD) | 60 (±14) |
| Gender, number of patients (%) | |
| Male | 32 (61) |
| Female | 20 [39] |
| Cause of benign rupture or leak, number of patients (%) | |
| Anastomotic | 32 (62) |
| Iatrogenic | 13 [25] |
| Boerhaave's syndrome | 4 [8] |
| Other | 3 [5] |
| Location of benign rupture or leak, number of patients (%) | |
| Distal esophagus | 13 [25] |
| Mid-esophagus | 24 (45) |
| Proximal esophagus | 11 [21] |
| Unknown | 4 [9] |
| Length of rupture or leak, cm (median (range)) | 2 (0.2-7) |
| Time interval between rupture and stent placement, number of patients (%) | |
| Within 24 hours | 5 [10] |
| After 24 hours | 47 (90) |
| Prior treatment for benign rupture or leak, number of patients (%) | |
| Stent placement in another hospital | 3 [5] |
| Surgery | 3 [5] |
| Clip placement | 1 [2] |
| None | 45 (88) |
| Antibiotic treatment, number of patients (%) | |
| Yes | 41.(79) |
| No | 11 [21] |
| Concurrent fluid drainage, number of patients (%) | |
| Yes | 24 (46) |
| No | 28 (54) |
| Total days of treatment with a stent, median (range) | 39 (1-742) |
| Tumor Grade | % |
| I | 2.1 |
| I B | 8.5 |
| II | 27.6 |
| II B | 2.1 |
| III A | 19.2 |
| III B | 6.5 |
| IV | 34 |
| Variables | Ever user (n = 11,013) | Nonuser (n = 3,055) | P-valuec |
| Age, yrs | 52.9 ± 15.0 | 33.2 ± 12.5 | < 0.001 |
| 18-29 | 842 (36.2) | 1,481 (63.8) | |
| 30-39 | 1,363 (61.7) | 848 (38.3) | |
| 40-49 | 1,898 (84.8) | 340 (15.2) | |
| 50-59 | 3,558 (93.3) | 255 (6.7) | |
| 60 ≥ | 3,352 (96.2) | 131 (3.8) | |
| Gender | |||
| Male | 5,053 (78.2) | 1,410 (21.8) | 0.01 |
| Female | 5,960 (78.4) | 1,645 (21.6) | Reference |
| Education | |||
| Less than high school | 5,248 (92.7) | 413 (7.3) | < 0.001 |
| High school | 4,502 (74.2) | 1,562 (25.8) | 0.76 |
| College or above | 1,262 (53.9) | 1,079 (46.1) | Reference |
| BMIa, kg/cm2 | |||
| ≥ 25.0 | 3,063 (85.1) | 536 (14.9) | 0.10 |
| 18.5-24.9 | 7,342 (77.1) | 2,183 (22.9) | 0.76 |
| < 18.5 | 577 (63.8) | 328 (36.2) | Reference |
| Waist circumferenceb, cm | |||
| ≥ 80 (female) or 90 (male) | 8,280 (81.8) | 1,847 (18.2) | 0.06 |
| < 80 (female) or 90 (male) | 2,665 (69.1) | 1,180 (31.9) | Reference |
| Second-hand smoke | |||
| Never | 2,149 (69.2) | 957 (30.8) | < 0.001 |
| Ever | 8,862 (80.9) | 2,098 (19.1) | Reference |
| Smoking | |||
| Current smoker | 2,717 (84.5) | 498 (15.5) | 0.01 |
| Ex-smoker | 604 (92.8) | 47 (7.2) | 0.78 |
| Never-smoker | 7,383 (75.4) | 2,408 (24.6) | Reference |
| Amount of smoking, pack-years | 8.0 ± 23.1 | 2.4 ± 11.2 | 0.24 |
| Relative risk per SD increase in domestic usage | ||||
| Unadjusted (95% CI) | Adjusted* (95% CI) | |||
| Respiratory | ||||
| Chronic obstructive pulmonary disease | 1.253 | 1.245 to 1.260 | 1.142 | 1.122 to 1.163 |
| Asthma | 1.199 | 1.176 to 1.223 | 1.093 | 1.032 to 1.158 |
| Pneumonia | 1.262 | 1.254 to 1.269 | 1.227 | 1.205 to 1.250 |
| Tuberculosis | 1.734 | 1.676 to 1.793 | 1.298 | 1.167 to 1.444 |
| Cardiovascular | ||||
| Ischaemic heart disease | 1.141 | 1.138 to 1.143 | 1.102 | 1.095 to 1.110 |
| Rheumatic heart disease | 1.209 | 1.184 to 1.234 | 1.240 | 1.166 to 1.318 |
| Stroke | 1.137 | 1.133 to 1.141 | 1.114 | 1.101 to 1.127 |
| Hypertension | 1.204 | 1.196 to 1.212 | 1.112 | 1.089 to 1.135 |
| Lively | Youthful | Exciting |
| More Sociable | More Spontaneous | More Active |
| More Natural/Down to earth | More Warm/Caring | More Self Confident |
| Enjoys the outdoors more | More Feminine | Pushy |
| More Modern | More Stylish | More Spirited/Fun |
| Higher income | More Sophisticated | Sensitive/caring |
| Friendly | Does things on the spur of the moment |
| Population characteristics | Number | Unweighted, % | Weighted, % | Elaidic acid (C18:1 t9)Weighted mean (SE) μM | Vaccenic acid (C18:1 t11)Weighted mean (SE) μM | Palmitelaidic acid (C16:1 t9)Weighted mean (SE) μM | Linolelaidic acid (C18:2 t9, 12)Weighted mean (SE) μM |
| Gender | |||||||
| Male (ref) | 701 | 48.1 | 48.8 | 36.40(1.87) | 43.12(1.96) | 7.43(0.28) | 3.04(0.15) |
| Female | 755 | 51.9 | 51.2 | 37.99(1.41) | 41.24(1.36) | 7.67(0.15) | 3.20(0.11) |
| Age, y | |||||||
| 20–39 (ref) | 509 | 35 | 42.8 | 34.98(1.27) | 41.23(1.33) | 7.30(0.19) | 2.96(0.10) |
| 40–59 | 429 | 29.5 | 36.0 | 39.26(2.47) * | 43.62(2.27) | 7.60(0.34) | 3.26(0.19) * |
| 60 | 518 | 35.5 | 21.2 | 38.27(1.36) * | 41.57(1.27) | 7.97(0.22) * | 3.21(0.13) * |
| Race | |||||||
| Non-Hispanic White (ref) | 695 | 47.7 | 75.0 | 38.97(1.75) | 43.83(1.67) | 7.97(0.19) | 3.31(0.15) |
| Non-Hispanic Black | 222 | 15.2 | 8.5 | 31.52(1.07) * | 37.80(1.19) * | 6.00(0.29) * | 2.39(0.08) * |
| Mexican American | 424 | 29.1 | 6.4 | 37.07(2.31) | 41.76(2.39) | 7.27(0.31) * | 2.94(0.18) * |
| Other Hispanic | 80 | 5.5 | 7.1 | 26.82(2.27) * | 33.41(2.26) * | 5.87(0.12) * | 2.43(0.08) * |
| Other race / multiracial | 35 | 2.5 | 3.0 | 34.49(5.04) | 34.28(6.28) | 6.05(0.75) * | 2.59(0.21) * |
| BMI, kg/m2 | |||||||
| Underweight (<18.5) | 24 | 1.6 | 2.4 | 31.68(1.28) | 40.01(1.96) | 6.88(0.43) | 2.28(0.14) |
| Normal weight (18.5–24.9) (ref) | 459 | 31.5 | 36.3 | 33.98(1.60) | 39.32(1.62) | 7.04(0.20) | 2.69(0.11) |
| Overweight (25–29.9) | 490 | 33.7 | 31.6 | 36.21(1.52) | 41.59(1.66) | 7.36(0.27) | 3.21(0.15) * |
| Obese (>30) | 483 | 33.2 | 29.7 | 42.67(1.88) * | 46.39(1.79) * | 8.43(0.21) * | 3.62(0.14) * |
| Alcohol use | |||||||
| No (ref) | 454 | 31.2 | 26.1 | 39.41(1.22) | 43.44(0.89) | 8.12(0.16) | 3.12(0.12) |
| Yes | 1002 | 68.8 | 73.9 | 36.44(1.67) * | 41.71(1.71) | 7.35(0.18) * | 3.12(0.13) |
| Smoking status | |||||||
| Nonsmoker (ref) | 720 | 49.5 | 46.8 | 35.58(1.82) | 41.08(1.75) | 7.53(0.22) | 2.94(0.13) |
| Former | 426 | 29.2 | 28.9 | 39.07(1.82) * | 43.70(1.71) | 8.08(0.26) | 3.29(0.16) * |
| Current | 310 | 21.3 | 24.3 | 38.16(1.92) | 42.40(2.08) | 6.97(0.32) | 3.27(0.16) * |
| Hypertensiona | |||||||
| No (ref) | 941 | 64.6 | 72.4 | 36.42(1.75) | 42.09(1.76) | 7.49(0.24) | 3.02(0.13) |
| Yes | 515 | 35.4 | 27.6 | 39.3(1.90) | 42.35(1.36) | 7.71(0.21) | 3.38(0.13) * |
| Diabetesb | |||||||
| No (ref) | 1338 | 91.9 | 94.9 | 36.48(1.44) | 41.57(1.34) | 7.43(0.16) | 3.09(0.12) |
| Yes | 118 | 8.1 | 5.1 | 50.89(5.37) * | 53.12(3.89) * | 9.81(0.71) * | 3.79(0.20)* |
| Self-reported cardiovascular diseases history | |||||||
| No (ref) | 1358 | 93.3 | 94.7 | 37.05(1.51) | 42.16(1.40) | 7.53(0.16) | 3.11(0.12) |
| Yes | 98 | 6.7 | 5.3 | 40.16(2.70) | 42.03(2.97) | 7.92(0.65) | 3.31(0.19) |
| Mortality status, n (%) | |||||||
| Assumed alive (ref) | 1235 | 84.8 | 90.0 | 36.65(1.45) | 41.82(1.39) | 7.45(0.17) | 3.12(0.12) |
| Assumed deceased | 221 | 15.2 | 10.0 | 42.27(3.00) * | 45.25(2.86) | 8.42(0.44) * | 3.18(0.15) |
| Overall | 1456 | 100 | 100 | 37.22(1.44) | 42.16(1.33) | 7.55(0.15) | 3.12(0.11) |
| Variable | n | Optical density |
| Sham-control | 10 | 0.0008 ± 0.00143 |
| CIA-control | 10 | 0.0266 ± 0.01948* |
| CIA-EA | 10 | 0.0078 ± 0.00604* |
| CIA-EA-SCH58261 | 10 | 0.0493 ± 0.00482∗# |
| CIA-SCH58261 | 10 | 0.0507 ± 0.00965∗# |
| SVM | Sen | Spec | Acc | MCC | Prec | F1 |
| 1 | 34.64 | 96.77 | 79.62 | 0.4338 | 80.37 | 48.42 |
| 2 | 34.5 | 96.72 | 79.54 | 0.431 | 80.03 | 48.21 |
| 3 | 32.68 | 97.41 | 79.54 | 0.4316 | 82.78 | 46.86 |
| 4 | 34.75 | 96.81 | 79.68 | 0.4358 | 80.62 | 48.57 |
| 5 | 34.78 | 96.82 | 79.7 | 0.4363 | 80.68 | 48.6 |
| 6 | 34.65 | 96.78 | 79.63 | 0.4339 | 80.39 | 48.43 |
| 7 | 34.51 | 96.72 | 79.55 | 0.4312 | 80.06 | 48.23 |
| 8 | 34.69 | 96.79 | 79.65 | 0.4347 | 80.48 | 48.48 |
| 9 | 34.77 | 96.83 | 79.7 | 0.4363 | 80.69 | 48.6 |
| 10* | 34.62 | 96.77 | 79.61 | 0.4334 | 80.32 | 48.39 |
| 1** | 38.49 | 95.21 | 79.54 | 0.4334 | 75.75 | 50.93 |
| 2 | 40.61 | 94.77 | 79.8 | 0.4433 | 74.86 | 52.6 |
| 3 | 42.47 | 94.66 | 80.25 | 0.4577 | 75.24 | 54.26 |
| 4 | 41.79 | 95.6 | 80.74 | 0.4715 | 78.32 | 54.47 |
| 5 | 40.21 | 96.62 | 81.05 | 0.4809 | 81.86 | 53.92 |
| 6 | 29.72 | 97.7 | 78.93 | 0.4107 | 83.06 | 43.76 |
| 7 | 28.86 | 98.12 | 79 | 0.414 | 85.21 | 43.1 |
| 8 | 28.3 | 98.33 | 79 | 0.4149 | 86.39 | 42.62 |
| 9 | 28.13 | 98.45 | 79.04 | 0.4167 | 87.12 | 42.52 |
| 10 | 27.72 | 98.66 | 79.08 | 0.4192 | 88.48 | 42.2 |
| Group | Taxon | N | Body mass (kg) range F-Ma | Locomotor behaviours |
| NWM | Lagothrix lagotricha | 7 | 7.0-9.3 | arboreal quadruped, with climbing and orthograde clamberingb |
| Ateles sp. | 4 | 7.3-8.9 | torso-orthograde suspensory; semi-brachiatorc | |
| Alouatta sp. | 13 | 5.4-7.2 | arboreal quadruped, with climbing and orthograde clambering | |
| Hominoids | Pongo pygmaeus | 25 | 35.8-78.5 | torso-orthograde suspensoryd |
| Pongo abelii | 9 | 35.6-77.9 | torso-orthograde suspensory | |
| Pan troglodytes verus | 14 | 41.6-46.3 | knuckle-walker (arboreal and terrestrial) and climbinge | |
| Pan troglodytes troglodytes | 25 | 45.8-59.7 | knuckle-walker (arboreal and terrestrial) and climbing | |
| Pan troglodytes schweinfurthii | 6 | 33.7-42.7 | knuckle-walker and climbing (proportion of arboreality varies from 33-68%) | |
| Pan paniscus | 19 | 33.2-45.0 | knuckle-walker (arboreal and terrestrial) and climbing, considered more arboreal than P. troglodytesf | |
| Homo sapiens | 146 | 54.4-62.2 | terrestrial biped | |
| Gorilla gorilla gorilla | 40 | 71.5-170.4 | terrestrial knuckle-walker (assumed to be less terrestrial than G.b.beringei)g | |
| Gorilla beringei graueri | 7 | 71.0-175.2 | terrestrial knuckle-walker (assumed to be less terrestrial than G.b.beringei) | |
| Gorilla beringei beringei | 9 | 97.5-162.5 | terrestrial knuckle-walker (most terrestrial of all Gorilla, 93-98% terrestrial) | |
| Symphalangus syndactylus | 5 | 10.7-11.9 | brachiatorh | |
| Hylobates lar | 27 | 5.4-5.9 | brachiator | |
| OWM | Presbytis sp. | 2 | 5.6-6.8 | arboreal quadruped, capable of leaping and forelimb suspensioni |
| Macaca mulatta | 16 | 8.8-11.0 | semi-terrestrial quadrupedj | |
| Macaca fascicularis | 7 | 3.6-5.4 | arboreal quadrupedk | |
| Papio Anubis | 6 | 13.3-25.1 | terrestrial quadrupedl | |
| Theropithecus gelada | 5 | 11.7-19.0 | terrestrial quadruped | |
| Chlorocebus aethiops | 4 | 3.0-5.5 | semi-terrestrial quadruped | |
| Erythrocebus patas | 3 | 6.5-12.4 | terrestrial quadruped | |
| Cercopithecus mitis | 12 | 3.9-5.9 | arboreal quadruped |
| Primer Name | Primer Sequence (5’to 3’) |
| VHSCDNA | GTATCATAAAAGATGATGAGTTATGTTACAAGGG |
| VHSPCRF | GTTGAACACAGAGTCATATCTCATAATCG |
| VHSPCRR | GGTGGAGACACGGTCCTCATCATTGGACGTGAGG |
| PJETFOR | CGACTCACTATAGGGAGAGCGGC |
| PJETREV | AAGAACATCGATTTTCCATGGCAG |
| VHSNF | GATGACGACTACCCCGAGGACTCTGAC |
| SACPSIF | CTCCACCGCGGTAATACGACTCACTATAGG |
| SACPSIR | GCTTTGATCAAAGAGAAATTCTTATAATCGTGCCG |
| PSIMFEF | CGGCACGATTATAAGAATTTCTCTTTG |
| PSIMFER | GGCCTGCCACAATTGCCTTGACCACC |
| SPEMUTN | CGTTGAACAAAAGAACTCAGTACTAGTATGGAAGGAGGAATTCGTGCAGCG |
| SNABIMUTN | CGACTACCCCGAGGACTCTGACTAATACGTACTCCCGTCTCATAACCAACATAG |
| SPEMUTP | GACAAACACTGAGATACTAGTATGGCTGATATTGAGATGAGCGAGTCC |
| SNABIMUTP | CGATCAAGGCGGAGCTGGACAAGCTAGAGTAGTACGTACACAACGCATCACAC |
| Indomethacin | Ibuprofen | ||
| (N = 161) | (N = 182) | p value | |
| Day of Life at Start of Treatment (mean, SD) | 3.3 ± 2.3 | 3.5 ± 2.7 | NS |
| PDA Closed, n (%) | 109 (68) | 129 (71) | 0.4 |
| PDA Ligation, n (%) | 45 (28) | 38 (21) | 0.1 |
| BPD, n (%) | 72 (45) | 90 (49) | 0.2 |
| NEC-related conditions, any, n (%) | 27 (17) | 32 (18) | 0.8 |
| NEC, n (%) | 6 (4) | 15 (8) | 0.08 |
| NEC-Like Illness (%) | 13 (8) | 5 (3) | 0.03* |
| Spontaneous Intestinal Perforations, n (%) | 8 (5) | 12 (7) | 0.5 |
| ROP, n (%) | 65 (52) | 41 (30) | <0.001* |
| Severe ROP: Grades III-V | 15 (12) | 15 (11) | 0.8 |
| IVH, any, n (%) | 58 (36) | 57 (31) | 0.4 |
| Severe IVH: Grade III/IV | 12 (8) | 12 (9) | 0.6 |
| PVL | 4 (2.4) | 3 (1.6) | 0.4 |
| Death, n (%) | 12 (7) | 16 (9) | 0.4 |
| PDSS | HAM-A | Frequency | ||||
| r | p value | r | p value | r | p value | |
| Mesor | 0.71 | 0.79 | 0.62 | 0.01 | 0.55 | 0.03 |
| Amplitude(circadian) | 0.22 | 0.41 | 0.35 | 0.19 | 0.16 | 0.55 |
| Amplitude(12 hour harmonic) | 0.00 | 1.00 | 0.42 | 0.10 | 0.46 | 0.08 |
| Acrophase(circadian) | 0.13 | 0.62 | 0.22 | 0.42 | 0.36 | 0.18 |
| Acrophase(12 hour harmonic) | -0.27 | 0.31 | -0.18 | 0.51 | -0.18 | 0.49 |
| Pair | Egg hatch rate | Number of progeny | Sex ratio (proportion male) | Status |
| PF 12.5.i | 0.67 | 23 | 0.609 | N |
| PF12.5.ii | 0.88 | 34 | 0.412 | N |
| PF12.6.i | 0.92 | 56 | 0.446 | N |
| PF12.6.ii | 0.77 | 18 | 0.556 | N |
| Sample code | Type | Yield (mg) | Melting point (°C) | Physical state |
| IA/01/1 | C-9154 analogue | 90% | 195-196 | White powdery solid |
| IA/24/1/B | Methyl ester | 160, (0.78 mmol) | 74 | Bright yellow crystalline solid |
| IA/21/1/B | Ethyl ester | 100, (0.46 mmol) | 63 | Light brown crystalline solid |
| IA/22/1/B | n-propyl ester | 170, (0.73 mmol) | 55 | Dark brown crystalline solid |
| IA/23/1/B | Isopropyl ester | 105, (0.45 mmol) | 70 | Dark brown crystalline solid |
| IA/19/1/B | n-butyl ester | 200, (0.81 mmol) | 42 | Yellow waxy solid |
| IA/20/1/B | 2-butyl ester | 150, (0.61 mmol) | 40 | Golden brown oil |
| IA/25/1/B | t-butyl ester | 2, (~0.01 mmol) | Not determined |
| Plain radiograph (n = 30) | Bone scan (n = 30) | CT (n = 26) | P-value | |
| Sensitivity | 0.0 (0.0–22.8) | 100.0 (77.2–100.0) | 76.5 (50.1–93.2) | 0.045 |
| Specificity | 100.0 (55.5–100.0) | 77.8 (40.0–97.2) | 100.0 (55.5–100.0) | 0.157 |
| Accuracy | 30.0 (14.7–49.4) | 93.3 (77.9–99.2) | 84.6 (65.1–95.6) | 0.046 |
| PPV | NaN | 91.3 (72.0–98.9) | 100.0 (66.1–100.0) | |
| NPV | 30.0 (14.7–49.4) | 100.0 (47.3–100.0) | 69.2 (38.6–90.9) |
| Gene | Primer | Enzyme |
| GSTM1 | Forward: GAACTCCCTGAAAAGCTAAAGC | |
| Reverse: GTTGGGCTCAAATATACGGTGG | ||
| GSTT1 | Forward: TTCCTTACTGGTCCTCACATCTC | |
| Reverse: CAGCTGCATTTGGAAGTGCTC | ||
| GSTP1 (Ile105Val, rs1695) | Forward: GTAGTTTGCCCAAGGTCAAG | BsmAI |
| Reverse: AGCCACCTGAGGGGTAAG | ||
| NQO1 (C609T, rs1800566) | Forward: AAGCCCAGACCAACTTCT | HinfI |
| Reverse: ATTTGAATTCGGGCGTCTGCTG | ||
| EPHX1 (Tyr113His, rs1051740) | Forward: CTTGAGCTCTGTCCTTCCCATCCC | Tth111I |
| Reverse: AATCTTAGTCTTGAAGTGACGGT | ||
| EPHX1 (His139Arg, rs2234922) | Forward: ACATCCACTTCATCCACGT | Rsa1 |
| Reverse: ATGCCTCTGAGAAGCCAT | ||
| HO-1 (5′-site GT repeats) | Forward: FAM-AGAGCCTGCAGCTTCTCAGA | |
| Reverse: ACAAAGTCTGGCCATAGGAC | ||
| XRCC1 (Arg280His, rs25489) | Forward: GGCTGGGACCACCTGTGTT | RsaI |
| Reverse: TTGACCCCCAGTGGTGCTAA | ||
| XRCC1 (Arg399Gln, rs25487) | Forward: TCTCCCTTGGTCTCCAACCT | MspI |
| Reverse: AGTAGTCTGCTGGCTCTGG | ||
| XPD (C156A, rs238406) | Forward: TGGAGTGCTATGGCACGATCTCT | TflI |
| Reverse: CCATGGGCATCAAATTCCTGGGA | ||
| hOGG1 (Ser326Cys, rs1052133) | Forward: ACTGTCACTAGTCTCACCAG | Fnu4HI |
| Reverse: TGAATTCGGAAGGTGCTTGGGGAAT | ||
| ATM (INV48 +238C>G, rs609429) | Forward: CCTGGTTATAAAATGAGAAGG | KpnI |
| Reverse: GCAGCAACTACCATTCATTGAG |
| Target | Base URL extension |
| Homepage | fbcv |
| Term request tracker | fbcv/tracker |
| Pre-reasoned OBO version | fbcv/dpo-simple.obo |
| Full OWL version | fbcv/dpo-non-classified.owl |
| Full details of all available versions | fbcv/downloads |
| Individual term details for FBcv_0000423 | FBcv_0000423 |
| Subjects | Outcome | Number of eventsa | Q2 versus Q1 | Q3 versus Q1 | Q4 versus Q1 | P for linear trend |
| HR (95% CI) | HR (95% CI) | HR (95% CI) | ||||
| All subjects | All-cause mortality | 8.39 | 1.05 (0.77 to 1.43) | 1.29 (0.96 to 1.73) | 1.63 (1.22 –to 2.17) | <0.001*** |
| Cancer mortality | 3.88 | 1.07 (0.69 to 1.68) | 1.47 (0.96 to 1.25) | 1.60 (1.04 to 2.43) | 0.014* | |
| CVD mortality | 2.34 | 1.24 (0.67 to 2.29) | 1.30 (0.71 to 2.36) | 1.94 (1.09 to 3.42) | 0.016* | |
| Mortality from causes other than cancer and CVD | 2.16 | 0.92 (0.50 to 1.68) | 1.08 (0.60 to 1.93) | 1.49 (0.86 to 2.60) | 0.096 | |
| Men | All-cause mortality | 11.14 | 0.98 (0.67 to 1.45) | 0.98 (0.68 to 1.42) | 1.50 (1.08 to 2.09) | 0.020* |
| Cancer mortality | 4.92 | 1.54 (0.86 to 2.75) | 1.23 (0.68 to 2.21) | 1.96 (1.15 to 3.35) | 0.027* | |
| CVD mortality | 3.13 | 0.74 (0.34 to 1.61) | 0.86 (0.43 to 1.72) | 1.41 (0.76 to 2.60) | 0.208 | |
| Mortality from causes other than cancer and CVD | 3.09 | 0.65 (0.03 to 1.40) | 0.86 (0.44 to 1.67) | 1.15 (0.62 to 2.12) | 0.557 | |
| Women | All-cause mortality | 6.30 | 1.45 (0.86 to 2.46) | 1.57 (0.91 to 2.71) | 2.04 (1.22 to 2.34) | 0.004* |
| Cancer mortality | 3.13 | 1.51 (0.77 to 2.99) | 1.25 (0.59 to 2.62) | 1.62 (0.81 to 3.23) | 0.295 | |
| CVD mortality | 1.74 | 1.18 (0.36 to 3.86) | 1.91 (0.61 to 6.00) | 2.73 (0.93 to 8.06) | 0.012* | |
| Mortality from causes other than cancer and CVD | 1.46 | 1.66 (0.52 to 5.25) | 2.17 (0.68 to 6.96) | 2.40 (0.78 to 7.38) | 0.106 |
| Assay | Coefficient of variation | |
| Intra-assay (%) | Inter-assay (%) | |
| OPG | 3.53 | 5.78 |
| sRANKL | 9.38 | 12.00 |
| sRAGE | 4.00 | 7.15 |
| esRAGE | 5.20 | 8.50 |
| Ingredients % | Basal diet | DPS2 | DPS4 | DPS6 |
| Corn | 67.58 | 65.54 | 63.64 | 61.55 |
| SBOM (CP 44%) | 23 | 23.09 | 23.20 | 23.35 |
| Corn gluten (CP 62%) | 3.0 | 3.0 | 3.0 | 3.0 |
| Corn oil | 3.4 | 3.36 | 3.27 | 3.17 |
| Limestone | 1.15 | 1.12 | 1.10 | 1.05 |
| Dicalcium phosphate | 1.27 | 1.30 | 1.30 | 1.30 |
| L-lysine∗ | 0.14 | 0.13 | 0.13 | 0.12 |
| Dl-methionine∗∗ | 0.01 | 0.01 | 0.01 | 0.01 |
| P. dactylifera seeds | 0.0 | 2.0 | 4.0 | 6.0 |
| Vitamin and mineral premix∗∗∗ | 0.3 | 0.3 | 0.3 | 0.3 |
| NaCl | 0.15 | 0.15 | 0.15 | 0.15 |
| Total | 100 | 100 | 100 | 100 |
| Calculated and analyzed composition | ||||
| ME | 3187.63 | 3189.41 | 3188.58 | 3188.10 |
| CP % | 18.14 | 18.13 | 18.12 | 18.14 |
| Lysine % | 0.96 | 0.96 | 0.96 | 0.96 |
| Methionine % | 0.32 | 0.32 | 0.32 | 0.32 |
| Calcium % | 0.80 | 0.80 | 0.80 | 0.80 |
| Av. (P) | 0.35 | 0.35 | 0.35 | 0.35 |
| Before pregnancy | 1st trimester | 2nd trimester | 3rd trimester | 6 months post-partum | ||
| Mean sexual frequency for all respondents | 1.8 | 1.2 | 1.4 | 1.35 | 1.36 | |
| Circumcised females | Yes | 1.8* | 1.1* | 1.3 | 1.3 | 1.2* |
| No | 2.1 | 1.4 | 1.5 | 1.4 | 1.6 | |
| Episiotomy performed at delivery | Yes | — | — | — | — | 1.3 |
| No | — | — | — | — | 1.2 | |
| Mode of delivery | Vaginal | — | — | — | — | 1.2** |
| Caesarean section | — | — | — | — | 2.3 | |
| Partners said to be engaged in extramarital affairs | Yes | 1.5 | 1.1 | 1.0* | 0.9* | 1.2 |
| No | 1.9 | 1.2 | 1.5 | 1.4 | 1.4 |
| Control Group | Intervention Group | |||||
| N=51 | N=51 | |||||
| Study period | 6 m (i) | 6 m (f) | Final | 6 m (i) | 6 m (f) | Final |
| Length of time (mean [SD], days) | 180.2[41.8] | 190.5[6.4] | 370.7[41.3] | 196.8[29.3] | 190.2[56.4] | 387.0[39.8]a |
| Appointments | ||||||
| Total cost (US$) /day | 8.65 | 6.49 | 7.53 | 8.01 | 6.12 | 7.08 |
| Individual mean [SD] (US$) | 0.17[0.08] | 0.13[0.09] | 0.15[0.07] | 0.16[0.09] | 0.12[0.08] | 0.14[0.07] |
| Laboratory tests | ||||||
| Total cost (US$) /day | 38.07 | 25.35 | 31.48 | 33.33 | 22.96 | 28.24 |
| Individual mean [SD] (US$) | 0.75[0.74] | 0.50[0.46] | 0.62[0.43] | 0.65[0.61] | 0.45[0.43] | 0.55[0.44] |
| Procedures | ||||||
| Total cost (US$) /day | 3.75 | 4.81 | 4.29 | 20.28 | 2.11 | 11.36 |
| Individual mean [SD] (US$) | 0.07[0.22] | 0.09[0.21] | 0.08[0.17] | 0.40[1.11] | 0.04[0.09] | 0.22[0.57] |
| Hospitalization | ||||||
| Total cost (US$) /day | 2.62 | 2.53 | 2.57 | 2.30 | 1.17 | 1.74 |
| Individual mean [SD] (US$) | 0.05[0.30] | 0.05[0.18] | 0.05[0.17] | 0.05[0.13] | 0.02[0.10] | 0.03[0.09] |
| Pharmacist | ||||||
| Total cost (US$) /day | 0.0 | 0.0 | 0.0 | 2.20 | 1.39 | 1.80 |
| Individual mean [SD] (US$) | NA | NA | NA | 0.05[0.02] | 0.03[0.02] | 0.04[0.02] |
| Total | ||||||
| Final cost/day (US$) | 53.09 | 39.18 | 45.88 | 66.13 | 33.74 | 50.23 |
| Individual mean [SD] (US$) | 1.04[0.99] | 0.77[0.70] | 0.90[0.60] | 1.30[1.33] | 0.66[0.55] | 1.00[0.81] |
| Total excluding procedures | ||||||
| Final cost/day (US$) | 49.34 | 34.36 | 41.58 | 45.84 | 31.63 | 38.87 |
| Individual mean [SD] (US$) | 0.97[0.94] | 0.67[0.63] | 0.82[0.56] | 0.90[0.71] | 0.62[0.05] | 0.77[0.53] |
| Variables | Results |
| Demographic variables: | |
| Age, years | 53.3 (8.7) (28–68) |
| Gender, F/M | 34 (82.9)/ 7 (17) |
| Cardiovascular risk factors: | |
| Family history of CVD | 20 (48.8) |
| Current/Ex-smokers | 23 (56.1) |
| Hypertension | 17 (41.5) |
| Diabetes | 3 (7.3) |
| CKD3a (eGFR 45–59 ml/min/1.73 m2) | 2 (4.9) |
| AI abnormal | 11 (26.8) |
| BMI > 30 kg/m2 | 5 (12.2) |
| Physical inactivity | 23 (56.1) |
| RA related variables | |
| Disease duration, years | 19.2 (9.2) (8–45) |
| Erosions (X-ray of hands/feet) | 35 (85.4) |
| Extra-articular symptoms | 28 (68.3) |
| Positive RF-IgM | 33 (80.5) |
| Positive anti-CCP2 | 30 (73.2) |
| ESR, mm/h | 19.2 (16.0) (2–64) |
| CRP, mg/l | 14.35 (37.5) (0.1–228.5) |
| Average CRP (6 years), mg/l | 11.02 (9.9) (0.9–37.3) |
| Low RA activity (DAS28 ≤ 3.2) | 23 (56.1) |
| Current glucocorticoid use | 18 (43.9) |
| Current conventional synthetic DMARD | 39 (95.1) |
| Current biological DMARD | 32 (78.1) |
| Vaginal delivery | Uterine rupture | Maternal morbidity* | Perinatal morbidity** | |||||||||
| Type of labor | n (%) | OR (95% CI) | p | n (%) | OR (95% CI) | p | n (%) | OR (95% CI) | p | n (%) | OR (95% CI) | p |
| Spontaneous n=1,828 (51.6) | 1,483 (81.1) | Ref | 13 (0.7) | Ref | 17 (0.9) | Ref | 6 (0.3) | Ref | ||||
| Induction or augmentation n=1,716 (48.4) | 1,221 (71.2) | 0.69 [0.49-0.67] | <0.01 | 18 (1.0) | 1.5 [0.7-3.0] | 0.28 | 26 (1.5) | 1.6 [0.9-3.0] | 0.11 | 9 (0.5) | 1.6 [0.6-4.5] | 0.37 |
| Prostaglandins n=515 (14.5) | 323 (62.7) | 0.39 [0.32-0.48] | <0.01 | 4 (0.8) | 1.1 [0.4-3.4] | 0.88 | 6 (1.2) | 1.3 [0.5-3.2] | 0.63 | 4 (0.8) | 2.4 [0.7-8.5] | 0.18 |
| Oxytocin (only) n=1,201 (33.9) | 898 (74.8) | 0.69 [0.58-0.82] | <0.01 | 14 (1.2) | 1.6 [0.8-3.5] | 0.20 | 20 (1.7) | 1.8 [0.9-3.5] | 0.08 | 5 (0.4) | 1.3 [0.4-4.2] | 0.70 |
| Prostaglandins (only) n=274 (7.7) | 165 (60.2) | 0.35 [0.27-0.46] | <0.01 | 2 (0.7) | 1.0 [0.2-4.5] | 0.97 | 3 (1.1) | 1.2 [0.3-4.0] | 0.79 | 2 (0.7) | 2.2 [0.4-11.1] | 0.33 |
| Prostaglandins + Oxytocin n=241 (6.8) | 158 (65.6) | 0.44 [0.33-0.59] | <0.01 | 2 (0.8) | 1.2 [0.3-5.2] | 0.84 | 3 (1.2) | 1.3 [0.4-4.6] | 0.64 | 2 (0.8) | 2.5 [0.5-12.7] | 0.25 |
| Oxytocin (induction) n=251 (7.1) | 193 (76.9) | 0.77 [0.56-1.06] | 0.14 | 3 (1.2) | 1.7 [0.5-6.0] | 0.41 | 4 (1.6) | 1.7 [0.6-5.2] | 0.33 | 0 (0.0) | NA | |
| Oxytocin (augmentation) n=950 (26.8) | 705 (74.2) | 0.67 [0.56-0.81] | <0.01 | 11 (1.2) | 1.6 [0.7-3.7] | 0.23 | 16 (1.7) | 1.8 [0.9-3.6] | 0.09 | 5 (0.5) | 1.6 [0.5-5.3] | 0.44 |
| Total N=3,544 (100) | 2,704 (76.3) | 31 (0.9) | 43 (1.2) | 15 (0.4) |
| Source | F statistic | p | Estimated means (standard error) |
| Talker variability | 0.505 | 0.481 | 0 4.351 (0.101) single-talker |
| 4.289 (0.089) multiple-talker | |||
| Talker Variability × Modality of Presentation | 0.000 | 0.988 | 4.282 (0.143) audio only single-talker |
| 4.221 (0.125) audio only multiple-talkers | |||
| 4.420 (0.143) audio-visual single-talker | |||
| 4.357 (0.125) audio-visual multiple-talkers | |||
| Modality of presentation | 0.653 | 0.423 | 4.252 (0.120) audio-only |
| 4.389 (0.120) audio-visual |
| Characteristics | All patients (n = 468) | Phase I (n = 281) | Phase II (n = 187) | P value |
| Age, years | 60.4 ± 16.2 | 59.7 ± 17.7 | 61.4 ± 13.5 | 0.255 |
| Female sex, n (%) | 172 (36.8) | 103 (36.7) | 69 (36.9) | 1.000 |
| APACHE II score | 26.1 ± 8.3 | 25.4 ± 8.2 | 27.2 ± 8.2 | 0.018* |
| Weight, kg | 63.7 ± 17.8 | 63.7 ± 17.8 | 63.6 ± 18.0 | 0.946 |
| Ventilated days preextubation, median (IQR) | 2 (1–4) | 2 (1–4) | 3 (1–5) | 0.509 |
| Main diagnosis, n (%) | 0.085 | |||
| Pneumonia | 130 (27.8) | 67 (23.8) | 63 (33.7) | |
| Nonpneumonia sepsis | 72 (15.4) | 45 (16.0) | 27 (14.4) | |
| COPD | 16 (3.4) | 7 (2.5) | 9 (4.8) | |
| Asthma | 29 (6.2) | 16 (5.7) | 13 (7.0) | |
| Fluid overload | 32 (6.8) | 21 (7.5) | 11 (5.8) | |
| Stroke | 11 (2.4) | 10 (3.6) | 1 (0.5) | |
| Seizure | 30 (6.4) | 19 (6.8) | 11 (5.9) | |
| Othera | 148 (31.6) | 96 (34.2) | 52 (27.8) | |
| Comorbidity, n (%) | ||||
| Diabetes mellitus | 184 (39.4) | 100 (35.7) | 84 (44.9) | 0.053 |
| Hypertension | 255 (54.6) | 151 (53.9) | 104 (55.6) | 0.776 |
| IHD | 111 (23.8) | 60 (21.4) | 51 (27.3) | 0.151 |
| CHF | 38 (8.1) | 14 (5.0) | 24 (12.8) | 0.003* |
| Asthma | 66 (14.1) | 37 (13.2) | 29 (15.5) | 0.500 |
| COPD | 30 (6.4) | 14 (5.0) | 16 (8.6) | 0.129 |
| Bronchiectasis | 8 (1.7) | 1 (0.4) | 7 (3.7) | 0.008* |
| OSA | 23 (4.9) | 12 (4.3) | 11 (5.9) | 0.514 |
| CKD | 107 (23.0) | 59 (21.2) | 48 (25.7) | 0.263 |
| CLD | 26 (5.6) | 18 (6.4) | 8 (4.3) | 0.411 |
| Stroke | 59 (12.7) | 40 (14.3) | 19 (10.2) | 0.204 |
| Cancer | 34 (12.1) | 24 (12.8) | 24 (12.8) | 0.886 |
| Before | After | P value | ES | IC | |
| External rotator | |||||
| Positive peak torque at 60 deg.s−1 (Nm) | 43.3 ± 7.7* | 40.6 ± 6.4 | 0.02 | 0.38 | −0.13 to −0.63 |
| Positive total work at 60 deg.s−1 (J) | 51.7 ± 9.8* | 46.7 ± 8.5 | 0.01 | 0.54 | −0.24 to-0.84 |
| Positive peak torque at 300 deg.s−1 (Nm) | 35.2 ± 5.0 | 34.5 ± 2.5 | 0.41 | 0.17 | 0.19 to −0.53 |
| Average power at 300 deg.s−1 (W) | 65.3 ± 14.4 | 59.2 ± 10.3 | 0.12 | 0.48 | 0.032 to −0.99 |
| Negative peak torque at 90 deg.s−1 (Nm) | 45.2 ± 9.8 | 38.9 ± 9.5 | 0.06 | 0.65 | −0.096 to −1.2 |
| Negative peak torque at 300 deg.s−1 (Nm) | 44.7 ± 6.2* | 40.4 ± 4.5 | 0.04 | 0.79 | |
| Internal rotator | |||||
| Positive peak torque at 60 deg.s−1 (Nm) | 71.3 ± 13.7* | 60.9 ± 10.2 | 0.01 | 0.86 | −0.37 to −1.3 |
| Positive total work at 60 deg.s−1 (J) | 90.9 ± 16.9* | 77.8 ± 13.1 | 0.00 | 0.86 | −0.86 to −0.86 |
| Positive peak torque at 300 deg.s−1 (Nm) | 66.5 ± 12.3* | 61.3 ± 12.3 | 0.00 | 0.42 | −0.42 to −0.42 |
| Average power at 300 deg.s−1 (W) | 113.3 ± 29.4* | 94.8 ± 29.1 | 0.02 | 0.63 | −0.22 to −1 |
| Negative peak torque at 90 deg.s−1 (Nm) | 79.8 ± 13.6 | 68.9 ± 17.2 | 0.06 | 0.70 | −0.1 to −1.3 |
| Negative peak torque at 300 deg.s−1 (Nm) | 69.9 ± 14.6 | 62.9 ± 12.9 | 0.16 | 0.51 | 0.051 to −1.1 |
| Balance ratios | |||||
| Conventional ratio | 0.61 ± 0.1 | 0.67 ± 0.1 | 0.063 | 0.60 | −0.081 to −1.1 |
| Functional ratio | 0.68 ± 0.1 | 0.67 ± 0.2 | 0.806 | 0.06 | 0.37 to −0.49 |
| AC | Date of creation | Ground-truth location(s) | Prediction results | GO total number | Essential GO terms |
| D3DTV9 | 26-Nov-2014 | Nucleus | Nucleus | 13 | GO:0000166, GO:0016787, GO:0003676, GO:0003723, GO:0004386, GO:0046872, GO:0051607, GO:0005524 |
| E9PAV3 | 19-Feb-2014 | Cytoplasm, Nucleus | Cytoplasm, Nucleus | 9 | GO:0015031, GO:0003677, GO:0005634, GO:0005737, GO:0006351, GO:0006355, GO:0006810 |
| B7ZW38 | 26-Nov-2014 | Nucleus | Nucleus | 5 | GO:0000166, GO:0030529, GO:0003676, GO:0003723, GO:0005634 |
| P0DMR3 | 07-Jan-2015 | Cytoplasm | Cytoplasm | 22 | GO:0000166, GO:0016740, GO:0016874, GO:0003824, GO:0046872, GO:0005524, GO:0005575, GO:0008152 |
| P0DML3 | 09-Jul-2014 | Extracellular | Extracellular | 6 | GO:0046872, GO:0005179, GO:0005576, GO:0007165 |
| P0DMN0 | 03-Sep-2014 | Cytoplasm | Cytoplasm | 16 | GO:0016740, GO:0030968, GO:0044267, GO:0044281, GO:0005737, GO:0005829, GO:0006629, GO:0006805 |
| C9JSJ3 | 29-Oct-2014 | Nucleus | Nucleus | 4 | GO:0003677, GO:0005634, GO:0006351, GO:0006355 |
| Parameter | R | P value |
| W/H | 0.55 | <0.0001 |
| BMI | 0.264 | 0.017 |
| TG | 0.23 | 0.037 |
| Chol | −0.04 | 0.86 |
| LDL-C | −0.038 | 0.73 |
| HDL-C | −0.21 | 0.05 |
| VLDL-C | 0.23 | 0.03 |
| ApoB | 0.087 | 0.44 |
| ApoA1 | −0.204 | 0.06 |
| TG/HDL-C | 0.283 | 0.01 |
| LDL-C/HDL-C | 0.13 | 0.24 |
| LDL size | −0.25 | 0.025 |
| DEC2 | HIF-1α expression scale* | Total | |||
| 0 | 1 | 2 | 3 | ||
| 0 | 0 (0%) | 4 (8%) | 2 (4%) | 1 (2%) | 7 (14%) |
| 1 | 2 (4%) | 13 (26%) | 11 (22%) | 4 (8%) | 30 (60%) |
| 2 | 0 (0%) | 2 (4%) | 2 (4%) | 7 (14%) | 11 (22%) |
| 3 | 0 (0%) | 0 (0%) | 0 (0%) | 2 (4%) | 2 (4%) |
| Total | 2 (4%) | 19 (38%) | 15 (30%) | 14 (28%) | 50 (100%) |
| FNA | CB | FNA and CB | ||||
| Suspected hepatic metastasis | ||||||
| Specific diagnosis | 56% | (70/124) | 68% | (34/50) | 60% | (75/124) |
| ∗Diagnosis malignant versus benign | 93% | (115/124) | 96% | (48/50) | 94% | (117/124) |
| Suspected primary neoplasms | ||||||
| Specific diagnosis | 70.5% | (43/61) | 67.5% | (27/40) | 79% | (48/61) |
| Total | 85.4% | (158/185) | 83% | (75/90) | 89.1% | (165/185) |
| Patients (n = 458) | |||
| Baseline characteristics | % or mean | (n or SD) | |
| Men% | 24.9 | (114) | |
| Women% | 74.7 | (342) | |
| Age mean years (SD) | 54.0 | (7.4) | |
| Weight mean kg (SD) | 96.4 | (18.3) | |
| Starting BMI mean kg/m2 (SD) | 36.0 | (5.9) | |
| Starting BMI kg/m2% | <30 | 9.8 | (45) |
| 30-34 | 43.9 | (201) | |
| 35-39 | 23.8 | (109) | |
| ≥40 | 21.2 | (97) | |
| not recorded | 1.3 | (6) | |
| Smoking status% | smoker | 14.4 | (66) |
| not recorded | 18.8 | (86) | |
| Diabetes Status% | diabetic | 11.6 | (53) |
| not recorded | 15.7 | (72) |
| Photographic ICDAS score UR6 occlusal | |||||||||
| 0 | 2 | 3 | 4 | 5 | 6 | F | S | ||
| Clinical ICDAS Score UR6 Occlusal | 0 | 506 | 8 | 0 | 0 | 0 | 0 | 2 | 5 |
| 2 | 252 | 327 | 26 | 4 | 2 | 0 | 7 | 7 | |
| 3 | 2 | 66 | 48 | 3 | 1 | 0 | 1 | 1 | |
| 4 | 2 | 25 | 15 | 25 | 4 | 0 | 1 | 1 | |
| 5 | 0 | 1 | 5 | 1 | 7 | 0 | 2 | 1 | |
| 6 | 0 | 0 | 0 | 0 | 0 | 7 | 0 | 0 | |
| F | 10 | 3 | 0 | 0 | 0 | 0 | 138 | 4 | |
| S | 4 | 1 | 2 | 0 | 0 | 0 | 12 | 187 |
| Variables | Comparative group | Intervention group |
| Sex | ||
| Male | 382 (62.2%) | 511 (73.3%) |
| Female | 232 (37.78%) | 186 (26.7%) |
| Age | ||
| 18–24 | 608 (99%) | 657 (94.3%) |
| 25–30 | 6 (1%) | 40 (5.7%) |
| Religion | ||
| Orthodox | 321 (52.3%) | 341 (48.9%) |
| Catholic | 32 (5.2%) | 17 (2.4%) |
| Protestant | 153 (24.9%) | 150 (21.5%) |
| Muslim | 100 (16.3%) | 165 (23.7%) |
| Other∗ | 8 (1.3%) | 24 (3.4%) |
| Ethnic group | ||
| Oromo | 362 (59%) | 495 (71%) |
| Amhara | 150 (24.4%) | 106 (15.2%) |
| Tigrea | 32 (5.2%) | 30 (4.3%) |
| Sidama | 22 (3.6%) | 21 (3%) |
| Gurage | 6 (1%) | 24 (3.4%) |
| Other∗∗ | 42 (6.8%) | 21 (3%) |
| Marital status | ||
| Single | 567 (92.3%) | 586 (84.1%) |
| In relationship | 41 (6.7%) | 85 (12.2%) |
| Married | 6 (1%) | 26 (3.7%) |
| Income | ||
| <300 | 418 (68%) | 514 (73.7%) |
| >300 | 196 (32%) | 183 (26.3%) |
| Immersion Time/h | EV-0.1 MPa | EV-3.5 MPa | EGF-0.1 MPa | EGF-3.5 MPa |
| 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| 24 | 6.02 | −4.01 | 6.42 | 2.31 |
| 36 | −2.02 | 3.07 | −1.79 | 0.27 |
| 48 | −4.49 | 0.52 | 0.77 | −3.53 |
| 60 | −1.18 | 1.67 | −4.56 | −0.31 |
| 72 | −2.81 | −2.49 | −5.81 | −0.84 |
| 84 | 0.68 | 2.24 | −6.53 | 2.89 |
| 96 | −7.43 | 4.70 | −4.47 | −3.48 |
| 108 | −1.36 | −5.6 | 0.35 | 1.04 |
| 120 | 1.43 | 5.04 | 3.28 | −1.55 |
| 132 | 7.56 | −3.64 | 10.83 | 0.00 |
| 144 | 6.07 | −4.95 | 11.19 | 7.63 |
| 156 | 8.45 | 1.01 | 4.10 | −4.63 |
| 168 | 4.58 | −2.82 | 12.40 | 3.79 |
| 180 | 7.23 | 5.56 | −2.48 | −6.25 |
| 192 | 0.93 | −11.27 | 9.56 | 3.34 |
| Mean value of MI | Standard deviation of MI | Num of positive values | Num of negative values | Num of values ofdifferent sign | Min value | Max value | |
| GSE18655_grade1 | 0.00024 | 0.0015 | 6298 | 2918 | N/A | −0.0011 | 0.0858 |
| GSE18655_grade2 | 0.00020 | 0.0017 | 6468 | 2748 | −0.0018 | 0.0949 | |
| GSE18655_grade3 | 0.0004 | 0.0021 | 6650 | 2566 | −0.0029 | 0.0582 | |
| GSE19536_A(72) | 0.00036 | 0.0022 | 3912 | 1272 | 2052 | −0.0010 | 0.1293 |
| GSE19536_B(72) | 0.00053 | 0.0040 | 3388 | 1796 | −0.0022 | 0.2279 | |
| GSE19536_BasalLike(68) | 0.0017 | 0.0056 | 3491 | 998 | 1217 | −0.0033 | 0.1648 |
| GSE19536_NormalLike(68) | 0.0056 | 0.008 | 4200 | 420 | −0.002 | 0.1279 | |
| GSE21036_cancer | 0.0165 | 0.0212 | 10 | 474 | 56 | −0.002 | 0.1446 |
| GSE21036_norm | 0.0086 | 0.0146 | 46 | 438 | −0.0015 | 0.1565 |
| Complication | EN group(n = 8) | EN+PN group(n = 9) |
| Surgery related complications | ||
| Pancreatic leakage (minor leakage) | 0 | 1 |
| Anastomotic leakage (minor leakage) | 1 | 0 |
| Ileus | 1 | 0 |
| Ulcer at anastomotic portion | 0 | 1 |
| Wound infection | 3 | 1 |
| General complications | ||
| Pulmonary | 1 | 0 |
| Total number of patients with complications | 5 | 4 |
| Mortality | 1 | 0 |
| No significant differences noted. |
| Food outlets | Accessibility/availability measures | All cases | Type 1 diabetes | Type 2 diabetes | |||
| Mean (SD) | Range | Mean (SD) | Range | Mean (SD) | Range | ||
| Supermarket | Distance to nearest (miles) | 2.9 (2.7) | 0.0, 17.4 | 2.9 (2.6) | 0.0, 15.6 | 3.1 (3.1) | 0.2, 17.4 |
| Number in 2-mile buffer | 1.1 (1.5) | 0.0, 9.0 | 1.1 (1.6) | 0.0, 9.0 | 1.2 (1.4) | 0.0, 6.0 | |
| Density (number per sq. mile) | 1.1 (0.7) | 0.0, 2.6 | 1.1 (0.7) | 0.0, 2.5 | 1.1 (0.8) | 0.0, 2.6 | |
| Fast food | Distance to nearest (miles) | 2.6 (2.5) | 0.0, 15.9 | 2.5 (2.4) | 0.0, 15.9 | 2.9 (3.1) | 0.2, 15.7 |
| Number in 1-mile buffer | 1.2 (2.7) | 0.0, 17.0 | 1.2 (2.7) | 0.0, 17.0 | 1.4 (2.7) | 0.0, 14.0 | |
| Density (number per sq. mile) | 1.7 (2.0) | 0.0, 9.8 | 1.7 (2.0) | 0.0, 9.2 | 1.8 (2.1) | 0.0, 9.8 |
| Category | Age (years) | Hb (g/dL) | Parasite density (% of parasitized RBCs) |
| Complicated cases | 2.384 (±1.239) | 9.579 (±0.900) | 10.542 (±2.704) |
| Uncomplicated controls | 2.796 (±1.315) | 12.338 (±1.278) | 7.596 (±2.040) |
| P value | 0.007 | <0.0001 | <0.0001 |
| Patients/reference group | Mean | SD | Comment Original publication |
| MS | 35.4 | 12.1 | Present data |
| Stroke | 42.1 | 12.7 | Present data |
| Male, age 40–49 | 64.2 | 16.3 | German Health Survey 1998 (20) (N = 6964 participants, age 18–80) |
| Male, age 50–59 | 61.5 | 18.1 | German Health Survey 1998 (20) |
| Female, age 40–49 | 57.4 | 18.8 | German Health Survey 1998 (20) |
| Female, age 50–59 | 57.7 | 18.8 | German Health Survey 1998 (20) |
| Parameter | Leaf oil | Bark oil |
| Specific gravity (20°C) | 1.030–1.050 | 1.010–1.030 |
| Optical rotation (°) (20°C) | 1°96′–0°40′ | Slightly laevorotatory |
| Refractive index (20°C) | 1.529–1.537 | 1.573–1.591 |
| Aldehyde content | 4% | 65–76% |
| Eugenol content | 77.3–90.5% | 4–10% |
| Solubility characteristics | Soluble in 1.5 volumes of 70% alcohol | Soluble in 2.0–3.0 volumes of 70% alcohol |
| Degree of comfort | Attending to patients with mental illness | Dealing with mentally sick people | ||
| Frequency | Percent | Frequency | Percent | |
| Extremely uncomfortable | 22 | 19.8 | 28 | 25.2 |
| Uncomfortable | 54 | 48.6 | 41 | 36.9 |
| Comfortable | 31 | 27.9 | 37 | 33.3 |
| Extremely comfortable | 4 | 3.6 | 5 | 4.5 |
| TOTAL | 111 | 100.0 | 111 | 100.0 |
| Weight (kg) | Wafers or Bars per Day | |
| BP-100TM | NumTrey | |
| Bar | Wafer | |
| 3.0–3.4 | 2 | 17 |
| 3.5–4.9 | 2.5 | 20 |
| 5.0–6.9 | 4 | 27 |
| 7.0–9.9 | 5 | 40 |
| 10.0–14.0 | 6 | 53 |
| 14.0–19.0 | 9.5 | 79 |
| 19.0–23.0 | 13 | 106 |
| 23.0–30.0 | 16 | 131 |
| >30.0 | 200 kcal/kg/day | 200 kcal/kg/day |
| Variable | PFS | OS | |||
| Hazard ratio (95% CI) | P value | Hazard ratio (95% CI) | P value | ||
| Beclin 1 (high vs. low) | 1.833 (1.016-3.308) | 0.044 | 1.233 (0.861-1.766) | 0.252 | |
| Age (≥56 y vs. <56 y) | 0.695 (0.426-1.133) | 0.144 | 1.166 (0.844-1.613) | 0.352 | |
| Gender (Male vs. Female) | 1.459 (0.864-2.464) | 0.157 | 0.984 (0.703-1.379) | 0.927 | |
| Subtypes (Intrahepatic vs. Extrahepatic) | 0.596 (0.362-0.984) | 0.043 | 0.614 (0.439-0.859) | 0.004 | |
| Largest tumor size (≥5 cm vs. <5 cm) | 1.934 (1.187-3.150) | 0.008 | 1.903 (1.371-2.642) | < 0.001 | |
| Vascular invasion (Positive vs. Negative) | 1.899 (1.168-3.086) | 0.010 | 1.416 (1.014-1.977) | 0.041 | |
| HBV infection (Positive vs. Negative) | 1.620 (0.957-2.743) | 0.072 | 1.139 (0.781-1.662) | 0.498 | |
| Liver cirrhosis (Positive vs. Negative) | 0.574 (0.312-1.056) | 0.074 | 0.811 (0.518-1.267) | 0.357 | |
| Cholecystolithiasis (Positive vs. Negative) | 0.904 (0.474-1.727) | 0.761 | 0.944 (0.614-1.452) | 0.793 | |
| Histological grade (well/moderate vs. poor) | 2.869 (1.508-5.458) | 0.001 | 2.633 (1.714-4.043) | < 0.001 | |
| Tumor surgery (R0 vs. R1/R2) | 3.465 (1.691-7.101) | 0.001 | 3.095 (1.824-5.249) | < 0.001 | |
| Serum CA199 (≥35 unit/ml vs. <35 unit/ml) | 1.857 (0.867-3.979) | 0.111 | 1.477 (0.931-2.342) | 0.097 | |
| Serum CA125 (≥35 unit/ml vs. <35 unit/ml) | 1.844 (0.954-3.565) | 0.069 | 1.679 (1.046-2.695) | 0.032 | |
| Serum CEA (≥5 ug/L vs. <5 ug/L) | 1.661 (0.911-3.029) | 0.098 | 2.063 (1.394-3.053) | < 0.001 | |
| Serum AFP (≥8.1 ug/L vs. <8.1 ug/L) | 1.096 (0.571-2.105) | 0.783 | 1.019 (0.645-1.610) | 0.936 | |
| Serum total bilirubin (≥23.9 umol/L vs. <23.9 umol/L) | 0.762 (0.469-1.237) | 0.272 | 0.801 (0.577-1.113) | 0.187 | |
| Tumor stage (T1+2 vs. T3+4) | 1.292 (0.781-2.139) | 0.318 | 1.595 (1.131-2.249) | 0.008 | |
| Node stage (N0 vs. N1) | 1.330 (0.804-2.199) | 0.266 | 1.416 (1.010-1.984) | 0.043 | |
| TNM stage (1+2 vs. 3+4) | 2.197 (1.332-3.623) | 0.002 | 2.152 (1.541-3.006) | < 0.001 |
| Nutritional regime | Males (N) Means ± SE (in days) | Females (N) Means ± SE (in days) | χ2* | P |
| Glucose (6%) | (148) 17.3 ± 0.6 | (151) 17.2 ± 0.6 | 0.004 | 0.94 |
| T. stans | (145) 14.2 ± 0.8 | (154) 13.2 ± 0.6 | 0.89 | 0.34 |
| S. didymobotrya | (131) 11.9 ± 0.5 | (142) 11.4 ± 0.5 | 0.01 | 0.88 |
| R. communis | (143) 10.9 ± 0.5 | (142) 12.6 ± 0.6 | 3.07 | 0.07 |
| H. patens | (136) 8.1 ± 0.4 | (150) 7.4 ± 0.4 | 0.88 | 0.34 |
| L. camara | (149) 7.6 ± 0.3 | (145) 6.7 ± 0.3 | 2.93 | 0.08 |
| P. hysterophorus | (138) 4.7 ± 0.3 | (141) 4.7 ± 0.3 | 0.002 | 0.96 |
| Water (-ve control) | (148) 3.8 ± 0.1 | (149) 3.8 ± 0.1 | 0.01 | 0.90 |
| None (2nd -ve control) | (144) 2.9 ± 0.07 | (143) 3.1 ± 0.07 | 2.58 | 0.10 |
| ATIC mRNA expression△ | p value | ||
| Variable | Low (117) | high (117) | (chi-square) |
| Gender | |||
| Male | 83 | 81 | 0.8865 |
| Female | 34 | 36 | |
| Diagnosis Age | |||
| ≤ 50 | 23 | 30 | 0.3488 |
| > 50 | 94 | 87 | |
| AFP (ng/mL) | |||
| ≤ 200 | 97 | 74 | 0.0011* |
| > 200 | 20 | 43 | |
| Hepatitis status | |||
| Negative | 61 | 44 | 0.0352* |
| Positive | 56 | 73 | |
| Vascular Invasion | |||
| No | 85 | 69 | 0.0384* |
| Yes | 32 | 48 | |
| Histologic Grade | |||
| G1 | 17 | 9 | 0.0006* |
| G2 | 64 | 43 | |
| G3-G4 | 36 | 65 | |
| TNM stage | |||
| I | 78 | 56 | 0.0086* |
| II | 24 | 31 | |
| III-IV | 15 | 30 |
| Subset | Reference range | Probands | Goodness of fit | Spouses | Goodness of fit | ||||
| % subset sum | % below | % within | % above | p-value* | % below | % within | % above | p-value | |
| CD3+ | 56-86 | 0.95 | 98.1 | 0.95 | 0.3 | 0.0 | 100.0 | 0.0 | 0.2 |
| CD4+ | 33-58 | 7.6 | 78.3 | 14.1 | 0.0001 | 1.8 | 80.7 | 17.5 | 0.0001 |
| CD8+ | 13-39 | 12.3 | 81.1 | 6.6 | 0.0001 | 8.8 | 86.0 | 5.2 | 0.004 |
| CD19+ | 5-22 | 9.4 | 89.6 | 1.0 | 0.0001 | 1.7 | 96.5 | 1.8 | 0.9 |
| CD 16+56+ | 5-26 | 0.0 | 91.5 | 8.5 | 0.0001 | 3.5 | 94.7 | 1.8 | 0.8 |
| Residue | pKa | Buried (%) | Desolvation effects | Hydrogen bond | Coulombic interaction | Atoms cofactor | ||
| Regular | RE | Side chain | Backbone | |||||
| Tyr345 G | 11.99 | 56 % | 0.90 438 | 0.00 0 | 0.21 Asp315 G | –0.02 Arg3180.90 Asp315 | ||
| Asp315 | 2.63 | 97 | 3.82 554 | 1.17 0 | –1.60 His313 G–0.85 Lys319 G–0.20 Tyr342 G–0.21 Tyr345 G | –0.08 Tyr345 G | –0.10 Arg318–0.32 His316–1.13 His313–1.66 Lys319 | =>N3 FAD |
| Arg318 | 11.00 | 92 | –1.93 540 | 0.00 0 | 0.21 Glu450.04 Asp2960.10 Asp3150.02 Tyr345 | =>N10 FAD=>N10 FAD | ||
| Tyr292 | 9.95 | 38 | 1.12 387 | 0.00 0 | –0.77 Lys285 G | 0.00 Xxx0 X | 0.08 Asp281 G0.10 Asp290–0.01 Lys102–0.58 Lys285 | |
| Asp281 | 3.91 | 32 | 1.47 370 | 0.13 0 | –0.18 Asp281 G–0.19 Lys285 G | -0.08 Lys2790.02 Glu 339 | ||
| Asp290 | 3.07 | 3 | 0.53 290 | 0.02 0 | –0.85 Lys102 G | –0.02 Asp290 G | –0.03 Lys 285–0.38 Lys102 | |
| Lys102 | 11.07 | 0 | –0.67 268 | 0.00 0 | 0.85 Asp290 G | 0.01 Tyr292 G0.38 Asp 290 | ||
| Lys285 | 10.17 | 45 | –2.04 406 | 0.00 0 | 0.77 Tyr 292 G | 0.34 Asp281 GX0.03 Asp290 G0.58 Tyr292 | ||
| Tyr213 | 11.13 | 23 | 0.86 347 | 0.00 0 | 0.27 Asp352 | |||
| Asp352 | 3.50 | 5 | 0.42 295 | 0.01 0 | -0.52 Asp352 G–0.09 Leu353 G | –0.02 Lys217–0.10 Arg349 |
| Component | Changes in SLE T cells | Reference |
| TCRζ | ||
| Decreased TCRζ expression/phosphorylation | Grammatikos et al. (26), Kyttaris et al. (27), Pang et al. (29), and Takeuchi et al. (28) | |
| 3′ UTR variants leading to instable versions of TCRζ | Chowdhury et al. (30), Gorman et al. (31), and Tsuzaka et al. (32) | |
| Syk | ||
| Replaces canonical ZAP-70 | Krishnan et al. (33) and Tanaka et al. (34) | |
| More potent signal transduction | Tanaka et al. (34) | |
| Increased expression: inability of CREMα to repress transcription | Ghosh et al. (35) | |
| Calcium signaling | ||
| Increased recruitment of NFATc2 into the nucleus | Kyttaris et al. (36) | |
| → Elevated expression of CD154 | ||
| Enhanced nuclear import of CAMK IV | Juang et al. (37) | |
| → Elevated expression of CREMα | ||
| Other signaling components | ||
| LAT displaced from lipid rafts | Abdoel et al. (38) | |
| Aberrant phosphorylation of Erk | Cedeno et al. (39) and Yi et al. (40) | |
| Genes identified by GWAS | ||
| UBASH3A | Diaz-Gallo et al. (41) | |
| PP2AC | Katsiari et al. (42), and Tan et al. (43) | |
| TNFAIP3 | Graham et al. (44) | |
| SLAM | Morel et al. (45) |
| Variable | Mean (SD) | Range |
| Age (years) | 65.6 (9.5) | 49 – 80 |
| Duration of disease (years) | 14.3 (5.7) | 5 – 23 |
| MDS-UPDRS-3 | 51.7 (15.8) | 15 – 83 |
| MDS-UPDRS-4 | 8.6 (6.4) | 0 – 20 |
| NMSS total | 74.9 (28.9) | 39 – 140 |
| PDQ-8 total | 37.3 (16.3) | 12.5 – 65.6 |
| HADS total | 16.3 (6.6) | 5 – 28 |
| ACE-R total | 90.1 (7.6) | 73 – 100 |
| Antibiotic class | |||||
| Strains | Carb-apenem | Cephalo-sporin | Aminogly-coside | Fluoro-quinolone | |
| Antibiotics* | IPM | CFP | CAZ | GM | CIP |
| ATCC 27853 | 29 | 30 | 33 | 21 | 34 |
| 1 | 29 | 22 | 28 | 21 | 28 |
| 3 | 12 | 25 | 28 | 21 | 24 |
| 6 | 34 | 28 | 33 | 23 | 32 |
| 11 | 30 | 28 | 30 | 21 | 32 |
| 19 | 28 | 0 | 0 | 0 | 0 |
| 26 | 0 | 10 | 0 | 9 | 0 |
| 38 | 0 | 9 | 0 | 8 | 0 |
| 43a | 9 | 0 | 0 | 16 | 0 |
| 47 | 21 | 12 | 0 | 12 | 0 |
| Treatment | Urea (g) | ERP (g) | K source (g) |
| T0 | 0.00 | 0.00 | 0.00 |
| T1 | 4.84 | 7.45 | 2.48 MOP |
| T2 | 3.24 | 4.95 | 53.02 RS humin |
| T3 | 3.58 | 5.67 | 68.90 RH humin |
| T4 | 3.86 | 6.36 | 63.22 SD humin |
| T5 | 3.94 | 6.48 | 43.39 EFB humin |
| T6 | 2.92 | 4.51 | 50.95 RS compost |
| T7 | 0.83 | 0.00 | 164.46 RH compost |
| T8 | 0.26 | 1.07 | 227.48 SD compost |
| T9 | 3.71 | 5.31 | 53.05 EFB compost |
| Variable | Total | KLK5- negative KLK5- positive | p value | |
| Menopausal status* | ||||
| Pre/peri | 54 | 22 (40.7) | 32 (59.3) | 0.005b |
| Post | 47 | 33 (70.2) | 14 (29.8) | |
| Gradec | ||||
| I | 3 | 1 (33.3) | 2 (66.7) | |
| II | 30 | 21 (70.0) | 9 (30.0) | 0.34d |
| III | 34 | 25 (73.5) | 9 (26.5) | |
| TNM Tumor size | ||||
| <2 cm | 26 | 17 (65.4) | 9 (34.6) | |
| 2-5 cm | 37 | 27 (73.0) | 10 (27.0) | 0.79d |
| > 5 cm | 4 | 3 (75.0) | 1 (25.0) | |
| ER status | ||||
| Negative | 16 | 7 (43.8) | 9 (56.3) | 0.028b |
| Positive | 51 | 39 (76.5) | 12 (23.5) | |
| PR status | ||||
| Negative | 24 | 15 (62.5) | 9 (37.5) | 0.42b |
| Positive | 43 | 31 (72.1) | 12 (27.9) |
| Crossa | Genotype | Total | |
| amhy+ (%) | amhy− (%) | ||
| A | 21 (46.7) | 24 (53.3) | 45 |
| B | 16 (35.6) | 29 (64.4) | 45 |
| C | 21 (51.2) | 20 (49.8) | 41 |
| D | 20 (52.6) | 18 (47.4) | 38 |
| Total | 78 (46.2) | 91 (53.8) | 169 |
| Days | Scenario 1 | Scenario 2 | Scenario 3 | Scenario 4 | Scenario 5 | Scenario 6 | Scenario 7 |
| 1 | ● | ● | ● | ● | ● | ● | ● |
| 2 | ● | ● | ● | ● | ● | ● | ● |
| 3 | ● | ● (± α h) | ○ | ● | ●1 | ● | ● |
| 4 | ●1 | ●1 | ● | ●1 | ●1 | ○ | ● (+ 4 h)1 |
| 5 | ●1 | ●1 | ● | ● (± β h)1 | ●1 | ●1 | ●1 |
| 6 | ●1 | ●1 | ●1 | ●1 | ○1 | ●1 | ●1 |
| n | 24 | 24 | 24 | 24 | 24 | 24 | 72 |
| t (h) | 24 | 24 | 24 | 24 | 24 | 24 | 72 (-4) |
| ni (X-ray) | 70 | 52 | 24 | 60 | 69 (+24) | 48 | 65 |
| CTT (h) | 70 | 52 | 24 | 60 | 93 | 48 | 61.4 |
| Rest | Placebo | Fermented milk | |
| Serum hsCRP (ng·mL-1) | 88.9 ± 11.7 | 113.6 ± 22.1 | 79.3 ± 10.6 |
| Serum TNF-α (pg·mL-1) | 0.161 ± 0.002 | 0.166 ± 0.001 | 0.170 ± 0.004 |
| Serum carbonyl protein (nmol·mg-1) | 0.086 ± 0.003 | 0.089 ± 0.004 | 0.096 ± 0.003 |
| Urine 8-OHdG (μg) | 1.82 ± 0.16 | 1.70 ± 0.16 | 1.72 ± 0.19 |
| Score | P value | OR (95% CI) |
| HRD-LOH | 0.069 | 3.0 (0.89, 9.8) |
| HRD-TAI | 0.00016 | 5.8 (2.1, 16) |
| HRD-LST | 0.00014 | 7.4 (2.4, 23) |
| Variable/domain | Personal | Social environment | Physical environment | Total score |
| Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD | |
| Age cluster | ||||
| Young | 31.9 ± 8.3 | 8.7 ± 2.9 | 11.5 ± 3.6 | 52.2 ± 12.5 |
| Middle age | 32.5 ± 9.0 | 9.3 ± 2.8 | 12.0 ± 3.8 | 53.7 ± 13.2 |
| elderly | 32.8 ± 10.3 | 8.9 ± 2.8 | 12.1 ± 4.1 | 53.8 ± 15.1 |
| p value | 0.667 | 0.059 | 0.294 | 0.417 |
| Ethnicity | ||||
| Malay | 34.1 ± 9.0a | 8.9 ± 2.7 | 11.8 ± 3.7 | 54.9 ± 13.3a |
| Chinese | 31.2 ± 8.9 | 9.1 ± 3.0 | 11.9 ± 3.8 | 52.1 ± 13.4 |
| p value | <0.001* | 0.350 | 0.689 | 0.007* |
| Marital status | ||||
| Single | 32.2 ± 7.7 | 8.4 ± 2.5 | 11.7 ± 3.5 | 52.2 ± 11.2 |
| Married | 32.4 ± 9.4 | 9.2 ± 2.9a | 11.9 ± 3.9 | 53.6 ± 13.9 |
| p value | 0.717 | 0.002* | 0.552 | 0.278 |
| Employment status | ||||
| Unemployed | 32.3 ± 9.4 | 8.3 ± 2.6 | 12.2 ± 3.9 | 52.8 ± 13.8 |
| Employed | 32.5 ± 8.9 | 9.4 ± 2.9a | 11.7 ± 3.7 | 53.5 ± 13.2 |
| p value | 0.826 | <0.001* | 0.170 | 0.473 |
| Educational level | ||||
| Primary | 35.3 ± 9.4a | 9.4 ± 3.1 | 13.7 ± 4.1a | 58.5 ± 13.9a |
| Secondary | 33.0 ± 9.1a | 9.1 ± 2.9 | 12.0 ± 3.7b | 54.0 ± 13.4b |
| Tertiary | 30.3 ± 8.5b | 8.8 ± 2.7 | 11.0 ± 3.4c | 50.0 ± 12.3c |
| p value | <0.001* | 0.166 | <0.001* | <0.001* |
| Monthly household income | ||||
| <RM1500 | 34.7 ± 9.8a | 8.9 ± 2.7 | 12.8 ± 4.0a | 56.4 ± 14.2a |
| RM1500-RM3500 | 32.5 ± 8.6b | 9.2 ± 3.0 | 12.0 ± 3.8a | 53.6 ±13.0a |
| >RM3500 | 30.5 ± 8.6c | 8.9 ± 2.8 | 11.0 ± 3.4b | 50.7 ± 12.7b |
| p value | <0.001* | 0.399 | <0.001* | <0.001* |
| BMI | ||||
| Underweight | 32.4 ± 10.0 | 9.0 ± 3.1 | 13.4 ± 3.8 | 54.8 ± 14.9 |
| Normal | 31.0 ± 9.0a | 8.8 ± 2.9a | 11.8 ± 3.9 | 51.5 ± 13.5a |
| Overweight | 33.1 ± 8.7b | 9.1 ± 2.8 | 11.6 ± 3.4 | 53.9 ± 12.8a |
| Obese | 36.3 ± 8.8c | 9.8 ± 2.7b | 12.4 ± 4.2 | 58.5 ± 13.3b |
| p value | <0.001* | 0.034* | 0.073 | <0.001* |
| Waist circumference | ||||
| <90cm | 31.2 ± 8.9 | 8.8 ± 3.0 | 12.0 ± 3.8 | 51.9 ± 13.4 |
| ≥90cm | 33.7 ± 9.1a | 9.3 ± 2.8a | 11.8 ± 3.7 | 54.8 ± 13.3a |
| p value | <0.001* | 0.043* | 0.546 | 0.003* |
| Physical activity | ||||
| Sedentary | 38.2 ± 7.5a | 10.7 ± 2.4a | 13.4 ± 3.3a | 62.4 ± 10.1a |
| Insufficiently active | 32.5 ± 8.9b | 9.1 ± 2.8b | 12.0 ± 3.7b | 53.5 ± 13.0b |
| Sufficiently active | 30.8 ± 9.0c | 8.5 ± 2.8c | 11.4 ± 3.9b | 50.7 ± 13.8c |
| p value | <0.001* | <0.001* | <0.001* | <0.001* |
| Feature | Wheeled Vehicle | Tracked Vehicle | Low-Altitude Helicopter | |||
| Car | Truck | SUV | Van | |||
| Weight (kg) | 1,425 | 6,800 | 1,635 | 1,713 | 40,200 | 3,850 |
| Number of Cylinders | 4 | 6 | 4 | 5 | 10 | 8 |
| Engine Capacity | 78 | 170 | 110 | 140 | 3,240 | 1,468 |
| Recognition rates (%) | |||
| Method | No. of training samples | Average recognition rates (%) | |
| 3 | 4 | ||
| GWT | 79.65 | 82.5 | 81.1 |
| KDCV | 69.5 | 75 | 72.25 |
| GWT-LDA | 82.76 | 85.33 | 84.1 |
| GWT-KDCV (RBF) | 81 | 82.50 | 81.75 |
| GWT-KDCV (Cosine) | 83 | 85 | 84.5 |
| GWT-KDCV (RBF, low-energized) | 88.5 | 91.5 | 90 |
| GWT-KDCV (Cosine, low-energized) | 92.5 | 95.75 | 94.1 |
| Sample | Added (μM) | Found (μM) | RSD (%)a | Recovery(%) |
| 1 | 50.0 | 51.2 | 3.1 | 102.5 |
| 2 | 100.0 | 98.5 | 3.2 | 98.5 |
| 3 | 150.0 | 151.9 | 2.8 | 101.3 |
| Technique | Description | Metrics | Evidence of changes in trauma | Population |
| Time domain | Estimation of variability using statistics and measures of central tendency [3] | HRVi | ↓ predicts mortality, ICH, adrenal insufficiency [11, 15, 19–22, 36] | ICU |
| Uncoupling | ↑ reflects acidosis, coagulopathy, MOSF, AI, severe TBI, ↑ ICP, predicts mortality [6, 9, 12, 22] | ICU | ||
| SDNN | ↓ predicts TBI, mortality, acidosis, LSI [16, 23] | PrehospitalERICU | ||
| RMSSD | ↓ reflects TBI, hemorrhage, mortality [23, 28, 47] | ERICU | ||
| Frequency domain | Calculation of power (amplitude) of contributing frequencies to an underlying signal [18] | TP | ↓ reflects ↑ICP, TBI, prolonged neurologic recovery, need for LSI, mortality, brain death [10, 28, 43] | ICUOutpatient |
| LF | ↓ reflects ↑ICP, TBI, hemorrhage, need for LSI, mortality, brain; ↑ reflects ↑CI, HR, MAP death [4, 10, 27, 28, 37, 43, 48, 49]. | ERICU | ||
| HF | ↓ reflects trauma, ↑ICP, need for LSI, hemorrhage, brain death, and mortality [10, 37, 43, 47, 50, 51] | Prehospital | ||
| LF/HF | ↑ reflects ↑ICP, ↓CPP; ↓ reflects brain death, mortality, hemorrhage, ↓GCS, poor neurologic outcome [5, 7, 10, 27, 48, 51] | PrehospitalICU | ||
| Entropy | Measurement of overall disorder, randomness, or irregularity of a physiologic signal [18] | MSE | ↓ predicts mortality [13, 35, 36, 45] | ICU |
| ApEn | ↓ reflects trauma, burn, hemorrhage, brain death, and ↑ICP, MOSF, predicts mortality; ↑ reflects resuscitation [8, 14, 25, 29, 34, 37, 52] | Prehospital | ||
| SampEn | ↓ reflects trauma, mortality, burn, and hemorrhage;↑ reflects resuscitation; predicts LSI [8, 25, 43] | Prehospital | ||
| FDCL | ↓ reflects hemorrhage; ↑ reflects resuscitation;↓ predicts LSI [17] | Prehospital | ||
| FDDA | ↓ reflects need for LSI, hemorrhage, mortality [8, 25, 43] | Prehospital | ||
| DFA | ↓ reflects mortality; predicts LSI [8, 25, 43] | Prehospital | ||
| SOD | ↑ reflects need for LSI, mortality [8, 25, 43] | Prehospital | ||
| StatAv | ↓ reflects mortality [25] | Prehospital |
| Probe Name | Gene | Log Rank P-value for 2 groups (median split) | Log Rank P-value for 3 groups (tertile split) |
| merck_NM_001216_at_CA9 | CA9 | 0.03* | 0.01* |
| merck2_DQ892208_at_CA9 | CA9 | 0.04* | 0.02* |
| merck_NM_001218_s_at_CA12 | CA12 | <0.01* | 0.02* |
| merck_AK096845_a_at_CA12 | CA12 | <0.0001* | <0.01* |
| merck2_BC087838_at_CA12 | CA12 | <0.01* | <0.01* |
| merck_NM_001017978_s_at_CXorf61 | CXorf61 | <0.01* | 0.08 |
| merck_BX538327_at_DSG3 | DSG3 | 0.53 | 0.10 |
| merck_NM_001944_a_at_DSG3 | DSG3 | 0.33 | 0.65 |
| merck2_M76482_at_DSG3 | DSG3 | 0.48 | 0.88 |
| merck_NM_001447_at_FAT2 | FAT2 | 0.78 | 0.49 |
| merck_NM_023915_s_at_GPR87 | GPR87 | 0.15 | 0.04* |
| merck_NM_032551_s_at_KISS1R | KISS1R | 0.94 | 0.88 |
| merck_NM_014400_at_LYPD3 | LYPD3 | 0.03* | <0.01* |
| merck_NM_014331_at_SLC7A11 | SLC7A11 | <0.01* | 0.02* |
| merck_AI924527_a_at_TMPRSS4 | TMPRSS4 | 0.75 | 0.46 |
| merck2_NM_001083947_at_TMPRSS4 | TMPRSS4 | 0.41 | 0.74 |
| merck2_NM_183247_a_at_TMPRSS4 | TMPRSS4 | 0.93 | 0.57 |
| Weeks postinfection | ||||||
| 4 | 7 | 10 | ||||
| Control rats | Infected rats | Control rats | Infected rats | Control rats | Infected rats | |
| TAS mol/g tissue | 110.6 ± 6.5 | 93.5 ± 7.3a | 108.2 ± 6.9 | 91.4 ± 7.5a | 112.5 ± 6.1 | 98.8 ± 7.7a |
| KEGG category | Distinct ECs | ECs found in the data (% abundance) | N° of matches |
| Energy metabolism | 173 | 92 (53.5%) | 3,857 |
| Carbon fixation | 25 | 21 (84%) | 986 |
| Methane metabolism | 33 | 12 (36.4%) | 202 |
| Nitrogen metabolism | 58 | 30 (51.7%) | 739 |
| Oxidative phosphorylation | 17 | 09 (52.9%) | 972 |
| Photosynthesis | 03 | 01 (33%) | 168 |
| Redutive carboxylate cycle (CO2 fixation) | 13 | 13 (100%) | 531 |
| Sulfur metabolism | 30 | 12 (40%) | 267 |
| Biodegradation of Xenobiotics | 217 | 66 (30.4%) | 2,495 |
| DDT degradation | 10 | 03 (30%) | 74 |
| 1,2-Dichloroethane degradation | 05 | 04 (80%) | 85 |
| 1,4-Dichlorobenzene degradation | 22 | 06 (27.3%) | 74 |
| 2,4-Dichlorobenzoate degradation | 29 | 03 (10.3%) | 18 |
| 3-Chloroacrylic acid degradation | 04 | 04 (100%) | 185 |
| Atrazine degradation | 12 | 04 (33.3%) | 24 |
| Benzoate degradation via CoA ligation | 45 | 23 (51%) | 994 |
| Benzoate degradation via hydroxylation | 50 | 18 (36%) | 158 |
| Biphenyl degradation | 13 | 03 (23.1%) | 71 |
| Caprolactam degradation | 22 | 10 (45.5%) | 131 |
| Carbazole degradation | 11 | 01 (9.1%) | 03 |
| Ethylbenzene degradation | 09 | 03 (33.3%) | 207 |
| Fluorene degradation | 13 | 03(23.1%) | 64 |
| Naphthalene and anthracene degradation | 21 | 03 (14.3%) | 188 |
| Styrene degradation | 21 | 09 (42.9%) | 73 |
| Tetrachloroethene degradation | 07 | 01 (14.3%) | 57 |
| Toluene and xylene degradation | 22 | 07 (31.8%) | 32 |
| γ-Hecachlorocyclohexane degradation | 24 | 07 (29.2%) | 57 |
| Carbohydrate metabolism | 576 | 284 (49.3%) | 9,901 |
| Aminosugars metabolism | 41 | 25 (61%) | 589 |
| Ascorbate and aldarate metabolism | 43 | 18 (41.9%) | 367 |
| Butanoate metabolism | 53 | 34 (64.2%) | 1,802 |
| C5-Branched dibasic acid metabolism Fructose | 17 | 03 (17.6%) | 126 |
| and mannose metabolism | 66 | 28 (42.4%) | 591 |
| Galactose metabolism | 37 | 19 (51.4%) | 529 |
| Glycolysis/Gluconeogenesis | 42 | 29 (69%) | 858 |
| Glyoxylate and dicarboxylate metabolism | 58 | 30 (51.7%) | 676 |
| Inositol metabolism | 09 | 07 (77.8%) | 90 |
| Inositol phosphate metabolism | 30 | 05 (16.4%) | 34 |
| Nucleotide sugars metabolism | 34 | 18 (52.9%) | 517 |
| Pentose and glucuronate interconversions | 56 | 27(48.2%) | 229 |
| Pentose phosphate pathway | 39 | 31 (79.5%) | 846 |
| Propanoate metabolism | 49 | 34 (69.4%) | 1032 |
| Pyruvate metabolism | 65 | 39 (60%) | 1,117 |
| Starch and sucrose metabolism | 73 | 33 (45.2%) | 498 |
| AGG | AGGPEN | DMEAN | DMODE | SBA | |
| Cronbach’s α | 0.75 | 0.76 | 0.79 | 0.77 | 0.68 |
| min | 31.0 | 24.6 | 31.3 | 18.3 | 49.1 |
| max | 83.2 | 85.0 | 85.9 | 86.8 | 83.9 |
| range | 52.2 | 60.4 | 54.6 | 68.5 | 34.8 |
| median | 66.9 | 65.3 | 71.3 | 67.0 | 72.6 |
| mean | 63.9 | 62.5 | 66.8 | 62.8 | 71.2 |
| SD | 11.77 | 13.17 | 12.95 | 16.30 | 7.72 |
| CI (mean, 0.95) | 3.15 | 3.53 | 3.47 | 4.37 | 2.07 |
| Name | Descriptions | Reference |
| Bacterial strains | ||
| E. coli BL21 (DE3) | F-, dcm, ompT, gal, lon, hsdSB (rB−, mB−), λ (DE3[lacI, lacUV5-T7 gene 1, ind1, sam7,nin5]) | Lab stock |
| J3 | E. coli BL21 (DE3) harboring rbcLS-pET30a + (M259T) | [15] |
| JB | E. coli BL21 (DE3) harboring both PBAD-his6-prkA-pACYC184 and rbcLS-pET30a + (M259T) | [15] |
| MZ | E. coli BL21 (DE3) Δzwf | [16] |
| MZL | MZ, Δldh | This study |
| MZLF | MZL, Δfrd | This study |
| MZLF1 | MZLF harboring PBAD-his6-prkA-pACYC184 | This study |
| MZLF3 | MZLF harboring rbcLS-pET30a + (M259T) | This study |
| MZLFB | MZLF harboring both PBAD-his6-prkA-pACYC184 and rbcLS-pET30a + (M259T) | This study |
| Plasmids | ||
| pKD46 | araC, bla, oriR101, repA101 (Ts), araC-ParaB-γ-β-exo (encode λ Red recombinases), temperature-conditional replicon | [30] |
| pkD13 | bla, FRT-kan-FRT | [30] |
| pCP20 | FLP+, λ cI857+,λ PR Pepts, bla, catF | [31] |
| PBAD-his6-prkA-pA CYC184 | Recombinant plasmid carries prkA gene (derived from Synechococcus PCC7492) for the overexpresion of phosphoribulokinase (PrkA) under the control of PBAD | [13] |
| rbcLS-pET30a + (M259T) | Recombinant plasmid carries engineered rbcLS gene (originated from Synechococcus PCC6301) for the overexpresion of engineered Rubisco (M259T) under the control of PT7 | [13] |
| rbcLS-pET30a + (M259T, K198G) | Recombinant plasmid carries engineered rbcLS gene (originated from Synechococcus PCC6301) for the overexpresion of engineered Rubisco (M259T and K198G) under the control of PT7 | This study |
| rbcLS-pET30a + (M259T, K198G, D200G, E201G) | Recombinant plasmid carries engineered rbcLS gene (originated from Synechococcus PCC6301) for the overexpresion of engineered Rubisco (M259T, K198G, D200G, and E201G) under the control of PT7 | This study |
| rbcLS-pET30a + (M259T, K198G, K172G) | Recombinant plasmid carries engineered rbcLS gene (originated from Synechococcus PCC6301) for the overexpresion of engineered Rubisco (M259T, K198G, and K172G) under the control of PT7 | This study |
| rbcLS-pET30a + (M259T, K198G, K331G) | Recombinant plasmid carries engineered rbcLS gene (originated from Synechococcus PCC6301) for the overexpresion of engineered Rubisco (M259T, K198G, and K331G) under the control of PT7 | This study |
| Dosimetry Parameter | Mean % Diff | t test score | P value |
| D90 | 0.61 | 1.74 | 0.0842 |
| V100 | 0.07 | 0.68 | 0.4990 |
| V150 | 3.67 | 4.95 | 0.0001 |
| V200 | 20.47 | 11.30 | 0.0001 |
| GPA score | SIR score | BSBM score | ||||||
| 0 | 0.5 | 1 | 0 | 1 | 2 | 0 | 1 | |
| Age | ≥60 | 51-59 | ≤50 | ≥60 | 51-59 | ≤50 | NA | |
| KPS | <70 | 70-80 | 90-100 | ≤50 | 60-70 | >70 | 50-70 | 80-100 |
| Control of primary cancer | NA | PD | PR-SD | CR-NED | No | Yes | ||
| Volume of the largest BM (cc) | NA | >13 | 5-13 | <5 | NA | |||
| No. of BM | >3 | 2-3 | 1 | ≥3 | 2 | 1 | NA | |
| EC metastasis | (+) | (−) | NA | (+) | (−) |
| Screening tool | Positive result | Sensitivity | Specificity | Study Populations |
| (95% CI) | (95% CI) | |||
| AUDIT-C | ≥ 4 (men) | 86 (80-92) men | 89 (85-93) men | Primary care [24] |
| (3 items)* | ≥ 3 (women) | 73 (66-79) women | 91 (89-93) women | |
| Quantity-Frequency | Exceeding recommended | 88 (83-94) men | 84 (80-89) men | Primary care [24] |
| (3 items)* | drinking limits | 68 (61-75) women | 91 (89-93) women | |
| Heavy-drinking day | Any heavy days (≥ 4 drinks women, ≥ 5 drinks men) | 83 (71-90) men | 72 (61-81) men | Primary care [27] |
| past year (1 item) | 81 (64-91) women | 84 (76-89) women |
| SCD (n = 60) | HbAA (n = 59) | p | |
| Age* (years) | 7.92 (6.98-9.98) | 5.45 (4.67-6.35) | 0.001 |
| Weight (kg) | 23.18 (19.11) | 20.54 (8.34) | 0.077 |
| Temperature (°C) | 37.90 (1.12) | 38.62 (1.12) | 0.001 |
| Jaundice (n) | 42 (79.2 %) | 4 (6.7 %) | < 0.001 |
| Spleen size (cm) | 1.27 (2.73) | 0.20 (0.81) | 0.008 |
| Liver size (cm) | 3.42 (4.70) | 0.43 (1.32) | < 0.001 |
| Parasite density* (/μL) | 1,197 (645-2221) | 11,774 (5256-26375) | 0.0006 |
| Haemoglobin (g/dL) | 6.56 (2.22) | 9.71 (2.16) | <0.0001 |
| WBC (109/L) | 23.95 (18.45) | 10.21 (5.92) | <0.0001 |
| Platelet count (109/L) | 254.8 (133.9) | 154.9 (106.1) | <0.0002 |
| Treatment | ctb | csb | del | r | cf | ra | Total aberrationsa |
| Solvent control : Tween-80 (1%) | - | 1 | - | 6 | 6 | - | 13 ± 0.58 |
| Methyl methansulfonate (MMS) | - | 16 | - | 17 | 12 | - | 44 ± 3.06 |
| TOF enriched extract | - | 3 | - | 3 | 3 | - | 9 ± 1.53 |
| Aqueous extract | - | 4 | - | 4 | 2 | - | 10 ± 0.62 |
| Methanolic extract | - | - | - | 3 | 11 | - | 14 ± 0,58 |
| Solvent control : Tween-80 (5%) | - | - | - | 10 | 7 | - | 17 ± 1.15 |
| Ethyl acetate extract | - | 2 | - | 12 | 5 | - | 19 ± 1.53 |
| Ingredient | Control Cream | Test Cream |
| Xyliance | 4% | 4% |
| Kendi oil | 0.5% | 0.5% |
| Phenoxyethanol | 0.5% | 0.5% |
| Aqua | QS | QS |
| Rhodosorus marinus extract/Dexamethasone | 1% or 3%/0.2% |
| Days after SIV infection | |||||
| Animal # | Day 14 | Day 18 | Day 21 | Day 28 | |
| 206 | blood | 100%a (17/17)b | 14.3% (3/21) | 0% (0/26) | NDc |
| milk | 100% (30/30) | 87.5% (28/32) | 17.4% (4/23) | 0% (0/17) | |
| 257 | blood | 100% (29/29) | 90.9% (20/22) | 38.5% (10/26) | 0% (0/20) |
| milk | 100% (21/21) | 100% (30/30) | 54.5% (12/22) | 0% (0/31) | |
| 402 | blood | 100% (28/28) | 12.5% (3/24) | 7.7% (2/26) | ND |
| milk | 100% (18/18) | 31.0% (9/29) | 16.7% (1/6) | 0% (0/32) | |
| 403 | blood | 100% (29/29) | 54.2% (13/24) | 9.4% (3/32) | ND |
| milk | 100% (23/23) | 47.6% (10/21) | 17.4% (4/23) | 0% (0/31) |
| Parameters | Respondents | Mbarali district (%) | Momba district (%) | p value |
| Age of household head (years) | ||||
| 15-30 | 120 | 1.7 | 11.7 | 0.013 |
| 31-45 | 120 | 52.5 | 45 | |
| 46-60 | 120 | 35 | 29.2 | |
| >60 | 120 | 10.8 | 14.2 | |
| Experience of keeping cattle (years) | ||||
| <5 | 120 | 1.7 | 11.7 | 0.005 |
| 5-10 | 120 | 35 | 37.5 | |
| >10 | 120 | 63.3 | 50.8 | |
| Level of education of the household head | ||||
| No formal education | 120 | 0.8 | 25 | <0.0001 |
| Primary education | 120 | 80 | 65 | |
| Secondary education | 120 | 19.2 | 9.2 | |
| College education | 120 | 0 | 0.8 | |
| Land owned by the household | ||||
| <5 acres | 120 | 3.3 | 15.8 | 0.01 |
| 5-10 acres | 120 | 36.7 | 34.2 | |
| 11-50 acres | 120 | 57.5 | 46.7 | |
| >50 acres | 120 | 2.5 | 3.3 | |
| Number of cattle raised by the household | ||||
| <10 cattle | 120 | 3.3 | 34.2 | <0.0001 |
| 10-50 cattle | 120 | 68.3 | 59.2 | |
| >50 cattle | 120 | 28.3 | 6.7 |
| Delusions of guilt | Delusions of grandiosity | Persecutory delusions | Somatic delusions | None of these delusional types | |
| Schizophrenia | 2 (1.7%) | 7 (6.0%) | 33 (28.4%) | 7 (6.0%) | 76 (75.5%) |
| Delusional disorder | 0 | 1 (2.4%) | 21 (50.0%) | 3 (7.1%) | 19 (45.2%) |
| Schizoaffective disorder, manic type | 0 | 2 (22.2) | 1 (11.1%) | 0 | 6 (66.7%) |
| Schizoaffective disorder, mixed type | 0 | 0 | 1 (14.3%) | 1 (14.3%) | 5 (71.4%) |
| Schizoaffective disorder, depressive type | 2 (8.3%) | 0 | 4 (16.7%) | 0 | 18 (75.0%) |
| Bipolar I disorder, current episode manic | 0 | 16 (21.6) | 7 (9.5%) | 1 (1.4%) | 54 (73.0%) |
| Bipolar I disorder, current episode mixed | 1 (9.1%) | 1 (9.1%) | 3 (27.3%) | 1 (9.1%) | 7 (63.6%) |
| Bipolar disorder, current episode depressed with psychotic features | 6 (42.9%) | 0 | 6 (42.9%) | 4 (28.6%) | 3 (21.4%) |
| Major depressive disorder with psychotic features | 24 (47.1%) | 0 | 3 (5.9%) | 6 (11.8%) | 22 (43.1%) |
| Between-group differences | MDD > all other groups except BD and BM (p < 0.001)BD > all other groups except BM and SAD (p < 0.01) | M > MDD and SC (p < 0.001)SAMA > MDD (p < 0.05) | SC (p < 0.05), DD (p < 0.01), and BD (p < 0.05) > MDDDD (p < 0.01) and BD (p < 0.05) > M | BD > M (p < 0.01) |
| Item | Common themes | Groups | Quotes |
| Description and causes of fatigue. | Overwhelming physical tiredness with consequences on difficulties to move | Common in all groups: RA, AxSpA and fibromyalgia | I feel that my body is broken and every movement is as if I was moving a mountain |
| The need to rest more | RA and fibromyalgia | In the morning when I see my kids, I already feel tired and I even feel that I did not want to wake up | |
| A sense of freezing of the body | AxSpA | When I have fatigue, my body is wooden and I move with difficulty | |
| A toxin in the body | RA and AxSpA | It is toxic in my body, everything becomes difficult | |
| Fatigue and pain | Close association between fatigue and pain | Common in all groups: RA, AxSpA and fibromyalgia | |
| Daily patterns of fatigue | Fatigue is more in the morning | AxSpA | When I get up I feel that I am very tired and I wait for one hour to be able to move |
| Fatigue is more in the evening | RA, AxSpA | At the end of the day when I have finished my tasks I feel that my body is broken | |
| No special daily patterns | Fibromyalgia | ||
| Consequences of fatigue | Fatigue affected physical activity to the extent that participants did their work only minimally | Common in all groups: RA, AxSpA and fibromyalgia | I do important things only |
| Social activities became limited to the close family and to very important occasions. | RA and fibromyalgia (female only) | I go to weddings and condolence gatherings only, because of my fatigue | |
| Fatigue affected leisure activities markedly | RA and fibromyalgia | I forget what leisure means | |
| A difficulty in reaching the place of work | Common in all groups: RA, AxSpA and fibromyalgia | I can hardly walk to my work though it is only about 30 min | |
| Women told their husbands to marry again | RA and fibromyalgia | I asked my husband to marry again, he needs a healthy woman and I am too tired | |
| A decrease in male sexual activity | AxSpA | I get fatigued easily and this is a problem for my sexual life | |
| Coping strategies | Dividing big tasks into smaller multiple tasks | Common in all groups: RA, AxSpA and fibromyalgia | |
| Getting help from family members | RA | My mother and sisters help me to complete my daily tasks |
| Cluster | TRANSFAC Annotations | |||
| A | V$POU3F2_02 | |||
| V$ISRE_01: interferon-stimulated response element | ||||
| V$DEAF1_01 | ||||
| V$E2F1_Q3_01 | ||||
| V$MAZR_01: MAZ related factor | ||||
| V$KROX_Q6 | ||||
| V$E2F1DP1_01: E2F-1:DP-1 heterodimer | ||||
| V$HNF1_Q6 | ||||
| V$E2F_Q3_01 | ||||
| V$E2F1_Q6: E2F-1 | ||||
| Cluster | Common GO Parent Node | Gene Ontology | GO Level | GO Name |
| B | signal transduction [4] GO:0007165 | GO:0007264 | 6 | small GTPase mediated signal transduction |
| GO:0007165 | 4 | signal transduction | ||
| GO:0007242 | 5 | intracellular signaling cascade | ||
| C | programmed cell death [5] GO:0012501 | GO:0006917 | 8 | induction of apoptosis |
| GO:0012502 | 7 | induction of programmed cell death | ||
| GO:0043068 | 6 | positive regulation of programmed cell death | ||
| GO:0043065 | 7 | positive regulation of apoptosis | ||
| GO:0050794 | 3* | regulation of cellular process | ||
| GO:0016265 | 3* | death | ||
| GO:0008219 | 4* | cell death | ||
| GO:0012501 | 5 | programmed cell death | ||
| GO:0006915 | 6 | apoptosis | ||
| GO:0043067 | 5 | regulation of programmed cell death | ||
| GO:0042981 | 6 | regulation of apoptosis | ||
| D | response to stress [4] GO:0006950 | GO:0006950 | 4 | response to stress |
| E | macromolecule metabolic process [4] GO:0043170 | GO:0006493 | 9 | O-linked glycosylation |
| GO:0043170 | 4 | macromolecule metabolism | ||
| GO:0044260 | 5 | cellular macromolecule metabolism | ||
| GO:0019222 | 4* | regulation of metabolism | ||
| F | transcription [6] GO:0006350 | GO:0006350 | 6 | transcription |
| GO:0045449 | 6 | regulation of transcription | ||
| GO:0019219 | 5* | regulation of nucleo-base, -side, -tide and nucleic acid metabolism | ||
| GO:0006355 | 7 | regulation of transcription, DNA-dependent | ||
| GO:0006351 | 7 | transcription, DNA-dependent | ||
| G | cell cycle process [6] GO:0022402 | GO:0000082 | 7 | G1/S transition of mitotic cell cycle |
| GO:0000132 | 11 | mitotic spindle orientation | ||
| H | mevalonate transport [8] GO:0015728 | GO:0015728 | 8 | mevalonate transport |
| Age in years (Mean ± SD) | 30.4 ± 7.7 | |||
| Gender# (%) | Female2,144 (44.5%) | Male2,675 (55.5%) | ||
| Residency Year# of residents | R1 = 1,638 | R2 = 1,578 | R3 = 1,152 | >R3 = 685 |
| Variables | Total (n = 2068) | Survivors (n = 1464) | Non-survivors (n = 604) | P value |
| Age (years) | 62.3 ± 0.4 | 59.3 ± 0.5 | 69.3 ± 0.5 | <0.001 |
| Male (n (%)) | 1177 (56.9%) | 817 (55.8%) | 360 (59.6%) | 0.113 |
| Weight (kg) | 82.4 ± 0.5 | 83.4 ± 0.6 | 79.8 ± 0.9 | <0.001 |
| Reasons for admission | ||||
| Cardiac disorder (n (%)) | 627 (30.3%) | 405 (27.6%) | 222 (36.8%) | <0.001 |
| Cerebral disorder (n (%)) | 367 (17.7%) | 282 (19.3%) | 85 (14.1%) | 0.005 |
| Gastrointestinal disorder (n (%)) | 177 (8.5%) | 130 (8.9%) | 47 (7.8%) | 0.417 |
| Respiratory disorder (n (%)) | 345 (16.7%) | 226 (15.4%) | 119 (19.7%) | 0.018 |
| Sepsis (n (%)) | 1010 (48.8%) | 661 (45.1%) | 349 (57.8%) | <0.001 |
| Type of ICU | ||||
| Medical (n (%)) | 706 (34.1%) | 474 (32.3%) | 232 (38.4%) | 0.009 |
| Cardiac (n (%)) | 547 (26.4%) | 346 (23.6%) | 201 (33.2%) | <0.001 |
| Surgical (n (%)) | 356 (17.2%) | 266 (18.2%) | 90 (14.9%) | 0.073 |
| AKI incidence (n (%)) | 464 (22.4%) | 249 (17.0%) | 215 (35.6%) | <0.001 |
| Maximum SOFA score (median (IQR)) | 6 (3–8) | 5 (3–8) | 7 (4–10) | <0.001 |
| Fluid balance (ml/kg/48 hours) | –21.4 ± 0.4 | –-21.5 ± 0.5 | –20.9 ± 0.7 | 0.231 |
| Fluid intake (ml/kg/48 hours) | 52.2 ± 0.6 | 53.7 ± 0.7 | 48.3 ± 1.0 | <0.001 |
| Urine output (ml/kg/48 hours) | 65.3 ± 0.7 | 67.4 ± 0.8 | 60.1 ± 1.3 | <0.001 |
| Diuretics (n (%)) | 778 (37.6%) | 489 (33.4%) | 289 (47.8%) | <0.001 |
| Blood products (n (%)) | 490 (23.7%) | 300 (20.5%) | 190 (31.2%) | <0.001 |
| Neonate causes | Level 1 | Level 2A | Level 2B |
| Birth asphyxia | 461 | 0 | 0 |
| Congenital malformation | 250 | 0 | 0 |
| Meningitis (serious infection) | 6 | 0 | 0 |
| Pneumonia (serious infection) | 84 | 5 | 0 |
| Preterm delivery (<33 weeks gestational age [GA]) without respiratory distress syndrome (RDS) | 353 | 0 | 0 |
| Preterm delivery (with or without RDS) and sepsis | 75 | 1 | 0 |
| Preterm delivery (without RDS) and birth asphyxia | 89 | 0 | 0 |
| Preterm delivery (without RDS) and sepsis and birth asphyxia | 34 | 0 | 0 |
| Respiratory distress syndrome (33-36 weeks GA) | 13 | 0 | 0 |
| Respiratory distress syndrome (<33 weeks GA) | 97 | 0 | 0 |
| Sepsis (serious infection) | 127 | 1 | 0 |
| Sepsis with local bacterial infection | 32 | 1 | 0 |
| Stillbirth | 1,001 | 1 | 0 |
| Tetanus | 4 | 0 | 0 |
| Clinical group | Age at diagnosis(mean and range) | Preexisting cardiovascular disease/hypertension | Preexisting type II diabetes | Smoker/exsmoker | Mean follow-up time posttreatment (years) | Mean time to onset of Grade 3 proctitis (range) |
| Control | 69 (60–77) | 8/20 | 3/20 | 8/20 | 6 | N/A |
| Radiosensitive | 73 (68–76) | 6/10 | 1/10 | 4/10 | 7 | 21 months(9–41 months) |
| Group | Protein length (aa) | Exon number | Exon length (nt) | ||||||
| Mean | Median | K | Mean | Median | K | Mean | Median | K | |
| Alveolata | 535 | 364 | e | 3.6 | 2 | i | 449 | 161 | h |
| Amoebozoa | 463 | 351 | f | 3.1 | 2 | j | 448 | 192 | f |
| Chlorophyta | 490 | 369 | e | 5.4 | 3 | g | 270 | 139 | j |
| Choanoflagellida | 648 | 459 | b | 8.2 | 6 | b | 237 | 113 | m |
| Cryptophyta | 435 | 316 | h | 6.5 | 5 | c | 199 | 82 | n |
| Excavata | 471 | 334 | g | 1.1 | 1 | m | 1330 | 935 | a |
| Fungi | 462 | 381 | d | 3.3 | 2 | k | 421 | 195 | e |
| Haptophyta | 367 | 294 | i | 3.7 | 3 | h | 295 | 164 | g |
| Ichthyosporea | 637 | 494 | a | 4.8 | 4 | d | 398 | 152 | i |
| Metazoa | 595 | 439 | c | 10.1 | 7 | a | 176 | 126 | l |
| Nucleariida | 690 | 499 | a | 4.8 | 4 | e | 429 | 216 | c |
| Rhodophyta | 411 | 334 | g | 1.9 | 1 | n | 665 | 330 | b |
| Stramenopila | 467 | 356 | f | 3.5 | 2 | l | 399 | 196 | d |
| Streptophyta | 436 | 363 | f | 5.7 | 4 | f | 230 | 128 | k |
| Model | Bayes factor |
| 40° Head orientation | |
| Body orientation + hemifield | 1 |
| All other models | >100 |
| 20° Head orientation | |
| Body orientation + hemifield | 1 |
| Body orientation * hemifield | 22 |
| All other models | >100 |
| UEBMI | URBMI | |||
| Insured | Uninsured | Insured | Uninsured | |
| Dependent variable | ||||
| Outpatient visit rate (%) | 13.02 | 7.69 | 12.74 | 7.93 |
| Inpatient visit rate (%) | 6.11 | 5.52 | 4.68 | 2.99 |
| Need variables | ||||
| Female | 47.3 | 50.5 | 58.5 | 58.5 |
| 45-59 | 34.1 | 36.7 | 23.5 | 23.0 |
| 60+ | 16.8 | 15.0 | 16.4 | 16.5 |
| Health status | 79.2 | 80.2 | 81.5 | 81.9 |
| Illness | 12.9 | 12.8 | 12.3 | 10.2 |
| Chronic disease | 16.6 | 17.0 | 18.7 | 16.0 |
| Control variables | ||||
| Annual personal expenditure | 7192 | 7322 | 6840 | 7026 |
| Married | 82.6 | 81.9 | 63.5 | 61.5 |
| Other married status | 8.5 | 8.3 | 10.8 | 11.6 |
| Commercial health insurance | 5.1 | 4.3 | 4.7 | 4.0 |
| Household population | 3.5 | 3.6 | 3.5 | 3.5 |
| Distance to the nearest health institution | 10.0 | 8.8 | 9.8 | 9.5 |
| Classification | BMI (kg/m2) | |
| Underweight (A) | Thinness class III | < 16.00 |
| Thinness class II | 16.00-16.99 | |
| Thinness class I | 17.00-18.49 | |
| Normal (B) | Eutrophia | 18.50-22.99 |
| 23.00-24.99 | ||
| Overweight (C) | Pre-obesity | 25.00-27.49 |
| 27.50-29.99 | ||
| Obesity (D) | Obesity class I | 30.00-32.49 |
| 32.50-34.99 | ||
| Obesity class II | 35.00-37.49 | |
| 38.00-39.99 | ||
| Obesity class III | ≥ 40.00 |
| Principal Components | |||||
| PC1 | PC2 | PC3 | PC4 | PC5 | |
| BMI | 0,80 | 0,20 | −0,23 | 0,20 | −0,28 |
| Waist circumference | 0,75 | 0,23 | −0,39 | 0,18 | −0,15 |
| Systolic blood pressure | 0,72 | −0,21 | 0,03 | 0,39 | 0,38 |
| Diastolic blood pressure | 0,56 | −0,38 | 0,03 | 0,35 | 0,54 |
| Fasting plasma glucose | 0,19 | −0,15 | −0,31 | −0,59 | 0,36 |
| Insulin | 0,62 | 0,35 | −0,32 | −0,17 | −0,11 |
| Total cholesterol | −0,03 | −0,95 | 0,00 | −0,04 | −0,23 |
| Triglycerides | 0,45 | −0,42 | −0,20 | −0,44 | −0,07 |
| HDL cholesterol | −0,55 | −0,24 | 0,41 | 0,20 | −0,09 |
| LDL cholesterol | 0,05 | −0,88 | −0,12 | 0,02 | −0,22 |
| C-reactive protein | 0,50 | −0,05 | 0,23 | 0,30 | −0,37 |
| FCD | −0,29 | −0,13 | −0,63 | 0,14 | −0,22 |
| RBCV | −0,58 | 0,01 | −0,65 | 0,24 | 0,10 |
| RBCVmax | −0,67 | −0,15 | −0,51 | 0,27 | 0,14 |
| TRBCVmax | 0,52 | −0,36 | 0,01 | −0,06 | 0,05 |
| Proportion of total variation | 29% | 16.5% | 12% | 8% | 7% |
| CATEGORY | ISSUES | EXAMPLES |
| Human resources | Teachers | “Some people hate school because teachers are terrible, they are not teaching and do not know how to teach.” |
| Managers | “Managers do not care about our quality of life.” | |
| Moral abuse | Residents and teachers | “There are arrogant teachers.” |
| Demandings | Personal, familiar, institutional, and social | “The least I can do is to push myself as much as I can do.” |
| “Pressure in the medical program is big.” | ||
| Eating habits | Inadequate eating habits | “I learned from a resident to put lots of sugar in my coffee to curb the hunger.” |
| Financial resources | Financial dependence | “You cannot work during the program; I feel bad for being dependent on my parents.” |
| Lack of care with own health | Students adopt unhealthy life | “You see many medical students getting sick, being down, neglecting one's own body, unable to reflect on these things.” |
| Sleep | Sleep privacy | “I want, I need to sleep. I cannot do more shifts and study.” |
| Time | Demands of the program | “I think excessive workload decreases quality of life. You have class every day and then you have to study but you also have many other things in your life.” |
| “In the program there’s a lack of quality of life. Lack of time to lose, to think about life, plans, dreams.” |
| Variables | n | Survival Status | Univariate | Multivariate | |||
| 1-Year(n) | 2-Year(n) | Median survival (months) | P | RR | P | ||
| Sex | |||||||
| Male | 51 | 24.2 | 4.4 | 7.8 ± 1.6 | 1 | ||
| Female | 33 | 25.6 | 11.0 | 6.7 ± 0.5 | 0.862 | 1.054 | 0.845 |
| Age | |||||||
| ≤60 years old | 41 | 33.1 | 5.5 | 7.8 ± 1.6 | 1 | ||
| >60 years old | 43 | 16.5 | 8.2 | 6.7 ± 0.8 | 0.844 | 1.451 | 0.153 |
| Clinical symptoms | |||||||
| Asymptomatic | 15 | 21.8 | 6.7 | 6.7 ± 0.5 | 1 | ||
| Symptomatic | 69 | 66.7 | 19 | 13.1 ± 1.1 | 0.001 | 3.923 | < 0.001 |
| Diameter (cm) | |||||||
| ≤5 | 13 | 53.8 | 23.1 | 13.3 ± 2.8 | 1 | ||
| 5-10 | 39 | 15.0 | 3.0 | 6.8 ± 0.5 | 2.476 | 0.025 | |
| ≥10 | 32 | 23.6 | 3.9 | 5.2 ± 0.4 | 0.013 | 3.165 | 0.011 |
| Intrahepatic lesions | |||||||
| Solitary | 63 | 26.6 | 7.1 | 6.8 ± 1.0 | 1 | ||
| Multiple nodules | 21 | 18.5 | 6.2 | 5.2 ± 0.7 | 0.604 | 1.794 | 0.050 |
| Tumor types | |||||||
| Peripheral ICC | 57 | 20.8 | 6.2 | 6.7 ± 1.0 | 1 | ||
| Central ICC | 27 | 31.9 | 8.0 | 6.8 ± 2.5 | 0.843 | 1.663 | 0.079 |
| LN metastases | |||||||
| Asynchronous | 13 | 69.2 | 15.4 | 14.2 ± 2.3 | 1 | ||
| Synchronous | 71 | 15.5 | 5.2 | 5.9 ± 0.7 | 0.002 | 1.794 | 0.025 |
| CA19-9 (U/L) | |||||||
| ≤37 | 13 | 36.9 | 18.5 | 7.8 ± 2.4 | 1 | ||
| 37-600 | 26 | 32.6 | 4.1 | 9.6 ± 1.4 | 1.639 | 0.232 | |
| ≥600 | 45 | 16.4 | 5.5 | 5.5 ± 0.7 | 0.307 | 1.343 | 0.451 |
| EBRT | |||||||
| Yes | 35 | 38.5 | 9.6 | 9.5 ± 1.1 | 1 | ||
| No | 49 | 14.6 | 4.9 | 5.1 ± 0.3 | 0.003 | 2.962 | < 0.001 |
| TACE | |||||||
| Yes | 28 | 39.9 | 4.0 | 10.0 ± 1.4 | 1 | ||
| No | 56 | 16.6 | 8.3 | 5.9 ± 0.7 | 0.201 | 0.893 | 0.689 |
| De Qi Characteristics | Acupuncture | Mock laser | |||
| C 1 | C2 | De Qi Characteristics | C 1 | C 2 | |
| Dull pain | .857 | Heaviness | .914 | ||
| Sharp pain | .823 | Aching | .887 | ||
| Throbbing | .770 | Deep pressure | .857 | ||
| Cold | .761 | Soreness | .836 | ||
| Tingling | .728 | Fullness/ Distension | .766 | ||
| Warmth | .697 | Warmth | .727 | ||
| Aching | .575 | Tingling | .668 | ||
| Fullness/ Distension | −.912 | Sharp pain | .614 | ||
| Soreness | −.899 | Numbness | .511 | ||
| Deep pressure | −.847 | Throbbing | .889 | ||
| Heaviness | −.781 | Cold | .847 | ||
| Numbness | −.664 | Dull pain | .598 |
| Body weight | BMI | WC | VFA | SFA | FPG | 2-h PG | HOMA-IR | OGIS | HOMA-β | II | |
| Essential AAs | |||||||||||
| Histidine | — | — | — | — | — | — | — | — | — | — | — |
| Isoleucine | 0.413 | 0.305 | 0.345 | 0.332 | — | — | — | — | — | — | — |
| Leucine | 0.488 | 0.300 | 0.361 | 0.413 | — | — | — | — | — | — | — |
| Lysine | 0.307 | — | 0.290 | — | — | 0.236 | — | — | −0.257 | — | — |
| Methionine | — | — | — | — | — | — | — | — | — | — | — |
| Phenylalanine | 0.276 | — | — | — | — | — | — | — | — | — | — |
| Threonine | — | — | — | — | — | — | — | — | — | — | — |
| Tryptophan | — | — | — | 0.289 | — | — | — | — | — | — | — |
| Valine | 0.539 | 0.387 | 0.482 | 0.397 | — | 0.254 | — | 0.219 | −0.297 | — | — |
| Nonessential AAs | — | ||||||||||
| Alanine | — | — | — | — | — | — | — | — | — | — | — |
| Arginine | — | — | — | — | — | — | — | — | — | — | — |
| Asparagine | — | — | — | — | — | — | — | — | — | — | — |
| α-ABA | — | — | — | — | — | — | — | — | — | — | — |
| Citrulline | — | — | −0.242 | — | −0.395 | — | — | −0.291 | — | −0.375 | — |
| Cystine | 0.276 | — | 0.285 | — | — | 0.236 | — | — | — | — | — |
| Glutamate | 0.548 | 0.443 | 0.528 | 0.568 | — | 0.439 | 0.302 | 0.292 | −0.458 | — | — |
| Glutamine | −0.241 | −0.289 | −0.326 | −0.272 | −0.396 | — | −0.220 | −0.398 | — | −0.311 | — |
| Glycine | −0.333 | −0.418 | −0.426 | −0.426 | −0.294 | — | −0.247 | −0.317 | 0.303 | −0.231 | — |
| Ornithine | — | — | — | — | — | — | — | — | — | — | — |
| Proline | — | — | — | — | — | — | — | — | — | — | — |
| Serine | −0.368 | −0.273 | −0.351 | −0.379 | — | — | — | — | 0.258 | — | — |
| Taurine | — | — | — | — | — | −0.240 | — | — | — | — | — |
| Tyrosine | 0.335 | — | 0.314 | 0.252 | — | 0.269 | — | — | −0.327 | — | — |
| Alleles | Controls n = 426 (%) | Patients n = 164 (%) | OR (95% CI) | P value |
| rs4938723 | ||||
| T | 570 (66.9) | 236 (72.0) | 1.0 (ref) | |
| C | 282 (33.1) | 92 (28.0) | 0.79 (0.60–1.04) | 0.10 |
| TP-53 | ||||
| G | 513 (60.2) | 197 (60.1) | 1.0 (ref) | |
| C | 339 (39.8) | 131 (39.9) | 1.01 (0.78–1.31) | 0.96 |
| Acyl donor | Enzyme activity (U/g) | ees (%) | |
| 1 | Methanol | 41.05 ± 0.65 | 24.11 ± 0.06 |
| 2 | Ethanol | 44.16 ± 1.20 | 12.12 ± 0.03 |
| 3 | 1-Propanol | 33.05 ± 1.57 | 16.22 ± 0.08 |
| 4 | 1-Butanol | 84.50 ± 1.12 | 53.42 ± 0.06 |
| 5 | 1-Pentanol | 95.87 ± 0.75 | 66.41 ± 0.11 |
| 6 | 1-Hexanol | 88.11 ± 0.93 | 54.50 ± 0.12 |
| 7 | 1-Heptanol | 91.29 ± 0.58 | 61.01 ± 0.12 |
| 8 | 1-Octanol | 91.43 ± 0.56 | 69.42 ± 0.07 |
| 9 | 1-Nonanol | 103.9 ± 3.91 | 73.91 ± 0.05 |
| 10 | 1-Decanol | 106.8 ± 2.56 | 83.51 ± 0.03 |
| 11 | Isobutanol | 93.61 ± 2.56 | 74.91 ± 0.05 |
| 12 | Isoamylol | 108.95 ± 2.56 | 87.51 ± 0.06 |
| 13 | Isooctanol | 115.46 ± 3.12 | 95.72 ± 0.04 |
| 14 | tert-Butanol | ND | ND |
| 15 | tert-Amyl alcohol | ND | ND |
| 16 | 1,2-Ethanediol | ND | ND |
| LD blocka | SNP | Genotype | n | Hazard ratio | 95% confidence interval | P for trend | |
| IRS1 | 1 | rs1801278 | GG | 990 | |||
| GA, AA | 115 | 0.82 | 0.58, 1.17 | ||||
| 1 | rs13306465 | GG | 999 | ||||
| GA, AA | 97 | 1.44 | 1.07, 1.94 | ||||
| 1 | rs1801123 | AA | 823 | ||||
| AG, GG | 279 | 1.37 | 1.11, 1.69 | ||||
| IGF1R | 11 | rs8038415 | CC | 281 | |||
| CT | 536 | 1.11 | 0.88, 1.41 | ||||
| TT | 270 | 1.40 | 1.07, 1.83 | 0.015 | |||
| 11 | rs17847201 | GG | 350 | ||||
| GA | 581 | 0.87 | 0.69, 1.10 | ||||
| AA | 154 | 0.77 | 0.56, 1.05 | 0.091 |
| Characteristics | 2005-2006 | 2006-2007 | 2007-2008 | 2008-2009 |
| No. of programs enrolledin ILC | 23 | 63 | 80 | 87 |
| No. of ILC registrants | 5596 | 6920 | 6136 | 10,327 |
| Total no. of participantscompleting CKD module | 560 | 1322 | 1435 | 1686 |
| Population included in currentstudy* | ||||
| No. of programs | 23 | 61 | 76 | 87 |
| No. of participants (%) | 509 | 1233 | 1351 | 1609 |
| PGY-1 | 161 (32) | 466 (36) | 503 (37) | 698 (43) |
| PGY-2 | 176 (34) | 399 (32) | 483 (36) | 482 (30) |
| PGY-3 | 172 (34) | 388 (32) | 365 (27) | 429 (27) |
| Programs affiliated with renalfellowship, n (%) | 11 (48) | 27 (43) | 33 (43) | 38 (44) |
| Programs by regional ESKDrate, n (%) | ||||
| Located in region withhighest ESKD rate | 6 (26) | 26 (43) | 26 (34) | 27 (31) |
| Located in region withlowest ESKD rate | 1 (4) | 6 (10) | 4 (5) | 9 (10) |
| Mean pre-test score,% (SD) | 45.1 (18.2) | 49.3 (19.3) | 57.0 (20.2) | 55.2 (19.8) |
| Gene (species) | Sequence 5′→3′ |
| CCL-2 (Homo sapiens) (NM 002982.3) | Fw: TCA GCC AGA TGC AAT CAA TG |
| Rev: ACA CTT GCT GCT GGT GAT TCT | |
| IL-1β (Homo sapiens) (NM 000576.2) | Fw: AGC CAA TCT TCA TTG CTC AAG T |
| Rev: AGT CAT CCT CAT TGC CAC TGT | |
| IL-6 (Homo sapiens) (NM 000600.3) | Fw: CAG CCC TGA GAA AGG AGA CAT |
| Rev: AGC CAT CTT TGG AAG GTT CA | |
| IFN-γ (Homo sapiens) (NM 000619.2) | Fw: TGG AAA GAG GAG AGT GAC AGA A |
| Rev: TTG GAT GCT CTG GTC ATC TTT A | |
| TNF-α (Homo sapiens) (NM 000594.3) | Fw: CTC TCT CCC CTG GAA AGG AC |
| Rev: ATC ACT CCA AAG TGC AGC AG | |
| IL- 10 (Homo sapiens) (NM 000572.2) | Fw: TGTCATCGATTTCTTCCCTGT |
| Rev: TGC CTT TCT CTT GGA GCT TAT T | |
| RPL-27(Homo sapiens) (NM 000988.3) | Fw: CCG AAA TGG GCA AGT TCA T |
| Rev: CCA TCA TCA ATG TTC TTC ACG A | |
| IL-8 (Homo sapiens) (NM 000584.3) | Fw: AGC TCT GTG TGA AGG TGA T |
| Rev: TTT GGG GTG GAA AGG TTT G | |
| ZAG (Homo sapiens) (NM 001185.3) | Fw: CCA GGA GAA CCA AGA TGG TC |
| Rev: CTG CTT CCA ATC CTC CAT TC | |
| PIF (Homo sapiens) (NM 005268627.1) | Fw: AGG AAG CAG AGA TCC AGC CT |
| Rev: GGC TCC TTT ACC CAC GCT TT | |
| HPRT1(Homo sapiens) (NM 000194.2) | Fw: TGG CGT CGT GAT TAG TGA TG |
| Rev: CTT GAG CAC ACA GAG GGC TA |
| Active drugs | PG | TMP | PG | TMP | PG | TMP | Interday RSD%* | |
| Nominal concentration (μg/mL) | 80 | 0.08 | 100 | 0.1 | 120 | 0.12 | PG | TMP |
| Day 1 | 99.74 | 100.29 | 100.65 | 98.56 | 100.28 | 100.72 | 0.456 | 1.146 |
| Day 2 | 100.38 | 98.92 | 100.96 | 101.24 | 99.92 | 99.78 | 0.521 | 1.172 |
| Day 3 | 98.86 | 100.79 | 99.99 | 100.62 | 98.99 | 99.71 | 0.628 | 0.579 |
| Mean | 99.66 | 100.34 | 100.53 | 100.14 | 99.73 | 100.1 | 0.488 | 0.139 |
| Intraday RSD% | 0.76 | 0.97 | 0.49 | 1.4 | 0.66 | 0.56 |
| Tool | URL | References |
| BLAST | http://blast.ncbi.nlm.nih.gov/Blast.cgi | (18) |
| MAFFT MSA | http://www.ebi.ac.uk/Tools/msa/mafft/ | (19) |
| NetMHCpan | http://www.cbs.dtu.dk/services/NetMHCpan/ | (20) |
| NetMHCIIpan | http://www.cbs.dtu.dk/services/NetMHCIIpan/ | (21) |
| Search tool for HPV antigens | http://cvc.dfci.harvard.edu/hpv/HTML/search.php | |
| Search tool for T cell epitope/HLA ligand | http://cvc.dfci.harvard.edu/hpv/HTML/searchT.php | |
| Blast HPVdb | http://cvc.dfci.harvard.edu/hpv/HTML/blast.php | |
| MSA of HPV sequences | http://cvc.dfci.harvard.edu/hpv/HTML/alignment.php | |
| Sequence variability analysis tool | http://cvc.dfci.harvard.edu/hpv/HTML/varability.php | (14) |
| T cell epitope/HLA ligand visualization tool | http://cvc.dfci.harvard.edu/hpv/HTML/viewEpitope.php | |
| Classification of the viruses based on cancer risk | http://cvc.dfci.harvard.edu/hpv/HTML/classification.php | |
| HLA binding prediction tool | Embedded in each antigen entry table | |
| T cell epitope/HLA ligand conservation analysis tool | Embedded in each experimentally validated T cell epitope/HLA entry table; also embedded in each HLA binding prediction result page. |
| Variable | ACRT | STRT1 | STRT2 | Total | p-value | |
| (45 Gy) | (60-63 Gy) | (> 63 Gy) | ||||
| n = 119 | n = 90 | n = 91 | ||||
| Age | median(range) | 68(41,100) | 67(44,88) | 73(47,95) | 69.5(41,100) | < 0.001 |
| Gender | Female | 48(40.3%) | 43(47.8%) | 50(54.9%) | 141(47.0%) | 0.108 |
| Male | 71(59.7%) | 47(52.2%) | 41(45.1%) | 159(53.0%) | ||
| Smoking Status | Never | 8(6.8%) | 2(2.2%) | 4(4.4%) | 14(4.7%) | 0.224 |
| Quit | 70(59.8%) | 45(50.6%) | 53(58.2%) | 168(56.6%) | ||
| Current | 39(33.3%) | 42(47.2%) | 34(37.4%) | 115(38.7%) | ||
| Karnofsky Performance Status score | 90 | 3(2.5%) | 5(5.6%) | 6(6.6%) | 14(4.7%) | < 0.001 |
| 80 | 35(29.4%) | 58(64.4%) | 40(44.0%) | 133(44.3%) | ||
| 70 | 47(39.5%) | 23(25.6%) | 38(41.8%) | 108(36.0%) | ||
| ≤ 60 | 34(28.6%) | 4(4.4%) | 7(7.7%) | 45(15.0%) | ||
| Presenting Weight | No | 56(51.4%) | 67(75.3%) | 61(67.8%) | 184(63.9%) | 0.002 |
| loss ≥ 5% | Yes | 53(48.6%) | 22(24.7%) | 29(32.2%) | 104(36.1%) | |
| Tumor Stage | IIIA | 37(31.1%) | 50(55.6%) | 57(62.6%) | 144(48.0%) | < 0.001 |
| IIIB | 82(68.9%) | 40(44.4%) | 34(37.4%) | 156(52.0%) | ||
| Tumor Histology | Adenocarcinoma | 37(31.4%) | 31(35.2%) | 41(45.6%) | 109(36.8%) | 0.142 |
| Squamous | 42(35.6%) | 34(38.6%) | 32(35.6%) | 108(36.5%) | ||
| NSC-NOS | 39(33.1%) | 23(26.1%) | 17(18.9%) | 79(26.6%) | ||
| Tumor Grade | Well | 3(2.5%) | 0(0%) | 4(4.4%) | 7(2.3%) | 0.069 |
| Moderate | 11(9.2%) | 12(13.3%) | 10(11.0%) | 33(11.0%) | ||
| Poor | 37(31.1%) | 42(46.7%) | 29(31.9%) | 108(36.0%) | ||
| Unclear | 68(57.1%) | 36(40.0%) | 48(52.7%) | 152(50.7%) | ||
| Tumor Size (cm) | median(range) | 5(1,11.5) | 5(1.5,10.5) | 4.2(1,9) | 5(1,11.5) | 0.039 |
| Induction | No | 96(80.7%) | 29(32.2%) | 64(70.3%) | 189(63.0%) | < 0.001 |
| Chemotherapy | Yes | 23(19.3%) | 61(67.8%) | 27(29.7%) | 111(37.0%) | |
| Adjuvant | No | 105(88.2%) | 85(94.4%) | 86(94.5%) | 276(92.0%) | 0.15 |
| Chemotherapy | Yes | 14(11.8%) | 5(5.6%) | 5(5.5%) | 24(8.0%) |
| FT BMD | W BMD | FN BMD | T BMD | |
| β | β | β | β | |
| Age | -0.015* | -0.019* | -0.001* | -0.014* |
| LDL | 0.238* | 0.151 | 0.241* | 0.078 |
| CA IMT | -0.467* | -0.054* | -0.383* | -0.489* |
| Gene | Low n-3 LC-PUFA HL/LL | High n-3 LC-PUFA HH/LH | ||
| Microarray | RT-qPCR | Microarray | RT-qPCR | |
| LC-PUFA biosynthesis | ||||
| Δ5fad | −1.03 | 1.35 | ||
| Δ6fad | 1.04 | −1.32 | ||
| elovl2 | −1.28 to −1.41 | −1.51 | −1.82 to −1.97 | −1.62 |
| Cholesterol biosynthesis | ||||
| ipi | −3.95 | 1.31 | ||
| mev | −1.40 | 1.14 | ||
| 7dchr | −1.01 | 1.09 | ||
| srebp2 | −2.09 | 1.29 | ||
| Lipid transport and lipoprotein metabolism | ||||
| lrp1 | −1.82 | −1.08 | ||
| apoA4a | −1.37 | −0.95 | ||
| apoA4b | −2.43 | −1.80 | ||
| lpl | −1.18 | −1.05 | ||
| Immune response | ||||
| cfh | −1.33 to −1.56 | −1.24 | −1.56 to −1.69 | −1.31 |
| trim25 | −5.64 | −2.09 | −4.34 | −2.33 |
| lect2 | 3.16 | 1.23 | 4.86 | 4.84 |
| Characteristics | Healthcare worker (%) n = 114 | Other (%)an = 41 |
| Country | ||
| Mozambique | 35 (31%) | 36 (88%) |
| India | 20 (18%) | 0 (0%) |
| Nigeria | 19 (17%) | 5 (12%) |
| South Africa | 40 (35%) | 0 (0%) |
| Facility level | ||
| Community | 40 (35%) | NA |
| Primary health centre | 34 (30%) | NA |
| Hospital | 40 (35%) | NA |
| Age (years) | ||
| 15–20 | 1 (1%) | 6 (15%) |
| 21–30 | 36 (32%) | 16 (39%) |
| 31–40 | 37 (32%) | 15 (37%) |
| 41–50 | 25 (22%) | 2 (5%) |
| 51–60 | 13 (11%) | 2 (5%) |
| Missing | 2 (2%) | 0 (0) |
| Gender | ||
| Female | 99 (87%) | 39 (95%) |
| Male | 14 (12%) | 2 (5%) |
| Missing | 1 (1%) | 0 (0%) |
| Years of experience | ||
| 0–5 | 41 (36%) | NA |
| 6–10 | 38 (33%) | NA |
| 11+ | 27 (24%) | NA |
| Missing | 8 (1%) | NA |
| Position 1 | NY-3356 Genome | IC Plasmids | Amino Acid Change | Location |
| 1285 | T | C | Silent | E |
| 3840 | T | C | Silent | NS2A |
| 70292 | G | A | Silent | NS4B |
| 7826 | T | C | V➔A | NS5 |
| 8067 | G | A | Silent | NS5 |
| 9123 | C | T | Silent | NS5 |
| 10613 | C | T | Silent | 3’ UTR |
| 10783 | C | T | Silent | 3’ UTR |
| Observed characteristics | Type of operation | |||
| Loop colostomy | Hartmann’s procedure | |||
| Age (X ± SD) | 65.68 ± 14.828 | 66.93 ± 11.020 | bp = 0.678 | |
| Gender | m | 12 (42.90%) | 23 (50.00%) | ap = 0.551 |
| f | 16 (57.10%) | 23 (50.00%) | ||
| Randomization groups | > 60 god, ASA ≥ 3 | 12 (16.20%) | 17 (23.00%) | ap = 0.265 |
| > 60 god, ASA < 3 | 4 (5.4%) | 16 (21.60%) | ||
| < 60 god, ASA ≥ 3 | 3 (4.10%) | 3 (4.10%) | ||
| < 60 god, ASA < 3 | 9 (12.20%) | 10 (13.50%) | ||
| Surgical complications | Yes | 2 (2.7%) | 2 (2.7%) | ap = 0.579 |
| No | 25 (34.2%) | 44 (60.3%) | ||
| Nonsurgical complications | Yes | 3 (4.1%) | 9 (12.3%) | ap = 0.347 |
| No | 24 (32.9%) | 37 (50.7%) |
| Bioprosthesis type | Manufacturer | Valve diameters (mm) |
| Trifecta | St. Jude Medical, Minneapolis, USA | 19 to 29 |
| Mitroflow | Sorin Group, Saluggia, Italy | 19 to 29 |
| Carpentier-Edwards Magna Ease | Edwards Lifesciences, Irvine, USA | 19 to 29 |
| Clinicopathologic characteristics | NH (n = 25) | PTC (n = 25) | FC (n = 25) | OvFC (n = 25) | UDC (n = 22) | P |
| Age Range (mean ± SD) | 20 – 79 (51 ± 17.3) | 20 – 72 (49 ± 15.1) | 15 – 80 (49 ± 20.2) | 27 – 87 (61 ± 16.2) | 47 – 84 (69 ± 12.01)* | 0.0002* |
| Gender | 22 F (88%) 3 M (12%) | 16 F (64%) 9 M (36%) | 19 F (76%) 6 M (24%) | 17 F (68%) 8 M (32%) | 16 F (73%) 6 M (27%) | NS |
| Tumor stage | N/A | (n = 25) | (n = 25) | (n = 25) | (n = 22) | |
| pT1 | 9 | 4 | 4 | 0 | N/A | |
| pT2 | 3 | 14 | 8 | 0 | N/A | |
| pT3 | 13 | 7 | 11 | 0 | N/A | |
| pT4 | 0 | 0 | 2 | 22# | N/A |
| Process Modes | Position (cm) | Velocity (cm/s) | Attitude (°) | ||||||
| North | East | Down | North | East | Down | Roll | Pitch | Heading | |
| IC-PPP | 6.6 | 8.9 | 6.6 | 6.7 | 7.2 | 8.3 | - | - | - |
| IC-PPP/INS | 3.2 | 4.8 | 5.5 | 1.0 | 1.1 | 0.8 | 0.021 | 0.026 | 0.092 |
| LC-PPP/INS | 4.2 | 6.5 | 6.1 | 1.2 | 1.1 | 0.9 | 0.022 | 0.027 | 0.095 |
| Underlying medical condition | All | <5 years | 5 - 59 years | 60+ years | Pregnant or postpartum | |||||
| N = 183 | n = 29 | n = 134 | n = 20 | n = 27 | ||||||
| Cases | % | Cases | % | Cases | % | Cases | % | Cases | % | |
| Obesity | 27 | 15 % | 0 | 0 % | 23 | 17 % | 4 | 21 % | 2 | 7 % |
| Diabetes Mellitus | 23 | 13 % | 0 | 0 % | 16 | 12 % | 7 | 37 % | 2 | 7 % |
| Asthma | 20 | 11 % | 2 | 7 % | 15 | 11 % | 3 | 16 % | 5 | 18 % |
| Other chronic metabolic disease | 15 | 8 % | 1 | 3 % | 9 | 7 % | 5 | 26 % | 0 | 0 % |
| Immunosuppression | 15 | 8 % | 2 | 7 % | 10 | 7 % | 3 | 16 % | 1 | 4 % |
| Chronic lung disease | 10 | 5 % | 0 | 0 % | 8 | 6 % | 2 | 11 % | 2 | 7 % |
| Chronic seizures | 11 | 6 % | 3 | 10 % | 8 | 6 % | 0 | 0 % | 0 | 0 % |
| Chronic cardiac disease | 7 | 4 % | 1 | 3 % | 5 | 4 % | 1 | 5 % | 3 | 11 % |
| Cerebral palsy | 7 | 4 % | 1 | 3 % | 6 | 4 % | 0 | 0 % | 0 | 0 % |
| At least one chronic condition | 112 | 61 % | 11 | 38 % | 82 | 61 % | 19 | 100 % | 14 | 50 % |
| All gabor | Papillary gabor | Reticular gabor | All FFT | Papillary FFT | Reticular FFT | |
| 95% CI | −0.999 to −0.209 | −0.999 to 0.284 | −0.999 to −0.276 | −0.370 to 0.999 | −0.574 to 0.997 | −0.171 to 0.999 |
| P value | 0.0128 | 0.0206 | 0.0111 | 0.0413 | 0.0683 | 0.0272 |
| R2 | 0.950 | 0.920 | 0.956 | 0.842 | 0.7454 | 0.8941 |
| Follow-up | Targeted group | Nontargeted group | Medium alone |
| (n = 8) | (n = 8) | (n = 8) | |
| 0 d | 0.140 ± 0.024 | 0.156 ± 0.029 | 0.134 ± 0.030 |
| 1 d | 0.463 ± 0.032 | 0.160 ± 0.031 | 0.155 ± 0.032 |
| 3 d | 0.328 ± 0.057 | 0.145 ± 0.029 | 0.122 ± 0.025 |
| 7 d | 0.237 ± 0.025 | 0.109 ± 0.031 | 0.140 ± 0.024 |
| 10 d | 0.182 ± 0.028 | 0.118 ± 0.041 | 0.126 ± 0.021 |
| Korea | Japan | |
| Expenditures on health by type of funding (%) | ||
| GG/SS/POP/PI | 11/46/37/6 | 9/73/15/2 |
| Share of hospital inpatient expenditures for MSD (%) | 9 | 6 |
| Health care system | ||
| Out-of-pocket healthcare expenditures as a share of total household consumption (%) | 4.6 | 2.2 |
| Sickness leave | No | 66.7% of average daily basic wage up to 18 months |
| Share of WMSD in workers’ compensation (%) | ||
| WMSD/total compensated diseases | 71.5 | 66.6 |
| WMSD/total compensated injury and diseases | 5.8 | 4.3 |
| Parameter | Cirrhosis | Controls |
| Bilirubin (total, mg/dL) | 1.44 ± 0.95 | 0.89 ± 0.24 |
| Albumin (gm/dL) | 4.0 ± 0.5 | 3.7 ± 0.9 |
| PT (secs) | 14.4 ± 1.8 | 11.4 ± 0.8 |
| Ascites | 2/26 | 0/13 |
| Enceplalopathy | 0/26 | 0/13 |
| Symbol | Chr | UCSC annotated features | CpG island | Δ β-value | Bootstrap 95% CI |
| OBFC2B | 12 | Promoter associated | Shore | 0.386 | (0.227, 0.551) |
| GPR75; LOC100302652 | 2 | 5′UTR; 1st Exon; Enhancer | Island | 0.349 | (0.184, 0.515) |
| AIRE | 21 | Within 100 bp of TSS | Island | 0.267 | (0.094, 0.444) |
| MIMT1; PEG3;ZIM2 | 19 | Within 500 bp of TSS; 5′UTR; 5′UTR | Island | 0.207 | (0.088, 0.332) |
| CIRBP; C19orf24 | 19 | Body; Within 1000 bp of TSS | Island | 0.176 | (0.097, 0.256) |
| SMG6; SRR | 17 | Within 500 bp of TSS; 5′UTR | Shore | 0.125 | (0.039, 0.214) |
| GPR12 | 13 | 5′UTR | Island | -0.095 | (-0.161, -0.030) |
| Rab | Determination on WPBs | Method | siRNA effect on VWF release | Comment | Reference |
| Rab27a | Endogenous expression and overexpression | Western blot, RT-PCR, and IF | Increase or decrease | – | 26,34,47,50 |
| Rab27b | Overexpression | RT-PCR | Decrease | Level of expression very low | 47 |
| Rab3A | Overexpression | RT-PCR | Decrease | – | 47 |
| Rab3B | Endogenous expression and overexpression | Western blot, RT-PCR, and IF | No effect | – | 47,50 |
| Rab3D | Endogenous expression and overexpression | Western blot, RT-PCR, and IF | Decrease or no effect | Endogenous Rab3D weakly detectable in 5% of cells | 47,50,52 |
| Rab15 | Overexpression | RT-PCR | Decrease | – | 47 |
| Rab33a | Overexpression | RT-PCR | No effect | – | 47 |
| Rab37 | Overexpression | RT-PCR | No effect | Low expression (cycle time 39.74) | 47 |
| Region | Number | Mean ± SD | Min–max | Median | Lower quartile | Upper quartile | |
| NP (ng g−1 dw) | Bornholm Deep | 13 | 14.04 ± 21.50 | ND–71.92 | 3.21 | 1.64 | 22.88 |
| S-W Gotland Deep | 13 | 68.67 ± 95.50 | 0.43–239.88 | 8.09 | 1.51 | 170.08 | |
| Gdansk Deep | 13 | 27.39 ± 30.60 | 0.71–74.59 | 5.60 | 2.07 | 57.36 | |
| Slope of the Gdansk Deep | 13 | 2.47 ± 4.53 | ND–15.80 | 0.59 | 0 | 2.96 | |
| OP (ng g−1 dw) | Bornholm Deep | 13 | 3.71 ± 2.04 | ND–7.99 | 3.72 | 3.18 | 5.00 |
| S-W Gotland Deep | 13 | 5.96 ± 3.77 | 2.08–13.01 | 3.99 | 3.38 | 7.83 | |
| Gdansk Deep | 13 | 1.72 ± 1.52 | 0.25–5.61 | 1.39 | 0.83 | 1.88 | |
| Slope of the Gdansk Deep | 13 | 1.46 ± 2.55 | ND–9.68 | 0.58 | 0.40 | 1.58 |
| Odds ratio | 95 % C.I. for odds ratio | P value | ||
| Lower | Upper | |||
| External environment | ||||
| Area of residence | ||||
| Rural | 1 | |||
| Urban | 1.364 | 1.081 | 1.721 | 0.009 |
| Education | ||||
| Non | 1 | |||
| Primary | 1.666 | 1.297 | 2.141 | 0.001 |
| Secondary + | 1.929 | 1.380 | 2.697 | 0.001 |
| Adult education | 1.191 | .688 | 2.063 | 0.533 |
| Wealth index | ||||
| Wealth index(score) | 2.293 | 1.988 | 2.644 | 0.001 |
| Parity | ||||
| Parity >2 | 1 | |||
| Parity 1-2 | 2.222 | 1.786 | 2.765 | 0.001 |
| Enabling factors | ||||
| Ante natal care | ||||
| No | 1 | |||
| Yes | 3.342 | 2.306 | 4.844 | 0.001 |
| Need factors | ||||
| Complications during pregnancy | ||||
| No/Non-serious complication | 1 | |||
| Serious complication | 1.606 | 1.319 | 1.957 | 0.001 |
| Gene | Sequence |
| GK | forward 5′-TTGAGACCCGTTTCGTGTCA – 3′ |
| reverse 5′-AGGGTCGAAGCCCCAGAGT -3′ | |
| L-PK | forward 5′-TGATGATTGGACGCTGCAA – 3′ |
| reverse 5′-GAGTTGGTCGAGCCTTAGTGATC – 3′ | |
| HK2 | forward 5′-AACCGAACAAGCTGGTGTAC-3′ |
| reverse 5′-TGCACACATCTATAGGTGGC-3′ | |
| ACC | forward 5′-CAACGCCTTCACACCACCTT -3′ |
| reverse 5′-AGCCCATTACTTCATCAAAGATCCT -3′ | |
| FAS | forward 5′-TGCTCCCAGCTGCAG -3′ |
| reverse 5′-GCCCGGTAGCTCTGGGTGTA -3′ | |
| ACOX1 | forward 5′-AAGAAATCCCCACTGAACAAAACA -3′ |
| reverse 5′-CCCAGGGAAACTTCAAAGCTT -3′ | |
| CPT1a | forward 5′-ATATCAAGGACAGCAGGCACAT -3′ |
| reverse 5′-CTCAGCAGCCTCCCATGCT -3′ | |
| CPT1 b | forward 5′-CAGCCATGCCACCAAGATC -3′ |
| reverse 5′-CTTGGGCAGTGATGTTTGGA -3′ | |
| CD36 | forward 5′-CAGCCTCCTTTCCACCTTTTG-3′ |
| reverse 5′-AAGGCGTTGGCTGGAAGAA-3′ | |
| PGC1α | forward 5′-ATACCGCAAAGAGCACGAGAAG-3′ |
| reverse 5′-CTCAAGAGCAGCGAAAGCGTCACAG-3′ | |
| PPARα | forward 5′-GGGATGAAGAGGGCTGAGC-3′ |
| reverse 5′-TGATTAACATTGGGCCGGTT-3′ | |
| BCAT2 | forward 5′-GGCGGACCCTTCATTCGT-3′ |
| reverse 5′-TTCCCCCCCAACTTGCA-3′ | |
| BCKDHα | forward 5′-CCAGGGTTGGTGGGATGAG-3′ |
| reverse 5′-GGCTTCCATGACCTTCTTTCG-3′ | |
| UBE2B | forward 5′-AACGCAGTTATATTTGGACCAGAAG-3′ |
| reverse 5′-ACGGTTGGTGGTTTATTTGGAT-3′ | |
| CAD | forward 5′-CGCAGTGTTTCACAGTCGTCTT-3′ |
| reverse 5′-TGGACTTGTCACTGTTGTACTTATGG-3′ | |
| CCK | forward 5′-CAGGTCCGCAAAGCTCCTT3′ |
| reverse 5′-TCCAGGCTCTGCAGGTTCTT-3′ | |
| PYY | forward 5′-CGGCAGCGGTATGGAAAA-3′ |
| reverse 5′-TGTGAAGAGCAGTTTGGAGAACA-3′ | |
| GLP-1 | forward 5′-CTCCCGCCGTGCTCAA-3′ |
| reverse 5′-TTGTTCCGGTTCCTCTTGGT-3′ | |
| GIP | forward 5′-CTGCTGGTGCTCCTGTTCCT-3′ |
| reverse 5′-CATGGGATCGGAACTCAACCT-3′ |
| Time (weeks) | NC group | DN group | BH group |
| 8 | 3.158 ± 0.505 | 7.059 ± 0.586* | 5.894 ± 0.418*# |
| 12 | 3.273 ± 0.520 | 8.024 ± 0.693* | 6.103 ± 0.521*# |
| 16 | 3.281 ± 0.299 | 9.211 ± 0.453* | 6.723 ± 0.283*# |
| Discipline | Number |
| Medical | 11,323 |
| Nurses and midwives | 40,926 |
| Dentists | 3,176 |
| Pharmacists | 1,100 |
| Other HCW | 16,640 |
| Administrative staff | 34,533 |
| Total | 107,698 |
| Chi-square test of model fit | DF | Model comparison (Δ Chi-square) | Δ DF | RMSEA | CFI | TLI | SRMR | ||
| A | (M ->DV) | 728.378*** | 145 | 0.044 | 0.931 | 0.920 | 0.047 | ||
| B | (IV-> DV) | 829.245*** | 144 | −100.867*** (A–B) | 1 | 0.048 | 0.919 | 0.905 | 0.053 |
| C | (IV -> M -> DV) | 718.757*** | 143 | 110.488*** (B–C) | 1 | 0.044 | 0.932 | 0.920 | 0.045 |
| 9.621** (A–C) | 2 |
| Key challenges | Solutions | Future implications |
| 1) Identification of centres willing/able to participate in the study | ||
| • Identifying centres with interest/capacity to participate in research and the correct people to discuss participation with proved difficult via conventional means (unsolicited mail/email).• Limitations in dedicating time or resources to external research projects due to clinical workloads and lack of designated support staff were common reasons for non-participation cited by centres. Levels of remuneration provided to centres for participation in the study were considered insufficient by some centres.• Availability of NHS staff participating in research having completed Good Clinical Practice (GCP) training. | • The ZQOL study was accepted into the National Institute for Health Research Clinical Research Network (NIHR CRN) portfolio. NIHR were able to offer wide range of support services including:o Access to existing networks of centres with interests in participating in research.o Provision of support to centres interesting in participating in research.o Exploring centre eligibility for additional remuneration for participation in NIHR CRN-approved studies.o Delivering GCP training to centres interesting in participating in studies. | • Experiences indicate the need for greater links between commissioners of research and primary/secondary care centres.• A refocusing of targets for primary care centres, to provide staff with opportunities and incentives for partaking in research is needed.• Current R&D approval process makes no concessions for non-interventional research. R&D requirements should be proportionate to the risks associated with patient participation in such studies. |
| 2) Obtaining Ethics and Research & Development (R&D) Management Approval | ||
| • Information and documentation required to support R&D applications was a barrier to participation for a number of centres.• Significant variation in timelines for R&D approval at a local and regional level (i.e. England, Scotland, Wales & Northern Ireland) led to significant delays in the study.• R&D approval process requires that extensive tri-partite agreements between the study sponsor, co-ordinating CRO and R&D department be agreed and signed. However, there is no standard template available for such agreements. | • ZQOL study organisers implemented a number of practical solutions including:o Minimising the number of R&D approvals by seeking participation of clusters of centres in the same NHS trust.o Implemented a staged study roll-out such that R&D applications for key centres were prioritised and R&D applications could occur in parallel to patient recruitment.• NIHR CRN can also provide assistance:o As a NIHR-CRN portfolio adopted study, more likely to be considered for priority review by R&D depts.o NIHR CRN local research network teams are able to offer support and guidance to co-ordinating CROs throughout England. | • Current R&D approval process makes no concessions for non-interventional research. R&D requirements should be proportionate to the risks associated with patient participation in such studies.• A move to standardise R&D approval process across NHS trusts in England would reduce burden (and barriers) to research for study organisers and NHS staff interested in participating in research. |
| 3) Recruitment of Study Participants | ||
| • Recruitment of HZ patients in primary care was slower than envisaged, a likely result of practical and organisational factors:o As an acute condition, HZ patients had to be recruited on initial presentation to physicians and did not allow searches of eligible participants via patient medical records.o At the time of the study there will only limited opportunities for notifications and reminders to be incorporated into electronic-record systems on presentation of incident cases.• Lack of unique identifiers or codes in electronic-record systems made it difficult to identify PHN patients for participation in the ZQOL study. | • To ensure that study recruitment quotas were met, additional centres were recruited for participation in the study and study timelines were extended.• NIHR CRN local research networks and the co-ordinating CRO were in regular contact with centre staff so to ensure to provide support where needed. | • Standardisation of medical record keeping and greater integration of record and monitoring systems would be to the benefit of facilitating real-world research.• Centres having systems in place to confirm the feasibility of recruitment numbers and having opportunity to work alongside study organisers could facilitate the development of study inclusion/exclusion criteria that are less restrictive to recruitment in real-world practice. |
| Overall survival | Disease specific survival | |||
| Covariate | Hazard ratio (95% CI) | p value | Hazard ratio (95% CI) | p value |
| Age | 0.99 (0.97-1.01) | 0.26 | 0.99 (097–1.01) | 0.16 |
| Female gender | 0.71 (0.42-1.20) | 0.20 | 0.61 (0.34-1.11) | 0.11 |
| First Nations (vs Non) | 4.20 (1.43-12.27 | 0.01 | 4.57 (1.31-15.92) | 0.02 |
| Smoking (vs non-smoker) | 1.29 (0.65-2.58) | 0.47 | 1.41 (0.65-3.10) | 0.39 |
| Alcohol use | 0.65 (0.31-1.36) | 0.25 | 0.63 (0.27-1.45) | 0.27 |
| Treatment | ||||
| S + CRT (ref) | 1 | 1 | ||
| S + RT | 0.72 (0.26-1.94) | 0.51 | 0.76 (0.21-2.71) | 0.67 |
| CRT | 2.01 (0.39-10.96) | 0.39 | 1.94 (0.20-19.04) | 0.57 |
| RT | 4.45 (1.22-16.31) | 0.02 | 8.43 (1.89-37.63) | 0.01 |
| S | 1.43 (0.42-4.91) | 0.57 | 1.42 (0.65-3.11) | 0.52 |
| TNM stage advanced | 1.34 (0.58-3.10) | 0.49 | 0.98 (0.39-2.47) | 0.97 |
| Case | Case summary | Examination type | Performing department | Allegation |
| 1 | Middle-aged female presented with calf pain. Ultrasound study reported to be negative. Patient had fatal pulmonary embolism. (2012 WL 1100657 [Ohio App. 7 Dist]) | DVT | Radiology | Failure to perform complete examination |
| 2 | Teen-aged female presented with calf pain, palpitations and pre-syncope. EKG and chest x-ray normal. Patient died of massive pulmonary embolism. (2012 WL 1605709 (La.App. 5 Cir.), 11–1006 [La.App. 5 Cir. 5/8/12]) | DVT | Not performed | Failure to perform |
| 3 | Teen-aged boy presented after motor vehicle collision. No abdominal imaging was performed. Patient was discharged and died that night at home with liver laceration and hemoperitoneum. (721 S.E.2d 238) | FAST | Not performed | Failure to perform |
| 4 | Adult female presented with abdominal pain. Right upper quadrant ultrasound scheduled next day. Positive for cholecystitis. Alleged delay in diagnosis prolonging hospitalization and causing complications. (2009 WL 2473514) | RUQ | Radiology | Failure to perform in a timely manner |
| 5 | Adolescent male 8 days status post knee arthroscopy presented with chest pain. Diagnosed with pleurisy and discharged. Patient subsequently died of bilateral pulmonary emboli. (2012 WL 5910796) | DVT | Not performed | Failure to perform |
| Variables | Utilization (HP visits) | Crude OR (95% CI) | Adjusted OR (95% CI) | |
| Yes | No | |||
| Mothers’ occupation | ||||
| Housewife | 837 | 204 | 1.0 | 1.0 |
| Farmers and others | 197 | 80 | 0.600 (0.444, 0.811) | 0.920 (0.494, 1.715) |
| Family Income | ||||
| 562 and below | 228 | 103 | 1.0 | 1.0 |
| 563-760 | 253 | 77 | 1.484 (1.051, 2.096) | 1.189 (0.774, 1.827) |
| 761-960 | 277 | 76 | 1.647 (1.167, 2.323) | 1.275 (0.817, 1.989) |
| 961 and above | 276 | 28 | 4.453 (2.831, 7.005) | 3.867 (1.630, 5.040)* |
| Heard about HEP | ||||
| No | 51 | 56 | 1.0 | 1.0 |
| Yes | 983 | 228 | 4.734 (3.155, 7.104) | 1.198 (.604, 2.377) |
| Understanding HEP | ||||
| No | 284 | 144 | 1.0 | 1.0 |
| Yes | 750 | 140 | 2.716 (2.074, 3.557) | 1.573 (1.056, 2.343)** |
| Perception on quality of services in HP | ||||
| Bad | 35 | 39 | 1.0 | 1.0 |
| Good | 999 | 245 | 4.544 (2.819, 7.323) | 0.634 (0.356, 1.127) |
| Perception about the conduct of HEWs | ||||
| Bad | 38 | 32 | 1.0 | 1.0 |
| Good | 996 | 252 | 3.328 (2.039, 5.434) | 0.804 (0.455, 1.421) |
| Frequency of home visits | ||||
| No visits or less frequent visits | 450 | 173 | 1.0 | 1.0 |
| More frequent visits | 584 | 111 | 2.023 (1.547, 2.645) | 1.289 (1.028, 1.826)** |
| Household graduation status | ||||
| Not graduated | 203 | 109 | 1.0 | 1.0 |
| 1-2 years s | 509 | 127 | 2.152 (1.589, 2.914) | 1.310 (0.780, 1.830) |
| 3 years | 212 | 26 | 4.378 (2.739, 6.999) | 2.150 (1.058, 4.365)** |
| 4-5 years | 110 | 22 | 2.685 (1.607, 4.487) | 1.666 (0.736, 3.771) |
| Group | n | Before Treatment | After Treatment | Comparison | |
| F | P | ||||
| Moxibustion Group | 15 | 28.27 ± 6.64 | 9.00 ± 4.05 | 417.009 | <0.001 |
| Control Group | 13 | 27.38 ± 3.95 | 21.46 ± 4.31 | 45.260 | <0.001 |
| Total Amount | 28 | 27.86 ± 27.86 | 14.79 ± 7.54 | 373.207 | <0.001 |
| Comparison between groups | F | 0.175 | 62.040 | ||
| P | 0.679 | <0.001 |
| ARDS patients | Age- and sex-matched reference values | P value | |
| Mean (SD) | Mean (SD) | ||
| EQ5D index at 6 months | |||
| Patients under 65 | 0.55 (0.37) | 0.85 (0.06) | <0.001 |
| Patients 65 and above | 0.62 (0.37) | 0.77 (0.02) | 0.003 |
| EQ5D at 12 months | |||
| Patients under 65 | 0.58 (0.35) | 0.85 (0.06) | <0.001 |
| Patients 65 and above | 0.58 (0.38) | 0.77 (0.02) | <0.001 |
| Total sample | Respondents | Non-respondents | |||||
| N | % | n | % | n | % | P-value* | |
| Sex | |||||||
| Male | 48 910 | 48.9 | 23 240 | 46.8 | 23 407 | 51.4 | <0.001 |
| Female | 51 090 | 51.1 | 26 466 | 53.2 | 22 140 | 48.6 | |
| Age | |||||||
| 20–39 | 27 706 | 27.7 | 12 251 | 24.6 | 15 455 | 30.7 | <0.001 |
| 40–59 | 37 106 | 37.1 | 20 305 | 40.9 | 16 801 | 33.4 | |
| 60–79 | 28 868 | 28.9 | 15 748 | 31.7 | 13 120 | 26.1 | |
| 80- | 6 320 | 6.3 | 1 402 | 2.8 | 4 918 | 9.8 | |
| Marital statusa | |||||||
| Single | 31 140 | 32.8 | 12 475 | 25.1 | 18 665 | 41.2 | <0.001 |
| Married/living together | 63 807 | 67.2 | 37 140 | 74.9 | 26 667 | 58.8 | |
| Educational levela | |||||||
| Low | 24 770 | 27.2 | 9 540 | 19.7 | 15 230 | 35.6 | <0.001 |
| Medium | 40 659 | 44.6 | 22 155 | 45.8 | 18 504 | 43.3 | |
| High | 25 752 | 28.2 | 16 724 | 34.5 | 9 028 | 21.1 | |
| Income levela | |||||||
| Low | 22 440 | 23.6 | 8 072 | 16.3 | 14 368 | 31.7 | <0.001 |
| Medium | 48 126 | 50.7 | 25 712 | 41.8 | 22 414 | 49.4 | |
| High | 24 382 | 25.7 | 24 382 | 31.9 | 8 551 | 18.9 | |
| Employment statusa | |||||||
| Workning | 59 961 | 63.1 | 33 961 | 68.4 | 26 000 | 57.3 | <0.001 |
| Pensioners | 23 193 | 24.4 | 11 294 | 22.7 | 11 899 | 26.2 | |
| Out of workforce | 11 911 | 12.5 | 4 410 | 8.9 | 7 501 | 16.5 | |
| Ethnic groupsa | |||||||
| Danish | 86 248 | 90.8 | 46 543 | 93.8 | 39 705 | 87.6 | <0.001 |
| Immigrants | 8 038 | 8.5 | 2 858 | 5.8 | 5 180 | 11.4 | |
| Descendants of Immigrants | 661 | 0.7 | 214 | 0.4 | 447 | 1.0 | |
| GP contactsa | |||||||
| Average contacts to GP in 2011 | 8.1 | 7.6 | 8.5 | <0.001 |
| Variable | 25th percentile | 50th percentile | 75th percentile | Standard deviation |
| GC | 0.298 | 0.318 | 0.353 | 0.041 |
| RHI | 0.218 | 0.233 | 0.260 | 0.033 |
| 80/20 ratio | 5.550 | 6.570 | 8.155 | 1.965 |
| All-cause mortality rate (/100,000) | 378.5 | 416.3 | 441.7 | 48.8 |
| Community population | 165,980.8 | 280,277.0 | 363,011.0 | 143,540.9 |
| Percent of over 65 years in community population (%) | 8.9 | 10.8 | 13.8 | 4.1 |
| Ratio of social welfare expenditure (%) | 23.9 | 30.9 | 44.6 | 12.2 |
| Number of physicians (/1,000) | 1.6 | 2.0 | 2.8 | 2.5 |
| Smoking rate (%) | 22.0 | 24.0 | 25.0 | 2.7 |
| Drinking rate (%) | 56.0 | 59.0 | 61.0 | 4.9 |
| 2016 | 2017 | 2018 | 2019 | ||||||||||||
| Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | |
| Protocol development | X | ||||||||||||||
| Training of research coordinators and physicians | X | X | X | X | |||||||||||
| Training of nurses for motivational counseling (yearly refresher training) | X | X | X | ||||||||||||
| Obtaining informed consent, recruitment, and baseline interview | X | X | X | X | |||||||||||
| Auditing and site visit monitoring (every 2 weeks) | X | X | X | X | X | X | X | X | X | X | X | X | |||
| Trial supervision | X | X | X | X | |||||||||||
| Monthly Trial Management Committee meeting | X | X | X | X | X | X | X | X | X | X | X | X | |||
| Telephone follow-up by nurses (monthly until 3 months and then every 3 months) | X | X | X | X | X | X | X | X | X | X | X | X | |||
| Follow-up by clinical research coordinators (every 4 months by telephone; annually on site) | X | X | X | X | X | X | X | X | X | X | X | ||||
| Data Safety and Monitoring Board meeting (every 6 months) | X | X | X | X | X | X | X | ||||||||
| Trial Steering Committee Meeting (every 6 months) | X | X | X | X | X | X | X | ||||||||
| Quality assessment | X | X | X | X | X | ||||||||||
| Progress or interim report | X | ||||||||||||||
| Data analysis | X | X | |||||||||||||
| Manuscript writing | X | X | |||||||||||||
| Final report | X | X |
| I | II | % change | Cohen's d | |||
| Mean ± SD | (95% CI) | Mean ± SD | (95% CI) | |||
| Lower body WAnT | ||||||
| Maximal power (W) | 722 ± 113∧ | 657–788 | 751 ± 124∗∧ | 679–822 | 4.0 | 0.24 |
| Mean power (W) | 562 ± 73∧ | 520–605 | 577 ± 80∧ | 531–624 | 2,7 | 0.19 |
| Relative peak power (W/kg) | 10.6 ± 0.8∧ | 10.1–11.1 | 11.0 ± 1.0∗ | 10.4–11.5 | 3.8 | 0.44 |
| Relative mean power (W/kg) | 8.2 ± 0.5∧ | 8.0–8.5 | 8.4 ± 0.5∧ | 8.2–8.7 | 2.4 | 0.40 |
| Fatigue index (%) | 25.6 ± 6.5 | 21.8–29.4 | 26.2 ± 5.9 | 22.8–29.6 | 2.3 | 0.09 |
| Upper body WAnT | ||||||
| Maximal power (W) | 575 ± 123 | 504–647 | 586 ± 120 | 517–656 | 1.9 | 0.09 |
| Mean Power (W) | 444 ± 84 | 395–493 | 464 ± 86† | 414–513 | 4.5 | 0.23 |
| Relative peak power (W/kg) | 8.4 ± 1.3 | 7.7–9.2 | 8.6 ± 1.3 | 7.8–9.2 | 2.4 | 0.15 |
| Relative mean power (W/kg) | 6.5 ± 0.8 | 6.0–7.0 | 6.8 ± 0.9† | 6.2–7.3 | 4.6 | 0.35 |
| Fatigue index (%) | 27.7 ± 6.0 | 24.2–31.1 | 24.2 ± 5.7∗ | 20.9–27.5 | −12.6 | 0.59 |
| Trait | OR (95% CI) | p |
| Total serum IgE | 1.60 (1.24, 2.07) | < 0.0001 |
| Atopy | 3.09 (1.39, 6.87) | 0.006 |
| Food allergen test positive | 2.04 (0.99, 4.20) | 0.053 |
| Eosinophilia | 3.56 (1.30, 9.73) | 0.013 |
| Controls | Patients | |||||||
| Scene | Object | Face | Total | Scene | Object | Face | Total | |
| (A) MEAN ERROR RATE (PERCENTAGE ERROR) | ||||||||
| Color | 0.67 | 0.50 | 1.33 | 0.83 | 9.10 | 5.38 | 12.05 | 8.85 |
| Grayscale | 1.00 | 0.50 | 1.67 | 1.06 | 10.51 | 6.79 | 16.28 | 11.20 |
| Total | 0.83 | 0.50 | 1.50 | 0.94 | 9.81 | 6.09 | 14.17 | 10.02 |
| (B) HARMONIC MEAN RESPONSE TIMES (s) | ||||||||
| Color | 1.03 | 0.97 | 1.03 | 1.01 | 1.90 | 1.73 | 1.62 | 1.75 |
| Grayscale | 1.00 | 0.94 | 0.98 | 0.97 | 1.99 | 1.69 | 1.57 | 1.75 |
| Total | 1.01 | 0.95 | 1.01 | 0.99 | 1.94 | 1.71 | 1.59 | 1.75 |
| Diets | Intestine | Liver | Muscle | Brain |
| HD | ||||
| LD | fabp7b | |||
| LND | fabp1b.1, fabp7b | fabp7a | ||
| LFD | fabp7a | fabp11a |
| Univariate analysis | Multivariate analysis | |||||
| OR | 95% CI for OR | p | OR | 95% CI for OR | P | |
| Total cholesterol: high (n = 93) vs normal (n = 178) | ||||||
| Overweight/obese at study entry | 1.760 | 1.032–3.003 | 0.0379 | 1.764 | 1.013–3.073 | 0.0451 |
| Age at study entry | 2.101 | 1.467–3.010 | <0.0001 | 2.093 | 1.461–2.997 | <0.0001 |
| ≤ 40 | 1 | - | ||||
| 41–45 | 1.490 | 0.494–4.489 | 0.4789 | |||
| 46–50 | 3.838 | 1.397–10.548 | 0.0091 | |||
| > 50 | 7.020 | 1.989–24.772 | 0.0025 | |||
| LDL cholesterol: high (n = 152) vs normal (n = 115) | ||||||
| Received corticosteroid premedication during chemotherapy | 7.576 | 1.724–33.33 | 0.0074 | 5.747 | 1.264–26.32 | 0.0236 |
| Received adjuvant tamoxifen | 0.388 | 0.209–0.720 | 0.0027 | 0.342 | 0.179–0.656 | 0.0012 |
| Overweight/obese at study entry | 2.468 | 1.407–4.330 | 0.0016 | 2.560 | 1.410–4.649 | 0.0020 |
| Age at study entry | 1.626 | 1.192–2.217 | 0.0021 | 1.625 | 1.165–2.266 | 0.0042 |
| ≤ 40 | 1 | - | ||||
| 41–45 | 0.963 | 0.420–2.212 | 0.9298 | |||
| 46–50 | 1.763 | 0.813–3.823 | 0.1510 | |||
| > 50 | 5.383 | 1.493–19.407 | 0.0101 | |||
| HDL cholesterol: low (n = 18) vs. normal (n = 251) | ||||||
| Ever smoker | 4.357 | 0.836–22.707 | 0.0806 | 7.772 | 1.102–54.827 | 0.0397 |
| Post/peri- menopausal at study entry | 3.881 | 1.243–12.114 | 0.0196 | 3.629 | 1.144–11.509 | 0.0286 |
| Overweight/obese at study entry | 8.193 | 1.845–36.372 | 0.0057 | 7.786 | 1.742–34.795 | 0.0072 |
| Triglyceride: high (n = 62) vs. normal (n = 209) | ||||||
| Adjuvant taxane-containing chemotherapy | 2.040 | 1.124–3.704 | 0.0192 | 2.552 | 1.317–4.944 | 0.0055 |
| Weight gain >2% | 2.258 | 1.171–4.355 | 0.0150 | 2.213 | 1.084–4.517 | 0.0292 |
| Overweight/obese at study entry | 2.306 | 1.282–4.149 | 0.0053 | 2.775 | 1.446–5.325 | 0.0021 |
| Age at study entry | 1.641 | 1.118–2.410 | 0.0114 | 1.969 | 1.285–3.017 | 0.0019 |
| ≤ 40 | 1 | - | ||||
| 41–45 | 1.355 | 0.401–4.573 | 0.6246 | |||
| 46–50 | 2.558 | 0.842–7.773 | 0.0978 | |||
| > 50 | 3.733 | 0.964–14.461 | 0.0566 |
| Midwives | Child health nurses | Dental hygienists/dental nurses | |||||||
| Raising the topic with more than half or all pregnant women (%) | Wilcoxon Signed Rank Test | Raising the topic with more than half or all parents (%) | Wilcoxon Signed Rank Test | Raising the topic with more than half or all clients (%) | Wilcoxon Signed Rank Test | ||||
| Topic | Pre | Post | p-value | Pre | Post | p-value | Pre | Post | p-value |
| Psychosocial health | 73 | 86 | .048 | 47 | 64 | .053 | - | - | - |
| Men’s violence against women/children | 59 | 82 | .010 | 11 | 36 | .000 | - | - | - |
| Tobacco | 91 | 96 | .581 | 72 | 89 | .059 | 79 | 84 | .690 |
| Alcohol | 91 | 96 | .414 | 64 | 81 | .109 | 0 | 21 | .026 |
| Drugs | 91 | 82 | .269 | 19 | 36 | .004 | - | - | - |
| Weight/BMI | 76 | 86 | .107 | 11 | 13 | .169 | 5 | 26 | .006 |
| Discretionary foods | 59 | 41 | .790 | 23 | 43 | .005 | 47 | 100 | .001 |
| Regular meals | 59 | 46 | .941 | 34 | 55 | .035 | 53 | 100 | .001 |
| Beverage intake | - | - | - | - | - | - | 63 | 100 | .000 |
| 5 fruits and vegetables a day | 67 | 82 | .191 | 21 | 53 | .000 | 32 | 100 | .000 |
| 30 min daily physical activity | 59 | 68 | .129 | 11 | 36 | .000 | - | - | - |
| Parenthood/parent relationships | 77 | 77 | .623 | 64 | 83 | .107 | - | - | - |
| Tooth brushing/dental health (child) | - | - | - | 55 | 89 | .001 | - | - | - |
| Weight/BMI (child) | - | - | - | 77 | 81 | .805 | - | - | - |
| 5 fruits and vegetables a day (child) | - | - | - | 45 | 66 | .002 | - | - | - |
| Regular meals (child) | - | - | - | 83 | 85 | .907 | - | - | - |
| Discretionary foods (child) | - | - | - | 55 | 68 | .026 | - | - | - |
| Physical activity (child) | - | - | - | 72 | 87 | .068 | - | - | - |
| Psychosocial health (child) | - | - | - | 79 | 87 | .337 | - | - | - |
| Characteristics | No. patients(%) | ZC3H15 immunoreactivity* | P value | |
| High | Low | |||
| Gender | ||||
| Male | 230(88.12) | 125 | 105 | 0.1017 |
| Female | 31(11.88) | 12 | 19 | |
| Age (yrs) | ||||
| <40 | 38(14.55) | 20 | 18 | 0.6719 |
| 40-60 | 166(63.60) | 90 | 76 | |
| >60 | 57(21.84) | 27 | 30 | |
| AFP | ||||
| ≤20 (ng/mL) | 98(37.69) | 41 | 57 | 0.0064 |
| >20 | 163(62.31) | 97 | 66 | |
| HBV | ||||
| Negative | 33(12.64) | 14 | 19 | 0.2154 |
| Positive | 228(87.36) | 123 | 105 | |
| Histological grading | ||||
| Well | 1(0.36) | 0 | 1 | 0.0705 |
| Moderate | 25(10.51) | 8 | 17 | |
| Poorly | 234(88.77) | 129 | 105 | |
| Largest tumor size | ||||
| <3cm | 70(26.82) | 39 | 31 | 0.6355 |
| 3-10cm | 152(58.24) | 76 | 76 | |
| >10cm | 39(14.94) | 22 | 17 | |
| Presence of satellite nodules | ||||
| Negative | 73(27.97) | 33 | 40 | 0.1419 |
| Positive | 188(72.03) | 104 | 84 | |
| Vascular invasion | ||||
| Negative | 109(41.76) | 46 | 63 | 0.0049 |
| Positive | 152(58.23) | 91 | 61 | |
| HbeAg | ||||
| Negative | 202(77.39) | 102 | 100 | 0.2323 |
| Positive | 59(22.61) | 35 | 24 | |
| Tumorous number | ||||
| 1 | 208(79.69) | 108 | 100 | 0.7162 |
| >=2 | 53(20.30) | 29 | 24 | |
| Child-Pugh Classification | ||||
| Child-A | 237(90.80) | 123 | 114 | 0.5542 |
| Child-B | 24(9.20) | 11 | 13 | |
| UICC stage | ||||
| I+II | 204(78.16) | 106 | 98 | 0.7458 |
| III+IV | 57(21.84) | 31 | 26 |
| Severe (n = 12) | Mild (n = 5) | ||
| Birth Weight (g) | 2500(2400–3000)a | 3100 (3000–3600) | p = 0.04 |
| Day of illness at hospital presentation | 2.5 (2–3.5) | 5 (5–5) | p = 0.02 |
| Incubation period (days) | 7 (7–10) | 6 (5–7) | p = 0.04 |
| HLA alleles | Risk allele (RA) | Risk allele frequency | P-value | OR | CD groups | ||
| Indian | African | European | |||||
| HLA-DQ2.2 (rs2395182) | T | 0.83 | 0.73 | 0.76 | 1.06 × 10−5 | 2.72 [1.74–4.25] | Pediatric |
| 6.26 × 10−5 | 1.99 [1.42–2.79] | Adult | |||||
| HLA-DQ2.2 (rs7775228) | T | 0.73 | 0.83 | 0.85 | 1.14 × 10−4 | 1.89 [1.36–2.63] | Pediatric |
| 5.08 × 10−7 | 2.12 [1.58–2.84] | Adult | |||||
| HLA-DQ2.5 (rs2187668) | A | 0.16 | 0.06 | 0.10 | 3.46 × 10−28 | 6.03 [4.38–8.30] | Pediatric |
| 2.45 × 10−34 | 5.99 [4.49–7.98] | Adult | |||||
| HLA-DQ8 (rs7454108) | T | 0.94 | 0.97 | 0.89 | 0.08 | 1.72 [0.93–3.18] | Pediatric |
| 0.20 | 1.37 [0.84–2.22] | Adult | |||||
| HLA-DQ4 (rs4713586) | T | 0.98 | 0.92 | 0.94 | 0.03 | 9.05 [1.18–69.50] | Pediatric |
| 0.03 | 3.71 [1.18–11.78] | Adult |
| Outcomes | Conventional periodn = 79 (%) | MALDI-TOF periodn = 75 (%) | P Value† |
| Time to pathogen identification (hours) | 86.9 ± 30.4 | 62.5 ± 23.1 | < 0.001 |
| Time to effective therapy (hours) | 27.8 ± 32.4 | 17.1 ± 25.7 | 0.031 |
| 30-day all-cause mortality | 7 (8.9) | 5 (6.7) | 0.612 |
| Time to microbiological clearance (days) | 4.1 ± 3.0 | 3.4 ± 2.0 | 0.081 |
| Length of ICU stay (days) | 14.1 ± 26.0 | 11.7 ± 12.8 | 0.719 |
| 30-day Recurrence of same BSI | 2 (2.5) | 0 (0.0) | 0.497 |
| NaHS (μmol/L) | 5′- GMP (μmol/L) | P |
| Basal (0) | 0.45 ± 0.08 | |
| 3 | 0.31 ± 0.09 | 0.27 |
| 50 | 0.15 ± 0.04 ** | 0.01 |
| 300 | 0.21 ± 0.06* | 0.03 |
| Mouse primers | Oligonucleotide sequences (5’−3’) | |
| Aldh1a1-/- | Forward | TGAGCAAATCCTCCACAGCCCTGTTC |
| Reverse | CTGCTAAAGCGCATGCTCCAGACTG | |
| Aldh1a3 flox | Forward | TCTCTGACCAGCTTTCCAACCTTCAG |
| Reverse | CTCAAACCAGCACCACCTCCATATTG | |
| Sox9 flox | Forward | TCAGCAAGACTCTGGGCAAGCTCT |
| Reverse | CTCAAAATCTGAGCCACTCCCTC | |
| Tyr-Cre, Pax6-α-Cre | Forward | CCTGGAAAATGCTTCTGTCCGT |
| Reverse | GTGTCCACATAGTCATTGGCAGAGTG | |
| Sox9-Tg, Kdr-BAC-EGFP | Forward | AGCTGACCCTGAAGTTCATCTG |
| Reverse | GTCGTCCTTGAAGAAGATGGTG | |
| Flt1-BAC-tdsRed | Forward | GCTGCAGGCGCGGAGAAGGGCTCTC |
| Reverse | CTTCACGTACACCTTGGAGC | |
| IL2 (internal control) | Forward | GCCTAGAAGATGAACTTGGACCTCTG |
| Reverse | GTGGAAGGATTCACTTGCACAGTGAC | |
| Human RPE primers | ||
| Sox9 | Forward | CGTACCCGCACTTGCACAAC |
| Reverse | TCTCGCTCTCGTTCAGAAGTC | |
| Vegfa | Forward | TGCCCGCTGCTGTCTAAT |
| Reverse | TCTCCGCTCTGAGCAAGG | |
| β-actin | Forward | CCAACCGCGAGAAGATGA |
| Reverse | CCAGAGGCGTACAGGGATAG |
| Survey items | Overall (n=48) | Completely achieved ILP goals and objectives | |
| ‘No’ (n=25) | ‘Yes’ (n=23) | ||
| ILP helpful in structuring ACE learning objectives (Rate 1–5), no. (%) | |||
| 1-3 ratings | 12 (25 %) | 10 (40 %) | 2 (9 %) |
| 4-5 ratings | 36 (75 %) | 15 (60 %) | 21 (91 %) |
| ILP helpful in organizing goals for career (Rate 1–5), no. (%) | |||
| 1-3 ratings | 19 (40 %) | 15 (60 %) | 4 (17 %) |
| 4-5 ratings | 29 (60 %) | 10 (40 %) | 19 (83 %) |
| Variable | CF1 | CF2 | CF3 |
| As | −0.06 | 0.00 | 0.95 |
| Cd | 0.02 | 0.85 | 0.16 |
| Cr | 0.86 | 0.12 | −0.13 |
| Cu | 0.83 | 0.09 | −0.30 |
| Hg | 0.54 | 0.14 | 0.20 |
| Ni | 0.88 | 0.00 | 0.09 |
| Pb | 0.25 | 0.78 | −0.19 |
| Zn | 0.91 | 0.19 | −0.14 |
| Eigenvalue | 3.36 | 1.40 | 1.14 |
| % Total variance | 42.02 | 17.55 | 14.21 |
| Cumulative % variance | 42.02 | 59.56 | 73.78a |
| Variable | HE group (n = 58) | Control group (n = 59) | P-value |
| Historical information | |||
| Esophageal varices | 60% | 66% | 0.518 |
| Variceal bleeding | 21% | 24% | 0.693 |
| Variceal band ligation | 24% | 24% | 0.952 |
| Medications | |||
| Non-selective beta blockers | 36% | 44% | 0.386 |
| Narcotics | 14% | 8% | 0.394 |
| Centrally acting medicationsa | 41% | 15% | 0.002 |
| Diureticsb | 88% | 63% | 0.002 |
| Laboratory tests | |||
| Na <135 mmol/L | 69% | 68% | 0.892 |
| Creatinine > 1 mg/dL | 31% | 29% | 0.793 |
| CT scan findings | |||
| Liver antero-posterior diameter ≤6 cm | 91% | 68% | 0.001 |
| Liver cranio-caudal diameter ≤16 cm | 69% | 58% | 0.203 |
| Spleen diameter ≥16 cm | 47% | 53% | 0.517 |
| Nodular liver | 86% | 68% | 0.018 |
| Caudate lobe hypertrophy | 55% | 64% | 0.308 |
| Paraesophageal varices | 67% | 63% | 0.608 |
| Splenorenal varices | 72% | 83% | 0.166 |
| Umbilical vein recanalization | 60% | 58% | 0.765 |
| Presence of ascites | 55% | 49% | 0.515 |
| Portal vein diameter ≤12 mm | 58% | 28% | 0.001 |
| Duplex ultrasound findings | |||
| Portal vein flow velocity <16 cm/s | 26% | 20% | 0.475 |
| Hepatofugal flow | 16% | 7% | 0.132 |
| Hepatic artery resistive index ≥0.75 | 33% | 39% | 0.527 |
| Male | Control (mg/kg) | Alstonia scholaris Extract Dose (mg/kg) | ||
| 250 | 500 | 1000 | ||
| TP (g/L) | 67.21 ± 3.34 | 65.34 ± 4.5 | 70.32 ± 2.3 | 69.73 ± 1.52 |
| Albumin (g/L) | 28.40 ± 2.21 | 29.42 ± 0.46 | 32.37 ± 0.22 | 32.15 ± 1.40 |
| Globulin (g/L) | 38.24 ± 1.29 | 41.00 ± 3.03 | 39.62 ± 0.51 | 42.63 ± 2.50 |
| ALP (IU/L) | 113.3 ± 4.5 | 114.7 ± 14.7 | 121.7 ± 11.3 * | 117.67 ± 6.9 * |
| Bilirubin (mol/L) | 2.13 ± 0.59 | 2.70 ± 0.73 | 2.39 ± 0.47 | 2.84 ± 0.36 |
| AST (IU/L) | 221.32 ± 12.4 | 246.5 ± 21.3 | 257.3 ± 21.4 ** | 248.67 ± 16.6 * |
| ALT (IU/L) | 49.0 ± 3.61 | 59.33 ± 1.86 * | 54.67 ± 2.19 * | 57.33 ± 3.76 * |
| Variable | n | % |
| Surgical approach | ||
| Laparoscopic, completely closed | 20 | 90 |
| Hand-assisted laparoscopic | 1 | 4.5 |
| Lap converted to open | 1 | 4.5 |
| No. of metastases resected | 45 | |
| 1 | 14 | 64 |
| 2 | 3 | 14 |
| ≥ 3 | 5 | 23 |
| Segment of liver resected | ||
| Combined segment 2 and 3 | 2 | 9 |
| Segment 3 | 8 | 36 |
| Segment 5 | 2 | 9 |
| Segment 6 | 8 | 36 |
| Segment 7 | 1 | 4.5 |
| Segment 8 | 1 | 4.5 |
| Size (cm) of tumor resected (mean/median (range)) | 3.4/3 (0.3-8) | |
| Operative specifics (mean/median (range)) | ||
| Intraoperative blood loss (mL) | 256/100 (50–1400) | |
| Operative time (minutes) | 194/193 (90–305) | |
| Use of pringle | 3 | 14 |
| Parenchymal transection with ultrasonic device | 21 | 95 |
| Parenchymal transection with endovascular stapler | 15 | 68 |
| Duration of hospitalization (days) (mean/median (range)) | 4/3 (1–10) | |
| Postoperative complication | 3 | 14 |
| Bile leak | 1 | 4.5 |
| Rapid atrial fibrillation | 1 | 4.5 |
| Colitis | 1 | 4.5 |
| Protein 1 | Protein 2 | VAST | DALI | CE | FATCAT | Yang & Tung's | de Brevern et al.'s | Our SA |
| 1fxia | 1ubq | 48(2.10) | 60(2.60) | 64(3.80) | 63(3.01) | 59(2.76) | 76(2.89) | 58(2.64) |
| 1ten | 3hhrb | 78(1.60) | 86(1.90) | 87(1.90) | 87(1.90) | 57(2.57) | 73(2.31) | 90(2.24) |
| 3hlab | 2rhe_ | - | 63(2.50) | 85(3.50) | 79(2.81) | 54(2.65) | 78(3.01) | 79(2.87) |
| 2azaa | 1paz_ | 74(2.20) | 81(2.50) | 85(2.90) | 87(3.01) | 70(2.34) | 57(2.23) | 87(2.40) |
| 1cewi | 1mola | 71(1.9) | 81(2.30) | 69(1.90) | 83(2.44) | 52(2.37) | 53(2.35) | 61(1.83) |
| 1cid_ | 2rhe_ | 85(2.20) | 95(3.30) | 94(2.70) | 100(3.11) | 54(2.75) | 53(2.49) | 55(2.08) |
| 1crl_ | 1ede | - | 211(3.40) | 187(3.20) | 269(3.55) | 167(3.35) | 120(3.47) | 187(3.25) |
| 2sim_ | 1nsba | 284(3.80) | 286(3.80) | 264(3.00) | 286(3.07) | 121(2.75) | 121(2.96) | 137(3.2) |
| 1bgea | 2gmfa | 74(2.50) | 98(3.50) | 94(4.10) | 100(3.19) | 27(3.34) | 77(2.8) | 78(2.72) |
| 1tie_ | 4fgf_ | 82(1.70) | 108(2.00) | 116(2.90) | 117(3.05) | 91(3.15) | 62(3.45) | 115(3.05) |
| Average RMSD/aligned-residues | 0.0226 | 0.0238 | 0.0261 | 0.0229 | 0.0373 | 0.0363 | 0.0278 |
| ORF Clusters features | MFL x MHP* | MFL x MHR* | MFL x MHP x MHR* |
| OCs 100% conserved | 44 | 17 | 12 |
| OCs Partially conserved | 44 | 35 | 33 |
| OCs Without conservation | 29 | 62 | - |
| Conceptualization | Description |
| Revolution | • Health’s increasing role in foreign policy is transformative of the health-foreign policy nexus• Health collapses the traditional distinction between high and low politics and creates a new political space in which health isan overriding normative value and the ultimate goal of foreign policy• Health is broadly conceived and encompasses the social determinants of health• Is consistent with health discourses that focus on health as a human right and the “health for all” ideal |
| Remediation | • Health’s rise as foreign policy issue reflects the continued persistence of the traditional hierarchy of foreign policy functions• Health has become another issue that needs to be addressed through traditional approaches to foreign policy, or as astrategic vehicle through which traditional foreign policy goals can be achieved• Foreign policy attention on health is focused when disease crises appear and fades when crises drop off the political spotlight•Provides the strongest explanation for why health has risen as a foreign policy issue |
| Regression | • Health’s integration into foreign policy is a regressive development – an indicator that health problems are getting worse• The increasing attention paid to health across the functions of foreign policy signifies the failure of public health efforts• Connecting health with the high politics of foreign policy threatens to tarnish long-standing associations of health withnormative values• Public health’s wish for health to become more politically prominent may have come true but in a way that threatens whatwas special about health in the first place |
| EU | Australia | Japan | WHO | Canada | Korea, India, Singapore, Malaysia | |
| Synonym | Biosimilars | Biosimilars | Follow-on Biologics | Similar Biotherapeutic Product | Subsequent Entry Biologic | Biosimilars |
| Scope | Mainly recombinant protein drugs | Recombinant protein drugs | ||||
| Principles | • Generic approach is not appropriate for SEB. | |||||
| • SEB should be similar to the reference biologic with respect to quality, safety and efficacy. | ||||||
| • Step-wise comparability approach: the reduction of non-clinical and clinical data required will only be considered after the similarity of the SEB and reference biologic is proven in terms of quality. | ||||||
| • Case by case approach for different classes of products. | ||||||
| • Pharmacovigilance is stressed. | ||||||
| Reference product | Authorized in the EU | Authorized in Japan | Authorized in a region with a well-established regulatory framework | |||
| Manufacture | • Same standards required by the national regulatory agency for originator products. | |||||
| • Full chemistry and manufacture data package. | ||||||
| Physio-chemical | • Primary and higher-order structure. | |||||
| • Post translational modifications. | ||||||
| Purity | • Process-related and product-related impurities. | |||||
| Non clinical | • In-vitro such as cell-based assays and receptor-binding studies. | |||||
| Stability | Accelerated degradation studies and studied under various stress conditions | Not necessary | Accelerated degradation studies and studied under various stress conditions | |||
| Pharmacokinetic study design & criteria | • Single dose, steady-state studies or repeated determinations of pharmacokinetics | |||||
| • Cross over or parallel. | ||||||
| • Include absorption and elimination characteristics. | ||||||
| • Use the traditional 80-125% equivalence range. | ||||||
| PD | Pharmacodynamic (PD) markers should be selected and comparative PK/PD studies may be appropriate | |||||
| Efficacy | Comparability margins should be pre-specified and justified | Observer or double-blinded. Equivalence or non-inferiority | Equivalence | |||
| Safety/pharmacovigilance | • Pre-licensing safety data and risk management plan. Post authorization safety and/or efficacy studies may be required. | |||||
| • Adverse reactions must be reported. | ||||||
| • Same rules apply to reference biologic and SEB. | ||||||
| INN vs. new generic name | INN | Unique generic name | Suffix “BS” added to INN | INN with biological qualifier (proposed) | INN but will follow WHO guidance | INN |
| Extrapolation of indications | • Assessed on a case-by-case basis. | |||||
| • At least one clinical study required in the most sensitive population measuring the clinical endpoints likely to show a difference. |
| Pharmacovigilance area of interest | ||||||
| Activity type | Adverse events | Counterfeit drugs | Drug quality assurance | PV NOS | N/A | Total |
| Behaviour change communication | 6 (85.7) | 1 (14.3) | 7 (2.4) | |||
| Improve regulatory system | 1 (3.1) | 6 (18.8) | 14 (53.1) | 11 (34.4) | 32 (11.1) | |
| Improving supply chain | 1 (6.7) | 7 (46.7) | 7 (46.7) | 15 (5.2) | ||
| Laboratory supplies and training | 6 (15.4) | 27 (69.2) | 6 (15.4) | 39 (13.5) | ||
| Operations research | 2 (66.7) | 1 (33.3) | 3 (1.0) | |||
| Surveillance | 3 (8.3) | 10 (27.8) | 21 (58.3) | 2 (5.6) | 36 (12.5) | |
| Training/capacity building | 1 (9.1) | 6 (54.5) | 4 (36.4) | 11 (3.8) | ||
| Pharmacovigilance NOS | 2 (6.3) | 1 (3.1) | 23 (71.9) | 6 (18.8) | 32 (11.1) | |
| Pharmacovigilance NOS-unfunded | 26 (100) | 26 (9.0) | ||||
| Surveillance-not funded | 5 (100) | 5 (1.7) | ||||
| Context onlya | 39 (100) | 39 (13.5) | ||||
| Historical activityb | 12 (17.4) | 37 (53.6) | 17 (24.6) | 3 (4.4) | 69 (24.0) | |
| Total | 14 (4.9) | 40 (13.9) | 154 (53.5) | 49 (17.0) | 42 (14.6) |
| Schizophrenic Patient Variables | Values |
| Schizophrenia Severity | Severe/Other |
| Schizophrenia Heavy Alcohol Use | Yes/No |
| Schizophrenia Heavy Drug Use | Yes/No |
| Schizophrenia | Paranoid/Undiff |
| Schizophrenia Sudden Death | Yes/No |
| Schizophrenia Suicide | Yes/No |
| Schizophrenia Lifetime Antipsychotics >45,000 | Yes/No |
| Schizophrenia Antichollnergic | Yes/No |
| Schizophrenia Antidepressants | Yes/No |
| Schizophrenia Stabilizer | Yes/No |
| Schizophrenia Lithium | Yes/No |
| Schizophrenia Valproate | Yes/No |
| Reads | Assembler | Contig | Scaffold | Transf | Untransf | Shared | Masked |
| Sim | allp | 57 | 7 | 21 | 1 | 18 | 12 |
| Sim | sga_m75 | 504 | 463 | NA | NA | NA | NA |
| Sim | sga_m77 | 513 | 479 | NA | NA | NA | NA |
| Sim | soap_K69 | 1481 | 698 | 255 | 451 | 137 | 44 |
| Sim | soap_K71 | 1469 | 769 | NA | NA | NA | NA |
| Bs-1 | allp | 66 | 9 | 35 | 0 | 23 | 15 |
| Bs-1 | sga_m75 | 899 | 711 | NA | NA | NA | NA |
| Bs-1 | sga_m77 | 871 | 687 | NA | NA | NA | NA |
| Bs-1 | soap_K69 | 1916 | 670 | 365 | 429 | 210 | 95 |
| Bs-1 | soap_K71 | 1909 | 692 | NA | NA | NA | NA |
| Total | Diagnosis | Clinical therapy & drug resistance | Case reports | Vaccine development | Epidemiology | Health education | Interventions and control | Others | |
| HIV/AIDS | 24025 (100%) | 1229 (5.1%) | 2706 (11.3%) | 2105 (8.7%) | 561 (2.3%) | 6243 (26.0%) | 696 (2.9%) | 1135 (4.7%) | 9350 (39.0%) |
| Parasites | 14911 (100%) | 1354 (9.1%) | 1928 (12.9%) | 2201 (14.7%) | 132 (0.9%) | 3667 (24.6%) | 101 (0.7%) | 835 (5.6%) | 4693 (31.5%) |
| Variable | Control(n = 91) | Intervention(n = 92) | |
| Age | mean (sd) | 57.5 (15.1) | 57.2 (17.0) |
| Gender | % | M: 61 | M: 62 |
| APACHE II | mean (sd) | 19.5 (7.2) | 19.4 (12.6) |
| MV hours | mean (sd) | 135 (117) | 142 (159) |
| medianc (IQR) | 91 (48-179) | 76 (41-180) | |
| ICU LOS days | mean (sd) | 8.6 (7.5) | 9.4 (8.7) |
| median (IQR) | 6 (4-10.5) | 6 (4-11) | |
| Hospital LOS days | mean (sd) | 23.2 (16.9) | 24.8 (20.4) |
| median (IQR) | 18.5 (12-27.5) | 18.5 (12-30) | |
| SF-36 PFa | mean (sd) | 28.8 (10.2) | 27.1 (12.3) |
| 6MWT distance metresa | mean (sd) | 324 (143) | 291 (129) |
| SF-36 PCSb | mean (sd) | 32.7 (8.6) | 31.7 (10.0) |
| SF-36 MCSb | mean (sd) | 39.8 (13.5) | 36.7 (15.1) |
| Variable | Beclin 1 expression | |||
| All Cases | Low | High | p Value | |
| HER2 expression in total cases(41) | 0.008 | |||
| Negative | 26 | 21(80.8%) | 5(19.2%) | |
| Positive | 15 | 6(40.0%) | 9(60.0%) | |
| HER2 expression in ER positive cases(25) | 0.002 | |||
| Negative | 18 | 16(88.9%) | 2(11.1%) | |
| Positive | 7 | 1(14.3%) | 6(85.7%) | |
| HER2 expression in ER negative cases(16) | 1.000 | |||
| Negative | 8 | 5(62.5%) | 3(37.5%) | |
| Positive | 8 | 5(62.5%) | 3(37.5%) |
| MALL expression | |||
| Negative | Positive | ||
| Variables | (n = 58) | (n = 145) | P-value |
| Age (y) | 0.319 | ||
| <65 | 20 (34.5) | 61 (42.1) | |
| ≥65 | 38 (65.5) | 84 (57.9) | |
| Gender | 0.151 | ||
| Male | 20 (34.5) | 66 (45.5) | |
| Female | 38 (65.5) | 79 (54.5) | |
| Tumor location | 0.286 | ||
| Right colon | 30 (51.7) | 54 (37.2) | |
| Transverse colon | 5 (8.6) | 14 (9.7) | |
| Left colon | 4 (6.9) | 16 (11.0) | |
| Sigmoid colon | 19 (32.8) | 61 (42.1) | |
| T category | 0.639 | ||
| T1 | 2 (3.4) | 6 (4.1) | |
| T2 | 4 (6.9) | 19 (13.1) | |
| T3 | 23 (39.7) | 53 (36.6) | |
| T4 | 29 (50.0) | 67 (46.2) | |
| N category | 0.008* | ||
| N0 | 28 (48.3) | 80 (55.2) | |
| N1 | 13 (22.4) | 48 (33.1) | |
| N2 | 17 (29.3) | 17 (11.7) | |
| M category | 0.118 | ||
| M0 | 50 (86.2) | 135 (93.1) | |
| M1 | 8 (13.8) | 10 (6.9) | |
| Vessin invasion | 0.027* | ||
| No | 50 (86.2) | 139 (95.9) | |
| Yes | 8 (13.8) | 6 (4.1) | |
| Differentiation | 0.214 | ||
| Well | 29 (50.0) | 70 (48.3) | |
| Moderate | 17 (29.3) | 57 (39.3) | |
| Poor | 12 (20.7) | 18 (12.4) | |
| AJCC stage | 0.351 | ||
| I-II | 27 (46.6) | 78 (53.8) | |
| III-IV | 31 (53.4) | 67 (46.2) | |
| Recurrence and metastasis | 0.016* | ||
| No | 25 (46.3) | 92 (65.2) | |
| Yes | 29 (53.7) | 49 (34.8) | |
| Patient survival | 0.004* | ||
| No | 30 (51.7) | 44 (30.3) | |
| Yes | 28 (48.3) | 101 (69.7) |
| Group of patients | Survivin positive | Survivin negative | Total |
| COX-2 positive | 55 | 8 | 63 |
| COX-2 negative | 15 | 15 | 30 |
| Total | 70 | 23 | 93 |
| Characteristic | Healthy volunteers | RA patients |
| (N = 7) | (N = 10) | |
| Age: mean (range) | 56 (49–62) | 63 (49–80) |
| Gender (% female) | 43% | 50% |
| Line | Number of Individuals | Duplication | Deletion | HeR | Aneuploid | TOTAL |
| ACSRsyn1 | 16 | 2 | 2 | 0 | 0 | 4 |
| Bronowski | 16 | 0 | 1 | 0 | 0 | 1 |
| Daichousen (fuku) | 16 | 0 | 0 | 1 | 1 | 2 |
| Maris Haplona | 48 | 1 | 8 | 0 | 1 | 10 |
| Surpass 400 | 16 | 0 | 0 | 0 | 0 | 0 |
| Svalof’s Gulle | 16 | 1 | 0 | 0 | 1 | 2 |
| Tribune | 16 | 2 | 2 | 0 | 1 | 5 |
| Topas | 16 | 0 | 1 | 0 | 1 | 2 |
| PAK85912 | 46 | 5 | 4 | 5 | 3 | 17 |
| Zhongyou821 | 48 | 3 | 2 | 0 | 4 | 9 |
| Rainbow | 254 | 12 | 22 | 30 | 13 | 77 |
| Individual Outcome Variables | Time 1 INTMean (SD) | Time 2 INTMean (SD) | Time 1 CONMean (SD) | Time 2 CONMean (SD) |
| Girl's BMI | 20.1 (4.4) | 20.4 (4.5) | 19.1 (2.9) | 19.2 (3.0) |
| Girl's BMI percentile | 65.2 (27.0) | 64.8 (26.9) | 64.5 (23.8) | 62.2 (23.2) |
| Girl's BMI z-score | 0.57 (0.94) | 0.55 (0.94) | 0.38 (0.75) | 0.36 (0.74) |
| Parent BMIa | 29.1 (6.4) | 29.5 (6.9) | 29.1 (6.7) | 30.0 (7.5) |
| Family meals/weeka (scale 0-21) | 11.2 (4.2) | 10.9 (3.6) | 11.4 (5.0) | 12.1 (4.7) |
| Girl days/week of 60 min. MVPAb (scale 0-7) | 4.2 (1.8) | 3.9 (1.7) | 4.5 (1.9) | 3.5 (1.8) |
| Percent of parents meeting MVPA standarda | 46.7 | 42.0 | 33.3* | 36.4 |
| Girl FV servings/dayb (scale 0-8) | 5.0 (2.0) | 4.9 (1.7) | 3.7 (1.9)* | 3.7 (1.8)* |
| Parent FV Servings/daya (scale 0-8) | 3.9 (1.5) | 4.4 (1.6) | 3.7 (1.8) | 4.4 (1.5) |
| Girl eating with TV scaleb (scale 0-4) | 1.1 (0.7) | 0.8 (0.7) | 1.1 (0.8) | 1.1 (0.7) |
| Parent eating with TV scalea (scale 0-4) | 1.8 (0.7) | 1.7 (0.7) | 2.0 (0.8) | 2.1 (0.7)* |
| Girl days/week SSB consumptionb (scale 0-7) | 3.1 (2.2) | 2.3 (2.4) | 2.6 (2.4) | 2.2 (2.4) |
| Parent days/week SSB consumptiona (scale 0-7) | 1.8 (2.2) | 2.0 (2.6) | 2.7 (2.7) | 2.4 (2.8) |
| Item | Number | Percent | Adjusted OR* | 95% CI | ||
| A smoke-free hospital would improve the quality of care the patient receives (Agree) | Admin** | 90 | 82.6% | 1.0 | ||
| Physicians | 223 | 83.8% | 1.4 | 0.63 | 3.1 | |
| Nurses | 227 | 90.4% | 2.2 | 0.84 | 5.7 | |
| Smoke from someone else's cigarette is unhealthy for non-smokers (Agree) | Admin | 97 | 89.8% | 1.0 | ||
| Physicians | 260 | 97.7% | 4.6 | 1.41 | 15.1 | |
| Nurses | 245 | 97.2% | 3.6 | 1.04 | 12.6 | |
| The smoking habits of health professionals influence others (Agree) | Admin | 100 | 91.7% | 1.0 | ||
| Physicians | 258 | 97.0% | 3.0 | 0.93 | 10.0 | |
| Nurses | 236 | 93.7% | 1.7 | 0.51 | 5.9 | |
| Cessation programs should be offered to employees (Agree) | Admin | 101 | 92.7% | 1.0 | ||
| Physicians | 254 | 95.5% | 6.8 | 1.68 | 27.3 | |
| Nurses | 239 | 95.2% | 2.2 | 0.60 | 7.7 | |
| A hospital should be a smoke-free environment (Agree) | Admin | 105 | 97.2% | 1.0 | ||
| Physicians | 256 | 96.2% | 1.2 | 0.30 | 4.6 | |
| Nurses | 246 | 97.6% | 1.4 | 0.27 | 7.4 | |
| Hospital employees who work in offices or areas removed from direct patient care should be allowed to smoke (Disagree) | Admin | 76 | 69.7% | 1.0 | ||
| Physicians | 196 | 73.7% | 1.4 | 0.77 | 2.6 | |
| Nurses | 155 | 61.3% | 0.7 | 0.36 | 1.3 | |
| A smoke-free policy is hard to enforce (Disagree) | Admin | 46 | 42.2% | 1.0 | ||
| Physicians | 142 | 53.6% | 2.1 | 1.28 | 3.5 | |
| Nurses | 104 | 41.6% | 1.2 | 0.66 | 2.0 | |
| Having a smoke-free policy is unfair to smokers (Disagree) | Admin | 90 | 84.1% | 1.0 | ||
| Physicians | 234 | 88.0% | 2.6 | 1.08 | 6.1 | |
| Nurses | 223 | 88.8% | 1.2 | 0.47 | 3.1 | |
| Hospitals with smoke-free policies are likely to lose patients (Disagree) | Admin | 86 | 79.6% | 1.0 | ||
| Physicians | 205 | 77.1% | 2.6 | 1.24 | 5.4 | |
| Nurses | 186 | 73.5% | 0.9 | 0.45 | 2.0 | |
| Smoking bans at hospitals would positively influence job performance (Agree) | Admin | 59 | 54.6% | 1.0 | ||
| Physicians | 190 | 71.7% | 2.0 | 1.21 | 3.3 | |
| Nurses | 190 | 75.7% | 2.1 | 1.20 | 3.6 | |
| Smoking bans at hospitals would positively affect the public image of the hospital (Agree) | Admin | 74 | 68.5% | 1.0 | ||
| Physicians | 245 | 92.8% | 5.5 | 2.79 | 10.8 | |
| Nurses | 226 | 89.7% | 3.3 | 1.63 | 6.6 |
| Rhomboid type | A Strepto | B Strepto | C Strepto | D Strepto | E Strepto | E Myco | AB Myco |
| A Strepto | – | ||||||
| B Strepto | 0.29474 | – | |||||
| C Strepto | 0.35789 | 0.35789 | – | ||||
| D Strepto | 0.40001 | 0.38947 | 0.16842 | – | |||
| E Strepto | 0.43158 | 0.38947 | 0.40000 | 0.42105 | – | ||
| E Myco (Rv1337) | 0.46316 | 0.53684 | 0.48421 | 0.50526 | 0.29474 | – | |
| AB Myco (Rv0110) | 0.23158 | 0.29500 | 0.33684 | 0.36842 | 0.35789 | 0.51579 | – |
| Cytokine | Total papers | Total ratios | References |
| IL-4 | 6 | 7 | Hensley et al., 2002, 2003; Kim et al., 2006; Beers et al., 2008; Chiu et al., 2008; Audet et al., 2012 |
| IL-6 | 8 | 12 | Hensley et al., 2002, 2003; Weydt et al., 2004; Xie et al., 2004; Kim et al., 2006; Chiu et al., 2008; Audet et al., 2012; Dibaj et al., 2012 |
| IL-10 | 3 | 6 | Hensley et al., 2002, 2003; Finkelstein et al., 2011 |
| IL-1α | 5 | 6 | Hensley et al., 2003; Kiaei et al., 2006; Kim et al., 2006; Kassa et al., 2009; Neymotin et al., 2009 |
| IL-1β | 12 | 20 | Hensley et al., 2003; Kang et al., 2003; Xie et al., 2004; Kiaei et al., 2006; Kim et al., 2006; Kassa et al., 2009; Neymotin et al., 2009; Fang et al., 2010; Zhao et al., 2010; Berger et al., 2011; Audet et al., 2012; Valente et al., 2012 |
| IL-12 | 6 | 12 | Hensley et al., 2002, 2003, 2006; Kiaei et al., 2006; Kim et al., 2006; Dibaj et al., 2012 |
| TNF-α | 18 | 39 | Yoshihara et al., 2002; Hensley et al., 2003; Chen et al., 2004; Weydt et al., 2004; Xie et al., 2004; Perrin et al., 2005; Henkel et al., 2006; Kim et al., 2006; Zhang et al., 2008; Cheroni et al., 2009; Neymotin et al., 2009; Fang et al., 2010; Takeuchi et al., 2010; Finkelstein et al., 2011; Pollari et al., 2011; Audet et al., 2012; Valente et al., 2012 |
| GFAP | 46 | 164 | Olsen et al., 2001; Yoshihara et al., 2002; Liu and Martin, 2006; Ohta et al., 2006; Pardo et al., 2006; Guan et al., 2007; Petrik et al., 2007; Yin et al., 2007; Beers et al., 2008; Pitzer et al., 2008; Poesen et al., 2008; Shibata et al., 2008; Boucherie et al., 2009; Cheroni et al., 2009; Kassa et al., 2009; Keller et al., 2009, 2011; Ringer et al., 2009; Sekiya et al., 2009; Yang et al., 2009, 2011; Guo et al., 2010, 2011; Israelsson et al., 2010; Jokic et al., 2010; Moreno-Igoa et al., 2010; Shimazawa et al., 2010; Steinacker et al., 2010; Suzuki et al., 2010; Tsai et al., 2010; Berger et al., 2011; Finkelstein et al., 2011; Genestine et al., 2011; Zhu and Sheng, 2011; Gifondorwa et al., 2012; Miquel et al., 2012; Valente et al., 2012 |
| Type I total | 56 | 241 | Olsen et al., 2001; Hensley et al., 2002, 2003, 2006; Yoshihara et al., 2002; Kang et al., 2003; Chen et al., 2004; Weydt et al., 2004; Xie et al., 2004; Perrin et al., 2005; Henkel et al., 2006; Kiaei et al., 2006; Kim et al., 2006; Liu and Martin, 2006; Ohta et al., 2006; Pardo et al., 2006; Guan et al., 2007; Petrik et al., 2007; Yin et al., 2007; Beers et al., 2008; Pitzer et al., 2008; Poesen et al., 2008; Shibata et al., 2008; Zhang et al., 2008; Boucherie et al., 2009; Cheroni et al., 2009; Kassa et al., 2009; Keller et al., 2009, 2011; Neymotin et al., 2009; Ringer et al., 2009; Sekiya et al., 2009; Yang et al., 2009, 2011; Fang et al., 2010; Guo et al., 2010, 2011; Israelsson et al., 2010; Jokic et al., 2010; Moreno-Igoa et al., 2010; Shimazawa et al., 2010; Steinacker et al., 2010; Suzuki et al., 2010; Takeuchi et al., 2010; Tsai et al., 2010; Zhao et al., 2010; Berger et al., 2011; Finkelstein et al., 2011; Genestine et al., 2011; Pollari et al., 2011; Audet et al., 2012; Dibaj et al., 2012; Gifondorwa et al., 2012; Miquel et al., 2012; Valente et al., 2012 |
| Type II total | 10 | 25 | Hensley et al., 2002, 2003; Weydt et al., 2004; Xie et al., 2004; Kim et al., 2006; Beers et al., 2008; Chiu et al., 2008; Finkelstein et al., 2011; Audet et al., 2012; Dibaj et al., 2012 |
| Factor | Adjusted OR | 95% CI | P value |
| Age | 1.032 | 0.991–1.075 | 0.129 (NS) |
| Gender | |||
| Female | 1 | ||
| Male | 0.341 | 0.083–1.402 | 0.136 (NS) |
| Bedbound | |||
| No | 1 | ||
| Yes | 7.332 | 0.419–128.341 | 0.173 (NS) |
| Albumin | 0.886 | 0.774–1.014 | 0.078 (NS) |
| Bilirubin | 0.996 | 0.984–1.008 | 0.522 (NS) |
| Laterality | |||
| Unilateral | 1 | ||
| Bilateral | 8.101 | 1.766–37.156 | 0.007 |
| Complexity | |||
| Simple | 1 | ||
| Complex | 2.050 | 0.304–13.809 | 0.555 (NS) |
| Stricture | |||
| No | 1 | ||
| Yes | 2.564 | 0.530–12.403 | 0.242 (NS) |
| Ectasia | |||
| No | 1 | ||
| Yes | 0.895 | 0.184–4.355 | 0.891 (NS) |
| Liver atrophy | |||
| No | 1 | ||
| Yes | 3.584 | 0.594–21.619 | 0.164 (NS) |
| Liver abscess | |||
| No | 1 | ||
| Yes | 6.058 | 0.960–38.230 | 0.055 (NS) |
| Extrahepatic stones | |||
| No | 1 | ||
| Yes | 1.228 | 0.274–5.509 | 0.789 (NS) |
| Treatment | |||
| Operative | 1 | ||
| Non-operative | 26.843 | 4.856–148.394 | 0.001 |
| Formulation (%)/treatment | T1 | T2 | T3 |
| TV surimi | 91.25 | – | – |
| MSTM surimi | – | 76.25 | 91.25 |
| Cold water | – | 15.00 | – |
| Soybean-concentrated protein | 4.00 | 4.00 | 4.00 |
| Cassava starch | 2.00 | 2.00 | 2.00 |
| Cure salt | 0.25 | 0.25 | 0.25 |
| Global sausage SV 800 | 0.80 | 0.80 | 0.80 |
| Cochonilha carmim | 0.05 | 0.05 | 0.05 |
| Refined salt | 1.65 | 1.65 | 1.65 |
| Dependent variable | Independent variable | Beta | 95% CI | P |
| Physical functioning | Age | -7.49 | -11.92-3.06 | 0.001 |
| GHQ-28 score | -19.28 | -27.21- -11.34 | < 0.001 | |
| Elbows pain | -30.53 | -47.94- -13.12 | 0.001 | |
| Low back pain | -19.87 | -30.25- -9.49 | < 0.001 | |
| Role limitations due to physical health problems | BMI | -8.21 | -16.56-0.14 | 0.054 |
| GHQ-28 score | -23.33 | -36.89- -9.78 | 0.001 | |
| Hip pain | -26.70 | -48.34- -5.05 | 0.016 | |
| Bodily pain | Age | 7.21 | 1.77-12.64 | 0.010 |
| GHQ-28 score | 8.71 | 0.51-16.91 | 0.038 | |
| Hip pain | 6.58 | 5.45-31.51 | 0.006 | |
| Upper back pain | 6.79 | 11.68-38.55 | < 0.001 | |
| General health | Female Gender | 6.38 | 2.41-10.35 | 0.002 |
| Vitality | GHQ-28 score | -13.07 | -19.39- -8.44 | < 0.001 |
| Elbows pain | -12.56 | -23.49- -1.62 | 0.025 | |
| Social functioning | GHQ-28 score | --3.71 | -7.33- - 0.09 | 0.045 |
| Role limitations due to emotional health problems | Female gender | -11.53 | -23.04- -0.03 | 0.049 |
| GHQ-28 score | -19.97 | -32.03 - -7.92 | 0.001 | |
| Upper back pain | -29.49 | -47.30- -11.68 | 0.001 | |
| Mental health | GHQ-28 score | -5.06 | -8.91 - -1.208 | < 0.001 |
| DIMENSION PHYSICAL | GHQ-28 score | -9.53 | -13.41- -5.66 | < 0.001 |
| Neck pain | -8.00 | -14.07- -1.93 | 0.010 | |
| DIMENSION MENTAL | GHQ-28 score | -8.50 | -11.67- -5.32 | < 0.001 |
| Upper back pain | -5.58 | -10.47- -0.68 | 0.026 |
| N | Multiplicative Model | Additive Model | ||||||
| Coefficient | Value | SE | Units | Coefficient | Value | SE | Units | |
| 389 | b * | 0.0021 | 3.4 × 10−5 | °C−1 d−1 | b | 0.0024 | 3.8 × 10−5 | °C−1 d−1 |
| 389 | g * (plus) | 9.464 | 1.080 | dh−1 | g (plus) | 11.40 | 0.983 | dh−1 |
| 389 | g * (neg) | −9.822 | 1.078 | dh−1 | g (neg) | −11.02 | 0.921 | dh−1 |
| 389 | h * | 0.499 | 0.060 | h−1 | h | 10.20 | 0.438 | OC h−1 |
| 389 | k * | 0.333 | 0.066 | d J−1 | k | 0.228 | 0.023 | d J−1 |
| 207 | b * | 0.0021 | 4.2 × 10−5 | °C−1 d−1 | b | 0.0025 | 3.7 × 10−5 | °C−1 d−1 |
| 207 | g * (plus) | 7.975 | 1.461 | dh−1 | g (plus) | 12.92 | 0.804 | dh−1 |
| 207 | g * (neg) | −11.62 | 1.353 | dh−1 | g (neg) | −14.64 | 0.795 | dh−1 |
| 207 | h * | 0.460 | 0.050 | h−1 | h | 11.94 | 0.484 | °C h−1 |
| 207 | k * | 0.297 | 0.068 | d J−1 | k | 0.302 | 0.018 | d J−1 |
| Attribute | Value | % of Total |
| Genome size (bp) | 4,024,382 | 100.00% |
| DNA coding region (bp) | 3,618,708 | 89.92% |
| DNA G+C content (bp) | 2,845,385 | 70.70% |
| Number of replicons | 1 | |
| Extrachromosomal elements | 0 | |
| Total genes | 3,710 | 100.00% |
| RNA genes | 57 | 1.54% |
| rRNA operons | 2 | |
| Protein-coding genes | 3,653 | 98.46% |
| Pseudo genes | 90 | 2.43% |
| Genes with function prediction | 2,645 | 71.29% |
| Genes in paralog clusters | 360 | 7.70% |
| Genes assigned to COGs | 2,674 | 72.08% |
| Genes assigned Pfam domains | 2,871 | 77.39% |
| Genes with signal peptides | 1,101 | 29.68% |
| Genes with transmembrane helices | 860 | 23.18% |
| CRISPR repeats | 0 |
| Group | Dose (mg/kg) | Sleep latency (min) | Sleeping time (min) |
| Normal | 60 | 8 ± 1 | 36 ± 3 |
| DZP | 3 | 6 ± 1* | 75 ± 3* |
| ME | 800 | 12 ± 0.5* | 45 ± 2* |
| ME | 1000 | 6 ± 1* | 112 ± 3* |
| Median (Inter-quartile range) or N (%) | *p-value | ||
| Variables | HCC (n = 62) | Non-HCC (n = 57) | |
| Age (years) | 49.5(35–55) | 36(32–51) | p = 0.05 |
| Gender M:F | 48:14 | 38:19 | p = 0.19 |
| AST (u/L) | 89(68–112) | 12(7–23) | p < 0.001 |
| ALT (u/L) | 36(22–54) | 8(5–16) | p < 0.001 |
| Total Bilirubin (μmol/l) | 60.3(28–144) | 18(11.1-29) | p < 0.001 |
| Albumin (g/l) | 30(26–35) | 36(34–39) | p < 0.001 |
| INR | 1.19(1–1.4) | 1.1(1–1.2) | p = 0.22 |
| Positive for HBsAg | 41(66.1 %) | 42(73.7 %) | p = 0.52 |
| Positive for Anti-HCV | 0 %) | 1(1.8 %) | p = 0.30 |
| Laboratorial Parameters | Control Group n = 43 | SCD Groups n = 72 | p Value | ||
| Median | IQR (P25–P75) | Median | IQR (P25–P75) | ||
| Hemoglobin (g/dL) | 13.5 | 12.8–14.7 | 8.0 | 7.1–9.3 | <0.001 |
| Hematocrit (%) | 40.1 | 38.7–44.1 | 23.6 | 21.4–28.1 | <0.001 |
| Leukocytes (×103/mm3) | 5.8 | 4.9–6.6 | 10.7 | 7.6–13.9 | <0.001 |
| Lymphocytes (%) | 37.1 | 33.0–42.1 | 38.4 | 30.8–46.0 | 0.676 |
| Hepcidin (ng/mL) | 7.2 | 5.6–11.6 | 5.3 | 2.5–10.9 | 0.014 |
| Ferritin (ng/mL) | 29.8 | 17.1–68.5 | 228.7 | 69.4–703.5 | <0.001 |
| Ferritin/Leukocytes ratio | 6.3 | 3.1–13.2 | 27.5 | 7.2–77.0 | <0.001 |
| Serum iron (μg/dL) | 105.0 | 69.0–129.0 | 119.0 | 92.0–158.8 | 0.012 |
| TIBC (μg/dL) | 333.0 | 301.0–383.0 | 293.0 | 233.3–347.0 | 0.001 |
| TS (%) | 31.4 | 20.5–41.8 | 43.1 | 30.1–62.5 | <0.001 |
| LDH (U/L) | 349.0 | 293.0–391.0 | 818.0 | 619.8–1198.0 | <0.001 |
| GDF-15 (pg/mL) | 504.8 | 396.0–652.4 | 1299.2 | 618.4–1553.1 | <0.001 |
| IL-6 (pg/mL) | 0.0 | 0.0–2.5 | 3.8 | 2.4–8.9 | <0.001 |
| GO.ID | Term | p-Value |
| Topic 2 | ||
| GO:0001054 | RNA polymerase I activity | 2.5e-07 |
| GO:0043022 | ribosome binding | 4.8e-06 |
| GO:0030515 | snoRNA binding | 5.0e-06 |
| GO:0005524 | ATP binding | 6.1e-06 |
| Topic 3 | ||
| GO:0003713 | transcription coactivator activity | 7.6e-07 |
| GO:0003730 | mRNA 3’-UTR binding | 4.6e-06 |
| GO:0004843 | ubiquitin-specific protease activity | 7.7e-06 |
| Topic 4 | ||
| GO:0020037 | heme binding | 2.2e-19 |
| O:0008395 | steroid hydroxylase activity | 5.9e-18 |
| O:0019825 | oxygen binding | 6.5e-14 |
| O:0005506 | iron ion binding | 9.2e-13 |
| O:0004364 | glutathione transferase activity | 1.5e-12 |
| O:0008392 | arachidonic acid epoxygenase activity | 1.9e-12 |
| O:0005102 | receptor binding | 4.2e-11 |
| GO:0004867 | serine-type endopeptidase inhibitor activity | 1.1e-10 |
| GO:0009055 | electron carrier activity | 1.3e-10 |
| GO:0070330 | aromatase activity | 2.6e-10 |
| GO:0042803 | protein homodimerization activity | 7.4e-10 |
| GO:0008201 | heparin binding | 1.5e-09 |
| GO:0002020 | protease binding | 2.5e-08 |
| GO:0051087 | chaperone binding | 6.0e-07 |
| GO:0003988 | acetyl-CoA C-acyltransferase activity | 8.4e-07 |
| GO:0016836 | hydro-lyase activity | 1.0e-06 |
| GO:0004602 | glutathione peroxidase activity | 1.0e-06 |
| GO:0004601 | peroxidase activity | 1.3e-06 |
| GO:0030170 | pyridoxal phosphate binding | 1.6e-06 |
| GO:0004029 | aldehyde dehydrogenase (NAD) activity | 2.4e-06 |
| GO:0001848 | complement binding | 3.1e-06 |
| GO:0016616 | oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor | 3.2e-06 |
| GO:0050660 | flavin adenine dinucleotide binding | 3.8e-06 |
| GO:0005507 | copper ion binding | 4.1e-06 |
| GO:0016709 | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen | 5.3e-06 |
| GO:0032403 | protein complex binding | 5.7e-06 |
| GO:0051537 | 2 iron, 2 sulfur cluster binding | 7.8e-06 |
| Characteristics | Total (n, %) |
| Number | 73 |
| Age (years) | 67.0 (SD 14.1) |
| Sex male | 52 (71.2) |
| Admission NIHSS score | 9.3 (SD 3.2) |
| Admission GCS score | 5.6 (SD 2.0) |
| Smoking | 30 (41.1) |
| Excess alcohol consumption | 22 (30.1) |
| Pre-existing illnesses | |
| Hypertension | 53 (72.6) |
| Diabetes | 36 (49.3) |
| Coronary heart disease | 14 (19.2) |
| Liver disease (except for hepatic cirrhosis) | 0 (0) |
| Kidney disease | 2 (2.7) |
| Chest X ray | 73 (100) |
| Chest CT | 58 (79.5) |
| GGOs | 40/58 (69.0) |
| Consolidation opacities | 31/58 (53.4) |
| Pleural effusions | 14/58 (24.1) |
| Air bronchogram | 11/58 (19.0) |
| Tachypnea (RR ≥ 25 breaths/min) | 67 (91.8) |
| Fever (T ≥ 37.5 °C) | 43 (58.9) |
| PaO2/FiO2 (mmHg) | 143.5 (SD 59.0) |
| APACHE II score | 28.2 (SD 10.4) |
| pH value | 7.38 (SD 0.57) |
| Acidosis (pH < 7.35) | 11 (15.1) |
| Albumin (g/L) | 26.1 (SD 9.2) |
| Treatment | |
| Corticosteroids | 47 (64.4) |
| No respiratory response | 16/47 (34.0) |
| Respiratory response | 31/47 (66.0) |
| Ventilatory support | 63 (86.3) |
| Non-invasive ventilation alone | 14/63 (22.2) |
| Non-invasive ventilation followed by intubation | 16/63 (25.4) |
| First line invasive ventilation | 33/63 (52.4) |
| Time from diagnosis to corticosteroids (days) | 6.5 (SD 3.5) |
| Outcomes | |
| Duration of IMV (days) | 8.5 (SD 5.5) |
| Hospital LOS (days) | 23.0 (SD 7.0) |
| Hospital mortality | 29 (39.7) |
| Indicator | Baseline | Follow-Up | ATT | |||||||
| Control | Treated | Difference | p | Control | Treated | Difference | p | DID b | p | |
| Left-behind | ||||||||||
| BMI_sd a | 1.011 | 0.994 | −0.017 | 0.288 | 1.011 | 0.986 | −0.025 | 0.223 | −0.008 | 0.756 |
| Weight_sd | 0.986 | 0.928 | −0.058 | 0.006 | 0.995 | 0.943 | −0.052 | 0.046 | 0.006 | 0.846 |
| Height_sd | 1.020 | 0.996 | −0.024 | 0.003 | 1.032 | 1.016 | −0.016 | 0.037 | 0.008 | 0.415 |
| Father-left | ||||||||||
| BMI_sd | 1.011 | 1.000 | −0.011 | 0.563 | 1.011 | 1.006 | −0.005 | 0.843 | 0.006 | 0.861 |
| Weight_sd | 0.986 | 0.939 | −0.047 | 0.091 | 0.995 | 0.950 | −0.045 | 0.209 | 0.002 | 0.962 |
| Height_sd | 1.020 | 0.998 | −0.022 | 0.034 | 1.032 | 1.010 | −0.022 | 0.013 | 0.000 | 0.982 |
| Mother-left | ||||||||||
| BMI_sd | 1.011 | 0.986 | −0.025 | 0.241 | 1.011 | 0.955 | −0.056 | 0.011 | −0.031 | 0.320 |
| Weight_sd | 0.986 | 0.909 | −0.077 | 0.005 | 0.995 | 0.931 | −0.064 | 0.031 | 0.013 | 0.735 |
| Height_sd | 1.020 | 0.992 | −0.028 | 0.009 | 1.032 | 1.027 | −0.005 | 0.656 | 0.023 | 0.142 |
| Hit rate (confirmed hits with selectivity over mammalian cell cytotoxicity) | G+ve | G-ve | Fungi |
| CO-ADD academic hit rate | 0.66% | 0.21% | 0.98% |
| Commercial hit rate | 0.03% | 0.008% | ND |
| Treatment and Age Groupa | SPR, % (95% CI) | SCR, % (95% CI) | GMT, (95% CI) |
| LD HA/AS03B | |||
| 18–40 y (n = 27) | 96.3 (81.0–99.9) | 96.3 (81.0–99.9) | 98.3 (71.8–134.5) |
| 41–64 y (n = 29) | 86.2 (68.3–96.1) | 75.9 (56.5–89.7) | 88.1 (62.0–125.0) |
| LD HA/AS03A | |||
| 18–40 y (n = 31) | 100 (88.8–100) | 100 (88.8–100) | 202.4 (150.2–272.6) |
| 41–64 y (n = 25) | 80.0 (59.3–93.2) | 76.0 (54.9–90.6) | 72.6 (46.1–114.3) |
| MD HA/AS03B | |||
| 18–40 y (n = 27) | 100 (87.2–100) | 100 (87.2–100) | 156.1 (110.9–219.6) |
| 41–64 y (n = 27) | 85.2 (66.3–95.8) | 77.8 (57.7–91.4) | 72.2 (50.0–104.4) |
| MD HA/AS03A | |||
| 18–40 y (n = 31)b | 100 (88.8–100) | 100 (88.4–100) | 173.0 (137.2–218.0) |
| 41–64 y (n = 24) | 91.7 (73.0–99.0) | 91.7 (73.0–99.0) | 126.9 (85.9–187.6) |
| HD HA nonadjuvanted | |||
| 18–40 y (n = 30) | 43.3 (25.5–62.6) | 36.7 (19.9–56.1) | 21.9 (14.9–32.2) |
| 41–64 y (n = 26) | 11.5 (2.4–30.2) | 7.7 (.9–25.1) | 13.0 (9.0–18.9) |
| Placebo | |||
| 18–40 y (n = 61) | 0.0 (.0–5.9) | 0.0 (.0–5.9) | 5.1 (4.9–5.3) |
| 41–64 y (n = 51) | 0.0 (.0–7.0) | 0.0 (.0–7.0) | 5.9 (5.3–6.6) |
| Molecular subtypes | Immunohistochemical characterization |
| Luminal A | ER + and/or PR+, HER2- CK8/18+ |
| Luminal B | ER + and/or PR+, HER2+, CK8/18+ |
| HER2+ | ER-, PR-, HER2+ |
| basal-like | ER-, PR-, HER2- and CK 5/6+, HER1+ and/or CK14+ |
| Unclassified | ER-, PR-, HER2-, CK 5/6-, HER1- and CK14- |
| DNA adduct levels/HPV infection | Protein expression | p-value | |
| Negative (%) | Positive (%) | ||
| XRCC3 | |||
| High/+ (n = 24) | 15 (62.5) | 9 (37.5) | |
| High/− (n = 44) | 11 (25.0) | 33 (75.0) | |
| Low/+ (n = 6) | 3(50.0) | 3 (50.0) | |
| Low/− (n = 26) | 6 (23.1) | 20 (76.9) | 0.007 |
| XRCC5 | |||
| High/+ (n = 24) | 14 (58.3) | 10 (41.7) | |
| High/− (n = 44) | 6 (13.6) | 38 (86.4) | |
| Low/+ (n = 6) | 6 (100.0) | 0 (0.0) | |
| Low/− (n = 26) | 9 (34.6) | 17 (65.4) | <0.0001 |
| Control group | |||
| Score | 2 weeks | 14 weeks | 26 weeks |
| Total | -0.06 | -0.05 | +0.01 |
| Symptom domain | -0.21 | -0.14 | -0.11 |
| Mental domain | 0.0 | 0.0 | 0.0 |
| Function domain | +0.05 | +0.02 | +0.14 |
| Jurisdiction | Health policy change in studied period | Cost sharing mechanism | References | |
| Outpatient/Inpatient services | Pharmaceuticals | |||
| 1 Czech Rep | Introduction of formal fees | Until the end of 2007, outpatient and inpatient services were free of charge. Since 2008, formal OOPs exists; a flat fee of 30 CZK (€1.2) per doctor visit, 60 CZK (€2.4) per hospital day as well as spa hotels, 90 CZK (€3.6) per ambulatory visit outside of working hours. An annual ceiling of CZK 5000 (€200) for expenses related to doctor visits and drug costs was introduced. Since 2009, a new ceiling of CZK 2500 (€100) for those below 18 and above 65 was launched. A flat fee per doctor visit for children was eliminated. Since 2012, a flat fee for hospital and spa stay was reduced to 100 CZK per stay (€3.92 EUR). The dental care is paid by OOPs too. Some groups such as poor, pregnant woman, chronically ill children, patients with infectious diseases are exempted from formal OOPs.(Exchange rate used; 1 EUR = 250 CZK) | Until 2008, some form of co-payments existed. A prescription fee of 30 CZK (1.18 EUR) per item was introduced in 2008. Since 2009, a difference between actual and reimbursement price is paid out of pocket if it is higher than prescription fee. | [3, 22] |
| 2 Estonia | Introduction of formal fees | Since 1995, a fee of €0.30 (EEK 5) per first initial outpatient consultation at public hospitals and/or health centers exists, a free price setting for specialists. Since 2002, no fees for GP visits (except for home GP visit which is €3.2) but ambulatory specialist care at maximum fee of €3.20 (EEK 50) unless a referral within the same institution or specialty is granted. Hospital fees are implemented at 1.6 EUR per day, for up to 10 days per episode of illness. Some exemptions for children, pregnant woman and emergency care apply. (Exchange rate used; 1 EUR = 15.6 EEK) | Co-payment consist of a prescription fee of €1.30 plus the difference between actual price and reimbursement level. The general reimbursement rate is 50 % of the pharmaceutical price up to a maximum reimbursement of €12.00 (EEK 200) per prescription. The reimbursement of drugs for chronic disease, children, seniors and disabled is higher, up to 100 % . | [40, 41] |
| 3 Hungary | Introduction of formal fees | To limited extend, some form of copayments already existed since 1989 (medical devices, spas, specialist treatment outside of standard patient’s pathway etc.). Since 2007 formal co-payments were introduced; app €1 per ambulatory visit and per hospital day. After the referendum held in 2008, they were abolished. | Since 2007 reimbursement rates have been decreased from 50 to 25 %; from 70 to 55 %; and from 90 to 85 %. For drugs with a special reimbursement of 90 %, three levels of coverage was established: 50, 70 and 90 %. For drugs fully reimbursed, a minimum €1 (300 HUF) fee per prescription was introduced. For special attentionpatients eligible for free of charge drugs, a monthly limit of 40 EUR was established. OOPs apply above that sum. Eligibility for special attention is defined by GP. (Exchange rate used; 1 EUR = 250 HUF) | [21, 34] |
| 4 Slovakia | Introduction of formal fees | The formal copayments were introduced in 2003. Since then, app. €0.66 is paid per doctor visit and app. 1.66 EUR per hospital day, app €1.99 per emergency care visit,€0.07 per km for ambulance transport and between €4.98 and 7.30 per food and accommodation in spas. In 2006, user fees for a doctor’s visit and daily hospital stay were abolished. (Exchange rate used; 1 EUR = 40.03 SKK) | Until 2003, some form of co-payments existed. Since then €0.5 EUR prescription fee has to be paid. It was reduced to €0.17in 2006. If there is a difference between the price of the drug and the reimbursement level, patient has to cover it as well. | [11, 42] |
| Data collection | |
| X-ray source | PF BL-5A |
| Wavelength (Å) | 1.0000 |
| Space group | P41212 |
| Unit-cell parameters (Å) | a = b = 91.3, c = 265.4 |
| Resolution (Å)a | 20.0-2.20 (2.28-2.20) |
| Observed reflections | 689047 |
| Unique reflections | 55949 |
| Completeness (%)a | 96.5 (81.0) |
| Rmerge (%)a,b | 9.2 (23.9) |
| <I>/<σ(I) > a | 55.6 (11.4) |
| Refinement | |
| Resolution range (Å) | 20.0-2.20 |
| Rfactor(%)c | 19.2 |
| Rfree(%)d | 23.0 |
| Protein atoms | 8020 |
| NADPH atoms | 192 |
| Water molecules | 302 |
| r.m.s deviaton from ideal | |
| Bond lengths (Å) | 0.011 |
| Bond angles (deg.) | 1.43 |
| Ramachandran plote | |
| Most favored regions (%) | 91.7 |
| Allowed regions (%) | 8.3 |
| Step | Candidate genes | Wilks’ Lambda | Exact F | |
| Statistic | p value | |||
| 1 | TNFAIP3 | 0.404 | 59.002 | <0.001 |
| 2 | IL-21 | 0.300 | 45.521 | <0.001 |
| 3 | c-REL | 0.261 | 35.809 | <0.001 |
| 4 | RGS1 | 0.235 | 30.143 | <0.001 |
| 5 | LPP | 0.222 | 25.272 | <0.001 |
| Parameter | Model LR | AR(1) | AR(2) | AR(3) | AR(4) | AR(5) | Model LME |
| intercept | 9.6448 | 9.6309 | 9.6441 | 9.6560 | 9.6617 | 9.6633 | 9.6719 |
| (0.0142) | (0.0206) | (0.0231) | (0.0243) | (0.0246) | (0.0247) | (0.0243) | |
| Age | -0.0045 | -0.0043 | -0.0044 | -0.0045 | -0.0047 | -0.0047 | -0.0049 |
| (0.0003) | (0.0005) | (0.0006) | (0.0006) | (0.0006) | (0.0007) | (0.0006) | |
| Season(Warm) | -0.0627 | -0.0615 | -0.0681 | -0.0699 | -0.0693 | -0.0694 | -0.0698 |
| (0.0089) | (0.0074) | (0.0066) | (0.0066) | (0.0067) | (0.0067) | (0.0067) | |
| DPV | -0.0610 | -0.0469 | -0.0350 | -0.0385 | -0.0440 | -0.0474 | -0.0636 |
| (Donation) | (0.0092) | (0.0089) | (0.0079) | (0.0074) | (0.0072) | (0.0072) | (0.0068) |
| γ1 | — | 0.5158 | 0.3685 | 0.3053 | 0.2746 | 0.2630 | — |
| — | (0.0061) | (0.0068) | (0.0076) | (0.0082) | (0.0087) | — | |
| γ2 | — | — | 0.2888 | 0.2080 | 0.1766 | 0.1621 | — |
| — | — | (0.0078) | (0.0087) | (0.0084) | (0.0091) | — | |
| γ3 | — | — | — | 0.2207 | 0.1730 | 0.1581 | — |
| — | — | — | (0.0095) | (0.0104) | (0.0109) | — | |
| γ4 | — | — | — | — | 0.1488 | 0.1257 | — |
| — | — | — | — | (0.0123) | (0.0129) | — | |
| γ5 | — | — | — | — | — | 0.0829 | — |
| — | — | — | — | — | (0.0167) | — |
| Factors | Concepts | Health professionals’ experiences, barriers and facilitators & possible improvements with regard to: |
| Guideline related factors | Feasibility of the recommended guideline and the protocol derived from the guideline | - Guideline- Protocol- EHR- Consults- Collaboration with other continence professionals: Informing the woman’s GP after the consult by means of a letter, Advices for referrals, diagnostics and treatments |
| Compatibility of the protocol: the extent to which the recommended protocol is practical | likewise | |
| Individual health professional factors | Competences (=skills, attitude and knowledge) needed: the extent to which the targeted health professionals have competences they need | - Competences needed- Training/educational needs- Learning experiences |
| Health professionals’ engagements and satisfaction with the intervention | - Involvement & Satisfaction (both rated on a 0–10 scale) | |
| Patient factors | Patient behaviour: patient’s response to consults | - Patient’s response to consults, advices- Factors that influence patient’s response to nurses’ care, e.g., financial issues |
| Patient motivation: the targeted healthcare professional’s (perceived) ability to motivate patients to adhere | - Motivating patients to adhere | |
| Patient preferences: the targeted healthcare professional’s (perceived) ability to pay attention to patient preferences | - Paying attention to patient preferences | |
| Professional interactions | Referral processes: processes for communication between the targeted healthcare professionals and targeted patients | - Nurse’s interaction with GPs- Nurse’s interaction with community pharmacists- Nurse’s interaction between GPs and community pharmacists |
| Incentives and resources | Financial incentives: the extent to which patients, individual health professionals and organisations have financial incentives or disincentives to adhere | - Financial issues that influenced adherence among patients, GPs and community pharmacists |
| Information system: the extent to which the EHR facilitates or hinders adherence | - EHR | |
| Capacity for organisational change | Mandate, authority and accountability for making necessary changes | - Mandate for treatment change in participating women. |
| Regulations, rules, policies: the extent to which organisational regulations, rules or policies facilitate or hinder necessary changes. | - Regulations, rules and policies. | |
| Social, political and legal factors | Payer or funder policies: the extent to which payer or funder policies may affect implementation of necessary changes | - Payer or funder policies facilitating or hindering implementation of necessary changes |
| Legislation: the extent to which legislation may affect implementation of necessary changes | - Legislation affecting implementation of necessary changes |
| 10-year breast cancer specific | 5-year BDDM | |||||
| Variant | P-value | HR | 95% CI | P-value | HR | 95% CI |
| -903GA | 0.01521 | 1.90 | 1.13 to 3.20 | 0.00201 | 2.07 | 1.31 to 3.29 |
| -975GC | 0.00357 | 2.68 | 1.38 to 5.21 | 0.01220 | 2.33 | 1.20 to 4.52 |
| -1026CA | 0.01829 | 2.06 | 1.13 to 3.77 | 0.28165 | 1.44 | 0.74 to 2.79 |
| any | 0.00002 | 2.17 | 1.52 to 3.10 | 0.00011 | 1.97 | 1.40 to 2.79 |
| moderate injury (n = 38) | severe injury (n = 63) | total (n = 101) | RTA (n = 68) | Fall (n = 24) | |
| Gender | |||||
| Male (%) | 31(82) | 52(83) | 83(82) | 54(79) | 22(92) |
| Female(%) | 7(18) | 11(17) | 18(18) | 14(21) | 2(8) |
| Age | |||||
| Range | 19–83 | 16–79 | 16–83 | 16–83 | 28–78 |
| Mean (SD) | 43.86(16.85) | 40.46(17.56) | 41.67(17.47) | 38.23(17.54) | 49.92(15.47) |
| Marital status | |||||
| Married(%) | 31(82) | 39(62) | 70(69) | 42(62) | 21(88) |
| Unmarried(%) | 5(13) | 19(30) | 24(24) | 21(31) | 1(4) |
| Divorced(%) | 1(2) | 3(4) | 4(4) | 3(4) | 1(4) |
| Widowed(%) | 1(2) | 2(3) | 3(3) | 2(3) | 1(4) |
| Education level | |||||
| No formal education | 3(8) | 2(3) | 5(5) | 1(1) | 3(13) |
| Primary education | 5(13) | 5(8) | 10(10) | 7(10) | 2(8) |
| Secondary Education | 28(74) | 54(86) | 82(81) | 57(84) | 18(75) |
| Degree | (0) | 2(3) | 2(2) | 2(3) | 0(0) |
| ASCOT score (%) | |||||
| ASCOT Mean(SD) | 0.90(0.06) | 0.61(0.22) | 0.72(0.23) | 0.72(0.22) | 0.67(0.25) |
| TRISS Mean(SD) | 0.97(0.02) | 0.86(0.14) | 0.90(0.12) | 0.91(0.11) | 0.86(0.16) |
| RTS Mean(SD) | 6.81(0.24) | 4.53(0.84) | 5.39(1.30) | 5.34(1.30) | 5.30(1.37) |
| ISS Mean(SD) | 6.87(4.41) | 5.57(4.69) | 6.06(4.61) | 6.09(4.02) | 6.00(5.08) |
| GCS | |||||
| < 9 | 0(0) | 63(100) | 63(62) | 44(65) | 15(63) |
| 9–12 score | 38(100) | 0(0) | 38(38) | 24(35) | 9(38) |
| Mechanism of injury | |||||
| RTA | 24(63) | 44(70) | 68(67) | 68(100) | 0(0) |
| Fall | 9(24) | 15(24) | 24(24) | 0(0) | 24(100) |
| Other | 5(13) | 4(6) | 9(9) | 0(0) | 0(0) |
| Length of ICU stay(days) | |||||
| Median(IQR) | 6(8) | 5(6) | 6 (8.75) | 6(8) | 5.5(24) |
| Range | 1–91 | 0–122 | 0–122 | 1–95 | 0–122 |
| DT sensitivity, ψ | DT duration (days) | Total radiation (Gy) | TCP |
| 5 | 238 | 76.84* | 0.499 |
| 247 | 72.32* | 0.505 | |
| 50 | 204 | 74.58* | 0.503 |
| 222 | 63.28 | 0.500 |
| Variable | Group APioglitazone(n = 42) | Group BOther treatment(n = 39) | Pvalue |
| Age, years (range) | 64.3 ± 8.1 (44-77) | 64.8 ± 7.5 (48-81) | 0.78 |
| Female gender, n (%) | 27 (64) | 28 (72) | 0.49 |
| Hypertensives, n (%) | 31 (74) | 32 (82) | 0.27 |
| Hyperlipidaemics, n (%) | 26 (62) | 27 (69) | 0.64 |
| Ever smokers, n (%) | 14 (33) | 10 (26) | 0.48 |
| Family history of CAD | 23 (55) | 24 (62) | 0.35 |
| Duration of diabetes, years | 10.2 ± 6.6 | 9.0 ± 6.9 | 0.41 |
| Metformin | 31 (74) | 26 (67) | 0.63 |
| Sulfonylurea | 31 (74) | 27 (69) | 0.81 |
| Metformin & Sulfonylurea | 20 (48) | 15 (38) | 0.50 |
| Antihypertensives, n (%) | 27 (64) | 27 (69) | 0.81 |
| Diuretics, n (%) | 6 (14) | 8 (21) | 0.56 |
| ACE or AT-II inhibitors, n (%) | 22 (52) | 22 (56) | 0.82 |
| β-blockers, n (%) | 1 (2) | 3 (8) | 0.35 |
| Calcium channel blockers, n (%) | 12 (29) | 11 (28) | 1.00 |
| Statin, n (%) | 18 (43) | 17 (44) | 1.00 |
| Antiplatelets, n (%) | 5 (12) | 4 (10) | 1.00 |
| Clonidine group | Clonidine and Dextromethorphan group | P value | |
| Number of patients | 30 | 30 | — |
| Initial symptoms score | 2.7 ± 1.9 | 3.4 ± 2.6 | 0.17 |
| Age | 29.3 ± 3.5 | 28.9 ± 4.3 | 0.56 |
| Systolic blood pressure | 125.2 ± 13.6 | 125.4 ± 12.5 | 0.67 |
| Diastolic blood pressure | 75.4 ± 10.1 | 74.9 ± 10.1 | 0.98 |
| FBP-OSEM | FBP-TOF | FBP-TPSF | OSEM-TOF | OSEM-TPSF | TOF-TPSF | |
| 2 min | 0.40 | 0.74 | 0.64 | 0.53 | 0.64 | 0.87 |
| 5 min | 0.34 | 0.66 | 0.55 | 0.59 | 0.71 | 0.87 |
| 10 min | 0.86 | 0.98 | 0.73 | 0.87 | 0.86 | 0.85 |
| 30 min | 0.91 | 0.94 | 0.80 | 0.85 | 0.90 | 0.94 |
| Active Synchronous | Passive Synchronous | Active Synchronous | Active Asynchronous | |
| Congruent | Congruent | Incongruent | Congruent | |
| FMD group | ||||
| Ownership statements vs. Ownership controls | Z = -3.757; p < 0.001 | Z = -3.427; p = 0.001 | Z = -2.379; p = 0.017 | Z = -0.880; p = 0.379 |
| Agency statements Vs. Agency controls | Z = -3.542; p < 0.001 | Z = -1.700; p = 0.089 | Z = -4.019; p < 0.001 | Z = -0.916; p = 0.360 |
| Ownership statements vs. Agency statements | Z = -2.534; p = 0.011 | Z = -3.082; p = 0.002 | Z = -3.827; p < 0.001 | Z = -2.508; p = 0.012 |
| HC group | ||||
| Ownership statements vs. Ownership controls | Z = -3.666; p < 0.001 | Z = -3.626; p < 0.001 | Z = -3.163; p = 0.002 | Z = -0.427; p = 0.669 |
| Agency statements vs. Agency controls | Z = -3.925; p < 0.001 | Z = -0.987; p = 0.324 | Z = -3.927; p < 0.001 | Z = -1.442; p = 0.149 |
| Ownership statements vs. Agency statements | Z = -3.341; p = 0.001 | Z = -2.834; p = 0.005 | Z = -3.788; p < 0.001 | Z = -1.661; p = 0.097 |
| Storage Condition (−80 °C) | Fucoxanthin | Fucoxanthinol | ||||
| Concentration (ng/mL) | Accuracy (%) | RSD (%) | Concentration (ng/mL) | Accuracy (%) | RSD (%) | |
| 1 freeze-thaw cycle | 12.25 | 82.55 | 4.03 | 9.4 | 99.60 | 4.83 |
| 90.0 | 87.40 | 1.78 | 75 | 89.05 | 5.00 | |
| 360 | 80.35 | 3.78 | 300 | 89.45 | 4.03 | |
| 2 freeze-thaw cycles | 12.25 | 102.20 | 6.64 | 9.4 | 101.90 | 12.63 |
| 90.0 | 80.35 | 0.44 | 75 | 91.30 | 8.83 | |
| 360 | 86.75 | 3.67 | 300 | 91.75 | 8.25 | |
| 3 freeze-thaw cycles | 12.25 | 113.0 | 7.51 | 9.4 | 118.0 | 5.52 |
| 90.0 | 90.55 | 3.36 | 75 | 99.70 | 6.10 | |
| 360 | 85.95 | 1.89 | 300 | 98.60 | 0.14 |
| Characteristic | Frequency | Percent | M (SD) | Range |
| Age | 51.50 (14.56) | 18–89 | ||
| Duration of RD symptoms in years | 18.84 (16.49) | 0–75 | ||
| Years since RD diagnosis | 9.76 (11.46) | 0–70 | ||
| Number of RDs perparticipant | ||||
| 1 | 1058 | 87% | ||
| 2 | 130 | 11% | ||
| 3 | 22 | 2% | ||
| 4 | 4 | <1% | ||
| 5 | 4 | <1% | ||
| Gender | ||||
| Female | 935 | 77% | ||
| Male | 279 | 23% | ||
| Other | 4 | <1% | ||
| Income | ||||
| under $10,000 | 58 | 5% | ||
| $10,000–20,000 | 95 | 8% | ||
| $20,001–30,000 | 118 | 10% | ||
| $30,001–45,000 | 127 | 11% | ||
| $45,001–60,000 | 161 | 14% | ||
| $60,001–75,000 | 128 | 11% | ||
| $75,001–90,000 | 107 | 9% | ||
| $90,001 and above | 376 | 32% | ||
| Race/ethnicity | ||||
| American Indian orAlaska native | 11 | 1% | ||
| Asian | 23 | 2% | ||
| Black or African American | 13 | 1% | ||
| Hispanic or Latino/a | 31 | 3% | ||
| Native Hawaiian orPacific Islander | 2 | 6% | ||
| White | 1149 | 94% | ||
| Other | 31 | 3% |
| Tumbi hospital (%) | Dodoma hospital (%) | All (%) | |
| Occupational injury | |||
| Needle stick (used needle) | 64 (37.4)* | 41 (17.8) | 105 (26.2) |
| Blood stained sharp objects | 64 (37.4)* | 37 (16.1) | 101 (25.2) |
| Blood or body fluid splash | 81 (47.4)* | 73 (31.7) | 154 (38.4) |
| Blood or body fluid contact with ulcerated or abraded skin | 63 (36.8)* | 38 (16.5) | 101 (25.2) |
| Human bite | 45 (26.3)* | 21 (9.1) | 66 (16.5) |
| At least one occupational injury | 98 (57.3)* | 94 (40.9) | 192 (47.9) |
| Managing occupational exposure | |||
| Good practice | 118 (69.0) | 158 (68.7) | 276 (68.8) |
| Year | 2010 | 2010 |
| Group | BFM | Japanese Childhood AML Cooperative Study |
| Induction Therapy | ATRA+IDA+VP/CA+VP+DNR | ATRA+IDA+CA |
| No. of Pts | 81 | 58 |
| Consolidation Therapy | CA+IDA+HD-CA+VP16 | HD-CA+MTZ+ATRA+PIRARUBI CIN+ACLARUBICIN |
| EFS (%) | 73 (5 years) | 91 (7 years) |
| OS (%) | 89 (5 years) | 93 (7 years) |
| Size of facial image | Size of LBP operator | ||
| 3 × 3 operator | 5 × 5 operator | 7 × 7 operator | |
| 64 × 64 | 16.617 | 14.656 | 13.966 |
| 96 × 96 | 15.584 | 13.503 | 13.612 |
| 128 × 128 | 16.784 | 12.878 | 12.693 |
| 160 × 160 | 16.803 | 13.376 | 12.730 |
| 192 × 192 | 17.711 | 13.809 | 13.119 |
| 220 × 250 | 18.365 | 13.460 | 12.813 |
| Variables | Group C (n = 35) | Group T (n = 35) | P value |
| Time from TAP to incision(min) | 47.0(44.3–50.2) | 46.9(43.5–47.8) | 0.626 |
| Incision length(cm) | 30.0(23.8–35.0) | 25.0(20.0–35.0) | 0.703 |
| Operation time(min) | 193.9(172.7–287.1) | 193.8(159.7–261.9) | 0.377 |
| Intraoperative intravenous crystalloids | 2250(1750–3030) | 2250(1750–3120) | 0.872 |
| Estimated blood loss (mL) | 200.0(100.00–350.0) | 200.0(100.0–400.0) | 0.345 |
| Urine output(mL) | 200.0(150.0–400.0) | 200.0(140.0–400.0) | 0.894 |
| Intraoperative Propofol(mg) | 1168.7(986.0–1681.1) | 1121.7(866.1–1291.2) | 0.276 |
| Extubation time(min) | 59.9(51.7–85.0) | 45.35(39.9–61.25)* | 0.022 |
| Surgeon | 0.097 | ||
| Group 1 | 10 | 10 | |
| Group 2 | 3 | 0 | |
| Group 3 | 11 | 5 | |
| Group 4 | 7 | 13 | |
| Group 5 | 4 | 7 | |
| Anesthetist | 0.632 | ||
| Group 1 | 19 | 17 | |
| Group 2 | 16 | 18 | |
| Intraoperative ephedrine use | 1.000 | ||
| yes(n) | 4 | 5 | |
| No(n) | 31 | 30 | |
| Intraoperative antihypertensives | 0.002 | ||
| yes(n) | 24 | 10* | |
| No(n) | 11 | 25 |
| Fraction or COMBI | Primary (% activity) | Secondary (EC50, μg/mL) | |||||
| μg/mL | MAR3D7a | MARK1b | HEK293c | BJd | MAR3D7a | MARK1b | |
| f8/c9 | 23.68 | 43.4 | 37 | 2.15 | −0.85 | ||
| f9/c8 | 35.75 | 95.2 | 80.2 | 2.52 | 6.63 | 8.15 | 7.57 |
| f10/c7 | 23.68 | 97.4 | 95 | 8.13 | 4.91 | 0.53 | 0.63 |
| f11/c6 | 14.39 | 96.9 | 96.5 | 5.29 | 0 | 2.02 | 3.6 |
| f12/c5 | 8.37 | 92.8 | 93.4 | 7.42 | 0.7 | 0.61 | 0.81 |
| f13/c5 | 5.57 | 92 | 92.4 | 3.59 | 0.45 | 0.39 | 0.45 |
| f14/c4 | 5.11 | 89.9 | 96 | 5.05 | −0.48 | 0.86 | 2.07 |
| f15/c4 | 7.43 | 84.9 | 97.6 | 6.94 | 0.56 | 1.11 | 10.61 |
| f16/c3 | 11.14 | 84.4 | 93.7 | 10.1 | 1.13 | 0.21 | 4.77 |
| f17/c2 | 6.96 | 95.7 | 94.6 | 1.09 | 1.48 | 1.66 | 1.7 |
| f18/c2 | 5.11 | 76.9 | 39 | 3.12 | −0.94 | ||
| f19/c1 | 4.18 | 35.6 | 21.2 | 1.29 | 0.64 |
| Characteristic | mean ± SD, or N(%) |
| Gender | |
| Male | 85 (38.3) |
| Female | 137(61.7) |
| Marital status | |
| Married | 205 (92.3) |
| Not married | 17 (7.7) |
| Mean age (years) | 64.5 ± 6.4 |
| Age categories | |
| <60 | 48 (21.6) |
| 60-69 | 119 (53.6) |
| ≥70 | 55 (24.8) |
| Education | |
| Illiteracy or elementary school | 21 (9.5) |
| Junior high school | 85 (38.3) |
| Senior high school | 64 (28.8) |
| Technical school or college | 52 (23.4) |
| Family per capita month income (RMB) | |
| <2000 | 102 (45.9) |
| ≥2000 | 120 (54.1) |
| Family history of diabetes | |
| Yes | 86 (38.7) |
| No | 136 (61.3) |
| Clinical symptoms | |
| Yes | 96 (43.2) |
| No | 126 (56.8) |
| Complications | |
| Yes | 155 (69.8) |
| No | 67 (30.2) |
| Duration of diabetes (years) | |
| <4 | 64 (28.8) |
| 5-9 | 72 (32.4) |
| 10-14 | 56 (25.2) |
| ≥15 | 30 (13.5) |
| Mean BMI (kg/m2) | 24.9 ± 3.4 |
| BMI categories* | |
| <24 | 91 (41.0) |
| ≥24 | 131 (59.0) |
| Adsorbent | Concentration (mg/L) | qe(exp) (mg/g) | Pseudo first order values | Pseudo second order values | |||||
| qe(Calc) (mg/g) | k1 (min−1) | R2 | qe(Calc) (mg g−1) | k2 (g mg−1 min−1) | h (mg g−1min−1) | R2 | |||
| CS | 260 | 133.71 | 123.19 | 7.83 × 10−2 | 0.9959 | 142.85 | 7.96 × 10−4 | 16.24 | 0.9980 |
| 300 | 169.23 | 127.84 | 7.18 × 10−2 | 0.9950 | 169.49 | 8.27 × 10−4 | 23.75 | 0.9983 | |
| 340 | 191.29 | 125.14 | 6.52 × 10−2 | 0.9915 | 196.07 | 8.42 × 10−4 | 32.37 | 0.9973 | |
| 380 | 185.93 | 151.01 | 6.70 × 10−2 | 0.9953 | 199.60 | 5.74 × 10−4 | 22.87 | 0.9979 | |
| TS | 260 | 133.71 | 74.03 | 10.13 × 10−2 | 0.9904 | 140.84 | 2.14 × 10−3 | 42.45 | 0.9985 |
| 300 | 145.91 | 92.44 | 9.70 × 10−2 | 0.9968 | 147.05 | 1.69 × 10−3 | 36.54 | 0.9985 | |
| 340 | 167.81 | 104.47 | 9.44 × 10−2 | 0.9952 | 172.41 | 1.38 × 10−3 | 41.02 | 0.9978 | |
| 380 | 149.19 | 73.65 | 9.05 × 10−2 | 0.9961 | 153.84 | 2.00 × 10−3 | 47.33 | 0.9980 |
| Item | X1 (h) | X2 (°C) | X3 (Ac:Al) a | X4 (%) | Predicted yield (%) | Experimental yield (%) |
| Lipozyme® RMIM | 4.00 | 57.51 | 2.12 | 46.41 | 97.56 ± 3.61 | 94.21 ± 1.56 |
| Novozym® 435 | 3.65 | 57.84 | 2.35 | 34.38 | 98.39 ± 1.61 | 98.24 ± 0.11 |
| General recommendations | Rehabilitation should be undertaken by individuals with relevant skills and knowledge communication between teams and professionals over the rehabilitation pathway should occur |
| Pathway-specific recommendations | |
| During critical care stay | Assess risk of post-ICU disability |
| Commence goal-oriented rehabilitation early | |
| Involve families and carers | |
| Provide illness-related information to patient and family | |
| Optimise provision of nutrition | |
| At ICU discharge | Screen patient for physical and psychological issues |
| Plan individualised rehabilitation programme with defined goals | |
| Provide information to patients and families about rehabilitation pathway, likely morbidity, ICU stay, and transition to general ward environment | |
| During ward based care | Repeat screening for physical and psychological issues |
| Offer individualised rehabilitation programme with defined goals, provided by a multidisciplinary team | |
| Regularly update rehabilitation programme and goals, making specialist referral where appropriate | |
| Offer structured self-directed and supported rehabilitation manual for at least 6 weeks to appropriate patients | |
| Prior to hospital discharge | Perform a functional assessment including physical and psychological elements, evaluating the impact on patient activities of daily living and participation |
| Ensure support for outstanding issues are arranged, including ongoing rehabilitation by community services | |
| Provide patient and family with relevant information, including information about their ICU stay | |
| At 2–3 months post-ICU discharge | Review patient as outpatient and perform functional assessment |
| Refer for ongoing rehabilitation and/or specialist support according to individual need | |
| Adapted from [36] |
| SNP-candidates | Morph | Uni | Rep | Total |
| Total | 96231 | 74341 | 165790 | |
| Filter coverage | 66569 | 57009 | 113776 | |
| Diff. Bwn. samples | 21417 | 22252 | 42869 | |
| Diff. Bwn. morphs | 11385 | 12953 | 23974 | |
| Delta > 0.5 | AC | 396 | 285 | 672 |
| Delta > 0.5 | SB | 526 | 353 | 872 |
| Delta > 0.75 | AC | 95 | 68 | 159 |
| Delta > 0.75 | SB | 155 | 95 | 248 |
| Delta > 0.95 | AC | 17 | 13 | 30 |
| Delta > 0.95 | SB | 29 | 4 | 33 |
| Variables | Frequency (percentage) | |
| Gender (females) | 212 (58.1) | |
| Age at diagnosis (years): | ||
| ≤ 5 | 24 (6.6) | |
| 6–10 | 170 (46.6) | |
| 11-15 | 171 (46.8) | |
| Residence (urban or semi-urban): | 178 (48.8) | |
| Mitral valve disease | 359 (98.4) | |
| Pure mitral stenosis (all grades) | 35 (10.0) | |
| Mitral stenosis with regurgitation (all grades) | 91 (24.9) | |
| Mitral regurgitation, no stenosis (all grades) | 233 (63.8) | |
| Multi-valvular involvement (mitral valve disease included): | ||
| Aortic valve disease (regurgitation and/or stenosis) | 257 (70.4) | |
| Tricuspid valve disease (regurgitation and/or stenosis) | 299 (81.9) | |
| Mean transmitral diastolic pressure gradient (n = 108): | ||
| <10 mmHg | 4 (3.5) | |
| 10 – 20 mmHg | 40 (35.7) | |
| 21 – 30 mmHg | 61 (54.5) | |
| >30 mmHg | 3 (2.7) | |
| Mitral valve score for severe mitral stenosis (n = 19) | ||
| ≤8 | 2 (10.5) | |
| >8 | 17 (89.5) | |
| Functional class (New York Heart Association): | ||
| I | 10 (2.7) | |
| II | 276 (75.6) | |
| III | 27 (7.4) | |
| IV | 52 (14.2) | |
| On secondary prophylaxis against recurrence of rheumatic fever (at the time of referral) | 272 (74.5) |
| Variable | Odds ratio | 95% confidence interval | Coefficient | S.E. | Significance | |
| Predisposing | ||||||
| Race/ethnicity (ref. = non-Hispanic White) | ||||||
| Black | 1.738 | 1.371 | 2.203 | 0.552 | 0.120 | *** |
| Hispanic/Latina | 1.799 | 1.126 | 2.875 | 0.587 | 0.239 | ** |
| Other race | 0.726 | 0.444 | 1.187 | −0.319 | 0.250 | |
| Age | 1.000 | 0.992 | 1.009 | 0.001 | 0.004 | |
| Educational attainment (ref. = no high school diploma) | ||||||
| High school | 1.092 | 0.781 | 1.529 | 0.088 | 0.171 | |
| Some college | 1.068 | 0.743 | 1.535 | 0.065 | 0.185 | |
| College or greater | 1.349 | 0.941 | 1.935 | 0.299 | 0.184 | |
| Married | 1.304 | 1.094 | 1.554 | 0.265 | 0.089 | ** |
| Enabling | ||||||
| Poverty status (1 = poor, 0 = non-poor) | 0.979 | 0.714 | 1.341 | −0.021 | 0.160 | |
| Employment status (1 = employed, others = 0) | 1.206 | 0.994 | 1.463 | 0.186 | 0.098 | * |
| Insured (1 = having health insurance, 0 = no health insurance) | 3.857 | 2.616 | 5.687 | 1.349 | 0.198 | *** |
| Source of healthcare | ||||||
| Community health center | 2.728 | 1.449 | 5.138 | 1.003 | 0.322 | ** |
| Private practice | 2.053 | 1.228 | 3.432 | 0.719 | 0.262 | ** |
| Outpatient clinic | 1.671 | 0.882 | 3.166 | 0.513 | 0.326 | |
| Experienced medical discrimination | 0.784 | 0.563 | 1.092 | −0.243 | 0.168 | |
| Community connection | 1.056 | 0.988 | 1.130 | 0.054 | 0.034 | |
| Group membership | 1.060 | 0.996 | 1.128 | 0.058 | 0.031 | * |
| Respondent residence—city (ref = suburban) | 1.026 | 0.849 | 1.240 | 0.025 | 0.096 | |
| Need | ||||||
| Poor or fair self-rated health | 0.700 | 0.570 | 0.861 | −0.356 | 0.105 | *** |
| Constant | −1.475 | 0.462 | *** | |||
| N | 3261 | |||||
| Akaike Inf. Crit. | 3613.910 |
| Method: 95% LSD | |||
| Pass | Count | LS Mean | Homogeneous Groups |
| 0 | 21 | 1135.93 | X |
| 1 | 21 | 1245.32 | X |
| 2 | 21 | 1285.31 | X |
| 3 | 21 | 1287.18 | X |
| 4 | 21 | 1307.01 | X |
| 5 | 21 | 1320.83 | X |
| Transgene | Description | Efficacy | Promoter | Assay | Publication |
| R2 | SIV rev + env shRNA | 68%–80% inhibition of viral replication | U6 | SIV challenge, CEMx174 cell line | Parket al. 2005 [77] |
| L2R | HIV LTR + rev miRNA cassette | >98% inhibition of viral replication | CMV | HIV challenge, U87.CD4.CXCR4 cell line | Parket al. 2009 [78] |
| TAR + L2R | Tat inducible HIV LTR + rev miRNA cassette + TAR | >98% inhibition of viral replication | Tat inducible LTR-Hsp fusion | ||
| TAR + R | Tat inducible rev miRNA cassette + TAR | >98% inhibition of viral replication | Tat-inducible LTR-Hsp fusion | ||
| TAR | TAR | >98% inhibition of viral replication | LTR | ||
| Sh1 | anti tat/rev shRNA | 4 log reduction of viral replication | U6 | HIV challenge, CD34-derived macrophages | Tayloret al. 2008 [79] |
| C46 | membrane associated fusion inhibitor | 4 log reduction of viral replication | MSCV | ||
| Sh1 + C46 + RevM10 | tat/rev shRNA + membrane-associated fusion inhibitor + dominant negative Rev | significantly increased relative to C46 alone | U6, MSCV, PGK | HIV challenge of protected and unprotected cells in CEMx174 cell line | |
| C46 | membrane associated fusion inhibitor | 5.2-fold increase in cell survival +3.1-fold decrease in HIV p24/cell | MSCV | ||
| 4 log reduction of viral replication | SFFV | SHIV challenge, CEM.NKR-CCR5 lymphocytes | Kiemet al. 2010 [27] | ||
| 15–20 fold reduction of viral replication | SFFV | SHIV or HIV single viral cycle challenge, MAGI-CCR5 cell line | |||
| SI + C46 | tat/rev shRNA + membrane associated fusion inhibitor | 5 fold reduction of viral replication | U6, SFFV | ||
| SII + SI + R5 + C46 | two tat/rev shRNAs + CCR5 shRNA + membrane associated fusion inhibitor | 23 fold reduction of viral replication | H1, SFFV | ||
| 4 log reduction of viral replication | SHIV challenge, CEM.NKR-CCR5 lymphocytes | ||||
| SI + C46 | tat/rev shRNA + C46 | 4 log reduction of viral replication | U6, SFFV | ||
| SII + SI + R5 | two tat/rev shRNAs + CCR5 shRNA | 180 fold reduction of viral replication | H1 |
| Characteristic* | Type 2 diabetes cases (n=1775) | Controls (n=1295) | p value† |
| Age (years) | 65.8 (9.2) | 65.7 (9.1) | 0.93 |
| Female, n (%) | 1,014 (57) | 731 (56) | 0.71 |
| BMI (kg/m2) | 30.6 (5.6) | 28.9 (5.4) | <0.0001 |
| Race/ethnicity, n (%) | 0.15 | ||
| Caucasian | 608 (34) | 493 (38) | |
| Hispanic | 937 (53) | 642 (50) | |
| African American | 216 (12) | 153 (12) | |
| Blood pressure (mm Hg) | |||
| Systolic | 149 (19) | 148 (18) | 0.32 |
| Diastolic | 85 (11) | 86 (10) | 0.0008 |
| Hypercholesterolemia, n (%)‡ | 1,017 (57) | 673 (52) | 0.003 |
| History of LVH, n (%) | 319 (18) | 174 (13) | 0.0007 |
| History of CHF, n (%)** | 84 (5) | 25 (2) | <0.0001 |
| History of smoking, n (%) | 706 (40) | 507 (39) | 0.73 |
| ARVC Total (N = 155) | ECG-positive ARVC (N = 89) | ECG-negative ARVC (N = 66) | p-valueECG-positive vs ECG-negative | |
| Age | 42.1 ± 17.3 | 42.0 ± 17.4 | 41.7 ± 17.6 | 0.861 |
| Sex (% male) | 106 (68.4%) | 63 (70.8%) | 43 (65.2%) | 0.488 |
| Proband (%) | 111 (71.6%) | 71 (79.8%) | 30 (45.5%) | 0.012 |
| I. Imaging | 155 (100%) | 89 (100%) | 66 (100%) | 1.000 |
| major, % | 111 (71.6%) | 68 (76.4%) | 43 (65.2%) | 0.082 |
| minor, % | 89 (57.4%) | 60 (67.4%) | 29 (43.9%) | 0.005 |
| II. Tissue characterization of the wall, biopsies performed (% of patients) | 70 (45.2%) | 39 (43.8%) | 31 (47.0%) | 0.745 |
| major, % | 53 (75.7%) | 31 (79.1%) | 22 (71.0%) | 0.576 |
| minor, % | 63 (90.0%) | 36 (92.3%) | 27 (87.1%) | 0.454 |
| III. Repolarization abnormality | ||||
| major, % | 54 (34.8%) | 54 (60.7%) | 0 (0.0%) | <0.001 |
| minor, % | 20 (12.9%) | 20 (22.5%) | 0 (0.0%) | <0.001 |
| IV. Depolarization abnormality | ||||
| major, % | 13 (8.4%) | 13 (14.6%) | 0 (0.0%) | <0.001 |
| minor, % | 17 (11.0%) | 17 (19.1%) | 0 (0.0%) | <0.001 |
| V. Arrhythmia | ||||
| major, % | 44 (28.4%) | 26 (29.2%) | 18 (27.3%) | 0.858 |
| minor, % | 64 (41.3%) | 42 (47.2%) | 22 (33.3%) | 0.1000 |
| VI. Family history | ||||
| major, % | 84 (54.2%) | 48 (53.9%) | 35 (53.0%) | 1.000 |
| VII. Genotype positive | 48 (31.0%) | 29 (32.6%) | 19 (28.8%) | 0.726 |
| PLN (% genotype positive) | 1 (2.1%) | 0 (0.0%) | 1 (5.3%) | 0.396 |
| TTN (% genotype positive) | 11 (22.9%) | 8 (27.6%) | 3 (15.8%) | 0.488 |
| PKP2 (% genotype positive) | 23 (47.9%) | 17 (58.6%) | 6 (31.2%) | 0.083 |
| DSC2 (% genotype positive) | 2 (4.2%) | 1 (3.5%) | 1 (5.3%) | 1.000 |
| DSG2 (% genotype positive) | 12 (25.0%) | 6 (20.7%) | 6 (31.5%) | 0.501 |
| DSG3 (% genotype positive) | 2 (4.2%) | 1 (3.5%) | 1 (5.30%) | 1.000 |
| DSP (% genotype positive) | 8 (16.7%) | 6 (20.7%) | 2 (10.56%) | 0.4510 |
| Residue | W | Ac(%) | Sn(%) | Sp(%) | Mcc | FPR |
| 7 | 74.94 | 51.80 | 87.33 | 0.43 | 0.13 | |
| 9 | 75.02 | 52.17 | 87.26 | 0.44 | 0.13 | |
| S | 11 | 75.54 | 53.00 | 87.61 | 0.45 | 0.12 |
| 13 | 75.78 | 53.46 | 87.73 | 0.45 | 0.12 | |
| 15 | 76.15 | 54.53 | 87.74 | 0.46 | 0.12 | |
| 7 | 72.44 | 46.76 | 89.11 | 0.41 | 0.11 | |
| 9 | 72.47 | 48.14 | 88.26 | 0.41 | 0.12 | |
| T | 11 | 72.39 | 50.35 | 86.70 | 0.41 | 0.13 |
| 13 | 72.70 | 50.47 | 87.13 | 0.42 | 0.13 | |
| 15 | 72.63 | 50.12 | 87.24 | 0.41 | 0.13 | |
| 7 | 70.38 | 36.69 | 91.60 | 0.36 | 0.08 | |
| 9 | 71.76 | 41.45 | 90.84 | 0.39 | 0.09 | |
| Y | 11 | 71.84 | 41.12 | 91.19 | 0.39 | 0.09 |
| 13 | 72.31 | 42.11 | 91.33 | 0.40 | 0.09 | |
| 15 | 72.12 | 40.74 | 91.88 | 0.39 | 0.08 |
| Lesion | Age | Site | Cytomorphology | IHQ |
| Ganglioneuroma | 80% < 10 years | Retroperitoneum, posterior mediastinum, pelvis, head and neck | Mature ganglion cells, myxoid stroma, schwann cells, neurites | NSE, Syp, PS-100 (+)CK, Actin (-) |
| Ganglioneuroblastoma | 90% < 5 years | Retroperitoneum, posterior mediastinum | Neuroblasts, rosettes, neuropil, mature ganglion cells, myxoid stroma, schwann cells, neurites | NSE, Syp, PS-100 (+)CK, Actin (-) |
| Neuroblastoma | 90% < 5 years | Retroperitoneum, posterior mediastinum | Neuroblasts, rosettes, neuropil, necrosis | NSE, Syp, PS-100, NbP (+)CK, Actin (-) |
| Nerve Sheath Tumors | 30–50 years | Posterior mediastinum, retroperitoneum, limbs | Cohesive aggregates of spindle cells, myxoid background | NSE, PS-100 (+)CK, Actin (-) |
| Proliferative fasciitis, Proliferative myositis | All ages | Limbs, head and neck, chest wall | Spindle cells, plump cells ganglion cell-like cells, lack of myxoid background | Vimentin, Actin, PS-100, SMA (+)Syp, CK, NSE (-) |
| Professional category | Grade | Experience/ service | Annual salary prior to OSD | Annual salary as at 1 July 2009 | Total annual salary package as at 1 July 2009* | % Increase Year 1 | % Accumulative increase Year 2 |
| Medical intern | R117 501 ($13873)^ | R228 828 ($27016) | R314 023 ($37075) | 31 % - 53% | |||
| Medical officer (Community service) | R174 243 ($20572) | R286 086 ($33776) | R392 599 ($46352) | 9.8 % - 18.9% | 6.1% | ||
| Medical officer | Grade 1 | 0 – 4 years | R174 243 ($20572) | R332 016 ($39199) | R365 217 ($43119) | 9 % - 25% | 12% |
| Grade 2 | 5 – 9 years | R247 512 ($29222) | R385 314 ($45492) | R423 846 ($50041) | 26 % - 44% | 14% | |
| Grade 3 | > 10 years | R391 026 ($46166) | R447 174 ($52795) | R491 892 ($58075) | 46 % - 68% | 20% | |
| Medical specialist | Grade 1 | 0 – 4 years | R491 892 ($58075) | 1.8 % - 18% | 13% | ||
| Grade 2 | 5 – 9 years | R554 109 ($65420) | 14.7 % - 32.9% | 20% | |||
| Grade 3 | > 10 years | R624 198 ($73695) | 29.2 % - 49.8% | 26% | |||
| Principal specialist | R769 271 - R962 174 ($90823-113598) | R932 399 ($110083) | 4.6 % - 25.1% | ||||
| Chief specialist | R932 399 ($110083) | R1.2 million ($141677) | 7.9 % - 29% |
| Time (week) | Body weight (kg) | TEE (kcal/day) | Mean energy intake (kcal/day) | Net energy intake (kcal/day) |
| 0 | 69.39 | 1934.33 | 3538.72 | 1604.39 |
| S1 | 68.35 | 1884.53 | 1658 | −226.53 |
| S2 | 66.8 | 1835.21 | 1658 | −177.21 |
| S3 | 65.76 | 1786.36 | 1648.88 | −137.48 |
| S4 | 64.29 | 1737.6 | 1610.88 | −126.72 |
| S5 | 63.33 | 1691.55 | 1645.94 | −45.61 |
| S6 | 62.16 | 1643.45 | 1639.16 | −4.29 |
| S7 | 61.11 | 1595.75 | 1639.03 | 43.28 |
| S8 | 60.31 | 1548.28 | 1634.84 | 86.56 |
| S9 | 59.56 | 1500.8 | 1620.41 | 119.61 |
| S10 | 58.71 | 1453.31 | 1595.31 | 142 |
| S11 | 58.14 | 1405.63 | 1578.72 | 173.09 |
| S12 | 57.28 | 1357.94 | 1525.16 | 167.22 |
| S13 | 56.6 | 1346.8 | 1515.69 | 168.89 |
| S14 | 56.16 | 1335.67 | 1492.84 | 157.17 |
| S15 | 55.69 | 1324.54 | 1459.94 | 135.4 |
| S16 | 54.7 | 1313.39 | 1430.5 | 117.11 |
| S17 | 54.28 | 1302.28 | 1488.81 | 186.53 |
| S18 | 54.08 | 1291.1 | 1486.44 | 195.34 |
| S19 | 53.51 | 1281.22 | 1519.72 | 238.5 |
| S20 | 53.18 | 1271.34 | 1515.47 | 244.13 |
| S21 | 52.99 | 1261.46 | 1538.75 | 277.29 |
| S22 | 52.9 | 1251.58 | 1554.06 | 302.48 |
| S23 | 52.83 | 1241.7 | 1581.19 | 339.49 |
| S24 | 52.57 | 1231.83 | 1641.63 | 409.8 |
| Sliding window (SW) | Most significant result | ||||
| HCV Genotype | |||||
| 1 | 2 | 1 | 2 | ||
| SNPs/SW | No. of SW | SW | SW | Pvalue | Pvalue |
| 1 | 4 | - | - | - | - |
| 2 | 3 | S1.S2 | S3.S4 | 0.0208* | 0.0546 |
| 3 | 2 | S2.S4 | S2.S4 | 0.0540 | 0.1099 |
| 4 | 1 | S1.S4 | S1.S4 | 0.0397* | 0.1585 |
| AP group | EP group | |
| Number of patients | 149 | 150 |
| Sex | ||
| Male | 114 (76.5 %) | 113 (75.3 %) |
| Female | 35 (23.5 %) | 37 (24.7 %) |
| Median age, years (SD)a | 58.0 (13.0) | 59.0 (13.0) |
| ECOG PS | ||
| 0 | 42 (28.2 %) | 32 (21.3 %) |
| 1 | 107 (71.8 %) | 118 (78.7 %) |
| Stage | ||
| IIIB | 3 (2.0 %) | 9 (6.0 %) |
| IV | 146 (98.0 %) | 141 (94.0 %) |
| Metastasisb | 148 (99.3 %) | 144(96.0 %) |
| Lung | 18 (12.1 %) | 22 (14.7 %) |
| Bone | 60 (40.3 %) | 65 (43.3 %) |
| Brain | 30 (20.1 %) | 17 (11.3 %) |
| Liver | 37 (24.8 %) | 41 (27.3 %) |
| Other | 82 (55.0 %) | 78 (52.0 %) |
| MicroRNA | No. of brain-expressed target genes | No. of brain-expressed target genes, P<0.05 | P enrichment | No. of significant targets (corr) | No. of significant pathways |
| miR-499-5p | 286 | 59 | 0.7172 | 4 | 12 |
| miR-708-5p | 174 | 37 | 0.9265 | 2 | 1 |
| miR-1908-5p | 56 | 17 | 0.1422 | 1 | 5 |
| FEV1 loss < 15% (n = 28) | FEV1 loss ≥15% (n = 7) | p-value | |
| Age | 37 ± 13 | 45 ± 10 | 0.11 |
| FEV1% pred.at T0 | 90 ± 17 | 98 ± 13 | 0.25 |
| FEV1/FVC at T0 | 77 ± 9 | 72 ± 7 | 0.25 |
| Current smoking | 8 (29%) | 2 (29%) | 1.0 |
| Pack years* | 11 (17) | 11 (17) | 0.42 |
| Total exposure time (months) | 46 (91) | 62 (169) | 0.32 |
| Symptomatic exposure time (months) | 11 (19) | 19 (49) | 0.40 |
| Antigen | Labeled cells | Clone | Conjugate | Sourcea |
| CD45 | Pan-leukocyte | YKIX716.13 | PE | AbD Serotec |
| CD18 | Pan-leukocyte | CA1.4E9 | AF647 | AbD Serotec |
| CD3 | T cells | CA17.2A12 | FITC | AbD Serotec |
| CD5 | T cells | YKIX322.2 | PE | AbD Serotec |
| CD4 | T helper/regulatory cells, neutrophils, activated monocytes | YKIX302.9 | FITC | AbD Serotec |
| CD8α | Cytotoxic T cell | YCATE55.9 | PE | AbD Serotec |
| TCRαβ | T cells | CA15.8G7 | None | UC-Davis |
| CD21 | B cells | B-ly4 | PE | BD-Biosciences |
| CD22 | B cells | RFB4 | PE | Abcam |
| CD14 | Monocytes | Tük4 | PE | Dako |
| CD34 | Stem cell | 1H6 | PE | BD-Biosciences |
| MHCII | Lymphocytes, monocytes | YKIX334.2 | FITC | AbD Serotec |
| CD11b | Neutrophils, monocytes | CA16.3E10 | None | AbD Serotec |
| CD11c | Monocytes, neutrophils, | CA11.6A1 | None | AbD Serotec |
| CD11d | T subset, some monocytes | CA11.8H2 | None | AbD Serotec |
| CD1c | T subset, B subset, monocytes | CA13.9H11 | None | UC-Davis |
| Anti-pmn | Neutrophil | CAD048A | None | VMRD |
| CD90 (Thy-1) | Lymphocytes, monocytes, stem cells, eosinophils | CA1.4G8 | None | UC-Davis |
| CD61 | Platelets | SZ21 | PE | Beckman-Coulter |
| Results of conventional RT-PCR | Total | |||
| Positive | Negative | |||
| Results of NanoSign® Influenza A/B antigen kit | Positive | 158 | 23 | 181 |
| Negative | 41 | 801 | 842 | |
| Total | 199 | 824 | 1,023 |
| Independent variables | Unadjusted Rate Ratio (95 % CI)a | P value | Adjusted Rate Ratio (95 % CI)b | P value |
| Age at each pre-recruitment year (per year) | 1.0 (1.0. 1.0) | 0.048 | 1.0 (1.0, 1.0) | 0.012 |
| Time (per year) | 1.2 (1.1. 1.2) | <0.001 | 1.1 (1.0, 1.1) | <0.001 |
| Female gender | 1.1 (0.9, 1.5) | 0.349 | 1.0 (0.8, 1.2) | 0.813 |
| Aboriginals (yes vs. no) | 0.9 (0.7, 1.3) | 0.635 | 1.1 (0.8, 1.4) | 0.617 |
| White (yes vs. no) | 1.1 (0.8, 1.4) | 0.594 | 0.9 (0.7, 1.1) | 0.217 |
| Schizophrenia (yes vs. no) | 7.7 (6.4, 9.3) | <0.001 | 4.7 (3.9, 5.6) | <0.001 |
| Bipolar disorder (yes vs. no) | 5.7 (4.6, 7.0) | <0.001 | 2.2 (1.8, 2.6) | <0.001 |
| Personality disorder (yes vs. no) | 3.0 (2.3, 3.9) | <0.001 | 1.6 (1.8, 2.6) | <0.001 |
| Depressive disorder (yes vs. no) | 3.2 (2.7, 3.8) | <0.001 | 1.6 (1.3, 1.9) | <0.001 |
| Anxiety-neurotic disorder (yes vs. no) | 2.8 (2.3, 3.5) | <0.001 | 1.5 (1.2, 1.8) | <0.001 |
| Alcohol dependence (yes vs. no) | 2.5 (1.9, 3.2) | <0.001 | 1.5 (1.2, 2.0) | 0.001 |
| Drug dependence (yes vs. no) | 2.4 (2.0, 2.9) | <0.001 | 1.5 (1.2, 1.7) | <0.001 |
| Non-psychiatric service utilizationc | ||||
| High (≥32) | 3.4 (2.7, 4.3) | <0.001 | 2.3 (1.9, 2.8) | <0.001 |
| Medium (16 to 31) | 2.1 (1.7, 2.7) | <0.001 | 1.5 (1.2, 1.8) | <0.001 |
| Low (≤15) | Reference | - | Reference | - |
| Patients with: | ||||||
| 2 positive Criteria | Crit1+ | Crit2+ | Crit3+ | Crit4+ | ||
| Crit2+ | 11 | |||||
| Crit3+ | 75 | 36 | ||||
| Crit4+ | 10 | 7 | 19 | |||
| Crit5+ | 9 | 2 | 4 | 4 | ||
| 3 positive Criteria | Crit12+ | Crit13+ | Crit14+ | Crit23+ | Crit24+ | |
| Crit3+ | 109 | |||||
| Crit4+ | 4 | 39 | 10 | |||
| Crit5+ | 9 | 78 | 5 | 5 | 8 | |
| 4 positive Criteria | Crit1234+ | Crit1235+ | Crit1245+ | Crit1345+ | Crit2345+ | |
| 22 | 37 | 9 | 63 | 0 | ||
| 5 positive Criteria | Crit12345+ | |||||
| 35 |
| No. | Group | Treatment | Radiationa | Microgravity |
| 1 | Spaceflight | Spaceflight static slot | 1.92 mGy | μg |
| 2 | Spaceflight control | Spaceflight 1g-centrifuge slot | 2.27 mGy | 1g |
| 3 | Ground control | Ground static slot | – | 1g |
| Haplogroup | Gene vs Geography | p | Gene vs Language | p |
| R5 | 0.1276 | 0.0475 | 0.1748 | 0.2 |
| R6 | 0.2654 | 0.037 | 0.13248 | 0.19 |
| R7 | 0.299 | 0.023 | 0.219 | 0.225 |
| R8 | 0.211496 | 0.01753 | 0.23248 | 0.31 |
| R30 | 0.189917 | 0.127 | 0.1348 | 0.28 |
| R31 | 0.172 | 0.1873 | 0.141 | 0.25 |
| Characteristics | Variables | AMA (%) | STMA (%) |
| Gender | Male | 27 | 26 |
| Female | 23 | 24 | |
| Marital status | Single (never married) | 6.1 | 2.7 |
| Married | 32.7 | 40.1 | |
| Cohabitation | 2 | 2 | |
| Separated | 1.4 | 2.7 | |
| Divorced | 5.4 | 1.4 | |
| Widowed | 3.4 | 0 | |
| Level of education | No education | 15.4 | 12.8 |
| Primary | 16.8 | 15.4 | |
| Secondary | 16.1 | 17.4 | |
| Tertiary | 2 | 4 | |
| Employment | No | 36.7 | 33.3 |
| Yes | 14.3 | 15.7 | |
| Age group | 40–44 | 2 | 3.3 |
| 45–49 | 11 | 7.3 | |
| 50–54 | 12 | 8 | |
| 55–59 | 8.7 | 10.7 | |
| 60–64 | 6 | 6.7 | |
| 65–69 | 4 | 6 | |
| 70+ | 6 | 8 | |
| Number of years living in the city (year group) | 35–39 | 13.3 | 10.7 |
| 40–44 | 8 | 10 | |
| 45–49 | 10.7 | 9.3 | |
| 50–54 | 7.3 | 6 | |
| 55–59 | 4.7 | 6 | |
| 60–64 | 2 | 2.7 | |
| 65–69 | 2 | 1.3 | |
| 70+ | 2 | 4 | |
| N = 150 | 75 | 75 |
| Support Male Circumcision | ||||
| Variables | Total (4, 874) | Yes (3,276) | No (1,598) | P-values |
| n (%) | n (%) | n (%) | ||
| Education | ||||
| No education | 892 (18.3) | 431 (48.3) | 461 (51.7) | <0.0001 |
| Primary | 3125 (64.1) | 2130 (68.2) | 995 (31.8) | |
| Secondary | 710 (14.6) | 592 (83.4) | 118 (16.6) | |
| Tertiary | 147 (3.02) | 123 (83.7) | 24 (16.3) | |
| Age groups | ||||
| 15–24 | 1356 (27.8) | 956 (70.5) | 400 (29.5) | <0.0001 |
| 25–34 | 1819 (37.3) | 1267 (69.7) | 552 (30.4) | |
| 35–44 | 1195 (24.5) | 769 (64.4) | 426 (35.7) | |
| 45 and over | 504 (10.3) | 284 (56.4) | 220 (43.7) | |
| Wealth Index | <0.0001 | |||
| Poorest | 1032 (21.2) | 511 (49.5) | 521 (50.5) | |
| Poorer | 1113 (22.8) | 674 (60.6) | 439 (39.4) | |
| Middle | 985 (20.2) | 682 (69.2) | 303 (30.8) | |
| Richer | 878 (18.0) | 660 (75.2) | 218 (24.8) | |
| Richest | 866 (17.8) | 749 (86.5) | 117 (13.5) | |
| Religion | ||||
| Catholic | 2093 (42.9) | 1206 (57.6) | 887 (42.4) | <0.0001 |
| Protestant | 1572 (32.3) | 1069 (68.0) | 503 (32.0) | |
| Pentecostal | 396 (8.1) | 263 (66.4) | 133 (33.6) | |
| Muslim | 604 (12.4) | 575 (95.2) | 29 (4.8) | |
| Other religion | 209 (4.3) | 163 (78.0) | 46 (22.0) | |
| Place of Residence | ||||
| Urban | 643 (13.2) | 542 (84.3) | 101 (15.7) | <0.0001 |
| Rural | 4231 (86.8) | 2734 (64.6) | 1497 (35.4) | |
| Access to Health facility | ||||
| Yes | 1788 (36.7) | 1262 (70.6) | 526 (29.4) | <0.0001 |
| No | 3086 (63.3) | 2014 (65.3) | 1072 (34.7) | |
| Ethnic groups | ||||
| Baganda | 596 (12.23) | 523 (87.75) | 73 (12.25) | <0.0001 |
| Banyankole | 402 (8.25) | 274 (68.16) | 128 (31.84) | |
| Basoga | 481 (9.87) | 464 (96.47) | 17 (3.53) | |
| Bakiga | 266 (5.46) | 155 (58.27) | 111 (41.73) | |
| Itesa | 449 (9.21) | 243 (54.12) | 206 (45.88) | |
| Other | 2680 (54.99) | 1,617 (60.34) | 1,063 (39.66) |
| Pollutants | No. of other sites | Median correlation (range) |
| Fine particles and components | ||
| 24-hr avg PM2.5 | 12b | 0.88 (0.46–0.95) |
| 24-hr avg PM2.5 | 3c | 0.88 (0.76–0.95) |
| Major ions | ||
| 24-hr avg SO42– | 3 | 0.90 (0.76–0.94) |
| 24-hr avg NO3– | 3 | 0.88 (0.75–0.90) |
| Carbon | ||
| 24-hr avg OC | 3 | 0.43 (0.38–0.69) |
| 24-hr avg EC | 3 | 0.47 (0.37–0.52) |
| Metals and metalloids | ||
| 24-hr avg Si | 3 | 0.96 (0.68–0.96) |
| 24-hr avg K | 3 | 0.71 (0.60–0.74) |
| 24-hr avg Ca | 3 | 0.35 (0.30–0.37) |
| 24-hr avg Fe | 3 | 0.54 (0.39–0.74) |
| 24-hr avg Cu | 3 | 0.03 (–0.09–0.05) |
| 24-hr avg Zn | 3 | 0.03 (–0.02–0.11) |
| 24-hr avg Pb | 3 | 0.08 (0.04–0.22) |
| Criteria gases | ||
| 8-hr max O3 | 13d | 0.85 (0.72–0.94) |
| 1-hr max CO | 3 | 0.62 (0.17–0.71) |
| 1-hr max NO2 | 8 | 0.64 (0.27–0.70) |
| 1-hr max SO2 | 10 | –0.03 (–0.10–0.12) |
| Abbreviations: avg, average; max, maximum. aThese are partial correlations, computed as the correlations between residuals from linear models for each of the pollutants that included all of the covariates in our epidemiologic models; all correlations exclude data from 4 July 2001, 4 July 2002, and 5 July 2002. bIncludes data from all sites at which PM2.5 was measured. cIncludes data from a subset of PM2.5 sites at which PM2.5 components were also measured (every 3 or 6 days). dOnly two sites other than Tudor Ave. provided year-round O3 data; restricting the analysis to these sites produced similar results: median, 0.84 (range, 0.82–0.87). |
| Tertiary hospitals (n = 50) Mean (SD) score | General hospitals (n = 109) Mean (SD) score | |
| Reduction of rate of intubation and ventilation | 4.5 (1.0) | 4.8 (0.7) |
| Reduction in need for inter-hospital transfer | 4.0 (1.2) | 4.7 (0.7) |
| Reduction in length of stay | 3.9 (1.0) | 4.2 (0.8) |
| Reduction in complication rate | 3.9 (1.2) | 4.3 (0.9) |
| Improved patient tolerance | 3.9 (1.1) | 4.2 (0.9) |
| Reduced need for sedation | 3.6 (1.2) | 3.5 (1.2) |
| Parent/Carer Satisfaction | 4.0 (0.9) | 3.9 (1.1) |
| Measurement year | 2008 | 2010 | 2013 |
| Participation | |||
| All measured children (n, % of eligible) | 1142 (86) | 1448 (85) | 1868 (91) |
| Girls/boys (% of eligible) | 85/86 | 84/85 | 91/90 |
| Completed FQ (n, % of measured) | 833 (73) | 1085 (75) | 1134 (61) |
| Girls/boys (% of measured) | 76/70 | 76/74 | 61/61 |
| Distribution of children according to individual socioeconomic characteristics from FQ | |||
| Maternal education % low/high | 54/46 | 55/45 | 44/56 |
| Maternal employment | 79/21 | 82/18 | 85/15 |
| % employed/not employed1 |
| Importance of the Water Supply Issue to the Household | Percentage |
| Absolutely not important | 10 |
| Not important | 10 |
| Between important and not important | 8 |
| Important | 38 |
| Very important | 34 |
| Time | Side Swing (°) | Regions | Positioning Accuracy | Average Offset | Relative Accuracy | ||
| dx | dy | mx | my | ||||
| 27 December 2014 15:27 | −3.820 | Yili | 13.141 | −11.581 | −6.212 | 1.665 | 1.721 |
| 9 February 2015 11:10 | −5.532 | Anyang | 6.429 | 5.356 | −3.557 | 1.355 | 1.399 |
| 16 March 2015 13:20 | 4.152 | Songshan | 7.020 | 4.271 | −5.572 | 1.323 | 1.413 |
| 1 May 2015 16:13 | 3.318 | Anyang | 8.381 | −3.564 | −7.586 | 0.831 | 1.896 |
| 23 July 2015 15:27 | −2.243 | Yili | 15.747 | −14.197 | 6.815 | 1.385 | 1.125 |
| 12 September 2015 14:15 | 7.436 | Dongying | 18.288 | 15.734 | −9.323 | 1.255 | 1.133 |
| 20 October 2015 13:30 | −5.616 | Sanya | 21.099 | 16.388 | −13.29 | 1.421 | 0.847 |
| 25 December 2015 16:55 | 2.378 | Taiyuan | 17.676 | −14.988 | −9.372 | 1.006 | 1.155 |
| RMS | 14.464 | 11.916 | 8.197 | 1.302 | 1.374 |
| Type 1 diabetes n = 199 | All controls n = 178 | p value | |
| Sex (male:female) | 98:101 | 84:94 | 0.69 |
| Age (years) | 14.4 ± 1.6 | 14.4 ± 2.1 | 0.80 |
| Height (cm) | 163 ± 10 | 162 ± 11 | 0.25 |
| Weight (kg) | 60.7 ± 14.3 | 54.7 ± 13.8 | <0.0001 |
| BSA (m2) | 1.65 ± 0.22 | 1.57 ± 0.23 | 0.0006 |
| Insulin administration (%) | |||
| Pump | 60.8 | – | |
| Multiple injections | 30.2 | – | |
| Smoking status n (%) | |||
| Never smoked | 181 (92.8) | 63 (100) | |
| Smoked few puffs to a whole cigarette in my life | 9 (4.6) | 0 | |
| Only 2 to 3 cigarettes in my life | 1 (0.5) | 0 | |
| More than 3, but fewer than 100 cigarettes in my life | 1 (0.5) | 0 | |
| >100 cigarettes in my life, none in the past month | 1 (0.5) | 0 | |
| >100 cigarettes in my life, some in the last month but not every day | 1 (0.5) | 0 | |
| >100 cigarettes in my life, at least 1 cigarette every day during the last month | 2 [1] | 0 | |
| BMI (kg/m2) | 22.6 ± 4.3 | 20.6 ± 3.7 | <0.0001 |
| SBP (mmHg) | 113 ± 10 | 110 ± 9 | 0.0005 |
| SBP z-score for height | 0.2 ± 0.9 | −0.1 ± 0.9 | 0.0011 |
| DBP (mmHg) | 62 ± 7 | 58 ± 7 | <0.0001 |
| DBP z-score for height | −0.3 ± 0.6 | −0.6 ± 0.7 | <0.0001 |
| MBP (mmHg) | 77 ± 7 | 75 ± 7 | 0.0053 |
| PP (mmHg) | 51 ± 9 | 52 ± 8 | 0.48 |
| HR (bpm) | 66 ± 9 | 68 ± 12 | 0.036 |
| Diabetes duration (years) | 7.2 ± 3.1 | – | − |
| Glucose (mmol/l) | 9.7 ± 4.4 | 4.7 ± 0.7 | <0.0001 |
| HbA1c (%) | 0.085 ± 0.012 | 0.054 ± 0.002 | <0.0001 |
| HbA1c mmol/mol | 84.9 ± 12.4 | 53.8 ± 2.4 | <0.0001 |
| Cholesterol (mmol/L) | 4.3 ± 0.88 | 4.24 ± 0.83 | 0.5158 |
| HDL cholesterol (mmol/L) | 1.6 ± 0.36 | 1.46 ± 0.28 | 0.0004 |
| LDL cholesterol (mmol/L) | 2.3 ± 0.71 | 2.36 ± 0.74 | 0.6109 |
| Triglycerides (mmol/L) | 0.84 ± 0.37 | 0.93 ± 0.40 | 0.0945 |
| Creatinine (mmol/L) | 54 ± 9 | 56 ± 11 | 0.1149 |
| eGFR (mL/min/1.73 m2) | 113 ± 17 | 108 ± 17 | 0.0405 |
| UK samples positive/total (%) | Nigerian samples positive/total (%) | p value | |
| Molecular markers | |||
| ER | 20/34 (58.8) | 9/34 (26.5) | p = 0.0142 |
| PR | 18/34 (52.9) | 10/34 (29.4) | p = 0.0846 |
| ERBB2 | 15/34 (44.1) | 8/34 (23.5) | p = 0.1241 |
| CCND1 | 9/33 (27.3) | 2/33 (6.1) | p = 0.0475 |
| P53 | 13/34 (38.2) | 17/34 (50) | p = 0.4637 |
| Histological Grade | |||
| Grade 1 | 1/34 (2.9) | 2/34 (5) | p = 1 (Fisher’s exact) |
| Grade 2 | 12/34 (35.3) | 8/34 (23.5) | p = 0.4246 |
| Grade 3 | 21/34 (61.8) | 24/34 (70.6) | p = 0.6082 |
| Healthcare professional | Gender | Description of Role |
| Respiratory Physician | Female | Assessment of COPD and comorbidities, preparation and review of COPD treatment plans |
| Registered Clinic Nurse | Female | Support assessments, administer aspects of treatment plan (eg smoking cessation counselling, instruction in inhaler technique, case coordination |
| Research Assistant | Female | Case coordination, data entry and management |
| General Practitioner | Male | Prepare health care plan, receive and integrate test results in between study visits, provide referrals to specialists, allied health and Respiratory HEAL |
| Relative Risk | 95% Confidence Interval | P-value | |
| Gleason 7 vs. 6 | 1.37 | 1.19, 1.56 | <0.0001 |
| Gleason 8 to10 vs. 6 | 1.56 | 1.37, 1.78 | <0.0001 |
| Gleason 8 to10 vs. 7 | 1.14 | 1.04, 1.25 | 0.004 |
| Surgical Margin R1 vs. R0 | 1.43 | 1.26, 1.62 | <0.0001 |
| Stage 3a vs. 2 | 1.16 | 1.05, 1.28 | 0.002 |
| Specialty: | |||
| Radiation oncology vs. Urology | 1.26 | 1.15, 1.38 | <0.0001 |
| Group | ≤35 years old | 36-38 years old | 39-40 years old | >40 years old | ||||
| Variable | RC | p | RC | p | RC | p | RC | p |
| Laboratory outcomes | ||||||||
| Fertilization rate | -0.001 | NS | 0.000 | NS | 0.001 | NS | -0.002 | NS |
| High quality D3 embryos | -0.001 | NS | 0.000 | NS | 0.000 | NS | 0.000 | NS |
| High quality Embryo rate | -0.005 | <0.01 | -0.006 | 0.025 | 0.002 | NS | -0.002 | NS |
| Blastocyst formation rate | -0.005 | <0.01 | -0.007 | 0.042 | 0.004 | NS | -0.004 | NS |
| Transferred embryos | 0.000 | <0.01 | 0.000 | NS | 0.000 | NS | 0.000 | NS |
| Endometrium | 0.000 | NS | 0.000 | NS | 0.001 | NS | 0.000 | NS |
| All N = 15 | 18 years or younger N = 25 | Over 18 Years N = 18 | |
| Medication class | Number prescribed this medication | Number prescribed this medication | Number prescribed this medication |
| Citalopram | 5 (9.1%) | 2 (8.0%) | 3 (10.0%) |
| Escitalopram | 3 (5.5%) | 0 (0.0%) | 3 (10.0%) |
| Fluoxetine | 39 (70.9%) | 23 (92.0%) | 16 (53.3%) |
| Paroxetine | 2 (3.6%) | 0 (0.0%) | 2 (6.7%) |
| Sertraline | 2 (3.6%) | 0 (0.0%) | 2 (6.7%) |
| Mirtazapine | 4 (7.3%) | 0 (0.0%) | 4 (13.5%) |
| Dependent variable | Independent variables | Odds ratio | CI (95%) | P value |
| Adiponectin | 0.7 | 0.33–1.07 | 0.06 | |
| Age | 0.9 | 0.8–1.1 | 0.9 | |
| PCOS | WC | 0.86 | 0.74–1.01 | 0.2 |
| BMI | 1.4 | 1–1.8 | 0.3 | |
| 25OHD | 1.9 | 1.3–2.5 | 0.002 |
| Feature | Control | Treatment | p |
| Fat necrosis* | 2.8±0.3 | 2.8±0.5 | 0.791 |
| Inflammatory infiltrate* | 3.6±0.1 | 3.4±0.2 | 0.247 |
| Interstitial Edema** | 4.0 (3.5-4.0) | 3.5 (3.5-3.8) | 0.382 |
| Hemorrhagic foci** | 4.0 (2.6-4.0) | 3.5 (3.0-3.8) | 0.622 |
| Age (mean ± SD) years | 64.3 (± 3.5) |
| Gender male/female | 12/8 |
| Pre-op logMAR VA (mean ± SD) | 1.15 ± 0.88 |
| Post-op logMAR VA (mean ± SD) | 0.55 ± 0.30 |
| Lens statusPhakic/IOL | 4/16 |
| Duration of detachment (mean ± SD) days | 6.25 ± 3.44 |
| Quadrants detached | 2.95 (± 0.75) |
| Location of the main breakSuperior/inferior quadrants | 16/4 |
| IOP pre-op | 11.7 ± 2.6 |
| IOP post-op | 18.9 ± 4.9 |
| IOP 2-hour post-op | 16.8 ± 4.7 |
| Picture name | Related distractor | Unrelated distractor | |
| Animals | Hert (deer) | Konijn | Piano |
| Konijn (rabbit) | Hert | Drumstel | |
| Zwaan (swan) | Geit | Bus | |
| Geit (goat) | Zwaan | Fluit | |
| Clothing | Jas (jacket) | Hemd | Molen |
| Hemd (singlet) | Jas | Tafel | |
| Rok (skirt) | Trui | Neus | |
| Trui (sweater) | Rok | Banaan | |
| Transportation | Auto (car) | Bus | Kanon |
| Bus (bus) | Auto | Konijn | |
| Trein (train) | Fiets | Kast | |
| Fiets (bicycle) | Trein | Trui | |
| Buildings | Kerk (church) | Fabriek | Zwaan |
| Fabriek (factory) | Kerk | Zwaard | |
| Molen (mill) | Kasteel | Dolk | |
| Kasteel (castle) | Molen | Oor | |
| Weapons | Dolk (dagger) | Zwaard | Arm |
| Zwaard (sword) | Dolk | Been | |
| Kanon (cannon) | Pistool | Bed | |
| Pistool (gun) | Kanon | Kan | |
| Kitchenware | Kan (pitcher) | Beker | Fabriek |
| Beker (cup) | Kan | Pistool | |
| Bord (plate) | Glas | Rok | |
| Glas (glass) | Bord | Kerk | |
| Furniture | Bed (bed) | Tafel | Gitaar |
| Tafel (table) | Bed | Kasteel | |
| Bureau (desk) | Kast | Geit | |
| Kast (wardrobe) | Bureau | Molen | |
| Body parts | Neus (nose) | Arm | Auto |
| Arm (arm) | Neus | Peer | |
| Been (leg) | Oor | Appel | |
| Oor (ear) | Been | Beker | |
| Fruit | Ananas (pineapple) | Banaan | Hert |
| Appel (apple) | Peer | Fiets | |
| Banaan (banana) | Ananas | Trein | |
| Peer (pear) | Appel | Hemd | |
| Music instruments | Drumstel (drums) | Gitaar | Bureau |
| Gitaar (guitar) | Drumstel | Jas | |
| Fluit (flute) | Piano | Bord | |
| Piano (piano) | Fluit | Glas |
| Secondary disability | Selection |
| Difficulties managing daily life | Societal supporta in terms of different forms of housing conditions |
| Problems at school | Special education (school for children with intellectual development disorders, primary school level) |
| Psychiatric disorderb | Average cost of depression, bipolar disorder, generalized anxiety disorder and schizophrenia |
| Alcohol/drug abuse | Alcohol abuse and/or illicit drug use |
| Suicidal ideation | No separate calculation |
| Included in other cost references | |
| Criminality | No separate calculation |
| Cost included in alcohol/drug abuse | |
| Inappropriate sexual behaviour | Not included |
| Lack of data | |
| Reduced working capacity | Productivity loss for individuals without employment |
| Mortality | No separate calculation |
| Cost included in alcohol/drug abuse | |
| Informal caring | Productivity loss for family member/relative/significant other |
| Variable | FLEEOX (n=99) (%) | XELOX (n=99) (%) | P |
| Response to NAC | 0.026 | ||
| CR | 13 (13.1) | 3 (3.0) | |
| PR | 67 (67.7) | 65 (65.7) | |
| SD | 9 (9.1) | 16 (16.2) | |
| PD | 10 (10.1) | 15 (15.2) | |
| RR (CR plus PR) | 80 (80.8) | 68 (68.7) | 0.018 |
| DCR (CR plus PR plus SD) | 89 (89.9) | 84 (84.8) | 0.196 |
| Characteristics | Altitude <1500 m | Altitude >1500 m | p-value |
| n = 26,896 | n = 3978 | ||
| COPD prevalence (%) | 9.9 | 8.5 | <0.005 |
| Mean FEV1 (Litre, SD) | 2.66 (0,85) | 2.45 (0.78) | 0.010 |
| Mean FVC (Litre, SD) | 3.47 (1.05) | 3.20 (0.90) | <0.001 |
| Mean FEV1/FVC (SD) | 76.8 (8.8) | 76.2 (10.0) | <0.001 |
| Sex – female (%) | 54.9 | 62.1 | <0.001 |
| Age (Mean, SD) | 56.2 (11.3) | 55.1 (11.3) | <0.001 |
| Never-smoker (%) | 48.6 | 56.5 | <0.001 |
| Dusty job (%) | 36.1 | 24.5 | <0.001 |
| Tuberculosis (%)a | 3.5 | 0.4 | <0.001 |
| Education >12 years (%) | 23.6 | 9.5 | <0.001 |
| Prior lung function test, ever (%)b | 28.1 | 4.1 | <0.001 |
| Self-reported diagnosis of COPD (%) | 5.1 | 3.9 | <0.001 |
| Proportion of correct prior diagnosis of COPD (%) | 37.0 | 31.2 | 0.158 |
| Proportion of undiagnosed COPD (%) | 80.8 | 85.8 | 0.029 |
| Animal yields | Advantages | Disadvantages |
| Milk, Eggs | Easily measurable, almost complete edible | Variation in protein, fat and energy yield, analyses may be useful |
| Body weight gain | Easily measurable | High portion of non edible fractions in the gains |
| Carcass weight | Easily measurable | Contains still fractions which are not edible (e.g., bones) |
| Meat, edible fraction | Completely edible | Categorization and separation not easy |
| Edible protein | Most important objective of animal production; comparison of various methods and sources to produce protein of animal origin | Categorization of various fractions as edible and difficulties to measure; additional analytical work; variation in N/protein content |
| Number (%) | Mean ± SD | Range | |
| Patient characteristics | |||
| Age (year) | 52 | 44.8 ± 14 | 22–78 |
| Gender | |||
| Male | 34 | ||
| Female | 18 | ||
| Seizures at presentation | 38 (73.1%) | ||
| Antiepileptic drugs | 37 | ||
| Seizure-free | 20 | ||
| Recurrent seizure | 18 | ||
| No seizures at presentation | 14 (29.9%) | ||
| Neurological function (RTOG) | 52 | 1.19 ± 1.15 | 0–3 |
| No neurological symptoms | 17 (32.7%) | ||
| Minor neurological symptoms | 21 (40.4%) | ||
| Moderate neurological symptoms | 14 (26.9%) | ||
| Professions (n = 52) | |||
| High education | 26 (50%) | ||
| Low education | 18 (34.6%) | ||
| Retired | 8 (15.4%) | ||
| Work situation (n = 52) | |||
| Working fully | 25 (48%) | ||
| Working half time | 11 (21%) | ||
| Not working, due to illness | 4 (8%) | ||
| Retired, unrelated to illness | 8 (15%) | ||
| Students | 2 (4%) | ||
| Unemployed | 2 (4%) | ||
| Changes in professional situation | 19 (36%) | ||
| Tumor characteristics | |||
| Affected hemisphere | |||
| Right | 20 (38.5%) | ||
| Left | 31 (38.5%) | ||
| Bilateral | 1 (1.9%) | ||
| Tumor location | 52 | ||
| Non-eloquent cortex | 8 | ||
| Non-eloquent cortico-subcortical | 12 | ||
| Eloquent cortico-subcortical | 32 | ||
| Insula | 9 | ||
| SMAa/Pre SMA | 5/2 | ||
| Primary somatosensory area | 6 | ||
| Primary motor area | 4 | ||
| Language area | 6 | ||
| Tumor volume (cm3) | 50 | 69.3 ± 57.3 | 2.8–267.8 |
| Smaller (<61 cm3) | 24 | ||
| Larger (>61 cm3) | 26 |
| Symptoms | Frequency | Number | Percentage |
| Sneezing | No symptoms | 1076 | 69.70% |
| Occasional | 398 | 25.80% | |
| Frequent | 69 | 4.50% | |
| Cough | No symptoms | 1380 | 89.40% |
| Occasional | 149 | 9.70% | |
| Frequent | 14 | 0.90% |
| Compound | Concentration | Relative activity |
| (mM) | (%) | |
| dl-threo-β-phenylserine | 20 | 100 |
| d-threo-β-phenylserine | 10 | 0 |
| dl-erythro-β-phenylserine | 20 | 840 |
| dl-threo-(2-thienyl)serine | 20 | 530 |
| (S)-phenylethanol | 10 | 6.9 |
| dl-hydroxynorvaline | 20 | 0 |
| l-threonine | 10 | 0 |
| d-threonine | 10 | 0 |
| l-allo-threonine | 10 | 0 |
| d-allo-threonine | 10 | 0 |
| l-serine | 10 | 0 |
| d-serine | 10 | 0 |
| l-phenylalanine | 10 | 0 |
| d-phenylalanine | 10 | 0 |
| Controls | Earthquake victims | |||
| Measures | Mean | SD | Mean | SD |
| ISI | 5.05 | 3.5 | 6.35 | 4 |
| IUS-12 | 35.00 | 15.2 | 42.54 | 16.7 |
| URS total score* | 121.03 | 12.1 | 128.56 | 13.3 |
| URS emotional uncertainty* | 26.53 | 6.1 | 31.69 | 7.4 |
| URS desire for control | 47.22 | 7.2 | 46.13 | 7.7 |
| URS cognitive uncertainty | 47.41 | 8.5 | 51.10 | 8.9 |
| STAI* | 37.63 | 8.2 | 42.46 | 7.8 |
| BDI | 6.54 | 5.2 | 8.56 | 5.8 |
| ASI-3 total score* | 10.90 | 8.3 | 18.21 | 13.3 |
| ASI-3 physical concerns | 3.41 | 3.9 | 5.46 | 5.6 |
| ASI-3 cognitive concerns* | 4.05 | 3.6 | 6.77 | 5.1 |
| ASI-3 social concerns* | 3.44 | 3.4 | 6.25 | 5.1 |
| EPQ-R Extraversion/Introversion | 9.05 | 2.8 | 8.48 | 3.2 |
| EPQ-R neuroticism* | 4.46 | 2.7 | 6.33 | 3.3 |
| EPQ-R psychoticism | 3.22 | 1.9 | 2.67 | 1.5 |
| No (%) | OR | Yes (%) | OR (95% CI) | P | |
| High TG | 10.6 | 1 | 23.3 | 1.4 (1.0–2.0) | 0.0334 |
| Low HDL-C | 11.0 | 1 | 12.6 | 0.9 (0.6–1.2) | 0.4507 |
| Hyperglycemia | 11.0 | 1 | 15.5 | 1.5 (0.9–2.5) | 0.0890 |
| MetS | 10.8 | 1 | 51.9 | 2.8 (1.5–5.4) | 0.0014 |
| Insulin | 7.7 | 1 | 16.6 | 1.6 (1.4–2.0) | <0.0001 |
| HOMA-IR | 7.5 | 1 | 15.4 | 1.6 (1.4–2.0) | <0.0001 |
| Left thalamic infarct patients (n = 12) | Healthy control participants (n = 25) | P value | dMTT subgroup (n = 7) | iMTT subgroup (n = 5) | P value | |
| Age (years) | 53.2 (14.6) [25, 75] | 52.6 (11.6) [25, 69] | 0.86 | 58.9 (16.6) [25, 75] | 45.2 (6.3) [38, 52] | 0.12 |
| Sex (female (F)/male (M)) | 3F/9M | 15F/10M | 0.05 | 1F/6M | 2F/3M | 0.31 |
| Education level (years) | 12.8 (4.1) [5, 17] | 13.6 (4.1) [5, 21] | 0.25 | 12.3 (4.2) [5, 17] | 11 (4.2) [5, 17] | 0.69 |
| Handedness (right (R)/left (L)/ambidextrous (A)) | 11 R/1A | 22R/3L | 0.17 | 6 R/1A | 5 R | 0.38 |
| Time since onset | 589 (588.9) days [3 months, 4 years 11 months] | – | – | 527 (647.2) days [3 months, 4 years 11 months] | 675 (556.1) days [3 months, 3 years 8 months] | 0.69 |
| Normalized volume of overall lesions (mm3) | 516.8 (265.2) [30, 982] | – | – | 679.6 (160.7) [538, 982] | 289 (208.5) [30, 605] | 0.005 |
| Clinical Training Programs in | Nation | Commenced |
| ROMP | ThailandThe Philippines Malaysia | 2007 (completed) 20092011 |
| DRMP | The Philippines Thailand | 20102010 |
| NMP | BangladeshThailand | 20102011 |
| Absolute power density (mean ± SE, μV2) | Relative power densitya (mean ± SE, %) | ||
| Eyes closed | Eyes open | Eyes closed | Eyes open |
| 23.9 ± 3.5* | 2.4 ± 0.2 | 60.8 ± 2.4* | 26.0 ± 1.7 |
| Number of familiesb | 46 | |
| Number of children < 12b | Age (years) | |
| 0–3 | 28 | |
| 3–6 | 27 | |
| 6–12 | 23 | |
| Total | 78 | |
| Number of children attending Mobile Crèches centerb | 0–3 | 27 |
| 3–6 | 26 | |
| 6–12 | 23 | |
| Total | 76 | |
| Average duration of attendance at Mobile Crèches center (child-days per child)c | 48 |
| History | • Activity and employment status |
| • Description of LBP | |
| • Response to previous treatment | |
| • Co-morbidities and medications | |
| Examination | • Vitals (height, weight, blood pressure) |
| • Orthopedic exam (Lasegue, Patrick Fabre, Kemp, Gaenslen, Femoral Nerve Stretch) | |
| • Neurologic exam (motor, sensory, reflex evaluation) | |
| • Soft tissue evaluation | |
| Imaging | • X-ray results (obtained if clinically warranted) |
| • DEXA results (obtained if clinically warranted) | |
| Biomechanical Assessment | • Torso strength (flexion, extension) |
| • Torso endurance (flexion, extension, lateral bridge) | |
| • Lumbar range of motion (flexion, extension, lateral bending, rotation) | |
| Psychosocial Assessment | • Disability (modified Roland Morris)[32,33] |
| • General health status (EuroQol) [34,35] | |
| • Fear avoidance (Fear Avoidance Beliefs Questionnaire)[36] | |
| • Kinesiophobia (Tampa Scale of Kinesiophobia)[37] | |
| • Coping style (Vanderbilt Pain Management Inventory)[38,39] | |
| • Pain self-efficacy (PSEQ)[40] | |
| • Depression (CES-D)[41,42] | |
| Preferences | • Which modalities were preferred |
| • Expectations for improvement with each modality (5 point scale) |
| WILD TYPE | ADIPONECTIN-/- | |||||||
| SHAM | TAC | SHAM | TAC | |||||
| STD | ω-3 PUFA | STD | ω-3 PUFA | STD | ω-3 PUFA | STD | ω-3 PUFA | |
| Serum Adiponectin (μg·ml-1) | 7.94 ± 1.23 | 8.74 ± 1.35 | 7.72 ± 1.27 | 7.48 ± 1.23 | 1.70 ± 0.12 | 1.56 ± 0.10 | 1.50 ± 0.10 | 1.49 ± 0.10 |
| Serum HMW Adiponectin (μg·ml-1) | 0.55 ± 0.03 | 0.78 ± 0.08# | 0.63 ± 0.05 | 0.73 ± 0.08 | 0.18 ± 0.03 | 0.18 ± 0.03 | 0.19 ± 0.02 | 0.19 ± 0.03 |
| Adiponectin mRNA in Epididymal Fat | 1.00 ± 0.17 | 1.10 ± 0.10 | 1.04 ± 0.14 | 1.18 ± 0.27 | 0 | 0 | 0 | 0 |
| PDK4 mRNA in LV | 1.00 ± 0.35 | 0.30 ± 0.03# | 0.29 ± 0.04* | 0.29 ± 0.04 | 0.27 ± 0.03 | 0.40 ± 0.11 | 0.37 ± 0.08 | 0.48 ± 0.14 |
| UCP3 mRNA in LV | 1.00 ± 0.14 | 0.88 ± 0.13 | 0.39 ± 0.07* | 0.47 ± 0.12 | 0.89 ± 0.12 | 0.96 ± 0.11 | 0.49 ± 0.09 | 0.59 ± 0.10 |
| Serum Glucose (mM) | 12.7 ± 0.6 | 11.6 ± 0.8 | 12.6 ± 1.0 | 11.4 ± 0.9 | 13.0 ± 0.9 | 12.7 ± 0.7 | 11.7 ± 0.4 | 13.1 ± 1.1 |
| Serum FFA (mM) | 0.69 ± 0.05 | 0.55 ± 0.04 | 0.76 ± 0.14 | 0.55 ± 0.07 | 0.82 ± 0.08 | 0.47 ± 0.06 | 0.61 ± 0.07 | 0.52 ± 0.08 |
| Serum Insulin (ng·ml-1) | 0.66 ± 0.16 | 0.90 ± 0.20 | 0.66 ± 0.16 | 0.48 ± 0.10 | 0.84 ± 0.23 | 0.54 ± 0.11 | 0.60 ± 0.10 | 0.34 ± 0.10 |
| Serum Leptin (ng·ml-1) | 2.56 ± 0.51 | 2.80 ± 0.70 | 1.62 ± 0.37 | 1.18 ± 0.28* | 3.83 ± 1.50 | 2.28 ± 0.82 | 1.85 ± 0.43 | 0.78 ± 0.14 |
| Serum Triglycerides (mg·ml-1) | 0.26 ± 0.05 | 0.25 ± 0.06 | 0.25 ± 0.07 | 0.28 ± 0.06 | 0.40 ± 0.09 | 0.23 ± 0.08 | 0.30 ± 0.04 | 0.25 ± 0.06 |
| HAQ-Pb | HAQ-Tc | |||||||
| Relation to the therapist | Satisfaction with therapeutic outcome | Helping alliance | Relation to the patient | Satisfaction with therapeutic outcome | Helping alliance | |||
| IIPa | M (SD) | r | r | r | r | r | r | |
| total score | 14.92 (3.69) | −0.10 | −0.15* | −0.14* | −0.05 | − 0.05 | −0.06 | |
| Domineering/ controlling | 8.31 (5.10) | −0.14* | −0.10 | − 0.13* | − 0.12 | −0.12 | − 0.13* | |
| Vindictive/ self-centred | 11.02 (5.19) | −0.17** | −0.18** | − 0.19** | − 0.11 | −0.11 | − 0.12 | |
| Cold/ distant | 14.79 (6.04) | −0.21* | −0.21** | − 0.23** | − 0.08 | −0.08 | − 0.09 | |
| Socially inhibited | 17.93 (6.71) | −0.16* | −0.23** | − 0.22** | − 0.11 | −0.11 | − 0.12* | |
| Non-assertive | 20.04 (6.68) | −0.03 | −0.12 | − 0.08 | 0.00 | 0.01 | 0.01 | |
| Overly accommodating | 17.49 (5.83) | 0.07 | −0.00 | 0.03 | 0.10 | 0.10 | 0.11 | |
| Self-sacrificing | 18.71 (5.29) | 0.11 | −0.01 | 0.06 | 0.08 | 0.08 | 0.09 | |
| Intrusive/ needy | 11.10 (5.33) | 0.05 | −0.09 | 0.08 | −0.01 | −0.02 | − 0.02 |
| Study population | Respondents | Respondents having consultations concerning sickness certification at least a few times a year | |||
| n | n | % of study population | n | % of the respondents | |
| All | 7665 | 5455 | 71 | 4019 | 74 |
| County | |||||
| Stockholm | 6794 | 4827 | 71 | 3446 | 71 |
| Östergötland | 871 | 628 | 72 | 573 | 91 |
| Sex | |||||
| Women | 3646 | 2710 | 74 | 2007 | 74 |
| Men | 4019 | 2745 | 68 | 2012 | 73 |
| Educational level1 | |||||
| Non-specialist | 1381 | 1046 | 76 | ||
| Specialist | 3995 | 2947 | 74 | ||
| No information | 79 | 26 | 33 | ||
| Mean age (years) | 48.2 | 48.3 | 47.7 |
| Symptoms (Discomforts) | after 1 ED | after 2 ED | after 3 ED | n |
| headache | 3 (8%) | 7 (19%) | 3 (8%) | 13 |
| light chest pain | - | - | 2 (5%) | 2 |
| stomachache | - | 2 (5%) | 5 (14%) | 7 |
| excitation | 9 (25%) | 6 (17%) | 8 (22%) | 23 |
| anxiety | 2 (5%) | - | - | 2 |
| shaking hands | - | 1 (3%) | 4 (11%) | 5 |
| somnolence | - | 8 (22%) | 5 (14%) | 13 |
| malaise and others | 3 (8%) | 9 (25%) | 10 (28%) | 22 |
| 2009 | 2004-08 | H1N1 Attributable | Rate Ratio: 2009:2004-08 | |
| British Columbia | ||||
| First Nations Reserves | 13.77 | 9.48 | 4.29 | 1.45 |
| Other Residents | 6.65 | 6.18 | 0.47 | 1.08 |
| Rate Ratio: | 2.07 | 1.53 | 9.13 | 1.35* |
| First Nations:Other | ||||
| Manitoba | ||||
| First Nations Reserves | 26.84 | 18.44 | 8.40 | 1.46 |
| Other Residents | 11.21 | 10.07 | 1.14 | 1.11 |
| Rate Ratio: | 2.39 | 1.83 | 7.36 | 1.31* |
| First Nations:Other | ||||
| Ontario | ||||
| First Nations Reserves | 16.84 | 11.74 | 5.10 | 1.44 |
| Other Residents | 7.35 | 5.54 | 1.81 | 1.33 |
| Rate Ratio: | 2.29 | 2.12 | 2.81 | 1.08* |
| First Nations:Other |
| Dataset | DaliLite | TM-align | CE | MICAN | DEDAL | SNAP | GANGSTA+ | SCALI | MASS | SAMO |
| MALIDUP-sq | 85.3 | 81.0 | 62.3 | 85.8 | 83.4 | 70.8 | 64.4 | 56.2 | 50.4 | 42.8 |
| MALISAM-sq | 67.3 | 53.7 | 21.2 | 65.5 | 56.2 | 43.4 | 36.0 | 35.8 | 21.3 | 17.0 |
| MALIDUP-ns | 37.9 | 43.0 | — | 85.6 | 81.4 | 71.3 | 63.3 | 54.2 | 51.5 | 19.0 |
| MALISAM-ns | 21.7 | 22.5 | — | 67.6 | 56.1 | 43.6 | 29.9 | 37.5 | 20.4 | 8.5 |
| Color Choice | Volunteer group | p value | ||
| HAD normal (n = 460) No. (%) Respondents | HAD anxious (n = 117) No. (%) Respondents | HAD depressed (n = 35) No. (%) Respondents | ||
| Positive | 212 (46.1%) | 39 (33.3%) | 8 (22.9%) | Chi-square (4) = 33.656; p < 0.001 |
| Neutral | 175 (38.0%) | 44 (37.6%) | 9 (25.7%) | |
| Negative | 73 (15.9%) | 34 (29.1%) | 18 (51.4%) |
| Use of CAM/conventional medicine | Frequency (%) |
| use only CAM | 166 (51.1) |
| use combination of CAM and conventional medicine | 159 (48.9) |
| Total | 325 (100) |
| Variable | Year of survey 2005 | Year of survey 2012 | p | ||
| n | % | n | % | ||
| Toilet | < 0.001 | ||||
| Absence | 169 | 36.5 | 284 | 34.8 | |
| Ceramic | 99 | 21.4 | 276 | 33.8 | |
| Wood | 195 | 42.1 | 257 | 31.4 | |
| Total | 463 | 100 | 817 | 100 | |
| Origin of water | |||||
| Rain | 4 | 0.9 | 18 | 2.2 | 0.001 |
| Public network | 160 | 34.6 | 239 | 29.8 | |
| Well or spring | 76 | 16.4 | 90 | 11.2 | |
| River | 223 | 48.2 | 456 | 56.8 | |
| Total | 463 | 100 | 803 | 100 | |
| Frequency of water shortage | |||||
| Never | 335 | 72.5 | 504 | 62.1 | < 0.001 |
| Rarely | 73 | 15.8 | 166 | 20.4 | |
| Often | 54 | 11.7 | 142 | 17.5 | |
| Total | 462 | 100 | 812 | 100 | |
| Treatment of drinking water | < 0.001* | ||||
| Boiled/Filtered and boiled | 61 | 13.3 | 48 | 6.1 | |
| Filtered | 20 | 4.4 | 32 | 4.1 | |
| Chlorinated at home | 244 | 53.3 | 449 | 57.5 | |
| Mineral | 2 | 0.4 | 9 | 1.2 | |
| Untreated | 131 | 28.6 | 243 | 31.1 | |
| Total | 458 | 100 | 781 | 100 | |
| Destination of trash | 0.675 | ||||
| Collection | 168 | 36.4 | 304 | 38.8 | |
| Buried/Burned/Thrown into river | 163 | 35.4 | 273 | 34.8 | |
| Thrown in open area | 130 | 28.2 | 207 | 26.4 | |
| Total | 461 | 100 | 784 | 100 | |
| Destination of sewage | < 0.001 | ||||
| Septic tank | 65 | 14.2 | 124 | 15.6 | |
| Cesspit | 130 | 28.4 | 317 | 39.8 | |
| Open pit | 210 | 46.0 | 276 | 34.7 | |
| Others | 52 | 11.4 | 79 | 9.9 | |
| Total | 457 | 100 | 796 | 100 |
| Cord plasma insulin | ||||||
| Unadjusted analysis | Adjusted analysis | |||||
| N | β | P-value | β | P-value | Adjusted model r2 | |
| Week-1 | ||||||
| SFT | 44 | 0.398 | 0.007 | 0.325 | 0.071 | 0.195; p = 0.026 |
| SCA | 36 | 0.464 | 0.004 | 0.390 | 0.039 | 0.310; p = 0.008 |
| PPA | 36 | 0.445 | 0.007 | 0.436 | 0.022 | 0.311; p = 0.008 |
| Week-6 | ||||||
| SFT | 40 | 0.294 | 0.065 | 0.292 | 0.146 | 0.122; p = 0.127 |
| SCA | 40 | 0.335 | 0.035 | 0.241 | 0.217 | 0.163; p = 0.074 |
| PPA | 40 | 0.307 | 0.054 | 0.287 | 0.119 | 0.268; p = 0.014 |
| Month-4 | ||||||
| SFT | 39 | 0.281 | 0.084 | 0.196 | 0.335 | 0.080; p = 0.215 |
| SCA | 39 | 0.175 | 0.287 | 0.056 | 0.794 | −0.044; p = 0.615 |
| PPA | 39 | 0.146 | 0.368 | 0.011 | 0.961 | −0.090; p = 0.799 |
| Year-1 | ||||||
| SFT | 41 | −0.072 | 0.653 | −0.017 | 0.937 | −0.080; p = 0.769 |
| SCA | 41 | 0.027 | 0.866 | 0.085 | 0.680 | −0.034; p = 0.585 |
| PPA | 41 | 0.062 | 0.698 | 0.198 | 0.290 | 0.137; p = 0.099 |
| Dam | Sire | Family | Contribution | Offspring males | Offspring females | Average weight in g (±se) | Average length in mm (±s.e) | P-value |
| Dam 1 | Sire 1 | 1 | 7.4 % | 4 | 9 | 194.2 (58.7) | 256.5 (20.9) | 0.27 |
| Dam 1 | Sire 2 | 2 | 10.8 % | 14 | 5 | 179.3 (34.1) | 249.5 (15.3) | 0.066 |
| Dam 1 | Sire 3 | 3 | 9.7 % | 5 | 12 | 181.9 (65.2) | 248.6 (31.4) | 0.15 |
| Dam 1 | Sire 4 | 4 | 17.7 % | 17 | 14 | 178.2 (48.2) | 248.7 (19.9) | 0.719 |
| Dam 2 | Sire 1 | 5 | 9.1 % | 5 | 11 | 148.1 (37) | 231.5 (16.1) | 0.21 |
| Dam 2 | Sire 2 | 6 | 12.6 % | 14 | 8 | 150.2 (54.9) | 233.0 (26.8) | 0.28 |
| Dam 2 | Sire 3 | 7 | 10.9 % | 3 | 16 | 170.0 (67.5) | 240.2 (28.3) | 0.0059** |
| Dam 2 | Sire 4 | 8 | 21.7 % | 25 | 13 | 160.5 (52.8) | 239.6 (24.7) | 0.074 |
| RV Strain (Origin) | GenBank Accession number | P-type |
| RF (Bovine) | U65924 | P[1] |
| SA11 (Simian) | M23188 | P[2] |
| RRV (Simian) | M18736 | P[3] |
| RV-5 (Human) | M32559 | P[4] |
| UK (Bovine) | M22306 | P[5] |
| Gottfried (Porcine) | M33516 | P[6] |
| OSU (Porcine) | X13190 | P[7] |
| Wa (Human) | M96825 | P[8] |
| K8 (Human) | D90269 | P[9] |
| 69M (Human) | M60600 | P[10] |
| B223 (Bovine) | D13394 | P[11] |
| H-2 (Equine) | L04638 | P[12] |
| MDR-13 (Porcine) | L07886 | P[13] |
| PA169 (Human) | D14724 | P[14] |
| Lp14 (Ovine) | L11599 | P[15] |
| EB (Murine) | U08419 | P[16] |
| 993–83 (Bovine) | D16352 | P[17] |
| L338 (Equine) | D13399 | P[18] |
| 4F (Porcine) | L10359 | P[19] |
| EHP (Murine) | U08424 | P[20] |
| Hg18 (Bovine) | AF237665 | P[21] |
| 160/01 (Lapine) | AF526374 | P[22] |
| A34 (Porcine) | AY174094 | P[23] |
| TUCH (rhesus macaque) | AY596189 | P[24] |
| Dhaka6 (Human) | AY773004 | P[25] |
| 134/04 – 15 (Porcine) | DQ061053 | P[26] |
| CMP034 (Porcine) | DQ534016 | P[27] |
| All Subjects | Non-abdominal obesity group | Abdominal obesity group | P | |
| n | 326 | 163 | 163 | |
| Age, y | 45.1 ± 8.1 | 45.3 ± 8.4 | 44.8 ± 7.7 | n.s. |
| Waist, cm | 84.8 ± 8.2 | 78.3 ± 4.7 | 91.2 ± 5.2 | <0.0001 |
| BMI, kg/m2 | 24.3 ± 3.3 | 22.1 ± 2.0 | 26.6 ± 2.8 | <0.0001 |
| SBP, mmHg | 123 ± 16 | 120 ± 14 | 127 ± 17 | <0.0001 |
| DBP, mmHg | 79 ± 12 | 76 ± 11 | 82 ± 13 | <0.0001 |
| TC, mg/dl | 208 ± 35 | 203 ± 33 | 214 ± 37 | 0.003 |
| TG, mg/dl | 131 ± 128 | 100 ± 53 | 162 ± 168 | <0.0001 |
| HDL-C, mg/dl | 58 ± 14 | 62 ± 15 | 53 ± 11 | <0.0001 |
| LDL-C, mg/dl | 125 ± 34 | 120 ± 31 | 129 ± 37 | 0.03 |
| FPG, mg/dl | 91 ± 10 | 89 ± 9 | 93 ± 10 | 0.0009 |
| HOMA-IR | 1.35 ± 2.03 | 0.75 ± 0.29 | 1.87 ± 2.67 | 0.03 |
| hs-CRP, mg/L | 0.68 ± 0.77 | 0.58 ± 0.82 | 0.78 ± 0.71 | 0.018 |
| IL-6, pg/ml | 1.26 ± 0.75 | 1.18 ± 0.66 | 1.34 ± 0.83 | 0.045 |
| Adiponectin, μg/ml | 6.3 ± 2.9 | 7.1 ± 3.3 | 5.5 ± 2.1 | < 0.0001 |
| Conditioned taste aversion | Passive avoidance | Morris water maze 19°C | Morris water maze 23°C | Object recognition | Object location | |
| Consolidation | No effect | No effect | No effect | No effect | Effect | Effect |
| Reconsolidation | Effect | Effect | No effect | No effect | Effect | Effect |
| Aversive task | +++ | +++ | ++ | + | 0 | 0 |
| Spatial task | No | No | Yes | Yes | No | Yes |
| Associative task | Yes | Yes | Yes | Yes | No | No |
| n | Mean age ± SD | T/S ratio ± SD | p* | |
| OA patients | 79 | 69.46 ± 8.97 | 0.986 ± 0.261 | 0.684 |
| Healthy controls | 166 | 51.92 ± 18.45 | 1.008 ± 0.287 | |
| Haplogroup J | 155 | 52.97 ± 17.60 | 1.039 ± 0.287 | 0.003** |
| Non-J | 90 | 65.22 ± 15.98 | 0.933 ± 0.254 |
| N | Mean | Increase | ||
| Age | (studies) | rate (%)† | (95% CI) | of rates‡ |
| 65-69 | 17 | 1.2 | (0.8-1.5) | |
| 70-74 | 19 | 3.7 | (2.6-4.7) | 3.0 |
| 75-79 | 21 | 7.9 | (6.2-9.5) | 2.1 |
| 80-84 | 20 | 16.4 | (13.8-18.9) | 2.0 |
| 85-89 | 16 | 24.6 | (20.5-28.6) | 1.5 |
| 90-94 | 6 | 39.9 | (34.4-45.3) | 1.6 |
| >95 | 6 | 54.8 | (45.6-63.9) | 1.3 |
| Week | Content and homework | |
| 1 | Browser: | Psychoeducation: |
| Information about panic | ||
| Defining goals of training | ||
| Setting up a reward list | ||
| Mobile: | Daily diary | |
| Registration of current panic event (event-based) | ||
| Daily summary of panic, avoidance, and mood | ||
| 2 | Browser: | Interoceptive exposure: |
| Bodily symptoms in panic | ||
| Avoidance | ||
| Safety behaviors | ||
| Mobile: | Respiratory interoceptive exposure exercises | |
| Daily diary | ||
| 3 | Browser: | In vivo exposure: |
| Defining an anxiety hierarchy | ||
| Mobile: | In vivo exposures | |
| Dizziness interoceptive exposure exercises | ||
| Daily diary | ||
| 4 | Browser: | Cognitive restructuring I: |
| Negative automatic thoughts | ||
| Defining anxiety project (training schedule for exposures) | ||
| Mobile: | In vivo exposures | |
| Further interoceptive exposure exercises | ||
| Daily diary | ||
| 5 | Browser: | Cognitive restructuring II: |
| Reality testing of automatic negative thoughts | ||
| Mobile: | In vivo exposures | |
| Further interoceptive exposure exercises | ||
| Daily diary | ||
| 6 | Browser: | Relapse prevention: |
| Early warning signs | ||
| Critical life events | ||
| Evaluation of training and its aims | ||
| Mobile: | Breathing and muscle relaxation exercises |
| n | Time to go to sleep n (%) | |||
| Before 19:00 | Between 19:00 and 21:00 | Later | ||
| Age group (years) | ||||
| < 5 | 49 | 4 (8.2) | 40 (88.9) | 5 (11.1) |
| 5–15 | 123 | – | 85 (69.1) | 38 (30.9) |
| 16–49 | 146 | – | 69 (47.3) | 77 (52.7) |
| > 49 | 27 | – | 10 (37.0) | 17 (63.0) |
| Total | 341 | 4 (1.2) | 204 (59.8) | 137 (40.2) |
| F | d.f. | P | |
| Size increase | |||
| Sex | 4.95 | 1, 697 | 0.03 |
| Treatment | 0.20 | 1, 697 | 0.65 |
| Sex × Treatment | 0.60 | 1, 697 | 0.44 |
| Weight increase | |||
| Sex | 4.95 | 1, 697 | 0.02 |
| Treatment | 0.20 | 1, 697 | 0.65 |
| Sex × Treatment | 0.60 | 1, 697 | 0.44 |
| Development rate | |||
| Sex | 41.13 | 1, 697 | <0.0001 |
| Treatment | 6.46 | 1, 697 | 0.01 |
| Sex × Treatment | 1.19 | 1, 697 | 0.28 |
| Lifespan | |||
| Sex | 22.55 | 1, 697 | <0.0001 |
| Treatment | 0.24 | 1, 697 | 0.62 |
| Sex × Treatment | 6.76 | 1, 697 | 0.009 |
| Tissue | Time (Months) | Control | Salmon b | Aimara c |
| Hair | 3 | 3.4 ± 1.2 | 6.5 ± 2 | 242 ± 11 * |
| 14 | 33 ± 26 | 30 ± 8 | 733 ± 201 * | |
| Kidney | 3 | 12 ± 3 | 16 ± 2 | 359 ± 200 * |
| 14 | 7 ± 2 | 21 ± 2 ° | 511 ± 1034 * | |
| Liver | 3 | 4.8 ± 0.4 | 4.5 ± 1.2 | 34 ± 18 * |
| 14 | 4 ± 2.6 | 7.7 ± 1.4 | 77 ± 11 * | |
| Muscles | 3 | 6 ± 2 | 6 ± 2 | 34 ± 18 * |
| 14 | 8 ± 8 | 13 ± 2 | 53 ± 11 * | |
| Brain | 3 | 9 ± 2 | 9 ± 2 | 23 ± 5 * |
| Hippocampus | 14 | 4 ± 5 | 11 ± 7 | 46 ± 4 * |
| Cortex | 14 | 1.5 ± 0.4 | 11 ± 7 | 35 ± 3 * |
| Striatum | 14 | 3 ± 3 | 11 ± 7 | 56 ± 11 * |
| Eyes | 14 | 3 ± 2 | 18 ± 5 ° | 61 ± 24 * |
| Lung | 14 | 8 ± 4 | 9 ± 2 | 74 ± 7 * |
| Intestines | 14 | 12 ± 11 | 4.1 ± 0.3 | 48 ± 9 * |
| Heart | 14 | 4 ± 3 | 7 ± 4 | 43 ± 9 * |
| Spleen | 14 | 9 ± 3 | 18 ± 11 | 45 ± 3 * |
| Skin | 14 | 18 ± 12 | 7 ± 4 | 24 ± 5 * |
| Blood | 14 | 6.4 ± 0.1 | 7.2 ± 0.1 | 27.7 ± 2.5 * |
| Feces | 14 | 6.5 ± 0.3 | 6.5 ± 1.1 | 34.8 ± 1.4 * |
| Term | Prime number | Relation | Modified Gödel Number |
| Term1 | 2 | ||
| Term2 | 3 | R1: Term2 is a Term1 | relation(is a) = 3 × 2 = 6 |
| Term3 | 5 | R2: Term3 is part of Term2 | relation(part of) = 5 × 3 × 2 = 30 |
| Term4 | 7 | R3: Term4 is a Term2 | relation(is a) = 7 × 3 × 2 = 42 |
| Table 3 | All grades | Grade 3 | ||
| n | % | n | % | |
| Skin | 5 | 19 | 1 | 4 |
| Lymph edema | 3 | 12 | ||
| Dysphagia | 2 | 8 | 1 | 4 |
| Xerostomia | 8 | 31 | ||
| Loss of taste | 4 | 15 | ||
| Hearing loss | 3 | 12 | 2 | 8 |
| Sinusitis | 1 | 4 | 1 | 4 |
| Hypothyreosis | 1 | 4 | ||
| Hoarseness | 1 | 4 | ||
| Dry eye | 1 | 4 | ||
| Skin infection* | 1 | 4 | 1 | 4 |
| Trismus | 1 | 4 |
| Health facility providers | Pharmacists | PMV operators | ||||
| Minimum age | n | % | n | % | n | % |
| Male condom | 692 | 73.1 | 410 | 76.3 | 474 | 70.7 |
| Pill | 906 | 86.9** | 318 | 81.8 | 313 | 79.9 |
| EC | 395 | 70.1*** | 292 | 82.9 | 183 | 75.4 |
| Injectable | 1071 | 88.5* | 289 | 84.1 | na | na |
| IUD | 560 | 93.2 | na | na | na | na |
| Minimum parity | ||||||
| Male condom | 692 | 3.0* | 410 | 2.9 | 474 | 5.7 |
| Pill | 906 | 38.3*** | 318 | 28.9 | 313 | 43.5 |
| EC | 395 | 12.7* | 292 | 12.3 | 183 | 20.2 |
| Injectable | 1071 | 64.7*** | 289 | 21.8 | na | na |
| IUD | 560 | 53.4 | na | na | na | na |
| Marital status | ||||||
| Male condom | 692 | 10.4 | 410 | 9.5 | 474 | 7.2 |
| Pill | 906 | 51.3*** | 318 | 41.5 | 313 | 57.5 |
| EC | 395 | 16.7** | 292 | 26.4 | 183 | 23.5 |
| Injectable | 1071 | 73.5*** | 289 | 45.3 | na | na |
| IUD | 560 | 67.3 | na | na | na | na |
| Overall bias score | ||||||
| Male condom | 692 | 0.9 | 410 | 0.9 | 474 | 0.8 |
| Pill | 906 | 1.8*** | 318 | 1.5 | 313 | 1.8 |
| EC | 395 | 1.0*** | 292 | 1.2 | 183 | 1.2 |
| Injectable | 1071 | 2.3*** | 289 | 1.5 | na | na |
| IUD | 560 | 2.1 | na | na | na | na |
| Totala | 3.7 | 3.6 | 3.8 |
| Unadjusted OR (95% CI) | Adjusted OR (95% CI)* | Pv | |
| Hillel Yaffe Medical Center vs. Carmel Medical Center | 3.20 (1.53-6.69) | 4.42 (1.70-11.46) | 0.002 |
| Arabs vs. Jews | 2.30 (1.16-4.54) | 2.32 (0.99-5.45) | 0.05 |
| Blood in the stool (yes vs. no) | 1.98 (1.00-3.91) | 2.78 (1.17-6.60) | 0.021 |
| Diarrhea (yes vs. no) | 0.34 (0.11-1.03) | 0.22 (0.05-1.1) | 0.06 |
| S.n | Criterion | Sensitivity | Specificity | PPV | NPV |
| 1. | Size > 6 cm | 0.95 | 0.57 | 0.67 | 0.93 |
| 2. | Size >8 cm | 0.75 | 0.76 | 0.75 | 0.76 |
| 3. | Shape: irregular, lobulated | 0.83 | 0.76 | 0.76 | 0.83 |
| 4. | Margins: infiltrative | 0.91 | 0.65 | 0.70 | 0.89 |
| 5. | Isointensity on T1W | 0.70 | 0.76 | 0.73 | 0.74 |
| 6. | Slight hyperintensity on T2W | 0.95 | 0.38 | 0.58 | 0.90 |
| 7. | heterogeneous lesion | 1 | 0.5 | 0.64 | 1 |
| 8. | Peritumoral edema | 0.95 | 0.5 | 0.63 | 0.92 |
| 9. | Absence of multiplicity | 0.54 | 0.15 | 0.37 | 0.26 |
| 10. | Intratumoral necrosis | 0.87 | 0.84 | 0.84 | 0.88 |
| 11. | Intratumoral hemorrhage | 0.70 | 0.65 | 0.65 | 0.70 |
| 12. | Intratumoral calcification | 0.70 | 0.88 | 0.85 | 0.76 |
| 13. | Absence of Intratumoral fat | 1 | 0.07 | 0.5 | 1 |
| 14. | Absence of Intratumoral fibrosis | 0.87 | 0.03 | 0.45 | 0.25 |
| 15. | Fascia penetration | 0.83 | 0.73 | 0.82 | 0.74 |
| 16. | Bone changes | 0.83 | 0.84 | 0.83 | 0.84 |
| 17. | Neurovascular involvement | 0.83 | 0.88 | 0.86 | 0.85 |
| 18. | Enhancement pattern (Heterogenous) | 1 | 0.07 | 0.5 | 1 |
| 19. | Absence of T1 hyperintense tracts | 1 | 0.11 | 0.51 | 1 |
| 20. | Absence of Fluid-fluid levels | 0.83 | 0.26 | 0.51 | 0.63 |
| patients | EMD | p* | |
| pCR | |||
| pCR | 19 (17.1) | 6.1 ± 1.8 | 0.033 |
| non-pCR | 92 (82.9) | 7.8 ± 3.2 | |
| TRG | |||
| TRG 0–1 | 50 (45.0) | 7.2 ± 3.1 | 0.355 |
| TRG 2–3 | 61 (55.0) | 7.7 ± 3.1 | |
| Downstaging | |||
| ypStage 0–I | 42 (37.8) | 7.1 ± 3.0 | 0.258 |
| ypStage II–III | 69 (62.2) | 7.8 ± 3.1 |
| Scales | PANSS | AIMS | BAS | SAS | AP (mg) | DUI | AGE | Subtype | Calgary |
| (CPZ equiv.) | (years) | (years) | (n) | ||||||
| Groups Control (n = 9) | 36.1/ | ||||||||
| m/sd | 8.43 | ||||||||
| Total (n = 11) | 74.09/ | 7.36/ | 1.18/ | 1.27/ | 638.84/ | 17.27/ | 42.09 | Paranoid (3) | 5.55 ± 2.8 |
| m/sd | 15.06 | 5.78 | 1.17 | 1.19 | 439.90 | 12.16 | 13.67 | Undiffer. (8) | |
| CA (n = 6) | 73.83/ | 10.67/ | 1.83/ | 1.33/ | 700.00/ | 22.50/ | 49.50/ | Paranoid (1) | 4.83 ± 3.31 |
| m/sd | 17.53 | 5.96 | 1.17 | 1.51 | 496.5 | 12.63 | 12.45 | Undiffer. (5) | |
| AA (N = 5) | 74.40/ | 3.40/ | 0.40/ | 1.20/ | 565.45/ | 11.00/ | 33.20/ | Paranoid (2) | 6.40 ± 2.07 |
| m/sd | 13.51 | 1.82 | 0.55 | 0.84 | 404.03 | 8.94 | 9.60 | Undiffer. (3) | |
| Analysis between users of CA and AA (Mann-Whitney test) | |||||||||
| U test | 14.5 | 4.5 | 4.5 | 13 | 11 | 5.5 | 4 | 8 | |
| P value | 0.93 | 0.05 | 0.05 | 0.93 | 0.54 | 0.08 | 0.05 | 0.25 | |
| Analysis between controls, AA, and CA (Kruskal-Wallis test) | |||||||||
| Chi-square | 5.94 | ||||||||
| P-value | 0.051 |
| Prevalence of TT post-intervention (cases per 1000 persons) | Incidence of CO post-intervention (cases per 10,000 persons per annum) | ||||||
| Intervention | Intensity of control effort | 5 years | 10 years | 20 years | 5 years | 10 years | 20 years |
| S | Low | 9.4 | 7.4 | 6.3 | 3.3 | 2.6 | 2.1 |
| Medium | 3.9 | 3.9 | 3.9 | 1.3 | 1.3 | 1.3 | |
| High | 1.8 | 1.8 | 1.8 | 0.6 | 0.6 | 0.6 | |
| A | Low | 13.5 | 13.6 | 13.6 | 4.6 | 4.6 | 4.6 |
| Medium | 12.8 | 13.0 | 13.1 | 4.3 | 4.4 | 4.4 | |
| High | 12.8 | 12.3 | 12.5 | 4.3 | 4.2 | 4.2 | |
| TR | Low | 13.6 | 12.6 | 9.1 | 4.6 | 4.3 | 3.1 |
| Medium | 13.4 | 11.9 | 6.8 | 4.6 | 4.1 | 2.4 | |
| High | 12.8 | 9.7 | 4.5 | 4.4 | 3.4 | 1.6 | |
| S + A | Low | 9.1 | 7.2 | 6.2 | 3.2 | 2.5 | 2.1 |
| Medium | 3.1 | 3.6 | 3.6 | 1.1 | 1.2 | 1.2 | |
| High | 1.4 | 1.6 | 1.7 | 0.5 | 0.5 | 0.6 | |
| S + TR | Low | 9.1 | 6.4 | 3.1 | 3.2 | 2.2 | 1.1 |
| Medium | 3.4 | 2.6 | 0.6 | 1.2 | 0.9 | 0.2 | |
| High | 0.6 | 0.3 | 0.2 | 0.4 | 0.1 | 0.1 | |
| A + TR | Low | 13.6 | 12.6 | 9.1 | 4.6 | 4.3 | 3.1 |
| Medium | 13.4 | 11.6 | 6.2 | 4.6 | 4.0 | 2.2 | |
| High | 12.8 | 9.1 | 4.1 | 4.4 | 3.2 | 1.4 | |
| S + A + TR | Low | 9.1 | 6.4 | 3.1 | 3.2 | 2.2 | 1.1 |
| Medium | 3.4 | 1.2 | 0.5 | 1.2 | 0.9 | 0.2 | |
| Hi | 1.2 | 0.1 | 0.1 | 0.4 | 0.1 | 0.1 | |
| None | 14.0 | 14.0 | 14.0 | 4.7 | 4.7 | 4.7 |
| WCO | BEO | |||||
| Searches | Avg. | Searches | Searches | Avg. | Searches | |
| Time (s) | per s | Time (s) | per s | |||
| LS | 879 | 0.095 | 9253 | 2032 | 0.1317 | 15429 |
| GACT | 146430 | 4.32 | 33896 | 30850 | 1.01 | 30433 |
| HC | 300650 | 13.82 | 21749 | 299580 | 11.41 | 26256 |
| miRNA | *activated vs resting | Q value |
| mir-211 | Down | 0.0026 |
| miR-148a | Up | 0.0340 |
| mir-141 | Down | 0.0445 |
| miR-155 | Up | 0.0445 |
| mir-184 | Down | 0.0445 |
| miR-15b | Up | 0.0445 |
| mir-30b | Down | 0.0445 |
| miR-150 | Down | 0.0445 |
| miR-148b | Up | 0.0445 |
| mir-16-2 | Up | 0.0445 |
| miR-216 | Down | 0.0445 |
| mir-185 | Down | 0.0445 |
| miR-18a | Up | 0.0445 |
| miR-17-5p | Up | 0.0448 |
| miR-130b | Up | 0.0448 |
| miR-516-3p | Down | 0.0448 |
| miR-106a | Up | 0.0500 |
| miR-21 | Up | 0.0500 |
| miR-95 | Down | 0.0551 |
| miR-20b | Up | 0.0833 |
| miR-425-5p | Up | 0.0833 |
| miR-181b | Up | 0.0833 |
| miR-181a | Up | 0.0833 |
| miR-135a | Down | 0.0833 |
| miR-181c | Up | 0.0853 |
| mir-203 | Down | 0.0855 |
| miR-15a | Up | 0.0855 |
| miR-483 | Down | 0.0855 |
| miR-182* | Down | 0.0855 |
| miR-20a | Up | 0.0855 |
| miR-181d | Up | 0.0909 |
| miR-98 | Up | 0.0911 |
| mir-326 | Down | 0.0986 |
| Health outcome | Studies exploring associations with weather/climate | Studies projecting the health impacts of climate change |
| Heat waves | ++ | + |
| Other extreme events | + | 0 |
| Waterborne and foodborne diseases | ++ | 0 |
| Vectorborne and zoonotic diseases | + | 0 |
| Air pollution (limited areas) | ++ | + |
| Aeroallergens | + | 0 |
| Other health impacts including mental health, nutritional issues related to food security, and population displacement | + | 0 |
| First assessment, first test (n = 63) | First assessment, second test (n = 63) | P-value for group difference† | Second assessment, first test (n = 61) | Second assessment, second test (n = 61) | P-value for group difference† | |
| Neck flexor muscle endurance test (supine), holding time, sec | 36.40 (33.25) | 30.92 (25.92) | 0.305 | 34.03 (23.74) | 38.10 (33.94) | 0.445 |
| Neck flexor muscle endurance test (sitting 45°), holding time, sec | 82.33 (57.23) | 72.70 (52.83) | 0.328 | 102.11 (82.34) | 85.13 (57.81) | 0.190 |
| Neck extensor test, holding time, sec | 36.21 (25.09) | 33.51 (23.56) | 0.535 | 37.02 (28.39) | 38.34 (25.72) | 0.787 |
| Parameters | Soda Wheat Straw BL 1 | Soda Barley Straw BL 1 | Soda-AQ 3Leucaena BL 1 | Soda-AQ 3Chamaecytisus BL 1 |
| pH | 10.72 ± 0.16 | 10.24 ± 0.011 | 9.85 ± 0.005 | 10.47 ± 0.006 |
| Density (g/mL) | 1.011 ± 0.002 | 1.004 ± 0.007 | 1.021 ± 0.002 | 1.017 ± 0.003 |
| Total Dry Solids (g/L) | 32.57 ± 0.13 | 45.67 ± 0.21 | 55.80 ± 0.21 | 51.74 ± 0.93 |
| Ash (g/L) | 15.99 ± 0.42 | 16.77 ± 1.22 | 23.69 ± 0.33 | 20.84 ±1.60 |
| Lignin (g/L) | 11.6 | 12.6 | 24.3 | 19.0 |
| Total monosaccharides (g/L) | 3.812 | 4.004 | 4.239 | 5.049 |
| Glucose (g/L) | 0.127 | 0.211 | 1.237 | 0.262 |
| Xylose (g/L) | 1.682 | 2.814 | 1.781 | 2.624 |
| Arabinose (g/L) | 0.706 | 0.240 | 0.428 | 0.649 |
| Acetyl groups (g/L) | 1.297 | 0.739 | 0.792 | 1.514 |
| HMF 2 (g/L) | 0.00 | 0.00 | 0.00 | 0.00 |
| Furfural (g/L) | 0.00 | 0.00 | 0.00 | 0.00 |
| Electrical conductivity (mS/cm) | 14.63 ± 0.01 | 13.007 ± 0.005 | 21.7 ± 0.42 | 21.4 ± 0.06 |
| Serial number | Dose (mg/ml) | Size of NPs (nm) | Time (h) | Head | Tail | Comet | Head DNA | Tail DNA | Tail moment | Olive tail moment |
| 1 | 0.0 | Nil | 0 | 51 | 52 | 103 | 72.62 | 27.37 | 14.23 | 10.27 |
| 2 | 1.0 | 100 | 12 | 50 | 51 | 104 | 72.62 | 26.43 | 14.12 | 10.17 |
| 3 | 1.0 | 100 | 24 | 51 | 52 | 103 | 72.61 | 27.32 | 14.13 | 10.17 |
| 4 | 1.0 | 100 | 36 | 52 | 53 | 104 | 72.51 | 27.03 | 14.23 | 10.23 |
| 5 | 1.0 | 100 | 48 | 51 | 52 | 104 | 72.61 | 27.31 | 14.34 | 11.23 |
| 6 | 1.0 | 50 | 12 | 50 | 51 | 104 | 72.62 | 26.43 | 14.12 | 10.17 |
| 7 | 1.0 | 50 | 24 | 51 | 52 | 102 | 71.12 | 27.32 | 14.13 | 10.17 |
| 8 | 1.0 | 50 | 36 | 52 | 53 | 104 | 72.51 | 27.03 | 14.23 | 10.23 |
| 9 | 1.0 | 50 | 48 | 51 | 52 | 104 | 72.61 | 27.31 | 14.34 | 11.23 |
| 10 | 3.0 | 100 | 12 | 77 | 56 | 133 | 82.5 | 17.49 | 9.79 | 7.79 |
| 11 | 3.0 | 100 | 24 | 111 | 144 | 255 | 85.39 | 18.62 | 21.03 | 12.82 |
| 12 | 3.0 | 100 | 36 | 105 | 176 | 281 | 73.24 | 26.75 | 57.04 | 25.17 |
| 13 | 3.0 | 100 | 48 | 109 | 116 | 225 | 60.67 | 39.32 | 45.6 | 33.83 |
| 14 | 3.0 | 50 | 12 | 83 | 42 | 125 | 89.12 | 10.87 | 4.56 | 4.66 |
| 15 | 3.0 | 50 | 24 | 71 | 62 | 133 | 81.98 | 18.01 | 11.17 | 8.18 |
| 16 | 3.0 | 50 | 36 | 71 | 74 | 245 | 91.25 | 18.74 | 6.47 | 8.23 |
| 17 | 3.0 | 50 | 48 | 75 | 121 | 296 | 57.59 | 42.41 | 51.3 | 27.63 |
| 18 | 5.0 | 100 | 12 | 83 | 32 | 115 | 90.96 | 9.03 | 2.89 | 4.22 |
| 19 | 5.0 | 100 | 24 | 77 | 52 | 129 | 70.83 | 15.16 | 15.16 | 12.64 |
| 20 | 5.0 | 100 | 36 | 129 | 74 | 203 | 83.72 | 16.27 | 12.04 | 14.34 |
| 21 | 5.0 | 100 | 48 | 105 | 176 | 281 | 73.24 | 26.75 | 47.09 | 25.17 |
| 22 | 5.0 | 50 | 12 | 113 | 87 | 200 | 85.8 | 14.19 | 12.34 | 10.42 |
| 23 | 5.0 | 50 | 24 | 115 | 132 | 247 | 80.92 | 19.07 | 25.18 | 16.43 |
| 24 | 5.0 | 50 | 36 | 85 | 155 | 240 | 65.69 | 34.32 | 53.17 | 27.82 |
| 25 | 5.0 | 50 | 48 | 65 | 135 | 242 | 35.69 | 64.31 | 86.8 | 41.53 |
| VAI | WC | WHtR | P-value (compare WC and VAI) | P-value (compare WHtR and VAI) | |
| Composite outcomes | |||||
| T = 4 years | 60.85 ± 2.87 | 59.26 ± 3.09 | 59.98 ± 3.07 | 0.63 | 0.79 |
| T = 5 years | 59.67 ± 2.97 | 60.69 ± 3.09 | 60.79 ± 3.08 | 0.76 | 0.73 |
| T = 6 years | 62.82 ± 3.01 | 61.83 ± 3.17 | 62.42 ± 3.14 | 0.77 | 0.90 |
| CV outcomes | |||||
| T = 4 years | 63.12 ± 3.06 | 62.23 ± 3.38 | 63.26 ± 3.36 | 0.80 | 0.97 |
| T = 5 years | 61.76 ± 3.16 | 63.06 ± 3.28 | 62.97 ± 3.29 | 0.71 | 0.73 |
| T = 6 years | 65.56 ± 3.15 | 64.31 ± 3.33 | 64.65 ± 3.31 | 0.72 | 0.79 |
| All-cause mortality | |||||
| T = 4 years | 57.41 ± 3.51 | 51.87 ± 3.91 | 51.44 ± 3.78 | 0.22 | 0.15 |
| T = 5 years | 57.41 ± 3.51 | 54.74 ± 3.62 | 54.91 ± 3.56 | 0.74 | 0.76 |
| T = 6 years | 57.08 ± 3.28 | 57.56 ± 3.54 | 58.16 ± 3.49 | 0.90 | 0.76 |
| ≤44 yrs | 45 – 59 yrs | 60 – 74 yrs | ≥75 yrs | |
| Indication | ||||
| Ischemia/CAD | 12.1% | 37.7% | 48.1% | 49.5% |
| Myocarditis/CMP | 63.6% | 36.6% | 22.5% | 16.5% |
| Viability | 5.3% | 17.0% | 19.2% | 22.4% |
| Stress CMR | 13.7% | 38.0% | 47.5% | 47.9% |
| Image quality | ||||
| Good | 92.6% | 90.8% | 86.2% | 80.1% |
| Moderate | 6.3% | 8.0% | 11.9% | 16.9% |
| Poor | 1.1% | 1.2% | 1.9% | 3.0% |
| Complications | ||||
| None | 98.4% | 96.7% | 95.5% | 94.4% |
| Mild | 1.6% | 3.3% | 4.5% | 5.5% |
| Severe | 0.0% | 0.1% | 0.0% | 0.0% |
| New diagnosis | 9.3% | 9.5% | 8.7% | 7.7% |
| Therapeutic consequence | 40.4% | 51.9% | 58.4% | 64.6% |
| TC (mmol/L) | TG (mmol/L) | HDL (mmol/L) | LDL (mmol/L) | |
| control | 13.8 ± 0.3 | 1.4 ± 0.2 | 3.7 ± 0.9 | 8.2 ± 0.8 |
| agmatine | 19 ± 4.1(p = 0.052) | 1.7 ± 0.6 (NS) | 8.6 ± 1.8 * | 11.7 ± 2.4 (NS) |
| Exposure variablesa\\Percentileb | Min | 5th | 25th | 50th | 75th | 95th | Max |
| As metabolites (μg g−1 crea) | |||||||
| MMA | 0.06 | 0.08 | 0.19 | 0.40 (1.10)c | 1.67 | 6.14 | 28.5 |
| DMA | 0.07 | 3.09 | 11.27 | 20.73 (14.58) | 29.5 | 70.75 | 129.1 |
| iAs | 0.11 | 0.19 | 0.41 | 0.83 (0.61) | 1.33 | 4.74 | 6.55 |
| tAs | 0.34 | 3.76 | 12.09 | 23.19 (16.29) | 33.29 | 76.02 | 137.5 |
| Self-rated health | |||||
| Improved | Worsening | Sustained good | Sustained poor | Total | |
| 277 (6) | 556 (13) | 2864 (68) | 543 (13) | 4240 (100) | |
| Sex | |||||
| Female | 241 (7) | 474 (13) | 2370 (67) | 475 (13) | 3560 (100) |
| Male | 36 (5) | 82 (12) | 494 (73) | 68 (10) | 680 (100) |
| Age (mean ± SD)a | 46 ± 9 | 48 ± 9 | 46 ± 9 | 49 ± 8 | 46 ± 9 |
| Current smoker (n, %) | 78 (7) | 184 (17)b | 657 (59)b | 191 (17)b | 1110 (100) |
| Body mass index (BMI) | |||||
| Underweight (>18.5) | 4 (10) | 4 (10) | 28 (70) | 4 (10) | 40 (100) |
| Normal weight (18.5–24.9) | 126 (5) | 264 (11) | 1706 (74) | 232 (10) | 2328 (100) |
| Overweight (25.0–29.9) | 106 (8) | 201 (14) | 873 (63) | 206 (15) | 1386 (100) |
| Obesity (<29.9) | 39 (9) | 76 (19) | 202 (50) | 89 (22) | 406 (100) |
| Financial situation at baseline | |||||
| Good | 80 (4) | 195 (11) | 1398 (78) | 131 (7) | 1804 (100) |
| Neither/nor | 143 (8) | 250 (14) | 1128 (63) | 275 (15) | 1789 (100) |
| Strained | 61 (9) | 111 (17) | 338 (52) | 137 (21) | 647 (100) |
| Change in financial situation | |||||
| Improved | 61 (7) | 102 (12) | 582 (70) | 91 (11) | 835 (100) |
| Unchanged | 179 (6) | 371 (13) | 2025 (69) | 362 (12) | 2937 (100) |
| Worsening | 37 (8) | 83 (18) | 257 (55) | 90 (19) | 468 (100) |
| Education at baseline | |||||
| Further | 162 (7) | 282 (12) | 1697 (70) | 268 (11) | 2401 (100) |
| Non-academic | 115 (6) | 274 (15) | 1167 (63) | 275 (15) | 1839 (100) |
| Managerial responsibility at baseline | |||||
| Top manager | 57 (6) | 109 (11) | 673 (71) | 109 (11) | 948 (100) |
| Otherc | 220 (7) | 447 (13) | 2191 (67) | 434 (13) | 3292 (100) |
| microRNA | Inhibitor Agent | Type of Disease | Investigation Status | Company/Ref |
| miR-10b | ASO | Glioblastoma | Preclinical | Regulus Therapeutics [108] |
| miR-21 | ASO | HCC, fibrosis | Preclinical | Regulus Therapeutics [109,110] |
| miR-155 | LNA-modified | T cell lymphoma and mycosis fungoides | Phase I | miRagen Therapeutics [111] |
| miR-221 | ASO | Pancreatic carcinoma | Preclinical | Regulus Therapeutics [110] |
| miR-122 | LNA-modified | HCV | Phase II | Santaris Pharma [112,113] |
| Clinical variables | PFS | OS | ||
| HR (95%CI) | P value | HR (95%CI) | P value | |
| Univariate analysis | ||||
| Age | 0.999 (0.975-1.023) | 0.915 | 1.003 (0.977-1.030) | 0.814 |
| Histologyclear cellEndometrioidMixed | Reference0.967 (0.585-1.671)1.896 (0.903-3.982) | 0.286 | Reference0.910 (0.514-1.611)1.845 (0.867-3.926) | 0.282 |
| ECOG performance0-12-3 | Reference1.895 (0.913-3.932) | 0.088 | Reference1.567 (0.678-3.621) | 0.296 |
| FIGO stageEarly stage (I-II)Late stage (III-IV) | Reference10.367 (6.460-16.638) | <0.001 | Reference7.413 (4.526-12.139) | <0.001 |
| Lymph node metastasisnegativepositive | Reference4.707 (2.786-7.952) | <0.001 | Reference3.048 (1.684-5.517) | <0.001 |
| Intraperitoneal metastasisnegativepositive | Reference6.182 (3.908-9.778) | <0.001 | Reference5.194 (3.213-8.398) | <0.001 |
| Residual tumor (cm)≤ 1> 1 | Reference5.639 (3.375-9.423) | <0.001 | Reference4.556 (2.651-7.831) | <0.001 |
| Preoperative ascites (ml)< 500≥ 500 | Reference2.914 (1.682-5.047) | <0.001 | Reference2.653 (1.473-4.779) | 0.001 |
| Preoperative CA125 (U/ml)< 35≥ 35 | Reference2.524 (1.561-4.079) | <0.001 | Reference2.570 (1.536-4.301) | <0.001 |
| Endometriosisnegativepositive | Reference0.187 (0.086-0.405) | <0.001 | Reference0.238 (0.109-0.518) | <0.001 |
| Multivariate analysis | ||||
| FIGO stageEarly stage (I-II)Late stage (III-IV) | Reference8.642 (5.339-13.988) | <0.001 | Reference6.158(3.732-10.163) | <0.001 |
| Preoperative CA125 (U/ml)< 35≥ 35 | Reference2.033 (1.249-3.309) | 0.003 | Reference2.150 (1.275-3.626) | 0.010 |
| Endometriosisnegativepositive | Reference0.284 (0.130-0.623) | 0.002 | Reference0.349 (0.159-0.765) | 0.009 |
| Evidence code type | Evidence code | Annotation errors | Total annotations | Percentage error rate |
| Experimental(manually assigned) | EXP | 977 | 5360 | 18.23 |
| IDA | 12 | 105764 | 0.01 | |
| IMP | 84 | 88283 | 0.10 | |
| IEP | 0 | 10129 | 0.00 | |
| IPI | 0 | 29877 | 0.00 | |
| IGI | 0 | 12914 | 0.00 | |
| Computational Analysis(manually assigned) | ISS | 85 | 228605 | 0.04 |
| ISO | 1 | 2975 | 0.03 | |
| ISA | 0 | 5921 | 0.00 | |
| ISM | 0 | 143 | 0.00 | |
| IGC | 0 | 483 | 0.00 | |
| RCA | 3 | 75175 | 0.00 | |
| Author statement(manually assigned) | TAS | 4070 | 46888 | 8.68 |
| NAS | 3 | 23578 | 0.01 | |
| Curator statement(manually assigned) | IC | 0 | 5682 | 0.00 |
| ND | 0 | 171817 | 0.00 | |
| Automatically Assigned | IEA | 639 | 844441 | 0.08 |
| Image | Speed up |
| Spine (MRI) | 32.7% |
| Chest (X-ray) | 33.1% |
| Fetus (ultrasonic) | 52.7% |
| Head (CT) | 53.6% |
| Primer target | Primer sequence (5′ to 3′) |
| Pgc-1α-a F | GCTTGACTGGCGTCATTCG |
| Pgc-1α-a R | ACAGAGTCTTGGCTGCACATGT |
| Pgc-1α-b F | GACATGGATGTTGGGATTGTCA |
| Pgc-1α-b R | ACCAACCAGAGCAGCACATTT |
| Pgc-1α-c F | AGTGACATGGATGTTGGGATTG |
| Pgc-1α-c R | GAATGCCTCCGGTTACTCACTT |
| Pgc-1α4 F | TCACACCAAACCCACAGAAA |
| Pgc-1α4 R | CTG GAA GAT ATG GCA CAT |
| FL-Pgc-1αF | TGCCATTGTTAAGACCGA |
| FL-Pgc-1αR | CCAGAGTCACCAAATGACC |
| total NT-Pgc-1α F | TGCCATTGTTAAGACCGA |
| total NT-Pgc-1α R | CCATATCTTCCAGTGACC |
| total Pgc-1α F | TGATGTGAATGACTTGGATACAGACA |
| total Pgc-1α R | GCT CAT TGT TGT ACT GGT TGG ATA TG |
| Variable | Status of LLIN usage number (%) | Crude OR (95 % CI) | Adjusted OR (95 % CI)a | p-value | |
| Yes N = 11,574 | No N = 2876 | ||||
| Age categories (years) | |||||
| 0–5 | 2511 (83.12) | 510 (16.88) | 1 | 1 | |
| 6–14 | 2808 (75.26) | 923 (24.71) | 1.17 (1.38–1.90) | 1.29 (1.11–1.49) | 0.001* |
| 15–45 | 4801 (80.86) | 1136 (19.14) | 1.17 (1.00–1.36) | 1.02 (0.90–1.16) | 0.745 |
| >45 | 1450 (82.58) | 306 (17.42) | 1.04 (0.83–1.31) | 0.69 (0.56–0.86) | 0.001* |
| Gender | |||||
| Male | 5542 (79.18) | 1457 (20.82) | |||
| Female | 6033 (80.96) | 1418 (19.04) | 0.90 (0.81–0.99) | 0.94 (0.85–1.04) | 0.236 |
| Number of household members | |||||
| 1 | 354 (84.88) | 62 (15.12) | 1 | 1 | |
| 2 | 683 (81.43) | 156 (18.57) | 1.28 (0.87–1.89) | 1.48 (0.97–2.24) | 0.066 |
| 3 | 1235 (85.05) | 217 (14.95) | 0.99 (0.65–1.51) | 1.34 (0.83–2.18) | 0.228 |
| 4 | 1924 (80.76) | 459 (19.24) | 1.34 (0.94–1.90) | 1.97 (1.27–3.07) | 0.003* |
| 5 | 1615 (79.53) | 416 (20.41) | 1.45 (1.01–2.06) | 2.16 (1.38–3.38) | 0.001* |
| 6 | 2231 (79.59) | 572 (20.41) | 1.44 (0.98–2.12) | 2.25 (1.36–3.71) | 0.002* |
| >6 | 3532 (78.04) | 994 (21.96) | 1.58 (1.09–2.29) | 2.27 (1.33–3.87) | 0.003* |
| Residence | |||||
| Urban | 2267 (80.98) | 532 (19.02) | |||
| Rural | 9306 (79.88) | 2344 (20.12) | 1.07 (0.81–1.42) | 1.06 (0.79–1.41) | 0.695 |
| Number of sleeping rooms | |||||
| 1 | 3670 (82.21) | 795 (17.79) | 1 | 1 | |
| 2 | 3871 (80.65) | 929 (19.35) | 1.11 (0.91–1.35) | 0.90 (0.72–1.12) | |
| 3 | 2546 (78.45) | 699 (21.55) | 1.27 (1.02–1.57) | 0.94 (0.73–1.21) | 0.329 |
| 4 | 903 (77.68) | 259 (22.32) | 1.33 (0.99–1.79) | 0.94 (0.67–1.32) | 0.621 |
| >4 | 421 (71.80) | 165 (28.20) | 1.81 (1.32–2.50) | 1.25 (0.88–1.76) | 0.732 |
| Spraying of rooms with insecticide | |||||
| No | 10,909 (80.06) | 2717 (19.94) | |||
| Yes | 643 (80.29) | 157 (19.71) | 0.99 (0.65–1.49) | 0.90 (0.88–1.76) | 0.605 |
| Number of children under 5 years | |||||
| 0 | 3433 (76.80) | 1037 (23.20) | 1 | 1 | |
| 1 | 3533 (81.37) | 808 (18.63) | 0.76 (0.63–0.92) | 0.77 (0.61–0.98) | 0.030* |
| 2 | 3268 (81.12) | 761 (18.88) | 0.77 (0.63–0.94) | 0.77 (0.61–0.96) | 0.023* |
| >2 | 1340 (83.28) | 269 (16.72) | 0.66 (0.47–0.93) | 0.67 (0.47–0.95) | 0.027* |
| Number of women of child bearing age | |||||
| 0 | 1784 (71.91) | 697 (28.09) | 1 | 1 | |
| 1 | 7213 (83.03) | 1474 (16.97) | 0.52 (0.44–0.62) | 0.46 (0.38–0.57) | 0.001* |
| >1 | 2576 (78.52) | 705 (21.48) | 0.70 (0.57–0.86) | 0.49 (0.37–0.65) | 0.001* |
| Relationship structure | |||||
| 1 related adult | 1784 (71.91) | 331 (18.30) | 1 | 1 | |
| 2 related adults | 7213 (83.03) | 1108 (17.25) | 0.93 (0.73–1.18) | 1.29 (0.96–1.1.74) | 0.004* |
| 3+ unrelated adults | 2576 (78.52) | 1437 (23.15) | 1.34 (1.07–1.70) | 1.60 (1.17–2.19) | 0.870 |
| Community distribution of malaria medicine | |||||
| No | 6270 (81.15) | 1456 (18.85) | 1 | 1 | |
| Yes | 4840 (78.54) | 1322 (21.46) | 1.18 (0.99–1.39) | 1.16 (0.97–1.38) | 0.100 |
| Do not know | 452 (82.71) | 95 (17.29) | 0.90 (0.61–1.33) | 0.87 (0.58–2.69) | 0.504 |
| Item | Factora | |||
| I | II | III | IV | |
| 10. Surfing | .74 | -.07 | -.02 | -.14 |
| 12. Flying Plane | .79 | -.04 | .09 | -.12 |
| 13. Diving | .54 | -.01 | .01 | .03 |
| 14. Skydiving | .66 | .05 | -.04 | .30 |
| 16. Jumping from Heights | .81 | .19 | -.18 | -.10 |
| 21. Skiing | .41 | -.23 | .15 | .14 |
| 1. Wild Parties | -.09 | .40 | .14 | .31 |
| 8. Disinhibited People | .05 | .37 | .39 | -.08 |
| 17. Exciting People | .04 | .69 | -.17 | -.01 |
| 19. Sexual Content Movies | .25 | .36 | .12 | -.13 |
| 20. Alcohol | -.04 | .84 | .23 | -.29 |
| 2. Body Smells | -.05 | -.12 | .42 | .03 |
| 5. Marihuana | .04 | -.11 | .99 | -.07 |
| 6. Hallucinogens Drugs | .01 | .06 | .90 | -.08 |
| 9. Stimulants | -.08 | .27 | .60 | .17 |
| 22. Dangerous Drugs | -.10 | .34 | .46 | .14 |
| 3. Unpredictable Places | .11 | -.04 | .02 | .48 |
| 7. Risk Appetite | .04 | -.11 | .13 | .79 |
| 11. Unplanned Trip | .14 | .01 | .03 | .41 |
| 15. Unpredictable Friends | .06 | .21 | -.09 | .36 |
| 18. Boredom Rejection | -.24 | .28 | -.10 | .48 |
| 23. Risk for Fun | .02 | .27 | .05 | .44 |
| Eigenvalues | 6.58 | 2.89 | 1.58 | 1.31 |
| % of Variance | 29.91 | 13.13 | 7.19 | 5.96 |
| Reliability estimate | .87 | .82 | .93 | .77 |
| Components | Composite Alpha | Extracted variance | Interobserver Reliabilitya | Item | Standb | Var. Error | Factor loadingc | Convergent validityd | Discriminant validity |
| Component 1 | 0.79 | 0.56 | 84.9 | Inflammation | 0.59 | 0.65 | 0.59 | 4.64 | 0.50 |
| Edema | 0.74 | 0.45 | 0.74 | 6.11 | |||||
| Pain | 0.89 | 0.21 | 0.81 | 6.68 | |||||
| Component 2 | 0.71 | 0.55 | 87.9 | Abscess | 0.71 | 0.49 | 0.78 | 5.24 | |
| Alveolar osteitis | 0.78 | 0.39 | 0.78 | 5.74 |
| LVH classification | LVH status | Total population QTd (ms) | p-value | Normotensive group QTd (ms) | p-value | Prehypertensive group QTd (ms) | p-value |
| Sokolow–Lyon | No LVH | 38.77 ± 11.31 | 0.88 | 39.11 ± 11.10 | 0.72 | 38.33 ± 11.72 | 0.88 |
| LVH | 38.13 ± 12.39 | 37.00 ± 11.94 | 39.25 ± 14.57 | ||||
| Araoye | No LVH | 38.78 ± 10.78 | 0.88 | 39.36 ± 10.89 | 0.33 | 39.97 ± 10.67 | 0.54 |
| LVH | 38.20 ± 16.44 | 33.75 ± 13.77 | 41.17 ± 18.61 | ||||
| LVMI | No LVH | 39.72 ± 10.24 | 0.97 | 40.60 ± 10.70 | 0.96 | 38.39 ± 9.58 | 0.87 |
| LVH | 40.00 ± 0.00 | 40.00 ± 0.00 | 40.00 ± 0.00 |
| Men | Women | |||
| Overweight OR (95% CI) | Obese OR (95% CI) | Overweight OR (95% CI) | Obese OR (95% CI) | |
| White | Ref | Ref | Ref | Ref |
| Black | 2.20 (1.54, 3.15) | 2.84 (1.54, 5.22) | 2.03 (1.26, 3.26) | 3.56 (1.57, 8.11) |
| Hispanic | 1.89 (1.30, 2.75) | 1.45 (0.69, 3.07) | 1.34 (0.85, 2.13) | 2.19 (0.96, 5.01) |
| Other | 1.04 (0.48, 2.23) | 1.21 (0.23, 5.27) | 1.58 (0.57, 4.35) | 3.94 (0.94, 15.53) |
| Study period (weeks) | |||||||||
| Time point | 3/16 | 4/16 | 5/16 | 6/16 | 7/16 | 8/16 | 9/16 | 10/16 | 11/16 |
| Enrolment | |||||||||
| Recruitment | X | X | X | X | |||||
| Eligibility screen | X | X | X | X | |||||
| Informed consent | X | X | X | X | |||||
| Allocation | X | X | X | X | |||||
| Interventions: | |||||||||
| Discussion group | X | X | X | X | X | X | |||
| Minimal support group (MSG) | X | X | X | X | X | X | |||
| Wait list control group (access to MSG) | X | X | X | X | X | ||||
| Assessments | |||||||||
| T1 | X | X | X | X | |||||
| Credibility/expectancy | X | X | X | X | X | ||||
| T2 | X | X | X | ||||||
| T3 | X | X | X | ||||||
| Study completion | X |
| Current year | Next year | |||
| Breeders, % | N | Failed breeders, % | N | |
| Breeders | 78.9 | 172 | 21.1 | 46 |
| Failed breeders | 82.0 | 50 | 18.0 | 11 |
| Medical claims with ICD-9-CM diagnosis codes | ||||
| Characteristic | Total patients (N = 214) | Schizophrenia only (n = 44) | Bipolar disorder only (n = 162) | Schizophrenia and bipolar disorder (n = 8) |
| Gender, n (%) | ||||
| Male | 74 (34.58) | 24 (54.55) | 48 (29.63) | 2 (25.00) |
| Female | 140 (65.42) | 20 (45.45) | 114 (70.37) | 6 (75.00) |
| Age, mean (±SD, median) | 43.02 (±12.84, 45) | 46.30 (±10.98, 46.50) | 41.99 (±13.34, 45) | 46.00 (±8.67, 44) |
| Mental health conditions, n (%) | ||||
| Depression | 76 (35.51) | 5 (11.36) | 69 (42.59) | 2 (25.00) |
| Anxiety disorder | 49 (22.90) | 3 (6.82) | 45 (27.78) | 1 (12.50) |
| Insomnia | 21 (9.81) | 2 (4.55) | 18 (11.11) | 1 (12.50) |
| Substance abuse | 0 | |||
| Alcohol | 8 (3.74) | 1 (2.27) | 7 (4.32) | 0 |
| Opiates | 4 (1.87) | 0 | 4 (2.47) | 0 |
| Mean | SD | Range | Skewa | Kurtosisa | |
| Adolescent self‐worth | 26.85 | 4.53 | 16–46 | −0.47 (−0.46) | 3.31 (3.30) |
| Parent report parent–child closeness | 39.09 | 4.66 | 21–50 | −0.09 (−0.08) | 2.75 (2.76) |
| Parent report expressions of affection | 57.35 | 14.55 | 23–123 | 0.41 (0.45) | 3.08 (3.34) |
| Subthemes | Data extracts |
| 4.1 Lack of empathy with the challenges of medication usage | ‘ ... They don't understand that you are wearing stuff on your head that makes you smell like you're painting fences ... it's really frustrating, they [clinicians] need to look at the impact of these treatments, maybe then they could understand why people aren't sticking to them.’ [P11: using topical therapy] |
| ‘My [GP] said, “Well use the coal tar during the day,” and I said, “Well I can't because it's too messy ... ,” and all she said was “Oh, well just wear gloves.” But it's impossible as I'm working with papers all the time.’ [P9: prescribed topical therapy but using herbal therapies] | |
| ‘It did kind of put me under a bit of stress, it affected my condition hugely. I really don't understand why [I was unable to be prescribed my preferred biologic], I mean, I try not to think about it too much but at the time it did cause me a lot of worry and upset ... there might have been a very good reason behind it but they didn't want to share it with me.’ [P3: prescribed a biologic] | |
| ‘I had to really look [possible side‐effects] up myself on the Internet. She [clinician] was quite blasé about it ... and I was reading all these blogs about side‐effects which worried me, so I wasn't happy that I wasn't getting all the information.’ [P13: using topical and oral therapy] | |
| ‘Nobody has ever really asked me how I feel about my psoriasis or how I deal with my psoriasis. Or what my feelings are. Nobody has ever asked me that.’ [P15: using topical therapy and photochemotherapy] | |
| 4.2 Lack of support reinforced rejection of psoriasis therapies | ‘I stopped going [to the GP] because they weren't helping ... because nothing [treatment] had worked there wasn't really much point in trying another one.’ [P9: prescribed topical therapy but using herbal therapies] |
| Anatomical region | L/R | Cluster level P(corrected) | Size (voxels) | Voxel level P (FDR-corrected) | Voxel level P (uncorrected) | MNI (mm) x y z | Voxel Z | ||
| Limbic lobe uncus | Left | 0.015 | 92 | 0.232 | 0.000 | −18 | 2 | −22 | 4.13 |
| Middle Frontal gyrus | Left | 0.083 | 66 | 0.018 | 0.000 | −18 | 46 | −14 | 5.21 |
| Cerebellum posterior Lobe | Right | 0.025 | 89 | 0.125 | 0.000 | 26 | −34 | −40 | 3.98 |
| Landscape characteristics | Definition |
| Habitat types | |
| Floodplain | Open, seasonally flooded grasslands |
| Grassland | Open, shrubbed, savannah grasslands |
| Acacia woodland | Open woodland with >70% Acacia species |
| Riparian woodland | Tall open mixed woodland located in riverine or historic riverine areas |
| Mopane woodland | Colophosphermum mopane dominated woodland |
| Landscape metrics | |
| Number of habitat patches (NP) | Measure of landscape fragmentation; metric equals the number of patches in the landscape. Value ranges from 1 if one patch covers entire landscape to a maximum equal to the total number of patches |
| Landscape mean patch shape index (MSI) | Measure of the average patch complexity within the landscape; metric equals 1 if average patch is square, increasing without limit as shape becomes more irregular |
| Index of juxtaposition and interspersion (IJI) | Measure of the intermixing of different habitat patches; probabilistic metric equals 0 if some habitat types are commonly found adjacent to each other but others are rarely found adjacent to each other, ranging to 100 when all habitat types are equally adjacent to all other habitat types |
| Clinical features | Patients at onset n | Cumulative number of patients at eight years n |
| Dactylitis | 15 | 24 |
| Nail pitting | 10 | 18 |
| Psoriasis | 11 | 14 |
| Psoriasis-like rash | 6 | 13 |
| Enthesitis | 37 | 41 |
| Model definition(relevant year in brackets) | External data definition(data source in brackets) | |
| Incidence | OUTCOME: Incidence of first AMI (2010) | Incidence of first AMI since 1998 (linked hospital episodes and mortality statistics, 2010). |
| Prevalence | Prevalence of ever having had an AMI (2010) | Prevalence of ever having had a doctor-diagnosed AMI (Health Survey for England, 2011). |
| Remission | Zeroa | Zero |
| Excess mortality | Excess mortality due to first AMI (2010) | Death where AMI is included anywhere on the death certificate (ONS mortality statistics, 2010). |
| Characteristics | Potential patients (n = 10) | Therapists (stage 1) (n = 4) | Therapists (stage 3) (n = 5) | |||
| n | % | n | % | n | % | |
| Sex | ||||||
| Male | 2 | 20 | 2 | 50 | 2 | 40 |
| Female | 8 | 80 | 2 | 50 | 3 | 60 |
| Age (in years) | ||||||
| 18–30 | 2 | 20 | 0 | 0 | 0 | 0 |
| 30–50 | 4 | 40 | 2 | 50 | 3 | 60 |
| 50–70 | 4 | 40 | 2 | 50 | 2 | 40 |
| Nationality | ||||||
| British | 10 | 100 | 4 | 100 | 5 | 100 |
| Highest level of education | ||||||
| < A-levels | 1 | 10 | 0 | 0 | 0 | 0 |
| A-levels | 2 | 20 | 0 | 0 | 0 | 0 |
| University degree | 5 | 50 | 1 | 25 | 1 | 20 |
| Post-graduate diploma | 0 | 1 | 25 | 2 | 40 | |
| Post-graduate degree | 1 | 10 | 1 | 25 | 1 | 20 |
| Doctoral degree | 1 | 10 | 1 | 25 | 1 | 20 |
| Mental health problem | ||||||
| Depression | 10 | 100 | N/A | N/A | ||
| Anxiety | 8 | 80 | N/A | N/A | ||
| Previous therapy experience | ||||||
| None | 4 | 40 | N/A | N/A | ||
| Cognitive behavioural therapy | 4 | 40 | N/A | N/A | ||
| Mindfulness-based cognitive therapy | 3 | 30 | N/A | N/A | ||
| Behavioural activation | 1 | 10 | N/A | N/A | ||
| Interpersonal psychotherapy | 1 | 10 | N/A | N/A | ||
| Area(s) of clinical training | ||||||
| Cognitive behavioural therapy | N/A | 4 | 100 | 5 | 100 | |
| Behavioural activation | N/A | 4 | 100 | 4 | 80 | |
| Eye movement desensitisation and reprocessing | N/A | 1 | 25 | 2 | 40 | |
| Interpersonal psychotherapy | N/A | 1 | 25 | 1 | 20 | |
| Dialectical behaviour therapy | N/A | 1 | 25 | 1 | 20 |
| Gene | Organ | LPS | LPS + HOCbl | P value (versus LPS) |
| IL-1β | Liver | − 8.30 ± 0.30 | −10.6 ± 0.3* | 0.0056 |
| Lung | 2.70 ± 0.50 | 2.1 ± 0.1 | 0.3046 | |
| TNF-α | Liver | − 86.90 ± 0.10 | −68.6 ± 0.2* | <0.0001 |
| Lung | − 2.10 ± 0.20 | −11.4 ± 0.1* | <0.0001 |
| Limbs = 421 | ||
| Mercury | Electronic device | |
| Brachial SBP (mmHg), mean (SD) | 140 (17) | 140 (17) |
| Dorsalis pedis SBP (mmHg), mean (SD) | 158 (30) | 157 (30) |
| Posterior tibial SBP (mmHg), mean (SD) | 160 (31) | 160 (30) |
| ABI, n (%) | ||
| Normal (0.91–1.39) | 340 (80.8) | 344 (81.7) |
| Abnormal (≤ 0.90) | 40 (9.5) | 37 (8.8) |
| Calcification (≥ 1.40) | 41 (9.7) | 40 (9.5) |
| Abnormal (≤ 0.70) | 14 (3.3) | 12 (2.8) |
| Symptoms | Prop | 95% CI | I2 (%) | Pop | Summary of case report data | |
| Studies/Patients | n | % | ||||
| Falls | 0.48 | 0.20, 0.77 | 84 | 5/252 | 2 | 4 |
| Fatigue | 0.46 | 0.21, 0.72 | 92 | 8/333 | 18 | 38 |
| Weakness | 0.45 | 0.32, 0.58 | 49 | 14/247 | 13 | 27 |
| Confusion | 0.44 | 0.33, 0.56 | 85 | 22/710 | 16 | 33 |
| Nausea | 0.36 | 0.24, 0.48 | 76 | 14/405 | 10 | 21 |
| Neurological symptoms | 0.51 | 0.22, 0.80 | 76 | 8/37 | 10 | 21 |
| Vomiting | 0.35 | 0.25, 0.45 | 68 | 13/549 | 9 | 19 |
| Dizziness | 0.31 | 0.15, 0.51 | 92 | 8/488 | 5 | 10 |
| Unconsciousness | 0.30 | 0.15, 0.48 | 75 | 11/181 | 13 | 27 |
| Seizures | 0.19 | 0.08, 0.33 | 84 | 10/405 | 10 | 21 |
| Chemicals | 24 h Area under the curve (mg/L-h) | |||
| Metabolic scenarioa | ||||
| Emin | Emax | LMCI | UMCI | |
| Benzene | 0.437 | 0.125 | 0.155 | 0.138 |
| Bromochloromethane | 0.913 | 0.229 | 0.305 | 0.257 |
| Bromodichloromethane | 2.380 | 0.356 | 0.523 | 0.422 |
| Carbon tetrachloride | 0.34 | 0.153 | 0.224 | 0.186 |
| Chloroethane | 0.156 | 0.069 | 0.084 | 0.076 |
| Chloroform | 0.599 | 0.185 | 0.257 | 0.211 |
| Dibromomethane | 1.659 | 0.336 | 0.466 | 0.384 |
| Dichloroethane (1,1-) | 0.391 | 0.138 | 0.181 | 0.158 |
| Dichloroethane (1,2-) | 1.142 | 0.205 | 0.305 | 0.241 |
| Dichloroethylene (1,1-) | 6.98 × 10−2 | 4.22 × 10−2 | 4.76 × 10−2 | 4.47 × 10−2 |
| Dichloroethylene (cis-1,2) | 0.702 | 0.174 | 0.214 | 0.188 |
| Dichloromethane | 0.65 | 0.157 | 0.206 | 0.174 |
| Ethylbenzene | 1.247 | 0.216 | 0.32 | 0.246 |
| Hexachloroethane | 3.071 | 0.494 | 1.774 | 0.738 |
| Hexane (n-) | 0.15 | 0.073 | 0.129 | 0.084 |
| Isoprene | 4.59 × 10−2 | 2.81 × 10−2 | 0.084 | 2.95 × 10−2 |
| Methyl chloride | 0.119 | 0.054 | 0.064 | 0.057 |
| Pentachloroethane | 2.584 | 0.418 | 0.929 | 0.595 |
| Styrene | 1.497 | 0.222 | 0.322 | 0.246 |
| Tetrachloroethane (1,1,1,2-) | 1.911 | 0.337 | 0.739 | 0.457 |
| Tetrachloroethane (1,1,2,2-) | 3.337 | 0.384 | 0.717 | 0.495 |
| Toluene | 0.74 | 0.168 | 0.223 | 0.188 |
| Trichloroethane (1,1,2-) | 1.876 | 0.284 | 0.474 | 0.355 |
| Trichloroethylene | 0.721 | 0.209 | 0.267 | 0.227 |
| Vinyl chloride | 6.68 × 10−2 | 3.79 × 10−2 | 4.25 × 10−2 | 3.98 × 10−2 |
| Xylene (m-) | 1.117 | 0.209 | 0.308 | 0.236 |
| Trait1 | No. of records | Mean | Standard deviation |
| BW6 | 511 | 802.33 | 133.58 |
| BW12 | 511 | 2027.06 | 360.27 |
| EP | 511 | 66.57 | 1.82 |
| BMP | 511 | 17.40 | 1.43 |
| LMP | 511 | 23.73 | 2.57 |
| Host | Bacteria | Effective against | Active compound | Reference |
| Barnacle B. amphitrite | Vibrio, Alteromonas, Alcaligenes, Flavobacterium, and Pseudomonas | Barnacle B. amphitrite | ? | Mary et al. (1993) |
| Algae, sponges, and ascidian Ciona intestinalis | Pseudomonas aurantia, P. citrea, P. piscicida, P. rubra, P. undina, P. ulvae, P. haloplanktis, P. luteoviolacea, P. tunicata, P. nigrifaciens | Polychaeta, Hydroides elegans, barnacle Balanus amphitrite, and ascidian Cliona intestinalis | ? | Holmström and Kjelleberg (1999), Holmström et al. (2002) |
| Nudibranch Archidoris pseudoargus | Pseudomonas sp. | Barnacle Balanus amphitrite | Phenazine-1-carboxylic acid, 2-n-hyptyl quinol-4-one, 1-hydroxyphenazine phenazine-1-carboxylic acid, pyolipic acid | Burgess et al. (2003) |
| Green alga Ulva reticulata | Vibrio alginolyticus | Polychaeta, Hydroides elegans | Polysaccharide >200 kDa consist of glucose, mannose, galactose, and glucosamine | Dobretsov and Qian (2002), Harder et al. (2004) |
| Soft coral Dendronephthya sp. | Vibrio sp., uncultured Ruegeria, unidentified a-Proteobacterium | Polychaeta, Hydroides elegans, bryozoan Bugula neritina | ? | Dobretsov and Qian (2004) |
| Sponge Halichondria okadai | Alteromonas sp. | Barnacle B. amphitrite | Ubiquinone | Kon-ya et al. (1995) |
| Ascidian Stomozoa murrayi | Acinetobacter sp. | Barnacle B. amphitrite | 6-bromindole- 3-carbaldehyde | Olguin-Uribe et al. (1997) |
| Green alga Ulva australis | Pseudoalteromonas tunicata and Phaeobacter sp. strain 2.10 | Bryozoan Bugula neritina | ? | Rao et al. (2007) |
| Brown alga Fucus serratus, F. vesiculosus, and the red alga Polysiphonia stricta | Natural communities, Photobacterium halotolerans and Ulvibacter litoralis, Shewanella basaltis, Pseudoalteromonas arctica, Shewanella baltica, and Bacillus foraminis | Barnacle Amphibalanus improvisus | ? | Nasrolahi et al. (2012) |
| Sponge Lissodendoryx isodictyalis | Winogradskyella poriferorum | Polychaete H. elegans and barnacle B. amphitrite | Poly-ether AE | Dash et al. (2009), Dash et al. (2011) |
| Gene | Forward primer | Backward primer | Size (bp) |
| GAPDH | GGTCGTATTGGGCGCCTGGTC | TGACGGTGCCATGGAATTTGCCA | 148 |
| KIFC1 | TCTCTGGGTGGTAGTGCTAAGA | TAAGTCACTTCCTGTTGGCCTG | 148 |
| SOX4 | GACCGGGACCTGGATTTTAACT | TGAAAACCAGGTTGGAGATGCT | 133 |
| PBX2 | AAGTTCCAAGAGGAGGCAAACA | TCCTGAGAGATTGAAAGAGCCG | 132 |
| ESRRG | GCTATCCTGCAGCTGGTAAAGA | GCTATCCTGCAGCTGGTAAAGA | 133 |
| KDM5B | CCCTCAGACACATCCTATTCCG | CAGTCCACCTCATCTCCTTCTG | 101 |
| PTGS2 | TGTATCCTGCCCTTCTGGTAGA | AAGGAGAATGGTGCTCCAACTT | 85 |
| EFNA1 | GTGGCAAAATCACTCACAGTCC | CTATGTAGAACCCGCACCTCTG | 91 |
| BCL2 | AGGATTGTGGCCTTCTTTGAGT | CGGTTCAGGTACTCAGTCATCC | 113 |
| SMAD4 | TGTTGATGACCTTCGTCGCTTA | ATGCTCTGTCTTGGGTAATCCG | 81 |
| PHACTR3 | TATGACAGGAGGGCAGACAAAC | GCTTGCTTGATGCATGTACCTC | 118 |
| C13orf27 | TCAGGCTCAGCAGATGAAATGT | TCCAGTGGATTTTATGGGGAGC | 85 |
| PMEPA | CTGAGCCACTACAAGCTGTCTG | CTTCTGAGGACAGGGCATCTTC | 85 |
| OXGR1 | ATCTTGAGGGTCATTCGGATCG | TGTCGCTGACCACCACATATAG | 148 |
| GPNMB | GTCACTGTGATCTCCCTCTTGG | TTTGCACGGTTGAGAAAGACAC | 116 |
| Predictors | OR | 95% CI | p-Value | Nagelkerke R2 |
| Perceived benefits of HSIV: | 0.631 | |||
| HSIV can prevent children from catching Influenza | 2.367 | (1.272, 4.404) | 0.007 | |
| Perceived barriers of HSIV: | ||||
| The HSIV will cause unknown side effects to children | 0.321 | (0.149, 0.691) | 0.004 | |
| Motivating factors of vaccination taking: | 3.675 | (1.745, 7.742) | 0.001 | |
| You would be more willing to give your children HSIV shots if the injection was cheap |
| Desmopressin (n = 45) | Control (n = 45) | P | |
| Propofol (mg) | 830 (195) | 780 (177) | 0.2 |
| Remifentanil (μg) | 1350 (235) | 1785 (260) | <0.001 |
| Esmolol (mg) | 15 (4.5) | 40 (7.5) | <0.001 |
| Nicardipine (mg) | 0.25 (0.06) | 0.26 (0.07) | 0.5 |
| References | SCI model | Methods | LncRNA expression changes | |||
| Animal | Method | Level | Sampling | |||
| 35 | Adult female SD rats (200–250 g) | Contusive spinal cord injury using an NYU impactor (10 g, 12.5 mm) | T10 | 1, 4 and 7 days post‐SCI | RNA sequencing | 1 dpo: 1 down, 6 up4 dpo: 5 down, 2 up7 dpo: 5 down, 2 up |
| 33 | Male ICR mice (20–25 g) aged 6–8 weeks | Multicenter Animal Spinal Cord Injury Study (MASCIS) Impactor weight‐drop device(5 g, 25 mm) | T10 | 1 day, 3 days, 1 week and 3 weeks post‐SCI | Microarray | 1 dpo: 181 down, 164 up3 dpo: 290 down, 212 up1 wpo: 565 down, 326 up3 wpo: 40 down, 141 up |
| 34 | Adult female SD rats aged 12–14 weeks | Moderate contusion injury | T9 | 1, 3 and 6 months post‐SCI | RNA sequencing | 1mpo: 17 down, 120 up3mpo: 77 down, 162 up6mpo: 54 down, 125 up |
| Characteristics of preliminary categories | Final categories | 1999/2000 | 2005 | 2010 | |||
| n | % | n | % | n | % | ||
| Permanent work | Non-precarious employment (NP) | 575 | 50.7 | 739 | 65.1 | 859 | 75.7 |
| + no or low self-rated risk of future unemployment (regardless of previous unemployment) | |||||||
| Contingent work | Non-precarious employment (NP) | 82 | 7.2 | 27 | 2.4 | 16 | 1.4 |
| + no self-rated risk of future unemployment+ no previous unemployment | |||||||
| All others with contingent work AND/OR moderate to high self-rated risk of future unemployment AND/OR previous unemployment | Precarious employment (PE) | 416 | 36.6 | 306 | 26.9 | 207 | 18.2 |
| Unemployed | Precarious employment (PE) | 62 | 5.5 | 63 | 5.6 | 53 | 4.7 |
| 1135 | 100 | 1135 | 100 | 1135 | 100 |
| Did not participate Patella lead level | Participated Patella lead level | |||
| Characteristic | Low (n = 90) | High (n = 103) | Low (n = 15) | High (n = 16) |
| Mean age in years ± SD at MRSa | 73.0 ± 6.2 | 78.0 ± 5.9 | 73.2 ± 4.7 | 80.7 ± 6.1 |
| Mean years ± SD of education | 15.3 ± 2.5 | 13.2 ± 2.6 | 16.3 ± 3.1 | 13.4 ± 2.6 |
| Mean ± SD serum creatinine (mg/dL) | 1.1 ± 0.5 | 1.1 ± 0.3 | 1.0 ± 0.2 | 1.2 ± 0.4 |
| Mean ± SD systolic blood pressure (mmHg) | 134 ± 16 | 134 ± 17 | 133 ± 15 | 135 ± 20 |
| Diabetes, n (%) | 7 (8) | 5 (5) | 0 | 1 (6) |
| Hypertension, n (%) | 28 (31) | 36 (35) | 4 (27) | 7 (44) |
| Taking hypertension medication, n (%) | 9 (10) | 15 (15) | 1 (7) | 6 (38) |
| Myocardial infarction, n (%) | 0 | 6 (6) | 0 | 1 (6) |
| Stroke, n (%) | 0 | 3 (3) | 0 | 1 (6) |
| Median (IQR) patella lead (μg/g bone) | 10 (6–14) | 48 (44–60) | 9 (5–15) | 63 (43–86) |
| Median (IQR) tibia lead (μg/g bone) | 11 (7–17) | 32 (24–41) | 13 (9–17) | 41 (38–59) |
| Sodium nitrite | Sodium nitrate | ||||
| Spiked level (μg·g−1) | Recovery (%) | SD | Spiked level (μg·g−1) | Recovery (%) | SD |
| 50 | 96 | 13.68 | 50 | 96 | 7.13 |
| 100 | 100 | 9.64 | 100 | 96 | 16.65 |
| 150 | 98 | 9.12 | 150 | 100 | 3.28 |
| 200 | 101 | 3.19 | 200 | 98 | 6.76 |
| Other | Division | FN | FP | |
| Other | 935 | 69 | 66 | 85 |
| Division | 99 | 3395 | 31 | 68 |
| FN/1:1 | 79 | 39 | 546 | 43 |
| FP | 17 | 7 | 28 | 1416 |
| Descriptor | SVM | unSVM | Bagging | unBagging | asBagging | PRIFEAB |
| BCUT | 98.2(0.1) | 97.9(0.1) | 97.6(0.1) | 97.8(0.1) | 68.3(0.4) | 67.3(0.2) |
| CONST | 98.2(0.1) | 98.3(0.1) | 98.2(0.1) | 98.2(0.1) | 65.3(0.5) | 66.2(0.3) |
| PROP | 98.1(0.1) | 97.8(0.1) | 97.6(0.1) | 97.8(0.1) | 70.3(0.3) | 70.8(0.2) |
| TOPO | 97.8(0.1) | 98.2(0.0) | 97.0(0.2) | 97.5(0.1) | 67.6(0.3) | 67.7(0.3) |
| Average | 98.1(0.1) | 98.1(0.1) | 97.6(0.1) | 97.8(0.1) | 67.9(0.4) | 68.0(0.3) |
| N | n female | Age range | |
| Tutor: Medical Doctor | 1 | 0 | 51 |
| Tutors: CO/AMO | 3 | 0 | 41 – 65 |
| Tutor: Nurse | 1 | 1 | 35 |
| Students: First year | 3 | 1 | 19 – 28 |
| Students: Second year | 3 | 1 | 22 – 35 |
| Students: Third year | 4 | 1 | 23 – 30 |
| Predictors | df | AICc | ΔAICc | wi |
| Δ Latitude of the 80% diversity contour | 3 | −348.31 | 0.00 | 0.65 |
| Δ Eastern U.S. winter temperature | 3 | −345.14 | 3.17 | 0.13 |
| Null | 2 | −344.74 | 3.57 | 0.11 |
| Global temperature anomaly | 3 | −342.55 | 5.76 | 0.04 |
| Northern hemisphere temperature anomaly | 3 | −342.42 | 5.88 | 0.03 |
| Eastern U.S. temperature anomaly | 3 | −342.42 | 5.88 | 0.03 |
| Correction Method | Mean Error before Correction (mm) | Mean Error after Correction (mm) | Standard Deviation before Correction (mm) | Standard Deviation after Correction (mm) |
| Interpolation | 2.737 | 0.325 | 2.781 | 0.549 |
| Function (FFT) | 2.737 | 0.400 | 2.781 | 0.581 |
| Test group* | Active control group* | Total | |||||||
| N | Mean | SD | N | Mean | SD | N | Mean | SD | |
| Usefulness of | |||||||||
| Toothbrushing supplies | 61 | 9.6 | 1.2 | 76 | 9.4 | 1.8 | 137 | 9.5 | 1.5 |
| Printed postcard messages | 54 | 7.2 | 3.6 | ||||||
| Voice telephone messages | 49 | 6.4 | 3.9 | ||||||
| Overall satisfaction | 61 | 9.5 | 1.1 | 76 | 9.5 | 0.9 | 137 | 9.5 | 0.9 |
| Old name* | New name* |
| N.CglI | H.CglI |
| N.NgoAVII | H.NgoAVII |
| Index | SS | df | MS | F | p |
| Pre-tests and post-tests of interaction | 34.16 | 1 | 17.08 | 0.10 | 0.900 |
| Anterior wall | |
| TCC | 16,5 μm |
| Spectral estimation Burg | 19,5 μm |
| Spectral estimation Yule-Walker | 21,3 μm |
| Posterior wall | |
| TCC | 16,5 μm |
| Spectral estimation Burg | 22,0 μm |
| Spectral estimation Yule-Walker | 17,0 μm |
| N (%) | |||
| Age, years | Median | 63.0 | |
| Range | 33–81 | ||
| Sex | Male | 31 (70.5%) | |
| Female | 13 (29.5%) | ||
| ECOG performance status | 0 | 24 (54.5%) | |
| 1 | 15 (34.1%) | ||
| 2 | 5 (11.4%) | ||
| Primary site | Colon | 22 (50.0%) | |
| Rectum | 20 (45.5%) | ||
| Colorectal | 2 (4.5%) | ||
| Metastatic sites | Liver | 31 (70.5%) | |
| Lung | 18 (40.9%) | ||
| Lymph nodes | 8 (18.2%) | ||
| Other (mediastinum, pelvis, perineum) | 4 (9.1%) | ||
| Peritoneum | 2 (4.5%) | ||
| Number of target lesions | 1 | 11 (25.0%) | |
| 2 | 12 (27.3%) | ||
| 3 | 10 (22.7%) | ||
| 4 or more | 11 (25.0%) | ||
| Prior therapy | Surgery | 38 (86.4%) | |
| Radiotherapy | 11 (25.0%) | ||
| Chemotherapy | |||
| Metastatic | 44 (100.0%) | ||
| Time from initial diagnosis to inclusion, months | Median | 17.0 | |
| Range | 2.8–81.1 |
| Host Strains with rpoB Alleles | Cell Viability (±SE) [% Plasmid Loss] Per Growth of Transformant at 42 °C | |
| [cII] a | [cII-oop-pO94] b | |
| 594 c | <0.001 (0.001) [100] | 0.08 (0.03) [0] |
| 594 rpoB B1 | <0.001 (<0.0001) [100] | 0.07 (0.01) [0] |
| 594 rpoB B8 | 0.01 (<0.0001) [78] | 0.13 (0.03) [0] |
| 594 rpoB C1 | 0.007 (0.10) [100] | 0.36 (<0.0001) [0] |
| 594 rpoB C4 | 0.003 (0.010) [0] | 0.07 (<0.0001) [0] |
| 594 rpoB C10 | 0.004 (0.001) [100] | 1.00 (0.01) [0] |
| 594 rpoB D2 | 0.38 (<0.0001) [0] | 0.10 (<0.0001) [81] |
| 594 rpoB D6 | 0.02 (0.01) [6] | 0.03 (0.01) [86] |
| Category of intervention | Effective interventions for nurse retention | Strength of evidence* |
| A. Education and continuous professional development interventions | -Recruitment from, and training in, rural areas | Moderate [26]# |
| -Targeted admission of students from rural background | Moderate [28]# | |
| -Early and increased exposure to rural practice during undergraduate studies | ||
| -Support for continuous professional development | ||
| B. Regulatory interventions | -Increased opportunities for recruitment to civil service | Low [25]# |
| -Recognizing overseas qualifications | ||
| -Producing different types of health workers | ||
| C. Financial incentives | -Direct and indirect financial incentives (direct payments, service-requiring scholarships, educational loans with service requirements, loan repayment programs) | Moderate [24]# |
| Low [25] | ||
| D. Personal and professional support | -General improvement in rural infrastructure (housing, roads, phones, water supplies, radio communication, etc.) | Strong [25] |
| -Supportive supervision (mentorship, preceptorship, clinical supervision) | Moderate [26]# | |
| -Measures to reduce health workers’ feeling of isolation (professional/specialist networks, telemedicine and telehealth) | Moderate [27]# |
| Brain region | MR image | PET image | ||||
| Volume(mm3) | Mean voxel Activity concentrationa (kBq·mL−1) | Mean ROI activity(Bq) | Volume(mm3) | Mean voxelActivity concentrationb (kBq·mL−1) | Mean ROIactivity(Bq) | |
| Left striatum | 16.4 | 0.50 | 8.19 | 15.3 | 0.52 | 7.95 |
| Right striatum | 15.1 | 0.50 | 7.56 | 14.7 | 0.50 | 7.30 |
| Hippocampus | 26.4 | 0.50 | 13.22 | 26.8 | 0.50 | 13.38 |
| Frontal cortex | 46.1 | 0.50 | 23.03 | 48.6 | 0.50 | 24.13 |
| Posterior cortex | 49.6 | 0.50 | 24.80 | 48.9 | 0.49 | 23.96 |
| Medulla oblongata | 15.7 | 0.50 | 7.85 | 15.8 | 0.49 | 7.75 |
| Cerebellum | 86.7 | 0.50 | 43.35 | 86.0 | 0.49 | 42.14 |
| Reaction type | All reactions | Reaction following GAb | ||
| N | % of all reactionsa | N | % of reaction types, where reaction followed GA | |
| Nausea and/or vomiting | 400 | 27.5% | 295 | 73.8% |
| Pruritus | 243 | 16.7% | 232 | 95.5% |
| Constipation | 155 | 10.6% | 107 | 69.0% |
| Diarrhea (9/88 with vomiting) | 88 | 6.0% | 0 | 0.0% |
| Somnolence (without cardio-respiratory symptoms) | 50 | 3.4% | 34 | 68.0% |
| Respiratory depression (41)/arrest (3) | 44 | 3.0% | 43 | 97.7% |
| Candidiasis | 41 | 2.8% | 0 | 0.0% |
| Urinary retention | 40 | 2.7% | 37 | 92.5% |
| Rash | 31 | 2.1% | 3 | 9.7% |
| Hypokalemia | 25 | 1.7% | 0 | 0.0% |
| Hypotension | 22 | 1.5% | 9 | 40.9% |
| Hepatotoxicity(6)/increased transaminases (12)c | 18 | 1.2% | 1 | 5.6% |
| Stomatitis | 16 | 1.1% | 0 | 0.0% |
| Myoclonus | 15 | 1.0% | 14 | 93.3% |
| Pancytopenia | 13 | <1% | 0 | 0.0% |
| Hyperglycemia | 12 | <1% | 0 | 0.0% |
| Hypertension | 11 | <1% | 2 | 18.2% |
| Allergic reactions | 10 | <1% | 3 | 30.0% |
| Pain (4/10 pain in jaw, 2/10 back pain) | 10 | <1% | 0 | 0.0% |
| Other reactions ( occurred <10 times) | 213 | 14.6% | 65 | 30.5% |
| Total | 1,457 | 845 | 58.0% |
| Number of patients | Disease progression | Localized | P Value |
| Age(Range) | 57.19 (36.85-74.92) | 60.61 (44.38-91.38) | 0.1692 |
| Median Time to Relapse (years) | 1.59 (0.23-4.91) | ||
| Median Followup (years) | 6.47 (4.53-13.84) | ||
| Sex | |||
| Male | 21 | 22 | |
| Female | 7 | 15 | 0.2898 |
| Smoking Status | |||
| Yes | 15 | 15 | |
| No | 13 | 22 | 0.3256 |
| Tumor Stage11 | |||
| T2 | 6 | 15 | 0.1176 |
| T3 | 22 | 22 | |
| Fuhrman Grade | |||
| Grade 1-2 | 7 | 22 | |
| Grade 3-4 | 21 | 15 | *0.0066 |
| Matrix | Original (μg/kg) | Spiked (μg/kg) | Determined (μg/kg) | Recovery (%)1 |
| Potato chips | 53.2 | 100 | 151.2 | 98.0 ± 0.8 |
| Chips (except potato chips) | <LOQ | 100 | 97.7 | 97.7 ± 1.0 |
| Biscuits | 21.7 | 100 | 119.3 | 97.6 ± 2.7 |
| French fries | 35.7 | 100 | 135.3 | 99.5 ± 3.2 |
| Chocolate products | <LOQ | 100 | 96.7 | 96.7 ± 3.2 |
| Breakfast cereals | 9.7 | 100 | 117.3 | 107.6 ± 0.7 |
| Tea products | 13.3 | 100 | 107.8 | 94.5 ± 0.2 |
| Seasoned laver | <LOQ | 100 | 102.7 | 102.7 ± 3.7 |
| Nuts products | <LOQ | 100 | 105.0 | 105.0 ± 1.6 |
| Subjects | Experimental (non obstructive CAD) group (n) | Control (obstructive CAD) Group (n) | P value* |
| Females | 143 | 141 | 0.888 |
| Males | 99 | 101 | 0.906 |
| Input level | Running speech (mean (dB SPL), SE (dB)) | Isolation (mean (dB SPL), SE (dB)) | t-statistic, df | P value | Critical P value | |
| 55 | 85.66, 2.28 | 83.66, 2.51 | 4.437, 9 | 0.002* | 0.017 | |
| Overall level | 65 | 94.61, 2.38 | 92.72, 2.55 | 3.803, 9 | 0.004* | 0.033 |
| 75 | 101.97, 2.36 | 100.9, 2.66 | 1.173, 9 | 0.121 | 0.050 | |
| 55 | 86.35, 2.27 | 85.96, 2.31 | 4.234, 9 | 0.002* | 0.017 | |
| Onset level | 65 | 95.18, 2.35 | 94.93, 2.38 | 2.739, 9 | 0.023* | 0.033 |
| 76 | 102.48, 2.41 | 102.43, 2.44 | 0.446, 9 | 0.653 | 0.050 |
| Methods | FLAT | HTD | HTD-CS | HB | HB-CS | TPR | TPR-W |
| Single-source | |||||||
| BIOGRID | 0.2643 | 0.3759 | 0.4160 | 0.3385 | 0.4183 | 0.3902 | 0.4367 |
| String | 0.2203 | 0.2677 | 0.3135 | 0.2138 | 0.3007 | 0.2801 | 0.3048 |
| PFAM BINARY | 0.1756 | 0.2003 | 0.2482 | 0.1468 | 0.2407 | 0.2532 | 0.2738 |
| PFAM LOGE | 0.2044 | 0.1567 | 0.2541 | 0.0997 | 0.2847 | 0.3005 | 0.3160 |
| Expr. | 0.1884 | 0.2506 | 0.2889 | 0.2006 | 0.2781 | 0.2723 | 0.3053 |
| Seq. sim. | 0.1870 | 0.2532 | 0.2899 | 0.2017 | 0.2825 | 0.2742 | 0.3088 |
| Multisource (data fusion) | |||||||
| Kernel fusion | 0.3220(22) | 0.5401(44) | 0.5492(32) | 0.5181(53) | 0.5505(32) | 0.5034(29) | 0.5592(28) |
| Odds Ratio | [95% Confidence Interval] | p-value | |
| Age group | 1.08 | 1.02 - 1.51 | 0.02 |
| Family history of renal disease | 1.12 | 0.76 - 1.45 | 0.05 |
| School education | 0.99 | 0.76 - 2.54 | 0.17 |
| Physical inactivity | 0.65 | 0.57 - 0.99 | 0.05 |
| Hypertension | 2.15 | 1.61 - 4.36 | 0.03 |
| Diabetes | 1.22 | 0.33 - 40.74 | 0.63 |
| Obesity | 1.33 | 1.05 - 1.98 | 0.04 |
| Source of variation | df | SSD | VC | % total | P |
| 1. Regions divided by rivers | |||||
| Among regions | 4 | 168.349 | 0.507 | 23.87 | <0.001 |
| Among populations within regions | 44 | 356.604 | 1.075 | 50.60 | <0.001 |
| Within populations | 297 | 161.099 | 0.542 | 25.53 | <0.001 |
| Total | 345 | 686.052 | 2.125 | ||
| 2. Glaciated versus nonglaciated regions during Great Patagonian Glaciation | |||||
| Among regions | 1 | 10.703 | −0.013 | −0.68 | n.s. |
| Among populations within regions | 47 | 514.250 | 1.477 | 73.64 | <0.001 |
| Within populations | 297 | 161.099 | 0.542 | 27.04 | <0.001 |
| Total | 345 | 686.052 | 2.006 |
| Amplified Region | Forward | Reverse |
| c-KIT exon 8 | 5'-CAGCAGTCTGACCTATGGC -3' | 5'-GCTCAGCTCCTGGACAGAAA-3' |
| c-KIT exon 9 | 5'-GATTGATTGATTGATTTTCCTAG-3' | 5'-GCAGGCAGAGCCTAAACATC-3' |
| c-KIT exon 11 | 5'-CATTTGTTCTCTACCCTAAGTGCT-3' | 5'-GTTCCCTAAAGTCATTGTTACACG-3' |
| c-KIT exon 13 | 5'-CTGATTAAGTCGGATGCGGC-3' | 5'-CAAGCACTGTCGCAATGG-3' |
| c-KIT exon 17 | 5'-ATAGCAGCATTCTCGTGTTG-3' | 5'-AACTAAAATCCTTCACTGGACTG-3' |
| PDGFRA exon 12 | 5'-TTAATGGCTCTGATTGCTCAC-3' | 5'-CACCCAGTGCTCATAACCTC-3' |
| PDGFRA exon 14 | 5'-ACTGGTTTTGGTTCCCACAG -3' | 5'-CAATGATTCGCAGCAACG-3' |
| PDGFRA exon 18 | 5'-TAGCTCAGCCGTGGGTATG-3' | 5'-CACATGAGCAGAGATGTCAGG-3' |
| Year range | No. records | Mortality (%) | Countries |
| An. arabiensis | |||
| Up to 2000 (first year = 1996) | 3 | Min 100 | South Africa |
| Max 100 | |||
| Mean 100 | |||
| 2001–2005 | 67 | Min 75 | Cameroon, Kenya, Madagascar, Mozambique, Nigeria, South Africa, Sudan, Tanzania |
| Max 100 | |||
| Mean 95.6 | |||
| 2006–2010 | 218 | Min 0 | Burkina Faso, Cameroon, Chad, Ethiopia, Kenya, Mozambique, Senegal, Sudan, Tanzania, The Gambia, Uganda, Zambia, Zimbabwe |
| Max 100 | |||
| Mean 79.3 | |||
| 2011–2015 | 161 | Min 9 | Ethiopia, Kenya, Malawi, Mali, South Africa, Senegal, Sudan, Tanzania, Uganda |
| Max 100 | |||
| Mean 74.7 | |||
| An. coluzzii | |||
| 2001–2005 | 38 | Min 19 | Benin, Cameroon, Nigeria |
| Max 100 | |||
| Mean 89.7 | |||
| 2006–2010 | 144 | Min 0.9 | Benin, Burkina Faso, Cameroon, Côte d’Ivoire, Ghana, Mali, Nigeria |
| Max 100 | |||
| Mean 73.2 | |||
| 2011–2015 | 44 | Min 1 | Benin, Burkina Faso, Cameroon, Côte d’Ivoire, Mali, Mozambique, Liberia |
| Max 100 | |||
| Mean 60.6 | |||
| An. gambiae | |||
| Up to 2000 (first year = 1999) | 10 | Min 100 | Zambia |
| Max 100 | |||
| Mean 100 | |||
| 2001–2005 | 55 | Min 27 | Angola, Burundi, Cameroon, Equatorial Guinea, Mozambique, Nigeria, Uganda |
| Max 100 | |||
| Mean 88.82 | |||
| 2006–2010 | 139 | Min 0 | Benin, Burkina Faso, Burundi, Cameroon, Congo, Ghana, Guinea, Kenya, Malawi, Mozambique, Uganda, Zambia |
| Max 100 | |||
| Mean 75.2 | |||
| 2011–2015 | 48 | Min 0 | Cameroon, DRC, Ghana, Kenya, Mali, Tanzania, Uganda |
| Max 100 | |||
| Mean 48.7 | |||
| An. melas | |||
| All years (2005) | 4 | Min 100 | Cameroon |
| Max 100 | |||
| Mean 100 | |||
| An. quadriannulatus | |||
| All years (2002) | 1 | Min 100 | South Africa |
| Max 100 | |||
| Mean 100 |
| Ukraine | Kazakhstan | Azerbaijan | |||||||
| Respondentsa | Respondentsa | Respondentsa | |||||||
| without BA | with BA | p-value | without BA | with BA | p-value | without BA | with BA | p-value | |
| Valid N | 871 | 70 | 693 | 237 | 817 | 115 | |||
| Any co-morbidity, % | 42.0 | 62.9 | 0.001 | 20.8 | 50.6 | < 0.001 | 51.4 | 77.4 | < 0.001 |
| Hypertension, % | 13.1 | 37.1 | < 0.001 | 21.6 | 40.1 | < 0.001 | 16.2 | 27.0 | 0.006 |
| Diabetes, % | 3.2 | 5.7 | 0.291 | 3.5 | 4.2 | 0.689 | 4.8 | 9.6 | 0.044 |
| Cardiovascular disease, % | 6.0 | 14.3 | 0.013 | 7.0 | 13.9 | 0.001 | 3.5 | 8.7 | 0.015 |
| Abnormal blood lipids, % | 4.3 | 10.0 | 0.039 | 10.0 | 17.3 | 0.004 | 1.0 | 3.5 | 0.050 |
| Depression, % | 0.5 | 1.4 | 0.322 | 0.4 | 0.8 | 0.607 | 1.7 | 3.5 | 0.263 |
| Anxiety, % | 0.2 | 0.0 | 1.000 | 0.6 | 0.4 | 1.000 | 2.6 | 3.5 | 0.758 |
| Osteoporosis, % | 0.6 | 1.4 | 0.374 | 1.5 | 2.5 | 0.384 | 0.5 | 0.9 | 1.000 |
| Tuberculosis, % | 0.5 | 1.4 | 0.321 | 2.2 | 1.7 | 0.794 | 0.7 | 7.0 | < 0.001 |
| Pneumonia, % | 18.9 | 38.6 | < 0.001 | 11.8 | 27.8 | < 0.001 | 5.5 | 12.2 | 0.009 |
| Allergic rhinitis, % | 3.6 | 15.7 | < 0.001 | 5.6 | 21.9 | < 0.001 | 6.9 | 20.9 | < 0.001 |
| Australia | Spain | UK | Total | ||||||||
| Predictor | No./total cases1 | % | OR2 (95% CI) | No./total cases | % | OR (95% CI) | No./total cases | % | OR (95% CI) | % | Multivariate OR3 |
| Family history4 | |||||||||||
| 0 | 7/500 | 1.4 | 1.0 | 13/696 | 1.9 | 1.0 | 20/1470 | 1.4 | 1.0 | 1.5 | 1.0 |
| 1 | 4/76 | 5.3 | 3.9 (1.1, 13.7) | 3/35 | 8.6 | 4.9 (1.3, 18.2) | 4/101 | 4.0 | 3.0 (1.0, 8.9) | 5.2 | 3.8 (1.9, 7.5) |
| 2+ | 3/20 | 15.0 | 12.4 (3.0, 52.3) | 3/16 | 18.8 | 12.1 (3.1, 47.7) | 7/15 | 46.7 | 63.4 (21.0, 19.8) | 25.5 | 23.2 (11.3, 47.6) |
| No. of primaries5 | |||||||||||
| 1 | 14/581 | 2.4 | n/a | 8/644 | 1.2 | 1.0 | 20/1495 | 1.4 | 1.0 | 1.3 | 1.0 |
| 2 | 0/14 | 0 | 6/80 | 7.5 | 6.5 (2.2, 19.1) | 4/73 | 5.5 | 4.3 (1.4, 12.9) | 6.5 | 5.4 (2.5, 11.6) | |
| 3+ | 0/1 | 0 | 5/23 | 21.7 | 22.1 (6.6, 74.2) | 7/18 | 38.9 | 46.9 (16.5, 133.5) | 29.3 | 32.4 (14.7, 71.2) |
| Untreated n. 77 | IFN-β treated n.41 | p-value* | ||||
| Time-varying covariates | Baseline | Change | Baseline | Change | Baseline | Change |
| Relapse rate** | 0.2 ± 0.3 | 0.0 ± 0.4 | 0.7 ± 0.5 | -0.1 ± 0.6 | <0.0001 | 0.37 |
| EDSS | 3.1 ± 1.7 | 0.4 ± 0.8 | 3.0 ± 1.8 | 0.4 ± 1.1 | 0.84 | 0.93 |
| BDI | 9.5 ± 7.7 | 1.3 ± 10.3 | 10.8 ± 9.2 | 2.2 ± 9.8 | 0.57 | 0.88 |
| FSS | 2.5 ± 1.8 | 1.1 ± 1.7 | 2.8 ± 1.9 | 1.2 ± 1.8 | 0.53 | 0.75 |
| MMSE-c | 28.5 ± 2.0 | -0.6 ± 2.4 | 28.1 ± 3.7 | -0.5 ± 2.5 | 0.78 | 0.70 |
| MSQoL-54 Measures | ||||||
| Physical health composite score | 65.5 ± 21.4 | -5.5 ± 17.2 | 65.1 ± 22.3 | -9.1 ± 18.9 | 0.91 | 0.45 |
| Mental health composite score | 69.1 ± 19.8 | 1.2 ± 20.2 | 71.6 ± 18.2 | -12.1 ± 19.1 | 0.54 | 0.006 |
| Physical function | 67.7 ± 35.8 | -2.3 ± 14.7 | 69.5 ± 35.4 | -8.8 ± 19.1 | 0.80 | 0.13 |
| Health perceptions | 47.5 ± 23.4 | -3.0 ± 23.1 | 48.7 ± 22.7 | -6.0 ± 26.9 | 0.76 | 0.64 |
| Energy | 47.7 ± 22.6 | 1.1 ± 23.0 | 47.0 ± 23.0 | -1.2 ± 23.0 | 0.91 | 0.57 |
| Role limitation-physical | 67.6 ± 43.5 | -4.6 ± 42.9 | 65.2 ± 40.7 | -14.3 ± 41.8 | 0.48 | 0.52 |
| Bodily pain | 79.7 ± 25.7 | -8.7 ± 30.9 | 74.0 ± 29.7 | -8.1 ± 28.6 | 0.39 | 0.41 |
| Sexual function | 83.1 ± 26.6 | -6.0 ± 35.6 | 81.5 ± 27.0 | -12.0 ± 36.5 | 0.67 | 0.62 |
| Social function | 74.2 ± 23.3 | -5.8 ± 23.4 | 74.4 ± 21.3 | -10.0 ± 21.5 | 0.87 | 0.49 |
| Health distress | 70.8 ± 23.0 | -2.0 ± 31.6 | 71.9 ± 20.4 | -13.3 ± 24.0 | 0.98 | 0.06 |
| Overall quality of life | 67.5 ± 19.0 | -1.0 ± 22.3 | 64.4 ± 18.8 | -8.6 ± 24.3 | 0.46 | 0.17 |
| Cognitive function | 78.6 ± 20.6 | -0.4 ± 23.0 | 82.4 ± 20.6 | -12.2 ± 23.9 | 0.31 | 0.06 |
| Emotional well-being | 57.1 ± 22.8 | 5.4 ± 43.2 | 59.5 ± 16.7 | -21.6 ± 42.5 | 0.65 | 0.014 |
| Role limitation- emotional | 70.6 ± 43.3 | 0.4 ± 27.2 | 78.9 ± 36.3 | -6.4 ± 21.0 | 0.37 | 0.22 |
| Satisfation with sexual function | 60.4 ± 26.7 | 2.0 ± 34.9 | 54.3 ± 30.6 | -3.7 ± 37.0 | 0.33 | 0.40 |
| Change in health | 47.1 ± 19.9 | 0.5 ± 21.3 | 50.6 ± 22.7 | 4.6 ± 35.5 | 0.43 | 0.36 |
| Primary antibodies | Secondary antibodies | ||||||
| Antibody | Company | Tissue | Dilution | Antibody | Company | Tissue | Dilution |
| Brn-3a | Santa Cruz | Retina | 1:100 | Donkey anti-goat Alexa Fluor 488 | Dianova | Retina | 1:1000 |
| C1q | Quidel | Retina | 1:2500 | Donkey anti-goat IgG Cy3 | Abcam | Retina | 1:750 |
| C3 | Cedarlane | Retina | 1:500 | Goat anti-rabbit IgG Cy 3 | Linaris | Retina | 1:500 |
| Optic nerve | 1:500 | Optic nerve | 1:500 | ||||
| C5b-9 (MAC) | Biozol | Retina | 1:100 | Donkey anti-mouse Dy Light 488 | Dianova | Retina | 1:250 |
| Optic nerve | 1:100 | Goat anti-mouse Alexa Flour 488 | Invitrogen | Optic nerve | 1:500 | ||
| MASP2 | Biozol | Retina | 1:400 | Donkey anti-rabbit Alexa Fluor 555 | Invitrogen | Retina | 1:400 |
| Optic nerve | 1:100 | Optic nerve | 1:700 | ||||
| MBP | Millipore | Optic nerve | 1:100 | Goat anti-mouse Alexa Flour 488 | Invitrogen | Optic nerve | 1:500 |
| Control | Minority frame | Majority frame | ||||
| Cookie acceptance | No | Yes | No | Yes | No | Yes |
| Low impulsivity | 31% (14) | 69% (31) | 54% (37) | 46% (32) | 23% (13) | 77% (43) |
| N | 45 | 69 | 56 | |||
| High impulsivity | 12% (5) | 88% (38) | 36% (14) | 64% (25) | 16% (6) | 84% (32) |
| N | 43 | 39 | 38 | |||
| Low risk | 30% (11) | 70% (26) | 59% (31) | 41% (22) | 23% (10) | 77% (34) |
| n | 37 | 53 | 44 | |||
| High risk | 16% (8) | 84% (43) | 36% (20) | 64% (35) | 18% (9) | 82% (41) |
| n | 51 | 55 | 50 |
| BaP | XPA | XPC | ERCC4 | ERCC5 | ERCC1 | |
| 0 μM | RCC4-VHL | 1.00 ± 0.02 | 1.00 ± 0.14 | 1.00 ± 0.08 | 1.00 ± 0.10 | 1.00 ± 0.09 |
| RCC4 | 0.94 ± 0.05 | 0.98 ± 0.12 | 0.98 ± 0.03 | 1.16 ± 0.11 | 1.09 ± 0.06 | |
| 0.1 μM | RCC4-VHL | 1.02 ± 0.04 | 1.04 ± 0.16 | 0.95 ± 0.08 | 0.98 ± 0.08 | 1.01 ± 0.02 |
| RCC4 | 1.15 ± 0.05 | 1.17 ± 0.19 | 0.89 ± 0.02 | 1.21 ± 0.12 | 1.17 ± 0.09 |
| Federal state | Percentage Av positive in total (x/y) [95% CI] | Percentage Cv positive in total (x/y) [95% CI] | Percentage Ea positive in total (x/y) [95% CI] | Percentage Av + Cv positive (x/y) [95% CI] | Percentage Av + Ea positive (x/y) [95% CI] | Percentage Cv + Ea positive (x/y) [95% CI] | Percentage Av + Cv + Ea positive (x/y) [95% CI] |
| Hesse | 19.1 (17/89)[11.5–28.8] | 30.3 (27/89)[21.0–41.0] | 71.9 (64/89)[61.4–80.9] | 1.1 (1/89)[0.0–6.1] | 11.2 (10/89)[5.5–19.7] | 23.6 (21/89)[15.2–33.8] | 4.5 (4/89)[1.2–11.1] |
| Rhineland-Palatinate | 27.3 (33/121)[19.6–36.1] | 25.6 (31/121)[18.1–34.4] | 75.2 (91/121)[66.5–82.6] | 0.8 (1/121)[0.0–4.5] | 11.6 (14/121)[6.5–18.7] | 15.7 (19/121)[9.7–23.4] | 8.3 (10/121)[4.0–14.7] |
| Thuringia | 8.4 (30/359)[5.7–11.7] | 35.1 (126/359)[30.1–40.3] | 66.9 (240/359)[61.7–71.7] | 0.3 (1/359)[0.0–1.5] | 3.6 (13/359)[1.9–6.1] | 26.5 (95/359)[22.0–31.3] | 2.2 (8/359)[1.0–4.3] |
| Total | 14.1 (80/569)[11.3–17.2] | 32.3 (184/569)[28.5–36.4] | 69.4 (395/569)[65.5–73.2] | 0.5 (3/569)[0.1–1.5] | 6.5 (37/569)[4.6–8.9] | 23.7 (135/569)[20.3–27.4] | 3.9 (22/569)[2.4–5.8] |
| Baseline | Two sessions | After pre-treatment | Start pain rehab treatment | Finish pain rehab treatment | 6 months after T3 | ||
| Abbr. | T0a | T1 | T2a | T3a | T4 | ||
| Covariates | |||||||
| Demographics patient | x | ||||||
| Primary outcome effect evaluation | |||||||
| Participation | USER-P | x | x | x | x | ||
| Secondary outcomes effect evaluation | |||||||
| Physical functioning/disability | PDI | x | x | x | x | ||
| Pain intensity | VAS | x | x | x | x | ||
| Main complaints | PSC | x | x | x | x | ||
| Drop-out/adherence | # | # | |||||
| Self-efficacy/perceived competence | GSE | x | x | x | x | ||
| Pain-specific self-efficacy scale | CPSS_V2 | x | x | x | x | ||
| Cost-effectiveness evaluation | |||||||
| Cost questionnaire | Tic-P | x | x | x | |||
| Productivity losses | SF-HLQ | x | x | x | |||
| Quality of life/health status | SF-36 | x | x | x | x | ||
| Potential active ingredients MI | |||||||
| Stages of change | MPRCQ 2 | x | x | ||||
| MI integrity/fidelity | * | ||||||
| Potential moderators | |||||||
| Credibility and expectancy of the treatment | CEQ | x | x | x | |||
| Motivation | TMQ | x | x | ||||
| Depression | BDI | x | x | x | |||
| Acceptance | AAQ-II | x | x | x | |||
| Flexible goal-adjustment | FGA | x | x | x | |||
| Process evaluation | |||||||
| Satisfaction with (pre-)treatment | x + | ||||||
| Client-centeredness | CCCQ | x | |||||
| Feasibility | + |
| Activity limitation | No | Some | Profound | |||
| Percentage with health indicatora | RR (95% CI)b | Percentage with health indicatora | RR (95% CI)b | Percentage with health indicatora | RR (95% CI)b | |
| Health and well-being | ||||||
| Poor self-perceived health | 2.2 | 1 | 27.4 | 1.33 (1.32–1.37) | 64.8 | 2.78 (2.50–3.00) |
| Poor dental status | 9.5 | 1 | 21.8 | 1.52 (1.40–1.65) | 31.1 | 1.85 (1.68–2.03) |
| Pain or discomfort in musculoskeletal system | 71.4 | 1 | 92.1 | 1.27 (1.25–1.29) | 93.5 | 1.28 (1.26–1.31) |
| Headache | 31.2 | 1 | 44.6 | 1.50 (1.43–1.57) | 49.6 | 1.72 (1.61–1.83) |
| Fatigue | 53.2 | 1 | 74.7 | 1.39 (1.35–1.43) | 83.5 | 1.51 (1.47–1.56) |
| Dyssomnia | 30.0 | 1 | 51.9 | 1.72 (1.64–1.80) | 62.9 | 2.10 (1.98–2.23) |
| Psychological symptoms | 29.9 | 1 | 49.5 | 1.69 (1.61–1.76) | 61.6 | 2.11 (1.99–2.24) |
| Stress | 14.0 | 1 | 33.7 | 2.46 (2.29–2.64) | 55.3 | 4.05 (3.74–4.38) |
| Hypnotics/sedatives (prescription-only) | 4.1 | 1 | 14.9 | 3.32 (2.92–3.77) | 27.0 | 5.89 (5.08–6.84) |
| Hypnotics/sedatives (over-the-counter) | 0.8 | 1 | 2.1 | 2.71 (1.97–3.71) | 2.6 | 3.32 (2.10–5.26) |
| Analgesics (prescription-only) | 11.9 | 1 | 35.7 | 2.89 (2.69–3.10) | 54.0 | 4.32 (3.98–4.69) |
| Analgesics (over-the-counter) | 34.7 | 1 | 43.0 | 1.30 (1.24–1.36) | 40.6 | 1.28 (1.19–1.39) |
| Laxatives (prescription-only) | 2.9 | 1 | 11.5 | 3.70 (3.19–4.30) | 20.3 | 6.61 (5.53–7.89) |
| Laxatives (over-the-counter) | 0.4 | 1 | 1.2 | 3.19 (2.05–4.97) | 1.8 | 4.66 (2.59–8.40) |
| No sexual contact | 26.2 | 1 | 37.8 | 1.19 (1.13–1.25) | 51.4 | 1.30 (1.24–1.38) |
| Unsatisfied with sexual life | 14.2 | 1 | 18.9 | 1.40 (1.29–1.53) | 22.0 | 1.62 (1.41–1.85) |
| Mean growth rate (SD) non-manual social class | Mean difference (95% CI) manual vs. non-manual social class | |
| Birth length, cm Growth rate, cm/month | 50.173 (1.642) | −0.439 (−0.599 to −0.279) |
| 0–3 months | 3.553 (0.241) | 0.087 (0.016 to 0.158) |
| 3–12 months | 1.626 (0.136) | −0.002 (−0.030 to 0.026) |
| 1–3 years | 0.836 (0.071) | −0.015 (−0.026 to −0.005) |
| 3–10 years | 0.531 (0.035) | −0.008 (−0.013 to −0.003) |
| Method | Total number | Disorder number | Success rate |
| Subcutaneous injection of sesame oil | 10 | 0 | 0.00% |
| Subcutaneous injection of DHEA | 40 | 25 | 62.50% |
| PBMS | Comparison of PBMS parameters between study groups | ||||
| Domains | control | intervention | range | p | |
| Sub-domains | |||||
| 1 Attitude | 3.5 (1.9) | 3.0 (1.8) | 0-9 | .04* | |
| a: expectations regarding outcomes | 1.8 (0.6) | 1.6 (0.6) | 0-3 | .001* | |
| b: values of expected outcomes | 1.8 (0.6) | 1.8 (0.6) | 0-3 | .55 | |
| 2 Social norm | 2.1 (1.2) | 1.7 (1.0) | 0-9 | .006* | |
| a: assumed attitudes of important others | 1.9 (0.6) | 1.8 (0.7) | 0-3 | .28 | |
| b: motivation to comply with these norms | 1.1 (0.4) | 1.0 (0.4) | 0-3 | .004* | |
| 3 Control beliefs | 3.2 (2.1) | 2.9 (2.1) | 0-9 | .313 | |
| a: assumed facilitators or barriers | 1.6 (0.7) | 1.4 (0.8) | 0-3 | .14 | |
| b: perceived power of these factors | 1.8 (0.6) | 1.7 (0.7) | 0-3 | .42 | |
| Intention estimate | 8.9 (4.1) | 7.5 (4.4) | 0-27 | .04* |
| Objective | Control Group | Coadministration Group | Noninferiority Analysis |
| Primary objectives | |||
| HZ/su VRR (95% CI), %b | n = 388 | n = 382 | ... |
| 97.9 (96.0–99.1) | 95.8 (93.3–97.6) | ND | |
| Noninferiority of anti-gE GMCCoadmin (95% CI), mIU/mL | n = 388 | n = 382 | GMCControl/GMCCoadmin (95% CI)c |
| GMC | 56848 (53 598–60 295) | 52 861 (48 386–57 749) | ND |
| Adjusted GMCc | 56 247 (52 177–60 635) | 52 152 (48 356–56 245) | 1.08 (0.97–1.20)d |
| Noninferiority of influenza GMT by strain (95% CI), 1/dilution | n = 394 | n = 384 | GMTControl/GMTCoadmin (95% CI)c |
| GMT | |||
| A/H1N1 | 193.2 (170.2–219.4) | 196.2 (172.2–223.5) | ND |
| A/H3N2 | 66.8 (60.4–74.0) | 65.4 (59.0–72.5) | ND |
| B/Victoria | 185.2 (168.0–204.1) | 177.2 (161.6–194.2) | ND |
| B/Yamagata | 423.3 (388.0–461.8) | 433.7 (401.3–468.7) | ND |
| Adjusted GMTc | |||
| A/H1N1 | 194.3 (173.0–218.1) | 187.5 (166.7–210.8) | 1.04 (0.88–1.22)d |
| A/H3N2 | 65.9 (60.3–72.0) | 63.7 (58.3–69.7) | 1.03 (0.91–1.17)d |
| B/Victoria | 181.6 (166.7–197.8) | 170.2 (156.1–185.6) | 1.07 (0.95–1.20)d |
| B/Yamagata | 413.9 (383.4–446.8) | 423.5 (392.0–457.5) | 0.98 (0.88–1.09)d |
| Secondary objectives | |||
| Noninferiority of influenza SCRs by strain (95% CI), %e | n = 394 | n = 384 | SCRControl – SCRCoadmin (95% CI)f |
| A/H1N1 | 60.9 (55.9–65.8) | 60.4 (55.3–65.3) | 0.50 (−6.36 to 7.35)d |
| A/H3N2 | 35.3 (30.6–40.2) | 35.4 (30.6–40.4) | −0.14 (−6.85 to 6.57)d |
| B/Victoria | 42.9 (37.9–47.9) | 37.2 (32.4–42.3) | 5.65 (−1.24 to 12.49) |
| B/Yamagata | 37.6 (32.8–42.6) | 40.1 (35.2–45.2) | −2.54 (−9.37 to 4.31)d |
| Estimates | Local adaptation contrasts | |||||||||
| Measure (n) | Local scale (1) | Small scale (2) | Intermediate scale (3) | Large-scale (4) | 1 vs. 2 | 1 vs. 3 | 1 vs. 4 | 1 + 2 vs. 3 | 1 + 2 vs. 4 | 1 + 2 + 3 vs. 4 |
| Infectivity (n > 1076) | 0.662 | 0.586 | 0.711 | 0.663 | NS | NS | NS | NS | NS | NS |
| Time to sporulation (n > 667) | 8.275 | 8.437 | 8.261 | 8.174 | NS | NS | NS | NS | 0.08 | 0.10 |
| Aggressiveness (n > 660) | 3.156 | 3.092 | 3.196 | 3.238 | NS | NS | NS | NS | 0.04 | 0.07 |
| Colony size (n > 660) | 2.201 | 2.012 | 2.356 | 2.294 | NS | NS | NS | 0.03 | 0.08 | NS |
| Fitness 1 (n > 660) | 2.274 | 2.213 | 2.327 | 2.385 | NS | NS | 0.07 | NS | 0.01 | 0.02 |
| Fitness 2 (n > 660) | 1.485 | 1.456 | 1.506 | 1.534 | NS | NS | 0.08 | NS | 0.01 | 0.02 |
| Sexual spore production (n > 342) | 0.158 | 0.148 | 0.285 | 0.183 | NS | 0.08 | NS | 0.04 | NS | NS |
| Groups | UACR (mg/g) | Total |
| Normal albuminuria (NA) (n = 35) | UACR < 30 | n = 80 |
| Microalbuminuria (MA) (n = 30) | 30 ≤ UACR < 300 | |
| Clinical albuminuria (CA) (n = 15) | UACR ≥ 300 | |
| Normal group (NC) (n = 80) | Non-diabetic subjects | n = 80 |
| Factors related to attitude | Number | Mean score | SD | P – Value |
| Location | 396 | 78.52 | 14.97 | |
| Rural | 306 | 77.78 | 14.97 | P = 0.066 |
| Urban | 90 | 81.02 | 13.74 | |
| Age | 396 | 78.52 | 14.75 | |
| 18–24 Years | 24 | 82.96 | 13.28 | P = 0.000 |
| 25–34 Years | 89 | 83.74 | 14.74 | |
| 35–44 Years | 135 | 76.76 | 13.84 | |
| 45–54 Years | 115 | 77.72 | 14.78 | |
| 55–60 Years | 33 | 71.15 | 14.77 | |
| Gender | 396 | 78.52 | 14.75 | |
| Male | 73 | 82.97 | 15.26 | P = 0.004 |
| Female | 323 | 77.51 | 14.46 | |
| Caste | 396 | 78.52 | 14.75 | |
| Dalit | 35 | 69.69 | 12.55 | P = 0.000 |
| Non Dalit | 361 | 79.37 | 14.68 | |
| Provider’s Type | 396 | 78.52 | 14.75 | |
| Dr/HA/AHW | 87 | 82.64 | 15.10 | P = 0.000 |
| Nurse/ANM | 94 | 85.59 | 13.45 | |
| FCHVs | 215 | 73.75 | 13.40 |
| All patients | CN-AML patients | |||||
| Final model | HR | 95% CI | P-value | HR | 95% CI | P-value |
| Presence of unfavorable karyotype | 2.54 | 1.56–4.12 | <0.001 | NA | NA | NA |
| Presence of SNP-A lesion(s) | 2.25 | 1.39–3.65 | 0.001 | 2.38 | 1.28–4.43 | 0.006 |
| Presence of NPM1 mutation | 1.12 | 0.67–1.87 | 0.68 | NA | NA | NA |
| Presence of EVI1 overexpression | 1.63 | 0.87–3.06 | 0.12 | NA | NA | NA |
| Presence of DNMT3A mutation | NA | NA | NA | 1.91 | 1.02–3.56 | 0.042 |
| Presence of IDH2R140 mutation | NA | NA | NA | 0.38 | 0.09–1.63 | 0.19 |
| Randomization in the GO arm | 0.75 | 0.49–1.13 | 0.17 | 0.51 | 0.27–0.98 | 0.043 |
| Closest taxon | Log inactivation | Resistance (log10(CFU·100 mL−1)) | |||
| Maximum | Treatment | Minimum | Treatment | ||
| A. hydrophila | 0.84 | 10.43 | TI 30 mg·L−g/15 min | 11.27 | TII 20 mg·L−g/0 min |
| E. coli | 1.31 | 10.15 | TI 8 mg·L−g/30 min | 11.45 | TIII 8 mg·L−g/30 min |
| E. coli PD3 | 1.86 | 10.62 | TIII 30 mg·L−g/0 min | 12.48 | TI 30 mg·L−g/0 min |
| E. coli BL21 | 0.80 | 10.37 | TI 8 mg·L−g/0 min | 11.18 | TII 20 mg·L−g/0 min |
| E. cloacae | 0.81 | 10.38 | TIII 30 mg·L−g/30 min | 11.19 | TIII 8 mg·L−g/0 min |
| Characteristic | EBT (n = 7) | 3DRT (n = 14) | IMRT (n = 11) | P |
| Age (mean ± SD) | 60.4 ± 17.4 | 58.2 ± 12.0 | 52.3 ± 7.6 | 0.32 |
| Sex (female%) | 100 | 29 | 64 | 0.007 |
| Race (Caucasian%) | 85.7 | 64.2 | 63.6 | 0.55 |
| ECOG (mean ± SD) | 0.21 ± 0.41 | 0.17 ± 0.39 | 0.20 ± 0.42 | 0.84 |
| Pre-RT CEA (median (range) ng/mL) | 4.5 (1.5–15.5) | 7.4 (1.5–168.1) | 3.7 (1.5–11.9) | 0.35∗ |
| Pre-RT tumor volume (median (range) cm3) | 13.1 (0.9–26.4) | 25.2 (6.3–119.0) | 6.1 (1.9–76.6) | 0.11∗ |
| Time between pre-RT MRI and RT start (mean ± SD days) | 20 ± 11 | 22 ± 10 | 34 ± 31 | 0.30 |
| Number. T3 (%) | 5 (71) | 12 (86) | 8 (73) | 0.66 |
| Number T4 (%) | 0 (0) | 2 (14) | 0 (0) | 0.25 |
| Number N0 (%) | 4 (57) | 4 (29) | 3 (27) | 0.36 |
| Number N1 (%) | 3 (43) | 8 (57) | 6 (55) | 0.82 |
| Number N2 (%) | 0 (0) | 2 (14) | 0 (0) | 0.25 |
| Distance of tumor from anal verge (mean ± SD cm) | 6.2 ± 1.9 | 8.4 ± 5.0 | 5.4 ± 2.5 | 0.80 |
| Characteristics | Fresh frozen tissue (%) | Paraffin-embedded tissue (%) |
| Gender | ||
| Male | 103 (66) | 88 (56) |
| Female | 53 (34) | 70 (44) |
| Age (years) | ||
| <70 | 48 (32) | 59 (37) |
| ≥70 | 104 (68) | 99 (63) |
| Location | ||
| Colon | 98 (63) | 77 (49) |
| Rectum | 57 (37) | 81 (51) |
| Stage | ||
| I | 20 (14) | 25 (16) |
| II | 73 (50) | 61 (39) |
| III | 34 (23) | 40 (25) |
| IV | 18 (12) | 31 (20) |
| Differentiation | ||
| Well/moderately | 110 (73) | 107 (68) |
| Poorly | 40 (27) | 50 (32) |
| All patients | Anti-CCP | P value | |||
| Negative | Positive | ||||
| Age | <50* | 45 (75%) | 8 (17.8%) | 37 (82.2%) | NS |
| ≥50 | 15 (25%) | 2 (13.3%) | 13 (86.7%) | ||
| Sex | female | 54 (90%) | 9 (16.7%) | 45 (83.3%) | NS |
| male | 6 (10%) | 1 (16.7%) | 5 (83.3%) | ||
| Duration | <6m | 3 (5%) | 1 (33.3%) | 2 (66.7%) | NS |
| ≥6m | 57 (95%) | 9 (15.8%) | 48 (84.2%) | ||
| Smoking | yes | 5 (8.3%) | 1 (20%) | 4 (80%) | NS |
| no | 55 (91.7%) | 9 (16.4%) | 46 (83.6%) | ||
| CRP | <18 * | 26 (43.3%) | 7 (26.9%) | 19 (73.1%) | NS |
| ≥18 | 34 (56.7%) | 3 (8.8%) | 31 (91.2%) | ||
| RF | +ve | 43 (71.7%) | 4 (9.3%) | 39 (90.7%) | 0.02 |
| 6 (35%) | 11 (65%) | ||||
| ESR-1 | <32 * | 14 (23.3%) | 5 (35.7%) | 9 (64.3%) | 0.04 |
| ≥32 | 46 (76.7%) | 5 (10.9%) | 41 (89.1%) | ||
| ANA | +ve | 22 (36.7%) | 0 (0%) | 22 (100%) | 0.03 |
| -ve | 38 (63.3%) | 10 (40.8%) | 28 (59.2%) | ||
| AKA | +ve | 31 (52%) | 3 (10%) | 28 (90%) | |
| -ve | 29 (48%) | 17 (59%) | 12 (41%) | 0.05 | |
| Grade of activity (DAS) | |||||
| - Mild or moderete | 25 (41.7%) | 9 (31.6%) | 16 (68.4%) | 0.001 | |
| - Severe | 35 (58.3%) | 1 (9.8%) | 34 (90.2%) | ||
| Larsen score | <35* | 19 (31.7%) | 6 (10%) | 13 (21.7%) | 0.05 |
| ≥35 | 41(68.3%) | 4 (6.7%) | 37 (61.7%) | ||
| HLA-DRB1*04 | +ve | 21 (35%) | 2 (9.5%) | 19 (90.5%) | NS |
| -ve | 39 (65%) | 8 (20.5%) | 31 (79.5%) | ||
| HLA-RB1*01 | +ve | 27 (45%) | 5 (19%) | 22 (81%) | NS |
| -ve | 33 (55%) | 5 (15%) | 28 (85%) |
| Characteristics | Synbiotics (n = 43) | Placebo (n = 42) | p-Value |
| Sex * | |||
| Male | 7 (16.3) | 5 (11.9) | 0.533 |
| Female | 36 (83.7) | 37 (88.1) | |
| Age (years) φ | 29.5 ± 8.34 | 27.5 ± 6.5 | 0.368 |
| Ethnicity * | |||
| Malay | 36 (83.7) | 38 (90.5) | 0.332 |
| Non-Malay | 7 (16.3) | 4 (9.5) | |
| Weight (kg) φ | 59.4 ± 11.7 | 58.7 ± 12.6 | 0.911 |
| Height (m) φ | 1.59 ± 0.09 | 1.59 ± 0.09 | 0.738 |
| BMI (kg/m2) φ | 23.6 ± 4.1 | 23.6 ± 4.1 | 0.578 |
| Waist circumference (cm) φ | 80.0 ± 9.5 | 80.0 ± 9.5 | 0.977 |
| Germany | Greece | Norway | Spain | Sweden | UK | ||
| Absenteeism, hours/week | n | 187 | 249 | 233 | 131 | 196 | 132 |
| 3.2 (8.8) | 1.5 (5.1) | 0.9 (4.7) | 2.1 (7.1) | 0.7 (3.4) | 0.4 (2.7) | ||
| Presenteeism (work hours lost/week due to reduced productivity while working) | n | 158 | 252 | 231 | 122 | 178 | 118 |
| 5.7 (8.6) | 5.1 (7.7) | 6.7 (6.2) | 4.7 (8.2) | 7.7 (7.5) | 3.5 (6.6) | ||
| Lost work productivity score* | n | 189 | 248 | 231 | 120 | 196 | 131 |
| 16.7 (22.6) | 12.3 (17.3) | 18.1 (16.9) | 17.1 (26.9) | 17.0 (16.1) | 9.1 (16.4) |
| Phylogenetic Group | A | B | |||||||||||
| A1 | A2 | A3 | |||||||||||
| Predicted CDS | EhV-84 | EhV-86 | EhV-88 | EhV-145 | EhV-164 | EhV-201 | EhV-203 | EhV-207 | EhV-208 | EhV-99B1 | EhV-202 | EhV-18 | EhV-156 |
| hypothetical protein | 27 | 3 | 4 | 7 | 8 | 4 | 4 | 9 | 9 | 6 | 18 | 9 | 6 |
| putative endonuclease | 2 | ||||||||||||
| putative membrane protein | 2 | 1 | 1 | 4 | |||||||||
| putative transposase | 1 | ||||||||||||
| putative DUF814 domain containing protein | 1 | ||||||||||||
| zinc finger protein | 1 | ||||||||||||
| putative ribonuclease | 1 | 1 | |||||||||||
| glycosyltransferase family 29 (sialyltransferase) | 1 | 1 | |||||||||||
| Total | 27 | 5 | 4 | 8 | 9 | 4 | 5 | 9 | 9 | 15 | 18 | 11 | 8 |
| study | yi1 | yi2 | ni1 | ni2 | pi1 | pi2 |
| 1 | 14 | 14 | 131 | 136 | 0.1068 | 0.1029 |
| 2 | 21 | 17 | 385 | 134 | 0.0545 | 0.1268 |
| 3 | 14 | 24 | 57 | 48 | 0.2456 | 0.5000 |
| 4 | 6 | 18 | 38 | 40 | 0.1579 | 0.4500 |
| 5 | 12 | 35 | 1011 | 760 | 0.0118 | 0.0460 |
| 6 | 138 | 175 | 1370 | 1336 | 0.1007 | 0.1310 |
| 7 | 15 | 20 | 506 | 524 | 0.0296 | 0.0382 |
| 8 | 6 | 2 | 108 | 103 | 0.0555 | 0.0194 |
| 9 | 65 | 40 | 153 | 102 | 0.4248 | 0.3921 |
| Exposure time [min] | HIV-1 titer [TCID50/ml] after exposure to uncoated and coated coverslip and after washing with 0.49 ml of PBS | HIV-1 titer reductiona | p-valueb | |||
| Coverslip #1 | Coverslip #2 | Coverslip #3 | ||||
| Uncoated coverslip | 5 | 3981 | 3981 | 3981 | - | - |
| 20 | 3981 | 1000 | 3981 | - | - | |
| Coated coverslip by heat polymerization | 5 | 251 | 1259 | 1000 | 79 % | <0.001 |
| 20 | 316 | 251 | 316 | 90 % | <0.05 | |
| Coated coverslip by photopolymerization | 5 | 63 | 63 | 63 | 98 % | <0.001 |
| 20 | 0 | 20 | 0 | 99.8 % | <0.05 |
| Gender | Functional dyspepsia | Organic dyspepsia | Total |
| Male | 72 | 40 | 112 |
| Female | 120 | 64 | 184 |
| Total | 192 | 104 | 296 |
| Names | Sequence (5′–3′) | Tm (°C) | Mw |
| Osa-miR156 | UGA CAG AAG AGA GUG AGC AC | 57.3 | 6279 |
| (Biotin)-miD156rk | (Biotin)-A CGT GCT CAC TCT CTT CTG TCA | 60.5 | 6587+ |
| (DIG)-miD156rk | (DIG)-A CGT GCT CAC TCT CTT CTG TCA | 60.5 | 6587+ |
| miD156 | TGA CAG AAG AGA GTG AGC AC | 57.3 | 6201+ |
| miD156(−1) | TGA gAG AAG AGA GTG AGC AC | 55.4 | 6241 |
| miD156(−3) | aGA CAG gAG gGA GTG AGC AC | 57.4 | 6242 |
| miD156(−5) | aGA CAG gAG tGA GTc AGC gC | 59.5 | 6193+ |
| let-7a | UGA GGU AGU AGG UUG UAU AGU U | 46.1 | 7244 |
| (Biotin)-let-7rk | (Biotin)-ACA ACT ATA CAA CCT ACT ACC TCA | 52.6 | 7166+ |
| (DIG)-let-7rk | (DIG)-ACA ACT ATA CAA CCT ACT ACC TCA | 52.6 | 7166+ |
| Test microorganisms | Inhibition zone diameter (mm) ¥ | MIC (μg/ml) | MIC of penicillin (μg/ml) |
| Bacillus subtilis MTCC 736 | 25 ± 1.0 | 2.0 | 0.5 |
| Bacillus circulans MTCC 8074 | 23 ± 1.2 | 3.0 | 0.5 |
| Bacillus megaterium MTCC 8075 | 26 ± 1.5 | 2.0 | 0.5 |
| Staphylococcus aureus MTCC 96 | 31 ± 0.9 | 0.5 | 0.25 |
| Staphylococcus aureus (Clinical isolate) | 30 ± 0.9 | 0.5 | 0.25 |
| Micrococcus luteus MTCC 2987 | 25 ± 1.3 | 2.0 | 0.5 |
| Mycobacterium phlei MTCC 1724 | 25 ± 1.0 | 2.0 | 0.5 |
| Mycobacterium smegmatis MTCC 6 | 21 ± 0.5 | 3.0 | 1.0 |
| Escherichia coli MTCC 739 | ND | ND | |
| Klebsiela pneumoniae MTCC 3040 | ND | ND | |
| Pseudomonas aeruginosa MTCC 2453 | ND | ND |
| 6-11y (n=3,033) | 12-19y (n=5,432) | 20-50y (n=7,635) | ≥51y (n=6,752) | ||||||
| Category1 | calories | % total | calories | % total | calories | % total | calories | % total | p-value |
| Grain-based desserts | 139 | 6.9 | 131 | 5.8 | 129 | 5.5 | 134 | 7.1 | <0.001 |
| Yeast breads | 129 | 6.4 | 143 | 6.3 | 145 | 6.1 | 150 | 7.9 | <0.001 |
| Pizza | 119 | 5.9 | 169 | 7.5 | 109 | 4.6 | 41 | 2.2 | <0.001 |
| Reduced fat milk | 112 | 5.6 | 81 | 3.6 | 48 | 2.0 | 43 | 2.3 | <0.001 |
| Chicken and chicken mixed dishes | 104 | 5.2 | 140 | 6.2 | 141 | 6.0 | 91 | 4.8 | <0.001 |
| Soda, energy and sports drinks | 94 | 4.7 | 187 | 8.2 | 161 | 6.8 | 58 | 3.0 | <0.001 |
| Pasta and pasta mixed dishes | 93 | 4.6 | 84 | 3.7 | 84 | 3.6 | 58 | 3.1 | <0.001 |
| Potato/corn/other chips | 71 | 3.5 | 83 | 3.7 | 61 | 2.6 | 37 | 1.9 | <0.001 |
| Ready-to-eat cereals | 71 | 3.5 | 62 | 2.7 | 40 | 1.7 | 45 | 2.4 | <0.001 |
| Dairy desserts | 69 | 3.4 | 53 | 2.3 | 46 | 2.0 | 56 | 3.0 | <0.001 |
| Sausage, franks, bacon and ribs | 60 | 3.0 | 49 | 2.2 | 59 | 2.5 | 52 | 2.7 | <0.001 |
| Whole milk | 60 | 3.0 | 42 | 1.8 | 27 | 1.1 | 17 | 0.9 | <0.001 |
| Candy | 57 | 2.9 | 62 | 2.7 | 50 | 2.1 | 38 | 2.0 | <0.001 |
| Beef and beef mixed dishes2 | 55 | 2.8 | 89 | 3.9 | 102 | 4.3 | 82 | 4.4 | <0.001 |
| Fruit drinks | 55 | 2.7 | 57 | 2.5 | 37 | 1.5 | 18 | 0.9 | <0.001 |
| Mexican mixed dishes | 50 | 2.5 | 81 | 3.6 | 85 | 3.6 | 35 | 1.9 | <0.001 |
| Regular cheese | 50 | 2.5 | 57 | 2.5 | 61 | 2.6 | 43 | 2.3 | 0.039 |
| Fried white potatoes | 48 | 2.4 | 62 | 2.7 | 57 | 2.4 | 31 | 1.7 | <0.001 |
| Quickbreads | 32 | 1.6 | 44 | 1.9 | 61 | 2.6 | 44 | 2.3 | <0.001 |
| Nuts/seeds and nut/seed mixed dishes | 30 | 1.5 | 28 | 1.2 | 41 | 1.7 | 52 | 2.7 | <0.001 |
| Egg and egg mixed dishes | 27 | 1.3 | 30 | 1.3 | 43 | 1.8 | 43 | 2.3 | <0.001 |
| Rice and rice mixed dishes | 26 | 1.3 | 34 | 1.5 | 55 | 2.3 | 32 | 1.7 | <0.001 |
| Burgers2 | 25 | 1.2 | 45 | 2.0 | 36 | 1.5 | 16 | 0.8 | <0.001 |
| Alcoholic beverages | 0 | 0.0 | 18 | 0.8 | 125 | 5.3 | 66 | 3.5 | <0.0014 |
| Others3 | 436 | 21.7 | 437 | 19.2 | 558 | 23.6 | 612 | 32.3 | - |
| Parameter | All subjects% | M% | F% | P |
| Living with one’s family | 63.1 | 78.6 | 51.5 | <0.001** |
| Regular exercise | 61.7 | 84.1 | 44.5 | <0.001** |
| Smokes cigarettes | 19.7 | 13.6 | 24.2 | 0.023 |
| Consumed alcoholic beverages | 36.1 | 39.3 | 33.7 | NS |
| Experienced drugs | 16.4 | 17.0 | 15.9 | 0.01* |
| OMG | SG | pvalue | OBG | pvalue | |
| BV/TV (%) | 16.38 ± 5.69 | 29.47 ± 6.52* | 0.001 | 22.39 ± 5.26* | 0.005 |
| Tb. Th (μm) | 48.96 ± 8.64 | 85.36 ± 9.35* | 0.001 | 72.96 ± 7.37* | 0.002 |
| Tb. N (L/mm) | 1.69 ± 0.16 | 2.05 ± 0.16* | 0.005 | 1.89 ± 0.11* | 0.008 |
| Tb. Sp (μm) | 763.85 ± 138.24 | 369.42 ± 102.34* | 0.001 | 587.56 ± 185.21* | 0.008 |
| ES/BS (%) | 18.27 ± 4.82 | 9.50 ± 4.42* | 0.007 | 14.27 ± 4.23** | 0.044 |
| Oc. N (L/mm2) | 0.26 ± 0.08 | 0.10 ± 0.06* | 0.001 | 0.20 ± 0.05** | 0.039 |
| O. Pm (%) | 30.35 ± 6.32 | 18.84 ± 6.47** | 0.030 | 31.13 ± 5.08 | - |
| L. Pm (%) | 15.03 ± 1.26 | 8.63 ± 1.09* | 0.001 | 16.98 ± 3.25** | 0.041 |
| BFR/BV (%/year) | 36.85 ± 6.23 | 58.27 ± 7.03* | 0.002 | 61.23 ± 13.91* | 0.001 |
| Variable | Experiment 1 | Experiment 2 | ||
| controls | db cAMP | controls | db cAMP | |
| Hypothalamus | ||||
| ADCYAP1 | 0.56±0.02 | 0.78±0.02* | 0.41±0.02 | 0.59±0.02 |
| GHRH# | 0.51±0.04 | 1.39±0.05** | 0.38±0.05 | 0.72±0.08* |
| CRH# | 0.94±0.03 | 1.53±0.06* | 0.66±0.02 | 0.97±0.05* |
| POMC | 0.81±0.01 | 1.00±0.01* | 0.46±0.03 | 1.81±0.01** |
| PC1# | 0.33±0.02 | 0.80±0.05* | 0.64±0.04 | 0.99±0.01* |
| PC2# | 0.35±0.02 | 0.55±0.03 | 0.71±0.02 | 0.82±0.01 |
| Pituitary gland | ||||
| GHRHR# | 0.72±0.01 | 0.95±0.01* | 0.45±0.01 | 0.46±0.01 |
| GH# | 0.50±0.02 | 1.20±0.01** | 0.39±0.01 | 0.84±0.03* |
| CRHR | 0.59±0.03 | 0.62±0.03 | 0.59±0.01 | 0.75±0.08 |
| POMC# | 0.49±0.02 | 1.13±0.01* | 0.42±0.01 | 0.82±0.01* |
| TRHR | 0.51±0.01 | 0.58±0.03 | 0.39±0.02 | 0.53±0.01 |
| TSH | 1.44±0.04 | 1.49±0.02 | 0.66±0.04 | 0.88±0.03 |
| Liver | ||||
| GHR# | 0.55±0.01 | 1.06±0.03** | 0.86±0.01 | 0.93±0.05 |
| IGF-1# | 0.50±0.01 | 1.14±0.01** | 0.57±0.01 | 1.10±0.02* |
| SOD (% of Control) | Catalase (% of Control) | Glutathione Reductase (% of Control) | Glucose-6-phosphate Dehydrogenase (% of Control) | |
| BDP 2 μg | 135 ± 2 | 136 ± 3 | 134 ± 3 | 132 ± 3 |
| BDP 5 μg | 105 ± 3 | 102 ± 4 | 103 ± 3 | 127 ± 4 |
| BDP 10 μg | 192 ± 5 | 204 ± 7 | 183 ± 2 | 237 ± 2 |
| Use diversity | D. sisso | A. modesta | A. nilotica | C. desidua | M. boxifolia | Z. nummularia | M. nigra | M. azidarach | W. coagulans | R. stricta | Total | Rank |
| Construction | 5 | 2 | 3 | 1 | 2 | 3 | 4 | 3 | 1 | 1 | 25 | 2 |
| Agriculture | 4 | 2 | 2 | 3 | 2 | 2 | 2 | 1 | 1 | 1 | 20 | 5 |
| Firewood | 3 | 4 | 3 | 2 | 3 | 2 | 3 | 2 | 2 | 2 | 26 | 1 |
| Fodder | 2 | 3 | 3 | 2 | 2 | 3 | 3 | 2 | 3 | 1 | 24 | 3 |
| Medicinal | 1 | 3 | 3 | 3 | 2 | 2 | 1 | 2 | 3 | 3 | 23 | 4 |
| Total | 15 | 14 | 14 | 11 | 11 | 12 | 13 | 10 | 10 | 8 | ||
| Rank | 1 | 2 | 2 | 5 | 5 | 4 | 3 | 6 | 6 | 7 | ||
| Market price in US$/Kg | 0.6 | 0.5 | 0.5 | 0.2 | 0.53 | 0.4 | 0.4 | 0.2 | 0.9 | 0.8 |
| Group | n | Expression of ELF | |
| High | Low | ||
| Normal liver tissues | 20 | 20(100.0%) | 0(0.0%) |
| Adjacent tissues* | 84 | 65(77.4%) | 19(22.6%) |
| HCC tissues*# | 84 | 40(47.6%) | 44(52.4%) |
| Externality category | UK | USA | Germany | |||
| € million | € per kg a.i. | € million | € per kg a.i. | € million | € per kg a.i. | |
| Pesticides in drinking water | 217 | 9.06 | 851 | 2.00 | 137 | 5.15 |
| Pollution incidents, fish deaths and monitoring costs | 15 | 0.68 | 122 | 0.29 | 39 | 1.47 |
| Biodiversity and wildlife losses | 23 | 1.01 | 157 | 0.37 | 5 | 0.18 |
| Cultural, landscape and tourism | 90 | 3.98 | nd | nd | nd | nd |
| Bee colony losses | 2 | 0.08 | 109 | 0.26 | 2 | 0.04 |
| Acute effects of pesticides on human health | 2 | 0.08 | 127 | 0.30 | 21 | 0.80 |
| Totals | 349 | 15.5 | 1366 | 3.2 | 202 | 7.6 |
| ABTS (μmol/mL) | DPPH (μmol/mL) | FRAP (mmol/mL) | |
| Raw hydrolysate supernatant | 5.34 ± 1.29 | 0.18 ± 0.08 | 0.60 ± 0.04 |
| After ultrasound treatment | 5.92 ± 0.96 | 0.27 ± 0.07 | 0.73 ± 0.04 |
| After autoclaving | 7.03 ± 1.34 | 0.24 ± 0.05 | 0.79 ± 0.05 |
| ADAPT-ITT phase | Methodology |
| 1. Assessment | Conducted focus groups/needs assessment with Community Advisory Board (CAB) |
| 2. Decision | Decision regarding type of intervention was pre-determined by evidence base; however, decisions regarding characteristics of the intervention (equipment and study structure) were made. |
| 3. Administration | Theater testing was conducted during the CAB focus groups with patient stakeholders prior to intervention implementation. |
| 4. Production | A draft of the tailored intervention was presented to the CAB for further feedback and approval. |
| 5. Topical experts | The study team specifically recruited topical experts for CAB membership; see Table 2. |
| 6. Integration | CAB input was integrated into the final adapted version of the intervention; the telehealth software company revised the software to reflect CAB recommendations. |
| 7. Training | Both clinical and installation experts received training with regard to study structure and equipment use. |
| 8. Testing | A pilot test of the intervention was conducted with 10 patients to identify “hands-on” challenges requiring adaptation; a focus group was then held with 4 of those patients to further explore these challenges and solutions |
| MRI (+) | MRI (−) | p Value | |||||||
| Systematic cores n = 2696 (A) | Targeted cores n = 345 (B) | Systematic cores n = 3542 (C) | A vs B | A vs C | B vs C | ||||
| Cores of cancer, n (%) | 333 | (12.3) | 108 | (31.3) | 355 | (10.0) | <0.0001 | 0.004 | <0.0001 |
| Cores including GP 4 or more, n (%) | 229 | (8.4) | 80 | (23.1) | 210 | (5.9) | <0.0001 | 0.0001 | <0.0001 |
| Median percentage of core length involved by cancer (IQR) | 30 | (10–60) | 50 | (20–70) | 20 | (10–50) | 0.0011 | 0.10 | <0.0001 |
| Healthy Controls (n = 50) | Patients (n = 50) | p-Value | |
| Gender female—n (%) | 15 (30.0%) | 17 (34.0%) | 0.83 |
| Age—median years (p 25–75) | 59 (50–68) | 60 (51–69) | 0.47 |
| Serum sCD154—median ng/mL (p 25–75) | 0.98 (0.80–1.46) | 1.79 (1.22–3.56) | <0.001 |
| PFT and Polygraphy (during withdrawal) | n = 15 |
| FEV1/FVC (%) | 79.5 ± 7.4 |
| FEV1 (%) | 69.2 ± 16.4 |
| FVC (%) | 70.2 ± 17.3 |
| AHI (n/h) | 53.5 ± 26.9 |
| RT < 90% (%) | 21.8 ± 24.2 |
| ODI ≥ 4% (n/h) | 42.1 ± 39.5 |
| No. | Species | GenBank accession No. | Locality | Voucher ID |
| 1 | Cyrtodactylus badenensis | KF929505 | Vietnam, Tay Ninh Prov. | KIZ13689 |
| 2 | C. bansocensis | KU175573 | Laos, Khammouane Prov. | VNUF–R.2015.20 |
| 3 | C. bansocensis | KU175574 | Laos, Khammouane Prov. | NUOL-R-2015.21 |
| 4 | C. bobrovi | KT004368 | Vietnam, Hoa Binh Prov. | IEBR-A.2015.30 |
| 5 | C. bobrovi | KT004369 | Vietnam, Hoa Binh Prov. | VNMN-A.2015.61 |
| 6 | C. calamei | KX064043 | Laos, Khammouane Prov. | NUOL-R-2015.22 |
| 7 | C. calamei | KX064044 | Laos, Khammouane Prov. | VNUF-R.2015.28 |
| 8 | C. cryptus | KF169971 | Vietnam, Quang Binh Prov. | PNKB3 |
| 9 | C. cryptus | KF169972 | Vietnam, Quang Binh Prov. | PNKB4 |
| 10 | C. cryptus | KX064038 | Laos, Khammouane Prov. | VNUF-R.2014.69 |
| 11 | C. elok | HM888478 | Malaysia | ZMMU-RAN1991 |
| 12 | C. darevskii | HQ967221 | Laos, Khammouane Prov. | ZISP-FN256 |
| 13 | C. darevskii | HQ967223 | Laos, Khammouane Prov. | ZISP-FN223 |
| 14 | C. hinnamnoensis | KX064045 | Laos, Khammouane Prov. | IEBR-A.2013.89 |
| 15 | C. hinnamnoensis | KX064046 | Laos, Khammouane Prov. | IEBR-A.2013.90 |
| 16 | C. hinnamnoensis | KX064047 | Laos, Khammouane Prov. | VNUF-R.2015.11 |
| 17 | C. hinnamnoensis | KX064048 | Laos, Khammouane Prov. | VNUF-R.2015.3 |
| 18 | C. hinnamnoensis | KX064049 | Laos, Khammouane Prov. | NUOL-R-2015.9 |
| 19 | C. lomyenensis | KJ817436 | Laos, Khammouane Prov. | IEBR-KM2012.54 |
| 20 | C. lomyenensis | KP199942 | Laos, Khammouane Prov. | IEBR-KM2012.52 |
| 21 | C. interdigitalis | KX077901 | Laos, Khammouane Prov. | VNUF-R.2014.50 |
| 22 | C. jaegeri | KT004364 | Laos, Khammouane Prov. | IEBR-A.2013.55 |
| 23 | C. jaegeri | KT004365 | Laos, Khammouane Prov. | NUOL-R.2013.1 |
| 24 | C. jaegeri | KT004366 | Laos, Khammouane Prov. | VFU-TK914 |
| 25 | C.cf. jarujini | KX077907 | Laos, Bolikhamxay Prov. | VNUF-R.2015.7 |
| 26 | C. khammouanensis | HM888467 | Laos, Khammouane Prov. | ZISP-FN191 |
| 27 | C. khammouanensis | HM888469 | Laos, Khammouane Prov. | ZISP-FN257 |
| 28 | C. kingsadai | KF188432 | Vietnam, Phu Yen Prov. | IEBR-A.2013.3 |
| 29 | C.cf. martini | KF929537 | China, Yunnan Prov. | KIZ201103 |
| 30 | C. multiporus | HM888472 | Laos, Khammouane Prov. | ZISP-FN3 |
| 31 | C. multiporus | HM888471 | Laos, Khammouane Prov. | ZISP-FN2 |
| 32 | C. otai | KT004370 | Vietnam, Hoa Binh Prov. | IEBR-A.2015.26 |
| 33 | C. otai | KT004371 | Vietnam, Hoa Binh Prov. | IEBR-A.2015.27 |
| 34 | C. puhuensis | KF929529 | Vietnam, Thanh Hoa Prov. | KIZ11665 |
| 35 | C.aff. pulchellus | HQ967202 | Malaysia | ZMMU-R-12643-3 |
| 36 | C.aff. pulchellus | HQ967203 | Malaysia | ZMMU-R-12643-4 |
| 37 | C. pageli | KJ817431 | Laos, Vientiane Prov. | ZFMK91827 |
| 38 | C. pageli | KX077902 | Laos, Vientiane Prov. | NQT2010.36 |
| 39 | C. pageli | KX077903 | Laos, Vientiane Prov. | NQT2010.37 |
| 40 | C. phongnhakebangensis | KF929526 | Vietnam, Quang Binh Prov. | PNKB2011.30 |
| 41 | C. phongnhakebangensis | KF929527 | Vietnam, Quang Binh Prov. | PNKB2011.32 |
| 42 | C. pseudoquadrivirgatus | KF169963 | Vietnam, Thua Thien - Hue Prov. | ITBCZ3001 |
| 43 | Cyrtodactylussp. 1 | KP199949 | Vietnam, Da Nang, Ba Na | ZMMU-R-13095-2 |
| 44 | C. quadrivirgatus | HM888465 | Malaysia | ZMMU-RAN1989 |
| 45 | C. quadrivirgatus | HM888466 | Malaysia | ZMMU-RAN1990 |
| 46 | C. roesleri | KF929532 | Vietnam, Quang Binh Prov. | PNKB2011.34 |
| 47 | C. roesleri | KF929531 | Vietnam, Quang Binh Prov. | PNKB2011.3 |
| 48 | C. rufford | KU175572 | Laos, Khammouane Prov. | VFU-R.2015.14 |
| 49 | C. sommerladi | KX064039 | Laos, Khammouane Prov. | IEBR-A.2015.37 |
| 50 | C. sommerladi | KX064040 | Laos, Khammouane Prov. | VNUF-R.2013.22 |
| 51 | C. sommerladi | KX064041 | Laos, Khammouane Prov. | VNUF-R.2013.87 |
| 52 | C. sommerladi | KX064042 | Laos, Khammouane Prov. | IEBR-A.2015.39 |
| 53 | C. spelaeus | KP199947 | Laos, Vientiane Prov. | ZMMU-R-13980-3 |
| 54 | C. spelaeus | KP199948 | Laos, Vientiane Prov. | ZMMU-R-13980-1 |
| 55 | C. soudthichaki | KX077904 | Laos, Khammouane Prov. | NUOL-R-2015.5 |
| 56 | C. soudthichaki | KX077905 | Laos, Khammouane Prov. | VFU-R.2015.18 |
| 57 | C. soudthichaki | KX077906 | Laos, Khammouane Prov. | IEBR-A.2015.34 |
| 58 | C. teyniei | KJ817430 | Laos, Khammouane Prov. | IEBR-KM2012.77 |
| 59 | C. teyniei | KP199945 | Laos, Khammouane Prov. | IEBR-KM2012.77 |
| 60 | C. vilaphongi | KJ817434 | Laos, Luang Prabang Prov. | NUOL-R-2013.5 |
| 61 | C. vilaphongi | KJ817435 | Laos, Luang Prabang Prov. | IEBR-A.2013.103 |
| 62 | C. wayakonei | KJ817438 | Laos, Luang Nam Tha Prov. | ZFMK91016 |
| 63 | C. wayakonei | KP199950 | Laos, Luang Nam Tha Prov. | ZMMU-R-13981-1 |
| 64 | Cyrtodactylus thathomensissp. nov. | MG791873 | Laos, Xiangkhouang Prov. | ZMMU-R-14919-1 |
| 65 | Cyrtodactylus thathomensissp. nov. | MG791874 | Laos, Xiangkhouang Prov. | ZISP 29731 |
| 66 | Cyrtodactylus thathomensissp. nov. | MG791875 | Laos, Xiangkhouang Prov. | ZMMU R-15384 |
| Clinicopathologic Characteristics | |
| Age at diagnosis (years) | |
| Median (range) | 62 (30–80) |
| Histology (n (%)) | |
| Ductal | 44 (90%) |
| Lobular | 5 (10%) |
| Histologycal grade (n (%)) | |
| I and II | 39 (80%) |
| III | 10 (20%) |
| UICC stage (n (%)) | |
| IIB | 6 (12%) |
| IIIA + IIIB | 11 (22%) |
| IV | 32 (65%) |
| ER status (n (%)) | |
| positive | 49 (100%) |
| negative | 0 (0%) |
| PR status(n (%)) | |
| positive | 33 (67%) |
| negative | 16 (33%) |
| HER2 status (n(%)) | |
| positive | 8 (16%) |
| negative | 41 (84%) |
| Univariate Analysis of log(MIF) over Time | |||||
| Den DF | F Value | P-Value | Slope Estimator | SD (Estimator) | |
| Continuous variable | |||||
| Age | 47.7 | 0.03 | 0.8604 | −0.00239 | 0.01351 |
| BMI | 47.8 | 0.34 | 0.5605 | −0.02082 | 0.03551 |
| Baseline MIF, logarithmized | 42.2 | 11.44 | 0.0016 * | 0.4456 | 0.1317 |
| Categorical variable | |||||
| Gender (male) | 48 | 0.07 | 0.7942 | −0.0857 | 0.3267 |
| Endovascular repair | 48.2 | 0.01 | 0.9172 | −0.02937 | 0.2809 |
| Continuous variable (repeated measurements) | |||||
| Serum creatinine | 171 | 3.11 | 0.0796 | 0.2094 | 0.1187 |
| Apache II | 137 | 12.92 | 0.0005 * | 0.04273 | 0.01189 |
| Men/Boys | Women/Girls | |||||||
| Caritas population | Barcelona residents | Caritas population | Barcelona residents | |||||
| Direct Assistance Services | Housing Mediation Service | Overall | Deprived social classes (IV and V) | Direct Assistance Services | Housing Mediation Service | Overall | Deprived social classes (IV and V) | |
| Adults | ||||||||
| Regular or poor self-reported health | 24.4 | 45.8 | 11.2 | 12.8 | 53.1 | 60.3 | 15.3 | 20.5 |
| Quality of life, below the median score in Cáritas | 35.6 | 51.4 | 5.6 | 4.4 | 47.7 | 58.9 | 8.3 | 13.1 |
| Poor mental health (Goldberg-12) | 62.2 | 75.0 | 11.5 | 12.1 | 66.9 | 72.6 | 15.2 | 17.4 |
| Self-reported depression or anxiety the previous year | 57.8 | 70.8 | 5.8 | 6.8 | 63.8 | 86.1 | 9.2 | 10.6 |
| Consumption of tranquilizers, antidepressants, or sleeping pills the previous 2 days | 6.7 | 18.1 | 6.7 | 8.3 | 15.4 | 30.1 | 15.7 | 13.8 |
| Self-reported migraine or frequent headaches during the previous year | 28.9 | 38.9 | 3.6 | 3.6 | 62.3 | 65.8 | 8.5 | 7.9 |
| Self-reported backache during the previous year | 37.8 | 63.4 | 12.0 | 15.8 | 73.9 | 83.6 | 19.2 | 18.9 |
| 6 or less daily mean hours of sleep (working days) | 45.5 | 56.9 | 22.1 | 22.1 | 53.1 | 61.1 | 24.9 | 30.6 |
| Children | ||||||||
| Regular or poor health status | 22.7 | 7.1 | 0.9 | NE | 22.9 | 22.0 | 1.7 | NE |
| Poor mental health (SDQ questionnaire) | 61.3 | 45.2 | 3.1 | NE | 37.5 | 25.0 | 5.1 | NE |
| Recurrent otitis during the previous year | 20.5 | 19.0 | 3.6 | NE | 31.9 | 19.5 | 1.6 | NE |
| Not having had breakfast everyday before leaving home | 15.9 | 26.2 | 6.4 | 15.4 | 20.8 | 22.0 | 8.4 | 14.5 |
| GENE | Sense | Anti-sense | Product |
| ABCA1 | 5’-AGGCCCAGACCTGTAAATGC-3’ | 5’-CTCACCAACCTTGCCAACTTC-3’ | 450 bp |
| SREBP2 | 5’-CAGACGCCAAGATGCACAAG-3’ | 5’-TGGCTCATCTTTGACCTTTGC-3’ | 323 bp |
| CYP7A1 | 5’-CATTTGGGCACAGAAGCATTG-3’ | 5’-AGGCAGCGGTCTTTGAGTTAG-3’ | 174 bp |
| NR1H3 (LXR α) | 5’-AAGAAACTGAAGCGGCAAGA-3’ | 5’-AGCAATGAGCAAGGCAAACT-3’ | 555 bp |
| PRKAA2 (AMPK α2) | 5’-TCAATCGTTCTGTCGCCAC-3’ | 5’-ATACGGTTTGCTCTGACTTCG-3’ | 530 bp |
| HMGCR | 5’-CTCCGCAGGCTATTTGTTCAG-3’ | 5’-GCTAAGAGCGTTCGTGGGTC-3’ | 620 bp |
| GAPDH | 5’-ACTCCTCCACCTTTGACGCTG-3’ | 5’-CTCTCTTCCTCTTGTGCTCTTGC-3’ | 182 bp |
| District | Percentage (%) scores of: | ||||||
| Total points | Reports | Management of supplies | Information management | Meetings | Technical support | Referrals | |
| Nadowli | 58.9 | 77.4 | 71.7 | 69.7 | 33.6 | 42.5 | 58.6 |
| Wa Municipal | 73.3 | 90.3 | 87.5 | 88.5 | 51.0 | 61.1 | 61.6 |
| Wa East | 54.1 | 74.5 | 78.9 | 74.8 | 39.2 | 0.0 | 57.2 |
| Wa West | 60.1 | 64.1 | 66.8 | 74.0 | 43.1 | 0.0 | 52.6 |
| Lawra | 30.0 | 46.6 | 30.6 | 28.8 | 26.0 | 12.9 | 35.2 |
| Parameter | Estimate | Std. error | p-Value |
| Intercept | −3.96 | 2.90 | 0.18 |
| Stimulation | 1.46 | 0.74 | 0.05 |
| Time | 0.39 | 0.10 | <0.01 |
| Quadrant | 3.27 | 0.74 | <0.01 |
| Sequence | 5.99 | 0.98 | <0.01 |
| Time × sequence | −0.18 | 0.07 | 0.01 |
| Variance components | SD | ||
| Subjects | 6.72 |
| Total | Cases | Controls | pa | |
| Number of participants (%)b | 2,042 (100) | 681 (33.4) | 1361 (66.7) | |
| Sex (%) | 0.955 | |||
| Male | 1,390 (68.1) | 463 (68.0) | 927 (68.1) | |
| Female | 652 (31.9) | 218 (32.0) | 434 (31.9) | |
| Age (mean, year) | 56.1 ± 9.3 | 56.5 ± 9.6 | 56.0 ± 9.1 | 0.258 |
| Body mass index (kg/m2) | 0.437 | |||
| < 25 | 1,374 (67.3) | 466 (68.4) | 908 (66.7) | |
| ≥ 25 | 668 (32.7) | 215 (31.6) | 453 (33.3) | |
| Tobacco smoking (%) | 0.088 | |||
| Never | 909 (44.5) | 308 (45.2) | 601 (44.2) | |
| Former | 742 (36.3) | 228 (33.5) | 514 (37.8) | |
| Current | 391 (19.15) | 145 (21.3) | 246 (18.1) | |
| Alcohol drinking (%) | 0.001 | |||
| Never | 619 (30.3) | 208 (30.5) | 411 (30.2) | |
| Former | 220 (10.8) | 97 (14.2) | 123 (9.0) | |
| Current | 1,203 (58.9) | 376 (55.2) | 827 (60.76) | |
| Regular exercise (%) | < .001 | |||
| Yes | 1,029 (50.4) | 217 (31.9) | 812 (59.6) | |
| No | 1,006 (49.3) | 646 (68.1) | 542 (39.8) | |
| Missing | 7 (0.3) | - | 7 (0.5) | |
| First-degree family history of colorectal cancer (%) | 0.039 | |||
| Yes | 127 (6.2) | 53 (7.8) | 74 (5.4) | |
| No | 1,915 (93.8) | 628 (92.2) | 1,287 (94.6) | |
| Marital status (%) | < .001 | |||
| Married or with a partner | 1,800 (88.2) | 576 (84.6) | 1,224 (89.9) | |
| Single | 171 (8.4) | 82 (12.0) | 89 (6.5) | |
| Never married | 65 (3.2) | 21 (3.1) | 44 (3.2) | |
| Missing | 6 (0.3) | 2 (0.3) | 4 (0.3) | |
| Education level (%) | < .001 | |||
| Middle school graduate or less | 439 (21.5) | 249 (36.6) | 190 (14.0) | |
| High school graduate | 855 (41.9) | 261 (38.3) | 594 (43.6) | |
| College graduate or more | 739 (36.2) | 171 (25.1) | 568 (41.7) | |
| Missing | 9 (0.4) | - | 9 (0.7) | |
| Household income (10,000 won/month) | < .001 | |||
| < 100 | 176 (8.6) | 91 (13.4) | 85 (6.3) | |
| 100–200 | 373 (18.3) | 143 (21.0) | 230 (16.9) | |
| 201–400 | 883 (43.2) | 301 (44.2) | 582 (42.8) | |
| > 400 | 570 (28.0) | 146 (21.4) | 424 (31.2) | |
| Missing | 40 (2.0) | - | 40 (2.9) | |
| Dietary zinc intake (mg/day) | 8.4 ± 1.6 | 8.1 ± 1.4 | 8.5 ± 1.6 | < .001 |
| Time I | Time II | |||||||
| As range (μg/dL) | Freq | Freq% | CumulFreq | CumulFreq% | Freq | Freq% | CumulFreq | CumulFreq% |
| 2.800–2.999 | 0 | 0.0 | 204 | 100.0 | 0 | 0.0 | 204 | 100.0 |
| 2.600–2.799 | 1 | 0.5 | 204 | 100.0 | 0 | 0.0 | 204 | 100.0 |
| 2.400–2.599 | 1 | 0.5 | 203 | 99.5 | 0 | 0.0 | 204 | 100.0 |
| 2.200–2.399 | 2 | 1.0 | 202 | 99.0 | 0 | 0.0 | 204 | 100.0 |
| 2.000–2.199 | 0 | 0.0 | 200 | 98.0 | 1 | 0.5 | 204 | 100.0 |
| 1.800–1.999 | 7 | 3.4 | 200 | 98.0 | 0 | 0.0 | 203 | 99.5 |
| 1.600–1.799 | 7 | 3.4 | 193 | 94.6 | 0 | 0.0 | 203 | 99.5 |
| 1.400–1.599 | 14 | 6.9 | 186 | 91.2 | 0 | 0.0 | 203 | 99.5 |
| 1.200–1.399a | 26 | 12.7 | 172 | 84.3 | 1 | 0.5 | 203 | 99.5 |
| 1.000–1.199 | 23 | 11.3 | 146 | 71.6 | 4 | 2.0 | 202 | 99.0 |
| 0.800–0.999 | 28 | 13.7 | 123 | 60.3 | 11 | 5.4 | 198 | 97.1 |
| 0.600–0.799 | 42 | 20.6 | 95 | 46.6 | 14 | 6.9 | 187 | 91.7 |
| 0.400–0.599 | 34 | 16.7 | 53 | 26.0 | 66 | 32.4 | 173 | 84.8 |
| 0.200–0.399 | 13 | 6.4 | 19 | 9.3 | 81 | 39.7 | 107 | 52.5 |
| 0.000–0.199 | 6 | 2.9 | 6 | 2.9 | 26 | 12.7 | 26 | 12.7 |
| Total | 204 | 100.0 | 204 | 100.0 | 204 | 100.0 | 204 | 100.0 |
| Manufacturer | Name of Product | Vaccine Type | Adjuvant | Produced in | Age Recommended |
| Abbot healthcare | Trivalent: Influvac Imuvac | Inactivated | None | Egg | From 6 months |
| AstraZeneca | Quadrivalent: Fluenz Tetra (Flumist quadrivalent) Trivalent: Fluarix Alpharix Influsplit | Live attenuated | None | Egg | From 24 months to 17 years Trivalent: From 6 months |
| GlaxoSmithKline | Quadrivalent: Fluarix Tetra Alpharix Tetra Influsplit Tetra | Inactivated/split | None | Egg | From 3 years |
| Novartis | Trivalent: Agrippal Fluvirin Fluad | Inactivated/subunit | None None Squalene (MF59) | Egg | From 6 years From 4 years From 65 years |
| Pfizer/CSl Australia | Trivalent: Afluria Enzira | Inactivated | None | Egg | From 5 years |
| Sanofi Pasteur | Trivalent: Vaxigrip Intanza 9 μg Intanza 15μg | Inactivated | None | Egg | From 6 months From 18-59 years From 60 years |
| Stimuli | P1 | N1 | P2 | N2 | P3 | LPP |
| FSS, RSS | 100–140 ms | 130–150 ms | 150–220 ms | 150–250 ms | 250–500 ms | |
| AA, RA, IA | 100–180 ms | 170–220 ms | 190–330 ms | 275–350 ms | 340–590 ms | 500–1000 ms |
| Variable | Bacteremic | Non-bacteremic | p value |
| (n = 38) | (n = 106) | ||
| Age under 50 years | 9 (23.7) | 25 (23.6) | 1.00 |
| Age 50–64 years | 13 (34.2) | 31 (29.2) | 0.68 |
| Age 65–74 years | 6 (15.8) | 27 (25.5) | 0.27 |
| Age over 75 years | 10 (26.3) | 23 (21.7) | 0.65 |
| Immunocompromised | 7 (18.4) | 11 (10.4) | 0.25 |
| Shock at ICU admission | 23 (60.5) | 63 (59.4) | 1.00 |
| Invasive mechanical ventilation | 28 (73.7) | 78 (73.6) | 1.00 |
| Acute kidney injury | 17 (44.7) | 43 (40.6) | 0.70 |
| Rapid radiographic spread | 24 (63.2) | 53 (50.0) | 0.19 |
| Combined therapy | 34 (89.5) | 86 (81.1) | 0.31 |
| Antibiotic initiated 0 to 3 hours | 18 (47.4) | 55 (51.9) | 0.71 |
| ICU mortality | 11 (28.9) | 26 (24.5) | 0.67 |
| Monitoring dates | Albendazole treated risk cattle cohort | Placebo treated risk cattle cohort | ||||||
| Trypanosome cases | Cattle-months | IDR | 95 % CI5 | Trypanosome cases | Cattle-months | IDR | 95 % CI5 | |
| Intervention area | ||||||||
| Jun - Nov 2008 | 1 | 247.6 | 0.004 | 0.000-0.020 | 8 | 293.6 | 0.031 | 0.010-0.050 |
| Nov 2008 – Feb 2009 | 1 | 192.8 | 0.005 | 0.000-0.026 | 0 | 209.2 | 0 | 0 |
| Feb – Jun 2009 | 1 | 240.3 | 0.004 | 0.000-0.021 | 1 | 256.3 | 0.004 | 0.000-0.019 |
| Jun – Nov 2009 | 0 | 517.5 | 0 | 0 | 0 | 493.1 | 0 | 0 |
| Total | 31 | 1198.2 | 0.003 | 0.001-0.007 | 92 | 1252.2 | 0.007 | 0.004-0.013 |
| Control area | ||||||||
| Jun - Nov 2008 | 3 | 56.7 | 0.053 | 0.013-0.144 | 4 | 65.2 | 0.061 | 0.019-0.148 |
| Nov 2008 – Feb 2009 | 3 | 52.8 | 0.057 | 0.014-0.155 | 2 | 48.6 | 0.041 | 0.007-0.136 |
| Feb – Jun 2009 | 7 | 45.2 | 0.155 | 0.068-0.306 | 5 | 49.7 | 0.10 | 0.037-0.223 |
| Jun – Nov 2009 | 2 | 73.8 | 0.027 | 0.005-0.090 | 2 | 108.2 | 0.002 | 0.003-0.061 |
| Total | 153 | 228.5 | 0.066 | 0.038-0.106 | 134 | 272.3 | 0.048 | 0.027-0.080 |
| Method 1 | Method 2 | Method 3 | Method 4 | Method 5 | |
| Mean | 0.20 | 0.10 | 0.10 | 0.23 | 0.45 |
| SD | 0.24 | 0.22 | 0.21 | 0.24 | 0.15 |
| Method 1 | |||||
| Method 2 | 0.93 | ||||
| Method 3 | 0.93 | 0.99 | |||
| Method 4 | 0.98 | 0.90 | 0.92 | ||
| Method 5 | 0.29 | 0.14 | 0.19 | 0.38 |
| % (N) | |
| Histological subtype | |
| Epidermoid carcinoma | 100 (392/392) |
| Initial anatomic site | |
| Glans | 74.0(216/392) |
| Undetermineda | 15.0 (44/392) |
| Foreskin | 11.0 (32/392) |
| Histologic grade | |
| Grade 1 | 38.9 (123/316) |
| Grade 2 | 54.1 (171/316) |
| Grade 3 | 7.0 (22/316) |
| Primary tumor (T stage) | |
| Tis | 0.6 (2/335) |
| T1(a, b) | 33.0 (107/335) |
| T2 | 44.6 (145/335) |
| T3 | 17.5 (57/335) |
| T4 | 4.3 (14/335) |
| Regional lymph nodes (N stage) | |
| N0 | 46.0 (107/233) |
| N1 | 8.6 (20/233) |
| N2 | 28.7 (67/233) |
| N3 | 16.7 (39/233) |
| Distant metástasis | |
| M0 | 45.9 (180/392) |
| M1 | 2.3 (9/392) |
| Mx | 51.8 (203/392) |
| Staging | |
| Stage 0 | 26.0 (95/366) |
| Stage 1 | 30.0 (110/366) |
| Stage 2 | 26.5 (97/366) |
| Stage 3 | 15.3 (56/366) |
| Stage 4 | 2.2 (8/366) |
| Study | Measure | Assessed variable | Time of assessment |
| Study 1 cultural validity | Cultural Relevance Questionnaire (CRQ) | Culturally adapted internet-delivered treatment | Completed by experts and users before the trial. |
| Study 2 efficacy trial | Patient Health Questionnaire (PHQ-9) | Depression symptoms | Baseline, post-treatment and follow- up |
| Generalised Anxiety Disorder 7 (GAD-7). | Anxiety symptoms | Baseline, post-treatment and follow- up | |
| Sociodemographic & Clinical History Questionnaire | Gender, age, marital status, education, occupation, socioeconomic status and clinical history | Baseline | |
| Helpful and Hindering Aspects of Treatment (HAT) | Helpful and hindering aspects of treatment | After each session | |
| Satisfaction with Treatment (SAT) | Satisfaction with therapy | Post-treatment |
| Author, date | Conclusions | Contributions |
| Levy et al., 2009 [1] | AUT is not a monogenic disorder, in many individuals may be the result of a complex amalgam of multiple simultaneous genetic variations, and present morphological and functional brain abnormalities. | Highlights the importance of understanding biological markers, patterns of cortical organization and connectivity in advancing the treatment of AUT. |
| Baron-Cohen et al., 2000 [19] | Unlike those with TD in ToM tests, patients with AS or AUT do not show activation of the amygdala when making mentalistic inferences from the eyes. The amygdala may be one of many abnormal neural regions in AUT. | Highlights the role of the amygdala in the symptoms of ASD. |
| Castelli et al., 2002 [20] | The physiological cause for the mentalizing dysfunction in AUT can be a bottleneck in the interaction between perceptual processes of higher and lower order. | Relates the difficulties in understanding socially relevant movements in AUT to information processing in the visual cortex. |
| Brunet et al., 2000 [21] | Attribution of intentions to others is associated with a complex brain activity involving the right medial prefrontal cortex when a nonverbal task is used. | Presents data that validate hypothesis of abnormal brain activation in patients with impaired mentalizing. |
| Castelli et al., 2000 [22] | The regions responsible for processing information about intentions and the ability to make inferences about the mental states of others may have evolved from the ability to make inferences about the actions of other creatures. | Suggests evolutionary history for the abilities that make ToM. |
| Pierce et al., 2001 [23] | Compared to typical individuals, autistic \"see\" faces using different neural systems, unique to each individual. | Experiential factors play an important role in the development of the fusiform facial area, related to the processing faces. |
| Scholz et al., 2009 [24] | There are neighboring but distinct regions in the right temporo-parietal junction involved in ToM and orientation of attention. | Identifies difficulties in the investigation of brain functions that occupy regions close to each other or overlapping. |
| Johnson et al., 2007 [25] | There is involvement of frontal and parietal attentional networks and sub-cortical excitatory systems in ADHD and a prefrontal cortex dysfunction in children with HFA. | Provides detailed evidence of dysfunction in sustained attention in ADHD significantly higher than in HFA. |
| Kana et al., 2007 [26] | The neural circuit linked to inhibition in individuals with ASD is atypically activated and is less synchronized, leaving inhibition to be accomplished by strategic control rather than automatically. | Identifies dysfunction in inhibitory cortical level, being disorganized and desynchronized. |
| Schultz et al., 2000 [27] | Individuals with ASD demonstrate during facial discrimination, a pattern of brain activity consistent with strategies based on characteristics or traits more typical of the perception of non-facial objects. | Highlights possible dysfunction in processing stimuli related to biological and inanimate objects in ASD. |
| Dapretto et al., 2006 [28] | A dysfunctional mirror neuron system may underlie the social deficits of autism. | Substantiates hypothesis of the importance of mirror neurons in the development of social functions. |
| Jones et al., 2008 [29] | The behavior of eye contact is already noticeably compromised in children two years of age with ASD, accompanying the person with autism for life. | Subsidizes and highlights the importance of early diagnosis of ASD. |
| Manufacturer | Diameter (mm) | Mean Life | St. Dev |
| Ace | 4.5 | 10115 | 4426 |
| Biomet | 4.0 | 1502 | 615 |
| 5.0 | 360881 | 469213 | |
| Synthes | 3.9 | 1413 | 490 |
| 4.9 | 16121 | 3426 | |
| Howmedica – Alta | 3.7 | 888 | 608 |
| 5.0 | 1000000 | -1 | |
| Russell-Taylor | 4.5 | 18238 | 4009 |
| 5.0 | 46736 | 13702 | |
| S&N – Trigen | 5.0 | 436248 | 487507 |
| Study | Parameter estimate | Standard error | Weight in fixed effects model | Weight in random effects model |
| ACT | −0.01220 | 0.01223 | 0.03788 | 0.11078 |
| LRC | 0.01437 | 0.01063 | 0.05015 | 0.11780 |
| DASH | −0.01362 | 0.02348 | 0.01028 | 0.06695 |
| DISC | 0.18181 | 0.25408 | 0.00009 | 0.00105 |
| DPP | −0.02086 | 0.00964 | 0.06098 | 0.12205 |
| MRFIT | 0.00043 | 0.00608 | 0.15329 | 0.13568 |
| PREMIER | −0.01004 | 0.01002 | 0.05644 | 0.12043 |
| TOHP I | −0.02998 | 0.01887 | 0.01591 | 0.08289 |
| TOHP II | −0.00820 | 0.01495 | 0.02535 | 0.09887 |
| WHI | 0.02844 | 0.00310 | 0.58964 | 0.14351 |
| Outcome | Per 10 μg/m3 PM2.5 exposure | Per 10 ppb NO2 exposure | ||
| mmHg (95% CI) | p-Value | mmHg (95% CI) | p-Value | |
| Systolic blood pressure | ||||
| Model 1 | 0.8 (0.3, 1.3) | 0.002 | –0.4 (–0.6, –0.1) | 0.003 |
| Model 2 | 0.9 (0.4, 1.4) | < 0.001 | 0.2 (–0.1, 0.4) | 0.17 |
| Model 3 | 1.9 (1.0, 2.8) | < 0.001 | 0.3 (0.0, 0.6) | 0.07 |
| Model 4 | 1.5 (0.7, 2.4) | < 0.001 | 0.2 (0.0, 0.5) | 0.09 |
| Model 5 | 1.4 (0.6, 2.3) | < 0.001 | 0.2 (0.0, 0.5) | 0.10 |
| Diastolic blood pressure | ||||
| Model 1 | 0.8 (0.4, 1.1) | < 0.001 | –0.3 (–0.5, –0.2) | < 0.001 |
| Model 2 | 0.7 (0.4, 1.1) | < 0.001 | –0.1 (–0.3, 0.0) | 0.11 |
| Model 3 | 0.7 (0.1, 1.3) | 0.03 | –0.2 (–0.4, 0.0) | 0.10 |
| Model 4 | 0.5 (–0.1, 1.0) | 0.12 | –0.2 (–0.4, 0.0) | 0.06 |
| Model 5 | 0.4 (–0.2, 1.0) | 0.15 | –0.2 (–0.4, 0.0) | 0.05 |
| Mean arterial pressure | ||||
| Model 1 | 0.8 (0.4, 1.2) | < 0.001 | –0.3 (–0.5, –0.2) | < 0.001 |
| Model 2 | 0.8 (0.4, 1.2) | < 0.001 | 0.0 (–0.2, 0.1) | 0.72 |
| Model 3 | 1.1 (0.4, 1.7) | 0.001 | 0.0 (–0.2, 0.2) | 0.84 |
| Model 4 | 0.8 (0.2, 1.4) | 0.01 | 0.0 (–0.2, 0.2) | 0.67 |
| Model 5 | 0.8 (0.2, 1.4) | 0.01 | –0.1 (–0.2, 0.2) | 0.63 |
| Pulse pressure | ||||
| Model 1 | 0.1 (–0.3, 0.4) | 0.73 | –0.1 (–0.2, 0.1) | 0.59 |
| Model 2 | 0.2 (–0.2, 0.5) | 0.42 | 0.3 (0.1, 0.5) | < 0.001 |
| Model 3 | 1.2 (0.6, 1.9) | < 0.001 | 0.4 (0.2, 0.6) | < 0.001 |
| Model 4 | 1.1 (0.4, 1.7) | < 0.001 | 0.4 (0.2, 0.6) | < 0.001 |
| Model 5 | 1.0 (0.4, 1.7) | 0.001 | 0.4 (0.2, 0.6) | < 0.001 |
| Model 1: Included age and race/ethnicity. Model 2: Model 1 + household income, education, marital status, working ≥ 20 hr per week outside the home, perceived stress score, and socioeconomic status z-score. Model 3: Model 2 + Rural-Urban Continuum Codes and unpenalized thin-plate regression splines for latitude and longitude. Model 4: Model 3 + body mass index, waist-to-hip ratio, smoking status, alcohol use, history of diabetes, and history of hypercholesterolemia. Model 5: Model 4 + blood pressure medication use. |
| Data collection | Measurement tool | Data collected method | Timeframe |
| Measurement of total ulcer area | Centimetres squared; | Research assistant | Weekly: Post-treatment until healed or at 6 months |
| Tracing from photographs and counting squares | |||
| Measurement of ulcer depth | Centimetres; | Treating podiatrist | Weekly: post-treatment until healed or at 6 months |
| Using sterile probe | |||
| Ulcer pain | Visual analogue pain scale 100 mm | Treating podiatrist | Weekly: Pre-treatment, during treatment, post-treatment until healed or 6 months |
| Quality of life | EQ-5D-5 L tool | Participant questionnaire | Initial treatment, at 3 months, at 6 months |
| Direct health costs | |||
| Consumable costs for treatments | In dollars for each treatment | Treating podiatrist | Weekly, per participant until healed or at 6 months |
| Medicare Benefit Scheme (MBS) | MBS Care database, in dollars | Extraction from MBS database | End of project for each participant from initial to final treatment |
| Pharmaceutical Benefit Scheme (PBS) | PBS Care database, in dollars | Extraction from PBS database | End of project for each participant from initial to final treatment |
| Inpatient data | Monash Health: | Hospitalisation costs | Monash Health: |
| Admission duration, reason for admission, imaging and interventions, obtained from the patient record and from the Victorian Admitted Episodes Database | End of project | ||
| External organisation: End of project | |||
| External organisation: Admission duration, reason for admission, costs of any surgery for diabetes-related foot ulcers will be estimated using WEISS funding | |||
| Hospital based services (outpatient data) | Hours – time spent | Treating podiatrist | Weekly per participant until healed or at 6 months |
| Medical imaging and pathology for outpatients | Dollars – hospital based costs | Treating podiatrist | Monthly per participant until healed or at 6 months |
| Community based services | Number and cost of appointments | Participant interview | Monthly until healed or at 6 months |
| Private health appointments | Number and cost of appointments, eligibility for private health subsidies | Participant interview | Monthly until healed or at 6 months |
| Royal District Nursing Service for ulcer management | Frequency and cost of service | Participant interview | Monthly until healed or at 6 months |
| Ongoing ulcer care products | Valued using market prices | Participant interview | Monthly until healed or at 6 months |
| Parking costs for appointments | Dollars | Participant interview | Monthly until healed or at 6 months |
| Transportation costs to travel to appointments | Estimated through Australian Tax Office car rate cents per km | Participant interview | Monthly until healed or at 6 months |
| Productivity costs | |||
| Time taken from work for participant and/or any family member | Salary and hours taken from work | Participant/family interview | Monthly until healed or at 6 months |
| RI of interest | Tc-99m | I-123 | ||||
| Acquisition (photopeak count ratio) | None | FiveEW-woDR | FiveEW | None | FiveEW-woDR | FiveEW |
| Single (%) | 25.6 | 4.1 | 2.4 | 14.3 | 72.6 | 39.9 |
| Dual (Tc:I = 1:9) (%) | 700.4 | 27.0 | 35.5 | 14.3 | 72.6 | 39.9 |
| Dual (Tc:I = 2:8) (%) | 325.5 | 9.7 | 17.1 | 14.3 | 72.6 | 39.9 |
| Dual (Tc:I = 3:7) (%) | 200.5 | 4.0 | 11.0 | 14.3 | 72.6 | 40.0 |
| Dual (Tc:I = 4:6) (%) | 138.1 | 1.1 | 7.9 | 14.3 | 72.6 | 40.0 |
| Dual (Tc:I = 5:5) (%) | 100.6 | 0.6 | 6.1 | 14.3 | 72.6 | 40.0 |
| Dual (Tc:I = 6:4) (%) | 75.6 | 1.8 | 4.8 | 14.3 | 72.7 | 40.1 |
| Dual (Tc:I = 7:3) (%) | 57.7 | 2.6 | 4.0 | 14.3 | 72.7 | 40.2 |
| Dual (Tc:I = 8:2) (%) | 44.3 | 3.2 | 3.3 | 14.3 | 72.8 | 40.5 |
| Dual (Tc:I = 9:1) (%) | 33.9 | 3.7 | 2.8 | 14.3 | 73.1 | 41.2 |
| Dual (mean ± SD) (%) | 186.3 ± 213.8 | 6.0 ± 8.3 | 10.3 ± 10.5 | 14.3 ± 0 | 72.7 ± 0.2 | 40.2 ± 0.4 |
| 6MWD (m) | Overall | GROC < 2 | GROC ≥ 2 | P value |
| Pre-intervention | ||||
| Mean (SD) | 294.7 (78.4) | 269.2 (93.9) | 297.0 (77.3) | 0.41 |
| Post-intervention | ||||
| Mean (SD) | 330.0 (77.6) | 278.4 (91.9) | 334.3 (75.3) | 0.091 |
| Change from baseline | ||||
| Mean (SD) | 35.0 (45.2) * | 9.3 (18.2) | 37.3 (46.2) | 0.011 † |
| Explanatory variable | d.f. | Mean square | F-value | P |
| TREATMENT | 2 | 0.4168 | 5.08 | 0.0302 |
| LARVAE | 1 | 0.2237 | 3.44 | 0.0670 |
| TREATMENT (DAY) | 9 | 0.0831 | 1.28 | 0.2603 |
| Error | 92 | 0.0651 |
| Variable (units) | Men | Women | P value |
| N | 141 | 16 | - |
| Age (y) | 41.9 ± 9.7 | 42.0 ± 6.1 | 0.98 |
| Body mass (kg) | 75.0 ± 9.2 | 56.6 ± 7.1 | <0.01 |
| Body surface area (m2) | 1.9 ± 0.1 | 1.6 ± 0.1 | <0.01 |
| Height (m) | 176 ± 7 | 161 ± 5 | <0.01 |
| Body mass index (kg · m−2) | 24.1 ± 2.2 | 20.9 ± 1.2 | <0.01 |
| Best race time (min) | 217 ± 34 | 240 ± 32 | 0.03 |
| Running experience (yr) | 10.7 ± 9.8 | 9.5 ± 5.9 | 0.67 |
| Completed marathons (number) | 7 ± 3 | 5 ± 2 | 0.42 |
| Average training distance · week−1 (km) | 62.7 ± 27.8 | 59.5 ± 26.6 | 0.69 |
| Training sessions of running · week−1 (number) | 4.3 ± 1.0 | 4.4 ± 1.0 | 0.68 |
| Murine models of infection | Immune outcome | Reference |
| FrCasE virus (MLV) | Enhanced memory cellular CD8+ responses | 43 |
| Influenza | Prolonged Ag presentation by DC; enhanced proliferation of CD8+ T cells | 64 |
| RSV | Modification of CD4+/CD8+ T-cell balance | 65 |
| LCMV | Innate immune activation;induction of virus-specific CD8+ T-cell response | 66 |
| N test group=23N control group=23 | Baseline | 3 months | 6 months | Difference t0-t3 | Difference t0-t6 |
| BoP (%) | |||||
| TestControl | 17.0 (13.0, 19.0) ***16.0 (13.0, 19.0) *** | 6.0 (4.0, 9.0) *** ††9.0 (5.0, 12.0) *** | 12.0 (9.0, 14.0) ***11.0 (8.0, 17.0) *** | 10.0 (8.0, 12.0) *** †9.0 (6.0, 11.0) *** | 5.0 (3.0, 8.0) ***4.0 (2.0, 7.0) *** |
| TestControl | 16.5 ± 4.016.7 ± 5.5 | 6.2 ± 3.08.7 ± 3.7 | 11.5 ± 4.913.0 ± 6.7 | 10.3 ± 3.18.0 ± 4.0 | 5.0 ± 4.03.7 ± 5.6 |
| SBI (%) | |||||
| Test groupControl group | 18.0 (14.0, 23.0) ***16.0 (14.0, 21.0) *** | 12.0 (8.0, 15.0) ***11.0 (7.0, 15.0) *** | 13.0 (11.0, 18.0) ***13.0 (11.0, 15.0) *** | 7.0 (4.0, 11.0) ***8.0 (4.0, 12.0) *** | 4.0 (0.0, 8.0) **4.0 (3.0, 8.0) ** |
| TestControl | 18.7 ± 6.518.1 ± 5.6 | 11.8 ± 4.410.3 ± 4.3 | 13.4 ± 5.213.4 ± 3.8 | 6.8 ± 5.27.8 ± 5.4 | 5.2 ± 5.74.7 ± 5.9 |
| Mean PD (mm) | |||||
| TestControl | 3.3 (3.1, 3.6) ***3.2 (3.1, 3.5) *** | 2.1 (2.0, 2.2) *** ††2.2 (2.0, 2.5) *** | 2.2 (2.0, 2.3) *** ††2.3 (2.1, 2.5) *** | 1.2 (0.8, 1.2) *** †1.0 (0.9, 1.5) *** | 1.1 (0.8, 1.2) ***1.0 (0.8, 1.5) *** |
| TestControl | 3.3 ± 0.43.3 ± 0.3 | 2.1 ± 0.32.3 ± 0.2 | 2.2 ± 0.22.3 ± 0.3 | 1.2 ± 0.31.0 ± 0.3 | 1.1 ± 0.31.0 ± 0.3 |
| Mean AL (mm) | |||||
| Test groupControl group | 3.5 (3.3, 3.7) ***3.5 (3.3, 3.7) *** | 2.5 (2.4, 2.6) *** ††2.8 (2.5, 2.9) *** | 2.6 (2.5, 2.7) *** ††2.8 (2.7, 3.0) *** | 0.9 (0.8, 1.1) *** †††0.7 (0.6, 0.8) *** | 0.9 (0.7, 1.0) *** †††0.6 (0.5, 0.7) *** |
| TestControl | 3.5 ± 0.23.4 ± 0.3 | 2.5 ± 0.32.7 ± 0.3 | 2.6 ± 0.22.8 ± 0.3 | 1.0 ± 0.30.7 ± 0.2 | 0.9 ± 0.20.6 ± 0.2 |
| Sites PD > 5 mm (n) | |||||
| TestControl | 18.0 (13.0,27.0)19.0 (9.0, 25.0) | 0.0 (0.0, 2.0)1.0 (0.0, 5.0) | 0.0 (0.0, 2.0)2.0 (0.0, 6.0) | 17.0 (13.0, 26.0)17.0 (8.0, 22.0) | 18.0 (13.0, 25.0)16.0 (7.0, 22.0) |
| TestControl | 18.7 ± 10.319.4 ± 13.0 | 1.1 ± 1.72.7 ± 3.3 | 1.3 ± 2.23.4 ± 4.2 | 17.6 ± 9.216.7 ± 10.2 | 17.4 ± 8.716.0 ± 9.9 |
| Mean sites PD>5 mm (n) | |||||
| TestControl | 5.3 (5.0, 5.5)5.3 (5.0, 5.5) | 3.0 (2.8, 3.3)3,0 (2.8, 3.3) | 3.0 (2.8, 3.5)3.0 (2.8, 3.3) | 2.5 (2.3, 2.5)2.3 (2.0, 2.5) | 2.3 (2.0, 2.5)2.3 (2.0, 2.3) |
| TestControl | 5.3 ± 0.45.3 ± 0.4 | 3.0 ± 0.43.0 ± 0.3 | 3.1 ± 0.43.1 ± 0.3 | 2.3 ± 0.22.3 ± 0.3 | 2.2 ± 0.32.2 ± 0.4 |
| Sites AL > 5 mm (n) | |||||
| TestControl | 21.0 (14.0, 31.0)21.0 (12.0, 27.0) | 2.0 (0.0, 3.0)2.0 (0.0, 6.0) | 1.0 (0.0, 3.0)3.0 (0.0, 8.0) | 21.0 (14.0, 27.0)16.0 (12.0, 24.0) | 21.0 (14.0, 27.0)16.0 (9.0, 23.0) |
| Test Control | 21.3 ± 11.522.3 ± 14.7 | 2.1 ± 3.33.4 ± 4.2 | 2.4 ± 3.74.3 ± 4.4 | 19.2 ± 9.518.9 ± 11.7 | 18.9 ± 9.118.0 ± 11.7 |
| Mean sites AL > 5 mm (n) | |||||
| TestControl | 4.0 (4.0, 4.3)4.0 (4.0, 4.3) | 2.8 (2.8, 3.0)3.0 (2.8, 3.0) | 3.0 (3.0, 3.0)3.0 (3.0, 3.3) | 1.3 (1.3, 1.5)1.3 (1.0, 1.5) | 1.0 (1.0, 1.3)1.0 (0.8, 1.3) |
| TestControl | 4.2 ± 0.34.1 ± 0.2 | 2.9 ± 0.22.9 ± 0.3 | 3.1 ± 0.23.1 ± 0.2 | 1.3 ± 0.21.2 ± 0.3 | 1.1 ± 0.31.0 ± 0.2 |
| Fungi | Bacteria | |||||||
| Endorhiza | Rhizosphere | Endorhiza | Rhizosphere | |||||
| P | D | P | D | P | D | P | D | |
| C/W | 0.3 | 0.8 | 0.5 | 0.3 | 0.03 | 8.2 | 0.03 | 7.8 |
| C/G | 0.03 | 8.7 | 0.06 | 2.9 | 0.03 | 5.2 | 0.03 | 7.1 |
| C/GW | 0.03 | 12.4 | 0.17 | 1.2 | 0.03 | 8.4 | 0.03 | 22.1 |
| W/G | 0.03 | 14.7 | 0.3 | 1.3 | 0.06 | 5.2 | 0.03 | 12.4 |
| W/GW | 0.03 | 23 | 0.08 | 1.3 | 0.1 | 5.1 | 0.03 | 13.4 |
| G/GW | 0.2 | 3.6 | 0.03 | 2.1 | 0.06 | 2.4 | 0.03 | 14.4 |
| Sample | Residual level, mg/kg | μg/product | ||||||||
| 2,6-TDI | IPDI-1 | IPDI-2 | 2,4-TDI | PI | CHI | 4,4′-MDI | H12MDI | Total | Total | |
| Glove 1 | 0.013 | ND | ND | ND | ND | ND | 0.064 | ND | 0.077 | 0.40 |
| Glove 2 | ND | ND | 0.011 | ND | ND | ND | 3.0 | 0.022 | 3.0 | 18.7 |
| Pastry bag | 0.029 | ND | ND | 0.004 | ND | ND | 0.014 | ND | 0.047 | 7.4 |
| 2,6-TDA | IPDA | 2,4-TDA | ANL | CHA | 4,4′-MDA | H12MDA | Total | Total | ||
| Glove 1 | ND | ND | ND | 1.0 | ND | 29 | ND | 30 | 106 | |
| Glove 2 | ND | ND | ND | 0.73 | 0.43 | 0.92 | 3.5 | 5.6 | 35 | |
| Pastry bag | ND | ND | ND | ND | ND | ND | ND | ND | ND |
| # layers | # hidden units | Sens. | Spec. | F1 | Macro Ave. | Mic. Ave. |
| 1 | 512 | 0.823 | 0.904 | 0.724 | 0.864 | 0.89 |
| 1 | 1024 | 0.83 | 0.911 | 0.738 | 0.87 | 0.896 |
| 1 | 1536 | 0.828 | 0.909 | 0.735 | 0.869 | 0.895 |
| 1 | 2048 | 0.818 | 0.913 | 0.735 | 0.865 | 0.896 |
| 2 | 512 | 0.836 | 0.909 | 0.739 | 0.872 | 0.896 |
| 2 | 1024 | 0.822 | 0.91 | 0.733 | 0.866 | 0.894 |
| 2 | 1536 | 0.824 | 0.912 | 0.736 | 0.868 | 0.896 |
| 2 | 2048 | 0.816 | 0.911 | 0.731 | 0.864 | 0.894 |
| 3 | 512 | 0.827 | 0.907 | 0.731 | 0.867 | 0.893 |
| 3 | 1024 | 0.835 | 0.904 | 0.73 | 0.869 | 0.892 |
| 3 | 1536 | 0.833 | 0.904 | 0.73 | 0.869 | 0.892 |
| 3 | 2048 | 0.831 | 0.906 | 0.732 | 0.869 | 0.893 |
| 4 | 512 | 0.813 | 0.91 | 0.727 | 0.862 | 0.893 |
| 4 | 1024 | 0.83 | 0.905 | 0.73 | 0.867 | 0.892 |
| 4 | 1536 | 0.829 | 0.909 | 0.736 | 0.869 | 0.895 |
| 4 | 2048 | 0.799 | 0.914 | 0.726 | 0.857 | 0.894 |
| Baseline method | 0.971 | 0.765 | 0.632 | 0.868 | 0.801 |
| Number of conditions | OR | 95% CI | p-value |
| No chronic health condition | REFERENCE | ||
| Arthritis only | 1.64 | 1.13 – 2.38 | 0.0099 |
| Arthritis and one other condition | 2.95 | 1.82 – 4.80 | <.0001 |
| Arthritis and two other conditions | 2.80 | 1.50 – 5.26 | 0.0013 |
| Arthritis and three or more other conditions | 8.68 | 5.24 – 14.38 | <.0001 |
| Risky sexual practices | ||||
| Bivariate model | Model-I | Model-II | Final model | |
| Variables/characteristics | Crude IRR (95% CI) | Adj. IRR (95% CI) | Adj. IRR (95% CI) | Adj. IRR (95% CI) |
| Parental monitoring | ||||
| Low | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) |
| Medium | 0.84 (0.676, 1.048) | 0.71 (0.705, 1.102) | 0.89 (0.717, 1.128) | 0.92 (0.729, 1.148) |
| High | 0.65 (0.479, 0.895)a | 0.88 (0.515, 0.974)a | 0.70 (0.508, 0.971)a | 0.72 (0.520, 0.986)a |
| SRH communication | ||||
| Very poor | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) |
| Poor | 0.84 (0.646, 1.107) | 0.90 (0.687, 1.192) | 0.92 (0.699, 1.221) | 0.94 (0.723, 1.271) |
| Satisfactory | 0.73 (0.579, 0.926)a | 0.80 (0.629, 1.025) | 0.79 (0.622, 1.025) | 0.82 (0.637, 1.051) |
| Parenting styles | ||||
| Neglectful | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) |
| Permissive | 0.92 (0.674, 1.256) | 0.92 (0.674, 1.257) | 0.96 (0.703, 1.331) | 0.94 (0.685, 1.300) |
| Authoritarian | 0.82 (0.572, 1.178) | 0.90 (0.625, 1.300) | 1.00 (0.688, 1.464) | 1.00 (0.686, 1.471) |
| Authoritative | 0.71 (0.536, 0.965)a | 0.77 (0.571, 1.039) | 0.86 (0.627, 1.178) | 0.85 (0.619, 1.168) |
| Sex of the adolescent | ||||
| Male | 1 (Ref) | 1 (Ref) | 1 (Ref) | |
| Female | 1.16 (0.949, 1.413) | 1.19 (0.963, 1.490) | 1.23 (0.985, 1.537) | |
| Adolescent living arrangements | ||||
| With biological mother and father | 1 (Ref) | 1 (Ref) | 1 (Ref) | |
| Other living arrangements | 1.09 (0.898, 1.344) | 1.01 (0.819, 1.262) | 1.03 (0.825, 1.272) | |
| Family wealth index | ||||
| Low | 1 (Ref) | 1 (Ref) | 1 (Ref) | |
| Medium | 1.16 (0.901, 1.482) | 1.11 (0.862, 1.426) | 1.11 (0.859, 1.423) | |
| High | 0.78 (0.591, 1.056) | 0.81 (0.598, 1.084) | 0.82 (0.607, 1.100) | |
| Data-not obtained | 0.95 (0.702, 1.283) | 0.89 (0.657, 1.228) | 0.89 (0.649, 1.214) | |
| Expendable pocket money per month | ||||
| ≤100 ETB | 1 (Ref) | 1 (Ref) | 1 (Ref) | |
| 101–200 ETB | 0.92 (0.716, 1.190) | 0.92 (0.714, 1.197) | 0.88 (0.676, 1.140) | |
| Greater than 200 ETB | 1.11 (0.881, 1.390) | 1.09 (0.861, 1.403) | 1.05 (0.817, 1.346) | |
| Schooling of the adolescents | ||||
| In-school | 1 (Ref) | 1 (Ref) | 1 (Ref) | |
| Out-of-school | 1.39 (1.111, 1.751)a | 1.23 (0.953, 1.576) | 1.23 (0.958, 1.591) | |
| Ever drunk alcohol | ||||
| No | 1 (Ref) | 1 (Ref) | ||
| Yes | 0.93 (0.765, 1.136) | 0.89 (0.713, 1.106) | ||
| Ever chewed Khat | ||||
| No | 1 (Ref) | 1 (Ref) | ||
| Yes | 1.26 (1.035, 1.537)a | 1.33 (1.065, 1.659)a |
| Parameter | Value |
| Highest heart rate | 119 ± 25 beats/minute |
| Highest respiratory rate | 31.7 ± 8.9 breaths/minute |
| Mean APACHE II score | 19.8 ± 7.8 |
| Mean SAPS II score | 40.2 ± 16.1 |
| Mean white cell count | 13.2 ± 10.1 × 109/l |
| Mean haemoglobin | 12.4 ± 2.2 g/dl (lowest value: 7.8 g/dl) |
| Mean platelet count | 217 ± 218 × 109/l |
| Mean [urea] | 13.6 ± 7.6 mmol/l |
| Mean [creatinine] | 222 ± 218 μmol/l |
| Within-group difference | Between-group difference | Between-group P-value | ||
| Acu-TENS | Placebo-TENS | |||
| Heart rate (beat min−1) | −4.50 (0.49) | 0.79 (0.21) | −5.29 (0.37) | .000 |
| SBP (mmHg) | −4.95 (0.89) | 0.35 (1.14) | −5.30 (0.85) | .206 |
| Rate pressure product | −940.9 (123.9) | 140.9 (123.6) | −1081.0 (115.2) | .010 |
| Item | Home care group (n = 69) | Hospital care group (n = 69) | P | Standardized difference |
| Gender (n, male/female) | 35/34 | 36/33 | 0.87 | 0.03 |
| Age (yr, mean ± SD) | 70.7 ± 13.9 | 70.7 ± 10.8 | 0.99 | 0.002 |
| Primary site (n) | 1.00 | |||
| Lung | 11 | 13 | 0.08 | |
| Stomach/esophagus | 22 | 23 | 0.03 | |
| Liver/biliary tract/pancreas | 17 | 15 | 0.07 | |
| Large intestine | 9 | 8 | 0.04 | |
| Breast | 2 | 2 | 0 | |
| Others | 8 | 8 | 0 | |
| Performance status (n) | 0.99 | |||
| 0 | 0 | 0 | (incalculable) | |
| 1 | 12 | 12 | 0 | |
| 2 | 22 | 20 | 0.06 | |
| 3 | 27 | 28 | 0.03 | |
| 4 | 8 | 9 | 0.04 | |
| Use anti-cancer agents (n, used/unused)a | 1/68 | 2/67 | 1.00 | 0.10 |
| Group 1 n = 131 (70.4%) | Group 2 n = 55 (29.6%) | p-value | All patients | |
| Males/females | 67/64 | 22/33 | 0.199 | 89/97 |
| Mean age (years) | 53.50 ± 17.10 | 61.78 ± 15.38 | 0.002* | 55.94 ± 17.00 |
| Urban residence | 112 (85.5%) | 42 (76.4%) | 0.141 | 154 (82.8%) |
| Duration of hypertension (years) | 5.57 ± 6.62 | 7.87 ± 8.83 | 0.054 | 6.24 ± 7.21 |
| Dyspnoea (NYHA III or IV) | 46 (35.1%) | 33 (60.0%) | 0.002* | 79 (42.5%) |
| Peripheral oedema | 34 (26.0%) | 30 (54.6%) | < 0.001* | 64 (34.4%) |
| Smoking | 6 (4.6%) | 1 (1.8%) | 0.676 | 7 (3.8%) |
| Alcohol | 13 (9.9%) | 4 (7.3%) | 0.681 | 17 (9.1%) |
| Diabetes mellitus | 11 (8.4%) | 5 (9.1%) | 0.878 | 16 (8.6%) |
| Stroke/TIA | 15 (11.5%) | 2 (3.6%) | 0.103 | 17 (9.1%) |
| Anaemia | 19 (14.5%) | 18 (32.7%) | 0.016* | 37 (19.1%) |
| Renal failure | 20 (15.3%) | 15 (27.3%) | 0.101 | 35 (18.8%) |
| Systolic BP (mmHg) | 156.61 ± 30.50 | 149.25 ± 28.16 | 0.150 | 154.54 ± 29.97 |
| Diastolic BP (mmHg) | 95.11 ± 20.26 | 93.19 ± 18.51 | 0.570 | 100.88 ± 86.80 |
| Pulse pressure (mmHg) | 61.54 ± 22.95 | 56.06 ± 18.35 | 0.141 | 60.00 ± 21.85 |
| Heart rate | 88.52 ± 16.45 | 102.58 ± 19.45 | < 0.001* | 92.47 ± 18.41 |
| PCV (%) | 28.67 ± 10.67 | 30.46 ± 8.61 | 0.534 | 29.57 ± 9.63 |
| Serum urea (mmol/l) | 14.30 ± 11.21 | 14.16 ± 10.98 | 0.963 | 14.24 ± 11.00 |
| Serum creatinine (μmol/l) | 585.72 ± 789.49 | 333.33 ± 383.36 | 0.155 | 477.55 ± 654.72 |
| Beta coefficient | SE | t | p-value | |
| Occupation | 0.558 | 0.187 | 2.98 | 0.003 |
| Length of VMW career | 0.007 | 0.003 | 2.28 | 0.023 |
| Reason for becoming VMW | -0.649 | 0.089 | -7.33 | <0.001 |
| Knowledge of malaria transmission | 0.989 | 0.136 | 7.30 | <0.001 |
| Knowledge of vector species | 0.307 | 0.151 | 2.04 | 0.042 |
| Knowledge of vector breeding places | 0.574 | 0.139 | 4.13 | <0.001 |
| Coverage | EC main | EC sub | EC subsub | ||
| RGK | TOP1 | 100% | 22 (61.1%) | 14 (38.9%) | 12 (33.3%) |
| TOP3 | 56 (51.9%) | 30 (27.8%) | 24 (22.2%) | ||
| TOP5 | 86 (47.8%) | 37 (20.6%) | 27 (15.0%) | ||
| E-zyme | TOP1 | 61.1% | 14 (63.6%) | 10 (45.5%) | 8 (36.4%) |
| TOP3 | 42 (63.6%) | 24 (36.4%) | 18 (27.3%) | ||
| TOP5 | 57 (51.8%) | 30 (27.3%) | 24 (21.8%) |
| Parameters | Symbol | Value |
| Duty factor | β | 1/2, 4/5, 5/6 |
| Turning radius | Rturning | 600 mm, 800 mm, 1000 mm |
| Straight radius | RStraight | Inf |
| Running time | T | 30 s |
| The moment of straight to turning | TS-T | 10 s |
| The moment of turning to straight | TT-S | 20 s |
| Gait period | Tperiod | 1 s |
| Variable | Baseline | Three months | P value |
| ESR (mean ± SD, mm in the first hour) | 25.4 ± 22.4 | 12.8 ± 18.5 | 0.038 |
| CRP (mean ± SD, mg/L) | 17.6 ± 18.4 | 10.8 ± 15.9 | 0.058 |
| Prednisone use, n (%) | 7 (44) | 7 (44) | 1.0 |
| Prednisone dose (mean ± SD, mg/day) | 2.0 ± 2.5 | 2.8 ± 5.2 | 0.24 |
| Article | Method | MCInc/MCIc | Scans | ACC (%) | SEN (%) | SPE (%) | AUC |
| Cui et al., 2011 | Multivariate predictors (MRI, CSF, and NM scores) | 87/56 | baseline | 67.1 | 96.4 | 48.3 | 0.796 |
| Ye et al., 2012 | SLR+SS (MRI, genetic, and cognitive measures) | 177/142 | baseline | – | – | – | 0.859 |
| Eskildsen et al., 2013 | Patterns of cortical thinning | 134/122 | 6 months | 75.8 | 75.4 | 76.1 | 0.809 |
| 134/123 | 12 months | 72.9 | 75.8 | 70.2 | 0.762 | ||
| Raamana et al., 2015 | Thickness network fusion | 130/56 | baseline | 64.0 | 65.0 | 64.0 | 0.680 |
| Proposed | Combination of MRI and thickness network | 83/76 | baseline | 66.0 | 55.3 | 75.9 | 0.735 |
| 83/61 | 6 months | 76.4 | 65.6 | 84.3 | 0.813 | ||
| 83/63 | 12 months | 74.7 | 65.1 | 81.9 | 0.785 | ||
| 83/42 | 18 months | 73.9 | 70.5 | 77.1 | 0.773 |
| Performance measures | Base case | Case 1 | Case 2 | Case 3 | Case 4 | |
| Examination quantity | Total | 326.9 | 321.3 | 324.6 | 324.0 | 324.0 |
| Emergency patients | 132.6 | 134.1 | 133.2 | 132.7 | 132.0 | |
| Outpatients | 127.4 | 122.3 | 126.2 | 125.4 | 125.0 | |
| Inpatients | 66.8 | 64.9 | 65.1 | 65.9 | 67.0 | |
| Wait time (min) | Total | 53.9 | 29.3 | 30.4 | 31.1 | 30.1 |
| Emergency patients | 1.8 | 2.0 | 1.9 | 2.0 | 1.9 | |
| Outpatients | 96.6 | 53.6 | 54.7 | 56.6 | 54.8 | |
| Inpatients | 78.0 | 43.0 | 44.5 | 45.8 | 44.2 | |
| Equipment utilization | 99.3% | 97.9% | 98.8% | 98.5% | 98.7% |
| kappa | |
| presence of activity periods | 0.905* |
| presence of rhythmical activity | 0.786* |
| ICC (95% CI) | |
| amount of activity periods | 0.967 (0.951–0.978)* |
| dominant frequency | 0.739 (0.624–0.822)* |
| second prevalent frequency | 0.787 (0.672–0.864)* |
| third prevalent frequency | 0.789 (0.672–0.867)* |
| minimal frequency | 0.351 (0.149–0.525)# |
| maximal frequency | 0.831 (0.750–0.887)* |
| highest value of acceleration peaks | 0.841 (0.768–0.893)* |
| Theory | Favourable impact of coach change on team performance | Slope of the favourable impact over time |
| Vicious-circle theory | NO | |
| Ritual scapegoating theory | NO | |
| Common-sense theory | YES | = |
| Current study | YES | > in the short term and= in the long term |
| Normal versus tumor biomarkers | LN negative versus LN positive biomarkers |
| SLC39A5, C3orf32, TP73, CD1B, PCDHGA4, PCDHGA11, PCDHGA9, PCDHGA1, PCDHGB1, PCDHGB6, PCDHGA12, PCDHGB3, PCDHGB7, PCDHGA6, PCDHGA8, PCDHGA10, PCDHGA5, PCDHGB4, PCDHGA3, PCDHGA2, PCDHGB2, PCDHGA7, PCDHGB5, C20orf197, SLC16A5, FUT8, SLC15A2, C17orf93, PRAC, OCLN, TMEM144, FGF2, PDX1, CCL1, LILRB5, LCE3D, GPR45, LPO, CGB5 | LAT2, TTC13, ARV1, NMT1, DCAKD, GJA1, OR7A17, LOX, KRT19, ZNF655, KRTAP4-4, TAAR5, SEMA3E, HOXD1 |
| Phytoestrogen | Corr CC | p-Value | Corr CC | p-Value |
| Habitual (μg/Day) vs. Urine (μg/g Creatinine) | Recent (μg/Day) vs. Urine (μg/g Creatinine) | |||
| Daidzein | −0.024 | 0.840 | 0.099 | 0.420 |
| Genistein | −0.034 | 0.784 | 0.374 | 0.002 |
| Equol | 0.126 | 0.283 | 0.079 | 0.500 |
| Glicitein | 0.055 | 0.657 | 0.120 | 0.330 |
| Biochanin A | 0.012 | 0.923 | 0.160 | 0.190 |
| Formononetin | −0.024 | 0.841 | 0.170 | 0.160 |
| Total Isoflavones | 0.002 | 0.983 | 0.460 | 0.0001 |
| Secoisolariciresinol | 0.009 | 0.934 | 0.230 | 0.060 |
| Matairesinol | 0.079 | 0.524 | 0.028 | 0.810 |
| Enterolactone | −0.035 | 0.775 | 0.067 | 0.580 |
| Enterodiol | −0.168 | 0.171 | 0.130 | 0.270 |
| Total lignans | −0.111 | 0.359 | 0.550 | 0.000 |
| Naringenin | 0.069 | 0.571 | 0.620 | 0.000 |
| Luteolin | −0.104 | 0.398 | −0.200 | 0.090 |
| Kaempferol | −0.084 | 0.496 | 0.040 | 0.690 |
| Quercetin | 0.154 | 0.212 | 0.027 | 0.820 |
| Total Flavonoids | 0.055 | 0.653 | 0.240 | 0.043 |
| Coumestrol | −0.035 | 0.800 | 0.120 | 0.320 |
| Resveratrol | 0.337 | 0.005 | 0.005 | 0.960 |
| Total Phytoestrogens | 0.730 | 0.000 | 0.410 | 0.0007 |
| Viruses detected | Patients with acute diarrhea (N = 145) (%) |
| Norovirus GII | 59 (40.7) |
| Norovirus GI | 17 (11.7) |
| Astrovirus | 5 (3.5) |
| Rotavirus | 2 (1.4) |
| Adenovirus 40/41 | 0 (0.0) |
| Coinfections | 11 (8.0) |
| Norovirus GI + GII | 5 (3.5) |
| Norovirus GI + Rotavirus A | 1 (0.7) |
| Norovirus GI + Astrovirus | 1 (0.7) |
| Norovirus GII + Astrovirus | 4 (2.8) |
| At least one virus detected | 94 (64.8) |
| No virus detected | 51 (35.2) |
| Lab #1 (Sequencing) | Lab #2 (Sequencing) | Lab #3 (Sequencing) | Lab #4 (Primer Extension) | Lab #5 (Real Time PCR) | |
| Specimen Requirements | Preferred sample type*:Slides from FFPE block 1H&E stained slide sections with tumor circled; 4 matching unstained slides,10 microns each. | Preferred sample type: Archival FFPE or frozen surgical biopsies confirmed to contain >50% tumor by a surgical pathologist.1 H&E slide; 5 unstained sections,10 microns each. | Preferred sample type: FFPE tissue 6 unstained sections,10 microns each. | Preferred sample type: Pre-cut slides from FFPE. Send all slides within 5–7 days of cutting. Air dry. Do not oven dry. Store specimen at room temperature (20–23.5°C). 5 unstained sections, 7 microns each | Preferred sample type: FFPE block, unstained slides, or fresh snap frozen biopsy 5 unstained sections, 7 microns each |
| Genotyping | Method: PCR amplification followed by Direct Sanger sequencing (Big Dye v. 1.1)Detected mutations: KRAS codons 12 and 13 | Method: PCR amplification followed by standard bidirectional sequencing on ABI 3100. Detected mutations: KRAS codons 12 and 13 | Method: PCR amplification followed by sequencing.Detected mutations: KRAS codons 12,13 and 61 | Method: Single nucleotide primer extension with fragment analysis by capillary electrophoresis using a modified SNaPshot assay. Detected mutations: KRAS codons 12 and 13 | Methods are propietary: qualitative real time PCR Detected mutations: KRAS codons 12 and 13 |
| Lower Limit of Detection | 20% when ≥ 40% tumor cells present | 20% | 15-20% | 10% when ≥ 2% tumor cells present | 1-5% |
| Behavior | HIV positives |
| Had sex past year | 71.3 |
| Had steady partner past year | 50.3 |
| Used condoms with steady partner past month | |
| Never | 47.7 |
| Seldom | 23.9 |
| Often | 13.6 |
| Always | 14.8 |
| Had sex with casual female partner past year | 35.4 |
| Used condoms with casual female partners past month | |
| Never | 42.3 |
| Seldom | 22.5 |
| Often | 13.5 |
| Always | 21.6 |
| Sold sex last year | 2.7 |
| Purchased sex last year | 20.0 |
| Condom use with FSW last month | |
| Never | 45.2 |
| Seldom | 20.2 |
| Often | 6.7 |
| Always | 27.9 |
| Gave used needle to other IDU last week | 21.1 |
| CspA | CspZ | ErpPa | ErpCa | ErpAa | p43 | BBK32 | BGA66 | BGA71 | CD59-like protein | |
| Synonyms and other designations | CRASP-1 | CRASP-2 | CRASP-3 | CRASP-4 | CRASP-5 | – | – | – | – | – |
| BbCRASP-1 | BbCRASP-2 | BbCRASP-3 BBN38 | BbCRASP-4 | BbCRASP-5 | ||||||
| BBA68 | BBH06 | ErpI | ||||||||
| ZS7.A68 | ErpN | |||||||||
| FHBP | BBP38 | |||||||||
| BBL39 | ||||||||||
| OspE | ||||||||||
| Gene name | cspA | cspZ | erpP | erpC | erpA | ND | bbk32 | bga66 | bga71 | ND |
| Origin | Bb, Ba, Bs | Bb | Bb | Bb | Bb | Bb | Bb | Bba | Bba | Bb |
| Confers serum resistance | Yes | Yes | No | No | No | ND | Yes | Yes | Yes | ND |
| Interaction with complement regulators/components | FH | FH | FHR-1 | FHR-1 | FHR-1 | C4Bp | C1r | C7, C8, C9, TCC | C7, C8, C9, TCC | TCC |
| FHL-1 | FHL-1 | FHR-2 | FHR-2 | FHR-2 | ||||||
| C7, C8, C9, TCC | FHR-5 | FHR-5 | ||||||||
| Interaction with plasmin(ogen) | Yes | Yes | Yes | Yes | Yes | ND | ND | ND | ND | ND |
| Affected complement pathways | AP, TP | AP | – | – | – | CP/LP(?) | CP | TP | TP | TP |
| Danish early-vaccination era data set | Global post-vaccination era data set | |
| Length of sequences | 800 | 800 |
| Number of sequences | 18 | 40 |
| Average number of differences | 12.2 | 31.0 |
| # synonymous substitutions | 26 | 131 |
| # non-synonymous substitutions | 32 | 71 |
| Average Pi (nucleotide diversity) | ||
| 1. all sites | 0.014 | 0.040 |
| 2. synonymous sites | 0.030 | 0.109 |
| 3. non-synonymous sites | 0.009 | 0.019 |
| Transition/transversion bias | 2.2 | 9.4 |
| Codon usage bias (ENC) | 53 | 55 |
| Cholelithiasis | |||||
| Yes(n = 3725) | No(n = 11175) | OR | 95% CI | P value | |
| Obesity | 30 (0.81%) | 42 (0.38%) | 2.16 | 1.35 - 3.45 | 0.001* |
| Diabetes mellitus | 513 (13.77%) | 1 236 (11.06%) | 1.31 | 1.17 - 1.47 | < 0.001* |
| Hyperlipidemia | 662 (17.77%) | 1 349 (12.07%) | 1.62 | 1.46 - 1.8 | < 0.001* |
| Chronic kidney disease | 57 (1.53%) | 136 (1.22%) | 1.27 | 0.92 - 1.73 | 0.142 |
| Hepatitis B | 108 (2.90%) | 143 (1.28%) | 2.31 | 1.79 - 2.97 | < 0.001* |
| Hepatitis C | 82 (2.20%) | 76 (0.68%) | 3.3 | 2.41 - 4.52 | < 0.001* |
| Cirrhosis | 65 (1.74%) | 65 (0.58%) | 3.05 | 2.16 - 4.32 | < 0.001* |
| Menopause# | 304 (14.45%) | 612 (6.70%) | 1.65 | 1.41 - 1.93 | < 0.001* |
| Characteristics | Number (%) | Characteristics | Number (%) |
| Kebele | Religion | ||
| Yikaho | 63(15.1) | Orthodox Christian | 337(80.6) |
| Mahdid | 62(14.8) | Muslims | 81(19.4) |
| Bambaho | 126(30.1) | Educational level | |
| Dubaba | 167(40) | Illiterate | 248(59.3) |
| Gender | Primary (grades 1–8) | 142(34.0) | |
| Male | 262(62.7) | Secondary and above | 28(6.7) |
| Female | 156(37.3) | Occupation | |
| Age (years) | Farmer | 349(83.5) | |
| 18-24 | 67(16.0) | Others | 69(16.5) |
| 25-49 | 303(72.5) | Family size | |
| 50-64 | 35(8.4) | 1-4 | 230(55.0) |
| 65+ | 13(3.1) | 5+ | 188(45.0) |
| Ethnicity | |||
| Amhara | 293(70.1) | ||
| Agew | 63(15.1) | ||
| Gumuz | 62(14.8) | ||
| Marital status | |||
| Unmarried | 48(11.5) | ||
| Married | 365(85.2) | ||
| Others | 14(3.3) |
| Protein | Gene | Hz vs WT (fold change) | P value | Hz + IGF-1 vs Hz (fold change) | P value |
| IGF-1R and Intracellular signaling | |||||
| Insulin-like growth factor 1 receptor | igf1r | 1.44 | 0.0001 | 1.29 | 0.001 |
| Neuroblastoma ras oncogene | nras | 1.53 | 0.0004 | −1.08 | 0.001 |
| Jun oncogene | jun | −2.03 | 0.0006 | 1.05 | 0.01 |
| FBJ osteosarcoma oncogene | fos | −1.44 | 0.001 | −1.16 | 0.13 |
| Inflammation and apoptosis | |||||
| Chemokine (C-C motif) receptor 5 | ccr5 | 4.38 | 0.0001 | −4.87 | 0.0001 |
| Chemokine (C-C motif) ligand 6 | ccl6 | 4.34 | 0.0002 | −4.02 | 0.0001 |
| Colony stimulating factor 1 receptor | csf1r | 2.49 | 0.0004 | −2.41 | 0.0006 |
| Complement component 1, q subcomponent, α p | c1qa | 5.40 | 0.0002 | −3.43 | 0.0006 |
| Lysozyme 2 | lyz2 | 2.99 | 0.0019 | −2.31 | 0.004 |
| Lymphocyte antigen 96 | ly96 | 1.71 | 0.003 | −1.38 | 0.04 |
| Interleukin 10 receptor beta | il10rb | 1.75 | 0.004 | −1.80 | 0.004 |
| Serum amyloid A 1 | saa1 | 3.74 | 0.0004 | −1.70 | 0.006 |
| Secreted phosphoprotein 1 | spp1 | 2.44 | 0.001 | −1.80 | 0.005 |
| Allograft inflammatory factor 1 | aif1 | 1.95 | 0.0001 | −2.82 | 0.00006 |
| Apoptotic peptidase activating factor 1 | apaf | 1.05 | 0.05 | −1.05 | 0.05 |
| Cytoskeleton | |||||
| Tubulin, beta 2A | tubb2a | −2.49 | 0.001 | 1.56 | 0.002 |
| Vinculin | vcl | −1.49 | 0.003 | 1.31 | 0.06 |
| MAP/microtubule affinity-regulating kinase 2 | mark2 | −1.52 | 0.01 | 1.34 | 0.05 |
| Actin, beta | actb | 1.65 | 0.0006 | −1.58 | 0.0001 |
| Serine/threonine kinase 11 | stk11 | −1.38 | 0.019 | 1.36 | 0.05 |
| Myosin IB | myo1b | 1.43 | 0.05 | −1.37 | 0.03 |
| Intercellular junctions | |||||
| Claudin 1 | cldn1 | −1.04 | 0.21 | −1.23 | 0.18 |
| Claudin 7 | cldn7 | 1.48 | 0.003 | −1.15 | 0.12 |
| Claudin 14 | cldn14 | 2.37 | 0.0006 | −1.78 | 0.0003 |
| Junction adhesion molecule 2 | Jam2 | 1.23 | 0.03 | −1.60 | 0.006 |
| Cadherin 5 | cdh5 | 1.70 | 0.0006 | −1.80 | 0.0001 |
| Desmocollin 2 | dsc2 | 1.46 | 0.003 | −1.46 | 0.001 |
| Extracellular matrix | |||||
| Integrin beta 2 | itgb2 | −2.46 | 0.0006 | 2.03 | 0.0001 |
| Connective tissue growth factor | ctgf/bp8 | −1.60 | 0.001 | −1.57 | 0.006 |
| Proteoglycan 4 | prg4 | 2.21 | 0.006 | −2.24 | 0.0001 |
| Collagen, type I, alpha 2 | col1a2 | −1.58 | 0.001 | 1.13 | 0.02 |
| Collagen, type III, alpha 1 | col3a1 | −1.71 | 0.0003 | 1.08 | 0.38 |
| Collagen, type V, alpha 2 | col5a2 | 1.66 | 0.0001 | −3.99 | 0.0006 |
| Fibronectin 1 | fn1 | 1.50 | 0.005 | −1.45 | 0.003 |
| Animal | Model | Preconditioning time/approach | TLR/ischemia | Result and mechanism | Author | Reference |
| Mice | MCAO, 60-min ischemia, 24-h reperfusion | 72 h/12-min ischemia | Ischemic preconditioning | Decrease brain infarction volume, and IRF gene participate in brain protection | Stevens SL | [79] |
| Mice | MCAO, 60-min ischemia, 6-h reperfusion | 24 h/IP | TLR2, Pam3CSK4 | Decrease brain infarction and edema, improve neurological function, and maintain BBB function | Hua F | [60] |
| Mice | MCAO, 45-min ischemia, 24-h reperfusion | 72 h/subcutaneous injection | TLR3, poly-ICLC | Decrease brain infarction volume and improve neurological function | Packard AEB | [63] |
| Mice | MCAO, 120-min ischemia, 22-h reperfusion | 24 h/systemic injection | TLR3 poly-IC | Decrease brain infarction volume and neurological defect and lower the levels of TNF-α and IL-6 in cortex and striatum | Pan LN | [66] |
| Mice | MCAO, 60-min ischemia, 24-h reperfusion | 1 h/IP | TLR3 poly-IC | Decrease brain infarction and prevention of Fas/FADD interaction | Zhang X | [67] |
| Spontaneously hypertension rats | MCAO, 120-min ischemia, 22-h reperfusion | 2, 3, 4 days/IV | TLR4 LPS | Decrease brain infarction volume, mediated by TNF-α | Tasaki K | [72] |
| Mice | MCAO, 120-min ischemia, 47-h reperfusion | 48 h/IP | TLR4 LPS | Decrease brain infarction volume, inhibit the infiltration of neutrophil and activation of the microglia | Rosenzweig HL | [73] |
| Mice | MCAO, 40-, 45-, 60-min ischemia, 24-h reperfusion | 72 h/IP | TLR4 LPS | Decrease brain infarction volume that was mediated by IRF3 | Marsh B | [61] |
| Mice | MCAO, 40-to 60-min ischemia, 24-h reperfusion | 72 h/subcutaneous injection | TLR4 LPS | Decrease brain infarction volume, and TRIF-IRF3 play vital role | Vartanian KB | [58] |
| Mice | MCAO, 60-min ischemia, 24-h reperfusion | 72 h/IP | TLR4 | Decrease brain infarction volume, and inhibit TNF-α signaling pathway after cerebral ischemia | Rosenzweig HL | [76] |
| Mice | MCAO, 45-to 60-min ischemia, 23-h reperfusion | 72 h/subcutaneous injection | TLR7 GDQ | Decrease brain infarction volume and neurological functional score that was protected through I type interferon | Leung PY | [62] |
| Mice | MCAO, 60-min ischemia, 72-h reperfusion | 30 min/IV | TLR8 R848 | Increase neurological function defect and mortality, activate pro-apoptotic JNK pathway and inflammation | Tang SC | [56] |
| Mice | MCAO, 60-min ischemia, 24-h reperfusion | 72 h/IP | TLR9 CpG-ODN | Decrease brain infarction volume and TNF-α play a vital role | Stevens SL | [64] |
| Mice | MCAO, 60-min ischemia, 24-h reperfusion | 72 h/IP or subcutaneous injection | TLR9 CpG-ODN | Decrease brain infarction volume and IRF gene participate in cerebral protection after ischemia | Stevens SL | [79] |
| Mice | MCAO, 60-min ischemia, 24-h reperfusion | 1 h/IP | TLR9 CpG-ODN | Decrease brain infarction and activation of PI3K/Akt signaling | Lu C | [78] |
| Variable | Category | A/A | G/A | Total | P value |
| Surfactant | Yes | 26 (92.9%) | 2 (7.1%) | 28 (100%) | 0.271 |
| No | 174 (82.9%) | 36 (17.1%) | 210 (100%) | ||
| Ventilator | Yes | 31 (93.9%) | 2 (6.1%) | 33 (100%) | 0.094 |
| No | 169 (82.4%) | 36 (17.6%) | 205 (100%) | ||
| Death | Yes | 22 (95.7%) | 1 (4.3%) | 23 (100%) | 0.139 |
| No | 178 (82.8%) | 37 (17.2%) | 215 (100%) |
| Sl. number | Age | Gender | Site | Size | Histopathological category |
| Case1 | 40 | Female | Gingiva | 1-2 cm | Cellular phase |
| Case2 | 40 | Female | Buccal mucosa | 1-2 cm | Capillary phase, LCH type |
| Case3 | 09 | Male | Buccal mucosa | <1 cm | Capillary phase, non-LCH type |
| Case4 | 23 | Female | Gingiva | 1-2 cm | Involutionary phase |
| Population | Region of interest | Emax, % | EC50, ng/mL |
| EC | Hippocampus | 89.1 (CV%: 9.6) | 2.05 (CV%: 33.4) |
| Striatum | 88.8 (CV%: 7.5) | 1.67 (CV%: 29.7) | |
| Frontal cortex | 80.1 (CV%: 8.9) | 1.57 (CV% 36.2) | |
| AD | Hippocampus | 85.9 (CV%: 4.1) | 1.29 (CV%: 21.5) |
| Striatum | 87.8 (CV%: 1.8) | 1.11 (CV%: 10.7) | |
| Frontal cortex | 81.1 (CV%: 3.2) | 1.06 (CV%: 19.6) |
| Factors | Moxi | (%) | Non-Moxi | (%) |
| Number | 276 | 1992 | ||
| Age | 44.78 | 38.5 | ||
| Sex (male) | 150 | (54.3) | 1129 | (56.7) |
| Site of disease | ||||
| Pulmonary | 165 | 59.8 | 1182 | 59.3 |
| Meningeal | 12 | 4.3 | 9 | 0.5 |
| Central Nervous System | 2 | 0.7 | 4 | 0.2 |
| Ocular | 10 | 3.6 | 12 | 0.6 |
| Other extra-pulmonary | 87 | 31.5 | 786 | 39.4 |
| Country of origin | ||||
| Australian | 22 | 8.0 | 219 | 11.0 |
| Overseas | 254 | 92.0 | 1773 | 89.0 |
| HIV status | ||||
| Positive | 5 | 1.8 | 32 | 1.6 |
| Negative | 67 | 24.3 | 328 | 16.5 |
| Unknown | 204 | 73.9 | 1632 | 81.9 |
| Diagnosis method | ||||
| Culture | 217 | 78.6 | 1521 | 76.3 |
| Histological | 13 | 4.7 | 161 | 8.1 |
| PCR/NAT | 19 | 6.9 | 116 | 5.8 |
| Radiological | 9 | 3.3 | 126 | 6.3 |
| Clinical | 17 | 6.2 | 58 | 2.9 |
| Microscopic Examination | 1 | 0.4 | 10 | 0.5 |
| Sensitivities - Of culture positive cases | ||||
| Fully sensitive | 148 | 68.2 | 1410 | 92.6 |
| MDRTB | 39 | 18.0 | 0 | 0.0 |
| XDRTB | 2 | 0.9 | 0 | 0.0 |
| Other resistance patterns | 26 | 12.0 | 103 | 6.8 |
| Isoniazid Resistance | 24 | 92.3 | 97 | 94.2 |
| Rifampicin resistance | 1 | 3.8 | 0 | 0.0 |
| Pyrazinamide resistance | 1 | 3.8 | 2 | 1.9 |
| Ethambutol resistance | 0 | 0.0 | 3 | 2.9 |
| Other agents | 0 | 0.0 | 1 | 1.0 |
| Sensitivity results pending | 2 | 0.9 | 9 | 0.6 |
| Sample | Spiked Level (mg/kg) | Recovery (%) | RSD a (%) |
| fresh tea leaf | 0.01 | 92.3 ± 6.51 | 10.2 |
| 0.05 | 84.3 ± 5.84 | 10.4 | |
| 0.5 | 77.7 ± 4.67 | 8.6 |
| Fractions/compounds | IC50(μg/ml) | |||
| LLC | A2780 | HepG2 | A549 | |
| HE | 660.11 ± 16.71 | 246.97 ± 18.78 | 288.95 ± 17.84 | 294.96 ± 24.46 |
| WE | 614.74 ± 19.55 | 208.38 ± 23.57 | 279.09 ± 13.06 | 461.26 ± 28.38 |
| CE | 97.55 ± 4.02 | 88.50 ± 5.26 | 128.26 ± 12.55 | 172.59 ± 6.59 |
| TAFU | 39.37 ± 2.36 | 27.65 ± 1.84 | 51.10 ± 2.84 | 58.60 ± 3.99 |
| Verticine | 16.53 ± 0.82 | 48.41 ± 2.58 | 53.38 ± 3.16 | 97.58 ± 3.72 |
| Vericinone | 3.03 ± 0.32 | 17.03 ± 0.89 | 14.64 ± 0.65 | 47.39 ± 1.90 |
| Imperialine | 66.26 ± 3.46 | 39.18 ± 2.21 | 84.26 ± 4.46 | 117.84 ± 6.29 |
| Peimisine | 20.75 ± 1.44 | 17.43 ± 0.80 | 92.07 ± 4.89 | 36.11 ± 1.70 |
| FGD content analysis | Men – young FGD |
| Meaning unit | I think smoking is not related to sugar disease but there must be small part that can affect sugar disease; most smokers, including me, we usually deny |
| Condensed meaning unit | Smoking is related to diabetes ‘but small part’; smokers deny bad effect of smoking; |
| Codes | Smoking only partly related to diabetes |
| Smokers deny bad effect of smoking | |
| Aware of healthy lifestyle but ignoring | |
| Codes cluster | Diabetes content area: |
| - | |
| Risk factors content area: | |
| Smoking only partly related to diabetes | |
| Smokers deny bad effect of smoking | |
| Aware of healthy lifestyle but ignoring |
| Plate temperature Tw (K) | RaK | Nu | Nuavg | Nu/RaK0.5 | Nu/RaK0.5[[1-4]] |
| 303 | 69.5325 | 3.6319 | 6.6569 | 0.4356 | ≈0.44 |
| 313 | 139.0649 | 5.0880 | 8.959 | 0.4315 | 0.44 |
| 323 | 208.5974 | 6.2634 | 10.5969 | 0.4337 | 0.44 |
| 333 | 278.1298 | 7.2200 | 11.8779 | 0.4329 | 0.44 |
| 353 | 417.2597 | 8.8231 | 13.8479 | 0.4320 | 0.44 |
| 373 | 556.2597 | 10.1248 | 15.3437 | 0.43 | 0.44 |
| Ligand | Mutagenicity | Carcinogenicity | |||
| Salmonella typhimurium(CPDB) | Salmonella typhimurium(Kazius/Bursi) | Rodent(multiple sex) | Rat(both sex) | Mouse(both sex) | |
| SAHA | no | no | no | no | yes |
| 1a | no | no | no | no | no |
| 1b | no | no | no | no | yes |
| 1c | no | no | no | no | no |
| 1d | no | no | no | no | no |
| 1e | no | no | yes | no | no |
| 1f | no | no | no | no | no |
| 2a | no | no | no | no | yes |
| 2b | no | no | no | no | yes |
| 2c | no | no | no | no | yes |
| 2d | no | no | no | no | yes |
| 2e | no | no | no | no | yes |
| 2f | no | no | no | no | yes |
| Variable | n(%) n = 105 |
| Age (mean(SD)) | 63.4 (20.1) |
| Age category | - |
| 20–49 | 24(23) |
| 50–74 | 38(36) |
| 75–84 | 25(24) |
| 85+ | 18(17) |
| Female | 67(64) |
| Secondary care antibiotic use | 77(73) |
| Trimethoprim 1 | 63(82) |
| Co-amoxiclav 1 | 22(29) |
| Amoxicillin 1 | 66(86) |
| Nitrofurantoin 1 | 3(4) |
| Visited hospital in previous 12 months | 53(50) |
| Antibiotic use in previous 12 months | - |
| Yes | 21(20) |
| Unknown 2 | 79(75) |
| Co-morbidity | - |
| Asthma | 14(13) |
| Diabetes mellitus | 16(15) |
| COPD | 3(3) |
| History of smoking | 46(44) |
| msSNP | Location error by the composite likelihood approach | |||||||
| Causal SNP out | Causal SNP in | |||||||
| SNP density (kb/SNP) | No. SNPs | No. regions | χ21 | Location error | LD | kb | LD | kb |
| Full (11) | 15701 | 126 | 2324 | 153 | 57 | 13 | 55 | 14 |
| 1/2 (22) | 7850 | 125 | 1762 | -2 | 5 | -19 | 5 | -20 |
| 1/3 (33) | 5233 | 118 | 2324 | 153 | 153 | 40 | 6 | 40 |
| 1/4 (44) | 3925 | 106 | 1762 | -2 | -65 | -56 | -57 | -53 |
| 1/5 (54) | 3140 | 94 | 2274 | 42 | -24 | -35 | -15 | -36 |
| 1/6 (65) | 2616 | 82 | 1285 | 20 | 20 | 20 | 10 | 15 |
| 1/8 (87) | 1962 | 64 | 1601 | 65 | -58 | -64 | -47 | -58 |
| 1/10 (109) | 1570 | 52 | 726 | -106 | -55 | -59 | -24 | -46 |
| 1/15 (163) | 1046 | 34 | 486 | -887 | 294 | 26 | 0 | 3 |
| 1/20 (217) | 785 | 26 | 726 | -106 | -97 | -160 | -26 | -43 |
| 1/25 (272) | 628 | 20 | 348 | -9 | 69 | -120 | 60 | -79 |
| 1/30 (326) | 523 | 17 | 229 | 188 | 362 | -25 | 0 | -25 |
| Epidemiological and demographic variable | Number of cases | Deaths | Case fatality rate | Incidence rate | |
| n | % | n | % | /100,000 | |
| Region of probable infection site | |||||
| North | 95 | 3.5 | 40 | 42.1 | 0.34 |
| Northeast | 11 | 0.4 | 5 | 45.4 | <0.01 |
| Southeast | 423 | 14.2 | 194 | 45.8 | 0.05 |
| South | 574 | 19.3 | 192 | 33.4 | 0.25 |
| Midwest | 472 | 15.9 | 184 | 38.9 | 0.90 |
| Left blank or unknown | 177 | 10.3 | 63 | 34.4 | – |
| Infection zone | |||||
| Urban | 151 | 8.6 | 60 | 39.7 | – |
| Rural | 1261 | 72.0 | 460 | 36.5 | – |
| Periurban | 110 | 6.3 | 48 | 42.7 | – |
| Left blank or unknown | 230 | 13.1 | 108 | 51.3 | – |
| Gender | |||||
| Male | 1338 | 76.4 | 503 | 37.6 | 0.04 |
| Female | 414 | 23.6 | 173 | 41.6 | <0.01 |
| Left blank | 0 | 0.0 | 0 | 0.0 | <0.01 |
| Ethnic group | |||||
| White | 1047 | 59.8 | 368 | 35.1 | – |
| Black | 91 | 5.2 | 40 | 44.0 | – |
| Asian | 18 | 1.0 | 4 | 22.2 | – |
| Mixed race | 363 | 20.7 | 165 | 45.5 | – |
| Indigenous | 38 | 2.2 | 3 | 7.9 | – |
| Left blank | 195 | 11.1 | 96 | 49.2 | – |
| Age | |||||
| Less than 1 year | 7 | 0.4 | 4 | 57.14 | 0.01 |
| 1–4 years | 6 | 0.3 | 1 | 16.7 | <0.01 |
| 5–9 years | 20 | 1.1 | 7 | 35.0 | 0.01 |
| 10–14 years | 43 | 2.5 | 16 | 37.2 | 0.02 |
| 15–19 years | 91 | 5.2 | 58 | 63.7 | 0.03 |
| 20–34 years | 426 | 24.3 | 282 | 66.2 | 0.04 |
| 35–49 years | 662 | 37.8 | 205 | 31.0 | 0.09 |
| 50–64 years | 363 | 20.7 | 92 | 25.3 | 0.09 |
| 65+ | 134 | 7.6 | 11 | 8.2 | 0.05 |
| Univariate | Multivariatea | |||
| Group | OR (95 % CI) | P | OR (95 % CI) | P |
| Moderate to severe hypoatremia | 1.91 (1.197–3.033) | 0.007 | 3.61 (1.438–9.049) | 0.006 |
| Mild hyponatremia | 1.65 (1.047–2.610) | 0.031 | 2.45 (1.051–5.705) | 0.038 |
| Normonatremia | 1 (Reference) | 1 (Reference) | ||
| Mild hypernatremia | 1.03 (0.560–1.908) | 0.917 | 1.06 (0.461–2.438) | 0.890 |
| Moderate to severe hypernatremia | 2.32 (1.203–4.453) | 0.012 | 2.94 (1.119–7.722) | 0.029 |
| No incident diabetes (n = 2590) | Incident diabetes (n = 297) | p≤* | |
| Age (years) | 44 ± 17 | 47 ± 15 | 0.101 |
| Sex (% women) | 60 | 61 | 0.662 |
| Systolic BP (mmHg) | 122 ± 17 | 127 ± 17 | 0.02 |
| Diastolic BP (mmHg) | 75 ± 11 | 78 ± 11 | 0.003 |
| Heart rate (bpm) | 68 ± 11 | 70 ± 11 | 0.02 |
| Body mass index (kg/m2) | 30 ± 7 | 35 ± 7 | 0.0001 |
| Waist circumference (cm) | 100 ± 16 | 113 ± 16 | 0.0001 |
| GFRMDRD (mL/min/1.73 m2) | 92 [78–108] | 92 [79–109] | 0.178† |
| Cholesterol (mg/dL) | 187 ± 37 | 187 ± 39 | 0.370 |
| HDL-c (mg/dL) | 50 ± 15 | 44 ± 14 | 0.0001 |
| Triglycerides (mg/dL) | 120 [86–171] | 147 [107–196] | 0.002† |
| Fasting glucose (mg/dL) | 96 ± 13 | 109 ± 25 | 0.0001 |
| Fasting insulin (mIU/mL) | 11 [7–17] | 21 [13–31] | 0.0001† |
| HOMA-R | 2.6 [1.6–4.2] | 5.2 [3.4–8.3] | 0.0001† |
| Fibrinogen (mg/dL) | 347 [304–399] | 367 [322–427] | 0.01† |
| PAI-1 (mg/dL) | 42 [26–65] | 58 [38–93] | 0.01† |
| Fat-free mass (kg) | 53 ± 12 | 59 ± 14 | 0.04 |
| Adipose mass (kg) | 35 ± 10 | 40 ± 8 | 0.0001 |
| LVDD index (cm/m) | 3.09 ± 0.25 | 3.16 ± 0.29 | 0.008 |
| LV mass index (g/m2.7) | 38.0 ± 8.8 | 42.2 ± 10.3 | 0.0001 |
| Relative wall thicknessa | 0.32 ± 0.05 | 0.33 ± 0.04 | 0.006 |
| LAV index (mL/m2)b | 11.4 ± 3.0 | 13.1 ± 3.0 | 0.0001 |
| Ejection fraction (%) | 63 ± 5 | 64 ± 5 | 0.2 |
| Urinary albumin/creatinine | 6.55 [4.22–12.08] | 8.32 [4.95–16.56] | 0.152† |
| NH White | NH Black | Hispanic | Asian/PI | |||||
| n=11,347 | 86.92% | n=772 | 5.91% | n=601 | 4.60% | n=334 | 2.56% | |
| Screening service | ||||||||
| Well visit (n = 13,054) | ||||||||
| Yes (%) | 1374 | 12.11 | 78 | 10.10 | 70 | 11.65 | 49 | 14.67 |
| OR (95% CI) | ref | ref | 0.82 | 0.64, 1.04 | 0.96 | 0.74, 1.24 | 1.25 | 0.92, 1.70 |
| aOR (95% CI)d | ref | ref | 0.82 | 0.64, 1.05 | 0.81 | 0.62, 1.05 | 0.98 | 0.72, 1.35 |
| Influenza vaccination (n = 13,054) | ||||||||
| Yes (%) | 7643 | 67.36 | 347 | 44.95 | 317 | 52.75 | 222 | 66.47 |
| OR (95% CI) | ref | ref | 0.40 | 0.34, 0.45 | 0.54 | 0.46, 0.64 | 0.96 | 0.76, 1.21 |
| aOR (95% CI)d | ref | ref | 0.40 | 0.33, 0.44 | 0.61 | 0.51, 0.72 | 1.15 | 0.91, 1.45 |
| 2 Influenza vaccinations a(n = 13,054) | ||||||||
| Yes (%) | 4828 | 42.55 | 155 | 20.08 | 143 | 23.79 | 136 | 40.72 |
| OR (95% CI) | ref | ref | 0.34 | 0.28, 0.41 | 0.42 | 0.35, 0.51 | 0.93 | 0.74, 1.15 |
| aOR (95% CI)d | ref | ref | 0.33 | 0.27, 0.39 | 0.47 | 0.39, 0.57 | 1.08 | 0.86, 1.36 |
| Breast cancer screeningb (n = 6145) | ||||||||
| Yes (%) | 3876 | 74.15 | 283 | 65.36 | 218 | 69.21 | 117 | 68.82 |
| OR (95% CI) | ref | ref | 0.66 | 0.53, 0.81 | 0.78 | 0.61, 1.00 | 0.77 | 0.55, 1.07 |
| aOR (95% CI)d | ref | ref | 0.64 | 0.52, 0.79 | 0.82 | 0.64, 1.05 | 0.82 | 0.58, 1.14 |
| Diabetes screeningc (n = 5933) | ||||||||
| Yes (%) | 1684 | 32.23 | 123 | 37.85 | 94 | 37.75 | 54 | 40.30 |
| OR (95% CI) | ref | ref | 1.28 | 1.01, 1.61 | 1.28 | 0.98, 1.66 | 1.42 | 1.00, 2.01 |
| aOR (95% CI)d | ref | ref | 1.34 | 1.06, 1.71 | 1.35 | 1.03, 1.77 | 1.47 | 1.02, 2.10 |
| Prognostic feature | P value | OR | 95% CI | |
| Gender [male/female] | 0.185 | 2.745 | 0.618 | 12.193 |
| ECOG 1 vs. 0 | 0.020 | 0.336 | 0.134 | 0.842 |
| ECOG 2 vs. 0 | 0.047 | 0.121 | 0.015 | 0.974 |
| ICIQ group mild vs. moderate | 0.394 | 1.76 | 0.48 | 6.449 |
| ICIQ group mild vs. severe | 0.382 | 0.504 | 0.109 | 2.342 |
| Surgeon experience <100 vs. >100 prev. rCx [y/n] | 0.021 | 3.442 | 1.203 | 9.847 |
| Nerve-sparing [y/n] | 0.165 | 2.029 | 0.747 | 5.511 |
| Radiation therapy [y/n] | 0.999 | 0 | 0 | . |
| Symptoms [y/n] | 0.109 | 0.458 | 0.176 | 1.192 |
| Urge [y/n] | 0.259 | 0.486 | 0.139 | 1.702 |
| Daytime continence [y/n] | 0.032 | 3.131 | 1.101 | 8.908 |
| Daily pad usage 2 vs. 0-1 | 0.817 | 0.859 | 0.238 | 3.105 |
| Daily pad usage >2 vs. 0-1 | 0.995 | 0.996 | 0.274 | 3.616 |
| Effect | β | SE | P-Value | |
| MVPA | Intercept | 3.233 | 0.397 | <0.001 |
| Maturity Offset | −0.077 | 0.098 | 0.434 | |
| Maturity Offset* Maturity Offset | 0.026 | 0.009 | 0.005 | |
| Sex (ref = girl) | 1.574 | 0.335 | <0.001 | |
| Family Support | 0.677 | 0.128 | <0.001 | |
| Maturity Offset* Family Support | −0.080 | 0.028 | 0.004 | |
| Family Support* Sex (ref = girl) | −0.298 | 0.118 | 0.012 | |
| Friend Support | 0.267 | 0.055 | <0.001 | |
| Mother’s Ed | 0.355 | 0.192 | 0.065 | |
| MVPA- | Intercept | 2.070 | 0.274 | <0.001 |
| PM Weekday | Maturity Offset | −0.251 | 0.050 | <0.001 |
| Maturity Offset* Maturity Offset | 0.026 | 0.009 | 0.004 | |
| Sex (ref = girl) | 0.385 | 0.126 | 0.002 | |
| Family Support | 0.315 | 0.065 | <0.001 | |
| Friend Support | 0.352 | 0.056 | <0.001 | |
| Mother’s Ed | 0.455 | 0.194 | 0.019 |
| Men (n = 416) | Women (n = 538) | Both sexes (n = 954) | |||||||
| Prevalence | 95% CI | Cases/All | Prevalence | 95% CI | Cases/All | Prevalence | 95% CI | Cases/All | |
| Combined Astana city and Akmol village | |||||||||
| Prevalence of HC among all | 28.4% | 24.0–32.7 | 118/416 | 44.1% | 39.8–48.3 | 237/538 | 37.2% | 34.1–40.3 | 355/954 |
| Awareness among all cases of HC | 47.5% | 38.3–56.6 | 56/118 | 61.2% | 54.9–67.4 | 145/237 | 56.6% | 51.4–61.8 | 201/355 |
| Treatment among all cases of HC | 33.1% | 24.4–41.7 | 39/118 | 44.3% | 37.9–50.7 | 105/237 | 40.6% | 35.4–45.7 | 144/355 |
| Treatment among aware | 67.9% | 55.2–80.5 | 38/56 | 71.7% | 64.3–79.1 | 104/145 | 70.7% | 64.3–77.0 | 142/201 |
| Control among all cases of HC | 26.3% | 18.2–34.3 | 31/118 | 21.9% | 16.6–27.2 | 52/237 | 23.4% | 19.0–27.8 | 83/355 |
| Control among treated | 79.5% | 66.2–92.7 | 31/39 | 49.5% | 39.8–59.2 | 52/105 | 57.6% | 49.5–65.8 | 83/144 |
| Astana city (urban, n = 480) | |||||||||
| Prevalence of HC among all | 38.2% | 31.7–44.7 | 84/220 | 57.3% | 51.3–63.4 | 149/260 | 48.5% | 44.1–53.0 | 233/480 |
| Awareness among all cases of HC | 56.0% | 45.1–66.8 | 47/84 | 72.5% | 65.2–79.7 | 108/149 | 66.5% | 60.4–72.6 | 155/233 |
| Treatment among all cases of HC | 36.9% | 26.4–47.4 | 31/84 | 49.7% | 41.5–57.8 | 74/149 | 45.1% | 38.6–51.5 | 105/233 |
| Treatment among aware | 63.8% | 49.6–78.1 | 30/47 | 68.5% | 59.6–77.4 | 74/108 | 67.1% | 59.6–74.6 | 104/155 |
| Control among all cases of HC | 29.8% | 19.8–39.7 | 25/84 | 24.8% | 17.8–31.9 | 37/149 | 26.6% | 20.9–32.3 | 62/233 |
| Control among treated | 80.7% | 65.9–95.4 | 25/31 | 50.0% | 38.3–61.7 | 37/74 | 59.1% | 49.5–68.6 | 62/105 |
| Akmol village (rural, n = 474) | |||||||||
| Prevalence of HC among all | 17.4% | 12.0–22.7 | 34/196 | 31.7% | 26.2–37.2 | 88/278 | 25.7% | 21.8–29.7 | 122/474 |
| Awareness among all cases of HC | 26.5% | 10.8–42.1 | 9/34 | 42.1% | 31.5–52.6 | 37/88 | 37.7% | 29.0–46.4 | 46/122 |
| Treatment among all cases of HC | 23.5% | 8.5–38.6 | 8/34 | 35.2% | 25.0–45.4 | 31/88 | 32.0% | 23.6–40.4 | 39/122 |
| Treatment among aware | 88.9% | 63.3–114.5 | 8/9 | 81.1% | 67.8–94.3 | 30/37 | 82.6% | 71.2–94.0 | 38/46 |
| Control among all cases of HC | 17.7% | 4.1–31.1 | 6/34 | 17.1% | 9.0–25.1 | 15/88 | 17.2% | 10.4–24.0 | 21/122 |
| Control among treated | 75.0% | 36.3–113.7 | 6/8 | 48.4% | 29.8–67.0 | 15/31 | 53.9% | 37.5–70.2 | 21/39 |
| Run (session) | Total Samples | Average Strokes per Minute (SPM) | Number of Observation slices | Type of run |
| A | 6,500 | 33.4 | 13 | inner-club competition |
| B | 8,000 | 15.4 | 8 | training |
| C | 4,500 | 32.0 | 9 | inner-club competition |
| D | 5,000 | 31.2 | 10 | inner-club competition |
| E | 8,000 | 15.0 | 8 | recovery |
| AUC (95% CI) | Fold change∗ | P | ||
| ANC, 103/μL | 0.6001 (0.5689–0.6313) | — | — | |
| FBG, mmol/L | 0.5876 (0.5561–0.6191) | — | — | |
| SCr, μmol/L | 0.5545 (0.5225–0.5869) | — | — | |
| SBP, mmHg | 0.5767 (0.5457–0.6077) | — | — | |
| Model 1 | ANC × FBG | 0.6179 (0.5872–0.6486) | — | — |
| Model 2 | ANC × FBG × SBP | 0.6282 (0.6068–0.6676) | 1.67 | 0.5188 |
| Model 3 | ANC × FBG × SBP × SCr | 0.6372 (0.5978–0.6586) | 3.12 | 0.5338 |
| DerSimonian and Laird results | Calculations for Hartung-Knapp-Sidik Jonkman | ||||
| Study | Study results HR yi | Weights wi | ln(yi) | (ln(yi )–ln(y))2 | wi×(ln(yi )–ln(y))2 |
| Cornelissen 2009 | 0.81 | 5.0 | −0.21 | 0.00 | 0.02 |
| De Witte 1994 | 0.67 | 2.1 | −0.40 | 0.06 | 0.13 |
| Fielding 2009 | 0.80 | 11.5 | −0.22 | 0.01 | 0.06 |
| Goldstone 2008 | 0.91 | 46.7 | −0.09 | 0.00 | 0.15 |
| Hunault 2004 | 0.56 | 2.9 | −0.58 | 0.18 | 0.53 |
| Labar 2004 | 0.98 | 9.3 | −0.02 | 0.02 | 0.16 |
| Ribera 2005 | 1.24 | 3.9 | 0.22 | 0.13 | 0.52 |
| Sebban 1994 | 0.75 | 12.7 | −0.29 | 0.02 | 0.24 |
| Takeuchi 2002 | 0.95 | 3.9 | −0.05 | 0.01 | 0.04 |
| Ueda 1998 | 0.66 | 2.0 | −0.42 | 0.07 | 0.14 |
| y = 0.86 | Sum: 100.0 | Sum: 1.99 | |||
| 10 studies, I2 = 0.0, τ2 = 0.0. | |||||
| DL pooled result [95% CI]: HR = 0.86 [0.77, 0.97]; z = −2.48; P–value = 0.013. | |||||
| HKSJ pooled result [95% CI]: HR = 0.86 [0.77, 0.96]; t = −3.19; P–value = 0.011 (df = 9). |
| Characteristics | Mean (SD); n (%) | Range: |
| Age in years | 77.7 (5.89) | 66-90 |
| Women | 25 (45.5%) | N/A |
| At least 1 fall in last 12 months | 14 (25%) | N/A |
| BMI | 25.8 (4.4) | 14-42 |
| Years of education | 12.1 (3.4) | (8-20) |
| Cognition | ||
| MMSE Score (0-30) | 26.8 (2.1) | 21-30 |
| MoCA score | 22.4 (3.2) | 15-28 |
| Letter Number Sequencing (LNS) | 7.6 (2.4) | 3-13 |
| TMT A (seconds) | 55.8 (20.9) | 23-102 |
| TMT B (seconds) | 178.8 (108.6) | 55-539 |
| Digit Symbol Coding | 41 (14.4) | 19-71 |
| Gait Velocity (m/s) | ||
| Single Gait Velocity (sGV) | 0.87 (0.2) | 0.44-1.50 |
| Verbal Gait Velocity (vGV) | 0.65 (0.2) | 0.32-1.00 |
| Counting Gait Velocity (cGV) | 0.63 (0.2) | 0.34-1.06 |
| RSSI location | SVD imaging biomarker | Frequency [i.e., number of patients (%)] | Median volume or score (IQR) | % [median (IQR)] of total ICV |
| Total brain | RSSI | 187/187 (100) | 0.75 (0.84) ml | 0.05 (0.06) |
| WMH | 187/187 (100) | 16.82 (30) ml | 1.18 (2.18) | |
| Cavitated WMH | 64/187 (34) | 1.15 (1.45) ml | 8.02 (9.29)× 10−4 | |
| Lacunes | 87/187 (46) | 0.17 (0.22) ml | 1.15 (1.48)× 10−4 | |
| Perivascular spaces | 186/187 (99) | BG score: 2 (1) | Not applicable | |
| CS score: 3 (1) | ||||
| Microbleeds | 92/187 (49) | 1 (3) (n = 187) | Not applicable | |
| 3 (3) (n = 92) | ||||
| Old cortical stroke lesions | 41/187 (22) | 0.54 (2.08) ml | 3.84 (16.26)× 10−4 | |
| Left hemisphere | RSSI | 97/187 (52) | 0.71 (1.11) ml | 0.05 (0.08) |
| WMH | 97/97 (100) | 12.61 (25.30) ml | 0.94 (1.95) | |
| Cavitated WMH | 32/97 (33) | 1.19 (1.57) ml | 8.65 (11.92)× 10−4 | |
| Lacunes | 44/97 (45) | 0.17 (0.20) ml | 1.30 (1.40)× 10−4 | |
| Perivascular spaces | 97/97 (100) | BG score: 2 (2) | Not applicable | |
| CS score: 3 (1) | ||||
| Microbleeds | 50/97 (52) | 1 (3) (n = 97) | Not applicable | |
| 3 (3) (n = 50) | ||||
| Old cortical stroke lesions | 21/97 (22) | 0.70 (3.52) ml | 4.69 (27.00)× 10−4 | |
| Right hemisphere | RSSI | 78/187 (42) | 0.79 (0.82) ml | 0.5 (0.06) |
| WMH | 78/78 (100) | 23.09 (28.24) ml | 1.64 (2.09) | |
| Cavitated WMH | 29/78 (37) | 1.06 (1.42) ml | 7.04 (8.19)× 10−4 | |
| Lacunes | 37/78 (47) | 0.17 (0.35) ml | 1.15 (2.11)× 10−4 | |
| Perivascular spaces | 77/78 (99) | BG score: 2 (1) | Not applicable | |
| CS score: 3 (1) | ||||
| Microbleeds | 38/78 (49) | 1 (2) (n = 78) | Not applicable | |
| 2 (4) (n = 38) | ||||
| Old cortical stroke lesions | 17/78 (22) | 0.67 (1.81) ml | 4.61 (11.80)× 10−4 | |
| Both hemispheres | RSSI | 5/187 (3) | 1.77 (2.81) ml | 0.14 (0.02) |
| WMH | 5/5 (100) | 60.47 (73.52) ml | 4.98 (4.28) | |
| Cavitated WMH | 2/5 (40) | 1.25 ml | 7.78 × 10−4 | |
| Lacunes | 4/5 (80) | 0.17 (0.35) ml | 1.18 (2.08)× 10−4 | |
| Perivascular spaces | 5/5 (100) | BG score: 2 (2) | Not applicable | |
| CS score: 2 (2) | ||||
| Microbleeds | 3/5 (60) | 2 | Not applicable | |
| Old cortical stroke lesions | 1/5 (20) | 0.32 ml | 1.93 × 10−4 | |
| Cerebellum/ brainstem | RSSI | 7/187 (4) | 0.33 (0.20) ml | 0.02 (0.02) |
| WMH | 7/7 (100) | 19.69 (16.66) ml | 1.27 (1.19) | |
| Cavitated WMH | 1/7 (14) | 0.49 ml | 3.14 × 10−4 | |
| Lacunes | 2/7 (28) | 0.09 ml | 0.61 × 10−4 | |
| Perivascular spaces | 7/7 (100) | BG score: 2 (1) | Not applicable | |
| CS score: 2 (2) | ||||
| Microbleeds | 1/7 (29) | 1 | Not applicable | |
| Old cortical stroke lesions | 2/7 (28) | 0.61 ml | 4.92 × 10−4 |
| Name | Sel | Rec | VRec | VarN | M | MM | CEM | Seq | Tree | Ref |
| FPG | Yes | Yes | No | No | Yes | No | No | Yes | No | JH |
| EasyPop | No | Yes | No | No | Yes | Yes | No | No | Yes | B01 |
| SimuPop | Yes | Yes | Yes | Yes | Yes | Yes | No | No | Yes | P05 |
| FREEGENE | Yes | Yes | Yes | Yes | Yes | No | No | No | No | H07 |
| GenomePop | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | C08 |
| Variable | Number of workers | Cases | LBP (%) | χ2 | P |
| Age | |||||
| < 25 | 48 | 41 | 85.4 | 0.839 | 0.657 |
| 25~ | 90 | 81 | 90.0 | ||
| 30~ | 13 | 12 | 92.3 | ||
| Working-age | |||||
| < 1 | 27 | 24 | 88.9 | 0.194 | 0.907 |
| 1~ | 64 | 56 | 87.5 | ||
| 3~ | 60 | 54 | 90.0 | ||
| Weight (kg) | |||||
| < 60 | 31 | 27 | 87.1 | 0.856 | 0.652 |
| 60~ | 60 | 55 | 91.7 | ||
| 70~ | 60 | 52 | 86.7 | ||
| Height (cm) | |||||
| < 170 | 53 | 48 | 90.6 | 3.949 | 0.139 |
| 170~ | 49 | 40 | 81.6 | ||
| 175~ | 49 | 46 | 93.9 | ||
| Physical exercise | |||||
| yes | 38 | 34 | 89.5 | 0.027 | 1.000 |
| no | 113 | 100 | 88.5 | ||
| Smoking | |||||
| Yes | 57 | 51 | 89.5 | 0.049 | 1.000 |
| No | 94 | 83 | 88.3 | ||
| Drinking | |||||
| Yes | 130 | 114 | 87.7 | 1.030 | 0.469 |
| No | 21 | 20 | 95.2 | ||
| Using the computer time during your spare time(h) | |||||
| < 1 | 17 | 17 | 100 | 11.926 | 0.008 |
| 1~ | 32 | 26 | 81.2 | ||
| 2~ | 51 | 50 | 98.0 | ||
| 3~ | 51 | 41 | 80.4 | ||
| The height of chair(cm) | |||||
| < 35 | 17 | 15 | 88.2 | 0.086 | 0.958 |
| > 50 | 21 | 19 | 90.5 | ||
| 35–50 | 111 | 98 | 88.3 | ||
| The height of desk (cm) | |||||
| < 50 | 76 | 68 | 89.5 | 9.691 | 0.008 |
| > 72 | 50 | 48 | 96.0 | ||
| 50–72 | 25 | 18 | 72.0 | ||
| Legroom underneath the desk | |||||
| Yes | 111 | 96 | 86.5 | 1.906 | 0.240 |
| No | 38 | 36 | 94.7 | ||
| Whether the keyboard and mouse at the same height | |||||
| Yes | 137 | 120 | 87.6 | 1.681 | 0.362 |
| No | 12 | 12 | 100.0 | ||
| Backrest | |||||
| Yes | 45 | 36 | 80.0 | 3.610 | 0.069 |
| No | 46 | 43 | 93.5 |
| Educational levels | |||||
| Junior high school | High school | Junior or career college | University or higher education | P for trend | |
| Men | |||||
| Number of subjects | 10 350 | 8437 | 1074 | 1968 | |
| Age, years | 50.5 | 48.1 | 47.5 | 46.7 | <0.001 |
| Previous history of stroke, ischemic heart disease, or cancer, % | 3.6 | 3.0 | 2.8 | 2.3 | <0.001 |
| Current drinker, % | 64.3 | 69.3 | 65.1 | 65.9 | 0.006 |
| Current smoker, % | 54.9 | 53.1 | 51.0 | 47.0 | <0.001 |
| High perceived mental stress, % | 20.0 | 29.3 | 33.9 | 43.8 | <0.001 |
| Living with spouse, % | 76.0 | 86.4 | 87.9 | 90.6 | <0.001 |
| Full-time worker, % | 96.0 | 97.4 | 97.8 | 97.8 | <0.001 |
| Women | |||||
| Number of subjects | 12 624 | 8894 | 2305 | 504 | |
| Age, years | 50.7 | 48.0 | 46.3 | 45.7 | <0.001 |
| Previous history of stroke, ischemic heart disease, or cancer, % | 4.1 | 3.3 | 3.9 | 3.1 | 0.08 |
| Current drinker, % | 9.0 | 11.0 | 11.0 | 10.2 | <0.001 |
| Current smoker, % | 7.6 | 6.8 | 6.5 | 6.5 | 0.02 |
| High perceived mental stress, % | 18.5 | 22.8 | 29.3 | 40.9 | <0.001 |
| Living with spouse, % | 69.6 | 81.6 | 81.6 | 83.2 | <0.001 |
| Full-time worker, % | 74.0 | 76.7 | 76.5 | 85.9 | <0.001 |
| Participant characteristics | N (%) |
| Gender | |
| Men | 1 (6) |
| Women | 16 (94) |
| Mean age (years) | 38 (range 30–47) |
| Mean age of allergic children (years) | 3 (range 0.5-10) |
| First health care contact | |
| Emergency Department | 10 (59) |
| Family Physician | 4 (23) |
| Other | 3 (18) |
| Allergen associated with first reaction | |
| Tree nuts | 6 (35) |
| Peanuts | 4 (24) |
| Fish | 2 (12) |
| IC50 (ng mL−1): median (values obtained with two independent experiments) | |||||
| Fraction Weight (%) | Distribution of PnTX-G (%) | KB cells (72 h of incubation) | Neuro2A cells (24 h of incubation) | Undifferentiated Caco-2 cells (48 h of incubation) | |
| F1 | 4.9 | 0 | 1023 (958, 1088) | N.R. (45%) | N.R. (44.5%) |
| F2 | 50.3 | 0 | 0.21 (0.18, 0.24) | 11 (5–17) | N.R. (41.6%) |
| F3 | 26.5 | 100 | 2.59 (2.55, 2.63) | 25 (44–6) | N.R. (42.6%) |
| F4 | 4.6 | 0 | 53.6 (45.4, 61.8) | 575 (760–390) | N.R. (25.2%) |
| F5 | 13.8 | 0 | 62.7 (55.9, 69.5) | 1140 (800–1480) | N.R. (41.1%) |
| Question | Percent of responses correct (2011–2012) | Percent of responses correct (2012–2013) | Percent of responses correct (2013–2014) |
| There is no cure for asthma | 80.8 | 84.9 | 90.3 |
| Although asthma causes breathing problems, asthma episodes are not dangerous | 93.8 | 96.4 | 97.9 |
| Taking medications every day can help prevent an asthma episode | – | 87.9 | 86.5 |
| A person should take steroids for asthma to grow muscle mass for better athletic ability | 86.8 | 89.7 | 91.2 |
| Inhaled steroids have the same side effects as steroids taken by mouth | 55.0 | 68.5 | 66.8 |
| Very little can be done to reduce environmental triggers of asthma | 69.0 | 76.1 | 78.2 |
| Asthma medications are not addictive | 51.4 | 55.9 | 66.6 |
| People with asthma should not participate in sports | 97.2 | 96.4 | 98.2 |
| Asthma episodes always occur suddenly, without warning | 71.5 | 78.1 | 84.4 |
| Asthma can be caused by emotional stress or other psychological problems | 31.9 | 82.0 | 83.6 |
| A rescue or reliever medication (albuterol) helps during an asthma episode by making you breathe faster | 47.6 | 63.3 | 65.1 |
| No decrease in haemoglobin, n (%) | With a decrease in haemoglobin, n (%) | |
| Celecoxib N = 872 | 841 (96.44) | 31 (3.56) |
| Diclofenac N = 438 | 412 (94.06) | 26 (5.94) |
| OR = 1.71 (1.00–2.92) |
| NTM lung diseases patients (N = 84) | Non-NTM BE patients (N = 47) | P value | |||
| Any isolates | 17 | (20.2%) | 12 | (25.5%) | 1.00 |
| Single isolate in one patient | 15 | (19.7%) | 12 | (26.7%) | 0.38 |
| Klebsiella pneumoniae | 4 | (4.8%) | 5 | (10.6%) | 0.28 |
| Streptococcus pneumoniae | 1 | (1.2%) | 1 | (2.1%) | 1.00 |
| Streptococcus species, viridans group | 1 | (1.2%) | 0 | 1.00 | |
| Methicillin-sensitive Staphylococcus aureus | 1 | (1.2%) | 0 | 1.00 | |
| Methicillin-resistant Staphylococcus aureus | 2 | (2.4%) | 0 | 0.54 | |
| Pseudomonas fluorescens | 1 | (1.2%) | 0 | 1.00 | |
| Pseudomonas putida | 1 | (1.2%) | 0 | 1.00 | |
| Pseudomonas aeruginosa | 2 | (2.4%) | 5 | (10.6%) | 0.10 |
| Aeromonas hydrophila | 1 | (1.2%) | 1 | (2.1%) | 1.00 |
| Neisseria species | 1 | (1.2%) | 0 | 1.00 | |
| Multiple microorganisms | 2 | (2.4%) | 0 | 0.54 | |
| Methicillin-sensitive Staphylococcus aureus and Pseudomonas fluorescens | 1 | (1.2%) | 0 | 1.00 | |
| Methicillin-resistant Staphylococcus aureus and Klebsiellapneumoniae | 1 | (1.2%) | 0 | 1.00 |
| Disease condition | No (n, %) | Somewhat (n, %) | Yes (n, %) | |||
| Endocrine disorders (diabetes mellitus, thyroid disease) | 81 | 36.7 % | 65 | 29.4 % | 75 | 33.9 % |
| Acute coronary syndrome | 3 | 1.4 % | 41 | 18.6 % | 177 | 80.1 % |
| Hypertension | 119 | 54.1 % | 60 | 27.3 % | 41 | 18.6 % |
| Thromboembolic disease (DVT and PE) | 65 | 29.4 % | 53 | 24.0 % | 103 | 46.6 % |
| Asthma/COPD | 192 | 86.9 % | 18 | 8.1 % | 11 | 5.0 % |
| Trauma | 76 | 34.5 % | 61 | 27.7 % | 83 | 37.7 % |
| Partner abuse | 6 | 2.7 % | 48 | 21.7 % | 167 | 75.6 % |
| Carotid/vertebral artery dissections | 162 | 73.6 % | 35 | 15.9 % | 23 | 10.5 % |
| Neurologic conditions (multiple sclerosis, myasthenia gravis, CVA, seizures, headache) | 67 | 30.3 % | 60 | 27.1 % | 94 | 42.5 % |
| GI conditions (biliary disease, dyspepsia, IBS, appendicitis, abdominal pain) | 55 | 24.9 % | 64 | 29.0 % | 102 | 46.2 % |
| Substance abuse | 121 | 55.0 % | 63 | 28.6 % | 36 | 16.4 % |
| Depression/suicide | 39 | 17.8 % | 51 | 23.3 % | 129 | 58.9 % |
| Urinary tract disorders | 18 | 8.1 % | 45 | 20.4 % | 158 | 71.5 % |
| Sexually transmitted diseases | 25 | 11.3 % | 49 | 22.2 % | 147 | 66.5 % |
| HIV/AIDS | 144 | 65.5 % | 46 | 20.9 % | 30 | 13.6 % |
| Autoimmune disease | 27 | 12.3 % | 67 | 30.5 % | 126 | 57.3 % |
| Pulmonary disease (sarcoidosis, PPH) | 129 | 58.4 % | 53 | 24.0 % | 39 | 17.6 % |
| Osteoporosis/fracture management | 41 | 18.6 % | 44 | 19.9 % | 136 | 61.5 % |
| Pain management | 150 | 68.2 % | 44 | 20.0 % | 26 | 11.8 % |
| Pharmacokinetics | 135 | 61.4 % | 63 | 28.6 % | 22 | 10.0 % |
| Communication styles | 60 | 27.1 % | 81 | 36.7 % | 80 | 36.2 % |
| Explicit LearningGroup (n = 40) | Implicit Learning Group (n = 40) | ControlGroup (n = 40) | |
| T1Intervention | 30 side-step cutting trials -Detailed verbal instructions on performance will be given | 30 side-step cutting trials - Best performance will be shown | 30 side-step cutting trials -No feedback on performance will be given |
| T2Retention test (one week post intervention) | 30 side-step cutting trials -No feedback on performance will be given | 30 side-step cutting trials -No feedback on performance will be given | 30 side-step cutting trials -No feedback on performance will be given |
| T3Retention test (one month post intervention) | 30 side-step cutting trials -No feedback on performance will be given | 30 side-step cutting trials -No feedback on performance will be given | 30 side-step cutting trials -No feedback on performance will be given |
| Population/Gender (N) | G6PD variant allele frequency | ||||||
| Mahidol | Viangchan | Chinese 4 | Union | Canton | Kaiping | Gaohe | |
| Thai | |||||||
| Male (84) | 0.04 | 0.01 | - | 0.01 | 0.02 | 0.012 | - |
| Female (233) | 0.01 | 0.006 | 0.006 | 0.002 | - | 0.002 | 0.002 |
| Burmese | |||||||
| Male (11) | 0.18 | - | - | - | - | - | - |
| Female (172) | 0.07 | - | - | - | - | 0.003 | - |
| Models | BM | GM-A | GM-B | LRM-1 | LRM-2 |
| BM | 100 % (46) | 78 % (36) | 74 % (34) | 76 % (35) | 76 % (35) |
| GM-A | . | 100 % (46) | 96 % (44) | 87 % (40) | 91 % (42) |
| GM-B | . | . | 100 % (46) | 87 % (40) | 91 % (42) |
| LRM-1 | . | . | . | 100 % (46) | 96 % (44) |
| LRM-2 | . | . | . | . | 100 % (46) |
| Demographic information | Patients |
| Sex Ratio | 12 women and 7 men |
| Age (years) | 56 ± 8.96 |
| Height (cm) | 164.52 ± 5.09 |
| Weight (kg) | 76.52 ± 12.87 |
| BMI (Kg/m2) | 28.33 ± 4.65 |
| Diabetic History (years) | 11.84 ± 6.93 |
| A. niger DS03043 | A. niger CBS513.88 | |
| A | ||
| μ (h−1) | 0.14 ± 0.01 | 0.10 ± 0.01 |
| qS (mmol/gDCW h) | 1.83 ± 0.01 | 1.46 ± 0.01 |
| qGA (μmol/gDCW h)a | 0.40 ± 0.03 | 0.05 ± 0.00 |
| qCIT (mmol/gDCW h) | 0.02 ± 0.00 | 0.11 ± 0.01 |
| qOA (mmol/gDCW h) | 0.11 ± 0.01 | 0.35 ± 0.02 |
| qO2 (mmol/gDCW h) | 2.94 ± 0.03 | 2.67 ± 0.02 |
| qCO2 (mmol/gDCW h) | 3.21 ± 0.02 | 2.79 ± 0.05 |
| B | ||
| YX/S (mmol/mmol) | 0.49 ± 0.03 | 0.47 ± 0.02 |
| YGA/S (mmol/mmol) | 0.12 ± 0.01 | 0.02 ± 0.00 |
| YCIT/S (mmol/mmol) | 0.01 ± 0.00 | 0.07 ± 0.01 |
| YOA/S (mmol/mmol) | 0.02 ± 0.00 | 0.07 ± 0.01 |
| YCO2/S (mmol/mmol) | 0.30 ± 0.02 | 0.32 ± 0.03 |
| Carbon recovery | 94 % | 95 % |
| Axillary vs. tympanic temperature | Correlation Coefficient | Bias ± SD | 95% CI | Limits of agreement |
| 0.697 | −0.093 ± 0.72 | −0.20; 0.02 | −1.54 to 1.36 |
| Carbon Monoxide (ppm) | CO StdDev (ppm) | Nicotine (mg/m3) | Gravimetric TSP (mg/m3) | TSP StdDev (mg/m3) | |
| Day 1 | 157.73 | 11.04 | 41.31 | 2.29 | |
| Day 2 | 172.50 | 11.37 | 50.55 | 3.36 | |
| Day 3 | 217.27 | 7.86 | 12.10 | 65.76 | 3.26 |
| Day 4 | 216.36 | 11.42 | 63.77 | 7.60 | |
| Day 5 | 230.91 | 18.41 | 70.47 | 7.75 | |
| Day 8 | 243.64 | 8.69 | 75.00 | 6.05 | |
| Day 9 | 240.00 | 10.00 | 73.67 | 2.55 | |
| Day 10 | 264.09 | 5.84 | 13.70 | 83.58 | 3.02 |
| Day 11 | 263.33 | 6.61 | 82.61 | 6.15 | |
| Day 12 | 265.91 | 13.75 | 85.51 | 7.67 | |
| Day 15 | 255.00 | 11.55 | 83.57 | 3.99 | |
| Day 16 | 229.09 | 8.01 | 75.12 | 3.43 | |
| Day 17 | 166.25 | 9.16 | 48.31 | 6.33 | |
| Day 18 | 167.14 | 3.93 | 50.48 | 2.33 | |
| Day 19 | 188.64 | 8.39 | 9.40 | 56.28 | 2.74 |
| Day 22 | 230.00 | 9.57 | 63.77 | 3.84 | |
| Day 23 | 205.71 | 14.84 | 64.73 | 5.44 | |
| Day 24 | 213.18 | 6.03 | 71.38 | 2.81 | |
| Day 25 | 214.44 | 3.91 | 10.40 | 71.01 | 1.45 |
| Day 26 | 211.82 | 5.13 | 73.43 | 3.02 | |
| Day 29 | 215.00 | 2.89 | 68.36 | 7.69 | |
| Day 30 | 213.64 | 3.23 | 66.36 | 1.67 | |
| Day 31 | 216.67 | 6.12 | 66.67 | 2.62 | |
| Day 32 | 233.64 | 7.45 | 8.80 | 80.44 | 8.17 |
| Day 33 | 235.56 | 11.30 | 74.16 | 5.81 | |
| Day 36 | 231.36 | 8.97 | 71.74 | 2.51 | |
| Day 37 | 234.00 | 15.78 | 11.90 | 62.56 | 3.58 |
| Day 38 | 244.09 | 16.40 | 69.56 | 5.07 | |
| Day 39 | 237.73 | 6.84 | 11.90 | 82.97 | 4.68 |
| Day 40 | 232.73 | 5.18 | 71.50 | 7.26 | |
| Day 43 | 252.78 | 11.76 | 65.94 | 6.91 | |
| Day 44 | 239.55 | 8.50 | 9.70 | 81.64 | 5.86 |
| Day 45 | 238.33 | 5.59 | 82.61 | 4.75 | |
| Day 46 | 247.50 | 6.12 | 76.54 | 6.79 | |
| Day 47 | 256.67 | 4.08 | 73.14 | 6.22 | |
| Mean: | 225.21 | 8.73 | 10.86 | 70.11 | 4.7 |
| StDev | 27.87 | 3.91 | 1.76 | 10.82 | 2.04 |
| Overall cohort | PS-matched cohort | |||||||
| Group A | Group B | Difference Group B – Group A | p | Group A | Group B | Difference Group B – Group A | p | |
| n. GP Visits mean (±SE) | 0.84 (±0.09) | 0.38 (±0.12) | -0.46 | <0.001 | 0.85 (±0.15) | 0.38 (±0.12) | -0.47 | <0.001 |
| Specialist visits mean (±SE) | 0.66 (±0.08) | 0.28 (±0.07) | -0.38 | <0.001 | 0.68 (±0.11) | 0.28 (±0.07) | -0.40 | <0.001 |
| n. Hospitalizations mean (±SE) | 0.13 ± 0.04 | 0.08 ± 0.04 | -0.05 | 0.372 | 0.15 ± 0.06 | 0.08 ± 0.04 | -0.08 | 0.11 |
| Days of Hospitalizations mean (±SE) | 0.19 ± 0.07 | 0.08 ± 0.04 | -0.12 | 0.348 | 0.28 ± 0.12 | 0.08 ± 0.04 | -0.20 | 0.09 |
| n. Relapses mean (±SE) | 0.53 (±0.08) | 0.28 (±0.07) | -0.26 | 0.106 | 0.53 (±0.12) | 0.28 (±0.07) | -0.25 | 0.12 |
| Days of inactivity mean (±SE) | 1.62 (±0.26) | 0.68 (±0.20) | -0.95 | 0.088 | 1.53 (±0.37) | 0.68 (±0.20) | -0.85 | 0.12 |
| Characteristics | Categories | Crude riskratios | 95% confidence intervals | P-value |
| Women’s age (years) | 13-19 | 1.00 | ||
| 20-24 | 0.96 | 0.33 - 2.79 | 0.942 | |
| 25-29 | 1.50 | 0.51 - 4.40 | 0.460 | |
| 30-34 | 4.43 | 1.30 - 15.09 | 0.017 | |
| 35 and above | 28.5 | 2.97 - 273.31 | 0.004 | |
| Parity | Multiparous | 1.00 | ||
| Primigravidae | 0.26 | 0.13 - 0.50 | < 0.001 | |
| Women’s KIR genotype | Not KIR AA | 1.00 | ||
| KIR AA | 1.18 | 0.63 - 2.20 | 0.608 | |
| Gestational age (weeks) | 24-34 | 1.00 | ||
| 35-37 | 0.52 | 0.23 -1.18 | 0.120 | |
| 38 and above | 0.32 | 0.15 - 0.67 | 0.003 | |
| HIV status | Negative | 1.00 | ||
| Positive | 10.42 | 1.19 - 91.23 | 0.034 | |
| Urine protein level at recruitment | 2+ | 1.00 | ||
| 3+ | 0.91 | 0.41- 2.01 | 0.815 | |
| 4+ | 1.76 | 0.84 - 3.69 | 0.132 | |
| Previous hypertension in pregnancy | No | 1.00 | ||
| Yes | 0.79 | 0.30 - 2.08 | 0.633 | |
| No prior pregnancy | 0.25 | 0.12 - 0.49 | < 0.001 | |
| Severity of pre-eclampsia | Mild | 1.00 | ||
| Severe | 3.85 | 1.69 - 8.80 | 0.001 |
| Isolate | Geographic origin | Year | Sourcea | Alternative ID | GenBank/ EBI accession number |
| Rs 10 | New Brunswick, Canada | 2009 | Salmo salar (sw) | ERR327945 | |
| Rs 2 | New Brunswick, Canada | 2005 | S. salar (sw) | ERR327951 | |
| Rs 3 | New Brunswick, Canada | 2005 | S. salar (fw) | ERR327947 | |
| Rs 4 | New Brunswick, Canada | 2006 | S. salar (sw) | ERR327946 | |
| Rs 5 | New Brunswick, Canada | 2007 | S. salar (sw) | ERR327950 | |
| Rs 6 | New Brunswick, Canada | 2007 | S. salar (sw) | ERR327953 | |
| Rs 8 | New Brunswick, Canada | 2008 | S. salar (sw) | ERR327944 | |
| BPS 91 | Nanaimo, BC, Canada | 1991 | Oncorhynchus gorbuscha | ERR327952 | |
| BQ96 91-1 | Nanaimo, BC, Canada | 1996 | Oncorhynchus kisutch | ERR327963 | |
| DR143 | Alberta, Canada | 1972 | Salvelinus fontinalis (fw)b | ERR327954 | |
| 5006 | Bella Bella, BC, Canada | 1996 | O. kisutch (sw) | 960046 | ERR327942 |
| 5223 | Kvinnherad, Hordaland, Norway | 2005 | S. salar (sw) | 2005-50-579 | ERR327964 |
| 6553 | Hemne, Sør-Trøndelag, Norway | 2008 | S. salar (sw) | 2008-09-495 | ERR327955 |
| 6642 | Hemne, Sør-Trøndelag, Norway | 2008 | S. salar | 2008-06-633 | ERR327956 |
| 6694 | Hemne, Sør-Trøndelag, Norway | 2008 | Oncorhynchus mykiss (sw) | ERR327962 | |
| 6695 | Hemne, Sør-Trøndelag, Norway | 2008 | O. mykiss (sw) | 2008-06-631 | ERR327968 |
| 6863 | Osterøy, Hordaland, Norway | 2009 | O. mykiss (sw) | ERR327965 | |
| 7439 | Sognefjorden, Sogn og Fjordane, Norway | 1984 | S. salar | 1984-40.992 | ERR327971 |
| 7441 | Storfjord, Møre og Romsdal, Norway | 1985 | S. salar | 1985-09-667 | ERR327966 |
| 7448 | Stranda, Møre og Romsdal, Norway | 1986 | S. salar | 1986-09-4366 | ERR327970 |
| 7449 | Skjervøy, Troms, Norway | 1987 | S. salar | 1987-09-932 | ERR327969 |
| 7450 | Askøy, Hordaland, Norway | 1987 | S. salar | 1987-09-1185 | ERR327967 |
| 684 | Aurland, Sognefjorden, Norway | 1987 | S. trutta (fw) | ERR327958 | |
| 1205 | UK | 2001 | O. mykiss | 3104-67 | ERR327930 |
| 5007 | Scotland | 2005 | O. mykiss | 0180-18 | ERR327923 |
| 7105 | UK | 2007 | O. mykiss (fw) | P0416 T83 10-3 2 | ERR327932 |
| 9025 | Yorkshire, England, UK | 2009 | O. mykiss (fw) | 16251-1 | ERR327912 |
| 96071 | England, Hampshire, site Z, UK | 1996 | O. mykiss (fw) | ERR327927 | |
| 99326 | Wales, site Y, UK | 1999 | O. mykiss (fw) | 2119-8 | ERR327938 |
| 99327 | UK | 1997 | O. mykiss (fw) | 970313-2 | ERR327931 |
| 99329 | Wales, site X, UK | 1998 | O. mykiss (fw) | 980036-125 | ERR327937 |
| 99332 | Wales, site Y, UK | 1999 | O. mykiss (fw) | 2119-3 | ERR327943 |
| 99333 | Wales, site X, UK | 1998 | O. mykiss (fw) | 980036-102 | ERR327921 |
| 99341 | Hampshire, site Z, England, UK | 1998 | O. mykiss (fw) | 980109-20 | ERR327949 |
| 99344 | Hampshire, England, UK | 1998 | O. mykiss (fw) | 980106-1.1.5 | ERR327940 |
| 99345 | Wales, site X | 1998 | O. mykiss (fw) | 980070-18 | ERR327948 |
| NCIMB 1114 | River Dee, Scotland, UK | 1962 | S. salar (fw)b | 5005 | ERR327908 |
| NCIMB 1116 | River Dee, Scotland, UK | 1962 | S. salar (fw)b | 96056 | ERR327907 |
| MT239 | Scotland, UK | 1988 | S. salar | ERR327913 | |
| MT1363 | Strathclyde, Scotland, UK | 1993 | O. mykiss (sw) | ERR327920 | |
| MT3277 | Dumfries and Galloway Site A, Scotland,UK | 2008 | O. mykiss (fw) | ERR327926 | |
| MT3313 | Central, Scotland, UK | 2008 | O. mykiss (fw) | ERR327925 | |
| MT3315 | Strathclyde Site B, Scotland, UK | 2008 | O. mykiss (fw) | ERR327928 | |
| MT1262 | Highlands, Scotland, UK | 1992 | S. salar (fw) | ERR327922 | |
| MT1351 | Highlands, Scotland, UK | 1993 | S. salar (sw) | ERR327904 | |
| MT1470 | Tayside, Scotland, UK | 1994 | O. mykiss (fw) | ERR327910 | |
| MT1511 | Strathclyde Site B, Scotland, UK | 1994 | O. mykiss (fw) | ERR327914 | |
| MT1880 | Strathclyde, Scotland, UK | 1996 | S. salar (sw) | ERR327909 | |
| MT2622 | Strathclyde, Scotland, UK | 2002 | O. mykiss (sw) | ERR327929 | |
| MT2943 | Highlands, Scotland, UK | 2005 | S. salar (sw) | ERR327936 | |
| MT2979 | Highlands, Scotland, UK | 2005 | O. mykiss (fw) | ERR327935 | |
| MT3106 | Strathclyde, Scotland, UK | 2006 | O. mykiss (fw) | ERR327939 | |
| MT3479 | Orkney, Scotland, UK | 2008 | S. salar (sw) | ERR327933 | |
| MT3482 | Strathclyde, Scotland, UK | 2009 | S. salar (sw) | ERR327934 | |
| MT3483 | Strathclyde, Scotland, UK | 2009 | S. salar (sw) | ERR327941 | |
| MT444 | Western Isles, Scotland, UK | 1988 | S. salar (sw) | ERR327916 | |
| MT452 | Dumfries and Galloway Site A, Scotland,UK | 1988 | O. mykiss (fw) | ERR327918 | |
| MT839 | Highlands, Scotland, UK | 1990 | S. salar (sw) | ERR327917 | |
| MT861 | Scotland | 1990 | S. salar (sw) | ERR327919 | |
| Car 96 | Washington State, USA | 1996 | O. tshawytscha | ERR327957 | |
| D6 | Oregon, USA | 1982 | O. tshawytscha | ERR327961 | |
| GR5 | Montana, USA | 1997 | T. thymallus (fw)b | 980036-87 | ERR327959 |
| WR99 c2 | Washington State, USA | 1999 | O. kisutch | ERR327960 | |
| NCIMB 2235 | Oregon, USA | 1974 | O. tshawytscha (sw) | ATCC33209 | ERR327911 |
| 05372K | Grande Ronde Basin, Oregon, USA | 2005 | O. tshawytscha (sw) | ERR327906 | |
| Carson 5b | Confluence Tyee Creek & Wind River, WA, USA | 1994 | O. tshawytscha (fw) | ERR327905 | |
| Cow-chs-94 | Cowlitz River, Washington | 1994 | O. tshawytscha (fw) | ERR327915 | |
| ATCC 33209c | Oregon, USA | 1974 | O. tshawytscha (sw) | NC_010168.1 | |
| NCIMB 1111d | — | Not known | Not known | 5004 | ERR327924 |
| Location, study period (reference) | PM size | Type of fuel | Mean (μg/m3) | Notes |
| China | ||||
| Shenyang, China, May 2006 (this study) | PM10 | Crop residue | Total: 100.6Cooking times: 202.1 | Based on ~14 hr/day (0530–1930) for 5 consecutive days3 households |
| Jilan, China, Nov–Dec 2001, Feb–Mar 2003, 2004 (Fischer and Koshland 2007) | PM4 | Multiple fuels: coal, biomass, gas, electricity | Daily average: 3121-hr peak: 1,880 | Based on 24-hr periods and 1-hr peak values70 household-days37 households |
| Gansu, China, Mar–Apr 2003, Dec 2003–Jan 2004 (Jin et al. 2005) | PM4 | Wood and crop residue | Mar–Apr 2003: 518Dec 2003–Jan 2004: 661 | Based on 24-hr/day periodsMar–Apr 2003: 72 households with 1 day of measurement, 6 households with 4 days of measurementDec 2003–Jan 2004: 17 households with 1 day of measurement, 6 households with 2–3 days of measurement |
| Guizhou, China, Mar–Apr 2003, Dec 2003–Jan 2004 (Jin et al. 2005) | PM4 | Coal, wood, and crop residue | Mar–Apr 2003: 352Dec 2003–Jan 2004: 301 | Based on 24-hr/day periodsMar–Apr 2003: 76 households with 1 day of measurement, 7 households with 2–4 days of measurementDec 2003–Jan 2004: 16 households with 1 day of measurement, 6 households with 2–3 days of measurement |
| Inner Mongolia, China, Dec 2003–Jan 2004 (Jin et al. 2005) | PM4 | Wood and crop residue | 718 | Based on 24-hr/day periods49 households with 1 day of measurement, 4 households with 3 days of measurement |
| Shaanxi, China, Mar–Apr 2003, Dec 2003–Jan 2004 (Jin et al. 2005) | PM4 | 50% coal, 50% wood and crop residue | Mar–Apr 2003: 187Dec 2003–Jan 2004: 223 | Based on 24-hr/day periodsMar–Apr 2003: 75 households with 1 day of measurement, 6 households with 4 days of measurementDec 2003–Jan 2004: 18 households with 1 day of measurement, 6 households with 3 days of measurement |
| Guizhou, China, Jan 2003 (He et al. 2005) | PM4 | Coal (3 households), coal and biomass (1 household) | 1,944 | Based on 24-hr/day periods for 4 consecutive days4 households |
| Shaanxi, China, Feb 2003 (He et al. 2005) | PM4 | Coal and biomass for cooking, coal for heating | 205 | Based on 24-hr/day periods for 4 consecutive days4 households |
| Zhejiang, Hubei, and Shaanxi, China, Jun–Aug 2002, Dec 2002–Jan 2003 (Edwards et al. 2007) | PM4 | Crop residues | Summer: 282.9Winter: 456.4 | Based on 24-hr periods48 households for summer, 25 for winter |
| Bolivia | ||||
| Cantuyo, Jan 1994–Oct 1995 (Albalak et al. 1999) | PM10 | Dung | 1,830 | Based on 6-hr periods (0500–1100)/day every 6 days for 3 consecutive weeks for each month of study period12 households |
| India | ||||
| Pauri District, Garhwal Himalaya, northern India, Aug 1989–Jul 1990 (Saksena et al. 1992) | TSP | Wood | Cooking times: 5,600Noncooking times: 820 | Based on 15-hr periods12 households |
| Tamil Nadu, southern India, Jul–Dec 1999 (Balakrishnan et al. 2002) | PM4 | Wood and crop residue | Indoor kitchen without partitions: 1,442Kitchen with partitions: 970 | Based on 10- to 12-hr/day periods for 1–3 daysWithout partitions: 105 householdsWith partitions: 68 households |
| Andhra Pradesh, southern India, Jan–May 2001 (Balakrishnan et al. 2004) | PM4 | WoodDung | Wood: 500Dung: 732 | Based on 22- to 24-hr/day sampling periods for 3–4 daysWood: 270 householdsDung: 97 households |
| Guatemala | ||||
| Quetzaltenango, May–Nov 1993 (Naeher et al. 2000) | PM2.5PM10TSP | Wood | PM2.5: 527.9,a 96.5bPM10: 717.1,a 186.3bTSP: 835.8,a 275.5b | Based on three 22-hr sampling periods3 households |
| La Victoria, Jan 1999 (Bruce et al. 2004) | PM3.5 | Wood and crop residue | 1,019a351b | Based on one 24-hr measurement/ household11 households with open fires, 5 with planchas |
| La Victoria, Dec 1998–Jul 1999 (Albalak et al. 2001) | PM3.5 | Wood | 1,560a280b | Based on 24-hr measurements taken 6 times at 1-month intervals10 households of each stove type |
| Coefficient | Standard error | P | Adjusted R2 | |
| Overall survival | ||||
| Sampling time | 0.2797 | 0.1995 | 0.18 | 4.16% |
| Metastatic status | −0.0362 | 0.1089 | 0.744 | −11.16% |
| Sample size | −0.0006 | 0.0006 | 0.401 | 2.35% |
| Cut-off value | 0.0020 | 0.0016 | 0.229 | 23.59% |
| Country | 0.0277 | 0.1945 | 0.889 | −11.56% |
| Study quality | −0.0316 | 0.1196 | 0.795 | −9.52% |
| Disease-free survival | ||||
| Sampling time | 0.2377 | 0.4092 | 0.579 | −14.75% |
| Metastatic status | −0.0380 | 0.2159 | 0.865 | −19.67% |
| Sample size | −0.0004 | 0.0011 | 0.739 | −14.88% |
| Cut-off value | 0.0017 | 0.0028 | 0.566 | −7.16% |
| Country | 0.0376 | 0.3659 | 0.921 | −19.62% |
| Study quality | 0.0832 | 0.2664 | 0.764 | −17.38% |
| Orifices | n right | % right | n left | % left |
| 1 | 7 | 7.2 | 6 | 6.3 |
| 2 | 8 | 8.2 | 17 | 17.7 |
| 3 | 28 | 28.9 | 21 | 21.9 |
| 4 | 22 | 22.7 | 21 | 21.9 |
| 5 | 17 | 17.5 | 15 | 15.6 |
| 6 | 8 | 8.2 | 10 | 10.4 |
| 7 | 5 | 5.2 | 5 | 5.2 |
| 8 | 2 | 2.1 | 1 | 1.0 |
| sum | 97 | 100 | 96 | 100 |
| AGI | Annotation | P-score | References |
| AT2G30870 | ERD13, glutathione-S-transferase PHI 10 | 32 | Ryu et al. (2009), Carter et al. (2004) and Marmagne et al. (2007) |
| AT2G45820* | Remorin, putative DNA-binding protein, salt-induced | 22 | Benschop et al. (2007), Nelson et al. (2006) and Kreps et al. (2002) |
| AT1G04690 | KAB1, KV-BETA1 (potassium channel beta subunit) | 18 | Maathuis (2006) |
| AT3G18240* | Unknown protein, phosphorylated | 18 | de la Fuente van Bentem et al. (2008) |
| AT1G53070* | Legume lectin family protein, cell wall asscociated | 15 | |
| AT1G09210* | CRT2, Calreticulin 2; calcium ion binding | 13 | Jiang et al. (2007) |
| AT1G56340* | CRT1, Calreticulin 1; calcium ion binding | 12 | Jiang et al. (2007) |
| AT5G38480* | GRF3, 14-3-3 PSI, overexpression confers salt tolerance | 9 | Marmagne et al. (2007) and Du et al. (2008) |
| AT3G02750* | PP2C, protein phosphatase 2C family, group E | 9 | Bassel et al. (2008) |
| AT5G19440 | CAD, Cinnamyl-alcohol dehydrogenase, putative | 9 | Marmagne et al. (2007) |
| AT3G18820 | RAB71, (Arabidopsis RAB GTPase homolog G3F); GTP binding | 8 | Marmagne et al. (2007) |
| AT2G02990 | RNS1, (Ribonuclease 1); cell wall/plasma membrane associated | 8 | |
| AT1G02090* | CSN7, MAP kinase kinase; subunit of COP9 signalosome | 7 | |
| AT5G16050* | GRF5, 14-3-3 UPSILON (general regularory factor 5) | 6 | Marmagne et al. (2007) |
| AT2G43940 | Thiol methyltransferase, putative, chloroplast envelope | 6 | |
| AT5G07340 | Calnexin, putative, vacuolar | 6 | Schmidt et al. (2007) |
| AT1G28200 | FIP1 (FH interacting protein 1), VirF-interacting protein FIP1 | 5 | |
| AT1G78300 | GRF2, 14-3-3 OMEGA, (general regularory factor 2) | 5 | Chang et al. (2009) |
| AT3G06300 | P4H-2, (prolyl-4-hydroxylase, isoform 2); endomembrane system | 5 | |
| AT1G77120* | ADH1, (alcohol dehdrogenase 1); salt stress-responsive | 5 | de la Fuente van Bentem et al. (2008) and Jiang et al. (2007) |
| AT5G67500 | VDAC2 (voltage-dependent anion channel 2), seedling development | 5 | Yan et al. (2009) and Lee et al. (2009) |
| AT3G01280 | VDAC1 (voltage-dependent anion channel 1) | 5 | Lee et al. (2009) |
| AT1G74020 | SS2 (STRICTOSIDINE SYNTHASE 2); strictosidine synthase | 5 | Marmagne et al. (2007) |
| AT4G17720* | RNA recognition motif (RRM)-containing protein, phosphorylated | 5 | de la Fuente van Bentem et al. (2006) |
| AT4G18800 | RABA1D (Arabidopsis RAB GTPase homolog A1D); | 5 | Marmagne et al. (2004) |
| AT3G61990 | O-methyltransferase family 3 protein, cytosolic | 4 | |
| AT1G22280* | PAPP2C, phytochrome-associated protein phosphatase 2C; group F | 4 | de la Fuente van Bentem et al. (2008) and Phee et al. (2008) |
| AT3G15260* | PP2C, protein phosphatase 2C family, group F | 4 |
| VARIABLE, n (%) | MAIN SAMPLE (N = 10283) | SUBSAMPLE (N = 496) |
| Age, mean (Years) | 61.7a b | 69 c d |
| Gender | ||
| Male | 3333 (32) | 181 (37) |
| Female | 6946 (68) | 312 (63) |
| Race | ||
| Blacks | 3750 (36) | 192 (41) |
| Whites | 6533 (64) | 281 (59) |
| Education | ||
| ≤ High or trade | 2441 (24) | 32 (7) |
| Some College | 2237 (22) | 91 (19) |
| College degree | 3403 (33) | 160 (34) |
| ≥ Graduate School | 2085 (21) | 185 (40) |
| Income (Self) mean (past 12 months) | $40 K (4.4)e | $31 K (4.0)f |
| < $10 K (1) | 5353 (17) | 44 (10) |
| $11–20 K (2) | 1987 (20) | 56 (13) |
| $21–30 K (3) | 1660 (17) | 63 (14) |
| $31–50 K (4) | 2159 (22) | 100 (22) |
| $51–75 K (5) | 1233 (13) | 93 (21) |
| $76–100 K (6) | 532 (5) | 49 (11) |
| > $101 K (7) | 508 (5) | 43 (9) |
| Variable | OR | p | 95% conf. interval |
| Received blood transfusion | |||
| Age | 1.12 | <0.01 | 1.06–1.19 |
| Sex | 1.35 | 0.32 | 0.74–2.46 |
| Bilirubin | 0.81 | 0.01 | 0.69–0.95 |
| No blood transfusion | |||
| Age | 1.01 | 0.85 | 0.94–1.07 |
| Sex | 1.80 | 0.06 | 0.98–3.29 |
| Bilirubin | 0.86 | 0.20 | 0.69–1.08 |
| Placebo(n = 6) | Ascorbic acid(n = 5) | |
| Male/Female (numbers) | 2/4 | 3/2 |
| Age (years)b | 16 (13-24) | 19 (14-24) |
| Median nerve MNCV (m/s)a | 17.9 (6.0) | 17.2 (1.7) |
| Median nerve minimal F response latency (ms)a | 83.8 (28.0)* | 77.1 (10.6) |
| CMAP amplitude abductor pollicis brevis muscle (mV)a | 3.9 (1.1) | 4.0 (1.2) |
| Three point grip (N)a | 50.9 (14.4) | 73.8 (24.7) |
| Foot dorsiflexors (N)a | 79.5 (14.0) | 91.1 (26.9) |
| ISSb | 2 (0-8) | 3 (1-6) |
| CMTNSb | 10 (7-20) | 13 (7-17) |
| ODSSb | 3 (2-4) | 2 (2-4) |
| ALDSa | 86.8 (6.5) | 89.0 (0.5) |
| Nine hole peg test (s)a | 26.3 (6.6) | 23.5 (1.8) |
| 50 m walking (s)a | 31.9 (2.0) | 29.2 (3.2) |
| RT inhibitors | EC50 (nM)a | |
| Subtype B HIV-1 | Subtype C HIV-1 | |
| ZDV | 12.9 ± 5.9 | 34.8 ± 12.9 |
| 3TC | 45.4 ± 16.4 | 105.9 ± 40.2 |
| TFV | 334.8 ± 140.9 | 304.8 ± 93.1 |
| NVP | 50.2 ± 29.6 | 170.4 ± 79.5 |
| EFV | 0.6 ± 0.2 | 1.3 ± 0.4 |
| ETR | 0.9 ± 0.4 | 0.5 ± 0.01 |
| Ibague(n = 855) | Rural area(n = 1,556) | |||
| n | % | n | % | |
| Sex | ||||
| Male | 293 | 34.4 | 487 | 31.4 |
| Female | 559 | 65.6 | 1,065 | 68.6 |
| Age group | ||||
| Under 15 | 143 | 16.7 | 454 | 29.2 |
| 15 or more | 713 | 83.3 | 1,101 | 70.8 |
| Place of residence | ||||
| Ibague | 841 | 98.4 | 7 | 0.5 |
| Rural village | 14 | 1.6 | 1,544 | 99.5 |
| Treatment | Vehicle control | Positive control MMC(0.20 μg/mL) | NR-INF-02(2500.00 μg/mL) | NR-INF-02(791.14 μg/mL) | NR-INF-02(250.36 μg/mL) | |||||
| R1 | R2 | R1 | R2 | R1 | R2 | R1 | R2 | R1 | R2 | |
| Total number of metaphase analyzed | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Normal | 99 | 100 | 92 | 92 | 98 | 97 | 98 | 96 | 98 | 100 |
| Chromatid break | 1 | — | — | 4 | 1 | — | 1 | — | — | — |
| Chromosome break | — | — | — | 1 | — | 1 | — | — | — | — |
| Deletion | — | — | — | 1 | — | — | — | — | 1 | — |
| Ring | — | — | 3 | 1 | 1 | — | — | — | 1 | — |
| Dicentric | — | — | 5 | 1 | — | 2 | — | 1 | — | — |
| Fragment | — | — | — | — | — | — | — | 1 | — | — |
| Gap | — | — | — | — | — | — | 1 | 1 | — | — |
| Ploidy | — | — | — | — | — | — | — | 1 | — | — |
| Endoreduplication | — | — | — | — | — | — | — | — | — | — |
| Total aberrations | 1 | 0 | 8 | 8 | 2 | 3 | 1 | 1 | 2 | 0 |
| Total aberrations (Mean ± SD) | 0.50 ± 0.70 | 8.00 ± 0.00* | 2.50 ± 0.70 | 1.0 ± 0.00 | 1.00 ± 1.41 | |||||
| Mitotic Index (Mean ± SD) | 5.35 ± 0.49 | 2.63 ± 0.10* | 3.75 ± 1.06 | 4.25 ± 0.35 | 4.0 ± 0.42 |
| Sample ID | Estimated Daily Intakes (EDI) | |||||||||
| Al | Mn | Pb | Cd | Hg | As | Cr | Ni | Cu | Zn | |
| PNY1 | 9.60 × 10−3 | 8.09 × 10−3 | 8.80 × 10−6 | 5.64 × 10−7 | 5.32 × 10−6 | 3.20 × 10−6 | 3.75 × 10−5 | 3.61 × 10−4 | 1.31 × 10−3 | 1.51 × 10−3 |
| PNY2 | 1.11 × 10−2 | 3.62 × 10−2 | 1.50 × 10−5 | 4.39 × 10−7 | 5.24 × 10−6 | 1.40 × 10−5 | 1.01 × 10−4 | 4.98 × 10−4 | 1.17 × 10−3 | 1.57 × 10−3 |
| PNY3 | 1.07 × 10−2 | 4.72 × 10−2 | 7.79 × 10−6 | 3.89 × 10−7 | 2.75 × 10−6 | 2.52 × 10−6 | 3.11 × 10−5 | 4.22 × 10−4 | 1.03 × 10−3 | 1.47 × 10−3 |
| PNY4 | 1.27 × 10−2 | 1.23 × 10−2 | 5.72 × 10−6 | 3.51 × 10−7 | 3.52 × 10−6 | 3.14 × 10−6 | 3.83 × 10−5 | 4.59 × 10−4 | 9.52 × 10−4 | 1.45 × 10−3 |
| PNY5 | 2.53 × 10−2 | 2.24 × 10−2 | 6.40 × 10−6 | 1.15 × 10−7 | 3.01 × 10−6 | 4.56 × 10−6 | 3.91 × 10−5 | 4.52 × 10−4 | 1.42 × 10−3 | 1.84 × 10−3 |
| PNY6 | 1.04 × 10−2 | 3.46 × 10−2 | 5.34 × 10−6 | 2.63 × 10−7 | 2.75 × 10−6 | 2.34 × 10−6 | 4.95 × 10−5 | 6.70 × 10−4 | 8.78 × 10−4 | 1.59 × 10−3 |
| PNY7 | 1.54 × 10−2 | 9.36 × 10−3 | 6.40 × 10−6 | 5.64 × 10−7 | 1.20 × 10−6 | 2.62 × 10−6 | 3.19 × 10−5 | 4.04 × 10−4 | 8.42 × 10−4 | 1.76 × 10−3 |
| PNY8 | 1.54 × 10−2 | 3.56 × 10−2 | 4.03 × 10−6 | 4.89 × 10−7 | 1.20 × 10−6 | 2.37 × 10−6 | 2.71 × 10−5 | 4.32 × 10−4 | 9.52 × 10−4 | 1.36 × 10−3 |
| PNY9 | 1.73 × 10−2 | 1.67 × 10−2 | 7.82 × 10−6 | 7.27 × 10−7 | 4.04 × 10−6 | 3.14 × 10−6 | 9.58 × 10−5 | 8.49 × 10−4 | 9.92 × 10−4 | 1.38 × 10−3 |
| PNY10 | 1.50 × 10−2 | 2.08 × 10−2 | 6.13 × 10−6 | 4.64 × 10−7 | 3.44 × 10−6 | 6.49 × 10−6 | 4.39 × 10−5 | 5.99 × 10−4 | 8.12 × 10−4 | 1.45 × 10−3 |
| PNY11 | 1.34 × 10−2 | 3.39 × 10−2 | 7.22 × 10−6 | 3.76 × 10−7 | 3.01 × 10−6 | 4.71 × 10−6 | 4.07 × 10−5 | 6.73 × 10−4 | 8.34 × 10−4 | 1.69 × 10−3 |
| PNY12 | 1.23 × 10−2 | 1.08 × 10−2 | 7.26 × 10−6 | 1.50 × 10−7 | 5.58 × 10−6 | 5.54 × 10−6 | 8.62 × 10−5 | 5.81 × 10−4 | 1.05 × 10−3 | 1.73 × 10−3 |
| PNY13 | 1.04 × 10−2 | 1.40 × 10−2 | 4.85 × 10−6 | 3.89 × 10−7 | 7.30 × 10−6 | 2.25 × 10−6 | 2.63 × 10−5 | 4.23 × 10−4 | 9.08 × 10−3 | 1.31 × 10−3 |
| Mean | 1.38 × 10−2 | 2.32 × 10−2 | 7.14 × 10−6 | 4.86 × 10−7 | 3.72 × 10−6 | 4.38 × 10−6 | 4.98 × 10−5 | 5.25 × 10−4 | 1.01 × 10−3 | 1.55 × 10−3 |
| PLY1 | 1.65 × 10−1 | 2.24 × 10−2 | 3.30 × 10−5 | 7.77 × 10−7 | 3.86 × 10−6 | 7.20 × 10−6 | 1.75 × 10−4 | 5.54 × 10−4 | 8.86 × 10−4 | 5.21 × 10−4 |
| PLY2 | 2.23 × 10−1 | 1.27 × 10−1 | 3.20 × 10−5 | 9.03 × 10−7 | 4.47 × 10−6 | 9.02 × 10−6 | 1.43 × 10−4 | 8.09 × 10−4 | 7.03 × 10−4 | 4.66 × 10−4 |
| PLY3 | 2.61 × 10−1 | 1.93 × 10−1 | 3.18 × 10−5 | 8.40 × 10−7 | 4.04 × 10−6 | 1.11 × 10−6 | 5.91 × 10−5 | 3.56 × 10−4 | 5.51 × 10−4 | 4.51 × 10−4 |
| PLY4 | 3.26 × 10−1 | 5.02 × 10−2 | 4.76 × 10−5 | 7.02 × 10−7 | 6.01 × 10−6 | 8.74 × 10−6 | 9.10 × 10−5 | 6.38 × 10−4 | 7.85 × 10−4 | 5.17 × 10−4 |
| PLY5 | 2.69 × 10−1 | 6.10 × 10−2 | 4.46 × 10−5 | 7.52 × 10−7 | 5.84 × 10−6 | 1.02 × 10−5 | 1.59 × 10−4 | 5.20 × 10−4 | 8.83 × 10−4 | 5.68 × 10−4 |
| PLY6 | 2.26 × 10−1 | 1.16 × 10−1 | 3.62 × 10−5 | 5.89 × 10−7 | 6.36 × 10−6 | 8.25 × 10−6 | 9.18 × 10−5 | 3.15 × 10−4 | 3.70 × 10−4 | 4.00 × 10−4 |
| PLY7 | 3.68 × 10−1 | 3.24 × 10−2 | 3.19 × 10−5 | 7.40 × 10−7 | 7.64 × 10−6 | 9.45 × 10−6 | 9.42 × 10−5 | 7.58 × 10−4 | 6.76 × 10−4 | 7.33 × 10−4 |
| PLY8 | 2.26 × 10−1 | 9.66 × 10−2 | 2.11 × 10−5 | 8.90 × 10−7 | 3.69 × 10−6 | 5.82 × 10−6 | 8.46 × 10−5 | 4.33 × 10−4 | 4.22 × 10−4 | 4.73 × 10−4 |
| PLY9 | 3.99 × 10−1 | 8.74 × 10−2 | 2.61 × 10−5 | 7.27 × 10−7 | 7.39 × 10−6 | 6.59 × 10−6 | 1.87 × 10−4 | 6.98 × 10−4 | 4.27 × 10−4 | 4.69 × 10−4 |
| PLY10 | 3.07 × 10−1 | 7.40 × 10−2 | 3.11 × 10−5 | 6.14 × 10−7 | 4.64 × 10−6 | 9.33 × 10−6 | 9.10 × 10−5 | 6.75 × 10−4 | 5.01 × 10−4 | 4.51 × 10−4 |
| PLY11 | 3.07 × 10−1 | 7.94 × 10−2 | 3.82 × 10−5 | 8.90 × 10−7 | 6.27 × 10−6 | 8.50 × 10−6 | 5.99 × 10−5 | 1.96 × 10−4 | 5.17 × 10−4 | 5.43 × 10−4 |
| PLY12 | 2.34 × 10−1 | 2.67 × 10−2 | 4.04 × 10−5 | 5.02 × 10−7 | 4.72 × 10−6 | 8.28 × 10−6 | 5.51 × 10−5 | 2.95 × 10−4 | 3.36 × 10−4 | 3.34 × 10−4 |
| PLY13 | 3.42 × 10−1 | 8.86 × 10−2 | 4.14 × 10−5 | 1.09 × 10−7 | 5.93 × 10−6 | 1.39 × 10−5 | 2.32 × 10−4 | 7.44 × 10−4 | 5.29 × 10−4 | 5.28 × 10−4 |
| Mean | 2.81 × 10−1 | 8.11 × 10−2 | 3.50 × 10−5 | 7.71 × 10−7 | 5.45 × 10−6 | 8.95 × 10−6 | 1.17 × 10−4 | 5.38 × 10−4 | 5.84 × 10−4 | 4.96 × 10−4 |
| Protein Name | Uniprot ID | Function | Up- or downregulateda |
| DNA-dependent protein kinase catalytic subunit | P78527 | Serine/threonine-protein kinase, molecular sensor for DNA damage. | Up |
| Lumican | P51884 | Collagen fibril organization, epithelial cell migration and tissue repair. | Down |
| Tetranectin | P05452 | Binds plasminogen and isolated kringle 4. Packaging molecules for exocytosis. | Down |
| Gelsolin | P06396 | Key regulator of actin filament assembly and disassembly. | Down |
| Cartilage acidic protein 1 | Q9NQ79 | Upregulated by BMP4 in mesenchymal stem cells undergoing chondrogenic differentiation. | Down |
| Matrin-3 | P43243 | Transcription and interaction with other nuclear matrix proteins to form the internal fibrogranular network. | N/A |
| Glucose-6-phosphate isomerase | P06744 | Glycolytic enzyme and angiogenic factor (AMF) that stimulates endothelial cell motility. | N/A |
| Coactosin-like protein | Q14019 | Binds to F-actin in a calcium-independent manner. | N/A |
| Peptidyl-prolyl cis-trans isomerase A | P62937 | Accelerates the folding of proteins. | N/A |
| Myeloperoxidase | P05164 | Produces hypochlorous acid (HOCl) used by the neutrophils to kill bacteria and other pathogens. | N/A |
| Golgin subfamily B member 1 | Q14789 | Forms intercisternal cross-bridges of the Golgi complex. | N/A |
| 2′-deoxynucleoside 5′-phosphate N-hydrolase 1 | O43598 | Catalyses cleavage of the N-glycosidic bond of deoxyribonucleoside 5′-monophosphates. | N/A |
| Group P (n = 13) | Group R(n = 28) | P value | |
| Mean decrease in Hb† (g/dL ± SD‡) | 0.21 ± 0.66 | 0.37 ± 0.67 | 0.55 |
| Mean procedure time (min ± SD) | 87.5 ± 51.3 | 99.5 ± 46.1 | 0.28 |
| Incidence of perforation, % (n) | 0.0 (0) | 3.6 (1) | 0.49 |
| Incidence of clip use, % (n) | 38.5 (5) | 57.1 (16) | 0.27 |
| Incidence of muscle injury, % (n) | 15.4 (2) | 28.6 (8) | 0.36 |
| Incidence of postoperative fever, % (n) | 7.7 (1) | 10.7 (3) | 0.76 |
| Incidence of postoperative bleeding, % (n) | 0.0 (0) | 3.6 (1) | 0.49 |
| Percentage of patients who resumed eating on the day after ESD, % (n) | 76.9 (10) | 82.1 (23) | 0.81 |
| Material | Thermal conductivity | Specific heat | Density | Electrical conductivity |
| k(W/m⋅K) | c(J/kg⋅K) | ρ(kg/m3) | σ(S/m) | |
| Plastic | 0.026 | 1045 | 70 | 10-5 |
| Electrode | 70 | 840 | 6450 | 108 |
| Saline | 0.58 | 3200 | 1004 | a(3) |
| Hepatic tissue | 0.502 | 3455 (1) | 1080 (1) | b(3) |
| 2155 (2) | 370.44 (2) |
| Beijing (n = 151) | Suzhou (n = 180) | Guangzhou (n = 178) | p-Value 1 | Post hoc Test 2 | |
| B-carotene | 1.7 (1.3–3.2) | 2.4 (1.7–4.3) | 2.7 (1.7–5.0) | <0.001 * | C1 < C2 = C3 |
| β-cryptoxanthin | 1.1 (0.8–2.0) | 3.6 (2.1–7.7) | 2.8 (1.7–5.2) | <0.001 * | C1 < C3 < C2 |
| Lutein | 2.2 (1.0–4.1) | 4.9 (2.6–7.9) | 5.8 (2.9–8.7) | <0.001 * | C1 < C2 = C3 |
| Lycopene | 1.7 (1.3–2.8) | 1.7 (1.3–2.7) | 2.1 (1.4–3.8) | 0.006 * | C1 = C2 < C3 |
| Zeaxanthin | 0.8 (0.4–1.4) | 1.1 (0.7–2.0) | 1.1 (0.7–1.5) | <0.001 * | C1 < C2 = C3 |
| α-tocopherol | 215 (117–333) | 296 (208–478) | 285 (148–479) | <0.001 * | C1 < C2 = C3 |
| γ-tocopherol | 71 (48–107) | 94 (59–148) | 53 (31–88) | <0.001 * | C3 < C1 < C2 |
| Stats | infAP | infNDCG | P@10 (+partial) | NDCG@10 | P@10 (-partial) | UIR | |
| SIB Text Mining | rank | 1/10 | 5/10 | 5/10 | 3/10 | 2/10 | 2/10 |
| score | 0.3664 | 0.4258 | 0.7533 | 0.6271 | 0.3467 | 0.51 | |
| All participants | median | 0.2994 | 0.4250 | 0.7500 | 0.5806 | 0.3100 | 0.13 |
| min | 0.0876 | 0.3580 | 0.5333 | 0.4265 | 0.1600 | −1.00 | |
| 1st quartile | 0.2570 | 0.3954 | 0.7150 | 0.5546 | 0.2700 | −0.43 | |
| 3rd quartile | 0.3219 | 0.4433 | 0.7600 | 0.6234 | 0.3333 | 0.40 | |
| max | 0.3664 | 0.5132 | 0.8267 | 0.6861 | 0.4267 | 0.82 |
| Level | Snail | NF-κB | ||
| Mean (95% CI) | Median (95% CI) | Mean (95% CI) | Median (95% CI) | |
| Low | 38.36 (34.54–42.19) | 39.0 (36.74–41.26) | 37.96 (34.42–41.50) | 39.0 (37.04–40.96) |
| High | 29.20 (25.76–32.64) | 28.0 (20.58–35.42) | 28.42 (24.42–32.41) | 27.0 (16.27–37.73) |
| Variable | Simple myopia | P value | Astigmatism | P value | ANOVA (four groups) | ||
| MMC | No MMC | Paired t-test | MMC | No MMC | Paired t-test | ||
| UCVA (in logMAR) | 0 ± 0 | 0.1 ± 0.141 | P = 0.1872 | 0.04 ± 0.137 | 0 ± 0 | P = 0.1872 | 0.4624 |
| BCVA (in logMAR) | 0 ± 0 | 0.05 ± 0.070 | P = 0.1631 | 0.04 ± 0.137 | 0 ± 0 | P = 0.1703 | 0.5193 |
| Refractive error | 0 | −0.03 ± 0.08 | P = 0.1631 | −0.027 ± 0.098 | −0.016 ± 0.056 | P = 0.0613 | 0.4798 |
| K-reading | 39.23 ± 2.1 | 40.58 ± 1.23 | P = 0.0495 | 39.33 ± 1.7 | 40.98 ± 1.35 | P < 0.0001 | 0.0049 |
| Haze formation | 0 | 0.14 ± 0.287 | P = 0.0560 | 0 | 0.31 ± 0.32 | P < 0.0001 | <0.0001 |
| Mean genome size (1C; pg) | ||||
| *R1 | *R2 | *R3 | Mean ± SD | |
| Lestrimellita sp (diploid males) | 0.460 | 0.465 | 0.465 | 0.463 ± 0.003 |
| Lestrimellita sp (females) | 0.455 | 0.465 | 0.470 | 0.463 ± 0.008 |
| E-KNG | Q-KNG | Q-TSR | E-TSR | |
| Number of values | 105 | 105 | 105 | 105 |
| Minimum | -0.435 | 0.051 | 0.029 | -0.009 |
| 25% Percentile | 0.308 | 0.465 | 0.200 | 0.164 |
| Median | 0.971 | 1.181 | 0.968 | 0.796 |
| 75% Percentile | 1.585 | 1.772 | 1.695 | 1.625 |
| Maximum | 2.126 | 2.081 | 2.109 | 2.075 |
| Mean | 0.963 | 1.139 | 0.983 | 0.904 |
| Std. Deviation | 0.663 | 0.629 | 0.696 | 0.693 |
| Std. Error | 0.065 | 0.061 | 0.068 | 0.068 |
| Lower 95% CI of mean | 0.835 | 1.017 | 0.848 | 0.770 |
| Upper 95% CI of mean | 1.091 | 1.260 | 1.118 | 1.038 |
| Coeff. of variation | 68.84% | 55.23% | 70.84% | 76.62% |
| Gestational age | n | Colonization with enterococci | Colonization with multidrug-resistant enterococci | % multidrug-resistant enterococci |
| All patients | 274 | 63 (22.9%) | 36 (13.1%) | 57.1% |
| ≥ 37 weeks of gestation | 117 | 24 (20.5%) | 10 (8.5%) | 41.7% |
| 32 – 36 weeks of gestation | 94 | 18 (19.1%) | 7 (7.4%) | 38.9% |
| < 32 weeks of gestation | 63 | 21 (33.3%) | 19 (30.2%) | 90.5% |
| Dimensions of KCSE scale | n | Score range | Mean (SD) | No of items | Cron-bach’s alpha | Item-total correlation r > 0.20 | Inter-item correlations r > 0.20 & r < 0.70 |
| Attitude | 174 | 2.8–4 | 3.6 (0.27) | 9 | 0.63 | 8/9, 89% | 12/36, 33% |
| Dynamic state | 165 | 2.4–4 | 3.4 (0.40) | 5 | 0.54 | 4/5, 80% | 6/10, 60% |
| Knowledge | 172 | 1–4 | 3.0 (0.59) | 7 | 0.91 | 7/7, 100% | 20/21, 95% |
| Skills | 170 | 1.1–4 | 3.0 (0.50) | 7 | 0.86 | 7/7, 100% | 21/21, 100% |
| Total scale | 150 | 8.2–16.0 | 13.0 (1.44) | 28 | 0.91 | 24/28, 86% |
| 1.5 T | 3 T | |
| Number | 9 | 10 |
| Male;Female | 3:6 | 4:6 |
| Age (years) | 52 [45.5–61.5] | 50 [45.25–53] |
| Body-mass Index (kg/m2) | 22.9 [20.1–26.9] | 25.9 [22.5–29.4] |
| Ejection Fraction (%) | 63.6 ± 4.9 | 61.1 ± 4.1 |
| Grade 10 | Grade 11 | Grade 12 | TOTAL | |||||||||||||
| boys | girls | boys | girls | boys | girls | boys | girls | |||||||||
| Scale | M | SD | M | SD | M | SD | M | SD | M | SD | M | SD | M | SD | M | SD |
| (1) AV | 5.32 | 4.11 | 3.43 | 2.76 | 5.93 | 4.56 | 3.54 | 2.88 | 5.22 | 3.93 | 3.22 | 2.48 | 5.51 | 4.24 | 3.41 | 2.72 |
| (2) RB | 3.69 | 2.85 | 2.86 | 1.99 | 4.38 | 3.27 | 2.99 | 2.25 | 3.91 | 2.84 | 2.82 | 1.99 | 3.98 | 3.01 | 2.89 | 2.07 |
| (3) US | 0.33 | 1.50 | 0.06 | 0.51 | 0.57 | 1.98 | 0.14 | 0.79 | 0.28 | 1.38 | 0.04 | 0.29 | 0.40 | 1.66 | 0.08 | 0.56 |
| (4) SS | 1.19 | 2.24 | 1.45 | 2.45 | 1.34 | 2.45 | 1.52 | 2.45 | 1.08 | 2.06 | 1.18 | 2.08 | 1.22 | 2.28 | 1.40 | 2.36 |
| (5) SU | 2.41 | 3.32 | 1.11 | 2.04 | 3.37 | 3.94 | 1.22 | 2.08 | 2.82 | 3.51 | 1.10 | 1.89 | 2.83 | 3.61 | 1.14 | 2.01 |
| (6) HBICA Total | 12.75 | 10.76 | 8.88 | 7.40 | 15.43 | 12.31 | 9.37 | 7.82 | 13.18 | 10.77 | 8.29 | 6.39 | 13.77 | 11.38 | 8.86 | 7.28 |
| Characteristic | Partial helmet law | Universal helmet law | P-value* |
| Number of motorcycle operators | N = 28,207 | N = 45,552 | |
| Helmet used | 42 % | 88 % | <0.01 |
| Age (Median) | 37 | 36 | 0.52 |
| Male | 93 % | 93 % | 0.77 |
| Single Vehicle Crash | 39 % | 45 % | <0.01 |
| Crash at Intersection | 36 % | 40 % | <0.01 |
| Night time | 18 % | 17 % | <0.01 |
| Speed relateda | 10 % | 17 % | <0.01 |
| Suspicion of alcohol or drugsa | 9 % | 5 % | <0.01 |
| Rural locationa | 17 % | 31 % | <0.01 |
| Poor Surface Conditions | 6 % | 7 % | <0.01 |
| Crash record linked to a medical record | 55 % | 58 % | <0.01 |
| Died at the scene | 3 % | 3 % | 0.62 |
| Breach Code | Sprint ≤1400 m (n) | Mile 1406–1750 m (n) | Middle 1800–2400 m (n) | Total (n) |
| 8 | 55 | 24 | 13 | 92 (23. 90%) |
| 9 | 29 | 11 | 4 | 44 (11.43%) |
| 16 | 33 | 10 | 11 | 54 (14.03%) |
| 17 | 84 | 42 | 42 | 168 (43.64%) |
| Other | 18 | 6 | 3 | 27 (7.01%) |
| Total | 219 (56.88%) | 93 (24.16%) | 73 (18.96%) | 385 |
| Reference | Basin | Number of sequences | Number of species | Intraspecific distance (%) | Intrageneric distance (%) |
| Pugedo et al., 2016 | Jequitinhonha | 260 | 52 | 0-11.43 (0.44) | 1.09-21.55 (12.16) |
| Nascimento et al., 2016 | Itapecuru | 440 | 64 | 0-8.9 (0.80) | 2.65-7.70 (5.13) |
| Benzaquem et al., 2015∗ | Amazon | 110 | 14 | 0-9.8 (2.8) | 2.2-22.5 (19.0) |
| Gomes et al., 2015 | Mucuri | 141 | 37 | 0-3.24 (0.74) | 4.29-18.44 (9.5) |
| Pereira et al., 2013 | Upper Paraná | 1244 | 254 | 0-8.5 (1.3) | 0-24.9 (6.8) |
| Carvalho et al., 2011 | São Francisco | 431 | 101 | 0-10.54 (0.5) | 0-22.88 (10.61) |
| Pereira et al., 2011 | Paraíba do Sul | 295 | 58 | 0-3.48 (0.13) | 0.93-22.89 (10.36) |
| Present study | Doce | 306 | 68 | 0-21.82 (2.59) | 0-24.2 (11.4) |
| Practitioners | Patients |
| 1) Theoretical Stance | 1) Reasons for Therapy |
| A) Integrity of Self | A) specific, individual reason based on symptoms, illness, or sense of dis-ease |
| B) Human Capacity for Embodiment | B) motivational drive to seek new resources for active coping |
| C) Central Role Of Embodiment And Integrity Of Self To The Practice | |
| 2) The Practice | 2) Engagement in the practice and what happens from the patients' point of view |
| A) Breath and Breathing | A) Process |
| B) Repetition and Training | B) Shift in Awareness |
| a) Negative Emotion | |
| b) Body Sensation | |
| C) Noticing/Discriminating/Discerning | C) Engagement in |
| a) Self Regulation | |
| b) Self Care | |
| D) Goal of Practice: Integration of Mind, Body and Life Context | D) Integration of Mind, Body and Life Context |
| a)Context | |
| b) Mind-Body Integration |
| ACS | SAP | |||||||
| MACE | MI | MACE | MI | |||||
| (-) | (+) | (-) | (+) | (-) | (+) | (-) | (+) | |
| VVV of DBP, mm Hg | 6.6 ± 3.3 | 7.5 ± 3.0 | 6.7 ± 3.3 | 6.4 ± 3.0 | 7.2 ± 4.8 | 5.1 ± 3.8 | 7.1 ± 4.8 | 4.5 ± 3.1 |
| Average of SBP, mm Hg | 124 ± 13 | 130 ± 9 | 125 ± 13 | 135 ± 12 | 130 ± 13 | 129 ± 17 | 130 ± 13 | 130 ± 1 |
| Average of DBP, mm Hg | 73 ± 9 | 75 ± 8 | 73 ± 9 | 82 ± 6 | 73 ± 8 | 74 ± 7 | 73 ± 8 | 76 ± 3 |
| Maximum DBP, mm Hg | 79 ± 10 | 82 ± 11 | 79 ± 10 | 87 ± 12 | 82 ± 12 | 79 ± 10 | 81 ± 12 | 81 ± 2 |
| Minimum SBP, mm Hg | 114 ± 15 | 117 ± 10 | 114 ± 15 | 119 ± 14 | 119 ± 13 | 118 ± 13 | 119 ± 13 | 121 ± 12 |
| Minimum DBP, mm Hg | 66 ± 10 | 66 ± 8 | 65 ± 9 | 74 ± 4 | 66 ± 9 | 67 ± 6 | 66 ± 9 | 71 ± 6 |
| Characteristics | No (%) |
| 20–24 | 9 (27.3) |
| 25–34 | 9 (27.3) |
| 35–49 | 12 (36.3) |
| >50 | 3 (9.1) |
| 2 to 5 | 16 (48.5) |
| 6 to 9 | 4 (12.1) |
| 10 to 20 | 10 (30.3) |
| >20 | 3 (9.1) |
| Boots | 8 (24) |
| Apron | 1 (3) |
| Mask | 2 (3) |
| Gloves | 0 (0) |
| Glasses | 2 (6) |
| Respirator | 2 (6) |
| Plastic for the back | 15 (46) |
| Waterproof garment | 1 (3) |
| Compound name | Retention time (min) | Cells | Leaves | [M-H]− | Diagnosticm/zions |
| cis-4-pCoQA (4) | 7.35 | ✓ | ✓ | 337.0933 | 173 |
| trans-4- pCoQA (1) | 7.96 | ✓ | ✓ | 337.0957 | 173 |
| trans-5-pCoQA (2) | 7.69 | ✓ | ✓ | 337.0886 | 191 |
| cis-5-pCoQA (3) | 10.54 | ✓ | 337.0949 | 191 | |
| cis-3-CQA (6) | 4.55 | ✓ | ✓ | 353.0875 | 191, 179, 135 |
| trans-3-CQA (5) | 4.61 | ✓ | ✓ | 353.0787 | 191, 179, 135 |
| trans-4-CQA (7) | 6.13 | ✓ | ✓ | 353.0864 | 191, 179, 173, 135 |
| trans-5-CQA (8) | 5.81 | ✓ | ✓ | 353.0829 | 191, 135 |
| cis-5-CQA (9) | 7.55 | ✓ | ✓ | 353.0809 | 191, 135 |
| trans-4-FQA (12) | 6.17 | ✓ | 367.0429 | 173 | |
| trans-5-FQA (10) | 5.84 | ✓ | ✓ | 367.0708 | 191 |
| cis-5-FQA (11) | 9.41 | ✓ | ✓ | 367.0847 | 191 |
| Caffeoylglycoside (13) | 5.60 | ✓ | ✓ | 341.0894 | 179 |
| Feruloylglycoside (14) | 7.09 | ✓ | 355.1012 | 193 | |
| 3,4-diCQA (15) | 5.21 | ✓ | 515.1509 | 191, 179, 173, 135 | |
| 4,5-diCQA (16) | 5.50 | ✓ | ✓ | 515.1404 | 191, 179, 135 |
| 3,5-diCQA (17) | 6.30 | ✓ | ✓ | 515.1477 | 191, 179, 135 |
| 3-CQA glycoside (18) | 4.78 | ✓ | 515.1261 | 191, 179, 135 | |
| 5-CQA glycoside (19) | 5.47 | ✓ | 515.1354 | 191, 135 |
| Period | Ticks collected | Animals inspected | Infestation rate (%) |
| May-June (2014) | 600 | 87 | 71 |
| July-August | 370 | 77 | 69 |
| September-October | 231 | 77 | 58 |
| November-December | 201 | 47 | 60 |
| January-February (2015) | 159 | 55 | 49 |
| March-April | 377 | 75 | 64 |
| Total (over year) | 1,938 | 418 | 63 |
| Scheme sponsorship | State | Recruitment method | Code |
| Private | Victoria | Direct contact with researcher | E1 |
| Private | Victoria | Scheme | E2 |
| Private | Victoria | Scheme | E3 |
| Private | Victoria | Scheme | E4 |
| Private | Victoria | Scheme | E5 |
| Private | Victoria | Scheme | E6 |
| Private | Queensland | Scheme | E7 |
| Private | Queensland | Scheme | E8 |
| Private | Queensland | Scheme | E9 |
| Not-for-profit | Victoria | Direct contact with researcher | E10 |
| Not-for-profit | Victoria | Scheme | E11 |
| Not-for-profit | Victoria | Scheme | E12 |
| Not-for-profit | Victoria | Scheme | E13 |
| Not-for-profit | Victoria | Scheme | E14 |
| Not-for-profit | Victoria | Scheme | E15 |
| Not-for-profit | Queensland | Direct contact with researcher | E16 |
| R2 = | p < | Tones | Clicks | Gabors | Music | ||
| Language ~ Tones + Clicks + Gabors | 0.671 | 0.001 | β = | 0.495 | 0.505 | 0.054 | − |
| p = | 0.054 | 0.155 | 0.786 | − | |||
| Language ~ Tones + Clicks + Gabors + Music | 0.919 | 6×10-7 | β = | 0.181 | 0.261 | -0.023 | 0.655 |
| p = | 0.191 | 0.165 | 0.822 | 3×10-5 | |||
| Language ~ Tones + Clicks + Gabors | 0.646 | 0.002 | β = | 0.302 | 0.435 | 0.229 | − |
| p = | 0.139 | 0.119 | 0.323 | − | |||
| Language ~ Tones + Clicks + Gabors + Music | 0.923 | 5×10-7 | β = | 0.065 | 0.273 | 0.071 | 0.696 |
| p = | 0.525 | 0.055 | 0.533 | 2×10-5 | |||
| Language ~ Tones + Clicks + Gabors | 0.606 | 0.004 | β = | 0.636 | 0.520 | 0.090 | − |
| p = | 0.068 | 0.030 | 0.706 | − | |||
| Language ~ Tones + Clicks + Gabors + Music | 0.846 | 4×10-5 | β = | 0.287 | 0.092 | 0.009 | 0.599 |
| p = | 0.220 | 0.595 | 0.956 | 6×10-4 |
| Connection Resiliency | Self-Powered WSN | MEDiSN | ||
| Failure Sequences | Elapsed Time (s) | Failure Sequences | Elapsed Time (s) | |
| 1 | 24 | 1500 | 18 | 600 |
| 2 | 552 | 9720 | 306 | 2160 |
| 3 | 12,144 | 32,580 | 4896 | 2820 |
| Subscale/Criterion | Factor | ||
| 1 | 2 | 3 | |
| SAWS critical life experience | 0.047 | 0.702 | 0.220 |
| SAWS emotional regulation | 0.165 | 0.869 | −0.007 |
| SAWS reminiscence and reflectiveness | 0.119 | 0.814 | −0.230 |
| SAWS openness | 0.115 | 0.410 | 0.682 |
| SAWS humor | 0.174 | 0.589 | 0.277 |
| ASTI | 0.303 | 0.580 | 0.565 |
| 3D-WS reflective dimension | 0.218 | −0.022 | 0.782 |
| 3D-WS affective dimension | −0.016 | 0.202 | 0.833 |
| 3D-WS cognitive dimension | 0.372 | −0.205 | 0.753 |
| BWP uncertainty | 0.711 | 0.209 | −0.123 |
| BWP value relativism | 0.758 | 0.052 | 0.127 |
| BWP contextualism | 0.850 | 0.149 | 0.104 |
| BWP factual knowledge | 0.865 | 0.093 | 0.268 |
| BWP procedural knowledge | 0.743 | 0.133 | 0.408 |
| Wound Infections | Non-Wound Infections |
| Cellulitis/Abscess (11/31) | Seromas (20/31) |
| Pre-Operative Prophylactic Antibiotics | |
| Cefazolin 8/11 (73%) | Cefazolin 16/20 (80%) |
| Clindamycin 1/11 (9%) | Clindamycin 3/20 (15%) |
| Vancomycin 1/11 (9%) (plus gentamicin) | Vancomycin 0/20 (0%) |
| Unknown 1/11 (9%) | Unknown 1/20 (5%) |
| The Relationship between Pre-Operative Antibiotics and Post-Operative Wound Cultures | |
| Cefazolin (8/11) | Cefazolin |
| associated isolates *: | associated isolates *: |
| MSSA = 3 | CoNS = 6 |
| MRSA = 2 | MSSA = 1 |
| M. fortuitum = 1 | VSE = 1 |
| Unknown = 2 | E. coli = 2 |
| Clindamycin | Proteus sp. = 1 |
| associated isolates: | Unknown = 2 |
| E. coli = 7 | Culture negative = 7 |
| Vancomycin (1/11) (plus gentamicin) | Clindamycin |
| associated isolates: | associated isolates: |
| K. pneumoniae = 2 | CoNS = 2 |
| Culture negative = 2 |
| CYP transcripts of O. sanctum | CYP transcripts of O. basilicum | Functions | |||
| Arabidopsisannotation | Lamiaceae annotation | Arabidopsisannotation | Lamiaceae annotation | ||
| CYP72A14 | 2 | - | 8 | - | Phenylpropanoid Metabolism |
| CYP73A1 | 5 | 7 | 23 | 33 | Cinnamate 4-hydroxylase (C4H) |
| CYP75B1 | 8 | - | 8 | - | Flavonoid biosynthesis |
| CYP81D1 | 2 | - | 16 | - | Phenylpropanoid Metabolism |
| CYP81F3 | 1 | - | 9 | - | Phenylpropanoid Metabolism |
| CYP84A1 | 2 | - | 1 | - | Coniferaldehyde 5-hydroxylase |
| CYP93D1 | - | - | 1 | - | Phenylpropanoid Metabolism |
| CYP98A3 | 12 | - | 25 | - | 4-Coumaryl shikimic/quinic ester 3′-hydroxylase. |
| CYP98A14 | - | 16 | - | 46 | p-Coumaryl shikimate hydroxylase |
| CYP707A2 | 5 | - | 4 | - | Phenylpropanoid Metabolism (abscisic acid 8′-hydroxylase) |
| CYP707A3 | 12 | - | 13 | - | Secondary metabolism (abscisic acid 8′-hydroxylase) |
| CYP710A1 | 3 | - | 7 | - | Phenylpropanoid Metabolism |
| CYP711A1 | 1 | - | 1 | - | Core phenylpropanoid metabolism |
| CYP712A1 | - | - | 2 | - | Stilbene, coumarine and lignin biosynthesis |
| Variable | All (n = 76) | Males (n = 36) | Females (n = 40) | p (Males vs. Females) |
| Age (years) | 34.8 ± 10.4 | 35 ± 18 | 36 ± 18 | 0.7549 a |
| BMI (kg/m2) | 24.0 ± 2.9 | 25.0 ± 2.7 | 23.0 ± 2.9 | 0.0009a |
| Smoking, n (%) | ||||
| Current | 0 (0) | 0 (0) | 0 (0) | |
| Ever | 18 (24) | 8 (23) | 10 (24) | |
| Never | 58 (76) | 27 (77) | 31 (76) | ns |
| Use of Se-containing supplements in the past 6 months, n (%) | ||||
| Yes | 5 (7) | 3 (9) | 2 (5) | |
| No | 71 (93) | 32 (91) | 39 (95) | ns |
| Mean plasma Se ± SD (μg/L) | ||||
| Baseline | 65.2 ± 16.5 | 65.2 ± 16.6 | 65.3 ± 16.5 | 0.9729 b |
| After two weeks | 101.1 ± 24.5 | 98.7 ± 22.8 | 103.3 ± 26.1 | 0.3907 a |
| After six weeks | 99.1 ± 20.3 | 95.0 ± 16.9 | 102.7 ± 22.4 | 0.0928 b |
| After four weeks of washout | 76.5 ± 15.6 | 75.3 ± 15.3 | 77.6 ± 16.1 | 0.7777 b |
| p (ANOVA) | <0.0001 | <0.0001 | <0.0001 |
| Similarity searches | Common molecules | Common scaffolds | ||
| SF | GF | SF | GF | |
| 1 | 3705 | 7759 | 1821 | 3771 |
| 5 | 473 | 469 | 277 | 290 |
| 10 | 107 | 81 | 69 | 51 |
| 15 | 37 | 23 | 25 | 15 |
| 20 | 20 | 18 | 12 | 9 |
| 25 | 24 | 1 | 8 | 1 |
| i) 7 weeks old | ||||
| +/+ | m1/+ | m1/m1 | ||
| No. of transplantation | 9 | 24 | 10 | |
| Tumor developed | 9 | 24 | 4 | |
| Dead or degrading | 0 | 0 | 6* | |
| large (1.0 - 2.0 cm) | 8 | 24 | 0 | |
| middle (0.5 - 1.0 cm) | 1 | 0 | 0 | |
| small (< 0.5 cm) | 0 | 0 | 4 | |
| Ectoderm | 9 | 24 | 4 | |
| Mesoderm | 8 | 21 | 0 | |
| Endoderm | 4 | 14 | 2 | |
| ii) 1 week old | ||||
| +/+ | m1/+ | m1/m1 | ||
| No. of transplantation | 3 | 8 | 5 | |
| Tumor developed | 3 | 7 | 5 | |
| Dead or degrading | 0 | 1 | 0 | |
| large (1.0 - 2.0 cm) | 0 | 0 | 0 | |
| middle (0.5 - 1.0 cm) | 2 | 5 | 0 | |
| small (< 0.5 cm) | 1 | 2 | 5 | |
| Ectoderm | 3 | 7 | 0 | |
| Mesoderm | 2 | 5 | 0 | |
| Endoderm | 2 | 4 | 0 |
| dm-7-RR | RR | YR | dm-7-LR | LR | LY | LW | LF | Total MC | |
| average | 47 | 780 | 230 | 41 | 1700 | 840 | 300 | 580 | 3400 |
| median | 11 | 85 | 81 | 7.6 | 160 | 530 | 100 | 260 | 480 |
| maximum | 170 | 4600 | 1200 | 230 | 7900 | 2300 | 990 | 1800 | 14,000 |
| minimum | 4.3 | 3.8 | 1.2 | 0.89 | 3.0 | 24 | 10 | 8.0 | 26 |
| n detected | 8 | 10 | 10 | 10 | 10 | 4 | 4 | 4 | 10 |
| n not detected | 2 | 0 | 0 | 0 | 0 | 6 | 6 | 6 | 0 |
| Organism | Common name | Group | Annotation status |
| Acanthamoeba castellanii | Amoeba | BCM-HGSCa | Server set up in progress |
| Helicoverpa armigera | Cotton bollworm | CSIROb | Server set up and analysis in progress |
| Pythium ultimum | Pythium blight | GMOD | Used one contig to teach a GMOD course |
| Zea maize | Corn | Iowac | Server set up in progress |
| Manduca sexta | Goliath moth | Kansasd | Server set up in progress |
| Mayetiola destructor | Hessian fly | Kansas | Server set up and analysis in progress |
| Acromyrmex echinatior | Leaf cutting ant | Missouri | |
| Apis mellifera | Honey bee | LBNL/Missouri | Server is available for ongoing annotation |
| Atta cephalotes | Leaf cutting ant | Missouri | |
| Bombus impatiens | Eastern bumble bee | Missouri | Used internally to test deployment |
| Bos taurus | Cow | Missouri | Used internally; new assembly in progress |
| Cardiocondyla obscurior | Ant, tramp species | Missouri | Community is currently annotating |
| Monodelphis domestica | Gray, short-tailedopossum | Missouri | Server is available for ongoing annotation |
| Pogonomyrmex barbatus | Red harvester ant | Missouri | Community is currently annotating |
| Varroa destructor | Varroa mite | Missouri | Computational gene prediction has begun |
| Wasmannia auropunctata | Electric ant | Missouri | Community is currently annotating |
| Pungitius pungitius | Nine spine stickleback | Utahe | Analysis in progress |
| Over 40 species | Pigeons | Utah | Analysis in progress |
| Characteristic | Adjusted Odds Ratio (95% Confidence Interval) for Remaining Uninsured for Entire Year |
| Child uninsured >6 months at baseline | 3.8 (1.4, 10.3) |
| African-American/black race/ethnicitya | 2.8 (1.1, 7.3) |
| Male child gender | 2.4 (0.97, 5.8) |
| Primary caregiver employed | 0.5 (0.2, 1.4) |
| Child born in US | 0.2 (0.01, 3.7) |
| Combined annual family income below federal poverty threshold | 0.4 (0.1, 1.4) |
| Density (kg/m3) | Thermal conductivity (W/(m °C)) | Conductivity (S/m) | Specific heat capacity (J/(kg· °C)) | |
| Myocardium | 1200 | 0.55 | 0.222 | 3200 |
| Blood | 1000 | 0.543 | 0.667 | 4180 |
| Radiofrequency electrode | 21,500 | 71 | 4,000,000 | 132 |
| Diet | ALT | AST | ||
| Euthyroid | Thyroid alt | Euthyroid | Thyroid alt | |
| Control | 43.3 ± 24.73 ab | 38.5 ± 38.50 b | 151.6 ± 85.46 a | 94.4 ± 47.99 a |
| Lard 25% | 46.9 ± 13.20 ab | 39.4 ± 5.70 ba | 115.1 ± 69.18 a | 112.3 ± 47.81 a |
| Soy oil 25% | 51.5 ± 11.30 ab | 46.9 ± 18.82 ba | 148.7 ± 96.39 a | 153.9 ± 102.30 a |
| Lard 37% | 46.7 ± 9.06 a | 48.11 ± 14.89 ba | 128.6 ± 65.53 a | 149.8 ± 105.54 a |
| Soy oil 37% | 53.8 ± 12.72 a | 48.4 ± 10.84 ba | 143.9 ± 88.59 a | 121.7 ± 62.99 a |
| Sample | Temperature (oC) | KF (mmol/g/kPa1/n) | n (-) | r2 (-) |
| ACF | 25 | 0.1051 | 1.59 | 0.9998 |
| 40 | 0.0689 | 1.48 | 0.9998 | |
| 55 | 0.0490 | 1.38 | 0.9998 | |
| CN1/ACF | 25 | 0.0813 | 1.58 | 0.9998 |
| 40 | 0.0492 | 1.46 | 0.9998 | |
| 55 | 0.0315 | 1.33 | 0.9999 | |
| CN2/ACF | 25 | 0.0987 | 1.61 | 0.9997 |
| 40 | 0.0550 | 1.43 | 0.9999 | |
| 55 | 0.0336 | 1.34 | 0.9999 |
| FGD | Age range at point of FGD | Mean age | No of participants | Male | Female | SCT | CT |
| FGD 1 | 13–15 | 13.5 | 6 | 4 | 2 | 4 | 2 |
| FGD 2 | 15–17 | 15.7 | 7 | 2 | 5 | 5 | 2 |
| FGD 3 | 19–24 | 21 | 7 | 4 | 3 | 2 | 5 |
| FGD 4 | 16–20 | 18 | 5 | 2 | 3 | 2 | 3 |
| Pool code | Region: Site | Elevation (m) | Coordinates | Date | Pool size | Species | Virus detected |
| T1 | Aegean: Canakkale | 280 | 39°29'36.1\"N, 26°19'26.7\"E | 08/2015 | 20 | Cx. theileri | Culex theileri flavivirus |
| T2 | Aegean: Canakkale | 280 | 39°29'36.1\"N, 26°19'26.7\"E | 08/2015 | 20 | Cx. theileri | Culex theileri flavivirus |
| T3 | Thrace: Kirklareli | 80 | 41°36'48.6\"N, 26°57'56.3\"E | 08/2015 | 43 | Cx. theileri | Culex theileri flavivirus |
| T4 | Thrace: Kirklareli | 80 | 41°36'48.3\"N, 26°57'56.5\"E | 11/2014 | 21 | Cx. pipiens (s.l.) | Culex theileri flavivirus |
| T5 | Thrace: Edirne | 206 | 41°48'53.7\"N, 26°49'00.7\"E | 10/2014 | 1 | Ur. unguiculata | Unknown Flavivirus |
| T6 | Thrace: Kirklareli | 80 | 41°36'48.6\"N, 26°57'56.3\"E | 07/2014 | 52 | Ae. caspius | Ochlerotatus caspius flavivirus |
| T7 | Thrace: Kirklareli | 120 | 41°40'23.2\"N, 26°58'51.1\"E | 06/2014 | 41 | Ae. caspius | Ochlerotatus caspius flavivirus |
| T8 | Thrace: Kirklareli | 80 | 41°36'48.3\"N, 26°57'56.5\"E | 10/2014 | 24 | Cx.pipiens (s.l.) | West Nile virus |
| T9 | Thrace: Kirklareli | 317 | 41°36'48.6\"N, 26°57'56.3\"E | 08/2014 | 7 | Cx. theileri | Culex theileri flavivirus |
| T10 | Thrace: Kirklareli | 317 | 41°51'48.3\"N, 27°00'59.2\"E | 08/2014 | 1 | Cx. theileri | Culex theileri flavivirus |
| T11 | Thrace; Kirklareli | 112 | 41°38'12.4\"N, 27°10'36.3\"E | 07/2014 | 3 | Cs. annulata (♂) | Flavivirus AV-2011 |
| Basal Metabolic Rate | Specific Heat | Blood Perfusion Coeff. | Thermal Conductivity | |
| Ao | Cp | B | K | |
| [J/(m3 s)] | [J/kg °C] | [J/ (m3 s °C)] | [J/m s °C] | |
| Air | 0 | 1000 | 0 | 0.03 |
| Blood | 0 | 3640 | 0 | 0.549 |
| BoneCancellous | 590 | 1300 | 3300 | 0.4 |
| BoneCortical | 610 | 1300 | 3400 | 0.4 |
| BrainGreyMatter | 7100 | 3700 | 40000 | 0.57 |
| BrainWhiteMatter | 7100 | 3600 | 15925 | 0.5 |
| Cartilage | 1600 | 3500 | 9000 | 0.47 |
| Cerebellum | 7100 | 3700 | 40000 | 0.57 |
| CerebroSpinalFluid | 0 | 4200 | 0 | 0.62 |
| Cornea | 0 | 4200 | 0 | 0.58 |
| Dura | 860 | 2802 | 4830 | 0.31 |
| Fat | 300 | 2500 | 1700 | 0.25 |
| MucousMembrane | 1600 | 3300 | 9000 | 0.43 |
| Muscle | 690 | 3600 | 2700 | 0.5 |
| Nerve | 7100 | 3500 | 40000 | 0.46 |
| Skin Dry | 1620 | 3500 | 9100 | 0.42 |
| Skin Wet | 1620 | 3500 | 9100 | 0.42 |
| Tongue* | 690 | 3600 | 2700 | 0.5 |
| VitreousHumor | 0 | 4200 | 0 | 0.6 |
| Item | Factor loading | Description | Original item no. | Initial factor | Mean (SD) | ritem-total correlation |
| 1 | 0.722 | Cuando tengo deseos intensos de comer, una vez que empiezo no puedo parar. [When I crave something, I know I won't be able to stop eating once I start] | 2 | Lack of control | 3.01 (1.84) | 0.722** |
| 2 | 0.679 | A veces, cuando como lo que se me antoja, pierdo control y como demasiado. [If I eat what I am craving, I often lose control and eat too much] | 3 | Lack of control | 3.86 (1.85) | 0.687** |
| 3 | 0.734 | Sin duda alguna, las ganas de comer me hacen pensar cómo voy a conseguirlo [Food cravings invariably make me think of ways to get what I want to eat.] | 5 | Intentions to eat | 2.98 (1.87) | 0.735** |
| 4 | 0.734 | No hago más que pensar en la comida. [I feel like I have food on my mind all the time] | 6 | Food-related thoughts | 2.29 (1.56) | 0.722** |
| 5 | 0.650 | A veces me encuentro pensativo preocupado con comida. [I find myself preoccupied with food] | 8 | Food-related thoughts | 2.58 (1.73) | 0.648** |
| 6 | 0.679 | Cada vez que deseo comer algo en particular me pongo a hacer planes para comer. [Whenever I have cravings, I find myself making plans to eat] | 18 | Intentions to eat | 3.22 (1.89) | 0.685** |
| 7 | 0.623 | Siento deseos de comer cuando estoy aburrida, enfadada, o triste. [I crave foods when I feel bored, angry, or sad] | 20 | Negative affect | 3.19 (1.85) | 0.634** |
| 8 | 0.719 | No tengo la fuerza de voluntad de resistir mis deseos de comer lo que se me antoja. [I have no will power to resist my food crave] | 25 | Lack of control | 3.54 (1.99) | 0.724** |
| 9 | 0.795 | Una vez que me pongo a comer tengo problemas en dejar de comer. [Once I start eating, I have trouble stopping] | 26 | Lack of control | 2.79 (1.87) | 0.788** |
| 10 | 0.783 | Por mucho que lo intento, no puedo parar de pensar en comer. [I can't stop thinking about eating no matter how hard I try] | 27 | Food-related thoughts | 2.30 (1.66) | 0.771** |
| 11 | 0.791 | Si me dejo llevar por la tentación de comer pierdo todo mi control. [If I give in to a food craving, all control is lost] | 29 | Lack of control | 2.53 (1.85) | 0.784** |
| 12 | 0.784 | Cada vez que se me antoja una comida sigo pensando en ella hasta que me la como. [Whenever I have a food craving, I keep on thinking about eating until I actually eat the food] | 31 | Food-related thoughts | 3.08 (1.88) | 0.782** |
| 13 | 0.779 | Cuando tengo muchas ganas de comer algo estoy obsesionado con comerlo. [If I am craving something, thoughts of eating it consume me] | 32 | Food-related thoughts | 3.02 (1.86) | 0.777** |
| 14 | 0.633 | A menudo deseo comer cuando siento emociones fuertes. [My emotions often make me want to eat] | 33 | Negative affect | 2.72 (1.79) | 0.638** |
| 15 | 0.673 | Es difícil resistir la tentación de tomar comidas apetecibles que están a mi alcance. [It is hard for me to resist the temptation to eat appetizing foods that are within reach] | 35 | Cue-depending eating | 3.91 (1.94) | 0.683** |
| Apixaban | LMWH/VKA/Placebo | Difference | Apixaban | LMWH/VKA | Difference | |
| Number of events(total population) | ||||||
| Recurrent VTE and VTE-related death | 514 | 577 | −62 | 514 | 508 | 6 |
| VTE-related death | 63 | 71 | −8 | 63 | 63 | 0 |
| Recurrent PE | 130 | 146 | −16 | 130 | 129 | 1 |
| Recurrent DVT | 321 | 359 | −39 | 321 | 316 | 5 |
| Major bleeds | 123 | 136 | −13 | 123 | 149 | −26 |
| CRNM bleed | 603 | 631 | −28 | 603 | 714 | −111 |
| Treatment discontinuation due to adverse events | 109 | 58 | 51 | 109 | 139 | −30 |
| Costs | ||||||
| Anticoagulant costs | £1121 | £98 | £1023 | £1121 | £98 | £1023 |
| Monitoring and administration costsa | £63 | £261 | -£200 | £63 | £446 | -£385 |
| Event-related costs | £4069 | £4214 | -£145 | £4069 | £4170 | -£101 |
| QALYs | 8.488 | 8.386 | 0.101 | 8.488 | 8.425 | 0.063 |
| Life-years | 10.421 | 10.311 | 0.110 | 10.421 | 10.375 | 0.046 |
| Cost per QALY gained | £6692 | £8528 |
| Participants (n) | Age mean (SD) | E-learning interest mean (SD) | E-learning experience mean (SD) | |
| Prior clinical knowledge | Male (18) | 26.16 (4.33) | 4.33 (1.23) | 3.72 (1.13) |
| Female (32) | 24.56 (5.49) | 3.94 (1.19) | 3.31 (1.26) | |
| Total (50) | 25.14 (5.12) | 4.08 (1.21) | 3.46 (1.22) | |
| No prior clinical knowledge | Male (18) | 24.00 (2.52) | 4.67 (0.84) | 4.00 (1.28) |
| Female (40) | 22.37 (2.64) | 4.15 (1.05) | 3.45 (0.93) | |
| Total (58) | 22.88 (2.67) | 4.31 (1.01) | 3.62 (1.07) |
| Assay | LK>LK Ri | DH44>LK Ri | DH44>DH44 Ri | LK>DH44 Ri |
| Effect of manipulation | Global LK knockdown | LK knockdown in ABLKs | Global DH44 knockdown | DH44 knockdown in ABLKs |
| Desiccation survival | ↑**** | ↑**** | No effect | ↑**** |
| Starvation survival | ↑**** | ↑**** | ↑**** | ↑**** |
| Ionic stress survival | ↑**** | ↑**** | ↑**** | ↑**** |
| Chill coma recovery | No effect | ↑* | ↑* | ↑* |
| Feeding | No effect | No effect | No effect | ↓**** |
| Water content | ↑** | ↑**** | No effect | No effect |
| # G | # loc | PPL | Br | Hj (S.E.) | FIS | Filled seeds (%) | Seed viability (%) | |
| Northwestern European J. communis populations | ||||||||
| Cour | 9 | 104 | 73 | 1.73 | 0.409 (0.012) | 0.27 | 4.41 | 0.10 |
| Heiderbos* | 30 | 104 | 100 | 1.85 | 0.337 (0.014) | 0.42 | 15.28 | 5.49 |
| Resteigne | 24 | 104 | 90 | 1.65 | 0.343 (0.013) | 0.46 | 9.47 | 5.49 |
| Cocquerel | 18 | 104 | 98 | 1.93 | 0.364 (0.012) | -0.06 | 2.70 | 0.44 |
| Grattepanche | 32 | 104 | 100 | 1.94 | 0.386 (0.011) | 0.04 | 1.73 | 0.58 |
| Hühnermoor | 33 | 104 | 94 | 1.75 | 0.331 (0.014) | 0.47 | 11.95 | 4.58 |
| Ecksberg | 12 | 104 | 96 | 1.94 | 0.389 (0.012) | 0.00 | 11.45 | 3.89 |
| Meenser Heide | 14 | 104 | 87 | 1.82 | 0.363 (0.013) | -0.02 | 18.98 | 2.76 |
| Weinberg | 12 | 104 | 90 | 1.86 | 0.371 (0.013) | 0.10 | 10.02 | 4.92 |
| Boshuizerbergen | 35 | 104 | 99 | 1.75 | 0.344 (0.012) | 0.46 | 3.80 | 1.50 |
| Kootwijkerzand | 12 | 104 | 98 | 1.93 | 0.347 (0.013) | -0.14 | 5.21 | 0.48 |
| Loenen | 21 | 104 | 98 | 1.90 | 0.363 (0.011) | 0.22 | 6.69 | 2.32 |
| Mantingerzand | 34 | 104 | 87 | 1.91 | 0.346 (0.013) | 0.02 | 2.70 | 0.14 |
| Flemish J. communis populations | ||||||||
| Heiderbos* | 57 | 94 | 100 | 1.86 | 0.359 (0.012) | 0.37 | NA | NA |
| Kattevennen | 26 | 94 | 98 | 1.86 | 0.382 (0.011) | 0.41 | NA | NA |
| Hesselberg | 26 | 94 | 96 | 1.83 | 0.364 (0.013) | 0.33 | NA | NA |
| TE1 (n = 24) | TE2 (n = 22) | TE3 (n = 30) | TE4 (n = 25) | |
| Condition | D | CN | D | CN |
| Sex | ||||
| Girls | 11 (45.8%) | 13 (59.1%) | 15 (50.0%) | 15 (60.0%) |
| Boys | 13 (54.2%) | 9 (40.9%) | 15 (50.0%) | 10 (40.0%) |
| Age, mean (SD) | 10.58 (0.58) | 10.46 (0.67) | 10.43 (0.57) | 10.48 (0.51) |
| Race/ethnicity | 23 Latino | 21 Latino | 25 Latino | 22 Latino |
| 1 European American | 1 Asian | 3 African American | 2 African American | |
| 2 Filipino | 1 European American |
| Daytime | Nighttime | 24 h | |
| SBP | |||
| Symptomatic | 124.7 ± 25.2 | 131.2 ± 26.6 | 126.7 ± 25.1 |
| Asymptomatic | 123.1 ± 13.8 | 122.1 ± 19.9 | 122.5 ± 14.5 |
| DBP | |||
| Symptomatic | 76.6 ± 13.3 | 80.3 ± 14.6 | 77.7 ± 13.2 |
| Asymptomatic | 77.9 ± 12.2 | 75.9 ± 10.1 | 77.1 ± 11.3 |
| HR | |||
| Symptomatic | 78.8 ± 14.7 | 74.2 ± 14.4 | 77.6 ± 14.4 |
| Asymptomatic | 75.9 ± 15.2 | 69.7 ± 14.8 | 74.5 ± 14.4 |
| AD event | |||
| Symptomatic | 2.7 ± 2.0 | 3.0 ± 2.9 | 5.7 ± 3.5 |
| Asymptomatic | 3.3 ± 1.7 | 2.7 ± 3.0 | 6.0 ± 3.3 |
| Domains | Patients n = 15 | Controls n = 15 | p-value |
| Somatisation | 0.647 (0.496) | 0.357 (0.366) | 0.005 (0.013) |
| Obsessive-Compulsive | 0.670 (0.578) | 0.447 (0.253) | 0.14 |
| Interpersonal sensitivity | 0.453 (0.504) | 0.313 (0.295) | 0.55 |
| Depression | 0.753 (0.666) | 0.190 (0.167) | 0.01 (0.03) |
| Anxiety | 0.40 (0.417) | 0.27 (0.492) | 0.05 (0.09) |
| Hostility | 0.42 (0.581) | 0.22 (0.308) | 0.3 |
| Phobic Anxiety | 0.11 (0.168) | 0.30 (0.082) | 0.08 |
| Paranoid Ideation | 0.42 (0.64) | 0.16 (0.181) | 0.33 |
| Psychoticism | 0.19 (0.292) | 0.04 (0.063) | 0.16 |
| Global severity index | 0.502 (0.444) | 0.243 (0.123) | 0.04 (0.08) |
| Positive symptom distress index | 1.0 (1.73) | 3.33 (11.8) | 0.6 |
| Time of assessment | Survival | |||
| 1 year | 2 years | 3 years | 5 years | |
| After day 28 | 33.0% | 27.0% | 23.9% | 19.8% |
| After ICU discharge (male and female) | 61.8% | 50.6% | 44.7% | 37.0% |
| After ICU discharge (male) | 64.7% | 53.8% | 46.0% | 37.7% |
| After ICU discharge (female) | 53.8% | 41.6% | 41.6% | 36.3% |
| General population (male, age 65 years)a | 98.3% | 96.5% | 94.6% | 90.3% |
| General population (female, age 65 years)a | 99.2% | 98.4% | 97.4% | 95.2% |
| Antibiotic coated (n=31) | Antibiotic non-coated (n=40) | p | |
| Mean age (years) | 48.5 | 51.2 | >0.05 |
| Positive culture n (%) | 4 (13) | 14 (35) | 0.002 |
| Median follow-up (months) | 29 (8 to 38) | 53 (14 to 82) | <0.05 |
| Mean revision time after first implant (years) | 7.1 (2.4 to 8) | 9.4 (0.8 to 17) | <0.05 |
| Gene | Gene information | GO term |
| APOLD1 | Apolipoprotein L domain containing 1 | Response to abiotic stimulus |
| ATP13A4 | ATPase type 13A4 | Transmembrane transport |
| ATP1A2 | ATPase, Na+/K+ transporting, alpha 2 polypeptide | Behavior / response to abiotic stimulus / transmembrane transport |
| CIART | Circadian associated repressor of transcription | Behavior |
| GJA1 | Gap junction protein, alpha 1, 43 kDa | Behavior / response to abiotic stimulus / transmembrane transport |
| GPR37 | G protein-coupled receptor 37 (endothelin receptor type B-like) | Behavior |
| HIF3A | Hypoxia inducible factor 3, alpha subunit | Response to abiotic stimulus |
| IGFBP7 | Insulin-like growth factor binding protein 7 | Response to abiotic stimulus |
| MLC1 | Megalencephalic leukoencephalopathy with subcortical cysts 1 | Response to abiotic stimulus / transmembrane transport |
| PLOD2 | Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 | Response to abiotic stimulus |
| PREX2 | Phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 2 | Behavior |
| PTN | Pleiotrophin | Behavior |
| S1PR1 | Sphingosine-1-phosphate receptor 1 | Behavior |
| SDC2 | Syndecan 2 | Response to abiotic stimulus |
| SDC4 | Syndecan 4 | Response to abiotic stimulus |
| SLC14A1 | Urea transporter,Kidd blood group | Transmembrane transport |
| SLC1A2 | Glial high affinity glutamate transporter | Behavior / response to abiotic stimulus / transmembrane transport |
| SLC1A3 | Glial high affinity glutamate transporter | Behavior / response to abiotic stimulus / transmembrane transport |
| SLC4A4 | Sodium bicarbonate cotransporter | Transmembrane transport |
| SLC5A11 | Sodium/inositol cotransporter | Transmembrane transport |
| SLC7A11 | Anionic amino acid transporter light chain, xc- system | Transmembrane transport |
| SLCO1C1 | Solute carrier organic anion transporter | Transmembrane transport |
| TP53BP2 | Tumor protein p53 binding protein 2 | Response to abiotic stimulus |
| VEGFA | Vascular endothelial growth factor A | Behavior / response to abiotic stimulus |
| Data flow stages | |||
| Tool | SQS | Action property | Activity(Yes or No) |
| Data collection | |||
| Primary self-quantification tools | Digifit, BodyTrack and Wikilife | C | Yes |
| Primary self-quantification tools and apps | U | Yes | |
| Data transmission | |||
| Universal Serial Bus (USB) network | Digifit, BodyTrack and Wikilife | S | No |
| Application has a feature for importing data | U | Yes | |
| Data storing | |||
| Files (e.g., XML, CSV, etc.) | Digifit website, BodyTrack and Wikilife | C | Yes |
| Data aggregation | |||
| Connector | Digifit, BodyTrack and Wikilife | S | No |
| Web-based application | C | Yes | |
| Data visualisation | |||
| Web-based application | Digifit website, BodyTrack, and Wikilife | C | Yes |
| Data sharing | |||
| Application has a feature for sharing data with social networks such as Facebook | Digifit website, BodyTrack, and Wikilife | C | Yes |
| Application has a feature for importing data | C | Yes |
| Overall | GFR categorya | ||||
| G1 | G2 | G3a | G3b-G5 | ||
| MDRD vs. CKD-EPIcrecys | 16.7 (15.9%) | 17.5 (15.1%) | 16.1 (18.3%) | 6.4 (11.1%) | 2.2 (6.0%) |
| MDRD vs. CKD-EPIcre | 6.8 (7.1%) | 7.1 (6.6%) | 6.9 (8.4%) | 1.7 (3.1%) | 0.3 (0.8%) |
| MDRD vs. CKD-EPIcys | 22.9 (20.6%) | 24.3 (20.4%) | 20.0 (22.2%) | 4.6 (8.2%) | 3.5 (9.1%) |
| MDRD vs. LM | 4.7 (5.6%) | 9.6 (9.9%) | 1.5 (1.9%) | 1.4 (2.6%) | 2.6 (7.7%) |
| MDRD vs. FAScre | 3.3 (3.6%) | 5.1 (4.7%) | 2.0 (2.5%) | 2.9 (5.5%) | 0.1 (0.1%) |
| CKD-EPIcrecys vs. CKD-EPIcre | 9.9 (10.4%) | 10.1 (9.8%) | 9.8 (13.2%) | 5.4 (10.6%) | 1.9 (5.4%) |
| CKD-EPIcrecys vs. CKD-EPIcys | 6.2 (5.6%) | 6.6 (5.7%) | 4.3 (5.3%) | 1.1 (2.0%) | 0.8 (2.3%) |
| CKD-EPIcrecys vs. LM | 21.4 (25.6%) | 24.0 (26.1%) | 17.6 (24.8%) | 8.3 (16.6%) | 4.8 (14.9%) |
| CKD-EPIcrecys vs. FAScre | 13.4 (14.6%) | 12.6 (12.3%) | 16.2 (22.8%) | 9.4 (19.0%) | 2.0 (5.6%) |
| CKD-EPIcre vs. CKD-EPIcys | 16.1 (14.5%) | 16.8 (14.2%) | 14.6 (16.8%) | 3.5 (6.2%) | 3.4 (9.0%) |
| CKD-EPIcre vs. LM | 11.5 (13.7%) | 15.0 (15.8%) | 8.2 (11.0%) | 3.3 (6.3%) | 2.9 (8.9%) |
| CKD-EPIcre vs. FAScre | 3.5 (3.8%) | 2.2 (2.1%) | 5.6 (7.4%) | 4.6 (8.9%) | 0.4 (1.1%) |
| CKD-EPIcys vs. LM | 27.6 (33.0%) | 30.1 (33.5%) | 22.1 (32.2%) | 7.0 (13.9%) | 6.1 (18.7%) |
| CKD-EPIcys vs. FAScre | 19.7 (21.4%) | 19.4 (19.4%) | 22.3 (32.7%) | 8.0 (16.0%) | 3.0 (8.7%) |
| LM vs. FAScre | 8.0 (8.7%) | 13.5 (12.4%) | 3.5 (4.4%) | 1.2 (2.3%) | 2.1 (5.7%) |
| Pneumococcal serotype | Twofold response to vaccination | Post-vaccination anti-CP† antibody concentration | ||
| ≥0.35 μg/mL | ≥1.00 μg/mL | ≥5.00 μg/mL | ||
| 6B (n = 10) | 8 | 7 | 3 | 1 |
| 9V (n = 7) | 5 | 7 | 5 | 2 |
| 19A (n = 1) | 0 | 1 | 1 | 0 |
| 19F (n = 6) | 5 | 5 | 3 | 2 |
| 23F (n = 7) | 6 | 6 | 3 | 1 |
| Probe ID | Symbol | Hazard Ratio | β | P value | AUC |
| A_24_P21161 | GPR85 | 0.368 | −1.000 | 1.16E-05 | 0.7188 |
| A_23_P215687 | GPR85 | 0.135 | −2.002 | 1.55E-05 | 0.8244 |
| A_24_P300021 | SHOX2 | 3.151 | 1.148 | 2.00E-05 | 0.8846 |
| A_23_P134684 | HMBOX1 | 0.103 | −2.273 | 5.18E-05 | 0.9382a |
| A_24_P102293 | SLITRK5 | 0.552 | −0.594 | 5.44E-05 | 0.9182 |
| A_23_P210323 | CEP68 | 0.149 | −1.904 | 5.87E-05 | 0.9239 |
| A_24_P417526 | FRG1B | 0.217 | −1.528 | 7.51E-05 | 0.9346 |
| A_23_P138574 | ATE1 | 0.112 | −2.189 | 7.83E-05 | 0.9379 |
| A_23_P3602 | NUDT7 | 0.348 | −1.056 | 9.58E-05 | 0.9290 |
| A_24_P167984 | ATMIN | 0.052 | −2.957 | 0.0001195 | 0.9274 |
| Free-ranging | Captive | |||||
| N* | Mean ± SD | Median (25th, 75th percentiles) | N | mean ± SD | Median (25th, 75th percentiles) | |
| NDF | 8 | 63.6 ± 6.5 | 67.0 (56.7,68.0)A | 12 | 51.8 ± 5.9 | 51.2 (48.3,53.0)B |
| ADF | 8 | 43.0 ± 4.4a | 43.0 (40.0,46.7) | 8 | 36.9 ± 6.1b | 37.9 (31.5,41.2) |
| ADL | 8 | 35.2 ± 6.7 | 37.7 (31.8,39.4)A | 8 | 25.1 ± 5.0 | 23.7 (23.0,25.3)B |
| TFN | 8 | 4.3 ± 0.2a | 4.3 (4.1,4.4) | 12 | 3.7 ± 0.6b | 3.9 (3.0,4.2) |
| NDF-N | 8 | 3.2 ± 0.3a | 3.2 (2.9,3.5) | 8 | 1.2 ± 0.7b | 0.9 (0.7,1.9) |
| MFN | 8 | 1.1 ± 0.5 | 0.9 (0.7,1.6)A | 8 | 2.4 ± 0.7 | 2.1 (2.0,2.4)B |
| TA | 8 | 9.3 ± 2.0a | 8.8 (7.6,10.6) | 12 | 13.9 ± 4.1b | 13.6 (10.4,15.8) |
| AIA | 8 | 1.1 ± 1.1 | 0.7 (0.2,1.8)A | 8 | 2.8 ± 4.0 | 1.2 (0.4,3.4)B |
| Time segment in s | Probe 1 | Probe 2 | Probe 3 | Probe 4 | ||||
| M | SE | M | SE | M | SE | M | SE | |
| CONTROL GROUP | ||||||||
| 5 | 0.028 | 0.022 | 0.079 | 0.044 | 0.071 | 0.041 | 0.032 | 0.020 |
| 10 | 0.144 | 0.039 | 0.164 | 0.052 | 0.134 | 0.052 | 0.098 | 0.048 |
| 15 | 0.134 | 0.041 | 0.26 | 0.07 | 0.142 | 0.052 | 0.135 | 0.049 |
| 20 | 0.201 | 0.051 | 0.381 | 0.082 | 0.179 | 0.059 | 0.214 | 0.068 |
| 25 | 0.322 | 0.078 | 0.519 | 0.084 | 0.343 | 0.079 | 0.332 | 0.058 |
| 30 | 0.505 | 0.081 | 0.702 | 0.066 | 0.642 | 0.072 | 0.75 | 0.068 |
| 35 | 0.668 | 0.056 | 0.774 | 0.066 | 0.809 | 0.07 | 0.886 | 0.047 |
| 40 | 0.724 | 0.064 | 0.727 | 0.069 | 0.905 | 0.044 | 0.892 | 0.055 |
| 45 | 0.719 | 0.063 | 0.726 | 0.066 | 0.921 | 0.037 | 0.914 | 0.046 |
| 50 | 0.74 | 0.062 | 0.708 | 0.076 | 0.828 | 0.07 | 0.873 | 0.053 |
| M | 0.419* | 0.023 | 0.504 | 0.025 | 0.498 | 0.03 | 0.513 | 0.021 |
| DYSPHORIC GROUP | ||||||||
| 5 | 0.068 | 0.039 | 0.167 | 0.061 | 0.164 | 0.054 | 0.14 | 0.052 |
| 10 | 0.271 | 0.066 | 0.214 | 0.07 | 0.111 | 0.045 | 0.148 | 0.052 |
| 15 | 0.221 | 0.056 | 0.179 | 0.065 | 0.138 | 0.052 | 0.18 | 0.063 |
| 20 | 0.291 | 0.061 | 0.245 | 0.057 | 0.19 | 0.06 | 0.189 | 0.063 |
| 25 | 0.491 | 0.07 | 0.433 | 0.076 | 0.37 | 0.074 | 0.259 | 0.069 |
| 30 | 0.651 | 0.069 | 0.62 | 0.084 | 0.645 | 0.071 | 0.606 | 0.073 |
| 35 | 0.698 | 0.061 | 0.786 | 0.059 | 0.76 | 0.069 | 0.731 | 0.073 |
| 40 | 0.707 | 0.068 | 0.853 | 0.042 | 0.809 | 0.056 | 0.844 | 0.048 |
| 45 | 0.76 | 0.051 | 0.793 | 0.06 | 0.839 | 0.059 | 0.873 | 0.043 |
| 50 | 0.769 | 0.065 | 0.79 | 0.054 | 0.849 | 0.056 | 0.816 | 0.059 |
| M | 0.493* | 0.020 | 0.508 | 0.021 | 0.488 | 0.026 | 0.479 | 0.022 |
| Species | Reads/Contigs | Number | Average size (nt) | Total nt |
| B. tuediae | Raw reads | 547,061 | 547 | 299,232,484 |
| Trimmed reads | 546,903 | 333 | 182,128,133 | |
| All contigs | 64,442 | 591 | 38,101,858 | |
| Large contigs | 5072 | 1380 | 6,997,895 | |
| Single reads | 118,104 | 279 | 33,008,862 | |
| H. digitata | Raw reads | 546,974 | 543 | 296,833,666 |
| Trimmed reads | 546,846 | 331 | 181,169,361 | |
| All contigs | 54,293 | 613 | 33,255,104 | |
| Large contigs | 5083 | 1430 | 7,272,471 | |
| Single reads | 105,695 | 260 | 27,786,964 |
| Time seizure free after breakthrough seizure (months) | Number at risk | Risk of seizure in following 12 months. % |
| 6 | 119 | 32 (28 to 36) |
| 9 | 99 | 24 (21 to 27) |
| 12 | 80 | 17 (15 to 19) |
| Variant | Total | CIN1 | CIN2 | CIN3 | ICC | Adjusted ORa(95% CI) | |
| HPV52 | A1 | 2 | 0 | 0 | 2 | 0 | - |
| A2 | 0 | 0 | 0 | 0 | 0 | - | |
| B1 | 0 | 0 | 0 | 0 | 0 | - | |
| B2 | 31 | 9 | 9 | 6 | 7 | - | |
| C | 0 | 0 | 0 | 0 | 0 | - | |
| D | 0 | 0 | 0 | 0 | 0 | - | |
| HPV58 | A1 | 13 | 6 | 3 | 2 | 2 | 1.0 (reference) |
| A2 | 19 | 7 | 5 | 4 | 3 | 1.47 (0.35–6.17) | |
| A3 | 3 | 1 | 0 | 1 | 1 | 1.71 (0.12–23.9) | |
| B | 0 | 0 | 0 | 0 | 0 | ND | |
| C | 1 | 0 | 1 | 0 | 0 | ND | |
| D | 0 | 0 | 0 | 0 | 0 | ND |
| MZ twins | DZ twins | |||
| Male | Female | Male | Female | |
| Mean age | 35.09 (15.27) | 35.63 (15.20) | 31.57 (13.98) | 31.88 (13.45) |
| Mean HRS | 5.85 | 5.5 | 6.08 | 5.79 |
| Mean PADUA | 6.99 | 6.7 | 7.04 | 6.99 |
| Tics (prevalence) | 192 | 188 | 175 | 162 |
| Cardiac contractility dP/dt (mmHg/sec) | |
| Control | SHR |
| 1622 ± 120 | 1056 ± 182* |
| Corpus | Named entity types |
| GE | Protein |
| ID | Protein, chemical, organism, Regulon-operon, |
| two-component-system | |
| EPI | Protein |
| DNAm | Protein |
| EPTM | Protein |
| mTOR | Protein, Drug, ion, simple molecule, tag |
| MLEE | Protein, drug or compound, cellular component, cell, tissue, |
| organ, anatomical system, organism, [ ...] |
| Homeless | Housed | |
| Cause of death | N (%) | N (%) |
| HIV/AIDS | 156 (78%) | 905 (83%) |
| Hepatitis | 41 (21%) | 130 (12%) |
| Liver disease | 39 (20%) | 160 (15%) |
| Septicemia | 35 (18%) | 121 (11%) |
| Mental illness | 33 (17%) | 52 (5%) |
| Heart disease | 29 (15%) | 201 (18%) |
| Pneumonia (non-AIDS-related) | 27 (14%) | 172 (16%) |
| Non-AIDS cancer | 12 (6%) | 139 (13%) |
| Health Behaviour | Group | Net change% | Odds Ratio for change | 95% CI | NNT# |
| Fish | Intervention | +7.06 | 1.37* | 1.11-1.64 | 15 |
| Control | +0.84 | ||||
| Spread | Intervention | +5.06 | 1.28* | 1.06-1.51 | 21 |
| Control | +0.37 | ||||
| Salt | Intervention | +5.43 | 1.19* | 1.05-1.38 | 24 |
| Control | +1.23 | ||||
| Veg and fruit | Intervention | +3.14 | 1.24 | 0.91-1.68 | 37 |
| Control | +0.49 | ||||
| Meat | Intervention | +7.17 | 1.16 | 0.93-1.44 | 38 |
| Control | +4.48 | ||||
| Milk | Intervention | +4.62 | 1.11 | 0.96-1.29 | 45 |
| Control | +1.80 | ||||
| Alcohol | Intervention | +3.88 | 1.16 | 0.96-1.37 | 45 |
| Control | +1.12 | ||||
| Physical activity | Intervention | +0.48 | 1.06 | 0.86-1.30 | 58 |
| Control | −1.34 | ||||
| Body weight | Intervention | −0.12 | 0.96 | 0.85-1.09 | 161 |
| Control | −0.82 | ||||
| Smoking | Intervention | +0.24 | 0.97 | 0.86-1.12 | 1000 |
| Control | +0.36 |
| Male | Female | ||||||
| Group | N | Mean | SD | N | Mean | SD | |
| Permissiveness | Non-Koreans in US | 79 | 3.34 | .860 | 140 | 3.25 | .884 |
| Koreans in US | 20 | 3.26 | .909 | 24 | 3.76 | .754 | |
| Koreans in Korea | 30 | 3.78 | .958 | 68 | 3.60 | .774 | |
| Unpredictability | Non-Koreans in US | 79 | 3.59 | .683 | 140 | 3.56 | .749 |
| Koreans in US | 20 | 3.43 | .712 | 24 | 3.52 | .801 | |
| Koreans in Korea | 30 | 3.27 | 1.03 | 68 | 3.19 | .707 | |
| Incomprehensibility | Non-Koreans in US | 79 | 3.46 | .674 | 140 | 3.55 | .685 |
| Koreans in US | 20 | 3.31 | .888 | 24 | 3.56 | .650 | |
| Koreans in Korea | 30 | 3.52 | .741 | 68 | 3.49 | .772 | |
| Noncommunication | Non-Koreans in US | 79 | 2.59 | .746 | 140 | 2.67 | .704 |
| Koreans in US | 20 | 2.85 | .829 | 24 | 2.85 | .972 | |
| Koreans in Korea | 30 | 2.62 | .652 | 68 | 2.38 | .697 | |
| Right to Prevent | Non-Koreans in US | 79 | 2.27 | .816 | 140 | 2.11 | .784 |
| Koreans in US | 20 | 2.33 | .878 | 24 | 1.71 | .570 | |
| Koreans in Korea | 30 | 1.75 | .598 | 68 | 1.61 | .510 | |
| Preventability | Non-Koreans in US | 79 | 2.20 | .745 | 140 | 2.33 | .747 |
| Koreans in US | 20 | 1.85 | .745 | 24 | 1.94 | .712 | |
| Koreans in Korea | 30 | 2.12 | .715 | 68 | 2.14 | .615 | |
| Relation-Caused | Non-Koreans in US | 79 | 3.47 | .769 | 140 | 3.53 | .780 |
| Koreans in US | 20 | 3.70 | .750 | 24 | 3.58 | .670 | |
| Koreans in Korea | 30 | 3.67 | .802 | 68 | 3.26 | .725 | |
| Duration of Suicidal Process | Non-Koreans in US | 79 | 3.08 | .544 | 140 | 3.06 | .520 |
| Koreans in US | 20 | 2.82 | .567 | 24 | 2.88 | .535 | |
| Koreans in Korea | 30 | 3.03 | .596 | 68 | 3.16 | .627 |
| miRNAs repressing NF-κB signaling | ||||
| miRNA | Gene | Transcripts | CS | CSP |
| miR-24 | MYD88 | NM_001172569, NM_002468, NM_001172568, NM_001172567, NM_001172566 | -0.319 | 95 |
| RASL11B | NM_023940 | -0.35 | 96 | |
| RELA | NM_021975, NM_001145138 | -0.307 | 93 | |
| miR-124 | TRIM22 | NM_001199573, NM_006074 | -0.339 | 96 |
| BECN1 | NM_003766 | -0.339 | 96 | |
| miR-210 | CCNL2 | NM_001039577 | -0.275 | 85 |
| miR-491 | PLEKHB1 | NM_021200, NM_001130033, NM_001130035, NM_001130034, NM_001130036 | -0.314 | 98 |
| TULP3 | NM_003324 | -0.278 | 97 | |
| TNFSF10 | NM_001190943 | -0.336 | 99 | |
| miR-506 | RELA | NM_021975, NM_001145138 | -0.401 | 98 |
| miRNAs activating NF-κB signaling | ||||
| miRNA | Gene | Transcripts | CS | CSP |
| MATN2 | NM_030583, NM_002380 | -0.351 | 96 | |
| miR-30a | GPR161 | NM_153832 | -0.298 | 93 |
| PTGER2 | NM_000956 | -0.328 | 95 | |
| miR-34b | TLR7 | NM_016562 | -0.356 | 98 |
| miR-125b | IKBKG | NM_001099857, NM_001099856, NM_001145255 | -0.297 | 92 |
| MAP3K11 | NM_002419 | -0.337 | 95 | |
| miR-141 | PTGDR | NM_000953 | -0.3 | 97 |
| miR-184 | TNK2 | NM_001010938, NM_005781 | -0.452 | 94 |
| SLC7A5 | NM_003486 | -0.306 | 85 | |
| miR-452* | LPAR2 | NM_004720 | -0.304 | 95 |
| STMN1 | NM_001145454 | -0.367 | 98 | |
| NFKBIE | NM_004556 | -0.288 | 94 | |
| miR-544 | TSPAN13 | NM_014399 | -0.279 | 92 |
| No | Compound name | Area (%) | No | Compound name | Area (%) |
| 1 | 3-Methyl butanol | 0.14 | 19 | β-Phellandrene | 0.34 |
| 2 | Eugenol | 1.33 | 20 | α -Thujene | 1.26 |
| 3 | 1,8-Cineole | 0.24 | 21 | β -Caryophyllene | 0.7 |
| 4 | α -Pinene | 0.99 | 22 | γ-Terpinene | 2.77 |
| 5 | Geranyl acetone | 0.5 | 23 | Camphene | 0.14 |
| 6 | cis-Sabinene hydrate | 0.68 | 24 | α-Franesene | 0.7 |
| 7 | iso-Amylpropionate | 0.23 | 25 | Terpinolene | 0.22 |
| 8 | β-Bisabolene | 3.77 | 26 | β-Pinene | 0.32 |
| 9 | Linalool | 3.32 | 27 | α-Bisabolene | 0.51 |
| 10 | Myrcene | 2.43 | 28 | Nonanal | 0.24 |
| 11 | Caryophyllene oxide | 1.53 | 29 | trans-2-Carene-4-ol | 0.73 |
| 12 | 4-Terpineol | 4.1 | 30 | β-Udesmol | 0.32 |
| 13 | iso-Butyl-2-methyl butyrate | 0.19 | 31 | α-Terpineol | 0.42 |
| 14 | Heptadecane | 0.19 | 32 | 3-Carene | 0.36 |
| 15 | Thymyl methyl ether | 1.21 | 33 | α-Bisabolol | 0.27 |
| 16 | α-Terpinene | 0.73 | 34 | trans-Dihydrocarvone | 0.26 |
| 17 | Musk ambrette | 0.08 | 35 | para-Cymene | 5.61 |
| 18 | Carvacrol | 63.17 |
| Demographic variables | N | % | |
| Gender | Males | 409 | 55.5 |
| Females | 328 | 44.5 | |
| Year | First | 149 | 20.2 |
| Second | 183 | 24.8 | |
| Third | 152 | 20.6 | |
| Fourth | 143 | 19.4 | |
| Fifth | 69 | 9.3 | |
| Sixth | 41 | 5.6 |
| BALP (U/L) | Dpd (nmol/L) | |||||
| Control | CDNR | P value | Control | CDNR | P value | |
| Day −1 | 3.582 ± 1.207 | 3.473 ± 1.391 | 0.882 | 3.665 ± 1.421 | 2.862 ± 0.577 | 0.229 |
| Day 14 | 4.887 ± 1.610 | 4.606 ± 1.649 | 0.762 | 2.964 ± 1.118 | 2.614 ± 0.710 | 0.532 |
| Day 28 | 5.909 ± 2.235 | 5.120 ± 2.458 | 0.557 | 2.761 ± 1.657 | 2.303 ± 0.624 | 0.540 |
| Day 42 | 4.991 ± 1.605 | 5.283 ± 2.153 | 0.785 | 2.791 ± 1.586 | 1.891 ± 0.411 | 0.208 |
| UP1 | UP2 | UPps | SO1 | SO2 | |
| Number of analysed branches | 1,257 | 14,326 | 1,298 | 1,807 | 13,374 |
| Branches with ω < 1 (%)a | 1,144 (91.01) | 12,515 (87.36) | 993 (76.50) | 1,799 (99.56) | 13,329 (99.66) |
| Mean ω for branches with ω < 1 | 0.41 | 0.49 | 0.59 | 0.28 | 0.29 |
| Branches with ω > 1 (%)a | 113 (8.99) | 1,811 (12.64) | 305 (23.50) | 8 (0.44) | 45 (0.34) |
| Mean ω for branches with ω > 1 | 1.55 | 1.52 | 1.67 | 1.37 | 1.44 |
| Branches with ω > 1.2 (%)a | 73 (5.81) | 1,099 (8.78) | 205 (15.79) | 4 (0.22) | 23 (0.17) |
| Mean ω for branches with ω > 1.2 | 1.81 | 1.80 | 1.95 | 1.64 | 1.79 |
| Mean ω ± SE | 0.51 ± 0.44 | 0.62 ± 0.47 | 0.84 ± 0.65 | 0.28 ± 0.17 | 0.29 ± 0.17 |
| Probe | Primer 1 | Primer 2 | |
| APOA1 | CTGCCAGAAATGCCGAGCCTG | CTTTGAGCACATCCACGTACA | GCCGTGCTCTTCCTGAC |
| APOB | CTGGATACCGTGTATGGAAACTGCTCC | CATTGCCCTTCCTCGTCTT | CCAGAGACAGAAGAAGCCAAG |
| CPS1 | TCCAGCAATCATTCCGGCCAAGA | CCACAGGATTTAAGATACCCCAG | GTAATTGTTCAGCCACACCAAG |
| CYP1A1 | TCTGTGATGTCCCGGATGTGGC | CCCAACCCTTCCCTGAATG | TTCTTCTCCTGACAGTGCTCAATC |
| FGA | CAGGCAGACGATCCTCATGGAAAACA | CAGCCCCACCCTTAGAAAAG | CTCCTTCAGCTAGAAAGTCACC |
| FGG | AATAAGGGAGCTAAACAGAGCGGGC | CAAAGACACGGTGCAAATCC | TTCCAGACCCATCGATTTCAC |
| GSTA1 | CGGGCTGACATTCATCTGGTGGA | AAATCGCTACTTCCCTGCC | GGAAGCTGGAGATAAGACTGG |
| HGD | ATGCAGGCCACTCACAAAGTCTACTT | AGCAAGCCATTGTTAGACTT | CCTGATCCTAACCAGCTTAGATG |
| HNF1A | CAGGTTGGTGGTGTCGGTGATGA | GCCCTCTACAGCCACAAG | CAGTGTCTGAGGTGAAGACC |
| HNF4A | CAAGAAATGCTTCCGGGCTGGC | ATAGCTTGACCTTCGAGTGC | TGGACAAAGACAAGAGGAACC |
| LXR | TGCATAGCTCGTTCCCCAGCATTT | CCCTTCAGAACCCACAGAG | CGCAGCTCAGAACATTGTAGT |
| RPL13A | AGCAGTACCTGTTTAGCCACGATGG | GCCTTCACAGCGTACGA | CGAAGATGGCGGAGGTG |
| RXR | AGTACTGCCGCTACCAGAAGTGC | AGGACTGCCTGATTGACAAG | GACTCCACCTCATTCTCGTTC |
| SERPINA1 | TGGTGCCTGAAGCTGAGGAGAC | AGCCAGGGAGACAGGGA | CTTAAATACGGACGAGGACAGG |
| SLC10A1 | AACCTCAGCATTGTGATGACCACCT | TGTACAGGAGGAGAGGCATC | ACCTGTCCAATGTCTTCAGTC |
| TF | CTGTGTCAACTGTGTCCAGGGTGT | TGAGCCACGTAAACCTCTTG | AGTATTGGTTAAGGGTGGAGC |
| TTR | AGCAGCCTAGCTCAGGAGAAGTGA | CAGGTTTGCAGTCAGATTGG | CCATCCTGCCAAGAATGAGT |
| Comorbid condition | Patients | Age group [years] | Gender [%] | |||
| <40 | 40–59 | ≥60 | Male | Female | ||
| N (%) | n (%) | n (%) | n (%) | n (%) | n (%) | |
| Coronary heart disease | 202 | 7 (3.5) | 71 (35.1) | 124 (61.4) | 66 (32.7) | 136 (67.3) |
| Cerebrovascular disease | 99 | — | 21 (21.2) | 78 (78.8) | 26 (26.3) | 73 (73.7) |
| Diabetes mellitus | 174 | 9 (5.2) | 54 (31.0) | 111 (63.8) | 66 (27.9) | 108 (62.1) |
| Cancer | 351 | 19 (5.4) | 162 (46.2) | 170 (48.4) | 81 (23.1) | 270 (76.9) |
| Congestive heart failure | 113 | 1 (0.9) | 12 (10.6) | 100 (88.5) | 23 (20.4) | 90 (79.6) |
| Chronic obstructive pulmonary disease | 68 | 8 (11.8) | 25 (36.5) | 35 (51.5) | 19 (27.9) | 49 (72.1) |
| Comorbidities | ||||||
| 0 | 1736 | 614 (35.4) | 921 (53.1) | 201 (11.6) | 358 (20.6) | 1378 (79.4) |
| 1 | 504 | 40 (7.9) | 257 (51.0) | 207 (41.1) | 142 (28.2) | 362 (71.8) |
| ≥2 | 204 | 2 (1.0) | 40 (19.6) | 162 (79.4) | 55 (27.0) | 149 (73.0) |
| Total | 2444 | 656 (26.8) | 1218 (49.8) | 570 (23.3) | 555 (22.7) | 1889 (77.3) |
| SVR (n = 251) | Response failure (n = 105) | P values | |
| Gender (males%) | 145 (57.8) | 52 (49.5) | 0.154 |
| Age ≥ 40 years (n%) | 123 (49.60) | 80 (77.7) | <0.001 |
| IVDU (n%) | 95 (37.8) | 16 (15.4) | <0.001 |
| Alcohol abuse (n%) | 27 (11.2) | 14 (14.1) | 0.442 |
| BMI (kg/m2) | 23.1 ± 3.8 | 24.6 ± 4.5 | 0.035 |
| Overweight (n%) | 24 (28.6) | 25 (50.0) | 0.013 |
| Genotype distribution | <0.001 | ||
| Genotype 1 | 111 (45.5) | 53 (52.5) | |
| Genotype 2 | 17 (7.0) | 6 (5.9) | |
| Genotype 3 | 98 (40.2) | 15 (14.9) | |
| Genotype 4 | 18 (7.4) | 27 (26.7) | |
| High viral load (n%) | 39 (40.6) | 28 (45.8) | 0.515 |
| Abnormal ALT (n%) | 236 (96.7) | 95 (95.0) | 0.447 |
| Abnormal AST (n%) | 199 (86.1) | 77 (86.5) | 0.931 |
| Hepatic steatosis (n%) | 64 (25.7) | 49 (46.7) | <0.001 |
| Severe inflammation (n%) | 9 (3.8) | 8 (8.5) | 0.080 |
| Advanced fibrosis (n%) | 26 (10,5) | 30 (28,6) | <0.001 |
| Cirrhosis (n%) | 7 (2,8) | 14 (13,3) | <0.001 |
| Type of IFN | 0.987 | ||
| PegIFNα-2a (n%) | 69 (28.6) | 27 (28.7) | |
| PegIFNα-2b (n%) | 172 (71.4) | 67 (71.3) | |
| Dosage adherence (n%) | 173 (80.8) | 60 (82.2) | 0.799 |
| Covariates | OR | 95% CI | P-value |
| Unemployment (n=131) | 0.97 | 0.24-3.77 | 0.961 |
| Light physical activity (hours/week)(n=130) | 1.00 | 0.93-1.08 | 0.947 |
| Moderate physical activity (hours/week)(n=130) | 0.87 | 0.70-1.07 | 0.193 |
| Vigorous physical activity (hours/week)(n=131) | 0.91 | 0.66-1.26 | 0.588 |
| MIDAS score (0-270)(n=131) | 1.02 | 1.00-1.04 | 0.032 |
| MIDAS-intensity (NRS 0-10) (n=131) | 1.49 | 1.03-2.15 | 0.034 |
| MIDAS-frequency (days last 3 months) (n=131) | 1.02 | 1.00-1.04 | 0.032 |
| Neuroticism score (12-60) (n=131) | 1.06 | 0.99-1.13 | 0.069 |
| Extraversion score (12-60) (n=131) | 0.96 | 0.88-1.04 | 0.275 |
| Openness score (12-60) (n=131) | 0.99 | 0.91-1.08 | 0.763 |
| Agreeableness score (12-60) (n=131) | 1.00 | 0.93-1.08 | 0.970 |
| Conscientiousness score (12-60) (n=131) | 0.95 | 0.87-1.03 | 0.206 |
| RT | Isolate namea | RFLP typeb | IIIB-specific PCRc | Alleles at the following loci | ||||
| recA | gyrB | fliC | cepIR | dsbA | ||||
| Group 1 | ||||||||
| 74 | MDII-143p | I | + | 9 | 10 | 2 | 4 | 1 |
| 112 | MDII-151p | I | + | 9 | 8 | 2 | 4 | 1 |
| Group 2 | ||||||||
| 100 | MDIII-B604 | I | + | 9 | 9 | 4 | 4 | 1 |
| 17 | MexII-968 | I | + | 9 | 9 | 1 | 4 | 1 |
| Group 3 (RT-4-complex) | ||||||||
| 115 | MDIII-B752 | J' | + | 10 | 9 | 2 | 7 | 1 |
| 21 | MDIII-P378 | J' | + | 10 | 4 | 2 | 1 | 1 |
| 21 | MexII-864 | J' | + | 10 | 4 | 2 | 1 | 1 |
| 3 | MexII-57 | J' | + | 10 | 10 | 2 | 1 | 2 |
| 7 | MexII-60 | J' | + | 10 | 10 | 2 | 8 | 2 |
| 7 | MexII-857 | J' | + | 10 | 10 | 2 | 8 | 2 |
| 6 | MexII-815 | J' | + | 10 | 10 | 2 | 1 | 1 |
| 53 | MexII-845 | J' | + | 10 | 8 | 1 | 1 | 1 |
| 31 | MexII-940 | J' | + | 10 | 9 | 1 | 1 | 1 |
| 36 | MexII-945 | J' | + | 10 | 4 | 2 | 6 | 1 |
| 4* | MexII-967 | J' | + | 10 | 9 | 2 | 1 | 1 |
| 67 | MexII-974 | J' | + | 10 | 8 | 2 | 6 | 1 |
| 57 | MexII-994 | J' | + | 10 | 8 | 2 | 1 | 2 |
| Group 4 | ||||||||
| 50 | MexII-867 | ukd | + | 11 | 8 | 6 | 1 | 1 |
| 46 | MexII-976 | I | + | 9 | 8 | 6 | 1 | 1 |
| Singletons | ||||||||
| 80 | MCII-168 | J' | + | 10 | 5 | 3 | 6 | 2 |
| 27 | MDII-129r | I | + | 9 | 4 | 2 | 6 | 2 |
| 75 | MDIII-B250 | J' | + | 10 | 8 | 4 | 4 | 1 |
| 114 | MDIII-B716 | I | + | 9 | 4 | 2 | 7 | 1 |
| 28 | MDIII-P410 | I | + | 9 | 4 | 5 | 7 | 2 |
| 22 | MDIII-P461 | J' | + | 10 | 4 | 2 | 7 | 2 |
| 29 | MDIII-T228 | I | + | 9 | 4 | 4 | 1 | 1 |
| 103 | MDIII-T521 | J' | + | 10 | 9 | 4 | 4 | 2 |
| 70 | MexII-206 | uke | + | 13 | 10 | 5 | 7 | 2 |
| 47 | MexII-264 | J' | + | 10 | 2 | 1 | 2 | 2 |
| 48 | MexII-828 | J' | + | 10 | 2 | 2 | 4 | 1 |
| 33 | MexII-863 | J' | + | 10 | 4 | 6 | 10 | 2 |
| Pathological target | Putative mechanism | Examples of supporting references | Form of MS most likely to benefit |
| T- and B-cells | Limit cell proliferation in the periphery and possibly in the CNS | Lederman et al., 1984 | RRMS |
| Warnke et al., 2009 | |||
| Sweeney et al., 2011 | |||
| Cytokines | Modulate cytokine production in the periphery and possibly in the CNS | Del Vecchio et al., 2002 | RRMS |
| Weibach et al., 2004 | |||
| Leung et al., 2005 | |||
| Perivascular iron (heme) deposits | Limit iron catalyzed tissue damage to myelin, the BBB, etc. | Wu et al., 1993 | RRMS |
| Guy et al., 1994 | |||
| Nakamura et al., 2004 | |||
| Stabilize HIF-1α | Schofield and Ratcliffe, 2005 | ||
| Semenza, 2012 | |||
| Singh et al., 2012 | |||
| Demyelination and axonal injury leading to release of iron (or heme) containing products | Limit amplification of tissue damage by iron catalyzed reactions | Wu et al., 1993 | RRMS/SPMS |
| Kadiiska et al., 1995 | |||
| Nakamura et al., 2004 | |||
| Merkofer et al., 2006 | |||
| Stabilize HIF-1α | Schofield and Ratcliffe, 2005 | ||
| Semenza, 2012 | |||
| Singh et al., 2012 | |||
| Activated and iron enriched macrophage, microglia or astrocytes | Limit production of ROS | Rajesh et al., 2004 | RRMS/SPMS |
| Limit production of proinflammatory cytokines | Molina-Holgado et al., 2008 | ||
| Rathnasamy et al., 2011, 2013 | |||
| Limit production of MMP-9 | Mairuae et al., 2011 | ||
| Improve glutamate uptake to lower extracellular levels | Fernandes et al., 2011 | ||
| Altered mitochondrial function in neurons | Limit ROS production by mitochondria | Richardson et al, 2001 | RRMS/SPMS |
| Liang et al., 2008 | |||
| Im et al., 2012 | |||
| Limit caspase-3 activation by mitochondria | Zhang et al., 2009 | ||
| Enhanced iron deposition in deep gray matter | Limit glutamate excitotoxicity | Papazisis et al., 2008 | RRMS/SPMS |
| Yu et al., 2009 | |||
| Protect against oxidative stress | Molina-Holgado et al., 2008 | ||
| Reduce brain iron uptake | Crowe and Morgan, 1994 | ||
| Lessen iron induced inhibition of DNA repair machinery | Li et al., 2009 | ||
| Stabilize HIF-1α | Schofield and Ratcliffe, 2005 | ||
| Semenza, 2012 | |||
| Singh et al., 2012 |
| Anatomical location | Talairach coordinates | Volume (mm3) | ||
| x | y | z | ||
| VOCALIZATIONS > ACTION SOUNDS (P < 0.001) | ||||
| Left aSTG | −58 | −4 | 2 | 20,069 |
| Left temporal pole | −34 | 10 | −34 | 31 |
| Right aSTG | 54 | −4 | 1 | 16,801 |
| Right precentral g. (M1) | 47 | 0 | 48 | 3303 |
| ACTIONS SOUNDS > VOCALIZATIONS (P < 0.001) | ||||
| Left Posterior Insula | −36 | −28 | 18 | 1216 |
| Right Posterior Insula | 32 | −16 | 15 | 761 |
| ACTIONS SOUNDS > VOCALIZATIONS (P < 0.05) | ||||
| Left MFG | −43 | 9 | 32 | 2848 |
| Left Parietal | −42 | −36 | 31 | 2011 |
| Left pSTS | −52 | −50 | 3 | 964 |
| Left aIFS/vlPFC | −45 | 41 | 8 | 4908 |
| Right aIFS/vlPFC | 30 | 29 | 6 | 2836 |
| Variable factorsa | Eye irritationOR (95% CI) | General symptomsOR (95% CI) | Upper respiratoryOR (95% CI) | Skin symptomsOR (95% CI) |
| N = 2587 | N = 2502 | N = 2483 | N = 2684 | |
| Too much air movement | 0.78 (0.55–1.09) | 0.95 (0.69–1.32) | 1.00 (0.66–1.53) | 0.61 (0.31–1.23) |
| Too little air movement | 1.00 (0.87–1.15) | 1.31 (1.14–1.50)** | 1.23 (1.03–1.49)* | 1.13 (0.84–1.54) |
| Too hot | 1.09 (0.94–1.26) | 1.15 (1.00–1.33) | 1.26 (1.03–1.54)* | 1.13 (0.80–1.60) |
| Varying room temperature | 1.16 (0.98–1.36) | 1.00 (0.85–1.18) | 1.03 (0.82–1.29) | 1.11 (0.77–1.60) |
| Too cold | 0.97 (0.80–1.18) | 1.38 (1.13–1.68)** | 1.12 (0.87–1.44) | 0.91 (0.61–1.35) |
| Air too humid | 1.21 (1.02–1.45) * | 1.12 (0.94–1.34) | 0.89 (0.69–1.13) | 0.98 (0.67–1.43) |
| Air too dry | 1.49 (1.25–1.77)** | 1.23 (1.02–1.47)* | 1.78 (1.44–2.19)** | 2.56 (1.83–3.57)** |
| Static electricity | 1.38 (1.01–1.90)* | 1.08 (0.76–1.53) | 0.68 (0.43–1.05) | 1.10 (0.63–1.90) |
| Noise | 1.23 (0.99–1.52) | 1.50 (1.22–1.84)** | 1.34 (1.03–1.76) * | 1.22 (0.81–1.86) |
| Airflow from air conditioner | 1.11 (0.96–1.28) | 1.11 (0.96–1.28) | 1.13 (0.93–1.36) | 0.89 (0.64–1.25) |
| Odors from air conditioner | 1.07 (0.83–1.39) | 1.01 (0.77–1.32) | 0.94 (0.67–1.31) | 1.25 (0.75–2.09) |
| Mold odor | 0.90 (0.66–1.24) | 0.84 (0.61–1.16) | 1.09 (0.75–1.58) | 0.64 (0.35–1.17) |
| Dust and dirt | 1.08 (0.88–1.32) | 1.10 (0.90–1.34) | 1.22 (0.96–1.55) | 0.82 (0.55–1.22) |
| Tobacco smoke odor | 1.22 (1.03–1.43)* | 1.23 (1.04–1.45) * | 1.19 (0.97–1.46) | 1.23 (0.88–1.70) |
| Unpleasant chemical odor | 1.03 (0.69–1.56) | 0.87 (0.57–1.32) | 1.56 (1.01–2.42) * | 2.52 (1.44–4.42)** |
| Unpleasant other odorb | 1.19 (1.00–1.42) | 1.37 (1.15–1.64)** | 1.20 (0.96–1.50) | 1.55 (1.10–2.19)* |
| Treatment | Dose | Analgesic response (mean time in seconds ± SEM) | |||
| 30 min | 60 min | 90 min | 120 min | ||
| Control (normal saline) | 1.0 mL/kg | 7.03 ± 0.44 | 7.34 ± 0.44 | 7.71 ± 0.25 | 7.32 ± 0.21 |
| E5 | 1.0 mg/kg | 17.66 ± 1.54 | 19.76 ± 0.26* | 18.41 ± 0.47* | 17.91 ± 0.45* |
| E3 | 1.0 mg/kg | 22.51 ± 2.01 | 25.36 ± 0.21* | 25.66 ± 0.29* | 21.05 ± 0.33* |
| Standard (Piroxicam suspension) | 1.0 mg/kg | 16.95 ± 0.26* | 17.41 ± 0.37* | 18.3 ± 0.84* | 17.81 ± 1.79* |
| n | CD8+ | CD19+ | CD3+ | CD4+ | NK | |
| Case group | 715 | 29.3 ± 11.6* | 3.0 ± 2.7* | 69.3 ± 11.9 | 35.1 ± 10.2 | 15.1 ± 8.3* |
| Control group | 100 | 24.7 ± 6.1 | 13.6 ± 3.9 | 69.6 ± 10.5 | 35.7 ± 7.3 | 17.0 ± 5.2 |
| P value | < 0.001 | < 0.001 | 0.798 | 0.578 | 0.026 |
| Gene with likely pathogenic variant | Steroid-resistant nephrotic syndrome (number of patients) | Haematuria/Alport syndrome (number of patients) | ||||
| Age group* | ≤18 years (n=209) | >18 years (n=46) | Total (n=255) | ≤18 years (n=20) | >18 years (n=15) | Total (n=35) |
| NPHS1 | 12 | 0 | 12 | 0 | 0 | 0 |
| WT1 | 9 | 2 | 11 | 0 | 0 | 0 |
| NPHS2 | 7 | 0 | 7 | 0 | 0 | 0 |
| LMX1B | 4 | 0 | 4 | 0 | 0 | 0 |
| INF2 | 0 | 3 | 3 | 0 | 0 | 0 |
| LAMB2 | 3 | 0 | 3 | 0 | 0 | 0 |
| MYH9 | 2 | 0 | 2 | 0 | 0 | 0 |
| PLCE1 | 2 | 0 | 2 | 0 | 0 | 0 |
| ACTN4 | 1 | 0 | 1 | 0 | 0 | 0 |
| SCARB2 | 0 | 1 | 1 | 0 | 0 | 0 |
| SMARCAL1 | 1 | 0 | 1 | 0 | 0 | 0 |
| TRPC6 | 0 | 1 | 1 | 0 | 0 | 0 |
| COL4A3 | 0 | 1 | 1 | 3 | 2 | 5 |
| COL4A4 | 1 | 1† | 2 | 0 | 2 | 2 |
| COL4A5 | 2 | 1 | 3 | 5 | 5 | 10 |
| Total | 44 | 10 | 54 | 8 | 9 | 17 |
| Predicted class | |||||
| Cluster 1 | Cluster 2 | Cluster 3 | Cluster 4 | ||
| Actual class | Cluster 1 | 199 | 49 | 1 | 25 |
| Cluster 2 | 5 | 441 | 2 | 0 | |
| Cluster 3 | 0 | 0 | 221 | 0 | |
| Cluster 4 | 0 | 0 | 0 | 312 |
| Extracted Plant | Extracted Part | IC50 (mg/mL) | Lead Substance | Content (μg/mg) | IC50 | |
| Arbutus unedo (strawberry tree) | fruit | n.d. 1 | arbutin | 20.0 ± 1.3 | n.d. 1 | n.d. 1 |
| Camellia sinensis (tea) | dried leaves | n.d. 1 | caffeine | 131.6 ± 5.0 | 0.9 ± 0.1 mg/mL | 4.8 ± 0.6 mM |
| Cynara scolymus (artichoke) | dried leaves | 0.9 ± 0.1 | 3,4-diCQA | 2.5 ± 0.5 | >500 μg/mL (49%) | >1.0 mM |
| luteolin | <0.08 | 11.8 ± 2.9 μg/mL | 41 ± 10 μM | |||
| luteolin-7-O-glucuronide | 2.7 ± 0.3 | n.d. 1 | n.d. 1 | |||
| luteolin-7-O-glucoside | 4.9 ± 1.0 | n.d. 1 | n.d. 1 | |||
| apigenin | <0.08 | n.d. 1 | n.d. 1 | |||
| Zingiber officinale (ginger) | dried rhizome | 1.7 ± 0.2 | [6]-gingerol | 10.0 ± 0.6 | >500 μg/mL (38%) | >1.7 mM |
| lipoid fraction (GLE) | ~50 | 455 ± 19 μg/mL | - | |||
| hydrophilic fraction (GWE) | ~950 | 10.5 ± 1.9 mg/mL | - |
| Control sheep (n = 18) | Disease-stressed sheep (n = 10) | Combined groups (n = 10 + 10) | |||
| Gene symbol | Stability value (M) | Gene symbol | Stability value (M) | Gene symbol | Stability value (M) |
| SDHA | 0.316 | YWHAZ | 0.624 | SDHA | 0.591 |
| YWHAZ | 0.342 | GAPDH | 0.634 | YWHAZ | 0.593 |
| HPRT | 0.344 | SDHA | 0.667 | ACTB | 0.596 |
| RPL19 | 0.361 | ACTB | 0.701 | G6PD | 0.666 |
| B2M | 0.362 | B2M | 0.720 | GAPDH | 0.681 |
| ACTB | 0.377 | G6PD | 0.740 | GYPC | 0.698 |
| GYPC | 0.412 | GYPC | 0.848 | RPL19 | 0.746 |
| TFRC | 0.455 | RPL19 | 1.000 | B2M | 0.760 |
| G6PD | 0.486 | HPRT | 1.188 | HPRT | 0.882 |
| PGK1 | 0.498 | PGK1 | 1.466 | TFRC | 1.158 |
| GAPDH | 0.579 | TFRC | 1.485 | PGK1 | 1.295 |
| Guideline | Source | |
| 1 | Use Dex/sal for MIF (unless documented why not) | NICE |
| 2 | Use fluid with 130–154mmol/l sodium for any resus | NICE |
| 3 | Receive 0.6-1.4mmol/Kg/day of maintenance sodium | NICE |
| 4 | Give <2.5L/day Dex/saline | NICE |
| 5 | Patients with Critical Care induced hypernatraemia | Local |
| Protein Cnt | ID Cnt | Ambiguity | |
| EPPI | 6,955 | 184,633 | 26.55 |
| EPPI species | 6,955 | 17,357 | 2.50 |
| TE | 8,539 | 103,016 | 12.06 |
| TE species | 8539 | 12,705 | 1.49 |
| Parameter | ITS | trnL-F | Combines |
| Number of accession | 49 | 49 | 49 |
| Range of sequence length (bp) | 642–643 | 799–801 | 1442–1443 |
| Characters of data matrix | 643 | 800 | 1443 |
| Number of constant sites (%) | 584 (90.82%) | 793 (99.13%) | 1377 (96.09%) |
| Number of parsimony-information sites (%) | 55 (8.55%) | 7 (0.88%) | 62 (4.32%) |
| Number of autopomorphic-information sites (%) | 4 (0.62%) | 0 (0.00%) | 4 (0.28%) |
| Consistency index (CI) | 0.892 | 0.969 | 0.891 |
| Retention index (RI) | 0.955 | 0.958 | 0.947 |
| Rescaled consistency index (RC) | 0.852 | 0.928 | 0.844 |
| Homoplasy index (HI) | 0.108 | 0.031 | 0.109 |
| Hormonal tests | Values (normal range) |
| Plasmatic cortisol | <39 nmol/L (126.8–656.5) |
| Plasmatic aldosterone | 14.2 pg/mL (18–232) |
| Plasmatic renin | 12.9 μmU/mL (4–50) |
| Plasmatic noradrenaline | 278.2 pg/mL (100–400 lying, 200–700 standing) |
| Plasmatic adrenaline | 15.4 pg/mL (<50 lying, <100 standing) |
| Plasmatic dopamine | Nondetectable (0–80) |
| Urinary normetanephrines | 289 μg/g creat (46–256) |
| Urinary metanephrines | 98.8 μg/g creat (27–155) |
| Urinary vanillylmandelic acid | 29.1 mg/24 H (1.8–6.7) |
| Urinary 5-hydroxyindoleacetic acid | 6.8 mg/24 H (0.7–8.2) |
| GO ID | Molecular Function | Observed Gene Count | FDR |
| GO.0004702 | receptor signaling protein serine/threonine kinase activity | 15 | 3.13E-21 |
| GO.0005515 | protein binding | 7 | 2.03E-05 |
| GO.0004708 | MAP kinase kinase activity | 41 | 2.41E-05 |
| GO.0017137 | Rab GTPase binding | 5 | 2.74E-05 |
| GO.0031489 | myosin V binding | 6 | 0.000307 |
| GO.0017022 | myosin binding | 4 | 0.000381 |
| GO.0004709 | MAP kinase kinase kinase activity | 5 | 0.000518 |
| GO.0005488 | binding | 4 | 0.00169 |
| GO.0017075 | syntaxin-1 binding | 59 | 0.00354 |
| GO.0004707 | MAP kinase activity | 3 | 0.00402 |
| GO.0004674 | protein serine/threonine kinase activity | 3 | 0.00636 |
| GO.0004946 | bombesin receptor activity | 9 | 0.0113 |
| GO.0005102 | receptor binding | 2 | 0.0128 |
| GO.0004908 | interleukin-1 receptor activity | 14 | 0.018 |
| GO.0019905 | syntaxin binding | 2 | 0.0215 |
| GO.0019899 | enzyme binding | 4 | 0.0253 |
| GO.0004871 | signal transducer activity | 15 | 0.032 |
| GO.0005179 | hormone activity | 16 | 0.0377 |
| GO.0060089 | molecular transducer activity | 4 | 0.0377 |
| GO.0086083 | cell adhesive protein binding involved in bundle of Hiscell-Purkinje myocyte communication | 17 | 0.0377 |
| Accession NO. | Strain name | Year | Province | Host | Length | Biological sample |
| KU641013 | LN1401 | 2014 | Liaoning | Chicken | 2298 bp | Liver |
| KU645511 | LN1402 | 2014 | Liaoning | Chicken | 2298 bp | Liver |
| KU645514 | HB1404 | 2014 | Hebei | Chicken | 2298 bp | Liver |
| KU645516 | HB1517 | 2015 | Hebei | Chicken | 2298 bp | Liver |
| KU645518 | JS1501 | 2015 | Jiangsu | Chicken | 2298 bp | Bone marrow |
| KU645508 | JS1502 | 2015 | Jiangsu | Chicken | 2298 bp | Bone marrow |
| KU645509 | JS1503 | 2015 | Jiangsu | Chicken | 2298 bp | Bone marrow |
| KU645520 | HN1405 | 2014 | Henan | Chicken | 2298 bp | Liver |
| KU645512 | HN1504 | 2015 | Henan | Chicken | 2298 bp | Liver |
| KU645517 | SD1513 | 2015 | Neimenggu | Chicken | 2298 bp | Bone marrow |
| KU645513 | BJ1406 | 2014 | Beijing | Chicken | 2298 bp | Bone marrow |
| KU641014 | JN1503 | 2015 | Shandong | Chicken | 2298 bp | Bone marrow |
| KU645523 | SD1505 | 2015 | Shandong | Chicken | 2298 bp | Liver |
| KU645507 | SD1507 | 2015 | Shandong | Chicken | 2298 bp | Liver |
| KU645519 | SD1508 | 2015 | Shandong | Chicken | 2298 bp | Bone marrow |
| KU645510 | SD1509 | 2015 | Shandong | Chicken | 2298 bp | Bone marrow |
| KU598851 | SD1510 | 2015 | Shandong | Chicken | 2298 bp | Bone marrow |
| KU641015 | SD1511 | 2015 | Shandong | Chicken | 2298 bp | Liver |
| KU645506 | SD1512 | 2015 | Shandong | Chicken | 2298 bp | Liver |
| KU645521 | SD1514 | 2015 | Shandong | Chicken | 2298 bp | Liver |
| KU645515 | SD1515 | 2015 | Shandong | Chicken | 2298 bp | Liver |
| KU645522 | SD1518 | 2015 | Shandong | Chicken | 2298 bp | Liver |
| KU645524 | CAV-Dog | 2015 | Shandong | Dog | 2298 bp | Feces |
| KU645525 | CAV-Mouse | 2015 | Shandong | Mouse | 2298 bp | Feces |
| No community sports participation | Community sports participation | |||
| No extracurricular school-based sports participation | Extracurricular school-based sports participation | No extracurricular school-based sports participation | Extracurricular school-based sports participation | |
| β (S.E.) | β (S.E.) | β (S.E.) | β (S.E.) | |
| Boys | 3.38 (0.10)a | 3.97 (0.07)b | 4.28 (0.09)c | 4.38 (0.04)c |
| Girls | 3.71 (0.08)a# | 3.74 (0.07)a# | 4.16 (0.07)b | 4.28 (0.05)b# |
| Country | Total number of notified TB cases | TB notification rate per 100 000 | Number of notified TB in foreigna | Percentage foreign |
| Bulgaria | 2649 | 35.0 | 2 | 0.1 |
| Estonia | 329 | 24.5 | 58 | 17.6 |
| Finland | 327 | 6.1 | 105 | 32.1 |
| Greece | 489 | 4.3 | 231 | 47.2 |
| Hungary | 1741 | 17.4 | 21 | 1.2 |
| Latvia | 934 | 41.5 | 62 | 6.6 |
| Lithuania | 1938 | 58.2 | 47 | 2.4 |
| Poland | 7509 | 19.7 | 46 | 0.6 |
| Romania | 21 078 | 98.2 | 38 | 0.2 |
| Slovakia | 439 | 8.1 | 8 | 1.8 |
| Total | 37 433 | 35.2 | 618 | 1.7 |
| Antibiotic | MIC (μg/ml) |
| Ampicillin | 9.8 |
| Nafcillin | 1.25 |
| Ciprofloxacin | 25 |
| Nalidixic acid | 312 |
| Chloramphenicol | 1.25 |
| Minocycline | 0.97 |
| Tetracycline | > 50 |
| Erythromycin | > 10 |
| Clindamycin | 5 |
| Kanamycin | 6 |
| Rifampin | 0.4 |
| Metronidazole | 0.5 |
| Vancomycin | 1.0 |
| Rat | Targeta | Angle (°)b | int. diam. (μm)c | Volume (nL)d | Survival (days)e |
| 18 | OC2L/ParP | 30 | 6.7 | 20 | 19 |
| 19 | ParP | 30 | 7.0 | 80 | 19 |
| 24 | S1 PMBSF | 45 | 7.1 | 5 | 18 |
| 25 | S1 PMBSF | 45 | 7.5 | 20 | 19 |
| 26 | S1 PMBSF | 45 | 7.1 | 20 | 18 |
| 27 | OC2L | 45 | 8.4 | 10 | 19 |
| 30 | OC2L | 45 | 7.2 | 10 | 18 |
| 31 | ParP | 30 | 9.2 | 20 | 19 |
| 33 | OC2M | 0 | 9.0 | 20 | 13 |
| 35 | S1 trunk | 0 | 8.4 | 20 | 15 |
| 36 | S1 trunk | 0 | 6.8 | 20 | 14 |
| 37 | MCx | 0 | 6.7 | 20 | 13 |
| 38 | MCx | 0 | 7.0 | 20 | 13 |
| 39 | S1 PMBSF | 45 | 7.0 | 20 | 12 |
| 41 | S1 DZ | 45 | 8.0 | 20 | 12 |
| 42 | S1 DZ | 45 | 8.3 | 20 | 11 |
| State | State Policy Extensiveness* | Geographic Area |
| California | High | West |
| Georgia | Middle | Southeast |
| Illinois | Middle/Low | Midwest |
| Massachusetts | Low | Northeast (township oriented) |
| New York | High | Northeast (not township oriented) |
| Texas | Middle | South Central |
| High worry (Group 1) N = 35 | GAD community (Group 2) N = 28 | GAD clients (Group 3) N = 32 | Panic clients (Group 4) N = 24 | F (3, 113) | Partial η2 | Post hoc p < .05 | |
| Attentional Control Questionnaire | 47.73 (8.12) | 48.60 (6.65) | 42.98 (7.62) | 46.02 (7.92) | 3.10* | .08 | 2 > 3 |
| Meta Cognitions Questionnaire | 69.32 (11.49) | 72.22 (12.18) | 78.73 (13.66) | 66.55 (17.26) | 4.42** | .11 | 3 > 1, 4 |
| Worry Domains Questionnaire | 21.43 (9.27) | 24.29 (6.70) | 27.31 (6.07) | 19.63 (8.87) | 5.11** | .12 | 3 > 1, 4 |
| Antigen | Clone | Supplier | Dilution | Antigen retrieval |
| PR | Mouse Monoclonal, 16 | Leica Microsystems | 1:100 | citrate |
| ER | Mouse Monoclonal, 6F11 | Leica Microsystems | 1:100 | citrate |
| Vim | Mouse monoclonal, V9 | Leica Microsystems | 1:400 | citrate |
| CEA | Mouse monoclonal, 12-140-10 | Leica Microsystems | 1:100 | trypsin |
| Unadjusted OR (95% CI) | Model 1 | Model 2 | Model 3 | |
| Adjusted OR (95% CI)* | Adjusted OR (95% CI)* | Adjusted OR (95% CI)* | ||
| All Years | 3.14 (2.74 to 3.60) | 1.89 (1.65 to 2.17) | 1.87 (1.62 to 2.17) | 1.87 (1.61 to 2.16) |
| 2004 only | 4.68 (3.07 to 7.13) | 2.91 (1.69 to 4.99) | 2.96 (1.74 to 5.02) | 2.95 (1.74 to 5.00) |
| 2005 only | 3.78 (2.45 to 5.84) | 2.91 (1.90 to 4.45) | 2.82 (1.73 to 4.59) | 2.82 (1.74 to 4.56) |
| 2006 only | 2.41 (1.82 to 3.19) | 1.84 (1.43 to 2.38) | 1.79 (1.35 to 2.37) | 1.77 (1.33 to 2.34) |
| 2007 only | 2.40 (1.91 to 3.01) | 1.80 (1.46 to 2.23) | 1.94 (1.59 to 2.36) | 1.93 (1.58 to 2.35) |
| 2008 only | 2.68 (2.15 to 3.35) | 1.95 (1.58 to 2.39) | 1.92 (1.53 to 2.41) | 1.92 (1.53 to 2.41) |
| 2009 only | 2.45 (1.93 to 3.11) | 1.70 (1.35 to 2.14) | 1.67 (1.26 to 2.20) | 1.67 (1.26 to 2.20) |
| Variables | Univentricular | Biventricular | P |
| PDA flow* (L/min/m2) | 1.70 (0.56 to 2.53) | 0.61 (−1.48 to 3.23) | 0.0147 |
| AAo flow (L/min/m2) | 0.56 (−0.19 to 1.08) | 1.82 (−0.16 to 2.92) | 0.0006 |
| Contribution of PDA to Qs (%) | 56.59 (39.77 to 100) | 24.14 (−87.16 to 100) | 0.0013 |
| LVEDVi (ml/m2) | 15.75 (11.8 to 30.3) | 27 (17.7 to 71.2) | 0.024 |
| AR ratio | 0.72 ± 0.14 (0.52 to 0.92) | 0.54 ± 0.17 (0.28 to 0.89) | 0.01 |
| Drug | Paw volume increase over time (ml ± SD) and effect (% of negative control) | |||||||
| 1 hr | 3 hr | 5 hr | 7 hr | |||||
| Saline | 0.63 ± 0.09 | 0.92 ± 0.14 | 0.84 ± 0.13 | 0.81 ± 0.14 | ||||
| Arnica D4 | 0.59 ± 0.15 | -7 | 0.90 ± 0.14 | -2 | 0.86 ± 0.15 | 3 | 0.74 ± 0.15 | -8 |
| Apis D4 | 0.57 ± 0.08 | -10 | 0.83 ± 0.14 | -10 | 0.80 ± 0.13 | -5 | 0.67 ± 0.12 | -17 |
| Atropa D4 | 0.61 ± 0.09 | -4 | 0.96 ± 0.09 | 4 | 0.81 ± 0.10 | -3 | 0.74 ± 0.15 | -9 |
| Hamamelis D4 | 0.62 ± 0.13 | -3 | 0.95 ± 0.15 | 3 | 0.87 ± 0.17 | 5 | 0.69 ± 0.12 | -15 |
| Lachesis D6 | 0.64 ± 0.16 | 1 | 0.86 ± 0.22 | -7 | 0.85 ± 0.20 | 2 | 0.81 ± 0.12 | 0 |
| Phosphorus D6 | 0.59 ± 0.09 | -8 | 0.94 ± 0.13 | 2 | 0.88 ± 0.16 | 6 | 0.74 ± 0.13 | -9 |
| Indomethacin i.m. | 0.54 ± 0.12 | -14 | 0.69 ± 0.12 | -25 | 0.63 ± 0.11 | -25 | 0.49 ± 0.05 | -40 |
| Condition | SMM and M, number (%) | Maternal deaths |
| Peritonitis | 58(30) | 16 |
| Hemorrhage | 45(18.7) | 10 |
| Hypertensive disease | 55(28.6) | 9 |
| Cancer | 5(1.5) | 4 |
| -pancreatic (1) | ||
| -breast cancer (2) | ||
| -leukemia (1) | ||
| Cardiomyopathy | 7(3.6) | 3 |
| Malaria | 6(3) | 2 |
| Pulmonary Embolism | 2 (2.2) | 0 |
| Pulmonary Disease | 1 (1.1) | 1 |
| Diabetes | 2(2.2) | |
| -severe hypoglycemia, | ||
| -diabetic coma | ||
| Hepatic Disease | 2(2.2) | 0 |
| -cirrhosis | ||
| -hepatic abscess | ||
| Neurologic | 2(2.2) | |
| -stroke postpartum | ||
| -coma of unknown etiology) | ||
| Anesthetic complications | 2(2.2) | |
| Epilepsy | 1 (1.1) | 0 |
| Other* | 7(3.6) | 5 |
| Total number of patients experiencing severe maternal morbidity + mortalitya | 192 | 50 |
| Source | 1 | 2 | 3 | 4 | |||||||
| Farm | A | B | D | E | C | F | G | ||||
| Health status | SPF | SPF | Non-SPF | SPF | Non-SPF | Non-SPF | |||||
| Generation | G1 | G2 | GX | G1 | G2 | G2 | GX | G1 | G2 | GX | GX |
| No. pigs: | |||||||||||
| Performance | 47 | 684 | 373 | 92 | 259 | 148 | 300 | 94 | 398 | 72 | 175 |
| Immune traits | 47 | 0 | 373 | 92 | 68 | 59 | 300 | 94 | 0 | 72 | 175 |
| APP | 0 | 0 | 373 | 0 | 0 | 0 | 300 | 0 | 0 | 72 | 175 |
| No. groups: | |||||||||||
| Sires | 21 | 42 | 27 | 23 | 5 2,3 | 5 2,3 | 17 | 10 | 52 | 11 | 55 |
| Full-sib families | 33 | 155 | 200 | 53 | 53 | 53 | 121 | 19 | 53 | 18 | 72 |
| Genetic lines | 8 | 4 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 8 | 13 |
| Breed | LW | LW | LW | LW | LW | LW | LW | LW | LW | LR | LW |
| Variables | At the time of enrollment | Follow-up | |||||||||
| Cluster 1 | Cluster 2 | Cluster 3 | Cluster 4 | P value | Cluster 1 | Cluster 2 | Cluster 3 | Cluster 4 | P value | ||
| Total serum IgE levels (IU/mL) | mean (N) | 746.8 (51) | 306.1 (40) | 1238.0 (28) | 175.0 (111) | <0.001 | 378.9 (35) | 148.7 (22) | 447.7 (17) | 77.2 (68) | <0.001 |
| 95% CI | 519.3–974.3 | 125.4–486.9 | 738.0–1738.0 | 87.7–262.6 | 296.8–460.9 | 86.0–211.4 | 268.3–627.1 | 45.0–109.5 | |||
| Blood eosinophil, % | mean (N) | 5.7 (51) | 5.3 (40) | 6.2 (29) | 3.6 (112) | <0.001 | 4.4 (35) | 3.8 (22) | 5.4 (17) | 3.1 (69) | 0.002 |
| 95% CI | 4.6–6.8 | 4.1–6.5 | 4.9–7.6 | 2.8–4.3 | 3.5–5.3 | 2.5–5.1 | 3.8–7.0 | 2.7–3.6 |
| Variable | Group at the beginning of treatment | Group at the definitive brace removal | ||
| Gender | Girls | 87 (97%) | Girls | 87 (97%) |
| Boys | 3 (3%) | Boys | 3 (3%) | |
| Mean age | Girls | 13 years | Girls | 15 years 10 months |
| Boys | 13 years 4 months | Boys | 15 years 8 months | |
| Curvative type | Double-major | 67 (74.4%) | Double-major | 67 (77.0%) |
| Lumbar | 3 (3.3%) | Lumbar | - | |
| Thoracic | 7 (7.8%) | Thoracic | 7 (8.0%) | |
| Thoraco- lumbar | 13 (14.4%) | Thoraco-lumbar | 13 (14.9%) | |
| Cobb angle | Double-major | 20.9° 20,0° | Double-major | 20.6° 16.9° |
| Thoracic | 20.3° | Thoracic | 17.3° | |
| Thoraco- lumbar | 24.1° | Thoraco- lumbar | 21.5° | |
| SkeletalMaturity | Risser 0 | 33 (36.7%) | Achieved | |
| Risser 1 | 15 (16.7%) | |||
| Risser 2 | 21 (23.3%) | |||
| Risser 3 | 14 (15.6%) | |||
| Risser 4 | 7 (7.8%) | |||
| Theoretical VC | Girls | 3.2 litres | Girls | 3.6 litres |
| Boys | 4.1 litres | Boys | 4.5 litres | |
| FVC | Girls | 2.3 litres | Girls | 2.7 litres |
| Boys | 2.9 litres | Boys | 4 litres |
| Total N = 456 n (%) | RV + N = 201 n (%) | RV – N = 253 n (%) | p-value | ||
| Gender | Male | 236 (51.9) | 95 (47.3) | 140 (55.6) | 0.079 |
| Female | 219 (48.1) | 106 (52.7) | 112 (44.4) | ||
| Age-groups (3-groups) | 0–12 | 166 (36.4) | 79 (39.3) | 87 (34.4) | 0.063 |
| 12–24 | 184 (40.4) | 86 (42.8) | 97 (38.3) | ||
| 24–36 | 106 (23.2) | 36 (17.9) | 69 (27.3) | ||
| Age-groups (5-groups) | 0–2 | 10 (2.2) | 4 (2.0) | 6 (2.4) | 0.028 |
| 2–6 | 42 (9.2) | 14 (7.0) | 28 (11.1) | ||
| 6–12 | 114 (25.0) | 61 (30.3) | 53 (20.9) | ||
| 12–24 | 184 (40.4) | 86 (42.8) | 97 (38.3) | ||
| 24–36 | 106 (23.2) | 36 (17.9) | 69 (27.3) | ||
| RV vaccination | Complete | 109 (24.5) | 20 (10.0) | 89 (36.6) | 0.001 |
| Partial | 15 (3.4) | 2 (1.0) | 13 (5.3) | ||
| None | 321 (72.1) | 179 (89.1) | 141 (58.0) | ||
| Breastfeeding | Yes | 376 (83.0) | 171 (85.9) | 204 (80.6) | 0.137 |
| Continue with breastfeeding | Yes | 51 (13.6) | 30 (17.5) | 21 (10.3) | 0.041 |
| Number of previous episodes of AGE | 1 | 80 (52.3) | 41 (67.2) | 39 (42.9) | 0.045 |
| 2 | 42 (27.5) | 13 (21.3) | 29 (27.5) | ||
| 3 | 18 (11.8) | 5 (8.2) | 13 (11.8) | ||
| >3 | 13a (8.5) | 2 (3.2) | 10 (11.0) | ||
| Previous hospitalizations for AGE | Yes | 9 (2.0) | 3 (1.5) | 6 (2.4) | 0.737 |
| Attendance at day care center (currently) | Yes | 210 (46.6) | 80 (40.2) | 128 (51.2) | 0.020 |
| Characteristics | Metabolically Normal Obesity n = 114 (%) | Metabolically Abnormal Obesity n = 36 (%) | p-value | p* |
| Age (years, median, range) | 8,85 (5,92–11,10) | 11,12 (9,93–13,36) | < 0,001 | |
| Sex | 0.09 | |||
| Boys | 63 (55) | 14 (39) | ||
| Girls | 51(45) | 22 (61) | ||
| Birth weight (Kg, median, range) | 3.310 (3.020–3.560) | 3.175 (2.940–3.580) | 0.5 | |
| Comorbidity | 0.9 | |||
| No | 104 (91) | 33 (92) | ||
| Yes | 10 (9) | 3 (8) | ||
| Mother’s obesity (n = 123) | 0.003 | 0,02 | ||
| Nonobese (BMI < 25 Kg/m2) | 19 (20) | 1 (4) | ||
| Overweight (25 < BMI < 30 Kg/m2) | 32 (34) | 4 (14) | ||
| Obese (BMI?30/Kg/m2) | 44 (46) | 23 (82) | ||
| Father’s obesity (n = 68) | 0.6 | |||
| Nonobese (BMI < 25 Kg/m2) | 10 (18) | 3 (25) | ||
| Overweight (25 < BMI < 30 Kg/m2) | 21 (38) | 4 (33) | ||
| Obese (BMI?30 /Kg/m2) | 25 (45) | 5 (42) | ||
| Term pregnancy (n = 123) | ||||
| Full-term birth | 91 (97) | 28 (97 | 0.9 | |
| Premature birth | 3 (3) | 1 (3) | ||
| Feeding (n = 129) | 0.1 | |||
| Breastfeeding | 25 (26) | 4 (13) | ||
| Formula or mixed | 73 (74) | 27 (87) | ||
| BMI (Z-score, median, range) | 4,42[3,94–5,28] | 4,9[4,05–5,38] | < 0,001 | |
| Overweight or obesity | ||||
| Overweight | 6 (5) | 0 (0) | 0.6 | |
| Obesity | 108 (95) | 36 (100) | ||
| Systolic blood pressure (mmHg, median, range) | 111 (106–121) | 133.5 (123.5–138.5) | 0.001 | |
| Diastolic blood pressure (mmHg, median, range) | 70 (66–77) | 79.5 (72.5–84.5) | 0.06 | |
| Waist circumference (cm, median, range) | 85 (78–96) | 103 (94–109) | < 0.001 | < 0.001 |
| Waist-to-height ratio | 0.62 [0.58–0.67] | 0.66 [0.61–0.69] | 0.3 |
| Setting | Level | Type of participants | Type of interviews | Number of interviews |
| MoH | Principal | Policy makers | Key informant | 3 |
| HSB | Principal | Policy makers | Key informant | 2 |
| ZACH | Principal | Policy makers | Key informant | 1 |
| MEPMO | Principal | Policy makers | Key informant | 1 |
| ELB/local clinics | Local/agent | Policy makers | Key informant | 3 |
| Local clinics | Local/agent | Sisters in charge/personnel managers | In-depth | 7 |
| Local clinics | Local/agent | Healthcare workers | Sample | 19 |
| Community | Local/agent | Community members | Focus group discussions (10 people each) | 5 |
| SLE | HD | |
| Number of cases | 103 | 65 |
| Number of visits (2 or more) | 180 (60) | 65 (0) |
| Mean age, years (range) | 44 (25–68) | 33 (19–59) |
| Sex, female/male/unknown, n | 90/13/0 | 31/9/24 |
| Race, AA/EA/LA/AsA/IrA/unknown1, n | 35/50/12/3/3/0 | 10/18/6/3/2/25 |
| Race by visit (AA/EA/LA/AsA/IrA/unknown)1, n | 64/86/20/7/3/0 | 10/18/6/3/2/25 |
| Active/inactive by SLEDAI, number of patients | 49/131 | N/A |
| Main clinical features, number of patients | ||
| Malar rash | 9/94 | N/A |
| Discoid lesions | 2/101 | N/A |
| Photosensitivity | 8/95 | N/A |
| Oral ulcers | 7/96 | N/A |
| Arthritis | 17/86 | N/A |
| Serositis | 4/99 | N/A |
| Pleuritis | 5/98 | N/A |
| Nephritis | 49/54 | N/A |
| Seizures | 2/101 | N/A |
| Psychosis | 1/102 | N/A |
| Wildtype | Mahidolheterozygote | Chinese-4heterozygote | Kaipingheterozygote | Mahidolhomozygote | Mahidol-Canton | Total | Overall allelicfrequency ofall variants | Allelic frequencyof Mahidol variant | |
| Sgaw Karen | 91 | 47 | 1 | 1 | 7 | 0 | 147 | 21.4% | 20.7% |
| Poe Karen | 34 | 12 | 0 | 1 | 4 | 0 | 51 | 20.6% | 19.6% |
| Burman | 67 | 9 | 1 | 2 | 0 | 1 | 80 | 8.8% | 6.3% |
| “Muslim” | 11 | 0 | 0 | 0 | 0 | 0 | 11 | 0.0% | 0.0% |
| Other | 6 | 1 | 0 | 0 | 0 | 0 | 7 | 7.1% | 7.1% |
| “Mixed” | 16 | 5 | 0 | 0 | 0 | 0 | 21 | 11.9% | 11.9% |
| Total | 225 | 74 | 2 | 4 | 11 | 1 | 317 | 16.3% | 15.3% |
| Therapeutic modalities | Frequency (%) |
| Concomitant radio-chemotherapy | 66 (43.7) |
| Concomitant radio chemotherapy followed by surgery | 22 (14.9) |
| Exclusive radiotherapy | 12 (7.9) |
| Surgery followed by exclusive radiotherapy | 25 (16.6) |
| Surgery followed by concomitant radio chemotherapy | 21 (13.9) |
| Surgery alone | 4 (2.6) |
| Palliative chemotherapy | 1 (0.7) |
| Description | Notation | Baseline value | Reference |
| Population size | N | 100,000 | assumed |
| Average life expectancy at birth | 1/μ | 69.4 (years) | [1] |
| Transmission coefficient of obesity | β | 2.96 × 10-7 (per year) | [12] |
| Non-contagious hazard of obesity | ε | 0.012 (per year) | [13] |
| Relative hazard of obesity among ex-obese | σ | 8.0 | [12] |
| Average duration of obesity | 1/γ | 35.8 (years) | [13] |
| Curative or not | N | Mean | Std. deviation | Std. error mean | |
| Group statistics | |||||
| Total HNA score | Curative | 3671 | 26.08 | 34.312 | .566 |
| Not curative | 1293 | 41.13 | 41.040 | 1.141 | |
| Number of problems | Curative | 3675 | 5.86 | 5.460 | .090 |
| Not curative | 1297 | 7.64 | 6.576 | .183 | |
| Minutes and seconds for HNA completion | Curative | 3675 | 6 min 56 s | 5 min 53 s | 6 s |
| Not curative | 1297 | 8 min 36 s | 7 min 5 s | 11 s |
| Sample | Litter Concentrations | Application Rates | Analyst | ||
| Fe | As | Fe | As | ||
| Litter from 2012 | 2200 ± 252 | 2.5 ± 3.0 | 7.41 | 0.009 | This study |
| Litter from 2014 | 1106 ± 89 | 5.2 ± 0.4 | 3.73 | 0.013 | This study |
| TGCT | HD | NHL | L | S | BT | Behcet | MS | |
| n | 2315 | 1175 | 439 | 360 | 208 | 40 | 68 | 73 |
| Age (year, median) | 28.8 | 26 | 28.8 | 27.5 | 23.1 | 28.2 | 29.7 | 30.3 |
| % ≤ 20 year-old | 7.1 | 19.1 | 15.7 | 20.6 | 35.6 | 25 | 5.9 | 5.5 |
| % Childless | 53 | 61.3 | 54.1 | 54.1 | 75.4 | 72.5 | 39.7 | 24.7 |
| Time between onset of symptoms and care at CAMH clinic | n (%) |
| Within a week | 29 (17.5) |
| More than a week but less than a month | 7 (4.2) |
| 1–6 months | 50 (30.1) |
| 7–12 months | 22 (13.2) |
| 13–24 months | 24 (14.5) |
| 25–36 months | 14 (8.4) |
| 37–48 months | 8 (4.8) |
| 49 months/more | 12 (7.2) |
| Characteristics | N (%) |
| Sex | |
| Male | 1087 (53.9%) |
| Female | 931 (46.1%) |
| Age (years) | |
| <3 | 65 (3.2%) |
| 3 to <4 | 294 (14.6%) |
| 4 to <5 | 604 (29.9%) |
| 5 to <6 | 670 (33.2%) |
| ≥6 | 385 (19.1%) |
| Residence | |
| Outlander | 765 (37.9%) |
| Native | 1253 (62.1%) |
| Town | |
| Fengjiang | 1264 (62.6%) |
| Pengjie | 754 (37.4%) |
| Father's education | |
| Primary school | 585 (29.0%) |
| Middle and high school | 1335 (66.2%) |
| College or higher | 98 (4.9%) |
| Father's occupation | |
| Lead-related | 1033 (51.2%) |
| Not lead-related | 985 (48.8%) |
| Mother's education | |
| Primary school | 709 (35.1%) |
| Middle and high school | 1197 (59.3%) |
| College or higher | 112 (5.6%) |
| Mother's occupation | |
| Lead-related | 926 (45.9%) |
| Not lead-related | 1092 (54.1%) |
| Cares' education | |
| Primary school | 877 (43.5%) |
| Middle and high school | 1055 (52.3%) |
| College or higher | 86 (4.3%) |
| Yearly household income (RMB) | |
| <10000 | 679 (33.7%) |
| 10000–15000 | 977 (48.4%) |
| >15000 | 362 (17.9%) |
| Item | Concentrate mix (%) | Rye straw (%) | BF-based silage2) (%) |
| Dry matter | 87.9 | 90.0 | 58.3 |
| Organic matter | 91.7 | 95.4 | 88.5 |
| Crude protein | 16.4 | 4.2 | 16.9 |
| Ether extract | 2.5 | 0.2 | 3.9 |
| Neutral detergent fiber | 32.7 | 67.7 | 50.6 |
| Acid detergent fiber | 19.5 | 41.7 | 38.9 |
| Hemicellulose | 13.2 | 25.9 | 11.7 |
| Crude fiber | 11.3 | 37.8 | 31.2 |
| Nitrogen free extracts | 61.5 | 53.3 | 36.6 |
| Crude ash | 8.3 | 4.6 | 11.5 |
| Township | Population Density | Population | Area Percentage of TRs > 10−5 | Area Percentage of TRs > 10−4 | ||||||
| (Person/km2) | (Person) | F1 | F2 | F3 | F4 | F1 | F2 | F3 | F4 | |
| Pingtong | 3133.17 | 203,866 | 100.0% | 87.4% | 100.0% | 100.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Linyuan | 2182.87 | 70,476 | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 34.0% | 42.6% | 0.0% |
| Donggang | 1638.03 | 48,262 | 100.0% | 100.0% | 100.0% | 100.0% | 13.6% | 93.2% | 100.0% | 0.0% |
| Daliao | 1565.19 | 111,191 | 85.7% | 85.7% | 85.7% | 85.7% | 34.7% | 0.0% | 0.0% | 0.0% |
| Chaozhou | 1289.98 | 54,738 | 100.0% | 71.7% | 30.0% | 20.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Linbian | 1231.17 | 19,235 | 100.0% | 100.0% | 100.0% | 100.0% | 55.2% | 89.7% | 96.6% | 0.0% |
| Sinyuan | 957.74 | 36,692 | 100.0% | 100.0% | 100.0% | 100.0% | 65.2% | 30.3% | 54.6% | 0.0% |
| Wandan | 906.33 | 52,085 | 100.0% | 100.0% | 96.6% | 100.0% | 5.7% | 0.0% | 0.0% | 0.0% |
| Changzih | 762.90 | 30,429 | 53.7% | 43.3% | 94.0% | 70.2% | 0.0% | 0.0% | 0.0% | 0.0% |
| Linluo | 695.76 | 11,313 | 100.0% | 42.3% | 100.0% | 100.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Neipu | 685.94 | 56,148 | 56.8% | 45.5% | 92.1% | 23.9% | 0.0% | 0.0% | 0.0% | 0.0% |
| Jiadong | 653.46 | 20,247 | 100.0% | 100.0% | 100.0% | 100.0% | 62.5% | 35.4% | 39.6% | 0.0% |
| Dashu | 644.81 | 43,190 | 98.2% | 40.0% | 96.4% | 100.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Zhutian | 609.46 | 17,719 | 100.0% | 92.3% | 57.7% | 82.7% | 0.0% | 0.0% | 0.0% | 0.0% |
| Nanzhou | 581.23 | 11,026 | 100.0% | 100.0% | 100.0% | 100.0% | 3.0% | 48.5% | 72.7% | 0.0% |
| Jiouru | 527.67 | 22,172 | 83.1% | 49.4% | 71.4% | 84.4% | 0.0% | 0.0% | 0.0% | 0.0% |
| Kanding | 523.70 | 16,374 | 97.6% | 97.6% | 90.5% | 90.5% | 7.1% | 7.1% | 33.3% | 0.0% |
| Fangliao | 441.36 | 25,482 | 98.7% | 75.3% | 98.7% | 98.7% | 42.9% | 0.0% | 0.0% | 14.3% |
| Yanpu | 413.82 | 26,629 | 27.9% | 87.3% | 26.6% | 30.4% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cishan | 402.70 | 38,100 | 30.7% | 59.1% | 1.1% | 11.4% | 0.0% | 0.0% | 0.0% | 0.0% |
| Ligang | 389.06 | 26,814 | 52.1% | 18.8% | 7.3% | 26.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Wanluan | 344.43 | 20,918 | 55.7% | 88.6% | 67.1% | 2.9% | 0.0% | 0.0% | 0.0% | 0.0% |
| Meinong | 343.73 | 41,258 | 60.7% | 77.4% | 64.3% | 29.8% | 0.0% | 0.0% | 0.0% | 0.0% |
| Gaoshu | 283.08 | 25,520 | 5.5% | 75.2% | 61.5% | 71.6% | 0.0% | 0.0% | 0.0% | 0.0% |
| Xinpi | 173.39 | 10,232 | 98.8% | 41.2% | 83.5% | 81.2% | 0.0% | 0.0% | 2.4% | 0.0% |
| Average | 855.23 | 41,604.64 | 80.21% | 75.12% | 76.98% | 72.38% | 15.60% | 13.53% | 17.67% | 0.57% |
| Linkage group | Length (cM) | Number of markers | Number of bins | Largest gap (cM) | Mean gap size (cM) |
| LG1 | 479.62 | 999 | 196 | 16.70 | 2.46 |
| LG2 | 475.13 | 1032 | 242 | 17.87 | 1.97 |
| LG3 | 422.07 | 883 | 194 | 9.46 | 2.19 |
| LG4 | 378.83 | 952 | 188 | 13.59 | 2.03 |
| LG5 | 373.16 | 765 | 166 | 14.89 | 2.26 |
| LG6 | 369.61 | 882 | 176 | 15.41 | 2.11 |
| LG7 | 346.04 | 768 | 151 | 16.73 | 2.31 |
| LG8 | 295.54 | 599 | 132 | 14.47 | 2.26 |
| LG9 | 291.43 | 725 | 135 | 14.55 | 2.17 |
| LG10 | 270.71 | 655 | 114 | 16.40 | 2.40 |
| LG11 | 257.19 | 554 | 114 | 13.72 | 2.28 |
| LG12 | 252.32 | 520 | 126 | 13.29 | 2.02 |
| LG13 | 238.96 | 678 | 125 | 15.32 | 1.93 |
| LG14 | 229.81 | 457 | 99 | 11.53 | 2.35 |
| LG15 | 227.36 | 659 | 122 | 11.09 | 1.88 |
| LG16 | 176.71 | 400 | 83 | 14.44 | 2.16 |
| LG17 | 159.37 | 293 | 78 | 16.55 | 2.07 |
| LG18 | 130.74 | 265 | 63 | 7.99 | 2.11 |
| LG19 | 111.63 | 276 | 52 | 11.50 | 2.19 |
| LG20 | 100.27 | 273 | 53 | 14.37 | 1.93 |
| LG21 | 63.56 | 199 | 31 | 12.62 | 2.12 |
| LG22 | 60.07 | 123 | 24 | 10.00 | 2.61 |
| LG23 | 48.62 | 113 | 27 | 4.30 | 1.87 |
| LG24 | 38.49 | 94 | 16 | 8.79 | 2.57 |
| LG25 | 26.81 | 85 | 22 | 5.08 | 1.28 |
| LG26 | 20.17 | 91 | 15 | 4.03 | 1.44 |
| LG27 | 15.99 | 72 | 12 | 4.03 | 1.45 |
| TOTAL | 5860.21 | 13,412 | 2756 |
| Collection time | Pollen viability (%) | |||
| A | G | M | Q | |
| 05:00–06:00 | 20.2 ± 1.1a | 16.2 ± 1.2a | 11.9 ± 2.1a | 15.5 ±1.6a |
| 06:00–07:00 | 15.9 ± 0.5b | 11.4 ± 0.8b | 6.7 ± 0.9b | 9.1 ± 1.0b |
| 07:00–08:00 | 10.3 ± 0.9c | 7.3 ± 0.6c | 4.1 ± 0.3c | 4.8 ± 0.6c |
| Training Standards in Implant Dentistry, 2016 | |
| 1 | Basic sciences: surgical anatomy, pathological process, bone defects, healing processes |
| 2 | Implant science: design and materials, limitations |
| 3 | Patient assessment and medical considerations |
| 4 | Case assessment and treatment planning: straightforward and complex cases |
| 5 | Radiographic assessment and Ionising Radiation Medical Exposure Regulations (IRMER) |
| 6 | Communication and informed consent |
| 7 | Infection control and asepsis |
| 8 | Soft tissue management (raising flaps and suturing) |
| 9 | Hard tissue management (autogenous bone augmentation, guided bone regeneration) |
| 10 | Pharmacological management |
| 11 | Surgical techniques for implant placement procedures |
| 12 | Implant-supported restorative procedures |
| 13 | Complications and their management |
| 14 | Long-term monitoring of implants |
| 15 | Record-keeping, documentation and quality assurance |
| All (n = 91) | CAD groups | p-Value | ||
| CAD (n = 46) | Non-CAD (n = 45) | |||
| Age (years) | 79 ± 9 | 79 ± 7 | 78 ± 7 | 0.283 |
| Male gender, n (%) | 47 (52) | 32 (67) | 15 (33) | 0.001 |
| STS-PROM score | 6 ± 5 | 7 ± 5 | 6 ± 5 | 0.559 |
| EuroScore 2 | 7 ± 5 | 9 ± 4 | 5 ± 4 | 0.004 |
| Hypertension, n (%) | 71 (78) | 41 (89) | 30 (67) | 0.010 |
| Dyslipidemia, n (%) | 59 (65) | 35 (76) | 24 (53) | 0.023 |
| Diabetes, n (%) | 35 (38) | 19 (41) | 16 (36) | 0.573 |
| Class III or IV NYHA, n (%) | 61 (67) | 30 (65) | 31 (69) | 0.710 |
| Prior PCI, n (%) | 8 (9) | 8 (17) | ||
| Prior CABG, n (%) | 16 (19) | 16 (35) | ||
| CVD, n (%) | 21 (23) | 13 (28) | 8 (18) | 0.235 |
| PAD, n (%) | 35 (17) | 21 (46) | 14 (31) | 0.154 |
| COPD, n (%) | 39 (43) | 17 (37) | 22 (49) | 0.250 |
| GFR (mL/min/m2) | 58 ± 28 | 50 ± 19 | 64 ± 33 | 0.012 |
| Renal dysfunction, n (%) | 60 (66) | 37 (82) | 23 (50) | 0.008 |
| AF, n (%) | 29 (32) | 15 (33) | 14 (31) | 0.878 |
| Permanent pacemaker, n (%) | 7 (8) | 3 (7) | 4 (9) | 0.672 |
| Echocardiografic evaluation | ||||
| AVA, cm2 | 0.6 ± 0.1 | 0.6 ± 0.2 | 0.6 ± 0.1 | 0.850 |
| Mean AV gradient (mmHg) | 51 ± 13 | 50 ± 13 | 52 ± 13 | 0.505 |
| LVEF (%) | 50 ± 10 | 47 ± 10 | 53 ± 9 | 0.006 |
| LV dysfunctiona, n (%) | 30 (33) | 21 (46) | 9 (20) | 0.0210 |
| Moderate or severe MR, n (%) | 5 (7) | 1 (2) | 4 (9) | 0.125 |
| Procedure features | ||||
| Transarterial access, n (%) | 87 (96) | 44 (96) | 43 (96) | 0.982 |
| Transapical access, n (%) | 4 (4) | 2 (4) | 2 (4) | 0.999 |
| Medtronic/coreValve, n (%) | 79 (87) | 38 (83) | 41 (91) | 0.231 |
| Edwards SAPIEN, n (%) | 12 (13) | 8 (17) | 4 (9) | 0.072 |
| Controls (n = 50) | Patients (n = 150) | p | |
| Age years | 52.94 ± 9.87 | 54.72 ± 3.46 | >0.05 |
| Min–max | (28–70) | (28–73) | |
| Gender (M/F) | (22/28) | (55/95) | |
| Total M2BP (ng/mL) | 14.97 ± 3.46 | 176.65 ± 22.14 | <0.001 |
| Min–max | (10–21.3) | (40.2–192.5) | |
| Percentile 50 median | 182.400 | ||
| CEA (ng/mL) | 4.26 ± 1.37 | ||
| Min–max | (2–5) | ||
| Percentile 50 median | 4.800 |
| Default setting n=25,πi=0.5i | n=50,πi=0.5i | n=75,πi=0.5i | πi=0.25i, n=50 | πi=3i, n=50 |
| 0.41 | 0.41 | 0.41 | 0.41 | 0.42 |
| Default setting α=10−5 | α=10−2 | α=10−3 | α=10−4 | α=10−6 |
| 0.41 | 0.37 | 0.40 | 0.41 | 0.42 |
| Default setting g4=2.0 | g4=0.0 | g4=1.0 | g4=5.0 | g4=10.0 |
| 0.41 | 0.39 | 0.41 | 0.41 | 0.41 |
| Default setting r=25.0 | r=0.0 | r=1.0 | r=15.0 | g=35.0 |
| 0.41 | 0.36 | 0.38 | 0.41 | 0.41 |
| Default setting a=25.0 | a=0.0 | a=50.0 | a=75.0 | a=100.0 |
| 0.41 | 0.40 | 0.41 | 0.41 | 0.41 |
| Cal. Time | mu-prob | mu-prob = 0.2 | mu-prob = 0.1 | mu-prob = 0.01 | |
| Psize | |||||
| psize = 50 | 2.81 | 2.76 | 2.60 | ||
| psize = 100 | 2.72 | 2.86 | 2.45 | ||
| psize = 200 | 2.54 | 2.65 | 2.33 | ||
| psize = 500 | 2.63 | 2.83 | 2.58 |
| PPV (%) | Sensitivity (%) | ||
| Jitterbug | raw | 37.16 | 89.72 |
| filtered | 92.7 | 85.05 | |
| RetroSeq | extended +/- 100 bp and merged | 61.01 | 90.26 |
| extended, merged and filtered | 87.31 | 88.21 |
| SalB (μg/mL) | Re (μg/mL) | SalB:Re | 1:2 | ||
| Dose | Effect | Dose | Effect | Dose | Effect |
| 10 | 0.3399475 | 20 | 0.34045 | 10 | 0.6768475 |
| 20 | 0.455375 | 40 | 0.456825 | 20 | 0.743375 |
| 30 | 0.5746225 | 60 | 0.5885125 | 30 | 0.8105175 |
| 40 | 0.6177875 | 80 | 0.650175 | 40 | 0.89841 |
| 50 | 0.66165175 | 100 | 0.70795 | 50 | 0.929985 |
| 60 | 0.7272075 | 120 | 0.78258 | 60 | 0.983965 |
| eMayo | UCEIS | panMayo | ||||
| Spearman coefficient (R) | p | Spearman coefficient (R) | p | Spearman coefficient (R) | p | |
| Disease extension | −0,04 | 0,687 | −0,078 | 0,429 | 0,339 | <0.001 |
| partial Mayo Score | 0,714 | <0.001 | 0,714 | <0.001 | 0,692 | <0.001 |
| CRP | 0,306 | 0,004 | 0,481 | <0.001 | 0,481 | <0.001 |
| Leukocytes | 0,283 | 0,007 | 0,276 | 0,009 | 0,278 | 0,009 |
| Haematocrit | −0,237 | 0,025 | −0,3 | 0,004 | −0,3 | 0,004 |
| Haemoglobin | −0,238 | 0,024 | −0,337 | 0,001 | −0,337 | 0,001 |
| Thrombocytes | 0,175 | 0,102 | 0,307 | 0,003 | 0,307 | 0,003 |
| Serum Iron | −0,352 | 0,001 | −0,499 | <0.001 | −0,499 | <0.001 |
| Riley Score | 0,724 | <0.001 | 0,691 | <0.001 | 0,691 | <0.001 |
| Calprotectin | 0,399 | 0,019 | 0,349 | 0,043 | 0,349 | 0,043 |
| MMP-9 | 0,505 | <0.001 | 0,554 | <0.001 | 0,554 | <0.001 |
| Time (min.) | Regression Equations | Correlation Coefficient |
| 2 | A= -0.029 + 7.7 × 10-3C | r=0.9670 |
| 4 | A= -0.022 + 0.012C | r=0.9870 |
| 6 | A=-0.029 + 0.016C | r=0.9950 |
| 8 | A= -0.025 + 0.019C | r=0.9950 |
| 10 | A= -0.012 + 0.021C | r=0.9970 |
| 12 | A= -0.018 + 0.024C | r=0.9997 |
| 14 | A= -0.024 +0.027C | r=0.9999 |
| 15 | A= -0.023 + 0.026C | r=0.9999 |
| n | % | Mean (SD) | |
| Overall satisfactiona | 4.2 (0.77) | ||
| Not at all | 93 | 0.9 | - |
| To a small extent | 170 | 1.7 | - |
| To some extent | 955 | 9.5 | - |
| To a large extent | 4797 | 48.0 | - |
| To a very large extent | 3987 | 39.9 | - |
| Benefit of treatmenta | 4.0 (0.92) | ||
| No benefit | 189 | 1.9 | - |
| Little benefit | 424 | 4.3 | - |
| Some benefit | 1861 | 18.8 | - |
| Large benefit | 4368 | 44.1 | - |
| Very large benefit | 3064 | 30.9 | - |
| Malpracticea | 4.6 (0.86) | ||
| To a very large extent | 182 | 1.8 | - |
| To a large extent | 235 | 2.3 | - |
| To some extent | 653 | 6.4 | - |
| To a small extent | 1018 | 10.0 | - |
| Not at all | 8051 | 79.4 | - |
| Patient-reported experiencesb | |||
| Waiting time (elective patients) | 4535 | - | 64.0 (28.8) |
| Doctor services | 10,153 | - | 73.7 (19.0) |
| Nursing services | 10,245 | - | 75.4 (17.4) |
| Information | 10,124 | - | 71.0 (21.0) |
| Contact with next of kin | 7138 | - | 77.7 (20.8) |
| Standard | 10,199 | - | 72.6 (17.2) |
| Organization | 10,034 | - | 68.0 (20.2) |
| Discharge information | 8114 | - | 58.3 (31.3) |
| Cooperation with other health services | 6071 | - | 63.8 (29.8) |
| Sociodemographic variables | |||
| Age, years | 10,477 | 61.1 (17.9) | |
| Gender, % women | 10,477 | 55.1 | - |
| Self-perceived health | |||
| Excellent | 693 | 7.5 | - |
| Very good | 1,755 | 19.0 | - |
| Good | 3,139 | 34.0 | - |
| Rather good | 2,477 | 26.8 | - |
| Poor | 1,162 | 12.6 | - |
| Education | |||
| Primary school | 2,504 | 27.3 | - |
| Secondary school | 3,560 | 38.8 | - |
| University/college < 4 years | 2,149 | 23.4 | - |
| University/college 4 years or more | 974 | 10.6 | - |
| Models (Prevent/Treatemnt) | Materials | Effect | Dose (Dose-Effect) | Bioactive Compounds | References |
| Rats treated with ethanol diet (Prevent) | Green tea | ↑ Enzymes, non-enzymatic antioxidants; ↓ lipid and protein oxidation | 7 g/L in ethanol Lieber-DeCarli diet | Epicatechin, epicatechin gallate | [84] |
| Rats treated with ethanol (Prevent) | Ziziphus mauritiana leaf | ↓ ALT, AST, ALP, total bilirubin, CAT; ↑ GSH-Px, glutathione reductase and SOD | 200 and 400 mg/kg b.w. (Dose-effect) | Tannins, saponins and phenolic compounds | [42] |
| Rats sub-chronically exposed to ethanol (Prevent) | Amaranthus hypochondriacus seed | ↓ MDA, NADPH; ↑ Cu, Zn-SOD | 140 g/kg in diet | Total phenols | [87] |
| Mice with acute alcohol-induced liver injury (Prevent) | Peduncles of Hoveniadulcis | ↓ ALT, AST, MDA; ↑ SOD, GSH-Px | 100, 350 and 600 mg/kg b.w. (Dose-effect) | Non-starch polysaccharide | [86] |
| Rats treated with ehanol (Prevent) | Methanolic extract from Hammada scoparia leaves | ↓ Aminotransferase, glycogen synthase kinase-3 β, lipid peroxidation; ↑ GSH-Px | 200 mg/kg b.w. | Phenolic compounds | [85] |
| Mice with chronic alcoholic liver damage (Prevent) | Jujube honey | ↓ Lipoprotein oxidation, AST, ALT, MAD, 8-hydroxy-2-deoxyguanosine; ↑ GSH-Px | 27 and 54 g /kg b.w. (Dose-effect) | Phenolic acids | [88] |
| Mice with alcohol-induced hepatotoxicity (Treatment) | Freeze-dried, germinated and fermented mung bean | ↑ Antioxidant levels, NO | 200 and 1000 mg/kg b.w. | [89] | |
| Chronic ethanol exposure in rats (Prevent) | Virgin olive oil | ↓ Transaminases levels, hepatic lipid peroxidation; ↑ GSH-Px, SOD and CAT | 5% (wt/wt) in diet | Tocopherols, chlorophyll, total polyphenols | [90] |
| Ethical considerations | Supporting arguments | Opposing arguments | Questions to direct future research |
| Tobacco harm reduction | |||
| Potential for smoking cessation | E-cigarettes may be as effective as the nicotine patch. | Inconclusive evidence of efficacy for smoking cessation. | What is the efficacy of nicotine and non-nicotine e-cigarettes for smoking cessation and reduction? |
| Potential for smoking reduction | Demonstrated in multiple studies. | Unlikely that cigarette reduction results in significant health benefits. | What is the long-term impact of dual use of e-cigarettes and tobacco cigarettes on health outcomes? |
| Product safety | |||
| Potential for long-term adverse effects | Unknown impact of long-term propylene glycol inhalation. | No documented serious adverse events to date. | What are the long-term safety implications of nicotine and non-nicotine e-cigarette use? |
| Propylene glycol inhalation causes short-term respiratory irritation. | |||
| Autonomy to use a product of unknown risk | Ethical imperative given informed consent. | Public health concerns trump individual rights. | How should consumer rights be weighed against public health concerns? |
| Use among non-smokers | |||
| Potential to lead to nicotine addiction | Perceived harmlessness may lead never smokers to initiate e-cigarettes. | No evidence for increased nicotine addiction to cause net public health harms. | What is the long-term health impact of nicotine addiction? |
| Potential gateway effect | Nicotine acts as a priming agent for the brain. | Unclear implications for transitioning to tobacco cigarettes. | How many non-smokers initiating e-cigarettes transition to other tobacco products, including cigarettes? |
| Use among youth | |||
| Potential to lead to nicotine addiction | Minors require protection. | No evidence of increased nicotine addiction causing net public health harms. | How many youth initiating e-cigarettes report continuous long-term product use (1 year or longer)? |
| E-liquid flavorings are attractive to youth. | |||
| Potential gateway effect | Nicotine is a priming agent for the brain. | Unclear implications for transitioning to tobacco cigarettes. | How many youth initiating e-cigarettes transition to other tobacco products, including cigarettes? |
| Nicotine poisoning among children | Increased calls to poison control centers. | None. | To what extent can the risk of nicotine poisoning among children be mitigated? |
| E-liquid flavors are appealing to youth. | |||
| Use in public places | |||
| Potential for passive vaping | Stem cell cytotoxicity. | Limited evidence that passive vaping poses significant health concerns. | What is the long-term impact of passive vaping and second-hand vapor exposure? |
| Aerosolized nicotine emissions. | |||
| Renormalized smoking culture | |||
| Potential to subvert decades of anti-smoking efforts | Increased acceptability of smoke-like vapor and smoking behavior. | No evidence that e-cigarettes would be conflated with tobacco cigarettes. | How are the increased awareness and use of e-cigarettes affecting perceptions of cigarette smoking? |
| Market ownership | |||
| Unethical collaboration with the tobacco industry | Public health endorsement of e-cigarettes increases tobacco company market share. | Possible necessity to collaborate with the tobacco industry to achieve public health gains. | What are the public health implications of tobacco industry ownership of major e-cigarette brands? |
| Lesser illness severity (HoNOS ≥21) (n = 21) | Greater illness severity (HoNOS <21) (n = 26) | P-value ( t-test) | |
| Counts/ day | 303697 (194674) | 259940 (112820) | 0.12 ns |
| Steps/ day | 8563 (3996) | 8562 (3237) | 0.63 ns |
| Light activity (mins/day) | 197 (42) | 214 (48) | 0.56 ns |
| Moderate activity (mins/day) | 42 (28) | 35 (25) | 0.72 ns |
| Vigorous activity (mins/day) | 5 (16) | 2 (3) | 0.05 ns |
| Wear time (mins/day) | 784 (89) | 809 (96) | 0.5 ns |
| Sedentary time (mins/day) | 540 (75) | 559 (83) | 0.65 ns |
| Genotyped (n) | |||||||||
| DPS | Tributary/Region | MPG | # pops | Lineage | Run | Min | Max | Mean | Total |
| Southwest WA | Columbia Estuary | n/a | 4 | Coastal | Winter | 43 | 164 | 85.8 | 343 |
| Lower Columbia | Clackamas | Cascade | 4 | Coastal | Mixed | 43 | 92 | 60.3 | 241 |
| Lower Columbia | Other | Cascade; Gorge | 9 | Coastal | Mixed | 28 | 94 | 68.1 | 613 |
| Upper Willamette | Willamette | Willamette | 3 | Coastal | Mixed | 39 | 93 | 60.7 | 182 |
| Upper Willamette | Willamette/West Side | Willamette | 3 | Coastal | Winter | 25 | 30 | 27.0 | 81 |
| Middle Columbia | Klickitat | Cascade East Slope | 10 | Inland | Summer | 33 | 48 | 43.4 | 434 |
| Middle Columbia | Deschutes | Cascade East Slope | 5 | Inland | Summer | 31 | 63 | 51.4 | 257 |
| Middle Columbia | John Day | John Day | 10 | Inland | Summer | 18 | 107 | 36.3 | 363 |
| Middle Columbia | Yakima | Yakima | 7 | Inland | Summer | 21 | 59 | 36.9 | 258 |
| Middle Columbia | Other | Mixed | 7 | Inland | Mixed | 34 | 148 | 100.1 | 701 |
| Upper Columbia | Wenatchee | Upper Columbia/East Slope Cascades | 6 | Inland | Summer | 19 | 99 | 40.8 | 245 |
| Upper Columbia | Other | Upper Columbia/East Slope Cascades | 5 | Inland | Summer | 90 | 99 | 94.3 | 475 |
| Snake | Lower Snake | Lower Snake | 6 | Inland | Summer | 49 | 105 | 83.5 | 501 |
| Snake | Lower Clearwater | Clearwater | 5 | Inland | Summer | 49 | 156 | 107.8 | 539 |
| Snake | M. F. Clearwater | Clearwater | 14 | Inland | Summer | 35 | 99 | 56.4 | 789 |
| Snake | S. F. Clearwater | Clearwater | 4 | Inland | Summer | 36 | 104 | 57.8 | 231 |
| Snake | Grande Ronde | Grande Ronde | 7 | Inland | Summer | 45 | 95 | 62.7 | 439 |
| Snake | Imnaha | Imnaha | 4 | Inland | Summer | 23 | 61 | 41.5 | 166 |
| Snake | S. F. Salmon | Salmon | 4 | Inland | Summer | 39 | 45 | 43.5 | 174 |
| Snake | M. F. Salmon | Salmon | 8 | Inland | Summer | 23 | 84 | 48.3 | 386 |
| Snake | Upper Salmon | Salmon | 7 | Inland | Summer | 37 | 117 | 83.1 | 582 |
| Snake | Other Salmon | Salmon | 7 | Inland | Summer | 43 | 99 | 55.1 | 386 |
| Snake | Hatchery | Mixed | 6 | Inland | Summer | 89 | 146 | 104.2 | 625 |
| Total | 145 | 9011 |
| Factor | Discharged alive (n = 135) | In-hospital death (n = 14) | Hazard Ratio (95% CI) | P-value | ||
| n | Summary | n | Summary | |||
| Etiology | 122 | 14 | ||||
| Hepatitis | 35 (28.7) | 7 (50.0) | Reference | |||
| Alcoholic liver disease | 26 (21.3) | 3 (21.4) | 0.34 (0.08, 1.4) | 0.13 | ||
| Cryptogenic disease | 18 (14.8) | 2 (14.3) | 0.46 (0.09, 2.3) | 0.33 | ||
| NASH | 17 (13.9) | 1 (7.1) | 0.16 (0.02, 1.3) | 0.09 | ||
| Others | 8 (6.6) | 0 (0.0) | 0.16 (0.02, 1.3) | 0.091 | ||
| Albumin | 129 | 3.1 ± 0.7 | 14 | 2.2 ± 0.8 | 0.34 (0.14,0.81) | 0.015 |
| Bilirubin | 129 | 1.4 [0.9, 2.6] | 14 | 11.0 [4.2, 17.3] | 1.07 (1.02, 1.1) | 0.007 |
| Blood urea nitrogen | 131 | 16 [11, 26] | 14 | 34 [27, 60] | 1.02 (1.01, 1.03) | <0.001 |
| Serum creatinine | 131 | 0.86 [0.70, 1.2] | 14 | 1.5 [1.2, 2.9] | 1.6 (1.2, 2.3) | 0.004 |
| Hemoglobin | 134 | 10.3 ± 2.3 | 14 | 8.5 ± 2.1 | 0.75 (0.55, 1.02) | 0.064 |
| Platelets | 130 | 84.5 [57, 142] | 14 | 64.5 [37, 92] | 0.99 (0.98, 1.00) | 0.13 |
| INR | 132 | 1.2 ± 0.24 | 14 | 2.0 ± 0.84 | 3.7 (2.1, 6.5) | <0.001 |
| Partial thromboplastin time | 121 | 30.9 [27.5, 34.7] | 14 | 43.3 [34.4, 63.6] | 1.2 (1.04, 1.3)a | 0.009 |
| Ascites | 132 | 12 | 0.93 (0.49, 1.8) | 0.83 | ||
| None | 74 (56.1) | 5 (41.7) | ||||
| Mild | 20 (15.2) | 1 (8.3) | ||||
| Moderate/severe | 38 (28.8) | 6 (50.0) | ||||
| Encephalopathy | 131 | 11 | 2.1 (0.99,4.6) | 0.052 | ||
| None | 114 (87.0) | 4 (36.4) | ||||
| Grade 1–2 | 14 (10.7) | 6 (54.5) | ||||
| Grade 3–4 | 3 (2.3) | 1 (9.1) | ||||
| MELD score | 124 | 12.0 ± 5.1 | 14 | 27.0 ± 9.0 | 1.1 (1.08, 1.2) | <0.001 |
| CTP score | 124 | 7.5 ± 1.9 | 11 | 11.0 ± 1.8 | 1.5 (1.1, 2.0) | 0.005 |
| Child-Pugh class | 124 | 11 | 4.0 (1.2, 13.4) | 0.025 | ||
| A | 46 (37.1) | 0 (0.0) | ||||
| B | 59 (47.6) | 3 (27.3) | ||||
| C | 19 (15.3) | 8 (72.7) |
| Mean (μg/L) | Geometric mean (μg/L) | |||||
| Surrogate | Low | Medium | High | Low | Medium | High |
| MEHP | ||||||
| Day 0 | 19.9 | 28.9 | 44.7 | 9.3 | 11.5 | 18.3 |
| Day 1 | 9.5 | 55.7 | 19.4 | 5.1 | 26.3 | 11.0 |
| Day 2 | 18.8 | 26.2 | 49.3 | 7.1 | 11.1 | 25.2 |
| Day 30 | 5.6 | 44.9 | 37.6 | 4.4 | 24.3 | 14.2 |
| Day 31 | 5.6 | 43.8 | 39.0 | 4.4 | 20.1 | 18.4 |
| Day 32 | 23.6 | 23.2 | 48.6 | 11.2 | 9.2 | 20.5 |
| Day 90 | 10.0 | 29.7 | 53.5 | 5.0 | 12.7 | 29.9 |
| Day 91 | 9.5 | 30.1 | 53.5 | 5.1 | 14.3 | 24.8 |
| Day 92 | 10.2 | 31.1 | 51.5 | 6.1 | 11.7 | 27.5 |
| MBzP | ||||||
| Day 0 | 4.9 | 11.2 | 14.3 | 3.1 | 7.5 | 13.2 |
| Day 1 | 6.6 | 9.3 | 15.2 | 2.9 | 7.8 | 13.3 |
| Day 2 | 7.8 | 9.2 | 14.0 | 4.3 | 6.0 | 12.8 |
| Day 30 | 6.3 | 11.2 | 12.8 | 3.9 | 8.5 | 8.9 |
| Day 31 | 6.6 | 10.1 | 14.0 | 2.9 | 8.0 | 12.8 |
| Day 32 | 7.2 | 10.1 | 13.4 | 3.5 | 7.5 | 11.9 |
| Day 90 | 8.3 | 11.1 | 11.0 | 4.2 | 7.8 | 9.2 |
| Day 91 | 8.0 | 9.9 | 12.9 | 3.7 | 7.8 | 10.6 |
| Day 92 | 7.2 | 9.9 | 13.7 | 3.5 | 7.8 | 11.3 |
| MEP | ||||||
| Day 0 | 73.2 | 158.4 | 172 | 28.9 | 46.8 | 94.4 |
| Day 1 | 26.6 | 199.6 | 163 | 15.8 | 98.3 | 64.1 |
| Day 2 | 30.2 | 113 | 276 | 6.2 | 70.2 | 97.8 |
| Day 30 | 146 | 92.8 | 186 | 24.4 | 39.7 | 139 |
| Day 31 | 26.6 | 104 | 291 | 15.8 | 53.1 | 146 |
| Day 32 | 26.6 | 182 | 186 | 15.8 | 55.0 | 139 |
| Day 90 | 30.2 | 158 | 216 | 16.2 | 50.2 | 153 |
| Day 91 | 33.4 | 155 | 216 | 16.0 | 50.7 | 153 |
| Day 92 | 63.9 | 132 | 216 | 20.3 | 42.4 | 153 |
| MBP | ||||||
| Day 0 | 16.3 | 30 | 30.5 | 12.7 | 22.8 | 28.3 |
| Day 1 | 16.7 | 24.9 | 37.3 | 13.1 | 21.6 | 29.3 |
| Day 2 | 16.7 | 26.3 | 35.5 | 13.1 | 20.5 | 31.4 |
| Day 30 | 18.0 | 23.4 | 38.1 | 13.5 | 18.6 | 34.7 |
| Day 31 | 16.3 | 27.7 | 34.0 | 12.7 | 22.7 | 28.5 |
| Day 32 | 16.7 | 27.7 | 33.6 | 13.1 | 22.7 | 27.6 |
| Day 90 | 26.4 | 24.4 | 28.4 | 19.8 | 21.6 | 19.4 |
| Day 91 | 21.7 | 22.0 | 36.3 | 14.4 | 18.7 | 32.3 |
| Day 92 | 21.3 | 26.6 | 30.5 | 13.9 | 21.3 | 28.3 |
| MMP | ||||||
| Day 0 | 4.2 | 7.9 | 30.2 | 2.0 | 5.6 | 23.2 |
| Day 1 | 4.0 | 9.4 | 28.3 | 2.4 | 5.2 | 21.3 |
| Day 2 | 5.0 | 7.3 | 30.2 | 4.1 | 3.3 | 23.2 |
| Day 30 | 3.9 | 8.1 | 30.2 | 2.1 | 5.3 | 23.2 |
| Day 31 | 4.3 | 9.2 | 28.3 | 2.5 | 5.0 | 21.3 |
| Day 32 | 4.9 | 11.5 | 24.8 | 3.3 | 5.7 | 13.7 |
| Day 90 | 4.2 | 12.4 | 24.3 | 2.0 | 6.2 | 19.9 |
| Day 91 | 4.3 | 12.3 | 24.3 | 2.5 | 5.3 | 19.9 |
| Day 92 | 4.0 | 12.5 | 24.3 | 2.2 | 5.8 | 19.9 |
| MBS-RK | MBS-VK | RK-VK | ||
| Shoulder joint angle | RMSE | 9.5° (±2.9) | 5.2° (±1.5) | 8.5° (±3.6) |
| p | 0.83 | 0.92 | 0.86 | |
| Elbow joint angle | RMSE | 11.4° (±2.0) | 8.2° (±1.3) | 13.0° (±2.3) |
| p | 0.97 | 0.98 | 0.96 |
| Johnson et al. | Dong et al. | |
| Probe length (nucleotides) | 60 | 60 |
| Median genomic region between probes (nucleotides) | 10 | 153 |
| Number of probes/array | 244 000 | 44 000 |
| Average length of DNA segment hybridized to the array | 497 | 600 |
| Amplification technique | Ligation-Mediated Amplification | Whole Genome Amplification |
| Estimates derived by U.S. EPA (2005) | Estimates derived using the Kwon et al. data | |||||||||
| Pathway | Mean | 50th | 75th | 95th | 99th | Mean | 50th | 75th | 95th | 99th |
| Total (playset + deck) | 11.0 | 6.1 | 13.0 | 39.0 | 84.0 | 3.0 | 2.7 | 3.7 | 5.6 | 8.1 |
| Total playset | 5.4 | 3.0 | 5.9 | 18.0 | 38.0 | 1.7 | 1.4 | 2.2 | 3.9 | 7.0 |
| Residue ingestion from playset | 3.1 | 1.2 | 3.3 | 12.0 | 26.0 | 0.7 | 0.6 | 0.9 | 1.8 | 2.5 |
| Soil ingestion from playset | 0.7 | 0.2 | 0.7 | 2.8 | 6.7 | 0.5 | 0.2 | 0.6 | 2.1 | 4.5 |
| Residue dermal contact from playset | 1.5 | 0.7 | 1.8 | 6.0 | 13.0 | 0.4 | 0.4 | 0.6 | 0.8 | 1.1 |
| Soil dermal contact from playset | 0.1 | 0.1 | 0.2 | 0.4 | 0.8 | 0.1 | 0.0 | 0.1 | 0.2 | 0.4 |
| Total deck | 5.9 | 2.8 | 6.6 | 21.0 | 48.0 | 1.2 | 1.2 | 1.6 | 2.3 | 2.8 |
| Residue ingestion from deck | 3.6 | 1.5 | 3.9 | 13.0 | 33.0 | 0.7 | 0.6 | 0.9 | 1.4 | 2.0 |
| Soil ingestion from deck | 0.1 | 0.0 | 0.1 | 0.4 | 1.3 | 0.1 | 0.0 | 0.1 | 0.4 | 0.8 |
| Residue dermal contact from deck | 2.2 | 1.0 | 2.4 | 8.0 | 18.0 | 0.5 | 0.5 | 0.6 | 0.8 | 1.0 |
| Soil dermal contact from deck | 0.0 | 0.0 | 0.0 | 0.1 | 0.2 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 |
| All women | Women 66-79 years | Women 80+ years | |||||||
| HRR | 95% Conf int | P value | HRR | 95% Conf int | P value | HRR | 95% Conf int | P value | |
| Recurrent MI/Fatal CHD (29 days-365 days) | |||||||||
| N (Events) | 6,528 | (889) | 3,646 | (375) | 2,882 | (514) | |||
| Ed < HS | 1.07 | (0.77, 1.48) | 0.698 | 1.40 | (0.79, 2.48) | 0.245 | 0.97 | (0.65, 1.44) | 0.869 |
| Ed HS < BS | 1.01 | (0.73, 1.40) | 0.957 | 1.44 | (0.82, 2.55) | 0.206 | 0.87 | (0.58, 1.31) | 0.504 |
| Zip Inc q1 | 1.02 | (0.77, 1.33) | 0.914 | 0.89 | (0.59, 1.32) | 0.555 | 1.11 | (0.77, 1.60) | 0.580 |
| Zip Inc q2 | 1.09 | (0.86, 1.39) | 0.465 | 0.91 | (0.64, 1.29) | 0.602 | 1.24 | (0.90, 1.71) | 0.198 |
| Zip Inc q3 | 1.04 | (0.83, 1.30) | 0.740 | 0.87 | (0.62, 1.20) | 0.394 | 1.19 | (0.88, 1.60) | 0.263 |
| Zip Inc q4 | 1.00 | (0.80, 1.25) | 0.983 | 0.81 | (0.58, 1.14) | 0.228 | 1.17 | (0.87, 1.59) | 0.296 |
| Recurrent MI/Fatal CHD (366 days-5 years) | |||||||||
| N (Events) | 4,681 | (833) | 2,837 | (402) | 1,844 | (431) | |||
| Ed < HS | 1.36 | (0.99, 1.88) | 0.060 | 1.19 | (0.76, 1.88) | 0.445 | 1.52 | (0.98, 2.37) | 0.064 |
| Ed HS < BS | 1.17 | (0.85, 1.62) | 0.335 | 0.92 | (0.58, 1.44) | 0.700 | 1.46 | (0.94, 2.27) | 0.096 |
| Zip Inc q1 | 0.80 | (0.61, 1.05) | 0.104 | 0.78 | (0.52, 1.17) | 0.226 | 0.82 | (0.57, 1.19) | 0.300 |
| Zip Inc q2 | 0.97 | (0.77, 1.22) | 0.816 | 1.06 | (0.77, 1.46) | 0.717 | 0.89 | (0.65, 1.23) | 0.493 |
| Zip Inc q3 | 0.88 | (0.71, 1.09) | 0.235 | 0.88 | (0.64, 1.20) | 0.421 | 0.89 | (0.66, 1.20) | 0.429 |
| Zip Inc q4 | 0.70 | (0.56, 0.87) | 0.002 | 0.75 | (0.54, 1.03) | 0.072 | 0.65 | (0.47, 0.90) | 0.009 |
| EmA | TG2-ab (U) | |||||||
| Patient | GFD years | Medium 24 h | PT-gliadin 24 h | PT-gliadin 48 h | Medium 24 h | PT-gliadin 24 h | PT-gliadin 48 h | |
| 12 | 1 | neg | neg | neg | 2.0 | 4.8 | 13.3 | |
| 13 | 2 | neg | neg | neg | 8.8 | 6.9 | 4.4 | |
| 14 | 4 | neg | neg | neg | 2.2 | 6.2 | 10.3 | |
| 15 | 4 | neg | neg | neg | 2.5 | 1.7 | 2.6 | |
| 16 | 6 | neg | neg | neg | 8.1 | 7.7 | 12.4 | |
| 17 | 7 | neg | neg | neg | 2.4 | 3.7 | 1.9 | |
| 18 | 8 | neg | neg | neg | 2.5 | 1.3 | 1.7 | |
| 19 | 14 | neg | neg | neg | 0.9 | 2.9 | 0.7 | |
| 20 | 20 | neg | neg | neg | 11.6 | 2.5 | 11.6 | |
| Median | neg | neg | neg | Median | 2.5 | 3.7 | 4.4* |
| Case number | Date of collection* | Temperature (°C)† | Humidity (%)† | |||
| Pre‡ | Post | Pre | Post | Pre | Post | |
| 6 | June 30 | July 21 | 24.6 | 28.3 | 78.1 | 61.3 |
| 7 | July 9 | July 30 | 26.3 | 30.1 | 65.4 | 62.3 |
| 8 (R) and 8 (O)§ | July 13 | August 3 | 26.3 | 29.1 | 69.1 | 65.4 |
| 9 | July 28 | August 18 | 29.7 | 28.9 | 79.0 | 79.3 |
| 10 | August 19 | September 9 | 28.9 | 27.6 | 69.5 | 71.7 |
| 11 | August 26 | September 16 | 24.6 | 23.8 | 82.9 | 84.8 |
| 12 | September 14 | October 5 | 24.5 | 23.3 | 64.1 | 82.0 |
| 13 | September 19 | October 10 | 22.0 | 21.5 | 69.3 | 55.1 |
| 14 | September 23 | October 14 | 21.4 | 20.6 | 57.9 | 61.8 |
| Main options | Choices among main options | Ancillary manoeuvres among main option and choices |
| Loop colostomy (C) (bridge to resection or palliation) | ||
| Primary resection with end colostomy: Hartmann’s procedure (HP) | ||
| Resection and primary anastomosis (RPA) | Total/subtotal colectomy (TC) | Intraoperative colonic irrigation (ICI)Manual decompression (MD)Covering stoma |
| Segmental colectomy (SC) | ||
| Tube decompression | ||
| Endoscopic colonic stenting by self-expanding metallic stents (SEMS) | Bridge to surgery | |
| Palliation |
| Factor | Subgroup | Patients on glargine | Patients on other types of insulin | p-value |
| (N = 13) | (N = 66) | |||
| Breast surgical procedure | Quadrantectomy or lumpectomy Mastectomy | 7 | 23 | 0.20 |
| 6 | 43 | |||
| Axillary surgical procedure | Sentinel node biopsy | 5 | 24 | 0.78 |
| Lymphadenectomy | 8 | 42 | ||
| Adjuvant Chemotherapy | No | 9 | 50 | 0.72 |
| Yes | 4 | 16 | ||
| Adjuvant Hormone therapy | No | 3 | 6 | 0.17 |
| Yes | 10 | 60 | ||
| Adjuvant Trastuzumab | No | 13 | 62 | 1.00 |
| Yes | 0 | 4 | ||
| Adjuvant Radiotherapy | No | 5 | 32 | 0.49 |
| Yes | 8 | 34 | ||
| Outcome | Alive | 13 | 63 | 1.00 |
| Died of disease | 0 | 3 |
| SNP IDHit Orientation | Group | Genotype Frequency | Allele Frequency | Association SignificanceP-value/Odds ratio (95% CI) | |||
| rs35069869 | Women | AA | AG | GG | A | G | |
| A/G | T1D without DN | 174 (0.489) | 153 (0.430) | 29 (0.081) | 0.704 | 0.211 | |
| T1D with DN | 135 (0.509) | 109 (0.411) | 21 (0.079) | 0.715 | 0.285 | 0.661 a | |
| Men | |||||||
| T1D without DN | 125 (0.519) | 101 (0.419) | 15 (0.062) | 0.728 | 0.272 | ||
| T1D with DN | 150 (0.479) | 137 (0.438) | 26 (0.083) | 0.698 | 0.302 | 0.273 a | |
| rs35368790 | Women | GG | GC | CC | G | C | |
| G/C | T1D without DN | 168 (0.471) | 151 (0.423) | 38 (0.106) | 0.682 | 0.318 | |
| T1D with DN | 134 (0.511) | 107 (0.408) | 33 (0.105) | 0.716 | 0.284 | 0.204 a | |
| Men | |||||||
| T1D without DN | 107 (0.442) | 110 (0.455) | 25 (0.103) | 0.669 | 0.331 | ||
| T1D with DN | 146 (0.466) | 134 (0.428) | 33 (0.105) | 0.681 | 0.319 | 0.696 a | |
| rs7639705 | Women | TT | TG | GG | T | G | |
| T1165G | T1D without DN | 213 (0.603) | 125 (0.354) | 15 (0.043) | 0.780 | 0.220 | |
| Leu359Ile | T1D with DN | 188 (0.712) | 65 (0.246) | 11 (0.042) | 0.835 | 0.165 | 0.017/0.701 (0.524-0.938) a0.018/0.757 b |
| Men | |||||||
| T1D without DN | 157 (0.651) | 73 (0.303) | 11 (0.046) | 0.803 | 0.197 | ||
| T1D with DN | 183 (0.590) | 115 (0.371) | 12 (0.039) | 0.776 | 0.224 | 0.275 a |
| Systemic | Oligoarthritis | RF − poly-arthritis | RF + poly-arthritis | Enthesitis-related arthritis | All JIA patients | Healthy | |
| N = 25 | N = 19 | N = 38 | N = 3 | N = 15 | N = 100 | N = 198 | |
| Female | 17 (68%) | 13 (68.4%) | 28 (73.7%) | 3 (100%) | 7 (46.7%) | 68 (68%) | 98 (49.5%)* |
| Age at visit | 9.7 (5.5–13.8) | 13.1 (10.9–15.2) | 14.1 (10.3–16.2) | 17.1 (16–17.9) | 13.1 (9.5–16.2) | 12.9 (9.6–16)* | 10.4 (8.7–12.7)* |
| Age at onset | 2.7 (2–5.8) | 4 (3–6.2) | 4.9 (2–7.2) | 10 (9–14.7) | 8.6 (3.9–10.7) | 4.8 (2.2–7.4)* | |
| Disease duration | 4.5 (1.1–8.9) | 8.1 (5.4–11.2) | 9 (4.7–11.1) | 7.9 (1.3–8.1) | 4.7 (1.5–7.2) | 7.4 (2.6–10.2)* | |
| ESR | 15 (7–22) | 9 (9–15) | 12.5 (8–19) | (–) | 11 (3–14) | 12 (8–18) | |
| MD VAS (0–10 cm) | 1.5 (0.5–4) | 1.5 (1–3) | 3.3 (1–4.5) | 1 (0.5–1.5) | 1.5 (0.5–3) | 2 (0.5–3.8) | |
| No. of swollen joints | 0 (0–1) | 0 (0–2) | 1.5 (0–4) | 0 (0–1) | 1 (0–2) | 0 (0–3) | |
| No. of joints with pain | 0 (0–0) | 0 (0–0) | 0 (0–0) | 0 (0–0) | 0 (0–0) | 0 (0–0) | |
| No. of joints with LOM | 0 (0–0) | 0 (0–0) | 0 (0–0) | 0 (0–0) | 0 (0–0) | 0 (0–0) | |
| No. of active joints | 0 (0–2) | 0 (0–2) | 1.5 (0–4) | 0 (0–1) | 1 (0–2) | 1 (0–3) | |
| Active systemic features | 1 (4%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (1%) | |
| ANA status | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | |
| Uveitis | 0 (0%) | 1 (5.3%) | 1 (2.6%) | 0 (0%) | 0 (0%) | 2 (2%) | |
| PF total score | 0 (0–5) | 0 (0–1) | 1.5 (0–4) | 0 (0–3) | 1 (0–3) | 0 (0–3.5) | 0 (0–0)# |
| Pain VAS | 1 (0–4) | 1.5 (0.5–3.5) | 2 (1–5) | 1 (0–1.5) | 1.5 (0.5–4) | 1.5 (0.5–4) | 0 (0–0)# |
| Disease activity VAS | 1.5 (0.5–4) | 1 (0.5–1.5) | 2.8 (1–5) | 1 (0–1) | 1.5 (1–3.5) | 1.5 (0.5–4) | |
| Well-being VAS | 1.5 (0.5–3.5) | 2 (0.5–4) | 2.8 (1–4) | 0.5 (0–2) | 1.5 (0.5–4) | 2 (0.5–3.8) | |
| HRQoL-PhH | 2 (0–4) | 0 (0–1) | 1 (0–3) | 0 (0–2) | 1 (0–2) | 1 (0–3) | 0 (0–0)# |
| HRQoL-PsH | 3 (0–5) | 1 (0–3) | 1.5 (0–3) | 0 (0–4) | 3 (1–3) | 2 (0–3) | 0 (0–1)# |
| HRQoL total score | 5 (1–9) | 3 (0–3) | 3 (0–6) | 2 (0–4) | 3 (1–5) | 3 (0–5) | 0 (0–1)# |
| Pain/swell. in > 1 joint | 7 (28%) | 7 (36.8%) | 22 (57.9%) | 0 (0%) | 9 (60%) | 45 (45%)* | 0 (0%)# |
| Morning stiffness > 15 min | 2 (8%) | 0 (0%) | 7 (18.4%) | 0 (0%) | 1 (6.7%) | 10 (10%) | 0 (0%)# |
| Subjective remission | 9 (36%) | 3 (15.8%) | 18 (47.4%) | 0 (0%) | 4 (26.7%) | 34 (34%) | |
| In treatment | 23 (92%) | 19 (100%) | 38 (100%) | 3 (100%) | 13 (86.7%) | 96 (96%) | |
| Reporting side effects | 5/23 (21.7%) | 1 (5.3%) | 5 (13.2%) | 0 (0%) | 1/13 (7.7%) | 12/96 (12.5%) | |
| Taking medication regularly | 22/23 (95.7%) | 19 (100%) | 36 (94.7%) | 2 (66.7%) | 13/13 (100%) | 92/96 (95.8%) | |
| With problems attending school | 0 (0%) | 0 (0%) | 3/31 (9.7%) | 0 (0%) | 0 (0%) | 3/75 (4%) | 0 (0%)* |
| Satisfied with disease outcome | 23 (92%) | 19 (100%) | 33 (86.8%) | 3 (100%) | 14 (93.3%) | 92 (92%) |
| Manufacturer and phantom type | Speed of sound [m/s] | Attenuation [dB/cm/MHz] | Young’s modulus [kPa] |
| ATS hydrogel-based [25] | 1540 | n/a | n/a |
| ATS rubber-based [25] | 1440–1460 | 0.48–0.52 | n/a |
| CIRS hydrogels [26, 27] | 1480–1600 | 0.45–0.75 | 3–48 |
| Madsen agar with evaporated milk [16] | 1541–1543 | 0.1–0.7 | n/a |
| Hall gelatins [28] | 1559–1600 | n/a | 3–126 |
| King hydrogel-baseda [29] | 1539–1583 | 0.51–0.55 | n/a |
| Our gelatins with evaporated milk: | |||
| 125-bloom | 1532–1574 | 0.45–0.55 | 8–11 |
| 175-bloom | 1536–1566 | 0.45–0.61 | 16–22 |
| 250-bloom | 1543–1563 | 0.46–0.62 | 24–34 |
| Parameter | Search | Approach | Terminal phase | |||
| F | M | S | L | |||
| Pulse duration [ms] | 2.4 ± 0.3 | 2.1 ± 0.1 | 1.7 ± 0.1 | 1.4 ± 0.2 | 1.0 ± 0.1 | 0.9 ± 0.1 |
| 1.9 − 2.8 | 1.9 − 2.2 | 1.6 − 1.9 | 1.1 − 1.7 | 0.8 − 1.3 | 0.8 − 1.2 | |
| Pulse interval [ms] | 41.6 ± 10.5 | 17.9 ± 1.5 | 11.0 ± 1.2 | 7.9 ± 1.6 | 5.9 ± 0.7 | |
| 24 − 62 | 15 − 21 | 8.9 − 14 | 6.2 − 11 | 5.1 − 7.8 | ||
| Repetition rate [calls/s] | 25.6 ± 6.8 | 56.3 ± 4.9 | 91.9 ± 9.6 | 130.7 ± 22.8 | 172.3 ± 18.0 | |
| 16 − 42 | 48 − 66 | 74 − 113 | 87 − 161 | 129 − 195 | ||
| Bandwidth [kHz] | 22.9 ± 3.1 | 25.4 ± 1.9 | 23.5 ± 2.8 | 19.6 ± 2.6 | 15.1 ± 2.2 | 13.6 ± 1.7 |
| 17 − 29 | 23 − 29 | 18 − 28 | 16 − 24 | 11 − 20 | 11 − 16 | |
| Peak frequency [kHz] | 56.4 ± 2.2 | 55.4 ± 2.1 | 55.9 ± 2.7 | 54.8 ± 3.2 | 54.2 ± 2.8 | 53.2 ± 3.6 |
| 53 − 60 | 50 − 58 | 52 − 62 | 47 − 59 | 49 − 59 | 47 − 58 | |
| Sweep rate [kHz/ms] | 9.7 ± 0.9 | 12.3 ± 1.1 | 13.5 ± 1.5 | 14.5 ± 1.7 | 15.3 ± 2.4 | 15.2 ± 2.0 |
| 7.9 − 11 | 10 − 14 | 11 − 16 | 12 − 18 | 10 − 19 | 12 − 19 | |
| Duty cycle [%] | 6.4 ± 1.3 | 12.2 ± 1.2 | 16.0 ± 1.9 | 17.6 ± 3.0 | 17.2 ± 2.7 | |
| 4.2 − 8.9 | 9.8 − 14 | 13 − 20 | 13 − 24 | 13 − 23 |
| Kawasaki Disease | Febrile Condition | P-value | |
| n = 23 (59.0%) | n = 16 (41.0%) | ||
| Age (months)a | 43.2 [5.0, 152.0, 27.1-49.6] | 64.3 [6.0, 188.0, 38.1-90.6] | 0.125 |
| Male | 15 (65.2%) | 9 (69.2%) | 1.000 |
| Ethnicity | |||
| Asian | 8 (34.8%) | 0 (0%) | 0.044 |
| African American | 1 (4.4%) | 0 (0%) | |
| Caucasian | 5 (21.7%) | 7 (43.8%) | |
| Hispanic | 6 (26.1%) | 8 (50.0%) | |
| Mixed | 3 (13.0%) | 1 (6.3%) |
| Precision | Recall | F-Measure | Accuracy | |
| ALL-40 | 0.927 | 0.886 | 0.906 | 0.982 |
| ALL-90 | 0.955 | 0.88 | 0.916 | 0.984 |
| ALL-140 | 0.952 | 0.91 | 0.93 | 0.986 |
| ALL-190 | 0.951 | 0.903 | 0.926 | 0.986 |
| ALL-240 | 0.949 | 0.904 | 0.926 | 0.985 |
| ALL-290 | 0.948 | 0.899 | 0.923 | 0.985 |
| ALL-340 | 0.945 | 0.902 | 0.923 | 0.985 |
| Outcome | No. of studies | Factor tested | P | Adjusted R2 |
| Total symptom score | 9 | age | 0.296 | 2.69% |
| ethnicity | 0.254 | 6.74% | ||
| risk of bias | 0.026 | 49.92% | ||
| Severity of inattention | 5 | age | 0.16 | 54.94% |
| ethnicity | 0.421 | −5.75% | ||
| risk of bias | 0.345 | 0.80% | ||
| Severity of Hyp-Imp | 5 | age | 0.972 | −40.99% |
| ethnicity | 0.257 | 29.91% | ||
| risk of bias | 0.022 | 100.00% |
| Age (in years) | ||||||||
| 3 | 4 | 5 | 6 | 7 | 8–9 | 10–11 | Total | |
| Boys | 32 | 31 | 31 | 31 | 15 | 14 | 13 | 167 |
| Girls | 29 | 24 | 32 | 26 | 16 | 12 | 18 | 157 |
| All | 61 | 55 | 63 | 57 | 31 | 26 | 31 | 324 |
| Normal | BCA | |
| n = 30 | n = 88 | |
| Sex | ||
| Male | 22 (73%) | 70 (79.5%) |
| Female | 8 (27%) | 18 (20.5%) |
| Age | ||
| Mean | 66.3 | 69.1 |
| Range | 43–81 | 40–91 |
| Staging pT-stage | ||
| pTa | n.a. | 13 (14.8%) |
| pTis | n.a. | 13 (14.8%) |
| pT1 | n.a. | 18 (20.5%) |
| pT2 | n.a. | 12 (13.6%) |
| pT3 | n.a. | 15 (17.0%) |
| pT4 | n.a. | 17 (19.3%) |
| Lymph node metastasis | n.a. | 23 (26.1%) |
| Distant metastasis | n.a. | 2 (2.3%) |
| Grading | ||
| grade 1 | n.a. | 9 (10.2%) |
| grade 2 | n.a. | 31 (35.2%) |
| grade 3 | n.a. | 48 (54.5%) |
| Variables | β | SE | Wald χ2 | P-value | OR | 95% CI of OR |
| Age | 0.055 | 0.006 | 73.581 | 0.000 | 1.056 | 1.043–1.070 |
| Female | 0.947 | 0.158 | 35.953 | 0.000 | 2.578 | 1.892–3.514 |
| BMI | 0.073 | 0.024 | 8.851 | 0.003 | 1.075 | 1.025–1.128 |
| TSH | -0.243 | 0.083 | 8.630 | 0.003 | 0.784 | 0.667–0.922 |
| H. pylori infection | 0.329 | 0.139 | 5.633 | 0.018 | 1.390 | 1.059–1.824 |
| Characteristic | HR | 95% CI | p-value | |
| Age | Per year | 0.99 | 0.96–1.02 | 0.47 |
| Hormone receptor status | Negative | 1 (reference) | ||
| Positive | 1.50 | 0.56–4.06 | 0.41 | |
| HER2 Status | Negative | 1 (reference) | ||
| Positive | 0.89 | 0.35–2.25 | 0.80 | |
| Grading | Per grade | 1.45 | 0.70–3.00 | 0.32 |
| Therapy line | Per line | 0.98 | 0.75–1.26 | 0.85 |
| CTC count | 0 | 1 (reference) | ||
| ≥1 | 4.20 | 1.86–9.46 | 0.001 |
| Subset | No outbreaks (%) | One outbreak (%) | Two or more outbreaks (%) | Number of self-reported A(H5N1) outbreaks (average) |
| 1 | 15.4 | 38.5 | 46.2 | 1.6 |
| 2 | 50.0 | 30.0 | 20.0 | 0.8 |
| 3 | 35.7 | 35.7 | 28.6 | 1.1 |
| 4 | 58.7 | 33.3 | 8.3 | 0.5 |
| 5 | 45.0 | 20.0 | 35.0 | 1.2 |
| 6 | 37.5 | 62.5 | 0.0 | 0.6 |
| DHEA IM group compared to CTR1 | DHEA IM group compared to CTR3 | ||||
| Name gene set | # Genes | p-value | FDR | p-value | FDR |
| DHEA_IM_vs_CTR1_up | 98 | - | - | 0.000* | 0.000 |
| DHEA_IM_vs_CTR1_down | 208 | - | - | 0.000* | 0.071 |
| DHEA_IM_vs_CTR3_up | 46 | 0.000* | 0.000 | - | - |
| DHEA_IM_vs_CTR3_down | 19 | 0.826 | 0.823 | - | - |
| DHEA_PO_vs_CTR1_up | 65 | 0.000* | 0.000 | 0.751 | 0.887 |
| DHEA_PO_vs_CTR1_down | 73 | 0.000* | 0.000 | 0.861 | 0.899 |
| DHEA_PO_vs_CTR3_up | 31 | 0.032* | 0.073 | 0.000* | 0.000 |
| DHEA_PO_vs_CTR3_down | 34 | 0.312 | 0.413 | 0.000* | 0.000 |
| Depreter_et_al_up | 11 | 0.015* | 0.031 | 0.381 | 0.657 |
| DHEA PO group compared to CTR1 | DHEA PO group compared to CTR3 | ||||
| Name gene set | # Genes | p-value | FDR | p-value | FDR |
| DHEA_PO_vs_CTR1_up | 65 | - | - | 0.000* | 0.000 |
| DHEA_PO_vs_CTR1_down | 73 | - | - | 0.007* | 0.002 |
| DHEA_PO_vs_CTR3_up | 31 | 0.173 | 0.292 | - | - |
| DHEA_PO_vs_CTR3_down | 34 | 0.015* | 0.014 | - | - |
| DHEA_IM_vs_CTR1_up | 98 | 0.000* | 0.000 | 0.000 | 0.479 |
| DHEA_IM_vs_CTR1_down | 208 | 0.000* | 0.000 | 0.000* | 0.000 |
| DHEA_IM_vs_CTR3_up | 46 | 0.706 | 0.738 | 0.000* | 0.000 |
| DHEA_IM_vs_CTR3_down | 19 | 0.009* | 0.006 | 0.002* | 0.001 |
| Depreter_et_al_up | 11 | 0.029* | 0.030 | 0.887 | 1.000 |
| Data process | How and when measured |
| Frequency of dressing changes in both trial arms | This was calculated from the number of treatment monitoring forms completed by the research nurses indicating a dressing change and included forms completed both prospectively and retrospectively |
| Such data were collected retrospectively when a participant changed location or was self-caring. In such instances, the research nurse would consult patient notes or records kept by the patient to determine the number of dressing changes over a specified period of time | |
| Duration of treatment with allocated trial treatment | Calculated as the difference between the date a patient receiving their allocated treatment to the date they stopped receiving this treatment. This information was available from treatment monitoring forms (as described above) |
| Reasons for ceasing allocated trial treatment | When, in the clinical judgement of the nurses, a patient could no longer receive their allocated trial treatment, the reason for treatment change was recorded on a treatment monitoring form |
| Define common adverse events in the study population | All serious and non-serious adverse events that occurred in participants were recorded on adverse events forms. The nature, description and relationship of the event to trial treatment were recorded. The research nurse indicated whether the event was considered to be related to the reference pressure ulcer |
| Tumor types | 56 expression CD | ||
| Negative | Positive | ||
| Pleomorphic adenoma | 6 cases(40%) | 9cases(60%) | |
| Low-grade malignant tumors(Mucoepidermoid carcinoma grade I) | 8 cases(100%) | 0 case(0%) | |
| high-grade malignant tumors | Mucoepidermoid carcinoma grade III | 6 cases(27.3%) | 1 case(4.5%) |
| Adenoid cystic carcinoma | 3 cases(13.6%) | 12 cases(54.5%) |
| Excluded from Analysis | Included in Analysis | ||
| Basic Stats | N = 1534 | N = 946 | ANOVA |
| Mean | 43.9 * | 42.6 | |
| Median | 42 | 41 | |
| Std Err | 0.39 | 0.42 | |
| Min-max | 16–89 | 16–87 | |
| p = 0.04 | |||
| N | 81 ** | 93 | |
| Mean | 62.0 | 60.8 | |
| Median | 62 | 62 | |
| Std Err | 1.5 | 1.27 | |
| Min-max | 30–89 | 34–86 | |
| p = 0.54 | |||
| 90 (6%) | 93 (10%) | Chi Square | |
| p <0.001 | |||
| No fluid | 929 (61%) | 714 (75%) | |
| Insufficient specimen | 45 (3%) | 19 (2%) | |
| Normal | 232 (15%) | 89 (9%) | |
| Hyperplasia | 234 (15%) | 97 (10%) | |
| Atypia | 81 (5%) | 27 (3%) | |
| [Unable to classify] | 13 (1%) | ||
| p <0.001 |
| Total | EDSS mild | EDSS moderate | EDSS severe | ||||
| Depressive symptoms | No depressive symptoms | Depressive symptoms | No depressive symptoms | Depressive symptoms | No depressive symptoms | ||
| n = 173 | n = 39a | n = 72 | n = 16b | n = 14 | n = 16c | n = 16 | |
| Women, n (%) | 116 (67) | 28 (72) | 51 (71) | 9 (56) | 7 (47) | 10 (62) | 11 (69) |
| Mean age, years (sd) | 46 (12) | 42 (13) | 43 (11) | 47 (9) | 55 (10) | 56 (11) | 53 (12) |
| Cohabiting, n (%) | 123 (71) | 31 (79) | 51 (71) | 11 (69) | 9 (64) | 11 (69) | 11 (69) |
| Working full- or part-time, n (%)d | 114 (66) | 24 (65) | 59 (84) | 7 (47) | 7 (64) | 0 | 7 (46) |
| Immunomodulatory treatment, n (%) | 146 (84) | 30 (77) | 57 (79) | 15 (94) | 14 (100) | 14 (88) | 16 (100) |
| Mean years since diagnosis, (sd) | 13 (10) | 9 (7) | 12 (10) | 15 (10) | 15 (10) | 19 (9) | 20 (11) |
| Disease severity, n (%) | |||||||
| EDSS mild 1.0-3.5 | 111 (64) | 1.8 (1.0-3.5) | 1.8 (1.0-3.5) | ||||
| EDSS moderate 4.0-5.5 | 30 (17) | 4.7 (4.0-5.5) | 4.6 (4.0-5.5) | ||||
| EDSS severe 6.0-9.5 | 32 (18) | 7.3 (6.0-8.0) | 7.0 (6.0-8.0) | ||||
| Disease course, n (%) | |||||||
| Relapsing remitting | 106 (61) | 35 (90) | 62 (86) | 3 (19) | 4 (29) | 0 | 2 (13) |
| Secondary progressive | 58 (34) | 1 (2) | 7 (10) | 12 (75) | 9 (64) | 16 (100) | 13 (81) |
| Primary progressive | 9 (5) | 3 (8) | 3 (4) | 1 (6) | 1 (7) | 0 | 1 (6) |
| Chinese name | Full scientific name | Parts of plant use | % | Dose of dry plant | Constituent | Dose after extraction | Function in Chinese medicine |
| Huang Qi | Radix Astragali | Dry root | 15 | Astragaloside | 3.75 | Tonifies Qi | |
| Sheng Di | Rehmannia glutinosa Libosch | Dry root | 15 | 3.75 | Nourishes Yin | ||
| Shan Zhu Yu | Fructus Cornus | Dry fruit | 5 | Loganin | 1.25 | Tonifies the liver and kidney and retains the essence | |
| Bai Shao | Paeonia lactiflora | Dry root | 15 | Paeoniflorin | 3.75 | Nourishes blood and preserves Yin | |
| Dan Pi | Cortex Moutan Radicis | Dry root and stem | 15 | Paeonol | 3.75 | Clears deficient fire and heat | |
| She She Cao | Herba Hedyotidis Diffusae | Dry leaf | 15 | Oleanic acid | 3.75 | Clears heat and resolves toxins | |
| Total | 100 | 80 | 20 |
| Genes | 5’ Primer sequence | 3’ Primer sequence |
| CD14 | CCGCTGCCTCTGGAAG | GGCGAGTGTGCTTGGG |
| TLR4 | GTCCTCAGTGTGCTTGTAG | ATCCTGGCTTGAGTAGATAAC |
| MD-2 | CACCATGAATCTTCCAAAGC | CTTGAAGGAGAATGATATTGTTG |
| MyD88 | CGGATGGTGGTGGTTGTCTC | CGCTTCTGATGGGCACCT |
| GAPDH | CTGAGTACGTCGTGGAGTC | AAATGAGCCCCAGCCTTC |
| Total Number of Samples | Number of Samples < Background PM2.5 Level N (%) | Area (m2) Med (IQR) | Number of Smokers Occupied Med (IQR) | Number of Ventilator Med (IQR) | ||
| Pre-ban (2013) | Overall | 99 | 23 (23.2) | 204.5 (107.5–360) | 4 (1–9) | 10 (4–16) |
| Billiards | 30 | 5 (16.7) | 232.0 (110.0–484.0) | 3 (2–6) | 8 (4–10) | |
| Pubs | 30 | 10 (33.3) | 132.5 (55.0–225.0) | 2 (0–4) | 5 (2–14) | |
| Computer game rooms | 39 | 8 (20.5) | 262.5 (156.0–368.0) | 6 (4–13) | 16 (9–26) | |
| Post-ban (2014) | Overall | 64 | 18 (28.1) | 114.7 (72.0–206.1) | 0 (0–4) | 13 (7–18) |
| Billiards | 15 | 3 (20.0) | 198.0 (117.6–286.0) | 4 (3–6) | 12 (9–16) | |
| Pubs | 29 | 10 (34.5) | 75.0 (54.0–112.8) | 0 | 10 (3–15) | |
| Computer game rooms | 20 | 5 (25.0) | 141.2 (106.5–284.7) | 1 (0–10) | 19 (15–34) |
| Maternal PCB concentration (ng/g lipid) | Model R2 | ||||
| Model 1: preconception PCBs | 0.22 | ||||
| Explained variation | 22% | ||||
| Model 2: preconception PCBs + prenatal PCBs | 0.26 | ||||
| Explained variation | 25% | 6% | |||
| Model 3: preconception PCBs + prenatal PCBs + postnatal PCBs | 0.28 | ||||
| Explained variation | 20% | 8% | 2% | ||
| Model 4: preconception PCBs + prenatal PCBs + postnatal PCBs + breast-feeding duration | 0.56 | ||||
| Explained variation | 15% | 2% | < 1% | 32% |
| Variables | Expected difference, mean | Expected standard deviation | α | Power % | |
| Primary outcome | 10 years risk of CVD (%) | 2.5 | 5.9 | 0.0166 | 0.90 |
| Secondary outcomes | WC (cm) | 5 | 14 | 0.0166 | 0.75 |
| BP (mm Hg) | 5 | 12 | 0.0166 | 0.88 | |
| RHR (per minutes) | 10 | 20 | 0.0166 | 0.97 | |
| HDL (mmol/l) | 0.2 | 0.4 | 0.0166 | 0.97 | |
| Non-HDL (mmol/l) | 0.45 | 1.1 | 0.0166 | 0.87 | |
| HbA1c (mmol/mol) | 0.5 | 1.1 | 0.0166 | 0.94 | |
| FEV1 (L) | -0.36 | 0.92 | 00166 | 0.84 | |
| VO2max | 3.5 | 9 | 0.0166 | 0.73 | |
| Sedentary (minutes/day) | 60 | 140 | 0.0166 | 0.90 | |
| MVPA (Minutes/day) | 20 | 40 | 0.0166 | 0.97 |
| GmPOPB-S577A_25mer | GmPOPB-D661A_25mer | GmPOPB-S577A_35mer | GmPOPB-H698A_35mer | apo_GmPOPB | |
| Data collection | |||||
| Space group | P 21 21 21 | P 21 21 21 | P 21 | P 21 21 21 | P 21 21 2 |
| Cell dimensions | |||||
| a, b, c | 99.1, 114.7, 141.3 | 99.0, 114.9, 141.3 | 100.8, 142. 6, 116.4 | 99.2, 115 141. 5 | 90.89, 105.62, 86.96 |
| α, β, γ | 90.0, 90.0, 90.0 | 90.0, 90.0, 90.0 | 90.0, 90.29, 90.0 | 90.0, 90.0, 90.0 | 90.0, 90.0, 90.0 |
| Resolution | 1.44 (1.49–1.44) | 1.62 (1.678–1.62) | 2.19 (2.268–2.19) | 2.9 (3.0–2.9) | 2.4 (2.49–2.4) |
| Unique reflections | 288,485 (28,320) | 204,059 (20,188) | 163,136 (16,107) | 32,664 (1690) | 31,441 (2534) |
| Completeness (%) | 99.7 (99) | 100 (100) | 97 (96) | 97 (93) | 99 (77) |
| Mean I/sigma (I) | 9.3 (1.3) | 6.9 (1.0) | 6.7 (1.2) | 6.8 (1.7) | 14.5 (2.2) |
| R-merge | 0.114 (1.01) | 0.059 (0.69) | 0.112 (1.0) | 0.068 (0.53) | 0.029 (0.56) |
| R-meas | 0.063 (0.588) | 0.084 (0.98) | 0.27 (1.5) | 0.096 (0.52) | 0.036 (0.72) |
| Redundancy | 6.0 (6.6) | 6.7 (6.6) | 2.0 (2.0) | 1.8 (1.6) | 5.1 (3.3) |
| Refinement | |||||
| Resolution range | 43.3–1.44 | 46.9–1.62 | 82.3–2.19 | 32.0–2.9 | 45.44–2.4 |
| Reflections used in refinement | 288,428 (28,313) | 203,960 (20,185) | 163,135 (16,107) | 32,664 (1690) | 31,437 (2534) |
| Rwork/Rfree | 0.17/0.19 | 0.20/0.23 | 0.23/0.26 | 0.255/0.303 | 0.21/0.25 |
| Protein residues | 1478 | 1478 | 3014 | 1484 | 703 |
| RMS(bonds) | 0.015 | 0.020 | 0.012 | 0.007 | 0.007 |
| RMS(angles) | 1.28 | 1.82 | 1.42 | 1.10 | 1.17 |
| Ramachandran favored (%) | 97 | 97 | 97 | 97 | 97 |
| Ramachandran allowed (%) | 2.5 | 2.5 | 3.1 | 2.9 | 2.3 |
| Ramachandran outliers (%) | 0.14 | 0.3 | 0.3 | 0.48 | 0.29 |
| Rotamer outliers (%) | 0.24 | 1.4 | 0.95 | 1.1 | 0.34 |
| Clashscore | 3.73 | 1.63 | 1.02 | 3.42 | 2.64 |
| Average B-factor | 15 | 21 | 15 | 32 | 44 |
| Macromolecules | 14 | 20 | 14 | 34 | 43 |
| Solvent | 27 | 31 | 43 | 37 | 38 |
| Point of view | OQRA | PQRA |
| Computation | Every time a request initiated. | Precomputes paths from a source to all destinations. |
| Scalability | Limited. | Large-scale networks. |
| Suitability | When requests arise infrequently. | When requests arise very frequent. |
| Pros | Optimal routing during congestion state. | (i) Saves time.(ii) Better scalability.(iii) Improved load balancing. |
| Cons | Puts excessive time on packet processing. | (i) Path oscillation.(ii) Nonoptimal routing during congestion.(iii) Resources consumption.(iv) Complexity. |
| Research | Altitude (m) | Sample size | AMS | Normal | Diagnosis of AMS with cut-off value | Age (mean) | BMI (mean) | Sex (m/f) | ||||||
| Smoking | Non-smoking | Smoking | Non-smoking | Smoking | Non-smoking | AMS | Normal | AMS | Normal | AMS | Normal | |||
| Ren, 2015 [14] | 4300 | 16 | 64 | 3 | 32 | 13 | 32 | LLS > 3 | 38.1 | 38.6 | 24.7 | 26.2 | 9/26 | 22/23 |
| Wu, 2012 [17] | 4525 | 182 | 200 | 71 | 102 | 111 | 98 | LLS >3 OR LLS >4 | ||||||
| You, 2012 [19] | 4300 | 138 | 176 | 36 | 83 | 102 | 93 | LLS > 4 | 20.08 | 20.25 | 21.31 | 21.47 | 119/0 | 195/0 |
| MacInnis, 2013 [26] | 4380 | 147 | 344 | 42 | 125 | 105 | 219 | LLS ≥ 3 | 100/67 | 244/80 | ||||
| Mairer, 2010(a) [28] | 3454 | 9 | 66 | 4 | 26 | 5 | 40 | LLS ≥ 4 | 35.1 | 34.5 | 23.4 | 23.3 | 25/5 | 39/6 |
| Mairer, 2010(b) [28] | 3817 | 13 | 67 | 3 | 25 | 10 | 42 | 36.2 | 38.1 | 23.5 | 22.8 | 22/6 | 41/11 | |
| Mairer, 2009 [27] | 3500 | 61 | 370 | 12 | 58 | 49 | 312 | LLS ≥ 4 | 38.4 | 37.2 | 23.7 | 23.3 | 50/20 | 266/86 |
| Schneider, 2002(a) [4] | 4559 | 56 | 331 | 16 | 103 | 40 | 228 | ESQ ≥ 0.70 | 38.2 | 22.6 | 314/73 | |||
| Schneider, 2002(b) [4] | 4559 | 72 | 368 | 21 | 99 | 51 | 269 | 37.0 | 22.7 | 359/81 |
| Variable | Total population, N=565 | Current use of LARC, N=179 |
| n (%) | n (%) | |
| Knowledge of LARC | ||
| a) Knowledge of duration of protection from pregnancy | ||
| IUD | 387 (68.5) | 136 (75.98) |
| Implant | 395 (69.9) | 139 (77.65) |
| Injectable | 494 (87.4) | 161 (89.94) |
| b) Knowledge of site of administration | ||
| IUD | 429 (75.9) | 148 (82.68) |
| Implant | 453 (80.2) | 158 (88.27) |
| Injectable | 519 (91.9) | 171 (95.53) |
| Pathway/substance | n | % | P-value |
| Animal faeces | 73 | 48.7 | |
| Raw meat | 57 | 38.0 | |
| Soil | 40 | 26.7* | P = 0.036a |
| Food | 39 | 26.0 | |
| Arthropods | 37 | 24.7 | |
| No idea | 37 | 24.7 | |
| Mother to child | 31 | 20.7 | |
| Plants | 20 | 13.3 | |
| Environmental contamination | 18 | 12 | |
| Claw scratch | 1 | 0.7* | P < 0.0001b |
| TOP 20 Nthy-ori-3.1 down-regulated genes | TOP 20 Nthy-ori-3.1 up-regulated genes | ||||
| Gene | Control FPKM | siRNA FPKM | Gene | Control FPKM | siRNA FPKM |
| MIR103A2 | 26.53 | 0 | OR5H14 | 0 | 0.70 |
| MIR103B2 | 205.72 | 0 | ACKR1 | 0 | 1.19 |
| MIR1227 | 8.63 | 0 | MIR5193 | 0 | 1.35 |
| MIR1231 | 10.49 | 0 | PTGIR | 0 | 1.39 |
| MIR1260B | 12.48 | 0 | BAALCOS | 0 | 1.48 |
| MIR1279 | 314.85 | 0 | CASC8 | 0 | 1.48 |
| MIR1304 | 11.15 | 0 | CTSE | 0 | 1.79 |
| MIR1324 | 8.08 | 0 | FDCSP | 0 | 2.03 |
| MIR15A | 47.29 | 0 | MIR5572 | 0 | 2.08 |
| MIR181B2 | 12.28 | 0 | MIR548I2 | 0 | 2.75 |
| MIR191 | 13.06 | 0 | CCL4 | 0 | 4.53 |
| MIR192 | 5.77 | 0 | MIR1178 | 0 | 4.86 |
| MIR194-1 | 16.51 | 0 | SNORA16B | 0 | 5.04 |
| MIR2278 | 14.21 | 0 | MIR1224 | 0 | 5.21 |
| MIR27B | 10.30 | 0 | MIR492 | 0 | 5.58 |
| MIR302C | 25.72 | 0 | MIR221 | 0 | 5.72 |
| MIR3176 | 43.99 | 0 | SNORA79 | 0 | 6.68 |
| MIR3190 | 22.54 | 0 | MIR577 | 0 | 7.14 |
| MIR3192 | 17.62 | 0 | MIR1207 | 0 | 7.28 |
| MIR320B2 | 2.41 | 0 | SNORA70B | 0 | 7.43 |
| ALT (%) | AST (%) | GLDH (%) | |
| HepG2 | 100 | 100 | 100 |
| cHCC | 25.8 | 27.7 | 19 |
| MDCK | 0 | 8 | 10 |
| Characteristic | Percentage* | Sample size |
| Gender (female) | 87.8% | 983 |
| Age | 983 | |
| <50 years | 2.0% | |
| 50–59 years | 14.5% | |
| 60–69 years | 30.0% | |
| 70–79 years | 33.7% | |
| ≥80 years | 19.7% | |
| BMD based on most recent lowest T-score, mean (SD) | −2.16 (1.55) | 946 |
| Additional fracture risk factors | 977 | |
| Previous fragility fracture | 27.8% | |
| Systemic glucocorticoids for >3 months | 8.5% | |
| Previous fragility fracture and systemic glucocorticoids for >3 months | 3.3% | |
| Length of treatment for osteoporosis | 980 | |
| <1 year | 11.3% | |
| 1–5 years | 43.8% | |
| >5 years | 44.9% | |
| Osteoporosis therapy | 983 | |
| Bisphosphonate | 79.0% | |
| Selective estrogen-receptor modulator | 3.0% | |
| Hormone therapy | 2.3% | |
| Parathyroid hormone | 2.2% | |
| Calcitonin | 1.3% | |
| Prescribed supplementation | 983 | |
| Calcium | 84.8% | |
| Vitamin D | 84.8% |
| A: Comparison between patients with active TB and control subjects | ||||
| P < 0.02 | 0.02≤P < 0.05 | 0.05≤P < 0.10 | ||
| Patients versus control subjects | 18 | 12 | 24 | |
| B: Comparison between stimulated and unstimulated conditions | ||||
| P < 0.02 | 0.02≤P < 0.05 | 0.05≤P < 0.10 | ||
| Patients | Mtb antigens versus no stimuli | 0 | 2 | 2 |
| Mitogen versus no stimuli | 3 | 5 | 11 | |
| Control subjects | Mtb antigens versus no stimuli | 0 | 1 | 13 |
| Mitogen versus no stimuli | 2 | 83 | 8 |
| Study/year | Sample size (I/C) | Setting | Prophylaxis drugs | Comparator | Patient characteristics (I/C) | ||||
| Age, mean, (years) | Disease severity, median (IQR) or mean (SD) | Patient receiving EN, n/N (%) | MV (%) | Follow up (months) | |||||
| Alhazzani et al. 2017 [18] | 49/42 | Mixed | Pantoprazole 40 mg once daily IV | Placebo | 62/55 | APACHE II score21 (17–26)/22(14–27) | 81/91 (89) | 100/100 | Unknown |
| El-Kersh et al. 2017 [29] | 55/47 | MICU | Pantoprazole 40 mg once daily IV | Placebo | 62/58 | SAPS II score41 (34.5–53)/44 (34–54) | 102/102 (100) | 100/100 | Unknown |
| Selvanderan et al. 2016 [27] | 106/108 | Mixed | Pantoprazole 40 mg once daily IV | Placebo | 52/52 | APACHE III score66 (26)/66 (28) | 214/214 (100) | 100/100 | 12 |
| Lin et al. 2016 [28] | 60/60 | Mixed | Lansoprazole OD 30 mg once daily | No prophylaxis | 67/65 | APACHE II score21.3 (6.7)/19.9 (6.9) | 120/120 (100) | 100/100 | 1 |
| Ben-menachem et al. 1994 [22] | 200/100 | MICU | Cimetidine 900 mg InfusionSucralfate OD 1 g every 6 h | No prophylaxis | 60/60 | APACHE II score17.4 (7.3)/16.5 (6.9) | 198/300 (67) | 74/65 | 10 |
| Apte et al. 1992 [21] | 16/18 | MICU | Ranitidine 50 mg/every 6 h IV | No prophylaxis | 27/26 | MTS score11 (4–16)/10 (6–16) | 34/34 (100) | 31/22 | Unknown |
| Van den Berg et al. 1985 [23] | 14/14 | Mixed | Cimetidine 20 mg/kg/every 24 h IV | Placebo | 44/48 | - | 17/28 (61) | 100/100 | Unknown |
| Experiment | Power (W) | Duration (s) | Tip-to-Tip Distance (mm) | Orientation | Peak Pressure (kPa) |
| 1 | 5 | 74 | 0.5 | Parallel | 71.6 |
| 2 | 3 | 105 | 1.2 | Parallel | 48.4 |
| 3 | 4 | 60 | 2.5 | Parallel | 5.8 |
| 4 | 5 | 52 | 5 | Perpendicular | 1.9 |
| Parameters | NC Group | HFD Group | HFD + Met | HFD + WE | HFD + 50% ME | HFD + ME |
| CRI-I = TC/HDL | 1.53 ± 0.03 b | 4.50 ± 0.57 d | 2.40 ± 0.10 b | 3.53 ± 0.26 d | 3.18 ± 0.16 a,d | 4.48 ± 0.39 d |
| CRI-II = LDL/HDL | 0.41 ± 0.05 b | 5.62 ± 1.10 d | 1.42 ± 0.19 b | 2.28 ± 0.24 b | 1.92 ± 0.17 b | 3.29 ± 0.44 a,d |
| AC = (TC–HDL)/HDL | 0.60 ± 0.06 b | 6.14 ± 1.18 d | 1.64 ± 0.21 b | 2.52 ± 0.26 b | 2.18 ± 0.16 b | 3.93 ± 0.64 a,d |
| Variables | Frequency | % | |
| Age in years | 10–29 | 276 | 71.5 |
| 30–39 | 70 | 18.1 | |
| 40–49 | 25 | 6.5 | |
| >50 | 15 | 3.9 | |
| Sex | Male | 220 | 57 |
| Female | 166 | 43 | |
| Marital status | Single | 247 | 64 |
| Married | 21 | 5.4 | |
| Divorced/Separated | 118 | 30.6 | |
| Income/$ USD | <117.5 | 56 | 14.5 |
| 117.5–177.5 | 182 | 47.2 | |
| 178–250 | 112 | 29 | |
| >250 | 36 | 9.3 | |
| Educational level | Diploma | 37 | 9.6 |
| BSc | 328 | 85 | |
| MSc | 21 | 5.4 | |
| Service years | < year | 80 | 20.7 |
| 1–5 years | 192 | 49.7 | |
| 6–10 | 40 | 10.4 | |
| 11–15 | 29 | 7.5 | |
| 16–20 | 25 | 6.5 | |
| >20 | 20 | 5.2 |
| Position | δH (J in Hz) | δC | HMBCa |
| 2 | — | 162.7 | |
| 3 | 6.16 1H, d (9.6) | 115.7 | C-2, 4a |
| 4 | 7.64 1H, d (9.6) | 145.7 | C-2, 5 |
| 4a | — | 116.9 | |
| 5 | 6.90 1H, s | 105.9 | C-4, 6, 7, 8a |
| 6 | — | 151.8 | |
| 7 | — | 143.1 | |
| 8 | — | 142.7 | |
| 8a | — | 144.0 | |
| 1′ | 5.20 1H, d (7.5) | 103.9 | C-7 |
| 2′ | 3.55 1H, dd (7.5, 9.0) | 75.7 | C-1′, 3′, |
| 3′ | 3.47 1H, t (9.0) | 77.9 | C-2′, 4′ |
| 4′ | 3.40 (1H, t, 9.0) | 72.2 | C-3′, 5′ |
| 5′ | 3.50 1H, m | 75.9 | C-4′ |
| 6′ | 4.39 1H, dd (11.4, 7.2) | 64.4 | C-4′, 5′ |
| 4.34 1H, dd (11.4, 2.0) | |||
| 1′′ | — | 127.1 | |
| 2′′/6′′ | 7.32 2H, d (8.7) | 131.3 | C-4′′ |
| 3′′/5′′ | 6.80 2H, d (8.7) | 117.1 | C-1′′, 4′′ |
| 4′′ | — | 161.5 | |
| 7′′ | 7.37 1H, d (15.9) | 146.5 | C-1′′, 2′′/6′′, 9′′ |
| 8′′ | 6.10 1H, d (15.9) | 114.9 | C-7′′, 9′′ |
| 9′′ | — | 168.7 | |
| 6-OMe | 3.88 3H, s | 57.2 | C-6 |
| 8-OMe | 3.99 3H, s | 62.5 | C-8 |
| Parameter | DB |
| HISTogram parameter ( HIST ) | 0.53 |
| Zero Crossing parameter (ZC) | 0.70 |
| Auto Regressive coefficients (AR) | 1.01 |
| Integral Absolute Value (IAV) | 1.24 |
| Name | Sequence 5'-3' | Description |
| H-exon 2-3 reverse | ATTTGTGATACCCCTCGACGAG | Normal human ERCC1 transcript reverse primer |
| Hskin4RTreverse | TGTACAGAGATCGCCCTGCTCTATGC | Larger Human ERCC1 transcript reverse primer |
| REV1 | CGGTCCTCCAGAACCATAGA | Larger Human ERCC1 transcript reverse primer |
| Oligo dT anchor | GACCACGCGTATCGATGTCGACTTTTTTTTTTTTTTTTV (V=A, C or G) | Anchor primer |
| PCR anchor | GACCACGCGTATCGATGTCGA | Internal anchor primer |
| Antibiotics | Disk Potency (μg) | Susceptible | Intermediate | Resistant |
| Chloramphenicol (C) | 30 | 41(100%) | 0 | 0 |
| Erythromycin (E) | 15 | 38(92.5%) | 0 | 3(7.5%) |
| Ampicillin (AMP) | 10 | 35(85.4%) | 0 | 6(14.6%) |
| Vancomycin (VA) | 30 | 34(83%) | 0 | 7(17%) |
| Penicillin G (P) | 10 | 33(80.5%) | 0 | 8(19.5%) |
| Clindamycin (DA) | 2 | 30(73.2%) | 0 | 11(26.8%) |
| Cefotaxime (CTX) | 30 | 27(65.9%) | 0 | 14(34.1%) |
| Tetracycline (TE) | 30 | 3(7.3%) | 1(2.4%) | 37(90.2%) |
| 2008 | 2009 | 2010 | 2011 | ||
| N | CM | 304 | 295 | 269 | 297 |
| ICHM | 366 | 366 | 375 | 376 | |
| Female (n (%)) | CM | 187 (61.5%) | 166 (56.3%) | 150 (55.8%) | 171 (57.6%) |
| ICHM | 222 (60.7%) | 213 (58.2%) | 207 (55.2%) | 223 (59.3%) | |
| Age (mean (SD) (median, range)) | CM | 80.8 (8.5) (83, 60 to 101) | 80.6 (9.3) (83, 60 to 101) | 81.3 (9.2) (83, 60 to 98) | 81.3 (9.5) (83, 60 to 100) |
| ICHM | 80.5 (8.4) (82, 60 to 100) | 79.5 (8.9) (81, 60 to 99) | 80.3 (8.8) (82, 60 to 99) | 79.9 (9.3) (81, 60 to 100) | |
| Functional status (mean (SD) (median, range)) | CM | 2.0 (0.8) (2, 1 to 4) | 2.3 (0.9) (2, 1 to 5) | 2.3 (0.9) (2, 1 to 5) | 2.3 (0.9) (2, 1 to 5) |
| ICHM | 2.2 (0.9) (2, 1 to 5) | 2.2 (0.9) (2, 1 to 5) | 2.1 (0.9) (2, 1 to 5) | 2.1 (0.9) (2, 1 to 5) |
| Diamniadio District | Rufisque District | |||||
| Before | During | % Increase | Before | During | % Increase | |
| Number of contraceptives provided | 8,351 | 11,935 | 43% | 17,551 | 22,779 | 30% |
| Pills | 4,540 | 6,097 | 34% | 9,465 | 11,867 | 25% |
| Injectables | 3,568 | 5,277 | 48% | 7,224 | 9,373 | 30% |
| Implants | 187 | 470 | 151% | 536 | 1,097 | 105% |
| Intrauterine devices (IUDs) | 56 | 91 | 63% | 326 | 442 | 36% |
| Long-acting methods | 243 | 561 | 131% | 862 | 1,539 | 79% |
| Couple-years of protection | 2,164 | 3,932 | 82% | 5,977 | 9,340 | 56% |
| Men with varicocele | Men without varicocele | |||
| Normal sperm | Sperm disturbances | Normal sperm | Sperm disturbances | |
| Dark-eyed men | 25.6% | 74.4% | 16.7% | 83.3% |
| Light-eyed men | 44.4% | 55.6% | 23.4% | 76.6% |
| P | 0.419 | 0.586 |
| Variables | No (%) |
| Perceived need* | |
| Food | 114 (97.4%) |
| Shelter | 88 (75.2%) |
| Water (Drinking & Washing) | 74 (63.2%) |
| Clothes | 55 (47.0%) |
| Information about Family Members/relatives | 35 (29.9%) |
| Adsorbents for Menstrual Hygiene | 22 (18.8%) |
| Mobiles | 17 (14.5%) |
| Medicine/First aid | 13 (11.1%) |
| Safe place | 12 (10.3%) |
| Soap | 8 (6.8%) |
| Cattle | 7 (6.0%) |
| X. dendrorhousstrains | ||||
| CBS 6938 | CBS-CYP51+/− | |||
| Cultivation Time (h) | 48 | 120 | 48 | 120 |
| Sterols: | 5.6 ± 0.2 | 3.8 ± 0.4 | 3.2 ± 0.7 | 4.9 ± 0.8 |
| Total Carotenoids: | 24 ± 5 (100) | 256 ± 18 (100) | 325 ± 115 (100) | 486 ± 54 (100) |
| Astaxanthin | 19 ± 4 (78) | 174 ± 23 (68) | 95 ± 27 (29) | 203 ± 20 (42) |
| Phoenicoxanthin | 2.5 ± 0.7(10) | 30.0 ± 0.8 (12) | 37 ± 15 (11) | 74 ± 14 (15) |
| Canthaxanthin | ND | ND | 9 ± 5 (3) | 12 ± 6 (3) |
| Echinenone | ND | ND | 4 ± 7 (1) | ND |
| β-carotene | ND | 12 ± 6 (5) | 67 ± 33 (21) | 55 ± 15 (11) |
| Lycopene | ND | ND | 7 ± 6 (2) | ND |
| Monocyclic carotenoids | 2.8 ± 0.8 (11) | 40 ± 3 (16) | 107 ± 40 (33) | 149 ± 27 (31) |
| Taxon | Dry (n = 16) | Wet (n = 16) | Pooled SEM | P-value | q-value |
| Actinobacteria | 16.5 | 0.1 | 3.8 | 0.011 | 0.068 |
| Bacteroidetes | 8.7 | 15.9 | 4.7 | 0.010 | 0.062 |
| Firmicutes | 73.6 | 57.6 | 7.7 | 0.090 | 0.539 |
| Fusobacteria | 0.3 | 23.1 | 2.9 | <0.000 | <0.000 |
| Proteobacteria | 0.4 | 1.1 | 0.2 | 0.008 | 0.047 |
| Unclassified bacteria | 0.5 | 2.1 | 0.2 | <0.000 | 0.002 |
| Past Week NSSI Measures | n | d | p |
| Number of NSSI episodes (ABASI) | 1514 | .13 | .01 |
| Medical severity of NSSI (ABASI) | 1239 | .29 | <.001 |
| Impulsivity of NSSI (ABASI) | 1234 | -.01 | .87 |
| Craving for NSSI (ABUSI total score) | 1476 | 1.16 | <.001 |
| Past Year NSSI Methods (ABASI) | |||
| Cut | 676 | .13 | .09 |
| Scratch | 676 | .20 | .01 |
| Burn | 676 | .12 | .11 |
| Tattoo/Pierce | 676 | .01 | .91 |
| Choke | 676 | .33 | <.001 |
| Pull Hair | 676 | .20 | .01 |
| Draw Blood | 676 | .09 | .25 |
| Insert/Embed | 676 | .19 | .01 |
| Hit | 345 | .45 | <.001 |
| Bang | 676 | .28 | <.001 |
| Prevent Wound Healing | 676 | .24 | .002 |
| Fall Down | 676 | .00 | .99 |
| Break Bones | 676 | .11 | .16 |
| Gouge | 676 | .05 | .51 |
| Fight | 676 | .11 | .14 |
| Ingest/Swallow | 676 | .09 | .25 |
| Mutilate Genitals | 343 | .00 | 1 |
| Worsen Medical Condition/Ignore Medical Advice | 676 | .23 | .003 |
| Past Year Number of NSSI Methods (ABASI) | 676 | .52 | <.001 |
| Past Year Number of Days with NSSI (ABASI) | 345 | .65 | <.001 |
| Variable | Univariate Analysis | Multivariate Analysis | ||
| HR (95% CI) | p Value | HR (95% CI) | p Value | |
| Age (years) | 0.976 (0.944–1.008) | 0.140 | ||
| BMI (kg/m2) | 0.863 (0.715–1.042) | 0.127 | ||
| L3 SMI (cm2/m2) | 0.904 (0.830–0.984) | 0.020 | 0.909 (0.836–0.985) | 0.020 |
| Child-Pugh score | 0.840 (0.312–2.265) | 0.730 | ||
| Albumin (g/dL) | 0.556 (0.180–1.722) | 0.309 | ||
| PLT (×104/mL) | 1.049 (0.992–1.111) | 0.096 | ||
| log (AFP) | 1.793 (1.162–2.767) | 0.008 | 1.274 (1.0580–1.534) | 0.010 |
| log (PIVKA-II) | 1.024 (0.857–1.224) | 0.794 | ||
| Stage (IVB vs. others) | 1.062 (0.407–2.770) | 0.902 | ||
| Combination therapy (yes vs. no) | 0.533 (0.188–1.509) | 0.236 |
| Gene ID | Gene | Protein description | Mean RPKM WT | Mean RPKM ΔgacA | ΔgacA/WT | P-value |
| gacS/gacA | ||||||
| Pchl3084_3491 | gacA | Response regulator | 266.9 | 1.43 | 0.01 | 0.00 |
| Pchl3084_4333 | gacS | Sensor protein | 29.17 | 21.15 | 0.73 | 0.05 |
| phz genes | ||||||
| Pchl3084_4951 | phzX | Phenazine biosynthesis protein | 40.50 | 4.52 | 0.11 | 0.03 |
| Pchl3084_4952 | phzY | Phenazine biosynthesis protein | 37.87 | 5.28 | 0.14 | 0.03 |
| Pchl3084_4953 | phzF | Phenazine biosynthesis protein | 20.00 | 2.63 | 0.13 | 0.03 |
| Pchl3084_4954 | phzA | Phenazine biosynthesis protein | 8.52 | 0.78 | 0.09 | 0.15 |
| Pchl3084_4955 | phzB | Phenazine biosynthesis protein | 13.47 | 2.08 | 0.15 | 0.04 |
| Pchl3084_4956 | phzC | Phenazine biosynthesis protein | 8.24 | 1.90 | 0.23 | 0.00 |
| Pchl3084_4957 | phzD | Phenazine biosynthesis protein | 7.63 | 1.40 | 0.18 | 0.10 |
| Pchl3084_4958 | phzO | Phenazine biosynthesis protein | 44.23 | 21.70 | 0.49 | 0.06 |
| Regulatory genes | ||||||
| Pchl3084_4949 | phzI | Autoinducer synthase | 5.24 | 1.50 | 0.29 | 0.01 |
| Pchl3084_4950 | phzR | Transcriptional activator | 125.1 | 67.12 | 0.54 | 0.02 |
| Pchl3084_1189 | rpoS | Sigma factor | 1045.7 | 101.8 | 0.10 | 0.03 |
| Pchl3084_5155 | pip | Phenazine-inducing protein | 123.4 | 105.4 | 0.85 | 0.04 |
| Pchl3084_1659 | iopA | Inducer of phenazine A | 49.10 | 8.35 | 0.17 | 0.01 |
| Pchl3084_1660 | iopB | Inducer of phenazine B | 20.71 | 2.51 | 0.12 | 0.00 |
| Pchl3084_3224 | rpeA | Sensor histidine kinase | 46.78 | 49.28 | 1.05 | 0.67 |
| Pchl3084_3225 | rpeB | Response regulator | 45.37 | 55.20 | 1.22 | 0.07 |
| Pchl3084_2449 | csaI | Autoinducer synthase | 8.15 | 8.72 | 1.07 | 0.65 |
| Pchl3084_2451 | csaR | Transcriptional activator | 0.54 | 0.38 | 0.71 | 0.50 |
| Pchl3084_0554 | hfq | RNA chaperone | 1642.19 | 1408.2 | 0.84 | 0.28 |
| Pchl3084_4387 | rsmA | Translational regulator | 151.82 | 307.24 | 2.02 | 0.03 |
| Pchl3084_2024 | rsmE | Translational regulator | 292.7 | 204.83 | 0.70 | 0.06 |
| Pchl3084_3970 | rsmX | ncRNA | 1486.51 | 201.13 | 0.14 | 0.02 |
| Pchl3084_5419 | rsmY | ncRNA | 38112.4 | 329.2 | 0.01 | 0.02 |
| Pchl3084_1190 | rsmZ | ncRNA | 1679.64 | 261.26 | 0.16 | 0.05 |
| Grade | Description |
| 0 | No changes |
| 1 | Doubtful narrowing of joint space and possible osteophytic lipping |
| 2 | Definite osteophytes and possible narrowing of joint space |
| 3 | Moderate multiple osteophytes, definite narrowing of joint space, and some sclerosis, and possible deformity of bone ends |
| 4 | Large osteophytes, marked narrowing of joint space, severe sclerosis and definite deformity of bone ends |
| cELISA assay | Total | |||
| P | N | |||
| Skin test | P | 45 | 31 | 76 |
| N | 45 | 177 | 222 | |
| Total | 90 | 208 | 298 |
| Indicator | Baseline | Mid-term | End-term | DID adjusted BL-ML | Sig. | DID adjusted BL-EL | Sig. | |||||||||
| Comparison | Intervention | Comparison | Intervention | Comparison | Intervention | |||||||||||
| % | N | % | N | % | N | % | N | % | N | % | N | |||||
| Proportion of women reporting health worker introduction | 26% | 53 | 37% | 68 | 30% | 89 | 38% | 120 | 40% | 62 | 49% | 85 | −4% | 0.77 | −4% | 0.82 |
| Proportion of women reporting having been clinically examined | 57% | 53 | 46% | 68 | 99% | 89 | 96% | 120 | 92% | 62 | 91% | 85 | 5% | 0.73 | 6% | 0.75 |
| Proportion of women reporting having received an explanation of the examination | 100% | 30 | 100% | 31 | 64% | 88 | 58% | 115 | 54% | 57 | 58% | 77 | −5% | 0.69 | −2% | 0.85 |
| Proportion of women reporting having received medication/treatment | 92% | 53 | 71% | 68 | 87% | 89 | 88% | 120 | 66% | 62 | 79% | 85 | 23% | 0.07 | 29% | 0.03* |
| Proportion of women reporting having received an explanation for the medication | 59% | 49 | 63% | 48 | 42% | 77 | 46% | 106 | 56% | 41 | 73% | 67 | −3% | 0.85 | 12% | 0.54 |
| Proportion of women reporting having had a blood test done | 26% | 53 | 47% | 68 | 21% | 89 | 8% | 120 | 23% | 62 | 36% | 85 | −35% | 0.03 | −2% | 0.90 |
| Proportion of women reporting having received an explanation for the test | 93% | 14 | 75% | 32 | 32% | 19 | 30% | 10 | 64% | 14 | 65% | 31 | 9% | 0.69 | 10% | 0.65 |
| Proportion of women reporting consent being sought before procedures were performed | 55% | 53 | 61% | 66 | 62% | 87 | 63% | 112 | 68% | 60 | 75% | 77 | −5% | 0.73 | 1% | 0.96 |
| Proportion of women having been encouraged to ask questions | 36% | 53 | 49% | 68 | 25% | 89 | 33% | 120 | 45% | 62 | 58% | 85 | −8% | 0.63 | 2% | 0.89 |
| Proportion of women reporting being offered to have guardian during delivery | 42% | 53 | 57% | 68 | 22% | 89 | 58% | 120 | 50% | 62 | 55% | 85 | 18% | 0.29 | 3% | 0.87 |
| Proportion of women reporting their privacy/confidentiality being protected | 96% | 53 | 96% | 68 | 91% | 89 | 94% | 120 | 90% | 62 | 96% | 85 | 3% | 0.67 | 8% | 0.55 |
| Proportion of women reporting blood pressure was checked before delivery | 53% | 53 | 51% | 68 | 49% | 89 | 37% | 120 | 61% | 62 | 65% | 85 | −15% | 0.22 | 19% | 0.26 |
| Proportion of women reporting blood pressure was checked after delivery | 40% | 53 | 44% | 68 | 66% | 89 | 57% | 116 | 45% | 58 | 68% | 81 | −13% | 0.36 | 19% | 0.25 |
| Country | Region | Classification category of country for ZIKV transmission as per WHO | Number of cases reported |
| American Samoa | American Samoa | Category 3 (interrupted transmission areas) | 51 |
| Angola | Angola | Category 1 (virus transmission areas followed by new/re introduction of virus) | 2 |
| Argentina | Chaco, Formosa, Salta, Tucuman | Category 1 (virus transmission areas followed by new/re introduction of virus) | 4 |
| Bahamas | Bahamas | Category 1 (virus transmission areas followed by new/re introduction of virus) | 25 |
| Bangladesh | Bangladesh | Category 2 (virus transmission areas following previous circulation of virus) | 1 |
| Brazil | Acre, Alagoas, Amapa Amazonas, Ceara, Distrito Federal, Espirito Santo, Goias, Mato Grosso, Mato Grosso Do Sul, Minas Gerais, Para, Paraiba, Parana, Pernambuco, Piaui, Rio Grande Do Norte, Rio Grande Do Sul, Rondonia, Roraima, Santa Catarina, Sao Paulo, Sergipe, Tocantin | Category 1 (virus transmission areas followed by new/re introduction of virus) | 27 |
| Bahia, Maranhao | Category 2 (newly documented intense transmission areas) | ||
| Rio de Janeiro | Category 2 (virus transmission areas following previous circulation of virus) | ||
| Colombia | Colombia | Category 1 (virus transmission areas followed by new/re introduction of virus) | 46 |
| Costa Rica | Costa Rica | Category 1 (virus transmission areas followed by new/re introduction of virus) | 23 |
| Dominican Republic | Dominican Republic | Category 1 (virus transmission areas followed by new/re introduction of virus) | 30 |
| India | Gujarat, Tamil Nadu | Category 2 (virus transmission areas following previous circulation of virus) | 2 |
| Indonesia | Bali, Bangka Belitung, Banten, Bengkulu, Daerah Istimewa Yogyakarta, Dki Jakarta, Gorontalo, Jambi, Jawa Barat, Jawa Tengah, Jawa Timur, Kalimantan Barat, Kalimantan Selatan, Kalimantan Tengah, Kalimantan Timur, Kepulauan-Riau, Lampung, Maluku, Maluku Utara, Nanggroe Aceh Darussalam, Nusa Tenggara Barat, Nusa Tenggara Timur, Papua, Papua Barat, Riau, Sulawesi Barat, Sulawesi Selatan, Sulawesi Tengah, Sulawesi Tenggara, Sulawesi Utara, Sumatera Barat, Sumatera Selatan, Sumatera Utara | Category 2 (virus transmission areas following previous circulation of virus) | 31 |
| Malaysia | Malaysia | Category 2 (virus transmission areas following previous circulation of virus) | 8 |
| Mexico | Aguascalientes, Baja California, Baja California Sur, Campeche, Chiapas, Coahuila, Colima, Guerrero, Hidalgo, Jalisco, Michoacan, Morelos, Nayarit, Nuevo Leon, Oaxaca, Puebla, Quintana Roo, San Luis Potosi, Sinaloa, Sonora, Tabasco, Tamaulipas, Veracruz, Yucatan, Zacatecas | Category 1 (virus transmission areas followed by new/re introduction of virus) | 25 |
| Philippines | Philippines | Category 2 (virus transmission areas following previous circulation of virus) | 57 |
| Thailand | Thailand | Category 2 (newly documented intense transmission areas) | 33 |
| United States of America | Cameron | Category 1 (virus transmission areas followed by new/re introduction of virus) | 202 |
| Broward, Miami-Dade, Palm Beach, Pinellas | Category 3 (interrupted transmission areas) | ||
| Vietnam | Vietnam | Category 2 (newly documented intense transmission areas) | 232 |
| Total | East | West | p-value* | ||
| Age | mean (95% CI) | 31.6 (30.8, 32.3) | 35.2 (33.9, 36.5) | 30.0 (29.1, 30.9) | p < 0.001 |
| range | (5, 80) | (8, 74) | (5, 80) | ||
| missing | 61 | 7 | 54 | ||
| Weight (kg) | mean (95% CI) | 52.9 (52.3, 53.5) | 55.2 (53.9, 56.4) | 52.3 (51.6, 53.0) | p < 0.001 |
| range | (15, 92) | (18, 85) | (15, 92) | ||
| missing | 223 | 164 | 59 | ||
| Initial parasite | geometric mean (95% CI) | 17998 (16861, 19135) | 20478 (18189, 22766) | 16958 (15663, 18253) | p = 0.007 |
| density | range | (520, 116960) | (560, 116000) | (520, 116960) | |
| missing | 0 | 0 | 0 | ||
| Sex | male (%) | 1071 (81.1) | 334 (85.2) | 737 (79.4) | p = 0.014 |
| female (%) | 249 (18.9) | 58 (14.8) | 191 (20.6) | ||
| missing | 7 | 0 | 7 |
| Number of criteria positively scored | Sensitivity | Specificity |
| 1. criteria or more | 0.88 | 0.31 |
| 2. criteria or more | 0.85 | 0.41 |
| 3. criteria or more | 0.83 | 0.52 |
| 4. criteria or more | 0.78 | 0.69 |
| 5. criteria or more | 0.70 | 0.85 |
| 6. criteria or more | 0.50 | 0.94 |
| 7. criteria | 0.18 | 0.98 |
| Confounder | Variables | How to measure |
| Demographic characteristics | Age, sex, social status, family size, educational attainment, occupational history, income | Questionnaire |
| Lifestyle | Smoking, alcohol | Questionnaire |
| Genetic factor | Family history of diabetes/hypertension | Questionnaire |
| Drugs | Different medications for diabetes and hypertension | Clinical record |
| CHr pgmean (SD) | RSf fLmean (SD) | |
| Healthy | 33.2 (1.6) | 100.9 (5.3) |
| IDA | 24.5 (4.4) | 88.1 (7.8) |
| IDA APR | 25.6 (2.5) | 84.7 (4.1) |
| ACD | 30.8 (5.1) | 105.5 (10.9) |
| CKD | 31.6 (3.5) | 110.6 (8.7) |
| Subgroup | No. of studies | ES (95% CI) | P value | Heterogeneity test | |
| I2(%) | P value | ||||
| T, ES was described by OR | |||||
| All | 15 | 1.23 (0.98–1.55) | 0.074 | 0 | 0.636 |
| OC | 5 | 1.32 (0.89–1.97) | 0.173 | 1.9 | 0.396 |
| LC | 4 | 1.08 (0.70–1.67) | 0.721 | 0 | 0.469 |
| NPC | 3 | 1.50 (0.86–2.60) | 0.150 | 0 | 0.682 |
| HNC | 2 | 0.92 (0.46–1.83) | 0.808 | 62.9 | 0.101 |
| N, ES was described by OR | |||||
| All | 17 | 1.28 (1.03–1.60) | 0.027 | 21.6 | 0.202 |
| OC | 6 | 1.49 (1.01–2.20) | 0.043 | 0 | 0.604 |
| LC | 4 | 0.90 (0.46–1.76) | 0.763 | 65.4 | 0.034 |
| NPC | 3 | 1.36 (0.88–2.09) | 0.165 | 0 | 0.381 |
| HNC | 3 | 1.38 (0.83–2.28) | 0.215 | 27.9 | 0.250 |
| TNM, ES was described by OR | |||||
| All | 14 | 1.33 (1.06–1.66) | 0.015 | 0 | 0.505 |
| OC | 5 | 1.58 (1.05–2.37) | 0.030 | 0 | 0.926 |
| LC | 2 | 1.22 (0.67–2.25) | 0.519 | 56.4 | 0.130 |
| NPC | 3 | 1.01 (0.61–1.67) | 0.979 | 0 | 0.843 |
| HNC | 3 | 1.64 (1.02–2.62) | 0.041 | 64.8 | 0.058 |
| OS, ES was described by HR | |||||
| All | 19 | 1.93 (1.29–2.90) | 0.001 | 87.9 | 0.000 |
| OC | 5 | 1.65 (0.90–3.03) | 0.106 | 53.3 | 0.073 |
| LC | 3 | 4.80 (0.73–31.6) | 0.103 | 90.6 | 0.000 |
| NPC | 6 | 1.51 (0.52–4.42) | 0.452 | 94.5 | 0.000 |
| HNC | 2 | 1.79 (0.85–3.77) | 0.128 | 55.6 | 0.013 |
| RFS, ES was described by HR | |||||
| All | 7 | 2.02 (1.00–4.08) | 0.050 | 82.5 | 0.000 |
| LC | 3 | 2.35 (0.98–5.63) | 0.055 | 49.3 | 0.139 |
| NPC | 2 | 2.24 (0.31–16.2) | 0.422 | 94.3 | 0.000 |
| DFS, ES was described by HR | |||||
| All | 3 | 5.14 (2.84–9.31) | 0.000 | 61.6 | 0.074 |
| Nucleotides | Amino acids | ||||||
| MCMCTreeWAG + G | PhyloBayesLG + G | PhyloBayesCAT-GTR + G | MCMCTree GTR + G | PhyloBayes GTR + G | PhyloBayesCAT-GTR + G | TimeTreemean/medianb | |
| Turtles and archosaurs MRCA | 229 (200 to 253) | 228 (208 to 252) | 249 (233 to 270) | 228 (188 to 256) | 225 (212 to 240) | 258 (238 to 274) | 244/265 |
| Archosaurs MRCA | 200 (166 to 231) | 188 (162 to 217) | 211 (186 to 236) | 209 (168 to 241) | 201 (180 to 221) | 226 (199 to 249) | 238/245 |
| Turtles MRCA | 121 (63 to 183) | 126 (85 to 166) | 147 (104 to 185) | 107 (53 to 183) | 133 (93 to 171) | 167 (120 to 207) | 207/211 |
| Caretta/Emys + Cheloinidis | 77 (40 to 127) | 83 (47 to 117) | 99 (64 to 139) | 69 (34 to 129) | 90 (52 to 125) | 115 (71 to 154) | 97/99 |
| Emys/Chelonoidis | 65 (25 to 116) | 71 (38 to 102) | 87 (54 to 124) | 52 (16 to 112) | 74 (39 to 106) | 95 (56 to 131) | 70/70 |
| Caiman/Alligator | 72 (15 to 156) | 54 (33 to 86) | 61 (35 to 93) | 60 (11 to 160) | 39 (21 to 66) | 46 (24 to 87) | 70/72 |
| Podarcis/Python + Anolis | 171 (119 to 218) | 150 (116 to 183) | 134 (100 to 172) | 167 (108 to 219) | 150 (122 to 181) | 119 (90 to 151) | 190/178 |
| Python/Anolis | 147 (81 to 198) | 136 (98 to 71) | 127 (93 to 167) | 141 (58 to 199) | 135 (101 to 161) | 105 (74 to 136) | 171/163 |
| Variable | Year/Region | With WNV Mean Rank | Without WNV Mean Rank | z-score | P |
| Precipitation | 2002/East | 701 | 695 | -0.16 | 0.88 |
| 2002/West | 776 | 619 | -2.31 | 0.021 | |
| 2003/East | 733 | 694 | -0.53 | 0.6 | |
| 2003/West | 465 | 637 | -4.57 | <0.001 | |
| 2004/East | 678 | 695 | -0.14 | 0.89 | |
| 2004/West | 626 | 623 | -0.23 | 0.98 | |
| 2005/East | 679 | 695 | -0.96 | 0.92 | |
| 2005/West | 623 | 624 | -0.01 | 0.99 | |
| 2006/East | 421 | 697 | -2.27 | 0.023 | |
| 2006/West | 526 | 625 | -1.35 | 0.18 | |
| Dewpoint | 2002/East | 708 | 695 | -0.74 | 0.94 |
| 2002/West | 581 | 625 | -0.65 | 0.52 | |
| 2003/East | 747 | 694 | -0.71 | 0.48 | |
| 2003/West | 479 | 636 | -4.15 | <0.001 | |
| 2004/East | 516 | 696 | -1.49 | 0.14 | |
| 2004/West | 512 | 625 | -1.08 | 0.28 | |
| 2005/East | 547 | 695 | -0.91 | 0.37 | |
| 2005/West | 616 | 624 | -0.11 | 0.91 | |
| 2006/East | 881 | 694 | -1.55 | 0.12 | |
| 2006/West | 450 | 627 | -2.4 | 0.017 | |
| Max. Temp. | 2002/East | 780 | 694 | -1.04 | 0.3 |
| 2002/West | 579 | 625 | -0.67 | 0.5 | |
| 2003/East | 730 | 695 | -0.49 | 0.63 | |
| 2003/West | 607 | 636 | -0.48 | 0.64 | |
| 2004/East | 536 | 696 | -1.32 | 0.19 | |
| 2004/West | 412 | 626 | -2.05 | 0.041 | |
| 2005/East | 532 | 696 | -1.0 | 0.32 | |
| 2005/West | 557 | 625 | -1.01 | 0.31 | |
| 2006/East | 877 | 694 | -1.51 | 0.13 | |
| 2006/West | 559 | 625 | -0.88 | 0.38 | |
| Min. Temp. | 2002/East | 741 | 694 | -0.57 | 0.57 |
| 2002/West | 532 | 626 | -1.38 | 0.17 | |
| 2003/East | 712 | 695 | -0.234 | 0.81 | |
| 2003/West | 483 | 636 | -4.04 | <0.001 | |
| 2004/East | 598 | 695 | -0.80 | 0.42 | |
| 2004/West | 397 | 626 | -2.19 | 0.029 | |
| 2005/East | 556 | 696 | -0.85 | 0.40 | |
| 2005/West | 486 | 627 | -2.08 | 0.037 | |
| 2006/East | 820 | 694 | -1.04 | 0.30 | |
| 2006/West | 397 | 628 | -3.12 | 0.002 |
| Tissue type | Pegcantratinib (MF) | CT340 (MF) | Ratio |
| Skin with anagen follicles | 1.05 | 1.05 | 1.00 |
| Cylindroma and spiradenoma | 0.97 | 0.96 | 1.01 |
| Cylindroma only | 1.07 | 1.05 | 1.02 |
| Spiradenoma only: | 0.92 | 1.01 | 0.91 |
| – Mean | 1.00 | 1.02 | 0.99 |
| – SD | 0.07 | 0.04 | 0.05 |
| – CV (%) | 7.1 | 3.9 | 5.0 |
| Case no. | @Age/ $Gender | Stage | Grade | #Recurrence | MSI |
| BC 1 | 45/M | T2 | High, G3 | 2 | *High (BAT – 26, BAT – 40) |
| BC 2 | 59/M | T1 | High, G2 | 1 | High (BAT – 26, BAT – 40, D9S1851) |
| BC 3 | 66/M | Ta | Low, G1 | 0 | High (D9S283, D9S1851) |
| BC 4 | 39/M | T2 | High, G3 | 0 | High (BAT – 26, BAT – 40, D9S283) |
| BC 5 | 72/M | T2 | High, G3 | 0 | High (BAT – 40, D9S1851) |
| BC 6 | 59/M | T2 | High, G2 | 1 | Low (D9S1851) |
| BC 7 | 78/M | T2 | High, G3 | 0 | High (D9S283, D9S1851) |
| BC 8 | 52/M | Ta | High, G2 | 0 | High (BAT – 40, D9S283, D9S1851) |
| BC 9 | 71/M | Ta | High, G2 | 0 | **Low (BAT – 40) |
| BC 10 | 84/M | T1 | High, G2 | 0 | ***MSS |
| BC 11 | 55/M | T1 | High, G1 | 0 | MSS |
| BC 12 | 53/M | T2 | High, G2 | 0 | Low (D18S58) |
| BC 13 | 52/M | T3 | High, G3 | 0 | High (D9S283, D9S1851) |
| BC 14 | 40/M | T3 | High, G3 | 0 | MSS |
| BC 15 | 55/M | T2 | High, G3 | 0 | MSS |
| BC 16 | 60/M | T2 | High, G3 | 0 | High (BAT – 40, D9S283, D18S58) |
| BC 17 | 66/M | T1 | High, G3 | 1 | High (BAT – 40, D2S123, D9S283, D9S1851, D18S58) |
| BC 18 | 80/M | T1 | High, G3 | 1 | High (BAT – 26, D9S283, D18S58) |
| BC 19 | 42/M | T1 | High, G2 | 0 | Low (D9S283) |
| BC 20 | 73/M | T3a | High, G3 | 0 | MSS |
| BC 21 | 55/M | T2 | High, G3 | 0 | Low (D2S123) |
| BC 22 | 58/M | T2 | High, G3 | 0 | High (BAT – 26, D2S123) |
| BC 23 | 70/M | T1 | High, G2 | 0 | Low (BAT – 26) |
| BC 24 | 53/M | Ta | High, G3 | 0 | High (D9S1851, D18S58) |
| BC 25 | 60/M | T2 | High, G3 | 0 | High (D9S283, D9S1851) |
| BC 26 | 54/M | Ta | Low, G1 | 0 | MSS |
| BC 27 | 72/M | Ta | High, G2 | 0 | MSS |
| BC 28 | 58/M | T1 | High, G3 | 0 | Low (D9S283) |
| BC 29 | 80/M | T2 | High, G3 | 0 | High (D9S283, D9S1851) |
| BC 30 | 64/M | Ta | High, G2 | 2 | Low (BAT – 40) |
| BC 31 | 74/M | Ta | High, G3 | 0 | High (D9S283, D9S1851) |
| BC 32 | 60/M | T1 | Low, G1 | 0 | MSS |
| BC 33 | 41/M | T1 | Low, G1 | 3 | Low (BAT – 26) |
| BC 34 | 66/ F | T2 | High, G3 | 0 | High (D2S123, D9S283) |
| BC 35 | 53/M | T1 | Low, G1 | 0 | Low (D2S123) |
| BC 36 | 66/M | T1 | High, G2 | 1 | High (D2S123, D9S283, D18S58) |
| BC 37 | 55/M | T2 | High, G3 | 0 | High (BAT – 26, BAT – 40, D9S1851) |
| BC 38 | 65/M | T2 | High, G3 | 0 | Low (D18S58) |
| BC 39 | 69/M | T1 | Low, G1 | 0 | Low (D9S283) |
| BC 40 | 74/M | T1 | High, G2 | 1 | MSS |
| BC 41 | 72/ F | T2 | Low, G1 | 0 | MSS |
| BC 42 | 71/M | T1 | High, G3 | 1 | Low (D9S283) |
| BC 43 | 64/M | T2 | High, G3 | 0 | High (BAT – 40, D9S1851) |
| BC 44 | 73/M | T1 | High, G2 | 1 | Low (D9S283) |
| Total | Physical | Psychological | Self-Esteem | Family | Friends | School | ||||||||
| OR | 95%CI | OR | 95%CI | OR | 95%CI | OR | 95%CI | OR | 95%CI | OR | 95%CI | OR | 95%CI | |
| Age (years) | 0.98 | (0.94-1.02) | 1.02 | (0.98-1.07) | 0.98 | (0.94-1.03) | 0.95 | (0.91-1.00) | 1.03 | (0.98-1.09) | 1.05 | (1.01-1.10) | 0.89 | (0.85-0.92) |
| Gender | ||||||||||||||
| Girls | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||||||
| Boys | 1.07 | (0.94-1.23) | 1.32 | (1.13-1.56) | 1.16 | (0.99-1.36) | 1.01 | (0.86-1.18) | 1.02 | (0.82-1.26) | 1.23 | (1.03-1.46) | 0.87 | (0.73-1.03) |
| respondents | ||||||||||||||
| Mother | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||||||
| Father | 1.07 | (0.85-1.34) | 1.23 | (0.97-1.56) | 1.14 | (0.87-1.48) | 1.31 | (1.03-1.67) | 1.18 | (0.87-1.60) | 0.94 | (0.73-1.21) | 1.02 | (0.80-1.31) |
| Mother and Father | 1.11 | (0.79-1.56) | 1.55 | (1.13-2.11) | 1.12 | (0.72-1.74) | 1.27 | (0.87-1.85) | 0.86 | (0.51-1.45) | 0.81 | (0.54-1.23) | 0.75 | (0.52-1.08) |
| Other Person | 0.61 | (0.31-1.17) | 2.08 | (1.12-3.88) | 0.47 | (0.11-1.94) | 0.70 | (0.29-1.71) | 1.16 | (0.44-3.03) | 0.81 | (0.38-1.72) | 0.55 | (0.27-1.09) |
| region | ||||||||||||||
| East | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||||||
| West | 0.99 | (0.84-1.16) | 0.99 | (0.84-1.18) | 0.90 | (0.74-1.10) | 1.10 | (0.96-1.27) | 0.91 | (0.75-1.10) | 0.98 | (0.82-1.17) | 1.23 | (1.05-1.44) |
| Migration background | ||||||||||||||
| No | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||||||
| Yes | 1.47 | (1.15-1.88) | 0.92 | (0.72-1.19) | 1.33 | (0.95-1.87) | 1.28 | (0.96-1.72) | 1.79 | (1.35-2.39) | 1.36 | (1.05-1.76) | 0.67 | (0.53-0.85) |
| Social status | ||||||||||||||
| Low | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||||||
| Intermediate | 0.87 | (0.73-1.03) | 1.00 | (0.82-1.21) | 0.75 | (0.60-0.93) | 1.04 | (0.85-1.28) | 1.01 | (0.78-1.29) | 0.81 | (0.66-0.99) | 1.03 | (0.87-1.23) |
| Upper | 0.91 | (0.75-1.11) | 1.02 | (0.83-1.25) | 0.78 | (0.61-1.00) | 1.07 | (0.87-1.33) | 0.90 | (0.67-1.19) | 0.66 | (0.53-0.83) | 1.18 | (0.96-1.46) |
| Family climate | ||||||||||||||
| Normal | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||||||
| Borderline | 0.86 | (0.70-1.07) | 1.16 | (0.91-1.48) | 0.71 | (0.54-0.94) | 0.98 | (0.78-1.21) | 0.84 | (0.65-1.09) | 0.85 | (0.66-1.10) | 0.97 | (0.79-1.20) |
| In deficite | 0.73 | (0.55-0.97) | 1.22 | (0.92-1.61) | 0.50 | (0.35-0.73) | 0.62 | (0.47-0.84) | 1.15 | (0.80-1.64) | 0.91 | (0.67-1.24) | 1.04 | (0.80-1.36) |
| Parent rated total SDQ | ||||||||||||||
| Normal | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||||||
| Borderline | 0.35 | (0.24-0.50) | 0.65 | (0.47-0.90) | 0.27 | (0.17-0.44) | 0.54 | (0.38-0.75) | 0.47 | (0.32-0.68) | 0.39 | (0.26-0.58) | 0.47 | (0.34-0.67) |
| Abnormal | 0.15 | (0.10-0.23) | 0.36 | (0.24-0.54) | 0.15 | (0.09-0.27) | 0.23 | (0.16-0.33) | 0.27 | (0.16-0.47) | 0.30 | (0.19-0.47) | 0.38 | (0.27-0.53) |
| Parent rated health status | ||||||||||||||
| Very good | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||||||
| Good | 0.55 | (0.47-0.65) | 0.54 | (0.45-0.64) | 0.67 | (0.55-0.79) | 0.62 | (0.52-0.74) | 0.92 | (0.74-1.13) | 0.68 | (0.58-0.81) | 0.74 | (0.64-0.87) |
| Moderate/bad/very bad | 0.22 | (0.15-0.31) | 0.26 | (0.18-0.37) | 0.38 | (0.23-0.62) | 0.41 | (0.29-0.57) | 0.72 | (0.48-1.10) | 0.45 | (0.32-0.65) | 0.59 | (0.43-0.82) |
| CSHCN-Screener | ||||||||||||||
| Negativ | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||||||
| Positiv | 0.93 | (0.75-1.16) | 0.86 | (0.69-1.09) | 0.73 | (0.53-1.02) | 0.79 | (0.64-0.98) | 0.91 | (0.72-1.15) | 0.78 | (0.59-1.02) | 0.92 | (0.74-1.14) |
| pain (last 3 month) | ||||||||||||||
| No | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||||||
| Yes | 0.91 | (0.76-1.10) | 0.90 | (0.75-1.08) | 1.07 | (0.85-1.34) | 0.93 | (0.79-1.10) | 0.91 | (0.72-1.15) | 1.23 | (1.01-1.51) | 1.07 | (0.88-1.28) |
| Child rating (10 points) | 0.28 | (0.25-0.32) | 0.50 | (0.47-0.53) | 0.26 | (0.23-0.29) | 0.39 | (0.36-0.42) | 0.46 | (0.43-0.50) | 0.40 | (0.37-0.43) | 0.47 | (0.44-0.50) |
| R2 | 38.6 | 30.9 | 42.6 | 48.2 | 35.2 | 40.1 | 36.1 |
| Statements | At my PHCC,a management is positive toward our work with promotion of healthy lifestyles | At my PHCC, we collaborate with other stakeholders such as municipalities and community associations about our patients’ lifestyles | At my PHCC, there are incentives to promote healthy lifestyles among our patients | At my PHCC, there are local guidelines/care programs on how we should promote healthy lifestyles among our patients | At my PHCC, there are many factors that facilitate the promotion of healthy lifestyles among our patients | At my PHCC, there are many factors that hinder the promotion of healthy lifestyles among our patients | I perceive there is a need for National CPGsb for lifestyle interventions in the work at my PHCC | |||||||
| Characteristics | % | P-value | % | P-value | % | P-value | % | P-value | % | P-value | % | P-value | % | P-value |
| Profession | 0.782 | 0.207 | 0.465 | 0.618 | 0.154 | 0.729 | 0.049 | |||||||
| Registered nurse | 80 | 37 | 60 | 63 | 37 | 17 | 77 | |||||||
| Public health nurse | 71 | 22 | 57 | 51 | 42 | 17 | 84 | |||||||
| Physician | 68 | 20 | 63 | 50 | 43 | 12 | 65 | |||||||
| Residentc | 68 | 14 | 50 | 50 | 14 | 18 | 68 | |||||||
| General practitioner | 72 | 19 | 72 | 72 | 38 | 25 | 75 | |||||||
| Years in profession | 0.489 | 0.829 | 0.111 | 0.948 | 0.075 | 0.861 | 0.783 | |||||||
| 0–10 | 74 | 22 | 54 | 51 | 27 | 18 | 79 | |||||||
| ≥11 | 70 | 23 | 63 | 52 | 37 | 17 | 78 | |||||||
| Total | 71 | 22 | 59 | 51 | 33 | 17 | 78 |
| Type of triangulation | Example | |
| Data source triangulation | Existing data review | Analyzed main health problem by reviewing existing health data from CDC |
| Investigation | Prioritized health problem by investigating health problem and risk factors with different methods | |
| Methods triangulation | Participation (Ranking) | Prioritized health problem by listing and ranking health concerns (people's perceived needs and priorities) |
| FGD | Discussed the health problems, risk factors and their influencing factors (people's perceived needs, priorities, influence factors) | |
| Key informant interview | Assessed the health resources for health promotion (resources, policy) | |
| Questionnaires | Surveyed the health problems (\"actual needs\"), risk factors | |
| Researchers triangulation | Teachers | Role of moderator in 4 FGDs and key informants interviews, and analyzed all FGDs and key informants interviews |
| Graduates | Role of moderator in 8 FGDs |
| Menstrual | Follicular | Luteal | |||||
| r | 95% CI | r | 95% CI | r | 95% CI | ||
| Craving (VAS) | Number of cigarettes | 0.611*** | 0.20–0.84 | 0.598*** | 0.18–0.83 | 0.718*** | 0.38–0.89 |
| CO concentration | 0.530** | 0.09–0.80 | 0.430* | 0.08–0.69 | 0.811*** | 0.55–0.93 | |
| Depressiveness (CES-D) | Number of cigarettes | 0.387* | 0.02–0.66 | 0.374* | 0.01–0.65 | 0.546** | 0.24–0.77 |
| CO concentration | 0.490** | 0.03–0.78 | 0.484** | 0.02–0.78 | 0.607*** | 0.20–0.84 | |
| Menstrual phase-associated symptoms(MDQ) | Number of cigarettes | 0.405* | 0.05–0.67 | 0.097 | −0.28–0.45 | 0.530** | 0.08–0.80 |
| CO concentration | 0.488** | 0.03–0.78 | 0.274 | −0.10–0.58 | 0.588** | 0.17–0.83 |
| Classification results L2-norm SVM | ||||||
| Features | Accuracy (%) | Accuracy p-value | Sensitivity (%) | Specificity (%) | Sparsity (%) | Stability (%) |
| Event-related fMRI dataset | ||||||
| Sparse inverse covariance | 73.68 | 0.01⁎ | 73.68 | 73.68 | – | 37.81 ± 0.26 |
| Full inverse covariance | 44.73 | > 0.05 | 47.37 | 42.11 | – | 9.90 ± 0.78 |
| Correlation | 68.42 | 0.02⁎ | 84.21 | 52.63 | – | 9.29 ± 1.56 |
| Partial correlation | 65.78 | > 0.05 | 73.68 | 57.89 | – | 11.33 ± 0.16 |
| Block-related fMRI dataset | ||||||
| Sparse inverse covariance | 78.33 | 0.01⁎ | 80.00 | 76.67 | – | 25.81 ± 0.45 |
| Full inverse covariance | 40.00 | > 0.05 | 20.00 | 60.00 | – | 12.81 ± 0.89 |
| Correlation | 60.00 | > 0.05 | 86.67 | 33.33 | – | 8.61 ± 2.17 |
| Partial correlation | 58.33 | > 0.05 | 53.33 | 63.33 | – | 10.93 ± 0.78 |
| Sample month | Raw sludge enteric virus (PFU/4 g) | Treated biosolids enteric virus (PFU/4 g) |
| 1 | < 1 | < 1 |
| 2 | < 1 | < 1 |
| 3 | < 1 | < 1 |
| 4 | < 1 | < 1 |
| 5 | < 1 | < 1 |
| 6 | 5 | < 1 |
| 7 | 2 | < 1 |
| 8 | 1 | < 1 |
| 9 | 1 | < 1 |
| 10 | 7 | < 1 |
| 11 | 6 | 1 |
| 12 | 31 | < 1 |
| Landmarks on single curves | |
| Sellion | The most posterior point of the frontonasal soft tissue contour in the midline of the base of the nasal root |
| The point of maximal curvature of the mid‐line nasal profile curve at its nasal root end | |
| Subnasale | The point where the nasal septum merges with the upper cutaneous lip in the mid‐sagittal plane |
| The point of maximal curvature on the mid‐line curve at the base of the nasal septum | |
| Alare | The most lateral point on each alar contour |
| The point of maximal curvature along the alar curve | |
| Alare crest | The facial insertion of each alar base |
| The point of maximum curvature on the alar curve where this meets the paranasal area | |
| Cheilion | The point located at each labial commissure |
| The point of maximum curvature at the lateral end of the labial seal curve | |
| Sublabiale | The most posterior mid‐point on the labiomental soft tissue contour that defines the border between the lower lip and the chin |
| The point of maximal curvature in the mid‐line curve as it passes through the mentolabial sulcus | |
| Tragion | The point located at the upper margin of each tragus |
| The point of maximum curvature at the superior end of the tragus curve | |
| Otobasion inferius | The point of attachment of the ear lobe to the cheek, which determines the lower border of the ear insertion |
| The final point at the preauricular end of the ear rim curve. |
| Characteristic | Patients | Controls | |
| n = 57 (%) | n = 20 (%) | ||
| Age (years, mean ± SD) | 55.4 ± 12.8 | 54.8 ± 14.3 | 0.853* |
| <55 | 28 (49) | 12 (60) | 0.48** |
| ≥55 | 29 (51) | 8 (40) | |
| Menopause | |||
| Pre-menopausal | 24 (42.1) | N/A | |
| Post-menopausal | 33 (57.9) | N/A | |
| Histology | |||
| Ductal | 50 (87.7) | ||
| Lobular | 5 (8.8) | ||
| Other | 2 (3.5) | ||
| Histological grade | |||
| 1 | 7 (12.3) | ||
| 2 | 25 (43.9) | ||
| 3 | 23 (40.4) | ||
| TNM Stage | |||
| I | 14 (24.6) | ||
| II | 13 (22.8) | ||
| III | 17 (29.8) | ||
| IV | 13 (22.8) | ||
| Lymph nodes involved | |||
| No | 20 (35.1) | ||
| Yes | 37 (64.9) | ||
| Hormonal Receptors | |||
| Positive | 42 (73.7) | ||
| Negative | 14 (24.6) | ||
| HER2 | |||
| Positive | 14 (24.6 ) | ||
| Negative | 42 (73.7 ) | ||
| MIB1 | |||
| <25% | 40 (70.2) | ||
| >25% | 14 (24.6) | ||
| Type | |||
| Luminal | 32 (56.1) | ||
| HER2 | 14 (24.6) | ||
| Triple negative | 10 (17.5) | ||
| R0 | 28 (49.1) | ||
| R2 | 29 (50.9) |
| Effect (b) | PCBMR | Single-Trait Association | ||||||
| GEN | ADD | DOM | REC | GEN | ADD | DOM | REC | |
| 0 | 4.7 | 5 | 5.6 | 3.9 | 5.0(3.2) | 5.3(2.7) | 5.7(3.3) | 4.2(2.4) |
| 0.5 | 7.6 | 8.8 | 7.5 | 6.4 | 7.4(4.1) | 8.4(4.7) | 7.1(4.6) | 6.1(3.3) |
| 1 | 18.1 | 22.4 | 22 | 11.2 | 17.8(11.2) | 22.4(16.2) | 21.2(14.1) | 11.2(7.2) |
| 1.5 | 35.3 | 45.2 | 40.1 | 20.3 | 35.8(24.8) | 45.8(34.3) | 40.2(28.4) | 20.2(13.8) |
| 2 | 60.4 | 70.1 | 66 | 29.2 | 60.2(50.3) | 70.2(59.8) | 66.5(54.9) | 28.9(22.0) |
| 2.5 | 79.2 | 87.4 | 82.5 | 40.8 | 79.1(70.1) | 86.8(79.0) | 82.2(75.1) | 40.2(30.2) |
| 3 | 91.2 | 95.9 | 93.4 | 50.6 | 91.1(85.5) | 95.8(91.7) | 93.3(88.6) | 50.7(40.4) |
| 3.5 | 97.2 | 99.3 | 97.6 | 62 | 97.6(94.9) | 99.4(98.0) | 97.8(96.0) | 62.5(50.6) |
| 4 | 99.6 | 99.7 | 99.5 | 75.4 | 99.4(98.9) | 99.7(99.5) | 99.5(99.0) | 75.9(63.9) |
| Time | Acupuncture | Counselling | Usual care | Effect of trial arm | |||||
| Week | Mean | SE | Mean | SE | Mean | SE | F | df | p |
| 2 | 5.56 | 0.136 | 5.73 | 0.143 | 5.74 | 0.195 | 0.48 | 2 | .621 |
| 3 | 5.76 | 0.134 | 5.56 | 0.142 | 5.60 | 0.191 | 0.54 | 2 | .582 |
| 4 | 5.49 | 0.133 | 5.54 | 0.142 | 5.44 | 0.191 | 0.10 | 2 | .909 |
| 5 | 5.26 | 0.132 | 5.30 | 0.142 | 5.57 | 0.188 | 0.98 | 2 | .375 |
| 6 | 5.10 | 0.135 | 5.18 | 0.144 | 5.25 | 0.193 | 0.22 | 2 | .806 |
| 7 | 4.95 | 0.137 | 5.03 | 0.146 | 5.31 | 0.193 | 1.23 | 2 | .292 |
| 8 | 4.80 | 0.141 | 4.95 | 0.147 | 5.35 | 0.198 | 2.60 | 2 | .074 |
| 9 | 4.78 | 0.144 | 4.74 | 0.152 | 5.15 | 0.199 | 1.56 | 2 | .211 |
| 10 | 4.62 | 0.147 | 4.57 | 0.154 | 5.39 | 0.207 | 5.91 | 2 | .003 |
| 11 | 4.67 | 0.153 | 4.69 | 0.161 | 5.67 | 0.213 | 8.55 | 2 | .000 |
| 12 | 4.60 | 0.157 | 4.47 | 0.165 | 5.64 | 0.219 | 10.08 | 2 | .000 |
| 13 | 4.36 | 0.162 | 4.62 | 0.172 | 5.20 | 0.225 | 4.60 | 2 | .010 |
| 14 | 4.21 | 0.169 | 4.64 | 0.176 | 5.10 | 0.238 | 4.82 | 2 | .008 |
| 15 | 4.18 | 0.177 | 4.53 | 0.185 | 5.11 | 0.243 | 4.78 | 2 | .008 |
| 16 | 4.18 | 0.184 | 4.39 | 0.193 | 5.24 | 0.253 | 5.93 | 2 | .003 |
| Study | N | TP | FN | TN | FP | Sensitivity% (CI) | Specificity% (CI) | PPV% (CI) | NPV% (CI) |
| Marcellin 2011 [60] | 79 | 39 | 1 | 38 | 1 | 97.5 (85.7–100) | 97.4 (82.4–99.4) | 97.5 (88.5–100) | 97.4 (92.5–100) |
| Martinez de Tejada 2006 [52] | 34 | 20 | 0 | 13 | 1 | 100 (79.9–100) | 92.8 (64.2–99.6) | 95.2 (74.1–99.7) | 100 (71.7–100) |
| Akercan 2005 [54] | 45 | 25 | 0 | 19 | 1 | 100 (83.4–100) | 95.0 (73.1–99.7) | 96.1 (78.4–99.8) | 100 (79.1–100) |
| Erdermoglu 2004 [47] | 71 | 35 | 1 | 34 | 1 | 97.2 (83.8–99.8) | 97.1 (83.4–99.8) | 97.2 (83.8–99.8) | 97.1 (83.4–99,8) |
| Darj 1998 [51] | 75 | 44 | 2 | 27 | 2 | 95.6 (84.0–99.2) | 93.1 (75.8–98.8) | 95.7 (84.0–99.2) | 93.1 (75.8–98.8) |
| Gaucherand 1997 [53] | 69 | 34 | 1 | 34 | 0 | 97.1 (83.4–99.8) | 100 (87.4–99.8) | 100 (87.4–100) | 97.1 (83.4–99.8) |
| Guibourdenche 1999 [48] | 30 | 15 | 0 | 14 | 1 | 100 (74.6–100) | 93.3 (66.0–99.7) | 93.8 (67.7–99.7) | 100 (73.2–100) |
| Rutanen 1996 [12] | 130 | 55 | 0 | 71 | 4 | 100 (91.9–100) | 94.7 (86.2–98.3) | 93.2 (82.7–97.8) | 100 (93.6–100) |
| Actim PROM® pooled | 533 | 267 | 5 | 250 | 11 | 98.2 (95.5–99.3) | 95.8 (92.4–97.8) | 96.0 (92.8–97.9) | 98.0 (95.2–99.3) |
| Abdelazim 2012 [58] | 150 | 73 | 2 | 74 | 1 | 97.3 (89.8–99.5) | 98.7 (91.8–99.9) | 98.6 (91.7–99.9) | 97.4 (90.0–99.5) |
| Marcellin 2011 [60] | 79 | 38 | 2 | 38 | 1 | 95.0 (82.4–99.4) | 94.8 (79.3–98.0) | 95.0 (84.7–100) | 94.8 (87.9–100) |
| AmniSure® pooled | 229 | 111 | 4 | 112 | 2 | 96.5 (90.8–98.9) | 98.2 (93.2–99.7) | 98.2 (93.1–99.7) | 96.5 (90.9–98.9) |
| Characteristic | Standardized coefficients | P-value | 95 % Confidence Interval for B | |
| Beta | Lower bound | Lower bound | ||
| Number of medications for each patient | 0.556 | <0.001 | 0.196 | 0.288 |
| Patient age group | 0.045 | 0.381 | −0.090 | 0.235 |
| Number of comorbid diseases the patient have | 0.049 | 0.367 | −0.056 | 0.151 |
| AUC | SE | 95 % CI | Cutoffa | Sensitivity (%) | Specificity (%) | Correctly classifiedb (%) | |
| Aβ42 | 0.935 | 0.0394 | 0.806–0.989 | 853 | 100 | 83.87 | 87 |
| ttau | 0.733 | 0.132 | 0.565–0.863 | 352 | 71.43 | 77.42 | 76 |
| ptau | 0.675 | 0.139 | 0.504–0.818 | 86 | 42.86 | 93.55 | 84 |
| Aβ42/ttau | 0.880 | 0.0878 | 0.734–0.963 | 2.258 | 85.71 | 90.32 | 89 |
| Specificity of 90 % | Sensitivity (%) | 95 % CI | Cutoffa | Differencec (%) | P valued | Correctly classifiedb (%) | |
| Aβ42 | 85.71 | 11.54–100.00 | 798 | 7.90 | 0.25 | 89 | |
| ttau | 57.14 | 14.29–100.00 | 465 | 10.53 | 0.125 | 82 | |
| ptau | 42.96 | 0.00–85.71 | 87 | 5.26 | 0.5 | 79 | |
| Aβ42/ttau | 85.71 | 28.57–100.00 | 2.263 | 0 | 1 | 89 | |
| Specificity of 95 % | Sensitivity (%) | 95 % CI | Cutoffa | Differencec (%) | P valued | Correctly classifiedb (%) | |
| Aβ42 | 42.86 | 4.05–100.00 | 672 | 21.05 | 0.008 | 87 | |
| ttau | 14.29 | 0.00–85.71 | 566 | 23.69 | 0.004 | 82 | |
| ptau | 28.57 | 0.00–71.43 | 94 | 2.63 | 1 | 82 | |
| Aβ42/ttau | 71.43 | 8.71–100.00 | 2.093 | 7.90 | 0.25 | 92 |
| Highest stage of education achieved by participants’ parent(s) No. (%) | Entry route into Undergraduate Medical Education No. (%) | Medical Degree Type No. (%) | Medical Degree Stage No. (%) |
| - Primary Level 1 (5)- Secondary Level14 (70)- Tertiary Level 5(25) | -Direct entry from Tertiary Education15 (75)-Gap year between Tertiary Education and Medical School 2 (10)-Graduate Entry 3 (15) | -Extended (6 Years) 11 (55)-MBBS (5 Years) 9 (45) | -Pre-Clinical Stage 10 (50%)-Clinical Stage 10 (50%) |
| Total 20(100) | Total 20(100) | Total 20(100) | Total 20(100) |
| LI-PD group (n = 17) | NLI-PD group (n = 14) | Control group (n = 20) | P, LI-PD cf. NLI-PD | P, LI-PD cf. control | P, NLI-PD cf. control | |
| Men | 12 | 6 | 12 | 0.157 | 0.731 | 0.487 |
| Women | 5 | 8 | 8 | |||
| Age, y | 63.59 ± 8.62 | 63.07 ± 9.43 | 64.85 ± 8.27 | 0.843 | 0.653 | 0.564 |
| Age at onset, y | 55.06 ± 10.92 | 56.36 ± 10.95 | NA | 0.781 | NA | NA |
| Formal education, y | 10.53 ± 2.67 | 11.00 ± 3.60 | 10.95 ± 2.69 | 0.780 | 0.637 | 0.983 |
| Disease duration, y | 8.53 ± 4.49 | 6.71 ± 3.29 | NA | 0.327 | NA | NA |
| Hoehn-Yahr stage | 2.50 ± 0.55 | 2.57 ± 0.39 | NA | 0.415 | NA | NA |
| UPDRS part II | 15.69 ± 8.39 | 11.79 ± 4.87 | NA | 0.138 | NA | NA |
| UPDRS part III | 38.87 ± 12.11 | 32.86 ± 8.76 | NA | 0.135 | NA | NA |
| HAMD-17 scores | 8.88 ± 2.34 | 7.86 ± 2.18 | 7.45 ± 2.44 | 0.691 | 0.208 | 1.000 |
| MoCA scores | 19.60 ± 4.75 | 22.75 ± 3.14 | 25.80 ± 1.64 | 0.142 | 0.000b | 0.021b |
| Variables | Overall | p-Value | Women | p-Value | Men | p-Value |
| N = 7504 | N = 766 | N = 6738 | ||||
| OR (95% CI) | OR (95% CI) | OR (95% CI) | ||||
| Age (by five-year increment) | 1.31 (1.24–1.39) | <0.0001 | 1.36 (0.97–1.89) | 0.074 | 1.30 (1.23–1.38) | <0.0001 |
| BMI (kg/m2) | ||||||
| 25–29.9 | 2.18 (1.89–2.51) | <0.0001 | 2.66 (0.95–7.45) | 0.062 | 2.01 (1.74–2.32) | <0.0001 |
| ≥30 | 5.68 (4.75–6.79) | <0.0001 | 7.00 (1.46–33.6) | 0.015 | 5.27 (4.40–6.31) | <0.0001 |
| Elevated blood pressure * | 2.59 (2.24–3.00) | <0.0001 | 2.29 (0.51–10.4) | 0.28 | 2.36 (2.03–2.73) | <0.0001 |
| Waist circumference ∫ | 4.95 (4.27–5.73) | <0.0001 | 4.39 (1.61–12.0) | 0.0038 | 4.94 (4.26–5.74) | <0.0001 |
| Serum TG ≥ 150 mg/dL | 4.61 (3.97–5.34) | <0.0001 | 3.70 (1.02–13.5) | 0.047 | 4.28 (3.68–4.97) | <0.0001 |
| FPG ≥ 100 mg/dL | 1.94 (1.63–2.30) | <0.0001 | 12.64 (4.34–36.8) | <0.0001 | 1.74 (1.46–2.07) | <0.0001 |
| Low serum HDL $ | 2.60 (2.24–3.02) | <0.0001 | 2.93 (1.08–7.91) | 0.034 | 2.72 (2.33–3.17) | <0.0001 |
| Total cholesterol ≥ 200 mg/dL | 2.90 (2.50–3.37) | <0.0001 | 1.39 (0.39–4.95) | 0.61 | 2.86 (2.45–3.33) | <0.0001 |
| Current alcohol intake | 1.32 (1.15–1.53) | <0.0001 | 1.20 (0.38–3.77) | 0.75 | 1.20 (1.04–1.39) | 0.012 |
| Metabolic syndrome (ATPIII) | 5.90 (5.04–6.91) | <0.0001 | 23.53 (8.09–68.5) | <0.0001 | 5.36 (4.57–6.28) | <0.0001 |
| Metabolic syndrome (IDF) | 6.35 (5.38–7.49) | <0.0001 | 20.83 (6.93–62.64) | <0.0001 | 5.81 (4.92–6.87) | <0.0001 |
| Antibody (host, clonality, Company) | Purpose | Dilution |
| FGFR1 (rabbit, polyclonal, Santa Cruz Biotechnology, CA) | IHC | 1:150 |
| FGFR2 (rabbit, polyclonal, Santa Cruz Biotechnology, CA) | IHC | 1:150 |
| FGF7 (rabbit, polyclonal, Santa Cruz Biotechnology, CA) | IHC | 1:150 |
| FGF7 (rabbit, polyclonal, Abcam, Cambridge, UK) | WB | 1:200 |
| FGF10 (rabbit, polyclonal, Santa Cruz Biotechnology, CA) | IHC | 1:150 |
| FGF10 (goat, polyclonal, Peprotech Inc., Rocky Hill, NJ) | WB | 1:200 |
| p-p44/42 MAPK (Thr202/Tyr204) (rabbit, polyclonal, Cell Signaling, Beverly, MA) | WB | 1:1,000 |
| Akt (rabbit, polyclonal, Cell Signaling, Beverly, MA) | WB | 1:1,000 |
| p-Akt (Ser473) (rabbit, polyclonal, Cell Signaling, Beverly, MA) | WB | 1:1,000 |
| Actin (mouse, monoclonal, Amersham, Buckinghamshire, UK) |
| N = 54 | Test site | |||
| A | C2 | L | C1 | |
| Average speed (km.h−1) | 23.1 ± 1.3a* | 21.1 ± 1.0b | 21.2 ± 0.8b | 22.4 ± 0.9a |
| HR (beats.mn−1) | 142.2 ± 15.2 | 140.0 ± 9.3 | 141.2 ± 13.7 | 146.9 ± 1 |
| RMSSD (ms) | 6.4 ± 2.7a* | 3.2 ± 1.0b | 2.7 ± 1.3c | 4.0 ± 1.6b |
| SD2 (ms) | 38.3 ± 12.1 | 34.2 ± 23.2 | 23.7 ± 17.8 | 34.8 ± 16.7 |
| LF (ms2) | 12.6 ± 3.3 | 11.2 ± 3.9 | 6.9 ± 1.5 | 13.7 ± 5.8 |
| HF (ms2) | 9.3 ± 6.5 | 8.1 ± 5.1 | 8.7 ± 5.5 | 13.8 ± 6.6 |
| LF/HF | 1.6 ± 0.7 | 1.6 ± 0.6 | 1.1 ± 0.6 | 1.2 ± 0.6 |
| LFnu (%) | 60.1 ± 11.8 | 60.3 ± 8.9 | 48.4 ± 15.7 | 51.0 ± 14.4 |
| HFnu (%) | 39.9 ± 11.8 | 39.7 ± 8.9 | 51.6 ± 15.7 | 49.0 ± 14.4 |
| Characteristics | Controls n = 67 | NSTEMI n = 38 | STEMI n = 30 |
| Age | 66 ± 12 | 72 ± 15 | 72 ± 13 |
| M/F | 46/21 | 29/9 | 21/9 |
| Diabetes Mellitus | 8 | 8 | 4 |
| Prior IHD | 29 | 18 | 12 |
| Hemoglobine, g/l | 135 ± 15 | 132 ± 15 | 132 ± 16 |
| Platelet count, ×109/l | 224 ± 74 | 218 ± 51 | 222 ± 66 |
| Cholesterol mmol/l | - | 4,67 ± 0,94 | 4,60 ± 0,79 |
| Triglycerides mmol/l | - | 1,19 ± 0,46 | 1,28 ± 0,94 |
| BMI | - | 24 ± 2,8 | 27 ± 3,2 |
| Raw material | Cellulose | Hemicellulose | Lignin | Ash |
| Wheat straw | 44.2 (1.8) | 26.5 (1.9) | 22.4 (1.7) | 2.8 (0.6) |
| Rice straw | 36.1 (2.6) | 27.2 (3.2) | 19.7 (2.5) | 12.1 (2.8) |
| Poplar | 39.2 (1.1) | 18.8 (1.4) | 29.6 (1.6) | 1.5 (1.2) |
| Up/Down-regulatedc | Regulated by | ||||||||||
| Genea | Enzymeb | CAZy family | ΔxlnR | ΔaraR | ΔrhaR | ΔgalX | ΔamyR | This study | Literature | Reference | |
| E-1 | An15g04900 (eglD) | LPMO | AA9 | 2.1 | −1.2 | −1.7 | −1.6 | −1.8 | nd | nr | [38] |
| An03g00190 (pelB) | PEL | PL1 | – | – | – | 1.2 | 1.0 | nd | nr | [73] | |
| E-2 | An07g09760 | BGL | GH3 | – | – | – | – | – | nd | nr | [38] |
| An08g01100 | EXG | GH5 | 1.6 | 1.1 | 1.1 | – | 3.8 | nd | nr | [38] | |
| An11g03200 (inuA/inuB) | INU | GH32 | – | – | – | – | – | nd | InuR | [8, 79] | |
| An12g08280 (inuE/inu1) | INX | GH32 | 2.9 | 2.0 | 1.9 | 5.2 | 4.1 | nd | InuR | [8] | |
| An02g04900 (pgaB) | PGA | GH28 | 2.6 | −2.3 | – | 2.2 | −2.1 | nd | GaaR | [15, 34, 80] | |
| An08g11070 (sucA/suc1) | SUC | GH32 | – | – | – | – | – | nd | InuR | [9, 81, 82] |
| Year | Public Hospitals | Public medic patients | |
| Outpatients (95% CI) | # of hospitalizations | ||
| 1918 | 20.11 (16.43, 25.90) | 12.20 (10.59, 14.38) | 32.21* (28.48, 39.82) |
| 1919 | 14.55 (11.89, 18.74) | 36.70* (31.85, 43.27) | 26.64* (22.70, 31.73) |
| 1920 | 1.72 (1.40, 2.21) | 19.83* (17.21, 23.38) | 8.27 (7.09, 9.92) |
| Surface material | SBS | ARI | |
| Enamel | Chi-square test | 18.512 | 11.686 |
| Df | 2 | 2 | |
| Asymptotic significance | 0.000 | 0.003 | |
| SR Adoro | Chi-square test | 0.281 | 1.636 |
| Df | 2 | 2 | |
| Asymptotic significance | 0.869 | 0.441 | |
| Filtek Supreme XTE | Chi-square test | 20.847 | 14.017 |
| Df | 2 | 2 | |
| Asymptotic significance | 0.000 | 0.001 | |
| Wisil | Chi-square test | 6.970 | 6.444 |
| Df | 2 | 2 | |
| Asymptotic significance | 0.031 | 0.040 | |
| Dispersalloy | Chi-square test | 9.223 | 6.691 |
| Df | 2 | 2 | |
| Asymptotic significance | 0.010 | 0.035 | |
| Herador | Chi-square test | 3.583 | 8.561 |
| Df | 2 | 2 | |
| Asymptotic significance | 0.167 | 0.014 | |
| e.max Press | Chi-square test | 23.086 | 11.600 |
| Df | 2 | 2 | |
| Asymptotic significance | 0.000 | 0.003 | |
| ZirCAD | Chi-square test | 16.423 | 15.612 |
| Df | 2 | 2 | |
| Asymptotic significance | 0.000 | 0.000 | |
| Mark II | Chi-square test | 9.762 | 19.815 |
| Df | 2 | 2 | |
| Asymptotic significance | 0.008 | 0.000 |
| Year | Number of districts | Districts reporting at least one suspected case | Number of suspected cases reported | Blood specimens collected | Confirmed cases | Districts with confirmed cases | |||
| n | n | % | n | n | % | n | % | ||
| 2003 | 144 | 52 | 36.1 | 156 | 156 | 100 | 3 | 1.3 | Bafia, Méri, Ntui |
| 2004 | 159 | 80 | 50.3 | 434 | 434 | 100 | 2 | 0.5 | Ngaoundéré Rural |
| 2005 | 159 | 88 | 55.3 | 831 | 831 | 100 | 2 | 0.2 | Yoko |
| 2006 | 167 | 114 | 68.2 | 859 | 859 | 100 | 1 | 0.2 | Messamena |
| Variable | Univariate | Multivariate | |
| p value | p value | HR (95% CI) | |
| Male gender | <0.0001 | 0.0104 | 1.42 (1.08–1.85) |
| Age > 55 years | <0.0001 | <0.0001 | 8.33 (6.49–10.75) |
| Distant metastasis (M1) | <0.0001 | <0.0001 | 6.06 (3.92–9.35) |
| Extrathyroid extension (Ex) | <0.0001 | <0.0001 | 2.22 (1.74–2.82) |
| Tumor size (T) | |||
| >4.0 cm | <0.0001 | <0.0001 | 2.27 (1.71–3.00) |
| 2.1–4.0 cm | 0.8425 | 0.7321 | 1.04 (0.82–1.33) |
| Clinical node metastasis (N1) | |||
| >3.0 cm | <0.0001 | <0.0001 | 2.64 (1.81–3.85) |
| <3.0 cm | <0.0001 | 0.0025 | 1.52 (1.16–1.99) |
| Extranodal tumor extension (LN-Ex) | <0.0001 | 0.0073 | 1.75 (1.16–2.64) |
| Type of ZnO nanostructure | Turn-on field (V μm-1) | Threshold field (V μm-1) | β |
| Leaf-like (30 min) | 2.94 | 4.35 | 2,800 |
| Long NWs arrays (60 min) | 3.69 | 5.72 | 2,526 |
| Needle-like | 3.87 | 5.65 | 2,284 |
| Patient no. | CSF leakage | Leakage pattern | Location of CSF leakage | Exact location of CSF leakage |
| 1 | + | Pseudodiverticular | Left T11/12 | + |
| 2 | + | Gray rim | L1 | + |
| 3 | − | − | − | |
| 4 | + | Gray rim | T12/L1 | + |
| 5 | + | Pseudodiverticular | Left L2/3 and L3/4 | + |
| 6 | + | Gray rim | T3 | + |
| 7 | + | Gray rim | From C5/6 to L1/2 | Extensive |
| 8 | + | Gray rim | From C1/2 to T10/11 | Extensive |
| 9 | + | Pseudodiverticular | Right L3/4 and L4/5 | + |
| 10 | + | Gray rim | L4/5/S1 | + |
| 11 | + | Gray rim and pseudodiverticular | From T12 to L2 | Extensive |
| 12 | + | Gray rim | From cervical to upper T-spine | Extensive |
| 13 | + | Gray rim | T-spine | Extensive |
| 14 | + | Pseudodiverticular | Both T11/12 | + |
| 15 | + | Gray rim | C5/6/7 and T7/8/9 | Extensive |
| 16 | + | Pseudodiverticular | Right C5/6 | + |
| 17 | + | Gray rim | T5/6 | + |
| 18 | + | Gray rim and pseudodiverticular | From C4 to T4 | Extensive |
| Variable | MetS= Yes, n (%) | COR (95% CI) | P-value | AOR (95% CI) | P-value | |
| Gender | Men | 44 (37.9) | 1.00 | 1.00 | ||
| women | 72 (62.1) | 1.6 (0.97–2.74) | 0.06 | 1.7 (0.66–4.4) | 0.27 | |
| Residence: | Rural | 20 (17.2) | 1.00 | 1.00 | ||
| Urban | 96 (82.8) | 2.3 (1.2–4.2) | 0.007 | 1.3 (0.54–3.1) | 0.54 | |
| Age in years: | ≤30 | 2 (1.7) | 1.00 | 1.00 | ||
| 31–45 | 31 (26.7) | 5.7 (1.16–27.8) | 0.03 | 5.8 (0.54–3.1) | 0.08 | |
| 46–60 | 41 (35.3) | 4.8 (1.0–22.9) | 0.05 | 4.5 (0.62–32.8) | 0.14 | |
| ≥61 | 42 (36.2) | 6.8 (1.4–32.7) | 0.02 | 8.2 (1.1–62.4) | 0.04 | |
| Marital status: | Single | 5 (4.3) | 1.00 | 1.00 | ||
| Married | 106 (91.4) | 2.5 (1.1–74) | 0.03 | 7.2 (1.4–35.9) | 0.02 | |
| Divorced/widowed | 5 (4.3) | 13 (1.2–140.7) | 0.02 | 16.4 (1.1–244.2) | 0.04 | |
| Occupation: | Farmer | 11 (9.5) | 1.00 | 1.00 | ||
| Employed | 36 (31.0) | 2.2 (0.93–5.26) | 0.07 | 0.86 (0.24–3.07) | 0.81 | |
| Housewife | 49 (42.2) | 3.36 (1.4–7.9) | 0.006 | 2.1 (0.56–7.93) | 0.27 | |
| Retirement pension | 11 (9.5) | 4.1 (1.25–13.5) | 0.02 | 5.3 (1.1–25.9) | 0.04 | |
| Merchants | 9 (7.8) | 1.27 (0.42–3.8) | 0.67 | 1.0 (0.22–4.76) | 0.97 | |
| Monthly income: | No income/dependent | 8 (6.9) | 1.00 | 1.00 | ||
| <1000 birr | 50 (43.1) | 2.6 (1.1–61) | 0.02 | 2.2 (0.74–6.55) | 0.15 | |
| 1001–2000 birr | 31 (26.7) | 6.0 (2.3–15.8) | <0.0001 | 3.6 (1.1–12.5) | 0.04 | |
| >2001 birr | 27 (23.3) | 4.2 (1.6–10.8) | 0.003 | 5.8 (1.5–22.3) | 0.01 | |
| BMI, Kg/m2: | Normal (18.5–24.9) | 30 (25.9) | 1.00 | 1.00 | ||
| Underweight (<18.5) | 4 (3.4) | 0.57 (0.15–2.19) | 0.42 | 0.89 (0.17–4.5) | 0.89 | |
| Overweight (25–29.9) | 49 (42.2) | 3.5 (1.9–6.4) | <0.0001 | 2.8 (1.4–5.9) | 0.005 | |
| Obese (≥30) | 33 (28.4) | 9.5 (3.9–22.9) | <0.0001 | 10.7 (3.8–29.8) | <0.0001 | |
| Duration since the diagnosis of HTN | <5 years | 73 (62.1) | 1.00 | 1.00 | ||
| 6–10 years | 21 (18.1) | 0.73 (0.38–1.38) | 0.33 | 0.61 (0.27–1.38) | 0.24 | |
| >11 years | 22 (19.0) | 2.5 (1.1–57) | 0.02 | 2.0 (0.75–5.5) | 0.16 | |
| Doing exercises regularly: | Yes | 25 (21.6) | 1.00 | 1.00 | ||
| No | 91 (78.4) | 1.7 (0.95–3.0) | 0.07 | 1.9 (0.89–4.3) | 0.09 | |
| FHCD | No | 84 (72.4) | 1.00 | 1.00 | ||
| Diabetes | 12 (10.3) | 2.5 (0.89–6.8) | 0.08 | 1.4 (0.36–5.4) | 0.62 | |
| Hypertension | 20 (17.2) | 2.1 (0.95–4.4) | 0.06 | 2.3 (0.9–5.9) | 0.08 | |
| Intensity of Physical activity: | Low | 52 (44.8) | 057 (0.26–1.22) | 0.15 | 0.61 (0.22–1.74) | 0.36 |
| Moderate | 43 (37.1) | 0.61 (0.27–1.35) | 0.22 | 0.5 (0.18–1.4) | 0.19 | |
| High | 21 (18.1) | 1.00 | 1.00 |
| Instrument | Unprepared apical area (%) | Unprepared coronal area (%) | ||
| Mean ± SD | Min-Max | Mean ± SD | Min-Max | |
| ProTaper Next | 11.03 ± .96 | 10.11–12.8 | 55.70 ± 1.25 | 53.26–57.19 |
| WaveOne | 12.06 ± 1.21 | 9.25–13.10 | 55.53 ± 1.01 | 53.48–57.24 |
| P value | .683c | .684c |
| Heart evaluation parameters | CRT | IMRT |
| Average maximum heart dose (cGy) | 5295.26 | 5209.87 |
| Range (cGy) | 4858.3–5743.8 | 4895.17–5862.8 |
| P-value | 0.08 | 0.08 |
| All studies (n = 102) | Randomized trials (n = 25) | Nonrandomized studies (n = 77) | |
| Number of participants | 66 386 | 7172 | 59 214 |
| Age range of participants (years) | 18–99 | 29–89 | 18–99 |
| Number of participating centres (%) | |||
| Single | 58 (57) | 13 (52) | 45 (58) |
| Multiple | 44 (43) | 12 (48) | 32 (42) |
| IRB or ethical approval reported (%) | 52 (51) | 14 (56) | 38 (49) |
| Tumour site (%) | |||
| Colon | 10 (9) | 2 (8) | 7 (9) |
| Rectum | 54 (53) | 11 (44) | 44 (55) |
| Mixed colon and rectum | 38 (38) | 12 (48) | 26 (34) |
| Surgical approach (%) | |||
| Laparoscopy | 1 (1) | 0 | 1 (1) |
| Hand‐assisted laparoscopy | 0 | 0 | 0 |
| Open | 5 (5) | 1 (4) | 4 (5) |
| Mixed | 13 (12) | 9 (36) | 5 (6) |
| Not reported or incomplete information reported | 83 (81) | 15 (60) | 67 (87) |
| Neoadjuvant treatmenta (%) | |||
| Radiotherapy alone | 20 (20) | 9 (36) | 11 (14) |
| Chemotherapy alone | 0 | 0 | 0v (0.0) |
| Chemoradiotherapy | 22 (22) | 3 (12) | 18 (24) |
| None | 7 (7) | 1 (4) | 6 (8) |
| Not reported or incomplete information reported | 53 (51) | 12 (48) | 42 (54) |
| Adjuvant treatmenta (%) | |||
| Chemotherapy or chemoradiotherapy | 56 (55) | 16 (64) | 40 (52) |
| None | 0 | 0 | 0 |
| Not reported or incomplete information reported | 46 (45) | 9 (36) | 37 (48) |
| Number of PROMs reported | |||
| 1 | 43 | 10 | 33 |
| 2 | 47 | 12 | 35 |
| 3 | 6 | 2 | 4 |
| 4 | 4 | 1 | 3 |
| 5 | 2 | 0 | 2 |
| Right | p | Left | p | |||
| Female | Male | Female | Male | |||
| Mean±SD | Mean±SD | Mean±SD | Mean±SD | |||
| Cervical region | ||||||
| Short-axis diameter (mm) | 3.59±0.78 | 3.53±0.7 | 0.823 | 3.7±0.75 | 3.99±0.76 | 0.345 |
| Long-axis diameter (mm) | 11.35±4.04 | 10.85±2.6 | 0.717 | 11.75±2.52 | 11.85±2.95 | 0.931 |
| S/L | 0.34±0.12 | 0.34±0.1 | 0.926 | 0.33±0.08 | 0.35±0.07 | 0.403 |
| Submandibular region | ||||||
| Short-axis diameter (mm) | 3.82±1.02 | 3.92±1.05 | 0.823 | 3.85±0.59 | 4.65±1.34 | 0.063 |
| Long-axis diameter (mm) | 12.45±3.55 | 13.26±5.3 | 0.654 | 12.18±2.32 | 11.68±1.51 | 0.533 |
| S/L | 0.33±0.12 | 0.32±0.1 | 0.836 | 0.32±0.07 | 0.40±0.12 | 0.055 |
| Submental region | ||||||
| Short-axis diameter (mm) | 4.29±0.85 | 5.04±1.6 | 0.152 | 4.27±0.73 | 4.83±1.68 | 0.301 |
| Long-axis diameter (mm) | 13.85±3.15 | 16.64±5.6 | 0.147 | 15.45±2.65 | 16.98±6.29 | 0.445 |
| S/L | 0.33±0.12 | 0.31±0.07 | 0.665 | 0.28±0.07 | 0.29±0.06 | 0.741 |
| Figure # | Algorithms Used | Initial Benefit | Acquired Benefit | Lost Benefit | Overall Distance | Solution Time (s) |
| 11a | Greedy TA Heuristic MP | 21,000 | 9479 | 11,521 | 2446 | 1.85 |
| 11b | Greedy TA Heuristic MP | 21,000 | 9440 | 11,560 | 2462 | 2.73 |
| Construct | Transgene | Progeny | n |
| ebEx498 | 92 ± 16 | 11 | |
| xyEx175 | 123 ± 15 | 10 | |
| xyEx177 | 115 ± 17 | 11 | |
| xyEx1 | 2 ± 1 | 10 | |
| xyEx2 | 1 ± 0.62 | 9 | |
| xyEx3 | 6 ± 2 | 9 | |
| xyEx27 | 11 ± 4 | 10 | |
| xyEx30 | 8 ± 4 | 10 | |
| xyEx34 | 17 ± 4 | 10 | |
| xyEx36 | 83 ± 15 | 9 | |
| xyEx37 | 110 ± 10 | 8 | |
| xyEx41 | 123 ± 15 | 10 | |
| N2 (wild type) | 185 ± 5 | 10 | |
| spe-42(tn1231) | 0 | 24 | |
| spe-42(tm2421) | 0 | 15 |
| Epigenetic discovery | Health promotion research innovation domains | Example translational research questions |
| Individual variation in whether risk exposures negatively influence gene expression | Improving motivational potency of health communications | Evaluating relative benefit of validating beliefs about individual variability in extent of harm produced by risk behaviors on motivation |
| Intervention adherence can prompt measurable gene expression | Intervention targeting and tailoring | Comparative effectiveness of targeting relapse prevention approach based on gene expression profile following intervention participation |
| New technology to measure epigenetic processes (e.g., methylation) in saliva and blood samples | Novel biomarkers of intervention impact | Evaluate intervention adherence on gene expression in randomized effectiveness trials |
| MCAA+ | MCAA− | NHS | PLG+ | |
| Age (mean) | 61.0 | 59.2 | 58.7 | 59.6 |
| Age (SD) | 10.5 | 13.3 | 3.7 | 12.3 |
| M:F (ratio) | 33:23 (1.43) | 30: 21 (1.43) | 25: 15 (1.67) | 27: 18 (1.5) |
| Patient | 1 | 2 | 3 |
| Age(year) | 47 | 39 | 48 |
| Follow-up(month) | 70 | 54 | 5 |
| Outcome | Favorable | Favorable | Favorable |
| Pre-operation upper-limb blood pressure(mm Hg) | 125/65 | 135/65 | 145/50 |
| Pre-operation lower-limb blood pressure(mm Hg) | 100/55 | 110/50 | 125/45 |
| Post-operation upper-limb blood pressure(mm Hg) | 125/65 | 125/80 | 130/80 |
| Post-operation lower-limb blood pressure(mm Hg) | 130/70 | 130/80 | 130/75 |
| Characteristic§ | Levels of sCD40L | ||||
| High | Medium-Low | p | |||
| No. | (%) | No. | % | ||
| Age: | |||||
| <= 39 | 8 | (40.0) | 8 | (20.0) | |
| 40–54 | 9 | (45.0) | 14 | (35.0) | |
| >= 55 | 3 | (15.0) | 18 | (45.0) | 0.02 |
| Sex: | |||||
| Men | 16 | (80.0) | 28 | (68.3) | |
| Women | 4 | (20.0) | 13 | (31.7) | 0.51 |
| T: | |||||
| 1 | 4 | (20.0) | 9 | (23.1) | |
| 2A-2B | 8 | (40.0) | 18 | (46.2) | |
| 3–4 | 8 | (40.0) | 12 | (30.8) | 0.78 |
| N: | |||||
| 0 | 2 | (10.0) | 11 | (28.9) | |
| 1 | 10 | (50.0) | 12 | (31.6) | |
| 2–3 | 8 | (40.0) | 15 | (39.5) | 0.36 |
| M: | |||||
| 0 | 13 | (68.4) | 38 | (95.0) | |
| 1 | 6 | (31.6) | 2 | (5.0) | 0.01 |
| Stage: | |||||
| I-II | 6 | (31.6) | 14 | (42.4) | |
| III-IVa-IVb | 7 | (36.8) | 17 | (51.5) | |
| IVc | 6 | (31.6) | 2 | (6.1) | 0.11 |
| LMP-1 expression | |||||
| Negative cases | 23 | (95.8) | 19 | (70.4) | |
| Positive cases | 1 | (4.2) | 8 | (29.6) | 0.03 |
| df | AIC | BIC | logLik | |
| m.rel.index | 8 | 2043373 | 2043457 | −1021678 |
| m.freq.index | 8 | 2043326 | 2043410 | −1021655 |
| Time point (min) | 42.5 | 47.5 | 52.5 | 57.5 | 62.5 | 72.5 | 72.5 | 77.5 | 82.5 | 87.5 |
| Bias (%) | 53 | 46 | 40 | 32 | 25 | 22 | 18 | 12 | 9 | 0 |
| Factor 1 | 0.877 | 0.898 | 0.977 | 0.973 | 0.967 | 0.986 | 0.963 | 0.975 | 0.843 | 0.8573 |
| Factor 2 | 0.453 | 0.423 | −0.105 | −0.068 | −0.104 | −0.116 | −0.205 | −0.102 | −0.499 | 0.376 |
| Characteristic | Number (%) |
| Age(months) | |
| 0–11 | 166(24.3%) |
| 12–23 | 189(27.7%) |
| 24–35 | 101(14.7%) |
| 36–47 | 116(16.9%) |
| 48–59 | 112(16.4%) |
| Sex | |
| Male | 421(61.6%) |
| Female | 263(38.4%) |
| Season | |
| Spring(January–March) | 161(23.5%) |
| Summer(April–June) | 252(36.8%) |
| Autumn(July–September) | 123(18.0%) |
| Winter(October–December) | 148(21.6%) |
| Clinical Symptoms | |
| Nausea | 60(10.8%) |
| Vomiting | 114(20.6%) |
| Abdominal pain | 268(48.3%) |
| Fever(> 37.2 °C) | 97(17.4%) |
| others | 16(2.9%) |
| Serology (serologicmarkers)∗ | Endoscopy of duodenum (mucosal morphologic alternations∗∗) | Genotype (genetic markers) | |
| IgA anti-tissue transglutaminase antibodies (IgA anti-tTG, IgG anti-tTG antibodies) | Mucous membrane thickness | HLA-typing | |
| Anti-endomysial antibodies (AEA, IgA-anti-EMA) | Villus height | ||
| Anti-deamidated gliadin peptide (IgA anti-DGP, IgG anti-DGP) | Crypt depth | ||
| Crypt-villus ratio | |||
| Limitations | Specificity and sensitivity of test method; the active period of the disease; long-term gluten-free diet | Similar histological pattern of some other diseases; long-term gluten-free diet | — |
| Caf1 | Ccr4 | |||
| Gene | Synonyms | Gene | Synonyms | |
| Saccharomyces cerevisiae | POP2 | CAF1 | CCR4 | FUN27, NUT21 |
| Schizosaccharomyces pombe | caf1 | pop2 | CCR4 | |
| Caenorhabditis elegans | CCF-1 | CCR-4 | ||
| Drosophila melanogaster | Pop2 | CAF1 | Twin | CCR4 |
| Xenopus laevis | Cnot7 | caf1, caf-1 | Cnot6 | CCR4A |
| Cnot8 | pop2, calif | Cnot6l | CCR4B | |
| Danio rerio | Cnot7 | zgc:153168 | Cnot6 | Zgc:65822 |
| Cnot8 | zgc:63844 | Cnot6l | Zgc:111987 | |
| Mus musculus | Cnot7 | Caf1 | Cnot6 | |
| Cnot8 | Cnot6l | |||
| Homo sapiens | CNOT7 | Caf1; Caf1a | CNOT6 | Ccr4; Ccr4a |
| CNOT8 | Pop2; Calif; Caf1b | CNOT6L | Ccr4-like; |
| Variablesa | High risk (n = 1170) | Not high risk (n = 563) | P value* | |
| Gender | ||||
| Male | 463 (39.6) | 372 (66.1) | <0.001 | |
| Female | 707 (60.4) | 191 (33.9) | ||
| Age (years) (M ± SD) | 50.27 ± 10.83 | 50.46 ± 10.86 | 0.777 | |
| 31- 45b | 459 (39.2) | 212 (37.7) | 0.737 | |
| 46- 60 | 485 (41.5) | 244 (43.3) | ||
| 61 year& above | 226 (19.3) | 107 (19.0) | ||
| Religion | ||||
| Islam | 796 (68.0) | 377 (67.0) | 0.386 | |
| Hindu | 358 (30.6) | 180 (32.0) | ||
| Christian | 16 (1.4) | 6 (1.1) | ||
| Family size | ||||
| Small (less than 4 persons) | 564 (48.2) | 274 (48.7) | 0.275 | |
| Medium (5 – 8 persons) | 541 (46.2) | 273 (48.5) | ||
| Large (>9) | 65 (5.6) | 16 (2.8) | ||
| Type of family | ||||
| Nuclear family | 982 (83.9) | 475 (84.4) | 0.815 | |
| Joint family | 188 (16.1) | 88 (15.6) | ||
| Marital status | ||||
| Never married/Divorced/ Separated/ Widowed | 129 (11.5) | 66 (11.7) | 0.887 | |
| Married | 1037 (88.6) | 497 (88.3) | ||
| Education | ||||
| Illiterate/ Signature/Gonoshikha | 512 (43.8) | 249 (44.2) | 0.729 | |
| Primary level | 336 (28.7) | 163 (29.0) | ||
| Secondary level and above | 322 (27.5) | 151 (26.8) | ||
| Gross National Income (per capita, US$) | ||||
| Low income (≤905) | 345 (29.5) | 150 (26.6) | 0.175 | |
| Lower-middle income (906–3595) | 818 (69.9) | 410 (72.8) | ||
| Upper-middle income (3596–11115) | 7 (0.6) | 3 (0.5) | ||
| Employment status | ||||
| Unemployed/ sacked from the present job/ Retired | 78 (6.7) | 25 (4.4) | 0.001 | |
| Office work/ Business/ Skilled labour | 104 (8.9) | 85 (15.1) | ||
| House maker/farmer | 846 (72.3) | 306 (54.4) | ||
| Rickshaw puller/day labour/ Others | 142 (12.1) | 147 (26.1) |
| Factors | Have you ever attended VCT (N (%)) | |||
| Yes | No | χ2 | p-value | |
| Religion | ||||
| Protestant | 36(29.3) | 87(70.7) | 5.6 | 0.13 |
| Catholic | 39(37.1) | 66(62.9) | ||
| Muslims | 21(47.7) | 23(52.3) | ||
| Others | 11(29.7) | 26(70.3) | ||
| Professional groups | ||||
| Medical students (MD) | 35(32.7) | 65(32.2) | 0.98 | 0.80 |
| Nursing | 33(30.8) | 60(29.7) | ||
| Physiotherapist | 14(13.1) | 21(10.4) | ||
| Others | 25(23.4) | 56(27.7) | ||
| Age group | ||||
| 18–21 | 16(15) | 31(15.3) | 3.9 | 0.14 |
| 22–23 | 30(28) | 78(38.6) | ||
| 24–25 | 61(57) | 93(46) | ||
| Gender | ||||
| Male | 38(35.5) | 74(36.6) | 0.04 | 0.85 |
| Female | 69(64.5) | 128(63.4) | ||
| Ever had sex | ||||
| Yes | 106(99.1) | 194(96) | 2.26 | 0.17 |
| No | 1(0.9) | 8(4.0) |
| Total | |
| No. of patients | 394 |
| Age (years) | |
| Mean ± SD | 57.0 ± 12.8 |
| Range | 28-94 |
| Tumor size (cm) | |
| ≤2.0 | 197 (50.0%) |
| 2.1-5.0 | 183 (46.5%) |
| >5.0 | 12 (3.1%) |
| Unknown | 2 (0.4%) |
| No. of positive lymph nodes | |
| 0 | 207 (52.5%) |
| 1-3 | 108 (27.4%) |
| 4-9 | 23 (5.9%) |
| ≥10 | 15 (3.8%) |
| Unknown | 41 (10.4%) |
| Tumor grade | |
| 1 | 111 (28.2%) |
| 2 | 113 (28.7%) |
| 3 | 146 (37.1%) |
| Unknown | 24 (6.0%) |
| ERα | |
| Negative | 31(7.9%) |
| Positive | 363 (92.1%) |
| PgR | |
| Negative | 86 (21.8%) |
| Positive | 306 (77.7%) |
| Unknown | 2 (0.5%) |
| HER2 status | |
| Negative | 278 (70.6%) |
| Positive | 41 (10.4%) |
| Unknown | 75 (19.0%) |
| Adjuvant therapy | |
| None | 30 (7.6%) |
| Endocrine therapy | 177 (44.9%) |
| Chemotherapy | 29 (7.4%) |
| Combined | 155 (39.3%) |
| Unknown | 3 (0.8%) |
| Patient number | Patient age | Early or late infection | Procedure | Time after first washout that NPWT was applied | Duration of NPWT | Number of NPWT changes | Long-term outcome |
| 1 | 17 years | Late | Corrective surgery for severe scoliosis | 0 days | 21 days | 3 | Metalwork retained, no infection |
| 2 | 46 years | Early | Instrumented lumbar spine fusion | 0 days | 14 days | 2 | Metalwork retained, no infection |
| 3 | 43 years | Early | Instrumented lumbar spine fusion | 0 days | 14 days | 2 | Metalwork retained, no infection |
| 4 | 41 years | Early | Instrumented anterior lumbar spine fusion | 0 days | 15 days | 2 | Metalwork retained, no infection |
| 5 | 72 years | Early | Instrumented lumbar spine fusion | 0 days | 14 days | 2 | Metalwork retained, no infection |
| MAA Category | Commercial Agreement | Payment for Performance Agreement | Coverage with Evidence Development |
| Contract type | • Discount-based contract | • Permanent risk-shifting agreement (outcomes guarantee/insurance) applied on a per-patient basis | • Provisional agreement until new, clearly specified evidence develops from a cohort of patients |
| Collection and analysis of patient health outcomes data by the payer | • None | • Per patient | • Cohort of patients |
| Timeframe of the MAA | • Permanent/not linked to final decision-making | • Permanent/not linked to final decision-making based on new robust evidence | • Temporary/provisional until new evidence allows making a final decision |
| Underlying concept (payer perspective) | • Reducing pharmaceutical expenditure | • Avoiding inefficient expenditure on treating patients who do not respond to a drug and who cannot be identified ex ante (by permanently linking the payment to drug's performance in individual patients) | • Reducing uncertainty about drug's real-life effectiveness (by linking a final HTA, reimbursement and/or pricing decision to drug's performance in a cohort of patients, during a defined test period) |
| Examples | • Flat price per patient (regardless of the number of doses administered)• Cost Sharing• Rebate• Discount | • Payment for performance• Pay-back for non performance | • Temporary coverage on a condition that new evidence reduces uncertainty about a pre-specified health outcome:- Real-life effectiveness- Higher efficacy in a pre-specified subpopulation of patients- Long-term effect- Improved patient's adherence- Reduction of use of health care resources (e.g. hospitalization) |
| All patients | Cases | Control | |
| Samples | 10,324 | 6,564 | 5,072b |
| Identified CNVs | 14,226a | 9,186 | 495,916 |
| Type of CNVs: | |||
| Loss | 7,554 | 5,101 | 343,489 |
| Gain | 6,672 | 4,085 | 152,427 |
| Average CNV length (Kb) | 3,336 | 3,014 | 31 |
| Type of inheritance: | |||
| De novo constitutive | 14,501 | 2,454 | |
| Inherited from normal parent | 9,345 | 1,945 | |
| Inherited from parent with similar phenotype to child | 1,345 | 240 | |
| Unknown | 21,946 | 3,638 |
| Flexion | Extension | |||||
| Pre-operation | 13 months after the operation | 18 months after the operation | Pre-operation | 13 months after the operation | 18 months after the operation | |
| Left hip | 0°-25° | 0°-85° | 0°-110° | Flexion deformity | 0°-15° | 0°-15° |
| Right hip | 0°-15° | 0°-80° | 0°-105° | 0°-10° | 0°-10° | |
| Left knee | 0°-15° | 0°-100° | 0°-125° | 0° | 0° | |
| Right knee | 0°-10° | 0°-90°, | 0°-127° | 0° | 0° |
| Trait | Description (ability assessed) | CLDRC-RD (564) | UK-RD (958) | SLIC (498) | CLDRC-ADHD (163) |
| WRead | Reading real words | x (0.918) | x (0.918) | x (0.902) | x (0.871) |
| WSpell | Spelling real words | x (0.813) | x (0.852) | x (0.862) | x (0.764) |
| PD | Ability to convert letter strings into sounds, according to given phonetic rules | x (0.895, 0.861)* | x (0.809) | x (0.821, 0.729)* | |
| PA | Ability to recognize and manipulate speech sounds (phonemes) | x (0.801) | x† | x (0.744) | |
| OC | Ability to recognize a word as an orthographic unit and to retrieve the corresponding phonological form | x (0.764) | x (0.888) | x (0.644) | |
| NWR | Ability to repeat nonsense words orally presented | x (0.493) | x (0.665) | x (0.355) | |
| ELS | Sentence recalling and production (expressive domain of language) | x (0.856) | |||
| RLS | Listening and auditory comprehension (receptive domain of language) | x (0.837) | |||
| VIQ | Verbal reasoning | x | x | x | x |
| PIQ | Logical reasoning | x | x | x | x |
| PC1 | Common variance in reading and language skills | 544 | 914 | 245 | 159 |
| IQ-adjusted PC1 | Common variance in reading and language skills, not shared with general cognitive abilities | 544 | 878 | 245 | 159 |
| T-cell development | Naive T-cell homeostasis | T-cell activation | T-cell differentiation | T-cell memory | References | |
| Slc7a5–/– mice | No | No | T-cell activation↓ | Th1 and Th17 cells↓ | Not available | 11 |
| Slc1a5–/– mice | No | (1) For young micea: No (2) For older miceb: CD4+ T cells↓CD44loCD62Lhi CD4+ T cells↑ | Activation of mTORC1 in T cellsc↓ | Th1 and Th17 cells↓ | (1) For young micea: No(2) For older miceb: Memory CD4+ T cells↓ | 10 |
| Slc6a1–/– mice | No | No | IL-2 secretion and CD69 expression in T cellsc ↑ | Th1 cells↑ | Not available | 9, 71 |
| Term | Number of medications | Number of studies | References |
| Polypharmacy | ≥ 2 for > 240 days (long term) | 1 | [101] |
| ≥ 5 medications in the same month | 1 | [103] | |
| > 5 medications for ≥ 90 days | 1 | [104] | |
| ≥ 5 medications in the same quarter of a year | 1 | [105] | |
| ≥ 5 medicines at hospital discharge | 1 | [106] | |
| 5 to 9 medicines on the day of maximum number of prescriptions of the study year (on the day of the study year when the number of medications prescribed was highest) | 1 | [107] | |
| 5 to 9 medications for ≥ 90 days | 1 | [108] | |
| 5 to 9 medicines during hospital stay | 1 | [109] | |
| ≥ 10 medicines during hospital stay | 1 | [110] | |
| Major polypharmacy | ≥ 10 on the day of maximum number of prescriptions of the study year (on the day of the study year when the number of medications prescribed was highest) | 1 | [107] |
| Hyperpolypharmacy | ≥ 10 medications for ≥90 days | 1 | [108] |
| Excessive polypharmacy | ≥ 10 medications in the same quarter of a year | 1 | [105] |
| ≥ 10 medications during hospital stay | 1 | [109] | |
| Persistent polypharmacy | ≥ 5 medications for 181 days | 1 | [52] |
| Chronic polypharmacy | ≥ 5 medications in 1 month for 6 months (consecutive or not) in a year | 1 | [111] |
| Category | Treatment group (n = 16) | Control group (n = 12) | P value |
| Age (months) | 136 (93–216) | 140 (96–176) | 0.82 |
| Weight (kgs) | 7.70 (1.44–27.82) | 4.75 (1.63–29.09) | 0.39 |
| Coughing | 8/16 | 7/12 | 0.78 |
| Abdominal Distension | 5/16 | 0/12 | 0.18 |
| Respiratory Distress | 13/16 | 10/12 | 0.73 |
| Lethargy | 8/16 | 5/12 | 0.67 |
| Syncope | 2/16 | 4/12 | 0.64 |
| Exercise Intolerance | 8/16 | 6/12 | 1.0 |
| Water Microbe | Amplified NuclearRibosomal Regions | Primer Sets (from 5' to 3') | PCR Program |
| Bacteria [19,20] | 16S rRNA V4-V5 region | 515F: GTGCCAGCMGCCGCGGTAA907R: CCGTCAATTCCTTTGAGTTT | 95°C for 2 min, 30 cycles of 95°C for 30 s, 55°C for 30 s, 72°C for 30 s, with a final extension at 72°C for 5 min |
| Fungi [21] | Internal transcribedspacer-1 (ITS1) region | 1737F:GGAAGTAAAAGTCGTAACAAGG2043R:GCTGCGTTCTTCATCGATGC | 95°C for 1 min, 30 cycles of 95°C for 10 s, 55°C for 30 s, 72°C for 30 s, with a final extension at 72°C for 5 min |
| whale | age/sex | year | tag duration (days) | min. latitude (° S) | max. SST (°C) |
| 1 | adult/female | 2009 | 08 Jan–16 Jan (9) | 64 | 2.3 |
| 2 | adult/female | 2009 | 14 Jan–27 Jan (14) | 67 | 2.1 |
| 3 | adult/female | 2009 | 15 Jan–31 Jan (17) | 60 | 2.9 |
| 4 | adult/female | 2009 | 24 Jan–13 Feb (21) | 51 | 11.2 |
| 5 | subadult/male | 2010 | 13 Feb–24 Feb (12) | 63 | 2.1 |
| 6 | adult/female | 2010 | 13 Feb–21 May (98) | 30 | 22.4 |
| 7 | adult/female | 2010 | 13 Feb–01 Jun (109) | 30 | 22.4 |
| 8 | adult/male | 2011 | 13 Jan–31 Jan (19) | 67 | 1.8 |
| 9 | adult/female | 2011 | 13 Jan–25 Feb (44) | 37 | 22.9 |
| 10 | adult/female | 2011 | 15 Jan–16 Apr (93) | 36 | 20.9 |
| 11 | adult/female | 2011 | 15 Jan–22 Apr (99) | 30 | 24.2 |
| 12 | adult/female | 2011 | 24 Jan–13 Feb (21) | 65 | 1.9 |
| Age (yrs) | Weight (kg) | Gender | Ethnicity | Indication | Target INR | Drug Interaction(s) | Therapeutic warfarin dose (mg/d) | Reference |
| 69 | 79.8 | Female | Japanese | AFib | 1.5–20 | NR | 0.5 | [8] |
| 71 | 82 | Male | White | AFib | 2.0–3.0 | Amiodarone | 0.9 | [11] |
| 58 | 70 | Male | Japanese | AFib | NR | Propafenone | 0.25–0.75 | [12] |
| 68 | 70 | Female | Chinese | AFib | 2.0–3.0 | NR | 0.63 | [13] |
| 50 | 88 | Male | Chinese | AFib | 2.0–3.0 | NR | 1.25 | [13] |
| 74 | 54 | Female | White | AFib | 2.0–3.0 | Amiodarone/Atorvastatin | 0.5 | Present case |
| N | % | |
| Clozapine | 9 | 39 |
| Other antipsychotics | 14 | 61 |
| Traditional antipsychotics | 6 | 26 |
| Atypical antipsychotics | 8 | 35 |
| Mood stabilizers | 5 | 22 |
| Clozapine dose | 481 ± 218 mg (range 300 - 900) | |
| Serum level of clozapine | 1671 ± 1164 μmol/l (range 326 - 3333) |
| Barrier | 1st Barrier | 2nd Barrier | 3rd Barrier | Total | |||
| Freq | % | Freq | % | Freq | % | N | |
| Delay before care is received | 59 | 10.9 | 35 | 6.5 | 9 | 1.7 | 103 |
| Long distance to treatment centres | 6 | 1.1 | 24 | 4.5 | 11 | 2 | 41 |
| Financial challenges | 68 | 12.6 | 24 | 4.4 | 19 | 3.5 | 111 |
| Job insecurity | 14 | 2.6 | 7 | 1.3 | 5 | 0.9 | 26 |
| No challenge | 198 | 36.7 | 350 | 64.8 | 418 | 77.4 | 966 |
| Shortage of drugs and other commodities | 72 | 13.3 | 34 | 6.3 | 12 | 2.2 | 118 |
| Fear of side effects | 26 | 4.8 | 8 | 1.5 | 2 | 0.4 | 36 |
| Stigmatisation | 7 | 1.3 | 6 | 1.1 | 3 | 0.6 | 16 |
| Total | 540 | 100 | 540 | 100 | 540 | 100 | 1620 |
| Variable | Unadjusted | Adjusted for CRP/AGP 2 |
| Participants (n) 3 | 770 | 770 |
| Hb concentration, g/dL 4 | 9.6 (9.5,9.8) | - |
| Anemia, Hb < 10.5 g/dL (2nd trimester) or 11.0 g/dL (1st, 3rd trimester) | 601 (79.0) | - |
| Mild anemia (Hb 10.0–10.4 or 10.9 g/dL) | 173 (22.7) | - |
| Moderate anemia (Hb 7.0–9.9 g/dL) | 402 (52.8) | - |
| Severe anemia (Hb < 7.0 g/dL) | 26 (3.4) | - |
| Ferritin, μg/L | 30.5 (28.5, 32.7) | 27.3 (25.8, 28.8) |
| Iron deficiency, ferritin < 15 μg/L | 137 (17.8) | 159 (20.7) |
| sTfR, mg/L | 7.8 (7.5, 8.1) | - |
| Iron deficiency, sTfR > 8.3 mg/L | 275 (35.7) | - |
| pZn, μg/dL | 51.7 (51.0, 52.4) | 52.3 (51.6, 53.0) |
| Zinc deficiency, pZn < 50 μg/dL 5 | 311 (43.4) | 292 (40.7) |
| RBP, μmol/L | 1.05 (1.03, 1.08) | 1.07 (1.05, 1.10) |
| RBP < 0.70 μmol/L | 68 (8.8) | 57 (7.4) |
| Inadequate or marginal status, RBP < 1.32 μmol/L | 622 (80.8) | 614 (79.7) |
| B12, pmol/L | 169.9 (165.1, 174.9) | - |
| Inadequate status, B12 < 148 pmol/L | 259 (34.8) | - |
| Marginal status, B12, 148–221 pmol/L | 324 (43.5) | - |
| Folate, nmol/L | 10.5 (10.1, 10.9) | - |
| Inadequate status, folate < 10 nmol/L | 328 (44.3) | - |
| Micronutrient deficiency anemia 6 | ||
| Iron deficiency anemia (Anemia + ferritin < 15 μg/L) | 124 (16.3) | 142 (18.7) |
| Iron deficiency anemia (Anemia + sTfR > 8.3 mg/L) | 250 (32.9) | - |
| B12 deficiency anemia (Anemia + B12 < 148 pmol/L) | 208 (28.3) | - |
| Folate-deficiency anemia (Anemia + and folate < 10 nmol/L) | 265 (36.4) | - |
| Multiple micronutrient (MNN) deficiency 7 | ||
| 0 | 25 (3.6) | 24 (3.5) |
| 1 | 131 (19.0) | 131 (19.0) |
| 2 | 212 (30.8) | 222 (32.3) |
| 3 | 173 (25.2) | 164 (23.8) |
| 4 | 114 (16.6) | 114 (16.6) |
| 5 | 33 (4.8) | 33 (4.8) |
| AGP, g/L | 0.39 (0.38,0.40) | - |
| AGP > 1 g/L | 23 (3.0) | - |
| CRP, mg/L | 2.2 (2.0, 2.4) | - |
| CRP > 5 mg/L | 189 (24.6) | - |
| Malaria antigenemia (elevated HRP2) 8 | 97 (12.6) | - |
| Country | Year of data collection | Male | Female | ||||||||||||
| lung | stomach | large bowel | prostate | kidney | urinary bladder | lung | stomach | large bowel | breast | cervix | ovary | kidney | urinary bladder | ||
| Croatia | 2005 | 63.7 | 17.7 | 43.5 | 38.7 | 11.1 | 18.4 | 13.6 | 6.9 | 23.4 | 55.8 | 9.2 | 11.7 | 4.7 | 4.1 |
| Czech Republic | 2005 | 58.2 | 11.2 | 58.7 | 59.5 | 22.6 | 22.3 | 15.5 | 5.8 | 28.8 | 61.7 | 13.3 | 12.4 | 9.8 | 6.0 |
| Hungary | 2002 | 94.6 | 20.5 | 56.6 | 34.0 | 14.7 | 19.6 | 24.9 | 9.5 | 33.7 | 63.0 | 15.7 | 11.1 | 6.6 | 5.1 |
| Poland | 2006 | 60.2 | 12.8 | 29.3 | 27.3 | 9.1 | 15.9 | 14.5 | 4.9 | 17.2 | 44.5 | 11.5 | 11.1 | 4.7 | 3.0 |
| Romania | 2002 | 50.0 | 17.6 | 22.0 | 16.8 | 5.5 | 15.4 | 8.5 | 6.8 | 14.4 | 44.3 | 23.9 | 9.4 | 2.8 | 3.3 |
| Central Serbia | 2004 | 64.2 | 12.9 | 33.7 | 20.1 | 6.5 | 17.4 | 18.4 | 7.2 | 20.9 | 57.9 | 24.3 | 10.9 | 3.8 | 4.2 |
| Slovakia | 2004 | 55.8 | 16.1 | 55.5 | 33.9 | 14.9 | 15.9 | 10.4 | 7.0 | 27.7 | 49.7 | 15.2 | 11.5 | 6.6 | 4.1 |
| Parameters | Lead (Pb) | Cadmium (Cd) | Zinc (Zn) | Iron (Fe) | References |
| Water concentration (ppm) | 0.33 ± 0.03 | 0.02 ± 0.00* | 0.01 ± 0.00** | 2.61 ± 0.07** | This study |
| Liver concentration (ppm) | 0.35 ± 0.04 | 0.04 ± 0.00* | 2.17 ± 0.30** | 11.66 ± 1.32** | This study |
| Bioaccumulation factor | 1.06 | 2.00 | 217.00 | 4.46 | This study |
| Maximum acceptable water limit (ppm) | 0.01 | 0.003 | 3.00 | 0.30 | NIS (2007) |
| 0.01 | 0.01 | 5.00 | 0.30 | WHO (2003) [24] | |
| Maximum acceptable liver limit (mgkg-1) | 0.01 | 0.01 | 5.00 | 0.30 | WHO (2003) [24] |
| Factor | Prokaryotic community (P/R) | Fungal community (P/R) | |||
| Chao1 (Richness) | Shannon | Chao1 (Richness) | Shannon | ||
| Na | 0.489/-0.006 | 0.592/-0.033 | 0.280/0.042 | 0.067/0.156 | |
| S | 0.001/0.526 | 0.001/0.610 | 0.320/0.012 | 0.319/0.029 | |
| P | 0.021/0.100 | 0.214/0.049 | 0.067/0.181 | 0.188/0.080 | |
| Ca | 0.223/0.026 | 0.085/0.088 | 0.690/-0.056 | 0.004/0.228 | |
| K | 0.007/0.118 | 0.150/0.080 | 0.340/0.053 | 0.431/0.006 | |
| Mg | 0.002/0.156 | 0.002/0.350 | 0.646/-0.075 | 0.158/0.103 | |
| Fe | 0.001/0.238 | 0.047/0.136 | 0.494/-0.027 | 0.404/0.007 | |
| Al | 0.001/0.225 | 0.020/0.165 | 0.347/0.029 | 0.356/0.023 | |
| As | 0.878/-0.049 | 0.627/-0.042 | 0.143/0.146 | 0.776/-0.078 | |
| B | 0.549/-0.012 | 0.269/0.033 | 0.299/0.031 | 0.784/-0.079 | |
| Ba | 0.001/0.287 | 0.012/0.196 | 0.001/0.467 | 0.261/0.044 | |
| Cd | 0.461/0.001 | 0.553/-0.030 | 0.017/0.362 | 0.514/-0.019 | |
| Co | 0.001/0.245 | 0.012/0.187 | 0.414/0.013 | 0.491/-0.011 | |
| Cr | 0.001/0.295 | 0.011/0.201 | 0.421/-0.012 | 0.455/-0.003 | |
| Cu | 0.317/0.017 | 0.627/-0.037 | 0.591/-0.071 | 0.971/-0.156 | |
| Ga | 0.001/0.270 | 0.009/0.206 | 0.342/0.008 | 0.215/0.064 | |
| Ge | 0.200/0.033 | 0.072/0.144 | 0.322/-0.008 | 0.969/-0.125 | |
| Hg | 0.001/0.167 | 0.159/0.072 | 0.417/-0.009 | 0.326/0.024 | |
| Li | 0.259/0.022 | 0.475/-0.002 | 0.332/0.035 | 0.148/0.101 | |
| Mn | 0.001/0.218 | 0.062/0.121 | 0.337/0.026 | 0.266/0.047 | |
| Ni | 0.004/0.167 | 0.025/0.158 | 0.462/-0.021 | 0.216/0.072 | |
| Pt | 0.918/-0.056 | 0.454/-0.025 | 0.524/-0.044 | 0.574/-0.047 | |
| Sr | 0.417/0.004 | 0.177/0.064 | 0.712/-0.064 | 0.001/0.433 | |
| Ti | 0.001/0.282 | 0.009/0.225 | 0.225/0.079 | 0.195/0.062 | |
| Zn | 0.813/-0.041 | 0.931/-0.092 | 0.979/-0.117 | 0.837/-0.110 | |
| Rb | 0.136/0.051 | 0.398/0.01 | 0.094/0.178 | 0.139/0.097 | |
| TCE | 0.985/-0.076 | 0.899/-0.084 | 0.177/0.099 | 0.091/0.122 | |
| pH | 0.779/-0.035 | 0.849/-0.07 | 0.396/0.015 | 0.390/0.016 | |
| Moisture | 0.004/0.158 | 0.057/0.101 | 0.005/0.275 | 0.281/0.043 | |
| Longitude | 0.020/0.129 | 0.006/0.162 | 0.930/-0.075 | 0.287/0.021 | |
| Latitude | 0.007/0.160 | 0.047/0.107 | 0.836/-0.065 | 0.205/0.046 |
| Fatty acid | Overall N = 3196 | Male N = 1434 | Female N = 1762 | P value* |
| Myristic, C14:0 | 0.31 (0.08) | 0.29 (0.07) | 0.32 (0.09) | <0.0001 |
| Palmitic, C16:0 | 21.29 (1.24) | 21.24 (1.21) | 21.34 (1.26) | 0.031 |
| Stearic, C18:0 | 18.11 (0.95) | 18.20 (0.89) | 18.04 (1.00) | <0.0001 |
| Lignoceric, C24:0 | 0.43 (0.16) | 0.44 (0.16) | 0.42 (0.16) | 0.012 |
| Palmitoleic, C16:1 | 0.35 (0.19) | 0.31 (0.18) | 0.39 (0.19) | <0.0001 |
| Oleic, C18:1 | 13.88 (1.06) | 13.90 (1.06) | 13.85 (1.06) | 0.23 |
| Eicosenoic, C20:1 | 0.27 (0.11) | 0.28 (0.12) | 0.27 (0.10) | <0.0001 |
| Nervonic, C24:1 | 0.45 (0.15) | 0.46 (0.15) | 0.43 (0.15) | <0.0001 |
| trans Palmitoleic, C16:1 trans | 0.17 (0.05) | 0.16 (0.05) | 0.17 (0.05) | 0.0052 |
| trans Oleic, C18:1 trans | 1.62 (0.55) | 1.62 (0.57) | 1.61 (0.54) | 0.56 |
| trans Linoleic, C18:2 trans | 0.25 (0.08) | 0.24 (0.08) | 0.25 (0.08) | 0.0021 |
| alpha-Linolenic, C18:3n3 | 0.19 (0.10)† | 0.17 (0.09) | 0.20 (0.11) | <0.0001 |
| Eicosapentaenoic (EPA), C20:5n3 | 0.74 (0.46)† | 0.71 (0.42) | 0.76 (0.49) | 0.0011 |
| Docosapentaenoic, C22:5n3 | 2.74 (0.46) | 2.80 (0.46) | 2.70 (0.45) | <0.0001 |
| Docosahexaenoic (DHA), C22:6n3 | 4.88 (1.38) | 4.82 (1.39) | 4.92 (1.37) | 0.043 |
| Linoleic, C18:2n6 | 11.19 (1.74) | 11.03 (1.63) | 11.33 (1.81) | <0.0001 |
| gamma-Linolenic, C18:3n6 | 0.08 (0.09) | 0.08 (0.12) | 0.09 (0.07) | 0.089 |
| Eicosadienoic, C20:2n6 | 0.28 (0.05) | 0.28 (0.05) | 0.28 (0.05) | 0.23 |
| Eicosatrienoic, C20:3n6 | 1.59 (0.36) | 1.59 (0.36) | 1.59 (0.35) | 0.66 |
| Arachidonic, C20:4n6 | 16.78 (1.62) | 16.79 (1.57) | 16.77 (1.66) | 0.66 |
| Docosatetraenoic, C22:4n6 | 3.76 (0.83) | 3.92 (0.83) | 3.63 (0.81) | <0.0001 |
| Docosapentaenoic, C22:5n6 | 0.66 (0.19) | 0.67 (0.19) | 0.64 (0.19) | <0.0001 |
| Factor | Effect on efficiency | Implications |
| Decreased morale | Decrease | Increase staff support and supervision, plan for retention, access to ART |
| Increased experience | Increase | Plan to increase retention to keep experienced staff |
| Increased training | Increase long term (short-term training time may decrease efficiency) | Plan for quality training on-hire (practical and didactic), continuing education, work to integrate into preclinical education in health services |
| Staff flexibility | Potentially increase | Provide education and support to encourage staff willing to expand/change roles to increase efficiency of the overall programme |
| Number | |||
| Round 1 | Round 2 | Round 3 | |
| Participant response rate | 34/49 (70%) | 33/34 (97%) | 32/33 (97%) |
| Gender | |||
| Male | 8 (23.5%) | 8 (24.2%) | 7 (21.9%) |
| Female | 26 (76.4%) | 25 (75.8%) | 25 (78.1%) |
| Age (years) | |||
| 30–40 | 6 (17.6%) | 5 (15.1%) | 5 (15.6%) |
| 41–50 | 14 (41.2%) | 14 (42.4%) | 14 (43.8%) |
| 51–60 | 14 (41.2%) | 14 (42.4%) | 13 (40.6%) |
| Work experience (years) | |||
| 5–15 | 25 (73.5%) | 24 (72.7%) | 23 (71.9%) |
| 16–25 | 8 (23.5%) | 8 (24.2%) | 8 (25%) |
| 26–30 | 1 (2.9%) | 1 (3.03%) | 1 (3.1%) |
| Education level | |||
| Bachelor's degree | 13 (38.2%) | 13 (39.4%) | 12 (37.5%) |
| Master's degree | 17 (50%) | 16 (48.5%) | 16 (50%) |
| PhD | 4 (11.8%) | 4 (12.1%) | 4 (12.5%) |
| Profession | |||
| Nurse | 24 (70.6%) | 24 (72.7%) | 23 (71.9%) |
| Physician | 3 (8.8%) | 3 (9.1%) | 3 (9.4%) |
| Psychiatrist | 2 (5.9%) | 2 (6.0%) | 2 (6.3%) |
| Psychologist | 2 (5.9%) | 1 (3.0%) | 1 (3.1%) |
| Social worker | 1 (2.9%) | 1 (3.0%) | 1 (3.1%) |
| Alcoholics Anonymous membership | 1 (2.9%) | 1 (3.0%) | 1 (3.1%) |
| Health officer | 1 (2.9%) | 1 (3.0%) | 1 (3.1%) |
| Region | |||
| North | 6 (17.64%) | 6 (18.18%) | 6 (18.78%) |
| South | 4 (11.76%) | 4 (12.12%) | 4 (12.52%) |
| Central | 4 (11.76%) | 4 (12.12%) | 3 (9.39%) |
| Northeast | 20 (58.8%) | 19 (57.57%) | 19 (59.47%) |
| Compounds | Ee/au | (ΔEb) kcal/mol | EBSSE | (ΔEb-bsse) kcal/mol | Ec | (ΔEcb) kcal/mol | H\\au | ΔH kcal/mol |
| L-Dopa | −705.45367 | −705.25677 | −705.24186 | |||||
| LD-W1 | −781.92896 | −10.559 | −781.91194 | −0.11922 | −781.70706 | −8.206 | −781.68921 | −8.788 |
| LD-W2 | −781.91946 | −4.598 | −781.91112 | −0.63377 | −781.69836 | −2.783 | −781.68007 | −3.026 |
| LD-W3 | −781.92633 | −8.905 | −781.90779 | −2.72335 | −781.70373 | −5.939 | −781.68652 | −7.073 |
| Water | −76.45846 | −76.43716 | −76.43339 |
| A/CPA patients | Pure APA patients | P value | |
| Number of cases | 22 | 392 | |
| Age (years) | 40.32 ± 6.37 | 38.37 ± 7.76 | 0.1255 |
| Age range (years) | 26–51 | 19–58 | |
| Female, n (%) | 14, 63.64% | 219, 52.87% | 0.3252 |
| BMI (kg/m2) | 25.45 ± 3.22 | 25.28 ± 3.44 | 0.8111 |
| Tumor size (mm) | 24.50 ± 11.34 | 18.92 ± 7.98 | 0.0318∗ |
| SBP (mmHg) | 181.4 ± 31.55 | 180.6 ± 26.57 | 0.8180 |
| DBP (mmHg) | 108.2 ± 13.26 | 109.2 ± 14.87 | 0.7071 |
| Duration of HT (years) | 11.91 ± 8.26 | 9.46 ± 7.30 | 0.1489 |
| Stroke, n (%) | 3 (13.64%) | 22 (5.61%) | 0.1242 |
| Heart disease, n (%) | 8 (36.36%) | 41 (10.46%) | 0.0003† |
| CVE history, n (%) | 11 (50%) | 63 (16.07%) | <0.0001† |
| Glucose intolerance/diabetes, n (%) | 13 (59.09%) | 85 (21.68%) | <0.0001† |
| Lipid metabolic disorder, n (%) | 9 (40.91%) | 108 (27.55%) | 0.1757 |
| Osteopenia/osteoporosis, n (%) | 3 (13.64%) | 4 (1.02%) | <0.0001† |
| Metabolic syndrome, n (%) | 8 (36.36%) | 72 (18.37%) | 0.0375∗ |
| Cortisol excess screening, n (%)‡ | 22 (100%) | 392 (100%) | — |
| Confirmation test performed, n (%)§ | 22 (100%) | 264 (67.35%) | — |
| Aldosterone excess screening, n (%) | 22 (100%) | 392 (100%) | — |
| Confirmation test performed, n (%) | 22 (100%) | 392 (100%) | — |
| Error type and antimicrobial | Organism | No. of errors | MICa | AST resultb | Breakpointa | Reportable rangea | ||||
| AXDX | REF | AXDX | REF | S | R | Low | High | |||
| Very major errors | ||||||||||
| Daptomycin | Staphylococcus aureus | 1 | 0.5 | ≥2 | S | NS | 1 | N/A | 0.25 | 2 |
| Erythromycin | Staphylococcus warneric | 1 | 0.25 | ≥16 | S | R | 0.5 | 8 | 0.125 | 16 |
| Cefoxitin (MRSA/MRS) | Staphylococcus epidermidis | 4 | N/A | N/A | NEG | POS | 4 | 8 | 4 | 8 |
| Staphylococcus haemolyticus | 1 | N/A | N/A | NEG | POS | 4 | 8 | 4 | 8 | |
| Erythromycin-clindamycin (MLSb) | Staphylococcus warneri | 1 | N/A | N/A | NEG | POS | 2 | 4 | 2 | 4 |
| Major errors | ||||||||||
| Ampicillin | Enterococcus faecium | 1 | 16 | 8 | R | S | 8 | 16 | 2 | 32 |
| Daptomycin | Enterococcus faecium | 1 | ≥8 | 2 | NS | S | 4 | N/A | 1 | 8 |
| Doxycyclinec | Staphylococcus hominis subsp. hominis | 1 | 16 | 4 | R | S | 4 | 16 | 1 | 32 |
| Staphylococcus aureus | 4 | ≥32 | 2 | R | S | 4 | 16 | 1 | 32 | |
| Erythromycin | Staphylococcus aureus | 1 | ≥16 | 0.25 | R | S | 0.5 | 8 | 0.125 | 16 |
| Cefoxitin (MRSA/MRS) | Staphylococcus epidermidis | 1 | N/A | N/A | POS | NEG | 4 | 8 | 4 | 8 |
| Staphylococcus aureus | 1 | N/A | N/A | POS | NEG | 4 | 8 | 4 | 8 | |
| Erythromycin-clindamycin (MLSb) | Staphylococcus epidermidis | 1 | N/A | N/A | POS | NEG | 2 | 4 | 2 | 4 |
| Staphylococcus warneri | 1 | N/A | N/A | POS | NEG | 2 | 4 | 2 | 4 | |
| TMP-SMXc,d | Staphylococcus aureus | 1 | ≥8 | 2 | R | S | 2 | 4 | 0.5 | 8 |
| 2 | ≥8 | ≤0.5 | R | S | 2 | 4 | 0.5 | 8 | ||
| 2 | 4 | 1 | R | S | 2 | 4 | 0.5 | 8 | ||
| 2 | 4 | ≤0.5 | R | S | 2 | 4 | 0.5 | 8 | ||
| Staphylococcus lugdunensis | 3 | 4 | ≤0.5 | R | S | 2 | 4 | 0.5 | 8 |
| Target population (n = 5) | Key stakeholders (n = 5) | |
| Gender | Male (4) | Male (3) |
| Age | 21–34 years (mean: 26 years) | 23–38 years (mean: 29 years) |
| Educational status | Primary (1) | High-school (2) |
| Secondary (2) | Bachelors (2) | |
| High-school (1) | Masters (1) | |
| Bachelors (1) | ||
| Countries visited | Malaysia (2) | n/a |
| Saudi Arabia (1) | ||
| Qatar (1) | ||
| UAE (1) | ||
| Occupation | Domestic service (1) | Coordinator (1) |
| Driver (1) | Counselor (2) | |
| Construction (2) | Field worker (2) | |
| Cook (1) | ||
| Work experience | 3–8 years (mean: 5.2 years) | 1–6 years (mean: 4.4 years) |
| No. (%) | |
| State of health | |
| Good | 349 (37.0) |
| Poor | 595 (63.0) |
| Emotional status | |
| Blank | 144 (15.3) |
| Unhappy (ever) | 99 (10.5) |
| Ordinary | 343 (36.3) |
| happy | 348 (36.9) |
| No response | 10 (1.1) |
| Smoking | |
| No | 925 (98.0) |
| <5 cigarettes per day | 11 (1.2) |
| 6 ~ 10 cigarettes per day | 5 (0.5) |
| 11 ~ 20 cigarettes per day | 3 (0.3) |
| Alcohol use | |
| No | 856 (90.7) |
| <1 time per week | 63 (6.7) |
| 1 ~ 2 times per week | 18 (1.9) |
| 3 ~ 6 times per week | 6 (0.6) |
| ≥1 time per day | 1 (0.1) |
| Religion | |
| No | 580 (61.4) |
| Yes | 364 (38.6) |
| Exercise regularly | |
| No | 487 (51.6) |
| Yes | 457 (48.4) |
| Exercise duration (years) | |
| <3 | 93 (9.9) |
| 3 ~ 5 | 116 (12.3) |
| 6 ~ 10 | 118 (12.5) |
| >10 | 74 (7.8) |
| No response | 46 (4.9) |
| Total Median Costs | MRI | No MRI | ||||||
| (N = 53,653) | (N = 10,776) | (N = 42,877) | ||||||
| Characteristicsb of women | N | % | Median | IQR ($) | Median | IQR ($) | Median | IQR ($) |
| Total | 53,653 | 100 % | $1,353 | (818–2,042) | $2,251 | (1,783–2,971) | $1,152 | (708–1,727) |
| Stage | ||||||||
| 0 | 8,533 | 16 % | $1,721 | (1,232–2,368) | $2,627 | (2,090–3,228) | $1,524 | (1,160–2,085) |
| I | 25,146 | 47 % | $1,393 | (878–2,080) | $2,255 | (1,799–2,985) | $1,190 | (781–1,751) |
| II | 14,328 | 27 % | $1,106 | (627–1,838) | $2,093 | (1,662–2,776) | $891 | (547–1,442) |
| III | 3,838 | 7 % | $1,008 | (535–1,76) | $2,078 | (1,631–2,775) | $825 | (452–1,345) |
| IV | 503 | 1 % | $927 | (449–1,685) | $2,023 | (1,690–2,791) | $738 | (405–1,294) |
| Unknown | 1,305 | 2 % | $1,310 | (815–1,938) | $2,118 | (1,620–2,743) | $1,176 | (741–1,712) |
| Histology (invasive) | ||||||||
| Ductal | 33,134 | 62 % | $1,259 | (751–1,953) | $2,186 | (1,742–2,892) | $1,068 | (664–1,641) |
| Lobular | 5,005 | 9 % | $1,359 | (765–2,061) | $2,155 | (1,736–2,837) | $1,025 | (615–1,576) |
| Mixed | 3,177 | 6 % | $1,346 | (795–2,094) | $2,264 | (1,774–2,968) | $1,058 | (656–1,580) |
| Other | 3,804 | 7 % | $1,232 | (714–1,877) | $2,178 | (1,623–2,927) | $1,078 | (648–1,674) |
| Grade | ||||||||
| High | 12,125 | 24 % | $1,392 | (877–2,083) | $2,284 | (1,811–3,050) | $1,191 | (772–1,754) |
| Intermediate | 22,522 | 45 % | $1,351 | (822–2,054) | $2,238 | (1,776–2,944) | $1,129 | (708–1,715) |
| Low | 15,133 | 30 % | $1,289 | (726–1,969) | $2,212 | (1,747–2,899) | $1,100 | (636–1,676) |
| Nodal Status | ||||||||
| Positive | 11,009 | 25 % | $1,119 | (623–1,851) | $2,113 | (1,652–2,842) | $890 | (534–1,439) |
| Negative | 32,952 | 75 % | $1,379 | (847–2,074) | $2,242 | (1,788–2,951) | $1,158 | (739–1,734) |
| ER Status | ||||||||
| Positive | 40,999 | 84 % | $1,367 | (827–2,061) | $2,249 | (1,787–2,971) | $1,152 | (716–1,732) |
| Negative | 7,978 | 16 % | $1,263 | (728–1,960) | $2,231 | (1,747–2,935) | $634 | (634–1,633) |
| Size | ||||||||
| <1 cm | 12,455 | 25 % | $1,569 | (1,090–2,253) | $2,451 | (1,967–3,184) | $1,369 | (987–1,936) |
| 1 to <2 cm | 19,135 | 39 % | $1,348 | (824–2,031) | $2,187 | (1,745–2,925) | $1,127 | (723–1,716) |
| 2 to <5 cm | 15,281 | 31 % | $1,098 | (610–1,826) | $2,097 | (1,660–2,798) | $891 | (532–1,459) |
| 5+ cm | 2,620 | 5 % | $1,057 | (535–1,870) | $2,133 | (1,719–2,810) | $840 | (438–1,420) |
| Primary Treatment | ||||||||
| Mastectomy | 19,650 | 37 % | $1,267 | (696–1,955) | $2,265 | (1,746–3,028) | $1,053 | (602–1,686) |
| BCSc without Radiation | 12,972 | 24 % | $1,362 | (838–2,035) | $2,285 | (1,782–2,955) | $1,198 | (744–1,744) |
| BCSc with Radiation | 21,031 | 39 % | $1,413 | (909–2,126) | $2,230 | (1,801–2,925) | $1,201 | (602–1,762) |
| Number of days in Diagnostic/preoperative Window | ||||||||
| <= Median (25 days) | 27,779 | 52 % | $1,172 | (685–1,768) | $2,009 | (1,626–2,543) | $1,056 | (633–1,588) |
| > Median (25 days) | 25,874 | 48 % | $1,593 | (998–2,354) | $2,392 | (1,878–3,229) | $1,272 | (828–1,915) |
| Reason of Intake | Cat | Dog |
| Stray | 100 (80.6%) | 58 (47.5%) |
| People Issues (allergic, relocating, etc.) | 5 (4.0%) | 16 (13.1%) |
| Deceased Caretaker | 3 (2.4%) | 1 (0.8%) |
| Negligence | 2 (1.6%) | 0 (0%) |
| Abandoned (chip and no reclaim) | 0 (0%) | 9 (7.4%) |
| Animal Illness | 13 (10.5%) | 27 (22.1%) |
| Behavior | 1 (11.9%) | 11 (9.0%) |
| Time steps | Experiment-1 | Experiment-2 | Experiment-3 | Experiment-4 |
| t0 | 75.12% | 92.80% | 55.02% | 67.90% |
| t1 | 78.07% | 95.40% | 80.01% | 72.42% |
| t2 | 78.39% | 94.64% | 75.42% | 53.79% |
| t3 | 78.76% | 95.56% | 95.72% | 61.30% |
| t4 | 78.33% | 95.89% | 79.17% | 55.70% |
| t5 | 81.11% | 94.89% | 31.97% | 68.11% |
| t6 | 59.72% | 96.02% | 66.80% | 72.33% |
| t7 | 55.60% | 96.12% | 91.19% | 63.88% |
| t8 | 57.41% | 96.08% | 75.35% | 79.23% |
| t9 | 57.12% | 96.23% | 74.83% | 62.25% |
| t10 | 50.26% | 97.07% | 54.56% | 63.04% |
| t11 | 57.20% | 97.71% | 49.06% | 49.57% |
| t12 | 55.68% | 97.33% | 58.64% | 68.43% |
| t13 | 84.71% | 97.74% | 95.73% | 67.83% |
| t14 | 87.05% | 97.82% | 72.06% | 51.28% |
| t15 | 85.03% | 97.11% | 83.78% | 79.36% |
| t16 | 81.62% | 97.56% | 95.87% | 68.08% |
| t17 | 85.39% | 97.59% | 97.00% | 50.38% |
| t18 | 82.83% | 96.38% | 53.05% | 68.15% |
| t19 | 81.01% | 96.52% | 43.29% | 53.84% |
| t20 | 27.91% | 63.11% | 31.24% | 36.31% |
| t21 | 29.84% | 67.49% | 35.47% | 39.92% |
| t22 | 27.96% | 63.14% | 27.56% | 34.19% |
| t23 | 28.86% | 66.94% | 22.00% | 41.38% |
| Figure | Figure 13(a) | Figure 13(b) | Figure 14(a) | Figure 14(b) |
| Target | Species | Dilution | Reference |
| Primary antibodies | |||
| Nrf2 | Rabbit | 1:100 | ab31163; Abcam, UK |
| AhR | Rabbit | 1:200 | sc-5579; H-211; Santa Cruz, Heidelberg, Germany |
| Secondary antibodies | |||
| Anti-rabbit | Goat | 1:2000 | AS09 633; Agrisera, Vännas, Sweden |
| 1a | 7b | ||||
| Position | δC | δH (J Hz) | Position | δC | δH (J Hz) |
| 1a | 43.8 | 1.12, m | 2 | 161.6 | |
| 1b | 1.18, m | 3 | 87.5 | 5.65, s | |
| 2a | 18.7 | 1.53, m | 4 | 169.1 | |
| 2b | 1.76, m | 5 | 149.2 | ||
| 3a | 38.3 | 1.20, m | 6 | 107.7 | 7.26, s |
| 3b | 1.69, m | 7 | 131.4 | ||
| 4 | 39.2 | 8 | 143.7 | ||
| 5 | 45.9 | 1.80, m | 9 | 132.1 | |
| 6 | 69.3 | 5.67, m | 10 | 105.9 | |
| 7a | 28.8 | 2.12, m | 11 | 65.4 | 4.67, d (6.5) |
| 7b | 2.47, m | 12 | 119.8 | 5.47, d (6.5) | |
| 8 | 37.0 | 2.87, t (8.0) | 13 | 137.3 | |
| 9 | 50.7 | 2.40, m | 14 | 18.1 | 1.74, s |
| 10 | 35.7 | 15 | 25.5 | 1.76, s | |
| 11a | 69.4 | 4.28,dd (5.5,10) | 16 | 61.2 | 4.80, d (4.0) |
| 11b | 4.47, d (9.5) | 17 | 56.7 | 3.94, s | |
| 12 | 181.2 | ||||
| 13 | 20.3 | 0.88, s | |||
| 14a | 71.2 | 3.03, d (6.5) | |||
| 14b | 3.56, d (6.0) | ||||
| 15 | 19.1 | 1.43, s | |||
| 1′ | 168.1 | ||||
| 2′ | 132.0 | ||||
| 3′ | 130.6 | 7.95,dd (1.5,7.0) | |||
| 4′ | 129.6 | 7.48, d (8.0) | |||
| 5′ | 134.1 | 7.60, t (7.5) | |||
| 6′ | 129.6 | 7.47, d (7.5) | |||
| 7′ | 130.6 | 7.97, dd (1.5,7.0) |
| Tumor and normal cells | Cis-3M-RESIC50 (μM)* | ResveratrolIC50 (μM)* |
| Unstimulated human peripheral T cells | >10.0 | N.D |
| PHA-stimulated human peripheral T cells** | 0.23 | N.D |
| Human acute T cell leukemia Jurkat E6.1 | 0.07 | 110.1 |
| Human acute T cell leukemia Jurkat (JT/Neo) | 0.08 | 97.5 |
| Human acute T cell leukemia Jurkat (JT/BCL-2) | >10.0 | >250.0 |
| Human monoblastoid U937 | 0.08 | 86.6 |
| Human promyelocytic leukemia HL-60 | 0.08 | 60.5 |
| Human cervical carcinoma HeLa | 0.17 | 193.4 |
| Variable | Categories | Unadjusted Odd ratio (CI) |
| Fistula size | Large (> 3 cm) | 5.33(0.93-30.50) |
| Medium (1-3 cm) | 0.63(1.39-2.86) | |
| Small (< 3 cm) | 1 | |
| Level of vaginal scarring | Moderate severe | NA |
| Mild or no scarring | 1 | |
| Urethral involvement | Circumferential | 10.50 (1.39-79.13)* |
| Partial/Juxta | 5 (1.14-22.00)* | |
| Urethral involvement | ||
| No urethral involvement | 1 | |
| Class of Fistula | Type II b | 5.56(1.34-23.02)* |
| Type II a | O.625(0.06-6.30) | |
| Type I | 1 | |
| Previous Repair | Yes | 4.8(1.27-18.11)* |
| No | 1 |
| Adult n (%) (n = 186)a | Paediatric n (%) (n = 17)a | p-value | |
| Pulmonary TB | 125 (67) | 14 (82) | 0.198 |
| Multidrug-resistant TB | 7 (6) | 2 (14) | 0.099 |
| Method TB detected | |||
| Screening performed at arrival | 35 (19) | 7 (41) | 0.029 |
| During contact tracing of another TB patient | 14 (8) | 4 (24) | 0.026 |
| Sought care for symptoms or by chance | 137 (74) | 6 (35) | <0.01 |
| Time from arrival to Finland to diagnosis of TB | |||
| < 3 months | 39 (21) | 9 (53) | <0.01 |
| 3–23 months | 51 (27) | 4 (24) | 0.73 |
| ≥ 24 months | 80 (43) | 4 (24) | 0.119 |
| Unknown | 16 (9) | 0 (0) | 0.254 |
| Person had resided in | |||
| Reception centre in Finland | 27 (15) | 8 (47) | <0.01 |
| Refugee camp abroad | 25 (13) | 5 (29) | 0.076 |
| No TB-related symptoms | 40 (22) | 10 (59) | <0.01 |
| ISTH score | Predicted score from PT | Predicted score from PT + APTT | Predicted score from PT/APTT |
| 2 | 3.44 | 3.37 | 3.70 |
| 2 | 3.48 | 3.49 | 3.43 |
| 2 | 3.34 | 3.31 | 3.29 |
| 2 | 3.34 | 3.31 | 3.29 |
| 2 | 3.36 | 3.32 | 3.40 |
| 2 | 3.34 | 3.31 | 3.29 |
| 2 | 3.38 | 3.39 | 3.23 |
| Scale | Men | Women | d (Men-Women) | ||||
| α | M | SD | α | M | SD | ||
| Vigor | 0.89 | 3.03 | 0.89 | 0.88 | 2.87 | 0.91 | 0.17 |
| Calmness | 0.88 | 3.90 | 0.66 | 0.88 | 3.90 | 0.71 | 0.00 |
| Mature personality | 0.93 | 3.90 | 0.58 | 0.93 | 3.93 | 0.61 | −0.05 |
| Impulsiveness | 0.65 | 2.57 | 0.52 | 0.68 | 2.46 | 0.57 | 0.18 |
| Self confidence | 0.78 | 3.60 | 0.60 | 0.81 | 3.32 | 0.67 | 0.41 |
| Culture | 0.85 | 3.39 | 0.67 | 0.83 | 3.61 | 0.64 | −0.32 |
| Sociability | 0.85 | 3.18 | 0.67 | 0.84 | 3.15 | 0.68 | 0.06 |
| Leadership | 0.82 | 2.81 | 0.82 | 0.82 | 2.56 | 0.84 | 0.29 |
| Social sensitivity | 0.83 | 3.71 | 0.63 | 0.85 | 3.99 | 0.64 | −0.42 |
| Tidiness | 0.88 | 3.49 | 0.71 | 0.88 | 3.61 | 0.74 | −0.17 |
| All participants(N = 2,467) | ||
| Age, years | 58.3 (15.7) | |
| Sex, women, n | 1,438 (58.3%) | |
| Regular exercise,an | 831 (33.8%) | |
| Smoking | Current smoker, n | 381 (15.5%) |
| Ex-smoker, n | 460 (18.7%) | |
| Alcohol consumption, g/week | 72.1 (133.7) | |
| Body mass index, kg/m2 | 23.1 (3.4) | |
| Systolic blood pressure, mm Hg | 132.1 (19.4) | |
| Diastolic blood pressure, mm Hg | 79.4 (11.1) | |
| HbA1c (NGSP), % | 5.8 (0.8) | |
| Total cholesterol, mg/dL | 206.3 (35.1) | |
| HDL cholesterol, mg/dL | 62.6 (16.0) | |
| Hypertension,bn | 1,158 (46.9%) | |
| Diabetes mellitus,cn | 254 (10.3%) | |
| Hypercholesterolemia,dn | 1,030 (41.8%) | |
| Low HDL cholesterol,en | 181 (7.3%) |
| Characteristic | No. of participants (n = 15) |
| Age [median (range)] | 47 (33–59) |
| Sex | |
| Male | 8 |
| Female | 7 |
| Ethnicity | |
| White British | 13 |
| Other | 2 |
| Profession | |
| Surgeon | 5 |
| Clinical oncologist | 3 |
| Specialist nurse | 4 |
| Research nurse | 1 |
| Specialist radiographer | 1 |
| Speech and language therapist | 1 |
| Geographic area of sample, no. | |
| North West England | 4 |
| North East England | 2 |
| South West England | 1 |
| London | 4 |
| South East England | 3 |
| Wales | 1 |
| Ethiopia | Kenya | |||
| Urban | Rural | Urban | Rural | |
| Age | ||||
| 15–24 | 15.9 | 15.9 | 12.5 | 10.3 |
| 25–34 | 37.3 | 33.4 | 39.1 | 34.1 |
| 35–44 | 29.2 | 28.7 | 28.8 | 32.3 |
| 45+ | 17.6 | 21.9 | 19.6 | 23.3 |
| p-Value | 0.000 | 0.000 | 0.000 | 0.000 |
| Marital status | ||||
| Single | 55.4 | 51.8 | 50.2 | 49.7 |
| Married | 42.7 | 45.5 | 45.9 | 49.6 |
| Widow/divorced | 1.9 | 2.7 | 3.9 | 0.7 |
| p-Value | 0.598 | 0.55 | 0.577 | 0.208 |
| Religion | ||||
| Christian | 49.2 | 24.2 | 77.2 | 82.8 |
| Moslem | 50.1 | 72.0 | 16.5 | 9.1 |
| Other | 0.7 | 3.8 | 6.4 | 8.2 |
| p-Value | 0.000 | 0.000 | 0.000 | 0.000 |
| Education | ||||
| Nil | 12.9 | 49.0 | 14.0 | 16.0 |
| Primary | 40.0 | 45.1 | 46.8 | 49.6 |
| Secondary | 27.1 | 3.9 | 29.6 | 19.5 |
| Higher | 20.0 | 2.0 | 9.5 | 14.8 |
| p-value | 0.000 | 0.000 | 0.000 | 0.000 |
| Occupation | ||||
| Agriculture | 59.5 | 57.8 | 18.8 | 23.9 |
| Managerial | 8.8 | 9.1 | 17.2 | 28.0 |
| Sales/service | 13.6 | 15.2 | 11.4 | 29.7 |
| Manual | 10.1 | 10.4 | 27.5 | 14.0 |
| Unemployed | 8.0 | 7.6 | 25.1 | 4.4 |
| p-Value | 0.449 | 0.000 | 0.000 | 0.002 |
| Wealth status | ||||
| Poorest | 2.1 | 36.6 | 40.1 | 59.8 |
| Poorer | 0.5 | 19.1 | 11.9 | 6.6 |
| Middle | 0.7 | 16.4 | 7.8 | 3.6 |
| Richer | 6.9 | 19.8 | 37.4 | 28.2 |
| Richest | 89.7 | 8.0 | 2.8 | 1.8 |
| p-Value | 0.017 | 0.000 | 0.000 | 0.000 |
| Drinks alcohol | ||||
| No | 47.4 | 47.5 | 37.8 | 35.4 |
| Yes | 52.6 | 52.5 | 62.2 | 64.6 |
| p-Value | 0.821 | 0.274 | 0.000 | 0.000 |
| Data | Characteristics | Description |
| Classes of deprivation | Group 1: low deprivation | Census block with high median income, low proportion of households without a car, low proportion with non-owner-occupied primary residences |
| Group 2: moderate deprivation | Census block with median income average, medium proportion of households without a car, medium proportion with non-owner-occupied primary residences | |
| Group 3: high deprivation | Census block with low median income, high proportion of households without a car, high proportion with non-owner-occupied primary residences |
| 95% Confidence Interval for odds | ||||
| P value | OR | Lower | Upper | |
| Gender(female) | 1.259 | 5.725 | ||
| Jobless | <.001 | 1.870 | 1.412 | 2.478 |
| Illegal Income | .001 | 1.617 | 1.217 | 2.150 |
| Substance use of family members | .005 | 1.471 | 1.125 | 1.925 |
| pleasure/enjoyment as cause of first injection | .001 | 1.583 | 1.209 | 2.074 |
| First place of drug use (Roofless public places) | .003 | 1.558 | 1.157 | 2.097 |
| First place of drug use (Roofed public places) | .019 | 1.621 | 1.084 | 2.424 |
| Alone injection | <.001 | .515 | .388 | .682 |
| Groin injection | .013 | 1.642 | 1.111 | 2.427 |
| Testis injection | .022 | 1.573 | 1.068 | 2.318 |
| Nonfatal overdose | <.001 | 1.686 | 1.282 | 2.216 |
| Arresting in past year | .022 | 1.385 | 1.049 | 1.829 |
| Position at foot contact (deg) | ||||
| Flexion | Ext. tibial rot. | Varus | ||
| ICC | 0.93 | 0.94 | 0.95 | |
| SEM (deg) | 1.80 | 1.42 | 0.61 | |
| Displacement during landing (deg) | ||||
| Flexion | Int. tibial rot. | Varus | Valgus | |
| ICC | 0.96 | 0.87 | 0.64 | 0.86 |
| SEM (deg) | 1.41 | 2.18 | 1.22 | 0.39 |
| Electromyographic data (%MVC) | ||||
| Rectus femoris | Hamstrings | |||
| ICC | 0.79 | 0.62 | ||
| SEM (%) | 10.84 | 9.49 |
| Metric | F | R2 | p value* | |
| HC (n = 29)vsRTT (n = 50) | Unweighted UniFrac | 6.84 | 0.08 | ≤0.003 |
| Weighted UniFrac | 15.6 | 0.16 | ≤0.003 | |
| Bray-Curtis | 6.94 | 0.08 | ≤0.003 | |
| HC (n = 29)vsRTT-C (n = 34) | Unweighted UniFrac | 5.59 | 0.08 | ≤0.003 |
| Weighted UniFrac | 12.1 | 0.16 | ≤0.003 | |
| Bray-Curtis | 5.39 | 0.08 | ≤0.003 | |
| HC (n = 29)vsRTT-NC (n = 14) | Unweighted UniFrac | 5.27 | 0.11 | ≤0.003 |
| Weighted UniFrac | 8.75 | 0.17 | ≤0.003 | |
| Bray-Curtis | 5.47 | 0.11 | ≤0.003 | |
| RTT-C (n = 34)vsRTT-NC (n = 14) | Unweighted UniFrac | 1.31 | 0.02 | 0.180 |
| Weighted UniFrac | 1.10 | 0.02 | 0.687 | |
| Bray-Curtis | 1.76 | 0.03 | 0.180 |
| CECA22* | CECA10 | CECA6 | CECA4 | ||
| N° of items | 22 | 10 | 6 | 4 | |
| Scoring distribution | |||||
| Valid observations | 132 | 133 | 134 | 134 | |
| Mean | 44.9 | 44.6 | 38.8 | 53.4 | |
| SD | 17.5 | 22.3 | 23.9 | 29.3 | |
| Percentile 50 | 43.7 | 40 | 37.5 | 53.1 | |
| % scoring 0 | 0 | 0 | 5 | 3 (2.2%) | |
| % scoring 100 | 0 | 1 | 2 | 8 (5.9%) | |
| Correlation item-global scoring | 0.21–0.72 | 0.53–0.73 | 0.65–0.79 | 0.78–0.89 | |
| Reliability (Cronbach's alpha) | 0.87 | 0.86 | 0.84 | 0.86 | |
| Results of Rasch analysis | Person separation | 2.28 | 2.21 | 1.87 | 1.79 |
| Person reliability | 0.84 | 0.83 | 0.78 | 0.76 |
| Insomnia (N = 17) | Controls (N = 15) | p-values | |
| HbA1c (%) | 5.3 (0.3) | 5.4 (0.3) | >0.05 |
| Fasting blood glucose (mg/dl) | 97.6 (8.2) | 96.3 (10.3) | >0.05 |
| Blood glucose after 30 min (mg/dl) | 138.7 (22.1) | 156. 9 (30.3) | >0.05 |
| Blood glucose after 60 min (mg/dl) | 120.3 (20.8) | 135.9 (49.9) | >0.05 |
| Blood glucose after 120 min (mg/dl) | 100.5 (14.8) | 105.1 (28.7) | >0.05 |
| Area under the curve for glucose (mg/dl) | 14,043. 8 (1,319.7) | 15,422.0 (3,710.5) | >0.05 |
| Toxicity | Grade | ACRT | STRT1 | STRT2 | Total | p-value |
| (45 Gy) | (60-63 Gy) | (> 63 Gy) | ||||
| n = 154 | n = 99 | n = 239 | ||||
| Esophagitis | 0-1 | 107(89.9%) | 80(88.9%) | 82(90.1%) | 269(89.7%) | 0.958 |
| ≥ 2 | 12(10.1%) | 10(11.1%) | 9(9.9%) | 31(10.3%) | ||
| Dysphagia | 0-1 | 110(92.4%) | 75(83.3%) | 80(87.9%) | 265(88.3%) | 0.126 |
| ≥ 2 | 9(7.6%) | 15(16.7%) | 11(12.1%) | 35(11.7%) | ||
| Pneumonitis | 0-1 | 105(88.2%) | 71(78.9%) | 71(78.0%) | 247(82.3%) | 0.093 |
| ≥ 2 | 14(11.8%) | 19(21.1%) | 20(22.0%) | 53(17.7%) | ||
| Radiation Dermatitis | 0-1 | 117(98.3%) | 79(87.8%) | 78(85.7%) | 274(91.3%) | 0.002 |
| ≥ 2 | 2(1.7%) | 11(12.2%) | 13(14.3%) | 26(8.7%) | ||
| Nausea/Vomiting | 0-1 | 115(96.6%) | 79(87.8%) | 87(95.6%) | 281(93.7%) | 0.022 |
| ≥ 2 | 4(3.4%) | 11(12.2%) | 13(14.3%) | 26(8.7%) | ||
| Weight loss | 0-1 | 115(96.6%) | 81(90.0%) | 90(98.9%) | 286(95.3%) | 0.020 |
| ≥ 2 | 4(3.4%) | 9(10.0%) | 1(1.1%) | 14(4.7%) |
| S. No | Lubricant | Speed (kmph) | Load (N) |
| 1 | Racer-4 | 40-60 | 10-50 |
| 2 | Racer-4 + 0.05% Cu | 40-60 | 20-80 |
| 3 | Racer-4 + 0.1% Cu | 40-60 | 20-80 |
| 4 | Racer-4 + 0.2% Cu | 40-60 | 20-80 |
| 5 | Racer-4 + 0.05% TiO2 | 40-60 | 20-80 |
| Factors | Simple regression | Multiple regression | |||
| Unstandardizedcoefficient(B) | P value | Unstandardizedcoefficient(B) | Standardizedcoefficient(beta) | P value | |
| Gly1057Asp polymorphism in IRS-2 | |||||
| Asp/Asp(n = 41) | reference | reference | reference | ||
| Gly/Gly(n = 69) + Gly/Asp(n = 80) | 0.007 | 0.902 | −0.023 | −0.029 | 0.678 |
| Age(year) | −0.002 | 0.245 | −0.003 | −0.107 | 0.147 |
| Diabetes mellitus | 0.194 | <0.001 | 0.151 | 0.213 | 0.003 |
| Hypertension | 0.103 | 0.037 | 0.078 | 0.115 | 0.121 |
| Male | 0.019 | 0.697 | −0.032 | −0.048 | 0.574 |
| Smoking | 0.013 | 0.800 | −0.012 | −0.017 | 0.830 |
| Total cholesterol(mmol/L) | 0.033 | 0.197 | 0.040 | 0.114 | 0.103 |
| Serum creatinine(μmol/L) | 0.002 | 0.019 | 0.003 | 0.206 | 0.007 |
| Body mass index(kg/m2) | 0.023 | <0.001 | 0.017 | 0.189 | 0.008 |
| Spice | Frequency of dishes prepared | |||||
| Daily | Weekly | Monthly | ||||
| N | Intake mean ± S.D (Median) | N | Intake mean ± S.D (Median) | N | Intake mean ± S.D (Median) | |
| Chillies | 157 | 2.1 ± 1.3 (1.8) | 186 | 3.8 ± 3.88 (2.32) | 21 | 3.0 ± 1.92 (2.25) |
| Turmeric | 156 | 0.6 ± 0.46 (0.66) | 171 | 0.82 ± 0.53 (0.72) | 24 | 0.73 ± 0.46 (0.6) |
| Cumin | 61 | 1.22 ± 1.14 (1.0) | 125 | 1.85 ± 1.78 (1.2) | 12 | 1.66 ± 1.07 (1.4) |
| Coriander | 27 | 0.8 ± 0.65 (0.5) | 62 | 1.5 ± 1.74 (0.84) | 7 | 2.47 ± 2.22 (3.5) |
| Mustard | 34 | 0.55 ± 0.31 (0.5) | 81 | 1.24 ± 0.95 (1.0) | 7 | 1.65 ± 1.2 (1.12) |
| Cloves | - | - | 105 | 0.33 ± 0.62 (0.11) | 16 | 0.48 ± 0.68 (0.12) |
| Cardamom | 6 | 0.67 ± 0.64 (0.63) | 134 | 0.37 ± 0.57 (0.25) | 18 | 0.5 ± 0.36 (0.32) |
| Cinnamon | - | - | 102 | 0.74 ± 0.83 (0.5) | 15 | 1.03 ± 0.83 (0.8) |
| Caraway | - | - | 94 | 1.1 ± 1.07 (0.7) | 18 | 1.22 ± 0.89 (0.92) |
| Black pepper | 28 | 0.69 ± 0.87 (0.5) | 64 | 1.07 ± 1.16 (0.5) | 16 | 1.07 ± 0.81 (0.72) |
| Nutmeg | - | - | 23 | 0.11 ± 0.07 (0.11) | 7 | 0.22 ± 0.19 (0.14) |
| Mace | - | - | 18 | 0.19 ± 0.13 (0.16) | 5 | 0.27 |
| Asafoetida | 17 | 0.37 ± 0.16 (0.4) | 16 | 0.72 ± 0.49 (0.5) | - | |
| Fenugreek | - | - | 25 | 0.68 ± 0.65 (0.4) | 4 | 2.04 |
| Carom seeds | - | - | 13 | 0.69 ± 0.64 (0.45) | 5 | 0.66 |
| NC | MCI | AD | |
| NC | 15/16 | 1/1 | 0/0 |
| MCI | 2/1 | 14/16 | 3/1 |
| AD | 0/0 | 3/1 | 14/16 |
| Category | Part A | Part B | Part C | Total |
| Preferred Term | (N = 12) | (N = 10) | (N = 10) | (N = 32) |
| N (%) | N (%) | N (%) | N (%) | |
| Subjects with Any Adverse Event | 1 (8.3) | 3 (30.0) | 7 (70.0) | 11 (34.4) |
| Subjects with Any Study Drug Related Adverse Event | 0 (0.0) | 0 (0.0) | 1 (10.0) | 1 (3.1)a |
| Subjects with Any Serious Adverse Event | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Subjects with Any Study Drug Related Serious Adverse Event | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Subjects with Any Adverse Event Leading to Discontinuation | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Phe-free milk | Phe-free amino acid powder (A-1) | Low Phe peptide powder (MP-11) | |
| Protein (g) | 15.8 | 93.7 | 75 |
| Fat (g) | 17.1 | 0 | 0 |
| Carbohydrate (g) | 60.4 | 0 | 7.2 |
| Ash content (g) | 3.68 | 2.9 | 7.4 |
| Water substance (g) | 2.97 | 3.4 | 2.8 |
| Energy (kcal) | 458 | 375 | 329 |
| Phe (mg) | 0 | 0 | 280 |
| Ca (mg) | 360 | 0 | 1100 |
| Mg (mg) | 34 | 0 | 300 |
| Na (mg) | 168 | 880 | 620 |
| K (mg) | 440 | 0 | 1400 |
| P (mg) | 270 | 0 | 600 |
| Cl (mg) | 320 | 1900 | 300 |
| Fe (mg) | 6 | 0 | 15 |
| Zn (mg) | 2.5 | 0 | 20 |
| Cu (μg) | 280 | 0 | 1000 |
| I (μg) | 25 | 0 | 150 |
| Se (μg) | 1 | 2 | 11 |
| Vit A (IU) | 1500 | 0 | 0 |
| Vit B1 (mg) | 0.36 | 0 | 0 |
| Vit B2 (mg) | 0.6 | 0 | 0 |
| Vit B6 (mg) | 0.4 | 0 | 0 |
| Vit B12 | 1 | 0 | 0 |
| Vit C (mg) | 48 | 0 | 0 |
| Vit D (IU) | 300 | 0 | 0 |
| Vit E (mg) | 4.38 | 0 | 0 |
| Ca pantothenate (mg) | 2 | 0 | 0 |
| Niacin (mg) | 5 | 0 | 0 |
| Folate (mg) | 0.1 | 0 | 0 |
| Choline (mg) | 50 | 0 | 0 |
| Biotin (μg) | 0 | 0 | 0.6 |
| Prevalence per 10,000 | Crude incidence per 10,000 | Mortality per 100,000 | Fatality per 1,000 | |||||
| Age | Rate | C.I. 95% | Rate | C.I. 95% | Rate | C.I. 95% | Rate | C.I. 95% |
| 0-17 years | 44.05 | 42.61-45.49 | 3.96 | 3.52-4.39 | 10.21 | 8.01-12.41 | 3.59 | 1.37-5.81 |
| 0-12 months | 25.73 | 21.23-30.24 | 25.73 | 21.23-30.24 | 0.56* | 0.35*-0.77* | 19.23 | 4.74-33.72 |
| 1-17 years | 45.22 | 43.71-46.72 | 4.26 | 3.80-4.73 | 7.29 | 6.69-7.90 | 2.98 | 0.92-5.04 |
| 1-14 years | 46.25 | 44.58-47.93 | 4.41 | 3.89-4.92 | 8.00 | 7.30-8.69 | 3.10 | 0.81-5.39 |
| 15-17 years | 40.26 | 36.84-43.68 | 3.57 | 2.55-4.59 | 3.93 | 2.86-5.00 | 2.36 | 0.00-6.99 |
| 18-64 years | 31.34 | 30.72-31.96 | 3.70 | 3.48-3.91 | 9.03 | 7.97-10.09 | 3.70 | 2.33-5.07 |
| over 65 years | 17.68 | 16.83-18.53 | 2.90 | 2.56-3.25 | 28.51 | 25.10-31.91 | 26.79 | 17.49-36.10 |
| TOTAL | 33.09 | 32.56-33.62 | 3.85 | 3.67-4.03 | 13.04 | 12.02-14.06 | 5.99 | 4.58-7.40 |
| Compound Administered | Subject ID | R-baclofen (ng/mL) | S-baclofen (ng/mL) | S-M1 (ng/mL) | |||
| Plasma | Urine | Plasma | Urine | Plasma | Urine | ||
| Racemic Baclofen 10 mg | P1-01 | 45.2 | 1880 | 35.6 | 1400 | 24.9 | 254 |
| P1-04 | 42.4 | 1030 | 39.9 | 806 | 27.5 | 146 | |
| P1-06 | 35.5 | 1120 | 31.2 | 892 | 19.5 | 183 | |
| P1-07 | 36.9 | 1230 | 32.1 | 857 | 18.7 | 142 | |
| P2-02 | 42.7 | 514 | 35.9 | 460 | 25.1 | 75.1 | |
| P2-05 | 40.3 | 652 | 34.1 | 553 | 16.4 | 99.4 | |
| P2-08 | 37.5 | 552 | 31.6 | 457 | 20.1 | 95 | |
| Mean | 40.1 | 997 | 34.3 | 775 | 21.7 | 142 | |
| SD | 3.6 | 482 | 3.1 | 333 | 4.1 | 61.6 | |
| STX209 5mg | P1-02 | 40.1 | 1610 | - | 370* | - | - |
| P1-03 | 37.7 | 866 | - | - | - | - | |
| P1-05 | 36.4 | 1730 | - | - | - | - | |
| P1-08 | 31.3 | 892 | - | - | - | - | |
| P2-01 | 35.1 | 942 | - | - | - | - | |
| P2-06 | 35.4 | 446 | - | - | - | - | |
| P2-07 | 31.6 | 422 | - | - | - | - | |
| Mean | 35.4 | 987 | |||||
| SD | 3.2 | 513 |
| 25 JIA patientswith secondary LOE | 28 JIA patientswithout secondary LOE | |
| median age (range) | 14.4 (6.0-27.0) years | 13.8 (7.6-21.5) years |
| Sex | 21 female, 4 male | 18 female, 10 male |
| median ADM dose (range) | 25.8 (10.7-58.8) mg/m2 every other week | 24.3 (6.6-37.1) mg/m2 every other week |
| median duration of anti-TNF therapy (range) | 2.2 (0.2-6.0) years | 1.3 (0.2-10.4) years |
| MTX comedication | 12/25 (48.0%) | 15/28 (53.6%) |
| median MTX dose (range) | 10.0 (3.9-12.1) mg/m2 weekly | 10.8 (7.7-13.4) mg/m2 weekly |
| ETIOLOGY | NO. OF PATIENTS | PERCENTAGE |
| ONCOLOGICAL RES. | 75 | 42.1% |
| TMJ ANKYLOSIS | 35 | 19.6% |
| POST-TRAUMATIC | 44 | 24.7% |
| OSTEOMYELITIS OF MANDIBLE | 24 | 13.5% |
| TOTAL | 178 | 100 % |
| Factor | Estimate | SE | Chi-square | P value |
| F14 | 0.0197 | 0.0184 | 1.14 | 0.2857 |
| F3 | 0.1558 | 0.0304 | 26.34 | <0.0001 |
| F9 | 0.0498 | 0.0185 | 7.22 | 0.0072 |
| PM6 | PM7 | |||
| E (kcal/mol) | ∆E (kcal/mol) | E (kcal/mol) | ∆E (kcal/mol) | |
| Isolated molecule | ||||
| Plumbagin | −84.56 | −87.09 | ||
| BCD | −1614.25 | −1648.53 | ||
| MBCD | −1543.64 | −1573.87 | ||
| HPBCD | −1659.94 | −1701.90 | ||
| Inclusion Complex | ||||
| BCD-I | −1704.99 | −6.18 | −1768.09 | −32.47 |
| BCD-II | −1704.97 | −6.15 | −1765.72 | −30.10 |
| BCD-I–BCD-II | −0.03 | −2.37 | ||
| MBCD-I | −1636.23 | −8.03 | −1702.37 | −41.41 |
| MBCD-II | −1640.97 | −12.78 | −1699.12 | −38.17 |
| MBCD-I–MBCD-II | 4.75 | −3.24 | ||
| HPBCD-I | −1753.57 | −9.08 | −1820.19 | −31.21 |
| HPBCD-II | −1750.20 | −5.70 | −1829.73 | −40.75 |
| HPBCD-I–HPBCD-II | −3.38 | 9.54 |
| Control | Intervention | Comparison | Treatment effect | P value | |
| Maternal | n = 75 | n = 79 | (95% CI) | ||
| GDM | 24 (32%) | 22 (28%) | Risk difference | −4% (−19 to 13) | 0.574 |
| Risk ratio | 0.87 (0.54 to 1.41) | ||||
| Neonatal | n = 84 | n = 86 | |||
| LGA | 7 (8%) | 7 (8%) | Risk difference | 0% (−8 to 8) | 0.982 |
| Risk ratio | 0.99 (0.36 to 2.7) | ||||
| >4 Kg | 16 (19%) | 13 (15%) | Risk difference | −4% (−15 to 8) | 0.518 |
| Green alga/land plant | Size (bp) | IR size (bp) | Genes (no.) a | Introns (no.) b | GenBank accession no. |
| Charophyceae | |||||
| Chara vulgaris | 184,933 | 10,919 | 127 | 2/16 | GenBank:NC_008097 |
| Chaetosphaeridium globosum | 131,183 | 12,431 | 125 | 1/17 | GenBank:NC_004115 |
| Chlorokybus atmophyticus | 152,254 | 7,640 | 138 | 1/0 | GenBank:DQ422812 |
| Mesostigma viride | 118,360 | 6,057 | 137 | 0 | GenBank:NC_002186 |
| Staurastrum punctulatum | 157,089 | - | 121 | 1/7 | GenBank:NC_008116 |
| Zygnema circumcarinatum | 165,372 | - | 125 | 1/12 | GenBank:NC_008117 |
| Land Plants | |||||
| Acorus calamus | 153,821 | 25,697 | 110 | 1/20 | GenBank:NC_007407 |
| Amborella trichopoda | 162,686 | 26,651 | 111 | 1/20 | GenBank:NC_005086 |
| Anthoceros formosae | 161,162 | 15,744 | 120 | 2/20 | GenBank:NC_004543 |
| Arabidopsis thaliana | 154,478 | 26,264 | 110 | 1/20 | GenBank:NC_000932 |
| Atropa belladonna | 156,687 | 17,031 | 111 | 1/20 | GenBank:NC_004561 |
| Calycanthus floridus | 153,337 | 23,296 | 111 | 1/20 | GenBank:NC_004993 |
| Cucumis sativus | 155,293 | 24,753 | 111 | 1/20 | GenBank:NC_007144 |
| Eucalyptus globulus | 160,286 | 26393 | 109 | 1/20 | GenBank:NC_008115 |
| Huperzia lucidula | 154,373 | 15,314 | 119 | 1/20 | GenBank:NC_006861 |
| Lactuca sativa | 152,765 | 25,033 | 111 | 1/20 | GenBank:NC_007578 |
| Lotus japonicus | 150,519 | 25,156 | 109 | 1/20 | GenBank:NC_002694 |
| Marchantia polymorpha | 121,024 | 10,058 | 120 | 1/19 | GenBank:NC_001319 |
| Nicotiana tabacum | 155,939 | 25,341 | 110 | 1/20 | GenBank:NC_001879 |
| Nymphaea alba | 159,930 | 25,177 | 111 | 1/20 | GenBank:NC_006050 |
| Oenothera elata | 163,935 | 27,807 | 109 | 1/18 | GenBank:NC_002693 |
| Oryza sativa | 134,525 | 20,799 | 108 | 1/17 | GenBank:NC_001320 |
| Panax ginseng | 156,318 | 26,071 | 111 | 1/20 | GenBank:NC_006290 |
| Phalaenopsis aphrodite | 148,964 | 23,787 | 99 | 1/18 | GenBank:NC_007499 |
| Physcomitrella patens | 122,890 | 9,589 | 116 | 1/20 | GenBank:NC_005087 |
| Pinus thunbergii | 119,707 | - | 106 | 1/15 | GenBank:NC_001631 |
| Saccharum officinarum | 141,182 | 22795 | 108 | 1/17 | GenBank:NC_006084 |
| Spinacia oleracea | 150,725 | 25,073 | 110 | 1/19 | GenBank:NC_002202 |
| Triticum aestivum | 134,545 | 20,703 | 108 | 1/17 | GenBank:NC_002762 |
| Zea mays | 140,384 | 22,748 | 108 | 1/17 | GenBank:NC_001666 |
| Prasinophyceae | |||||
| Nephroselmis olivacea | 200,799 | 46,137 | 128 | 0 | GenBank:NC_000927 |
| Trebouxiophyceae | |||||
| Chlorella vulgaris | 150,613 | - | 112 | 3/0 | GenBank:NC_001865 |
| Ulvophyceae | |||||
| Oltmannsiellopsis viridis | 151,933 | 18,510 | 104 | 5/0 | GenBank:NC_008099 |
| Pseudendoclonium akinetum | 195,867 | 6,039 | 105 | 27/0 | GenBank:NC_008114 |
| Chlorophyceae | |||||
| Chlamydomonas reinhardtii | 203,827 | 22,211 | 94 | 5/2 | GenBank:NC_005353 |
| Scenedesmus obliquus | 161,452 | 12,022 | 96 | 7/2 | GenBank:NC_008101 |
| Stigeoclonium helveticum | 223,902 | - | 97 | 16/5 | GenBank:DQ630521 |
| N-starved cells | P-starved cells | |
| Total sequences collected | 2,259,219 | 1,501,972 |
| Total signatures | 44,779 | 27,722 |
| Reliable, significant signatures | 27,217 | 20,161 |
| Signatures unique to library | 10,756 | 3,700 |
| All patients (n = 129) | Trastuzumab-resistant patient (n = 32) | Trastuzumab-sensitive patients (n = 97) | P-value | |
| Age at diagnosis | 59 (30-84) | 60 (30-82) | 58 (32-84) | 0.623 |
| Sex | 0.931 | |||
| Male | 96 (74.4%) | 24 (75.0%) | 72 (74.2%) | |
| Female | 33 (25.6%) | 8 (25.0%) | 25 (25.8%) | |
| Histology | 0.031 | |||
| Adeno, WD | 7 (5.4%) | 0 (0%) | 7 (7.2%) | |
| Adeno, MD | 76 (58.9%) | 16 (50.0%) | 60 (61.9%) | |
| Adeno, PD | 33 (25.6%) | 9 (28.1%) | 24 (24.7%) | |
| SRC carcinoma | 13 (10.1%) | 7 (21.9%) | 6 (6.2%) | |
| Previous surgery | 0.491 | |||
| Yes | 42 (32.6%) | 12 (37.5%) | 30 (30.9%) | |
| No | 87 (67.4%) | 20 (62.5%) | 67 (69.1%) | |
| Location of tumor | 0.420 | |||
| Proximal | 31 (24.0%) | 6 (18.8%) | 25 (25.8%) | |
| Distal | 98 (76.0%) | 26 (81.3%) | 72 (74.2%) | |
| Peritoneal metastasis | 0.225 | |||
| Yes | 45 (34.9%) | 14 (43.8%) | 31 (32.0%) | |
| No | 84 (65.1%) | 18 (56.3%) | 66 (68.0%) | |
| Liver metastasis | 0.951 | |||
| Yes | 53 (41.1%) | 13 (40.6%) | 40 (41.2%) | |
| No | 76 (58.9%) | 19 (59.4%) | 57 (58.8%) | |
| Bone metastasis | 0.025 | |||
| Yes | 15 (11.6%) | 8 (25.0%) | 7 (7.2%) | |
| No | 104 (80.6%) | 22 (68.8%) | 82 (84.5%) | |
| N/A | 10 (7.8%) | 2 (6.3%) | 8 (8.2%) | |
| Lung metastasis | 0.985 | |||
| Yes | 16 (12.4%) | 4 (12.5%) | 12 (12.4%) | |
| No | 113 (87.6%) | 28 (87.5%) | 85 (87.6%) | |
| Performance status | 0.001 | |||
| ECOG 0 | 72 (55.8%) | 8 (25.0%) | 64 (66.0%) | |
| ECOG 1 | 42 (32.6%) | 18 (56.3%) | 24 (24.7%) | |
| ECOG ≥2 | 15 (11.7%) | 6 (18.7%) | 9 (9.2%) | |
| Regimen | 0.896 | |||
| Herceptin-FP | 17 (13.2%) | 4 (12.5%) | 13 (13.4%) | |
| Herceptin-XP | 112 (86.8%) | 28 (87.5%) | 84 (86.6%) | |
| HER2 IHC | 0.475 | |||
| 2+ | 31 (24.0%) | 10 (31.3%) | 21 (21.6%) | |
| 3+ | 98 (76.0%) | 22 (68.8%) | 76 (78.4%) | |
| HER2 amplification index | 7.0 ± 5.9 | 7.7 ± 6.3 | 4.1 ± 1.4 | 0.005 |
| PTEN expression | 0.017 | |||
| Loss | 11 (16.4%) | 5 (38.5%) | 6 (11.1%) | |
| Intact | 56 (83.6%) | 8 (61.5%) | 48 (88.9%) | |
| PIK3R1 genotype | 0.460 | |||
| Variant | 16 (23.2%) | 5 (31.3%) | 12 (22.2%) | |
| Wildtype | 53 (76.8%) | 11 (68.8%) | 42 (77.8%) |
| CKD (n= 6) | CKD + pravastatin (n= 5) | |
| Focal glomerulosclerosis (%) | ||
| Normal | 32.9 ± 7.6 | 23.4 ± 13.1 |
| Partial | 48.1 ± 10.6 | 62.7 ± 10.4 |
| Total | 19.0 ± 6.7 | 14.0 ± 15.8 |
| Tubulo-interstitial damage | ||
| Fibrosis | 0.78 ± 0.31 | 0.85 ± 0.14 |
| Inflammation | 1.72 ± 0.54 | 1.66 ± 0.22 |
| Atrophy | 1.09 ± 0.65 | 0.56 ± 0.09 |
| Dependent variables: | Complaints of generalised anxiety | |
| MEN | WOMEN | |
| B | B | |
| Intercept | -0.027 *** | -0.004 |
| Contextual effects | ||
| Unemployment rate | 0.032 | 0.075 |
| Median area income (in euros) | 0.245 | 1.214 |
| Density | -0.081 | 0.032 |
| Individual effects | ||
| Social support | -0.018 *** | -0.028 *** |
| Current employment situation (ref.: paid labour) | ||
| Retired | 0.003 | 0.003 |
| Disabled | 0.091 *** | 0.101 *** |
| Unemployed | 0.022 *** | 0.022 *** |
| Househusband/wife | -0.028 | -0.011 * |
| Student and others | 0.032 ** | 0.102 |
| Educational level (ref.: tertiary education) | ||
| No diploma or primary education | 0.008 * | 0.038 *** |
| Lower secondary | 0.009 * | 0.017 *** |
| Higher secondary | -0.001 | 0.010 *** |
| Equivalent income of the household (ref.: > 2.500 €) | ||
| < 750 € | 0.018 ** | 0.017 * |
| 750 - 1.000 € | 0.009 | 0.013 * |
| 1.000 - 1.500 € | 0.002 | 0.005 |
| 1.500 - 2.500 € | -0.002 | -0.002 |
| Missing income | -0.008 | -0.011 * |
| Age | -0.002 | -0.002 |
| Household type (ref.: couple with child(ren)) | ||
| Single | -0.001 | -0.001 |
| Single with child(ren) | -0.010 | 0.008 |
| Couple | 0.006 | 0.009 * |
| Complex household | 0.004 | 0.003 |
| Year | First Author | No | Sex | Age | Site | Complications | Treatment | Incision | LOS (days) |
| 1991 [13] | Hale | 22 | M | 85 | Sigmoid | Incarceration | Hartmann’s + intra-abdominal internal ring closure | Midline laparotomy | NA |
| 2003 [12] | Tan | 23 | M | 62 | Sigmoid | Incarceration | High anterior resection + left orchidectomy + intra-abdominal closure of hernial defect | Left iliac fossa transverse | NA |
| 2003 [7] | Kouraklis | 24 | M | 79 | Sigmoid | Perforation | Hartmann’s + loop colostomy + interval reversal and open hernioplasty | Left groin | 10 |
| 2003 [16] | Cervinka | 25 | M | 69 | Sigmoid | Incarceration | Sigmoidectomy + anastomosis + defunctioning transverse colostomy + herniorrhaphy (Bassini) | Left groin | NA |
| 2008 [17] | Slater | 26 | M | 66 | Sigmoid | Incarceration | Hartmann’s + left orchidectomy + internal ring closure | Left groin + midline laparotomy | NA |
| 2008 [17] | Slater | 27 | M | 73 | Sigmoid | Perforation | Hartmann’s + left orchidectomy + internal ring closure | L groin + Left modified Rutherford-Morrison | NA |
| 2009 [18] | Ruiz-Tovar | 28 | M | 67 | Sigmoid | Perforation without contamination | Sigmoidectomy and anastomosis + hernioplasty (Lichtenstein) | Left groin + midline laparotomy | 7 |
| 2010 [19] | Ko | 29 | M | 84 | Sigmoid | Perforation | Hartmann’s + herniorrhaphy | Laparotomy | Deceased |
| 2010 [20] | Mai | 30 | M | 83 | Sigmoid | Strangulation | Hartmann’s + herniorrhaphy | Lower midline + left groin | NA |
| 2011 [5] | Pernazza | 31 | M | 70 | Caecum | Incarceration | Laparoscopic right hemicolectomy + herniorrhaphy | Laparoscopy + bilateral groin incisions | 5 |
| 2012 [6] | Carr | 32 | M | 65 | Sigmoid | Incarceration | Laparoscopic high anterior resection + open biosynthetic hernioplasty | Laparoscopy + left groin | 4 |
| 2013 [21] | Meniconi | 33 | F | 78 | Caecum | Incarceration | Open right hemicolectomy + herniorrhaphy | Midline laparotomy + right groin | NA |
| 2013 [22] | Tan | 34 | M | 63 | Sigmoid | Perforation | Hartmann’s + herniorrhaphy | Midline laparotomy + left groin | 10 |
| 2016 [23] | Kulasegaran | 35 | M | 66 | Sigmoid | Perforation + necrotising infection | Hartmann’s + debridement + staged skin graft | Left groin + midline laparotomy | NA |
| 2016 [24] | Diao | 36 | M | 48 | Transverse colon | Perforation | Transverse colectomy + herniorrhaphy + orchidectomy + partial scrotectomy | Left groin | NA |
| 2017 [25] | Sharma | 37 | M | 84 | Caecum | None | Open right hemicolectomy + herniorrhaphy | Right transverse | NA |
| 2018 | Current report | 38 | M | 83 | Ascending colon | Incarceration | Laparoscopic right hemicolectomy + laparoscopic defect closure | Laparoscopy | 10 |
| Normotensive pregnancy (n = 3183) | Gestational hypertension (n = 145) Beta (95% CI) | P value | Pre-eclampsia (n = 63) Beta (95% CI) | P value | |
| Retinal arteriolar caliber (SDS) | |||||
| Full model | Ref | –0.20 (–0.34, –0.05) | 0.007 | –0.40 (–0.62, –0.19) | 0.0002 |
| Retinal venular caliber (SDS) | |||||
| Full model | Ref | 0.22 (0.07–0.36) | 0.003 | 0.08 (–0.13, 0.30) | 0.45 |
| Medium | Time | ||||
| 0 day | 1 day | 3 days | 5 days | 7 days | |
| Water | 208.7 ± 12.6 | 214.2 ± 10.1 | 217.7 ± 9.5 | 224.4 ± 10.6 | 227.8 ± 13.4 |
| PBS plus 10% (v/v) FBS | 254.5 ± 5.7 | 260.1 ± 4.5 | 279.6 ± 7.7 | 288.9 ± 10.2 | 302.5 ± 9.8 |
| PBS | 286.6 ± 18.5 | 310.6 ± 35.8 | 347.0 ± 37.4 | 369.6 ± 41.2 | 404.4 ± 25.9 |
| 1.0 mol/L NaCl | 542.7 ± 50.4 | 784.1 ± 45.7 | 1,009.2 ± 66.3 | 1,445.4 ± 57.1 | 1,667.8 ± 87.0 |
| Cell lines | IC50 | |||
| GEM (μM) | OSI-027 (μM) | OSI-027 (μM) + GEM (μM) | Interaction | |
| Panc-1 | 14.79 (10.34 to 19.20) | 21.93 (17.37 to 26.48) | OSI8.951 (8.309 to 9.594)GEM0.8951 (0.8309 to 0.9594) | 0.465 synergy |
| BxPC-3 | 0.7716 (0.6574 to 1.356) | 8.551 (7.913 to9.187) | OSI 3.041 (2.799 to9.594)GEM 0.3041 (0.279 to 0.959) | 0.749 synergy |
| CFPAC-1 | 0.6796 (0.6082 to 0.751) | 13.96 (13.06 to 14.85) | OSI 2.702 (2.554 to2.850)GEM0.2702 (0.2554 to 0.2850) | 0.59 synergy |
| Statistical value | DR: VC | DR: RMSSD | DR: max-min | VR | Rest: VC | Rest: RMSSD | DR: max/min | PI |
| Ancova F | 10.854 | 8.492 | 9.016 | 0.380 | 6.512 | 0.493 | 6.467 | 2.70 |
| p-value | <0.01 | <0.04 | <0.005 | n.s. | <0.02 | n.s. | <0.02 | n.s. |
| Targeta | Nucleotide sequence (5′ to 3′) | Amplicon size (bp) | Reference |
| cfbb | F: CACACATGCTGTTGGAGTTCAGTTGA | 138 | This study |
| R: ACGAAGTCGACAGCATCACACGAAA | |||
| erm(A)/(TR) | F: CCGGCAAGGAGAAGGTTATAATGA | 190 | Otaguiri et al. [5] |
| R: GCATTCACCCGTTGACTCATTTCC | |||
| erm(B) | F: GCTCTTGCACACTCAAGTCTCGAT | 117 | Otaguiri et al. [5] |
| R: ACATCTGTGGTATGGCGGGTAAGT | |||
| mef(A/E) | F: GCGATGGTCTTGTCTATGGCTTCA | 225 | Otaguiri et al. [5] |
| R: AGCTGTTCCAATGCTACGGAT | |||
| RNaseP | F: AGATTTGGACCTGCGAGCG | 64 | WHO [27] |
| R: GAGCGGCTGTCTCCACAAGT | |||
| IGS1 | F: GTCATTTCAGCTGGCGCCATCGATAC | 260 | Tavares et al. [32] |
| R: TTGCCGCATAACGCATCTTAGCCA |
| Outcome | RCN (monetized) | ASBL (monetized) | SER (monetized) | ASBL + SER (monetized) |
| Cycling mode share by 2051 (%) | 5 | 20 | 5 | 40 |
| LV mode share by 2051 (%) | 75 | 65 | 55 | 40 |
| Proportion of people considering cycling always/mostly safe by 2040 | 0.4 | 0.7 | 0.3 | 0.9 |
| LVKT (billion km) | –3.5 | –7 | –10 | –18.5 |
| Cyclist injuries | ||||
| Fatalities | 200 (620) | 360 (1,100) | 85 (250) | 250 (850) |
| Serious injuries | 4,000 (1,300) | 7,000 (2,300) | 1,600 (500) | 5,000 (1,600) |
| Car crashes | ||||
| Car occupant fatalities | –70 (–220) | –120 (–370) | –170 (–527) | –340 (–1,000) |
| Air pollution | ||||
| Mortality | –10 (–7.5) | –20 (–15) | –40 (–30) | –80 (–60) |
| Hospitalizations | –5 (–0.02) | –15 (–0.04) | –20 (–0.06) | –40 (–0.12) |
| COPD incidence | –10 (–0.75) | –30 (–2.25) | –55 (–4) | –90 (–6.75) |
| Restricted activity days | –12,500 (–1) | –37,200 (–4) | –57,700 (–6) | –112,200 (–11) |
| Air pollution total | (–9) | (–21) | (–40) | (–78) |
| All-cause mortality | –650 (–2,000) | –1,850 (–5,700) | –650 (–2,000) | –4,000 (–12,400) |
| Greenhouse gas emissions (megatons) | –3 (–120) | –8 (–360) | –13 (–520) | –26 (–1040) |
| Fuel cost ($NZ million) | (–600) | (–1,800) | (–600) | (–3,900) |
| Infrastructure cost ($NZ million) | (45) | (250) | (380) | (630) |
| Net benefit ($NZ million) | –770 | –2,550 | –1,780 | –13,090 |
| Benefit–cost ratio | 18 | 18 | 6 | 24 |
| Abbreviations: LV, light vehicle; LVKT, light vehicle kilometers travelled. Numbers with a negative sign represent savings. Monetized figures are given in parentheses and are in millions of New Zealand dollars. Benefit–cost ratios are calculated from the net public health benefits and infrastructure costs shown. |
| Independent variables | β coefficient(Standardized β coefficient) | 95% CI | p-value |
| Age | 0.061 (0.082) | - 0.101 – 0.222 | 0.461 |
| BMI | 1.509 (0.230) | 1.056–1.961 | < 0.001† |
| Fasting blood glucose | 0.044 (0.044) | - 0.042 – 0.131 | 0.315 |
| Dyslipidemia (Yes vs. No) | - 1.014 (1.497) | - 3.961 – 1.934 | 0.499 |
| High risk alcohol drinking habit (Yes vs. No) | - 0.851 (1.412) | - 3.630 – 1.929 | 0.547 |
| Smoking status (Yes vs. No) | - 1.244 (1.446) | - 4.091 – 1.602 | 0.390 |
| Adequate exercise (Yes vs. No) | - 2.324 (1.396) | - 5.073 – 0.425 | 0.097 |
| Family history of hypertension (Yes vs. No) | 4.066 (2.304) | - 0.469 – 8.601 | 0.079 |
| Per doubling of blood cadmiuma | 2.171 (0.855) | 0.487–3.854 | 0.012† |
| Per doubling of blood leada | - 0.636 (1.029) | - 2.661 – 1.389 | 0.537 |
| R2 = 0.212 (p < 0.001) |
| All | Followed the advices | Contacted GP | Re-contact Casualty clinic | |||||||
| N = 100 | YesN = 93 | NoN = 7 | p-value | YesN = 22 | NoN = 78 | p-value | YesN = 11 | NoN = 89 | p-value | |
| Origin of caller | 0.08 | > 0.99 | > 0.99 | |||||||
| Native Norwegian | 84 | 80 | 4 | 19 | 65 | 10 | 74 | |||
| Others | 16 | 13 | 3 | 3 | 13 | 1 | 15 | |||
| Gender of caller | 0.34 | > 0.99 | 0.07 | |||||||
| Men | 22 | 22 | 0 | 5 | 17 | 5 | 17 | |||
| Women | 78 | 71 | 7 | 17 | 61 | 6 | 72 | |||
| Time of day | 0.009 | 0.47 | > 0.99 | |||||||
| Daytime | 37 | 34 | 3 | 9 | 28 | 4 | 33 | |||
| Afternoon | 42 | 42 | 0 | 7 | 35 | 5 | 37 | |||
| Night | 21 | 17 | 4 | 6 | 15 | 2 | 19 | |||
| Got enough time | 0.06 | 0.39 | > 0.99 | |||||||
| Yes | 94 | 89 | 5 | 20 | 74 | 11 | 83 | |||
| No | 3 | 2 | 1 | 1 | 2 | 0 | 3 | |||
| Partly | 3 | 2 | 1 | 1 | 2 | 0 | 3 | |||
| Got worse | 0.53 | 0.039 | 0.012 | |||||||
| Yes | 10 | 9 | 1 | 5 | 5 | 4 | 6 | |||
| No | 90 | 84 | 6 | 17 | 73 | 7 | 83 | |||
| Got answers to the questions | < 0.0001 | 0.024 | ||||||||
| Yes | 79 | 79 | 0 | 13 | 66 | 10 | 69 | > 0.99 | ||
| No | 6 | 3 | 3 | 2 | 4 | 0 | 6 | |||
| Partly | 15 | 11 | 4 | 7 | 8 | 1 | 14 | |||
| Trusted the nurse | < 0.0001 | 0.32 | 0.64 | |||||||
| Yes | 74 | 74 | 0 | 14 | 60 | 10 | 64 | |||
| No | 8 | 6 | 2 | 3 | 5 | 0 | 8 | |||
| Partly | 18 | 13 | 5 | 5 | 13 | 1 | 17 |
| Protein Symbol | Protein Name | Organism | Function | Swiss Prot ID |
| OPN (SSP1) | Osteopontin, secreted phosphoprotein 1 | Homo sapiens | Matrix mineralization, immunity | P10451 |
| DMP1 | Dentin matrix protein 1 | Homo sapiens | Osteoblast differentiation, nucleation of hydroxyapatite | Q13316 |
| MEPE | Matrix extracellular phosphoglycoprotein | Homo sapiens | Phosphate excretion, mineralization | Q9NQ76 |
| BSP | Bone sialoprotein | Homo sapiens | Matrix mineralization, hydroxyapatite binding, cell attachment | P21815 |
| DSPP | Dentin sialophosphoprotein | Homo sapiens | Dentinogenesis | Q9NZW4 |
| AMELX | Amylogenin | Homo sapiens | Enamel formation; extracellular scaffold, crystal growth | Q99217 |
| Stm | Starmaker | Danio rerio (zebrafish) | Otolith formation | A2VD23 |
| OMM-64 | Otolith matrix macromolecule-64 | Oncorhynchus mykiss (rainbow trout) | Otolith formation | B1Q2L9 |
| Question | Response rate (percentage; n = 86) |
| 14. How did you usually use the video clips in PHARMACY 301? | 79 |
| 15. How did watching the Pharmville clips help you in PHARMACY 301? | 64 |
| 16. Which families are the most realistic and why? | 35 |
| 17. Which are the most unrealistic and why? | 28 |
| 18. Do you have any suggestions for improving Pharmville? | 48 |
| 19. Do you have any suggestions for where else the Pharmville families could be included in the BPharm programme? | 19 |
| 20. How do feel that Pharmville and the related clips helped your learning? | 35 |
| 21. Space for any other comments about Pharmville that you would like to make. | 17 |
| Runs order | Operating conditions | Response Dry cell mass (g/l) | |
| A | B | ||
| 1 | 1 | 1 | 13.66 ± 0.08 |
| 2 | 0 | 1 | 14.96 ± 0.06 |
| 3 | 0 | 0 | 15.28 ± 0.01 |
| 4 | −1 | 1 | 15.44 ± 0.04 |
| 5 | −1 | 0 | 16.04 ± 0.01 |
| 6 | 0 | 1 | 14.55 ± 0.13 |
| 7 | −1 | 0 | 16.12 ± 0.06 |
| 8 | 1 | −1 | 15.14 ± 0.05 |
| 9 | −1 | 0 | 15.88 ± 0.05 |
| 10 | 0 | 0 | 14.69 ± 0.02 |
| 11 | 1 | 0 | 15.55 ± 0.02 |
| 12 | −1 | 0 | 16.20 ± 0.03 |
| 13 | 1 | −1 | 14.87 ± 0.05 |
| 14 | −1 | 1 | 15.99 ± 0.07 |
| 15 | 0 | −1 | 15.91 ± 0.06 |
| 16 | −1 | 0 | 16.17 ± 0.07 |
| UHI Assessment TOOL | Geographical Cover | Scale of the Assessment | Type of Assessment | User Input Parameters | Tool Output |
| Decision Support System (DSS) UHI project | Bologna/Modena, Venice/Padua, Wien, Stuttgart, Lodz/Warsaw, Ljubljana, Budapest and Prague. | Supra-metropolitan | Phase 1: Mapping Urban Heat. Phase 2: Understanding regulations and policies related to UHI (greenery: street or roof, material reflectance...) | 1/Location, 2/Scale (building or urban) 3/Typology of the intervention (building, facade, roofs, surface lots, urban structure and urban green) 4/Economic assessment 5/Skills. | 1/climate change assessment (Change in annual mean temperature per decade, changes in annual near-surface temperature for 30 year periods and heat wave frequency), 2/a set of normative applicable to the selected area and skills, 3/a set of potential mitigation strategies. |
| CE Urban Heat Island Atlas UHI project | Central Europe region | Regional | Phase 1: Mapping Urban heat related parameters. | 1/Location | 1/Air temperature 2/Digital elevation models 3/Land surface temperature 4/Land cover regional scale (corine) 5/Urban land use. |
| STAR tools GRaBS project | North West region of England | Neighbourhood | Phase 4: Testing conceptual design | 1/Location 2/Land cover proposal (% of buildings, major roads, other impervious surfaces, green and blue surfaces and bare soil or gravel surfaces) 3/Temperature scenario for 2050 (Baseline temperature, 2050’s 10% probability level, 50% probability level or 90% probability level). | 1/Maximum surface temperature |
| London unified model (Londum) | City of London | City | Phase 1: Simluation map of the Urban Heat Island of the existing city. Phase 4: Simulation map of the Urban Heat Island of the projected city. | 1/ Volume (Reflection, Shadowing, conduction of heat into the buildings, flux of heat into the atmosphere). Provided by the tool for the city of London. | 1/Urban heat island intensity (air temperature at 1,5m height). |
| ADMS model | City of London | Neighbourhood | Phase 1: Simluation map of the Urban Heat Island of the existing city. Phase 4: Simulation map of the Urban Heat Island of the projected city. | 1/Location 2/Surface cover (Albedo, evapotranspiration, thermal admittance). | 2/Air temperature variations -due to land cover- at 2m height. |
| London site-specific air temperature prediction model (LSSAT) | City of London | Neighbourhood | Phase 1: Air temperature mapping at a particular time. Phase 4: Air temperature prediction based on intervention proposed. | 1/Location | 1/Hourly prediction of air temperature based on site specific transects (Global solar radiation, cloud cover, wind velocity and relative humidity). |
| EPA Mitigation Impact Screening Tool (MIST) | U.S.A. 230 cities | City | Phase 4: Testing the mitigation effect of the selected mitiation strategy. | 1/Location 2/The latitude 3/the cooling degree day (CDD) 4/the heating degree day (HDD) 5/the population 6/the mean annual temperature 7/the typical peak (one hour) ozone 8/Mitigation strategy (albedo or vegetation modification). | Calculation of the effect of the mitigation strategy 1/Reduction of the mean city temperature 2/Cooling degree days 3/the heating degree day 4/the typical 1hr and 8hr max ozone 5/The energy consumption. |
| Item | SE | LE | SEM | P value |
| Sow BW (kg) | ||||
| At insemination | 72.7 | 72.9 | 0.9 | 0.840 |
| At day 90 of pregnancy | 127.9 | 117.0 | 1.9 | 0.002 |
| Litter size | 12.0 | 11.8 | 0.9 | 0.856 |
| Fetal weight (g) | 574.4 | 507.7 | 17.9 | 0.039 |
| CV, % | 14.86 | 12.72 | 1.48 | 0.345 |
| Pharmacological agents | Neonatal rat spinal cord preparation | Decerebrate cat preparation | Acute spinal cat | Early chronic spinal cat | Late chronic spinal cat | Late chronic spinal rat |
| Edrophonium (EDRO) | ↑↑ | ↔ | ||||
| AChE inhibitor | ||||||
| Neostigmine (NEO) | ↑↑ | |||||
| AChE inhibitor | ||||||
| EDRO + ACh | ↔ | |||||
| AChE inhibitor + acetylocholine | ||||||
| EDRO + tubocurarine | ↔ | |||||
| AChE inhibitor + nicotinic antagonist | ||||||
| Clonidine | ↑↑ | |||||
| NA agonist | ||||||
| EDRO + clonidine | ↑↑ | |||||
| AChE inhibitor+ NA agonist | ||||||
| Clonidine (low dose) | ↔ | |||||
| NA agonist | ||||||
| Atropine | ↔ | ↔ | ↑↑ | |||
| muscarinic antagonist | ||||||
| Atropine + clonidine (low dose) | ↑↑ | |||||
| muscarinic antagonist + NA agonist | ||||||
| Clonidine (low dose) + atropine | ↑↑ | |||||
| NA agonist + muscarinic antagonist | ||||||
| Carbachol | ↓↓ | ↓↓ | ||||
| cholinergic agonist | ||||||
| Carbachol + atropine | ↑↑ | ↑↑ | ||||
| cholinergic agonist + muscarinic antagonist | ||||||
| Atropine + carbachol | ↓↓ | |||||
| muscarinic antagonist + cholinergic agonist | ||||||
| EDRO + atropine | ↑↓↓ | |||||
| AChE inhibitor + muscarinic antagonist | ||||||
| EDRO + telenzepine | ↔ | |||||
| AChE inhibitor + M1 antagonist | ||||||
| EDRO + telenzepine (high dose) | ↓↓ | |||||
| AChE inhibitor + M1 antagonist | ||||||
| EDRO + methoctramine (METHOC) | ↑↓ | |||||
| AChE inhibitor + M2 antagonist | ||||||
| EDRO + METHOC (high dose) | ↓↓ | |||||
| AChE inhibitor + M2 antagonist | ||||||
| EDRO + 4-diphenylacetoxy-N-methylpiperidine metiodide (4-DAMP) | ↓↓ | ↑↑ | ||||
| AChE inhibitor + M3 antagonist | ||||||
| MT-3 | ↔ | |||||
| M4 antagonist | ||||||
| Mecamylamine | ↔ | |||||
| nicotinic antagonist | ||||||
| Mecamylamine + atropine | ↔ | |||||
| nicotinic antagonist + muscarinic antagonist | ||||||
| Dihydro-β-erythrpidine | ↑↑ | |||||
| nicotinic antagonist |
| Samples with decreased expression (n) | Gene symbol | Mean log ratio | Range of log ratio | Samples with increased expression (n) | Mean log ratio | Range of log ratio |
| 11 | CD14 | -2.99 | -0.27/-5.38 | 0 | - | - |
| 10 | TIA1 | -0.68 | -0.24/-1.05 | 1 | - | 0.77 |
| 10 | YWHAH | -0.72 | -0.27/-1.80 | 0 | - | - |
| 10 | PPP3CA | -0.69 | -0.34/-1.14 | 0 | - | - |
| 10 | ITGB2 | -2.87 | -0.58/-5.11 | 0 | - | - |
| 9 | PDGFRA | -1.32 | -0.42/-3.30 | 2 | 2.62 | 1.21/4.03 |
| 9 | RASA1 | -0.93 | -0.42/-1.17 | 0 | - | - |
| 8 | LDHB | -0.60 | -0.32/-1.25 | 2 | 1.11 | 0.64/1,58 |
| 8 | CSF1R | -3.05 | -0.63/-5.08 | 0 | - | - |
| 8 | RARA | -0.95 | -0.51/-1.23 | 0 | - | - |
| 7 | ANXA4 | -1.10 | -0.64/-1.16 | 4 | 1.37 | 0.84/2.33 |
| 7 | CTSB | -0.93 | -0.23/-1.97 | 3 | 0.94 | 0.82/1.13 |
| 7 | DAPK1 | -1.35 | -0.59/-2.07 | 2 | 1,40 | 1.19/1.60 |
| 7 | CASP1 | -1.69 | -0.71/-2.90 | 2 | 1.44 | 0.97/1.90 |
| 7 | PRF1 | -1.68 | -0.54/-3.68 | 2 | 0.79 | 0.67/0.91 |
| 7 | EPHB4 | -1.30 | -0.68/-2.34 | 1 | - | 0.30 |
| 7 | HCK | -1.79 | -0.39/-3.65 | 1 | - | 1.08 |
| 7 | ESD | -0.76 | -0.44/-0.95 | 1 | - | 0.36 |
| 7 | DHCR24 | -1.97 | -0.75/-4.34 | 0 | - | - |
| 7 | PPP1CB | -0.99 | -0.62/-1.56 | 0 | - | - |
| 7 | MYO18A/TIAF1 | -1.23 | -0.67/-2.02 | 0 | - | - |
| 7 | BIRC5 | -2.95 | -1.17/-4.91 | 0 | - | - |
| 7 | PDGFRB | -1.28 | -0.61/-2.26 | 0 | - | - |
| 7 | ATG5 | -1.39 | -0.61/-3.19 | 0 | - | - |
| 7 | DOCK1 | -0.86 | -0.40/-1.23 | 0 | - | - |
| 7 | PTPN13 | -1.97 | -0.69/-3.17 | 0 | - | - |
| 7 | BTK | -1.78 | -0.39/-3.28 | 0 | - | - |
| 7 | SYK | -4.26 | -0.34/-8.06 | 0 | - | - |
| Patient | Age | Site | Stage | Primary date | Primary therapy* | Recurrence | Expiry |
| 1 | 50 | Retromolar trigone | IV | 2009/05/30 | S+CCRT | ||
| 2 | 55 | Oral tongue | IV | 2010/10/24 | S+CCRT | ||
| 3 | 59 | Buccal mucosa | IV | 2011/05/04 | S+CCRT | ||
| 4 | 56 | Buccal mucosa | IV | 2010/05/31 | S+CCRT | 2010/08/09 | 2010/10/31 |
| 5 | 49 | Buccal mucosa | IV | 2010/07/27 | S+CCRT | 2010/11/24 | 2011/06/07 |
| 6 | 48 | Buccal mucosa | III | 2009/10/06 | S+C/T | 2009/12/29 | 2010/02/11 |
| Acid fast bacilli | Total | ||
| negative for AFB | positive for AFB | ||
| Giant cells | |||
| Not present | 50 | 25 | 75 |
| Present | 6 | 19 | 25 |
| Total | 56 | 44 | 100 |
| Parameters | ≤5 (n = 92) | 6–15 (n = 26) | ≥16 (n = 18) | P value |
| TAC, g/dL | 2.37 ± 0.57 | 2.55 ± 0.43 | 2.71 ± 39 | 0.025 |
| MDA, μmol/L | 3.74 ± 1.11 | 3.82 ± 1.18 | 3.50 ± 0.88 | 0.60 |
| BMI, kg/m2 | 24.46 ± 3.80 | 26.06 ± 3.34 | 25.61 ± 2.88 | 0.09 |
| Parameter | P-value |
| Region | 0.027 |
| Age | 0.103 |
| Gender | 0.168 |
| Histology | 0.906 |
| Stage | 0.901 |
| Smoking status | 0.668 |
| Diabetes mellitus | 0.142 |
| β-coefficient | OR | 95% CI | p-value | |
| Measurements at sea level (after variable selection) | ||||
| age | 0.075 | 1.08 | 0.99–1.18 | 0.092 |
| BUN | −0.259 | 0.77 | 0.60–0.99 | 0.040* |
| Measurements at 3700 m (after variable selection) | ||||
| age | 0.090 | 1.09 | 0.98–1.23 | 0.110 |
| SpO2 | −0.191 | 0.84 | 0.76–0.93 | 0.001** |
| HR | 0.029 | 1.03 | 1.00–1.07 | 0.042* |
| SBP | −0.019 | 0.98 | 0.95–1.01 | 0.091 |
| BUN | −0.452 | 0.64 | 0.46–0.88 | 0.007** |
| OR | 95% CI | P-value | |
| Ser/Ser vs. Asn/Asn | 5.68 | 4.83–6.70 | < 0.0001 |
| Ser/Ser vs. Asn/Ser | 4.93 | 4.28–5.68 | < 0.0001 |
| Ser/Ser vs. Asn/Asn + Asn/Ser | 5.21 | 4.65–5.85 | < 0.0001 |
| Pneumonia (n=5709) | ||
| Without rickets | With rickets | |
| n=5600 | n=109 | |
| Deaths n (%) | 345 (6.16) | 9 (8.26) |
| Odds-ratio | 1.37 (p-value = 0.32) | |
| Severe malnutrition (n=727) | ||
| Without rickets | With rickets | |
| n=680 | n=47 | |
| Deaths n (%) | 88 (12.94) | 2 (4.26) |
| Odds-ratio | 0.30 (p-value = 0.11) | |
| Malnutrition (Severe, moderate, mild) (n=1150) | ||
| Without rickets | With rickets | |
| n=1079 | n=71 | |
| Deaths n (%) | 118 (10.94) | 3 (4.23) |
| Odds-ratio | 0.36 (p-value = 0.11) | |
| Dehydration (n=2233) | ||
| Without rickets | With rickets | |
| n=2180 | n=53 | |
| Deaths n (%) | 230 (10.55) | 4 (7.55) |
| Odds-ratio | 0.69 (p-value = 0.65) | |
| Diarrhea, n=2805 | ||
| Without Rickets | With Rickets | |
| n=2772 | n=33 | |
| Deaths n (%) | 172 (6.2) | 2 (6.06) |
| Odds-ratio | 0.97 (p-value=1.00) |
| State | NE level | Ih | Apical function | |
| Asleep | Low | High | Isolated from soma | |
| Awake | Moderate | Moderate | Selective amplification | |
| Attentive | High | Low | Inc. Selectivity & Amplif. | |
| High arousal | Maximum | Minimum | Selective drive e.g., Stereotypical impulses | |
| Anesthetized Ketamine propofol Isoflurane | Low | Minimum | Non-selective slow waves |
| Relative Normalised Expression | |||||||
| Receptor Class | Accession Number | Gene Name | BMM | TEPM | |||
| 2 h | 6 h | 24 h | 1 h | 7 h | |||
| Repressed by LPS in BMM and TEPM | |||||||
| Class A | |||||||
| NM_009924 | Cnr2 | 0.2 | 0.1 | 0.3 | 0.3 | 0.1 | |
| NM_009911 | Cxcr4 | 0.3 | 0.1 | 7.1 | 0.7 | 0.1 | |
| NM_183031 | Ebi2 | 0.2 | 0.1 | 0.1 | 0.4 | 0.2 | |
| NM_004230 | Edg5 | 0.2 | 0.5 | 2.0 | 0.4 | 0.6 | |
| NM_022320 | Gpr35 | 0.2 | 0.4 | 1.6 | 0.6 | 0.1 | |
| NM_030258 | Gpr146 | 0.1 | 0.4 | 1.0 | 0.4 | 0.1 | |
| NM_008772 | P2ry1 | 0.3 | 0.1 | 0.2 | 0.3 | 0.1 | |
| NM_175116 | P2ry5 | 0.1 | 0.1 | 0.7 | 0.3 | 0.1 | |
| NM_013641 | Ptger1 | 0.7 | 0.5 | 0.3 | 0.7 | 0.3 | |
| NM_008965 | Ptger4 | 3.1 | 0.5 | 1.0 | 1.9 | 0.3 | |
| Repressed by LPS in BMM | |||||||
| Class A | |||||||
| NM_007420 | Adrb2 | 0.3 | 0.1 | 0.1 | 1.9 | 0.8 | |
| NM_009779 | C3ar1 | 0.7 | 0.5 | 0.3 | 0.8 | 0.6 | |
| NM_007577 | C5r1 | 1.1 | 0.7 | 0.1 | 3.0 | 1.1 | |
| NM_009915 | Ccr2 | 0.5 | 0.4 | 0.2 | 0.8 | 0.9 | |
| NM_009910 | Cxcr3 | 0.7 | 0.1 | 0.1 | 1.6 | 0.9 | |
| NM_009987 | Cx3cr1 | 0.5 | 0.1 | 0.1 | 1.0 | 0.7 | |
| NM_030720 | Gpr84 | 8.3 | 10.0 | 0.2 | 7.7 | 50.0 | |
| NM_027571 | P2ry12 | 0.5 | 0.1 | 0.2 | 1.0 | 1.0 | |
| Class B | |||||||
| NM_018782 | Calcrl | 1.0 | 2.6 | 0.2 | 0.6 | 7.1 | |
| Repressed by LPS in TEPM | |||||||
| Class A | |||||||
| NM_007719 | Ccr7 | 1.0 | 5.0 | 1.9 | 0.4 | 2.9 | |
| NM_021381 | Prokr1 | 0.8 | 33.3 | 7.1 | 0.3 | 0.1 | |
| NM_198168 | Ppp2r5b | 1.0 | 1.3 | 1.1 | 0.8 | 0.5 | |
| NM_008964 | Ptger2 | 2.4 | 1.3 | 11.1 | 0.3 | 0.1 | |
| Class B | |||||||
| NM_080437 | Celsr3 | 0.8 | 1.2 | 2.3 | 0.2 | 0.2 | |
| NM_173036 | Gpr97 | 0.8 | 1.0 | 0.8 | 0.5 | 0.2 | |
| NM_016894 | Ramp1 | 1.0 | 1.0 | 1.0 | 0.5 | 0.2 | |
| Class C | |||||||
| NM_022420 | Gprc5b | 1.0 | 1.0 | 1.3 | 0.8 | 0.1 |
| Presence of IFG | ||||
| Characteristics | Yes (%) | N (%) | COR | AOR |
| Age | ||||
| < 25 | 7 (2.0) | 336 (98.0) | 1.0 | 1.0 |
| 25–34 | 28 (7.7) | 334 (92.3) | 4.0 (1.7–9.3) | 1.8 (0.7–4.8) |
| 35–44 | 39 (27.5) | 103 (72.5) | 18.2 (7.9–41.9) | 3.1 (0.8–12.0) |
| ≥ 45 | 46 (51.8) | 43 (48.3) | 51.4 (21.8–120.9) | 4.9 (1.1–23.1) |
| Police rank | ||||
| Lower rank | 47 (6.6) | 663 (93.4) | 1.0 | 1.0 |
| Middle rank | 23 (18.4) | 102 (81.6) | 3.2 (1.9–5.5) | 0.5 (0.2–1.1) |
| Higher rank | 50 (49.5) | 51 (50.5) | 13.8 (8.5–22.6) | 0.9 (0.9–2.6) |
| Years of service | ||||
| 1–10 | 20 (7.0) | 268 (93.0) | 1.0 | 1.0 |
| 11–20 | 27 (13.3) | 254 (86.7) | 4.3 (2.3–14.3) | 2.4 (1.0–6.1) |
| > 20 | 73 (47.1) | 82 (52.9) | 24.8 (14.4–42.9) | 3.3 (0.9–11.9) |
| Family history | ||||
| Yes | 31 (47.0) | 35 (53.0) | 5.8 ((2.3–7.8) | 3.2 (1.4–7.5) |
| No | 89 (11.5) | 704 (88.5) | 1.0 | 1.0 |
| Ever Smoked | ||||
| Yes | 20 (31.7) | 43 (68.3) | 3.6 (2.0–6.4) | 1.0 (0.4–1.4) |
| No | 100 (11.5) | 773 (88.7) | 1.0 | 1.0 |
| Chewing Khat | ||||
| Yes | 5 (41.7) | 7 (58.3) | 5.6 (1.8–18.0) | 2.8 (0.6–17.8) |
| Yes, daily | 21 (22.8) | 71 (77.2) | 2.3 (1.4–4.0) | 2.5 (1.0–6.4) |
| No, at all | 94 (11.3) | 738 (88.7) | 1.0 | 1.0 |
| Current alcohol consumption | ||||
| Yes | 91 (13.9) | 565 (86.1) | 1.5 (0.2–11.6) | 0.8 (0.4–1.4) |
| No | 1 (10.0) | 9 (90.0) | 1.0 | 1.0 |
| Physical activity | ||||
| Vigorous | 20 (4.8) | 401 (95.2) | 1.0 | 1.0 |
| Moderate | 18 (10.2) | 159 (89.8) | 2.3 (1.2–4.4) | 1.5 (0.7–3.0) |
| Poor | 82 (24.3) | 256 (75.7) | 6.4 (3.8–10.7) | 1.6 (0.7–3.7) |
| Hypertension | ||||
| Yes | 76 (45.5) | 91 (54.5) | 13.8 (8.9–21–2) | 4.5 (2.6–7.8) |
| No | 44 (5.7) | 725 (94.3) | 1.0 | 1.0 |
| BMI | ||||
| < 25 | 46 (6.1) | 707 (93.90 | 1.0 | 1.0 |
| 25–29.9 | 64 (38.1) | 104 (61.9) | 9.5 (6.2–14.6) | 3.0 (1.7–5.4) |
| ≥ 30 | 10 (66.7) | 5 (33.3) | 30.7 (10.1–93.7) | 6.0 (1.2–30.2) |
| WHR | ||||
| Obese | 54 (32.3) | 113 (67.7) | 5.1 (3.4–7.7) | 4.5 (2.6–7.8) |
| Normal | 66 (8.6) | 703 (91.4) | 1.0 | 1.0 |
| V1 | V2 | V3 | V4 | |
| V1 | 1.00 (69) | 0.37 (69)** | 0.07 (69) | 0.08 (69) |
| 1.00 (165) | 0.35 (109)** | 0.10 (96) | 0.24 (89)* | |
| V2 | 1.00 (69) | 0.21 (69) | 0.19 (69) | |
| 1.00 (120) | 0.21 (113)* | 0.21 (76) | ||
| V3 | 1.00 (69) | 0.24 (69)* | ||
| 1.00 (172) | 0.28 (93)** | |||
| V4 | 1.00 (69) | |||
| 1.00 (105) |
| Mean | SD | Maximum | Minimum | |
| Maximum level of low back pain in the past year | 8.81 | 1.13 | 10 | 7 |
| Number of days without pain in the past year | 37.04 | 51.82 | 174 | 0 |
| Number of days with low pain in the past year | 149.37 | 86.12 | 303 | 0 |
| Number of days with moderate pain in the past year | 119.29 | 51.94 | 210 | 22 |
| Number of days with high pain in the past year | 57.04 | 68.72 | 262 | 0 |
| Clinical Factors | No. of patients (%) | P value b | No. of patients (%) | ||||
| Total | Low MTV a | High MTV a | Low TLG a | High TLG a | P value b | ||
| Age | 0.607 | 0.737 | |||||
| ≤60 y | 53 | 28(61) | 25(56) | 26(57) | 27(60) | ||
| >60 y | 28 | 18(39) | 20(44) | 20(43) | 18(40) | ||
| NCCN-IPI score | <0.001 | <0.001 | |||||
| 0-3 | 52 | 37(80) | 15(33) | 35(76) | 17(38) | ||
| 4-8 | 39 | 9(20) | 30(67) | 11(24) | 28(62) | ||
| Ann Arbor Stage | 0.003 | 0.037 | |||||
| I/II | 34 | 24(52) | 10(22) | 22(48) | 12(27) | ||
| III/IV | 57 | 22(48) | 35(48) | 24(52) | 33(73) | ||
| B symptoms | <0.001 | 0.008 | |||||
| No | 41 | 29(63) | 12(27) | 27(59) | 14(31) | ||
| Yes | 50 | 17(37) | 33(73) | 19(41) | 31(69) | ||
| Performance status | 0.002 | 0.037 | |||||
| ECOG 0-1 | 71 | 42(91) | 29(64) | 40(87) | 31(69) | ||
| ECOG >1 | 20 | 4(9) | 16(36) | 6(13) | 14(31) | ||
| No. of extranodal sites | 0.072 | 0.17 | |||||
| 0-1 | 55 | 32(70) | 23(51) | 31(67) | 24(53) | ||
| 2 or more | 36 | 14(30) | 22(49) | 15(33) | 21(47) | ||
| LDH level | 0.002 | 0.002 | |||||
| normal | 55 | 35(85) | 20(44) | 35(76) | 20(44) | ||
| elevated | 36 | 11(24) | 25(56) | 11(24) | 25(56) |
| Country | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
| Angola | |||||||
| Country | 2 267 799 | 6 933 500 | 9 536 500 | 17 327 500 | 25 494 500 | 30 988 000 | 34 542 500 |
| GAVI | 4 669 500 | 11 969 500 | 13 225 500 | 13 387 000 | 2 565 500 | 1 567 000 | 0 |
| Armenia | |||||||
| Country | 193 804 | 292 500 | 494 000 | 620 000 | 848 000 | 953 500 | 1 082 000 |
| GAVI | 563 500 | 444 500 | 1 037 500 | 742 500 | 262 500 | 166 500 | 0 |
| Azerbaijan | |||||||
| Country | 1 224 450 | 940 000 | 1 673 000 | 1 910 000 | 2 606 500 | 3 105 000 | 3 028 500 |
| GAVI | 387 000 | 3 607 500 | 2 389 000 | 1 827 500 | 413 500 | 0 | 0 |
| Bhutan | |||||||
| Country | 39 068 | 51 500 | 91 500 | 93 000 | 130 500 | 132 500 | 133 500 |
| GAVI | 98 000 | 105 000 | 74 000 | 38 500 | 0 | 0 | 0 |
| Bolivia | |||||||
| Country | 730 675 | 614 000 | 2 058 500 | 3 073 500 | 3 804 500 | 5 083 000 | 5 134 000 |
| GAVI | 1 192 500 | 1 683 500 | 3 400 000 | 2 610 000 | 881 000 | 0 | 0 |
| Congo | |||||||
| Country | 563 712 | 1 506 000 | 2 382 000 | 2 986 000 | 4 034 500 | 4 349 500 | 4 513 500 |
| GAVI | 3 490 000 | 3 979 000 | 3 061 000 | 2 273 000 | 400 000 | 230 000 | 0 |
| Georgia | |||||||
| Country | 239 941 | 299 000 | 571 500 | 824 000 | 1 229 000 | 1 448 500 | 1 710 000 |
| GAVI | 650 500 | 545 500 | 904 500 | 974 500 | 369 500 | 250 000 | 0 |
| Guyana | |||||||
| Country | 36 447 | 87 500 | 133 000 | 240 500 | 288 500 | 378 000 | 365 000 |
| GAVI | 603 000 | 397 000 | 232 500 | 214 000 | 93 500 | 0 | 0 |
| Honduras | |||||||
| Country | 1 088 385 | 1 467 500 | 2 042 000 | 2 708 500 | 3 572 000 | 3 578 500 | 3 365 000 |
| GAVI | 5 084 000 | 3 886 500 | 2 484 000 | 2 057 000 | 0 | 0 | 0 |
| Indonesia | |||||||
| Country | — | 2 088 500 | 11 787 500 | 20 765 500 | 27 420 500 | 32 638 000 | 32 314 500 |
| GAVI | — | 10 024 000 | 23 931 500 | 13 843 500 | 6 855 500 | 0 | 0 |
| Kiribati | |||||||
| Country | 15 475 | 24 000 | 17 000 | 37 000 | 51 500 | 61 500 | 60 000 |
| GAVI | 15 500 | 89 500 | 36 500 | 38 500 | 9 500 | 0 | 0 |
| Moldova | |||||||
| Country | 154 092 | 283 500 | 489 500 | 728 500 | 1 002 500 | 1 149 500 | 1 116 000 |
| GAVI | 482 000 | 762 500 | 816 000 | 642 500 | 136 000 | 0 | 0 |
| Mongolia | |||||||
| Country | 129 985 | 266 500 | 424 000 | 489 500 | 658 000 | 668 000 | 676 000 |
| GAVI | 428 500 | 544 000 | 307 000 | 171 500 | 0 | 0 | 0 |
| Sri Lanka | |||||||
| Country | 943 752 | 646 500 | 1 928 500 | 1 796 500 | 1 823 500 | 1 906 000 | 1 860 500 |
| GAVI | 2 313 000 | 2 811 000 | 271 500 | 68 500 | 0 | 0 | 0 |
| Total | |||||||
| Country | 7 627 585 | 15 500 500 | 33 628 500 | 53 600 000 | 72 964 000 | 86 439 500 | 89 901 000 |
| GAVI | 19 977 000 | 40 849 000 | 52 170 500 | 38 888 500 | 11 986 500 | 2 213 500 | 0 |
| Pathogen | Number of patients | Gender (male/female) | Median age (min–max) | Mortality (%) (survivors/death) |
| S. pneumoniae | 14 | 5/81 | 5.5 (0–40) | 46% (7/6)1 |
| N. meningitidis | 22 | 10/92 | 5.5 (1–60) | 27% (16/6) |
| H. influenzae | 9 | 7/2 | 2 (1–4) | 0% (9/0) |
| Author | Derivation sample | Validation sample | Predictors | Outcomes | Performance in the validation sample | Presentation of a simplified score |
| Pillai et al. | 208 patients from India with severe TBI | 26 patients from the same centre | 1-oculocephalic reflex2-motor GCS3-midline shift | Death or vegetative state | Sensitivity (75%)Specificity (67%)PPV 50% | No |
| Signorini et al | 372 patients from Scotland with moderate and severe TBI | 520 patients from the same centre | 1-GCS2-ISS3-pupils reactivity and 4-haematoma (CT scan) | Survival at 1 year | A.U.R.O.C (0.835)Error rate (15.2%)Brier score (0.1160)Hosmer-Lemeshow(p < 0.001) | Nomogram |
| Signorini et al | 110 patients from Scotland with moderate and severe TBI | 140 patients from the same centre | 1-GCS2-ISS3-pupils reactivity and 4-haematoma (CT scan)5-ICP measures | Survival at 1 year | Not reported | No |
| Hukkelhoven et al. | 134 patients from Netherlands with moderate and severe TBI | 180 patients from the same centre | 1-age2-motor GCS3-pupils reactivity4-pupillary size5-hypotension6-ISS | Raised ICP | A.U.R.O.C. (0.50)Hosmer-Lemeshow(p = 0.18) | No |
| Hukkelhoven et al. | 275 patients from Netherlands with moderate and severe TBI | 250 patients from the same centre | 1-age2-cause of injury3-pupils reactivity4-pupillary size5-hypotension6-ISS | Surgical removable lesions | A.U.R.O.C. (0.67)Hosmer-Lemeshow(p = 0.01) | No |
| Hukkelhoven et al. | 2269 patients from 2 trials in high income countries with moderate and severe TBI | 796 patients from Europe | 1-age2-motorGCS3-pupils reactivity4-hypoxia5-hypotension6-CT classification7-subarachnoid haemorrhage | Death or disability at 6 months | A.U.R.O.C. (0.83)Hosmer-Lemeshow(p = 0.05) | Score chart |
| Hukkelhoven et al. | 2269 patients from 2 trials in high income countries with moderate and severe TBI | 796 patients from Europe and 746 from the United States | 1-age2-motor GCS3-pupils reactivity4-hypoxia5-hypotension6-CT classification7-subarachnoid haemorrhage | Death at 6 months | A.U.R.O.C. (0.87/0.89)Hosmer-Lemeshow(p = 0.42/<0.001) | Score chart |
| Rank | Feature name | Mean SP | Mean ME | P-value | Rank | Feature name | Mean SP | Mean ME | P-value |
| 1 | Degree | 36.6 | 86.9 | 2.8e-106 | 21 | 42 | 0.00631 | 0.0108 | 8.2e-45 |
| 2 | 57 | 0.00207 | 0.00584 | 2.5e-95 | 22 | 16 | 0.0657 | 0.0502 | 1.2e-44 |
| 3 | 43 | 0.00486 | 0.0104 | 9.8e-86 | 23 | 47 | 0.00333 | 0.00622 | 2.7e-44 |
| 4 | 45 | 0.006 | 0.0113 | 5.2e-82 | 24 | 10 | 0.00372 | 0.00619 | 1.5e-43 |
| 5 | 50 | 0.00407 | 0.00853 | 3.6e-81 | 25 | 36 | 0.00772 | 0.0125 | 1.3e-41 |
| 6 | 13 | 0.0895 | 0.0552 | 9.5e-79 | 26 | 65 | 0.00099 | 0.00263 | 7.6e-38 |
| 7 | 3 | 0.0556 | 0.0363 | 1.2e-76 | 27 | 32 | 0.0145 | 0.0206 | 1.4e-31 |
| 8 | 58 | 0.00211 | 0.00563 | 1.4e-76 | 28 | 66 | 0.00116 | 0.00263 | 5.9e-29 |
| 9 | 15 | 0.0871 | 0.0558 | 3.8e-76 | 29 | 34 | 0.00912 | 0.0136 | 1.7e-26 |
| 10 | 64 | 0.00076 | 0.00315 | 3.9e-74 | 30 | 38 | 0.00576 | 0.00866 | 3.4e-26 |
| 11 | 33 | 0.00999 | 0.0166 | 2.1e-66 | 31 | 55 | 0.00267 | 0.00481 | 2.3e-23 |
| 12 | 48 | 0.00309 | 0.00716 | 3.7e-66 | 32 | 23 | 0.0152 | 0.0197 | 1.1e-22 |
| 13 | 54 | 0.0033 | 0.00707 | 3.7e-65 | 33 | 61 | 0.00211 | 0.00397 | 6e-22 |
| 14 | 22 | 0.0491 | 0.0344 | 2.8e-63 | 34 | 40 | 0.00921 | 0.0133 | 9e-21 |
| 15 | 60 | 0.00176 | 0.00444 | 9.9e-61 | 35 | 59 | 0.00186 | 0.003 | 9.8e-21 |
| 16 | 56 | 0.00187 | 0.0048 | 7.1e-58 | 36 | 7 | 0.0117 | 0.0144 | 5.6e-20 |
| 17 | 6 | 0.00608 | 0.00917 | 9e-53 | 37 | 62 | 0.00172 | 0.0029 | 2.1e-19 |
| 18 | 44 | 0.00651 | 0.0107 | 2.4e-50 | 38 | 67 | 0.00076 | 0.00156 | 1.1e-17 |
| 19 | 1 | 0.0265 | 0.0199 | 3.4e-48 | 39 | 14 | 0.0474 | 0.039 | 2.4e-17 |
| 20 | 53 | 0.0044 | 0.00793 | 2.3e-46 | 40 | 46 | 0.00712 | 0.00968 | 2.2e-16 |
| Mild TBI | Moderate TBI | Severe TBI | p-value | |
| Number of patients | 229 | 85 | 54 | - |
| Age at time of injury (years) | ||||
| Mean ± standard deviation | 23.7 ± 16.6 | 29.0 ± 20.9 | 22.5 ± 16.4 | 0.038 |
| Range (minimum - maximum) | 1.0 - 66.0 | 1.0 - 76.0 | 1.0 - 60.0 | |
| median | 20.0 | 28.0 | 19.0 | |
| Age at time of reexamination (years) | ||||
| Mean ± standard deviation | 44.2 ± 16.9 | 43.4 ± 20.08 | 26.5 ± 16.5 | 0.018 |
| Range (minimum - maximum) | 12.0 - 87.0 | 11.0 - 87.0 | 12.0 - 76.0 | |
| median | 41.0 | 42.0 | 34.5 | |
| Time to reexamination (years) | ||||
| Mean ± standard deviation | 20.3 ± 6.5 | 14.2 ± 4.1 | 14.0 ± 3.9 | <0.001 |
| Number of patients <18 years | 101 | 33 | 26 | 0.531 |
| (%) | (44.1%) | (38.8%) | (48.1%) | |
| Gender distribution (♂: ♀) | 129: 100 | 57: 28 | 40: 14 | 0.026 |
| Injury Severity (ISS) | - | 14.8 ± 7.5 | 21.4 ± 7.1 | <0.001 |
| New Injury Severity (NISS) | - | 24.3 ± 12.3 | 36.3 ± 14.8 | <0.001 |
| Marital status at follow-up | ||||
| - Single | 40.7% | 42.2% | 64.8% | 0.010 |
| - Married or cohabitant | 51.0% | 50.6% | 24.1% | |
| - Divorced | 8.3% | 7.2% | 11.1% | |
| Housing situation before TBI | ||||
| - in rented accommodation | 51.2% | 46.8% | 38.5% | 0.249 |
| Housing situation at follow-up | ||||
| - in rented accommodation | 50.2% | 42.0% | 38.5% | 0.205 |
| - confinement in bed | 0.0% | 0.0% | 5.6% | <0.001 |
| Variable | Case (n=127) | Control (127) |
| Number (%) | Number (%) | |
| Ethnicity | ||
| Oromo | 122(96.1) | 123(96.9) |
| Others | 5(3.9) | 4(3.1) |
| Religion | ||
| Muslim | 124(97.6) | 123(96.9) |
| Christian | 3(2.4) | 4(3.1) |
| Education status of mother | ||
| Illiterate | 115(90.6) | 102(80.3) |
| Literate | 12(9.4) | 25(19.7) |
| Occupation of mother | ||
| Housewife | 92(72.4) | 95(74.8) |
| Farmer | 31(24.4) | 30(23.6) |
| Merchant | 4(3.1) | 2(0.8) |
| Age of mothers (years) | ||
| <20 | 5(3.9) | 3(2.4) |
| 20-34 | 85(66.9) | 98(77.2) |
| ≥35 | 37(29.2) | 26(20.4) |
| Marital status | ||
| Married | 121(95.3) | 126(99.2) |
| Widowed | 6(4.7) | 1(0.8) |
| Sex of infants | ||
| Male | 74(58.3) | 73(57.5) |
| Female | 53(41.7) | 54(42.5) |
| Variables | Cuppingn = 30 | Restingn = 30 | P |
| Gender (%) | 0.640 | ||
| Male | 3 (10.0) | 2 (6.7) | |
| Female | 27 (90.0) | 28 (93.3) | |
| Age (mean ± SD) | 43.6 ± 8.0 | 42.5 ± 7.4 | 0.486 |
| Method | MDR | AntEpiSeeker | BOOST | MegaSNPHunter | KNN-MDR |
| Power | N/A | 0.65 | 0.67 | 0.80 | 0.74 |
| Corrected power | N/A | 0.15 | 0.28 | 0.12 | 0.63 |
| Patient | HAX-1 | ER | |||
| Normal | Tumor | Tumor | |||
| Cytoplasm | Nucleus | Cytoplasm | Nucleus | Nucleus | |
| 1 | 0 | - | 2 | - | + |
| 2 | 0/1 | - | 1 | - | - |
| 3 | 1 | - | 1 | - | - |
| 4 | 0 | - | 0 | - | - |
| 5 | 0 | - | 1 | - | - |
| 6 | 0 | - | 1 | - | - |
| 7 | 1 | - | 0 | + | + |
| 8 | 0 | - | 2 | + | + |
| 9 | 0 | - | 1 | - | - |
| 10 | 2 | - | 2 | - | + |
| 11 | 1 | - | 1/2 | - | + |
| 12 | 0 | - | 2 | + | + |
| 13 | 0 | - | 2 | - | - |
| 14 | 0 | - | 2 | + | + |
| 15 | 0 | - | 3 | - | - |
| Ricketts analysis | Pretreatment (16 years, 4 months) | Posttreatment (19 years, 8 months) | ||||
| Norm | Value | Deviation | Norm | Value | Deviation | |
| Cranial relations | ||||||
| Facial axis (°) | 90 ± 3.5 | 88.4 | vertical growth type | 90 ± 3.5 | 89.0 | dolichofacial face type |
| Mandibular plane (°) | 23.6 ± 4 | 34.0 | 29.6 ± 4 | 29.9 | ||
| Mandibular arc (°) | 26 ± 4 | 30.1 | 27.7 ± 4 | 26.4 | ||
| Lower facial height (°) | 45 ± 4 | 54.1 | 45 ± 4 | 58.1 | ||
| Maxillary depth (°) | 90 ± 3 | 87.4 | maxilla ortho- to retrognathic | 90 ± 3 | 89.7 | maxilla orthognathic |
| SN-Palatal plane (°) | 7.3 ± 3 | −3.3 | anterior rotation of maxilla | 7.3 ± 3 | −1.2 | less anterior rotation of maxilla |
| Facial (angle) depth (°) | 89.4 ± 3 | 84.6 | mandible prognathic | 90.6 ± 3 | 85.7 | mandible prognathic |
| Facial taper | 68 ± 3 | 61.4 | posterior rotation of mandible | 68 ± 3 | 64.4 | less posterior rotation of mandible |
| Convexity of point A (mm) | −0.4 ± 2 | 2.6 | slight skeletal class III | −1.6 ± 2 | 3.8 | skeletal class III |
| Denture Relations | ||||||
| Upper incisor to A-Pog (mm) | 3.5 ± 2 | 10.7 | distinctly protruded | 3.5 ± 2 | 9.6 | slightly less protruded |
| Upper incisor to FH (°) | 111 ± 4 | 105.5 | slightly retroinclined | 111 ± 4 | 107.4 | normally inclined |
| Upper molar to PtV(mm) | 19.3 ± 1 | 15.2 | upper dental arch retruded | 22.7 ± 1 | 18.3 | upper dental arch retruded |
| Lower incisor to A-Pog (mm) | 1 ± 2 | 6.5 | distinctly protruded | 1 ± 2 | 7.1 | distinctly protruded |
| Lower incisor inclination (°) | 22 ± 4 | 24.5 | normally inclined | 22 ± 4 | 23.4 | normally inclined |
| Interincisal angle (°) | 130 ± 6 | 132.4 | normal | 130 ± 6 | 131.8 | normal |
| Molar relation (mm) | −3.0 ± 2 | −2.6 | Angle class I | −3.0 ± 2 | −1.1 | Angle class I |
| Incisor Overjet (mm) | 2.5 ± 1 | 4.6 | increased | 2.5 ± 1 | 2.5 | normal |
| Incisor Overbite (mm) | 2.5 ± 1 | 3.2 | increased | 2.5 ± 1 | 2.2 | normal |
| Esthetic Relations | ||||||
| Lower lip – E-Plane(mm) | −2 ± 2 | −3.9 | lower lip slightly retruded | < -2 ± 2 | −4.3 | lower lip slightly retruded |
| Author | Year, Country | Investigation period | No. of colic cases | Distribution of cases | Cases euthanized or dead % | Short-term survival rates (%) | ||||||
| Medical % | Surgical % | Without any treatment | Medical cases | Cases undergoing surgery | ||||||||
| During surgery | After recovery | Overall | Medically treated cases | Surgically treated cases | ||||||||
| [3] | 1989, USA | 1974-1984 | 320 | 41 | 59 | 16 | 6 | 31 | 25 | 59 | 94 | 44 |
| [7] | 2005, Germany | 1990-1997 | 1431 | 80 | 20 | * | 7 | 35 | 16 | 84 | 93 | 49 |
| [5] | 2003, The Netherlands | 1999-2000 | 649 | 64 | 36 | 8 | 15 | 26 | 21 | 69 | 85 | 54 |
| [6] | 2005, Canada | 1992-2002 | 604 | 54 | 46 | 21 | 6 | 26 | 14 | 66 | 94 | 60 |
| [8] | 2009, Israel | 2003-2006 | 208 | 30 | 70 | 6 | 8** | 34 | 71 | 92 | 66 | |
| [9] | 2009, South Africa | 1998-2007 | 929 | 60 | 40 | 3 | 7 | 21 | 13 | 79 | 93 | 66 |
| UHLA*** | 2013, Denmark | 2000-2009 | 1588 | 69 | 31 | 10 | 13 | 44 | 14 | 68 | 87 | 42 |
| Place, author's and years of Examination | Prevalence of schistosomiasis | |
| Schistosoma haematobium % | Schistosoma mansoni % | |
| This study | ||
| Before mass treatment 2002 | 13.6 | 36.3 |
| After mass treatment 2008 | 18.6 | 31.0 |
| Mali (Clements et al.) (26) | ||
| Before mass treatment (1989) | 25.7 | 7.4 |
| After mass treatment (2006) | 38.3 | 6.7 |
| Mali (Landoure A et al.) (27) | ||
| Before mass treatment (2004) | 88.0 | 17.0 |
| After mass treatment (2010) | 61.0 | 12.0 |
| Tanzania (Poggensee G et al.) (28) | ||
| Before mass treatment 1996 | 36.7 | 22.9 |
| After mass treatment 2002 | 33.6 | 00.7 |
| into | from | ||||
| AG-T | MEX | SA1 | SA2 | USA | |
| AG-T | 99 (96.4–100) | 0.3 (0–1.6) | 0.3 (0–1.7) | 0.3 (0–1.6) | 0.2 (0–1.7) |
| MEX | 0 (0–0.2) | 99 (98.5–100) | 0 (0–0.3) | 0.3 (0–1.1) | 0.2 (0–0.6) |
| SA1 | 0 (0–0.4) | 0.2 (0–0.9) | 95.3 (93.0–97.4) | 4.2 (2.2–6.4) | 0 (0–0.9) |
| SA2 | 0 (0–0.4) | 0.1 (0–0.6) | 0.3 (0–1.5) | 99.2 (97.7–100) | 0.3 (0–1.1) |
| USA | 0 (0–0.1) | 0 (0–0.2) | 0 (0–0.2) | 0 (0–0.2) | 99.9 (99.6–100) |
| Cigarettes: ‘surgeon general’s warning’ | Smokeless tobacco: ‘warning’ |
| Smoking causes lung cancer, heart disease, emphysema, and may complicate pregnancy | This product may cause mouth cancer |
| Quitting smoking now greatly reduces serious risks to your health | This product may cause gum disease and tooth loss |
| Smoking by pregnant women may result in fetal injury, premature birth, and low birth weight | Proposed: this product contains nicotine and is addictive |
| Cigarette smoke contains carbon monoxide | Compromise: this product is not a safe alternative to cigarettes |
| Variable | >18.50 | 18.50–24.99 | 25.0–29.99 | ≥30 | p Value |
| (n = 141) | (n = 1164) | (n = 225) | (n = 72) | ||
| Duration of stimulation (d) | 10.35 ± 2.17 | 10.01 ± 2.55 | 10.09 ± 2.19 | 10.52 ± 1.72 | 0.53 |
| Total dose of gonadotrophin (IU) | 2439 ± 1403 | 2658 ± 1406 | 2573 ± 1029 | 2788 ± 1222 | 0.58 |
| Ovarian stimulation protocol n (%) | |||||
| GnRH antagonist | 101 (71.6%) | 842 (72.3%) | 180 (80.0%) | 53 (73.6%) | |
| Long | 32 (22.7%) | 262 (22.5%) | 37 (16.4%) | 16 (22.2%) | |
| Others | 8 (5.7%) | 60 (5.2%) | 8 (3.6%) | 3 (4.2%) | 0.41 |
| E2 on hCG day (pg/mL) | 1823.07 ± 969.29 | 1716 ± 1092 | 1883 ± 1354 | 1571 ± 872 | 0.17 |
| Retrieved oocytes (n) | 8.26 ± 5.87 | 8.17 ± 6.09 | 7.88 ± 5.83 | 6.22 ± 4.73 | 0.06 |
| MII (%) | 74.56 ± 21.93 | 76.93 ± 24.75 | 73.15 ± 24.96 | 67.24 ± 30.55 | 0.005 a |
| Cycles without oocytes n (%) | 12 (8.5%) | 98 (8.4%) | 20 (8.9%) | 10 (13.9%) | 0.46 |
| Used oocytes (n) | 5.61 ± 3.94 | 5.99 ± 4.12 | 5.62 ± 4.29 | 4.19 ± 3.43 | 0.003 a |
| ICSI (%) | 110/129 (85.3%) | 902/1066 (84.6%) | 181/205 (88.3%) | 56/62 (90.3%) | 0.37 |
| Fertilization rate (%) | 68.05 ± 28.61 | 67.22 ± 27.12 | 66.34 ± 29.47 | 60.98 ± 28.49 | 0.35 |
| Embryo quality score | 1.90 ± 0.66 | 2.03 ± 0.71 | 1.96 ± 0.73 | 1.92 ± 0.77 | 0.27 |
| Day of ET | |||||
| Day 3 | 52/84 (61.9) | 486/763 (63.7) | 91/140 (65.0) | 39/50 (78.0) | |
| Day 5 | 32/84 (38.1) | 277/763 (36.3) | 49/140 (35.0) | 11/50 (22.0) | 0.22 |
| Embryos transferred (n) | 1.69 ± 0.64 | 1.74 ± 0.62 | 1.73 ± 0.69 | 1.68 ± 0.59 | 0.81 |
| Blastulation rate (%) | 53.57 ± 23.09 | 56.57 ± 22.46 | 53.07 ± 20.75 | 52.65 ± 29.47 | 0.46 |
| Primer Name | Sequence | Gene |
| CSnmrAF | AGTAGGGTAGGCAGCATCCA | Check for PC-06 (NmrA) |
| CSnmrAR | GCGCACTATTTCTGAGCAGC | Check for PC-06 |
| pen1 | ATGTCCAGATCCCTAACCCAC | Screen for penP deletion |
| pen2 | CATAATTGGGGTCACCTGATG | Screen for penP deletion |
| CSpenCF | CGTCGACAGAATCTCCAGCT | Check for penC |
| CSpenCR | TCATCCATCACACCGCGATT | Check for penC |
| CSjanCF | GGGGAAGGTAGCCATGCTTT | Check for janC |
| CSjanCR | TGCGGATATTACGAGGCGAC | Check for janC |
| jan1 | CCAATGTTAGAGTCCCAACG | Screen for jan P deletion |
| jan2 | GTCGTATACTCCCCGACATG | Screen for jan P deletion |
| CSP450F | ACGGTCACGGTCAAGTCTTC | Check for PJ-13 (P450) |
| CSP450R | CGTTACAGGGCCGGGTATTT | Check for PJ-13 (P450) |
| CSjanQF | TACAGGCCAGCTCTTCAACC | Check for janQ |
| CSjanQR | TCGGACATCTTTCGCACCAA | Check for janQ |
| CS janD intF | GGACTTACAAGGCTTTCGCA | Screen for janD deletion |
| CS janD intR | ACGCTTAAAGCCCAGAAACA | Screen for janD deletion |
| CSFADF | CTTCCTCGTGCCCTTGACAT | Check for janO (FAD) |
| CSFADR | GACCATGCTGTACCGAACGT | Check for janO (FAD) |
| Translocation | Translocation partner | ATRA response |
| t(11;17) (q23;q21) [5] | PLZF (promyelocytic leukaemia zinc finger protein) | Resistant |
| t(5;17) (q35;q21) [6] | NPM (nucleophosmin) | Sensitive |
| t(11;17) (q13;q21) [7] | NUMA (nuclear mitotic apparatus) | Sensitive |
| der(17) [8] | STAT5b (signal transducer and activator of transcription) | Resistant |
| t(3;15) (q26;q13) (present case) | Sensitive |
| N = 1094 | Total | Males (n = 506) | Females (n = 588) | χ2 |
| Age, mean (SD) | 53.1(11.4) | 53.8(11.6) | 52.5(11.1) | |
| Marital status (% married /living together) | 54.6 | 61.1 | 49.0 | p < 0.05 |
| Level of education (%) | ||||
| High | 41.7 | 41.1 | 41.9 | p >0.05 |
| Middle | 27.1 | 28.4 | 26.0 | |
| Low | 26.5 | 25.2 | 27.5 | |
| Not applicable | 4.7 | 5.0 | 4.6 | |
| Frequency of exercise | ||||
| Do not exercise/hardly | 10.6 | 12.7 | 8.7 | p >0.05 |
| Once per week | 10.2 | 10.3 | 10.1 | |
| Twice or more per week | 79.2 | 76.9 | 81.2 | |
| Smoking (%) | ||||
| No | 76.1 | 74.4 | 77.5 | p >0.05 |
| Yes | 23.9 | 25.6 | 22.5 | |
| Obesity (BMI ≥ 30 kg/m2) (%) | 16.9 | 15.2 | 18.4 | p >0.05 |
| MDD-S# (%) | 12.5 | 10.0 | 14.7 | p < 0.05 |
| MDD-R# (%) | 8.2 | 5.4 | 10.6 | p < 0.05 |
| 1. Was an 'a priori' design provided?The research question and inclusion criteria should be established before the conduct of the review. | □ Yes□ No□ Can't answer□ Not applicable |
| 2. Was there duplicate study selection and data extraction?There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. | □ Yes□ No□ Can't answer□ Not applicable |
| 3. Was a comprehensive literature search performed?At least two electronic sources should be searched. The report must include years and databases used (e.g. Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. | □ Yes□ No□ Can't answer□ Not applicable |
| 4. Was the status of publication (i.e. grey literature) used as an inclusion criterion?The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. | □ Yes□ No□ Can't answer□ Not applicable |
| 5. Was a list of studies (included and excluded) provided?A list of included and excluded studies should be provided. | □ Yes□ No□ Can't answer□ Not applicable |
| 6. Were the characteristics of the included studies provided?In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g. age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. | □ Yes□ No□ Can't answer□ Not applicable |
| 7. Was the scientific quality of the included studies assessed and documented?'A priori' methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. | □ Yes□ No□ Can't answer□ Not applicable |
| 8. Was the scientific quality of the included studies used appropriately in formulating conclusions?The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. | □ Yes□ No□ Can't answer□ Not applicable |
| 9. Were the methods used to combine the findings of studies appropriate?For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e. Chi-squared test for homogeneity, I2). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e. is it sensible to combine?). | □ Yes□ No□ Can't answer□ Not applicable |
| 10. Was the likelihood of publication bias assessed?An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test). | □ Yes□ No□ Can't answer□ Not applicable |
| 11. Was the conflict of interest stated?Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. | □ Yes□ No□ Can't answer□ Not applicable |
| Nutrient | Amount (DM) |
| Crude protein | 76.9% |
| Crude fat | 1.9% |
| Ca | 12.31% |
| P | 1.03% |
| Na | 4.09% |
| K | 0.3% |
| Mg | 2.08% |
| S | 0.24% |
| Mn | 615 ppm |
| Zn | 924 ppm |
| Cu | 308 ppm |
| Co | 26 ppm |
| I | 87 ppm |
| Se | 6–8 ppm |
| Vitamin A | 90,200 IU/kg |
| Vitamin D | 9020 IU/kg |
| Vitamin E | 226 IU/kg |
| Rumensin® 0.68 g/kg | 616 g/t |
| Tylan ® 0.14 g/kg | 123 g/t |
| # | m/z | z | m | Sequence proposal | Alignment | Protein homologue |
| 1 | 1185.6 | 3 | 3553.8 | SNVLYGPDTPTLSQSLGNS | Query: NVLYGPDTPTLSQS | CEACAM8 |
| NVLYGPD PT+S S | P31997 | |||||
| Sbjct: NVLYGPDAPTISPS | H. sapiens | |||||
| 2 | 693.3 | 3 | 2076.9 | BXXTVESVPPNAAEGKDALLR | Query: TVESVPPNAAEGKDALL | CEACAM8 |
| 1039 | 2 | T+E VP NAAEGK+ LL | P31997 | |||
| Sbjct: TIEAVPSNAAEGKEVLL | H. sapiens | |||||
| 3 | 553.2 | 2 | 1104.4 | BVTTPGPAYSGR | Query: TPGPAYSGR | CEACAM8 |
| TPGPAYS R | P31997 | |||||
| Sbjct: TPGPAYSNR | H. sapiens | |||||
| 4 | 656.8 | 4 | 2623.2 | B [VL]LPGDTASLTWFK [W/GE/AD/SV]TVLPXXK | Query: WFKGETV | CEACAM8 |
| 875.4 | 3 | W+KGETV | P31997 | |||
| Sbjct: WYKGETV | H. sapiens | |||||
| 5 | 539.2 | 2 | 1076.4 | BLLLYVLDTK | Query: BLLLYVLDT | Q9NOP7 |
| +++ YV+ T | CEA protein | |||||
| Sbjct: RIIGYVIAT | P. hamadryas | |||||
| 6 | 425.2 | 2 | 848.4 | BFETALLR | No match | |
| 7 | 386.2 | 2 | 770.4 | BTVPDSPR | No match |
| Nutritional factors | Chick -starter diet | Chick-Grower diet | |
| 1. | ME* Kcal/ kg | 2915 | 2915 |
| 2. | Crude protein % | 17.50 | 15.00 |
| 3. | Fat % | 3-4 | 3-4 |
| 4. | Fibre % | 3-4 | 3-4 |
| 5. | Lysine % | 0.70 | 0.75 |
| 6. | Methionine % | 0.40 | 0.35 |
| 7. | Calcium % | 1.00 | 1.00 |
| 8. | Total Phosphorus % | 0.70 | 0.60 |
| 9. | Vitamin A (I.U.) | 4550 | 4450 |
| 10. | Vitamin D (I.U.) | 1600 | 1600 |
| 11. | Vitamin E (I.U.) | 15.0 | 15.0 |
| 12. | Vitamin K (mg) | 1.00 | 1.00 |
| 13. | Choline (mg) | 45.0 | 45.0 |
| 14. | Linoleic acid % | 1.00 | 1.00 |
| Pharmacist | PMV | |||||||
| Any FP training | No FP training | Any FP training | No FP training | |||||
| Minimum age | n | % | n | % | n | % | n | % |
| Male condom | 172 | 79.7 | 238 | 74.0 | 213 | 75.6* | 261 | 66.7 |
| Pill | 148 | 89.2*** | 170 | 75.3 | 153 | 85.0* | 160 | 75.0 |
| EC | 127 | 89.8** | 165 | 77.6 | 89 | 82.0* | 94 | 69.2 |
| Injectable | 130 | 88.5 | 159 | 80.5 | na | na | na | na |
| Minimum parity | ||||||||
| Male condom | 172 | 2.9 | 238 | 2.9 | 213 | 7.5 | 261 | 4.2 |
| Pill | 148 | 29.1 | 170 | 28.8 | 153 | 42.5 | 160 | 44.4 |
| EC | 127 | 11.8 | 165 | 12.7 | 89 | 25.8 | 94 | 14.9 |
| Injectable | 130 | 22.3 | 159 | 21.4 | na | na | na | na |
| Marital status | ||||||||
| Male condom | 172 | 7.6 | 238 | 10.9 | 213 | 6.6 | 261 | 7.7 |
| Pill | 148 | 43.9 | 170 | 39.4 | 153 | 61.4 | 160 | 53.8 |
| EC | 127 | 24.4 | 165 | 27.9 | 89 | 31.5* | 94 | 16.0 |
| Injectable | 130 | 41.5 | 159 | 48.4 | na | na | na | na |
| Bias score | ||||||||
| Male condom | 172 | 0.9 | 238 | 0.9 | 213 | 0.9* | 261 | 0.8 |
| Pill | 148 | 1.6 | 170 | 1.4 | 153 | 1.9 | 160 | 1.7 |
| EC | 127 | 1.3 | 165 | 1.2 | 89 | 1.4** | 94 | 1.0 |
| Injectable | 130 | 1.5 | 159 | 1.5 | na | na | na | na |
| Totala | 3.8 | 3.5 | 4.2 | 3.5 |
| Genotypes/alleles | Patients (47) | Controls (76) |
| ID | 26 (55.3%) | 34 (44.7%) |
| DD | 14 (29.8%) | 30 (39.5%) |
| II | 7 (14.9%) | 12 (15.8%) |
| AC | 20 (42.6%) | 31 (40.8%) |
| AA | 25 (53.2%) | 40 (52.6%) |
| CC | 2 (4.2%) | 5 (6.6%) |
| MT | 23 (48.9%) | 40 (52.6%) |
| MM | 17 (36.2%) | 24 (31.6%) |
| TT | 7 (14.9%) | 12 (15.8%) |
| D allele presence | 40 (85.1%) | 64 (84.2%) |
| I allele presence | 33 (70.2%) | 46 (60.5%) |
| A allele presence | 45 (95.7%) | 71 (93.4%) |
| C allele presence | 22 (46.8%) | 36 (47.3%) |
| M allele presence | 40 (85.1%) | 64 (84.2%) |
| T allele presence | 30 (63.8%) | 52 (68.4%) |
| Assumptions | Justification |
| 66.45% of standard care monitoring occurs in primary care with practice nurses | Based on previous TAR (manufacturers submission for TA256)70 |
| 60% of the cohort have atrial fibrillation, 40% have an artificial heart valve | In line with the observed proportions of patients with these conditions in self-monitoring trials68 |
| Average age of the cohort is 65 years, and 55% are male | In line with the observed mean age of included patients with these conditions in self-monitoring trials68 |
| 50% of self-monitoring people self-test, 50% self-manage | Self- assumption |
| The increase in the number of tests performed per year with self-monitoring is 23 | In line with the observed frequency of self-testing in self-monitoring trials68 |
| Relative treatment effects are estimated and applied separately for self-testing and self-management | Derived from the observed event rates in cohorts of people being managed under current standard models of care. Relative risks of these events resulting from improved/reduced INR control, conferred by self-monitoring, were derived from the meta-analysis of RCTs of self-monitoring versus standard practice. (see section on clinical effectiveness results) |
| 15% of participants do not commence self-monitoring following training | Based on the RCT literature43 and the expert advisory committee consultation |
| 10% of participants discontinue self-monitoring within a year of commencing | Based on consideration of the views of the expert advisory committee (∼5%) and a rate of 14% reported in the largest UK-based trial.43 |
| Self-monitoring device costs are annuitized over 5 years to account for the potential for loss and accidental damage | It was assumed that the NHS would pay for devices and loan them out to patients. As such they were annuitized over their expected useful life, to provide an equivalent annual/quarterly cost of use |
| 75% of devices are reused by another patient when a patient discontinues self-monitoring | In line with a previous UK-based economic evaluation71 |
| HR (95% CI) | P | |
| ABDC treatment | 3.63 (1.57-8.34) | 0.003 |
| Candida spp. load until day 5 | 1.19 (0.70-2.02) | 0.51 |
| Candida spp. load after day 5 | 0.67 (0.31-1.47) | 0.32 |
| Duration of colonization until day 5 | 0.96 (0.90-1.02) | 0.13 |
| Duration of colonization after day 5 | 0.92 (0.88-0.96) | <0.001 |
| CPIS day 7 | 0.91 (0.76-1.10) | 0.32 |
| LIS day 7 | 0.60 (0.40-0.91) | 0.02 |
| Clinical Features | Colombia | Mexico | Latinos USA (NLAAS) | USA(NCS-R) | ||||
| n¥ | %(95%CI)* | n¥ | %(95%CI)* | n¥ | %(95%CI)* | n¥ | %(95%CI)* | |
| Recurrent hazard-laden smoking | 9 | 3 (1, 5) | 7 | 3 (<1, 5) | 15 | 6 (3, 9) | 59 | 3 (2, 4) |
| Social problems | 13 | 5 (2, 7) | 8 | 3 (<1, 5) | 5 | 2 (<1, 3) | 27 | 1 (1, 2) |
| Continued smoking despite experiencing these problems‡ | 9 | 4 (1, 6) | 6 | 2 (<1, 4) | 4 | 2 (<1, 3) | 22 | 1 (1, 2) |
| Work problems | 8 | 2 (<1, 4) | 6 | 2 (<1, 4) | 5 | 1 (<1, 3) | 24 | 1 (<1, 2) |
| Legal problems | 6 | 2 (<1, 4) | 3 | 1 (<1, 2) | Not available** | 5 | Not estimated |
| Persistent Organic Pollutants | ∆ cMetS Score | Relative Change of Glucose (%) | Relative Change of HDL−c (%) | Relative Change of TG (%) | Relative Change of SBP (%) | Relative Change of DBP (%) | ||||||||||||
| β | 95% CI | β | 95% CI | β | 95% CI | β | 95% CI | β | 95% CI | β | 95% CI | |||||||
| PCB 52 | 0.64 a | 0.21 | 1.07 | 1.91 | −0.46 | 4.29 | −0.21 | −2.74 | 2.33 | 2.66 | 0.05 | 5.26 | 0.45 | −1.42 | 2.32 | 2.05 | −0.55 | 4.65 |
| PCB 101 | 0.40 | −0.03 | 0.82 | −0.13 | −2.46 | 2.19 | 0.09 | −2.36 | 2.54 | 1.52 | −1.03 | 4.07 | 0.09 | −1.72 | 1.90 | 0.86 | −1.68 | 3.40 |
| PCB 118 | 0.56 | −0.08 | 1.20 | 1.06 | −2.45 | 4.56 | 0.20 | −3.50 | 3.91 | 2.01 | −1.84 | 5.86 | 0.15 | −2.58 | 2.89 | 2.93 | −0.87 | 6.74 |
| PCB 138 | 0.31 | −0.17 | 0.80 | −0.50 | −3.13 | 2.12 | −0.08 | −2.85 | 2.70 | 0.59 | −2.30 | 3.48 | 0.71 | −1.32 | 2.75 | 3.01 a | 0.20 | 5.82 |
| PCB 153 | 0.14 | −0.23 | 0.50 | 0.21 | −1.76 | 2.18 | 0.86 | −1.21 | 2.93 | 0.14 | −2.03 | 2.31 | 0.95 | −0.57 | 2.48 | 2.33 a | 0.21 | 4.45 |
| PCB 156 | 0.22 | −0.31 | 0.76 | −1.77 | −4.64 | 1.11 | −1.90 | −4.93 | 1.14 | 0.63 | −2.55 | 3.82 | 1.43 | −0.80 | 3.67 | 2.76 | 0.35 | 5.88 |
| PCB 180 | 0.25 | −0.14 | 0.63 | 1.03 | −1.04 | 3.10 | −0.52 | −2.71 | 1.67 | 1.35 | −0.93 | 3.63 | 1.36 | −0.25 | 2.97 | 2.05 | −0.20 | 4.30 |
| ΣPCB | 0.60 | −0.04 | 1.24 | −0.58 | −4.02 | 2.85 | −0.84 | −4.55 | 2.87 | 3.66 | −0.15 | 7.47 | 1.22 | −1.49 | 3.93 | 4.84 a | 1.11 | 8.57 |
| Marker PCB | 0.51 | −0.11 | 1.12 | −0.81 | −4.10 | 2.49 | −0.34 | −3.91 | 3.22 | 3.71 a | 0.05 | 7.36 | 1.54 | −1.06 | 4.15 | 4.44 a | 0.85 | 8.03 |
| Dioxin-like PCB | 0.09 | −0.50 | 0.68 | −2.24 | −5.39 | 0.91 | −0.49 | −3.91 | 2.93 | 0.72 | −2.81 | 4.25 | 0.72 | −1.78 | 3.23 | 3.01 | −0.46 | 6.48 |
| HCB | 0.13 | −0.10 | 0.36 | −1.22 | −2.46 | 0.01 | 0.49 | −0.83 | 1.81 | 1.09 | −0.27 | 2.46 | 0.18 | −0.80 | 1.15 | 0.49 | −0.88 | 1.85 |
| trans-Nonachlor | −0.09 | −0.61 | 0.43 | −0.84 | −3.65 | 1.96 | 1.25 | −1.71 | 4.20 | 0.19 | −2.90 | 3.28 | −0.26 | −2.43 | 1.91 | 1.83 | −1.20 | 4.86 |
| β-HCH | −0.13 | −0.45 | 0.19 | 0.65 | −1.10 | 2.39 | 1.91 a | 0.09 | 3.74 | −1.13 | −3.05 | 0.79 | 0.20 | −1.16 | 1.57 | 1.05 | −0.86 | 2.95 |
| p,p’-DDT | 0.03 | −0.58 | 0.64 | 1.28 | −1.99 | 4.56 | 2.11 | −1.34 | 5.56 | −0.31 | −3.93 | 3.30 | −0.15 | −2.72 | 2.41 | 1.70 | −1.89 | 5.28 |
| p,p’-DDE | −0.01 | −0.40 | 0.37 | 0.94 | −1.14 | 3.01 | 2.03 | −0.15 | 4.20 | −0.88 | −3.17 | 1.41 | 0.30 | −1.31 | 1.92 | 1.61 | −0.64 | 3.87 |
| ECW | ECS | ECT | NW | |
| ECW | 1 | 0.33 | ||
| ECS | 1 | 1 | 0.33 | |
| ECT | 1 | 1 | 1 | 0.33 |
| Crude plant extracts | LC50 | ||
| 6 hrs | 12 hrs | 24 hrs | |
| HE I | — | 3943 | 3880 |
| CE I | 2836 | 183 | 2 |
| ME I | 2840 | 183 | 16 |
| CE II | 2836 | 542 | 79 |
| BE II | 2840 | 545 | 194 |
| groups | Rhizoma Coptidis | Radix Scutellariae | Cortex Phellodendri | Fructus Gardeniae |
| F1 | 3 | 2 | 2 | 3 |
| F2 | 6 | 2 | 2 | 3 |
| F3 | 3 | 4 | 4 | 6 |
| F4 | 3 | 4 | 2 | 12 |
| F5 | 3 | 2 | 8 | 6 |
| F6 | 3 | 8 | 4 | 3 |
| F7 | 12 | 4 | 8 | 3 |
| F8 | 6 | 1 | 2 | 6 |
| F9 | 6 | 4 | 1 | 3 |
| Reagent | AS | DRG | LB | KOH | NP/PEG | |
| Metabolites | Terpenes and steroids | Alkaloids | Triterpenes and steroids | Coumarins and anthraquinones | Flavonoids andphenolic acids | Saponins |
| L. origanoides leaves | ||||||
| HEFL | ++ | − | + | + | + | − |
| DIFL | + | − | + | + | + | − |
| EAFL | + | − | + | − | ++ | + |
| AQFL | + | − | + | − | + | + |
| L. origanoides stems | ||||||
| HEFS | ++ | − | + | + | − | − |
| DIFS | + | − | + | − | + | − |
| EAFS | + | − | + | − | ++ | + |
| AQFS | + | − | + | − | + | + |
| Variable | Patients with vascular events (n = 7) | Patients without vascular events(n = 83) |
| Age (years), median (IQR) | 47 (31–62) | 50 (40–62) |
| Males, n (%) | 4 (57.1%) | 43 (51.8%) |
| Personal history VTE, n (%) | 1 (14.3%) | 6 (7.2%) |
| Family history VTE, n (%) | 1 (14.3%) | 7 (8.4%) |
| Unprovoked SVT, n (%) | 2 (28.6%) | 31 (37.4%) |
| Liver cirrhosis, n (%) | 3 (42.9%) | 11 (13.3%) |
| Solid cancer, n (%) | 0 (0%) | 6 (7.2%) |
| Myeloproliferative neoplasm, n (%) | 1 (14.3%) | 6 (7.2%) |
| Recent abdominal surgery, n (%) | 0 (0%) | 10 (12.1%) |
| Hormonal therapy, n (%)* | 1 (33.3%) | 10 (25.0%) |
| Inflammatory bowel disease, n (%) | 0 (0%) | 5 (6.0%) |
| JAK2 V617F mutation, n (%)** | 1 (20.0%) | 2 (5.4%) |
| Factor V Leiden or prothrombin G20210A mutation, n (%)** | 1 (20.0%) | 8 (16.0%) |
| Previous VKA treatment duration (months), median (IQR) | 9.9 (3.2–12.9) | 12.7 (7.2–24.0) |
| Time within therapeutic range (%), median (IQR) | 68 (67–80) | 62 (56–75) |
| Antiplatelet therapy during follow-up, n (%) | 2 (28.6%) | 12 (14.5%) |
| Tests | Patient’s data | Units | Reference ranges |
| Cortisol dynamic | 1 (confirmed twice) | nmol/L | |
| ACTH | 46.2 | pg/mL | <46.0 |
| Na+ | 134 | mmol/L | 136 to 145 |
| K+ | 4.1 | mmol/L | 3.3 to 4.8 |
| Cl- | 112 | mmol/L | 98 to 108 |
| Urea | 52 | mg/dL | 12 to 40 |
| Creatinine | 2.4 | mg/dL | 0.7 to 1.2 |
| Ca2+ | 9.3 | mg/dL | 8.9 to 10.2 |
| Random glucose | 119 | mg/dL | |
| Magnesium | 2.49 | mg/dL | 1.7 to 2.55 |
| ALT | 5 | g/dL | 0 to 41 |
| AST | 24 | U/L | 0 to 40 |
| Alkaline phosphatase | 53 | U/L | 40 to 129 |
| Albumin | 3.4 | g/dL | 3.4 to 4.8 |
| Total bilirubin | 0.3 | mg/dL | 0 to 1.0 |
| Tissue transglutaminase | 2.7 | U/mL | <15 |
| T4 | 10.6 | pmol/L | 11.5 to 22.7 |
| T3 | 2.7 | pmol/L | 3.5 to 6.5 |
| TSH | 10.61 | μIU/mL | 0.55 to 4.78 |
| ATG | 82.5 | IU/mL | <100 |
| ATPO | 670.7 (+ve) | IU/mL | <50 |
| Anti-adrenal antibodies | Negative | <1:10 | |
| Blood culture | Negative | ||
| Urine culture | Negative | ||
| Stool culture | Negative |
| Variable | Company | Prestudy period(n = 166/133)c | Study period(n = 174/144)c | Age-adjusted HR(95% CI) | HR adjusted modeld(95% CI) | ||
| Number | Incidence | Number | Incidence | ||||
| Acute injuries, all | Int | 83 | 3.37 | 60 | 2.47 | 0.77 (0.42 to 1.39) | 0.79 (0.41 to 1.51) |
| Ctrl | 58 | 3.63 | 63 | 3.21 | |||
| Lower extremity | Int | 53 | 2.15 | 32 | 1.32 | 0.84 (0.40 to 1.78) | 0.86 (0.38 to 1.92) |
| Ctrl | 39 | 2.44 | 38 | 1.94 | |||
| Knee | Int | 22 | 0.89 | 20 | 0.82 | 1.05 (0.37 to 2.99) | 1.48 (0.46 to 4.81) |
| Ctrl | 13 | 0.81 | 14 | 0.71 | |||
| Ankle | Int | 20 | 0.81 | 5 | 0.21 | 0.23 (0.06 to 0.85) | 0.17 (0.04 to 0.68) |
| Ctrl | 9 | 0.56 | 17 | 0.87 | |||
| Upper extremity | Int | 14 | 0.57 | 14 | 0.58 | 1.04 (0.30 to 3.62) | 0.93 (0.24 to 3.56) |
| Ctrl | 10 | 0.63 | 8 | 0.41 | |||
| Total number of off-duty dayse | Int | 303 | 12.3 | 203 | 8.4 | 0.69 (0.26 to 1.82) | 0.64 (0.23 to 1.79)f |
| Ctrl | 198 | 12.4 | 217 | 11.1 | |||
| Discharged from military serviceg | Int | 17 | 0.69 | 13 | 0.54 | 0.68 (0.24 to 1.97) | 0.72 (0.24 to 2.12)f |
| Ctrl | 11 | 0.69 | 15 | 0.76 | |||
| Follow-up days | |||||||
| Int | 24,599 | 24,292 | |||||
| Ctrl | 15,963 | 19,628 |
| Food item | Adjusted OR* (95 % CI) | P value |
| Cold appetizer—pork liver | 3.23 (1.26–8.30) | 0.01 |
| Lamb chops, carrots, radish wrapped in lotus leaves | 3.98 (1.74–9.11) | 0.001 |
| Diet | Echolocation Call Type | Bat Species |
| Fruits | Broadband clicks of short duration | Egyptian fruit bat |
| Moths, beetles, flies and other insects | Narrowband with dominant fundamental harmonic | Eastern red bat |
| Flying insects and small fruits | Multiharmonic narrowband, faintly audible to humans | Black-bearded tomb bat |
| Aquatic insects like midges, crane flies and black flies | Short, broadband, with dominant fundamental harmonic | Daubenton’s bat |
| Large insects, spiders and small vertebrates | Short, multiharmonic broadband | Greater false vampire bat |
| Moths | Long, multiharmonic broadband | Madagascar sucker-footed bat |
| Butterfly, moths and beetles | Constant frequency (CF) & Frequency Modulated (FM) | Greater horseshoe bat |
| Beetles, moths, flies, wasps, and flying ants | Downswept FM narrowband | Big brown bat |
| Beetles, moths, flies, and small insects | FM broadband | Townsend’s big-eared bat |
| Control | Mild | Moderate to severe | |
| (n = 6) | (n = 10) | (n = 10) | |
| PMN (%) | 10.6 ± 1.7 | 3.8 ± 1.7 | 18.6 ± 11.3 |
| Lymph (%) | 2.5 ± 0.5 | 2.3 ± 0.8 | 3.4 ± 1.5 |
| Macrophage (%) | 85 ± 21 | 93.8 ± 2.3 | 68 ± 21 |
| Variables | Univariate | Multivariate | ||
| P value | P value | OR (95% CI) | ||
| Control group | ||||
| Age, y | 0.041 | 0.125 | ||
| Female sex | 0.463 | |||
| AF duration, months | 0.008 | 0.016 | 1.013 (1.002–1.023) | |
| NYHA class | 0.094 | 0.130 | ||
| Diabetes | 0.127 | 0.394 | ||
| Hypertension | 0.250 | |||
| LAD, mm | 0.114 | 0.246 | ||
| Long duration group | ||||
| Age, y | 0.594 | |||
| Female sex | 0.424 | |||
| AF duration, months | 0.064 | 0.049 | 1.007 (1.001–1.013) | |
| NYHA class | 0.397 | |||
| Diabetes | 0.205 | 0.084 | ||
| Hypertension | 0.044 | 0.008 | 1.062 (1.016–1.110) | |
| LAD, mm | 0.310 |
| No. | Name | Country | Year | Accession Number |
| 1 | CH-1a | China | 1996 | AY032626 |
| 2 | BJ-4 | China | 2000 | AF331831 |
| 3 | HB-1(sh)/2002 | China | 2002 | AY150312 |
| 4 | JXA1 | China | 2006 | EF112445 |
| 5 | HUB2 | China | 2006 | EF112446 |
| 6 | HuN4 | China | 2007 | EF635006 |
| 7 | SY0608 | China | 2007 | EU144079 |
| 8 | CH-1R | China | 2008 | EU807840 |
| 9 | HB-1 | China | 2008 | EU360130 |
| 10 | WUH4 | China | 2011 | JQ326271 |
| 11 | QYYZ | China | 2011 | JQ308798 |
| 12 | SD16 | China | 2012 | JX087437 |
| 13 | JXA1-R | China | 2012 | JQ804986 |
| 14 | HEB-2013 | China | 2013 | KJ591659 |
| 15 | HB-XL | China | 2013 | KP162169 |
| 16 | LMY | South Korea | 2002 | DQ473474 |
| 17 | VR-2332 | USA | 1992 | AY150564 |
| 18 | EuroPRRSV | USA | 1999 | AY366525 |
| 19 | RespPRRS MLV | USA | 1994 | AF066183 |
| 20 | Lelystad virus | Europe | 1991 | M96262 |
| No | SSR | Africa | Asia | Central America | South America |
| 1 | Jc01 A | 0.09 | 0.02 | 0.39 | 0.15 |
| 2 | Jc01 B | 0.10 | 0.00 | 0.19 | 0.15 |
| 3 | Jc01 C | 0.12 | 0.02 | 0.33 | 0.15 |
| 4 | Jc03 A | 0.00 | 0.00 | 0.46 | 0.00 |
| 5 | Jc05 A | 0.00 | 0.00 | 0.42 | 0.00 |
| 6 | Jc07 B | 0.00 | 0.08 | 0.65 | 0.00 |
| 7 | Jc08 A | 0.00 | 0.00 | 0.26 | 0.00 |
| 8 | Jc09 A | 0.05 | 0.00 | 0.63 | 0.15 |
| 9 | Jc10 A | 0.00 | 0.00 | 0.06 | 0.00 |
| 10 | Jc10 B | 0.00 | 0.00 | 0.35 | 0.00 |
| 11 | Jc13 A | 0.09 | 0.00 | 0.56 | 0.15 |
| 12 | Jc14 B | 0.00 | 0.08 | 0.65 | 0.00 |
| 13 | Jc17 A | 0.37 | 0.38 | 0.37 | 0.37 |
| 14 | Jc28 A | 0.00 | 0.00 | 0.54 | 0.00 |
| Sensitivity (95% CI) | Specificity (95% CI) | Positive predictive value (95% CI) | Negative predictive value (95% CI) | |
| GBS>0 | 100 (87.7–100) | 0 (0–2.9) | 18.3 (12.5–25.4) | - |
| PRS >0 | 100 (87.7–100) | 12 (6.9–19) | 20.3 (13.9–28) | 100 (78.2–100) |
| CRS >2 | 96.4 (81.7–99.9) | 20 (13.4–28.1) | 21.3 (14.5–29.4) | 96.2 (80.4–99.9) |
| CSMCPI ≥5 | 53.6 (33.9–72.5) | 60.8 (51.7–69.4) | 23.4 (13.8–35.7) | 85.4 (76.3–92) |
| Dataset | DB size | Prior | Posterior | MetAssign | mzMatch | CAMERA |
| std1.NEG | 100 | 0.93 | 0.93 | 0.90 | 0.68 | 0.17 |
| 600 | 0.71 | 0.74 | 0.81 | 0.56 | 0.16 | |
| 1000 | 0.57 | 0.63 | 0.76 | 0.49 | 0.16 | |
| std1.POS | 100 | 0.80 | 0.79 | 0.73 | 0.53 | 0.15 |
| 600 | 0.42 | 0.48 | 0.55 | 0.34 | 0.13 | |
| 1000 | 0.29 | 0.38 | 0.50 | 0.27 | 0.13 | |
| std2.NEG | 100 | 0.90 | 0.88 | 0.83 | 0.61 | 0.11 |
| 600 | 0.64 | 0.67 | 0.70 | 0.47 | 0.11 | |
| 1000 | 0.52 | 0.58 | 0.65 | 0.40 | 0.11 | |
| std2.POS | 100 | 0.85 | 0.85 | 0.83 | 0.66 | 0.10 |
| 600 | 0.35 | 0.44 | 0.52 | 0.32 | 0.09 | |
| 1000 | 0.24 | 0.34 | 0.44 | 0.24 | 0.08 | |
| std3.NEG | 100 | 0.66 | 0.67 | 0.69 | 0.39 | 0.15 |
| 600 | 0.29 | 0.35 | 0.40 | 0.21 | 0.13 | |
| 1000 | 0.22 | 0.29 | 0.34 | 0.15 | 0.13 | |
| std3.POS | 100 | 0.51 | 0.53 | 0.54 | 0.47 | 0.18 |
| 600 | 0.11 | 0.17 | 0.21 | 0.11 | 0.16 | |
| 1000 | 0.06 | 0.12 | 0.17 | 0.06 | 0.15 |
| Parameter | MEAN | STD | MIN | MAX |
| ACCX [g] | 0.09 | 0.20 | −0.95 | 0.59 |
| ACCY [g] | 0.88 | 0.17 | 0.27 | 1.99 |
| ACCZ [g] | 0.11 | 0.43 | −1.13 | 1.02 |
| Characteristic | Control (n = 62) | Template-developed (n = 68) | Bespoke user-tested (n = 63) | Total (n = 193) |
| Gender, n (%) | ||||
| Male | 24 (38.7) | 32 (47.8) | 27 (43.6) | 83 (43.5) |
| Age | ||||
| Mean (SD) | 78.3 (5.8) | 78.6 (6.6) | 77.5 (7.8) | 78.1 (6.8) |
| Fallen in previous 6 months? n (%) | ||||
| Yes | 23 (37.1) | 29 (43.3) | 27 (42.9) | 79 (41.2) |
| No | 39 (62.9) | 36 (53.7) | 36 (57.1) | 111 (57.8) |
| Don’t know | 0 (0.0) | 2 (3.0) | 0 (0.0) | 2 (1.0) |
| If fallen in previous 6 months, how many times? | ||||
| Median (min,max) | 1 (1, 5) | 1 (1, 20) | 1 (1, 6) | 1 (1, 20) |
| Worried about having a fall during the previous 4 weeks | ||||
| All of the time | 4 (6.5) | 3 (4.5) | 4 (6.4) | 11 (5.7) |
| Most of the time | 1 (1.6) | 4 (6.0) | 2 (3.2) | 7 (3.7) |
| A good bit of the time | 6 (9.7) | 3 (4.5) | 4 (6.4) | 13 (6.8) |
| Some of the time | 19 (30.7) | 13 (19.4) | 9 (14.3) | 41 (21.4) |
| A little of the time | 23 (37.1) | 27 (40.3) | 29 (46.0) | 79 (41.2) |
| None of the time | 9 (14.5) | 17 (25.4) | 15 (23.8) | 41 (21.4) |
| Short Falls Efficacy Scale – International (FES-I)a | ||||
| Mean (SD) | 13.1 (5.0) | 11.7 (4.3) | 12.1 (4.5) | 12.3 (4.7) |
| Frenchay Activities Index (FAI)a | ||||
| Mean (SD) | 47.2 (6.7) | 46.5 (7.2) | 46.4 (7.1) | 46.6 (7.0) |
| Non-vertex n/N, (%) N = 369 | Vertex n/N, (%) 1,055 | Crude odds ratio (95% CI) | Adjusted odds ratioa (95% CI) | |
| Maternal death | 0/369 (0.0) | 1/1055 (0.1) | * | * |
| ICU admission | 17/369 (4.6) | 18/1055 (1.7) | 2.78 (1.42 – 5.45) | 1.30 (0.88 – 1.94) |
| Blood transfusion | 22/369 (6.0) | 35/1055 (3.4) | 1.84 (1.07 – 3.18) | 1.23 (0.67 – 2.25) |
| Hysterectomy | 0 / 369 (0.0) | 0/1055 (0.0) | * | * |
| 3rd/4th degree perineal laceration | 5/369 (1.4) | 20/1055 (1.9) | 0.71 (0.27 – 1.91) | * |
| Gene Expression | Normal-Weight Control (n = 10) | Morbidly Obese (n = 30) | ||
| VAT | SAT | VAT | SAT | |
| Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD | |
| IL-6 | 2.38 ± 1.52 | 17. 07 ± 11.66 | 61.09 ± 14.13 * | 86.40 ± 28.71 * |
| Adiponectin | 0.77 ± 0.32 | 0.58 ± 0.30 | 0.53 ± 0.27 | 0.29 ± 0.17 * |
| Lipocalin-2 | 0.006 ± 0.003 | 0.029 ± 0.02 | 0.02 ± 0.01 | 0.064 ± 0.03 |
| TNFα | 0.039 ± 0.02 | 0.076 ± 0.06 | 0.26 ± 0.20 * | 0.043 ± 0.02 |
| Resistin | 0.008 ± 0.004 | 0.016 ± 0.005 | 0.030 ± 0.02 * | 0.030 ± 0.02 |
| Sample | Chemical Composition (in wt %) | ||
| Ni | Ti | Al | |
| NiTi46 | 54.0 | 46.0 | - |
| NiTiAl1 | 53.5 | 45.5 | 1.0 |
| NiTiAl3 | 52.4 | 44.6 | 3.0 |
| NiTiAl5 | 51.3 | 43.7 | 5.0 |
| NiTiAl7 | 50.2 | 42.8 | 7.0 |
| Surgical procedure classification (three-character ICD 10 code) | Number of hospital discharges | Number of adverse events (%) | Degree of disability (no. of patients) | ||||
| Sick leave ≤ 3 months | 1-15% | 16-30% | > 30% | Death | |||
| Primary prosthetic replacement of hip joint (NFB**) | 50,733 | 304 (0.6) | 18 | 259 | 22 | 4 | 1 |
| Primary prosthetic replacement of knee joint (NGB**) | 23,600 | 187 (0.8) | 12 | 163 | 9 | 2 | 1 |
| Decompression of spinal cord and nerve roots (ABC**) | 17,507 | 168 (1.0) | 12 | 120 | 12 | 22 | 2 |
| Fracture surgery of femur (NFJ**) | 68,123 | 105 (0.2) | 9 | 80 | 14 | 1 | 1 |
| Fracture surgery of ankle and foot femur (NHJ**) | 22,490 | 103 (0.5) | 8 | 92 | 2 | 2 | 0 |
| Fracture surgery of knee and lower leg (NGJ**) | 12,594 | 92 (0.7) | 5 | 84 | 3 | 0 | 0 |
| Variable | Odds ratio | Lower 95 % CI | Upper 95 % CI | P value |
| Body Area (n = 194, m = 18) | ||||
| Girth | Ref | |||
| Back | 2.56 | 1.61 | 4.07 | <0.0001 |
| Tail | 0.44 | 0.26 | 0.74 | 0.002 |
| Contact Material (n = 163, m = 18) | ||||
| Bark | Ref | |||
| Carpet | 0.52 | 0.15 | 1.79 | 0.301 |
| Blanket | 0.78 | 0.30 | 2.02 | 0.612 |
| Rice Sack | 2.10 | 0.74 | 5.96 | 0.164 |
| Saddle Weight (n = 191, m = 18) | ||||
| Light (<10 kg) | Ref | |||
| Heavy (>10 kg) | 0.65 | 0.21 | 2.03 | 0.458 |
| Break** (n = 194 , m = 18) | ||||
| No | Ref | |||
| Yes | 0.54 | 0.18 | 1.67 | 0.286 |
| Age (n = 133, m = 17) | ||||
| 1.03 | 1.002 | 1.05 | 0.034 | |
| Working Hours/Day (n = 194, m = 18) | ||||
| Working Hours/Day | 3.79 | 1.41 | 10.18 | 0.008 |
| Working Hours/Day Squared | 0.90 | 0.83 | 0.97 | 0.009 |
| Simulation Parameters | Value |
| map dimension | 2 km × 1.5 km |
| Simulation time | 1000 sec |
| Vehicle speed | 0–15 m/s |
| Velocity threshold | 7 m/s |
| MAC/PHY | IEEE 802.11p |
| Vehicle density | 100–500 |
| Route generator | SUMO |
| HFNO group | Venturi mask group | P value | |
| (n = 52) | (n = 48) | ||
| Primary endpoint | |||
| Number (%) of patients requiring mechanical ventilation | 8 (15 %) | 4 (8 %) | 0.36 |
| Noninvasive mechanical ventilation | 6a | 3a | |
| Invasive mechanical ventilation | 4 | 2 | |
| Secondary endpoints, median [25th–75th percentile] | |||
| Discomfort VAS scoreb at 120 min | 3 [1–5] | 3 [0–5] | 0.88 |
| Dyspnea VAS scoreb at 120 min | 3 [2 – 6] | 3 [1–6] | 0.87 |
| Thirst VAS scoreb at 120 min | 6 [3–8] | 6 [5 – 9] | 0.40 |
| Respiratory rate at 120 min, breaths/min | 25 [22–29] | 25 [21–31] | |
| Heart rate at 120 min, beats/min | 98 [90–110] | 99 [83–112] | 0.43 |
| Gene-set ID | Gene-set Description | Gene N# |
| hi015 | Predicted haploinsufficiency (most inclusive) | 8862 |
| hi035 | Predicted haploinsufficiency | 4136 |
| hi055 | Predicted haploinsufficiency (most stringent) | 2214 |
| ExpsNov_BrainFeAd_sp | Specific expression in human adult or fetal brain (Novartis Tissue Atlas) | 1285 |
| Synapse_GrantFull | Post-synaptic density components | 1407 |
| FMR1_Targets_Darnell | FMR1 targets (Darnell et al) | 840 |
| FMR1_Targets_Ascano | FMR1 targets (Ascano et al) | 927 |
| thrEXPR_log2rpkm | Expressed in brain (BrainSpan) | 13802 |
| thr4.86_log2rpkm | Expressed in brain, very high (BrainSpan) | 4595 |
| thr3.32_log2rpkm | Expressed in brain, high/medium (BrainSpan) | 4604 |
| thr0.84_log2rpkm | Expressed in brain, medium/low (BrainSpan) | 4603 |
| thr.MIN_log2rpkm | Not expressed in brain (BrainSpan) | 4600 |
| PhHs_NervSys_ADX | Human nervous system phenotype (HPO), autosomal dominant or X-linked | 620 |
| PhHs_NervSys_All | Human nervous system phenotype (HPO) | 784 |
| PhHs_MindFun_ADX | Higher mental function phenotype (HPO), autosomal dominant or X-linked | 395 |
| PhHs_MindFun_All | Higher mental function phenotype (HPO) | 687 |
| MmHs_Neuro_All | Mouse neuro phenotype (MGI/MPO) | 3479 |
| MmHs_Extend_All | Mouse developmental phenotype (MGI/MPO) | 4314 |
| NeuroF_large | Neurobiological function, inclusive | 2601 |
| NeuroF_small | Neurobiological function, stringent | 1088 |
| Total | Total gene count | 18203 |
| P1 | N1 | P2 | ||||
| Latency (ms) | Amplitude (microvolts) | Latency (ms) | Amplitude (microvolts) | Latency (ms) | Amplitude (microvolts) | |
| Older nonmusicians | 65 (8) | 2.02 (1.1) | 104 (10) | −0.02 (0.95) | 171 (15) | 2.0 (1.4) |
| Older musicians | 61 (8) | 2.24 (0.8) | 109 (12) | 0.27 (1.1) | 174 (15) | 1.69 (1.0) |
| Younger musicians | 74 (10) | 1.84 (0.75) | 105 (11) | 0.21 (0.88) | 147 (10) | 2.21 (1.1) |
| Younger nonmusicians | 74 (10) | 2.00 (0.76) | 103 (11) | 0.199 (1.2) | 146 (11) | 2.43 (0.81) |
| Variable | Time Period 1: April 6-May 5 | Time period 2: Aug 4- Sept 2 | Time period 3: Oct 3-Nov 1 | Total | |||
| Cluster 1 | Outside cluster 1 | Cluster 2 | Outside cluster 2 | Cluster 3 | Outside cluster 3 | All cases 2010 | |
| Number of Cases | 62 | 36 | 58 | 54 | 17 | 49 | 1,134 |
| % Male | 42% | 44% | 40% | 54% | 53% | 49% | 52% |
| Age in months (median, IQR) | 13 (7,32) | 24 (12,55) | 9 (6, 57) | 9 (6, 33) | 12 (7,64) | 13 (7,43) | 12 (7,29) |
| HIV infection status | |||||||
| Infected | 2 (3%) | 0 (0%) | 1 (2%) | 6 (11%) | 3 (18%) | 3 (6%) | 41 (4%) |
| Exposed | 4 (7%) | 3 (8%) | 10 (18%) | 6 (11%) | 2 (12%) | 5 (10%) | 100 (9%) |
| Not infected | 51 (84%) | 33 (92%) | 39 (70%) | 38 (72%) | 11 (65%) | 33 (67%) | 905 (80%) |
| Unknown | 4 (7%) | 0 (0%) | 6 (11%) | 3 (6%) | 1 (6%) | 8 (16%) | 80 (7%) |
| Measles vaccination status | |||||||
| Vaccinated | 16 (26%) | 8 (22%) | 10 (18%) | 8 (15%) | 2 (12%) | 8 (16%) | 221 (20%) |
| Not Vaccinated | 36 (58%) | 21 (58%) | 31 (54%) | 31 (59%) | 8 (47%) | 25 (51%) | 618 (55%) |
| Unknown | 10 (16%) | 7 (19%) | 16 (28%) | 14 (26%) | 7 (41%) | 16 (33%) | 286 (25%) |
| Performance objectives | Determinants | |
| Information/knowledge | Self-efficacy/skills | |
| To own LLINs | Explain the benefits of LLINs ownership | Demonstrate how a net should be used |
| To fight bedbugs | Explain the importance of fighting bedbugs as hindrances of LLINs use | Demonstrate how the technique should be done using hot water and local laundry powder soap (OMO) |
| To use LLINs every night | Explain the importance of using LLINs every night | Use of LLINs in spite of warm weather or weather changes |
| To allow IRS at household level | Describe IRS benefits | Allow IRS in master roomAllow IRS in storage rooms |
| To cover households water collection instruments | Explain how water collection instruments can be a source of mosquito breeding. | Cover water collection instruments every time |
| To clear mosquito breeding sites surrounding homesteads | Explain the importance of clearing water pits and bushes surrounding the homesteads | Perform regular cleaning activities at household level |
| To own a health insurance | Describe the importance of a health insurance in prompt health care-seeking | Participate in solidarity groups to enable regular contribution |
| To provide education on malaria symptoms | Describe common malaria symptoms | Identify common malaria symptoms |
| To promote early fever/malaria care-seeking (within 24 h) | Describe the importance of early care-seeking | Take a decision of seeking care promptly |
| To raise community awareness on the importance of diagnostic test before treatment | Describe the importance of a lab confirmed treatment for proper care and prevention of treatment resistance | Seek care at health facility (health centre/hospital) |
| To raise community awareness on the importance of malaria medication compliance | Describe the importance of treatment compliance to prevent disease relapse and treatment resistance | Adhere to the advice/treatment provided |
| To ensure proper training before implementation of larval source control | To provide knowledge on mosquito reproduction, malaria preventive measures and larval source control using biological substances | Attend onsite practical training |
| To adhere to the implementation plan | Discuss how larval source control will be implementedTo explain the use of reporting formats | Participate in actual implementation of larval source control |
| NA added (μmol L-1) | NA found (μmol·L-1) | RSD (%) | Recovery (%) | Mean (%) |
| 10.00 | 9.832 | 3.4 | 98.3 | 101.8 |
| 40.00 | 41.03 | 2.1 | 102.6 | |
| 50.00 | 52.23 | 2.7 | 104.5 | |
| 70.00 | 69.42 | 1.9 | 99.2 | |
| 90.00 | 93.78 | 2.9 | 104.2 |
| Company | Founded | Guidance and usage |
| EDAP TMS | 1979 | US |
| SonaCare Medical (previously US-HIFU, International HIFU and Focus Surgery) | 1997 | US |
| Chongqing HAIFU | 1999 | Both |
| China Medical | 1999 | US |
| Insightec | 1999 | MR |
| Image Guided Therapy | 2001 | MR—animals |
| Shanghai A&S | 2001 | Both |
| Mirabilis | 2004 | US |
| Theraclion | 2004 | US |
| Medsonic | 2005 | MR |
| Philips Healthcare | 2005 | MR |
| Supersonic Imagine | 2005 | Both |
| Profound | 2008 | MR |
| EyeTechCare | 2008 | Visual |
| Alpinion | 2008 | US |
| International Cardio Corporation | 2009 | US |
| Kona Medical | 2009 | US |
| Histosonic | 2009 | US |
| FUS instruments | 2009 | MR—animals |
| Acublate | 2010 | Both |
| Complex | H-bond/vdW contact AH..B/A..B | E(2), kcal/mol | Cstr, Å/mDyn |
| 1 | C1H...O2 | 0.36 | 39.549 |
| 2 | C1H...N3 | 1.00 | 22.928 |
| 3 | C1H...O2 | 0.76 | 37.566 |
| C1H...N3 | 0.03 | 33.407 | |
| 8 | C1H...N3 | 3.53 | 11.200 |
| 9 | C6H...O2 | 3.27 | 16.085 |
| C5H..N3 | 0.55 | 66.521 | |
| C1H...O2 | 1.00 | 27.809 | |
| 10 | C1H...O2 | 0.29 | 126.112 |
| C1H...N3 | 0.74 | 43.476 | |
| C6H...O2 | 3.98 | 11.659 |
| Nomenclature | rs | Nucleotide changes | Effect | n | Genotype frequencies, % | Allele frequencies, % | |||
| wt | ht | vt | p | q | |||||
| CYP2C8*2 | rs11572103 | T805A | I269F | 383 | 99.22 | 0.78 | 0.00 | 99.61 | 0.39 |
| CYP2C8*3 | rs11572080+ rs10509681 | G416A+ A1196G | R139K + K399R | 390 | 83.85 | 15.64 | 0.51 | 91.67 | 8.33 |
| CYP2C9*2 | rs1799853 | C430T | R144C | 391 | 79.54 | 20.20 | 0.26 | 89.64 | 10.36 |
| CYP2C9*3 | rs1057910 | A1075C | I359L | 394 | 81.22 | 17.77 | 1.02 | 90.10 | 9.90 |
| CYP2C19*2 | rs4244285 | G681A | Splicing defect | 393 | 58.52 | 39.19 | 2.29 | 78.12 | 21.88 |
| CYP2C19*3 | rs4986893 | G636A | W212X | 388 | 97.94 | 2.06 | 0.00 | 98.97 | 1.03 |
| CYP3A4*1B | rs2740574 | A-392 G | 5'NTO change | 389 | 94.86 | 5.14 | 0.00 | 97.43 | 2.57 |
| CYP3A4*2 | rs55785340 | T664C | S222P | 391 | 100.00 | 0.00 | 0.00 | 100.00 | 0.00 |
| CYP3A5*3 | rs776746 | A6986G | R487C | 392 | 0.26 | 11.99 | 87.76 | 6.25 | 93.75 |
| CYP2B6*5 | rs3211371 | C1459T | Splicing defect | 390 | 85.64 | 12.56 | 1.79 | 91.92 | 8.08 |
| Patients with anti-C1q autoantibodies | Patients without anti-C1q autoantibodies | r value(P value) | Patients with levels of C1q above 40.97 μg/ml | Patients with levels of C1q under 40.97 μg/ml | r value(P value) | |
| Median(range) | Median(range) | Median(range) | Median(range) | |||
| Histopathological data | ||||||
| Activity Indices score | 9(0,19) | 7(0,16) | 0.238(<0.001) | 4(0,19) | 9(0,19) | −0.327(<0.001) |
| Endocapillary hypercellularity | 3(0,3) | 2(0,3) | 0.249(<0.001) | 3(0,3) | 1(0,3) | −0.337(<0.001) |
| Cellular crescents | 2(0,6) | 0(0,6) | 0.167(0.013) | 2(0,6) | 0(0,6) | −0.182(0.007) |
| Karyorrhexis/fibrinoid necrosis | 2(0,6) | 0(0,4) | 0.175(0.009) | 2(0,6) | 0(0,2) | −0.310(<0.001) |
| Subendothelial hyaline deposits | 1(0,3) | 1(0,3) | 0.171(0.012) | 1(0,3) | 0(0,3) | −0.312(<0.001) |
| Interstitial inflammation | 1(0,3) | 1(0,3) | NS | 1(0,3) | 1(0,3) | NS |
| Leukocyte infiltration | 1(0,3) | 1(0,3) | 0.159(0.019) | 1(0,3) | 1(0,3) | −0.246(<0.001) |
| Chronicity Indices score | 2(0,9) | 2(0,10) | NS | 2(0,10) | 2(0,9) | NS |
| Glomerular sclerosis | 0(0,3) | 0(0,3) | NS | 0(0,3) | 0(0,3) | 0.146(0.031) |
| Fibrous crescents | 0(0,3) | 0(0,3) | NS | 0(0,3) | 0(0,2) | NS |
| Tubular atrophy | 1(0,3) | 1(0,3) | NS | 1(0,3) | 1(0,3) | NS |
| Interstitial fibrosis | 1(0,3) | 1(0,3) | NS | 1(0,3) | 1(0,3) | NS |
| Treatment type | IC50 values (μM) | ||
| on HepG2 cells | on A549 cells | on B16 cells | |
| Duopafei® | 0.96 ± 0.05 | 0.74 ± 0.02 | 0.72 ± 0.10 |
| DTX-micelles | 0.34 ± 0.02** | 0.44 ± 0.05* | 0.49 ± 0.08** |
| Blank micelles | 12.84 ± 0.12 | 29.62 ± 1.02 | 13.79 ± 0.24 |
| Tusablea | |||
| Algorithm | Eight | Eleven | Twelve |
| Random Tweak | 1.99 | 8.47 | 10.17 |
| CCDb | 159.46 | 511.10 | 527.77 |
| Wriggling | 5.67 | 28.50 | 22.50 |
| PLOP-build | 3.39 | 35.00 | 71.67 |
| Direct Tweak | 34.00 | 73.44 | 75.65 |
| LOOPYbb | 22.86 | 62.21 | 59.15 |
| Characteristic | Round 1 | Round 2 |
| n-size | n-size | |
| Response rate | 46 | 22 |
| Subjects | ||
| Male / Female | 30/8 | 15/6 |
| Location | ||
| Europe | 18 | 9 |
| Oceania | 8 | 5 |
| United States | 5 | 4 |
| Caribbean | 2 | 1 |
| Canada | 1 | - |
| Africa | 1 | 1 |
| South America | 1 | 1 |
| India | 1 | - |
| South East Asia | 1 | - |
| Discipline | ||
| Public health(incl.epidemiology) | 21 | 11 |
| Law (public health/social justice) | 4 | 3 |
| Geography | 3 | 2 |
| Agriculture | 2 | 2 |
| Transport | 2 | 1 |
| Policy | 1 | 1 |
| Nutrition | 1 | 1 |
| Environmental health | 1 | - |
| Planning (urban) | 2 | - |
| Economics | 1 | - |
| Sector | ||
| Academia | 22 | 10 |
| Not-for profit organisation | 3 | 3 |
| Government | 12 | 7 |
| Industry | 1 | 1 |
| Age – group | Number | (%) |
| 20 - 29 | 7 | 12.5% |
| 30 - 39 | 10 | 17.9% |
| 40 - 49 | 12 | 21.4% |
| 50 - 59 | 17 | 30.4% |
| ≥ 60 | 10 | 17.9% |
| Total | 56 | 100% |
| Mean ± SD = 44.96 ± 13.80 | Range = (21,80) | |
| SEX | Number | %age |
| Female | 50 | 89.3% |
| Male | 6 | 10.7% |
| Whole cohort | HSES | LSES | p value* | ||||
| N | Mean (SD) | N | Mean (SD) | N | Mean (SD) | ||
| Age (years) | 1343 | 8.0 (2.4) | 673 | 8.0 (2.3) | 670 | 8.1 (2.5) | 0.4 |
| Birth weight (kg) | 960 | 3.3 (0.6) | 482 | 3.2 (0.6) | 478 | 3.3 (0.6) | 0.2 |
| Maternal age (years) | 1131 | 35.0 (6.0) | 610 | 35.1 (6.1) | 521 | 35.0 (5.9) | 0.8 |
| Maternal weight (kg) | 1081 | 72.1 (12.1) | 556 | 72.5 (12.4) | 482 | 71.6 (11.9) | 0.2 |
| Maternal height (cm) | 1038 | 163.1 (8.2) | 581 | 163.5 (8.5) | 500 | 162.6 (7.9) | 0.1 |
| Maternal BMI (kg/m2) | 993 | 27.3 (5.0) | 539 | 27.3 (5.1) | 454 | 27.3 (4.9) | 0.99 |
| Child weight (kg) | 1343 | 25.3 (7.9) | 673 | 26.4 (8.4) | 670 | 24.2 (7.2) | <0.001 |
| Child height (cm) | 1343 | 124.6 (14.6) | 673 | 126.2 (14.7) | 670 | 123.0 (14.3) | <0.001 |
| Child BMI (kg/m2) | 1343 | 15.9 (2.2) | 673 | 16.2 (2.4) | 670 | 15.7 (1.9) | <0.001 |
| BMI children < 6 years | 222 | 15.5 (2.0) | 104 | 15.7 (2.2) | 118 | 15.4 (1.9) | 0.35 |
| BMI children 6–10 years | 896 | 15.7 (2.1) | 466 | 16.0 (2.3) | 430 | 15.5 (1.7) | <0.001 |
| BMI children >10 years | 225 | 17.1 (2.4) | 103 | 17.7 (2.6) | 122 | 16.7 (2.1) | 0.002 |
| Crohn's disease | Healthy controls | |
| Number (Male/Female) | 16 (7/9) | 16 (9/7) |
| Median [range] age (years) | 42 [22-66] | 33 [22-62] |
| Disease location | L1: 2 | - |
| L2: 6 | - | |
| L3: 8 | - | |
| Previous bowel resection | 6 |
| S. aureus isolate | ||||||
| Antibiotic | #1 | #2* | #6 | #18 | #19 | #20 |
| Cefazolin | 0.11 | 0.55 | 0.08 | 0.13 | 0.12 | 0.36 |
| Cefoxitin | 0.11 | 0.64 | 0.09 | 0.12 | 0.12 | 0.30 |
| Cefepime | 0.68 | 0.44 | 0.80 | 0.58 | 0.47 | 0.66 |
| Mzmax | SS | DF | RMC | F-Ratio | P-Value | Contribution (%) |
| N | 0.5677 | 2 | 0.2838 | 7.75 | 0.0010 | 4.86 |
| F | 0.4028 | 2 | 0.2014 | 5.50 | 0.0063 | 3.45 |
| B | 5.0963 | 2 | 2.5481 | 69.59 | <0.0001 | 43.67 |
| N–F | 1.3567 | 4 | 0.3392 | 9.26 | <0.0001 | 11.63 |
| N–B | 1.6521 | 4 | 0.4130 | 11.28 | <0.0001 | 14.16 |
| F–B | 0.3234 | 4 | 0.0808 | 2.21 | 0.0784 | 2.77 |
| Error | 2.2702 | 62 | 0.0366 | – | – | 19.45 |
| Corrected Total | 11.6692 | 80 | – | – | – | – |
| Background characteristics | Percent | Selected independent variables | Percent |
| Maternal age (years) | 27.3 ± 5.5* | Mode of delivery | |
| 15–24 | 38.0 | Vaginal delivery | 37.4 |
| 25–29 | 34.3 | Vaginal delivery + episiotomy | 41.3 |
| 30–34 | 16.8 | C-section | 21.3 |
| 35–51 | 11.0 | Brought infant formula to delivery room | 21.3 |
| Maternal education | Experienced breastfeeding problems | 10.6 | |
| Primary school or less | 11.4 | Received breastfeeding support from a family member | |
| Secondary school | 48.2 | During pregnancy | 31.8 |
| High school | 24.5 | During first 3 days after delivery | 31.9 |
| College or higher | 15.9 | Received breastfeeding support from a health care provider | |
| Female child | 48.0 | During pregnancy | 44.1 |
| Rural area of residence | 83.3 | During first 3 days after delivery | 31.6 |
| SES in quartiles | 25.0 | Exposure to infant feeding messages on TV in past 30 days | |
| Saw only breastfeeding information | 2.6 | ||
| Saw only infant formula advertising | 36.5 | ||
| Saw both infant formula and breastfeeding advertising | 43.3 | ||
| Saw neither message | 17.6 |
| 100,000a | |||||||
| Expected molecules target | 1,000,000 | 200,000 | 150,000 | A | B | C | 10,000 |
| Observed molecules targetb | 1,173,333 | 290,000 | 255,000 | 115,000 | 110,667 | 97,333 | 11,200 |
| SD | 161,658 | 35,000 | 91,788 | 5,000 | 9,292 | 3,055 | 2,081 |
| CV | 13.78% | 12.07% | 36% | 4.35% | 8.40% | 3.14% | 21.89% |
| Characteristics | Frequency | % | |
| Gender | Male | 230 | 57.50 |
| Female | 170 | 42.50 | |
| Level of selfitis | Borderline | 136 | 34.00 |
| Acute | 162 | 40.50 | |
| Chronic | 102 | 25.50 | |
| Age | 16 to 20 years | 224 | 56.00 |
| 21 to 25 years | 136 | 34.00 | |
| 26 to 30 years | 27 | 06.75 | |
| Above 30 years | 13 | 03.25 | |
| Number of selfies taken per day | 1 to 4 selfies | 223 | 55.75 |
| 5 to 8 selfies | 141 | 35.25 | |
| More than 8 selfies | 36 | 09.00 | |
| Number of postings per day | None | 136 | 34.00 |
| At least one time to three times | 162 | 40.50 | |
| More than three times | 102 | 25.50 |
| Baseline | Outcomes | ||||
| Measure | 1 Month | 3 Month | 6 Month | 12 Month | |
| Demographic factors | |||||
| Age, sex, race/ethnicity, educational attainment, employment status, martial/partner status, type of housing | X | ||||
| Smoking history | |||||
| Number of cigarettes per day, use of other tobacco products, use of electronic-cigarette, number of years smoking, prior quit attempt, smoker in household, home smoking policy | X | ||||
| Nicotine dependence (time to first cigarette) | X | ||||
| Previous cessation medication use | X | ||||
| Importance in ability to quit | X | ||||
| Confidence in ability to quit/stay quit | X | X | X | X | |
| Tobacco abstinence status–self-report | |||||
| Cigarette smoking status | X | X | X | X | X1 |
| Non-cigarette tobacco use status | X | X | X | X | X1 |
| Electronic-cigarette use | X | X | X | X | X1 |
| Tobacco abstinence status–biochemical validation | |||||
| Saliva cotinine or expired aired CO | X | ||||
| Quit attempt (>24 hours) | X | X | |||
| Hospital admission or emergency room visit | X | X | X | ||
| Quality of life (EQ-5D) | X | X | |||
| Anxiety and depression symptoms (PHQ-4) | X | X | X | X | |
| Alcohol use (AUDIT-C) | X | X | |||
| Other non-tobacco substance use | X | ||||
| Satisfaction with IVR | X | X | |||
| Satisfaction with Quit Coach | X | X | |||
| Smoking during index hospital stay | X | ||||
| Smoking cessation medication used after discharge | X | X | X | ||
| Smoking cessation counseling used after discharge | X | X | X | ||
| Other smoking cessation programs/resources used | X | X | X |
| Indicators Groups (IG) | Number of species per IG | Number of grid cells required to represent all species from each IG | Percentage of species represented by IG (%) | Land cost-effective by IG ($) |
| Brachycephalidae | 35 | 9 | 63 | 30,929,850 |
| Bufonidae | 33 | 9 | 59 | 30,929,850 |
| Cycloramphidae | 41 | 11 | 69 | 37,803,150 |
| Hylidae | 184 | 26 | 69 | 89,352,900 |
| Hylodidae | 33 | 13 | 65 | 44,676,450 |
| Leiuperidae | 31 | 8 | 71 | 27,493,200 |
| Leptodactylidae | 30 | 11 | 65 | 37,803,150 |
| Microhylidae | 21 | 8 | 59 | 27,493,200 |
| Locus | Fragment | PCR product length (bp) | Number of tandem repeats | ||
| Fragment analysis | Sequencing | Fragment analysis1 | Sequencing | ||
| Ms27 | 1 | 285 | 282 | 2.4 | 2.0 |
| 2 | 290 | 288 | 3.3 | 3.0 | |
| 3 | 295 | 294 | 4.2 | 4.0 | |
| Ms28 | 1 | 189 | 190 | 2.8 | 3.0 |
| 2 | 201 | 202 | 4.8 | 5.0 | |
| 3 | 207 | 208 | 5.8 | 6.0 | |
| 4 | 213 | 214 | 6.8 | 7.0 | |
| Ms34 | 1 | 107 | 112 | 1.2 | 2.0 |
| 2 | 113 | 118 | 2.2 | 3.0 | |
| 3 | 124 | 130 | 4.1 | 5.0 | |
| 4 | 136 | 142 | 6.1 | 7.0 | |
| 5 | 143 | 148 | 7.1 | 8.0 | |
| 6 | 148 | 153 | 8.1 | 9.0 | |
| Ms20b | 1 | 252 | 258 | 4.4 | 4.5 |
| 2 | 269 | 273 | 4.9 | 5.0 | |
| 3 | 349 | 354 | 7.3 | 7.5 | |
| Ms24 | 1 | 165 | 163 | 9.3 | 9.0 |
| 2 | 179 | 177 | 11.3 | 11.0 | |
| 3 | 192 | 191 | 13.1 | 13.0 | |
| 4 | 287 | 289 | 26.7 | 27.0 | |
| Ms31 | 1 | 130 | 136 | 2.1 | 3.0 |
| 2 | 145 | 150 | 4.3 | 5.0 |
| Loci | Male | Female | ||||||
| NC (%) | AITD (%) | P value | OR/95% CI | NC (%) | AITD (%) | P value | OR/95% CI | |
| rs2046068 | ||||||||
| AA | 195 (68.66) | 147 (63.09) | 0.230 | 364 (64.20) | 475 (64.02) | 0.955 | ||
| CC | 7 (2.47) | 11 (4.72) | 24 (4.23) | 34 (4.58) | ||||
| AC | 82 (28.87) | 75 (32.19) | 179 (31.57) | 233 (31.40) | ||||
| A | 472 (83.10) | 369 (79.18) | 0.108 | 0.774/0.566–1.058 | 907 (79.98) | 1183 (79.72) | 0.867 | 0.984/0.811–1.193 |
| C | 96 (16.90) | 97 (20.82) | 227 (20.02) | 301 (20.28) | ||||
| rs2227478 | ||||||||
| TT | 195 (68.66) | 148 (63.52) | 0.329 | 363 (64.02) | 474 (63.88) | 0.982 | ||
| CC | 8 (2.82) | 11 (4.72) | 24 (4.23) | 33 (4.45) | ||||
| TC | 81 (28.52) | 74 (31.76) | 180 (31.75) | 235 (31.67) | ||||
| T | 471 (82.92) | 370 (79.40) | 0.148 | 0.794/0.580–1.086 | 906 (79.89) | 1183 (79.88) | 0.901 | 0.989/0.816–1.199 |
| C | 97 (17.08) | 96 (20.60) | 228 (20.11) | 301 (20.28) | ||||
| rs2227485 | ||||||||
| CC | 76 (26.76) | 64 (27.47) | 0.880 | 170 (29.98) | 251 (33.83) | 0.171 | ||
| TT | 70 (24.65) | 53 (22.74) | 126 (22.22) | 174 (23.45) | ||||
| CT | 138 (48.59) | 116 (49.79) | 271 (47.80) | 317 (42.72) | ||||
| C | 290 (51.06) | 244 (52.36) | 0.676 | 1.054/0.825–1.346 | 611 (53.88) | 819 (55.19) | 0.505 | 1.054/0.903–1.231 |
| T | 278 (48.94) | 222 (47.64) | 523 (46.12) | 665 (44.81) | ||||
| rs1179251 | ||||||||
| CC | 119 (41.90) | 104 (44.63) | 0.449 | 235 (41.45) | 323 (43.53) | 0.048∗ | ||
| GG | 31 (10.92) | 18 (7.73) | 54 (9.52) | 97 (13.07) | ||||
| CG | 134 (47.18) | 111 (47.64) | 278 (49.03) | 322 (43.40) | ||||
| C | 372 (65.49) | 319 (68.45) | 0.314 | 1.143/0.881–1.484 | 748 (65.96) | 968 (65.23) | 0.696 | 0.968/0.823–1.139 |
| G | 196 (34.51) | 147 (31.55) | 386 (34.04) | 516 (34.77) | ||||
| rs11611206 | ||||||||
| GG | 232 (81.69) | 184 (78.97) | 0.602 | 454 (80.07) | 598 (80.59) | 0.387 | ||
| AA | 1 (0.35) | 2 (0.86) | 3 (0.53) | 9 (1.21) | ||||
| GA | 51 (17.96) | 47 (20.17) | 110 (19.40) | 135 (18.20) | ||||
| G | 515 (90.67) | 415 (89.06) | 0.391 | 0.837/0.558–1.256 | 1018 (89.77) | 1331 (89.69) | 0.946 | 0.991/0.768–1.279 |
| A | 53 (9.33) | 51 (10.94) | 116 (10.23) | 153 (10.31) |
| Biochemical category | Disease name | OMIM# | Gene(s) | Treatment | Effect | Level of evidence |
| Amino acids | PSAT deficiency | 610992 | PSAT1 (AR) | L-serine & +/−glycine supplements | Primary/targeting underlying pathophysiology | 4 |
| PSPH deficiency (Serine deficiency) | 614023 | PSPH (AR) | L-serine & +/−glycine supplements | Primary/targeting underlying pathophysiology | 4 | |
| Creatine | Arginine:glycine amidinotransferase (AGAT) deficiency | 612718 | GATM (AR) | Creatine supplements | Primary/targeting underlying pathophysiology | 4 |
| Creatine transporter deficiency | 300352 | SLC6A8 (X-linked) | Creatine, glycine, arginine supplements | Primary/targeting underlying pathophysiology | 4 | |
| Fatty acid oxidation | Carnitine palmitoyltransferase I deficiency | 255120 | CPT1A (AR) | Low-fat, high carbohydrate diet, avoid fasting, Medium Chain Triglyceride oil | Stablizilng/preventative treatment | 4 |
| Hyperhomocystinuria | Cobalamin deficiencies (e.g., C, D, E, F, G) | 251110, 277400, 277410, 236270, 277380 | MMACHC, MMADHC, MTRR, LMBRD1, MTR (AR) | Hydroxy-/cyanocobalamin (+/− diet restriction, betaine, B12) | Stabilizing/preventative treatment | 4 |
| Lipid storage (Leukodystrophy) | Cerebrotendinous xanthomatosis (CTX) | 213700 | CYP27A1 (AR) | Chenodeoxycholic acid | Stabilizing/preventative treatment | 4 |
| Organic acids | HMG-CoA lyase deficiency | 246450 | HMGCL (AR) | Protein restriction, avoid fasting, emergency regimen | Stabilizing/preventative treatment | 4-5 |
| mHMG-CoA synthase deficiency | 605911 | HMGCS2 (AR) | Avoid fasting,emergency regimen, +/−dietary precursor restriction | Stabilizing/preventative treatment | 5 | |
| SCOT deficiency | 245050 | OXCT1 (AR) | Avoid fasting, protein restriction, emergency regimen | Stabilizing/preventative treatment | 5 | |
| Urea cycle | Carbamoyl phosphate synthetase (CPS) deficiency | 237300 | CPS1 (AR) | Dietary protein restriction, arginine supplement, sodium benzoate, phenylbutyrate (Liver transplantation) | Stabilizing/preventative treatment (primary/targeting underlying pathophysiology) | 2b (4) |
| Citrullinemia type I (ASS deficiency) | 215700 | ASS1 (AR) | Dietary protein restriction, arginine supplement, sodium benzoate, phenylbutyrate (Liver transplantation) | Stabilizing/preventative treatment (primary/targeting underlying pathophysiology) | 2b (4) | |
| N-acetyl-glutamate synthetase deficiency | 237310 | NAGS (AR) | Dietary protein restriction, arginine supplement, sodium benzoate, phenylbutyrate (Liver transplantation) | Stabilizing/preventative treatment | 4 |
| Bacteria | Aligner | Bracket | P |
| n/N (%) | n/N (%) | ||
| S. mutans | |||
| Present T0 | 13/15 (87%) | 14/15 (93%) | 1.00 |
| Present T1 | 12/15 (80%) | 12/15 (80%) | 1.00 |
| Present T2 | 12/15 (80%) | 14/15 (93%) | 0.60 |
| L. acidophilus | |||
| Present T0 | 0/15 (0%) | 0/15 (0%) | NC |
| Present T1 | 0/15 (0%) | 1/15 (7%) | 1.00 |
| Present T2 | 0/15 (0%) | 1/15 (7%) | 1.00 |
| S. sanguinis | |||
| Present T0 | 15/15 (100%) | 15/15 (100%) | NC |
| Present T1 | 15/15 (100%) | 15/15 (100%) | NC |
| Present T2 | 15/15 (100%) | 15/15 (100%) | NC |
| Average percent nucleotide identity (APNI) | |||||||
| Lactobacillus plantarum strains | WJL | WCFS1 | ST-III | P-8 | NC8 | IPLA88 | plantarumF |
| ZJ316 | 98.8 | 98.9 | 98.9 | 99.1 | 98.9 | 99.2 | 98.9 |
| plantarumF | 99.3 | 99.1 | 99.3 | 98.9 | 99.9 | 99.1 | 99.0 |
| IPLA88 | 99.1 | 99.3 | 99.1 | 98.9 | 99.1 | ||
| NC8 | 99.2 | 99.1 | 99.3 | 98.9 | |||
| P-8 | 98.7 | 98.9 | 98.9 | ||||
| ST-III | 99.6 | 99.1 | |||||
| WCFS1 | 98.9 | ||||||
| Lactobacillus species | fructivoransF | fructivorans KCTC 3543 | brevisF | brevis KB290 | brevis EW | brevis ATCC 27305 | |
| brevis ATCC 14869 | 89.4 | 87.6 | 99.0 | 97.7 | 99.0 | 88.6 | |
| brevis ATCC 27305 | 87.0 | 85.3 | 91.3 | 92.2 | 90.0 | ||
| brevis EW | 89.8 | 88.8 | 98.7 | 97.6 | |||
| brevis KB290 | 88.7 | 87.4 | 97.5 | ||||
| brevisF | 89.7 | 88.3 | |||||
| fructivorans KCTC 3543 | 97.3 |
| Name gene | Oligo direct | Oligo reverse | PCR conditions | Cycle number | GeneInfo identifier |
| 18S | CTACCACATCCAAGGAAGGCA | TTTTTCGTCACTACCTCCCCG | 95°C 15 sec | 35 | 124517659 |
| 67°C 30 sec | |||||
| ERK1 | CTAAAGCCCTCCAACCTGCT | CAGCCCACAGACCAGATGT | 95°C 15 sec | 45 | 158138506 |
| 60°C 30 sec | |||||
| STAT3 | AAAGTCAGGTTGCTGGTCAAA | TGCCGTTGTTGGATTCTTC | 95°C 15 sec | 45 | 76253927 |
| 60°C 30 sec |
| Region | x | y | z | tpeak | pcorr(puncorr) | |
| TEMPORALLY STABLE EFFECTS: POST-REAL rTMS > POST-SHAM rTMS | ||||||
| Haptic S2—crossmodal: VHi | ||||||
| No significant results | ||||||
| Haptic S2—unimodal: HHi | ||||||
| No significant results | ||||||
| Visual S2—crossmodal: HVi | ||||||
| No significant results | ||||||
| Visual S2—unimodal: VVi | >haptic S2 | |||||
| L FG | −33 | −43 | −26 | 2.70 | 0.051§ | 0.289§ |
| L pIPS | −30 | −64 | 55 | 2.91 | 0.034§ | 0.192§ |
| LINEAR TIME DEPENDENT EFFECTS: POST-REAL rTMS > POST-SHAM rTMS | ||||||
| Haptic S2—crossmodal: VHi × time > visual S2 | >visual S2 | |||||
| L parahippocampus / FG | −36 | −16 | −20 | 5.69 | 0.001 | (<0.001) |
| R middle frontal gyrus | 39 | −4 | 61 | 5.46 | 0.004 | 0.014 |
| R superior frontal gyrus | 27 | 5 | 64 | 5.13 | 0.013 | (<0.001) |
| R anterior parahippocampus | 24 | −1 | −26 | 5.28 | 0.007 | |
| L pSTS/MTG | −48 | −73 | 13 | 5.14 | 0.013 | (<0.001) |
| R pSTS/MTG | 42 | −70 | 10 | 4.66 | (<0.001) | (<0.001) |
| R LO | 48 | −73 | −2 | 3.56 | 0.006§ | 0.024§ |
| L aIPS | −36 | −37 | 37 | 3.55 | 0.006§ | 0.002§ |
| L pIPS | −21 | −67 | 49 | 3.65 | 0.005§ | 0.001§ |
| R pIPS | 27 | −61 | 46 | 2.99 | 0.026§ | 0.017§ |
| Haptic S2—unimodal: HHi × time | ||||||
| No significant results | ||||||
| Visual S2—crossmodal: VHi × time | ||||||
| No significant results | ||||||
| Visual S2—unimodal: VVi × time | ||||||
| No significant results |
| Probe | BRCA1/2-N, median % (range) | Non-BRCA-related-N, median % (range) | Test statistica | p Value |
| BRCA1.1 | 2 (0–3) | 3 (0–5) | 15.500 | 0.325 |
| BRCA1.2 | 17 (13–26) | 13 (13–17) | 8.500 | 0.057 |
| BRCA1.3 | 9 (6–16) | 7 (5–8) | 8.000 | 0.050 |
| BRCA2.1 | 19 (15–26) | 16 (14–19) | 8.500 | 0.060 |
| BRCA2.2 | 8 (6–16) | 6 (5–12) | 12.000 | 0.158 |
| BRCA2.3 | 13 (10–28) | 9 (8–14) | 6.500 | 0.031* |
| BRCA2.4 | 8 (6–9) | 5 (5–6) | 2.000 | 0.005* |
| Algorithm 1 | Algorithm 2 | Algorithm 3 | Algorithm 4 | |||||
| Descriptor elements count | avg. | std. dev. | avg. | std. dev. | avg. | std. dev. | avg. | std. dev. |
| 3 | 4.3 | 0.5 | 7.8 | 0.5 | 9.4 | 0.5 | 5.3 | 0.5 |
| 4 | 5.3 | 0.6 | 8.9 | 0.7 | 15.1 | 0.9 | 7.0 | 1.3 |
| 5 | 5.1 | 0.8 | 8.0 | 1.8 | 20.5 | 4.9 | 13.3 | 11.2 |
| 6 | 5.9 | 0.9 | 12.4 | 2.3 | 39.5 | 6.1 | 42.2 | 48.6 |
| 7 | 6.1 | 0.9 | 14.0 | 2.5 | 61.5 | 6.8 | 97.0 | 124.6 |
| 8 | 6.2 | 0.9 | 14.8 | 2.8 | 91.1 | 7.5 | 448.8 | 372.2 |
| 9 | 6.0 | 1.1 | 16.5 | 3.5 | 109.8 | 7.6 | 2743.7 | 3362.4 |
| 10 | 5.9 | 1.1 | 16.2 | 4.0 | 121.8 | 9.7 | 12267.0 | 21504.2 |
| 11 | 6.6 | 1.3 | 28.5 | 7.4 | 140.6 | 8.3 | 256785.6 | 424309.9 |
| Concentration (mg/mL) | The ratio of green and red fluorescence |
| Control | 1.332 ± 0.045 |
| 0.005 | 1.420 ± 0.042∗∗ |
| 0.025 | 1.088 ± 0.037∗∗ |
| 0.1 | 0.801 ± 0.042∗∗ |
| Positive control | 0.477 ± 0.033∗∗ |
| Clinical Variables | ET (n = 50) | ScT (n = 51) | p Value * |
| Gestational age, wks, median (IQR) | 28 (26–31) | 26 (24–29) | 0.05 |
| Birth weight, g, median (IQR) | 1060 (770–2000) | 750 (580–1100) | 0.003 |
| ≤1000 g, n (%) | 23 (46) | 37 (72.5) | 0.008 |
| 1001–1500 g, n (%) | 11 (22) | 5 (5.8) | 0.11 |
| >1500 g, n (%) | 16 (32) | 9 (17.6) | 0.11 |
| SGA, n (%) | 5 (10) | 13 (25.5) | 0.07 |
| Inborn, n (%) | 44 (88) | 44 (86.3) | 1 |
| Twin, n (%) | 14 (28) | 11 (21.6) | 0.49 |
| Male, n (%) | 31 (62) | 33 (64.7) | 0.83 |
| Apgar 1 min, median (IQR) | 5 (2–7) | 5 (2–6) | 0.43 |
| Apgar 5 min, median (IQR) | 8 (7–8) | 7 (7–8) | 0.66 |
| Resuscitation in delivery room, n (%) 1 | 42 (84) | 45 (88.2) | 0.57 |
| Early-onset sepsis, n (%) | 27 | 14 | 0.008 |
| Late-onset sepsis, n (%) | 23 | 37 | 0.008 |
| Age at sepsis evaluation, d, median (IQR) | 2 (0–11) | 9 (3–22) | 0.003 |
| Weight at sepsis evaluation, g, median (IQR) | 1212.5 (820–1960) | 880 (600–1610) | 0.05 |
| Time between sepsis and septic shock, h, median (IQR) | 4.5 (3–10) | 13 (5–29) | 0.001 |
| Time between septic shock and ET, h, median (IQR) | 7 (4–18) | NA | NA |
| Sample | Metal organic line pressure (Torr) | Nanowire diameter (nm) | Gate-to-nanowire distance (nm) | Gate length (nm) | Source-to-drain distance (nm) |
| a | 0 | 29 | 120 | 750 | 1,200 |
| b | 0.05 | 33 | 140 | 700 | 1,200 |
| c | 0.1 | 39 | 140 | 750 | 1,250 |
| d | 0.2 | 40 | 160 | 870 | 1,400 |
| e | 0.4 | 80 | 140 | 1,700 | 2,500 |
| Genea | Reference (PubMedID) | Affected in | Peak length (bp) | Peak to transcription start site (bp) | Promoter class |
| Nos1 | 20645313 | Hippocampus | 334 | -3,719 | LCP |
| Map6 | 16624526 | Hippocampus | 169 | -2,382 | ICP |
| Drd5 | 11304828 | Hippocampus | 844 | 41 | HCP |
| Cacna1c | 23183239 | Hippocampus | 425 | -3,692 | LCP |
| Bdnf | 16818862 | Hippocampus | 329 | -492 | ICP |
| Gsksb | 18500637 | Hippocampus | 573 | -1,042 | HCP |
| Tf | 18045615 | Hippocampus | 159 | -3,020 | LCP |
| Cnp | 16389193 | Hippocampus | 464 | 1,198 | HCP |
| Amacr | 20875727 | Hippocampus | 558 | 164 | HCP |
| Psen2 | 19232479 | Hippocampus | 249 | 620 | LCP |
| Pax6 | 10376119 | Hippocampus | 341 | 326 | ICP |
| Dlx1 | 18384059 | Hippocampus | 431 | -2,043 | HCP |
| Dlx1 | 18384059 | Cerebellum | 1,330 | 257 | HCP |
| Cnp | 16389193 | Cerebellum | 769 | 940 | HCP |
| Psen2 | 19232479 | Cerebellum | 455 | 442 | LCP |
| Pax6 | 10376119 | Cerebellum | 349 | -3,481 | ICP |
| Stx1a | 15219469 | Cerebellum | 149 | 72 | HCP |
| Drd5 | 11304828 | Cerebellum | 264 | -169 | HCP |
| Mmp9 | 20037727 | Cerebellum | 138 | -325 | LCP |
| Tnf | 11244489 | Cerebellum | 269 | 49 | LCP |
| Grin1 | 12679240 | Cerebellum | 264 | -1,595 | HCP |
| Tf | 18045615 | Cerebellum | 749 | -1,704 | LCP |
| Dlg4 | 21151988 | Cerebellum | 134 | -1,459 | LCP |
| Amacr | 20875727 | Cerebellum | 138 | -48 | HCP |
| Dao | 19685198 | Cerebellum | 287 | -2,385 | LCP |
| Dlx1 | 18384059 | Liver | 171 | -2,993 | HCP |
| Cnp | 16389193 | Liver | 644 | -2,644 | HCP |
| Sod2 | 15193990 | Liver | 550 | 594 | HCP |
| Drd5 | 11304828 | Liver | 369 | -316 | HCP |
| Il6 | 20393813 | Liver | 789 | -3,030 | LCP |
| Comt | 11381111 | Liver | 638 | -3,542 | HCP |
| Apoe | 14674716 | Liver | 2,158 | -1,223 | LCP |
| Drd2 | 18829695 | Liver | 257 | -91 | HCP |
| Nos1 | 20645313 | Liver | 348 | 172 | LCP |
| Drd1 | 20127886 | Liver | 540 | 739 | LCP |
| Mentorship demographics | No. (%) | |||
| (N=389 with mentor) | ||||
| Male | Female | p | Fisher Exact Test | |
| Department of mentor | ||||
| Same department | 255 (91.1) | 95 (91.3) | 0.93 | 1.0 |
| Another department | 25 (8.9) | 9 (8.7) | ||
| Position of mentor | ||||
| Dept. Chair / Professor | 67 (23.9) | 22 (21.4) | 0.62 | 0.66 |
| Associate Prof. | 59 (21.1) | 27 (26.2) | ||
| Lecturer | 58 (20.7) | 19 (18.4) | ||
| Assistant Prof. | 80 (28.6) | 32 (31.1) | ||
| Other | 16 (5.7) | 3 (2.9) | ||
| Mentor assignment initiated by | ||||
| Mentor | 242 (87.7) | 84 (88.4) | <0.01 | 0.01 |
| Mentee | 34 (12.3) | 11 (11.6) | ||
| Other | 4 (1.4) | 8 (7.8) | ||
| Mentoring Meeting Frequency | ||||
| Every month or more | 213 (76.1) | 83 (79.8) | 0.44 | 0.50 |
| Other (combining all other categories) | 67 (23.9) | 21 (20.2) | ||
| Satisfaction with Mentoring | ||||
| Very satisfied/ A little satisfied | 212 (75.7) | 75 (72.8) | 0.56 | 0.60 |
| Not Satisfied\\Neutral | 68 (24.3) | 28 (27.2) |
| Characteristics | ||
| Body mass index | >30 Kg/m2 | 10 (8.4%) |
| Onset of labour | Spontaneous | 87 (73.1%) |
| Induced | 21 (17.6%) | |
| Augmented | 11 (9.2%) | |
| Use of oxytocin | None | 44 (37.0%) |
| Yes | 75 (63.0%) | |
| <4 cm = 19, 4–7 cm = 30, 8–10 cm = 26 | ||
| Position of fetal head | Right/left/direct occipitoanterior | 34 (28.5%) |
| Right//left/direct occipitoposterior | 40 (33.6%) | |
| Occipitotransverse | 43 (36.1%) | |
| Others | 2 (1.8%) | |
| Station of the fetal head (distance of the leading bony point of fetal skull below the ischial spines, measured in centimeters) | Above −1 | 1 |
| −1 | 2 | |
| 0 | 68 | |
| +1 | 48 | |
| +2 | 2 | |
| Fetal size | Mean 3588 g (2365 g–4840 g) | |
| Operator experience | Trainee <5 years | 13 (10.9%) |
| Trainee 6-7 years | 82 (68.9%) | |
| Consultant (>8 years) | 24 (20.2%) | |
| Time of decision to perform operative vaginal birth | 0800–1700 | 36 (30.3%) |
| 1701–2000 | 11 (9.2%) | |
| 2001–0759 | 72 (60.5%) | |
| Length of second stage of labour (in cases where the indication was “failure to progress”) | <3 hr | 5.2% |
| 3.01–≤4 hr | 14.4% | |
| ≥4.01 hr | 80.4% |
| Variables | NSCLC patients | Disease controls | Healthy controls | P value |
| Number of subjects | 188 | 112 | 130 | |
| Age (years) | 45.2 ± 12.3 | 47.1 ± 11.4 | 47.9 ± 13.2 | >0.05 |
| Sex (M/F) | 118/70 | 61/51 | 72/58 | >0.05 |
| BMI (kg/m2) | 25.3 ± 2.7 | 26.1 ± 3.0 | 25.5 ± 2.7 | >0.05 |
| Smoking subjects (M/F) | 94/17 | 45/15 | 60/17 | >0.05 |
| SBP (mmHg) | 130 ± 15 | 132 ± 14 | 133 ± 12 | >0.05 |
| DBP (mmHg) | 82 ± 10 | 80 ± 11 | 79 ± 12 | >0.05 |
| Glu (mmol/L) | 5.12 ± 1.55 | 5.30 ± 1.69 | 5.25 ± 1.77 | >0.05 |
| WBC (109/L) | 6.17 ± 2.22 | 5.74 ± 3.01 | 5.42 ± 2.15 | >0.05 |
| PLT (109/L) | 190.1 ± 21.5 | 199.3 ± 18.0 | 210.1 ± 20.1 | >0.05 |
| CRP (mg/L) | 5.5 (0.5–19.5)△ | 4.5 (0.5–14.6)△ | 2.4 (0.5–7.6) | <0.05 |
| PT (seconds) | 11.0 ± 3.1 | 11.6 ± 2.6 | 11.7 ± 2.2 | >0.05 |
| aPTT (seconds) | 24.1 ± 5.0 | 25.8 ± 3.9 | 26.0 ± 3.8 | >0.05 |
| Fbg (g/L) | 3.35 ± 1.20∗ | 2.68 ± 1.30 | 2.54 ± 2.01 | <0.01 |
| D-D (mg/L) | 0.65 ± 0.14∗ | 0.42 ± 0.10 | 0.26 ± 0.04 | <0.01 |
| FVIII:C (%) | 107.5 ± 12.3∗ | 95.1 ± 11.2 | 91.2 ± 13.0 | <0.05 |
| AT (%) | 77.0 ± 10.1∗ | 92.4 ± 10.8 | 98.5 ± 13.1 | <0.01 |
| TFPI-1 (ng/ml) | 51.0 ± 8.6∗ | 79.2 ± 13.2 | 87.1 ± 15.9 | <0.01 |
| N | Complications | Additional comments | Surgical procedure |
| 5 | Equipment failure | Loose halter | Exploratory laparotomy |
| Tail hair broke | Sarcoid removal | ||
| Tail hair broke | Tooth extraction | ||
| Tail rope slipped off | Castration | ||
| Facial paralysis | Wound closure | ||
| 4 | Poor quality | Fell down after standing | Arthroscopy |
| Several attempts to stand | Arthroscopy | ||
| Lost shoe and broke hoof wall | Sarcoid removal | ||
| None | Arthroscopy | ||
| 3 | Long recovery | None | Tumour removal |
| None | Exploratory laparotomy | ||
| Cardiac arrest. Resuscitated | Arthroscopy | ||
| 2 | Excitation | Respiratory problem | Neurectomy |
| Wound to coronary band. | Desmotomy/Neurectomy | ||
| 2 | Myopathy | None | Exploratory laparotomy |
| None | Metatarsal fracture repair | ||
| 1 | Restless | Dog–sitting position | Eye surgery |
| 1 | Hindlimb Weakness | None | Mandibular fracture |
| Variables | SCA2 patients | Preclinical carriers | Healthy controls | ||||||
| ICC | p | H | ICC | p | H | ICC | p | H | |
| Saccade velocity (°/s) | 0.47 | 0.002 | ~94% | 0.19 | 0.222 | NA | 0.136 | 0.289 | NA |
| Saccade accuracy (%) | 0.16 | 0.170 | NA | 0.20 | 0.208 | NA | 0.013 | 0.473 | NA |
| Saccade latency (ms) | 0.16 | 0.170 | NA | 0.13 | 0.294 | NA | 0.286 | 0.121 | NA |
| Gene identifier | Gene label | Description | Protein identifier |
| http://bio2rdf.org/sgd:S000004688 | YMR083W | Mitochondrial alcohol dehydrogenase isozyme III | http://bio2rdf.org/sgd:S000004688gp |
| http://bio2rdf.org/sgd:S000000349 | YBR145W | Alcohol dehydrogenase isoenzyme V | http://bio2rdf.org/sgd:S000000349gp |
| http://bio2rdf.org/sgd:S000002624 | YDR216W | Carbon source-responsive zinc-finger transcription factor | http://bio2rdf.org/sgd:S000002624gp |
| http://bio2rdf.org/sgd:S000000819 | YER017C | Component of the mitochondrial inner membrane m-AAA protease | http://bio2rdf.org/sgd:S000000819gp |
| http://bio2rdf.org/sgd:S000001306 | YIL044C | ADP-ribosylation factor (ARF) GTPase activating protein (GAP) effector | http://bio2rdf.org/sgd:S000001306gp |
| Histotypea | Cell lineb | IC50 μM (± SE)c,f | Genetic alterationd | Doubling time (hours)e,f |
| RHABDOMYOSARCOMA | RD/18 | 6.8 (± 2.1) | Altered 11p15.5 chromosome | 22 ± 0.1 |
| SJ-RH4 | 5.6 (± 1.3) | (2;13)(q35;q14) PAX3 FKHR | 25 ± 1.2 | |
| SJ-RH30 | 9.9 (± 2.7) | (2;13)(q35;q14) PAX3 FKHR | 26 ± 1.0 | |
| OSTEOSARCOMA | IOR/OS10 | 5.5 (± 1.3) | Complex Karyotype | 30.4 ± 2.6 |
| IOR/OS9 | 8.6 (± 1.8) | Complex Karyotype | 44.5 ± 2.4 | |
| Saos-2 | 11.9 (± 3.1) | Complex Karyotype | 36.1 ± 4.4 | |
| Saos-2/DX580 | 39.3 (± 2.6) | Complex Karyotype | 75.6 ± 5.7 | |
| Saos-2/CDDP6ug | 43.3 (± 6.8) | Complex Karyotype | 44.3 ± 4.1 | |
| U-2OS | 12.5 (± 0.7) | Complex Karyotype | 18.3 ± 0.2 | |
| U-2OS/DX580 | 16.5 (± 0.4) | Complex Karyotype | 45.3 ± 4.7 | |
| U-2OS/CDDP4ug | 56.1 (± 1.4) | Complex Karyotype | 38.6 ± 4.1 | |
| EWING SARCOMA | 6647 | 3.1 (± 1.4) | t(11;22)(q24;q12) EWSR1-FLI1 TYPE II | 29 ± 2.3 |
| LAP-35 | 11.6 (± 0.7) | t(11;22)(q24;q12) EWSR1-FLI1 TYPE II | 48.6 ± 4.2 | |
| SK-N-MC | 3.9 (± 0.5) | t(11;22)(q24;q12) EWSR1-FLI1 TYPE I | 26.9 ± 0.5 | |
| TC-71 | 2.6 (± 1.4) | t(11;22)(q24;q12) EWSR1-FLI1 TYPE I | 14.9 ± 1.4 | |
| TC/DOXO8 | 5.0 (± 0.1) | t(11;22)(q24;q12) EWSR1-FLI1 TYPE I | 22.6 ± 2.8 | |
| h-MSC | MES1 | >50 | n.d. | n.d. |
| MES2 | >50 | n.d. | n.d. | |
| DP-15 | >50 | n.d. | n.d. |
| Spice | Number of portion sizes | Level of intake (% of portion sizes) | ||
| <1.0 | 1.0-5.0 | >5.0 | ||
| R. chillies | 364 | 15.1 | 69.5 | 15.4 |
| Turmeric | 351 | 78.3 | 21.7 | - |
| Cumin | 198 | 39.4 | 54.5 | 6.1 |
| Coriander | 97 | 57.7 | 35 | 7.2 |
| Mustard | 121 | 61.1 | 38.8 | - |
| Cloves | 122 | 92.6 | 7.4 | - |
| Cardamom | 170 | 93 | 7 | - |
| Cinnamon | 118 | 75.4 | 24.6 | - |
| Caraway | 109 | 63.3 | 36.7 | - |
| B. pepper | 108 | 67.6 | 32.4 | - |
| Nutmeg | 30 | 100 | - | - |
| Mace | 23 | 100 | - | - |
| Fenugreek | 31 | 71 | 29 | - |
| Asafoetida | 41 | 78 | 22 | - |
| Carom | 25 | 76 | 24 | - |
| Country | Paliperidone (maximum), % |
| Austria | 0.04 |
| Belgium | 4.8 |
| Bury PCT | 0.07 |
| Ireland (GMS population) | 1.01 |
| Scotland | 0.03 |
| Spain (Catalonia) | 3.99 |
| Sweden | 1.5 |
| Walking Speed (Steps/min) | Actual ZVI Number | Detected ZVI Number | |
| Fixed Threshold Method | Adaptive ZVI Detection Algorithm | ||
| 80 | 100 | 102 | 100 |
| 100 | 100 | 100 | 100 |
| 120 | 100 | 94 | 100 |
| Total Epidemic Size | Days to Epidemic Season Peak | Length of Epidemic Season | |
| Regression Intercept (S.E.) | 321.0 (417) | 87.5 (13.5) | 192.3 (24.0) |
| Regression Slope (S.E.) | 15383 (7175) | -255.3 (233) | -659 (413) |
| Regression Model p-value | 0.08 | 0.32 | 0.17 |
| R2 | 0.48 | 0.19 | 0.20 |
| Root Mean Square Error | 17.6 | 3.2 | 4.2 |
| Mean of Absolute % Error | 16 | 11 | 8 |
| Men (n = 10,235) | Women (n = 12,234) | |||||
| Deaths | Univariate | Multivariableb | Deaths | Univariate | Multivariableb | |
| Smoking category | ||||||
| Never smokers | 209 | 1.00 | 1.00 | 273 | 1.00 | 1.00 |
| Long-term quitters | 313 | 1.29 (1.09, 1.54) | 1.21 (1.01, 1.44) | 84 | 1.01 (0.79, 1.29) | 1.03 (0.80, 1.32) |
| Short-term quitters | 118 | 2.13 (1.70, 2.68) | 1.87 (1.49, 2.35) | 33 | 1.10 (0.77, 1.58) | 1.14 (0.79, 1.64) |
| Light smokers | 71 | 2.26 (1.73, 2.96) | 2.02 (1.54, 2.65) | 66 | 1.93 (1.47, 2.53) | 2.00 (1.52, 2.63) |
| Heavy smokers | 329 | 4.20 (3.53, 5.00) | 3.49 (2.90, 4.18) | 103 | 2.82 (2.23, 3.55) | 2.75 (2.16, 3.48) |
| Body weight status | ||||||
| Optimal BMI | 164 | 1.00 | 1.00 | 114 | 1.00 | 1.00 |
| Low BMI | 90 | 1.78 (1.37, 2.30) | 1.61 (1.23, 2.07) | 127 | 1.38 (1.07, 1.78) | 1.34 (1.04, 1.73) |
| Overweight | 535 | 1.28 (1.08, 1.53) | 1.16 (0.97, 1.38) | 185 | 1.10 (0.87, 1.39) | 1.08 (0.85, 1.37) |
| Obesity | 251 | 1.83 (1.50, 2.22) | 1.51 (1.23, 1.86) | 133 | 1.56 (1.21, 2.00) | 1.55 (1.19, 2.02) |
| Alcoholic drinks/day | ||||||
| ≤2 (men)/ ≤0.5 (women) | 494 | 1.00 | 1.00 | 343 | 1.00 | 1.00 |
| 2.1 to 4 (men)/ 0.6 to 1 (women) | 299 | 1.36 (1.18, 1.57) | 1.24 (1.07, 1.44) | 101 | 0.87 (0.70, 1.09) | 0.86 (0.69, 1.08) |
| >4 (men)/ >1 (women) | 247 | 2.07 (1.78, 2.42) | 1.50 (1.28, 1.75) | 115 | 1.24 (1.00, 1.53) | 1.15 (0.92, 1.44) |
| Leisure time physical activity | ||||||
| Low versus high | 555/485 | 1.11 (0.98, 1.26) | 1.05 (0.93, 1.19) | 310/249 | 1.24 (1.05, 1.46) | 1.16 (0.98, 1.37) |
| Processed/red meat consumption | ||||||
| High versus low | 393/647 | 1.43 (1.26, 1.62) | 1.21 (1.06, 1.38) | 72/487 | 1.54 (1.20, 1.97) | 1.40 (1.08, 1.80) |
| Vegetable/fruit consumption | ||||||
| Low versus high | 578/462 | 1.32 (1.16, 1.49) | 1.19 (1.05, 1.35) | 222/337 | 1.19 (1.01, 1.41) | 1.11 (0.93, 1.32) |
| Cereal consumption | ||||||
| Low versus high | 596/444 | 1.19 (1.06, 1.35) | 1.08 (0.96, 1.23) | 407/152 | 1.10 (0.91, 1.33) | 1.04 (0.86, 1.26) |
| Fish consumption | ||||||
| Low versus high | 427/613 | 1.11 (0.98, 1.26) | 1.04 (0.91, 1.18) | 296/263 | 1.20 (1.02, 1.42) | 1.17 (0.99, 1.39) |
| Dairy product consumption | ||||||
| High versus low | 407/633 | 0.92 (0.81, 1.05) | 1.07 (0.95, 1.22) | 277/282 | 0.95 (0.81, 1.12) | 1.02 (0.86, 1.21) |
| Early phase | Middle phase | Late phase | Total | |
| CORRECT RESPONSES | ||||
| Literal compliment | 2022.88 (464.33) | 553.59 (146.04) | 754.90 (148.53) | 3226.34 (858.03) |
| Literal criticism | 2771.90 (737.72) | 607.19 (165.84) | 975.49 (658.10) | 3879.39 (1050.40) |
| Ironic criticism | 2788.04 (1168.27) | 516.56 (126.70) | 809.08 (212.46) | 4113.68 (1389.53) |
| INCORRECT RESPONSES | ||||
| Ironic criticism | 2905.82 (1894.20) | 537.87 (129.48) | 932.28 (378.45) | 4375.97 (2175.79) |
| Mean | Median | Min | Max | Range*1 | SD*2 | |
| Referral rate of participating GPs | 0.68 | 0.65 | 0.53 | 0.88 | 0.35 | 0.11 |
| Referral rate of non-participating GPs | 0.74 | 0.76 | 0.47 | 1.00 | 0.53 | 0.15 |
| Molecular Class | Number of Molecules Altered Within Each Pathway |
| Nitrite (80 mg/day) | |
| Glycerophospholipids | 13 |
| Sphingolipids | 2 |
| Glycerolipids | 1 |
| Fatty Acyls | 3 |
| Carbohydrates and Carbohydrate Conjugates | 1 |
| Carboxylic Acids and Derivatives | 2 |
| Imidazole Ribonucleosides and Ribonucleotides | 1 |
| Pyridines and Derivatives | 1 |
| Peptide Hormones | 1 |
| Unknown | 20 |
| Nitrite (160 mg/day) | |
| Glycerophospholipids | 9 |
| Sphingolipids | 2 |
| Carboxylic Acids and Derivatives | 2 |
| Polypeptide | 1 |
| Pyridines and Derivatives | 1 |
| Unknown | 18 |
| NO. | TF | Target | p. DCG | Cor.1 | Cor.2 | Type | NO. | TF | Target | p. DCG | Cor.1 | Cor.2 | Type |
| 1 | AHR | TLE4* | 6.77E–23 | 0.94 | 0.14 | 0 | 26 | NFYA | PANK2* | 5.37E–05 | –0.13 | 0.97 | 1 |
| 2 | ZEB1 | ATP12A* | 3.56E-73 | -0.54 | 0.95 | 1 | 27 | MRPL36 | NR4A1* | 1.34E–08 | 0.88 | –0.94 | 1 |
| 3 | FOXL1* | CBX6 | 0.014521 | 0.95 | 0.13 | 0 | 28 | NF1 | NUPL2* | 1.86E–35 | 0.91 | 0.10 | 0 |
| 4 | CEBPB | PLEKHM1* | 0.000574 | 0.18 | 0.94 | 0 | 29 | ZEB1 | OTOF* | 2.62E–07 | 0.06 | -0.96 | 1 |
| 5 | CREB1 | TGM1* | 0.001644 | 0.87 | 0.05 | 0 | 30 | HAND1 | PITX2* | 5.83E–06 | -0.90 | -0.01 | 0 |
| 6 | CREB1 | CROCCP2* | 5.02E–09 | 0.92 | 0.07 | 0 | 31 | PLAU | LNP1* | 2.00E–19 | -0.01 | -0.92 | 0 |
| 7 | PATZ1 | DYRK2* | 2.79E–16 | -0.88 | -0.02 | 0 | 32 | PSG1 | YRDC* | 6.27E–11 | 0.11 | 0.93 | 0 |
| 8 | FOS | FEZ2* | 0.000107 | 0.03 | 0.96 | 0 | 33 | RFX1 | SNORA21* | 3.87E–38 | 0.98 | -0.05 | 1 |
| 9 | MYCN | FLRT2* | 9.32E–05 | 0.29 | -0.98 | 1 | 34 | RFX1 | LOC283481* | 3.34E–55 | 0.96 | -0.33 | 1 |
| 10 | FOSL1* | HIVEP3 | 6.37E–06 | 0.94 | 0.02 | 0 | 35 | SOX9* | FLAD1 | 8.34E–09 | -0.92 | -0.10 | 0 |
| 11 | FOSL1* | DSCAML1 | 6.37E–06 | 0.91 | 0.16 | 0 | 36 | SREBF1 | PHOX2B* | 0.002661 | 0.89 | 0.06 | 0 |
| 12 | GATA1 | COL19A1* | 9.63E–10 | 0.12 | 0.93 | 0 | 37 | SRF* | C4orf7 | 1.23E–18 | -0.96 | 0.74 | 1 |
| 13 | JUN* | GRIA4 | 4.30E–10 | -0.60 | 0.97 | 1 | 38 | SRF* | SHMT1 | 1.23E─18 | -0.92 | -0.12 | 0 |
| 14 | SRF* | HCG18 | 1.23E─18 | -0.91 | -0.14 | 0 | 39 | STAT5B | TRAK2* | 1.42E─06 | 0.45 | -0.95 | 1 |
| 15 | HLF* | LRRTM4 | 0.022779 | 0.92 | 0.18 | 0 | 40 | TCF3 | C11orf61* | 0.003455 | -0.87 | -0.10 | 0 |
| 16 | E2F5 | ID1* | 0.008474 | -0.88 | -0.11 | 0 | 41 | TFAP4* | BSCL2 | 3.03E–16 | -0.06 | -0.94 | 0 |
| 17 | JUN* | ZNF830 | 4.30E–10 | -0.09 | -0.93 | 0 | 42 | TLX2* | C3orf70* | 0.03 | -0.97 | 1 | |
| 18 | JUN* | SPOP | 4.30E–10 | -0.11 | -0.95 | 0 | 43 | FOXL1* | TOB1 | 0.014521 | -0.88 | -0.11 | 0 |
| 19 | JUN* | GAK | 4.30E–10 | -0.43 | 0.96 | 1 | 44 | TLX2* | TSPAN8 | 6.53E–06 | -0.94 | -0.11 | 0 |
| 20 | JUN* | CHURC1 | 4.30E–10 | 0.51 | -0.95 | 1 | 45 | CREB1 | VPS26A* | 6.76E–05 | 0.92 | 0.05 | 0 |
| 21 | PAX5 | KCTD7* | 1.14E–05 | 0.97 | -0.54 | 1 | 46 | SRF* | VWA3A | 1.23E–18 | -0.89 | -0.08 | 0 |
| 22 | JUN* | KLF6 | 4.30E–10 | 0.89 | 0.12 | 0 | 47 | YY1 | ZNF518A* | 1.93E–119 | 0.90 | 0.04 | 0 |
| 23 | MZF1 | MID1* | 0.006234 | 0.96 | -0.28 | 1 | 48 | POU2F1 | ZNF518A* | 1.93E–119 | 0.98 | -0.15 | 1 |
| 24 | MZF1 | EPHB2* | 0.012953 | -0.93 | -0.13 | 0 | 49 | ZSCAN1 | KRT13* | 4.80E–10 | 0.89 | 0.15 | 0 |
| 25 | SRF* | NDUFA1 | 1.23E–18 | 0.88 | 0.12 | 0 |
| Total number of hits | Standard articles retrieved | ||
| Keyword search (basic topic + sex differences search) | Stroke | 301 | 33/94 |
| (stroke AND sex difference*); filters: human, Englishor(diabetes AND sex difference*); filters: human, English | Diabetes | 539 | 23/95 |
| TTUHSC SGSH PubMed search tool: Basic | Stroke | 566 | 50/94 |
| (sex based OR sex factors OR sex distribution OR sex characteristics OR sex dimorphism OR gender difference* OR gender based) AND (gender[ti] OR sex[ti]); filters: human, EnglishTotal number of hits at the time of validation: 21,315 | Diabetes | 1027 | 62/95 |
| TTUHSC SGSH PubMed search tool: Expanded | Stroke | 1623 | 77/94 |
| (sex based OR sex factors OR sex distribution OR sex characteristics OR sex dimorphism OR gender difference* OR female) AND (gender[ti] OR sex[ti] OR women[ti] OR female[ti]); filters: human, EnglishTotal number of hits at the time of validation: 97,972 | Diabetes | 5569 | 81/95 |
| ASD (n = 20) | TD (n = 23) | Statistics | |||
| (M, SD) | (M, SD) | t orχ2 | df | p | |
| Age (M, SD) | 13.2 ± 2.1 | 12.5 ± 2.2 | t = 1.100 | 41 | 0.278 |
| Gender (males:females) | 14:6 | 17:6 | χ2 = 0.393 | 1 | 0.531 |
| CARS (M, SD) | 34.1 ± 2.4 | 17.7 ± 1.3 | t = 28.955 | 41 | <0.001 |
| Isoch. | −1.21 | −1.03 | −0.83 | −0.60 | −0.40 | −0.20 | 0.00 | 0.19 | 0.41 | 0.59 | 0.98 | 1.21 | |
| Mean | 253 | 267 | 272 | 272 | 272 | 258 | 272 | 273 | 272 | 263 | 271 | 260 | 266 |
| SD | 4.37 | 19.38 | 15.43 | 16.14 | 15.79 | 21.02 | 15.96 | 16.77 | 16.05 | 17.15 | 15.26 | 12.37 | 28.29 |
| Dietary change | Epigenetic effects | Outcome | Species | Reference |
| Vitamin B12, folate and methionine deficient | DNA methylation | Hypomethylation in methyl-deficient diet | Sheep | Sinclair et al., 2007 |
| Betaine supplementation | DNA methylation | Increased global measures of DNA methylation | Chicks | Hu et al., 2015 |
| Betaine supplementation | DNA methylation, Histone modification | PEPCK1 hypomethylated and enriched for H3K27me3. PEPCK2 and FBP1 hypermethylated and enriched for H3K4me3 | Neonatal Piglets | Cai et al., 2014 |
| Zinc supplementation | DNA methylation | Hypomethylation and increased expression of gene A20 | Hens | Li et al., 2015 |
| Variable zinc levels | DNA methylation | Hypermethylation in regulatory regions of gene ZIP4 | Piglets | Karweina et al., 2015 |
| Restrictive feeding | Histone modification | Increased global measures of H3K9 acetylation and reduction in H3K9me3 in IUGR pigs subjected to restrictive feeding | Pigs | Nebendahl et al., 2016 |
| Folic acid supplementation | DNA methylation | Hypermethylation in IUGR piglets with folic acid supplementation compared to piglets fed control diet | Pigs | Jing-bo et al., 2013 |
| Maternal protein insufficiency | DNA methylation | Hypomethylation in POMC and GR in the sheep brain | Sheep | Begum et al., 2012 |
| Methylating micronutrients | DNA methylation | IYD gene differentially methylated between groups of pigs with extreme obesity related phenotypes | Pigs | Braunschweig et al., 2012 |
| Marker | Two-point LOD score values at recombination fraction (θ=) | Zmax | θmax | |||||
| 0.0 | 0.1 | 0.2 | 0.3 | 0.4 | 0.5 | |||
| D1S1677 | -4.21 | 1.37 | 1.38 | 1.00 | 0.45 | 0 | 1.38 | 0.2 |
| D1S 2878 | 4.82 | 3.98 | 3.05 | 2.03 | 0.93 | 0 | 4.82 | 0.0 |
| D1S 382 | 1.52 | 1.25 | 0.96 | 0.65 | 0.32 | 0 | 1.52 | 0.0 |
| D1S 1158 | -1.51 | 1.39 | 1.31 | 0.98 | 0.54 | 0 | 1.39 | 0.1 |
| D1S 2630 | 1.85 | 1.62 | 1.09 | 0.51 | 0.09 | 0 | 1.85 | 0.0 |
| D1S 196 | -2.37 | 0.50 | 0.52 | 0.34 | 0.11 | 0 | 0.52 | 0.2 |
| D1S 218 | 3.00 | 2.88 | 2.38 | 1.65 | 0.78 | 0 | 3.00 | 0.0 |
| D1S 2818 | 5.46* | 4.52 | 3.48 | 2.34 | 1.09 | 0 | 5.46 | 0.0 |
| D1S 238 | -5.5 | 0.84 | 0.80 | 0.59 | 0.32 | 0 | 0.84 | 0.1 |
| Histological results | ||||
| HPV Genotype | < CIN 2(n = 44) | CIN 2(n = 12) | CIN 3(n = 18) | ICC |
| HPV 16 | 32% (14/44) | 25% (3/12) | 44%(8/18) | |
| HPV 53 | 25% (11/44) | 17% (2/12) | 28% (5/18) | 1 |
| HPV 52 | 16% (7/44) | 42% (5/12) | 17% (3/18) | |
| HPV 56 | 18% (8/44) | 8% (1/12) | 33% (6/18) | |
| HPV 58 | 16% (7/44) | 42% (5/12) | 6% (1/18) | |
| HPV 18 | 16% (7/44) | 25% (3/12) | 17% (3/18) | |
| HPV 35 | 14% (6/44) | 25% (3/12) | 18% (4/18) | |
| HPV 31 | 7% (3/44) | 33% (4/12) | 18% (4/18) | |
| HPV 33 | 7% (4/44) | 25% (3/12) | 28% (5/18) | |
| HPV 39 | 7% (3/44) | 17% (2/12) | 17% (3/18) | |
| HPV 45 | 0% | 8% (1/12) | 11% (2/18) | |
| HPV 59 | 2% (1/44) | 8% (1/12) | 11% (2/18) | |
| HPV 66 | 20% (9/44) | 8% (1/12) | 9% (1/18) | |
| HPV 68 | 7% (3/44) | 0% (0/12) | 9% (1/18) | |
| Multiple HPV coinfection | 60% (26/44) | 83% (10/12) | 67% (12/18) |
| Region | Methylation status | # CpG in | # of molecules detected | % of total | ||||
| MseI frag. | Ampl-icon | Exp 1 | Exp 2 | Exp 3 | Exp 4 | |||
| 1 | unmethylated | 0 | 0 | 1 | 0 | 3.0 | ||
| Hha-methylated | 2 | 0 | 0 | 0 | ||||
| HpaII-methylated | 11 | 2 | 1 | 0 | 3.0 | |||
| Fully methylated | 54 | 11 | 15 | 16 | 93.9 | |||
| 2 | unmethylated | 0 | 0 | 1 | 1 | 11.8 | ||
| Hha-methylated | 0 | 0 | 0 | 0 | ||||
| HpaII-methylated | 2 | 1 | 1 | 0 | 5.9 | |||
| Fully methylated | 12 | 11 | 6 | 8 | 82.4 | |||
| 3 | unmethylated | 0 | 0 | 15 | 14 | 7 | 5 | 80.4 |
| Hha-methylated | 3 | 2 | 0 | 0 | 0 | 0 | 0 | |
| HpaII-methylated | 3 | 1 | 0 | 0 | 0 | 0 | 0 | |
| Fully methylated | 23 | 17 | 0 | 6 | 1 | 3 | 19.6 |
| Trial I (unselective supplementation in all mothers from week 18) | Trial II (selective supplementation in nutritionally at risk mothers from week 28) | |||||||||
| Trial Group | Protein, Carbohydrate and Vitamins1 | Carbohydrate and vitamins2 | Vitamins only3 | p7 | Protein, Carbohydrate and Vitamins4 | Carbohydrate and vitamins5 | Vitamins only6 | p7 | ||
| Mean Birthweight kg | Original trial (n) | 3.01 ± 0.06 (47) | 3.02 ± 0.07 (50) | 3.06 ± 0.07 (45) | 0.87 | 3.34 ± 0.14 (14) | 2.95 ± 0.15 (17) | 3.01 ± 0.07 (14) | 0.09 | |
| Traced participants (n) | 2.97 ± 0.07 (40) | 2.96 ± 0.07 (41) | 3.07 ± 0.08 (38) | 0.53 | 3.34 ± 0.14 (14) | 2.96 ± 0.17 (15) | 3.01 ± 0.07 (13) | 0.15 | ||
| Assessed in clinic (n)8 | 3.11 ± 0.09 (21) | 2.95 ± 0.08 (23) | 3.08 ± 0.12 (21) | 0.48 | 3.23 ± 0.13 (8) | 3.42 ± 0.15 (4) | 3.03 ± 0.11 (8) | 0.18 |
| Independent variables1 | Coefficients (SE) | z-value(P value) | Odds ratio (OR) | 95% CI OR |
| Age | −0.005 (0.01) | −0.49 (0.63) | 0.99 | (0.98, 1.01) |
| Marital status (married) | 0.25 (0.21) | 1.21 (0.23) | 1.28 | (0.85, 1.93) |
| Level of education2 | ||||
| 12 years formal education | 0.63 (0.25) | 2.52 (0.01) | 1.87 | (1.15, 3.07) |
| University graduate | 1.28 (0.24) | 5.35 (0.0) | 3.60 | (2.24, 5.77) |
| Family history (Yes) | 0.40 (0.23) | 1.79 (0.08) | 1.49 | (0.96, 2.32) |
| Personal history (Yes) | 0.84 (0.47) | 1.80 (0.07) | 2.32 | (0.93, 5.77) |
| Attending in screening and educational program (Yes) | 0.95 (0.32) | 2.99 (0.003) | 2.58 | (1.39, 4.81) |
| Factors | Domains | Major themes and their dimensions |
| Enabling | Availability of support | Formal support |
| Conflict with centre's hours of operation | ||
| Lack of an effective appointment reminder system | ||
| Proximity to the centre | ||
| Difficulties in locating the centre | ||
| Regular physician visits | ||
| Informal support | ||
| Dependent on family assistance | ||
| Family responsibilities | ||
| Familiarity with resources | Diabetes education centre and its services | |
| Familiarity with DEC services | ||
| Predisposing | Self-efficacy | Diabetes self-management |
| Sufficient amount of information | ||
| Adherent to self-management activities | ||
| Non-adherent to self-management activities | ||
| Attitudes | Diabetes education | |
| Level of priority | ||
| Apathy | ||
| Co-morbidity | Competing health conditions | |
| Need | Perceived/evaluated | Disease severity |
| Patient judgment of severity | ||
| Physician judgment of severity |
| Method | P | R | F | Sn | PPV | Acc |
| MCODE | 0.612 | 0.081 | 0.142 | 0.273 | 0.345 | 0.307 |
| CFinder | 0.451 | 0.15 | 0.225 | 0.56 | 0.22 | 0.351 |
| CMC | 0.224 | 0.377 | 0.281 | 0.472 | 0.58 | 0.523 |
| RRW | 0.581 | 0.277 | 0.375 | 0.32 | 0.605 | 0.44 |
| COACH | 0.472 | 0.38 | 0.421 | 0.477 | 0.498 | 0.487 |
| CORE | 0.275 | 0.691 | 0.394 | 0.566 | 0.537 | 0.551 |
| Ours | 0.626 | 0.559 | 0.59 | 0.509 | 0.663 | 0.581 |
| Outcome | RR | 95% Confidence interval | p-value |
| Total cesarean SSIs | 1.10 | 0.58–2.08 | 0.765 |
| Cesarean incisional SSIs | 0.23 | 0.03–1.78 | 0.158 |
| Cesarean organ/space SSIs | 1.62 | 0.83–3.18 | 0.160 |
| Variable | b | SE | Wald | p | Odds ratio (95% CI) |
| Unadjusted model | |||||
| EAL | 0.25 | .20 | 1.59 | .207 | 1.28 (0.87, 1.89) |
| CCC–S score | −0.20 | .01 | 1,420.33 | < .001 | 0.82 (0.81, 0.83) |
| CCC–S × EAL | 0.02 | .01 | 1.28 | .258 | 1.02 (0.99, 1.04) |
| Constant | 2.01 | .05 | 1,508.96 | < .001 | |
| Adjusted model | |||||
| EAL | 0.24 | .20 | 1.48 | .223 | 1.28 (0.86, 1.89) |
| CCC–S score | −0.19 | .01 | 1,256.44 | < .001 | 0.83 (0.82, 0.84) |
| CCC–S × EAL | 0.01 | .01 | 0.77 | .381 | 1.01 (0.98, 1.04) |
| Male sex | −0.56 | .06 | 89.58 | < .001 | 0.57 (0.51, 0.64) |
| Age in months | 0.07 | .01 | 68.00 | < .001 | 1.07 (1.06, 1.09) |
| IDACI rank | < 0.01 | < .01 | 4.84 | .028 | 1.00 (1.00, 1.00) |
| Constant | −2.46 | .56 | 19.45 | < .001 |
| Sampling sites | n | NA | PA (%) | A | HO | HE | FIS |
| All individuals tested | 313 | 64 | — | 5.818 | 0.430 ± 0.113 | 0.578 ± 0.148 | 0.255 |
| Microsatellite dataset I | |||||||
| East (North and South) | 151 | 61 | 32 (52.46 %) | 5.546 | 0.532 ± 0.150 | 0.618 ± 0.156 | 0.141 |
| Northeast | 107 | 59 | 20 (33.90 %) | 5.364 | 0.559 ± 0.153 | 0.613 ± 0.164 | 0.089 |
| Russia | 88 | 57 | 13 (22.81 %) | 5.182 | 0.569 ± 0.151 | 0.619 ± 0.159 | 0.082 |
| Belarus + Estonia | 19 | 42 | 2 (4.76 %) | 3.818 | 0.503 ± 0.230 | 0.54 ± 0.207 | 0.095 |
| Southeast(Romania) | 44 | 35 | 2 (5.71 %) | 3.182 | 0.464 ± 0.170 | 0.496 ± 0.139 | 0.065 |
| West | 162 | 32 | 3 (9.38 %) | 2.909 | 0.336 ± 0.161 | 0.439 ± 0.201 | 0.236 |
| France | 73 | 29 | 1 (3.45 %) | 2.636 | 0.389 ± 0.182 | 0.430 ± 0.206 | 0.095 |
| Spain | 89 | 29 | 1 (3.45 %) | 2.636 | 0.291 ± 0.184 | 0.353 ± 0.215 | 0.178 |
| Microsatellite dataset II | |||||||
| North Dvina | 40 | 54 | 3 (5.56 %) | 4.909 | 0.563 ± 0.188 | 0.618 ± 0.181 | 0.090 |
| West Dvina | 28 | 47 | 2 (4.26 %) | 4.273 | 0.546 ± 0.187 | 0.582 ± 0.185 | 0.064 |
| Volga | 39 | 51 | 2 (3.92 %) | 4.636 | 0.560 ± 0.147 | 0.598 ± 0.146 | 0.065 |
| Charentes | 9 | 25 | — | 2.273 | 0.364 ± 0.223 | 0.409 ± 0.213 | 0.117 |
| Garonne | 44 | 33 | 1 (3.03 %) | 3 | 0.373 ± 0.186 | 0.426 ± 0.205 | 0.128 |
| Adour | 23 | 26 | — | 2.364 | 0.451 ± 0.233 | 0.432 ± 0.198 | −0.045 |
| Cantabrian rivers | 16 | 25 | — | 2.273 | 0.317 ± 0.193 | 0.382 ± 0.252 | 0.176 |
| Ebro | 73 | 29 | — | 2.636 | 0.285 ± 0.185 | 0.337 ± 0.210 | 0.155 |
| Year | Milestone | References |
| 1994 | Discovery of serum autoantibodies recognizing the nuclear DFS-IIF pattern in patients with interstitial cystitis | [4] |
| 1997 | Partial cDNA sequence encoding the autoepitope region of the DFS70 autoantigen deposited in GenBank under accession number U94319 | [3] |
| 1998 | Discovery of transcription co-activator p75, later known to be identical to DFS70 and LEDGFp75 | [13] |
| 1999 | Discovery of LEDGFp75 using autoantibodies from a cataract patient | [14] |
| 2000 | Characterization of DFS70 using autoantibodies from patients with atopic dermatitis and other conditions, and initial observation that these autoantibodies are present at low frequencies in SARD patients | [3] |
| 2001–2002 | Demonstration that DFS70/LEDGFp75 is cleaved during cell death into fragments that are recognized by autoantibodies | [32, 98] |
| 2003–2004 | Discovery of DFS70/LEDGFp75 as a key cellular co-factor of HIV-1 integration | [17-20] |
| 2004 | Initial observation that anti-DFS70/LEDGFp75 autoantibodies are present in apparently healthy individuals | [125] |
| 2004 | Identification of a major B cell autoepitope in the carboxy-terminal region of DFS70/LEDGFp75 | [62] |
| 2005 | Identification of DFS70/LEDGFp75 as a tumor associated autoantigen | [99] |
| 2005 | Demonstration that anti-DFS70/LEDGFp75 autoantibodies are a very common occurrence in human sera screened for ANAs by HEp-2 IIF in a clinical laboratory and can be detected in a wide array of immunological conditions | [7] |
| 2008 | Observation that patients producing anti-DFS70/LEDGFp75 autoantibodies as the only serum ANA pattern are rarely diagnosed with SARD | [28] |
| 2011–2012 | Description of anti-DFS70/LEDGFp75 autoantibodies as a potential exclusion biomarker for SARD | [26, 107] |
| 2012 | Development of a highly specific ANA test based on immunoadsorption of anti-DFS70/LEDGFp75 autoantibodies | [5] |
| 2012 | Introduction of a new algorithm for ANA testing that considers anti-DFS70/LEDGFp75 autoantibodies | [6] |
| 2013 | First commercially available diagnostic test (Inova Diagnostics) for the detection of anti-DFS70/ LEDGFp75 antibodies | N/A |
| Group I (n=29) | Group II (n=31) | Group III (n=24) | Group IV (n=32) | Group V (n=27) | P values * | |
| Severe inflammation in semen | Severe inflammation in EPS and/or post-M | Mild inflammation in semen, EPS and/or post-M | Oligospermia without inflammation | Controls | ||
| Age (y) | 33.6 ± 6.2 | 31.0 ± 7.8 | 31.7 ± 5.2 | 32.2 ± 6.6 | 30.0 ± 5.2 | NS |
| Period of abstinence (d) | 3.7 ± 1.4 | 3.9 ± 1.7 | 3.2 ± 0.9 1 | 3.9 ± 1.5 | 5.9 ± 6.7 1 | p=0.024 |
| Total sperm count (M) | 57.8 ± 51.8 1 | 41.2± 45.6 2 | 36.8 ± 53.1 3 | 12.6 ± 26.3 4 | 446.7 ± 295.8 1-4 | p<0.001 |
| Semen volume (ml) | 4.4 ± 1.6 | 4.5 ± 1.5 | 4.1 ± 1.5 | 4.1 ± 1.5 | 4.4 ± 1.7 | NS |
| Motility A+B (%) | 37.3 ± 17.4 1 | 34.3 ± 14.3 2 | 36.1 ± 18.3 3 | 27.0 ± 19.0 4 | 50.0 ± 11.5 1-4 | p<0.001 |
| Morphologically normal spermatozoa (%) | 6.0 ± 4.7 1 | 5.6 ±4.1 2 | 5.5 ± 4.1 3 | 4.1 ± 3.4 4 | 12.7 ± 7.0 1-4 | p<0.001 |
| WBCs in semen (M/ml) | 2.7 ± 1.9 1-4 | 0.2 ± 0.2 1 | 0.3 ± 0.2 2 | 0.0 ± 0.1 3 | 0.0 ± 0.1 4 | p<0.001 |
| IL-6 in semen (pg/ml) | 154 ± 161 1-4 | 39 ± 41 1 | 28 ± 18 2 | 22 ± 15 3 | 20 ± 12 4 | p<0.001 |
| WBCs in EPS (M/ml) | 2.3 ± 3.3 | 4.5 ± 5.5 1,2 | 0.4 ± 0.3 1 | 0.0 ± 0.1 2 | nd | p<0.001 |
| WBCs in post-M by cytology (WBC per HPF visual field) | 6.7 ± 7.3 1 | 12.6 ± 11.7 1,2,3 | 0.8 ± 0.8 2 | 0.7 ± 0.8 3 | nd | p<0.001 |
| WBCs in post-M by haemocytometer (WBC/mm3) | 98.2 ± 172.2 1,2 | 69.3 ± 123.1 3,4 | 0.1 ± 0.3 1,3 | 0.3 ± 0.6 2,4 | nd | p=0.002 |
| IL-6 in EPS (pg/ml) | 209 ± 223 1,2 | 283 ± 784 3,4 | 45 ± 58 1,3 | 37 ± 16 2,4 | nd | p=0.002 |
| DC in seminal plasma (μM) | 11.6 ± 6.0 1,2 | 9.9 ± 7.4 3,4 | 9.2 ± 7.5 | 5.5 ± 4.1 1,3 | 5.1 ± 2.0 2,4 | p<0.001 |
| ROS-TAC score | 5.9 ± 4.1 1-3 | 4.5 ± 3.5 4,5 | 3.5 ± 2.9 1 | 2.3 ± 1.6 2,4 | 1.8 ± 0.9 3,5 | p<0.001 |
| 8-isoprostanes in urine (ng/mmol creatinine) | 86.7 ± 26.3 1-3 | 69.9 ± 34.9 4,5 | 51.1 ± 27.2 1 | 49.3 ± 21.6 2,4 | 39.3 ± 14.8 3,5 | p<0.001 |
| Characteristicb | Cases | Controls | ||
| Adult Glioma Study (n = 622) | The Cancer Genome Atlas (n = 70) | Adult Glioma Study (n = 602) | Illumina iControls (n = 3,390) | |
| Age | 55 ± 0.5 | 54 ± 1.7 | 56 ± 0.6 | 29 ± 0.4 |
| GENDER | ||||
| Male | 398 (64%) | 40 (57%) | 319 (53%) | 1,254 (37%) |
| Female | 224 (36%) | 30 (43%) | 283 (47%) | 2,136 (63%) |
| TUMOR SUBTYPE | ||||
| Grade III | 97 (16%) | 0 (0%) | – | – |
| Grade IV | 525 (84%) | 70 (100%) | – | – |
| Components | East-West | North-South | Vertical | |
| RMS | ||||
| Relative positioning | Code (m) | 0.66 | 1.07 | 1.80 |
| Carrier-phase (cm) | 1.35 | 2.49 | 3.15 | |
| Velocity estimation (cm/s) | 1.35 | 1.70 | 3.23 |
| Variable | ß (95 % CI) | P | Adjusted R2 |
| PAP | 2.0 (0.3, 3.8) | 0.025 | 0.19 |
| PCWP | 4.0 (0.8, 7.3) | 0.017 | 0.22 |
| RAP | 5.6 (2.3, 8.9) | 0.002 | 0.38 |
| Estimate | Standard error | z Value | Pr(>|z|) | |
| Reference value: the fifth graders | ||||
| Intercept | -0.89 | 0.13 | -6.68 | 0.000*** |
| Strategy | -0.37 | 0.09 | -4.36 | 0.000*** |
| Cued strategy | 1.18 | 0.09 | 13.69 | 0.000*** |
| Correct sum | 0.00 | 0.00 | 2.11 | 0.035* |
| Sum of unit digits | 0.02 | 0.02 | 0.74 | 0.458 |
| Arithmetic fluency | -0.01 | 0.01 | -0.89 | 0.371 |
| Age value: the third graders | ||||
| Age | 0.11 | 0.19 | 0.58 | 0.561 |
| Age × Strategy | 1.03 | 0.12 | 8.36 | 0.000*** |
| Age × Cued strategy | -0.82 | 0.12 | -6.64 | 0.000*** |
| Age × Sum of unit digits | 0.00 | 0.04 | 0.00 | 0.999 |
| Age × Correct sum | 0.00 | 0.00 | -1.67 | 0.096 |
| Age × Arithmetic fluency | 0.01 | 0.01 | 0.40 | 0.689 |
| Age value: the seventh graders | ||||
| Age | -0.42 | 0.18 | -2.27 | 0.023* |
| Age × Strategy | 0.09 | 0.13 | 0.74 | 0.460 |
| Age × Cued strategy | 1.27 | 0.13 | 9.94 | 0.000*** |
| Age × Correct sum | 0.00 | 0.00 | -0.11 | 0.911 |
| Age × Sum of unit digits | -0.03 | 0.04 | -0.86 | 0.389 |
| Age × Arithmetic fluency | 0.01 | 0.01 | 0.49 | 0.628 |
| Disease category | # of specific genes | Total genes | % of specific genes |
| ASD | 189 | 321 | 69.8 |
| FASD | 27 | 106 | 25.5 |
| CP | 23 | 124 | 22.1 |
| Gr A (N = 32) | Gr B (N = 87) | P value | |
| Mean follow-up | 710 ± 242 | 766 ± 426 days | 0.48 |
| Binary restenosis rate (by duplex US PSV ratio>2.5) | |||
| 6 months | 11/30 = 37% | 11/80 = 14% | 0.007 |
| 12 months | 20/30 = 67% | 24/74 = 32% | 0.001 |
| 24 months | 19/23 = 83% | 31/55 = 56% | 0.028 |
| Target vessel revascularization rate | |||
| 6 months | 9/30 = 30% | 7/80 = 9% | 0.005 |
| 12 months | 16/30 = 53% | 21/73 = 29% | 0.018 |
| 24 months | 15/23 = 65% | 24/53 = 45% | 0.11 |
| Stent fracture rate | |||
| 12 months | 0 | 3/122 (2.5%) | 0.51 |
| 24 months | 1/16 (6.3%) | 5/74 (6.8%) | 0.71 |
| Metabolite | Gene involved in biosynthesis | Locus number | Biological Evidence | Reference |
| Pyoverdine | pvdSL; pvdIJKDEONMP; fpvI; pvdA | PSF113_1749-1750; PSF113_1836-1847; PSF113_1856-1860 | Yes | [2] |
| Pyridine-2,6-bis-thiocarboxylic acid (PDTC) | pdtCKPELMFGHIJON | PSF113_2605-2618 | No | |
| 2,4 diacetyl-phloroglucinol (DAPG) | phlIEDBCAFGH | PSF113_2457-2464 | Yes | [4] |
| Hydrogen cyanide (HCN) | hcnABC | PSF113_2367-2369 | Yes | [83] |
| Putative Lankacidin | lkcABCDEFGJ; pqqFABCDEG | PSF113_3657-3666; PSF113_5383-5388 | No | |
| PKS-like metabolite | PSF113_3045-3053 | No |
| Parameter | P | Odds ratio (OR) | 95% confidence interval (CI) |
| Maternal age | 0.846 | 0.995 | 0.943–1.050 |
| Multiparity | 0.293 | 0.751 | 0.459–1.235 |
| Previous uterine surgery (including myomectomy, caesarean section, reconstructive surgery, or septum resection) | 0.490 | 1.132 | 0.718–1.784 |
| BMI | |||
| Extremely low (under 18.5) | 0.402 | 0.538 | 0.126–2.290 |
| High (above 30) | 0.544 | 0.764 | 0.320–1.823 |
| Supernumerary embryos developed in IVF cycle | 0.275 | 1.269 | 0.827–1.946 |
| Transfer of 2 embryos | 0.043 | 1.952 | 0.020–3.735 |
| Spontaneous cycle ET | 0.064 | 0.417 | 0.150–1.164 |
| Abrupt | Gradual 1 | Gradual 2 | All treatments | |
| Randomized, n | 41 | 40 | 42 | 123 |
| Safety population, n | 40 | 39 | 42 | 121 |
| Completed, % | 75 | 72 | 88 | 79 |
| Discontinued, % | 25 | 28 | 12 | 21 |
| Adverse event | 5 | 15 | 5 | 8 |
| Withdrew consent | 10 | 8 | 0 | 6 |
| Insufficient response | 5 | 0 | 0 | 2 |
| Lost to follow-up | 0 | 3 | 2 | 2 |
| Noncompliance | 0 | 0 | 2 | 1 |
| Other | 5 | 3 | 2 | 2 |
| Survival rate | |||||||
| Total mRNA injected (pg) | 1 day | 2 daysa | 4 days | 6 days | 15 days | 18 weeks | |
| WT | N.A. | 86% (6/7) | 80% (4/5) | 80% (4/5) | 80% (4/5) | 80% (4/5) | 80% (4/5) |
| TALEN1 | 300 | 88% (7/8) | 83% (5/6) | 0% (0/6) | 0% (0/6) | 0% (0/6) | 0% (0/6) |
| 200 | 90% (9/10) | 88% (7/8) | 13% (1/8) | 13% (1/8) | 13% (1/8) | 13% (1/8) | |
| 100 | 100% (9/9) | 100% (7/7) | 43% (3/7) | 29% (2/7) | 14% (1/7) | 0% (0/7) | |
| 50 | 100% (8/8) | 100% (6/6) | 83% (5/6) | 83% (5/6) | 67% (4/6) | 33% (2/6) | |
| TALEN2 | 300 | 100% (8/8) | 33% (2/6) | 0% (0/6) | 0% (0/6) | 0% (0/6) | 0% (0/6) |
| 200 | 88% (7/8) | 67% (4/6) | 0% (0/6) | 0% (0/6) | 0% (0/6) | 0% (0/6) | |
| 100 | 100% (8/8) | 100% (6/6) | 50% (3/6) | 50% (3/6) | 0% (0/6) | 0% (0/6) | |
| 50 | 100% (8/8) | 83% (5/6) | 67% (4/6) | 50% (3/6) | 50% (3/6) | 50% (3/6) |
| Cat Demographics | Free Cats n = 73 (%) | Normal-Fee Cats n = 78 (%) |
| Cat Ages | ||
| Age range | 1–16 years | 1–14 years |
| Age mean | 4 years | 3 years |
| Cat Sex | ||
| TOTAL females | 52 (71) | 57 (73) |
| Female adults | 46 (63) | 54 (69) |
| Female matures | 6 (8) | 3 (4) |
| TOTAL males | 21 (29) | 21 (27) |
| Male adults | 16 (22) | 19 (24) |
| Male matures | 5 (7) | 2 (3) |
| Pelage Varieties | ||
| Blacks and Browns | 9 (12) | 6 (8) |
| Calicos and Tortoiseshells | 8 (11) | 17 (22) |
| Brindles and Gingers | 9 (12) | 4 (5) |
| Greys and Whites | 9 (12) | 13 (17) |
| Piebalds | 12 (16) | 13 (17) |
| Tabbies | 26 (36) | 25 (32) |
| Cat Fate | ||
| Alive and Retained by original adopter | 68 (93) | 75 (96) |
| 1 Dead | 3 (4) | 0 (0) |
| 2 Returned to shelter | 0 (0) | 3 (4) |
| 3 Rehomed privately | 1 (1) | 0 (0) |
| 4 Ran away | 1 (1) | 0 (0) |
| Variable | Total (N = 118) | Non–diabetes mellitus (N = 109) | Diabetes mellitus (N = 9) | P |
| Gastric lavage, n (%) | 95 (80.5) | 89 (81.7) | 6 (66.7) | 0.275 |
| Active charcoal and magnesium citrate, n (%) | 88 (74.6) | 83 (76.1) | 5 (55.6) | 0.173 |
| Atropine, n (%) | 116 (98.3) | 108 (99.1) | 8 (88.9) | 0.023* |
| Pralidoxime, n (%) | 115 (97.5) | 107 (98.2) | 8 (88.9) | 0.089 |
| Time from poisoning to hospital, hours (median, IQR) | 3.0 (2.0, 5.0) | 3.0 (2.0, 5.0) | 3.5 (2.0, 9.0) | 0.893 |
| Duration of follow-up, months (median, IQR) | 1.25 (0.40, 9.06) | 1.23 (0.43, 8.63) | 2.27 (0.25, 15.67) | 0.219 |
| Mortality, n (%) | 18 (15.3) | 15 (13.8) | 3 (33.3) | 0.117 |
| Cause of death, n (%) | 0.333 | |||
| Cardiogenic | 10 (8.5) | 8 (7.3) | 2 (22.2) | |
| Respiratory failure | 6 (5.1) | 5 (4.6) | 1 (11.1) | |
| Sepsis | 2 (1.7) | 2 (1.8) | 0 (0.0) |
| Bariatric Surgery (N = 34) | Lifestyle Intervention (N = 34) | P | |
| Age (yrs) | 43.3 ± 9.4 | 40.9 ± 10.5 | 0.33 |
| % Female | 76.5 | 76.5 | 1.00 |
| % Race | 0.25 | ||
| White | 79.4 | 70.6 | |
| African-American | 5.9 | 14.7 | |
| American Indian/Alaskan Native | 2.9 | 0.0 | |
| Native Hawaiian/Other Pacific Islander | 2.9 | 0.0 | |
| Other | 8.8 | 5.9 | |
| Don’t know | 0.0 | 8.8 | |
| % Ethnicity | 1.00 | ||
| Non-Hispanic | 91.2 | 91.2 | |
| Hispanic | 8.8 | 8.8 | |
| BMI (kg/m2) | 46.2 ± 7.8 | 45.0 ± 4.9 | 0.49 |
| Weight (kg) | 129.9 ± 27.6 | 127.7 ± 19.6 | 0.71 |
| American (N = 419)* | Taiwanese (N = 2062) | P-value | |
| Age | 53.2 ± 13.7 | 47.6 ± 13.6 | |
| Gender | <.0001 | ||
| Female | 64.6% (265/410) | 51.5% | |
| Male | 35.4% (145/410) | 48.5% | |
| Acute myocardial infarction | 6% (24/399) | 2.9% | 0.0567 |
| Comorbidities | |||
| Hypertension | 86.6% (356/411) | 81.1% | 0.0081 |
| Diabetes mellitus | 8.7% (36/412) | 15.0% | 0.0008 |
| Dyslipidemia | 45.7% (188/411) | 34.6% | <.0001 |
| Arrhythmia | 25.9% (103/398) | 19.3% | 0.0028 |
| Heart failure | 9.5% (38/400) | 10.5% | 0.5527 |
| Valvular heart disease | 14.4% (57/397) | 8.5% | 0.0003 |
| Peripheral vascular disease | 16.5% (66/400) | 6.6% | <.0001 |
| Registered indications | Prophylaxis of bleeding related to surgical or invasive interventions as well as treatment of bleeding in patients with |
| -Congenital hemophilia A or B if inhibitors are present (>5 Bethesda units) or if a strong increase of inhibitors must be expected upon administration of factor VIII or IX [41] | |
| - Acquired hemophilia [42] | |
| - Congenital factor VII deficiency [43] | |
| - Glanzmann thrombasthenia with antibodies to glycoprotein IIb/IIIa and/or human leucocyte antigen and presence or history of refractoriness to platelet concentrates [44] | |
| Potential indications | Prophylaxis of surgical bleeding in patients with reduced activity or deficiency of coagulation factors, especially with specific inhibitors to plasmatic factors [45] and acquired von Willebrand disease [46] |
| Treatment of bleedings after all conventional measures have failed in patients with | |
| - Chronic liver disease [47] | |
| - Thrombocytopathy [48] | |
| - Platelet-refractory thrombopenia [49] | |
| - Bleeding complications due to trauma or surgery in patients without any detectable systemic impairment of hemostasis (references in Tables 3 and 4) | |
| - Drug-induced bleeding, especially by hirudine (in connection with supportive measures), danaparoid, fondaparinux, and glycoprotein IIb/IIIa inhibitors [50] |
| Hol | Tul | Ban | Bis | Gau | Mit | Yak | Anc | BubB | BubC | Ind | Mur | Syn | Ela | |
| TN | -0.13 | 0.1 | 1.4 | 1.2 | 1.6 | 1.0 | 0.9 | 2.4 | 4.2 | 3.9 | 5.0 | 4.2 | 4.1 | 7.4 |
| TC | -0.25 | 0.15 | 2.6 | 2.1 | 3.0 | 1.9 | 1.6 | 4.5 | 7.7 | 7.0 | 9.1 | 7.9 | 7.7 | 13.7 |
| Compression Bulge Anterior BulgeL | ||||||
| Var. | Df | Sum of Sq. | Mean Square | F Value | p-Value | Significance Code |
| C10 | 1 | 0.00066 | 0.00066 | 35.8 | 2.41 × 10−8 | *** |
| C0 | 1 | 0.00031 | 0.00031 | 16.7 | 8.01 × 10−5 | *** |
| Fiber12 | 1 | 0.00008 | 0.00008 | 4.1 | 4.47 × 10−2 | * |
| Fiber56 | 1 | 0.00006 | 0.00006 | 3.1 | 7.96 × 10−2 | . |
| Fiber78 | 1 | 0.00004 | 0.00004 | 2.0 | 1.58 × 10−1 | |
| Fiber910 | 1 | 0.00005 | 0.00005 | 2.6 | 1.09 × 10−1 | |
| Annulus_E | 1 | 0.00149 | 0.00149 | 81.5 | 4.25 × 10−15 | *** |
| Annulus_μ | 1 | 0.08796 | 0.08796 | 4805.3 | <2.2 × 10−16 | *** |
| Cartil_E | 1 | 0.04237 | 0.04237 | 2314.5 | <2.2 × 10−16 | *** |
| Cartil_μ | 1 | 0.00054 | 0.00054 | 29.4 | 3.24 × 10−7 | *** |
| Residuals | 117 | 0.00214 | 0.00002 |
| Domain/outcome | Questionnaire/items | Assessment time point | Reference | |||
| Primary Outcome | t1 | t2 | t3 | t4 | ||
| Physical functioning | Hannover Functional Ability Questionnaire (FfbH-R) | x | x | x | x | [51] |
| Secondary Outcomes | ||||||
| Pain | ||||||
| Pain intensity | Numeric Rating Scale (NRS) | x | x | x | x | [52] |
| Pain status | Graded Chronic Pain Status (GCPS) | x | x | x | x | [53] |
| Physical activity | Freiburg questionnaire on physical activity (FFkA) | x | x | x | [54] | |
| Emotional functioning | ||||||
| Depression | Patient Health Questionnaire (PHQ-D) | x | x | x | x | [55] |
| Anxiety | Generalized anxiety disorder 7-item scale (GAD-7) | x | x | x | x | [56] |
| Health related quality of life | Short-Form-12 (SF-12) | x | x | x | x | [57] |
| Stress | Perceived Stress Scale (PSS) | x | x | x | x | [58] |
| Pain related cognitions, emotions and behavior | ||||||
| Cognitive and behavioral pain coping strategies | Pain Management Questionnaire (FESV) | x | x | x | x | [59] |
| Fear-avoidance and endurance-related responses to pain | Avoidance-Endurance Questionnaire (AEQ) | x | x | x | x | [60] |
| Pain related fear | Tampa Scale for Kinesiophobia (TSK) | x | x | x | x | [61,62] |
| Motivational and volitional determinants of physical activity | ||||||
| risk perception (3 items), self-efficacy (3 items), outcome expectancies (11items), experiences with physical activity (5 items), self-concordance (12 items), intention (7 items), action (4 items) and coping (4 items) planning, action control (6 items) | x | x | x | x | [63-67] | |
| Stage of change algorithm for physical activity | two Items (Have you performed moderate physical for 30 minutes or longer on a minimum of 3 days per week? and \"Since when are you as regularly active as you are now?\"; possible answers: 1. Question: no, and I don’t intend to do so; no, but I am thinking about doing so; no, but I have the strong intention to do so; yes, but it is difficult to me; yes, and it is easy for me; 2. Question: open) | x | x | x | x | [68,69] |
| Attitudes towards performing physical activity | modified Version of Short-Questionnaire to measure cognitive and affective attitudes toward sports activities | x | x | x | x | [70] |
| Treatment satisfactions with exercise therapy | 18 items (e.g. “I would recommend the exercise therapy other patients.” measured by using a six-point ordinal scale with 1= “absolutely agree”, 6=“absolutely disagree”; e.g. “The time extent of the exercise therapy, I perceived as...” measured by using a five-point ordinal scale with 1=“far too high“, 5=“far too low“; e.g. “Overall, how do you rate the exercise therapy?” measured by using a six-point ordinal scale with 1= “very satisfied”, 6=not “satisfied at all”) | x | self-designed | |||
| Treatment satisfactions with the rehabilitation process | five items (e.g. “Overall, how do you rate the rehabilitation process?”) measured by using a ten-point ordinal scale (1= “very poor”, 10 = „excellent“) | x | self-designed | |||
| Others | ||||||
| Demographic characteristics | sex, age, height, nationality, marital status, education, monthly income, weight, self-reported work status | x | [71] | |||
| Social medical characteristics | a) self-reported low back pain related sick leave, use of health care services, medication use for the last six month and self-reported plan to apply for retirement, severe disabilities | x | [71] | |||
| b) diagnosis, work status and physical capability taken from the hospital discharge report | x | |||||
| Aftercare | a) aftercare recommendations taken from the hospital discharge report | x | self-designed | |||
| b) self-designed; five items (e.g. “Have you participated in the last twelve months in a medically prescribed exercise therapy to rehabilitation aftercare?” with the option to answer yes/no) | x | |||||
| Job satisfaction | scale on job satisfaction (IRES-3) | x | x | [72] |
| Incremental Difference: Complete Banvs.Current Legislation | Incremental Difference: Optimistic Case | Incremental Difference: Worst Case | |
| Gross Intervention Costs (C) | 3,994,645 | 1,996,438 | 5,067,102 |
| AMI Treatment Costs Saved (T) | 40,051,602 | 237,927,598 | 1,626,740 |
| All Tobacco-Attributable Treatment Costs Saved (T) | 99,609,250 | 946,905,837 | 2,527,779 |
| Net Costs (AMI Treatment) *(C-T) | –36,056,957 | –235,931,160 | 3,440,362 |
| Net Costs (All Tobacco-Attributable Disease Treatment) * (C-T) | –95,614,605 | –944,909,399 | 2,539,322 |
| AMI Cases Averted (A) | 17,478 | 53,361 | 13,109 |
| Smokers Quitting (Q) | 221,154 | 385,100 | 46,060 |
| Life Years Gained (L) | 437,589 | 891,945 | 45,268 |
| Incremental Cost-Effectiveness Ratios | |||
| Cost per LY Gained (C-T)/(L) | Cost Saving | Cost Saving | 56 (USD) Highly Cost-Effective |
| Cost per LY Gained w/out Medical Treatment Saved (C/L) | 9.13 (USD) Highly Cost-Effective | 2.24(USD) Highly Cost-Effective | 112 (USD) Highly Cost-Effective |
| Cost per AMI Case Averted (C-T)/A | Cost Saving | Cost Saving | 262 (USD) Highly Cost-Effective |
| Cost per AMI Case Averted w/out Medical Treatment Saved (C/A) | 229 (USD) Highly Cost-Effective | 37 (USD) Highly Cost-Effective | 387 (USD) Highly Cost-Effective |
| stx1a | stx2a | stx2d | stx1a+2a | stx1a+2d | stx negative | Total | |
| ST21 | 353 | 20 | 2 | 44 | 1 | 17 | 437 |
| SLV of ST21 | 5 | 1 | 0 | 0 | 0 | 0 | 6 |
| ST29 | 1 | 27 | 3 | 0 | 0 | 45 | 76 |
| SLV of ST29 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Total | 359 | 48 | 5 | 44 | 1 | 63 | 520 |
| T. trichiura Uganda | T. trichiura China | T. trichiura Ecuador | |
| T. trichiura Uganda | 0.979** | 0.932*** | |
| T. trichiura China | 0.984** | 0.551* | |
| T. trichiura Ecuador | 0.967*** | 0.778* |
| Experimental treatment | Staphylococcus aureus | Streptococcus agalactiae | Group G Streptococci | Streptococcus pyogenes | Streptococcus pneumoniae | Biofilm-forming strainS. aureus (ATCC 25923) | Nonbiofilm-forming strainE. coli (ATCC 25922) |
| OD ± SD | OD ± SD | OD ± SD | OD ± SD | OD ± SD | OD ± SD | OD ± SD | |
| With compound FR4 | 0.254 ± 0.004 | 0.205 ± 0.005 | 0.199 ± 0.010 | 0.191 ± 0.003 | 0.230 ± 0.004 | 0.246 ± 0.004 | 0.186 ± 0.004 |
| Without compound | 0.484 ± 0.008 | 0.215 ± 0.002 | 0.253 ± 0.002 | 0.304 ± 0.003 | 0.371 ± 0.002 | 0.395 ± 0.003 | 0.216 ± 0.073 |
| With compound FR5* | 0.224 ± 0.004 | 0.166 ± 0.005 | 0.158 ± 0.002 | 0.153 ± 0.005 | 0.224 ± 0.004 | 0.166 ± 0.005 | 0.158 ± 0.002 |
| Without compound | 0.368 ± 0.028 | 0.304 ± 0.003 | 0.377 ± 0.122 | 0.363 ± 0.079 | 0.445 ± 0.042 | 0.030 ± 0.038 | 0.224 ± 0.005 |
| With compound FR13 | 0.208 ± 0.004 | 0.205 ± 0.004 | 0.195 ± 0.004 | 0.216 ± 0.004 | 0.235 ± 0.004 | 0.254 ± 0.004 | 0.165 ± 0.004 |
| Without compound | 0.404 ± 0.003 | 0.276 ± 0.056 | 0.262 ± 0.003 | 0.257 ± 0.024 | 0.277 ± 0.002 | 0.378 ± 0.003 | 0.254 ± 0.003 |
| With 2(5H)-furanone (+ve control) | 0.119 ± 0.002 | 0.123 ± 0.003 | 0.116 ± 0.004 | 0.117 ± 0.001 | 0.121 ± 0.001 | 0.107 ± 0.004 | 0.116 ± 0.002 |
| Without compound | 0.257 ± 0.003 | 0.216 ± 0.005 | 0.206 ± 0.055 | 0.202 ± 0.099 | 0.214 ± 0.030 | 0.216 ± 0.005 | 0.211 ± 0.002 |
| With BHI broth (−ve control) | 0.057 ± 0.038 | 0.050 ± 0.006 | 0.021 ± 0.002 | 0.069 ± 0.020 | 0.095 ± 0.012 | 0.084 ± 0.006 | 0.084 ± 0.006 |
| Without compound | 0.254 ± 0.003 | 0.243 ± 0.045 | 0.211 ± 0.002 | 0.243 ± 0.045 | 0.270 ± 0.042 | 0.243 ± 0.002 | 0.208 ± 0.074 |
| Aurora A and p27 expression | P | ||||
| 2H | 1H1L | 2L | |||
| Sex | |||||
| Male | 63 | 54 | 7 | 2 | 0.191 |
| Female | 17 | 15 | 2 | 0 | |
| Age (years) | |||||
| <60 | 27 | 22 | 5 | 0 | 0.071 |
| >=60 | 53 | 47 | 6 | 0 | |
| Tumor volume (cm3) | |||||
| <=5 | 46 | 40 | 6 | 0 | 0.203 |
| >5 | 34 | 29 | 3 | 2 | |
| Tumor location | |||||
| Up | 19 | 15 | 4 | 0 | 0.687 |
| Middle | 22 | 19 | 3 | 0 | |
| Down | 39 | 35 | 4 | 0 | |
| Pathological grade | |||||
| II | 26 | 20 | 6 | 0 | 0.991 |
| II–III | 25 | 25 | 0 | 0 | |
| III | 29 | 24 | 3 | 2 | |
| Invasion stage | |||||
| Mucosal and submucosal | 1 | 1 | 0 | 0 | 0.372 |
| Muscular layer | 8 | 7 | 1 | 0 | |
| Serous membrane and outmembrane | 71 | 61 | 8 | 2 | |
| Lymph node metastasis | |||||
| 0 | 17 | 16 | 1 | 0 | 0.510 |
| 1–6 | 36 | 29 | 7 | 0 | |
| >=7 | 27 | 24 | 3 | 0 | |
| TNM stage | |||||
| I | 5 | 5 | 0 | 0 | 0.031 |
| II | 22 | 19 | 3 | 0 | |
| III | 46 | 41 | 3 | 2 | |
| IV | 7 | 4 | 3 | 0 | |
| Total | 80 | 80 |
| Inhalation repeats | PIF cut-off value (L/min) | Sensitivity (%) | Specificity (%) | AUC | Positive predictive value (%) | Negative predictive value (%) |
| I | 140 | 84 | 53 | 0.69 | 81 | 59 |
| II | 120 | 86 | 69 | 0.83 | 69 | 86 |
| III | 100 | 89 | 76 | 0.89 | 59 | 95 |
| IV | 100 | 87 | 71 | 0.86 | 48 | 95 |
| Q1 a | Q2 a | Q3 a | Q4 a | Pb | n | β % c | 95% CI | ||
| Men n=2 264 | |||||||||
| PNNS-GS range | ≤8.05 | [8.05-9.30] | [9.30-10.70] | >10.70 | |||||
| BMI kg/m2 | 26.4 (25.9-26.9) | 25.7 (25.2-26.2) | 25.7 (25.2-26.2) | 25.2 (24.7-25.7) | <.0001 | 2264 | -6.49 | -8.40 | -4.54 |
| WC (cm)d | 94.8 (93.3-96.2) | 92.5 (91.1-93.9) | 92.1 (90.7-93.5) | 90.1 (88.8-91.5) | <.0001 | 2264 | -8.37 | -10.15 | -6.55 |
| HC (cm)d | 100.4 (99.5-101.3) | 99.0 (98.1-99.9) | 99.2 (98.3-100.1) | 98.1 (97.3-99.0) | <.0001 | 2261 | -6.57 | -8.47 | -4.63 |
| WHR | 0.94 (0.94-0.95) | 0.93 (0.93-0.94) | 0.93 (0.92-0.94) | 0.92 (0.91-0.93) | <.0001 | 2261 | -7.41 | -9.19 | -5.59 |
| WHtR | 0.54 (0.54-0.55) | 0.53 (0.52-0.54) | 0.53 (0.52-0.54) | 0.52 (0.51-0.52) | <.0001 | 2264 | -8.26 | -10.00 | -6.47 |
| % body fat | 21.2 (20.1-22.4) | 19.7 (18.7-20.8) | 19.7 (18.6-20.7) | 17.7 (16.8-18.7) | <.0001 | 2235 | -8.60 | -10.40 | -6.76 |
| trunk fat mass (kg)d | 10.2 (9.4-11.0) | 9.1 (8.4-9.9) | 9.0 (8.3-9.8) | 7.7 (7.1-8.4) | <.0001 | 2235 | -7.27 | -9.12 | -5.38 |
| % trunk fat | 22.3 (20.9-23.9) | 20.5 (19.2-21.9) | 20.3 (19.0-21.7) | 17.8 (16.6-19.0) | <.0001 | 2235 | -9.11 | -11.00 | -7.22 |
| leg fat mass (kg)d | 4.99 (4.73-5.27) | 4.58 (4.34-4.83) | 4.61 (4.37-4.87) | 4.26 (4.03-4.49) | <.0001 | 2235 | -9.05 | -10.88 | -7.18 |
| % leg fat | 19.5 (18.8-20.3) | 18.4 (17.7-19.2) | 18.6 (17.9-19.3) | 17.4 (16.8-18.1) | <.0001 | 2235 | -6.81 | -8.56 | -5.02 |
| TLR | 2.04 (1.95-2.13) | 1.98 (1.90-2.07) | 1.95 (1.86-2.04) | 1.81 (1.73-1.89) | <.0001 | 2235 | -8.11 | -10.10 | -6.05 |
| Women n=5 638 | |||||||||
| PNNS-GS range | ≤8.17 | [8.17-9.52] | [9.52-10.80] | >10.8 | |||||
| BMI kg/m2 | 24.0 (23.5-24.4) | 23.9 (23.5-24.3) | 23.7 (23.3-24.1) | 23.3 (22.8-23.7) | <.0001 | 5639 | -2.73 | -3.99 | -1.45 |
| WC (cm)d | 81.3 (80.2-82.5) | 80.8 (79.7-81.9) | 79.9 (78.8-81.0) | 78.9 (77.8-80.0) | <.0001 | 5639 | -3.96 | -5.21 | -2.69 |
| HC (cm)d | 99.3 (98.4-100.2) | 98.9 (98.0-99.8) | 98.5 (97.5-99.4) | 97.6 (96.6-98.5) | <.0001 | 5636 | -3.28 | -4.57 | -1.97 |
| WHR | 0.82 (0.81-0.83) | 0.82 (0.81-0.82) | 0.81 (0.80-0.82) | 0.81 (0.80-0.82) | <.0001 | 5636 | -2.92 | -4.22 | -1.60 |
| WHtR | 0.50 (0.49-0.51) | 0.50 (0.49-0.50) | 0.49 (0.48-0.50) | 0.49 (0.48-0.49) | <.0001 | 5639 | -4.09 | -5.32 | -2.85 |
| % body fat | 29.5 (28.7-30.4) | 29.2 (28.4-30.1) | 28.6 (27.7-29.4) | 27.6 (26.8-28.5) | <.0001 | 5590 | -4.18 | -5.44 | -2.89 |
| trunk fat mass (kg)d | 9.3 (8.6-10.0) | 9.1 (8.5-9.9) | 8.8 (8.1-9.5) | 8.3 (7.6-8.9) | <.0001 | 5590 | -1.20 | -1.61 | -0.79 |
| % trunk fat | 24.8 (23.7-25.9) | 24.7 (23.6-25.9) | 23.9 (22.8-25.0) | 22.8 (21.8-23.9) | <.0001 | 5590 | -3.47 | -4.79 | -2.15 |
| leg fat mass (kg)d | 8.2 (7.9-8.5) | 8.1 (7.8-8.4) | 7.9 (7.6-8.2) | 7.6 (7.4-7.9) | <.0001 | 5590 | -2.09 | -2.81 | -1.37 |
| % leg fat | 36.3 (35.7-37.0) | 35.9 (35.3-36.6) | 35.4 (34.8-36.0) | 34.7 (34.1-35.3) | <.0001 | 5590 | -4.71 | -5.91 | -3.49 |
| TLR | 1.04 (1.00-1.07) | 1.05 (1.01-1.08) | 1.02 (0.99-1.06) | 1.00 (0.96-1.04) | 0.001 | 5590 | -0.67 | -1.12 | -0.21 |
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | |
| A | 224 | 228 | 186 | 146 | 213 | 67 | 756 | 0 | 865 | 670 | 770 | 444 | 282 | 131 | 182 | 164 | 185 | 184 | 141 | 179 | 165 |
| C | 226 | 203 | 239 | 229 | 310 | 84 | 0 | 5 | 0 | 0 | 0 | 15 | 99 | 274 | 272 | 273 | 273 | 264 | 286 | 283 | 304 |
| G | 301 | 291 | 333 | 302 | 225 | 71 | 0 | 8 | 2 | 0 | 119 | 224 | 437 | 394 | 301 | 337 | 275 | 303 | 328 | 276 | 275 |
| T | 146 | 175 | 139 | 220 | 149 | 675 | 141 | 884 | 30 | 201 | 8 | 214 | 79 | 98 | 142 | 123 | 164 | 146 | 142 | 159 | 153 |
| Con | N | N | N | N | N | T | A | T | A | A | A | D | W | N | N | N | N | N | N | N | N |
| FIGO stage after definitive histology | |||||||
| PresumedStage on MRI | IA | IB | IC | IIA | IIB | IIIA | Total |
| IA | 28.5% | 43% | 14.2% | 0 | 14.2% | 0 | 14 |
| IB | 31.5% | 40% | 23% | 5.5% | 0 | 0 | 35 |
| IC | 0 | 18.5% | 74% | 3.7% | 0 | 3.7 | 27 |
| IIA | 0 | 67% | 33% | 0 | 0 | 0 | 3 |
| IIB | 0 | 50% | 0 | 0 | 0 | 50% | 2 |
| IIIA | 0 | 0 | 100% | 0 | 0 | 0 | 1 |
| Total | 18.3% | 34% | 39% | 3.5% | 2.5% | 2.5% | 82 |
| Low ox-LDL<69.4 U/L(n = 80) | High ox-LDL≥ 69.4 U/L(n = 80) | P-value* | |
| Women (%) | 60.8 | 52.6 | 0.305 |
| Age (y) | 23.1 ± 3.6 | 23.4 ± 3.4 | 0.145 |
| BMI (kg/m2) | 21.6 ± 2.8 | 22.4 ± 3.0 | 0.046 |
| Waist circumference (cm) | 78.0 ± 8.7 | 78.3 ± 8.7 | 0.863 |
| Waist-to-hip ratio | 0.8 ± 0.1 | 0.8 ± 0.1 | 0.469 |
| Sum of 4 ST (mm) | 42.6 ± 16.8 | 45.0 ± 20.4 | 0.369 |
| Truncal fat (%) | 57.4 ± 7.1 | 59.3 ± 6.1 | 0.069 |
| Total body fat (%) | 23.8 ± 6.1 | 23.4 ± 7.0 | 0.735 |
| Body fat mass (kg) | 15.0 ± 5.2 | 14.7 ± 5.4 | 0.303 |
| Systolic blood pressure (mmHg) | 109 ± 9 | 110 ± 9 | 0.239 |
| Diastolic blood pressure (mmHg) | 74 ± 7 | 73 ± 7 | 0.257 |
| Glucose (mg/dL) | 90.8 ± 7.0 | 90.3 ± 6.3 | 0.394 |
| Insulin (μU/mL)** | 10.3 ± 5.0 | 10.2 ± 6.0 | 0.302 |
| HOMA-IR** | 2.3 ± 1.2 | 2.3 ± 1.3 | 0.245 |
| Total cholesterol (mg/dL) | 153.4 ± 27.8 | 166.5 ± 33.5 | 0.007 |
| HDL-c (mg/dL) † | 47.3 ± 12.4 | 45.7 ± 10.4 | 0.342 |
| LDL-c (mg/dL) | 91.0 ± 26.6 | 100.2 ± 26.4 | 0.009 |
| Triacylglycerol (mg/dL) | 96.1 ± 49.1 | 103.2 ± 38.5 | 0.059 |
| Total cholesterol-to-HDL-c ratio† | 3.3 ± 0.6 | 3.8 ± 0.9 | <0.001 |
| Uric acid (mg/dL) | 3.4 ± 1.1 | 3.7 ± 1.1 | 0.049 |
| GPx activity (nmol/[mL/min])‡ | 487.9 ± 231.3 | 659.1 ± 299.2 | 0.002 |
| Selenium (ng/g of nail)§ | 396.2 ± 88.0 | 365.5 ± 76.7 | 0.033 |
| Zinc (μg/g of nail)§ | 124.5 ± 57.7 | 132.3 ± 68.7 | 0.212 |
| Copper (μg/g of nail)§ | 7.4 ± 5.5 | 7.1 ± 7.1 | 0.247 |
| Observation | Genotype | Males | Females |
| Body weight (g) | WT | 31.5 ± 18.8 | 20.3 ± 0.9 |
| TG | 25.5 ± 1.7* | 22.2 ± 0.9 | |
| Body length (mm) | WT | 92.8 ± 0.9 | 86.6 ± 0.5 |
| TG | 89.4 ± 1.0* | 87.8 ± 1.1 | |
| Grip strength (score 0–4) | WT | 2.4 ± 0.2 | 1.0 ± 0 |
| TG | 0.8 ± 0.2** | 1.6 ± 0.2 | |
| Wire maneuver (score 0–4) | WT | 1.4 ± 0.2 | 2.8 ± 0.5 |
| TG | 4.0 ± 0*** | 2.0 ± 0.6 | |
| Tail elevation (score 0–2) | WT | 2.0 ± 0 | 1.4 ± 0.2 |
| TG | 1.2 ± 0.2* | 1.2 ± 0.2 |
| Quartile 1 | Quartile 2 | Quartile 3 | Quartile 4 | |
| NBA | 340.6 (357.7) | 371.5 (374.9) | 364.6 (369.7) | 408.9 (398.6) |
| NFL | 65.0 (60.2) | 64.4 (59.7) | 65.6 (57.7) | 67.7 (63.4) |
| NHL | 313.7 (359.3) | 366.6 (424.8) | 394.9 (424.6) | 410.9 (402.6) |
| n | Age (years) | Education (years) | Frailty index | Social vulnerability index | Protection index | CASI error at baseline | |
| Full cohort | 3,845 | 77.9 (4.7) | 10.5 (3.2) | 0.15 (0.09) | 0.25 (0.13) | 0.36 (0.12) | 17.8 (16.4) |
| Alive at first follow-up | 3,347 | 77.4 (4.4) | 10.6 (3.2) | 0.14 (0.08) | 0.25 (0.13) | 0.37 (0.11) | 15.5 (12.5) |
| Dead at first follow-up | 498 | 80.9 (5.4) | 9.8 (3.3) | 0.19 (0.10) | 0.30 (0.15) | 0.30 (0.14) | 33.1 (27.7) |
| Alive at second follow-up | 2,759 | 76.9 (4.0) | 10.7 (3.2) | 0.14 (0.08) | 0.24 (0.12) | 0.37 (0.11) | 14.1 (9.9) |
| Dead at second follow-up | 1,086 | 80.3 (5.3) | 10.0 (3.2) | 0.18 (0.10) | 0.29 (0.0.13) | 0.32 (0.13) | 27.4 (24.1) |
| ID | No. of seed | FA level | Oleic acid (C18:1) | Linoleic acid (C18:2) | Linolenic acid (C18:3) | Erucic acid (C22:1 ) |
| WG4-3 | 18 | Mean ± SD a | 20.1 ± 2.4** | 2.7 ± 0.9** | 3.0 ± 0.8** | 65.5 ± 3.4** |
| Max | 26.3 | 4.7 | 5.4 | 69.3 | ||
| Min | 16.8 | 1.6 | 1.9 | 54.6 | ||
| WG4-4 | 20 | Mean ± SD | 20.0 ± 1.1** | 2.3 ± 0.5** | 3.0 ± 0.5** | 67 ± 2.5** |
| Max | 21.9 | 3.3 | 4.1 | 70.8 | ||
| Min | 18.0 | 1.5 | 2.3 | 60.7 | ||
| WG4-5 | 19 | Mean ± SD | 21.9 ± 3.5** | 2.1 ± 1.8** | 2.3 ± 0.9** | 63.5 ± 3.2 |
| Max | 27.4 | 7.6 | 5.4 | 66.6 | ||
| Min | 11.5 | 1.0 | 1.5 | 55.5 | ||
| WG19-4 | 19 | Mean ± SD | 22.6 ± 2.3** | 1.6 ± 0.2** | 2.5 ± 0.3** | 60.7 ± 5.2 |
| Max | 29.5 | 2.1 | 3.1 | 65.9 | ||
| Min | 20.4 | 1.3 | 1.8 | 46.1 | ||
| WG19-5 | 20 | Mean ± SD | 21.4 ± 3.2** | 2.7 ± 1.8** | 3.3 ± 0.7* | 60 ± 4.6 |
| Max | 27.1 | 9.5 | 5.3 | 64.1 | ||
| Min | 11.3 | 1.3 | 2.3 | 50.2 | ||
| WG19-6 | 20 | Mean ± SD | 18.0 ± 0.9* | 2.0 ± 0.4** | 2.4 ± 0.3** | 66.2 ± 1.0** |
| Max | 20.0 | 2.9 | 3.0 | 68.0 | ||
| Min | 16.4 | 1.4 | 1.9 | 64.5 | ||
| Control | 19 | Mean ± SD | 12.0 ± 0.5 | 8.2 ± 0.4 | 5.1 ± 0.2 | 63.1 ± 0.8 |
| Max | 12.8 | 9.0 | 5.6 | 64.4 | ||
| Min | 10.9 | 7.5 | 4.7 | 61.6 |
| Sample ID | Tumor type | Tumor cell (%) | Sequencing depth (x) | JAK2 p.V617F allele fraction (%) | Co-occurring mutation (allele fraction %) |
| 592 | Non-small cell carcinoma | 30 | 1999 | 8.2 | KRAS p.G12V (17.2) |
| 664 | Adenocarcinoma with squamous features | 50 | 1996 | 7 | BRAF p.V600E (27.3) |
| 717 | Adenocarcinoma | 40 | 1273 | 2 | - |
| 915 | Favoring adenocarcinoma | 60 | 1539 | 2.1 | EGFR exon19 del (52.1) |
| 1182 | Adenocarcinoma | 40 | 1997 | 2.4 | BRAF p.V600E (10.4) |
| 1200 | Mucinous adenocarcinoma | 10 | 1422 | 10.5 | KRAS p.G12V (4.8) |
| 1527 | Adenocarcinoma | 30 | 1997 | 10.8 | - |
| 1588 | Adenocarcinoma, acinar type | 20 | 892 | 6.5 | - |
| 1825 | Adenocarcinoma with mucinous features | 30 | 1998 | 13.4 | KRAS p.G12C (25.4) |
| Instrument | Before therapy (t1) | Four weeks after therapy (t2) | One year after therapy (t3) | Statistics (t1 to t3) | ||||||
| N | Mean Value | SD | Mean Value | SD | Mean Value | SD | Wilcoxon-Test | Effect size d | ||
| SCL-90 R | Global Severity Index | 11 | 0.93 | 0.38 | 0.57 | 0.21 | 0.44 | 0.33 | p = 0.008** | 1.30 |
| Positive Symptom Total | 11 | 44.4 | 12.9 | 36.3 | 10.4 | 27.1 | 16.5 | p = 0.016* | 1.08 | |
| Positive Symptom Distress Index | 11 | 1.84 | 0.39 | 1.4 | 0.19 | 1.37 | 0.29 | p = 0.013* | 1.27 | |
| G1 Somatization | 11 | 0.65 | 0.43 | 0.5 | 0.49 | 0.36 | 0.28 | p = 0.028* | 0.68 | |
| G2 Obsessive-Compulsive | 11 | 0.99 | 0.55 | 0.6 | 0.38 | 0.6 | 0.4 | p = 0.052 | 0.70 | |
| G3 Interpersonal Sensitivity | 11 | 1.21 | 0.51 | 0.92 | 0.49 | 0.46 | 0.44 | p = 0.011* | 1.49 | |
| G4 Depression | 11 | 1.63 | 0.6 | 0.79 | 0.47 | 0.48 | 0.4 | p = 0.004** | 2.14 | |
| G5 Anxiety | 11 | 0.84 | 0.39 | 0.4 | 0.26 | 0.35 | 0.47 | p = 0.014* | 1.05 | |
| G6 Hostility | 11 | 1.08 | 0.59 | 0.57 | 0.45 | 0.85 | 0.73 | p = 0.563 | 0.24 | |
| G7 Phobic Anxiety | 11 | 0.43 | 0.61 | 0.25 | 0.42 | 0.29 | 0.5 | p = 0.572 | 0.23 | |
| G8 Paranoid Ideation | 11 | 0.54 | 0.32 | 0.52 | 0.37 | 0.32 | 0.32 | p = 0.233 | 0.58 | |
| G9 Psychoticism | 11 | 0.42 | 0.4 | 0.3 | 0.21 | 0.18 | 0.22 | p = 0.075 | 0.64 | |
| S10 Additional Items | 11 | 9.42 | 5.04 | 5.88 | 2.85 | 4.91 | 3.65 | p = 0.032* | 1.01 | |
| YSR | Global Score | 11 | 71.5 | 11.3 | 45.5 | 22.6 | 41.8 | 19.2 | p = 0.003** | 1.82 |
| Internalizing Behavior | 11 | 26.8 | 5.3 | 15.9 | 8.1 | 14.6 | 9.3 | p = 0.007** | 1.54 | |
| Externalizing Behavior | 11 | 19.7 | 8.4 | 15.2 | 9.5 | 14.5 | 7.4 | p = 0.008** | 0.57 | |
| Social Withdrawal | 11 | 7.08 | 2.61 | 4.38 | 3.16 | 3.91 | 2.77 | p = 0.016* | 1.13 | |
| Somatic Complaints | 11 | 4.0 | 2.63 | 2.63 | 2.13 | 3.09 | 2.94 | p = 0.505 | 0.26 | |
| Anxious/Depressed | 11 | 17.08 | 4.5 | 9.75 | 5.2 | 8.09 | 7.03 | p = 0.008** | 1.47 | |
| Social Problems | 11 | 4.0 | 2.22 | 2.13 | 1.64 | 1.91 | 2.21 | p = 0.058 | 0.86 | |
| Schizoid/Obsessive | 11 | 3.0 | 2.34 | 1.5 | 1.51 | 0.91 | 1.45 | p = 0.011* | 1.04 | |
| Attention Problems | 11 | 8.67 | 2.35 | 3.88 | 2.03 | 4.45 | 3.14 | p = 0.005** | 1.46 | |
| Delinquent Behaviors | 11 | 6.42 | 3.26 | 5.0 | 2.62 | 4.55 | 2.07 | p = 0.041* | 0.54 | |
| Aggressive Behaviors | 11 | 13.25 | 5.71 | 10.13 | 7.02 | 9.91 | 5.74 | p = 0.014* | 0.54 | |
| DIKJ | Average Score Per Item | 10 | 0.78 | 0.2 | 0.45 | 0.21 | 0.41 | 0.23 | p = 0.022* | 1.51 |
| Ligand | Kd (μM) | ΔH (kcal/mol) | TΔS (kcal/mol) | n Value |
| α-KG | 34.4 ± 6.63 | −6.03 ± 0.56 | 0.06 | 0.80 ± 0.05 |
| NOG | 5.35 ± 1.26 | −5.14 ± 0.20 | 2.05 | 1.04 ± 0.03 |
| Succinate | ND | ND | ND | ND |
| U | ND | ND | ND | ND |
| T | 32.0 ± 5.24 | −8.45 ± 0.74 | -2.32 | 0.52 ± 0.03 |
| 5hmU | 30.5 ± 5.59 | −10.8 ± 1.19 | -4.59 | 0.45 ± 0.04 |
| 5fU | 108 ± 13.0 | −8.73 ± 0.60 | -3.31 | 0.20 ± 0.00 |
| 5caU | ND | ND | ND | ND |
| Category | Gene | Homolog | WT1 | WT2 | MT | Description | Reference |
| Iron transport | Ftr1 | HMPREF1120_04509 | 6.76 | 64.20 | 53.35 | High-affinity iron transporter | Stearman et al., 1996 |
| Fet3 | HMPREF1120_04510 | 42.88 | 23.29 | Ferrooxidoreductase Fet3 | |||
| SidF | HMPREF1120_01438 | 4.55 | 3.58 | 5.95 | Acetyl CoA:N6-hydroxylysine acetyl transferase | Chen et al., 2014 | |
| SidD | HMPREF1120_01440 | 8.74 | 4.41 | 6.92 | Nonribosomal peptide synthase Pes1 | ||
| SidA | HMPREF1120_07635 | 7.34 | 4.25 | 8.73 | L-ornithine N5-oxygenase | ||
| SidC | HMPREF1120_07636 | 2.46 | Nonribosomal siderophore peptide synthase SidC | ||||
| Sit1 | HMPREF1120_01434 | 4.47 | 7.10 | MFS transporter, SIT family, siderophore-iron: H+ symporter | Heymann et al., 2000; Petris, 2004 | ||
| HMPREF1120_02555 | 7.07 | 5.76 | 7.22 | MFS transporter, SIT family, siderophore-iron: H+ symporter | |||
| HMPREF1120_07838 | 14.26 | 16.02 | 10.33 | MFS transporter, SIT family, siderophore-iron: H+ symporter | |||
| Copper pransport | Crt | HMPREF1120_00028 | 4.74 | Copper transporter family | Petris, 2004 | ||
| HMPREF1120_05417 | 7.31 | Copper transporter family | |||||
| HMPREF1120_00028 | 4.72 | Copper transporter | |||||
| Atx1 | HMPREF1120_03801 | 4.78 | Heavy metal associated domain, Cu receptor | Lin et al., 1997 |
| Structural themes | Referential themes |
| To be prepared for emergency situations | Focus on overview of accident site and patient and on need of feedback |
| To observe the situation -Ready to act Confirmation and Validation of one’s knowledge | |
| Confidence in one’s own leadership | Focus on handling leadership. |
| Responsibility of leadership in emergency situations and | |
| Combining theory and practice | |
| Developing professional knowledge | Focus on how the work strategy changes based on the competency of the colleague and the need for competence and skills development. |
| Lack of a prehospital work strategy, Supporting novices, - Being alone,Being familiar with the equipment, Seeking new knowledge and Practicing critical scenarios |
| Variable | Healthy controls (n = 17) | Individuals with schizophrenia (n = 16) | t (df = 31)* | P value |
| Age (years) | 43.65 ± 11.32 | 48.69 ±8.38 | −1.446 | .158 |
| Gender | 3 females; 14 males | 4 females; 12 males | NA | NA |
| Education (years) | 15.47± 1.81 | 13.00 ± 2.25 | 3.487 | .001 |
| Subject's SES | 2.23± 1.01 | 3.63 1.41 | −2.992 | .006 |
| Parental SES | 2.54 ± 0.88 | 3.13 ± 1.45 | −1.275 | .213 |
| Onset age (years) | NA | 30.23 ± 11.95 | NA | NA |
| Duration (years) | NA | 17.15± 11.32 | NA | NA |
| Chlorpromazine equivalent (mg) | NA | 381.13 ± 247.18 | NA | NA |
| Medication type | NA | First generation = 3 Second generation = 9 | NA | NA |
| Positive scale PANSS | NA | 23.87 ±9.41 | NA | NA |
| Negative scale PANSS | NA | 22.33± 9.56 | NA | NA |
| General psychopathology PANSS | NA | 43.00 ± 14.64 | NA | NA |
| Total psychopathology PANSS | NA | 89.20 ± 30.17 | NA | NA |
| Flavonoid class | Molecular Weight | Glycosylation | Metabolic conversion | Colonic microflora |
| General | Decreases bioavailability | Generally removed | Major factor in bioavailability; can take place in small intestine, liver and colon; usually to glucuronides but also sulphation and methylation [39]; facilitates urinary and biliary excretion [39]. | Influence availability; catabolize compounds to low molecular weight compounds that are readily absorbed [58]. |
| Flavan-3-ols (monomeric) | Major bioactive forms: conjugates of epicatechin [41]; catechin: methyl, sulfate and glucuronic acid conjugates; epicatechin: mainly to sulfate conjugates, no glucuronidation [41]. | |||
| Proanthocyanidins | Decreases bioavailability [40]. | Major bioactive forms: conjugates of epicatechin [41]; oligomeric procyanidins can absorb in small intestine [51]. | Influences polymeric proanthocyanidin degradation [50]. | |
| Flavonols | Sugars and their position affects bioavailability [44]. | Potentially active metabolites: glucuronides [44]. | Facilitates glucuronidation [60]. | |
| Anthocyanins | Anthocyanin derivatives (flavan-3-ol-anthocyanin dimer) can potentially be absorbed with less efficiency [47]. | Sometimes found with sugars intact in circulation [55]. | Major intestinal metabolites: glucuronide and sulfate conjugates of protocatechuic acid and phloroglucinaldehyde [46]; anthocyanin derivatives metabolically more resistant than parent compounds [47]. | |
| Isoflavones | Aglycone more bioavailable; possible deglycosylation prior hepatic metabolism [48]. | Metabolize daidzein to equol [58]. | ||
| Flavanones | Rapid absorption, low bioavailability [49]. | Extensive first-pass metabolism partly by intestinal bacteria degraded into phenolic compounds [49]. |
| Rabbit no. | Control collagena (absorbance) | Loaded collagen (absorbance) | Difference |
| 1 | 37.8 | 31.8 | -6.0 |
| 2 | 29.8 | 28.2 | -1.6 |
| 3 | 31.1 | 33.0 | 1.9 |
| 4 | 42.6 | 38.3 | -4.3 |
| 5 | 31.0 | 32.1 | 1.1 |
| 6 | 39.5 | 37.5 | -2.0 |
| Mean | 35.3 | 33.5 | -1.8 |
| SD | 5.3 | 3.8 | 3.0 |
| Significanceb | >0.05 |
| # | Name | Tag/Fusion protein, positiona and lengthb | TEV protease cleavage site | Mode of expression | EAEA repeat | Selection markerc | Plasmid size (bp) | ||
| 1 | PPpRSFC | – | – | – | NA | Intracellular | NA | Zeocin | 4,840 |
| 2 | pPpRSFC-MFalpha | – | – | – | NA | Secretory | Yes | Zeocin | 5,104 |
| 3 | pPpRSFC-MFalpha-noEAEA | – | – | – | NA | Secretory | No | Zeocin | 5,092 |
| 4 | pPpRSFC-pGAP | – | – | – | NA | Intracellular | NA | Zeocin | 3,771 |
| 5 | pPpRSFC-pGAP-MFalpha | – | – | – | NA | Secretory | Yes | Zeocin | 4,035 |
| 6 | pPpRSFC-pGAP-MFalpha-noEAEA | – | – | – | NA | Secretory | No | Zeocin | 4,023 |
| 7 | pPpRSFC-N-eGFP | eGFP | N | 240 | No | Intracellular | NA | Zeocin | 5,584 |
| 8 | pPpRSFC-C-eGFP | eGFP | C | 239 | No | Intracellular | NA | Zeocin | 5,584 |
| 9 | pPpRSFC-MFalpha-N-eGFP | eGFP | N | 239 | No | Secretory | Yes | Zeocin | 5,848 |
| 10 | pPpRSFC-MFalpha-C-eGFP | eGFP | C | 239 | No | Secretory | Yes | Zeocin | 5,848 |
| 11 | pPpRSFC-N-Myc | MYC | N | 11 | No | Intracellular | NA | Zeocin | 4,870 |
| 12 | pPpRSFC-C-Myc | MYC | C | 10 | No | Intracellular | NA | Zeocin | 4,870 |
| 13 | pPpRSFC-MFalpha-N-Myc | MYC | N | 10 | No | Secretory | Yes | Zeocin | 5,134 |
| 14 | pPpRSFC-MFalpha-C-Myc | MYC | C | 10 | No | Secretory | Yes | Zeocin | 5,134 |
| 15 | pPpRSFC-N-FLAG | FLAG | N | 9 | No | Intracellular | NA | Zeocin | 4,864 |
| 16 | pPpRSFC-C-FLAG | FLAG | C | 8 | No | Intracellular | NA | Zeocin | 4,864 |
| 17 | pPpRSFC-MFalpha-N-FLAG | FLAG | N | 8 | No | Secretory | Yes | Zeocin | 5,128 |
| 18 | pPpRSFC-MFalpha-C-FLAG | FLAG | C | 8 | No | Secretory | Yes | Zeocin | 5,128 |
| 19 | pPpRSFC-N-His-ncs | His | N | 7 | No | Intracellular | NA | Zeocin | 4,858 |
| 20 | pPpRSFC-C-His-ncs | His | C | 6 | No | Intracellular | NA | Zeocin | 4,858 |
| 21 | pPpRSFC-MFalpha-N-His-ncs | His | N | 6 | No | Secretory | Yes | Zeocin | 5,122 |
| 22 | pPpRSFC-MFalpha-C-His-ncs | His | C | 6 | No | Secretory | Yes | Zeocin | 5,122 |
| 23 | pPpRSFC-N-His | His | N | 7 | Yes | Intracellular | NA | Zeocin | 4,879 |
| 24 | pPpRSFC-C-His | His | C | 6 | Yes | Intracellular | NA | Zeocin | 4,879 |
| 25 | pPpRSFC-MFalpha-N-His | His | N | 6 | Yes | Secretory | Yes | Zeocin | 5,143 |
| 26 | pPpRSFC-MFalpha-C-His | His | C | 6 | Yes | Secretory | Yes | Zeocin | 5,143 |
| 27 | pPpRSFC-N-MBP | MBP | N | 367 | Yes | Intracellular | NA | Zeocin | 5,959 |
| 28 | pPpRSFC-C-MBP | MBP | C | 366 | Yes | Intracellular | NA | Zeocin | 5,959 |
| 29 | pPpRSFC-MFalpha-N-MBP | MBP | N | 366 | Yes | Secretory | Yes | Zeocin | 6,223 |
| 30 | pPpRSFC-MFalpha-C-MBP | MBP | C | 366 | Yes | Secretory | Yes | Zeocin | 6,223 |
| 31 | pPpRSFC-N-Strep | Strep | N | 9 | Yes | Intracellular | NA | Zeocin | 4,885 |
| 32 | pPpRSFC-C-Strep | Strep | C | 8 | Yes | Intracellular | NA | Zeocin | 4,885 |
| 33 | pPpRSFC-MFalpha-N-Strep | Strep | N | 8 | Yes | Secretory | Yes | Zeocin | 5,149 |
| 34 | pPpRSFC-MFalpha-C-Strep | Strep | C | 8 | Yes | Secretory | Yes | Zeocin | 5,149 |
| 35 | pPpRSFC-HIS | – | – | – | NA | Intracellular | NA | HIS4 | 7,683 |
| 36 | pPpRSFC-HIS-MFalpha | – | – | – | NA | Secretory | Yes | HIS4 | 7,947 |
| 37 | pPpRSFC-HIS-MFalpha-noEAEA | – | – | – | NA | Secretory | No | HIS4 | 7,935 |
| 38 | pPpRSFC-HIS-pGAP | – | – | – | NA | Intracellular | NA | HIS4 | 6,614 |
| 39 | pPpRSFC-HIS-pGAP-MFalpha | – | – | – | NA | Secretory | Yes | HIS4 | 6,878 |
| 40 | pPpRSFC-HIS-pGAP-MFalpha-noEAEA | – | – | – | NA | Secretory | No | HIS4 | 6,866 |
| Characteristic | Value |
| Total number | 35 |
| Median age (IQR) in months | 20 (16–22) |
| Females (%) | 19 (54%) |
| Median children in household (range) | 3 (1–6) |
| Smokers in household (%) | 11 (31%) |
| Received 3 doses of pentavalent vaccine | 91.4% |
| Received at least 1 dose of pentavalent vaccine | 100.0% |
| # | Assumption |
| 1 | There is active secretion of compounds from blood to the lumen of the kidney's proximal tubules and reverse reabsorption (Liu et al., 2012) |
| 2 | Only an unbound drug could be filtrated or secreted from plasma to the lumen of the kidneys |
| 3 | The urinary excretion (Qurine) is similar for all compounds |
| 4 | Delay (lag) in absorption (Nerella et al., 1993; van der Walt et al., 2013) is included in all models to create a more precise description of plasma PK data |
| 5 | The site of action for SGLT2 inhibitors is in the lumen of the kidney's proximal tubules |
| 6 | The maximal inhibition level of SGLT2 (Imax) induced by compounds is equal to 1 (100%) (Grempler et al., 2012) |
| 7 | All rate equations are to be described as mass action law |
| MOCOS | |||
| c.1881delG /c.1782delG | |||
| G/G | G/del | del/del | |
| Affected animals | 4 | ||
| Obligate carriers | 3 | ||
| Tyrolean Grey population controls | 1151 | 50 | |
| Controls of other breedsa | 1225 | ||
| Total | 2376 | 53 | 4 |
| Health Claims (Dedicated Children’s Channels) | 2010 (%) | % Change v 2008 (+/−) | 2010 All Channels (%) |
| Contains essential nutrients e.g., calcium, vitamins, antioxidants | 39.7 | +29 | 33.4 |
| Part of your five a day | 28.9 | +4.9 | 10.3 |
| Organic | 10.4 | +8.8 | 5.0 |
| Wholegrain | 8.3 | −11.8 | 7.8 |
| Low fat | 4.7 | +2.8 | 9.8 |
| No added sugar | 3.7 | −0.5 | 2.1 |
| Contains only natural ingredients | 3.1 | −12.2 | 15.9 |
| Contains fibre | 0.6 | +0.6 | 1.3 |
| Is low calorie/light | 0.6 | −5.1 | 5.1 |
| Configuration | Packets Received per Second | |||
| CSR1 | CSR2 | CSR3 | Average | |
| CSR devices transmit each packet one | 0.62 | 1.41 | 1.08 | 1.04 |
| CSR devices transmit each packet three times | 1.16 | 1.76 | 1.91 | 1.61 |
| Variables | Control subjects (n = 62) | Type 1 diabetes (n = 53) | Ketosis-onset diabetes (n = 208) | Non-ketotic type 2 diabetes (n = 215) | p values | *p values |
| Male (%) | 43 (69.4%) | 31 (58.5%) | 153 (73.6%) | 122 (56.7%) | 0.002 | 0.030 |
| Age (years) | 47 ± 11 | 49 ± 18 | 49 ± 15 | 56 ± 14 | <0.001 | <0.001 |
| Smoking (n, %) | 38 (61.3%) | 17 (32.1%) | 84 (40.4%) | 65 (30.2%) | <0.001 | 0.001 |
| Alcohol (n, %) | 40 (64.5%) | 14 (26.4%) | 37 (17.8%) | 36 (16.7%) | <0.001 | <0.001 |
| Hypertension (%) | 25 (40.3%) | 11 (20.8%) | 81 (38.9%) | 98 (45.6%) | 0.011 | 0.035 |
| CCEs (%) | 0 (0.0%) | 2 (3.8%) | 10 (4.8%) | 31 (14.4%) | 0.002 | 0.023 |
| LLDs (%) | 15 (24.2%) | 10 (18.9%) | 63 (30.3%) | 70 (32.6%) | 0.641 | 0.712 |
| AHDs (%) | 19 (30.6%) | 8 (15.1%) | 68 (32.7%) | 95 (44.2%) | 0.012 | 0.029 |
| Aspirin (%) | 8 (12.9%) | 18 (34.0%) | 66 (31.7%) | 74 (34.4%) | 0.009 | 0.013 |
| BMI (kg/m2) | 24.14 ± 3.67 | 22.34 ± 4.35 | 25.05 ± 3.54 | 25.16 ± 3.59 | <0.001 | <0.001 |
| WHR | 0.92 ± 0.07 | 0.89 ± 0.07 | 0.91 + 0.06 | 0.91 + 0.06 | 0.019 | 0.475 |
| **Weight category | <0.001 | <0.001 | ||||
| Underweight | 3 (4.4%) | 8 (15.1%) | 3 (1.4%) | 2 (0.9%) | —— | —— |
| Overweight | 20 (32.3%) | 6 (11.3%) | 48 (23.1%) | 49 (22.8%) | —— | —— |
| Obesity | 22 (35.5%) | 11 (20.8%) | 97 (46.6%) | 109 (50.7%) | —— | —— |
| SBP (mmHg) | 124 ± 16 | 125 ± 17 | 127 ± 15 | 130 ± 17 | 0.042 | 0.146 |
| DBP (mmHg) | 78 ± 12 | 79 ± 10 | 81 ± 11 | 81 ± 9 | 0.101 | 0.023 |
| *TG (mmol/l) | 1.18 (0.88-1.92) | 1.21 (0.84-1.55) | 1.44 (1.00-2.19) | 1.49 (1.08-2.21) | 0.001 | 0.019 |
| TC (mmol/l) | 4.84 ± 1.02 | 4.83 ± 1.09 | 5.03 ± 1.22 | 4.82 ± 1.22 | 0.323 | 0.695 |
| HDL-C (mmol/l) | 1.28 ± 0.35 | 1.13 ± 0.26 | 1.05 ± 0.27 | 1.11 ± 0.25 | <0.001 | <0.001 |
| LDL-C (mmol/l) | 2.71 ± 0.88 | 3.24 ± 0.97 | 3.40 ± 1.03 | 3.12 ± 0.97 | <0.001 | 0.075 |
| *Cr (μmol/l) | 71 (56–82) | 59 (48–79) | 68 (58–80) | 67 (54–79) | 0.036 | 0.442 |
| *UAE (mg/24 h) | —— | 9.9 (7.1-18.1) | 10.3 (6.5-23.8) | 8.9 (6.4-24.8) | 0.823 | 0.917 |
| *eGFR (ml/min/1.73 m2) | 103 (93–116) | 109 (89–136) | 112 (92–134) | 98 (82–118) | 0.432 | 0.588 |
| *FPG (mmol/l) | 4.96 (4.67-5.24) | 7.99 (6.02-11.44) | 9.74 (7.63-12.45) | 7.53 (6.39-9.67) | <0.001 | <0.001 |
| *2 h PPG (mmol/l) | 5.84 (5.04-6.58) | 14.66 (10.49-19.61) | 16.66 (12.94-20.79) | 13.14 (10.39-16.66) | <0.001 | <0.001 |
| *FCP (ng/mL) | 2.05 (1.6-3.03) | 0.6 (0.3-0.84) | 1.23 (0.74-1.92) | 2.02 (1.36-2.93) | <0.001 | 0.030 |
| *2 h C-P (ng/mL) | 7.99 (6.56-9.92) | 0.92 (0.62-1.77) | 2.31 (1.55-3.66) | 4.65 (3.12-6.35) | <0.001 | 0.004 |
| HA1C (%) | 5.3 ± 0.34 | 12.39 ± 2.36 | 11.83 ± 2.05 | 9.81 ± 2.58 | <0.001 | <0.001 |
| Surface | Contact angle (deg.) | Contact angle hysteresis (deg.) | Sliding angle (deg.) |
| TO-SHS | 169±4 | 45±15 | >45 |
| TO-SLIPS | 124±1 | 1.4±0.5 | 3.0±0.3 |
| Dose (mg kg−1) | Fatty change | Hydropic swelling | Mild inflammation | Mild fibrosis |
| Saline | 0/4 | 0/4 | 0/4 | 0/4 |
| 30 | 0/4 | 0/4 | 0/4 | 0/4 |
| 100 | 0/4 | 0/4 | 4/4 | 0/4 |
| 300 | 0/4 | 1/4 | 4/4 | 0/4 |
| 1000 | 2/4 | 4/4 | 4/4 | 0/4 |
| 3000 | 2/4 | 4/4 | 4/4 | 2/4 |
| Sample | a (m2·kW−1·s−1/2) | b (s−1/2) | R2 |
| NC-F, 1 g | 0.03537 | −0.1046 | 0.9459 |
| NC-F, 2 g | 0.03117 | 0.23889 | 0.30557 |
| NC-C; 1 g | 0.01161 | −0.01993 | 0.99933 |
| NC-C; 2 g | 0.011 | −0.00607 | 0.99423 |
| ORa (95% CI) | p-Value | |
| Cannabisb | ||
| Use at 1 time-point | 1.32 (0.94–1.86) | 0.112 |
| Use at 2 time-points | 1.71 (1.08–2.70) | 0.023 |
| Use at 3 time-points | 2.08 (1.16–3.74) | 0.025 |
| Use at 4 time-points | 2.44 (1.06–5.63) | 0.036 |
| Cocaineb | ||
| Use at 1 time-point | 1.04 (0.71–1.53) | 0.842 |
| Use at 2 time-points | 0.68 (0.41–1.14) | 0.154 |
| Use at 3 time-points | 1.16 (0.59–2.28) | 0.674 |
| Use at 4 time-points | 0.59 (0.21–1.63) | 0.304 |
| Alcoholb | ||
| Use at 1 time-point | 1.13 (0.84–1.52) | 0.420 |
| Use at 2 time-points | 1.09 (0.74–1.61) | 0.656 |
| Use at 3 time-points | 1.36 (0.84–2.21) | 0.209 |
| Use at 4 time-points | 2.32 (1.25–4.28) | 0.007 |
| n, mean (SD) | GLM analysis | ||||
| Subgroup variable | Category | PTA | TAU | Difference and 95%CI | p-value |
| Age at screening (year) | |||||
| ≤61 | 33,6.08 (1.49) | 45,5.69 (1.53) | 0.08 (−0.44,0.59) | 0.7752 | |
| >61 | 35,6.51 (1.54) | 45,5.79 (1.54) | 0.70 (0.23,1.17) | 0.0036 | |
| Gender | |||||
| Male | 43,6.33 (1.52) | 52,5.86 (1.49) | 0.29 (−0.17,0.75) | 0.2108 | |
| Female | 25,6.24 (1.56) | 38,5.58 (1.58) | 0.51 (−0.03,1.04) | 0.0636 | |
| Number of comorbidities | |||||
| ≤1 | 43,6.13 (1.64) | 59,5.94 (1.45) | 0.21 (−0.18,0.60) | 0.2892 | |
| >1 | 25,6.59 (1.26) | 31,5.37 (1.63) | 0.84 (0.15,1.54) | 0.0167 | |
| Parkinson’s disease duration (year) | |||||
| ≤4 | 37,6.56 (1.30) | 52,5.88 (1.55) | 0.47 (−0.03,0.96) | 0.0630 | |
| >4 | 31,5.98 (1.71) | 38,5.56 (1.50) | 0.33 (−0.17,0.83) | 0.1917 |
| p3-m2 | p3-m1 | p3-p4 | p3 L | p3 W | p4 L | p4 Wtr | p4 Wtal | P3 L | P3W | |
| Type Sh 434 | 6.3 | 4.8 | 3. 15 | 1 | 1.35 | 1.5 | 1.5 | 1.35 | ||
| MPC/L-0001 (LUS-29) | 4.75 | 3.35 | 2 | 0.8 | 1 | 1.35 | 1.25 | 1.15 | ||
| LUS-078 | 1.0;1.0 | 1.75;1.8 | ||||||||
| RHN-A/12 | 1.0 | 1.5 |
| Life Satisfactiona | 2005 | 2007 | 2009 | 2011 | 2013 |
| Health | |||||
| 1 | 781 (22.2) | 535 ((17.6) | 461 (17.4) | 207 (8.93) | 130 (6.6) |
| 2 | 1455 (41.4) | 1365 (44.8) | 935 (35.3) | 693 (29.8) | 614 (31.4) |
| 3 | 662 (18.8) | 658 (21.6) | 821 (31.0) | 930 (40.0) | 844 (43.2) |
| 4 | 582 (16.6) | 470 (15.4) | 413 (15.6) | 475 (20.4) | 352 (18.0) |
| 5 | 35 (1.0) | 19 (0.6) | 19 (0.7) | 21 (0.9) | 14 (0.7) |
| Finance | |||||
| 1 | 449 (12.8) | 291 (9.6) | 299 (11.3) | 164 (7.1) | 115 (5.9) |
| 2 | 1335 (38.0) | 1145 (37.6) | 949 (35.8) | 718 (30.9) | 530 (27.1) |
| 3 | 1153 (32.8) | 1072 (35.2) | 957 (36.1) | 962 (41.4) | 904 (46.3) |
| 4 | 552 (15.7) | 520 (17.1) | 429 (16.2) | 449 (19.3) | 372 (19.0) |
| 5 | 26 (0.7) | 19 (0.6) | 17 (0.6) | 33 (1.4) | 33 (1.7) |
| Housing | |||||
| 1 | 95 (2.7) | 54 (1.8) | 54 (2.0) | 31 (1.3) | 20 (1.0) |
| 2 | 614 (17.5) | 376 (12.3) | 259 (9.8) | 287 (12.3) | 161 (8.2) |
| 3 | 1086 (30.9) | 974 (32.0) | 1010 (38.1) | 1011 (43.5) | 902 (46.2) |
| 4 | 1595 (45.4) | 1544 (50.7) | 1263 (47.6) | 926 (39.8) | 816 (41.8) |
| 5 | 127 (3.6) | 99 (3.3) | 66 (2.5) | 71 (3.1) | 55 (2.8) |
| Family Relationships | |||||
| 1 | 47 (1.3) | 19 (0.7) | 24 (0.9) | 8 (0.4) | 13 (0.7) |
| 2 | 218 (6.2) | 135 (4.6) | 97 (3.8) | 130 (5.8) | 86 (4.5) |
| 3 | 980 (27.9) | 897 (30.5) | 900 (34.8) | 971 (43.1) | 739 (38.6) |
| 4 | 2073 (59.1) | 1735 (59.0) | 1476 (57.0) | 1075 (47.7) | 950 (49.6) |
| 5 | 190 (5.4) | 157 (5.3) | 92 (3.6) | 70 (3.1) | 126 (6.6) |
| Neighbor Relationships | |||||
| 1 | 20 (0.6) | 11 (0.4) | 35 (1.3) | 17 (0.7) | 6 (0.3) |
| 2 | 216 (6.1) | 159 (5.2) | 124 (4.7) | 146 (6.3) | 117 96.0) |
| 3 | 955 (27.2) | 1001 (32.9) | 1138 (43.2) | 1105 (47.9) | 928 (47.7) |
| 4 | 2087 (59.4) | 1721 (56.5) | 1283 (48.7) | 986 (42.7) | 797 (40.9) |
| 5 | 238 (6.8) | 155 (5.1) | 56 (2.1) | 53 (2.3) | 99 (5.1) |
| Pool | DMRs (Number) | DMRs (%) |
| Bulgarian females (patients/controls) | 293 | 1.1 |
| Bulgarian males (patients/controls) | 948 | 3.4 |
| Serbian females (patients/controls) | 947 | 3.4 |
| Serbian males (patients/controls) | 944 | 3.4 |
| Time | AUC | CRI | Predicting | Sensitivity (CI) | Specificity (CI) | PPV (CI) | NPV (CI) |
| A. Training set | |||||||
| 12 h | 0.83 | <0.04 | Poor outcome | 0.27 (0.11–0.50) | 1.00 (0.86–1.00) | 1.00 (0.54–1.00) | 0.60 (0.43–0.75) |
| >0.90 | Good outcome | 0.13 (0.03–0.32) | 1.00 (0.85–1.00) | 1.00 (0.29–1.00) | 0.51 (0.35–0.67) | ||
| 18 h | 0.69 | <0.19 | Poor outcome | 0.28 (0.10–0.53) | 1.00 (0.85–1.00) | 1.00 (0.48–1.00) | 0.63 (0.45–0.79) |
| >0.91 | Good outcome | 0.05 (0.00–0.22) | 1.00 (0.81–1.00) | 1.00 (-) | 0.46 (0.30–0.63) | ||
| 24 h | 0.87 | <0.35 | Poor outcome | 0.45 (0.23–0.68) | 1.00 (0.85–1.00) | 1.00 (0.66–1.00) | 0.68 (0.49–0.83) |
| >0.61 | Good outcome | 0.57 (0.35–0.77) | 1.00 (0.83–1.00) | 1.00 (0.75–1.00) | 0.67 (0.47–0.83) | ||
| 36 h | 0.74 | <0.32 | Poor outcome | 0.28 (0.10–0.53) | 1.00 (0.86–1.00) | 1.00 (0.48–1.00) | 0.65 (0.75–1.00) |
| >0.91 | Good outcome | 0.04 (0.00–0.21) | 1.00 (0.81–1.00) | 1.00 (-) | 0.44 (0.28–0.60) | ||
| B. Test set | |||||||
| 12 h | 0.74 | <0.02 | Poor outcome | 0.13 (0.02–0.40) | 1.00 (0.83–1.00) | 1.00 (0.16–1.00) | 0.60 (0.42–0.77) |
| >1.00 | Good outcome | 0.00 (0.00–0.17) | 1.00 (0.78–1.00) | - | 0.43 (0.26–0.60) | ||
| 18 h | 0.94 | <0.18 | Poor outcome | 0.59 (0.33–0.82) | 1.00 (0.85–1.00) | 1.00 (0.69–1.00) | 0.76 (0.56–0.90) |
| >0.57 | Good outcome | 0.64 (0.41–0.83) | 1.00 (0.80–1.00) | 1.00 (0.77–1.00) | 0.68 (0.46–0.85) | ||
| 24 h | 0.87 | <0.29 | Poor outcome | 0.55 (0.32–0.76) | 1.00 (0.86–1.00) | 1.00 (0.73–1.00) | 0.71 (0.53–0.85) |
| >0.69 | Good outcome | 0.25 (0.10–0.47) | 1.00 (0.85–1.00) | 1.00 (0.54–1.00) | 0.55 (0.38–0.70) | ||
| 36 h | 0.84 | <0.22 | Poor outcome | 0.30 (0.12–0.54) | 1.00 (0.86–1.00) | 1.00 (0.54–1.00) | 0.63 (0.46–0.78) |
| >1.00 | Good outcome | 0.00 (0.00–0.14) | 1.00 (0.83–1.00) | - | 0.45 (0.30–0.61) |
| Author | Patient (n) (age/sex) | Procedure | Cardiac rhythm | Cause | Management | Outcome |
| Chowdhury and West [3] | 50 y ♀ | Awake craniotomy (frontal tumor) | Bradycardia, asystole (25 s) | TCR (scalp traction) | Release scalp traction; cessation propofol and remifentanil infusions | No neurological deficit |
| Prabhu et al. [4] | 65 y ♂ | Awake craniotomy (temporal tumor) | Bradycardia and asystole (8–10 s × 2 times) | TCR (dura cautery) | Cessation of cautery, atropine | No neurological deficit |
| Sinha et al. [5] | 18 y ♂ | Epilepsy surgery | Bradycardia (2 episodes), asystole (9 s) | ↑Parasympathetic response 2° to amygdala resection; warm and cold saline irrigation | Atropine; cessation of stimulus | No neurological deficit |
| Sato et al. [6] | 6/42 [18–34 y; ♀ = 3, ♂ = 2] | Epilepsy surgery | Sinus bradycardia (<1 min) | ↑Parasympathetic tone 2° to limbic stimulation | Procedure interruption; atropine | No neurological deficit |
| Tyler et al. [7] | 22 y ♀ | Craniotomy (parietal tumor) | Asystole | Intracranial hematoma (dural closure) | Hematoma evacuation | No neurological deficit |
| Wasnick et al. [8] | 70 ♂ | Epidural suction drain | Severe bradycardia | Intracranial hypotension | Release of suction | No neurological deficit |
| Alfery et al. [9] | 18 ♀ | VP shunt | VT, VF | Intracranial hypotension | Lidocaine, CPR | No neurological deficit |
| Karamchandani et al. [10] | 65 ♀ | Subgaleal suction drain | Multiple severe bradycardia | Intracranial hypotension | Release of suction, atropine | No neurological deficit |
| Bhagat et al. [11] | 2 patients[both 60 ♂] | Subgaleal suction drain | Severe bradycardia, Asystole | Intracranial hypotension | Release of suction, atropine | No neurological deficit |
| Method | Rank | Rank | TPR in top | TPR in top | TPR in top | TPR in top | AUC | Rank difference |
| median | average | 1% (%) | 5% (%) | 10% (%) | 30% (%) | p-value | ||
| Genome-wide prioritizations | ||||||||
| Scuba | 8.13 | 17.45 ± 22.33 | 10.4 | 41.7 | 58.3 | 79.2 | 0.83 | - |
| MKL1class [12] | 14.28 | 25.79 ± 26.96 | 2.1 | 27.1 | 45.8 | 66.7 | 0.74 | 1.2 ·10−5 * |
| ProDiGe [13] | 7.89 | 18.40 ± 23.77 | 10.4 | 43.8 | 54.2 | 79.2 | 0.82 | 9.5 ·10−2 |
| Mean (SD) | P value | |||
| 1st trimester | 2nd trimester | 3rd trimester | ||
| Completion time (minutes) | 21.8 (7.5) | 19.2 (6.8) | 16.3 (5.1) | < 0.0001 |
| Reported meals (N) | 5.1 (0.9) | 4.8 (1.1) | 5.0 (1.2) | 0.13 |
| Reported items (N) | 20.5 (4.0) | 20.3 (4.1) | 19.4 (4.0) | 0.025 |
| Complications | Group 1 | Group 2 | ||
| To adult | To pediatrics | En-bloc | Single | |
| Renal vein thrombosis | — | 1 (early nephrectomy) | — | 2 (graft loss) |
| Renal arterial thrombosis | 1 (graft loss) | — | — | — |
| Significant lymphocele | 1 (percutaneous drainage) | — | 1 (percutaneous drainage) | 1 |
| Ureteral fistula | 1 (surgical repair) | — | — | 1 (surgical repair) |
| Ureteral stenosis | 1 (surgical repair) | — | — | 1 (surgical repair) |
| n of cases | IPAT | PSP | IPAT & PSP | |
| CF and RP/CP | 48 | 14 (29.2) | 11 (22.9) | 19 (39.6) |
| CF without pancreatitis | 35 | 2 (5.7) | 3 (8.5) | 4 (11.4) |
| healthy subjects | 80 | 3 (3.8) | 8 (10) | 11 (13.7) |
| Chi square and (p) | 20.4 (p < 0.001) | 4.39 (p = 0.11) | 14.5 (p < 0.001) |
| Gene | F/R | Primer sequence | Position | Tm |
| PEPT1 | Forward | CCCTGAAGTGAAGGTGTTTGAAGATA | 1772–1797 | 60.6 |
| NM_005073 | Reverse | GAATTGGCCCCTGACATGAA | 2168–2188 | 59.3 |
| PEPT2 | Forward | CTACCACAATATGCCCTGGTTACA | 1894–1917 | 58.8 |
| NM_001145998 | Reverse | GCCACTGAACTGTGCCACAA | 2045–2064 | 59.3 |
| ALAS1 | Forward | GGATTCGAAACAGCCGAGTG | 1371–1390 | 59.3 |
| NM 000688 | Reverse | GAAGGTGATTGCTCCAAACTCAT | 1542–1564 | 58.3 |
| ALAD | Forward | CCTCGGTTCCAACCAACTGAT | 157–177 | 59.8 |
| NM_000031 | Reverse | GATAGGCTGTATGTCATCAGGAACA | 319–343 | 58.2 |
| HMBS | Forward | CAAGGACCAGGACATCTTGGAT | 835–856 | 58.9 |
| NM_000190 | Reverse | CCAGACTCCTCCAGTCAGGTACA | 984–1006 | 59.2 |
| UROS | Forward | TCAGCACTGCCTCTTCTATTTCC | 668–691 | 58.7 |
| NM_000375 | Reverse | CTGGGTGTGCAACTGTCTGATAC | 761–789 | 58.3 |
| UROD | Forward | CGGGAGTGTGTGGGGAA | 982–998 | 57.2 |
| NM_000374 | Reverse | AAGCAGACGTGAGTGTTTATGCA | 1178–1200 | 58.6 |
| ABCB6 | Forward | CAGAAGGGCCGTATTGAGTTTG | 2033–2054 | 59.6 |
| NM_005689 | Reverse | ATTGTCGGCGATGGTGTCA | 2308–2326 | 59.5 |
| CPOX | Forward | GGCGGAGATGTTGCCTAAGAC | 401–421 | 59.7 |
| NM_000097 | Reverse | AATGCTCACCCCAGCCTTTT | 709–728 | 59.5 |
| PPOX | Forward | CAGGAGTCCTGGGAATCGTGTA | 1251–1272 | 59.9 |
| NM_000309 | Reverse | TGCCTAGCTGACTCTAGTTTTTGC | 1509–1533 | 58.1 |
| FECH | Forward | GGAAATCCATTGTTCTCTAAGGC | 1252–1274 | 57.0 |
| NM_001012515 | Reverse | CTAAATAACACCCTCTCCACATCG | 1462–1485 | 57.8 |
| ABCG2 | Forward | CTAAGCAGGGACGAACAATCATC | 1188–1210 | 58.8 |
| NM_004827 | Reverse | TCCTGCTTGGAAGGCTCTATG | 1447–1467 | 58.2 |
| HIF-1alpha | Forward | GGCGCGAACGACAAGAA | 420–436 | 58.0 |
| NM 001530 | Reverse | CAAAACCATCCAAGGCTTTCA | 682–702 | 58.7 |
| HO-1 | Forward | GCTCAAAAAGATTGCCCAGAA | 518–538 | 58.1 |
| NM_002133 | Reverse | TCACATGGCATAAAGCCCTACA | 926–947 | 59.1 |
| LFD | LFD+NDEA | HFD | HFD+NDEA | F-Ratio | P-Value | |
| AβPP | 4.392 ± 0.423 | 3.966 ± 0.458 | 3.026* ± 0.215 | 3.228 ± 0.299 | 3.099 | 0.039 |
| Tau | 3.380 ± 0.272 | 2.689 ± 0.255 | 3.310 ± 0.270 | 1.938*** ± 0.209 | 7.023 | 0.001 |
| ChAT | 0.170 ± 0.016 | 0.147 ± 0.026 | 0.164 ± 0.014 | 0.115§ ± 0.007 | 0.001 | |
| AChE | 0.824 ± 0.081 | 1.080 ± 0.137 | 0.747 ± 0.099 | 0.795 ± 0.048 | ||
| IL-1β | 0.047 ± 0.004 | 0.047 ± 0.010 | 0.052 ± 0.005 | 0.023* ± 0.003 | 4.627 | 0.008 |
| IL6 | 0.052 ± 0.006 | 0.045 ± 0.006 | 0.050 ± 0.005 | 0.034 ± 0.005 | ||
| TNF-α | 0.022 ± 0.002 | 0.035 ± 0.005 | 0.034 ± 0.005 | 0.036 ± 0.004 |
| Pain score ribs | Pain score iliac crest | |
| Hospital admission, oral analgesics | 5 | Not applicable |
| Pre-operative, with epidural catheter | 3-6 | Not applicable |
| Post-operative day 3, with epidural catheter | 1-2 | 4-5 |
| Discharge home, oral analgesics | 1-2 | 3-5 |
| Data set | n | MI Re | KNNI Re | SVRI Re | ELMI {Re, Ri} |
| Breast | 3 | 4.79% | 4.86% | 4.71% | {4.52%, 3.18%} |
| 5 | 8.23% | 8.38% | 5.96% | {4.90%, 3.31%} | |
| 7 | 14.75% | 14.29% | 12.45% | {10.42%, 5.59%} | |
| Iris | 1 | 23.96% | 5.65% | 5.13% | {4.77%, 2.09%} |
| 2 | 43.67% | 13.72% | 8.07% | {8.12%, 6.52%} | |
| 3 | 65.49% | 21.06% | 12.89% | {12.92%, 9.23%} | |
| Seeds | 2 | 21.05% | 12.38% | 9.26% | {9.47%, 4.13%} |
| 4 | 28.39% | 13.62% | 10.83% | {9.65%, 4.86%} | |
| 6 | 40.93% | 27.34% | 18.37% | {17.02%, 12.53%} | |
| Wine | 3 | 31.26% | 27.18% | 26.51% | {26.17%, 1.64%} |
| 6 | 33.98% | 27.93% | 27.14% | {26.83%, 1.58%} | |
| 9 | 38.02% | 30.36% | 28.33% | {27.25%, 3.67%} | |
| Segment | 3 | 12.71% | 10.46% | 9.52% | {6.89%, 1.37%} |
| 7 | 15.83% | 12.38% | 10.07% | {7.16%, 3.25%} | |
| 11 | 20.23% | 17.35% | 12.06% | {10.35%, 3.76%} | |
| Satimag | 7 | 41.28% | 40.70% | 33.62% | {29.63%, 12.81%} |
| 9 | 44.75% | 42.36% | 36.59% | {30.87%, 18.24%} | |
| 19 | 52.96% | 51.22% | 47.67% | {36.92%, 22.75%} |
| Control group | LNM group | P | |
| Initial visual ID of RLN (%) | 179/185 (96.8%) | 152/156 (97.4%) | 0.76a |
| Final ID of RLN (%) | 179/185 (96.8%) | 156/156 (100%) | 0.03a |
| P | — | 0.12a | — |
| Initial visual ID of EBSLN (%) | 73/185 (39.5%) | 67/156 (42.9%) | 0.51 |
| Final ID of EBSLN (%) | 73/185 (39.5%) | 118/156 (75.6%) | <0.01 |
| P | — | <0.01 | — |
| Algorithm | precision | recall | f-measure |
| SHC[31,32] | 0.4447 | 0.3430 | 0.3873 |
| SC[13] | 0.3612 | 0.3555 | 0.3584 |
| MCL[12] | 0.3569 | 0.3879 | 0.3717 |
| Newman[8] | 0.4665 | 0.4186 | 0.4413 |
| RNSC[9] | 0.4067 | 0.4696 | 0.4359 |
| ISHC | 0.6624 | 0.3620 | 0.4673 |
| Class | T. urticae | P. ulmi | P. citri |
| A | 18 | 10 | 7 |
| B | 6 | 4 | 4 |
| C | 78 | 28 | 26 |
| D | 2 | 2 | 2 |
| E | 2 | 2 | 2 |
| F | 6 | 6 | 6 |
| G | 23 | 12 | 8 |
| H | 22 | 18 | 12 |
| Total | 157 | 82 | 67 |
| Vascularization ≤ 1 point | |||
| No | Yes | ||
| Target IOP not reached | No | 39 | 3 |
| Yes | 10 | 5 | |
| Agreement | Kappa | .31 |
| Dependent measure | Condition | Descriptive statistics | Inferential statistics | ||||||||||
| Group | Condition | Group × condition | |||||||||||
| ASD (n = 19) | Comparison (n = 20) | Total | F(1, 37) | p | r | F(1, 37) | p | r | F(1, 37) | p | r | ||
| Proportion of time in target quadrant | Visible | 0.91 (0.04) | 0.89 (0.07) | 0.90 (0.05) | |||||||||
| Hidden | 0.79 (0.17) | 0.85 (0.08) | 0.82 (0.13) | ||||||||||
| Total | 0.85 (0.13) | 0.87 (0.08) | 0.86 (0.11) | ||||||||||
| 0.61 | 0.439 | 0.13 | 16.16 | <0.001 | 0.55 | 3.72 | 0.062 | 0.30 | |||||
| Latency to reach target (seconds) | Visible | 66.12 (13.94) | 60.24 (7.52) | 63.10 (11.37) | |||||||||
| Hidden | 87.33 (26.49) | 68.15 (10.83) | 77.50 (22.03) | ||||||||||
| Total | 76.73 (23.49) | 64.20 (10.04) | 70.30 (18.86) | ||||||||||
| 7.61 | 0.009 | 0.41 | 33.62 | <0.001 | 0.69 | 7.01 | 0.012 | 0.40 | |||||
| Proportion of successful trials | Visible | 0.99 (0.06) | 1.00 (0.00) | 0.99 (0.04) | |||||||||
| Hidden | 0.86 (0.19) | 0.96 (0.09) | 0.91 (0.16) | ||||||||||
| Total | 0.92 (0.15) | 0.98 (0.06) | 0.95 (0.12) | ||||||||||
| 5.59 | 0.023 | 0.36 | 12.41 | 0.001 | 0.50 | 3.84 | 0.058 | 0.31 | |||||
| Velocity (virtual units/second) | Visible | 7.07 (1.05) | 7.51 (0.70) | 7.30 (0.90) | |||||||||
| Hidden | 7.60 (1.00) | 8.02 (0.68) | 7.82 (0.87) | ||||||||||
| Total | 7.33 (1.05) | 7.77 (0.73) | 7.56 (0.92) | ||||||||||
| 2.80 | 0.103 | 0.27 | 27.17 | <0.001 | 0.65 | 0.01 | 0.92 | 0.02 | |||||
| Path length (virtual units) | Visible | 443.65 (23.32) | 438.72 (34.51) | 441.12 (29.31) | |||||||||
| Hidden | 634.33 (167.05) | 537.28 (79.26) | 584.56 (137.02) | ||||||||||
| Total | 538.99 (152.23) | 488.00 (78.31) | 512.84 (122.07) | ||||||||||
| 4.56 | 0.039 | 0.33 | 61.98 | <0.001 | 0.79 | 6.29 | 0.017 | 0.38 | |||||
| Cumulative distance to target (virtual units) | Visible | 30989 (7933) | 28349 (4186) | 29635 (6353) | |||||||||
| Hidden | 46373 (20316) | 33307 (7673) | 39672 (16392) | ||||||||||
| Total | 38681 (17093) | 30828 (6597) | 34654 (13343) | ||||||||||
| 7.16 | 0.011 | 0.40 | 19.61 | <0.001 | 0.59 | 5.15 | 0.029 | 0.35 |
| Temperature shift | Blood feeding | Temperature shift + Blood feeding | |||||||
| Microarray | RT-qPCR | Microarray | RT-qPCR | RT-qPCR | |||||
| Gene ID | Annotation | Fold change (replicate 1; replicate 2) | Fold change | p-value | Fold change (replicate 1; replicate 2) | Fold change | p-value | Fold change | p-value |
| A1G_00295 | cell surface antigen-like protein Sca10 | ND | -1.67 | 0.0000 | -2.33 (-2.39; -2.27) | -4.76 | 0.0000 | -8.33 | 0.0000 |
| A1G_00515 | ADP,ATP carrier protein | ND | NS | -1.96 (-1.91; -2.02) | -2.17 | 0.0000 | -2.13 | 0.0000 | |
| A1G_00520 | glycerol-3-phosphate transporter | ND | NS | -1.73 (-1.62; -1.83) | -2.70 | 0.0000 | -2.22 | 0.0000 | |
| A1G_00680 | 30S ribosomal protein S2 | ND | 1.41 | 0.0018 | -2.46 (-2.62; -2.29) | -4.00 | 0.0000 | -2.86 | 0.0000 |
| A1G_00685 | elongation factor Ts | ND | NS | -1.79 (-1.79; -1.78) | -2.94 | 0.0000 | -2.70 | 0.0000 | |
| A1G_00810 | type IV secretion system protein VirB3 | ND | 1.45 | 0.0016 | -1.98 (-2.07; -1.89) | -2.78 | 0.0000 | -1.92 | 0.0000 |
| A1G_01445 | cell surface antigen-like protein Sca8 | ND | 1.43 | 0.0080 | -5.41 (-5.66; -5.15) | -12.5 | 0.0000 | -8.33 | 0.0000 |
| A1G_01495 | ferredoxin | ND | NS | 2.19 (2.30; 2.09) | 1.36 | 0.0000 | 1.29 | 0.0012 | |
| A1G_01525 | glutaredoxin 3 | ND | -1,25 | 0.0019 | 2.68 (3.12; 2.23) | 1.93 | 0.0000 | 1.54 | 0.0000 |
| A1G_02205 | virB9 protein | ND | -1.27 | 0.0045 | 2.38 (2.42; 2.35) | 1.56 | 0.0000 | NS | |
| A1G_02230 | virB10 protein | ND | NS | 1.72 (1.69; 1.76) | 1.55 | 0.0000 | 1.81 | 0.0000 | |
| A1G_02235 | type IV secretion system ATPase VirB11 | ND | -1.35 | 0.0002 | 1.68 (1.70; 1.66) | 2.00 | 0.0000 | 1.49 | 0.0000 |
| A1G_02240 | type IV secretion system component VirD4 | ND | -1.19 | 0.0196 | 1.83 (1.72; 1.94) | 1.64 | 0.0000 | 1.38 | 0.0000 |
| A1G_02555 | thioredoxin peroxidase 1 | ND | NS | 1.67 (1.59; 1.75) | 1.84 | 0.0000 | 2.06 | 0.0000 | |
| A1G_02680 | 16S rRNA-processing protein RimM | ND | NS | -2.06 (-2.18; -1.93) | -2.78 | 0.0000 | -2.33 | 0.0000 | |
| A1G_02785 | site-specific tyrosine recombinase XerD | 1.53 (1.53; 1.53) | 1.86 | 0.0000 | -2.69 (-2.52; -2.87) | -4.35 | 0.0000 | -2.27 | 0.0000 |
| A1G_03790 | cell surface antigen | -1.79 (-1.99; -1.60) | -1.96 | 0.0000 | ND | 1.40 | 0.0002 | 0.72 | 0.0000 |
| A1G_05315 | chaperonin GroEL | ND | 1.46 | 0.0006 | -1.71 (-1.53; -1.88) | -2.27 | 0.0000 | -1.54 | 0.0000 |
| A1G_05630 | cold shock-like protein | 1.92 (1.98; 1.87) | 1.36 | 0.0063 | ND | -1.96 | 0.0000 | -1.43 | 0.0002 |
| A1G_05960 | bicyclomycin resistance protein | 1.57 (1.60; 1.53) | 1.82 | 0.0000 | ND | -5.88 | 0.0000 | -3.33 | 0.0000 |
| A1G_05625 | ATP-dependent RNA helicase RhlE | ND | NS | -2.87 (-3.13; -2.62) | -4.76 | 0.0000 | -3.85 | 0.0000 | |
| A1G_06265 | ADP,ATP carrier protein | ND | 1.47 | 0.0005 | -2.30 (-2.20; -2.41) | -4.17 | 0.0000 | -2.78 | 0.0000 |
| A1G_06705 | NADH dehydrogenase subunit J | ND | 1.46 | 0.0018 | -2.02 (-2.11; -1.93) | -4.17 | 0.0000 | -2.86 | 0.0000 |
| A1G_06710 | NADH dehydrogenase subunit K | ND | NS | -4.08 (-4.59; -3.56) | -12.5 | 0.0000 | -10.00 | 0.0000 | |
| A1G_06715 | NADH dehydrogenase subunit L | ND | 1.46 | 0.0124 | -1.75 (-1.97; -1.54) | -7.14 | 0.0000 | -5.00 | 0.0000 |
| A1G_07470 | DNA mismatch repair protein | -1.62 (-1.69; -1.54) | -1.22 | 0.0481 | ND | 1.32 | 0.0001 | NS | |
| A1G_00825 | hypothetical protein A1G_00825 | ND | 1.62 | 0.0012 | -1.68 (-1.77; -1.59) | -3.03 | 0.0000 | -1.85 | 0.0000 |
| A1G_02840 | hypothetical protein A1G_02840 | ND | NS | -3.03 (-3.30; -2.77) | -6.67 | 0.0000 | -7.14 | 0.0000 | |
| A1G_06350 | hypothetical protein A1G_06350 | ND | NS | 3.57 (4.12; 3.01) | 1.76 | 0.0000 | 1.86 | 0.0000 | |
| A1G_07480 | hypothetical protein A1G_07480 | -2.62 (-3.02; -2.21) | -1.49 | 0.0001 | 2.51 (2.41; 2.62) | 2.39 | 0.0000 | 1.59 | 0.0000 |
| A1G_00185 | hypothetical protein A1G_00185 | ND | NS | 2.02 (2.13; 1.92) | 2.00 | 0.0000 | 1.74 | 0.0000 | |
| A1G_00820 | hypothetical protein A1G_00820 | ND | 1.77 | 0.0001 | -1.83 (-1.88; -1.78) | -4.00 | 0.0000 | -2.22 | 0.0000 |
| A1G_01380 | hypothetical protein A1G_01380 | ND | NS | 2.71 (2.69; 2.73) | 2.35 | 0.0000 | 1.96 | 0.0000 | |
| A1G_03000 | hypothetical protein A1G_03000 | ND | 2.53 | 0.0000 | -7.2 (-8.32; -6.07) | -7.14 | 0.0000 | -2.78 | 0.0000 |
| A1G_06745 | hypothetical protein A1G_06745 | ND | NS | 2.82 (2.94; 2.69) | 1.69 | 0.0000 | 1.85 | 0.0000 | |
| A1G_05315 | chaperonin GroEL | ND | 1.46 | 0.0006 | -1.71 (-1.53; -1.88) | -2.27 | 0.0000 | -1.54 | 0.0000 |
| A1G_05630 | cold shock-like protein | 1.92 (1.98; 1.87) | 1.36 | 0.0063 | ND | -1.96 | 0.0000 | -1.43 | 0.0002 |
| Time period 6 month intervals | Mean proportion of CVD services delivered | Difference from baseline | t-test | P* |
| Baseline | 0.29 | - | - | - |
| 2 | 0.26 | -0.04 | -0.81 | 0.42 |
| 3 | 0.20 | -0.09 | -2.14 | 0.03 |
| 4 | 0.23 | -0.06 | -1.41 | 0.16 |
| 5 | 0.28 | -0.01 | -0.37 | 0.71 |
| 6 | 0.24 | -0.05 | -1.12 | 0.26 |
| AHC participation (intervention) | ||||
| 7 | 0.48 | 0.19 | 4.04 | < 0.001 |
| 8 | 0.42 | 0.13 | 2.55 | 0.01 |
| 9 | 0.72 | 0.43 | 8.48 | < 0.001 |
| 10 | 0.62 | 0.33 | 6.42 | < 0.001 |
| 11 | 0.52 | 0.23 | 4.25 | < 0.001 |
| 12 | 0.57 | 0.28 | 5.18 | < 0.001 |
| Assembler | Sequencing | Strains | Insert size | Read length (bp) | Number of reads | Raw read coverage | Assembled bases (Mb) | Contig coverage | Contig N50 |
| FuzzyPath | Illumina | CAST/Ei | 200 bp | 36 | 173 million | 65× | 76.03 | 80.0% | 2,315 |
| Velvet* | Illumina | CAST/Ei | 200 bp | 36 | 173 million | 65× | 58.09 | 61.15% | 391 |
| ABySS | Illumina | CAST/Ei | 200 bp | 36 | 173 million | 65× | 72.80 | 76.63% | 1,022 |
| FuzzyPath | Illumina | A/J | 200 bp | 36 | 112 million | 42× | 55.87 | 58.8% | 959 |
| Phusion | Capillary | A/J | 3-5 kb | 400-900 | 357,100 | 2.5× | 81.2 | 85.5% | 3,377 |
| FuzzyPath | Hybrid | A/J† | Hybrid† | Hybrid† | Hybrid† | Hybrid† | 85.54 | 90.0% | 5,793 |
| Infant HIV exposure category | p-Valueb | ||
| HEU (N = 60) | HUU (N = 72a) | ||
| Maternal characteristics | |||
| Mean (SD) maternal age at enrollment | 28.0 (5.1) | 25.9 (6.2) | 0.05 |
| Substance use during pregnancy, N (%) | |||
| Alcohol | 13 (21.7) | 8 (11.1) | 0.15 |
| Tobacco | 16 (26.7) | 10 (13.9) | 0.08 |
| Marijuana | 4 (6.7) | 0 (0.0) | 0.04 |
| Crack or cocaine | 2 (3.3) | 0 (0.0) | 0.20 |
| Maternal employment, N (%) | 22 (36.7) | 41 (56.9) | 0.02 |
| Mean (SD) years of completed education | 7.6 (3.2) | 9.3 (2.4) | 0.001 |
| Mean (SD) number of prior pregnancies | 2.3 (1.9) | 1.2 (1.3) | <0.0001 |
| Mean (SD) parity | 1.8 (1.6) | 1.0 (1.1) | 0.001 |
| Mean (SD) number of people living in the household | 4.4 (2.0) | 4.7 (1.7) | 0.32 |
| Mean (SD) CD4 count (cells/mm3) at hospital discharge | 563.9 (266.7) | – | – |
| Mean (SD) CD4% at hospital discharge | 32.0 (9.4) | – | – |
| Mean (SD) viral load (log10 copies/mL) at hospital discharge | 2.23 (0.81) | – | – |
| Viral load <400 copies/mL at hospital discharge, N (%) | 51 (85.0) | – | – |
| ARV use during pregnancy, N (%) | – | – | |
| Zidovudine monotherapy | 25 (41.7) | – | – |
| Combination antiretrovirals | 35 (58.3) | ||
| Infant characteristics | |||
| Mean (SD) gestational age at birth (weeks) | 38.7 (1.2) | 39.2 (1.4) | 0.01 |
| Female gender, N (%) | 25 (41.8) | 36 (50.0) | 0.38 |
| Mean (SD) birth weight (g) | 3176.4 (381.5) | 3346.5 (422.7) | 0.02 |
| Small for gestational age (<10th percentile), N (%) | 2 (3.3) | 0 (0.0) | 0.20 |
| Large for gestational age (>90th percentile), N (%) | 7 (11.7) | 16 (22.2) | 0.17 |
| Not breastfeeding, N (%) | 60 (100) | 1 (1.4) | <0.0001 |
| SOCIODEMOGRAPHIC AND CLINICAL CHARACTERISTICS | TREATMENT GROUP(N = 22)MEAN ± SD | WAITING LIST CONTROL GROUP (N = 24)MEAN ± SD | P |
| Age (years) | 48.6 ± 11.2 | 53.0 ± 11.4 | 0.20 |
| Sex (F/M) | 15/7 | 20/4 | 0.27 |
| BMI (kg/m2) | 24.9 ± 4.0 | 24.1 ± 3.1 | 0.47 |
| Pain at rest (PR) | 45.5 ± 20.9 | 42.3 ± 18.0 | 0.58 |
| Duration of neck pain (years) | 6.3 ± 6.1 | 8.0 ± 7.6 | 0.41 |
| Expected effectiveness of cupping therapy(VAS from 0 = not effective at all to 100 = highly effective) | 82.8 ± 13.6 | 72.4 ± 21.3 | 0.06 |
| Formal only (n = 88) | Formal and informal (n = 377) | Informal only (n = 201) | No help (n = 944) | ||||||||||||
| N | n | % | (95% CI) | n | % | (95% CI) | n | % | (95% CI) | n | % | (95% CI) | Χ2 | p | |
| Socio-demographic | |||||||||||||||
| Gender | 11.63 | <0.001 | |||||||||||||
| Male | 702 | 36 | 5.2 | (3.7-7.2) | 65 | 8.9 | (7.0-11.3) | 130 | 17.9 | (15.3-20.9 | 471 | 67.9 | (64.3-71.3) | ||
| Female | 908 | 52 | 5.8 | (4.4-7.6) | 136 | 14.7 | (12.5-17.2) | 247 | 25.9 | (23.0-29.0) | 473 | 53.6 | (50.1-57.0) | ||
| Age | 4.09 | <0.001 | |||||||||||||
| 16-25 | 387 | 16 | 4.2 | (2.6-6.7) | 43 | 11.8 | (8.7-15.8) | 108 | 28.8 | (24.3-33.6) | 220 | 55.2 | (50.1-60.2) | ||
| 26-40 | 521 | 24 | 4.6 | (3.1-6.9) | 76 | 15.1 | (12.2-18.7) | 141 | 28.1 | (24.2-32.4) | 280 | 52.1 | (47.5-56.6) | ||
| 41-55 | 398 | 29 | 7.4 | (5.1-10.4) | 55 | 14.8 | (11.5-18.9) | 80 | 20.7 | (16.9-25.1) | 234 | 57.1 | (52.0-62.1) | ||
| 56 or older | 304 | 19 | 6.2 | (3.9-9.6) | 27 | 9.4 | (6.5-13.5) | 48 | 16.5 | (12.5-21.3) | 210 | 68.0 | (62.1-73.3) | ||
| Ethnic group | 1.10 | 0.356 | |||||||||||||
| White | 987 | 58 | 6.1 | (4.7-7.9) | 133 | 13.5 | (11.3-15.9) | 231 | 23.2 | (20.5-26.2) | 565 | 57.2 | (53.8-60.6) | ||
| Black Caribbean | 137 | 11 | 8.0 | (4.4-14.2) | 14 | 11.1 | (6.7-17.8) | 34 | 24.1 | (17.0-32.9) | 78 | 56.8 | (47.8-65.5) | ||
| Black African | 225 | 11 | 4.7 | (2.6-8.4) | 21 | 10.3 | (6.7-15.6) | 46 | 19.2 | (14.5-25.0) | 147 | 65.7 | (58.6-72.2) | ||
| Asian | 60 | 0 | - | 7 | 12.9 | (6.3-24.5) | 20 | 33.7 | (21.9-48.0) | 33 | 53.4 | (40.1-66.3) | |||
| Other | 199 | 8 | 4.0 | (2.0-7.9) | 25 | 12.8 | (8.8-18.3) | 45 | 23.8 | (17.9-30.9) | 121 | 59.4 | (52.1-66.4) | ||
| Relationship status | 4.48 | 0.004 | |||||||||||||
| Married/cohabitating | 739 | 32 | 4.7 | (3.3-6.7) | 79 | 11.0 | (8.8-13.6) | 154 | 20.8 | (17.9-24.0) | 474 | 63.5 | (59.6-67.2) | ||
| Non-married/non-cohabitating* | 871 | 56 | 6.4 | (4.9-8.3) | 122 | 14.3 | (12.0-17.0) | 233 | 25.3 | (22.3-28.6) | 470 | 54.0 | (50.3-57.6) | ||
| Migration status | 2.07 | 0.102 | |||||||||||||
| Non-migrant | 970 | 56 | 6.0 | (4.6-7.8) | 120 | 12.4 | (10.4-14.8) | 206 | 21.4 | (18.8-24.3) | 588 | 60.2 | (56.8-63.5) | ||
| Migrant | 633 | 29 | 4.6 | (3.2-6.6) | 81 | 13.5 | (10.9-16.6) | 170 | 26.2 | (22.8-30.0) | 353 | 55.7 | (51.4-59.9) | ||
| Socio-economic | |||||||||||||||
| Employment status | 3.03 | 0.001 | |||||||||||||
| Employed | 863 | 38 | 4.6 | (3.3-6.2) | 87 | 10.5 | (8.5-12.8) | 210 | 24.5 | (21.6-27.7) | 528 | 60.4 | (56.9-63.9) | ||
| Unemployed | 164 | 16 | 10.2 | (6.2-16.2) | 31 | 18.9 | (13.5-25.7) | 41 | 25.4 | (19.0-33.1) | 76 | 45.6 | (37.8-53.5) | ||
| Student | 239 | 12 | 4.9 | (2.7-8.7) | 28 | 12.7 | (8.8-18.0) | 63 | 26.9 | (21.5-33.1) | 136 | 55.5 | (48.9-61.9) | ||
| Other | 336 | 22 | 6.4 | (4.2-9.8) | 53 | 14.8 | (11.3-19.1) | 61 | 18.2 | (14.2-23.0) | 200 | 60.6 | (54.9-65.9) | ||
| Education | 1.90 | 0.049 | |||||||||||||
| No qualifications | 230 | 16 | 6.5 | (3.9-10.7) | 28 | 12.0 | (8.2-17.2) | 37 | 15.9 | (11.5-21.6) | 149 | 65.6 | (58.8-71.8) | ||
| GCSE | 318 | 24 | 7.9 | (5.2-11.7) | 43 | 13.7 | (10.2-18.2) | 78 | 24.8 | (20.2-30.0) | 173 | 53.6 | (47.9-59.3) | ||
| A-level | 407 | 23 | 5.7 | (3.8-8.6) | 53 | 13.5 | (10.2-17.6) | 100 | 25.1 | (20.9-29.8) | 231 | 55.7 | (50.6-60.7) | ||
| Degree or above | 655 | 25 | 4.0 | (2.7-5.9) | 77 | 12.2 | (9.8-15.1) | 162 | 24.7 | (21.5-28.3) | 391 | 59.1 | (55.1-63.0) | ||
| Annual household income | 2.38 | 0.005 | |||||||||||||
| £0-5,475 | 133 | 11 | 7.1 | (3.9-12.6) | 36 | 27.3 | (19.8-36.3) | 20 | 16.1 | (10.3-24.4) | 66 | 49.5 | (40.4-58.6) | ||
| £5,476-12,097 | 201 | 14 | 6.6 | (3.8-11.2) | 31 | 15.1 | (10.7-21.1) | 48 | 23.2 | (17.7-29.9) | 108 | 55.0 | (47.7-62.1) | ||
| £12,098-20,753 | 196 | 7 | 4.0 | (1.9-8.4) | 23 | 12.2 | (8.1-17.9) | 49 | 24.5 | (18.8-31.4) | 117 | 59.3 | (51.8-66.3) | ||
| £20,754-31,494 | 167 | 11 | 6.4 | (3.5-11.3) | 16 | 9.9 | (6.1-15.7) | 43 | 25.2 | (18.9-32.8) | 97 | 58.5 | (50.4-66.2) | ||
| £31,495 or more | 662 | 30 | 4.7 | (3.3-6.7) | 75 | 11.6 | (9.3-14.4) | 156 | 23.6 | (20.4-27.1) | 401 | 60.1 | (56.2-63.9) |
| Patient no. (with cartilage damage) | Teres ligament | Joint capsule | ||
| S100 | Substance P | S100 | Substance P | |
| 1. | + | + | - | - |
| 4. | - | + | + | - |
| 5. | + | + | + | + |
| 9. | + | + | - | - |
| 11. | + | + | + | + |
| 12. | + | + | - | - |
| 15. | + | + | - | - |
| 16. | + | + | + | - |
| 17. | - | - | - | + |
| Extracted peatland drains | |||||
| Linear validation dataset | Drain | No drain | Total | Producer accuracy | |
| Drain | 193 | 131 | 324 | 0.60 | |
| No drain | 39 | 2637 | 2676 | 0.99 | |
| 2830 | |||||
| Total | 232 | 2768 | 3000 | ||
| User accuracy | 0.83 | 0.95 | |||
| Kappa statistic | 0.66 | OA | 0.94 |
| Genes | Identity | Major function |
| Genes that promote neuronal integrity during aging | ||
| daf-16 | FoxO transcription factor | Upregulation of stress resistance genes |
| hsf-1 | Heat shock transcription factor | Upregulation of small heat shock protein expression |
| mec-1 | EGF and Kunitz domain-containing ECM protein | Mechanosensory transduction, nerve attachment |
| mec-2 | Stomatin-like | Mechanosensory transduction |
| mec-4 | DEG/ENaC family sodium channel | Mechanosensory transduction |
| mec-5 | Atypical collagen | Mechanosensory transduction, nerve attachment |
| mec-6 | Paraoxonase | Mechanosensory transduction |
| mec-9 | EGF and Kunitz domain-containing ECM protein | Mechanosensory transduction, nerve attachment |
| mec-10 | DEG/ENaC family sodium channel | Mechanosensory transduction |
| mec-12 | α-tubulin | Mechanosensory transduction, axon transport |
| jkk-1 | JNK kinase | Activation of JNK; synaptic vesicle localization |
| jnk-1 | c-Jun N-terminus kinase (JNK) | Heat and stress response; locomotion |
| mek-1 | Mitogen activated protein kinase (MAPK) kinase/MKK7 | Stress and starvation response |
| lmn-1 | Laminin | Regulation of nuclear organization and function |
| ptl-1 | Tau/microtubules-associated protein | Microtubule stabilization? |
| unc-13 | Munc-13 | Synaptic vesicle fusion |
| unc-18 | Munc-18 | Synaptic vesicle docking |
| Genes that accelerate neuronal aging | ||
| daf-2 | Insulin-like growth factor receptor | Larval development, dauer formation, etc |
| dgk-1 | Diacylglycerol kinase | Inhibition of synapse transmission |
| slo-1 | BK-type potassium channel | Muscle inactivation, neuronal excitability, etc |
| Ribosomal protein gene | Chromosomal assignment in C. elegans | Number of 5' codons omitted from analysis | Coding nucleotides used for analysis |
| rpl-1 | III | 3 | 642 |
| rpl-2 | V | 0 | 783 |
| rpl-10 | II | 5 | 630 |
| rpl-14 | I | 5 | 402 |
| rpl-16 | III | 5 | 597 |
| rpl-23 | III | 5 | 408 |
| rpl-26 | II | 3 | 423 |
| rpl-27 | I | 6 | 393 |
| rpl-27a | I | 8 | 420 |
| rpl-28 | V | 7 | 387 |
| rpl-29 | IV | 0 | 189 |
| rpl-30 | I | 4 | 339 |
| rpl-31 | I | 8 | 345 |
| rpl-32 | II | 8 | 381 |
| rpl-34 | IV | 4 | 330 |
| rpl-35 | III | 8 | 348 |
| rpl-38 | V | 6 | 195 |
| rpl-39 | V | 8 | 132 |
| rps-1 | III | 6 | 762 |
| rps-8 | IV | 3 | 618 |
| rps-14 | III | 8 | 435 |
| rps-20 | I | 0 | 357 |
| rps-21 | III | 0 | 267 |
| rps-24 | IV | 0 | 396 |
| rps-25 | IV | 7 | 336 |
| rps-27 | V | 0 | 255 |
| rps-28 | IV | 0 | 201 |
| Total number of nucleotides: | 10,971 |
| Primary antibody | Manufacturer | Cat. number | Dilution | Source |
| OCT4 | Abcam | ab18976 | 1/250 | Rabbit |
| NANOG | Abcam | ab21624 | 1/100 | Rabbit |
| SSEA4 | Abcam | ab16287 | 1/100 | Mouse |
| TRA-1-81 | Abcam | ab16289 | 1/100 | Mouse |
| TRA-1-60 | Abcam | ab16288 | 1/100 | Mouse |
| SOX1 | Abcam | ab87775 | 1/200 | Rabbit |
| PAX6 | DSHB | 3B5 | 1/50 | Mouse |
| OTX2 | Abcam | ab21990 | 1/500 | Rabbit |
| LHX2 | Santa Cruz Biotechnology | sc-81311 | 1/200 | Mouse |
| SIX3 | Rockland | 600-401-A26 | 1/500 | Rabbit |
| MCM2 | Abcam | ab4461 | 1/400 | Rabbit |
| CHX10 | Millipore | ab9016 | 1/200 | Sheep |
| FIBRONECTIN | Abcam | ab2413 | 1/200 | Rabbit |
| ZO-1 | Thermo Fisher | 33-9100 | 1/400 | Mouse |
| BRN3 | Santa Cruz Biotechnology | sc-6026 | 1/200 | Goat |
| AP2 | DSHB | 3B5a | 1/35 | Mouse |
| PROX1 | Abcam | ab101851 | 1/2000 | Rabbit |
| PKC-α | Abcam | ab32376 | 1/2000 | Rabbit |
| CRALBP | Abcam | ab15051 | 1/500 | Mouse |
| Rhodopsin | Abcam | ab3267 | 1/200 | Mouse |
| S opsin | Gift from Dr. Jeremy Nathans | / | 1/5000 | Rabbit |
| L/M opsin | Gift from Dr. Jeremy Nathans | / | 1/5000 | Rabbit |
| Recoverin | Millipore | ab5585 | 1/500 | Rabbit |
| PDE6α | Abcam | ab5665 | 1/100 | Rabbit |
| Gtα-1 | Santa Cruz Biotechnology | sc-136143 | 1/2000 | Mouse |
| Males N (%) | Females N (%) | Age in years median (Range) | |
| Balochistan | 52 (55%) | 42 (45%) | 29 (4 to 70) |
| Islamabad | 62 (72%) | 23 (28%) | 26 (3 to 75) |
| KPK | 231 (63%) | 133 (37%) | 22 (0.3 to 75) |
| Punjab | 126 (64%) | 71 (36%) | 24 (0.4 to 65) |
| Sindh | 38 (62%) | 23 (38%) | 28 (0.3 to 65) |
| Task | Satisfactory | Unsatisfactory |
| (1) Performs a “time-out” and places monitors on patient (pulse oximetry and NIBP). | — | — |
| (2) Verifies that spinal kit tray, nonsterile and sterile gloves (correct size), and cleansing solution are present. | — | — |
| (3) Palpates the superior aspects of the iliac crests and identifies the intersection at the L4 spinous process with nonsterile gloves on. Marks position at the L3/L4 or L4/L5 interspace. | — | — |
| (4) Cleans the overlying skin with chlorhexidine. | — | — |
| (5) Opens the spinal tray before placing sterile gloves on. | — | — |
| (6) Puts on sterile gloves with proper technique. | — | — |
| (7) Applies sterile drapes. | — | — |
| (8) Draws up lidocaine in the 3cc syringe and bupivacaine in the 5cc syringe. Administers local anesthesia in a wheal at the previously marked site. | — | — |
| (9) Injects more anesthetic in the correct location and angle. | — | — |
| (10) Inserts the introducer needle in the middle of the interspace with a slight cephalad angulation of 10 to 15 degrees. The bevel of the spinal needle should be in the sagittal plane. | — | — |
| (11) Advances spinal needle through anatomic structures until the subarachnoid space is reached. May experience a popping sensation as the ligamentum flavum is crossed. | — | — |
| (12) Withdraws the stylet each time a pop is felt to assess for CSF flow. | — | — |
| (13) Confirms CSF flow by aspiration before and after injecting anesthetic. | — | — |
| (14) Removes the spinal and introducer needle together once completed. | — | — |
| (15) Applies pressure with the provided 2 × 2 gauze and assesses good hemostasis. | — | — |
| (16) Removes the drape, lays the patient, and observes vitals. Disposes of all sharps and biohazard material appropriately. | — | — |
| KEGG pathway | Count | P value | ||
| HFF1_24 h vs HFF1 | Up-regulated gene | hsa04622: RIG-I-like receptor signaling pathway | 6 | 9.35E-05 |
| hsa04620: Toll-like receptor signaling pathway | 5 | 0.0043 | ||
| hsa04623: Cytosolic DNA-sensing pathway | 4 | 0.0057 | ||
| HFF1_48 h vs HFF1 | Up-regulated gene | hsa04620: Toll-like receptor signaling pathway | 6 | 0.0209 |
| hsa04622: RIG-I-like receptor signaling pathway | 5 | 0.0249 | ||
| Down-regulated gene | hsa05410: Hypertrophic cardiomyopathy (HCM) | 4 | 0.0479 | |
| HFF1_72 h vs HFF1 | Up-regulated gene | hsa00330: Arginine and proline metabolism | 6 | 0.0076 |
| hsa00480: Glutathione metabolism | 5 | 0.0287 | ||
| hsa00250: Alanine, aspartate and glutamate metabolism | 4 | 0.0349 | ||
| Down-regulated gene | hsa04510: Focal adhesion | 13 | 4.57E-05 | |
| hsa04810: Regulation of actin cytoskeleton | 10 | 0.0056 | ||
| hsa05200: Pathways in cancer | 11 | 0.0272 | ||
| ES vs HFF1 | Up-regulated gene | hsa05217: Basal cell carcinoma | 14 | 9.58E-06 |
| hsa04310: Wnt signaling pathway | 22 | 1.28E-04 | ||
| hsa05200: Pathways in cancer | 36 | 2.29E-04 | ||
| hsa00330: Arginine and proline metabolism | 10 | 0.0029 | ||
| Down-regulated gene | hsa04510: Focal adhesion | 40 | 8.73E-08 | |
| hsa00520: Amino sugar and nucleotide sugar metabolism | 13 | 1.09E-04 | ||
| hsa04512: ECM-receptor interaction | 18 | 2.52E-04 | ||
| hsa04142: Lysosome | 20 | 0.0019 | ||
| iPS vs HFF1 | Up-regulated gene | hsa04310: Wnt signaling pathway | 16 | 2.39E-04 |
| hsa05217: Basal cell carcinoma | 8 | 0.0029 | ||
| hsa00250: Alanine, aspartate and glutamate metabolism | 6 | 0.0041 | ||
| hsa00260: Glycine, serine and threonine metabolism | 6 | 0.0041 | ||
| Down-regulated gene | hsa04510: Focal adhesion | 56 | 1.46E-11 | |
| hsa04512: ECM-receptor interaction | 27 | 3.06E-07 | ||
| hsa00520: Amino sugar and nucleotide sugar metabolism | 16 | 2.84E-05 | ||
| hsa04810: Regulation of actin cytoskeleton | 42 | 1.43E-04 |
| Indicator | 0 mg/L | 1 mg/L | 5 mg/L | 10 mg/L | 20 mg/L | 40 mg/L | 80 mg/L |
| Spontaneous movements of 36 hpf (bends/30 seconds) | 11.17 ± 2.32 | 9.50 ± 1.52 | 10.17 ± 1.47 | 8.17 ± 2.79∗∗ | 6.83 ± 1.94∗∗ | 7.83 ± 1.17∗∗ | 9.17 ± 1.17 |
| Heart rate of 60 hpf (bends/30 seconds) | 67.00 ± 2.45 | 64.50 ± 2.88 | 60.67 ± 4.17∗ | 64.00 ± 4.24 | 75.50 ± 3.27∗∗ | 70.67 ± 5.74 | 71.00 ± 3.58 |
| Malformation rate (%) | 5.00 ± 1.00 | 6.67 ± 1.73 | 8.33 ± 1.73 | 13.30 ± 1.73∗∗ | 26.67 ± 4.58∗∗ | 25.00 ± 3.00∗∗ | 43.33 ± 4.58∗∗ |
| SV-BA (×102 μm) | 1.90 ± 0.19 | 2.07 ± 0.27 | 2.15 ± 0.28 | 2.70 ± 0.45∗∗ | 3.13 ± 0.26∗∗ | 3.05 ± 0.47∗∗ | 3.32 ± 0.26∗∗ |
| Area of pericardial edema (×104 μm2) | 2.48 ± 0.53 | 2.60 ± 0.65 | 2.97 ± 0.32 | 4.05 ± 0.67∗∗ | 5.43 ± 0.64∗∗ | 5.50 ± 0.97∗∗ | 5.55 ± 0.75∗∗ |
| Area of sac-yolk edema (×105 μm2) | 2.44 ± 0.10 | 2.56 ± 0.10 | 2.42 ± 0.22 | 2.83 ± 0.16∗∗ | 3.17 ± 0.23∗∗ | 3.49 ± 0.27∗∗ | 3.41 ± 0.27∗∗ |
| Body length (mm) | 3.11 ± 0.21 | 3.13 ± 0.18 | 3.16 ± 0.11 | 3.03 ± 0.08 | 2.96 ± 0.14 | 2.82 ± 0.20∗∗ | 2.80 ± 0.18∗∗ |
| Author (reference number) | Gender | GA (wks) | Clinical features of LCH involvement | Outcome (survival) |
| Vade et al. [10] | F | 35 | Skin, hepatosplenomegaly, pulmonary failure | Died (9 days) |
| Gee et al. [11] | M | 33 | Skin, pulmonary failure | Died (36 hrs) |
| Aviner et al. [12] | F | 32 | Skin, followed by multiorgan failure | Died (26 days) |
| Lee et al. [8] | M | 36 | Hydrops fetalis, skin, multiorgan failure | Died (12 days) |
| Cheng et al. [9] | M | 33 | Hydrops fetalis, skin, pleural effusion | Died (36 hrs) |
| Herbrüggen et al. [13] | M | 35 | Skin, at 3 months, pulmonary and thymic mass | Alive |
| Present case | F | 33 | Skin, hypovolemic shock, pulmonary failure | Died (57 hrs) |
| Ontology 8a – Regex | Ontology 7b – Voting | |||
| Total number of top-level terms | 662 | 1886 | ||
| Number of sampled top-level terms | 200 | 30.2% of total | 200 | 10.6% of total |
| Number of sampled top-level terms relevant to animal behaviour | 84 | 42% of sample | 82 | 41% of sample |
| Proportionate number of top- level animal behaviour terms in the whole ontology | 278 | 773 | ||
| Number of sampled top-level an imal behaviour terms not found in the other ontology | 44 | 22% of sample | 77 | 38.5% of sample |
| Proportionate number of top- level animal behaviour terms in the whole ontology not found in the other ontology | 145 | 727 |
| Parameters | Group | ||
| Control diet | 5% CL diet | 10% CL diet | |
| Food Intake (g/day) | 2.25 ± 0.01 | 2.22 ± 0.04 | 2.24 ± 0.03 |
| Initial body weight (g) | 13.9 ± 0.32 | 13.7 ± 0.27 | 13.7 ± 0.28 |
| Final body weight (g) | 25.7 ± 0.43 | 24.8 ± 0.54 | 24.5 ± 0.40 |
| Liver weight (g/100 g body weight) | 4.50 ± 0.11 | 3.88 ± 0.17* | 3.67 ± 0.12** |
| White adipose tissue weight (g/100 g body weight) | |||
| Total† | 6.03 ± 0.47 | 5.75 ± 0.36 | 5.26 ± 0.28 |
| Abdominal§ | 4.34 ± 0.35 | 4.36 ± 0.31 | 4.00 ± 0.22 |
| Epididymal | 2.18 ± 0.16 | 2.13 ± 0.16 | 1.98 ± 0.11 |
| Perirenal | 0.81 ± 0.14 | 0.80 ± 0.07 | 0.64 ± 0.06 |
| Omental | 1.35 ± 0.08 | 1.44 ± 0.10 | 1.37 ± 0.08 |
| Subcutaneous | 1.69 ± 0.12 | 1.39 ± 0.06 | 1.26 ± 0.08** |
| Serum parameters | |||
| Triglyceride (mg/dL) | 35.0 ± 3.41 | 40.5 ± 3.71 | 32.2 ± 3.10 |
| Total cholesterol (mg/dL) | 107 ± 4 | 107 ± 4 | 114 ± 3 |
| Non-esterified fatty acid (mEq/dL) | 9.68 ± 0.89 | 8.41 ± 0.40 | 6.56 ± 0.56** |
| Glucose (mg/dL) | 210 ± 11 | 242 ± 11 | 211 ± 25 |
| Insulin (ng/mL) | 1.70 ± 0.23 | 1.74 ± 0.18 | 1.79 ± 0.31 |
| Adiponectin (ng/mL) | 3.58 ± 0.11 | 3.51 ± 0.15 | 3.30 ± 0.13 |
| Variable | LBC (M, SD) (n = 1031) | NLBC (M, SD) (n = 992) | t | p |
| Total | 20.98, 6.273 | 21.66, 5.877 | 2.498 | 0.013 |
| Gender | ||||
| Male | 20.99, 6.313 | 21.56, 5.975 | 1.460 | 0.145 |
| Female | 21.05, 6.264 | 21.79, 5.772 | 1.910 | 0.056 |
| Grade | ||||
| Grade 4 | 22.14, 5.623 | 22.75, 5.245 | 0.907 | 0.365 |
| Grade 5 | 22.74, 7.324 | 22.50, 6.235 | -0.272 | 0.786 |
| Grade 6 | 20.64, 6.467 | 21.64, 6.504 | 1.400 | 0.162 |
| Grade 7 | 20.59, 5.993 | 21.51, 5.332 | 2.277 | 0.023 |
| Grade 8 | 20.43, 5.450 | 21.71, 5.246 | 2.385 | 0.018 |
| Grade 9 | 20.07, 5.990 | 20.67, 6.317 | 0.968 | 0.334 |
| Educational level | ||||
| Elementary school (grades 4–6) | 21.77, 6.584 | 22.23, 6.058 | 1.059 | 0.290 |
| Middle school (grades 7–9) | 20.43, 5.992 | 21.24, 5.712 | 2.380 | 0.017 |
| Variables | ALL N=383 | Right hemiparesis 208 (54%) | Left hemiparesis 157 (41%) | Bilateral hemipareses 18 (5%) | P-Value |
| mean±SD, n (%) | |||||
| Age in years | 54.9±15.3 | 58.8±16.4 | 57.9±14.8 | 47.9±14.7 | 0.019 |
| Gender | |||||
| Male | 213(56) | 124(60) | 82(52) | 7(39) | 0.13 |
| Female | 170(44) | 84(40) | 75(48) | 11(61) | |
| Discharge disposition | |||||
| Home | 374(98) | 204(98) | 153(98) | 17(94) | 0.61 |
| Not to home | 9(2) | 4(2) | 4(2) | 1(6) | |
| LOS in days | 47.5±28.7 | 47.5±32.1 | 48.9±28.4 | 59.6±37.5 | 0.28 |
| P-Value3 | P-Value2 | Control Group | P- Value1 | After Treatment | Before Treatment | |
| 0.042** | 0.002* | 72.4±28.4 | 0.021* | 58.02±15.33 | 51.06±17.77 | TNF-α |
| 0.07** | 0.002* | 97.54±66.04 | 0.056* | 65.67±38.31 | 54.66±31.50 | IL-1α |
| Test Condition | Filter Medium | ||||
| System A | System B | System C | System D | ||
| HLR (m3/m2/d) | Inflow (mg/L) | 170.7 ± 61.4 | 170.7 ± 61.4 | 203.2 ± 51.5 | 203.2 ± 51.5 |
| 0.5 | Outflow (mg/L) | 36.5 ± 9.1 | 51.1 ± 17.0 | 94.6 ± 25.1 | 52.8 ± 13.6 |
| % removal | 76.9 ± 7.3 | 68.8 ± 7.5 | 54.6 ± 2.7 | 73.9 ± 4.1 | |
| 1.0 | Outflow (mg/L) | 68.3 ± 29.1 | 78.3 ± 24.5 | 130.1 ± 32.8 | 85.4 ± 17.3 |
| % removal | 65.2 ± 11.9 | 51.8 ± 4.1 | 33.9 ± 3.7 | 57.0 ± 2.7 | |
| 2.0 | Outflow (mg/L) | 78.8 ± 15.6 | 110.6 ± 33.5 | 152.7 ± 35.4 | 111.6 ± 24.5 |
| % removal | 49.4 ± 14.7 | 33.7 ± 4.2 | 22.9 ± 3.3 | 40.6 ± 6.0 | |
| 3.0 | Outflow (mg/L) | 113.3 ± 41.0 | 114.8 ± 35.6 | 143.9 ± 29.8 | 119.5 ± 29.7 |
| % removal | 30.5 ± 18.2 | 33.0 ± 8.6 | 26.8 ± 5.0 | 42.7 ± 3.1 |
| Super-obese group | Comparison | OR | AORb | |
| (N = 370) | (N = 621) | |||
| % | % | |||
| Complications during pregnancy | ||||
| Medical problems during pregnancy | 33.3 | 13 | 3.35 (2.43–4.62) | 2.89 (2.64–4.11) |
| Obstetric problems during pregnancy | 42 | 23.2 | 2.40 (1.81–3.17) | 2.42 (1.77–3.29) |
| Gestational diabetes | 15.6 | 7.2 | 2.36 (1.56–3.59) | 2.52 (1.58–4.65) |
| Gestational hypertension | 12.3 | 1.5 | 9.33 (4.50–19.33) | 10.24 (4.67–22.44) |
| Preeclampsia | 8.5 | 2.6 | 3.42 (1.85–6.35) | 3.43 (1.72–6.84) |
| Obstetric | ||||
| Labour | 65.8 | 77.6 | 0.55 (0.42–0.74) | 0.49 (0.35–0.68) |
| Induction of labour | 58.3 | 26.9 | 3.81 (2.75–5.28) | 4.33 (3.21–6.24) |
| Caesarean section | 52 | 31.7 | 2.33 (1.79–3.65) | 2.73 (2.02–3.69) |
| Perinatal outcomes (singletons only) | ||||
| Birthweight ≥4500 g | 10.1 | 0.8 | 13.44 (5.22–34.57) | 19.94 (6.81–58.36) |
| Admitted to NICU | 23.7 | 13.9 | 1.93 (1.38–2.71) | 1.83 (1.27–2.65) |
| Need for transfer | 8.5 | 2.7 | 3.39 (1.82–6.31) | 3.81 (1.93–7.55) |
| Preterm birth <37 weeks | 10.1 | 8.1 | 1.28 (0.81–2.00) | 1.18 (0.72,1.93) |
| Maternal outcomes | ||||
| Admission to ICU | 2.2 | 0.5 | 4.56 (1.25–17.32) | 7.38 (1.52–35.87) |
| Admission to HDU | 4.3 | 0.8 | 5.58 (2.43–15.37) | 5.40 (1.78–16.38) |
| Admission to either ICU or HDU | 6.2 | 1.3 | 5.09 (2.25–11.51) | 5.67 (2.31–13.93) |
| Composites | Relatives items |
| Parental sensitivity | Acknowledging; imitating; elaborating; parent gaze; positive affect; vocal appropriateness, clarity; appropriate range of affect; resourcefulness; praising; affectionate touch; supportive presence; infant led interaction |
| Parent intrusiveness | Forcing-physical manipulation; overriding, intrusiveness; parent negative affect, anger; parent anxiety; criticizing; parent-led interaction |
| Parent limit setting | Consistency of style; resourcefulness; appropriate structure, limit setting |
| Child compliance | Compliance to parent; reliance on parent for help; on-task persistence |
| Child withdrawal | Child negative emotionality, fussy; withdrawal; labile affect; avoidance of parent |
| Child engagement | Joint attention; child positive affect; affection to parent; alertness; fatigue; vocalizations, verbal output; initiation; competent use of the environment; creative-symbolic play; infant-led interaction |
| Dyadic joint negative state | Parent negative affect, anger; hostility; child negative emotionality, fussy; withdrawal, labile affect; fatigue; constriction; tension |
| Dyadic reciprocity | Parent gaze; positive affect; praising; affectionate touch; joint attention; child positive affect; vocalization, verbal output; initiation; dyadic reciprocity; adaptation-regulation; fluency |
| PRISMA statement results | ||||||||
| Yes | Partial | No | ||||||
| Title | 1 | Title | 221 | (93%) | 13 | (5%) | 2 | (0%) |
| Abstract | 2 | Structured summary | 82 | (35%) | 147 | (62%) | 7 | (3%) |
| Introduction | 3 | Rationale | 233 | (98%) | 3 | (1%) | 0 | (0%) |
| Methods | 4 | Objectives | 143 | (60%) | 90 | (38%) | 3 | (1%) |
| 5 | Protocol and registration | 2 | (1%) | 35 | (15%) | 199 | (84%) | |
| 6 | Eligibility criteria | 209 | (88%) | 27 | (11%) | 0 | (0%) | |
| 7 | Information sources | 235 | (99%) | 1 | (0%) | 0 | (0%) | |
| 8 | Search | 59 | (25%) | 177 | (75%) | 0 | (0%) | |
| 9 | Study selection | 134 | (57%) | 30 | (13%) | 72 | (30%) | |
| 10 | Data collection process | 149 | (63%) | 16 | (7%) | 71 | (30%) | |
| 11 | Data items | 127 | (54%) | 64 | (27%) | 45 | (19%) | |
| 12 | Risk of bias in individual studies | 103 | (43%) | 79 | (33%) | 54 | (23%) | |
| 13 | Summary measures | 235 | (99%) | 0 | (0%) | 1 | (0%) | |
| 14 | Synthesis of results | 234 | (99%) | 2 | (1%) | 0 | (0%) | |
| 15 | Risk of bias across studies | 152 | (64%) | 30 | (13%) | 54 | (23%) | |
| 16 | Additional analyses | 101 | (43%) | 12 | (5%) | 123 | (52%) | |
| Results | 17 | Study selection | 112 | (47%) | 91 | (38%) | 33 | (14%) |
| 18 | Study characteristics | 132 | (56%) | 94 | (40%) | 10 | (4%) | |
| 19 | Risk of bias within studies | 76 | (32%) | 84 | (36%) | 76 | (32%) | |
| 20 | Results of individual studies | 162 | (68%) | 36 | (15%) | 39 | (16%) | |
| 21 | Synthesis of results | 235 | (99%) | 1 | (0%) | 0 | (0%) | |
| 22 | Risk of bias across studies | 136 | (57%) | 35 | (15%) | 65 | (27%) | |
| 23 | Additional analyses | 90 | (38%) | 24 | (10%) | 122 | (51%) | |
| Discussion | 24 | Summary of evidence | 232 | (98%) | 4 | (2%) | 0 | (0%) |
| 25 | Limitations | 139 | (59%) | 38 | (16%) | 59 | (25%) | |
| 26 | Conclusions | 232 | (98%) | 4 | (2%) | 0 | (0%) | |
| Funding | 27 | Funding | 114 | (48%) | 0 | (0%) | 122 | (51%) |
| Patients with total lipid profile | CVD + DM (n = 753) | CVD (w/o DM) (n = 280) | DM (w/o CVD) (n = 586) | SCORE ≥ 10% (n = 30) |
| LDL-C ≥ 1.8 mmol/L and LDL-reduction <50% [%] | 74.4 | 63.9 | 65.4 | 80.0 |
| Low HDL-C (<1.0 [men]/1.2 [women] mmol/L) [%] | 68.4 | 52.9 | 48.3 | 56.7 |
| Elevated TG (>1.7 mmol/L) [%] | 65.1 | 38.2 | 39.1 | 53.3 |
| All patients | (n = 829) | (n = 312) | (n = 629) | (n= 30) |
| LDL-C ≥ 1.8 mmol/L and LDL-reduction <50% [%]* | 74.4 | 63.9 | 65.4 | 80.0 |
| Low HDL-C (<1.0 [men]/1.2 [women] mmol/L) [%]†‡ | 69.4 | 54.8 | 50.0 | 56.7 |
| Elevated TG (>1.7 mmol/L) [%]‡ | 61.1 | 35.3 | 38.7 | 53.3 |
| NorthernTanna(n = 364) | Northern TannaHighlands(n = 515) | Southern Tanna(n = 370) | Aneityum(n = 517) | Total(n = 1766) | ||
| Male | 47.3 (172) | 48.1 (245) | 50.3 (186) | 48.6 (251) | 48.5 (854) | |
| Sex | Female | 52.8 (192) | 51.9 (264) | 49.7 (184) | 51.5 (266) | 51.5 (906) |
| Not recorded | 0 | 6 | 0 | 0 | 6 | |
| 0-5 | 18.4 (67) | 23.1 (119) | 14.1 (52) | 17.4 (90) | 18.6 (328) | |
| 5-20 | 48.4 (176) | 42.9 (221) | 52.7 (195) | 42.4 (219) | 45.9 (811) | |
| Age (Years) | 20-80 | 33.2 (121) | 34.0 (175) | 33.2 (123) | 40.2 (208) | 35.5 (627) |
| Total | 100 (364) | 100 (515) | 100 (370) | 100 (517) | 100 (1766) | |
| No | 21.8 (79) | 61.7 (269) | 11.1 (41) | 10.1 (52) | 26.1 (441) | |
| Used a bed net the night before the survey | Yes | 78.2 (284) | 38.3 (167) | 88.9 (329) | 89.9 (465) | 73.8(1245) |
| Not recorded | 1 | 79 | 0 | 0 | 80 |
| Difference | PSF + TOF vs. PSF | 3D-OSEM + TOF vs. 3D-OSEM | ||
| Low TBR | High TBR | Low TBR | High TBR | |
| ** | n.s. | ** | n.s. | |
| Median | 10.4 | 1.8 | 8.6 | −0.1 |
| IQR | 3.1 to 19.0 | −0.8 to 5.5 | 3.3 to 14.8 | −6.0 to 2.4 |
| Range | 1.0 to 27.2 | −16.7 to 27.9 | −5.9 to 17.5 | −13.9 to 24.0 |
| Cell line | Gq mutant | G11 mutant | BRAF mutant |
| Melanocytes | WT | WT | WT |
| OCM1 | WT | WT | V600E |
| OCM3 | WT | WT | V600E |
| OMM1 | WT | Q209L | WT |
| OMM2.3* | Q209P | WT | WT |
| Mel270* | Q209P | WT | WT |
| LOXIMVI | WT | WT | V600E |
| M14 | WT | WT | V600E |
| MALME-3M | WT | WT | V600E |
| MDA-MB-435 | WT | WT | V600E |
| SK-MEL-2 | WT | WT | V600E |
| SK-MEL-28 | WT | WT | V600E |
| SK-MEL-5 | WT | WT | V600E |
| ACC-257 | WT | WT | V600E |
| UACC-62 | WT | WT | V600E |
| Tolvaptan group | Conventional group | p value | |
| Number | 26 | 180 | |
| Age (years) | 75 ± 11 | 74 ± 12 | 0.88 |
| Sex (male,%) | 15 (58) | 96 (53) | 0.68 |
| BMI (kg/m2) | 23.8 ± 4.4 | 23.6 ± 4.4 | 0.77 |
| Previous HF hospitalization | 2.1 ± 1.7 | 0.5 ± 0.9 | <0.001 |
| Etiology of heart failure | |||
| Ischemic heart disease | 8 (31) | 68 (38) | 0.87 |
| Dilated cardiomyopathy | 5 (19) | 30 (17) | |
| Valvular heart disease | 5 (19) | 26 (14) | |
| Others | 8 (31) | 56 (31) | |
| Comorbid disease | |||
| Hypertension | 20 (77) | 136 (76) | 0.88 |
| Diabetes mellitus | 14 (54) | 81 (45) | 0.40 |
| Dyslipidemia | 10 (38) | 73 (41) | 0.84 |
| Atrial fibrillation | 19 (73) | 69 (38) | <0.001 |
| Vital sign on admission | |||
| Heart rate (bpm) | 79 ± 18 | 96 ± 27 | <0.001 |
| SBP (mmHg) | 123 ± 27 | 150 ± 38 | <0.001 |
| DBP (mmHg) | 71 ± 17 | 84 ± 22 | <0.01 |
| Blood chemistry on admission | |||
| Hemoglobin (g/dl) | 10.3 ± 2.1 | 11.5 ± 2.3 | <0.05 |
| BUN (mg/dl) | 48 ± 27 | 28 ± 17 | <0.001 |
| Scr (mg/dl) | 2.0 ± 1.0 | 1.5 ± 1.4 | <0.001 |
| eGFR (ml/min/1.73 m2) | 30.7 ± 17.6 | 50.1 ± 27.3 | <0.001 |
| eGFR <30 ml/min/1.73 m2 (%) | 15 (58) | 47 (26) | <0.005 |
| Na (mEq/l) | 137 ± 6 | 139 ± 4 | 0.22 |
| K (mEq/l) | 4.3 ± 1.0 | 4.2 ± 0.7 | 0.38 |
| BNP (pg/ml) | 746 (241–1527) | 845 (465–1693) | 0.23 |
| Medication on admission | |||
| β-blockers | 18 (69) | 59 (33) | <0.001 |
| RAS inhibitors | 20 (77) | 98 (54) | <0.05 |
| Loop diuretics | 26 (100) | 92 (51) | <0.001 |
| Thiazide diuretics | 8 (26) | 16 (9) | <0.005 |
| Aldosterone antagonists | 14 (54) | 32 (18) | <0.05 |
| Device therapy | 7 (27) | 28 (16) | 0.15 |
| Diagnosis | Diagnostic Clues | |
| Psoriasis | Usually involves extensor, palmar, plantar, nails and extensor areas. Thick plaques sharply limited with silvery white scales. Positive family history. Arthritis present in 10% of patients. Uncommon in children. | |
| Atopic Dermatitis | First appearance after 3 months of age, pruritus and restlessness are common. Frequently involves scalp, cheeks and extensor areas. Flexures involvement is more frequent in older ages. Family history of atopy such as eczema, allergic rhinitis and asthma. Self resolved by age 12. | |
| Tinea Capitis | Commonly seen in children, frequently accompanied by hair loss patches with “black dots” (broken hair). Highly contagious. KOH examination of the hair shaft and fungal culture confirm the diagnosis. Household members of patient should be examined. | |
| Rosacea | Usually targets the face. Papulopustules and telangiectasias on the malar, nose and perioral regions with slight desquamation. Recurrent edema and flushing. | |
| Systemic Lupus Erythematous (SLE) | In acute stage, butterfly rash on face that spares the nose bridge or nasolabial folds. Photosensitivity is common. Skin lesions are generally associated with other clinical signs of SLE. Histology and serologic tests such as antinuclear autoantibodies confirm the diagnosis. | |
| Others | Pemphigus Foliaceous | Erythema, scaling and crusting that first present on the scalp and face can expand to chest and back. Histology, direct immunofluorescence with anti-desmoglein antibodies confirm diagnosis. |
| Pityriasis Rosea | Abrupt onset, appearance of herald patch and resolution within weeks. | |
| Secondary syphilis | Peripheral lymph-adenopathy, mucosal lesions and palmoplantar macula-papules. Serology tests such as VDRL/ RPR, FTA-ABS* confirm diagnosis. | |
| Diaper Dermatitis | Occurs on convex skin surfaces in contact with diaper, such as lower abdomen, genitalia, buttocks and upper thighs. Spares skin folds. Pustules are common. | |
| Langerhans cell histiocytosis | Multisystem disease. Brown to purplish papules prone to coalesce on the scalp, retro-auricular areas, axillae and inguinal folds. Possible lytic bone lesions, liver, spleen and lung involvement. Histology confirms diagnosis. |
| Assembler | Type† | Splits reads* | Author | Cost | Source available | URL |
| CAP3 | OLC† | No | X Huang and A Madan [38] | Free for use at non-profit organizations | No | http://seq.cs.iastate.edu/ |
| CLC Assembly Cell 3.0 | de Bruijn graph | Yes | CLC | Request quote or trial license | No | http://www.clcbio.com/ |
| MIRA 3.0 | OLC | No | Bastien Chevreux [40] | Free | Yes, GPL | http://sourceforge.net/projects/mira-assembler/ |
| Newbler 2.3 and Newbler 2.5 | OLC | Yes | Roche 454 [37] | Free for academic use | No | http://454.com/products-solutions/analysis-tools/gs-de-novo-assembler.asp |
| SeqMan NGen 2.1 | OLC | No | DNAStar [41] | Request quote or trial license | No | http://www.dnastar.com/t-products-seqman-ngen.aspx |
| Trait | b( P , DGV ) | r( DGV , P ) | Accuracy |
| 14:0 | 0.93 | 0.43 | 0.57 |
| 16:0 | 0.95 | 0.38 | 0.53 |
| 18:0 | 0.66 | 0.20 | 0.27 |
| cis-9 18:1 | 0.77 | 0.26 | 0.35 |
| cis-12 18:1 | 0.89 | 0.18 | 0.35 |
| trans-12 18:1 | 0.03 | 0.01 | 0.03 |
| 18:3n3 | 0.13 | 0.01 | 0.03 |
| 18:3n6 | 0.22 | 0.06 | 0.21 |
| 20:3n3 | -0.47 | -0.02 | -0.06 |
| 20:3n6 | -0.04 | -0.01 | -0.02 |
| 20:4 | 0.03 | 0.00 | 0.01 |
| CLAc9t11 | 1.53 | 0.10 | 0.29 |
| CLAt10c12 | 0.04 | 0.00 | 0.01 |
| LCFA | 0.95 | 0.42 | 0.57 |
| MCFA | 0.95 | 0.43 | 0.57 |
| MUFA | 0.87 | 0.26 | 0.38 |
| PUFA | 0.37 | 0.04 | 0.08 |
| SFA | 0.84 | 0.34 | 0.45 |
| PUFA/SFA | 0.45 | 0.06 | 0.12 |
| (14:0+16:0)/All | 0.94 | 0.40 | 0.55 |
| Al | 0.92 | 0.43 | 0.56 |
| n3 | -0.01 | -0.01 | -0.01 |
| n6 | 0.18 | 0.02 | 0.07 |
| n3/n6 | 0.00 | 0.00 | 0.00 |
| MZ | DZ | Total no pairs | ||
| IBS | Concordant pairs | 14 | 10 | 24 |
| Discordant pairs | 95 | 193 | 288 | |
| Probandwise concordance rate | 0.23 | 0.09* | ||
| Depression | Concordant pairs | 67 | 82 | 149 |
| Discordant pairs | 232 | 455 | 687 | |
| Probandwise concordance rate | 0.22 | 0.15* | ||
| Anxiety | Concordant pairs | 56 | 55 | 111 |
| Discordant pairs | 186 | 422 | 608 | |
| Probandwise concordance rate | 0.23 | 0.12* |
| Ashford et al.[46](MMSE) | Gibbons et al.[48]UK (MMSE) | Gibbons et al.[48]US (MMSE) | Mungas and Reed[1](BIMCT/MMSE) | |
| Truncated above upper limit | Recall: tree | No ifs ands or buts | ||
| Recall: flag | Recall nouns | |||
| 1st quartile (most difficult) | Serial sevens: subtraction 5 | Orientation to date | Orientation to date | Recall ‘42’ (BIMCT) |
| Serial sevens: subtraction 3 | Verbal directions | No ifs ands or buts | Recall ‘Market Street’ (BIMCT) | |
| Orientation to date | Intersecting pentagons | Intersecting pentagons | Recall ‘John’ (BIMCT) | |
| Recall: Ball | Serial sevens | Serial sevens | Recall ‘Chicago’ (BIMCT) | |
| Recall ‘Brown’ (BIMCT) | ||||
| 2nd quartile | Serial sevens: subtraction 4 | Orientation to year | Recall nouns | Orientation to year (BIMCT/MMSE) |
| Serial sevens: subtraction 2 | Orientation to county/streets | Orientation to day | Orientation to month (BIMCT/MMSE) | |
| Orientation to day | Orientation to day | Orientation to year | Age (BIMCT) | |
| Orientation to county | Orientation to month | Orientation to season | ||
| Orientation to month | Orientation to month | |||
| Serial sevens: subtraction 1 | Orientation to county/streets | |||
| Orientation to year | ||||
| Orientation to season | ||||
| Orientation to place | ||||
| Orientation to floor | ||||
| 3rd quartile | Orientation to city | Orientation to state/county | Orientation to address | Orientation to state (MMSE) |
| Intersecting pentagons | Write sentence | Verbal directions | Type of work (BIMCT) | |
| Orientation to state | Orientation to | Write sentence | Count forward (BIMCT) | |
| Write sentence | Season | Orientation to place | Name watch (MMSE) | |
| No ifs ands or buts | Orientation to Address | Orientation to city | ||
| Name watch | ||||
| Verbal directions: paper-on floor | ||||
| 4th quartile (least difficult) | Close eyes | Repeat nouns | Orientation to state | Place of birth (BIMCT) |
| Repeat: flag | Orientation to city/town/village | Close eyes | Name pencil (MMSE) | |
| Name pencil | Orientation to room | Name objects | Name (BIMCT) | |
| Repeat: ball | ||||
| Repeat: tree | ||||
| Verbal directions: paper-take in right hand | ||||
| Verbal directions: paper-fold in half | ||||
| Truncated below 0 | Close eyes | Repeat nouns | ||
| Name objects |
| Chr | GWAS QTL | Bi-parental counterpart | Bins | Marker associated with GLS resistance QTL | Source of variationa | Minor allele frequency | Physical coordinate | SNP effects | Heritability of a SNPb | Maximum heritability of a chromosome |
| 1 | DTS_1.1 | 1.01-1.02 | GLS-SNP-5365 | [T/G] | 0.30 | 12,255,366 | 0.07989852 | 0.001049039 | 0.003070336 | |
| 1 | GLS1.1 | 1.02 | GLS-SNP-1590 | [ | 0.43 | 15,354,490 | −0.01960145 | 0.003070336 | 0.003070336 | |
| 1 | DTS_1.2 | 1.02 | GLS-SNP-0156 | [T/C] | 0.42 | 22,510,157 | 0.04407421 | 0.003070336 | 0.003070336 | |
| 1 | DTS_1.3 | 1.03 | GLS-SNP-0538 | [A/G] | 0.23 | 35,460,539 | 0.04052954 | 0.003070336 | 0.003070336 | |
| 1 | DTS_1.4 | 1.03 | PZE-101061225 | [G/T] | 0.12 | 45,115,245 | −0.04252824 | 0.003070336 | 0.003070336 | |
| 1 | DTS_1.5 | 1.03 | GLS-SNP-2651 | [A/G] | 0.32 | 48,092,652 | 0.41783421 | 0.003070336 | 0.003070336 | |
| 1 | DTS_1.6 | 1.05 | GLS-SNP-2138 | [T/C] | 0.46 | 101,832,139 | 0.43211445 | 0.003070336 | 0.003070336 | |
| 1 | DTS_1.7 | 1.07 | GLS-SNP-5094 | [A/G] | 0.49 | 203,245,095 | −0.69856342 | 0.003070336 | 0.003070336 | |
| 1 | GLS 1.2 | QTLGLSchr1 | 1.08 | PZE-101188909 | [ | 0.23 | 234,309,200 | −0.01785890 | 0.001971469 | 0.003070336 |
| 6 | GLS 6.1 | QTLGLSchr6 | 6.04 | PZE-106058730 | [ | 0.34 | 107,475,955 | −0.00632726 | 0.000293801 | 0.00093559 |
| 6 | GLS 6.2 | 6.04 | PZE-106066216 | [T/ | 0.42 | 118,304,229 | 0.01101481 | 0.000935590 | 0.00093559 | |
| 6 | DTS_6.1 | 6.05 | Mo17-10397 | [T/C] | 0.41 | 151,787,329 | 0.04365824 | 0.000243429 | 0.00093559 | |
| 6 | GLS 6.3 | 6.05 | PZE-106100504 | [T/ | 0.32 | 153,414,853 | 0.00639998 | 0.000282006 | 0.00093559 | |
| 6 | DTS_6.2 | 6.06 | GLS-SNP-4138 | [A/C] | 0.45 | 155,634,139 | 0.06046048 | 0.000701479 | 0.00093559 | |
| 6 | GLS 6.4 | 6.06 | MAGI_11553-2 | [T/ | 0.37 | 156,981,627 | 0.00610662 | 0.000281211 | 0.00093559 | |
| 7 | DTS_7.1 | 7.00 | PZE-107000932 | [T/C] | 0.50 | 1,121,016 | −0.00193525 | 0.000617793 | 0.000660398 | |
| 7 | GLS 7.1 | 7.00 | PZE-107004786 | [T/ | 0.40 | 3,074,900 | 0.00916059 | 0.000660398 | 0.000660398 | |
| 7 | GLS 7.2 | QTLGLSchr7 | 7.02 | PZE-107020739 | [ | 0.37 | 19,500,572 | −0.00603602 | 0.000265353 | 0.000660398 |
| 7 | DTS_7.2 | 7.02 | PZE-107020739 | [G/A] | 0.37 | 19,500,572 | 0.00248297 | 0.000107170 | 0.000660398 | |
| 7 | DTS_7.3 | 7.02 | PZE-107083430 | [C/T] | 0.23 | 125,687,825 | 0.00226143 | 0.000585325 | 0.000660398 | |
| 7 | DTS_7.4 | 7.03 | PZE-107094672 | [A/G] | 0.4 | 144,404,803 | −0.00229674 | 0.000599634 | 0.000660398 | |
| 7 | DTS_7.5 | 7.03 | PZE-107099659 | [T/C] | 0.32 | 154,472,118 | 0.00345513 | 0.002230712 | 0.000660398 | |
| 8 | GLS 8.1 | 8.01 | GLS-SNP-7688 | [ | 0.26 | 6,253,558 | −0.00608691 | 0.000242320 | 0.000585845 | |
| 8 | GLS 8.2 | QTLGLSchr8a | 8.02 | PZE-108020413 | [T/ | 0.48 | 19,550,800 | 0.00468907 | 0.000177343 | 0.000585845 |
| 8 | 8.02 | PZE-108022710 | [T/ | 0.43 | 21,753,432 | 0.00584096 | 0.000269140 | 0.000585845 | ||
| 8 | GLS 8.3 | QTLGLSchr8b | 8.03 | PZE-108047250 | [ | 0.46 | 79,142,282 | −0.00521772 | 0.000218764 | 0.000585845 |
| 8 | 8.03 | PZE-108050268 | [A/ | 0.10 | 87,682,262 | 0.00806870 | 0.000204892 | 0.000585845 | ||
| 8 | GLS 8.4 | 8.05-8.06 | GLS-SNP-1344 | [ | 0.30 | 154,247,344 | −0.00922446 | 0.000585845 | 0.000585845 | |
| 8 | 8.05-8.06 | PZE-108098666 | [ | 0.23 | 155,016,277 | −0.00709668 | 0.000296117 | 0.000585845 | ||
| 8 | 8.05-8.06 | PZE-108098682 | [ | 0.22 | 155,029,958 | −0.00890310 | 0.000450864 | 0.000585845 | ||
| 8 | GLS 8.5 | 8.05-8.06 | PZE-108101351 | [ | 0.13 | 157,169,975 | −0.01000713 | 0.000374213 | 0.000585845 | |
| 8 | DTS_7.1 | 8.05-8.06 | GLS-SNP-8600 | [T/G] | 0.25 | 145,906,568 | −0.00301422 | 0.000131115 | 0.000585845 | |
| 8 | DTS_7.2 | 8.06 | PZE-108109056 | [A/C] | 0.31 | 162,535,081 | 0.00382457 | 0.000270955 | 0.000585845 | |
| 8 | DTS_7.3 | 8.06 | GLS-SNP-6472 | [T/C] | 0.38 | 162,586,473 | 0.00290281 | 0.000154292 | 0.000585845 | |
| 8 | DTS_7.4 | 8.06 | GLS-SNP-8795 | [T/G] | 0.45 | 163,616,966 | −0.00209331 | 0.000435068 | 0.000585845 |
| Definition | Grade | Ki-67% | Mitotic index |
| NET - neuroendocrine tumour, low grade | G1 | ≤2 | <2 |
| NET - neuroendocrine tumour, intermediate grade | G2 | 3 to 20 | 2 to 20 |
| NET - neuroendocrine carcinoma, high grade | G3 | >20 | >20 |
| Ectopic pregnancya | Preterm delivery among live-born infantsb | |||
| n (prevalence %) | Adjusted odds ratio (95% confidence interval) | n (prevalence %) | Adjusted odds ratio (95% confidence interval) | |
| Mother not diagnosed with SLE | 5 (0.7%) | 1.0 (-) | 26 (4.7%) | 1.0 (-) |
| Mother diagnosed with SLE | 5 (1.4%) | 3.6 (0.7–18.7) | 19 (7.3%) | 1.5 (0.7–3.2) |
| Pregnancy conceived prior to SLE diagnosis | 3 (0.8%) | 3.1(0.5–17.9) | 12 (4.7%) | 1.2(0.5–2.8) |
| Pregnancy conceived after SLE diagnosis | 2 (0.6%) | 7.5 (0.9–62.5) | 7 (2.7%) | 3.4 (1.2–10.0) |
| Block 1 set | Block 2 set | Block 3set | Block 4 set | Block 5 set | Block 6 set | Block 7 set | Block 8 set |
| NT | NT | NT | NT | NT | NT | NT | NT |
| NT | NT | NT | NT | NT | NT | NT | NT |
| NT | NT | NT | NT | NT | NT | NT | NT |
| NT | NT | OG1 | NT | NT | OG2 | NT | NT |
| NT | NT | OG1 | NT | NT | OG2 | NT | NT |
| NT | OG2 | OG1 | NT | NT | OG2 | OG1 | NT |
| NT | OG2 | NT | T(probe) | T(probe) | NT | OG1 | NT |
| NT | OG2 | T(probe) | NT | NT | T(probe) | OG1 | NT |
| NT | NT | NT | NT | NT | NT | NT | NT |
| NT | T(probe) | NT | NT | NT | NT | NT(probe) | NT |
| NT | NT | NT | NT | NT | NT | NT | NT |
| PG1 | NT | NT | NT | NT | NT | NT | PG2 |
| PG1 | T | NT | NT | NT | NT | T | PG2 |
| PG1 | NT | NT | NT | NT | NT | NT | PG2 |
| NT | NT | NT | NT | NT | NT | NT | NT |
| T(probe) | NT | T | NT | NT | T | NT | T(probe) |
| NT | NT | NT | NT | NT | NT | NT | NT |
| NT | NT | NT | NT | NT | NT | NT | NT |
| NT | T | NT | NT | NT | NT | T | NT |
| NT | NT | NT | PG2 | PG1 | NT | NT | NT |
| NT | NT | NT | PG2 | PG1 | NT | NT | NT |
| NT | NT | NT | PG2 | PG1 | NT | NT | NT |
| NT | NT | NT | NT | NT | NT | NT | NT |
| NT | NT | NT | T(probe) | T(probe) | NT | NT | NT |
| T | NT | PG1 | NT | NT | PG2 | NT | T |
| NT | NT | PG1 | NT | NT | PG2 | NT | NT |
| NT | NT | PG1 | NT | NT | PG2 | NT | NT |
| NT | NT | NT | NT | NT | NT | NT | NT |
| NT | NT | T(probe) | NT | NT | T(probe) | NT | NT |
| T(probe) | PG2 | NT | OG2 | OG1 | NT | PG1 | T(probe) |
| NT | PG2 | NT | OG2 | OG1 | NT | PG1 | NT |
| NT | PG2 | NT | OG2 | OG1 | NT | PG1 | NT |
| NT | NT | NT | NT | NT | NT | NT | NT |
| NT | T(probe) | NT | T(probe) | T(probe) | NT | T(probe) | NT |
| OG1 | NT | NT | NT | NT | NT | NT | OG2 |
| OG1 | NT | NT | NT | NT | NT | NT | OG2 |
| OG1 | NT | T | T | T | T | NT | OG2 |
| NT | NT | NT | NT | NT | NT | NT | NT |
| T(probe) | NT | NT | NT | NT | NT | NT | T(probe) |
| NT | NT | NT | NT | NT | NT | NT | NT |
| NT | T(probe) | T(probe) | NT | NT | T(probe) | T(probe) | NT |
| NT | NT | NT | T | T | NT | NT | NT |
| NT | NT | NT | NT | NT | NT | NT | NT |
| T | NT | NT | NT | NT | NT | NT | T |
| NT | NT | NT | NT | NT | NT | NT | NT |
| Institutions | Key informant interview | Group Interview | Focus Group Discussion |
| National Level | |||
| MoH | 10 | 0 | 0 |
| PMU and CCM | 6 | 0 | 1 |
| WHO | 3 | 0 | 0 |
| SRs | 10 | 0 | 0 |
| TAIS | 1 | 0 | 0 |
| CARE International | 1 | 0 | 0 |
| Districts and CHCs | 8 | 5 | 6 |
| Health cadres and teachers | 5 | 1 | 0 |
| Local Authority | 5 | 0 | 0 |
| Community members | 0 | 0 | 9 |
| SR field officers | 6 | 2 | 0 |
| Donors | 3 | ||
| Total | 58 | 8 | 16 |
| Age at infection | Serotypea | Serologic responseb | Clinical categoryc | ||||||||||
| Infection order | 1 | 2 | 3 | 1 | 2 | 3 | 1 | 2 | 3 | 1 | 2 | 3 | |
| Indiv. | Titers > 10d | ||||||||||||
| 1 | 0 | 8.7 | 12.8 | 14.9 | ND | NEG | DEN4 | ND | S | S | SubC/nhDF | DHF | DHF |
| 2 | 0 | 8.9 | 10.9 | 12.2 | ND | ND | ND | ND | ND | ND | SubC | SubC | SubC |
| 3 | ND | 10.5 | 10.8 | 10.9 | NEG | DEN1 | NEG | S | S | S | nhDF/hDF | hDF | hDF |
| 4 | 0 | 7.7 | 8.7 | 11.0 | ND | ND | DEN2 | ND | ND | S | SubC/nhDF | SubC/nhDF | nhDF |
| 5 | 4 | 7.5 | 8.5 | 10.5 | ND | ND | ND | ND | ND | ND | SubC | SubC | SubC |
| 6 | 0 | 7.9 | 9.2 | 12.2 | ND | ND | ND | ND | ND | ND | SubC/nhDF | SubC | SubC |
| 7 | 0 | 7.9 | 9.4 | 12.8 | DEN1 | NEG | ND | S | S | ND | DHF | nhDF | SubC |
| 8 | 4 | 9.0 | 12.3 | 12.9 | ND | ND | DEN2 | ND | ND | S | SubC | SubC | DHF |
| 9 | ND | 5.9 | 9.3 | 10.2 | NEG | ND | ND | S | ND | ND | DHF | SubC | SubC |
| 10 | 4 | 7.8 | 9.0 | 10.3 | ND | ND | ND | ND | ND | ND | SubC/nhDF | SubC | SubC |
| 11 | ND | 9.1 | 11.1 | 11.8 | DEN1 | DEN3 | ND | S | S | ND | hDF | nhDF | SubC/nhDF |
| 12 | 0 | 7.8 | 10.8 | 12.3 | ND | ND | ND | ND | ND | ND | SubC/nhDF | SubC/nhDF | SubC |
| 13 | 0 | 7.8 | 8.8 | 10.1 | ND | ND | DEN2 | ND | ND | S | SubC/nhDF | SubC/nhDF | nhDF |
| 14 | ND | 5.3 | 8.7 | 9.8 | NEG | DEN2 | ND | S | S | ND | DHF | nhDF | SubC |
| Targeted Viruses | Name | Sequence of Oligonucleotide (5'–3') | Location | Amplicon Length |
| Hepatitis A Virus | Forward primer | GGT AGG CTA CGG GTG AAA C | 393~411 a | 116 nt |
| Reverse primer | CCT CCG GCG TTG AAT GGT TT | 489~508 a | ||
| Probe | FAM-ACA GCG GCG GAT ATT GGT GAG TTG TTA AGA-BHQ | 456~485 a | ||
| Hepatitis E Virus | Forward primer | GGT GGT TTC TGG GGT GAC | 5261~5278 b | 70 nt |
| Reverse primer | AGG GGT TGG TTG GAT GAA | 5313~5330 b | ||
| Probe | Cy5-TGA TTC TCA GCC CTT CGC-BHQ | 5284~5301 b |
| Variables | Group I (%) | Group II (%) | p-value |
| Mean cardiopulmonary bypass time (minutes) | 104 ± 41 | 98 ± 53 | 0.34 |
| Mean aortic cross-clamping time (minutes) | 82 ± 32 | 78 ± 37 | 0.41 |
| Annulus enlargement | 36 (13.6 %) | 4 (6.9 %) | 0.24 |
| Mitral valve replacement | 31 (11.7 %) | 4 (6.9 %) | 0.41 |
| Coronary artery bypass grafting | 37 (14 %) | 7 (12 %) | 0.87 |
| Total grafts | 66 (25 %) | 12 (20.7 %) | |
| Associated carotid endarterectomy | 4 (1.5 %) | 0 | 0.78 |
| Tricuspid valve repair | 8 (3 %) | 4 (6.9 %) | 0.30 |
| Postoperative outcome | |||
| Mean mechanical ventilation (hours) | 9.8 ± 9.5 | 12.3 ± 14 | 0.10 |
| Mean Intensive Care Unit stay (days) | 3 ± 6.4 | 2.7 ± 2.6 | 0.73 |
| Readmitted in Intensive Care Unit | 8 (3 %) | 3 (5.2 %) | 0.68 |
| Postoperative complications | 52 (19.6 %) | 14 (24 %) | 0.55 |
| Low cardiac output | 39 (14.7 %) | 9 (15.5 %) | 0.96 |
| Myocardial infarction | 10 (3.8 %) | 2 (3.5 %) | 0.79 |
| Ventricular arrhythmias | 27 (10 %) | 5 (8.6 %) | 0.91 |
| Heart Block | 4 (1.5 %) | 1 (1.7 %) | 0.64 |
| Reoperation for bleeding | 15 (5.7 %) | 3 (5.2 %) | 0.87 |
| Blood used | 126 (47.6 %) | 30 (52 %) | 0.67 |
| Pulmonary complications | 17 (6.4 %) | 5(8.6 %) | 0.75 |
| ARDS | 3 (1.1 %) | 1 (1.7 %) | 0.78 |
| Pneumonia | 9 (3.4 %) | 2 (3.5 %) | 0.71 |
| Reintubation | 12 (4.5 %) | 3 (5.2 %) | 0.90 |
| Neurological complications | 9 (3.4 %) | 0.33 | |
| Stroke | 2 (0.75 %) | 0 | 0.80 |
| Infectious complications | 14 (5.3 %) | 4 (6.9 %) | 0.87 |
| Septicemia | 5 (2 %) | 1 (1.7 %) | 0.65 |
| Deep sternal wound infection | 4 (1.5 %) | 2 (3.5 %) | 0.64 |
| Superficial sternal wound infection | 5 (2 %) | 1 (1.7 %) | 0.65 |
| Renal complications | 19 (7.2 %) | 9 (15.5 %) | 0.08 |
| Hemodialysis | 7 (2.6 %) | 3 (5.2 %) | 0.56 |
| Multi organ failure | 5 (2 %) | 1 (1.7 %) | 0.65 |
| Coagulopathy | 5 (2 %) | 1 (1.7 %) | 0.65 |
| Hospital death | 14 (5.3 %) | 4 (6.9 %) | 0.87 |
| Hospital death in reoperated patients | 6 (2.3 %) | 2 (3.5 %) | 0.22 |
| Causes of hospital death | |||
| Cardiac | 8 (3 %) | 3 (5.2 %) | 1.0 |
| Septicemia | 1 (0.4 %) | 0 | 1.0 |
| Intestinal infarction | 1 (0.4 %) | 0 | 1.0 |
| Multi organ failure | 3 (1.1 %) | 1 (1.7 %) | 1.0 |
| Aortic dissection | 1(0.4 %) | 0 | 1.0 |
| SDQ Variables | CBCL Variables | rs | p-value |
| Emotional symptoms | Anxiety/depression | 0.480 | 0.002 |
| Total internalizing problems | 0.503 | 0.001 | |
| Attention/hyperactivity | 0.412 | 0.008 | |
| Stress problem | 0.546 | <0.001 | |
| Total of EB problems | 0.437 | 0.005 | |
| Anxiety/depression | 0.437 | 0.005 | |
| Conduct problems | Total internalizing problems | 0.501 | 0.001 |
| Aggressive behavior | 0.600 | <0.001 | |
| Attention/hyperactivity | 0.489 | 0.001 | |
| Total externalizing problems | 0.675 | <0.001 | |
| Stress problem | 0.637 | <0.001 | |
| Total of EB problems | 0.664 | <0.001 | |
| Hyperactivity problem | Attention/hyperactivity | 0.586 | <0.001 |
| Stress problem | 0.466 | 0.002 | |
| Total of probelms | 0.401 | 0.010 | |
| Peer relationship problem | Anxiety/depression | 0.468 | 0.002 |
| Emotionally reactive | 0.422 | 0.007 | |
| Total internalizing problems | 0.474 | 0.002 | |
| Total of EB problems | 0.440 | 0.004 | |
| Prosocial behavior | Aggressive behavior | -0.340 | 0.030 |
| Withdrawal | -0.330 | 0.036 | |
| Total of difficulty | Attention/hyperactivity | 0.606 | <0.001 |
| Aggressive behavior | 0.486 | 0.001 | |
| Total externalizing problems | 0.595 | <0.001 | |
| Anxiety/depression | 0.579 | 0.001 | |
| Emotionally reactive | 0.486 | 0.002 | |
| Total internalizing problems | 0.596 | <0.001 | |
| Stress problem | 0.669 | <0.001 | |
| Total of EB problems | 0.641 | 0.001 | |
| Impact of the difficulty | Aggressive behavior | 0.540 | <0.001 |
| Total externalizing EB problems | 0.522 | <0.001 | |
| Total of problems | 0.467 | 0.003 |
| Clinicopathological parameters | na | ENAH expression | χ2 | P value | |
| High | Low | ||||
| All | 238 | 136 | 102 | ||
| Age (years) | |||||
| <55 | 116 | 65 | 51 | 0.114 | 0.736 |
| ≥55 | 122 | 71 | 51 | ||
| Gender | 1.021 | 0.312 | |||
| Male | 87 | 46 | 41 | ||
| Female | 151 | 90 | 61 | ||
| Tumor size | 15.025 | <0.001* | |||
| <3 cm | 51 | 17 | 34 | ||
| ≥3 cm | 187 | 119 | 68 | ||
| Tumor infiltration | 39.028 | <0.001* | |||
| T1 | 41 | 10 | 31 | ||
| T2 | 37 | 13 | 24 | ||
| T3 | 4 | 2 | 2 | ||
| T4a | 111 | 82 | 29 | ||
| T4b | 45 | 29 | 16 | ||
| Local lymph node metastasis | 16.250 | 0.001* | |||
| N0 | 84 | 36 | 48 | ||
| N1 | 44 | 23 | 21 | ||
| N2 | 37 | 23 | 14 | ||
| N3 | 73 | 54 | 19 | ||
| Distant metastasis | 0.015 | 0.903 | |||
| M0 | 213 | 122 | 91 | ||
| M1 | 25 | 14 | 11 | ||
| TNM staging | 40.926 | <0.001* | |||
| 1 | 48 | 9 | 39 | ||
| 2 | 96 | 61 | 35 | ||
| 3 | 65 | 50 | 15 | ||
| 4 | 29 | 16 | 13 |
| Domains | Amino acid Positions |
| PWWP1 | 323–388 |
| NLS1 | 512–529 |
| NLS2 | 1157–1174 |
| NLS3 | 1471–1488 |
| PHD1 | 1543–1589 |
| PHD2 | 1590–1639 |
| PHD3 | 1640–1693 |
| PHD4 | 1707–1751 |
| PWWP2 | 1756–1818 |
| AWS | 1890–1940 |
| SET | 1942–2065 |
| Post-SET | 2066–2082 |
| PHD5 | 2120–2160 |
| Intervention departments | Control departments | Significance tests | |||||||
| Baseline | Follow-up | Baseline | Follow-up | Group x Time | |||||
| N = 410 | N = 604 | N = 286 | N = 281 | (ANOVA) | |||||
| Indicators of patient care quality | M | SD | M | SD | M | SD | M | SD | F(df = 1); p |
| 1 Organization of physicians’ care | 4.20 | .82 | 4.23 | .75 | 4.13 | .76 | 4.01 | .84 | 3.67; .056† |
| 2 Quality of information from physicians | 4.08 | .83 | 4.16 | .77 | 3.88 | .88 | 3.93 | .81 | 0.14; n. s. |
| AEROBIC | |
| Frequency: | 20-60 min/day - 3-5 days/week |
| Intensity: | Light (< 40% HRR or VO2R); Moderate (40-60% HRR or VO2R); Hard (> 60% HRR or VO2R) |
| Type: | Walk or Cicle |
| RESISTANCE | |
| Frequency: | 2-3x/week |
| Intensity: | Light (40-50% 1MR); Moderate (60-80% 1MR); Hard (>80% 1MR) |
| Type: | Progressive (2-4 sets; 8-15 reps; Large Muscle Groups) |
| FLEXIBILITY | |
| Frequency: | 2-3x/week |
| Intensity: | 10-30 sec (to the point of discomfort) |
| Type: | Static Stretching, Dynamic, and PNF, with Emphasis on Spine and Trunk |
| BALANCE | |
| Frequency: | 10-15 min - 2-3x/week |
| Intensity: | There is no Evidence of the Intensity |
| Type: | Exercises Involving Motor Skills (Balance, Agility, Coordination, Gait, and Proprioception) |
| Groups | Lung | Lymph node | ||||||||
| Liver | Spleen | Kidney | Stomach | Intestine | Heart | |||||
| ++* | + | ++ | + | |||||||
| Group A | 0/5 | 0/5 | 0/5 | 0/5 | 0/5 | 0/5 | 0/5 | 0/5 | 0/5 | 0/5 |
| Group B | 2/5 | 3/5 | 5/5 | 0/5 | 3/5 | 2/5 | 2/5 | 3/5 | 2/5 | 2/5 |
| Group C | 4/5 | 1/5 | 4/5 | 1/5 | 0/5 | 1/5 | 3/5 | 0/5 | 3/5 | 2/5 |
| Group D† | 0/5 | 5/5 | 0/5 | 3/5 | 1/5 | 0/5 | 0/5 | 0/5 | 1/5 | 1/5 |
| Group E | 5/5 | 0/5 | 5/5 | 0/5 | 2/5 | 4/5 | 4/5 | 0/5 | 4/5 | 3/5 |
| Haplotypea | Controls (%) | Lung cancer | NSCLC | Adenocarcinoma | ||||||
| N (%) | OR (95%CI) | P | N (%) | OR (95%CI) | P | N (%) | OR (95%CI) | P | ||
| CC | 71(7.8) | 37(4.0) | 0.495(0.329-0.744) | <0.001* | 33(4.1) | 0.510(0.334-0.780) | 0.001* | 32(5.0) | 0.627(0.408-0.963) | 0.032* |
| CT | 396(43.5) | 399(42.6) | 0.975(0.811-1.172) | 0.787 | 342(42.5) | 0.971(0.801-1.176) | 0.762 | 259(40.2) | 0.883(0.719-1.084) | 0.234 |
| TC | 0(--) | 7(0.7) | -- | -- | 5(0.6) | -- | -- | 5(0.7) | -- | -- |
| TT | 443(48.7) | 493(52.7) | 1.193(0.993-1.432) | 0.059 | 424(52.7) | 1.192(0.986-1.442) | 0.070 | 348(54.1) | 1.261(1.030-1.545) | 0.025* |
| DATASET | ALL | GA-FS | H-MTL | GA-MTL | GA-MTL-IR | e-GA-MTL |
| M = 2 for ANN | ||||||
| Breast | 53.1(9.5) | 56.3(8.4) | 59.3(8.8) | 71.9(8.9) | 68.8(8.1) | 71.9(8.6) |
| Colon | 57.1(7.8) | 61.9(7.3) | 66.6(7.1) | 80.9(6.3) | 85.7(6.4) | 80.9(6.4) |
| Leukemia | 57.7(9.3) | 53.8(9.0) | 61.5(9.5) | 76.9(8.4) | 76.9(9.1) | 80.7(8.9) |
| Ovarian | 57.1(6.4) | 67.9(7.4) | 75.0(5.4) | 78.6(5.9) | 79.8(5.1) | 82.1(5.8) |
| Average | 56.3(8.3) | 60.0(8.0) | 65.6(7.7) | 77.1(7.4) | 77.8(7.2) | 78.9(7.4) |
| M = 10 for ANN | ||||||
| Breast | 64.3(8.5) | 67.3(8.7) | 65.7(8.3) | 75.4(8.3) | 71.8(7.5) | 75.8(8.0) |
| Colon | 62.0(7.5) | 71.2(7.2) | 75.2(6.5) | 85.1(6.7) | 82.9(6.1) | 83.9(6.3) |
| Leukemia | 65.3(8.8) | 69.2(8.4) | 76.3(8.8) | 84.6(8.9) | 83.1(8.1) | 85.6(8.3) |
| Ovarian | 61.9(7.5) | 65.4(7.7) | 78.6(6.4) | 80.9(6.8) | 82.1(6.4) | 83.3(6.8) |
| Average | 63.4(8.1) | 68.3(8.0) | 74.0(7.5) | 81.5(7.7) | 80.0(7.0) | 82.2(7.4) |
| Transplanted organ (n) | EAS characteristics and outcomes | ||||||||
| Authors, Year | Liver | Heart | Lung | Kidney | Patients undergoing EAS (n) | EAS Rate (%) | Surgical procedures (n) | Morbidity [n (%)] | Mortality [n (%)] |
| Cruz RJ Jr et al., 2012 [26] | 5677 | 7 | 0,12 | BR (7) | n/a | 2 (28.6) | |||
| Lahon B et al., 2011 [13] | 351 | 3 | 0.85 | BR (3) | n/a | 0 (0) | |||
| Paul S et al., 2009 [4] | 208 | 14 | 6.73 | LA (14) | n/a | 1 (7.1) | |||
| Miller CB et al., 2006 [41] | 229 | 2 | 0.87 | BR (1), LA (1) | n/a | 1 (50) | |||
| Karakayali H et al., 2002 [32] | 1038 | 1 | 0.10 | BR (1) | n/a | 0 (0) | |||
| Andreoni KA et al., 1999 [33] | 1417 | 4 | 0.28 | BR (4) | n/a | 1 (25) | |||
| Bhatia DS et al., 1997 [21] | 349 | 5 | 1.43 | BR (5) | 1 (20) | 0 | |||
| Total | 5677 | 349 | 788 | 2455 | 36 | 0.39 | BR (21), LA (15) | n/a | 5 (13.9) |
| Women | Test for group difference | Sign. | Effect size | Men | Test for group difference | Sign. | Effect size | |||
| Subscale | n | M(SD) | t | p | d | n | M(SD) | t | p | d |
| Sexual desire/frequency | 21.28 | <0.001 | 1.403 | 8.73 | <0.001 | 1.388 | ||||
| Before cancer | 520 | 6.85 (1.64) | 117 | 7.40 (1.33) | ||||||
| After cancer | 520 | 4.92 (1.86) | 117 | 5.86 (1.97) | ||||||
| Sexual desire/interest | 16.63 | <0.001 | 1.228 | 6.75 | <0.001 | 1.285 | ||||
| Before cancer | 516 | 8.82 (2.51) | 115 | 10.74 (2.12) | ||||||
| After cancer | 516 | 6.77 (2.62) | 115 | 9.17 (2.44) | ||||||
| Sexual arousal | 21.01 | <0.001 | 1.459 | 16.96 | <0.001 | 1.807 | ||||
| Before cancer | 509 | 11.17 (3.01) | 114 | 13.69 (1.42) | ||||||
| After cancer | 509 | 7.27 (3.12) | 114 | 9.26 (2.52) | ||||||
| Sexual orgasm | 18.13 | <0.001 | 1.342 | 16.32 | <0.001 | 1.924 | ||||
| Before cancer | 504 | 12.04 (2.95) | 109 | 12.29 (1.90) | ||||||
| After cancer | 504 | 8.72 (3.97) | 109 | 6.88 (3.32) | ||||||
| Total sexual functioning | 13.67 | <0.001 | 1.359 | 10.49 | <0.001 | 1.547 | ||||
| Before cancer | 446 | 42.22 (7.37) | 104 | 46.55 (5.36) | ||||||
| After cancer | 446 | 34.73(10.45) | 104 | 36.48 (9.30) |
| ABC subfamily | Bombyx mori | Drosophila melanogaster | Anopheles gambiae | Tribilium castaneum | Apis mellifera | Homo sapiens |
| A | 6 | 10 | 9 | 9 | 3 | 13 |
| B | 8 | 8 | 5 | 6 | 7 | 11 |
| C | 15 | 14 | 13 | 31 | 9 | 12 |
| D | 2 | 2 | 2 | 2 | 2 | 4 |
| E | 1 | 1 | 1 | 1 | 1 | 1 |
| F | 3 | 3 | 3 | 3 | 3 | 3 |
| G | 13 | 15 | 16 | 13 | 15 | 5 |
| H | 3 | 3 | 3 | 3 | 3 | 0 |
| Total | 51 | 56 | 52 | 68 | 43 | 48 |
| Intervention villages | Control village | |||||
| Village 12 | Village13 | Village 14 | Village15 | Total | Chikore | |
| S. haematobium | ||||||
| Number positive | 5 | 5 | 4 | 8 | 22 | 10 |
| Number negative | 98 | 58 | 42 | 57 | 255 | 69 |
| Prevalence | 4.9% | 7.9% | 8.7% | 12.3 | 7.9% | 12.7% |
| S. mansoni | ||||||
| Number positive | 0 | 3 | 3 | 3 | 9 | No data |
| Number negative | 103 | 60 | 43 | 62 | 268 | No data |
| Prevalence | 0 | 4.8 | 6.5 | 4.6 | 3.4% | No data |
| Strategy | Cost | Incremental cost | Live births | Cost per live birth | ICER vs. eS ET | ICER vs Embry Dx SET |
| eSET | €14,896 | - | 0.314 | €47,439 | ||
| Embryo-Dx SET | €16,687 | €1,791 | 0.43 | €38,807 | €15,439 | |
| DET | €18,952 | €2,265 | 0.473 | €40,068 | €25,509 | €52,674 |
| €4,056‡ |
| Dataset | SNVSniffer(M1) | VarScan2 | SomaticSniper | JSM2 | MuTect |
| Sensitivity (%) | |||||
| T1 | 66.86 | 38.29 | 61.148 | 0.001 | 91.43 |
| T2 | 82.35 | 35.29 | 63.73 | 0.00 | 93.14 |
| T3 | 72.36 | 59.35 | 75.61 | 0.00 | 95.93 |
| T4 | 93.55 | 83.87 | 87.10 | 0.00 | 96.77 |
| T5 | 75.00 | 43.75 | 68.75 | 0.00 | 97.92 |
| Time (h) | |||||
| T1 | 2.67 | 5.75 | 1.58 | 10.41 | 22.87 |
| T2 | 2.56 | 4.73 | 1.33 | 9.48 | 19.37 |
| T3 | 2.41 | 4.30 | 1.34 | 7.39 | 19.27 |
| T4 | 2.91 | 5.26 | 1.39 | 10.00 | 24.16 |
| T5 | 2.87 | 4.75 | 1.55 | 8.11 | 20.50 |
| Maternal Characteristics | n Without Missing Information | Adolescents n (%) | Adult Women n (%) | p-Value * |
| Late antenatal visit | 42,855 | 614 (30.7) | 5148 (12.6) | <0.001 |
| BMI, kg/m2 | 42,751 | <0.001 | ||
| <18.5 | 219 (11.0) | 2604 (6.4) | ||
| 18.5–24.9 | 1465 (73.3) | 25,985 (63.8) | ||
| ≥25 | 314 (15.7) | 12,164 (29.8) | ||
| Smoking | 39,888 | 604 (31.6) | 5875 (15.5) | <0.001 |
| Evidence of alcohol abuse | 43,318 | 7 (0.3) | 171 (0.4) | 0.631 |
| Evidence of drug abuse | 43,320 | 0 (0.0) | 14 (0.0) | 0.406 |
| Folic acid intake | 43,191 | 866 (42.9) | 22,117 (53.7) | <0.001 |
| Multivitamin intake | 43,192 | 961 (47.6) | 22,332 (54.2) | <0.001 |
| Infections of kidney in pregnancy 1 | 43,327 | 762 (37.5) | 13,980 (33.9) | 0.001 |
| Infections of the genital tract in pregnancy 2 | 43,327 | 495 (24.3) | 6600 (16.0) | <0.001 |
| Parity (para) | 39,249 | 160 (8.9) | 21,553 (57.6) | <0.001 |
| Characteristics | n (%) |
| Maternal age (years) | |
| <20 | 40 (9.1) |
| 20–24 | 163 (36.9) |
| 25–29 | 144 (32.6) |
| 30–34 | 66 (14.9) |
| ≥35 | 29 (6.6) |
| Parity | |
| 0 | 139 (31.5) |
| ≥1 | 303 (68.6) |
| Race/ethnicity | |
| Latina | 426 (96.4) |
| Non-Latina, white | 7 (1.6) |
| Other | 9 (2.0) |
| Marital status | |
| Married or living as married | 356 (80.5) |
| Unmarried | 86 (19.5) |
| Maternal education | |
| ≤6th grade | 188 (42.5) |
| Some high school | 158 (35.8) |
| High school graduate | 96 (21.7) |
| Family income | |
| ≤ Poverty | 272 (61.5) |
| Poverty–200% | 154 (34.8) |
| >200% | 16 (3.6) |
| Country of birth | |
| United States | 59 (13.4) |
| Mexico | 374 (84.6) |
| Other | 9 (2.0) |
| Years of residence in the United States | |
| ≤5 years | 230 (52.0) |
| 6–10 years | 99 (22.4) |
| ≥11 years | 63 (14.3) |
| Entire life | 50 (11.3) |
| Work status during pregnancy | |
| Did not work | 172 (38.9) |
| Some field or agricultural work | 181 (41.0) |
| Other work | 89 (20.1) |
| Prepregnancy body mass index (kg/m2) | |
| Underweight (<18.5) | 2 (0.5) |
| Normal (18.5–24.9) | 170 (38.5) |
| Overweight (25–29.9) | 175 (39.6) |
| Obese (>30) | 95 (21.5) |
| Smoked during pregnancy | |
| Yes | 26 (5.9) |
| No | 416 (94.1) |
| Any moves during pregnancy | |
| Yes | 182 (41.2) |
| No | 260 (58.8) |
| Low birth weighta infant | |
| Yes | 17 (3.9) |
| No | 425 (96.2) |
| Pretermb infant | |
| Yes | 30 (6.8) |
| No | 412 (93.2) |
| aLow birth weight is defined as <2,500g.bPreterm birth is defined as <37 weeks gestation. |
| Intake scenarios | Exposure for different ethyl carbamate concentration scenarios in spirits [ng/kg bw/day] | |||||
| Drinks per day | Volume of spirit consumed [mL] | Mean | Median | 90th percentile | 95th percentile | 99th percentile |
| 1 | 25 | 21 | 17 | 42 | 58 | 92 |
| 2 | 50 | 42 | 33 | 83 | 117 | 183 |
| 3 | 75 | 63 | 50 | 125 | 175 | 275 |
| 4 | 100 | 83 | 67 | 167 | 233 | 367 |
| 5 | 125 | 104 | 83 | 208 | 292 | 458 |
| ELISA titer anti-STn | ELISA titer anti-modified-STn | ||
| IgG | IgM | IgG | |
| KLH | < 100 | < 100 | ------ |
| 1-KLH | 15309 | < 100 | 15309 |
| 2-KLH | 293812 | < 100 | 588662 |
| 3-KLH | 7384 | < 100 | 14794 |
| 4-KLH | 555186 | < 100 | 1061530 |
| Complication | Total vivax | Total patients with severity sign | Pooled prevalence, % | 95% CI, % |
| Death | 46411 | 353 | 0.3 | 0.1–0.4 |
| Cerebral malaria | 45845 | 532 | 0.8 | 0.5–1.1 |
| Multiple convulsions | 46386 | 88 | 0.2 | 0–0.5 |
| Renal dysfunction | 46341 | 244 | 1.1 | 0.3–1.9 |
| Respiratory dysfunction | 46411 | 144 | 0.3 | 0.1–0.5 |
| Hepatic dysfunction | 46536 | 727 | 4.2 | 3.2–5.2 |
| Abnormal bleeding/DIC | 46346 | 206 | 0.6 | 0.2–1 |
| Haemoglobinuria | 46411 | 93 | 0.1 | 0–0.4 |
| Hypoglycaemia | 46381 | 44 | 1.8 | 0.9–2.7 |
| Metabolic acidosis | 46341 | 138 | 1 | 0–2.3 |
| Circulatory collapse/Shock | 46411 | 67 | 5.1 | 2.5–7.7 |
| Severe anaemia | 46411 | 2276 | 4 | 2.9–5.1 |
| Severe thrombocytopenia | 45775 | 888 | 8.6 | 5.4–11.8 |
| Phase | Start-up | Adaptation | HRT 24 | HRT 18 | HRT 12 |
| Days (d) | 1–58 d (58 d) | 59–151 d (93 d) | 152–185 d (34 d) | 186–240 d (55 d) | 241–297 d (57) |
| Benzothiazole (mg/L) | 0 | 1–50 | 50 | 50 | 50 |
| HRT (h) | 24 | 24 | 24 | 18 | 12 |
| Temperature (°C) | 35 | 35 | 35 | 35 | 35 |
| OLR (kg COD/m3·d) | 3.33 | 3.26 | 3.13 | 4.64 | 6.36 |
| KA (μM)a | |||||
| Comp.H | hCA I | hCA II | hCA IV | hCA VII | hCA IX |
| 1 | 18.4 | 54.2 | 47.1 | 20.6 | 31.4 |
| 2 | 1.60 | 21.7 | 0.0018 | 21.9 | 7.81 |
| 3 | 0.85 | 36.8 | 1.24 | 0.81 | 15.8 |
| 4 | 0.24 | 37.9 | 1.03 | 0.052 | 39.9 |
| 5 | 1.17 | 34.2 | 2.15 | 0.061 | 26.4 |
| 6 | 1.02 | 25.8 | 1.70 | 0.012 | 41.7 |
| 7 | 0.94 | 14.5 | 1.86 | 0.038 | 20.5 |
| 8 | 0.80 | 8.62 | 0.93 | 0.006 | 31.8 |
| 9 | 2.83 | 9.27 | 0.96 | 0.012 | 30.0 |
| 10 | 4.14 | 10.4 | 1.51 | 0.007 | 62.6 |
| 11 | 10.7 | 21.9 | 36.8 | 12.6 | 65.4 |
| 12 | 8.52 | 11.2 | 18.9 | 24.6 | 47.9 |
| 13 | 11.2 | 24.3 | 25.7 | 7.13 | 48.1 |
| 14 | 12.7 | 21.2 | 33.5 | 11.4 | 51.2 |
| 15 | 20.4 | 45.2 | 29.1 | 8.23 | 49.0 |
| 16 | 24.3 | 30.7 | 20.0 | 7.16 | 47.9 |
| 17 | 14.1 | 58.9 | 24.1 | 6.26 | 31.6 |
| 18 | 9.64 | 63.4 | 28.3 | 9.51 | 47.9 |
| 19 | 17.8 | 44.5 | 29.0 | 8.44 | 58.2 |
| 20 | 10.4 | 41.8 | 30.5 | 0.78 | 57.6 |
| HST | 2.10 | 125 | 4.03 | 37.6 | 35.2 |
| Recovered (N = 20) | Non-recovered (N = 21) | p-value | |
| Age (years) | 62.0 (51.8 - 79.8) | 67 (56.4 - 75.5) | 0.860 |
| Creatinine at admission (mg/dL) | 1.0 (0.8 - 1.4) | 1.0 (0.8 - 1.4) | 0.860 |
| Glomerular filtration rate, MDRD (mL/min) | 69.5 (46.0 - 99.5) | 72.0 (42.5 - 89.5) | 0.835 |
| T0 urea (mg/dL) | 134 (78.5 - 146.0) | 140 (90 - 166) | 0.630 |
| T0 creatinine (mg/dL) | 2.8 (2.2 - 5.0) | 2.1 (1.8 - 3.4) | 0.650 |
| T0 Systolic blood pressure (mmHg) | 93 (91.5 - 103.2) | 97 (89 - 100) | 0.630 |
| T0 Diastolic blood pressure (mmHg) | 48.5 (42 - 54.2) | 45 (42 - 50.0) | 0.162 |
| T0 Central venous pressure (mmHg) | 12.5 (10.2 - 14.0) | 12 (9.0 - 14.5) | 0.885 |
| T0 albumin (g/L) | 24.5 (20.0 - 27.0) | 24 (18.5 - 25.5) | 0.278 |
| T0 lactate (mmol/L) | 2.5 (1.6 - 5.6) | 3.5 (1.7 - 4.8) | 0.873 |
| T0 Hb (g/dL) | 11.3 (10.2 - 12.4) | 10.2 (8.6 - 12.0) | 0.440 |
| T0 pH | 7.32 (7.18 - 7.38) | 7.29 (7.24 - 7.38) | 0.642 |
| RIFLE | |||
| R | 3 (15.0) | 2 (9.5) | 0.406 |
| I | 9 (45.0) | 8 (38.1) | |
| F | 8 (40.0) | 11 (52.4) | |
| T0 PaO2/FiO2 ratio | 210 (160 - 280) | 200 (95 - 225) | 0.425 |
| Pre-ICU days | 0 (0 - 1.5) | 2 (0.0 - 9.5) | 0.140 |
| ICU stay days | 15 (8 - 25) | 5 (2.5 - 12.5) | 0.086 |
| Cumulative fluid balance (mL) | 3850 (1425 - 8025) | 11500 (6625 - 16275) | 0.004 |
| ICU/initiation of renal replacement therapy | 1.0 (0.0 - 2.0) | 1.0 (0.0 - 1.5) | 0.925 |
| Hospital admission/initiation of renal replacement therapy | 1.0 (0.0 - 4.0) | 4.0 (1.0 - 15.0) | 0.158 |
| SAPS II | 51 (45.8 - 56.2) | 73 (54 - 84) | 0.005 |
| Congestive heart failure | 4 | 5 | 0.77 |
| Cirrhosis | 0 | 5 | 0.020 |
| Approach | Accuracy (%) | ||
| Precision | Recall | F1 Score | |
| Hierarchical MEMM [39] | 67.9 | 55.5 | 61.08 |
| 3D SMoSIFT [1] | 74.8 | 65.8 | 70.01 |
| Ni et al., 2013 [46] | 75.9 | 69.5 | 72.56 |
| Guptal et al., 2013 [47] | 78.1 | 75.4 | 76.73 |
| Zhang and Tian 2012 [48] | 86.0 | 84.0 | 84.99 |
| MFSK 2016 [9] | 87.1 | 83.8 | 85.42 |
| Zhu et al., 2014 [43] | 93.2 | 84.6 | 88.69 |
| Parisi et al., 2015 [44] | 91.9 | 90.2 | 91.47 |
| DBMM [45] | 91.1 | 91.9 | 91.50 |
| Proposed feature (ALSTF) | 89.7 | 86.1 | 87.86 |
| Methods | Our algorithm | Traditional method |
| Computation time (s) | 163 | 217 |
| MSE | 4.39 × 10-4 | 4.79 × 10-4 |
| Three weeks before treatment | Penultimate treatment day | Last treatment day | Reference data (n = 74 *) | |
| Treated | 2.72 | 2.67 | 2.99 | 2.43 ± 0.56 |
| Control | 3.09 | 2.09 | 2.69 | 2.43 ± 0.56 |
| FP | Metrics | BCF R2 | BCF RMSE | LogP R2 | LogP RMSE | DES | UTI |
| Extended | 37 | 0.546 | 0.917 | 0.775 | 0.872 | 0.970 | 0.971 |
| Extended | 34 | 0.546 | 0.919 | 0.776 | 0.870 | 0.970 | 0.970 |
| Extended | 18 | 0.542 | 0.922 | 0.777 | 0.869 | 0.965 | 0.965 |
| Pubchem | 28 | 0.541 | 0.906 | 0.772 | 0.870 | 0.963 | 0.963 |
| Extended | 42 | 0.534 | 0.919 | 0.780 | 0.858 | 0.961 | 0.962 |
| Default | 18 | 0.549 | 0.913 | 0.766 | 0.890 | 0.954 | 0.955 |
| Extended | 13 | 0.541 | 0.913 | 0.770 | 0.875 | 0.954 | 0.954 |
| Default | 34 | 0.549 | 0.913 | 0.765 | 0.891 | 0.953 | 0.953 |
| Extended | 1 | 0.540 | 0.917 | 0.770 | 0.876 | 0.950 | 0.950 |
| Default | 37 | 0.549 | 0.913 | 0.764 | 0.893 | 0.950 | 0.950 |
| Diseases | BBB proteins and affected mechanisms |
| Alzheimer's disease | BBB disruption and permit peripheral IgG to brain. Decrease P-gp and accumulate amyloid-β in brain [67]. |
| Parkinson's disease | BBB disruption increases therapeutic agent concentration and reduces efficacy of Pgp [6]. |
| Stroke | Astrocytes secrete TGFβ that downregulates tissue plasminogen activator (tPA) and anticoagulant thrombomodulin (TM) [68]. |
| Epilepsy | Transient BBB opening and upregulation of multiple drug resistance (MRD1) Pgp [69]. |
| Trauma | Opening of BBB, release of IL-6 from astrocytes, and neuroinflammation [70]. |
| HIV | BBB TJ disruption. Loss of glycoproteins and apoptosis of endothelial cell lead to increase diameter of cortical vessels [71]. |
| Infectious processes | Increase CSF/serum albumin ratio. Bacterial lipopolysaccharides affect BBB TJ [72]. |
| Brain tumours | Breakdown of BBB TJ, overexpress folate, insulin, and transferrin receptor, and downregulation of claudin 1/3 [73]. |
| Ischaemic brain oedema | BBB breakdown due to MMP9 release by neutrophils and degradation of occludin, claudins, and JAM [74]. |
| MOI | ||||||
| 1 | 10 | 50 | 100 | 500 | 1000 | |
| Infection rates | 0.47 ± 0.04 | 5.83 ± 0.07 | 10.65 ± 0.11 | 16.19 ± 0.31 | 20.27 ± 0.52 | 30.42 ± 2.31 |
| Survivil rates | 90.33 ± 1.21 | 85.27 ± 1.37 | 82.11 ± 1.63 | 81 ± 1.42 | 62.23 ± 2.15 | 40.25 ± 2.13 |
| Combinations | Sensitivity(%) | Specificity(%) | PPV(%) | NPV(%) |
| YKL-40 | 70.21 | 84.13 | 62.26 | 88.33 |
| CEA | 10.64 | 96.80 | 55.56 | 74.23 |
| CYFRA21-1 | 40.43 | 92.06 | 65.52 | 80.56 |
| YKL-40 or CEA | 70.21 | 83.20 | 61.11 | 88.14 |
| YKL-40 or CYFRA21-1 | 78.72 | 77.78 | 56.92 | 90.74 |
| CEA or CYFRA21-1 | 46.80 | 89.60 | 62.86 | 81.75 |
| YKL-40 or CEA or CYFRA21-1 | 78.72 | 76.80 | 56.06 | 90.57 |
| Variables | Characteristics | All (N = 1179) | Females (N = 486) | Males (N = 693) | Chi-square |
| n (%) | n (%) | n (%) | (p-value) | ||
| Age | Younger (≤ 22 years) | 608 (51.6) | 215 (44.0) | 393 (56.9) | <.001 |
| Older (> 22 years) | 571 (48.4) | 271 (56.0) | 300 (43.1) | ||
| Role of religion while growing up | Major role of religion while growing up | 736 (62.5) | 334 (68.5) | 402 (58.2) | <.001 |
| Minor role of religion while growing up | 443 (37.5) | 154 (31.5) | 289 (41.8) | ||
| Area of growing up | Urban | 610 (51.7) | 272 (56.0) | 338 (48.8) | .009 |
| Rural | 569 (48.3) | 214 (44.0) | 355 (51.2) | ||
| Alcohol use in the last 12 months | Abstainers of alcohol | 520 (46.8) | 240 (54.3) | 280 (41.9) | <.001 |
| Seldom users of alcohol in last 12 months | 450 (40.5) | 163 (36.9) | 287 (43) | ||
| Frequent users of alcohol in last 12 months | 140 (12.6) | 39 (8.8) | 101 (15.1) | ||
| Missing | 69 | 44 | 25 | ||
| Alcohol use in relation to sexual activity* | Non-Use of alcohol in relation to sexual activity | 391 (79) | 146 (83.4) | 245 (76.6) | .002 |
| Use of alcohol in relation to sexual activity | 104 (21) | 29 (16.6) | 75 (23.4) | ||
| Missing | 95 | 27 | 68 | ||
| Alcohol use at latest occasion of sexual intercourse* | Non-Use of alcohol at latest occasion of sexual intercourse | 360 (72.9) | 133 (76.9) | 227 (70.7) | .001 |
| Use of alcohol at latest occasion of sexual intercourse | 134 (27.1) | 40 (23.1) | 94 (29.3) | ||
| Missing | 96 | 29 | 67 | ||
| Condom use with new partner | Consistent use of condom with new partner | 603 (57.8) | 216 (50.8) | 387 (62.6) | <.001 |
| Inconsistent condom use with new partner | 440 (42.2) | 209 (49.2) | 231 (37.4) | ||
| Missing | 136 | 61 | 75 | ||
| Number of sexual partners in past 12 months | 0-1 sexual partner in last 12 months | 680 (66.4) | 324 (77.5) | 356 (58.5) | <.001 |
| 2 or more sexual partners in last 12 months | 344 (33.6) | 94 (22.4) | 250 (41.3) | ||
| Missing | 155 | 68 | 87 |
| PYD Measure | Before | After | Change | 95% CI | t (p) |
| Mean (SD) | Mean (SD) | ||||
| Caring | 69.99 (16.67) | 71.49 (18.55) | 1.51 | −7.71, 10.73 | 0.34 (0.74) |
| Character | 77.30 (15.96) | 75.33 (9.70 ) | - 1.97 | −9.75, 5.81 | −0.53 (0.60) |
| Competence | 69.73 (16.24) | 69.27 (9.87) | - 0.46 | - 6.79, 5.86 | −0.15 (0.88) |
| Connection | 78.24 (11.00) | 77.67 (9.94) | - 0.57 | −6.44, 5.31 | −0.20 (0.84) |
| Confidence | 82.58 (12.87) | 74.69 (12.79) | −7.89 | −16.09, 0.30 | −2.02 (0.06) |
| Control group (N = 23) | CBT group (N = 25) | CBT with drink group (N = 24) | |||||
| Mean | SD | Mean | SD | Mean | SD | F-values | |
| POMS-TA | 10.09 | 5.23 | 14.84 | 8.76 | 13.83 | 7.23 | 2.81† |
| POMS-D | 7.09 | 8.49 | 11.96 | 12.32 | 12.04 | 11.55 | 1.57 |
| POMS-F | 5.35a | 4.09 | 9.84b | 7.00 | 12.54c | 7.01 | 7.99** a < b*, a < c** |
| SSAS | 26.26 | 6.74 | 27.00 | 7.22 | 29.46 | 5.29 | 1.59 |
| MSCL | 1.78 | 2.04 | 1.92 | 2.27 | 3.17 | 2.35 | 2.79† |
| GSES | 9.87 | 3.44 | 7.84 | 4.45 | 8.67 | 4.21 | 1.50 |
| All patients (n = 121) | mRS = 0–1 (n = 75) | mRS = 2–6 (n = 46) | P-value | |
| Age (mean ± SD) | 63.4 ± 11.3 | 63.2 ± 10.5 | 63.8 ± 12.6 | 0.769 |
| Sex, n(%) | 0.490 | |||
| Men | 85(70.2) | 51(68) | 34(73.9) | |
| Female | 36(29.8) | 24(32) | 12(26.1) | |
| Risk factor, n(%) | ||||
| Hypertension | 61(50.8) | 36(48.6) | 25(54.3) | 0.544 |
| Diabetes | 33(27.3) | 14(18.7) | 19(41.3) | 0.007 |
| Hyperlipidemia | 17(14) | 7(9.3) | 10(21.7) | 0.057 |
| Atrial fibrillation | 22(18.2) | 16(21.3) | 6(13) | 0.251 |
| Current smoking | 31(25.6) | 20(26.7) | 11(23.9) | 0.736 |
| Previous coronary artery disease | 14(11.6) | 10(13.3) | 4(8.7) | 0.564 |
| Previous stroke or TIA | 11(9.1) | 6(8.0) | 5(10.9) | 0.746 |
| NIHSS on admission, (med, IQR) | 4[3–5] | 4[2–4] | 4[3–5] | 0.003 |
| (mean ± SD) | 3.6 ± 1.2 | 3.4 ± 1.2 | 4.0 ± 1.1 | 0.004 |
| Onset to rt-PA time, (mean± SD) | 143.1 ± 61.4 | 141.6 ± 57.9 | 145.6 ± 67.2 | 0.728 |
| Blood glucose on admission, mg/dL | 143.4 ± 52.6 | 134.7 ± 44.9 | 157.6 ± 61.0 | 0.019 |
| Initial systolic blood pressure, mmHg | 145.6 ± 26.3 | 145.4 ± 27.9 | 145.8 ± 23.5 | 0.924 |
| Etiologic stroke subtypes, n(%) | 0.302 | |||
| Small vessel disease | 25(20.7) | 13(17.3) | 12(26.1) | 0.248 |
| Large artery disease | 36(29.8) | 22(29.3) | 14(30.4) | 0.298 |
| Cardiac embolism | 34(28.1) | 26(34.7) | 8(17.4) | 0.040 |
| Undetermined etiology | 26(21.5) | 14(18.7) | 12(26.1) | 0.335 |
| Lesions on pretreatment DWI, n(%) | 0.317 | |||
| Acute infarcts (+) | 110(91.7) | 67(89.3) | 43(95.6) | |
| No lesions | 10(8.3) | 8(10.7) | 2(4.4) | |
| Lesion patterns on DWI, n(%) | ||||
| Perforating artery infarcts | 27(22.3) | 12(16) | 15(32.6) | 0.033 |
| Pial infarcts | 51(42.1) | 40(53.3) | 11(23.9) | 0.001 |
| Borderzone infarcts | 6(5) | 5(6.7) | 1(2.2) | 0.406 |
| Territorial infarcts | 17(14) | 10(13.3) | 7(15.2) | 0.772 |
| Perforating artery infarcts plus | 20(16.5) | 8(10.7) | 12(26.1) | 0.027 |
| Deep MCA infarcts (PAI + PAI plus) | 47(38.8) | 20(26.7) | 27(58.7) | < 0.001 |
| Angiographic findings of relevant artery, n(%) | 0.383 | |||
| No stenosis or occlusion | 62(51.2) | 42(56) | 20(43.5) | |
| Stenosis (> 50%) | 19(15.7) | 10(13.3) | 9(19.6) | |
| Occlusion | 40(33.1) | 23(30.7) | 17(37) | |
| Steno-occlusive disease, n(%) | 59(48.8) | 33(44) | 26(56.5) | 0.181 |
| END, n(%) | 14(11.6) | 3(4) | 11(23.9) | 0.002 |
| Symptomatic ICH, n(%) | 2(1.7) | 1(1.3) | 1(2.2) | 1.000 |
| Device | Magnitude (%) | Phase (min) |
| Inductive voltage divider | 0.0002 | 0.069 |
| Shunt | 0.01 | 0.3 |
| DMM | 0.01 | 0.583 |
| Moroccan N = 14,490 | Turkish N = 10,316 | Surinamese N = 8,619 | Moluccan N = 1,064 | Dutch N = 33,725 | p-value | |
| Total costs (mean, SE) | 3049.8 (67.3)4 | 3149.4 (79.6)4 | 3843.4 (87.2)4 | 2300.0 (247.9)4 | 3473.3 (44.0) | <0.0001 |
| GP services (mean, SE)5 | 56.8 (0.5)4 | 58.7 (0.6)4 | 60.8 (0.6)4 | 42.0 (1.8)4 | 48.7 (0.3) | <0.0001 |
| Receipt of prescriptions (mean, SE)6 | 819.4 (15.8)4 | 855.8 (18.7)4 | 871.2 (20.5)4 | 545.9 (58.3)4 | 727.2 (10.4) | <0.0001 |
| Physical therapy (mean, SE)7 | 141.3 (3.4)4 | 139.3 (4.1)4 | 186.4 (4.5) | 122.5 (12.7)4 | 176.7 (2.3) | <0.0001 |
| Hospital services (mean, SE)8 | 1854.3 (59.6)4 | 1922.7 (70.5)4 | 2478.0 (77.2) | 1472.1 (219.5)4 | 2303.6 (39.0) | <0.0001 |
| Medical aids (mean, SE)9 | 178.1 (6.5)4 | 172.9 (7.7)4 | 247.0 (8.4)4 | 117.4 (24.0)4 | 217.2 (4.3) | <0.0001 |
| Year | Host age | ||||
| Site | N | 1 | 2 | 3 | |
| 2002 | Urwitałt | 64 | 0.0 (0.0–23.8) | 0.0 (0.0–13.4) | 0.0 (0.0–13.4) |
| Tałty | 70 | 4.5 (0.2–22.2) | 6.5 (1.9–17.4) | 17.6 (5.0–41.7) | |
| Pilchy | 69 | 0.0 (0.0–17.6) | 11.5 (3.2–30.4) | 8.3 (1.5–26.7) | |
| Overall by year | 203 | 5.4 (3.7–7.8) | |||
| 2006 | Urwitałt | 95 | 7.7 (1.4–24.6) | 4.5 (0.7–17.7) | 4.0 (0.2–19.6) |
| Tałty | 65 | 7.7 (1.4–24.6) | 0.0 (0.0–22.2) | 12.5 (3.5–31.0) | |
| Pilchy | 67 | 24.1 (11.5–43.0) | 38.5 (16.6–65.8) | 76.0 (56.1–89.0) | |
| Overall by year | 227 | 18.1 (14.7–21.9) | |||
| 2010 | Urwitałt | 86 | 0.0 (0.0–20.8) | 25.0 (12.9–41.9) | 11.5 (3.2–30.4) |
| Tałty | 96 | 11.5 (3.2–30.4) | 13.0 (3.7–32.4) | 19.1 (8.8–36.6) | |
| Pilchy | 56 | 11.8 (2.1–35.0) | 50.0 (24.3–75.7) | 32.1 (23.2–42.6) | |
| Overall by year | 238 | 19.7 (16.2–23.8) | |||
| Overall by age | 8.7 (4.4–16.0) | 13.7 (10.8–17.3) | 20.8 (17.2–24.9) | ||
| Overall | 668 | 14.8 (12.5–17.5) |
| Cases(n) | Ref(n) | Odds ratio* | Confidence interval (95%) | ||
| Household economy | |||||
| Non-poor | Close | 68 | 317 | Ref | |
| Remote | 48 | 159 | 1.40 | 0.92 - 2.13 | |
| Poor | Close | 10 | 41 | Ref | |
| Remote | 54 | 80 | 2.84 | 1.30 - 6.21 | |
| Mother's ethnicity | |||||
| Kinh | Close | 45 | 226 | Ref | |
| Remote | 23 | 104 | 1.30 | 0.75 - 2.28 | |
| Minority | Close | 33 | 92 | Ref | |
| Remote | 79 | 135 | 1.61 | 0.99 - 2.62 | |
| Maternal education | |||||
| Completed1° school (≥5 y) | Close | 68 | 325 | Ref | |
| Remote | 46 | 165 | 0.84 | 0.86 - 2.01 | |
| Not completed1° school (<5 y) | Close | 10 | 33 | Ref | |
| Remote | 54 | 73 | 2.59 | 1.16 - 5.82 |
| Men | Women | ||||||||
| IHD mortality | Stroke mortality | IHD mortality | Stroke mortality | ||||||
| Median | Age-adjusted HR | Multivariate HRa | Age-adjusted HR | Multivariate HRa | Age-adjusted HR | Multivariate HRa | Age-adjusted HR | Multivariate HRa | |
| Cases (n) | 1,308 | 1,142 | 454 | 370 | 596 | 500 | 317 | 261 | |
| Person-years subcohort (n) | 17,057 | 15,017 | 17,426 | 15,017 | 20,512 | 18,241 | 20,512 | 18,241 | |
| Tap water characteristics | |||||||||
| Total water hardness (mmol/L) | |||||||||
| ≤ 1.5 (soft) | 1.1 | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| 1.6–2 (medium hard) | 1.7 | 1.07 (0.89–1.29) | 0.96 (0.76–1.20) | 0.89 (0.68–1.17) | 0.81 (0.59–1.14) | 1.16 (0.91–1.47) | 1.24 (0.93–1.66) | 0.81 (0.60–1.12) | 0.92 (0.64–1.32) |
| > 2 (hard) | 2.4 | 1.08 (0.91–1.29) | 1.04 (0.85–1.28) | 0.93 (0.73–1.19) | 0.90 (0.66–1.21) | 0.99 (0.79–1.23) | 0.93 (0.71–1.21) | 0.84 (0.64–1.11) | 0.86 (0.62–1.20) |
| p for trend | 0.34 | 0.69 | 0.58 | 0.46 | 0.90 | 0.58 | 0.22 | 0.37 | |
| Calcium concentration (mg/L) | |||||||||
| Quintiles | |||||||||
| 15–40 | 34.0 | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| > 40–51 | 47.6 | 0.92 (0.74–1.14) | 0.79 (0.59–1.06) | 0.77 (0.57–1.06) | 0.67 (0.44–1.03) | 1.02 (0.78–1.34) | 1.11 (0.77–1.61) | 0.83 (0.59–1.16) | 0.98 (0.62–1.55) |
| 53–64 | 57.5 | 1.05 (0.81–1.38) | 0.87 (0.59–1.27) | 1.03 (0.71–1.51) | 1.14 (0.67–1.97) | 1.31 (0.94–1.82) | 1.49 (0.91–2.43) | 0.91 (0.60–1.41) | 1.12 (0.61–2.07) |
| > 64–81 | 80.0 | 1.05 (0.85–1.29) | 0.91 (0.65–1.28) | 0.81 (0.60–1.10) | 0.80 (0.49–1.31) | 1.01 (0.77–1.32) | 1.15 (0.73–1.80) | 0.73 (0.52–1.03) | 0.86 (0.48–1.52) |
| 82–157 | 107.0 | 1.14 (0.87–1.47) | 0.91 (0.60–1.38) | 0.95 (0.65–1.38) | 1.18 (0.62–2.22) | 1.03 (0.74–1.43) | 1.11 (0.59–2.07) | 0.87 (0.57–1.31) | 1.01 (0.47–2.19) |
| p for trend | 0.19 | 0.88 | 0.69 | 0.66 | 0.85 | 0.75 | 0.22 | 0.71 | |
| Magnesium concentration (mg/L) | |||||||||
| Quintiles | |||||||||
| 1.7–3.8 | 3.4 | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| 4.2–6.0 | 4.9 | 1.06 (0.84–1.34) | 1.04 (0.76–1.42) | 0.88 (0.64–1.23) | 0.82 (0.53–1.29) | 1.14 (0.85–1.53) | 1.08 (0.73–1.58) | 0.85 (0.58–1.24) | 0.84 (0.52–1.35) |
| 6.0–8.0 | 7.3 | 1.10 (0.87–1.39) | 1.21 (0.87–1.71) | 0.70 (0.50–1.00) | 0.80 (0.48–1.33) | 0.87 (0.64–1.17) | 0.75 (0.49–1.18) | 0.86 (0.59–1.23) | 0.84 (0.49–1.43) |
| > 8.0–8.2 | 8.1 | 0.97 (0.78–1.22) | 0.95 (0.67–1.33) | 0.84 (0.62–1.16) | 0.87 (0.53–1.44) | 1.14 (0.86–1.52) | 0.97 (0.62–1.53) | 1.02 (0.72–1.44) | 1.10 (0.62–1.96) |
| 8.5–26.2 | 10.6 | 1.19 (0.93–1.53) | 1.23 (0.82–1.86) | 0.84 (0.59–1.20) | 0.69 (0.37–1.31) | 1.10 (0.81–1.50) | 0.89 (0.50–1.59) | 0.82 (0.55–1.23) | 0.77 (0.38–1.57) |
| p for trend | 0.43 | 0.71 | 0.29 | 0.44 | 0.55 | 0.66 | 0.70 | 0.97 |
| n | Mean (SD) or % | |
| Age | 5052 | 46.0 (9.0) |
| Job seniority | 4979 | 8.6 (7.1) |
| BMI | ||
| Normal | 2842 | 58.8% |
| Overweight | 1415 | 29.3% |
| Obese | 577 | 11.9% |
| Smoking | 1776 | 35.5% |
| Physical workloada | 4917 | 19.4 (9.7) |
| Leisure physical activity | ||
| Sedentary | 183 | 3.7% |
| Light physical activity | 2039 | 41.0% |
| Moderate physical activity | 2535 | 50.9% |
| Vigorous physical activity | 220 | 4.4% |
| Psychosocial work environmentb | ||
| Emotional demands | 5011 | 46.9 (17.9) |
| Influence at work | 5010 | 45.6 (20.0) |
| Role clarity | 5011 | 74.3 (14.2) |
| Leadership quality | 4931 | 57.2 (21.5) |
| Low back pain | ||
| No pain | 1558 | 31.2% |
| Subchronic pain | 2327 | 46.6% |
| Chronic pain | 1113 | 22.3% |
| Neck and shoulder pain | ||
| No pain | 1470 | 29.4% |
| Subchronic pain | 2113 | 42.2% |
| Chronic pain | 1423 | 28.4% |
| Knee pain | ||
| No pain | 3215 | 64.5% |
| Subchronic pain | 1166 | 23.4% |
| Chronic pain | 601 | 12.1% |
| Astrocytoma | Medulloblastoma | Craniopharyngioma | Germ cell tumors | Ependymal tumours | ||||
| Country | Author | Period | Age(yrs) | |||||
| China | 1990-2009 | 0-19 | 29.2% | 13.1% | 12.3% | 8.1% | 6.2% | |
| Taipei | Wong et al. [11] | 1975-2004 | 0-18 | 36.9% | 15.8% | 9.8 | 12.7% | 6.8% |
| Japan | Makino et al. [12] | 1989-2008 | 0-15 | 38.6% | 13.1% | 13.7 | 14.4% | 5.2% |
| India | Asirvatham et al. [8] | 1990-2004 | 0-18 | 49.7% | 12.0% | 10.3% | 3.0% | 5.2% |
| France | Bauchet et al. [9] | 2004-2006 | 0-19 | 32.9% | 13.1% | 5.4% | 3.6% | 8.6% |
| Brazil | Pinho et al. [10] | 1989-2009 | 0-21 | 37.7% | 16.3% | 12.5% | 7.0% | 8.1% |
| US | CBTRUS [6] | 2004-2007 | 0-19 | 33.1% | 12.0% | 3.6% | 4.8% | 6.7% |
| Tiotropium | Control | Hazard ratio(tiotropium versus control)*(95% CI) | |
| Time to first exacerbation, median month | |||
| Q1 | 19.4 | 14.6 | 0.80 (0.70 to 0.92) |
| Q2 | 22.4 | 13.6 | 0.83 (0.73 to 0.94) |
| Q3 | 16.6 | 16.3 | 0.97 (0.86 to 1.11) |
| Q4 | 14.9 | 12.7 | 0.88 (0.78 to 1.01) |
| Time to first exacerbation leading to hospitalization (first quartile), month | |||
| Q1 | NA | 39.9 | 0.72 (0.57 to 0.91) |
| Q2 | 47.2 | 32.5 | 0.73 (0.59 to 0.90) |
| Q3 | 37.0 | 40.2 | 1.05 (0.86 to 1.30) |
| Q4 | 28.5 | 26.0 | 0.98 (0.81 to 1.18) |
| Node name | Links | Links in background | Links to seed | Links in subnetwork | z-score |
| FUT4 | 3 | 11429 | 2 | 29 | 22.86 |
| ICAM5 | 4 | 11429 | 2 | 29 | 19.77 |
| PRTN3 | 9 | 11429 | 2 | 29 | 13.10 |
| IL2RA | 22 | 11429 | 3 | 29 | 12.47 |
| ICAM3 | 10 | 11429 | 2 | 29 | 12.41 |
| VIL2 | 32 | 11429 | 3 | 29 | 10.25 |
| ITGAM | 15 | 11429 | 2 | 29 | 10.06 |
| EZR | 34 | 11429 | 3 | 29 | 9.93 |
| KNG1 | 22 | 11429 | 2 | 29 | 8.23 |
| RANBP9 | 22 | 11429 | 2 | 29 | 8.23 |
| A2M | 24 | 11429 | 2 | 29 | 7.86 |
| PTPRC | 35 | 11429 | 2 | 29 | 6.42 |
| GRB2 | 196 | 11429 | 2 | 29 | 2.13 |
| Simulated Data | Mediated SEM | Mixed Model without Mediator | ||||||
| Effect Size | Effect Distribution | Effect | Bias (%) | Coverage Probability (%) | Power (%) | Bias (%) | Coverage Probability (%) | Power (%) |
| Large | Equal | Total | -0.8 | 94 | 100 | -0.8 | 94 | 100 |
| Direct | Total | -0.8 | 94 | 100 | -0.8 | 93 | 100 | |
| Indirect | Total | 0.9 | 94 | 100 | -0.6 | 94 | 100 | |
| Medium | Equal | Total | -1.5 | 94 | 95 | -1.5 | 93 | 94 |
| Direct | Total | -1.5 | 94 | 97 | -1.5 | 93 | 96 | |
| Indirect | Total | -1.3 | 94 | 93 | -1.3 | 93 | 92 | |
| Medium-Small | Equal | Total | -2.0 | 94 | 80 | -2.0 | 93 | 80 |
| Direct | Total | -0.9 | 94 | 84 | -0.9 | 93 | 83 | |
| Indirect | Total | -1.8 | 94 | 80 | -1.8 | 93 | 79 | |
| Small | Equal | Total | -3.7 | 94 | 32 | -3.7 | 93 | 32 |
| Direct | Total | -3.9 | 94 | 36 | -4.0 | 93 | 35 | |
| Indirect | Total | -3.7 | 94 | 34 | -3.7 | 93 | 33 |
| Clinical parameter | Vehicle | SMI 6877002 | Statistics |
| Incidence (%) | 100 | 100 | |
| Survival (%) | 100 | 100 | |
| AUC | 10.6 | 8.7 | P = 0.0804 |
| Mean clinical score (day 13) | 2.9 | 2.0 | P = 0.1160 |
| Mean day of onset | 11.1 | 11.5 | P = 0.4740 |
| Mean peak disease severity | 3.4 | 2.9 | P = 0.0184 |
| % Body weight loss (day 12 compared to day 0) | 5.4 | 4.7 | P = 0.2636 |
| Industry (type of animal) | No. (%) | |
| Campylobacteriosis | Cryptosporidiosis | |
| Total | 557 (100.0) | 93 (100.0) |
| Animal production | 380 (68.2) | 73 (78.5) |
| (Cattle and other bovines) | 271 (71.3) | 63 (86.3) |
| (Chicken and other poultry) | 35 (9.2) | 0 (—) |
| (Swine) | 21 (5.5) | 0 (—) |
| (Other/Multiple farm animals) | 53 (14.0) | 10 (13.7) |
| Animal slaughtering and processing | 91 (16.3) | 5 (5.4) |
| (Beef cattle processing) | 52 (57.1) | 2 (40.0) |
| (Poultry processing) | 13 (14.3) | 0 (—) |
| (Swine processing) | 10 (11.0) | 2 (40.0) |
| (Multiple animals/Unspecified) | 16 (17.6) | 1 (20.0) |
| Veterinary services | 24 (4.3) | 7 (7.5) |
| Other (shelter, rescue, pet store) | 62 (11.1) | 8 (8.6) |
| RFS | OS | |||
| HR (95%CI) | P value | HR (95%CI) | P value | |
| Univariate analysis | ||||
| Age, yrs (<50 vs. ≥50) | 0.994 (0.973-1.015) | 0.553 | 0.659 (0.315-1.534) | 0.368 |
| Gender (male vs. female) | 1.160 (0.046-2.910) | 0.753 | 1.037 (0.307-3.507) | 0.953 |
| HBsAg (negative vs. positive) | 1.996 (0.622-6.400) | 0.245 | 1.627 (0.383-6.913) | 0.509 |
| HBeAg (negative vs. positive) | 0.929 (0.420-2.054) | 0.856 | 2.457 (0.831-7.262) | 0.104 |
| AFP,ng/ml (≤400 vs. >400) | 1.847 (1.081-3.156) | 0.025 | 3.016 (1.326-6.859) | 0.008 |
| Liver cirrhosis (absent vs. present) | 0.886 (0.493-1.594) | 0.686 | 0.792 (0.341-1.838) | 0.587 |
| Vascular invasion (absent vs. resent) | 2.183 (1.167-4.084) | 0.015 | 4.228 (1.798-9.942) | 0.001 |
| Intrahepatic metastasis (absent vs. present) | 3.674 (2.056-6.566) | 0.000 | 3.079 (1.270-7.764) | 0.013 |
| Tumor size, cm (≤5 vs. >5) | 2.884 (1.358-6.125) | 0.006 | 1.720 (0.644-4.589) | 0.279 |
| Tumor number (single vs. multiple) | 3.464 (1.932-6.211) | 0.000 | 2.622 (1.038-6.622) | 0.041 |
| Differentiation (poor/moderate vs. well) | 1.986 (1.084-3.641) | 0.026 | 3.729 (1.391-10.000) | 0.009 |
| AJCC stage(I-II vs. III-IV) | 3.131 (1.805-5.430) | 0.000 | 5.081 (2.273-11.360) | 0.000 |
| PBLD (low vs. high) | 0.447 (0.260-0.769) | 0.004 | 0.384 (0.165-0.894) | 0.027 |
| Multivariate analysis | ||||
| Tumor size, cm (≤5 vs. >5) | 2.839 (1.270-6.345) | 0.011 | ||
| AJCC stage (I-II vs. III-IV) | 2.400 (1.137-5.066) | 0.022 | 9.349 (1.754-49.842) | 0.009 |
| PBLD (low vs. high) | 0.502 (0.282-0.891) | 0.019 | 0.364 (0.138-0.957) | 0.040 |
| Language | Number of Manual signs | Number of mouth gestures | % of signs accompanied by mouth gestures | Number of mouthings | % of signs accompanied by mouthings |
| British Sign Language | 1552 | 539 | 35 | 560 | 36 |
| Sign Language of the Netherlands | 1162 | 458 | 39 | 299 | 26 |
| Swedish Sign Language | 1619 | 624 | 39 | 831 | 51 |
| RA control | MTX group | TAC group | TAC + MTX group | |
| n = 35 | n = 55 | n = 29 | n = 14 | |
| Male/female | 12/23 | 11/44 | 9/20 | 1/13 |
| Age in years, mean ± SD | 70.54 ± 10.84 | 63.80 ± 11.50 | 69.28 ± 9.87 | 61.00 ± 11.68 |
| Weight in kg, mean ± SD | 53.32 ± 9.54 | 52.87 ± 11.83 | 52.22 ± 12.24 | 50.84 ± 9.42 |
| BMI, mean ± SD | 21.79 ± 3.47 | 21.69 ± 3.69 | 21.84 ± 4.43 | 21.51 ± 3.23 |
| RA duration in years, mean ± SD | 11.66 ± 12.52 | 14.11 ± 10.90 | 10.52 ± 9.74 | 12.14 ± 7.07 |
| MTX dose in mg/week, mean ± SD | - | 7.80 ± 2.37 | - | 8.29 ± 3.22 |
| TAC dose in mg/day, mean ± SD | - | - | 2.05 ± 0.74 | 1.64 ± 0.57 |
| Use of prednisolone, number (%) of patients | 21 (60.0) | 30 (54.5) | 21 (72.4) | 6 (42.9) |
| Prednisolone dose in mg/day, mean ± SD | 6.06 ± 4.23 | 4.98 ± 2.97 | 3.89 ± 1.99 | 3.00 ± 1.26 |
| DAS28 (CRP), mean ± SD | 2.79 ± 1.17 | 2.61 ± 0.98 | 2.79 ± 1.23 | 2.10 ± 0.71 |
| HAQ-DI, mean ± SD | 0.85 ± 0.84 | 0.62 ± 0.76 | 0.76 ± 0.88 | 0.53 ± 0.41 |
| SDAI, mean ± SD | 9.03 ± 6.32 | 8.15 ± 7.33 | 10.36 ± 10.63 | 4.60 ± 4.06 |
| CDAI, mean ± SD | 7.83 ± 5.40 | 7.45 ± 6.73 | 9.68 ± 10.51 | 3.95 ± 3.84 |
| IP (%) | 6 (17.1) | 7 (12.7) | 13 (44.8) | 0 |
| COPD (%) | 3 (8.6) | 1 (1.8) | 2 (6.9) | 0 |
| Smoking history (%) | 3 (8.6) | 5 (9.1) | 3 (10.3) | 1 (7.1) |
| Associative memory training group | Active control group | |||||
| Pre training M (SD) | Post training M (SD) | Effect size | Pre training M (SD) | Post training M (SD) | Effect size | |
| Item memory | −0.19 (0.85) | 0.29 (0.79) | 0.58 | −0.08 (0.70) | −0.04 (0.62) | 0.06 |
| Associative memory | −0.04 (0.70) | 0.13 (0.59) | 0.13 | −0.13 (0.55) | −0.03 (0.81) | 0.15 |
| Spatial memory | −0.23 (0.68) | 0.18 (0.55) | 0.67 | −0.07 (0.65) | −0.12 (0.76) | 0.28 |
| Reasoning | −0.03 (0.73) | 0.19 (0.87) | 0.28 | −0.20 (0.66) | −0.05 (0.64) | 0.38 |
| IC50 (μM)a | |||
| Compound | HCT-116 | HepG-2 | MCF-7 |
| 6a | >100 | >100 | >100 |
| 6b | >100 | 94.62 ± 6.93 | >100 |
| 6c | >100 | 58.34 ± 2.38 | >100 |
| 6d | 95.46 ± 4.08 | 52.95 ± 1.87 | >100 |
| 6e | 37.46 ± 1.24 | 24.55 ± 0.47 | 55.34 ± 2.72 |
| 6f | >100 | >100 | >100 |
| 6g | >100 | >100 | >100 |
| 6h | >100 | >100 | >100 |
| 6i | 3.67 ± 1.79 | 13.00 ± 0.67 | 3.58 ± 0.28 |
| 6j | 14.00 ± 1.02 | 18.41 ± 1.03 | 25.87 ± 1.88 |
| 6k | 25.42 ± 1.22 | 12.74 ± 0.83 | 14.38 ± 0.98 |
| 6l | 99.14 ± 4.52 | 83.78 ± 3.41 | >100 |
| 6m | 95.59 ± 5.88 | 83.74 ± 2.29 | >100 |
| 6n | 8.57 ± 0.52 | 3.97 ± 0.19 | 1.04 ± 0.08 |
| 6o | 80.50 ± 2.48 | 57.00 ± 1.44 | 94.00 ± 1.44 |
| 6p | 27.80 ± 0.96 | 60.60 ± 2.92 | 27.20 ± 1.58 |
| 6q | 5.99 ± 0.42 | 3.81 ± 0.13 | 7.67 ± 0.62 |
| 6r | >100 | >100 | >100 |
| 9a | >100 | >100 | >100 |
| 9b | >100 | >100 | >100 |
| 9c | >100 | >100 | >100 |
| 9d | 55.30 ± 1.78 | 27.70 ± 1.04 | 98.40 ± 5.74 |
| 9e | >100 | 91.60 ± 5.44 | >100 |
| 9f | 98.20 ± 4.44 | >100 | >100 |
| 11a | 70.13 ± 3.20 | 55.25 ± 3.18 | 39.42 ± 1.06 |
| 11b | >100 | >100 | >100 |
| 11c | >100 | >100 | >100 |
| Dox. | 3.70 ± 0.26 | 3.56 ± 0.17 | 2.57 ± 0.18 |
| GO term ID | Functional area (GO term of category biological process) | No. of genes |
| GO:0033555 | Multicellular organismal response to stress | 2 |
| GO:0070997 | Neuron death | 3 |
| GO:0050877 | Neurological system process | 5 |
| GO:0009991 | Response to extracellular stimulus | 5 |
| GO:0007399 | Nervous system development | 6 |
| GO:0071704 | Organic substance metabolic process | 11 |
| GO:0016043 | Cellular component organization | 13 |
| GO:0065007 | Biological regulation | 17 |
| Temperature (°C) | Activity (U/mL)±SD |
| 30 | 0.073148±0.000327 |
| 35 | 0.154167±0.000655 |
| 40 | 0.078241±0.000982 |
| 45 | 0.037963±0.000327 |
| Outcome over the last three months | ControlN=301 | Brief adviceN=291 | Coefficient/OR*95% CI |
| Weekly alcohol consumption (units) | |||
| Mean (SD) | 20.3 (16.6) | 18.1 (15.6) | −2.33 |
| Median (IQR) | 15.7 (8.3–29.9) | 14.1 (6.5–25.1) | −4.69 to 0.03 |
| Had unprotected sex (%) | |||
| No | 123 (40.9) | 137 (47.1) | 0.89 |
| Yes | 178 (59.1) | 154 (52.9) | 0.63 to 1.25 |
| Average units on drinking days | |||
| Mean (SD) | 10.4 (5.8) | 9.3 (5.3) | −1.13 |
| Median (IQR) | 9.4 (6.5–13.4) | 8.6 (5.6–11.4) | −1.96 to −0.29 |
| Proportion of days abstinent | |||
| Mean, (SD) | 70.7 (22.6) | 70.9 (22.1) | 0.20 |
| Median (IQR) | 75.6 (62.2–87.8) | 75.6 (58.9–87.8) | −3.03 to 3.44 |
| Drinking excessively (M-SASQ) (%) | |||
| No | 55 (18.3) | 70 (24.1) | 0.70 |
| Yes | 246 (81.7) | 221 (75.9) | 0.46 to 1.05 |
| Number of sexual partners | |||
| Mean (SD) | 1.9 (2.9) | 1.6 (2.2) | −0.13 |
| Median (IQR) | 1 (1–2) | 1 (1–2) | −0.29 to 0.02 |
| Number of unprotected partners | |||
| Mean (SD) | 0.8 (1.1) | 0.6 (0.8) | −0.11 |
| Median (IQR) | 1 (0–1) | 1 (0–1) | −0.31 to 0.08 |
| Occurrence of regretted sex (%) | |||
| No | 273 (90.7) | 263 (90.4) | 1.05 |
| Yes | 28 (9.3) | 28 (9.6) | 0.60 to 1.84 |
| Unprotected sex after drinking (%) | |||
| No | 165 (54.8) | 183 (62.9) | 0.79 |
| Yes | 136 (45.2) | 108 (37.1) | 0.56 to 1.11 |
| Unprotected sex after feeling drunk (%) | |||
| No | 245 (81.4) | 234 (80.4) | 1.15 |
| Yes | 56 (18.6) | 57 (19.6) | 0.76 to 1.75 |
| Unplanned pregnancy (n=316) | |||
| No | 160 (98.8) | 152 (98.7) | 1.05 |
| Yes | 2 (1.2) | 2 (1.3) | 0.16 to 6.79 |
| New diagnosis of sexually transmitted infection | |||
| No | 287 (95.3) | 283 (97.3) | 0.58 |
| Yes | 14 (4.7) | 8 (2.7) | 0.25 to 1.384 |
| Health related quality of life (SD) | 0.922 (0.144) | 0.910 (0.150) | −0.013−0.037 to 0.109 |
| Conditions | Reactor 1 | Reactor 2 |
| Carrier | Corncob | Concrete block |
| External carbon | No | Phase 1: no |
| Phase 2: yes (C/N = 2.5) | ||
| Phase 3: yes (C/N = 3.5) | ||
| Microbial test | Unused corncob | Unused concrete |
| Used corncob (surface) | Used concrete (surface) | |
| Used corncob (core) | Used concrete (core) |
| Parameters | Chronic HBV patients | Health volunteers |
| No. | 22 | 20 |
| Age (years) | ||
| Mean ± SD | 45.9 ± 8.1 | 38.5 ± 11.8* |
| Median | 46 | 36.5 |
| Range | 30–61 | 25–58 |
| Sex N(%) | ||
| Male | 17 (77.3) | 14 (70) |
| Female | 05 (22.7) | 6 (30) |
| Years from HBV diagnosis | ||
| Mean ± SD | 10.3 ± 1.6 | NA |
| HBV DNA (log10 copies/ml) | ||
| Mean | 5.8 | NA |
| SD | 0.2 | |
| ALT (U/L) | ||
| Median | 27.6 | 15.4* |
| Range | 10.1–445.6 | 5.6–37.5 |
| AST (U/L) | ||
| Median | 26.8 | 11.3* |
| Range | 7.1–312.4 | 2.5–25.4 |
| HbsAg (log 10 IU/ml) | ||
| Median | 1082.5 | NA |
| Range | 90.0–12795.0 |
| Program | Nucleotide | Exon | Gene | |||
| Sensitivity | Specificity | Sensitivity | Sensitivity | Specificity | Sensitivity | |
| Pair-wise GeneMapper | 99.95 | 99.93 | 91.3 | 95.1 | 52.2 | 52.2 |
| Multiple species GeneMapper | 99.95 | 99.93 | 91.5 | 95.2 | 52.6 | 52.6 |
| Methods | TP | FP | FN |
| [24, 25] | 93.4% | 0.18% | 6.6% |
| Proposed | 96.8% | 0.12% | 3.2% |
| Subject | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| Accuracy | 88.23% | 92.10% | 78.57% | 86.53% | 77.77% | 67.39% | 68.18% | 80.35% | 69.04% | 69.56% |
| Variables | IS (n = 198) | Controls (n = 236) | P value |
| Age (years, mean ± SD) | 57.2 ± 11.8 | 55.4 ± 11.7 | 0.12 |
| Gender (%) | |||
| Male | 122 (61.6) | 155 (65.7) | 0.38 |
| Female | 76 (38.4) | 81 (34.3) | |
| Hypertension (%) | 119 (60.1) | 22 (9.3) | <0.001 |
| Diabetes mellitus (%) | 40 (20.2) | 8 (3.4) | <0.001 |
| Hypercholesterolemia (%) | 27 (13.6) | 26 (11.0) | 0.41 |
| Hypertriglyceridemia (%) | 56 (28.3) | 61 (25.8) | 0.57 |
| Mbeya | Mtwara | Mwanza | ||||||||||
| Health facilities (N = 18) | Non-HF AM providers (N = 38)a | Health facilities (N = 16) | Non-HF AM providers (N = 21) | Health facilities (N = 26) | Non-HF AM providers (N = 89) | |||||||
| N | % (95% CI) | N | % (95% CI) | N | % (95% CI) | N | % (95% CI) | N | % (95% CI) | N | % (95% CI) | |
| % of outlets with anti-malarials in stock | 18 | 100.0 | 38 | 100.0 | 16 | 100.0 | 20 | 95.2 (87.6–102.9) | 26 | 100.0 | 81 | 91.0 (86.0–96.0) |
| % of outlets with RDTs in stock or microscopy | 16 | 88.9 (76.7–101.1) | 3 | 7.9 (0.7–15.1) | 11 | 68.8 (49.7–87.8) | 0 | 0.0 | 21 | 80.8 (68.1–935.) | 1 | 1.2 (− 0.71–2.96) |
| Benign prostatic hyperplasia patients | n = 49 |
| IPSS Score (Barry et al., 1992) | |
| 0–7 | 0 |
| 8–19 | 24 |
| 20–35 | 17 |
| Unknown | 8 |
| Prostate cancer patients | n = 30 |
| Gleason score (Epstein, 2010) | |
| 6 (3+3) | 19 |
| 7 (3+4) | 3 |
| 7 (4+3) | 4 |
| Unknown | 4 |
| Antibiotica | Minimal inhibitory concentration (μg/ml)b | |||||||
| NVT2001S | ΔompK35 | ΔompK36 | ΔompK35/36 | |||||
| NOc | LCP | NO | LCP | NO | LCP | NO | LCP | |
| Aztreonam | ≤1 | ≤1 | ≤1 | ≤1 | ≤1 | ≤1 | ≤1 | ≤1 |
| Ampicillin | ≥ | ≥ | ≥ | ≥ | ≥ | ≥ | ≥ | ≥ |
| Piperacillin/TZB | ≤4 | ≤4 | ≤4 | ≤4 | ≤4 | ≤4 | ≤4 | ≤4 |
| Cefazolin | ≤8 | ≤8 | ≤8 | ≤8 | ≥ | ≥ | ||
| Cephalothin | ≤8 | ≤8 | ≤8 | ≤8 | ≥ | ≥ | ||
| Cefoxitin | ≤4 | ≤4 | ≤4 | ≤4 | ||||
| Ceftriaxone | ≤1 | ≤1 | ≤1 | ≤1 | ≤1 | ≤1 | ≤1 | ≤1 |
| Cefpodoxime | ≤0.25 | ≤0.25 | ≤0.25 | ≤0.25 | ≤0.25 | ≤0.25 | 0.5 | 0.5 |
| Cefotaxime | ≤0.25 | ≤0.25 | ≤0.25 | ≤0.25 | ≤0.25 | ≤0.25 | ≤0.25 | ≤0.25 |
| Cefotaxime/CLA | ≤0.12 | ≤0.12 | ≤0.12 | ≤0.12 | ≤0.12 | ≤0.12 | 0.25 | 0.25 |
| Ceftazidime | ≤0.25 | ≤0.25 | ≤0.25 | ≤0.25 | ≤0.25 | ≤0.25 | 0.5 | 0.5 |
| Ceftazidime/CLA | ≤0.12 | ≤0.12 | 0.25 | 0.25 | ≤0.12 | ≤0.12 | 0.5 | 0.5 |
| Cefepime | ≤1 | ≤1 | ≤1 | ≤1 | ≤1 | ≤1 | ≤1 | ≤1 |
| Ciprofloxacin | ≤1 | ≤1 | ≤1 | ≤1 | ≤1 | ≤1 | ≤1 | ≤1 |
| Gentamicin | ≤4 | ≤4 | ≤4 | ≤4 | ≤4 | ≤4 | ≤4 | ≤4 |
| Radiographic OA | Pain | Mean | SE | 95% CI of the mean | P-value | 95% CI for difference | ||
| Lower | Upper | |||||||
| sC2C | K/L 1 | - | 5.49 | 0.04 | 5.40 | 5.57 | 0.02* | -0.19 to -0.04 |
| Ln (pmol/ml) | + | 5.75 | 0.07 | 5.61 | 5.91 | |||
| K/L 2 | - | 5.43 | 0.07 | 5.29 | 5.57 | 1.00 | -0.36 to 0.35 | |
| + | 5.44 | 0.11 | 5.21 | 5.66 | ||||
| sCPII | K/L 1 | - | 7.38 | 0.07 | 7.24 | 7.52 | 0.01* | -0.83 to -0.10 |
| Ln (ng/ml) | + | 7.84 | 0.11 | 7.62 | 8.07 | |||
| K/L 2 | - | 7.05 | 0.11 | 6.83 | 7.28 | 1.00 | -0.44 to 0.71 | |
| + | 6.92 | 0.18 | 6.56 | 7.28 | ||||
| uCTX-II/Cr | K/L 1 | - | 5.04 | 0.14 | 4.76 | 5.32 | 0.07 | -1.48 to 0.03 |
| Ln (ng/μmol creatinine) | + | 5.77 | 0.22 | 5.32 | 6.22 | |||
| K/L 2 | - | 5.38 | 0.23 | 4.92 | 5.83 | <0.05* | -2.36 to -0.05 | |
| + | 6.56 | 0.36 | 5.82 | 7.29 | ||||
| sC2C | K/L 1 | - | 0.15 | 0.03 | 0.10 | 0.20 | 1.00 | -1.12 to 0.17 |
| /sCPII | + | 0.12 | 0.04 | 0.04 | 0.21 | |||
| K/L 2 | - | 0.27 | 0.04 | 0.19 | 0.36 | 1.00 | -0.17 to 0.26 | |
| + | 0.23 | 0.07 | 0.09 | 0.37 | ||||
| uCTX-II/sCPII | K/L 1 | - | 0.09 | 0.06 | -0.03 | 0.22 | 1.00 | -0.39 to 0.29 |
| + | 0.14 | 0.10 | -0.06 | 0.35 | ||||
| K/L 2 | - | 0.42 | 0.10 | 0.21 | 0.63 | <0.05* | -1.07 to 0 | |
| + | 0.95 | 0.17 | 0.62 | 1.29 | ||||
| uNTX/Cr | K/L 1 | - | 3.71 | 0.11 | 3.48 | 3.93 | 1.00 | -0.89 to 0.33 |
| Ln (ng/ml creatinine) | + | 3.99 | 0.18 | 3.62 | 4.35 | |||
| K/L 2 | - | 3.33 | 0.18 | 2.96 | 3.70 | 0.73 | -1.49 to 0.41 | |
| + | 3.87 | 0.29 | 3.27 | 4.47 | ||||
| sHA | K/L 1 | - | 2.77 | 0.13 | 2.51 | 3.03 | 0.06 | -1.40 to 0.01 |
| Ln (pmol/ml) | + | 3.46 | 0.21 | 3.04 | 3.89 | |||
| K/L 2 | - | 3.66 | 0.21 | 3.24 | 4.09 | 1.00 | -1.42 to 0.78 | |
| + | 3.98 | 0.34 | 3.29 | 4.67 |
| Swab | N | ||
| Score Card | Bacterial | Viral | |
| Positive | 21 | 19 | 40 |
| (True Positive) | (False Positive) | ||
| Negative | 2 | 40 | 42 |
| (False Negative) | (True Negative) | ||
| N | 23 | 59 | 82 |
| Microbiology of prosthetic infection (1 day- > 1 year) after haernia or ventral mesh repair | |
| Staphylococcus aureus | 50–60 % |
| Staphylococcus spp | 10–20 % |
| Enterococcus spp | 10–20 % |
| Gram-neg | 5–10 % |
| Pseudomonas, Streptococcus spp, Mycobacteria spp, mixed flora | rare |
| Richest Quintile | Poorest Quintile | Difference | Ratio | |||||||
| Earliest Survey | Latest Survey | Earliest Survey | Latest Survey | Earliest Survey | Latest Survey | p-val | Earliest Survey | Latest Survey | p-val | |
| Stunting | 47.7 | 27.4 | 59.3 | 47.1 | −11.6 | −19.7 | 0.057 | 0.8 | 0.6 | 0.002 |
| Wasting | 8.9 | 7.4 | 12.1 | 11.7 | −3.2 | −4.3 | 0.656 | 0.7 | 0.6 | 0.559 |
| Underweight | 31.0 | 16.6 | 43.8 | 33.4 | −12.8 | −16.8 | 0.237 | 0.7 | 0.5 | 0.003 |
| NNMR | 42.3 | 45.3 | 33.7 | 36.8 | 8.6 | 8.4 | 0.991 | 1.3 | 1.2 | NA |
| IMR | 88.2 | 67.7 | 77.9 | 67.0 | 10.3 | 0.7 | 0.669 | 1.1 | 1.0 | NA |
| U5MR | 137.6 | 78.4 | 136.1 | 89.7 | 1.5 | −11.3 | 0.603 | 1.0 | 0.9 | NA |
| Measles vaccination | 53.1 | 79.9 | 18.7 | 47.1 | 34.3 | 32.8 | 0.825 | 2.8 | 1.7 | 0.023 |
| Full immunization | 34.8 | 50.9 | 7.2 | 17.5 | 27.6 | 33.4 | 0.419 | 4.8 | 2.9 | 0.153 |
| Contraceptive | 26.1 | 57.2 | 3.2 | 30.9 | 23.0 | 26.2 | 0.538 | 8.3 | 1.8 | 0.000 |
| ANC4+ | 34.8 | 60.2 | 4.1 | 8.6 | 30.7 | 51.7 | 0.000 | 8.6 | 7.0 | 0.481 |
| SBA | 25.4 | 55.6 | 0.9 | 4.5 | 24.5 | 51.0 | 0.000 | 29.6 | 12.3 | 0.060 |
| Item # | VII. Monitoring, Evaluation, and Information Systems | Burkina Faso | Dominican Republic—national | Dominican Republic—subnational | Ghana | Mali | Total | ||||||
| N | Score | N | Score | N | Score | N | Score | N | Score | N | Score | ||
| 1. | Monitoring and evaluation of national HRH plan | 16 | 5.1 | 22 | 4.5 | 14 | 5.4 | 16 | 4.8 | 22 | 5.1 | 90 | 5.0 |
| 2. | Monitoring and evaluation implementation capacity | 16 | 4.7 | 23 | 4.8 | 15 | 5.6 | 16 | 4.6 | 24 | 4.4 | 94 | 4.8 |
| 3. | Use of data in HRH planning | 18 | 5.2 | 22 | 4.4 | 15 | 4.6 | 16 | 4.9 | 24 | 5.3 | 95 | 4.9 |
| 4. | Staffing and employment information system | 19 | 4.1 | 21 | 3.9 | 14 | 4.2 | 16 | 5.5 | 24 | 4.8 | 94 | 4.5 |
| 5. | Interoperability | 16 | 4.1 | 22 | 4.4 | 12 | 4.7 | 15 | 3.9 | 19 | 5.1 | 84 | 4.4 |
| 6. | National health workforce registry | 15 | 4.8 | 21 | 4.6 | 14 | 5.4 | 15 | 5.1 | 21 | 5.8 | 86 | 5.1 |
| 7. | Health worker licensure and registration system | 16 | 5.3 | 22 | 5.0 | 15 | 6.4 | 17 | 7.6 | 20 | 4.6 | 90 | 5.8 |
| 8. | Information and communications technology infrastructure and capacity | 18 | 3.8 | 23 | 4.9 | 16 | 5.8 | 18 | 4.4 | 25 | 5.0 | 100 | 4.8 |
| Average respondents and scores | 17 | 4.6 | 22 | 4.6 | 14 | 5.3 | 16 | 5.1 | 22 | 5.0 | 92 | 4.9 |
| Variables | Results |
| Male, n (%) | 20 (48.8) |
| Age, years | 49.39 ± 0.82 |
| Position, n (%) | |
| President of hospital | 1 (2.4) |
| Vice president of hospital | 2 (4.9) |
| Director of department | 30 (73.2) |
| Vice director of department | 7 (17.1) |
| No position | 1 (2.4) |
| Title, n (%) | |
| Chief physician | 35 (85.4) |
| Vice-chief physician | 6 (14.6) |
| Experience in the clinical work of digestive diseases, n (%) | |
| >20 years | 33 (80.5) |
| 10–20 years | 8 (19.5) |
| Grade of hospital, n (%) | |
| Tertiary, class A | 35 (85.4) |
| Tertiary, class B | 5 (12.2) |
| Second level, class A | 1 (2.4) |
| Number of beds in the hospital, n (%) | |
| >1000 | 34 (82.9) |
| 800–1000 | 3 (7.3) |
| 500–800 | 3 (7.3) |
| Others | 1 (2.4) |
| Number of beds in the Department of Gastroenterology, n (%) | |
| >120 | 8 (19.5) |
| 80–120 | 10 (24.4) |
| 40–80 | 15 (36.6) |
| Others | 8 (19.5) |
| Number of patients with liver cirrhosis admitted to the Department of Gastroenterology every year, n (%) | |
| >200 | 19 (46.3) |
| 100–200 | 9 (22.0) |
| 50–100 | 13 (31.7) |
| Number of patients with liver cirrhosis and gastroesophageal varices admitted to the Department of Gastroenterology every year, n (%) | |
| >200 | 15 (36.6) |
| 100–200 | 7 (17.1) |
| 50–100 | 16 (39.0) |
| Others | 3 (7.3) |
| Measure | Content validity | Construct validity | Internal consistency | Interrater agreement | Reliability | Responsiveness |
| Cosmesis visual analog scale (VAS) | ? | ? | ? | ? | ? | ? |
| Disabilities of the arm, shoulder, and hand questionnaire (DASH) | + | + | + | + | + | + |
| Hand function visual analog scale (VAS) | ? | ? | ? | ? | ? | ? |
| Hand-specific ADL questionnaire | ? | 0 | 0 | ? | ? | ? |
| Michigan Hand Outcomes Questionnaire (MHQ) | + | + | + | + | + | + |
| Patient Evaluation Measure (PEM) | 0 | + | + | 0 | + | + |
| Patient-Rated Wrist Evaluation | + | + | + | 0 | + | + |
| Perceived grip strength scale | ? | ? | ? | ? | ? | ? |
| Scale of hand-specific activity performance | ? | ? | ? | ? | ? | ? |
| Variable | Patients (n) | Number of patients (IMP-Expression) (%) | p-Value (linear by linear) | |||
| 0 | 1 | 2 | 3 | |||
| pT-status | 0.5 | |||||
| pT2 | 213 | 46 (21.6%) | 131 (61.5%) | 34 (16%) | 2 (0.9%) | |
| pT3&4 | 212 | 25 (11.8%) | 163 (76.9%) | 23 (10.8%) | 1 (0.5%) | |
| Gleason score | 0.048 | |||||
| 5-6 | 129 | 29 (22.5%) | 85 (65.9%) | 14 (10.9%) | 1 (0.8%) | |
| 7 | 182 | 28 (15.4%) | 127 (69.8%) | 26 (14.3%) | 1 (0.5%) | |
| 8-9 | 114 | 14 (12.3%) | 82 (71.9%) | 17 (14.9%) | 1 (0.9%) | |
| Margin status | 0.115 | |||||
| R0 | 262 | 54 (20.6%) | 171 (65.3%) | 34 (13%) | 3 (1.1%) | |
| R1 | 163 | 17 (10.4%) | 123 (75.5%) | 23 (14.1%) | 0 (0%) | |
| PSA (pre-OP) | 0.21 | |||||
| < 10 ng/ml | 192 | 37 (19.3%) | 130 (67.7%) | 24 (12.5%) | 1 (0.5%) | |
| ≥10 ng/ml | 233 | 34 (14.6%) | 164 (70.4%) | 33 (14.2%) | 2 (0.9%) | |
| Age | 0.693 | |||||
| ≤64 y | 230 | 33 (14.3%) | 168 (73%) | 27 (11.7%) | 2 (0.9%) | |
| > 64 y | 195 | 38 (19.5%) | 126 (64.6%) | 30 (15.4%) | 1 (0.5%) |
| NAbs | OSEs | Properties/Functions |
| T15/E06 | PC head-group of oxidized phosphatidylcholine | Blockage of OxLDL uptake by macrophages (Horkko et al., 1999; Binder et al., 2003)Binding to OxLDL and apoptotic cells and atherosclerotic lesions (Palinski et al., 1996; Chang et al., 1999, 2004)Inhibition of apoptotic cell/blebs mediated endothelial cell activation resulting in decreased monocyte adhesion (Huber et al., 2002; Chang et al., 2004)Inhibition OxPAPC-induced IL-6 secretion by lung tissue macrophage (Imai et al., 2008)Enhancement of in vivo apoptotic cell clearance in B cell-deficient (μMT) and sIgM-/- mice (Ogden et al., 2005; Chen et al., 2009a)Protection from atherosclerosis (Binder et al., 2003; Faria-Neto et al., 2006)Clinical score reduction in collagen induced arthritis (Chen et al., 2009a) |
| E014 | Malondialdehyde | Binding to OxLDL, apoptotic cells, and atherosclerotic lesions (Palinski et al., 1996)Binding to apoptotic and cholesterol induced microvesicles (Huber et al., 2002; Liu et al., 2012) |
| NA-17 | Malondialdehyde | Binding to OxLDL and apoptotic cells (Chou et al., 2009)Enhancement of clearance of apoptotic cells by macrophages in Rag1-/- mice in vivo (Chou et al., 2009) |
| LR01 | Oxidized cardiolipin | Binding to OxLDL, apoptotic cells, and atherosclerotic lesions (Tuominen et al., 2006) |
| Prevalence (%) in Control arm | Reduction in Prevalence due to each intervention (ECF or HH) individually | Prevalence (%) in ECF or HH arm | Overall number of communities needed (equally split into 4 arms) |
| k = 0.15 | |||
| 0.6 | 30% | 0.42 | 24 |
| 0.8 | 30% | 0.56 | 20 |
| 1.0 | 30% | 0.7 | 18 |
| 1.0 | 20% | 0.8 | 41 |
| 1.0 | 10% | 0.9 | 168 |
| k = 0.2 | |||
| 0.6 | 30% | 0.42 | 30 |
| 0.8 | 30% | 0.56 | 26 |
| 1.0 | 30% | 0.7 | 24 |
| 1.0 | 20% | 0.8 | 54 |
| 1.0 | 10% | 0.9 | 227 |
| k = 0.25 | |||
| 0.6 | 30% | 0.42 | 45 |
| 0.8 | 30% | 0.56 | 42 |
| 1.0 | 30% | 0.7 | 39 |
| 1.0 | 20% | 0.8 | 93 |
| 1.0 | 10% | 0.9 | 398 |
| Independent Variables ** | Intercept | US-Born | SE | p value |
| α-Carotene | 4.59 | −1.03 | 0.21 | <0.0001 |
| β-Carotene | 18.13 | −3.27 | 0.84 | 0.0001 |
| β-Cryptoxanthin | 17.2 | −3.79 | 0.75 | <0.0001 |
| Lutein/zeaxanthin | 21.76 | −3.754 | 0.75 | <0.0001 |
| Lycopene | 19.99 | 1.15 | 0.84 | 0.1713 |
| Vitamin A | 38.66 | −1.59 | 0.72 | 0.0263 |
| Vitamin E | 782.36 | −43.15 | 12.81 | 0.0008 |
| Adverse events | All treated patients (n = 42) | |
| Any grade | Grade 3–5a | |
| Skin and subcutaneous tissue disorders | ||
| Pruritus | 6 (14.3) | 0 |
| Maculopapular rash | 6 (14.3) | 0 |
| Vitiligo | 3 (7.1) | 0 |
| Skin hypopigmentation | 2 (4.8) | 0 |
| Dry skin | 2 (4.8) | 0 |
| General disorders and administration site conditions | ||
| Malaise | 5 (11.9) | 0 |
| Endocrine disorders | ||
| Hypothyroidism | 4 (9.5) | 0 |
| Hyperthyroidism | 2 (4.8) | 0 |
| Hypophysitis | 2 (4.8) | 1 (2.4) |
| Gastrointestinal disorders | ||
| Diarrhea | 3 (7.1) | 0 |
| Nausea | 2 (4.8) | 0 |
| Abdominal pain | 2 (4.8) | 0 |
| Upper abdominal pain | 2 (4.8) | 0 |
| Colitis | 2 (4.8) | 1 (2.4) |
| Laboratory results | ||
| Elevated AST | 3 (7.1) | 0 |
| Elevated eosinophil count | 3 (7.1) | 0 |
| Elevated ALT | 2 (4.8) | 0 |
| Blood and lymphatic system disorders | ||
| Anemia | 2 (4.8) | 2 (4.8) |
| Probe/Chromosome | S.ita-Y1(c) | Qing 9(c) | S.adh-W94(c) | S.lac-W74(c) | S.par-W79(c) | S.pal-N193(c) | S.gla-W12(c) | S. are-N196(c) | S. pli-N195(c) |
| S. vir-Q24(p) | √ | × | ×* | × | × | × | ×* | × | × |
| S. adh-W94(p) | ×* | √ | × | × | × | ×* | × | × | |
| S. gri-W8(p) | ×* | ×* | √ | × | × | × | × | × | |
| Qing 9(p) | √ | ||||||||
| S. gla-W12(p) | √ | × | × | × | |||||
| S. pli-N195(p) | √ | × |
| Variables | No. of patients (n = 74) | Percentage (%) |
| Gender | ||
| Male | 32 | 43.24 |
| Female | 42 | 56.76 |
| Age (years) | 54.36 ± 13.13 | - |
| Hospital stay (days) | 19.47 ± 10.19 | - |
| Clinical presentation | ||
| Gastrointestinal hemorrhage | 37 | 50.00 |
| Abdominal pain | 25 | 33.78 |
| Palpable mass | 5 | 6.76 |
| othersa | 7 | 9.46 |
| Tumor location (portion) | ||
| First | 17 | 22.97 |
| Second | 35 | 47.30 |
| Third | 12 | 16.22 |
| Forth | 10 | 13.51 |
| Tumor size (cm) | 5.08 ± 2.90 | - |
| No. of mitosis | ||
| ≤5/50 HPF | 41 | 55.41 |
| 6–10/50 HPF | 27 | 36.49 |
| >10/50 HPF | 6 | 8.10 |
| Modified NIH risk classification | ||
| Low | 32 | 43.24 |
| Intermediate | 8 | 10.81 |
| High | 34 | 45.96 |
| Mutational analysis | ||
| KIT exon 11 | 9 | 12.16 |
| KIT exon 9 | 3 | 4.05 |
| NA | 62 | 83.78 |
| Preoperative imatinib therapy | 1 | 1.35 |
| Postoperative adjuvant therapy | 16 | 21.62 |
| Patients with emergency visit | 5 | 6.76 |
| Patients with metastases at diagnosis | 2 | 2.70 |
| Tumor recurrence or metastasis | 19 | 25.68 |
| Death case | 14 | 18.92 |
| Placebo | 1-day | 3-day | 7-day | |
| Number of subjects | 26 | 26 | 27 | 27 |
| Age (years)* | 41.0 ± 2.2 | 41.9 ± 2.2 | 38.5 ± 1.7 | 36.5 ± 1.4 |
| Gender | ||||
| Male | 9 | 6 | 14 | 16 |
| Female | 17 | 20 | 13 | 11 |
| Duration of SAR (years)* | 13.4 ± 1.3 | 19.3 ± 1.8 | 16.8 ± 1.7 | 17.5 ± 1.6 |
| Specific IgE titer* | 3.77 ± 0.19 | 3.88 ± 0.19 | 3.70 ± 0.12 | 3.56 ± 0.18 |
| TNSS in screening* | 0.05 ± 0.03 | 0.10 ± 0.04 | 0.11 ± 0.05 | 0.14 ± 0.04 |
| YoudenCut-off | Sensitivity (%) | Specificity (%) | AUC | 95% CI | P-value | ||
| Rest | GLS (%) | >−18.55 | 77.27 | 68.18 | 0.72 | 0.56–0.87 | 0.006 |
| GLSR (s−1) | >−91.09 | 68.18 | 72.73 | 0.75 | 0.60–0.89 | 0.0008 | |
| E’ (s−1) | ≤84.53 | 86.36 | 54.55 | 0.70 | 0.54–0.86 | 0.01 | |
| A’ (s−1) | ≤108.86 | 100 | 32 | 0.59 | 0.42–0.77 | 0.28 | |
| Stress | GLS (%) | >−19.80 | 77.3 | 72.7 | 0.82 | 0.70–0.94 | <0.001 |
| GLSR (s−1) | >−99.7 | 63.6 | 86.4 | 0.74 | 0.58–0.89 | 0.003 | |
| E’ (s−1) | ≤81.65 | 50 | 82 | 0.67 | 0.50–0.83 | 0.04 | |
| A’ (s−1) | ≤58.65 | 36.36 | 86.36 | 0.58 | 0.41–0.76 | 0.34 | |
| Strain modela | 28% | 96 | 68 | 0.87 | 0.76–0.97 | <0.0001 |
| Morbidity | Measuring instrument | Data source |
| Diagnoses | ICD-10 codes | chart review |
| Diseases | self-developed questionnaire | GP interview |
| self-developed questionnaire | patient interview | |
| Four-Dimensional Symptom Questionnaire (4DSQ) [11] | patient interview | |
| Geriatric Depression Scale (GDS) [12] | patient interview | |
| Clinical Dementia Rating (CDR) [13] | rated by interviewer | |
| Functional Status | ||
| Activities of daily living | Barthel Index [22] | patient interview |
| Instrumental Activities of Daily Living (IADL) Scale [23] | patient interview | |
| Motor skills | FFB-Mot [24] | patient interview |
| Vision and hearing | 2 items rated on a 4 point scale | patient interview |
| Cognitive impairment | CERAD [25] subtests word list and animal naming | cognitive tests by interviewer |
| Letter Digit Substitution Test (LDST) [26] | cognitive tests by interviewer | |
| Pain | Graded Chronic Pain Scale (GCPS) [27] | patient interview |
| Health-related quality of life | EuroQoL (EQ-5D) Scale [28] | patient interview |
| Resources/Risk Factors | ||
| Physical risk factors | Body-Mass-Index and Waist-to-Hip-Ratio | physical checkup by GP |
| Physical activity | International Physical Activities Questionnaire (IPAQ) [29] | patient interview |
| Nutrition | 12 items for frequency and portion size of nutriments | patient interview |
| Alcohol use | AUDIT-C [30] | patient interview |
| total amount of alcohol consumption per week | patient interview | |
| Smoking behavior | 9 items indicating current smoking status and pack years | patient interview |
| General self-efficacy | General Self-efficacy Scale [31] | patient interview |
| Social support | F-SOZU K14 [32] | patient interview |
| Medical care | Patient Assessment of Chronic Illness Care (PACIC) [33] | patient interview at baseline |
| age and gender of GP/size and location of surgery | GP interview | |
| Utilization of medical services (incl. medication) | 15 items (short form), respectively 91 items (long form) | patient interview |
| Sociodemographic Data | ||
| Age and gender | age and gender | chart review |
| Migrant status | standardised indicators for mapping migrant status [34] | patient interview at baseline |
| Marital status | marital status | patient interview |
| Living conditions | independent or assisted living | patient interview |
| Household size | household size/household members under 15 years | patient interview |
| Education | CASMIN classification [35] | patient interview at baseline |
| Former occupation | German epidemiological standard questionnaire [36] | patient interview at baseline |
| Income | household size adjusted net income | patient interview |
| Wealth | home ownership | patient interview |
| ß | SE (ß) | Stand. ß | T | p | |
| Annual fastest men | |||||
| 6 hrs | 0.015 | 0.130 | 0.023 | 0.114 | 0.910 |
| 12 hrs | -0.023 | 0.155 | -0.029 | -0.151 | 0.881 |
| 24 hrs | 0.193 | 0.118 | 0.275 | 1.642 | 0.110 |
| 48 hrs | 0.184 | 0.147 | 0.229 | 1.248 | 0.223 |
| 72 hrs | 0.084 | 0.222 | 0.084 | 0.377 | 0.710 |
| 6 d | 0.039 | 0.154 | 0.047 | 0.252 | 0.803 |
| 10 d | 0.296 | 0.432 | 0.194 | 0.686 | 0.506 |
| Annual fastest women | |||||
| 6 hrs | 0.033 | 0.182 | 0.041 | 0.183 | 0.856 |
| 12 hrs | 0.330 | 0.126 | 0.450 | 2.617 | 0.014* |
| 24 hrs | -0.058 | 0.124 | -0.086 | -0.465 | 0.645 |
| 48 hrs | 0.249 | 0.140 | 0.318 | 1.775 | 0.087 |
| 72 hrs | 0.136 | 0.316 | 0.107 | 0.430 | 0.673 |
| 6 d | 0.385 | 0.083 | 0.666 | 4.640 | <0.0001* |
| 10 d | -0.067 | 0.401 | -0.048 | -0.166 | 0.871 |
| Male | Female | Age < 55 years | Age ≥ 55 years | OA | RA | THR | TKR | |
| Core domains | ||||||||
| Joint pain | 8 (7–9) | 9 (8–9) | 9 (7–9) | 9 (8–9) | 9 (8–9) | 9 (7–9) | 9 (8–9) | 9 (7–9) |
| *** | ** | |||||||
| Function | 9 (8–9) | 9 (8–9) | 9 (8–9) | 9 (8–9) | 9 (8–9) | 9 (8–9) | 9 (8–9) | 9 (8–9) |
| *** | * | * | ||||||
| Patient satisfaction | 8 (8–9) | 9 (8–9) | 9 (8–9) | 9 (8–9) | 9 (8–9) | 8 (8–9) | 9 (8–9) | 8 (8–9) |
| *** | *** | |||||||
| Revision surgery | 7 (4–9) | 8 (5–9) | 7 (5–9) | 8 (5–9) | 8 (5–9) | 7 (5–9) | 8 (5–9) | 7 (5–9) |
| *** | ||||||||
| Adverse events | 8 (6–9) | 9 (7–9) | 8 (7–9) | 8 (7–9) | 8 (7–9) | 8 (5–9) | 8 (7–9) | 8 (6–9) |
| *** | ||||||||
| Death | 9 (5–9) | 9 (6–9) | 9 (6–9) | 9 (6–9) | 9 (6–9) | 8 (6–9) | 9 (7–9) | 9 (5–9) |
| *** | * | |||||||
| Additional domains | ||||||||
| Cost | 7 (5–8) | 7 (5–9) | 7 (5–8) | 7 (5–8) | 7 (5–8) | 7 (5–9) | 7 (5–8) | 7 (5–8) |
| *** | * | |||||||
| Patient participation | 7 (6–9) | 8 (7–9) | 8 (6–9) | 8 (6–9) | 8 (6–9) | 8 (7–9) | 8 (6–9) | 8 (6–9) |
| *** |
| No. households without bed nets (%, 95 % CI) | No. households with untreated bed nets (%, 95 % CI) | No. households with expired ITNs/LLINs (%, 95 % CI) | No. households with ITNs/LLINs (%, 95 % CI) | |
| Sex of household head | ||||
| Male (n = 144) | 1 (0.7, 0–3.8) | 59 (41, 32.9–49.5) | 36 (25, 18.2-32.9) | 126 (87.5, 81–92.4) |
| Female (n = 524) | 1 (0.2, 0–1.1) | 185 (35.3, 31.2–39.6) | 20 (3.8, 2.3–5.8) | 477 (91, 88.3–93.3) |
| x2 value | - | 1.56 | 66.0 | 1.60 |
| P-value | - | 0.2110 | <0.0001 | 0.2054 |
| Age of household head (years) | ||||
| <35 (n = 233) | 0 (0, 0–1.6) | 89 (38.2, 31.9–44.8) | 34 (14.6, 10.3–19.8) | 208 (89.3, 84.6–92.9) |
| ≥35 (n = 435) | 2 (0.5, 0.06–1.7) | 155 (35.6, 31.1–40.3) | 22 (5.1, 3.2–7.6) | 395 (90.8, 87.7–93.3) |
| x2 value | - | 0.43 | 17.96 | 0.41 |
| P-value | - | 0.5117 | 0.00002 | 0.5237 |
| Ethnics | ||||
| Kachin (n = 610) | 2 (0.3, 0.04–1.2) | 303 (49.7, 45.6–53.7) | 54 (8.9, 6.7–11.4) | 556 (91.1, 88.6–93.3) |
| Othersa (n = 58) | 0 (0, 0–6.1) | 24 (41.4, 28.6–55.1) | 2 (3.4, 0.4–11.9) | 47 (81.0, 68.6–90.1) |
| x2 value | - | 1.46 | 1.37 | 6.17 |
| P-value | - | 0.2273 | 0.2415 | 0.0130 |
| School education years | ||||
| Illiterate (n = 144) | 0 (0, 0–2.5) | 52 (36.1, 28.3–44.5) | 1 (0.7, 0–3.8) | 126 (87.5, 81–92.4) |
| 1–3y (n = 129) | 1 (0.8, 0.02–4.2) | 49 (38, 29.6–46.9) | 2 (1.6, 0.2–5.5) | 120 (93, 87.2–96.8) |
| 4–6y (n = 225) | 0 (0, 0–1.6) | 75 (33.3, 27.2–39.9) | 40 (17.8, 13–23.4) | 216 (96, 92.5–98.2) |
| 7–9y (n = 117) | 1 (0.9, 0.02–4.7) | 42 (35.9, 27.2–45.3) | 13 (11.1, 16.1–18.3) | 106 (90.6, 83.8–95.2) |
| ≥10y (n = 53) | 0 (0, 0–6.7) | 26 (49.1, 35.1-63.2) | 0 (0, 0–6.7) | 35 (66, 51.7–78.5) |
| x2 value | 3.45 | 4.73 | 50.76 | 46.23 |
| P-value | 0.4849 | 0.3164 | <0.0001 | <0.0001 |
| Family wealth index | ||||
| 1 Most poor (n = 498) | 1 (0.2, 0–1.1) | 175 (35.1, 30.9–39.5) | 28 (5.6, 3.8–8) | 467 (93.8, 91.3–95.7) |
| 2 (n = 116) | 0 (0, 0–3.1) | 51 (44, 34.8–53.5) | 27 (23.3, 15.9–32) | 113 (97.4, 92.6–99.5) |
| 3 (n = 24) | 1 (4.2, 0.1–21.1) | 10 (41.7, 22.1–64.4) | 1 (4.2, 0.1–21.1) | 17 (70.8, 48.9–87.4) |
| 4 (n = 10) | 0 (0, 0–60.2) | 8 (80, 44.4–97.4) | 0 (0, 0–60.2) | 6 (60, 26.2–87.8) |
| 5 Least poor (n = 0) | 0 | 0 | 0 | 0 |
| x2 value | 12.19 | 11.11 | 38.77 | 39.06 |
| P-value | 0.0068 | 0.0111 | <0.0001 | <0.0001 |
| Geographical zone | ||||
| Lowland (n = 226) | 0 (0, 0–1.6) | 102 (45.1, 38.5–51.9) | 6 (2.7, 1.0–5.7) | 202 (89.4, 84.6–93.1) |
| Foothill (n = 299) | 0 (0, 0–1.2) | 94 (31.4, 26.2–37.0) | 11 (3.7, 1.9–6.5) | 262 (87.6, 83.3–91.1) |
| Mid hill (n = 18) | 1 (5.6, 0.1–27.3) | 6 (33.3, 13.3–59.0) | 8 (44.4, 21.5–69.2) | 18 (100.0, 81.5–100.0) |
| Upper hill (n = 125) | 1 (0.8, 0.02–4.4) | 42 (33.6, 25.4–42.6) | 31 (24.8, 17.5–33.3) | 121 (96.8, 92.1–99.2) |
| x2 value | 19.29 | 11.10 | 92.01 | 10.59 |
| P-value | 0.0002 | 0.0112 | <0.0001 | 0.0141 |
| Total (n = 668) | 2 (0.3, 0.04–1.1) | 244 (36.5, 32.9–40.3) | 56 (8.4, 6.4–10.7) | 603 (90.2, 87.8–92.4) |
| Noise receiving point | Noise at boundary of substation | |||
| Plan A | Plan B | Plan C | Plan D | |
| Point 1 | 62.1 | 62 | 48.5 | 47 |
| Point 2 | 57.5 | 53.5 | 55.5 | 41.9 |
| Point 3 | 54.1 | 52.7 | 49 | 38.8 |
| Point 4 | 56.1 | 55.9 | 45.1 | 41.1 |
| Point 5 | 52.2 | 51.9 | 41.5 | 37.2 |
| Point 6 | 51.7 | 51.5 | 40.3 | 36.7 |
| Point 7 | 55.3 | 55.3 | 41 | 40.3 |
| Point 8 | 55.7 | 55.5 | 45.3 | 40.7 |
| Point 9 | 54 | 53.1 | 47.4 | 38.8 |
| Point 10 | 53.8 | 48.9 | 52.4 | 38.2 |
| Point 11 | 53.8 | 48.8 | 52.3 | 38.1 |
| Point 12 | 52.3 | 52.1 | 40.4 | 37.2 |
| Point 13 | 53.6 | 53.4 | 43.2 | 38.6 |
| Point 14 | 51.3 | 51 | 40.2 | 36.2 |
| Point 15 | 50.9 | 50.8 | 38.7 | 35.9 |
| Point 16 | 52.4 | 52.4 | 38.6 | 37.4 |
| Characteristics | Awareness (n) | x2 | P – value | Percentage % |
| Sex | ||||
| Male | 51 | 1.03 | 0.31 | 43.2 |
| Female | 67 | 56.8 | ||
| Age | ||||
| 18–29 | 8 | 6.8 | ||
| 30–39 | 22 | 18.6 | ||
| 40–49 | 42 | 31.58 | p < 0.0001 | 35.6 |
| 50–59 | 20 | 16.9 | ||
| 60–69 | 10 | 22.0 | ||
| Total | 118 | 100 | ||
| Religious affiliation | ||||
| Christian | 109 | 92.4 | ||
| Muslim | 9 | 0.12 | 0.73 | 7.6 |
| Total | 118 | 100 | ||
| Educational status | ||||
| None | 21 | 17.8 | ||
| Primary | 35 | 29.7 | ||
| Junior High School | 50 | 20.37 | p < 0.0001 | 42.4 |
| Senior High School | 10 | 8.5 | ||
| Tertiary level | 2 | 1.7 | ||
| Total | 118 | 100 |
| Causes of deatha | All patients (n = 345) | Patients with primary GF (n = 22) | Patients without primary GF (n = 323) |
| Relapse | 18 (5.2 %) | 1 (4.5 %) | 17 (5.3 %) |
| Infections | 27 (7.8 %) | 8 (36.4 %) | 19 (5.9 %) |
| Hemorrhage | 7 (2.0 %) | 3 (13.6 %) | 4 (1.2 %) |
| GVHD | 3 (0.9 %) | 0 (0 %) | 3 (0.9 %) |
| Others | 8 (2.4 %) | 1 (4.5 %) | 7 (2.1 %) |
| Primer (F: forward, R: reverse) | Sequence (5′–3′) | Product size (base pairs) | Description |
| fimA-F | CTAAATCCGCCGATCAAA | 193 | Type-1 fimbrial gene |
| fimA-R | GAGGAGACAGCCAGCAAA | 193 | Type-1 fimbrial gene |
| fimZ-F | GACGAACACCCTATTGTAAGA | 202 | Type-1 fimbrial gene |
| fimZ-R | GTTCCTGGATAGATTTGATTC | 202 | Type-1 fimbrial gene |
| flhD-F | GCATACATCCGAGTTGCTAA | 237 | Flagellar gene |
| flhD-R | TGAGTCAAACGGGTGATC | 237 | Flagellar gene |
| fliZ-F | GGAATATGTCGTGCGTTTA | 221 | Flagellar gene |
| fliZ-R | TATCAGAACTGGCGGTAAA | 221 | Flagellar gene |
| invF-F | TGAGAATGCTGGGAGAAGAC | 194 | SPI-1 gene |
| invF-R | AAAATGTGAAGGCGATGAGT | 194 | SPI-1 gene |
| sseB-F | AACGTGCCAGAAATACCCAG | 199 | SPI-2 gene |
| sseB-R | CCTTTATCCAGCTTCCCATG | 199 | SPI-2 gene |
| 16S-F | TTCCTCCAGATCTCTACGCA | 552 | Housekeeping gene 16S |
| 16S-R | GTGGCTAATACCGCATAACG | 552 | Housekeeping gene 16S |
| Stages | R1 | R2 | R3 | R4 | R5 | R6 | R7 |
| Pre-processing of each view (normal calculation, format conversion, etc.) | 5 m | 4m30s | 4m | 3m30s | 3m | 2m30s | 2m |
| Definition of the ortho-image from the 3D model | 2m | 1m47s | 1m35s | 1m23s | 1m13s | 1m2s | 45s |
| Definition of corresponding pairs between the model and the external image | 3m | 3m10s | 3m20s | 3m30s | 3m45s | 4m5s | 5m |
| New colour modification/assignation | 1m | 56s | 50s | 43s | 35s | 31s | 23s |
| Filling of colour-holes | 10m | 9m6s | 8m10s | 7m15s | 6m25s | 5m30s | 4m |
| Merging of colour with the whole coloured model | 3m | 2m40s | 2m20s | 2m | 1m49s | 1m36s | 1m10s |
| Virus | EV71 | CV-A16 | CV-A6 | EV71and CV-A16 co-infection | Untyped EV | |||||||||||||||||
| V-P | P | Cons ratio (%) | M | F | P | Cons ratio (%) | M | F | P | Cons ratio (%) | M | F | P | Cons ratio (%) | M | F | P | Cons ratio (%) | M | F | ||
| Age year | 0- | 219 | 69 | 5.39 | 43 | 26 | 46 | 4.24 | 33 | 13 | 39 | 7.47 | 28 | 11 | 7 | 8.54 | 5 | 2 | 58 | 10.07 | 34 | 24 |
| 1- | 718 | 264 | 20.61 | 176 | 88 | 150 | 13.81 | 95 | 55 | 173 | 33.14 | 103 | 70 | 17 | 20.73 | 9 | 8 | 114 | 19.79 | 75 | 39 | |
| 2- | 714 | 270 | 21.08 | 173 | 97 | 208 | 19.15 | 123 | 85 | 115 | 22.03 | 70 | 45 | 19 | 23.17 | 13 | 6 | 102 | 17.71 | 59 | 43 | |
| 3- | 1063 | 376 | 29.35 | 245 | 131 | 376 | 34.62 | 229 | 147 | 117 | 22.41 | 74 | 43 | 27 | 32.93 | 15 | 12 | 167 | 28.99 | 101 | 66 | |
| 4- | 504 | 177 | 13.82 | 113 | 64 | 192 | 17.68 | 127 | 65 | 48 | 9.20 | 33 | 15 | 9 | 10.98 | 7 | 2 | 78 | 13.54 | 41 | 37 | |
| 5- | 163 | 64 | 5.00 | 37 | 27 | 61 | 5.62 | 40 | 21 | 13 | 2.49 | 11 | 2 | 1 | 1.22 | 0 | 1 | 24 | 4.17 | 15 | 9 | |
| ≥6 | 166 | 61 | 4.76 | 33 | 28 | 53 | 4.88 | 30 | 23 | 17 | 3.26 | 11 | 6 | 2 | 2.44 | 0 | 2 | 33 | 5.73 | 23 | 10 | |
| Total | 3547 | 1281 | 36.12 | 820 | 461 | 1086 | 30.62 | 677 | 409 | 522 | 14.72 | 330 | 192 | 82 | 2.31 | 49 | 33 | 576 | 16.24 | 348 | 228 | |
| Ratio (M/F) | 1.78 | 1.66 | 1.72 | 1.48 | 1.53 |
| Allocation concealment methods | Number of trials (%) |
| Unclear/not reported | 282 (71.76) |
| Central concealment | 21 (5.34) |
| Sequentially numbered, opaque and sealed envelopes | 24 (6.11) |
| Unsafe envelopes | 15 (3.82) |
| Non-safe methods of allocation | 51 (12.98) |
| Total | 393 (100) |
| Caffeine source | Birth weight (Marsal) | Birth weight (Skjaerven) | Birth weight (Gardosi) | ||||||
| β (g) | 95% CI | P valuea | β (g) | 95% CI | P valuea | β (g) | 95% CI | P valuea | |
| Unadjusted: | |||||||||
| Total | -28 | -32 to-25 | <10-48 | -27 | -31 to-23 | <10-44 | -12 | -16 to-9 | <10-10 |
| Coffee, all types | -25 | -29 to-21 | <10-30 | -22 | -26 to-18 | <10-24 | -15 | -19 to-11 | <10-12 |
| Caffeinated soft drinksb | -11 | -24 to 1 | 0.08 | -19 | -32 to-6 | 0.005 | -18 | -30 to-5 | 0.006 |
| Black tea | -53 | -65 to-41 | <10-18 | -53 | -65 to-42 | <10-18 | -3 | -15 to 8 | 0.5 |
| Chocolate | -164 | -222 to-106 | <10-7 | -196 | -254 to-138 | <10-10 | 159 | 103 to 215 | <10-7 |
| Adjusted: | |||||||||
| Total | -28 | -32 to-24 | <10-43 | -25 | -29 to-21 | <10-34 | -21 | -24 to-17 | <10-25 |
| Coffee, all types | -24 | -28 to-19 | <10-26 | -20 | -24 to-15 | <10-18 | -19 | -24 to-15 | <10-19 |
| Caffeinated soft drinksb | -34 | -47 to-22 | <10-7 | -38 | -50 to-25 | <10-8 | -23 | -35 to-11 | <3 × 10-4 |
| Black tea | -50 | -61 to-39 | <10-17 | -48 | -59 to-36 | <10-15 | -29 | -40 to-18 | <10-6 |
| Chocolate | -129 | -188 to-70 | <10-4 | -133 | -192 to-73 | <10-4 | -4 | -62 to 53 | 0.9 |
| Group division (n) | Mean alpha angle ± SD |
| Semiprofessional group (14) | 55.16 ± 6.58° |
| Amateur group (14) | 51.65 ± 4.43° |
| P value | 0.11 |
| Characteristics/Outcome | Group I | Group II | Group I and II |
| 600/750 mg ≥30 kg | 300/375 mg 15 – 30 kg | All Participants | |
| Number enrolled | 208 | 238 | 446 |
| Number completed | 203 | 228 | 431 |
| Withdrawal/loss to follow up | 5(2.5%) | 10(4.45) | 15(3.5%) |
| Adequate Clinical and Parasitological Response (ACPR) | |||
| Day 28* | 202(99.5%) | 222(97.4%) | 424(97.45%) |
| Parasite Clearance Time | 40.1 hrs | 42.4 hrs | 41.3 |
| USDA | F009 | G002 | W106 | |
| USDA | 185 | 183 | 51 | |
| F009 | 24 | 203 | 184 | |
| G002 | 51 | 45 | 176 | |
| W106 | 16 | 28 | 49 |
| GS Method | F/B | S/F | K/F | M/F | O/P | O/DM | Mean |
| RR-BLUP | 0.28 | 0.25 | 0.17 | 0.14 | 0.17 | 0.14 | 0.19 |
| BA | 0.29 | 0.24 | 0.19 | 0.15 | 0.17 | 0.17 | 0.20 |
| BB | 0.29 | 0.24 | 0.21 | 0.14 | 0.16 | 0.16 | 0.20 |
| BC | 0.29 | 0.23 | 0.20 | 0.14 | 0.18 | 0.18 | 0.20 |
| BL | 0.28 | 0.24 | 0.17 | 0.14 | 0.17 | 0.16 | 0.19 |
| BRR | 0.29 | 0.23 | 0.18 | 0.13 | 0.18 | 0.19 | 0.20 |
| SVM | 0.30 | 0.30 | 0.14 | 0.22 | 0.28 | 0.22 | 0.24 |
| RF | 0.19 | 0.25 | 0.24 | 0.34 | 0.14 | 0.28 | 0.24 |
| Mean | 0.28 | 0.25 | 0.19 | 0.18 | 0.18 | 0.19 |
| HAS2 | ZEISS Objective | ||
| Parameter | Value | Parameter | Value |
| Overall dimensions | 30 mm × 30 mm | f | 85 mm |
| Image sensor format | 1024 × 1024 pixels | F/# | 1.4 |
| Pixel size | 18 μm | Diameter | 60.7 mm |
| ADC resolution | 12 bit | Image diameter | 43 mm |
| Saturation voltage output | 1.49 V | FOV | 12.42 deg |
| Full well capacity | 105 e | Pixel scale | 44.15 arcsec/pix |
| Quantum Efficiency | 45% (500–650 nm) | ||
| Spectral response | 33.3% (400–900 nm ) | ||
| Conversion factor | 14.8 μV/e | ||
| Dark current | 12.5 e/pix/s | ||
| RON | 2 e/pix |
| Outcome measures | Baseline (n = 15) | Post-trial (n = 15) | P value |
| CWIT | |||
| Color naming | 48.35 ± 18.86 | 52.35 ± 22.57 | 0.0999 |
| Word reading | 34.00 ± 10.97 | 35.35 ± 9.77 | 0.3249 |
| Inhibition | 91.00 ± 39.25 | 93.57 ± 41.39 | 0.4525 |
| TMT | |||
| Visual scanning | 38.76 ± 15.76 | 43.52 ± 15.98 | 0.1149 |
| Number sequencing | 55.73 ± 19.87 | 61.80 ± 23.49 | 0.0507 |
| Letter sequencing | 61.92 ± 34.05 | 66.21 ± 30.77 | 0.1262 |
| Motor speed | 58.75 ± 27.39 | 62.31 ± 25.90 | 0.2433 |
| HVLT-R | |||
| Free recall | 17.66 ± 5.56 | 16.73 ± 6.21 | 0.2019 |
| Delayed recall | 4.92 ± 2.36 | 6.28 ± 3.14 | 0.0130* |
| Retention | 76.16 ± 29.21 | 81.22 ± 27.32 | 0.1866 |
| Recognition | 8.06 ± 3.08 | 8.93 ± 2.34 | 0.0793 |
| SDMT | |||
| Correct written | 27.00 ± 10.25 | 26.78 ± 9.96 | 0.4525 |
| Correct oral | 31.00 ± 14.17 | 28.46 ± 15.59 | 0.1374 |
| ANOVA | ||||||
| Source of variation | SS | df | MS | F | P value | F crit |
| Effect of biofilm type* | 0.7377 | 1 | 0.7377 | 0.1692 | 0.6837 | 4.170877 |
| Effect of bracket | 7.9896 | 2 | 3.9948 | 0.9164 | 0.4109 | 3.31583 |
| Interaction | 2.1777 | 2 | 1.0888 | 0.2498 | 0.7806 | 3.31583 |
| Within | 130.7769 | 30 | 4.3592 | |||
| Total | 141.6819 | 35 |
| Early-onset Disease (n = 22) | Late-onset Disease (n = 46) | Totala(n = 68) | |
| Sex (female/male) | 6/16 | 25/21 | 31/37 |
| Bacterial isolation site | |||
| Blood | 20 (90.9%) | 28 (60.9%) | 48 (70.6%) |
| CSFb | 2 (9.1%) | 18 (39.1%) | 20 (29.4%) |
| Serotypec | |||
| Ia | 1 (4.5%) | 1 (2.2%) | 2 (2.9%) |
| Ib | 5 (22.7) | 5 (10.9%) | 10 (14.7%) |
| III | 15 (68.2%) | 38 (82.6%) | 53 (77.9%) |
| V | 1 (4.5%) | 2 (4.3%) | 3 (4.4%) |
| Session | Depression-specific topics | Diabetes-specific topics added |
| 1 | Psychoeducation | Connection diabetes and depression |
| 2 | Behavioural activation | Worrying about diabetes-related complications |
| 3 | Problem solving I | Diabetes and relationship/sexuality |
| 4 | Problem solving II | Rumination about diabetes |
| 5 | Behavioural activation, focus on physical activity and self-esteem | Physical activity and diabetes |
| 6 | Plan for the future | Conversation with a general practitioner |
| Additional components | ||
| Session | Depression-specific topics | Diabetes-specific topics added |
| 7 | Overweight/obesity | Diabetes and nutrition |
| 8 | Insomnia | --- |
| Session | Depression-specific topics | Diabetes-specific topics added |
| Booster | Summary: Behavioural activation; Problem solving | Choice of the known topics (1-6) |
| Applied in specialty | Auditioned in specialty | % matched at audition (n) | |
| Radiation oncology | 5 | 5 | 80 (4) |
| PM&R | 6 | 5 | 60 (3) |
| Orthopedics | 33 | 31 | 58 (18) |
| Plastic surgery | 7 | 7 | 57 (4) |
| Pediatrics | 120 | 65 | 49 (32) |
| Psychiatry | 35 | 16 | 44 (7) |
| Anesthesia | 47 | 17 | 41 (7) |
| Med/peds | 12 | 5 | 40 (2) |
| Internal medicine | 150 | 69 | 39 (27) |
| Neurosurgery | 6 | 6 | 33 (2) |
| Urology | 11 | 11 | 36 (4) |
| Emergency medicine | 59 | 56 | 32 (18) |
| Ophthalmology | 19 | 17 | 35 (6) |
| Otolaryngology | 14 | 12 | 33 (4) |
| Neurology | 15 | 10 | 30 (3) |
| Family medicine | 50 | 24 | 29 (7) |
| Radiology | 46 | 28 | 28 (8) |
| OB/GYN | 41 | 30 | 23 (7) |
| Dermatology | 20 | 18 | 17 (3) |
| General surgery | 44 | 33 | 3 (1) |
| Pathology | 9 | 5 | 0 |
| Prelim medicine only | 3 | 0 | 0 |
| Total CAS Score | Rating of Intervention Effectiveness | Total No. Studies with each CAS Score | ||
| 0 | 0.5 | 1 | ||
| 0 | 1 | 0 | 0 | 1 |
| 1 | 1 | 1 | 0 | 2 |
| 2 | 1 | 3 | 0 | 4 |
| 3 | 0 | 7 | 11 | 18 |
| 4 | 0 | 1 | 6 | 7 |
| Total No. Studies at each Level of Effectiveness | 3 | 12 | 17 | 32 |
| Characteristics | Number of patients | % |
| Total analyzed | 149 | |
| Sex | ||
| Males | 59 | 40 |
| Females | 90 | 60 |
| Median Age (years) | 48 | |
| Range | 16–85 | |
| AJCC stage | ||
| IA | 50 | 33 |
| IB | 22 | 15 |
| IIA | 36 | 24 |
| IIB | 12 | 8 |
| IIC | 1 | 1 |
| III | 28 | 19 |
| Primary site | ||
| Head and Neck | 13 | 9 |
| Superior limbs | 23 | 15 |
| Inferior limbs | 47 | 32 |
| Trunk | 63 | 42 |
| Unknown | 3 | 2 |
| Laboratory tests | result | Normal range |
| K | 5.2 | 3.4–5.3 mmol /L |
| Na | 137 | 137–147 mmol /L |
| Cl | 102 | 99–108 mmol /L |
| Ca | 9.5 | 8.7–10.7 mg /dL |
| Lactate | 4 | 0.9–1.8 mmol /L |
| Ammonia | 150 | 25-80 mmol /L |
| FBS | 85 | 60–99 mg /dL |
| BUN | 7 | 5–18 mg /dL |
| Cr | 0.7 | 0.75–1.20 mg /dL |
| Characteristics | Females (number) | Age (years) | Duration of symptoms (months) | Symptoms preceeding malignancy (number) | Malignancy | |
| All tumors (number) | Lung cancer (number) | |||||
| All patients | 11/18 | 61 (48–76) | 4 (1–36) | 15/18 | 16/18 | 14/18 |
| Peripheral neuropathy | 5/8 | 59 (54–76) | 3 (1–36) | 7/8 | 7/8 | 5/8 |
| Encephalitis | 6/10 | 61 (48–74) | 4 (1–15) | 8/10 | 9/10 | 9/10 |
| Rhombencephalitis | 3/7 | 61 (48–73) | 13 (3–15) | 6/7 | 6/7 | 6/7 |
| Limbic encephalitis | 3/3 | 55, 61, 74 | 1, 3, 4 | 2/3 | 3/3 | 3/3 |
| p value | 1.0 | 0.6 | 0.5 | 1.0 | 1.0 | 0.3 |
| Attribute | Value | % of Total |
| Genome size (bp) | 3,086,721 | 100.00 |
| DNA coding (bp) | 2,284,152 | 74.00 |
| DNA G+C (bp) | 2,147,191 | 69.56 |
| DNA scaffolds | 109 | |
| Total genes | 2,422 | 100.00 |
| Protein coding genes | 2,363 | 97.56 |
| RNA genes | 50 | 2.06 |
| Pseudo genes | 9 | 0.37 |
| Genes in internal clusters | 811 | 34.32 |
| Genes with function prediction | 1633 | 67.42 |
| Genes assigned to COGs | 1858 | 76.71 |
| Genes with Pfam domains | 2038 | 84.14 |
| Genes with signal peptides | 539 | 22.81 |
| Genes with transmembrane helices | 527 | 22.25 |
| CRISPR repeats | 1 | 0.41 |
| Dependent variable in all regressions: IHD mortality | Adjusting for Beef Consumption | Adjusting for Coconut Oil Consumption | Adjusting for Milk Consumption | Adjusting for Butter Consumption | Adjusting for Cheese Consumption | Adjusting for Pork Consumption | Adjusting for Chicken Consumption |
| Palm oil consumption (kg per-capita) | 18.9 | 3.3 | -3.4 | -1.2 | 1.7 | 19 | 19 |
| [7.7 - 30] | [-1.4 - 7.9] | [-39 - 32] | [-43 - 41] | [-40 - 43] | [8.0 - 30] | [8.4 - 30] | |
| Additional effect of palm oil in developing countries (kg per-capita) | 52 | 149 | 70 | 59 | 65 | 41 | 72 |
| [26 - 78] | [93 - 205] | [19 - 120] | [-58 - 175] | [-58 - 188] | [10 - 72] | [18 - 126] | |
| Cigarette consumption (pieces per-capita) | -0.00 | 0.26 | 0.01 | 0.05 | 0.07 | -0.03 | 0.11 |
| [-0.29 - 0.29] | [0.15 - 0.37] | [-0.18 - 0.21] | [-0.20 - 0.29] | [-0.15 - 0.28] | [-0.23 - 0.18] | [-0.26 - 0.48] | |
| Log per-capita GDP (%) | -2,259 | -728 | -2,262 | -2,116 | -2,469 | -2,370 | -2,191 |
| [-3,201 - -1,317] | [-1,061 - -395] | [-2,830 - -1,695] | [-2,851 - -1,381] | [-3,160 - -1,779] | [-3,271 - -1,469] | [-3,002 - -1,381] | |
| 1980s (compared to 1990s) | -176 | 6.7 | -171 | -133 | -152 | -162 | -154 |
| [-348 - -4.7] | [-68 - 82] | [-341 - -1.2] | [-304 - 38] | [-328 - 23] | [-353 - 28] | [-425 - 118] | |
| Beef consumption (kg per-capita) | 6.6 | ||||||
| [-17 - 30] | |||||||
| Coconut oil consumption (kg per-capita) | 21 | ||||||
| [-35 - 77] | |||||||
| Milk consumption (kg per-capita) | 4.8 | ||||||
| [-0.7 - 10] | |||||||
| Butter consumption (kg per-capita) | -50 | ||||||
| [-119 - 19] | |||||||
| Cheese consumption (kg per-capita) | 32 | ||||||
| [-15 - 79] | |||||||
| Pork consumption (kg per-capita) | 9.6 | ||||||
| [-10 - 29] | |||||||
| Chicken consumption (kg per-capita) | 6.3 | ||||||
| [-30 - 43] | |||||||
| Constant | 23,221 | 7,942 | 23,066 | 22,180 | 25,213 | 24,411 | 22,299 |
| [13,631 - 32,811] | [4,505 - 11,379] | [17,424 - 28,708] | [14,900 - 29,460] | [18,243 - 32,183] | [15,454 - 33,368] | [13,483 - 31,115] | |
| Observations | 217 | 153 | 181 | 177 | 177 | 209 | 202 |
| R-squared | 0.60 | 0.89 | 0.70 | 0.64 | 0.64 | 0.61 | 0.59 |
| Number of countries | 22 | 13 | 20 | 19 | 19 | 21 | 20 |
| PE patients | DVT patients | |
| (n=305) | (n=138) | |
| Fatal pulmonary embolism | 76 (24.9%) | 6 (4.3%) |
| Respiratory insufficiency | 55 (18.0%) | 22 (15.9%) |
| Neoplasia | 44 (14.4%) | 37 (26.8%) |
| Infection | 32 (10.5%) | 14 (10.1%) |
| Fatal bleeding | 17 (5.6%) | 8 (5.8%) |
| Heart failure | 10 (3.3%) | 6 (4.4%) |
| Sudden death | 6 (2.0%) | 6 (4.4%) |
| Multi-organ failure | 6 (2.0%) | 5 (3.6%) |
| Myocardial infarction | 5 (1.6%) | 2 (1.5%) |
| Bowel occlusion | 3 (1.0%) | 1 (0.7%) |
| Liver insufficiency | 2 (0.7%) | 1 (0.7%) |
| Stroke | 1 (0.3%) | 2 (1.4%) |
| Terminal renal insufficiency | 1 (0.3%) | 2 (1.4%) |
| Critical limb ischemia | 1 (0.3%) | 0 |
| Other | 11 (3.6%) | 2 (1.5%)0 |
| Unknown | 35 (11.5%) | 24 (17.4%) |
| Characteristics | n | % |
| Age (y) | ||
| ≤35 | 110 | 10.7 |
| 36–50 | 527 | 51.1 |
| >50 | 395 | 38.3 |
| cT stage | ||
| T1 | 575 | 55.7 |
| T2 | 398 | 38.5 |
| Tx | 59 | 5.7 |
| pT stage | ||
| T1 | 658 | 63.8 |
| T2 | 271 | 26.2 |
| Tx | 103 | 10.0 |
| pN stage | ||
| N0 | 736 | 71.3 |
| N1 | 209 | 20.3 |
| N2 | 50 | 4.8 |
| N3 | 30 | 3.9 |
| Unknown | 7 | 0.7 |
| Grade | ||
| G1 | 83 | 8.1 |
| G2 | 590 | 57.4 |
| G3 | 354 | 34.5 |
| Menopausal status | ||
| Pre- | 652 | 63.2 |
| Post- | 379 | 36.8 |
| Margin status | ||
| Negative | 823 | 79.7 |
| Carcinoma in situ | 87 | 8.4 |
| Invasive carcinoma | 122 | 11.8 |
| Presence of LVI | 114 | 11.9 |
| Presence of EIC | 102 | 9.9 |
| ER or PR positive | 826 | 80.0 |
| HER-2 positive | 216 | 12.0 |
| Histological subtype | ||
| Invasive ductal carcinoma | 805 | 78.0 |
| Presence of DCIS component | 83 | 8.0 |
| Invasive lobular carcinoma | 29 | 2.8 |
| Other | 115 | 11.2 |
| Breast cancer subtype | ||
| Luminal A | 540 | 52.3 |
| Luminal B | 154 | 14.9 |
| Luminal-HER-2 | 132 | 12.8 |
| HER-2 positive | 84 | 8.1 |
| TN | 122 | 11.8 |
| Perceived general health ('excellent/very good/good' = 1) | |||
| Model 1a | Model 1b | Model 2 | |
| % of green (1 km) | .010 (.003) [p = .002] | .011 (.003) [p = .005] | |
| % of green (3 km) | .006 (.005) [p = .194] | ||
| Time spent on cycling for commuting purposes (minutes) | -.001 (.001) [p = .095] |
| Rice | Arabidopsis | ||||
| Groups | Tissues | Genes | Groups | Tissues | Genes |
| Preferential expression in young vegetative tissues | |||||
| IA | Youngest seedling (w/o root) | CESA5,6; CSLC1,7; CSLD4 | IIIC | Youngest seedling (w/o root) | CESA5; CSLC4; CSLA3,7 |
| IB | Young seedling (w/root) | CESA1,3,8; CSLF6,8; CSLC2; BC1L14 | IIID | Young seedling (w/root) | CESA1,3,6,2; COB |
| Preferential expression in reproductive stages | |||||
| / | / | / | IA | Seed, silique | CESA9,10; COBL2,6 |
| IIA(a) | Hull | CSLF2, 7 | Silique | CSLC5 | |
| IIA(b) | Stem, hull | CESA4,7,9; BC1 | IB | Stem, silique | CESA4,7,8;COBL4 |
| / | / | / | IC | Flowers(sepals) | CSLG2,3; CSLB2 |
| / | / | / | Flowers(Carpels) | CSLG1 | |
| IIB | Flag leaf and sheath | CSLE1; CSLH3; CESA11 | / | / | / |
| IIC | Flag leaf and endosperm | CSLA3,6,11; BC1L9 | / | / | / |
| Preferential expression in tissues undergoing rapid extension | |||||
| / | / | / | IIA | Shoot apex, Cauline leaf, Carpel | CSLD5; CSLC8; CSLA15; COBL1,7 |
| / | / | / | IIB | Flowers (Carpels) | CSLD6; CSLA1,2,10,11 |
| IIIB | Stamen and endosperm | CSLC9,CSLD3,5; CSLH2; BC1L5 | IIC | Stamen (Pollen) | CSLA9; CSLC6,12; CSLD1,4; COBL10,11 |
| IIID | Radicle and root | CSLD1,2; CSLC3; CSLF3; BC1L1 | IIIA, IIIB | Roots | CSLD2,3; CSLA14; CSLB3,4;COBL5,8,9; CSLE1 |
| IIIA | Callus and young panicle | CSLA2,4,7; CSLE2; CSLH1 | / | / | / |
| IIIC | Young panicle | CESA2,9; CSLC10; BC1L2 | / | / | / |
| IIIE | Seed imbibition | CESA1; CSLF9 | - | - | - |
| Classification Algorithm | Acronym |
| Fisher Discriminant Analysis | FDA |
| Fuzzy Min-Max Neural Network | FMMNN |
| Kernel Linear Discriminant Analysis | GK-FDA |
| Kernel Support Vector Machine | GK-SVM |
| Fuzzy C-Means | FCM |
| Target | cyp19a2-1 | vasa-3 | vasa-5 | vtg1-3 |
| effect | -/↑ 164 | ↑ 61.6/- | ↑ 143/- | -/↑ 74.7 |
| PlateliaTM Dengue NS1 Ag-ELISA | Sensitivity(95% CI) | p-value | ||
| Overall sensitivity | Non-dissociated | 47.8(39.3 – 56.4) | p < 0.001 | |
| Heat dissociated | 57.7(49.5 – 65.5) | |||
| Type of infection | Primary | Non-dissociated | 80.9(58.1 – 94.6) | p < 0.001 |
| Heat dissociated | 84.6(65.1 – 95.6) | |||
| Secondary | Non-dissociated | 42.0(33.0 – 51.4) | p < 0.001 | |
| Heat dissociated | 52.3(43.3 – 61.1) |
| Assemblathon metrics | RJ | SGA | Edena | LEAP |
| Number of contigs | 120712 | 231594 | 120462 | 113428 |
| Genome size (bp) | 34894545 | 34894545 | 34894545 | 34894545 |
| Total contigs length | 45667531 | 55880641 | 44737441 | 43099113 |
| - as% of genome | 130.87 | 160.14 | 128.21 | 123.51 |
| Mean contig size | 378.32 | 241.29 | 371.38 | 379.97 |
| Median contig size | 132 | 101 | 120 | 117 |
| Longest contig | 41352 | 41352 | 41352 | 39379 |
| Shortest contig | 102 | 100 | 100 | 101 |
| Contigs > 500 bp | 13467 (11.16%) | 13416 (5.79%) | 13439 (11.16%) | 13430 (11.84%) |
| Contigs > 1 Kbp | 8700 (7.21%) | 8684 (3.75%) | 8696 (7.22%) | 8578 (7.56%) |
| Contigs > 10 Kbp | 264 (0.22%) | 264 (0.11%) | 264 (0.22%) | 228 (0.20%) |
| N50 | 1614 | 815 | 1699 | 1617 |
| L50 | 5684 | 10118 | 5416 | 5488 |
| NG50 | 2737 | 2739 | 2733 | 2461 |
| LG50 | 3120 | 3113 | 3121 | 3429 |
| Plantagora metrics | RJ | SGA | Edena | LEAP |
| Covered Bases | 34343945 | 34357693 | 34300114 | 12968118 |
| Ambiguous Bases | 159997 | 154584 | 182952 | 696334 |
| Misassemblies | 4 | 4 | 4 | 3693 |
| Misassembled Contigs | 4 | 4 | 4 | 2344 |
| Misassembled Contig Bases | 1283 | 417 | 1245 | 2797710 |
| SNPs | 104 | 125 | 120 | 46270 |
| Insertions | 5 | 2 | 1 | 2403 |
| Deletions | 43 | 23 | 28 | 5187 |
| Positive Gaps | 2679 | 2471 | 2925 | 26495 |
| Internal Gaps | 0 | 0 | 0 | 21 |
| External Gaps | 2679 | 2471 | 2925 | 26474 |
| - total length | 547408 | 558921 | 589979 | 19064103 |
| - average length | 204 | 226 | 202 | 720 |
| Negative Gaps | 110888 | 218908 | 110811 | 18198 |
| Internal Overlaps | 0 | 0 | 0 | 17 |
| External Overlaps | 110888 | 218908 | 110811 | 18181 |
| - total length | −10247647 | −20078971 | −9424823 | −1859835 |
| - average length | −92 | −92 | −85 | −102 |
| Redundant Contigs | 864 | 1158 | 607 | 6329 |
| Unaligned Contigs | 3262 | 4686 | 3221 | 60563 |
| - partial | 18 | 57 | 21 | 3252 |
| - total length | 462668 | 599320 | 447922 | 27666823 |
| Ambiguous Contigs | 2631 | 3876 | 2619 | 799 |
| - total length | 369284 | 483895 | 366418 | 93102 |
| Groups | VT | AF |
| sham (n=5) | 0 | 0 |
| t-AUCB(5 mg/L)+ sham (n=5) | 0 | 0 |
| MI (n=10) | 7(70%)* | 3(30%)* |
| t-AUCB(0.2 mg/L) + MI (n=5) | 3(60%) | 1(20%) |
| t-AUCB(1 mg/L) + MI (n=5) | 2(40%)# | 1(20%) |
| t-AUCB(5 mg/L) + MI (n=8) | 3(38%)# | 2(25%) |
| Population | Sample size | Sampling location | Longitude and latitude |
| 90 | Minqing County, Fujian Province, | 118.3, 25.6 | |
| Han | 95 | Chengdu City, Sichuan Province, | 104.1, 30.6 |
| 30 | Yining, Xinjiang Autonomous Region | 80.5, 43.3 | |
| Oroqen | 66 | Arlihe, Inner Mongolia Autonomous Region | 131.0, 53.5 |
| Ewenk | 45 | Molidawa, Inner Mongolia Autonomous Region | 118.6, 48.0 |
| Korean | 157 | Yanji City, Jilin Province | 121.4, 40.2 |
| Daur | 37 | Molidawa, Inner Mongolia Autonomous Region | 118.6, 40.8 |
| Hezhen | 95 | Tongjiang, Heilongjiang Province | 132.5, 46.7 |
| Man | 103 | Xiuyan City, Liaoning Province | 123.2, 40.2 |
| Kyrgyz | 42 | Wuqia, Xinjiang Autonomous Region | 73.4, 39.2 |
| Uygur | 57 | Yining City, Xinjiang Autonomous Region | 80.5, 43.3 |
| Mongol | 99 | Hailar City, Inner Mongolia Autonomous Region | 126.0, 51.0 |
| Hui | 118 | Tongxin County, Ningxia Autonomous Region | 105.9, 36.9 |
| Xibo | 74 | Yili, Xinjiang Autonomous Region | 80.5, 43.3 |
| Hazakh | 91 | Yining City, Xinjiang Autonomous Region | 80.5, 43.3 |
| Bouyei | 115 | Guizhou City, Yunnan Province | 105.7, 26.0 |
| Cost | Parameter | Overall cost of treatment | Proportion of total cost | |
| Average | SD | |||
| Direct Medical | Diagnostic | 37.63 (0.48) | 189.71 (2.42) | 28 |
| Medicine | 1064.19 (13.56) | 1427.04 (18.18) | ||
| Consultant fee | 26.37 (0.34) | 121.38 (1.55) | ||
| Registration/admission fee | 14.54 (0.19) | 11.42 (0.15) | ||
| Medical materials (syringe/cannula etc) | 27.32 (0.35) | 62.43 (0.80) | ||
| Bed/ Cabin charge | 0.28 (0.00) | 7.95 (0.10) | ||
| Direct Non-Medical | Transportation cost | 246.58 (3.14) | 427.76 (5.45) | 12.41 |
| Food items | 113.82 (1.45) | 239.77 (3.05) | ||
| Informal payment | 7.40 (0.09) | 22.65 (0.29) | ||
| Caregiver’s payment | 0.01 (0.00) | 0.35 (0.00) | ||
| Materials (mug/glass etc.) | 22.65 (0.29) | 70.59 (0.90) | ||
| Lodging | 0.00 (0.00) | 0.01 (0.00) | ||
| Caregivers expenditure | 127.87 (1.63) | 456.80 (5.820 | ||
| Total direct cost | 1688.17 (21.51) | 2010.95 (25.62) | 40.4 | |
| In-direct cost | Patient income loss | 310.51 (3.96) | 1374.40 (17.51) | |
| Caregiver’s income loss | 2179.50 (27.76) | 3445.12 (43.89) | ||
| Total indirect cost | 2490.01 (31.72) | 3881.48 (49.45) | 59.6 | |
| Total cost | 4178.68 (53.23) | 5166.20 (65.81) | 100 |
| Variants Coding | Log Reduction | |||
| P. fluorescens | Y. enterocolitica | B. cereus | S. aureus | |
| C0T0 | 2.2 ± 0.26 | 0.3 ± 0.13 | 9.2 ± 0.06 | 0.9 ± 0.13 |
| C0.05T0 | 9.5 ± 0.05 | 0.3 ± 0.06 | 9.2 ± 0.06 | 2.0 ± 0.23 |
| C0.1T0 | 9.5 ± 0.05 | 0.5 ± 0.07 | 9.2 ± 0.06 | 2.2 ± 0.06 |
| C0T3 | 4.7 ± 4.12 | 0.3 ± 0.11 | 9.2 ± 0.06 | 0.9 ± 0.27 |
| C0.05T3 | 9.5 ± 0.05 | 1.5 ± 0.32 | 9.2 ± 0.06 | 1.7 ± 0.48 |
| C0.1T3 | 9.5 ± 0.05 | 9.3 ± 0.07 | 9.2 ± 0.06 | 9.2 ± 0.06 |
| C0T20 | 2.3 ± 0.23 | 0.7 ± 0.26 | 9.2 ± 0.06 | 1.4 ± 0.10 |
| C0.05T20 | 9.5 ± 0.05 | 9.3 ± 0.07 | 9.2 ± 0.06 | 9.2 ± 0.06 |
| C0.1T20 | 9.5 ± 0.05 | 9.3 ± 0.07 | 9.2 ± 0.06 | 9.2 ± 0.06 |
| Author | N | PD-L1 (%) | Histology (%) | Stage (%) | Correlation withPD-L1 positive | Prognosis ofPD-L1 positive |
| 1-49%/ >50% | ADs/Sq/others | I/II/III/IV | ||||
| Reck M1 | 1653 | -/30.2 | - | 0/0/0/100 | - | - |
| Herbst RS2 | 2222 | 37.9/28.5 | - | 0/0/0/100 | - | - |
| Garon EB7 | 824 | 37.6/23.2 | 81.0*/17.2/1.8 | 0/0/0/100 | KRAS mutation | - |
| Cooper WA12 | 678 | 20.8/7.4 | 40.7/40.0/19.3 | 50/50(II+III)/0 | Younger: High tumor grade | Better |
| He Y14 | 139 | -/18.0 | 28.8/58.3/12.9 | 41.7/25.2/28.1/5.0 | NS | Poor |
| Sorensen SF15 | 204 | 50/25 | 72/21.6/6.4 | -/-/-/88 | NS | NS |
| Rangachari D26 | 71 | 28.2/29.6 | 100/0/0 | 25.4(I-III)/74.6 | Smoking | - |
| Present study | 170 | 24.7/10.6 | 55.3/44.7 | 29.4/25.3/45.3/0 | Histology; TILs; tumor stage | NS |
| Total population (n = 257) | SR-group(n = 148) | AF-group (n = 109) | p Value | OR (95% CI) | |
| Follow-up Minor vascular complication | |||||
| 30 days | 22.6% (58/257) | 22.3% (33/148) | 22.9% (25/109) | 1.00 | 1.09 (0.61–1.96) |
| 3 months | 23.0% (59/257) | 22.3% (33/148) | 23.9% (26/109) | 0.767 | 1.09 (0.61–1.96) |
| 6 months | 24.8% (60/241) | 23.9% (33/137) | 26.0% (27/104) | 0.764 | 1.12 (0.62–2.01) |
| 12 months | 27.3% (60/219) | 26.4% (33/124) | 28.4% (27/95) | 0.762 | 1.11 (0.61–2.01) |
| Follow-up Major bleeding | |||||
| 30 days | 3.5% (9/257) | 4.1% (6/148) | 2.8% (3/109) | 0.737 | 0.67 (0.16–2.74) |
| 3 months | 3.9% (10/257) | 4.7% (7/148) | 2.8% (3/109) | 0.525 | 0.57 (0.14–2.26) |
| 6 months | 4.5% (11/241) | 5.8% (8/137) | 2.9% (3/104) | 0.360 | 0.48 (1.13–1.87) |
| 12 months | 5.5% (12/219) | 7.2% (9/124) | 3.2% (3/95) | 0.240 | 0.42 (0.11–1.60) |
| Follow-up Minor bleeding | |||||
| 30 days | 19.8% (51/257) | 21.6% (32/148) | 17.4% (19/109) | 1.00 | 1.09 (0.61–1.96) |
| 3 months | 19.8% (51/257) | 21.6% (32/148) | 17.4% (19/109) | 0.767 | 1.09 (0.61–1.96) |
| 6 months | 21.0% (51/241) | 23.0% (32/137) | 18.3% (19/104) | 0.764 | 1.12 (0.62–2.01) |
| 12 months | 23.1% (51/219) | 25.4% (32/124) | 20.0% (19/95) | 0.762 | 1.11 (0.61–2.01) |
| Genotype | Actual Values | Expected Value | χ2 | p |
| T102C | ||||
| TT | 108 | 120.95 | 3.589 | 0.166 |
| TC | 194 | 169.33 | ||
| CC | 48 | 58.84 | ||
| A-1438G | ||||
| AA | 73 | 74.61 | 0.205 | 0.902 |
| AG | 181 | 174.21 | ||
| GG | 96 | 99.36 |
| Risk factors | Univariate | Multivariate | ||
| P-value | RR | 95%CI | P-value | |
| Age, ≤60 vs. >60 years | 0.006* | 0.763 | ||
| Gender, male vs. female | 0.24 | |||
| Site, Head and neck vs. Body and tail | 0.15 | |||
| Tumor size, ≤3.5 vs. >3.5cm | 0.55 | |||
| Tumor differentiation, well/moderate vs. poor | 0.000* | 1.896 | 1.077-3.337 | 0.027* |
| Stage (AJCC), I-II vs. III-IV | 0.001* | 3.614 | 1.228-10.64 | 0.020* |
| T stage, pT1-T2 vs. pT3-T4 | 0.27 | |||
| Lymph nodes, negative vs. positive | 0.012* | 0.26 | ||
| Metastasis, negative vs. positive | 0.010* | 1.397 | 0.775-2.520 | 0.012* |
| CD133, negative vs. positive | 0.000* | 2.208 | 1.161-4.203 | 0.016* |
| BMI-1, negative vs. positive | 0.000* | 2.661 | 1.256-5.638 | 0.011* |
| Co-expression of CD133 and BMI-1, others vs. CD133+/BMI-1+ | 0.000* | 3.523 | 1.365-9.089 | 0.009* |
| AE | CE | FW | |
| Total drink volume (mL) | 2292.25 ± 457.99 | 2279.26 ± 483.63 | 2360.44 ± 519.75 |
| Test drink volume (mL) | 772.46 ± 93.17 | 774.73 ± 100.9 | 770.83 ± 96.88 |
| Water drink volume (mL) | 1519.79 ± 388.04 | 1504.52 ± 428.92 | 1589.62 ± 476.92 |
| Total urine volume (mL) | 1295.5 ± 457.56 | 1348.25 ± 450.94 | 1363.25 ± 520.44 |
| Fluid retention (%) | 43.5 ± 17.1 | 40.8 ± 18.1 | 42.2 ± 14.3 |
| Index | Group | 0-week | 2-week | 4-week | 8-week | 12-week |
| TC | NDG | 1.67 ± 0.43 | 1.72 ± 0.45 | 1.72 ± 0.25 | 1.98 ± 0.55 | 2.02 ± 0.58 |
| HH | 1.80 ± 0.20 | 1.88 ± 0.22 | 2.59 ± 0.76*# | 18.57 ± 1.25**## | 19.08 ± 1.31**## | |
| TG | NDG | 1.06 ± 0.31 | 1.09 ± 0.45 | 1.11 ± 0.38 | 1.28 ± 0.35 | 1.36 ± 0.55 |
| HH | 1.09 ± 0.15 | 1.12 ± 0.11 | 2.09 ± 0.87*# | 3.83 ± 1.75**## | 4.07 ± 1.54**## | |
| HDL | NDG | 0.61 ± 0.20 | 0.69 ± 0.26 | 0.65 ± 0.31 | 0.58 ± 0.17 | 0.76 ± 0.27 |
| HH | 0.53 ± 0.07 | 0.55 ± 0.09 | 1.21 ± 0.35*# | 2.04 ± 1.11**## | 2.12 ± 1.23**## | |
| LDL | NDG | 0.93 ± 0.21 | 0.95 ± 0.33 | 1.01 ± 0.49 | 0.89 ± 0.27 | 0.98 ± 0.25 |
| HH | 0.94 ± 0.26 | 1.06 ± 0.24 | 1.84 ± 0.36*# | 14.68 ± 1.42**## | 15.13 ± 1.64**## |
| Subtheme | Quote |
| Previous experiences with teletraining | “What I actually find more useful [in Rural Grand Rounds] is quite often he gets paediatricians, emergency medicine from [bigger regional centres], from everywhere who actually do speeches and talks” [PF 4] |
| “So yeah, that lack of physical-ness about the situation means often you can get apathetic and sometimes just be a bit blasé about it all and sign on just because you have to sign on” [PF 3] | |
| “Oh, I think it serves a purpose. So these people are spread off all over North Queensland and the distances that are involved are prohibitive for everyone together on a really regular basis” [PF 3] | |
| Face to Face versus videoconference learning | “I think any access to any teaching would be appropriate and even if you do not pick up at come place like do not pick up as much from face to face teaching...Sometimes telehealth teaching can teach you maybe if you do pick up 50% of it just because it's ongoing” [PF 5] |
| “I think tele-training is the way of the future especially for people in our area that more and more of us are going out to rural sites” [RR 2] | |
| Peer teaching | “The best benefit is you get to experience different thinking outside the box and different ways of doing things that apply to rural areas, rather than the textbook stuff that does not always apply” [PF 6] |
| “I enjoy catching up with people that are in a similar role and have a chance to debrief and have a chance to learn from each other and that is not really a lot of opportunity for that, and the peer education, just people in the same situation and learning from things they have seen and done before, that is probably the only thing I have noticed as a difference” [PF 1] | |
| Teaching skills using videoconference | “I think though that there are certain skills that you need to do person - face-to-face and have immediate feedback on” [RG 2] |
| “Unfortunately the technology is what people take away from those learning opportunities; they do not take away the actual message of simulation” [RG 6] | |
| “There is no reason why they cannot create a resus with a mannequin, put a dress on it and bring it to the ED and run their own simulation. We all have inherent skills and knowledge. Doing simple stuff, it does not need to be complex” [RG 6] | |
| “The biggest issue with rural is that often you plan to do something every week ...then it just falls off the radar... I think you'd need to have a bunch of passionate people at a centralised location to really push it to happen every week” [PF 4] | |
| “I do not see why you would need someone to teach a practical skill online as a teleconference when you can use YouTube, pause it and revisit all of the steps” [PF 6] | |
| Didactic versus interactive sessions | “Interactive, I definitely prefer, but sometimes in the early years of GP training, a lot of the stuff was a bit didactic, but I did not mind that, I found it to be quiet useful” [GPRNH] |
| “There would be scope for that as long as it's not didactic lectures, as long as there can be interaction and the facilitators have a skill in that and the people who are being educated, the students, are prepared enough to interact...it would have to be an interactive thing otherwise you can get that from a YouTube, cannot you?” [RG 3] |
| Emotive coping | ||||||
| Univariate | Multivariatea | |||||
| Variables | OR | (95% CI) | p-value | OR | (95% CI) | p-value |
| Sex (female) | 4.07 | (1.12–14.79) | 0.03 | 3.39 | (1.01–11.40) | 0.005 |
| Age | 0.94 | (0.90–0.99) | 0.02 | 0.93 | (0.88–0.97) | 0.004 |
| Single (0–1) | 1.17 | (0.28–4.93) | 0.83 | |||
| University education (0–1) | 0.34 | (0.07–1.63) | 0.17 | |||
| Immigrants (0–1) | 0.31 | (0.08–1.19) | 0.08 | |||
| Physical activity (1–4) | 0.08 | (0.04–0.21) | <0.0001 | 0.13 | (0.06–0.32) | <0.0001 |
| Sleep problems (0–20) | 1.35 | (1.20–1.51) | <0.0001 | 1.25 | (1.11–1.42) | 0.0002 |
| Mental strain at work (2–10) | 2.00 | (1.48–2.70) | <0.0001 | 1.44 | (1.08–1.91) | 0.005 |
| Stress at home (0–5) | 2.17 | (1.43–3.29) | 0.0003 | 1.15 | (0.74–1.77) | 0.89 |
| Life events (0–30) | 1.29 | (1.12–1.49) | 0.0006 | 1.21 | (1.04–1.41) | 0.01 |
| Characteristic | N | % |
| Age (Years) | ||
| <40 | 39 | 5.6 |
| 40-49 | 165 | 23.7 |
| 50-59 | 215 | 30.9 |
| 60-69 | 214 | 30.8 |
| 70+ | 62 | 8.9 |
| BMI (kg/m2) | ||
| <21 | 98 | 14.1 |
| 21-24.9 | 228 | 32.8 |
| 25-29.9 | 218 | 31.4 |
| 30+ | 151 | 21.8 |
| Biopsy technique | ||
| Stereotactic | 381 | 54.8 |
| Ultrasound-guided | 194 | 27.9 |
| MRI-guided | 120 | 17.3 |
| Referral group | ||
| Screening | 83 | 11.9 |
| History of breast cancer | 90 | 13.0 |
| Clinical symptoms | 128 | 18.4 |
| Only images | 394 | 56.7 |
| BIRADS | ||
| 2-3 | 75 | 10.8 |
| 4 | 346 | 49.8 |
| 5 | 204 | 29.3 |
| 6 | 70 | 10.1 |
| Radiological findings | ||
| Radiological focus | 396 | 57.0 |
| Microcalcification | 346 | 49.8 |
| Mammographic breast density (ACR) | ||
| almost entirely fatty | 58 | 8.4 |
| fibroglandular | 282 | 41.0 |
| heterogenous dense | 283 | 41.1 |
| extremely dense | 65 | 9.5 |
| Mammographic breast density (Computer-based assessment) | ||
| <10% | 242 | 34.8 |
| 10% to <25% | 181 | 26.0 |
| 25% to <50% | 186 | 26.8 |
| ≥50% | 86 | 12.4 |
| Adult learning disability | Head and neck cancer | Other | ||||
| Non aspiration pneumonia | Aspiration pneumonia | Non aspiration pneumonia | Aspiration pneumonia | Non aspiration pneumonia | Aspiration pneumonia | |
| Number of subjects (M/F) | 8/8 | 3/6 | 23/16 | 1/3 | 269/211 | 96/43 |
| Age in years (mean ± sd) | 52 ± 17 | 56 ± 11 | 59 ± 13 | 70 ± 17 | 73 ± 16 | 80 ± 13 |
| Characteristics | PE factor | DE factor | NC factor | PS factor | NE factor | CS factor |
| Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | |
| Residential area | ||||||
| Summer house area | 0.78 (0.89) | −0.08 (1.07) | 0.21 (1.01) | −0.24 (0.91) | 0.26 (1.08) | −0.32 (0.99) |
| Ger area | −0.34 (0.93) | −0.18 (0.86) | −0.09 (1.06) | 0.14 (0.99) | −0.25 (0.95) | 0.18 (1.09) |
| Apartment area | −0.18 (0.91) | −0.18 (0.94) | −0.02 (0.99) | −0.05 (1.00) | 0.31 (0.99) | 0.12 (0.89) |
| Luxury residential area | 0.30 (0.94) | 0.75 (0.94) | −0.05 (0.86) | 0.02 (1.04) | 0.01 (0.94) | −0.29 (0.87) |
| P value | <0.001 | <0.001 | 0.042 | 0.005 | <0.001 | <0.001 |
| Education | ||||||
| Basic education | −0.22 (1.14) | −0.23 (0.93) | −0.05 (1.14) | −0.16 (1.11) | 0.07 (1.03) | −0.05 (1.18) |
| High school | −0.01 (0.95) | −0.20 (0.92) | 0.06 (1.06) | 0.00 (0.93) | 0.03 (0.93) | 0.04 (0.93) |
| Vocational education | −0.02 (1.03) | −0.21 (0.92) | 0.04 (0.88) | −0.07 (0.94) | −0.10 (0.96) | 0.04 (1.02) |
| College or university | 0.09 (0.98) | 0.19 (0.99) | −0.05 (1.01) | 0.10 (1.02) | −0.01 (1.04) | 0.08 (0.93) |
| Graduate school | 0.04 (0.91) | 0.46 (1.13) | −0.02 (0.79) | −0.02 (1.03) | −0.01 (1.06) | −0.35 (1.07) |
| P value | 0.139 | <0.001 | 0.770 | 0.211 | 0.764 | 0.014 |
| Household income, monthly | ||||||
| <500,000 MNT (<250 USD) | −0.06 (1.13) | −0. 17 (0.97) | −0.11 (1.11) | 0.03 (1.06) | −0.04 (1.11) | 0.12 (1.11) |
| ≥500,000 and <800,000 MNT(≥250 and <400 USD) | −0.14 (0.93) | −0.29 (0.95) | −0.01 (1.04) | −0.14 (1.01) | −0.02 (0.90) | 0.11 (1.11) |
| ≥800,000 and <1,200,000 MNT(≥400 and <600 USD) | −0.04 (0.99) | −0.03 (0.92) | 0.18 (1.00) | 0.05 (0.88) | −0.04 (0.95) | −0.14 (0.85) |
| ≥1,200,000 and <2,500,000 MNT(≥600 and <1240 USD) | 0.07 (0.90) | 0.16 (0.98) | −0.09 (0.91) | 0.11 (1.06) | 0.10 (1.03) | 0.05 (0.89) |
| ≥2,500,000 MNT (≥1240 USD) | 0.47 (1.02) | 0.89 (0.89) | 0.01 (0.78) | 0.02 (0.98) | 0.05 (1.06) | −0.33 (0.87) |
| P value | <0.001 | <0.001 | 0.068 | 0.151 | 0.710 | 0.002 |
| Clinical/Laboratory/ Radiological Finding | Specification |
| Impaired consciousness or unrousable coma | Glasgow Coma Scale ≤10b |
| Multiple convulsions | >2 episodes within 24 h or generalized seizures |
| Respiratory distress or acidotic breathing | Requirement of noninvasive or endotracheal mechanical ventilationb or respiratory rate of ≥40 breaths/min on room air |
| Circulatory collapse or shock | Systolic blood pressure <80 mm Hg or ≤80 mm Hg despite volume repletion |
| Acute pulmonary edema | Verified radiologically |
| Acute respiratory distress syndrome | Verified radiologically |
| Acute kidney injury/renal impairment | Serum creatinine >265 μmol/L |
| Acidosis or hyperlactatemia | pH <7.25 or plasma bicarbonate <15 mmol/L or lactate >5 mmol/L |
| Clinical jaundice plus evidence of other vital organ dysfunction | Bilirubin >50 μmol/L together with circulatory instability, respiratory distress, impaired consciousness, severe coagulopathy, or acute kidney injury |
| Severe normocytic anemia | Hemoglobin <70 g/L not related to other cause than the malaria infection |
| Abnormal bleeding | Spontaneous bleeding from gums, mouth, or gastrointestinal tract |
| Macroscopic hemoglobinuria | Unequivocally related to acute malaria and verified by urine dipstick |
| Hypoglycemia | Blood glucose <2.2 mmol/L |
| Hyperparasitemia | Parasitemia >5% |
| T1 | |||||
| Excellent/very good N (%) | Good N (%) | Fair/poor N (%) | TotalN (%) | ||
| T0 | Excellent/very good | 142 (19.7) | 81 (11.3) | 7 (1.0) | 230 (32.0) |
| Good | 111 (15.4) | 293 (40.8) | 31 (4.3) | 435 (60.5) | |
| Fair/poor | 6 (0.8) | 29 (4.0) | 19 (2.7) | 54 (7.5) | |
| Total | 259 (35.9) | 403 (56.1) | 57 (8.0) | 719 (100.0) |
| Lab studies | Outdoor studies | |
| 1980-1985 | Collection & screening of algae | Wastewater treatment, small pond studies |
| 1985-1990 | Classification of algae biochemistry & physiology of lipid production | Large pond studies |
| 1990-1996 | Genetic engineering | Systems analysis & resource assessment |
| Age group (years) | Male | Female | Total | |||
| Levels of Systolic Blood Pressure (SBP) in different age groups (mmHg, median (Q25; Q75) | ||||||
| SBP | Q25; Q75 | SBP | Q25; Q75 | SBP | Q25; Q75 | |
| 25–34 | 127.5 | 119.5; 137.5 | 116.0 | 109.0; 125.0 | 120.5 | 111.5; 130.5 |
| 35–44 | 134.3 | 124.3; 142.8 | 121.5 | 113.0; 132.0 | 126.0 | 116.0; 138.5 |
| 45–54 | 140.0 | 129.5; 148.5 | 130.5 | 118.5; 142.5 | 134.0 | 122.0; 145.0 |
| 55–64 | 144.0 | 135.0; 158.5 | 141.0 | 130.0; 156.5 | 142.5 | 132.5; 157.0 |
| Levels of Diastolic Blood Pressure (DBP) in different age groups (mmHg, median (Q25; Q75) | ||||||
| DBP | Q25; Q75 | DBP | Q25; Q75 | DBP | Q25; Q75 | |
| 25–34 | 78.5 | 73.0; 84.5 | 74.5 | 69.0; 81.0 | 76.0 | 71.0; 82.5 |
| 35–44 | 83.5 | 76.3; 91.0 | 79.5 | 72.5; 88.0 | 82.0 | 74.0; 89.0 |
| 45–54 | 88.5 | 81.5; 93.0 | 82.0 | 72.5; 90.0 | 85.0 | 76.0; 91.5 |
| 55–64 | 88.0 | 80.5; 95.5 | 86.0 | 80.0; 94.0 | 87.0 | 80.0; 95.0 |
| Hypertension prevalence in different age groups (% ± 95% CI) | ||||||
| % (n) | 95% CI | % (n) | 95% CI | % (n) | 95% CI | |
| 25–34 | 27.0 (n = 44) | 6.86 | 10.8 (n = 25) | 3.92 | 17.5 (n = 69) | 3.72 |
| 35–44 | 43.3 (n = 52) | 8.82 | 32.1 (n = 62) | 6.66 | 36.4 (n = 114) | 5.29 |
| 45–54 | 71.0 (n = 103) | 7.39 | 53.0 (n = 134) | 6.15 | 59.5 (n = 237) | 4.90 |
| 55–64 | 79.9 (n = 143) | 5.88 | 76.7 (n = 198) | 5.15 | 78.0 (n = 341) | 3.92 |
| Hypertension awareness in different age groups (% ± 95% CI) | ||||||
| % (n) | 95% CI | % (n) | 95% CI | % (n) | 95% CI | |
| 25–34 | 70.5 (n = 31) | 6.27 | 76.0 (n = 19) | 4.51 | 72.5 (n = 50) | 10.58 |
| 35–44 | 82.7 (n = 43) | 7.25 | 79.0 (n = 49) | 5.49 | 80.7 (n = 92) | 7.25 |
| 45–54 | 73.8 (n = 76) | 6.86 | 79.9 (n = 107) | 4.70 | 77.2 (n = 183) | 5.29 |
| 55–64 | 80.4 (n = 115) | 5.88 | 77.3 (n = 153) | 5.10 | 78.6 (n = 268) | 4.31 |
| PCI | CABG | PCI and/or CABG | |||||||
| State | No. of Cases | Rate | Ratio to Mean (95% CI) | No. of Cases | Rate | Ratio to Mean (95% CI) | No. of Cases | Rate | Ratio to Mean (95% CI) |
| AZ | 10,576 | 287 | 1.08 (1.06, 1.10) | 5,131 | 138 | 0.93 (0.91, 0.96) | 15.520 | 420 | 1.03 (1.01, 1.04) |
| CA | 50,436 | 239 | 0.90 (0.89, 0.91) | 28,537 | 136 | 0.92 (0.91, 0.93) | 78,099 | 371 | 0.91 (0.90, 0.91) |
| CO | 6,932 | 261 | 0.98 (0.96, 1.00) | 3,035 | 118 | 0.80 (0.77, 0.83) | 9,856 | 374 | 0.91 (0.90, 0.93) |
| FL | 47,423 | 340 | 1.28 (1.27, 1.29) | 26,023 | 182 | 1.23 (1.22, 1.25) | 72,713 | 517 | 1.26 (1.25, 1.27) |
| IA | 7,411 | 326 | 1.22 (1.20, 1.25) | 3,440 | 150 | 1.02 (0.99, 1.05) | 10,796 | 474 | 1.16 (1.14, 1.18) |
| MD | 9,307 | 257 | 0.97 (0.95, 0.99) | 4,620 | 129 | 0.88 (0.85, 0.90) | 13,779 | 382 | 0.93 (0.92, 0.95) |
| NY | 33,429 | 245 | 0.92 (0.91, 0.93) | 18,182 | 134 | 0.91 (0.90, 0.92) | 51,352 | 377 | 0.92 (0.91, 0.93) |
| OR | 4,716 | 186 | 0.70 (0.68, 0.72) | 3,812 | 152 | 1.03 (1.00, 1.06) | 8,452 | 335 | 0.82 (0.80, 0.84) |
| SC | 8,053 | 281 | 1.06 (1.03, 1.08) | 4,859 | 170 | 1.15 (1.12, 1.18) | 12,804 | 447 | 1.09 (1.07, 1.11) |
| WA | 8,765 | 218 | 0.82 (0.80, 0.84) | 5,475 | 139 | 0.94 (0.92, 0.97) | 14,121 | 354 | 0.86 (0.85, 0.88) |
| WI | 10,994 | 282 | 1.06 (1.04, 1.08) | 6,704 | 172 | 1.17 (1.14, 1.20) | 17,469 | 448 | 1.09 (1.08, 1.11) |
| Total | 198,042 | 266 | 109,818 | 147 | 304,961 | 409 | |||
| Ratio of Highest/Lowest Rates | 1.83 | 1.54 | 1.54 |
| Number | Vitamin E succinate (%) | Vitamin E acetate (%) | Gamma- tocopheryl succinate(%) |
| 1 | 112.5 ± 8.4 | 0 | 0.38 |
| 2 | 116.9 ± 8.3 | 0 | 0.46 |
| 3 | 104.2 ± 9.7 | 0 | 0.71 |
| 4 | 103.9 ± 3.3 | 0 | 0.47 |
| 5 | 99.5 ± 7.1 | 0 | 0.37 |
| 6 | 106.1 ± 2.8 | 0 | 0.29 |
| 7 | 110.5 ± 5.9 | 0 | 0.74 |
| 8 | 106.4 ± 5.5 | 0 | 0.41 |
| 9 | 116.8 ± 4.2 | 0 | 0.94 |
| 10 | 110.0 ± 5.1 | 0 | 0.55 |
| 11 | 103.7 ± 2.9 | 0 | 0.81 |
| 12 | 119.3 ± 4.3 | 0 | 0.57 |
| 13 | 0 | 9.3 | 0 |
| 14 | 0 | 84.7 | 0 |
| Trimmed population | Stratified-matched population | |||||
| Rituximab (n = 265) | Anti-TNF (n = 737) | Standardized difference | Rituximab(n = 205) | Anti-TNF(n = 205) | Standardized difference | |
| Demographics | ||||||
| White, % | 87.6 | 83.5 | 0.114 | 84.4 | 87.3 | 0.084 |
| Female, % | 81.1 | 79.2 | 0.049 | 82.9 | 81.0 | 0.051 |
| Age, mean (SD), years | 57.8 (11.7) | 56.1 (12.4) | 0.139 | 57.6 (11.7) | 58.0 (11.5) | 0.037 |
| Insurance | ||||||
| Medicare, % | 37.7 | 29.4 | 0.176 | 33.7 | 39.0 | 0.111 |
| Medicaid, % | 7.2 | 6.4 | 0.032 | 7.3 | 6.3 | 0.039 |
| Private insurance, % | 76.6 | 78.7 | 0.050 | 76.1 | 74.6 | 0.034 |
| No insurance, % | 1.1 | 2.3 | 0.090 | 1.5 | 1.5 | 0.000 |
| History of comorbidities | ||||||
| Cardiovascular disease, % | 11.3 | 7.3 | 0.137 | 9.8 | 11.7 | 0.063 |
| Cancer, % | 9.4 | 7.7 | 0.061 | 10.2 | 8.8 | 0.050 |
| Diabetes, % | 9.8 | 10.7 | 0.030 | 10.2 | 10.7 | 0.016 |
| Clinical characteristics | ||||||
| Disease duration, mean (SD), years | 15.4 (10.2) | 11.4 (9.4) | 0.408 | 14.6 (10.3) | 15.1 (10.5) | 0.047 |
| Tender joint count, mean (SD) | 9.6 (7.3) | 8.7 (7.3) | 0.117 | 9.5 (7.2) | 9.1 (7.8) | 0.058 |
| Swollen joint count, mean (SD) | 8.0 (5.6) | 7.5 (5.7) | 0.097 | 7.9 (5.5) | 7.4 (5.8) | 0.086 |
| Patient global assessment, mean (SD) | 54.3 (23.6) | 50.6 (25.0) | 0.154 | 53.2 (23.4) | 52.7 (25.5) | 0.023 |
| Physician global assessment, mean (SD) | 42.7 (20.2) | 39.3 (20.1) | 0.169 | 42.3 (19.7) | 39.8 (19.1) | 0.130 |
| Patient pain, mean (SD) | 56.5 (24.5) | 53.2 (25.5) | 0.132 | 55.3 (24.8) | 53.0 (26.2) | 0.093 |
| Disability index (mHAQ), mean (SD) | 0.78 (0.5) | 0.64 (0.5) | 0.270 | 0.74 (0.5) | 0.72 (0.5) | 0.040 |
| Clinical Disease Activity Index, mean (SD) | 27.3 (12.5) | 25.2 (11.9) | 0.172 | 27.0 (12.0) | 25.7 (12.3) | 0.100 |
| Prior medication use | ||||||
| Prior nbDMARDs, n, mean | 1.6 | 1.1 | 0.396 | 1.4 | 1.4 | 0.031 |
| Prior use of ≥2 anti-TNF agents, % | 63.0 | 26.6 | 0.786 | 54.6 | 54.6 | 0.000 |
| Prior use of non–anti-TNF biologic agents, % | 40.8 | 13.0 | 0.657 | 31.7 | 33.2 | 0.031 |
| Concomitant medications | ||||||
| Prednisone, % | 43.8 | 29.3 | 0.303 | 39.0 | 38.5 | 0.010 |
| Methotrexate, % | 57.7 | 55.9 | 0.037 | 57.1 | 51.7 | 0.108 |
| Non-methotrexate nbDMARD, % | 29.1 | 24.8 | 0.095 | 29.8 | 30.2 | 0.011 |
| Gene Family Member | Enriched Genes | Cases | Controls | Gene Network Association | |||||
| No. | Frequency | No. | Frequency | # | Frequency | Pfisher | Enrichment | Pperm | |
| AKAP13 | 7/7 | 1.00 | 16 | 0.0035 | 1 | 0.0002 | 1.14E−04 | 16.43 | 0.012 |
| BAG1 | 7/7 | 1.00 | 15 | 0.0032 | 1 | 0.0002 | 2.18E−04 | 15.40 | 0.014 |
| CALM1 | 9/10 | 0.90 | 14 | 0.0030 | 1 | 0.0002 | 4.16E−04 | 14.37 | 0.002 |
| CASP6 | 16/17 | 0.94 | 46 | 0.0100 | 6 | 0.0013 | 2.96E−09 | 7.91 | 0.012 |
| GTF2H3 | 23/26 | 0.88 | 42 | 0.0091 | 8 | 0.0017 | 3.66E−07 | 5.41 | 0.009 |
| MAP3K5 | 11/12 | 0.92 | 34 | 0.0074 | 4 | 0.0008 | 2.02E−07 | 8.76 | 0.012 |
| NCOR1 | 9/10 | 0.90 | 26 | 0.0056 | 2 | 0.0004 | 1.11E−06 | 13.37 | 0.004 |
| PARP1 | 5/5 | 1.00 | 5 | 0.0011 | 0 | 0.0000 | 2.95E−02 | inf | 0.012 |
| PTPN13 | 6/6 | 1.00 | 9 | 0.0019 | 0 | 0.0000 | 1.75E−03 | inf | 0.007 |
| TCEA1 | 22/26 | 0.85 | 39 | 0.0084 | 7 | 0.0015 | 5.94E−07 | 5.74 | 0.009 |
| LA responses (mmol.L−1) | Pre-RF | Beg-RF | End-RF | After-RF | F | p |
| Resting LA | 1.27±0.33 | 1.11±0.28 | 1.18±0.30 | 1.12±0.37 | 1.45 | 0.240 |
| LA at 8 km.h−1 | 1.91±0.50 | 1.85±0.40 | 1.79±0.38 | 1.66±0.45 | 2.15 | 0.107 |
| LA at 10 km.h−1 | 2.68±0.81 | 2.73±0.55 * | 2.54±0.57 | 2.38±0.58 | 3.24 | 0.031 |
| LA at 11 km.h−1 | 3.82±0.99 * | 3.93±0.71 # | 3.58±0.73 | 3.37±0.85 | 7.67 | 0.000 |
| LA at 12 km.h−1 | 5.80±1.44 * | 6.15±1.34 # | 5.48±1.20 | 5.14±1.35 | 12.24 | 0.000 |
| Primer name | Direction | Nucleotide sequence (5' to 3') |
| KSC138-9 | Forward | GCACAATAAATTGGGCCTGA |
| Reverse | GCGAGTGTTGGGCTAAGTCT | |
| KSC138-10 | Forward | CACGAATGTGAATTTGATCG |
| Reverse | CGACCAAGGAGATAAAAACAGA | |
| KSC138-17 | Forward | TGGAAATTCTGTGCACTTGGTG |
| Reverse | TAAAGCCGCCTAGCCGATTG | |
| KSC138-22 | Forward | TGCAGCAATAATCAATCAAATAGAA |
| Reverse | TTCAATCAAATTTAGCACGTGTATT | |
| KSC138-23 | Forward | CGGTCCAGATTTAATTCTTTCACTC |
| Reverse | TTTCCGTTTTGTCACCCTGCT | |
| BARCSOYSSR_09_1388 | Forward | TTGCACTCTCCAAACCAAGA |
| Reverse | ATGCACTCTGCTCGACACAT | |
| BARCSOYSSR_09_1415 | Forward | CACCATCCACTCCAGTTCCT |
| Reverse | CTCCACGTGTTAGACGGGTT |
| Decoy | RNA | Length | Method | Enrichment score (RMSD) | Enrichment score (DI) | ||||||
| 3dRNAscore | KB | RASP | Rosetta | 3dRNAscore | KB | RASP | Rosetta | ||||
| Position restrained dynamics and REMD (A) | 1duq | 26 | X-ray | 8.5 | 7.6 | 7.6 | 7.1 | 8.3 | 7.5 | 7.6 | 7.0 |
| 1f27 | 30 | X-ray | 8.3 | 7.9 | 6.6 | 6.2 | 8.1 | 7.8 | 6.6 | 6.2 | |
| 1msy | 27 | X-ray | 7.5 | 5.7 | 5.7 | 3.6 | 7.6 | 6.0 | 5.6 | 3.5 | |
| 1nuj | 24 | X-ray | 7.7 | 7.3 | 5.2 | 6.9 | 7.4 | 7.2 | 5.2 | 6.7 | |
| 434d | 14 | X-ray | 8.0 | 7.7 | 7.0 | 6.8 | 7.6 | 7.7 | 6.9 | 6.8 | |
| Normal modes (B) | 1duq | 26 | X-ray | 7.5 | 7.0 | 5.7 | 3.8 | 6.9 | 7.0 | 5.7 | 3.5 |
| 1esy | 19 | NMR | 4.9 | 5.4 | 4.5 | 5.6 | 6.5 | 5.5 | 4.7 | 5.7 | |
| 1f27 | 30 | X-ray | 5.9 | 5.8 | 3.7 | 2.6 | 6.7 | 5.8 | 3.7 | 2.5 | |
| 1i9v | 76 | X-ray | 6.1 | 2.6 | 5.3 | 3.0 | 5.5 | 2.7 | 5.1 | 3.0 | |
| 1kka | 17 | NMR | 5.7 | 4.6 | 4.1 | 4.6 | 6.9 | 4.3 | 4.1 | 4.8 | |
| 1msy | 27 | X-ray | 5.9 | 5.6 | 2.2 | 4.6 | 6.7 | 5.4 | 2.7 | 4.5 | |
| 1nuj | 24 | X-ray | 7.1 | 7.4 | 5.9 | 2.4 | 4.5 | 7.0 | 5.9 | 2.2 | |
| 1qwa | 21 | NMR | 3.5 | 3.2 | 2.0 | 3.8 | 3.7 | 3.3 | 2.2 | 3.9 | |
| 1×9k | 62 | X-ray | 6.7 | 1.6 | 5.2 | 3.0 | 3.1 | 1.9 | 5.2 | 2.8 | |
| 1xjr | 46 | X-ray | 7.7 | 5.4 | 7.9 | 2.2 | 6.2 | 5.0 | 7.9 | 2.5 | |
| 1ykq | 19 | X-ray | 4.6 | 3.4 | 3.5 | 2.8 | 5.0 | 3.3 | 3.8 | 2.5 | |
| 1zih | 12 | NMR | 7.7 | 5.4 | 5.7 | 6.6 | 6.9 | 5.3 | 5.7 | 6.5 | |
| 28sp | 28 | NMR | 5.7 | 4.0 | 6.5 | 1.8 | 5.7 | 4.5 | 6.7 | 2.9 | |
| 2f88 | 34 | NMR | 6.8 | 5.4 | 4.9 | 4.4 | 4.1 | 5.4 | 4.7 | 4.2 | |
| 434d | 14 | X-ray | 7.7 | 7.4 | 7.4 | 5.2 | 6.9 | 7.4 | 7.6 | 5.2 | |
| FARNA (C) | 1a4d | 41 | NMR | 2.4 | 3.8 | 2.0 | 0.8 | 2.1 | 4.0 | 2.0 | 0.7 |
| 1csl | 28 | X-ray | 2.0 | 1.5 | 1.6 | 1.3 | 2.4 | 1.4 | 1.6 | 1.4 | |
| 1dqf | 19 | X-ray | 4.2 | 1.8 | 2.8 | 1.0 | 3.6 | 2.0 | 3.2 | 1.0 | |
| 1esy | 19 | NMR | 3.2 | 3.7 | 4.8 | 1.2 | 3.8 | 3.5 | 4.2 | 1.1 | |
| 1i9x | 26 | X-ray | 3.4 | 1.3 | 2.2 | 1.5 | 4.0 | 1.5 | 3.6 | 1.6 | |
| 1j6s | 24 | X-ray | 0.2 | 1.4 | 0.2 | 0.6 | 1.6 | 1.7 | 0.8 | 0.5 | |
| 1kd5 | 22 | X-ray | 3.2 | 0.3 | 0.8 | 0.2 | 2.4 | 0.5 | 1.6 | 0.3 | |
| 1kka | 17 | NMR | 1.4 | 1.2 | 0.6 | 0.6 | 2.0 | 0.8 | 0.8 | 0.6 | |
| 1l2x | 27 | X-ray | 0.6 | 3.2 | 1.0 | 1.8 | 1.5 | 3.2 | 1.2 | 1.8 | |
| 1mhk | 32 | X-ray | 1.6 | 1.2 | 1.6 | 1.0 | 1.4 | 1.2 | 1.4 | 1.2 | |
| 1q9a | 27 | X-ray | 2.6 | 0.5 | 0.8 | 0.8 | 3.2 | 0.5 | 1.2 | 0.8 | |
| 1qwa | 21 | NMR | 2.2 | 1.2 | 0.4 | 1.0 | 1.4 | 1.3 | 0.6 | 1.0 | |
| 1xjr | 46 | X-ray | 2.4 | 2.0 | 2.4 | 1.2 | 3.2 | 1.9 | 3.4 | 1.0 | |
| 1zih | 12 | NMR | 4.8 | 5.0 | 4.8 | 2 | 6.8 | 5.5 | 7.2 | 1.9 | |
| 255d | 24 | X-ray | 2.4 | 0.7 | 0.6 | 1.3 | 2.0 | 0.7 | 0.6 | 1.1 | |
| 283d | 24 | X-ray | 1.4 | 0.8 | 0.8 | 0.7 | 1.8 | 0.8 | 1.0 | 0.7 | |
| 28sp | 28 | NMR | 2.8 | 1.5 | 3.0 | 1.7 | 3.8 | 1.2 | 4.2 | 1.8 | |
| 2a43 | 26 | X-ray | 2.2 | 2.0 | 1.4 | 0.6 | 3.2 | 1.8 | 2.0 | 0.6 | |
| 2f88 | 34 | NMR | 3.2 | 1.3 | 2.2 | 1.3 | 3.6 | 1.3 | 1.6 | 1.2 | |
| Average values | (A) | 8.0 | 7.2 | 6.4 | 6.1 | 7.8 | 7.2 | 6.4 | 6.0 | ||
| (B) | 6.2 | 4.9 | 5.0 | 3.8 | 5.7 | 4.9 | 5.0 | 3.8 | |||
| (C) | 2.3 | 1.8 | 1.8 | 1.1 | 2.8 | 1.8 | 2.2 | 1.1 | |||
| X-ray | 4.8 | 3.8 | 3.7 | 2.8 | 4.7 | 3.8 | 3.9 | 2.7 | |||
| NMR | 4.2 | 3.5 | 3.5 | 2.7 | 4.4 | 3.5 | 3.7 | 2.8 | |||
| All | 4.5 | 3.7 | 3.6 | 2.7 | 4.6 | 3.7 | 3.8 | 2.7 |
| Mumias (Control site) | Butere (intervention site) | |||||||
| Health indicator | Baseline | Endline | Change | p-value | Baseline | Endline | Change | p-value |
| ANC | 66.3 | 56.0 | -10.3 | <0.0001 | 47.7 | 72.0 | 24.2 | <0.0001 |
| HFD | 49.5 | 46.3 | -3.2 | 0.173 | 41.1 | 47.2 | 6.1 | <0.0001 |
| Water | 31.6 | 81.1 | 49.5 | <0.0001 | 37.1 | 93.2 | 56.0 | <0.0001 |
| Latrine | 91.1 | 96.0 | 4.9 | <0.0001 | 80.5 | 94.5 | 14.0 | <0.0001 |
| Card | 85.1 | 86.3 | 1.2 | 0.486 | 91.0 | 89.3 | -1.7 | 0.025 |
| ITN | 58.7 | 94.5 | 35.7 | <0.0001 | 61.4 | 91.4 | 29.9 | <0.0001 |
| Penta 1 | 92.0 | 92.1 | 0.1 | 0.95 | 91.4 | 91.7 | 0.3 | 0.732 |
| Penta 3 | 87.5 | 88.6 | 1.1 | 0.46 | 89.5 | 90.1 | 0.7 | 0.417 |
| Food | 62.3 | 81.3 | 19.0 | <0.0001 | 36.0 | 56.4 | 20.3 | <0.0001 |
| Databases | PubMed | Embase | CINAHL |
| (“Saudi Arabia”[MeSH]) AND “Diabetes Mellitus, Type 2” [MeSH] | 114 (76), Ex: 38 (date range) | 1015 (853) Ex: 162 (DR) | 20 (20) Ex: 0 (DR) |
| (“Referral and Consultation” [MeSH]) AND “Saudi Arabia” [MeSH] | 77 (34) Ex: 43 (date range) | 0 | 51 (39) Ex: 12 (DR) |
| ((“Referral and Consultation” [MeSH]) AND “Saudi Arabia” [MeSH]) AND “Diabetes Mellitus, Type 2” [MeSH] | 0 | 0 | 0 |
| Total | 1277 |
| Exercise | Dosage |
| Abduction in sidelying | 3 sets of 10 at a 10 RM resistance |
| Unilateral hip abduction performed in sidelying with the use of ankle cuff weights | |
| Abduction in standing | 3 sets of 10 with moderate resistance band |
| Unilateral hip abduction performed in standing with the use of resistance band | |
| Standing wall isometric hip abduction | 3 sets of 10 with 5 second holds |
| Performed in unipedal stance with the opposite limb in 90 degrees of hip and knee flexion. Exercises will be done for both limbs. | |
| Adduction in sidelying | 3 sets of 10 at a 10 RM resistance |
| Unilateral hip adduction performed in sidelying with the use of ankle cuff weights if possible | |
| Abduction in standing | 3 sets of 10 with moderate resistance band |
| Unilateral hip abduction performed in standing with the use of resistance band | |
| Towel squeezes | 3 sets of 10 with 5 second holds |
| Bilateral isometric hip adduction against a rolled-up towel in sitting |
| Study | Genotype | Sex | N | Key Experimental Outcomes |
| Epithelial CellProliferation | WT | Both | 14 | In Fgf15-/- mice, we detected a shift of proliferating cells to upper crypt zones (P <0.001). |
| M | 8 | |||
| F | 6 | |||
| Fgf15-/- | Both | 15 | ||
| M | 8 | |||
| F | 7 | |||
| No Carcinogen Treatment | WT | Both | 12 | After >1 year surveillance without carcinogen treatment, no WT or Fgf15-/- mouse developed colon neoplasia. |
| M | 4 | |||
| F | 8 | |||
| Fgf15-/- | Both | 17 | ||
| M | 9 | |||
| F | 8 | |||
| Colon Tumor Induction (AOM/DSS) | WT | Both | 14 | Colon tumors were detected in 27 of 29 mice; Fgf15-/- mice had more colon tumors overall (P = 0.003), and in males (P = 0.03) and females (P < 0.05) considered separately. |
| M | 6 | |||
| F | 8 | |||
| Fgf15-/- | Both | 15 | ||
| M | 7 | |||
| F | 8 |
| Item | Person-time | % |
| Utilization of health services | ||
| Saw a doctor | 118 | 36.4 |
| Self-medication | 108 | 33.3 |
| Non use | 98 | 30.3 |
| Total | 324 | 100.0 |
| Type of selected medical institutions | ||
| Village health clinics or community health service stations | 53 | 44.6 |
| Township hospital | 7 | 6.2 |
| District-level hospital | 20 | 16.9 |
| City-level hospital or above | 15 | 12.3 |
| Unlicensed private clinic | 24 | 20.0 |
| Total | 118 | 100.0 |
| Barriers to delivery | Quotes |
| Time | “Did not have time to complete all activities”. (Teacher, school 20, self-evaluation data) |
| Environment | “It was weather more than anything you know. The game where we had to have the cones and you had to turn them over, we were out in a force 10 gale and they were just blowing everywhere and they were getting really upset”. (Teacher, school 1, interview data) |
| Educational understanding | “Some children didn’t have good knowledge of human body - this meant that they needed lots of support with bean bag game”. (Teacher (1), school 41, self-evaluation data) |
| Behaviour | “I quite often had characters in a bit of a sulk because of it [being put on the ‘smokers’ team]”. (Teacher, school 13, interview data) |
| Children’s preferences | “Used the same messages but changed the sport to basketball instead of football due to previous issues with some of the girls engaging with the context. The children loved the session”. (Teacher (1), school 8, self-evaluation data) |
| Total = 939 individuals | |||
| Parameter | NGT n = 473 (50.4%) | Pre-DM n = 250 (26.6%) | T2DM n = 216 (23%) |
| Age (years) | |||
| Mean ± SD | 48.5 ± 12.9 | 52 ± 10.6* | 55.8 ± 10.4∗† |
| Median [IQR] | 50 [40–58] | 52 [45–59] | 57 [49–62] |
| Women, n (%) | 328 (69.3) | 168 (67.2) | 142 (65.7) |
| BMI (kg/m2) | |||
| Mean ± SD | 28 ± 4.6 | 29.3 ± 4.4* | 30.4 ± 5.2∗† |
| Median [IQR] | 27.5 [24.7–31] | 29 [26.1–31.7] | 29.6 [26.8–32.8] |
| BMI ≥ 30 kg/m2, n (%) | 150 (31.7) | 99 (39.6) | 102 (47.2)* |
| WC (cm) | |||
| Mean ± SD | 91.3 ± 12.2 | 95.6 ± 9.9* | 98.3 ± 11.2∗† |
| Median [IQR] | 91 [82–99] | 95 [89–102] | 98 [91-105] |
| Hypertension, n (%) | 137 (28.9) | 77 (30.8) | 117 (54.1)∗† |
| Currents smoking, n (%) | 107 (22.6) | 48 (19.2) | 48 (22.2) |
| FH of T2DM, n (%) | 234 (49.4) | 146 (58.4) | 147 (68)* |
| FH of CVD, n (%) | 71 (15) | 38 (15.2) | 34 (15.7) |
| Variable | Placebo Frequency (%) | Caffeine Frequency (%) |
| Nervousness | 1 (4.8) | 5 (23.8) |
| AA homozygotes | 1 (20) | 0 (0) |
| C allele carriers | 0 (0) | 5 (31.3) |
| Insomnia | 3 (14.3) | 7 (33.3) |
| AA homozygotes | 0 (0) | 2 (40.0) |
| C allele carriers | 3 (18.8) | 5 (31.3) |
| Gastrointestinal problems | 0 (0) | 3 (14.3) |
| AA homozygotes | 0 (0) | 1 (20.0) |
| C allele carriers | 0 (0) | 2 (12.5) |
| Activeness | 3 (14.3) | 6 (28.6) |
| AA homozygotes | 2 (40.0) | 1 (20.0) |
| C allele carriers | 1 (6.3) | 5 (31.3) |
| Irritability | 0 (0) | 2 (9.5) |
| AA homozygotes | 0 (0) | 0 (0) |
| C allele carriers | 0 (0) | 2 (12.5) |
| Muscular pain | 4 (19) | 3 (14.3) |
| AA homozygotes | 0 (0) | 0 (0) |
| C allele carriers | 4 (25.0) | 3 (18.8) |
| Headache | 5 (23.8) | 4 (19.0) |
| AA homozygotes | 1 (20) | 1 (20) |
| C allele carriers | 4 (25.0) | 3 (18.8) |
| S.no. | Lab. no. | Binary code | Octal code | ST | Lineage |
| 1 | LN 8 | □□□■■■□■■■■■■■■■■■■■■■■■■■■■□□□□■□■■□□□■■■■ | 73777777413071 | Unidentified | Unidentified |
| 2 | AC 74 | ■□□□□□□■■■■■■■■■■■■■□□□■■■■■□■■■□□□□■■■■■■■ | 403777617560771 | Unidentified | Unidentified |
| 3 | AC 544 | ■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■□□□□■■■■■■■ | 777777777760771 | 53 | T1 |
| 4 | F 85 | □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■■■■■■■■■ | 3771 | 1 | BEIJING |
| 5 | F99 | ■■■■■■■■■■■■■■■■■■■■■■■■■□■□□□□■□□□□■■■■■■■ | 777777775020771 | Unidentified | Unidentified |
| Variable | Dominant | Non-dominant | Diff | AI% | p value | Effect size |
| Ankle angles (deg) | ||||||
| DorsiF (+)/PlantF(−) | 11.1 ± 7.6 | 12.0 ± 7.3 | 0.9 | 8 | 0.28 | 0.41 |
| Ever(+)/ Inv(−) | 5.4 ± 2.4 | 4.5 ± 2.7 | 0.9 | 17 | 0.39 | 0.33 |
| IntR(+)/ExtR(−) | −33.5 ± 13.2 | −29.1 ± 12.4 | 4.4 | 14 | 0.37 | 0.35 |
| Ankle moments (Nm/kg) | ||||||
| PlantF(+)/DorsiF(−) | 1.9 ± 0.4 | 2.0 ± 0.4 | 0.1 | 5 | 0.59 | 0.21 |
| Ever(+)/ Inv(−) | 0.7 ± 0.2 | 0.7 ± 0.1 | 0.0 | 0 | 0.91 | 0.04 |
| IntR(+)/ExtR(−) | 0.1 ± 0.1 | 0.2 ± 0.1 * | 0.1 | 67 | 0.04 | 0.74 |
| Knee angles (deg) | ||||||
| Flex(+)/Ext(−) | 57.4 ± 6.0 | 60.3 ± 10.2 | 2.9 | 5 | 0.37 | 0.35 |
| Var(+)/Valg(−) | −7.5 ± 5.0 | −6.1 ± 7.1 | 1.4 | 21 | 0.54 | 0.23 |
| IntR(+)/ ExtR(−) | 21.2 ± 9.4 | 24.7 ± 10.5 | 3.5 | 15 | 0.36 | 0.35 |
| Knee moments (Nm/kg) | ||||||
| Ext (+)/Flex(−) | 2.6 ± 0.5 | 2.5 ± 0.6 | 0.1 | 4 | 0.84 | 0.08 |
| Valg(+)/Var(−) | −2.5 ± 1.0 | −2.3 ± 0.8 | 0.2 | 8 | 0.55 | 0.23 |
| IntR(+)/ExtR(−) | 0.4 ± 0.1 | 0.3 ± 0.2 | 0.1 | 29 | 0.23 | 0.46 |
| Hip angles (deg) | ||||||
| Flex(+)/Ext(−) | 45.1 ± 11.9 | 49.4 ± 15.9 | 4.3 | 9 | 0.42 | 0.31 |
| Add(+)/ Ab(−) | −17.9 ± 6.7 | −18.0 ± 7.6 | 0.1 | 1 | 0.96 | 0.02 |
| IntR(+)/ExtR(−) | 22.4 ± 10.1 | 27.2 ± 12.5 | 4.8 | 20 | 0.27 | 0.42 |
| Hip moments (Nm/kg) | ||||||
| Ext (+)/Flex(−) | 4.0 ± 1.4 | 4.5 ± 1.6 | 0.5 | 12 | 0.34 | 0.37 |
| Ab(+)/Add(−) | −3.6 ± 1.4 | −3.3 ± 1.3 | 0.3 | 9 | 0.61 | 0.20 |
| IntR(+)/ExtR(−) | 1.3 ± 0.5 | 1.2 ± 0.5 | 0.1 | 8 | 0.91 | 0.04 |
| Pelvis angles (deg) | ||||||
| AntT(+)/PostT(−) | 2.2 ± 5.1 | 3.7 ± 7.5 | 1.5 | 49 | 0.56 | 0.23 |
| Contra Drop(+)/Contra Lift(−) | 15.0 ± 5.9 | 14.4 ± 7.8 | 0.6 | 4 | 0.81 | 0.09 |
| IntR(+)/ExtR(−) | −11.1 ± 13.1 | −11.2 ± 12.3 | 0.1 | 1 | 0.98 | 0.01 |
| Thorax angles (deg) | ||||||
| Flex(+)/Ext(−) | 30.5 ± 5.8 | 28.5 ± 6.4 | 2.0 | 7 | 0.41 | 0.32 |
| LatFlex(+)/MedFlex(−) | 21.0 ± 7.9 | 21.8 ± 5.5 | 0.8 | 4 | 0.75 | 0.12 |
| ExtR(+)/ IntR(−) | −11.8 ± 6.6 | −11.6 ± 5.6 | 0.2 | 2 | 0.93 | 0.03 |
| Ground reaction forces (N/kg) | ||||||
| Vertical | 15.1 ± 2.9 | 16.9 ± 4.4 | 1.8 | 11 | 0.21 | 0.48 |
| Medial/lateral | 1.3 ± 0.8 | 1.5 ± 1.1 | 0.2 | 14 | 0.52 | 0.25 |
| Longitudinal | 9.5 ± 1.7 | 10.2 ± 2.7 | 0.7 | 7 | 0.42 | 0.31 |
| Timing (s) | ||||||
| Ground contact time | 0.32 ± 0.04 | 0.35 ± 0.06 | 0.03 | 9 | 0.11 | 0.6 |
| Escalation phase | Extension phase | |||||
| Dose level(mg/kg) | No. of patients | DLT | Patients with grade 3–4 lirilumab-related adverse events | Dose level(mg/kg) | No. of patients | Patients with grade 3–4 lirilumab-related adverse events |
| 0.015 | 3 | 0 | 0 | 0.015 | 9 | 5 |
| 0.3 | 3 | 0 | 0 | |||
| 1 | 4 | 0 | 0 | |||
| 3 | 4 | 0 | 0 | 3 | 8 | 2 |
| 6 | 3 | 0 | 1a | |||
| 10 | 3 | 0 | 0 |
| Protein | Activator | Repressor |
| AP1 | [AP1 SEP] | [AG AG] |
| AP3 | [AP1 SEP], [AG SEP], [AP3 PI] | |
| PI | [AP1 SEP], [AG SEP], [AP3 PI] | |
| AG | [AG SEP], [AG AG] | [AP1 AP1] |
| SHP | [AG SEP] | [PI AP3] |
| SEP | [AG SEP], [AP1 SEP], [SEP SEP] |
| Solvent | Δf | Ex | Emmax | (vA-vF)*(10-3) cm-1 | Symbols and labels in Figure 3 |
| AB | 0.32 | 275 | 388 | 10.6 | AB |
| AB | 0.32 | 280 | 389 a | 10.0 | AB |
| AB | 0.32 | 237 | 396 a | 16.9 | (AB) |
| AN | 0.30 | 275 | 346 b | 7.5 | AN |
| AN | 0.30 | 275 | 402 b | 11.5 | AN |
| AN | 0.30 | 272 | 343 c | 7.6 | AN |
| AN | 0.30 | 231 | 344 c | 14.2 | (AN) |
| EtOH | 0.30 | 275 | 365 | 9.0 | EtOH |
| EtOH | 0.30 | 275 | 365 d | 9.0 | EtOH |
| EtOH | 0.30 | 235 | 373 d | 15.7 | (EtOH) |
| DMSO | 0.26 | 280 | 353 | 7.4 | DMSO |
| DMSO | 0.26 | 276 | 351 | 7.7 | DMSO |
| Blend composition | Electrospinning parameters | ||
| Voltage, kV | Solution supply rate, ml/h | Distance between spinneret and collector, cm | |
| 3% Tec-80A + 5% GL | 19.0 | 1.3 | 20 |
| 3% Tec-80A + 10% GL | 18.5 | 1.3 | 20 |
| 3% Tec-80A + 15% GL | 18.5 | 1.2 | 19.5 |
| 3% Tec-80A + 20% GL | 20.0 | 1.2 | 19.5 |
| 5% Tec-80A + 5% GL | 19.5 | 1.3 | 20 |
| 5% Tec-80A + 10% GL | 22.5 | 1.4 | 20 |
| 5% Tec-80A + 15% GL | 21.0 | 1.4 | 18.5 |
| 5% Tec-80A + 20% GL | 20.0 | 1.3 | 18.5 |
| 7% Tec-80A + 5% GL | 21.0 | 1.5 | 20 |
| 7% Tec-80A + 10% GL | 22.1 | 1.3 | 20 |
| 7% Tec-80A + 15% GL | 24.0 | 1.2 | 19 |
| 7% Tec-80A + 20% GL | 24.0 | 1.0 | 19 |
| UEBMI | NCMS | |||||||
| Expenditure (¥) | Out-of-pocket payment (%) | Hospital stay (day) | Expenditure per day (¥) | Expenditure (¥) | Out-of-pocket payment (%) | Hospital stay (day) | Expenditure per day (¥) | |
| 2004 | 4786.32 | 2147.93(44.88) | 10.36 | 462.00 | 4208.13 | 3786.05(89.97) | 8.65 | 486.49 |
| 2005 | 4956.01 | 2113.56(42.65 | 10.45 | 474.26 | 4430.15 | 3889.23(87.79) | 8.14 | 544.24 |
| 2006 | 4869.11 | 2032.97(41.75) | 11.08 | 439.45 | 4275.56 | 3653.04(85.44) | 7.46 | 573.13 |
| 2007 | 9935.18 | 2990.43(30.10) | 14.67 | 677.24 | 4485.92 | 3803.16(84.78) | 9.03 | 496.78 |
| 2008 | 6908.14 | 2561.68(37.08) | 13.11 | 526.94 | 4362.49 | 3693.41(84.66) | 8.20 | 532.01 |
| 2009 | 7080.39 | 2416.01(34.12) | 14.02 | 505.02 | 5596.96 | 4375.81(78.18) | 10.28 | 544.45 |
| 2010 | 7299.08 | 2277.33(31.20) | 13.87 | 526.25 | 5875.66 | 3874.93(65.95) | 10.39 | 565.51 |
| 2011 | 6458.69 | 1669.90(25.86) | 12.68 | 509.36 | 5590.74 | 3099.93(55.45) | 9.84 | 568.16 |
| 2012 1sthalf | 5830.09 | 1427.57(24.49) | 10.17 | 573.26 | 5903.05 | 2596.72(43.99) | 10.38 | 568.69 |
| Gene | Accession number | Probe sequence (5′-> 3′) |
| Cd68 | NM_001031638 | ATCCTCATTTCTTCAGCATGCAATTGACTCAACAGAGTTATCTCCCTTCTCTGTCTTTAAA |
| RT1-Bb | NM_001004084 | CAGCTGTGACAGTTGTGAAATACCCTAGCTTCTGATAACAGAATGAGTTACTTCTTCCCAA |
| Cd86 | NM_020081 | TAAGCAAGGATACCCGAAACCTACAAAGATGTATTTTTTGATAACTAATA |
| Cd80 | NM_012926 | TGAATCTGAGCTGTACACCATTAGTAGCCAACTAGACTTCAACACGACGTACGACCACTTA |
| Ccl17 | NM_057151 | CTGCACAGACCCCAAAGACAAGCATGTGAAGAAGGCCATCAGACACCTGAAAAACCAAAGA |
| Ccl22 | NM_057203 | GATATCTGTGCTGACCCCAGGATGCTCTGGGTGAAGAAGATACTCCACAAGTTGGCCTAGA |
| Ccl22 | NM_057203 | AAATAAATTTGCTTGCTCCTTTGGAGGGAACAGTGGCCTGGCTTAGCTGAGTGAATGGATA |
| II12a | NM_053390 | ACTTCAGAGCCACAATCATCAGCAGATCACTCTGGACAGAAACATGCTGATGGCTATTGAA |
| II12b | NM_022611 | TTGGTCCACCGAGATTTTAAAAAATTTCAAAAATAAGACTTTCCTGAAGTGTGAAGCACCA |
| Cd40 | NM_134360 | ATGGAGGAAAAGCTTTGGCGTCAGGGGTCCGCAGTAATATCTACAGAGTGCAGCAATGCAA |
| Cd40 | NM_134360 | ACTGCACAGCTCTTGAGAAGACCCAATGCCAACCGTGCGACTCAGGCGAATTCTCAGCTCA |
| Ox40L | NM_053552 | TTGTGTTACAATACAGTGCGTATGTCTTGAACCTCCAGAAAGTCTGAAGGCTACTAATCCA |
| Variables | Number (n) | R-Ras expression | p-value | |
| Positive (n=83) | Negative (n=109) | |||
| Gender | 0.389 | |||
| Male | 112 | 45 | 67 | |
| Female | 80 | 38 | 42 | |
| Ages (years) | 0.528 | |||
| >=65 | 91 | 42 | 49 | |
| <65 | 101 | 41 | 60 | |
| Tumor location | 0.661 | |||
| ascending colon | 97 | 41 | 56 | |
| transverse colon | 7 | 2 | 5 | |
| descending colon | 88 | 40 | 48 | |
| CEA level (mg/L) | 7.20±7.00 | 17.46±34.66 | 0.008* | |
| Tumor differentiation | 0.886 | |||
| Well | 21 | 10 | 11 | |
| Moderate | 135 | 57 | 78 | |
| Poor | 36 | 16 | 20 | |
| AJCC stage | 0.751 | |||
| IIIA | 7 | 4 | 3 | |
| IIIB | 124 | 53 | 71 | |
| IIIC | 61 | 26 | 35 |
| Clinical parameters | Correlation coefficient | P-value (2-tailed) |
| CEA | −0.023 | 0.885 |
| CA125 | −0.025 | 0.883 |
| CA153 | 0.007 | 0.966 |
| CA199 | −0.048 | 0.761 |
| CA724 | 0.175 | 0.288 |
| CYFRA21-1 | −0.110 | 0.493 |
| NSE | −0.168 | 0.308 |
| SCC | −0.398 | 0.012a |
| Women | Men | ||||||
| Increased use | OR | 95% CI | OR | 95% CI | |||
| Any substance | PTSD symptoms | *1.143 | 1.112 | 1.174 | *1.108 | 1.088 | 1.129 |
| Exposure to incident | *1.215 | 1.080 | 1.367 | 1.106 | 1.000 | 1.223 | |
| Pharmaceuticals | PTSD symptoms | *1.172 | 1.125 | 1.221 | *1.139 | 1.103 | 1.176 |
| Exposure to incident | *1.304 | 1.122 | 1.517 | 1.206 | 1.042 | 1.397 | |
| Alcohol | PTSD symptoms | *1.116 | 1.074 | 1.159 | *1.110 | 1.086 | 1.135 |
| Exposure to incident | *1.177 | 1.010 | 1.372 | 1.008 | 0.892 | 1.139 | |
| Cannabis | PTSD symptoms | *1.148 | 1.057 | 1.246 | *1.101 | 1.068 | 1.135 |
| Exposure to incident | *1.517 | 1.180 | 1.951 | 1.076 | 0.918 | 1.261 | |
| Tobacco | PTSD symptoms | *1.098 | 1.066 | 1.132 | *1.078 | 1.055 | 1.100 |
| Exposure to incident | 1.095 | 0.959 | 1.250 | 1.117 | 0.999 | 1.249 |
| 3 weeks | 5 weeks | |||
| HF | HFPL | HF | HFPL | |
| (n = 10) | (n = 8) | (n = 9) | (n = 10) | |
| Initial body wt (g) | 17.6 ± 0.5 | 17.1 ± 0.9 | 18.0 ± 0.5 | 17.6 ± 0.8 |
| Final body wt (g) | 23.6 ± 0.5 | 23.8 ± 0.6 | 27.7 ± 0.6 | 28.8 ± 0.8 |
| Wt gain (g) | 6.0 ± 0.3 | 6.7 ± 0.6 | 9.7 ± 0.7 | 11.3 ± 0.5 |
| Liver wt (g) | 1.20 ± 0.04 | 1.07 ± 0.06 | 1.35 ± 0.06 | 1.29 ± 0.04 |
| Liver wt/body wt (g/100 g) | 5.07 ± 0.17 | 4.48 ± 0.15 * | 4.90 ± 0.20 | 4.47 ± 0.09 |
| Food intake (g/mouse/day) | 3.5 ± 0.3 | 3.2 ± 0.1 | 2.9 ± 0.1 | 3.1 ± 0.1 |
| Fecal excretion (g/mouse/day) | 0.23 ± 0.02 | 0.26 ± 0.01 | 0.23 ± 0.01 | 0.22 ± 0.01 |
| Model 2 | B | SE | HR | 95% CI | p | |
| Inferior | Superior | |||||
| Male gender | .68 | .23 | 1.97 | 1.27 | 3.08 | 0.003 |
| Age | .09 | .01 | 1.09 | 1.06 | 1.12 | <0.001 |
| Lipid-lowering drugs | -.57 | .24 | .56 | .35 | .91 | 0.019 |
| Triglycerides ADA categories | ||||||
| - Satisfying criteria | 1 | 0.025 | ||||
| - Partially satisfying criteria | .72 | .30 | 2.05 | 1.14 | 3.68 | 0.017 |
| - Not satisfying criteria | .55 | .24 | 1.73 | 1.08 | 2.77 | 0.022 |
| Antidiabetic treatment | ||||||
| - Diet | 1 | 0.006 | ||||
| - Biguanides | -.79 | .38 | .45 | .22 | .96 | 0.038 |
| - Sulfonylureas | -.73 | .64 | .48 | .14 | 1.68 | 0.253 |
| - Biguanides + Sulfonylureas | -.86 | .35 | .42 | .21 | .84 | 0.014 |
| - Insulin | .17 | .35 | 1.18 | .60 | 2.33 | 0.630 |
| - Insulin + OHA | -.18 | .37 | .84 | .41 | 1.72 | 0.631 |
| Threshold on Wells scale = 2 | Thrombosis | Without Thrombosis |
| Number of points on the Wells scale: >2 | 40 | 60 |
| Number of points on the Wells scale: ≤2 | 20 | 928 |
| Sensitivity: 66.66% | Positive predictive value: 40.00% | |
| Specificity: 93.93% | Negative predictive value: 97.89% |
| Probabilities | |||||
| Variable | No RX | rFVIIa (40 mcg) | rFVIIa (80 mcg) | Utilities | Range |
| Mild post-ICH deficit (mRS 0–1) | 0. 08 | 0. 17 | 0. 21 | 0. 81 | 0. 70–0. 95 |
| Moderate post-ICH deficit (mRS 2–3) | 0. 23 | 0. 29 | 0. 29 | 0. 55 | 0. 2–0. 65 |
| Severe post-ICH deficit (mRS 4–5) | 0. 40 | 0. 37 | 0. 30 | 0. 25 | (-0. 2)-0. 45 |
| Death after ICH | 0. 29 | 0. 18 | 0. 18 | 0 | 0 |
| Arterial thromboembolic event | 0. 02 | 0. 02 | 0. 55 | ||
| Probability of dying after ATE | 0. 29 | 0. 29 |
| 1.5T SSFP 1.2x1.2x6mm3 | 7T FGRE 1.2x1.2x6mm3 | 7T FGRE 1.3x1.3x4mm3 | p-value | |
| RVEDV [ml] | 0.5850 | |||
| Median | 146.2 | 138.6 | 152.1 | |
| Min. - Max. | 127.4 - 202.3 | 124-0 - 207.7 | 121.4 - 222.8 | |
| RVESV [ml] | 0.5462 | |||
| Median | 65.2 | 62.4 | 69.3 | |
| Min. - Max. | 57.4 - 91.1 | 53.7 - 93.5 | 54.6 - 103.6 | |
| RVEF [%] | 0.2789 | |||
| Median | 55.0 | 56.7 | 55 | |
| Min. - Max. | 54 - 57 | 54 - 58 | 54 - 58 | |
| RVM [g] | 0.0743 | |||
| Median | 35 | 36 | 33 | |
| Min. - Max. | 26 - 49 | 24 - 53 | 26 - 51 |
| Country | Existing laws alluding to quality and patient safety |
| Jordan | In Jordanian law, the Public Health Code includes articles that emphasize the state’s responsibility to provide healthcare, and the Ministry of Health’s responsibility regarding health matters as follows: - Provide illness prevention, curative measures and supervisory services. - Organize and supervise private and public sector health services. - Provide citizens with health insurance within the allotted parameters. - Establish health, educational and training institutions related to the Ministry and to supervise their management once established. |
| As stipulated in Jordanian Law 9 (1999), the High Health Council is responsible for drafting health policies and developing strategic plans as well as planning health services to ensure equitable access to and provision of outstanding health services to all population. Other institutions include Jordanian Medical Council, Supreme Council for Population, Jordanian Nursing Council, National Council for Family Affairs, General Organization for Food and Drug Administration and Department of Joint Procurement | |
| Lebanon | The Ministerial Decree 7612, issued by the parliament in 2002, which amends the legislative decree 139/83 (1983), states that “the MOPH has the right to evaluate, classify and accredit hospitals according to their status, field of specialty and range of services provided”. The decree 482/1 (2009) sets a national Committee for Accreditation of Hospitals, chaired by the Director General of Health. |
| Type of paper | EpidemiologyN papers (%)N citations | Eur Respir JN papers (%)N citations |
| National | 17 (71)53 | 10 (53)18 |
| (US) | 9 (38)68 | 1 (5)6 |
| (other) | 8 (33)37 | 9 (48)18 |
| International | 7 (29)54 | 9 (48)23 |
| Inter-European | 1 (4)16 | 6 (32)25 |
| Patients | Professionals |
| - Do you know anything about lifestyle modification (diet, exercise, etc.) in order to change your mood and depression?- All of you have taken part in a research project about modifying lifestyles. Did these recommendations that were given to you show you something new that you did not know?- Did you follow the recommendations for modifying lifestyles?If NOT, why didn’t you follow them?- How did you feel when you followed the recommendations? And when you didn’t?- What difficulties did you encounter in implementing the recommendations?- Do you think these recommendations helped you?- What do you think about the doctor’s role?- And about the way of carrying out this modification?- Do you think another type of intervention would have helped you? Would an educational group or another kind of intervention have helped you?- Do you think there is something more that can be done to help you to modify your lifestyle when depressed? | - How do you think you should make recommendations for modifying life styles?- And to a patient with depression?- Do you know how this intervention can help him/her?- Do you think these recommendations can be effective? And do you believe the patient thinks that they work?- What difficulties do you think depressed patients have in changing their behaviour?- And what feelings do they have?- And as for modifying lifestyles, do you work in a different way in the case of a depressed patient?- What do you think is necessary in order to be effective when modifying lifestyles?- What do you think about educational groups?- And about follow-up?- Do you think these interventions are feasible from PC?- What difficulties do you encounter when giving this type of advice?- What is the appropriate level (or department or system) to implement this kind of interventions? |
| Risperidone | Olanzapine | Quetiapine | Ziprasidone | Aripiprazole | FGAs | No medication | |
| Subjects (M/F) | 47 (35/12) | 13 (6/7) | 44 (29/15) | 2 (2/0) | 1 (0/1) | 5 (3/2) | 39 (22/17) |
| Mean Age (SD) | 11.54 (3.13) | 15.16 (2.12) | 13.31 (2.97) | 14.63 (0.36) | 16.77 | 15.22 (1.16) | 11.88 (3.27) |
| Mean Dose mg (SD) | 1.18 (0.78) | 10.77 (4.83) | 196.02 (175.58) | 30.00 (14.14) | 7.50 | - | - |
| CPZ Equiv mg (SD) | 58.78 (39.09) | 215.38 (96.58) | 261.36 (234.10) | 50.00 (23.57) | 100.00 | 119.29 (111.33) | - |
| On-Label Use (% of total on drug) | 11 (23.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (100.0) | 0 (0.0) | - |
| Off-Label Use (% of total on drug) | 36 (76.6) | 13 (100.0) | 44 (100.0) | 2 (100.0) | 0 (0.0) | 5 (100.0) | - |
| Titrated Switch Pre Hosp (% of switches) | 1 (3.1) | 2 (6.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (3.1) | 2 (6.3) |
| Titrated Switch Post Hosp (% of switches) | 1 (3.1) | 2 (6.3) | 2 (6.3) | 0 (0.0) | 1 (3.1) | 0 (0.0) | 0 (0.0) |
| Immediate Switch Pre Hosp (% of switches) | 0 (0.0) | 0 (0.0) | 2 (6.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (6.3) |
| Immediate Switch Post Hosp (% of switches) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Gap Switch Pre Hosp (% of switches) | 0 (0.0) | 2 (6.3) | 3 (9.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 3 (9.4) |
| Gap Switch Post Hosp (% of switches) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Overlapped Switch Pre Hosp (% of switches) | 3 (9.4) | 1 (3.1) | 4 (12.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (6.3) |
| Overlapped Switch Post Hosp (% of switches) | 0 (0.0) | 0 (0.0) | 1 (3.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Process | 2o rate constant (#min-1) | Enzyme | Enz # | 1o rate const (min-1) | PTM modifying rate | Rate MF | Reference |
| Synthesis (NULL → FOXO) | 0.0055 | E2F1 | 300 | 5.5 | [45] Figure 1 | ||
| Cytoplasm → nuclear transport | - | - | - | 0.1/0.55 = 0.182 | [3], [46] | ||
| Akt-Phos Pa | 0.1 | [46] | |||||
| IKK-Phos Pd | 0.5 | [47] Figure 1 | |||||
| JNK-Phos Pe | 10 | [44] | |||||
| Nuclear → cytoplasm transport | - | - | - | 0.1 × 0.55 = 0.055 | [3], [46] | ||
| Akt-Phos Pa | 10 | [46] | |||||
| IKK-phos Pd | 10 | [47] | |||||
| JNK-Phos Pe | 0.1 | [44] | |||||
| Nuclear → DNAbound transport | - | - | - | 0.25 | [48] | ||
| Akt-Phos Pa | 0.5 | [49] Figure 6B | |||||
| DNAbound → Nuclear transport | - | - | - | 0.25 × 0.5 = 0.125 | [48] | ||
| basal phosphorylation | 5 × 10-5 | ||||||
| basal dephosphorylation | 1 × 10-6 | ||||||
| akt_phos_factor | 6 | ||||||
| ikk phos_factor | 3 | ||||||
| jnk phos_factor | 2 | ||||||
| FOXO → FOXO_Pa | akt phos_factor × basal phosphorylation | Akt | (104) | 0.5 | [50] Figure 1C | ||
| FOXO_Pa → FOXO | basal dephosphorylation | PP2A | 5 × 105 | 0.5 | |||
| FOXO → FOXO_Pd | ikk phos_factor × basal phosphorylation | IKK | (104) | 0.5 | [47] | ||
| FOXO_Pd → FOXO | basal dephosphorylation | PP2A | 5 × 105 | 0.5 | |||
| FOXO → FOXO_Pe | jnk phos_factor × basal phosphorylation | JNK | (104) | 0.5 | [44] | ||
| FOXO_Pe → FOXO | basal dephosphorylation | PP2A | 5 × 105 | 0.5 | |||
| FOXO → FOXO_pUb | 1 × 10-6 | SCF/MDM2 | 103 | 10-3 | [45] Figure 1; also [51] | ||
| Akt (Pa) | 3 | [45] Figure 1 | |||||
| IKK (Pd) | 22 | [47] Figure 5F | |||||
| Degradation (FOXO_pUb → NULL) | 1 × 10-4 | Proteasome | 103 | 0.1 | [45] Figure 1 |
| Family | Species | Size of mt DNA (bp) | GenBank accession no. |
| Babesiidae | B. orientalis | 5996 | KF218819 |
| B. bovis | 6005 | EU075182 | |
| B. bovis | 5970 | AB499088 | |
| B. bigemina | 5924 | AB499085 | |
| B. caballi | 5847 | AB499086 | |
| B. gibsoni | 5865 | AB499087 | |
| B. rodhaini | 6929 | AB624357 | |
| Theileriidae | T. parva | 5895 | Z23263 |
| T. parve | 5924 | AB499089 | |
| T. equi | 8246 | AB499091 | |
| T. orientalis | 5957 | AB499090 | |
| T. annulata | 5905 | NT167255 | |
| Plasmodiidae | P. falciparum | 5967 | M76611 |
| Simulation | 1 | 2 | 3 | 4 | 5 | 6 |
| First 1,000 iterations (the initial peak number = 11) | ||||||
| peak birth (RGP) | 0.00E-4 | 0.00E-4 | 0.00E-4 | 0.00E-4 | 0.00E-4 | 0.00E-4 |
| peak birth (RJ) | 0.00E-4 | 0.00E-4 | 0.00E-4 | 0.00E-4 | 0.00E-4 | 0.00E-4 |
| peak death (RGP) | 6.70E-3 | 1.55E-2 | 1.55E-2 | 1.33E-2 | 1.55E-2 | 1.55E-2 |
| peak death (RJ) | 6.70E-3 | 1.55E-2 | 1.55E-2 | 1.33E-2 | 1.55E-2 | 1.55E-2 |
| peak mutation (RGP) | 1.72E-2 | 3.53E-2 | 3.94E-2 | 1.30E-2 | 5.90E-3 | 2.73E-2 |
| peak mutation (RJ) | 1.93E-2 | 3.33E-2 | 4.42E-2 | 1.30E-2 | 5.90E-3 | 2.17E-2 |
| First 50,000 iterations (the initial peak number = 1) | ||||||
| peak birth (RGP) | 1.70E-4 | 1.26E-4 | 1.26E-4 | 1.70E-4 | 1.27E-4 | 8.50E-5 |
| peak birth (RJ) | 1.27E-4 | 1.26E-4 | 8.44E-5 | 1.28E-4 | 1.27E-4 | 8.43E-5 |
| peak death (RGP) | 0.00E-4 | 4.26E-5 | 2.12E-4 | 4.20E-5 | 2.53E-4 | 7.59E-4 |
| peak death (RJ) | 1.26E-4 | 4.25E-5 | 2.54E-4 | 4.20E-5 | 4.21E-5 | 7.21E-4 |
| peak mutation (RGP) | 1.71E-2 | 4.27E-2 | 4.08E-2 | 1.21E-2 | 8.96E-3 | 1.02E-2 |
| peak mutation (RJ) | 1.56E-2 | 3.04E-2 | 4.90E-2 | 8.51E-3 | 6.38E-3 | 1.41E-2 |
| Cause of hospitalization | Cause of death | |||
| Event | N | % | N | % |
| WHO stage 2 events | 1 | 0.65 | 0 | 0 |
| WHO 3 non-specific events | 10 | 6.45 | 0 | 0 |
| WHO 3 severe events | 58 | 37.42 | 11 | 44 |
| WHO stage 4 events | 29 | 18.71 | 10 | 40 |
| WHO stage 4 cachexia | 9 | 5.81 | 0 | 0 |
| Non-AIDS-defining infection | 42 | 27.10 | 4 | 16 |
| Non-AIDS-defining disease | 3 | 1.94 | 0 | 0 |
| Secondary effects to treatment | 2 | 1.29 | 0 | 0 |
| Uncategorised | 1 | 0.65 | 0 | 0 |
| Total | 155 | 100.00 | 25 | 100 |
| Microscopy | PCR | ||||||||
| N | Pf | Pv | Pm | Po | Pf/Pv | Pf/Pm | Pv/Po | Negative | |
| Pf | 135 | 117 | 2 | 0 | 0 | 13 | 3 | 0 | 0 |
| Pv | 94 | 0 | 82 | 0 | 2 | 9 | 0 | 1 | 0 |
| Pm | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Pf/Pv | 31 | 0 | 0 | 0 | 0 | 30 | 1 | 0 | 0 |
| Negative | 864 | 23 | 15 | 0 | 0 | 0 | 0 | 0 | 826 |
| Total | 1125 | 140 | 99 | 1 | 2 | 52 | 4 | 1 | 826 |
| Patient N° | |||||
| 1. | 2. | 3. | 4. | 5. | |
| Duration of tube feeding (days) | 7 | 15 | 8 | 6 | 9 |
| Parenteral nutritional support | none | none | 12 kcal/kg/day (9 days) | none | none |
| The start of liquid diet per os | 4 | 7 | 7 | 6 | 6 |
| Cumulative nitrogen balance during first 7 days after surgery | -6 grams | -18 grams | 4 grams | 0 gram | -8 grams |
| ICU free days | 9 | 23 | 12 | 9 | 9 |
| Length of hospital stay | 10 | 28 | 12 | 9 | 12 |
| Complications | none | myocardial infarction | urinary infection | none | wound infection |
| Outcome | discharged | died in 28th post day | discharged | discharged | discharged |
| Age < 30 years (n =3148) | Age 30-39 years (n = 9310) | Age 40-49 years (n = 13747) | Age ≥ 50 years (n = 3520) | |||||
| Patients | Controls | Patients | Controls | Patients | Controls | Patients | Controls | |
| Diagnosis of EOC | ||||||||
| Yes | 2 | 3 | 10 | 4 | 18 | 22 | 9 | 7 |
| No | 571 | 2572 | 1781 | 7515 | 3005 | 10702 | 549 | 2955 |
| IR | 4.99 | 1.78 | 9.89 | 0.96 | 10.66 | 3.38 | 35.81 | 5.80 |
| Crude HR (95% CI) | 2.80 (0.47-16.74) | 1.00 | 13.80 (3.80-50.11)** | 1.00 | 3.03 (1.62-5.64)* | 1.00 | 6.74 (2.51-18.10)* | 1.00 |
| Adjusted HR (95% CI) | 3.34 (0.54-20.60) | 1.00 | 19.41 (5.02-75.10)** | 1.00 | 3.41 (1.76-6.61)* | 1.00 | 9.63 (3.27-28.37)** | 1.00 |
| Aged parental clone | Origin | Overall haematopoietic chimerism (%±s.d.) | Overall relative chimerism (%±s.d.) | Lineage distribution of test cells in 1°transplants, iPS chimeras and 2° transplants (%±s.d.) | Lineage distribution of young cells (blastocyst/morula-derived; %±s.d.) | ||||
| T cell | B cell | Myeloid | T cell | B cell | Myeloid | ||||
| M/E clone 1 (myeloid only) | 1° Transplant | NA | NA | 0 | 0 | 100 | NA | NA | NA |
| iPS chimera | 26.9 | 100 | 11.2 | 60.6 | 28.2 | 45.5 | 32.3 | 22.2 | |
| 2° Transplant, iPS origin (n=4) | 25.8±3.6 | 113.9±45.4 | 8.7±4.9 | 75.4±10.9 | 15.9±8.9 | 22.7±9.5 | 62±6.2 | 15.3±3.5 | |
| M/E clone 2 (myeloid only) | 1° Transplant | NA | NA | 0 | 0 | 100 | NA | NA | NA |
| iPS chimera | 25.5 | 100 | 20.1 | 60.9 | 19 | 58.5 | 26.1 | 15.3 | |
| 2° Transplant, iPS origin (n=4) | 18.6±3.3 | 73.1±12.8 | 10.1±1.7 | 76.9±6.1 | 13.1±6.8 | 26±4.4 | 61.5±3.6 | 12.5±4.2 | |
| M/E clone 3 (myeloid only) | 1° Transplant | NA | NA | 0 | 0 | 100 | NA | NA | NA |
| iPS chimera | 55.4 | 100 | 32.9 | 36.8 | 30.3 | 55.8 | 27.2 | 17 | |
| 2° Transplant, iPS origin (n=4) | 60.9±10.4 | 109.9±18.7 | 22.3±6 | 60.9±1.1 | 16.8±6.4 | 42.7±5.2 | 41±7.2 | 16.3±6.3 | |
| M/B/E clone 1 (T-cell deficient) | 1° Transplant | NA | NA | 0 | 16.5 | 83.5 | NA | NA | NA |
| iPS chimera | 33.7 | 100 | 11.5 | 69.2 | 19.3 | 36.9 | 51.8 | 11.3 | |
| 2° Transplant, iPS origin (n=5) | 27.6±9.7 | 79.7±32.8 | 22.4±6.2 | 64.7±10.1 | 13±5.9 | 43.7±6.1 | 40.7±7.8 | 15.6±2.3 | |
| M/B/E clone 2 (T-cell deficient) | 1° Transplant | NA | NA | 0 | 24.5 | 75.5 | NA | NA | NA |
| iPS chimera | 22.4 | 100 | 29.5 | 31.7 | 38.8 | 62.3 | 22.3 | 15.4 | |
| 2° Transplant, iPS origin (n=5) | 21.4±4.1 | 71.9±31.5 | 12.8±3.7 | 78.8±3.3 | 8.3±2.6 | 29.8±5.3 | 54.3±1.7 | 15.9±6.3 |
| Training Dataset : Protein {:Chain}{:Domain Boundaries} | ||||
| 1a6q:297–368 | 1lok:A | 1etx:A | 1nj4:A:263–355 | 1egw:A |
| 1ako | 1lqp:A | 1ew4:A | 1nls | 1erz:A |
| 1ayl:228–540 | 1ltz:A | 1eyq:A | 1nzi:A:1–117 | 1ftr:A:1–148 |
| 1ayo:A | 1m1n:A | 1eyv:A | 1o08:A | 1gpr |
| 1bx4:A | 1mf7:A | 1f60:A:241–334 | 1o1x:A | 1gxu:A |
| 1byq:A | 1mgp:A | 1g61:A | 1oi7:A:122–288 | 1h16:A |
| 1c5k:A:35–162 | 1mn8:A | 1gs9:A | 1qnf:205–475 | 1h4x:A |
| 1c97:A:2–528 | 1mv8:A:203–300 | 1gso:A:-2–103 | 1qre:A | 1hqs:A |
| 1cip:A:61–181 | 1nf9:A | 1hbn:A:2–269 | 1qtn:A | 1hs6:A:1–208 |
| 1cuk:156–203 | 1nvm:A:291–341 | 1hx0:A:404–496 | 1who | 1hz4:A |
| 1d8c:A | 1o98:A:77–310 | 1i1w:A | 2pth | 1jid:A |
| 1ejx:A | 1oo0:A | 1iom:A | 2uag:A:298–437 | 1k4g:A |
| 1evl:A:533–642 | 1orv:A:39–508 | 1j3a:A | 3grs:364–478 | 1kj9:A:113–318 |
| 1f46:A | 1p3d:A:107–321 | 1jat:A | 4eug:A | 1kq1:A |
| 1fye:A | 1qhp:A:577–686 | 1jhf:A:73–198 | 16pk | 1kqf:A:34–850 |
| 1g8l:A:327–409 | 1qna:A:17–115 | 1jkx:A | 1bkr:A | 1dfu:P |
| 1gdn:A | 1rl6:A:7–81 | 1k3x:A:125–213 | 1c8z:A | 1mwx:A:139–327 |
| 1gpj:A:303–404 | 1tfe | 1k3y:A:81–222 | 1cs0:B:2–152 | 1p5u:A:148–234 |
| 1h4a:X:1–85 | 4ubp:B | 1k7k:A | 1dg6:A | 1qop:A |
| 1heu:A:164–339 | 1af7:11–91 | 1kbl:A:377–509 | 1di6:A | 1whi |
| 1hp1:A:363–550 | 1aie | 1kmt:A | 1dmh:A | 1xxa:A |
| 1hqk:A | 1bd8 | 1lam:1–159 | 1dqe:A | 2ilk |
| 1ir1:S | 1cqm:A | 1ld8:A | 1duv:G:1–150 | 2sns |
| 1kb0:A:1–573 | 1dl2:A | 1m15:A:2–95 | 1dw9:A:87–156 | 2spc:A |
| 1kqp:A | 1dto:A | 1me4:A | 1dy5:A | 3nul |
| 1l8a:A:701–886 | 1e39:A:360–505 | 1me8:A:2–101 | 1e58:A | 8ruc:A:9–147 |
| 1l8b:A | 1e4c:P | 1mg4:A | 1eaz:A | 1a77:209–316 |
| 1ldg:164–329 | 1ekr:A | 1moo:A | 1ez3:A | 1a8o |
| 1lkk:A | 1elk:A | 1muw:A | 1f8n:A:6–149 | 1c1d:A:1–148 |
| 1lqt:A:2–108 | 1exm:A:313–405 | 1mvl:A | 1fdr:101–248 | 1crz:A:141–409 |
| 1m1g:A:132–190 | 1fwx:A:8–451 | 1n55:A | 1fsg:A | 1czp:A |
| 1m26:A | 1gmi:A | 1n60:B:7–146 | 1fx2:A | 1dci:A |
| 1mj4:A | 1gs5:A | 1n61:C:1–177 | 1g8m:A:4–200 | 1mfm:A |
| 1n1b:A:271–598 | 1gtk:A:220–313 | 1n8k:A:1–163 | 1gkm:A | 1g7s:A:329–459 |
| 1n3l:A | 1hf8:A | 1nm8:A:9–385 | 1gmx:A | 1gkp:A:2–54 |
| 1n62:A:82–163 | 1hlr:A:311–907 | 1o26:A | 1got:G | 1gxr:A |
| 1ns5:A | 1hq1:A | 1ofd:A:1240–1507 | 1gqz:A:1–130 | 1hxk:A:31–411 |
| 1nxj:A | 1ijy:A | 1oht:A | 1gvo:A | 1i9c:A |
| 1oe1:A:1–159 | 1ix9:A:1–90 | 1or7:A:-1–111 | 1h05:A | 1iu7:A:212–628 |
| 1p5v:A:7–147 | 1iz5:A:2–120 | 1ox0:A:-5–251 | 1h3n:A:226–417 | 1j8b:A |
| 1qhv:A | 1jos:A | 1qcz:A | 1hb6:A | 1jp3:A |
| 1qqf:A | 1k0r:A:184–262 | 1qh4:A:103–381 | 1i2t:A | 1jsd:A |
| 1qsa:A:1–450 | 1khb:A:10–259 | 1qnx:A | 1i4j:A | 1jw9:B |
| 1rss | 1khd:A:12–80 | 1d0c:A | 1ikt:A | 1k8y:B |
| 1tig | 1kp8:A:2–136 | 1dd3:A:1–57 | 1ixb:A:91–205 | 1kek:A:416–668 |
| 1yge:150–839 | 1krh:A:106–205 | 1dj0:A:7–114 | 1ixh | 1kpf |
| 2tps:A | 1kwm:A:1A-95A | 1dow:A | 1j6z:A:4–146 | 1ku1:A |
| 7odc:A:44–283 | 1kyp:A | 1dqi:A | 1jke:A | 1mc2:A |
| 1awq:A | 1l6p:A | 1e6i:A | 1k4i:A | 1lb3:A |
| 1bd0:A:2–11 | 1mix:A:195–308 | 1ei5:A:336–417 | 1k6d:A | 1m9n:A:201–593 |
| 1bxy:A | 1mla:198–307 | 1f86:A | 1knl:A | 1mgt:A:89–169 |
| 1byi | 1n5u:A:2–196 | 1f9y:A | 1l2h:A | 1nkp:A |
| 1chd | 1np7:A:1–204 | 1fhu:A:1–99 | 1l5o:A | 1npk |
| 1cxq:A | 1o8b:A:199–218 | 1fjj:A | 1lm4:A | 1pcf:A |
| 1d5t:A:292–388 | 1oew:A | 1fmt:A:207–314 | 1m6y:A:115–215 | 1qqq:A |
| 1sei:A | 2aop:149–345 | 1a8d:248–452 | 1bkf | 1kwf:A |
| 1uro:A | 4uag:A:1–93 | 1b8z:A | 1chm:A:2–156 | 1dl5:A:214–317 |
| Variable name | ICC (95 % CI)a,b |
| Maternal information | |
| Pre-pregnancy weight | 0.97 (0.96 –0.97) |
| Admission weight | 0.94 (0.94 –0.95) |
| Height | 0.90 (0.89 –0.92) |
| Antenatal information | |
| Gravida | 0.76 (0.73 –0.78) |
| Previous term deliveries | 0.99 (0.98 –0.99) |
| Previous preterm deliveries | 0.86 (0.85 –0.88) |
| Previous spontaneous abortions | 0.92 (0.91 –0.93) |
| Previous therapeutic abortions | 0.90 (0.88 –0.91) |
| Previous cesarean deliveries | 0.99 (0.99 –0.99) |
| Previous vaginal deliveries | 0.99 (0.99 –0.99) |
| Number of living children | 0.98 (0.98 –0.99) |
| Third trimester hemoglobin | 0.85 (0.83 –0.87) |
| Gestational age at first ultrasound, in weeks | 0.92 (0.90 –0.93) |
| Gestational age at first ultrasound, in days | 0.90 (0.89 –0.92) |
| Total prior admissions this pregnancy | 0.59 (0.55 –0.63) |
| School years completed | 0.92 (0.90 –0.94) |
| Number of antenatal visits | 0.91 (0.90 –0.92) |
| Labour and delivery information | |
| Cervical dilation on admission | 0.88 (0.86 –0.90) |
| Cervical dilation prior to cesarean delivery | 0.96 (0.95 –0.97) |
| Postpartum hemoglobin value | 0.98 (0.98 –0.98) |
| Antimicrobial agent | No. (%) of H. pylori-resistant strains | ||
| 2006–2008 [13] | 2009–2011 | P value(1) | |
| n = 115 | n = 51 | ||
| CLA(2) | 39 (34%) | 11 (22%) | 0,16 NS(3) |
| LEV(2) | 6 (5%) | 8 (16%) | 0,05(4) |
| Age | 0.025 | 0.05 | 0.10 | 0.90 | 0.95 | 0.975 |
| 0.4 | 0.2 | 0.3 | 0.5 | 1.8 | 2.0 | 2.2 |
| 1.0 | 0.3 | 0.4 | 0.6 | 1.9 | 2.0 | 2.2 |
| 2.0 | 0.4 | 0.6 | 0.7 | 1.9 | 2.1 | 2.2 |
| 3.0 | 0.6 | 0.7 | 0.8 | 1.9 | 2.1 | 2.2 |
| 4.0 | 0.7 | 0.8 | 0.9 | 2.0 | 2.1 | 2.2 |
| 5.0 | 0.8 | 0.9 | 1.0 | 2.0 | 2.1 | 2.2 |
| 6.0 | 0.9 | 1.0 | 1.1 | 2.0 | 2.1 | 2.2 |
| 7.0 | 0.9 | 1.0 | 1.2 | 2.0 | 2.1 | 2.2 |
| 8.0 | 1.0 | 1.1 | 1.2 | 2.0 | 2.1 | 2.2 |
| 9.0 | 1.0 | 1.1 | 1.2 | 2.0 | 2.1 | 2.2 |
| 10.0 | 1.1 | 1.1 | 1.2 | 2.0 | 2.1 | 2.2 |
| 11.0 | 1.1 | 1.1 | 1.2 | 2.0 | 2.1 | 2.1 |
| 12.0 | 1.1 | 1.1 | 1.2 | 1.9 | 2.0 | 2.1 |
| 13.0 | 1.0 | 1.1 | 1.2 | 1.9 | 2.0 | 2.1 |
| 14.0 | 1.0 | 1.1 | 1.2 | 1.9 | 2.0 | 2.1 |
| 15.0 | 0.9 | 1.0 | 1.1 | 1.8 | 1.9 | 2.0 |
| 16.0 | 0.9 | 1.0 | 1.1 | 1.8 | 1.9 | 2.0 |
| 17.0 | 0.8 | 0.9 | 1.0 | 1.7 | 1.8 | 1.9 |
| 17.8 | 0.7 | 0.8 | 0.9 | 1.7 | 1.8 | 1.9 |
| Crude OR (95% CI) | Adjusted OR (95% CI) | |
| Female gender (vs male) | 0.9 (0.5–1.5) | |
| Zhuang ethnicity (vs Han and others) | 0.8 (0.5–1.5) | |
| Age group (years): ref. = < 30 | ||
| 30–39 | 0.8 (0.4–1.6) | |
| 40–49 | 0.9 (0.4–1.8) | |
| ≥ 50 | 0.7 (0.3–1.5) | |
| Education level: ref. = Illiterate | ||
| Elementary school | 4.2 (1.4–12.2) | |
| Junior high school | 3.2 (1.1–9.5) | |
| High school or higher | 4.1 (1.1–15.1) | |
| Marital status: ref. = unmarried | ||
| Married | 0.8 (0.5–1.4) | |
| Divorced or widowed | 0.6 (0.2–1.9) | |
| Occupation: ref. = unemployed | ||
| Farmer | 1.5 (0.8–2.7) | |
| Other | 1.1 (0.3–3.5) | |
| Annual family income level: ref. = low | ||
| Middle | 0.7 (0.4–1.3) | |
| High | 1.0 (0.5–2.1) | |
| Cause of disease | ||
| Other non-organic severe mental disorders (vs organic psychoses) | 11.5 (1.6–84.6) | 11.6 (1.6–86.0) |
| Disease duration (years) | 1.0 (0.9–1.0) | |
| PANSS score | ||
| Positive scale | 1.0 (0.9–1.0) | |
| Negative scale | 1.0 (0.9–1.0) | |
| General psychopathology | 1.0 (0.9–1.0) | |
| Caregiver | ||
| Yes (vs no) | 6.2 (2.0–18.3) | 3.21 (1.2–8.3) |
| Caregiver’s gender | ||
| Female (vs male) | 1.3 (0.6–2.4) |
| R di Pearson p<.05 | PF | PRF | BP | GHP | V | SRF | ERF | MH |
| Depression | -0.16 | -0.21 | -0.49* | -0.19 | -0.21 | -0.2 | -0.14 | -0.17 |
| Date | WWTP 1 | WWTP 2 | WWTP 3 | WWTP 4 | WWTP 5 |
| Jan | <0.006473 | <0.006473 | <0.006473 | 0.43 | <0.006473 |
| Feb | <0.006473 | 1.74 | <0.006473 | 0.49 | 0.43 |
| Mar | <0.006473 | 3.72 | NP | <0.006473 | <0.006473 |
| Apr | <0.006473 | 6.03 | <0.006473 | 0.21 | <0.006473 |
| May | <0.006473 | 4.81 | <0.006473 | <0.006473 | <0.006473 |
| Jun | <0.006473 | 5.63 | <0.006473 | NP | <0.006473 |
| Jul | <0.006473 | 2.28 | NP | 1.32 | <0.006473 |
| Aug | <0.006473 | 12.20 | NP | <0.006473 | <0.006473 |
| Sep | <0.006473 | 3.29 | NP | 0.69 | <0.006473 |
| Oct | <0.006473 | 1.66 | <0.006473 | 0.76 | <0.006473 |
| Nov | 0.75 | 5.74 | NP | 0.85 | <0.006473 |
| Dec | <0.006473 | 4.45 | <0.006473 | 1.86 | <0.006473 |
| Evaluation criteria | Description | Temperature and duration | Reference | |
| Treatment | Recovery | |||
| Germination stage | ||||
| Vigor of germination | Vigor of germination (%) = Number of germinated grains/Number of total grains × 100 | 14°C/7-17 d | - | (Han et al. [2006]) |
| Seedling survival rate | Seedling survival rate (%) = Surviving seedlings/Sprouting seeds × 100, determined when shoots are about 5 mm long. | 2°C/3 d | 20°C/7 d | (Zhou et al. [2012]) |
| Seedling stage | ||||
| Fresh weight (FW) | Changes in FW of plants after cold treatment can be used as an indicator of cold damage. | 10°C/1-48 h | - | (Bonnecarrère et al. [2011]) |
| Survival rate | Survival rate (%) after cold treatment is calculated as the Number of surviving plants/Total number plants treated × 100 | 4°C/6 d | 26°C/6 d | (Zhang et al. [2011b]) |
| Leaf emergence | New leaf emergence demonstrates maintained vigor and increased growth. | 4°C/7 d | 25°C/10 d | (Xie et al. [2012]) |
| Seedling growth | 1 = dark green seedlings, 3 = light green seedlings, 5 = yellow seedlings, 7 = brown seedlings, 9 = seedlings dead. | 9°C/8-14 d | - | (Kim and Tai [2011]; IRRI [2002]; Andaya and Tai [2006]) |
| Leaf growth | A score of 1–3 (tolerant, all leaves normal, no apparent visual injury), or 4–9 (susceptible, all leaves wilted, seedlings apparently dead). | 10°C/7 d | 25°C/7 d | (Suh et al. [2012]) |
| Metabolic assessments | Metabolites include EL, proline, MDA, and AsA, and GSH. | 9°C/1-14 d | - | (Tian et al. [2011]; Zhang et al. [2011a]; Kim and Tai [2011]; Yang et al. [2012]) |
| Enzyme activities | Enzymes include POD, SOD, and CAT, and APX. | 4°C/0-4 d | 25°C/7 d | (Bonnecarrère et al. [2011]; Huang et al. [2009]; Sato et al. [2001]) |
| Reproductive stage | ||||
| Spikelet fertility (CGC) | Spikelet fertility is calculated as the ratio of filled grains to the total number of florets, basing on cold greenhouse cultivation. | 12°C/6 d | Until maturation | (Sato et al. [2011]) |
| Spikelet fertility (CDWI) | Spikelet fertility is calculated as the same as spikelet fertility (CGC), but the cold treatment is based on cold deep-water irrigation. | 18-19°C/~60 d | - | (Shirasawa et al. [2012]) |
| Algorithm | Proposed | No Preprocessing | No Verification |
| Recognition rate | 97.8% | 98.1% | 68.0% |
| Computation time | 1018 | 4951 | 736 |
| Case | Response time to deviation | Response time to math | ||||
| Mean | Standarddeviation | Difference(dual-single) | Mean | Standarddeviation | Difference(dual-single) | |
| Case 1 | 0.9480 | 0.1314 | p < 0.01 | 1.1479 | 0.3061 | p < 0.01 |
| Case 2 | 0.9856 | 0.1269 | p > 0.01 | 1.1277 | 0.2724 | p < 0.01 |
| Case 3 | 0.9865 | 0.1231 | p > 0.01 | 1.0975 | 0.2727 | p < 0.01 |
| Single (baseline) | 1 | 0.1553 | 1 | 0.2168 |
| Year | Tumor type | No. of cases | Culture condition | Authors |
| 1999 | Renal cell carcinoma Colorectal carcinoma Lymphoma | 10 | IFN-γ, anti-CD3, IL2 plus IL-2 transgene | Schmidt-Wolf IG et al. [33] |
| 2005 | Lymphoma | 9 | IFN-γ, anti-CD3, and IL2 | Leemhuis T et al. [14] |
| 2006 | Gastric carcinoma | 57 | IFN-γ, anti-CD3, IL2 and IL-1alpha | Jiang JT et al. [34] |
| 2007 | Leukemia | 11 | IFN-γ, anti-CD3 and IL2 | Introna M et al. [35] |
| 2008 | Non-small cell lung cancer | 59 | IFN-γ, anti-CD3, IL2 and IL-1alpha | Wu CP et al. [36] |
| 2009 | Hepatocellular carcinoma | 127 | IFN-γ, anti-CD3, IL2 and IL-1lalpha | Hui D et al. [37] |
| 2009 | Renal cell carcinoma and lymphoma | 6 | IFN-γ, anti-CD3, and IL2 | Olioso P et al. [38] |
| 2010 | Gastric carcinoma | 156 | IFN-γ, anti-CD3, IL2, and IL-1alpha | Jiang JT et al. [39] |
| 2011 | relapsed hematologic malignancies | 18 | IFN-γ, anti-CD3, and IL2 | Laport GG et al. [40] |
| 2012 | Renal cell carcinoma | 74 | IFN-γ, anti-CD3, IL2, IL-1beta | Liu L et al. [41] |
| Baseline (T0) | T1 | T2 | T3 | |
| Mean arterial pressure (mmHg) | ||||
| Control | 91.5 ± 4.2 | 93 ± 4.1 | 94 ± 4.8 | 76.1 ± 2.3 |
| LPS | 88.7 ± 1.3 | 49 ± 5.1## | 54.9 ± 6.2## | 42.2 ± 4.4### |
| LPS + FR | 90.8 ± 1.3 | 53.5 ± 3.2## | 82.7 ± 2.1* | 56.6 ± 2.1*,## |
| LPS + BT | 89.5 ± 2.2 | 54.1 ± 1.7## | 86.8 ± 1.7* | 61.1 ± 3.2* |
| Heart rate (beats per minute) | ||||
| Control | 232.9 ± 8.5 | 247.7 ± 7.7 | 248 ± 6.4 | 249.9 ± 13.4 |
| LPS | 236.3 ± 11.9 | 225.6 ± 5.2 | 226.9 ± 5.9 | 221 ± 8.5 |
| LPS + FR | 227.9 ± 8.7 | 219 ± 5.1 | 259 ± 7.7 | 258 ± 4.3 |
| LPS + BT | 255.3 ± 7.7 | 252.1 ± 5.6 | 258 ± 5.3 | 254.6 ± 6.5 |
| Renal blood flow (ml/min) | ||||
| Control | 7.5 ± 0.8 | 5.1 ± 0.2 | 5.2 ± 0.3 | 4.3 ± 0.2 |
| LPS | 7.1 ± 0.5 | 0.8 ± 0.3# | 0.9 ± 0.3### | 0.6 ± 0.3### |
| LPS + FR | 6.3 ± 0.2 | 0.4 ± 0.1## | 5.4 ± 0.9** | 1.6 ± 0.3# |
| LPS + BT | 6.6 ± 0.7 | 0.8 ± 0.3# | 3.2 ± 0.4* | 1.8 ± 0.3# |
| Renal vascular resistances (dynes·s·cm–5) | ||||
| Control | 1291.9 ± 128.2 | 1823.2 ± 88.2 | 1844.4 ± 155.9 | 1784.3 ± 96.4 |
| LPS | 1275.2 ± 77.6 | 17,820 ± 7905.5 | 18,631.9 ± 11,394.9 | 20,237.7 ± 7939.2 |
| LPS + FR | 1449.9 ± 61.8 | 18,860.5 ± 6758.4 | 1853.3 ± 336.2 | 4390.5 ± 920.3 |
| LPS + BT | 1431.3 ± 124.1 | 12,133.9 ± 3493.6 | 2919.9 ± 388.8 | 4860.7 ± 1828.1 |
| Bacterial name | Inhibitory effects* |
| Acetic bacteria | - |
| Bacillus subtilis | + |
| E. coli | +++ |
| Lactobacillus fermenti | - |
| Lactobacillus plantarum ZJ316 | - |
| Lactococcus lactis | - |
| Listeria monocytogenes | ++ |
| Micrococcus luteus | + |
| Pseudomonas aeruginosa | + |
| Pseudomonas putida | ++++ |
| Shigella flexneri | ++ |
| Saccharomyces cerevisiae | - |
| Salmonella | ++ |
| Shigella dysenteriae | + |
| Staphylococcus aureus | + |
| Staphylococcus citreus | + |
| Vibrio parahaemolyticus | - |
| Second versus first tertile | Third versus first tertile | |||
| Group | β ± SE | p-Value | β ± SE | p-Value |
| Full (wet weight) | ||||
| Systolic | 0.023 ± 0.09 | 0.0088 | 0.028 ± 0.10 | 0.0092 |
| Diastolic | 0.034 ± 0.09 | 0.0002 | 0.035 ± 0.10 | 0.0011 |
| Full (lipid adjusted) | ||||
| Systolic | 0.030 ± 0.008 | 0.01 | 0.032 ± 0.01 | 0.006 |
| Diastolic | 0.033 ± 0.008 | 0.0002 | 0.037 ± 0.10 | 0.0005 |
| Normotensive (wet weight) | ||||
| Systolic | 0.007 ± 0.006 | 0.57 | 0.020 ± 0.007 | 0.035 |
| Diastolic | 0.013 ± 0.007 | 0.06 | 0.020 ± 0.008 | 0.04 |
| Normotensive (lipid adjusted) | ||||
| Systolic | 0.011 ± 0.006 | 0.075 | 0.023 ± 0.007 | 0.002 |
| Diastolic | 0.018 ± 0.007 | 0.012 | 0.026 ± 0.008 | 0.003 |
| Parameters | AZT | AZT + NAR | AZT + VITE | d4T | d4T + NAR | d4T + VITE | Control |
| Final body weight (g) | 307.2 ± 3.7 a | 316.8 ± 1.99 # | 303.2 ± 4.2 | 303.8 ± 4.1 a | 304.2 ± 5.2 | 315.7 ± 7.5 * | 316.6 ± 3.4 |
| Wet liver weight (g) | 7.87 ± 0.24 aaa | 6.65 ± 0.17 ### | 6.92 ± 0.20 ## | 7.134 ± 0.20 a | 6.45 ± 0.17 * | 6.68 ± 0.21 * | 6.57 ± 0.20 |
| Liver index (%) | 2.30 ± 0.05 a | 2.19 ± 0.02 # | 2.44 ± 0.06 # | 2.35 ± 0.03 a | 2.11 ± 0.07 ** | 2.31 ± 0.01 * | 2.27 ± 0.03 |
| Bax/Bcl-2 ratio | 7.20 ± 0.46 aaa | 1.18 ± 0.11 ### | 1.14 ± 0.12 ### | 5.42 ± 0.23 aaa | 1.02 ± 0.05 *** | 0.76 ± 0.1 *** | 3.18 ± 0.27 |
| Insertions of transgenes | Relative levels of mRNA* |
| P{hsp83-AtSPO11-1 cDNA, A5-1} | 3.40 ± 0.40 |
| P{hsp83-AtSPO11-2 cDNA, 2M3-1} | 9.22 ± 2.72 |
| P{hsp83-OsSPO11A cDNA, 3M2-3} | 13.88 ± 3.59 |
| P{hsp83-OsSPO11B cDNA, M6-2} | 19.85 ± 4.50 |
| P{hsp83-OsSPO11B cDNA, F3-2} | 14.57 ± 6.32 |
| P{hsp83-OsSPO11D cDNA, F2-1} | 3.17 ± 0.36 |
| P{hsp83-OsSPO11DY213F, F22-F2} | 4.22 ± 0.84 |
| P{hsp83-OsSPO11DY213F, M33-F1} | 3.76 ± 1.39 |
| Parameter | c-MYC Nuclear Expression | Significance | ||
| ADA3 Nuclear Expression | Low No (%) | High No.(%) | x2 | p value |
| Low No(%) | 172 (49.1) | 178 (50.9) | 23.79 | <0.0001 |
| High No(%) | 69 (29.0) | 169 (71.3) |
| Mycobacterium smegmatis | Fold change | P-value | Gene name | Ortholog in Mtb | Annotated function |
| MSMEG_5576 | 3.4 | 2.2E-02 | – | – | d-mannonate oxidoreductase |
| MSMEG_4920 | 4.9* | 7.9E-04 | fadA4 | Rv1323 | Acetyl-CoA acetyltransferase |
| MSMEG_4718 | −1.8* | 4.8E-01 | bkaR | Rv2506 | TetR transcriptional regulator (bkaR)* |
| MSMEG_4717 | 9.0* | 3.7E-05 | accD1 | Rv2502c | Acetyl/propionyl-coenzyme A carboxylase (β subunit) |
| MSMEG_4716 | 15.0 | 1.5E-05 | accA1 | Rv2501c | Acetyl/propionyl-coenzyme A carboxylase (α subunit) |
| MSMEG_4715 | 13.7 | 5.8E-06 | fadE19 | Rv2500c | Acyl-CoA dehydrogenase |
| MSMEG_4714 | 9.5 | 1.1E-04 | Rv2499c | Rv2499c | Hydratase |
| MSMEG_4713 | 16.5 | 4.6E-06 | citE | Rv2498c | HpcH/HpaI aldolase/citrate lyase family protein |
| MSMEG_4712 | 8.4 | 1.1E-04 | bkdA | Rv2497c | Part of branched-chain keto-acid dehydrogenase complex† |
| MSMEG_4711 | 3.3 | 3.3E-02 | bkdB | Rv2496c | Part of branched-chain keto-acid dehydrogenase complex* |
| MSMEG_4710 | 1.8 | 4.9E-01 | bkdC | Rv2495c | Part of branched-chain keto-acid dehydrogenase complex* |
| MSMEG_4005 | −3.2 | 2.5E-02 | – | – | Calcium-binding protein |
| MSMEG_2080 | 3.1 | 3.3E-02 | fadE23 | Rv3140 | Putative acyl-CoA dehydrogenase |
| MSMEG_1885 | 3.3 | 2.2E-02 | Rv3230c | Rv3230c | Iron–sulphur cluster binding domain protein |
| MSMEG_1548 | 3.0 | 4.3E-02 | – | – | Dehydratase (propanediol utilization) |
| MSMEG_1543 | 3.2 | 2.3E-02 | Rv0458 | Rv0458 | EPTC-Inducible aldehyde dehydrogenase |
| MSMEG_0881 | −3.4 | 2.2E-02 | – | – | Hypothetical protein |
| MSMEG_0066 | 3.3 | 2.2E-02 | esxA | Rv3875 | Early secretory antigenic target |
| Microwave biosensor [42] | Terahertz biosensor [48] | Plasmonic biosensor [55] | |
| Unit size | mm | um | nm |
| Operating frequency | GHz | THz | 100–800 THz |
| Application field | Detect binding of biomolecules | Detect biomolecular composition | Detect refractive index of biomolecules |
| Sensitivity | 20 MHz | 4 GHz | 32,000 nm per RIU |
| Advantages | Low cost | High concentration of electric field | High sensitivity |
| Drawbacks | Large area | Higher cost | High cost, complicated fabricated process |
| Men (n = 371) | Women (n = 438) | Total (n = 809) | |||||||
| Healthy (n = 300) | Controlled asthma (n = 59) | Uncontrolled asthma (n = 12) | Healthy (n = 306) | Controlled asthma (n = 66) | Uncontrolled asthma (n = 66) | Healthy (n = 606) | Controlled asthma (n = 125) | Uncontrolled asthma (n = 78) | |
| Age, years , median (IQR) | 50.0 (28.0)* | 36.0 (25.0)* | 56.5 (15.0)* | 55.00 (20) | 50.00 (28) | 53.50 (22) | 53.0 (24)* | 43.0 (28.0)* | 54.0 (21.5)* |
| BMI, median (IQR) | 25.4 (5.0) | 24.7 (4.0) | 27.6 (4.0) | 24.67 (6) | 24.98 (7) | 26.26 (8) | 25.1 (5) | 24.9 (5.1) | 26.6 (6.6) |
| SES, n (%) | |||||||||
| High | 26 (8.8) | 10 (16.9) | 2 (16.7) | 15 (5.0) | 4 (6.1) | 1 (1.5) | 41 (6.8) | 14 (11.2) | 3 (3.9)* |
| Medium | 238 (80.4) | 45 (76.3) | 7 (58.3) | 224 (73.9) | 56 (84.8) | 49 (75.4) | 462 (77.1) | 101 (80.8) | 56 (72.7) |
| Low | 32 (10.8) | 4 (6.8) | 3 (25.0) | 64 (21.1) | 6 (9.1) | 15 (23.1) | 96 (16.0) | 10 (8.0) | 18 (23.4) |
| Smoking, n (%) | |||||||||
| Never | 147 (49.0) | 30 (50.8) | 5 (41.7) | 259 (84.6) | 50 (75.8) | 51 (77.3) | 406 (67–0) | 80 (64.0) | 56 (71.8) |
| Ever | 153 (51.0) | 29 (49.2) | 7 (58.3) | 47 (15.4) | 16 (24.2) | 15 (22.7) | 200 (33.0) | 45 (36.0) | 22 (28.2) |
| Daily sitting time, min, median (IQR) | 240.0 (240.0)**,§ | 300.0 (330.0)**, § | 180.0 (195.0)** | 180.00 (180) | 180.00 (180) | 180.00 (210) | 180.0 (180.0)** | 240.0 (300.0)** | 180.0 (187.5)** |
| VPA, MET-min/week, median (IQR) | 340.0 (1920.0)§ | 960.0 (2880.0)§ | 960.0 (5130.0) | 0.00 (560)**, §§ | 0.00 (960)** | 0.00 (1380)**, §§ | 0.0 (960.0) | 240.0 (1440.0) | 0.0 (1920.0) |
| MPA, MET-min/week, median (IQR) | 60.0 (720.0)§ | 280.0 (960.0)§ | 120.0 (720.0) | 280.00 (3360) | 280.00 (3360) | 450.00 (3360) | 280.0 (1680.0) | 280.0 (1680.0) | 360.0 (3360.0) |
| WPA, MET-min/week, median (IQR) | 346.5 (693.0) | 594.0 (941.0) | 577.5 (1361.0) | 429.00 (759) | 346.50 (743) | 346.50 (594) | 396.0 (742.5) | 462.0 (1089.0) | 371.3 (594.0) |
| Total PA, MET-min/week, median (IQR) | 1657.5 (3627.0) | 2000.0 (4194.0) | 2253.0 (6373.0) | 1680.00 (4347) | 1732.50 (5993) | 2273.00 (4499) | 16660. (3861.6) | 1878.0 (5579.5) | 2273.0 (4499.3) |
| Overall PA level, n(%) | |||||||||
| Low | 91 (30.3) | 18 (25.0) | 3 (25.0) | 83 (27.1) | 22 (33.3) | 17 (25.8) | 174 (28.7) | 40 (32.0) | 20 (25.6) |
| Moderate | 114 (38.0) | 24 (40.7) | 5 (41.7) | 114 (37.3) | 21 (31.8) | 23 (34.8) | 228 (37.6) | 45 (36.0) | 28 (35.9) |
| HEPA | 95 (31.7) | 17 (28.8) | 4 (33.3) | 109 (35.6) | 23 (34.8) | 29 (39.4) | 204 (33.7) | 40 (32.0) | 30 (38.5) |
| 2007 PA recommendation, n(%) | |||||||||
| No | 161 (53.7) | 27 (45.8) | 5 (41.7) | 151 (49.3) | 31 (47.0) | 29 (43.9) | 312 (51.5) | 58 (46.4) | 34 (43.6) |
| Yes | 139 (46.3) | 32 (54.2) | 7 (58.3) | 155 (50.7) | 35 (53.0) | 37 (56.1) | 294 (48.5) | 67 (53.6) | 44 (56.4) |
| EGFR-IHC result | EGFR-FISH result | |||||||||||||
| System 1 | System 4 | FISH Positive | Amplification | |||||||||||
| N | L | M | H | P | L | H | P | No | Yes | P | No | Yes | P | |
| Gender | ||||||||||||||
| Male | 80 | 42 | 32 | 6 | 0.724 | 74 | 6 | 0.509 | 52 | 28 | 0.022 | 74 | 6 | 0.861 |
| Female | 16 | 7 | 7 | 2 | 14 | 2 | 15 | 1 | 15 | 1 | ||||
| Age | ||||||||||||||
| <60 | 34 | 24 | 8 | 2 | 0.017 | 22 | 12 | 0.422 | 22 | 12 | 0.422 | 32 | 2 | 0.694 |
| >60 | 62 | 25 | 31 | 6 | 45 | 17 | 45 | 17 | 57 | 5 | ||||
| Tumor site | ||||||||||||||
| Upper | 1 | 0 | 1 | 0 | 0.181 | 1 | 0 | 0.607 | 1 | 0 | 0.313 | 1 | 0 | 0.413 |
| Middle | 33 | 12 | 17 | 4 | 29 | 4 | 20 | 13 | 29 | 4 | ||||
| Lower | 62 | 37 | 21 | 4 | 58 | 4 | 46 | 16 | 59 | 3 | ||||
| T-stage | ||||||||||||||
| T1 | 5 | 2 | 3 | 0 | 0.889 | 5 | 0 | 0.499 | 3 | 2 | 0.552 | 5 | 0 | 0.602 |
| T2 | 24 | 13 | 9 | 2 | 23 | 1 | 15 | 9 | 23 | 1 | ||||
| T3 | 67 | 34 | 27 | 6 | 60 | 7 | 49 | 18 | 61 | 6 | ||||
| Vaso invasion | ||||||||||||||
| No | 77 | 34 | 35 | 8 | 0.020 | 69 | 8 | 0.142 | 54 | 23 | 0.884 | 70 | 7 | 0.172 |
| Yes | 19 | 15 | 4 | 0 | 19 | 0 | 13 | 6 | 19 | 0 | ||||
| Nerve invasion | ||||||||||||||
| No | 62 | 34 | 24 | 4 | 0.497 | 59 | 3 | 0.094 | 44 | 18 | 0.735 | 59 | 3 | 0.212 |
| Yes | 34 | 15 | 15 | 4 | 29 | 5 | 23 | 11 | 30 | 4 | ||||
| LN metastases | ||||||||||||||
| No | 52 | 29 | 22 | 1 | 0.046 | 51 | 1 | 0.013 | 39 | 13 | 0.227 | 51 | 1 | 0.028 |
| Yes | 44 | 20 | 17 | 7 | 37 | 7 | 28 | 16 | 38 | 6 | ||||
| Necrosis | ||||||||||||||
| No | 38 | 21 | 16 | 1 | 0.258 | 36 | 2 | 0.378 | 27 | 11 | 0.828 | 37 | 1 | 0.155 |
| Yes | 58 | 28 | 23 | 7 | 52 | 6 | 40 | 18 | 52 | 6 | ||||
| Mitoses (/10HPF) | ||||||||||||||
| ≤20 | 29 | 12 | 15 | 2 | 0.645 | 27 | 2 | 0.307 | 18 | 11 | 0.06 | 27 | 2 | 0.768 |
| 20~50 | 37 | 20 | 13 | 4 | 32 | 5 | 31 | 6 | 35 | 2 | ||||
| ≥50 | 30 | 17 | 11 | 2 | 29 | 1 | 18 | 12 | 27 | 3 | ||||
| Tumour differentiation | ||||||||||||||
| G2 | 61 | 33 | 26 | 2 | 0.061 | 43 | 18 | 0.844 | 43 | 18 | 0.844 | 57 | 4 | 0.715 |
| G3 | 35 | 16 | 13 | 6 | 24 | 11 | 24 | 11 | 32 | 3 |
| Location | Number of HC‐markers (Table S2) | Estimated proteome size | Proteome coverage (%) | GFP localization (%) | Correct GFP localization (%) |
| CYT | 2512 | 5587 | 45 | 15 | 74 |
| ER | 323 | 716 | 45 | 40 | 82 |
| EXC | 1495 | 3320 | 45 | 5 | 40 |
| GLG | 239 | 524 | 45 | 41 | 92 |
| MT | 1073 | 2383 | 45 | 22 | 83 |
| NCL | 3274 | 7274 | 45 | 14 | 87 |
| PRX | 135 | 295 | 45 | 61 | 85 |
| PLTD | 1437 | 3192 | 45 | 20 | 80 |
| PM | 1193 | 2649 | 45 | 22 | 85 |
| VAC | 213 | 469 | 45 | 46 | 84 |
| Amino Acid Pattern | T1 | T2 | T3 | p for Trend |
| Pattern 1 | ||||
| Crude | 1.00 | 0.97 (0.79–1.20) | 1.07 (0.87–1.31) | 0.61 |
| Model 1 | 1.00 | 0.97 (0.78–1.19) | 1.06 (0.86–1.29) | 0.67 |
| Model 2 | 1.00 | 0.97 (0.85–1.30) | 1.05 (0.78–1.19) | 0.85 |
| Pattern 2 | ||||
| Crude | 1.00 | 1.00 (0.82–1.22) | 0.87 (0.71–1.07) | 0.33 |
| Model 1 | 1.00 | 0.92 (0.76–1.13) | 0.83 (0.68–1.03) | 0.24 |
| Model 2 | 1.00 | 0.91 (0.74–1.11) | 0.81 (0.65–1.01) | 0.17 |
| Pattern 3 | ||||
| Crude | 1.00 | 0.95 (0.77–1.17) | 1.30 (1.07–1.58) | 0.003 |
| Model 1 | 1.00 | 1.00 (0.81–1.24) | 1.24 (1.01–1.51) | 0.04 |
| Model 2 | 1.00 | 1.00 (0.81–1.24) | 1.24 (1.02–1.52) | 0.05 |
| Trend percentage at T3 per T1-T2 risk state | ||||
| T1-T2 risk state (N = 180,767) | (0) | (1) | Comparison of order | Trend statistic (Z) |
| Low-Lowa | 82.4(1) | 17.6 | Vs. d | -68.2* |
| Low-Mediumb | 52.5(3) | 47.5 | Vs. g | -11.4* |
| Low-Highc | 35.8(5) | 64.2 | Vs. e | -44.7* |
| Medium-Lowd | 58.6(2) | 41.4 | Vs. b | -11.2* |
| Medium-Mediume | 34.0(6) | 66.0 | Vs. h | -18.0* |
| Medium-Highf | 21.5(8) | 78.5 | Vs. i | -27.7* |
| High-Lowg | 43.5(4) | 56.5 | Vs. c | -26.2* |
| High-Mediumh | 22.6(7) | 77.4 | Vs. f | -43.8* |
| High-Highi | 11.7(9) | 88.3 | - | - |
| Characteristics | Scabies infected cases, n | % |
| No. of cases | 14 883 (100.0%) | |
| Age (mean ± SD, years) | 52.4 ± 21.0 | |
| 20–29 | 2831 | 19.0 |
| 30–39 | 2190 | 14.7 |
| 40–49 | 2259 | 15.2 |
| 50–59 | 2065 | 13.9 |
| 60–69 | 1537 | 10.3 |
| ≥70 | 4001 | 26.9 |
| Sex | ||
| Female | 7026 | 47.2 |
| Male | 7857 | 52.8 |
| Comorbidity disease* | ||
| Chronic pulmonary disease | 3054 | 20.5 |
| Diabetes | 2396 | 16.1 |
| Hypertension | 4905 | 33.0 |
| Peptic ulcer disease | 2502 | 16.8 |
| Mild liver disease | 1113 | 7.5 |
| Congestive heart failure | 808 | 5.4 |
| Rheumatologic disease | 667 | 4.5 |
| Cerebrovascular disease | 2773 | 18.6 |
| Malignancy | 572 | 3.8 |
| Parkinson disease | 808 | 5.4 |
| Tuberculosis | 522 | 3.5 |
| Chronic kidney disease | 223 | 1.5 |
| Liver cirrhosis | 1294 | 8.7 |
| Hyperlipidemia | 901 | 6.1 |
| Heart disease | 3672 | 24.7 |
| Anemia | 1169 | 7.9 |
| Epilepsy | 420 | 2.8 |
| Insured amount (NTD) | ||
| <20,000 | 4385 | 29.5 |
| 20,000–40,000 | 7656 | 51.4 |
| 40,000–60,000 | 2012 | 13.5 |
| ≧60,000 | 830 | 5.6 |
| Insured region in Taiwan | ||
| Northern | 6569 | 44.1 |
| Middle | 3374 | 22.7 |
| Southern | 4363 | 29.3 |
| Eastern and outlying islands | 577 | 3.9 |
| Variable | Total (n = 240) (%) |
| Teaching years | |
| (1) (1–<10) | 116 (48.3%) |
| (2) (10–<20) | 86 (35.8%) |
| (3) (20–<30) | 38 (15.8%) |
| Classes per day | |
| (1) (1–4) | 184 (76.7%) |
| (2) (5–7) | 56 (23.3%) |
| Classes per week | |
| (1) (1–9) | 15 (6.2%) |
| (2) (10–19) | 142 (59.2%) |
| (3) (20–30) | 83 (34.6%) |
| Daily hours | |
| (1) (3–6) | 27 (11.2%) |
| (2) (7–9) | 213 (88.8%) |
| Students per class | |
| (1) (5–19) | 16 (6.7%) |
| (2) (20–34) | 151 (62.9%) |
| (3) (35–50) | 73 (30.4%) |
| MIGS ID | Property | Term | Evidence codea |
| Classification | Domain Bacteria | TAS [70] | |
| Phylum Cyanobacteria | TAS [71, 72] | ||
| Class Oscillatoriophycideae | TAS [73] | ||
| Order Chroococcales | TAS [73, 74] | ||
| Family Microcystaceae | TAS [74] | ||
| Genus Microcystis | TAS [71, 75] | ||
| Species M. panniformis | TAS [15, 31] | ||
| Strain: M. panniformis FACHB1757 | TAS [26] | ||
| Gram stain | Gram-negative | TAS [76] | |
| Cell shape | Spherical cells | TAS [15] | |
| Motility | Non-motile | NAS | |
| Sporulation | None | TAS [76] | |
| Temperature range | Mesophile | NAS | |
| Optimum temperature | 29.5 °C | IDA | |
| pH range; Optimum | pH 7.50-9.21; pH 8.33 | IDA | |
| Carbon source | Autotroph, heterotroph | NAS | |
| MIGS-6 | Habitat | Fresh water | NAS |
| MIGS-6.3 | Salinity | 1.0 % (maximum) | IDA |
| MIGS-22 | Oxygen requirement | Aerobic | NAS |
| MIGS-15 | Biotic relationship | Free-living | NAS |
| MIGS-14 | Pathogenicity | Microcystins (MCY) | TAS [25, 77] |
| MIGS-4 | Geographic location | Isolated Lake Taihu, China | IDA |
| MIGS-5 | Sample collection | August, 2015 | IDA |
| MIGS-4.1 | Latitude | 31.421 N | IDA |
| MIGS-4.2 | Longitude | 120.201E | IDA |
| MIGS-4.3 | Depth | Surface 0.5 m | IDA |
| MIGS-4.3 | Altitude | 11 m | IDA |
| Recipient vessels | Venous number (%) | Arterial number (%) |
| Retrograde IM vessel | 11 (44) | 16 (64) |
| Anterograde IM vessel | 6 (24) | 0 (0) |
| Superior pedicle continuity | 5 (20) | 5 (20) |
| Inferior pedicle continuity | 3 (12) | 3 (12) |
| Thoracodorsal vessel | 1 (4) | 1 (4) |
| Intercostal perforator | 0 (0) | 0 (0) |
| Pectoral vein | 0 (0) | 0 (0) |
| Variables | ρ | P |
| Diagnosis of ANbp | 0.525 | 0.017* |
| Age | 0.345 | 0.136 |
| Body mass index | 0.168 | 0.479 |
| Duration of illness | 0.536 | 0.015* |
| Current menstruation | 0.281 | 0.230 |
| Use of sedative drugs | 0.332 | 0.152 |
| CES-D | 0.318 | 0.172 |
| Vomiting | 0.561 | 0.010* |
| Chewing | -0.061 | 0.798 |
| Laxative overuse | 0.407 | 0.075 |
| Uretic misuse | 0.280 | 0.232 |
| #1 | Rheumatic Heart Disease or Disease, Rheumatic Heart or Diseases, Rheumatic Heart or Heart Disease, Rheumatic or Bouillaud Disease or Disease, Bouillaud |
| #2 | IL 10-1082 |
| #3 | mutation |
| #4 | polymorphism |
| #5 | variant |
| #6 | #1 AND #2 AND (#3 OR #4 OR #5) |
| Dosimetric Criteria | Treatment planning system | Knowledge based engineering tool |
| Spinal Cord Maximum Dose (Gy) | 40 ± 2 | 44 ± 2 |
| Esophagus Maximum Dose (Gy) | 68 ± 3 | 75 ± 2 |
| Heart V30 Gy (%) | 16 ± 4 | 15 ± 3 |
| Heart V45 Gy (%) | 10 ± 3 | 9 ± 2 |
| Lung V20Gy (%) | 27 ± 2 | 29 ± 2 |
| Lung mean dose (Gy) | 17 ± 1 | 18 ± 2 |
| Residential | Time | Sunlight Intensity (lux) | Temperature (°C) | Humidity (%) |
| Tebet Barat | 08.00 | 44,900 | 28.7 | 79.4 |
| 12.00 | 64,700 | 32.7 | 63.4 | |
| 16.00 | 24,400 | 27.4 | 57.7 | |
| Jagakarsa | 08.00 | 26,800 | 31.4 | 72.6 |
| 12.00 | 57,900 | 29.7 | 60.1 | |
| 16.00 | 43,400 | 33.2 | 57.9 | |
| Pasar Minggu | 08.00 | 64,800 | 26.2 | 71.6 |
| 12.00 | 62,300 | 34.7 | 55.9 | |
| 16.00 | 26,100 | 32.5 | 61.2 | |
| Cipulir | 08.00 | 29,900 | 31.5 | 71.8 |
| 12.00 | 77,900 | 33.9 | 54.5 | |
| 16.00 | 23,000 | 32.7 | 67.1 |
| FOV (mm) | Res (mm) | TR (ms) | TE (ms) | FA (deg) | BW (Hz/px) | Scan time (s) | # views | |
| UTE T1 | 160×160×160 | 1.0×1.0×1.0 | 11 | 0.05 | 8, 36 | 1008 | 167 | 15000 |
| UTE T2* | 160×160×160 | 1.0×1.0×1.0 | 6 | 0.05, 0.09, 0.13, 0.17, 0.25 | 15 | 1008 | 122 | 20000 |
| Marker name | Position (galGal3 assembly) | Upper primer | Lower primer | PCR annealing T° |
| SEQALL0348 | GCTCAGCACCTCCTCCTC | AGAAAGCAGCCTCACAAAGC | 55°C | |
| SEQALL0349 | AGGGTTTCCAAGTGGTGTTG | ACCTTGCCTGAGACTGGTG | 55°C | |
| SEQALL0350 | CGACAGATGGTCAAGAATGG | ACACAGTTCTTCGCTGTACG | 55°C | |
| SEQALL0468 | TTGCCATTCGAAACATCAAC | GGACTCTGCTGTGCCAAATAC | 50°C | |
| SEQALL0469 | TGAGATGATGAATGGCTTGG | ATATGCAGCAGGGCTCATTC | 58°C | |
| SEQALL0470 | CACAGGTCCACGAGAAAAGG | TGCAGTCCTTCACATTCTGC | 58°C | |
| SEQALL0471 | AGCATCATGACAGTCCAACC | AGGCCAAATTGTCTCACTCG | 58°C | |
| SEQALL0472 | ATCATGCGGCAGAAAAAGAG | AAATCCATCAGCCTGACAGC | 50°C | |
| SEQALL0473 | GAGAGGGAGGGAGATGAAGG | GAAGAGCTCGTGCAAAAAGC | 58°C | |
| SEQALL0474 | TAGGGTTTGGCTGTTGTCTG | CATTTGGAAACCCAGAGCAG | 58°C | |
| SEQALL0475 | ACAGGATGCTGCTGCTCAC | AATGTTTCCCTTTCCCAACC | 58°C | |
| SEQALL0476 | AGCCAAATCCTGTTTCATGC | TGTCCTTTCTGGGAGAGACG | 58°C | |
| SEQALL0477 | CATCCAAGTAACCCCACCTG | TGTAAGGTGTAGGGCGTTGG | 58°C | |
| SEQALL0478 | TGGCTTATGGCAACAAAAATC | TGGCCGGTAGTGGATAAAAG | 58°C | |
| SEQALL0479 | GATGTTCCTGGCACTTATAGGG | TTTCCCTTTGTTTCTGCATCC | 58°C | |
| SEQALL0481 | GCAGCTGCTGTTCCACAAG | GCTCATTGCATTTTTGCTTTC | 58°C | |
| SEQALL0482 | GGAAGTGTGTGTTATGGACTGG | CTAGGCTGGAACTGGCAGTAG | 58°C | |
| SEQALL0483 | TCTTGGAGATCACGGGAAAG | TGCAACATCAGGACAAGAGG | 58°C | |
| SEQALL0484 | CGAGTCTGCTGAATGGACAC | GCGCAATTAATTCAGGAAGG | 58°C | |
| SEQALL0485 | GACCACACAGTCACACGTCAG | TCTGGAGGAAGCAATAAGAAGTG | 58°C | |
| SEQALL0486 | TTCCCCAGGTGCTCTATCAG | ACCATCGTCTCCTGCCATAG | 58°C |
| Characteristics | n (%) | Mean ± S.D |
| Age (years) | 49.7 ± 14.1 | |
| 24 – 34 | 14 (15.6) | |
| 35 – 49 | 30 (33.3) | |
| 50 – 64 | 28 (31.1) | |
| ≥ 65 | 18 (20.0) | |
| Gender | ||
| Males | 44 (48.9) | |
| Females | 46 (51.1) | |
| Ethnicity | ||
| Chinese | 62 (68.9) | |
| Malay | 19 (21.1) | |
| Others | 9 (10.0) | |
| Educational Level | ||
| No formal education | 10 (11.1) | |
| Primary school | 33 (36.7) | |
| Secondary School | 40 (44.4) | |
| Tertiary education | 7 (7.8) | |
| Current employment status | ||
| Unemployed | 64 (71.1) | |
| Government | 2 (2.2) | |
| Private | 14 (15.6) | |
| Part time | 10 (11.1) | |
| Current estimated household income (monthly) | ||
| <RM 1000 | 22 (24.5) | |
| RM 1000 - RM 2000 | 28 (31.1) | |
| RM 2001 - RM 3000 | 19 (21.1) | |
| > RM 3000 | 21 (23.3) | |
| Primary renal diagnosis | ||
| Unknown cause* | 30 (33.3) | |
| Diabetes mellitus | 20 (22.2) | |
| Glomerulonephritis | 7 (7.8) | |
| Hypertensive nephrosclerosis | 7 (7.8) | |
| Systemic Lupus Erythaematosus (SLE) | 6 (6.7) | |
| Others** | 10 (11.1) | |
| Presence of co-morbidities | ||
| Hypertension | 62 (68.9) | |
| Diabetes mellitus | 23 (25.6) | |
| Cardiovascular disease | 7 (7.8) | |
| Number of prescribed medications | ||
| Vitamin and mineral supplements | 85 (94.4) | |
| Calcium carbonate | 79 (87.8) | |
| Erythropoietin (EPO) | 45 (50.0) | |
| Hypercholesterolaemia drugs | 41 (45.6) | |
| Antihypertensive drug | 35 (38.9) | |
| Oral diabetic agent (ODA) | 18 (20.0) | |
| Insulin | 5 (5.6) | |
| Duration of dialysis (months) | 90 | 55.2 ± 39.0 |
| Blood flow (ml/minute) | 90 | 297 ± 39 |
| Kt/V | 90 | 1.6 ± 0.5 |
| nPCR (g/kg/day) | 56 | 1.1 ± 0.3 |
| Glycerol Content (%) | Elastic Modulus (MPa) | Elongation at Break (%) | Tensile Strength (MPa) |
| 0 | 0.64 ±0.09 | 53.58 ±8.69 | 0.21 ±0.05 |
| 10 | 4.08 ±0.53 | 130.37 ±29.67 | 0.73 ±0.09 |
| 20 | 3.70 ±0.45 | 168.24 ±31.47 | 1.15 ±0.07 |
| 30 | 2.68 ±0.32 | 244.67 ±51.70 | 1.12 ±0.08 |
| 40 | 2.26 ±0.26 | 271.33 ±42.51 | 1.18 ±0.08 |
| Variable | GlavonoidTM Pre(n = 11) | GlavonoidTM Post(n = 11) | PlaceboPre(n = 11) | PlaceboPost(n = 11) |
| Insulin (μU·mL-1) | 7.9 ± 1.3 | 9.2 ± 1.5 | 9.1 ± 0.5 | 8.4 ± 1.2 |
| HOMA-IR | 1.6 ± 0.3 | 2.0 ± 0.4 | 1.9 ± 0.1 | 1.9 ± 0.3 |
| Adiponectin (μg·mL-1) | 17.8 ± 1.7 | 19.0 ± 2.7 | 15.3 ± 3.4 | 15.3 ± 3.2 |
| Resistin (ng·mL-1) | 5.7 ± 0.4 | 5.9 ± 0.6 | 5.1 ± 0.7 | 4.8 ± 0.5 |
| Glucose (mg·dL-1) | 84.4 ± 1.9 | 85.7 ± 2.9 | 83.4 ± 2.7 | 88.0 ± 4.2 |
| BUN (mg·dL-1) | 13.6 ± 1.2 | 12.6 ± 1.3 | 12.7 ± 1.0 | 13.8 ± 1.3 |
| Creatinine (mg·dL-1) | 1.0 ± 0.1 | 1.0 ± 0.1 | 0.9 ± 0.0 | 0.9 ± 0.0 |
| BUN:Creatinine | 14.2 ± 0.8 | 13.1 ± 0.6 | 14.3 ± 1.5 | 15.0 ± 1.6 |
| Sodium (mmol·L-1)*† | 137.5 ± 0.4 | 139.0 ± 0.5 | 138.9 ± 0.5 | 139.0 ± 0.5 |
| Potassium (mmol·L-1) | 4.1 ± 0.1 | 4.2 ± 0.1 | 4.3 ± 0.1 | 4.5 ± 0.2 |
| Chloride (mmol·L-1) | 102.5 ± 1.1 | 102.1 ± 0.7 | 102.7 ± 0.6 | 103.1 ± 0.5 |
| CO2 (mmol·L-1) | 24.0 ± 0.9 | 26.0 ± 0.8 | 24.3 ± 0.7 | 25.3 ± 0.7 |
| Calcium (mg·dL-1) | 9.4 ± 0.1 | 9.2 ± 0.1 | 9.4 ± 0.2 | 9.1 ± 0.1 |
| Protein (g·dL-1) | 6.9 ± 0.1 | 6.9 ± 0.1 | 6.9 ± 0.1 | 7.0 ± 0.1 |
| Albumin (g·dL-1) | 4.3 ± 0.1 | 4.3 ± 0.1 | 4.3 ± 0.1 | 4.3 ± 0.1 |
| Globulin (g·dL-1) | 2.6 ± 0.1 | 2.6 ± 0.1 | 2.6 ± 0.1 | 2.7 ± 0.1 |
| A:G | 1.7 ± 0.1 | 1.7 ± 0.1 | 1.7 ± 0.1 | 1.7 ± 0.1 |
| Bilirubin (mg·dL-1) | 0.5 ± 0.1 | 0.4 ± 0.1 | 0.6 ± 0.1 | 0.5 ± 0.1 |
| Alk Phos (IU·L-1) | 67.5 ± 6.8 | 65.3 ± 6.5 | 72.6 ± 6.3 | 70.9 ± 7.4 |
| AST (SGOT) (IU·L-1)** | 23.7 ± 2.5 | 26.7 ± 2.3 | 21.2 ± 2.1 | 19.9 ± 0.9 |
| ALT (SGPT) (IU·L-1) | 23.5 ± 4.0 | 28.9 ± 5.2 | 20.5 ± 3.9 | 21.2 ± 4.9 |
| HCV seropositivity status groups(number of subjects) | group AHCV Ab(−)n = 968 | group B and CHCV Ab(+)n = 109 | group B | group C | All subjectsn = 1077 |
| HCV Ab(+) Ag(−)n = 39 | HCV Ab(+) Ag(+)n = 70 | ||||
| all-cause death (crude mortality) | 356 (92.7) | 50 (127) | 14 (94.0) | 36 (147) | 406 (95.9) |
| adjusted mortality (95% CI) | 71.9 (62.6–81.3) | 123 (88.6–158) | 80.4 (37.9–123) | 156 (104–207) | 96.5 (75.5–118) |
| RR (95% CI) | REF | 1.71 (1.27–2.30) | 1.12 (0.66–1.91) | 2.16 (1.53–3.07) | |
| cardiovascular (crude mortality) | 173 (45.1) | 21 (53.4) | 4 (26.9) | 17 (69.5) | 194 (45.8) |
| adjusted mortality (95% CI) | 37.2 (30.5–43.9) | 53.0 (30.0–76.0) | 24.3 (0.40–48.2) | 73.5 (38.0–109) | 40.5 (25.3–55.7) |
| RR (95% CI) | REF | 1.42 (0.90–2.44) | 0.65 (0.24–1.76) | 1.98 (1.19–3.28) | |
| infectious disease-related (crude mortality) | 97 (25.3) | 15 (38.1) | 5 (33.6) | 10 (40.9) | 112 (26.5) |
| adjusted mortality (95% CI) | 17.8 (13.1–22.5) | 35.6 (17.1–54.1) | 25.7 (2.70–48.7) | 43.6 (16.3–71.0) | 27.1 (16.5–37.7) |
| RR (95% CI) | REF | 1.99 (1.15–3.43) | 1.45 (0.50–3.56) | 2.46 (1.27–4.76) | |
| liver disease-related (crude mortality) | 2 (0.52) | 5 (12.7) | 1 (6.71) | 4 (16.4) | 7 (1.65) |
| adjusted mortality (95% CI) | 0.40 (0.00–1.10) | 9.80 (0.00–21.5) | 5.70 (0.00–17.4) | 12.8 (0.00–29.6) | 3.10 (0.00–6.60) |
| RR (95% CI) | REF | 24.2 (4.56–128) | 13.7 (1.24–152) | 30.8 (5.34–178) |
| Off-treatment analysis | ||||||
| Included | Excluded | FREEDOM25 | ||||
| Placebo (N1 = 470) | Denosumab (N1 = 327) | Placebo (N2 = 520) | Denosumab (N2 = 466) | Placebo (N3 = 3906) | Denosumab (N3 = 3902) | |
| Baseline characteristics | ||||||
| Age, years (mean ± SD) | 73 ± 5 | 73 ± 5 | 74 ± 5 | 73 ± 5 | 72 ± 5 | 72 ± 5 |
| Prevalent fracture, n (%) | ||||||
| Vertebral | 122 (26) | 89 (27) | 155 (30) | 107 (23) | 915 (23) | 929 (24) |
| Nonvertebral | 149 (32) | 107 (33) | 168 (32) | 149 (32) | 1177 (30) | 1163 (30) |
| BMD T-score (mean ± SD) | ||||||
| Lumbar spine | −2.8 ± 0.7 | −2.8 ± 0.8 | −2.8 ± 0.7 | −2.8 ± 0.7 | −2.8 ± 0.7 | −2.8 ± 0.7 |
| Total hip | −2.1 ± 0.9 | −2.0 ± 0.9 | −2.1 ± 0.8 | −2.0 ± 0.8 | −1.9 ± 0.8 | −1.9 ± 0.8 |
| Prior bisphosphonate use, n (%) | 62 (13) | 46 (14) | 66 (13) | 61 (13) | 521 (13) | 472 (12) |
| Duration, years | ||||||
| n1 | 54 | 41 | 56 | 54 | 460 | 415 |
| Mean | 1.0 | 1.0 | 0.9 | 0.9 | 0.9 | 0.9 |
| Median (Q1, Q3) | 0.8 (0.3, 1.4) | 1.0 (0.1, 2.0) | 0.5 (0.2, 1.0) | 1.0 (0.2, 1.5) | 0.5 (0.2, 1.6) | 0.8 (0.2, 1.3) |
| Per-subject follow-up, yearsa | ||||||
| Mean | 0.8 | 0.8 | 0.3 | 0.3 | 2.8 | 2.8 |
| Median (Q1, Q3) | 0.5 (0.3, 1.4) | 0.5 (0.2, 1.4) | 0 (0,0) | 0 (0, 0) | 3.0 (3.0, 3.0) | 3.0 (3.0, 3.0) |
| Apoptotic cells sub-G1 | G1 | S | G2/M | |
| FemX | ||||
| Control | 0.30 | 58.19 | 15.42 | 22.87 |
| T. candida | 5.34 | 47.64 | 15.09 | 31.93 |
| U. barbata | 6.90 | 46.65 | 9.36 | 37.09 |
| Norstictic acid | 18.20 | 43.81 | 15.30 | 18.62 |
| Usnic acid | 10.18 | 54.38 | 14.64 | 20.37 |
| LS 174 | ||||
| Control | 2.55 | 49.53 | 12.06 | 32.21 |
| T. candida | 15.83 | 47.35 | 15.89 | 20.66 |
| U. barbata | 13.87 | 46.47 | 16.82 | 22.85 |
| Norstictic acid | 16.92 | 52.34 | 15.28 | 16.49 |
| Usnic acid | 12.89 | 52.77 | 15.06 | 19.28 |
| Characteristic | Total cohort(n = 63) | Yoga group(n = 29) | Control group(n = 34) |
| Age (y) | 37.2 ± 10.8 | 38.2 ± 10.1 | 36.3 ± 11.4 |
| Women (n; %) | 50; 79% | 23; 79% | 27; 79% |
| Body weight (kg) | 88.5 ± 21.0 | 86.4 ± 21.2 | 90.4 ± 21.0 |
| Body mass index (BMI) (kg/m2) | 30.5 ± 6.2 | 29.9 ± 6.2 | 30.9 ± 6.3 |
| Obese (BMI 30+) (n; %) | 27; 43% | 11; 38% | 16; 47% |
| Waist circumference (cm) | 94.7 ± 14.7 | 93.9 ± 14.5 | 95.3 ± 15.1 |
| Stress score (DASS-21) | 23.8 ± 6.0 | 23.3 ± 6.0 | 24.3 ± 6.1 |
| Current smoker or quit in last 6 months (n; %) | 3; 5% | 1; 3% | 2; 6% |
| Source | d.f. | MS | F | P |
| Line | 3 | 0.006 | 2.119 | 0.269 |
| Cactus | 1 | 0.004 | 1.145 | 0.365 |
| Line × Cactus | 3 | 0.003 | 2.623 | 0.067 |
| Wing Length | 1 | 0.001 | 1.048 | 0.309 |
| Error | 71 | 0.001 |
| Characteristic | All Countries | South Africa | Tanzania | Zimbabwe |
| Qualitative FGDs (parents) | N = 192 | n = 59 | n = 60 | n = 73 |
| Mean age, y (SD) | 39.9 (11.5) | 40.5 (10.1) | 36.1 (10.1) | 42.5 (12.8) |
| Gender | ||||
| Female | 97 (50.5) | 30 (50.8) | 31 (51.7) | 36 (49.3) |
| Male | 95 (49.5) | 29 (49.2) | 29 (48.3) | 37 (50.7) |
| Setting | ||||
| Urban | 89 (46.4) | 18 (30.5) | 16 (26.7) | 55 (75.3) |
| Periurban | 43 (22.4) | 13 (22.0) | 30 (50.0) | 0 (0.0) |
| Rural | 60 (31.3) | 28 (47.5) | 14 (23.3) | 18 (24.7) |
| Completed primary education | ||||
| No | 31 (16.2) | 18 (30.5) | 5 (8.3) | 8 (11.0) |
| Yes | 161 (83.9) | 41 (69.5) | 55 (91.7) | 65 (89.0) |
| Quantitative survey (adolescents) | N = 1293 | n = 299 | n = 498 | n = 496 |
| Mean age, y (SD) | 13.5 (3.1) | 13.8 (3.0) | 12.0 (2.6) | 14.7 (3.0) |
| Age group, y | ||||
| 10–14 | 836 (64.7) | 187 (62.5) | 413 (82.9) | 236 (47.6) |
| 15–19 | 457 (35.3) | 112 (37.5) | 85 (17.1) | 260 (52.4) |
| Setting | ||||
| Urban | 696 (53.8) | 107 (35.8) | 233 (46.8) | 356 (71.8) |
| Periurban | 192 (14.9) | 50 (16.7) | 142 (28.5) | 0 (0.0) |
| Rural | 405 (31.3) | 142 (47.5) | 123 (24.7) | 140 (28.2) |
| SES wealth scorea | ||||
| Low | 443 (34.3) | 15 (5.0) | 333 (66.9) | 95 (19.2) |
| Moderate | 419 (32.4) | 94 (31.4) | 151 (30.3) | 174 (35.1) |
| High | 424 (32.8) | 183 (61.2) | 14 (2.8) | 227 (45.8) |
| Religion | ||||
| Christian | 1231 (95.2) | 269 (90.0) | 480 (96.4) | 482 (97.2) |
| Muslim | 20 (1.6) | 2 (0.7) | 13 (2.6) | 5 (1.0) |
| Traditional | 13 (1.0) | 0 (0.0) | 0 (0.0) | 13 (4.4) |
| Agnostic/other | 25 (1.9) | 4 (0.8) | 9 (1.8) | 12 (4.0) |
| Ever had sex | ||||
| No | 1073 (83.0) | 231 (77.3) | 410 (82.3) | 432 (87.1) |
| Yes | 219 (16.9) | 67 (22.4) | 88 (17.7) | 64 (12.9) |
| Most talked-to adult with personal mattersb | ||||
| Mother | 411 (31.9) | 150 (50.8) | 124 (25.0) | 137 (27.6) |
| Father | 301 (23.4) | 42 (14.2) | 113 (22.8) | 146 (29.4) |
| Brother | 199 (15.5) | 37 (12.5) | 71 (14.3) | 91 (18.3) |
| Other family memberc | 198 (15.4) | 48 (16.3) | 56 (11.3) | 94 (19.0) |
| Other adultd | 30 (2.3) | 11 (3.7) | 8 (1.6) | 11 (2.2) |
| Does not talk with adultsabout personal matters | 148 (11.5) | 7 (2.4) | 124 (25.0) | 17 (3.4) |
| Patients code | Sex | Infection status | CD4 | HIV load | HCV load |
| H1* | F | HIV | 288 | 140222 | NUL |
| H2 | M | HIV | 56 | 373429 | NUL |
| H3 | F | HIV | 400 | 46189 | NUL |
| H4 | M | HIV | 218 | 95726 | NUL |
| H5 | M | HIV | 508 | 1665 | NUL |
| HC1* | F | HIV/HCV | 325 | <75 | 79000 |
| HC2 | M | HIV/HCV | 422 | <74 | 63999 |
| HC3 | M | HIV/HCV | 590 | <75 | 216000 |
| HC4 | F | HIV/HCV | 399 | <75 | 1200000 |
| HC5 | F | HIV/HCV | 331 | 123 | 5,070,000 |
| C1* | F | HCV | 517 | NUL | 85426 |
| C2 | F | HCV | 397 | NUL | >1000000 |
| C3 | F | HCV | 354 | NUL | >1000000 |
| C4 | M | HCV | 516 | NUL | 417070 |
| C5 | M | HCV | 389 | NUL | >1000000 |
| N1* | F | Negative | N/A | NUL | NUL |
| N2 | F | Negative | N/A | NUL | NUL |
| N3 | M | Negative | N/A | NUL | NUL |
| N4 | M | Negative | N/A | NUL | NUL |
| N5 | M | Negative | N/A | NUL | NUL |
| Percentage cilia | Length, μm | |||||
| Cycling | Assemb | Disassemb | Cycling | Assemb | Disassemb | |
| Empty | 1.7 ± 0.8 | 42.1 ± 3.7 | 12.6 ± 1.4 | 1.7 ± 0.4 | 4.1 ± 0.1 | 2.9 ± 0.1 |
| AurA | 0 | 26.5 ± 2.8 | 8.8 ± 0.9 | 0 | 4.1 ± 0.1 | 3.1 ± 0.2 |
| Nek2 | 0.5 ± 0.5 | 27.8 ± 2.3 | 7.2 ± 1.9 | 0.9 ± 0.5 | 4.2 ± 0.1 | 3.0 ± 0.1 |
| AurA/Nek2 | ND | 13.3 ± 1.0 | 15.5 ± 1.6 | ND | 7.2 ± 0.2 | 7.0 ± 0.3 |
| AurAKD | ND | 31.7 ± 1.8 | 13.6 ± 1.3 | ND | 4.5 ± 0.2 | 4.0 ± 0.1 |
| Nek2KD | ND | 32.2 ± 1.2 | 16.8 ± 1.8 | ND | 5.3 ± 0.2 | 3.2 ± 0.2 |
| AurAKD/Nek2KD | ND | 34.5 ± 2.7 | 25.6 ± 1.5 | ND | 14.0 ± 0.8 | 10.1 ± 0.3 |
| AurA/Nek2KD | ND | 12 ± 1.3 | 18 ± 2.0 | ND | 3.9 ± 0.1 | 3.3 ± 0.1 |
| AurAKD/Nek2 | ND | 11 ± 1.0 | 19.6 ± 2.0 | ND | 3.4 ± 0.2 | 3.0 ± 0.1 |
| R42 | 9.1 ± 1.3 | 47.2 ± 2.9 | 22.3 ± 3.0 | 4.2 ± 0.3 | 4.3 ± 0.1 | 3.4 ± 0.2 |
| R42/AurA | 1 ± 0.4 | 24.8 ± 2.1 | 7.2 ± 1.0 | 2.6 ± 0.7 | 4.3 ± 0.1 | 2.7 ± 0.1 |
| R42/Nek2 | 0.8 ± 0.4 | 18.4 ± 2.6 | 12.5 ± 2.6 | 2.2 ± 0.8 | 4.0 ± 0.1 | 3.0 ± 0.1 |
| OT siRNA | 4.8 ± 1.3 | 46 ± 4.6 | 26.3 ± 8.6 | 2.6 ± 0.2 | 4.0 ± 0.1 | 2.9 ± 0.1 |
| R42 siRNA | 3.4 ± 0.7 | 41 ± 2.2 | 24 ± 4.0 | 2.7 ± 0.2 | 3.6 ± 0.1 | 3.4 ± 0.2 |
| Empty-MLN | ND | 26.4 ± 3.1 | 13.2 ± 1.3 | ND | 6.4 ± 0.4 | 5.3 ± 0.4 |
| Empty + MLN | ND | 33.4 ± 1.7 | 18.3 ± 3.3 | ND | 6.8 ± 0.4 | 4.8 ± 0.4 |
| Nek2-MLN | ND | 25.2 ± 2.3 | 10.6 ± 1.5 | ND | 5.9 ± 0.4 | 4.8 ± 0.4 |
| Nek2 + MLN | ND | 36.2 ± 2.0 | 17.5 ± 1.4 | ND | 6.3 ± 0.3 | 4.8 ± 0.4 |
| Empty-rac | ND | 46 ± 3.7 | 17.6 ± 2.0 | ND | 4.6 ± 4.7 | 5.3 ± 0.6 |
| Empty + rac | ND | 43 ± 5.8 | 27.7 ± 2.3 | ND | 10.8 ± 1.2 | 6.4 ± 0.6 |
| AurA-rac | ND | 33 ± 4.4 | 14.3 ± 2.3 | ND | 5.3 ± 0.7 | 3.8 ± 0.3 |
| AurA + rac | ND | 48.4 ± 5.6 | 28 ± 5.0 l | ND | 7.4 ± 0.9 | 11.8 ± 1.3 |
| Contig | Accession numbera | Name and/or putative function | Organism | E -value |
| Cell wall degradation | ||||
| Contig 27 – SS_024 | SS1G_01493 | β-xylosidaseb | S. sclerotiorum | 3e-15 |
| Contig 45 – SS_041 | SS1G_13255.3 | β-1,4-glucanaseb | S. sclerotiorum | 6e-73 |
| Contig 57 – SS_052 | SS1G_08474 | β-1,3-glucanase precursor | S. sclerotiorum | 6e-05 |
| Contig 98 – SS_091 | SS1G_07146.3 | Cellobiohydrolaseb | S. sclerotiorum | 2e-40 |
| Contig 124 – SS_116 | SS1G_12937 | Glycosyl hydrolase | S. sclerotiorum | 2e-32 |
| Contig 145 – SS_136 | SS1G_07393 | β-1,3-glucanase | S. sclerotiorum | 1e-64 |
| Contig 42 – SS_038 | SS1G_02789 | Glucan endo-1,3-β-glucosidaseb | S. sclerotiorum | 3e-22 |
| Contig 33 – SS_029 | SS1G_01005 | α-glucosidaseputative | S. sclerotiorum | 3e-40 |
| Contig 18 – SS_016 | SS1G_12021 | β-1,6-glucanase putative | S. sclerotiorum | 5e-18 |
| Protein degradation | ||||
| Contig 25 – SS_022 | SS1G_0336 | Serine peptidase putative | S. sclerotiorum | 3e-43 |
| Contig 26 – SS_023 | SS1G_06534 | Serin endopeptidase | S. sclerotiorum | 2e-53 |
| Contig 16 – SS_014 | SS1G_03181 | Aspartyl proteaseb | S. sclerotiorum | 2e-20 |
| Contig 13 – SS_011 | SS1G_00624 | Acid proteaseb | S. sclerotiorum | 8e-15 |
| Contig 62 – SS_057 | SS1G_11818 | Vacuolar protease A | S. sclerotiorum | 4e-53 |
| Contig 74 – SS_068 | SS1G_00477 | Ubiquitin homeostasis protein lub1 (phospholipase) | S. sclerotiorum | 1e-12 |
| Contig 63 – SS_058 | SS1G_0770 | Proteasome component PRE6 | S. sclerotiorum | 3e-47 |
| Contig 61 – SS_056 | SS1G_01331 | Translocation protein Sec62 putative | S. sclerotiorum | 1e-22 |
| Intracellular transport | ||||
| Contig 40 – SS_036 | SS1G_07860 | Protein SEY1 | S. sclerotiorum | 6e-42 |
| Contig 77 – SS_071 | SS1G_09620 | Hypothetical protein (GTPase) | S. sclerotiorum | 2e-04 |
| Contig 103 – SS_096 | SS1G_10229 | GTP-binding protein EsdC | S. sclerotiorum | 1e-51 |
| Contig 160 – SS_150 | SS1G_08784 | GTP-binding protein | S. sclerotiorum | 6e-33 |
| Contig 148 – SS_139 | SS1G_11149 | SEC24 related gene family (GTPase) | S. sclerotiorum | 3e-31 |
| Contig 9 – SS_007 | SS1G_02490 | DENN domain-containing protein | S. sclerotiorum | 2e-32 |
| Contig 86 – SS_080 | SS1G_09635 | Geranylgeranyl pyrophosphate synthetase (biosynthesis of secondary metabolites) | S. sclerotiorum | 5e-25 |
| Oxidative stress | ||||
| Contig 53 – SS_048 | SS1G_14466 | Oxidoreductase, 2-nitropropane dioxygenase family | S. sclerotiorum | 9e-19 |
| Contig 44 – SS_040 | SS1G_12928 | Peroxidase/catalase | S. sclerotiorum | 2e-38 |
| Contig 88 – SS_082 | SS1G_10037 | Cytochrome P450 | S. sclerotiorum | 4e-29 |
| Contig 161 – SS_151 | SS1G_06754 | Zinc transcription factor | S. sclerotiorum | 4e-42 |
| Contig 153 – SS_143 | SS1G_11235 | 2-nitropropane dioxygenase | S. sclerotiorum | 2e-44 |
| Others | ||||
| Contig 10 – SS_008 | SS1G_06319 | Perilipin MPL1- like protein CAP 20b | S. sclerotiorum | 1e-07 |
| Contig 97 – SS_090 | SS1G_03197 | pH-response regulator protein | S. sclerotiorum | 2e-09 |
| Contig 75 – SS_069 | SS1G_10538 | Ceramidase | S. sclerotiorum | 6e-20 |
| Contig 142 – SS_133 | SS1G_00477 | Phospholipase | S. sclerotiorum | 1e-12 |
| Group | Test group | Control group | t | P |
| Duration of operation (min) | 180.4±48.9 | 179.7±66.4 | 1.513 | >0.05 |
| Intraoperative bleeding volume (mL) | 390.5±90.3 | 384.6±89.5 | 0.023 | >0.05 |
| Length of hospital stay (d) | 22.0±4.5 | 23.1±5.6 | 0.804 | >0.05 |
| VAS score (point) | 1.76±1.09 | 5.22±2.90 | 8.196 | <0.05 |
| Fracture healing time (week) | 6.34±1.12 | 6.25±1.17 | 0.082 | >0.05 |
| MBSR sessions completed | Number of participants | Percentage (%) |
| All | 3 | 12% |
| 7 | 8 | 32% |
| 6 | 3 | 12% |
| 5 | 1 | 4% |
| 4 | 0 | 0% |
| 3 | 1 | 4% |
| 2 | 1 | 4% |
| 1 | 4 | 16% |
| 0 | 4 | 16% |
| Variable | Hazard ratio (95% CI) | P |
| Age: ≥50 versus <50 | 0.63 (0.08–5.19) | 0.67 |
| Age: ≥60 versus <60 | 0.55 (0.13–2.32) | 0.42 |
| Tumor size: >2 cm versus ≤2 cma | 2.20 (0.25–19.75) | 0.48 |
| Tumor type: ILC versus other | 1.89 (0.23–15.41) | 0.55 |
| Tumor type: DCIS versus invasive cancer | 1.61 (0.38–6.75) | 0.52 |
| ER status: negative versus positivea | 5.87 (0.97–35.34) | 0.053 |
| Margins: negative versus close/positive | 7.63 (1.45–40.0) | 0.016 |
| Multifocality: yes versus no | 2.36 (0.28–19.99) | 0.43 |
| LVI: present versus nonea,b | — | 0.60 |
| Nodal status: positive versus negativea,b | — | 1.0 |
| Variable | 1 | 2 | 3 | 4 |
| RIGHT/FRONTAL QUADRANT | ||||
| 1. Congruence effect | ||||
| 2. Association effect | 0.055 | |||
| 3. Stroop interference | 0.037 | 0.099 | ||
| 4. Listening span | −0.486* | 0.001 | 0.094 | |
| LEFT/FRONTAL QUADRANT | ||||
| 1. Congruence effect | ||||
| 2. Association effect | 0.223 | |||
| 3. Stroop interference | −0.125 | 0.05 | ||
| 4. Listening span | −0.283 | −0.044 | 0.094 | |
| RIGHT/POSTERIOR QUADRANT | ||||
| 1. Congruence effect | ||||
| 2. Association effect | −0.225 | |||
| 3. Stroop interference | 0.262 | 0.035 | ||
| 4. Listening span | −0.032 | 0.159 | 0.094 | |
| LEFT/POSTERIOR QUADRANT | ||||
| 1. Congruence effect | ||||
| 2. Association effect | 0.455* | |||
| 3. Stroop interference | −0.132 | 0.131 | ||
| 4. Listening span | 0.516** | 0.622** | 0.094 |
| Species | Lot | Seeds/well | Linear regression | R2 |
| Phelipanche ramosa | St Martin de Fraigneau, France, 2005 | 120 | A = 0.0023 gs + 0.011 | 0.976 |
| Orobanche cumana | Longeville-sur-mer, France, 2009 | 110 | A = 0.0019 gs + 0.009 | 0.965 |
| Orobanche minor | Japan, 2010 | 80 | A = 0.0043 gs + 0.032 | 0.977 |
| Striga hermonthica | Gadarif, Soudan, 1999 | 90 | A = 0.0127 gs + 0.016 | 0.920 |
| 1994–1999 | 2000–2004 | 2005–2009 | ||||||||||
| Empirical data | Spectrum estimate | Empirical data | Spectrum estimate | Empirical data | Spectrum estimate | |||||||
| Age group | Number of deaths | Number of person years | Mortality rate (95% CI) | Mortality rate | Number of deaths | Number of person years | Mortality rate (95% CI) | Mortality rate | Number of deaths | Number of person years | Mortality rate (95% CI) | Mortality rate |
| Men | ||||||||||||
| 15–19 | 19 | 6,064 | 3.13 (2–4.91) | 3.06 | 19 | 6,275 | 3.03 (1.93–4.75) | 2.69 | 15 | 7,654 | 1.96 (1.18–3.25) | 2.31 |
| 20–24 | 19 | 4,716 | 4.03 (2.57–6.32) | 4.86 | 17 | 5,029 | 3.38 (2.1–5.44) | 4.23 | 20 | 5,229 | 3.82 (2.47–5.93) | 3.58 |
| 25–29 | 25 | 3,615 | 6.91 (4.67–10.23) | 7.51 | 24 | 4,089 | 5.87 (3.93–8.76) | 6.81 | 31 | 4,165 | 7.44 (5.23–10.58) | 5.60 |
| 30–34 | 49 | 3,312 | 14.80 (11.18–19.58) | 10.24 | 32 | 3,344 | 9.57 (6.77–13.53) | 10.09 | 28 | 4,096 | 6.84 (4.72–9.90) | 8.07 |
| 35–39 | 45 | 2,654 | 16.96 (12.66–22.71) | 13.95 | 33 | 2,922 | 11.30 (8.03–15.89) | 14.60 | 37 | 3,249 | 11.39 (8.25–15.72) | 11.85 |
| 40–44 | 21 | 1,903 | 11.04 (7.2–16.93) | 15.02 | 49 | 2,425 | 20.21 (15.27–6.74) | 16.14 | 31 | 2,744 | 11.30 (7.94–16.06) | 13.10 |
| 45–49 | 31 | 1,609 | 19.26 (13.55–27.39) | 15.38 | 31 | 1,688 | 18.36 (12.91–26.11) | 16.09 | 25 | 2,254 | 11.09 (7.49–16.41) | 13.55 |
| 50–54 | 25 | 1,333 | 18.76 (12.68–27.76) | 15.29 | 25 | 1,290 | 19.39 (13.1–28.69) | 14.90 | 31 | 1,563 | 19.83 (13.94–28.19) | 12.73 |
| 55–59 | 23 | 1,005 | 22.89 (15.21–34.44) | 25.15 | 24 | 1,093 | 21.95 (14.71–32.75) | 23.61 | 21 | 1,147 | 18.31 (11.94–28.08) | 19.97 |
| 60 + | 126 | 2,387 | 52.79 (40.33–69.79) | 62.28 | 138 | 2,500 | 55.20 (42.35–71.80) | 59.95 | 135 | 2,801 | 48.20 (36.34–63.88) | 56.86 |
| Women | ||||||||||||
| 15–19 | 10 | 5,265 | 1.90 (1.02–3.53) | 2.59 | 19 | 5,774 | 3.29 (2.1–5.16) | 2.23 | 17 | 6,881 | 2.47 (1.54–3.97) | 1.80 |
| 20–24 | 35 | 4,983 | 7.02 (5.04–9.78) | 4.81 | 28 | 4,954 | 5.65 (3.9–8.19) | 4.23 | 10 | 5,310 | 1.88 (1.01–3.5) | 3.43 |
| 25–29 | 35 | 4,164 | 8.40 (6.03–11.71) | 8.97 | 36 | 4,572 | 7.87 (5.68–10.92) | 8.71 | 29 | 4,767 | 6.08 (4.23–8.75) | 6.82 |
| 30–34 | 46 | 3,598 | 12.78 (9.58–17.07) | 10.85 | 46 | 3,728 | 12.34 (9.24–16.47) | 12.17 | 25 | 4,423 | 5.65 (3.82–8.37) | 9.44 |
| 35–39 | 25 | 2,619 | 9.55 (6.45–14.13) | 12.15 | 40 | 3,164 | 12.64 (9.27–17.24) | 14.16 | 28 | 3,402 | 8.23 (5.68–11.92) | 11.87 |
| 40–44 | 22 | 2,059 | 10.69 (7.04–16.23) | 11.48 | 30 | 2,436 | 12.31 (8.61–17.61) | 13.04 | 25 | 2,995 | 8.35 (5.64–12.35) | 10.94 |
| 45–49 | 18 | 1,566 | 11.50 (7.24–18.25) | 14.00 | 21 | 1,884 | 11.15 (7.27–17.1) | 14.80 | 23 | 2,379 | 9.67 (6.42–14.55) | 12.35 |
| 50–54 | 19 | 1,368 | 13.89 (8.86–21.78) | 14.30 | 20 | 1,406 | 14.22 (9.18–22.04) | 13.74 | 19 | 1,733 | 10.97 (6.99–17.19) | 11.30 |
| 55–59 | 19 | 1,079 | 17.62 (11.24–27.62) | 13.84 | 20 | 1,186 | 16.87 (10.88–26.14) | 12.63 | 18 | 1,363 | 13.21 (8.32–20.97) | 10.71 |
| 60+ | 151 | 2,866 | 52.69 (40.21–69.00) | 55.60 | 132 | 3,113 | 42.40 (36.31–48.81) | 53.60 | 139 | 3,612 | 38.48 (33.45–4497) | 51.03 |
| Cutpoint | Method | Level of burden | |||
| Heavy | Medium | Mild | None | ||
| 0.9 | PP | 0.788 | 0.982 | 1.052 | 1.028 |
| AT | 0.749 | 0.983 | 1.052 | 1.017 | |
| IV | 2.977 | 3.269 | 1.710 | 1.184 | |
| 0.85 | PP | 0.776 | 0.950 | 1.019 | 1.028 |
| AT | 0.742 | 0.933 | 1.014 | 1.009 | |
| IV | 2.647 | 2.629 | 1.531 | 1.175 | |
| 0.8 | PP | 0.752 | 0.909 | 1.006 | 1.020 |
| AT | 0.711 | 0.886 | 0.994 | 1.009 | |
| IV | 2.362 | 2.195 | 1.421 | 1.175 | |
| 0.75 | PP | 0.729 | 0.905 | 1.000 | 1.028 |
| AT | 0.690 | 0.886 | 0.979 | 1.015 | |
| IV | 2.110 | 1.894 | 1.347 | 1.167 | |
| 0.7 | PP | 0.715 | 0.883 | 1.001 | 1.021 |
| AT | 0.679 | 0.865 | 0.984 | 1.015 | |
| IV | 1.915 | 1.647 | 1.289 | 1.159 | |
| 0.65 | PP | 0.694 | 0.870 | 0.996 | 1.021 |
| AT | 0.662 | 0.858 | 0.985 | 1.008 | |
| IV | 1.728 | 1.468 | 1.243 | 1.152 | |
| 0.6 | PP | 0.686 | 0.860 | 0.985 | 1.013 |
| AT | 0.656 | 0.852 | 0.970 | 1.008 | |
| IV | 1.560 | 1.336 | 1.213 | 1.144 | |
| 0.55 | PP | 0.669 | 0.859 | 0.981 | 1.014 |
| AT | 0.636 | 0.856 | 0.971 | 1.001 | |
| IV | 1.413 | 1.235 | 1.179 | 1.144 | |
| 0.5 | PP | 0.665 | 0.854 | 0.970 | 1.013 |
| AT | 0.629 | 0.842 | 0.957 | 1.000 | |
| IV | 1.291 | 1.158 | 1.147 | 1.144 |
| Age of onset | Study population | Annual reported non-fatal early cases | Annual reported non-fatal late cases | Annual reported deaths | Annual YLLs with 0% under-reporting (age weighted) | Annual YLLs with 0% under-reporting (non-age weighted) | Annual deaths with 69% under-reporting | Annual YLLs with 69% under-reporting (age weighted) | Annual YLLs with 69% under-reporting (non-age weighted) |
| 0–4 | 7145 | 1.6 (0–3) | 2.1 (0–4) | 0.1 (0–1) | 4 (0–28) | 3.5 (0–24.8) | 2.8 (0.5–5.5) | 86.9 (17–170) | 71.4 (13.9–140.1) |
| 5–14 | 12432 | 5.7 (2–13) | 11.4 (3–17) | 1 (0–3) | 33.2 (0–100.5) | 24 (0–73.3) | 12.7 (4.2–27) | 423.2 (141.1–902.5) | 308.7 (102.4–660.5) |
| 15–29 | 12687 | 9.9 (3–16) | 16.7 (9–23) | 0.7 (0–2) | 19.7 (0–52.8) | 14.9 (0–40.4) | 19 (7–34.8) | 552.7 (199.1–1027.2) | 406.3 (147.3–752.8) |
| 30–44 | 6857 | 4.6 (1–8) | 9.4 (4–18) | 0.6 (0–1) | 10.3 (0–18.7) | 9.8 (0–18) | 10.1 (4.4–21.8) | 210.6 (90.6–444.7) | 184.6 (79.8–391.8) |
| 45–59 | 4668 | 2.4 (0–5) | 6.7 (3–10) | 0.1 (0–1) | 1.9 (0–13.1) | 2.1 (0–15) | 6.5 (2.1–12.2) | 83.4 (28.6–154.3) | 93.3 (31.4–171.5) |
| 60–69 | 1850 | 2.4 (0–5) | 4.1 (3–7) | 0.9 (0–2) | 6.1 (0–16.4) | 8.7 (0–22.6) | 5.4 (1.6–10.4) | 39.4 (10.4–74.3) | 55.6 (15–105.9) |
| 70–79 | 781 | 0.1 (0–1) | 2.3 (0–4) | 0.3 (0–1) | 1.1 (0–4.4) | 1.9 (0–7.5) | 1.9 (0–4.6) | 8 (0–19.2) | 13.5 (0–32.5) |
| 80+ | 235 | 0.6 (0–3) | 0.4 (0–2) | 0.1 (0–1) | 0.2 (0–1.2) | 0.4 (0–3) | 0.8 (0–3.5) | 1.6 (0–6.5) | 3.5 (0–14.3) |
| Totals | 46655 | 27.3 (7–48) | 53.3 (24–73) | 3.9 (1–8) | 76.4 (17.3–160) | 65.4 (16.2–132.1) | 59.2 (25.2–109.1) | 1405.8 (608.8–2657.2) | 1136.8 (493–2132.2) |
| Solvents | Possible replacement |
| benzonitrile | 1,4-cineol |
| 1-hexanol | N,N-diethylolcapramide |
| sulfolane | ethylene glycol |
| methyl tert-butyl ether | diethyl succinate |
| diethyl ether | ethylhexyllactate |
| 2-pentanol | gamma-valerolactone |
| 2-methyl-2-propanol | glycerol, cyclopentyl methyl ether |
| trifluoroethanol | methyl ricinoleate |
| diphenyl ether | isopropyl palmitate |
| n-propylamine | ricinoleic acid |
| propionitrile | 1,4-cineol |
| ethylenediamine | diisobutyl adipate |
| 2,6-dimethylpyridine | ethyl acetate |
| 4-picoline | ethanol/water(80:20)vol |
| diethylamine | glycerol-1,2,3-triethyl ether, dihydromyrcenol |
| morpholine | ethanol/water(90:10)vol |
| diethylene glycol | glycerol-1-ethyl monoether |
| 2-aminoethanol | glycerol-1-methyl monoether |
| 3-pentanol | glycerol-2-methyl monoether |
| aniline | dimethyl phthalate |
| 2-methyl-2-butanol | 2-furfuraldehyde |
| nitroethane | butyl myristate |
| Clinicopathologic Characteristic | Number | Oct4 | p value | Sox2 | p value | ||
| Negative N (%) | Positive N (%) | Negative N (%) | Positive N (%) | ||||
| T stage | 0.496 | 0.353 | |||||
| T1 | 44 | 33 (44.0) | 11 (52.4) | 40 (47.6) | 4 (33.3) | ||
| T2-T4 | 52 | 42 (56.0) | 10 (47.6) | 44 (52.4) | 8 (66.7) | ||
| N stage | 0.208 | 0.749 | |||||
| N0 | 62 | 46 (61.3) | 16 (76.2) | 55 (65.5) | 7 (58.3) | ||
| N1-N3 | 34 | 29 (38.7) | 5 (23.8) | 29 (34.5) | 5 (41.7) | ||
| Histologic grade | 0.201 | 0.641 | |||||
| I | 1 | 0 (0.0) | 1 (4.8) | 1 (1.2) | 0 (0.0) | ||
| II | 8 | 6 (8.0) | 2 (9.5) | 8 (9.5) | 0 (0.0) | ||
| III | 87 | 69 (92.0) | 18 (85.7) | 75 (89.3) | 12 (100.0) | ||
| LVI | 0.508 | 1.000 | |||||
| Absent | 58 | 44 (58.7) | 14 (66.7) | 51 (60.7) | 7 (58.3) | ||
| Present | 38 | 31 (41.3) | 7 (33.3) | 33 (39.3) | 5 (41.7) | ||
| P53 overexpression | 0.757 | 0.757 | |||||
| Negative | 44 | 35 (46.7) | 9 (42.9) | 39 (46.4) | 5 (41.7) | ||
| Positive | 52 | 40 (53.3) | 12 (57.1) | 45 (53.6) | 7 (58.3) | ||
| Ki-67 | 0.446 | 1.000 | |||||
| < 20% | 11 | 10 (13.3) | 1 (4.8) | 10 (11.9) | 1 (8.3) | ||
| ≥ 20% | 85 | 65 (86.7) | 20 (95.2) | 74 (88.1) | 11 (91.7) | ||
| HER2 | 0.531 | 0.531 | |||||
| Negative | 56 | 45 (60.0) | 11 (52.4) | 48 (57.1) | 8 (66.7) | ||
| Positive | 40 | 30 (40.0) | 10 (47.6) | 36 (42.9) | 4 (33.3) | ||
| CD44(+)CD24(−) | 0.655 | 0.526 | |||||
| < 10% | 36 | 29 (38.7) | 7 (33.3) | 33 (39.3) | 3 (25.0) | ||
| ≥ 10% | 60 | 46 (61.3) | 14 (66.7) | 51 (60.7) | 9 (75.0) | ||
| ALDH1 | 0.022 | 1.000 | |||||
| < 10% | 73 | 61 (81.3) | 12 (57.1) | 64 (76.2) | 9 (75.0) | ||
| ≥ 10% | 23 | 14 (18.7) | 9 (42.9) | 20 (23.8) | 3 (25.0) | ||
| Vimentin | 0.458 | 0.107 | |||||
| < 10% | 62 | 47 (62.7) | 15 (71.4) | 57 (67.9) | 5 (41.7) | ||
| ≥ 10% | 34 | 28 (37.3) | 6 (28.6) | 27 (32.1) | 7 (58.3) | ||
| E-cadherin loss | 0.555 | 0.437 | |||||
| < 50% | 54 | 41 (54.7) | 13 (61.9) | 46 (54.8) | 8 (66.7) | ||
| ≥ 50% | 42 | 34 (45.3) | 8 (38.1) | 38 (45.2) | 4 (33.3) |
| Item | Criteria | Assessment |
| Validity | a) Are findings presented objectively?• Clear rationale and justification• Findings presented and discussed within appropriate context• Similar to existing literature and if not, reasons explained• Conflict of interest statement | YesNoUnclearN/A |
| b) Are the authors conclusions justified?• Transparency• Results consistent with those described in discussion• Conclusions based on empirical findings | YesNoUnclearN/A | |
| Reliability | a) Is the research methodology clearly described?• Study population and surveillance system described• Can identify the research design• Methods carried out in a rigorous and transparent manner | YesNoUnclearN/A |
| b) Is methodology appropriate for the scope of research?a• Comparison with an appropriate reference standard (i.e. a data source other than notification data)?o Is the sensitivity of the reference standard described? Are cases verified?o Is the population base for notifications and supplementary data sources drawn from same catchment area?o Is there an adequate description of case ascertainment?o Are cases ascertained for the same time period in both datasets?• Are the data sources to be compared clearly identified and described/referenced?• What case definition is used? Is the same definition applied to all data sources?• Are the methods for linkage described?o Were the identifiers unique and available?o How complete was the link? (% linked)o How accurate was the link? (i.e. were individuals linked who were not supposed to be or vice versa)o Were duplicate cases identified and removed?• How precise are results? (confidence interval width)• Were any statistical measures of agreement used (did authors express level of agreement using a statistic)?• For capture-recapture methods:o If dependency between data sources is suspected, are ≥3 or more data sources used, along with log linear modelling methods, to account for this dependency? | YesNoUnclearN/A | |
| c) Is the research methodology free from bias?• Are there major sources of bias?• Can the study be reproduced? | YesNoUnclearN/A | |
| d) Are ethics procedures described?• Approval from ethics review board• Individual consent | YesNoUnclearN/A | |
| e) Can I be confident about findings?• Were sources of information quality assessed?• Any major methodological flaws? | YesNoUnclearN/A | |
| Applicability | Can results be applied within the scope of public health?• Do the results of the study apply to the issue under consideration (i.e. are surveillance systems and supplementary data sources similar to Ontario?)? | YesNoUnclearN/A |
| Exposures | Low | High | P for difference | Odds ratios with 95% confidence interval for psychological impairment (High category is reference) | |
| MICRONUTRIENTS | |||||
| Haemoglobin | 28.7 (6.2) | 28.5 (7.6) | 0.92 | 1.43 | (0.48, 4.21) |
| Ferritin | 26.6 (8.0) | 29.1 (7.0) | 0.20 | 0.50 | (0.16, 1.51) |
| Calcium | 29.4 (6.9) | 25.7 (7.7) | 0.03 | 1.47 | (1.21, 4.31) |
| Vitamin D | 29.9 (10.2) | 28.2 (6.2) | 0.39 | 1.43 | (0.48, 4,21) |
| Zinc | 29.0 (9.2) | 28.4 (6.7) | 0.77 | 0.78 | (0.26, 2.31) |
| Vitamin B1 | 28.0 (6.6) | 28.8 (7.7) | 0.62 | 0.63 | (0.24, 1.64) |
| Vitamin B2 | 27.4 (8.9) | 28.9 (6.8) | 0.47 | 1.23 | (0.43, 3.55) |
| Vitamin B6 | 28.7 (7.7) | 28.5 (7.2) | 0.95 | 0.78 | (0.26, 2.31) |
| Vitamin B12 | 28.2 (5.9) | 28.6 (7.7) | 0.85 | 1.43 | (0.48, 4.21) |
| Folic acid | 28.9 (7.6) | 28.8 (7.3) | 0.94 | 0.91 | (0.21, 3.96) |
| Vitamin C | 28.1 (7.4) | 28.7 (7.3) | 0.79 | 1.50 | (0.20, 3.70) |
| MACRONUTRIENTS | |||||
| Energy | 30.8 (8.3) | 27.9 (6.9) | 0.24 | 1.94 | (0.65, 5.81) |
| Protein | 30.4 (8.3) | 28.0 (6.9) | 0.48 | 1.68 | (0.55, 5.11) |
| Fat | 29.6 (8.0) | 28.2 (7.1) | 0.22 | 1.05 | (0.36, 3.11) |
| Calcium | 30.4 (8.8) | 27.7 (6.6) | 0.03 | 1.43 | (1.08, 3.19) |
| Iron | 31.4(8.8) | 27.7 (6.6) | 0.046 | 3.04 | (1.02, 9.26) |
| Name | Sequence (5′→3′) | Position from ATG | Experimental use |
| ChsV-1 | CAAGGACGAAAAGAGAGTAAC | + 2769 (s) | RT-PCR |
| ChsV-3 | TGTTGGTAGTTGTGATAATCGT | + 2985 (as) | RT-PCR |
| B2m-F | TTTTCATCTGTCTTCCCCTGT | + 3105 (s) | RT-PCR |
| B2m-R | GTATGTATCAGTCTCAGTGGG | + 3362 (as) | RT-PCR |
| pyrG-F2 | TGCCTCAGCATTGGTACTTG | - 670 (s) | Deletion vector |
| pyrG-R2 | GTACACTGGCCATGCTATCG | + 1335 (as) | Deletion vector |
| 112092-F1 | TGAGTTCTGCTTCTTCGTCTG | - 970 (s) | Deletion vector and probe |
| 112092-R1 | caagtaccaatgctgaggcaGGGGCTTTCTGGATGATGAGT | - 19 (as) | Deletion vector and probe |
| 112092-F2 | cgatagcatggccagtgtacGTAGTAGCGTTGAATAAAGAGT | + 1327 (s) | Deletion vector |
| 112092-R2 | GTGAGTTTCTGCTTGAATTTGT | + 2456 (as) | Deletion vector |
| 112092-F3n | ACGAAGAATCAGCAATTACACA | - 917 (s) | Deletion vector |
| 112092-R3n | ACTCCATCAACTTTTATAAGCC | + 2398 (as) | Deletion vector |
| 108920-F1 | TTTTGCAGGCTTTTATTACATTT | - 1063 (s) | Deletion vector |
| 108920-R2 | ACCTATGCAATGCCTCCGATGCGA | - 791 (s) | Deletion vector |
| 108920-F2 | cgatagcatggccagtgtacCCATTGGCATCACGGATCAGCA | + 563 (as) | Deletion vector |
| 108920-R1 | caagtaccaatgctgaggcaTGCTGCTGCGTACTGACTGATGT | + 2312 (s) | Deletion vector and probe |
| 108920-F1 | GATGCAGGTTGTGATGGAAC | + 3123 (as) | Deletion vector and probe |
| Classification (α-angle) | Number (%) |
| Pathologic (>57°) | 64 (14.6) |
| Borderline (51–56°) | 66 (15.1) |
| Subtle (46–50°) | 64 (14.6) |
| Very subtle (43–45°) | 88 (20.1) |
| Normal (≤42°) | 156 (35.6) |
| Source | Age (months) sex | Time of sample colection | Symptomsaor signs | Clinical diagnosis | Comorbidity | Time in hospital (days) | Coinfecting viruses |
| infant | 3/M | November 01, 2005 | fever | bronchiolitis | / | 3 | hRV |
| infant | 6/M | January 19, 2006 | hypoxia, fever | asthmatic bronchitis | / | 6 | RSV, hRV |
| Transplanted adult | February 2006, 180 days after transplantation | pharingodinia | pharingodinia | / |
| All women | ZDV monotherapy | Combination therapy | ||||
| Parameter | 2–6 months | 6–12 months | 2–6 months | Parameter | 2–6 months | 6–12 months |
| CD4 count | −12.2, P = .51 | 10.0, P = .46 | −19.5, P = .52 | CD4 count | −12.2, P = .51 | 10.0, P = .46 |
| CD4+ % | −0.01, P = .96 | −0.13, P = .46 | 0.06, P = .82 | CD4+ % | −0.01, P = .96 | −0.13, P = .46 |
| Log10 HIV RNA | −0.07, P = .35 | −0.04, P = .43 | −0.10, P = .25 | Log10 HIV RNA | −0.07, P = .35 | −0.04, P = .43 |
| Region | Disposable Income | FAS Index | Std. Deviation | Family Car | Own Bedroom | No. of Computers | No. of Bathrooms | Dishwasher in Home | Family Holidays |
| (CZK/Year) | Mean (0–13) | Mean (0–2) | Mean (0–1) | Mean (0–3) | Mean (0–3) | Mean (0–1) | Mean (0–3) | ||
| Prague | 264,100 | 8.1090 | 2.3646 | 1.3873 | 0.5679 | 2.5261 | 1.3583 | 0.7496 | 1.7844 |
| Central Bohemia | 216,633 | 7.9662 | 2.3401 | 1.5832 | 0.6667 | 2.4073 | 1.4861 | 0.7063 | 1.6183 |
| Plzeň | 205,083 | 7.5646 | 2.4755 | 1.4984 | 0.5679 | 2.2411 | 1.3222 | 0.6605 | 1.6284 |
| South Moravia | 203,208 | 7.5845 | 2.3741 | 1.4306 | 0.616 | 2.4108 | 1.3778 | 0.6517 | 1.6713 |
| Hradec Králové | 198,052 | 7.3255 | 2.3201 | 1.4579 | 0.5941 | 2.2442 | 1.3954 | 0.6502 | 1.4634 |
| Vysočina | 195,304 | 7.1183 | 2.4678 | 1.5197 | 0.5759 | 2.2495 | 1.459 | 0.6434 | 1.5424 |
| Pardubice | 193,820 | 7.0297 | 2.3404 | 1.4406 | 0.5503 | 2.2585 | 1.3488 | 0.6431 | 1.4397 |
| South Bohemia | 193,653 | 7.3271 | 2.2867 | 1.4797 | 0.5871 | 2.2576 | 1.414 | 0.6645 | 1.5814 |
| Zlin | 189,825 | 7.2367 | 2.3199 | 1.4714 | 0.5994 | 2.3472 | 1.4548 | 0.6445 | 1.5503 |
| Liberec | 189,176 | 7.5447 | 2.2164 | 1.3525 | 0.5683 | 2.1903 | 1.2939 | 0.5992 | 1.5 |
| Moravia-Silesia | 184,014 | 7.7997 | 2.3226 | 1.3021 | 0.5205 | 2.31 | 1.3333 | 0.5837 | 1.5208 |
| Olomouc | 183,173 | 7.1465 | 2.3534 | 1.3548 | 0.5574 | 2.2951 | 1.361 | 0.563 | 1.5322 |
| Karlovy Vary | 181,819 | 7.8075 | 2.3894 | 1.3993 | 0.6269 | 2.2229 | 1.2607 | 0.5709 | 1.5635 |
| Ústí nad Labem | 174,662 | 7.3046 | 2.3696 | 1.2746 | 0.602 | 2.2266 | 1.2955 | 0.5706 | 1.577 |
| Source | No. of samples analyzed | No. of samples positive (%) |
| Well (n = 45) | 241 | 72 (29.9) |
| Tap (n = 8) | 56 | 4 (7.1) |
| Stream (n = 1) | 21 | 11 (52.4) |
| Total | 318 | 87 (27.4) |
| # | Name | Sequence |
| F1 | SpeI-KDM4C-F1 | GTACTAGTATGGAGGTGGCCGAGGTGGAA |
| R1 | XhoI-KDM4C-R2121 | ACTTGTTCCATCCTCCTCGAGGAAGGCATTGGGTGGAG |
| F2 | Eco47III-D2A-F | GAGCCTCAGCGCTATGGCTTCTGAGTCTGAAACTCTGAAT |
| R2 | SalI-KDM4A-R2150 | CTGCAGCCAGTCGACGTGAAGCACATTTCTGGAATC |
| F3 | XhoI-KDM4A-F2181 | TCTACTCCTTATCTCGAGGAGGATGGCACCAGCATAC |
| R3 | SalI-D2A-R | CATGTCGACCGCTCCATGATGGCCCGGTATAGTGCAG |
| F4 | SalI-KDM4C-F2083 | GCGGTCGACCGAAGAAAATATAGAATATTCTCCACCCAATG |
| R4 | XmaI-D2C-R | ATCCCGGGTCTGTCTCTTCTGGCACTTCTTCTGGAAA |
| F5 | SalI-KDM4C-F2083 | GCGGTCGACCGAAGAAAATATAGAATATTCTCCACCCAATG |
| R5 | XhoI-KDM4C-R2595 | GGCTCGAGCTTATGTCGAAAGCATGTAATGTTCACCAC |
| F6 | XhoI-KDM4A-F2656 | GACTCGAGATTCCTAATTTGGAGCGTGCC |
| R6 | SalI-KDM4A-R2655 | AGGGTCGACCTTGTGCCGAAAGCAGGTAATGAAG |
| F7 | SalI-KDM4C-F2598 | ACGGTCGACGACAACCCCAACGTGAAGTCCAAGG |
| R7 | XhoI-KDM4C-R2802 | GGCTCGAGCAGCTTCAGACAGTCTCGGCTCACGATATC |
| F8 | XhoI-KDM4A-F2865 | GACTCGAGACTCCTCCTGCTGAAGGGGAAGT |
| R8 | SalI-KDM4A-R2862 | AGGGTCGACAAACTGGAGACAGTCCTGGCTCACTA |
| F9 | SalI-KDM4C-F2805 | ACGGTCGACGACCCACCTGCTGAGGGAGAAGTCGTC |
| F10 | BamHI-KDM4C-RDTF-DNLY-F | GTTTGATGATGGATCCTTTAGCGATAACTTATATCCTGAGGATATCGTG |
| R10 | BamHI-KDM4C-RDTF-DNLY-R | CACGATATCCTCAGGATATAAGTTATCGCTAAAGGATCCATCATCAAAC |
| F11 | BamHI-KDM4A-DNLY-RTDF-F | ACTTTGATGATGGATCCTTCAGCCGCGATACCTTTCCTGAGGACATAGT |
| R11 | BamHI-KDM4A-DNLY-RTDF-R | ACTATGTCCTCAGGAAAGGTATCGCGGCTGAAGGATCCATCATCAAAGT |
| F12 | BamHI-KDM4C-R919D-F | TGTTTGATGATGGATCCTTTAGCGACGACACATTTCCTGAGGAT |
| R12 | BamHI-KDM4C-R919D-R | ATCCTCAGGAAATGTGTCGTCGCTAAAGGATCCATCATCAAACA |
| R13 | EcoR571-KDM4C-S198M | GCATGGCACACTGAAGACATGGACCTCTATATGATTAATTATCTCCAC |
| 0–6 months | >6 months | |||||
| Baseline characteristics | n1 | Crude HR(95% CI) | Adjusted2 HR(95% CI)n = 10 283 | Crude HR(95% CI) | Adjusted2 HR(95% CI)n = 10 283 | |
| Age | Per 10-year increase | 14 633 | 1.5(1.3 to 1.7) | 1.5(1.3 to 1.8) | 1.4(1.1 to 1.7) | 1.6(1.2 to 2.2) |
| eGFR (reference ≥60 mL/min) | <60 mL/min | 13 003 | 7.2(5.0 to 10.5) | 4.6(2.9 to 7.2) | 1.5(0.5 to 4.7) | 1.3(0.4 to 4.3) |
| CD4 (reference ≥200 cells/μL) | 100–199 cells/μL | 11 686 | 1.8(1.1 to 2.9) | 2.1(1.2 to 3.5) | 0.8(0.4 to 1.5) | 0.8(0.4 to 1.6) |
| 50–99 cells/μL | 3.7(2.2 to 6.0) | 4.1(2.4 to 6.9) | 1.3(0.6 to 2.9) | 1.2(0.5 to 2.9) | ||
| <50 cells/μL | 6.2(4.0 to 9.7) | 7.9(4.9 to 12.9) | 2.4(1.2 to 4.7) | 3.1(1.5 to 6.4) | ||
| Weight (reference ≥60 kg) | <60 kg | 13 887 | 2.1(1.6 to 2.8) | 1.6(1.1 to 2.1) | 1.3(0.8 to 2.0) | 1.2(0.7 to 2.2) |
| Concomitant ARV (reference NNRTI) | PI | 14 571 | 1.9(0.8 to 4.7) | 2.0(0.5 to 8.2) | 2.8(0.9 to 8.9) | 6.1(1.4 to 25.6) |
| Parameter | All Patients | ARMD Group | Non-ARMD Group | P Value: ARMD Versus Non-ARMD |
| Unilateral BHR | ||||
| No. (%) of patients | 323 (100) | 38 (12) | 285 (88) | |
| Sex (F/M) | 117/206 | 27/11 | 90/195 | <0.0001‡ |
| Age at blood test†(yr) | 63.0 (32.5-84.4) | 59.8 (34.3-77.5) | 63.4 (32.5-84.4) | 0.0673 |
| Time between op. and blood test†(yr) | 9.1 (1.9-15.2 ) | |||
| Femoral head size†(mm) | 50.5 (38-58) | 47.2 (38-58) | 50.9 (38-58) | 0.0001‡ |
| Bilateral BHR | ||||
| No. (%) of patients | 93 (100) | 17 (18) | 76 (82) | |
| Sex (F/M) | 33/60 | 12/5 | 21/55 | 0.0022‡ |
| Age at blood test†(yr) | 63.5 (36.5-82.6) | 59.3 (49.4-70.4) | 64.4 (36.5-82.6) | 0.0069‡ |
| Time between op. and blood test†(yr) | 8.2 (1.2-14.3 ) | |||
| Femoral head size†(mm) | 50.7 (42-58) | 48.4 (42-54) | 51.0 (42-58) | 0.0088‡ |
| Unilateral Corail-Pinnacle | ||||
| No. (%) of patients | 294 (100) | 20 (7) | 274 (93) | |
| Sex (F/M) | 210/84 | 12/8 | 198/76 | 0.3599 |
| Age at blood test†(yr) | 78.7 (52.1-95.4) | 74.0 (54.6-87.8) | 79.1 (52.1-95.4) | 0.0143‡ |
| Time between op. and blood test†(yr) | 3.6 (1.1-8.4 ) |
| Leading health care problems (ICD code) | Female | Male | ||
| Moran’s I | p-valuea | Moran’s I | p-valuea | |
| Infectious and parasitic diseases (ICD 01-07) | 0.34 | 0.0001 | 0.36 | 0.0001 |
| Neoplasms (ICD 08-17) | 0.71 | 0.0001 | 0.66 | 0.0001 |
| Endocrine, nutritional and metabolic diseases and immunity disorders (ICD 18-19) | 0.60 | 0.0002 | 0.54 | 0.0137 |
| Diseases of the blood and blood-forming organs (ICD 20) | 0.46 | 0.0001 | 0.45 | 0.0001 |
| Mental disorders (ICD 21) | 0.49 | 0.0001 | 0.43 | 0.0001 |
| Diseases of the nervous system and sense organs (ICD 22-24) | 0.63 | 0.0001 | 0.61 | 0.0001 |
| Diseases of the circulatory system (ICD 25-30) | 0.70 | 0.9985 | 0.56 | 0.0001 |
| Diseases of the respiratory system (ICD 31-32) | 0.42 | 0.0001 | 0.53 | 0.0001 |
| Diseases of the digestive system (ICD 33-34) | 0.64 | 0.0001 | 0.62 | 0.0001 |
| Diseases of the genitourinary system (ICD 35-37) | 0.45 | 0.0001 | 0.46 | 0.0001 |
| Diseases of the skin and subcutaneous tissue (ICD 42) | 0.46 | 0.0001 | 0.41 | 0.0001 |
| Diseases of the musculoskeletal system and connective tissue (ICD 43) | 0.73 | 0.9968 | 0.67 | 0.9966 |
| Congenital anomalies (ICD 44) | 0.51 | 0.0001 | 0.58 | 0.0001 |
| Certain conditions originating in the perinatal period (ICD 45) | 0.62 | 0.0001 | 0.64 | 0.0001 |
| Signs, symptoms and ill-defined conditions (ICD 46) | 0.69 | 0.0001 | 0.65 | 0.0001 |
| Injury and poisoning (ICD 47-56, E47-56) | 0.57 | 0.2056 | 0.59 | 0.0691 |
| Other reasons for contact with health services (V0) | 0.68 | 0.5394 | 0.65 | 0.0014 |
| Complications of pregnancy, childbirth and the puerperium (ICD 38-41) | 0.47 | 0.0001 | n.d. | n.d. |
| Parameters | Coefficients | ||||
| Effect of EQ-5D domains | Additional effect of patient groups | Additional effect of valuation own health | |||
| Cancer | RA | General population | Cancer + RA + Gen. pop | Cancer + RA | |
| Constant | 0.96 (0.03) | 0.98 (0.04) | 0.93 (0.02) | 0.94 (0.01)* | 0.78 (0.03)* |
| Mobility (2) | -0.04 (0.06) | -0.02 (0.07) | -0.04 (0.03) | -0.04 (0.02)* | -0.03 (0.04) |
| Self-care (2) | -0.03 (0.05)* | -0.02 (0.06) | -0.10 (0.03) | -0.07 (0.02)* | -0.02 (0.04) |
| Usual activities (2) | -0.04 (0.06)* | -0.02 (0.07) | -0.02 (0.03) | -0.04 (0.02)* | -0.03 (0.04) |
| Pain/discomfort (2) | -0.10 (0.04)* | -0.08 (0.05)* | -0.09 (0.02) | -0.09 (0.01)* | -0.09 (0.03)* |
| Anxiety/depression (2) | -0.06 (0.05)* | -0.03 (0.06) | -0.13 (0.03) | -0.11 (0.02)* | -0.05 (0.04) |
| Mobility (3) | -0.32 (0.07)* | -0.38 (0.08)* | -0.17 (0.04)* | -0.18 (0.02)* | -0.35 (0.05)* |
| Self-care (3) | -0.07 (0.06)* | -0.16 (0.07) | -0.14 (0.03)* | -0.15 (0.02)* | -0.10 (0.04) |
| Usual activities (3) | -0.09 (0.07)* | -0.06 (0.08) | -0.06 (0.04) | -0.07 (0.02)* | -0.08 (0.05) |
| Pain/discomfort (3) | -0.44 (0.05)* | -0.35 (0.06)* | -0.32 (0.03)* | -0.34 (0.02)* | -0.40 (0.04)* |
| Anxiety/depression (3) | -0.28 (0.05)* | -0.22 (0.06)* | -0.30 (0.03)* | -0.33 (0.02)* | -0.26 (0.04)* |
| N3 | -0.12 (0.05)* | -0.12 (0.06) | -0.25 (0.03) | -0.21 (0.02)* | -0.11 (0.04)* |
| Cancer patient | - | - | - | 0.07 (0.02)* | - |
| RA patient | - | - | - | 0.12 (0.02)* | - |
| TTO value own state | - | - | - | - | 0.22 (0.03)* |
| R2 | 0.45 | 0.49 | 0.40 | 0.41 | 0.49 |
| Mean percentage density (95% confidence interval)a,b | ||||
| Chemical | Nondetected | Below mediand | Above mediand | Ptrendc |
| n = 225 | n = 19 | n = 18 | ||
| Mono-ethyl phthalate | 13.1 (11.9, 14.3) | 13.0 (9.1, 17.7) | 18.2 (13.4, 23.7) | 0.07 |
| n = 88 | n = 88 | n = 87 | ||
| Propyl paraben | 12.7 (10.9, 14.8) | 13.3 (11.4, 15.4) | 13.9 (12.0, 16.1) | 0.41 |
| n = 121 | n = 72 | n = 71 | ||
| Butyl paraben | 14.4 (12.7, 16.3) | 12.4 (10.4, 14.7) | 12.4 (10.4, 14.7) | 0.13 |
| n = 228 | n = 19 | n = 16 | ||
| Octylphenol | 13.5 (12.3, 14.7) | 11.3 (7.6, 15.6) | 14.5 (9.9, 19.9) | 0.93 |
| n = 155 | n = 55 | n = 54 | ||
| Nonylphenol | 14.1 (12.6, 15.6) | 12.1 (9.8, 14.7) | 12.5 (10.1, 15.1) | 0.21 |
| n = 193 | n = 35 | n = 34 | ||
| Bisphenol A | 12.6 (11.4, 14.0) | 13.7 (10.7, 17.1) | 17.6 (14.1, 21.5) | 0.01 |
| Intra-assay | Inter-assay | |||
| Specimens | Mean (U/L) | CV (%) | Mean (U/L) | CV (%) |
| Low | 40.3 | 2.00 | 33.4 | 2.60 |
| Medium | 160.0 | 2.27 | 130.0 | 1.38 |
| High | 765.7 | 1.27 | 656.3 | 3.47 |
| Linear probability models | Maximum likelihood proceduresb | |||
| OLS | 2SLS | Probit | Bivariate probit | |
| Land rental | 0.365 (0.142) ** | 0.135 (0.033) ** | 0.277 (0.063) ** | 0.151 (0.038) ** |
| Plot size | 0.033 (0.007) ** | 0.040 (0.011) ** | 0.044 (0.014) ** | 0.044 (0.009) ** |
| Soil fertility | −0.037 (0.039) | −0.016 (0.023) | −0.012 (0.030) | −0.021 (0.041) |
| Soil slope | 0.039 (0.020) * | 0.033 (0.021) | 0.030 (0.025) | 0.015 (0.025) |
| Soil depth | 0.067 (0.019) ** | 0.060 (0.017) ** | 0.079 (0.020) ** | 0.073 (0.022) ** |
| Dist. from home | 0.000 (0.001) | 0.001 (0.000) | 0.000 (0.000) | 0.001 (0.001) |
| Cropping season | 0.122 (0.036) ** | 0.141 (0.042) ** | 0.154 (0.051) ** | 0.136 (0.039) ** |
| Household size | 0.012 (0.008) | 0.006 (0.005) | 0.002 (0.005) | 0.006 (0.004) |
| Total asset | −0.000 (0.000) | 0.000 (0.000) | −0.000 (0.000) | 0.000 (0.000) |
| Head age | −0.001 (0.001) | −0.002 (0.001) | −0.002 (0.001) ** | −0.002 (0.001) |
| Head gender | 0.062 (0.055) | 0.033 (0.057) | 0.075 (0.066) | 0.096 (0.062) |
| Head marital status | 0.041 (0.061) | 0.050 (0.072) | 0.070 (0.041) | 0.050 (0.034) |
| Head education | 0.002 (0.003) | 0.003 (0.002) * | 0.004 (0.003) | 0.003 (0.002) * |
| Main market dist. | −0.002 (0.000) ** | −0.002 (0.000) ** | −0.002 (0.000) ** | −0.002 (0.000) ** |
| Extension office dist. | 0.000 (0.000) | −0.001 (0.000) | −0.001 (0.000) | −0.000 (0.000) |
| Total land holding | −0.001 (0.001) | −0.001 (0.001) | −0.001 (0.001) | −0.001 (0.001) |
| Unmet credit need | −0.019 (0.003) ** | −0.014 (0.003) ** | −0.008 (0.003) * | −0.009 (0.001) ** |
| Years living in village | 0.008 (0.005) | 0.005 (0.014) | 0.013 (0.020) | 0.004 (0.014) |
| Cooperation membership | 0.012 (0.015) | 0.012 (0.042) | 0.021 (0.018) | 0.003 (0.022) |
| Constant | 0.127 (0.148) | 0.189 (0.095) ** | ||
| F statistic | 16.81 ** | 16.33 ** | ||
| F test of 1st stage IV | 79.19 ** | |||
| Underidentificationc | 64.95 ** | |||
| Weak identificationd | 54.11 | |||
| LR / Wald chi-square | 286.26 ** | 536.60 ** | ||
| ρadoption and land rental | 0.213 ** |
| Cpd. | IC50 (μM) | |||||
| CDK5/p25 | GSK3α/β | DYRK1A | DYRK2 | CLK1 | CLK2 | |
| 3a | > 10 | > 10 | > 10 | > 10 | > 10 | > 10 |
| 3b | > 10 | > 10 | > 10 | > 10 | > 10 | > 10 |
| 3c | > 10 | 8.5 | 0.070 | – | – | – |
| 5d | > 10 | > 10 | 0.041 | 0.6 | 0.5 | 7.7 |
| Variable | p-Value | HR | 95% CI |
| Intestinal type vs. others | 0.0025 | 0.5156 | 0.3143–0.8457 |
| HLR type vs. others | <0.0001 | 2.6683 | 1.7298–4.1160 |
| Stage I/II vs. III/IV | <0.0001 | 2.9569 | 1.8946–4.6148 |
| pT2/pT3 vs. pT4 | <0.0001 | 2.6042 | 1.4849–4.5670 |
| pN0 vs. pN1/pN2/pN3 | 0.0021 | 2.2075 | 1.4088–3.4592 |
| CD8 > 9.5 cells/HPF | 0.015 | 0.5637 | 0.3358–0.9462 |
| EBV+/MSI vs. MSS/EBV− | 0.003 | 1.8981 | 1.2207–2.9513 |
| PD-L1 ≥ 5% vs. <5% | 0.012 | 0.4102 | 0.2408–0.6988 |
| One visit | Two or more visits | |||||
| Characteristic | N | % | HIV prev.a | N | % | HIV prev.a |
| Total | 94020 | 34.1 | 8865 | 58.6 | ||
| Sex | ||||||
| Female | 35083 | 37.3% | 38.6 | 3486 | 39.3% | 68.3 |
| Male | 58937 | 62.7% | 31.5 | 5379 | 60.7% | 52.3 |
| Age | ||||||
| 15-19 | 1784 | 1.9% | 16.3 | 72 | 0.8% | 44.4 |
| 20-29 | 22433 | 23.9% | 46.7 | 2336 | 26.4% | 74.1 |
| 30-39 | 28396 | 30.2% | 48.8 | 3245 | 36.6% | 71.8 |
| 40-49 | 18901 | 20.1% | 29.4 | 1727 | 19.5% | 48.9 |
| 50+ | 22506 | 23.9% | 8.5 | 1485 | 16.8% | 17.2 |
| Education | ||||||
| None/primary | 61528 | 65.4% | 30.4 | 5105 | 57.6% | 54.5 |
| Secondary/graduate | 32492 | 34.6% | 41.2 | 3760 | 42.4% | 64.1 |
| Current marital status | ||||||
| Married | 74800 | 79.6% | 33.9 | 7502 | 84.6% | 57.7 |
| Unmarried | 19220 | 20.4% | 34.9 | 1363 | 15.4% | 63.6 |
| Occupation | ||||||
| Housewife | 15974 | 17.0% | 39.2 | 1763 | 19.9% | 64.9 |
| Other/unemployed | 9006 | 9.6% | 12.9 | 579 | 6.5% | 21.6 |
| Professional/manager | 2642 | 2.8% | 48.5 | 260 | 2.9% | 69.2 |
| Skilled | 35733 | 38.0% | 40.2 | 3625 | 40.9% | 65.8 |
| Student | 723 | 0.8% | 5.4 | 26 | 0.3% | 23.1 |
| Unskilled | 29942 | 31.8% | 30 | 2612 | 29.5% | 51.8 |
| Lifetime sexual partners | ||||||
| 0 or 1 | 57283 | 60.9% | 23.5 | 4898 | 55.3% | 46.4 |
| 2 or more | 36737 | 39.1% | 50.8 | 3967 | 44.7% | 73.6 |
| Compound | Target | p-eIF2α | Disease model | Disease effect | References |
| Salubrinal | PPP1R15A(GADD34)-PP1c/PPP1R15B-PP1c | ↑ | ALS (SOD1G93A)Prion disease | Beneficialdetrimental | [7, 88][65] |
| Guanabenz | PPP1R15A(GADD34)-PP1c | ↑ | ALS (TDP-43)ALS (SOD1 G93A) | Beneficial | [110, 112, 118] |
| Sephin1 | PPP1R15A(GADD34)-PP1c | ↑ | ALS (SOD1G93A); CMT1B | Beneficial | [21] |
| GSK2606414 | PERK inhibitor | ↓ | Prion disease | Beneficial | [3, 64] |
| ISRIB | eIF2β | Not changed | Prion disease | Beneficial | [28, 93, 96] |
| Variable | Number | Weighted %a |
| Total | 677.0 | 100.0 |
| Male | 302.0 | 48.0 |
| Age | ||
| <=35 years | 222.0 | 33.4 |
| 35 < years < =50 | 263.0 | 39.0 |
| 50 < years < =65 | 192.0 | 27.6 |
| SESb | ||
| Low | 201.0 | 31.2 |
| Medium | 165.0 | 24.0 |
| Medium-High | 198.0 | 28.9 |
| High | 113.0 | 15.9 |
| Education | ||
| Some Elementary | 36.0 | 5.0 |
| Complete Elementary | 67.0 | 10.1 |
| Some Middle School | 23.0 | 3.9 |
| Complete Middle School | 140.0 | 21.1 |
| Some High School | 29.0 | 4.4 |
| Complete Highschool | 162.0 | 23.2 |
| Some College | 34.0 | 5.5 |
| Complete College or more | 186.0 | 26.8 |
| Motor vehicle ownership | ||
| Car | 363.0 | 53.2 |
| Motorcycle | 32.0 | 5.1 |
| Either | 371.0 | 54.7 |
| Marital status | ||
| Single | 166.0 | 25.0 |
| Married or living with someone | 438.0 | 65.3 |
| Separated or Divorced | 56.0 | 7.4 |
| Widower | 17.0 | 2.4 |
| BMI Status | ||
| Under-nutrition (BMI < 20) | 22.0 | 3.2 |
| Normal (20 < =BMI < 25) | 165.0 | 24.2 |
| Overweight (25 < =BMI < 30) | 278.0 | 40.9 |
| Obese (BMI > =30) | 212.0 | 31.7 |
| Hematological index | Formula |
| Mentzer index (MI) (1973) | MCV/RBC |
| RDWI (1987) | MCV × RDW/RBC |
| Shine and Lal (S and L) (1977) | MCV × MCV × MCH/100 |
| Srivastava (1973) | MCH/RBC |
| Green and King (G and K) (1989) | MCV × MCV × RDW/Hb × 100 |
| Sirdah (2007) | MCV − RBC − (3 × Hb) |
| Ehsani (2005) | MCV − (10 × RBC) |
| England and Fraser (E and F) (1973) | MCV − (5 × Hb) − RBC − 3.4 |
| Ricerca (1987) | RDW/RBC |
| MDHL (1999) | (MCH/MCV) × RBC |
| MCHD (1999) | MCH/MCV |
| EXPREF | Total | N (case) | N (control) | Disease Case | Disease Control | Source | Detection Method | Reference |
| Exp25666440 | 23 | 11 | 12 | naïve Fabry patients | ERT | urine | nanoLC-ESI-MS/MS | [25] |
| Exp17301227 | 13 | N/A | N/A | 6 months of ERT | before treatment (baseline) | blood | nanoLC-ESI-MS/MS | [26] |
| Exp18339188a | 13 | N/A | N/A | 6 months of ERT | before treatment (baseline) | blood | microarray | [27] |
| Exp18339188b | 13 | N/A | N/A | naïve Fabry patients | healthy | blood | microarray | [27] |
| Exp20954982 | 30 | 20 | 10 | Fabry | healthy | urine | MALDI-TOF MS | [28] |
| Exp23385635 | 14 | 8 | 6 | Fabry | healthy | blood | MALDI-TOF MS | [29] |
| Exp23464927 | 10 | N/A | N/A | 12 months of ERT | before treatment (baseline) | urine | QTOF MS/MS | [30] |
| Exp25619383 | 46 | 32 | 14 | Fabry | healthy | blood | LC-MS/MS | [31] |
| Exp21698285 | 124 | 35 | 89 | naïve female Fabry | healthy | urine | CE-MS | [32] |
| Exp26490183 | 6 | N/A | N/A | short term of ERT | before treatment (baseline) | blood | Illumina MiSeq instrument | [8] |
| Exp25582508 | 32 | 16 | 16 | untreated Fabry males | healthy | urine | UPLC-ESI-TOF-MS | [33] |
| Technique | Type | Comments | References |
| Specific gene promoter: indicator protein fusions [i.e. beta-glucuronidase (GUS) or fluorescent proteins] | 1, B | Long lead times of >2 months to get stably expressed genes, homozygous gene expression, sequences other than the promoter may control gene expression, no guarantee that promoter fragment chosen is correct, not suitable for plants that cannot be transformed. | [5] |
| Laser Capture Microdissection (LCM) and Single Cell Sampling (SiCSA) | 2, A | Difficulty in isolating certain cell-types (e.g. vascular cells using SiCSA), long tissue prep (~2 weeks) for LCM, need for specialised equipment | [6,7] |
| in situ PCR | 3, B | No specialised equipment required apart from vibratome, simple and fast method. No detailed protocol for plants until this manuscript, especially for agarose- embedded vibratome- sectioned in tube PCR. Can be performed on plants that are difficult to, or cannot be transformed. We do not recommend fluorescence detection of in situ PCR products due to interference with autofluorescence from plant tissue. As it is possible to do separate PCRs on adjoining tissue sections or replicate tissues from other plants we see no great advantage in multiplexing in situ PCR as it causes multiple complications to what is a robust and relatively simple technique. We do not recommend multiplexing in situ PCR due to the differential abundance of transcripts in the same cell and consequently the saturation of products, generation of non-specific products and problems with signal separation. | |
| in situ hybridisation (ISH) | 3, B | High detection threshold (10–20 copies per cell for ISH vs 1–2 copies per cell for in situ PCR), need to design a specific probe that hybridises to RNA while in situ PCR uses the same primers as qPCR, much cheaper. The View RNA Assay (Affymetrix) enables automated multiple transcript detection using fluorescence by employing the principles of ISH to detect nucleic acid targets within specific cells/cell-types. Its use is limited to abundant transcripts and laboratories equipped with and/or experienced in FFPE (formalin-fixed paraffin embedded) and frozen tissue preparation. | [8] |
| Protoplasting of fluorescently labelled cells and single cell sorting (FACS) | 4, A | Can assay multiple transcripts at the same time. Potential damage responses of tissue. Needs specialised sorting flow cytometer. Limited to analysis of cells that are fluorescently labelled. Cannot give detail of all cells in which a particular gene is expressed. | [9,10] |
| Nuclear sorting, INTACT (isolation of nuclei tagged in specific cell types) or ribosomal binding techniques | 4, A | When combined with microarrays or RNAseq can assay multiple transcripts at the same time. Limited to analysis of cells that are fluorescently labelled. Cannot give detail of all cells in which a particular gene is expressed. Not easily replicated. | [11-13] |
| In situ RNA sequencing | 3, B | Offers the prospect of obtaining whole transcriptomes and more from single cells in tissue sections. Not yet optimised in any tissue. Has not been performed for plant tissue. | [14] |
| Total sample | Soda consumption categories | ||||
| N = 888 | None (n = 501) | 1 or less serv/wk. (n = 245) | ≥ 2 serv/wk. (n = 142) | Overall Groups P-value | |
| Model 1: | |||||
| Unadjusted | Referent | 1.30 (0.90–1.89) | 2.31 (1.53–3.49)* | 0.005 | |
| Model 2:b | |||||
| Adjusted | Referent | 1.04 (0.69–1.58) | 1.94 (1.22–3.07)* | 0.014 | |
| Model 3:c | |||||
| Adjusted | Referent | 1.04 (0.68–1.57) | 1.95 (1.22–3.11)* | 0.014 | |
| Model 4:d | |||||
| Adjusted | Referent | 1.00 (0.65–1.53) | 1.61 (0.98–2.66)† | 0.136 | |
| Fried food consumption categories | |||||
| N = 888 | None (n = 295) | 1 serv/wk. (n = 353) | 2–4 serv/wk. (n = 208) | ≥ 5 serv/wk. (n = 32) | Overall Groups P-value |
| Model 1: | |||||
| Unadjusted | Referent | 1.23 (0.82–1.82) | 1.99 (1.30–3.04)* | 3.72 (1.74–7.96)* | <0.001 |
| Model 2:b | |||||
| Adjusted | Referent | 1.06 (0.69–1.63) | 1.84 (1.15–2.92)* | 3.38 (1.44–7.96)* | 0.003 |
| Model 3:c | |||||
| Adjusted | Referent | 1.12 (0.72–1.73) | 1.89 (1.18–3.02)* | 3.50 (1.48–8.29)* | 0.003 |
| Model 4:e | |||||
| Adjusted | Referent | 1.12 (0.71–1.75) | 1.80 (1.08–3.00)* | 3.38 (1.36–8.38)* | 0.015 |
| Breakfast eatersa | Breakfast skippersb | P valuec | |
| n, % | 4188, 90.4 | 443, 9.6 | |
| Men, % | 78.2 | 73.8 | 0.04 |
| Age, year | 47.8 (7.1) | 46.0 (6.8) | <0.001 |
| Body mass index, kg/m2 | 22.9 (2.8) | 22.9 (3.0) | 0.78 |
| Smoking status, % | |||
| Current | 26.7 | 44.9 | <0.001 |
| Former | 23.4 | 14.2 | |
| Never | 49.9 | 40.9 | |
| Leisure-time physical activity, %d | |||
| ≥3 days/week | 75.5 | 84.2 | <0.001 |
| <3 days/week | 16.0 | 9.5 | |
| Work-time physical activity, yes, % | 5.3 | 7.7 | <0.01 |
| Family history of diabetes mellitus, yes, % | 14.8 | 17.4 | 0.14 |
| Fasting blood glucose, mg/dLe | 92.3 (92.0–92.6) | 92.5 (91.5–93.4) | 0.74 |
| Perceived stress, %d | |||
| Very much | 11.0 | 13.8 | 0.02 |
| Much | 40.1 | 39.7 | |
| Ordinary | 43.8 | 39.1 | |
| Little | 4.9 | 6.8 | |
| Sleep duration, %d | |||
| <7 hours/day | 52.9 | 61.6 | <0.001 |
| ≥7 hours/day | 45.5 | 35.7 | |
| Work schedule, %d | |||
| Without shift work or night shifts | 84.6 | 78.3 | <0.001 |
| With shift work but without night shifts | 1.9 | 1.4 | |
| Without shift work but with night shifts | 6.8 | 7.9 | |
| With shift work including night shifts | 4.9 | 11.3 | |
| Total energy intake, kcal/day | 1942 (538) | 1740 (553) | <0.001 |
| Alcohol consumption, g/day | 13.6 (19.2) | 18.1 (26.4) | <0.001 |
| Eating speed, %d | |||
| Very fast | 11.4 | 12.9 | 0.67 |
| Relatively fast | 35.8 | 37.9 | |
| Medium | 38.5 | 35.2 | |
| Slow | 12.6 | 12.4 | |
| Satiation eater, % | 61.2 | 59.1 | 0.24 |
| Fruits and vegetables intake, g/1000 kcal/day | 142.3 (67.0) | 118.7 (61.2) | <0.001 |
| Fish intake, g/1000 kcal/day | 84.1 (41.9) | 84.8 (39.4) | 0.74 |
| Frequency of whole-grain cereals intake, % | |||
| Always | 8.5 | 5.7 | 0.10 |
| Sometimes | 9.2 | 8.1 | |
| Rarely | 14.9 | 12.6 | |
| No | 67.4 | 73.6 | |
| Frequency of coffee intake, %d | |||
| ≥4 cups/day | 6.6 | 10.6 | 0.02 |
| 2–3 cups/day | 39.0 | 39.1 | |
| 1 cup/day | 24.3 | 23.7 | |
| <1 cup/day | 28.8 | 25.1 | |
| Frequency of sugar-sweetened beverages intake, %d | |||
| ≥1 serving/day | 5.5 | 9.3 | <0.001 |
| 4–6 servings/week | 5.3 | 7.0 | |
| 1–3 servings/week | 29.9 | 36.3 | |
| Never or rarely | 57.6 | 45.1 | |
| Snack intake, yes, % | 95.3 | 94.8 | 0.61 |
| Groups | N | Age | BMI | EBL | Duration | PreHGB | PreHCT | PostHGB | PostHCT |
| Group 1 | 42 | 24.69 ± 6.2 | 21.70 ± 3.8 | 680.95 ± 313.12 | 5:58 ± 1:19 | 12.94 ± 2.0 | 38.51 ± 4.8 | 9.76 ± 2.1 | 29.42 ± 5.6 |
| Group 2 | 19 | 22.79 ± 6.8 | 21.48 ± 3.0 | 744.74 ± 367 | 6:28 ± 1:07 | 14.14 ± 1.8 | 41.54 ± 4.8 | 9.82 ± 1.6 | 29.26 ± 4.2 |
| Group 3 | 21 | 20.76 ± 5.3 | 22.61 ± 3.9 | 495.24 ± 517.91 | 3:25 ± 2:00* | 13.64 ± 2.3 | 40.66 ± 6.7 | 11.25 ± 2.6 | 33.58 ± 7.7* |
| Group 4 | 10 | 22.10 ± 5.0 | 21.59 ± 3.8 | 665.00 ± 456.47 | 6:26 ± 1:11 | 13.97 ± 1.2 | 41.61 ± 3.5 | 10.53 ± 2.0 | 31.29 ± 5.4 |
| Total | 92 | 23.12 ± 6.1 | 21.85 ± 3.6 | 650.00 ± 397.8 | 5:32 ± 1:52 | 13.46 ± 2.0 | 39.96 ± 5.3 | 10.20 ± 2.2 | 30.54 ± 6.1 |
| p-value | 0.102 | 0.750 | 0.211 | <0.001* | 0.119 | 0.100 | 0.059 | 0.050* |
| Characteristics | NASH - HCC | Non-NASH - HCC | P |
| (n = 45) | (n = 1074) | ||
| Male gender* | 35 (77.8) | 888 (82.7) | 0.820 |
| Age at time of diagnosis# | 67.6 (46.6-89.9) | 65 (15.3-87.3) | 0.007 |
| Caucasian* | 45 (100) | 1055 (98.2) | 1,000 |
| Obesity* | 13 (28.9) | 158 (14.7) | 0.046 |
| BMI (kg/m2)# | 29 (19.4-49.6) | 26.6 (16.5-48.4) | 0.022 |
| Type II diabetes * | 30 (66.7) | 406 (37.8) | 0.024 |
| Hypertension* | 32 (71.1) | 485 (45.2) | 0.060 |
| Hyperlipidemia* | 18 (40) | 211 (19.6) | 0.016 |
| Myocardial infarction* | 6 (13.3) | 52 (4.8) | 0.035 |
| apoplectic stroke* | 4 (8.9) | 23 (2.1) | 0.025 |
| Cirrhosis* | 35 (77.8) | 858 (79.9) | 1,000 |
| Child-Turcotte-Pugh-Score* | |||
| A | 21 (46.7) | 421 (39.2) | 0.577 |
| B | 14 (31.1) | 301 (28) | 0.748 |
| C | 0 | 136 (12.7) | 0.012 |
| Bilirubin# | 0.8 (0.3-4.8) | 1.2 (0.2-78.3) | <0.001 |
| INR# | 1.1 (0.8-1.4) | 1.1 (0.9-3.2) | <0.001 |
| Creatinine# | 1 (0.6-7.5) | 0.9 (0.3-7.2) | 0.420 |
| Albumin# | 35 (19–52.6) | 34 (3–55.6) | 0.173 |
| Thrombocytopenia* | 15 (33.3) | 472 (43.9) | 0.394 |
| AFP# | 96.9 (1.5-96611) | 39 (0–624094.4) | 0.722 |
| MELD score# | 9 (6–21) | 10 (6–40) | 0.005 |
| Encephalopathy* | 0 | 44 (4,1) | 1.640 |
| Ascites* | 14 (31.1) | 235 (21.9) | 0.299 |
| Varices* | 10 (22.2) | 342 (31.8) | 0.420 |
| Portal vein thrombosis* | 13 (28.9) | 222 (20.7) | 0.290 |
| Recalled receiving information on: | CPan=106n (%) | PEan=619n (%) | p-value |
| Appropriate amount of weight gain | 89 (84.0) | 473 (76.4) | 0.085 |
| Exercise or active living during pregnancy | 83 (78.3) | 434 (70.1) | 0.085 |
| Nutrition | 92 (86.8) | 453 (73.2) | 0.003 |
| Taking vitamins or mineral supplements | 92 (86.8) | 543 (87.7) | 0.789 |
| Taking prescription or non-prescription drugs | 75 (70.8) | 430 (69.5) | 0.790 |
| Alcohol consumption during pregnancy | 77 (72.6) | 350 (56.5) | 0.002 |
| Cigarette smoking and second hand smoke | 71 (67.0) | 299 (48.3) | <0.001 |
| Working during pregnancy | 65 (61.3) | 343 (55.4) | 0.257 |
| Batch Code | Mean particle size(μm) mean ± SEM | % yield = (Practical yield / Theoretical yield) × 100 | Drug Entrapment (%) | Drug Encapsulation Efficiency (%) |
| K1 | 290.54± 6.52 | 90 | 1.33 | 02.39 |
| K2 | 378.88± 8.73 | 97 | 2.70 | 07.84 |
| K3 | 395.86±10.21 | 85 | 8.82 | 29.98 |
| K4 | 542.85± 9.60 | 78 | 9.38 | 36.58 |
| K5 | 216.84± 6.48 | 55 | 3.17 | 03.49 |
| K6 | 314.32± 8.44 | 60 | 5.04 | 15.92 |
| K7 | 321.06± 8.39 | 80 | 6.85 | 21.91 |
| K8 | 432.57± 9.68 | 76 | 8.84 | 22.15 |
| Population | Sample | Average | Standard deviation | Percentile 25% | Percentile 50% | Percentile 75% |
| General population | 4176 | 59.3125 | 30.99565 | 40 | 70 | 80 |
| General population (men) | 1739 | 64.64347 | 29.17882 | 50 | 75 | 85 |
| General population(women) | 2437 | 55.50841 | 31.69165 | 30 | 60 | 80 |
| General populationAge 16-44 | 2128 | 65.04229 | 31.28681 | 50 | 80 | 90 |
| General populationAge 45-65 | 1130 | 56.4177 | 30.0071 | 40 | 65 | 80 |
| General populationAge ≥ 65 | 918 | 49.59368 | 28.5296 | 25 | 50 | 70 |
| General populationSeniors IAge 65-74 | 568 | 50.27641 | 28.75174 | 30 | 55 | 70 |
| General populationSeniors IIAge 75-84 | 300 | 49.15 | 28.46545 | 20 | 55 | 70 |
| General populationSeniors IIIAge ≥ 85 | 50 | 44.5 | 26.25172 | 20 | 50 | 63 |
| Spirometry variable | Puncture approach | T0 | T30 | ||||
| Median (Q1, Q3) | Median differenceanterior-posterior (95 % CI) | p-value (two-sided) | Median (Q1, Q3) | Median differenceanterior-posterior (95 % CI) | p-value (two-sided) | ||
| VC [l] | anterior | 5.09 (3.98, 5.58) | 0.38 (−0.15, 0.88) | 0.167 | 3.98 (3.31, 4.67) | 0.40 (−0.08, 0.88) | 0.088 |
| posterior | 4.46 (3.90, 5.37) | 3.46 (2.90, 4.34) | |||||
| FEV1 [l/s] | anterior | 3.80 (3.34, 4.33) | 0.25 (−0.16, 0.63) | 0.174 | 3.05 (2.41, 3.44) | 0.34 (−0.09, 0.72) | 0.103 |
| posterior | 3.57 (3.01, 4.11) | 2.58 (2.05, 3.22) | |||||
| Sniff PmaxPeak [kPa] | anterior | 6.24 (4.84, 7.67) | −0.24 (−1.24, 0.83) | 0.655 | 5.13 (4.21, 7.22) | −0.23 (−1.04, 0.56) | 0.582 |
| posterior | 6.25 (5.09, 8.63) | 5.70 (4.54, 6.83) |
| Activity | Annual average E (mSv/yr) | Radiation source |
| Natural background due to external exposure (cosmic rays; terrestrial radionuclides) | 0.9 (0.4; 0.5) | Cosmic rays, terrestrial radionuclides |
| Natural background due to internal exposure (inhalation; ingestion) | 1.5 (1.2; 0.3) | Terrestrial radionuclides |
| Total natural background, worldwide | 2.4 | Cosmic rays, terrestrial radionuclides |
| Natural background due to cosmic rays, world average | 0.380 | Cosmic rays |
| Natural background due to cosmic rays, sea level | 0.270 | Cosmic rays |
| Natural background due to cosmic rays, 1600 m amsl | 0.570 | Cosmic rays |
| Natural background due to cosmic rays, 2200 m amsl | 0.820 | Cosmic rays |
| Natural background due to cosmic rays, 3900 m amsl | 2.020 | Cosmic rays |
| 8 hours of flight (London-New York) | 0.030 – 0.045 per flight | Cosmic rays |
| Negative Papers | Positive Papers | Paper Score |
| 10 | 100 | 0.60 |
| 20 | 100 | 0.63 |
| 30 | 100 | 0.63 |
| 40 | 100 | 0.64 |
| 10 | 200 | 0.56 |
| 20 | 200 | 0.59 |
| 30 | 200 | 0.58 |
| 40 | 200 | 0.60 |
| 10 | 300 | 0.60 |
| 20 | 300 | 0.63 |
| 30 | 300 | 0.64 |
| 40 | 300 | 0.66 |
| 10 | 400 | 0.61 |
| 20 | 400 | 0.65 |
| 30 | 400 | 0.66 |
| 40 | 400 | 0.66 |
| Feature | Value | |||
| D. rotundata (v0.1) | A. thaliana (TAIR10) | B. distachyon (v3.1) | O. sativa (v7_JGI 323) | |
| Total length (Mbp) | 594.23 | 119.67 | 271.16 | 374.47 |
| GC (%) | 35.83 | 36.06 | 46.40 | 43.57 |
| Number of scaffolds (≥ 0 bp) | 4723 | 7 | 10 | 14 |
| Number of scaffolds (≥ 1000 bp) | 4704 | 7 | 10 | 14 |
| Largest scaffold (Mbp) | 13.61 | 30.43 | 75.07 | 43.27 |
| N50 (Mbp) | 2.12 | 23.46 | 59.13 | 29.96 |
| N75 (Mbp) | 0.77 | 19.70 | 48.59 | 28.44 |
| Number of Ns per 100 kb | 282.45a | 155.60 | 155.85 | 44.13 |
| Ambiguous bases | 1,413,029 | – | – | – |
| Number of genes | 26,198 | 27,416 | 34,310 | 42,189 |
| Exons | ||||
| Number | 158,059 | 141,044 | 154,104 | 178,353 |
| Average number per gene | 6.03 | 5.14 | 4.49 | 4.25 |
| Total length (Mbp) | 42.43 | 33.49 | 39.01 | 46.85 |
| Average size (bp) | 268.43 | 237.46 | 253.15 | 262.70 |
| Average GC (%) | 44.08 | 43.70 | 51.02 | 51.12 |
| Introns | ||||
| Number | 105,663 | 86,212 | 85,484 | 94,345 |
| Average number per gene | 4.03 | 3.14 | 2.49 | 2.25 |
| Total length (Mbp) | 83.12 | 17.87 | 47.70 | 53.34 |
| Average size (bp) | 630.33 | 157.25 | 398.18 | 391.23 |
| Average GC (%) | 32.37 | 32.45 | 38.29 | 37.20 |
| Transposable elementsb | ||||
| % Total interspersed | 46.07 | 13.32 | 37.39 | 44.40 |
| Total interspersed total length (Mbp) | 274.51 | 15.94 | 101.39 | 166.27 |
| % Short interspersed nuclear elements (SINEs) | 0.02 | 0.17 | 0.38 | 0.88 |
| SINEs total length (Mbp) | 0.13 | 0.20 | 1.02 | 3.31 |
| % Long interspersed nuclear elements (LINEs) | 2.43 | 1.07 | 2.91 | 1.29 |
| LINEs total length (Mbp) | 14.46 | 1.29 | 7.90 | 4.83 |
| % Long terminal repeat (LTR) elements | 22.82 | 6.35 | 19.31 | 21.09 |
| LTR elements total length (Mbp) | 135.71 | 7.61 | 52.36 | 78.98 |
| % DNA elements | 6.70 | 3.08 | 7.11 | 16.7 |
| DNA elements total length (Mbp) | 39.83 | 3.69 | 19.27 | 62.82 |
| % Unclassified | 14.20 | 2.64 | 7.68 | 4.36 |
| Unclassified total length (Mbp) | 84.38 | 3.16 | 20.84 | 16.32 |
| Characteristics | Hazard Ratio (95% Confidence Interval)a |
| Age (continuous) | 1.01 (1.001–1.02)* |
| Sex, female (versus male) | 1.05 (0.80–1.37) |
| Charlson Comorbidity Index | |
| 0 | Reference |
| 1 | 0.90 (0.62–1.29) |
| ≥ 2 | 0.94 (0.68–1.31) |
| Observation periodb | |
| Period 1 in Pre-Campaign Year (weeks 1–5) | 3.22 (0.88–11.7) |
| Period 2 in Pre-Campaign Year (weeks 6–10) | 0.97 (0.20–4.80) |
| Period 3 in Pre-Campaign Year (weeks 11–15) | 2.27 (0.59–8.77) |
| Period 4 in Pre-Campaign Year (weeks 16–20) | 0.98 (0.20–4.85) |
| Period 5 in Pre-Campaign Year (weeks 21–25) | 0.98 (0.20–4.85) |
| Period 6 in Pre-Campaign Year (weeks 26–30) | 2.29 (0.59–8.87) |
| Period 7 in Pre-Campaign Year (weeks 31–35) | 0.99 (0.20–4.89) |
| Period 8 in Pre-Campaign Year (weeks 36–40) | 3.31 (0.91–12.0) |
| Period 9 in Pre-Campaign Year (weeks 41–45) | 1.00 (0.20–4.94) |
| Period 10 in Pre-Campaign Year (weeks 46–50) | Reference |
| Period 1 in Year 1 (weeks 1–5) | 2.99 (0.81–11.1) |
| Period 2 in Year 1 (weeks 6–10) | 1.34 (0.30–5.98) |
| Period 3 in Year 1 (weeks 11–15) | 1.34 (0.30–6.00) |
| Period 4 in Year 1 (weeks 16–20) | 7.09 (2.11–23.8)** |
| Period 5 in Year 1 (weeks 21–25) | 13.6 (4.21–44.1)*** |
| Period 6 in Year 1 (weeks 26–30) | 4.27 (1.20–15.1)* |
| Period 7 in Year 1 (weeks 31–35) | 3.23 (0.87–11.9) |
| Period 8 in Year 1 (weeks 36–40) | 2.16 (0.54–8.66) |
| Period 9 in Year 1 (weeks 41–45) | 1.45 (0.32–6.48) |
| Period 10 in Year 1 (weeks 46–50) | 2.55 (0.66–9.86) |
| Period 1 in Year 2 (weeks 1–5) | 2.91 (0.77–11.0) |
| Period 2 in Year 2 (weeks 6–10) | 3.30 (0.89–12.2) |
| Period 3 in Year 2 (weeks 11–15) | 1.84 (0.44–7.72) |
| Period 4 in Year 2 (weeks 16–20) | 1.48 (0.33–6.62) |
| Period 5 in Year 2 (weeks 21–25) | 1.49 (0.33–6.65) |
| Period 6 in Year 2 (weeks 26–30) | 2.24 (0.56–8.97) |
| Period 7 in Year 2 (weeks 31–35) | 1.50 (0.34–6.72) |
| Period 8 in Year 2 (weeks 36–40) | 1.13 (0.23–5.60) |
| Period 9 in Year 2 (weeks 41–45) | 1.89 (0.45–7.91) |
| Period 10 in Year 2 (weeks 46–50) | 1.90 (0.45–7.95) |
| Variable | G1 (n=15) | G2 (n=16) | G3 (n=16) | G4 (n=16) |
| 25(OH)D (ng/mL) | 14.0±3.3 | 19.5±2.3a | 24.0±2.3b | 36.7±7.7c |
| Age (years) | 61.7±3.6 | 60.8±2.9 | 58.8±2.9 | 61.3±2.8 |
| Body mass index (kg/m2) | 25.1±4.6 | 26.2±3.5 | 25.6±3.7 | 26.2±5.2 |
| Ethnicity | ||||
| White | 10 (66.7%) | 14 (87.5%) | 15 (93.7%) | 11 (68.7%) |
| Black | 4 (26.7%) | 2 (12.5%) | 1 (6.3%) | 4 (25%) |
| Other | 1 (6.6%) | 0 (0%) | 0 (0%) | 1 (6.3%) |
| Menopause (years)* | 16.2±7.3 | 14.0±5.8 | 13.1±5.2 | 12.7±3.9 |
| Smoking | 2 (13.3%) | 3 (18.7%) | 1 (6.2%) | 3 (18.7%) |
| HRT | 6 (40%) | 11 (68.7%) | 9 (56.2%) | 10 (66.7%) |
| Calcium supplementation | 8 (53.3%) | 8 (50%) | 15 (93.7%) | 6 (37.5%) |
| Bone mineral density (g/cm2) | ||||
| Vertebral column | 0.72±0.07 | 0.75±0.05 | 0.74±0.06 | 0.72±0.09 |
| Femur | 0.77±0.06 | 0.76±0.09 | 0.76±0.07 | 0.81±0.12 |
| Femoral neck | 0.69±0.06 | 0.71±0.08 | 0.70±0.05 | 0.76±0.09 |
| Blood group | n (%) | 5-year DFS (%) | 5-year OS (%) |
| A | 146 (37.4) | 38.1 | 46.9 |
| B | 108 (27.7) | 31.4 | 38.6 |
| O | 109 (27.9) | 32.8 | 42.9 |
| AB | 27 (6.9) | 23.8 | 30.3 |
| Non-O | 281 (72.1) | 33.2 | 43.2 |
| Element | Extraction in H2O | Extraction in 0.1 mol L−1HCl | Extraction in DTPA–CaCl2–TEA | Total contents | |||
| Copper mine environ (site 1) | Former iron mine environ (site 2) | Reference area (site 3) | Urban area (site 4) | ||||
| Ag | <0.01 | 0.02 ± 0.01 | <0.01 | 0.47 | 0.76 | 0.46 | 1.09 |
| Al | 23.9 ± 16.5 | 62.9 ± 46.2 | 0.78 ± 0.88 | 58992 | 61061 | 59467 | 59643 |
| As | <0.25 | <0.25 | <0.25 | 26.9 | 23.4 | 18.9 | 48.7 |
| Ba | 0.18 ± 0.05 | 10.9 ± 5.81 | 0.71 ± 0.40 | 311 | 403 | 343 | 437 |
| Ca | 104 ± 47.7 | 3421 ± 430 | 1222 ± 197 | 22677 | 20447 | 21954 | 35394 |
| Cd | 0.01 ± 0.001 | 0.05 ± 0.03 | 0.05 ± 0.03 | 1.06 | 0.96 | 0.86 | 0.59 |
| Cr | 0.04 ± 0.02 | 0.06 ± 0.03 | 0.01 ± 0.003 | 63.6 | 41.9 | 55.8 | 54.2 |
| Cu | 0.30 ± 0.06 | 1.57 ± 1.97 | 8.60 ± 6.65 | 100 | 63.7 | 34.3 | 79.0 |
| Fe | 27.9 ± 18.1 | 4.43 ± 4.84 | 28.0 ± 33.4 | 43025 | 32629 | 32646 | 31242 |
| K | 56.2 ± 15.6 | 155 ± 47.2 | 81.6 ± 26.6 | 23716 | 19805 | 16173 | 20290 |
| Li | 0.01 ± 0.004 | 0.04 ± 0.006 | 0.006 ± 0.005 | 7.79 | 5.70 | 7.74 | 9.81 |
| Mg | 21.7 ± 6.15 | 305 ± 79.6 | 103 ± 28.7 | 10676 | 6583 | 8956 | 8629 |
| Mn | 0.47 ± 0.31 | 44.4 ± 28.5 | 10.6 ± 2.82 | 521 | 577 | 575 | 567 |
| Mo | 0.04 ± 0.04 | 0.04 ± 0.02 | 0.03 ± 0.03 | 4.0 | 3.2 | 2.8 | 2.5 |
| Na | 6.91 ± 4.67 | 9.73 ± 5.94 | 6.06 ± 5.35 | 8582 | 9248 | 8506 | 7956 |
| Ni | 0.18 ± 0.05 | 0.84 ± 0.54 | 0.55 ± 0.22 | 19.6 | 39.0 | 23.9 | 34.0 |
| P | 16.6 ± 3.75 | 177 ± 24.8 | 5.19 ± 1.41 | 1385 | 931 | 995 | 2184 |
| Pb | 0.25 ± 0.07 | 0.38 ± 0.26 | 1.71 ± 1.15 | 24.4 | 44.8 | 36.8 | 83.9 |
| V | 0.08 ± 0.03 | 0.10 ± 0.08 | 0.06 ± 0.04 | 93.8 | 72.2 | 82.7 | 67.9 |
| Zn | 0.28 ± 0.11 | 6.02 ± 5.34 | 5.02 ± 5.10 | 78.8 | 72.9 | 73.2 | 181 |
| Concept given to justify why brain death is death | Neurologist responses (n = 192) [n (%; 95% confidence interval)] | Neurologists who agreed the conceptual basis makes brain death equivalent to death (n = 133) [n (%; 95% confidence interval)] |
| Higher brain concept | 63 (33%; 27-40%) | 52 (39%; 31-48%) |
| Loss of integration of body concept | 15 (8%; 5-13%) | 13 (10%; 6-16%) |
| Loss of integration alone | 7 (4%; 2-7%) | 7 (5%; 2-11%) |
| Loss of integration combined with higher brain concept | 8 (4%; 2-8%) | 6 (5%; 2-10%) |
| Prognosis concept | 9 (5%; 2-9%) | 5 (4%; 1-9%) |
| Prognosis of death certain | 7 (4%; 2-7%) | 3 (2%; 1-7%) |
| Quality of life statement | 2 (1%; 0-4%) | 2 (2%; 0-6%) |
| No concept given | 96 (50%; 43-57%) | 59 (44%; 36-53%) |
| Re-statement only: loss of brain function (the criterion) | 32 (17%; 12-23%) | 23 (17%; 12-25%) |
| No response (blank) | 64 (33%; 27-40%) | 36 (27%; 20-35%) |
| Vital work of organism concepta | 4 (2%; 1-5%) | 0 (0%; 0-2%) |
| Other | 9 (5%; 2-9%) | 4 (3%; 1-8%) |
| Sociocultural variables | C 1 | C 2 |
| NBI | 0.103 | -0.620 |
| Tourism | -0.702 | 0.597 |
| Food - Men | 0.882 | -0.096 |
| Food - Women | 0.798 | 0.357 |
| Medicinal - Men | 0.008 | 0.073 |
| Medicinal - Women | -0.307 | 0.736 |
| Food - <46 | 0.841 | 0.194 |
| Food - > 45 | 0.941 | 0.180 |
| Medicinal - <46 | -0.577 | 0.223 |
| Medicinal - >45 | 0.222 | 0.046 |
| Food - Stable job | 0.918 | 0.078 |
| Food - Unstable job | 0.845 | 0.386 |
| Medicinal - Stable job | -0.151 | 0.730 |
| Medicinal - Unstable job | -0.242 | 0.316 |
| Food - 1a5 years of residence | 0.531 | -0.463 |
| Food - 6a10 y o r | 0.348 | 0.747 |
| Food - 11a15 y o r | 0.615 | 0.159 |
| Food - 16 and+ y o r | 0.798 | 0.359 |
| Medicinal - 1a5 years of residence | 0.176 | -0.464 |
| Medicinal - 6a10 y o r | -0.392 | 0.284 |
| Medicinal - 11a15 y o r | 0.080 | -0.408 |
| Medicinal - 16 and+ y o r | -0.016 | 0.760 |
| SNP | LVRS Response Phenotype | All subjects(n = 203) | Upper lobe, low exercise(n = 59) | Upper lobe, high exercise(n = 84) | Non-upper lobe, low exercise(n = 23) | Non-upper lobe, high exercise(n = 37) | |||||
| β | p | β | p | β | p | β | p | β | p | ||
| rs3753658 | BODE | -0.8 | 0.008 | -1.3 | 0.01 | ||||||
| UCSD SOBQ | -7.7 | 0.02 | -11.7 | 0.05 | |||||||
| rs1877724 | Post-BD FEV1, liters | -0.06 | 0.04 | -0.13 | 0.01 | ||||||
| rs2234922 | BODE | 0.5 | 0.02 | 1.6 | 0.02 | ||||||
| Max work, watts | -3.7 | 0.05 | |||||||||
| rs1051741 | Max work, watts | -5.9 | 0.01 | -8.4 | 0.09 | -10.2 | 0.09 | ||||
| rs2292558 | Max work, watts | -5.1 | 0.03 | -8.4 | 0.09 | -10.2 | 0.09 |
| Round 1 | |
| Communicating about symptoms and quality of life | (1) Tell us about a time when you told your doctor or nurse about a symptom that was bothering you—like trouble sleeping or being sick to your stomach. What was difficult or easy about this time? |
| (2) How do you usually let your doctor or nurse know about these things? How does speaking Spanish affect what you do or do not tell your doctor or nurse? | |
| (3) Here is a list of symptoms and quality of life issues common for people during treatment for cancer. Is there anything missing? Is there anything on the list that is not easy to understand? | |
| Using the Internet | (4) How often do you use the Internet, and how do you access it—for example, from a computer, your phone? Do you know how to access the Internet yourself, or does someone help you? |
| (5) Are there websites or applications that you use to learn about health information or to track your activities, like exercise? What do you like about these websites or applications? | |
| Responding to Spanish ESRA-C mock website | (6) Why do you think this website would, or would not, be interesting or useful for you? |
| (7) Do you think most people can understand these questions clearly and give answers? | |
| (8) What do you think patients and their families would find most helpful about this information? How can we make it better? | |
| Round 2 | |
| Review of new patient narration | (1) How well does this new version meet the ideas you had about hearing from a patient's point of view? |
| (2) What thoughts did you have about the patient shown in the pictures who was telling her story? How similar are her concerns to the ones that you thought about when you were going to start treatment? | |
| Review of new website home page and introduction | (3) You saw the woman using the website to learn about getting help and then telling her nurse about problems she was having. How much does this encourage you to talk to your nurse or doctor? |
| (4) Did we explain well enough for you to understand that the answers you give on this website will go to your doctors and nurses? | |
| Review of messages in revised patient education and communication coaching | (5) If you put these three messages in order from most to least important for new patients to hear, what order would you put them in? Why? |
| (6) Are there any words in the website that do not sound right to you, or do you think we could say better? | |
| Working with interpreters | (7) If you have used professional interpreters, what have you learned about the process that you wish you had known before you started your treatment? If you have not, what would you like to know about using interpreters? |
| Emailing providers | (8) Have you had experience emailing your providers, and if so, how well did that work? |
| (9) How would you feel about being able to email a question in Spanish to a translator or bilingual provider who could ask your doctor or nurse and reply to you? | |
| Prioritizing future revisions | (10) The last thing we want to show you is a list of things that people suggested should be added to the website. If you like any of these ideas, or another idea you have, which of these should we work on first? |
| Subjects | 27 |
| Sex | 14 (51.8%) male |
| Age (years) | 7.92 (±2.52) |
| Weight (kilograms) | 34.89±14.89 |
| Height (meters) | 1.34±0.15 |
| BMI (kg/m2), z-score | 18.63±14.92, 0.09±1.88 |
| Tonsil size | Grades 3 and 4 |
| Tonsil volume, mean (cm3) ± standarddeviation | 7.41±3.77 |
| Gene | Forward primer (5′ to 3′) | Reverse primer (5′ to 3′) |
| MeCWINV1 | CGCGGATCCAAAATAGAGATGGAAGCAAT | CGCGTCGACATCATTTCTCAAACATACCC |
| MeCWINV2 | CATGCCATGGTCTTCTTCATCTTCAGTC | CGGGTTACCTTTTATCTTTAGCTCAGC |
| MeCWINV3 | TCAATCAAAGGAGCTATGGACA | GCACTGGCTTCTTTTATTTCATC |
| MeCWINV4 | TATGGATCCCTCACCAGCATGGCTATCA | CATGTCGACTGTCAACCCTGGCTATTTCTCA |
| MeCWINV5 | TCATCCCGCAAATTCAACATT | GCTTACTTCTTTTCCACCTTATTTTTT |
| MeCWINV6 | CTCATTATCCCAAACAGATCAACC | ATTCTCACTTCTTTAAGCAGTCTCA |
| HRCT score | MRI score | |||||
| 0 | 1 | 2 | 3 | 4 | ||
| Consolidation | 52 | 52 | ||||
| Alteration consistent with caseosis | undetermined | 4 | ||||
| Cavitation | 39 | 39 | ||||
| Ground glass | 6 | 2 | 1 | 4 | ||
| Nodule | 43 | 43 | ||||
| Tree in bud | 33 | 29 | ||||
| Interstitial changes | 14 | 1 | 4 | 13 | ||
| Lymph nodes | (Short axis > 10 mm) 38 | 56 | ||||
| Edema | undetermined | 50 | ||||
| Alteration consistent with colliquative necrosis | undetermined | 2 | ||||
| Alteration consistent with caseosis | undetermined | 4 | ||||
| Pleural involvement | 10 | 21 |
| Time | Flow | %Phase C1 | %Phase A | Curve |
| 0.0 | 0.20 | 10 | 90 | 6 |
| 1.0 | 0.20 | 10 | 90 | 6 |
| 40.0 | 0.20 | 100 | 0 | 6 |
| 45.0 | 0.30 | 100 | 0 | 6 |
| 50.0 | 0.20 | 10 | 90 | 3 |
| 58.0 | 0.20 | 10 | 90 | 6 |
| 59.0 | 0.20 | 10 | 90 | 6 |
| 78.0 | 0.20 | 100 | 0 | 6 |
| Term | Genes | p-value |
| hsa05214:Glioma | CDKN1A, CDK6 | 0.018 |
| hsa04115:p53 signaling pathway | CDKN1A, CDK6 | 0.019 |
| hsa05218:Melanoma | CDKN1A, CDK6 | 0.02 |
| hsa05220:Chronic myeloid leukemia | CDKN1A, CDK6 | 0.02 |
| hsa04066:HIF-1 signaling pathway | CDKN1A, TFRC | 0.028 |
| hsa04110:Cell cycle | CDKN1A, CDK6 | 0.035 |
| hsa05161:Hepatitis B | CDKN1A, CDK6 | 0.041 |
| Model 1 | Model 2 | Model 3 | Model 4 | |
| Independence | 1076 | 1076 | 717 | 279 |
| Chi-square | (378 df) | (378 df) | (171) | (55 df) |
| Average standardised residuals | 0.11 | 0.09 | 0.09 | 0.09 |
| Average off-diagonal st. residuals | 0.12 | 0.10 | 0.10 | 0.11 |
| Chi-squared fit | 534.7 | 520 | 213 | 67.7 |
| (df)s | (347 df) | (347 df) | (150 df) | (43) |
| P-value | 0.00001 | 0.00001 | 0.001 | 0.01 |
| Free parameters | 59 | 57 | 40 | 23 |
| Akaike's information criterion (AIC) | -193 | -173 | -87 | -18 |
| Bozodgan's version of AIC (C-AIC) | (-1437) | (-1424) | (-627) | (-173) |
| Comparative Fit Index (CFI) | 0.73 | 0.75 | 0.89 | 0.90 |
| Normed Fit Index (NFI) | 0.50 | 0.52 | 0.70 | 0.76 |
| Non-normed Fit Index (NNFI) | 0.71 | 0.73 | 0.87 | 0.86 |
| ρ of TER | p Value | ρ of Delay Time | p Value | |
| upregulation | −0.084 | 0.43 | 0.37 | 2.7 × 10−4 |
| maximal FC | −0.17 | 0.10 | 0.416 | 7.2 × 10−6 |
| maximal RPKM | −0.10 | 0.36 | 0.05 | 0.61 |
| GC content | −0.11 | 0.32 | −0.04 | 0.73 |
| CAI | −0.23 | 0.03 | −0.10 | 0.35 |
| ITE | −0.25 | 0.02 | −0.15 | 0.14 |
| RNA folding energy | 0.17 | 0.10 | 0.12 | 0.25 |
| regulated by Cra * | −0.03 | 0.75 | −0.29 | 0.01 |
| regulated by FNR * | −0.13 | 0.21 | −0.21 | 0.04 |
| regulated by Fur-Fe * | −0.12 | 0.28 | 0.22 | 0.04 |
| controlled by sigma S | −0.15 | 0.15 | −0.22 | 0.04 |
| Themes | Categories | Definitions |
| Development of national maternal healthguidelines | · Development Process | · the steps taken to develop and produce guidelines |
| · Stakeholder participation | · level of involvement of stakeholders in guideline development | |
| · National guidelines' relation to WHO recommendations | · how contents of national CPGs compare with WHO PCPNC guidelines | |
| Health workers' access to guidelines | Perceived access barriers | |
| · Distribution | · physical distribution of printed guidelines | |
| · Staff mobility | · frequent changes of work-place displaces guidelines from health facilities | |
| · Health workers' participation in training courses | · course curricula frequently used as CPGs, health workers dependent on courses to obtain up-to-date guidelines | |
| · Pocket sized guidelines | · personal portable guidelines for every health worker | |
| · Wall posters | · guidelines in a poster format increases availability for everybody working in the health facility | |
| Health workers' use of guidelines | · Low levels of guideline adherence | · perception among key informants of an overall low use of guidelines by front-line health workers |
| · Attitudes towards continuing education | · health workers do not usually update their knowledge independently from organised training | |
| · Effects of training | · limited change in clinical practice following courses | |
| · Format of guidelines - lack of usability | · presence of flow-charts, algorithms etc. | |
| · Negative beliefs about using guidelines during patient consultations | · perception that patients' trust will be undermined if health workers use CPGs during consultations |
| Variables | Beta (OR)** | 95% CI | P |
| Protein (g) | 0.011 | -0.04, 0.029 | 0.668 |
| Carbohydrates (g) | 0.129 | 0.012, 0.172 | 0.341 |
| Iron (mg) | 1.128 | 0.002, 0.161 | 0.031* |
| Thiamine (mg) | 0.018 | -0.040, 0.059 | 0.655 |
| Zinc (mg) | 0.029 | -0.002, 0.004 | 0.089 |
| Effect | Data structure | Type of test | Power | df (between) | df (within) | F | χ2 | p |
| Pairwise discrimination phase (d) | Normally distributed | Two-factor repeated-measures ANOVA | 0.96 | 1 | 9 | 17.58 | 0.002 | |
| Pairwise discrimination genotype (d) | Normally distributed | Two-factor repeated-measures ANOVA | 0.41 | 1 | 9 | 3.78 | 0.08 | |
| Pairwise discrimination interaction (d) | Normally distributed | Two-factor repeated-measures ANOVA with post hoc Bonferroni correction | 0.13 | 1 | 9 | 0.83 | 0.4 | |
| Pairwise discrimination phase (trials) | Normally distributed | Two-factor repeated-measures ANOVA | 0.62 | 1 | 9 | 6.45 | 0.03 | |
| Pairwise discrimination genotype (trials) | Normally distributed | Two-factor repeated-measures ANOVA | 0.16 | 1 | 9 | 1.10 | 0.3 | |
| Pairwise discrimination interaction (trials) | Normally distributed | Two-factor repeated-measures ANOVA | 0.06 | 1 | 9 | 0.13 | 0.7 | |
| Pairwise discrimination (survival curve) | Normally distributed | Mantel–Cox test | 0.06 | 1 | 0.53 | 0.5 | ||
| Pairwise discrimination reversal (survival curve) | Normally distributed | Mantel–Cox test | 0.07 | 1 | 0.48 | 0.5 |
| Authors/Year | Country | Design | Valable | OR (95% CI) |
| Chen 1995 [17] | England | Case–control | Severe life events | 11.64 (3.10-43.66) |
| Protheroe 1999 [19] | Australia | Case–control | Severe life events | 0.91 (0.47-1.81) |
| Kruk 2012 [20] | Poland | Case–control | Major life events | 5.33 (4.01-8.21) |
| Helgesson 2003 [21] | Sweden | Prospective | Stressful events | 2.1 (1.2-3.7) |
| Lillberg 2003 [22] | Finland | Prospective | Major life events | 1.35 (1.09-1.67) |
| Michael2009 [23] | America | Prospective | ≥4 life events | 0.91 (0.77-1.08) |
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 | |
| Pre CXL | 0 (0 %) | 0 (0 %) | 3 (12.5 %) | 8 (33.3%) | 13 (64.2%) |
| Post CXL | 16 (66.6%) | 8 (33.3%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Adverse reactions and treatment | Ketotifen | Placebo |
| Total no. of doses of OIT, n | 36 | 18 |
| Total no. of patients reporting symptoms | 3/4 | 2/2 |
| Total no. of doses with symptoms, n (% of total OIT doses) | 8/36 (22%) | 12/18 (67%) |
| Anaphylaxis, n (% of total OIT doses) | -* | 1 (5%) |
| Symptoms n, (% of OIT doses) | Ketotifen | Placebo |
| Gastrointestinal | 6/36 (17%) | 11/18 (61%) |
| Cutaneous | - | 1/18 (6%) |
| Lower respiratory | 2/36 (6%) | 1/18 (6%) |
| Oropharyngeal | - | 2/18 (11%) |
| Upper respiratory | - | - |
| Cardiovascular | - | - |
| OtherA | - | 2/18 (11%) |
| Treatment n, (% of OIT doses) | Ketotifen | Placebo |
| Epinephrine | - | - |
| Diphenhydramine | - | - |
| Cetirizine or other** | - | 1/18 (6%) |
| Prednisone | - | - |
| Salbutamol or other inhaled medication | - | 1/18 (6%) |
| Linear range | R2 | LOD (μg/kg) | RSD (%) | Recovery (%) |
| 20~200 μg/L | 0.9988 | 2.4 | 3.5 | 91~97 |
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | |
| PTGI total score | 1 | |||||||||
| PHQ-9 total score | 0.12* | 1 | ||||||||
| SAS total score | 0.14* | 0.66* | 1 | |||||||
| Relating to others | 0.89* | 0.14* | 0.13* | 1 | ||||||
| New Possibilities | 0.91* | 0.16* | 0.14* | 0.78* | 1 | |||||
| Personal strength | 0.82* | -0.03 | 0.03 | 0.62* | 0.70* | 1 | ||||
| Spiritual change | 0.59* | 0.14* | 0.20* | 0.50* | 0.46* | 0.34* | 1 | |||
| Appreciation of life | 0.78* | 0.09 | 0.15* | 0.61* | 0.64* | 0.61* | 0.43* | 1 | ||
| age | 0.01 | -0.02 | -0.05 | -0.06 | 0.06 | -0.00 | -0.02 | 0.04 | 1 |
| Identified symptom | TotalN (%) | MaleN (%) | FemaleN (%) | X2 | p value |
| Fatigue | 27 (9.8) | 9 (6.3) | 18 (13.6) | 4.18* | 0.041 |
| Insomnia | 47 (17.1) | 23 (16.1) | 24 (18.2) | 0.21 | 0.644 |
| Decreased appetite/weight loss | 13 (4.7) | 8 (5.6) | 5 (3.8) | 0.49 | 0.339 |
| Diminished ability to think | 37 (13.5) | 14 (9.8) | 23 (17.6) | 3.53* | 0.044 |
| Diminished interest in activities | 23 (8.4) | 12 (4.4) | 11 (4.0) | 0.003 | 0.566 |
| Parameters(mean ± SD) | GDM(n = 45) | Non-GDM(n = 45) | p value |
| Age (years) | 29.27 ± 6.87 | 26.84 ± 6.99 | 0.101 |
| Weight (Kg) | 72.84 ± 8.79 | 70.84 ± 8.39 | 0.273 |
| Height (cm) | 158.42 ± 6.31 | 159.40 ± 5.15 | 0.423 |
| BMI (Kg/m2) | 30.73 ± 4.82 | 29.56 ± 3.66 | 0.198 |
| SBP (mmHg) | 121.64 ± 6.28 | 120.33 ± 6.25 | 0.324 |
| DBP (mmHg) | 73.42 ± 2.83 | 72.82 ± 2.57 | 0.295 |
| Serum Cholesterol (mg/dl) | 174.56 ± 12.71 | 158.71 ± 8.96 | 0.001 |
| RBG (mg/dl) | 93.24 ± 4.64 | 83.91 ± 4.12 | 0.001 |
| Explanatory variables | βa | 95% CI for β | P value |
| Waiting time | |||
| 0–3 months | Reference | ||
| > 3–6 months | 0.013 | -0.016, 0.043 | 0.381 |
| > 6 months | 0.017 | -0.014, 0.047 | 0.286 |
| BMI | -0.003 | -0.005, -0.0004 | 0.020 |
| Affected joint (0 = hip, 1 = knee) | 0.013 | -0.009, 0.035 | 0.232 |
| 15D score at baseline | 0.752 | 0.637, 0.867 | <0.001 |
| Gender (0 = female, 1 = male) | -0.008 | -0.032, 0.015 | 0.479 |
| Age | -0.0004 | -0.002, 0.001 | 0.539 |
| Professional education (0 = no, 1 = yes) | -0.0003 | -0.023, 0.022 | 0.976 |
| Housing (0 = living alone, 1 = living with someone) | 0.009 | -0.016, 0.034 | 0.469 |
| Constant | 0.301 | ||
| R square | 0.613 | ||
| F | 21.430*** | ||
| n | 133 |
| Condition | Test | Absolute error (95% CI) | Symptomatic diagnosis-Tariff method with health care experience absolute error (95% CI) |
| Asthma | World Health Survey (WHS): Doctor (MD) diagnosis (Dx) [34] | 0.023 (0.020, 0.025) | 0.014 (0.012, 0.016) |
| WHS MD Dx OR asthma medications (Rx) [34] | 0.023 (0.020, 0.025) | ||
| WHS MD Dx OR asthma Rx OR wheezing/whistling attacks [34] | 0.092 (0.087, 0.095) | ||
| Angina pectoris | Rose questionnaire [35,36] | 0.082 (0.073, 0.088) | 0.020 (0.018, 0.022) |
| Depression | Composite international diagnostic interview questionnaire [37] | 0.059 (0.054, 0.064) | 0.016 (0.015, 0.017) |
| Topic | |
| Week 1 | |
| Day 1 | An Overview of Maternal-Infant Care |
| Day 2 | The Role of the Birth Attendant, Health Care Resources, and the Emergency Plan |
| Week 2 | |
| Day 3 | Sexual Organs, Sexual Desire, and Menstruation, Ovulation, and Fertilization |
| Day 4 | The Natural Development of Pregnancy |
| Week 3 | |
| Day 5 | The Choice of Motherhood, The Importance of Prenatal Care—Part 1 |
| Day 6 | The Importance of Prenatal Care—Part 2 |
| Week 4 | |
| Day 7 | Pregnancy Complications, Part 1 |
| Day 8 | Pregnancy Complications, Part 2 |
| Week 5 | |
| Day 9 | Signs and Symptoms of Danger during Pregnancy |
| Day 10 | Case Studies on Prenatal Care, Exam 1 |
| Week 6 | |
| Day 11 | Review Exam 1 |
| Day 12 | Tetanus Vaccine, Introduction to Stages of Labor |
| Week 7 | |
| Day 13 | Uncomplicated Labor: Stage One and Two |
| Day 14 | Uncomplicated Labor: Stage Two and Three |
| Week 8 | |
| Day 15 | Review of Stages of Labor, Basic Care of the Newborn |
| Day 16 | Complications during Labor and Delivery |
| Week 9 | |
| Day 17 | When to Refer during Labor |
| Day 18 | Neonatal Resuscitation, Immediate Post-Partum Care, Maternal Lactation |
| Week 10 | |
| Day 19 | Maternal Lactation Review, Post-Partum Care: Day 1 & 4 |
| Day 20 | Review of Normal and Complicated Labor, Exam 2 |
| Week 11 | |
| Day 21 | Medicinal Plants, Sharing of Experiences during Labor |
| Day 22 | Infection Prevention and Management, Sterilization of Birth Tools |
| Week 12 | |
| Day 23 | Family Planning Methods |
| Day 24 | Case Studies: Family Planning, Self Breast Exam |
| Week 13 | |
| Day 25 | Vaginal Infections and STIs |
| Day 26 | Nutrition and Malnutrition |
| Week 14 | |
| Day 27 | Complicated Labor |
| Day 28 | Cumulative Review, Final Exam |
| Ergonomic problems | ||||
| Categories | Working posture and type of examination | Equipment and physical factors | The patient’s physique and health | Work experience and knowledge |
| Subcategories | -Echocardiography-Vascular examinations-Bedside examination | -Ultrasonic device-Examination room including table and equipment to assist patients-Physical factors including light, noise and ventilation | -Patient constitution-Inpatients | -Lack of skills |
| Variables | Chi Square | 95% C.I. | Hazard Ratio | P Value |
| DFS | ||||
| 1. Cellular differentiation | 10.51 | 4.20 – 463.30 | 0.3101 | 0.005* |
| OS | ||||
| 1. Tumor Grade | 6.08 | 1.41 – 3.07 | 0.2741 | 0.01* |
| Number of people | Percentage (%) | |
| Before preferences learning | 3 | 7.65% |
| After preferences learning | 14 | 82.35% |
| Total number of people and percentage | 17 | 100% |
| N | ATPIII 2001 | ATPIII revised | WHO | IDF | |
| NHANES 1988-1994 [143] | 8,814 | 23.7% | |||
| NHANES 1988-1994 [144] | 8,608 | 23.9% | 25.1% | ||
| NHANES 1988-1994 [145] | 6,436 | 24.1% | 29.2% | ||
| NHANES 1999-2002 [145] | 1,677 | 27.0% | 32.3% | ||
| NHANES 1999-2002 [10] | 3,601 | 34.6% | 39.1% | ||
| NHANES 2003-2006 [13] | 3,423 | 34% |
| All | Group 1 | Group 2 | Group 3 | Group 4 | P - values | |
| (N = 203) | (N = 46) | (N = 64) | (N = 64) | (N = 29) | ||
| Age (years) | ||||||
| 0–1 | 15 (7%) | 5 (11%) | 7 (11%) | 2 (3%) | 1 (3%) | 0.198 |
| 1–5 | 56 (28%) | 15 (33%) | 20 (31%) | 13 (20%) | 8 (28%) | |
| 5–10 | 98 (48%) | 15 (33%) | 28 (44%) | 39 (61%) | 16 (55%) | |
| >10 | 34 (17%) | 11 (23%) | 9 (14%) | 10 (16%) | 4 (14%) | |
| Gender male | 132(65%) | 27 (59%) | 44 (69%) | 45 (70%) | 16 (55%) | 0.358 |
| Underlying medical conditions | 0.004 | |||||
| none | 60 (30%) | 13 (28%) | 16 (25%) | 24 (38%) | 7 (24%) | |
| asthma | 57 (28%) | 8 (17%) | 20 (31%) | 22 (34%) | 7 (24%) | |
| asthmatic diseases+ | 29 (14%) | 2 (5%) | 10 (16%) | 9 (14%) | 8 (28%) | |
| other respiratory problems++ | 8 (4%) | 3 (6%) | 2 (3%) | 2 (3%) | 1 (4%) | |
| immunocompromised * | 4 (2%) | 2 (5%) | 0 (0%) | 2 (3%) | 0 (0%) | |
| others** | 45 (22%) | 18 (39%) | 16 (25%) | 5 (8%) | 6 (20%) | |
| Heart Rate on admission | 146 | 138 | 150 | 150 | 150 | 0.072 |
| (bpm, median) IQR | 133-160 | 100-175 | 128-172 | 121-179 | 128-172 | |
| Respiratory Rate on admission | 37 | 24 | 40 | 38 | 40 | < 0.001 |
| (bpm, median) IQR | 28-42 | 14-34 | 20-60 | 23-53 | 17-63 | |
| Body Temperature on admission | 38.5 | 38.7 | 38.4 | 38.4 | 38.2 | 0.530 |
| (°C, median) IQR | 37.9-39.2 | 37.4-40.0 | 37.3-39.5 | 37.0-39.8 | 36.6-39.9 | |
| SpO2 on admission | 94 | 98 | 96 | 93 | 94 | < 0.001 |
| (%, median) IQR | 93-98 | 95-100 | 91-100 | 88-98 | 88-100 | |
| O2 demand on admission YES | 39 (19%) | 4 (9%) | 9 (14%) | 19 (30%) | 7 (24%) | 0.025 |
| O2 demand during admission YES | 129 (64%) | 10 (22%) | 41 (64%) | 53 (83%) | 25 (86%) | 0.002 |
| Time from the onset of illness (hr) | ||||||
| 0–5 | 38 (19%) | 11(23%) | 14 (22%) | 11 (17%) | 2 (7%) | 0.976 |
| 6–11 | 27 (13%) | 1 (2%) | 8 (12%) | 13 (20%) | 5 (17%) | |
| 12–23 | 61 (30%) | 18 (41%) | 14 (22%) | 15 (23%) | 14 (49%) | |
| 24–47 | 42 (21%) | 11 (23%) | 13 (20%) | 11 (17%) | 7 (24%) | |
| 48 - | 20 (10%) | 3 (7%) | 8 (12%) | 9 (14%) | 0 (0%) | |
| Unknown | 15 (7%) | 2 (4%) | 7 (12%) | 5 (9%) | 1 (3%) | |
| Systemic steroid use YES | 84 (41%) | 10 (22%) | 24 (38%) | 33 (52%) | 17 (59%) | 0.34 |
| Antibiotics use YES | 92 (45%) | 5 (11%) | 23 (36%) | 51 (80%) | 13 (45%) | 0.10 |
| Antiviral use YES | 191 (94%) | 42 (91%) | 60 (94%) | 62 (97%) | 27 (93%) | 0.994 |
| AOR single measure1 | ||||
| Knowledge measure | Bivariate OR | Mozambique | 4 Southern African countries2 | AOR all measures3 |
| Needles/razors | 1.13 (0.70–1.83) | 0.91 (0.55–1.49) | 0.86 (0.71–1.04) | 0.87 (0.52–1.45) |
| Blood contact | 1.11 (0.82–1.51) | 0.95 (0.70–1.30) | — | 0.93 (0.67–1.30) |
| Vaginal sex | 2.10 (1.16–3.80) | 1.85 (0.99–3.45) | 1.21 (1.07–1.37) | 1.93 (1.02–3.64) |
| Anal sex | 1.18 (0.92–1.51) | 1.03 (0.79–1.34) | — | 0.98 (0.75–1.28) |
| Stage | ||||
| 1 | 2 | 3 | P value | |
| Number of patients | 2 | 6 | 1 | |
| Location (%) | 1 | |||
| Mandible | 2 (100) | 5 (83.33) | 1 (100) | |
| Maxilla | 0 (0) | 1 (16.67) | 0 (0) | |
| Infection (%) | 0.0476* | |||
| Yes | 0 (0) | 5 (83.33) | 0 (0) | |
| No | 2 (100) | 1 (16.67) | 1 (100) | |
| Etiology (%) | 0.7222 | |||
| Extraction | 1 (50) | 3 (50) | 1 (100) | |
| Prosthesis problem | 0 (0) | 2 (33.33) | 0 (0) | |
| Periodontal problem | 0 (0) | 1 (16.67) | 0 (0) | |
| Spontaneous | 1 (50) | 0 (0) | 0 (0) | |
| Bisphosphonate type (%) | 0.25 | |||
| Combinationa | 2 (100) | 5 (83.33) | 0 (0) | |
| Only zoledronate | 0 (0) | 1 (16.67) | 0 (0) | |
| Only pamidronate | 0 (0) | 0 (0) | 1 (100) | |
| Treatmentb (%) | 0.6429 | |||
| Conservative | 2 (100) | 3 (50) | 1 (100) | |
| Invasive | 0 (0) | 3 (50) | 0 (0) | |
| Outcome (%) | 1 | |||
| 1 | 1 (100) | 4 (80) | 0 (0) | |
| 2 | 0 (0) | 1 (20) | 0 (0) | |
| Duration in months | 21 (17–25) | 19 (11–69) | 9 (9–9) | 0.2992 |
| Virus | % with HI titer ≥40 | |||
| Serum wave 1 (n = 59) | Serum wave 2 (n = 32) | Serum wave 3 (n = 33) | ||
| CA/07 | 81.4 (48/59) | 71.9 (23/32) | 78.8 (26/33) | |
| Thailand wave 1 | Thai/104 | 100 (59/59) | 100 (32/32) | 100 (33/33) |
| CBI6 | 98.3 (58/59) | 93.8 (30/32) | 100 (33/33) | |
| CBI10 | 91.5 (54/59) | 96.9 (31/32) | 100 (33/33) | |
| Thailand wave 2 | 34002 | 100 (59/59) | 90.6 (29/32) | 97 (32/33) |
| 34004 | 96.9 (57/59) | 100 (32/32) | 100 (33/33) | |
| NMA1 | 100 (59/59) | 93.8 (30/32) | 93.3 (31/33) | |
| Thailand wave 3 | BKK1 | 71.2 (42/59) | 81.3 (26/32) | 100 (33/33) |
| BKK2 | 89.8 (53/59) | 87.5 (28/32) | 97 (32/33) | |
| Thailand wave 4 | BKK4 | 93.2 (55/59) | 84.4 (27/32) | 100 (33/33) |
| BKK5 | 98.3 (58/59) | 100 (32/32) | 100 (33/33) |
| Patients (n) | HSR (n) | HSR (%) | p value1 | |
| Sex | ||||
| Female | 113 | 16 | 14.2 | 0,0147 |
| Male | 78 | 1 | 1.3 | |
| Prior exposure to platinum salts | ||||
| Yes | 45 | 8 | 17.8 | 0,0220 |
| No | 146 | 9 | 6.2 | |
| Atopic background | ||||
| Yes | 32 | 4 | 12.5 | 0,4367 |
| No | 159 | 13 | 8.2 |
| Oromia | SNNP | All | ||||
| n = 57 | n = 73 | n = 130 | ||||
| n | % | n | % | n | % | |
| Training Received by HEWsa | In past 3 years | In past 3 years | In past 3 years | |||
| Integrated refresher training | 56 | 98% | 67 | 92% | 123 | 95% |
| Possible severe bacterial infections management | 53 | 93% | 66 | 90% | 119 | 92% |
| Integrated community case management | 56 | 98% | 60 | 82% | 116 | 89% |
| Maternal, newborn, and child health | 52 | 91% | 57 | 78% | 109 | 84% |
| Health management information system | 30 | 53% | 72 | 99% | 102 | 78% |
| Tuberculosis prevention and control | 36 | 63% | 62 | 85% | 98 | 75% |
| Nutrition | 41 | 72% | 54 | 74% | 95 | 73% |
| Family planning | 36 | 63% | 54 | 74% | 90 | 69% |
| Malaria prevention and control | 41 | 72% | 31 | 42% | 72 | 55% |
| HIV/AIDS and sexually transmitted infections | 35 | 61% | 31 | 42% | 66 | 51% |
| Hygiene and environmental sanitation | 32 | 56% | 31 | 42% | 63 | 48% |
| Immunization | 32 | 56% | 28 | 38% | 60 | 46% |
| Adolescent reproductive health | 24 | 42% | 31 | 42% | 55 | 42% |
| First aid | 15 | 26% | 9 | 12% | 24 | 18% |
| Supervision and Technical Support Received | In past 3 months | In past 3 months | In past 3 months | |||
| Any supervision or technical supportb | 54 | 95% | 73 | 100% | 127 | 98% |
| By Primary Health Care Unit (PHCU)c | 53 | 93% | 67 | 92% | 120 | 92% |
| By Woreda Health Office (WoHO)d | 43 | 75% | 58 | 79% | 101 | 78% |
| Median | IQR | Median | IQR | Median | IQR | |
| If supervised by PHCU, times in past 3 months | 4.5 | (2–8) | 5 | (3–8) | 5 | (2–8) |
| If supervised by WoHO, times in past 3 months | 1 | (1–2) | 2 | (1–2) | 1 | (1–2) |
| Items | Mean age | Diagnosis | ACF | PIF + PD | One stage of ACF and PIF + PD |
| Present study | 67.6 y/o | Degenerative cervical kyphosis with stenosis | ABL: 135.2 ± 85.2 ml | ABL: 307.7 ± 92.3 ml | ABL: 442.9 ± 236.0 ml |
| MST: 136.8 ± 52.3 min | MST: 139.3 ± 50.4 min | MST: 314.5 ± 51.2 min | |||
| Du et al. [2] | 59.6 y/o | CSM/OPLL/cervical stenosis | None | ABL: 650 mL MST: 150 min | None |
| Epstein et al. [20] | 54.0 y/o | OPLL | None | None | ABL: 500 ml |
| MST: 522 min |
| Characteristic | Cluster 1 Most Severe (n = 30) | Cluster 2 Intermediate (n = 67) | Cluster 3 Least Severe (n = 67) |
| SF-36 Scales (mean ± sd) | |||
| Physical function | 49.5 ± 21.8 | 71.8 ± 20.1 | 91.0 ± 10.3 |
| Role physical | 12.5 ± 26.9 | 48.1 ± 36.0 | 92.5 ± 19.5 |
| Bodily pain | 39.5 ± 18.3 | 53.7 ± 16.5 | 79.4 ± 15.6 |
| General health | 45.4 ± 19.3 | 67.4 ± 13.8 | 85.3 ± 12.6 |
| Vitality | 14.3 ± 11.0 | 34.6 ± 15.8 | 69.6 ± 16.0 |
| Social function | 45.4 ± 24.0 | 67.9 ± 18.4 | 96.3 ± 8.7 |
| Role emotional | 47.8 ± 41.7 | 74.1 ± 35.2 | 96.0 ± 13.6 |
| Mental health | 61.5 ± 19.5 | 74.4 ± 13.5 | 86.9 ± 9.1 |
| MFI Scales (mean ± sd) | |||
| General fatigue | 18.4 ± 1.4 | 15.1 ± 2.7 | 8.7 ± 3.2 |
| Physical fatigue | 15.4 ± 2.7 | 11.6 ± 2.8 | 6.7 ± 2.1 |
| Mental fatigue | 15.9 ± 3.5 | 10.3 ± 3.9 | 6.6 ± 2.7 |
| Reduced motivation | 13.4 ± 4.0 | 10.3 ± 3.0 | 6.2 ± 2.0 |
| Reduced activity | 15.8 ± 3.3 | 11.9 ± 3.5 | 5.9 ± 2.0 |
| Symptom Inventory (mean ± sd) | 52.2 ± 24.8 | 21.6 ± 12.6 | 7.0 ± 8.5 |
| Class | Biophysical Features | Geographical Regions |
| 1 | lowest temperature and high chlorophyll a | south side of Bali, Sumbawa, Fores and Sumba |
| 2 | moderate biophysical conditions | Savu Sea (in the west) and Arafura Sea (in the east) |
| 3 | high chlorophyll a and high salinity | Van Dieman Gulf and Beagle Gulf (out of the SBS) |
| 4 | low chlorophyll a and high salinity | Timor Sea |
| 5 | the lowest chlorophyll a and the highest currents | Banda Sea, Molucca Sea (to the north), Ceram Sea (to the east), Flores Sea (to the southwest). |
| 6 | low chlorophyll a and medium currents | Bali Sea, Flores Sea and Gulf of Boni |
| 7 | the second highest overall temperature | Halmahera Sea and Molucca Sea |
| 8 | highest overall temperature | Gulf of Tomini and Makassar Strait (northeast of the SBS, south to the Equator) |
| 9 | high chlorophyll a and low salinity | Java Sea |
| Scenario | WI ORCF | GA BRCF | GA ARCF | RA BRCF | RA ARCF | TA ORCF |
| 1 | 29.2727 | 5.8364 | 6.3186 | 9.3091 | 9.3363 | 8.7455 |
| 2 | 109.3333 | 20.0000 | 23.7894 | 31.3333 | 31.3333 | 24.6667 |
| 3 | 383.2625 | 227.4618 | 229.1624 | 217.495 | 218.1787 | 295.495 |
| 4 | 217.3091 | 20.0364 | 21.6105 | 18.4364 | 18.5327 | 23.3455 |
| 5 | 250.8222 | 22.7778 | 24.6070 | 20.1778 | 20.5511 | 23.7778 |
| 6 | 557.3333 | 141.3333 | 150.0000 | 112.6667 | 117.7333 | 114.0000 |
| 7 | 2778.2573 | 2550.3018 | 2550.3139 | 2557.0901 | 2557.0901 | 2550.3018 |
| 8 | 898.7805 | 244.3707 | 249.9034 | 206.7951 | 209.8641 | 522.9854 |
| Gene name | Primers | Annealing temperature |
| hHSF4F | CCCCCTCAAGAAAGTGTGGAA | 60°C |
| hHSF4R | GAACCAAGGGCTGCATCAAG | 60°C |
| mHSF4F | GGCACCAGCTTCCTCGTAAG | 60°C |
| mHSF4R | CCTTCCGAAAACCATACATGTTG | 60°C |
| hCrygsF | CCCAACTTTGCTGGGTACATG | 60°C |
| hCrygsR | GGCCTCCACTAGGCAGATGA | 60°C |
| mCrygsF | AGCGTTGGATGGGCCTTAAT | 60°C |
| mCrygsR | GTTTCGTACATCTGACCGTTGAAG | 60°C |
| hBFSP1F | TTCAGTGGGAGAGAGATGTTGAAA | 60°C |
| hBFSP1R | CTCCTGGGTCTGGGACATGT | 60°C |
| mBfsp1F | AGACGCCCATCTCTCTGATCA | 60°C |
| mBfsp1R | AGGGCCTTCTGTCTCGGTTT | 60°C |
| hBFSP2F | TTCAGTGGGAGAGAGATGTTGAAA | 60°C |
| hBFSP2R | CTCCTGGGTCTGGGACATGT | 60°C |
| mBfsp2F | GCACCGGTCTGGATGATGTC | 60°C |
| mBfsp2R | ACGTGGACCACCTCTGTCTG T | 60°C |
| mLp82F | ATTGGCTTCGCCATCTACGA | 60°C |
| mLp82R | CCCGCATGTTGATGTAGGTTT | 60°C |
| mCalpain2F | ATGCGGAAAGCACTGGAAGA | 60°C |
| mCalpain2R | CCAAACACCGCACAAAATTG | 60°C |
| Animal models | Polyurethane scaffolds | Major conclusions | Reference |
| Iliac crest (sheep) | Porous scaffolds synthesized from HMDI, PEO-PPO-PEO, and PCL at various ratios. Pore size, 300 to 2,000 μm; porosity, 85% | At 18 and 25 months, all the defects in the ilium implanted with polyurethane bone substitutes had healed with new bone. | Gogolewski and Gorna ([2007]), Gogolewski et al. ([2006]) |
| The extent of bone healing depended on the chemical composition of the polymer from which the implant was made. | |||
| The implants from polymers with the incorporated calcium-complexing additive were the most effective promoters of bone healing, followed by those with vitamin D and polysaccharide-containing polymer. | |||
| There was no bone healing in the control defects. | |||
| Bone marrow stromal cells | BDI with PCL films | Bone marrow stromal cells were cultured on rigid polymer films under osteogenic conditions for up to 21 days. This study demonstrated the suitability of this family of PEUUs for bone tissue engineering applications. | Kavlock et al. ([2007]) |
| Femoral condyle | LTI with PCL-co-PGA-co-PDLLA | Extensive cellular infiltration deep to the implant and new bone formation at 6 weeks | Dumas et al. ([2010]) |
| Chondrocytes | Porous scaffolds synthesized from HMDI with PCL and ISO | Although the covalent incorporation of the isoprenoid molecule into the polyurethane chain modified the surface chemistry of the polymer, it did not affect the viability of attached chondrocytes. | Eglin et al. ([2010]) |
| The change of surface characteristics and the more open pore structure of the scaffolds produced from the isoprenoid-modified polyurethane are beneficial for the seeding efficiency and the homogeneity of the tissue-engineered constructs. |
| SPATA2 7–219 | HOIP 5–180 + SPATA2 334–344 | |
| Data Collection | ||
| Beamline | Diamond I02 | Diamond I02 |
| Space group | P 21 | P 43 |
| a, b, c (Å) | 43.48, 51.14, 56.29 | 89.04, 89.04, 53.56 |
| α, β, γ (°) | 90.00, 105.97, 90.00 | 90.00, 90.00, 90.00 |
| Wavelength | 0.9794 | 0.9795 |
| Resolution (Å) | 54.12–1.45 (1.48–1.45) | 62.96–2.70 (2.83–2.70) |
| Rmerge | 3.7 (32.7) | 7.2 (67.9) |
| < I / σI > | 12.1 (2.2) | 9.5 (2.0) |
| CC(1/2) | 0.99 (0.91) | 0.99 (0.61) |
| Completeness (%) | 90.2 (81.2) | 97.7 (99.7) |
| Redundancy | 3.0 (2.9) | 2.7 (2.7) |
| Refinement | ||
| Resolution (Å) | 54.11–1.45 | 62.96–2.70 |
| No. reflections | 37,458 | 11,425 |
| Rwork / Rfree | 18.2/22.5 | 23.3/28.1 |
| No. Atoms | ||
| Protein | 1,722 | 2,695 |
| Ligand/ion | 12 | 15 |
| Water | 308 | – |
| B Factors | ||
| Wilson B | 15.73 | 57.1 |
| Protein | 25.1 | 61.3 |
| Ligand/ion | 21.8 | 85.0 |
| Water | 38.0 | – |
| RMSDs | ||
| Bond lengths (Å) | 0.005 | 0.002 |
| Bond angles (°) | 0.772 | 0.526 |
| Ramachandran statistics (outliers, allowed, favored) | 0.0, 1.4, 98.6 | 0.0, 2.6, 97.4 |
| Sex and Age Groups | Unintentional Injury Code | Any Maltreatment Code | ||||
| Mean | SD | % with any risk documented | Mean | SD | % with any risk documented | |
| Males | ||||||
| <1 | .67 | 1.00 | 44.4 | 3.00 | 2.13 | 85.7 |
| 1-5 | .10 | .43 | 7.2 | 2.61 | 1.72 | 89.1 |
| 6-9 | .05 | .23 | 5.3 | 2.71 | 1.61 | 100.0 |
| 10-14 | .19 | .69 | 10.6 | 3.74 | 1.64 | 100.0 |
| 15-17 | .23 | .65 | 14.3 | 4.50 | 2.01 | 100.0 |
| Total | .17 | .58 | 10.8 | 3.11 | 1.91 | 92.3 |
| Females | ||||||
| <1 | .22 | .44 | 22.2 | 2.79 | 1.88 | 89.7 |
| 1-5 | .25 | 1.02 | 7.8 | 2.82 | 1.91 | 90.1 |
| 6-9 | .03 | .16 | 2.6 | 3.11 | 1.77 | 96.4 |
| 10-14 | .03 | .19 | 3.4 | 3.90 | 2.19 | 92.7 |
| 15-17 | .75 | 1.29 | 35.7 | 4.30 | 2.35 | 98.2 |
| Total | .24 | .85 | 11.5 | 3.47 | 2.15 | 93.1 |
| Total | ||||||
| <1 | .44 | .78 | 33.3 | 2.91 | 2.02 | 87.5 |
| 1-5 | .17 | .74 | 7.5 | 2.74 | 1.83 | 89.7 |
| 6-9 | .04 | .20 | 4.2 | 2.96 | 1.71 | 97.8 |
| 10-14 | .15 | .61 | 8.9 | 3.85 | 2.04 | 94.8 |
| 15-17 | .37 | .89 | 20.0 | 4.33 | 2.29 | 98.5 |
| Total | .19 | .68 | 11.0 | 3.34 | 2.07 | 92.8 |
| Variables | All (n=704) | Presence of NHS-EMH (n=40) | Absence of NHS-EMH (n=664) | P-value univariate | P-value multivariate |
| Age at referall in years median (range) | 64 (22–90) | 62.5 (38–79) | 64 (22–90) | 0.1 | |
| Male (%) | 454 (64%) | 25 (63%) | 429 (65%) | 0.8 | |
| Hemoglobin, g/dl median (range) | 10.5 (5.8–16.7) | 10.9 (7.5–13.8) | 10.4 (5.8–16.7) | 0.4 | |
| Hemoglobin <10 g/dl, n (%) | 331 (47%) | 14 (35%) | 317 (48%) | 0.1 | |
| Leukocytes, x109/l median (range) | 9.0 (0.8–236.1) | 12.6 (1.1–105.9) | 9 (0.8–236.1) | 0.01 | 0.8 |
| Leukocytes >11x109/l, n (%) | 279 (40%) | 23 (58%) | 256 (39%) | 0.02 | 0.009 |
| Leukocytes >25 x109/l, n (%) | 101 (14%) | 7 (18%) | 94 (14%) | 0.6 | |
| Platelets, x 109/l median (range) | 210.0 (10.0–2466.0) | 229.5 (13.0–1164.0) | 208.5 (10.0–2466.0) | 0.9 | |
| Platelets<450x109/l, n (%) | 595 (85%) | 34 (85%) | 561 (84%) | 0.9 | |
| Platelets <1000 x109/l, n (%) | 689 (98%) | 39 (98%) | 650 (98%) | 0.9 | |
| Circulating blasts % median (range) | 1 (0–15) | 0.5 (0–9) | 1 (0–15) | 0.3 | |
| Presence of constitutional symptoms, n (%) | 203 (29%) | 10 (25%) | 193 (29%) | 0.6 | |
| Presence of palpable splenomegaly N evaluable=680, n (%) | 509 (75%) | 29 (81%) | 480 (75%) | 0.4 | |
| DIPSS-plus risk N evaluable=685 | 0.2 | ||||
| Low | 93 (14%) | 6 (15%) | 87 (13%) | ||
| Intermediate-1 | 113 (16%) | 10 (25%) | 103 (16%) | ||
| Intermediate-2 | 252 (37%) | 16 (40%) | 236 (37%) | ||
| High | 227 (33%) | 8 (20%) | 219 (34%) | ||
| Driver mutations | 0.045 | ||||
| JAK2 mutated, n (%) | 463 (66%) | 20 (50%) | 443 (67%) | ||
| CALR type 1/type 1-like, n (%) | 112 (16%) | 12 (30%) | 100 (15%) | ||
| CALR type 2/type 2-like, n (%) | 22 (3%) | 3 (8%) | 19 (3%) | ||
| MPL mutated, n (%) | 38 (5%) | 2 (5%) | 36 (5%) | ||
| Triple negative, n (%) | 69 (10%) | 3 (8%) | 66 (10%) | ||
| CALR mutated, n (%) | 134 (19%) | 15 (38%) | 119 (18%) | ||
| Mutated versus unmutated | 0.002 | 0.0008 | |||
| Cytogenetic categories N evaluable=685 | |||||
| Normal | |||||
| Normal versus Abnormal | 417 (61%) | 26 (65%) | 391 (61%) | 0.6 | |
| Favorable | |||||
| Favorable versus unfavorable* | 605 (88%) | 38 (95%) | 567 (88%) | 0.2 | |
| ASXL1,N evaluable=467 | 178 (38%) | 14 (39%) | 164 (38%) | 0.9 | |
| SF3B1, N evaluable=401 | 35 (9%) | 4 (13%) | 31 (8%) | 0.4 | |
| U2AF1, N evaluable=445 | 71 (16%) | 2 (6%) | 69 (17%) | 0.1 | |
| SRSF2, N evaluable=461 | 70 (15%) | 7 (19%) | 63 (15%) | 0.5 | |
| TET2, N evaluable=179 | 32 (18%) | 3 (21%) | 29 (18%) | 0.7 | |
| EZH2, N evaluable=363 | 16 (4%) | 2 (7%) | 14 (4%) | 0.5 | |
| ZRSR2, N evaluable=179 | 19 (11%) | 2 (14%) | 17 (10%) | 0.6 | |
| IDH1, N evaluable=185 | 8 (4%) | 0 (0%) | 8 (5%) | 0.4 | |
| IDH2, N evaluable=186 | 14 (8%) | 2 (13%) | 12 (7%) | 0.4 |
| Central cardiologist | ||||
| No RV dysfunction (n) | RV dysfunction (n) | Total (n) | ||
| Local cardiologist | No RV dysfunction (n) | 55 | 4 | 59 |
| RV dysfunction (n) | 3 | 11 | 14 | |
| Total (n) | 58 | 15 | 73 |
| Before peritonitis | 12 hours peritonitis | 18 hours peritonitis | 24 hours peritonitis | ||
| Exhaled NO (pmol/kg/min) | Control | 6 (3 to 47) | 22 (6 to 72)b | 27 (11 to 98)b | 15 (14 to 141)b |
| AVP | 5 (4 to 9) | 14 (7 to 17)b | 12 (9 to 16)b | 8 (6 to 10)a | |
| Arterial NO3-+NO2- (μmol/gprotein) | Control | 0.5 (0.4 to 1.6) | 1.5 (0.6 to 2.1)b | 1.8 (0.9 to 2.6)b | 1.8 (1.3 to 2.7)b |
| AVP | 1.0 (0.6 to 1.3) | 1.4 (1.0 to 2.2)b | 1.3 (1.0 to 2.4)b | 1.2 (1.0 to 2.3)b | |
| Tumor necrosis factor-α (μmol/gprotein) | Control | 3 (2 to 3) | 10 (8 to 16)b | 20 (12 to 25)b | 27 (15 to 55)b |
| AVP | 2 (2 to 3) | 8 (7 to 11)b | 14 (12 to 19)b | 18 (15 to 29)b | |
| Interleukin 6 (μmol/gprotein) | Control | 1 (1 to 1) | 125 (56 to 286)b | 549 (252 to 1624)b | 753 (559 to 3443)b |
| AVP | 1 (0 to 3) | 83 (51 to 150)b | 216 (119 to 365)a, b | 354 (140 to 677)a, b |
| Label | Predicted function | Activity present in the following species | Activity suspected in T. maritimum |
| Iron uptake | |||
| MARIT_0169-0174 | Siderophore biosynthesis system, Tbs | Deep sea metagenome (Fujita et al., 2012) | Avendaño-Herrera et al., 2005b |
| MARIT_1312-1313 | Heme uptake mechanism, HmuYR | Porphyromonas gingivalis (Olczak et al., 2008; Wójtowicz et al., 2009) | Avendaño-Herrera et al., 2005b |
| MARIT_0141 – 0142 | Fe2+ uptake system, FeoAB | Porphyromonas gingivalis (Lau et al., 2016) | Avendaño-Herrera et al., 2005b |
| MARIT_1664 | Iron acquisition, uptake or storage, imelysin family protein | Synechococcus elongatus (Xu et al., 2011) | Avendaño-Herrera et al., 2005b |
| MARIT_1661 | Iron acquisition, uptake or storage, imelysin family protein | Synechococcus elongatus (Xu et al., 2011) | Avendaño-Herrera et al., 2005b |
| Stress resistance | |||
| MARIT_3105 | Superoxide dismutase [Mn/Fe], SodA | Staphylococcus carnosus (Barrière et al., 2001) | Suzuki et al., 2001 |
| MARIT_1670 | Superoxide dismutase [Fe], SodB | Legionella pneumophila (Amemura-Maekawa et al., 1996) | Suzuki et al., 2001 |
| MARIT_1821 | Superoxide dismutase [Cu–Zn], SodC | Schistosoma mansoni (da Silva et al., 1992) | Suzuki et al., 2001 |
| MARIT_0946 | KatG catalase | Geobacillus stearothermophilus (Singh et al., 2008) | Suzuki et al., 2001 |
| MARIT_2408 | KatA catalase | Pseudomonas aeruginosa (Brown et al., 1995) | Suzuki et al., 2001 |
| Toxins | |||
| MARIT_0124 | Cholesterol-dependent cytolysin | Capnocytophaga canimorsus (Gilbert, 2010) | Baxa et al., 1988 |
| MARIT_1085 | Collagenase | Cytophaga sp. (Sasagawa et al., 1995) | Baxa et al., 1988 |
| MARIT_1748 | Sphingomyelinase | Bacillus cereus (Oda et al., 2010) | |
| MARIT_2033 | Ceramidase | Pseudomonas aeruginosa (Ito et al., 2014) | |
| MARIT_2107 | Chondroitin AC lyase | Flavobacterium columnare (Suomalainen et al., 2006) | Rahman et al., 2014 |
| MARIT_2328 | Streptopain family protease | Streptococcus pyogenes (Nelson et al., 2011) | Wakabayashi et al., 1986; Baxa et al., 1988 |
| MARIT_2678 - 2687 | Sialoglycan degradation and uptake | Capnocytophaga canimorsus (Mally et al., 2008) |
| Sample items | %Agree |
| I am worried that other people might realize that I am HIV + if they see me taking my HIV medications. | 52 |
| I get frustrated taking my HIV medications because I have to plan my life around them. | 40 |
| I don’t like taking my HIV medications because they remind me that I am HIV + . | 40 |
| I feel that my healthcare provider takes my needs into account when making recommendations about which HIV medications to take. | 84 |
| Most people who are important to me who know I’m HIV positive support me in taking my HIV medications. | 88 |
| My healthcare provider doesn’t give me enough support when it comes to taking my medications as prescribed. | 24 |
| It frustrates me to think that I will have to take these HIV medications every day for the rest of my life. | 44 |
| I am worried that the HIV medications I have been prescribed will hurt my health. | 56 |
| It upsets me that the HIV medications I have been prescribed can affect the way I look. | 52 |
| It upsets me that the HIV medications I have been prescribed can cause side effects. | 64 |
| Smoking habit | Frequency among patients | Percentage | 95% Confidence interval |
| No | 106 | 77.9 | 70.1-84.2 |
| Yes | 27 | 19.9 | 13.9-27.5 |
| Unknown | 3 | 2.2 | 0.7-6.7 |
| No/minimal impairment(independent) | Moderate impairment(independent/unilateral support) | Severe impairment(bilateral support/wheelchair) | p value | ||
| Peroneal nerve | |||||
| Motor CV (m/sec) | CIDP | 40.4 ± 1.3 | 26.7 ± 14.7a | 21.0 ± 13.4 | 0.006 |
| MMN | 40.7 ± 6.8 | 37.2 ± 5.5 | 33.9 ± 3.1 | 0.099 | |
| CMAP amplitude (mV) | CIDP | 4.4 ± 3.0 | 1.7 ± 1.4a | 0.1 ± 0.2 | 0.016 |
| MMN | 3.1 ± 2.1 | 2.8 ± 1.8 | 1.1 ± 1.2 | 0.110 | |
| CSA popliteal fossa (mm2) | CIDP | 12.2 ± 3.1 | 17.9 ± 3.5a | 16.7 ± 2.0 | 0.045 |
| MMN | 10.5 ± 1.5 | 17.3 ± 4.3 | 14.0 ± 1.9 | 0.114 | |
| CSA fibular head (mm2) | CIDP | 8.8 ± 1.7 | 11.5 ± 3.0 | 11 ± 1.3 | 0.227 |
| MMN | 7.8 ± 1.5 | 10.5 ± 2.3 | 9.3 ± 2.3 | 0.112 | |
| Tibial nerve | |||||
| Motor CV (m/sec) | CIDP | 39.4 ± 6.6 | 32.7 ± 12.5 | 33.9 ± 0.9 | 0.121 |
| MMN | 37.4 ± 3.6 | 34.6 ± 4.5 | 35.9 ± 4.0 | 0.234 | |
| CMAP amplitude (mV) | CIDP | 3.9 ± 2.1 | 1.7 ± 2.4b | 0.3 ± 0.1 | 0.036 |
| MMN | 3.8 ± 1.1 | 2.3 ± 1.3 | 2.2 ± 2.7 | 0.048 | |
| CSA popliteal fossa (mm2) | CIDP | 15.9 ± 3.8 | 26.7 ± 4.1 | 19.7 ± 3.9 | 0.037 |
| MMN | 15.4 ± 3.9 | 23.8 ± 4.8 | 17.8 ± 2.2 | 0.241 | |
| CSA ankle (mm2) | CIDP | 12.6 ± 2.1 | 15.7 ± 3.8 | 11.8 ± 2.5 | 0.254 |
| MMN | 12.1 ± 2.4 | 14.5 ± 3.5b | 8.7 ± 2.0 | 0.032 | |
| Sural nerve | |||||
| Sensory CV (m/sec) | CIDP | 51.7 ± 3.3 | 25.1 ± 18.7 | 20.3 ± 18.3 | 0.255 |
| MMN | 48.8 ± 7.8 | 45.4 ± 1.6 | 44.4 ± 4.3 | 0.441 | |
| SNAP amplitude (μV) | CIDP | 4.5 ± 2.3 | 3.4 ± 3.7 | 1.7 ± 2.9 | 0.111 |
| MMN | 10.3 ± 6.1 | 9.9 ± 4.8 | 11.3 ± 5.4 | 0.638 | |
| CSA ankle (mm2) | CIDP | 3.3 ± 0.3 | 3.7 ± 0.8 | 3.3 ± 0.2 | 0.928 |
| MMN | 3.0 ± 1.1 | 2.7 ± 0.4 | 2.7 ± 0.5 | 0.958 |
| Mean (standard deviation) | Min value | Max value | |
| CGI-S | 4.16 (0.92) | 2 | 6 |
| PANSS total score | 79.4 (16.34) | 45 | 140 |
| PANSS positive score | 16.46 (5.15) | 7 | 33 |
| PANSS negative score | 23.19 (5.68) | 10 | 43 |
| PANSS general score | 39.75 (9.77) | 18 | 76 |
| V-SIR | 24.32 (7.82) | 9.4 | 49.19 |
| SCD total score | 7.6 (4.1) | 0 | 18 |
| Features | Patients | |
| n | Frequency % | |
| Gender | ||
| Males | 344 | 82.3 |
| Females | 74 | 17.7 |
| Age (years) | ||
| Min | 31 | |
| Max | 93 | |
| Mean ± SD | 66.7 ± 10.9 | |
| Median | 67 | |
| Smoking | ||
| Smokers | 283 | 67.7 |
| Nonsmokers | 117 | 28.0 |
| Not specified | 18 | 4.3 |
| Tumor stages | ||
| TIS | 1 | 0.2 |
| Ta | 91 | 21.8 |
| T1 | 198 | 47.4 |
| T2 | 72 | 17.2 |
| T3 | 27 | 6.5 |
| T4 | 27 | 6.5 |
| Not specified | 2 | 0.4 |
| Tumor grades | ||
| 1973 | ||
| CIS | 1 | 0.2 |
| G1 | 139 | 33.3 |
| G2 | 186 | 44.5 |
| G3 | 86 | 20.6 |
| Not specified | 6 | 1.4 |
| 2004 | ||
| PUNLMP | 11 | 2.6 |
| CIS | 1 | 0.2 |
| Low | 241 | 57.7 |
| High | 156 | 37.3 |
| Not specified | 9 | 2.2 |
| Recurrence | ||
| No | 268 | 64.1 |
| Yes | 150 | 35.9 |
| Groups | Ovarian weight | |
| mg | mg/g body weight | |
| Control | 22.79 ± 4.87 | 1.26 ± 0.29 |
| X-ray | 12.54 ± 8.06∗∗ | 0.71 ± 1.28∗∗ |
| NAC | 23.96 ± 5.46## | 1.19 ± 0.89## |
| NAC/X-ray | 20.79 ± 4.01## | 1.20 ± 0.28## |
| Final grade | ||||
| Grade | 1 | 2 | 3 | |
| Predicted grade | 1 | 21 | 0 | 0 |
| 2 | 5 | 35 | 9 | |
| 3 | 1 | 6 | 7 | |
| 1 or 2 | 7 | 1 | 1 | |
| 2 or 3 | 0 | 2 | 8 | |
| Not predicted | 1 | 1 | 0 |
| Nurse/midwives n = 13 | Doctors n = 05 | Administrators n = 06 | |
| Age (years) | |||
| <30 | 6 | 1 | 0 |
| 30-39 | 3 | 3 | 0 |
| 40-49 | 2 | 0 | 1 |
| ≥50 | 2 | 1 | 5 |
| Marital status | |||
| Single | 1 | 0 | 0 |
| Married | 12 | 5 | 6 |
| Widowed | 0 | 0 | 0 |
| Gender | |||
| Female | 13 | 0 | 0 |
| Male | 0 | 5 | 6 |
| Years of experience | |||
| 0-4 | 5 | 2 | 1 |
| 5-9 | 5 | 2 | 0 |
| 10-15 | 1 | 0 | 0 |
| 15+ | 2 | 1 | 5 |
| Hospital location | |||
| Urban | 8 | 4 | 3 |
| Peri-urban | 5 | 1 | 3 |
| Healthy sample | Overall sample | |||
| male | female | male | female | |
| N | 342 | 859 | 1275 | 1577 |
| Age , years | 46.2 ± 15.4 | 46.7 ± 13.8 | 52.5 ± 12.7 | 54.0 ± 14.9 |
| BaPWV, cm/s | 1339.3 ± 224.8 | 1294.8 ± 241.9 | 1524.8 ± 355.7 | 1578.6 ± 463.6 |
| BMI, kg/m2 | 23.8 ± 2.9 | 22.8 ± 2.9 | 24.7 ± 3.2 | 23.9 ± 3.4 |
| MAP, mmHg | 89.8 ± 7.3 | 85.3 ± 8.8 | 97.9 ± 18.8 | 94.7 ± 13.3 |
| SBP, mmHg | 123.9 ± 13.2 | 120.6 ± 12.1 | 131.8 ± 17.9 | 130.9 ± 20.9 |
| DBP, mmHg | 74.4 ± 7.5 | 70.2 ± 8.4 | 80.9 ± 24.1 | 76.6 ± 10.9 |
| Pulse pressure, mmHg | 46.0 ± 7.9 | 45.3 ± 9.1 | 50.9 ± 24.9 | 54.5 ± 14.9 |
| HR, beats/min | 70.8 ± 9.4 | 71.4 ± 9.4 | 70.9 ± 10.2 | 71.6 ± 10.1 |
| TC, mmol/L | 4.57 ± 0.81 | 4.75 ± 0.94 | 4.73 ± 0.94 | 5.09 ± 1.06 |
| HDL-C, mmol/L | 1.37 ± 0.29 | 1.44 ± 0.33 | 1.29 ± 0.29 | 1.39 ± 0.33 |
| LDL-C, mmol/L | 2.67 ± 0.62 | 2.75 ± 0.83 | 2.81 ± 0.76 | 3.02 ± 0.91 |
| TG, mmol/L | 1.53 ± 1.04 | 1.31 ± 0.87 | 1.80 ± 1.27 | 1.59 ± 0.99 |
| Fasting glucose, mmol/L | 4.9 ± 0.6 | 4.9 ± 0.5 | 5.4 ± 1.4 | 5.4 ± 1.6 |
| Hypertension, % | 0 | 0 | 50.3 | 47.8 |
| Diabetes, % | 0 | 0 | 23.7 | 21.1 |
| Smoking, % | 0 | 0 | 50.2 | 3.7 |
| Stroke, % | 0 | 0 | 7.2% | 6.5% |
| Ischemic heart disease, % | 0 | 0 | 10.9 | 7.1 |
| Medication | ||||
| ACEIs/ARBs, % | 0 | 0 | 9.9 | 8.9 |
| Statins, % | 0 | 0 | 6.6 | 4.9 |
| CCBs, % | 0 | 0 | 15.3 | 14.5 |
| Transcript ID | LG | Start position | Median reads per million (RPM) ± S.D. | Zebrafish homolog | |||
| Pacific Ocean males | Pacific Ocean females | Japan Sea males | Japan Sea females | ||||
| ENSGACT00000029029 | I | 7684495 | 2852.3 (227.8) | 4343.0 (1716.7) | 10218.3 (1270.0) | 4026.2 (860.8) | mir22a-1 |
| ENSGACT00000028961 | III | 7312510 | 563.3 (78.4) | 1250.9 (684.9) | 3683.1 (408.8) | 1115.0 (176.9) | mir7a-3 |
| ENSGACT00000028970 | VI | 4231011 | 2465.3 (127.5) | 2270.1 (62.9) | 1858.6 (244.0) | 1966.8 (141.3) | mir30c |
| ENSGACT00000029035 | XI | 1952924 | 9700.4 (165.6) | 11004.3 (1503.8) | 14871.2 (475.2) | 12259.0 (332.2) | mir152 |
| ENSGACT00000028984 | XIII | 7256736 | 609.2 (80.5) | 1294.3 (679.4) | 3601.1 (393.0) | 1134.8 (168.2) | mir7b |
| ENSGACT00000029072 | XIX | 2936579 | 547.6 (75.4) | 1228.1 (681.4) | 3503.5 (381.2) | 1073.8 (169.6) | mir7a-1 |
| ENSGACT00000029039 | XX | 15698389 | 568.3 (73.6) | 1245.5 (680.7) | 3560.3 (396.7) | 1099.6 (167.8) | mir7a-2 |
| If Rvala ≤ value | If Rval ≥ value | ||||||
| Study | Value | Intercept 1 | X1b | Value | Intercept 2 | X2b | R2 |
| GNHIES98 | 73.2698 | −0.2256 | 1.2197 | 73.2698 | 49.0336 | 0.5474 | 0.94 |
| DEGS1 | 121.9968 | 14.5310 | 0.7715 | 121.9968 | 102.1919 | 0.0530 | 0.79 |
| KiGGS | 60.5211 | 9.4005 | 1.0225 | 60.5211 | 52.4099 | 0.3119 | 0.81 |
| Cardiovascular risk indicators | 20 – 39 years | 40 – 59 years | ≥ 60 years | Total | p-value* |
| Total cholesterol (mg/dl) | 0.871 | ||||
| Normal | 238 (91.2) | 100 (90.9) | 78 (92.9) | 416 (91.4) | |
| Risk | 23 (8.8) | 10 (9.1) | 6 (7.1) | 39 (8.6) | |
| HDL-cholesterol (mg/dl) | 0.035 | ||||
| Normal | 78 (29.9) | 38 (34.5) | 38 (45.2) | 154 (33.8) | |
| Risk | 183 (70.1) | 72 (65.5) | 46 (54.8) | 301 (66.2) | |
| LDL-cholesterol (mg/dl) | 0.448 | ||||
| Normal | 242 (98.8) | 93 (96.9) | 77 (98.7) | 412 (98.3) | |
| Risk | 3 (1.2) | 3 (3.1) | 1 (1.3) | 7 (1.7) | |
| Triglycerides (mg/dl) | 0.003 | ||||
| Normal | 120 (46.0) | 41 (37.3) | 52 (61.9) | 213 (46.8) | |
| Risk | 141 (54.0) | 69 (62.7) | 32 (38.1) | 242 (53.2) | |
| Castelli index I | 0.128 | ||||
| Normal | 225 (86.2) | 94 (85.5) | 79 (94.) | 398 (87.5) | |
| Risk | 36 (13.8) | 16 (14.5) | 5 (6.0) | 57 (12.5) | |
| Castelli index II | 0.033 | ||||
| Normal | 227 (92.7) | 94 (97.9) | 77 (98.7) | 398 (95.0) | |
| Risk | 18 (7.3) | 2 (2.1) | 1 (1.3) | 21 (5.0) | |
| TG/HDL-C ratio | < 0.001 | ||||
| Normal | 98 (37.5) | 35 (31.8) | 49 (58.3) | 182 (40.0) | |
| Risk | 163 (62.5) | 75 (68.2) | 35 (41.7) | 274 (60.0) | |
| ApoB/ApoA1 ratio | 0.128 | ||||
| Normal | 229 (88.4) | 102 (92.7) | 79 (95.2) | 410 (90.7) | |
| Risk | 30 (11.6) | 8 (7.3) | 4 (4.8) | 42 (9.3) | |
| Framingham | < 0.001 | ||||
| Low risk | 261 (100.0) | 79 (71.8) | 1 (1.2) | 34 (74.9) | |
| Intermediate risk | 0 (0.0) | 24 (21.8) | 21 (25.0) | 45 (9.9) | |
| High risk | 0 (0.0) | 7 (6.4) | 62 (73.8) | 69 (15.2) | |
| Hs-CRP (mg/L) | 0.867 | ||||
| Low risk | 47 (18.0) | 19 (17.3) | 17 (20.5) | 83 (18.3) | |
| Intermediate risk | 102 (39.1) | 42 (38.2) | 27 (32.5) | 171 (37.7) | |
| High risk | 112 (42.9) | 49 (44.5) | 39 (47.0) | 200 (44.1) | |
| BMI (kg/m2) | < 0.001 | ||||
| Normal | 33 (12.6) | 10 (9.1) | 42 (50.0) | 85 (18.7) | |
| Risk | 228 (87.4) | 100 (90.9) | 42 (50.0) | 370 (81.3) | |
| Waist circumference (cm) | < 0.001 | ||||
| Normal | 118 (45.2) | 27 (24.5) | 41 (48.8) | 186 (40.9) | |
| Risk | 143 (54.8) | 83 (75.5) | 43 (51.2) | 269 (59.1) | |
| Hypertriglyceridemic waist | 0.001 | ||||
| Normal | 164 (62.8) | 54 (49.1) | 64 (76.2) | 282 (62.0) | |
| Risk | 97 (37.2) | 56 (50.9) | 20 (23.8) | 173 (38.0) | |
| Glycemia (mg/dL) | < 0.001 | ||||
| Low risk | 160 (61.3) | 46 (41.8) | 36 (42.9) | 242 (53.2) | |
| High risk | 101 (38.7) | 64 (58.2) | 48 (57.1) | 213 (46.8) | |
| Blood pressure (mm/Hg) | < 0.001 | ||||
| Low risk | 236 (90.4) | 86 (78.2) | 51 (60.7) | 373 (82.0) | |
| High risk | 25 (9.6) | 24 (21.8) | 33 (39.3) | 82 (18.0) |
| Total | N/100 orders | N/100 admissions | N/1000 patient-days | |
| Orders | 4942 | NA* | 7844 | 9709 |
| Medication error | 492 | 10 | 780 | 967 |
| Adverse drug events | 8 | 0.16 | 12.6 | 15.7 |
| Potential adverse drug events | 113 | 2.28 | 179.3 | 222 |
| Parameters | Value |
| Plant life | 30 years |
| Discount rate | 10% |
| Financing | 40% equity |
| Loan terms | 10-year loan at 8% APR |
| General plant depreciation | 200% declining balancea |
| General plant recovery period | 7 years |
| Steam plant depreciation | 150% declining balance |
| Steam plant recovery period | 20 years |
| Construction period | 3 years |
| 0-12 months | 8% of project cost |
| 12-24 months | 60% of project cost |
| 24-36 months | 32% of project cost |
| Working capital | 5% of fixed capital investment |
| Start-up time | 3 months |
| Revenues during start-up | 50% |
| Variable costs incurred during start-up | 75% |
| Fixed costs incurred during start-up | 100% |
| Patient characteristics | |
| Male/female | 49 (63.6%)/28 (36.4%) |
| Birth weight (gr) | 2930 ± 485 (range 4300-1800) |
| Gestational age at delivery (wk) | 37 ± 2 (range 42–32) |
| Term/preterm delivery | 40 (52%)/37 (48%) |
| Left/right side | 67 (87%)/10 (13%) |
| Inborn/outborn | 71 (92.2%)/6 (7.8%) |
| Prenatal diagnosis | 68 (88.3%) |
| Associated anomalies | 18 (23.4%) |
| Associated congenital heart diseases | 4 (5.2%) |
| date (day of chth) | ||
| (I day) | 1. | Doxorubicin 80 mg i.v. |
| 2. | Cis-Platinium 40 mg i.v. | |
| 3. | 5-FU 800 mg i.v. | |
| 4. | Roferon 9 MU | |
| (II day) | 1. | Cis-Platinium 40 mg i.v. |
| 2. | 5-FU 800 mg i.v. | |
| 3. | Roferon 9 M U | |
| (III day) | 1. | Cis-Platinium 40 mg i.v. |
| 2. | 5-FU 800 mg i.v. | |
| 3. | Roferon 9 M U | |
| (IV day) | 1. | Cis-Platinium 40 mg i.v. |
| 2. | 5-FU 800 mg i.v. | |
| 3. | Roferon 9 M U |
| Characteristics | mRNA profiling | microRNA profiling | Total subjects | ||||||
| Trisomy 21 (n = 3) | Normal (n = 5) | P value | Trisomy 21 (n = 4) | Normal (n = 5) | P value | Trisomy 21 (n = 7) | Normal (n = 10) | P value | |
| Maternal Age (years) | 34.6 ± 3.8 | 37.4 ± 3.9 | 0.853 | 30.3 ± 2.2 | 34.2 ± 3.1 | 0.628 | 32.1 ± 3.6 | 35.8 ± 3.7 | 0.062 |
| Gestational age (weeks) | 12.0 ± 0.0 | 12.2 ± 0.4 | 0.092 | 12.2 ± 0.4 | 12.4 ± 0.7 | 0.071 | 12.1 ± 0.4 | 12.3 ± 0.6 | 0.454 |
| Body mass index (kg/m2) | 22.3 ± 3.7 | 24.4 ± 6.2 | 0.545 | 21.8 ± 3.3 | 21.5 ± 1.2.2 | 0.874 | 22.0 ± 3.2 | 22.9 ± 4.7 | 0.659 |
| Gravidity | 2.7 ± 1.2 | 2.8 ± 0.8 | 0.446 | 1.8 ± 1.0 | 3.0 ± 1.6 | 0.210 | 2.1 ± 1.1 | 2.9 ± 1.2 | 0.201 |
| Nuchal translucency (mm) | 3.7 ± 1.4 | 4.9 ± 1.9 | 0.402 | 4.2 ± 0.8 | 3.3 ± 1.5 | 0.377 | 4.0 ± 1.0 | 4.1 ± 1.8 | 0.862 |
| Nullipara | 2 | 1 | 0.146 | 2 | 1 | 0.524 | 4 | 2 | 0.162 |
| Gender-ratio (female:male) | 1:2 | 1:4 | 1.000 | 1:3 | 1:4 | 1.000 | 2:5 | 2:8 | 1.000 |
| Characteristics | Patients |
| Median age (y) (range) | 52 (36–76) |
| Median parity (range) | 3 (0–9) |
| Median BMI (range) | 31.2 (21.4–41.5) |
| Prior surgery for prolapse including hysterectomy (n, %) | 3 (15) |
| Prior hysterectomy for benign tumor (n, %) | 4 (20) |
| Stage of prolapse | |
| Stage II (n, %) | 6 (30) |
| Stage III (n, %) | 12 (60) |
| Stage IV (n, %) | 2 (10) |
| Urinary incontinence (n, %) | 16 (80) |
| Sources of Attrition | N (%) | AAa (%) | EAa (%) | p-valuec,d |
| Deceased | 118 (26) | 59 (50) | 59 (50) | 1.000 |
| Frail | 23 (5) | 13 (57) | 10 (44) | 0.532 |
| Lost to Follow-Up | 87 (19) | 69 (79) | 18 (21) | < 0.001 |
| Passive Refusal | 29 (6) | 22 (76) | 7 (24) | 0.005 |
| Active Refusale | 206 (45) | 103 (50) | 103 (50) | 1.000 |
| Total | 463 (100) | 266 (58) | 197 (43) | 0.001 |
| Univariate analysis | Mulivariate analysis | |||||
| β | 95% CI | p | βadj | 95% CI | p | |
| Age of mother | −0.03 | (− 0.08,0.02) | 0.25 | 0.05 | (0.03,0.08) | < 0.0001 |
| Age of mother at birth of the first children | - 0.05 | (−0.02,-0.13) | 0.02 | −0.01 | (−0.04,0.01) | 0.39 |
| NUMBER OF CHILDERN | −0.23 | (−0.52,0.06) | 0.12 | 0.09 | (−0.20,0.42) | 0.50 |
| Mother’s Educational level | ||||||
| None | 1 | 1 | ||||
| 1 to 5 years | −1.04 | (−1.38,-0.70) | < 0.001 | 0.49 | (0.07,0.92) | 0.02 |
| 6 to 12 | −0.74 | (−1.13,-0.37) | < 0.001 | 1.18 | (0.79,1.58) | < 0.001 |
| University | 1.11 | (0.56,1.65) | < 0.001 | 2.07 | (1.43,2.71) | < 0.001 |
| Mother’s employment status, workinga | 1.42 | (0.34,2.50) | 0.01 | 1.70 | (0.69,2.8) | 0.003 |
| Children health status, chronic illnessb | −0.07 | (−0.45,0.30) | 0.70 | |||
| Family income | ||||||
| Low | 1 | 1 | ||||
| Medium | 0.60 | (0.22, 0.99) | 0.002 | 0.38 | (0.01,0.76) | 0.04 |
| High | - 1.20 | (−0.32,-2.09) | 0.007 | 0.45 | (− 0.43,1.33) | 0.31 |
| Activities | Advantages | Specific challenges | Response |
| School meetings | • Easy to organize | • Low attendance | • Follow-up school meetings organized |
| • Resource and time efficient | • Consenting decisions may be influenced by other parents | • Meetings held outside classrooms to minimize disruption | |
| • Follow-up consent meetings allowed time for consultations | • Disruption to school schedules | • Insistence on parental consent | |
| • Danger of proxy consent from relatives | • Household visits | ||
| Household visits | • Allows for more in-depth and one-on-one discussions of the study | • Difficulties in tracking households | • Use of village elders/community health workers to track parents |
| • Eliminates pressure and influence associated with school meetings | • Unavailability of parents at home | • Field workers sent to households early in the morning or late in the evening | |
| • Can allow joint decision-making to participate in research | • Time consuming | ||
| • Resource intensive |
| Fluorescent real-time PCR | Orientation | Sequencea (5'---3') | Amplicon length (bp) |
| TaqMan | Sense | CCGCCTTTGAGTGAGCTGATA | 210 |
| Anti-sense | TGTAGACAACATCCCCTCCCC | ||
| Probe | FAM CGCCGCAGCCGAACGACCGAG TAMRA | ||
| Sense | GTATTACCGCCTTTGAGTGAGCT | 510 | |
| Anti-sense | ATGACAATCAGCTACTTCACTGTTG | ||
| Probe | FAM CGCCGCAGCCGAACGACCGAG TAMRA | ||
| Sense | CCGCCTTTGAGTGAGCTGATA | 992 | |
| Anti-sense | CTCCGCTGGTCCGATTGAAC | ||
| Probe | FAM CGCCGCAGCCGAACGACCGAG TAMRA | ||
| Sense | CCGCCTTTGAGTGAGCTGATA | 1596 | |
| Anti-sense | AATGGTTTCTGACGTATGTGCTTAG | ||
| Probe | FAM CGCCGCAGCCGAACGACCGAG TAMRA | ||
| UTa | Sense | taggaacaggcggcgacgaATACAA CATCCGCTTGCCCTCATC | 195 |
| Anti-sense | TGCCAAAGGGTTCGTGTAG | ||
| Sense | taggaacaggcggcgacga ATACAA CATCCGCTTGCCCTCATC | 546 | |
| Anti-sense | GGGATAACGCAGGAAAGAACAT | ||
| Sense | CAGACGTGAAACCCAACATACC | 1032 | |
| Anti-sense | Taggaacaggcggcgacga ATACAA CCCAATAGCAGCCAGTCCCT | ||
| Sense | taggaacaggcggcgacga ATACAA TCTGCTGTAGTGAGTGGGTTGC | 1630 | |
| Anti-sense | GCCGATTGTCTGTTGTGCC | ||
| UT probe | FAM TCGTCGCCGCCTGTTCCTA TAMRA | ||
| AUDP probeb | Sense | taggaacaggcggcgacgagcgtgggacataAAACTCCATCCGCTTGCCCTCATC | 195 |
| Anti-sense | TGCCAAAGGGTTCGTGTAG | ||
| Sense | taggaacaggcggcgacgagcgtgggacataAAACTCCATCCGCTTGCCCTCATC | 546 | |
| Anti-sense | GGGATAACGCAGGAAAGAACAT | ||
| Sense | CAGACGTGAAACCCAACATACC | 1032 | |
| Anti-sense | taggaacaggcggcgacgagcgtgggacataAAACTCCCCAATAGCAGCCAGTCCCT | ||
| Sense | taggaacaggcggcgacgagcgtgggacataAAACCTCTCTGCTGTAGTGAGTGGGTTGC | 1630 | |
| Anti-sense | GCCGATTGTCTGTTGTGCC | ||
| FP | FAM TAGGAACAGGCGGCGACGAGCGTGGGACATA | ||
| QP | AGTCGTCGCCGCCTGTTCCTA Dabcyl |
| Compounds | |||||||||
| C | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 |
| 1 | 38.7 | 38.3a | 32.9 | 37.5 | 155.3 | 37.4 | 158.6 | 155.1 | 155.0 |
| 2 | 38.2 | 32.1 | 30.6 | 34.2 | 127.7 | 34.1 | 125.1 | 127.8 | 127.8 |
| 3 | 211.8 | 71.8 | 67.2 | 200.3 | 186.3 | 199.9 | 186.7 | 186.2 | 186.2 |
| 4 | 44.5 | 38.9 | 36.7 | 124.6 | 124.2 | 124.8 | 124.8 | 124.3 | 124.2 |
| 5 | 46.8 | 46.3 | 40.4 | 170.9 | 168.3 | 170.1 | 167.4 | 167.9 | 167.9 |
| 6 | 28.9 | 29.9 | 29.6 | 33.6 | 32.5 | 33.3 | 32.8 | 32.5 | 32.4 |
| 7 | 31.3 | 32.9 | 33.5 | 31.1 | 32.3 | 30.3 | 32.1 | 33.4 | 31.9 |
| 8 | 35.6 | 36.9 | 36.9 | 35.3 | 35.1 | 34.6 | 33.9 | 34.4 | 35.0 |
| 9 | 53.8 | 56.0 | 56.1 | 59.2 | 52.2 | 59.2 | 60.4 | 52.1 | 51.9 |
| 10 | 35.8 | 36.7 | 37.2 | 39.9 | 43.4 | 40.0 | 43.9 | 43.4 | 43.3 |
| 11 | 21.0 | 21.9 | 21.5 | 68.9 | 22.1 | 68.7 | 67.7 | 36.1 | 21.7 |
| 12 | 36.8 | 38.1a | 38.1 | 48.5 | 31.1 | 42.9 | 42.3 | 86.0 | 30.9 |
| 13 | 43.1 | 44.1 | 44.1 | 43.7 | 47.7 | 47.9 | 47.8 | 42.7 | 38.7 |
| 14 | 50.9 | 52.4 | 52.5 | 49.8 | 50.4 | 50.0 | 49.6 | 44.1 | 47.3 |
| 15 | 23.5 | 24.3 | 24.3 | 23.3 | 21.9 | 21.7 | 21.8 | 22.2 | 30.6 |
| 16 | 30.6 | 30.6 | 29.7 | 30.6 | 35.6 | 35.7 | 35.8 | 35.5 | 71.1 |
| 17 | 81.9 | 82.5 | 82.6 | 81.0 | 220.1 | 218.4 | 218.3 | 216.2 | 218.3 |
| 18 | 11.1 | 11.7 | 11.7 | 12.3 | 13.8 | 14.6 | 14.6 | 11.5 | 14.1 |
| 19 | 11.5 | 12.8 | 11.6 | 18.4 | 18.7 | 18.3 | 18.7 | 18.7 | 18.7 |
| Variables | Univariate analysis | ||
| HR | 95% CI | P | |
| Age (< 65 vs. ≥65) | 1.47 | 0.68–3.17 | NS |
| Gender (female vs. male) | 0.74 | 0.29–1.84 | NS |
| Stage (I vs. II vs. III) | 1.64 | 1.00–2.69 | 0.049 |
| Histology (adeno vs. other) | 1.50 | 0.69–3.27 | NS |
| Lymph node status (negative vs. positive) | 2.09 | 0.95–4.60 | NS |
| pT status (pT1a-2b vs. pT3–4) | 2.65 | 1.25–5.62 | 0.011 |
| Differentiation (poor vs. well-moderate) | 0.80 | 0.37–1.75 | NS |
| Smoking (smokers vs. nonsmokers) | 0.48 | 0.18–1.23 | NS |
| COPD (present vs. absent) | 1.17 | 0.54–2.55 | NS |
| M1 macrophages in islets (high vs. low) | 2.83 | 1.20–6.68 | 0.017 |
| M1 macrophages in stroma (high vs. low) | 1.91 | 0.86–4.25 | NS |
| Total M1 macrophages (high vs. low) | 1.43 | 0.63–3.21 | NS |
| M2 macrophages in islets (high vs. low) | 1.43 | 0.66–1.43 | NS |
| M2 macrophages in stroma (high vs. low) | 1.00 | 0.73–1.37 | NS |
| Total M2 macrophages (high vs. low) | 0.31 | 0.13–0.75 | 0.009 |
| IL-10 | 0.74 | 0.35–1.55 | NS |
| TNF-α | 1.16 | 0.55–2.45 | NS |
| IFN-γ | 0.67 | 0.31–1.43 | NS |
| HR (OS) | lower CI (95%) | upper CI (95%) | p-value | ||
| Gender | male | 1.000 | 0.026 | ||
| female | 0.518 | 0.290 | 0.925 | ||
| Age | per year | 1.022 | 0.994 | 1.051 | 0.121 |
| pT | 1 | 1.000 | <0.001 | ||
| 2 | 3.345 | 1.918 | 5.834 | ||
| 3 | 1.693 | 0.875 | 3.276 | ||
| 4 | 2.068 | 0.223 | 19.211 | ||
| pN | 0 | 1.000 | 0.038 | ||
| 1 | 1.441 | 0.879 | 2.361 | ||
| 2 | 0.554 | 0.149 | 2.057 | ||
| 3 | 6.048 | 1.288 | 28.387 | ||
| CD3i | high | 1.000 | 0.011 | ||
| low | 1.925 | 1.159 | 3.200 | ||
| HR (OS) | lower CI (95%) | upper CI (95%) | p-value | ||
| Gender | male | 1.000 | 0.044 | ||
| female | 0.551 | 0.308 | 0.985 | ||
| Age | per year | 1.026 | 0.997 | 1.056 | 0.077 |
| pT | 1 | 1.000 | 0.001 | ||
| 2 | 3.025 | 1.736 | 5.272 | ||
| 3 | 1.723 | 0.893 | 3.325 | ||
| 4 | 2.962 | 0.343 | 25.556 | ||
| pN | 0 | 1.000 | 0.040 | ||
| 1 | 1.471 | 0.892 | 2.426 | ||
| 2 | 0.602 | 0.168 | 2.163 | ||
| 3 | 5.952 | 1.269 | 27.904 | ||
| CD3i | diffuse | 1.000 | 0.010 | ||
| Distribution | focal | 1.941 | 1.173 | 3.210 | |
| HR (OS) | lower CI (95%) | upper CI (95%) | p-value | ||
| Gender | male | 1.000 | 0.088 | ||
| female | 0.597 | 0.329 | 1.080 | ||
| Age | per year | 1.022 | 0.995 | 1.049 | 0.112 |
| pT | 1 | 1.000 | <0.001 | ||
| 2 | 3.415 | 1.978 | 5.895 | ||
| 3 | 1.956 | 1.013 | 3.777 | ||
| 4 | 5.081 | 0.529 | 48.760 | ||
| pN | 0 | 1.000 | 0.048 | ||
| 1 | 1.248 | 0.773 | 2.014 | ||
| 2 | 0.388 | 0.105 | 1.432 | ||
| 3 | 5.210 | 1.110 | 24.457 | ||
| PD-L1 TCs | high | 1.000 | 0.026 | ||
| low | 1.801 | 1.074 | 3.021 |
| Characteristics (Total n = 126) | |
| Maternal | |
| Age, year | 32.8 ± 5.0 |
| Ethnicity | |
| European | 104 (83%) |
| Maori | 8 (6%) |
| Pacific | 1 (1%) |
| Other | 13 (10%) |
| Skin color 2 | |
| Very light | 67 (53%) |
| Light | 51 (41%) |
| Intermediate | 5 (4%) |
| Dark | 3 (2%) |
| Primiparous | 37 (29%) |
| Tertiary education 3 | 90 (71%) |
| Pre-pregnancy BMI, kg/m2 Primiparous | 25.0 ± 6.2 |
| Smoker | 9 (7%) |
| Antenatal vitamin D supplement use 4 | 35 (28%) |
| Supplement intake IU/day 4 | |
| Consumers only | 339 ± 269 |
| Infant | |
| Gestation, week | 39.3 ± 1.1 |
| Gender, male | 61 (48%) |
| Birth weight, g | 3506 ± 495 |
| Birth Season | |
| Spring | 30 (24%) |
| Summer | 28 (22%) |
| Autumn | 28 (22%) |
| Winter | 40 (32%) |
| Skin color 2 | |
| Very light | 2 (2%) |
| Light | 64 (50%) |
| Intermediate | 51 (40%) |
| Dark | 9 (7%) |
| Exclusive breast feeding 5 | 90 (71%) |
| Breastfeeding at week 20 | 110 (87%) |
| Infant vitamin D intake, 6 IU/day | |
| Consumers only | 96 ± 146 |
| Primer | Sequence (5' - 3') | Product size | Position in coding sequence | Reference |
| erm(A)-F | CCCGAAAAATACGCAAAATTTCAT | 590 | 15-38 | [23] |
| erm(A)-R | CCCTGTTTACCCATTTATAAACG | 604-582 | ||
| erm(B)-F | TGGTATTCCAAATGCGTAATG | 745 | 203-183 | |
| erm(B)-R | CTGTGGTATGGCGGGTAAGT | 541-522 | ||
| mef(A)-F* | CAATATGGGCAGGGCAAG | 317 | 38-55 | |
| mef(A)-R* | AAGCTGTTCCAATGCTACGG | 352-333 | ||
| tet(M)-F | GTGGACAAAGGTACAACGAG | 406 | 106-125 | |
| tet(M)-R | CGGTAAAGTTCGTCACACAC | 511-492 | ||
| tet(O)- F | AACTTAGGCATTCTGGCTCAC | 515 | 13-43 | |
| tet(O)- R | TCCCACTGTTCCATATCGTCA | 527-507 | ||
| tet(K)-F | GATCAATTGTAGCTTTAGGTGAAGG | 155 | 344-368 | |
| tet(K)-R | TTTTGTTGATTTACCAGGTACCATT | 498-474 | ||
| tet(L)-F | TGGTGGAATGATAGCCCATT | 229 | 384-403 | |
| tet(L)-R | CAGGAATGACAGCACGCTAA | 612-593 | ||
| 16S-rDNA-F | GAGTACGACCGCAAGGTTGA | 100 | 886-905 | |
| 16S-rDNA -R | CTGGTAAGGTTCTTCGCGTTG | 985-964 | ||
| ss-Tn916-1 | GCCATGACCTATCTTATA | 476 | 16083-16100 | [24] |
| ss-Tn916-2 | CTAGATTGCGTCCAA | 16559-16545 | ||
| tet(32)For | GAACCAGATGCTGCTCTT | 620 | 619-637 | [28] |
| Tet(32)Rev | CATAGCCACGCCCACATGAT | 1239-1220 | ||
| SScps2J-F | CAAACGCAAGGAATTACGGTATC | 236 | 209-231 | [29,30] |
| SScps2J-R | CATTTCCTAAGTCTCGCACC | 445-426 | ||
| tet(L)Ng-F | TCGTTAGCGTGCTGTCATTC | 698 | 680-700 | [31] |
| tet(L)-R-pDG364 | CTTAGAAATCCCTTTGAGAAT | 1378-1358 | This study | |
| tet(W)- F | TTGGAATTCTTGCCCATGTAGACGC | 1872 | 18-42 | This study |
| tet(W)- R | TTGTCCAGGCGGTTGTTTGGAC | 1889-1868 | ||
| tet(W)-F-HN | GGTGCAGTTGGAGGTTGTTT | 410 | 1179-1198 | |
| tet(W)-R-HN | CCTTCAATGCCTGTTCCAAT | 1569-1588 | ||
| tet(O)-F-pDG364 | ATGAAAATAATTAACTTAGG | 1920 | 1-19 | |
| tet(O)-R-pDG364 | TTAAGCTAACTTGTGGAACA | 1920-1901 | ||
| ss-tet(M)-whole-F | ACAGACAAAGAACTATCCTTAATG | 2500 | 419-396 | |
| ss-tet(M)-whole-R | GTACCCAGTTTAAGAATACCTTTATC | 161-136 | ||
| Additional primers used for sequencing | ||||
| tet(O)-2-F | TTCAAGACGCCTCCCTGTTC | 679-698 | This study | |
| tet(O)-2-R | ATTTGGCGGGACTTCTATGTGG | 1318-1296 | ||
| ss-tet(M)-Fseq1 | GTTAAATCACTACGATAT | 1763-1745 | ||
| ss-tet(M)-Rseq1 | ATAGTGTTCTTGGAGATA | 906-929 | ||
| ss-tet(M)-Fseq2 | GTATAATTTCATGTGTCG | 1162-1144 | ||
| ss-tet(M)-Rseq2 | AGATGGCGTACAAGCACA | 305-323 | ||
| ss-PAI-P8-tet(M)-R | GCCCTTTTGGGTTTTTGAAT | -33- -14 | ||
| ss-PAItetM-P9over F | GGGAATCCCCATTTTCCTAA | 366-347 |
| theoretical | measured | ||
| mass content | mass content | molar composition | |
| C | 53.0 ± 0.9% | 47.3 ± 0.1% | 1 |
| H | 6.6 ± 0.1% | 6.83 ± 0.04% | 1.733 |
| O | 23.2 ± 0.7% | 32.0 ± 0.8% | 0.508 |
| N | 16.7 ± 0.2% | 12.7 ± 0.5% | 0.23 |
| S | 1.6 ± 0.5% | 1.00 ± 0.05% | 0.008 |
| Total | 100.1 ± 2.4% | 99.7 ± 0.6% |
| Initial Experiment Results | Enhanced Results | ||
| Total Length Ratio | RMSE (m) | Total Length Ratio | RMSE (m) |
| 0.94 | 3.2 | 0.96 | 0.93 |
| Acute | Chronic | No Pain | p Value | |
| Total Number (n = 218) | 140 (64) | 33 (15) | 45 (21) | |
| Age n (%) | 0.897 | |||
| 19–25 | 97 (69) | 23 (70) | 33 (73) | |
| 26+ | 42 (30) | 10 (30) | 12 (27) | |
| Sex n (%) | 0.066 | |||
| Male | 50 (36) | 14 (42) | 25 (56) | |
| Female | 89 (64) | 19 (58) | 20 (44) | |
| Year in program n (%) | 0.490 | |||
| First year | 46 (33) | 15 (45) | 18 (40) | |
| Second year | 52 (37) | 12 (36) | 13 (29) | |
| Third year | 41 (29) | 6 (18) | 14 (31) | |
| Pain intensity mean (SD) 1 | 5.2 (2.0) | 5.9 (1.7) | - | 0.035 2 |
| Level of pain tolerated mean (SD) 1 | 6.1 (1.9) | 6.3 (1.8) | - | 0.544 |
| White (n = 93,325) | Black (n = 8,718) | Hispanic (n = 24,078) | Asian/Pacific Islander (n = 16,476) | American Indian (n = 587) | Total N = 143,184 | |
| Mean age in years ± SD | 61.49 ± 13.47 | 57.72 ± 13.51 | 55.13 ± 13.35 | 55.87 ± 12.93 | 57.50 ± 12.44 | 59.53 ± 13.67 |
| Age | ||||||
| <45 | 12.1% | 19.4% | 25.5% | 22.6% | 16.5% | 22,944 |
| 46–69 | 58.9% | 59.9% | 58.4% | 61.1% | 66.1% | 84,704 |
| 70+ | 29.0% | 20.7% | 16.0% | 16.2% | 17.4% | 35,536 |
| AJCC stage | ||||||
| Stage 1 | 50.7% | 37.1% | 38.3% | 45.0% | 43.8% | 67,435 |
| Stage 2 | 37.1% | 43.4% | 42.8% | 41.6% | 38.3% | 55,782 |
| Stage 3 | 9.5% | 14.5% | 15.3% | 10.6% | 13.6% | 15,664 |
| Stage 4 | 2.7% | 5.1% | 3.6% | 2.8% | 4.3% | 4,303 |
| ER/PR/HER2 subtype | ||||||
| ER+/PR+/HER2− | 61.3% | 44.2% | 52.2% | 56.1% | 56.9% | 83,169 |
| ER+/PR+/HER2+ | 8.7% | 8.9% | 10.3% | 11.3% | 9.5% | 13,293 |
| ER+/PR−/HER2− | 9.7% | 10.1% | 8.7% | 8.0% | 9.7% | 13,363 |
| ER+/PR−/HER2+ | 3.0% | 3.3% | 3.4% | 3.6% | 3.6% | 4,535 |
| ER−/PR+/HER2− | 0.7% | 1.1% | 1.0% | 0.8% | 0.7% | 1,131 |
| ER−/PR+/HER2+ | 0.3% | 0.6% | 0.6% | 0.4% | 0.2% | 539 |
| ER−/PR−/HER2− | 11.2% | 24.5% | 15.9% | 11.0% | 14.0% | 18,299 |
| ER−/PR−/HER2+ | 5.2% | 7.3% | 7.9% | 8.8% | 5.5% | 8,855 |
| Socioeconomic status (SES) | ||||||
| SES1-low | 6.6% | 25.4% | 28.0% | 7.2% | 18.4% | 16,424 |
| SES2 | 13.8% | 24.9% | 24.4% | 14.3% | 25.7% | 23,383 |
| SES3 | 20.2% | 21.8% | 20.1% | 19.3% | 26.1% | 28,953 |
| SES4 | 26.1% | 17.6% | 16.2% | 26.9% | 18.7% | 34,332 |
| SES5-high | 33.3% | 10.3% | 11.4% | 32.3% | 11.1% | 40,092 |
| Tumor grade | ||||||
| Well differentiated; grade I (low) | 25.6% | 14.5% | 16.9% | 18.3% | 20.3% | 32,367 |
| Moderately differentiated; grade II (low) | 43.7% | 35.1% | 40.2% | 43.0% | 42.6% | 60,820 |
| Poorly differentiated; grade III (high) | 29.5% | 48.4% | 41.1% | 37.3% | 36.1% | 47,969 |
| Undifferentiated; grade IV (high) | 1.3% | 2.0% | 1.8% | 1.3% | 1.0% | 2,028 |
| Tumor size (mm) | ||||||
| <1–4.99 | 6.3% | 4.8% | 5.0% | 6.7% | 5.6% | 8,650 |
| 5.00–9.99 | 18.7% | 12.0% | 12.6% | 14.5% | 14.3% | 23,968 |
| 10.00–19.99 | 38.6% | 33.0% | 34.2% | 36.1% | 35.8% | 53,306 |
| 20.00–49.99 | 28.7% | 36.9% | 36.6% | 34.0% | 32.9% | 44,623 |
| 50.00+ | 7.7% | 13.3% | 11.6% | 8.6% | 11.4% | 12,637 |
| Threshold | Net benefit | Point Estimate | Bootstrap Mean | Bootstrap confidence interval | |
| For: | (2000 replications) | 2.5th percentile | 97.5th percentile | ||
| 15 | All | 0.1288 | 0.1288 | 0.0922 | 0.1669 |
| Base | 0.1288 | 0.1290 | 0.0922 | 0.1669 | |
| Full | 0.1590 | 0.1613 | 0.1280 | 0.1955 | |
| Full vs All | 0.0302 | 0.0325 | 0.0172 | 0.0490 | |
| Full vs Base | 0.0302 | 0.0322 | 0.0170 | 0.0488 | |
| 25 | All | 0.0126 | 0.0126 | -0.0288 | 0.0559 |
| Base | 0.0748 | 0.0735 | 0.0432 | 0.1036 | |
| Full | 0.1167 | 0.1214 | 0.0919 | 0.1522 | |
| Full vs All | 0.1041 | 0.1088 | 0.0802 | 0.1369 | |
| Full vs Base | 0.0419 | 0.0479 | 0.0257 | 0.0712 | |
| 35 | All | -0.1393 | -0.1393 | -0.1871 | -0.0894 |
| Base | 0.0428 | 0.0410 | 0.0181 | 0.0662 | |
| Full | 0.0940 | 0.0965 | 0.0652 | 0.1291 | |
| Full vs All | 0.2333 | 0.2358 | 0.1990 | 0.2712 | |
| Full vs Base | 0.0511 | 0.0555 | 0.0293 | 0.0836 | |
| 60 | All | -0.8514 | -0.8513 | -0.9291 | -0.7703 |
| Base | 0.0149 | 0.0159 | -0.0041 | 0.0378 | |
| Full | 0.0547 | 0.0569 | 0.0331 | 0.0838 | |
| Full vs All | 0.9061 | 0.9083 | 0.8345 | 0.9824 | |
| Full vs Base | 0.0399 | 0.0410 | 0.0176 | 0.0676 | |
| 80 | All | -2.7027 | -2.7026 | -2.8581 | -2.5405 |
| Base | -0.0149 | -0.0028 | -0.0230 | 0.0243 | |
| Full | 0.0189 | 0.0223 | -0.0054 | 0.0527 | |
| Full vs All | 2.7216 | 2.7249 | 2.5649 | 2.8757 | |
| Full vs Base | 0.0338 | 0.0251 | 0.0000 | 0.0595 |
| AIM HI | CPRT | |
| Initial didactic training—lecture material, video examples, case illustrations, and hands-on practice with coaching and discussion | 12 h (over 2 days) | 8 h |
| Ongoing consultation/coaching—occurs while provider delivers intervention to target child and includes video-based feedback1 | 11 1-h sessions over 6 months (9 group, 2 indiv.) | 4 1-h group sessions and 6 individual coaching sessions over 5 months |
| Total length of training | 22 h/6 months | 18 h/6 months |
| Category | No. of children | No. of diarrheal episodes | Total time at risk (years) | Diarrheal incidence (episodes/child year) | Unadjusted IRR (95% CI) | Adjusted IRR* (95% CI) | P value |
| Study arm | |||||||
| No intervention | 109 | 85 | 80.8 | 1.05 (0.85–1.30) | Ref | Ref | – |
| Intervention (without safe storage) | 65 | 54 | 44.1 | 1.22 (0.94–1.60) | 1.15 (0.75–1.77) | 1.14 (0.75–1.77) | 0.530 |
| Intervention (with safe storage) | 102 | 61 | 76.8 | 0.79 (0.62–1.02) | 0.77 (0.52–1.14) | 0.76 (0.51–1.13) | 0.178 |
| Gender | |||||||
| Male | 146 | 102 | 102.7 | 0.99 (0.82–1.20) | Ref | Ref | – |
| Female | 130 | 98 | 99.0 | 0.98 (0.81–1.21) | 1.00 (0.71–1.40) | 1.05 (0.74–1.48) | 0.790 |
| Age of child (months)† | |||||||
| 0–6 | 94 | 37 | 40.9 | 0.90 (0.65–1.25) | Ref | Ref | – |
| 6–12 | 62 | 67 | 52.4 | 1.28 (1.00–1.62) | 1.32 (0.87–2.00) | 1.30 (0.85–1.98) | 0.222 |
| 12–18 | 58 | 44 | 59.1 | 0.75 (0.55–1.00) | 0.75 (0.47–1.21) | 0.74 (0.46–1.19) | 0.221 |
| 18–24 | 43 | 52 | 48.8 | 1.06 (0.81–1.40) | 1.09 (0.69–1.74) | 1.07 (0.67–1.70) | 0.783 |
| Factor | n | 2-year locoregional failure-free survival | 95% CI | P value |
| Age | 0.005 | |||
| Age ≤40 | 54 | 0.86 | 0.75–0.98 | |
| Age >40 | 158 | 0.98 | 0.95–1.00 | |
| Menopausal status | 0.52 | |||
| Premenopausal | 129 | 0.99 | 0.97–1.00 | |
| Postmenopausal | 84 | 0.97 | 0.91–1.00 | |
| BMI | 0.31 | |||
| BMI <30 | 72 | 0.95 | 0.88–1.00 | |
| BMI ≥30 | 83 | 0.97 | 0.92–1.00 | |
| T stage | 0.03 | |||
| Tis, T0–2 | 159 | 0.98 | 0.95–1.00 | |
| T3-4 | 47 | 0.89 | 0.78–1.00 | |
| N stage | 0.13 | |||
| N0 | 77 | 1.00 | 1.00-1.00 | |
| N+ | 128 | 0.94 | 0.88–1.00 | |
| Grading | 0.27 | |||
| G1-2 | 80 | 1.00 | 1.00-1.00 | |
| G3 | 93 | 0.93 | 0.86–1.00 | |
| Tumor subtype | 0.03 | |||
| Luminal A | 75 | 0.91 | 0.83–0.99 | |
| Others* | 114 | 0.99 | 0.97–1.00 | |
| Lymphovascular status | 0.02 | |||
| LV0 | 67 | 1.00 | 1.00-1.00 | |
| LV1 | 68 | 0.90 | 0.79–1.00 | |
| Type of surgery | 0.59 | |||
| Mastectomy | 121 | 0.96 | 0.91–1.00 | |
| BCS | 91 | 0.97 | 0.92–1.00 | |
| Residual tumor status | 0.56 | |||
| R0 | 163 | 0.97 | 0.93–1.00 | |
| R1 | 15 | 1.00 | 1.00-1.00 |
| A. Adolescents and adults | |||||
| Vaccination health states | Disease health states | ||||
| Local reaction | Systemic reaction | Mild cough | Severe cough | Pneumonia | |
| Mean (SD) adolescent utilities for short-term TTO (N = 94) | |||||
| 0% | 0.80 (0.32) | 0.68 (0.36) | 0.51 (0.39) | 0.35 (0.38) | 0.35 (0.37) |
| 5% | 0.95 (0.14) | 0.92 (0.16) | 0.87 (0.22) | 0.80 (0.28) | 0.80 (0.26) |
| 10% | 0.99 (0.03) | 0.99 (0.04) | 0.97 (0.08) | 0.96 (0.11) | 0.96 (0.08) |
| Mean (SD) adolescent utilities for long-term TTO (N = 81) | |||||
| 0% | 0.96 (0.06) | 0.92 (0.09) | 0.88 (0.10) | 0.82 (0.13) | 0.82 (0.14) |
| 5% | 0.97 (0.07) | 0.94 (0.11) | 0.91 (0.12) | 0.85 (0.18) | 0.85 (0.17) |
| 10% | 0.99 (0.05) | 0.97 (0.09) | 0.95 (0.11) | 0.91 (0.17) | 0.91 (0.15) |
| Mean (SD) adult utilities for short-term TTO (N = 72) | |||||
| 0% | 0.91 (0.24) | 0.83 (0.29) | 0.67 (0.38) | 0.58 (0.42) | 0.62 (0.40) |
| 5% | 0.97 (0.13) | 0.96 (0.14) | 0.90 (0.22) | 0.88 (0.23) | 0.88 (0.25) |
| 10% | 0.99 (0.04) | 0.99 (0.04) | 0.97 (0.07) | 0.97 (0.08) | 0.97 (0.08) |
| Mean (SD) adult utilities for long-term TTO (N = 56) | |||||
| 0% | 0.99 (0.02) | 0.97 (0.06) | 0.93 (0.09) | 0.88 (0.17) | 0.88 (0.18) |
| 5% | 1.0 (0.01) | 0.99 (0.03) | 0.97 (0.05) | 0.94 (0.13) | 0.94 (0.15) |
| 10% | 1.0 (0.00) | 1.0 (0.01) | 0.99 (0.02) | 0.97 (0.09) | 0.96 (0.12) |
| B. Infants | |||||
| Infant health states | |||||
| Infant respiratory complications | Infant neurologic complications | ||||
| Short-term TTO (N = 166) | |||||
| 0% | 0.27 (0.36) | 0.21 (0.33) | |||
| 5% | 0.71 (0.35) | 0.66 (0.36) | |||
| 10% | 0.92 (0.17) | 0.90 (0.19) | |||
| Long-term TTO (N = 147) | |||||
| 0% | 0.36 (0.18) | 0.33 (0.19) | |||
| 5% | 0.84 (0.21) | 0.78 (0.26) | |||
| 10% | 0.89 (0.20) | 0.84 (0.27) |
| Compound | Description | Applications | Remarks |
| In111-Capromab pendetide (ProstaScint) | A conjugation between the murine antibody 7E11.C5.3 and 111Inin the source of 111InCl3 by the action of the GYK-DTPA as a chelating agent. | Indicated for use in immunoscintigraphy, proven prostate carcinoma and patients who have undergone a prostatectomy and have rising prostate specific antigen (PSA) values and equivocal nonevidenced metastasis. | It is not indicated with patients with a high clinical suspicion of occult metastatic disease or for screening of prostate carcinoma. |
| In111-Satumomab pendetide (OncoScint) | It contains the murine MAb B72.3 which is directed to tumor-associated glycoprotein. It is labeled with 111InCl3 by conjugation with the chelating agent, GYK-DTPA.HCl. | Used for the detection of colorectal and ovarian cancers [35]. | After an incubation time of 30 min, the labeled mixture is suitable for use in the first 8 hours. |
| In111-Imciromab pentetate (MyoScint) | An antibody produced against myosin in the cell culture, and therefore binds to the heavy chain of myosin after in vivo administration. | Detection of myocardial infarction. | Contains the Fab fragment of a murine monoclonal antibody that is covalently bound to DTPA giving 111In -Imciromab pentetate. |
| In-111 and Y90-ibritumomab tiuxetan (Zevalin) | Zevalin consists of a murine monoclonal anti-CD20 antibody covalently conjugated to the metal chelator DTPA, which forms a stable complex with 111Infor imaging and with 90Y for therapy. | 90Y-ibritumomab tiuxetan is used for the treatment of some forms of B cell non-Hodgkin's lymphoma, a myeloproliferative disorder of the lymphatic system while its 111Inderivative is used to scan the predicted distribution of a therapeutic dosage of 90Y-ibritumomab in the body [36]. | The antibody binds to the CD20 antigen found on the surface of normal and malignant B cells (but not B cell precursors) allowing radiation from the attached isotope (Yetrium-90) and the cytotoxicity induced by the antibody serve to eliminate B cells from the body allowing a new population of healthy B cells to develop from lymphoid stem cells [37]. |
| Rituximab | An earlier version of anti-CD20 antibody and has also been approved under the brand name Rituxan for the treatment of non-Hodgkin's lymphoma (NHL). | It was approved for the treatment of patients with relapsed or refractory, lowgrade or follicular Bcell NHL, including patients with rituximab refractory follicular NHL. | In September 2009, ibritumomab received approval from the FDA for an expanded label for the treatment of patients with previously untreated follicular NHL, who achieve a partial or complete response to first-line chemotherapy. |
| Questions | Sub-questions |
| 1. What is the first thing that comes to mind when you hear the phrase “oral health”? | a. aWhat does “good oral health” mean to you?i. bWhen you think of your child, would you say that he or she has “good oral health”?ii. bHow would you describe a child who has good oral health?iii. bThink about your child’s friends, how would you describe those that have good oral health? |
| 2. What comes to mind when you hear the phrase “poor oral health”? | a. aWhen you think of your child, what could be thought of as poor oral health?i. bWhat could be thought as the worst thing for poor oral health?ii. bHow would you describe a child with poor oral health?b. aHow much of a problem is this among children in your family?i. bHow common is it among children in other families who live in this community? Among your friends?ii. bHow concerned are you about your son or daughter developing dental problems (dental decay)? |
| 3. As parents, how do you help your child have healthy teeth? | a. aWhat do you think parents can do (or you as a parent can do) to prevent dental problems in kids (your kids)?b. aAs a parent, what do you think are the most important ways to help a child have good oral health?c. bWhat activities can you do to improve your child’s oral health?d. cWhat about diet and oral health?e. cWhat about flouride and oral health?f. cWhat about the experiences of your other children? |
| 4. Tell me whether you think you can control your child’s oral health? | a. bAre there oral health problems that you feel you can control?i. cWhat would they be?ii. cWhat steps can you take to control the problem?iii. cYourself?iv. cWhat about other people? Can they do anything to control the problem?b. bWhen you can control an oral health problem, how does you child respond?c. bWhen you dealt with an oral health problem, how successful were you?d. cSo, you could not control a problem, then what did you do?i. bWhat was your child’s response?ii. bWhen you think about it now, does the problem still exist? |
| 5. Other than your family and those who provide care, is there anyone else that you think should or could have an important role in your child’s oral health? | a. bWhy? What do you think they can do to help?i. cWhat about role models in entertainment?ii. cWhat about advertising and media messages?iii. cWhat about public policies?iv. cWhat about insurance? |
| 6. What concerns do you have about your child’s future oral health? | a. bAs your child grows older, what oral health problems can affect him/her?i. cHow can poor oral health affect a child’s social and psychological well-being?ii. cHow can it affect a person’s chances of economic success?iii. cHow can it affect one’s general health over a lifetime? |
| 7. Tell me whether you think you can control your child’s oral health? | a. bAre there oral health problems that you feel you can control?i. cWhat would they be?ii. cWhat steps can you take to control the problem?iii. cYourself?iv. cWhat about other people? Can they do anything to control the problem?b. bWhen you can control an oral health problem, how does you child respond?c. bWhen you can dealt an oral health problem, how successful were you?d. cSo, you could not control a problem, then what did you do?i. bWhat was your child’s response?ii. bWhen you think about it now, does the problem still exist? |
| 8. Other than your family and those who provide care, is there anyone else that you think should or could have an important role in your child’s oral health? | a. bWhy? What do you think they can do to help?i. cWhat about role models in entertainment?ii. cWhat about advertising and media messages?iii. cWhat about public policies?iv. cWhat about insurance? |
| 9. What concerns do you have about your child’s future oral health? | a. bAs your child grows older, what oral health problems can affect him/her? |
| Dependent variable | Explanatory variable | Beta | Chi‐square | p value | OR (95% confidence interval [CI]) |
| Female gender | 1.13 | 5.18 | .023 | 3.08 (95% CI [1.17, 8.11]) | |
| MMP‐13 saliva | |||||
| CAL | 1.27 | 4.35 | .037 | 3.57 (95% CI [1.08, 11.82]) |
| Patient code | Age (years) | Sex | Clinical form | Location of lesion/Code | |
| Cutaneous | Mucosal | ||||
| 1 | 52 | M | MCL | Arm/1MCL-C | Oral / 1MCL-O |
| 2 | 48 | M | MCL | Nostril/2MCL-C | Oral/2MCL-O |
| 3 | 25 | M | MCL | Arm/3MCL-C | Nasal/3MCL-N |
| 4 | 54 | M | MCL | ND | Oral/4MCL-O |
| 5 | 47 | M | MCL | Arm/5MCL-C | Nasal/5MCL-N |
| Oral/5MCL-O | |||||
| 6 | 16 | M | MCL | ND | Nasal/6MCL-N |
| 7 | 50 | M | MCL | Face/7MCL-C | Nasal/7MCL-N |
| 8 | 29 | M | MCL | Trunk/8LMC-C | Nasal/8MCL-N |
| 9 | 55 | M | MCL | ND | Oral/9MCL-O |
| 10 | 42 | M | MCL | ND | Nasal/10MCL-N |
| 11 | 52 | F | MCL | Arm/11MCL-C | Nasal/11MCL-N |
| 12 | 25 | M | MCL | Trunk/12MCL-C | Oral/12MCL-O |
| 13 | 52 | F | MCL | ND | Oral/13MCL-O |
| 14 | 54 | M | MCL | Upper lip/14MCL-C | Nasal/14MCL-N |
| 15 | 69 | M | MCL | ND | Nasal/15MCL-N |
| 16 | 65 | M | MCL | ND | Oral/16MCL-O |
| 17 | 63 | F | ML | A | Nasal/17ML-N |
| 18 | 53 | M | ML | A | Nasal/18ML-N |
| 19 | 66 | F | ML | A | Nasal/19ML-N |
| 20 | 71 | M | ML | A | Nasal/20ML-N |
| 21 | 12 | M | ML | A | Nasal/21ML-N |
| 22* | 49 | F | ML | A | Nasal/22ML-N |
| 23* | 69 | M | ML | A | Nasal/23ML-N |
| 24* | 60 | M | ML | A | Nasal/24ML-N |
| 25* | 77 | M | ML | A | Nasal/25ML-N |
| 26* | 72 | M | ML | A | Nasal/26ML-N |
| 27* | 71 | F | ML | A | Nasal/27ML-N |
| 28* | 39 | M | ML | A | Nasal/28ML-N |
| 29* | 63 | M | ML | A | Nasal/29ML-N |
| 30* | 44 | F | ML | A | Nasal/30ML-N |
| 31* | 31 | F | ML | A | Nasal/31ML-N1 |
| Nasal/31ML-N2 | |||||
| 32* | 29 | F | ML | A | Nasal/32ML-N1 |
| Nasal/32ML-N2 | |||||
| 33* | 72 | F | ML | A | Oral/33LM-O |
| 34 | 49 | M | DL | Arm/ 34DL-C1 | Nasal/34DL-N |
| Trunk/34DL-C2 | |||||
| Leg/34DL-C3 | |||||
| 35 | 41 | M | DL | Nose/35DL-C | Nasal/35DL-N |
| Oral/35DL-O |
| Tested population | NGO facilities | Services for migrants | DU services | |
| N = 2949 (%) | N = 1597 (%) | N = 928 (%) | N = 424 (%) | |
| Median age (IQR) | 33 years (26–43) | 31 years (25–41) | 37 years (29–47) | 35 years (28–44) |
| Gender | ||||
| Men | 1934 (65.6) | 1123 (70.3) | 531 (57.2) | 280 (66. 0) |
| Women | 973 (33) | 445 (27.9) | 391 (42.1) | 137 (32.3) |
| Transgender | 32 (1.1) | 23 (1.5) | 4 (0.4) | 5 (1.2) |
| Unknown | 10 (0.3) | 6 (0.4) | 2 (0.2) | 2 (0.5) |
| Origin | ||||
| Italian | 1782 (60.4) | 1432 (89.7) | 86 (9.3) | 264 (62.3) |
| Foreigners | 1167 (39.6) | 165 (10.3) | 842 (90.7) | 160 (37.7) |
| Education (yy) | ||||
| ≤ 8 | 684 (23.2) | 167 (10.5) | 340 (36.6) | 177 (41.7) |
| > 8 | 2249 (76.3) | 1421 (88.9) | 583 (62.8) | 245 (57.8) |
| Unknown | 16 (0.5) | 9 (0.6) | 5 (0.6) | 2 (0.5) |
| Occupation | ||||
| Employed | 1478 (50.1) | 939 (58.8) | 413 (44.5) | 126 (29.7) |
| Occasional employed | 485 (16.4) | 426 (26.7) | 37 (4) | 22 (5.2) |
| Unemployed | 968 (32.8) | 223 (14) | 472 (50.9) | 273 (64.4) |
| Unknown | 18 (0.6) | 9 (0.6) | 6 (0.6) | 3 (0.7) |
| Marital status | ||||
| Never married | 1895 (64.3) | 1283 (80.3) | 374 (40.3) | 238 (56.1) |
| Married/Cohabiting | 694 (23.5) | 206 (12.9) | 378 (40.7) | 110 (25.9) |
| Married before | 305 (10.3) | 78 (4.9) | 156 (16.8) | 71 (16.7) |
| Unknown | 55 (1.9) | 30 (1.9) | 20 (2.2) | 5 (1.2) |
| Previous HIV test | ||||
| No | 1334 (45.2) | 565 (35.4) | 613 (66.1) | 156 (36.8) |
| Yes | 1545 (52.4) | 1016 (63.3) | 283 (30.5) | 246 (58.0) |
| Unknown | 70 (2.4) | 16 (1.0) | 32 (3.4) | 22 (5.2) |
| Previous STIa | ||||
| No | 2406 (81.6) | 1289 (80.7) | 777 (83.7) | 431 (80.4) |
| Yes | 392 (13.3) | 257 (16.1) | 90 (9.7) | 45 (10.6) |
| Unknown | 151 (5.1) | 52 (3.3) | 61 (6.6) | 38 (9.0) |
| Diagnosis | n | Percent |
| Small for gestational age | 11 | 26.8 |
| Disseminated intravascular coagulation | 5 | 12.2 |
| Respiratory distress syndrome | 7 | 17.1 |
| Sepsis | 21 | 51.2 |
| Anemia | 2 | 4.9 |
| Shock | 5 | 12.2 |
| Meconium aspiration syndrome | 2 | 4.9 |
| Hypoxic ischaemic encephalopathy | 19 | 46.3 |
| Acute kidney injury | 7 | 17.1 |
| Meningitis | 2 | 4.9 |
| Pulmonary hemorrhage | 2 | 4.9 |
| Hyperbilirubinemia | 3 | 7.3 |
| Necrotising enterocolitis | 1 | 2.4 |
| Persistent pulmonary hypertension | 3 | 7.3 |
| Intracranial haemorrhage | 1 | 2.4 |
| Congenital heart disease | 6 | 14.6 |
| Gastric ulcer model | Treatments (p.o.) | Dose (g/kg) | n | Ulcer index (mm) | Inhibition (%) |
| Ethanol-induced | Saline | – | 8 | 14.37 ± 2.88 | – |
| Ranitidine | 0.04 | 8 | 11.27 ± 2.49∗∗ | 29.01 | |
| AIG | 1.50 | 8 | 3.11 ± 0.47∗∗ | 80.43 | |
| AIG | 0.75 | 8 | 4.46 ± 0.51∗∗ | 71.93 | |
| Pylorus ligature-induced | Saline | – | 8 | 11.33 ± 3.78 | – |
| Ranitidine | 0.03 | 8 | 3.55 ± 0.63∗∗ | 68.68 | |
| AIG | 1.0 | 8 | 2.76 ± 0.67∗∗ | 75.63 | |
| AIG | 0.5 | 8 | 3.36 ± 0.78∗∗ | 70.33 | |
| Acetic acid-induced | Saline | – | 8 | 10.26 ± 1.52 | – |
| Ranitidine | 0.03 | 8 | 3.89 ± 0.48∗∗ | 64.37 | |
| AIG | 1.0 | 8 | 2.84 ± 0.53∗∗ | 72.49 | |
| AIG | 0.5 | 8 | 3.38 ± 0.64∗∗ | 63.15 |
| Characteristics | Total (n = 140) | TB Group (n = 70) | Control Group (n = 70) | P value |
| Gender: Male | 95 (68%) | 56 (80%) | 39 (56%) | 0.002 |
| Age, years, mean ± SD | 35.7 ± 7.6 | 34.4 ± 6.2 | 37.2 ± 8.7 | 0.028 |
| Body weight, Kgs, mean ± SD | 54.6 ± 9.6 | 54.7 ± 8.7 | 54.4 ± 10.6 | 0.827 |
| Body mass index, mean ± SD | 20.1 ± 2.9 | 19.7 ± 2.4 | 20.5 ± 3.4 | 0.097 |
| CD4 cell counts, cells/mm3, mean ± SD | 62 ± 74 | 61 ± 74 | 76 ± 75 | 0.823 |
| %CD4, median (IQR) | 5 ± 5 | 6 ± 5 | 5 ± 5 | 0.226 |
| Plasma HIV RNA, copies/ml, median (IQR) | 433,500 (169,000–750,000) | 505,000 (269,000–750,000) | 291,000 (94,600–714,000) | 0.014 |
| Plasma HIV RNA, Log copies/ml, median (IQR) | 5.6 (5.2–5.9) | 5.7 (5.4–5.9) | 5.6 (5.0–5.9) | 0.004 |
| ALP, mg/dl, median (IQR) | 98 (71–142) | 110 (75–154) | 91 (70–128) | 0.072 |
| AST, U/l, median (IQR) | 30 (20–50) | 36 (27–60) | 35 (26–47) | 0.371 |
| ALT, U/l, median (IQR) | 27 (19–42) | 27 (18–51) | 32 (22–49) | 0.169 |
| Total bilirubin, mg/dl, median (IQR) | 0.6 (0.4–0.7) | 0.6 (0.5–0.8) | 0.5 (0.4–0.7) | 0.051 |
| Most significant GO Biological Processes | |||||
| GO Term | GO ID | Changed Genes | Total Genes in Class | P-Value | Fraction |
| Cholesterol biosynthesis | GO:0006695 | 12 | 20 | 7.04E-09 | 0.600 |
| Nuclear mRNA splicing, via spliceosome | GO:0000398 | 29 | 110 | 9.77E-09 | 0.264 |
| glycolysis | GO:0006096 | 14 | 39 | 1.16E-07 | 0.359 |
| Protein biosynthesis | GO:0006412 | 38 | 247 | 8.00E-07 | 0.154 |
| transport | GO:0006810 | 50 | 415 | 8.94E-07 | 0.120 |
| Protein metabolism | GO:0019538 | 9 | 17 | 4.90E-06 | 0.529 |
| Protein folding | GO:0006457 | 28 | 174 | 5.59E-06 | 0.161 |
| Ribosome biogenesis | GO:0007046 | 6 | 14 | 3.22E-05 | 0.429 |
| metabolism | GO:0008152 | 39 | 316 | 9.36E-05 | 0.123 |
| tRNA processing | GO:0008033 | 8 | 33 | 5.32E-04 | 0.242 |
| Regulation of the cyclin dependent protein kinase activity | GO:0000079 | 8 | 34 | 9.72E-04 | 0.235 |
| Amino acid biosynthesis | GO:0008652 | 6 | 22 | 1.01E-03 | 0.273 |
| Lipid metabolism | GO:0006629 | 24 | 193 | 1.02E-03 | 0.124 |
| Regulation of progression through cell cycle | GO:0000074 | 27 | 200 | 1.14E-03 | 0.135 |
| Cell cycle | GO:0007049 | 41 | 338 | 1.64E-03 | 0.121 |
| Regulation of translational initiation | GO:0006446 | 7 | 22 | 1.88E-03 | 0.318 |
| Most significant GO Molecular Function. | |||||
| GO Term | GO ID | Changed Genes | Total Genes in Class | P-Value | Fraction |
| Nucleotide binding | GO:0000166 | 173 | 1405 | 6.92E-11 | 0.123 |
| RNA binding | GO:0003723 | 78 | 389 | 4.22E-10 | 0.201 |
| Oxidoreductase activity | GO:0016491 | 61 | 382 | 6.44E-10 | 0.160 |
| ATP binding | GO:0005524 | 123 | 1116 | 1.20E-09 | 0.110 |
| Unfolded protein binding | GO:0051082 | 28 | 143 | 2.68E-08 | 0.196 |
| Protein binding | GO:0005515 | 220 | 2514 | 1.77E-07 | 0.088 |
| Transferase activity | GO:0016740 | 101 | 958 | 1.86E-07 | 0.105 |
| L-ascorbic acid binding | GO:0031418 | 6 | 11 | 1.65E-05 | 0.545 |
| Lyase activity | GO:0016829 | 16 | 89 | 1.37E-04 | 0.180 |
| binding | GO:0005488 | 47 | 399 | 2.37E-04 | 0.118 |
| ATP-dependent RNA helicase activity | GO:0004004 | 7 | 18 | 4.61E-04 | 0.389 |
| Isomerase activity | GO:0016853 | 15 | 90 | 5.54E-04 | 0.167 |
| Ligase activity | GO:0016874 | 27 | 184 | 5.54E-04 | 0.147 |
| Oxidoreductase activity | GO:0016702 | 6 | 18 | 6.72E-04 | 0.333 |
| NAD binding | GO:0051287 | 8 | 24 | 7.05E-04 | 0.333 |
| Catalytic activity | GO:0003824 | 27 | 192 | 7.40E-04 | 0.141 |
| Transporter activity | GO:0005215 | 29 | 281 | 1.50E-03 | 0.103 |
| Kinase activity | GO:0016301 | 22 | 163 | 1.65E-03 | 0.135 |
| tRNA binding | GO:0000049 | 5 | 13 | 1.87E-03 | 0.385 |
| Most significant GO Cellular Component | |||||
| GO Term | GO ID | Changed genes | Total genes in class | P-value | Fraction |
| cytoplasm | GO:0005737 | 114 | 895 | 5.00E-10 | 0.127 |
| nucleus | GO:0005634 | 281 | 2999 | 5.00E-10 | 0.094 |
| mitochondrion | GO:0005739 | 70 | 528 | 1.01E-09 | 0.133 |
| endoplasmic reticulum | GO:0005783 | 49 | 405 | 2.47E-06 | 0.121 |
| mitochondrial inner membrane presequence translocase complex | GO:0005744 | 5 | 11 | 2.82E-04 | 0.455 |
| soluble fraction | GO:0005625 | 24 | 194 | 3.22E-04 | 0.124 |
| nucleolus | GO:0005730 | 12 | 59 | 1.09E-03 | 0.203 |
| Parameters | Vildagliptin (n-29) | P value* | Placebo (n-29) | P value* | P value+ | ||
| Pre treatment | Post treatment | Pre-treatment | Post treatment | ||||
| Body weight(kg) | 88±11.3 | 79±12.6 | 0.036 | 82 ±16.4 | 81±12.4 | 0.74 | 0.04 |
| BMI(kg/m2) | 30.7±4.2 | 27.5±5.2 | 0.005 | 29.6 ±0.4 | 29.4±0.7 | 0.88 | 0.028 |
| TC (mg/dl) | 252.6±24.4 | 220.6±20.2 | 0.031 | 260± 28.5 | 262±28.2 | 0.62 | 0.01 |
| TG(mg/dl) | 190±24.9 | 115±22.9 | 0.005 | 197±21.2 | 199±20.4 | 0.88 | 0.001 |
| LDL-C(mg/dl | 160±15.24 | 145±13.2 | 0.004 | 169±12.8 | 167±11.2 | 0.57 | 0.011 |
| HDL-C(mg/dl) | 29.6±5.8 | 45.5±4.9 | 0.001 | 28.3±6.0 | 33±6.2 | 0.98 | 0.02 |
| ALT(IU/L) | 78.2±17.2 | 48.6±14.8 | 0.036 | 76±18.9 | 72±2.2 | 0.76 | 0.04 |
| AST(IU/L) | 63.5±10.5 | 41.5± 9.6 | 0.002 | 61.2±11.1 | 58±10.5 | 0.81 | 0.001 |
| GGT (IU/L) | 18.5±5.8 | 19.7±7.7 | 0.62 | 19.7±6.43 | 20.8±7.5 | 0.43 | 0.67 |
| Feature | Control group (A) | Study group (B) |
| Number of pin-sites | 268 | 368 |
| AO tubular external fixation | 43 | 41 |
| Unilateral rail | 0 | 2 |
| Ilizarov device | 6 | 8 |
| Pin tract infection (patients)a | 11 (22.5 %) | 2 (4.1 %) |
| Pin tract infection (pin-sites)a | 38 (14.2 %) | 7 (1.9 %) |
| Trials | Intervention (n/N) | Control (n/N) | RR (95% CI) | P value | |
| LWDHW plus enalapril versus enalapril | 1 | 34/42 | 21/36 | 3.04 (1.10, 8.38) | 0.03 |
| Meta-analysis | 1 | 34/42 | 21/36 | 3.04 (1.10, 8.38) | 0.03 |
| Non-hospitalsN = 191 | HospitalsN = 34 | Chi-square (p-value) | |||
| Yesn (%) | Don't normally stockn (%) | Yesn (%) | Don't normally stockn (%) | ||
| AMT | 17 | 18 | 2 | 13 | 23.0 (.0001) |
| CQ | 111 | 1 | 5 | 1 | 20.4 (.0001) |
| Antibiotics | 16 | 5 | 4 | 3 | 4.6 (.10) |
| SP | 97 | 11 | 3 | 6 | 21.0 (.0001) |
| Quinine | 17 | 25 | 5 | 9 | 7.5 (.023) |
| Halofantrine | 24 | 28 | 3 | 14 | 15.9 (.0001) |
| Others | 46 | 5 | 5 | 1 | 1.0 (.60) |
| Isolate | Collection | Country | Yr of entry into collection | Sequencing technology | Reference |
| NCTC86_Dunne | NCTC | England | 1920 | Pacific Biosciences RS II, Illumina | 2 |
| NCTC86_Meric | NCTC | England | 1920 | Illumina MiSeq | 4 |
| NCTC86 | NCTC | England | 1920 | Illumina MiSeq | This study |
| CIP61.11 | Centre de Ressources Biologiques de l’Institut Pasteur | France | 1961 | Illumina MiSeq | This study |
| ATCC 4157 | ATCC | United States | Unknown | Illumina MiSeq | This study |
| DSM301 | DSMZ | Germany | 1970 | Illumina MiSeq | This study |
| Placebo (N = 112) | 25 mg/d Neramexane (N = 108) | 50 mg/d Neramexane (N = 107) | 75 mg/d Neramexane (N = 102) | |||||
| n | % | n | % | n | % | n | % | |
| Any adverse event | 4 | 3.6 | 7 | 6.5 | 9 | 8.4 | 21 | 20.6 |
| Dizziness | 1 | 0.9 | 2 | 1.9 | 7 | 6.5 | 15 | 14.7 |
| Vertigo | 0 | 0.0 | 1 | 0.9 | 2 | 1.9 | 5 | 4.9 |
| Nausea | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 2 | 2.0 |
| Fatigue | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 3 | 2.9 |
| Prevalence of elevated CRP (>10 mg/L) | |||||
| Group | % | Univariate p-value | Multivariate OR * | Multivariate p-value** | |
| Age | <50 | 14 | 0.49 | ||
| 50–59 | 13 | ||||
| 60–69 | 13 | ||||
| 70+ | 18 | ||||
| Sex | Male | 14 | 0.28 | ||
| Female | 18 | ||||
| NIHSS | <7 | 13 | 0.015 | (ref) | 0.03 |
| 7–13 | 25 | 2.15 | |||
| 14+ | 21 | 1.89 | |||
| OCSP classification | LACI | 15 | 0.005 | ||
| TACI | 26 | ||||
| PACI | 10 | ||||
| POCI | 19 | ||||
| Prior Cerebrovascular disease | No | 16 | 0.97 | ||
| Yes | 16 | ||||
| Pre-existing diabetes mellitus | No | 14 | 0.01 | (ref) | 0.04 |
| Yes | 27 | 1.96 | |||
| Smoking habits | Never smoker | 19 | 0.29 | ||
| Former smoker | 14 | ||||
| Current smoker | 12 | ||||
| Time to hospital | <3 hours | 13 | 0.20 | ||
| 3–5.9 hours | 20 | ||||
| 6–11.9 hours | 10 | ||||
| 12–23.9 hours | 18 | ||||
| Woke up with Stroke (<24 hours) | 17 | ||||
| Other (<24 hours) | 26 |
| Insular cortex | Posterior cingulate cortex | ||
| Right | Left | ||
| No. of participants | 4 | 4 | 4 |
| Peak latency (ms) | 191.0 ± 10.6 | 184.0 ± 4.6 | 468.0 ± 13.5 |
| GOF (%) | 95.3 ± 2.1 | 93.5 ± 1.6 | 95.8 ± 1.5 |
| Intensity (nA · m) | 25.0 ± 2.8 | 16.7 ± 2.5 | 16.4 ± 3.3 |
| Locations* | |||
| x (mm) | 41.8 ± 2.7 | −41.7 ± 3.1 | −8.3 ± 2.6 |
| y (mm) | −20.8 ± 4.2 | −26.2 ± 6.1 | −47.3 ± 5.0 |
| z (mm) | 8.9 ± 4.2 | 3.3 ± 7.9 | 25.7 ± 6.4 |
| Orientations* | |||
| θ (degrees) | 43.6 ± 12.9 | 34.8 ± 5.7 | 116.5 ± 23.3 |
| φ (degrees) | 82.6 ± 9.3 | 99.7 ± 12.9 | 275.6 ± 56.1 |
| Males (n = 196) | Females (n = 210) | Total (n = 406) | |
| Career aspiration | Mean (SD) | Mean (SD) | Mean (SD) |
| Private practice (n = 192) | 1.18 (1.44) | 0.61 (0.98) | 0.84 (1.22) |
| Hospital career (n = 172) | 2.19 (2.16) | 1.25 (1.41) | 1.72 (1.88) |
| Academic career (n = 42) | 6.66 (2.28) | 4.78 (2.49) | 6.24 (2.80) |
| Total (n = 406) | 2.51 (2.77) | 1.05 (1.51) | 1.76 (2.33) |
| Effect | F | P | Partial eta squared |
| Gender | F(1,400) = 21.77 | 0.001 | 0.05 |
| Career aspiration | F(2,400) = 101.61 | <0.001 | 0.34 |
| Gender × Career aspiration | F(2,400) = 2.04 | 0.131 | 0.01 |
| Odds ratio | 95% Confidentialinterval | P-value | |
| Laboratory variables | |||
| Gamma-glutamyltranspeptidase, IU/L | 1.009 | 0.953, 1.068 | 0.757 |
| Cumulative dose of medications, mg | |||
| Leflunomide (53 patients) | 1.000 | 1.000, 1.000 | 0.007 |
| Prednisolone (89 patients) | 1.000 | 1.000, 1.000 | 0.547 |
| Clinical presentatiton | No. of patients | No. of episods | Time* (median/month) | Treatment |
| Cholangitis | 5 | 9 | 19.5 (14–47) | Medical |
| -without real stricture | 3 | 3 | 28.3 | Medical |
| -with real stricture | 2 | 6 | 15.5 | Endoscopic (dilatation and/or stenting) |
| CBD stone | 2 | 2 | 21.5 (16–27) | Endoscopic (stone extraction) |
| Total | 7 | 11 |
| Awareness of ESCCAP Heartworm Guidelines | ||||||
| Number clinics responding (% responding) | ||||||
| Country | Not aware | Slightly aware | Moderately aware | Quite aware | Very aware | Responders |
| UK (non-endemic) | 22 (67) | 5 (15) | 3 (9) | 3 (9) | 0 (0) | 33 |
| Germany (non-endemic) | 40 (40) | 38 (38) | 20 (20) | 3 (3) | 0 (0) | 101 |
| Netherlands (non-endemic) | 32 (94) | 1 (3) | 1 (3) | 0 (0) | 0 (0) | 34 |
| France (non-endemic) | 63 (73) | 9 (10) | 10 (12) | 2 (2) | 2 (2) | 86 |
| France (endemic) | 29 (62) | 9 (19) | 4 (9) | 4 (9) | 1 (2) | 47 |
| Spain (non-endemic) | 25 (37) | 13 (19) | 22 (32) | 6 (9) | 2 (3) | 68 |
| Spain (endemic) | 15 (37) | 4 (10) | 10 (24) | 9 (22) | 3 (7) | 41 |
| Italy (non-endemic) | 35 (52) | 11 (16) | 14 (21) | 5 (7) | 2 (3) | 67 |
| Italy (endemic) | 56 (52) | 19 (18) | 20 (19) | 8 (7) | 4 (4) | 107 |
| Total (non-endemic) | 217 (56) | 77 (20) | 70 (18) | 19 (5) | 6 (2) | 389 |
| Total (endemic) | 100 (51) | 32 (16) | 34 (17) | 21 (11) | 8 (4) | 195 |
| Total | 317 (54) | 109 (19) | 104 (18) | 40 (7) | 14 (2) | 584 |
| Type of model or algorithm | Target product | Model-based target: knockout gene A or overexpress gene B | References |
| Dynamic flux balance analysis | Ethanol | Ethanol production pathway after 20 h | [163] |
| Genome-scale metabolic model | Prediction of growth rate with respect to photosynthetic quotient for ethanol and butanol production | Double reaction knock out of hydrolyase and dehydrogenase | [164] |
| In vivo carbon flux analysis | Homolanthionine | Deletion of methionine and cysteine biosynthesis repressor protein | [165] |
| Metabolic flux analysis | Hydrogen production | Deletion and addition of GAP1 and dehydrogenase, respectively | [166] |
| Metabolic flux analysis | Astaxanthin synthesis | – | [167] |
| Metabolic flux analysis | Fixed more CO2 and had a higher biomass yield | Alternate pathway for isoleucine synthesis (via citramalate synthase, CimA | [168] |
| Metabolic net fluxes | Hydrogen production | Disruption of hydrogenase and poly-β-hydroxybutyrate synthase | [169] |
| Severity of stress | |
| n = 85 | % |
| Severe | 33 |
| Moderate | 27 |
| Extreme | 22 |
| None/light | 8 |
| Catastrophic | 6 |
| N | % | Age (mean ± SD) | ||
| Sex | Male | 50 | 54.0% | 39.60 ± 7.32 |
| Female | 40 | 46.0% |
| Any first-degree relative | ||||||
| History of cancer (any site) | History of head and neck cancer | |||||
| ‡No | Yes | OR (95% CI)† | §No | Yes | OR (95% CI)† | |
| Cases/controls | Cases/controls | Cases/controls | Cases/controls | |||
| Smoking | ||||||
| Never | 19/563 | 27/559 | 1.1 (0.6-2.1) | 35/994 | 6/51 | 2.4 (1.0-7.0) |
| Ever | 231/1002 | 306/1030 | 1.3 (1.1-1.5) | 427/1785 | 58/104 | 2.7 (1.8-3.4) |
| Drinking | ||||||
| ≤2 glasses/day | 75/961 | 75/954 | 0.9 (0.6-1.4) | 123/1704 | 11/88 | 1.9 (1.0-3.5) |
| >2 glasses/day | 167/597 | 254/631 | 1.4 (1.0-1.8) | 329/1066 | 52/67 | 2.6 (1.2-3.3) |
| Smoking & drinking | ||||||
| NS & D ≤2 glasses/day | 16/412 | 17/425 | 0.9 (0.4-1.9) | 30/740 | 1/39 | 1.2 (0.3-4.7) |
| ES & D ≤2 glasses/day | 59/548 | 58/526 | 0.9 (0.6-1.4) | 93/962 | 10/47 | 1.6 (1.0-3.9) |
| NS & D >2 glasses/day | 3/147 | 8/129 | 2.7 (0.6-11.6) | 5/248 | 4/10 | 18.8 (2.9-119.8) |
| ES & D >2 glasses/day | 164/449 | 246/499 | 1.4 (1.0-1.8) | 324/815 | 48/57 | 2.1 (1.3-2.9) |
| Variable | Univariate analysis | Multivariate analysis | ||||
| HR | 95% CI | P value | HR | 95% CI | P value | |
| Sex (Female, Male) | 1.2533 | 0.7767-2.0222 | 0.3550 | |||
| Age (≤ 60, > 60) | 0.6990 | 0.4635-1.0542 | 0.0876 | |||
| Macroscopic types (Ul, Fu, Me) | 1.0699 | 0.7665-1.4935 | 0.6912 | |||
| Tumor location (Up, Mi, Lo) | 0.9403 | 0.6827-1.2950 | 0.7061 | |||
| Tumor size (≤ 5, > 5) | 2.3524 | 0.8957-2.0419 | 0.1510 | |||
| pT (T1-2, T3-4) | 1.3584 | 0.7046-2.6187 | 0.3604 | |||
| pN (N0, N1-3) | 2.0212 | 1.3201-3.0947 | 0.0012 | 1.8234 | 1.1259-2.9528 | 0.0146 |
| Grade (G1, G2, G3) | 1.0777 | 0.7912-1.4679 | 0.6352 | |||
| Stage (I/IIA, IIB/IIIC) | 1.9646 | 1.0188-3.7884 | 0.0438 | 1.3322 | 0.6337-2.8008 | 0.4493 |
| ANO1 (Neg, Pos) | 1.9141 | 1.2729-2.8782 | 0.0018 | 1.9031 | 1.2653-2.8624 | 0.0020 |
| Pre-VT SC-IAT | Embodiment after first session of VT | Embodiment after second session of VT | Post-VT SC-IAT | |||||
| M | SD | M | SD | M | SD | M | SD | |
| Synch black | 0.01 | 0.38 | 0.91 | 1.32 | 1.14 | 1.31 | 0.05 | 0.30 |
| Synch white | -0.05 | 0.35 | 1.32 | 1.46 | 1.31 | 1.68 | -0.01 | 0.37 |
| Asynch black | 0.01 | 0.44 | -0.82 | 1.51 | -0.39 | 1.71 | -0.11 | 0.28 |
| Asynch white | 0.05 | 0.35 | -0.93 | 1.46 | -0.74 | 1.64 | 0.10 | 0.37 |
| Group | n | Age (year) | Infertility duration (year) | BMI | Reproductive hormone level | |||
| FSH/IU·L-1 | LH/IU·L-1 | E2/pg·mL-1 | T/mmol·L-1 | |||||
| LE group | 52 | 26.4±4.2 | 3.4±1.1 | 22.4±4.5 | 7.1±1.5 | 5.7±1.1 | 57.7±13.5 | 1.41±0.5 |
| CC group | 52 | 27.1±4.7 | 3.2±0.7 | 23.4±1.5 | 6.9±1.2 | 5.5±0.9 | 54.5±12.7 | 1.45±0.3 |
| LE + HMG group | 52 | 27.7±5.2 | 3.3±1.3 | 22.6±2.6 | 6.8±1.1 | 5.9±1.2 | 61.5±15.8 | 1.42±0.2 |
| F | - | 0.703 | 0.311 | 0.515 | 0.211 | 0.163 | 1.635 | 1.785 |
| P | - | >0.05 | >0.05 | >0.05 | >0.05 | >0.05 | >0.05 | >0.05 |
| Input type | Database update | Functional Database support | Multiple organism support | Limitations for input genes | Statistics | |
| GeneSCF v1.1 | List of genes | Real-time | KEGG, GO, Reactome and NCG | Yes | No upper or lower limit | FE test a & FDR b |
| GeneSCF v1.0 | List of genes | Manual (preparation needed) | KEGG, GO, Reactome and NCG | No (Homo sapiens) | No upper or lower limit | FE test & FDR |
| GOrilla | List of genes | Weekly auto-update | GO | Yes | No upper limit but has lower limit | FE test & FDR |
| DAVID 6.7 | List of genes | Last known update 2010) | KEGG, GO, Reactome and Biocarta | Yes | Upper limit 3000 and no lower limit | FE test & FDR |
| DHFR | Regions (%) | Total N (%) | ||||
| Repeat Type | Delhi | Nadiad | Panna | Chennai | Kamrup | |
| Type 1 | 54.54 | 0 | 11.76 | 0 | 0 | 8 (11.26) |
| Type 2 | 36.34 | 100 | 76.47 | 100 | 100 | 60 (84.5) |
| Type 3 | 9.09 | 0 | 0 | 0 | 0 | 1 (1.4) |
| Type 4 | 0 | 0 | 11.76 | 0 | 0 | 2 (2.81) |
| Total (N) | 11 | 3 | 17 | 19 | 21 | 71 |
| DHPS | ||||||
| Type A | 10 | 10 | 0 | 5 | 21.05 | 9.27 |
| Type B | 90 | 85 | 83.34 | 90 | 26.31 | 75.25 |
| Type C | 0 | 0 | 5.55 | 5 | 0 | |
| Type D | 0 | 5 | 5.55 | 0 | 15.79 | 5.15 |
| Type E | 0 | 0 | 0 | 0 | 10.52 | 2.06 |
| Type F | 0 | 0 | 0 | 0 | 10.52 | 2.06 |
| Type G | 0 | 0 | 5.55 | 0 | 10.52 | 3.09 |
| Type H | 0 | 0 | 0 | 0 | 5.26 | 1.03 |
| Total (N) | 20 | 20 | 18* | 20 | 19* | 97 |
| Items | Cronbach’s alpha if items were deleted |
| Physical functioning | 0.845 |
| Mental health | 0.847 |
| Vitality | 0.849 |
| Role physical | 0.858 |
| General health | 0.853 |
| Bodily pain | 0.857 |
| Role emotional | 0.862 |
| Social functioning | 0.856 |
| Educational rescue policy | 0.871 |
| Orphan rescue policy | 0.871 |
| Employment rescue policy | 0.871 |
| Poverty rescue policy | 0.871 |
| Social security policy | 0.872 |
| Legal rescue policy | 0.872 |
| Crude extracta | Yieldb(g) | Yieldc(% of pollen sample) | Appearance |
| Corn bee pollen extracts | |||
| CMEb | 35.29 | 8.40 | Dark brown sticky solid |
| CDEb | 2.40 | 0.57 | Dark brown solid |
| CHEb | 18.13 | 4.32 | Yellow solid |
| Floral corn pollen extracts | |||
| CMEp | 9.02 | 2.15 | Dark brown solid |
| CDEp | 4.82 | 1.15 | Brown solid |
| CHEp | 7.87 | 1.87 | Dark green oil/wax |
| The Job stress Survey (JSS) Items | Lack of support leaders | Demanding job tasks | Time pressure | Lack of support co-workers |
| No participating in decisions | 0.84 | 0.20 | 0.03 | 0.04 |
| Lack recognition for good work | 0.80 | 0.14 | 0.03 | 0.28 |
| Poor or inadequate supervision | 0.61 | 0.28 | 0.13 | 0.18 |
| Difficult working with superior | 0.81 | 0.16 | 0.17 | 0.19 |
| Inadequate support by supervisor | 0.57 | 0.24 | 0.19 | 0.25 |
| Difficulty getting along with supervisor | 0.79 | 0.01 | 0.19 | 0.22 |
| Working overtime | 0.16 | 0.56 | 0.05 | 0.12 |
| Critical on the spot decisions | 0.20 | 0.73 | 0.16 | 0.10 |
| Assigned increased responsibility | 0.32 | 0.62 | 0.19 | 0.11 |
| Assignment of new duties | 0.11 | 0.75 | 0.24 | 0.03 |
| Perform duties not in job description | 0.04 | 0.67 | 0.33 | 0.16 |
| Frequent interruptions | 0.26 | 0.28 | 0.53 | 0.42 |
| Frequent change simple to demanding tasks | 0.06 | 0.44 | 0.61 | 0.16 |
| Excessive paperwork | 0.09 | 0.19 | 0.79 | 0.12 |
| Meeting deadline | 0.06 | 0.20 | 0.82 | 0.14 |
| Insufficient personal time | 0.24 | 0.12 | 0.66 | 0.04 |
| Fellow workers not doing job | 0.26 | 0.21 | 0.01 | 0.77 |
| Covering work for others | 0.31 | 0.18 | 0.27 | 0.56 |
| Poorly motivated co-workers | 0.26 | 0.05 | 0.24 | 0.79 |
| Sums of squared loadings | 3.9 | 2.9 | 2.9 | 2.1 |
| % variance | 20.4 | 15.3 | 15.1 | 11.0 |
| The Norwegian Ambulance Stress Survey (NASS) | Non-Emergency tasks | Serious operational tasks | Physical demands | |
| Hide feelings towards patients and relatives | 0.83 | 0.13 | 0.16 | |
| Not being able to express own opinion to patients or relatives | 0.82 | 0.08 | 0.19 | |
| Medical responsibility in the vehicle | 0.63 | 0.34 | 0.17 | |
| Negative attitude from relatives about the job you are doing | 0.60 | 0.29 | 0.07 | |
| The cumulative effect of frequently driving chronically ill patients | 0.54 | 0.25 | 0.24 | |
| Take care of seriously injured and dying patients | 0.52 | 0.57 | 0.15 | |
| Uncertainty about what you will meet on the scene of accident | 0.51 | 0.60 | 0.11 | |
| Incident with seriously injured friend or people you know | 0.19 | 0.73 | 0.12 | |
| Incident with seriously injured children | 0.09 | 0.83 | 0.15 | |
| Deal with acting-out and threatening patients | 0.18 | 0.70 | 0.22 | |
| Driving under difficult conditions | 0.34 | 0.62 | 0.18 | |
| Heavy lifting | 0.22 | 0.12 | 0.91 | |
| Carrying out the work under difficult conditions | 0.20 | 0.22 | 0.91 | |
| Working in bent or twisted positions | 0.18 | 0.25 | 0.87 | |
| Sums of squared loadings | 3.3 | 3.2 | 2.7 | |
| % variance | 23.3 | 22.7 | 19.3 |
| English 1st Language | N | Mean | SD | Age | N | Mean | SD | Student | N | Mean | SD | |
| Sum 18 Item | Yes | 229 | 37.96 | 7.72 | Younger | 133 | 38.56 | 7.66 | Yes | 114 | 38.19 | 7.99 |
| No | 28 | 39.57 | 9.37 | Older | 123 | 37.58 | 8.14 | No | 143 | 38.09 | 7.88 | |
| Sum Production | Yes | 236 | 20.05 | 4.56 | Younger | 138 | 20.42 | 4.54 | Yes | 117 | 20.15 | 4.65 |
| No | 29 | 20.93 | 5.18 | Older | 126 | 19.80 | 4.71 | No | 148 | 20.14 | 4.63 | |
| Sum Perception | Yes | 238 | 16.58 | 4.37 | Younger | 141 | 16.54 | 4.29 | Yes | 116 | 17.00 | 4.55 |
| No | 29 | 17.31 | 5.15 | Older | 125 | 16.75 | 4.63 | No | 151 | 16.40 | 4.38 | |
| Sum EQ | Yes | 224 | 17.34 | 5.72 | Younger | 133 | 18.28* | 5.40 | Yes | 112 | 17.35 | 5.87 |
| No | 29 | 19.28 | 5.85 | Older | 119 | 16.71* | 6.05 | No | 141 | 17.73 | 5.68 |
| Cut-off | No of studies | Co-sensitivity (95 % CI) | Co-specificity (95 % CI) | I2 (95%CI) | Pooled positive LR | Pooled negative LR |
| 1.5 cm | 1 | 0.93 | 0.16 | – | 1.1 | 0.43 |
| 2 cm | 2 | 0.95, 1 | 0.41, 0.20 | – | 1.61, 1.25 | 0.12, 0 |
| 2.5 cm | 3 | 0.79, 1, 0.84 | 0.84, 0.58, 0.66 | – | 4.93, 2.38, 2.47 | 0.25, 0, 0.24 |
| 3 cm | 7 | 0.83, (0.56–0.95) | 0.64, (0.45–0.79) | 92, (86–99) | 2.3, (1.5–3.5) | 0.27, (0.1–0.74) |
| 4 cm | 6 | 0.56, (0.35–0.75) | 0.85, (0.69–0.94) | 94, (89–99) | 3.8, (2.3–6.4) | 0.51, (0.35–0.75) |
| 5 cm | 6 | 0.31, (0.14–0.57) | 0.92, (0.80–0.97) | 93, (86–99) | 4, (1.9–8.3) | 0.74, (0.56–0.98) |
| 6 cm | 6 | 0.32, (0.11–0.63) | 0.92, (0.85–0.96) | 92, (85–99) | 4, (1.9–8.7) | 0.74, (0.51–1.08) |
| Men | Women | p-value* | |
| Number of patients | 289 | 284 | |
| Number of deaths | 41 | 21 | |
| Number of admissions | 1924 | 3139 | |
| Total time of follow-up (person-years) | 3420 | 3204 | |
| Follow-up time in years (mean, SD) | 11.8 (7.4) | 11.3 (7.4) | 0.37 |
| Age at first admission in years (mean, SD) | 31.2 (9.9) | 30.2(12.2) | 0.28 |
| Total number of days admitted (median, 1 and 3 quartile) | 70 (18.0, 214.5) | 111 (25.3, 293.0) | 0.013 |
| Number of admissions (median, 1 and 3 quartile) | 3 (1,8) | 4 (2,1) | 0.004 |
| % with personality disorder as only diagnosis (N) | 30.1 (89) | 23.9 (68) | 0.07 |
| PBMS | DMT status | |||||
| Domains | pre-test | RCT | pos- | p-value | ||
| Sub-domains | without /with | without /with | sible range | pre | RCT | |
| 1: Attitude | 2.1 / 4.6 | 2.4 / 4.1 | 0-9 | <.01 | <.01 | |
| a: expectations regarding outcomes | 1.4 / 2.0 | 1.5 / 1.9 | 0-3 | <.01 | <.01 | |
| b: values of expected outcomes | 1.4 / 2.2 | 1.5 / 2.1 | 0-3 | <.01 | <.01 | |
| 2: Social norm | 1.2 / 1.8 | 1.5 / 2.4 | 0-9 | .23 | <.01 | |
| a: assumed attitudes of important others | 1.2 / 2.0 | 1.5 / 2.2 | 0-3 | <.01 | <.01 | |
| b: motivation to comply with these norms | 1.0 / .9 | 1.0 / 1.1 | 0-3 | <.01 | .34 | |
| 3: Control beliefs | 1.6 / 4.7 | 2.1 / 4.1 | 0-9 | <.01 | <.01 | |
| a: assumed facilitators or barriers | 1.0 / 2.1 | 1.2 / 1.9 | 0-3 | <.01 | <.01 | |
| b: perceived power of these factors | 1.4 / 2.2 | 1.5 / 2.0 | 0-3 | <.01 | <.01 | |
| Intention estimate | 4.8 / 11.1 | 6.0 / 10.1 | 0-27 | <.01 | <.01 |
| SNP | Position | Alleles† | MAF | Beta | s.e. | P | Pemp |
| rs1333049 | 22,115,503 | C/G | 0.421 | 0.0119 | 0.012 | 3.45E-01 | 3.44E-01 |
| Characteristics | Yes (%) | No (%) |
| Ever received an introduction into work place ergonomics | 24 (14.7%) | 136 (83.4%) |
| Ever experienced work-related musculoskeletal problems | 123 (75.5%) | 40 (24.5%) |
| Musculoskeletal problems in the last four weeks (n=123) | 69 (56.1%) | 53 (43.1%) |
| Signed off due musculoskeletal problems last year (n=123) | 11 (8.9%) | 112 (91.1%) |
| Doing regularly short breaks for stretching exercises | 36 (22.1%) | 124 (76.1%) |
| Any known ametropia | 145 (89.0%) | 17 (10.4%) |
| Aggravation of ametropia since working in pathology (n=145) | 82 (56.6%) | 58 (40.0%) |
| Eye fatigue symptoms in the last month | 90 (55.2%) | 68 (41.7%) |
| Ever experienced occupational injuries in pathology | 135 (82.8%) | 28 (17.2%) |
| Experienced such injuries in the last year (n=135) | 37 (27.4%) | 95 (70.4%) |
| Remaining permanent damages from such injuries (n=135) | 5 (3.7%) | 127 (94.1%) |
| Ever experienced intolerance reactions against formalin | 41 (25.2%) | 118 (72.4%) |
| Any known allergy | 55 (33.7%) | 105 (64.4%) |
| Since working in pathology ever diseased with... | ||
| Tuberculosis | 2 (1.2%) | 153 (93.9%) |
| Positive tuberculin test only | 31 (19.0%) | 119 (73.0%) |
| Hepatitis B | 1 (0.6%) | 154 (94.5%) |
| Hepatitis C | 0 (0.0%) | 155 (95.1%) |
| HIV | 0 (0.0%) | 154 (94.5%) |
| Burnout | 14 (8.6%) | 141 (86.5%) |
| Depression | 11 (6.7%) | 144 (88.3%) |
| Hypertension | 11 (6.7%) | 144 (88.3%) |
| Diabetes mellitus type II | 3 (1.8%) | 152 (93.2%) |
| Malignancies | 3 (1.8%) | 149 (91.4%) |
| Sufficient hepatitis B immunisation | 153 (93.9%) | 9 (5.5%) |
| Ever received BCG (tuberculosis) immunisation | 128 (78.5%) | 31 (19.0%) |
| Smoking | 17 (10.4%) | 145 (89.0%) |
| Cut-resistant gloves available at workplace | 99 (60.7%) | 60 (36.8%) |
| Regular personal use of cut-resistant gloves at dissections/autopsies | 39 (23.9%) | 108 (66.3%) |
| Extraction of air in the dissection room considered sufficient | 94 (57.7%) | 66 (40.5%) |
| Method Label | Method Description | Library used within R statistical software | Number of iterations |
| CC | Complete case analysis: Analyses only cases with complete data for all covariates | - | |
| SI | Single imputation performed using PMM | 'pmm' function in 'mice' | 20 |
| MI-NORM | Multiple imputation (MI) using data augmentation approach [31] with a multivariate normal assumption for all variables | 'norm' [41] | 100 |
| MI-MIX | MI using data augmentation approach using a general location model | 'mix' [42] | 100 |
| MI-MIX-no truncating | MI using data augmentation approach using a general location model, but imputed values are not truncated to within plausible range | 'mix' [42] | 100 |
| MI-MICE | MI using regression switching imputation [9]. Linear model are used for continuous covariates and logistic model for binary covariates and dummy variables for categorical covariates | 'mice' [43] | 20 |
| MI-MICE-PMM | MI using MICE with PMM | 'pmm' function in 'mice' [43] | 20 |
| MI-MICE-PMM-no transformation | MI using MICE with PMM without transforming the incomplete covariates | 'pmm' function in 'mice' [43] | 20 |
| MI-Aregimpute | MI using flexible additive imputation models [20] with PMM | 'aregImpute' function in 'Hmisc' [44] | 1 |
| Case No. | Age(yrs) | FIGO score | AP | Interval time (mons) | Pretreatment serum β-hCG level | Site of metastases | Chemotherapy | Cause of death |
| 1 | 53 | 15 | Abortion | 180 | 99000.0 | Lung/brain/kidney | Not done | Brain hemorrhage, respiratory failure |
| 2 | 30 | 21 | Abortion | 10 | 906720.0 | Lung/brain/liver/kidney | Not done | Septic shock |
| 3 | 31 | 8 | Mole | 32 | 80.0 | Lung/brain | 5-FU*1d | Brain herniation |
| 4 | 25 | 12 | Mole | 27 | 57380.0 | Lung/brain | EMA*1 | Brain herniation |
| 5 | 32 | 12 | Term | 6 | 200000.0 | Lung/brain/kidney | FAEV*2d | Respiratory failure, cardiac arrest |
| 6 | 36 | 13 | Mole | 56 | 9306.0 | Lung/brain/bladder | FAEV*1d | Multiple organ failure |
| 7 | 26 | 15 | Term | 3 | 60436.5 | Lung/brain | FAEV*3d | Brain stem hemorrhage |
| 8a | 33 | 17 | Mole | 36 | 2400.0 | Lung/brain | FAEV*4d | Brain herniation |
| Characteristics | Antenatal care utilization (< 4 times and ≥ 4 times) | |
| BivariateOR (95% CI) | MultivariateOR (95% CI) | |
| Education | ||
| Illiterate | 1 | 1 |
| Informal education | 1.54 (1.22–1.95)* | 1.39 (1.10-1.77)* |
| Primary school | 1.81 (1.34–2.45)* | 1.38 (1.01-1.90)* |
| Secondary school | 2.85 (2.12–3.78)* | 1.94 (1.43-2.63)* |
| Intermediate and above | 3.49 (2.35–5.17)* | 2.41 (1.55-3.75)* |
| Occupation | ||
| Agriculture | 1 | 1 |
| Service | 1.63 (0.99-2.68) | 1.05 (0.61-1.80) |
| Business | 1.95 (0.92-4.15) | 1.34 (0.61-2.93) |
| Wage laborer | 1.33 (0.63-2.83) | 1.36 (0.63-2.94) |
| Housewife | 1.69 (1.31-2.17)* | 1.44 (1.10-1.89)* |
| Other | 1.09 (0.58-2.07) | 0.73 (0.37-1.42) |
| Wealth quintile | ||
| Lowest | 1 | 1 |
| Second | 0.91 (0.69–1.19) | 1.01 (0.76-1.33) |
| Middle | 0.95 (0.71–1.26) | 0.95 (0.70-1.28) |
| Fourth | 1.44 (1.10–1.90)* | 1.25 (0.93-1.67) |
| Highest | 1.72 (1.30–2.27)* | 1.38 (1.02-1.86)* |
| Knowledge of danger signs | ||
| No | 1 | 1 |
| Yes | 1.99 (1.67–2.38)* | 1.71 (1.41-2.07)* |
| Distance to health facility | ||
| > 30 min | 1 | 1 |
| ≤ 30 min | 1.69 (1.39-2.05)* | 1.44 (1.18-1.77)* |
| Organism | BlastX threshold | Matches against 454 unigenes | Matches against Sanger unigenes |
| Arabidopsis (31,921) | 1e-5 | 14250 (45%) | 10154 (32%) |
| 1e-10 | 12347 (39%) | 9561 (30%) | |
| 1e-20 | 9077 (28%) | 8410 (26%) | |
| Arabidopsis with transcript evidence (22,032) | 1e-5 | 12790 (58%) | 9542 (43%) |
| 1e-10 | 11265 (51%) | 9029 (41%) | |
| 1e-20 | 8489 (39%) | 8003 (36%) | |
| Populus (45,555) | 1e-5 | 17724 (39%) | 11580 (25%) |
| 1e-10 | 15383 (34%) | 10962 (24%) | |
| 1e-20 | 11190 (25%) | 9701 (21%) | |
| Oryza (66,710) | 1e-5 | 14510 (22%) | 9893 (15%) |
| 1e-10 | 12139 (18%) | 9193 (14%) | |
| 1e-20 | 8393 (13%) | 7834 (12%) |
| DATA CATEGORY | DATA |
| Counter IDIN | 37–95 |
| Station | 95 |
| County | 37 |
| City | 35 |
| Route | 65 |
| Mile point | 250.08 |
| AADT 2009 | 115,150 |
| AADT 2008 | 113,900 |
| AADT 2007 | 118,520 |
| AADT 2006 | 117,930 |
| AADT 2005 | 117,800 |
| AADT 2004 | 115,060 |
| AADT 2003 | 113,300 |
| AADT 2002 | 109,720 |
| AADT 2001 | 110,210 |
| K | 10 |
| D | 65 |
| TDHV | 8 |
| TADT | 11 |
| Heavy | 70 |
| Functional Class | 11 |
| Clinical features | |
| Number of patients | 13 |
| Women/men | 7/6 |
| Age (years), mean ± SD | 52.02 ± 19.01 |
| Triggering factor | |
| AOSD flare, number (%) | 13 (100) |
| Lymphoma, number (%) | 0 |
| Infectious disease, number (%) | 0 |
| Laboratory features | |
| WBC (103/mL), mean ± SD | 3.28 ± 1.36 |
| RBC (103/mL), mean ± SD | 3.31 ± 0.69 |
| HB (gr/dL), mean ± SD | 9.19 ± 2.05 |
| PLT (103/mL), mean ± SD | 55.52 ± 46.54 |
| Serum Ferritin (ng/mL), mean ± SD | 4362.15 ± 7569.70 |
| ESR (mm/hour), mean ± SD | 71.23 ± 30.19 |
| CRP (mg/L), mean ± SD | 74.76 ± 46.92 |
| Triglycerides (mg/dL), mean ± SD | 183.12 ± 69.33 |
| ASAT (IU/L), mean ± SD | 74.59 ± 41.89 |
| ALAT (IU/L), mean ± SD | 129.98 ± 91.21 |
| Treatments | |
| High dosage steroid pulses, number (%) | 13 (100) |
| Immunosuppressive drugs, number (%) | 7 (53.84) |
| Cyclosporine A, number (%) | 5 (38.46) |
| Methotrexate, number (%) | 2 (15.38) |
| Etoposide | 0 |
| Biologic drugs | 2 (15.38) |
| Deaths, number (%) | 10 (76.92) |
| Number of relapses in MAS-survivors patients, mean ± SD | 2.66 ± 1.69 |
| Section | Conventional1 | Enzymatic | ||
| % | (US$ × 100) | % | (US$ × 100) | |
| Grain handling | 8.2 | 6,500 | 8.7 | 6,500 |
| Steeping (or pretreatment) | 22.3 | 17,700 | 10.7 | 8,000 |
| Enzymatic treatment | 0 | 0 | 4.9 | 3,700 |
| Germ separation | 13.5 | 10,700 | 14.4 | 10,800 |
| Fiber separation | 23.7 | 18,800 | 25.9 | 19,400 |
| Gluten separation | 27.1 | 21,500 | 30.0 | 22,500 |
| Starch washing | 5.2 | 4,100 | 5.5 | 4,100 |
| TOTAL | 100.0 | 79,300 | 100.0 | 75,000 |
| Domain | Scale/items | Parent-report | Self-report |
| Sexual socialization | Friendship skills of child | 5 items | 5 items |
| Social acceptance by peers | 3 items | 6 items | |
| Romantic ability of child | - | 3 items | |
| Openness about intimacy | 4 items | 3 items | |
| Adequate dealing with boundaries | 8 items | - | |
| Sexual selfhood | Bodily perception | 3 items | 6 items |
| Self-esteem | - | 12 items | |
| Perceived social competence | - | 12 items | |
| Sexual knowledge of the child according to parent | 9 items | - | |
| Sexual behavior | Separate items on age or context appropriate behaviors, intimate experiences including age of onset and sexual orientation | 33 items | 41 items |
| Moderately/severely thin | Mildly thin | Overweight | Obese | |||||
| IMD decile | % (n) | RRR (95 % CI) | % (n) | RRR (95 % CI) | % (n) | RRR (95 % CI) | % (n) | RRR (95 % CI) |
| Girls | ||||||||
| Most advantaged | 0.71 (855) | - | 4.14 (4 998) | - | 14.45 (17 426) | - | 2.95 (3 563) | - |
| 2 | 0.76 (868) | 1.08 (0.98, 1.19) | 4.01 (4 606) | 0.98 (0.94, 1.02) | 15.09 (17 334) | 1.06 (1.04, 1.08) | 3.36 (3 980) | 1.19 (1.14, 1.25) |
| 3 | 0.74 (812) | 1.07 (0.97, 1.17) | 4.01 (4 426) | 0.99 (0.95, 1.03) | 15.46 (17 055) | 1.09 (1.07, 1.12) | 3.84 (4 236) | 1.33 (1.27, 1.39) |
| 4 | 0.75 (805) | 1.10 (1.00, 1.21) | 4.02 (4 315) | 1.00 (0.96, 1.05) | 15.97 (17 138) | 1.14 (1.11, 1.17) | 4.04 (4 334) | 1.41 (1.35, 1.48) |
| 5 | 0.79 (876) | 1.17 (1.07, 1.29) | 4.0 (4 408) | 1.01 (0.97, 1.05) | 16.12 (17 761) | 1.16 (1.14, 1.19) | 4.53 (4 990) | 1.60 (1.53, 1.67) |
| 6 | 0.86 (991) | 1.28 (1.17, 1.41) | 4.10 (4 739) | 1.05 (1.00, 1.09) | 16.53 (19 121) | 1.21 (1.19, 1.24) | 5.00 (5 784) | 1.79 (1.72, 1.87) |
| 7 | 0.89 (1 089) | 1.37 (1.25, 1.50) | 4.41 (5 374) | 1.15 (1.11, 1.20) | 17.06 (20 768) | 1.28 (1.25, 1.31) | 5.60 (6 816) | 2.05 (1.96, 2.13) |
| 8 | 1.02 (1 370) | 1.57 (1.44, 1.71) | 4.5 (6 042) | 1.18 (1.14, 1.23) | 16.77 (22 529) | 1.27 (1.25, 1.30) | 6.11 (18 210) | 2.25 (2.16, 2.34) |
| 9 | 1.06 (1 605) | 1.67 (1.53, 1.81) | 4.8 (7 254) | 1.28 (1.24, 1.33) | 17.25 (26 091) | 1.34 (1.31, 1.37) | 6.77 (10 238) | 2.54 (2.44, 2.64) |
| Least advantaged | 1.14 (2 009) | 1.80 (1.66, 1.95) | 4.73 (8 317) | 1.27 (1.23, 1.32) | 17.36 (30 561) | 1.36 (1.34, 1.39) | 7.18 (12 630) | 2.71 (2.61, 2.82) |
| Total n | 11 280 | 54 479 | 205 784 | 64 781 | ||||
| Boys | ||||||||
| Most advantaged | 0.65 (828) | - | 4.88 (6 183) | - | 9.97 (12 618) | - | 2.03 (2 573) | - |
| 2 | 0.68 (822) | 1.05 (0.96, 1.16) | 4.64 (5 608) | 0.96 (0.93, 1.00) | 10.71 (12 932) | 1.08 (1.06, 1.11) | 2.42 (2 920) | 1.20 (1.14, 1.27) |
| 3 | 0.67 (775) | 1.05 (0.95, 1.16) | 4.59 (5 295) | 0.96 (0.92, 1.00) | 11.22 (12 958) | 1.14 (1.11, 1.17) | 2.63 (3 033) | 1.32 (1.25, 1.39) |
| 4 | 0.75 (839) | 1.18 (1.07, 1.30) | 4.77 (5 352) | 1.01 (0.97, 1.05) | 11.61 (13 036) | 1.20 (1.17, 1.23) | 2.89 (3 243) | 1.47 (1.39, 1.55) |
| 5 | 0.78 (911) | 1.25 (1.14, 1.38) | 4.77 (5 544) | 1.02 (0.98, 1.06) | 11.93 (13 863) | 1.25 (1.22, 1.28) | 3.23 (3 748) | 1.65 (1.57, 1.74) |
| 6 | 0.84 (1 026) | 1.37 (1.25, 1.50) | 5.01 (6 088) | 1.08 (1.05, 1.12) | 12.30 (14 947) | 1.31 (1.28, 1.34) | 3.74 (4 539) | 1.94 (1.85, 2.04) |
| 7 | 0.91 (1 153) | 1.49 (1.36, 1.63) | 4.98 (6 328) | 1.09 (1.05, 1.13) | 12.82 (16 285) | 1.38 (1.35, 1.41) | 4.08 (5 188) | 2.15 (2.05, 2.25) |
| 8 | 1.03 (1 443) | 1.71 (1.56, 1.86) | 5.16 (7 242) | 1.14 (1.10, 1.18) | 13.02 (18 286) | 1.43 (1.40, 1.47) | 4.54 (6 384) | 2.42 (2.31, 2.54) |
| 9 | 1.11 (1 765) | 1.87 (1.72, 2.04) | 5.36 (8 504) | 1.21 (1.17, 1.25) | 13.33 (21 170) | 1.49 (1.46,1.53) | 5.08 (8 066) | 2.75 (2.62, 2.87) |
| Least advantaged | 1.16 (2 125) | 1.97 (1.81, 2.13) | 5.49 (10 062) | 1.25 (1.21, 1.29) | 13.63 (24 989) | 1.54 (1.51,1.58) | 5.33 (9 769) | 2.91 (2.78, 3.04) |
| Total n | 11 687 | 66 206 | 161 084 | 49 463 |
| Species | Ratio Gavage/i.p. | Mean Ratio |
| G. pacificus | >800, >1000, >340 | >713 |
| G. honu | 395, 500 | 448 |
| G. australes | 54, 108, 80, 94, 126, 79, 100 | 92 |
| G. cheloniae | 369, 170 | 270 |
| G. carpenteri | >16 | - |
| F. paulensis | >63 | - |
| G. polynesiensis | 1.7 | - |
| Up-regulated miRNAs | Down-regulated miRNAs |
| mmu-miR-2137 | mmu-miR-1199-3p |
| mmu-miR-5131 | mmu-miR-218-5p |
| mmu-miR-680 | mmu-miR-7a-5p |
| mmu-miR-5130 | mmu-miR-374c-5p |
| mmu-miR-144 | mmu-miR-449c-5p |
| mmu-miR-486 | mmu-miR-450a-2-3p |
| mmu-miR-711 | mmu-miR-696 |
| mmu-miR-449a | |
| mmu-miR-193 | |
| mmu-miR-34c-5p | |
| mmu-miR-2861 | |
| mmu-miR-211-3p | |
| mmu-miR-763 | |
| mmu-miR-128-2-5p | |
| mmu-miR-542-5p | |
| mmu-miR-3473 | |
| mmu-miR-511-3p | |
| mmu-miR-34c-5p | |
| mmu-miR-143-5p | |
| mmu-miR-5115 |
| Data source | Exhaustive search | KL1LR | ||||||
| # of GO terms (# in union) | AUC | # of GO terms (# in union) | AUC | NCG | ||||
| Protein-protein interactions | OPHID | 192 | 0.82 | 201 | 0.89 | 83 | ||
| Protein domain | Interpro | 522 | (697) | 0.87 | 408 | (518) | 0.89 | 266 |
| Pfam | 600 | 0.86 | 311 | 0.89 | 210 | |||
| Phenotype | MGI | 213 | 0.87 | 346 | 0.90 | 129 | ||
| Phylogenetic profile | BioMart | 33 | (95) | 0.83 | 59 | (166) | 0.88 | 4 |
| Inparanoid | 70 | 0.84 | 124 | 0.88 | 22 | |||
| Disease | OMIM | 41 | 0.85 | 32 | 0.88 | 3 | ||
| Gene expression | Zhang et al. | 28 | 0.81 | 147 | 0.90 | 10 | ||
| Su et al. | 21 | (55) | 0.82 | 158 | (309) | 0.89 | 8 | |
| Sage et al. | 16 | 0.83 | 113 | 0.90 | 7 |
| Criterion | Score | |
| No | Yes | |
| Tortuous vessels | 0 | 1 |
| Large vessels | 0 | 1 |
| Leakage | 0 | 1 |
| Defective flux | 0 | 1 |
| BMI classes | Mean | 95% C.I | N |
| Normal Weight | 21.7 | 20.8–22.6 | 84 |
| Overweight | 19.1 | 18.3–19.8 | 123 |
| Obese Class I | 18.2 | 17.3–19.1 | 77 |
| Obese Class II | 17.4 | 16.3–18.7 | 37 |
| Obese Class III | 17.0 | 15.9–18.1 | 59 |
| January | February | March | April | May | June | July | August | September | October | November | December | Total | |
| Girls | 7057 | 6897 | 7724 | 7414 | 7726 | 7303 | 7600 | 7544 | 7243 | 7078 | 6337 | 6552 | 86475 |
| Boys | 7280 | 7023 | 7781 | 7750 | 8184 | 7480 | 8021 | 7739 | 7624 | 7199 | 6567 | 6637 | 89285 |
| Total | 14337 | 13920 | 15505 | 15164 | 15910 | 14783 | 15621 | 15283 | 14867 | 14277 | 12904 | 13189 | 175760 |
| Patients with IBS | Healthy controls | p value | |
| (n = 89) | (n = 13) | ||
| Age in years, mean ± SD | 45.7 ± 12.9 | 43.3 ± 8.6 | 0.595 |
| Sex, male/female | 47/42 | 9/4 | 0.266 |
| BMI, kg/m2 | 22.1 ± 5.8 | 24.5 ± 2.9 | 0.245 |
| Anxiety, mean ± SD | 5.17 ± 3.16 | 2.77 ± 1.64 | 0.009 |
| Depression, mean ± SD | 5.52 ± 3.30 | 3.54 ± 2.50 | 0.041 |
| LES | 40.0 (11.0–75.0) | 8.0 (0.0–35.0) | <0.001 |
| Variables | Overall survival(RR, 95% CI) | p | Disease-specific survival(RR, 95% CI)) | p | Disease-free survival(RR, 95% CI) | p | Loco-regional control(RR, 95% CI) | p | Distant metastasis-free survival(RR, 95% CI) | p |
| T1-2 vs. T3-4 | 1.29, 0.56-2.98 | 0.56 | 1.42, 0.41-4.86 | 0.58 | 0.85, 0.34-2.16 | 0.73 | 1.44, 0.27-7.64 | 0.67 | 1.00, 0.36-2.81 | 1.00 |
| N0-2 vs. N3 | 2.47, 0.48-12.71 | 0.28 | 1.86, 0.15-23.26 | 0.63 | 2.85, 0.53-15.18 | 0.22 | 39.06, 1.55-983.27 | 0.03 | 2.77, 0.54-14.07 | 0.22 |
| Cranial nerve involvement | 0.71, 0.26-1.95 | 0.51 | 0.73, 0.17-3.13 | 0.67 | 0.65, 0.18-2.28 | 0.50 | 0.11, 0.006-2.10 | 0.14 | 0.95, 0.26-3.46 | 0.94 |
| Supraclavicular nodes | 0.74, 0.15-3.74 | 0.71 | 0.78, 0.06-9.59 | 0.85 | 0.45, 0.08-2.50 | 0.36 | 0.02, 0.001-0.87 | 0.04 | 0.68, 0.13-3.43 | 0.64 |
| GTVprn (13 ml) | 2.92, 1.22-6.98 | 0.02 | 4.10, 1.06-15.97 | 0.04 | 4.81, 1.73-13.36 | < 0.01 | 16.83, 1.48-190.78 | 0.02 | 2.50, 0.84-7.43 | 0.10 |
| Characteristics | n | P-valuea,b | Hazard ratioa,b | 95% CIa,b |
| Age | ||||
| < 20 | 18 (82%) | |||
| > 20 | 4 (18%) | 0.06 | 0.16 | 2.3 × 10−10–1.3 |
| Median | 13 | |||
| Gender | ||||
| Male | 15 (68%) | 0.05 | 0.20 | 1.9 × 10−10–1.2 |
| Female | 7 (32%) | |||
| Tumor volume (cm3) | ||||
| Median | 1,476 | 0.40 | 0.48 | 0.04–3.0 |
| Range | 85–10,590 | |||
| Tumor surface (cm2) | ||||
| Median | 19.2 | 0.43 | 0.50 | 0.02–3.3 |
| Range | 3.2–57.7 | |||
| Pattern on MRI | ||||
| Concentric | 19 (86%) | 0.72 | 0.47 | 0.10–2.1 |
| Longitudinal | 3 (14%) | |||
| Histologic response | ||||
| Good | 12 (54%) | – | – | – |
| Poor | 10 (46%) | – | – | – |
| Pathologic subtype | ||||
| Osteoblastic | 10 (46%) | – | – | – |
| Chondroblastic | 6 (27%) | – | – | – |
| Fibroblastic | 4 (18%) | – | – | – |
| Other | 2 (9%) | – | – | – |
| Location | ||||
| Distal femur | 22 (100%) | – | – | – |
| Metastatic disease | ||||
| No | 22 (100%) | – | – | – |
| Date | Advance | Applications |
| 1670s | Microscope invented by Leeuwenhoek | Visualize bacteria, protozoa |
| 1850s | Puerperal fever identified as infectious and interventions implemented by Semmelweis [23] | Hospital infection control motivated by growing understanding of microbial etiology |
| 1864 | Cholera transmission by water proven by Snow | Risk factor (mode of transmission) and prevention measure for specific infectious syndrome |
| 1890s | Proof of parasitic origin (Grassi) and mosquito transmission (Ross) of malaria | Vector control |
| 1890s | Identification of microbial etiologies for tuberculosis, anthrax, and so on; Koch’s postulates | Targeted diagnostics, therapeutics, and move from syndromic diagnosis to pathogen identification |
| 1900-1930s | Discovery of filterable animal viruses [24] | Influenza etiology settled (previously thought bacterial) [25] |
| 1910s-1950s | Phenotypic subspecies taxonomy: serotyping [26,27], phage typing [28] | Association of particular types with prognosis [27,29], drug resistance |
| 1944 | Discovery of DNA as the genetic material [30] | Basis for genotyping tools for molecular epidemiology |
| 1970 | Restriction enzymes [31] | Basis for restriction fragment length polymorphism approaches, including pulsed field gel electrophoresis |
| 1975-1985 | Sanger DNA sequencing [32], PCR [33] | Basis for variable number tandem repeat (VNTR) and multilocus sequence typing (MLST) approaches to characterize microbes and their genetic relatedness |
| 2000s-now | High-throughput rapid sequencing technologies | Microbial genome sequencing |
| Conditions | Biological Process | FDRp-value | Molecular Function | FDRp-value |
| Control | response to abiotic or biotic stimulus | 2.8e-19 | transcription factor activity | 3.4e-04 |
| response to stress | 1.6e-13 | other enzyme activity | 2.1e-03 | |
| other biological processes | 7.7e-10 | other molecular functions | 4.5e-02 | |
| Cold | response to stress | 4.9e-08 | transcription factor activity | 1.7e-07 |
| other biological processes | 1.3e-07 | receptor binding or activity | 3.8e-03 | |
| response to abiotic or biotic stimulus | 8.1e-06 | kinase activity | 2.9e-02 | |
| transcription | 3.3e-04 | |||
| signal transduction | 3.2e-03 | |||
| Genotoxic | response to abiotic or biotic stimulus | 2.9e-20 | kinase activity | 7.6e-06 |
| response to stress | 3.8e-16 | transcription factor activity | 8.9e-04 | |
| other biological processes | 1.8e-11 | transferase activity | 1.7e-03 | |
| signal transduction | 7.3e-03 | transporter activity | 1.4e-02 | |
| Osmotic | response to stress | 1.4e-16 | transferase activity | 7.0e-04 |
| response to abiotic or biotic stimulus | 1.4e-14 | kinase activity | 1.4e-03 | |
| other biological processes | 1.3e-08 | transcription factor activity | 1.3e-02 | |
| signal transduction | 1.3e-02 | other molecular functions | 4.3e-02 | |
| Salt | response to abiotic or biotic stimulus | 3.0e-12 | structural molecule activity | 1.1e-13 |
| response to stress | 6.0e-07 | transferase activity | 2.3e-03 | |
| other biological processes | 3.3e-03 | other enzyme activity | 2.4e-02 | |
| UV-B | response to abiotic or biotic stimulus | 3.1e-12 | transferase activity | 1.3e-02 |
| response to stress | 2.3e-11 | kinase activity | 1.4e-02 | |
| other biological processes | 1.6e-08 | |||
| Wounding | response to abiotic or biotic stimulus | 1.4e-17 | other enzyme activity | 6.3e-06 |
| response to stress | 1.0e-15 | transferase activity | 2.1e-03 | |
| other biological processes | 1.1e-10 | transcription factor activity | 2.1e-03 | |
| other metabolic processes | 4.7e-02 | hydrolase activity | 1.2e-02 | |
| transporter activity | 4.1e-02 | |||
| Drought | response to abiotic or biotic stimulus | 2.8e-19 | structural molecule activity | 7.9e-18 |
| response to stress | 6.0e-19 | transferase activity | 6.7e-05 | |
| other biological processes | 6.4e-10 | other enzyme activity | 3.8e-04 | |
| other metabolic processes | 1.8e-02 | |||
| Heat | other biological processes | 7.0e-12 | transferase activity | 9.3e-04 |
| response to abiotic or biotic stimulus | 7.7e-10 | other enzyme activity | 2.1e-03 | |
| response to stress | 3.4e-08 | hydrolase activity | 3.1e-02 | |
| electron transport or energy pathways | 9.5e-03 | |||
| Oxidative | response to abiotic or biotic stimulus | 7.3e-17 | transcription factor activity | 2.2e-03 |
| other biological processes | 6.5e-14 | other enzyme activity | 5.7e-03 | |
| response to stress | 7.7e-10 | kinase activity | 1.4e-02 | |
| transferase activity | 1.6e-02 |
| Did not require ICU(n = 249) | Required ICU (severe)(n = 18) | Pb value | |
| N (%) | N (%) | ||
| Any medical risk factor a | 115 (46.2) | 11 (61.1) | .22 |
| Influenza B strain | 47 (19.0) | 7 (38.9) | .04 |
| Iron‐deficient anaemia | 21 (8.4) | 5 (27.8) | .01 |
| Food allergy | 6 (2.4) | 2 (11.1) | .09 |
| Proportion less than 2 y of age | 150 (60.2) | 14 (77.8) | .14 |
| Antiviral prescribed | 34 (13.7) | 2 (11.8) | .82 |
| Antibiotic prescribed | 121 (48.8) | 9 (52.9) | .74 |
| Co‐infection identified | 99 (39.8) | 8 (47.1) | .55 |
| Baseline characteristics | Missed scheduled appointments (%) | RR | 95 % CI | p (value) | |
| Sex | Female | 4/153 (2.6) | 1 | ||
| Male | 33/304 (10.9) | 4.2 | 1.5–11.5 | 0.004 | |
| Age (years) | <25 | 5/82 (6.1) | 1 | ||
| 25–64 | 31/360 (8.6) | 1.4 | 0.6–3.5 | 0.21 | |
| ≥65 | 1/15 (6.7) | 1.1 | 0.1–8.7 | 1 | |
| HIV-Status | Negative | 34/346 (9.8) | 1 | ||
| Positive | 3/108 (2.8) | 0.3 | 0.1–0.9 | 0.03 | |
| Unknown | 0/3 (0) | - | - | ||
| Type of TB | New SS+ | 36/410 (9.8) | 1 | ||
| Retreatment | 1/47 (4.3) | 0.2 | 0.03–1.7 | 0.16 | |
| Place of treatment | CNHP-P | 21/259 (8.1) | 1 | ||
| DOT clinic | 16/198 (8.1) | 1.0 | 0.5–1.9 | 0.99 |
| Explanatory variable | Coefficient ± Standar Error | P |
| Body Fat at follow-up equation, kg | ||
| Leisure time physical activity at follow-up, METs/wk | −0.215 ± 0.091 | 0.019 |
| Calorie Intake at follow-up, 100 kcal | 0.328 ± 0.142 | 0.021 |
| Age at follow-up | 0.115 ± 0.036 | 0.001 |
| Height at follow-up | 0.520 ± 0.092 | < 0.001 |
| Constant | 28.399 ± 0.425 | < 0.001 |
| Leisure time physical activity at follow-up equation, METs/wk | ||
| Body fat at follow-up, kg | 1.059 ± 0.456 | 0.020 |
| Depression score at follow-up, CES-D* | −0.191 ± 0.095 | 0.045 |
| Age at follow-up | −0.025 ± 0.071 | 0.722 |
| Constant | −30.038 ± 12.750 | 0.018 |
| Calorie Intake at follow-up equation, 100 kcal | ||
| Body fat at follow-up, kg | −0.341 ± 0.183 | 0.063 |
| Depression score at follow-up, CES-D* | 0.188 ± 0.048 | < 0.001 |
| Age at follow-up | −0.067 ± 0.035 | 0.057 |
| Constant | 9.630 ± 5.285 | 0.068 |
| Error Covariances | ||
| Calorie intake with physical activity | −26.882 ± 20.302 | 0.185 |
| Brain regions | Voxels | X (MNI) | Y (MNI) | Z (MNI) | T value | |
| High BrAC group < control | ||||||
| Superior frontal gyrus | R | 750 | 15 | 21 | 57 | −4.6134 |
| R | 39 | 12 | 39 | −24 | −3.7952 | |
| Inferior frontal gyrus | R | 37 | 54 | 21 | 18 | −4.4388 |
| Hippocampal gyrus | R | 39 | 18 | −6 | −33 | −4.6794 |
| Inferior temporal gyrus | R | 30 | 33 | 9 | −45 | −4.2946 |
| High BrAC group > control | ||||||
| Middle frontal gyrus | L | 100 | −27 | 45 | 3 | 4.7207 |
| R | 42 | 12 | −21 | 60 | 6.4199 | |
| Basal ganglia | L | 468 | −27 | 12 | −3 | 5.7696 |
| Cerebellum | R | 114 | 9 | 48 | −24 | 6.8909 |
| Internal capsule | R | 39 | 9 | 0 | 6 | 3.9489 |
| Gene | Acc. No | Primer sequence (5′ to 3′) |
| Pparg (mouse) | NM_001127330 | F: GACCACTCGCATTCCTTT |
| R: CCACAGACTCGGCACTCA | ||
| Fabp4 (mouse) | NM_024406 | F: AAATCACCGCAGACGACA |
| R: CACATTCCACCACCAGCT | ||
| Runx2 (mouse) | NM_001146038 | F: ACTTCCTGTGCTCCGTGCTG |
| R: TCGTTGAACCTGGCTACTTGG | ||
| Osterix (mouse) | NM_130458 | F: ACCAGGTCCAGGCAACAC |
| R: GCAAAGTCAGATGGGTAAGTAG | ||
| Tmem64 (mouse) | NM_181401 | F: AGGAAGCGGCCTGAAGGT |
| R: GAAGGAAGAGCCACTGGGAT | ||
| β-actin (mouse) | NM_007393 | F: CTGTCCCTGTATGCCTCTG |
| R: TGATGTCACGCACGATTT |
| Dataset | Sum of Weights | |||||
| Deterministic Model | Stochastic Model | |||||
| Before Failure | After Failure | W-GAP | Before Failure | After Failure | W-GAP | |
| Dataset_1 | 37.6 | 33 | 12.2% | 36.3 | 36.3 | 0.0% |
| Dataset_2 | 35.9 | 31.6 | 12.0% | 35.3 | 33.8 | 4.2% |
| Dataset_3 | 35.9 | 26.4 | 26.5% | 32.9 | 32.9 | 0.0% |
| Dataset_4 | 33.1 | 23.6 | 28.7% | 32.1 | 26.9 | 16.2% |
| Dataset_5 | 27.7 | 21.7 | 21.7% | 26.5 | 21.9 | 17.4% |
| Dataset_6 | 34.6 | 30.4 | 12.1% | 33.9 | 33.9 | 0.0% |
| Dataset_7 | 32.2 | 31.1 | 3.4% | 31.4 | 31.4 | 0.0% |
| Dataset_8 | 34 | 25.8 | 24.1% | 32.5 | 30.9 | 4.9% |
| Dataset_9 | 34.5 | 26.9 | 22.0% | 32.4 | 32.4 | 0.0% |
| Dataset_10 | 29.4 | 26.1 | 11.2% | 28.3 | 28.3 | 0.0% |
| Average | 33.5 | 27.7 | 17.4% | 32.2 | 30.9 | 4.0% |
| Girls | Boys | ||
| Goodness-of-fit statistics | 1-factor model | 2- factor model | 1-factor model |
| χ2 | 8.13 | 4.41 | 4.44 |
| df | 5 | 4 | 5 |
| p | .15 | .35 | .49 |
| RMSEA | .028 | .018 | .00 |
| CFI | .98 | .99 | 1.00 |
| TLI | .97 | .98 | 1.02 |
| r | .61 |
| First outbreak (October 2013) | Second outbreak (July 2014) | |||||
| Water temperature: 23 °C | Water temperature: 26 °C | |||||
| Cage | Date stocked | Age at stocking (months) | Average weight at first outbreak (g) | Cumulative mortality (%) | Average weight at second outbreak (g) | Cumulative mortality (%) |
| 1 | April 2012 | 2 | 323 | 4,82 | 336 | 4,86 |
| 2 | April 2012 | 2 | 319 | 5,30 | 440 | 5,3 |
| 3 | July 2012 | 5 | 292 | 4,76 | 441 | 4,76 |
| 4 | April 2013 | 2 | 84 | 2,23 | 274 | 2,23 |
| Treatment | Days from transplant to initial bolting (d) | Days from transplant to 50% bolting (d) | Bolting rate by 30 April (%) | |||
| 2011 | 2012 | 2011 | 2012 | 2011 | 2012 | |
| Grand mean | 128.4 | 139.7 | 140.5 | - | 39.7 | 16.0 |
| Cultivars | ||||||
| JinGuan | 110.9ca | 118.6c | 125.8c | - | 53.9a | 26.7a |
| XiaHei | 145.2a | 158.9a | -a | - | 29.3c | 5.9c |
| YeFu | 129.1b | 141.6b | 130.8b | - | 36.0b | 15.5b |
| Sowing date | ||||||
| 08.20 | 118.0c | 124.2c | 119.8c | - | 64.5a | 30.1a |
| 09.09 | 125.6b | 141.9b | 136.8b | - | 39.7b | 12.6b |
| 09.29 | 141.7a | 152.9a | -a | - | 15.0c | 5.4c |
| Transplant location | ||||||
| Open field | 155.0a | 151.9a | -a | - | 9.3c | 5.6c |
| Cold shed | 123.7b | 138.4b | 132.8b | - | 44.7b | 16.0b |
| Plastic tunnel | 106.6c | 128.7c | 123.8c | - | 65.2a | 26.4a |
| F-test | ||||||
| Cultivar (C) | *** | *** | *** | NS | *** | *** |
| Sowing date (D) | *** | *** | *** | NS | *** | *** |
| Transplant location (L) | *** | *** | *** | NS | ** | *** |
| C*D | *** | *** | * | NS | *** | *** |
| C*L | *** | *** | NS | NS | * | *** |
| D*L | *** | *** | ** | NS | *** | *** |
| C*D*L | *** | *** | NS | NS | *** | *** |
| Brain region | BA | Cluster sizes | t-value | P value | Peak MNI coodinate | ||
| (voxels) | (Corr.) | X | Y | Z | |||
| R medial prefrontal cortex | 8 | 12 | 6.02 | <.05 | 9 | 27 | 57 |
| R middle frontal gyrus | 9 | 211 | 10.87 | <.05 | 3 | 48 | 21 |
| L middle temporal gyrus | 21 | 14 | −5.49 | <.05 | −66 | −54 | 3 |
| R superior temporal gyrus | 38 | 12 | −5.59 | <.05 | 54 | 12 | −18 |
| L primary somatosensory cortex | 2 | 19 | −3.88 | <.05 | −60 | −21 | 42 |
| R inferior parietal lobule | 40 | 10 | −10.94 | <.05 | 66 | −36 | 21 |
| L parahippocampal gyrus | ― | 11 | −5.62 | <.05 | −9 | −3 | −21 |
| R parahippocampal gyrus | 35 | 29 | 9.51 | <.05 | 30 | −6 | −21 |
| L anterior cingulate cortex | 32 | 12 | −4.74 | <.05 | −6 | 21 | 39 |
| R precuneus | 7 | 14 | 4.70 | <.05 | 18 | −66 | 33 |
| R insula | 13 | 10 | 5.47 | <.05 | 39 | 0 | 18 |
| R cerebellar tonsil | ― | 13 | 5.30 | <.05 | 9 | −60 | −48 |
| Category | Treatment adherence barriers |
| Stigma related factors | ▪ Fear of disclosure of child’s status to the teachers and family members by parents |
| ▪ Segregation by teachers and other children | |
| Lack of supportive environment at home | ▪ Inadequate support from parents |
| ➢ Parents move to farming areas without one to follow up on child’s treatment schedule | |
| ➢ Men do not provide enough treatment adherence support | |
| ➢ Extended family members do not provide support | |
| Lack of supportive environment from school | ▪ Teachers do not provide adequate support to children on ART |
| Health service delivery factors | ▪ Lack of child friendly counseling services |
| ▪ Inconvenient treatment schedule | |
| ▪ Longevity of treatment | |
| Patient factor | ▪ Forgetfulness |
| ▪ Feeling better |
| Factor | |
| 1 | |
| Me siento cansado y desanimado cuando me levanto por las mañanas | 0.612 |
| Mis músculos están tensos y doloridos | 0.650 |
| Tengo ataques de pánico | 0.388 |
| Rechino los dientes o aprieto la mandíbula | 0.342 |
| Tengo problemas de diarrea o estreñimiento | 0.400 |
| Necesito ayuda pare realizar mis actividades diarias | 0.476 |
| Soy sensible a la luz brillante | 0.440 |
| Me canso fácilmente cuando estoy físicamente activo | 0.724 |
| Siento dolor en todo mi cuerpo | 0.582 |
| Tengo dolores de cabeza | 416 |
| Tengo molestia en mi vejiga o sensación de quemazón al orinar | 0.294 |
| No duermo bien | 0.504 |
| Tengo dificultad para concentrarme | 0.436 |
| Tengo problemas en la piel como resequedad, picor o sarpullido | 0.299 |
| El estrés hace que mis síntomas físicos empeoren | 0.587 |
| Me siento triste o deprimido | 0.621 |
| Me siento con poca energía | 0.718 |
| Tengo tensión muscular en mi cuello y hombros | 0.555 |
| Tengo dolor en mi mandíbula | 0.426 |
| Algunos olores, como perfumes, me hacen sentir náuseas. | 0.269 |
| Tengo que orinar frecuentemente | 0.276 |
| Mis piernas se sienten incómodas e inquietas cuando intento dormir por la noche | 0.476 |
| Tengo dificultad para recordar cosas | 0.482 |
| Sufrí algún trauma cuando era niño (a) | 0.120 |
| Tengo dolor en mi zona pélvica | 0.289 |
| Symbol | 2 Days vs. Ctr | 4 Days vs. Ctr | 7 Days vs. Ctr | |||
| P-Value | Fold Change | P-Value | Fold Change | P-Value | Fold Change | |
| ANKRD50 | 2.82 × 10−2 | −1.323 | 2.32 × 10−6 | −2.191 | 2.35 × 10−4 | −1.749 |
| ANKRD36B | 4.65 × 10−3 | −2.292 | 1.85 × 10−3 | −2.546 | 9.24 × 10−3 | −1.979 |
| C9orf3 | 7.91 × 10−4 | −3.622 | 5.04 × 10−4 | −3.860 | 6.56 × 10−2 | −1.938 |
| CCDC88C | 1.82 × 10−1 | −1.363 | 1.51 × 10−1 | −1.398 | 6.70 × 10−3 | −2.041 |
| CYP24A1 | 9.28 × 10−1 | −1.027 | 8.44 × 10−1 | −1.060 | 3.32 × 10−2 | −2.011 |
| DGKH | 3.48 × 10−5 | −1.619 | 8.80 × 10−8 | −2.114 | 2.51 × 10−5 | −1.681 |
| DHFR | 3.77 × 10−4 | −1.779 | 6.90 × 10−4 | −1.717 | 3.10 × 10−5 | −2.139 |
| FAP | 2.07 × 10−1 | −1.562 | 4.72 × 10−1 | −1.284 | 3.01 × 10−2 | −2.314 |
| GTF2B | 2.33 × 10−2 | −1.580 | 6.39 × 10−4 | −2.131 | 1.37 × 10−3 | −2.072 |
| HDCA1 | 8.97 × 10−1 | −1.015 | 2.43 × 10−1 | −1.147 | 1.11 × 10−2 | −3.399 |
| HAS2 | 6.50 × 10−2 | −1.375 | 7.49 × 10−4 | −1.920 | 8.18 × 10−5 | −2.342 |
| LIF | 4.97 × 10−2 | −1.906 | 2.85 × 10−1 | −1.403 | 1.23 × 10−2 | −2.440 |
| LRRN1 | 2.41 × 10−1 | −1.422 | 1.78 × 10−1 | −1.501 | 1.71 × 10−2 | −2.217 |
| mir-21 | 5.77 × 10−4 | −2.677 | 6.96 × 10−5 | −3.347 | 7.02 × 10−3 | −2.131 |
| MPLKIP | 2.86 × 10−4 | −1.829 | 1.59 × 10−4 | −1.983 | 4.89 × 10−6 | −2.618 |
| NPIPL3 | 3.40 × 10−3 | −2.249 | 2.27 × 10−3 | −2.348 | 5.88 × 10−2 | −1.398 |
| NRG1 | 1.57 × 10−3 | −1.666 | 4.65 × 10−5 | −2.067 | 1.12 × 10−4 | −2.022 |
| PLA2G7 | 6.14 × 10−1 | −1.062 | 3.73 × 10−2 | −1.299 | 1.61 × 10−5 | −2.018 |
| PSD3 | 1.43 × 10−1 | −1.141 | 1.78 × 10−5 | −2.162 | 9.70 × 10−5 | −2.012 |
| RNF152 | 4.83 × 10−1 | −1.118 | 1.16 × 10−4 | −2.119 | 6.23 × 10−2 | −1.381 |
| SESN3 | 6.85 × 10−2 | −1.206 | 5.50 × 10−7 | −2.044 | 6.02 × 10−5 | −1.684 |
| SLC7A11 | 1.55 × 10−1 | −1.279 | 3.03 × 10−4 | −2.078 | 1.02 × 10−3 | −1.963 |
| SMAD2 | 4.59 × 10−3 | −1.526 | 9.51 × 10−6 | −2.195 | 2.76 × 10−4 | −1.848 |
| SMG1 | 1.43 × 10−4 | −2.030 | 2.45 × 10−5 | −2.503 | 4.67 × 10−4 | −1.395 |
| TAF1D | 7.99 × 10−3 | −1.961 | 2.85 × 10−3 | −2.177 | 2.71 × 10−2 | −1.770 |
| TRA2A | 1.38 × 10−3 | −2.456 | 3.45 × 10−3 | −2.229 | 6.73 × 10−4 | −1.357 |
| Patient Safety Culture Composite | Definition: The extent to which.... | Number of Survey Items |
| 1. Communication openness | Staff will freely speak up if they see something that may negatively affect patient care, and feel free to question those with more authority | 3 |
| 2. Feedback & communication about error | Staff are informed about errors that happen, given feedback about changes put into place based on event reports, and discuss ways to prevent errors | 3 |
| 3. Frequency of events reported | Mistakes of the following types are reported:1) mistakes caught and corrected before affecting the patient, 2) mistakes with no potential to harm the patient, and 3) mistakes that could harm the patient, but do not | 3 |
| 4. Handoffs & transitions | Important patient care information is transferred across hospital units and during shift changes | 4 |
| 5. Management support for patient safety | Hospital management provides a work climate that promotes patient safety and shows that patient safety is a top priority | 3 |
| 6. Nonpunitive response to error | Staff feel that their mistakes are not held against them, and mistakes are not kept in their personnel file | 3 |
| 7. Organizational learning--Continuous improvement | Mistakes have led to positive changes and changes are evaluated for their effectiveness | 3 |
| 8. Overall perceptions of patient safety | Procedures and systems are good at preventing errors and there is a lack of patient safety problems | 4 |
| 9. Staffing | There are enough staff to handle the workload and work hours are appropriate to provide the best care for patients | 4 |
| 10. Supervisor/manager expectations and actions promoting safety | Supervisors/managers consider staff suggestions for improving patient safety, praise staff for following patient safety procedures, and do not overlook patient safety problems | 4 |
| 11. Teamwork across units | Hospital units cooperate and coordinate with one another to provide the best care for patients | 4 |
| 12. Teamwork within units | Staff support one another, treat each other with respect, and work together as a team | 4 |
| Oligonucleotide | Sequence |
| NUCKS F (forward) | 5'-AATTCACAGGAAGATAGTGAGG-3' |
| NUCKS R (reverse) | 5'-TCACTGTAG CCTTTAGTCTGGG-3' |
| GAPDH forward | 5'-ATGGGGAAGGTGAAGGTCGGAGTC-3' |
| GAPDH reverse | 5'-GAACATGGGGGCGTCAGCAGAG-3' |
| NUCKS Fq (forward, real-time PCR) | 5'-TCTGATGATGCAGATGAAGATTA-3' |
| NUCKS Rq (reverse, real-time PCR) | 5'-CTGCTGAGTGAGAATCATCC-3' |
| NUCKS FL probe | 5'-TCTTGGTCTTCACATCTTTGTCTTCT-FL-3' |
| NUCKS LC probe | 5'-LC640-AGTCCTCACTATCTTCCTGTGAATTCTTT-3' |
| Characteristics of the partner at the first sexual relation | Sex (%) | |
| Women | Men | |
| Type of relationship | ||
| Namorado (steady boyfriend/girlfriend) | 86 | 45 |
| Husband/wife/living together | 4 | 1 |
| Eventual partner | 9 | 48 |
| Prostitute | — | 5 |
| Was it also the partner's first sexual relation? | ||
| Yes | 14 | 37 |
| No | 83 | 57 |
| Do not know | 3 | 6 |
| Age difference between the interviewee and the partner | ||
| The partner is younger | 2 | 10 |
| Same age (±1 year) | 24 | 52 |
| The partner is older (2–4 years) | 36 | 24 |
| The partner is much older (5 years and more) | 38 | 15 |
| The partner was in school | ||
| Yes | 50 | 76 |
| No | 50 | 24 |
| Type of Patient/Specimen Type | 2011 | 2012 | 2013 | 2014 | ||||
| % | n1 | % | n1 | % | n1 | % | n1 | |
| Inpatients | 88.5 | 96 | 81.0 | 126 | 86.1 | 216 | 90.7 | 140 |
| Respiratory samples | 39.0 | 95 2 | 39.7 | 126 | 61.1 | 216 | 47.1 | 140 |
| Demographic | Number (%) |
| Gender | |
| Male | 64 (43.2) |
| Female | 84 (56.8) |
| Marital status | |
| Single | 57 (38.5) |
| Married | 44 (29.7) |
| Widowed | 10 (6.8) |
| Divorced | 36 (24.3) |
| Unknown | 1 (0.7) |
| Educational level | |
| None | 6 (4.1) |
| Primary | 45 (30.4) |
| Secondary | 83 (56.1) |
| University/post graduate | 13 (8.8) |
| Unknown | 1 (0.7) |
| Diagnosis | |
| Schizophrenia | 53 (35.8) |
| Paranoid Schizophrenia | 35 (23.6) |
| Delusional disorder | 10 (6.8) |
| Bipolar affective disorder (BPAD) | 15 (10.1) |
| Psychotic depression | 23 (15.5) |
| Other (i.e. schizoaffective disorder; non-specified psychosis) | 10 (6.8) |
| Unknown | 2 (1.4) |
| Employment status | |
| Unemployed | 68 (45.9) |
| Employed | 39 (26.3) |
| Homemaker | 35 (23.6) |
| Retired/other | 5 (3.4) |
| Unknown | 1 (0.7) |
| Indices of clinical burden of Sickle Cell Disease | Children | |
| n | % | |
| Duration of care since diagnosis | ||
| ≤ 6 months | 22 | 9.8 |
| > 6 months | 203 | 90.2 |
| Previous hospitalisation (range = 0–24) | ||
| No hospitalisation | 16 | 7.1 |
| Once | 32 | 14.2 |
| Twice | 85 | 37.8 |
| > twice | 92 | 40.9 |
| Previous blood transfusion (range = 0–10) | ||
| None | 67 | 29.8 |
| Once | 53 | 23.6 |
| Twice | 70 | 31.1 |
| > twice | 35 | 15.6 |
| Significant bone pain episodes | ||
| None | 13 | 5.8 |
| One | 41 | 18.2 |
| Twice | 25 | 11.1 |
| > twice | 146 | 64.9 |
| (A) 176 drug products | (B) 45 drug products | (C) 162 drug products | |
| Therapeutic group | |||
| A—alimentary tract and metabolism | 18 | 8 | 17 |
| B—blood and blood-forming organs | 9 | 3 | 8 |
| C—cardiovascular system | 20 | 3 | 20 |
| D—dermatologicals | 6 | 3 | 5 |
| G—genitourinary system and sex hormones | 13 | 1 | 13 |
| H—systemic hormonal preparations, excluding sex hormones and insulins | 7 | 1 | 6 |
| J—anti-infectives for systemic use | 25 | 5 | 23 |
| L—anti-neoplastic and immunomodulating agents | 10 | 3 | 10 |
| M—musculoskeletal system | 6 | 3 | 6 |
| N—nervous system | 24 | 8 | 23 |
| P—anti-parasitic products, insecticides, and repellents | 2 | 0 | 1 |
| R—respiratory system | 15 | 4 | 10 |
| S—sensory organs | 6 | 1 | 6 |
| V—various | 15 | 2 | 14 |
| Re-examination dates | |||
| January 2009 to December 2009 | 45 | 6 | 42 |
| January 2010 to December 2010 | 44 | 13 | 42 |
| January 2011 to December 2011 | 30 | 9 | 27 |
| January 2012 to December 2012 | 21 | 5 | 20 |
| January 2013 to December 2013 | 19 | 8 | 16 |
| January 2014 to December 2014 | 17 | 4 | 15 |
| Variables | Mean±SD |
| BMI (Kg/m2) | 43.40 ± 20.20 |
| Post-Load PG (mg/dL) | 80.00±15.80 |
| SBP (mmHg) | 127.60 ± 26.70 |
| DBP (mmHg) | 80.00 ± 15.80 |
| FPG (mg/dL) | 93.40 ± 19.80 |
| Waist Circumference (CM) | 182.84 ± 101.10 |
| Indication for surgery | Frequency | Percentage |
| Bleeding duodenal ulcers not responding to either medical or endoscopic treatment | 5 | 26.3 |
| Gastric malignancy | 6 | 31.6 |
| Gastrointestinal stroma tumour | 8 | 42.1 |
| Survey I (n = 2200) | Survey II (n = 2203) | |||||||
| VL | H | VL | H | |||||
| OR | 95 % CI | OR | 95 % CI | OR | 95 % CI | OR | 95 % CI | |
| Parent characteristics | ||||||||
| Mother’s education | ||||||||
| College Grad | ___ | ___ | ___ | ___ | ||||
| Some college | 1.30 | .96/1.76 | 1.35 | .99/1.85 | 1.09 | .80/1.49 | 1.06 | .77/1.44 |
| HS Grad | .73 | .51/1.03 | 1.37 | 1.19/1.88 | .83 | .58/1.18 | 1.50 | 1.10/2.04 |
| Less than HS | .46 | .21/1.00 | 2.27 | 1.37/3.75 | .44 | .19/1.03 | 1.96 | 1.69/3.14 |
| Parent smokes | ||||||||
| No | ___ | ___ | ___ | ___ | ||||
| Yes | .76 | .57/1.03 | 2.10 | 1.62/2.73 | .77 | .56/1.06 | 2.08 | 1.59/2.70 |
| Family engagement | ||||||||
| No. of days eat together | ||||||||
| <3 | ___ | ___ | ___ | ___ | ||||
| 3–5 | 1.16 | .84/1.61 | .51 | .38/.67 | 1.10 | .79/1.53 | .54 | .41/.73 |
| 6> | 1.54 | 1.12/2.11 | .48 | .35/.65 | 1.17 | .85/1.62 | .49 | .36/.66 |
| No. times do things for fun | ||||||||
| <2 | ___ | ___ | ___ | ___ | ||||
| 2–4 | .79 | .60/1.03 | .73 | .55/.96 | 1.18 | .89/1.57 | .52 | .41/.67 |
| 5> | 1.07 | .74/1.56 | .77 | .51/.98 | 1.51 | 1.05/2.17 | .36 | .23/.55 |
| Parent monitoring | ||||||||
| No. of four best friends parents know well | ||||||||
| 0–1 | ___ | ___ | ___ | ___ | ||||
| 2–3 | .87 | .59/1.26 | .67 | .48/.94 | .84 | .57/1.25 | .82 | .59/1.18 |
| 4 | 1.38 | .95/1.99 | .49 | .35/.70 | 1.24 | .85/1.81 | .53 | .37/.77 |
| No. four best friend’s parents parents know well | ||||||||
| 0–1 | ______ | ___ | ___ | ___ | ||||
| 2–3 | 1.44 | 1.06/1.96 | .60 | .46/.77 | 1.07 | .78/1.45 | .62 | .49/.82 |
| 4 | 1.87 | 1.33/2.65 | .31 | .21/.46 | 1.37 | .98/1.91 | .43 | .31/.81 |
| Your parents tell on friend smoking | ||||||||
| No | ___ | ___ | ___ | ___ | ||||
| Not sure | 1.36 | .78/2.36 | .49 | .34/.70 | 1.27 | .64/2.53 | .47 | .29/.77 |
| Yes | 2.03 | 1.24/3.30 | .22 | .16/.31 | 1.89 | 1.30/2.97 | .28 | .21/.37 |
| Friend’s parents tell on you smoking | ||||||||
| No | ___ | ___ | ___ | ___ | ||||
| Not sure | 1.13 | .61/2.09 | .49 | .34/.70 | 1.02 | .46/2.22 | .49 | .21/.82 |
| Yes | 1.51 | .86/2.65 | .22 | .16/.31 | 1.56 | .93/2.64 | .22 | .16/.30 |
| Subfamily | Gene identification | Domain organisation | Amino acids | |
| ABCB | ||||
| ABCB1 | PFE1150w | PfMDR1 | (MSD-NBD)2 | 1419 |
| ABCB2 | PF14_0455 | PfMDR2 | MSD-NBD | 1024 |
| ABCB3 | PF11_0466 | MSD-NBD | 872 | |
| ABCB4 | PFC0125w | MSD-NBD | 1365 | |
| ABCB5 | PF13_0218 | MSD-NBD | 925 | |
| ABCB6 | PF13_0271 | MSD-NBD | 1049 | |
| ABCB7 | PFL0495c | MSD-NBD | 855 | |
| ABCC | ||||
| ABCC1 | PFA0590w | PfMRP1 | (MSD-NBD)2 | 1822 |
| ABCC2 | PFL1410c | PfMRP2 | (MSD-NBD)2 | 2108 |
| ABCE | ||||
| ABCE1 | MAL13 P1.344 | (NBD)2 | 619 | |
| ABCF | ||||
| ABCF1 | PF11_0225 | (NBD)2 | 815 | |
| ABCF2 | pfGCN20PF08_0078 | (NBD)2 | 1419 | |
| ABCG | ||||
| ABCG1 | PF14_0244 | NBD-MSD | 660 | |
| ABCI | ||||
| ABCI1 | PF14_0133 | NBD | 347 | |
| ABCI2 | PF14_0321 | NBD | 171 | |
| ABCI3 | PFC0875w | MSD-NBD-MSD | 3133 |
| Climate model | |||
| Time period | Median | Minimal | Maximal |
| 1986–2005 | 20.7 (27.4) | ||
| 2026–2045 | 22.9 (30.0) | 21.6 (28.9) | 22.9 (30.2) |
| 2081–2100 | 26.1 (35.1) | 24.6 (32.4) | 28.5 (37.7) |
| Patient | Gene | Varianta | Patient cancer historyb |
| Discovered cancer gene mutations (163 disease-gene panel)c | |||
| BRCA1.60 | CHEK2 | c.573+1G>A | Breast-47, 49 |
| BRCA1.61 | ATM | p.Glu2290⁎ | Unaffected-24 |
| BRCA2.7 | RAD50 | c.3G>A | Breast-49 |
| BRCA2.13 | ATM | p.Glu1978⁎ | Breast-28, 39, 55; Skin-49 |
| BRCA2.65 | CDKN2B | p.Glu35⁎ | Melanoma-50 |
| BRCA2.93 | CHEK2 | p.Gln20⁎ | Breast-37, 61; Ovarian-56 |
| Discovered cancer gene mutations (ClinVar)c | |||
| BRCA1.48 | ERCC3 | p.Arg109⁎ | Breast-39; Skin-61, 66 |
| BRCA1.73 | DLEC1 | c.2436-2A>G | Breast-32 |
| BRCA1.74 | FANCC | p.Arg548⁎ | Breast-42, 53, 55 |
| DPC* | Type | Pathological findings† | ||
| Lung | Inguinal Lymph Nodes | Heart | ||
| 14 | I | Moderate focal/multifocal bronchointerstitial pneumonia (3/3) | Lymphadenopathy (3/3) | Mild multifocal perivascular lymphohistiocytic myocarditis (1/3) |
| II | Moderate diffuse/multifocal bronchointerstitial pneumonia (2/3) | Lymphadenopathy (3/3) | Mild multifocal perivascular lymphohistiocytic myocarditis. (3/3) | |
| Control | No lesions (2/2) | No lesions (2/2) | No lesions (2/2) | |
| 21 | I | Moderate diffuse interstitial pneumonia (2/2), moderate peribronchiolar and perivascular lymphohistiocytic cuffing (2/2) | Lymphadenopathy (2/2) | Mild multifocal perivascular lymphohistiocytic myocarditis (1/2) |
| II | Mild to moderate diffuse interstitial pneumonia (2/2), severe peribronchiolar and perivascular lymphohistiocytic cuffing (1/2) | Lymphadenopathy (2/2) | Very mild multifocal perivascular lymphohistiocytic myocarditis (1/2) | |
| Control | No lesions (1/1) | No lesions (1/1) | No lesions (1/1) |
| Believes PPM has exposed him/her to hazardous chemicals | Felt he/she was coughing, breathless or wheezing due to something in the air | Believes the industry will affect children born in the future in the community | Believes the industry will expose him/her to hazards if it opens in the future | Worries about getting health problems in the future because of a polluted environment | |||||||
| OR | 95% CI | OR | 95% CI | OR | 95% CI | OR | 95% CI | OR | 95% CI | ||
| Demographic | Distance from PPM | 2.747* | 1.199-6.295 | 1.039‡ | 0.560-1927 | 1.132‡ | 0.502-2.554 | ||||
| Presence of a child in the HH | 34.769* | 1.390-869.96 | |||||||||
| Respondent completed HS | 3.105* | 1.394-6.918 | 2.553* | 1.086-6.004 | |||||||
| Employment Status | 0.434‡ | 0.188-1.004 | 0.383* | 0.167-0.879 | 0.365* | 0.150-0.886 | |||||
| HH health Indicators | Perception of health | 0.527‡ | 0.239-1.162 | 0.479* | 0.261-0.878 | 0.299* | 0.135-0.660 | 0.237** | 0.108-0.517 | 0.332* | 0.149-0.738 |
| Somebody in the HH has one of the conditions (heart, respiratory or skin disease) | 1.788‡ | 0.755-4.237 | 1.980* | 1.031-3.802 | 2.192‡ | 0.963-4.990 | 2.594* | 1.096-6.143 | |||
| Respiratory symptoms | Coughed phlegm daily for ≥ 2 months, 2 yrs in a row | 2.907* | 1.127-7.498 | ||||||||
| Had an attack of whistling or noisy sound in the chest when breathing | 2.881* | 1.402-5.920 | |||||||||
| Role of Industrial plant | Family depended on industry | 2.287* | 1.001-5.228 | 2.792* | 1.234-6.319 | ||||||
| Community benefited from industry | 2.289* | 0.997-5.257 | |||||||||
| Environmental awareness/knowledge | Ever actively looked for environmental health information | 1.883* | 1.002-3.537 | ||||||||
| Willing to participate in environmental campaigns | 2.297‡ | 0.713-7.396 | 2.985* | 1.031-8.645 | 3.127* | 1.100-8.888 | |||||
| Main Information source | Friends/relatives | 2.553* | 1.198-5.438 | 0.411* | 0.180-0.937 | 0.451* | 0.207-0.981 | ||||
| Church/Community leaders | 3.148* | 1.303-7.602 | 2.368* | 1.090-5.147 | 2.447* | 1.089-5.499 | |||||
| Omnibus Tests of Model Coefficients | Model (Sig.) | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | |||||
| Correctly predicted observations on average | 85.6% | 79.7% | 84.6% | 86% | 84.4% |
| Hemi | Region | ß | SE | p-value (uncorrected) | FDR-corrected p-value |
| R | Nucleus accumbens | −0.23 | 0.058 | 0.000077 | 0.0055 |
| L | Inferior parietal cortex | −0.38 | 0.10 | 0.00014 | 0.0055 |
| R | Superior parietal cortex | −0.42 | 0.12 | 0.00056 | 0.011 |
| R | Caudate nucleus | −0.28 | 0.081 | 0.00064 | 0.011 |
| L | Putamen | −0.24 | 0.071 | 0.00068 | 0.011 |
| L | Caudate nucleus | −0.23 | 0.071 | 0.0011 | 0.014 |
| R | Amygdala | −0.21 | 0.064 | 0.0012 | 0.014 |
| L | Supramarginal gyrus | −0.26 | 0.098 | 0.0076 | 0.076 |
| R | Supramarginal gyrus | −0.27 | 0.10 | 0.0090 | 0.076 |
| Outcome | General anaesthesia | Neuraxial anaesthesia | Combination |
| Major VTE and VTE-related mortality | 4.2%* | 3.1%* | 3.1% |
| (73/1731) | (101/3305) | (35/1147) | |
| MBE | 1.2% | 1.4% | 1.2% |
| (27/2311) | (59/4212) | (19/1539) | |
| MBE/CRBE | 4.9% | 5.6% | 5.7% |
| (114/2311) | (237/4212) | (88/1539) |
| RFB | Mineral Filler Quantity(g) | Mineral Filler A Vg = 0.26 | Mineral Filler B Vg = 0.11 | Mineral Filler C Vg = 0.19 | Mineral Filler D Vg = 0.32 | ||||||||
| S(g) | F(g) | S/F | S(g) | F(g) | S/F | S(g) | F(g) | S/F | S(g) | F(g) | S/F | ||
| 0.6 | 60 | 18.72 | 81.28 | 0.23 | 7.92 | 92.08 | 0.09 | 13.68 | 86.32 | 0.16 | 23.04 | 76.96 | 0.30 |
| 0.8 | 80 | 24.96 | 75.04 | 0.33 | 10.56 | 89.44 | 0.12 | 18.24 | 81.76 | 0.22 | 30.72 | 69.28 | 0.44 |
| 1 | 100 | 31.2 | 68.8 | 0.45 | 13.2 | 86.8 | 0.15 | 22.8 | 77.2 | 0.30 | 38.40 | 61.60 | 0.62 |
| 1.2 | 120 | 37.44 | 62.56 | 0.60 | 15.84 | 84.16 | 0.19 | 27.36 | 72.64 | 0.38 | 46.08 | 53.92 | 0.85 |
| 1.5 | 150 | 46.8 | 53.2 | 0.88 | 19.8 | 80.20 | 0.25 | 34.20 | 65.80 | 0.52 | 57.60 | 42.40 | 1.36 |
| Sanger technology | 454 FLX technology | Sanger + 454 FLX | |
| Total number of reads | 14,120 | 789,105 | - |
| Average length of read (bases) | 780 | 218 | - |
| Total number of reads in the assembly | 12,032 | 466,737 | 478,769 |
| Total number of contigs | 2,120 | 22,203 | 18,690 |
| Total number of singlets | 4,775 | 25,604 | - |
| Number of unique sequences | 6,895 | 47,807 | - |
| Average/Largest contig size | 995/3,560 | 1132/4,762 | 1180/4,762 |
| Sal | VH | SS | ES5 | ES10 | ||
| F0 | Area | 160.3 ± 23.6 | 164.5 ± 13.6 | 165.3 ± 12.5 | 160 ± 12.1 | 166.5 ± 26.5 |
| WCI | 00.0 ± 00.0 | 00.0 ± 00.0 | 00.0 ± 00.0 | 00.0 ± 00.0 | 00.0 ± 00.0 | |
| F1 | Area | 115.4 ± 15.9 | 113.1 ± 13.9 | 109.6 ± 12.1 | 95.5 ± 11.3∗ | 76.8 ± 16.06∗ |
| WCI | 31.9 ± 17.4 | 39.7 ± 11.5 | 37.7 ± 13.1 | 32.4 ± 11.7 | 50.5 ± 12.6 | |
| F2 | Area | 30.0 ± 11.3 | 25.2 ± 12.9 | 35.3 ± 10.4 | 15.9 ± 8.8∗ | 16.8 ± 8.1∗ |
| WCI | 84.7 ± 9.3 | 88.3 ± 7.9 | 81.3 ± 9.1 | 89.1 ± 6.05 | 89.9 ± 5.5 | |
| F3 | Area | 10.4 ± 3.4 | 9.1 ± 4.1 | 8.18 ± 3.6 | 2.8 ± 1.7∗ | 3.2 ± 1.5∗ |
| WCI | 94.3 ± 5.3 | 94.0 ± 5.3 | 94.9 ± 2.6 | 98.0 ± 1.2 | 96.7 ± 2.4 |
| B2 | HTK | Euro Collins | ||
| Osmolality (mosm/kg) | 323 | 310 | 406 | |
| Ions (mmol/l) | Na+ | 22 | 15 | 10 |
| K+ | 150 | 9 | 115 | |
| Mg++ | 10 | 4 | ||
| Cl- | 10 | 50 | 15 | |
| SO4- | 85 | |||
| Buffers (mmol/l) | PO4--- | 6 | ||
| HPO4-- | 43 | |||
| H2PO4- | 15 | |||
| HCO3- | 10 | |||
| Histidin | 198 | |||
| Osmotics (mmol/l) | Glucose | 198 | ||
| Mannitol | 30 | |||
| Saccharin | 40 | |||
| Colloids (mmol/l) | PEG | 25 |
| Primer name | Oligonucleotide | Product length | Product name |
| crdPG-1 | GTACTCGAGATTGTCGGCAGTCCAG | 607 | crdP |
| crdPG-2 | AGCTCCTCGCCCTTGCTCACCATGAAATCAACTCCTCTGT | ||
| GFP-1 | ACAGAGGAGTTGATTTCATGGTGAGCAAGGGCGAGGAGCT | 746 | GFP |
| GFP-2 | CGCGGATCCTTACTTGTACAGCTCGTCCATG | crdP | |
| crdP-1 | TCACCAACACCAACTCTGGA | ||
| crdP-2 | CATGAAATCAACTCCTCTGT | 607 | crdP |
| crdP142-1 | ATCGTCAGATGCCTATTTGT | 537 | crdP |
| crdP108-1 | AAATTAGTTAATGCAAT | 503 | crdP |
| crdP98-1 | TTAATGCAATTTTTACTATGTT | 493 | crdP |
| crdP53-1 | CCATTTCAATACTGCGGGAGG | 448 | crdP |
| crdP13-1 | AGGAGTTGATTTCATGCTGTT | 408 | crdP |
| crdP1-1 | ATGCTGTTCCGCAATAAG | 395 | crdA |
| crdA395-2 | TCGGTCCGCAGCAGCAAAG | ||
| q-crdA-1 | CAAGGCATAAGCGAAGACATC | 227 | crdA |
| q-crdA-2 | CTCCGTGTTTCAAGTGTGGTC | ||
| q-crdS-1 | AACCTGACGATTGCGATTGGG | 179 | crdS |
| q-crdS-2 | GTGTAGCACCAGAGCGTTTCG | ||
| q-crdC-1 | GTTCGGTCAGGATGCTCAAC | 248 | crdC |
| q-crdC-2 | GCCAAAGTTCGGAATCAATG | ||
| crdR-1 | GCCAGATCTATGACCGAGAATAAGAAAAAGCCT | 437 | crdR |
| crdR-2 | TTGAGCTCTTACTCGGCGTCGCCTTCG | ||
| NcrdR-1 | ACACTCGAGATACACCCGGTCCCTACCAGCATT | crdR | |
| NcrdR-2 | TTTGAGCTCCTTGTCCTTCTTCAGAAGCGTGT | 1302 | crdR |
| q-crdR-1 | TCGGAATGAGCCAGGAGAAGC | 238 | crdR |
| q-crdR-2 | TCAGCCGAGGACAGAAAGTCG | ||
| crdRup-1 | TCTGAGCTCTTCGGCGTTTCGGAATGGTTG | 2533 | CrdR |
| crdRdown-2 | CAACACAAGCTTAACCGTCACCTGGCTCTTGGCA | ||
| crdRcheckGm-2 | TTGGGCATACGGGAAGAAGT | 558 | Gm |
| crdRcheckGm-1 | CGGCTGATGTTGGGAGTAGG | 577 | |
| Rep-Kan-1 | ACGCGTCGACCTTGCCAGCCCGTGGATAT | 3266 | Km |
| Rep-Kan-2 | ACGCGTCGACTCTGTGATGGCTTCCATGTC | ||
| Gm-1 | ATAGTTGTCGAGATATTCACTAGTCGTCAGGTGGCACTTTTCG | 1302 | Gm |
| Gm-2 | CGCGGATCCGCTCTGCTGAAGCCAGTTAC | ||
| celAP1 | ACCCGGTCTATCCCATGA | ||
| celAP-2 | CATCCAGAAACTTTCCGT | 441 | celAP |
| relAP-1 | CCAGATTTCTCAAGGGTC | ||
| RelAP-2 | CATCATGCGATATTCCACA | 443 | relAP |
| crdRP-1 | GCGGCGATCCTAAATGTGAC | ||
| crdRP-2 | CATGCGGTCCTGACACTCG | 466 | crdRP |
| crdSP-1 | TCGGTCGGCACATGGGTCAAT | ||
| crdSP-2 | CATCGCCCTAACCTCGCAGT | 446 | crdSP |
| lectin | time (dpi/dpe)a | mucusb | SMCc | MNCd |
| UEAI | 0 | +/- | - | ++ |
| 14 | +/- | +/- | ++ | |
| 21 | + | + | ++ | |
| 60 | + | + | ++ | |
| WGA | 0 | ++ | ++ | ++ |
| 14 | ++ | ++ | ++ | |
| 21 | + | + | + | |
| 60 | + | + | + | |
| RCA120 | 0 | ++ | ++ | ++ |
| 14 | ++ | ++ | ++ | |
| 21 | ++ | ++ | + | |
| 60 | ++ | ++ | ++ | |
| DBA | 0 | ++ | ++ | ++ |
| 14 | ++ | ++ | ++ | |
| 21 | ++ | ++ | ++ | |
| 60 | + | + | ++ | |
| SBA | 0 | ++ | ++ | ++ |
| 14 | ++ | + | ++ | |
| 21 | ++ | ++ | ++ | |
| 60 | ++ | ++ | ++ | |
| PNA | 0 | + | ++ | ++ |
| 14 | + | + | ++ | |
| 21 | +/- | +/- | +/- | |
| 60 | + | + | ++ |
| HRV Index | Sitting Variable | Crude Model (N = 126) | Primary Adjusted Model (N = 126) | ||||||
| B | 95%CI Low | High | p | B | 95%CI Low | High | p | ||
| IBI (ms) | Occupational sitting | −17.00 | −35.80 | 1.81 | 0.08 | −24.24 | −46.98 | −1.50 | 0.04 |
| Leisure-time sitting | 6.80 | −7.97 | 21.57 | 0.36 | 0.41 | −14.43 | −15.25 | 0.96 | |
| RMSSD (ms) | Occupational sitting | −3.26 | 0.06 | −6.66 | 0.14 | −4.96 | −8.88 | −1.05 | 0.01 |
| Leisure-time sitting | 0.16 | 0.91 | −2.51 | 2.83 | 1.83 | −0.73 | 4.38 | 0.16 | |
| SDNN (ms) | Occupational sitting | −3.03 | −5.87 | −0.20 | 0.04 | −5.07 | −8.48 | −1.67 | 0.00 |
| Leisure-time sitting | 0.46 | −1.77 | 2.69 | 0.68 | 1.10 | −1.12 | 3.33 | 0.33 | |
| ln VLF | Occupational sitting | −0.10 | −0.20 | 0.01 | 0.06 | −0.19 | −0.32 | −0.05 | 0.01 |
| Leisure-time sitting | 0.03 | −0.05 | 0.11 | 0.50 | 0.00 | −0.09 | 0.09 | 0.98 | |
| ln LF | Occupational sitting | −0.13 | −0.25 | −0.01 | 0.03 | −0.18 | −0.32 | −0.04 | 0.01 |
| Leisure-time sitting | 0.05 | −0.04 | 0.14 | 0.30 | 0.07 | −0.02 | 0.17 | 0.11 | |
| ln HF | Occupational sitting | −0.12 | −0.26 | 0.03 | 0.12 | −0.12 | −0.27 | 0.04 | 0.14 |
| Leisure-time sitting | 0.00 | −0.12 | 0.11 | 0.95 | 0.08 | −0.02 | 0.19 | 0.13 | |
| ln LF/HF | Occupational sitting | −0.01 | −0.12 | 0.10 | 0.91 | −0.03 | −0.17 | 0.10 | 0.62 |
| Leisure-time sitting | 0.06 | −0.03 | 0.14 | 0.19 | −0.01 | −0.09 | 0.08 | 0.92 |
| 24‐hr mean Tb (°C) | 24‐hr maximum Tb (°C) | |||
| No feed | Feed | No feed | Feed | |
| Sex | ||||
| Male (n = 10) | 37.4 ± 0.1 | 37.8 ± 0.2 | 38.3 ± 0.2 | 38.8 ± 0.2 |
| Female (n = 3) | 37.6 ± 0.2 | 37.9 ± 0.2 | 38.5 ± 0.4 | 39.1 ± 0.3 |
| Intervention (home visit) | ||||
| Variable | No (N = 221) | Yes (N = 262) | P-value | |
| Age (years) | ||||
| Age (±SD) | 30.40 ± 8.57 | 30.49 ± 7.84 | 0.90 | |
| Education (N, %) | ||||
| None | 14 (6.33 %) | 7 (2.67 %) | 0.06 | |
| Primary level | 94 (42.53 %) | 98 (37.40 %) | ||
| Secondary level | 91 (41.18 %) | 117 (44.66 %) | ||
| Tertiary level | 22 (9.95 %) | 40 (15.27 %) | ||
| Religion (N, %) | ||||
| Catholic | 116 (52.49 %) | 131 (50.00 %) | 0.03 | |
| Baptist | 35 (15.84 %) | 22 (8.40 %) | ||
| Presbyterian | 32 (14.48 %) | 53 (20.23 %) | ||
| Pentecostal | 0 % | 3 (1.15 %) | ||
| Muslim | 38 (17.19 %) | 53 (20.23 %) | ||
| Marital status (N,%) | ||||
| Single | 39 (17.65 %) | 48 (18.32 %) | 0.25 | |
| Married | 164 (74.21 %) | 195 (74.43 %) | ||
| separated/divorced | 15 (6.79 %) | 10 (3.82 %) | ||
| Widowed | 3 (1.36 %) | 9 (3.44 %) | ||
| Occupation (N, %) | ||||
| Unemployed | 80 (36.20 %) | 98 (37.40 %) | 0.78 | |
| Employed | 141 (63.8 %) | 164 (62.60 %) | ||
| Number of children (N, %) | ||||
| 0–2 | 95 (42.99 %) | 126 (57.01 %) | 0.54 | |
| 3 > 5 | 120 (45.80 %) | 142 (54.20 %) |
| Preparation | Average finish line width (mm) |
| CCC 46 | 0.5 |
| MCC 24 | (0.5 + 1.2)/2 = 0.85 |
| MCC 46 | (0.5 + 0.8)/2 = 0.65 |
| ACC 21 | 1 |
| Peptide | COX-1 | COX-2 | ||||
| be | ir | hb | be | ir | hb | |
| GMD | −1.20 | 23 | 1 | −39.87 | 21 | 3 |
| GHE | −0.56 | 25 | 0 | −42.15 | 26 | 5 |
| YYV | — | — | — | — | — | — |
| Antibody | Growth inhibition (%) over the period of cultivation | |||
| 1 mg/ml IgG | ||||
| Day 1 | Day 2 | Day 3 | Day 4 | |
| GST | 9.5±9.9 | 5.3±5.5 | 10.7±7.4 | 10.5±3.7 |
| BbTRAP2 | 55.3±6.1* | 48.1±5.6* | 59.1±4.4*, ** | 73.6±4*, ** |
| BbRAP-1CT | 54.2±9.1* | 45.9±8.2* | 45.3±4.7* | 60.9±5.4* |
| BbMSA-2c | 19.2±17.9 | 17.7±8.2 | 26.1±8.9* | 43.1±5* |
| TB CX-test | AFB staining (+) | AFB staining (−) | Totals |
| TB CX-test(+) | 12 | 1* | 13 |
| TB CX-test(−) | 0 | 83 | 83 |
| Totals | 12 | 84 | 96 |
| Variable | Max | Min | Mean | SD |
| “Income” | 550.00 | 0.00 | 42.33 | 42.65 |
| “Spent” | 425.00 | 1.97 | 25.42 | 36.86 |
| “Pins” | 0.90 | 0.00 | 0.58 | 0.23 |
| Variables | Mean | 95% CI of the mean | Statistics (P values) |
| IBS symptom score | 1.57 | 0.10; 3.05 | P = 0.04 |
| Bacteroides | −0.01 | −0.11; 0.08 | ns (P = 0.77) |
| Faecalibacterium | −0.03 | −0.18; 0.12 | ns (P = 0.63) |
| Lachnospiraceae | 0.05 | −0.03; 0.13 | ns (P = 0.18) |
| “Common” Simpson's D | −0.04 | −0.15; 0.08 | ns (P = 0.50) |
| I | Ta (°C) | ||||
| 400 | 450 | 500 | 550 | ||
| Average height (AH) [nm] | (111)A | 23.4 | 25.4 | 28.9 | 32.2 |
| (110) | 22.6 | 24.7 | 28.2 | 31.2 | |
| (100) | 21.7 | 24.0 | 26.7 | 29.7 | |
| (111)B | 19.9 | 22.3 | 25.2 | 27.8 | |
| Average lateral diameter (LD) [nm] | (111)A | 128.6 | 133.8 | 138.5 | 143.4 |
| (110) | 122.5 | 128 | 133.8 | 141 | |
| (100) | 115 | 124.5 | 130.8 | 139.1 | |
| (111)B | 106.2 | 115.5 | 123.5 | 133.1 | |
| Average density (AD) [×108 cm−2] | (111)A | 139 | 123 | 110 | 99 |
| (110) | 148 | 131 | 118 | 107 | |
| (100) | 160 | 141 | 129 | 119 | |
| (111)B | 173 | 150 | 140 | 132 |
| Reason | No. of patients | % patients |
| Presence of any types of primary disease progression (n = 26) | ||
| Enlargement of tumor | 14 | 47 |
| Elevation of tumor marker | 7 | 23 |
| Carcinomatous pain | 5 | 17 |
| Obstructive jaundice | 5 | 17 |
| Duodenal hemorrhage | 2 | 7 |
| Absence of disease progression (n = 4) | ||
| Interstitial pneumonia | 4 | 13 |
| Antibodies | Manufacturer | Source | Reactivity | Dilution |
| CD34 | Sigma | Mouse | Rat | 1:100 |
| 5-HT | Immunostar | Rabbit | Rat | 1:20,000 |
| GFAP | Millipore | Rabbit | Rat | 1:50 |
| APC | Calbiochem | Mouse | Rat | 1:200 |
| NeuN | Immunostar | Rabbit | Rat | 1:500 |
| sTNF/TNFR1 signaling | |
| sTNF is necessary for the induction of autoimmune diseases [160] | |
| Association of TNF and TNFR1 polymorphisms with PD risk [14, 163] | |
| Association of TNFR1 polymorphism with MS risk [164] | |
| TNFR1 promotes neurodegeneration in retinal ischemia [165] | |
| TNFR1 mediates development of pain-induced depressive behavior [166] | |
| TNFR1 is essential for the development of MOG35–55 induced EAE [167–169] | |
| Inhibition of TNFR1 signaling strongly ameliorates EAE development [169] | |
| Blocking of sTNF improves functional outcome in EAE [170, 171] | |
| Blocking sTNF attenuates neurodegeneration in AD and PD models [172–174] | |
| TNFR1 mediates direct apoptosis of neurons via caspase 8 [175] | |
| memTNF/TNFR2 signaling | |
| TNFR2−/− mice show exacerbated neurodegeneration in EAE model [167–169] | |
| TNFR2−/− mice show exacerbated neurodegeneration in retinal ischemia [165] | |
| TNFR2 promotes OPC proliferation and remyelination [176] | |
| TNFR2 protects neurons against glutamate-induced excitotoxicity [142, 143] | |
| memTNF dependent activation of NFkB is neuroprotective in EAE [171] | |
| TNFR2 rescues neurons from oxidative stress-induced cell death [144] | |
| TNFR2 promotes oligodendrocyte maturation [177] | |
| TNFR2 promotes oligodendrocyte proliferation and maturation [178] | |
| TNFR2 protects OPCs against oxidative stress [179] |
| Structure | Damage Scale | Stiffness Adjustment | Flatfoot Stiffness (N/mm) |
| Superomedial spring | Stage IV | −7/8th | 39 |
| Inferomedial spring | Stage II | −3/8th | 94 |
| Talocalcaneal interosseus | Stage I | −1/8th | 236 |
| Plantar fascia | Stage I | −1/8th | 175 |
| Plantar metatarsocuneiform | Stage 0 | None | 90 |
| Plantar naviculocuneiform | Stage 0 | None | 180 |
| Long and short plantar | Stage 0 | None | 240 |
| Deep deltoid | Stage 0 | None | 200 |
| Anterior superficial deltoid | Stage I | −1/8th | 70 |
| Posterior superficial deltoid | Stage 0 | None | 117 |
| Usage | AAindex ID | Physicochemical properties |
| 100% | MEEJ800102 | Retention coefficient in HPLC, pH2.1 |
| 91% | WOLS870102 | Principal property value z2 |
| 87% | CASG920101 | Hydrophobicity scale from native proteins |
| 84% | NAKH900110 | Normalized composition of membrane proteins |
| 81% | FASG760105 | pK-C |
| 79% | FAUJ880105 | STERIMOL minimum width of the side chain |
| 76% | CHAM830107 | A parameter of charge transfer capability |
| 61% | QIAN880127 | Weights for coil at the window position of -6 |
| 59% | RACS820108 | Average relative fractional occurrence in AR (i-1) |
| 58% | DIGM050101 | Hydrostatic pressure asymmetry index, PAI |
| 56% | TANS770109 | Normalized frequency of coil |
| All patients (n = 1119) | LBBB (n = 221) | RBBB (n = 82) | IVCD (n = 67) | Narrow QRS (n = 749) | P value | |
| Age (years) | 51.1 ± 14.7 | 57.2 ± 12.0 | 53.1 ± 14.7 | 52.3 ± 14.5 | 48.9 ± 14.9 | <0.001a |
| Female gender, n (%) | 298(26.6) | 89(40.3) | 16(19.5) | 15(22.4) | 178(23.8) | <0.001 |
| History | ||||||
| Disease duration (years) | 2(0.5–6) | 4(1–9) | 4(1–8) | 3(1.5–6) | 2(0.35–5) | 0.001 |
| Essential hypertension, n (%) | 294(26.3) | 73(33.0) | 15(18.3) | 15(22.4) | 191(25.5) | 0.034 |
| Diabetes mellitus, n (%) | 160(14.3) | 24(10.9) | 15(18.3) | 6(9.0) | 115(15.4) | 0.142 |
| Atrial fibrillation, n (%) | 257(23.0) | 29(13.1) | 20(24.4) | 11(16.4) | 197(26.3) | <0.001 |
| Smoker, n (%) | 517(46.2) | 93(42.1) | 33(40.2) | 31(46.3) | 360(48.1) | 0.293 |
| Drinker, n (%) | 363(32.4) | 59(26.7) | 28(34.1) | 22(32.8) | 254(33.9) | 0.243 |
| NYHA class III and IVc, n (%) | 817(73.0) | 162(73.3) | 60(73.2) | 54(80.6) | 541(72.2) | 0.532 |
| Admission vital signs | ||||||
| SBP (mm Hg) | 113.0 ± 17.7 | 114.6 ± 17.3 | 110.2 ± 18.8 | 111.7 ± 19.8 | 113.0 ± 17.4 | 0.242 |
| DBP(mm Hg) | 72.5 ± 12.6 | 71.8 ± 12.4 | 71.8 ± 11.1 | 69.3 ± 12.4 | 73.0 + 12.8 | 0.099 |
| Heart rate, beat/min | 80.9 ± 17.4 | 78.3 ± 15.9 | 79.6 ± 15.5 | 78.6 ± 14.4 | 82.0 ± 18.2 | 0.023 |
| Laboratory values at admissionb | ||||||
| TB (mmol/L) | 26.2 ± 19.6 | 24.9 ± 19.1 | 25.3 ± 16.0 | 34.8 ± 26.7 | 26.0 ± 19.3 | 0.004 |
| DB (mmol/L) | 3.7(2.5–6.5) | 3.2(2.15–6.05) | 3.5(2.7–7.4) | 4.9(3.2–9.2) | 3.7(2.5–6.485) | 0.003 |
| Glucose (mmol/L) | 5.62 ± 1.85 | 5.86 ± 1.94 | 5.50 ± 1.52 | 5.34 ± 1.44 | 5.59 ± 1.89 | 0.150 |
| Triglyceride (mmol/L) | 1.57 ± 1.02 | 1.63 ± 0.99 | 1.58 ± 0.94 | 1.38 ± 0.70 | 1.56 ± 1.06 | 0.410 |
| Total cholesterol (mmol/L) | 4.61 ± 1.13 | 4.75 ± 1.12 | 4.52 ± 0.98 | 4.39 ± 1.23 | 4.59 ± 1.14 | 0.125 |
| Creatinine (μmol/L) | 92.8 ± 35.2 | 91.0 ± 26.4 | 94.9 ± 25.9 | 97.9 ± 40.7 | 92.6 ± 37.8 | 0.526 |
| BUN (μmol/L) | 7.95 ± 3.97 | 7.88 ± 2.67 | 8.04 ± 2.69 | 8.89 ± 4.68 | 7.88 ± 4.32 | 0.262 |
| CK-MB (IU/L) | 13.5 ± 7.76 | 13.1 ± 6.77 | 12.0 ± 6.70 | 13.7 ± 7.59 | 13.8 ± 8.14 | 0.229 |
| NT- Pro- BNP (fmol/mL) | 2010.3 ± 1567.5 | 1998.0 ± 1595.8 | 2170.5 ± 1679.8 | 2358.4 ± 1638.4 | 1962.4 ± 1538.0 | 0.315 |
| Electrocardiogram data | ||||||
| QRS duration (ms) | 119.6 ± 30.9 | 156.0 ± 24.4 | 153.3 ± 24.9 | 137.1 ± 23.1 | 103.6 ± 18.2 | <0.001 |
| QT (ms) | 405.7 ± 54.2 | 434.4 ± 50.6 | 429.1 ± 51.1 | 421.3 ± 38.7 | 393.2 ± 52.4 | <0.001 |
| P (ms) | 107.5 ± 21.6 | 102.7 ± 22.6 | 107.5 ± 23.6 | 108.2 ± 25.1 | 109.3 ± 20.3 | 0.005 |
| PR (ms) | 182.8 ± 32.9 | 184.9 ± 33.1 | 192.3 ± 42.0 | 193.6 ± 34.7 | 179.7 ± 30.7 | 0.001 |
| Echocardiography data | ||||||
| LV (mm) | 68.0 ± 9.3 | 71.4 ± 11.4 | 68.7 ± 8.3 | 70.9 ± 13.1 | 66.7 ± 8.0 | <0.001 |
| LVEF (%) | 31.9 ± 8.4 | 31.0 ± 8.2 | 31.8 ± 7.3 | 30.5 ± 9.0 | 32.3 ± 8.5 | 0.142 |
| RV (mm) | 23.6 ± 5.4 | 22.0 ± 5.0 | 24.1 ± 5.6 | 24.5 ± 5.5 | 24.0 ± 5.4 | <0.001 |
| LA (mm) | 43.9 ± 7.7 | 43.1 ± 7.9 | 45.8 ± 8.4 | 46.6 ± 8.9 | 43.7 ± 7.5 | 0.002 |
| PASP (>40 mmHg), n (%) | 203(18.1) | 35(15.8) | 24(29.3) | 15(22.4) | 129(17.2) | 0.031 |
| Medicine during admission | ||||||
| Diuretics, n (%) | 1059(94.6) | 205(92.8) | 76(92.7) | 63(94.0) | 715(95.5) | 0.362 |
| ACEI/ARB, n (%) | 951(85.0) | 182(82.4) | 70(85.4) | 54(80.6) | 645(86.1) | 0.396 |
| Beta-blockers, n (%) | 1017(90.9) | 195(88.2) | 69(84.1) | 56(83.6) | 697(93.1) | 0.002 |
| Digoxin, n (%) | 903(80.7) | 168(76.0) | 66(80.5) | 59(88.1) | 610(81.4) | 0.127 |
| Aspirin/anticoagulants n (%) | 721(64.4) | 131(59.3) | 52(63.4) | 34(50.7) | 504(67.3) | 0.013 |
| Spironolactone, n (%) | 1019(91.1) | 191(86.4) | 73(89.0) | 57(85.1) | 698(93.2) | 0.004 |
| Treatment groups | Continuous exposure profile | Cross-over exposure profile | ||
| CC | TT | CT | TC | |
| CC | 42 | 53 | 42 | |
| TT | 42 | 36 | 31 | |
| CT | 53 | 36 | 39 | |
| TC | 42 | 31 | 39 |
| XXY ID | Sequence (XX_Y) | N Species | freq (%) | N changes* |
| 1 | AAaTGAAGAAAAcGAAGA_ATGAAGA | 2 | 2.11 | 2 |
| 2 | AAaTGAAGAAAATGAAGA_ATGAAGA | 27 | 28.42 | 1 |
| 3 | AAaTGAAGAAAATGAAGA_ATGAgGA | 2 | 2.11 | 2 |
| 4 | AAaTGAAGAcAATGAAGA_ATGAAGA | 3 | 3.16 | 2 |
| 5 | AAaTGAgGAAAATGAAGA_ATGAAGA | 1 | 1.05 | 2 |
| 6 | AACaGAAGAAAAcGAAGA_ATGAAGA | 2 | 2.11 | 2 |
| 7 | AACcGAAGAAAAcGAAGA_ATGAAGA | 1 | 1.05 | 2 |
| 8 | AACTGAAGAAAAcGAAGA_ATGAAGA | 11 | 11.58 | 1 |
| 9 | AACTGAAGAAAATGAAGA_AcGAAGA | 1 | 1.05 | 1 |
| 10 | AACTGAAGAAAATGAAGA_ATGAAGA | 40 | 42.11 | 0 |
| 11 | AACTGAAGAcAATGAAGA_ATGAAGA | 3 | 3.16 | 1 |
| 12 | cAgTGAAGAAAATGAAGA_ATGAAGA | 1 | 1.05 | 2 |
| 13 | cAgTGAAGAtAAcGAAGA_ATGAAGA | 1 | 1.05 | 4 |
| Participants | Nationality | Sex | Age category | Migratory status | Health complaints | Received treatments while undocumented migrant in Denmark |
| P01 | Bangladeshi | Male | 31-40 | Failed asylum seeker | Dental problems, mental health problems | None |
| P02 | Bangladeshi | Male | 31-40 | Failed asylum seeker | Superficial wounds after assault, asthma | Prescription for medication fromgeneral practitioner |
| P03 | Bangladeshi | Male | 21-30 | Failed asylum seeker | Psoriasis, mental health problems | Treatment for psoriasis throughinformal networks of healthcare professionals and at a hospitaldermatology department |
| P04 | Bangladeshi | Male | 41-50 | Failed asylum seeker | Leg fracture, mental health problems, cancer suspicion | Treatment for a leg fracture at hospital ER, check-up athospital oncology department |
| P05 | Indian | Male | 41-50 | Failed asylum seeker | Diabetes, high blood pressure, heart disease, mental health problems | Treatment for depressionthrough informal networks ofhealthcare professionals. Medical supplies throughpersonal networks |
| P06 | Indian | Male | 31-40 | Overstayer | Dental problems, ulcer, sprained foot,mental health problems | Treatment for a sprained foot at hospital ER |
| P07 | Nepali | Male | 21-30 | Overstayer | None | None |
| P08 | Nepali | Male | 31-40 | Overstayer | Dental problems, mental health problems | None |
| P09 | Nepali | Male | 21-30 | Overstayer | Sprained hand, skin allergy | None |
| P10 | Nepali | Male | 21-30 | Overstayer | Mental health problems | None |
| Linear model | Ordered probit model | |
| Men 15-44 | ||
| Gap in VAS | 0.196 | 0.186 |
| Prevalence effect | -0.082 | -0.102 |
| Severity effect | 0.239 | 0.030 |
| Interaction | 0.038 | -0.012 |
| Women 65-74 | ||
| Difference | -0.902 | -0.664 |
| Prevalence effect | -0.575 | -0.699 |
| Severity effect | 0.305 | 0.372 |
| Interaction | -0.632 | -0.646 |
| Women 75 & more | ||
| Difference | -1.205 | -1.182 |
| Prevalence effect | -1.117 | -1.189 |
| Severity effect | -0.839 | -0.088 |
| Interaction | -0.049 | -0.905 |
| Study | Criteria used for prophylaxis | Antifungal used for prophylaxis | Invasive candidiasis | Commentary |
| Positive prophylactic studies | ||||
| *Slotman et al.1987 [77] | Abdominal surgery+ ≥ 3 risk factors | Ketoconazole 200 mg/d POPlacebo | 0/27 (0%)5/30 (17%)† | Costs: $4,800 vs. $10,000†LOS: 6.0 vs. 12.5 days† |
| *Savino et al.1992 [78] | Surgical patients+ hypermetabolism | Nystatin/norfloxacin POPlacebo | 6/25 (24%)13/21 (62%)‡ | NI per patient:0.9 vs. 2.0† |
| Desai et al.1992 [79] | Severely burned patients | Nystatin/polymyxin SDDNo prophylaxis | 34/1042 (3.3%)0/1439 (0%)† | Superficial infections:59 (21%) vs. 22 (10%)† |
| Eggimann et al.1999 [39] * | Abdominal surgery+ tertiary peritonitis | Fluconazole 400 mg/d IVPlacebo | 1/23 (9%)7/20 (35%)‡ | Candida peritonitis1 (4%) vs. 7 (35%)† |
| Pelz et al.2001 [43] * | Surgical patients+ LOS > 3 days | Fluconazole 400 mg/d POPlacebo | 11/130 (8%)20/130 (15%)† | > 75% colonized at randomization |
| Garbino et al.2002 [42] * | Mechanically ventilated > 96 h | Fluconazole 100 mg PO + SDDPlacebo + SDD | 4/103 (4%)10/101 (10%)‡ | Candidemia: 9 vs. 1(RR 0.1; CI 0.02-0.74)† |
| Jacobs et al.2003 [80] * | ICU+ septic shock | Fluconazole 200 mg IV/dPlacebo | 0/32 (0%)1/39 (3%)‡ | Mortality significantly reduced in peritonitis |
| He et al.2003 [81] | Severe acute pancreatitis | Fluconazole 100 mg IV/dPlacebo | 2/22 (9%)†7/23 (30%)† | Mortality 2/2 (100%)Mortality 3/7 (43%) |
| Negative prophylactic studies | ||||
| Savino et al.1994 [78] | Surgical patients+ LOS > 2 days | Nystatin 2 × 106 4 ×/d POKetoconazole 200 mg/d POClotrimazole 10 mg 3 ×/d PONo prophylaxis | 5/75 (7%)1/65 (2%)‡1/80 (1%)‡2/72 (3%)‡ | |
| Ables et al.2000 [82]* | Surgical patients+ LOS > 2 days + other risk factors | Fluconazole 3 mg/kg 3 ×/wPlacebo | 8/60 (13%)11/59 (19%)‡ | |
| Sandven et al.2002 [40]* | Surgery for peritonitis | Fluconazole 400 mg/d IVPlacebo | -- | Mortality rates NS4/53 (8%) vs. 8/56 (14%) |
| Schuster et al.2008 [83]* | ICU ≥ 4 d+ Fever > 4 d under broad-spectrum antibiotics+ APACHE II ≥ 16 | Fluconazole 400 mg/d IVPlacebo | 6/122 (5%)11/127 (9%)‡ |
| Ptosis | Group A | Group B |
| Excellent | 89% (57) | 83.9% (52) |
| Good | 9.4% (6) | 9.7% (6) |
| Fair | 1.6% (1) | 6.4% (4) |
| Poor | ||
| Very poor | ||
| p value | 0.440 |
| NHANES 2001–2010a | Sample size | Unweighted percent, % |
| All | 9,568 | 100.0 |
| Sex | ||
| Male | 4,690 | 49.0 |
| Female | 4,878 | 51.0 |
| Age (years) | ||
| 16–19 | 938 | 9.80 |
| 20–59 | 7,245 | 75.7 |
| ≥ 60 | 1,385 | 14.5 |
| Race/ethnicity | ||
| Non-Hispanic white | 4,280 | 44.7 |
| Non-Hispanic black | 1,802 | 18.8 |
| Mexican American | 2,264 | 23.7 |
| Other | 1,222 | 12.8 |
| Ratio of family income to poverty (PIR) | ||
| PIR < 1.0 | 1,669 | 17.5 |
| 1.0 ≤ PIR < 2.0 | 1,886 | 19.7 |
| 2.0 ≤ PIR < 3.0 | 1,410 | 14.7 |
| PIR ≥ 3.0 | 4,603 | 48.1 |
| Education | ||
| Below high school | 1,689 | 17.6 |
| High school/ general educational development | 1,718 | 18.0 |
| Some college or associate’s degree | 2,592 | 27.1 |
| College graduate or higher | 2,626 | 27.4 |
| Not reported | 943 | 9.90 |
| aThe combined data set was from five consecutive survey cycles: 2001–2002, 2003–2004, 2005–2006, 2007–2008 and 2009–2010. |
| Gene | Forward (5′-3′) | Reverse (5′-3′) |
| Egr1 | AACAACCCTACGAGCACCTG | AAAGGGGTTCAGGCCACAAA |
| Fgf2 | GCGACCCACACGTCAAACTA | CCGTGACCGGTAAGTGTTGTA |
| Fgf7 | TGTGGCAATCAAAGGGGTGG | AAGGCCACGAACATTTCCCC |
| Jak2 | AGTGTGCTACAGTGCTGGTC | TTCCTTGTTGCCAGATCCCG |
| Mmp9 | GCCGGGAACGTATCTGGAAA | GGTTGTGGAAACTCACACGC |
| Notch2 | AACTGCACCTCCTCACTTCG | CTCCTCGTTGTTGCATCCCT |
| Vim | CATGCGGCTGCGAGAAAAAT | GGTCAAGACGTGCCAGAGAA |
| Zeb2 | AAAGCAGTTCCCTTCTGCGA | AGGAGCCCGAGTGTGAAAAG |
| Hif1α | CTCATCCAAGGAGCCTTAACCT | TAACGTTCCAATTCCTGCTGC |
| Lox | AGGGCGGATGTCAGAGACTA | CATCCAGCAGGTCGTAGTGG |
| Cdh1 | CCACCAGATGACGATACCCG | GAATCACTTCCGGTCTGGCA |
| Category | Data Elements |
| Vascular Access | Dialysis catheter position |
| Dialysis catheter type (acute or tunneled) | |
| Dialysis catheter manufacturer | |
| Dialysis catheter size | |
| Any need for catheter manipulation (e.g. repositioning, replacement) | |
| CRRT Circuit | Any circuit interruptions/replacements and reasons |
| Priming solution (new circuits) | |
| CRRT-Related Anticoagulation | Anticoagulation type (heparin, citrate, none, other) |
| Anticoagulation dose | |
| Anticoagulation metrics | |
| CRRT Fluids | Type of solution |
| Modality (dialysate, pre- and/or post-replacement) and rate | |
| Solution additives | |
| CRRT Dose | Prescribed effluent dose |
| Machine Data Card | Delivered effluent dose |
| Type, number and duration of machine alarms and interruptions | |
| Filter life |
| Name | Description | Reference |
| Integrative plasmid set with URA3 selection marker flanked with direct repeats | ||
| pCfB126 | pX-2-USER-URA3-DR | Mikkelsen et al. (2012) |
| pCfB127 | pX-3-USER-URA3-DR | Mikkelsen et al. (2012) |
| pCfB128 | pX-4-USER-URA3-DR | Mikkelsen et al. (2012) |
| pCfB383 | pXI-1-USER-URA3-DR | Mikkelsen et al. (2012) |
| pCfB384 | pXI-2-USER-URA3-DR | Mikkelsen et al. (2012) |
| pCfB385 | pXI-3-USER-URA3-DR | Mikkelsen et al. (2012) |
| pCfB387 | pXI-5-USER-URA3-DR | Mikkelsen et al. (2012) |
| pCfB129 | pXII-1-USER-URA3-DR | Mikkelsen et al. (2012) |
| pCfB120 | pXII-2-USER-URA3-DR | Mikkelsen et al. (2012) |
| pCfB130 | pXII-4-USER-URA3-DR | Mikkelsen et al. (2012) |
| pCfB131 | pXII-5-USER-URA3-DR | Mikkelsen et al. (2012) |
| pCfB49 | pXII-1-ccdB-USER-URA3-DR | Mikkelsen et al. (2012) |
| Plasmids that contain LoxP-flanked selection marker cassettes | ||
| pUG6 | LoxP-KanMX | Gueldener et al. (2002) |
| pUG27 | LoxP-SpHIS5 | Gueldener et al. (2002) |
| pUG72 | LoxP-KlURA3 | Gueldener et al. (2002) |
| pUG73 | LoxP-KlLEU2 | Gueldener et al. (2002) |
| pSA40 | LoxP-CaLYS5 | Ito-Harashima & McCusker (2004) |
| Episomal replication vectors with USER cassette (the vectors were derived from pESC vector series, Agilent) | ||
| pCfB54 | pESC-URA-ccdB-USER | This study |
| pCfB55 | pESC-HIS-ccdB-USER | This study |
| pCfB132 | pESC-URA-USER | This study |
| pCfB291 | pESC-HIS-USER | This study |
| pCfB220 | pESC-LEU-USER | This study |
| EasyClone integrative vector set with loxP-flanked selection markers | ||
| pCfB255 | pX-2-LoxP-KlURA3 | This study |
| pCfB353 | pX-2-LoxP-KanMX | This study |
| pCfB257 | pX-3-LoxP-KlLEU2 | This study |
| pCfB258 | pX-4-LoxP-SpHIS5 | This study |
| pCfB388 | pXI-1-LoxP-KlLEU2 | This study |
| pCfB389 | pXI-2-LoxP-KlURA3 | This study |
| pCfB390 | pXI-3-LoxP-KlURA3 | This study |
| pCfB391 | pXI-5-LoxP-SpHIS5 | This study |
| pCfB259 | pXII-1-LoxP-KlLEU2 | This study |
| pCfB260 | pXII-2-LoxP-CaLYS5 | This study |
| pCfB262 | pXII-4-LoxP-SpHIS5 | This study |
| pCfB261 | pXII-5-LoxP-SpHIS5 | This study |
| Plasmids containing genes encoding fluorescent proteins | ||
| pWJ1163 | CFP | Reid et al. (2002) |
| pWJ1165 | YFP | Reid et al. (2002) |
| pWJ1350 | RFP | Lisby et al. (2003) |
| EasyClone vectors for expression of genes for fluorescent proteins in S. cerevisiae | ||
| pCfB393 | pX-2-LoxP-KlURA3-TEF1::CFP | This study |
| pCfB394 | pX-3-LoxP-KlLEU2-TEF1::RFP | This study |
| pCfB395 | pX-4- LoxP-SpHiS5-TEF1::YFP | This study |
| Episomal vectors for expression of genes for fluorescent proteins in S. cerevisiae | ||
| pCfB396 | pESC-URA-USER-TEF1::CFP | This study |
| pCfB397 | pESC-LEU-USER-TEF1::RFP | This study |
| pCfB398 | pESC-HIS-USER-TEF1::YFP | This study |
| Plasmid contains a cassette for expression of GFP in E. coli (used as positive control in USER cloning) | ||
| pCfB774 | pmExpCtrl | Dr Hao Lao, DTU |
| Specificity (%) | Sensitivity (%) | AUC | Confidence interval | |
| Roc 1 (Both H&R scores >0) | 83.3 | 61.1 | 72.3 | 63.61–82.22 % |
| Roc 2 (Both H&R scores >1) | 81.4 | 67.8 | 75.3 | 65.66–85.79 % |
| Roc 3 (Both H&R scores >2) | 77.5 | 81.2 | 80.9 | 69.49–92.24 % |
| Roc 4 (Both H&R scores >3) | 71.8 | 100.0 | 89.1 | 79.9 %–98.2 % |
| PA-PRP (n = 11) | HA (n = 10) | |
| Age, mean (SD) years | 49.91 (13.72) | 52.70 (10.30) |
| BMI, mean (SD) kg/m2 | 27.92 (11.94) | 30.87 (5.64) |
| Previous surgery, no. (%) | 5 (45 %) | 8 (80 %) |
| Gender (Male), no. (%) | 8 (72.73 %) | 7 (70 %) |
| Symptom duration, mean (SD) years | 8.50 (4.95) | 15 (7.07) |
| Cause of osteoarthritis, no. | ||
| Degeneration/unknown | 6 | 4 |
| Post joint injury/surgery | 3 | 3 |
| Sport related degeneration | 2 | 3 |
| AML(n=11) | ALL(n=9) | MM(n=26) | NHL(n=6) | HL(n=12) | P value | |
| IL-6 (pg/mL) | 95.10(55.10-140.90) | 89.90 (61.90-690) | 91.25(4.5-640) | 68.10(33-152.9) | 72.70(32-530) | 0.25 |
| IL-10 (pg/mL) | 86.20(68.50-640) | 75.90(26-133.9) | 87.75(41.40-588) | 93.86(55-112) | 86.05(58.20-215) | 0.25 |
| hs-CRP (mg/L) | 3(1-14) | 3(1-6) | 3(1-71) | 7(3-75) | 3(3-75) | 0.07 |
| IL-6 / IL-10 | 1.01(0.12-1.87) | 1.28(0.73-4.78) | 1.04(0.01 -8.59) | 0.84(0.29-1.60) | 0.76(0.22 -5.22) | 0.21 |
| Holistic wellness/well-being (encompassing each of physical, psychological, social, spiritual) | |||
| Physical | Psychological | Social | Spiritual |
| Biological markers | Absorption | Adjustment | Awareness |
| Disability | Anger | Advocacy | Balance |
| Energy | Anxiety | Economic | Enablement |
| Fatigue | Attitudes and Beliefs | Health care utilization | Energy |
| Function/Activities of Daily Living | Awareness | Cost-effectiveness | Harmony |
| Pain | Coping | Relationships | Hope |
| Pathology | Depression | Role function in daily life and work | Peace |
| Sleep | Empathy | Social support | Relaxation |
| Symptom management | Enablement | Socioeconomic | Spirituality |
| Energy | Social Strain | Transformation | |
| Patient expectations | Religiosity | ||
| General | |||
| Hope | |||
| Introversion | |||
| Locus of control | |||
| Mood | |||
| Openness to experience | |||
| Optimism/Pessimism | |||
| Patient knowledge | |||
| Patient motivation | |||
| Patient perceived self-efficacy | |||
| Patient perceptions of care | |||
| Patient perceptions of risk | |||
| Patient preference for control | |||
| Patient Satisfaction | |||
| Readiness | |||
| Relaxation | |||
| Resilience | |||
| Self-Esteem | |||
| Sense of Coherence | |||
| Stress | |||
| Trust | |||
| Quality of Life (assessing at least two of physical, psychological, social, spiritual) | |||
| Global | |||
| Multidimensional | |||
| Individualized | |||
| e.g. Measure Your Medical Outcome Profile, Measure Your Concerns and Well-being, Goal Attainment Scaling | |||
| Context of healing | |||
| Healing environment | |||
| Negotiations between patients and practitioners | |||
| Patient-centeredness of healing | |||
| Patient expectations | |||
| Patient-practitioner relationship | |||
| Practitioner attitudes towards integration | |||
| Practitioner attributes | |||
| Practitioner expectations | |||
| Practitioner experience | |||
| Attunement | |||
| Therapeutic Intent | |||
| Process of healing | |||
| Adjustment | |||
| Engagement with intervention experience | |||
| Personal growth | |||
| Transformation | |||
| Unstuckness |
| Rotarix® label | \"In the manufacturing process, porcine-derived materials are used.Porcine circovirus type 1 (PCV-1) is present in Rotarix. PCV-1 is not known to cause disease in humans.\" |
| RotaTeqTM label | \"In the manufacturing process for RotaTeq, a porcine-derived material is used. DNA from porcine circoviruses (PCV) 1 and 2 has been detected in RotaTeq. PCV-1 and PCV-2 are not known to cause disease in humans.\" |
| Probe set ID | Gene Symbol | Gene Title | Fold Change in Apcfl/fl p53-/- v WT |
| 1418368_at | Retnlb | resistin like beta | 0.002 |
| 1422422_at | Defcr4 | defensin related cryptdin 4 | 27.73 |
| 1425221_at | Agr3 | anterior gradient homolog 3 (Xenopus laevis) | 27.20 |
| 1460582_x_at | a | Nonagouti | 17.82 |
| 1421837_at | Rps18 | ribosomal protein S18 | 8.12 |
| 1422934_x_at | Defcr-rs7 | defensin related cryptdin, related sequence 7 | 30.91 |
| 452183_a_at | Gtl2 | GTL2, imprinted maternally expressed untranslated mRNA | 25.82 |
| 1421838_at | Rps18 | ribosomal protein S18 | 8.60 |
| 1459443_at | Kcnq1 | Potassium voltage-gated channel, subfamily Q, member 1 | 9.67 |
| 1447260_at | ENSMUSG000000734 | ENSMUSG00000073403 | 12.11 |
| 1426340_at | Slc1a3 | solute carrier family 1 (glial high affinity glutamate transporter), member 3 | 13.83 |
| 1455274_at | a | Nonagouti | 19.31 |
| 1422071_at | Lgals6 | lectin, galactose binding, soluble 6 | 11.52 |
| 1420748_a_at | Adat1 | adenosine deaminase, tRNA-specific 1 | 4.33 |
| 1423017_a_at | Il1rn | interleukin 1 receptor antagonist | 12.54 |
| 1449492_a_at | Lect2 | leukocyte cell-derived chemotaxin 2 | 43.73 |
| 1443536_at | Slc7a11 | solute carrier family 7 (cationic amino acid transporter, y+ system), member 11 | 13.16 |
| 1446728_at | D3Ertd797e | DNA segment, Chr 3, ERATO Doi 797, expressed | 2.39 |
| 1459779_s_at | Setd8 | SET domain containing (lysine methyltransferase) 8 | 6.92 |
| 1421257_at | Pigb | phosphatidylinositol glycan anchor biosynthesis, class B | 11.65 |
| 1446730_at | C79267 | Expressed sequence C79267 | 10.65 |
| 1459834_x_at | --- | --- | 4.64 |
| 1460604_at | Cybrd1 | cytochrome b reductase 1 | 22.55 |
| 1427580_a_at | Rian | RNA imprinted and accumulated in nucleus | 9.54 |
| 1418708_at | Apoc4 | apolipoprotein C-IV | 19.03 |
| 1422597_at | Mmp15 | matrix metallopeptidase 15 | 10.55 |
| 1434734_at | E130016E03Rik | RIKEN cDNA E130016E03 gene | 9.11 |
| 1441594_at | --- | --- | 5.86 |
| 1441624_at | Sorbs2 | sorbin and SH3 domain containing 2 | 3.78 |
| 1434028_at | Arnt2 | aryl hydrocarbon receptor nuclear translocator 2 | 11.43 |
| 1427967_at | Srgap2 | SLIT-ROBO Rho GTPase activating protein 2 | 9.36 |
| 1434497_at | 4933431E20Rik | RIKEN cDNA 4933431E20 gene | 7.73 |
| 1444538_at | Snd1 | Staphylococcal nuclease and tudor domain containing 1 | 8.68 |
| 1457636_x_at | --- | --- | 5.12 |
| 1436845_at | Axin2 | axin2 | 4.58 |
| 1457262_at | 2610207I05Rik | RIKEN cDNA 2610207I05 gene | 5.35 |
| 1431031_at | Arid4b | AT rich interactive domain 4B (Rbp1 like) | 3.55 |
| 1439380_x_at | Gtl2 | GTL2, imprinted maternally expressed untranslated mRNA | 7.69 |
| 1417520_at | Nfe2l3 | nuclear factor, erythroid derived 2, like 3 | 6.40 |
| 1446376_at | Rps6kb1 | ribosomal protein S6 kinase, polypeptide 1 | 5.88 |
| 1422882_at | Sypl | synaptophysin-like protein | 4.91 |
| 1444498_at | --- | --- | 7.23 |
| 1438258_at | Vldlr | very low density lipoprotein receptor | 6.85 |
| 1422954_at | Zfp60 | zinc finger protein 60 | 3.25 |
| 1425986_a_at | Dcun1d | DCUN1D1 DCN1, defective in cullin neddylation 1, domain containing 1 (S. cerevisiae) | 2.49 |
| 1430458_at | Supt6h | suppressor of Ty 6 homolog (S. cerevisiae) | 3.17 |
| 1434734_at | E130016E03Rik | RIKEN cDNA E130016E03 gene | 9.11 |
| 1435082_at | Syp1 | synaptophysin-like protein | 5.30 |
| 1437065_at | Zbtb20 | zinc finger and BTB domain containing 20 | 12.39 |
| 1441487_at | Trim2 | tripartite motif protein 2 | 5.68 |
| 1443628_at | --- | --- | 9.06 |
| 1447386_at | Usp2 | Ubiquitin specific peptidase 8 | 2.94 |
| 1455327_at | Senp2 | SUMO/sentrin specific peptidase 2 | 4.36 |
| Acridine orange | A cationic cytochemical stain specific for cell nuclei, especially DNA. It is used as a supravital stain and in fluorescence cytochemistry. It may cause mutations in microorganisms. |
| Acriflavine | 3,6-Diamino-10-methylacridinium chloride mixture. with 3,6-acridinediamine. Fluorescent dye used as a local antiseptic and also as a biological stain. It intercalates into nucleic acids thereby inhibiting bacterial and viral replication. |
| Aminacrine | A highly fluorescent anti-infective dye used clinically as a topical antiseptic and experimentally as a mutagen, due to its interaction with DNA. It is also used as an intracellular pH indicator. |
| Amsacrine | Aminoacridine derivative that is a potent intercalating antineoplastic agent. It is effective in the treatment of acute leukemias and malignant lymphomas, but has poor activity in the treatment of solid tumors. It is frequently used in combination with other antineoplastic agents in chemotherapy protocols. It produces consistent but acceptable myelosuppression and cardiotoxic effects. |
| Ethacridine | A topically applied anti-infective agent. |
| Nitracrine | Acridine antineoplastic agent used in mammary and ovarian tumors. It inhibits RNA synthesis. |
| Proflavine | 3,6-Diaminoacridine. Topical antiseptic used mainly in wound dressings. |
| Tacrine | A cholinesterase inhibitor that crosses the blood-brain barrier. Tacrine has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders. |
| Quinacrine | An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions as well as a form of contraception/sterilization. It is used in cell biological experiments as an inhibitor of phospholipase A2. |
| Loading of MWCNT (wt%) | Tg by DMA (°C) | CTE by TMA (×10−6 K−1) |
| Control | 161 ± 0.3 | 85 ± 0.3 |
| 0.1 | 160 ± 0.1 | 89 ± 0.9 |
| 0.25 | 162 ± 0.3 | 90 ± 1.2 |
| 0.4 | 163 ± 0.4 | 87 ± 1.4 |
| 0.5 | 163 ± 2.2 | 88 ± 0.9 |
| 0.75 | 161 ± 0.9 | 87 ± 0.3 |
| Drug(s) resistant to | Typical diseases | |
| Name of Bacterium | ||
| Escherichia coli | Cephalosporins and fluoroquinolones | Urinary tract infections and blood stream infections |
| Klebsiella pneumoniae | Cephalosporins and carbapenems | Pneumonia, blood stream, and urinary tract infections |
| Staphylococcus aureus | Methicillin | Wound and blood stream infections |
| Streptococcus pneumoniae | Penicillin | Pneumonia, meningitis, and otitis |
| Nontyphoidal Salmonella | Fluoroquinolones | Foodborne diarrhoea, blood stream infections |
| Shigella species | Fluoroquinolones | Diarrhoea (bacillary dysentery) |
| Neisseria gonorrhoeae | Cephalosporins | Gonorrhoea |
| Mycobacterium tuberculosis | Rifampicin, isoniazid, and fluoroquinolone [4] | Tuberculosis |
| Name of Fungi | ||
| Candida spp. | Fluconazole and echinocandins [5] | Candidiasis |
| Cryptococcus neoformans | Fluconazole [17] | Cryptococcosis |
| Aspergillus spp. | Azoles [18] | Aspergillosis |
| Scopulariopsis spp. | Amphotericin B, flucytosine, and azoles [19] | Onychomycosis |
| Name of Virus | ||
| Cytomegalovirus (CMV) | Ganciclovir and foscarnet [20] | In AIDS and oncology patients |
| Herpes simplex virus (HSV) | Acyclovir, famciclovir, and valacyclovir [21] | Herpes simplex |
| Human immunodeficiency | ||
| virus (HIV) | Antiretroviral drugs [22] | AIDS |
| Influenza virus | Adamantane derivatives (Amantadine and rimantadine) and neuraminidase inhibitors [23] | Influenza |
| Varicella zoster virus | Acyclovir and valacyclovir [21] | Chicken pox |
| Hepatitis B virus (HBV) | Lamivudine [24] | Hepatitis B |
| Name of Parasite | ||
| Plasmodia spp. | Chloroquine, artemisinin, and atovaquone [25] | Malaria |
| Leishmania spp. | Pentavalent antimonials, miltefosine, paromomycin, and amphotericin B [13, 14] | Leishmaniasis |
| Schistosomes | Praziquantel and oxamniquine [26, 27] | Schistosomiasis |
| Entamoeba | Metronidazole [28] | Amoebiasis |
| Trichomonas vaginalis | Nitroimidazoles [29] | Trichomoniasis |
| Toxoplasma gondii | Artemisinin, atovaquone, and sulfadiazine [10–12] | Toxoplasmosis |
| Frequency | Percentage | |
| Aetiology | ||
| Unknown | 294 | 66.2% |
| Stone | 44 | 9.9% |
| Nephrotic | 22 | 5.0% |
| Glomerulonephritis (nephritic) | 22 | 5.0% |
| Obstructive uropathy | 9 | 2.0% |
| SSK (small shrunken kidneys) | 28 | 6.3% |
| Others (Wilms, BOO, gastroenteritis, etc.) | 22 | 5.0% |
| VUR (vesicoureteral reflux) | 3 | .7% |
| Hepatitis B | ||
| Positive | 11 | 2.5% |
| Negative | 433 | 97.5% |
| Hepatitis C | ||
| Positive | 13 | 2.9% |
| Negative | 431 | 97.1% |
| Characteristic | LN group (n = 14) | P-value |
| Time since birth of first male child (yr) | ||
| 1 to 15 (n = 5) | 9.25 ± 12.37 | NS |
| >15 (n = 9) | 5.5 ± 9.6 | |
| Time since SLE diagnosis (yr) | ||
| 1 to 5 (n = 5) | 10 ± 13.6 | NS |
| >5 (n = 9) | 5.08 ± 8 | |
| Number of male pregnancies | ||
| 1 (n = 0) | 7.99 ± 10.75 | NS |
| >1 (n = 4) | 3.7 ± 7.5 | |
| Serum creatinine (mg/dl) | ||
| ≤1.5 mg/dl (n = 10) | 9.5 ± 11.2 | 0.026 |
| >1.5 mg/dl (n = 3) | 0.12 ± 0.2 |
| Methodology Followed | Start/End Point Needed | Tube Specific | No Automation | Seed Point Needed | time to detection | Surgical planning | Neuro-surgical planning | Arbitrary objects detection | Arbitrary image modality | Fine Vessel Accuracy | Main vessel Accuracy | Center-Line-Detection Accuracy | Module complexity | Feature Complexity |
| m1 | y | n | y | y | gt | Y | Y | n | y | gt | lt | y | gt | Lt |
| m2 | y | y | y | n | gt | Y | y | y | y | gt | gt | lt | lt | eq |
| m3 | y | y | n | n | gt | n | n | y | y | lt | eq | eq | lt | lt |
| m4 | y | n | n | n | lt | y | y | y | y | lt | lt | eq | lt | lt |
| m5 | y | n | y | y | gt | n | n | y | y | lt | y | lt | lt | lt |
| m6 | n | y | n | n | eq | y | y | n | y | eq | eq | eq | eq | eq |
| No. | Activity reviewed | Activities confirmed (Pa) | Additional predicted activities (Paa) |
| 78 | Antimicrobial antiviral antineoplastic | Antineoplastic (sarcoma) (0.413) | Atherosclerosis treatment (0.924)Genital warts treatment (0.600) |
| 79 | Cytotoxic antineoplastic | Antineoplastic (0.584)Antineoplastic (liver cancer) (0.797) | Endothelial growth factor antagonist (0.885)Angiogenesis inhibitor (0.632) |
| 80 | Not studied | – | Phobic disorders treatment (0.728)Antineurotic (0.685) |
| 81 | Not studied | – | Antineurotic (0.694)Phobic disorders treatment (0.648) |
| 82 | Not studied | – | Lysase stimulant (0.787)Kidney function stimulant (0.518) |
| 83 | Not studied | – | Lysase stimulant (0.787)Kidney function stimulant (0.518) |
| 84 | Interleukin 4 antagonist | – | Antiseborrheic (0.815)Kidney function stimulant (0.721)Phobic disorders treatment (0.749) |
| 85 | Antibacterial | – | Antineurotic (0.806)Phobic disorders treatment (0.752) |
| 86 | Not studied | – | Not predicted: MolCharge: 1 |
| 87 | Not studied | – | Not predicted: MolCharge: 1 |
| 88 | Cytotoxic | Antineoplastic (0.666)Antineoplastic (renal cancer) (0.614) | Pterin deaminase inhibitor (0.989)Natural killer cell stimulant (0.587) |
| 89 | Cytotoxic antifungal | – | Antiallergic (0.765)Cytostatic (0.712)Erythropoiesis stimulant (0.692) |
| 90 | Antineoplastic antileukemic | Antineoplastic (0.749)Antileukemic (0.622) | Genital warts treatment (0.936)DNA synthesis inhibitor (0.825)Cytostatic (0.701) |
| 91 | Antineoplastic antileukemic | Antineoplastic (0.752)Antileukemic (0.634) | Antimetabolite (0.938)DNA synthesis inhibitor (0.926)Neuroprotector (0.910) |
| 92 | Antibiotic | – | Antineoplastic (sarcoma) (0.730) |
| 93 | Not studied | – | Antineoplastic(0.768)Antibacterial (0.614)Antifungal (0.592) |
| 94 | Antimicrobial antiviral antineoplastic | Glycopeptide-like antibiotic (0.627)Antineoplastic(0.406) | Analgesic (0.637) |
| 95 | Antimicrobial antiviral antineoplastic | Glycopeptide-like Antibiotic (0.714)Antineoplastic (0.519)Antibacterial (0.409) | Analgesic (0.670) |
| 96 | Antimicrobial antiviral antineoplastic | Glycopeptide-like antibiotic (0.625)Antineoplastic(0.443) | Analgesic (0.601) |
| 97 | Antimicrobial antiviral antineoplastic | Glycopeptide-like antibiotic (0.713)Antineoplastic (0.547)Antibacterial (0.424) | Analgesic (0.641) |
| Mobile phase | Relation | Volume (mL) | Fractions | Residue (mg) |
| Dichloromethane | 100% | 500 | F4.3.1 | 0.4 |
| Dichloromethane : ethyl acetate | 90 : 10 | 500 | F4.3.2 | 3 |
| F4.3.3 | 59 | |||
| F4.3.4 | 91 | |||
| Dichloromethane : ethyl acetate | 80 : 20 | 500 | F4.3.5 | 256 |
| F4.3.6 | 65 | |||
| Dichloromethane : ethyl acetate | 60 : 40 | 500 | F4.3.7 | 146 |
| F4.3.8 | 8 | |||
| Dichloromethane : ethyl acetate | 40 : 60 | 500 | F4.3.9 | 6 |
| F4.3.10 | 111 | |||
| Dichloromethane : ethyl acetate | 20 : 80 | 500 | F4.3.11 | 63 |
| Ethyl acetate | 100% | 500 | F4.3.12 | 3 |
| Patient | Fp | ve* | vp | PS | SUV* | Cellularity | Tumor |
| (mL.min−1.100g−1) | (%) | (%) | (mL.min−1.100g−1) | (%) | localization, staging | ||
| Pretreatment | |||||||
| 1 | 313.7 | 30.3 | 8.1 | 53.8 | 14.3 | - | L, T2N0 |
| 2 | 378.6 | 39.2 | 12.0 | 59.7 | 16.8 | - | OC, T2N0 |
| 3 | 157.2 | 15.4 | 16.0 | 37.7 | 10.6 | - | OC, T2N0 |
| 4 | 366.5 | 60.5 | 13.7 | 81.9 | 11.4 | - | OC, T1N0 |
| 5 | 73.9 | 41.8 | 15.3 | 28.6 | 9.9 | - | OC, T1N0 |
| 6 | 136.1 | 30.9 | 11.1 | 69.2 | 13.4 | - | OC,T4N0 |
| 7 | 278.0 | 36.4 | 15.5 | 47.3 | 8.8 | - | L, T2N0 |
| 8 | 116.9 | 39.5 | 13.6 | 42.0 | 8.3 | - | OC, T2N1 |
| 9 | 93.7 | 41.9 | 13.0 | 82.9 | 16.2 | - | OC, T2N1 |
| 10 | 163.2 | 21.9 | 9.5 | 37.2 | 12.3 | - | L, T2N0 |
| 11 | 72.7 | 29.1 | 9.2 | 38.1 | 7.4 | - | OC, T2N0 |
| 12 | 286.6 | 49.8 | 5.6 | 40.9 | 28.9 | - | OC, T3N0 |
| 13*** | 128.0 | 37.0 | 10.8 | 44.6 | 14.8 | - | OC, T2N0 |
| 14 | 222.8 | 21.1 | 18.7 | 36.2 | 18.9 | - | OC, T2N2b |
| m ± SD | 199 ± 107 | 35 ± 12 | 12 ± 3.5 | 50 ± 17 | 14 ± 5.6 | - | |
| Post treatment | |||||||
| 1 | 281.1 | 30.3 | 9.0 | 42.6 | 9.2 | 77 | |
| 2 | 292.6 | 47.9 | 8.5 | 87.4 | 8.4 | 45 | |
| 3 | 305.9 | 40.1 | 11.8 | 45.6 | 4.8 | 38 | |
| 4 | 357.9 | 66.7 | 14.5 | 75.0 | 4.9 | 34 | |
| 5 | 40.8 | 46.1 | 8.6 | 31.4 | 11.4 | 55 | |
| 6 | 99.1 | 18.0 | 4.5 | 78.3 | 6.8 | 40 | |
| 7 | 219.6 | 38.7 | 2.2 | 40.4 | 4.5 | 54 | |
| 8 | 411.9 | 53.3 | 3.9 | 60.5 | 4.9 | 49 | |
| 9 | 72.4 | 68.4 | 31.2 | 30.7 | 4.3 | 25 | |
| 10 | 92.3 | 53.5 | 12.8 | 22.8 | 6.7 | 63 | |
| 11 | 75.9 | 77.6 | 14.6 | 44.1 | 3.9 | 35 | |
| 12 | 184.0 | 47.4 | 8.9 | 33.8 | 3.4 | 22 | |
| 13*** | 131.2 | 46.1 | 9.9 | 60.7 | 6.0 | 26 | |
| 14 | 359.2 | 33.7 | 13.7 | 53.7 | 8.3 | 36 | |
| m ± SD | 209 ± 126 | 48 ± 16 | 11 ± 7.0 | 51 ± 20 | 6.3 ± 2.3 | 42.8± 15.5 |
| B | S.E. | Wald | df | Sig. | Exp(B) | |
| TG | −0.634 | 0.402 | 2.489 | 1 | 0.115 | 0.530 |
| Chol | 0.511 | 0.825 | 0.384 | 1 | 0.536 | 1.667 |
| LDL | −1.944 | 2.172 | 0.801 | 1 | 0.371 | 0.143 |
| ApoA-I | −2.171 | 1.078 | 4.057 | 1 | 0.044 | 0.114 |
| ApoB | −1.004 | 2.411 | 0.173 | 1 | 0.677 | 0.366 |
| Constant | 3.639 | 1.575 | 5.335 | 1 | 0.021 | 38.052 |
| Total (N) | N of Death | Median survival (months)* | Mean survival (months) | P value | |
| Oct-4 | |||||
| Positive | 58 | 26 | 43 | 45.1 | 0.022 |
| Negative | 36 | 8 | * | 42.4 | |
| Sox2 | |||||
| Positive | 53 | 25 | 43 | 35.1 | 0.023 |
| Negative | 41 | 9 | * | 62.5 | |
| Gli1 | |||||
| Positive | 50 | 22 | 43 | 47.1 | 0.045 |
| Negative | 44 | 12 | * | 40.9 | |
| CD44 | |||||
| Positive | 40 | 24 | 30 | 37.7 | 0.000 |
| Negative | 54 | 10 | 43.5 | ||
| CD133 | |||||
| Positive | 31 | 14 | 43 | 33.7 | 0.124 |
| Negative | 63 | 20 | * | 57.3 | |
| p-AKT | |||||
| Positive | 78 | 30 | * | 53.3 | 0.300 |
| Negative | 16 | 4 | 46 | 41.7 | |
| p-ERK | |||||
| Positive | 36 | 18 | 34 | 33.4 | 0.014 |
| Negative | 58 | 16 | * | 57.5 |
| Ref. | Textural features | Classifier | Accuracy |
| Mannivannan [23] | Four types of local features with CPM-BoW encoding | Ensemble SVMs | 87.09% |
| Sansone [87] | Dense local descriptors with BoW encoding | SVM | 83.64% |
| Theodorakopoulos [88] | SIFT with VLAD encoding, LBP-based and morphological descriptors | SVM | 83.33% |
| Gao [89] | Raw image data with deep CNNs | Deep CNNs | 83.23% |
| Paisitkriangkrai [90] | Combination of different sets of low-level texture features | Boosting classifier | 81.55% |
| Ensafi [91] | SIFT and SURF descriptors with BoW sparse encoding | SVM | 80.81% |
| Nanni [92] | LBP-derived and morphological features | SVM | 78.27% |
| Codrescu [93] | Raw image data | Neural networks | 74.93% |
| Taormina [94] | Combination of different types of local texture features | kNN | 74.62% |
| Ponomarev [95] | Morphological and shape descriptors | SVM | 73.53% |
| Roberts [90] | Wavelet transform-based features | SVM | 66.99% |
| Compounds | Signals | Assign of Signals | S/N | Signal Intensity | Quantitative Value (mg) |
| CTX3C | H | Hydroxyl group 44 | 81 | 0.40 | 0.4060 ± 0.0038 |
| I | Olefin 2, 3, 13, 14, 18, 19, 23, 24 | - | - | 0.4408 ± 0.0018 | |
| J | 17-H | 37 | - | 0.4243 ± 0.0067 | |
| 51OHCTX3C | K | 17-H | <10 | 0.013 | 0.0134 ± 0.0002 |
| L | 38, 42-H | 25 | - | 0.01089 | |
| M | 22, 25-H | 10 | - | 0.01230 | |
| N | 17-H | 10 | - | 0.01085 |
| Termb | KEGG pathway | Countc | %d | Detected proteome backgrounde | Entire proteome backgroundf | |||
| P‐value | Fold enrichment | P‐value | Fold enrichment | Bonferroni | ||||
| In nonproducing condition (325 DAVID IDs in the 1396 detected proteome) | ||||||||
| cgl00020 | Citrate cycle (TCA cycle) | 15 | 4.6 | 4.98E‐06 | 2.9 | 2.59E‐12 | 9.3 | 4.02E‐10 |
| cgl00970 | Aminoacyl‐tRNA biosynthesis | 15 | 4.6 | 0.00 579 | 1.9 | 1.03E‐09 | 7.0 | 1.59E‐07 |
| cgl03010 | Ribosome | 26 | 8.0 | 0.00 582 | 1.6 | 1.98E‐10 | 4.2 | 3.07E‐08 |
| In glutamate‐producing condition (213 DAVID IDs in the 1181 detected proteome) | ||||||||
| cgl03010 | Ribosome | 24 | 12.1 | 0.00 101 | 1.8 | 1.18E‐11 | 5.2 | 1.48E‐09 |
| cgl00020 | Citrate cycle (TCA cycle) | 11 | 4.7 | 0.00 191 | 2.6 | 2.84E‐08 | 9.3 | 3.58E‐06 |
| cgl00970 | Aminoacyl‐tRNA biosynthesis | 13 | 6.1 | 0.00 541 | 2.2 | 5.11E‐09 | 8.2 | 6.44E‐07 |
| 209 proteins that contain reproducible and more than 2‐fold changed acetylation sites | ||||||||
| cgl00020 | Citrate cycle (TCA cycle) | 11 | 5.3 | 1.09E‐04 | 3.6 | 3.65E‐09 | 11.4 | 4.63E‐07 |
| CSX (−)MetX (−)(N = 39) | CSX (+)MetX (−)(N = 35) | CSX (−)MetX (+)(N = 15) | CSX (+)MetX (+)(N = 24) | pa | pb | |
| Adiponectin (μg/mL) | 12.3 (7.0, 18.9) | 3.4 (2.3, 7.2) | 4.0 (2.0, 9.1) | 2.8 (1.7, 7.7) | <0.001 | <0.001 |
| Leptin (ng/mL) | 3.3 (1.3, 8.1) | 5.1 (3.1, 11.0) | 8.1 (5.1, 18.5) | 8.7 (6.3, 17.4) | <0.001 | <0.001 |
| HOMA-IR | 1.04 (0.72, 2.47) | 1.93 (1.28, 2.62) | 2.40 (1.78, 4.21) | 2.23 (1.48, 5.89) | 0.009 | 0.005 |
| The 4 ALSI factors | Number of Questions | Mean | Mean as % of Max. | SEM | Cronbach’s α |
| Deep approach | 6 Questions | 19.84 | 66.10 | 0.22 | 0.71 |
| Surface approach | 4 Questions | 9.57 | 47.85 | 0.15 | 0.64 |
| Effort management /Organised studying | 4 Questions | 13.02 | 65.10 | 0.18 | 0.74 |
| Monitoring studying | 4 Questions | 13.70 | 68.50 | 0.15 | 0.58 |
| Variable | RR (CI 95%) | p value* |
| Diabetes mellitus | 1.3 (0.8–2) | 0.2 |
| Hepatopathy | 4 (2.7–5.9) | < 0.001 |
| Exposure to chemotherapy | 1.6 (0.9–2.7) | 0.1 |
| Energy intake (kcal/day) B (95 %-CI) | Standard. Beta (95 %-CI) | P-value | Satiety Response (score) B (95 %-CI) | Standard. Beta (95 %-CI) | P-value | |
| Weight | ||||||
| Birth weight | −7.1 (−30.9; 16.7) | −0.02 (−0.09; 0.05) | 0.56 | −0.01 (−0.04; 0.02) | −0.02 (−0.08; 0.04) | 0.51 |
| Conditional weight 0–1 month | 4.5 (−16.1; 25.2) | 0.01 (−0.05; 0.08) | 0.67 | −0.03 (−0.06; −0.00) | −0.06 (−0.12; −0.00) | 0.03 |
| Conditional weight 1–3 months | 29.7 (4.6; 54.8) | 0.09 (0.01; 0.16) | 0.02 | −0.05 (−0.08; −0.01) | −0.08 (−0.15; −0.01) | 0.006 |
| Conditional weight 3–6 months | 24.0 (1.8; 46.1) | 0.07 (0.01; 0.14) | 0.03 | −0.04 (−0.07; −0.01) | −0.07 (−0.13; −0.00) | 0.01 |
| Conditional weight 6–12 months | 8.9 (−14.5; 32.2) | 0.03 (−0.04; 0.10) | 0.46 | −0.07 (−0.10; −0.04) | −0.15 (−0.21; −0.08) | <0.001 |
| Conditional weight 12 months–5 years | 79.5 (29.4; 129.7) | 0.23 (0.08; 0.37) | 0.002 | −0.12 (−0.19; −0.06) | −0.23 (−0.37; −0.10) | <0.001 |
| Height | ||||||
| Conditional height 0–1 month | −42.0 (−66.6; −17.4) | −0.13 (−0.20; −0.05) | <0.001 | 0.01 (−0.02; 0.04) | 0.00 (−0.06; 0.06) | 0.48 |
| Conditional height 1–3 months | −35.1 (−58.4; −11.8) | −0.11 (−0.18; −0.04) | 0.003 | 0.00 (−0.03; 0.02) | −0.02 (−0.07; 0.04) | 0.94 |
| Conditional height 3–6 months | −9.0 (−29.9; 11.9) | −0.03 (−0.09; 0.03) | 0.40 | −0.02 (−0.05; 0.00) | −0.06 (−0.11; 0.00) | 0.06 |
| Conditional height 6–12 months | −9.4 (−31.4; 12.6) | −0.03 (−0.09; 0.04) | 0.40 | −0.02 (−0.04; 0.01) | −0.04 (−0.09; 0.02) | 0.12 |
| Conditional height 12 months–5 years | −37.4 (−72.4; −2.3) | −0.11 (−0.21; −0.01) | 0.04 | −0.02 (−0.05; 0.01) | −0.04 (−0.11; 0.03) | 0.24 |
| Gene name | N and D | Medium N | Medium D | |||
| Stability value* | SE | Stability value* | SE | Stability value* | SE | |
| RPLPO | 0.093 | 0.069 | 0.071 | 0.079 | 0.050 | 0.135 |
| TBP | 0.109 | 0.065 | 0.100 | 0.072 | 0.050 | 0.135 |
| PPIA | 0.318 | 0.085 | 0.201 | 0.087 | 0.335 | 0.131 |
| GAPDH | 0.374 | 0.096 | 0.376 | 0.138 | 0.393 | 0.148 |
| B2M | 0.258 | 0.075 | 0.181 | 0.083 | 0.125 | 0.089 |
| ACTB | 0.344 | 0.090 | 0.205 | 0.088 | 0.348 | 0.135 |
| Best gene: | RPLPO | RPLPO | RPLPO and TBP |
| Variable | Category | OR | 95% CI |
| Age (ref: < 50 years) | > 50 years | 0.49 | 0.09, 2.61 |
| Gender (ref: male) | Female | 0.52 | 0.11, 2.61 |
| Albumin (ref: > 3.5) | ≤3.5 | 16.3 | 1.14, 234.6 |
| ASA class (ref: 1-2) | > 2 | 6.67 | 1.22, 33.34 |
| Charlson score (re: = 0) | 1-2 | 0.59 | 0.07, 5.08 |
| 3 and above | 3.5 | 0.26, 46.3 |
| Serotonin | RANKL | P1NP | CTX | |
| OVX+Saline versus SHAM+Saline | 34.8% ### | 77.6% ### | 106% ### | 74.4% ### |
| OVX+WBV versus SHAM+Saline | 4.9% | 4.6% | 0.1% | 42.7% ### |
| OVX+ALN versus SHAM+Saline | 30.3% ### | 1.2% | -6.1% | 40.8% ### |
| OVX+WBV versus OVX+Saline | -22.2% *** | -41.1% *** | -51.4% *** | -18.2% ** |
| OVX+ALN versus OVX+Saline | -3.3% | -43.0% *** | -54.4% *** | -19.3% ** |
| OVX+WBV versus OVX+ALN | -19.5% △△△ | 3.4% | 6.6% | 1.3% |
| Item | Treatmentb | Pooled SEM | Contrastc | |||||
| Control | LPS | LPS + Low GLP-2 | LPS + High GLP-2 | 1 | 2 | 3 | ||
| Duodenum, g | 17.8 | 15.2 | 17.4 | 17.9 | 0.4 | 0.008 | 0.019 | 0.005 |
| Jejunum, g | 325 | 287 | 323 | 342 | 7 | 0.034 | 0.042 | 0.003 |
| Ileum, g | 43.8 | 38.5 | 42.2 | 47.1 | 1 | 0.035 | 0.134 | 0.001 |
| Gross weight of SI, g | 386 | 340 | 383 | 407 | 7 | 0.017 | 0.026 | 0.001 |
| SI weight index | 0.0402 | 0.0362 | 0.0385 | 0.0402 | 0.0006 | 0.016 | 0.147 | 0.015 |
| SCD incidence rates per 100.000 person years | All | Men | Women | Incidence rate ratio | p-value |
| 1–35 years | 2.7 (2.5–2.9) | 3.6 (3.2–3.9) | 1.8 (1,5–2,0) | 2.0 (1.7–2.4) | <0.01 |
| 1–18 years | 1.0 (0.9–1.2) | 1.3 (1.0–1.6) | 0.7 (0.5–1.0) | 1.7 (1.2–2.6) | 0.03 |
| 19–35 years | 4.4 (3.9–4.8) | 5.9 (5.3–6.5) | 2.8 (2.4–3.2) | 2.1 (1.8–2.6) | <0.01 |
| Parameter | Healthy donors | RCC patients | Patients < pT3 | Patients ≥ pT3 |
| Number of leukocytes | 6,260 ± 310 | 7,005 ± 350 | 6,500 ± 402 | 8,340 ± 563 |
| Granulocytes | 4,227 ± 310 | 5,103 ± 292 | 4,702 ± 354 | 6,139 ± 385 |
| Monocytes | 351 ± 39 | 375 ± 21 | 349 ± 22 | 441 ± 42 |
| Dendritic cells (DC) | 19 ± 2 | 16 ± 1 | 17 ± 1 | 13 ± 2 |
| Lymphocytes | 1,670 ± 111 | 1,566 ± 103 | 1,490 ± 110 | 1,760 ± 237 |
| Neutrophil-to-lymphocyte ratio (NLR) | 2.86 ± 0.37 | 3.93 ± 0,40 | 3.8 ± 0.5 | 4.27 ± 0.64 |
| Granulocyte/DC ratio | 249.4 ± 25 | 378.7 ± 31 | 318.1 ± 30 | 535.4 ± 60 |
| Rank | Active substance, drug formulation | No of prescriptions | Potentially harmful or known to be harmful excipients |
| 1 | Gentamicin, inj solution | 200 | Parabens, sodium metabisulphite |
| 2 | Simeticone, oral suspension | 108 | Sodium benzoate, saccharin sodium, silicium dioxide, sodium cyclamate, sorbic acid |
| 3 | Heparin, inj solution | 86 | Benzyl alcohol, parabens |
| 4 | Laurilsulphate + Sorbitol + Sodium citrate, rectal solution | 60 | Sorbic acid |
| 5 | Salbutamol, nebulisation solution | 54 | Benzalkonium chloride, propylene glycol |
| 6 | Dobutamine, inj solution | 45 | Sodium metabisulphite |
| 7 | Epinephrine, inj solution | 36 | Sodium metabisulphite |
| 8 | Iron, oral solution | 32 | Parabens, saccharin sodium |
| 9 | Budesonide, nebulisation solution | 31 | Polysorbate 80, disodiumedetate |
| 10 | Chloramphenicol, opthalmic solution | 29 | Benzalkonium chloride, polysorbate 80, borax, boric acid |
| 11 | Caffeine, solution | 29 | Sodium benzoate |
| 12 | Phenobarbital, tablet | 29 | Silicium dioxide, gelatin |
| 13 | Paracetamol, suppository | 29 | Disodium hydrogen phosphate |
| 14 | Piperacillin + tazobactam, inj solution | 25 | Disodium edetate |
| 15 | Paracetamol, inj solution | 24 | Disodium hydrogen phosphate |
| 16 | Hydrocortisone, inj solution | 23 | Benzyl alcohol, disodium hydrogen phosphate |
| 17 | Epoetin beta, inj solution | 22 | Disodium hydrogen phosphate, glycine, calcium chloride dihydrate, leucine, |
| 18 | Ibuprofen, inj solution | 21 | Trometamol |
| 19 | Hyoscine butylbromide, tablet | 20 | Silicium dioxide |
| 20 | Spironolactone, tablet | 18 | Silicium dioxide |
| 21 | Zidovudine, oral solution | 17 | Sodium benzoate, saccharin sodium |
| 22 | Fusidic acid, ophthalmic solution | 16 | Benzalkonium chloride, disodium edetate |
| 23 | Morphine, inj solution | 14 | Sodium metabisulphite |
| 24 | Phenobarbital, inj solution | 13 | Benzyl alcohol, propylene glycol |
| 25 | Heparin sodium, topical gel | 12 | Parabens, ethanol, trietanolamine, |
| 26 | Insulin, inj solution | 11 | Cresol |
| Control | Intervention | ||||
| Preintervention | Postintervention | Preintervention | Postintervention | p Value | |
| NOTECHS | 72.09 (3.36) | 70.09 (5.70) | 71.62 (5.69) | 75.44 (5.53) | 0.047 |
| WHO T/O attempted, n (%) | 5/11 (45) | 10/10 (100) | 11/26 (42) | 25/25 (100) | 0.640 |
| WHO T/O success, n (%) | 0/11 (0) | 2/10 (20) | 4/26 (15) | 23/25 (92) | <0.05 |
| WHO S/O attempted, n (%) | 0/11 (0) | 0/10 (0) | 2/26 (8) | 7/25 (28) | 0.125 |
| Glitch rate/h | 10.31 (3.79) | 10.79 (4.53) | 7.21 (2.73) | 10.20 (3.67) | 0.173 |
| Complication rate, n (%) | 162 (27.1) | 106 (25.7) | 140 (21.5) | 185 (26.8) | 0.05 |
| Length of stay (days) | 4.82 (13.5) | 4.93 (11.7) | 5.09 (11.1) | 5.38 (13.2) | 0.371 |
| Readmission rate, n (%) | 51 (8.5) | 37 (9.0) | 72 (13) | 74 (11) | 0.25 |
| Treatment | Dose (mg/kg b.w.) | Thickness of rat paw (cm) | ||||
| T1 h | T2 h | T3 h | T4 h | T5 h | ||
| Control | 3.21 ± 0.03 | 3.64 ± 0.04 | 3.95 ± 0.02 | 4.11 ± 0.03 | 4.06 ± 0.06 | |
| Indomethacin | 10 | 2.97 ± 0.04*** (45.71) | 3.06 ± 0.06*** (64.1) | 3.11 ± 0.03*** (69.72) | 3.14 ± 0.05*** (71.2) | 3.09 ± 0.04*** (74.17) |
| BRME | 100 | 3.07 ± 0.06 (11.42) | 3.42 ± 0.03* (15.39) | 3.57 ± 0.05** (25.69) | 3.66 ± 0.03*** (28) | 3.59 ± 0.06*** (30.83) |
| BRME | 200 | 3.08 ± 0.05 (14.29) | 3.28 ± 0.02** (35.9) | 3.37 ± 0.03*** (45.87) | 3.46 ± 0.04*** (45.6) | 3.39 ± 0.05*** (49.17) |
| BRME | 400 | 3.12 ± 0.04 (17.14) | 3.29 ± 0.02*** (41.02) | 3.41 ± 0.05*** (46.79) | 3.46 ± 0.04*** (49.6) | 3.39 ± 0.03*** (53.33) |
| Risk factors | Incisional SSI (+) | Incisional SSI (−) | β | SE | Hazard ratio (95 % CI) | p value |
| BMI (≥25/<25 kg/m2) | 8/10 | 8/49 | 0.31 | 1.60 | 2.28 (0.57–9.04) | 0.241 |
| VFA (≥100/<100 cm2) | 12/6 | 14/43 | 0.38 | 2.86 | 4.32 (1.18–15.80) | 0.027 |
| HV | NU | P values | |
| n | 35 | 33 | |
| Age [median (range)] | 32 (23–78) | 44 (18–78) | 0.004 |
| Sexe (% of female) | 62 % | 31 % | 0.003 |
| BMI [median (range)] | 26.1 (20.5–31.1) | 26.8 (18.8–37.1) | NS |
| Smokers | 28 % | 58 % | 0.03 |
| Daily alcohol | 0 % | 29 % | 0.003 |
| Comorbidities | |||
| Fracture history in the past year of visit | 6 % | 100 % | <0.001 |
| Rheumatic diseases (osteoarthritis, psoriatic arthritis and rheumatoid arthritis) | 0 % | 14 % | NS |
| Gastric (heartburn and esophagitis) | 0 % | 14 % | NS |
| Diabetes (NIDDM) | 0 % | 10 % | NS |
| Pulmonary (asthma, emphysema, chronic pulmonary disease, pneumothorax) | 0 % | 24 % | 0.006 |
| Cardiovascular (ischaemia, deep vein thrombosis, infarction) | 0 % | 14 % | NS |
| High blood pressure | 0 % | 17 % | NS |
| Hypercholesterolemia | 0 % | 17 % | NS |
| Hypothyroidism | 0 % | 0 % | NS |
| Hypovitamin D | 0 % | 3 % | NS |
| Treatment | |||
| NSAID and/or analgesic and/or tramadol | 0 % | 100 % | <0.001 |
| Anxiolytics | 0 % | 33 % | <0.001 |
| Transitions | Transversions | |||||
| A/G | C/T | A/C | A/T | G/C | G/T | |
| Numbers of allelic sites | 1,466 | 1,430 | 463 | 463 | 423 | 473 |
| Percentage of allelic sites | 31.07% | 30.31% | 9.81% | 9.81% | 8.97% | 10.03% |
| Total (Percentage) | 2,896 (61.38%) | 1,822 (38.62%) |
| IFN-beta clinical response | EDSS* | Relapses** | |||
| N | Resp. | % | |||
| MHC2TA mRNA level decreased + HHV-6 in serum | 21 | 5 | 23.8 | 1.5 | 1.2 |
| MHC2TA mRNA level increased without HHV-6 in serum | 99 | 58 | 58.6 | - 0.5 | 0.4 |
| p | 0.004 |
| SN | Age | Vaccine |
| 1 | Birth (0–11 Months) | BCG |
| 2 | Birth (as soon as possible within 14 days of life | OPV0 |
| 3 | 6 Weeks | Pentavalent 1, OPV1 |
| 4 | 10 Weeks | Pentavalent 2, OPV2 |
| 5 | 14 Weeks | Pentavalent 3, OPV3 |
| 6 | 9 Months | Measles, OPV4 |
| 7 | 18 Months | Measles |
| Northern California Family Cohort | |||||
| Source population | Contacted | Tier I | Tier II | Tier III | |
| Number of households | 11,850 | 1,955 | 499 | 186 | 30 |
| Age | *b | *b | |||
| Mean | 28.7 | 30.8 | 31.6 | 31.7 | 30.3 |
| Age group | *b | *b | |||
| Under 25 years | 27.8% | 17.2% | 13.4% | 11.3% | 16.7% |
| 25-34 years | 52.4% | 53.9% | 53.3% | 58.1% | 56.7% |
| 35-44 years | 19.5% | 28.3% | 33.1% | 30.1% | 26.7% |
| 45+ | 0.3% | 0.6% | 0.2% | 0.5% | 0.0% |
| Education level | *b | *b | **c | ||
| 0-8 years | 8.3% | 7.2% | 4.6% | 0.5% | 0.0% |
| 9-11 years | 12.8% | 10.4% | 6.4% | 1.6% | 6.7% |
| 12 years | 25.9% | 16.3% | 12.6% | 12.4% | 10.0% |
| 13-15 years | 19.9% | 20.2% | 21.0% | 22.0% | 10.0% |
| 16 years | 17.7% | 23.7% | 24.6% | 26.3% | 33.3% |
| >16 years | 15.4% | 22.3% | 30.7% | 37.1% | 40.0% |
| Race/ethnicityd | *b | *b | |||
| White | 71.0% | 71.3% | 80.0% | 79.6% | 93.3% |
| Asian | 20.2% | 23.6% | 15.6% | 16.2% | 6.7% |
| African American | 6.5% | 3.5% | 3.6% | 3.2% | 0.0% |
| Native American | 0.7% | 0.3% | 0.2% | 0.5% | 0.0% |
| Other/Missing | 1.6% | 1.3% | 0.6% | 0.5% | 0.0% |
| Hispanic identification | *b | *b | **c | ||
| Latino | 33.2% | 24.1% | 21.6% | 11.9% | 23.1% |
| Non-Latino | 66.5% | 75.6% | 78.2% | 87.6% | 76.9% |
| Missing | 0.3% | 0.3% | 0.2% | 0.5% | 0.0% |
| Place of birth | *b | *b | **c | ||
| USA | 55.3% | 56.8% | 68.5% | 76.3% | 80.0% |
| Mexico | 18.4% | 13.9% | 10.6% | 2.7% | 6.7% |
| Other | 26.2% | 29.2% | 20.6% | 21.0% | 13.3% |
| Missing | 0.1% | 0.1% | 0.2% | 0.0% | 0.0% |
| Publicly funded delivery | *b | *b | |||
| Yes | 33.6% | 21.5% | 17.0% | 8.6% | 13.3% |
| No | 66.2% | 78.4% | 82.6% | 91.4% | 86.7% |
| Missing | 0.2% | 0.2% | 0.4% | 0.0% | 0.0% |
| 2012 | 2013 | 2014 | |
| MTI Requests | 44,970 | 42,919 | 87,549 |
| # Items processed | 3,148,431 | 7,963,477 | 11,294,998 |
| MeSH on demand requests | – | – | 225,750 |
| # Different domains | 118 | 124 | 147 |
| Gene | Primer sequence | Base pairs | Source | |
| 18S | Forward sequence | TGG TCG CTC GCT CCT CTC C | 360 | NR_003286 |
| Reverse sequence | CGC CTG CTG CCT TCC TTG G | |||
| αSMA | Forward sequence | GTG TGA GGA AGA GGA CAG CA | 446 | X60732 |
| Reverse sequence | TAC GTC CAG AGG CAT AGA GG | |||
| Collagen I | Forward sequence | GAT GCG TTC CAG TTC GAG TA | 312 | Personal communication |
| Reverse sequence | GGT CTT CCG GTG GTC TTG TA | |||
| Collagen III | Forward sequence | TTA TAA ACC AAC CTC TTC CT | 255 | Personal communication |
| Reverse sequence | TAT TAT AGC ACC ATT GAG AC | |||
| COX-2 | Forward sequence | CAA ACT GCT CCT GAA ACC CAC TC | 82 | NM_001082388 |
| Reverse sequence | GCT ATT GAC GAT GTT CCA GAC TCC | |||
| IL-1β | Forward sequence | GCC GAT GGT CCC AAT TAC AT | 121 | M26295 |
| Reverse sequence | ACA AGA CCT GCC GGA AGC T | |||
| IL-6 | Forward sequence | CCT GCC TGC TGA GAA TCA CTT | 51 | AF469048 |
| Reverse sequence | CGA GAT ACA TCC GGA ACT CCA T | |||
| IL-8 | Forward sequence | CAA CCT TCC TGC TGT CTC TG | 145 | NM_001082293 |
| Reverse sequence | GGT CCA CTC TCA ATC ACT CT | |||
| iNOS | Forward sequence | CTG TGA CGT CCA GCG CTA CA | 119 | AF469048 |
| Reverse sequence | GCA CGG CGA TGT TGA TCT CTC GCC CT | |||
| PRG4 | Forward sequence | GAA CGT GCT ATA GGA CCT TC | 287 | NM_00127709 |
| Reverse sequence | CAG ACT TTG GAT AAG GTC TGC C | |||
| TGF-β | Forward sequence | CGG CAG CTG TAC ATT GAC TT | 271 | AF000133 |
| Reverse sequence | AGC GCA CGA TCA TGT TGG AC | |||
| TNF-α | Forward sequence | TCT AGT CAA CCC TGT GGC CC | 51 | NM_00108 |
| Reverse sequence | GCC CGA GAA GCT GAT CTG AG |
| Exercise | Description |
| Exercise 1Relaxing | Diaphragmatic breathing and postural elements such as alignment of the midline.The patient is supine on a mat with flexed knees and arms along the chest. |
| Exercise 2Raising arm, opening and closing punches | Lying on the bed, arms at sides, flexed knees. Slowly, lift parallel the arms till the upright position, opening and clenching the fists in order to contract the muscles of the arms. Maintain up the position, opening and closing the punches five times, and return to the starting position. Repeat ten times. |
| Exercise 3Stretching and releasing the arms. Recovery of the flexion. | Lying on the bed, flexed knees. Interlock the fingers and slowly bring to full flexion and then on the pillow; then put as much as possible while keeping your arms extended. Perform the technique of breathing for a minute. Repeat ten times. |
| Exercise 4 Turn the shoulders. Rotation-anteropulsion-retropulsion | Standing or sitting, rotate the shoulders for ten times. |
| Exercise 5Abduction and adduction of the arms—isometric strengthening | Lying or standing, bring the arms out, with extended elbows. Maintain the position for six seconds. Return to the starting position, slowly. Repeat for ten times. |
| Exercise 6Opening and closing elbows | Standing, legs apart. Place both hands on the hips with thumbs pointing backwards. Push your elbows back and forth without moving the hands. Repeat for ten times. |
| Exercise 7Run up the wall—recovery of flexion | Getting closer to the maximum height possible completely to the wall, stopping for few seconds, and trying to gently remove the hands from the wall. Repeat ten times. |
| Exercise 8Run up the wall by the side—recovery of abduction | With a bit of tape, standing with the unaffected side facing the wall, place the hand on the wall at shoulder height. Reaching a point with his hand, as high as possible, marking it with the piece of tape. Begin the exercise with the operated arm, and repeat ten times trying to get closer to the mark left on the wall. |
| Exercise 9Hand on the operated shoulder—recovery of the adduction | Sitting or standing, arms along the sides. Bring the hand of the operated limb to the contralateral shoulder. Return to starting position. Repeat ten times. |
| Exercise 10Rotate the arms—promoting the rotations | Standing with legs apart, raise your arms to the shoulder. Beginning with small movements, gradually increase the diameter up to do it without complaints. We recommend at least five full rotations. Finally, bring the arm down the side and remain at rest for a moment. |
| Exercise 11Run up the back—promoting the extension and intrarotation | Standing, place the hands behind the back and take with the healthy hand, the hand of the operated limb. Slowly slide the hands along the spine upwards to its possible and maintain the position for a few seconds. Then decline slowly. Repeat for ten times. |
| Exercise 12Opening and closing the elbows | Standing or sitting, with the feet firmly on the ground, interlock the hands ahead of face with the head upright. Slowly, raise the arms above the head and then behind the neck. Then open both elbows and close them for five times. If you feel discomfort at the wound, keep the position and work with the breathing. |
| Exercise 13Bar | Sitting or standing, hold the bar (about 110 cm long). Bring the arms forward and upward at the elbows extended. Flex elbows and bring the bar behind the head. Return slowly to starting position. Repeat ten times. |
| Exercise 14Codman's pendulum | Lying on a bed in a prone position, the arm perpendicular to the floor, make a circular motion clockwise and counterclockwise slowly. Repeat for ten times. |
| Exercise 15Flex on the front wall—to prevent the deficit of the scapula | Standing in front of the wall, put the hands against the wall parallel. Flex the arms. Repeat for ten times. |
| Plantation collaboration | I | II | III | IV | V | VI | VII |
| IRS/ITN re/treatment | PL in negotiation to cover; currently covered by MCP | PL in negotiation to cover; currently covered by MCP | PL in negotiation to cover; currently covered by MCP | PL subcontracts out; MCP supervises activities | PL conducts, MCP supervises activities | PL subcontracts out; MCP supervises activities | MCP covers |
| ITN distribution | PL in negotiation; currently covered by MCP during outbreaks | 50% of workers currently covered by PL, MCP covers during outbreaks | MCP covers during outbreaks | MCP covers during outbreaks | PL covers workers; MCP may add during outbreaks | PL distributes on ad-hoc basis; MCP covers during outbreaks | MCP covers during outbreaks |
| Variables | IHM | |||
| Model 1 | Model 2 | |||
| OR | 95% CI | OR | 95% CI | |
| Age | 1.07 | 0.995–1.14 | 1.07 | 0.995–1.16 |
| Sex | 2.27 | 0.41–12.64 | 1.19 | 0.18–7.73 |
| Cirrhosis | 1.12 | 0.30–4.27 | 1.20 | 0.30–4.84 |
| Treatment | 1.05 | 0.29–3.88 | 1.16 | 0.30–4.47 |
| MELD | 1.02 | 0.96–1.09 | 1.02 | 0.95–1.08 |
| Ammonia | - | 1.02 | 0.997–1.04 | |
| C = 0.703 | C = 0.761 |
| Characteristics | Median (Range) |
| Age, years | 70 (55-85) |
| PSA, ng/ml | 24.2 (2.6-269.6) |
| Hemoglobin, g/l | 124 (69-156) |
| ALP, U/l | 111 (47-2779) |
| LDH, U/l | 208 (114-2467) |
| ALB, g/l | 44.5 (32.3-52.2) |
| ECOG performance status, No. (%) | |
| 0-1 | 63 (90.0) |
| ≥2 | 7 (10.0) |
| Gleason score of primary lesion, No. (%) | |
| 5-7 | 30 (42.9) |
| 8-10 | 40 (57.1) |
| Site of metastatic disease1, No. (%) | |
| Bone | 65 (92.9) |
| Lymph node | 24 (34.3) |
| Liver | 5 (7.1) |
| Lung | 4 (5.7) |
| Other soft tissue | 5 (7.1) |
| Primer set | Primer 1 | Primer 2 | FAMTM Labelled Probe | VicTM Labelled Probe | Fluorescent Quencher | Anneal (1 minute) |
| TGFB1 -800G>A | gctatcgcctgcacacagc | aggacagaagcggtcccat | tgcctccaacgtcaccaccatc | tctgcctccaacatcaccaccatc | TAMRA | 62°C |
| TGFB1 -509C>T | ttagccacatgggaggtgct | ccaggcggagaaggcttaa | acccttccatccctcaggtgtcct | ccctcccatccttcaggtgtcctg | TAMRA | 62°C |
| TGFB1 +869T>C | caccacaccagccctgttc | ccaggcgtcagcaccagta | agcagcggcagca | cagcagcagcagc | None | 60°C |
| TGFB1 +915G>C | Developed by Applied Biosystems (USA) as a Research and Development Kit | None | 56°C |
| Inclusion criteria | Exclusion criteria |
| At least 16 years old | Present fracture or other joint pathology/bone matrix pathology |
| Visited the ER within one week after a lateral ankle sprain | A diagnosed OCD after primary inclusion |
| Agreed with being approached for this study | Medial ankle instability |
| Reported anterolateral ankle pain after an ankle sprain or ankle distortion | Previous ankle surgery |
| Filled out the baseline, 3-, or 6 month questionnaire; and the 12 month follow-up | An unreliable radiograph due to the angle in which it is made or low quality |
| Acute surgical repair or the ATFL/CFL or any other form of surgery within 12 months after the ER visit |
| PAX8 staining N (%) | P-value† | ||
| Clinical Feature | Low/Absent | Medium/High | |
| Stage | |||
| 1 | 17 (30) | 39 (70) | 0.013* |
| 2 | 6 (21) | 22 (79) | |
| 3 | 16 (14)* | 101 (86)* | |
| 4 | 5 (20) | 20 (80) | |
| Grade | |||
| G1 | 2 (7) | 25 (93) | 0.072 |
| G2 | 11 (24) | 35 (76) | |
| G3 | 30 (20) | 121 (80) | |
| Residual Disease | |||
| Optimal debulking | 21 (22) | 73 (78) | 0.391 |
| Sub-optimal debulking | 22 (17) | 106 (83) | |
| Histological type | |||
| Serous | 15 (12)* | 109 (88)* | 0.007* |
| Mucinous | 6 (35) | 11 (65) | |
| Endometrioid | 9 (29) | 22 (71) | |
| Clear Cell | 2 (11)* | 16 (89)* | |
| Undifferentiated | 10 (29) | 24 (71) | |
| Borderline | 3 (43) | 4 (57) |
| Types of home visits | Influencing conditions and causes | Strategies to achieve “productive performance” | Consequences of “productive performance” |
| • Visits on demand• Periodic visits• Nursing home round• Visits based on ad-hoc-decisions | • Nurse characteristics• Resident characteristics• Nursing home environment | Preparing strategies • Scheduling and planning • PreparingOn-site strategies • Gathering information • Seeking nurses ́ attendance • Decision making • Taking care of the residentInvesting strategies • Instructing and teaching • Dealing with documentation • Providing information | • Satisfaction• Annoyance• Disrespect• Avoiding contact to the nurses• Give up care |
| Criteria as provided in Figure 1 | Median, days (range) No. (%) | ≥0 days No. (%) | >0 days No. (%) | ≤0 days No. (%) | = 0 days No. (%) | <0 days No. (%) | Ref. |
| Lead times | |||||||
| 4A All histological tumor types | |||||||
| Criterion 1A, Rustin et al.† | 60 (0–248) | 14 (47) | 13 (43) | 1 (3) | 1 (3) | 0 | [8] |
| Criterion 1B, Tuxen et al.† | 27 (0–257) | 9 (30) | 7 (23) | 3 (10) | 2 (7) | 1 (3) | [7,20] |
| Criterion 1C, Tuxen et al.† | 87 (0–356) | 14 (47) | 13 (43) | 2 (7) | 1 (3) | 1 (3) | [7,20] |
| Criterion 1D, Tuxen et al.† | 66 (0–356) | 13 (43) | 12 (40) | 3 (10) | 1 (3) | 2 (7) | [7,20] |
| Criterion 2A, Rustin et al.‡ | 41 (0–369) | 43 (41) | 35 (34) | 30 (29) | 8 (8) | 22 (21) | [6] |
| Criterion 2B, Tuxen et al.‡ | 45 (0–775) | 50 (48) | 48 (46) | 15 (14) | 2 (2) | 13 (13) | [7,20] |
| Criterion 2C, Tuxen et al.‡ | 46 (0–775) | 53 (51) | 51 (49) | 16 (15) | 2 (2) | 14 (13) | [7,20] |
| 4B Serous epithelial tumors | |||||||
| Criterion 1A, Rustin et al.§ | 66 (0–248) | 9 (45) | 8 (40) | 1 (5) | 1 (5) | 0 | [8] |
| Criterion 1B, Tuxen et al.§ | 26 (0–75) | 8 (40) | 6 (30) | 2 (10) | 2 (10) | 0 | [7,20] |
| Criterion 1C, Tuxen et al.§ | 85 (0–169) | 11 (55) | 10 (50) | 1 (5) | 1 (5) | 0 | [7,20] |
| Criterion 1D, Tuxen et al.§ | 76 (0–169) | 10 (50) | 9 (45) | 2 (10) | 1 (5) | 1 (5) | [7,20] |
| Criterion 2A, Rustin et al.¶ | 30 (0–269) | 29 (45) | 25 (39) | 18 (28) | 4 (6) | 14 (22) | [6] |
| Criterion 2B, Tuxen et al.¶ | 47 (0–406) | 32 (50) | 31 (48) | 7 (11) | 1 (2) | 6 (9) | [7,20] |
| Criterion 2C, Tuxen et al.¶ | 52 (0–406) | 34 (53) | 33 (52) | 9 (14) | 1 (2) | 8 (13) | [7,20] |
| Treatments | invH | hilA | hilD | sipA | sipB | sopB | spvB |
| SE Ctrl | 1 a | 1 a | 1 a | 1 a | 1 a | 1 a | 1 a |
| SE + LR | –1.85 ± 0.08 b | –4.58 ± 1.13 b–d | –2.90 ± 0.15 b,c | –5.01 ± 0.76 b–d | –18.69 ± 0.46 g | –6.67 ± 1.39 b–d | –8.17± 1.55 b–d |
| SE + LD | –2.66± 0.14 b,c | –3.54 ± 0.71 b,c | –2.20 ± 0.10 b | –1.87 ± 0.15 b | –1.91 ± 0.19 b | –2.93 ± 0.44 b,c | –17.27 ± 3.26 f,g |
| SE + LP | –4.07± 0.84 a,b | –4.07 ± 0.38 b–d | –2.81 ± 0.28 b,c | –11.19± 0.36 d,e | –27.19 ± 0.66 i | –15.70± 0.54 e–g | –25.46 ± 0.91 h,i |
| ST Ctrl | 1 a | 1 a | 1 a | 1 a | 1 a | 1 a | 1 a |
| ST + LR | –11.31± 0.22 d,e | –2.31 ± 1.04 b,c | –2.74 ± 0.9 b,c | –2.89 ± 1.12 b | –19.35 ± 0.27 g | –3.55 ± 0.51 b,c | –7.16 ± 0.88 b–d |
| ST + LD | –3.98 ± 1.2 a,b | –3.98 ± 0.93 b–d | –2.09 ± 0.66 b | –1.37 ± 0.28 b | –1.78 ± 0.28 b | –1.89 ± 0.28 b | –10.40 ± 1.17 d,e |
| ST + LP | –3.05± 0.77 b,c | –1.45 ± 0.56 b | –2.72 ± 0.55 b,c | –12.13± 1.65 d–f | –28.92 ± 1.53 i | –6.00 ± 1.93 b–d | –25.46 ± 4.8 h,i |
| SH Ctrl | 1 a | 1 a | 1 a | 1 a | 1 a | 1 a | 1 a |
| SH + LR | –3.12 ± 0.64 b,c | –2.00 ± 0.2 a | –2.54 ± 0.6 b,c | –3.29 ± 0.16 b,c | –17.21 ± 3.45 f,g | –3.22 ± 0.33 b,c | –19.97 ± 0.22 g,h |
| SH+ LD | –4.42 ± 1.09 a,b | –5.76 ± 0.55 b–d | –2.04 ± 0.63 b | –1.67 ± 0.17 b | –3.29 ± 0.75 b,c | –2.22 ± 0.23 b | –19.61 ± 0.53 g,h |
| SH + LP | –5.45 ± 2.53 a,b | –12.11± 0.55 d–f | –2.68 ± 0.22 b,c | –10.53 ± 0.99 d,e | –27.96 ± 1.99 i | –4.69 ± 0.67 b–d | –30.86 ± 1.41 i |
| Instrument | Baseline (T0) | 2 months (T1) | 4 months (T2) | 8 months (T3) | 12 months (T4) | |
| Primary outcomes | ||||||
| Physical functioning | PCS of RAND-36 | x | x | x | x | |
| Direct and indirect costs | Tic-P | x | x | x | x | |
| Quality of life | EQ-5D-5L | x | x | x | x | x |
| Secondary outcomes | ||||||
| HRQoL | RAND-36 subscales | x | x | x | x | |
| Anxiety and depression | HADS | x | x | x | x | |
| Number/severity of symptoms | PHQ-15 | x | x | x | x | |
| Potential mediators | ||||||
| Health anxiety | Whitely Index | x | x | x | ||
| Illness perceptions | Brief IPQ | x | x | x | ||
| Cognitions and coping | CBRQ | x | x | x | ||
| Social problem-solving skills | SPSI-R:S | x | x | x | ||
| Mastery | Pearlin Mastery Scale | x | x | x | ||
| Working alliance | WAI-SFa | x | x |
| Sex | F | p | ||
| Male | Female | |||
| Left | ||||
| Anterior | 1202.93 (4.21) | 1180.06 (3.77) | 14.92 | 0.0001 |
| Middle | 2458.53 (10.52) | 2458.69 (9.43) | 0.0001 | 0.99 |
| Posterior | 585.90 (4.07) | 612.86 (3.64) | 24.32 | 0.000001 |
| Right | ||||
| Anterior | 1211.27 (5.22) | 1185.55 (4.68) | 13.44 | 0.0003 |
| Middle | 2346.08 (9.92) | 2347.33 (8.89) | 0.01 | 0.93 |
| Posterior | 564.98 (3.77) | 580.66 (3.37) | 9.59 | 0.002 |
| Q1:50.8 g/day (46.3, 53.6)a | Q2:59.6 g/day (57.8, 61.5)a | Q3:68.0 g/day (65.7, 70.4)a | Q4:81.6 g/day (76.3, 89.9)a | |
| Demographic and lifestyle factors | ||||
| N (cases) | 2173 (146) | 21,734 (128) | 2173 (145) | 2174 (142) |
| BMI (kg/m2) | 23.0 ± 3.5 | 23.2 ± 3.5 | 23.4 ± 3.4 | 23.6 ± 3.5 |
| PAL (×BMR) | 1.70 ± 0.32 | 1.65 ± 0.30 | 1.62 ± 0.29 | 1.60 ± 0.29 |
| Residence area | ||||
| Urban (%) | 19.8 | 26.2 | 36.5 | 44.4 |
| Gender | ||||
| Male (%) | 49.1 | 43.4 | 46.0 | 50.6 |
| Education level | ||||
| Low (%) | 52.7 | 46.0 | 39.9 | 32.3 |
| Middle (%) | 44.3 | 50.1 | 53.6 | 60.1 |
| High (%) | 3.0 | 3.9 | 6.4 | 7.6 |
| Annual income, RMB | ||||
| < 9000 | 68.5 | 65.2 | 53.6 | 50.7 |
| 9000–15,000 | 16.4 | 18.9 | 22.3 | 21.9 |
| > 15,000–25,000 | 10.4 | 10.7 | 14.9 | 16.9 |
| > 25,000 | 4.7 | 5.2 | 9.2 | 10.5 |
| Former or current smoking (%) | 33.4 | 30.2 | 28.0 | 33.1 |
| Tea consumption (yes, %) | 29.0 | 29.6 | 31.7 | 36.4 |
| Coffee consumption (yes, %) | 1.3 | 1.7 | 2.4 | 4.0 |
| Alcohol consumption (yes, %) | 20.9 | 17.3 | 20.7 | 22.2 |
| Daily nutrient intakes | ||||
| Total energy (kcal/day)b | 2277.1 ± 658.0 | 1976.1 ± 582.4 | 2031.8 ± 595.7 | 2234.5 ± 618.6 |
| Total protein (g/day)b | 52.4 ± 15.7 | 55.5 ± 15.5 | 65.4 ± 16.0 | 87.9 ± 22.6 |
| Total protein (energy%)b | 9.2 ± 1.1 | 11.3 ± 0.6 | 13.1 ± 1.0 | 16.0 ± 2.4 |
| Animal protein (g/day)b | 10.6 ± 8.8 | 12.8 ± 8.9 | 17.7 ± 10.4 | 29.0 ± 16.4 |
| From red meat (g/day)b | 7.2 ± 7.5 | 8.3 ± 7.7 | 10.5 ± 9.3 | 18.0 ± 14.5 |
| From poultry (g/day)b | 0.8 ± 2.3 | 1.0 ± 2.7 | 2.1 ± 4.4 | 4.3 ± 7.0 |
| From dairy (g/day)b | 0.1 ± 0.8 | 0.2 ± 1.0 | 0.5 ± 2.1 | 0.8 ± 2.8 |
| From egg (g/day)b | 2.2 ± 2.9 | 3.0 ± 3.5 | 3.9 ± 4.0 | 5.0 ± 5.6 |
| From seafood (g/day)b | 1.4 ± 2.9 | 2.0 ± 3.9 | 3.5 ± 5.3 | 7.3 ± 9.7 |
| Plant protein (g/day)b | 37.8 ± 13.5 | 37.7 ± 13.9 | 40.3 ± 16.1 | 47.1 ± 21.7 |
| From grain (g/day)b | 28.7 ± 11.4 | 28.0 ± 11.9 | 28.5 ± 13.7 | 27.0 ± 13.9 |
| From coarse cereals (g/day)b | 2.0 ± 3.8 | 1.7 ± 2.7 | 1.5 ± 2.8 | 1.3 ± 2.5 |
| From vegetable (g/day)b | 4.6 ± 3.0 | 4.5 ± 3.1 | 4.7 ± 3.3 | 5.5 ± 3.8 |
| From fruit (g/day)b | 0.2 ± 0.5 | 0.2 ± 0.5 | 0.2 ± 0.5 | 0.3 ± 0.6 |
| From legumes (g/day)b | 2.3 ± 3.8 | 3.2 ± 4.8 | 5.2 ± 6.5 | 11.3 ± 14.3 |
| From nuts and seeds (g/day)b | 0.3 ± 1.7 | 0.5 ± 2.0 | 0.7 ± 3.0 | 1.0 ± 3.5 |
| From tubers (g/day)b | 0.4 ± 0.4 | 0.4 ± 0.4 | 0.7 ± 0.6 | 1.9 ± 0.7 |
| Total fat (g/day)b | 86.3 ± 42.7 | 66.6 ± 30.8 | 67.5 ± 30.1 | 78.0 ± 31.9 |
| Total fat (energy%)b | 33.7 ± 11.6 | 30.1 ± 9.8 | 29.9 ± 9.6 | 31.4 ± 9.2 |
| Saturated fat (g/day)b | 10.7 ± 9.0 | 7.2 ± 5.4 | 7.2 ± 5.2 | 8.5 ± 5.6 |
| Monounsaturated fat (g/day)b | 21.2 ± 15.5 | 14.3 ± 10.6 | 14.0 ± 10.0 | 16.2 ± 11.1 |
| Polyunsaturated fat (g/day)b | 19.4 ± 17.2 | 13.7 ± 10.0 | 13.3 ± 9.5 | 14.2 ± 9.6 |
| Total carbohydrate (g/day)b | 324.5 ± 105.9 | 296.1 ± 98.6 | 299.2 ± 105.7 | 305.4 ± 106.0 |
| Total carbohydrate (energy%)b | 57.7 ± 11.7 | 60.2 ± 10.3 | 58.8 ± 10.2 | 54.5 ± 10.0 |
| Cholesterol (mg/day)b | 171.1 ± 154.7 | 206.8 ± 166.9 | 269.3 ± 175.4 | 395.1 ± 270.4 |
| Fiber (g/day)b | 10.5 ± 5.8 | 10.1 ± 5.0 | 11.6 ± 7.2 | 13.9 ± 8.9 |
| Characteristic | N = 981 (%) |
| Demographics and Health Habits from Patient Survey | |
| Age | |
| 64–74 years | 61 |
| 75 + years | 39 |
| Race | |
| Caucasian | 92 |
| African American | 8 |
| Gender | |
| Female | 51 |
| Marital status | |
| Never married | 5 |
| Married | 54 |
| Widowed | 33 |
| Divorced/separated | 9 |
| Employed | 15 |
| Household income | |
| <$10,000 | 18 |
| $10,000–19,999 | 39 |
| $20,000–39,999 | 29 |
| ≥$40,000 | 14 |
| Stratum | |
| Rural | 30 |
| Suburban | 45 |
| Veterans Affairs | 20 |
| Inner city | 5 |
| Smoking status | |
| Smoker | 11 |
| Quitter | 50 |
| Never smoker | 39 |
| Characteristics of Visits to Primary Care Office from Medical Records | |
| Visits/year to primary care officea (n) | |
| < 2 | 35 |
| 2 – 3 | 26 |
| 3 – 4 | 26 |
| ≥5 | 13 |
| Visits to identified primary care providerb | |
| 0 – 25% | 8 |
| 26 – 50% | 12 |
| 51 – 75% | 19 |
| 76 – 100% | 62 |
| Preventive Health Service Usage from Medical Records | |
| Annual influenza vaccine (up to 4 seasons) | 17 |
| Pneumococcal polysaccharide vaccine | 64 |
| Tetanus toxoid | 33 |
| Mammogram among women (n = 500) | |
| None | 11 |
| <1 year | 59 |
| ≥1 year | 30 |
| References | Number of cases | Sex | Age (years) | Sites of lesion | Procedure | Recurrence |
| Verma and Paul [15] | 1 | F | 39 | Metacarpal | En bloc resection, autograft | No |
| Gebert et al. [16] | 1 | F | 17 | Radius | En bloc resection, autograft | No |
| Koskinen [17] | 12 | N/A | Adult | Limb long bones | En bloc resection, allograft | No |
| Traibi et al. [20] | 7 | 6 M, 1 F | 17-40 | Ribs | Rib resection | No |
| Furukawa et al. [21] | 1 | F | 27 | Rib | Rib resection | No |
| Ayadi-Kaddour et al. [22] | 10 | 5 M, 5 F | 27-52 | Rib | Rib resection | No |
| Current report | 2 | M | 2.5, 6 | Ulna, fibula | En bloc resection and autograft | Yes |
| Setup | AIC score | BIC score | HQC score | Prob. score |
| 1000 individuals | ||||
| 1 mutation | 0.0787 ± 0.118 | 0.0705 ± 0.111 | 0.068 ± 0.111 | 0.068 ± 0.103 |
| 2 mutations | 0.061 ± 0.09 | 0.068 ± 0.113 | 0.059 ± 0.091 | 0.066 ± 0.103 |
| 200 individuals | ||||
| 1 mutation | 0.235 ± 0.230 | 0.214 ± 0.227 | 0.219 ± 0.227 | 0.220 ± 0.230 |
| 2 mutations | 0.148 ± 0.184 | 0.140 ± 0.179 | 0.140 ± 0.174 | 0.126 ± 0.174 |
| Controls(n = 10)n (%) | Diabetes (n = 20) n (%) | New diabetes (n = 8) n (%) | p | |
| MIBP | 9 (90) | 15 (75) | 7 (88) | 0.640 |
| MBP | 2 (20) | 3 (15) | 3 (38) | 0.435 |
| DNA Concentration | n | N | Cleavage(% ± SD) | Blastocyst development | EGFP+ Blastocysts | Net yield EGFP+ |
| (% ± SD)a | (% ± SD)b | Blastocysts (% ± SD)c | ||||
| 0 ng/μL | 3 | 57 | 49 (86.0 ± 4.9) | 18 (31.6 ± 4.1)d | 0 | 0 |
| 5 ng/μL | 3 | 110 | 83 (75.5 ± 2.1) | 28 (25.5 ± 1.7)de | 8 (28.6 ± 5.6)d | 7.3 ± 1.6 |
| 20 ng/μL | 3 | 98 | 72 (73.5 ± 1.8) | 22 (22.4 ± 6.8)de | 15 (68.2 ± 5.8)e | 15.3 ± 3.7 |
| 50 ng/μL | 3 | 106 | 76 (71.7 ± 5.6) | 15 (14.2 ± 3.8)e | 12 (80.0 ± 18.0)e | 11.3 ± 3.8 |
| Characteristics | n | HRM me (%) | MSP me (%) | PSQ me (%) | IDH1 mut (%) |
| All patients | 83 | 51.8 | 37.3 | 54.2 | 21.7 |
| Woman | 28 | 50.0 | 39.3 | 53.6 | 21.4 |
| Man | 55 | 52.7 | 36.4 | 54.5 | 21.8 |
| Age ≥70 | 27 | 44.4 | 25.9 | 44.4 | 0.0 |
| Age <70 | 56 | 55.4 | 42.9 | 58.9 | 32.1 |
| Grade III | 23 | 73.9 | 56.5 | 69.6 | 69.6 |
| Grade IV | 60 | 43.3 | 30.0 | 48.3 | 3.3 |
| Age Range | Number | Percentage (%) |
| 1-10 | 9 | 42.9 |
| 11-20 | 5 | 23.8 |
| 21-30 | 7 | 33.3 |
| Total | 21 | 100 |
| Authors (year of publication) | Population studied with CD | Prevalence of thyroid dysfunction |
| Collin et al. (1994) [19] | 355 | AITD* (19) 5.4% |
| Autoimmune hypothyroidism (11) 3.1% | ||
| Graves' disease (7) 2% | ||
| Counsell et al. (1994) [20] | 107 | Hyperthyroid (4) 3.7% |
| Hypothyroid (11) 10.3% | ||
| Velluzzi et al. (1998) [7] | 47 | Hypothyroid (2) 4.3% |
| Subclinical hypothyroid (3) 6.4% | ||
| Sategna-Guidetti et al. (2001) [9] | 241 | Hypothyroid (31) 12.9% |
| Hyperthyroid (3) 1.2% | ||
| Euthyroid AITD (39) 16.2% | ||
| Hakanen et al. (2001) [8] | 79 | AITD (11)13.9% |
| Graves' disease (3) 3.8% | ||
| Hypothyroid (8) 10.1% | ||
| Subclinical thyroid disease (8) 10.1% | ||
| Carta et al. (2002) [21] | 39 | Subclinical hypothyroid (3) 7.7% |
| Hadithi et al. (2007) [5] | 184 | Euthyroid (10) 5% |
| Overt hypothyroidism (22) 12% | ||
| Subclinical hypothyroid (7) 3.8% |
| Source of help beforehand | Source of help afterwards | |||||
| N = 558* | N = 137* | N = 421* | N = 526* | N = 133* | N = 393* | |
| N (%) | Male (%) | Female (%) | N (%) | Male (%) | Female (%) | |
| Friend | 221 (40) | 46 (34) | 175 (42) | 246 (47) | 57 (43) | 191 (49) |
| Someone in your family | 58 (11) | 10 (8) | 48 (12) | 118 (23) | 25 (20) | 96 (25) |
| Telephone helpline | 39 (8) | 5 (4) | 34 (9) | 15 (3) | 4 (3) | 11 (3) |
| Teacher | 33 (6) | 8 (6) | 25 (6) | 26 (5) | 9 (7) | 17 (5) |
| Psychologist/psychiatrist | 26 (5) | 8 (6) | 18 (5) | 39 (8) | 13 (10) | 28 (8) |
| GP/Doctor | 18 (4) | 2 (2) | 16 (4) | 37 (8) | 9 (7) | 29 (8) |
| Social worker | 16 (3) | 7 (6) | 9 (2) | 20 (4) | 6 (5) | 15 (4) |
| Drop-in/advice centre | 10 (2) | 2 (2) | 8 (2) | 7 (1) | 2 (2) | 5 (1) |
| Any other source | 45 (9) | 9 (7) | 36 (9) | 20 (4) | 7 (6) | 14 (4) |
| SCQ total | SRS raw score | |||||
| Factors | B | p | 95% | B | p | 95% |
| Constant | 12.44 | 0.204 | − 7.38/32.25 | − 21.43 | 0.615 | − 109.37/66.50 |
| Gender | 8.30 | 0.0003 | 4.34/12.24 | 20.95 | 0.022 | 3.42/38.48 |
| VABS II | − 0.08 | 0.44 | − 0.21/0.10 | 0.96 | 0.836 | − 0.74/0.61 |
| DBC | − 0.06 | 0.31 | − 0.25/0.08 | − 0.07 | 0.013 | 0.23/1.68 |
| Model’s R2 | 0.60 | 0.46 | ||||
| Model’s p value | 0.0008 | 0.010 |
| GP profession | |||||||
| # new patients consulted | US | UK | Germany | France | Spain | Italy | GP total |
| 0 | 20 | 5 | 2 | - | 1 | 1 | 29 |
| 1-4 | 45 | 32 | 25 | 23 | 18 | 35 | 178 |
| 5-9 | 22 | 7 | 17 | 17 | 14 | 10 | 87 |
| 10-19 | 25 | 6 | 6 | 10 | 12 | 4 | 63 |
| 20-29 | 5 | - | 1 | - | 2 | - | 8 |
| 30-49 | - | 2 | - | - | 2 | - | 4 |
| 50-99 | - | - | - | - | 1 | - | 1 |
| >100 | - | - | - | - | - | - | 0 |
| ENT profession | |||||||
| # new patients consulted | US | UK | Germany | France | Spain | Italy | ENT total |
| 0 | 4 | 1 | - | - | - | 1 | 6 |
| 1-4 | 8 | 3 | 1 | 4 | 2 | 10 | 28 |
| 5-9 | 9 | 1 | 1 | 6 | 9 | 11 | 37 |
| 10-19 | 23 | 11 | 6 | 21 | 18 | 10 | 89 |
| 20-29 | 21 | 12 | 6 | 9 | 12 | 10 | 70 |
| 30-49 | 14 | 13 | 10 | 2 | 6 | 8 | 53 |
| 50-99 | 19 | 10 | 11 | 5 | 4 | 2 | 51 |
| >100 | 8 | 3 | 15 | 3 | 1 | 1 | 31 |
| Site | Characteristic | Category | Unadjusted OR (95% CI) |
| Nouna | Malaria treatment in past 14 days | Yes vs no | 0.323 (0.215, 0.484) |
| Other medication in the past 14 days | Yes vs no | 0.563 (0.403, 0.788) | |
| Use of insecticide sprays over 7 days | Yes vs missing/no | 0.456 (0.225, 0.924) | |
| Age | Continuous | 1.159 (1.086, 1.236) | |
| Localization | Rural vs urban area | 2.635 (1.876, 3.701) | |
| Type of location | Town vs countryside | 0.386 (0.275, 0.542) | |
| Main house construction material: floor | Natural vs cement | 1.666 (1.191, 2.329) | |
| Main source of drinking water | Open vs closed | 0.712 (0.510, 0.993) | |
| Presence of electricity | Yes vs no | 0.401 (0.274, 0.588) | |
| Saponé | Malaria treatment in past 14 days | Yes vs no | 0.143 (0.066, 0.308) |
| Other medication in the past 14 days | Yes vs no | 0.300 (0.171, 0.529) | |
| Age | Continuous | 1.329 (1.242, 1.423) | |
| Main house construction material: roof | Iron sheet vs grass/palm | 0.631 (0.440, 0.906) |
| Allele | Slope | Efficiency (%) | R2 | y-intercepts |
| Wild-type-sensitive | 3.39 | 97.2 | 0.998 | 37.705 |
| Mutant-resistant | 2.59 | 142.7 | 0.991 | 36.531 |
| Women | Men | All | |
| N | 32 | 27 | 59 |
| Age (years) | 39.3 ± 10.5 | 39.3 ± 11.0 | 39.3 ± 10.6 |
| Body mass index (kg/m2) | 23.2 ± 3.1 | 25.8 ± 3.6** | 24.4 ± 3.6 |
| Total cholesterol (mmol/l) | 5.23 ± 0.87 | 5.76 ± 1.02* | 5.47 ± 0.97 |
| Triacylglycerol (mmol/l) | 0.96 ± 0.41 | 1.81 ± 1.27*** | 1.35 ± 0.71 |
| HDL cholesterol (mmol/l) | 1.88 ± 0.32 | 1.38 ± 0.23*** | 1.65 ± 0.38 |
| LDL cholesterol (mmol/l) | 2.91 ± 0.84 | 3.63 ± 0.92** | 3.21 ± 0.96 |
| ApoA-I (g/l) | 1.70 ± 0.20 | 1.46 ± 0.13*** | 1.59 ± 0.21 |
| ApoB (g/l) | 0.81 ± 0.20 | 1.00 ± 0.22** | 0.90 ± 0.23 |
| Lp(a) (U/l) | 266 ± 226 | 165 ± 201 | 220 ± 219 |
| fB-Glucose (mmol/l)a | 4.4 ± 0.4 | 4.6 ± 0.6 | 4.5 ± 0.5 |
| LDL diameter (nm) | 26.94 ± 0.45 | 26.40 ± 0.55*** | 26.70 ± 0.51 |
| cTAKES [4] | NOBLE Coder [20] | MetaMap [31, 32] | NCBO annotator [14] | |
| Modularity/configuration options | Modular text processing pipeline | Vocabulary (terminology);Term matching options and strategies | Text processing pipeline;Vocabulary (terminology);Term matching options and strategies | Vocabulary (terminology);Term matching options |
| Disambiguation of terms | Enabled through integration of the YTEX component [8] | Instead of through WSD, it uses heuristics to choose one concept among candidate concepts for the same piece of input text | Supported; based on:- removal of word senses based on a manual study of UMLS ambiguity- a WSD algorithm that chooses a concept with the most likely semantic type for a given context | Not supported |
| Vocabulary (terminology) | Subset of UMLS, namely SNOMED CT and RxNORM | Several pre-built vocabularies, based on subsets of UMLS(e.g. SNOMED CT, MeSH, RxNORM) | UMLS Metathesaurus | UMLS Metathesaurus and BioPortal ontologies (over 330 ontologies) |
| Speed* | Suitable for real-time processing | Suitable for real-time processing | Better for off-line batch processing | Suitable for real-time processing |
| Implementation form | Software (Java) library;Stand-alone application | Software (Java) library;Stand-alone application | Software library;originally version in Prolog;Java implementation, known as MMTX, is also available | RESTful Web service |
| Availability | open source;available under Apache License, v.2.0 | open-source;available under GNU Lesser General Public License v3 | open source;terms and conditions at: https://metamap.nlm.nih.gov/MMTnCs.shtml | closed source, but freely available |
| Specific features | Better performance on clinical texts than on biomedical scientific literature (its NLP components are trained on clinical texts) | Offers user interface for creating custom terminologies (to be used for annotation) by selecting and merging elements from several different thesauri/ontologies | Primarily developed for annotation of biomedical literature (MEDLINE/PubMed citations); performs better on this kind of text than clinical notes | It uses MGrep term-to-concept matching tool to get primary set of annotations; these are then extended using different forms of ontology-based semantic matching |
| URL | http://ctakes.apache.org/ | http://noble-tools.dbmi.pitt.edu/ | https://metamap.nlm.nih.gov/ | https://bioportal.bioontology.org/annotator |
| Eukaryotic organisms | % | Prokaryotic organisms | % |
| Chloromonas pseudoplatyrhyncha | 26.93 | Rhodoferax sp. | 21.94 |
| Stephanodiscus sp. | 18.17 | Unsequenced organisms | 17.84 |
| Unsequenced organisms | 17.87 | Flavobacterium sp. | 9.43 |
| Chromulinaceae sp. | 8.48 | Anabaena sp. | 8.85 |
| Synedra angustissima | 4.99 | Brevundimonas diminuta | 4.20 |
| Ochromonadales sp. | 3.01 | Hydrogenophaga sp. | 3.41 |
| Chlamydomonas sp. | 2.98 | Runella limosa | 2.47 |
| Micractinium pusillum | 1.62 | Haliscomenobacter sp. | 2.43 |
| Chlorella sp. | 1.08 | Rhodobacter sp. | 2.34 |
| Pythiaceae sp. | 1.07 | Planktophila limnetica | 2.13 |
| Agrobacterium tumefaciens | 2.11 | ||
| Sphingobacterium sp. | 2.03 | ||
| Ochrobactrum tritici | 1.98 | ||
| Brevundimonas variabilis | 1.83 | ||
| Sphingomonas sp. | 1.73 | ||
| Curvibacter sp. | 1.48 | ||
| Phenylobacterium falsum | 1.42 | ||
| Roseomonas stagni | 1.24 | ||
| Oceanicaulis sp. | 1.03 |
| Women using long-acting reversible contraception+(n = 866)Percentage | Women using highly effective short-term reversible contraception∧ (n = 12,098)Percentage | UnivariableOR (95% CI) | Multivariable OR (95% CI) | |
| Age∗ | ||||
| 16–24 | 14.6% | 25.8% | 0.33 (0.25, 0.45) | 0.46 (0.34, 0.61) |
| 25–30 | 35.3% | 37.3% | 0.56 (0.42, 0.74) | 0.66 (0.50, 0.89) |
| 31–39 | 35.7% | 28.5% | 0.74 (0.57, 0.96) | 0.80 (0.61, 1.04) |
| 40–50 | 14.4% | 8.5% | 1 | 1 |
| Education∗ | ||||
| None | 2.8% | 3.3% | 0.70 (0.42, 1.18) | 0.97 (0.57, 1.65) |
| Primary | 27.2% | 38.9% | 0.58 (0.45, 0.74) | 0.70 (0.56, 0.89) |
| Secondary | 70.0% | 57.8% | 1 | 1 |
| Marital status | ||||
| Married/cohabitating | 95.0% | 94.8% | 1.03 (0.72, 1.48) | |
| Single/divorced/widowed | 5.0% | 5.2% | 1 | |
| Religion | ||||
| Christian | 99.0% | 99.2% | 0.72 (0.26, 2/03) | |
| Other | 1.0% | 0.8% | 1 | |
| Living children, mean (SD) | 3.04 (0.08) | 2.76 (0.02) | 1.11 (1.06, 1.17) | |
| None | 1.9% | 2.8% | ||
| ≥1 | 98.1% | 97.2% | ||
| Socioeconomic status∗ | ||||
| Low | 27.6% | 39.3% | 1 | 1 |
| Medium | 42.9% | 40.5% | 1.51 (1.20, 1.90) | 1.02 (0.82, 1.25) |
| High | 29.6% | 20.2% | 2.09 (1.59, 2.74) | 1.42 (1.14, 1.78) |
| Household decision maker | ||||
| Woman | 64.8% | 60.2% | 1 | |
| Husband/male partner | 21.2% | 23.4% | 0.84 (0.66, 1.07) | |
| Decision made jointly | 13.9% | 16.1% | 0.80 (0.63, 1.01) | |
| Other | 0.0% | 0.03% | 0.17 (0.02, 1.29) | |
| Survey year∗ | ||||
| 2004 | 2.0% | 8.1% | 0.94 (0.46, 1.92) | 0.98 (0.48, 1.97) |
| 2005 | 4.9% | 15.2% | 1.25 (0.83, 1.88) | 1.27 (0.86, 1.89) |
| 2006 | 1.5% | 8.3% | 0.70 (0.37, 1.33) | 0.71 (0.38, 1.34) |
| 2007 | 6.8% | 26.5% | 1 | 1 |
| 2008 | 2.0% | 8.4% | 0.94 (0.50, 1.78) | 0.90 (0.48, 1.70) |
| 2010 | 13.6% | 8.9% | 5.90 (3.96, 8.80) | 5.50 (3.69, 8.35) |
| 2011 | 69.2% | 24.6% | 10.91 (7.96, 14.95) | 10.73 (7.87, 14.61) |
| Hazard ratio | P value | Standard Error | 95% CI | ||
| Age | |||||
| <40 | Reference | ||||
| [40, 65) | 1.9754 | 0.1070 | 0.8354 | 0.8623 | 4.5250 |
| ≥65 | 5.0853 | 0.0000 | 2.1284 | 2.2390 | 11.5499 |
| Gender | |||||
| Female | Reference | ||||
| Male | 1.4740 | 0.0040 | 0.1996 | 1.1303 | 1.9221 |
| Location | |||||
| Stomach | Reference | ||||
| Intestine | 1.6092 | 0.0010 | 0.2322 | 1.2127 | 2.1353 |
| Others | 1.9870 | 0.0010 | 0.4120 | 1.3235 | 2.9832 |
| Beginning of treatment | End of treatment | |||
| Patients | Initial angle | AOFAS score | Final angle | AOFAS score |
| 1 | 1 | 40 | 1 | 80 |
| 2 | 10 | 41 | 10 | 74 |
| 3 | 7 | 40 | 8 | 72 |
| 4 | 8 | 39 | 9 | 76 |
| 5 | 15 | 38 | 17 | 74 |
| 6 | 15 | 40 | 16 | 73 |
| 7 | 10 | 38 | 12 | 75 |
| 8 | 9 | 40 | 10 | 75 |
| 9 | 9 | 41 | 9 | 74 |
| 10 | 11 | 40 | 11 | 76 |
| 11 | 10 | 42 | 10 | 70 |
| 12 | 11 | 40 | 11 | 72 |
| 13 | 9 | 41 | 9 | 76 |
| 14 | 6 | 44 | 6 | 79 |
| 15 | 6 | 39 | 7 | 77 |
| 16 | 3 | 43 | 4 | 78 |
| 17 | 6 | 40 | 7 | 77 |
| 18 | 7 | 42 | 8 | 78 |
| 19 | 9 | 39 | 10 | 73 |
| 20 | 9 | 41 | 9 | 74 |
| 21 | 6 | 44 | 5 | 70 |
| 22 | 7 | 40 | 7 | 78 |
| Variable | Disease-Free Survival | Progression-Free Survival | ||||
| OverallPopulation67 pts | BCG | No BCG | OverallPopulation63 pts | BCG | No BCG | |
| 34 pts | 33 pts | 33 pts | 30 pts | |||
| Male vs. Female | 0.3400 | 0.3430 | 0.5647 | 0.3355 | 0.1887 | 0.9311 |
| Primary vs. Recurrent | 0.1926 | 0.5363 | 0.1614 | 0.6409 | 0.0519 | 0.2591 |
| Single vs. Multiple | 0.4756 | 0.7956 | 0.2035 | 0.6412 | 0.8857 | 0.3905 |
| Size <3cm vs. >3cm | 0.3926 | 0.2524 | 0.7226 | 0.7417 | 0.2783 | 0.4515 |
| HER-2 negative vs. HER-2 positive | 0.0013 | 0.0140 | 0.0125 | 0.0322 | 0.1290 | 0.1696 |
| Adjusted HRa | (95 % CI) | |
| Without antipsychotics | 1.40 | (1.18, 1.66) |
| With antipsychotics | 1.45 | (1.16, 1.82) |
| Without anticoagulant | 1.44 | (1.25, 1.65) |
| With anticoagulant | 1.24 | (0.76, 2.00) |
| Without antiplatelet | 1.41 | (1.23, 1.62) |
| With antiplatelet | 1.52 | (0.72, 3.22) |
| Without anti-inflammatory | 1.29 | (0.90, 1.85) |
| With anti-inflammatory | 1.44 | (1.24, 1.67) |
| Without anxiety or other mood disorders | 1.40 | (1.07, 1.82) |
| With anxiety or other mood disorders | 1.42 | (1.21, 1.66) |
| Without atrial fibrillation | 1.40 | (1.22, 1.62) |
| With atrial fibrillation | 1.57 | (0.98, 2.50) |
| Without coronary heart disease | 1.36 | (1.16, 1.60) |
| With coronary heart disease | 1.59 | (1.24, 2.05) |
| Without congestive heart failure | 1.44 | (1.25, 1.65) |
| With congestive heart failure | 1.15 | (0.68, 1.97) |
| Without chronic obstructive pulmonary disease | 1.49 | (1.29, 1.73) |
| With chronic obstructive pulmonary disease | 1.09 | (0.77, 1.54) |
| Without cancer | 1.42 | (1.24, 1.63) |
| With cancer | 0.94 | (0.26, 3.32) |
| Without diabetes mellitus | 1.20 | (0.99, 1.45) |
| With diabetes mellitus+ | 1.70 | (1.41, 2.05) |
| Without hypertension | 1.25 | (0.69, 2.27) |
| With hypertension | 1.42 | (1.24, 1.64) |
| Without hyperlipidemia | 1.41 | (1.18, 1.68) |
| With hyperlipidemia | 1.42 | (1.15, 1.76) |
| Antidepressants use before index date | ||
| No--New Users | 1.57 | (1.32, 1.86) |
| Yes--Prevalent Users | 1.23 | (0.99, 1.53) |
| Depression at Baseline (index date) or Post-stroke | ||
| No Depression | 1.55 | (1.32, 1.82) |
| Depression at Baseline | 1.49 | (0.99, 2.26) |
| Post-stroke Depression | 1.44 | (1.01, 2.07) |
| Brain regions | Peak MNI, mm | T score | ||
| X | Y | Z | ||
| MHE vs. Controls (FDR corrected, p < 0.05) | ||||
| Right fusiform gyrus | 24 | 0 | −49 | 5.11 |
| Right rectus | 6 | 51 | −21 | 4.25 |
| Right thalamus | 21 | −26 | 0 | −5.83 |
| Right superior frontal gyrus | 15 | −3 | 75 | 4.43 |
| Left paracentral lobule | −15 | −36 | 75 | 4.49 |
| Right postcentral gyrus | 12 | −45 | 78 | 4.59 |
| Right calcarine | 3 | −69 | 15 | −3.77 |
| NMHE vs. Controls (FDR corrected, p < 0.05) | ||||
| Right frontal pole | 6 | 54 | −27 | 4.22 |
| Right superior frontal gyrus | 12 | −12 | 78 | 4.51 |
| Right thalamus | 18 | −27 | 0 | −4.15 |
| Right calcarine | 6 | −69 | 18 | −4.84 |
| Left precentral gyrus | −27 | −21 | 72 | 5.18 |
| Left middle frontal gyrus | −42 | 30 | 45 | 5.60 |
| MHE vs. NMHE (uncorrected, p < 0.001) | ||||
| Right postcentral gyrus | 18 | −39 | 75 | 3.53 |
| Not Overusing Medication n = 11,542 | Overusing Medication n = 2107 | Total Sample n = 13,649 | Chi | P-value | |
| Sex | |||||
| Men | 3074 (26.6) | 621 (29.5) | 3695 (27.1) | 7.136 | 0.008 |
| Women | 8468 (73.4) | 1486 (70.5) | 9954 (72.9) | ||
| Ageb, years (mean ± SD) | 43.0 ± 13.6 | 45.8 ± 13.2 | 43.41 ± 13.62 | 8.891 | < 0.001 |
| Age group, years | |||||
| 18–24 | 899 (7.8) | 80 (3.8) | 979 (7.2) | 96.346 | < 0.001 |
| 25–34 | 2831 (24.5) | 409 (19.4) | 3240 (23.7) | ||
| 35–44 | 2775 (24.0) | 518 (24.6) | 3293 (24.1) | ||
| 45–54 | 2566 (22.2) | 546 (25.9) | 3112 (22.8) | ||
| 55–64 | 1572 (13.6) | 348 (16.5) | 1920 (14.1) | ||
| 65–74 | 815 (7.1) | 184 (8.7) | 999 (7.3) | ||
| 75+ | 84 (0.7) | 22 (1.0) | 106 (0.8) | ||
| Married | |||||
| No | 5261 (45.7) | 867 (41.4) | 6128 (45.1) | 13.436 | < 0.001 |
| Yes | 6245 (54.3) | 1229 (58.6) | 7474 (54.9) | ||
| Race | |||||
| Non-Caucasian | 2091 (18.2) | 361 (17.2) | 2452 (18.1) | 1.166 | 0.280 |
| Caucasian | 9379 (81.8) | 1736 (82.8) | 11,115 (81.9) | ||
| Household income, $ | |||||
| < 25,000 | 1254 (11.2) | 292 (14.2) | 1546 (11.6) | 17.025 | 0.002 |
| 25,000–49,999 | 2422 (21.6) | 444 (21.6) | 2866 (21.6) | ||
| 50,000–74,999 | 2493 (22.2) | 437 (21.3) | 2930 (22.1) | ||
| 75,000–99,999 | 1986 (17.7) | 363 (17.7) | 2349 (17.7) | ||
| ≥ 100,000 | 3070 (27.3) | 516 (25.1) | 3586 (27.0) | ||
| Education, ≥4-year college degree | |||||
| No | 4612 (40.0) | 1018 (48.3) | 5630 (41.2) | 51.000 | < 0.001 |
| Yes | 6930 (60.0) | 1089 (51.7) | 8019 (58.8) | ||
| BMIb, kg/m2 (mean ± SD) | 28.1 ± 7.4 | 28.9 ± 8.5 | 28.3 ± 7.6 | 4.380 | < 0.001 |
| BMI category | |||||
| Underweight | 329 (2.9) | 94 (4.5) | 423 (3.1) | 44.240 | < 0.001 |
| Normal | 4154 (36.0) | 645 (30.6) | 4799 (35.2) | ||
| Overweight | 3387 (29.3) | 588 (27.9) | 3975 (29.1) | ||
| Obese | 3672 (31.8) | 780 (37.0) | 4452 (32.6) | ||
| Health insurance | |||||
| No | 945 (8.2) | 184 (8.7) | 1129 (8.3) | 0.628 | 0.428 |
| Yes | 10,597 (91.8) | 1923 (91.3) | 12,520 (91.7) | ||
| Psychological symptomsc | |||||
| No | 9210 (79.8) | 1275 (60.5) | 10,485 (76.8) | 370.957 | < 0.001 |
| Yes | 2332 (20.2) | 832 (39.5) | 3164 (23.2) | ||
| Current smoker | |||||
| No | 10,387 (90.0) | 1718 (81.5) | 12,105 (88.7) | 126.127 | < 0.001 |
| Yes | 1155 (10.0) | 389 (18.5) | 1544 (11.3) |
| Trial | MEK Inhibitor | PI3K Inhibitor | Phase | Population |
| NCT01363232 | MEK162 | BKM120 | Phase I | Patients with advanced solid cancers (colorectal cancer, triple-negative breast cancer, pancreatic cancer, and other cancers harboring KRAS, BRAF and NRAS mutations) |
| NCT01392521 | BAY86-9766 | BAY80-6946 | Phase Ib | Patients with advanced solid cancers |
| NCT01449058 | MEK162 | BYL719 | Phase II | Patients with advanced solid cancers (colorectal cancer, esophageal cancer, pancreatic cancer, non-small cell lung cancer, and other advanced solid tumors harboring RAS or BRAF mutations) |
| Trial | MEK Inhibitor | PI3K/mTOR Inhibitor | Phase | Population |
| NCT00996892 | GDC-0973 | Pictilisb (GDC-0941) | Phase I | Patients with advanced solid cancers |
| NCT01337765 | MEK162 | BEZ235 | Phase 1 | Patients with advanced solid cancers (colorectal cancer, triple-negative breast cancer, pancreatic cancer, malignant melanoma, non-small cell lung cancer, and other cancers harboring KRAS, BRAF and NRAS mutation) |
| NCT01390818 | Pimasertib (MSC1936369B) | SAR245409 | Phase 1 | Patients with advanced solid cancers (colorectal cancer, pancreatic cancer, thyroid cancer, non-small cell lung cancer, renal cancer, breast cancer, melanoma, ovarian cancer) and any cancer diagnosed with aberrations in one or more the following genes: PTEN, BRAF, KRAS, NRAS, PI3KCA, ErbB1, ErbB2) |
| NCT01347866 | PD0325901 | PF-05212384 | Phase 1 | Patients with advanced solid cancers harboring KRAS or BRAF mutation and patients with KRAS mutation with no more than one prior systemic therapy regimen |
| Trial | MEK Inhibitor | AKT Inhibitor | Phase | Population |
| NCT01562275 | GDC-0973 | GDC-0068 | Phase 1 | Patients with locally advanced or metastatic solid tumors |
| Day 3 | Day 5 | |||||||
| Chemicals | ET | TO | CP | CP + PM | ET | TO | CP | CP + PM |
| Number | 11 | 11 | 12 | 11 | 9 | 9 | 12 | 10 |
| Mean (μm) | 725.3 | 785.2 | 401.2 | 487 | 1528.8 | 1751.6 | 718.4 | 1168.2 |
| SD | 209.3 | 225.7 | 171.9 | 134.1 | 375.2 | 408.1 | 219 | 293.1 |
| P-value (ET) | - | 0.26 | 0.2 E-4 | 2.4 E-3 | - | 0.12 | 2.7 E-6 | 1.6 E-2 |
| P-value (TO) | - | - | 7.5 E-5 | 6.1 E-4 | - | - | 2.2 E-7 | 1.1 E-2 |
| P-value (CP) | - | - | - | 0.1 | - | - | - | 2.7 E-4 |
| Checklist item | Condition | Session observed | Outcome |
| Timing from first slide to class exercise | Contact | First module | 10–12 min |
| Education | Second module | 10–26 min | |
| Time allocated to first exercise | Contact | First module | 8–13 min |
| Education | Second module | 5–10 min | |
| Are any slides skipped? | Contact | First module | No, in all observed classes. |
| Education | Second module | No, in all observed classes. | |
| Are pupils asked if they have questions? | Contact | First module | Yes, in all observed classes. |
| Education | Second module | Yes, in all observed classes. | |
| Are the majority of students engaging in class? | Contact | First module | Yes, in all observed classes. |
| Education | Second module | Yes, in all observed classes. | |
| Size of group for first exercise | Contact | First module | 2–7 |
| Education | Second module | 3–5 | |
| Does a facilitator visit each group during exercise? | Contact | First module | Yes, in all observed classes. |
| Education | Second module | Yes, in all observed classes. | |
| Do all groups manage to finish exercise in allocated time? | Contact | First module | Yes in 4 observed classes, no in 2 observed classes. |
| Education | Second module | Yes, in all observed classes. |
| Age groups | Men | Women | P-value3 | ||||
| Total n | Prevalence % (95% CI)1 | P-value2 | Total n | Prevalence % (95% CI)1 | P-value2 | ||
| Poor self-rated health | 0.7503 | 0.4270 | |||||
| 60 | 218 | 9.4 (5.8 - 14.8) | 256 | 10.3 (7.0 - 15.0) | 0.7328 | ||
| 65 | 132 | 12.9 (7.6 - 20.8) | 214 | 12.3 (7.7 - 18.9) | 0.8865 | ||
| 70 | 117 | 13.7 (8.5 - 21.4) | 164 | 12.6 (8.5 - 18.3) | 0.8102 | ||
| 75 | 82 | 14.8 (7.3 - 27.6) | 136 | 16.9 (10.9 - 25.2) | 0.7250 | ||
| 80+ | 66 | 12.0 (5.6 - 23.6) | 134 | 10.9 (6.4 - 18.1) | 0.8248 | ||
| Global limitations | 0.0001 | 0.0000 | |||||
| 60 | 218 | 26.3 (16.6 - 39.0) | 256 | 32.8 (24.9 - 41.9) | 0.1984 | ||
| 65 | 132 | 28.5 (19.6 - 39.4) | 214 | 37.4 (30.8 - 44.4) | 0.0808 | ||
| 70 | 117 | 43.0 (32.9 - 53.6) | 164 | 54.2 (43.7 - 64.4) | 0.0949 | ||
| 75 | 82 | 48.5 (33.9 - 63.5) | 136 | 60.6 (52.2 - 68.4) | 0.1107 | ||
| 80+ | 66 | 55.3 (41.0 - 68.8) | 134 | 74.1 (64.3 - 82.0) | 0.0060 | ||
| Mild and moderate limitations | 0.0098 | 0.0000 | |||||
| 60 | 218 | 21.4 (12.2-34.6) | 256 | 26.4 (19.1-35.3) | 0.2964 | ||
| 65 | 132 | 23.1 (14.9-33.9) | 214 | 31.8 (25.5-38.8) | 0.0745 | ||
| 70 | 117 | 35.3 (25.1-47.1) | 164 | 37.3 (27.5-48.2) | 0.7332 | ||
| 75 | 82 | 33.7 (22.0-47.9) | 136 | 48.9 (39.7-58.1) | 0.0499 | ||
| 80+ | 66 | 40.5 (28.0-54.3) | 134 | 43.1 (34.3-52.4) | 0.6706 | ||
| Severe limitations | 0.0201 | 0.0000 | |||||
| 60 | 218 | 4.9 (2.4-10.0) | 256 | 6.4 (3.5-11.5) | 0.4862 | ||
| 65 | 132 | 5.4 (2.4-11.5) | 214 | 5.6 (3.4-9.0) | 0.9551 | ||
| 70 | 117 | 7.6 (4.1-13.6) | 164 | 17.0 (10.8-25.7) | 0.0258 | ||
| 75 | 82 | 14.8 (7.5-27.0) | 136 | 11.7 (7.1-18.8) | 0.5554 | ||
| 80+ | 66 | 14.9 (8.4-25.0) | 134 | 31.1 (23.4-39.9) | 0.0089 |
| Perceived stress variables | Factor loading | ||
| Factor 1 | Factor 2 | Factor 3 | |
| Pressure and demands | Eigenvalue 5.97 Cronbach’s alpha 0.83 | ||
| I don’t have enough time | 0.754 | ||
| I feel under pressure from school demands | 0.698 | ||
| I feel helpless | 0.671 | ||
| I never feel really free | 0.641 | ||
| I feel under pressure from demands at home | 0.563 | ||
| I feel under pressure from my inner demands | 0.536 | ||
| I don’t feel rested after sleep | 0.531 | ||
| Activation/high tempo | Eigenvalue 1.41 Cronbach’s alpha 0.72 | ||
| I rush even if I don’t have to | 0.721 | ||
| I keep a high speed all the day | 0.700 | ||
| I eat rapidly even if I don’t have to | 0.576 | ||
| I do many things at the same time | 0.551 | ||
| I find it difficult to relax | 0.533 | ||
| Sleep problems | Eigenvalue 1.04 Cronbach’s alpha 0.82 | ||
| I sleep restlessly and shallow | 0.763 | ||
| I have difficulty falling asleep | 0.739 | ||
| I wake up early in the morning | 0.606 | ||
| I feel restless | 0.524 |
| QubitTM | Spike-in QubitTM | ||||||
| Kit | Sample vol. (μL) | Reading (pg/μL) | [RNA] (pg/μL) | Sample Vol. (μL) | Reading ± SD (pg/μL) | [RNA] ± SD (pg/μL) | CV |
| 1 | 20 | <20 | N.D. | 10 | 5.3 ± 0.7 | 106.0 ± 14.0 | 13.2% |
| 2 | 20 | < 20 | N.D. | 15 | 13.2 ± 1.8 | 176.4 ± 23.4 | 13.3% |
| 3 | 20 | < 20 | N.D. | 15 | 6.0 ± 0.3 | 80.0 ± 3.5 | 4.4% |
| Risk factor | |
| Curve progression | Female genderLarge curve magnitudeSkeletal immaturity |
| Female body type | Much thinnerDecreased body weightDecreased chest girthDecreased body mass index |
| No of patients with antibodies against: | IL-10 | IL-10R1 | IL-10R2 | IL-10 + IL-10R1 | IL-10 + IL-10R2 | IL-10 + IL-10R1 + IL-10R2 |
| IgG | 3 | 2 | 1 | 1 | 2 | 1 |
| IgA | 2 | - | - | 11 | - | - |
| Total noof patients | 5 | 2 | 1 | 2 | 2 | 1 |
| Group to group | 24 h | 36 h | 48 h |
| M to N (N to M) | 0.0829531 | 0.5042984 | 0.719462 |
| A to N | 0.0817174 | 0.5047401 | 0.728083 |
| B to N | 0.0851343 | 0.4010343 | 0.6504139 |
| C to N | 0.0323821 | 0.2762745 | 0.4558273 |
| D to N | 0.015723 | 0.1084588 | 0.1745785 |
| E to N | 0.0025864 | 0.0368022 | 0.0314098 |
| F to N | 0.0268291 | 0.1468612 | 0.3239829 |
| G to N | 0.0013232 | 0.0237961 | 0.0298026 |
| A to M | 0.0000178 | 0.0000031 | 0.0000308 |
| B to M | 0.0001493 | 0.0104849 | 0.0024807 |
| C to M | 0.028301 | 0.00672042 | 0.0430982 |
| D to M | 0.0780845 | 0.2296862 | 0.1965076 |
| E to M | 0.0578047 | 0.2727777 | 0.4580789 |
| F to M | 0.0210222 | 0.1120853 | 0.0879489 |
| G to M | 0.0769024 | 0.3455155 | 0.4808165 |
| Characteristics | Frequency | Percentage |
| Ever donated blood | 126 | 29.9 |
| Frequency of donation in lifetime (N = 126) | ||
| Once | 57 | 45.2 |
| Repeated | 69 | 54.8 |
| Donated in the past 5 years | 124 | 98.4 |
| Donated in the past 12 months | 123 | 97.6 |
| Types of donation | ||
| Voluntary | 114 | 90.5 |
| Paid | 2 | 1.6 |
| Replacement | 10 | 7.9 |
| Main reason(s) for the last time donation | ||
| Voluntarism | 114 | 90.5 |
| HIV results | 2 | 1.6 |
| Replacement | 10 | 7.9 |
| Would you donate blood again in the future? | ||
| Yes | 120 | 95.2 |
| No | 6 | 4.8 |
| The place of your last donation | ||
| Blood Transfusion Centre | 15 | 12 |
| Hospital | 28 | 22.4 |
| School | 82 | 65.6 |
| Experienced negative effect after donation | ||
| Yes | 39 | 31 |
| No | 87 | 69 |
| Postdonation negative effect (N = 39) | ||
| Pain | 1 | 1 |
| Dizziness | 37 | 94.9 |
| Fever | 1 | 2.6 |
| CMI | |||||
| n | L | 2 | 3 | 4 | 5 |
| 10 | 1000 | 0.308 | 0.928 | 1.000 | 1.000 |
| (0.279-0.337) | (0.912-0.944) | - | - | ||
| 5000 | 0.363 | 0.973 | 1.000 | 1.000 | |
| (0.333-0.393 | (0.963-0.983) | - | - | ||
| 10 000 | 0.383 | 0.966 | 1.000 | 1.000 | |
| (0.353-0.413) | (0.955-0.977) | - | - | ||
| 20 000 | 0.380 | 0.974 | 1.000 | 1.000 | |
| (0.350-0.410) | (0.964-0.984) | - | - | ||
| 25 | 1000 | 0.569 | 1.000 | 1.000 | 1.000 |
| (0.538-0.600) | - | - | - | ||
| 5000 | 0.662 | 1.000 | 1.000 | 1.000 | |
| (0.633-0.691) | - | - | - | ||
| 10 000 | 0.675 | 1.000 | 1.000 | 1.000 | |
| (0.646-0.704) | - | - | - | ||
| 20 000 | 0.682 | 1.000 | 1.000 | 1.000 | |
| (0.653-0.711) | - | - | - | ||
| 50 | 1000 | 0.740 | 1.000 | 1.000 | 1.000 |
| (0.715-0.769) | - | - | - | ||
| 5000 | 0.851 | 1.000 | 1.000 | 1.000 | |
| (0.829-0.873) | - | - | - | ||
| 10 000 | 0.869 | 1.000 | 1.000 | 1.000 | |
| (0.848-0.890) | - | - | - | ||
| 20 000 | 0.898 | 1.000 | 1.000 | 1.000 | |
| (0.880-0.917) | - | - | - | ||
| 100 | 1000 | 0.890* | 1.000* | 1.000* | 1.000* |
| (0.828-0.952) | - | - | - | ||
| 5000 | 0.970* | 1.000* | 1.000* | 1.000* | |
| (0.936-1.000) | - | - | - | ||
| 10 000 | 0.970* | 1.000* | 1.000* | 1.000* | |
| (0.936-1.000) | - | - | - | ||
| 20 000 | 0.970* | 1.000* | 1.000* | 1.000* | |
| (0.936-1.000) | - | - | - |
| Severity criteria | Score |
| Smoking status | |
| Never-smoker | 0 |
| Smoker | 1 |
| Symptoms | |
| No | 0 |
| Yes | 1 |
| PaO2, mmHg | |
| ≥80 | 0 |
| 60–80 | 1 |
| <60 | 2 |
| HRCT score | |
| ≤8 | 1 |
| 8–16 | 2 |
| 16–24 | 3 |
| 24–32 | 4 |
| DLCO, % predicted | |
| ≥80 | 0 |
| 60–80 | 1 |
| <60 | 2 |
| Body weight (grams) | Cholesterol (mg/dL) | |
| C57BL/6 | 30 ± 1 | 91 ± 5 |
| AS (15 weeks) | 31 ± 2 | 749 ± 148 |
| AS (30–35 weeks) | 28 ± 1 | 596 ± 52 |
| AS + apocynin (34–35 weeks) | 28 ± 1 | 592 ± 155 |
| Phytophthora infestans | Phytophthora sojae | Phytophthora ramorum | ||||||
| PITG accession number | Predicted intron number | Predicted length (residues) | Ps accession number | Predicted intron number | Predicted length (residues) | Pr accession number | Predicted intron number | Predicted length (residues) |
| 09387 | 2 | 815 | 109366 | 0 | 393 | 72239 | 0 | 389 |
| 12357 | 0 | 469 | 144332 | 0 | 472 | 84847 | 0 | 469 |
| - | - | - | 157552 | 5 | 379 | 77872 | 8 | 698 |
| 05114 | 2 | 545 | 132274 | 1 | 573 | 82845 | 1 | 548 |
| 10524 | 0 | 737 | 138576 | 0 | 751 | 84399 | 0 | 753 |
| 04975 | 1 | 512 | 136075 | 0 | 587 | 73566 | 0 | 582 |
| 05004 | 3 | 307 | - | - | - | 73546 | 0 | 432 |
| 08190 | 1 | 556 | 135399 | 0 | 585 | 78678 | 0 | 611 |
| 06900 | 5 | 479 | 135764 | 3 | 627 | 79884 | 4 | 644 |
| 02623 | 2 | 681 | 144093 | 2 | 719 | 77495 | 2 | 636 |
| 02624 | 2 | 350 | 144091 | 11 | 806 | 77493 | 3 | 360 |
| 11522 | 1 | 446 | 141367 | 0 | 531 | 74839 | 0 | 525 |
| Mantel r | Mantel P | K* P | Maddison and Slatkin P | Data type | Trait group | |
| All traits | 0.63 | 0.001 | – | – | Multiple traits | Group of traits |
| α niche traits | 0.38 | 0.001 | – | – | Multiple traits | Group of traits |
| β niche traits | 0.17 | 0.005 | – | – | Multiple traits | Group of traits |
| Voltinism | 0.25 | 0.001 | 0.001 | – | Ordinal | Life cycle |
| Adult life span | 0.40 | 0.001 | – | 0.001 | Nominal | Life cycle |
| Exoskeleton | 0.27 | 0.001 | – | 0.001 | Nominal | Morphology/physiology |
| Body shape | 0.26 | 0.001 | – | 0.001 | Nominal | Morphology/physiology |
| Respiration | 0.09 | 0.060 | – | 0.001 | Nominal | Morphology/physiology |
| BMWP | 0.14 | 0.001 | 0.001 | – | Quantitative | Morphology/physiology |
| Body size | 0.27 | 0.001 | 0.001 | – | Ordinal | Morphology/physiology |
| Flight capacity | 0.21 | 0.001 | 0.001 | – | Ordinal | Morphology/physiology |
| Shelter | 0.05 | 0.110 | – | 0.001 | Nominal | Behavioral |
| Reophily | 0.09 | 0.034 | – | 0.199 | Nominal | Behavioral |
| Micro habitat | 0.27 | 0.001 | – | 0.001 | Nominal | Behavioral |
| Trophic position | 0.20 | 0.001 | – | 0.001 | Nominal | Behavioral |
| Number of collected ovaries | Number of cultured COCs | Number of mature oocytes | Number of Cas9/sgRNA injection oocytes | Cleavage rate at 48 hr post activation | Blastocyst development rate at 144 hr post activation | |||
| Injected group | Untreated group | Injected group | Untreated group | Injected group | Untreated group | |||
| 400 | 810 | 420 | 195 | 225 | 52.8% (103/195)a | 40.4% (91/225)b | 14.4% (28/195)a | 13.3% (30/225)a |
| Type of toxicity | >60 and <65 years (n = 100) | ≥ 65 years (n = 80) | P* | ||||||||
| 0 | 1 | 2 | 3 | 4 | 0 | 1 | 2 | 3 | 4 | ||
| Anemia | 81 | 10 | 8 | 0 | 1 | 86 | 6 | 4 | 4 | 0 | 0.39 |
| Leukopenia | 54 | 15 | 19 | 7 | 5 | 45 | 11 | 26 | 11 | 6 | 0.13 |
| Neutropenia | 73 | 10 | 8 | 5 | 4 | 68 | 9 | 7 | 10 | 6 | 0.32 |
| Febrile Neutropenia | 100 | - | - | 0 | 0 | 96 | - | - | 4 | 0 | 0.05 |
| Infection | 97 | 0 | 1 | 2 | 0 | 95 | 0 | 2.5 | 2.5 | 0 | 0.50 |
| Fever | 98 | 0 | 2 | 0 | 0 | 98 | 2 | 0 | 0 | 0 | 0.83 |
| Thrombocytopenia | 90 | 7 | 2 | 0 | 1 | 91 | 4 | 1 | 3 | 1 | 0.83 |
| Bleeding | 98 | 1 | 0 | 1 | 0 | 100 | 0 | 0 | 0 | 0 | 0.21 |
| Nausea | 81 | 8 | 6 | 5 | 0 | 69 | 11 | 12 | 8 | 0 | 0.06 |
| Vomiting | 71 | 5 | 11 | 13 | 0 | 69 | 9 | 16 | 6 | 0 | 0.98 |
| Mucositis | 84 | 5 | 8 | 3 | 0 | 92 | 1 | 5 | 1 | 0 | 0.09 |
| Skin | 99 | 1 | 0 | 0 | 0 | 98 | 0 | 2 | 0 | 0 | 0.43 |
| Diarrhea | 96 | 1 | 0 | 3 | 0 | 96 | 3 | 1 | 0 | 0 | 0.91 |
| Constipation | 99 | 0 | 0 | 1 | 0 | 98 | 1 | 1 | 0 | 0 | 0.45 |
| Hepatic | 88 | 3 | 7 | 2 | 0 | 90 | 6 | 4 | 0 | 0 | 0.60 |
| Cardiac | 100 | 0 | 0 | 0 | 0 | 96 | 0 | 2.5 | 1 | 0 | 0.09 |
| Fatigue | 96 | 1 | 3 | 0 | 0 | 95 | 0 | 2.5 | 2.5 | 0 | 0.72 |
| Pulmonary | 100 | 0 | 0 | 0 | 0 | 99 | 1 | 0 | 0 | 0 | 0.27 |
| Abdominal pain | 99 | 0 | 0 | 1 | 0 | 99 | 0 | 0 | 1 | 0 | 0.88 |
| Chest pain | 99 | 0 | 0 | 1 | 0 | 100 | 0 | 0 | 0 | 0 | 0.37 |
| Heartburn | 99 | 0 | 1 | 0 | 0 | 98 | 0 | 2 | 0 | 0 | 0.44 |
| Headache | 99 | 0 | 0 | 1 | 0 | 100 | 0 | 0 | 0 | 0 | 0.38 |
| Confusion | 99 | 1 | 0 | 0 | 0 | 100 | 0 | 0 | 0 | 0 | 0.38 |
| Depression | 100 | 0 | 0 | 0 | 0 | 99 | 0 | 0 | 1 | 0 | 0.27 |
| Thrombophlebitis | 97 | 0 | 0 | 3 | 0 | 94 | 0 | 0 | 6 | 0 | 0.30 |
| Dysuria | 99 | 0 | 0 | 1 | 0 | 99 | 0 | 0 | 1 | 0 | 0.88 |
| Allergy | 99 | 0 | 0 | 1 | 0 | 100 | 0 | 0 | 0 | 0 | 0.37 |
| Weight gain | 100 | 0 | 0 | 0 | 0 | 99 | 0 | 1 | 0 | 0 | 0.27 |
| Weight loss | 99 | 0 | 1 | 0 | 0 | 99 | 1 | 0 | 0 | 0 | 0.89 |
| ID | ALBIA (>20) | CIA (>10,000) | ELISA (>20) | Gender | Age | Statin | ADO (ys) | CK* (25–160 U/L) | Necrosis |
| 3 | 928 | 201891 | 149.2 | F | 62 | + | 59 | 1000 | + |
| 5 | 496 | 213681 | 113.5 | F | 53 | − | 52 | 13777 | + |
| 6 | 960 | 259814 | 193.1 | M | 59 | − | 47 | 8500 | + |
| 9 | 1008 | 291111 | 184.9 | F | 22 | − | 18 | ND | + |
| 10 | 784 | 138696 | 284.3 | F | 16 | − | 13 | 1500 | + |
| 11 | 512 | 244281 | 381.8 | F | 66 | + | 60 | 6500 | + |
| 13 | 768 | 179810 | 153.5 | F | 69 | + | 63 | 492 | Very few fiber |
| 15 | 320 | 184190 | 174.7 | F | 44 | − | 21 | ND | + |
| 17 | 800 | 254442 | 139.4 | F | 60 | − | 54 | 6000 | + |
| 18 | 1136 | 218777 | 126.3 | F | 53 | + | 48 | 4106 | + |
| 26 | 280 | 119734 | 57.9 | M | 67 | + | 66 | 5700 | + |
| 27 | 576 | 180528 | 88.9 | F | 17 | − | 12 | 17000 | + |
| 28 | 528 | 288198 | 93.8 | M | 65 | − | 52 | 500 | + |
| 29 | 84 | 79904 | 29.8 | F | 75 | + | 73 | 7429 | No biopsy |
| 30 | 196 | 135149 | 49.7 | F | 72 | + | 68 | 3700 | + |
| 31 | 608 | 250484 | 324.1 | F | 35 | − | 26 | 5700 | + |
| 32 | 424 | 141861 | 932.1 | M | 81 | − | 82 | ND | + |
| 34 | 400 | 208075 | 118.5 | F | 84 | + | 83 | 4119 | ND |
| 37 | 212 | 160034 | 83.3 | F | 20 | − | 15 | 612 | + |
| 39 | 142 | 115671 | 56.6 | F | 67 | + | 58 | 2000 | − |
| Characteristics | 2000 | 2004 | 2007 | |||
| No ICH n = 34282 | ICH n = 230 | No ICH n = 47555 | ICH n = 289 | No ICH n = 56921 | ICH n = 340 | |
| No. (%) | ||||||
| Age (mean ± SD), y | 57.3 ± 14.5 | 58.9 ± 12 | 59.1 ± 14.1 | 58.6 ± 12.5 | 60.7 ± 13.9 | 60.7 ± 11.9 |
| Female | 18303 (53.4) | 107 (46.5) | 25598 (53.8) | 120 (41.5) | 30186 (53.0) | 155 (45.6) |
| Dialysis modality | ||||||
| Hemodialysis | 32340 (94.3) | 224 (97.4) | 44408 (93.4) | 279 (96.5) | 52569 (92.4) | 320 (94.1) |
| Peritoneal dialysis | 1942 (5.7) | 6 (2.6) | 2147 (6.6) | 10 (3.5) | 4352 (7.6) | 20 (5.9) |
| ICH in-hospital days | 11.2 (±15.9) | 10.9 (±11.3) | 13.2 (±15.2) | |||
| Comorbid conditions | ||||||
| Hypertension | 17192 (50.1) | 143 (62.2) | 25044 (52.7) | 170 (58.8) | 33072 (58.1) | 238 (70.0) |
| Diabetes | 11356 (33.1) | 101 (43.9) | 15897 (33.4) | 118 (40.8) | 21559 (37.9) | 166 (48.8) |
| Chronic liver disease | 7528 (21.9) | 26 (11.3) | 11902 (25.0) | 59 (20.4) | 14203 (24.9) | 91 (26.8) |
| Coronary artery disease | 6252 (18.3) | 48 (20.9) | 9290 (19.6) | 67 (23.2) | 12355 (21.7) | 88 (25.9) |
| Heart failure | 3795 (11.1) | 33 (14.3) | 5734 (12.1) | 34 (11.8) | 7300 (12.8) | 46 (13.5) |
| Prior stroke | 3153 (9.3) | 44 (19.1) | 4633 (9.8) | 63 (21.8) | 5815 (10.3) | 91 (26.8) |
| Chronic lung disease | 3021 (8.8) | 19 (8.3) | 3878 (8.2) | 24 (8.3) | 4209 (7.4) | 21 (6.2) |
| Peripheral artery disease | 1858 (5.4) | 11 (4.8) | 1621 (3.4) | 9 (3.1) | 2803 (4.9) | 27 (8.7) |
| Cancer | 1116 (3.2) | 2 (0.9) | 2752 (5.8) | 13 (4.5) | 4150 (7.3) | 21 (6.2) |
| Total sample (#78) | Exposed to DMD (#45) | Not-exposed (#33) | p | |
| Variables related to MS father | ||||
| Age, mean (SD) years (#78) | 34.8 (4.8) | 35.4 (5.3) | 33.9 (3.9) | 0.476* |
| Education, mean (SD) years (#62) | 13.4 (3.5) | 13.2 (3.3) | 13.8 (4.0) | 0.548* |
| Age at onset, mean (SD) years (#75) | 26.5(6.8) | 27.0 (7.2) | 25.7 (6.2) | 0.352* |
| Disease duration, mean (SD) years (#74) | 8.4 (5.9) | 8.5 (6.0) | 8.3 (5.9) | 0.812* |
| Smokers # (%) (#78) | 26 (33.3) | 14 (31.1) | 12 (36.4) | 0.627** |
| Alcohol # (%) (#78) | 14 (17.9) | 10 (22.2) | 4 (12.1) | 0.251** |
| Variables related to pregnancy and fetal outcomes | ||||
| Drug and toxin exposure # (%) (78) | - | - | - | - |
| Smoking exposure # (%) (78) | 5 (6.4) | 2 (4.4) | 3 (9.1) | 0.645§ |
| Alcohol exposure # (%) (#78) | - | - | - | - |
| Gestational age (weeks) (#72) | 38.9 (3.8) | 39.0 (2.1) | 38.7 (5.2) | 0.513* |
| Preterm delivery # (%) (#72) | 10 (13.9) | 7 (17.1) | 3 (9.7) | 0.499§ |
| Caesarean delivery # (%) (#75) | 24 (32.0) | 15 (34.1) | 9 (29.0) | 0.644** |
| Epidural analgesia # (%) (#75) | 16 (21.3) | 10 (22.7) | 6 (19.4) | 0.726** |
| Gender of the baby male/female (#75) | 36/39 | 21/23 | 15/16 | 0.955** |
| Birth-weight mean (SD) gr (#75) | 3301.3 (454.9) | 3282.3 (445.5) | 3328.4 (474.1) | 0.821* |
| Birth-length mean (SD) cm (#67) | 50.1 (2.2) | 49.9 (2.3) | 50.2 (2.1) | 0.649* |
| Type of abuse | Abusive incidents (n=209)* | |
| N | % | |
| Minor incidents | 208 | 99.9% |
| Major incidents | 55 | 26.0% |
| Severe incidents | 17 | 8.0% |
| Trial | Regiments | N | CR | OR | OS (months) | Median PFS (months) |
| Robak et al. [25] | RC | 18 | 13% | 67% | ND | 12 |
| versus RCC | 28 | 9% | 78% | ND | 12 | |
| Robak et al. [26] | FC | 276 | 13% | 58% | 46 | 20.6 |
| versus RFC | 276 | 24.3% | 69.6% | 64 | 30.6 | |
| Castro et al. [27] | Rituximab HDMP | 14 | 36% | 93% | ND | ND |
| Wierda [28] | Ofatumumab, FA-ref, | 95 | 0% | 51% | 14.2 | 5.5 |
| versus ofatumumab, BF-ref | 111 | 2% | 54% | 17.4 | 5.5 | |
| Gritti et al. [29] | Alemtuzumab | 18 | 8% | 44% | ND | 14.6 |
| Zent et al. [30] | PAR | 19 | 32% | 74% | 23 | 7 |
| Badoux et al. [31] | CFAR | 31 | 29% | 65% | 11 | 7 |
| O'Brien et al. [32] | FC | 120 | 9% | 17% | 34 | 6 |
| versus FC-oblimersen | 121 | 3% | 7% | 33 | 9 | |
| Chen et al. [33] | Lenalidomide | 25 | 0% | 56% | 24 | 24 |
| AFB1 Spiked Level (μg/kg) | AFB1 Recovery * (μg/kg) | R (%) | |||||
| Assay 1 | Assay 2 | Assay 3 | Assay 4 | Assay 5 | Mean ± SD | ||
| 5.0 | 4.67 | 4.64 | 4.34 | 4.54 | 4.49 | 4.54 ± 0.13 | 90.20 |
| 10.0 | 9.23 | 9.54 | 9.17 | 9.34 | 9.29 | 9.31 ± 0.14 | 93.14 |
| Parameters | Responders (n = 25) | Non-responders (n = 5) | p value |
| Age at treatment | |||
| ≤ 62 vs > 62 | 12 (48.0%) vs 13 (52.0%) | 3 (60.0%)/2 (40.0%) | 0.638 |
| Degree of progress | |||
| Locally advanced vs visceral metastases | 9 (36.0%)/16 (64.0%) | 1 (20.0%)/4 (80.0%) | 0.505 |
| Stage | |||
| IIIC or IV vs recurrence | 12 (48.8%)/13 (52.0%) | 3 (60.0%)/2 (40.0%) | 0.638 |
| ER | |||
| Negative vs positive | 16 (64.0%)/9 (36.0%) | 2 (40.0%)/3 (60.0%) | 0.334 |
| PgR | |||
| Negative vs positive | 17 (68.0%)/8 (32.0%) | 3 (60.0%)/2 (40.0%) | 0.740 |
| Ki67 | |||
| Negative vs positive | 14 (56.0%)/11 (44.4%) | 2 (40.0%)/3 (60.0%) | 0.529 |
| Treatment line | |||
| First vs other | 16 (64.0%)/9 (36.0%) | 1 (20.0%)/4 (80.0%) | 0.074 |
| CD8 | |||
| Negative vs positive | 16 (64.0%)/9 (36.0%) | 5 (100.0%)/0 (0.0%) | 0.116 |
| FOXP3 | |||
| Negative vs positive | 12 (48.8%)/13 (52.0%) | 3 (60.0%)/2 (40.0%) | 0.638 |
| CFR | |||
| Low/high | 10 (40.0%)/15 (60.0%) | 5 (100.0%)/0 (0.0%) | 0.013 |
| PD1 | |||
| Negative vs positive | 11 (44.0%)/14 (56.0%) | 3 (60.0%)/2 (40.0%) | 0.529 |
| PD-L1 | |||
| Negative vs positive | 17 (68.0%)/8 (32.0%) | 2 (40.0%)/3 (60.0%) | 0.250 |
| CD163 | |||
| Negative vs positive | 12 (48.8%)/13 (52.0%) | 3 (60.0%)/2 (40.0%) | 0.638 |
| PTEN | |||
| Negative vs positive | 13 (52.0%)/12 (48.8%) | 4 (80.0%)/1 (20.0%) | 0.264 |
| LAG3 | |||
| Negative vs positive | 16 (64.0%)/9 (36.0%) | 4 (80.0%)/1 (20.0%) | 0.505 |
| Species | Suckling Duration (s) | Reference |
| Southern right whales | 90–210 | Thomas & Taber 1984 [35] |
| Bowhead whale | <60 | Wursig et al., 1984 [36] |
| Gray whale | 20–76 | Smultea et al., 2017 [34] |
| Blue whale | 13–264 | Smultea et al., 2017 [34] |
| Fin whale | 30–138 | Smultea et al., 2017 [34] |
| Respondent nr. | Deceased patient | Family caregiver (Respondent) | ||||||
| Sex | Age | Diagnosis | Relation to patient | Sex | Age | Terminal leave | Occupation status | |
| 1 | Male | 72 | Lung cancer | Spouse | Female | 63 | No | On pension |
| 2 | Male | 72 | Lung cancer | Spouse | Female | 70 | No | On pension |
| 3 | Male | 63 | Primary tumour unknown | Spouse | Female | 55 | Yes | Active work |
| 4 | Female | 56 | Pancoast tumour (lung cancer) | Spouse | Male | 59 | No | Unemployed |
| 5 | Female | 63 | Lung cancer | Spouse | Male | 69 | No | On pension |
| 6 | Male | 57 | Lung cancer | Spouse | Female | 56 | Yes | Active work |
| 7 | Female | 53 | Breast cancer | Spouse | Male | 56 | Yes | Active work |
| Characteristic | n (%)a | |
| Maternal age (years) | ||
| < 27 | 13,614 | (20.6) |
| 27–29 | 17,880 | (27.0) |
| 30–32 | 16,517 | (25.0) |
| > 32 | 18,192 | (27.5) |
| Parity | ||
| Primiparous | 29,574 | (44.7) |
| Multiparous | 34,240 | (51.7) |
| Unknown | 2,389 | (3.6) |
| General maternal health | ||
| Very good | 33,454 | (50.5) |
| Average | 28,114 | (42.5) |
| Bad | 2,263 | (3.4) |
| Unknown | 2,372 | (3.6) |
| Socioeconomic status | ||
| High | 32,627 | (49.3) |
| Medium | 23,299 | (35.2) |
| Low | 5,220 | (7.9) |
| Unknown | 5,057 | (7.6) |
| Infant sex | ||
| Male | 33,779 | (51.0) |
| Female | 32,424 | (49.0) |
| Hypertension during pregnancy | ||
| Yes | 8,824 | (13.3) |
| No | 57,192 | (86.4) |
| Unknown | 187 | (0.3) |
| Gestational diabetes | ||
| Yes | 1,632 | (2.5) |
| No | 64,225 | (97.0) |
| Unknown | 346 | (0.5) |
| Smoking | ||
| Yes | 17,020 | (25.7) |
| No | 47,255 | (71.4) |
| Unknown | 1,928 | (2.9) |
| Maternal life stress during pregnancyb (score) | ||
| Low (0) | 19,793 | (29.9) |
| Low-medium (> 0 to ≤ 1) | 14,488 | (21.9) |
| Medium-high (> 1 to ≤ 3) | 20,377 | (30.8) |
| High (> 3) | 11,545 | (17.4) |
| Maternal emotional stress during pregnancyb (score) | ||
| Low (≤ 1) | 25,083 | (37.9) |
| Low-medium (> 1 to ≤ 2) | 11,432 | (17.3) |
| Medium-high (> 2 to ≤ 4) | 15,971 | (24.1) |
| High (> 4) | 13,717 | (20.7) |
| Maternal life stress after pregnancyb (score) | ||
| Low (0) | 32,296 | (48.8) |
| Low-medium (> 0 to ≤ 1) | 13,829 | (20.9) |
| Medium-high (> 1 to ≤ 2) | 9,725 | (14.7) |
| High (> 2) | 10,353 | (15.6) |
| Maternal emotional stress after pregnancyb (score) | ||
| Low (0) | 22,313 | (33.7) |
| Low-medium (> 0 to ≤ 1) | 12,557 | (19.0) |
| Medium-high (> 1 to ≤ 3) | 15,847 | (23.9) |
| High (> 3) | 15,486 | (23.4) |
| aPercentages may not total 100 because of rounding. bStress groups were defined by the closest possible cutoffs to the quartiles of their distribution. |
| Model | Aquatic species | Terrestrial species | ||||
| AEV | Pseudo-F | P | AEV | Pseudo-F | P | |
| Month | 67.3% | 9.9 | 0.0001 | 57.1% | 6.3 | 0.0001 |
| Humidity (H) | 16.0% | 6.0 | 0.0005 | 20.7% | 7.3 | 0.0006 |
| Temperature (T) | 23.1% | 8.8 | 0.0001 | 2.0% | 1.5 | 0.23 |
| Wind speed (W) | 7.6% | 3.2 | 0.012 | 12.7% | 4.5 | 0.009 |
| Cloud cover (C) | 3.1% | 1.8 | 0.10 | 13.4% | 4.7 | 0.007 |
| Air pressure | 0.9% | 1.2 | 0.26 | 0.1% | 1.0 | 0.38 |
| T + TH regime | 35.8% | 8.3 | 0.0001 | – | – | – |
| T + H | 35.7% | 8.2 | 0.0001 | – | – | – |
| H + TH regime | 33.2% | 7.5 | 0.0001 | 20.7% | 4.1 | 0.0002 |
| T + H + Wa | 38.8% | 6.5 | 0.0001 | – | – | – |
| T + H + W (month) | 0% | 1.0 | 0.55 | – | – | – |
| H + W + Cb | – | – | – | 37.3% | 5.8 | 0.0002 |
| H + W + C (month) | – | – | – | 18.7% | 2.4 | 0.038 |
| Odds ratio | 95% CI | p* | |
| Presence of psychotic symptoms | |||
| Switch | 0.34 | 0.08 to 1.48 | 0.152 |
| Augmentation | 3.25 | 1.02 to 10.31 | 0.045 |
| Number of major depressive episodes | |||
| Switch | 0.96 | 0.83 to 1.11 | 0.558 |
| Augmentation | 1.23 | 1.07 to 1.43 | 0.005 |
| Motion | Reconstructed ankle | Normal ankle |
| Dorsiflexion | 24.2° ± 5.84° | 24.7° ± 4.85°* |
| Plantarflexion | 43.7° ± 5.74° | 43.4° ± 4.10°* |
| Target | Sequences |
| IL-18 | Forward 5'-GAAACGTCAATAGCCAGTTGC-3' |
| Reverse 5'-TCCCATGCTCTTTCTCACAACA-3' | |
| IL-10 | Forward 5'-AGCAGATCAAGGAGACGTTC-3' |
| Reverse 5'-ATCAGCAGGTACTCCTCGAT-3' | |
| IL-8 | Forward 5’-TATCACTGGAGAGTCTCGCTGTC-3’ |
| Reverse 5’-TCAGTCCTCCTGCAGTGTATACC-3’ | |
| IFN-γ | Forward 5' - ACACTGACAAGTAAAGCCGCACA-3' |
| Reverse 5' -AGTCGTTCATCGGGAGCTTGGC-3' | |
| β-actin | Forward 5'-CAACACAGTGCTGTCTGGTGGTA-3' |
| Reverse 5'-ATCGTACTCCTGCTTGCTGATCC-3' |
| Disease Stage | Gene Symbol | Accession Number | Fold Change (FC) | |||
| HTA 2.0 | qRT-PCR | |||||
| Normal vs. HCV+ | CA | AA | CA | AA | ||
| SAA1 | NM_000331 | 3.36 | NA | 3.12 | 2.0* | |
| AOX1 | NM_001159 | 3.45 | NA | 3.10 | 3.3 | |
| SLC13A5 | NM_001143838 | 3.27 | NA | 3.51 | 3.0 | |
| HCCN vs. HCV+HCC | PCNA-AS1 | NR_028370 | 3.53 | NA | 3.2 | 0.99* |
| ROBO1 | NM_001145845 | 2.20 | NA | 2.9 | 0.20* | |
| DAB2 | NM_001244871 | 2.20 | NA | 3.0 | 0.55* | |
| IFI30 | NM_001244871 | 2.21 | NA | 2.0 | 0.72* | |
| SNORD82 | NR_004398 | -2.20 | NA | -2.0 | -2.0 |
| Characteristic | Systemic sclerosis (n = 90) | Systemic lupus erythematosus (n = 100) |
| Female | 78 (86.7%) | 87 (87%) |
| Age (years) | 57.7 ± 14.4 | 48.1 ± 15.1 |
| Disease duration (months) | 85.0 ± 96.0 | 69.6 ± 92.0 |
| Body mass index | 24.5 ± 4.0 | 25.2 ± 4.7 |
| Adipositas, body mass index >30 | 6 (6.7%) | 14 (14%) |
| Hypertension | 45 (50%) | 56 (56%) |
| Systolic blood pressure (mmHg) | 129.9 ± 23.2 | 130.6 ± 21.5 |
| Diastolic blood pressure (mmHg) | 75.9 ± 11.5 | 77.6 ± 10.6 |
| Mean number of antihypertensives | 0.8 (0, 4) | 0.9 (0, 6) |
| Diabetes | 4 (4.4%) | 6 (6%) |
| Pulmonary hypertension | 17 (18.9%) | 3 (3%) |
| Coronary heart disease | 10 (11.1%) | 9 (9%) |
| Peripheral artery vessel disease | 5 (5.6%) | 2 (2%) |
| Nicotine use, current or former | 43 (47.8%) | 53 (53%) |
| Nicotine pack-years | 10.7 ± 19.5 | 10.4 ± 16.2 |
| Triglyceride (mg/dl) | 139.2 ± 84.9 | 128.1 ± 69.9 |
| Cholesterol (mg/dl) | 216.5 ± 50.2 | 213.9 ± 59.6 |
| Low density lipoprotein (mg/dl) | 125.5 ± 39.2 | 123.7 ± 46.8 |
| High density lipoprotein (mg/dl) | 63.7 ± 18.7 | 64.4 ± 17.9 |
| Family history of cardiovascular disease | 12 (13.3%) | 16 (16%) |
| Mean Rodnan skin score (median, range) | 11 (9, 43) | – |
| Mean SLEDAI (median, range) | – | 11 (9, 60) |
| Mean SLICC (median, range) | – | 2 (2, 8) |
| Chronological age mean (std.) [min–max] | Age at implantation mean (std.) [min–max] | Duration of CI experience mean (std.) [min–max] | Age at profound hearing loss mean (std.) [min–max] | |
| NH adults | 34.8 (11.4) [21.2–50.9] | |||
| NH children | 11.8 (3.4) [6.1–18.1] | |||
| CI adults | 57.2 (3.6) [52.5–61.2] | 49.3 (7.3) [41.0–59.0] | 7.9 (4.9) [2.2–13.0] | 20.1 (18.5) [1.5–49.0] |
| CI children | 13.0 (3.0) [8.1–17.9] | 2.6 (2.3) [1.1–11.9] | 10.4 (3.5) [4.9–16.6] | 0.5 (1.1) [0.0–3.5] |
| Duloxetine | Venlafaxine | SSRI | Untreated | |||||
| N removed | N eligible remaining | N removed | N eligible remaining | N removed | N eligible remaining | N removed | N eligible remaining | |
| Member of commercial health insurance plan, with medical coverage and pharmacy benefits, and presence of qualifying eventa during the accrual period | 156,682 (100.0 %) | 231,793 (100 %) | 1,314,147 (100 %) | 1,577,784 (100 %) | ||||
| Baseline exclusions | ||||||||
| Less than 18 years at index date | 1396 | 155,286 (99.1 %) | 2482 | 229,311 (98.9 %) | 33,476 | 1,280,671 (97.5 %) | 60,552 | 1,517,232 (96.2 %) |
| Less than 12 months prior continuous enrollment | 79,819 | 75,467 (48.2 %) | 136,147 | 93,164 (40.2 %) | 780,943 | 499,728 (38.0 %) | 791,027 | 726,205 (46.0 %) |
| Prior dispensing of study drug or drug class in the baseline | 0 | 75,467 (48.2 %) | 23,753 | 69,411 (29.9 %) | 134,294 | 365,434 (27.8 %) | 334,496 | 391,709 (24.8 %) |
| Had no depression diagnosis in the baseline | 27,596 | 47,871 (30.6 %) | 24,844 | 44,567 (19.2 %) | 153,173 | 212,261 (16.2 %) | 0 | 391,709 (24.8 %) |
| Had hepatic injury/chronic hepatic condition in the baseline | 10,592 | 37,279 (23.8 %) | 9173 | 35,394 (15.3 %) | 39,354 | 172,907 (13.2 %) | 76,815 | 314,894 (20.0 %) |
| Region affected by Hurricane Katrina | 489 | 36,790 (23.5 %) | 509 | 34,885 (15.1 %) | 2020 | 170,887 (13.0 %) | 3556 | 311,338 (19.7 %) |
| Cohort assignment based on earliest qualifying index date (pre-propensity score matching) | 30,844 (19.7 %) | 29,243 (12.6 %) | 166,236 (12.6 %) | 311,338 (19.7 %) |
| Characteristic | No. of patients | Percent |
| Age | ||
| ≤75 | 31 | 51 |
| >75 | 30 | 49 |
| Gender | ||
| Male | 20 | 33 |
| Female | 41 | 67 |
| ECOG performance status | ||
| 0 | 4 | 7 |
| 1 | 28 | 46 |
| 2 | 22 | 36 |
| 3 | 7 | 11 |
| Smoking status | ||
| Never | 4 | 7 |
| Former | 44 | 72 |
| Current | 13 | 21 |
| Tobacco history (pack-years) | ||
| 0 | 4 | 7 |
| <40 | 20 | 33 |
| 40–50 | 21 | 34 |
| >50 | 16 | 26 |
| Baseline oxygen dependence | ||
| Yes | 19 | 31 |
| No | 42 | 69 |
| Reason for inoperability | ||
| Age | 11 | 18 |
| Pulmonary dysfunction | 49 | 80 |
| Other medical comorbidities | 1 | 2 |
| Variables | AUC | Cut-off | Sensitivity (%) | Specificity (%) |
| CAR | 0.641 | 0.03 | 54 | 73 |
| NLR | 0.560 | 3.13 | 28 | 88 |
| PLR | 0.538 | 188 | 28 | 83 |
| PNI | 0.631 | 49.2 | 78 | 49 |
| GPS | 0.543 | 0 | 24 | 84 |
| PI | 0.541 | 0 | 17 | 92 |
| discovery cohort | validation cohort | ||||||||
| ProbeSet Name | miRNA | R-SW | last/first (SW) | FC (elder/young) LIMMA | adj.P.Val LIMMA | RQ (Qpcr) | p-value | RQ (Qpcr) | p-value |
| hsa-miR-1281_st | miR-1281 | 0.921 | 2.778 | 2.509 | 4.64E-03 | 1.127 | 6.60E-01 | - | - |
| hsa-let-7i_st | let-7i | −0.853 | 0.498 | 0.455 | 4.64E-03 | 0.566 | 2.86E-02 | 0.226 | 1.53E-07 |
| hsa-miR-30b_st | miR-30b | −0.839 | 0.476 | 0.503 | 1.05E-01 | 0.777 | 1.07E-01 | 0.419 | 7.66E-07 |
| hsa-miR-15a_st | miR-15a | −0.874 | 0.465 | 0.525 | 9.39E-02 | 0.632 | 1.21E-01 | 0.219 | 1.23E-07 |
| hsa-let-7g_st | let-7g | −0.899 | 0.434 | 0.468 | 1.54E-02 | 0.578 | 1.14E-02 | 0.199 | 1.05E-08 |
| Positive Association with ERα | ||||
| qRT-PCR | METABRIC* | TCGA# | GSE20685§ | |
| Sample No. Analysed | n = 128 | n = 1,980 | n = 485 | n = 327 |
| ERα | 3.6E-18 | 2.4E-188 | 2.8E-47 | 9.6E-48 |
| PGR | 4.6E-11 | 9.6E-102 | 1.7E-29 | 6.4E-34 |
| PNR | 1.9E-10 | 4.9E-110 | 1.8E-34 | 1.5E-11 |
| AR | 7.6E-60 | 7.8E-28 | 8.0E-16 | |
| RORβ | 1.9E-06 | 1.7E-06 | 1.2E-02 | 3.4E-01 |
| RARα | 1.3E-06 | 3.0E-88 | 1.2E-24 | 1.3E-07 |
| TRβ | 9.2E-05 | 8.1E-01 | 1.7E-08 | 1.4E-08 |
| RORγ | 2.6E-04 | 2.3E-44 | 1.5E-15 | 7.3E-08 |
| LRH-1 | 1.9E-03 | 4.1E-03 | 5.8E-04 | 2.9E-01 |
| ERRγ | 6.0E-01 | 1.8E-05 | 4.4E-02 | 3.1E-01 |
| Negative Association with ERα | ||||
| qRT-PCR | METABRIC | TCGA | GSE20685 | |
| TLX | 5.5E-07 | 2.7E-10 | 1.6E-15 | 1.3E-02 |
| PPARα | 3.3E-04 | 1.1E-34 | 4.3E-28 | 1.4E-12 |
| DAX1 | 2.9E-02 | 1.7E-02 | 4.0E-03 | 6.7E-01 |
| Characteristic | 1 Portion Group (n=35) | 6 Portion Group (n=39) | Trend for change | ||
| Pre | Post | Pre | Post | between groups | |
| Male Sex (%) | 80 | - | 61.5 | - | 0.295 |
| BMI (kg/m2) | 30.1 (0.6) | 30.1 (0.7) | 30.7 (0.6) | 31.0 (0.6)d | 0.012 |
| Age (years) | 59.9 (1.23) | - | 58.2 (1.47) | - | 0.263 |
| Glucose (mmol/L) | 8.0 (6.6,9.6) | 8.5 (7.5,22.3) | 8.2 (7.0,8.9) | 8.9 (8.3,18.8) | 0.587 |
| Insulin (mU/L) | 13.7 (9.4,21.2) | 14.6 (7.5,22.3) | 11.9 (8.0,17.4) | 16.8 (8.3,18.8) | 0.470 |
| HbA1C (%) | 7.2 (0.2) | 7.1 (0.2)c | 7.1 (0.2) | 7.1 (0.2) | 0.068 |
| Duration of diabetes (years) | 6.7 (0.9) | - | 5.2 (0.7) | - | >0.05 |
| Triglycerides (mmol/L) | 1.82 (1.2,2.1) | 1.69 (1.1,2.1) | 1.73 (1.1,2.0) | 1.79 (1.2,2.2) | 0.168 |
| Total cholesterol (mmol/L) | 3.95 (0.13) | 3.86 (0.11) | 3.87 (0.12) | 3.93 (0.12) | 0.640 |
| HDL cholesterol (mmol/L) | 1.24 (0.05) | 1.20 (0.05) | 1.25 (0.05) | 1.23 (0.05) | 0.194 |
| Lipid lowering therapy (%) | 94 | - | 95 | - | >0.05 |
| Diabetic therapy (diet) (%) | 5 | - | 8 | - | >0.05 |
| Oral hypoglycaemic therapy (%) | 86 | - | 80 | - | >0.05 |
| Data set 1 | Gene | Mutation | Tissue | Mean coverage | PCR/CE | ScanIndel | GATK | Pindel | Scalpel | Platypus | FermiKit | Delly |
| 1-1 | CALR | DEL | BM | 46,913 | 52 | 52 | 52 | NC | NC | NC | NC | NC |
| 1-2 | EGFR | DEL | FFPE | 25,821 | 18 | 18 | 18 | NC | NC | 18 | NC | NC |
| 1-3 | KIT | DEL | FFPE | 12,990 | 6 | 6 | 6 | NC | NC | 6 | NC | NC |
| 1-4 | NPM1 | INS | BM | 21,387 | 4 | 4 | 4 | 4 | NC | NC | NC | NC |
| 1-5 | FLT3 | INS | BM | 4768 | 21 | 21 | 21 | 21 | NC | NC | NC | NC |
| 1-6 | FLT3 | INS | BM | 11,510 | 26 | 27 | NC | 27 | NC | NC | NC | NC |
| 1-7 | FLT3 | INS | BM | 26,747 | 49 | 51 | NC | 51 | NC | NC | NC | NC |
| 1-8 | FLT3 | INS | BM | 28,991 | 38 | 39 | NC | 39 | NC | NC | NC | NC |
| 1-9 | FLT3 | INS | BM | 26,734 | 90 | 93 | NC | 93 | NC | NC | 93 | NC |
| 1-10 | FLT3 | INS | BM | 16,152 | 75 | 78 | NC | 78 | NC | NC | NC | NC |
| 1-11 | FLT3 | INS | BM | 3528 | 32 | 33 | 33 | 33 | NC | NC | NC | NC |
| 1-12 | FLT3 | INS | BM | 3851 | 51 | 54 | 54 | 54 | NC | NC | NC | NC |
| 1-13 | FLT3 | INS | BM | 21,403 | 23 | 24 | 24 | 24 | NC | NC | NC | NC |
| 1-14 | FLT3 | INS | BM | 3070 | 45 | 48 | 48 | 48 | NC | NC | NC | NC |
| 1-15 | FLT3 | INS | BM | 4506 | 33 | 36 | 36 | 36 | NC | NC | NC | NC |
| 1-16 | FLT3 | NEG | BM | 4471 | NC | NC | NC | NC | NC | NC | NC | NC |
| 1-17 | FLT3 | NEG | BM | 4321 | NC | NC | NC | NC | NC | NC | NC | NC |
| 1-18 | FLT3 | NEG | BM | 6219 | NC | NC | NC | NC | NC | NC | NC | NC |
| 1-19 | FLT3 | NEG | BM | 5259 | NC | NC | NC | NC | NC | NC | NC | NC |
| 1-20 | FLT3 | NEG | BM | 4443 | NC | NC | NC | NC | NC | NC | NC | NC |
| 1-21 | FLT3 | NEG | BM | 5236 | NC | NC | NC | NC | NC | NC | NC | NC |
| 1-22 | FLT3 | NEG | BM | 4443 | NC | NC | NC | NC | NC | NC | NC | NC |
| Rotated component matrix | ||||
| Component | ||||
| 1 | 2 | 3 | 4 | |
| E1 | .772 | |||
| E2 | .720 | |||
| E3 | .786 | |||
| E4 | .839 | |||
| E5 | .781 | |||
| E6 | .840 | |||
| E7 | .824 | |||
| E8 | .787 | |||
| T1 | .699 | |||
| T2 | .843 | |||
| T3 | .845 | |||
| T4 | .827 | |||
| A1 | .823 | |||
| A2 | .824 | |||
| A3 | .518 | |||
| P1 | .764 | |||
| P2 | .740 | |||
| P3 | .816 | |||
| O1 | .761 |
| Quintile | n | Energy (kcal/Person/Day) | Sodium (g/Person/Day) | Sodium (g/Person/Day/2000kcal) | ||||
| 2004–2005 | 2012–2013 | 2004–2005 | 2012–2013 | 2004–2005 | 2012–2013 | 2004–2005 | 2012–2013 | |
| Costa Rica | 1,134,433 | 1,396,747 | 2315 | 2390 | 3.9 | 4,6 a | 3.4 | 3.9 a |
| I | 225,773 | 279,044 | 1896 | 1724 | 3.9 | 3,8 b | 4.1 | 4.4 b |
| II | 226,647 | 279,642 | 2065 | 2195 | 3.5 | 4.7 a | 3.4 | 4.3 a |
| III | 228,332 | 279,437 | 2276 | 2494 | 4.0 | 4.7 | 3.5 | 3.8 |
| IV | 226,503 | 279,409 | 2626 | 2679 | 4.4 | 4.9 a | 3.4 | 3.7 a |
| V | 227,178 | 279,215 | 2712 | 2669 | 3.9 | 4.7 a | 2.9 | 3.5 a |
| Gene name | Sequence (5’-3’) | Primer | Purpose | Acc. | |
| efficiency (%) | number | ||||
| Profilin2 (Pfn2) | F1 | CCAGCCACTCAATATGTCGT | cloning | [GenBank:KC460541] | |
| R2 | CAAGAACCTGGGAAACACAC | ||||
| F | ATCGCAGCACTTTATTCACC | 95.18 | qPCR | ||
| R | GCGTCCTCCTTGTAGAGGTT | ||||
| Peroxiredoxin 6 (Prdx6) | F | TATCGGTGAGACAGGACCAT | cloning | [GenBank:KC460539] | |
| R | TGGCGGTTTATTCTAAGTGC | ||||
| F | GATGAGATCGACAAGGATGG | 96.99 | qPCR | ||
| R | TCTATGACCCTCAGCAGCTC | ||||
| Flotillin1 (Flot1) | F | TCGCTGAAATAGGTCTCTGG | cloning | [GenBank:KC460542] | |
| R | ACTCAGCCTTCTTGGTGTTG | ||||
| F | ACCAGGACTACCTCCACTCC | 91.88 | qPCR | ||
| R | TACTGGGCAGACACCTTCTC | ||||
| Calpain small subunit 1 (Capns1) | F | TTCTCTTCTCACCGCAGAAC | cloning | [GenBank:KC460540] | |
| R | GACTTTTCCAGCTCCTCCTC | ||||
| F | AACATGGCAACATGGACTTT | 94.05 | qPCR | ||
| R | TTGACATCAAGGGAGATGGT | ||||
| Beta 2 Tubulin (Tubb2) | F | CAGCTACTTCGTGGAATGGA | 94.47 | qPCR | [GenBank:AAD56401] |
| R | CTGTTGCCGATGAAGGTTAC | ||||
| Cold inducible RNA binding protein (Cirbp) | F | CTCTTCGGAACTCTCAACCA | cloning | [GenBank:KC460543] | |
| R | AATACAGCCAGCCAAGTGAC | ||||
| F | GTATGGAAACATCGCCAAAG | 94.17 | qPCR | ||
| R | CTCGTCGGCATTATCAAACT | ||||
| Glutathione S-transferase omega1(Gsto1) | F | ATTGCGTCTTGGTCATTCAT | cloning | [GenBank:KC460544] | |
| R | ACAGGCCATAGTCGTAGTCG | ||||
| F | CTGAAACACTTCCTGGATGG | 95.60 | qPCR | ||
| R | GCGTGCATGGTTTCTTTAAC | ||||
| Ubiquitin (Ubi) | F | GGCCGCAAAGATGCAGAT | 96.10 | qPCR | [GenBank:EX735613] |
| R | CTGGGCTCGACCTCAAGAGT | ||||
| Acidic ribosomal protein (Arp) | F | TGATCCTCCACGACGATGAG | 95.37 | qPCR | [GenBank:EX741373] |
| R | CAGGGCCTTGGCGAAGA | ||||
| Interleukin 1β (il1β) | F | GGAGAACACGGACGACCTGA | qPCR | [GenBank:AJ535730] | |
| R | CGCACCATGTCACTGTCCTT |
| Primer | Sequence (5′→3′) | Length (bp) |
| lytA-ins F | GAAGATCTAGATTTGCCTCAAGTCGG | 421 |
| lytA-ins R | CCCCCGGGAGGGTCAACGTGGTCTGA | |
| lytA Fexp BamH I | GGGGATCCATGGAAATTAATGTGAGTAAAT | 6,723 |
| lytA Rexp Xho I | CCGCTCGAGTTTTACTGTAATCAAGCCATC | |
| pEVP3 F | ATCTCAGTTCGGTGTAGGTC | 1,068 |
| pEVP3 R | TTATTGGGATAAGTTAGAGCC | |
| ply F | ATGGCAAATAAAGCAGTAAATGACT | 1,416 |
| ply R | CTAGTCATTTTCTACCTTATCCTCT |
| Parameter | Hazard ratio (95% confidence interval) | P value |
| Myasthenia gravis | ||
| Yes vs. no | 3.807 (0.465, 31.153) | 0.213 |
| Surgery | ||
| Yes vs. no | 1.055 (0.766, 1.453) | 0.744 |
| Metastasis | ||
| Lymphogenous vs. hematogenous | 2.580 (1.341, 4.967) | 0.005 |
| TOLAC hospital (N=139) N (%) or Mean (SD) | |
| Anesthesia | |
| In-hospital | 129 (93.5) |
| Within 30 minutes | 9 (6.5) |
| Missing=1 | |
| Physician | |
| In-hospital | 117 (87.3) |
| Within 20-30 minutes | 17 (12.7) |
| Missing =5 | |
| Operating room immediately available | 134 (96.4) |
| Neonatal staff available | 136 (97.8) |
| Day of the week restrictions | |
| No restrictions | 135 (97.1) |
| Day of the week | 2 (1.4) |
| Time of day | 0 |
| Patient Restrictions | |
| Number of prior cesareans | 131 (94.2) |
| One prior cesarean | 45 (32.4) |
| No more than two prior cesareans | 86 (61.8) |
| Singleton pregnancy | 83 (59.7) |
| Time since last birth | 11 (7.9) |
| Weight or body mass index | 2 (1.4) |
| Spontaneous labor | 73 (52.5) |
| Induction or labor management methods permitted | |
| Prostaglandin gel/insert | 2 (1.4) |
| Foley | 66 (48.9) |
| Oxytocin | 128 (92.1) |
| Amniotomy | 131 (94.2) |
| Requirements of women with a TOLAC | |
| Continuous fetal monitoring | 138 (99.2) |
| Continuous IV | 138 (99.2) |
| Epidural in active labor | 27 (19.4) |
| Sliding Window Segmentation Approach | Window Overlap Value (%) | Window Size | Highest Classification Accuracy (%) |
| No Overlap | 0 | 4.5 | 96.12 |
| Overlap | 25 | 6 | 96.97 |
| Overlap | 50 | 6 | 97.30 |
| Overlap | 75 | 8 | 98.13 |
| Overlap | 90 | 12 | 98.38 |
| Number of participants | Mean | s.d. | Median | P-value | |
| Bipolar lithium | 30 | 3.04 | 0.43 | 3.05 | 0.04a |
| Bipolar non-lithium | 27 | 3.31 | 0.49 | 3.31 | |
| Controls | 22 | 3.12 | 0.21 | 3.07 | |
| Total | 79 | 3.16 | 0.42 | 3.10 |
| Variable | PD (n = 230) | Controls (n = 93) | P |
| Age at study enrollment (years) | 66.4 (9.5) | 68.0 (8.0) | 0.118 |
| Disease duration at study enrollment (years) | 0.6 (0.5) | ||
| Sex (% male) | 61.7 | 52.7 | 0.134 |
| Age leaving full‐time education (years) | 17.8 (3.7) | 18.0 (3.4) | 0.604 |
| UPDRS‐III | 27.9 (11.5) | ||
| MMSE | 28.8 (1.3) | 29.0 (1.2) | 0.078 |
| GDS‐15 | 2.9 (2.6) | 1.0 (1.6) | < 0.001 |
| LEDD (mg) | 194.5 (161.5) | ||
| CIRS systems score, median, (range) | 2 (0–7) | 3 (0–7) | 0.070 |
| Anti‐inflammatory drug use (%) | 32.6 | 33.3 | 0.900 |
| Sensitive | Species | |||
| coefficients | S. baicalensis | S. grandis | S. breviflora | S. bungeana |
| TEMPERATURE TREATMENTS | ||||
| T0 | −0.10 | 0.25 | −0.09 | −0.18 |
| T1.5 | 1.89 | 0.12 | 1.95 | 6.04 |
| T2.0 | 3.12 | 1.31 | 3.13 | 4.85 |
| T4.0 | 0.76 | −0.14 | 2.22 | 5.21 |
| T6.0 | 0.74 | −5.16 | 2.06 | 5.64 |
| PRECIPITATION TREATMENTS | ||||
| W−30% | −0.46 | −9.59 | −1.54 | 3.15 |
| W−15% | 6.32 | −6.97 | −0.07 | 9.45 |
| W0 | 3.21 | −0.45 | 3.62 | 8.44 |
| W+15% | 0.23 | 1.44 | 1.57 | 11.95 |
| W+30% | −1.03 | 4.24 | −1.28 | 3.73 |
| Pressure level 1 | Pressure level 2 | |||||
| Comparison | Diff of Ranks | Q | P < 0.05 | Diff of Ranks | Q | P < 0.05 |
| Control vs Wood | 0.600 | 1.897 | No | 1.120 | 3.542 | Yes |
| Control vs Metal | 0.210 | 0.664 | No | 0.140 | 0.443 | No |
| Control vs Acrylic | 1.830 | 5.787 | Yes | 0.740 | 2.340 | No |
| Control vs Sandpaper | 2.130 | 6.736 | Yes | 1.670 | 5.281 | Yes |
| Wood vs Metal | 0.390 | 1.233 | No | 0.980 | 3.099 | Yes |
| Wood vs Acrylic | 2.430 | 7.684 | Yes | 1.860 | 5.882 | Yes |
| Wood vs Sandpaper | 2.730 | 8.633 | Yes | 2.790 | 8.823 | Yes |
| Metal vs Acrylic | 2.040 | 6.451 | Yes | 0.880 | 2.783 | No |
| Metal vs Sandpaper | 2.340 | 7.400 | Yes | 1.810 | 5.724 | Yes |
| Acrylic vs Sandpaper | 0.300 | 0.949 | No | 0.930 | 2.941 | Yes |
| Pressure level 3 | Pressure level 4 | |||||
| Comparison | Diff of Ranks | Q | P < 0.05 | Diff of Ranks | Q | P < 0.05 |
| Control vs Wood | 0.600 | 1.897 | No | 0.400 | 1.265 | No |
| Control vs Metal | 0.210 | 0.664 | No | 0.450 | 1.423 | No |
| Control vs Acrylic | 0.040 | 0.126 | No | 1.380 | 4.364 | Yes |
| Control vs Sandpaper | 1.200 | 3.795 | Yes | 1.570 | 4.965 | Yes |
| Wood vs Metal | 0.810 | 2.561 | No | 0.050 | 0.158 | No |
| Wood vs Acrylic | 0.640 | 2.024 | No | 0.980 | 3.099 | Yes |
| Wood vs Sandpaper | 1.800 | 5.692 | Yes | 1.170 | 3.700 | Yes |
| Metal vs Acrylic | 0.170 | 0.538 | No | 0.930 | 2.941 | Yes |
| Metal vs Sandpaper | 0.990 | 3.131 | Yes | 1.120 | 3.542 | Yes |
| Acrylic vs Sandpaper | 1.160 | 3.668 | Yes | 0.190 | 0.601 | No |
| Number of patients N | 24 |
| Mean age | 64 |
| Minimum age | 46 |
| Maximum age | 83 |
| Standard deviation | 12 |
| Male: Female | 11 : 13 |
| Location of primary cancer (%) | |
| Tongue | 12 (50%) |
| Floor of mouth | 3 (13%) |
| Retromolar trigone | 2 (8%) |
| Larynx | 2 (8%) |
| Oropharynx | 2 (8%) |
| Alveolar ridge | 1 (4%) |
| Palate/maxilla | 1 (4%) |
| Sinonasal | 1 (4%) |
| Total | 24 (100%) |
| Overall (males + females) | Males | Females | ||||
| N cases | Cost per case (€) | N cases | Cost per case (€) | N cases | Cost per case (€) | |
| Admitted patients | ||||||
| Osseous injuries foot | 1,527 | 6,088 (1,469) | 969 | 4,475 (961) | 558 | 8,887 (2,349) |
| Ligamentous injuries foot | 36 | 2,582 (199) | 22 | 2,746 (244) | 14 | 2,322 (129) |
| Osseous injuries ankle | 8,737 | 7,383 (1,620) | 3,931 | 5,415 (998) | 4,806 | 8,993 (2,128) |
| Ligamentous injuries ankle | 2,869 | 2,780 (281) | 2,153 | 2,586 (251) | 716 | 3,364 (373) |
| Subtotal | 13,169 | 6,217 (1,307) | 7,075 | 4,417 (764) | 6,094 | 8,306 (1,937) |
| Non-admitted patients | ||||||
| Osseous injuries foot | 33,511 | 836 (126) | 16,418 | 687 (93) | 17,092 | 979 (157) |
| Ligamentous injuries foot | 5,203 | 685 (96) | 2,502 | 634 (85) | 2,701 | 732 (106) |
| Osseous injuries ankle | 15,916 | 1,308 (154) | 7,832 | 1,110 (129) | 8,084 | 1,500 (177) |
| Ligamentous injuries ankle | 40,368 | 684 (82) | 21,460 | 642 (69) | 18,908 | 731 (97) |
| Subtotal | 94,998 | 842 (110) | 48,213 | 733 (88) | 46,785 | 955 (133) |
| All patients | ||||||
| Osseous injuries foot | 35,038 | 1,065 (184) | 17,387 | 898 (141) | 17,650 | 1,229 (226) |
| Ligamentous injuries foot | 5,240 | 698 (97) | 2,525 | 653 (87) | 2,715 | 740 (106) |
| Osseous injuries ankle | 24,653 | 3,461 (673) | 11,763 | 2,549 (420) | 12,890 | 4,294 (904) |
| Ligamentous injuries ankle | 43,237 | 823 (92) | 23,613 | 819 (86) | 19,624 | 827 (107) |
| Total | 108,167 | 1,496 (255) | 55,288 | 1,204 (174) | 52,879 | 1,802 (338) |
| Antigen tested | May 2010 | November 2010 | May 2011 | November 2011 | Overall |
| No individuals | No = 47 | N = 46 | N = 47 | N = 48 | N = 188 |
| Ag MSP1 | |||||
| Mean OD [min–max] | 0.57 [0–1.93] | 0.62 [0–1.93] | 0.47 [0–1.36] | 0.82 [0–2.25] | 0.52 [0–2.25] |
| P. vivax | |||||
| Mean OD ratio [min–max] | 2.6 [1–7.1] | 2.9 [1–6.4] | 2.2 [1–4.5] | 3.7 [1–7.2] | 2.9 [1–7.2] |
| No positive (prevalence) | 40% | 41% | 25% | 31% | 53% |
| Pf MSP1p19 | |||||
| Mean OD [min–max] | 0.11 [0–0.98] | 0.21 [0–2.10] | 0.10 [0–1.19] | 0.30 [0–2.14] | 0.18 [0–2.14] |
| Mean OD ratio [min–max] | 2.5 [1–16.7] | 4.0 [1–34.7] | 2.3 [1–20.0] | 5.4 [1–33.8] | 3.5 [1–33.8] |
| Prevalence | 43% | 38% | 23% | 46% | 61% |
| Ag SE 07_03 | |||||
| Mean OD [min–max] | 0.58 [0–2.45] | 0.65 [0–2.41] | 0.48 [0–2.39] | 0.82 [0–2.59] | 0.63 [0–2.59] |
| Mean OD ratio [min–max] | 2.5 [1–10.5] | 2.8 [1–10.4] | 2.2 [1–9.6] | 3.5 [1–12.3] | 2.8 [1–12.3] |
| No positive (prevalence) | 45% | 37% | 28% | 46% | 63% |
| Type of study model | Experimental method [subject (age/weight), treatment dosage, duration of treatment] | Major activity | Mechanism of action | Reference |
| In vivo study | Outbred albino female ICR mice (20–26 g), yogurt containing DSW, 10.3 g hardness of CaCO3/L, 8 weeks | Increased populations of intestinal lactic acid bacteria.Decreased the activity of serum AST and ALT.Reduced TC, TC to HDL-C ratio, TAG, and HDL-C in serum. | ND. | [44] |
| In vivo study | HFD-induced obesity ICR (4 weeks), DSW, and DSW + 125 mg/kg SIE (DSS), ad libitum, treated with SIE once per day for 8 weeks | Reduced body weights in the DSW group by 3.95% and in the DSS group by 8.42%, respectively.Decreased plasma glucose levels in the DSW group by 14.9% and in the DSS group by 36.4%, respectively.Decreased serum levels of glucose, TAG, and leptin.Decreased insulin resistance index (HOMA-IR) values for the DSS-treated group by 38.2%. | Decreased size of the epididymal white, retroperitoneal white, and scapular brown adipose tissue.Increased levels of phosphorylated AMPK and its substrate and ACC in mice epididymal adipose tissues.Upregulated the expression levels of lipolysis-associated mRNA, PPAR-α, cluster of differentiation 36 (CD36), and energy expenditure-associated mRNA and UCP2 and CPT1 epididymal adipose tissues.Suppressed the expression of SREBP1 at the mRNA level. | [45] |
| In vivo study | Green tea leaves were soaked in desalinated DSW at 75°C for 10 min | Increased antioxidant activity. | Increased 2, 2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging activities by 83.98% and increased reducing power by 15%.Increased nitrite scavenging activity from 31.33 ± 0.05 to 37.12 ± 0.42%.Increased amounts of catechins and caffeine. | [38] |
| Parameter | Specification | Method |
| Identity DOTA-NOC | DOTA-NOC | Acceptance of raw material |
| Content: 68Ga | 90 – 110% of the declared 68Ga radioactivity | Ionization chambera |
| Content: DOTA-NOC | Maximum 50 μg | Quality by design: pre-filled vials with amount needed together with double check in batch recorda |
| Appearance | Clear, colourless solution | Visual inspectiona |
| pH | 4.0 to 8.0 | pH indicator stripa |
| Ethanol | Maximum 10% (V/V)/maximum 2.5 g per dose | Quality by design: risk-based approach eliminated need for routine test |
| Sterility | Sterile; bubble point >3,450 mbar | Validation of aseptic process together with filter integrity testa |
| Bacterial endotoxins | Less than 175 IU per dose | Quality by design: risk-based approach eliminated need for routine test |
| Impurity A | ≤3% | ITLCa |
| Impurity B | ≤2% | Validated ITLC method to replace HPLCa |
| Impurity C | ≤0.001% | Ionization chamber; assessed at time of acceptance of generator |
| Chr | Nucleotide polymorphism | Insertion | Deletion | Total | |||
| SNP | MNP | WAB56–104 | CG 14 | WAB56–104 | CG 14 | ||
| 1 | 360,381 | 11,386 | 1972 | 20,132 | 2804 | 24,478 | 49,386 |
| 2 | 316,206 | 10,336 | 1564 | 17,498 | 2320 | 21,101 | 42,483 |
| 3 | 306,733 | 9299 | 1293 | 16,964 | 1879 | 20,338 | 40,474 |
| 4 | 270,022 | 9601 | 1370 | 14,362 | 2061 | 17,316 | 35,109 |
| 5 | 251,323 | 8021 | 1377 | 13,075 | 2055 | 15,560 | 32,067 |
| 6 | 271,081 | 9447 | 1413 | 14,354 | 1997 | 17,557 | 35,321 |
| 7 | 254,203 | 8756 | 899 | 14,537 | 1314 | 17,184 | 33,934 |
| 8 | 221,116 | 7317 | 1131 | 11,605 | 1632 | 14,365 | 28,733 |
| 9 | 190,775 | 6350 | 666 | 10,347 | 893 | 12,284 | 24,190 |
| 10 | 201,301 | 7146 | 1771 | 9125 | 2600 | 11,457 | 24,953 |
| 11 | 238,964 | 8611 | 1884 | 11,917 | 2360 | 14,295 | 30,456 |
| 12 | 203,812 | 7230 | 1527 | 10,421 | 2084 | 12,631 | 26,663 |
| Un | 538 | 9 | 3 | 20 | 5 | 32 | 60 |
| Sy | 2363 | 59 | 7 | 113 | 2 | 119 | 241 |
| Total | 3,088,818 | 103,568 | 16,877 | 164,470 | 24,006 | 198,717 | 404,070 |
| Island | NA | HO | HE | Ar | F | HWD |
| Floreana | 0.136 (0.152) | 0.281 (0.091) | 0.44 5 (0.081) | 2.273 (0.825) | 0.353 (0.185) | D11Mgh5, D5Rat83, D16Rat81, D10Rat20, RfgC2 |
| Baltra | 0.066 (0.068) | 0.383 (0.091) | 0.458 (0.098) | 2.489 (1.047) | 0.153 (0.088) | D5Rat83, D16Rat81, RfgL1 |
| Bartolome | 0.092 (0.128) | 0.445 (0.096) | 0.533 (0.043) | 2.406 (0.601) | 0.215 (0.161) | D5Rat83, RfgL1 |
| Bainbridge | 0.173 (0.121) | 0.122 (0.048) | 0.339 (0.069) | 1.856 (0.576) | 0.584 (0.150) | D11Mgh5, D5Rat83, D16Rat81, D10Rat20, D9Rat13, RfgL1, RfgL4 |
| Bowditches | 0.115 (0.128) | 0.212 (0.064) | 0.348 (0.07) | 1.974 (0.66) | 0.344 (0.157) | D11Mgh5, D5Rat83, D16Rat81 |
| Eden | 0.046 (0.111) | 0.280 (0.099) | 0.333 (0.095) | 1.86 (0.795) | 0.119 (0.134) | D16Rat81, RfgL1 |
| Isabela | 0.134 (0.068) | 0.314 (0.057) | 0.508 (0.089) | 2.53 (0.967) | 0.384 (0.087) | D11Mgh5, D5Rat83, D16Rat81, D10Rat20, D9Rat13, RfgL1, RfgD6, RfgL4 |
| Marielas | 0.013 (0.037) | 0.344 (0.096) | 0.368 (0.09) | 1.885 (0.824) | 0.063 (0.162) | None |
| Pinzon | 0.125 (0.127) | 0.191 (0.075) | 0.348 (0.073) | 1.886 (0.572) | 0.459 (0.153) | D11Mgh5, D5Rat83, D16Rat81, D10Rat20, RfgL1, RfgL4 |
| Sombrero Chino | 0.123 (0.122) | 0.355 (0.095) | 0.524 (0.081) | 2.616 (0.902) | 0.350 (0.135) | D11Mgh5, D5Rat83, D16Rat81, D10Rat20, D9Rat13, RfgL1, RfgL4 |
| San Cristobal | 0.152 (0.094) | 0.338 (0.071) | 0.581 (0.081) | 2.919 (0.957) | 0.438 (0.072) | D11Mgh5, D16Rat81, D10Rat20, D9Rat13, RfgL1, RfgL4 |
| Santa Cruz | 0.129 (0.096) | 0.295 (0.075) | 0.467 (0.086) | 2.368 (0.768) | 0.353 (0.098) | D11Mgh5, D5Rat83, D16Rat81, D10Rat20, D9Rat13, RfgL1, RfgD6, RfgL4 |
| North Seymour | 0.081 (0.106) | 0.358 (0.086) | 0.479 (0.099) | 2.525 (0.99) | 0.195 (0.101) | D5Rat83, D16Rat81, D10Rat20, RfgL1 |
| Santiago | 0.129 (0.122) | 0.288 (0.075) | 0.477 (0.09) | 2.492 (0.965) | 0.364 (0.122) | D11Mgh5, D5Rat83, D16Rat81, D10Rat20, RfgL1 |
| Venecia | 0.114 (0.129) | 0.231 (0.089) | 0.380 (0.096) | 2.081 (0.877) | 0.497 (0.153) | D11Mgh5, D5Rat83, D16Rat81, RfgL1, RfgL4 |
| Total | 0.108 (0.113) | 0.296 (0.021) | 0.439 (0.022) | 3.247 (1.05) | 0.328 (0.035) | All loci, all populations P < 0.001 |
| LDL-C reduction <50% (n = 242) | LDL-C reduction ≥50% (n = 151) | p-value | |
| Female | 152 (62.8%) | 99 (65.6%) | 0.58 |
| Age (years) | 63.2 ± 13 | 66.4 ± 12.1 | 0.02 |
| Duration of DM (mo, median) | 13 | 13 | 0.29 |
| Duration of statin usage (mo, median) | 56 | 88 | <0.01 |
| Smoking | 7/215 (3.3%) | 3/133 (2.3%) | 0.86 |
| Alcohol | 17/213 (8.0%) | 10/132 (7.6%) | 0.89 |
| Family history of CHD | 1/112 (0.9%) | 4/72 (5.6%) | 0.08 |
| Body mass index (kg/m2) | 26.2 ± 4.9 | 26.6 ± 6.8 | 0.58 |
| Weight before statin treatment (kg) | 65.9 ± 12.6 | 67.4 ± 13.9 | 0.28 |
| Waist circumference (cm) | 94.6 ± 11.9 | 91.2 ± 10.4 | 0.19 |
| Weight reduction | 87/227 (38.3%) | 68/138 (49.3%) | 0.04 |
| SBP (mmHg) | 131.8 ± 14.3 | 74.9 ± 11.3 | 0.11 |
| DBP (mmHg) | 74.9 ± 11.3 | 73.8 ± 10.8 | 0.33 |
| Comorbidities | |||
| CHD | 35/242 (14.5%) | 20/151 (13.2%) | 0.74 |
| Stroke | 18/242 (7.4%) | 9/151 (6.0%) | 0.57 |
| Peripheral artery disease | 6/242 (2.5%) | 5/151 (3.3%) | 0.63 |
| Aortic aneurysm | 2/242 (0.8%) | 0/151 (0.0%) | 0.26 |
| Hypertension | 167/242 (69.0%) | 124/151 (82.0%) | <0.01 |
| Chronic kidney disease | 65/242 (26.9%) | 40/151 (26.5%) | 0.94 |
| Diabetic retinopathy | 0.79 | ||
| Normal | 135/206 (65.5%) | 94/136 (69.1%) | |
| NPDR | 51/206 (24.8%) | 30/136 (22.1%) | |
| PDR | 20/206 (9.7%) | 12/136 (8.8%) | |
| Diabetic neuropathy | 0.75 | ||
| Normal | 75/105 (71.4%) | 43/58 (74.1%) | |
| Impaired Monofilament | 21/105 (20.0%) | 9/58 (15.5%) | |
| Foot ulcer | 9/105 (8.6%) | 6/58 (10.4%) | |
| Diabetic nephropathy | 0.93 | ||
| MAU ≥ 30 mg/g creatinine | 71/175 (40.6%) | 48/117 (41.0%) | |
| MAU < 30 mg/g creatinine | 104/175 (59.4%) | 69/117 (59.0%) | |
| Statin potency | 0.19 | ||
| Low-intensity statin users | 106/242 (43.8%) | 56/151 (37.1%) | |
| Moderate-intensity statin users | 136/242 (56.2%) | 95/151 (62.9%) | |
| Pre-statin blood chemistry | |||
| Total cholesterol (mg/dl) | 204.7 ± 43.8 | 242.4 ± 39.1 | <0.01 |
| Triglyceride (mg/dl) | 153.5 ± 81.0 | 161.8 ± 74.6 | 0.35 |
| HDL (mg/dl) | 50.9 ± 16.3 | 51.1 ± 13.1 | 0.95 |
| LDL-C (mg/dl) | 125.7 ± 34.1 | 160.0 ± 33.2 | <0.01 |
| HbA1C (%) | 8.3 ± 2.0 | 7.7 ± 1.6 | <0.01 |
| FBS (mg/dl, median) | 158.9 | 169.4 | 0.32 |
| Parameter name | Percent of losses |
| Total amount of Cdc14 | 3.14 |
| SPN synthesis rate | 2.81 |
| Total amount of Esp1 | 2.60 |
| Total amount of Net1 | 2.57 |
| Degradation rate of Cdc20 | 2.53 |
| PPX inactivation by Esp1 | 2.51 |
| Efficiency of Cdc14-Net1 complex (RENT) formation | 2.50 |
| Time scale for protein activation | 2.41 |
| Net1 phosphorylation by Clb2 | 2.30 |
| Total amount of Mcm1 | 2.25 |
| Transcriptional activation of CDC20 by Mcm1 | 2.17 |
| Transcriptional activation of CLB2 by Mcm1 | 2.06 |
| Sigmoidicity of protein activation | 1.99 |
| Degradation rate of Swi5 | 1.99 |
| CKI phosphorylation rate | 1.96 |
| Cdh1 inactivation rate | 1.83 |
| Total amount of SBF | 1.79 |
| Clb2 degradation by active Cdc20 | 1.76 |
| Polo activation by Clb2 | 1.67 |
| Synthesis rate of Bck2 | 1.66 |
| No. genes | DQDA | DLDA | 1NN | Tree | SVM | MPCLR | MLDA |
| 5 | 0.113 | 0.113 | 0.210 | 0.226 | 0.113 | 0.097 | 0.097 |
| 10 | 0.177 | 0.177 | 0.161 | 0.290 | 0.129 | 0.097 | 0.129 |
| 15 | 0.113 | 0.129 | 0.129 | 0.242 | 0.145 | 0.113 | 0.113 |
| 20 | 0.145 | 0.129 | 0.161 | 0.258 | 0.129 | 0.113 | 0.129 |
| 30 | 0.145 | 0.129 | 0.161 | 0.194 | 0.145 | 0.129 | 0.113 |
| 40 | 0.145 | 0.129 | 0.145 | 0.210 | 0.145 | 0.129 | 0.129 |
| 50 | 0.145 | 0.145 | 0.194 | 0.226 | 0.145 | 0.145 | 0.113 |
| PM–AM | PM/AM | |
| Anterior wall of the left ventricle | 0.21 | 0.18 |
| Left ventricular free wall | 0.11 | 0.11 |
| Posterior wall of the left ventricle | 0.10 | 0.067 |
| Ventricular septum | 0.16 | 0.10 |
| Right ventricular wall | 0.15 | 0.04 |
| Characteristic | Full cohort (n = 10,004) | Survey responders (n = 635) | p value |
| Mean age (SD), yr | 8.0 (3.8) | 8.1 (3.8) | 0.35 |
| Age 0-2 yr, n (%) | 806 (8.1%) | 51 (8.0%) | |
| Age 3-5 yr, n (%) | 2155 (21.5%) | 143 (22.5%) | |
| Age 6-8 yr, n (%) | 2307 (23.1%) | 126 (19.8%) | |
| Age 9-11 yr, n (%) | 2402 (24.0%) | 165 (26.0%) | |
| Age 12-14 yr, n (%) | 2334 (23.3%) | 150 (23.6%) | |
| Male sex, n (%) | 5942 (59.4%) | 365 (57.5%) | 0.29 |
| Smoking status | 0.22 | ||
| Non smoker | 5651 (56.5%) | 366 (57.6%) | |
| Smoker | 532 (5.3%) | 31 (4.9%) | |
| Ex smoker | 77 (0.8%) | 6 (0.9%) | |
| Passive smoker | 152 (1.5%) | 3 (0.5%) | |
| Unknown smoking status | 3592 (35.9%) | 229 (36.1%) | |
| BMI, n | 5816 | 393 | |
| Mean BMI (SD) | 17.3 (5.3) | 17.1 (5.0) | 0.32 |
| Median BMI (range) | 16.6 (5.0-49.6) | 16.7 (5.2-47.7) | 0.75 |
| Asthma duration: mean (SD), yr | 4.3 (3.6) | 4.4 (3.6) | 0.56 |
| Median (range), yr | 3.7 (0.0-15.0) | 3.9 (0.0-14.0) | 0.62 |
| Asthma controller therapy prescription at index date, n (%) | 0.437 | ||
| ICS monotherapy | 9059 (90.6%) | 575 (90.6%) | |
| LABA in fixed dose combination | 574 (5.7%) | 43 (6.8%) | |
| ICS + LABA | 124 (1.2%) | 4 (0.6%) | |
| LTRA monotherapy | 91 (0.9%) | 6 (0.9%) | |
| ICS + LTRA | 55 (0.6%) | 1 (0.2%) | |
| Other | 101 (1.0%) | 6 (0.9%) |
| Profile | WD (m) | Vp (m/s) | HF (mW/m2) |
| KR9904-7 | 4472 | 1700 | 108 |
| 1800 | 102 | ||
| 1900 | 97 | ||
| KR9904-8 | 765 | 1450 (in seawater) | 38 |
| 792 | 1500 (in seawater) | 40 | |
| 818 | 1550 (in seawater) | 41 |
| Item | Baseline (N = 153) | End-line (N = 149) | ||||
| never/rarely | some-times | usually/always | never/rarely | some-times | usually/always | |
| Helps me if the problem is affecting how well I do my job | 17 (11.1%) | 22 (14.4%) | 114 (74.5%) | 9 (6%) | 12 (8.1%) | 128 (85.9%) |
| Listens to me and encourages me to solve my problem | 20 (13.1%) | 14 (9.2%) | 119 (77.8%) | 7 (4.7%) | 8 (5.4%) | 134 (89.9%) |
| Puts me in touch with a service that can help me, if this is what I need | 34 (22.2%) | 19 (12.4%) | 100 (65.4%) | 7 (4.7%) | 16 (10.7%) | 126 (84.6%) |
| Category | Predefined criteria | |||
| Non-activated neutrophil | intact cell | lobulated nucleus | positive NE staining in cytoplasmic granulae only | |
| Activated/NET-forming neutrophil | intact cell | altered nuclear morphology | positive NE staining in cytoplasm and/or nucleus | |
| Large amounts of NETs | extracellular fibrous structures | positive PI-staining | positive NE staining | extended, confluent and/or overlapping formations occupying at least 1 mm2 |
| Minor traces of NETs | extracellular fibrous structures | positive PI-staining | positive NE staining | ≤10 small-sized (≤50 μm2) nonoverlapping items per 100 mm2 |
| Reference | PrP source | PK | Denaturation | Antibodies | Detection method | Sensitivity* |
| [30] | rMoPrP, rOvPrP, rBoPrP, rHuPrP, and mice brain | − | − | C: 11G5D: 11G5-biotin | Sandwich ELISA | 6 ng of aggregated PrP |
| [13] | BSE bovine brain and scrapie ovine brain | + | − | C: 6H4D: n.r. | Sandwich ELISA | 6 pg rPrP/well30 pg/mL |
| [33] | Scrapie sheep brain and tonsils, BSE bovine brain, and scrapie hamster brain | + | − | D: SAF70Secondary AB conjugated with peroxidase | ELISA | 3 ng rBoPrP |
| [41] | sCJD human brain | + | − | C: 1E5D: 4F7-biotinStreptavidin-biotin-DNA | IPCR | n.r. |
| [42] | Scrapie hamster brain | + | − | C: 8b4 or 7A12D: 3F4-biotinStreptavidin-biotin-DNA | IPCR | 1 × 104 PrPSc molecules/mLor 19 fg/mL |
| [22] | BSE bovine brain | − | 0.1 M GdnSCN | C: 6H4D: rabbit antiserum C15SSwine anti-rabbit Ab-HRP | Sandwich ELISA | 1 ug PrPSc/mL |
| [26] | BSE bovine brain | − | 1 M GdnHCl6 M GdnHCl | C: FH11D: 3F4-Eu | DELFIA | 36 pg PrP/well |
| [23] | BSE bovine brain, CWD white-tailed deer, mule deer, and elk brains | + | 4 M GdnHCl | C: Fab D18D: recFab HuM-P-Eu | DELFIA | 1 ng rec β-MBo2M PrP/mL |
| [27] | Scrapie mouse and hamster brain | − | 8 M GdnHCl6 M GdnHCl | C: 11G5D: 7A12, 2F8, 8F9, and 8B4-biotin | Sandwich ELISA | 0.05–5 ng rHuPrP |
| [24] | Scrapie sheep brain | − | 6 M GdnHCl | C: FH11D: 8H4-Eu | DELFIA | 200 pg rOvPrP/well |
| [28] | vCJD human spleen and brain | − | 2 M GdnHCl6 M GdnHCL | C: FH11D: 3F4-Eu | DELFIA | 10 pg rHuPrP/mL |
| [20] | BSE ovine brain and scrapie ovine brain | + | Heath | C: SAF34D: Bar224-enzyme | Sandwich ELISA | n.r. |
| [39] | Scrapie hamster and sheep brain, CWD-infected white-tailed deer brain | − | 1% SDS | C: 11F12D: 5D6-biotinStreptavidin-Rhodamine Red X | SOFIA | 10 ag rHaPrP, rMoPrP, rOvPrP, and rDePr |
| [25] | TME hamster brain | + | 3 M GdnSCN | D: 3F4Goat anti-mouse-HRP | ELISA | n.r. |
| [37] | Paraffin-embedded scrapie ship, CWD white-tailed deer and TME cattle brains | − | Denaturation buffer (not specified) | HerdChek BSE-Scrapie Ag TestC: polyanionic ligandD: anti-PrP-HRP | ELISA | n.r. |
| [29] | CJD human brain | − | 3 M GdnSCN | C: V5B2D: EM20 | DELFIA | n.r. |
| Origin | pfcrt | pfmdr1 | Pfdhfr | Pfdhps | Number (Proportion %) | ||||
| 76 | 86 | Copy Number | 51 | 59 | 108 | 437 | 540 | ||
| Honduras | K | N | 1 | N | C | S | A | K | 30 (94)§ |
| Pacific | T | Y | 1 | I | R | N | A | K | 1 (3) |
| Africa | K | Y | 1 | I | R | N | G/A | K | 1 (3) |
| Months post treatment | |||||
| UFS-QoL parameter | Statistic | Screening(N = 107) | 1(N = 107) | 3(N = 102) | 6(N = 100) |
| SSS transformeda | |||||
| Mean (SD) | 34.4 (14.70) | 28.1 (15.00) | 27.2 (15.70) | 24 (16.10) | |
| 95 % CI | (31.6, 37.2) | (25.2, 30.9) | (24.2, 30.3) | (20.8, 27.2) | |
| HRQL transformeda | |||||
| Mean (SD) | 73 (18.80) | 78.1 (18.00) | 78.5 (19.50) | 82.2 (17.30) | |
| 95 % CI | (69.4, 76.6) | (74.7, 81.6) | (74.7, 82.4) | (78.7, 85.6) | |
| Total score | |||||
| Mean (SD) | 79.3 (25.10) | 71.3 (24.40) | 70.6 (26.10) | 65.4 (24.30) | |
| 95 % CI | (74.5, 84.1) | (66.7, 76) | (65.5, 75.7) | (60.5, 70.2) |
| Sample subset | Predicted category | N | Estimated error ± SD | Baseline error | Ratio |
| All phone samples | Person | 104 | 0.037 ± 0.062 | 0.500 | 13.63 |
| All shoe samples | Person | 211 | 0.010 ± 0.020 | 0.479 | 50.26 |
| P1 phone samples | Front/back | 52 | 0.417 ± 0.206 | 0.481 | 1.15 |
| P2 phone samples | Front/back | 52 | 0.268 ± 0.180 | 0.481 | 1.79 |
| P1 shoe samples | Shoe surface | 110 | 0.705 ± 0.125 | 0.736 | 1.05 |
| P2 shoe samples | Shoe surface | 101 | 0.796 ± 0.090 | 0.732 | 0.92 |
| Plasmid pools | Infected/inoculated C. quinoa plantsa | Infectious plasmids per pool |
| T7-cDNA Pool 1 | 0/10 | 0 |
| T7-cDNA Pool 2 | 0/26 | 0 |
| T7-cDNA Pool 3 | 10/16 | 1 |
| T7-cDNA Pool 4 | 0/26 | 0 |
| 70S-cDNA Pool 1 | 5/6 | 1 |
| 70S-cDNA Pool 2 | 4/6 | 1 |
| 70S-cDNA Pool 3 | 0/12 | 0 |
| Classifier algorithms | TP rate/Recall | FP rate | Accuracy | Precision | F-measure | MCC |
| Bayes Net | 0.662 | 0.214 | 0.782 | 0.076 | 0.136 | 0.169 |
| Decision Table | 0.268 | 0.243 | 0.744 | 0.028 | 0.051 | 0.009 |
| DTNB | 0.296 | 0.205 | 0.781 | 0.037 | 0.065 | 0.035 |
| Functional Tree | 0.648 | 0.253 | 0.744 | 0.063 | 0.115 | 0.141 |
| J48 | 0.620 | 0.211 | 0.784 | 0.072 | 0.129 | 0.155 |
| Logistic Regression | 0.690 | 0.20 | 0.797 | 0.084 | 0.149 | 0.190 |
| LWL (J48 + KNN) | 0.676 | 0.213 | 0.783 | 0.077 | 0.139 | 0.175 |
| Naive Bayes | 0.718 | 0.199 | 0.799 | 0.087 | 0.156 | 0.201 |
| NB Tree | 0.493 | 0.229 | 0.764 | 0.054 | 0.097 | 0.098 |
| Random Forest | 0.592 | 0.196 | 0.798 | 0.074 | 0.131 | 0.154 |
| SVM | 0.788 | 0.233 | 0.767 | 0.082 | 0.148 | 0.203 |
| Genotypic combination | Casesn (%) | Controlsn (%) | χ2 (P value)a | χ2 (P value)b |
| GSTM1/GSTT1: | ||||
| +,+/+,+ | 36 (34.6) | 112 (53.8) | 10.2 (0.001) | |
| −,−/+,+ | 56 (53.8) | 80 (38.5) | 6.6 (0.01) | 10.3 (0.006) |
| +,+/−,− | 12 (11.5) | 16 (7.7) | 1.2 (0.3) | |
| −,−/−,− | 0 (0.0) | 0 (0.0) | NA | NA |
| rs4646903 T>C/ rs1048943 A>G: | ||||
| TT/AA | 72 (69.2) | 120 (57.7) | 3.9 (0.04) | |
| TC/AG | 8 (7.7) | 24 (11.5) | 1.1 (0.3) | |
| TC/AA | 20 (19.2) | 64 (30.8) | 4.7 (0.03) | 13.9 (0.003) |
| CC/GG | 4 (3.8) | 0 (0.0) | 4.0 (0.047) | |
| rs1801133 C>T/ rs1801394 A>G: | ||||
| CC/AA | 0 (0.0) | 8 (3.8) | 4.2 (0.04) | |
| CC/AG | 56 (53.8) | 120 (57.7) | 0.4 (0.5) | |
| CC/GG | 20 (19.2) | 32 (15.4) | 0.7 (0.4) | |
| CT/AA | 0 (0.0) | 8 (3.8) | 4.2 (0.04) | 20.4 (0.0004) |
| CT/AG | 20 (19.2) | 40 (19.2) | 0.0 (1.0) | |
| CT/GG | 8 (7.7) | 0 (0.0) | 8.3 (0.0001) |
| KEGG level 2 pathway | Day 0 | Day 2 | Day 7 | Day 14 |
| Amino acid metabolism | 10.03 ± 0.75A | 9.99 ± 0.54A | 9.80 ± 0.63AB | 8.94 ± 1.22B |
| Biosynthesis of other secondary metabolites | 0.74 ± 0.13AB | 0.79 ± 0.09A | 0.78 ± 0.11AB | 0.66 ± 0.13B |
| Cell motility | 2.00 ± 0.62A | 1.92 ± 0.37AB | 1.74 ± 0.39AB | 1.41 ± 0.56B |
| Cellular processes and signaling | 3.70 ± 0.54A | 3.58 ± 0.37AB | 3.62 ± 0.5A | 3.01 ± 0.77B |
| Energy metabolism | 5.95 ± 0.24AB | 5.82 ± 0.2A | 5.89 ± 0.2A | 6.17 ± 0.34B |
| Genetic information processing | 2.68 ± 0.13A | 2.73 ± 0.11AB | 2.79 ± 0.1AB | 2.88 ± 0.2B |
| Metabolism | 2.37 ± 0.12A | 2.32 ± 0.13AB | 2.29 ± 0.12AB | 2.19 ± 0.21B |
| Metabolism of other amino acids | 1.71 ± 0.12A | 1.61 ± 0.07B | 1.54 ± 0.09B | 1.58 ± 0.09B |
| Metabolism of terpenoids and polyketides | 1.82 ± 0.32A | 1.8 ± 0.24A | 1.7 ± 0.25AB | 1.41 ± 0.47B |
| Nucleotide metabolism | 4.15 ± 0.34A | 4.31 ± 0.36AB | 4.4 ± 0.33AB | 4.67 ± 0.5B |
| Replication and repair | 9.24 ± 1.05A | 9.24 ± 0.9A | 9.6 ± 1.04A | 11.01 ± 1.85B |
| Signal transduction | 1.61 ± 0.23A | 1.54 ± 0.16A | 1.44 ± 0.18AB | 1.23 ± 0.36B |
| Transcription | 2.46 ± 0.17A | 2.71 ± 0.14B | 2.7 ± 0.23B | 2.44 ± 0.17A |
| Translation | 6.61 ± 1.3A | 6.61 ± 1.37A | 6.96 ± 1.39A | 8.88 ± 2.54B |
| Xenobiotics biodegradation and metabolism | 2.61 ± 0.32A | 2.39 ± 0.26AB | 2.12 ± 0.24B | 2.07 ± 0.48B |
| Never smoked | Former smoker | Current smoker | Ever smoker | |||||||
| Region | Countryb | Studyc | Rate | Weight | Rate | Weight | Rate | Weight | Rate | Weight |
| Canada | JAIN | 10.6 | 22.6 | 16.6 | 14.9 | 65.9 | 44.5 | 41.5 | 68.4 | |
| USA | ANDERS | 31.4 | 36.8 | 191.4 | 143.6 | |||||
| BROWN2 | 18.9 | 413.3 | 132.1 | 336.8 | 132.1 | 336.8 | 130.7 | 748.8 | ||
| BUFFLE | 9.8 | 20.0 | 32.7 | 17.5 | 46.7 | 61.6 | 39.6 | 130.4 | ||
| COMSTO | 25.7 | 8.5 | 63.4 | 5.6 | 163.5 | 21.4 | 123.2 | 33.3 | ||
| DORGAN | 13.2 | 48.4 | 51.4 | 217.4 | ||||||
| HAENSZ | 9.0 | 42.4 | 12.8 | 1.7 | 9.8 | 15.3 | 10.0 | 17.4 | ||
| LOMBA2 | 20.2 | 57.9 | 10.7 | 47.2 | ||||||
| OSANN | 12.9 | 48.7 | 76.4 | 42.6 | 157.6 | 159.9 | 129.3 | 235.9 | ||
| OSANN2 | 11.1 | 19.0 | 19.8 | 6.3 | 38.6 | 25.2 | 33.0 | 39.6 | ||
| WYNDE3 | 16.6 | 17.3 | 31.5 | 23.0 | ||||||
| WYNDE4 | 11.2 | 18.4 | 6.7 | 2.1 | ||||||
| WYNDE6 | 13.0 | 62.4 | 65.6 | 126.3 | 156.5 | 265.1 | 178.5 | 250.4 | ||
| SC America | Cuba | JOLY | 17.8 | 21.7 | 54.4 | 24.4 | ||||
| UK | ALDERS | 8.2 | 8.6 | 29.5 | 24.4 | |||||
| DOLL | 3.3 | 4.5 | 6.4 | 6.7 | ||||||
| Scandinavia | Norway | KREYBE | 21.7 | 9.6 | 16.1 | 5.9 | ||||
| Sweden | NOU | 29.8 | 15.6 | 26.3 | 6.8 | |||||
| Sweden | SVENSS | 8.8 | 18.5 | 16.0 | 9.0 | 34.3 | 22.1 | 26.9 | 31.8 | |
| W Europe | Germany | BECHER | 2.9 | 1.0 | 31.7 | 17.4 | ||||
| France | BENHAM | 5.8 | 18.2 | 14.0 | 3.9 | |||||
| Greece | KATSOU | 24.3 | 28.2 | 40.7 | 1.8 | 45.2 | 9.1 | 44.4 | 11.3 | |
| Austria | VUTUC | 19.6 | 52.8 | 31.2 | 9.5 | 29.2 | 12.0 | 30.1 | 21.1 | |
| E Europe | Hungary | ABRAHA | 17.2 | 17.2 | 45.1 | 20.7 | ||||
| Poland | STASZE | 8.6 | 13.9 | 9.4 | 1.0 | |||||
| Japan | SOBUE | 39.7 | 204.0 | 77.5 | 16.1 | 56.1 | 34.8 | 62.0 | 55.6 | |
| WAKAI | 44.0 | 81.8 | 110.9 | 2.3 | 48.0 | 7.5 | 58.1 | 10.8 | ||
| China | HK | CHAN | 50.9 | 29.4 | 99.1 | 17.4 | ||||
| China | GAO | 64.3 | 305.7 | 69.8 | 46.1 | |||||
| HK | KOO | 60.0 | 35.0 | 96.4 | 22.3 | |||||
| HK | LAMTH | 100.4 | 73.4 | 187.6 | 31.3 | |||||
| HK | LAMWK | 94.0 | 49.2 | 198.0 | 20.5 | |||||
| HK | LAMWK2 | 75.5 | 32.8 | 133.2 | 17.4 | |||||
| China | WUWILL | 45.7 | 184.2 | 62.8 | 124.3 | |||||
| China | XU3 | 34.5 | 7.9 | 44.8 | 3.5 | |||||
| China | ZHOU | 54.0 | 77.0 | 77.2 | 6.8 | |||||
| Other | S Korea | CHOI | 20.9 | 50.9 | 13.5 | 4.3 | ||||
| Singapore | SEOW | 66.1 | 30.8 | 156.2 | 7.8 |
| Measurand | Description | Nominal Value | Tolerance |
| L | Length | 11.80 mm | ±0.03 mm |
| a, c | Length | 3.00 mm | ±0.03 mm |
| b | Length | 1.50 mm | ±0.02 mm |
| d | Length | 1.35 mm | ±0.02 mm |
| A, B, C, D, E, F | Thickness | 1.00 mm | ±0.02 mm |
| Neutropenia | N |
| G2-G3 | 3 (10%) |
| G4 | 1 (4%) |
| Anemia | N |
| G2-G3 | 3 (10%) |
| G4 | _ |
| Thrombocytopenia | N |
| G2-G3 | 1(4%) |
| G4 | _ |
| N | Ne | He | He + siRNA | |
| CLK1 | 1 | 5.30 | 19.70 | 6.57 |
| CGADD45A | 1 | 1.33 | 0.71 | 1.01 |
| IGFPB4 | 1 | 2.06 | 1.21 | 2.14 |
| MCL1 | 1 | 1.69 | 1.16 | 2.09 |
| BIRC2 | 1 | 0.73 | ||
| BIRC4 | 1 | 0.76 | ||
| BIRC3 | 1 | 0.93 | 2.52 | |
| ING | 1 | 1.08 | ||
| JUN | 1 | 1.50 | 1.23 | 2.66 |
| MAP2K1 | 1 | 0.82 | 0.78 | |
| TANK | 1 | 5.42 | ||
| BAX | 1 | 1.53 | 0.87 | |
| IGFBP2 | 1 | 1.13 | 0.77 | 0.92 |
| MDM2 | 1 | 3.90 | 1.28 | 2.28 |
| BAK1 | 1 | 2.35 | 0.69 | 1.69* |
| CDKN1A | 1 | 2.61 | 0.65 | 1.41 |
| GPX1 | 1 | 2.27 | 0.59 | 1.09 |
| CDC2 | 1 | 0.89 | 0.29 | 0.35 |
| PCNA | 1 | 2.11 | 1.06 | |
| AKT2 | 1 | 4.46 | 2.31 | 1.90 |
| E2F5 | 1 | 1.23 |
| Group A | Group B | ||
| (URL + RIRS) | (URL alone) | ||
| Variable | 72 patients | 72 patients | P |
| Follow-up, mean, (SD), range (months) | 18.9 (10.2),14–32 | 18.5 (9.4),12–34 | 0.675 |
| Auxiliary treatment rate, no. (%) | 4 (5.6) | 50 (69.4) | <0.001 |
| Cause of auxiliary treatment in follow-up, no. (%) | |||
| Renal colic | 2 (2.8) | 10 (13.9) | |
| Repetatus urinary tract infection | 0 | 6 (8.3) | |
| Stone induced hematuria | 2 (2.8) | 10 (13.9) | |
| Increase in creatinine levels | 0 | 4 (5.6) | |
| Patient’s desire (increased stone duration) | 0 | 20 (27.8) | |
| Medical expulsive treatment, no. (%) | 2 (2.8) | 4 (5.6) | <0.001 |
| Patients required auxiliary procedures, no (%). | 2 (2.8) | 46 (63.9) | <0.001 |
| Auxiliary procedures, no | 2 | 62 | - |
| URL | 0 | 10 | |
| FURL | 0 | 12 | |
| ESWL | 0 | 26 | |
| PCNL | 2 | 4 | |
| Procedure per patient, mean, (SD), range | 1.03 (0.17),1–2 | 1.86 (0.76),1–3 | <0.001 |
| Medical cost per patient, mean, (SD), range (RMB) | 16431.2 (3425.3) | 13125.1 (2165.4) | <0.001 |
| 14985.3–21325.4 | 9105.1–15143.2 |
| NOS | ||||||||
| Study design | First author, year | Participants | Age range (years) | Definition of tooth loss | Focal point | Dose-response | Coding | Score |
| Cross-sectional study | Randolph, 2001 | 3,050 Mexican American | 65-99 | 15+ | F | NA | 011 11 1 | 5* |
| Klein, 2004 | 2,764 American | 53-96 | 1+ | F | NA | 011 11 1 | 5* | |
| Tanaka, 2005 | 1,002 Japanese pregnant women | 29.8 on average | 1+ | S | NA | 010 11 0 | 3 | |
| Hanioka, 2007 | 2,200 Japanese | 60-94 | Total tooth loss | S | NA | 101 10 1 | 4 | |
| Musacchio, 2007 | 1,226 Italian males | 65+ | Total tooth loss | S | NA | 101 11 1 | 5* | |
| Ojima, 2007 | 1,314 Japanese | 20-39 | 1+ | S | 3/4 levels | 111 01 1 | 5* | |
| Hanioka, 2007 | 3,999 Japanese | 40-94 | 9+ | S | 3/4 levels | 111 11 1 | 6* | |
| Mundt, 2007 | 2,501 German | 25-59 | 15th percentile | F | 3 levels | 111 11 1 | 6* | |
| Yanagisawa, 2009 | 547 Japanese males | 55-75 | 9+ | S | 3 levels | 110 11 0 | 4 | |
| Yanagisawa, 2010 | 1,088 Japanese males | 40-75 | 9+ | S | 3 levels | 110 11 0 | 4 | |
| NOS | ||||||||
| Study design | First author, year | Participants | Age range (years) | Duration of observation | Focal point | Dose-response | Coding | Score |
| Cohort study | Slade, 1997 | 693 Australian | 60+ | 2 years | F | NA | 10 01 110 | 4 |
| Krall, 2006 | 789 American males | 21-84 | 36 years | S | NA | 00 11 111 | 5* | |
| Okamoto, 2006 | 740 Japanese males | 30-59 | 4 years | S | 3 levels | 00 10 110 | 3 | |
| Dietrich, 2007 | 43,112 American male health professionals | 40-75 | 16 years | S | 5 levels | 01 11 111 | 6* | |
| Cunha-Cruz, 2008 | 12,264 American HMO members | 45-61 | 3 years | A | NA | 00 10 110 | 3 |
| Males (n=195) | Females (n=228) | P | |||
| Anthropometric variables | |||||
| Height (cm) | 175.0 | 6.8 | 162.5 | 6.7 | 0.000 |
| Weight (kg) | 66.2 | 12.2 | 59.8 | 14.6 | 0.000 |
| Body mass index (kg/m2) | 21.6 | 3.6 | 22.7 | 3.3 | 0.016 |
| ≥ 25 | 13.3 | 26.7 | 0.000 | ||
| ≥ 30 | 4.6 | 10.5 | 0.000 | ||
| Waist (cm) | 75.9 | 8.6 | 75.7 | 11.2 | ns |
| ≥ 94 (M); ≥80 (F) | 5.6 | 28.5 | 0.000 | ||
| ≥102 (M); ≥88 (F) | 2.1 | 14.9 | 0.000 | ||
| Waist/height ratio | 43.3 | 3.5 | 46.6 | 4.6 | 0.000 |
| ≥0.50 | 9.7 | 26.7 | 0.000 | ||
| Waist/hip ratio | 0.83 | 0.07 | 0.82 | 0.09 | 0.017 |
| Fat percent | 16.8 | 6.7 | 26.8 | 7.9 | 0.000 |
| Cardiovascular risk factors | |||||
| Daily cigarette smoking | 20.0 | 3.1 | 0.000 | ||
| Alcohol on ≥6 days/month | 19.5 | 5.7 | 0.000 | ||
| Physical activity >3000 MET-min/wk | 64.4 | 18.4 | 0.000 | ||
| Systolic blood pressure (mmHg) | 121.2 | 11.2 | 110.5 | 10.0 | 0.000 |
| Diastolic blood pressure (mmHg) | 67.0 | 8.1 | 69.1 | 8.0 | 0.008 |
| Total cholesterol (mmol/l) | 4.06 | 0.81 | 4.23 | 0.86 | 0.031 |
| LDL-cholesterol (mmol/l) | 2.28 | 0.74 | 2.56 | 0.81 | 0.000 |
| HDL-cholesterol (mmol/l) | 1.46 | 0.43 | 1.36 | 0.39 | 0.011 |
| Triglycerides (mmol/l) | 0.69 | 0.28 | 0.69 | 0.28 | ns |
| Glucose (mmol/l) | 5.24 | 0.58 | 4.96 | 0.58 | 0.000 |
| Uric acid (mmol/l) | 0.33 | 0.08 | 0.24 | 0.70 | 0.000 |
| KEGG pathwaysa | Percentage of significant CM genesb |
| Ribosome | 13.3 |
| Cell adhesion molecules (CAMs) | 10.0 |
| Antigen processing and presentation | 8.3 |
| Oxidative phosphorylation | 6.7 |
| Hematopoietic cell lineage | 6.7 |
| Leukocyte transendothelial migration | 6.7 |
| ECM-receptor interaction | 6.7 |
| Cytokine-cytokine receptor interaction | 5.0 |
| Glycolysis/Gluconeogenesis | 5.0 |
| Fructose and mannose metabolism | 5.0 |
| Regulation of actin cytoskeleton | 5.0 |
| T cell receptor signaling pathway | 5.0 |
| Jak-STAT signalling pathway | 5.0 |
| Axon guidance | 5.0 |
| Valine, leucine and isoleucine degradation | 5.0 |
| Focal adhesion | 5.0 |
| Tight junction | 5.0 |
| MAPK signaling pathway | 3.3 |
| B cell receptor signaling pathway | 3.3 |
| Tryptophan metabolism | 3.3 |
| Propanoate metabolism | 3.3 |
| Butanoate metabolism | 3.3 |
| Bile acid biosynthesis | 3.3 |
| Fatty acid metabolism | 3.3 |
| Adipocytokine signaling pathway | 3.3 |
| Neuroactive ligand-receptor interaction | 3.3 |
| Neurodegenerative Disorders | 3.3 |
| Samples | Polyomavirus No. (%) | Ref. virus No. (%) | ||||
| Total No. | MWPyV | JCPyV | BKPyV | EBV | ||
| Healthy children | ||||||
| No. 200 | Tonsil | 100 | 6 (6 %) | 0 | 0 | 38 (38 %) |
| Adenoid | 100 | 1 (1 %) | 0 | 0 | 37 (37 %) | |
| Blood | 100 | 0 | 0 | 0 | 12 (12 %) | |
| Urine | 100 | 0 | 0 | 0 | – | |
| Stoola | 100 | 0 | 0 | 0 | – | |
| Total No. | 500 | 7 (1.4 %) | 0 | 0 | – | |
| Autoimmune children | ||||||
| No. 40 | Blood | 40 | 0 | 6 (15 %) | 0 | 2 (5 %) |
| Urine | 40 | 0 | 40 (100 %) | 5 (12.5 %) | – | |
| Total No. | 80 | 0 | 46 (57.5 %) | 5 (6.25 %) | – |
| Socioeconomic position | Total group | Boys | Girls | |||
| Crude OR (95% CI) | AdjustedbOR (95% CI) | Crude OR (95% CI) | AdjustedcOR (95% CI) | Crude OR (95% CI) | AdjustedcOR (95% CI) | |
| Maternal educationd | ||||||
| High education | 1.0 (Reference) | 1.0 (Reference) | 1.0 (Reference) | |||
| Low education | 1.08 (1.00–1.18) | 0.94 (0.86–1.03) | 1.04 (0.93–1.17) | 0.93 (0.82–1.05) | 1.13 (1.00–1.27) | 0.96 (0.85–1.09) |
| Paternal educationd | ||||||
| High education | 1.0 (Reference) | 1.0 (Reference) | 1.0 (Reference) | |||
| Low education | 1.22*** (1.11–1.33) | 1.05 (0.96–1.16) | 1.21** (1.07–1.37) | 1.08 (0.94–1.23) | 1.23** (1.07–1.40) | 1.03 (0.90–1.19) |
| Maternal occupatione | ||||||
| Employed | 1.0 (Reference) | 1.0 (Reference) | 1.0 (Reference) | |||
| Unemployed–able to work | 0.78** (0.65–0.93) | 0.67*** (0.56–0.81) | 0.80 (0.63–1.03) | 0.71** (0.55–0.92) | 0.76* (0.58–0.99) | 0.63*** (0.48–0.82) |
| Paternal occupatione | ||||||
| Employed | 1.0 (Reference) | 1.0 (Reference) | 1.0 (Reference) | |||
| Unemployed–able to work | 0.78** (0.65–0.94) | 0.72*** (0.60–0.88) | 0.91 (0.70–1.17) | 0.87 (0.67–1.12) | 0.66** (0.49–0.87) | 0.59*** (0.44–0.78) |
| Substrate | Relative Activity (%) |
| o-nitrophenyl-β-d-galactopyranoside | 100 |
| p-nitrophenyl-β-d-galactopyranoside | 422 |
| p-nitrophenyl-β-d-glucopyranoside | <1 |
| p-nitrophenyl-β-d-xylopyranoside | <1 |
| p-nitrophenyl-β-d-lactopyranoside | <1 |
| p-nitrophenyl-β-d-glucuronide | <1 |
| p-nitrophenyl-a-d-galactopyranoside | <1 |
| p-nitrophenyl-β-l-arabinopyranoside | <1 |
| p-nitrophenyl-β-d-cellobioside | <1 |
| Database | SI | VO | VD | AD | RMSD | MD |
| IO on URNC | 80.56 | 67.80 | 22.84 | 0.003 | 0.092 | 92.54 |
| Questions (n = 10) | Answers | ||
| D | N | A | |
| The explanation of the GLIA dimensions is clear | 2 | 2 | 6 |
| The explanation of the use of the eGLIA tool is clear | 0 | 1 | 9 |
| The eGLIA tool is easy to use | 2 | 1 | 7 |
| The tool questions are easy to understand and apply | 2 | 6 | 2 |
| The tool questions were relevant to assessing implementability | 0 | 4 | 6 |
| The eGLIA tool helped identify obstacles to implementation | 1 | 1 | 8 |
| The eGLIA helped to judge recommendations systematically | 0 | 1 | 9 |
| Will use the eGLIA more often | 1 | 3 | 6 |
| haematocrit 25% | haematocrit 20% | P value | |||
| Median | IQR | Median | IQR | ||
| CI during CPB(l/m2/min) | 3.2 | 3.0-3.6 | 3.2 | 3.0-3.5 | 0.40 |
| Temperature during CPB(°C) | 35.5 | 35.0-35.9 | 35.7 | 35.4-36.0 | 0.21 |
| Cumulative norepinephrine-dosage during CPB (mg) | 0.06 | 0.04-0.09 | 0.05 | 0.02-0.09 | 0.41 |
| Urine volume during CPB(mL) | 148 | 80-250 | 150 | 86-177 | 0.94 |
| duration of anaesthesia(min) | 300 | 290-320 | 313 | 295-338 | 0.16 |
| duration of surgery(min) | 200 | 160-220 | 203 | 175-243 | 0.21 |
| CPB time(min) | 74 | 52-83 | 71 | 63-81 | 0.72 |
| aortic cross clamp time(min) | 45 | 32-58 | 44 | 38-49 | 0.81 |
| Length of ICU treatment(hours) | 22 | 20-24 | 23 | 21-27 | 0.29 |
| Length of mechanical ventilation(hours) | 10 | 8-13 | 11 | 10-14 | 0.10 |
| APACHE II score | 14 | 10-19 | 16 | 14-17 | 0.13 |
| Characteristic | Category | n | Proportion (%) |
| Sex | Male | 1021 | 45.6 |
| Female | 1220 | 54.4 | |
| Age (years) | 15–24 | 263 | 11.7 |
| 25–34 | 564 | 25.2 | |
| 35–44 | 399 | 17.8 | |
| 45–54 | 436 | 19.5 | |
| 55–64 | 276 | 12.3 | |
| ≥65 | 303 | 13.5 | |
| Education level | No formal education | 100 | 4.5 |
| Elementary school | 200 | 8.9 | |
| Junior middle school | 543 | 24.2 | |
| Senior middle school | 667 | 29.8 | |
| Bachelor level | 654 | 29.2 | |
| Master level or above | 71 | 3.2 | |
| Unanswered | 6 | 0.2 | |
| Marital status | Unmarried | 363 | 16.2 |
| Married | 1764 | 78.7 | |
| Divorced | 13 | 0.6 | |
| Widowed | 89 | 4.0 | |
| Unanswered | 12 | 0.5 | |
| Labor force status | Employed * | 1505 | 67.2 |
| Unemployed | 230 | 10.3 | |
| Retired | 322 | 14.4 | |
| Student | 184 | 8.2 | |
| Monthly income (RMB) | <2000 | 562 | 25.1 |
| 2000–3000 | 758 | 33.8 | |
| 3000–5000 | 616 | 27.5 | |
| 5000–10,000 | 225 | 10.0 | |
| >10,000 | 40 | 1.8 | |
| Unanswered | 40 | 1.8 | |
| Hukou | Urban | 1379 | 61.5 |
| Rural | 862 | 38.5 |
| AllN = 1135 | MaleN = 627 | FemaleN = 508 | pa | |||||||
| Mean | (SD) | Mean | (SD) | Mean | (SD) | |||||
| Energy intake (kcal) | 2274 | (246) | 2337 | (238) | 2198 | (233) | <0.001 | |||
| Energy intake (kJ) | 9782 | (1057) | 10049 | (1023) | 9453 | (1004) | <0.001 | |||
| Macronutrients | ||||||||||
| Proteins (g) | 57.9 | (13.6) | 62.3 | (14.5) | 52.4 | (9.9) | <0.001 | |||
| Carbohydrates (g) | 309.0 | (105.9) | 327.9 | (102.4) | 285.7 | (105.5) | <0.001 | |||
| Total sugar (g) | 133.8 | (16.0) | 146.4 | (9.6) | 118.2 | (4.4) | <0.001 | |||
| Fat (g) | 94.7 | (9.4) | 96.7 | (9.3) | 92.2 | (8.9) | <0.001 | |||
| SFA (g) | 31.8 | (3.7) | 33.7 | (3.2) | 29.3 | (2.7) | <0.001 | |||
| MUFA (g) | 26.9 | (3.2) | 27.8 | (3.1) | 25.8 | (3.1) | <0.001 | |||
| PUFA (g) | 10.4 | (1.5) | 11.0 | (1.4) | 9.6 | (1.1) | <0.001 | |||
| Micronutrients | ||||||||||
| Cholesterol (mg) | 236.1 | (26.1) | 237.4 | (26.3) | 234.4 | (25.8) | 0.060 | |||
| Fiber (g) | 33.4 | (3.7) | 35.4 | (3.2) | 31.0 | (2.6) | <0.001 | |||
| Vitamin C (mg) | 136.5 | (14.8) | 135.4 | (14.7) | 137.8 | (14.9) | 0.007 | |||
| Vitamin A (μg) | 581.2 | (71.3) | 577.4 | (70.5) | 586.0 | (72.1) | 0.044 | |||
| Vitamin B12 (μg) | 2.4 | (1.0) | 2.4 | (1.0) | 2.3 | (1.01) | 0.178 | |||
| Folate (μg) | 271.0 | (28.9) | 270.9 | (29.0) | 271.2 | (28.8) | 0.886 | |||
| Iron (mg) | 7.2 | (0.8) | 7.2 | (0.8) | 7.2 | (0.8) | 0.144 | |||
| Zinc (mg) | 6.5 | (0.5) | 6.5 | (0.5) | 6.4 | (0.5) | 0.176 | |||
| Calcium (mg) | 922.6 | (72.9) | 920.5 | (73.5) | 925.2 | (72.2) | 0.280 | |||
| Food groups | ||||||||||
| Pasta/rice (g) | 58.5 | (26.5) | 57.9 | (26.5) | 59.1 | (26.5) | 0.552 | |||
| Meat (g) | 37.8 | (27.4) | 37.0 | (27.1) | 38.8 | (27.7) | 0.412 | |||
| Fish (g) | 13.5 | (17.8) | 14.3 | (18.6) | 12.4 | (16.8) | 0.060 | |||
| Cheese (g) | 19.2 | (19.3) | 19.1 | (19.2) | 19.2 | (19.3) | 0.851 | |||
| Eggs (g) | 9.6 | (13.4) | 9.6 | (13.3) | 9.6 | (13.5) | 0.857 | |||
| Vegetables (g) | 42.5 | (62.9) | 40.4 | (62.2) | 45.1 | (63.7) | 0.214 | |||
| Fruit (g) | 56.1 | (65.7) | 55.2 | (66.6) | 57.3 | (64.7) | 0.592 | |||
| Sweets (g) | 27.1 | (38.7) | 26.1 | (35.5) | 28.5 | (42.2) | 0.233 | |||
| Fast foods (g) | 44.8 | (56.1) | 47.5 | (57.1) | 41.4 | (54.8) | 0.072 | |||
| Snacks (g) | 18.9 | (24.3) | 19.2 | (24.2) | 18.5 | (24.5) | 0.623 | |||
| Sugary Drinks (mL) | 58.3 | (85.0) | 60.1 | (85.0) | 56.1 | (85.1) | 0.450 |
| Both sexes (95% CI) | Male (95% CI) | Female (95% CI) | |
| Life expectancy, y | |||
| 1990 | 75.4 | 71.8 | 78.8 |
| 1995 | 75.8 | 72.5 | 78.9 |
| The Average HALex | |||
| All ages | |||
| 1990 | 0.87 (0.87, 0.88) | 0.88 (0.88, 0.88) | 0.87 (0.86, 0.87) |
| 1995 | 0.87 (0.86, 0.87) | 0.87 (0.87, 0.88) | 0.86 (0.86, 0.86) |
| 0–14 years | |||
| 1990 | 0.93 (0.93, 0.93) | 0.93 (0.93, 0.93) | 0.94 (0.93, 0.94) |
| 1995 | 0.93 (0.93, 0.93) | 0.93 (0.92, 0.93) | 0.94 (0.93, 0.94) |
| 15–24 years | |||
| 1990 | 0.92 (0.92, 0.92) | 0.93 (0.92, 0.93) | 0.91 (0.91, 0.91) |
| 1995 | 0.91 (0.91, 0.91) | 0.92 (0.92, 0.92) | 0.91 (0.90, 0.91) |
| 25–44 years | |||
| 1990 | 0.90 (0.90, 0.90) | 0.90 (0.90, 0.91) | 0.89 (0.89, 0.89) |
| 1995 | 0.89 (0.88, 0.89) | 0.9 (0.89, 0.90) | 0.88 (0.88, 0.88) |
| 45–64 years | |||
| 1990 | 0.82 (0.82, 0.83) | 0.83 (0.82, 0.83) | 0.82 (0.81, 0.82) |
| 1995 | 0.81 (0.81, 0.82) | 0.82 (0.82, 0.83) | 0.81 (0.80, 0.81) |
| 65+ years | |||
| 1990 | 0.73 (0.72, 0.74) | 0.74 (0.74, 0.75) | 0.72 (0.71, 0.73) |
| 1995 | 0.73 (0.72, 0.73) | 0.73 (0.73, 0.74) | 0.72 (0.71, 0.73) |
| Variable | Proportion % | N |
| Membership is a hallmark of professional person | ||
| Agree | 66.9 | 99 |
| Disagree | 33.1 | 49 |
| Chiropractic professional associations increase the visibility of the chiropractic profession within the UK | ||
| Yes | 78.4 | 116 |
| No | 21.6 | 32 |
| Forgo membership of the existing UK chiropractic associations if a suitable company providing indemnity insurance is available? | ||
| Yes | 35.1 | 52 |
| No | 64.9 | 96 |
| Grade | Evidence levels | Description |
| A | Ia, Ib | Requires at least one randomised controlled trial as part of the body of literature of overall good quality and consistency addressing the specific recommendation |
| B | IIa, IIb, III | Requires availability of well-conducted clinical studies but no randomised clinical trials on the topic of recommendation |
| C | IV | Requires evidence from expert committee reports or opinions and/or clinical experience of respected authorities. Indicates absence of directly applicable studies of good quality |
| Group 1 (Critical DSS) | Group 2 (Relative DSS) | Group 3 (Non- DSS) | p-value | |
| Vertebral Levels | 27 | 148 | 15 | |
| Gender | F: 11 | F: 19 | F: 4 | 0.65 |
| M: 6 | M: 10 | M:10 | ||
| Mean Age at Surgery (Years (±SD)) | F: 68.0 (11.0) | F: 67.1 (10.4) | F: 64.5 (9.0) | 0.26 |
| M: 67.0 (10.3) | M: 62.1 (12.9) | M: 47.4 (26.8) | ||
| Mean LF thickness (mm (±SD)) | R: 3.8 (1.4) | R: 3.4 (1.7) | R: 3.1 (0.6) | R: 0.45 |
| L: 4.0 (1.7) | L: 3.4 (1.6) | L: 3.3 (1.1) | L: 0.30 | |
| Mean Spinal Canal Diameter (mm (±SD)) | 12.7 (1.3) | 15.4 (1.3) | 17.7 (2.6) | <0.001* |
| Mean Disc Height (mm (±SD)) | 10.4 (2.3) | 9.9 (2.5) | 9.7 (2.9) | 0.58 |
| BMI (±SD) | 22.8 (2.3) | 24.3 (3.2) | 26.7 (3.7) | 0.06 |
| N level (kg ha−1) | Plant height (cm) | Productive tiller hill−1 | LAI | Days to maturity (d) | Number of spikelets panicle−1 | Fertility (%) | 1000-grain weight (g) |
| 0 | 96 | 8.6 | 4.6 | 105 | 83 | 89.6 | 24.6 |
| 100 | 100 | 9.1 | 5.2 | 108 | 111 | 85.3 | 27.6 |
| 125 | 103 | 12.1 | 5.4 | 110 | 121 | 88.6 | 26.7 |
| 150 | 106 | 13.4 | 5.6 | 112 | 134 | 92.0 | 28.1 |
| 175 | 106 | 14.2 | 6.0 | 115 | 142 | 90.0 | 28.1 |
| 200 | 108 | 14.7 | 6.1 | 120 | 145 | 91.0 | 28.4 |
| LSD0.05 | nsa | 1.2 | 0.1 | 3.2 | 8.7 | ns | 1.05 |
| Soil EC | Nematode gall rating | P uptake | GY | RHL | RHD | DSW | |
| Soil EC | 1 | ||||||
| Nematode gall rating | –0.07 | 1 | |||||
| P uptake | 0.37*** | 0.03 | 1 | ||||
| GY | 0.08 | 0.04 | –0.22* | 1 | |||
| RHL | –0.14 | –0.09 | –0.33*** | –0.07 | 1 | ||
| RHD | 0.07 | 0.08 | –0.02 | –0.04 | 0 | 1 | |
| DSW | –0.41 | –0.1 | –0.33*** | 0.16 | –0.04 | –0.02 | 1 |
| Characteristics | No. patients (%) | Median levels (interquartile range) | p |
| All patients | 221 (100 %) | 2.228 (0.416) | |
| Age (years) | 0.773a | ||
| ≤ 40 | 33 (14.9 %) | 2.160 (0.566) | |
| 41–55 | 94 (42.5 %) | 2.215 (0.410) | |
| 56–70 | 70 (31.7 %) | 2.291 (0.456) | |
| > 70 | 24 (10.9 %) | 2.198 (0.327) | |
| Menopausal status | 0.497b | ||
| Premenopausal | 113 (51.1 %) | 2.200 (0.447) | |
| Postmenopausal | 108 (48.9 %) | 2.250 (0.379) | |
| Tumor size | 0.188a | ||
| pT1 (≤2 cm) | 109 (49.3 %) | 2.239 (0.356) | |
| pT2 (2–5 cm) | 105 (47.5 %) | 2.237 (0.505) | |
| pT3/pT4 (>5 cm) | 7 (3.2 %) | 1.830 (0.614) | |
| Tumor gradec | 0.700a | ||
| I | 37 (16.7 %) | 2.207 (0.288) | |
| II | 77 (34.8 %) | 2.233 (0.366) | |
| III | 101 (45.7 %) | 2.264 (0.491) | |
| ER status | <0.001b | ||
| Positive | 125 (56.6 %) | 2.168 (0.407) | |
| Negative | 96 (43.4 %) | 2.311 (0.452) | |
| PgR status | 0.003b | ||
| Positive | 104 (47.1 %) | 2.159 (0.392) | |
| Negative | 117 (52.9 %) | 2.302 (0.425) | |
| HER2 status | 0.121b | ||
| Positive | 26 (11.8 %) | 2.299 (0.399) | |
| Negative | 195 (88.2 %) | 2.215 (0.432) |
| Disease stage | Least-squared mean (SEM) spleen weight (mg) | ||
| Negative control (naïve + vehicle) | Positive control (EAE + vehicle) | Teriflunomide (EAE + treatment) | |
| Onset | 467.4 (21.5) | 474.1 (18.5) | n/a |
| Acute attack | 464.8 (11.1) | 347.6 (6.1)‡ | 395.0 (9.6)† |
| Remission | 513.6 (17.4) | 417.4 (10.8)‡ | 472.3 (10.6)** |
| Relapse | 513.0 (9.2) | 437.5 (9.7)* | 511.2 (23.8)* |
| Characteristic | Frequency (%) |
| Age in yrs (mean ± SD) | 80.6 ± 9.3 |
| Race | |
| White | 25 (49) |
| Black | 23 (45) |
| Hispanic | 3 (6) |
| Gender | |
| Female | 42 (82) |
| Male | 9 (18) |
| Language | |
| English | 34 (67) |
| Non-English | 17 (33) |
| Insurance | |
| Medicare | 42 (82) |
| Medicaid | 2 (4) |
| Medicare managed care | 3 (6) |
| Medicare advantage (i.e., senior care options) | 3 (6) |
| Other | 1 (2) |
| Hospital length of stay in days (mean ± SD) | 6.1 ± 3.4 |
| Never-married | Married | Widowed | Divorced/separated | |
| Men | ||||
| Number of deaths from all causes | 5325 | 19995 | 3321 | 6533 |
| Number of deaths from all circulatory diseases | 1679 | 6031 | 1145 | 2025 |
| Person-years of exposure | 277508 | 1818415 | 99705 | 406618 |
| Women | ||||
| Number of deaths from all causes | 2027 | 10515 | 7490 | 3938 |
| Number of deaths from all circulatory diseases | 509 | 2248 | 2262 | 829 |
| Person-years of exposure | 175001 | 1670393 | 400626 | 447650 |
| Regulome DB score | (A) | (B) | (C) |
| No. of GWAS + LD SNPs (191482) | No. of (A) SNPs under VDR peaks (572) | No. of (B) SNPs under VDR peaks enriched for trait association (42) | |
| 1a | 21 | 1 | 0 |
| 1b | 272 | 15 | 1 |
| 1c | 6 | 0 | 0 |
| 1d | 148 | 3 | 0 |
| 1e | 7 | 0 | 0 |
| 1f | 3182 | 43 | 5 |
| 2a | 369 | 34 | 2 |
| 2b | 3182 | 109 | 7 |
| 2c | 137 | 8 | 0 |
| Total | 7324 | 213 | 15 |
| Lamb | Weight (kg) | Age (days) | Total lavage (mL/kg) | COtpud (mL/kg/min) initial–end | EVLWItpud (mL/kg) initial | EVLWItpud (mL/kg) end | EVLWItpdd (mL/kg) initial | EVLWItpdd (mL/kg) end | EVLWIgrav (mL/kg) | Final PEEP (mmHg) | Final OI |
| 1 | 8.1 | 21 | 125 | 221–243 | 12.8 | 17.0 | 11.1 | 15.8 | 15.1 | 7 | 19.7 |
| 2 | 7.4 | 21 | 303 | 254–66 | NA | NA | 12.3 | NA | 19.4 | 18 | 21.2 |
| 3 | 4.1 | 7 | 293 | 257–215 | 28.6 | 28.6 | 17.2 | 38.6 | 28.5 | 10 | 50.3 |
| 4 | 7.4 | 14 | 68 | 279–460 | 19.6 | NA | 11.5 | NA | 18.8 | 10 | 25.0 |
| 5 | 10.2 | 17 | 294 | 177–246 | 5.3 | 19.2 | 10.2 | 29.9 | 17.1 | 20 | 45.6 |
| 6 | 9.4 | 18 | 191 | 217–380 | 12.6 | 18.6 | 11.5 | 34.1 | 20.1 | 20 | 54.0 |
| 7 | 7.1 | 14 | 135 | 133–151 | 22.8 | NA | 16.3 | NA | 16.5 | 16 | 27.7 |
| 8 | 8.0 | 15 | 420 | 165–120 | 9.0 | 15.2 | 14.6 | 30.4 | 21.5 | 25 | 36.1 |
| 9 | 9.9 | 16 | 242 | 144–165 | 6.5 | NA | 21.6 | NA | 18.2 | 20 | 70.4 |
| 10 | 11.5 | 19 | 184 | 152–173 | 8.0 | NA | 8.8 | 49.1 | 29.8 | 15 | 52.2 |
| 11 | 12.3 | 22 | 98 | 150–117 | 7.0 | 33.3 | NA | NA | 24.3 | 15 | 56.8 |
| 12 | 5.6 | 4 | 0 | 373 | 17.5 | 17.5 | NA | NA | 13.3 | 5 | – |
| 13 | 6.7 | 4 | 0 | 253 | 15.8 | 15.8 | NA | NA | 11.8 | 5 | – |
| Characteristics | Healthy donors (n = 68) | Patients (n = 109) |
| Age—yearsa | 32 (28–40) | 37 (23–48) |
| Gender male—no. (%) | 32 (47%) | 38 (34.9%) |
| Caucasian race—% | 100% | 100% |
| Unrelated families | NA | 76 |
| Age at onset—yearsa | NA | 6 (3–14) |
| C1-INH-HAE—no. (%) | ||
| Type I | NA | 104 (95.4%) |
| Type II | NA | 5 (4.5%) |
| Prophylaxis—no. (%) | ||
| Tranexamic acid | NA | 4 (3.8%) |
| Attenuated androgens | NA | 15 (10%) |
| ≥12 attacks/year—no. (%) | NA | 40 (36.7%) |
| Items | Results of two–way repeated measures ANOVA | |||||
| Variables | SS (Type III) | DF | MF | F | p-value | |
| Systolic blood pressure (mmHg) | Time | 3778.705 | 1 | 3778.705 | 15.089 | <0.001 |
| Time* like or dislike | 0.250 | 1 | 0.250 | 0.001 | 0.975 | |
| Like or dislike | 2825.875 | 1 | 2825.875 | 4.338 | 0.043 | |
| Diastolic blood pressure (mmHg) | Time | 87.547 | 1 | 87.547 | 1.811 | 0.186 |
| Time* like or dislike | 8.002 | 1 | 8.002 | 0.166 | 0.686 | |
| Like or dislike | 292.517 | 1 | 292.517 | 0.702 | 0.407 | |
| Pulse rate (bpm) | Time | 172.163 | 1 | 172.163 | 11.987 | 0.001 |
| Time* like or dislike | 12.891 | 1 | 12.891 | 0.898 | 0.349 | |
| Like or dislike | 843.857 | 1 | 843.857 | 6.159 | 0.017 |
| RR interval expressions involved in QTc calculations | Intra-subject comparison with individual QT/RR hysteresis | ||||||
| Individual hysteresis | Universal hysteresis | 10 s RR average | 3-interval RR average | Universal hysteresis | 10 s RR average | 3-interval RR average | |
| QTc SD [ms] | 5.49 ± 1.10 | 5.52 ± 1.11 | 10.49 ± 1.94 | 11.41 ± 2.11 | 0.03 ± 0.11 | 5.00 ± 1.51 | 5.92 ± 1.68 |
| QTcL SD [ms] | 5.67 ± 1.14 | 5.70 ± 1.15 | 10.68 ± 2.00 | 11.58 ± 2.17 | 0.02 ± 0.08 | 5.00 ± 1.52 | 5.91 ± 1.68 |
| QTcP SD [ms] | 6.01 ± 1.21 | 6.04 ± 1.22 | 11.37 ± 2.07 | 12.31 ± 2.25 | 0.02 ± 0.01 | 5.37 ± 1.65 | 6.30 ± 1.81 |
| QTcF SD [ms] | 6.68 ± 1.71 | 6.72 ± 1.72 | 12.80 ± 2.09 | 14.08 ± 2.28 | 0.04 ± 0.09 | 6.08 ± 2.06 | 7.36 ± 2.25 |
| Facit-fatigue score | Mean (SE)* | P change from pre-SBRT# |
| Pre-SBRT | 43.78 (1.43) | − |
| Post-SBRT (Month) | ||
| 1 | 40.66 (1.43) | 0.02 |
| 3 | 42.81 (1.43) | 0.37 |
| 6 | 43.07 (1.45) | 0.87 |
| 9 | 41.13 (1.45) | 0.40 |
| 12 | 43.18 (1.43) | 0.61 |
| Characteristics | Adjusted OR (95% CI) | p-Value | |
| Age percentile (years) | |||
| 1–20 (18–46.9) | Reference | ||
| 21–40 (47–59.9) | 0.51 (0.18–1.39) | 0.19 | |
| 41–60 (60–66.9) | 0.58 (0.20–1.64) | 0.30 | |
| 61–80 (67–74.9) | 0.30 (0.09–1.00) | 0.05 | |
| 80–100 (75+) | 0.33 (0.10–1.10) | 0.73 | |
| Highest level of education attained | |||
| High school equivalent of year 10 or lower | Reference | ||
| High school completion | 1.15 (0.35–3.80) | 0.82 | |
| Diploma or trade certificate | 1.77 (0.74–4.25) | 0.20 | |
| Bachelor’s or postgraduate degree | 2.57 (0.99–6.67) | 0.05 | |
| Reason for attending 1 | |||
| To discuss symptoms, treatments or tests for diagnosed condition | Reference | ||
| To discuss symptoms or tests for undiagnosed condition | 0.62 (0.06–6.47) | 0.69 | |
| To receive tests or treatments for diagnosed condition | 4.83 (1.29–18.04) | 0.02 | |
| For a routine exam for a diagnosed condition | 1.92 (0.52–7.05) | 0.33 | |
| Appointment frequency in the last 6 months (continuous) | 1.41 (1.00–1.99) | 0.05 | |
| Health insurance coverage | |||
| Private health insurance | Reference | ||
| No private health insurance coverage | 2.10 (0.96–4.60) | 0.06 |
| Author, year | Age at diagnosis | Presentation | TSH receptor antibody | Cervical thyroidectomy before diagnosis struma ovarii | Prior pelvic exam that result negative | Ovarian scan before abdominal surgery | Ovarian findings | Years after Graves’ disease diagnosis | ||||||
| Exoph-thalmos | Thyroid bruit | Pelvic pressure symptoms | Pleural effusion | Ascites | Side | Maximum diameter (cm) | Malignancy | |||||||
| Kampers, 1970 [7] | 64 | Yes | NA | NA | NA | NA | NA | Yes | NA | NA | NA | NA | No | 18 |
| Lefort, 1981 [9] | 38 | Yes | NA | NA | No | No | Positive | NA | NA | Positive | Right | 7 | No | 12 |
| Lazarus, 1987 [15] | 48 | Yes | NA | NA | NA | Few | Positive | Yes | 14 years | Positive | Left | 9 | No | 24 |
| Kung, 1990 [10] | 40 | No | NA | No | NA | No | Positive | No | 23 weeks | NA | Right | 5 | No | 4 |
| Banyot, 1995 [1] | 30 | No | No | Yes | NA | NA | Negative | No | NA | Positive | Right | 7 | NA | 0 |
| Grandet, 2000 [16] | 78 | NA | NA | NA | NA | Few | NA | Yes | NA | Positive | Bilateral | 10 | No | 4 |
| Kano, 2000 [8] | 50 | NA | NA | NA | NA | Yes | Positive | No | NA | NA | Left | 7 | Yes | 0 |
| Mimura, 2001 [6] | 26 | No | No | NA | NA | NA | Positive | No | NA | Positive | Left | 16 | No | 4 |
| Sussman, 2002 [17] | 53 | No | NA | No | NA | NA | NA | No | NA | NA | Right | 7.5 | Yes | 5 |
| Bartel, 2005 [18] | 54 | NA | NA | NA | NA | NA | Positive | Yes | NA | Positive | Left | NA | No | 23 |
| Guida, 2005 [11] | 42 | Yes | NA | NA | No | Marked | NA | Yes | NA | Negative | Right | 12 | No | 1 |
| Teale, 2006 [4] | 36 | Yes | NA | NA | NA | NA | Positive | Yes | NA | NA | Left | 13.5 | No | 8 |
| Chiofalo, 2007 [19] | 42 | No | NA | Yes | NA | Yes | Positive | Yes | NA | Positive | Right | 12 | No | 0.5 |
| Wong, 2009 [2] | 44 | Yes | Yes | Yes | NA | NA | Positive | Yes | NA | NA | Left | NA | Yes | 1 |
| Anastasilakis, 2013 [3] | 49 | No | NA | NA | Yes | Moderate | Positive | No | NA | NA | Right | 18 | No | 2 |
| Our case, 2015 | 56 | Yes | No | No | No | Minimal | Positive | Yes | Not done | Positive | Right | 8 | No | 23 |
| Pif + VMY vs. VMY | |||
| Up-regulated | Fold | Down-regulated | Fold |
| EndoG | 8.77809E+30 | FIGF | −6.10476E+11 |
| CIDEB | 1.9687E+12 | ANGPT4 | −6.017072518 |
| PRSS54 | 1299.03 | GSK3A | −5.35 |
| BIK | 19.44 | INCA1 | −5.18 |
| MAP3K9 | 18.19 | TNFSF14 | −4.01 |
| ERBB3 | 15.17 | GDF15 | −4.01 |
| BRAT1 | 7.48 | HGF | −3.89 |
| CISH | 6.73 | BIRC3 | −3.41 |
| FADD | 6.73 | LIF | −2.85 |
| TP63 | 6.63 | NTF3 | −2.77 |
| CBX6 | 6.23 | DRD2 | −2.75 |
| SRC | 5.98 | SNCG | −2.67 |
| CBX7 | 5.98 | MAGEA9 | −2.67 |
| HDAC4 | 5.24 | ZNF385D | −2.67 |
| RASSF4 | 4.49 | CRIP3 | −2.67 |
| TRPM8 | 4.49 | TNFSF15 | −2.45 |
| ERBB2 | 4.06 | NAP1L6 | −2.45 |
| AKT1 | 3.84 | TENC1 | −2.33 |
| UNC5B | 3.83 | NRCAM | −2.23 |
| TNFRSF10D | 3.74 | DNAJB7 | −2.21 |
| NLRP12-14 | 3.74 | MAGEB2 | −2.19 |
| TP73 | 3.74 | PPAPDC2 | −2.14 |
| ARHGEF18 | 3.55 | PRSS12 | −2.14 |
| TNFRSF25 | 3.49 | CFLAR | −2.07 |
| FASTK | 3.48 | GADD45A | −2.07 |
| Antenatal Survey (n=180) | Postnatal Survey (n=228) | |
| Median age at participation (IQR) | 27.4 years (24.8, 30.9) | 28.3 years (24.8, 31.9) |
| Marital status | ||
| Married | 96/180 (53 %) | 99/228 (43 %) |
| Cohabiting | 50/180 (28 %) | 84/228 (37 %) |
| Single | 34/180 (19 %) | 45/228 (20 %) |
| Living as only adult in household | 12/179 (7 %) | 28/225 (12 %) |
| Disclosure of HIV status | ||
| To husband/partner or family or friend(s) | 162/178 (91 %) | 210/222 (95 %) |
| To no one at all | 16/178 (9 %) | 12/222 (5 %) |
| Smoking, alcohol and drug usea | ||
| Current smoker | 47/178 (26 %) | 74/225 (33 %) |
| Current alcohol use | 15/179 (8 %) | 18/224 (8 %) |
| Ever used marijuana | 25/178 (14 %) | 27/228 (12 %) |
| Ever used illicit drugs other than marijuana | 23/174 (13 %) | 23/215 (11 %) |
| Use of support servicesa | ||
| Currently using support group | 10/180 (5 %) | 33/228 (14 %) |
| Currently using peer counselling | 9/180 (5 %) | 85/228 (37 %) |
| Currently using social services | 39/180 (22 %) | 82/228 (36 %) |
| Currently using adherence programme | 4/180 (2 %) | 43/228 (19 %) |
| On ART for 4 weeks preceding surveyb | 180/180 (100 %) | 101/228 (44 %) |
| Thin Film | C3H8 (1 ppm) | |
| Trecovery (s) | Tresponse (s) | |
| CuO | 20 | 12 |
| Au:CuO | 30 | 34 |
| Ag:CuO | 26 | 18 |
| Cr:CuO | 10 | 24 |
| Pd:CuO | 35 | 15 |
| Pt:CuO | 55 | 12 |
| Sb:CuO | 92 | 30 |
| Si:CuO | 150 | 100 |
| Characteristic | Impaired†and Inadequate Reading Ability (S-TOFHLA < 16)‡ | Impaired†and Limited Reading Ability (S-TOFHLA < 23)‡ |
| Sensitivity (%) | 67 (58, 76) | 54 (47, 61) |
| Specificity (%) | 82 (80, 85) | 83 (81, 86) |
| Positive Predictive Power | 0.31 (0.25, 0.37) | 0.40 (0.34, 0.47) |
| Negative Predictive Power | 0.96 (0.94, 0.97) | 0.90 (0.88, 0.92) |
| Likelihood Ratio Positive (LR +) | 3.79 (3.12, 4.6) | 3.28 (2.67, 4.03) |
| Likelihood Ratio Negative (LR -) | 0.40 (0.30, 0.53) | 0.55 (0.47, 0.65) |
| Area under the ROC curve | 0.78 (0.73,0.83) | 0.73 (0.69, 0.78) |
| Subscales | Pretest | Posttest |
| Mean (SD) | Mean (SD) | |
| Physical | 55.5 (35.8) | 53.5 (38.1) |
| Role | 57.8 (32.4) | 59.8 (28.6) |
| Bodily pain | 59.0 (33.8) | 61.0 (37.5) |
| General health | 49.0 (24.6) | 49.8 (26.2) |
| Vitality | 48.5 (28.3) | 46.5 (28.6) |
| Social | 72.0 (28.4) | 71.5 (29.9) |
| Role/emotional | 62.3 (31.4) | 73.8 (28.2) |
| Mental health | 53.3 (13.1) | 63.3 (19.6) |
| PCS | 55.3 (24.0) | 55.3 (26.3) |
| MCS | 59.8 (19.1) | 63.8 (20.3)* |
| Characteristics | Median kappa coefficient (range) |
| Characteristics day 1 | |
| Position of the pronuclei | 0.74 (0.65-0.77) |
| Size of the pronuclei | 0.44 (0.33-0.57) |
| Cytoplasmic halo | -0.34 (-0.62-0) |
| Characteristics day 2 | |
| Number of blastomeres | 0.82 (0.80-0.93) |
| Degree of fragmentation | 0.58 (0.53-0.62) |
| Size of blastomeres | 0.59 (0.48-0.62) |
| Characteristics day 3 | |
| Number of blastomeres | 0.67 (0.57-0.82) |
| Degree of fragmentation | 0.59 (0.51-0.65) |
| Size of blastomeres | 0.55 (0.47-0.76) |
| Decision | 0.75 (0.72-0.88) |
| Sample | D10 (μm) | D50 (μm) | D90 (μm) | CI (%) |
| Untreated | 8.39 ± 0.24 a | 23.43 ± 0.32 a | 54.50 ± 0.61 a | 56.29 ± 0.08 a |
| MCC1.0 h | 5.35 ± 0.02 b | 15.90 ± 0.10 b | 40.43 ± 0.78 c | 47.89 ± 0.06 b |
| MCC2.0 h | 4.36 ± 0.06 c | 13.63 ± 0.21 c | 40.40 ± 1.51 c | 41.12 ± 0.09 c |
| MCC3.0 h | 4.18 ± 0.01 d | 13.20 ± 0.17 d | 48.73 ± 6.55 b | 36.44 ± 0.09 d |
| MCC4.0 h | 4.24 ± 0.04 c,d | 13.20 ± 0.17 d | 40.80 ± 3.70 c | 34.81 ± 0.08 e |
| MCC6.0 h | 3.76 ± 0.08 e | 11.50 ± 0.20 e | 29.97 ± 0.72 d | 31.63 ± 0.01 f |
| MCC8.0 h | 3.51 ± 0.07 f | 10.53 ± 0.06 f | 27.77 ± 0.47 d,e | 29.75 ± 0.03 g |
| MCC12.0 h | 3.21 ± 0.03 g | 9.72 ± 0.03 g | 24.70 ± 0.35 e | 25.24 ± 0.07 h |
| MCC16.0 h | 3.17 ± 0.09 g | 9.43 ± 0.12 g | 24.17 ± 0.40 e | 25.17 ± 0.02 h |
| Gene | Tissue | n | Effect size (se) | p value |
| MRPS6 | Aortic artery | 197 | 0.15 (0.05) | 3.5 × 10−3 |
| MRPS6 | Coronary artery | 118 | 0.14 (0.11) | 0.22 |
| MRPS6 | Tibial artery | 285 | 0.15 (0.05) | 1.8 × 10−3 |
| MRPS6 | Atrial appendage | 159 | −0.02 (0.09) | 0.88 |
| MRPS6 | Left ventricle (heart) | 190 | −0.16 (0.10) | 0.09 |
| MRPS6 | Liver | 97 | −0.19 (0.14) | 0.17 |
| MRPS6 | Whole blood | 338 | −0.09 (0.04) | 0.04 |
| KCNE2 | Aortic artery | 197 | 0.13 (0.07) | 0.06 |
| KCNE2 | Coronary artery | 118 | 0.09 (0.11) | 0.43 |
| KCNE2 | Tibial artery | 285 | 0.15 (0.06) | 0.02 |
| KCNE2 | Atrial appendage | 159 | 0.13 (0.16) | 0.41 |
| KCNE2 | Left ventricle (heart) | 190 | −0.06 (0.14) | 0.71 |
| KCNE2 | Liver | 97 | 0.05 (0.15) | 0.31 |
| KCNE2 | Whole blood | 338 | 8.40 × 10−3 (0.15) | 0.92 |
| Name of the test | Procedure | Results |
| Alkaloids | Mayer's test | + |
| Hager's test | + | |
| Saponins | Froth test | − |
| Flavonoids | Shinoda's test | + |
| Lead acetate test | + | |
| Tannins | Gelatin test | + |
| Glycosides | Libermann's Test | − |
| Keller Killiant's Test | − | |
| Polyphenols | Test for polyphenol | + |
| Total alkaloid content (mg of RE/g dry weight of CRE) | 0.0000703 | |
| Total flavonoid content (mg of QE/g dry weight of CRE) | 0.077825 | |
| Total polyphenol content (mg of GAE/g dry weight of CRE) | 0.110772 |
| Environmental Samples | 16S rRNA Positives (%) |
| Plant biofilms | 12/18 (66.7 a) |
| Water filtrates | 12/12 (100 a) |
| Plant detritus | 8/15 (53.3 a) |
| Soils | 8/15 (53.3 a) |
| Classification | Name of model |
| Peripheral NP | Neuroma model |
| Chronic constriction injury model (CCI) | |
| Partial sciatic nerve ligation model (PSL or Seltzer | |
| model) | |
| L5/L6 spinal nerve ligation model (SNL) | |
| Spared nerve injury | |
| Sciatic cryoneurolysis model (SCN) | |
| Inferior caudal trunk resection model (ICTR) | |
| Sciatic inflammatory neuritis model (SIN) | |
| Postherpetic neuralgia model (PHN) | |
| Diabetic neuropathic pain model | |
| Drugs-induced peripheral neuropathy model | |
| Bone cancer pain models | |
| HIV-induced neuropathy model | |
| Trigeminal Neuralgia model | |
| Orofacial pain model | |
| Central NP | Excitotoxic spinal cord injury (ESCI) |
| Photochemical SCI model | |
| Weight-drop or contusive SCI (Allen's Model) | |
| Spinal hemisection |
| SNP ID | Model | Genotype | Gastric cancer | Colorectal cancer | ||||
| OR (95 % CI) | P value | OR (95 % CI) | P value | |||||
| rs10795668 | Allele model | A/G | 0.94 | (0.80–1.10) | 0.419 | 0.86 | (0.70–1.02) | 0.082 |
| Overdominant model | A/G | 0.97 | (0.76–1.23) | 0.78 | 0.89 | (0.68–1.17) | 0.41 | |
| Log - additive model | – | 0.95 | (0.80–1.13) | 0.56 | 0.86 | (0.71–1.04) | 0.12 | |
| rs10788473 | Allele model | T/C | 1.04 | (0.88–1.22) | 0.655 | 0.98 | (0.82–1.17) | 0.817 |
| Overdominant model | T/C | 0.86 | (0.68–1.10) | 0.24 | 1.06 | (0.81–1.39) | 0.66 | |
| Log - additive model | – | 1.04 | (0.88–1.24) | 0.63 | 0.91 | (0.75–1.11) | 0.34 | |
| rs1665650 | Allele model | A/G | 1.02 | (0.86–1.21) | 0.85 | 1.09 | (0.91–1.30) | 0.363 |
| Overdominant model | A/G | 0.77 | (0.60–0.99) | 0.038* | 1.04 | (0.80–1.36) | 0.78 | |
| Log - additive model | – | 1 | (0.83–1.20) | 0.99 | 1.16 | (0.95–1.42) | 0.15 | |
| rs12413624 | Allele model | A/T | 0.9 | (0.77–1.05) | 0.191 | 0.81 | (0.68–0.96) | 0.018* |
| Overdominant model | A/T | 0.91 | (0.72–1.17) | 0.47 | 0.9 | (0.69–1.18) | 0.44 | |
| Log - additive model | – | 0.93 | (0.77–1.11) | 0.39 | 0.81 | (0.66–0.98) | 0.032* | |
| rs10500715 | Allele model | G/T | 1.09 | (0.90–1.32) | 0.387 | 1.04 | (0.85–1.28) | 0.699 |
| Overdominant model | G/T | 1.1 | (0.85–1.42) | 0.48 | 0.94 | (0.71–1.26) | 0.69 | |
| Log - additive model | – | 1.07 | (0.87–1.32) | 0.53 | 1.05 | (0.83–1.32) | 0.7 | |
| rs3824999 | Allele model | C/A | 0.94 | (0.80–1.10) | 0.432 | 1.14 | (0.95–1.35) | 0.151 |
| Overdominant model | C/A | 0.81 | (0.64–1.04) | 0.1 | 0.98 | (0.75–1.28) | 0.9 | |
| Log - additive model | – | 0.92 | (0.77–1.10) | 0.37 | 1.13 | (0.93–1.37) | 0.21 | |
| rs3802842 | Allele model | C/A | 1.02 | (0.88–1.20) | 0.774 | 1.19 | (1.00–1.40) | 0.541 |
| Overdominant model | C/A | 0.99 | (0.77–1.26) | 0.91 | 1.09 | (0.84–1.42) | 0.52 | |
| Log - additive model | – | 0.96 | (0.81–1.14) | 0.68 | 1.14 | (0.94–1.37) | 0.18 |
| PC (%) | Δbx | |||||||
| −3km | −2km | −1km | 0km | 1km | 2km | 3km | ||
| Δby | -3 km | 96.87 | 97.16 | 96.63 | 97.23 | 97.48 | 97.55 | 97.09 |
| -2 km | 96.85 | 96.86 | 97.03 | 97.23 | 97.26 | 97.10 | 97.06 | |
| -1 km | 97.21 | 96.80 | 96.37 | 96.91 | 96.62 | 96.95 | 97.00 | |
| 0 km | 97.43 | 97.37 | 96.79 | 97.24 | 97.26 | 97.43 | 96.95 | |
| 1 km | 97.19 | 97.04 | 97.67 | 97.52 | 97.11 | 97.16 | 97.17 | |
| 2 km | 97.07 | 97.20 | 97.17 | 96.90 | 97.62 | 97.67 | 97.32 | |
| 3 km | 97.26 | 97.08 | 97.28 | 96.88 | 97.19 | 97.17 | 97.11 |
| Control(n=8) | NE(n=8) | |
| Body | 40.4±1.84 | 36.4±1.28* |
| Brain | 1.31±0.11 | 1.27±0.08 NS |
| Cerebellum | 0.164±0.010 | 0.155±0.012 NS |
| Wild-Type Sibling | Mutant | |||||
| Gene | Control | 200 μM Neomycin | % HCs Remaining | Control | 200 μM Neomycin | % HCs Remaining |
| Ciliary axoneme and intraflagellar transport | ||||||
| dync2h1 (w46) | 12.13 ± 1.15 | 1.05 ± 0.33 | 8.65 | 8.65 ± 1.27 | 5.63 ± 1.26 | 65.13 |
| P < 0.0001 | P < 0.0001 | |||||
| wdr35 (w150) | 11.37 ± 0.92 | 1.84 ± 0.63 | 16.18 | 10.10 ± 0.89 | 6.17 ± 1.41 | 61.89 |
| P = 0.0002 | P < 0.0001 | |||||
| ift88 (tz288) | 12.38 ± 1.78 | 1.17 ± 0.71 | 9.42 | 9.27 ± 0.65 | 4.43 ± 1.70 | 47.74 |
| P < 0.0001 | P < 0.0001 | |||||
| traf3ip1 (tp49d) | 11.6 ± 1.43 | 1.08 ± 0.55 | 9.34 | 6.73 ± 0.79 | 4.78 ± 0.69 | 71.04 |
| P < 0.0001 | P < 0.0001 | |||||
| arl13b (hi459Tg) | 11.78 ± 1.54 | 1.65 ± 0.85 | 14.00 | 11.92 ± 1.01 | 1.30 ± 0.37 | 10.88 |
| P = 0.9556 | P = 0.7145 | |||||
| Transition zone | ||||||
| cc2d2a (w38) | 11.10 ± 1.72 | 1.53 ± 0.69 | 13.78 | 12.33 ± 1.93 | 3.68 ± 0.47 | 29.85 |
| P = 0.0975 | P = 0.0023 | |||||
| cc2d2a (w123) | 12.78 ± 2.5 | 1.17 ± 0.38 | 9.13 | 12.73 ± 2.24 | 3.05 ± 0.48 | 23.95 |
| P = 0.9973 | P = 0.0373 | |||||
| mks1 (w152) | 12.34 ± 0.86 | 1.26 ± 0.46 | 10.21 | 12.17 ± 0.83 | 2.88 ± 0.65 | 23.66 |
| P = 0.6768 | P < 0.0001 | |||||
| cep290 (fh378) | 12.30 ± 1.02 | 1.44 ± 0.34 | 11.70 | 12.19 ± 1.04 | 2.24 ± 0.88 | 18.34 |
| P = 0.7217 | P = 0.0244 |
| Antimicrobial resistance pattern | S. flexneri (6) | S. dysenteriae (4) | S. boydii (2) |
| AMP-AMC-CHL-CMX-STR | 1(16.7) | ||
| AMP-CHL-CMX-STR-TET | 1(16.7) | 1(25) | 2(100) |
| AMP-CHL-CMX-STR | 3(50) | 1(75) | |
| AMP-CHL-CMX | 1(16.7) |
| Pretreatment | Sample Point | Total Isolates | |||
| Point 1 | Point 2 | Point 3 | Point 4 | ||
| S | 35/5 | 55/0 | 22/0 | 47/4 | 159/9 |
| C | 34/6 | 34/2 | 36/1 | 40/4 | 144/13 |
| F | 51/12 | 46/1 | 32/4 | 29/3 | 158/20 |
| M | 47/11 | 57/3 | 24/0 | 37/3 | 165/17 |
| U | 43/10 | 41/3 | 26/1 | 33/4 | 143/18 |
| T | 4/0 | 3/0 | 3/0 | 11/1 | 21/1 |
| Total Isolates | 214/44 | 236/9 | 143/6 | 197/19 | 790/78 |
| Species/Serotypes | nb | Strains (source) | Species/Serotypes | nb | Strains (source) |
| Enterobacter sakazakii | 35 | ATCC 29544 (CIP) | Salmonella Hadar | 2 | (AFSSA) |
| CIP 104951 (CIP) | Salmonella Typhimurium | 2 | (AFSSA, BgVV) | ||
| CIP 104952 (CIP) | Salmonella Typhi | 1 | (AFSSA) | ||
| ES 1, ES 2, ES 5, | Salmonella Kottbuss | 1 | (AFSSA) | ||
| ES 9, ES 10, ES 16, | Salmonella Virchow | 1 | (AFSSA) | ||
| ES 17, ES 18, ES 19, | Salmonella Derby | 1 | (AFSSA) | ||
| ES 20, ES 23, ES 28, | Salmonella Enteritidis | 2 | (AFSSA, BgVV) | ||
| ES 29, ES 30, ES 32, | Salmonella Bredeney | 1 | (BgVV) | ||
| ES 34, ES 37, ES 40, | Salmonella Agona | 1 | (AFSSA) | ||
| ES 41, ES 44, ES 52, | Salmonella Indiana | 1 | (AFSSA) | ||
| ES 53 (IFF) | Salmonella Saintpaul | 1 | (AFSSA) | ||
| ES8110043 (BM) | Salmonella Montevideo | 1 | (AFSSA) | ||
| ES8311015 (BM) | Salmonella Anatum | 1 | (AFSSA) | ||
| ES8704047 (BM) | Salmonella Dublin | 1 | (BgVV) | ||
| ATCC 51329 (BM) | Salmonella (II) | 1 | (BgVV) | ||
| ES8405628 (BM) | Salmonella Senftenberg | 1 | (AFSSA) | ||
| ES810726 (BM) | Salmonella (IIIa) | 1 | (AFSSA) | ||
| HMPL118 (AFSSA) | Salmonella (IIIb) | 1 | (BgVV) | ||
| HMPL194 (AFSSA) | Salmonella Arizonae | 1 | (AFSSA) | ||
| HMPL1937 (AFSSA) | Serratia fonticola | 1 | CIP 78.64 (CIP) | ||
| HMPL1740 (AFSSA) | Serratia liquefaciens | 4 | (CTSCCV, AFSSA) | ||
| Enterobacter gergoviae | 1 | ATCC 33028 (CIP) | Serratia marcescens | 3 | (AFSSA) |
| Enterobacter hormaechei | 1 | ATCC 49162 (CIP) | Raoultella planticola | 1 | CIP 81.36 (CIP) |
| Enterobacter kobei | 1 | ATCC BAA-260 (CIP) | Yersinia enterocolitica | 2 | (AFSSA) |
| Enterobacter pyrinus | 1 | ATCC 49851 (CIP) | Aeromonas putrefaciens | 1 | (AFSSA) |
| Enterobacter sp. | 1 | CIP 53.120 (CIP) | Aeromonas hydrophila | 1 | (AFSSA) |
| Enterobacter amnigenus | 4 | (CTSCCV, AFSSA) | Acinetobacter sp. | 1 | (AFSSA) |
| Enterobacter cloacae | 18 | (AFSSA) | Acinetobacter baumanii | 1 | CIP 70.34 (CIP) |
| Enterobacter aerogenes | 5 | (AFSSA) | Acinetobacter johnsonii | 1 | (AFSSA) |
| Enterobacter agglomerans | 4 | (AFSSA) | Acinetobacter lwoffii | 1 | CIP 104272 (CIP) |
| Enterobacter intermedius | 3 | (AFSSA) | Pseudomonas fluorescens | 2 | (AFSSA) |
| Citrobacter freundii | 8 | (AFSSA) | Pseudomonas aeruginosa | 2 | (AFSSA) |
| Citrobacter koseri | 6 | i.e. ATCC 27028 (CIP, AFSSA) | Stenotrophomonas maltophilia | 1 | (AFSSA) |
| Citrobacter sp. | 1 | (AFSSA) | Campylobacter jejuni | 2 | CCUG 11284 |
| Citrobacter farmeri | 1 | (AFSSA) | Alcaligenes tolerans | 1 | CIP55.94 (CIP) |
| Escherichia coli (i.e. O86; O127:H6; O157:H7; O55; O145; O113:H2; O103) | 12 | i.e. NCTC12900 (AFSSA) | Alcaligenes faecalis | 1 | CIP62.32 (CIP) |
| Listeria monocytogenes | 5 | i.e. clip 74902 (CIP, AFSSA) | |||
| Escherichia vulneris | 1 | (AFSSA) | Listeria innocua | 1 | (AFSSA) |
| Escherichia hermanii | 1 | (AFSSA) | Listeria weshimeri | 1 | ATCC 35897 |
| Escherichia fergusonnii | 1 | (AFSSA) | Listeria seeligeri | 1 | Clip 12513 (CIP) |
| Buttiauxella agrestis | 1 | (AFSSA) | Listeria ivanovii | 1 | Clip 74915 (CIP) |
| Hafnia alvei | 5 | (AFSSA) | Enterococcus faecalis | 2 | (AFSSA) |
| Klebsiella pneumoniae | 8 | ATCC 13883 | Enterococcus faecium | 1 | (AFSSA) |
| Klebsiella terrigena | 1 | (CTSCCV) | Bacillus cereus | 4 | (AFSSA) |
| Klebsiella oxytoca | 3 | (AFSSA) | Bacillus subtilis | 1 | CIP52.65 (CIP) |
| Morganella. morganii | 1 | (AFSSA) | Bacillus megaterium | 1 | (AFSSA) |
| Pantoea sp. | 3 | (AFSSA) | Bacillus lentus | 1 | (AFSSA) |
| Pantoea agglomerans | 1 | ATCC 27155 | Staphylococcus aureus | 3 | i.e. ATCC 700699 |
| Providencia alcalifaciens | 1 | (AFSSA) | Staphylococcus haemolyticus | 1 | CIP 81.56 (CIP) |
| Providencia stuartii | 1 | (AFSSA) | Staphylococcus simulans | 1 | CIP 81.64 (CIP) |
| Proteus vulgaris | 2 | (AFSSA) | Staphylococcus lentus | 1 | CIP 81.63 (CIP) |
| Proteus morganii | 3 | (AFSSA) | Staphylococcus equorum | 1 | CIP 103502 (CIP) |
| Proteus mirabilis | 2 | (AFSSA) | Staphylococcus capitis | 1 | CIP 81.53 (CIP) |
| Photorhabdus luminescens | 1 | TTO1 (CIP) | Streptococcus dysgalactiae | 1 | CIP 102914 (CIP) |
| Shigella sonnei | 2 | (AFSSA) | Streptococcus equinus | 1 | CIP 103232 (CIP) |
| Shigella flexneri | 1 | ATCC 12022 | Streptococcus bovis | 1 | CIP 102302 (CIP) |
| Trait | Day 0 | Day 1 | Day 3 | Day 7 | P |
| pH | 6.43 (0.20)# | 5.55 (0.13) | - | - | |
| Conductivity | - | 6.50 (3.05) | 10.75 (2.65) | 11.55 (2.44) | 0.10 |
| CIE L* | - | 55.42 (2.01) | 54.80 (2.62) | 54.43 (3.95) | 0.73 |
| CIE a* | - | 7.32 (0.67) | 9.63 (3.71) | 9.34 (2.08) | 0.27 |
| CIE b* | - | 15.43 (0.48)a | 15.53 (0.46)a | 16.74 (1.12)b | 0.02 |
| Cook Loss (%) | - | 33.49 (3.40)a | 32.42 (2.62)a,b | 29.86 (3.93)b | 0.05 |
| Drip Loss (%) Day 1-3 | - | - | 3.91 (0.38)@ | - | |
| WBSF (N) | - | 45.67 (3.16)a | 40.31 (5.20)a | 32.01 (3.50)b | 0.002 |
| Intramuscular fat (%) | - | 0.8 (0.4) | - | - |
| Classification | Mutations and Relative Frequency |
| Congenital nevi | NRAS > BRAF |
| Spitz nevi | HRAS > BRAF > NRAS |
| Acquired nevi | BRAF > NRAS |
| Blue nevi | GNAQ > BRAF |
| Variables | Mean | Std. Dev. | Min | Max |
| Health outcome variables for men | ||||
| Diabetes rate (%) | 2.11 | 2.34 | 0.00 | 14.36 |
| Obesity rate (%) | 11.45 | 7.92 | 1.10 | 36.73 |
| Hypertension rate (%) | 24.18 | 9.46 | 7.99 | 46.20 |
| Average age | 44.86 | 3.42 | 37.76 | 55.24 |
| Health outcome variables for women | ||||
| Diabetes rate (%) | 2.31 | 2.41 | 0.00 | 14.73 |
| Obesity rate (%) | 14.62 | 9.02 | 0.93 | 38.30 |
| Hypertension rate (%) | 20.22 | 7.82 | 3.67 | 42.12 |
| Average age | 42.54 | 2.84 | 36.21 | 50.86 |
| Characteristic | No. | RECQL protein expression | ||||
| Low | High | p | ||||
| No. | % | No. | % | |||
| Total | 322 | 133 | 41.3 | 189 | 58.7 | |
| Age | ||||||
| ≤ 50 yr | 153 | 74 | 54.4 | 82 | 43.4 | 0.07 |
| > 50 yr | 169 | 62 | 45.6 | 107 | 56.6 | |
| Tumor size | ||||||
| ≤ 2 cm | 112 | 48 | 45.7 | 64 | 43.5 | 0.73 |
| > 2 cm | 140 | 57 | 54.3 | 83 | 56.5 | |
| Unknown | 70 | 28 | 42 | |||
| Lymph node status | ||||||
| Negative | 168 | 75 | 59.1 | 93 | 51.1 | 0.17 |
| Positive | 141 | 52 | 40.9 | 89 | 48.9 | |
| Unknown | 13 | 6 | 7 | |||
| ER status | ||||||
| Negative | 100 | 44 | 43.6 | 56 | 35.9 | 0.22 |
| Positive | 157 | 57 | 56.4 | 100 | 64.1 | |
| Unknown | 65 | 30 | 33 | |||
| PR status | ||||||
| Negative | 101 | 33 | 33.3 | 68 | 43.3 | 0.11 |
| Positive | 155 | 66 | 66.7 | 89 | 56.7 | |
| Unknown | 66 | 34 | 32 | |||
| HER2 status | ||||||
| Negative | 233 | 98 | 78.4 | 135 | 78.0 | 0.94 |
| Positive | 65 | 27 | 21.6 | 38 | 22.0 | |
| Unknown | 24 | 8 | 16 | |||
| TN | ||||||
| Yes | 29 | 7 | 7.8 | 22 | 14.8 | 0.19 |
| No | 210 | 83 | 92.2 | 127 | 85.2 | |
| Unknown | 83 | 43 | 40 | |||
| Adjuvant Therapy | ||||||
| C | 124 | 58 | 43.6 | 66 | 34.9 | 0.463 |
| E | 20 | 7 | 5.3 | 13 | 6.9 | |
| C + E | 147 | 56 | 42.1 | 91 | 48.1 | |
| No therapy | 31 | 12 | 9.0 | 19 | 10.1 |
| Before multiple imputation | After multiple imputation | |||||
| Model 1 | Model 2 | Model 3 | Model 1 | Model 2 | Model 3 | |
| Intercept | 0.05 (0.02)‡ | 0.02 (0.01)‡ | 0.01 (0.01)‡ | 0.04 (0.02)‡ | 0.02 (0.01)‡ | 0.01 (0.01)‡ |
| Household-level variables | ||||||
| Residential areas | ||||||
| (Rural) | ||||||
| Urban | 1.12 (0.04)‡ | 1.13 (0.05)‡ | 1.13 (0.05)‡ | 1.13 (0.04)‡ | 1.12 (0.05)‡ | 1.12 (0.05)‡ |
| Birth attendants | ||||||
| (Non-health professional) | ||||||
| Health professional | 1.53 (0.06)‡ | 1.52 (0.06)‡ | 1.53 (0.06)‡ | 1.57 (0.06)‡ | 1.57 (0.06)‡ | 1.56 (0.06)‡ |
| Mothers’ employment status | ||||||
| (Unemployed) | ||||||
| Employed | 0.96 (0.03) | 0.97 (0.03) | 0.96 (0.03) | 0.94 (0.03) | 0.94 (0.03) | 0.94 (0.03)* |
| Mothers’ age | ||||||
| (≤20 years) | ||||||
| 21–30 years | 1.13 (0.07)† | 1.14 (0.07)† | 1.13 (0.07)† | 1.14 (0.07)† | 1.14 (0.07)† | 1.14 (0.07) † |
| >30 years | 1.14 (0.07)† | 1.14 (0.07)† | 1.14 (0.07)† | 1.14 (0.07)† | 1.14 (0.07)† | 1.14 (0.07)† |
| Mothers’ education | ||||||
| (Primary or less) | ||||||
| Secondary | 1.19 (0.04)‡ | 1.19 (0.04)‡ | 1.20 (0.04)‡ | 1.19 (0.04)‡ | 1.19 (0.04)‡ | 1.19 (0.04)‡ |
| Higher | 1.36 (0.08)‡ | 1.35 (0.08)‡ | 1.36 (0.08)‡ | 1.35 (0.08)‡ | 1.35 (0.08)‡ | 1.35 (0.08)‡ |
| Log households income | 1.20 (0.04)‡ | 1.20 (0.04)‡ | 1.20 (0.04)‡ | 1.22 (0.04)‡ | 1.20 (0.04)‡ | 1.22 (0.04)‡ |
| District-level variables | ||||||
| Local health expenditure as a proportion of total expenditure (%) | 7.68 (12.03) | 8.56 (14.40) | ||||
| Hospitals/1,000 population | 0.52 (1.16) | 0.44 (1.02) | ||||
| Health centres/1,000 population | 0.65 (0.18) | 0.64 (0.18) | ||||
| Village health posts/1,000 population | 1.71 (0.16)‡ | 1.88 (0.18)‡ | ||||
| Proportion of urban population | 1.68 (0.39)† | 2.10 (0.59)‡ | 1.91 (0.46)‡ | 2.47 (0.71)‡ | ||
| Population density | 0.99 (0.00)‡ | 0.99 (0.00)† | 0.99 (0.00)‡ | 0.99 (0.00)† | ||
| Log GDP per capita | 0.87 (0.06)* | 0.88 (0.06)* | 0.93 (0.71) | 0.92 (0.07)* | ||
| Between district variance | 1.09 | 1.05 | 1.01 | 1.20 | 1.20 | 1.10 |
| ICC | 0.25 | 0.24 | 0.23 | 0.27 | 0.27 | 0.25 |
| MOR | 2.71 | 2.65 | 2.61 | 2.85 | 2.84 | 2.72 |
| Demographic characteristic | Frequency | % |
| Campus location | ||
| Site 1 | 47 | 18.7 |
| Site 2 | 205 | 81.3 |
| Year of study | ||
| Year 2 | 184 | 74.5 |
| Year 3 | 43 | 17.4 |
| Year 4 | 16 | 6.5 |
| Gender | ||
| Female | 230 | 91.3 |
| Male | 22 | 8.7 |
| Marital status | ||
| Single/Divorced | 205 | 82.0 |
| Married/living with a partner | 45 | 18.0 |
| Living arrangement | ||
| With the family | 235 | 94.0 |
| On campus | 2 | 0.8 |
| Off campus | 13 | 5.2 |
| Employment status | ||
| Employed | 28 | 11.1 |
| Not employed | 224 | 88.9 |
| Based on Annual Mileage: Magnusson and Colleagues [32] | Based on Tyres Sold: Swedish National Chemicals Inspectorate [33] | |||||
| Wear mg/km | Total Mileage in 2012 (×106 km) | Total Wear 2012 Tonnes/Year | Mass of Tyres Consumed Annually kg | Weight Loss (17%) kg | Total Wear 2002 tonnes/year | |
| Passenger car | 50 | 62,940 | 3147 | |||
| Bus/lorry | 700 | 14,416 | 10,091 | |||
| Total | 77,356 | 13,238 | 60,000,000 | 10,000,000 | 10,000 |
| Characteristics | Oftena | ||||
| n | % | OR crude | 95% CI | p | |
| Self-rated health | |||||
| Good/very good | 387 | 18.3 | 1.00 | <0.001 | |
| Regular | 224 | 25.7 | 1.54 | (1.27–1.86) | |
| Poor/very poor | 92 | 40.4 | 3.01 | (2.26–4.02) | |
| Absenteeism in the past 12 months | |||||
| None | 358 | 20.8 | 1.00 | 0.116 | |
| Up to 9 days | 200 | 22.6 | 1.11 | (0.91–1.35) | |
| 10 days or more | 147 | 24.8 | 1.25 | (1.00–1.56) |
| Host | Demographic factor | Positive animals percentage | |
| Sheep (n = 189) | Gender | Male (128) | 66 (34.9%)a |
| Female (61) | 20 (10.6%) | ||
| Age | Group I (84) | 47 (24.9%)a | |
| Group II (89) | 36 (19.0%) | ||
| Group III (16) | 3 (1.6%) | ||
| Source | imported (82) | 53 (28.1%) | |
| Local (107) | 33 (17.5%) | ||
| Goat (n = 123) | Gender | Male (65) | 38 (30.9%)a |
| Female (58) | 12 (9.8%) | ||
| Age | Group I (44) | 22 (17.9%)a | |
| Group II (60) | 24 (19.5%) | ||
| Group III (19) | 4 (3.3%) | ||
| Source | Imported (41) | 34 (27.6%) | |
| Local (82) | 16 ( 13.0%) |
| Items | Group | Villus Height (μm) | Crypt Depth (μm) | Villus Height/Crypt Depth |
| Jejunum | Control | 1212.27 ± 47.79 a | 249.78 ± 12.50 a | 4.86 ± 0.29 |
| 200 mg/kg | 1381.83 ± 36.21 b | 370.41 ± 10.03 b | 3.69 ± 0.37 | |
| Ileum | Control | 1175.01 ± 59.35 a | 213.96 ± 33.02 a | 5.58 ± 0.56 |
| 200 mg/kg | 1417.10 ± 75.12 b | 411.05 ± 45.39 b | 3.49 ± 0.51 |
| StudypopulationN=79 | Aggressivesubjectsn=31 | Non-aggressivesubjectsn=48 | Significancep | |
| Mean age | 82.7±8.7 | 80.2±11.2 | 84.4±6.2 | 0.1 |
| Sex (% female) | 50 (63.3) | 14 (45.2) | 36 (75.0) | 0.01 |
| Marital status (% living alone) | 50 (63.3) | 15 (48.4) | 35 (72.9) | 0.028 |
| MMSE mean±SD | 17.9±7.1 | 15.13±7.8 | 19.7±5.9 | 0.009 |
| CMAI mean±SD | 46.2±22.1 | 63.3±25.8 | 35.2±8.5 | <0.001 |
| F-RAGE mean±SD | 9.3±13.1 | 21.7±12.9 | 1.2±3.1 | <0.001 |
| NPI mean±SD | 16.4±11.6 | 22.1±10.9 | 12.8±10.7 | <0.001 |
| RA with MAC-PD | RA without MAC-PD | Total | |
| Anti-GPL ab, positive | 8 | 4 | 12 |
| Anti-GPL ab, negative | 2 | 355 | 357 |
| Total | 10 | 359 | 369 |
| Emergency level | No. | Admitted to | Admission risk, |
| hospital | % (95% CI) | ||
| A | 28,630 | 18,440 | 64.4 (63.8-65.0) |
| B | 25,419 | 13,190 | 51.9 (51.3-52.5) |
| C | 1,112 | 475 | 42.7 (39.8-45.7) |
| D | 109 | 34 | 31.2 (22.7-40.8) |
| All | 55,270 | 32,139 | 58.1 (57.7-58.6)* |
| Variable | Coefficient | t-Statistic | p-value |
| C | 0.912 | 9.44 | 0.000 |
| AGE | 1.78E-05 | 0.009 | 0.993 |
| EDU | 0.034 | 1.030 | 0.307 |
| OCC | 0.025 | 0.706 | 0.483 |
| MASI | 0.000 | 0.251 | 0.803 |
| TR | 0.001 | 0.525 | 0.601 |
| MS | 0.013 | 0.387 | 0.700 |
| INC | 1.40E-07 | 0.238 | 0.813 |
| Patient Number | Age | Gender | Tumour location | Initial MRI Dimensions (cm) | PTV volume (cm3) |
| 1 | 29 | F | L anterior chest wall | 6.5 × 3.6 × 2.1 | 534 |
| 2 | 47 | M | R posterior chest wall | 10.0 × 3.5 × 5.5 | 2082 |
| 3 | 64 | M | R anterior chest wall | 6.9 × 2.6 × 3.0 | 767 |
| 4 | 34 | F | L axilla | 7.6 × 11.8 × 11.5 | 1017 |
| 5 | 34 | M | L axilla and lateral chest wall | 10.5 × 12.5 × 5.0 | 3896 |
| 6 | 22 | M | R axilla and supraclavicular fossa | 10.3 × 5.9 × 5.2 | 1303 |
| 7 | 46 | M | R anteriolateral chest wall | 15.0 × 20.0 × 6.0 | 4539 |
| 8 | 49 | M | L anterior chest wall | 8.5 × 5.6 × 6.8 | 950 |
| 9 | 41 | F | L anterior chest wall | 4.3 × 1.4 × 2.5 | 416 |
| 10 | 20 | M | L neck and supraclavicular fossa | 8.7 × 5.5 × 6.7 | 646 |
| Site | Treatment | IRR (95%CI) | P value |
| Kilifi | Carbon dioxide only | 0.57(0.21 – 1.52) | 0.255 |
| Kilifi | Blend 2 | 1.33 (0.50 -3.57) | 0.552 |
| Kilifi | Blend 4 | 0.95(0.36- 2.56) | 0.931 |
| Kilifi | Hexanoic acid | 2.2 (0.82- 5.87) | 0.109 |
| Mean | SD | No. | p-value | ||
| Items from CAD and renal failure (lecture format the same for each group) | Live lecture | 4.42 | 1.08 | 12 | |
| CD-ROM | 4.88 | 2.00 | 17 | ||
| t-test† | 0.22 (one-tailed) | ||||
| Mann Whitney U | 0.56 (exact test) | ||||
| Levene's Test for equality of variances | 0.026 | ||||
| Items from other four lectures (lecture format differed for control & treatment groups) | Live lecture | 9.25 | 3.11 | 12 | |
| CD-ROM | 9.00 | 2.72 | 17 | ||
| t-test† | 0.41 (one-tailed) | ||||
| Mann Whitney U | 0.91 (exact test) | ||||
| Levene's Test for equality of variances | 0.96 |
| Drugs |
| Acetaminophen |
| Antiretroviral therapy (e.g., stavudine, zidovudine, and lamivudine) |
| β-2 agonists (e.g., salbutamol, terbutaline) |
| Biguanides (e.g., metformin, phenformin) |
| Isoniazid |
| Lactulose |
| Linezolid |
| Nalidixic acid |
| Niacin |
| Nitroprusside sodium |
| Propofol |
| Simvastatin |
| Theophylline |
| Vasoactive drugs (e.g., epinephrine, norepinephrine) |
| AVERAGE PROBABILITY | Sensitivity | Specificity | AUC | |||||||||
| Ensemble classifier | Individual classifiers | Ensemble classifier | Individual classifiers | Ensemble classifier | Individual classifiers | |||||||
| min | max | average | min | max | average | min | max | average | ||||
| Ensemble 1 | 0.73 | 0.64 | 0.73 | 0.68 | 0.90 | 0.90 | 0.95 | 0.93 | 0.95 | 0.73 | 0.94 | 0.84 |
| Ensemble 2 | 0.82 | 0.55 | 0.82 | 0.69 | 0.95 | 0.86 | 1.00 | 0.93 | 0.98 | 0.73 | 0.96 | 0.88 |
| Ensemble 3 | 0.73 | 0.64 | 0.73 | 0.65 | 0.95 | 0.81 | 0.95 | 0.91 | 0.97 | 0.73 | 0.94 | 0.88 |
| Ensemble 4 | 0.82 | 0.55 | 0.73 | 0.64 | 0.90 | 0.81 | 1.00 | 0.92 | 0.97 | 0.83 | 0.95 | 0.90 |
| Ensemble 5 | 0.82 | 0.55 | 0.82 | 0.66 | 0.95 | 0.81 | 1.00 | 0.92 | 0.98 | 0.73 | 0.96 | 0.89 |
| Recommended or adequate treatment | ||||
| Characteristic | No. of consultations or mean value | OR (95% CI) | n (%) | OR (95% CI) |
| Final multivariate models | ||||
| Health worker received | ||||
| Study supports | N = 28 | 3.0 (1.0, 8.6) | 15 (53.6) | 1.5 (0.6, 3.7) |
| Usual supports | N = 42 | ref. | 19 (45.2) | ref. |
| No. supervisory visits, past 6 months (ranging from 0-4) | mean = 0.9 | 2.1 (1.1, 3.9) | -- | 1.6 (1.1, 2.3) |
| Consultation duration, in minutes (ranging from 5 to 131) | median = 16 | 1.04 (1.00, 1.08) | -- | --b |
| No. of IMCI classifications(ranging from 1 to 4) | mean = 2.8 | --b | -- | 2.0 (1.2, 3.3) |
| Causal pathway variable omittedfrom multivariate modelling | ||||
| Health worker correctly diagnosed pneumonia | ||||
| Yes | N = 49 | 49.8 (5.6, 442.1) | 28 (68.3) | 14.2 (4.0, 50.3) |
| No | N = 21 | ref. | 6 (20.7) | ref. |
| Gender | Genotype | ||||
| A | B | C | D | Not typed | |
| Male | 30 | 9 | 48 | 45 | 6 |
| Female | 3 | 3 | 7 | 16 | 2 |
| Total | 33(19.53%) | 12(7.10%) | 55(32.54%) | 61(36.09%) | 8(4.73%) |
| Semen variable | Before maca N = 9 | After maca N = 9 | P value |
| Volume (mL) | 2.23 ± 0.28 | 2.91 ± 0.28 | <0.05 |
| pH | 7.47 ± 0.09 | 7.44 ± 0.07 | NS |
| Sperm count (106/mL) | 67.06 ± 18.61 | 90.33 ± 20.46 | NS |
| Total sperm count (106/mL) | 140.95 ± 31.05 | 259.29 ± 68.17 | <0.05 |
| Motile sperm count (106/mL) | 87.72 ± 19.87 | 183.16 ± 47.84 | <0.05 |
| Sperm motility grade a (%) | 29.00 ± 5.44 | 33.65 ± 3.05 | NS |
| Sperm motility grade a + b (%) | 62.11 ± 3.64 | 71.02 ± 2.86 | <0.05 |
| Normal sperm morphology (%) | 75.50 ± 2.02 | 76.90 ± 1.23 | NS |
| Ultraviolet (UV)-Curable Resin | |
| Density | 0.95 mm |
| Viscosity | 600 MPa·s |
| CNB | Surgical biopsy | |
| Procedures/patients | 66/591 | 20/20 |
| Males/females | 32/27 | 15/5 |
| Median age (range) | 63.5 (24–85) | 60 (42–72) |
| >75 years old | 11 | 0 |
| Imaging modalities | CT 51 US 15 | – |
| Surgical procedures | – | Laparotomy 15 Laparoscopic surgery 2 |
| Sampling sites | Paraaortic LN 24 Mesenteric LN 13 Paravertebral mass 9 Retroperitoneum mass 8 Pelvic mass 6 Adrenal gland 4 Splenic LN 1 Parapancreatic mass 1 | Mesenteric LN 9 Paraaortic LN 5 Retroperitoneal mass 3 Hepatic LN 1 Ext. iliac LN 1 Omentum mass 1 |
| Microorganisms | ICU-A | ICU-B | ICU-C | Total |
| Gram-positive cocci | 23 | 10 | 8 | 41 |
| Coagulase-negative Staphylocci | 13 | 9 | 2 | 24 |
| Staphylococcus aureus | 9 | 0 | 4 | 13 |
| Enteroccocus sp. | 1 | 1 | 2 | 4 |
| Gram-negative bacilli | 15 | 1 | 9 | 25 |
| Enterobacteriaceae | 12 | 1 | 5 | 17 |
| Other Gram-negative Bacilli | 3 | 0 | 4 | 7 |
| Yeasts | 4 | 0 | 1 | 5 |
| Total | 42 | 11 | 18 | 71 |
| Dataset a | KNG95 | KNG01 | FKO | NGY | KMM | NGN |
| Date (FY) | 1995–1996 | 2001–2003 | 2003 | 2004 | 2011–2012 | 2013 |
| Location b | KNG Pref. | KNG Pref. | FKO Pref. | NGY City | KMM Pref. | NGN Pref. |
| Line c | TSL | TSL | SSL | TSL | KSL | HSL |
| Number of trains d | ||||||
| Daytime (7:00–22:00) | 234 | 265 | 142 | 249 | 112 | 62 |
| Nighttime (22:00–7:00) | 16 | 22 | 18 | 21 | 17 | 7 |
| Method | Visit-Mail e | Visit-Mail e | Visit-Mail e | Interview | Visit-Visit e | Mail-Mail e |
| Housing type (DH; AB) f | DH | DH & AB | DH | DH | DH & AB | DH |
| Annoyance | unbearable | ICBEN g | ICBEN g | ICBEN g | ICBEN g | ICBEN g |
| Response proportion (%) h | 72 | 57 | 66 | 58 | 45 | 45 |
| Sample size | 709 | 872 | 358 | 175 | 559 | 294 |
| Country | Author | Setting | Number | Measure | Prevalence |
| Lesotho | Hollifield et al. 1990 | Rural | 356 | DIS | 23.5% F14.7% M |
| Zimbabawe | Abas & Broadhead, 1997 | Urban | 172 | SSQ | 15.7% F 1 month, 30.8% F 1 year |
| South Africa | Haavenaar et al. 2008 | Periurban | 209 | SRQ | 34.9% M and F |
| South Africa | Haavenaar et al. 2008 | Rural | 222 | SRQ | 27.0% M and F |
| South Africa | Hamad et al. 2008 | Urban | 257 | CES-D | 64.5% F, 50.4 % M |
| Nigeria | Gureje et al. 2006 | Probability sample of 8 states | 4,984 | CIDI | 12.1% life time; 5.8% 12 month prevalence M and F |
| Ethiopia | Tafari et al. 1991 | Rural | 2,000 | SRQ | 11.2% M and F |
| Uganda | Orley and Wing 1979 | Rural | PSE | ||
| Sudan | Rahim and Cederblad | Urban | SRQ/DSM III | 16.6% M and F |
| Test | Positives (%) | Negatives (%) | |
| T=3months | |||
| Culture (N=305) | Eradication | 11 (7) | 141 (93) |
| Placebo | 99 (65) | 54 (35) | |
| H&E stains (N=305) | Eradication | 19 (12) | 133 (88) |
| Placebo | 112 (73) | 41 (27) | |
| IHC stains (N=68) | Eradication | 29 (85) | 5 (15) |
| Placebo | 7 (20) | 27 (79) | |
| Serology (N=203) | Eradication | 92 (91) | 9 (9) |
| Placebo | 94 (92) | 8 (8) | |
| T=12months | |||
| Serology (N=304) | Eradication | 96 (64) | 55 (36) |
| Placebo | 138 (90) | 15 (10) |
| Characteristic | Normal No % | Underweight No % | Overweight No % | Obese No % | Total |
| Social class | |||||
| Upper | 244 (84.4) | 12 (4.1) | 25 (8.7) | 8 (2.8) | 289 (100) |
| Middle | 327 (86.7) | 23 (6.1) | 20 (5.3) | 7 (1.9) | 377 (100) |
| Lower | 248 (84.4) | 26 (8.8) | 18 (6.1) | 2 (0.7) | 294 (100) |
| Mother’s education | |||||
| No education | 47 (90.4) | 4 (7.7) | 1 (1.9) | 0 (0.0) | 52 (100) |
| Primary | 139 (87.4) | 10 (6.3) | 9 (5.7) | 1 (0.6) | 159 (100) |
| Secondary | 358 (86.1) | 26 (6.3) | 24 (5.8) | 8 (1.9) | 416 (100) |
| Technical/Commer | 55 (85.9) | 5 (7.8) | 3 (4.7) | 1 (1.6) | 64 (100) |
| Higher/University | 220 (81.8) | 16 (5.9) | 26 (9.7) | 7 (2.6) | 269 (100) |
| Family size | |||||
| ≤5 | 198 (84.6) | 19 (8.1) | 13 (5.6) | 4 (1.7) | 234 (100) |
| 6–10 | 563 (85.7) | 36 (5.5) | 45 (6.8) | 13 (2.0) | 657 (100) |
| 11–15 | 58 (84.1) | 6 (8.7) | 5 (7.2) | 0 (0.0) | 69 (100) |
| Hours spent watching TV | |||||
| 0–2 | 477 (86.1) | 33 (6.0) | 37 (6.7) | 7 (1.3) | 554 (100) |
| 3–4 | 238 (85.0) | 19 (6.8) | 19 (6.8) | 4 (1.4) | 280 (100) |
| ≥5 | 104 (82.5) | 9 (7.1) | 7 (5.6) | 6 (4.8) | 126 (100) |
| Snack intake/week | |||||
| Once | 101 (87.1) | 5 (4.3) | 6 (5.2) | 4 (3.4) | 116 (100) |
| 1–2 | 137 (87.3) | 11 (7.0) | 9 (5.7) | 0 (0.0) | 157 (100) |
| >3 | 199 (86.4) | 13 (5.7) | 13 (5.7) | 5 (2.2) | 230 (100) |
| Everyday | 382 (83.5) | 32 (7.0) | 35 (7.7) | 8 (1.8) | 457 (100) |
| Soft drink/week | |||||
| Once | 320 (84.2) | 26 (6.8) | 24 (6.3) | 10 (2.6) | 380 (100) |
| 1–2 times | 254 (87.0) | 20 (6.8) | 15 (5.1) | 3 (1.0) | 292 (100) |
| >3 | 161 (84.3) | 11 (5.8) | 16 (8.4) | 3 (1.6) | 191 (100) |
| Everyday | 84 (86.6) | 4 (4.1) | 8 (8.2) | 1 (1.0) | 97 (100) |
| Hyperparameter | Value | Number of Occurrences |
| criterion | entropy | 7 |
| gini | 37 | |
| max_features | 0.1 | 4 |
| 0.25 | 5 | |
| 0.5 | 7 | |
| 0.75 | 15 | |
| log2 | 2 | |
| sqrt | 2 | |
| null | 9 | |
| n_estimators | 10 | 3 |
| 100 | 17 | |
| 50 | 16 | |
| 500 | 6 |
| ID | Position* | Tm (°C) | Sequence (5′→3′) | Size (bp) |
| MYOC1 | 353–509 | 62 | F: GGCTGGCTCCCC AGTATATA | 174 |
| R: ACAGCTGGCATCTCAGGC | ||||
| MYOC2 | 491–658 | 62 | F: ACG TTG CTG CAG CTT TGG | 196 |
| R: GATGACTGACATGGCCTGG | ||||
| MYOC3 | 603–772 | 65 | F: AGTGGCCGATGCCAGTATAC | 189 |
| R: CTGGTCCAAGGTCAATTGGT | ||||
| MYOC4 | 670–864 | 62 | F: AGGCCATGTCAGTCATCCAT | 214 |
| R: TCTCTGGTTTGGGTTTCCAG | ||||
| MYOC5 | 778–958 | 60 | F: TGACCTTGGACCAGGCTG | 200 |
| R: CCTGGCCAGATTCTCATTTT | ||||
| MYOC6 | 928–1095 | 63 | F: TGGAGGAAGAGAAGAAGCGA | 187 |
| R: CTGCTGAACTCAGAGTCCCC | ||||
| MYOC7 | 1416–1630 | 62 | F: AACATAGTCAATCCTTGGGCC | 230 |
| R: TAAAGACCATGTGGGCACA | ||||
| MYOC8 | 1933–2091 | 60 | F: TTATGGATTAAGTGGTGCTTCG | 177 |
| R: ATTCTCCACGTGGTCTCCTG | ||||
| MYOC9 | 2069–2232 | 64 | F: AAGCCCACCTACCCCTACAC | 184 |
| R: AATAGAGGCTCCCCGAGTACA | ||||
| MYOC10 | 2195–2366 | 64 | F: ATACTGCCTAGGCCACTGGA | 190 |
| R: CAATGTCCGTGTAGCCACC | ||||
| MYOC11 | 2335–2512 | 63 | F: TGGCTACCACGGACAGTTC | 197 |
| R: CATTGGCGACTGACTGCTTA | ||||
| MYOC12 | 2480–2653 | 64 | F: GAACTCGAACAAACCTGGGA | 195 |
| R: CATGCTGCTGTACTTATAGCGG | ||||
| MYOC13 | 2624–2783 | 62 | F: AGCAAGACCCTGACCATCC | 179 |
| R: AGCATCTCCTTCTGCCATTG |
| Study | Status | Results | NCT identifier |
| Sorafenib versus placebo + FOLFOX or FOLFORI in the second-line treatment of colorectal cancer | Recruiting | Pending | NCT00889343 |
| Sorafenib + capecitabine in patients with pretreated advanced CRC | Recruiting | Pending | NCT01290926 |
| BAY 43-9006 plus cetuximab to treat colorectal cancer | Recruiting | Pending | NCT00326495 |
| Sorafenib + FOLFORI in CRC after failure of oxaliplatin therapy | Recruiting | Pending | NCT00839111 |
| Sorafenib + capecitabine in previously treated CRC | Recruiting | Pending | NCT01471353 |
| Sorafenib + irinotecan in metastatic CRC and KRAS mutation | Completed | Pending | NCT00989469 |
| Sorafenib, cetuximab, and irinotecan in treating patients with mCRC | Ongoing, not recruiting | Pending | NCT00134069 |
| Sorafenib and bevacizumab versus single agent bevacizumab | Ongoing, not recruiting | Pending | NCT00826540 |
| External-Beam radiation therapy, capecitabine, and sorafenib in treating patients with locally advanced rectal cancer | Recruiting | Pending | NCT00869570 |
| Organism | Gene targeted | Primer Sequences 5' - > 3' | Amplicon size (bp) | Reference |
| A. phagocytophilum | ankA | F: CTATCATCCTTGGGTAGTGGCCT | 223 | This study |
| R: CTTCTGGTGTTCTCGGACCTTC | ||||
| gltA | F: ATATCTACCGGAACCCCCATAGC | 209 | ||
| R: AAAAGCTATGACCCTAGAGCGCGT | ||||
| groEL | F: GTGATTCGCACGCTCTTAGCAGT | 172 | ||
| R: GCCTTCAAGTTGCTGCTGTAAA | ||||
| Bos taurus | gapdh | F: TTCACACTCTCCTTCCAGGTACG | 217 | [30] |
| R: TCAGGGCCTTAGAGATGGAAA | ||||
| ywhaz | F: TACTCCGGACACAGGTAAGGGAC | 212 | ||
| R: AGAACCCAGCGGAAGAGAAG | ||||
| ppia | F: CTGTTCTAGGTTGGATGGCAAGC | 137 | ||
| R: TTTGTCCACAGTCAGCAATGGTGA |
| Day | Interval | Vial | Dose (mL) | Allergen dose (mcg/mL) |
| 1 | 2 | 0.1 + 0.2 | 0.0025 + 0.005 | |
| 8 | Weekly | 2 | 0.4 + 0.4 | 0.01 + 0.01 |
| 15 | Weekly | 3 | 0.1 + 0.2 | 0.025 + 0.05 |
| 22 | Weekly | 3 | 0.4 + 0.4 | 0.1 + 0.1 |
| 37 | Fortnightly | 3 | 0.8 | 0.2 |
| 67 | Monthly | 3 | 0.8 | 0.2 |
| 97 | Monthly | 3 | 0.8 | 0.2 |
| ...* | Monthly | 3 | 0.8 | 0.2 |
| Control (N = 20) | Half dose (N = 20) | Early administration (N = 21) | |
| Endometrial thickness | |||
| Mean ± SD (mm) | 6.7 ± 1.8 | 8.6 ± 1.5a | 9.4 ± 1.5a |
| < 8 mm | 17 (85.0%) | 6(30.0%) | 2(9.6%) |
| ≥ 8 mm | 3(15.0%) | 14(70.0%)a | 19(90.4%)a |
| Days until follicles maturation | 12.0 ± 1.5 | 13.6 ± 2.7b | 11.6 ± 2.3 |
| Number of follicles | |||
| ≥ 15 mm | 1.9 ± 1.0 | 1.8 ± 0.9 | 2.3 ± 0.9 |
| ≥18 mm | 1.3 ± 0.5 | 1.4 ± 0.6 | 1.4 ± 0.6 |
| Serum progesterone (ng/ml) | 22.3 ± 11.3 | 18.8 ± 7.3 | 18.8 ± 10.3 |
| Study report | Location | Source of cases | Number of cases | Source of comparison group without diarrhoea | Matching of comparison group | Number of children without diarrhoea |
| Bangladesh 1992a [16] | Matlab (rural) | Active household surveillance | Varied by pathogen (68 – 184) | Same community study cohort | Age and proximity of residence | Varied by pathogen (67 – 164) |
| Bangladesh 1992b [17] | Mirzapur (rural) | Active household surveillance | Varied by pathogen (53 – 153) | Same community study cohort | Age and proximity of residence | Varied by pathogen (46 – 213) |
| India 1989 [18] | New Delhi | Hospital admissions | 92 | Other wards with non-gastro-intestinal illnesses | Age and nutritional status | 92 |
| India 1992 [19] | New Delhi | Hospital admissions | 81 | Nutrition clinic with failure to thrive and weight for height = 90% of standard | Not matched | 32 |
| India 1999 [22] | Slum of New Delhi | Active household surveillance | 115 | Same community study cohort | Age, nutritional status and proximity of residence | 115 |
| Brazil 1990 [26] | Urban slum, Fortaleza | Active household surveillance | 40 | Same community study cohort | Not matched | 38 |
| Brazil 1995 [29] | Fortaleza | Hospital admissions | 56 | Children on other wards | By age | 42 |
| Brazil 2000 [4] | Shanty town, Fortaleza | Active household surveillance | 88 | Same community study cohort | By age and sex | 443 |
| Dependent variable | Acute MI | Genotype | Acute MI × Genotype | ||||||
| F | p | Partial Eta squared | F | p | Partial Eta squared | F | p | Partial Eta squared | |
| Serum ACE2 Levels | 19.22 | 0.00 | 0.29 | 1.69 | 0.19 | 0.04 | 11.98 | 0.00 | 0.16 |
| Early remission n = 387 | Arm 1 n = 83 | Arm 2 n = 78 | OOP n = 50 | |
| Patients with AE*, n (%) | 205/387 (53 %) | 53/83 (64 %) | 52/78 (67 %) | 27/50 (54 %) |
| Total number of AE | 408 | 129 | 109 | 58 |
| Cardiovascular | 25 | 5 | 8 | 4 |
| Pulmonary | 17 | 5 | 2 | 2 |
| Gastrointestinal | 67 | 16 | 14 | 12 |
| GI complaints | 8 | 2 | 2 | – |
| Nausea/emesis | 23 | 2 | 4 | 4 |
| Increased liver enzymes | 15 | 7 | 3 | 4 |
| Other | 21 | 5 | 5 | 4 |
| Neuro-psychiatric | 37 | 5 | 7 | 3 |
| Headache | 14 | – | 4 | 1 |
| Dizziness | 7 | 1 | – | 1 |
| Mood disorders | 4 | – | – | 1 |
| Other | 12 | 4 | 3 | – |
| Urogenital | 7 | 3 | 2 | 3 |
| Skin/mucous membranes | 45 | 18 | 15 | 3 |
| Rash | 19 | 8 | 5 | – |
| Hair loss/thinning | 4 | 1 | 1 | 1 |
| Sicca complaints | 3 | – | – | 1 |
| Eczema | 3 | 1 | – | – |
| Other | 16 | 8 | 9 | 1 |
| Infections | 106 | 38 | 41 | 18 |
| Upper airway tract | 29 | 11 | 16 | 10 |
| Gastrointestinal | 4 | 1 | – | 2 |
| Skin/mucosa | 14 | 2 | 4 | 2 |
| Pneumonia/bronchitis | 9 | 1 | 1 | 1 |
| Urinary tract | 15 | 7 | 5 | 1 |
| Influenza/unspecified fever | 25 | 10 | 6 | 1 |
| Other | 10 | 6 | 9 | 1 |
| Trauma/injury | 13 | 5 | 2 | 3 |
| Infusion reaction | 3 | 1 | – | – |
| Malaise | 9 | 5 | 1 | 1 |
| Surgical procedures without hospitalization | 13 | 5 | 4 | 1 |
| Other | 65 | 23 | 12 | 8 |
| Test | Meaning | P-value |
| 1 vs. only fixed effects | QTL additive effect | 6 × 10-7 |
| 2 vs. 0 | QTL additive effect conditional on infinitesimal effect | 3 × 10-7 |
| 3 vs. 0 | QTL additive and dominance effects conditional on infinitesimal effect | 2 × 10-6 |
| 4 vs. 0 | QTL additive effect nested within sex conditional on infinitesimal effect | 3 × 10-8 |
| 5 vs. 0 | Raw association signal conditional on infinitesimal effect | 5 × 10-7 |
| 6 vs. 4 | Association (SNP) signal conditional on linkage (QTL) signal | 0.43 |
| 6 vs. 5 | Linkage signal conditional on SNP signal | 7 × 10-3 |
| Direct costs of NSIs | |
| Testing for blood-borne viruses [6,26-30] in: | |
| NSI recipient – initial test | €38.76 |
| NSI recipient – follow-up test | €58.52 |
| Source patient (if known) | €43.91 |
| Cost of staffing and administration per NSI [26,31] | €68.81 |
| Cost of PEP for hepatitis B and HIV [19,25,32,33] per: | |
| NSI from a known and infected source | €374.61 |
| NSI from an unknown source | €918.76 |
| Cost of treatment of blood-borne viruses [19,25,34-38]: | €2,377.44 |
| Hepatitis B (year in which NSI occurred and per subsequent year for three years) | |
| Hepatitis C (year in which NSI occurred only) | €16,127.76 |
| HIV (year in which NSI occurred and per subsequent year) | €16,999.83 |
| Number of free nicotine patches provided | Group 12-week supply | Group 24-week supply | Group 36-week supply contingent upon first 2-weeks of use | Group 46-week supply | Group 58-week supply |
| 12-month quit rate* | 31.0% | 21.0% | 15.5% | 37.8% | 31.1% |
| 12-month intent-to-treat quit rate** | 19.1% | 12.9% | 7.0% | 23.1% | 22.6% |
| Sustained quitters* | 24.6% | 20.3% | 11.7% | 27.3% | 19.9% |
| Relapsed smokers* | 18.9% | 14.9% | 16.4% | 11.9% | 10.2% |
| Delayed quitters* | 6.4% | 0.7% | 3.8% | 10.5% | 11.3% |
| mNCV | CMAP | |
| Patient 1 | 39 m/s | 3.4 mV |
| Patient 2 | 45 m/s | 4.0 mV |
| Patient 3 | 32 m/s | 1.5 mV |
| Patient 4 | 32.4 m/s | 5.1 mV |
| Patient 5 | 34.1 m/s | 1.4 mV |
| Outcomes | N | p-Value | B-Coefficient | 95% Confidence Interval |
| FSH | ||||
| Tanner Stage 2 vs. Stage 1 | 170 | <0.001 | 1.034 | (0.554; 1.514) |
| Tanner Stage 3 vs. Stage 2 | 110 | <0.001 | 1.416 | (0.765; 2.067) |
| Tanner Stage 4 vs. Stage 3 | 72 | <0.001 | 1.821 | (0.986; 2.657) |
| Tanner Stage 5 vs. Stage 4 | 41 | 0.287 | −0.697 | (−1.985; 0.590) |
| LH | ||||
| Tanner Stage 2 vs. Stage 1 | 172 | <0.001 | 0.545 | (0.309; 0.781) |
| Tanner Stage 3 vs. Stage 2 | 111 | <0.001 | 1.163 | (0.843; 1.484) |
| Tanner Stage 4 vs. Stage 3 | 71 | <0.001 | 0.963 | (0.545; 1.380) |
| Tanner Stage 5 vs. Stage 4 | 40 | 0.805 | 0.080 | (−0.558; 0.718) |
| Oestradiol | ||||
| Tanner Stage 2 vs. Stage 1 | 173 | 0.07 | 6.120 | (−0.494; 12.733) |
| Tanner Stage 3 vs. Stage 2 | 112 | <0.001 | 19.993 | (10.968; 29.018) |
| Tanner Stage 4 vs. Stage 3 | 72 | 0.022 | 13.621 | (2.011; 25.230) |
| Tanner Stage 5 vs. Stage 4 | 41 | 0.006 | 25.320 | (7.430; 43.210) |
| Testosterone | ||||
| Tanner Stage 2 vs. Stage 1 | 174 | 0.186 | 0.548 | (−0.266; 1.363) |
| Tanner Stage 3 vs. Stage 2 | 111 | <0.001 | 5.237 | (4.127; 6.347) |
| Tanner Stage 4 vs. Stage 3 | 72 | <0.001 | 3.347 | (1.922; 4.772) |
| Tanner Stage 5 vs. Stage 4 | 41 | <0.001 | 4.621 | (2.425; 6.818) |
| SHBG | ||||
| Tanner Stage 2 vs. Stage 1 | 172 | 0.008 | −13.531 | (−23.454; −3.608) |
| Tanner Stage 3 vs. Stage 2 | 111 | <0.001 | −38.669 | (−52.146; −25.191) |
| Tanner Stage 4 vs. Stage 3 | 71 | 0.009 | −23.341 | (−40.904; −5.778) |
| Tanner Stage 5 vs. Stage 4 | 40 | 0.999 | 0.023 | (−26.805; 26.850) |
| OS | PFS | LR | ||||
| Parameter | HR [95% CI] | p-value | HR [95% CI] | p-value | HR [95% CI] | p-value |
| RT mode (IMRT vs. 3DCRT) | 0.716 [0.430; 1.191] | 0.198 | 0.830 [0.512; 1.344] | 0.448 | 0.812 [0.356; 1.852] | 0.620 |
| Age (continuous) | 1.006 [0.978; 1.035] | 0.676 | 1.009 [0.981; 1.037] | 0.525 | 0.962 [0.906; 1.022] | 0.211 |
| KPS (continuous) | 1.004 [0.973; 1.035] | 0.816 | 1.024 [0.992; 1.057] | 0.138 | 0.988 [0.940; 1.039] | 0.644 |
| T-stage (T3/4 vs. T1/2) | 1.177 [0.637; 2.178] | 0.603 | 1.226 [0.679; 2.212] | 0.499 | 1.170 [0.411; 3.328] | 0.768 |
| N-stage (N1-3 vs. N0) | 1.493 [0.779; 2.863] | 0.228 | 1.399 [0.764; 2.561] | 0.277 | 1.218 [0.408; 3.635] | 0.723 |
| Grade (G3 vs. G1/2) | 1.651 [0.996; 2.737] | 0.052 | 1.518 [0.938; 2.456] | 0.089 | 1.040 [0.455; 2.374] | 0.926 |
| Pretreatment Hemoglobin | 0.930 [0.821; 1.054] | 0.255 | 0.886 [0.783; 1.003] | 0.057 | 0.975 [0.821; 1.157] | 0.768 |
| Location | 1.002 [0.960; 1.046] | 0.935 | 0.992 [0.952; 1.033] | 0.689 | 1.030 [0.958; 1.107] | 0.422 |
| Histology (Adeno vs. SCC) | 1.555 [0.786; 3.076] | 0.205 | 1.630 [0.851; 3.125] | 0.141 | 1.354 [0.489; 3.750] | 0.560 |
| RT dose (continuous) | 0.946 [0.881; 1.015] | 0.122 | 0.955 [0.893; 1.021] | 0.173 | 0.763 [0.635; 0.916] | 0.004 |
| Treatment year (continuous) | 1.021 [0.934; 1.116] | 0.646 | 1.043 [0.958; 1.135] | 0.329 | 1.041 [0.893; 1.213] | 0.606 |
| Proliferation status (E2F1) | NKI 70-gene signature prognosis | ||
| Good | Poor | Total | |
| E2F1 ≤ p30 | 4/69 (5.7%) | 6/21 (28.6%) | 10/90 (11.1%) |
| E2F1 > p30 | 12/46 (26.1%) | 79/159 (49.6%) | 91/205 (44.4%) |
| Total | 16/115 (13.9%) | 85/180 (47.2%) | 101/295 (34.2%) |
| Length | Coefficient | Std. Err. | z | P > z | [95% Conf. | Interval] |
| Days | −0.1 mm | 0.1 mm | −1.16 | 0.25 | −.4 mm | .1 mm |
| Female vs. Male | 18 mm | 3 mm | 5.59 | 0.000 | 11 mm | 24 mm |
| Right vs. Left | 0 mm | 3 mm | −0.15 | 0.88 | −6 mm | 5 mm |
| Displaced | −9 mm | 4 mm | −2.19 | 0.03 | −16 mm | 0 mm |
| Mid vs. Lateral | 1 mm | 4 mm | 0.38 | 0.70 | −6 mm | 8 mm |
| Interaction displaced/time | ||||||
| Displaced over time | 0 mm | 0.1 mm | 0.61 | 0.54 | −0.2 mm | 0.4 mm |
| Length constant | 137 mm | 5 mm | 28.14 | 0.000 | 127 mm | 147 mm |
| PM (mg/m3) | Endotoxin (EU/m3) | |||||||
| Fuel/particle size | n | Range | Mean ± SD | Median | Range | Mean ± SD | Median | < LOD (n) |
| Nepal, TIP | ||||||||
| Wood | 16 | 0.22–4.08 | 1.14 (1.12) | 0.68 | 6–371 | 100 (113) | 43 | 4a |
| Dung | 15 | 0.91–12.8 | 3.78 (3.51) | 2.33 | 133–1,002 | 498 (291) | 365 | 0 |
| Malawi, Resp | ||||||||
| Wood | 4 | 1.40–9.65 | 4.73 (3.97) | 3.94 | 63–520 | 202 (217) | 113 | 1b |
| Maize crop residue | 2 | 0.65–9.56 | 5.11 (6.30) | 5.11 | 45–3,172 | 1,609 (2,211) | 1,609 | 1c |
| Model 2 | |||
| Coefficient | SE | P > |z| | |
| Salary | 0.00006 | 9.79e − 06 | 0.000 |
| Salary*health professionals | 0.00001 | 0.00001 | 0.217 |
| Place of work: district capital | −0.01274 | 0.08298 | 0.878 |
| Place of work: district capital*health professionals | −0.46284 | 0.10504 | 0.000 |
| Place of work: provincial capital | 0.10538 | 0.06535 | 0.107 |
| Place of work: provincial capital*health professionals | −0.30624 | 0.07642 | 0.000 |
| Housing | 0.53866 | 0.06060 | 0.000 |
| Housing*health professionals | 0.00126 | 0.07085 | 0.986 |
| Access to a loan | 0.38210 | 0.05889 | 0.000 |
| Access to a loan*health professionals | −0.07671 | 0.06722 | 0.254 |
| Formal education | 0.51927 | 0.06637 | 0.000 |
| Formal education*health professionals | −0.00102 | 0.07890 | 0.990 |
| Skills development | 0.26677 | 0.04949 | 0.000 |
| Skills development*health professionals | 0.01989 | 0.05856 | 0.734 |
| Availability of equipment and medicine | 0.25184 | 0.05697 | 0.000 |
| Availability of equipment and medicine*health professionals | 0.12082 | 0.06803 | 0.076 |
| Private practice | 0.10305 | 0.04295 | 0.016 |
| Private practice*health professionals | −0.02353 | 0.05097 | 0.644 |
| Const | −0.02475 | 0.02854 | 0.386 |
| Number of groups | 455 | ||
| Number of observations | 14 408 | ||
| Log likelihood | −4 269.1452 | ||
| Wald chi-square | 919.02 | ||
| Prob > chi-square | 0.0000 |
| Group | Operation | Treatment | Dose | Frequency | n | ||
| (μg·kg−1) | (μg·kg−1 per week) | ||||||
| 1 | Sham | Sham | Vehicle | — | — | 3/week | 5 |
| 2 | W3V | OVX | Vehicle | — | — | 3/week | 5 |
| 3 | W3M | OVX | TPTD | 6 | 18 | 3/week | 5 |
| 4 | W3H | OVX | TPTD | 30 | 90 | 3/week | 5 |
| 5 | D1V | OVX | Vehicle | — | — | 1/day | 5 |
| 6 | D1L | OVX | TPTD | 1.2 | 8.4 | 1/day | 5 |
| 7 | D1M | OVX | TPTD | 6 | 42 | 1/day | 5 |
| 8 | D1H | OVX | TPTD | 30 | 210 | 1/day | 5 |
| 9 | D2V | OVX | Vehicle | — | — | 2/day | 5 |
| 10 | D2L | OVX | TPTD | 1.2 | 16.8 | 2/day | 5 |
| 11 | D2M | OVX | TPTD | 6 | 84 | 2/day | 5 |
| 12 | D2H | OVX | TPTD | 30 | 420 | 2/day | 5 |
| 13 | D3V | OVX | Vehicle | — | — | 3/day | 5 |
| 14 | D3L | OVX | TPTD | 1.2 | 25.2 | 3/day | 5 |
| 15 | D3M | OVX | TPTD | 6 | 126 | 3/day | 5 |
| Patient details | Preoperative data | Data prior to withdrawal of epidural catheter |
| Age | Time of epidural catheterization | Time of withdrawal of epidural catheter |
| Sex | Time of blood testing | Time of blood testing |
| Epidural or intravenous analgesia | Activated partial thromboplastin time (aPTT) | Time and dosage of the last dose of low molecular weight heparin (LMWH) before withdrawal of epidural catheter |
| Reason for intravenous analgesia if applicable | Prothrombin time international normalised ratio (PT-INR) | Activated partial thromboplastin time (aPTT) |
| Level of epidural catheterization | Platelet count (Plc) | Prothrombin time international normalised ratio (PT-INR) |
| Blood haemoglobin level (Hb) | Platelet count (Plc) | |
| Serum albumin (Alb) | Blood haemoglobin level (Hb) | |
| Serum creatinine (Crea) |
| Genotype | Frequency | Percentage |
| 1 (all subtypes) | 1999 | 7.038 |
| 1(Undefined subtypes) | 237 | 0.834 |
| 1a | 1369 | 4.82 |
| 1b | 336 | 1.183 |
| 1c | 57 | 0.2 |
| 2 (all subtypes) | 1085 | 3.818 |
| 2 (Undefined subtypes) | 180 | 0.633 |
| 2a | 821 | 2.89 |
| 2b | 78 | 0.274 |
| 2c | 6 | 0.021 |
| 3 (all subtypes) | 22429 | 78.964 |
| 3 (Undefined subtypes) | 3104 | 10.92 |
| 3a | 16475 | 58.01 |
| 3b | 2772 | 9.76 |
| 3c | 75 | 0.264 |
| 3k | 3 | 0.01 |
| 4 (all subtypes) | 453 | 1.594 |
| 4 (Undefined subtypes) | 264 | 0.929 |
| 4a | 173 | 0.609 |
| 4b | 16 | 0.056 |
| 5 (all subtypes) | 29 | 0.101 |
| 5 (Undefined subtypes) | 5 | 0.017 |
| 5a | 24 | 0.084 |
| 6(all subtypes) | 37 | 0.13 |
| 6 (Undefined subtypes) | 25 | 0.088 |
| 6 | 12 | 0.042 |
| Undefined subtypes | 939 | 3.306 |
| Mixed | 1429 | 5.031 |
| Total | 28400 | 100 |
| Target population | Approach | Number conducted | Target population reached |
| Male and female adolescents | FGD | 6 | 48 |
| Women with children under 5 years | FGD | 6 | 32 |
| Men whose children have or have not been involved in any study conducted by KHRC | FGD | 6 | 37 |
| Women 45 years+ | FGD | 6 | 43 |
| Traditional leaders | IDI | 2 | 2 |
| Assembly men and women and government appointees. | IDI | 12 | 12 |
| Head of district commission for human rights and administrative justice. | IDI | 1 | 1 |
| District Information officer. | IDI | 1 | 1 |
| Church leaders | IDI | 2 | 2 |
| Ghana Private Road Transport Union (GPRTU ) Official | IDI | 1 | 1 |
| Health professionals | IDI | 3 | 3 |
| Traditional healer | IDI | 1 | 1 |
| Director of Agriculture | IDI | 1 | 1 |
| Unit committee members. | IDI | 1 | 1 |
| Chemical drug sellers | IDI | 2 | 2 |
| Ghana Police personnel | IDI | 2 | 2 |
| Community members | Radio discussions | 7 | ~52,000 |
| Community members | Community durbars | 33 | ~86,700 |
| Assembly members, the media, health professionals and other government organizations | Workshops | 5 | 145 |
| Landmarks | Lee et al. [13] Mean (mm) ± SD | Lee [16] Mean (mm) ± SD |
| Height of maxillary sinus roof | 33.45 ± 2.83 | 33.83 ± 3.40 |
| Maxillary sinus roof to posterior ethmoid roof | 14.08 ± 3.03 | Not measured |
| Maxillary sinus roof to sphenoid ostium | 2.76 ± 2.80 | 1.79 ± 3.09 |
| Maxillary sinus roof to sphenoid roof | 12.18 ± 3.20 | 12.02 ± 2.93 |
| Maxillary sinus roof to sphenoid floor | 5.94 ± 2.94 | 6.18 ± 2.88 |
| Automatic selection 450 K | Automatic selection EPIC | IDOL EPIC | Pa | |
| Probes | (n = 600) | (n = 600) | (n = 450) | |
| N(%) | N(%) | N(%) | ||
| CpG present on 450 K array | 600 (100) | 203 (34) | 140 (31) | 7.50E-29 |
| Enhancers (Phantom5) | 53 (9) | 108 (18) | 70 (16) | 3.13E-69 |
| DNase hypersensitive sites | 452 (75) | 467 (78) | 328 (73) | 6.66E-147 |
| Genomic context | ||||
| CpG island | 47 (8) | 24 (4) | 10 (2) | 4.35E-62 |
| Shores | 116 (19) | 55 (9) | 63 (14) | |
| Shelves | 95 (16) | 41 (7) | 35 (8) | |
| Open sea | 342 (57) | 480 (80) | 342 (76) | |
| Functional context | ||||
| TSS1500 | 73 (12) | 44 (7) | 38 (8) | 2.10E-102 |
| TSS200 | 46 (8) | 23 (4) | 11 (2) | |
| 5′ UTR | 76 (13) | 69 (12) | 46 (10) | |
| First exon | 20 (3) | 16 (3) | 7 (2) | |
| Body | 241 (40) | 283 (47) | 210 (47) | |
| 3′ UTR | 29 (5) | 11 (2) | 9 (2) | |
| Intergenic | 115 (19) | 152 (25) | 128 (28) |
| Variable | Coefficient | P |
| Prior history of radiation | −1.350 | .012 |
| Volume per injection, mL | 2.060 | .094 |
| Dosimetry Parameter | Planned | St Dev | Implanted | St Dev |
| D90 (Gy) | 175.5 | 9.6 | 177.7 | 10.5 |
| V100 (%) | 97.9 | 1.6 | 97.9 | 1.5 |
| V150 (%) | 64.1 | 7.3 | 66.5 | 7.9 |
| V200 (%) | 21.6 | 5.9 | 26.1 | 7.3 |
| Drug | Disease | NCT number | Phase |
| 5-Azacitidine | Beta thalassemia | NCT00005934 | Phase 2 |
| 5-Azacytidine + Na phenylbutyrate | Thalassemia major | NCT00007072 | Phase 2 |
| Resveratrol | Cardiovascular diseases | NCT01449110 | Phase 2 |
| Resveratrol | Trauma | NCT01321151 | Phase 1 |
| Resveratrol | Metabolic syndrome, obesity | NCT01150955 | Phase 1 |
| Curcumin | Irritable bowel syndrome | NCT00779493 | Phase 4 |
| Curcumin | Alzheimer disease | NCT00164749 | Phase 2 |
| Curcumin | Psoriasis | NCT00235625 | Phase 2 |
| N | Subfamily | Unit (bp) | Arrays | GC% | Length (bp) | Var% | HOR | ChrUn | WGS Chr |
| 1 | TR-24B-MM | 24 | 3 | 34.4 | 7636 | 28 | + | 2 | 11 |
| 2 | TR-24A-MM | 24 | 2 | 45.6 | 3540 | 22 | + | 2 | Un |
| 3 | TR-13A-MM | 13 | 1 | 56.0 | 4477 | 15 | + | 0 | 6 |
| 4 | TR-27B-MM | 27 | 1 | 63.5 | 3452 | 36 | + | 1 | Un |
| 5 | TR-28A-MM | 28 | 1 | 41.2 | 3195 | 23 | + | 1 | Un |
| 6 | TR-36A-MM | 36 | 1 | 64.0 | 3003 | 8 | + | 0 | 19 |
| 7 | TR-102A-MM | 102 | 1 | 45.7 | 3698 | 31 | - | 0 | X |
| 8 | TR-624A-MM | 624 | 1 | 43.3 | 3297 | 2 | - | 0 | Un |
| Assessment Period | ||||||||
| Measure | E1 | E2 | 2 weeks | 6 weeks | 13-weeks | 6 month | 1 year | 2 years |
| Height, weight | Monthly | Every 3 months | ||||||
| DXA | X | X | X | X | X | |||
| Waist Circumference | Monthly | Every 3 months | ||||||
| Blood Pressure | X | X | X | X | X | |||
| Aerobic fitness | X | X | X | X | X | |||
| Strength fitness | X | X | X | X | X | |||
| ActicalTM | X | X | X | X | X | |||
| 7-day PAR | X | X | X | X | X | |||
| Ultrasound | X | X | X | X | X | |||
| EKG | X | X | X | X | X | |||
| PAT | X | X | X | X | ||||
| Blood work | X | X | X | X | ||||
| 3-day food records | X | X | X | X | X | |||
| Quality of Life | X | X | X | X | X | |||
| Social Support | X | X | X | X | X | |||
| Outcome Expectations | X | X | X | X | X | X | ||
| Satisfaction | X | X | X | X | X | X | ||
| Enjoyment | X | X | X | X | X | X | ||
| Self-efficacy | X | X | X | X | X | X | ||
| Group Cohesion | X | X | ||||||
| Collaboration | X | X | ||||||
| Intentions | X | X | X | X | X | X |
| Patient | Age/years | LH (mIU/ml) | FSH (mIU/ml) | Prolactin (ng/ml) | Estradiol (pg/ml) | Progesterone (ng/ml) | Testosterone (ng/ml) | Follicle numbers | Clinical information |
| F1‐II1 | 34 | 6.58 | 17.49↑ | 19.55 | 40 | 0.15 | 0.85 | Left: 5, Right: 10 | BPES; Menarche 16 years; irregular cycles |
| F2‐II1 | 30 | 10.33 | 17.84↑ | 7.16 | 42 | 0.2 | 0.59 | Left: 2, Right: 3 | BPES; Menarche 15 years; irregular cycles |
| Survival | MYC CNA+ and MYC-R+ | MYC-R+ alone | MYC CNA+ alone | |||
| χ2 | P value | χ2 | P value | χ2 | P value | |
| Overall survival | ||||||
| MYC CNA+ and MYC-R+ | 2.819 | 0.093 | 0.066 | 0.797 | ||
| MYC-R+ alone | 2.819 | 0.093 | 0.339 | 0.560 | ||
| MYC CNA+ alone | 0.066 | 0.797 | 0.339 | 0.560 | ||
| Progression-free survival | ||||||
| MYC CNA+ and MYC-R+ | 3.481 | 0.062 | 4.499 | 0.034 | ||
| MYC-R+ alone | 3.481 | 0.062 | 3.400 | 0.054 | ||
| MYC CNA+ alone | 4.499 | 0.034 | 3.400 | 0.054 |
| Before sling | After sling | |
| PVDF | 15.4 (±4.3) | 5.6 (±5.9) |
| PP | 15.3 (±3.4) | 6.2 (±6.6) |
| Characteristics | Cases | CD40 mutant expression | χ2 | P | |
| Positive | Negative | ||||
| Sex | |||||
| Male | 58 | 33 | 25 | 0.286 | 0.593 |
| Female | 20 | 10 | 10 | ||
| Age (years) | |||||
| ≥60 | 48 | 36 | 12 | 2.849 | 0.091 |
| <60 | 30 | 17 | 13 | ||
| Tumor size (cm) | |||||
| ≥5 | 37 | 20 | 17 | 0.033 | 0.856 |
| <5 | 41 | 23 | 18 | ||
| Differentiation | |||||
| Well/moderate | 43 | 20 | 23 | 2.074 | 0.15 |
| Poor | 35 | 22 | 13 | ||
| Depth of tumor invasion | |||||
| Not to deep muscle layer | 10 | 1 | 9 | 9.444 | 0.002a |
| Deep muscle layer | 68 | 42 | 26 | ||
| Lymph nodes metastasis | |||||
| Yes | 60 | 39 | 21 | 7.802 | 0.005a |
| No | 18 | 5 | 13 | ||
| TNM stage | |||||
| I and II | 17 | 4 | 13 | 8.774 | 0.003a |
| III and IV | 61 | 39 | 22 |
| Variable | AHRR <36(n=181) | AHRR 36–46(n=202) | AHRR 47–58(n=197) | AHRR ≥59(n=211) | p Value(across all groups) |
| Age (years) | 71.1 (0.8) | 69.1 (0.8) | 67.8 (0.9) | 63.9 (0.9) | <0.001 |
| Resting heart rate (bpm) | 70 (2) | 71 (1) | 73 (1) | 80 (1) | <0.001 |
| Systolic blood pressure (mm Hg) | 121 (2) | 121 (2) | 121 (2) | 123 (2) | 0.71 |
| QRS interval (ms) | 126 (2) | 125 (2) | 122 (2) | 116 (2) | 0.01 |
| Haemoglobin (g/dL) | 129 (1) | 136 (1) | 136 (1) | 142 (1) | <0.001 |
| Sodium (mmol/L) | 139 (1) | 139 (1) | 140 (1) | 140 (1) | 0.12 |
| eGFR (mL/Kg/1.73 m2) | 49 (1) | 54 (1) | 56 (1) | 61 (1) | <0.001 |
| LV ejection fraction (%) | 33 (1) | 32 (1) | 32 (1) | 31 (1) | 0.58 |
| Minimum 24 h heart rate (bpm) | 59 (1) | 58 (1) | 56 (1) | 57 (1) | 0.37 |
| Maximum 24 h heart rate (bpm) | 86 (1) | 98 (1) | 108 (1) | 133 (1) | <0.001 |
| Ambulatory heart rate range (bpm) | 28 (1) | 41 (1) | 52 (1) | 76 (1) | <0.001 |
| Male sex (% (n)) | 73.5 (133) | 73.8 (149) | 74.1 (146) | 73.5 (155) | 0.99 |
| Ischaemic aetiology (% (n)) | 79 (143) | 69.3 (140) | 66 (130) | 42.2 (89) | <0.001 |
| NYHA class | 0.12 | ||||
| I | 14.4 (26) | 17.9 (36) | 25.4 (50) | 24.3 (51) | |
| II | 48.1 (87) | 46.3 (93) | 39.6 (78) | 48.1 (101) | |
| III | 35.4 (64) | 33.3 (67) | 33.5 (66) | 26.7 (56) | |
| IV | 2.2 (4) | 2.5 (5) | 1.5 (3) | 1 (2) | |
| Any device therapy (% (n)) | 36.5 (66) | 32.2 (65) | 24.9 (49) | 20.4 (43) | 0.002 |
| Cardiac resynchronisation (% (n)) | 28.7 (52) | 28.7 (58) | 23.4 (46) | 19 (40) | 0.06 |
| Implantable defibrillator (% (n)) | 18.2 (33) | 13.4 (27) | 8.6 (17) | 9 (19) | 0.01 |
| Any atrial fibrillation or flutter (% (n)) | 22 (39) | 23.9 (48) | 30.4 (58) | 48.8 (100) | <0.001 |
| Non-sustained VT (% (n)) | 36.9 (65) | 35.8 (72) | 37.6 (71) | 47.1 (96) | 0.08 |
| Diabetes (% (n)) | 40.9 (74) | 28.7 (58) | 20.8 (41) | 14.7 (31) | <0.001 |
| β-blocker use (% (n)) | 82.3 (149) | 81 (162) | 77.2 (152) | 76.6 (160) | 0.42 |
| β-blocker dose (mg bisoprolol/day) | 4.0 (0.3) | 3.4 (0.2) | 3.6 (0.2) | 3.1 (0.2) | 0.088 |
| ACEi/ARB use (% (n)) | 86.7 (157) | 87 (174) | 91.4 (180) | 87.6 (183) | 0.45 |
| MRA use (% (n)) | 45.9 (83) | 43.5 (87) | 41.1 (81) | 32.1 (67) | 0.03 |
| Furosemide dose (mg/day) | 66 (4) | 56 (4) | 52 (4) | 40 (3) | <0.001 |
| Age (Weeks) | Sex | CF1-CD | CF1-HCD | DF1-CD | DF1-HCD |
| Hepatic TGs content (mg/g tissue) | |||||
| 5 | Male | 76.4 ± 7 | 78 ± 8 | 77 ± 6 | 79 ± 6 |
| Female | 74 ± 6 | 76 ± 5 | 75 ± 5 | 76 ± 5 | |
| 10 | Male | 81 ± 8 | 85 ± 8 | 87 ± 7 | 91 ± 8* |
| Female | 78 ± 5 | 80 ± 6 | 81 ± 5*** | 85 ± 7* | |
| 15 | Male | 84 ± 7 | 92 ± 9* | 96 ± 8* | 105 ± 9*,** |
| Female | 81 ± 5 | 84 ± 7*** | 86 ± 7*** | 92 ± 7*,**,*** | |
| 20 | Male | 86 ± 8 | 94 ± 8* | 98 ± 6* | 109 ± 9*,** |
| Female | 83 ± 6 | 88 ± 6 | 92 ± 7* | 99 ± 10*,**,*** | |
| 25 | Male | 94 ± 9 | 99 ± 9 | 103 ± 9* | 111 ± 10*,** |
| Female | 87 ± 6 | 94 ± 7 | 98 ± 6* | 104 ± 8*,** | |
| 30 | Male | 98 ± 9 | 104 ± 10 | 108 ± 9* | 116 ± 10*,** |
| Female | 92 ± 7 | 96 ± 8 | 102 ± 8* | 110 ± 9*,** | |
| Muscular TGs content (mg/g tissue) | |||||
| 5 | Male | 1.52 ± 0.12 | 1.53 ± 0.1 | 1.6 ± 0.11 | 1.65 ± 0.13*,** |
| Female | 1.44 ± 0.11 | 1.5 ± 0.11 | 1.48 ± 0.12*** | 1.51 ± 0.12*** | |
| 10 | Male | 1.75 ± 0.1 | 1.9 ± 0.14* | 1.84 ± 0.14 | 2.25 ± 0.17*,** |
| Female | 1.63 ± 0.13*** | 1.82 ± 0.13* | 1.71 ± 0.13*** | 1.88 ± 0.12*,*** | |
| 15 | Male | 1.82 ± 0.12 | 2.1 ± 0.12* | 2.05 ± 0.16* | 2.74 ± 0.21*,** |
| Female | 1.71 ± 0.1*** | 1.85 ± 0.12*,*** | 1.89 ± 0.17*,*** | 2.2 ± 0.16*,**,*** | |
| 20 | Male | 2 ± 0.11 | 2.15 ± 0.14* | 2.20 ± 0.15* | 2.81 ± 0.17*,** |
| Female | 1.86 ± 0.14*** | 1.94 ± 0.13*** | 2.04 ± 0.17*,*** | 2.32 ± 0.21*,**,*** | |
| 25 | Male | 2.1 ± 0.12 | 2.2 ± 0.15 | 2.48 ± 0.2*,** | 2.96 ± 0.23*,** |
| Female | 1.94 ± 0.13*** | 2.1 ± 0.12* | 2.2 ± 0.16*,*** | 2.46 ± 0.21*,**,*** | |
| 30 | Male | 1.9 ± 0.1 | 2.2 ± 0.15* | 2.7 ± 0.15*,** | 3 ± 0.26*,** |
| Female | 1.85 ± 0.12 | 1.98 ± 0.11*** | 2.55 ± 0.18*,** | 2.78 ± 0.19*,**,*** |
| H2O | M9 medium | LB medium | 10 fold diluted LB medium | |
| Linear range of adenosine concentrations (mM) | 0.065–10 | 0.054–10 | 3.2–10 | 0.098–10 |
| Detection limit (mM) | 0.065 | 0.054 | 3.2 | 0.098 |
| Z′(calculated with 1 and 10 mM) | 0.881 | 0.911 | 0.652 | 0.902 |
| Concentration of adenosine/mM | S/B(H2O) | S/B(M9 medium) | S/B(LB medium) | S/B(10-fold diluted LB medium) |
| 0.01 | 1.08 | 2.76 | 1.03 | |
| 0.025 | 1.19 | 2.90 | 1.03 | |
| 0.05 | 1.38 | 3.08 | 1.07 | |
| 0.075 | 1.51 | 3.29 | 1.07 | |
| 0.1 | 1.66 | 3.56 | 1.08 | |
| 0.25 | 2.66 | 4.80 | 1.23 | |
| 0.5 | 4.31 | 6.88 | 1.44 | 1.44 |
| 0.75 | 6.14 | 9.27 | 1.46 | 1.66 |
| 1 | 7.79 | 11.65 | 1.50 | 1.89 |
| 2 | 14.37 | 16.97 | 1.61 | 2.82 |
| 3 | 19.59 | 24.69 | 1.73 | 3.83 |
| 4 | 24.80 | 32.62 | 1.84 | 4.64 |
| 5 | 31.15 | 38.84 | 1.95 | 5.27 |
| 6 | 36.31 | 47.54 | 2.01 | 6.29 |
| 7 | 42.47 | 54.51 | 2.11 | 7.02 |
| 8 | 47.33 | 62.92 | 2.21 | 7.79 |
| 9 | 52.85 | 65.68 | 2.30 | 8.97 |
| 10 | 58.54 | 71.32 | 2.35 | 9.51 |
| Lottery A | Lottery B | Expected value of Lottery A | Expected value of Lottery B |
| 10% 100 PLN; 90% 80 PLN | 10% 185 PLN; 90% 5 PLN | 82 | 23 |
| 20% 100 PLN; 80% 80 PLN | 20% 185 PLN; 80% 5 PLN | 84 | 41 |
| 30% 100 PLN; 70% 80 PLN | 30% 185 PLN; 70% 5 PLN | 86 | 59 |
| 40% 100 PLN; 60% 80 PLN | 40% 185 PLN; 60% 5 PLN | 88 | 77 |
| 50% 100 PLN; 50% 80 PLN | 50% 185 PLN; 50% 5 PLN | 90 | 95 |
| 60% 100 PLN; 40% 80 PLN | 60% 185 PLN; 40% 5 PLN | 92 | 113 |
| 70% 100 PLN; 30% 80 PLN | 70% 185 PLN; 30% 5 PLN | 94 | 131 |
| 80% 100 PLN; 20% 80 PLN | 80% 185 PLN; 20% 5 PLN | 96 | 149 |
| 90% 100 PLN; 10% 80 PLN | 90% 185 PLN; 10% 5 PLN | 98 | 167 |
| 100% 100 PLN; 0% 80 PLN | 100% 185 PLN; 0% 5 PLN | 100 | 185 |
| Sample | mPEG-acid (g) | Chitosan (g) | EDC (g) | NHS (g) |
| mPEG-g5-Chitosan | 0.43 | 0.50 | 0.20 | 0.12 |
| mPEG-g6-Chitosan | 0.43 | 0.45 | 0.20 | 0.12 |
| mPEG-g7-Chitosan | 0.43 | 0.40 | 0.20 | 0.12 |
| mPEG-g8-Chitosan | 0.43 | 0.35 | 0.20 | 0.12 |
| mPEG-g11-Chitosan | 0.43 | 0.30 | 0.20 | 0.12 |
| mPEG-g13-Chitosan | 0.24 | 0.25 | 0.20 | 0.12 |
| N | % | |
| Total number of patients | 14 | |
| Age | ||
| Median (Range) | 69.5 (38–88) | |
| Gender | ||
| Male | 9 | 64 |
| Female | 5 | 36 |
| Race | ||
| White | 14 | 100 |
| Performance Status (PS) | ||
| 0 | 7 | 50 |
| 1 | 7 | 50 |
| Extra-lymphatic sites involved | ||
| 0 | 8 | 57 |
| 1 | 1 | 7 |
| 2 | 3 | 21 |
| >2 | 2 | 14 |
| Elevated LDH | 6 | 43 |
| Bone Marrow Involvement | 1 | 7 |
| B symptom | 0 | 0 |
| Mediastinal mass | 0 | 0 |
| Lymph node or aggregate with a diameter >5 cm | 5 | 36 |
| Prior Treatment | ||
| Prior Chemotherapy | 14 | 100 |
| Prior Immunotherapy | 4 | 29 |
| Prior Radiation Therapy | 4 | 29 |
| Prior Surgery (with therapeutic intent) | 1 | 7 |
| Prior Bone Marrow Transplant* | 3 | 21 |
| Other Prior Therapy** | 1 | 7 |
| Protein | Gene symbol | Gene ID | Sequence 5′- 3′ F | Sequence 5′- 3′ R |
| Lipocalin2 | Lcn2 | 16819 | ATATGCACAGGTATCCTCAG | GAAACGTTCCTTCAGTTCAG |
| CD163 | Cd163 | 93671 | AGTCTGCTCACGATACATAG | TCCTTCTGGAATAGATTGGG |
| SNP marker | Position (bp)* | Location | SNP† | MAF‡ | P value§ | SLI association¶ |
| rs7806058 | 146007792 | Intron 1 | A/G | 0.35 | ns | − |
| rs6946112 | 146059217 | Intron 1 | C/T | 0.27 | ns | − |
| rs12703803 | 146062909 | Intron 1 | T/G | 0.29 | ns | − |
| rs2058377 | 146090070 | Intron 1 | A/G | 0.31 | ns | − |
| rs12667234 | 146111176 | Intron 1 | A/G | 0.30 | ns | − |
| rs2888335 | 146124574 | Intron 1 | T/C | 0.30 | ns | − |
| rs7805539 | 146160278 | Intron 1 | G/A | 0.28 | ns | − |
| rs4726793 | 146276890 | Intron 1 | A/G | 0.20 | ns | − |
| rs10277654 | 146352576 | Intron 1 | T/C | 0.44 | ns | − |
| rs7794745 | 146489606 | Intron 2 | A/T | 0.26 | ns | − |
| rs6945085 | 146691220 | Intron 3 | T/C | 0.09 | ns | − |
| rs1024676 | 146715861 | Intron 3 | C/T | 0.38 | ns | − |
| rs10282158 | 146738067 | Intron 3 | T/A | 0.06 | ns | − |
| rs7812091 | 146740577 | Intron 3 | T/C | 0.38 | ns | − |
| rs10500170 | 146848251 | Intron 8 | A/G | 0.16 | ns | − |
| rs1603453 | 146908919 | Intron 8 | T/A | 0.11 | ns | − |
| rs1603450 | 146913540 | Intron 8 | G/A | 0.18 | 0.0426* | − |
| rs10251377 | 147117454 | Intron 10 | A/G | 0.25 | ns | − |
| rs851715 | 147526906 | Intron 13 | A/G | 0.32 | ns | + |
| rs1177007 | 147546371 | Intron 13 | A/G | 0.31 | ns | − |
| rs10246256 | 147554807 | Intron 13 | T/C | 0.31 | ns | + |
| rs2710102 | 147574390 | Intron 13 | C/T | 0.49 | 0.0239* | + |
| rs759178 | 147575112 | Intron 13 | G/T | 0.49 | 0.0248* | + |
| rs17236239 | 147582305 | Intron 13 | A/G | 0.35 | 0.0851 | + |
| rs2538976 | 147585819 | Intron 13 | G/A | 0.50 | 0.0535 | + |
| rs2538963 | 147599446 | Intron 13 | G/A | 0.32 | ns | − |
| rs2710117 | 147601772 | Intron 14 | A/T | 0.38 | 0.0771 | + |
| rs10240503 | 147674978 | Exon 15 | A/G | 0.11 | ns | − |
| rs12155129 | 147856865 | Intron 17 | A/G | 0.06 | ns | − |
| rs11980146 | 147956733 | Intron 20 | A/G | 0.34 | ns | − |
| CHR | GENE | SNP | OR | L95 | U95 | P |
| 19 | APOE | rs157580 | 0.51 | 0.45 | 0.59 | 3.30E-21 |
| 5 | HMGCR | rs3846662 | 1.16 | 1.02 | 1.32 | 0.02 |
| 12 | MMAB/MVK | rs7298565 | 0.88 | 0.78 | 1 | 0.05 |
| 5 | TIMD4/HAVCR1 | rs1363232 | 0.89 | 0.78 | 1.01 | 0.06 |
| 15 | LIPC | rs1532085 | 0.89 | 0.78 | 1.01 | 0.07 |
| 16 | CETP | rs9989419 | 1.12 | 0.98 | 1.27 | 0.09 |
| 19 | NCAN | rs2304130 | 1.16 | 0.92 | 1.47 | 0.21 |
| 20 | HNF4A | rs1800961 | 0.8 | 0.55 | 1.16 | 0.24 |
| 18 | LIPG | rs4939883 | 1.09 | 0.92 | 1.28 | 0.32 |
| 16 | LCAT | rs2271293 | 0.91 | 0.75 | 1.1 | 0.33 |
| 1 | SORT1 | rs646776 | 1.07 | 0.92 | 1.24 | 0.4 |
| 1 | GALNT2 | rs10779835 | 0.95 | 0.84 | 1.08 | 0.44 |
| 9 | TTC39B | rs471364 | 1.07 | 0.88 | 1.3 | 0.48 |
| 2 | APOB | rs506585 | 1.05 | 0.9 | 1.23 | 0.53 |
| 19 | LDLR | rs2228671 | 0.96 | 0.79 | 1.17 | 0.66 |
| 2 | APOB | rs693 | 0.98 | 0.87 | 1.11 | 0.78 |
| 16 | CETP | rs3764261 | 0.99 | 0.86 | 1.13 | 0.86 |
| 9 | ABCA1 | rs3847303 | 0.99 | 0.82 | 1.19 | 0.92 |
| Years | Survival rate (%) | 95% confidence interval | |
| Overall survival | 2 | 90 | 80; 100 |
| 3 | 78 | 64; 96 | |
| 5 | 69 | 53; 90 | |
| Disease-free survival | 2 | 85 | 72; 100 |
| 3 | 85 | 72; 100 | |
| 5 | 79 | 65; 98 |
| Score | Symptoms |
| Grade 1 | Local paraesthesia (anesthesia, tingling, stinging) |
| Grade 2 | Hypersecretion (sweat, saliva) |
| Grade 3 | Impaired vision, hearing, speech, dysphagia |
| Grade 4 | Bilateral ptosis |
| Grade 5 | Severe dyspnea |
| Grade 6 | Severe consciousness disorders, motor and respiratory paralysis |
| Cell type | Species | Passage | Culture method | Reference |
| Chondrocyte | Human | P2 | Monolayer + 3D | [7] |
| ADSC | Human | P4 | Monolayer + 3D | [8] |
| SDSC | Human | P2 | Monolayer + 3D | [11] |
| BMSC | Human | P2 | Monolayer + 3D | [11] |
| Chondrocyte | Human | P2 | Monolayer | [11] |
| Chondrocyte | Rabbit | P0-P4 | Monolayer | [12] |
| Chondrocyte | Human | P0-P4 | Monolayer | [13] |
| SDSC | Human | P4-P7 | Monolayer + 3D | [14] |
| Chondrocyte | Human | P0-P4 | Monolayer + 3D | [15] |
| BMSC | Human | P1-P4 | Monolayer + 3D | [15] |
| Num. of genes | RSVM | SVM-RFE | SVM-t | |||
| CV2 | Mean SV | CV2 | Mean SV | CV2 | Mean SV | |
| 7129 | 22.09% | 51.34 | 22.09% | 51.34 | 22.09% | 51.34 |
| 6060 | 20.93% | 46.78 | 22.09% | 51.35 | 20.93% | 50.85 |
| 5151 | 20.93% | 45.07 | 22.09% | 51.40 | 19.77% | 50.20 |
| 4378 | 20.93% | 44.24 | 22.09% | 51.42 | 18.60% | 49.24 |
| 3721 | 20.93% | 43.99 | 22.09% | 51.35 | 15.12% | 48.22 |
| 3163 | 20.93% | 43.53 | 22.09% | 51.34 | 15.12% | 47.60 |
| 2689 | 20.93% | 43.38 | 22.09% | 51.36 | 15.12% | 47.38 |
| 2286 | 20.93% | 43.12 | 20.93% | 51.86 | 15.12% | 46.71 |
| 1943 | 22.09% | 43.17 | 20.93% | 52.79 | 12.79% | 46.05 |
| 1652 | 22.09% | 43.26 | 20.93% | 52.51 | 12.79% | 45.10 |
| 1404 | 22.09% | 43.12 | 20.93% | 51.84 | 13.95% | 43.78 |
| 1193 | 22.09% | 42.87 | 20.93% | 52.33 | 10.47% | 42.60 |
| 1014 | 22.09% | 42.86 | 20.93% | 51.15 | 8.14% | 41.84 |
| 862 | 22.09% | 42.24 | 22.09% | 51.64 | 8.14% | 41.50 |
| 733 | 22.09% | 41.47 | 22.09% | 52.21 | 9.30% | 41.03 |
| 623 | 22.09% | 41.55 | 23.26% | 51.72 | 12.79% | 40.07 |
| 530 | 22.09% | 40.85 | 23.26% | 51.28 | 11.63% | 39.71 |
| 450 | 22.09% | 40.40 | 23.26% | 50.59 | 10.47% | 39.20 |
| 382 | 22.09% | 39.08 | 23.26% | 50.70 | 9.30% | 38.34 |
| 325 | 22.09% | 38.62 | 23.26% | 50.77 | 11.63% | 37.43 |
| 276 | 22.09% | 38.52 | 24.42% | 49.21 | 9.30% | 36.62 |
| 235 | 22.09% | 38.71 | 24.42% | 48.27 | 11.63% | 36.06 |
| 200 | 22.09% | 37.28 | 24.42% | 47.67 | 12.79% | 35.59 |
| 170 | 22.09% | 36.33 | 24.42% | 45.84 | 12.79% | 35.13 |
| 144 | 22.09% | 36.19 | 23.26% | 44.64 | 15.12% | 33.88 |
| 122 | 24.42% | 35.43 | 24.42% | 42.81 | 15.12% | 33.48 |
| 104 | 24.42% | 34.30 | 24.42% | 40.87 | 15.12% | 32.59 |
| 88 | 24.42% | 32.87 | 29.07% | 39.02 | 16.28% | 31.99 |
| 75 | 24.42% | 31.28 | 26.74% | 36.56 | 17.44% | 31.92 |
| 64 | 26.74% | 29.84 | 25.58% | 34.08 | 16.28% | 31.80 |
| 54 | 26.74% | 27.41 | 25.58% | 30.07 | 17.44% | 31.97 |
| 46 | 26.74% | 25.94 | 26.74% | 27.50 | 15.12% | 31.90 |
| 39 | 25.58% | 24.42 | 25.58% | 25.10 | 12.79% | 32.30 |
| 33 | 23.26% | 22.53 | 29.07% | 23.09 | 11.63% | 32.66 |
| 28 | 20.93% | 20.42 | 26.74% | 19.87 | 15.12% | 32.97 |
| 24 | 20.93% | 18.86 | 24.42% | 19.31 | 13.95% | 33.16 |
| 20 | 23.26% | 16.94 | 25.58% | 16.59 | 16.28% | 33.51 |
| 17 | 23.26% | 15.83 | 24.42% | 15.71 | 16.28% | 33.58 |
| 14 | 22.09% | 16.42 | 23.26% | 16.15 | 17.44% | 34.08 |
| 12 | 24.42% | 17.72 | 26.74% | 17.03 | 16.28% | 34.55 |
| 10 | 25.58% | 19.76 | 26.74% | 19.95 | 13.95% | 35.15 |
| 8 | 24.42% | 22.45 | 29.07% | 22.60 | 15.12% | 36.01 |
| 7 | 24.42% | 23.64 | 27.91% | 24.16 | 16.28% | 36.44 |
| 6 | 29.07% | 25.35 | 27.91% | 25.97 | 17.44% | 36.87 |
| 5 | 27.91% | 27.86 | 30.23% | 28.73 | 18.60% | 37.50 |
| Group 1 | Group 2 | p | |
| N =58 | N= 219 | ||
| All-cause mortality, N (%) | 5 (8.6%) | 42 (19.9%) | 0.05 |
| Non-fatal ACS, N (%) | 2 (3.4%) | 32 (14.6%) | 0.03 |
| Stroke, N (%) | 0 (0%) | 5 (2.9%) | 0.2 |
| MACCE, N (%) | 7 (12.0%) | 70 (31.9%) | <0.01 |
| Baseline | 60 mins | 120 mins | 180 mins | 240 mins | ||
| EE | CON | 4.29 ± 0.28 | 4.57 ± 0.41 | 4.28 ± 0.26 | 4.29 ± 0.35 | 4.42 ± 0.33 |
| INS | 4.01 ± 0.24 | 3.88 ± 0.14 | 3.91 ± 0.21∗ | 3.78 ± 0.24 | 3.90 ± 0.16 | |
| RER | CON | 0.89 ± 0.04 | 0.80 ± 0.05 | 0.83 ± 0.02 | 0.82 ± 0.02 | 0.85 ± 0.02 |
| INS | 0.89 ± 0.04 | 0.94 ± 0.02∗ | 0.94 ± 0.02∗∗ | 0.92 ± 0.04 | 0.91 ± 0.02 | |
| CHO ox | CON | 0.17 ± 0.03 | 0.09 ± 0.03 | 0.12 ± 0.01 | 0.10 ± 0.02 | 0.13 ± 0.02 |
| INS | 0.16 ± 0.03 | 0.20 ± 0.02∗ | 0.19 ± 0.02∗∗ | 0.16 ± 0.03 | 0.17 ± 0.02 | |
| FAT ox | CON | 0.04 ± 0.01 | 0.09 ± 0.02 | 0.06 ± 0.01 | 0.07 ± 0.01 | 0.06 ± 0.01 |
| INS | 0.04 ± 0.01 | 0.02 ± 0.01∗ | 0.02 ± 0.01∗∗ | 0.03 ± 0.01 | 0.03 ± 0.01 |
| Library name | ||||||||
| AA9 | B421 | CHORI-514 | MCF7 | PM-1 | CHORI-510 | CHORI-518 | CHORI-520 | |
| Clinical sample designation | AA9 | B421 | S104 | MCF-7 | 25-48 | 860-7 | BT-474 | SK-BR-3 |
| Organ site | Brain | Breast | Breast | Breast cancer adenocarcinoma (metastasis - pleural effusion) | Prostate metastasis | Ovarian carcinoma | Ductal carcinoma | Breast cancer adenocarcinoma (metastasis - pleural effusion) |
| Therapies applied | Radiotherapy | Chemotherapy 4 months before surgery (CMF) | No radiation therapy or chemotherapy before surgery | N/A | Hormone ablation, palliative radiotherapy | No therapy before surgery | N/A | N/A |
| Patient status | Deceased | Deceased, no recurrence | No recurrence for 10 years | N/A | Deceased | Tumor recurred within 13 months | N/A | N/A |
| Total amount of tumor material used for library construction (mg) | 100 | 150 (20 mg effective) | 100 | N/A | 50 | 200 | N/A | N/A |
| Average clone size (± standard deviation; kb) | 129.1 ± 38.3 | 136.4 ± 29.2 | 166.1 ± 53.2 | 148.0 ± 30 | N/D | 149.3 ± 28.8 | 179 ± 23 | 154 ± 25 |
| Gene | Cell locale | Tissue | Modality of expression |
| HSPA8 | Cytosol. Translocate to nucleus and nucleoli upon heat shock. Surface of embryonic stem cells | Highly expressed in all tisuses | Constitutive. Moderately induced by heat shock |
| HSPA2 | Nucleus | Mostly in testis, skeletal and heart muscles, esophagous, brain | Constitutive |
| HSPA1A and HSPA1B | Cytosol. Nucleus and nucleoli upon heat shock | All tissues | Strongly induced by heat shock |
| HSPA1L | Mostly cytosol under basal conditions. Nucleus but not nucleoli upon heat shock | Spermatides | Constitutive. Not induced by heat shock |
| HSPA6 | Cytosol. Nucleus | Most tissues | Induced by heat shock. No basal expression |
| HSPA5 | Endoplasmic reticulum (ER) | All tissue | Induced by ER stressors |
| HSPA9B | Mitochondria. ER. Cytosol. Cytosolic vesicles. Membrane surface | Many tissues | Constitutive |
| STCH | Microsomas | All tissues | Constitutive |
| HSPA14 | Cytosol. Associated to ribosomes | Many tissues (low expression) | Undetermined |
| HSPA4 | Cytosolic (?) | Most tissues | Constitutive. Not induced by heat shock |
| HSPA4L | Cytosol. Nucleus upon heat shock | Mostly testis | Constitutive. Induced by heat shock in somatic cells but not in germ cells |
| HSPH1 | Cytosol. Nucleus upon heat shock, possibly nucleoli | Most tissues | Constitutive. Induced by heat shock |
| HYOU1 | ER. Cytosol (isoform 3) | Liver, pancreas. Highly expressed in cells with well developed ER | Induced by ER stressors |
| HSPA12A | Undetermined yet | Brain. Kidney. Muscle | Constitutive. Induced by stress |
| HSPA12B | Undetermined yet | Skeletal and heart muscles | Constitutive. Induced by stress |
| IAP | ||||||
| Normal (n =27) | Grade I (n = 55) | Grade II (n = 109) | Grade III (n = 78) | Grade IV (n = 32) | P† | |
| Shock | 7 (26) | 33 (60) | 75 (69·8) | 56 (72) | 24 (75) | < 0·001 |
| Renal failure | 15 (56) | 33 (60) | 66 (60·6) | 60 (77) | 27 (84) | < 0·001 |
| CRRT | 0 (0) | 12 (22) | 31 (28·4) | 34 (44) | 21 (66) | < 0·001 |
| Respiratory failure | 10 (37) | 32 (58) | 76 (69·7) | 55 (71) | 28 (88) | 0·007 |
| Mechanical ventilation | 5 (19) | 29 (53) | 62 (56·9) | 53 (68) | 27 (84) | 0·007 |
| Infected necrosis | 3 (11) | 9 (16) | 30 (27·5) | 32 (41) | 9 (28) | 0·005 |
| Surgery | 5 (19) | 15 (27) | 28 (25·7) | 35 (45) | 16 (50) | 0·006 |
| Decompressive laparotomy | 0 (0) | 0 (0) | 0 (0) | 3 (4) | 6 (19) | |
| Nutrition | 0·009 | |||||
| None | – | 9 (16) | 32 (29·4) | 16 (21) | 6 (19) | |
| Enteral | – | 22 (40) | 26 (23·9) | 15 (19) | 6 (19) | |
| Parenteral | – | 23 (42) | 45 (41·3) | 43 (55) | 19 (59) | |
| Enteral and parenteral | – | 1 (2) | 6 (5·5) | 4 (5) | 1 (3) | |
| ICU LOS (days)* | 5 (3–7) | 6 (3–14·3) | 10 (5–27) | 18 (6·8–32·3) | 11 (3·5–25) | < 0·001‡ |
| Hospital LOS (days)* | 15 (12–26) | 22 (13–38) | 24 (14–43) | 30 (8–59) | 17 (8–29) | < 0·001‡ |
| Mortality | 1 (4) | 11 (20) | 33 (30·3) | 31 (40) | 21 (66) | < 0·001 |
| Cause of death | < 0·001 | |||||
| Initial SIRS | 0 (0) | 5 of 11 (45) | 13 of 33 (39) | 7 of 31 (23) | 7 of 21 (33) | |
| Pancreatic infection | 0 (0) | 2 of 11 (18) | 4 of 33 (12) | 9 of 31 (29) | 7 of 21 (33) | |
| Non‐pancreatic infection | 0 (0) | 1 of 11 (9) | 7 of 33 (21) | 3 of 31 (10) | 2 of 21 (10) | |
| Other | 1 of 1 (100) | 3 of 11 (27) | 9 of 33 (27) | 12 of 31 (39) | 5 of 21 (24) |
| Study (reference) | Patients | Molecular marker | Ethnicity (Country) | Evaluation criteria | Sample size | Chemotherapeutic regimens | Outcomes |
| Goekkurt 2006, [11] | Patients with advanced GC | TS, GSTs, MTHFR, ERCC1-118 | European (Germany) | RECIST | 52 | 5-Fu+cisplatin + leucovorin | RR and OS |
| Ruzzo 2006 [14] | Patients with advanced GC | TS, GSTs, MTHFR, ERCC1-118 | European (Italy) | Others | 175 | fluorouracil/cisplatin | RR and OS |
| Shim 2010 [17] | Patients with recurrent or metastatic GC | GSTs | Asian (Korea) | RECIST | 200 | Paclitaxel/docetaxel +cisplatin | RR and OS |
| Park 2011 [18] | Patients with metastatic GC | ERCC1-118 | Asian (Korea) | RECIST | 108 | S-1 + cisplatin | RR and OS |
| Han 2010 [19] | Patients with recurrent or metastatic GC | TS, ERCC1-118 | Asian (Korea) | RECIST | 38 | 5-Fu+leucovorin +oxaliplatin | RR and OS |
| Stocker 2009 [20] | Neoadjuvant chemotherapy for locally advanced GC without distant metastasis | ERCC1-118 | European (Germany) | Others | 178 | 5-Fu+leucovorin +cisplatin | RR and OS |
| Seo 2009 [21] | Patients with recurrent or metastatic GC | TS, GSTs, ERCC1-118 | Asian (Korea) | RECIST | 94 | 5-Fu+ oxaliplatin/irinotecan | RR, OS and toxicity |
| Liu 2011 [22] | Patients with advanced GC | GSTs, ERCC1-118 | Asian (China) | NR | 126 | 5-FU+leucovorin +oxaliplatin | OS |
| Ott 2008 [23] | Neoadjuvant chemotherapy for locally advanced GC without distant metastasis | GSTs | European (Germany) | Others | 139 | 5-Fu+leucovorin + cisplatin | RR and OS |
| Li 2010 [24] | Patients with advanced GC | GSTs | Asian (China) | Others | 92 | 5-Fu +oxaliplatin | RR, OS and toxicity |
| Lu 2004 [25] | Patients with advanced GC | MTHFR | Asian (China) | WHO | 75 | 5-Fu+leucovorin | RR and toxicity |
| Huang 2009 [26] | Patients with GC after curative surgery | GSTs, ERCC1-118 | Asian (China) | NR | 102 | 5-Fu+leucovorin +oxaliplatin | OS |
| Shitara 2010 [27] | Patients with inoperable GC | TS, MTHFR | Asian (Japan) | NR | 132 | 5-Fu et al. | OS and toxicity |
| Huang 2009 [28] | Patients with GC after curative surgery | TS, MTHFR | Asian (China) | NR | 116 | 5-Fu+leucovorin et al. | OS |
| Ishida 2002 [29] | Patients with GC after surgery | TS | Asian (Japan) | NR | 51 | 5-Fu et al. | OS |
| Keam 2008 [30] | Patients with recurrent or metastatic GC | GSTs, ERCC1-118 | Asian (Korea) | WHO | 73 | 5-Fu+leucovorin +oxaliplatin | RR and OS |
| Goekkurt 2009, [31] | Patients with advanced GC | TS, GSTs, MTHFR, ERCC1-118 | European (Germany) | Others | 134 | 5-Fu+leucovorin +oxaliplatin/cisplatin | RR, OS and toxicity |
| Ott 2006 [32] | Neoadjuvant chemotherapy for patients with locally advanced GC | TS, MTHFR | European (Germany) | Others | 135 | 5-Fu+cisplatin | RR and OS |
| Ott 2011 [33] | Neoadjuvant chemotherapy for patients with locally advanced GC | MTHFR | European (Germany) | Others | 144 | 5-Fu+leucovorin + cisplatin | OS |
| Lee 2005 [34] | Patients with advanced GC | TS, MTHFR | Asian (Korea) | NR | 25 | 5-Fu et al. | OS |
| Median total number of lymph nodes for patients with nodal involvement | Median total number of lymph nodes for patients without nodal involvement | P-value | |
| PCG | 13.0 (10–17)* | 14.0 (11–18)* | 0.654 |
| PCG | PSG | ||
| Median number of involved lymph nodes | 3.0 (1–6)* | 2.5 (1–5)* | 0.904 |
| Number of patients | cEPCs(%) | P | |
| Stenosis | 0.012 | ||
| <70% | 48 | 0.052 ± 0.022 | |
| ≥70% | 60 | 0.091 ± 0.035 | |
| Number of intracranial symptomatic arteries | 0.578 | ||
| 1 | 30 | 0.065 ± 0.024 | |
| 2 | 26 | 0.058 ± 0.033 | |
| >2 | 52 | 0.067 ± 0.044 |
| Sample | CO (μmol·g−1) | |||
| Anhydride | Phenol | Carbonyl and Quinone | Pyrone and Chromene | |
| RN1 | – | – | 380 | 620 |
| RN1P | – | – | 14 | 140 |
| RN1A | 137 | 1310 | – | |
| RN2 | – | 52 | 60 | 800 |
| RN2D5 | – | 32 | – | 250 |
| RN2D10 | – | – | 30 | 270 |
| Indication | Number |
| Renal impairment and acidosis | 20 |
| Renal impairment and hyperkalaemia | 0 |
| Renal impairment, acidosis and hyperkalaemia | 6 |
| Renal impairment, acidosis and convulsions | 2 |
| Renal impairment, acidosis, hyperkalaemia and convulsions | 3 |
| Worsening renal function despite conservative measures | 5 |
| Worsening renal function and convulsions | 1 |
| Renal impairment and pulmonary oedema | 1 |
| Renal impairment, acidosis and pulmonary oedema | 1 |
| Total | 39 |
| Class of agent | Chemical/brand name | Preventive targets |
| Selective estrogen receptor modulators and other hormonal agents | Tamoxifen | Breast |
| Arzoxifene | Breast | |
| Acolbifene | Breast | |
| Raxoxifene/Evista® | Breast | |
| Finasteride | Prostate | |
| Nonsteroidal anti- inflammatory drugs | Celecoxib/Celebrex® | Colon, breast, prostate, bladder |
| Sulindac/Clinoril® | Esophagus, skin | |
| Aspirin | ||
| Minerals and micronutrients | Calcium compounds | Colon |
| Glucocorticoids | Budesonide | Lung |
| Retinoids | All-trans-retinoic acid tretinoin/Retin-A® | Cervix, esophagus, larynx, lung, |
| 9-cis-Retinoic acid alitretinoin/Panretin® | Nasopharynx, oral cavity, ovary | |
| 13-cis-Retinoic acid isotreninoin/Accutane® | ||
| 4-Hydroxyretinamide, (4-HPR) fenretinide |
| Authors | Publication year | Patient number | Gender | Age | Open (O) or laparoscopic ablation (L) | Symptom related to lymphangioma | Left/right adrenal gland | |
| 1 | Akand et al. [6] | 2013 | 1 | F | 44 | O | Pain | L |
| 2 | Sourial et al. [7] | 2013 | 1 | F | 52 | L | Nihil | L |
| 3 | Makni et al. [12] | 2012 | 2 | F/M | 40/40 | O/L | Nihil/pain | 2 L |
| 4 | Ellis et al. [2] | 2011 | 9 | 6 F/3 M | 28 to 56a | Not precised | 5 Nihil/4 pain | 6 R/3 L |
| 5 | Chien et al. [13] | 2008 | 8 | 6 F/2 M | 31 to 59a | Not precised | 4 Nihil/2 pain/1 fever/1 HTNb | 4 R/4 L |
| 6 | Bettaïeb et al. [8] | 2007 | 1 | F | 22 | Not precised | Pain | L |
| 7 | Ates et al. [9] | 2005 | 1 | F | 26 | O | Weakness | R |
| 8 | Garcia et al. [10] | 2004 | 1 | F | 22 | Not precised | Pain | R |
| 9 | Longo et al. [11] | 2000 | 1 | F | 30 | O | Pain | R |
| 10 | Trojan et al. [3] | 2000 | 1 | M | 40 | Not precised | Nihil | R |
| Primary screening | Triage test | Test positivity (%)1 | Sensitivity (95%-CI) | Specificity (95%-CI) | PPV (95%-CI) | NPV (95%-CI) | |||||
| Test | Threshold | CIN2+ | CIN3+ | CIN2+ | CIN3+ | CIN2+ | CIN3+ | CIN2+ | CIN3+ | ||
| Cytology | ASCUS+ | none | 7.5 | 61* (44-77) | 74# (52-90) | 94 (93-96) | 94 (92-95) | 28 (18-39) | 22 (13-32) | 98.6 (97.6-99.2) | 99.4 (98.7-99.8) |
| HR-HPV of ASCUS | 5.1 | 56 (38-72) | 70 (47-87) | 97 (96-98) | 96 (95-98) | 38 (25-52) | 30 (18-44) | 98.4 (97.4-99.1) | 99.3 (98.6-99.7) | ||
| GP5+/6+ PCR | HR-HPV | none | 14.0 | 86* (70-95) | 96# (78-99) | 88 (86-90) | 88 (86-90) | 21 (15-29) | 15 (10-22) | 99.5 (98.7-99.8) | 99.9 (99.4-100.0) |
| ASCUS+ | 3.2 | 47 (30-64) | 70 (47-87) | 98 (97-99) | 98 (97-99) | 50 (32-68) | 47 (30-65) | 98.1 (97.1-98.9) | 99.3 (98.6-99.7) |
| Mean | Median | Inter-quartile range | Direct cost as % of total cost of illness | |
| Total CNCD sample (n = 475) | 1040.82 | 40 | (1000, 0) | 56.8 % |
| Chronic pain conditions (n = 126) | 926.92 | 200 | (1268, 0) | 51.6 % |
| Chronic respiratory conditions (n = 98) | 623.60 | 0 | (900, 0) | 60.8 % |
| Chronic cardiovascular conditions (n = 95) | 1723.99 | 200 | (1600, 0) | 54.0 % |
| Chronic sense organ conditions (n = 65) | 465.35 | 0 | (357, 0) | 66.4 % |
| Chronic neuropsychiatric conditions (n = 47) | 1465.64 | 50 | (951, 0) | 65.2 % |
| Chronic digestive conditions (n = 42) | 929.05 | 70 | (1268, 0) | 53.3 % |
| GenBank accession no. | Gene name | Gene symbol | Fold change (HN2/control)a | Summary function |
| Highest response to HN2 | ||||
| BG080773 | AMP deaminase 3 | Ampd3 | 4.10 | Purine metabolism |
| BG066562 | proteasome (prosome, macropain) 26S subunit, non-ATPase, 7 | Psmd7 | 3.86 | Protein degradation |
| C87546 | serine/threonine kinase 11 | Stk11 | 3.83 | Cell cycle and polarity |
| BG086264 | polymerase (RNA) II, DNA directed | Polr2 | –3.27 | RNA synthesis |
| Neuronal function | ||||
| AI850277 | neuromedin | Nmu | 2.03 | Locomotor and stress response |
| A1848307 | staufen homolog 2 | Stauf2 | –2.14 | RNA transport |
| AI847890 | proteolipid protein | Plp | –2.16 | Myelination |
| Development | ||||
| BG088163 | split hand/foot deleted gene 1 | Shfdg1 | 3.08 | DNA repair |
| AU021923 | jagged 1 | Jag1 | 2.61 | Oligodendrocyte development |
| BG063365 | chemokine (C-X-C motif) receptor 4 | Cxcr4 | 2.39 | Neural progenitors |
| AI847007 | NCK-associated protein 1 | Nckap1 | –2.02 | Cell motility |
| AI843136 | N-myc downstream regulated 2 | Ndr2 | –2.23 | Neural differentiation |
| Apoptosis control | ||||
| C85471 | programmed cell death 8 | Pdcd8 | 2.69 | Apoptosis control |
| BG086831 | programmed cell death 4 | Pdcd4 | 2.13 | Apoptosis control |
| AI853558 | tumor necrosis factor receptor superfamily, member 12a | Tnfrsf12a | –2.11 | Nuclear factor-kappaB activation |
| Ubiquitin-proteasome pathway | ||||
| BG085363 | proteasome (prosome, macropain) 26S subunit, non-ATPase, 11 | Psmd11 | 2.71 | Proteasome (19S Lid) |
| AI843127 | huntingtin interacting protein 2 | Hip2 | 2.11 | Ubiqutiin-conjugating enzyme |
| AU020960 | proteaseome (prosome, macropain) 28 subunit, 3 | Psme3 | –2.41 | Proteasome (20S alpha subunit) |
| Growth and cell cycle control | ||||
| C86021 | growth differentiation factor 9 | Gdf9 | 3.61 | Cell growth |
| AI853288 | ras homolog gene family, member U | Arhu | 2.33 | Signal transduction |
| BG072244 | calmodulin 1 | Calm1 | 2.13 | Cell cycle |
| AI843756 | calmodulin 2 | Calm2 | –2.16 | Cell cycle |
| Miscellaneous genes of interest | ||||
| AI851097 | H1 histone family, member 2 | H1f2 | –2.36 | Chromatin compaction |
| AI849019 | myelin-associated oligodendrocytic basic protein | Mobp | –2.71 | Stuctural components of myelin |
| icddr,b service area | Government service area | |||||
| Cause of death | Male | Female | Total | Male | Female | Total |
| Communicable diseases (CDs) | 20.5 | 16.8* | 18.8 | 24.3 | 21.3* | 22.9* |
| ARI/pneumonia | 8.3 | 8.3 | 8.3 | 10.6 | 10.8 | 10.7* |
| Pulmonary tuberculosis | 10.0 | 5.8* | 8.1 | 11.0 | 6.8* | 9.1$ |
| Other CDs | 2.3 | 2.7 | 2.5 | 2.7 | 3.6$ | 3.1$ |
| Non-communicable diseases (NCDs) | 55.9 | 60.9* | 58.2 | 49.6 | 52.1$ | 50.7* |
| Stroke | 15.9 | 24.6* | 19.9 | 13.9 | 17.6* | 15.6* |
| Cardiac disease | 9.8 | 6.2* | 8.1 | 7.6 | 4.4* | 6.1* |
| COPD and asthma | 6.1 | 6.1 | 6.1 | 5.3 | 5.0 | 5.1* |
| Malignant neoplasm | 16.2 | 11.8* | 14.2 | 15.9 | 14.6 | 15.3 |
| Digestive system | 6.1 | 4.7* | 5.5 | 6.3 | 5.7 | 6.0 |
| Respiratory system | 5.8 | 2.2* | 4.1 | 6.1 | 4.2* | 5.2* |
| Other neoplasm | 4.3 | 4.9 | 4.6 | 3.5 | 4.7$ | 4.1 |
| Acute abdomen | 2.8 | 4.0* | 3.4 | 2.7 | 3.3 | 3.0 |
| Liver cirrhosis | 0.5 | 0.4 | 0.5 | 0.6 | 0.8 | 0.7 |
| Diabetes mellitus | 1.6 | 2.6* | 2.0 | 1.2 | 2.0$ | 1.5$ |
| Anaemia/malnutrition | 1.1 | 2.4* | 1.7 | 1.2 | 2.4* | 1.8 |
| Other NCD | 1.2 | 1.7 | 1.4 | 0.7 | 0.9 | 0.8* |
| Perinatal and neonatal causes | 6.8 | 5.0* | 6.0 | 7.5 | 7.3 | 7.4* |
| ARI, pneumonia, sepsis | 3.2 | 2.1* | 2.7 | 3.7 | 2.8$ | 3.3$ |
| Birth asphyxia | 0.9 | 0.7 | 0.8 | 1.4 | 1.4 | 1.4* |
| Prematurity | 1.9 | 1.6 | 1.8 | 1.3 | 2.1 | 1.7 |
| Other neonatal cause | 0.9 | 0.6 | 0.8 | 1.1 | 0.9 | 1.0 |
| Cause related to pregnancy | NA | 0.7 | 0.3 | Na | 1.0 | 0.5 |
| Injury and other external cause | 5.4 | 5.5 | 5.4 | 6.1 | 5.4 | 5.8 |
| Accidental drowning | 2.8 | 2.7 | 2.8 | 2.8 | 2.3 | 2.6 |
| Road traffic accident | 0.7 | 0.3* | 0.5 | 0.9 | 0.2* | 0.6 |
| International self-harm | 0.4 | 1.2* | 0.7 | 0.5 | 1.5* | 1.0 |
| Assault | 0.3 | 0.5 | 0.4 | 0.4 | 0.5 | 0.5 |
| Other cause | 1.1 | 0.8 | 1.0 | 1.4 | 1.0 | 1.2 |
| Indeterminate | 11.4 | 11.0 | 11.2 | 12.4 | 12.8 | 12.6$ |
| # VA with disease symptoma | 3217 | 2729 | 5,946 | 3,348 | 2,819 | 6,167 |
| Element | Certified value | Amino acids | Glucose | Lipids |
| [μg/kg] | ||||
| As | 26.67 ± 0.41 | 26.2 ± 1.3 | 27.2 ± 1.2 | 26.9 ± 1.2 |
| Cd | 22.79 ± 0.96 | 22.8 ± 1.2 | 23.1 ± 1.1 | 22.9 ± 0.8 |
| Pb | 27.89 ± 0.14 | 27.0 ± 1.4 | 27.7 ± 1.3 | 27.8 ± 1.2 |
| Hg* | 1.590 ± 0.018 | 1.57 ± 0.07 | 1.56 ± 0.06 | 1.61 ± 0.08 |
| Cr | 38.6 ± 1.6 | 37.5 ± 1.9 | 38.2 ± 1.6 | 37.9 ± 1.3 |
| Cu | 85.2 ± 1.2 | 87.5 ± 3.9 | 86.2 ± 4.2 | 84.3 ± 4.1 |
| Mn | 121.5 ± 1.1 | 120 ± 5.1 | 120 ± 6.0 | 123 ± 5.8 |
| Mo | 46.75 ± 0.26 | 46.8 ± 2.2 | 46.0 ± 2.2 | 47.4 ± 2.3 |
| Ni | 27.40 ± 0.80 | 27.0 ± 1.3 | 26.7 ± 1.3 | 27.3 ± 1.1 |
| V | 12.99 ± 0.37 | 12.9 ± 0.6 | 13.2 ± 0.6 | 12.9 ± 0.5 |
| Type | Number of reads | Percentage (%) |
| Total unique reads | 9,664,154 | 100 |
| Reads mapping to the transcripts | 9,193,054 | 95.13 |
| Reads mapping to target site | 6,916 | 0.072 |
| Total Number of input cDNAs | 77,024 | 100 |
| Number of covered cDNAs | 43,648 | 56.65 |
| Trial | N, inclusion criteria | Dose (dose per fraction) | Outcome | |
| Early hypofractionation trials | Lukka et al. [44] | 936GS 6–10 | 52.5 Gy (2.625 Gy)66 Gy (2 Gy) | 40% versus 43% 5-year freedom from biochemical failure |
| Yeoh et al. [45] | 217 | 55 Gy (2.75 Gy)64 Gy (2 Gy) | 53% versus 34% 7-year freedom from biochemical failure | |
| Modern superiority trials | Hoffman et al. [47] | 20499% low-intermediate risk | 72 Gy (2.4 Gy)75.6 Gy (1.8 Gy) | 96% versus 92% 5-year freedom from biochemical failure |
| Pollack et al. [49] | 303GS 6+ | 70.2 Gy (2.7 Gy)78 Gy (2.17 Gy) | 23% versus 21% 5-year biochemical or clinical disease failure | |
| Arcangeli et al. [48] | 168GS 7+ | 62 Gy (3.1 Gy)80 Gy (2 Gy) | 85% versus 79% 5-year freedom from biochemical failure | |
| Modern noninferiority trials | Dearnaley et al. [46] | 457 | 57 Gy (3 Gy)60 Gy (3 Gy)74 Gy (2 Gy) | Similar GU and GI toxicity ≥ grade 2 (<5%) |
| Incrocci [52] | 820Intermediate-high risk | 64.6 Gy (3.4 Gy)78 Gy (2 Gy) | Worse GI toxicity ≥ grade 2, similar GU toxicity | |
| RTOG 0415 [51] | 1101Low risk | 70 Gy (2.5 Gy)73.8 Gy (1.8 Gy) | Noninferior biochemical recurrence and overall survival, similar toxicity | |
| PROFIT [53] | Intermediate risk | 60 Gy (3 Gy)78 Gy (2 Gy) | Pending |
| Implicit review process measure | Acceptable care* | Extremely appropriate care** | ||
| Reviewer 1 | Reviewer 2 | Reviewer 1 | Reviewer 2 | |
| Initial data gathering by physician about acute problems | 163 (91.6) | 151 (84.8) | 12 (6.7) | 25 (14.0) |
| Physician integration of information and development of appropriate diagnoses | 147 (82.6) | 159 (89.3) | 10 (5.6) | 41 (23.0) |
| Physician initial treatment plan and orders | 117 (65.7) | 126 (70.8) | 10 (5.6) | 26 (14.6) |
| Physician plan for disposition and follow-up | 146 (82.0) | 167 (93.8) | 10 (5.6) | 64 (36.0) |
| Overall quality of care | 136 (76.4) | 141 (79.2) | 10 (5.6) | 22 (12.4) |
| Score for sorting | KSEARCH | SANS | BLAST | ||||
| k = 5 | k = 6 | k = 7 | k = 8 | w = 1000 | w = 2000 | ||
| Native | 0.51 | 0.55 | 0.49 | 0.44 | 0.56 | 0.54 | |
| Alignment | 0.52 | 0.56 | 0.49 | 0.44 | 0.60 | 0.62 | 0.95 |
| Mean accuracy | Mean reaction time (ms) | |||||||
| Task | Group | RT | ST | NT | RT | ST | NT | RG |
| CS | High | 1.00 | 0.97 | 0.88 | 346.72 | 390.01 | 454.67 | 43.29 |
| Low | 1.00 | 0.98 | 0.89 | 369.78 | 418.83 | 491.96 | 49.05 | |
| DD | High | 0.99 | 0.98 | 0.93 | 400.13 | 420.46 | 574.43 | 20.33 |
| Low | 0.99 | 0.98 | 0.93 | 417.35 | 440.78 | 595.11 | 23.43 | |
| VA | High | 1.00 | 0.97 | 0.93 | 323.27 | 382.87 | 539.70 | 59.60 |
| Low | 1.00 | 0.97 | 0.91 | 329.31 | 391.29 | 556.98 | 61.99 |
| Category # | Job title | # of participantsinterviewed |
| 1 | Laboratory Manager | 3 |
| 2 | Transfusion Safety Officer | 2 |
| 3 | Lab Technologist (Blood Bank) | 9 |
| 4 | Physicians - Blood Bank | 4 |
| 5 | Physicians - who use blood products | 7 |
| 6 | Hospital Administration | 4 |
| 7 | Hospital PR | 1 |
| 8 | Hospital Risk Management | 2 |
| 9 | Blood Suppliers (CBS, Hema-Quebec) | 9 |
| 11 | MoH (Provincial) | 2 |
| 13 | Recipients of blood products | 2 |
| 11 | Total | 45 |
| N | Whole sample | Boys | Girls | F | R2 | |
| Age 11 | ||||||
| Self-report | ||||||
| Behavior problems | 5057 | 8.79 (5.30) | 9.37 (5.36) | 8.28 (5.20) | 53.62**a | 0.01 |
| Moods and feelings | 5077 | 3.29 (3.85) | 3.43 (3.73) | 3.16 (3.95) | 6.11* | <0.01 |
| Victimisation | 5623 | 7.80 (7.39) | 8.68 (7.83) | 7.01 (6.87) | 69.66** a | 0.01 |
| Pubertal development | 5066 | 1.72 (0.58) | 1.54 (0.47) | 1.88 (0.62) | 536.44**a | 0.09 |
| Parent report | ||||||
| Behavior problems | 5056 | 6.82 (4.92) | 7.51 (5.06) | 6.22 (4.67) | 86.52**a | 0.02 |
| Moods and feelings | 5065 | 1.73 (2.75) | 1.83 (2.67) | 1.65 (2.82) | 5.54* | <0.01 |
| Antisocial personality | 5078 | 7.12 (4.32) | 7.93 (4.51) | 6.43 (4.02) | 154.04**a | 0.03 |
| Autism | 5245 | 4.69 (3.15) | 5.22 (3.31) | 4.23 (2.95) | 129.61**a | 0.02 |
| ADHD | 5070 | 13.27 (7.80) | 11.13 (8.73) | 7.87 (7.19) | 206.84**a | 0.04 |
| Age 14 | ||||||
| Self-report | ||||||
| Victimisation | 3173 | 7.64 (7.21) | 8.51 (7.78) | 6.93 (6.63) | 41.93**a | 0.01 |
| ADHD | 3054 | 13.28 (7.80) | 14.00 (8.33) | 12.68 (7.67) | 21.15** | <0.01 |
| Pubertal development | 2905 | 2.75 (0.61) | 2.46 (0.57) | 3.00 (0.53) | 815.16**a | 0.22 |
| Parent report | ||||||
| Victimisation | 2845 | 6.50 (7.65) | 6.81 (7.99) | 6.25 (7.34) | 4.49*a | <0.01 |
| Autism | 3039 | 36.94 (21.18) | 38.31 (12.74) | 35.75 (11.55) | 33.84**a | 0.01 |
| Antisocial personality | 3065 | 7.78 (5.05) | 8.67 (5.22) | 76.01 (4.78) | 84.53**a | 0.03 |
| ADHD | 3087 | 8.28 (7.96) | 9.95 (8.77) | 6.83 (6.85) | 121.10**a | 0.04 |
| Age 16 | ||||||
| Self-report | ||||||
| Behavior problems | 4815 | 9.49 (5.12) | 8.89 (4.93) | 9.96 (5.22) | 53.36**a | 0.01 |
| Anxiety | 4820 | 7.97 (5.87) | 6.10 (4.75) | 9.49 (6.22) | 481.33**a | 0.09 |
| Moods and feelings | 4821 | 3.60 (4.42) | 2.64 (3.49) | 4.38 (4.91) | 202.78**a | 0.04 |
| ADHD | 1073 | 4.74 (0.86) | 4.72 (0.85) | 4.76 (0.87) | 0.60 | <0.01 |
| Callous unemotional traits | 1070 | 19.61 (7.58) | 22.30 (7.88) | 17.96 6.91) | 80.93**a | 0.07 |
| Autism | 4818 | 11.88 (5.77) | 12.19 (5.70) | 11.63 (5.81) | 11.20** | <0.01 |
| Paranoid checklist | 4813 | 12.17 (10.63) | 11.76 (10.42) | 12.50 (10.78) | 5.73* | <0.01 |
| Anomalous perceptions | 4821 | 4.66 (6.01) | 4.28 (5.73) | 4.97 (6.21) | 16.07**a | <0.01 |
| Grandiosity and delusion | 4817 | 5.32 (4.43) | 5.84 (4.59) | 4.91 (4.25) | 53.26**a | 0.01 |
| Cognitive disorganization | 4815 | 3.96 (2.85) | 3.40 (2.72) | 4.41 (2.87) | 155.21**a | 0.03 |
| Hedonia | 4817 | 33.68 (7.93) | 31.52 (7.98) | 35.42 (7.44) | 299.96**a | 0.06 |
| Introvertive anhedonia | 4814 | 1.30 (1.32) | 1.47 (1.31) | 1.16 (1.31) | 61.13**a | 0.01 |
| Eating problems | 1067 | 3.18 (1.96) | 2.14 (1.40) | 3.84 (1.97) | 272.03**a | 0.18 |
| Peer victimisation | 2502 | 3.50 (3.22) | 4.09 (2.23) | 3.06 (3.14) | 63.92** | 0.03 |
| Sleep | 3747 | 7.87 (4.72) | 7.25 (4.33) | 8.41 (4.97) | 57.63**a | 0.02 |
| Substance use | 3747 | 2.58 (2.73) | 2.62 (2.82) | 2.55 (2.66) | 0.96 | <0.01 |
| Delinquency | 1074 | 5.34 (7.24) | 6.50 (7.87) | 4.61 (6.72) | 16.50**a | 0.02 |
| Pubertal development | 2234 | 3.36 (0.42) | 3.2 (0.41) | 3.49 (0.37) | 385.73** | 0.15 |
| Parent report | ||||||
| Behavior problems | 4836 | 3.80 (3.18) | 4.28 (3.36) | 3.41 (2.98) | 86.01**a | 0.02 |
| Anxiety | 4837 | 3.56 (4.20) | 2.71 (3.57) | 4.24 (4.53) | 176.97**a | 0.03 |
| Moods and feelings | 4834 | 0.97 (2.27) | 0.74 (1.83) | 1.16 (2.56) | 43.33**a | <0.01 |
| ADHD | 4832 | 6.73 (7.45) | 8.05 (8.25) | 5.66 (6.55) | 116.51**a | 0.03 |
| Negative symptoms | 4832 | 2.81 (3.87) | 3.17 (4.08) | 2.51 (3.67) | 33.45**a | <0.01 |
| Callous unemotional traits | 4835 | 17.55 (9.16) | 19.74 (9.39) | 15.77 (8.57) | 229.85**a | 0.05 |
| Autism | 4835 | 24.05 (10.63) | 25.97 (10.98) | 22.49 (10.07) | 126.94***a | 0.03 |
| Self-report | ||||||
| Age of menarche | 1864 | 12.75 (1.22) |
| Preoperatively | 1-Week | 1-Month | |
| cSystolic | 145 | 113 | 120 |
| cDiastolic | 99 | 68 | 78 |
| cPP | 46 | 45 | 42 |
| PWV | 11.6 | 10.6 | 10.9 |
| AI@75 | 28 | 14 | 7 |
| RM | 68 | 76 | 52 |
| AP | 15 | 6 | 4 |
| CI | 2.9 | 3.1 | 4.3 |
| PR | 1.41 | 0.99 | 0.85 |
| Description | Selected study |
| Critical endpoint | Acute irritation of the eyes and upper airways |
| A few (4 out of 27) individuals reacted with additional cough and slight airway obstruction | |
| Source | The Health Council of the Netherlands (2007) (Wieslander et al., 2001) |
| Species | Healthy human subjects (27) |
| Exposure regimen | Propylene glycol in aviation emergency training. Exposure to artificial mist generator in short-term inhalation exposure (~1 min) |
| Concentrations tested (mg/m3) | 0, 176-851 |
| Duration of exposure | Average rating on 10 questions before and after 1 min propylene glycol exposure every 30 min for 4 hours |
| NOAEL (mg/m3) | - |
| If no NOAEL, then value for LOAEL | Min = 176 |
| Max = 851 | |
| Mean = 309 | |
| Calv;max (mg/m3) | 430-603 |
| Source of Calv;max (mg/m3) | 1 puff (50 mL [5], 70 mL [6]) |
| MOE1-puff shisha-pen/100% transfer rate | Min range = 0.3-0.4 (~2.5-3x higher than in human study) |
| Max range = 1.4-2 | |
| Mean range = 0.5-0.7 (~1.4-2x higher than in human study) |
| Variables | n (%) | |
| Marital status | single | 47 (13.6) |
| married | 259 (75.1) | |
| divorced | 37 (10.7) | |
| widow | 2 (0.6) | |
| Education | primary | 1 (0.3) |
| vocational | 7 (2.0) | |
| secondary | 78 (22.6) | |
| higher | 259 (75.1) | |
| Place of residence | village | 41 (11.9) |
| town of up to 10,000 residents | 10 (2.9) | |
| town of up to 100,000 residents | 44 (12.7) | |
| city with more than 100,000 residents | 250 (72.5) | |
| Employment status | employed | 331 (96.5) |
| unemployed | 12 (3.5) | |
| Number of pregnancies | 0 | 42 (12.2) |
| 1 | 92 (26.8) | |
| >1 | 210 (61.0) |
| Outcomes | Standard Therapy (n = 32) | Acupuncture (n = 34) | p* |
| Primary outcomes | |||
| VAS | |||
| Mean VAS score at baseline (SD) | 8.02 (1.69) | 7.81 (1.48) | 0.6 |
| Mean VAS score after therapy (SD) | 3.89 (2.38) | 2.96 (1.84) | 0.08 |
| Mean change in VAS score (SD) | 4.12 (2.29) | 4.85 (1.87) | 0.12 |
| Response rate (>=2 VAS units decrease), % | 81.6 | 89.2 | 0.8 |
| Secondary outcomes | |||
| McGill score | |||
| Mean McGill score at baseline (SD) | 2.32 (1.05) | 2.38 (1.12) | 0.8 |
| Mean McGill score after therapy (SD) | 0.99 (0.69) | 0.99 (0.73) | 0.9 |
| Mean change in McGill score (SD) | 1.32 (0.85) | 1.33 (0.88) | 0.9 |
| Post-herpetic neuralgia at 3 months, % | 48.4 | 46.8 | 0.9 |
| Post-herpetic neuralgia at 6 months, % | 33.3 | 29.0 | 0.7 |
| Post-herpetic neuralgia at 12 months, % | 10.3 | 3.6 | 0.3 |
| Mean AUC during follow-up (SD) | 199(136) | 173(141) | 0.5 |
| Predictor | Odds Ratio | 95% Confidence Interval | |
| Age | 0.97 | 0.95 | 1.00* |
| Education | 0.93 | 0.87 | 1.01 |
| Services | 0.98 | 0.84 | 1.14 |
| Partner support | 0.88 | 0.80 | 0.97** |
| Mother support | 0.95 | 0.89 | 1.01 |
| Father support | 0.95 | 0.88 | 1.02 |
| Weeks pregnant | 1.01 | 0.99 | 1.02 |
| Single vs. married/living together | 0.93 | 0.68 | 1.28 |
| Informal housing vs. formal | 1.04 | 0.72 | 1.49 |
| Unemployed vs. employed | 1.09 | 0.76 | 1.56 |
| HH income < R2000 p/m | 1.52 | 1.15 | 2.01** |
| No income baby father | 1.20 | 0.78 | 1.83 |
| Tobacco use | 1.33 | 0.67 | 2.65 |
| Alcohol use | 1.22 | 0.89 | 1.66 |
| Relationship violence | 1.49 | 1.13 | 1.96** |
| Surgical procedure | Vault prolapse | POP-Q III | POP-Q IV |
| Sacrospinous fixation | 4 | 5 | 23 |
| Anterior colporrhaphy | 2 | 5 | 23 |
| Enterocele repair | 3 | 1 | 20 |
| Bladder neck suspension | 1 | - | 4 |
| Class | TP rate | FP rate | Precision | Recall | f-measure | ROC area | Accuracy |
| Migraine | 1 | 1 | 0.716 | 1 | 0.835 | 0.5 | 100.00% |
| Cluster | 0 | 0 | 0 | 0 | 0 | 0.5 | 0.00% |
| Tension | 0 | 0 | 0 | 0 | 0 | 0.5 | 0.00% |
| No headache | 0 | 0 | 0 | 0 | 0 | 0.5 | 0.00% |
| Weighted avg | 0.716 | 0.716 | 0.513 | 0.716 | 0.598 | 0.5 | 71.60% |
| Number of respondents | Percentage (95% CI) | |
| Equipment cost | 177 | 89.4% (85.7-93.1) |
| Training costs | 146 | 73.7% (68.4-79) |
| Challenges in training | 106 | 53.5% (47.5-59.5) |
| Transport times | 95 | 48% (42-54) |
| Concerns about delaying time to definitive care | 90 | 45.5% (39.5-51.5) |
| Ultrasound is beyond the scope of practice of providers | 76 | 38.4% (32.6-44.2) |
| Lack of evidence | 76 | 38.4% (32.6-44.2) |
| Approval by EMS administration | 25 | 12.6% (8.6-16.6) |
| Buy-in by other EMS medical directors | 21 | 10.6% (6.9-14.3) |
| Regulatory factors | 29 | 14.6% (10.4-18.8) |
| Variable | PPR | SE | p-Value | (95% CI) |
| LNight | 0.969 | 0.031 | 0.32 | (0.91, 1.031) |
| Sensitivity | ||||
| Not sensitive | 1 | |||
| Sensitive | 0.009 | 0.020 | 0.03 | (0, 0.691) |
| Lnight × Sensitive interaction | 1.105 | 0.043 | 0.01 | (1.024, 1.192) |
| Age | ||||
| 18–29 | 1 | |||
| 30–39 | 1.554 | 0.611 | 0.26 | (0.719, 3.359) |
| 40–49 | 1.484 | 0.556 | 0.29 | (0.712, 3.094) |
| 50–59 | 1.825 | 0.674 | 0.10 | (0.885, 3.763) |
| 60–69 | 1.687 | 0.660 | 0.18 | (0.783, 3.634) |
| 70–79 | 1.042 | 0.489 | 0.93 | (0.415, 2.612) |
| ≥80 | 1.505 | 0.833 | 0.46 | (0.508, 4.457) |
| Education | ||||
| No diploma | 1 | |||
| High school | 0.614 | 0.225 | 0.18 | (0.299, 1.261) |
| CEGEP | 0.837 | 0.295 | 0.61 | (0.419, 1.671) |
| University degree | 0.721 | 0.239 | 0.33 | (0.376, 1.383) |
| Sex | ||||
| Men | 1 | |||
| Women | 1.175 | 0.180 | 0.29 | (0.87, 1.586) |
| Constant | 0.162 | 0.311 | 0.34 | (0.004, 6.979) |
| Hematological parameter | N | Median | Mean | SE | Min–Max |
| PCV (%) | |||||
| Adult | 19 | 19.0 | 19.42 | 1.38 | 5–27 |
| Juvenile | 6 | 18.5 | 19.17 | 1.87 | 15–27 |
| Total solids* (mg/dl) | |||||
| Adult | 19 | 5.2 | 5.25 | 0.33 | 1.2–7.6 |
| Juvenile | 6 | 3.3 | 3.52 | 0.30 | 2.8–4.9 |
| WBC (×109/l) | |||||
| Adult | 19 | 3150 | 3617.86 | 428.90 | 1400–7800 |
| Juvenile | 8 | 3850 | 4375.00 | 684.20 | 2800–8400 |
| Heterophils (%) | |||||
| Adult | 21 | 45.0 | 46.19 | 1.66 | 35–64 |
| Juvenile | 8 | 42.5 | 41.88 | 3.19 | 25–54 |
| Lymphocytes (%) | |||||
| Adult | 21 | 30 | 30.90 | 1.34 | 23–43 |
| Juvenile | 8 | 35 | 34.75 | 3.17 | 22–50 |
| Monocytes (%) | |||||
| Adult | 21 | 19 | 17.57 | 1.14 | 8–28 |
| Juvenile | 8 | 14 | 15.38 | 3.18 | 3–32 |
| Eosinophils (%) | |||||
| Adult | 21 | 1.0 | 1.57 | 0.32 | 0–6 |
| Juvenile | 8 | 1.5 | 2.00 | 0.65 | 0–5 |
| Basophils (%) | |||||
| Adult | 21 | 3.0 | 3.90 | 0.50 | 0–9 |
| Juvenile | 8 | 5.5 | 6.00 | 1.12 | 2–12 |
| Average hours per month | Programs Reported Resident UseNo. (%) |
| < 1 h | 17 (38) |
| 1–2 h | 14 (31) |
| 3–5 h | 2 (4) |
| 6–10 h | 1 (2) |
| > 10 h | 1 (2) |
| No response | 10 (22) |
| Antibiotics | Cattle (3 isolates) | Buffalo (1 isolates) | Pig (6 isolates) | Total isolates (10) | ||||||||
| R | MS | S | R | MS | S | R | MS | S | R (%) | MS (%) | S (%) | |
| A | 00 | 02 | 01 | 00 | 01 | 00 | 02 | 01 | 03 | 02 (20) | 04 (40) | 04 (40) |
| G | 00 | 01 | 02 | 00 | 00 | 00 | 00 | 01 | 06 | 00 | 02 (20) | 08 (80) |
| K | 00 | 03 | 00 | 00 | 01 | 00 | 00 | 05 | 01 | 00 | 09 (90) | 01 (10) |
| Ak | 00 | 03 | 00 | 00 | 00 | 01 | 00 | 04 | 02 | 00 | 07 (70) | 03 (30) |
| Tr | 02 | 00 | 01 | 00 | 01 | 00 | 03 | 00 | 03 | 05 (50) | 01 (10) | 04 (40) |
| Economic Quantiles | Tobacco Use Prevalence (TP) | Tobacco Use Quantities (TQ) | ||||
| Men | Women | All | Men | Women | All | |
| Poorest | 26.0 | 4.1 | 14.0 | 12.6 | 8.4 | 11.9 |
| Poorer | 29.0 | 3.0 | 15.5 | 14.2 | 12.3 | 14.0 |
| Middle | 30.9 | 4.0 | 17.0 | 14.8 | 11.1 | 14.4 |
| Richer | 28.8 | 3.0 | 15.6 | 15.8 | 10.1 | 15.2 |
| Richest | 32.7 | 3.4 | 17.7 | 16.5 | 11.8 | 16.0 |
| p-value | <0.001 | 0.179 | <0.001 | <0.001 | 0.081 | <0.001 |
| rs4880 T > C | Cases, n (%) | Controls, n (%) | OR (95% CI) a | pa |
| TT | 319 (69.35%) | 426 (80.37%) | Reference | - |
| TC | 111 (24.13%) | 99 (18.68%) | 1.35 (0.79–2.81) | 0.195 |
| CC | 30 (6.52%) | 5 (0.94%) | 3.81 (1.22–5.67) | 0.013 |
| TC + CC | 141 (30.65%) | 104 (19.62%) | 2.75 (1.23–3.98) | 0.010 |
| p trend | 0.023 |
| Reference SSC-I (cos 0.98) | ||||
| SSC-II | DISO | SPE | PRGE | CHED |
| Rec | 89.0% | 94.5% | 59.7% | 49.6% |
| Prec | 71.6% | 90.0% | 96.8% | 49.4% |
| F-meas | 79.3% | 92.2% | 73.8% | 49.5% |
| Outcomes | Instrument | t0 | t1 | t2 | t3 | t4 | t5 | t6 |
| Primary endpoint | ||||||||
| Overall 2-year survival | Medical log (ongoing assessment) | |||||||
| Secondary endpoints | ||||||||
| 2-year non-relapse mortality, median (disease-free) survival | Medical log (ongoing assessment) | |||||||
| Quality of life | EORTC QLQ30 / HDC-29 module | X | X | X | X | X | X | X |
| Fatigue | Multidimensional Fatigue Inventory (MFI) | X | X | X | X | X | X | X |
| Muscle strength | Isometric and isokinetic strength of representative muscle groups for upper and lower extremity measured at the IsoMed2000® | X | X | X | X | |||
| Hand-Held-Dynamometer (isometric) | X | X | X | X | X | X | X | |
| Cardiorespiratory fitness | CPET (VO2peak) | X | X | X | X | |||
| 6-min Walk Test | X | X | X | X | X | X | X | |
| Body composition | bioelectrical impedance analysis, weight, height | X | X | X | X | X | X | X |
| Physical Activity | Accelerometry | X | X | X | X | X | X | |
| Depression | CES-D | X | X | X | X | X | X | X |
| Distress | NCCN-Distress | X | X | X | X | X | X | X |
| Locus of control | KKG (German) | X | X | X | X | X | X | X |
| Cognitive function | Trail-making-test | X | X | X | X | X | X | X |
| Common side-effects | VAS, every week, later every 3 weeks | |||||||
| Biomarker | Various methods (ELISA) | X | X | X | X | X | X | X |
| Oxidative stress marker | Analysed in urine samples | X | X | X | X | X | X | X |
| Others | ||||||||
| Socio-demographic factors | Recording of date of birth, education, occupation, familial situation, smoking, alcohol consumption | X | X | X | ||||
| Medical history | Recording of pre-existing diseases, therapies | X | ||||||
| Treatment data | Conditioning, complications | X | ||||||
| Karnofsky Performance Score | Physician rating | X | X | X | X | X | X | X |
| Medication (immunosuppression, corticosteroids, analgesics) | Recorded at each visit/phone call on a medication log form | X | X | X | X | X | X | X |
| Physical activity history | Physical activity in adolescence, pre-diagnosis, during, and after intervention is recorded, including walking, cycling, and sports activities | X | X | X | X |
| Individual components of global assessment of inflammation | Patients with grade 0, n (%) | |
| Difluprednate 0.05% (n=39) | Prednisolone acetate 1% (n=40) | |
| Anterior chamber cell | 30 (78.9) | 31 (77.5) |
| Anterior chamber flare | 29 (74.4) | 28 (70.0) |
| Corneal clarity | 37 (94.9) | 36 (90.0) |
| Conjunctival injection | 35 (89.7) | 37 (92.5) |
| Ciliary/limbal injection | 39 (100.0) | 40 (100.0) |
| Chemosis | 39 (100.0) | 39 (97.5) |
| Hypopyon | 39 (100.0) | 40 (100.0) |
| Vitritis | 39 (100.0) | 39 (97.5) |
| Wound integrity | 39 (100.0) | 40 (100.0) |
| Photophobia | 38 (97.4) | 38 (95.0) |
| Lacrimation | 39 (100.0) | 38 (95.0) |
| Decreased dose | Stable dose | Increased dose | Total | ||
| DAS | Remission: < 1.6, N (%) | 257 (13) | 1149 (56) | 629 (31) | 2035 (100) |
| aLDA: 1.6–2.4, N (%) | 179 (12) | 852 (55) | 511 (33) | 1542 (100) | |
| aMDA: 2.4–3.7, N (%) | 125 (9) | 770 (56) | 479 (35) | 1374 (100) | |
| aHDA: > 3.7, N (%) | 23 (11) | 110 (53) | 73 (35) | 206 (100) |
| Material Scan Rate Cathodic Threshold Potential | icorrfw (A/cm2) | CRfw (mm/year) | Ecorrfw (Vvs. SCE) | icorrbw (A/cm2) | CRbw (mm/year) | Ecorrbw (V vs. SCE) | Rp (Ω cm2) |
| WE43 10 mV/s ET = −1 Vvs. OCP | 3.92 × 10−5 | 5.68 × 10−1 | −1.51214 | 6.67 × 10−5 | 9.66 × 10−1 | −1.5432 | 276 |
| SD | 7.71 × 10−6 | 1.12 × 10−1 | 0.01187468 | 6.47 × 10−5 | 9.37 × 10−1 | 0.05866018 | |
| WE43 100 mV/s ET = −0.5 Vvs. OCP | 2.75 × 10−5 | 3.98 × 10−1 | −1.51482 | 2.48 × 10−5 | 3.59 × 10−1 | −1.5146 | 393 |
| SD | 1.07 × 10−6 | 1.55 × 10−2 | 0.00584739 | 1.52 × 10−6 | 2.20 × 10−2 | 0.00335857 | |
| WE43 100 mV/s ET = −1 Vvs. OCP | 3.03 × 10−5 | 4.38 × 10−1 | −1.54254 | 2.91 × 10−5 | 4.22 × 10−1 | −1.5400 | |
| SD | 4.77 × 10−6 | 6.92 × 10−2 | 0.00609286 | 2.95 × 10−6 | 4.28 × 10−2 | 0.00758571 | |
| Mg 10 mV/s ET = −1 Vvs. OCP | 1.48 × 10−4 | 2.14 | −1.4752 | 2.08 × 10−4 | 3.01 | −1.6444 | 59 |
| SD | 9.34 × 10−5 | 1.35 | 0.0671203 | 8.39 × 10−6 | 1.22 × 10−1 | 0.01472678 | |
| Mg 100 mV/s ET = −0.5 Vvs. OCP | 1.68 × 10−4 | 2.44 | −1.61504 | 1.72 × 10−4 | 2.49 | −1.6475 | 68 |
| SD | 1.24 × 10−5 | 1.80 × 10−1 | 0.01142817 | 3.56 × 10−6 | 5.16 × 10−2 | 0.00302476 | |
| Mg 100 mV/s ET = −1 Vvs. OCP | 5.40 × 10−5 | 7.82 × 10−1 | −1.5261 | 5.00 × 10−5 | 7.24 × 10−1 | −1.5457 | |
| SD | 2.51 × 10−6 | 3.64 × 10−2 | 0.00435603 | 2.28 × 10−6 | 3.31 × 10−2 | 0.00314754 |
| Ingredients | % of DM |
| Mix Silage | 39.00 |
| Mix Hay | 5.00 |
| Barley | 18.09 |
| Oats | 15.12 |
| Rape Seed Cake | 6.48 |
| Rape Seed Meal | 2.16 |
| Brewers Grain | 2.16 |
| Soybean Meal | 3.78 |
| Dried Sugar Beet Pulp | 5.40 |
| Wheat Bran | 0.81 |
| Mineral Mix1 | 2.00 |
| Nutrients analysis | % of DM |
| DM (%) | 52.50 |
| CP | 17.20 |
| NDF | 35.94 |
| Ether extract | 3.72 |
| Ash | 9.01 |
| Ca | 0.89 |
| P | 0.46 |
| NEL MJ/kg of DM | 6.95 |
| Isolate | Source | BioSample ID | SRA Run | GenBank accession number | PubMLST ID | rpoB allelic type (AT) | MLST STa | Novel MLST AT or STb |
| FSL H7-0926 | Pasteurized 2 % milk | SAMN03800014 | SRR2541537 | LOBD00000000 | 1774 | 90 | 667 | |
| FSL H8-0482 | Soil from areas adjacent to barns | SAMN03800015 | SRR2541601 | LOAZ00000000 | 1764 | 129 | 223 | |
| FSL H8-0488 | Water from hose in milking area | SAMN03800016 | SRR2541602 | LOBA00000000 | 1765 | 129 | 111 | |
| FSL K6-0040 | Raw milk | SAMN03800017 | SRR2541603 | LOBE00000000 | 1775 | 362 | 1101 | ilv 245, ST-1101 |
| FSL K6-0043 | Raw milk | SAMN03800018 | SRR2541604 | LOMW00000000 | 1763 | 363 | 1087 | pta 235, ST-1087 |
| FSL K6-0067 | Raw milk | SAMN03800019 | SRR2541605 | LOMN00000000 | 1762 | 365 | 1086 | gmk 138, pur 218, ST-1086 |
| FSL K6-0069 | Raw milk | SAMN03800020 | SRR2541606 | LOBB00000000 | 1756 | 194 | 1080 | glp 224, gmk 135, ilv 237, pta 233, ST-1080 |
| FSL K6-0073 | Raw milk | SAMN03800021 | SRR2541607 | LOMO00000000 | 1773 | 366 | 33 | |
| FSL K6-0267 | Raw milk | SAMN03800022 | SRR2541613 | LOMP00000000 | 1755 | 90 | 1090 | ST-1090 |
| FSL M8-0117 | Raw milk | SAMN03800023 | SRR2541639 | LONG00000000 | 1761 | 308 | 1085 | gmk 137, pyc 186, ST-1085 |
| FSL W8-0003 | Ricotta/mozzarella whey | SAMN03800024 | SRR2541640 | LOMQ00000000 | 1760 | 125 | 1084 | ilv 239, ST-1084 |
| FSL W8-0050 | Condensed product from evaporator | SAMN03800025 | SRR2541641 | LOMR00000000 | 1772 | 380 | 32 | |
| FSL W8-0169 | Raw milk | SAMN03800026 | SRR2541651 | LOBC00000000 | 1757 | 61 | 1081 | gmk 136, pta 234, ST-1081 |
| FSL W8-0268 | Evaporator - liquid | SAMN03800027 | SRR2541662 | LOMS00000000 | 1759 | 92 | 1083 | tpi 185, ST-1083 |
| FSL W8-0275 | Liquid milk whey permeate | SAMN03800028 | SRR2541668 | LOMT00000000 | 1771 | 463 | 1050 | |
| FSL W8-0483 | Liquid raw milk from silo | SAMN03800029 | SRR2541674 | LOMU00000000 | 1758 | 120 | 1082 | ilv 238, ST-1082 |
| FSL W8-0520 | Processed liquid milk | SAMN03800030 | SRR2541680 | LONH00000000 | 1770 | 481 | 1032 | |
| FSL W8-0523 | Liquid from blended whey silo | SAMN03800031 | SRR2541686 | LOMV00000000 | 1769 | 481 | 1032 | |
| FSL W8-0640 | Processed skim milk | SAMN03800032 | SRR2541688 | LOQA00000000 | 1754 | 154 | 1089 | ST-1089 |
| FSL W8-0824 | Finished dairy product | SAMN03800033 | SRR2541693 | LOQB00000000 | 1767 | 92 | 24 | |
| FSL W8-0932 | Processed skim milk | SAMN03800034 | SRR2541715 | LOQC00000000 | 1766 | 120 | 365 | |
| FSL W8-0767 | Milk powder | SAMN03800035 | SRR2541718 | LOQD00000000 | 1768 | 154 | 787 |
| Main nutrients | Rice porridge | Rice cereal * | Hard-boiled egg yolk |
| Energy, including dietary fibre (kJ) | 158 | 1537 | 1450 |
| Protein (g) | 0.7 | 6.8 | 16.1 |
| Fat (g) | 0.1 | 1.1 | 31.7 |
| Calcium (mg) | 2 | 6 | 115 |
| Iodine (ug) | 0.8 | 3.7 | 127.7 |
| Iron (mg) | 0.08 | 15.5 | 4.8 |
| Zinc (mg) | 0.12 | 7.8 | 2.7 |
| Riboflavin (B2) (mg) | 0.002 | 1.9 | 0.42 |
| Pyridoxine (B6) (mg) | 0.01 | 0 | 0.33 |
| Vitamin C (mg) | 0 | 33 | 0 |
| Folate, natural (μg) | 1 | 70 | 177 |
| Variable | Laser | Steel | Total | p-value |
| Age | 0.548 | |||
| Mean | 65.2 | 67.4 | 66.3 | |
| Range | - | - | 34-87 | |
| SD | 11.5 | 12.7 | 12.0 | |
| Gender | 1.0 | |||
| Male | 20 | 19 | 39 | |
| Female | 3 | 3 | 6 | |
| Diagnosis | 0.463 | |||
| a) Premalignant | ||||
| Moderate dysplasia | 0 | 2 | 2 | |
| Severe dysplasia/CIS | 6 | 3 | 9 | |
| b) Invasive SCC | ||||
| Well differentiated | 2 | 2 | 4 | |
| Moderately differentiated | 12 | 14 | 26 | |
| Poorly differentiated | 3 | 1 | 4 |
| 1991-1996 | 1997-2001 | 1991-2001 | |||||||||||||||||||
| Deaths | Controlling for age | Controlling for all variables (1) | Deaths | Controlling for age | Controlling for all variables (1) | Deaths | Controlling for age | Controlling for all variables (1) | |||||||||||||
| HR | 95% CI | HR | 95% CI | HR | 95% CI | HR | 95% CI | HR | 95% CI | HR | 95% CI | ||||||||||
| All causes of death | 17,923 | 1.36 | 1.29 | −1.43 | 1.22 | 1.15 | −1.28 | 23,757 | 1.37 | 1.31 | −1.43 | 1.22 | 1.17 | −1.28 | 41,680 | 1.37 | 1.32 | −1.41 | 1.22 | 1.18 | −1.26 |
| Malignant neoplasms | 7071 | 1.19 | 1.09 | −1.30 | 1.10 | 1.01 | −1.21 | 10,079 | 1.28 | 1.19 | −1.37 | 1.17 | 1.09 | −1.26 | 17,150 | 1.24 | 1.18 | −1.31 | 1.14 | 1.08 | −1.21 |
| Stomach cancer | 529 | 1.54 | 1.16 | −2.05 | 1.45 | 1.08 | −1.94 | 732 | 1.17 | 0.89 | −1.54 | 1.06 | 0.80 | −1.40 | 1,261 | 1.33 | 1.09 | −1.61 | 1.22 | 1.00 | −1.49 |
| Lung cancer | 2,248 | 1.18 | 1.01 | −1.38 | 1.01 | 0.86 | −1.18 | 3,091 | 1.44 | 1.28 | −1.63 | 1.19 | 1.05 | −1.35 | 5,339 | 1.33 | 1.21 | −1.46 | 1.11 | 1.01 | −1.23 |
| Cancer of intestine and rectum | 908 | 0.92 | 0.70 | −1.21 | 0.91 | 0.69 | −1.20 | 1,302 | 1.22 | 1.00 | −1.50 | 1.18 | 0.96 | −1.45 | 2,210 | 1.10 | 0.93 | −1.29 | 1.07 | 0.91 | −1.26 |
| Other cancers | 3,386 | 1.21 | 1.07 | −1.37 | 1.18 | 1.04 | −1.33 | 4,954 | 1.21 | 1.09 | −1.34 | 1.17 | 1.05 | −1.30 | 8,340 | 1.21 | 1.12 | −1.31 | 1.17 | 1.08 | −1.27 |
| Circulatory diseases | 5,474 | 1.19 | 1.08 | −1.32 | 1.09 | 0.98 | −1.20 | 7,208 | 1.24 | 1.14 | −1.35 | 1.13 | 1.03 | −1.23 | 12,682 | 1.22 | 1.14 | −1.30 | 1.11 | 1.04 | −1.18 |
| Acute myocardial infarction | 2,405 | 1.11 | 0.95 | −1.29 | 1.02 | 0.87 | −1.19 | 2,716 | 1.21 | 1.05 | −1.40 | 1.11 | 0.96 | −1.28 | 5,121 | 1.16 | 1.05 | −1.29 | 1.07 | 0.96 | −1.18 |
| Other ischaemic heart disease | 1,538 | 1.13 | 0.93 | −1.37 | 1.03 | 0.85 | −1.25 | 2,154 | 1.31 | 1.12 | −1.52 | 1.17 | 1.00 | −1.36 | 3,692 | 1.23 | 1.09 | −1.39 | 1.11 | 0.98 | −1.25 |
| Cerebro-vascular disease | 553 | 1.35 | 1.00 | −1.81 | 1.17 | 0.86 | −1.58 | 863 | 1.29 | 1.01 | −1.64 | 1.19 | 0.93 | −1.52 | 1,416 | 1.31 | 1.09 | −1.58 | 1.18 | 0.98 | −1.43 |
| Other circulatory diseases | 978 | 1.42 | 1.14 | −1.76 | 1.31 | 1.05 | −1.63 | 1,475 | 1.17 | 0.97 | −1.42 | 1.06 | 0.88 | −1.29 | 2,453 | 1.27 | 1.10 | −1.46 | 1.16 | 1.00 | −1.34 |
| Respiratory diseases | 406 | 1.50 | 1.07 | −2.08 | 1.34 | 0.95 | −1.87 | 974 | 1.44 | 1.16 | −1.78 | 1.22 | 0.98 | −1.52 | 1,380 | 1.45 | 1.21 | −1.74 | 1.25 | 1.04 | −1.51 |
| Alcohol-related diseases | 400 | 2.14 | 1.60 | −2.85 | 1.54 | 1.15 | −2.07 | 526 | 2.33 | 1.82 | −2.98 | 1.84 | 1.43 | −2.37 | 926 | 2.25 | 1.86 | −2.71 | 1.70 | 1.40 | −2.06 |
| Accidents and violence | 2,382 | 2.01 | 1.78 | −2.26 | 1.59 | 1.40 | −1.80 | 2,114 | 1.88 | 1.65 | −2.14 | 1.51 | 1.32 | −1.72 | 4,496 | 1.94 | 1.78 | −2.12 | 1.55 | 1.42 | −1.70 |
| Suicide | 943 | 1.94 | 1.60 | −2.35 | 1.58 | 1.30 | −1.93 | 879 | 1.81 | 1.47 | −2.22 | 1.44 | 1.17 | −1.78 | 1822 | 1.87 | 1.63 | −2.16 | 1.51 | 1.31 | −1.75 |
| Homicide | 87 | 2.78 | 1.59 | −4.85 | 2.10 | 1.18 | −3.73 | 50 | 2.17 | 0.98 | −4.83 | 1.44 | 0.63 | −3.29 | 137 | 2.55 | 1.62 | −4.03 | 1.83 | 1.15 | −1.94 |
| Traffic accidents | 611 | 1.67 | 1.29 | −2.14 | 1.35 | 1.04 | −1.75 | 454 | 1.51 | 1.11 | −2.05 | 1.26 | 0.92 | −1.73 | 1065 | 1.60 | 1.32 | −1.94 | 1.31 | 1.07 | −1.60 |
| Falls | 104 | 3.68 | 2.29 | −5.89 | 2.80 | 1.71 | −4.58 | 163 | 1.73 | 1.06 | −2.83 | 1.49 | 0.90 | −2.47 | 267 | 2.44 | 1.75 | −3.42 | 2.00 | 1.41 | −2.83 |
| Other accidents and violence | 637 | 2.10 | 1.67 | −2.63 | 1.58 | 1.25 | −2.00 | 568 | 2.31 | 1.82 | −2.91 | 1.81 | 1.42 | −2.30 | 1205 | 2.20 | 1.86 | −2.58 | 1.69 | 1.42 | −1.99 |
| All other causes | 2,590 | 1.60 | 1.41 | −1.82 | 1.33 | 1.17 | −1.51 | 3,382 | 1.58 | 1.41 | −1.77 | 1.36 | 1.22 | −1.53 | 5,972 | 1.59 | 1.46 | −1.73 | 1.35 | 1.24 | −1.47 |
| Cluster description | Codon | Size | Example organism (locus) |
| Selenocysteine | |||
| Formate dehydrogenase α subunit | TGA | 45 | Escherichia coli (b1474) |
| Selenide water dikinase | TGA | 12 | Haemophilus influenzae (HI0200m) |
| Glycine reductase complex selenoprotein A | TGA | 6 | Treponema denticola (TDE0745) |
| Glycine reductase complex selenoprotein B | TGA | 6 | Treponema denticola (TDE0078) |
| Heterodisulfide reductase subunit A | TGA | 6 | Methanococcus jannaschii (MJ1190m) |
| Coenzyme F420-reducing hydrogenase δ subunit | TGA | 5 | Methanococcus jannaschii (MJ1190a) |
| Formylmethanofuran dehydrogenase subunit B | TGA | 4 | Methanococcus jannaschii (MJ1194m) |
| Glutaredoxin-like | TGA | 3 | Carboxydothermus hydrogenoformans (CHY_0740) |
| Thioredoxin | TGA | 3 | Geobacter sulfurreducens (GSU3446) |
| Coenzyme F420-reducing hydrogenase α subunit | TGA | 3 | Methanococcus jannaschii (MJ0029) |
| HesB family | TGA | 3 | Desulfovibrio vulgaris (DVU_1382) |
| HesB family | TGA | 2 | Methanococcus maripaludis (MMP0252 + upstream) |
| Fe-S oxidoreductase | TGA | 2 | Desulfotalea psychrophila (DP1009) |
| DsbA-like | TGA | 2 | Desulfovibrio desulfuricans (Dde_1263 + upstream) |
| Periplasmic [NiFeSe] hydrogenase large subunit | TGA | 2 | Desulfovibrio vulgaris (DVU_1918) |
| Pyrrolysine | |||
| Monomethylamine methyltransferase | TAG | 7 | Methanosarcina acetivorans (MA0144) |
| Dimethylamine methyltransferase | TAG | 7 | Methanosarcina acetivorans (MA0532) |
| Trimethylamine methyltransferase | TAG | 6 | Methanosarcina acetivorans (MA0528) |
| Transcriptional regulator, TetR family | TAG | 2 | Methanosarcina acetivorans (MA2902) |
| Unknown | |||
| Cytochrome c family protein | TGA | 2 | Geobacter sulfurreducens (GSU2937 + GSU2936) |
| Hypothetical protein | TAG | 2 | Geobacter sulfurreducens (GSU2293 + downstream) |
| Intention-to-treat analysis | Per protocol analysis | |||||
| 1 Hz (n = 22) | 25 Hz (n = 24) | Group comparison | 1 Hz (n = 17) | 25 Hz (n = 23) | Group comparison | |
| Treatment period (days) | 77.9 ± 25.8 | 85.7 ± 11.4 | p = 0.22 | 89.0 ± 8.4 | 87.5 ± 7.5 | p = 0.67 |
| Average number of stimulated hours per day | 3.42 ± 0.59 | 3.44 ± 0.61 | p = 0.69 | 3.34 ± 0.62 | 3.44 ± 0.62 | p = 0.51 |
| Variables | Patients | KRAS | NRAS | BRAF | ||
| n | % | n | n | n | ||
| Age | ≤ 55 | 14 | 64 | 4 | 1 | 3 |
| > 55 | 8 | 44 | 2 | 0 | 1 | |
| Gender | male | 16 | 73 | 2 | 1 | 4 |
| female | 6 | 27 | 4 | 0 | 0 | |
| Histology | ADC with SRC | 3 | 14 | 0 | 0 | 1 |
| ADC without SRC | 19 | 86 | 6 | 1 | 3 | |
| Calcification | present | 3 | 14 | 1 | 0 | 0 |
| absent | 19 | 86 | 5 | 1 | 4 | |
| Sheldon Stage | I-II | 0 | 0 | 0 | 0 | 0 |
| IIIA | 10 | 45 | 2 | 1 | 2 | |
| IIIB | 7 | 32 | 4 | 0 | 1 | |
| IIIC | 1 | 5 | 0 | 0 | 0 | |
| IVA | 2 | 9 | 0 | 0 | 0 | |
| IVB | 2 | 9 | 0 | 0 | 1 | |
| IVC | 0 | 0 | 0 | 0 | 0 | |
| Mayo stage | I | 4 | 19 | 1 | 0 | 0 |
| II | 10 | 48 | 3 | 1 | 3 | |
| III | 5 | 24 | 2 | 0 | 0 | |
| IV | 2 | 9 | 0 | 0 | 1 | |
| missing | 1 | |||||
| LN or distant meta at diagn. | N0/M0 | 18 | 82 | 6 | 1 | 3 |
| N + / M+ | 4 | 18 | 0 | 0 | 1 | |
| Initial surgical treatment | partial CE | 15 | 68 | 5 | 0 | 3 |
| radical CE | 5 | 23 | 1 | 0 | 0 | |
| TURB | 2 | 9 | 0 | 1 | 1 | |
| Umbilectomy | yes | 11 | 50 | 4 | 0 | 2 |
| no | 11 | 50 | 2 | 1 | 2 | |
| LND | yes | 13 | 59 | 3 | 0 | 2 |
| no | 9 | 41 | 3 | 1 | 2 | |
| Chemotherapy | yes | 6 | 27 | 1 | 1 | 2 |
| no | 16 | 73 | 5 | 0 | 2 | |
| Progression | local recurrence | 2 | 9 | 1 | 1 | 1 |
| distant met | 2 | 9 | 1 | 0 | 0 | |
| both | 5 | 23 | 2 | 0 | 1 | |
| no progression | 13 | 59 | 3 | 0 | 2 |
| Alcohol intake (g/day) | ||||
| 0 | 0.1–5 | 5.1–15 | >15 | |
| No. of participans | 10,153 | 22,249 | 11,734 | 1,097 |
| Age at enrollment (mean) | 39.8 | 39.7 | 40.5 | 41.4 |
| Educational attainment >11 years, (%) | 46.3 | 56.3 | 61.4 | 61.7 |
| History of breast cancer in mother and/or sister (%) | 4.2 | 4.2 | 5.3 | 5.9 |
| Smoking habits (%) | ||||
| Never | 50.5 | 43.0 | 32.0 | 18.1 |
| Former | 28.2 | 35.3 | 40.7 | 40.7 |
| Current | 21.3 | 21.7 | 27.3 | 41.2 |
| Age at menarche (mean) | 12.9 | 13.0 | 13.0 | 13.1 |
| Women with more than 3 children (%) | 32.5 | 27.2 | 24.0 | 23.4 |
| Age at first child birth among parous women (mean) | 23.5 | 24.0 | 24.1 | 23.8 |
| Total duration of breast feeding (months) | 30.9 | 30.8 | 30.2 | 30.3 |
| Ever oral contraceptive use (%) | 75.1 | 85.0 | 88.2 | 89.7 |
| Post-menopause (%) | 4.4 | 3.8 | 4.3 | 3.7 |
| Body mass index (>25 kg/m2, %) | 31.9 | 24.1 | 21.1 | 24.6 |
| Location | Group | IHC grade# | P value* | ||||||
| Stroma | Cancer nest | − | + | ++ | +++ | ++++ | |||
| α-SMA | Positive$ | ND | Chronic nasopharyngitis (21) | 11 | 7 | 2 | 1 | 0 | 0.000 |
| NPC (18) | 0 | 4 | 0 | 7 | 7 | ||||
| CD133 | Positive | ND | Chronic nasopharyngitis (10) | 9 | 1 | 0 | 0 | 0 | 0.006 |
| NPC (30) | 8 | 9 | 9 | 4 | 0 | ||||
| VEGFR-2 | Positive | ND | Chronic nasopharyngitis (8) | 7 | 1 | 0 | 0 | 0 | 0.04 |
| NPC (10) | 2 | 5 | 1 | 2 | 0 | ||||
| CD34 | Positive | ND | Chronic nasopharyngitis (14) | 0 | 8 | 6 | 0 | 0 | 0.000 |
| NPC (24) | 0 | 0 | 3 | 7 | 14 | ||||
| CXCR4 | Positive | Positive | Chronic nasopharyngitis (6) | 0 | 3 | 1 | 2 | 0 | 0.041 |
| NPC (11) | 0 | 0 | 2 | 4 | 5 | ||||
| VEGF-A | Positive | Positive | Chronic nasopharyngitis (10) | 0 | 1 | 5 | 4 | 0 | 0.015 |
| NPC (19) | 0 | 0 | 2 | 9 | 8 | ||||
| SDF-1 | ND | Positive | Chronic nasopharyngitis (22) | 5 | 9 | 5 | 2 | 1 | 0.008 |
| NPC (20) | 3 | 0 | 7 | 5 | 5 |
| Japanese (n22) | Thai (n27) | |
| Mean ± SD (range) | Mean ± SD (range) | |
| Age (years) | 21.5 ± 0.7 (21–24) | 21.2 ± 2.2 (18–25) |
| Height (cm) | 159.9 ± 5.9 (151.7-170.5) | 160.6 ± 6.0 (146.0-170.0) |
| Body fat (%) | 23.0 ± 5.3a (12.2-35.4) | 26.7 ± 5.6a (15.8-36.1) |
| Weight (kg) | 49.5 ± 4.2 (43.6-58.3) | 51.2 ± 5.9 (41.4-64.6) |
| Body mass index (kg/m2) | 19.4 ± 1.5 (16.5-22.1) | 19.8 ± 2.0 (16.6-23.0) |
| Culture-Gram-PCR resultb | |||
| All tests negative | Isolated RT-PCR positive | All tests positive | |
| (n=329) | (n=20) | (n=75) | |
| Age in years (median, range) | 9 (0–64) | 11 (0–63) | 15 (0–78) |
| Altered mental status (%) | 66 (22.6) | 6 (40.0) | 47 (66.2) |
| Deaths (%) | 27 (9.1) | 2 (10.5) | 10 (14.3) |
| Median WBC (x106 cells/L, range)c | 430 (100–10,000) | 10,000 (32–10,000) | 8,600 (0–10,000) |
| >50% PMN cells (%) | 186 (56.7) | 18 (90.0) | 72 (96.0) |
| Median protein (g/L, range)d | 0.50 (0.20-5.00) | 2.90 (0.32-5.00) | 3.50 (0.28-5.00) |
| Median glucose (mmol/L, range) | 2.9 (1.1-3.9) | 1.6 (0.6-3.1) | 1.1 (1.1-3.2) |
| LAT positive (% of total LAT performed) | 1 (2.0) | 5 (38.5) | 25 (80.6) |
| Positive LAT concordant with RT-PCR (%)e | n/a | 5 (100.0) | 25 (100.0) |
| Antibiotic bioassay positive (%) | 28 (8.8) | 12 (63.2) | 41 (55.4) |
| Male | Female | Total | ||||||||||
| Cases | n | p-y | Rate | Cases | n | p-y | Rate | Cases | n | p-y | Rate | |
| 18–20 years | 175 | 61,333 | 70,412.87 | 2.49 | 101 | 61,303 | 68,905.12 | 1.47 | 276 | 122,636 | 139,317.98 | 1.98 |
| 20–25 years | 433 | 79,410 | 196,125.36 | 2.21 | 329 | 89,087 | 204,046.95 | 1.61 | 762 | 168,497 | 400,172.31 | 1.90 |
| 25–30 years | 566 | 111,187 | 260,050.38 | 2.18 | 458 | 122,885 | 275,279.73 | 1.66 | 1024 | 234,072 | 535,330.11 | 1.91 |
| 30–35 years | 818 | 134,560 | 332,654.60 | 2.46 | 796 | 140,318 | 343,610.41 | 2.32 | 1614 | 274,878 | 676,265.01 | 2.39 |
| 35–40 years | 1070 | 123,355 | 336,083.56 | 3.18 | 1157 | 125,302 | 341,845.69 | 3.38 | 2227 | 248,657 | 677,929.25 | 3.29 |
| 40–45 years | 1074 | 108,836 | 306,130.49 | 3.51 | 1060 | 110,765 | 309,832.41 | 3.42 | 2134 | 219,601 | 615,962.90 | 3.46 |
| 45–50 years | 823 | 93,700 | 272,812.94 | 3.02 | 833 | 98,233 | 280,717.22 | 2.97 | 1656 | 191,933 | 553,530.15 | 2.99 |
| 50–55 years | 874 | 81,114 | 239,243.53 | 3.65 | 903 | 88,311 | 256,471.30 | 3.52 | 1777 | 169,425 | 495,714.83 | 3.58 |
| 55–60 years | 917 | 71,745 | 207,713.86 | 4.41 | 937 | 77,261 | 222,700.73 | 4.21 | 1854 | 149,006 | 430,414.59 | 4.31 |
| 60–65 years | 1097 | 64,835 | 190,729.33 | 5.75 | 1080 | 71,241 | 207,353.03 | 5.21 | 2177 | 136,076 | 398,082.36 | 5.47 |
| 65–70 years | 1098 | 48,791 | 155,627.10 | 7.06 | 935 | 54,759 | 172,088.42 | 5.43 | 2033 | 103,550 | 327,715.52 | 6.20 |
| 70–75 years | 1214 | 41,283 | 116,993.45 | 10.38 | 890 | 51,806 | 143,029.88 | 6.22 | 2104 | 93,089 | 260,023.33 | 8.09 |
| 75–80 years | 1604 | 36,855 | 109,640.33 | 14.63 | 1115 | 52,422 | 149,267.10 | 7.47 | 2719 | 89,277 | 258,907.43 | 10.50 |
| 80–85 years | 1472 | 25,189 | 75,766.96 | 19.43 | 1204 | 43,904 | 125,031.08 | 9.63 | 2676 | 69,093 | 200,798.03 | 13.33 |
| 85–90 years | 978 | 12,965 | 39,021.71 | 25.06 | 1081 | 28,978 | 83,030.03 | 13.02 | 2059 | 41,943 | 122,051.74 | 16.87 |
| 90–110 years | 514 | 4952 | 13,917.42 | 36.93 | 873 | 15,937 | 44,495.90 | 19.62 | 1387 | 20,889 | 58,413.33 | 23.74 |
| Total | 14,727 | 1,100,110 | 2,922,923.88 | 5.04 | 13.752 | 1,232,512 | 3,227,704.99 | 4.26 | 28,479 | 2,332,622 | 6,150,628.88 | 4.63 |
| Specific primer | Primer sequences (5′–3′) |
| N type DlRans | Forward: AAGGACAGCTCTCATGGCTTTGC |
| Reverse: TGCCTCCATCACCGACGATGAC | |
| D type DlRans | Forward: TAGTGATCGTCGGCGATGGTGG |
| Reverse: TGCAGTGTCCCAGCAATAGAAGCG | |
| Fe-SOD | Forward: GGTCAGATGGTGAAGCCGTAGAG |
| Reverse: GTCTATGCCACCGATACAACAAACCC | |
| EF-1a | Forward: GATGATTCCCACCAAGCCCAT |
| Reverse: GGGTCCTTCTTCTCAACACTCT |
| Increasing ANNV (> 4) | Stable ANNV (-4 to 4) | Decreasing ANNV (< -4) | |||||||
| Parameter | PCa (n = 22) | BPH (n = 16) | p-value | PCa (n = 17) | BPH (n = 124) | p-value | PCa (n = 10) | BPH (n = 10) | p-value |
| Age (years) | 65* | 68.5 | 0.61 | 70 | 68 | 0.7 | 62 | 64 | 0.29 |
| tPSA (ng/mL) | 8.3 | 6.8 | 0.17 | 10.2 | 5.3 | 0.002 | 5.5 | 4.35 | 0.5 |
| %fPSA (%) | 8.0*$ | 13.15 | 0.017 | 15.15 | 17.4 | 0.85 | 11.2 | 13.8 | 0.1 |
| Volume (mL) | 33.5* | 36.5* | 0.34 | 50 | 53.5$ | 0.87 | 30.5* | 34* | 0.26 |
| Group | Swell degree (mg) | Inhibition rate (%) |
| Fenli | 5.13 ± 0.68 | 69.15 |
| DE MDTS | 5.86 ± 1.76 | 64.76 |
| Control | 16.63 ± 1.57 |
| Workflow | Sequential | Parallel |
| Preprocess (clipOverlap) | 2.82 | 2.91 |
| SNV: mutationSeq | 5.68 | 5.99 |
| SNV: Strelka | 2.60 | 4.49 |
| CNV: Titan | 29.34 | 36.31 |
| CNV: Sequenza | 8.24 | 9.40 |
| Gene Name | Primers |
| Rbcl (ribulose-1,5-bisphosphate carboxylase/oxygenase: Genbank-KR914695.1) | Rbcl1: ACGAATGTTTACGCGGTGGTCT |
| Rbcl2: GGTACACCCAACTCCTTAGCA | |
| CrtZ (carotenoid hydroxylase: Genbank-KP866868.1) | CrtZ1: ATCTTCGCCACCTACCTGAG |
| CrtZ2: CGGGCAGTCCATTGATGATT | |
| LcyB (lycopene beta cyclase: Genbank-AY182008.1) | LcyB1: CTTTGACCCAGCACGACTTG |
| LcyB2: TTAGGAACTTCTCGCCCTCT | |
| CrtISO (carotenoid isomerase: Genbank-KP780062.1) | CrtISO1: GCACCACTAACCTCATCACA |
| CrtISO2: CCTTCCAGCAGTCGTCATAA | |
| ZEP (zeaxanthin epoxidase: Genbank-KP780061.1) | ZEP1: TACCTCAACCCTGCTCCTGA |
| ZEP2: TTCGCCCTTCTCAAGCCTGT |
| WALK | JOG | |||||||||
| Phase | Joint | Plane | Barefoot | Thong | p;<0.05 | 95% CI | Barefoot | Thong | p;<0.05 | 95% CI |
| Contact | Ankle | Sagittal | 1.1(8.3) | 12.0(12.2) | 0.005* | −17.8, -4.04 | 13.0(7.6) | 21.1(10.4) | 0.005* | −13.2, -2.98 |
| Frontal | −7.5(3.6) | −10.0(5.8) | 0.694 | −3.23, 2.25, | −4.7(4.3) | −3.6(4.7) | 0.31 | −3.30, 1.14 | ||
| Transverse | 1.6(4.7) | 1.7(3.2) | 0.957 | −3.15, 3.00 | 3.6(5.0) | 1.4(5.8) | 0.194 | −1.30, 5.77 | ||
| Midfoot | Sagittal | −3.8(6.5) | −9.2(12.2) | 0.090 | −1.00, 11.9 | −3.5(6.5) | −6.6(11.9) | 0.203 | −1.92, 8.13 | |
| Frontal | 2.0 (2.9) | 0.6 (5.0) | 0.181 | −0.750, 3.55 | 1.2(3.6) | −2.6(6.5 | 0.042* | 0.15, 7.40 | ||
| Transverse | −3.6(3.6) | 1.0(4.0) | 0.441 | −5.21, 2.42 | −0.8(4.3) | 2.2(4.3) | 0.075 | −6.30, 0.35 | ||
| Hallux | Sagittal | 6.2(4.3) | 3.7(5.4) | 0.203 | −1.57, 6.65 | 4.3(4.7) | 3.3(6.5) | 0.694 | −4.41, 6.41 | |
| Midstance | Ankle | Sagittal | 7.6(5.8) | 12.6(10.4) | 0.124 | −11.44, 1.56 | 20.3(5.4) | 24.4(9.0) | 0.099 | −9.02, 0.88 |
| Frontal | −3.8(3.6) | −4.2(4.7) | 0.672 | −1.47, 2.20 | 0.3(4.7) | 1.0(4.7) | 0.492 | −2.94, 1.50 | ||
| Transverse | 4.1(4.3) | 2.5(4.0) | 0.315 | −1.74, 4.96 | 6.4(5.8) | 3.4(5.8) | 0.069 | −0.28, 6.40 | ||
| Midfoot | Sagittal | −0.8(6.1) | −7.4(12.6) | 0.052 | −0.065, 13.3 | 2.9(7.2) | −2.2(12.6) | 0.037* | 0.370, 9.73 | |
| Frontal | 3.6 (1.8) | 2.2 (5.0) | 0.231 | −1.02, 3.83 | 2.0(4.3) | −0.5(6.1) | 0.140 | −0.908, 5.71 | ||
| Transverse | 0.5(3.2) | 1.9(4.7) | 0.421 | −5.21, 2.33 | 0.1(4.7) | 2.8(4.0) | 0.085 | −5.82, 0.435 | ||
| Hallux | Sagittal | 1.1(2.9) | 1.2(4.7) | 0.926 | −2.99, 2.74 | −0.3(3.2) | 0.4(4.7) | 0.664 | −4.26, 2.81 | |
| Propulsive | Ankle | Sagittal | 12.4(8.3) | 16.4(11.5) | 0.282 | −3.74, 11.8 | 18.0(6.5) | 21.0(10.4) | 0.242 | −8.12, 2.27 |
| Frontal | −6.8(5.0) | −6.8(5.0) | 0.552 | −1.44, 2.56 | −3.6(4.3) | −3.0(4.7) | 0.536 | −2.68, 1.47 | ||
| Transverse | 0.1(5.4) | −1.3(4.3) | 0.383 | −1.97, 4.78 | 3.6(5.8) | 0.8(6.1) | 0.098 | −0.591, 6.09 | ||
| Midfoot | Sagittal | −3.4(7.2) | −10.1(12.6) | 0.044* | 0.205, 13.3 | −2.1(7.9) | −7.5(11.9) | 0.020* | −9.84, -1.01 | |
| Frontal | 2.5(1.8) | 1.9(4.7) | 0.645 | −2.07, 3.18 | 1.8(4.0) | −0.3(5.4) | 0.153 | −0.908, 5.13 | ||
| Transverse | −0.7(3.2) | 0.5(4.7) | 0.524 | −5.00, 2.69 | −0.7(4.3) | 1.7(3.6) | 0.107 | −5.37, 0.594 | ||
| Hallux | Sagittal | 7.0(4.3) | 6.0(6.8) | 0.675 | −3.89, 5.81 | 7.6(5.4) | 5.4(4.3) | 0.249 | −1.77, 6.30 | |
| Stance | Ankle | Sagittal | 9.1(6.8) | 14.4(8.3) | 0.122 | −12.32, 1.66 | 17.6(6.1) | 22.0(9.7) | 0.070 | −9.23, 0.416 |
| Frontal | −5.5(4.0) | −5.8(5.0) | 0.775 | −1.68, 2.19 | −2.8(4.3) | −2.0(4.3) | 0.426 | −2.86, 1.29 | ||
| Transverse | 1.9(4.7) | 0.7(4.0) | 0.444 | −2.11, 4.52 | 4.3(5.8) | 1.7(5.8) | 0.120 | −0.798, 6.06 | ||
| Midfoot | Sagittal | −2.5(6.5) | −9.0 (13.0) | 0.055 | −0.156, 13.3 | −1.1(7.2) | −5.6(11.9) | 0.051 | −0.31, 9.17 | |
| Frontal | 2.8(2.2) | 1.7(4.7) | 0.362 | −1.37, 3.48 | 1.7(4.0) | −0.9(5.8) | 0.102 | −0.596, 5.78 | ||
| Transverse | −0.2(3.2) | 1.2(4.3) | 0.435 | −5.20, 2.39 | −0.5(3.6) | 2.2(4.0) | 0.084 | −5.65, 0.409 | ||
| Hallux | Sagittal | 1.1(2.9) | 1.2(4.3) | 0.926 | −2.99, 2.74 | 4.9(4.3) | 3.5(3.2) | 0.384 | −2.08, 5.08 |
| Factors | The effects of selection criteria fulfillment and AFP on recurrence-free survival adjusted for | |||||
| Microvascular invasion | Poor tumor differentiation | Recipient age | ||||
| HR (95 % CI) | P | HR (95 % CI) | P | HR (95 % CI) | P | |
| Milan criteria and AFP | ||||||
| Within Milan criteria | 0.20 (0.08–0.50) | <0.001 | 0.19 (0.08–0.48) | <0.001 | 0.18 (0.07–0.44) | <0.001 |
| AFP >100 ng/ml | 3.98 (1.87–8.47) | <0.001 | 3.56 (1.69–7.52) | <0.001 | 3.46 (1.62–7.41) | 0.001 |
| UCSF criteria and AFP | ||||||
| Within UCSF criteria | 0.26 (0.12–0.57) | <0.001 | 0.25 (0.11–0.54) | <0.001 | 0.23 (0.10–0.50) | <.001 |
| AFP >100 ng/ml | 3.83 (1.81–8.12) | <0.001 | 3.31 (1.55–7.08) | 0.002 | 3.38 (1.58–7.22) | .002 |
| Up-to-7 criteria and AFP | ||||||
| Within up-to-7 criteria | 0.19 (0.08–0.42) | <0.001 | 0.17 (0.08–0.37) | <0.001 | 0.18 (0.08–0.38) | <.001 |
| AFP >100 ng/ml | 3.60 (1.69–7.64) | <0.001 | 3.18 (1.50–6.75) | 0.003 | 3.27 (1.53–6.99) | .002 |
| Test | Method |
| Blood testsAs listed in table 1, plus: | |
| Collagen C-telopeptide (CTX)Osteocalcin (OC) | Roche Elecsys beta cross-lapsRoche Elecsys 2010Canterbury District Health Board Laboratory |
| Weight at baseline and 6 months | Tanita electronic scales |
| Rule role | Rule example | Location term | |
| Ex. 1 | Type disambiguation | IF dead, decaying in term THEN type =Env | dead animal (Host) becomes dead animal (Env) |
| Ex. 2 | Boundary extension | IF nationality before term (Env) THEN include nationality | oil field (Env) becomes German oil field (Env) |
| Ex. 3 | Boundary reduction | IF irrelevant modifier in term THEN delete modifier | infected rodent (Host) becomes rodent (Host) |
| Rabbit antibody | Neutralization titers | Dog Sera A/Pa | Serological prevalence | ||||
| 3–68 | W191R | L198 T | A128T | Arrivala | Posta | ||
| 3–68 | >1024 | 16 | <4 | <4 | < 4 / 32 | 14/21c | 14/21 |
| W191R | <16 | 16,384 | <16 | <16 | < 4 / 64 | 6/30 | 5/30 |
| L198 T | <4 | <16 | 256 | 4 | 4 / nab | 8/29 | 8/29 |
| A128T | <4 | <16 | <4 | 256 | < 4 / 16 | 20/31 | 21/31d |
| Clients & informal caregivers (n = 28) | Health care providers (n = 20) | ||
| Urban (n = 16) | Male | 4 | 0 |
| Female | 8 | 4 | |
| Rural (n = 32) | Male | 1 | 1 |
| Female | 15 | 15 |
| Median duration of stay (days) for SARI cases | Median duration in ICU (days) for SARI cases with ICU treatment | Median duration of ventilation (hours) for ventilated SARI cases | ||||||||||||||||
| Case definition | < 5 | 5–14 | 15–34 | 35–59 | 60+ | all | < 5 | 5–14 | 15–34 | 35–59 | 60+ | all | < 5 | 5–14 | 15–34 | 35–59 | 60+ | all |
| BCD | 4 | 4 | 4 | 6 | 8 | 6 | 3 | 4 | 3 | 3 | 3 | 3 | 100 | 140.5 | 78 | 74 | 61 | 69 |
| SCD | 4 | 4 | 5 | 8 | 10 | 8 | 3 | 4 | 4 | 5 | 4 | 4 | 118 | 143 | 128.5 | 142 | 95 | 104 |
| TCD | 4 | 4 | 3 | 4 | 5 | 4 | 2 | 3 | 1 | 1 | 1 | 2 | 44 | 117 | 47 | 41.5 | 32 | 37 |
| Gene id | ContiguousE. histolytica DNA region ID | Length (bp) | Location of SNP(s) (bp) |
| EHI_080100 | DS571720 | 5179 | 2725-2730 |
| EHI_065250 | DS571302 | 38246 | 10296-10318 |
| Antimicrobial agents | MIC range | MIC50 | MIC90 | Resistance (%) | Susceptible (%) |
| Cefoperazone–sulbactam | 16–256 | 64 | 128 | 85.4 | 4.2 |
| Ampicillin–sulbactam | 16–128 | 64 | 128 | 93.8 | 0 |
| Piperacillin–tazobactam | 128 to >256 | >256 | >256 | 100 | 0 |
| Ceftazidime | 32–64 | 64 | 64 | 100 | 0 |
| Cefepime | 32–64 | 64 | 64 | 100 | 0 |
| Imipenem | 1–32 | 32 | 32 | 95.8 | 2.1 |
| Meropenem | 2–32 | 32 | 32 | 95.8 | 2.1 |
| Amikacin | 8 to >128 | >128 | >128 | 83.3 | 16.7 |
| Gentamicin | 2–64 | 64 | 64 | 95.8 | 4.2 |
| Ciprofloxacin | 16 | 16 | 16 | 100 | 0 |
| Levofloxacin | 4–32 | 8 | 32 | 91.7 | 0 |
| Trimethoprim–sulfamethoxazole | 1–16 | 16 | 16 | 97.9 | 2.1 |
| Colistin | 1–32 | 1 | 2 | 4.2 | 93.8 |
| Tigecycline | 0.25–2 | 0.5 | 1 | 0 | 100 |
| Group | Sequence | Repeat times |
| A1 | DYDRYSSALIAA | 5 |
| A3 | YWTPGYTPSQTE | 1 |
| A7 | NNSRDTALRWFV | 1 |
| A13 | GQPKTFLSVSEL | 5 |
| PCOS | Controls | p-value | |
| (N = 8048) | (N = 32192) | ||
| n (%) | n (%) | ||
| Age, years | |||
| Mean (SD) | 28.11 (6.89) | 28.11 (6.90) | 0.96a |
| 15–29 | 5026 (62.5) | 20159 (62.6) | 0.95 |
| 30–39 | 2534 (31.5) | 10072 (31.3) | |
| 40–49 | 488 (6.06) | 1961 (6.09) | |
| Follow-up duration, years | |||
| Mean (SD) | 5.90 (3.98) | 5.84 (3.96) | 0.24a |
| Disease entity | |||
| Obesity | 320 (3.98) | 303 (0.94) | < 0.001 |
| Hirsutism | 64 (0.80) | 17 (0.05) | < 0.001 |
| Irregular menstruation | 5346 (66.4) | 9303 (28.9) | < 0.001 |
| Infertility | 1643 (20.4) | 1119 (3.48) | < 0.001 |
| Comorbidity | |||
| Diabetes | 51 (0.63) | 99 (0.31) | < 0.001 |
| Hypertension | 237 (2.94) | 470 (1.46) | < 0.001 |
| Hyperlipidemia | 462 (5.74) | 757 (2.35) | < 0.001 |
| Atrial fibrillation | 5 (0.06) | 9 (0.03) | 0.14 |
| Chronic Kidney disease | 34 (0.42) | 73 (0.23) | 0.002 |
| Atherosclerosis | 10 (0.12) | 19 (0.06) | 0.05 |
| No. | Primer’s name | Forward sequence | Reverse sequence | Annealing time and temperature |
| 1 | otud4 | CCACCTCCTGCAGAACAAAAG | GGGTCTTGGTAAAGGCTCATT | 15 s/60 °C |
| 2 | cx43 (gja1) | TGCTGCGAACCTACATCATC | CGATGACGTTCAAGGCAAGA | 15 s/60 °C |
| 3 | sod2 | GTCACCGAGGAGAAGTACCA | CTGGTTAGGACAGGCAACAA | 15 s/60 °C |
| 4 | sod1 | GATTCCACGTCCACGAGTTT | CCCGAGAGTGAGATCACAGA | 15 s/60 °C |
| 5 | tgfb2 | AGTACTACGCCAAGGAGGTT | TAGGCGGGATGGCATTTTCC | 15 s/60 °C |
| 6 | myf5 | GGAGACGCCTGAAGAAAGTC | CCGGCAGGCTGTAGTAATTC | 15 s/60 °C |
| 7 | bdnf | CCCCATGAAAGAAGCAAACG | TACAAGTCCGCGTCCTTACT | 15 s/60 °C |
| 8 | gapdh | GTTTGTGATGGGCGTGAACC | GTCTTCTGGGTGGCAGTGAT | 15 s/60 °C |
| Subjects | /a/ | /e/ | /i/ | /o/ | /u/ | Total |
| Viet. hyponasality | 19.0 | 7.0 | 9.0 | 6.0 | 7.0 | 9.6 |
| Viet. hypernasality | 22.5 | 54.5 | 45.5 | 28 | 23 | 34.7 |
| Kor. hypernasality | 31.4 | 43.7 | 76.9 | 55.4 | 57.9 | 53.0 |
| Viet. control group | 19.0 | 8.0 | 12.0 | 11.0 | 8.0 | 11.6 |
| Kor. control group | 8.6 | 8.7 | 22.3 | 8.4 | 10.0 | 11.6 |
| Type | Div | Cov | Caller | ||||
| (%) | GATK UG | Platypus | SAMtools | GATK HC | FreeBayes | ||
| SNP | 0.05–1.00 | 10 | 87.3–89.8 (A) | 77.6–83.0 (C) | 85.9–88.4 (B) | 85.4–87.3 (B) | 84.1–88.1 (B) |
| SNP | 0.05–1.00 | 40–100 | 96.0–98.5 (A) | 87.6–96.0 (D) | 95.3–98.2 (B) | 95.3–97.4 (C) | 93.3–98.6 (C) |
| SNP | 5.00–10.00 | 10 | 82.2–88.0 (A) | 43.7–59.4 (E) | 80.7–85.5 (B) | 73.6–84.0 (C) | 61.3–74.3 (D) |
| SNP | 5.00–10.00 | 40–100 | 91.3–97.4 (A) | 42.0–64.1 (E) | 90.8–95.1 (B) | 85.7–95.3 (C) | 65.6–81.6 (D) |
| INDEL | 0.05–1.00 | 10 | 42.0–53.5 (D) | 69.1–74.9 (A) | 63.2–73.1 (C) | 69.7–74.5 (A) | 67.5–75.3 (B) |
| INDEL | 0.05–1.00 | 40–100 | 74.2–82.9 (C) | 77.8–85.5 (A) | 72.6–82.9 (C) | 77.9–83.3 (B) | 76.0–84.0 (B) |
| INDEL | 5.00–10.00 | 10 | 37.4–47.4 (D) | 64.1–70.9 (A) | 13.3–47.7 (E) | 58.4–69.0 (B) | 55.5–65.5 (C) |
| INDEL | 5.00–10.00 | 40–100 | 70.5–79.7 (B) | 72.8–81.7 (A) | 23.6–64.1 (D) | 70.8–78.6 (B) | 62.4–73.7 (C) |
| Organism | Inpatient | Outpatient | Pediatrics | Missing | Total |
| Streptococcus species | 162 | 16 | 19 | 9 | 206 |
| Neisseria species | 94 | 11 | 2 | 0 | 107 |
| Haemophilus species | 47 | 2 | 9 | 1 | 59 |
| Staphylococcus aureus | 34 | 1 | 1 | 0 | 36 |
| Escherichia coli | 13 | 7 | 1 | 1 | 22 |
| Other Gram negative | 20 | 2 | 0 | 0 | 22 |
| Other Gram positive | 12 | 0 | 1 | 0 | 13 |
| Enterococcus species | 8 | 0 | 1 | 0 | 9 |
| Acinetobacter species | 6 | 0 | 2 | 0 | 8 |
| ESBL’s Klebsiella pneumoniae | 6 | 1 | 0 | 0 | 7 |
| Klebsiella | 7 | 0 | 0 | 0 | 7 |
| Pseudomonas species | 0 | 0 | 7 | 0 | 7 |
| Total | 409 (81.3%) | 40 (8.0%) | 43 (8.5%) | 11 (2.2%) | 503 (100%) |
| Mesencephalon | |||||
| Most Discriminative Texture Parameters on Patients | p-values (patients) | p-values (controls) | Most Discriminative Texture Parameters on Controls | p-values (controls) | p-values (patients) |
| Teta4 | <0.001* | 0.105 | S(4,-4)DifVarnc | 0.002* | 0.519 |
| Teta3 | <0.001* | 0.020* | S(5,-5DifVarnc | 0.004* | 0.465 |
| S(5,5)Entropy | <0.001* | 0.105 | Teta3 | 0.020* | <0.001* |
| S(5,5)AngScMom | <0.001* | 0.020* | S(5,-5)DifEntrp | 0.004* | 0.413 |
| S(4,4)AngScMom | <0.001* | 0.432 | Teta2 | 0.014* | <0.001* |
| S(4,4)Entropy | <0.001* | 0.322 | S(4,-4)DifEnrtp | 0.002* | 0.372 |
| Teta2 | <0.001* | 0.014* | S(3,-3)DifVarnc | 0.002* | 0.160 |
| S(1,-1)DifVarnc | <0.001* | 0.375 | WavEnLL_s-2 | 0.027* | 0,472 |
| S(1,1)DifVarnc | <0.001* | 0.375 | S(5,-5)Contrast | 0.002* | 0.833 |
| S(3,3)AngScMom | <0.001* | 0.492 | S(4,-4)Contrast | 0.002* | 0.432 |
| Administration | Clearance | Side effects | ||
| GLP-1R agonist | Subctaneous | Weight loss | Gastrointestinal tract (GIT) | |
| Exenatide | Twice a day, once a week | Renal | + | ++/±* |
| Liraglutide | Once a day | Extrarenal | + | + |
| DPP-4 inhibitor | Oral | → | → | |
| Sitagliptin | Once a day | Renal | → | → |
| Vildagliptin | Twice a day | Renal | → | → |
| Saxagliptin | Once a day | Renal | → | → |
| Linagliptin | Once a day | Extrarenal | → | → |
| Anagliptin | Twice a day | Renal | → | → |
| Teneligliptin | Once a day | Extrarenal > renal | → | → |
| Alogliptin | Once a day | Renal | → | → |
| MIGS ID | Property | Term | Evidence codea |
| Classification | Domain Bacteria | TAS [37] | |
| Phylum Bacteroidaeota | TAS [3] | ||
| Class Flavobacteriia | TAS [38] | ||
| Order Flavobacteriales | TAS [39] | ||
| Family Flavobacteriaceae | TAS [40] | ||
| Genus Elizabethkingia | TAS [2] | ||
| Species Elizabethkingia meningoseptica | TAS [2] | ||
| Strain Em3 | TAS [2] | ||
| Gram stain | Negative | IDA | |
| Cell shape | Rod | IDA | |
| Motility | Non motile | IDA | |
| Sporulation | Non-spore-forming | NAS | |
| Temperature range | 4–40 °C | IDA | |
| Optimum temperature | 37 °C | IDA | |
| pH range; Optimum | 4–10; 8 | IDA | |
| Carbon source | Heterotroph | IDA | |
| Energy source | Varied; including glucose and mannitol | IDA | |
| MIGS-6 | Habitat | Human | NAS |
| MIGS-6.3 | Salinity | Not determined | |
| MIGS-22 | Oxygen requirement | Aerobic | NAS |
| MIGS-15 | Biotic relationship | Free-living | NAS |
| MIGS-14 | Pathogenicity | Pathogen | NAS |
| MIGS-4 | Geographic location | Michigan, USA | NAS |
| MIGS-5 | Sample collection time | February, 6, 2016 | NAS |
| MIGS-4.1 | Latitude | 42° 43′ 57′′ N | NAS |
| MIGS-4.2 | Longitude | 84° 33′ 20′′ W | NAS |
| MIGS-4.4 | Altitude | Not reported | NAS |
| Included trials | Selective head cooling | Whole body cooling | |||
| Gunn 1998 | Gluckman 2005 | Shankaran 2002 | Shankaran 2005 | Eicher 2005 | |
| Design | RCT | RCTMulticenter | RCTMulticenter | RCTMulticenter | RCTMulticenter |
| Number of participants | 26 | 234 | 19 | 208 | 65 |
| Gestation | ≥ 37 wks | ≥ 37 wks | ≥ 36 wks | ≥ 37 wks | ≥ 35 wks |
| Inclusion criteria (details see Table 2) | Asphyxia and moderate to severe HIE | Asphyxia and moderate to severe HIE | Asphyxia and moderate to severe HIE | Asphyxia and moderate to severe HIE | Asphyxia and HIE |
| Target temperature treatment group (°C) | 34.5–35.5 (n = 6)34.0–35.0 (n = 7)Not analyzed:36.0–36.5 (n = 6)35.5–35.9 (n = 6) | 34.0–35.0 | 34.5 | 33.5 | 32.5–33.5 |
| Target temperature control group (°C) | 36.8–37.2 | 36.5–37.5 | 36.5 | 36.5–37.0 | 36.5–37.5 |
| Site of temperature probe | Rectal | Rectal | Esophageal | Esophageal | Rectal |
| Average age at start of cooling (min) | 294 | 330 | 318 | 302 | 120 |
| Duration of cooling (h) | 48–72 | 72 | 72 | 72 | 48 |
| Cooling device | Servo-controlled cooling cap | Servo-controlled cooling cap | Two servo-controlled cooling blankets | Two servo-controlled cooling blankets | Ice bags followed by one servo-controlled cooling blanket |
| Primary outcome | Adverse events | Composite of death/severe disability | Adverse events | Composite of death/moderate or severe disability | Adverse events |
| Latest follow-up (months) | 18 | 18 | Follow-up not reported | 18–22 | 12 |
| Follow-up tools | Bayley II | Bayley IIGMF | - | Bayley IIGMF | Bayley IIVineland |
| Chromosome | Number of SNPs in EU regions | Sequence length of EU regions (Mb) | SNP density in EU regions (Kb/SNP) | Number of SNPs in HET regions | Sequence length of HET regions (Mb) | SNP density in HET regions (Kb/SNP) | Number of SNPs | Sequence length (Mb) | SNP density (Kb/SNP) |
| Chr.01 | 1012 | 14.8 | 14.6 | 425 | 41.1 | 96.6 | 1437 | 55.9 | 39.2 |
| Chr.02 | 1853 | 26.2 | 14.1 | 261 | 25.3 | 97.1 | 2114 | 51.6 | 24.3 |
| Chr.03 | 1160 | 18.8 | 16.2 | 212 | 28.9 | 136.1 | 1372 | 47.7 | 34.8 |
| Chr.04 | 1249 | 18.8 | 15.0 | 390 | 30.1 | 77.3 | 1639 | 49.2 | 30.0 |
| Chr.05 | 1425 | 21.8 | 15.3 | 83 | 18.8 | 227.1 | 1508 | 41.9 | 27.8 |
| Chr.06 | 1326 | 22.0 | 16.6 | 315 | 28.6 | 90.8 | 1641 | 50.6 | 30.9 |
| Chr.07 | 1630 | 27.5 | 16.9 | 168 | 17.0 | 101.4 | 1798 | 44.7 | 24.8 |
| Chr.08 | 1960 | 30.5 | 15.6 | 182 | 15.8 | 86.5 | 2142 | 46.9 | 21.9 |
| Chr.09 | 1262 | 17.4 | 13.8 | 369 | 29.2 | 79.0 | 1631 | 46.8 | 28.7 |
| Chr.10 | 1536 | 24.1 | 15.7 | 337 | 26.7 | 79.2 | 1873 | 50.9 | 27.2 |
| Chr.11 | 1241 | 24.3 | 19.6 | 111 | 14.7 | 132.2 | 1352 | 39.2 | 29.0 |
| Chr.12 | 1140 | 17.0 | 14.9 | 135 | 22.6 | 167.2 | 1275 | 40.1 | 31.5 |
| Chr.13 | 2086 | 29.5 | 14.1 | 171 | 14.7 | 86.2 | 2257 | 44.3 | 19.6 |
| Chr.14 | 1345 | 20.3 | 15.1 | 307 | 29.3 | 95.3 | 1652 | 49.7 | 30.1 |
| Chr.15 | 1779 | 22.9 | 12.9 | 309 | 27.5 | 89.1 | 2088 | 50.9 | 24.4 |
| Chr.16 | 1246 | 17.6 | 14.1 | 225 | 19.6 | 87.3 | 1471 | 37.3 | 25.4 |
| Chr.17 | 1422 | 20.1 | 14.2 | 289 | 21.6 | 74.7 | 1711 | 41.9 | 24.5 |
| Chr.18 | 2480 | 36.6 | 14.7 | 309 | 25.5 | 82.6 | 2789 | 62.3 | 22.3 |
| Chr.19 | 1660 | 27.4 | 16.5 | 331 | 23.2 | 70.0 | 1991 | 50.6 | 25.4 |
| Chr.20 | 1007 | 17.6 | 17.5 | 261 | 26.6 | 101.9 | 1268 | 46.8 | 36.9 |
| Average | 1491 | 22.8 | 15.4 | 260 | 24.3 | 102.9 | 1750 | 47.5 | 27.9 |
| Candidate Biomarker | Comparison | Difference | Lower CI | Upper CI | Q-value |
| CEA | Malignant/Non-malignant | 1.97 | 1.08 | 2.85 | 0 |
| CEA | Malignant/Healthy | 2.11 | 1.02 | 3.19 | 0 |
| IL.8 | Malignant/Healthy | 1.22 | 0.14 | 2.31 | 0 |
| Prolactin | Non-malignant/Healthy | 1.1 | 0.02 | 2.19 | 0.04 |
| Health professional/service | Communications sent out | Communications received | |
| 6 | Oncologist | 0 | 1 |
| 7 | Psychologist | 0 | 1 |
| 9 | Neurosurgeon | 5 | 1 |
| 16 | Primary nurse, Oncology | 0 | 0 |
| 23 | Family Physician | 0 | 1 |
| 30 | Pediatrician/Palliative Care | 0 | 0 |
| 36 | Oncologist | 0 | 1 |
| 38 | Oncologist | 0 | 2 |
| 42 | Pediatrician/Palliative Care | 0 | 1 |
| 44 | Neurosurgeon | 0 | 3 |
| 47 | Neurosurgeon | 3 | 0 |
| 78 | Canuck Place | 3 | 0 |
| Mean | 0.92 | 0.92 |
| Free attention (FA) | Attention to the right (AR) | Attention to the left (AL) | ||||||
| P | G | P | G | P | G | |||
| Mean | 1.04 | 0.67 | 2.18 | 2.63 | 2.31 | 1.71 | ||
| S.D | 1.22 | 0.98 | 1.70 | 2.88 | 2.06 | 2.21 | ||
| Mann-Whitney Test (P X G) | 0.288 | 1.00 | 0.396 |
| Magnetic Detection | Microbiological Tests | |||||||||
| Anti-Streptococcus agalactiae | Anti-GB Streptococci | |||||||||
| Mastitic Milk Isolates | Correctly Identified | Correctly Identified | Correctly Identified | |||||||
| n | n | % | MI 1 | n | % | MI | n | % | MI | |
| S. aureus | 1 | 0 | 0.0 | 0 | 1 | 100.0 | 0 | 0 | 0.0 | 1 |
| S. agalactiae | 13 | 7 | 70.0 | 3 | 2 | 25.0 | 6 | 13 | 100.0 | 0 |
| S. uberis | 11 | 3 | 33.3 | 6 | 5 | 62.5 | 3 | 8 | 72.7 | 3 |
| Streptococcus spp. | 4 | 0 | 0.0 | 3 | 2 | 50.0 | 2 | 1 | 25.0 | 3 |
| Staphylococcus spp. | 2 | 0 | 0.0 | 0 | 1 | 50.0 | 1 | 2 | 100.0 | 0 |
| Enterococcus spp. | 7 | 3 | 75.0 | 1 | 1 | 33.3 | 2 | 0 | 0.0 | 7 |
| Escherichia coli | 3 | 0 | 0.0 | 1 | 1 | 50.0 | 1 | 3 | 100.0 | 0 |
| Yeasts | 3 | 0 | 0.0 | 2 | 1 | 100.0 | 0 | 2 | 66.7 | 1 |
| Prototheca | 2 | 0 | 0.0 | 2 | 1 | 50.0 | 1 | 2 | 100.0 | 0 |
| TOTAL | 46 | 13 | 41.9 | 18 | 15 | 48.4 | 16 | 31 | 67.4 | 15 |
| NPWT (n = 19) | Usual care (n = 21) | Total (n = 40) | |
| Age (years)* | 58·8(15·1) | 56·9(13·9) | 57·8(14·4) |
| Sex ratio (M : F) | 11 : 8 | 11 : 10 | 22 : 18 |
| BMI (kg/m2)* | 29·2(5·6) | 29·0(6·0) | 29·1(5·7) |
| Diabetes | 12 | 12 | 24 |
| Peripheral arterial disease | 7 | 7 | 14 |
| Tobacco use | |||
| None | 13 | 10 | 23 |
| Ex‐smoker | 1 | 6 | 7 |
| Current (≤ 1 pack/day) | 2 | 4 | 6 |
| Current (> 1 pack/day) | 3 | 1 | 4 |
| Previous history of SWHSI | |||
| Yes | 5 | 5 | 10 |
| No | 11 | 15 | 26 |
| Unknown | 3 | 1 | 4 |
| Wound area (cm2)† | 18·2 (0·2–122·5) | 20·4 (2·3–93·2) | 19·3 (0·2–122·5) |
| < 28 | 10 | 11 | 21 |
| ≥ 28 | 9 | 10 | 19 |
| Wound duration (days)† | 7 (0–27) | 12 (1–142) | 7 (0–142) |
| Wound infected | |||
| Yes | 5 | 8 | 13 |
| No | 14 | 13 | 27 |
| Wound location | |||
| Foot | 11 | 13 | 24 |
| Abdomen | 3 | 3 | 6 |
| Leg | 3 | 1 | 4 |
| Breast | 1 | 1 | 2 |
| Groin | 0 | 2 | 2 |
| Buttocks | 0 | 1 | 1 |
| Perianal area | 1 | 0 | 1 |
| Type of surgery‡ | |||
| Elective | 12 | 18 | 30 |
| Emergency | 6 | 3 | 9 |
| Contamination level of surgery | |||
| Clean | 6 | 2 | 8 |
| Clean‐contaminated | 9 | 12 | 21 |
| Contaminated | 4 | 7 | 11 |
| SPACE | ESPACE | ||||
| No. | Gene | Degree | No. | Gene | Degree |
| 1 | PRC1 | 26 | 1 | AURKA | 36 |
| 2 | RRM2 | 17 | 2 | NKX2-1 | 35 |
| 3 | GPR116 | 16 | 3 | RRM2 | 18 |
| 4 | NKX2-1 | 16 | 4 | CYP2B7P1 | 16 |
| 5 | CYP2B7P1 | 15 | 5 | GPR116 | 16 |
| 6 | SFTPB | 15 | 6 | SFTPB | 15 |
| 7 | HOP | 13 | 7 | HOP | 12 |
| 8 | C1orf116 | 12 | 8 | HSD17B6 | 11 |
| 9 | HSD17B6 | 12 | 9 | PRC1 | 11 |
| 10 | TFF1 | 12 | 10 | TFF1 | 11 |
| 11 | CD302 | 10 | 11 | C1orf116 | 10 |
| 12 | FMO5 | 10 | 12 | CD302 | 10 |
| 13 | TPX2 | 8 | 13 | FMO5 | 10 |
| 14 | UBE2C | 10 | |||
| 15 | APC | 8 | |||
| 16 | CDKN3 | 8 | |||
| 17 | TPX2 | 8 |
| Model description | |||||
| Y | No. of variables | No. of observations | Degrees of freedom | ||
| SMR | 3 | 2306 | 2303 | ||
| Model fit | |||||
| R2 | Log likelihood | AIC | |||
| 0.2238 | -235.357 | 476.713 | |||
| Model estimation | |||||
| Variable | Coefficient | Std. Error | t-Statistic | P | |
| ρ | 0.4962 | 0.0231 | 21.496 | 0.0000 | |
| CONSTANT | 0.3605 | 0.0304 | 11.859 | 0.0000 | |
| AOD | 0.5367 | 0.1522 | 3.527 | 0.0004 | |
| Diagnostic tests | |||||
| Tests | DF | Value | p | ||
| Heteroskedasticity | Breusch-Pagan | 1 | 0.156 | 0.6933 | |
| Spatial dependence | Likelihood Ratio | 1 | 434.813 | 0.2745 |
| Cancer types | Key message(s) | Ref. |
| Breast cancer | Dephosphorylation of FOXO3a induced by Aplysin suppresses tumor growth by inhibiting cell proliferation and promoting apoptosis in cancer cells. | [89] |
| Prostate cancer | Deregulation of FOXO3a promotes prostate cancer progression in TRAMP mice. | [90] |
| Acute myeloid leukemia | Dephosphorylation of FOXO3a induced by hypomethylating agents promote apoptosis by upregulation of BIM and PUMA expression. | [91] |
| Colon cancer | Activation of FOXO3a by aldose reductase induces human colon cancer cell apoptosis by upregulating both DR5 and DR4. | [92] |
| Lung cancer | Deregulation of FOXO3a promotes DNMT3B overexpression leading to tumor growth in lung cancer. | [93] |
| Glioma | A high expression of FOXO3a is associated with glioblastoma progression and FOXO3a level independently indicates poor prognosis in Glioma patients. | [94] |
| Thyroid cancer | Nuclear FOXO3a promotes cell cycle progression by transcriptional upregulation of cyclin A1 and accelerates proliferation of human ATC cells. | [95] |
| Lung adenocarcinoma | FOXO3a gene inactivation occurs frequently in carcinogen-induced lung adenocarcinoma. | [96] |
| Oral squamous cell carcinoma | Constitutively active form of FOXO3a induces significant G1-phase arrest and apoptosis in OSCC cells | [97] |
| Neck cancer | Tumor patients with low FOXO3a expression have a poor prognosis compared with patients with high FOXO3a. | [98] |
| Urothelial cancer | FOXO3a suppresses invasiveness of urothelial cancer through regulation of Twist1, YB-1 and E-cadherin. | [99] |
| Osteosarcoma | Activation of FOXO3a by ionizing radiation induces cell apoptosis in osteosarcoma. | [100] |
| Bladder cancer | Upregulation of FOXO3a by Nkx2.8 suppresses bladder cancer proliferation. | |
| Gastric cancer | FOXO3a cooperates with RUNX3 to induce apoptosis by activating Bim in gastric cancer cells. | [60, 101] |
| Neuroblastoma | Inactivation of FOXO3a by AKT is essential for neuroblastoma cell survival. | [102] |
| Ovarian cancer | Inhibition of FOXO3a phosphorylation by BrMC upregulates Bim expression and leads to apoptosis in ovarian cancer cells. | [103] |
| Rate of failure in control group (%) | Rate of failure in the intervention group (%) | |||||
| 10 | 15 | 25 | ||||
| 80% power | 90% power | 80% power | 90% power | 80% power | 90% power | |
| 25 | 100 | 133 | ||||
| 30 | 62 | 82 | 121 | 161 | ||
| 35 | 43 | 57 | 73 | 97 | 329 | 440 |
| Variables | Renal cell carcinoma (n = 76) |
| Age (mean, years) | 61.3 ± 13.5 |
| Sex | |
| Male | 45 |
| Female | 31 |
| Tumor type | |
| Clear cell | 59 |
| Papillary | 11 |
| Chromophobe | 4 |
| Sarcomatoid carcinoma | 2 |
| Pathologic grade | |
| Grade 1 and 2 | 57 |
| Grade 3 and 4 | 19 |
| Tumor stage | |
| Stage 1 and 2 | 52 |
| Stage 3 and 4 | 24 |
| Study population | Non-pregnant group | Pregnant group | p-Value | |
| Difference between groups | ||||
| N = 728 | N = 235 | N = 493 | ||
| Age, Mean (SD) years | 32.5 (4.7) | 32.8 (4.2) | 32.4 (4.9) | 0.271 |
| Marital status, n (%) | N = 722 | N = 234 | N = 487 | |
| Married/co-habiting | 699 (96.8%) | 230 (98.3%) | 469 (96.1%) | |
| Other | 23 (3.2%) | 4 (1.7%) | 19 (3.9%) | |
| 0.122 | ||||
| Basic education, n (%) | N = 720 | N = 234 | N = 486 | |
| Elementary school | 165 (22.9%) | 42 (17.9%) | 123 (25.3%) | |
| Part of high school | 31 (4.3%) | 15 (6.4%) | 16 (3.3%) | |
| High school diploma | 514 (71.4%) | 173 (73.9%) | 341 (70.2%) | |
| Other | 10 (1.4%) | 4 (1.7%) | 6 (1.2%) | |
| 0.0492 | ||||
| Vocational education, n (%) | N = 718 | N = 232 | N = 486 | |
| No professional education/ diploma/degree | 76 (10.6%) | 25 (10.8%) | 51 (10.5%) | |
| Vocational course/school or apprenticeship | 236 (32.9%) | 70 (30.2%) | 166 (34.2%) | |
| Vocational diploma/degree | 174 (24.2%) | 54 (23.3%) | 120 (24.7%) | |
| Academic degree | 228 (31.8%) | 83 (35.8%) | 145 (29.8%) | |
| Other | 4 (0.6%) | 0 (0.0%) | 4 (0.8%) | |
| 0.342 | ||||
| Current work situation, n (%) | N = 722 | N = 234 | N = 488 | |
| Full-time work | 368 (51.0%) | 75 (32.1%) | 293 (60.0%) | |
| Part-time work | 70 (9.7%) | 25 (10.7%) | 45 (9.2%) | |
| Housewife | 191 (26.5%) | 87 (37.2%) | 104 (21.3%) | |
| Unemployed | 16 (2.2%) | 4 (1.7%) | 12 (2.5%) | |
| Maternity leave | 36 (5.0%) | 29 (12.4%) | 7 (1.4%) | |
| Other | 41 (5.7%) | 14 (6.0%) | 27 (5.5%) | |
| <0.0012 | ||||
| Annual household income, n (%) | N = 689 | N = 226 | N = 463 | |
| <20 000 euro/year | 33 (4.8%) | 9 (4.0%) | 24 (5.2%) | |
| 20 001-50 000 | 251 (36.4%) | 83 (36.7%) | 168 (36.3%) | |
| 50 001-100 000 | 366 (53.1%) | 116 (51.3%) | 250 (54.0%) | |
| >100 000 | 39 (5.7%) | 18 (8.0%) | 21 (4.5%) | |
| 0.282 |
| EC50 (μM) [conf. int.]* | ||||||
| Control Glutamate | EU1794-27 Glutamate | Fold Difference | Control Glycine | EU1794-27 Glycine | Fold Difference | |
| GluN2A | 2.9 [2.2, 4.0] | 1.1 [0.88, 2.1] | 2.3† | 0.57 [0.34, 0.96] | 0.38 [0.23, 0.64] | 1.6 |
| GluN2B | 1.2 [1.1, 1.3] | 0.65 [0.49, 0.85] | 2.0† | 0.28 [0.22, 0.36] | 0.14 [0.08, 0.24] | 2.9† |
| GluN2C | 0.67 [0.61, 0.73] | 0.22 [0.16, 0.31] | 3.3† | 0.23 [0.13, 0.40] | 0.10 [0.07, 0.15] | 2.4 |
| GluN2D | 0.21 [0.17,0.27] | 0.054 [0.028, 0.11] | 5.3† | 0.086 [0.077, 0.095] | 0.020 [0.013, 0.029] | 4.9† |
| 2003 | 2004 | 2005 | 2006 | 2007 | Total | |
| Number of complicated induced abortions | 23 | 13 | 11 | 18 | 46 | 111 |
| Number of admission into gynaecological ward | 757 | 716 | 471 | 785 | 818 | 3547 |
| Number of live births | 1543 | 1479 | 1512 | 1756 | 2101 | 8391 |
| Percentage of gynaecological admission | 3.0 | 1.8 | 2.3 | 2.3 | 5.6 | 3.1% |
| Ratio of complicated induced abortion per 1000 live births | 14.9 | 8.8 | 7.3 | 10.3 | 21.9 | 13.2/1000 |
| Year | Journal | Title of the paper | First author; volume number; page numbers |
| 2013 | Public health action | The burden and outcomes of childhood tuberculosis in Cotonou, Benina | Ade S; vol 314; no 1; 15–19 |
| 2013 | Public health action | MDR-TB treatment needs in patients previously treated for TB in Cotonou, Beninb | Ade S; vol 3; no 2; 160–165 |
| 2013 | Transactions of the royal society of tropical medicine and hygiene | National profile and treatment outcomes of adult smear-negative pulmonary TB patients in Beninb | Ade S; 10.1093/trstmh/trt092 |
| 2014 | PLoS One | National profile and treatment outcomes of patients with extrapulmonary tuberculosis in Benina | Ade S; vol 9; no 4; e95603 |
| 2015 | Public health action | Low prevalence of diabetes mellitus in patients with tuberculosis in Cotonou, Beninb | Ade S; vol 5; no 2; 147–149 |
| 2016 | BMC health services research | Follow-up and tracing of tuberculosis patients who fail to attend their scheduled appointments in Cotonou, Benin: a retrospective cohort studya | Ade S; vol 5; no 2; 7 pages; 10.1186/s12913-015-1219-z |
| 2016 | Tuberculosis research and treatment | Characteristics and treatment outcomes of retreatment tuberculosis patients in Beninb | Ade S; vol 2016, Article ID 1468631, 7 pages http://dx.doi.org/10.1155/2016/1468631 |
| 2016 | Tuberculosis research and treatment | Tuberculosis case finding in Benin, 2000–2014 and beyond: a retrospective cohort and Time Series Studyb | Ade S; volume 2016, Article ID 3205843, 9 pages http://dx.doi.org/10.1155/2016/3205843 |
| Factor | B | S.E. | Wald | P | OR | 95% CI |
| SDF-1α | 1.083 | 0.444 | 5.958 | 0.015 | 2.952 | 1.238–7.042 |
| CXCR4 | 0.546 | 0.634 | 4.742 | 0.039 | 1.726 | 1.499–5.973 |
| EBV-IgG status | 0.720 | 0.334 | 3.006 | 0.036 | 1.027 | 1.534–1.976 |
| T staging | 0.572 | 0.222 | 2.008 | 0.036 | 1.080 | 1.034–1.515 |
| N staging | 0.617 | 0.223 | 7.640 | 0.006 | 1.853 | 1.197–2.869 |
| TNM staging | 1.485 | 0.192 | 6.394 | 0.011 | 1.624 | 1.115–2.364 |
| Skull base invasion | 1.643 | 1.181 | 1.934 | 0.043 | 1.193 | 1.019–1.959 |
| Cervical lymph node metastasis | 0.915 | 1.099 | 2.693 | 0.045 | 2.496 | 1.290–2.497 |
| Treatment [Reference] | Annual exacerbation rate | Comparator | Annual exacerbation rate | Reduction in exacerbations | Exacerbation endpoint | Patient population | |
| Exacerbation entry criteria (No./year) | FEV1 % predicted | ||||||
| ICS | |||||||
| FP [131] | 0.93 | Placebo | 0.73 | NS | Primary | NA | <90 % (post-BD) |
| FP [13] | 0.93 | Placebo | 1.13 | 18 % | Secondary (moderate or severe) | NA | <60 % (pre-BD) |
| FP [65] | 1.05 | Placebo | 1.30 | 19 % | Secondary (any) | ≥1 | 25–70 % (pre-BD) |
| FP [132] | 0.99 | Placebo | 1.32 | 25 % | Secondary (any) | NA | <85 % (post-BD) |
| LABA/ICS | |||||||
| SFC [133] | 0.44 | Salmeterol | 0.48 | NS | Primary (severe) | ≥1 (last 14 days) | <70 % (pre-BD) |
| SFC [134] | 1.10 | Salmeterol | 1.59 | 30.4 % | Primary (moderate or severe) | ≥1 | <50 % |
| SFC [13] | 0.85 | PlaceboSalmeterolFP | 1.130.970.93 | 25 %12 %9 % | Secondary (moderate or severe) | NA | <60 % (pre-BD) |
| SFC [65] | 0.97 | Placebo | 1.30 | 25 % | Secondary (moderate) | ≥1 | 25–70 % (pre-BD) |
| SFC [135] | 1.06 | Salmeterol | 1.53 | 30.5 % | Primary | ≥1 | <50 % |
| SFC [61, 136] | 1.28 | Tiotropium | 1.32 | NS | Primary (moderate or severe) | NA | <50 % (post-BD) |
| SFC [137] | 0.92 | Salmeterol | 1.4 | 35 % | Primary (moderate or severe) | ≥2 | <50 % (post-BD) |
| Bud/Form [80] | 1.38 | PlaceboFormeterolBudesonide | 1.801.851.60 | 23.6 %NSNS | Primary (all) | ≥1 | <50 % (pre-BD) |
| Bud/Form [81] | 1.42 | PlaceboFormoterolBudesonide | 1.871.841.59 | 24 %23 %NS | Primary (severe) | ≥1 | <50 % |
| Bud/Form [138] | 0.70 (320/9 μg)0.79 (160/9 μg) | Formoterol | 1.07 | 34.6 %25.9 % | Primary (moderate or severe) | ≥1 | ≤50 % (pre-BD) |
| Bud/Form [139] | NR | Formoterol | NR | 36 % | Secondary (any) | ≥1 | ≤50 % (pre-BD) |
| FF/VI [79] | 0.81 | Vilanterol | 1.11 | 30 %(Pooled data) | Primary (moderate or severe) | ≥1 | <70 % (post-BD) |
| BDP/FOR [140] | 0.80 | Formoterol | 1.12 | 28 % | Primary (moderate or severe) | ≥1 | <50 % |
| BDP/FOR [141] | 0.41 | Bud/Form Formoterol | 0.420.43 | NS | Primary | ≥1 | 30–50 % (post-BD) |
| Triple therapy | |||||||
| Tiotropium + salmeterol + FP [64] | 1.37 | Tiotropium | 1.61 | NS | Secondary (any) | ≥1 | <65 % (post-BD) |
| Identified phenolic compounds | P. veris | P. elatior | ||||
| Mean | ±sd | CV (%) | Mean | ±sd | CV (%) | |
| (+)-Catechin | 312.11 | ±90.91∗∗ | 29.13 | 171.75 | ±57.26 | 33.34 |
| Orientin | 204.23 | ±78.03 ns | 38.21 | 149.13 | ±57.16 | 38.33 |
| Rutoside | 630.83 | ±199.15 | 31.57 | 1025.96 | ±237.21∗∗ | 23.12 |
| Hyperoside | nd | 265.30 | ±122.80 | 46.29 | ||
| Isorhamnetin-3-O-rutinoside | 740.24 | ±337.09 | 45.54 | 1142.75 | ±401.76∗∗ | 35.16 |
| Isorhamnetin-3-O-glucoside | 448.45 | ±143.39∗∗ | 31.97 | 124.73 | ±54.02 | 43.31 |
| Astragalin | 185.07 | ±38.79∗∗ | 20.96 | 117.27 | ±34.81 | 29.68 |
| Chlorogenic acid | 72.84 | ±22.81 ns | 31.31 | 55.38 | ±21.04 | 37.99 |
| Item | Group 1: feedback report (n = 9) | Group 2: feedback report with appendix (n = 11) | P-value | |
| Mean (CI) | Mean (CI) | |||
| Scale 1–10 | Scale 1–10 | |||
| 1a | I think that the patient safety culture feedback report is.... | |||
| Understandable | 6.1 (4.8–7.5) | 7.3 (6.0–8.6) | 0.04* | |
| Interesting | 7.6 (7.0–8.1) | 7.6 (6.7–8.6) | 0.53 | |
| Useful | 6.8 (3.0–7.5) | 7.2 (5.8–8.6) | 0.10 | |
| Relevant | 7.3 (6.8–7.9) | 7.8 (7.3–8.3) | 0.20 | |
| Well-ordered | 6.7 (5.9–7.4) | 7.5 (6.4–8.5) | 0.12 | |
| Complete | 6.9 (6.2–7.6) | 7.4 (6.6–8.2) | 0.45 | |
| Attractive (lay-out) | 6.8 (6.3–7.3) | 7.6 (7.0–8.3) | 0.04* | |
| N (%) | N (%) | |||
| 2b | Do you miss any results in this report? | 5 (56 %) | 7 (64 %) | |
| Yes | 1.000 | |||
| 3b | Which statement reflects the patient safety culture report best: | 6 (67 %) | 5 (46 %) | 0.49 |
| we now see suggestions to improve patient safety culture | 1 (11 %) | 4 (36 %) | ||
| we now have insight, but we do not know how to improve | 2 (22 %) | 1 (9 %) | ||
| this report has brought us little new information different statements | - | 1 (9 %) |
| Aguie | Guidan Roumdji | Maradi CU | Madarounfa | Total | ||
| Total population | ||||||
| Number of households/respondents | 735 | 735 | 735 | 735 | 2940 | |
| Number of children under 5 yo | 1550 | 2011 | 1736 | 1644 | 6941 | |
| Number (%) of households with | ||||||
| 1 to 2 children < 5 yo | 535 (72.8) | 463 (63.0) | 492 (66.9) | 518 (70.5) | 2008 (68.3) | |
| 3 to 5 children < 5 yo | 192 (26.1) | 211 (28.7) | 209 (28.5) | 200 (27.3) | 812 (27.7) | |
| more than 5 children < 5 yo | 8 (1.1) | 61 (8.3) | 34 (4.6) | 17 (2.3) | 120 (4.1) | |
| Number (%) of respondents with | ||||||
| 0 years of education | 680 (92.5) | 669 (91.0) | 534 (72.7) | 665 (90.5) | 2548 (86.7) | |
| 1 to 6 years of education | 35 (4.8) | 38 (5.2) | 72 (9.8) | 39 (5.3) | 184 (6.3) | |
| more than 6 years of education | 20 (2.7) | 28 (3.8) | 129 (17.6) | 31 (4/2) | 208 (7.1) | |
| Selected population | ||||||
| Selected children | 735 | 735 | 735 | 735 | 2940 | |
| Sex ratio M/F | 0.96 | 0.94 | 1.03 | 1.15 | 1.01 | |
| Age | ||||||
| median (month) (IQR) | 23 (12-35) | 23 (13-35) | 23 (12-36) | 25 (14-38) | 24 (13-36) | |
| < 1 year (%) | 214 (29.1) | 175 (23.9) | 184 (25.2) | 153 (20.9) | 726 (24.8) | |
| 1 - 2 years (%) | 202 (27.5) | 212 (29.0) | 203 (27.8) | 201 (27.5) | 818 (28.0) | |
| 2 - 3 years (%) | 163 (22.2) | 185 (25.3) | 169 (23.2) | 186 (25.4) | 703 (24.0) | |
| 3 - 4 years (%) | 106 (14.4) | 110 (15.1) | 104 (14.2) | 117 (16.0) | 437 (14.9) | |
| 4 - 5 years (%) | 49 (6.7) | 49 (6.7) | 70 (9.6) | 75 (10.2) | 243 (8.3) |
| Land-cover type | Proportion of area of suitable habitat (%) 1 | Mean habitat suitability (%) |
| Madrean Encinal | 6.3 | 47.1 |
| Madrean Pinyon-Juniper Woodland | 12.6 | 40.7 |
| Mogollon Chaparral | 2.5 | 38.8 |
| Chihuahuan Mixed Salt Desert Scrub | 2.5 | 34.7 |
| Madrean Lower Montane Pine-Oak Forest and Woodland | 1.4 | 34.6 |
| Apacherian-Chihuahuan Mesquite Upland Scrub | 10.6 | 22.6 |
| Apacherian-Chihuahuan Semi-Desert Grassland and Steppe | 28.2 | 18.9 |
| Chihuahuan Creosote, Mixed Desert and Thorn Scrub | 10.4 | 16.7 |
| Southern Rocky Mountain Ponderosa Pine Woodland | 8.5 | 14.6 |
| Colorado Plateau Pinyon-Juniper Woodland | 5.1 | 13.9 |
| Chihuahuan Stabilized Coppice Dune and Sand Flat Scrub | 1.2 | 8.3 |
| Sonoran Paloverde-Mixed Cacti Desert Scrub | 2.8 | 5.9 |
| Request | Time for the injury prevention request to be responded (ms) |
| Average | 8702.68164 |
| Median | 11257 |
| Cww [g l-1] | cvalencene [mg l-1] | Conversion [%]b | Yield [mg g-1 cdw] | Yield [mg l-1] |
| 70 | 409 | 15.1 | 3.35 | 61.6 |
| 70 | 613 | 13.2 | 4.40 | 80.9 |
| 70 | 818 | 11.8 | 5.22 | 96.0 |
| 140 | 409 | 21.8 | 2.42 | 89.1 |
| 280 | 409 | 23.0 | 1.28 | 94.2 |
| 140 | 818 | 14.1 | 3.14 | 118.5 |
| Rank | Topic | Mean | Median |
| 1 | Newborn circumcision | 1.36 | 1 |
| 2 | Reduce paraphimosis | 1.36 | 0 |
| 3 | Vasectomy | 1.18 | 0 |
| 4 | Drain hydrocoele | 1.00 | 0 |
| 5 | Bladder catheterization | 0.91 | 1 |
| 6 | Intracavernosal injections | 0.82 | 0 |
| 7 | Adult circumcision | 0 | 0 |
| 8 | Prostate biopsy | 0 | 0 |
| Baseline | Routine clinic visitsa | |
| Fasting plasma glucose | √ | √ |
| Fasting insulin | √ | √ |
| Glycated haemoglobin A1c | √ | √ |
| Serum triglycerides | √ | √ |
| Cholesterol | √ | √ |
| High-density lipoprotein | √ | √ |
| Low-density lipoprotein | √ | √ |
| Apolipoprotein B/apolipoprotein A1 | √ | √ |
| Serum sodium | √ | √ |
| Serum potassium | √ | √ |
| Serum renin | √ | √ |
| Serum osteocalcin | √ | √ |
| Serum procollagen I N-terminal propeptide | √ | √ |
| Variables | Sample distribution | OIDP = 0 | OIDP = 1 | OIDP ≥ 2 |
| n (%) | n (%) | |||
| Sex | ||||
| Male | 182(53.7) | 76(41.8) | 54(29.7) | 52(28.5) |
| Female | 157(46.3) | 66(42.0) | 48(30.6) | 43(27.4) |
| Skin color | ||||
| White | 270(79.7) | 113(41.9) | 83(30.7) | 74(27.4) |
| Blacks | 69(20.3) | 29(42.1) | 19(27.5) | 21(30.4) |
| Family income at child birth* | ||||
| > 6 | 45(13.3) | 21(46.6) | 17(37.9) | 7(15.5) |
| 1.1-6 | 232(68.6) | 94(40.5) | 66(28.5) | 72(31.0) |
| ≤ 1 | 61(18.1) | 27(44.3) | 18(29.5) | 16(26.2) |
| Maternal schooling at child birth | ||||
| ≥ 9 yr | 78(23.1) | 32(41.0) | 27(34.6) | 19(24.4) |
| 5 - 8 yr | 164(48.5) | 76(46.3) | 42(25.6) | 46(28.1) |
| ≤ 4 | 96(28.4) | 34(35.4) | 32(33.3) | 30(31.3) |
| Mother employment status at child aged 6 month | ||||
| No | 230(68.1) | 110(47.8) | 67(29.1) | 53(23.1) |
| Yes | 108(31.9) | 32(29.6) | 34(31.5) | 42(38.9) |
| Untreated dental caries at age 6 | ||||
| 0 | 124(36.7) | 54(43.5) | 40(32.3) | 30(24.2) |
| 1-3 | 92(27.2) | 38(41.3) | 25(27.2) | 29(31.5) |
| 4-19 | 122(36.1) | 50(41.0) | 36(29.5) | 36(29.5) |
| Open bite at age 6 yr | ||||
| No | 173(52.2) | 73(42.2) | 49(28.3) | 51(29.5) |
| Yes | 165(48.8) | 69(41.8) | 52(31.5) | 44(26.7) |
| Cross bite at age 6 yr | ||||
| No | 277(81.9) | 120(43.3) | 85(30.7) | 72(26.0) |
| Yes | 61(18.1) | 22(36.1) | 16(26.2) | 23(37.7) |
| Vmax (mM·min−1) | Km (μM) | |
| Al(III) (μM) | ||
| 0 | 28.1 | 23.8 |
| 30 | 30.3 | 16.1 |
| Nano-Al13 (μM) | ||
| 0 | 28.3 | 23.5 |
| 30 | 28.5 | 13.6 |
| Recreational | High school | University | Overall | |
| n = 56 (%) | n = 32 (%) | n = 52 (%) | n = 140 (%) | |
| Males (%) | 56 (100) | 19 (59.3) | 19 (36.53) | 94 (67.1) |
| Age (years) (mean ± SD) | 14.9 ± 2.0 | 16.1 ± 1.7 | 20.6 ± 2.0 | 17.3 ± 3.3 |
| Use ASD (%) | 8 (14.3) | 7 (21.9) | 31 (59.6) * | 46 (32.9) |
| Previous ankle injury (%) | 41 (73.2) | 28 (87.5) | 45 (86.5) | 114 (81.4) |
| Coach enforcement of ASD (%) | 4 (7.1) | 4 (12.5) | 24 (46.2) * | 32 (22.9) |
| Group <70 yrs (n) | Group ≥70 yrs (n) | |
| Pulmonary embolism | 2 | 4 |
| Hypertension | 6 | 8 |
| Atrial fibrillation | 5 | 5 |
| Pneumonia | 1 | 2 |
| Leucopenia | 4 | 7 |
| Prolonged ileus | 8 | 10 |
| Urinary tract infections | 4 | 6 |
| Drainage of intra-abdominal collection | 2 | 4 |
| Reoperation | 5 | 3 |
| Pancreatic fistula | 1 | 1 |
| Hemorrhage | 3 | 1 |
| Peritonitis | 1 | 1 |
| Variable | N (%) | Mean ± SD | p-value | |
| Gender | Men | 768 (79.8) | 26.25 ± 7.65 | < 0.01 |
| Women | 194 (20.2) | 22.61 ± 7.15 | ||
| Marriage | Single | 530 (53.5) | 24.59 ± 7.39 | 0.01 |
| Married | 461 (46.5) | 26.25 ± 7.97 | ||
| Age (years) | <20 | 17 (1.7) | 22.77 ± 8.59 | 0.01 |
| 20–29 | 299 (30.5) | 24.74 ± 7.82 | ||
| 30–39 | 420 (42.9) | 25.23 ± 8.04 | ||
| 40–49 | 190 (19.4) | 27.10 ± 6.85 | ||
| 50–59 | 49 (5.0) | 26.69 ± 6.47 | ||
| Education | Less than high school | 413 (42.2) | 24.91 ± 8.05 | 0.04 |
| College | 308 (31.5) | 24.44 ± 7.28 | ||
| University | 258 (26.4) | 26.47 ± 7.47 | ||
| Salary (US dollar/month) | <2000 | 345 (38.4) | 23.78 ± 8.14 | < 0.01 |
| 2000–3000 | 371 (41.3) | 26.06 ± 7.13 | ||
| ≥ 3000 | 183 (20.4) | 26.70 ± 7.24 |
| Variable | 0 min | 30 min | 60 min | 90 min |
| Heart rate (bpm)Meltdown® | 59 ± 3 | 63 ± 2 | 62 ± 2 | 63 ± 2 |
| Heart rate (bpm)Placebo | 59 ± 3 | 60 ± 3 | 62 ± 3 | 60 ± 3 |
| Systolic Blood Pressure (mmHg)Meltdown® * | 117 ± 2 | 122 ± 3 | 123 ± 2 | 122 ± 3 |
| Systolic Blood Pressure (mmHg)Placebo | 118 ± 2 | 118 ± 2 | 117 ± 1 | 116 ± 1 |
| Diastolic Blood Pressure (mmHg)Meltdown® | 72 ± 1 | 71 ± 2 | 72 ± 2 | 70 ± 2 |
| Diastolic Blood Pressure (mmHg)Placebo | 72 ± 1 | 72 ± 2 | 71 ± 1 | 71 ± 1 |
| Missed appointment | Missed doses | Total | |
| No | Yes | ||
| No | 694 (94.3) | 42 (5.7) | 736 |
| Yes | 17 (70.8) | 7 (29.2) | 24 |
| Tag sequence | Tags | TPMa | UniGene ID | Gene | Cluster name | Biological Functionb |
| TACCTGCAGA | 515 | 16930 | Hs.416073 | S100A8 | S100 calgranulin A | Regulation of cell cycle progression and differentiation. |
| TAGGTTGTCT | 356 | 11703 | Hs.374596 | TPT1 | Tumor protein, translationally-controlled 1 | Unknown |
| TTTCCTGCTC | 276 | 9073 | Hs.139322 | SPRR3 | Small proline-rich protein 3 | Cross-linked envelope protein of keratinocytes |
| GAGGGAGTTT | 201 | 6607 | Hs.523463 | RPL27A | Ribosomal protein L27a | Component of the ribosomal 60S subunit |
| GTGACCACGG | 188 | 6180 | Hs.436980 | GRIN2C | Glutamate receptor, N-methyl D-aspartate 2C | Ionotropic glutamate receptor |
| GTGGCCACGG | 184 | 6049 | Hs.112405 | S100A9 | S100 calcium binding protein A9 (calgranulin B) | Regulation of cell cycle progression and differentiation. |
| GGGCTGGGGT | 173 | 5687 | Hs.425125; Hs.90436 | RPL29; SPAG7 | Ribosomal protein L29; Sperm associated antigen 7 | Component of the ribosomal 60S subunit. |
| GCATAATAGG | 168 | 5523 | Hs.381123 | RPL21 | Ribosomal protein L21 | Component of the ribosomal 60S subunit. |
| TCAGATCTTT | 161 | 5292 | Hs.446628 | RPS4X | Ribosomal protein S4, X-linked | Component of the ribosomal 40S subunit. |
| GTTGTGGTTA | 155 | 5095 | Hs.99785 | FLJ21245 | Unknown | |
| GGATTTGGCC | 151 | 4964 | Hs.437594 | RPLP2 | Ribosomal protein, large P2 | Component of the ribosomal 60S subunit. |
| TTGGGGTTTC | 143 | 4701 | Hs.448738 | FTH1 | Ferritin, heavy polypeptide 1 | Important for iron homeostasis, stores iron in a soluble, nontoxic, readily available form. |
| TTGGTCCTCT | 138 | 4536 | Hs.381172 | RPL41 | Rribosomal protein L41 | Component of the ribosomal 60S subunit. |
| TGCACGTTTT | 130 | 4273 | Hs.265174 | RPL32 | Ribosomal protein L32 | Component of the ribosomal 60S subunit. |
| ACAAAGCATT | 128 | 4208 | Hs.369982 | IGFBP5 | Insulin-like growth factor binding protein 5 | IGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGF on cell culture. |
| AGGGCTTCCA | 122 | 4010 | Hs.401929 | RPL10 | Ribosomal protein L10 | Component of the ribosomal 60S subunit. |
| CCACTGCACT | 114 | 3747 | Hs.107003 | CCNB1IP1 | Cyclin B1 interacting protein 1 | Functions in progression of the cell cycle through G(2)/M. |
| GGCAAGCCCC | 107 | 3517 | Hs.148340 | RPL10A | ribosomal protein L10a | Component of the ribosomal 60S subunit. |
| CTGGGTTAAT | 105 | 3451 | Hs.334534 | GNS | Glucosamine (N-acetyl)-6-sulfatase | Lysosomal enzyme found in all cells. It is involved in the catabolism of heparin, heparan sulphate, and keratan sulphate. |
| TGCACTTCAA | 103 | 3386 | Hs.62886 | SPARCL1 | SPARC-like 1 (mast9, hevin) | Calcium ion binding |
| IL-10 variants | Cancer type | Studies | Allele contrast | Ht vs. WT Ho | VR Ho vs. WT Ho | Dominant model | Recessive model | |||||
| OR [95%CI] | Ph/I2 | OR [95%CI] | Ph/I2 | OR [95%CI] | Ph/I2 | OR [95%CI] | Ph/I2 | OR [95%CI] | Ph/I2 | |||
| −1082G>A | overall | 10 | 1.07 [0.98, 1.18] | 0.27/19% | 1.09 [0.76, 1.57] | <0.001/76% | 1.17 [0.89, 1.54] | 0.07/44% | 1.12 [0.82, 1.52] | 0.0004/70% | 1.10 [0.95, 1.28] | 0.11/37% |
| melanoma | 5 | 1.09 [0.94, 1.27] | 0.94/0% | 0.98 [0.75, 1.28] | 0.55/0% | 1.20 [0.88, 1.64] | 0.94/0% | 1.05 [0.81, 1.35] | 0.87/0% | 1.21 [0.95, 1.54] | 0.35/11% | |
| NMC | 5 | 1.05 [0.85, 1.29] | 0.04/61% | 1.22 [0.61, 2.41] | <0.001/88% | 1.17 [0.70, 1.97] | 0.005/73% | 1.22 [0.68, 2.22] | <0.001/86% | 1.00 [0.73, 1.37] | 0.06/56% | |
| BCC | 4 | 1.07 [0.86, 1.33] | 0.06/59% | 1.54 [0.67, 3.52] | <0.001/90% | 1.31 [0.70, 2.46] | 0.006/76% | 1.47 [0.70, 3.10] | <0.001/89% | 1.00 [0.81, 1.24] | 0.39/1% | |
| SCC | 2 | 1.03 [0.76, 1.40] | 0.16/49% | 0.66 [0.38, 1.14] | 0.33/0% | 0.62 [0.15, 2.58] | 0.05/75% | 0.76 [0.46, 1.26] | 0.80/0% | 0.73 [0.12, 4.41] | 0.002/89% | |
| −819C>T | overall | 7 | 0.86 [0.67, 1.11] | 0.02/61% | 0.82 [0.67, 1.00] | 0.43/0% | 0.83 [0.42, 1.64] | 0.02/59% | 0.84 [0.69, 1.01] | 0.19/31% | 0.89 [0.45, 1.74] | 0.02/60% |
| melanoma | 4 | 0.93 [0.76, 1.14] | 0.64/0% | 0.95 [0.73, 1.23] | 0.53/0% | 0.84 [0.48, 1.47] | 0.40/0% | 0.93 [0.72, 1.19] | 0.64/0% | 0.84 [0.49, 1.46] | 0.34/11% | |
| NMC | 3 | 0.77 [0.41, 1.45] | 0.001/85% | 0.67 [0.50, 0.91] | 0.60/0% | 0.74 [0.16, 3.41] | 0.004/82% | 0.70 [0.43, 1.16] | 0.06/64% | 0.87 [0.20, 3.75] | 0.005/81% | |
| BCC | 2 | 0.72 [0.54, 0.97] | 0.60/0% | 0.71 [0.48, 1.03] | 0.74/0% | 0.58 [0.28, 1.22] | 0.29/12% | 0.68 [0.48, 0.98] | 0.94/0% | 0.66 [0.32, 1.36] | 0.26/20% | |
| SCC | 2 | 0.74 [0.19, 2.83] | 0.001/90% | 0.68 [0.43, 1.09] | 0.36/0% | 0.57 [0.01, 26.7] | 0.01/85% | 0.68 [0.24, 1.94] | 0.03/78% | 0.68 [0.02, 26.5] | 0.01/83% | |
| −592C>A | overall | 9 | 0.90 [0.68, 1.19] | <0.001/79% | 0.80 [0.55, 1.16] | <0.001/80% | 0.95 [0.54, 1.66] | 0.006/62% | 0.83 [0.57, 1.20] | <0.001/82% | 1.10 [0.68, 1.77] | 0.04/51% |
| melanoma | 5 | 1.08 [0.90, 1.28] | 0.62/0% | 1.06 [0.84, 1.32] | 0.99/0% | 1.15 [0.73, 1.80] | 0.24/27% | 1.09 [0.88, 1.35] | 0.94/0% | 1.11 [0.71, 1.72] | 0.21/32% | |
| NMC | 4 | 0.73 [0.41, 1.30] | <0.001/90% | 0.55 [0.26, 1.17] | <0.001/89% | 0.77 [0.26, 2.29] | <0.001/81% | 0.59 [0.27, 1.27] | <0.001/91% | 1.09 [0.46, 2.60] | 0.02/71% | |
| BCC | 3 | 0.67 [0.37, 1.24] | <0.001/87% | 0.56 [0.20, 1.63] | <0.001/93% | 0.60 [0.24, 1.51] | 0.09/59% | 0.55 [0.20, 1.52] | <0.001/93% | 0.92 [0.56, 1.49] | 0.34/7% | |
| SCC | 2 | 0.74 [0.19, 2.83] | 0.001/90% | 0.68 [0.43, 1.09] | 0.36/0% | 0.57 [0.01, 26.7] | 0.01/85% | 0.68 [0.24, 1.94] | 0.03/78% | 0.68 [0.02, 26.5] | 0.01/83% |
| Presence/absence of IgG in oral fluid at six months | Presence/absence of IgG in oral fluid before measles vaccination at nine months | Presence/absence of IgM & IgG in oral fluid after measles vaccination | ||||
| Variable | OR | 95% CI | OR | 95% CI | OR | 95% CI |
| Gender (F, M) | 1.1 | 0.74–1.61 | 1.1 | 0.78–1.55 | 0.66 | 0.32–1.37 |
| Breast feeding (Yes, No) | 1.02 | 1–1.04 | 0.88 | 0.39–1.95 | 2.73 | 0.62–1.20 |
| Measles history (Yes, No) | 1.39 | 0.17–11.43 | 0.78 | 0.14–4.28 | 0.22 | 0.01–3.70 |
| Type of birth (Normal, Caesarean) | 0.94 | 0.81–1.83 | 1.18 | 0.58–2.39 | 0.54 | 0.12–2.51 |
| Low-birth-weight (Yes, No) | 1.03 | 0.25–4.21 | 0.78 | 0.44–1.36 | 0.36 | 0.13–1.94 |
| Prematurity (Yes, No) | 1.02 | 0.7–1.48 | 0.57 | 0.31–1.05 | 1.70 | 0.54–3.35 |
| Weight for height cat (≥ -2, <-2) | - | - | 0.78 | 0.32–1.87 | 1.18 | 0.12–1.01 |
| Weight for age cat (≥ -2, <-2) | 0.59 | 0.1–3.58 | 2.16 | 0.75–6.19 | 0.75 | 0.15–3.54 |
| Height for age cat (≥ -2, <-2) | 1.26 | 0.46–3.46 | 0.79 | 0.55–1.13 | 0.50 | 0.18–1.39 |
| Mother's IgG (Pos, Neg*) | 1.96 | 0.62–6.17 | 1.57 | 0.86–2.87 | 1.62 | 0.59–3.48 |
| Mother's age ≤ 28 y, ≥ 29 y | 0.81 | 0.29–2.32 | 1.15 | 0.61–2.19 | 1.08 | 0.67–1.75 |
| Variable | Frequency | (%) |
| Sex | ||
| Male | 241 | 54.7 % |
| Female | 199 | 45.3 % |
| Age | ||
| 15-24 | 89 | 20.2 % |
| 25-34 | 112 | 25.5 % |
| 35-44 | 85 | 19.3 % |
| 45-54 | 65 | 14.8 % |
| 55-64 | 49 | 11.1 % |
| >64 | 40 | 9.1 % |
| Ethnicity | ||
| Oromo | 306 | 69.5 % |
| Amhara | 50 | 11.5 % |
| Dawro | 43 | 9.8 % |
| Othersa | 41 | 9.3 % |
| Religion | ||
| Muslim | 332 | 75.5 % |
| Orthodox | 78 | 17.7 % |
| Protestant | 30 | 6.8 % |
| Educational status | ||
| Illiterate | 221 | 50.2 % |
| Read and write | 73 | 16.6 % |
| Elementary | 113 | 25.7 % |
| Secondary education | 33 | 7.5 % |
| & above | ||
| Occupations | ||
| Farmers | 260 | 59.1 % |
| House wives | 83 | 18.9 % |
| Students | 74 | 16.8 % |
| Othersb | 23 | 5.2 % |
| Gestation | Study cohort | Previous study cohort | ||
| N* | % | N** | % | |
| 14–17 weeks | 147 | 4 | 0 | 0 |
| 18–22 weeks | 578 | 16 | 0 | 0 |
| 23–27 weeks | 561 | 16 | 76 | 0 |
| 28–32 weeks | 550 | 16 | 258 | 0 |
| 33–39 weeks | 1,251 | 35 | 35,575 | 57 |
| 40–42 weeks | 452 | 13 | 26,837 | 43 |
| Total | 3,539 | 62,746 |
| gliomas | Number of cases (tissue cores) |
| Glioblastoma (GBM, WHO Grade IV) | 128 (256) |
| Anaplastic astrocytoma (AA, WHO Grade III) | 27 (54) |
| Diffuse astrocytoma (LGA, WHO Grade II) | 33 (66) |
| Anaplastic oligodendroglioma (AO, WHO Grade III) | 16 (32) |
| Oligodendroglioma (ODG, WHO Grade II) | 26 (52) |
| Anaplastic mixed oligoastrocytoma (AMOA, WHO Grade III) | 30 (60) |
| Oligoastrocytoma (MOA, WHO Grade II) | 32 (64) |
| non neoplastic brain tissue(NB) | 13 (26) |
| 1 | 2 | 3 | 4 | 5 | ||
| 1 | PTSD – Re-experiencing | |||||
| 2 | PTSD – Avoidance | 0.48** | ||||
| 3 | PTSD – Arousal | 0.48** | 0.49** | |||
| 4 | DSO – Affect Dysregulation | 0.37** | 0.40** | 0.48** | ||
| 5 | DSO – Disturbances in Self-Concept | 0.36** | 0.45** | 0.46** | 0.50** | |
| 6 | DSO – Difficulties in Interpersonal Relationships | 0.27** | 0.24** | 0.30** | 0.47** | 0.21* |
| SOFIT activity category | Control PE lessons (N = 97) | Intervention PE lessons (N = 96) | |||
| Mdn | IQR | Mdn | IQR | p | |
| Lesson Time | |||||
| Minutesa | 35.6 | 9.7 | 47.1 | 10.6 | 0001 |
| Sitting | |||||
| Minutes per lesson | 3.3 | (0.3,9.0) | 7.9 | (4.4,12.0) | 0.006 |
| Percentage of time per lesson | 12.3 | (2.7,44.1)) | 19.7 | (11.5,29.3) | 0.049 |
| Standing | |||||
| Minutes per lesson | 11.3 | (7.8,16.2) | 18.9 | (12.7,24.2) | 0.002 |
| Percentage of time per lesson | 44.4 | (32.1,56.7) | 43.6 | (31.7,52.2) | 0.448 |
| Walking | |||||
| Minutes per lesson | 4.3 | (2.4,6.6) | 9.2 | (5.7,12.5) | 0.004 |
| Percentage of time per lesson | 15.5 | (8.5,22.2) | 20.6 | (14.3,25.1) | 0.077 |
| Very Active | |||||
| Minutes per lesson | 5.6 | (2.7,6.6) | 6.4 | (4.7,9.1) | 0.006 |
| Percentage of time per lesson | 21.5 | (10.2,33.9) | 14.6 | (10.7,20.2) | 0.04 |
| MVPA (Walking plus Very Active) | |||||
| Minutes per lesson | 10.2 | (7.8,12.8) | 16.9 | (11.6,20.2) | 0.004 |
| Percentage of time per lesson | 33.6 | (27.8,42.2) | 35.4 | (28.1,43.2) | 0.09 |
| Test (n = 16) | Control (n = 17) | |
| Age, years | 74.7 (4.8) | 72.7 (8.2) |
| Male sex, n (%) | 7 (44%) | 7 (41%) |
| MMSE score | 23.0 (2.1) | 23.2 (1.8) |
| Time since diagnosis, months | 1.7 [0.4-15.3] | 1.4 [0.2-10.2] |
| BMI, kg/m2 | 24.2 (3.8) | 26.7 (3.3) |
| Educational level, n (%) | ||
| Low | 6 (37.5%) | 4 (23.5%) |
| Medium | 8 (50.0%) | 9 (52.9%) |
| High | 2 (12.5%) | 4 (23.5%) |
| Study product compliance | 96.4% (4.8) | 99.0% (1.6) |
| Complication | Number of complications (%) |
| Bleeding | 10 (3.8) |
| Aspiration | 2 (0.7) |
| Fistula | 2 (0.7) |
| Wound healing disorders | 1 (0.7) |
| Nerve lesions | 3 (1.1) |
| Other complications | 2 (0.7) |
| Subjectsb | Vbeta | CDR3 | BJ | Ratioc | ||
| J24 (CD4+) | BV24 | AAMYLCATS | SDRVSPL | HFGNGTRLTVTED | 1.6 | 22/25 |
| J23 | BV20 | SGFYLCAWS | VQVGWGETQ | YFGPGTRLLVLED | 2.5 | 12/21 |
| J24 (CD4+) | BV20 | SGFYLCAWS | TGTGHSPL | HFGNGTRLTVTED | 1.6 | 21/25 |
| J28 (CD8+) | BV20 | SGFYLCAWS | TGTGHSPL | HFGNGTRLTVTED | 1.6 | 20/24 |
| J38 | BV20 | SGFYLCAWS | TGTGHSPL | HFGNGTRLTVTED | 1.6 | 22/25 |
| J32 (CD4+) | BV14 | SLYFCASS | PGTTQETQ | YFGSGTRLLVLED | 2.5 | 18/23 |
| J25 | BV14 | SLYFCASS | PGTTQETQ | YFGPGTRLTVLED | 2.5 | 15/23 |
| J28 (CD8+) | BV14 | SLYFCASS | RHTGGTEA | FFGQGTRLTVVED | 1.1 | 19/30 |
| J29 | BV13.2 | TSVYFCASS | YDENEQ | FFGPGTRLTVLED | 2.1 | 16/22 |
| J31 (CD4+) | BV13.2 | TSVYFCASK | TKPVGEQ | FFGPGTRLTVLED | 2.1 | 15/23 |
| J42 | BV13.1 | TSVYFCASS | YSAGGPNEQ | FFGPGTRLTVLED | 2.1 | 18/25 |
| J34 (CD4+) | BV12 | TSVYFCAIR | KQGDSYEQ | YFGPGTRLTVTED | 2.7 | 17/23 |
| J35 | BV12 | TSVYFCASR | VRLITNYGY | TFGSGTRLTVVED | 1.2 | 24/24 |
| J39 (CD4+) | BV12 | TSVYFCATA | GGAPGQPQ | HFGDGTRLSILED | 1.5 | 16/24 |
| J23 | BJ5.1 | SALYLCASS | LDYSGNTI | YFGEGSWLTVVED | 1.3 | 22/27 |
| J25 (CD8+) | BJ5.1 | SALYLCASS | LDYSGNTI | YFGEGSWLTVVED | 1.3 | 22/27 |
| J30 | BJ5.1 | SALYLCASS | LDYSGNTI | YFGEGSWLTVVED | 1.3 | 22/25 |
| J24 | BV3 | SMYLCASG | PNYYEQ | YFGPGTRLTVTED | 2.7 | 23/25 |
| Activity category | Observed activity | Definition |
| (1) Nil physical activity | Lying in bed sleeping, talking, reading, eating, watching TV, or doing nothing in particular | Sedentary |
| (2) Minimal physical activity | Sitting supported out of bed while talking, reading, eating, or doing nothing | Sedentary |
| (3) Light physical activity | Rolling to sit up, sitting unsupported, or transferring with feet on floor | Physically active |
| (4) Moderate physical activity | Standing, walking, or climbing stairs | Physically active |
| AH | Positiona | Lengthb | Hydr. momc | Fract of residuesd | Lipid-binding properties | Ref | ||
| Hdr | LH | Ch | ||||||
| Hel 13-5 | n.a.e | 18 | 0.69 | 0.72 | 0.06 | 0.28 | Tubulates liposomes | 73 |
| GMAP210 | 1–38 (1979) | 38 | 0.48 | 0.37 | 0.05 | 0.05 | Golgi vesicles/abundant packing defects | 14, 25 |
| Nup133 | 247–267 (1156) | 21 | 0.44 | 0.38 | 0.05 | 0.10 | Nuclear pore membrane | 67 |
| CIDEA | 163–180 (219) | 18 | 0.53 | 0.5 | 0.11 | 0.17 | LDsf | 28 |
| CCTα | 236–294 (368) | 59 | 0.48* | 0.32 | 0.10 | 0.49 | Nuclear envelope/ER and LDs/liposomes | 6, 16,64 |
| Apolipoprotein-AI | 74–267 (267) | 186 (7 P)g | 0.39* | 0.40 | 0.065 | 0.35 | Lipoprotein particles | 48 |
| α-Synuclein | 1–89 (144) | 89 | 0.30* | 0.47 | 0.02 | 0.24 | Synaptic vesicles/neg. charged small liposomes | 44 |
| Plin3 | 114–204 (434) | 90 | 0.35* | 0.37 | 0.01 | 0.23 | LDs and cytosol | 11 |
| Plin4 | 70–1037 (1357) | 968 | (0.257)* | 0.35 | 0.002 | 0.15 | This study |
| Links between mutant GBA and PD | References |
| Subset of GD patients develop parkinsonism | Bembi et al. (2003), Neudorfer et al. (1996), Tayebi et al. (2001) |
| Genetic multi-centre study reporting statistically significant association between GBA mutations and PD | Sidransky et al. (2009) |
| Lewy bodies similar in PD brains with and without GBA mutations | Neumann et al. (2009), Parkkinen et al. (2011) |
| Accumulation and impaired turnover of α-synuclein in animal and cell models of GCase deficiency | Cullen et al. (2011), Fishbein et al. (2014), Manning-Boğ et al. (2009), Mazzulli et al. (2011), Osellame et al. (2013), Sardi et al. (2011), Schöndorf et al. (2014) |
| GCase activity decreased in sporadic PD | Gegg et al. (2012), Murphy et al. (2014) |
| α-synuclein affects GCase function | Gegg et al. (2012), Mazzulli et al. (2011), Sardi et al. (2013), Yap et al. (2011) |
| Type of atresia | Location | Survival | ||
| Jejunal(n = 11) | Ileal(n = 17) | Survivors(n = 20) | Non-survivors(n = 8) | |
| I | 1 | 1 | 2 | 0 |
| II | 1 | 1 | 0 | 2 |
| IIIa | 2 | 12 | 14 | 0 |
| IIIb | 4 | 1 | 2 | 3 |
| IV | 3 | 2 | 2 | 3 |
| Total | 11 | 17 | 20 | 8 |
| Locality/region | N | Tick-infested dogs | Tick-free dogs | Odds ratio (95% CI) | P | ||
| positive | negative | positive | negative | ||||
| Putignano (C) | 80 | 6 | 24 | 4 | 46 | 2.9 (0.7-11.2) | 0.1640 |
| Basilicata (D) | 50 | 5 | 13 | 1 | 31 | 11.9 (1.3-112.3) | 0.0184 |
| Sicilia (E) | 113 | 13 | 28 | 2 | 70 | 16.2 (3.4-76.7) | < 0.0001 |
| Madrigal de la Vera (F) | 51 | 9 | 32 | 2 | 8 | 1.1 (0.2-6.3) | 1.000 |
| Xanthi (G) | 23 | 1 | 8 | 0 | 14 | 5.1 (0.2-14.4) | 0.3913 |
| Functional group | Agricultural matrix(mean ± SD) | Mining matrix (mean ± SD) | F- statistics | ||||
| Edge | Interior | Edge | Interior | Dist.edge | Matrix | Interaction | |
| Terrestrial insectivores | 0.74 (0.08) | 0.79 (0.04) | 0.48 (0.30) | 0.69 (0.10) | 5.23* | 9.87** | 2.11* |
| All lower strata birds | 0.77 (0.12) | 0.71 (0.08) | 0.59 (0.14) | 0.55 (0.15) | 1.42 | 14.16*** | 0.05 |
| All upper strata birds | 0.53 (0.19) | 0.43 (0.10) | 0.36 (0.12) | 0.37 (0.15) | 0.68 | 4.78* | 0.96 |
| Obligate frugivores | 0.67 (0.16) | 0.61 (0.12) | 0.44 (0.31) | 0.34 (0.29) | 0.90 | 8.37** | 0.10 |
| Partial fruigivores | 0.72 (0.12) | 0.67 (0.06) | 0.66 (0.13) | 0.72 (0.07) | 0.07 | 0.00 | 2.03 |
| Salliers | 0.19 (0.12) | 0.18 (0.12) | 0.22 (0.19) | 0.18 (0.18) | 0.17 | 0.08 | 0.05 |
| Upper strata bark gleaners | 0.59 (0.40) | 0.48 (0.39) | 0.75 (0.37) | 0.60 (0.31) | 1.04 | 1.23 | 0.03 |
| Upper strata foliage gleaners | 0.26 (0.18) | 0.27 (0.05) | 0.17 (0.12) | 0.27 (0.11) | 1.84 | 1.16 | 0.93 |
| All bark gleaning insectivores | 0.59 (0.40) | 0.40 (0.40) | 0.83 (0.36) | 0.60 (0.31) | 2.06 | 2.31 | 0.13 |
| Lower strata bark gleaners | 0.89 (0.02) | 0.99 (0.01) | 0.70 (0.43) | 0.64 (0.42) | 0.08 | 9.78** | 0.08 |
| Lower strata foliage gleaners | 0.30 (0.12) | 0.38 (0.06) | 0.27 (0.10) | 0.34 (0.14) | 3.59 | 0.84 | 0.01 |
| Canopy insectivores | 0.41 (0.40) | 0.10 (0.07) | 0.27 (0.16) | 0.30 (0.32) | 2.06 | 0.07 | 3.05 |
| Raptors | 0.41 (0.30) | 0.74 (0.38) | 0.50 (0.41) | 0.81 (0.35) | 6.15* | 0.38 | < 0.01 |
| Granivores | 0.61 (0.45) | 0.67 (0.39) | 0.13 (0.20) | 0.13 (0.07) | 0.08 | 21.18*** | 0.06 |
| Omnivores | 0.20 (0.11) | 0.24 (0.11) | 0.18 (0.12) | 0.20 (0.10) | 0.49 | 0.42 | 0.04 |
| Nectarivores | 0.79 (0.32) | 0.75 (0.36) | 0.92 (0.22) | 0.90 (0.19) | 0.11 | 2.00 | < 0.01 |
| All insectivores | 0.42 (0.11) | 0.46 (0.06) | 0.42 (0.04) | 0.39 (0.13) | 0.04 | 1.21 | 1.11 |
| Lower strata aerial sweepers | 0.19 (0.12) | 0.42 (0.27) | 0.10 (0.15) | 0.35 (0.32) | 5.29* | 0.19 | 0.24 |
| Upper strata aerial sweepers | 0.19 (0.18) | 0.14 (0.09) | 0.13 (0.06) | 0.35 (0.41) | 0.94 | 0.90 | 2.69 |
| All aerial sweepers | 0.34 (0.08) | 0.21 (0.21) | 0.29 (0.10) | 0.31 (0.13) | 1.26 | 0.33 | 2.39 |
| Mediterranean Diet | Paleo Diet | |
| Lipids | Moderate Fat 40% of daily calories | Moderate-Low Fat 35% of daily calories |
| Proteins | Reduce processed and red meat. Increased plant-based protein, fish and poultry | Reduce processed and red meat. Increased plant-based protein, and meat from marine and game animals |
| Carbohydrates | Low Carbohydrate ≤40% of daily calories Fruits, vegetables, sugar, and grains | Moderate Carbohydrates ≤45–65% of daily calories Fruits and vegetables Decreased grains |
| BSS algorithm | Amari indices | ||
| Experiment 1:static uncoupled oscillators | Experiment 2: static coupled sources | Experiment 3: dynamic coupled oscillators | |
| AMICA | 0.31 | 0.37 | 0.25 |
| Extended Infomax | 0.31 | 0.38 | 0.25 |
| FastICA | 0.32 | 0.30 | 0.26 |
| PWC-ICA (1) | 0.35 | 0.29 | 0.28 |
| PWC-ICA (2) | 0.34 | 0.41 | 0.26 |
| PWC-ICA (4) | 0.35 | 0.41 | 0.24 |
| PWC-ICA (8) | 0.30 | 0.41 | 0.23 (p < 2.3E − 3) |
| PWC-ICA (1) Haar | 0.30 | 0.32 | 0.25 |
| PWC-ICA (2) Haar | 0.21 (p < 1.5E − 11) | 0.35 | 0.23 (p < 4.5E − 4) |
| PWC-ICA (4) Haar | 0.21 (p < 1.5E − 10) | 0.40 | 0.23 (p < 4.4E − 2) |
| PWC-ICA (8) Haar | 0.27 (p < 1.5E − 5) | 0.38 | 0.24 |
| Hilbert complex | 0.28 (p < 1.5E − 4) | 0.38 | 0.23 (p < 6.7E − 3) |
| Average baseline | 0.36 | 0.42 | 0.36 |
| RGT2 mutant designation | Causative constitutive mutation2 | Location in Rgt2 | Other (likely irrelevant) mutations2 |
| 87 | F113L | TM1 | |
| 93 | F113L | TM1 | |
| 58 | F113L | TM1 | H517R |
| 71 | F113L | TM1 | T130A, L161S |
| D116V | TM1 | F562L | |
| 68 | D116V | TM1 | D619G |
| 57 | D116G | TM1 | I398V, F527L, S754G |
| 100 | D116N | TM1 | A226T, Y330C |
| 111 | D116G, L552S | TM1, ICH5 | I111M, V324I, K570R |
| 83 | Q222P | TM4 | |
| 112 | Q222R | TM4 | |
| RGT2-11 | R231K | TM5 | |
| 98 | R231G | TM5 | D698G |
| 50 | R231G | TM5 | M58R |
| 103 | G232S | TM5 | V537A |
| G232S | TM5 | F465Y, S733L | |
| 86 | S236P | TM5 | F465Y, G471S |
| S236P | TM5 | K488R | |
| S253P, S443P | TM5, TM9 | ||
| 47 | D415N | TM8 | |
| 60 | W474R | TM10 | |
| 95 | V475M | TM10 | |
| L552S | ICH5 | N723I | |
| 85 | L552S | ICH5 | V404G |
| 1084 | V473G? | V473G, D611G, I626V | |
| 924 | ? | G103S, F111L |
| Humanities and social sciences | % | Natural and formal sciences | % | Applied sciences and professions | % | Total | % | ||
| University category | Highest research | 149 | 50 | 75 | 47 | 112 | 33 | 336 | 42 |
| Higher research | 113 | 38 | 54 | 34 | 146 | 42 | 313 | 39 | |
| Moderate research | 37 | 12 | 31 | 19 | 86 | 25 | 154 | 19 | |
| Total | 299 | 100 | 160 | 100 | 344 | 100 | 803 | 100 | |
| Tenure | Yes | 215 | 72 | 108 | 68 | 244 | 71 | 567 | 71 |
| No | 69 | 23 | 42 | 26 | 76 | 22 | 187 | 23 | |
| N/A | 15 | 5 | 10 | 6 | 24 | 7 | 49 | 6 | |
| Total | 299 | 100 | 160 | 100 | 344 | 100 | 803 | 100 | |
| Rank | Lecturer | 6 | 2 | 4 | 3 | 8 | 2 | 18 | 2 |
| Adjunct | 2 | 1 | 1 | 1 | 4 | 1 | 7 | 1 | |
| Assistant | 57 | 19 | 33 | 21 | 60 | 17 | 150 | 19 | |
| Associate | 100 | 33 | 37 | 23 | 92 | 27 | 229 | 29 | |
| Full | 92 | 31 | 66 | 41 | 147 | 43 | 305 | 38 | |
| University | 12 | 4 | 6 | 4 | 6 | 2 | 24 | 3 | |
| Emeritus | 18 | 6 | 4 | 3 | 12 | 3 | 34 | 4 | |
| Other | 12 | 4 | 9 | 6 | 15 | 4 | 36 | 4 | |
| Total | 299 | 100 | 160 | 100 | 344 | 100 | 803 | 100 | |
| Gender | Male | 156 | 52 | 114 | 71 | 177 | 51 | 447 | 56 |
| Female | 143 | 48 | 46 | 29 | 167 | 49 | 356 | 44 | |
| Total | 299 | 100 | 160 | 100 | 344 | 100 | 803 | 100 |
| H2-Db | H2-Kb | H2-Kk | ||||
| Additive Method | SVRMHC Method | Additive Method | SVRMHC Method | Additive Method | SVRMHC Method | |
| Numbers of outliers | 6 | 3 | 7 | 6 | 2 | 0 |
| r2 (self-consistency, outliers removed) | 0.946 | 0.983 | 0.989 | 0.97 | 0.933 | 0.973 |
| r2 (self-consistency, entire dataset) | 0.602 | 0.749 | 0.37 | 0.568 | 0.849 | 0.973 |
| Average Residual (entire dataset) | 0.403 | 0.17 | 0.443 | 0.382 | 0.178 | 0.039 |
| Average Residual (outliers removed) | 0.187 | 0.043 | 0.095 | 0.13 | 0.151 | 0.039 |
| q2 (LOO_CV) (outliers removed) | 0.401 | 0.456 | 0.454 | 0.486 | 0.456 | 0.721 |
| Striatal region | Reward scan | Expectation scan | No-drug scan | |||
| Early | Late | Early | Late | Early | Late | |
| Sensorimotor | ||||||
| Left | 2.44 ± 0.33 | 2.45 ± 0.28 | 2.47 ± 0.26 | 2.48 ± 0.27 | 2.57 ± 0.31 | 2.54 ± 0.36 |
| Right | 2.32 ± 0.38 | 2.34 ± 0.33 | 2.44 ± 0.30 | 2.44 ± 0.30 | 2.58 ± 0.36 | 2.56 ± 0.39 |
| Associative | ||||||
| Left | 1.97 ± 0.33 | 1.96 ± 0.29 | 2.02 ± 0.30 | 1.99 ± 0.27 | 2.19 ± 0.32 | 2.11 ± 0.33 |
| Right | 2.19 ± 0.31 | 2.21 ± 0.29 | 2.25 ± 0.29 | 2.22 ± 0.28 | 2.37 ± 0.33 | 2.31 ± 0.35 |
| Limbic | ||||||
| Left | 1.95 ± 0.31 | 1.96 ± 0.26 | 2.10 ± 0.20 | 2.11 ± 0.20 | 2.26 ± 0.37 | 2.18 ± 0.36 |
| Right | 1.91 ± 0.29 | 1.90 ± 0.22 | 1.90 ± 0.26 | 1.90 ± 0.28 | 1.99 ± 0.32 | 2.01 ± 0.25 |
| Strain1 | Genbank accession # | Experiment location | Strawberry tissue | Closest sequence relatives | ||
| Strain(s) | Genbank accession # | Homology % | ||||
| G1 | JN636809 | greenhouse | leaf | Candida sp. GA1S07 | FJ527144 | 98 |
| G2* | JN636810 | greenhouse | leaf | Cryptococcus sp. VTT C-04547 | DQ377668 | 100 |
| G3 | JN636811 | greenhouse | leaf | Sakaguchia dacryoidea CBS 6353 | AF189973 | 94 |
| G4 | JN636812 | greenhouse | leaf | Cryptococcus sp. KCTC 17100 | AF459675 | 100 |
| G5* | JN636813 | greenhouse | leaf | Sporobolomyces sp. KCTC 17098 | AF459715 | 95 |
| F1* | JN636806 | field | leaf | Cryptococcus sp. HB 982 | FM242574 | 99 |
| F2 | JN636807 | field | leaf | Cryptococcus heveanensis YFL1.1 | HQ629577 | 99 |
| F3 | JN636808 | field | ripe fruit | Rhodotorula graminis WP1 | EU563930 | 99 |
| F4* | JN636804 | field | unripe fruit | Pichia guilliermondii SYHZS-1 | EU809436 | 100 |
| F5* | JN636805 | field | unripe fruit | Metschnikowia pulcherrima Afen | EU272042 | 95 |
| PlaneDimers | TransComp1 | |
| INSPiRE | 0.681 | 0.529 |
| SPPIDER [21] | 0.330 | 0.150 |
| PresCont [5] | 0.330 | 0.170 |
| MetaPPISP [22] | 0.040 | 0.311 |
| Watermelon source | Cultivar | (Glucose)(%, w/v) | (Fructose)(%, w/v) | (Sucrose)(%, w/v) | (Amino N)μmol/ml) | (Citrulline)μmol/ml) |
| 2007 Hinton, OK, USA | Crunchy Red | 1.4 | 2.8 | 3.0 | 16.3 | 6.3 |
| 2007 Terral, OK, USA | Unknown | 2.0 | 3.6 | 2.0 | 33.6 | 15.4 |
| 2008 Louisiana, USA | Summer Flavor 800 | 1.9 | 3.5 | 2.8 | 33.9 | 12.6 |
| 2008 Lane, OK, USA | Sangria | 1.9 | 3.6 | 2.8 | 17.7 | 5.8 |
| 2008 Lane, OK, USA | Dixie Lee | 1.7 | 3.1 | 1.8 | 19.9 | 3.7 |
| Oxidative Stress Genes | Average ΔCt | 2 ^ -Δ Ct | Fold Expression | ||
| +DOX | −DOX | +DOX | −DOX | +DOX/− DOX | |
| glutathioneperoxidase2 (GPX2) | 8.68 | 7.06 | 2.4E-03 | 7.5E-03 | −3.07 |
| peroxidasin (PXDNL) | 12.48 | 10.16 | 1.8E-04 | 8.7E-04 | −4.99 |
| sulfiredoxin (SRXN1) | 6.08 | 5.06 | 1.5E-02 | 3.0E-02 | −2.03 |
| peroxiredoxin 2 (PRDX2) | 1.68 | 0.96 | 3.1E-01 | 5.1E-01 | −1.65 |
| COX2 | 4.78 | 4.06 | 3.6E-02 | 6.0E-02 | −1.65 |
| arachidonate 12-lipoxygenase (12-LOX) | 10.08 | 9.36 | 9.2E-04 | 1.5E-03 | −1.65 |
| superoxide dismutase 2 (SOD2) | 1.08 | 0.56 | 4.7E-01 | 6.8E-01 | −1.43* |
| superoxide dismutase 3 (SOD3) | 4.68 | 4.16 | 3.9E-02 | 5.6E-02 | −1.43* |
| Study | Input number | Baseline (%) | FNN | Accuracy (%) | number of subject | Input characteristic | |||
| multiple linear regression | multiple logistic regression | Case | Healthy control | 1 input | 2 inputs | ||||
| Original Study | 1 input | 63.46 | 73.88 | 69.23 | 73.72 | 57 | 99 | γ-GTP (IU/L) | − |
| 2 inputs | 63.71 | 77.43 | 75.81 | 75.81 | 45 | 79 | γ-GTP (IU/L) | WBC (cells/μL) | |
| Replication Study | 1 input | 50.00 | 64.96 | 64.18 | 66.44 | 2196 | 2196 | γ-GTP (IU/L) | − |
| 2 inputs | 50.00 | 67.14 | 66.10 | 68.53 | 2196 | 2196 | γ-GTP (IU/L) | WBC (cells/μL) |
| Forward | GDS1027 | GDS2545 | GDS2546 | GDS2547 | GDS3715 | |||||
| Orig | Modi | Orig | Modi | Orig | Modi | Orig | Modi | Orig | Modi | |
| KNN | 0.69 | 0.66 | 0.64 | 0.61 | 0.65 | 0.63 | 0.64 | 0.55 | 0.84 | 0.87 |
| SVM | 0.83 | 0.84 | 0.73 | 0.75 | 0.73 | 0.749 | 0.74 | 0.82 | 0.88 | 0.91 |
| Ft number | 11 | 14 | 10 | 15 | 8 | 10 | 9 | 16 | 8 | 13 |
| Primary aldosteronism N = 158 | ||
| Source | F statistic | p-value |
| Age | 0.28 | 0.598 |
| Sex | 13.15 | <0.001 |
| Hypertension duration | 1.98 | 0.162 |
| Mean blood pressure | 5.78 | 0.018 |
| UAldo, tertile | 6.11 | 0.003 |
| UNa, tertile | 7.29 | 0.001 |
| UAldo*UNa | 0.25 | 0.907 |
| Plant species | Origin | uPA inhibitoryactivity * |
| Amyris elemifera | Florida, Bahamas, Puerto Rico, West Indies, Central America. | + |
| Bidens alba L. | Native to South America. Pan tropical weed | − |
| Cananga odorata | Native to southern Asia and Philippines | + |
| Capparis cynophallophora | Florida, Bahamas, Puerto Rico, West Indies, Central America. | − |
| Colubrina elliptica | Puerto Rico, Florida, Bahamas, West Indies, Central Mexico to Venezuela | − |
| Croton lucidus | Native to PR, Bahamas, Greater Antilles, and Grand Cayman. | + |
| Erythroxylum areolatum | Bahamas, Greater Antilles, and South America | + |
| Exostema caribaeum | Florida, Bahamas, West Indies, Mexico, Central America, NE coast South America | − |
| Guaiacum officinale | Continental Tropical America, PR, West Indies | − |
| Kalanchoe pinnata | Native to Madagascar | − |
| Lantana camara | Pantropical | + |
| Plumeria alba L. | Central America and the Caribbean | − |
| Tabebuia heterophylla | Puerto Rico, Hispaniola, Virgin Islands, and Lesser Antilles. | + |
| Vanilla claviculata | Puerto Rico and Greater Antilles | − |
| GO attribute | No. of genes in category | No. of genes bound by Gcn5p (P value) | No. of genes bound by Sas3p (P value) | No. of genes bound by both (P value) |
| Cytosolic ribosome | 171 | 43 (3.6 × 10-26) | 54 (3.2 × 10-29) | 17 (9.4 × 10-16) |
| Ribosome | 284 | 51 (1.1 × 10-23) | 67 (8.6 × 10-28) | 21 (6.8 × 10-16) |
| Variable | With dementia (n = 36) | Without dementia (n = 36) | Chi-square | p-value |
| n (%) | n (%) | |||
| GENDER | ||||
| Male | 6 (16.7) | 19 (52.8) | 10.356 | 0.001 |
| Female | 30 (83.3) | 17 (47.2) | ||
| AGE | ||||
| 65–74 | 1 (2.8) | 7 (19.4) | 5.063 | 0.080 |
| 75–84 | 18 (50) | 15 (41.7) | ||
| > 84 | 17 (47.2) | 14 (38.9) | ||
| SCHOOLING | ||||
| < primary | 24 (66.7) | 23 (63.9) | 0.061 | 0.804 |
| ≥primary | 12 (33.3) | 13 (36.1) | ||
| MARITAL STATUS | ||||
| Single | 5 (13.9) | 8 (22.2) | 1.969 | 0.579 |
| Married | 7 (19.4) | 6 (16.7) | ||
| Widowed | 24 (66.7) | 21 (58.3) | ||
| Divorced | 0 (0) | 1 (2.8) | ||
| HOSPITALIZATION TIME | ||||
| < 1 year | 20 (55.6) | 21 (58.3) | 0.072 | 0.965 |
| 1–5 years | 11 (30.6) | 10 (27.8) | ||
| >5 years | 5 (13.9) | 5 (13.9) | ||
| AMOUNT RECEIVED BY THE OWNER OF SOCIAL SECURITY | ||||
| <€445 | 20 (55.6) | 28 (77.8) | 4.000 | 0.046 |
| ≥€445 | 16 (44.4) | 8 (22.2) | ||
| STATE SEVERITY BIMS | ||||
| Intact cognition | 1 (2.8) | 18 (50) | 27.300 | 0.000 |
| Moderate | 4 (11.1) | 8 (22.2) | ||
| Severe | 31 (86.1) | 10 (27.8) |
| Gene | # | A | B | C | Gene description | Accession numbers | |||
| Symbols | Mean | SD | Mean | SD | Mean | SD | |||
| hsp90+ | 8 | 5.03* | 0.79 | 0.20* | 0.16 | 0.79 | 0.15 | Heat shock protein 90. beta | NM_198210 |
| fas+ | 9 | 4.09* | 0.27 | 0.61* | 0.09 | 1.27 | 0.16 | Fas (TNF receptor superfamily, member 6) | XM_685355 |
| il1b | 14 | 3.71* | 0.47 | 0.42* | 0.05 | 2.05* | 0.34 | Interleukin 1, beta | NM_212844 |
| hspb+ | 7 | 3.51* | 0.33 | 0.52* | 0.04 | 2.27* | 0.32 | Heat shock protein. alpha-crystalline-related | NM 001008615 |
| Ifih | 7 | 2.78* | 0.47 | 0.48* | 0.02 | 0.78 | 0.04 | Novel protein similar to vertebrate interferon | XM_689032 |
| irf7 | 8 | 2.65* | 0.17 | 0.80 | 0.05 | 1.29 | 0.16 | Interferon regulatory factor 7 | NM_200677 |
| faslg+ | 11 | 2.38* | 0.28 | 0.84 | 0.05 | 0.91 | 0.26 | Fas ligand (TNF superfamily, member 6) | NM_001042701 |
| casp7+ | 7 | 2.23* | 0.07 | 0.55* | 0.04 | 1.36 | 0.11 | Caspase 7, apoptosis cysteine peptidase | NM_001020607 |
| jak1 | 17 | 2.21* | 0.14 | 0.76 | 0.07 | 1.25 | 0.12 | Janus kinase 1 | NM_131073 |
| stat3 | 13 | 2.17* | 0.24 | 0.80 | 0.10 | 1.18 | 0.07 | Signal transduction/activation transcription 3 | XM_002661113 |
| stat1a | 23 | 1.93* | 0.15 | 1.00 | 0.18 | 1.21 | 0.17 | Signal transduction/activation transcription 1a | NM_131480 |
| Ikbke | 9 | 1.90* | 0.12 | 0.69 | 0.03 | 1.65 | 0.19 | Inhibitor of kappa light polypeptide gene | NM_001002751 |
| Tnfsf | 8 | 1.82* | 0.54 | 0.73 | 0.21 | 1.16 | 0.39 | Tumor necrosis factor (ligand) superfamily | NM_001002593 |
| inpp5d | 7 | 1.75* | 0.11 | 0.79 | 0.01 | 1.09 | 0.08 | Inositol polyphosphate-5-phosphatase | XM_001922972 |
| irf6 | 8 | 0.73 | 0.12 | 0.90 | 0.29 | 2.15* | 0.56 | Interferon regulatory factor 6 | NM_200598 |
| Igm | 7 | 0.03* | 0.01 | 0.73 | 0.04 | 0.51* | 0.02 | Ig heavy chain constant region home design | AY643753 |
| Breed | n | Region-1 | Region-2 | Region-3 | |||||||||||
| A1 | B1 | C1 | D1 | A2 | B2 | C2 | D2 | A3 | B3 | C3 | |||||
| Merino | 68 | 50.0 | 48.5 | 0.0 | 1.5 | 55.2 | 5.2 | 9.6 | 30.2 | 66.9 | 11.8 | 21.3 | |||
| Romney | 71 | 52.8 | 41.6 | 4.9 | 0.7 | 76.8 | 0.0 | 4.9 | 18.3 | 49.3 | 1.4 | 49.3 | |||
| Suffolk | 42 | 53.6 | 46.4 | 0.0 | 0.0 | 75.0 | 1.2 | 0.0 | 23.8 | 35.7 | 0.0 | 64.3 | |||
| Texel | 22 | 56.8 | 43.2 | 0.0 | 0.0 | 100.0 | 0.0 | 0.0 | 0.0 | 65.9 | 6.8 | 27.3 | |||
| Corriedale | 41 | 39.0 | 57.3 | 0.0 | 3.7 | 75.6 | 2.4 | 6.1 | 15.9 | 28.1 | 3.7 | 68.3 | |||
| Perendale | 14 | 57.1 | 39.3 | 0.0 | 3.6 | 89.3 | 0.0 | 0.0 | 10.7 | 42.9 | 0.0 | 57.1 | |||
| Dorper | 39 | 76.9 | 23.1 | 0.0 | 0.0 | 56.4 | 1.3 | 38.5 | 3.9 | 53.9 | 5.1 | 41.0 | |||
| Dorset Down | 19 | 81.6 | 18.4 | 0.0 | 0.0 | 100.0 | 0.0 | 0.0 | 0.0 | 34.2 | 0.0 | 65.8 | |||
| Overall | 316 | 55.7 | 42.1 | 1.1 | 1.1 | 72.78 | 1.7 | 8.7 | 16.8 | 49.1 | 4.4 | 46.5 |
| Patients demographics | N, % (total 30) |
| Age (mean, SD) | 35.6 (9.3) |
| Gender | |
| Males | 6 (20.0) |
| Females | 24 (80.0) |
| Pre-op BMI (mean, SD) | 42.8 (5.8) |
| Diabetes | 4 (13.3) |
| History of smoking | 4 (13.3) |
| Type of bariatric surgery | |
| Sleeve gastrectomy RYG bypass | 28 (93.3) |
| 2 (6.7) |
| Significancea | |||||
| Valence | Percentage | Race/Ethnicity | Gender | Age | Education |
| Negative | 80% | – | – | – | – |
| Ambivalent or Neutral | 30% | * | + | – | – |
| Positive | 59% | – | – | – | – |
| Not discernible | 52% | – | – | – | – |
| Ingredient: | % |
| Corn | 59.36 |
| SBM, dehulled (48% CP) | 33.70 |
| Corn Oil | 3.00 |
| Dicalcium phosphate (Technical grade) | 1.47 |
| Calcium carbonate (Technical grade) | 1.21 |
| Salt, iodized | 0.45 |
| DL-methionine | 0.21 |
| L-lysine | 0.10 |
| Vitamin premix1 (no mineral) | 0.25 |
| Mineral premix2 (no Zn) | 0.25 |
| Total | 100.00 |
| ME, kcal/kg | 3,080 |
| CP, % | 21 |
| Ca3, % | 1.00 (1.3) |
| Nonphytate P3, % | 0.45 (0.40) |
| Lysine, % | 1.24 |
| Methionine + Cystein, % | 0.90 |
| Zinc (mg/kg) | 25 |
| Substrate | Dyad position | Translational shift |
| (base pairsa) | ||
| S1 | 74 | - |
| S1-CGG19 | 72 | −2 |
| S1-1AGGa | 74.75 | +0.75 |
| S1-1AGGb | 77.5 | +3.5 |
| S1-2AGG | 78 | +4 |
| Gene | Copy number change (diploid model) | All TCGA | ESCA_SCC TCGA | All TCGA (matched normal) | Bodymap | |||
| %ile | kIQR | %ile | kIQR | %ile | kIQR | Mean FC | ||
| APC | −1 (DLOH) | 84 | 1.1 | 70 | 0.41 | 86 | 0.88 | −1.17 |
| BAP1 | −1 (DLOH) | 1 | −1.5 | 0 | −1.77 | 0 | −2.33 | −1.79 |
| BRAF | 0 | 94 | 1.7 | 79 | 0.73 | 100 | 2.06 | 1.25 |
| CDK4 | 0 | 2 | −0.96 | 4 | −1.1 | 13 | −0.91 | 1.48 |
| CDK6 | 0 | 96 | 4.25 | 89 | 1.08 | 100 | 9.78 | 7.59 |
| CDKN1A | −1 (DLOH) | 60 | 0.2 | 56 | 0.06 | 56 | 0.11 | 1.44 |
| CDKN2A | −1 (DLOH) | 60 | 0.15 | 72 | 0.56 | 99 | 4.35 | 4.67 |
| CDKN2B | −1 (DLOH) | 96 | 3.74 | 90 | 1.43 | 91 | 1.78 | 3.91 |
| CTNNB1 | −1 (DLOH) | 86 | 1.06 | 97 | 2.49 | 91 | 1.5 | 1.73 |
| CYLD | 0 | 65 | 0.28 | 56 | 0.1 | 53 | 0.04 | −1.59 |
| DPH3 | 0 | 95 | 1.91 | 100 | 3.36 | 95 | 1.3 | −1.01 |
| E2F1 | 0 | 31 | −0.3 | 9 | −0.73 | 92 | 1.5 | 1.98 |
| E2F2 | 0 | 46 | −0.08 | 6 | −0.99 | 82 | 2.24 | 1.45 |
| E2F3 | −1 (DLOH) | 48 | −0.03 | 47 | −0.05 | 91 | 1.13 | 1.09 |
| EGFR | 0 | 99 | 17.91 | 93 | 3.62 | 100 | 29.5 | 16.72 |
| ERBB2 | 0 | 22 | −0.47 | 3 | −0.68 | 10 | −0.79 | 1.77 |
| EZH2 | 0 | 42 | −0.14 | 14 | −0.63 | 90 | 2.35 | 1.57 |
| FZD1 | 0 | 90 | 2.28 | 92 | 2.15 | 92 | 1.97 | 3.21 |
| FZD6 | 0 | 97 | 2.78 | 53 | 0.04 | 100 | 3.95 | 5.25 |
| FZD7 | 0 | 98 | 5.58 | 93 | 1.52 | 97 | 4.43 | 4.18 |
| GSK3B | +2 (ASCNA) | 100 | 5.08 | 97 | 2.22 | 100 | 8.58 | 3.62 |
| HRAS | 0 | 7 | −0.69 | 0 | −1.09 | 14 | −0.7 | 1.05 |
| JAG1 | 0 | 99 | 5.62 | 83 | 1.02 | 100 | 8.97 | 6.42 |
| KRAS | 0 | 96 | 2.45 | 90 | 1.24 | 100 | 4.41 | 1.83 |
| MDM2 | 0 | 97 | 3.31 | 97 | 4.19 | 99 | 5.89 | 2.86 |
| MDM4 | 0 | 93 | 2.08 | 90 | 2.07 | 100 | 3.26 | −1.07 |
| MUTYH | 0 | 1 | −0.97 | 2 | −1.37 | 5 | −0.91 | −1.14 |
| NOTCH1 | 0 | 96 | 3.16 | 82 | 0.96 | 100 | 4.81 | 5.35 |
| PIK3CB | +2 (ASCNA) | 89 | 1.19 | 82 | 0.98 | 87 | 1.05 | 1.76 |
| PTEN | −1 (DLOH) | 80 | 0.69 | 76 | 0.64 | 66 | 0.33 | 1.14 |
| RB1 | 0 | 95 | 1.82 | 64 | 0.29 | 100 | 3.31 | 2.26 |
| TP53 | 0 | 64 | 0.29 | 56 | 0.16 | 89 | 1.19 | 1.75 |
| TGFB1 | 0 | 79 | 0.73 | 18 | −0.49 | 94 | 1.75 | 1.77 |
| TGFBR1 | 0 | 94 | 1.79 | 90 | 1.45 | 97 | 2.05 | 1.86 |
| TGFBR2 | 0 | 99 | 3.84 | 100 | 6.67 | 81 | 0.82 | 1.15 |
| WNT10A | 0 | 96 | 8.33 | 89 | 1.54 | 100 | 14.41 | 18.52 |
| WNT5A | −1 (DLOH) | 83 | 1.09 | 33 | −0.13 | 91 | 2.12 | 2.9 |
| Gene or Construct | Accession No: | Primers | Template | Vector |
| NvStbm (in situ hybridization probe) | 1526895:4 | Forward 5' CGACAAAGCGAACCAATGTTTACTCT 3'Reverse 5' CCGACATCATGTAAGGGTTATACTCA 3' | Mixed stage N.vectensis cDNA | pGEM |
| NvStbm (Full-length) | 1526895:4 | Forward 5'GCCGGAATTCATGCCGCAATATCGTACCAAAGAC 3'Reverse 5' GCCTAGGCCTGACGGAGGTCTCCGAATTTAACTTG 3' | Mixed stage N.vectensis cDNA | pCS2+GFP |
| NvFz10 | XP_001630630 | Forward 5' AGTACGATCAGTGCGTCCCCCAATG 3'Reverse 5' CCGCCACGACTTGAATGTTTTTGTAG 3' | Mixed stage N.vectensis cDNA | pGEM |
| NvFz5 | XP_001634995 | Forward 5' GCGAAGAGATCACCATTCCCATGTGC 3'Reverse 5' ACCCACCAAACAGAGGAAGCCATTC 3' | Mixed stage N.vectensis cDNA | pGEM |
| SpAxin | XP_781992 | Forward 5' GCCGGAATTCATGAGTCTAGAAGTGTATAGGTTC 3'Reverse 5' GCCGAGGCCTGTGATCATCGACAGATTCCACCTG 3' | Blastula stage S. purpuratus cDNA | pCS2+GFP |
| Gd-dendrimer generation (G) | Peak concentration in orthotopic RG-2 gliomas (mM) | Peak concentration time point (min) | Peak concentration in ectopic RG-2 gliomas (mM) | Peak concentration time point (min) |
| Gd-G5 | 0.147 | 167 | 0.195 | 149 |
| Gd-G6 | 0.106 | 200 | 0.144 | 189 |
| Gd-G7 | 0.064 | 75 | 0.084 | 107 |
| Gd-G8 | 0.049 | 77 | 0.052 | 81 |
| DVT(n = 9) | PE(n = 9) | AF(n = 13) | Total(n = 31) | |
| COUNTRY (n) | ||||
| France | 3 | 3 | 5 | 11 |
| The Netherlands | 3 | 3 | 4 | 10 |
| The United States | 3 | 3 | 4 | 10 |
| GENDER (n) | ||||
| Male | 5 | 2 | 7 | 14 |
| Female | 4 | 7 | 6 | 17 |
| AGE (years) | ||||
| Range | 21 – 77 | 30 – 74 | 39 – 79 | 21 – 79 |
| Mean | 47.4 | 51.3 | 68.5 | 57.4 |
| LIVING SITUATION (n) | ||||
| Living alone | 3 | . | 5 | 8 |
| Living as a couple | 6 | 9 | 8 | 23 |
| LEVEL OF EDUCATION (n) | ||||
| Primary school | 1 | . | 3 | 4 |
| High school diploma | 3 | 3 | 3 | 9 |
| Some college or vocational school | 1 | 3 | 4 | 8 |
| College or university degree | 3 | 2 | 1 | 6 |
| Graduate or professional school | 1 | 1 | 1 | 3 |
| Other, please specify | . | . | 1 (grammar school) | 1 |
| EMPLOYMENT STATUS (n) | ||||
| Full-time paid employment | 4 | 1 | 1 | 6 |
| Part-time paid employment | 1* | 1* | 1 | 3 |
| Homemaker/housewife | . | 1 | 1 | 2 |
| Retired | 3 | 3 | 10 | 16 |
| Unemployed | . | 1 | . | 1 |
| Not working due to present health status | . | 2 | . | 2 |
| Other, please specify | 1 (disabled) | . | . | 1 |
| Models | T2DM | IFG | ||
| OR (95% CI) | P value | OR* (95% CI) | P value | |
| let-7b | ||||
| Univariate model | 1.36 (1.24, 1.49) | <0.001 | 1.25 (1.23, 1.38) | <0.001 |
| Multivariate model 1a | 1.36 (1.23, 1.49) | <0.001 | 1.22 (1.10, 1.35) | <0.001 |
| Multivariate model 2b | 1.35 (1.22, 1.50) | <0.001 | 1.23 (1.10, 1.37) | <0.001 |
| Multivariate model 3c | 1.33 (1.10, 1.50) | <0.001 | 1.20 (1.07, 1.35) | 0.002 |
| miR-142 | ||||
| Univariate model | 0.80 (0.74, 0.86) | <0.001 | 0.85 (0.78, 0.92) | <0.001 |
| Multivariate model 1a | 0.78 (0.73, 0.85) | <0.001 | 0.84 (0.77, 0.92) | <0.001 |
| Multivariate model 2b | 0.80 (0.74, 0.88) | <0.001 | 0.86 (0.79, 0.95) | 0.001 |
| Multivariate model 3c | 0.83 (0.75, 0.93) | <0.001 | 0.86 (0.78, 0.94) | 0.002 |
| miR-144 | ||||
| Univariate model | 1.10 (1.06, 1.14) | <0.001 | 1.08 (1.04, 1.12) | <0.001 |
| Multivariate model 1a | 1.10 (1.06, 1.14) | <0.001 | 1.12 (1.07, 1.18) | <0.001 |
| Multivariate model 2b | 1.09 (1.05, 1.13) | <0.001 | 1.11 (1.05, 1.17) | <0.001 |
| Multivariate model 3c | 1.08 (1.03, 1.13) | 0.004 | 1.12 (1.05, 1.18) | <0.001 |
| miR-29a | ||||
| Univariate model | 1.09 (1.03, 1.16) | 0.007 | 1.09 (1.02, 1.18) | 0.014 |
| Multivariate model 1a | 1.09 (1.02, 1.14) | 0.010 | 1.09 (1.01, 1.17) | 0.025 |
| Multivariate model 2b | 1.08 (1.01, 1.16) | 0.027 | 1.09 (1.01, 1.18) | 0.027 |
| Multivariate model 3c | 1.10 (1.00, 1.20) | 0.036 | 1.10 (1.01, 1.20) | 0.033 |
| Neurological status | n | Canal compromise (%) | Loss of vertebral body height (%) | kyphotic angle (degree) |
| A | 11 | 52.27 ± 9.73 | 42.18 ± 8.36 | 15.27 ± 4.00 |
| B | 16 | 50.38 ± 8.65 | 38.06 ± 12.34 | 15.75 ± 6.87 |
| C | 16 | 52.88 ± 7.32 | 41.63 ± 8.73 | 19.69 ± 8.11 |
| D | 10 | 48.90 ± 6.77 | 38.90 ± 5.78 | 17.70 ± 6.83 |
| Total | 53 | 51.25 ± 8.09 | 40.15 ± 9.40 | 17.21 ± 6.87 |
| *P > 0.05 | *P > 0.05 | *P > 0.05 |
| n | τ2 | Adjust τ2 | OR | 95% CI | p-value$ | Egger's test p-value | |
| Race | 35 | 0.0452 | 0.0460 | 0.90 | 0.72–1.12 | 0.345 | 0.011 |
| Study design | 35 | 0.0452 | 0.0423 | 1.09 | 0.90–1.34 | 0.382 | 0.039 |
| Quality score (per 1 score) | 35 | 0.0452 | 0.0425 | 1.08 | 0.97–1.19 | 0.152 | 0.063 |
| Kidney function of case | 35 | 0.0452 | 0.0341 | 1.21 | 0.95–1.54 | 0.129 | 0.108 |
| Gender (per 100%) | 33 | 0.0480 | 0.0502 | 1.00 | 0.70–1.42 | 0.977 | 0.087 |
| Age (per 10 year) | 34 | 0.0473 | 0.0436 | 1.09 | 0.98–1.20 | 0.104 | 0.093 |
| BMI (per 5 kg/m2) | 11 | 0.0393 | 0.0488 | 0.95 | 0.65–1.38 | 0.790 | 0.263 |
| Hypertension (per 100%) | 29 | 0.0552 | 0.0487 | 1.63 | 0.80–3.32 | 0.178 | 0.064 |
| DM (per 100%) | 25 | 0.0603 | 0.0352 | 0.69 | 0.48–1.00 | 0.051 | 0.017 |
| Smoke (per 100%) | 11 | 0.0102 | 0.0123 | 1.58 | 0.34–7.41 | 0.562 | 0.355 |
| Variables | rs3803304 | rs2494732 | ||
| CC | CG+GG | CC | CT+TT | |
| Affected breast | ||||
| Right | 28 (30.8) | 24 (26.4) | 24 (26.4) | 28 (30.8) |
| Left | 26 (28.6) | 13 (14.3) | 17 (18.7) | 22 (24.2) |
| OR (95% CI) | 0.6 (0.2-1.4) | 1.1 (0.5-3.6) | ||
| P value | P > 0.05, Q > 0.05 | P > 0.05, Q > 0.05 | ||
| Tumor stagea | ||||
| T1-T2 | 43 (48.9) | 27 (30.7) | 32 (36.4) | 38 (43.2) |
| T3-T4 | 8 (9.1) | 10 (11.4) | 7 (7.9) | 11 (12.5) |
| OR (95% CI) | 1.9 (0.7-5.7) | 1.3 (0.5-3.8) | ||
| P value | P > 0.05, Q > 0.05 | P > 0.05, Q > 0.05 | ||
| LN status | ||||
| + | 29 (31.9) | 18 (19.8) | 22 (24.1) | 25 (27.5) |
| - | 25 (27.5) | 19 (20.9) | 19 (20.9) | 25 (27.5) |
| OR (95% CI) | 1.2 (0.5-2.8) | 1.2 (0.5-2.6) | ||
| P value | P > 0.05, Q > 0.05 | P > 0.05, Q > 0.05 | ||
| ER status | ||||
| + | 33 (36.3) | 26 (28.6) | 26 (28.6) | 33 (36.3) |
| - | 21 (23.1) | 11 (12.1) | 15 (16.5) | 17 (18.7) |
| OR (95% CI) | 0.7 (0.3-1.6) | 0.9 (0.4-2.1) | ||
| P value | P > 0.05, Q > 0.05 | P > 0.05, Q > 0.05 | ||
| PR status | ||||
| + | 31 (34.1) | 24 (26.4) | 25 (27.5) | 30 (33.0) |
| - | 23 (25.3) | 13 (14.3) | 16 (17.6) | 20 (22.0) |
| OR (95% CI) | 0.7 (0.3-1.7) | 1.0 (0.4-2.4) | ||
| P value | P > 0.05, Q > 0.05 | P > 0.05, Q > 0.05 | ||
| HER2 status | ||||
| + | 12 (13.2) | 15 (16.5) | 11 (8.8) | 16 (20.9) |
| - | 42 (46.2) | 22 (24.2) | 30 (25.3) | 34 (45.1) |
| OR (95% CI) | 0.4 (0.2-1.0) | 0.8 (0.3-1.9) | ||
| P value | P > 0.05, Q > 0.05 | P > 0.05, Q > 0.05 | ||
| Surgical margins | ||||
| + | 33 (36.3) | 28 (30.8) | 25 (27.5) | 36 (39.6) |
| - | 21 (23.1) | 9 (9.9) | 16 (17.6) | 14 (15.4) |
| OR (95% CI) | 0.5 (0.1-1.3) | 0.6 (0.3-1.5) | ||
| P value | P > 0.05, Q > 0.05 | P > 0.05, Q > 0.05 |
| Group | Very low | Low | Moderate | High | ||||||
| Mean | SD | N | % | N | % | N | % | N | % | |
| All youth | 8.26 | 3.84 | 304 | 13.8 | 961 | 43.7 | 574 | 26.1 | 361 | 16.4 |
| Gender | ||||||||||
| Female | 8.20 | 3.64 | 134 | 12.4 | 485 | 45.0 | 290 | 26.9 | 168 | 15.6 |
| Male | 8.32 | 4.04 | 170 | 15.1 | 476 | 42.4 | 284 | 25.3 | 193 | 17.2 |
| Age | ||||||||||
| <14 | 7.04 | 3.07 | 146 | 21.8 | 400 | 51.5 | 183 | 23.6 | 48 | 5.9 |
| 14–15 | 8.66 | 3.78 | 84 | 14.5 | 278 | 39.9 | 197 | 28.3 | 138 | 19.2 |
| 16> | 9.17 | 4.31 | 74 | 12.0 | 283 | 40.0 | 194 | 26.7 | 175 | 23.7 |
| Regions | L/R | MNI (X, Y, Z) | Voxels (mm3) | t-Score |
| Thalamus | R | 14, -30, 10 | 28 | 2.9962 |
| Thalamus | L | -12, -28, 9 | 35 | 3.6621 |
| Posterior cingulate | R | -13, -50, 16 | 31 | 3.5521 |
| Posterior cingulate | L | 12, -45, 18 | 28 | 2.7536 |
| Angular gyrus | L | -56, -47, 39 | 35 | 3.8926 |
| Inferior parietal lobule | L | -50, -27, 25 | 28 | 3.6249 |
| GO:BP terms enriched in orthologs differentially expressed exclusively in C. elegans | |||||
| GO.ID | Term | Annotated | Significant | Expected | p-Value |
| GO:0018996 | molting cycle; collagen and cuticulin-based cuticle. | 157 | 17 | 4.19 | 5.70E-07 |
| GO:0040011 | locomotion | 789 | 34 | 21.07 | 0.0019 |
| GO:0040018 | positive regulation of multicellular organism growth | 167 | 11 | 4.46 | 0.0046 |
| GO:0006560 | proline metabolic process | 5 | 2 | 0.13 | 0.0067 |
| GO:0010171 | body morphogenesis | 322 | 16 | 8.6 | 0.0106 |
| GO:0009084 | glutamine family amino acid biosynthesis | 8 | 2 | 0.21 | 0.0178 |
| GO:0006694 | steroid biosynthetic process | 10 | 2 | 0.27 | 0.0277 |
| GO:0055114 | oxidation-reduction process | 219 | 11 | 5.85 | 0.0306 |
| GO:0006508 | proteolysis | 197 | 10 | 5.26 | 0.0362 |
| GO:0018991 | oviposition | 145 | 8 | 3.87 | 0.0387 |
| GO:MF terms enriched in orthologs differentially expressed exclusively in C. elegans | |||||
| GO.ID | Term | Annotated | Significant | Expected | p-Value |
| GO:0042302 | structural constituent of cuticle | 21 | 10 | 0.53 | 1.60E-11 |
| GO:0004222 | metalloendopeptidase activity | 50 | 6 | 1.25 | 0.0014 |
| GO:0016776 | phosphotransferase activity; phosphate group as acceptor | 5 | 2 | 0.13 | 0.0059 |
| GO:0016903 | oxidoreductase activity; acting on the aldehyde or oxo group of donors | 8 | 2 | 0.2 | 0.0157 |
| GO:0003854 | 3-beta-hydroxy-delta5-steroid dehydrogenase activity | 8 | 2 | 0.2 | 0.0157 |
| GO:0019205 | nucleobase; nucleoside; nucleotide kinase activity | 8 | 2 | 0.2 | 0.0157 |
| GO:0020037 | heme binding | 51 | 4 | 1.28 | 0.0374 |
| GO:0004601 | peroxidase activity | 14 | 2 | 0.35 | 0.0464 |
| Discharge status | Discharge status | |||||
| Early | Standard | aIRR (95% CI) | Early | Standard | aIRR (95% CI) | |
| Induction I | Induction II | |||||
| Antibiotics | 1698.0 | 1404.4 | 1.30 (1.13, 1.50)* | 1620.5 | 996.5 | 1.60 (1.46, 1.76)* |
| Antifungals | 848.5 | 889.5 | 0.91 (0.74, 1.12) | 814.8 | 857.4 | 0.97 (0.89, 1.07) |
| Antivirals | 70.7 | 145.6 | 0.59 (0.21, 1.62) | 114.8 | 151.2 | 0.67 (0.39, 1.13) |
| Vasopressors | 27.6 | 5.2 | 8.07 (3.50, 18.6)* | 32.7 | 6.8 | 4.54 (2.08, 9.89)* |
| Blood Products | 298.8 | 246.5 | 1.29 (1.09, 1.54)* | 238.7 | 221.5 | 1.06 (0.94, 1.19) |
| Platelets | 206.1 | 179.5 | 1.32 (1.05, 1.66)* | 150.2 | 144.5 | 1.03 (0.88, 1.21) |
| Packed RBC | 135.2 | 105.7 | 1.30 (1.06, 1.59)* | 144.9 | 106.8 | 1.20 (1.06, 1.36)* |
| FFP | 6.8 | 4.9 | 1.41 (0.44, 4.56) | 12.4 | 3.3 | 3.03 (1.23, 7.48)* |
| Parenteral Nutrition | 111.4 | 169.8 | 1.00 (0.50, 2.01) | 86.2 | 84.8 | 1.28 (0.76, 2.14) |
| Oxygen therapy | 40.9 | 13.3 | 5.14 (1.96, 13.5)* | 32.2 | 8.7 | 3.63 (1.79, 7.36)* |
| Intensification I | Intensification II | |||||
| Antibiotics | 1589.9 | 1030.4 | 1.52 (1.39, 1.67)* | 1862.1 | 1357.5 | 1.36 (1.25, 1.49)* |
| Antifungals | 775.3 | 853.1 | 0.93 (0.84, 1.03) | 882.9 | 915.9 | 0.96 (0.87, 1.07) |
| Antivirals | 116.2 | 170.1 | 0.70 (0.41, 1.19) | 109.0 | 165.4 | 0.62 (0.32, 1.21) |
| Vasopressors | 40.6 | 9.2 | 5.67 (2.63, 12.2)* | 45.7 | 14.0 | 3.56 (1.65, 7.66)* |
| Blood products | 259.3 | 228.7 | 1.17 (0.99, 1.38) | 383.1 | 319.6 | 1.25 (1.12, 1.40)* |
| Platelets | 168.3 | 154.5 | 1.21 (0.96, 1.52) | 287.0 | 244.2 | 1.26 (1.09, 1.46)* |
| Packed RBC | 151.4 | 109.6 | 1.42 (1.18, 1.72)* | 171.5 | 133.8 | 1.32 (1.11, 1.56)* |
| FFP | 5.6 | 2.2 | 4.31 (1.61, 11.5)* | 8.6 | 5.5 | 1.72 (0.56, 5.25)* |
| Parenteral Nutrition | 73.7 | 99.4 | 1.22 (0.75, 1.98) | 109.0 | 88.3 | 1.23 (0.82, 1.85) |
| Oxygen Therapy | 40.0 | 18.3 | 2.22 (1.10, 4.51)* | 46.3 | 16.2 | 2.85 (1.39, 5.83)* |
| OS Univariate analysis | OS Multivariate analysis | |||||
| Characteristics | 95.0% CIs | HR | P value | 95.0% CIs | HR | P value |
| Age (years) | ||||||
| <55 | 1.0 (ref.) | 1.0 (ref.) | ||||
| ≥55 | 0.99 to 2.69 | 1.63 | 0.056 a | 0.97 to 2.90 | 1.68 | 0.063 b |
| Gender | ||||||
| Female | 1.0 (ref.) | 1.0 (ref.) | ||||
| Male | 0.86 to 2.62 | 1.50 | 0.152 a | 0.64 to 2.72 | 1.32 | 0.461 b |
| Smoking history | ||||||
| Never smoking | 1.0 (ref.) | 1.0 (ref.) | ||||
| Current or ever Smoking | 0.85 to 2.28 | 1.39 | 0.194 a | 0.62 to 2.29 | 1.19 | 0.599 b |
| Differentiation | ||||||
| Well | 1.0 (ref.) | 1.0 (ref.) | ||||
| Moderate | 0.52 to 9.04 | 2.17 | 0.289 a | 0.34 to 6.66 | 1.50 | 0.598 b |
| Poor | 0.89 to 16.17 | 3.80 | 0.071 a | 0.54 to 11.32 | 2.46 | 0.247 b |
| pTNM stage, continuous | 1.01 to 1.32 | 1.15 | 0.038 a | 1.06 to 1.41 | 1.22 | 0.005 b |
| pT status | ||||||
| T1 | 1.0 (ref.) | - | - | - | ||
| T2 | 0.56 to 2.39 | 1.16 | 0.691 a | - | - | - |
| T3+ T4 | 0.83 to 4.43 | 1.92 | 0.129 a | - | - | - |
| pN status | ||||||
| N0+ N1 | 1.0 (ref.) | - | - | - | ||
| N2+ N3 | 0.60 to 1.63 | 0.99 | 0.980 a | - | - | - |
| pM status | ||||||
| M0 | 1.0 (ref.) | - | - | - | ||
| M1 | 0.83 to 2.68 | 1.49 | 0.184 a | - | - | - |
| Adjuvant chemotherapy | ||||||
| Yes | 1.0 (ref.) | 1.0 (ref.) | ||||
| No | 0.89 to 2.52 | 1.50 | 0.129 a | 1.08 to 3.48 | 1.94 | 0.027 b |
| EGFR mutation status | ||||||
| Positive | 1.0 (ref.) | 1.0 (ref.) | ||||
| Negative | 0.39 to 1.57 | 0.79 | 0.494 a | 0.33 to 1.64 | 0.73 | 0.452 b |
| Not performed | 0.63 to 2.00 | 1.12 | 0.695 a | 0.37 to 1.42 | 0.73 | 0.350 b |
| Anti-EGFR drug treatment | ||||||
| Yes | 1.0 (ref.) | 1.0 (ref.) | ||||
| No | 0.44 to 1.20 | 0.73 | 0.214 a | 0.46 to 1.41 | 0.81 | 0.450 b |
| Serum CEA | ||||||
| Normal (≤5 ng/ml) | 1.0 (ref.) | 1.0 (ref.) | ||||
| Elevated (>5ng/ml) | 0.84 to 2.27 | 1.38 | 0.204 a | 0.63 to 1.88 | 1.09 | 0.771 b |
| Plakoglobin expression | ||||||
| IRS 0-3 | 1.0 (ref.) | 1.0 (ref.) | ||||
| IRS 4-12 | 1.01 to 2.86 | 1.70 | 0.046 a | 1.12 to 3.37 | 1.94 | 0.019 b |
| Parameter | Treatment | Baseline | Pulmonary hypertension | |
| Pre-inhalation | 5 minutes after inhalation | |||
| Mw (mWatt·s/ml) | Iloprost | 8.29 ± 1.66 | 10.67 ± 2.45* | 8.08 ± 2.22 |
| Control | 7.54 ± 1.06 | 9.01 ± 1.27* | 9.24 ± 2.69 | |
| Emax (mmHg/ml) | Iloprost | 1.10 ± 0.46 | 1.51 ± 0.74 | 1.20 ± 0.66 |
| Control | 1.13 ± 0.62 | 1.29 ± 0.75 | 1.64 ± 0.95 | |
| LVEF (%) | Iloprost | 61 ± 5 | 63 ± 12 | 59 ± 13 |
| Control | 57 ± 9 | 53 ± 7 | 50 ± 5 | |
| τ/RR (ms) | Iloprost | 0.06 ± 0.02 | 0.08 ± 0.02 | 0.07 ± 0.01 |
| Control | 0.07 ± 0.01 | 0.07 ± 0.01 | 0.08 ± 0.02 | |
| β (ml-1) | Iloprost | 0.11 ± 0.03 | 0.11 ± 0.06 | 0.04 ± 0.03* |
| Control | 0.11 ± 0.04 | 0.13 ± 0.09 | 0.09 ± 0.05 | |
| C (ml/mmHg) | Iloprost | 0.72 ± 0.23 | 0.60 ± 0.20 | 0.64 ± 0.27 |
| Control | 0.88 ± 0.27 | 0.71 ± 0.25* | 0.66 ± 0.21* | |
| Ea (mmHg/ml) | Iloprost | 1.87 ± 0.51 | 1.68 ± 0.44 | 1.67 ± 0.50 |
| Control | 1.80 ± 0.46 | 1.93 ± 0.55 | 1.95 ± 0.56 | |
| Emax/Ea | Iloprost | 0.60 ± 0.24 | 0.92 ± 0.50 | 0.69 ± 0.30 |
| Control | 0.62 ± 0.24 | 0.67 ± 0.31 | 0.86 ± 0.48 |
| Characteristics | Patients | |||||
| 8010 | 8011 | 8013 | 8030 | 8031 | 8032 | |
| Age (years) | 50 | 47 | 59 | 69 | 56 | 49 |
| Lymphocytosis(×109/L) | 6,4 | 2,5 | 3,9 | 2,8 | 4,4 | 2,4 |
| Lymphocytosis(% total leukocytosis) | 58,4 | 32,1 | 36,5 | 42,5 | 56,6 | 48,7 |
| B cells/μL | 5250 | 1550 | 910 | 1200 | 2240 | 760 |
| Serum IgM(g/L) | 12,1 | 7,8 | 3,8 | 9,6 | 9,5 | 7,3 |
| Number of BCL-2/Ig rearrangementsa | 3 | 5 | 3 | 7 | 5 | 5 |
| HLA | A 2, 9 B 14, 44Dr 2, 5 | A 9, 30 B 13, 14Dr 5, 13 | A 9, 39 B 14, 35Dr 5, 13 | A 1, 3 B 7, 57Dr 7, 14 | ND | A 11, 29 B 35, 44Dr 7, 14 |
| Cigarette smokingb | Yes | Stopped × 7 years | Yes | Stopped × 3 years | Yes | Stopped × 5 years |
| Men | Women | |||
| TG | TC:HDL cholesterol | TG | TC:HDL cholesterol | |
| WCa | r = 0.14P = 0.007 | r = 0.20P < 0.001 | r = 0.12P = 0.0008 | r = 0.09P = 0.01 |
| BMIb | r = -0.024P = 0.66 | r = 0.0004P = 0.99 | r = 0.01P = 0.78 | r = 0.07P = 0.04 |
| Univariate analysis | ||
| Factor | Hazard Ratio | p value |
| Chloroquine treatment | 3.28 (1.41-7.63) | 0.006 |
| Female | 0.93 (0.46-1.91) | 0.85 |
| Age (years) | 0.96 (0.92-1.00) | 0.03 |
| Recruitment site(Jalalabad as reference) | ||
| Taloqan | 0.79 (0.26-2.43) | 0.68 |
| Maimana | 3.06 (1.42-6.61) | 0.004 |
| Parasitaemia | 0.86 (0.32-2.29) | 0.76 |
| Presence of gametocytes | 1.13 (0.46-2.77) | 0.784 |
| Haemoglobin at admission (g/dl) | 0.49 (0.37-0.65) | <0.001 |
| Adverse event, n (%) | DA-naive | DA-exposed | ||||
| Placebo (n = 195) | GEn 600 mg (n = 133) | GEn 1200 mg (n = 217) | Placebo (n = 50) | GEn 600 mg (n = 30) | GEn 1200 mg (n = 52) | |
| Any event | 149 (76) | 105 (79) | 187 (86) | 34 (68) | 27 (90) | 40 (77) |
| Somnolence | 12 (6) | 25 (19) | 54 (25) | 0 | 7 (23) | 7 (14) |
| Dizziness | 9 (5) | 20 (15) | 44 (20) | 2 (4) | 2 (7) | 15 (29) |
| Headache | 22 (11) | 12 (9) | 36 (17) | 5 (10) | 7 (23) | 4 (8) |
| Nasopharyngitis | 10 (5) | 13 (10) | 17 (8) | 6 (12) | 1 (3) | 4 (8) |
| Nausea | 8 (4) | 5 (4) | 15 (7) | 4 (8) | 4 (13) | 4 (8) |
| Fatigue | 10 (5) | 5 (4) | 15 (7) | 1 (2) | 3 (10) | 3 (6) |
| Diarrhea | 10 (5) | 3 (2) | 7 (3) | 2 (4) | 3 (10) | 3 (6) |
| Upper respiratory tract infection | 7 (4) | 6 (5) | 5 (2) | 2 (4) | 3 (10) | 1 (2) |
| Dry mouth | 4 (2) | 4 (3) | 11 (5) | 1 (2) | 1 (3) | 1 (2) |
| Constipation | 6 (3) | 0 | 7 (3) | 2 (4) | 3 (10) | 3 (6) |
| Insomnia | 6 (3) | 7 (5) | 4 (2) | 1 (2) | 1 (3) | 2 (4) |
| Irritability | 3 (2) | 2 (2) | 8 (4) | 0 | 4 (13) | 3 (6) |
| Back pain | 6 (3) | 4 (3) | 6 (3) | 1 (2) | 2 (7) | 1 (2) |
| Sinusitis | 5 (3) | 2 (2) | 6 (3) | 1 (2) | 3 (10) | 1 (2) |
| Increased weight | 3 (2) | 2 (2) | 7 (3) | 2 (4) | 2 (7) | 2 (4) |
| All patients (n = 92) | No postoperative delirium (n = 48) | Postoperative delirium (n = 44) | P | |
| Male, n (%) | 66 (60.6) | 35 (72.9) | 31 (70.4) | 0.082 |
| Body mass index (BMI) | 27.1 ± 3.9 | 27.1 ± 3.3 | 27.2 ± 4.5 | 0.91 |
| Mean age, (years) | 67.5 ± 8.9 | 64.5 ± 9 | 70.8 ± 7.8 | 0.001 |
| Alcohol abuse, n (%) | 10 (10.9) | 3 (6.2) | 7 (15.9) | 0.14 |
| Smoking, n (%) | 23 (25) | 7 (14.6) | 16 (36.3) | 0.016 |
| Diabetes, n (%) | 21 (22.8) | 10 (20.8) | 11 (25) | 0.63 |
| Arterial hypertension, n (%) | 89 (96.7) | 46 (95.8) | 43 (97.7) | 0.34 |
| Chronic obstructive lung disease, n (%) | 20 (21.7) | 7 (14.6) | 13 (29.5) | 0.09 |
| Renal insufficiency, n (%) | 13 (14.1) | 5 (10.4) | 8 (18.2) | 0.25 |
| Impaired left ventricular function, EF n (%): normal (≥55%) | 58 (63) | 30 (62.5) | 28 (65.1) | 0.7 |
| Mild (45-54%) | 16 (17.4) | 10 (20.8) | 5 (11.6) | |
| Moderate (36-44%) | 8 (8.7) | 3 (6.3) | 4 (9.3) | |
| Severe (≤35%) | 11 (12.5) | 5 (10.4) | 6 (14) | |
| History of stroke, n (%) | 7 (7.6) | 3 (6.3) | 4 (9.1) | 0.48 |
| Atrial fibrillation preoperative, n (%) | 13 (14.1) | 6 (12.5) | 7 (16.7) | 0.22 |
| Long-term glucocorticoid medication, n (%) | 5 (5.4) | 0 (0.0) | 5 (11.4) | 0.056 |
| Albumin g/l | 43.5 ± 3.4 | 44.4 ± 3.1 | 42.3 ± 3.4 | 0.003 |
| Hemoglobin g/dl | 13.2 ± 1.6 | 13.7 ± 1.5 | 12.7 ± 1.6 | 0.005 |
| Urea mg/dl | 37.9 ± 19.0 | 36.1 ± 13.9 | 40.2 ± 23.5 | 0.33 |
| Mean number of transfused packs of RBC | 3.0 ± 2.3 | 2.2 ± 1.8 | 3.8 ± 2.6 | 0.001 |
| Type of heart surgery (CABG/open heart surgery ± CABG) | 47/45 | 26/22 | 21/23 | 0.54 |
| Mean extracorporeal circulation time (min.) | 112 ± 41.5 | 108 ± 41.4 | 115 ± 42 | 0.37 |
| Postoperative intubation time (hrs) median (IQR [range]) | 13 (10-18 [4-91]) | 11 (9-14 [5–29]) | 18 (14-23[4-91]) | <0.001 |
| Time (days) spent in intensive and intermediate care unit, median (IQR [range]) | 5 (3-6 [2–17]) | 4 (3-5 [2–15]) | 6 (5-8 [2–17]) | <0.001 |
| Time (hrs) spent in intensive care unit, median (IQR [range]) | 23 (20-47 [11-289]) | 21 (19-24 [12-77]) | 46 (23-78[11-289]) | <0.001 |
| Benzodiazepine intake during the night of the sleep study (yes/no) | 22 (25.6) | 12 (27.9) | 10 (25.6) | 0.82 |
| MBL | IC50 (μM) | |||
| CBS | Bi(NAC)3 | Bi(NIT)3 | Bi(PCM)2 | |
| NDM-1 | 2.81 ± 0.34 | 1.65 ± 0.60 | 0.70 ± 0.13 | 2.80 ± 0.11 |
| VIM-2 | 3.55 ± 0.78 | 2.65 ± 0.57 | 1.20 ± 0.13 | 3.71 ± 1.19 |
| IMP-4 | 0.70 ± 0.08 | 2.80 ± 0.79 | 0.99 ± 0.19 | 1.00 ± 0.37 |
| Case # | TI #1 (min) | TI #2 (min) | TI#3 (min) | TI#4 (min) | TI#5 (min) |
| 1 | 5 | 3 | 2 | 41 | 51 |
| 2 | 5 | 3 | 2 | 41 | 51 |
| 3 | 3 | 2 | 2 | 42 | 49 |
| 4 | 1 | 2 | 7 | 44 | 54 |
| 5 | 1 | 1 | 3 | 41 | 46 |
| 6 | 1 | 3 | 3 | 41 | 48 |
| 7 | 2 | 2 | 2 | 40 | 46 |
| 8 | 2 | 2 | 3 | 39 | 46 |
| 9 | 2 | 3 | 3 | 52 | 60 |
| 10 | 1 | 2 | 2 | 44 | 49 |
| Classifier | SRCCATT | SRCCAWRST | SRCCAWLT |
| PCA | 1.7 × 10-13 | 4.7 × 10-12 | 1.4 × 10-10 |
| PLS | 1.3 × 10-5 | 8.5 × 10-3 | 1.6 × 10-4 |
| CCA | 6.8 × 10-7 | 5.4 × 10-6 | 2.1 × 10-7 |
| RCCA | 3.4 × 10-9 | 1.8 × 10-9 | 3.6 × 10-16 |
| Studies, n | SRR (95% CI) | I2(%) | Pheterogeneity | Pdifference | |
| All | 14 | 2.06 (1.50–2.85) | 96.7 | <0.001 | |
| Sex | 0.399 | ||||
| Male | 6 | 2.04(1.11 –3.74 | 98.3 | <0.001 | |
| Female | 3 | 2.67(1.27 –5.59) | 93.3 | <0.001 | |
| Locations | 0.029 | ||||
| Europe | 4 | 2.40(1.81– 3.18) | 49.3 | 0.116 | |
| USA | 8 | 1.65(1.32– 2.05) | 84.0 | <0.001 | |
| Asia | 2 | 2.99(1.18– 7.60) | 98.7 | <0.001 | |
| Smoking status | 0.289 | ||||
| Never | 3 | 2.32 (1.42–3.77) | 0 | 0.833 | |
| Ever | 3 | 1.60 (1.28-2.01) | 76.0 | <0.001 | |
| Diagnosis of COPD | 0.201 | ||||
| Physiological diagnosis | 6 | 2.02(1.69 –2.41) | 0 | 0.931 | |
| Disease registry | 3 | 2.75(0.87 –8.73) | 99.4 | <0.001 | |
| Self-report | 5 | 1.75(1.40 –2.19) | 80.2 | <0.001 | |
| COPD severity | 0.016 | ||||
| Mild | 4 | 1.46 (1.20–1.76) | 0 | 0.876 | |
| Moderate | 3 | 2.05(1.67–2.52) | 8.1 | 0.337 | |
| Severe | 3 | 2.44(1.73–3.45) | 0 | 0.438 | |
| Follow-up, years | 0.453 | ||||
| ≤5 | 7 | 1.87 (1.36–2.59) | 89.3 | <0.001 | |
| >5 | 7 | 2.23(1.41–3.53) | 96.3 | <0.001 | |
| Type of outcome | 0.948 | ||||
| Incidence | 10 | 2.06 (1.34–3.16) | 97.6 | <0.001 | |
| Mortality | 4 | 1.95 (1.71–2.23) | 0 | 0.775 |
| Diseases | Genetic variations of TRAFs | References |
| B cell malignancies | ||
| Multiple myeloma | Deletions or inactivating mutations of TRAF3, TRAF2 | [294-296] |
| SNPs of TRAF3 | [297] | |
| Splenic marginal zone lymphoma | Deletions or inactivating mutations of TRAF3 | [298,299] |
| B cell chronic lymphocytic leukemia | Deletions or inactivating mutations of TRAF3 | [298] |
| Mantle cell lymphoma | Deletions or inactivating mutations of TRAF3 | [298] |
| Waldenström’s macroglobulinemia | Deletions or inactivating mutations of TRAF3 | [300] |
| Hodgkin lymphoma | Deletion of TRAF3 | [301] |
| Diffuse large B-cell lymphoma | Inactivating mutations of TRAF2, TRAF5 | [302] |
| Non-Hodgkin lymphoma | SNPs of TRAF1 | [303] |
| Carcinomas | ||
| Breast cancers | Amplification of TRAF4 | [304] |
| Lung cancers | Amplification of TRAF4, TRAF6 | [304,305] |
| Osteosarcoma | Amplification of TRAF6 | [306] |
| Autoimmune diseases | ||
| Systemic lupus erythematosus | SNPs of TRAF6, TRAF1/C5 | [22,307,308] |
| Rheumatoid arthritis | SNPs of TRAF5, TRAF6, TRAF1/C5 | [22,309-311] |
| Immunodeficiencies | ||
| HSV-1 encephalitis | Inactivating mutation of TRAF3 | [312] |
| Other | ||
| Hypohidrotic ectodermal dysplasia | Inactivating mutation of TRAF6 | [313] |
| Mismatch distribution | Neutrality tests | |||
| SSD | R | Tajima's D | Fu's F | |
| Northern | 0.0230 (0.137) | 0.0453 (0.072) | 0.0730 (0.607) | 0.415 (0.614) |
| Central | 0.127 (0.012) | 0.240 (0.000) | 0.929 (0.851) | 7.498 (0.955) |
| Southern | 0.0923 (0.375) | 0.223 (0.070) | −0.251 (0.447) | 1.713 (0.822) |
| Overall | 0.017 (0.087) | 0.032 (0.000) | 1.101 (0.894) | 6.699 (0.896) |
| Approach | Pombe | Kinase | Chromosome | ESP | RNA |
| Filling with zeros | 1.01 | 1.00 | 1.01 | 1.00 | 1.00 |
| uKNN (K = 5) | 0.78 | 0.90 | 0.79 | 0.83 | 0.83 |
| BPCA(K = 300) | 0.74 | 0.89 | 0.85 | 0.80 | 0.82 |
| wNN (K = 50) | 0.71 | 0.85 | 0.75 | 0.79 | 0.78 |
| LLS (K = 20) | 0.68 | 0.85 | 0.73 | 0.76 | 0.77 |
| # spots (percent of total) | # genes (percent of total) | ||
| all | SIG1 | 4273 (51.6) | 6708 (52.2) |
| NON-SIG2 | 4000 (48.4) | 6141 (47.8) | |
| Total | 8273 (100) | 12849 (100) | |
| large gene families3 | SIG | 739 (50.1) | 1010 (51.5) |
| NON-SIG | 735 (49.9) | 950 (48.5) | |
| Total | 1474 (100) | 1960 (100) | |
| minus large gene families | SIG | 3534 (52.0) | 5698 (52.3) |
| NON-SIG | 3265 (48.0) | 5191 (47.7) | |
| Total | 6799 (100) | 10889 (100) |
| Age group | |||||
| Total | Young adult | Adult | Elderly | P | |
| Anorectal angle (o) | |||||
| At rest | 102 ± 24 | 114 ± 28 | 94 ± 21 | 103 ± 19 | 0.09 |
| Contraction | 83 ± 21 | 91 ± 13 | 77 ± 25 | 86 ± 19 | 0.20 |
| Valsalva maneuver | 97 ± 24 | 100 ± 28 | 91 ± 22 | 105 ± 21 | 0.21 |
| Evacuation | 122 ± 22 | 119 ± 24 | 118 ± 22 | 133 ± 15 | 0.09 |
| Perineal descent (cm) | |||||
| At rest (length) | 4.0 ± 1.9 | 3.2 ± 1.1 | 4.2 ± 1.6 | 4.3 ± 3.3 | 0.41 |
| Contraction(length) | 3.0 ± 2.1 | 2.2 ± 1.9 | 3.3 ± 2.0 | 3.5 ± 2.7 | 0.37 |
| Valsalva maneuver(length) | 5.5 ± 2.4 | 5.8 ± 3.1 | 5.1 ± 1.9 | 5.7 ± 2.6 | 0.71 |
| Evacuation(length) | 7.7 ± 2.0 | 8.4 ± 1.1 | 7.4 ± 2.3 | 7.5 ± 2.3 | 0.45 |
| Puborectalis muscle (cm) | |||||
| At rest | 20 ± 5 | 20 ± 5 | 20.9 ± 3.7 | 19.8 ± 5.8 | 0.79 |
| Contraction | 19 ± 5 | 19 ± 6 | 20.4 ± 4.1 | 19.6 ± 5.8 | 0.77 |
| Valsalva maneuver | 21 ± 4 | 21 ± 3 | 20.9 ± 3.9 | 21.1 ± 4.1 | 0.99 |
| Evacuation | 20 ± 5 | 19 ± 6 | 21.1 ± 3.6 | 19.3 ± 5.4 | 0.56 |
| Length of the anal canal (cm) | |||||
| At rest | 4.6 ± 1.3 | 4.5 ± 1.2 | 4.7 ± 1.0 | 4.5 ± 1.8 | 0.89 |
| Contraction | 6.1 ± 1.6 | 6.1 ± 2.0 | 6.2 ± 1.6 | 5.8 ± 1.3 | 0.81 |
| Valsalva maneuver | 3.7 ± 1.6 | 3.2 ± 1.9 | 3.9 ± 1.6 | 3.8 ± 1.2 | 0.94 |
| Evacuation | 2.4 ± 1.2 | 2.6 ± 1.4 | 2.6 ± 1.4 | 2.5 ± 1.0 | 0.97 |
| Opening of the anal canal (cm) | |||||
| At rest | 0.9 ± 0.4 | 0.9 ± 0.3 | 1.0 ± 0.3 | 0.9 ± 0.5 | 0.72 |
| Contraction | 0.7 ± 0.3 | 0.7 ± 0.3 | 0.8 ± 0.2 | 0.7 ± 0.4 | 0.57 |
| Valsalva maneuver | 0.9 ± 0.5 | 0.8 ± 0.2 | 1.0 ± 0.5 | 1.1 ± 0.6 | 0.35 |
| Evacuation | 1.4 ± 0.4 | 1.4 ± 0.4 | 1.3 ± 0.4 | 1.3 ± 0.3 | 0.76 |
| Emptying of the rectal ampulla (%) | 70 ± 20 | 54 ± 25 | 79 ± 12 | 74 ± 11 | 0.001 |
| Category | Variable name | Variable definition |
| Political Domain | Embassies | Absolute number of in-country embassies and high commissions |
| Organizations | Absolute number of memberships in international organizations | |
| Military | Trade in conventional arms as a share of military spending | |
| Economic domain | Trade | Imports + exports of goods and services as a share of GDP |
| FDI | Gross foreign direct stocks as a share of GDP | |
| Capital | Gross private capital flows as a share of GDP | |
| Social & Cultural Domain | Migrants | Those who changes their country of usual residence per 100 inhabitant |
| Tourism | International arrivals + departures per 100 inhabitants | |
| Technological Domain | Phone | Incoming + outgoing international telephone traffic in minutes per capita |
| Internet | Internet users as a share of population | |
| Ecological Domain | Eco footprint | Ecological deficit in global ha |
| recomWell IgG assay | Axiom assay | ||||
| Seroprevalence | 95 % CI | Seroprevalence | 95 % CI | ||
| Age groups | 20–29 | 0 % (0/7) | 14 % (1/7) | 0-43* | |
| 30–39 | 0 % (0/9) | 0 % (0/9) | |||
| 40–49 | 16 % (4/25) | 1.1–31 | 24 % (6/25) | 7–41 | |
| 50–59 | 20 % (7/35) | 6.4–34 | 43 % (15/35) | 26–60 | |
| 60–69 | 19 % (7/36) | 3.2–33 | 47 % (17/36) | 31–64 | |
| 70–79 | 67 % (8/12) | 39–95 | 67 % (8/12) | 39–95 | |
| 80–89 | 0 % (0/2) | 50 % (1/2) | 0–100* | ||
| Total | 21 % (26/126) | 13–28 | 38 % (48/126) | 29–47 | |
| Sex | male | 20 % (24/118) | 13–28 | 39 % (46/118) | 30–48 |
| female | 25 % (2/8) | 0–57* | 25 % (2/8) | 0–57* | |
| Hunting area | East (E) | 26 % (9/34) | 11–42 | 52 % (17/34) | 34–69 |
| Northwest (NW) | 14 % (9/65) | 5–22 | 31 % (20/65) | 19–42 | |
| Southwest (SW) | 30 % (8/27) | 12–47 | 41 % (11/27) | 22–60 |
| PfNapL | PfNapS | Vps75 | yNAP-1 | hSET | |
| Effect binding | |||||
| 1 | I136 | N112 | S95 | - | F115 |
| 2 | I147 | K120 | S104 | K230 | R123 |
| No effect on binding to PfNapL | PfNapS | Vps75 | yNAP-1 | hSET | |
| 1* | D192 | E161 | Q150 | D278 | S162 |
| 2 | H227 | E187 | G181 | N314 | T191 |
| 3* | T230 | T191 | R184 | D317 | T194 |
| 4 | Y259 | P198 | D198 | Y342 | D202 |
| 5* | E260 | D199 | S199 | S343 | E203 |
| 6* | K266 | R205 | S205 | K349 | K209 |
| 7 | D223 | W183 | K177 | E320 | Disordered |
| Microglia (load (%)) | No dementia | Dementia with Alzheimer’s pathology | ||||
| β | 95 % CI (β) | P | β | 95 % CI (β) | P | |
| Iba1 | 0.37 | (0.29; 0.45) | <0.001 | −0.13 | (−0.32; 0.05) | 0.154 |
| CD68 | −1.54 | (−2.96;−0.13) | 0.033 | −12.17 | (−15.13; −9.21) | <0.001 |
| HLA-DR | 0.18 | (−0.04; 0.41) | 0.116 | −1.11 | (−1.59; −0.64) | <0.001 |
| MSR-A | −0.69 | (−1.38; 0.00) | 0.051 | −4.94 | (−6.82; −3.07) | <0.001 |
| CD64 | 0.27 | (−0.03; 0.58) | 0.076 | 1.08 | (0.15; 2.02) | 0.023 |
| Region | Time consumed (hours) | |
| Local group | 12.00-19.20 (12.48 ± 2.40) | |
| Group 1 | Within-Sichuan group | 24.00-84.00 (47.76 ± 18.72) |
| Outside-Sichuan group | 48.00-108 (64.08 ± 13.92) | |
| Group 2 | 0.03-0.08 (0.04 ± 0.03) |
| Species | Peptide | Ensembl gene ID | Genome assembly | Comment |
| Coelacanth | NPY | ENSLACG00000001891 | LatCha1 | |
| Human | NPY | ENSG00000131096 | GRCh37 | |
| Coelacanth | PYY | ENSLACG00000015096 | LatCha1 | |
| Human | PYY | ENSG00000131096 | GRCh37 | |
| Coelacanth | Pancreatic polypeptide | Not annotated in database (JH126680.1:1,154,715–1,154,819) | ||
| Human | Pancreatic polypeptide | ENSG00000108849 | GRCh37 |
| Database | Type | Species | Method | Entries |
| Unipep | N-Glycosylated proteins and peptides | Homo sapiens | Hydrazide chemistry & Solid Phase Extraction, in-silico triptic digestion of IPI proteins, and prediction of NXS/T glycosylation site with proteotypic potential | 2265 |
| Glycofly | N-Glycosylated proteins and peptides | Drosophila melanogaster | Hydrazide chemistry and Solid Phase Extraction | 740 |
| Glycofish | N-Glycosylated proteins and peptides | Danio Rerio | Hydrazide chemistry and Solid Phase Extraction | 269 |
| GlycoSuiteDB | O-linked and N-linked Glycoproteins and glycans | Published glycoproteins with different methods | 9436 | |
| GlycoProtDB | N2 and mouse tissues N-Glycoproteins | Caenorhabditis elegans | Lectin Concavilin A Chromatography | 1465 |
| Mus Musculus | ||||
| O-GlycBase NetOGlyc | O and C-Glycosylated proteins | Combination of references | Data curation from literature and coupling ZFN gene targeting, SimpleCell and Lectin Chromatography | 2413 |
| 3000 | ||||
| dbOGAP | O-GlcNAcylated proteins | Homo Sapiens | Curation from literature and SVM based prediction | 798 (exp) 300 (pred) |
| Mus Musculus | ||||
| Rattus Norvegicus | ||||
| Drosophila Melanogaster | ||||
| Xenopus Laevis |
| Is it possible to reduce the chance of getting the HIV virus by doing the following? | Yes (n = 171; Male) | Yes (n = 231; Female) | ||
| n | % | n | % | |
| Always using a condom | 161 | 94 | 222 | 96 |
| Having one uninfected sexual partner | 150 | 87 | 184 | 79 |
| Clinical male circumcision | 138 | 80 | 180 | 77 |
| Abstinence | 145 | 84 | 210 | 90 |
| Non-participation | Model 1 b | Model 2 c | |
| / total n (%) | aOR (95% CI) | aOR (95% CI) | |
| Total KCL | |||
| <7 | 725/1138 (63.7) | reference | |
| ≥7 | 467/595 (78.5) | 1.14 (0.87, 1.49) | |
| Unknown | 667/883 (75.5) | 1.21 (0.95, 1.53) | |
| IADL | |||
| <3 | 1404/2098 (67.0) | reference | reference |
| ≥3 | 310/341 (90.9) | 2.42 (1.60, 3.64)** | 2.28 (1.50, 3.46)** |
| Unknown | 145/177 (81.9) | 1.79 (1.11, 2.89)* | 1.63 (0.99, 2.67) |
| Physical function/strength | |||
| <3 | 1075/1614 (66.6) | reference | reference |
| ≥3 | 555/694 (80.0) | 1.36 (1.07, 1.73)* | 1.28 (1.00, 1.65)* |
| Unknown | 229/308 (74.4) | 1.11 (0.81, 1.52) | 0.92 (0.65, 1.30) |
| Malnutrition | |||
| <2 | 1466/2114 (69.4) | reference | reference |
| 2 | 38/52 (73.1) | 0.76 (0.39, 1.46) | 0.78 (0.40, 1.53) |
| Unknown | 355/450 (78.9) | 1.32 (1.00, 1.74)* | 1.25 (0.93, 1.67) |
| Oral function | |||
| <2 | 1311/1887 (69.5) | reference | reference |
| ≥2 | 433/587 (73.8) | 0.85 (0.68, 1.08) | 0.80 (0.63, 1.03) |
| Unknown | 115/142 (81.0) | 1.33 (0.83, 2.13) | 1.16 (0.69, 1.94) |
| Socialization | |||
| <1 | 995/1507 (66.0) | reference | reference |
| ≥1 | 788/1013 (77.8) | 1.23 (1.00, 1.51) | 1.17 (0.94, 1.46) |
| Unknown | 76/96 (79.2) | 1.47 (0.84, 2.58) | 1.42 (0.78, 2.59) |
| Memory | |||
| <1 | 1095/1602 (68.4) | reference | reference |
| ≥1 | 668/888 (75.2) | 0.98 (0.80, 1.20) | 0.92 (0.75, 1.14) |
| Unknown | 96/126 (76.2) | 1.06 (0.66, 1.70) | 0.85 (0.51, 1.42) |
| Mood | |||
| <2 | 1008/1508 (66.8) | reference | reference |
| ≥2 | 557/736 (75.7) | 1.06 (0.84, 1.33) | 0.99 (0.78, 1.26) |
| Unknown | 294/372 (79.0) | 1.29 (0.92, 1.81) | 1.15 (0.81, 1.64) |
| Dominant model – infection outcome | ||||||
| APOL1 haplotype | T.b.g Disease | T.b.g Carriage | Association analysis*T.b.g Disease/Carriage | |||
| Number | % | Number | % | OR [95% CI] | P | |
| G1 Haplotype†,‡ rs73885319 (A>G) + rs60910145 (T>G) | ||||||
| G1 | 36 | 23.4 | 25 | 48.1 | 0.33 [0.17 to 0.64] | 0.0012 |
| Non-G1 | 118 | 76.6 | 27 | 51.9 | ||
| Total | 154 | 100.0 | 52 | 100.0 | ||
| G2 Haplotype‡ rs71785313 (TTATAA>del6) | ||||||
| G2 | 50 | 31.6 | 4 | 7.3 | 5.87 [2.16 to 20.01] | 0.0001 |
| Non-G2 | 108 | 68.4 | 51 | 92.7 | ||
| Total | 158 | 100.0 | 55 | 100.0 |
| Variables | No. of studies | Ala/Ala vs Val/Val | Ala/Ala vs Ala/Val | Ala/Val vs Val/Val | ||||||
| OR (95% CI) | Ph | P | OR (95% CI) | Ph | P | OR (95% CI) | Ph | P | ||
| Total | 51 | 0.870(0.789 0.958) | 0.001 | 0.005 | 0.969(0.923 1.016) | 0.206 | 0.191 | 0.895(0.821 0.976) | 0.021 | 0.012 |
| Asian | 19 | 0.787(0.645 0.961) | 0.017 | 0.019 | 0.929(0.843 1.023) | 0.212 | 0.132 | 0.865(0.753 0.993) | 0.300 | 0.039 |
| Caucasian | 25 | 0.869(0.741 1.020) | 0.040 | 0.319 | 1.004(0.921 1.095) | 0.137 | 0.926 | 0.910(0.778 1.064) | 0.031 | 0.238 |
| Mixed | 7 | 0.925(0.793 1.079) | 0.050 | 0.087 | 0.958(0.898 1.022) | 0.946 | 0.191 | 0.912(0.778 1.068) | 0.050 | 0.253 |
| Variables | No. of studies | Ala/Val + Ala/Val vs Val/Va (dominant) | Ala/Ala vs Ala/Val + Val/Va (recessive) | Ala allele vs Val allele | ||||||
| OR (95% CI) | Ph | P | OR (95% CI) | Ph | P | OR (95% CI) | Ph | P | ||
| Total | 51 | 0.882(0.808 0.963) | 0.004 | 0.005 | 0.944(0.898 0.993) | 0.055 | 0.026 | 0.935(0.887 0.986) | 0.000 | 0.013 |
| Asian | 19 | 0.826(0.703 0.972) | 0.075 | 0.021 | 0.890(0.799 0.991) | 0.043 | 0.034 | 0.877(0.801 0.960) | 0.003 | 0.008 |
| Caucasian | 25 | 0.916(0.790 1.063) | 0.030 | 0.247 | 0.985(0.908 1.069) | 0.141 | 0.720 | 0.883(0.805 0.968) | 0.052 | 0.359 |
| Mixed | 7 | 0.888(0.758 1.041) | 0.029 | 0.144 | 0.946(0.890 1.006) | 0.773 | 0.076 | 0.957(0.838 1.094) | 0.000 | 0.523 |
| Brain regions | MNI coordinate | BA | Clustersize | T-score | ||
| x | y | z | ||||
| F–NF | ||||||
| Medial⋅Superior frontal gyrus | 3 | 33 | 48 | 8 | 17 | 5.23 |
| Lt. middle temporal gyrus | −66 | −39 | −6 | 21 | 28 | 5.21 |
| Lt. middle temporal gyrus | −63 | −36 | 3 | 22 | 4.58 | |
| Lt. inferior frontal gyrus/insula | −39 | 15 | 9 | 45/13 | 17 | 4.81 |
| −30 | 24 | 6 | 45 | 4.64 | ||
| Lt. medial frontal gyrus | −3 | 36 | 48 | 8 | 12 | 4.60 |
| NF–F | ||||||
| No significant activation | ||||||
| E–I | ||||||
| No significant activation | ||||||
| I–E | ||||||
| Rt. inferior parietal lobule | 42 | −54 | 48 | 40 | 10 | 5.02 |
| Rt. superior parietal lobule | 36 | −57 | 54 | 7 | 3.87 | |
| (I_F–I_NF)–(E_F–E_NF) | ||||||
| Rt. superior parietal lobule | 27 | −57 | 45 | 7 | 33 | 4.74 |
| Rt. precuneus | 24 | −72 | 51 | 7 | 3.37 | |
| Lt. fusiform gyrus | −48 | −57 | −15 | 37 | 10 | 4.22 |
| Rt. middle frontal gyrus | 48 | 33 | 18 | 46 | 10 | 3.70 |
| (E_F–E_NF)–(I_F–I_NF) | ||||||
| No significant activation |
| Amino Acid | mg/g Crude Protein | FAO Report mg/g Protein a | AAS |
| histidine | 38.6 ± 2.3 | 16 | 2.41 |
| isoleucine | 54.5 ± 0.0 | 30 | 1.82 |
| leucine | 102.1 ± 0.1 | 61 | 1.67 |
| lysine | 80.2 ± 5.2 | 48 | 1.67 |
| threonine | 44.3 ± 3.2 | 25 | 1.77 |
| tryptophan | 6.0 ± 0.0 | 6.6 | 0.91 |
| valine | 62.4 ± 2.3 | 40 | 1.56 |
| methionine | 6.4 ± 0.1 | - | - |
| cysteine | 24.1 ± 0.0 | - | - |
| SAA | 30.5 | 23 | 1.33 |
| tyrosine | 31.3 ± 1.3 | - | - |
| phenylalanine | 76.9 ± 2.0 | - | - |
| AAA | 108.2 | 41 | 1.88 |
| aspartic acid | 146.1 ± 5.1 | - | - |
| serine | 68.5 ± 3.5 | - | - |
| glutamic acid | 209.5 ± 4.3 | - | - |
| proline | 53.6 ± 1.7 | - | - |
| glycine | 46.5 ± 3.4 | - | - |
| alanine | 51.4 ± 1.4 | - | - |
| arginine | 74.8 ± 6.0 | - | - |
| AAS | 0.91 | - | - |
| Limiting amino acid | tryptophan | - | - |
| Name | Company | Catalog number | Antibody concentration |
| DAB2IP | Abcam | ab87811 | 1 : 1000 or 1 : 200 |
| E-cadherin | Cell Signaling Technology | 3195 | 1 : 500 |
| Vimentin | Cell Signaling Technology | 5741 | 1 : 500 |
| p-ERK1/2 | Cell Signaling Technology | 4370 | 1 : 1000 |
| ERK1/2 | Cell Signaling Technology | 4695 | 1 : 1000 |
| GAPDH | Beyotime | AG019 | 1 : 2000 |
| α-tubulin | Sigma-Aldrich | T6199 | 1 : 2000 |
| Intentions * | Male (n) | Female (n) | |||||||||
| 5 | 4 | 3 | 2 | 1 | 5 | 4 | 3 | 2 | 1 | p | |
| After the delivery, I would not try to establish breastfeeding. I would bottle-feed my child with formula milk. | 0 | 1 | 4 | 13 | 25 | 0 | 3 | 5 | 18 | 85 | / |
| I would breastfeed my child even if the child’s father does not support my decision to breastfeed. | 17 | 19 | 5 | 1 | 1 | 67 | 26 | 10 | 6 | 2 | / |
| I would not breastfeed in public, for example in a restaurant or in a park. | 9 | 11 | 9 | 8 | 6 | 27 | 26 | 29 | 19 | 10 | / |
| A child’s mother and father should make a joint decision about breastfeeding. | 17 | 15 | 7 | 3 | 1 | 11 | 30 | 33 | 20 | 17 | 0.000 |
| Returning to work would not make me stop breastfeeding. | 9 | 9 | 23 | 1 | 1 | 40 | 38 | 25 | 5 | 3 | 0.002 |
| I find it acceptable to breastfeed after a child turns one if a child so desires. | 9 | 11 | 11 | 9 | 3 | 17 | 30 | 27 | 24 | 13 | / |
| I would breastfeed my child in accordance with doctors’ recommendations, regardless of close family members’ opinions. | 19 | 18 | 5 | 0 | 1 | 38 | 42 | 21 | 8 | 2 | / |
| I would not breastfeed my child after he/she turns two. | 12 | 13 | 13 | 2 | 3 | 44 | 30 | 27 | 6 | 4 | / |
| Estimate | Standard Error | Chi-Square (df = 1) or t-value | Odds Ratio | 95% Confidence Interval | p-value | |
| W1 drinking predicting stroke | -0.31 | 0.10 | 10.8 | 0.73 | 0.61–0.88 | 0.001 |
| W1 drinking predicting heart disease | -0.2 | 0.08 | 5.8 | 0.82 | 0.69–0.96 | 0.02 |
| W1 drinking predicting diabetes | -0.30 | 0.13 | 5.4 | 0.74 | 0.57–0.95 | 0.02 |
| W1 drinking predicting falls | -0.09 | 0.06 | 2.5 | 0.91 | 0.81–1.02 | 0.12 |
| W1 drinking predicting hip fracture | -0.42 | 0.17 | 5.8 | 0.66 | 0.47–0.92 | 0.02 |
| W1 Drinking predicting % any ADL | -0.22 | 0.05 | 19.9 | 0.80 | 0.73–0.88 | 0.0001 |
| W1 Drinking predicting % any IADL | -0.18 | 0.04 | 17.3 | 0.83 | 0.77–0.91 | 0.0001 |
| W1 drinking predicting total # Chronic Illnesses | -0.03 | 0.01 | -2.6 | --- | --- | 0.01 |
| W1 drinking predicting CES-D | -0.1 | 0.03 | -3.0 | --- | --- | 0.01 |
| W1 drinking predicting TICS-R | 0.17 | 0.08 | 2.14 | --- | --- | 0.03 |
| WNV-L vs. E | CHIKV-L vs. E | ||||||
| Symbol | Entrez gene name | Log2 fold change | P-value | Symbol | Entrez gene name | Log2 fold change | P-value |
| Lcn2 | Lipocalin 2 | 4.87 | 6.81E-10 | Cxcl10 | Chemokine (C-X-C motif) ligand 10 | 5.09 | 4.38E-13 |
| Cxcl9 | Chemokine (C-X-C motif) ligand 9 | 4.80 | 4.46E-11 | Lcn2 | Lipocalin 2 | 4.73 | 4.48E-09 |
| Ubd | Ubiquitin D | 4.76 | 2.59E-17 | Ccl5 | C-C motif chemokine ligand 5 | 4.19 | 4.22E-10 |
| Tnfaip2 | TNF alpha induced protein 2 | 4.71 | 4.00E-13 | Ifi204 | Interferon activated gene 204 | 4.18 | 5.19E-11 |
| Ccl5 | C-C motif chemokine ligand 5 | 4.43 | 3.01E-11 | Gbp2 | Guanylate binding protein 2 | 4.13 | 1.34E-13 |
| Gzmb | Granzyme B | 4.39 | 4.20E-15 | Lilrb4 | Leukocyte immunoglobulin like receptor 4 | 4.12 | 5.84E-11 |
| Slfn12l | Schlafen family member 12 like | 4.07 | 1.39E-08 | Acod1 | Aconitate decarboxylase 1 | 4.08 | 6.77E-12 |
| Ifnb1 | Interferon beta 1 | 3.89 | 9.13E-16 | Cxcl9 | Chemokine (C-X-C motif) ligand 9 | 4.02 | 6.94E-09 |
| Ccl13 | C-C motif chemokine ligand 13 | 3.89 | 1.92E-13 | Ms4a4b | Membrane-spanning 4-domains, subfamily A, member 4B | 3.99 | 3.74E-08 |
| Lilrb4 | Leukocyte immunoglobulin like receptor B4 | 3.89 | 6.82E-11 | Tnfaip2 | TNF alpha induced protein 2 | 3.89 | 1.48E-10 |
| Pol subtype | ||||||||||
| Env subtype | A | B | C | D | F | G | H | 01_AE | 02_AG | UA |
| A-like | 59 | 3 | 1 | 3 | 1 | 71 | 16 | |||
| B | 3 | 1 | 4 | 2 | 2 | |||||
| C | 1 | 62 | 1 | |||||||
| D | 5 | 1 | ||||||||
| F | 6 | |||||||||
| G | 1 | 12 | 5 | 5 | ||||||
| H | 1 | |||||||||
| CRF01AE | 57 | |||||||||
| UA | 2 | 2 | 8 |
| Range | Mean (SD) | |
| Temperature, centigrade | 36–38 | 37 ± 0.5 |
| Systolic blood pressure, mmHg | 100–190 | 140 ± 24 |
| Diastolic blood pressure, mmHg | 60–140 | 86 ± 22 |
| Heart rate | 66–100 | 84 ± 11 |
| Respiratory rate | 14–26 | 18 ± 3 |
| FRR (%) | ||
| User | EEG | Multi-Task |
| 1 | 6.00 | 2.00 |
| 2 | 0.00 | 0.00 |
| 3 | 2.00 | 0.00 |
| 4 | 12.00 | 16.00 |
| 5 | 16.00 | 8.00 |
| 6 | 2.00 | 6.00 |
| 7 | 10.00 | 6.00 |
| 8 | 14.00 | 0.00 |
| 9 | 8.00 | 6.00 |
| 10 | 4.00 | 4.00 |
| 11 | 2.00 | 2.00 |
| 12 | 2.00 | 4.00 |
| 13 | 10.00 | 2.00 |
| 14 | 10.00 | 0.00 |
| 15 | 8.00 | 2.00 |
| Mean (std) | 7.07 (4.95) | 3.87 (4.24) |
| Variables | HOMA-IR quartiles | ||||
| Q1 | Q2 | Q3 | Q4 | p for linear | |
| (<1.13) | (1.13–1.65) | (1.65–2.65) | (>2.65) | trend | |
| Age (years) | 10.3 ± 1.9 | 10.3 ± 1.8 | 10.8 ± 1.6 | 11.4 ± 1.3 | <0.001 |
| Body composition | |||||
| BMI (kg/m2) | 17.3 ± 2.6 | 18.4 ± 2.8 | 19.6 ± 3.2 | 21.4 ± 3.6 | <0.001 |
| Body fat (%) | 7.9 ± 6.5 | 8.6 ± 6.4 | 10.1 ± 6.4 | 16.5 ± 8.2 | <0.001 |
| WC (cm) | 62.5 ± 10.2 | 64.9 ± 10.3 | 69.2 ± 10.6 | 74.5 ± 10.1 | <0.001 |
| Blood pressure | |||||
| SBP (mmHg) | 104.2 ± 14.8 | 106.1 ± 13.0 | 107.4 ± 13.7 | 110.8 ± 15.2 | <0.001 |
| DBP (mmHg) | 63.8 ± 11.0 | 64.1 ± 8.8 | 65.1 ± 8.9 | 66.7 ± 11.8 | <0.001 |
| Metabolic profiles | |||||
| TG (mg/dL) | 70.0 ± 29.9 | 77.9 ± 41.1 | 95.5 ± 50.1 | 110.8 ± 55.2 | <0.001 |
| TC (mg/dL) | 169.3 ± 29.5 | 171.3 ± 29.5 | 173.3 ± 27.8 | 182.7 ± 39.1 | <0.001 |
| HDL-C (mg/dL) | 61.3 ± 13.5 | 58.7 ± 12.6 | 53.8 ± 12.8 | 50.3 ± 11.9 | <0.001 |
| Glucose (mg/dL) | 86.2 ± 8.2 | 90.9 ± 8.6 | 91.6 ± 8.1 | 95.5 ± 10.7 | <0.001 |
| Insulin (μU/mL) | 3.8 ± 1.1 | 6.2 ± 0.9 | 9.3 ± 1.5 | 17.0 ± 6.3 | <0.001 |
| Breeds | MAF ± s.d. | Ho ± s.d. | He ± s.d. | F± s.d. | Ne |
| Valle del Belice | 0.290 ± 0.003 | 0.364 ± 0.126 | 0.379 ± 0.155 | 0.055 ± 0.150 | 369 |
| Comisana | 0.294 ± 0.004 | 0.382 ± 0.129 | 0.382 ± 0.114 | 0.025 ± 0.031 | 400 |
| Pinzirita | 0.301 ± 0.005 | 0.388 ± 0.122 | 0.390 ± 0.108 | 0.016 ± 0.042 | 685 |
| Peg | Coupled Score | Abstract Coupling Score | Function |
| fig|243277.1.peg.316 | 6 | 0.38 | Translation elongation factor Tu |
| fig|243277.1.peg.318 | 39 | 0.65 | Transcription antitermination protein NusG |
| fig|243277.1.peg.319 | 24 | 0.61 | LSU ribosomal protein L11p (L12e) |
| fig|243277.1.peg.320 | 36 | 0.64 | LSU ribosomal protein L1p (L10Ae) |
| fig|243277.1.peg.321 | 11 | 0.58 | LSU ribosomal protein L10p (P0) |
| fig|243277.1.peg.322 | 25 | 0.67 | LSU ribosomal protein L7/L12 (L23e) |
| fig|243277.1.peg.324 | 34 | 0.64 | DNA-directed RNA polymerase beta' subunit |
| fig|243277.1.peg.354 | -1 | 0.42 | SSU ribosomal protein S12p (S23e) |
| fig|243277.1.peg.355 | - | 0.5 | SSU ribosomal protein S7p (S5e) |
| fig|243277.1.peg.4033 | - | 0.35 | Preprotein translocase subunit SecE |
| fig|243277.1.peg.356 | - | 0.27 | Translation elongation factor G |
| Component score | SOFA | MOD |
| Cardiovascular | 56% | 18% |
| Respiratory | 43% | 23% |
| Coagulation | 6% | 4% |
| Renal | 0.5% | 0.5% |
| Hepatic | 1% | 0% |
| Specimens ID | Multiplex | WHO | ||||||
| Flu A | H7 | N9 | RP | Flu A | H7 | N9 | RP | |
| 20130405-5 | 24.26 ± 0.35a | 24.45 ± 0.21 | 25.03 ± 0.3 | 20.83 ± 0.3 | 24.77 ± 0.31 | 25.07 ± 0.15 | 24.85 ± 0.5 | 21.03 ± 0.3 |
| 20130406-32 | 26.43 ± 0.21 | 26.32 ± 0.31 | 26.23 ± 0.36 | 22.48 ± 0.35 | 26.43 ± 0.26 | 25.98 ± 0.15 | 26.52 ± 0.26 | 22.23 ± 0.15 |
| 20130407-69 | 20.15 ± 0.3 | 20.37 ± 0.32 | 20.7 ± 0.4 | 24.23 ± 0.32 | 19.78 ± 0.35 | 20.68 ± 0.36 | 20.07 ± 0.21 | 23.66 ± 0.31 |
| 20130409-92 | 31.33 ± 0.26 | 30.65 ± 0.36 | 31.23 ± 0.32 | 26.72 ± 0.4 | 30.85 ± 0.31 | 31.04 ± 0.5 | 31.2 ± 0.32 | 26.17 ± 0.25 |
| Full study population | Nested case-control samples for different case-control ratios | ||||||
| DVT + | DVT- | Cases | Controls | ||||
| Test results | n = 289 | n = 1006 | n = 289 | 1:1n = 289 | 1:2n = 578 | 1:3n = 867 | 1:4n = 1156 |
| D-dimer test abnormal | 271 (94) | 621 (62) | 271 (94) | 178 (61) | 357 (62) | 535 (62) | 713 (62) |
| Calf difference, cm* | 3.2 (1.7) | 2.1 (1.6) | 3.2 (1.7) | 2.1 (1.6) | 2.1 (1.6) | 2.1 (1.6) | 2.1 (1.6) |
| Age, years* | 61.9 (16.8) | 59.4 (17.7) | 61.9 (16.8) | 59.4 (17.8) | 59.5 (17.8) | 59.4 (17.8) | 59.4 (17.7) |
| Male gender | 137 (47) | 330 (33) | 137 (47) | 94 (33) | 190 (33) | 282 (33) | 380 (33) |
| Plan | Plane | 6 MV Gamma Passing Rate (%) | Plane | 18 MV Gamma Passing Rate (%) |
| I1 Multitarget | Isocenter | 93.9 | Isocenter | 95.9 |
| I2 Mock Prostate | Isocenter | 91.7 | Isocenter | 91.9 |
| I3 Mock H&N | Isocenter | 94.0 | Isocenter | 95.0 |
| I4 Easy C‐Shape | Isocenter | 95.5 | Isocenter | 89.3 |
| 6 MV Mean | 93.8 | 18 MV Mean | 93.3 | |
| 6 MV SD | 1.6 | 18 MV SD | 3.0 | |
| 6 MV CL | 9.3 | 18 MV CL | 12.9 | |
| Overall (6 & 18 MV) Mean | 93.4 | |||
| Overall Standard Deviation | 2.3 | |||
| Overall Confidence Limit | 11.0 |
| Transcription factor family | L1 vs. L2 (transcript) Up-or down-regulated | L1 vs. L3 (transcript) Up-or down-regulated | L2 vs. L3 (transcript) Up-or down-regulated | |||
| Up | Down | Up | Down | Up | Down | |
| AP2 | 1 | 13 | 14 | 0 | 4 | 10 |
| ARF | 12 | 11 | 15 | 10 | 17 | 8 |
| ARR | ||||||
| B-ARR | 12 | 12 | 9 | 15 | 8 | 16 |
| A-ARR | 11 | 1 | 10 | 2 | 4 | 8 |
| AUX/IAA | 6 | 38 | 3 | 41 | 18 | 15 |
| B3 | 4 | 1 | 3 | 2 | 1 | 4 |
| bHLH | 13 | 20 | 11 | 12 | 11 | 20 |
| bZIP | 3 | 7 | 1 | 8 | 3 | 7 |
| BEE | 0 | 3 | 0 | 3 | 0 | 3 |
| Zinc finger | ||||||
| C2H2-type | 3 | 11 | 5 | 9 | 7 | 7 |
| C3HC4-type | 7 | 6 | 7 | 6 | 9 | 3 |
| CCCH-type | 3 | 5 | 4 | 4 | 4 | 4 |
| B-box-type | 1 | 4 | 4 | 1 | 4 | 1 |
| C3H4 type | 2 | 10 | 2 | 10 | 12 | 0 |
| CAMTA | 15 | 5 | 15 | 5 | 13 | 7 |
| ERF | 17 | 30 | 15 | 32 | 16 | 30 |
| GATA | 0 | 9 | 1 | 8 | 4 | 5 |
| GRAS | 5 | 13 | 8 | 10 | 9 | 8 |
| MADS | 2 | 5 | 5 | 2 | 6 | 1 |
| MYB | 18 | 27 | 16 | 29 | 18 | 23 |
| HSP | 3 | 10 | 6 | 9 | 9 | 5 |
| NAC | 16 | 21 | 9 | 28 | 16 | 18 |
| NF-YA | 3 | 1 | 4 | 0 | 2 | 2 |
| NF-YB | 0 | 4 | 1 | 3 | 4 | 0 |
| R2R3-MYB | 0 | 8 | 0 | 8 | 5 | 3 |
| SPL | 4 | 1 | 4 | 1 | 2 | 3 |
| TCP | 4 | 10 | 1 | 13 | 1 | 13 |
| TGA | 1 | 3 | 1 | 3 | 3 | 1 |
| WRKY | 8 | 28 | 9 | 27 | 16 | 19 |
| RDQ Scale | Effect size | Standardized response mean | ||
| Esomeprazole | Placebo | Esomeprazole | Placebo | |
| Heartburn | 2.05 | 0.85 | 1.52 | 0.74 |
| Regurgitation | 1.36 | 0.63 | 1.31 | 0.60 |
| Dyspepsia | 1.05 | 0.56 | 0.99 | 0.57 |
| GERDa | 2.13 | 0.93 | 1.68 | 0.79 |
| Median $ (IQR) | |||
| MostPopular1 | First-linequality-assured ACT | Oral Artemisinin Monotherapy | |
| Benin2 | 0.65 a (0.43, 1.08) N = 462 | 3.24 b (1.94, 5.77) N = 216 | 8.10 (8.07, 10.45) N = 56 |
| DRC | 0.39 a (0.26, 0.52) N = 1, 258 | 1.86 b (1.03, 3.61) N = 252 | 3.23 (2.45, 4.13) N = 956 |
| Madagascar | 0.36 a (0.36, 0.36) N = 1, 847 | 0.14 b (0.10, 0.57) N = 302 | (0 and 7.33) N = 2 |
| Nigeria3 | 0.54 a (0.40, 0.81) N = 4, 061 | 6.40 b (5.05, 6.74) N = 372 | 3.24 (2.70, 3.77) N = 1, 438 |
| Uganda4 | 0.50 a (0.30, 0.75) N = 653 | 4.48 b (2.49, 5.97) N = 81 | 9.55 (7.96, 11.94) N = 229 |
| Zambia | 0.40 a (0.30, 0.61) N = 261 | 9.63 b (3.01, 11.04) N = 83 | 6.74 (5.72, 6.74) N = 16 |
| Subtypes of epilepsy | T. gondiin (%) | Pvalue | Toxocaran (%) | Pvalue |
| Idiopathic | 16/117 (13.67) | 0.8 | 25/117(21.36) | 0.2 |
| Febrile seizure(Special syndrome) | 2/10 (20) | 0/10(0) | ||
| Generalized | 2/14 (14.28) | 3/14 (21.42) |
| Anamnestic and clinicalFeatures of red flags | Sign and symptoms ofSpecific shoulder pain |
| Fever, shivering, changes in body temperature overnight, diaphoresis, nausea, unexplainable sweating overnight, vomiting, sphincteric complaints, diarrhoea, paleness, fatigue, lurching, fainting, exhaustion, excessive and unexplainable weakness, not linked to any physical effort, unexplainable loss of weight, skin rash, unexplainable multiple hematoma, lumps over the body, deformities, inability to lay supine in bed, marked muscle weakness, marked restriction of movement, limb atrophy, local pain and pain during load when age is less than 20 years old and more than 50. | Recent trauma of the shoulder complex, high reactivity of symptoms, pain during the night, limitation of flexion (< 90° both passive and active), apprehension, fear of movement and/or weakness during humeral external rotation. |
| Measure(n=) | HIF-1αH-scoreMean(± sd) | GLUT-1H-scoreMean(± sd) | CA-IXH-scoreMean(± sd) | MVDfrequencyhigh(%) | CK 5/6frequencypositive(%) | VEGF-Apg/mlMean(± sd) | IGF-1ng/mlMean(± sd) |
| Nodal status1 | 0.073 | 0.22 | 0.0068 | 0.65 | 0.10 | 0.40 | 0.77 |
| N0 (12) | 44.38(± 27.08) | 107.08(± 43.47) | 63.65(± 24.79) | 1/12(8.33%) | 1/12(8.33%) | 323.39(± 167.41) | 103.2(± 22.27) |
| N1 (12) | 100.21(± 67.46) | 131.88(± 46.19) | 64.17(± 67.78) | 8/12(66.7%) | 4/12(33.33%) | 370.00(± 189.65) | 109.93(± 35.57) |
| N2 (4) | 93.75(± 47.72) | 99.38(± 42.93) | 38.75(± 7.77) | 2/4(50%) | 0/4(0.0%) | 230.13(± 50.22) | 114.67(± 32.40) |
| Grade1 | 0.0064 | 0.013 | 0.075 | 0.0009 | 0.0069 | 0.15 | 0.29 |
| 1 (5) | 41.5(± 19.57) | 108.50(± 31.60) | 72.5(± 19.04) | 0/5(0.0%) | 0/5(0.0%) | 348.75(± 126.36) | 102.03(± 21.77) |
| 2 (13) | 50.96(± 36.29) | 94.23(± 37.63) | 42.31(± 16.09) | 2/13(15.38%) | 0/13(0.0%) | 401.92(± 209.77) | 119.19(± 34.50) |
| 3 (10) | 124.0(± 58.47) | 149.75(± 42.22) | 77.63(± 72.38) | 9/10(90.0%) | 5/10(50%) | 236.67(± 89.36) | 97.92(± 22.48) |
| ER status1 | 0.18 | 0.046 | 0.052 | 0.038 | 0.18 | 0.14 | 0.075 |
| Negative (5) | 131.50(± 70.83) | 142.0(± 53.19) | 120.50(± 73.56) | 5/5(100%) | 2/5(40%) | 245.98(± 109.29) | 87.49(± 17.57) |
| Positive (23) | 63.15(± 45.72) | 111.09(± 42.43) | 47.23(± 26.94) | 6/23(26.09%) | 3/23(13.04%) | 354.38(± 176.18) | 113.46(± 28.75) |
| PR status1 | 0.15 | 0.024 | 0.018 | 0.013 | 0.059 | 0.069 | 0.074 |
| Negative (6) | 122.08(± 67.42) | 151.25(± 52.70) | 118.13(± 66.05) | 6/6(100%) | 3/6(50%) | 237.44(± 99.96) | 90.77(± 17.66) |
| Positive (22) | 62.61(± 46.72) | 107.16(± 38.92) | 44.54(± 24.22) | 5/22(22.73%) | 2/22(9.09%) | 364.36(± 176.92) | 113.85(± 29.64) |
| ρ | ρ-partial | |
| Baseline disability | 0.46‡ | |
| Age | 0.26‡ | 0.28‡ |
| Somatization | 0.40‡ | 0.23‡ |
| Depression | 0.35‡ | 0.25‡ |
| Time since onset of pain | 0.14† | 0.13† |
| Coping resources | −0.15† | −0.12* |
| Resilience | −0.21‡ | −0.18‡ |
| Gender | 0.02 | 0.08 |
| Primary Rd until progression (n=9) | Primary Rd stopped before progression (n=11) | Primary Rd stopped with progression and restarted (n=5) | Rd induction followed by SCT (n=8) | |
| Age, years, median (range) | 65 (36–70) | 60 (40–78) | 55 (32–75) | 62 (36–73) |
| Prior plasma cell disorder, N | 6 (3 MGUS/SMM; 3 plasmacytoma) | 3 (3 MGUS/SMM) | 3 (2 MGUS/SMM; 1 plasmacytoma) | 3 (1 MGUS/SMM; 2 plasmacytoma) |
| MDE at presentation | Bone, 8Anemia, 1 | Bone, 10Anemia, 1 | Bone, 3Anemia, 1Hypercalcemia, 1 | Bone, 7Anemia, 1 |
| Molecular classification, N | Trisomies, 5t(11;14) 1t(11;14) plus trisomy, 1Isolated del 13, 1Normal/insufficient, 1 | Trisomies, 6t(11;14), 1Not done, 4 | Trisomies, 3Normal/insufficient, 1Not done, 1 | Trisomies, 4Isolated del 13, 2Normal/insufficient, 2 |
| Best response to therapy | CR, 7VGPR, 2 | CR, 9VGPR, 1 PR, 1 | CR, 2VGPR, 2 PR, 1 | CR, 7PR, 1 |
| Variable | Control M (SD) | MCI M (SD) | AD M (SD) | P1 | P* | P* | P* | ||
| Control × MCI | Control × AD | MCI × AD | |||||||
| RAVLT – Immediate recall (A1 to A5) | 46.55 (2.11) | 38.35 (1.52) | 25.45 (1.94) | <0.001 | 0.006 | <0.001 | <0.001 | ||
| Delayed Recall (A7) | 9.53 (0.68) | 6.79 (0.49) | 2.69 (0.62) | <0.001 | 0.004 | <0.001 | <0.001 | ||
| REC | 14.56 (0.54) | 13.04 (0.39) | 10.48 (0.52) | <0.001 | 0.067 | <0.001 | <0.001 | ||
| BNT | 52.84 (1.54) | 49.55 (1.1) | 46.44 (1.41) | 0.012 | 0.237 | 0.009 | 0.234 |
| Input | Membership Function | ||
| RSSI Level | Weak | Medium | Strong |
| Number of Neighbours | Low | Medium | High |
| Distance to each neighbour | Near | Medium | Far |
| Characteristic (N = 148) | Number | Percent |
| Gender | ||
| Female | 126 | 85.1 |
| Grade level | ||
| Freshman | 36 | 24.3 |
| Sophomore | 38 | 25.7 |
| Junior | 39 | 26.4 |
| Senior | 35 | 23.6 |
| Experience of dementia education | ||
| Yes | 63 | 42.6 |
| Average time of Experienced education (n = 63) | ||
| Less than 2 h | 35 | 55.6 |
| More than 2 h | 28 | 44.4 |
| Family member with dementia | ||
| Yes | 24 | 16.2 |
| Experience in caring for persons with dementia | ||
| Yes | 63 | 42.6 |
| Cared for people with dementia during clinical placement | ||
| Yes | 62 | 41.9 |
| Exposure to information on dementia | ||
| Yes | 111 | 75.0 |
| Information sourcesa (n = 111) | ||
| Broadcasting | 64 | 43.2 |
| Educational resources | 64 | 43.2 |
| Internet | 40 | 27.0 |
| Family/relatives | 24 | 16.2 |
| Newspaper | 21 | 14.2 |
| Magazine | 2 | 1.4 |
| Others | 10 | 6.8 |
| Degrees of freedom | 90% | 95% |
| 1 | 2.71 | 3.84 |
| 2 | 4.61 | 5.99 |
| 3 | 6.25 | 7.81 |
| 4 | 7.78 | 9.49 |
| Scale | Factor | N | % |
| SCL-90-R | Without psychopathology > 0.99 | 62 | 44.6 |
| Somatization (SOM) > 0.99 | 47 | 33.8 | |
| Obsessive-compulsive (OC) > 0.99 | 43 | 30.9 | |
| Interpersonal sensitivity (IS) > 0.99 | 19 | 13.7 | |
| Depression (DEP) > 0.99 | 50 | 36.0 | |
| Anxiety (ANX) > 0.99 | 33 | 23.7 | |
| Hostility (HOS) > 0.99 | 28 | 20.1 | |
| Phobic anxiety (PHO) > 0.99 | 18 | 12.9 | |
| Paranoid ideation (PAR) > 0.99 | 23 | 16.5 | |
| Psychoticism (PSY) > 0.99 | 7 | 5.0 | |
| MQ | Vital exhaustion > 18 | 71 | 51.1 |
| Clade | Combined-data and mtDNA | Combined-data and nucDNA | mtDNA and nucDNA |
| Balistid fish | 16% | 24% | 11% |
| Scarine fish | 83% | 63% | 50% |
| Hemiphractid frogs | 64% | 52% | 30% |
| Hylid frogs | 27% | 44% | 13% |
| Plethodon salamanders | 73% | 27% | 23% |
| Phrynosomatid lizards | 37% | 71% | 26% |
| Alcid birds | 91% | 33% | 23% |
| Caprimulgid birds | 53% | 82% | 38% |
| Cotingid birds | 53% | 71% | 35% |
| Dicaeid birds | 80% | 34% | 24% |
| Emydid turtles | 54% | 60% | 37% |
| Cervid mammals | 99% | 37% | 27% |
| Murid rodents (Philippines) | 30% | 63% | 23% |
| Murid rodents (Sahul) | 55% | 96% | 53% |
| Mean | Sd | Median | Iqr | P-value | |
| Sex | |||||
| M | 118.17 | 18.37 | 117.5 | 17 | 0.0326* |
| F | 112.46 | 19.13 | 114 | 20 | |
| University | |||||
| Pavia | 120 | 20.06 | 118 | 16 | 0.0001** |
| Rome Biomedico Campus | 109.77 | 15.81 | 110.5 | 19 | |
| Rome Tor Vergata | 111.70 | 20.81 | 116 | 14 | |
| Education | |||||
| Junior (I – II years) | 112.46 | 14.31 | 114 | 17 | 0.0253* |
| Senior (III year) | 116.18 | 26.59 | 118 | 24 |
| Human region | Avian region | Reference |
| Nucleus accumbens (nAc) | Nucleus accumbens (nAc) | Balint and Csillag (2007), Husband and Shimizu (2011) |
| Ventral tegmental area (VTA) | Ventral tegmental area (VTA) | Bottjer (1993), Reiner et al. (1994) |
| Caudate nucleus | Lateral striatum (LSt) | Karten (1969), Reiner et al. (1998) |
| Hippocampus (Hp) | Hippocampus (Hp) | Erichsen et al. (1991) |
| Medial amygdala (MeA) | Nucleus taeniae of the amygdala (TnA) | Cheng et al. (1999), Reiner and Karten (1985) |
| Prefrontal cortex (PFC) | Caudolateral nidopallium (NCL) | Mogensen and Divac (1982), Waldmann and Güntürkün (1993) |
| 2007 | 2012 | ||||||
| Exposed to the intervention | |||||||
| Never | Once | Twice or more | Total | p* | P** | ||
| (n = 210) | (n = 63) | (n = 180) | |||||
| Knowledge of HIV prevention methods | 38.8% | 59.0% | 71.4% | 79.4% | 68.6% | <10−3 | <10−3 |
| Condom use during the most recent sexual encounter with a sex worker | 35.5% | 40.5% | 68.3% | 78.5% | 60.3% | <10−3 | 0.34 |
| Systematic condom use with a sex worker in the previous 12 months | 12.8% | 10.5% | 19.0 | 35.0 | 21.4% | <10−3 | 0.38 |
| Voluntary HIV testing and counselling in the previous 12 months | 4.3% | 6.7% | 27.0% | 57.8% | 29.6% | <10−3 | 0.20 |
| Knowledge of non-AIDS STI symptoms (men) | 24.6% | 25.7% | 31.7% | 36.7% | 30.7% | 0.02 | 0.75 |
| Knowledge of non-AIDS STI symptoms (women) | 13.4% | 9.5% | 14.3% | 20.0% | 14.2% | 0.03 | 0.15 |
| Knowledge that the results of HIV test would remain confidential | 23.3% | 75.1% | 83.9% | 92.2% | 83.2% | <10−3 | <10−3 |
| Mortality 2003 | Mortality 2010 | Unadjusted HR | Adjusted HR * | Adjusted HR † | |
| N/total (%) | N/total (%) | (95% CI) | (95% CI) | (95% CI) | |
| Total | 333/1624 (20.5) | 488/3809 (12.8) | 0.59 (0.51-0.67) | 0.65 (0.56-0.75) | 0.79 (0.65-0.96) |
| LVEF ≤40% | 277/1379 (20.1) | 408/3141 (13.0) | 0.61 (0.52-0.71) | 0.67 (0.57-0.78) | 0.85 (0.69-1.05) |
| LVEF >40% | 56/245 (22.9) | 79/668 (11.8) | 0.47 (0.31-0.74) | 0.58 (0.40-0.84) | 0.51 (0.30-0.89) |
| Study | Type of study | No. of patients receiving short-term radiotherapy (%) | Experimental group^No of DR/No of patients(%) | Control groupNo of DR/No of patients (%) | P value |
| Nowacki et al. (2004) [4] | Randomized | 78 (40.4) | 10/97(10.3) | 27/96(28.1) | 0.002 |
| Collin et al. (2012) [19] | Randomized | 54 (100.0) | 9/26(34.6) | 14/28(50.0) | 0.467 |
| Present study | Randomized | 162 (100.0) | 9/81(11.1) | 21/81(25.9) | 0.026 |
| Total | – | 294 (72.9) | 28/204(13.7) | 60/205(29.3) | < 0.001 |
| Factor | Coefficient | Z | P |
| Range (native) | 1.122 | 3.16 | 0.0016* |
| Fish (present) | 0.106 | 0.25 | 0.8000 |
| Food Quality (low) | 1.128 | 3.18 | 0.0015* |
| Range*Fish | 0.042 | 0.09 | 0.9300 |
| Range*Food Quality | −1.178 | −2.67 | 0.0075* |
| Fish*Food Quality | −0.988 | −1.88 | 0.0600 |
| Range*Fish*Food Quality | 1.254 | 1.99 | 0.0470* |
| Number of parathyroid glands in resected specimen | P-value | |||||
| Variable | 0 (A) N = 364 | 1(B) N = 80 | 2 or more (C) N = 10 | Total n = 454 | A versus B | B versus C |
| CND | <0.001 | 0.749 | ||||
| None | 118 (32.4%) | 4 (5.0%) | 0 | 122 (26.9%) | ||
| Unilateral | 91 (25.0%) | 13 (16.3%) | 2 (20.0%) | 106 (23.3%) | ||
| Bilateral | 155 (42.6%) | 63 (78.8%) | 8 (80.0%) | 226 (49.8%) | ||
| Retrieved CLN (No) | 5.0 ± 5.5 | 7.4 ± 5.2 | 7.7 ± 2.8 | 5.5 ± 5.5 | < 0.001 | 0.641 |
| Metastatic CLN (No) | 1.2 ± 2.6 | 2.1 ± 3.3 | 2.3 ± 2.8 | 1.4 ± 2.8 | 0.001 | 0.748 |
| Lateral ND | 51/364 (14.0%) | 18/80 (22.5%) | 2/10 (20%) | 71/454 (15.6%) | 0.062 | 0.610 |
| Operation time (minutes) | 162.2 ± 73.7 | 179.1 ± 93.6 | 198.0 ± 142.5 | 166.0 ± 79.6 | 0.218 | 0.651 |
| PTH, preop | 38.35 ± 15.06 | 39.13 ± 14.09 | 34.23 ± 12.37 | 38.38 ± 14.81 | 0.701 | 0.432 |
| PTH, postop 1 day | 14.77 ± 11.82 | 11.71 ± 8.90 | 11.95 ± 11.32 | 14.15 ± 11.32 | 0.062 | 0.716 |
| PTH, postop 1 week | 21.39 ± 13.46 | 18.89 ± 11.12 | 17.07 ± 9.13 | 20.86 ± 13.02 | 0.125 | 0.813 |
| PTH, postop 6 months | 32.54 ± 15.04 | 31.25 ± 15.33 | 26.22 ± 14.87 | 32.11 ± 15.10 | 0.378 | 0.346 |
| Dec. ratio, postop 1 day | 58.65 ± 33.43 | 63.54 ± 35.55 | 67.55 ± 15.98 | 59.74 ± 33.49 | 0177 | 0.722 |
| Dec. ratio, postop 1 week | 40.52 ± 38.23 | 49.45 ± 24.49 | 41.39 ± 38 | 41.39 ± 38.63 | 0.248 | 0.910 |
| Dec. ratio, postop 6 months | 7.09 ± 53.72 | 13.24 ± 50.51 | 21.49 ± 43.53 | 8.71 ± 52.80 | 0.124 | 0.813 |
| Hypoparathyroidism | ||||||
| Temporary | 194/364 (53.3%) | 53/80 (66.3%) | 7/10 (70%) | 254 (55.9%) | 0.010 | 0.697 |
| Permanent | 13/364 (3.6%) | 6/80 (7.5%) | 1/10 (10%) | 20 (4.4%) | 0.128 | 0.575 |
| IV calcium administration | 27/364 (7.4%) | 10/80 (12.5%) | 3/10 (30%) | 40/454 (8.8%) | 0.177 | 0.155 |
| Vocal cord paralysis | 0.787 | 0.093 | ||||
| None | 351 (96.2%) | 77 (96.3%) | 8 (80%) | 436 (96.0%) | ||
| Temporary | 12 (3.3%) | 3 (3.8%) | 2 (20%) | 17 (3.7%) | ||
| Permanent | 1 (0.3%) | 0 | 0 | 1 (0.2%) | ||
| Hematoma | 15/364 (4.1%) | 4/80 (5%) | 0 | 19/454 (4.2%) | 0.760 | 0.619 |
| EGFR/ACTB (cutoff 0.05) | EFEMP1/ACTB (cutoff 0.06) | |||||
| All gliomasa | All gliomas | GBM(95 pts, 88 died) | AA(36 pts, 23 died) | OT(35 pts, 18 died) | ||
| 1.0 (0.7, 1.4) | P = 0.85 | 0.6 (0.4, 1.0) | P = 0.037 | 0.7 (0.4, 1.1) | 1.0 (0.4, 2.3) | 2.4 (0.5, 11) |
| Carbon source | Dry weight of mycelial mat (mg/flask) | Protein content (mg/ml) | Cellulase | ||
| aFPase (FPU/ml) | bCMCase (U/ml) | cΒ-glucosidase (U/ml) | |||
| Sarbose | 420 | 2.17 | 3.53 | 8.23 | 1.16 |
| Maltose | 369 | 2.37 | 8.24 | 10.35 | 1.67 |
| Sucrose | 275 | 2.05 | 5.40 | 13.18 | 1.87 |
| Lactose | 497 | 2.78 | 9.12 | 24.70 | 2.32 |
| Dextrose | 412 | 2.45 | 5.18 | 10.35 | 1.04 |
| Galactose | 445 | 2.12 | 6.82 | 14.35 | 2.01 |
| Cellobiose | 338 | 1.92 | -nd- | 14.12 | 1.46 |
| CMC | 529 | 1.97 | 4.71 | 18.82 | 1.95 |
| Control | 378 | 2.28 | 5.99 | 11.99 | 1.98 |
| Source | WT categories | Sample size | HR (95%CI) | |
| OS | DFS/RFS/EFS | |||
| Pronzato et al. [13] 1989 | ≤35 days | 116 | Reference | − |
| >35 days | 113 | 2.61 (1.26−5.39) | ||
| Colleoni et al. [30] 2000 | <21 days | 599 | − | 0.88 (0.76−1.03) |
| ≥21 days | 1,189 | Reference | ||
| Kerbrat, et al. [31] 2005 | < 28 days | 1,614 | − | 0.85 (0.65−1.05) |
| 28–42 days | 883 | Reference | ||
| >42 days | 105 | |||
| Cold et al. [8] 2005 (I) | 1–3 wks | 58 | Reference | − |
| 3–4 wks | 92 | 0.929 (0.441−1.957) | ||
| 4–5 wks | 75 | 1.549 (0.761−3.149) | ||
| 5–13 wks | 127 | 1.588 (0.856−2.948) | ||
| Cold et al. [8] 2005 (II) | 1–3 wks | 1,509 | Reference | − |
| 3–4 wks | 1,581 | 1.021 (0.903−1.155) | ||
| 4–5 wks | 1,423 | 0.890 (0.782−1.012) | ||
| 5–13 wks | 1,552 | 1.002 (0.884−1.136) | ||
| Cold et al. [8] 2005 (III) | 1–3 wks | 188 | Reference | − |
| 3–4 wks | 305 | 1.218 (0.800−1.854) | ||
| 4–5 wks | 263 | 1.045 (0.716−1.525) | ||
| 5–13 wks | 328 | 1.238 (0.861−1.782) | ||
| Hershman et al. [18] 2006 | <1 month | 2,361 | Reference | − |
| 1–2 months | 1,846 | 1.00 (0.88−1.14) | ||
| 2–3 months | 323 | 1.08 (0.85−1.36) | ||
| >3 months | 477 | 1.46 (1.21−1.75) | ||
| Lohrisch et al. [16] 2006 | ≤4 wks | 993 | Reference | − |
| 4–8 wks | 1,272 | |||
| 8–12 wks | 217 | |||
| 12–24 wks | 112 | 1.6 (1.2−2.3) | ||
| Nurgalieva et al. [19] 2013 | ≤3 months | 12,748 | Reference | − |
| >3 months | 1,632 | 1.53 (1.32– 1.80) | ||
| Downing et al. [15] 2014 (I) | ≤3 wks | 557 | Reference | − |
| 3–6wks | 3,253 | 0.90 (0.73−1.12) | ||
| 6–10wks | 1,897 | 0.88 (0.70−1.10) | ||
| >10wks | 393 | 1.49 (1.13−1.95) | ||
| Downing et al. [15] 2014 (II) | ≤3 wks | 1,186 | Reference | − |
| 3–6wks | 2,279 | 1.00 (0.85−1.18) | ||
| 6–10wks | 652 | 1.10 (0.88−1.37) | ||
| >10wks | 149 | 1.16 (0.80−1.67) | ||
| Gagliato et al. [14] 2014 | ≤30 days | 2,716 | Reference | Reference |
| 31–60 days | 2,994 | 1.05 (0.94– 1.18) | 1.04 (0.94−1.14) | |
| ≥61 days | 1,117 | 1.19 (1.02– 1.38) | 1.10 (0.97−1.25) | |
| Farolfi et al. [12] 2015 | ≤7 wks | 818 | Reference | Reference |
| >7 wks | 103 | 1.14 (0.96–1.34) | 1.15 (1.02–1.30) | |
| chavez et al. [17] 2015 | ≤30 days | 5,224 | Reference | − |
| 31–60 days | 12,432 | 0.98 (0.87–1.09) | ||
| 61–90 days | 4,765 | 1.01 (0.88–1.16) | ||
| ≥91 days | 2,422 | 1.34 (1.15–1.57) | ||
| Ke-Da et al. [11] 2016 | 0–4 wks | 871 | Reference | Reference |
| 4–8 wks | 446 | 1.43 (0.94−2.19 ) | 1.14 (0.83–1.56) | |
| >8 wks | 91 | 2.02 (1.10– 3.71) | 1.86 (1.19–2.90) |
| Difficulty | SE | Classified groups for DIF | MNSQ | |||||
| Logits | Logits | Gender | Education | Age | Disease | Outfit | Infit | |
| Interpersonal skills | ||||||||
| 2 | 0.27 | 0.10 | 0.05 | 0.08 | 0.36 | 0.63* | 1.05 | 1.05 |
| 4 | 0.17 | 0.11 | 0.00 | 0.04 | 0.50 | 0.35 | 0.82 | 0.80 |
| 3 | -0.01 | 0.10 | 0.06 | 0.01 | 1.46* | 0.38 | 1.11 | 1.09 |
| 1 | -0.11 | 0.10 | 0.06 | 0.08 | 0.95* | 0.34 | 0.98 | 1.01 |
| 5 | -0.52 | 0.10 | 0.04 | 0.08 | 0.70* | 0.34 | 0.85 | 0.85 |
| Communication of information | ||||||||
| 9 | 0.51 | 0.10 | 0.10 | 0.08 | 0.73* | 0.14 | 0.81 | 0.84 |
| 8 | 0.22 | 0.10 | 0.08 | 0.13 | 1.09* | 0.44 | 0.90 | 0.86 |
| 6 | 0.01 | 0.10 | 0.13 | 0.05 | 0.60* | 0.15 | 0.95 | 0.90 |
| 7 | 0.00 | 0.10 | 0.08 | 0.06 | 0.33 | 0.36 | 0.88 | 0.84 |
| Patient engagement and enablement | ||||||||
| 9 | 0.52 | 0.10 | 0.06 | 0.03 | 0.76* | 0.50 | 1.24 | 1.24 |
| 6 | 0.3 | 0.10 | 0.06 | 0.09 | 0.74* | 0.75* | 0.83 | 0.80 |
| 7 | 0.1 | 0.10 | 0.04 | 0.04 | 0.57* | 0.34 | 1.05 | 1.10 |
| 15 | 0.03 | 0.10 | 0.04 | 0.17 | 1.25* | 0.65* | 1.18 | 1.11 |
| 16 | -0.13 | 0.10 | 0.24 | 0.09 | 0.54* | 0.31 | 0.76 | 0.69 |
| 14 | -0.21 | 0.10 | 0.23 | 0.19 | 1.07* | 0.77* | 1.30 | 1.22 |
| 8 | -0.3 | 0.10 | 0.00 | 0.12 | 0.36 | 0.19 | 1.00 | 0.89 |
| Overall satisfaction | ||||||||
| 19 | -0.06 | 0.10 | 0.11 | 0.10 | 0.47 | 0.24 | 1.22 | 1.10 |
| 17 | -0.26 | 0.10 | 0.14 | 0.02 | 0.80* | 0.33 | 1.04 | 1.10 |
| 18 | -0.69 | 0.11 | 0.09 | 0.05 | 0.37 | 0.59* | 0.83 | 0.76 |
| Technical competence | ||||||||
| 21 | 0.27 | 0.10 | 0.08 | 0.08 | 0.84* | 0.59* | 1.14 | 1.12 |
| 20 | -0.13 | 0.10 | 0.03 | 0.05 | 0.21 | 0.85* | 1.02 | 0.95 |
| MEAN | 0.00 | 0.10 | 0.08 | 0.08 | 0.70 | 0.44 | 1.00 | 0.97 |
| S.D. | 0.30 | 0.00 | 0.06 | 0.05 | 0.33 | 0.21 | 0.16 | 0.15 |
| Study groups | No. tested/no. (%) seropositive | ||
| Females | Males | Total | |
| KNP employees with outdoor activity | 5/2 (40) | 23/12 (52.2) | 28/14 (50.0) |
| KNP employees with indoor activity | 18/0 (0.0) | 14/7 (50.0) | 32/7 (21.9) |
| Subtotal | 23/2 (8.7) | 37/19 (51.4) | 60/21 (35.0) |
| Recreational group | 9/2 (22.2) | 5/0 (0.0) | 14/2 (14.3) |
| Total | 32/4 (12.5) | 42/19 (45.2) | 74/23 (31.1) |
| Control groupa | 8/1 (12.0) | 22/3 (13.6) | 30/4 (13.3) |
| Thyroid lesions simulating a squamoid pattern | Differential features |
| Pure squamous cells carcinoma | (i) Entirely composed of squamous cells; (ii) no evidence of another type of thyroid carcinoma in close proximity. |
| Primary head and neck squamous cell carcinoma | (i) Presence of in situ component in head and neck structures;(ii) features of “ab extrinseco” involvement of thyroid parenchyma; (iii) PAX8 is consistently negative. |
| Metastatic squamous cell carcinoma of the lung | (i) Presence of a lung nodule clinically detected;(ii) PAX8 is consistently negative. |
| Diffuse sclerosing variant of papillary thyroid carcinoma | (i) Abundant psammoma bodies;(ii) neoplastic cells retain nuclear features of PTC;(iii) immunoreactivity for thyroglobulin. |
| Mucoepidermoid carcinoma | (i) Combination of squamoid and mucinous components; (ii) thought to represent papillary carcinoma with extreme degree of squamous and mucinous metaplasia; (iii) low grade thyroid neoplasm. |
| Sclerosing mucoepidermoid carcinoma with eosinophilia | (i) Fibrohyaline stroma;(ii) striking infiltration of eosinophils; (iii) mucin secretion is often present; (iv) typically arising in Hashimoto thyroiditis (thought to derive from metaplastic squamous nests associated with inflammatory infiltrate). |
| CASTLE(carcinoma with thymus-like elements) | (i) Lymphoepithelioma-like carcinoma with foci of squamous differentiation; (ii) pushing margins; (iii) immunoreactivity for CD5, bcl-2, high molecular weight keratin, mcl-1 (thought to be ectopic thymic carcinoma arising from remnants of the branchial pouch); (iv) usually indolent behavior with tendency to late recurrences. |
| Terms of Delivery | Trichomonas vaginalis infection | P-value | |||
| Study group (positive cases) | Control group (negative cases) | ||||
| No. | (%) | No. | (%) | ||
| Preterm birth | 19 | (54.28) | 36 | (13.58) | 0.001 |
| Full term birth | 14 | (40) | 216 | (81.5) | 0.001 |
| Post term birth | 2 | (5.7) | 13 | (4.9) | 0.83 |
| Total | 35 | (100) | 265 | (100) |
| Assumptions | Projected reduction in diabetes prevalence compared to no intervention | |||
| Moderate-risk [millions] | High-risk [millions] | Population [millions] | Combined [millions] | |
| Base case assumptions: | ||||
| Flat background diabetes incidence rate* | 1.2 [3.1] | 0.5 [1.2] | 0.3 [0.7] | 1.4 [3.6] |
| Lifestyle intervention will reduce yearly diabetes incidence rate by 12.5% in target population | ||||
| Population-wide intervention will reduce the yearly diabetes incidence rate by 2% among all US adults | ||||
| Adjustments to base case assumptions | ||||
| Increasing background incidence rate* | 1.4 [3.7] | 0.5 [1.4] | 0.3 [0.8] | 1.6 [4.2] |
| Lifestyle intervention will reduce yearly diabetes incidence rate by 25% in target population | 2.5 [6.4] | 1.0 [2.6] | 0.3 [0.7] | 2.7 [6.9] |
| Lifestyle intervention will reduce yearly diabetes incidence rate by 6.25% in target population | 0.6 [1.5] | 0.3 [0.6] | 0.3 [0.7] | 0.8 [2.0] |
| Population-wide intervention will reduce yearly diabetes incidence rate by 1% among all US adults | 1.2 [3.1] | 0.5 [1.2] | 0.2 [0.3] | 1.1 [2.8] |
| Population-wide intervention will reduce yearly diabetes incidence rate by 4% among all US adults | 1.2 [3.1] | 0.5 [1.2] | 0.6 [1.4] | 1.6 [4.0] |
| Coefficient (95%CI of coefficient) | P-value | ||
| Axial length (mm) | Age (years) | −0.007 (−0.012 to −0.003) | <0.001 |
| Sex (male/female) | 0.111 (0.035 to 0.186) | 0.004 | |
| Education (Each year in school) | 0.011 (0.005 to 0.016) | <0.001 | |
| Height (cm) | 0.025 (0.021 to 0.029) | <0.001 | |
| Weight (Kg) | 0.005 (0.003 to 0.007) | <0.001 | |
| Anterior Chamber depth (mm) | Age (years) | −0.013 (−0.014 to −0.012) | <0.001 |
| Sex (male/female) | 0.038 (0.012 to 0.064) | 0.004 | |
| Education (Each year in school) | 0.004 (0.002 to 0.005) | <0.001 | |
| Height (cm) | 0.003 (0.002 to 0.004) | <0.001 | |
| Weight (Kg) | 0.002 (0.002 to 0.003) | <0.001 | |
| Lens thickness (mm) | Age (years) | 0.018 (0.017 to 0.019) | <0.001 |
| Sex (male/female) | 0.026 (0.01 to 0.043) | <0.001 | |
| Education (Each year in school) | −0.002 (−0.004 to −0.001) | 0.005 | |
| Height (cm) | NS | ||
| Weight (Kg) | −0.001 (−0.002 to −0.001) | <0.001 | |
| Vitreous chamber depth (mm) | Age (years) | −0.011 (−0.015 to −0.007) | <0.001 |
| Sex (male/female) | NS | ||
| Education (Each year in school) | 0.009 (0.004 to −0.014) | <0.001 | |
| Height (cm) | 0.023 (0.021 to −0.026) | <0.001 | |
| Weight (Kg) | 0.004 (0.001 to −0.006) | <0.001 |
| Target head angle (degrees) | |||||||
| −80 | −60 | −40 | −20 | 0 | 20 | 40 | |
| Pitch experiment | |||||||
| Qualitative descriptions | 11 | 12 | 12 | 11 | 12 | 11 | 12 |
| Switch‐press measures | |||||||
| DI, MV, PV, D | 8 | 8 | 12 | 10 | 12 | 11 | 11 |
| OF, in‐phase | 7 | 3 | 10 | 9 | 10 | 2 | 4 |
| OF, out‐phase | 5 | 3 | 7 | 7 | 8 | 3 | 2 |
| Roll experiment | |||||||
| Qualitative descriptions | N/A | N/A | 10 | 11 | 11 | 11 | 10 |
| Switch‐press measures | |||||||
| DI, MV, PV, D | N/A | N/A | 10 | 11 | 11 | 11 | 10 |
| OF, in‐phase | N/A | N/A | 8 | 8 | 10 | 8 | 4 |
| OF, out‐phase | N/A | N/A | 5 | 7 | 8 | 8 | 6 |
| Ofloxacin | Injectable drugs | TotalResistance to either Fluoroquinolone or injectable drugsN (%) | ||
| OfloxacinR, n (%) | KanamycinR, n (%) | CapreomycinR, n (%) | ||
| New MDR patients (n = 5) | 0 (0) | 0 (0) | 0 | 0 (0) |
| Previously treated MDR patients (n = 33) | 1 (3) | 1 (3) | 5 (15.2) | 7 (21.2) |
| Total | 1 | 1 | 5 | 7 (18.4) |
| Ectoparasite | Postlactating females | Nonreproductive females |
| (n = 17) | (n = 97) | |
| Spinturnix americanus | 41.2%, 0.5 (0.7, 0–2) | 38%, 0.7 (1.2, 0–5) |
| Myodopsylla insignis | 47.1%, 1.1 (1.6, 0–5) | 32%, 0.7 (1.3, 0–7) |
| Macronyssus crosbyi | 0 | 7.2%, 0.1 (0.3, 0–2) |
| Cimex adjunctus | 0 | 0 |
| Androlaeps casalis | 0 | 1%, 0.02 (0.2, 0–2) |
| Acanthophthirius spp. | 0 | 1%, 0.02 (0.2, 0–2) |
| Any ectoparasite | 76.5%, 1.6 (1.4, 0–5) | 66%, 1.5 (1.7, 0–5) |
| Finding | Illustrating data |
| Localized changes, with minimal impact on wider clinical systems or resource-allocation decisions, may be sustained relatively easily | Case D: ‘The long term viability is very, very strong, it's viewed as an essential service, the patients need to be seen by a [clinical specialist in the mainstream clinical area] and they need to be seen by a geneticist, so they either come to our clinic or they get pushed back into the existing clinics. [...] I think we're probably pretty cost neutral for the trust, the activity we're doing is probably no different to what would be happening in the clinic and we're probably a little bit more economically efficient I would guess’. (Mainstream consultant clinical specialist) |
| Where impact on wider clinical systems and resource-allocation decisions is present, embedding the organizational innovation into the wider clinical system may secure its sustainability | Case C: ‘We've got an established service that everyone knows about, and the route for all these patients is through [Case C service], so there isn't any gynaecologist messing around—in my view, that's what I would have called it, they'd be messing around with patients who had been referred by their GP. Now these patients are all passed through [the service] before they come to gynaecology. So they may still come [to me], but they come with expert information upfront about the risk and the options that they've got available’. (Gynaecological oncologist in referring department) |
| ‘In the end [our case to the commissioners] was more, ‘If you don't fund this there's going to be a great black hole that no-one can pick up’. I think that's how it was funded in the end’. (Lead nurse) | |
| Services that are not embedded into the wider system may be seen as supplementary rather than as a core part of provision, and are more vulnerable to decommissioning | Case B: ‘The money wasn't there, there wasn't identified any money, but I think there's also that it wasn't priority for the Primary Care Trust, nobody had any targets to reach for genetics, there was no ‘must dos’ about genetics and so it was easy for it to slip down the radar. [...] The priorities were the national priorities to do with waiting times, with, cancer, for heart disease, for prevention, so there were quite a large number of priorities for any Primary Care Trust, we didn't have unusual priorities other than the national priorities in health. And there were so many, there still are, but there were so many it's quite hard to do anything other than to meet the priorities’. (PCT former senior clinical manager) |
| No. | Themes | OSPE | OSCE | Frequency | Total |
| 1. | Curriculum | ||||
| Syllabus | + | ++ | 3 | 7 | |
| Repetition | +++ | + | 4 | ||
| 2. | Skills assessment | ||||
| Practical/clinical skills | ++ | +++ | 5 | 12 | |
| Concepts | +++ | + | 4 | ||
| Competence | ++ | + | 3 | ||
| 3. | Confidence | ||||
| Confidence | ++ | + | 3 | 6 | |
| Comfort | ++ | + | 3 | ||
| 4. | Fairness of exam | ++ | ++ | 4 | 4 |
| 5. | Impact on learning | ||||
| Improved learning | + | + | 2 | 5 | |
| Future learning | + | ++ | 3 | ||
| 6. | Stress | ||||
| Stress | ++++ | ++++ | 8 | 17 | |
| Time | ++++++ | +++ | 9 | ||
| 7. | Organisation of exam | ++ | ++ | 4 | 4 |
| 8. | Examiners’ calibration | +++ | ++++++++ | 8 | 11 |
| Intention to treat | Modified intention to treat | |||||
| Antibiotic treatmentn = 22 | No antibiotic treatmentn = 36 | P value | Antibiotic treatmentn = 18 | No antibiotic treatmentn = 26 | P value | |
| Tracheostomy | 5 (22) | 5 (13) | >0.999 | 5 (27) | 5 (19) | 0.716 |
| Corticosteroid use | 8 (36) | 19 (52) | 0.283 | 6 (33) | 13 (50) | 0.359 |
| Septic shock | 1 (4) | 7 (19) | 0.134 | 1 (5) | 5 (19) | 0.375 |
| ICU-acquired infections other than VAT and VAPa | 7 (31) | 18 (50) | 0.274 | 6 (33) | 13 (50) | 0.359 |
| Bacteremia | 6 (27) | 13 (36) | 0.572 | 5 (27) | 8 (30) | >0.999 |
| Urinary tract infection | 2 (9) | 5 (13) | 0.698 | 2 (11) | 5 (19) | 0.682 |
| Others | 2 (9) | 2 (5) | >0.999 | 2 (11) | 2 (7) | >0.999 |
| Total duration of antibiotic treatment, days | 25 ± 14 | 19 ± 15 | 0.149 | 24 ± 15 | 17 ± 15 | 0.104 |
| Antibiotic treatment before VAT | 18 (81) | 29 (80) | >0.999 | 15 (83) | 23 (88) | 0.676 |
| Antibiotic treatment during the 8 days following random assignment | 22 (100) | 21 (58) | <0.001 | 18 (100) | 10 (38) | <0.001 |
| Reasons for antibiotic treatment during the 8 days following random assignment | ||||||
| VAT | 22 (100) | 0 (0) | <0.001 | 18 (100) | 0 (0) | <0.001 |
| VAP | 0 (0) | 15 (41) | <0.001 | 0 (0) | 10 (38) | 0.003 |
| Other infections | 0 (0) | 6 (16) | 0.073 | 0 (0) | 0 (0) | NA |
| Antibiotic treatment after day 8 post-random assignment | 6 (27) | 8 (22) | 0.756 | 3 (16) | 5 (19) | >0.999 |
| Site | Ever smoked cigarettes, even one or two puffs | Ever smokers who initiated smoking before age 10 | Never smokers susceptible to initiate smoking in the next year |
| Huancayo, 2000 | 47.1 (40.9–53.5) (n = 963) | 18.1 (13.6–23.6) (n = 429) | 29.7 (24.8–35.1) (n = 495) |
| Lima, 2000 | 54.6 (49.5–59.6) (n = 1,189) | 13.5 (11.1–16.4) (n = 605) | 25.4 (20.6–31.0) (n = 545) |
| Tarapoto, 2000 | 42.5 (35.6–49.8) (n = 750) | 10.9 (7.6–15.3) (n = 305) | 19.2 (15.5–23.6) (n = 416) |
| Trujillo, 2000 | 46.5 (38.7–54.5) (n = 1,005) | 12.3 (9.1–16.4) (n = 429) | 25.5 (19.7–32.2) (n = 553) |
| Huancayo, 2003 | 58.6 (52.9–64.1) (n = 966) | 11.6 (8.4–15.7) (n = 550) | 25.8 (22.0–29.9) (n = 384) |
| Lima, 2003 | 59.6 (52.9–66.0) (n = 998) | 13.6 (10.2–17.8) (n = 587) | 30.5 (24.2–37.8) (n = 388) |
| Tarapoto, 2003 | 48.7 (43.5–54.0) (n = 1,082) | 8.3 (5.9–11.6) (n = 505) | 19.6 (15.6–24.4) (n = 554) |
| Trujillo, 2003 | 44.5 (39.0–50.2) (n = 1,305) | 13.1 (9.6–17.7) (n = 585) | 22.7 (20.8–24.7) (n = 697) |
| Response rate | NR | |||
| Prosody+ | Prosody− | Prosody+ | Prosody− | |
| Healthy controls (CI 95%) | 96 ± 4 (94, 98) | 84 ± 7 (81, 87) | 3 ± 4(2, 2) | 10 ± 7(7, 14) |
| Patients with schizophrenia (CI 95%) | 78 ± 16 (70, 86) | 58 ± 19 (49, 67) | 22 ± 17 (14, 30) | 37 ± 20 (28, 47) |
| Clinical trials | Interventions | URL |
| 124I-Metaiodobenzylguanidine (MIBG) PET/CT Diagnostic Imaging and Dosimetry for Patients With Neuroblastoma: A Pilot Study | Radiation: 124I-MIBG (no-carrier added)Radiation: 124I-MIBG (carrier added) | https://ClinicalTrials.gov/show/NCT01583842 |
| European Low and Intermediate Risk Neuroblastoma Protocol (low and intermediate pediatric NB and neonatal suprarenal masses) | Drug: chemotherapy | https://ClinicalTrials.gov/show/NCT01728155 |
| Phase II Study of Proton Radiation Therapy for Neuroblastoma | Radiation: proton beam radiation therapy | https://ClinicalTrials.gov/show/NCT02112617 |
| Immunomonitoring of Children With Neuroblastoma | Immunological analyses | https://ClinicalTrials.gov/show/NCT01295762 |
| Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma | Biological: adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH | https://ClinicalTrials.gov/show/NCT00911560 |
| Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma | Laboratory biomarker analysis; cytology specimen collection procedure | https://ClinicalTrials.gov/show/NCT00904241 |
| Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma | Drug: dasatinibDrug: rapamycinDrug: irinotecanDrug: temozolomideDrug: irinotecanDrug: temozolomide | https://ClinicalTrials.gov/show/NCT01467986 |
| Study of DNA in Blood Samples From Patients With Neuroblastoma | Laboratory biomarker analysisGenetic: polymerase chain reactionGenetic: polyacrylamide gel electrophoresisGenetic: DNA analysis | https://ClinicalTrials.gov/show/NCT00898391 |
| Monitor Response to Treatment in Neuroblastoma Using 3&Apos;-Deoxy-3&Apos;-Fluorothymidine-Positron Emission Tomography (FLT-PET) | Device: FLT-PET | https://ClinicalTrials.gov/show/NCT01308905 |
| Expanded Access Study of Fenretinide Lym-X-Sorb Plus Ketoconazole in Neuroblastoma | Drug: fenretinide Lym-X-Sorb oral powderDrug: ketoconazole | https://ClinicalTrials.gov/show/NCT02075177 |
| Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults with Neuroblastoma and Osteosarcoma | Biological: IL-2Biological: GD2Bi-aATCBiological: GM-CSFOther: laboratory evaluations of immune responses | https://ClinicalTrials.gov/show/NCT02100930 |
| Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma | Biological: anti-GD2 3F8 monoclonal antibodyDrug: GM-CSF (granulocyte-macrophage colony-stimulating factor)Drug: oral isotretinoin | https://ClinicalTrials.gov/show/NCT02100930 |
| Fenretinide Lym-X-Sorb+Ketoconazole+Vincristine for Recurrent or Resistant Neuroblastoma | Drug: fenretinide/LXS oral powderDrug: ketoconazoleDrug: vincristine | https://ClinicalTrials.gov/show/NCT02163356 |
| Pilot Study of Activated T-Cell Therapy for Refractory/Relapsed Neuroblastoma | Biological: activated T lymphocyte | https://ClinicalTrials.gov/show/NCT01802138 |
| 3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN | Genetic: iC9-GD2 T-cell lymphocytes – frozen cellsGenetic: iC9-GD2 T-cell lymphocytes – fresh cellsDrug: cyclophosphamideDrug: fludarabineDrug: pembrolizumab | https://ClinicalTrials.gov/show/NCT01822652 |
| Capacity areas/skills for HPSR+A | Proportion of staff requiring additional training (n = 123), n (%) |
| HPSR+A technical skills and conceptual underpinnings, | |
| e.g. what is HPSR+A and what constitutes HPSR+A approaches to research and teaching | 101 (82.0) |
| HPSR+A research and writing | |
| Writing research methodologies | 84 (68.0) |
| Writing briefing notes for politicians, policymakers, external funders and donors | |
| 80 (65.0) | |
| Writing papers for academic journals | 78 (63.0) |
| Management and administration | |
| Leadership | 92 (75.0) |
| Effective networking | 94 (76.0) |
| Financial and information management | |
| Identifying and applying for external funding sources | 95 (77.0) |
| Creating and managing effective and efficient financial reporting systems | 91 (74.0) |
| Creating and managing effective internal information systems | 101 (82.0) |
| Variable | n | % | SE (P) |
| Sex | |||
| Male | 207 | 62.9 | 2.67 |
| Female | 121 | 36.8 | 2.66 |
| Age (y) | |||
| <40 | 11 | 3.3 | 0.98 |
| 41–50 | 58 | 17.6 | 2.10 |
| 51–60 | 72 | 22.8 | 2.31 |
| >60 | 158 | 56.2 | 2.74 |
| Marital status | |||
| Single | 14 | 4.3 | 1.12 |
| Married | 264 | 8.2 | 1.51 |
| Other | 16 | 4.8 | 1.18 |
| Unknown | 12 | 3.6 | 1.03 |
| Ethnicity | |||
| Afro-Trinidadian | 80 | 24.3 | 2.36 |
| Indo-Trinidadian | 238 | 72.3 | 2.47 |
| Other (including mixed race) | 11 | 3.3 | 0.98 |
| Highest level of education | |||
| Primary | 213 | 64.7 | 2.63 |
| Secondary | 103 | 31.2 | 2.56 |
| Other | 2 | 0.6 | 0.43 |
| Unknown | 6 | 1.8 | 0.73 |
| Employment status | |||
| Employed | 62 | 18.8 | 2.15 |
| Unemployed | 256 | 77.8 | 2.29 |
| Unknown | 11 | 3.3 | 0.98 |
| Religion | |||
| Hindu | 180 | 54.7 | 2.74 |
| Islam | 27 | 8.2 | 1.51 |
| Christian | 75 | 22.8 | 2.31 |
| Other | 39 | 11.9 | 1.79 |
| Unknown | 8 | 2.4 | 0.84 |
| Variables | Cases | Controls | Adjusted OR ratio | P value |
| No. (%) | No. (%) | (95% Cl) | ||
| Family size (mean 95% Cl) | 5.8(5.3-6.4) | 4.8(4.4-5.1) | 1.359(1.026-1.799) | 0.032 |
| Sleeping on bed | 74(82.2%) | 183(94.8%) | 0.158(0.028-0.898) | 0.037 |
| Ref. ground | 16(17.8%) | 10(5.2%) | 1 | |
| Cracked house wall (Yes) | 60 (66.7%) | 84 (44.4%) | 6.368(1.585-25.580) | 0.009 |
| Ref. (un-cracked) | 30(33.3%) | 105(55.6%) | 1 | |
| Own goats (Yes) | 37(41.1%) | 43(22.3%) | 6.445(1.463-28.384) | 0.014 |
| Ref. (No) | 53(58.9%) | 150(77.7%) | 1 | |
| Sleeping outside the house under bed net | 16(17.8%) | 118(61.1%) | 0.093(0.024-0.357) | 0.001 |
| Ref. (without bed net) | 74(82.2%) | 75(38.9%) | 1 | |
| Smoking house (Yes) | 50(56.2%) | 168(87.0%) | 0.082(0.011-0.630) | 0.016 |
| Ref. (No) | 39(43.8%) | 25(13.0%) | 1 | |
| Number of days stayed in the farm field (mean 95% CL) | 91.3(61.7-120.9) | 8(5.9-10) | 1.100(1.015-1.192) | 0.020 |
| Treatment | Dose mg kg−1 | Cotton pellet granuloma |
| Weight of pellets Mean ± SEM | ||
| Control | 0.3 mL | 51.73 ± 2.35 |
| Indomethacin | 10 | 19.82 ± 2.52 (61.68)b |
| EEDR | 100 | 37.24 ± 2.00 (27.99)NS |
| EEDR | 200 | 30.85 ± 3.72 (40.36)b |
| EEDR | 400 | 29.77 ± 3.76 (42.44)a |
| Characteristic | All | LGE [IQR] | Non-LGE [IQR] | p value |
| (n = 20) | (n = 8) | (n = 12) | ||
| Age (years) | 77 [65-82] | 75 [70-80] | 78 [65-84] | 0.4 |
| Female sex, n (%) | 18 (90%) | 8 (100%) | 10 (83%) | 0.5 |
| Triggering factor (emotional/physical) | 15 (75%) | 7 (88%) | 8 (67%) | 0.6 |
| Chest pain | 18 (90%) | 8 (100%) | 10 (83%) | 0.5 |
| Cardiac event | ||||
| CHF | 3 (15%) | 2 (25%) | 1 (8%) | 0.5 |
| Cardiogenic shock | 3 (15%) | 3 (38%) | 0 (0%) | 0.049* |
| Peak creatine kinase level (IU/L) | 204 [141-223] | 212 [203-243] | 146 [107-221] | 0.09 |
| Serum noradrenaline elevation | 11 (55%) | 4 (50%) | 7 (58%) | 1.0 |
| ECG abnormalities | 20 (100%) | 8 (100%) | 12 (100%) | 1.0 |
| ST elevation | 12 (60%) | 7 (88%) | 5 (42%) | 0.07 |
| ST depression | 2 (10%) | 0 (0%) | 2 (17%) | 0.5 |
| T inversion | 10 (50%) | 2 (25%) | 8 (67%) | 0.2 |
| LVOT obstruction | 1 (5%) | 1 (13%) | 0 (0%) | 0.4 |
| Ejection fraction (LVG) (%) | 49 [45-53] | 49 [44-52] | 49 [47-53] | 0.7 |
| Typical TTC | 11 (55%) | 5 (63%) | 6 (50%) | 0.7 |
| Time from symptom onset to CMR (days) | 5 [3-6] | 5 [3-6] | 4 [3-6] | 0.8 |
| Ejection fraction (CMR) (%) | 51 [45-54] | 50 [43-53] | 51 [50-58] | 0.6 |
| Duration to normalization (days) | ||||
| Electrocardiography | 151 [132-188] | 215 [175-363] | 140 [112-151] | 0.005* |
| Echocardiography | 10 [6-14] | 15 [10-18] | 7 [5-13] | 0.03* |
| Successful Aging Approach | Definition | References |
| Biomedical | Absence of multi-morbidity | [6] |
| Psycho-Cognitive | Absence of depression, absence of anxiety, no cognitive impairment, regular functioning, quality of life, resilience | [3,12,14,38] |
| Lay View Approach | Presence of well-being, good self perceived health | [8,12] |
| Combined Approach | Optimal functioning | [6,12] |
| Country and Year | Criteria used for identifying asymptomatic malaria cases | Study subjects, sample size | Follow-up protocol and duration | Ref. |
| Africa | ||||
| Gabon, 2003 | No clinical symptoms of malaria with a P. falciparum positive blood smear, asymptomatic for at least 5 days during follow-up. | Children6 months to 10 years, N = 60 | Examined once daily for 7 days thereafter, once every 2 days | [37] |
| Tanzania, 2006 | Presence of P. falciparum on blood smear, axillary temperature of < 37.5°C, and no other symptoms or signs of malaria | Children4-59 months,N = 127 | No follow-up. | [33] |
| South America | ||||
| Brazilian Amazon, 2002 | Individuals positive by microscopy, and/or positive by PCR; and individuals negative by microscopy that subsequently became positive by PCR. | All age groups,N = 172 | Follow-up to day 10 and 60. | [21] |
| Colombia, 2008 | Presence of microscopic asexual parasite stages of P. falciparum, P. vivax or P. malariae or of mixed infections in blood, which persisted for at least two weeks without causing any symptoms, or as the detection of parasite DNA by PCR on day 0 in people who remained asymptomatic during the follow-up period. | Individuals2-78 years,N = 21 | Follow-up on days 14 and 28. | [19] |
| Asia | ||||
| Papua, 2003 | No fever history or treatment for malaria within the past week, no clinical evidence of malaria or other infection, no diarrhea, and no current pregnancy but both P. falciparum and P. vivax positive individuals | Adults> 16 years,N = 105 | Supervised overnight at local health center. A third axillary temperature was recorded the following morning. | [38] |
| Indonesia, 2010 | Presence of asexual P. falciparum or P. vivax parasitemia in the absence of fever (temperature ≤ 37.9°C) and of clinical signs or symptoms suggestive for malaria or another infectious disease. | Children5-15 years,N = 381 | No follow-up. | [27] |
| Samples | Inhibition zones ± (mm)1 | |||||
| E. coliCCMB261 | S. aureus CCMB262 | S. aureus CCMB263 | P. aeruginosaCCMB268 | C. albicansCCMB286 | C. parapsilosisCCMB288 | |
| L. alnifolia leaves | R | 10.2 ± 1.3 | 10 ± 0.5 | R | R | R |
| L. alnifolia stems | R | 12.3 ± 1.0 | 13.9 ± 0.8 | R | R | R |
| L. alnifolia flowers | R | 8.4 ± 0.9 | R | R | R | 6.9 ± 0.1 |
| L. origanoides leaves | R | 13.0 ± 0.5 | 12.0 ± 0.9 | R | 11.7 ± 0.4 | 7.1 ± 0.4 |
| L. origanoides stems | R | R | R | R | R | R |
| L. thymoides leaves | R | 11.2 ± 1.0 | 9.7 ± 1.3 | R | R | R |
| L. thymoides stems | R | 8.7 ± 0.6 | R | R | R | R |
| L. thymoides flowers | R | 8.5 ± 1.5 | R | R | R | R |
| Cloramphenicol2 | 15.8 ± 1.7 | 22.6 ± 2.2 | R | 8.5 ± 0.9 | — | — |
| Nystatin3 | — | — | — | — | 17.5 ± 0.9 | 16.6 ± 0.9 |
| Characteristics | n (N = 157) | % | |
| Age | <19 years | 3 | 1.9 |
| 20–24 years | 104 | 66.3 | |
| 25–29 years | 47 | 29.9 | |
| >30 years | 3 | 1.9 | |
| Gender | Male | 67 | 42.7 |
| Female | 88 | 56.1 | |
| Marital status | Divorced | 2 | 1.3 |
| Not Married | 151 | 96.2 | |
| Married | 4 | 2.5 | |
| Educational level | Bachelor degree | 120 | 76.4 |
| Master degree | 14 | 8.9 | |
| Doctor degree | 23 | 14.6 | |
| Work experience in the health sector | <6 months | 52 | 33.1 |
| 6–12 months | 53 | 33.8 | |
| 12–24 months | 44 | 28.0 | |
| 24–36 months | 3 | 1.9 | |
| >36 months | 5 | 3.2 | |
| Hours worked daily | <6 h | 9 | 5.7 |
| 6–8 h | 86 | 54.8 | |
| 8–10 h | 41 | 26.1 | |
| 10–12 h | 18 | 11 | |
| >12 h | 3 | 1.9 | |
| Night shifts/week | <1 | 34 | 21.7 |
| 1 | 71 | 45.2 | |
| >1 | 46 | 29.3 | |
| 0 | 6 | 3.8 | |
| Clinic service visits/week | <5 | 99 | 63.1 |
| 5–9 | 19 | 12.1 | |
| 10–14 | 7 | 4.5 | |
| 15–19 | 6 | 3.8 | |
| >20 | 26 | 16.6 | |
| Discharges/month | <5 | 49 | 31.2 |
| 5–9 | 35 | 22.3 | |
| 10–14 | 24 | 15.3 | |
| 15–19 | 15 | 12.1 | |
| >20 | 30 | 19.1 |
| Neonatal characteristic | Newborn-monotherapy dyadsMean (SE) or n (%) | Newborn-triple therapy dyadsMean (SE) or n (%) | p value |
| Gender | |||
| Male | 45 (53%) | 18 (49%) | NS |
| Gestational age (weeks)∗ | 38 (0.2) | 37 (0.5) | <0.01 |
| Birth weight (g)∗ | 3079 (63) | 2864 (96) | NS |
| Small for gestational age | 18 (21%) | 3 (8%) | NS |
| Toxicology screen | |||
| Positive | 10 (12%) | 23 (62%) | <0.05 |
| NICU admission | 19 (22%) | 20 (54%) | <0.01 |
| Length of stay in hospital (days)∗ | 3 (0.5) | 8 (2) | <0.05 |
| CPS involved | 15 (18%) | 26 (70%) | <0.01 |
| ARV site | Total number of patients |
| Thamaga primary hospital | 1646 |
| Nkoyaphiri clinic | 1726 |
| Gabane clinic | 392 |
| Thamaga clinic | 114 |
| Mmankgodi clinic | 70 |
| Kopong clinic | 200 |
| Mmopane clinic | 120 |
| Total | 4268 |
| Group | No. mice | Vaccine and administration | Anti‐HCV Abs | Days post‐prime | ||||
| Prime | 2xboost | 0 | 14 | 28 | 42 | |||
| Serum IgM | 0/5 | 0/5 | 0/5 | 0/5 | ||||
| 0 | 5 | Serum IgG | 0/5 | 0/5 | 0/5 | 0/5 | ||
| Faeces IgA | 0/5 | 0/5 | 0/5 | 0/5 | ||||
| im | Feeding | Serum IgM | 0/5 | 5/5 | 5/5 | 5/5 | ||
| 1 | 5 | HEK293T‐E1E2 | Lettuce E1E2 | Serum IgG | 0/5 | 0/5 | 0/5 | 4/5 |
| Faeces IgA | 0/5 | 4/5 | 4/5 | 4/5 | ||||
| Feeding | Serum IgM | 0/7 | 0/7 | 1/7 | 2/7 | |||
| 2 | 7 | Lettuce‐E1E2∆N6 | Serum IgG | 0/7 | 0/7 | 0/7 | 0/7 | |
| Faeces IgA | 0/7 | 3/7 | 3/7 | 3/7 | ||||
| Feeding | Serum IgM | 0/5 | 0/5 | 1/5 | 1/5 | |||
| 3 | 5 | Lettuce‐E1E2 | Serum IgG | 0/5 | 0/5 | 0/5 | 0/5 | |
| Faeces IgA | 0/5 | 0/5 | 0/5 | 0/5 | ||||
| 4 | 5 | im | im | Serum IgM | 0/5 | ND | 5/5 | 5/5 |
| HEK293T‐E1E2 | HEK293T‐E1E2 | Serum IgG | 0/5 | ND | 5/5 | 5/5 | ||
| Faeces IgA | ND | ND | 5/5 | 5/5 |
| species | factors associated with chick-a-dee call variation | references |
| black-capped chickadee Poecile atricapillus | species | [48,68–70] |
| flock | [71,72] | |
| individual | [73] | |
| predator | [74–76] | |
| boreal chickadee P. hudsonicus | individual | [77] |
| chestnut-backed chickadee P. rufescens | individual | [78] |
| Carolina chickadee P. carolinensis | species | [48] |
| local population | [79] | |
| individual | [80] | |
| energetic state | [81] | |
| predator | [82–85] | |
| food | [87,88] | |
| flight | [59,82] | |
| Mexican chickadee P. sclateri | individual | [89] |
| mountain chickadee P. gambeli | species | [68,69] |
| individual | [90] | |
| flight | [91] | |
| tufted titmouse Baeolophus bicolor | individual | [92] |
| predator | [83,93,94] | |
| crested tit Lophophanes cristatus | proximity to cover | [95,96] |
| willow tit Poecile montana | predator | [97] |
| n | %* | |
| Number of patients | 635 | |
| Median age at time of VIT-initiation (years) (range) | 39 | (5–77) |
| Male/female | 322/313 | |
| Results of allergy testing | ||
| Vespula (vulgaris/germanica) mono sensitization | 251 | 39.5 |
| Honey bee (Apis mellifera) mono sensitization | 33 | 5.2 |
| Double sensitization | 351 | 55.3 |
| Severity of anaphylaxis to pre-VIT index field sting | ||
| Large local reaction | 8 | 1.3 |
| Grade I (mild) | 171 | 26.9 |
| Grade II (moderate) | 321 | 50.6 |
| Grade III (severe) | 135 | 21.3 |
| Treatment course | ||
| Mean duration of VIT (years) (range) | 3.9 | (3–13) |
| Mean observation time after VIT (years) (range) | 7.0 | (0–17) |
| Disease | No. withdrawals/treated patients | Inefficacy or loss of efficacy | Adverse event | Persistent remission | On-demand treatment | Patient request | Switch to canakinumab |
| AOSD | 20/35 | 14 | 3 | 1 | 0 | 2 | 2 |
| Gout | 18/28 | 0 | 0 | 17 | 1 | 0 | 0 |
| SJIA | 16/26 | 7 | 3 | 5 | 0 | 1 | 6 |
| CAPS | 11/21 | 1 | 1 | 1 | 0 | 8 | 3 |
| MKD | 7/10 | 2 | 2 | 0 | 0 | 3 | 4 |
| FMF | 6/13 | 1 | 3 | 0 | 1 | 1 | 3 |
| SAPHO | 7/9 | 5 | 2 | 0 | 0 | 0 | 0 |
| Schnitzler’s syndrome | 3/7 | 1 | 2 | 0 | 0 | 0 | 1 |
| Spondylo arthritis | 5/5 | 2 | 3 | 0 | 0 | 0 | 0 |
| Vasculitis | 2/4 | 2 | 0 | 0 | 0 | 0 | 2 |
| Chondro calcinosis | 2/4 | 1 | 0 | 1 | 0 | 0 | 0 |
| TRAPS | 1/3 | 1 | 0 | 0 | 0 | 0 | 0 |
| GPP | 2/3 | 1 | 0 | 1 | 0 | 0 | 0 |
| Polychondritis | 1/3 | 1 | 0 | 0 | 0 | 0 | 0 |
| NAPS12 | 2/2 | 2 | 0 | 0 | 0 | 0 | 0 |
| Total | Sham | 0.5 mA | 1.0 mA | 1.5 mA | ||||||
| N | 87 | 22 | 22 | 22 | 21 | |||||
| RT negative | 1170.90 | (21.73) | 1135.21 | (34.23) | 1213.46 | (42.21) | 1164.88 | (45.87) | 1170.02 | (51.81) |
| RT neutral | 1151.04 | (20.25) | 1110.98 | (34.62) | 1206.59 | (42.62) | 1117.34 | (38.04) | 1170.09 | (45.57) |
| AC negative | 79.66 | (0.76) | 81.48 | (1.49) | 79.20 | (1.61) | 80.11 | (1.78) | 77.77 | (1.02) |
| AC neutral | 80.89 | (0.81) | 81.70 | (1.74) | 80.91 | (1.66) | 81.59 | (1.43) | 79.29 | (1.72) |
| RF | PCVA | ||||
| Median | 95% UI | Median | 95% UI | ||
| Adult | No HCE | 0.726 | (0.721, 0.730) | 0.624 | (0.619, 0.631) |
| HCE | 0.772 | (0.769, 0.776) | 0.675 | (0.669, 0.680) | |
| Child | No HCE | 0.763 | (0.755, 0.769) | 0.632 | (0.626, 0.642) |
| HCE | 0.779 | (0.775, 0.785) | 0.682 | (0.671, 0.690) | |
| Neonate | No HCE | 0.720 | (0.710, 0.732) | 0.695 | (0.682, 0.705) |
| HCE | 0.726 | (0.717, 0.734) | 0.733 | (0.719, 0.743) |
| 5-HT | Motilin | VIP | Somatostatin | |||||
| TDCA | −0.07 | 0.76 | 0.11 | 0.65 | 0.23 | 0.32 | 0.19 | 0.43 |
| TCA | −0.33 | 0.15 | −0.02 | 0.93 | 0.01 | 0.96 | 0.09 | 0.71 |
| TLCA | −0.06 | 0.81 | −0.10 | 0.69 | 0.06 | 0.80 | −0.17 | 0.48 |
| Variable | Elderly | Middle aged | Young | P value |
| TChol | 79(44%) | 161 (42%) | 11(31%) | 0.3 |
| HDL-C | 98(54%) | 205(53%) | 15(41%) | 0.3 |
| LDL-C | 129 (71%) | 286(74%) | 26 (72%) | 0.7 |
| TG | 18 (10%) | 56(15%) | 1(2%) | 0.05 |
| Patients | NMO/NMOSD | MS |
| Number | 20 | 8 |
| Age | 49.4 ± 3.9 | 43.0 ± 4.8 |
| Male:Female | 4:16 | 4:4 |
| Disease duration | 8.1 ± 2.0 | 9.9 ± 3.7 |
| Relapses in the last 2 years | 1.2 ± 0.3 | 2.3 ± 0.5 |
| EDSS∗ score in disease remission | 3.3 ± 0.5 | 4.1 ± 1.0 |
| % Change in relative probability of delivery with a 5-min increase in travel timea | |
| Delivery at any facility | −30.0 |
| Public facility delivery | −28.2 |
| Private facility delivery | −32.9 |
| NGO facility delivery | −28.6 |
| Cell Types | Species/Cell Lines | Melotonin Effects | Receptor Types | Melatonin Concentrations | References | |
| Leydig cell | mouse | Inhibition of steroid production | Inhibition of StAR protein expression | Mt1 and/or Mt2 | 10 nM to 1 μM | [21] |
| MA-10 | Inhibition of progesterone production | Mt1 and/or Mt2 | 10 nM to 1 μM | [21] | ||
| Rat | Inhibition of steroid production | Inhibition of androgen production | - | 4 pM to 4 μM | [40] | |
| Inhibition of GnRH-dependent intracellular Ca2+release | - | 0.2 pM | [46] | |||
| Hamster | Inhibition of steroid production | Stimulation of CRH production | Mt1 | 1 and 10 μM | [12,54] | |
| Stimulation of tyrosine phosphatases activity | Mt1 | 1 and 10 μM | [54] | |||
| Inhibition of erk and jnk phosphorylation | Mt1 | 1 and 10 μM | [54] | |||
| Downregulation of c-fos and c-jun expression | Mt1 | 1 and 10 μM | [54] | |||
| Inhibition of StAR, Hsd3b and Hsd17b3 expression | Mt1 | 1 and 10 μM | [12,54] | |||
| Inhibition of cAMP generation | Mt1 | 1 μM | [12] | |||
| Inhibition of androgen production | Mt1 | 100 pM to 1 μM | [12,54] | |||
| Sertoli cell | Rat | Regulation of energy metabolism | Inhibition of basal lactate production | Mt1 and Mt2 | 1 mM | [33] |
| Upregulation of the insulin-stimulated lactate generation | Mt1 and Mt2 | 1 mM | [33] | |||
| Stimulation of GLUT1 protein expression and glucose consumption | 1 mM | [33] | ||||
| Inhibition of LDH protein expression and activity | Mt1 and Mt2 | 1 mM | [33] | |||
| Stimulation of acetate production | 1 mM | [33] | ||||
| Prevention of testicular damage | Regulation of intracellular redox state | Mt1 and Mt2 | 1 mM | [33] | ||
| Hamster | Prevention of testicular damage | Stimulation of the responsiveness to FSH during testicular development | - | 25 μg daily injection (1 to 15 wk) | [24] | |
| Bovine | Stimulation of cell growth/proliferation | Downregulation of mRNA P21 expression | Mt1 and Mt2 | 0.3 to 1 nM | [59] | |
| Regulation of spermatogenesis | Upregulation of Cyclin D1, Cyclin E, Pdgfa, Dhh, Ocludin and Claudin expression | Mt1 and Mt2 | 0.3 to 1 nM | [59] | ||
| Goat | Stimulation of SSCs proliferation | Stimulation of GDNF production | Mt1 and Mt2 | 1 nM and 1 μM | [73] |
| Demographics | |
| Mean age, years (range) | 32 (11–55) |
| Male : female | 43 : 8 |
| Transfusion requirements, units (range) | 7 (3–12) |
| Intervention group | Control group | P Value* | |||||
| T1a | T2a | T3a | T1a | T2a | T3a | ||
| Rural (n = 1539) | 0.11 ± 0.20 | 0.15 ± 0.23 | 0.15 ± 0.24 | 0.11 ± 0.20 | 0.16 ± 0.23 | 0.18 ± 0.24 | < 0.001 |
| Urban (n = 1512) | 0.12 ± 0.21 | 0.16 ± 0.23 | 0.16 ± 0.23 | 0.12 ± 0.24 | 0.17 ± 0.27 | 0.19 ± 0.29 | < 0.001 |
| Elementary school (n = 2451) | 0.09 ± 0.18 | 0.12 ± 0.21 | 0.13 ± 0.22 | 0.08 ± 0.18 | 0.12 ± 0.22 | 0.14 ± 0.22 | < 0.001 |
| Secondary school (n = 600) | 0.23 ± 0.26 | 0.29 ± 0.28 | 0.27 ± 0.28 | 0.26 ± 0.29 | 0.32 ± 0.30 | 0.36 ± 0.34 | < 0.001 |
| Suspected myopia (n = 997) | 0.34 ± 0.20 | 0.39 ± 0.24 | 0.39 ± 0.24 | 0.36 ± 0.24 | 0.44 ± 0.27 | 0.48 ± 0.29 | < 0.001 |
| Non-suspected myopia (n = 2054) | 0.005 ± 0.05 | 0.03 ± 0.09 | 0.03 ± 0.09 | 0.004 ± 0.04 | 0.039 ± 0.09 | 0.06 ± 0.10 | < 0.001 |
| Combined (n = 3051) | 0.12 ± 0.20 | 0.15 ± 0.23 | 0.16 ± 0.24 | 0.12 ± 0.22 | 0.16 ± 0.25 | 0.19 ± 0.27 | < 0.001 |
| Item | Component | |
| 1 | 2 | |
| Pain | 0.555 | −0.162 |
| Shortness of breath | 0.497 | −0.318 |
| Weakness or lack of energy | 0.547 | −0.379 |
| Nausea | 0.251 | −0.779 |
| Vomiting | 0.196 | −0.694 |
| Poor appetite | 0.398 | −0.236 |
| Constipation | 0.305 | −0.001 |
| Mouth problems | 0.558 | −0.305 |
| Drowsiness | 0.433 | −0.320 |
| Poor mobility | 0.672 | −0.050 |
| Itching | 0.361 | −0.317 |
| Difficulty sleeping | 0.506 | −0.386 |
| Restless legs | 0.150 | −0.223 |
| Feeling anxious | 0.537 | −0.303 |
| Feeling depressed | 0.586 | −0.218 |
| Changes in skin | 0.329 | −0.345 |
| Diarrhoea | 0.187 | −0.486 |
| Muscle cramps | 0.229 | −0.358 |
| Variable | Current contraceptive use n (%) | Unadjusted RR (95% CI) | Adjusted RR (95% CI) |
| Age (completed years) | p = 0.45 | ||
| 13–19 | 9 (36.0) | 1 | − |
| 20–29 | 154 (50.8) | 1.41 (0.83, 2.41) | − |
| 30+ | 131 (50.6) | 1.40 (0.82, 2.40) | − |
| Level of education | p = 0.001;p trend < 0.001 | p = 0.02;p trend = 0.03 | |
| No formal education | 16 (38.1) | 1 | 1 |
| ≤ Basic education | 123 (44.6) | 1.17 (0.78, 1.76) | 0.90 (0.64, 1.25) |
| > Basic education | 154 (59.0) | 1.55 (1.04, 2.31) | 1.13 (0.82, 1.58) |
| Marital Status | p = 0.33 | ||
| Single | 24 (43.6) | 1 | − |
| Married | 270 (50.0) | 1.17 (0.86, 1.60) | − |
| Occupation | p = 0.01 | p = 0.11 | |
| Unemployed | 46 (39.6) | 1 | 1 |
| Semi-skilled employment | 172 (50.4) | 1.27 (0.99, 1.63) | 1.29 (1.01, 1.66) |
| Skilled employment | 75 (59.5) | 1.50 (1.15, 1.96) | 1.20 (0.92, 1.56) |
| Number of living children | p = 0.32 | ||
| 1–2 | 196 (48.6) | 1 | − |
| 3+ | 97 (53.0) | 1.09 (0.92, 1.29) | − |
| Number of ANC visits | p = 0.06 | p = 0.24 | |
| < 7 | 109 (46.2) | 1 | 1 |
| 7+ | 184 (54.3) | 1.18 (0.99, 1.39) | 1.10 (0.94, 1.29) |
| FP discussed during ANC | p = 0.01 | p = 0.001 | |
| No | 71 (41.8) | 1 | 1 |
| Yes | 208 (58.9) | 1.41 (1.16, 1.72) | 1.28 (1.07, 1.53) |
| FP discussed during PNC | p = 0.33 | ||
| No | 12 (46.0) | 1 | − |
| Yes | 283 (51.5) | 1.24 (0.80, 1.93) | − |
| FP discussed during CWC | p = 0.56 | ||
| No | 17 (51.4) | 1 | − |
| Yes | 271 (51.1) | 1.11 (0.78, 1.59) | − |
| Discusses FP with partner | p < 0.001 | p = 0.03 | |
| No | 74 (37.0) | 1 | 1 |
| Yes | 217 (60.6) | 1.64 (1.34, 2.00) | 1.22 (1.01, 1.47) |
| Desire to space children | p < 0.001 | p = 0.14 | |
| No | 54 (36.2) | 1 | 1 |
| Yes | 242 (54.9) | 1.51 (1.20, 1.90) | 1.16 (0.95, 1.41) |
| Resumed sexual intercourse | p = 0.01 | p = 0.70 | |
| No | 192 (46.8) | 1 | 1 |
| Yes | 104 (57.8) | 1.23 (1.05, 1.45) | 1.03 (0.89, 1.19) |
| Resumed menses | p = 0.61 | ||
| No | 215 (49.5) | 1.05 (0.88, 1.25) | − |
| Yes | 81 (52.9) | 1 | − |
| Previous contraceptive use | p < 0.001 | p < 0.001 | |
| No | 82 (28.5) | 1 | 1 |
| Yes | 214 (70.9) | 2.45 (2.04, 3.03) | 1.91 (1.56, 2.33) |
| Measurement | Location | Data points | Sampling rate | |||
| Parameter | Method | Performed by | Laboratory | Office | d-1 (overall) | s-1 |
| Physiological | ||||||
| Sitting time | IPAQ-long | questionnaire - interview | x | 1 (4) | n.a.d | |
| Physical activity | IPAQ-long | questionnaire - interview | x | 1 (4) | n.a.d | |
| Mental workload | NASA-TLX | questionnaire | x | 1 (4) | n.a.d | |
| Salivary cortisol | saliva collection | Salivette + cortisol ELISA | xa | 8 (32) | n.a.d | |
| Heart-rate | ECG | ECG recorder | xb | n.a.c | 250 | |
| Body movements | acceleration | ECG recorder | xb | n.a.c | 250 | |
| Cognitive | ||||||
| Working speed | text editing task | computer software (matlab) | x | 5 (20) | >1000 | |
| Reaction time | Stroop-test | computer software (matlab) | x | 5 (20) | >1000 | |
| Attention | d2R-test | test sheet | x | 5 (20) | n.a.d | |
| Office based | ||||||
| Body postures | logging tool | computer software (C#) | x | n.a.c | >1000 | |
| Postural changes | logging tool | computer software (C#) | x | n.a.c | >1000 |
| Patient type | RCTs n (%) |
| Medical/Surgical | 106 (43) |
| Medical only | 56 (23) |
| Bronchiolitis | 16 (6) |
| Sepsis/Shock | 13 (5) |
| Asthma | 8 (3) |
| Other medical | 19 (8) |
| Surgical only | 60 (24) |
| Cardiac surgery | 46 (19) |
| Noncardiac surgery | 14 (6) |
| Trauma/Burns only | 26 (10) |
| Traumatic brain Injury | 13 (5) |
| Burns | 13 (5) |
| Neoadjuvant (n = 80) | Adjuvant (n = 90) | P | |
| PHS (days) | 11 (7–33) | 11 (5–51) | 0.920a |
| PHS with complications (days) | 15 | 17 | 0.503b |
| PHS without complications (days) | 11 | 11 | 0.972a |
| Patients with complications | 15 (18.8%) | 20 (22.2%) | 0.704 |
| Non-surgical complications | |||
| Pneumonia | 1 (1.3%) | 3 (3.3%) | 0.623 |
| Pleural effusion | 0 (0.0%) | 2 (2.2%) | 0.499 |
| Gastrointestinal motility disorders | 3 (3.8%) | 3 (3.3%) | 1.000 |
| Thrombosis | 1 (1.3%) | 1 (1.1%) | 1.000 |
| Renal dysfunction | 1 (1.3%) | 1 (1.1%) | 1.000 |
| Catheter-related sepsis | 1 (1.3%) | 0 (0.0%) | 0.471 |
| Other (urinary, thrombocytopenia) | 1 (1.3%) | 4 (4.4%) | 0.372 |
| Surgical complications | |||
| Anastomotic leakage | 0 (0.0%) | 2 (2.2%) | 0.499 |
| Surgical site infection | 5 (6.2%) | 6 (6.7%) | 1.000 |
| Postoperative hemorrhage | 3 (3.8%) | 1 (1.1%) | 0.343 |
| Wound dehiscence | 0 (0.0%) | 2 (2.2%) | 0.499 |
| Lymphorrhea | 2 (2.5%) | 1 (1.1%) | 0.602 |
| Ileus | 0 (0.0%) | 1 (1.1%) | 1.000 |
| Biliary fistula | 1 (1.3%) | 0 (0.0%) | 0.471 |
| Pre-supplementation | Post-supplementation | |||||
| Measure | Subjects reporting GIT symptoms post-supplement (mean) | Subjects GIT symptom free post-supplement (mean) | P value | Subjects reporting GIT symptoms post- supplement (mean) | Subjects GIT symptom free post-supplement (mean) | P value |
| General health indices | ||||||
| Neurological index | 1.3 | 0.5 | < 0.004 | 1.0 | 0.4 | ns |
| Chalder fatigue scale | ||||||
| Total fatigue scores | 14.2 | 11.8 | ns | 12.6 | 8.9 | ns |
| Amino acids | ||||||
| (Relative % abundance) | ||||||
| Asparagine | 6.60% | 4.78% | < 0.03 | 6.11% | 4.89% | ns |
| Hydroxylysine | 1.62% | 1.15% | < 0.05 | 1.72% | 1.32% | ns |
| Hydroxyproline | 0.58% | 0.34% | < 0.04 | 0.65% | 0.52% | ns |
| Variable | Glaucoma group n = 8777 | Control group n = 35,108 | p-value |
| n (%) | n (%) | ||
| Age, year, (mean±SD) | 59.4±13.6 | 59.4±13.6 | 1.000 |
| Age, categorical | 1.000 | ||
| 30–50 | 2228 (25.4) | 8912 (25.4) | |
| 50–60 | 2012 (22.9) | 8048 (22.9) | |
| 60–70 | 2239 (25.5) | 8956 (25.5) | |
| ≥ 70 | 2298 (26.2) | 9192 (26.2) | |
| Gender | 1.000 | ||
| Male | 4376 (49.9) | 17,504 (49.9) | |
| Female | 4401 (50.1) | 17,604 (50.1) | |
| Charlson comorbidity index | < 0.0001 | ||
| < 3 | 7463 (85.0) | 309,339 (88.1) | |
| ≥3 | 1314 (15.0) | 4169 (11.9) | |
| Insurance cost | < 0.0001 | ||
| < 40,000 NTD | 7618 (86.8) | 31,052 (88.4) | |
| ≥40,000 NTD | 1159 (13.2) | 4056 (11.6) | |
| Urbanization level | < 0.0001 | ||
| Urban | 6761 (77.0) | 25,464 (72.5) | |
| Rural | 2016 (23.0) | 9644 (27.5) | |
| Living alone | 0.62 | ||
| No | 7973 (90.8) | 32,830 (90.7) | |
| Yes | 804 (9.2) | 3278 (9.3) | |
| Substance abuse | |||
| No | 8704 (99.2) | 34,786 (99.1) | 0.49 |
| Yes | 73 (0.8) | 322 (0.9) | |
| Depression during the follow-up period | 515 (5.9) | 1282 (3.7) | < 0.0001 |
| Municipality | % Speaking indigenous language | % Speaking Zapotec monolingual | % Speaking Zapotec monolingual | % Of 15 year-old or older who read and write in Spanish | Average number of years in school | % Of the population engaged in primary production activities |
| Year 2000 | Year 2000 | Year 1950 | Year 2000 | Year 2000 | Year 2000 | |
| Juchitán de Zaragoza | 70.01 | 8.81 | 27.26 | 52.11 | 6.26 | 13.89 |
| San Blas Atempa | 92.76 | 24.87 | 72.08 | 39.95 | 3.56 | 33.79 |
| Santa María Xadani | 97.71 | 34.07 | 83.33 | 32.05 | 3.36 | 35.01 |
| Total cohort | <70 years | ≥70 years | |
| Demographics | |||
| N (%) | 2280 | 1497 (65.7) | 783 (34.3) |
| Age, mean (SD) [1] | 61.1 (17.0) | 52.2 (13.6) | 78.2 (6.2) |
| Gender (male), n (%) [1] | 1315 (57.7) | 821 (54.8) | 494 (63.1) |
| Included at University Medical Centre, n (%) | 1860 (81.6) | 1271 (84.9) | 589 (75.2) |
| Co-morbidities, n (%) | |||
| COPD [2] | 349 (15.3) | 158 (10.6) | 191 (24.4) |
| Heart failure [1] | 329 (14.4) | 133 (8.9) | 196 (25.0) |
| Liver disease [1] | 113 (5.0) | 94 (6.3) | 19 (2.4) |
| Renal disease [1] | 416 (18.2) | 261 (17.4) | 155 (19.8) |
| Nursing home [2] | 138 (6.1) | 46 (3.1) | 92 (11.7) |
| Immune-compromised [2] | 951 (41.7) | 720 (48.1) | 231 (29.5) |
| Malignancy – [1] | 253 (11.1) | 155 (10.4) | 98 (12.5) |
| Malignancy + [3] | 345 (15.1) | 244 (16.3) | 101 (12.9) |
| DNR status (%) (6) | 478 (21.0) | 185 (12.4) | 293 (37.4) |
| Suspected source of infection, n (%) | |||
| Pulmonary | 1059 (46.4) | 620 (41.4) | 439 (56.1) |
| Urogenital | 675 (29.6) | 397 (26.5) | 278 (35.5) |
| Abdominal | 396 (17.4) | 273 (18.2) | 123 (15.7) |
| Skin | 198 (8.7) | 145 (9.7) | 53 (6.8) |
| Neurological | 48 (2.1) | 35 (2.3) | 13 (1.7) |
| other | 396 (17.4) | 301 (20.1) | 95 (12.1) |
| Vital signs on admission | |||
| Systolic blood pressure, mean (SD) (241) | 131.9 (25.9) | 129.8 (23.5) | 135.7 (29.3) |
| Heart rate, mean (SD) (45) | 108.0 (20.3) | 110.2 (19.7) | 103.8 (20.9) |
| Respiratory rate, mean (SD) (558) | 24.0 (7.2) | 22.83 (6.9) | 25.73 (7.5) |
| Oxygen saturation, mean (SD) (71) | 95.2 (4.8) | 95.8 (4.6) | 94.1 (5.2) |
| Temperature (°C), mean (SD) (94) | 38.72 (1.11) | 38.74 (1.06) | 38.69 (1.20) |
| Altered mental status n (%) (420) | 370 (16.2) | 161 (10.8) | 209 (26.7) |
| Laboratory analysis on admission | |||
| Lactate (mmol/l), median (IQR) (293) | 1.9 (1.4–2.6) | 1.8 (1.4–2.6) | 2.0 (1.5–2.8) |
| Platelets (×109/l), median (IQR) (41) | 209 (151–280) | 207 (148–279) | 213.5 (156–286) |
| INR median (IQR), (702) | 1.1 (1–1.4) | 1.1 (1.0–1.29) | 1.2 (1.0–2.4) |
| Creatinine (μg/l), median (IQR) [16] | 87 (67–120) | 83 (64–110) | 95 (74–134) |
| Urea (mmol/l), median (IQR) (40) | 7.0 (5.1–10.2) | 6.2 (4.6–8.8) | 8.8 (6.6–12.5) |
| Band cells >5%, n (%) | 179 (7.9) | 103 (6.9) | 76 (9.7) |
| Bilirubin (μmol/l), median (IQR) (349) | 12 (8–19) | 12 (8–18) | 12 (9–20) |
| Treatment variables | |||
| Time to antibiotics (min), median (IQR) [23] | 103 (58–167) | 109 (63–174) | 91 (51–152) |
| Fluid resuscitation (L during ED stay), median (IQR) | 1 (0.5–1.5) | 1 (0.5–1.5) | 1 (0.5–1.5) |
| Supplementary oxygen (L/min), median (IQR) (85) | 3 (0–5) | 2 (0–5) | 3 (2–6) |
| Before | After | |
| N | 39249 | 39249 |
| Analgesics (N, %) | ||
| Represcribed pregabalin use | — | 4009 (10.2) |
| 1-2-line drugs | 5416 (13.8) | 3213 (8.2) |
| Continued use | — | 1761 (4.5) |
| New use | — | 1348 (3.4) |
| Changed/added drugs | — | 104 (0.3) |
| TCAs | 837 (2.1) | 448 (1.1) |
| Gabapentin | 355 (0.9) | 197 (0.5) |
| Neurotropin | 3775 (9.6) | 2106 (5.4) |
| Duloxetine | 501 (1.3) | 455 (1.2) |
| Mexiletine | 310 (0.8) | 221 (0.6) |
| Opioids | 8171 (20.8) | 5954 (15.2) |
| Continued use | — | 1580 (4.0) |
| New use | — | 2894 (7.4) |
| Changed/additions of drugs/route | — | 1480 (3.8) |
| Oral opioids | 5008 (12.8) | 3350 (8.5) |
| Continued use | — | 1358 (3.5) |
| New use | — | 1649 (4.2) |
| Changed/added drugs | — | 160 (0.4) |
| Changed/additions of route | — | 183 (0.5) |
| Nonoral opioids | 4737 (12.1) | 3368 (8.6) |
| Continued use | — | 702 (1.8) |
| New use | — | 1465 (3.7) |
| Changed/added drugs | — | 527 (1.3) |
| Changed/additions of route | — | 674 (1.7) |
| Weak opioids | 3238 (8.2) | 2377 (6.1) |
| Continued use | — | 710 (1.8) |
| New use | — | 1444 (3.7) |
| Changed/added drugs | — | 76 (0.2) |
| Changed/additions of the strength | — | 147 (0.4) |
| Strong opioids | 5928 (15.1) | 3963 (10.1) |
| Continued use | — | 1010 (2.6) |
| New use | — | 1644 (4.2) |
| Changed/added drugs | — | 1062 (2.7) |
| Changed/additions of the strength | — | 247 (0.6) |
| Characteristic | No. of wells (column %) | p | |
| Normoxic (n = 196) | Low O2 (n = 57) | ||
| Pipe type | |||
| No pipe | 14 (7.1) | 4 (7.0) | 0.018∗ |
| Iron | 155 (79.1) | 36 (63.2) | |
| PVC | 27 (13.8) | 17 (29.8) | |
| Iron ladder | 58 (29.6) | 21 (36.8) | 0.380∗ |
| Cement casing | 172 (87.8) | 48 (84.2) | 0.634∗ |
| Leakage of water | 89 (45.4) | 23 (40.4) | 0.600∗ |
| Rust occurrence | |||
| On ladder | 31 (15.8) | 17 (29.8) | 0.029∗ |
| On pipe | 73 (37.2) | 17 (29.8) | 0.383∗ |
| On leaked water | 16 (8.2) | 2 (3.5) | 0.379† |
| Surroundings | |||
| Large tree (>2 m) | 131 (66.8) | 36 (63.2) | 0.721∗ |
| Small tree (<2 m) | 75 (38.3) | 24 (42.1) | 0.712∗ |
| Hut | 61 (31.1) | 19 (33.3) | 0.877∗ |
| Rubbish, oil | 18 (9.2) | 4 (7.0) | 0.791† |
| Roof | 8 (4.1) | 1 (1.7) | 0.688† |
| Cover (>80%) | 9 (4.6) | 10 (17.5) | 0.003† |
| Soil type | |||
| Loam | 168 (85.7) | 36 (63.2) | <0.001† |
| Sandy loam | 16 (8.2) | 15 (26.3) | |
| Sandy | 3 (1.5) | 5 (8.8) | |
| Sandy clay | 6 (3.1) | 0 (0) | |
| Clay | 1 (0.5) | 1 (1.8) | |
| Clay loam | 2 (1) | 0 (0) | |
| Period since last rain (d) | |||
| 0 | 57 (29.1) | 11 (19.3) | <0.001∗ |
| 1 | 131 (66.8) | 31 (54.4) | |
| 2 | 8 (4.1) | 15 (26.3) | |
| Water‡ | |||
| Color—not clear | 25 (13.2) | 7 (12.5) | 0.887∗ |
| Odor—not fresh | 39 (20.6) | 19 (33.9) | 0.040∗ |
| Characteristic | n = 133 |
| Age (years)a | 67.2 ± 9.4 |
| Sex | |
| Male | 77 |
| Female | 56 |
| Diagnosis | |
| Pancreatic carcinoma | 49 |
| Cholangiocarcinoma | 49 |
| Ampullary carcinoma | 13 |
| Intraductal papillary mucinous neoplasm | 6 |
| Neuroendocrine tumor | 5 |
| Others | 11 |
| Total bilirubin (mg/dL)a | 4.9 ± 5.5 |
| Preoperative biliary drainage | |
| Yes | 93 |
| No | 40 |
| Operation | |
| PD | 20 |
| SSPPD | 41 |
| PPPD | 72 |
| Operation time (min)a | 454.3 ± 99.8 |
| Blood loss (mL)a | 990.6 ± 701.3 |
| Transfusion | |
| Yes | 33 |
| No | 100 |
| Baseline | 10% O2 | Recovery | ||||
| GFP (n = 4) | Cre (n = 6) | GFP (n = 4) | Cre (n = 6) | GFP (n = 4) | Cre (n = 6) | |
| Heart rate (BPM) | ||||||
| Pre | 527 ± 13 | 504 ± 26 | 665 ± 11 | 656 ± 10 | 559 ± 20 | 560 ± 26 |
| Post | 495 ± 28 | 579 ± 10* | 665 ± 16 | 721 ± 7*** | 524 ± 30 | 633 ± 14* |
| Systolic blood pressure (mmHg) | ||||||
| Pre | 129 ± 6 | 128 ± 5 | 124 ± 3 | 132 ± 3 | 129 ± 4 | 124 ± 6 |
| Post | 135 ± 5 | 152 ± 7* | 126 ± 6 | 129 ± 5 | 128 ± 7 | 126 ± 6 |
| Diastolic blood pressure (mmHg) | ||||||
| Pre | 62 ± 7 | 68 ± 6 | 62 ± 5 | 69 ± 5 | 62 ± 6 | 66 ± 6 |
| Post | 68 ± 6 | 81 ± 8* | 65 ± 6 | 64 ± 4 | 63 ± 5 | 61 ± 7 |
| Respiratory rate (min−1) | ||||||
| Pre | 185 ± 5 | 199 ± 7 | 280 ± 6 | 263 ± 7 | 145 ± 11 | 167 ± 10 |
| Post | 191 ± 3 | 199 ± 8 | 271 ± 3 | 266 ± 6 | 153 ± 9 | 155 ± 9 |
| Minute volume (au g−1 min−1) | ||||||
| Pre | 1.0 ± 0.1 | 1.0 ± 0.1 | 3.4 ± 0.1 | 3.3 ± 0.2 | 1.1 ± 0.1 | 1.2 ± 0.1 |
| Post | 1.0 ± 0.1 | 1.1 ± 0.1 | 3.2 ± 0.2 | 3.5 ± 0.2 | 1.1 ± 0.1 | 1.4 ± 0.1 |
| Markers | ADHLSC | BM-MSC [14, 15] | ASC [15] |
| CD73 | 98.3% (95.0–99.7) | ≥95% (guideline) | ≥95% |
| CD90 | 91.5% (86.9–95.0) | ≥95% (guideline) | ≥95% |
| CD105 | 96.7% (93.8–99.6) | ≥95% (guideline) | ≥95% |
| CD11b | 0.7% (0.0–2.0) | ≤2% (guideline) | ≤2% |
| CD14 | 2.0% (0.0–3.26) | ≤2% (guideline) | ≤2% |
| CD19 | 0.5% (0.0–2.0) | ≤2% (guideline) | ≤2% |
| CD45 | 1.1% (0.0–2.8) | ≤2% (guideline) | ≤2% |
| HLA-DR | 0.8%± 0.5 | ≤2% (guideline) | ≤2% |
| CD34 | 1.3% (0.1–2.6) | 0.1% (0.0−0.1) | 9.0% (5.1–30.1) |
| CD36 | 3.5% (0.0–12.0) | 0.1% (0.0−0.2) | 11.5% (4.8–13.4) |
| CD91 | 0.7% (0.0−1.7) | N.D. | 47.6% (12.7–87.4) |
| CD140b | 93.8% (99.4–78.6) | 54.3% (45.9–87.5) | 79.9% (49.2–87.5) |
| CD141 | 7.2% (4.2–12.8) | N.D. | ≥95% |
| CD201 | 53.3% (0.17–81.1) | 2.0% (1.8–4.8) | 13.6% (9.5–25.6) |
| Measure | DF | F | P |
| DASS-depression | 1.61 | .24 | .79 |
| DASS-anxiety | 1.60 | 1.72 | .19 |
| DASS-stress | 1.61 | 2.05 | .14 |
| DASS-total | 1.60 | 1.39 | .26 |
| FS (Wellbeing) | 1.45 | .57 | .57 |
| Comparison | P-value | Comparison | P-value |
| Breast/Colon | 0.0001 | Colon/SCC | 0.135 |
| Breast/SCC | 0.114 | Colon/KA | 0.027 |
| Breast/KA | 0.0001 | KA/SCC | 0.0001 |
| Breast (T)/Breast (M) | 0.723 | MSI-High/MSI-Low | 0.443 |
| DL-CNN vs RS1 | AI-CALS vs RS1 | DL-CNN vs RS2 | AI-CALS vs RS2 | |
| Average minimum distance AVDIST | ||||
| Pre-treatment | 4.8 ± 1.8mm | 5.3 ± 2.7mm | 4.9 ± 3.4mm | 4.5 ± 1.9mm |
| Post-treatment | 4.3 ± 1.7mm | 4.4 ± 1.8mm | 4.7 ± 3.1mm | 4.9 ± 3.7mm |
| Both | 4.6 ± 1.8mm | 4.8 ± 2.3mm | 4.8 ± 3.2mm | 4.7 ± 2.9mm |
| Jaccard index JACCARD3D | ||||
| Pre-treatment | 45.3 ± 8.5% | 42.5 ± 14.1% | 46.8 ± 9.3% | 42.8 ± 12.5% |
| Post-treatment | 29.8 ± 17.7% | 32.9 ± 14.8% | 28.8 ± 19.7% | 28.6 ± 18.2% |
| Both | 37.5 ± 15.8% | 37.7 ± 15.2% | 37.8 ± 17.8% | 35.7 ± 17.1% |
| Targets | MLC leaf width | ||
| 10 mm | 4 mm | p value | |
| Pgtv | |||
| Dmax | 7056.1 ± 127.2 | 6996.3 ± 88.9 | 0.24 |
| Dmin | 6035.5 ± 113.7 | 6132.2 ± 107.4 | 0.06 |
| Dmean | 6495.2 ± 39.0 | 6491.1 ± 30.4 | 0.44 |
| PTV | |||
| Dmean | 5478.5 ± 78.4 | 5489.2 ± 64.3 | 0.74 |
| Location | N | A | SD | Ho | SD | He | SD |
| Bolungarvik | 11 | 2.08 | 0.79 | 0.24 | 0.21 | 0.29 | 0.25 |
| Grafarvogur, Reykjavik | 12 | 2.33 | 0.65 | 0.43 | 0.26 | 0.42 | 0.18 |
| Storhofdi Lighthouse | 15 | 2.83 | 1.03 | 0.32 | 0.23 | 0.39 | 0.22 |
| Kalfafell | 7 | 1.25 | 0.45 | 0.14 | 0.30 | 0.12 | 0.22 |
| Reydarfjordur | 16 | 2.17 | 0.94 | 0.25 | 0.26 | 0.26 | 0.23 |
| Asbrandsstadir | 12 | 2.67 | 0.78 | 0.24 | 0.18 | 0.34 | 0.16 |
| Sveinbjarnargerdi | 8 | 3.50 | 1.17 | 0.36 | 0.18 | 0.47 | 0.15 |
| Total/mean | 81 | 2.40 | 0.83 | 0.28 | 0.23 | 0.33 | 0.20 |
| Females | Males | Unadjusted OR (95 % CI) | Adjusted ORa (95 % CI) | |||
| Number | Percent | Number | Percent | |||
| Totalb | 3750 | 326 | ||||
| Morphology | ||||||
| Ductal carcinoma | 2693 | 83.6 | 253 | 95.1 | Reference | Reference |
| Lobular carcinoma | 276 | 8.6 | 4 | 1.5 | 0.15 (0.06–0.41) | 0.14 (0.05–0.43) |
| Medullary carcinoma | 60 | 1.9 | 2 | 0.8 | 0.35 (0.09–1.46) | 0.46 (0.10–2.11) |
| Other | 193 | 6.0 | 7 | 2.6 | 0.39 (0.18–0.83) | 0.54 (0.24–1.23) |
| TNM stage | ||||||
| 0–1 | 560 | 40.2 | 44 | 29.5 | Reference | Reference |
| 2 | 629 | 45.1 | 70 | 47.0 | 1.42 (0.95–2.10) | 1.97 (1.20–3.23) |
| 3–4 | 205 | 14.7 | 35 | 23.5 | 2.17 (1.37–3.44) | 3.55 (1.96–6.44) |
| Histologic grade | ||||||
| Grade 1 | 149 | 5.9 | 8 | 3.5 | Reference | Reference |
| Grade 2 | 1057 | 41.7 | 92 | 39.8 | 1.62 (0.77–3.41) | 1.88 (0.76–4.67) |
| Grade 3 | 1329 | 52.4 | 131 | 56.7 | 1.84 (0.88–3.83 | 2.66 (1.08–6.55) |
| Lymph node status | ||||||
| Negative | 1398 | 52.4 | 123 | 50.2 | Reference | Reference |
| Positive | 1270 | 47.6 | 122 | 49.8 | 1.09 (0.84–1.43) | 1.55 (1.12–2.14) |
| ER status | ||||||
| Negative | 650 | 22.7 | 8 | 3.3 | Reference | Reference |
| Positive | 2211 | 77.3 | 236 | 96.7 | 8.67 (4.26–17.66) | 10.59 (5.15–21.80) |
| PR status | ||||||
| Negative | 892 | 35.0 | 30 | 13.2 | Reference | Reference |
| Positive | 1654 | 65.0 | 198 | 86.8 | 3.56 (2.41–5.26) | 5.04 (3.17–8.04) |
| HER2 status | ||||||
| Negative | 1404 | 85.9 | 126 | 83.4 | Reference | Reference |
| Positive | 230 | 14.1 | 25 | 16.6 | 1.21 (0.77–1.90) | 1.22 (0.70–2.11) |
| Subtypes | ||||||
| ER+ and/or PR+, HER2− | 1112 | 69.8 | 118 | 81.9 | Reference | Reference |
| ER+ and/or PR+, HER2+ | 182 | 11.4 | 22 | 15.3 | 1.14 (0.70–1.84) | 1.18 (0.65–2.13) |
| ER−, PR−, HER2+ | 40 | 2.5 | 2 | 1.4 | 0.47 (0.11–1.98) | 0.42 (0.09–1.98) |
| Triple-negative (ER−, PR−, HER2−) | 260 | 16.3 | 2 | 1.4 | 0.07 (0.02–0.30) | 0.05 (0.01–0.22) |
| ER+ and/or PR+, HER2− vs. others | 0.51 (0.33–0.79) | 0.42 (0.25–0.70) |
| Daily Cannabis Users | Cannabis Non-Users | |
| Sample Size (N) | 243 | 244 |
| Gender | 81% male; 19% female | 51% male; 49% female |
| Average Age* | M = 37.8, SD = 13.3 | M = 28.2, SD = 11.0 |
| Maximum Income Bracket** | M = $44,431, SD = $23,027 | M = $39,640, SD = $24,159 |
| Causative factors | Numbers |
| Antenatal | 38 (11.7 %) |
| Intrapartum | 220 (67.9 %) |
| Placental abruption | 87 |
| Cord prolapse | 16 |
| Uterine rupture | 15 |
| Maternal hypoxic event | 8 |
| Fetal exsanguination | 8 |
| Clinical CAM (Group I ) | 19 |
| Non clinical CAM (Group II) | 67 |
| Perinatal | 8 (2.5 %) |
| Fetal central nervous system or systemic infection | 8 |
| Miscellaneous | 58 (17.9 %) |
| Suspected CAM | 54 |
| Unknown causes | 4 |
| Total | 324 |
| Interactions | Patientsn = 624n (%) |
| Potential drug-drug interactions | 492 (78.8) |
| Number of potential drug-drug interactions* | |
| 1 | 154 (24.7) |
| 2 | 92 (14.7) |
| 3–4 | 154 (24.7) |
| ≥ 5 | 92 (14.7) |
| Type D | 24 (3.8) |
| ACE* inhibitors + potassium-sparing diuretics (or potassium supplementation) | 11 (1.8) |
| NSAID*+ Methotrexate | 5 (0.8) |
| NSAID* +anticoagulants (or glucocorticoids) | 5 (0.8) |
| β blocking agents + Verapamil (or Fluoxetin) | 3 (0.4) |
| Type C | 468 (75.0) |
| ACE* inhibitors + NSAID* | 252 (40.4) |
| NSAID*+ low dose ASA* | 212 (34.0) |
| NSAID*+ sulfonylureas | 128 (20.5) |
| ACE* inhibitors + low dose ASA* | 130 (20.8) |
| β blocking agents + NSAID* | 107 (17.1) |
| NSAID* + Diuretics | 105 (16.8) |
| ACE* inhibitors + glybenclamide | 68 (10.9) |
| NSAID*+ other NSAID* | 51 (8.2) |
| ACE* inhibitors + thiazide diuretics | 47 (7.6) |
| Pravastatin + bezafibrate | 35 (5.6) |
| Pentoxiyilline + antihypertensives | 37 (5.9) |
| Metformin+ ranitidine | 40 (6.5) |
| Glibenclamide + antimycotics or cotrimoxazole | 24 (3.9) |
| Furosemide + ACE* inhibitors | 21 (3.4) |
| ACE* inhibitors + antiacids | 19 (3.1) |
| Alendronate + NSAIDs* | 18 (2.9) |
| Insulin + antihypertensive | 18 (2.9) |
| Pentoxifylline + hypoglycemic agents | 14 (2.2) |
| Acetaminophen + carbamazepin | 14 (2.2) |
| Ranitidine + azole type of antimycotics | 11 (1.8) |
| Others | 61 (9.4) |
| Potential drug-disease interactions | 400 (64.1) |
| Number of potential drug-disease interactions | |
| 1 | 346 (55.4) |
| ≥ 2 | 54 (8.7) |
| NSAIDs* in patients with hypertension and/or chronic heart failure | 384 (61.5) |
| β blocking agents in patients with diabetes mellitus | 31 (5.0) |
| NSAIDs* in patients with chronic renal insufficiency | 18 (2.9) |
| NSAIDs* in patients with previous peptic ulcer | 8 (1.3) |
| Thiazides diuretics in patients with gout | 7 (1.1) |
| Metformin in patients with chronic renal insufficiency or congestive heart failure | 6 (1.0) |
| β blocking agents in patients with peripheral vascular disease | 4 (0.6) |
| β blocking agents in patients with asthma/COPD* | 3 (0.5) |
| Others | 5 (1.0) |
| District | Number | Percent |
| Gulu | ||
| Total anaemia | 117 | 32.9 |
| Mild anaemia | 82 | 23.0 |
| Moderate anaemia | 32 | 9.0 |
| Severe anaemia | 3 | 0.8 |
| Hoima | ||
| Total anaemia | 47 | 12.1 |
| Mild anaemia | 35 | 9.0 |
| Moderate anaemia | 10 | 2.5 |
| Severe anaemia | 2 | 0.5 |
| Gene type | Number of genes* | Differentially expressed* | Enrichment p-value** | Enrichment status+ |
| Housekeeping | 3292 | 29 | 1.60E-13 | Depleted |
| Weak promoter | 5262 | 118 | 0.07 | Depleted |
| Narrow promoter | 930 | 43 | 1.20E-04 | Enriched |
| Broad promoter | 1279 | 51 | 9.50E-04 | Enriched |
| Bivalent | 3400 | 166 | 4.90E-18 | Enriched |
| CT | MRI | DSA | ||||||||||||
| unenhanced | enhancement | unenhanced | Gd-DTPA-enhanced | enhancement | ||||||||||
| shape | border | density | Arterial phase | Venous phase | shape | border | T1WI | T2WI | DWI | Arterialphase | Venousphase | Delayphase | ||
| case1 | M-R-O | well | hypo | hetero | moderate | Lob | well | hypo | hyper | sig. Hyper | hetero | hyper | moderate | hyper |
| case2 | M-R-O | well | hypo | hetero | moderate | Lob | well | hypo | hyper | sig. Hyper | hetero | moderate | mild | hyper |
| case3 | M-R | well | hypo | hetero | moderate | Lob | well | hypo | hyper | hyper | hetero | moderate | mild | hyper |
| case4 | M-R-O | well | hypo | hetero | moderate | Lob | well | hypo | hyper | sig. Hyper | hetero | hyper | moderate | hyper |
| case5 | M-R-O | well | hypo | hetero | moderate | Lob | well | hypo | hyper | sig. Hyper | hetero | hyper | moderate | hyper |
| case6 | M-O | well | hypo | hetero | moderate | M-N | well | hypo | hyper | sig. Hyper | hetero | moderate | mild | hyper |
| case7 | M-O | well | hetero, hypo | hetero | moderate | M-N | well | hypo | hyper | sig. Hyper | hetero | moderate | mild | hyper |
| case8 | S-R | well | hypo | homo | mild | nodule | well | hypo | hyper | hyper | homo | moderate | mild | hyper |
| case9 | M-N | well | hypo | hyper | sig. Hyper | hetero | moderate | mild | hyper | |||||
| case10 | M-N | well | hypo | hyper | sig. Hyper | hetero | mild | mild | hyper | |||||
| case11 | Irr | well | hetero | hyper | hyper | hetero | hetero | hetero | hetero |
| Outlet type | ||||
| Anti-malarials | Private | Not-for-profit | ||
| Median price (range) USD | Median price ratio | Median price (range) USD | Median price ratio | |
| AL* | 0.94 (0.63-1.25) | 1.88 | 0.75 (0.63-1.00) | 1.5 |
| Other forms of ACT** | 6.0 (1.88-10.63) | 12 | 2.5 (1.88-3.13) | 5 |
| Quinine* | 1.0 (0.75-1.25) | 1.33 | 0.75 (0.63-1.13) | 1 |
| UUY (Phe) | AAY (Asn) | AAR (Lys) | AGR (Arg) | ||||
| Leu | 0.00 | Asn | -0.02 | Lys | -0.27 | Gly | 0.00 |
| Ile | 0.32 | Asp | 0.00 | Gln | -0.16 | Ser | 0.36 |
| Phe | 0.41 | Glu | 0.23 | Glu | 0.00 | Ala | 0.48 |
| Met | 0.73 | Gln | 0.53 | Arg | 0.24 | Asn | 0.68 |
| Val | 0.75 | Lys | 1.09 | Asn | 0.46 | Thr | 0.69 |
| Tyr | 2.17 | His | 1.11 | His | 1.04 | Pro | 0.77 |
| Cys | 2.21 | Ser | 1.20 | Asp | 1.13 | Asp | 0.80 |
| Trp | 2.37 | Pro | 1.21 | Pro | 1.89 | Gln | 0.86 |
| Thr | 2.83 | Thr | 1.27 | Thr | 2.10 | Cys | 0.86 |
| His | 3.38 | Arg | 1.55 | Tyr | 2.27 | His | 0.88 |
| Pro | 3.41 | Ala | 1.92 | Ser | 2.66 | Glu | 0.92 |
| Ala | 3.55 | Tyr | 2.11 | Met | 3.62 | Met | 1.11 |
| Gln | 4.18 | Gly | 2.20 | Ala | 3.84 | Lys | 1.14 |
| Ser | 4.39 | Met | 2.50 | Trp | 3.86 | Val | 1.22 |
| Asn | 4.76 | Cys | 2.79 | Phe | 4.48 | Tyr | 1.22 |
| Arg | 4.98 | Leu | 3.05 | Leu | 4.81 | Arg | 1.23 |
| Glu | 5.24 | Phe | 3.06 | Gly | 4.81 | Leu | 1.26 |
| Lys | 5.37 | Val | 3.06 | Cys | 4.99 | Ile | 1.32 |
| Asp | 5.77 | Trp | 3.06 | Val | 5.06 | Phe | 1.36 |
| Gly | 6.02 | Ile | 3.29 | Ile | 5.26 | Trp | 1.58 |
| Introduced Mutation | B19V Internalization (%) in the Presence of Competing VP1u 1 | Remaining VP1u Function (%) 2 |
| Truncations | ||
| WT | 4.0 | 100 |
| ∆N5 | 4.1 | 99.9 |
| ∆N11 | 17.0 | 20.5 |
| ∆N20 | 52.9 | 3.7 |
| ∆N30 | 97.4 | 0.1 |
| ∆C126 | 3.7 | 108.4 |
| ∆C137 | 4.5 | 90.0 |
| ∆C147 | 4.9 | 81.3 |
| ∆C159 | 28.1 | 10.8 |
| ∆C170 | 84.8 | 0.8 |
| Mutations in helix 1 | ||
| E14A | 3.4 | 121.3 |
| F15C | 47.5 | 4.7 |
| F15W | 20.6 | 16.2 |
| A16S | 4.1 | 98.5 |
| V19A | 28.8 | 10.4 |
| V19S | 31.1 | 9.3 |
| Y20C | 26.3 | 11.8 |
| Y20W | 6.6 | 60.1 |
| Q21A | 14.4 | 25.1 |
| Q21P | 50.7 | 4.1 |
| Q22A | 66.2 | 2.2 |
| Q22P | 90.8 | 0.4 |
| F23S | 41.6 | 5.9 |
| F26S | 24.4 | 13.1 |
| Y27C | 71.4 | 1.7 |
| Y27W | 26.4 | 11.8 |
| K29A | 4.2 | 96.4 |
| Double-glycine mutations | ||
| WW8/9GG | 26.8 | 11.5 |
| TD33/34GG | 52.3 | 3.9 |
| SL48/49GG | 62.1 | 2.6 |
| EN54/55GG | 50.7 | 4.1 |
| LF59/60GG | 85.3 | 0.7 |
| VariableOral morphine equivalents, mg | Pre Group(n = 276) | ERAS Group(n = 96) | p-value |
| Total Opioid use, Mean (SD) | 163.8 (73.2) | 111.4 (46.0) | < 0.001* |
| Intraop Opioid use, Mean (SD) | 93.6 (33.8) | 73.4 (29.8) | < 0.001* |
| PACU Opioid use, Mean (SD) | 36.7 (30.8) | 15.4 (19.3) | < 0.001* |
| Hospital Floor Opioid use, Mean (SD) | 33.4 (44.5) | 22.6 (19.3) | 0.001* |
| Lichen species | Phenolics contentμg of pyrocatechol equivalent | Flavonoid contentμg of rutin equivalent |
| C. furcata | 12.95 ± 1.065 | 10.55 ± 1.099 |
| L. atra | 73.02 ± 1.275 | 54.77 ± 1.231 |
| L. muralis | 43.19 ± 1.085 | 34.56 ± 1.074 |
| Disease | Days after inoculation | |||||
| 8 | 11 | 14 | 17 | 20 | ||
| Cercospora leaf spot | Overall accuracy [%] | 98.90 | 89.01 | 96.58 | 98.73 | |
| Kappa coefficient | 0.99 | 0.53 | 0.92 | 0.98 | ||
| Diseased leaf area [%] | 0 | 6.56 | 7.61 | 20.92 | ||
| Powdery mildew | Overall accuracy [%] | 94.34 | 96.79 | 97.23 | 90.18 | |
| Kappa coefficient | 0.88 | 0.91 | 0.95 | 0.84 | ||
| Diseased leaf area [%] | 14.40 | 19.37 | 41.94 | 50.04 | ||
| Sugar beet rust | Overall accuracy [%] | 61.70 | ||||
| Kappa coefficient | 0.56 | |||||
| Diseased leaf area [%] | 2.89 |
| Knowledge domain | Unadjusted OR (95 % CI) | Adjusted OR (95 % CI) |
| Overall knowledge | 1.02 (0.64, 1.63) | 1.07 (0.65, 1.75) |
| Child health | 1.29 (0.50, 1.24) | 1.19 (0.73, 1.96) |
| Postpartum | 1.24 (0.78, 1.95) | 1.22 (0.75, 1.99) |
| Newborn care | 1.24 (0.78, 1.95) | 1.16 (0.70, 1.90) |
| Injury prevention | 1.24 (0.77, 1.98) | 1.19 (0.71, 1.98) |
| Nutrition | 1.05 (0.67, 1.66) | 1.05 (0.65, 1.74) |
| Family planning | 0.97 (0.61, 1.52) | 0.99 (0.61, 1.60) |
| HIV | 0.85 (0.54, 1.34) | 0.88 (0.54, 1.44) |
| Pregnancy | 0.79 (0.50, 1.24) | 0.77 (0.47, 1.27) |
| Infection prevention | 0.79 (0.50, 1.25) | 0.75 (0.47, 1.20) |
| Malaria | 0.68 (0.43, 1.09) | 0.69 (0.42, 1.15) |
| S. No. | Name of the seed | Hot water extraction (%) | Pressurized hot water extraction (%) | Solvent extraction (%) |
| 1. | Syzygium cumini | 16.07 | 49.24 | 78.14 |
| 2. | Citrus sinensis | 19.80 | 74.79 | 75.65 |
| 3. | Mangifera indica | 59.54 | 84.76 | 65.17 |
| 4. | Vitis vinifera | 68.87 | 79.86 | 83.31 |
| 5. | Manilakara zapota | 44.72 | 81.59 | 81.24 |
| 6. | Artocarpus heterophyllus | 40.92 | 87.52 | 82.68 |
| Male | ||||
| Heinz 1706 | LA716 | Periclinal 1 | ||
| Female | Heinz 1706 | Yes | Yes | Yes |
| LA716 | No | Yes | No | |
| Periclinal 1 | No | Yes | No |
| U2OS-Cas9 | U2OS-Cas9 | U2OS-Cas9 | HeLa-Cas9 | HeLa-Cas9 | HeLa-Cas9 | |
| No gRNA | EMX1-RNA | EMX1-BNA-5 | No gRNA | EMX1-RNA | EMX1-BNA-5 | |
| EMX1 | 0.004 | 69.181 | 27.393 | <0.003 | 69.118 | 25.649 |
| EMX1-OT1 | 0.005 | 12.233 | <0.003 | 0.009 | 11.677 | <0.003 |
| EMX1-OT2 | 0.031 | 1.007 | 0.020 | 0.025 | 0.607 | 0.020 |
| EMX1-OT3 | 0.068 | <0.003 | 0.047 | 0.005 | <0.003 | <0.003 |
| EMX1-OT4 | 0.073 | <0.003 | <0.003 | 0.042 | 0.016 | 0.051 |
| EMX1-OT5 | <0.003 | 0.113 | 0.002 | 0.060 | 0.141 | <0.003 |
| Province | District | Village | No. of larvae |
| Nangarhar | Behsood | Banaghar, Samarkhel, Saracha | 200 |
| Jalalabad | Bagrami | 200 | |
| Kama | Banajur, Sabirlalay, Sangarsary | 200 | |
| Kunar | Chawkay | Babur | 200 |
| Nurgal | Nurgal | 200 | |
| Assadabad | Asadabad | 200 |
| PCR target | Midguts from mosquitoes fed on gametocyte cultureMean Cp (95% CI) | Midguts with microscopy-confirmed P. falciparum oocystsMean Cp (95% CI) |
| EHV | 24.75(24.68–24.82) | 24.14(23.68–24.61) |
| RPS7 | 22.85(22.68–23.02) | 23.03(22.0–24.07) |
| Characteristics | IRS (n=798) No (%) | Replastered (n=59) No (%) | Owns at least one LLIN (n=1,879) No (%) | Uses at least one LLIN (n=630) No (%) | Chi-square test (P value) |
| Heard about malaria (n=2,867) | |||||
| Yes | 670 (84.0) | 56 (94.9) | 1,559 (83.0) | 534 (84.8) | 3.12 (0.08) |
| No | 128 (16.0) | 3 (5.1) | 320 (17.0) | 96 (15.2) | |
| Malaria is a communicable disease (n=2,463) | |||||
| Yes | 464 (58.1) | 35 (59.3) | 1,064 (56.6) | 416 (66.0) | 35.20 (0.0001) |
| No | 191 (23.9) | 18 (30.5) | 448 (23.8) | 107 (16.9) | |
| I do not know | 11 (14) | 3 (5.1) | 39 (2.1) | 9 (1.4) | |
| Route of transmission of malaria (n=1,413) | |||||
| Mosquito bite | 365 (46.0) | 26 (44.1) | 668 (35.6) | 339 (53.8) | 99.80 (0.0001) |
| Others | 97 (12.2) | 9 (15.3) | 400 (21.3) | 79 (12.5) | |
| Malaria is a preventable disease (n=2,463) | |||||
| Yes | 591 (74.1) | 47 (79.7) | 1,296 (69.0) | 490 (77.8) | 45.18 (0.0001) |
| No | 73 (9.1) | 8 (13.6) | 193 (10.3) | 39 (6.2) | |
| I don't know | 7 (0.9) | 1 (1.7) | 73 (3.9) | 6 (1.0) | |
| Malaria is a severe disease (n=2,463) | |||||
| Yes | 665 (83.3) | 55 (93.2) | 1,540 (82.0) | 527 (83.7) | Not valid |
| No | 4 (0.5) | 0 (0.0) | 11 (0.6) | 5 (0.8) | |
| I don't know | 1 (0.1) | 1 (1.7) | 2 (0.1) | 2 (0.3) | |
| Malaria is a curable disease (n=2,463) | |||||
| Yes | 669 (83.4) | 56 (94.9) | 1,472 (78.3) | 526 (83.5) | Not valid |
| No | 2 (0.3) | 0 (0.0) | 79 (4.2) | 5 (0.8) | |
| I don't know | 0 (0.0) | 0 (0.0) | 1 (0.02) | 1 (0.2) |
| Proton concordant & HiSeq discordant | HiSeq concordant & Proton discordant | All concordant | Both discordant | |||
| Total | HiSeq = Proton | All discordant | ||||
| Average | 64 | 1849 | 76945 | 216 | 202 | 14 |
| %CV | 19.6 | 55.6 | 1.24 | 4.23 | 5.51 | 31.6 |
| Common | 1 | 43 | 66472 | 80 | 67 | 1 |
| Label claim Mg/tablet | Amount added % | Total amount added (mg) | Amount recovered* (mg) ± SD | % Recovery ± SD (n = 3) |
| Risperidone | 50 | 1 | 0.99 ± 0.02 | 99.66 ± 1.79 |
| 2 | 100 | 2 | 2.01 ± 0.02 | 100.21 ± 1.11 |
| 150 | 3 | 3.01 ± 0.04 | 100.31 ± 1.46 |
| EcoRI primers | MseI primers | ||
| Name | Sequence | Name | Sequence |
| E1 | AAC | M1 | CAA |
| E2 | AAG | M2 | CAC |
| E3 | ACA | M3 | CAG |
| E4 | ACT | M4 | CAT |
| E5 | ACC | M5 | CTA |
| E6 | ACG | M6 | CTC |
| E7 | AGC | M7 | CTG |
| E8 | AGG | M8 | CTT |
| Control | Group F0.5 | Group F1.0 | |
| Gender (M/F) | 17/13 | 14/16 | 15/15 |
| Age (yrs) | 78.2 ± 9.2 | 79.6 ± 6.1 | 82.1 ± 7.9 |
| BMI (kg/m2) | 23.3 ± 2.2 | 25.2 ± 1.5 | 24.5 ± 2.5 |
| ASA (II/III) | 24/6 | 25/5 | 27/3 |
| Hypertension | 26/4 | 24/6 | 26/4 |
| Diabetes | 17/13 | 18/12 | 15/15 |
| Drug allergies | 3/27 | 3/27 | 4/26 |
| Smoking history | 11/19 | 12/18 | 11/19 |
| Snoring | 10/20 | 9/21 | 8/22 |
| Colonoscopy time (min) | 15.2 ± 1.8 | 14.6 ± 2.2 | 16.2 ± 1.9 |
| All diarrhea cases | Severe cases | ||||||
| n | %* | 95% CI | deff | n | %* | 95% CI | |
| Total (N = 2940) | 1066 | 36.8 | [33.7-40.0] | 3.2 | 98 | 3.4 | [2.2-4.6] |
| By district | |||||||
| Aguie (N = 735) | 250 | 34.0 | [28.2-39.8] | 2.9 | 15 | 1.5 | [0.6-2.5] |
| Guidan Roumdji (N = 735) | 273 | 40.1 | [33.1-47.1] | 5.2 | 28 | 5.3 | [2.2-8.5] |
| Maradi CU (N = 735) | 219 | 32.0 | [27.4-36.7] | 2.0 | 14 | 1.8 | [0.7-2.9] |
| Madarounfa (N = 735) | 324 | 44.2 | [38.7-49.6] | 1.2 | 41 | 5.5 | [3.2-7.8] |
| By age (months) | |||||||
| 0-2 (N = 100) | 19 | 16.6 | [8.1-25.0] | 1.3 | 1 | 1.5 | [0.0-4.4] |
| 3-5 (N = 160) | 49 | 35.0 | [22.8-47.1] | 3.0 | 4 | 3.8 | [0.0-9.1] |
| 6-11 (N = 382) | 202 | 54.2 | [48.0-60.5] | 1.7 | 17 | 4.0 | [0.2-6.1] |
| 12-17 (N = 206) | 203 | 52.1 | [45.8-58.3] | 1.7 | 18 | 4.0 | [0.9-7.0] |
| 18-23 (N = 153) | 150 | 37.3 | [30.3-44.3] | 2.0 | 9 | 1.3 | [0.3-2.3] |
| 24-59 (N = 1492) | 443 | 28.8 | [25.2-32.3] | 2.3 | 49 | 3.7 | [2.2-5.1] |
| Property | PRD File | FAM File |
| Identifier | PRD_######, e.g., PRD_000001 | FAM_######, e.g., FAM_000001 |
| Name | Molecule name | Family name |
| Description | • Molecular formula and weight | • List of member PRD identifiers |
| • Specific function (class) | • Literature references | |
| • Structural details (type) | ||
| Chemical details | • List of polymer and nonpolymer entities comprising the molecule | • Synonyms for PRD family members collected from various resources including the PDB and primary citations |
| • Polymer or subcomponent sequence• Description of how all components in the molecule are linked | • Reference database IDs and links to various resources that provide information about the family members | |
| ○ Intra-entity linkages between components in polymer entities | • Family specific annotations | |
| ○ Inter-entity linkages between polymer segments and nonpolymer components (for molecules with grouped representation) | ○ IDs and information about related small molecule crystal structures in the CSD16 | |
| ○ Corresponding literature references | ||
| Biological details | Name of organism producing the molecule (for naturally produced molecules) and source of this information (e.g. from a database, author or literature) | Annotations about structural, functional and mechanistic details for family members, including pharmacological action (where appropriate) |
| Time of measurement | Before therapy | After therapy (RCI) | Follow-up (RCI) |
| Outcome variable | |||
| PG-13 | 42 | 31 (2.66) | 23 (4.59) |
| CAPS—total | 50 | 27 (3.61) | 13 (5.81) |
| CAPS—Intrusion | 17 | 7 (2.66) | 5 (3.19) |
| CAPS—Avoidance | 25 | 14 (2.27) | 6 (3.92) |
| CAPS—Hyper arousal | 10 | 6 (1.23 NS) | 2 (2.47) |
| BDI | 22 | 15 (2.09) | 11 (3.28) |
| MAP | Anti-MAP IgG | |
| T1DM | 3/10 (30%) | 5/10 (50%) |
| T2DM | 1/2 (50%) | 1/2 (50%) |
| CONTROL | 3/6 (50%) | 2/6 (33.33%) |
| Premises | Area (Wales) | Location and Violence Strata | |||||||
| Urban | Town/Fringe | Rural | |||||||
| North | West | South East | High | Low | High | Low | High | Low | |
| Total (N = 30) | 4 | 2 | 24 | 8 | 6 | 3 | 10 | 1 | 2 |
| Intervention (N = 16) | 2 | 1 | 13 | 5 | 3 | 1 | 6 | 0 | 1 |
| Control (N = 14) | 2 | 1 | 11 | 3 | 3 | 2 | 4 | 1 | 1 |
| Health problem | Overall | Boy | Girl Significance |
| Myopia | 27.1 | 25.8 | 28.5*** |
| Caries | 69.6 | 70.0 | 69.1*** |
| Obesity | 9.5 | 10.6 | 8.4*** |
| Dysarthria | 2.5 | 3.0 | 2.0*** |
| Cryptorchidism | - | 2.1 | - |
| Heart murmur | 1.5 | 1.6 | 1.5 |
| Scoliosis | 0.4 | 0.4 | 0.4 |
| Atopic dermatitis | 0.2 | 0.2 | 0.2 |
| Dysregulated miRNA (Reference) | Expression status | Proposed target gene |
| miR-1 [53] let-7d [55] miR-17 and miR-20a [57] miR-29 [58-59] miR-34 [63] miR-99 family (miR-100 and miR-99a) [64] miR-125b [41] miR-126 [66] miR-133a [67] miR-138 [70-71] miR-153 [72] miR-200 [73] miR-200c [74] miR-222 [75] miR-363 [77] miR-375 [1] | Underexpression Underexpression Underexpression Underexpression Overexpression Underexpression Underexpression Underexpression Underexpression Underexpression Underexpression Underexpression Underexpression Underexpression Underexpression Underexpression | TAGLN2Twist, Snail ITGβ8 LAMC2, ITGA6, TGF-β Unknown IGFIR, mTOR KLF13, CXCL1 and FOXA1 VEGF-A, bFGF MSN GNA12, RhoC and ROCK2 SNAI1 and ZEB2 ZEB1,ZEB2 BMI1/ZEB1 MMP-1 Podoplanin(PDPN) Unknown |
| Total | FUG | CUG | MFUG | MUG | NUG | |
| Range (cm) | 0.8–12.9 | 0.9–7.2 | 2.5–12.9 | 2.2–6.9 | 1.3–6.0 | 0.8–6.4 |
| Mean ± SD | 4.43 ± 2.37 | 3.38 ± 1.45 | 6.66 ± 2.66 | 4.45 ± 1.46 | 3.65 ± 1.68 | 3.67 ± 1.85 |
| Internet Resource | URL |
| Sequence motif searches | |
| Pfam | http://www.sanger.co.uk/Pfam/ |
| PRINTS | http://www.biochem.ucl.ac.uk/bsm/dbbrowser/PRINTS/ |
| Prosite | http://www.expasy.org/prosite/ |
| SMART | http://smart.embl-heidelberg.de |
| Superfamily | http://supfam.mrc-lmb.cam.ac.uk/SUPERFAMILY/hmm.html |
| Structural comparison | |
| CATH | http://www.cathdb.info/latest/index.html |
| DaliLite | http://www.ebi.ac.uk/DaliLite/ |
| SCOP | http://scop.mrc-lmb.cam.ac.uk/scop/ |
| SSM | http://www.ebi.ac.uk/msd-srv/ssm/ |
| Alignment software | |
| BLAST | http://www.ncbi.nlm.nih.gov/blast/Blast.cgi |
| ClustalW | http://www.ebi.ac.uk/Tools/clustalw2/ |
| Dcode | http://www.dcode.org |
| MEGA | http://www.megasoftware.net/ |
| Muscle | http://www.ebi.ac.uk/muscle/ |
| T-coffee | http://www.tcoffee.org/ |
| Alignment optimization | |
| GBlocks | http://molevol.ibmb.csic.es/Gblocks.html |
| GeneDoc | http://www.nrbsc.org/gfx/genedoc/index.html |
| PHYLIP | http://evolution.genetics.washington.edu/phylip.html |
| Phylogenetic analysis software | |
| MrBayes | http://mrbayes.csit.fsu.edu/ |
| PhyML | http://atgc.lirmm.fr/phyml/ |
| PHYLIP | http://evolution.genetics.washington.edu/phylip.html |
| Tree-Puzzle | http://www.tree-puzzle.de/ |
| MEGA | http://www.megasoftware.net/ |
| Visualization | |
| Pymol (structural) | http://pymol.sourceforge.net/ |
| NJplot (phylogeny) | http://pbil.univ-lyon1.fr/software/njplot.html |
| MEGA | http://www.megasoftware.net/ |
| Swiss-Model (structural) | http://swissmodel.expasy.org/ |
| TreeView (phylogeny) | http://taxonomy.zoology.gla.ac.uk/rod/treeview.html |
| Databases | |
| Ensembl (Sanger project) | http://www.ensembl.org |
| PDB | http://www.rcsb.org/pdb/home/home.do |
| NCBI | http://www.ncbi.nlm.nih.gov/sites/gquery?itool=toolbar |
| Superfamily | http://supfam.mrc-lmb.cam.ac.uk/SUPERFAMILY/hmm.html |
| UniProt | http://www.expasy.uniprot.org/ |
| Parameter | Pediatric Journals(n = 42) | General Journals(n = 68) |
| Risk of Bias† | ||
| Adequate Sequence Generation | 29 (69) | 53 (78) |
| Adequate Concealment of Allocation | 23 (55) | 50 (74) |
| Adequate Blinding of Participants and Providers | 21 (50) | 34 (50) |
| Adequate Blinding of Outcome Assessment | 25 (60) | 53 (78) |
| Adequate Handling of Missing Data | 30 (72) | 53 (78) |
| Stable plaque (SP) | Unstable plaque (UP) | P value | |||
| Median | 25–75% CI | Median | 25–75% CI | ||
| Fibrous cap (in μm) | 267 | 181–440 | 96 | 0–223 | 0.02 |
| LCR | 0.21 | 0.08–0.28 | 0.64 | 0.54–0.76 | <0.001 |
| Neovessels (/0.2 mm2) | 0 | 0–0.3 | 3 | 3–5 | <0.001 |
| Antipsychotics | MAOIs | Anticonvulsants/Anxiolytics/Others | |
| Chlorpromazine | Hydroxylamine | Benztropine | Phenylephrine |
| Haloperidol | Selegiline | Phenytoin | Phenobarbital |
| Sulpiride | Pargyline | Diazepam | Chlordiazepoxide |
| Flupenthixol | Quinacrine | Nitrazepam |
| I.D. 34 | I.D. 56 | I.D. 81 | |
| Tube voltage [kV] | 220 | 220 | 160 |
| Tube current [μA] | 180 | 180 | 160 |
| Power [W] | 39.6 | 39.6 | 25.6 |
| Exposure time [ms] | 499 | 499 | 999 |
| Filter | Cu 1 mm | Cu 1 mm | none |
| Number of projections | 1200 | 1200 | 1200 |
| Voxel size [μm] | 28 | 34 | 49.5 |
| FOV in horizontal plane [mm] | 33 | 58 | 82 |
| FOV vertical [mm] | 74 | 104 | 75 |
| Measurement time [min] | 40 | 60 | 20* |
| MFI (mean ± SD) | pDC | mDC | ||||
| Pre | Post | p | Pre | Post | p | |
| HLA-DR | 1673.5 ± 525.4 | 1523.4 ± 531.1 | 0.0092 | 2867.8 ± 440.9 | 2661.0 ± 573.2 | 0.1507 |
| CD83 | 548.5 ± 187.7 | 755.0 ± 683.6 | 0.3982 | 374.9 ± 108.1 | 620.7 ± 392.5 | 0.0865 |
| CD86 | 714.7 ± 174.0 | 743.6 ± 139.0 | 0.6359 | 1462.2 ± 322.8 | 1303.2 ± 328.0 | 0.4298 |
| ICOSL | 554.1 ± 223.8 | 640.4 ± 209.8 | 0.5265 | 498.2 ± 257.8 | 501.2 ± 133.7 | 0.9219 |
| PD-L1 | 316.1 ± 110.7 | 376.8 ± 111.7 | 0.1848 | 272.0 ± 68.9 | 326.1 ± 88.6 | 0.1311 |
| HLA-G | 356.7 ± 57.8 | 409.9 ± 62.3 | 0.0583 | 567.7 ± 120.5 | 587.5 ± 108.4 | 0.6944 |
| IL-T4 | 2303.6 ± 632.8 | 2743.4 ± 718.6 | 0.0165 | 1797.7 ± 424.0 | 2294.4 ± 570.7 | 0.0669 |
| CD39 | 349.7 ± 116.9 | 437.8 ± 143.6 | 0.0456 | 1516.8 ± 269.2 | 1761.7 ± 527.6 | 0.2601 |
| PD-L1/CD86 | 0.447 ± 0.110 | 0.5217 ± 0.197 | 0.3830 | 0.189 ± 0.042 | 0.268 ± 0.116 | 0.0929 |
| Maternal exposure | Baseline | Follow-up |
| Commuting | ||
| Low activity | 1.00 | 1.00 |
| High activity | 2.72 (1.08, 6.87)‡ | 3.13 (1.37, 7.16)† |
| Leisure-time sports | ||
| Low activity | 1.00 | 1.00 |
| High activity | 3.61 (1.14, 11.41)‡ | 0.87 (0.26, 2.93) |
| Sedentary | ||
| Low sedentarybehavior | * | 1.00 |
| High sedentarybehavior | * | 0.58 (0.35, 0.97)‡ |
| Error size | Mean | SD | 95% CI |
| Hit | 6.86 | 3.86 | [5.05, 8.67] |
| Small error | 6.80 | 4.36 | [4.76, 8.85] |
| Medium error | 7.61 | 4.65 | [5.43, 9.78] |
| Large error | 10.48 | 4.68 | [8.28, 12.67] |
| No med (n = 82) | Metf (n = 132) | SU (n = 38) | Combi (n = 94) | All (n = 346) | |
| Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | |
| Age (years) | 60.7 (5.1) | 59.6 (5.2) | 60.6 (6.0) | 60.0 (5.2) | 60.1 (5.3) |
| SBP (mmHg) | 169.7 (20.7) | 162.7 (20.2) | 162.5 (27.6) | 162.4 (26.3) | 164.3 (23.1) |
| DBP (mmHg) | 86.9 (7.3) | 89.9 (9.9) | 93.1 (11.1) | 88.0 (11.9) | 89.3 (10.7) |
| Cholesterol (mmol/l)* | 5.6 (1.0) | 5.6 (1.0) | 5.8 (1.3) | 5.7 (1.1) | 5.6 (1.1) |
| LDL (mmol/l) | 3.5 (0.9) | 3.7 (0.9) | 3.9 (1.2) | 3.8 (0.9) | 3.7 (1.0) |
| HbA1c (%)* | 6.3 (0.8) | 7.3 (1.4) | 7.0 (1.1) | 8.2 (1.8) | 7.3 (1.5) |
| BMI (kg/m2)* | 29.2 (4.3) | 31.9 (4.7) | 29.7 (4.3) | 30.3 (4.4) | 30.6 (4.6) |
| Weight (kg)* | 85.9 (15.7) | 93.8 (15.6) | 86.1 (16.7) | 88.2 (15.1) | 89.5 (15.9) |
| Waist circumference* | 104.2 (12.2) | 110.0 (11.4) | 104.6 (14.6) | 106.6 (11.7) | 107.1 (12.2) |
| Statin use (n, (%)) | 7 (8.8) | 17 (13.2) | 5 (14.3) | 14 (15.1) | 43 (13.1) |
| True stenosis [%] | Heart rate [bpm] | Method | Plaque diameter [mm] | Vessel diameter [mm] | Stenosis [%] | Deviation [PP] |
| 12.5% | 50 | High pitch | 1.13 ± 0.19 | 4.17 ± 0.35 | 27.0 ± 3.5 | 14.5 |
| Gating | 1.03 ± 0.19 | 4.23 ± 0.45 | 24.4 ± 3.7 | 11.9 | ||
| 70 | High pitch | 1.12 ± 0.18 | 4.14 ± 0.35 | 27.1 ± 3.4 | 14.6 | |
| Gating | 1.03 ± 0.19 | 4.26 ± 0.41 | 24.1 ± 3.6 | 11.6 | ||
| 90 | High pitch | 1.11 ± 0.19 | 4.15 ± 0.30 | 26.7 ± 3.5 | 14.2 | |
| Gating | 1.03 ± 0.19 | 4.22 ± 0.40 | 24.4 ± 3.4 | 11.9 | ||
| 25% | 50 | High pitch | 1.63 ± 0.34 | 4.35 ± 0.38 | 37.2 ± 5.7 | 12.2 |
| Gating | 1.53 ± 0.33 | 4.35 ± 0.49 | 35.0 ± 4.6 | 10.0 | ||
| 70 | High pitch | 1.65 ± 0.33 | 4.33 ± 0.36 | 37.8 ± 5.1 | 12.8 | |
| Gating | 1.53 ± 0.34 | 4.35 ± 0.51 | 34.8 ± 4.6 | 9.8 | ||
| 90 | High pitch | 1.66 ± 0.35 | 4.29 ± 0.39 | 38.4 ± 5.8 | 13.4 | |
| Gating | 1.61 ± 0.36 | 4.36 ± 0.51 | 36.7 ± 5.2 | 11.7 | ||
| 50% | 50 | High pitch | 2.19 ± 0.37 | 4.06 ± 0.20 | 53.9 ± 8.0 | 3.9 |
| Gating | 2.08 ± 0.28 | 3.95 ± 0.18 | 52.7 ± 6.2 | 2.7 | ||
| 70 | High pitch | 2.16 ± 0.36 | 4.00 ± 0.23 | 54.0 ± 7.9 | 4.0 | |
| Gating | 2.11 ± 0.27 | 3.99 ± 0.14 | 52.9 ± 6.1 | 2.9 | ||
| 90 | High pitch | 2.20 ± 0.38 | 4.05 ± 0.21 | 54.4 ± 8.4 | 4.4 | |
| Gating | 2.11 ± 0.32 | 3.96 ± 0.19 | 53.1 ± 6.7 | 3.1 |
| IFT-A | IFT-B | |||||||
| IFT122 | IFT140 | IFT172 | IFT52 | IFT80 | IFT88 | TTC-26 | TTC30a | |
| Attheya septentrionalis | + | |||||||
| Aulacoseira subarctica | + | + | + | + | + | + | ||
| Chaetoceros curvisetus | + | + | + | |||||
| Corethron hystrix | + | |||||||
| Corethron pennatum | + | + | ||||||
| Coscinodiscus wailesii | + | + | + | + | + | + | ||
| Cyclotella meneghiniana | + | + | + | + | ||||
| Dactyliosolen fragilissimus | + | + | ||||||
| Ditylum brightwellii | + | + | + | + | + | + | + | |
| Extubocellulus spinifer | + | + | + | + | ||||
| Leptocylindrus aporus | + | + | + | |||||
| Leptocylindrus danicus | + | + | + | + | + | + | + | + |
| Leptocylindrus hargravesii | + | + | + | + | + | + | + | |
| Minutocellus polymorphus | + | + | + | + | ||||
| Odontella aurita | + | + | + | + | + | + | + | |
| Proboscia alata | + | + | + | + | + | + | + | + |
| Proboscia inermis | + | + | + | |||||
| Rhizosolenia setigera | + | + | + | + | + | |||
| Skeletonema marinoi | + | + | + | |||||
| Skeletonema menzelii | + | + | ||||||
| Stephanopyxis turris | + | + | + | + | + | + | + | |
| Thalassiosira pseudonanaa | + | + | + | |||||
| Thalassiosira rotula | + | + | + | |||||
| Thalassiosira weissflogii | + | + | + | + | + | + | + | + |
| Cell type | Environment | Number of animals | Peripheral | Intermediate | Central |
| % EdU + a | % EdU + a | % EdU + a | |||
| Number of cells | Number of cells | Number of cells | |||
| Vsx2orJ | orJ | 4 | 4% ± 2% | 20% ± 3% | 31% ± 2% |
| 1,880 cells | 2,554 cells | 2,490 cells | |||
| Vsx2orJ | Mutant chimera | 5 | 26% ± 8% | 21% ± 4% | 21% ± 5% |
| 732 cells | 798 cells | 519 cells | |||
| Vsx2wt | Wild type | 3 | 40% ± 5% | 47% ± 4% | 32% ± 3% |
| 1,390 cells | 2,207 cells | 2,186 cells | |||
| Vsx2wt | Control chimera | 4 | 46% ± 5% | 42% ± 5% | 28% ± 1% |
| 594 cells | 1,093 cells | 883 cells | |||
| Yfp+ | Mutant chimera | 3 | 43% ± 8% | 43% ± 8% | 32% ± 5% |
| 1,209 cells | 2,608 cells | 2,169 cells | |||
| Yfp+ | Control chimera | 4 | 47% ± 2% | 44% ± 3% | 38% ± 1% |
| 809 cells | 1,048 cells | 1,378 cells |
| Seropositivity S1 | Seropositivity S6 | |||||||
| Proportion (%) | aOR | 95% CI | p value | Proportion (%) | aOR | 95% CI | p value | |
| Village | 0.0336 | 0.7022 | ||||||
| Xe Xua | 56.9 | 1.00 | 51.6 | 1.00 | ||||
| Tu Nak | 40.4 | 432.80 | [0.5–403,860] | 56.9 | 1.12 | [0.6–2.2] | ||
| Tak Lang | 44.4 | 0.02 | [0.001–0.6] | 31.3 | 0.70 | [0.2–2.1] | ||
| Age group (years) | < 0.0001 | 0.0001 | ||||||
| 0.5–10 | 18.8 | 1.00 | 26.7 | 1.00 | ||||
| 11–25 | 47.1 | 1.99 | [0.8–5] | 46.7 | 1.31 | [0.5–3.3] | ||
| > 25 | 87.9 | 17.38 | [5–58] | 92.6 | 16.96 | [4.0–71.2] | ||
| Occupation | 0.0009 | 0.1167 | ||||||
| School | 33.9 | 1.00 | 33.0 | 1.00 | ||||
| Farmer | 78.2 | 1.83 | [0.7–5] | 86.0 | 2.01 | [0.6–6.6] | ||
| Other | 7.7 | 0.13 | [0.04–0.4] | 24.3 | 0.54 | [0.2–1.2] | ||
| Main material of roof | 0.738 | NS | ||||||
| Leaves | 36.4 | 1.00 | ||||||
| Aluminium (tole) | 50.3 | 1.09 | [0.7–2] | |||||
| Education | 0.95 | [0.8–1.1] | 0.477 | NS | ||||
| Household | 1.04 | [1.0–1.1] | 0.045 | NS | ||||
| House structure | NS | 0.01 | ||||||
| On ground | 82.4 | 1.00 | ||||||
| On stilts | 48.1 | 0.24 | [0.1–0.7] | |||||
| Nr of buffaloes owned | NS | 0.63 | [0.4–0.9] | 0.021 | ||||
| Total number of bednets in the household | NS | 0.72 | [0.5–1.0] | 0.051 | ||||
| Total number of nights spent in the field | NA | 1.00 | [1.0–1.0] | 0.854 | ||||
| Working in the forest during the study | NA | 0.55 | [0.2–1.5] | 0.255 | ||||
| Total number of nights spent in the forest | NA | 1.93 | [0.6–6.5] | 0.286 | ||||
| Having slept in another cluster during the study | NA | 0.98 | [0.3–3.1] | 0.973 |
| Patient | Mild (n e %) | Moderate (n e %) | Severe (n e %) | p-value | |
| Diagnosis | AD | 28 (30.1%) | 31 (33.3%) | 8 (8.6%) | <0.001* |
| VD | 3 (3.2%) | 0 (0%) | 0 (0%) | ||
| FTD | 3 (3.2%) | 2 (2.2%) | 4 (4.3%) | ||
| LBD | 0 (0%) | 1 (1.1%) | 0 (0%) | ||
| OD | 6 (6.5%) | 4 (4.3%) | 3 (3.2%) | ||
| Evolution (months) | Mean (±SD) | 53 (±40) | 58 (±41) | 99 (±39) | <0.001**,a |
| Comorbidities | DM | 12 (12.9%) | 9 (9.7%) | 2 (2.2%) | NS |
| Hypertension | 24 (25.8%) | 25 (26.9%) | 3 (3.2%) | 0.011**,a | |
| VbD | 7 (7.5%) | 6 (6.4%) | 4 (4.3%) | NS | |
| CvD | 12 (12.9%) | 18 (19.3%) | 4 (4.3%) | NS | |
| Other | 21 (22.6%) | 13 (14%) | 5 (5.4%) | NS | |
| Total by stage Mean (±SD) | 1.8 (±1.2) | 1.8 (±1.2) | 1.1 (±1.3) | NS | |
| Caregiver | Disease after taking on carer role | 14 (15%) | 15 (16%) | 9 (10%) | |
| How long after (in months) Mean (±SD) | 29 (±24) | 30 (±24) | 35 (±15) | ||
| Use of medication prescribed by doctor | 33 (36%) | 29 (31%) | 13 (14%) |
| Description | Example selected for inclusion |
| Promises (of reduced pain) | If I’m thinner/lose more weight then rejection and criticism won’t hurt so much. |
| Consolation | I may not be doing so well in some areas of my life but at least I’m thin. |
| Self-congratulations (on eating behaviour etc.) | I’m doing really well in controlling my eating today. |
| Threats | If I don’t keep my eating under control, I’m going to get obese and be rejected by everyone. |
| Cautions regarding eating | That food/eating situation is dangerous. I’m going to have to be really careful about what I eat. |
| Need to purge | I’m worried that I’ve eaten too much. I need to get rid of it by purging. |
| Need to exercise | I can’t afford to just sit around, I have to exercise more. |
| Self-disappointment (at ability to meet dietary ideals) | I’m so disappointed at myself: I’ve failed to live up to my dietary ideals again. |
| Self-abuse | I am so pathetic and useless. I have no discipline or self-control. |
| Self-punishment | Because I have failed to live up to my dietary ideals I deserve to be punished by denying myself food or exercising harder. |
| Self-criticism (lack of self-worth) | I’m such a failure. I try really hard to do well and make friends but I’m just not the type of person I want to be. |
| Comparisons (with others) | Look at her she’s so thin and she does it so easily. Why can’t I be like her? |
| Reinterpretations | When they say things like “you’re looking well”, what they’re really meaning is how much weight I’ve put on. |
| Sensory misperceptions | Just feel that stomach/Look at those thighs (etc.). I feel/look so fat/terrible. |
| Denial (of symptoms) | Feeling tired and/or cold doesn’t mean there’s anything wrong with me. I just have to be stronger. |
| Moral judgements | Practising self-restraint is an important virtue. I despise people who have no self-control. |
| Ruination of life | My concern about food and weight is threatening the other things I want to achieve/get out of life. |
| Weariness (of constantly thinking about food) | I’m so fed up of constantly thinking about food and what I eat. |
| Misery (of living with an ED) | Life is so miserable/lonely living like this. |
| Lost identity | I feel like I don’t really know who I am/what I stand for any more. I’ve lost touch with the real me. |
| Need for secrecy | People mustn’t find out the way I think or behave concerning food. |
| Rebellion | I’m fed up of trying to control what I eat. I’m just going to eat whatever and as much as I want! |
| Pride in ED | When I think about how self-controlled I am around food compared to the average person, I feel quite proud of what I can achieve. |
| Fear of life without ED | If I let go of my strict control and ideals around eating, I’m really quite frightened about what life would be like. |
| Random sample | Symptom sample | Total | |
| Total RAV population N | 708 | 427 | 1135 |
| GA2LEN + RAV SPT N | 54 | 36 | 90 |
| RAV SPT only N | 654 | 391 | 1044 |
| Age (SD) | 33.7 (7.0) | 33.7 (7.1) | 33.7 (7.1) |
| Female (%) | 379 (53.5) | 245 (57.4) | 624 (55.0) |
| Asthma (%) | 66 (9.3) | 211 (49.4) | 277 (24.4) |
| Rhinitis (%) | 303 (42.8) | 288 (67.5) | 591 (52.1) |
| Focus groups | Systematic review | Online user-generated content | |
| METHODS | |||
| Main approach | Eight focus groups (n = 74) | Searching of databases from the earliest date to October 2014 | Analysis of 3,373 reader comments posted online in response to a news article on incentives |
| Inclusion criteria: UK adults, aged 18+ years | Databases searched: Medline; Embase; Web of Knowledge; CINAHL; PsycINFO; ASSIA; Sociological Abstracts; Scopus; The Philosopher’s Index; Cochrane Library; SSCI; IBSS | News article topic: feasibility study of financial incentives for breastfeeding | |
| Method: face-to-face focus groups; audio-recorded; lasting on average 60 min | Inclusion criteria: English language title Published in a peer-reviewed journal Explored acceptability of financial incentives for healthy behaviors Acceptability explored in the public, policy makers, potential recipients, and practitioners | Online news sites searched: BBC; Guardian; Daily Mail; Telegraph; Independent; The Sun | |
| Analytical approach: thematic analysis using NVivo 10 | Analytical approach: thematic analysis using NVivo 10 | Inclusion criteria: popular websites defined as those that achieved an average monthly audience of at least five million unique viewers per month across laptop computers, desktop computers, and mobile devices in April and May 2013 Analytical approach: thematic analysis using NVivo 10 | |
| RESULTS | |||
| Main themes | The nature of fair exchange | Fair exchange | Children are a lifestyle choice |
| Design and delivery of incentive schemes | Design and delivery | Financial incentives for breastfeeding are discriminatory and divisive | |
| Effectiveness and cost-effectiveness | Effectiveness and cost-effectiveness | Creating a culture of entitlement | |
| Recipients | Recipients | Financial incentives for breastfeeding are potentially insulting | |
| Impact on individuals and wider society | Impact on individuals and wider society | Psychological impacts on recipients | |
| “Other” issues | Effectiveness and cost-effectiveness | ||
| Generating initial motivation | |||
| Design and delivery | |||
| Informed choice |
| Interaction | Odds ratio | Lower 95% CI | Upper 95% CI |
| Model GP | |||
| age ≥60 | |||
| low SES to high | 1.84 | 1.54 | 2.20 |
| middle SES to high | 1.57 | 1.32 | 1.87 |
| age<60 | |||
| low SES to high | 0.99 | 0.89 | 1.09 |
| middle SES to high | 0.96 | 0.86 | 1.06 |
| age ≥60 vs age<60 | |||
| low SES | 4.46 | 3.93 | 5.05 |
| middle SES | 3.91 | 3.45 | 4.44 |
| high SES | 2.39 | 2.04 | 2.80 |
| Model SD | |||
| age ≥60 | |||
| low SES to high | 1.05 | 0.83 | 1.33 |
| middle SES to high | 1.08 | 0.86 | 1.35 |
| age<60 | |||
| low SES to high | 0.48 | 0.41 | 0.56 |
| middle SES to high | 0.78 | 0.68 | 0.90 |
| age ≥60 to age<60 | |||
| low SES | 4.66 | 3.85 | 5.65 |
| middle SES | 2.93 | 2.47 | 3.49 |
| high SES | 2.13 | 1.75 | 2.60 |
| Ebolavirus | IgM+ | IgG+ | Reference |
| SUDV | 2/3 (67%) | 2/3 (67%) | [67] |
| SUDV | NR | 6/27 (22%) | [68] |
| EBOV | 3/7 (43%) | 4/7 (57%) | [66] |
| EBOV | 1/3 (33%) | 0/3 (0%) | [40] |
| Total SUDV | 2/3 (67%) | 8/30 (27%) | |
| Total EBOV | 4/10 (40%) | 4/10 (40%) | |
| Total Combined | 6/13 (46%) | 12/40 (30%) |
| All proteins | Human proteins | |
| Total proteins | 550,299 | 20,186 |
| PTM proteins | 112,985 | 13,080 |
| PPI annotation (string) | 326,227 | 17,833 |
| PTM & PPI proteins | 65,907 | 12,541 |
| Drug-binding proteins(DrugBank) | – | 1980 |
| PTM & drug-binding proteins | – | 1404 |
| xthr | xtbs | xthr and xtbs | |
| Number of sequences reads obtained | 30272 | 27602 | 57874 |
| Number of clone sequences obtained | 16548 | 14901 | 31449 |
| Number of valid sequences | 26440 | 22345 | 48785 |
| Number of clones with valid sequences | 15540 | 12266 | 27806 |
| Number of clones with 5' and 3' EST | 9354 | 11486 | 20840 |
| Number of clones with 5' EST only | 4831 | 0 | 4831 |
| Number of clones with 3' EST only | 1355 | 780 | 2135 |
| Average trimmed EST length | 522 | 546 | 534 |
| Number of contigs | 4327 | 4002 | 8756 |
| Number of contigs groups | 497 | 289 | 842 |
| Number of contigs grouped | 1210 | 649 | 2209 |
| Number of unique contigs | 3117 | 3353 | 6547 |
| Nulmber of clones in contigs | 9616 | 9268 | 15642 |
| Number of singletons | 7958 | 4262 | 17018 |
| Number of clones in singletons | 5924 | 2998 | 12164 |
| Number of putative transcripts | 9538 | 6640 | 19553 |
| Max. assembled sequence length | 3028 | 3144 | 3028 |
| Average assembled sequence length | 732 | 782 | 745 |
| Max. assembled sequence size | 147 | 144 | 159 |
| Average assembled sequence size | 6 | 5 | 5 |
| Number of contigs containing | |||
| 1 | 509 | 97 | 1152 |
| 2 | 1779 | 2155 | 3730 |
| 3 | 452 | 362 | 905 |
| 4–5 | 587 | 545 | 1159 |
| 6–10 | 505 | 476 | 952 |
| 11–20 | 283 | 207 | 479 |
| 21–30 | 91 | 90 | 174 |
| 31–50 | 80 | 41 | 118 |
| 50–100 | 31 | 26 | 76 |
| >100 | 10 | 3 | 11 |
| N of articles | |
| Exclusively women | 15 |
| Pregnant | 8 |
| Reproductive age/infertility evaluation | 3 |
| Postpartum | 2 |
| Others | 2 |
| Patients (men and women) | 10 |
| Inpatients | 4 |
| Primary care | 3 |
| Others | 3 |
| College students (men and women) | 10 |
| General population (men and women, online) | 1 |
| Total | 36 |
| Age group (years) | Total | RVID (cm) | PADP (mm Hg) | TRVel (m/s) | PASP (mm Hg) | TVIRVOT (cm) | PVCSA (cm2) | PBF (L/min) | PVRECHO (Woods unit) |
| Study group | |||||||||
| A (18 - 25) | 30 | 2.92 | 10.4 | 2.20 | 192 | 24.7 | 3.56 | 6.73 | 1.04 |
| B (26 - 32) | 16 | 2.9 | 10 | 2.24 | 20.2 | 24.4 | 3.47 | 6.68 | 1.09 |
| C (33 - 40) | 14 | 3.10 | 10.9 | 2.26 | 20 | 24.36 | 3.57 | 6.65 | 1.08 |
| Total | 60 | 2.95 | 10.4 | 2.23 | 19.7 | 24.52 | 3.57 | 6.70 | 1.06 |
| Control group | |||||||||
| A (18 - 25) | 8 | 2.80 | 10.3 | 1.94 | 16.7 | 20.7 | 3.49 | 5.22 | 1.20 |
| B (26 - 32) | 4 | 2.84 | 9.9 | 2.2 | 19.4 | 20.9 | 3.52 | 5.23 | 1.28 |
| C (33 - 40) | 3 | 2.8 | 10.2 | 2.4 | 23.4 | 20.8 | 3.53 | 5.19 | 1.30 |
| Total | 15 | 2.8 | 10.2 | 2.16 | 19.1 | 20.7 | 3.52 | 5.22 | 1.22 |
| Against | For |
| Mutilates healthy organCauses psychological distressInflicts a woundDestroys ability to be fruitfulViolates prohibition against castration | Prolongs life |
| Probabilities for Post Hoc Tests Error: Between MS = 13.662, df = 4,314.0 | ||||||||
| Fan | Fan blades position | {1} | {2} | {3} | {4} | {5} | {6} | |
| {1} | B | 1.5 | 0.062871 | 0.123359 | 0.000020 | 0.000020 | 0.000020 | |
| {2} | B | 3 | 0.062871 | 0.999825 | 0.000063 | 0.000020 | 0.000020 | |
| {3} | B | 4.5 | 0.123359 | 0.999825 | 0.000031 | 0.000020 | 0.000020 | |
| {4} | B+F | 1.5 | 0.000020 | 0.000063 | 0.000031 | 0.000189 | 0.000046 | |
| {5} | B+F | 3 | 0.000020 | 0.000020 | 0.000020 | 0.000189 | 0.998916 | |
| {6} | B+F | 4.5 | 0.000020 | 0.000020 | 0.000020 | 0.000046 | 0.998916 |
| Models | CoP (FIG, 2009) | Model A | Model B | Model C | Model D | Model E |
| R | .842(a) | .799(a) | .977(a) | .792(a) | .888(a) | .888(a) |
| R2 | .709 | .638 | .955 | .628 | .788 | .788 |
| Adjusted R2 | .689 | .614 | .952 | .603 | .774 | 774 |
| Std. E. of the Estimate | .762 | 1.901 | .468 | .298 | 43.161 | 17.217 |
| ΔR2 | .709 | .638 | .955 | .628 | .788 | 788 |
| ΔF | 35.948 | 26.036 | 310.568 | 24.896 | 54.809 | 54.920 |
| df1 | 4 | 4 | 4 | 4 | 4 | 4 |
| df2 | 59 | 59 | 59 | 59 | 59 | 59 |
| p | .000 | .000 | .000 | .000 | .000 | .000 |
| Consistent** increased brain activation across ROI’s after treatment (n = 6) | Consistent** decrease (or unchanged) brain activation across ROIs after treatment (n = 7) | Mixed neuroplastic pattern across ROIs after treatment (n = 10) | p value* | |
| AMAT at baseline (s), mean (SD) | 1691.6(479) | 1070.5(753) | 2041.7(349) | 0.04 |
| AMAT improvement (s), mean (SD) | 693.3(471) | 169.8 (203) | 430(309) | 0.02 |
| Age in years, mean(SD) | 58.17(6.8) | 57.57 (13.6) | 51.7(14.6) | ns |
| Time since stroke, in years, mean(SD) | 2.28(1.5) | 1.99 (1.3) | 1.34(0.4) | ns |
| Patients who underwent a given number of invasive diagnostic procedures (%) | ||
| RIC (N = 195) | Non-RIC (N = 132) | |
| Total number of invasive diagnostic procedures performed | ||
| 0a | 9 (5) | 10 (8) |
| 1 | 99 (51) | 68 (51) |
| 2 | 67 (34) | 41 (31) |
| ≥3 | 20 (10) | 13 (9) |
| All individuals | |||||||
| Age groups | 2–3 years | 4–8 years | 9–18 years | 19–50 years | 51–70 years | 71+ years | |
| Total dairy, cup/equivalents | Current | 2.38 ± 0.11 | 2.04 ± 0.05 | 2.05 ± 0.06 | 1.65 ± 0.04 | 1.46 ± 0.04 | 1.28 ± 0.03 |
| Modeled | 2.43 ± 0.10 | 2.39 ± 0.04 | 3.00 ± 0.04 | 3.03 ± 0.03 | 2.99 ± 0.03 | 2.91 ± 0.02 | |
| Calcium, mg/d | Current | 1037 ± 35 | 975 ± 17 | 1047 ± 21 | 1025 ± 15 | 933 ± 14 | 814 ± 13 |
| Modeled | 1054 ± 34 | 1081 ± 15 | 1329 ± 16 | 1436 ± 12 | 1387 ± 11 | 1300 ± 11 | |
| Magnesium, mg/d | Current | 200 ± 4 | 211 ± 2 | 247 ± 4 | 307 ± 5 | 302 ± 4 | 256 ± 4 |
| Modeled | 201 ± 4 | 218 ± 2 | 266 ± 4 | 335 ± 5 | 332 ± 4 | 289 ± 4 | |
| Protein, g/d | Current | 53.3 ± 1.2 | 59.4 ± 0.7 | 75.2 ± 1.2 | 87.2 ± 1.0 | 79.3 ± 1.1 | 64.3 ± 1.2 |
| Modeled | 53.7 ± 1.2 | 62.5 ± 0.6 | 83.3 ± 1.1 | 98.9 ± 0.9 | 92.2 ± 1.1 | 78.1 ± 1.1 | |
| Vitamin A, RAE/d | Current | 581 ± 15 | 579 ± 11 | 598 ± 18 | 599 ± 13 | 664 ± 12 | 658 ± 17 |
| Modeled | 587 ± 15 | 615 ± 11 | 692 ± 16 | 736 ± 12 | 815 ± 11 | 819 ± 16 | |
| Vitamin D, μg/d | Current | 7.1 ± 0.2 | 5.8 ± 0.1 | 5.3 ± 0.1 | 4.7 ± 0.1 | 4.9 ± 0.1 | 4.7 ± 0.1 |
| Modeled | 7.2 ± 0.2 | 6.4 ± 0.1 | 6.7 ± 0.1 | 6.8 ± 0.1 | 7.3 ± 0.1 | 7.2 ± 0.1 | |
| Potassium, mg/d | Current | 2035 ± 37 | 2049 ± 23 | 2261 ± 42 | 2705 ± 36 | 2799 ± 38 | 2457 ± 39 |
| Modeled | 2049 ± 37 | 2134 ± 23 | 2485 ± 39 | 3031 ± 34 | 3160 ± 36 | 2843 ± 37 | |
| Calories, kcal/d | Current | 1456 ± 23 | 1728 ± 16 | 2088 ± 24 | 2276 ± 22 | 2011 ± 20 | 1649 ± 27 |
| Modeled | 1460 ± 23 | 1757 ± 15 | 2164 ± 24 | 2388 ± 21 | 2135 ± 20 | 1781 ± 26 | |
| Saturated Fat, g/d | Current | 19.2 ± 0.6 | 22.3 ± 0.4 | 26.6 ± 0.4 | 28.0 ± 0.4 | 25.5 ± 0.4 | 20.2 ± 0.4 |
| Modeled | 19.3 ± 0.6 | 22.7 ± 0.4 | 27.5 ± 0.4 | 29.1 ± 0.4 | 26.9 ± 0.4 | 21.7 ± 0.4 | |
| Sodium, mg/d | Current | 2113 ± 44 | 2617 ± 37 | 3392 ± 70 | 3742 ± 39 | 3375 ± 46 | 2717 ± 52 |
| Modeled | 2124 ± 44 | 2681 ± 37 | 3563 ± 69 | 3992 ± 37 | 3651 ± 45 | 3013 ± 51 |
| Spontaneous deliveriesa | Provider-initiated deliveries | All deliveries | ||||||||
| Gestation lengthb | Late preterm | Early term | Full term (reference) | Late preterm | Early term | Full term (reference) | Late preterm | Early term | Full term (reference) | |
| N | 1812 | 9701 | 56 527 | 1 007 | 4535 | 7824 | 2819 | 14054 | 64351 | |
| Unadjusted analyses | OR (95% CI)c | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | |
| Anxiety groupsd | Very high | 1.5 (1.1-2.0) | 1.3 (1.2-1.5) | - | 1.7 (1.2-2.3) | 1.3 (1.0-1.6) | - | 1.8 (1.4-2.2) | 1.4 (1.3-1.6) | - |
| High | 1.2 (0.9-1.6) | 1.0 (0.9-1.2) | - | 0.9 (0.6-1.2) | 1.0 (0.9-1.3) | - | 1,2 (1.0-1.5) | 1.1 1.0-1.2) | - | |
| Low | 1.2 (1.1-1.4) | 1.1 (1.0-1.1) | - | 1.1 (1.0-1.3) | 1.1 (1.0-1.2) | - | 1.2 (1.2-1.4) | 1.1 (1.1-1.2) | - | |
| Very low (reference) | - | - | - | - | - | - | - | - | - | |
| Adjusted analyses | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | |
| Anxiety groups | Very high | 1.4 (1.0-1.8) | 1.3 (1.1-1.5) | - | 1.7 (1.2-2.4) | 1.3 (1.0-1.6) | - | 1.7 (1.3-2.0) | 1.4 (1.3-1.6) | - |
| High | 1.1 (0.9-1.5) | 1.0 (0.9-1.1) | - | 0.9 (0.6-1.3) | 1.0 (0.9-1.3) | - | 1.1 (0.9-1-4) | 1.1 (1.0-1.2) | - | |
| Low | 1.2 (1.0-1.3) | 1.0 (1.0-1.1) | - | 1.1 (1.0-1.2) | 1.1 (1.0-1.2) | - | 1.2 (1.1-1.3) | 1.1 (1.1-1.2) | - | |
| Very low (reference) | - | - | - | - | - | - | - | - | - |
| Author | Country (ethnicity) | Cases/controls | Diagnosis of cases | Selection of controls |
| Selvaraj | India (Asian) | 210/120 | Smear, culture, radiological, clinical response confirmed PTB | Normal healthy spouses and Tuberculosis Research Centre staff, ethnicity and area of residence matched |
| Fitness | Malawi (African) | 181/533 | Smear, culture, histology confirmed TB, HIV negative | No history or symptom of TB; not first or second degree relatives of the cases; age, sex and area of residence matched |
| Vejbaesya | Thailand (Asian) | 149/147 | Smear, culture, clinical and radiological response confirmed PTB, HIV negative | Unrelated healthy blood bank donors |
| Ates | Turkey (Caucasian) | 128/80 | Smear, culture, pathological, radiological , clinical response confirmed PTB,EPTB | No history of TB noted on chest radiography, age and sex matched |
| Trajkov | Republic of Macedonia (Caucasian) | 75/301 | Smear/culture confirmed PTB | No family history of TB, nationality and area of residence matched |
| Merza | Iran (Asian) | 117/60 | Smear and radiological confirmed PTB | Nurses, doctors and TB staff with no laboratory or clinical sign of diseases development, age, sex and nationality matched |
| Sharma | India (Asian) | 185/155 | Smear, culture, histology, radiological , clinical response confirmed PTB,EPTB,HIV negative without chronic illness | Without a family history of TB or any other related disease and a possibility of a latent tuberculosis infection, socioeconomic status and ethnicity matched |
| Anoosheh | Iran (Asian) | 93/103 | Smear and culture confirmed PTB | No history of TB |
| Lin | China (Asian) | 46/40 | Pathological examination and clinical response confirmed EPTB | NR |
| Molecular species | 4 months | 10 months | 15 months | |||
| Fold Changes 1 | p-value 2 | Fold Changes 1 | p-value 2 | Fold Changes 1 | p-value 2 | |
| Metabolites derived from arachidonic acid | ||||||
| Prostaglandin D2 | 0.99 | 0.941 | 0.46 | < 0.001*** | 0.63 | 0.059 |
| Thromboxane B2 | 1.24 | 0.113 | 0.66 | 0.013* | 1.07 | 0.845 |
| 12-HHT | 1.19 | 0.149 | 0.67 | 0.005** | 0.98 | 0.952 |
| 12-HETE | 0.90 | 0.777 | 1.77 | 0.049* | 1.03 | 0.931 |
| 15-HETE | 1.03 | 0.747 | 0.71 | <0.001*** | 0.87 | 0.604 |
| 11,12-EpETrE | 0.84 | 0.225 | 0.83 | 0.007** | 1.04 | 0.886 |
| 14,15-EpETrE | 0.85 | 0.053 | 0.79 | 0.029* | 0.97 | 0.810 |
| Metabolites derived from eicosapentaenoic acid | ||||||
| 17,18-diHETE | 2.12 | < 0.001*** | 1.10 | 0.602 | 1.42 | 0.300 |
| Metabolites derived from docosahexaenoic acid | ||||||
| 19,20-diHDoPE | 1.72 | 0.002** | 1.20 | 0.251 | 1.38 | 0.261 |
| Matchsticks (%) | Nine-dot (%) | Eight-coin (%) | |
| s_inc+ | |||
| Initial | 40.0 ± 11.2 | 0.0 ± 0.0 | 5.0 ± 5.0 |
| Retest | 66.7 ± 14.2 | 36.8 ± 11.4 | 21.1 ± 9.6 |
| s_inc- | |||
| Initial | 39.0 ± 11.8 | 9.0 ± 9.1 | 0.0 ± 0.0 |
| Retest | 72.7 ± 14.1 | 20.0 ± 13.3 | 33.3 ± 11.4 |
| w_inc+ | |||
| Initial | 48.0 ± 11.2 | 10 ± 6.6 | 10.0 ± 6.6 |
| Retest | 90.9 ± 9.1 | 26.3 ± 10.4 | 42.1 ± 11.6 |
| w_inc- | |||
| Initial | 56.0 ± 12.1 | 6.0 ± 5.9 | 17.0 ± 9.0 |
| Retest | 87.5 ± 12.5 | 31.3 ± 12.0 | 33.3 ± 12.6 |
| PLR < 160 | PLR ≥ 160 | p | |||
| No. | % | No. | % | ||
| Age | 0.756 | ||||
| < 60 years | 54 | 49.5 | 55 | 50.5 | |
| ≥ 60 years | 34 | 52.3 | 31 | 47.7 | |
| Gender | 0.011 | ||||
| Male | 66 | 57.9 | 48 | 42.1 | |
| Female | 22 | 36.7 | 38 | 63.3 | |
| Previous operation | 0.004 | ||||
| + | 68 | 58.6 | 48 | 41.4 | |
| - | 20 | 34.5 | 38 | 65.5 | |
| Adjuvant chemotherapy | < 0.001 | ||||
| + | 49 | 66.2 | 25 | 33.8 | |
| - | 39 | 39.0 | 61 | 70.9 | |
| Lauren’s classification | 0.078 | ||||
| Diffuse | 20 | 50.0 | 20 | 50.0 | |
| Intestinal | 14 | 56.0 | 11 | 44.0 | |
| Mixed | 42 | 44.7 | 52 | 55.3 | |
| Unknown | 12 | 80.0 | 3 | 20.0 | |
| CEA | 0.195 | ||||
| < 5 ng/ml | 64 | 54.2 | 54 | 45.8 | |
| ≥ 5 ng/ml | 24 | 42.9 | 32 | 57.1 | |
| Number of metastasis | 0.070 | ||||
| 1 | 42 | 44.2 | 53 | 55.8 | |
| > 1 | 46 | 58.2 | 33 | 41.8 |
| Demographics | Estimated glomerular filtration rates (mL/min/1.73 m2) | P | |||
| < 60 | ≥ 60 - < 90 | ≥ 90 - 120 | ≥ 120 | ||
| Patient no., n (%) | 72 (8.1) | 390 (44.1) | 345 (39) | 77 (8.7) | |
| Gender (F/M), n | 20/52 | 53/337 | 30/315 | 8/69 | < 0.001 |
| Age, years | 59 ± 8.9 | 55.8 ± 8.3 | 51.1 ± 9 | 50.2 ± 8.5 | < 0.001 |
| Smoking, n (%) | 38 (52.7) | 238 (61.1) | 211 (60.3) | 57 (74) | 0.118 |
| CAD, n (%) | 9 (12.5) | 80 (20.5) | 56 (16.2) | 14 (18.2) | 0.262 |
| Diabetes mellitus, n (%) | 30 (41) | 113 (29) | 66 (19) | 19 (24.6) | 0.137 |
| Hypertension, n (%) | 49 (68) | 169 (43.3) | 103 (29.8) | 23 (29%) | 0.072 |
| Follow-up, months | 18.9 ± 16 | 21.8 ± 15.6 | 22.8 ± 14.1 | 22.1 ± 13 | 0.245 |
| Hospitalization, days | 9.2 ± 5.3 | 7.8 ± 4.4 | 7.1 ± 3.8 | 7.7 ± 4.6 | 0.004 |
| eGFR | 50.5 ± 9.2 | 76.7 ± 7.3 | 101.3 ± 8 | 134 ± 12.2 | < 0.001 |
| Admission creatine, mg/dL | 1.4 ± 0.4 | 1.03 ± 0.1 | 0.83 ± 0.07 | 0.67 ± 0.05 | < 0.001 |
| CK-MB, U/L | 310 ± 215 | 216 ± 182 | 231 ± 177 | 225 ± 186 | < 0.001 |
| Leucocyte, 103/μL | 14.5 ± 4.7 | 13 ± 4 | 12.7 ± 3.4 | 12.6 ± 3.1 | 0.004 |
| Hemoglobin, mg/dL | 13.9 ±1.3 | 14.2 ± 1.3 | 14.1 ± 1.1 | 14.2 ± 0.9 | 0.625 |
| Admission glucose, mg/dL | 203 ± 104 | 161 ± 75 | 147 ± 64 | 157 ± 88 | < 0.001 |
| Potassium | 4.4 ± 0.6 | 4.1 ± 0.5 | 4.1 ± 0.47 | 4.05 ± 0.49 | < 0.001 |
| Stent diameter, mm | 3.1 ± 0.37 | 3.13 ± 0.36 | 3.15 ± 0.32 | 3.06 ± 0.34 | 0.277 |
| Stent length, cm | 21.4 ± 9 | 19.5 ± 6.8 | 18.5 ± 6.2 | 20.4 ± 5.8 | 0.013 |
| Ejection fraction, % | 42.2 ± 12 | 48.2 ± 10.2 | 49.2 ± 10.1 | 51.1 ± 8.8 | < 0.001 |
| Socio–demographic characteristic | N | Per cent (95 % CI) |
| Age group – | ||
| 11–15 years | 53 | 3.3 (2.4–4.2) |
| 16–17 years | 74 | 5.5 (4.3–6.7) |
| Highest level of parent/carer education – | ||
| Bachelor degree or higher | 54 | 4.7 (3.4–6.0) |
| Diploma or cert III/IV | 44 | 3.0 (2.1–4.0) |
| Year 11 or 12 | 13 | 3.4 (1.5–5.3) |
| Year 10 or below | 16 | 5.7 (2.7–8.6) |
| Parent/carer labour force status – | ||
| Both carers employed | 59 | 3.4 (2.5–4.3) |
| One carer employed, one carer not in employment | 29 | 4.8 (2.8–6.8) |
| Both carers not in employment | 7 | 8.7 (2.3–15.0) |
| Sole carer employed | 24 | 3.9 (2.3–5.5) |
| Sole carer not in employment | 8 | 3.5 (0.9–6.1) |
| Not stated | 0 | – |
| Housing tenure – | ||
| Owned outright | 12 | 2.5 (1.0–4.1) |
| Owned with a mortgage | 65 | 3.5 (2.6–4.4) |
| Rented – public housing | 9 | 6.5 (2.4–10.6) |
| Rented – other | 41 | 5.3 (3.5–7.1) |
| Other | 0 | – |
| Annual household income – | ||
| Less than $52,000 | 32 | 4.4 (2.8–6.0) |
| $52,000–129,000 | 54 | 3.6 (2.6–4.6) |
| $130,000 or more | 37 | 4.3 (2.9–5.8) |
| Child’s country of birth – | ||
| Australia | 107 | 3.7 (3.0–4.5) |
| Overseas | 20 | 5.0 (2.6–7.4) |
| Family type – | ||
| Intact family | 73 | 3.8 (2.9–4.7) |
| Step family | 7 | 3.7 (0.7–6.7) |
| Blended familya | 11 | 4.4 (1.6–7.1) |
| Lone parent family | 33 | 3.9 (2.5–5.3) |
| Other family | 3 | 8.8 (0.00–18.8) |
| Geographic level of remoteness – | ||
| Major cities | 97 | 4.6 (3.6–5.5) |
| Inner regional Australia | 22 | 2.8 (1.6–4.0) |
| Outer regional Australia | 6 | 2.6 (0.2–5.0) |
| Remote Australia | 2 | 3.7 (0.0–8.8) |
| Feature | Description | Information gain |
| Feature 1 | Number of neighbours in which the label is assigned | 0.16 |
| Feature 2 | Sum of similarity scores between the document and all the neighbours’ document where the label appears | 0.17 |
| Feature 3 | Check whether all constituted tokens of the label appear in the target document | 0.01 |
| Feature 4 | Check whether one of the label entries appears in the target document | 0.03 |
| Feature 5 | Frequency of the label if it is contained in the document | 0.03 |
| Feature 6 | Check if the label is contained in the document title | 0.02 |
| Larval temperature (°C) | |||||
| Adult temperature (°C) | 27 ± 1 (with respect to 23 °C) | 31 ± 1 (with respect to 23 °C) | 31 ± 1 (with respect to 27 °C) | ||
| 1st blood meal | Log odds of laying eggs | −0.783b | −1.658 | −0.876 | |
| 23 ± 1 | log-likelihood ratio test | −1.187 | −2.455 | −1.515 | |
| p-value | 0.235 | 0.014 | 0.130 | ||
| 27 ± 1 | Log odds of laying eggs | −2.565 | −4.069 | −1.504 | |
| log-likelihood ratio test | −2.383 | −3.828 | −3.086 | ||
| p-value | 0.017 | <0.001 | 0.002 | ||
| 31 ± 1 | Log odds of laying eggs | 0.767c | −0.028 | −0.795 | |
| log-likelihood ratio test | 1.386 | −0.048 | −1.392 | ||
| p-value | 0.166 | 0.962 | 0.164 | ||
| 2nd blood meal | Log odds of laying eggs | −1.952 | −3.312 | −1.36 | |
| 23 ± 1 | log-likelihood ratio test | −2.398 | −3.805 | −2.276 | |
| p-value | 0.016 | <0.001 | 0.023 | ||
| 27 ± 1 | Log odds of laying eggs | −1.161 | −2.496 | −1.335 | |
| log-likelihood ratio test | −1.613 | −3.486 | −2.534 | ||
| p-value | 0.107 | <0.001 | 0.011 | ||
| 31 ± 1 | Log odds of laying eggs | 1.121 | 0.359 | −0.762 | |
| log-likelihood ratio test | 1.557 | 0.465 | −1.218 | ||
| p-value | 0.120 | 0.642 | 0.223 |
| Sample | Layer thickness [nm] mean ± standard deviation |
| NCO-sP(EO-stat-PO) sample1 | 19.6 ± 0.4 |
| NCO-sP(EO-stat-PO) sample2 | 24.4 ± 1.0 |
| NCO-sP(EO-stat-PO) sample3 | 12.0 ± 0.8 |
| Doped Atoms X | Concentration (%) | Band Gap (eV) | CBM | VBM |
| - | 0.00 | 1.59 | Γ | Γ |
| S | 1.56 | 1.52 | Γ | Γ |
| S | 2.78 | 1.48 | Γ | Γ |
| S | 6.25 | 1.43 | Γ | Γ |
| O | 6.25 | 1.54 | Y | Γ |
| Te | 6.25 | 1.39 | Γ | Γ |
| PTU-induced AAV | Primary AAV | |
| (n = 17) | (n = 64) | |
| Male/female | 2/15 | 32/32 |
| Age (years) | 30.8 ± 15.2 | 60.48 ± 15.14 |
| Scr (μM) | ||
| Mean ± SD | 75.62 ± 40.64 | 339.11 ± 237.71 |
| Range | 38-176.9 | 70-1007 |
| Renal insufficiency at diagnosis | 13 (76.4%) | 48 (75%) |
| ESR (mm/1 hour) | 46.92 ± 38.86 | 70.05 ± 40.14 |
| Skin rash | 5(29.4%) | 7 (10.9%) |
| Arthralgia | 9(52.9%) | 15(23.4%) |
| Muscle pain | 6 (35.3%) | 10 (15.6%) |
| Lung | 6 (35.3%) | 43 (67.2%) |
| ENT | 6 (35.2%) | 27(42.2%) |
| Ophthalmic | 2 (11.8%) | 14(21.9%) |
| Gastrointestinal | 3(17.6%) | 11(17.2%) |
| Nervous system | 1 (5.9%) | 10(15.6%) |
| BVAS | ||
| Mean ± SD | 17.1 ± 5.5 | 20.27 ± 5.18 |
| Range | 7-31 | 13-36 |
| PAHs | Percentage (%) | PAHs | Percentage (%) | ||
| Urban/agricultural soil | Forest soil | Urban/agricultural soil | Forest soil | ||
| Naphthalene | 0.60-16.20 | 0.38-1.95 | Benzo [a] anthracene | 5.81-8.30 | 5.29-8.06 |
| Acenaphthylene | 0.13-0.45 | 0.06-0.71 | Chrysene | 5.34-11.57 | 10.01-12.71 |
| Acenaphthene | 0.69-12.17 | 0.73-2.45 | Benzo [b] fluoranthene | 4.87-6.21 | 6.98-10.27 |
| Fluorene | 0.58-5.19 | 0.47-2.26 | Benzo [k] fluoranthene | 3.27-4.07 | 3.40-4.56 |
| Phenanthrene | 4.44-9.26 | 4.79-9.44 | Benzo [a] pyrene | 5.20-7.62 | 6.27-9.83 |
| Anthracene | 0.79-1.45 | 0.74-1.79 | Benzo [ghi] perylene | 4.11-6.67 | 4.72-6.67 |
| Fluoranthene | 12.30-22.14 | 14.40-22.65 | Dibenzo [a,h] anthracene | 1.10-1.59 | 1.11-1.83 |
| Pyrene | 8.72-16.30 | 9.48-13.86 | Indeno [1,2,3-cd] pyrene | 7.67-12.62 | 8.76-13.34 |
| Clinical Characteristics | Mean (±SD) or Frequency(%) |
| Mean Age in years | 34.1±13.01 |
| Sex | |
| Males | 126 (60.3%) |
| Females | 83 (39.7%) |
| Location of pain | |
| Flank Pain | 156 (75.4%) |
| Costovertebral angle pain | 53 (24.6%) |
| Radiation | |
| None | 85 (48.8%) |
| Front | 64 (30.6%) |
| Groin | 50 (23.9%) |
| Genitalia | 10 (4.7%) |
| Onset of pain | |
| Sudden | 100 (47.8%) |
| Gradual | 109 (52.2%) |
| Severity of pain | |
| Mild to Moderate | 133 (63.6%) |
| Severe | 76 (36.4%) |
| Pain Character | |
| Colicky | 122 (58.4%) |
| Continuous | 87 (41.6%) |
| Urinary symptoms | |
| None | 56 (26.8%) |
| Dysuria | 99 (47.4%) |
| Frequency/urgency | 39 (18.7%) |
| Hematuria | 15 (7.2%) |
| Systemic symptoms | |
| None | 90 (43.1%) |
| Nausea, vomiting | 109 (52.2%) |
| Fever | 10 (4.7%) |
| Aggravating factors | |
| None | 111 (53.1%) |
| Movement | 67 (32.1%) |
| Rest | 31 (14.8%) |
| Past history of renalstones | |
| Yes | 60 (28.8%) |
| No | 149 (71.2%) |
| Findings on examination | |
| None | 152 (72.7%) |
| Costovertebral angle tenderness | 57 (27.3%) |
| Primary site | N | HR | 95% CI | |
| CUP (reference) | 2881 | 1 | ||
| Colorectal cancer | 1438 | 0.61 | 0.57 | 0.65 |
| Pancreatic cancer | 460 | 1.71 | 1.54 | 1.90 |
| Stomach cancer | 322 | 1.16 | 1.02 | 1.31 |
| Liver cancer | 188 | 1.58 | 1.36 | 1.84 |
| Lung cancer | 2453 | 0.98 | 0.92 | 1.04 |
| Kidney cancer | 284 | 0.71 | 0.62 | 0.80 |
| Bladder cancer | 139 | 0.93 | 0.78 | 1.11 |
| Prostate cancer | 1259 | 0.24 | 0.22 | 0.26 |
| Breast cancer | 202 | 0.53 | 0.45 | 0.61 |
| All known primaries | 6745 | 0.69 | 0.66 | 0.72 |
| Sample name | Raw reads | Clean reads | Clean bases | Error rate (%) | Q20 (%) | Q30 (%) | GC content (%) |
| MT1 | 16301802 | 16084513 | 1.61G | 0.03 | 97.25 | 91.76 | 43.5 |
| MT2 | 14403818 | 14223118 | 1.42G | 0.03 | 97.27 | 91.76 | 43.44 |
| MT3 | 14197855 | 14025066 | 1.4G | 0.03 | 97.31 | 91.87 | 43.53 |
| WT1 | 13520581 | 13347784 | 1.33G | 0.03 | 97.23 | 91.68 | 43.6 |
| WT2 | 14715034 | 14532229 | 1.45G | 0.03 | 97.29 | 91.82 | 43.49 |
| WT3 | 15229307 | 15027468 | 1.5G | 0.03 | 97.28 | 91.82 | 43.42 |
| Name or code | MIC (mg/L) [μM] | GIC50 RAW264.7 (mg/L) [μM] | SI (=GIC50/MIC) | Mtb-MurE HPLC IC50 (μM) | |
| M. bovis BCG | M. tuberculosis H37Rv | ||||
| (S)-Leucoxine (1) | 25 [70] | 30 [84] | 125 [352] | 5.0 | 820 |
| Norcoclaurine (2) | >100 [>369] | ND | 425 [1566] | <4.3 | 837 |
| 3 | >100 [>392] | ND | 81 [313] | <0.81 | ND |
| 4 | >100 [>413] | ND | 60 [248] | <0.60 | ND |
| 5 | >100 [>369] | ND | 91 [335] | <0.91 | ND |
| 6 | >100 [>389] | ND | 92 [358] | <0.92 | ND |
| 7 | >100 [>389] | ND | 88 [342] | <0.88 | ND |
| 8 | >100 [>389] | ND | 87 [338] | <0.87 | ND |
| 9 | >100 [>404] | ND | 56 [226] | >0.56 | ND |
| 10 | 100 [271] | ND | >250 [>566] | >2.5 | ND |
| 11 | >100 [>334] | ND | 87 [291] | <0.87 | ND |
| 12 | >100 [>342] | ND | >250 [>855] | ND | ND |
| 13 | 100 [346] | ND | >250 [>864] | >2.5 | ND |
| 14 | >100 [>444] | ND | 85 [377] | <0.85 | ND |
| 15 | >100 [>420] | ND | 188 [789] | <1.9 | ND |
| 16 | 100 [418] | ND | 195 [683] | 2.0 | ND |
| 17 | >100 [>369] | ND | 64 [236] | <0.64 | ND |
| 18 | >100 [>317] | ND | 56 [178] | <0.56 | ND |
| 19 | >100 [>332] | ND | 50 [166] | <0.50 | ND |
| 20 | 100 [334] | ND | 190 [602] | 1.9 | 237 |
| 21 | >100 [>299] | ND | 47 [141] | <0.47 | ND |
| 22 | >100 [>448] | ND | 178 [797] | <1.8 | ND |
| 23 | >100 [>404] | >100 [>404] | 45 [182] | <0.45 | ND |
| 24 | 80 [275] | 60 [206] | 1.6 [5.5] | 0.02 | 186 |
| 25 | >100 [>319] | ND | 181 [578] | <1.8 | ND |
| 26 | >100 [>291] | ND | 183 [533] | <1.8 | ND |
| 27 | 100 [353] | ND | 150 [529] | 1.5 | >1000 |
| 28 | 20 [55] | ND | 47 [130] | 2.3 | <111 |
| 29 | >100 [>351] | ND | 75 [263] | <0.75 | 471 |
| 30 | >100 [>332] | ND | 89 [295] | <0.89 | ND |
| 31 | >100 [>317] | ND | 137 [434] | <1.4 | ND |
| 32 | >100 [>317] | ND | 181 [574] | <1.8 | ND |
| 33 | >100 [>332] | ND | 5.5 [18] | <0.055 | 148 |
| 34 | >100 [>371] | ND | 181 [672] | <1.8 | >1000 |
| 35 | 60 [172] | ND | 121 [348] | 2.0 | <111 |
| 36 | 40 [121] | 60 [181] | 41 [124] | 1.0 | ND |
| 37 | 20 [53] | 40 [106] | 30 [80] | 1.5 | 165 |
| 38 | 50 [118] | 30 [71] | 28 [66] | 0.56 | <111 |
| 39 | 40 [97] | 40 [97] | 73 [178] | 1.8 | ND |
| 40 | >50 [>168] | >100 [>336] | 220 [740] | <4.4 | 300 |
| Isoniazid | 0.1 [0.73] | 0.1 [0.73] | 3000a | 30 000 | >1000 |
| Rifampicin | 0.05 [0.061] | 0.05 [0.061] | 700a | 14 000 | ND |
| Cedrela | Cordia | Swietenia | Tabebuia | |
| Cedrela | 0 | 0.1759 | 0.0274 | 0.0394 |
| Cordia | 0.0863 | 0 | 0.0066 | 0.0905 |
| Swietenia | 0.8157 | 0.0891 | 0 | 0.5315 |
| Tabeuia | 0.0834 | 0.0023 | 0.4700 | 0 |
| Patients presenting to a hospital with hip fracture (N = 78) | Admitted, n (%) | Not admitted, n (%) | |
| Age (in years) | 50–59 | 7 (26) | 15 (29) |
| 60–69 | 6 (22) | 12 (23) | |
| 70–79 | 9 (33) | 10 (20) | |
| 80–89 | 4 (15) | 11 (22) | |
| 90 and above | 1 (4) | 3 (6) | |
| t test | −1.993 (p = 0.040) | ||
| Gender | Male | 14 (52) | 28 (55) |
| Female | 13 (48) | 23 (45) | |
| χ2 | 0.066 (p = 0.797) | ||
| Type of fracture | IC | 11 (41) | 19 (37) |
| IT | 15 (55) | 29 (57) | |
| ST | 1 (4) | 3 (6) | |
| χ2 | 0.224 (p = 0.893) | ||
| Total | 27 (35) | 51 (65) |
| IBDelphi | PLINK (all) | King robust (all) | PLINK (by pop.) | King homo (by pop.) | |
| PLINK (all) | .947 | 1 | .880 | .963 | .962 |
| King robust (all) | .739 | .880 | 1 | .814 | .831 |
| PLINK (by pop.) | .926 | .963 | .814 | 1 | .964 |
| King homo (by pop.) | .919 | .962 | .831 | .964 | 1 |
| IBDelphi | 1 | .947 | .739 | .926 | .919 |
| Tested in past 12 m | Not tested in past 12 m | P* | |
| Overall number of subjects (N = 349**) | 260 | 89 | |
| Facilitators by code** | |||
| Health concerns for self or others | 65 (15.4) | 12 (12.5) | 0.47 |
| Perceived risk | 15 (3.6) | 3 (3.1) | 0.83 |
| Lab characteristic | 15 (3.6) | 3 (3.1) | 0.83 |
| Access to transportation | 36 (8.6) | 11 (11.5) | 0.37 |
| Mobile testing center/SEP | 75 (17.8) | 13 (13.5) | 0.31 |
| Adequate time | 9 (2.1) | 4 (4.2) | 0.25 |
| Knowledge of testing | 25 (6.7) | 9 (9.4) | 0.22 |
| Free testing | 85 (20.2) | 13 (13.5) | 0.13 |
| Access to MD/PCP | 28 (6.7) | 5 (5.2) | 0.60 |
| Not having to take initiative | 5 (1.2) | 0 (0) | 0.28 |
| Rapport with provider | 10 (2.4) | 2 (2.1) | 0.86 |
| Confidentiality | 8 (1.9) | 1 (1.0) | 0.56 |
| Motivation | 5 (1.2) | 1 (1.0) | 0.90 |
| Other | 16 (3.8) | 8 (8.3) | 0.06 |
| Nothing | 24 (5.7) | 11 (11.5) | 0.04 |
| Identification | Description of the gene | Primers | Primer efficiency |
| A-E4 | Mitogen-activated protein kinase | F: 5′- GAAGATGAGAAACCACAAGCG | 90 % |
| R: 5′- CATTCTGAGGAACTTGGAGAGG | |||
| C-G1 | Importin subunit alpha1a | F: 5′- GAACTCATTTTGTGCCCCATC | 92 % |
| R: 5′- GCTGAGGGATTGGAAAAGATTG | |||
| E188 | Intracellular Ras-group-related LRR protein 9 | F: 5′- GAGAGGCAGGATTGGAGATTG | 94 % |
| R: 5′- TCCGCATCCTTCAACATCTTC | |||
| E-E3 | Polyadenylate-binding protein RBP47 | F: 5′- TCCTAATGAGCCTAACAAACCTG | 92 % |
| R: 5′- TCCGTCTTATTGCCTTCCAC | |||
| VHA-A1 | V-ATPase catalytic subunit A1 | F: 5’- CGAGAAGGAAAGCGAGTATGG | 107 % |
| R: 5’- TCATTCACCATCAGACCAGC | |||
| B-D5 | Vacuolar H + -ATPase V0 sector | F: 5′- GCAGTCATTATCAGTACCGGG | 89 % |
| R: 5′-TCTAACACCAGCATCACCAAC | |||
| B-E2 | Pectin acetylesterase | F: 5’-CACACCCACAAAGAGAAACAG | 103 % |
| R: 5’-TTCCAAGAATGCCCCTTCAG | |||
| 12. | XTH | F: 5’-AGAGGTGGGCTTGAGAAAAC | 93 % |
| R: 5’-GAACCCAACGAAGTCTCCTATAC | |||
| B-D9 | 26S proteasome | F: 5’-TCTTGTCCTCTTTCTGTTCCTTATC | 95 % |
| R: 5’-AATCCTTGCCTCACTTCCAG | |||
| C-A3 | Histone H2B | F: 5′- TTGGTAACAGCCTTAGTTCCTC | 89 % |
| R: 5′- AAAGCCTACCATCACTTCTCG | |||
| PP2ACS | PROTEIN PHOSPHATASE 2A catalytic subunit | F: 5’- CGATGTGTGATCTCCTATGGTC | 98 % |
| R: 5’- AAGCTGATGGGCTCTAGAAATC |
| Anti-Ro antibody | ||||
| B | SE* | 95% CI | P-value | |
| Constant | 1.709 | 0.236 | 1.218 to 2.200 | 0.000 |
| IL-21 (pg/ml) | 0.001 | 0.000 | 0.000 to 0.001 | 0.014 |
| IgG1 (ug/ml) | 0.013 | 0.004 | 0.004 to 0.022 | 0.008 |
| SCG Feature Point | AS | MC | IM | AO | IC | RE | AC | MO | RF |
| mean | 1.04 | 1.41 | 1.78 | 0.37 | 1.49 | 1.22 | 1.30 | 1.34 | 1.10 |
| ± SD | 0.7 | 0.5 | 0.8 | 0.7 | 0.6 | 0.8 | 0.4 | 0.7 | 0.6 |
| Time (d) | Number of identified proteinsa | Number of secreted proteinsb (percentage of identified proteins) |
| 0 | 89 | 31 (35 %) |
| 7 | 1009 | 150 (15 %) |
| 14 | 1077 | 163 (15 %) |
| 21 | 1149 | 170 (15 %) |
| 28 | 1151 | 170 (15 %) |
| 42 | 1035 | 157 (15 %) |
| Tested N = 3810 | Untested N = 904 | p-value | |
| n (%) | n (%) | ||
| Patient characteristics | |||
| Age | (n = 3810) | (n = 904) | |
| < 1 years | 1756(46.1) | 418(46.2) | 0.94 |
| 1- < 5 years | 2054(53.9) | 486(53.8) | |
| Mean age (years)a | 1.4(1.1) | 1.4(1.1) | 0.99 |
| Gender | (n = 3810) | (n = 904) | |
| Male | 2056(54.0) | 524(58.0) | 0.03 |
| Illness Severity | |||
| Death | (n = 3810) | (n = 904) | |
| Discharged dead | 103(2.7) | 177(19.6) | <0.01 |
| Oxygen saturation | (n = 3796) | (n = 900) | |
| < 90 % | 628(16.5) | 157(17.4) | 0.52 |
| Mean Oxygen saturationa | 93.7(6.8) | 93.4(7.6) | 0.26 |
| miRNA name | Log Fc | Log CPM | p value | FDR |
| hsa-miR-96 | 5.89073 | 2.930204 | 0.000245 | 0.000186 |
| hsa-miR-1224 | 5.217967 | 3.015217 | 0.000519 | 0.000361 |
| hsa-miR-1293 | 3.171918 | 14.19242 | 0.00203 | 0.001093 |
| hsa-miR-4467 | 3.174797 | 12.62878 | 0.00204 | 0.001093 |
| hsa-miR-6848 | 4.143784 | 3.760948 | 0.00578 | 0.002233 |
| hsa-miR-6849 | 3.118348 | 7.30397 | 0.00826 | 0.003 |
| hsa-miR-4488 | 3.184877 | 5.073045 | 0.000404 | 0.010436 |
| hsa-miR-425 | 3.481839 | 4.249725 | 0.000572 | 0.012611 |
| hsa-miR-4732 | 2.578799 | 8.273334 | 0.000616 | 0.013178 |
| hsa-miR-484 | 2.389806 | 7.714758 | 0.001566 | 0.028757 |
| hsa-miR-5094 | 5.125813 | 1.680093 | 0.002864 | 0.04123 |
| County | Yunlin (industrialized county) | Yilan (reference county) | ||||||
| Area (km2)a | 1290.835 | 2143.625 | ||||||
| Year | 1996–1998 | 1999–2002 | 2002–2004 | 2005–2007 | 1996–1998 | 1999–2002 | 2002–2004 | 2005–2007 |
| Population (person)a | 752,427 | 746,241 | 742,797 | 725,672 | 465,120 | 465,004 | 464,107 | 460,398 |
| Number of large manufacturingb | 35 | 42 | 48 | 42 | 22 | 21 | 25 | 22 |
| Agricultural land (Hectare)c | 112,870 | 112,364 | 111,992 | 112,550 | 58,265 | 158,641 | 164,438 | 200,826 |
| Number of doctors (/1000 people)a | 0.66 | 0.71 | 0.76 | 0.92 | 0.86 | 1.00 | 1.12 | 1.19 |
| Number of hospital (/1000 people)a | 0.031 | 0.032 | 0.029 | 0.026 | 0.030 | 0.032 | 0.026 | 0.026 |
| Life expectancy at birth | 74.05 | 74.88 | 75.51 | 76.16 | 74.84 | 75.8 | 76.88 | 77.65 |
| Life expectancy at 5 years old | 69.74 | 70.52 | 71.12 | 71.69 | 70.62 | 71.51 | 72.59 | 73.31 |
| Life expectancy at 65 years old | 15.98 | 16.63 | 17.17 | 17.78 | 16.59 | 17.05 | 17.94 | 18.64 |
| Mortality rate (/10000) | 671.41 | 611.04 | 681.14 | 751.94 | 698.77 | 684.57 | 695.4 | 744.42 |
| N (%) | |
| Surgical resection | |
| Yes/no | 13 (25)/40 (75) |
| Margin: R0/R1 | 10 (19)/3 (6) |
| Type of surgery | |
| Liver resection | 3 (6) |
| CRS and HIPEC | 5 (9) |
| Primary tumor resection and liver resection | 3 (6) |
| Primary + CRS and HIPEC1 | 1 (28) |
| Lung resection | 1 (2) |
| Authors | Population | Outcome parameters | Validity | Quality | Quantity | Activity |
| Dobkin et al. [33] | Stroke | Walking speed, bouts of walking, gait symmetry | Leave-one-subject-out method | - | x | Walking |
| Zampieri et al. [44] | PD | Stride length, stride velocity, cadence, peak arm swing velocity on the MAS, and turning velocity | Leave-one-subject-out method | - | x | Sitting, standing, walking, turning |
| Mizuike et al. [37] | Stroke | Accelerometers derivatives, raw RMS, normalized RMS, autocorrelation function | Cross-validation | x | x | Walking |
| Prajapati et al. [40] | Stroke | Walking bouts, total walking time, gait speed, number of steps, gait symmetry, swing symmetry, cadence | Cross-validation | x | - | Walking |
| Statement | N | Mean [Range] |
| Feel supported in carrying out my work at the clinic | 20 | 4.05 [2-5] |
| Feel confident when carrying out my work at the clinic | 20 | 4.65 [4-5] |
| Feel the work I do is important and well valued | 20 | 4.55 [2-5] |
| Find the work load at the clinic is too demanding | 20 | 3.3 [2-5] |
| The facilities at the KCC clinic are adequate for me to carry out my work | 20 | 2.65 [1-5] |
| Work at KCC is stressful | 20 | 2.3 [1-5] |
| Training that I have undertaken has improved my skills | 20 | 4.7 [4-5] |
| Training has improved the knowledge | 20 | 4.4 [4-5] |
| Quality of care I provide has improved | 20 | 4.6 [4-5] |
| Each patient is given the right amount of time | 20 | 3.45 [2-5] |
| Cut-Off | Sensitivity | 1-Specificity |
| 0 | 1.000 | 1.000 |
| 1 | 1.000 | 0.944 |
| 2 | 1.000 | 0.901 |
| 3 | 1.000 | 0.789 |
| 4 | 1.000 | 0.606 |
| 5 | 0.927 | 0.408 |
| 6 | 0.805 | 0.296 |
| 7a | 0.683 | 0.141 |
| 8 | 0.390 | 0.042 |
| 9 | 0.122 | 0.000 |
| 10 | 0.000 | 0.000 |
| Effect Size | CV Method | WRS Method | ||
| FP mean(STD) | TP mean(STD) | FP mean(STD) | TP mean(STD) | |
| 0.1 | 1.0(1.0) | 4.1(4.15) | 0.65(0.85) | 0.25(0.54) |
| 0.2 | 0.6(0.73) | 37.4(14.47) | 0.75(0.83) | 0.1(0.3) |
| 0.3 | 1.1(1.04) | 85.45(11.1) | 0.9(1.09) | 0.1(0.3) |
| 0.4 | 0.9(0.77) | 97.95(3.25) | 0.85(0.91) | 0.05(0.22) |
| Disease | Gene | Inheritance mode | Other clinical features (main) |
| Monogenic diseases causing small artery occlusion (lacunar) ischemic stroke | |||
| CADASIL [78] | NOTCH3 | autosomal dominant | migraine with aura, mood disturbance, progressive cognitive impairment |
| CARASIL [79, 80] | HTRA1 | autosomal recessive | alopecia, dementia, gait disturbance, low back pain, mood disturbance |
| RVCL [81–84] | TREX1 | autosomal dominant | visual loss, stroke, dementia, seizures, headache, personality disorders |
| Monogenic diseases causing large artery and small artery occlusion (lacunar) ischemic stroke | |||
| Sickle cell disease [85, 86] | HBB | autosomal recessive | more seldom hemorrhagic stroke, vaso-occlusive or painful crisis, retinopathy, chronic leg ulcers, increased susceptibility to infection, anemia |
| Homocystinuria [87, 88] | CBS* | autosomal recessive* | thromboembolism, mental retardation, ectopia lentis, skeletal abnormalities |
| Fabry disease [89–91] | GLA | X-linked | acroparesthesia, hypohidrosis, angiokeratoma, chronic kidney disease, cardiomyopathy |
| PXE [92–94] | ABCC6 | autosomal recessive | peau d’orange lesions, ocular complications, hypertension, peripheral artery disease, coronary artery disease, gastrointestinal bleeding |
| Monogenic diseases causing ischemic stroke of other etiologies | |||
| Vascular EDS [95–98] | COL3A1 | autosomal dominant | dissection and rupture of arteries, rupture or hollow organs, easy bruising, thin skin with visible veins |
| Marfan syndrome [99–102] | FBN1* | autosomal dominant | aortic root dilatation and dissection, ectopia lentis, marfanoid habitus, dural ectasia, pneumothorax |
| Monogenic mitochondrial disorders | |||
| MELAS [103–105] | tRNA Leu | maternal inheritance | seizures, recurrent headaches, anorexia, recurrent vomiting, myopathy with exercise intolerance |
| Monogenic diseases causing intracerebral hemorrhage | |||
| CAA [106–110] | APP, CST3 | autosomal dominant | dementia, transient neurological symptoms and seizures |
| COL4A1 syndrome [111–115] | COL4A1 | autosomal dominant | more seldom lacunar ischemic stroke, porencephaly, intracranial aneurysms, retinal arteriolar tortuosities and haemorrhage, cataract, Axenfeld-Rieger syndrome, hematuria, renal cysts, mild renal failure, muscle cramps |
| Group; cases | Dc, mm | Dc, mean ±SD, mm | Age, mean ± SD, y | Body mass index, mean ± SD, kg/m2 | Rate of expansion, mean ± SD |
| 1; N = 16 | Dc = 0 | 0.0 ± 0.0 | 45.6 ± 9.8 | 19.5 ± 1.8 | 1.3 ± 0.1 |
| 2; N = 24 | 0 < Dc < 10 | 4.0 ± 2.2 | 47.3 ± 10.3 | 21.9 ± 2.5 | 1.4 ± 0.2 |
| 3; N = 10 | 10 ≤ Dc | 13.2 ± 3.7 | 53.6 ± 10.4 | 22.7 ± 1.8 | 1.5 ± 0.2 |
| Mangifera indica L.Nutrition value per 100 g | |
| Energy | 60 Kcal |
| Fruit composition | Quantity |
| Carbohydrates | 14.98 g |
| Protein | 0.82 g |
| Fat | 0.38 g |
| Fiber | 1.6 g |
| Vitamins | |
| Vitamin C | 36.4 mg |
| Vitamin E | 1.12 mg |
| Vitamin A | 1082 IU |
| Niacin (vit B3) | 669 μg |
| Pantothenic acid (vit B5) | 160 μg |
| Pyridoxine (vit B6) | 119 μg |
| Riboflavin (vit B2) | 38 μg |
| Thiamin (vit B1) | 28 μg |
| Folates | 43 μg |
| Vitamin K | 4.2 μg |
| Minerals | |
| Potassium | 168 mg |
| Phosphorus | 14 mg |
| Calcium | 11 mg |
| Magnesium | 10 mg |
| Sodium | 1 mg |
| Copper | 110 μg |
| Iron | 160 μg |
| Manganese | 27 μg |
| Zinc | 90 μg |
| Carotenoids | |
| β−Carotene | 445 μg |
| α−Carotene | 17 μg |
| Cultivar (cv.) | Number of samples | Geographical origin |
| Coratina | 10 | Bari (Apulia, Italy) |
| Ogliarola Garganica | 10 | Gargano, Foggia (Apulia, Italy) |
| Ogliarola Barese | 10 | Bari (Apulia, Italy) |
| Cima di Mola | 10 | Bari (Apulia, Italy) |
| Picholine | 10 | Bari (Apulia, Italy) |
| Peranzana | 3 | San Severo, Foggia (Apulia, Italy) |
| Carolea | 8 | Calabria |
| Rossanese | 3 | Calabria |
| Picual | 3 | Spain |
| Kalamata | 3 | Greece |
| Koroneiki | 3 | Greece |
| Workflow A | Workflow B | Workflow C |
| + ease of application | + very straightforward, no parameters or thresholds | + can integrate many existing programs |
| + software is available | + guaranteed result in several rounds | + different algorithms address particular properties of promoters |
| + the spectrum of existing methods covers all particular aspects of transcriptional regulation | + optimization of a collection of combinatorial modules instead of optimization of each module separately | |
| – big number of methods to choose from (over 150 can be found in the Internet) | – may lead to a scission of a functional module rendering all parts non functional | – huge number of predicted features require much memory and CPU = > specificity filtering should be applied before modules optimization |
| – relative performance of methods differs for different datasets | – high lab work and time investments | |
| – chance of a correct prediction is ~5-10% [5] | ||
| – impossible to estimate the number of required rounds |
| First author | Year | Ethnicity | Disease | Sample | Number | Gender (M/F) | Age (years) | Method | NOS score | ||
| Tumor | Benign | Normal | |||||||||
| Longo [29] | 2014 | Caucasians | HNSCC | Tissue | 96 | 0 | 79 | 75/21 | 59 (20~90) | qMSP | 8 |
| Liu [28] | 2013 | Asians | CC | Tissue | 40 | 0 | 40 | 0/40 | — | MSP | 6 |
| Weiss [10] | 2011 | Caucasians | HNSCC | Tissue | 49 | 0 | 31 | — | 63.7 ± 11.8 | MSP | 7 |
| Yang [9] | 2010 | Caucasians | CC | Tissue | 60 | 40 | 20 | — | 46 (38~57) | qMSP | 7 |
| Yanatatsaneejit [20] | 2008 | Asians | NPC | Tissue | 46 | 0 | 20 | — | — | Duplex MSP | 6 |
| Brait [5] | 2008 | Caucasians | BCa | Tissue | 93 | 0 | 26 | — | 67 (39~83) | qMSP | 8 |
| 25 | 0 | 5 | — | 66 (34~84) | qMSP | ||||||
| Yu [21] | 2003 | Asians | BCa | Tissue | 132 | 23 | 0 | 107/25 | — | MSP | 8 |
| Kitkumthorn [19] | 2006 | Asians | CC | Tissue | 30 | 24 | 25 | — | — | Duplex MSP | 6 |
| Tokumaru [12] | 2004 | Asians | HNSCC | Tissue | 20 | 0 | 11 | — | — | MSP | 6 |
| Yu [21] | 2003 | Asians | HCC | Tissue | 28 | 0 | 28 | — | — | MSP | 6 |
| Migraine in AH-group | Migraine in Non-AH group | Total | |
| Females | 6 (50 %) | 48 (33 %) | 54 (34 %) |
| Males | 1 (11 %) | 7 (8 %) | 8 (8 %) |
| Total | 7 (33 %) | 55 (24 %) | 62 (24 %) |
| Plants | Colony forming units at 600 mg/ml | Colony forming units at 450 mg/ml | ||||||
| 10 (min) | 20 (min) | 40 (min) | 0 minutes (ctrl) | 10 (min) | 20 (min) | 40 (min) | 0 minutes (ctrl) | |
| S. aculeastrum | 5.00 ± 1.70b | 4.00 ± 1.70ab | 4.00 ± 1.70a | 43 ± 1.70c | 5.00 ± 1.60b | 4.00 ± 1.60ab | 4.00 ± 1.60a | 43 ± 1.60c |
| P. africana | 6.00 ± 1.70b | 5.00 ± 1.70ab | 4.00 ± 1.70a | 72 ± 1.70c | 5.00 ± 1.60b | 4.00 ± 1.60ab | 4.00 ± 1.60a | 72 ± 1.60c |
| S. cordatum | 5.00 ± 1.70b | 4.00 ± 1.70ab | 3.00 ± 1.70a | 34 ± 1.70c | 5.00 ± 1.60b | 4.00 ± 1.60ab | 3.00 ± 1.60a | 34 ± 1.60c |
| L. kituiensis | 16.00 ± 1.70b | 12.00 ± 1.70ab | 8.00 ± 1.70a | 44 ± 1.70c | 17.00 ± 1.60b | 14.00 ± 1.60ab | 12.00 ± 1.60a | 44 ± 1.60c |
| O. lamiifolium | 13.00 ± 1.70b | 11.00 ± 1.70ab | 8.00 ± 1.70a | 56 ± 1.70c | 15.00 ± 1.60b | 11.00 ± 1.60ab | 10.00 ± 1.60a | 56 ± 1.60c |
| S. oleracea | 14.00 ± 1.70b | 14.00 ± 1.70ab | 11.00 ± 1.70a | 58 ± 1.70c | 16.00 ± 1.60b | 13.00 ± 1.60ab | 10.00 ± 1.60a | 58 ± 1.60c |
| 0 extracts (ctrl) | 76.00 ± 1.70a | 76.00 ± 1.70a | 74.00 ± 1.70a | 81.00 ± 1.70a | 76.00 ± 1.60a | 76.00 ± 1.60a | 74.00 ± 1.60a | 81.00 ± 1.60a |
| 30 bp VNTR | 941 G/T | |||||||
| Allele | Allele | |||||||
| 2R | 3R | 4R | 5R | Short (2R, 3R) | Long (4R, 5R) | G | T | |
| Transmitted | 2 | 52 | 38 | 1 | 54 | 39 | 55 | 35 |
| Non-transmitted | 0 | 40 | 53 | 0 | 39 | 54 | 35 | 55 |
| χ2 (P-value) | 2.42, 1df (0.120) | 4.48, 1df (0.034) |
| T. muris L1 assay | Adult T. muris assay | |
| Duration of drug assaya | 24 hours | 72 hours |
| Number of parasites per well | 20 to 200 | 2 to 4 |
| Dissection of animal host required | No | Yes |
| Subjective analysis | Yes | Yes |
| Viability marker alternative | No | Yesb |
| Total operational hours | 3.5 hoursc | 6.5 hoursd |
| Applicability to high-throughput screening | No | No |
| Air pollutant | |||||
| Time lag | PM10 | CO | NO | NO2 | O3 |
| Fibrinogen | |||||
| I24–48 | 0.4 (−1.1, 1.8) | 0.0 (−1.7, 1.8) | 0.1 (−1.0, 1.3) | 0.4 (−1.7, 2.5) | −0.6 (−3.2, 2.1) |
| I48–72 | 1.0 (−0.5, 2.4) | 0.0 (−1.8, 1.9) | 0.3 (−0.8, 1.4) | 1.4 (−0.6, 3.4) | −1.4 (−3.8, 1.0) |
| I72–96 | 0.2 (−1.6, 2.0) | −0.1 (−1.9, 1.7) | 0.1 (−1.1, 1.4) | −0.4 (−2.3, 1.4) | 0.5 (−1.7, 2.8) |
| CRP | |||||
| I24–48 | 1.9 (−5.6, 9.4) | 3.2 (−6.4, 12.8) | 3.6 (−2.9, 10.0) | 6.5 (−4.9, 17.8) | −0.5 (−14.7, 13.8) |
| I48–72 | 5.8 (−2.0, 13.5) | −1.9 (−12.5, 8.7) | 0.1 (−6.5, 6.7) | −0.1 (−11.0, 10.8) | 3.7 (−9.7, 17.2) |
| I72–96 | 3.4 (−6.2, 12.9) | −4.5 (−15.3, 6.3) | −4.6 (−12.0, 2.9) | −6.9 (−17.2, 3.5) | 5.9 (−6.8, 18.7) |
| Q1 (cm.mmol.l-1) <2752 | Q2 (cm.mmol.l-1) 2755-5040 | Q3 (cm.mmol.l-1) 5043-8265 | Q4 (cm.mmol.l-1) 8268-54948 | P for trends† | |
| Number of participants* | 947 | 954 | 939 | 947 | |
| Age (years) | 40.6(10.4) | 46.5(11.7) | 49.9(11.6) | 52.1(10.8) | |
| SBP (mmHg) | 112.7(15.7) | 120.9(18.7) | 127.7(21.8) | 133.2(21.9) | <0.001 |
| DBP (mmHg) | 74.6(9.4) | 78.3(10.1) | 82.0(10.7) | 84.3(10.8) | <0.001 |
| MAP (mmHg) | 87.3(10.5) | 92.5(11.8) | 97.2(13.1) | 100.6(13.2) | <0.001 |
| Pulse pressure (mmHg) | 38.1(11.8) | 42.5(14.5) | 45.7(16.8) | 48.9(16.8) | <0.001 |
| Pulse (beat per minute) | 80.9(11.9) | 81.0(12.1) | 80.8(11.9) | 81.7(12.0) | <0.012 |
| BMI (kg.m-2) | 24.7(3.5) | 27.9(3.6) | 29.9(4.2) | 31.7(4.5) | <0.001 |
| Waist-to-hip ratio (%) | 78.5(6.5) | 85.3(6.6) | 88.5(6.8) | 92.2(7.0) | <0.001 |
| Waist-to-height ratio (%) | 49.9(5.2) | 57.1(5.4) | 61.3(5.9) | 65.4(6.2) | <0.001 |
| Lipid accumulation product | 17.8(1.6) | 42.9(1.2 | 73.0(1.2) | 135.6(1.4) | <0.001 |
| Triglycerides (mmol.l-1) | 1.0(1.4) | 1.4(1.3) | 2.0(1.3) | 3.2(1.4) | <0.001 |
| Total cholesterol (mmol.l-1) | 5.0(1.0) | 5.5(1.0) | 6.0(1.1) | 6.5(1.3) | <0.001 |
| Non-HDL-C (mmol.l-1) | 3.8(0.9) | 4.3(1.0) | 4.9(1.1) | 5.5(1.3) | <0.001 |
| HDL-C (mmol.l-1) | 1.3(0.3) | 1.2(0.3) | 1.1(0.3) | 1.0(0.3) | <0.001 |
| FPG (mmol.l-1) | 5.0(1.3) | 5.3(1.6) | 5.9(2.3) | 6.5(2.8) | <0.001 |
| 2h-PCPG (mmol.l-1) | 5.8(1.8) | 6.5(2.3) | 7.4(3.2) | 8.7(4.2) | <0.001 |
| Assignment to intervention (%) | 362 (38.2) | 387 (40.6) | 363 (38.7) | 365 (38.5) | 0.657 |
| Diabetes | 46 (4.9) | 104 (10.9) | 197 (21.0) | 322 (34.0) | <0.001 |
| Hypertension | 288 (28.3) | 472 (42.5) | 585 (62.3) | 699 (73.8) | <0.001 |
| Smoking | 44 (4.7) | 37 (3.9) | 30 (3.2) | 28 (3.0) | 0.748 |
| Family history of premature CVD | 92 (9.7) | 107 (11.2) | 129 (13.7) | 131 (13.8) | <0.010 |
| Incident** CHD (95% CIs) | 1.1 (0.6-2.2) | 3.6 (2.4-5.2) | 7.4 (5.7-9.7) | 11.2 (8.9-14.0) | <0.001 |
| Incident** CVD (95% CIs) | 1.3 (0.7-2.4) | 4.1 (2.9-5.8) | 8.3 (6.4-10.7) | 13.0 (10.5-16.0) | <0.001 |
| Mortality** rate (95% CIs) | 2.4(1.5-3.7) | 2.5(1.6-3.9) | 4.1(2.9-5.8) | 4.5(3.3-6.3) | 0.673 |
| Sense | Antisense | |
| Reference gene | ||
| Gapdh | 5′-ggcaaattcaacggcaca-3′ | 5′-gttagtggggtctcgctcctg-3′ |
| Inflammation marker | ||
| S100A8 | 5′-tgtcctcagtttgtgcagaatataaat-3′ | 5′-tttatcaccatcgcaaggaactc-3′ |
| S100A9 | 5′-ggcaaaggctgtgggaagt-3′ | 5′-ccattgagtaagccattcccttta-3′ |
| Mobilization markers | ||
| CCL2 | 5′-ttggctcagccagatgca-3′ | 5′-cctactcattgggatcatcttgct-3′ |
| CX3CL1 | 5′-gtgccattgtcctggagac-3′ | 5′-catttctccttcgggtcag-3′ |
| KC | 5′-tggctgggattcacctcaa-3′ | 5′-gagtgtggctatgacttcggttt-3′ |
| MIP-1α | 5′-caagtcttctcagcgccatatg-3′ | 5′-tcttccggctgtaggagaagc-3′ |
| Cell markers | ||
| CX3CR1 | 5′-gagtatgacgattctgctgagg-3′ | 5′-cagaccgaacgtgaagacgag-3′ |
| CCR2 | 5′-ctatctgctcaacttggccatct-3′ | 5′-tgagcccagaatggtaatgtga-3′ |
| Ly6C | 5′-gcagtgctacgagtgctatgg-3′ | 5′-actgacgggtctttagtttcctt-3′ |
| F4/80 | 5′-aatcctgtgaagatgtgg-3′ | 5′-gagtgttgatgcaaatgaag-3′ |
| Adhesion molecules | ||
| LFA1 | 5′-gaatgtatgaagggcaaagtc-3′ | 5′-gcagcaaactggtaggaag-3′ |
| VCAM | 5′-ccaagtctctccaaaagatatacagctt-3′ | 5′-atgacggtgtctccctct-3′ |
| L-selectin | 5′-actgctctgttgtgacttcc-3′ | 5′-tgtatggcgactaaatctgtg-3′ |
| PECAM1 | 5′-tccctgggaggtcgtccat-3′ | 5′-gaacaaggcagcggggttta-3′ |
| VE-cadherin | 5′-tcctcttgcatcctcactatcaca-3′ | 5′-gtaagtgaccaactgctcgtgaat-3′ |
| locus | primer | source | sequence |
| COI | LCO_Hym (C1-J-1514) | [75] | 5'-TATCAACCAATCATAAAGATATTGG-3' |
| C1-J-1580 | new | 5'-ACATCTTTAAGAATAATTATTCG-3' | |
| Nancy-short (C1-N-2194) | [76] | 5'-CCCGGTAAAATTAAAATATAAAC-3' | |
| Pat (TL2-N-3014) | [76] | 5'-TCCAATGCACTAATCTGCCATATTA-3' | |
| 28S | 28S for (D2-3665F) | [82] | 5'-AAGAGAGAGTTCAAGAGTACGTG-3' |
| 28Srev (D3-4283R) | [82] | 5'-TAGTTCACCATCTTTCGGGTCCC-3' | |
| TPI | L1F | [83] | 5'-CTKCGTBGGNGGNAACTGGAAGATGA-3' |
| L1R | [83] | 5'-CCRATRGCCCANACNGGYTCRTA-3' |
| Range(mA) | Heaterresistance (Ω) | Thermocoupleresistance (Ω) | Output emf(mV) | Reversalerror (μA/A) | Timeconstant (s) |
| 5 | 50 to 60 | 8 to 13 | 11 | 50 | <2 |
| 10 | 30 to 40 | 7 to 8 | 9 | 220 | <2 |
| 20 | 20 to 25 | 3 to 5 | 9 | 250 | <2 |
| 30 | 6 to 7 | 3 to 5 | 9 | 240 | <2 |
| 50 | 3 to 4 | 3 to 5 | 9 | 100 | <2 |
| 100 | 1 to 2 | 3 to 5 | 10 | 140 | <2 |
| 250 | 0.5 to 1.0 | 2 to 4 | 11 | 130 | <3 |
| PEF (L/s) | PEF:PIF | |
| Control | 0.68 ± 0.28 | 0.85 ± 0.14 |
| Treadmill | 1.68* ± 0.51 | 0.90 ± 0.10 |
| Flutter® | 1.53* ± 0.25 | 1.13* ± 0.37 |
| 0 additional risk | 1 additional risk | 2 additional risk | 3 additional risk | 4 additional risk | |
| Physical Activity Risk | |||||
| No | 88 | 223 | 211 | 114 | 30 |
| Yes | 168 | 591 | 815 | 481 | 157 |
| Age(y) | n | Males | Females | ||
| Mean ± SEM * | % Anemic | Mean ± SEM * | % Anemic | ||
| 0–4.9 | 252 | 123.9 ± 1.6 | 15.6 | 122.8 ± 2.0 | 15.7 |
| 5–11 | 181 | 131.7 ± 0.9 | 9.9 | 130.6 ± 1.1 | 12.4 |
| 12–14 | 182 | 140.9 ± 2.2 | 8.8 | 132.5 ± 1.8 | 5.7 |
| 15–19 | 194 | 152.8 ± 1.7 | 2.4 | 131.0 ± 1.4 | 10.2 |
| 20–49 | 663 | 156.6 ± 1.1 | 2.5 | 127.2 ± 1.0 | 17.1 |
| ≥50 | 358 | 149.1 ± 1.4 | 5.5 | 128.0 ± 0.9 | 18.0 |
| Code | Value | %agea | Description |
| J | 140 | 7.28 | Translation |
| A | 0 | 0 | RNA processing and modification |
| K | 101 | 5.25 | Transcription |
| L | 128 | 6.66 | Replication, recombination and repair |
| B | 1 | 0.05 | Chromatin structure and dynamics |
| D | 24 | 1.25 | Cell cycle control, mitosis and meiosis |
| Y | 0 | 0 | Nuclear structure |
| V | 47 | 2.45 | Defense mechanisms |
| T | 62 | 3.23 | Signal transduction mechanisms |
| M | 66 | 3.43 | Cell wall/membrane biogenesis |
| N | 5 | 0.26 | Cell motility |
| Z | 0 | 0 | Cytoskeleton |
| W | 0 | 0 | Extracellular structures |
| U | 26 | 1.35 | Intracellular trafficking and secretion |
| O | 56 | 2.91 | Posttranslational modification, protein turnover, chaperones |
| C | 79 | 4.11 | Energy production and conversion |
| G | 40 | 2.08 | Carbohydrate transport and metabolism |
| E | 137 | 7.13 | Amino acid transport and metabolism |
| F | 61 | 3.17 | Nucleotide transport and metabolism |
| H | 58 | 3.02 | Coenzyme transport and metabolism |
| I | 41 | 2.13 | Lipid transport and metabolism |
| P | 77 | 4.01 | Inorganic ion transport and metabolism |
| Q | 15 | 0.78 | Secondary metabolites biosynthesis, transport and catabolism |
| R | 179 | 9.31 | General function prediction only |
| S | 133 | 6.92 | Function unknown |
| - | 554 | 28.82 | Not in COGs |
| Mean (SD) Larsen score | p value | |||
| No BMD loss | Moderate BMD loss | Severe BMD loss | ||
| Baseline (SD) | 3.2 (4,23) | 4.3 (4.81) | 6.0 (6.28) | 0.039 |
| 1 year (SD) | 4.0 (4.68) | 5.3 (5.45) | 7.3 (6.38) | 0.024 |
| 2 years (SD) | 5.4 (5.1) | 6.9 (5.6) | 8.8 (6.04) | 0.056 |
| GT1M | GT3X | Actitrainer | |
| Belgium (n = 109) | 0% | 96% | 4% |
| Greece (n = 142) | 0% | 0% | 100% |
| Hungary (n = 140) | 67% | 0% | 33% |
| The Netherlands (n = 104) | 0% | 0% | 100% |
| Switzerland (n = 192) | 37% | 63% | 0% |
| Total sample (n = 687) | 33% | 43% | 24% |
| Response | N | % |
| Nothing would happen | 34 | 30.1 |
| My Doctor (the researcher) would not be happy with me | 10 | 8.8 |
| I don't know | 8 | 7.1 |
| Could be a bad decision for me clinically | 38 | 33.6 |
| Others | 23 | 20.4 |
| \"I might regret not utilizing the opportunity for the free treatment\" | ||
| \"How can I stop participation when I have come to seek medical help?\" | ||
| \"I would discourage others who want to join\" | ||
| \"I would spoil their work.\" | ||
| \"It is compulsory\" | ||
| \"It shows that there is no reason for my coming\" | ||
| \"It is a research work, I can't stop\" | ||
| \"I would be insulting the Doctors by stopping\" | ||
| \"I would have cheated myself\" | ||
| \"It shows that I'm not serious\" | ||
| \"I can't stop because Doctor is doing something good\" | ||
| \"I would go back with the problem I came with\" | ||
| \"Doctor would go away\" | ||
| \"I can't say I would stop participation since I chose to come for my health sake\" | ||
| \"My conscience would not allow me because it is helpful\" | ||
| \"I want to know what they are doing\" etc |
| H-SLI | TD | F | p | |
| Non-word repetition | ||||
| 1 syllable | 96.9 (1.3) | 98.7 (0.7) | 1.385 | 0.249 |
| 2 syllable | 94.2 (1.0) | 97.6 (0.8) | 7.53 | 0.009 |
| 3 syllable | 86.6 (2.7) | 97.6 (0.7) | 15.601 | 0.001 |
| 4 syllable | 64.7 (3.3) | 85.7 (2.1) | 27.967 | <0.001 |
| TAPS-3 number memory | ||||
| Forward | 7.3 (0.5) | 10.9 (0.5) | 23.069 | <0.001 |
| Reversed | 8.9 (0.4) | 11.9 (0.6) | 16.04 | <0.001 |
| Conners’ ADHD Index | 54.9 (2.4) | 47.9 (1.3) | 6.629 | 0.016 |
| Group | Surgery time* (mean ± SD) | Extubation time* (mean ± SD) |
| TRA | 95.3 ± 17.4 | 6.6 ± 2.4 |
| MET 0.5 | 98.2 ± 15.2 | 7.2 ± 1.6 |
| MET 0.7 | 98.5 ± 12.8 | 7.3 ± 2.2 |
| Median ± SD of PRB expression (2^-∆Ct) | |||
| PRB status at day 1 | Day 1 | Day 15 | |
| Control group | PRB+ | 0.014 ± 0.01 | 0.010 ± 0.02 |
| PRB- | 0.007 ± 0.00 | 0.007 ± 0.001 | |
| Treated group | PRB+ | 0.014 ± 0.01 | 0.011 ± 0.01 |
| PRB- | 0.006 ± 0.002 | 0.006 ± 0.003 |
| Drug | Brain disease | Mechanism | Reference |
| ω-3 PUFA | ADHD | Nonspecific antioxidant effect | [151, 152] |
| Vitamin C | Vascular dementia | Free radical scavenger | [153] |
| Hyperbaric O2 | Autism | Anti-inflammatory and reduces oxidative stress | [157] |
| H2S | Focal cerebral ischemia/reperfusion | Inhibits oxidative phosphorylation, inflammation, and apoptosis | [159] |
| H2-rich saline | Focal or global cerebral ischemia/reperfusion | Reduces oxidative stress and inflammation | [160, 161] |
| Lithium | Healthy volunteers | Prevents/or reverses DNA damage, lipid peroxidation, and free radical formation | [164] |
| Pifithrin-μ | Perinatal hypoxic-ischemic brain damage | Inhibition of the apoptotic pathways and reduction of the oxidative stress | [166] |
| Telmisartan | Vascular dementia | Anti-inflammatory and antioxidant effects | [174–176] |
| Nanodrugs | ROS scavengers | [177] | |
| Triterpenoids | Parkinson | Antioxidants via Nrf2/ARE pathway | [146] |
| PPARgamma agonists | Neurodegenerative diseases | Anti-inflammatory | [162–164] |
| eGFR (mL/min/1.73 m2) | Albuminuria | ||||||
| N = 966,436 | N = 966,436 | ||||||
| ≥60 | 45-59 | 30-44 | 15-29 | None | Mild | Heavy | |
| N = 892,350 | N = 52,237 | N = 16,926 | N = 4,923 | N = 877,076 | N = 75,421 | N = 13,939 | |
| Female | 53 | 58 | 61 | 59 | 60 | 51 | 42 |
| Aboriginal | 1 | 1 | 1 | 2 | 2 | 3 | 4 |
| Diabetes, | 12 | 21 | 29 | 35 | 9 | 18 | 34 |
| Hypertension | 38 | 65 | 81 | 84 | 29 | 41 | 56 |
| Cerebrovascular dis | 3 | 7 | 11 | 12 | 2 | 4 | 7 |
| Congestive heart failure | 2 | 8 | 15 | 25 | 2 | 5 | 9 |
| Myocardial infarction | 3 | 6 | 11 | 15 | 2 | 4 | 6 |
| Socioeconomic status | |||||||
| Pensioner | 33 | 73 | 84 | 78 | 22 | 31 | 35 |
| Low | 18 | 12 | 7 | 8 | 15 | 14 | 14 |
| Low with subsidy | 2 | 2 | 2 | 3 | 3 | 5 | 6 |
| CRP (mg/L) | P value | |
| SDNN < 20 ms (n = 256) | 8.06 ± 9.06 | 0.031 |
| SDNN ≥20 ms (n = 126) | 5.92 ± 9.10 |
| Main Reason for Being Here | Frequency | Percent |
| Fracture | 6 | 12.8 |
| Strain, sprain, dislocation | 7 | 14.9 |
| Cut, bite, penetrating injury, open wound | 19 | 40.4 |
| Bruise, scrape, superficial wound | 9 | 19.1 |
| Concussion, closed head injury | 2 | 4.3 |
| Organ system injury/multiple organ injury | 2 | 4.3 |
| Other | 1 | 2.1 |
| Unknown | 1 | 2.1 |
| Total | 47 | 100.0 |
| Parameter | HCC in NCL; n = 93 | HCC in LC; n = 571 | p | |||
| n/median | %/range | n/median | %/range | |||
| Gender | Male | 68 | 73 | 468 | 82 | 0.045 |
| Female | 25 | 27 | 103 | 18 | ||
| Age | 69 | 32-85 | 66 | 31-85 | 0.004 | |
| BMI | 24.68 | 19.18-38.5 | 27.1 | 18.07-46.30 | <0.001 | |
| ECOG status | n = 79 | n = 428 | 0.432 | |||
| 0 | 37 | 46.84 | 195 | 45.56 | ||
| 1 | 30 | 37.97 | 148 | 34.58 | ||
| 2 | 12 | 15.19 | 72 | 16.82 | ||
| 3 or 4 | 0 | 0 | 13 | 3.04 | ||
| Diabetes mellitus | Yes | 42 (n = 59) | 71.2 | 308 (n = 368) | 83.7 | 0.020 |
| History of nicotine abuse | Yes | 22 (n = 55) | 40.0 | 110 (n = 231) | 47.6 | 0.308 |
| Etiology | Alcohol | 14 | 15.05 | 285 | 49.91 | 0.008 |
| Viral | 7 | 7.53 | 91 | 15.94 | ||
| NAFLD | 6 | 6.45 | 37 | 6.48 | ||
| Other | 13 | 13.98 | 93 | 16.29 | ||
| Unknown | 53 | 56.99 | 65 | 11.38 |
| Sample number | Biofilm formation (OD) at 660 nm | Biofilm inhibition by biosurfactant (OD) at 660 nm | % inhibition of biofilm |
| 1 | 0.316 | 0.183 | 41.38 ± 1.09 |
| 2 | 0.239 | 0.152 | 36.62 ± 1.13 |
| 3 | 0.388 | 0.173 | 54.71 ± 1.27 |
| 4 | 0.281 | 0.147 | 47.68 ± 0.54 |
| 5 | 0.226 | 0.139 | 38.49 ± 0.68s |
| Comparison of number of knots along the sessions between loop & winding method | ||||||||
| S1 | S2 | S3 | S4 | S5 | S6 | S7 | S8 | |
| Loop | 3 | 4 | 5 | 5 | 6 | 7 | 7 | 7 |
| Wind | 3 | 6 | 8 | 9 | 11 | 12 | 14 | 15 |
| Z-value | 0.24 | 3.14 | 3.77 | 3.58 | 3.78 | 3.81 | 3.83 | 3.87 |
| P value | 0.853# | 0.0001∗∗ | 0.0001∗∗ | 0.0001∗∗ | 0.0001∗∗ | 0.0001∗∗ | 0.0001∗∗ | 0.0001∗∗ |
| Weeks of Treatment | Group | Overall Mean | ||
| A (Control) | B (Treatment 1) | C (Treatment 2) | ||
| 0 | 5.25 ± 0.95d-h | 4.50 ± 0.29fgh | 3.75 ± 0.48 h | 4.50 ± 0.38D |
| 5 | 3.38 ± 0.24 h | 5.00 ± 0.41d-h | 4.50 ± 0.29fgh | 4.29 ± 0.26D |
| 6 | 3.75 ± 0.48 h | 5.75 ± 0.14c-g | 4.75 ± 0.25e-h | 4.75 ± 0.30CD |
| 7 | 4.00 ± 0.41gh | 6.50 ± 0.20a-e | 6.00 ± 0.41b-f | 5.50 ± 0.37BC |
| 8 | 3.63 ± 0.38 h | 6.50 ± 0.20a-e | 6.75 ± 0.32a-d | 5.63 ± 0.46ABC |
| 9 | 3.63 ± 0.38 h | 7.38 ± 0.24abc | 7.38 ± 0.24abc | 6.13 ± 0.55AB |
| 10 | 3.75 ± 0.48 h | 7.63 ± 0.24abc | 7.88 ± 0.13ab | 6.42 ± 0.59AB |
| 11 | 3.63 ± 0.38 h | 7.88 ± 0.31ab | 8.00 ± 0.20a | 6.50 ± 0.63A |
| 12 | 3.63 ± 0.24 h | 7.88 ± 0.13ab | 8.13 ± 0.13a | 6.54 ± 0.63A |
| Mean | 3.85 ± 0.17B | 6.56 ± 0.21A | 6.35 ± 0.28A |
| Percent Correct | F-Measure | |||||||||||
| Activity | C4.5 | SMO | VP | DT | RF | Best | C4.5 | SMO | VP | DT | RF | Best |
| Get drink | 96.86 | 99.32 | 95.37 | 96.87 | 100.00 | 100.00 | 0.83 | 0.96 | 0.57 | 0.80 | 1.00 | 1.00 |
| Go to bed | 89.26 | 89.54 | 90.36 | 90.23 | 91.43 | 91.43 | 0.00 | 0.00 | 0.03 | 0.00 | 0.30 | 0.30 |
| Leave the house | 97.96 | 97.96 | 94.56 | 97.02 | 97.42 | 97.96 | 0.94 | 0.94 | 0.74 | 0.91 | 0.92 | 0.94 |
| Prepare breakfast | 96.19 | 95.91 | 94.82 | 91.02 | 97.82 | 97.82 | 0.75 | 0.71 | 0.56 | 0.29 | 0.83 | 0.83 |
| Prepare dinner | 95.51 | 96.18 | 96.06 | 94.39 | 97.82 | 97.82 | 0.42 | 0.51 | 0.30 | 0.33 | 0.64 | 0.64 |
| Take a shower | 98.36 | 98.23 | 94.04 | 90.63 | 98.63 | 98.63 | 0.90 | 0.89 | 0.44 | 0.00 | 0.91 | 0.91 |
| Use the toilet | 89.26 | 88.19 | 84.91 | 87.08 | 91.44 | 91.44 | 0.89 | 0.87 | 0.84 | 0.88 | 0.91 | 0.91 |
| No of isolates | Locus | Fragment length (bp) | No. of alleles | Gene diversity ± SD | No. of polymorphic sites | Avg. number of nucleotide differences | Nucleotide diversity ± SD |
| 56 | acsA | 390 | 20 | 0.904 ± 0.027 | 23 | 5.15325 | 0.01321 ± 0.00095 |
| 56 | aroE | 498 | 10 | 0.827 ± 0.025 | 69 | 9.10909 | 0.01829 ± 0.00507 |
| 56 | guaA | 373 | 15 | 0.868 ± 0.034 | 14 | 2.62013 | 0.00702 ± 0.00062 |
| 54 | mutL | 442 | 14 | 0.764 ± 0.055 | 28 | 3.16702 | 0.00717 ± 0.00169 |
| 56 | nuoD | 366 | 6 | 0.642 ± 0.048 | 11 | 1.52922 | 0.00418 ± 0.00081 |
| 56 | ppsA | 370 | 14 | 0.879 ± 0.024 | 39 | 4.61364 | 0.01247 ± 0.00347 |
| 56 | trpE | 443 | 15 | 0.876 ± 0.023 | 19 | 4.50260 | 0.01016 ± 0.00076 |
| Predictors | Regression coefficient | Odds ratio | 95% CI | Risk score = Regression coefficient × 25 |
| Pre-existing diseases (CCI >3) | 2.02 | 7.52 | 2.01 to 28.1 | 50.5 |
| Parent to children <18 years | 1.26 | 3.51 | 1.39 to 8.89 | 31.5 |
| Previous psychological problems | 1.14 | 3.13 | 1.12 to 8.76 | 28.5 |
| In-ICU agitation | 0.8 | 2.23 | -0.80 to 6.22 | 20 |
| Unemployed/sick-leave at ICU admission | 0.48 | 1.62 | -0.54 to 4.88 | 12 |
| Appeared depressed in ICU | 0.30 | 1.35 | -0.55 to 3.31 | 7.5 |
| Items | n | Visited physician during past 12 months? | P | |
| Yes | No | |||
| Self-medication during past 12 months | ||||
| Yes | 242 (52.0) | 71 (29.3) | 171 (70.7) | <0.001 |
| No | 223 (48.0) | 134 (60.1) | 89 (39.9) | |
| Have periodic physical examinations | ||||
| Yes | 255 (54.8) | 145 (56.9) | 110 (43.1) | <0.001 |
| No | 210 (45.2) | 60 (28.6) | 150 (71.4) | |
| Been a patient in hospital in previous 3 years(respondent or family member) | ||||
| Yes | 275 (59.1) | 146 (53.1) | 129 (46.9) | <0.001 |
| No | 190 (40.9) | 59 (31.1) | 131 (68.9) | |
| Have medical insurance | ||||
| Yes | 288 (61.9) | 145 (50.4) | 143 (49.6) | 0.001 |
| No | 177 (38.1) | 60 (33.9) | 117 (66.1) | |
| Pay attention to health examinations | ||||
| Yes | 88 (18.9) | 55 (62.5) | 33 (37.5) | 0.001 |
| No | 377 (81.1) | 150 (39.8) | 227 (60.2) | |
| Volunteered to help others during past 12 months | ||||
| Yes | 45 (9.7) | 29 (64.4) | 16 (35.6) | 0.004 |
| No | 420 (90.3) | 176 (41.9) | 244 (58.1) | |
| Smoking habit | ||||
| Smoker | 138 (29.7) | 48 (34.8) | 90 (65.2) | 0.009 |
| Nonsmoker | 327 (70.3) | 157 (48.0) | 170 (52.0) | |
| Visited friend or loved one in hospital during past 12 months | ||||
| Yes | 257 (55.3) | 127 (49.4) | 130 (50.6) | 0.01 |
| No | 208 (44.7) | 78 (37.5) | 130 (62.5) | |
| Want to participate in group support activities | ||||
| Yes | 44 (9.5) | 27 (61.4) | 17 (38.6) | 0.015 |
| No | 421 (90.5) | 178 (42.3) | 243 (57.7) | |
| Radio use | ||||
| Yes | 239 (51.4) | 93 (38.9) | 146 (61.1) | 0.021 |
| No | 226 (48.6) | 112 (49.6) | 114 (50.4) | |
| Lack of legal documents as reason for not visiting health facility | ||||
| Yes | 122 (26.2) | 43 (35.3) | 79 (64.7) | 0.022 |
| No | 343 (73.8) | 162 (47.2) | 181 (52.8) | |
| Have periodic dental examination | ||||
| Yes | 256 (55.0) | 125 (48.8) | 131 (51.2) | 0.023 |
| No | 209 (45.0) | 80 (38.3) | 129 (61.7) | |
| Internet use | ||||
| Yes | 221 (47.5) | 86 (38.9) | 135 (61.1) | 0.033 |
| No | 244 (52.5) | 119 (48.8) | 125 (51.2) | |
| Get health-related instruction from religious people | ||||
| Yes | 144 (31.0) | 74 (51.4) | 70 (48.6) | 0.034 |
| No | 321 (69.0) | 131 (40.8) | 190 (59.2) | |
| Want information on child health care | ||||
| Yes | 44 (9.5) | 13 (29.5) | 31 (70.5) | 0.041 |
| No | 421 (90.5) | 192 (45.6) | 229 (54.4) | |
| Pay attention to weight | ||||
| Yes | 62 (13.3) | 20 (32.3) | 42 (67.7) | 0.044 |
| No | 403 (86.7) | 185 (45.9) | 218 (54.1) | |
| Pay attention to food and nutrition | ||||
| Yes | 343 (73.8) | 142 (41.4) | 201 (58.6) | 0.05 |
| No | 122 (26.2) | 63 (51.6) | 59 (48.4) | |
| Want information on food and nutrition | ||||
| Yes | 191 (41.1) | 74 (38.7) | 117 (61.3) | 0.053 |
| No | 274 (58.9) | 131 (47.8) | 143 (52.2) |
| Cisplatin concentration | Apoptosis level |
| 0.0 | 0.0 |
| 0.0001 | 0.0 |
| 0.001 | 5E-6 |
| 0.01 | 4.67E-4 |
| 0.1 | 2.96E-2 |
| 0.5 | 0.16 |
| 1.0 | 0.23 |
| Measure | Outcome results |
| Maternal | |
| Dams’ daily mean fluid consumption (mL/day) | |
| For 14 days before mating | 14.7 ± 0.8 |
| During gestation | 29.5 ± 1.8 |
| PND1–PND10 | 46.8 ± 3.7 |
| Dams’ weight (g) | |
| 14 days before mating | 223 ± 6 |
| At mating | 247 ± 7 |
| Total weight gain during pregnancy | 127 ± 6 |
| Mating success rate (%) | 93.8 ± 1.2 |
| Litter and physical milestones | |
| Length of gestation (days) | 20.5 ± 0.2 |
| Mean litter size (pups) | 11.9 ± 0.4 |
| Sex distribution at birth [male/female (%)] | 54/46 |
| Litter mortality (dead newborn pups/litter) | 0.2 ± 0.1 |
| Pup mortality during lactation (%) | 1.9 ± 0.1 |
| Eye opening [male/female (%)] | |
| At PND14, one or both eyes | 78 ± 5/75 ± 6 |
| At PND16, both eyes | 100/100 |
| Female offspring body weight (g) | |
| At birth (PND0) | 6.12 ± 0.14 |
| PND10 | 20.3 ± 1.2 |
| PND21 | 50.1 ± 2.1 |
| PND90 | 254.6 ± 4.8 |
| Number | Compound | tR (min) | HR-L | HR-D | SR |
| mg g−1 DW | mg g−1 DW | mg g−1 DW | |||
| 1 | 3-O-Caffeoylquinic acid | 4.0 | 0.06 (4.80)a | — | 0.70 (0.34)b |
| 2 | 5-O-Caffeoylquinic acid | 7.4 | 5.12 (2.24)b | 1.96 (2.92)a | 18.26 (0.46)c |
| 3 | 4-O-Caffeoylquinic acid | 8.1 | 0.12 (5.03)b | 0.06 (2.35)a | 0.42 (0.95)c |
| 4 | 1,3-Di-O-caffeoylquinic acid | 10.2 | 0.22 (3.90)b | 0.12 (2.68)a | 1.21 (1.88)c |
| 5 | Quercetagetin hexoside | 10.7 | 0.96 (1.65) | — | — |
| 6 | Quercetin hexoside | 11.4 | 0.93 (1.71) | — | — |
| 7 | Quercetin hexoside | 11.9 | 0.52 (0.61) | — | — |
| 8 | 20-Hydroxyecdysone | 12.0 | — | — | 5.60 (1.36) |
| 9 | Luteolin hexoside | 12.1 | 0.27 (1.43) | — | — |
| 10 | Patuletin hexoside | 12.2 | 0.25 (1.24) | — | — |
| 11 | 3,4-Di-O-caffeoylquinic acid | 13.1 | 0.22 (0.95)b | 0.15 (3.67)a | 0.52 (2.62)c |
| 12 | 3,5-Di-O-caffeoylquinic acid | 13.4 | 3.08 (3.32)b | 1.92 (2.75)a | 8.47 (0.51)c |
| 13 | 1,5-Di-O-caffeoylquinic acid | 13.9 | 0.28 (3.28)b | 0.12 (3.01)a | 1.44 (2.75)c |
| 14 | 4,5-Di-O-caffeoylquinic acid | 14.1 | 1.97 (3.39)c | 1.23 (1.77)b | 1.04 (2.05)a |
| 15 | 1,4,5-Tri-O-caffeoylquinic acid | 15.3 | 1.38 (4.67)b | 1.08 (2.86)a | — |
| 16 | Tricaffeoylquinic acid derivative | 15.6 | 5.97 (4.88)c | 4.34 (2.09)b | 0.26 (2.18)a |
| 17 | Tricaffeoylquinic acid derivative | 16.4 | 0.66 (0.24)b | 0.47 (4.58)a | 2.88 (1.38)c |
| Group | First dose (μg/kg) 30–60 min before surgery | Second dose (μg/kg) 24 h after surgery | Total dose (μg/kg) |
| 1 | 0.25 | 0.25 | 0.5 |
| 2 | 0.5 | 0.5 | 1.0 |
| 3 | 0.75 | 0.5 | 1.25 |
| 4 | 1.0 | 0.5 | 1.5 |
| 5 | 1.0 | 1.0 | 2.0 |
| Number of patients tested and pathological findings (N = 33) | ||
| Number (%) | Pathology (%) | |
| Gluten antibodies | 21 (63.6) | 0 (0.0) |
| Anti-nucleus antibodies | 14 (42.4) | 0 (0.0) |
| Cobalamin | 23 (69.7) | 3 (9.1) |
| Folate | 23 (69.7) | 0 (0.0) |
| TSH/FT4 | 30 (91.0) | 2 (15.2) |
| Cortisol | 10 (30.3) | 1 (3.0) |
| ACTH | 5 (15.2) | 0 (0.0) |
| CK | 24 (72.7) | 1 (3.0) |
| ASAT | 24 (72.7) | 0 (0.0) |
| Creatine | 31 (93.9) | 0 (0.0) |
| CRP | 30 (90.9) | 0 (0.0) |
| Haemoglobin | 33 (100) | 1 (3.0) |
| SR | 29 (87.8) | 1 (3.0) |
| Urine dip sticks | 19 (57.5) | 0 (0.0) |
| Scaffold Designation | Composition | |||
| Chitosan (Ch) 1% | Gelatin (Gel) 1% | nHAp 0.25% | nCuZn Alloy 0.01% | |
| Final Concentrations in Blend (%) | ||||
| Ch/Gel | 0.5 | 0.25 | - | - |
| Ch/Gel/nHAp | 0.5 | 0.25 | 0.0625 | - |
| Ch/Gel/nHAp/nCuZn | 0.5 | 0.25 | 0.0625 | 0.00025 |
| Absence of protective haplotypes | At least one protective haplotypes | ||
| Anti-MAP2694 Abs | Negative | 258 (71 %) | 103 (29 %) |
| Positive | 122 (80 %) | 31 (20 %) |
| Variable | Place of delivery | P value | |
| Home | Facility | ||
| N = 906 (100%) | N = 1372 (100%) | ||
| Maternal age | 0.107 | ||
| 15–19 | 23 (38.0%) | 38 (62.0%) | |
| 20–24 | 153 (40.0%) | 228 (60.0%) | |
| 25–29 | 206 (36.4%) | 360 (63.6%) | |
| 30–34 | 223 (45.5%) | 267 (54.5%) | |
| 35–39 | 165 (38.4%) | 288 (63.6%) | |
| 40–44 | 93 (38.6%) | 148 (61.4%) | |
| 45–49 | 45 (51.2%) | 43 (48.8%) | |
| Wealth index | 0.000 | ||
| Poorest | 452 (53.7%) | 389 (46.3%) | |
| Poorer | 301 (41.9%) | 418 (58.1%) | |
| Middle | 138 (29.7%) | 327 (70.3%) | |
| Richer | 13 (5.9%) | 207 (94.1%) | |
| Richest | 3 (8.4%) | 31 (91.6%) | |
| Educational level | 0.000 | ||
| No education | 468 (53.4%) | 409 (46.6%) | |
| Primary | 213 (41.1%) | 305 (58.9%) | |
| Secondary | 223 (26.4%) | 620 (73.6%) | |
| Higher | 3 (6.9%) | 38 (93.1%) | |
| Ecological zone | 0.000 | ||
| Coastal zone | 302 (34.7%) | 569 (65.3%) | |
| Forest zone | 256 (34.4%) | 490 (65.6%) | |
| Savannah zone | 348 (52.7%) | 313 (47.3%) | |
| Getting money needed for treatment | 0.000 | ||
| Big problem | 531 (46.0%) | 623 (54.0%) | |
| Not a big problem | 375 (33.4%) | 749 (66.6%) | |
| Ethnicity | 0.000 | ||
| Akan | 296 (31.0%) | 659 (69.0%) | |
| Ga/Dangme | 38 (43.0%) | 52 (57.0%) | |
| Ewe | 104 (37.6%) | 172 (62.4%) | |
| Guan | 16 (34.3%) | 30 (65.7%) | |
| Mole–Dagbani | 181 (37.8%) | 297 (62.2%) | |
| Grusi | 28 (37.9%) | 46 (62.1%) | |
| Gurma | 217 (73.9%) | 77 (26.1%) | |
| Mande | 5 (15.9%) | 27 (84.1%) | |
| Other | 21 (66.8%) | 10 (33.2%) | |
| Parity | 0.000 | ||
| One birth | 90 (27.5%) | 238 (72.5%) | |
| Two births | 139 (36.6%) | 240 (63.4%) | |
| Three births | 146 (34.9%) | 273 (65.1%) | |
| Four births or more | 531 (46.1%) | 621 (53.9%) | |
| Partner's education | 0.000 | ||
| No education | 396 (56.0%) | 311 (44.0%) | |
| Primary | 129 (40.9%) | 187 (59.1%) | |
| Secondary | 361 (32.0%) | 767 (68.0%) | |
| Higher | 20 (15.8%) | 106 (84.3%) | |
| Distance to health facility | 0.000 | ||
| Big problem | 422 (51.8%) | 392 (48.2%) | |
| Not a big problem | 485 (33.1%) | 979 (66.9%) |
| Household characteristics | Value |
| % of houses with | |
| Land ownership | 42.2 |
| Head of household with agriculture related occupation | 18.1 |
| Ground water as main source of drinking water | 61.8 |
| Piped water in own house | 26.2 |
| Access to water seal latrine | 74.7 |
| Wood/cow dung as main Fuel used for cooking | 69.1 |
| Tobacco smoker in the HH | 60.5 |
| Mean (Standard Deviation) number of | |
| Persons per household | 5.97 (2.61) |
| Children ≤ 10 years per household | 1.75 (1.54) |
| Sleeping rooms per household | 1.89 (0.98) |
| No. | Age/sex | Etiology | Defect location | Flap dimensions (cm) | Complications |
| 1 | 45/f | Trauma | Heel avulsion | 24×11 | Partial graft loss at lower donor site |
| 2 | 45/m | Verrucous carcinoma of heel | Heel | 23×10 | None |
| 3 | 42/m | Trauma | Avulsion of heel and sole of midfoot | 28×14 | Patchy graft loss, healed within 20 days with dressings. |
| 4 | 38/f | Squamous cell carcinoma of heel | Heel region | 26×12 | None |
| 5 | 42/m | Verrucous carcinoma | Heel region | 23×10 | None |
| 6 | 60/m | Squamous cell carcinoma of heel | Heel region extending in to the sole | 26×11 | Partial graft loss at lower donor site |
| 7 | 43/f | Trauma | Medial malleolus with dorsal foot region | 25×10 | None |
| 8 | 48/m | Verrucous carcinoma | Heel region | 22×10 | Exposed fibula – 5 cm fibula excised and covered with left flap during final inset |
| 9 | 49/f | Trauma | Medial malleolus region | 21×10 | None |
| 10 | 38/m | Trauma | Heel with tendoachillis region | 24×11 | Partial graft loss at lower donor site |
| Group S (n = 29) | Group SD (n = 29) | |
| Coughing episode | ||
| 1–5 | 12 (41.4) | 22 (75.9) |
| 6–10 | 10 (34.5) | 7 (24.1) |
| >10 | 7 (24.1) | 2 (6.9) |
| Sleeping disturbance | 20 (69.0) | 11 (37.9) |
| Satisfaction | ||
| Favorable | 19 (65.5) | 27 (93.1) |
| A little | 9 (31.0) | 2 (6.9) |
| Not favorable | 1 (3.4) | 0 |
| (1) Events were classified as related to knowledge-acquisition goals if their content fulfilled any of the following criteria and did not conflict | |
| with the criteria for emotional goals. | |
| (a) Knowledge-acquisition goals related to the future (if an event referred to words related to time, such as 6 months later, or in the future; the event was classified as related to knowledge-acquisition goals. There was also a wide range of non-future events which were coded as present-focused events). | e.g., “The problems in middle school math competitions became increasingly difficult in today’s classes, which stumped a number of my classmates. Only three questions were covered in the two classes, and I did still not understand the problem-solving process. I was very concerned about my future studies.” |
| (b) Knowledge acquisition | e.g., “This morning, I attended a project in which student volunteers taught us how to use computers face-to-face at the University of Posts and Telecommunications. The two problems that I didn’t understand before were solved. Thus, I was very happy.” |
| (c) An individual’s observation, understanding; learning of social survival skills through interaction with others; and inspiration for knowledge acquisition from the people around them, events, and their own life experiences. | e.g., “Today, I went to the Aging Lab at Beijing Normal University to take part in tests. It was a very happy thing and I acquired much knowledge constantly. It’s never too late to learn.” |
| (d) Realization of one’s own shortcomings through interaction with others and engagement in periodic self-assessment. | e.g., “The lesson on the Study on New Venture’s Creation was boring. The teacher suddenly asked, ‘What are you interested in? What do you care about?’ Then, I realized that I did not know how to answer these questions. I have spent days and months without doing anything meaningful. While listening to classmates’ answers, I was lost in thought.” |
| (e) Use of activities and events to provide information (reading books, etc.) | e.g., “On Friday evening, I turned on the computer and watched Tian tian Xiang shang, a famous, entertaining talk-show in China. The hosts sounded very happy. I should imitate their speech to improve my public-speaking skills.” |
| (2) Events were classified as related to emotional goals if their content fulfilled any of the following criteria and did not conflict | |
| with the criteria for knowledge-acquisition goals. | |
| (a) Emotional goals related to the present (if the event referred to words related to time, such as now, the present, and were within 6 months; the event was classified as related to emotional goals). | e.g., “On Sunday, my husband’s colleague, whom we had not seen for many years, was coming. We were all happy. They were very excited when they chatted about their time at the company.” |
| (b) Mood control rather than pursuit of new knowledge (emotion can be affected by tourism, scenery, environment, weather, prices, or physical conditions, and individuals can acquire emotional experience and become inspired by events and the people around them). | e.g., “This morning, when I pulled back the curtain, a silver world appeared outside the window! Snow was everywhere, just lying on the trees. An unseasonable snowfall gave a surprise to spring. Particularly in these days of the hazy weather, the snow scene was a rare and beautiful thing.” |
| (c) Preference for spending time with family and close friends, rather than going to a party to obtain emotional satisfaction (sometimes, individuals need to feel needed and supported by others, and people acquire positive emotional experience by helping others). | e.g., “On the way to the library, a man asked me how to get to the classroom. I explained the way to him clearly and patiently. I had a strong feeling of presence and being needed as soon as he thanked me, which made me very happy.” |
| (d) A focus on the meaning of life and emotional intimacy (individual’s might seek to control their own moods or to engender a positive emotional experience). | e.g., “Although it was late, I still went for a walk with my friend. After I poured out my problems to her, I felt quite relaxed. She calmed me down and let me think about some things objectively. I thanked her a lot.” |
| (e) A focus on emotional rewards achieved through various activities or participation in social activities for the sake of an emotional experience. | e.g., “I had a good time with my friends at the beginning of this morning’s exercise. The teacher who taught us to make fans came to the classroom at 9:00. Some of her behaviors made us feel uncomfortable. I attended this class for pleasure, but I was unhappy. So I left the classroom and looked for pleasure elsewhere.” |
| (3) If an event could be classified as related to either an emotional or a knowledge-acquisition goal; it was classified as a mixed event. | e.g., “Today, in art class, the teacher taught us how to draw a peony. It was good to understand new things; it put us in a good mood and we gained something.” |
| (4) Descriptions of some events were too simple and did not contain distinguishing information. These events were considered non-specific. | |
| Examples of these events include “Let the robot clean the house” or “Cooking meat for dinner.” |
| Method | P | R | F | Sn | PPV | Acc |
| MCODE | 0.576 | 0.096 | 0.164 | 0.282 | 0.328 | 0.304 |
| CFinder | 0.396 | 0.257 | 0.312 | 0.612 | 0.297 | 0.437 |
| CMC | 0.283 | 0.505 | 0.363 | 0.523 | 0.526 | 0.525 |
| RRW | 0.541 | 0.365 | 0.436 | 0.378 | 0.557 | 0.459 |
| COACH | 0.418 | 0.529 | 0.467 | 0.545 | 0.481 | 0.512 |
| CORE | 0.16 | 0.662 | 0.258 | 0.569 | 0.567 | 0.568 |
| Ours | 0.537 | 0.699 | 0.607 | 0.583 | 0.578 | 0.581 |
| OR (95% CI) | β | P | OR | |
| UA | 0.994-0.999 | -0.003 | 0.006 | 0.997 |
| PLT | 0.993-0.999 | -0.004 | 0.020 | 0.996 |
| Fibrillation | 1.691-11.389 | 1.479 | 0.002 | 4.389 |
| Diabetes | 1.193-3.674 | 0.739 | 0.010 | 2.094 |
| Leukocyte | 1.078-1.257 | 0.152 | 0.000 | 1.164 |
| Trait | Total cases | Pathologically confirmed cases |
| DLB | 788 | 667 |
| AD | 959 | 113 |
| PD | 804 | 0 |
| Pathway name | No. of genes | p-Value |
| Antigen processing and presentation | 9 | 0 |
| Chemokine signaling pathway | 13 | 0 |
| Complement and coagulation cascades | 7 | 0 |
| Cytokine-cytokine receptor interaction | 23 | 0 |
| Natural killer cell mediated cytotoxicity | 9 | 0 |
| Classical Complement Pathway | 3 | 1.00E-04 |
| Complement Pathway | 3 | 4.00E-04 |
| Alternative Complement Pathway | 2 | 0.0021 |
| Granzyme A mediated Apoptosis Pathway | 2 | 0.0036 |
| Toll-like receptor signaling pathway | 4 | 0.0071 |
| Intestinal immune network for IgA production | 3 | 0.009 |
| CCR3 signaling in Eosinophils | 2 | 0.0111 |
| Caspase Cascade in Apoptosis | 2 | 0.0121 |
| NOD-like receptor signaling pathway | 3 | 0.0121 |
| MAPK signaling pathway | 6 | 0.0168 |
| ECM-receptor interaction | 3 | 0.0232 |
| Jak-STAT signaling pathway | 4 | 0.0284 |
| IFN gamma signaling pathway | 1 | 0.0478 |
| B Lymphocyte Cell Surface Molecules | 1 | 0.0611 |
| T cell receptor signaling pathway | 3 | 0.069 |
| n | % | Median | Range | Interquartile range | |
| Wait time for first visit (time 1) | 6 | 1–24 | 3–9 | ||
| 1 month | 3 | 5.3% | |||
| 2 months | 7 | 12.3% | |||
| 3 months | 10 | 17.5% | |||
| 4 months | 4 | 7.0% | |||
| 5 months | 1 | 1.8% | |||
| 6 months | 10 | 17.5% | |||
| 7 months | 2 | 3.5% | |||
| 8–9 months | 5 | 8.8% | |||
| 10–12 months | 7 | 12.3% | |||
| 13–18 months | 5 | 8.8% | |||
| 19–24 months | 3 | 5.3% | |||
| Wait time from first visit to diagnosis (time 2) | 1 | 0–6.5 | 0.5–2 | ||
| 0 months | 7 | 12.3% | |||
| 0.25 months | 3 | 5.3% | |||
| 0.5 months | 5 | 8.8% | |||
| 0.75 months | 5 | 8.8% | |||
| 1 month | 18 | 31.6% | |||
| 1.5 months | 2 | 3.5% | |||
| 2 months | 7 | 12.3% | |||
| 3 months | 4 | 7.0% | |||
| 4.5 months | 2 | 3.5% | |||
| ≥ 6 months | 4 | 7.0% | |||
| Total wait from referral to diagnosis | 7 | 2–26 | 4–12 | ||
| < 2 months | 3 | 5.3% | |||
| 2–3 months | 6 | 10.5% | |||
| 4 months | 6 | 10.5% | |||
| 5–6 months | 7 | 12.3% | |||
| 7–8 months | 9 | 15.8% | |||
| 9–10 months | 8 | 14.0% | |||
| 11–12 months | 2 | 3.5% | |||
| 13–14 months | 6 | 10.5% | |||
| 15–18 months | 3 | 5.3% | |||
| 19–22 months | 4 | 7.0% | |||
| 23–26 months | 3 | 5.3% |
| Predisposing factor | Mechanism of action |
| Moisture [1, 3, 12] | Increased relative moisture of the skinDamage to the skin barrier |
| Friction [3, 10, 11] | Friction between diaper and damp skin increases skin damage (convex regions) |
| Urine [1, 3, 9] | Presence of urea causes irritation and is the base product for conversion to ammonia |
| Feces [1, 3, 9, 13, 20] | The presence of lipases and proteases causes skin damage with filaggrin proteolysis and increased NMFa and TWELb |
| Ammonia and increased pH [1, 3, 12, 13] | Conversion of urea to ammonium hydroxide by bacterial flora (main responsible, Bacillus ammoniagenes)Increase in pH from 5.5 to 6.8–7.15 |
| Microorganisms [1, 3, 12, 13, 16–19, 21, 22] | BacteriaStaphylococcus aureus (isolated most frequently)Other: (β-hemolytic) Streptococcus sp., E. coli and Bacteroides sp.More than 80 %C. albicans (80−90 %)Other: C. tropicalis, C. parapsilosis, C. glabrata |
| Use of antibiotics [1, 3, 9, 21, 22] | Use of broad-spectrum antibiotics causes increased Candida spp. |
| Association with other conditions [1, 3, 11] | Seborrheic dermatitis, inverse psoriasis, epidermolysis bullosa, granuloma gluteale infantum and acrodermatitis enteropathica |
| Plastid type | Plastid size (μm) | Protein content (pg/plastid) |
| Chloroplasts (7-days-old light-grown leaves) | 3.24 ± 0.23 | 8.13 ± 1.42 |
| Leucoplasts (4-days-old dark-grown roots) | 1.81 ± 0.21 | 1.85 ± 0.63 |
| Before treatment | After 1 month | After 3 months | After 6 months | |||||
| Group (no. of subjects) | Mn-Cells | CBPI | Mn-Cells | CBPI | Mn-Cells | CBPI | Mn-Cells | CBPI |
| A (8) | 10.00 ± 2.00 | 1.73 | ||||||
| 8.00 ± 4.73 | 1.73 | |||||||
| 5.83 ± 0.75 | 1.70 | |||||||
| 5.00 ± 0.89 | 1.69 | |||||||
| 4.00 ± 2.97 | 1.75 | |||||||
| 4.00 ± 2.00 | 1.73 | |||||||
| 3.67 ± 0.82 | 1.69 | |||||||
| 2.00 ± 0.89 | 1.88 | |||||||
| B (9) | 17.00 ± 4.69 | 1.82 | 4.00 ± 1.79 | 1.79 | ||||
| 7.83 ± 4.12 | 1.70 | 15.00 ± 6.13 | 1.74 | |||||
| 7.00 ± 1.55 | 1.74 | 3.00 ± 0.89 | 1.85 | |||||
| 6.00 ± 3.58 | 1.92 | 2.50 ± 0.84 | 1.56 | |||||
| 5.67 ± 1.21 | 1.63 | 4.67 ± 1.03 | 1.63 | |||||
| 5.33 ± 2.07 | 1.78 | 2.17 ± 1.33 | 1.69 | |||||
| 4.00 ± 1.29 | 1.77 | 2.67 ± 0.82 | 1.78 | |||||
| 3.00 ± 0.89 | 1.58 | 5.33 ± 1.03 | 1.67 | |||||
| 2.67 ± 0.82 | 1.77 | 3.67 ± 0.82 | 1.68 | |||||
| C (13) | 16.00 ± 4.34 | 1.88 | 14.00 ± 2.37 | 1.81 | 5.00 ± 1.78 | 1.75 | ||
| 11.67 ± 4.08 | 1.70 | 6.67 ± 1.63 | 1.68 | 5.50 ± 1.38 | 1.66 | |||
| 8.83 ± 2.32 | 1.76 | 13.00 ± 2.53 | 1.74 | 7.33 ± 2.50 | 1.76 | |||
| 8.00 ± 0.89 | 1.69 | 8.17 ± 3.60 | 1.74 | 6.00 ± 1.67 | 1.70 | |||
| 7.00 ± 2.19 | 1.67 | 4.00 ± 3.03 | 1.75 | 8.00 ± 1.79 | 1.84 | |||
| 7.00 ± 1.41 | 1.79 | 3.00 ± 2.53 | 1.72 | 5.17 ± 2.32 | 1.82 | |||
| 6.00 ± 1.27 | 1.77 | 10.00 ± 2.83 | 1.85 | 1.67 ± 1.03 | 1.72 | |||
| 4.83 ± 2.14 | 1.75 | 7.83 ± 2.32 | 1.80 | 5.00 ± 2.10 | 1.78 | |||
| 4.00 ± 1.27 | 1.76 | 6.67 ± 1.03 | 1.85 | 3.67 ± 1.21 | 1.92 | |||
| 4.00 ± 2.00 | 1.73 | 4.33 ± 1.21 | 1.66 | 5.33 ± 1.37 | 1.66 | |||
| 3.00 ± 3.03 | 1.74 | 3.00 ± 1.55 | 1.73 | 3.67 ± 1.63 | 1.69 | |||
| 2.83 ± 2.14 | 1.75 | 3.00 ± 1.27 | 1.84 | 7.67 ± 2.94 | 1.73 | |||
| 2.00 ± 0.89 | 1.80 | 2.83 ± 1.47 | 1.85 | 9.67 ± 4.41 | 1.81 | |||
| D (8) | 21.00 ± 5.22 | 1.76 | 10.00 ± 5.37 | 1.74 | 13.67 ± 3.50 | 1.85 | 5.00 ± 0.89 | 1.71 |
| 6.17 ± 1.17 | 1.81 | 5.33 ± 1.03 | 1.81 | 6.50 ± 1.38 | 1.84 | 5.67 ± 0.82 | 1.78 | |
| 4.17 ± 1.47 | 1.73 | 2.00 ± 2.28 | 1.77 | 11.50 ± 4.85 | 1.77 | 3.50 ± 1.64 | 1.80 | |
| 3.17 ± 2.86 | 1.65 | 3.00 ± 1.41 | 1.74 | 1.50 ± 1.05 | 1.67 | 3.33 ± 0.52 | 1.67 | |
| 3.00 ± 1.79 | 1.78 | 16.00 ± 2.19 | 1.85 | 2.00 ± 1.41 | 1.72 | 5.67 ± 1.37 | 1.79 | |
| 2.67 ± 1.75 | 1.74 | 3.00 ± 1.27 | 1.72 | 4.83 ± 2.48 | 1.78 | 5.17 ± 1.17 | 1.74 | |
| 2.00 ± 0.63 | 1.80 | 8.17 ± 3.76 | 1.78 | 5.50 ± 2.34 | 1.68 | 4.33 ± 1.03 | 1.64 | |
| 2.00 ± 0.63 | 1.69 | 2.00 ± 1.27 | 1.70 | 27.83 ± 3.71 | 1.78 | 3.67 ± 0.82 | 1.70 | |
| Total no. of patients | 38 | 38 | 30 | 30 | 21 | 21 | 8 | 8 |
| Mean ± SD | 6.06 ± 4.29 | 1.75 ± 0.07 | 5.97 ± 4.12 | 1.76 ± 0.08 | 7.00 ± 5.65 | 1.76 ± 0.07 | 4.54 ± 0.96 | 1.73 ± 0.06 |
| p-Value (t-test/Wilcoxon) | 0.75/0.75 | 0.53/0.41 | 0.60/0.96 | 0.61/0.78 | 0.67/0.55 | 0.54/0.81 |
| Variable | Change in Mean CSA | Change in Type II CSA | Change in Type I CSA | |
| Fold change AR | r | 0.60 | 0.60 | 0.47 |
| P | 0.003 | 0.002 | 0.023 | |
| Free Testosterone AUC | r | 0.06 | 0.07 | 0.10 |
| P | 0.771 | 0.760 | 0.639 | |
| IL-6 AUC | r | 0.48 | 0.42 | 0.51 |
| P | 0.019 | 0.047 | 0.013 | |
| GH AUC | r | 0.39 | 0.40 | 0.38 |
| P | 0.069 | 0.061 | 0.073 | |
| IGF-1 AUC | r | -0.30 | -0.27 | -0.23 |
| P | 0.165 | 0.219 | 0.292 | |
| Cortisol AUC | r | -0.02 | 0.00 | -0.09 |
| P | 0.919 | 0.990 | 0.670 | |
| TNF-alpha AUC | r | 0.02 | -0.05 | 0.10 |
| P | 0.919 | 0.812 | 0.652 | |
| CRP AUC | r | 0.18 | 0.13 | 0.06 |
| P | 0.420 | 0.567 | 0.784 |
| Formula | Observations | Grade |
| F1 | Rapidly forming clear emulsion | A |
| F2 | Rapidly forming clear emulsion | A |
| F3 | Rapidly forming clear emulsion | A |
| F4 | Rapidly forming clear emulsion | A |
| F5 | Rapidly forming clear emulsion | A |
| F6 | Rapidly forming clear emulsion | A |
| F7 | Rapidly forming clear emulsion | A |
| F8 | Rapidly forming clear emulsion | A |
| Primary antibody | Manufacturer (Cat. No.) | Pretreatment | Working dilution |
| Mouse anti-CD20 monoclonal antibody | Zymed, San Diego, CA, USA (18-0155) | HP CB (pH 6.0) | 1:100 |
| Mouse anti-CD79A monoclonal antibody | Novocastra, New Castle, Tyne and Wear, UK (RTU-CD79α-192) | HP CB (pH 6.0) | Ready to use |
| Mouse anti-CD3ε monoclonal antibody | Novocastra, New Castle, Tyne and Wear, UK (RTU-CD3-PS1) | HP CB (pH 6.0) | Ready to use |
| Mouse anti-CD45RO monoclonal antibody | Zymed, San Diego, CA, USA (08-1365) | HP CB (pH 6.0) | Ready to use |
| Mouse anti-CD5 monoclonal antibody | Zymed, San Diego, CA, USA (08-1283) | HP CB (pH 6.0) | Ready to use |
| Mouse anti-CD10 monoclonal antibody | Novocastra, New Castle, Tyne and Wear, UK (RTU-CD10-270) | HP CB (pH 6.0) | Ready to use |
| Mouse anti-CD23 monoclonal antibody | Novocastra, New Castle, Tyne and Wear, UK (RTU-CD23-1B12) | HP CB (pH 6.0) | Ready to use |
| Mouse anti-CD30 monoclonal antibody | Zymed, San Diego, CA, USA (08-0155) | HP CB (pH 6.0) | Ready to use |
| Mouse anti-CD56 monoclonal antibody | Zymed, San Diego, CA, USA (08-0152) | HP CB (pH 6.0) | Ready to use |
| Mouse anti-Bcl-6 monoclonal antibody | Zymed, San Diego, CA, USA (08-1426) | HP EDTA (pH 9.0) | Ready to use |
| Mouse anti-ALK monoclonal antibody | Zeta, Sierra Madre, CA, USA (Z2035) | HP EDTA (pH 8.0) | Ready to use |
| Mouse anti-Ki-67 monoclonal antibody | Zymed, San Diego, CA, USA (18-0192Z) | HP CB (pH 6.0) | 1:50 |
| Mouse anti-TdT monoclonal antibody | Zymed, San Diego, CA, USA (18-7237) | HP EDTA (pH 9.0) | 1:50 |
| Mouse anti-TIA-1 monoclonal antibody | Zeta, Sierra Madre, CA, USA (Z2183) | HP CB (pH 6.0) | Ready to use |
| Mouse anti-Perforin monoclonal antibody | Zeta, Sierra Madre, CA, USA (Z2118) | HP CB (pH 6.0) | Ready to use |
| Mouse anti-Granzyme B monoclonal antibody | Newmarket Scientific, Newmarket, Suffolk, UK (MS-1157-s) | HP CB (pH 6.0) | Ready to use |
| Mouse anti-PD-1 monoclonal antibody | Zymed, San Diego, CA, USA (0381) | HP CB (pH 6.0) | 1:100 |
| Goat anti-CXCL13 polyclonal antibody | Zymed, San Diego, CA, USA (0043) | HP CB (pH 6.0) | 1:100 |
| Mouse anti-CD4 monoclonal antibody | Zymed, San Diego, CA, USA (0032) | HP CB (pH 6.0) | 1:200 |
| Rabbit anti-CD8 monoclonal antibody | Zymed, San Diego, CA, USA (0043) | HP CB (pH 6.0) | 1:100 |
| Non-PD | PDa | |||
| Gender | Male | Female | Male | Female |
| Number | 10 | 11 | 14 | 12 |
| Age (years) | 70 ± 3.2 | 71 ± 3.2 | 73 ± 2.1 | 73 ± 2.6 |
| Disease duration (years) | NAb | NA | 5.8 ± 0.60 | 4.8 ± 0.60 |
| The nursing home as my home | Interpersonal care quality |
| ‘Being at home in a nursing home’ | ‘Care for and alleviation of medical, physical and psychological needs’ |
| ‘Paying the price for 24-hour care’ | ‘Protecting the resident’s integrity’ |
| ‘Personal habits and institutional routines’ | ‘Psychosocial well-being’ |
| ‘Meaningful activities for a meaningful day’ |
| District name | Upazila Health Complex (UHC) | Samples (N) | K13 Nested PCR and sequencing N (%) | Non-synonymous Mutation N (%) |
| Bandarban | Lama UHC | 14 | 149(100) | 0(0.0) |
| Cox’s Bazar | Ramu and Ukhia UHC | 74 | 69(93.2) | 0(0.0) |
| Netrokona | Durgapur and Kalmakanda UHC | 10 | 9(90) | 0(0.0) |
| Mymensingh | Haluaghat UHC | 2 | 2(100) | 0(0.0) |
| Khagrachari | Matiranga UHC | 154 | 144(93.5) | 2*(1.29) |
| Rangamati | Rajasthali UHC | 6 | 5(66.7) | 0(0.0) |
| Moulvibazar | Sreemangal and Kamalganj UHC | 11 | 11(100) | 0(0.0) |
| Total | 271 | 254(93.7) | 2(0.78) |
| Genomic resources | Source material | Number |
| Mapping populations | ||
| DH line | Chiffu-401-42 × Kenshin-402-43 | 78 lines (F2 generation) |
| RI line | Chiffu-401-42 × Kenshin-402-43 | 201 lines (F8 generation) |
| BAC libraries | ||
| HindIII (KBrH) | Chiffu-401-42 | 56592 clones (115 kb(1)) |
| BamHI (KBrB) | Chiffu-401-42 | 50688 clones (124 kb(1)) |
| Sau3AI (KBrS) | Chiffu-401-42 | 55296 clones (100 kb(1)) |
| cDNA libraries | ||
| 22 cDNA libraries | Different tissues of Chiffu-401-42 and Jangwon including leaves, roots, cotyledons, stems,seedlings, ovules, siliques, anthers | — |
| BAC-end sequences | KBrH, KBrB, and KBrS clones | 200017 sequences |
| ESTs | 22 cDNA clones | 129928 sequences |
| BAC shotgun sequences | KBrH, KBrB, and KBrS clones | on-going(2) |
| Equipment contents of the emergency caesarean section tray | Equipment for neonatal resuscitation and stabilization |
| Scalpel with no. 10 blade | Overbed warmer |
| Lower end of Balfour retractor | Neonatal airway supplies |
| Pack of sponges | Umbilical access |
| 2 Kelly clamps | Medications (e.g., epinephrine 1 : 10 000) |
| Needle driver | |
| Russian forceps | |
| Sutures and suture scissors |
| Dataset | Proposed method | Greedy | |
| (α=0.5) | r=0.05 | r=0.001 | |
| USA - Netherlands | 25.10% | 8.28% | 7.60% |
| USA - Belgium | 19.04% | 5.22% | 6.09% |
| USA - Sweden | 19.71% | 5.32% | 5.51% |
| Netherlands - Belgium | 18.11% | 8.84% | 10.09% |
| Netherlands - Sweden | 18.85% | 7.92% | 7.78% |
| Belgium - Sweden | 17.13% | 11.57% | 11.31% |
| Age (years) | 16 | 17 | 18 | 19 | 20 | All |
| N | 22 | 40 | 28 | 50 | 31 | 171 |
| CAARMS positive | 1(4.5%) | 10 (25%) | 10 (35.7%) | 11 (22%) | 7 (22.6%) | 39(22.8%) |
| 95% confidence interval | 1.1 -21.9% | 14.2 – 40.3% | 20.7 – 54.3% | 12.8 – 35.3% | 11.4 – 40% | 17.2 – 29.7% |
| Admitting medical diagnosis | Number of subjects (total n = 126) |
| Stroke (all types) | 38 |
| General medical (nonbrain)1 | 23 |
| Brain tumor (all types) | 22 |
| Neurological disease (brain)2 | 20 |
| Orthopedic3 | 14 |
| Hydrocephalus (all types) | 9 |
| Female | Male | |
| Succeeded in returning to workplace ** | 49 (48.0 %) | 237 (67.3 %) |
| Relapse of psychiatric symptoms ** | 37 (36.3 %) | 71 (20.2 %) |
| Moved to another medical facility | 6 (5.9 %) | 12 (3.4 %) |
| Retirement or other | 10 (9.8 %) | 32 (9.1 %) |
| Total | 102 | 352 |
| Variables | Correlation | P |
| FIQ | −0.32 | <0.001 |
| PCS | −0.55 | < 0.001 |
| HADS-dep | −0.57 | <0.001 |
| HADS-ans | −0.51 | <0.001 |
| PVAS | −0.12 | 0.113 |
| CPAQ | 0.44 | <0.001 |
| MAS | 0.39 | <0.001 |
| Gene category | List hits | Population hits | EASE score |
| (GO biological process) | (Total = 348) | (Total = 10,937) | |
| response to external stimulus | 67 | 1263 | 2.52E-05 |
| response to biotic stimulus | 61 | 821 | 6.47E-10 |
| defense response | 57 | 756 | 1.62E-09 |
| immune response | 56 | 682 | 9.89E-11 |
| response to pest/pathogen/parasite | 27 | 444 | 1.92E-03 |
| antigen processing, endogenous antigen via MHC class I | 4 | 12 | 5.63E-03 |
| response to stress | 37 | 784 | 1.57E-02 |
| signal transduction | 97 | 2196 | 3.43E-04 |
| intracellular signaling cascade | 47 | 761 | 1.62E-05 |
| protein kinase cascade | 12 | 155 | 1.04E-02 |
| activation of MAPK | 4 | 16 | 1.30E-02 |
| phosphate metabolism | 33 | 662 | 1.13E-02 |
| phosphorylation | 28 | 524 | 8.90E-03 |
| protein amino acid phosphorylation | 26 | 478 | 9.74E-03 |
| RNA splicing, via transesterification reactions | 8 | 83 | 1.61E-02 |
| Exogenous variable | Endogenous variable | |||||||
| Arm movement speed (plate tapping) | Agility (10x5m shuttle run) | Explosive strength of the legs (standing broad jump) | Trunk strength (sit-ups) | Explosive strength of trunk and shoulder girdle (1kg medicine ball throw) | MAP | Flexibility (sit and reach) | ||
| Body height | −0.677 | −0.635 | 0.638 | 0.581 | 0.702 | 0.309 | ||
| Body mass | 0.302 | |||||||
| BMI | 0.488 | 0.233 | ||||||
| Rohrer’s index | ||||||||
| ∑ of skinfold thickness | 0.123 | −0.437 | −0.220 | −0.588 | −0.455 | |||
| LBM | 0.605 | |||||||
| Objective quality of life index | −0.177 | 0.216 | 0.114 | |||||
| Subjective quality of life index | 0.110 | −0.090 | 0.136 | |||||
| R | 0.649 | 0.494 | 0.685 | 0.543 | 0.727 | 0.924 | 0.308 | |
| R2 | 0.422 | 0.244 | 0.469 | 0.295 | 0.529 | 0.854 | 0.095 | |
| F | 22.620 | 9.992 | 27.370 | 13.002 | 34.862 | 181.37 | 3.255 | |
| p | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.025 |
| Mikołajskie september | Mamry september | ||||
| Microscope | DGGE-ITS | Microscope | DGGE-ITS | ||
| taxon | (cells/mL) | taxon | (cells/mL) | ||
| Snowella litoralis | 3 | Snowella litoralis | 118 | ||
| Snowella lacustris | 31 | Snowella lacustris | 1 | ||
| Woronichinia compacta | 1 | ||||
| Woronichinia naegeliana | 2 | ||||
| Chroococcus spp. | <1 | Chroococcus spp. | 13 | ||
| Aphanothece spp. | 779 | ||||
| Microcystis aeruginosa | 19 | Microcystis | |||
| Microcystis flos-aquae | 7 | ||||
| Microcystis smithii | 5 | ||||
| Aphanocapsa spp. | 34 | Aphanocapsa spp. | 4599 | ||
| Aphanocapsa planctonica | 4 | Aphanocapsa planctonica | 75 | ||
| Coelosphaerium kuetzingianum | 2 | ||||
| Coelosphaerium minutissimum | 3 | Coelosphaerium minutissimum | 18 | ||
| Merismopedia punctata | 1 | ||||
| Cyanodictyon reticulatum | 2 | ||||
| Cyanodictyon cf. planctonicum | 7 | ||||
| Lemmermanniella pallida | 4 | ||||
| Synechococcus-like/Cyanobium-like | 60042 | Synechococcus | Synechococcus-like/Cyanobium-like | 76386 | Synechococcus |
| Aphanizomenon gracile | 839 | Aphanizomenon (?) | Aphanizomenon gracile | 336 | Aphanizomenon (?) |
| Cuspidothrix issatschenkoi | 20 | Cuspidothrix issatschenkoi | Cuspidothrix issatschenkoi | 25 | Cuspidothrix issatschenkoi |
| Dolichospermum | Dolichospermum lemmermannii | 1 | Dolichospermum | ||
| Phormidium (?) | Phormidium (?) | ||||
| Planktothrix agardhii | 45 | Planktothrix | Planktothrix | ||
| Planktothrix suspensa | |||||
| Pseudanabaenaceae | Pseudanabaenaceae | ||||
| Leptolyngbya | |||||
| Limnothrix lauterbornii | 128 | Limnothrix lauterbornii | 154 | ||
| Limnothrix redekei | 692 | Limnothrix redekei | 742 | ||
| Planktolyngbya limnetica | 5455 | Planktolyngbya limnetica | 3293 | ||
| Pseudanabaena catenata | 5963 | Pseudanabaena catenata | 1393 | ||
| Pseudanabaena limnetica | 18172 | Pseudanabaena limnetica | 24635 | ||
| Pseudanabaena mucicola | 10 | ||||
| Romeria (?) | Romeria gracilis | 214 | Romeria (?) | ||
| unassigned sequences | unassigned sequences | ||||
| nonsequenced | nonsequenced |
| Variable | Cases (n = 50) | Controls (n = 44) | p-values |
| Age (yrs)* | 30.78 (19-41) | 30.68 (19-40) | 0.893 |
| Body mass index (kg/m2)* | 30.26 ± 2.21 | 31.07 ± 1.69 | 0.211 |
| Duration of Infertility (yrs)* | 3.93 (2.5-10) | 5.0 (2-16) | 0.041 |
| < 5 years | 26 (52 %) | 31 (70.5 %) | 0.068 |
| ≥5 years | 24 (48 %) | 13 (29.5 %) | |
| Type of infertility | |||
| Primary | 36 (72 %) | 35 (79.5 %) | 0.396 |
| Secondary | 14 (28 %) | 9 (20.5 %) | |
| Previous parity | 9 (18 %) | 6 (13.6 %) | 0.564 |
| Previous abortion | 10 (20 %) | 6 (13.6 %) | 0.413 |
| Previous ICSI/IUI | 17 (34 %) | 9 (20.5 %) | 0.308 |
| Anti C.trachomatis IgM + ve | 3/50 (6 %) | 0/44 (0 %) | 0.099 |
| Anti C.trachomatis IgG + ve | 18 (36 %) | 8 (18.2 %) | 0.054 |
| Ratio of IgM* | 0.37 ± 0.26 | 0.59 ± 0.24 | < 0.05 |
| Ratio of IgG* | 1.26 ± 0.99 | 0.87 ± 0.63 | 0.03 |
| PCR positive | 3/50 (6 %) | 0/44 (0 %) | 0.09 |
| Antisperm Abs positive | 3/50 (6 %) | 1/44 (2.3 %) | 0.372 |
| Variables | Class II | Class III |
| Gender (male) | 38.56 (11.78–126.19) * | 57.27 (13.56–241.85) * |
| Age a | ||
| 31–40 | 1.47 (0.60–3.58) | 8.08 (2.03–32.18) * |
| >40 | 1.29 (0.48–3.49) | 8.35 (2.01–34.74) * |
| Ethnicity b | ||
| Minority | 2.14 (0.74–6.23) | 1.36 (0.40–4.64) |
| Educational background c | ||
| Master | 1.10 (0.51–2.38) | 0.55 (0.25–1.20) |
| PhD | 0.96 (0.42–2.18) | 0.54 (0.24–1.19) |
| Married status d | ||
| Married | 0.98 (0.41–2.36) | 1.83 (0.53–6.33) |
| Divorced or widowed | 1.19 (0.17–8.27) | 3.47 (0.53–22.59) |
| Position e | ||
| Non–HCPs | 1.09 (0.56–2.12) | 0.71 (0.37–1.39) |
| Knowledge f | ||
| ≥23 | 1.19 (0.66–2.13) | 1.35 (0.72–2.51) |
| Attitude g | ||
| ≥9 | 1.22 (0.68–2.19) | 1.68 (0.90–3.15) |
| Causes of preterm labor | Spontaneous preterm labor | PROM | Preterm elective termination of pregnancy | Term labor | |
| Group | |||||
| Case (progesterone) | |||||
| Number | 0 | 4 | 0 | 48 | |
| Percentage | 0% | 7.7% | 0% | 92.3% | |
| Control (placebo) | |||||
| Number | 3 | 2 | 3 | 39 | |
| Percentage | 6.4% | 4.3% | 6.4% | 83% |
| Characteristics | n = 60(%) | miR-335-5p mRNA expression | p value | CPNE1 mRNA expression | p value | ||
| high | low | high | low | ||||
| (n = 15) | (n = 45) | (n = 53) | (n = 7) | ||||
| Age | |||||||
| ≤65 | 41 (68%) | 9 | 32 | 0.432 | 36 | 5 | 0.851 |
| > 65 | 19 (32%) | 6 | 13 | 17 | 2 | ||
| Gender | |||||||
| Male | 38 (63%) | 10 | 28 | 0.757 | 34 | 4 | 0.718 |
| Female | 22 (37%) | 5 | 17 | 19 | 3 | ||
| Histology | |||||||
| Adenocarcinoma | 33 (55%) | 7 | 26 | 0.479 | 30 | 3 | 0.661 |
| Squamous cell carcinoma | 17 (28%) | 4 | 13 | 14 | 3 | ||
| Others | 10 (17%) | 4 | 6 | 9 | 1 | ||
| Smoking status | |||||||
| Yes | 33 (55%) | 7 | 26 | 0.454 | 30 | 3 | 0.492 |
| No | 27 (45%) | 8 | 19 | 23 | 4 | ||
| Clinical stage | |||||||
| I/II | 24 (40%) | 4 | 20 | 0.224 | 21 | 3 | 0.870 |
| III/IV | 36 (60%) | 11 | 25 | 32 | 4 | ||
| Lymph node metastasis | |||||||
| No | 24 (40%) | 10 | 14 | 0.015 | 18 | 6 | 0.009 |
| Yes | 36 (60%) | 5 | 31 | 35 | 1 |
| Dataset | Number | Overlap | P Valuea | Odds Ratio |
| Expressed genes for Smaug-dependent decay (embryos 2–3 hr) | 3956 | |||
| Smaug-dependent decay genes (embryos 2–3 hr, 5% FDR)b | 418 | |||
| Smaug-dependent-miR target genes | 1507 | 151 | 4.9 × 10−6 | 1.6 |
| Expressed genes for Smaug-dependent decay (embryos 2–3 hr) | 3956 | |||
| Smaug-dependent decay genes (embryos 2–3 hr, 5% FDR)c | 341 | |||
| Smaug-dependent-miR target genes | 1507 | 128 | 3.1 × 10−6 | 1.7 |
| Expressed genes for Smaug-RIP (embryos 0–3 hr) | 4481 | |||
| Smaug-RIP genes (embryos 0–3 hr, 5% FDR) | 339 | |||
| Smaug-dependent-miR target genes | 1200 | 101 | 0.11 | 1.1 |
| Variables | All (N = 663) | Depressive symptoms (n = 321) | Non-depressive symptoms (n = 338) | Statistic |
| N (%)Mean (SD) | N (%)Mean (SD) | N (%)Mean (SD) | t/χ2, p | |
| HIV-related variables | ||||
| Diagnosed with HIV in this pregnancy | ||||
| No, before | 304 (45.9%) | 146 (45.2%) | 158 (46.5%) | .107; .743 |
| Yes | 359 (54.1%) | 177 (54.8%) | 182 (53.5%) | |
| Disclosure of HIV serostatus to anyone | ||||
| No | 185 (27.9%) | 98 (30.3%) | 87 (25.6%) | 1.86; .173 |
| Yes | 478 (72.1%) | 225 (69.7%) | 253 (74.4%) | |
| Months since ART initiation | 13.0 (23.9) | 11.8 (22.3) | 14.0 (25.3) | 1.09; .277a |
| Has HIV-positive children | ||||
| No or do not know | 498 (94.9%) | 252 (97.3%) | 246 (92.5%) | 6.23; .012 |
| Yes | 27 (5.1%) | 7 (2.7%) | 20 (7.5%) | |
| Internalized AIDS stigma | ||||
| Score 0 | 391 (59.0%) | 173 (53.6%) | 218 (64.1%) | 7.63; .006 |
| Score 1 or more | 272 (41.0%) | 150 (46.4%) | 122 (35.9%) | |
| Skipped medication in the past 7 days | ||||
| Non-adherent (<100%) | 218 (32.9%) | 132 (40.9%) | 86 (25.3%) | 18.20; <.001 |
| Adherent (100%) | 445 (67.1%) | 191 (59.1%) | 254 (74.6%) | |
| Partner variables | ||||
| Disclosure of HIV serostatus to partner | ||||
| No | 275 (41.5%) | 145 (44.9%) | 130 (38.2%) | 3.02; .082 |
| Yes | 388 (58.5%) | 178 (55.1%) | 210 (61.8%) | |
| HIV-positive partner | ||||
| No or do not know | 497 (75.0%) | 253 (78.3%) | 244 (71.8%) | 3.80; .051 |
| Yes | 166 (25.0%) | 70 (21.7%) | 96 (28.2%) | |
| Condom use at last sex | ||||
| Yes | 317 (47.8%) | 176 (54.5%) | 141 (41.5%) | 11.25; <.001 |
| No | 346 (52.2%) | 147 (45.5%) | 199 (58.5%) | |
| IPV | ||||
| No mild or severe physical violence | 533 (80.4%) | 239 (74.0%) | 294 (86.5%) | 16.36; <.001 |
| Mild or severe physical violence | 130 (19.6%) | 84 (26.0%) | 46 (13.5%) | |
| Male involvement index | 7.15 (3.0) | 6.7 (3.2) | 7.6 (2.8) | 3.58; <.001 |
| Suspected VOC | Healthy vs. Benign + Cancer | Healthy + Benign vs. Cancer | Cancer vs. DCIS | Triple Negative vs. Other | HER2+ vs. Other | HER2 + status*vs. Other | HER2+ status (Non Luminal) vs. Other | HER2+ status (Luminal) vs. Other |
| Ethanol | X | X | X | X | ||||
| Acetone | X | X | ||||||
| Cyclopentane | X | |||||||
| Carbonic acid, dimethyl ester (DMC) | X | X | X | |||||
| Pentane, 2, 3-dimethyl- | X | X | ||||||
| Heptane | X | X | ||||||
| Toluene | X | |||||||
| Cyclohexane, 1, 4-dimethyl- | X | X | ||||||
| Acetic acid, butyl ester | X | |||||||
| Benzene, 1, 3-dimethyl- | X | X | ||||||
| 2-Propenoic acid, butyl ester | X | X | ||||||
| alpha.-Pinene | X | X | ||||||
| 5-Hepten-2-one, 6-methyl- | X | |||||||
| 1-Hexanol, 2-ethyl- | X | |||||||
| Sensitivity | 86 | 78 | 70 | 40 | 67 | 68 | 100 | 73 |
| Specificity | 70 | 61 | 83 | 95 | 76 | 72 | 57 | 70 |
| Accuracy | 83 | 72 | 81 | 87 | 74 | 70 | 82 | 72 |
| p-value | < 0.0001 | < 0.0001 | 0.0001 | 0.006 | 0.0001 | < 0.0001 | 0.0047 | 0.0018 |
| AUC | 0.93 | 0.79 | 0.88 | 0.78 | 0.83 | 0.82 | 0.91 | 0.87 |
| Clinical manifestations/Hospitalization | Number of events | Number of doses per event | Rate per 10,000 dosesb | |
| Local | ||||
| Pain | 189 | 4,040 | 2.5 | |
| Nodule | 163 | 4,684 | 2.1 | |
| Abscess | 33 | 23,138 | 0.4 | |
| Lymphadenitis | 33 | 23,138 | 0.4 | |
| Ulcer | 1 | 763,548 | 0.1 | |
| Systemic | ||||
| Headache | 1 | 763,548 | 0.1 | |
| Nausea | 10 | 76,355 | 0.1 | |
| Diarrhea | 23 | 33,198 | 0.3 | |
| Vomiting | 54 | 14,140 | 0.7 | |
| Cyanosis | 27 | 28,280 | 0.4 | |
| Malaise | 23 | 33,198 | 0.3 | |
| Irritability | 102 | 7,486 | 1.3 | |
| Sleepiness | 44 | 17,353 | 0.6 | |
| Myalgia | 7 | 109,078 | 0.1 | |
| Exanthema | 46 | 16,599 | 0.6 | |
| Jaundice | 1 | 763,548 | 0.1 | |
| Parotitis | 20 | 38,177 | 0.3 | |
| Fever | 344 | 2,220 | 4.5 | |
| < 38°C | 51 | 14,971 | 0.7 | |
| 38|-|39,4°C | 196 | 3,896 | 2,6 | |
| ≥ 39.5°C | 68 | 11,229 | 0.9 | |
| Hypotonic-hyporesponsive episode | 67 | 11,396 | 0.9 | |
| Adenoiditis | 18 | 42,419 | 0.2 | |
| Arthralgia | 1 | 763,548 | 0.1 | |
| Hypersensitivity | 11 | 69,413 | 0.1 | |
| Seizure | 25 | 30,542 | 0.3 | |
| Loss of consciousness | 6 | 127,258 | 0.1 | |
| Myelitis | 1 | 763,548 | 0.1 | |
| Paresis | 1 | 763,548 | 0.1 | |
| Hospitalization | 16 | 47,722 | 0.2 |
| Criterion | ALARM (n,%) | Control (n,%) | p-value |
| N = 68 | N = 70 | ||
| Anticonvulsant administered | |||
| Magnesium sulphate | 26, 38.2% | 20, 28.6% | |
| Valium | 7, 10.3% | 7, 10.0% | |
| None | 35, 51.5% | 43, 61.4% | 0.455 |
| Blood pressure recorded every four hours after birth | |||
| Yes | 15, 22.1% | 13, 18.6% | |
| No | 53, 77.9% | 57, 81.4% | 0.675 |
| Urinary output measured at least once in 24 hours | |||
| Yes | 22, 32.4% | 22, 31.4% | |
| No | 46, 67.6% | 48, 68.6% | 1.000 |
| Test of bleeding time | |||
| Yes | 5, 7.4% | 10, 14.3% | |
| No | 63, 92.6% | 60, 85.7% | 0.275 |
| Test of coagulation rate | |||
| Yes | 5, 7.4% | 9, 12.9% | |
| No | 63, 92.6% | 61, 87.1% | 0.346 |
| Platelet count | |||
| Yes | 22, 32.4% | 17, 24.3% | |
| No | 46, 67.6% | 53, 75.7% | 0.346 |
| Albumin test | |||
| Yes | 18, 26.5% | 18, 26.1% | |
| No | 50, 73.5% | 51, 73.9% | 1.00 |
| Total severe (pre-) eclampsia score | 25.2% | 23.2% | 0.621 |
| Strain | NRRL2338 | Px | ||
| COG | Functional categories | % COG probesets | % Probesets with q-value < = 0.001 | % Probesets with q-value < = 0.001 |
| I | Cellular processes and signaling | |||
| I.1 | Cell cycle control, cell division, chromosome partitioning | 0,35 | 0,99 | 0,69 |
| I.2 | Cell motility | 0,01 | 0 | 0 |
| I.3 | Cell wall/membrane/envelope biogenesis | 2,05 | 3,22 | 3,81 |
| I.4 | Defense mechanisms | 0,89 | 0,00 | 0,87 |
| I.5 | Intracellular trafficking, secretion, and vesicular transport | 0,24 | 0,25 | 0,69 |
| I.6 | Posttranslational modification, protein turnover, chaperones | 1,90 | 5,94 | 3,99 |
| I.7 | Signal transduction mechanisms | 1,91 | 0,99 | 1,91 |
| II | Information storage and processing | |||
| II.1 | Amino acid transport and metabolism | 0,01 | 0 | 0 |
| II.2 | Cell wall/membrane/envelope biogenesis | 0,01 | 0 | 0 |
| II.3 | Chromatin structure and dynamics | 0,01 | 0 | 0 |
| II.4 | General function prediction only | 0,30 | 0,50 | 0,35 |
| II.5 | Nucleotide transport and metabolism | 0,07 | 0 | 0 |
| II.6 | Posttranslational modification, protein turnover, chaperone | 0,04 | 0 | 0 |
| II.7 | Replication, recombination and repair | 2,44 | 0,74 | 2,43 |
| II.8 | RNA processing and modification | 0,01 | 0 | |
| II.9 | Secondary metabolites biosynthesis, transport catabolism | 0,04 | 0 | |
| II.10 | Signal transduction mechanisms | 0,71 | 0,50 | 0,69 |
| II.11 | Transcription | 7,20 | 2,23 | 3,29 |
| II.12 | Translation, ribosomal structure and biogenesis | 2,48 | 4,21 | 10,75 |
| III | Metabolism | |||
| III.l | Amino acid transport and metabolism | 6,60 | 0 | 8,15 |
| III.2 | Carbohydrate transport and metabolism | 6,08 | 7,67 | 6,59 |
| III.3 | Cell wall/membrane/envelope biogenesis | 0,38 | 0 | 0,17 |
| III.4 | Coenzyme transport and metabolism | 2,63 | 5,20 | 4,33 |
| III.5 | Energy production and conversion | 4,79 | 9,90 | 8,15 |
| III.6 | Inorganic ion transport and metabolism | 2,68 | 4,21 | 2,25 |
| III.7 | Lipid transport and metabolism | 4,24 | 2,72 | 5,03 |
| III.8 | Nucleotide transport and metabolism | 1,27 | 2,97 | 3,64 |
| III.9 | Posttranslational modification, protein turnover, chaperones | 0,08 | 0 | 0,17 |
| III.10 | Secondary metabolites biosynthesis, transport catabolism | 2,90 | 2,48 | 2,77 |
| III. 11 | Signal transduction mechanisms | 0,16 | 0 | 0 |
| IV | Poorly characterized | |||
| IV.1 | Function unknown | 32,11 | 27,23 | 22,70 |
| IV.2 | General function prediction only | 7,37 | 8,17 | 6,59 |
| Total probesets | 7060 | 404 | 577 |
| No. | Name | Concentration of β-asarone (mg/kg) | Concentration of α-asarone (mg/kg) | Source |
| 1 | Product 1 | Not detected | Not detected | – |
| 2 | Product 2 | Not detected | Not detected | – |
| 3 | Product 3 | 273.6 ± 21.6 | 40 ± 1.2 | Acori tatarinowii Rhizoma |
| 4 | Product 4 | Not detected | Not detected | – |
| 5 | Product 5 | 230.9 ± 21.3 | 34.7 ± 1.2 | Acori tatarinowii Rhizoma |
| 6 | Product 6 | 4.8 ± 0.2 | 5.0 ± 0.2 | Acori tatarinowii Rhizoma |
| 7 | Product 7 | 11.2 ± 0.1 | 47.7 ± 3.0 | Acori graminei Rhizoma |
| 8 | Product 8 | 181.6 ± 5.4 | 106.1 ± 1.0 | – |
| 9 | Product 9 | Not detected | Not detected | – |
| 10 | Product 10 | Not detected | Not detected | – |
| 11 | Product 11 | 181.6 ± 5.4 | 106.1 ± 1.0 | unknown source |
| 12 | Product 12 | 4.3 ± 0.3 | 13.3 ± 0.1 | unknown source |
| 13 | Product 13 | 3.2 ± 0.2 | 10.9 ± 3.3 | Asari radix et Rhizoma |
| 14 | Product 14 | 241.5 ± 10.5 | 53.2 ± 1.2 | unknown source |
| 15 | Product 15 | Not detected | Not detected | – |
| 16 | Product 16 | Not detected | Not detected | – |
| 17 | Product 17 | Not detected | Not detected | – |
| 18 | Product 18 | 243.5 ± 18.2 | 144.3 ± 7.1 | unknown source |
| 19 | Product 19 | Not detected | Not detected | – |
| 20 | Product 20 | 425.7 ± 28.2 | 62.8 ± 3.1 | Acori tatarinowii Rhizoma |
| 21 | Authentic herb Acori tatarinowii | 7679.8 ± 85.7 | 679.1 ± 20.3 | Acori tatarinowii Rhizoma |
| Clinical symptom | Symptom frequency level | Level definition | % per level | Mean utility (±SD)a | Mean utility (±SD)a | Difference between utilities, adjusted mean (±SD)a | P valueb |
| EQ-5D | OAB-5D | ||||||
| Micturitions/24 h | 1 | < 8 | 21.2 | 0.85 (±0.21) | 0.90 (±0.08) | 0.046 (±0.396) | <.0001 |
| 2 | 8 - < =10 | 30.7 | 0.84 (±0.20) | 0.87 (±0.09) | 0.025 (±0.458) | <.0001 | |
| 3 | 10 - < =12 | 22.7 | 0.82 (±0.21) | 0.85 (±0.09) | 0.015 (±0.401) | 0.0205 | |
| 4 | 12 - < = 14 | 13.2 | 0.80 (±0.22) | 0.82 (±0.09) | 0.007 (±0.325) | 0.3073 | |
| 5 | > 14 | 12.3 | 0.78 (±0.23) | 0.80 (±0.09) | 0.007 (±0.331) | 0.3477 | |
| Incontinence episodes/24 h | 1 | 0 | 50.3 | 0.85 (±0.19) | 0.89 (±0.08) | 0.032 (±0.470) | <.0001 |
| 2 | > 0 - < = 1 | 19.7 | 0.82 (±0.20) | 0.85 (±0.09) | 0.019 (±0.320) | 0.0006 | |
| 3 | 1 - < =2 | 11.0 | 0.80 (±0.22) | 0.83 (±0.09) | 0.009 (±0.262) | 0.1529 | |
| 4 | 2 - < =3 | 6.9 | 0.78 (±0.23) | 0.81 (±0.09) | 0.006 (±0.229) | 0.4157 | |
| 5 | > 3 | 12.2 | 0.76 (±0.26) | 0.79 (±0.09) | 0.004 (±0.290) | 0.5353 |
| Characteristic | Patients with asthma | Patients without asthma | P-Value* |
| No. (%) (n = 137) | No. (%) (n = 336) | ||
| Tachypnea | 60/137 (44) | 110/336 (33) | 0.07 |
| Tachycardia | 88/137 (64) | 213/336 (63) | 0.86 |
| Intensive care unit admission | 37/133 (28) | 108/321 (34) | 0.31 |
| Mechanical ventilation | 16/127 (13) | 69/301 (23) | 0.02 |
| Acute respiratory distress syndrome | 9/129 (7) | 38/292 (13) | 0.10 |
| Sepsis syndrome | 7/128 (6) | 31/291 (11) | 0.12 |
| Death | 5/137 (4) | 32/332 (10) | 0.04 |
| Influenza antiviral agent receipt | |||
| Any during hospitalization | 101/137 (74) | 270/336 (80) | 0.15 |
| ≤ 2 days of illness onset | 49/99 (50) | 106/269 (39) | 0.10 |
| ≤ 2 days of admission | 79/92 (86) | 219/253 (87) | 0.87 |
| Median days from illness onset to antiviral initiation (range) | 3 (0 – 18) | 3 (0 – 32) | 0.06 |
| Other treatment | |||
| Antibiotics | 101/137 (74) | 260/336 (77) | 0.40 |
| Steroids | 83/137 (61) | 96/336 (29) | <0.01 |
| Films with Agarose Mass Concentrations (%) | Areas of the Antibacterial Zone (A, mm2) | |
| S. aureus | E. coli | |
| 0 | 89.29 ± 1.23 | 83.83 ± 0.95 |
| 20 | 78.89 ± 0.89 | 51.52 ± 2.11 |
| 40 | 71.64 ± 2.06 | 37.38 ± 1.58 |
| 60 | 70.56 ± 1.55 | 30.43 ± 0.73 |
| 80 | 22.09 ± 1.17 | 13.91 ± 1.35 |
| Treatment priority | Probability |
| 0 | 0.1 |
| 1 | 0.2 |
| 2 | 0.3 |
| 3 | 0.4 |
| Areca nut chewers | ||||
| Non chewers | Raw areca chewers | Areca with tobacco additives | P-value for trend | |
| Total participants | 722 | 231 | 117 | |
| Central Obesity | ||||
| Obese, n(%) | 231 (32.0) | 94 (40.7) | 57 (48.7) | |
| Odds Ratio (95% CI)a | reference | 1.46 (1.07-1.98) | 2.02 (1.36-3.00) | <0.001 |
| Odds Ratio (95% CI)b | reference | 1.42 (0.97-2.06) | 1.65 (1.03-2.63) | 0.015 |
| Raised blood pressure | ||||
| Raised BP cases, n(%) | 234 (32.4) | 89 (38.5) | 58 (49.6) | |
| Odds Ratio (95% CI)a | reference | 1.31 (0.96-1.78) | 2.05 (1.38-3.04) | <0.001 |
| Odds Ratio (95% CI)b | reference | 1.23 (0.89-1.70) | 1.87 (1.25-2.81) | 0.003 |
| Reduced HDL | ||||
| Reduced HDL cases, n(%) | 233 (32.8) | 104 (45.0) | 58 (50.0) | |
| Odds Ratio (95% CI)a | reference | 1.72 (1.27-2.33) | 2.06 (1.39-3.06) | <0.001 |
| Odds Ratio (95% CI)b | reference | 1.55 (1.11-2.17) | 1.66 (1.09-2.54) | 0.003 |
| Hypertrigylceridemia | ||||
| Hypertriglyceridemia cases, n(%) | 150 (20.8) | 72 (31.2) | 41 (35.0) | |
| Odds Ratio (95% CI)a | reference | 1.73 (1.24-2.41) | 2.06 (1.35-3.13) | <0.001 |
| Odds Ratio (95% CI)b | reference | 1.82 (1.28-2.59) | 2.04 (1.32-3.16) | <0.001 |
| Hyperglycemia | ||||
| Hyperglycemia cases, n(%) | 88 (12.2) | 43 (18.6) | 26 (22.2) | |
| Odds Ratio (95% CI)a | reference | 1.65 (1.11-2.46) | 2.06 (1.26-3.36) | 0.001 |
| Odds Ratio (95% CI)b | reference | 1.48 (0.97-2.27) | 1.80 (1.08-3.00) | 0.011 |
| Item | PTV location | Median (range, min–max) | p value* | ||||
| IMRT | PSPT | SSPT | IMRT vs PSPT | IMRT vs SSPT | PSPT vs SSPT | ||
| PTV CI | WV | 0.85 (0.72–0.88) | 0.70 (0.69–0.71) | 0.91 (0.89–0.92) | <0.05 | <0.05 | <0.05 |
| PG | 0.92 (0.87–0.92) | 0.83 (0.62–0.87) | 0.94 (0.90–0.90) | <0.05 | <0.05 | <0.05 | |
| SS | 0.89 (0.88–0.92) | 0.74 (0.72–0.83) | 0.92 (0.90–0.94) | <0.05 | <0.05 | <0.05 | |
| BG | 0.88 (0.86–0.91) | 0.80 (0.74–0.82) | 0.94 (0.93–0.95) | <0.05 | <0.05 | <0.05 | |
| PTV GI | WV | 3.30 (3.08–3.75) | 1.90 (1.85–2.04) | 2.12 (1.99–2.19) | <0.05 | <0.05 | <0.05 |
| PG | 3.89 (3.47–4.62) | 2.90 (2.50–3.25) | 2.50 (2.36–3.34) | <0.05 | <0.05 | NS | |
| SS | 3.82 (3.71–4.14) | 2.78 (2.64–3.27) | 2.59 (2.48–2.87) | <0.05 | <0.05 | NS | |
| BG | 3.77 (3.46–4.23) | 2.35 (2.18–2.57) | 2.30 (2.23–2.60) | <0.05 | <0.05 | NS | |
| PTV HI | WV | 0.97 (0.96–0.98) | 0.95 (0.94–0.95) | 0.98 (0.98–0.98) | <0.05 | <0.05 | <0.05 |
| PG | 0.96 (0.95–0.97) | 0.97 (0.96–0.98) | 0.98 (0.97–0.98) | NS | <0.05 | NS | |
| SS | 0.96 (0.95–0.97) | 0.97 (0.96–0.98) | 0.97 (0.95–0.98) | NS | NS | NS | |
| BG | 0.97 (0.97–0.98) | 0.97 (0.97–0.98) | 0.97 (0.97–0.98) | NS | NS | <0.05 | |
| PTV PQI | WV | 4.06 (3.82–4.73) | 2.89 (2.75–3.11) | 2.37 (2.23–2.46) | 0.043 | 0.043 | 0.043 |
| PG | 4.39 (3.92–5.55) | 3.38 (3.12–5.47) | 2.70 (2.54–3.83) | 0.043 | 0.043 | 0.043 | |
| SS | 4.46 (4.26–4.88) | 3.92 (3.62–4.05) | 2.95 (2.88–3.12) | 0.043 | 0.043 | 0.043 | |
| BG | 4.45 (4.00–4.93) | 3.01 (2.81–3.59) | 2.49 (2.44–2.86) | 0.043 | 0.043 | 0.043 |
| Investigators | Year | n | Study design | Stent type | AVF or AVG | Primary patency (%) | (months) | ||
| 3 M | 6 M | 12 M | |||||||
| Vogel and Parise [12] | 2004 | 53 | Retrospective | SMART | AVG | 77 (61–93) | 51 (34–67) | 20 (12–27) | mean 8.9 |
| Vogel and Parise [14] | 2005 | 25 | Prospective, Non-randomized | SMART | AVG | 88 (75–100) | 67 (48–86) | 41 (21–61) | mean 8.2 |
| Pan et al. [21] | 2005 | 12 | Retrospective | Wallstent, Jostent | AVF | 92 ± 8 | 81 ± 12 | 31 ± 17 | n/a |
| Liang et al. [22] | 2006 | 23 | Observational | Wallstent, nitinol | AVG | 69 ± 9 | 41 ± 10 | 30 ± 10 | n/a |
| Maya and Allon [23] | 2006 | 14 | Prospective, Non-randomized | Wallstent, SMART, Protégé, Fluency | AVG | 48 | 19 | n/a | median 2.8 |
| Chan, M.R. et al. [24] | 2008 | 211 | Retrospective | SMART | AVG | 69 | 25 | n/a | median 4.4 |
| Current study | 2011 | 50 | Prospective, Observational | SMART | Both | 79 ± 9 | 51 ± 15 | 27 ± 16 | median 3.8 |
| 25 | AVF | 80 ± 10 | 65 ± 16 | 32 ± 21 | median 5.2 | ||||
| 25 | AVG | 76 ± 15 | 28 ± 22 | 19 ± 17 | median 2.9 |
| Component (g/kg) | Group | ||||
| NFD | HFD | GR | SV0.5 | SV2 | |
| Casein | 210 | 265 | 265 | 265 | 265 |
| L-cystine | 3 | 4 | 4 | 4 | 4 |
| Corn starch | 280 | – | – | – | – |
| Maltodextrin | 50 | 160 | 150 | 155 | 140 |
| Sucrose | 325 | 90 | 90 | 90 | 90 |
| Lard | 20 | 310 | 310 | 310 | 310 |
| Soybean oil | 20 | 30 | 30 | 30 | 30 |
| Cellulose | 37.15 | 65.5 | 65.5 | 65.5 | 65.5 |
| Mineral mixture1 | 35 | 48 | 48 | 48 | 48 |
| Vitamin mixture2 | 15 | 21 | 21 | 21 | 21 |
| Calcium phosphate, dibasic | 2 | 3.4 | 3.4 | 3.4 | 3.4 |
| Choline bitartrate | 2.75 | 3 | 3 | 3 | 3 |
| Yellow food color | 0.1 | – | – | – | – |
| Blue food color | – | 0.1 | 0.1 | 0.1 | 0.1 |
| Garcinia cambogia extract of 60% (–)-hydroxycitric acid | – | – | 10 | – | – |
| Solidago virgaurea var. gigantea 10% ethanol extract | – | – | – | 5 | 20 |
| Total (g) | 1000 | 1000 | 1000 | 1000 | 1000 |
| Energy (kcal/g) | 3.7 | 5.1 | 5.1 | 5.1 | 5.1 |
| Protein (% of kcal) | 20.1 | 18.3 | 18.3 | 18.3 | 18.3 |
| Carbohydrate (% of kcal) | 69.8 | 21.4 | 21.4 | 21.4 | 21.4 |
| Fat (% of kcal) | 10.2 | 60.3 | 60.3 | 60.3 | 60.3 |
| Well | Biochemical test | Result |
| 2 | D-amygdalin (AMY) | − |
| 4 | Phosphatidylinositol phospholipase C (PIPLC) | − |
| 5 | D-xylose (dXYL) | − |
| 8 | Arginine dihydrolase 1 (ADH1) | + |
| 9 | Beta-galactosidase (BGAL) | − |
| 11 | Alpha-glucosidase (AGLU) | − |
| 13 | Ala-Phe-Pro arylamidase (APPA) | − |
| 14 | Cyclodextrin (CDEX) | − |
| 15 | L-aspartate arylamidase (AspA) | − |
| 16 | Beta galactopyranosidase (BGAR) | − |
| 17 | Alha-mannosidase (AMAN) | − |
| 19 | Phosphatase (PHOS) | + |
| 20 | Leucine arylamidase (LeuA) | + |
| 23 | L-proline arylamidase (ProA) | − |
| 24 | Beta glucuronidase (BGURr) | − |
| 25 | Alpha-galactosidase (AGAL) | − |
| 26 | L-pyrrolidonyl-arylamidase (PyrA) | − |
| 27 | Betaglucuronidase (BGUR) | − |
| 28 | Alanine arylamidase (AlaA) | − |
| 29 | Tyrosine arylamidase (TyrA) | − |
| 30 | D-sorbitol (dSOR) | − |
| 31 | Urease (URE) | − |
| 32 | Polymixin b resistance (POLYB) | + |
| 37 | D-galactose (dGAL) | + |
| 38 | D-ribose (dRIB) | + |
| 39 | L-lactate alkalinization (ILATk) | − |
| 42 | L-actose (LAC) | − |
| 44 | N-acetyl-d-glucosamine (NAG) | + |
| 45 | D-maltose (dMAL) | + |
| 46 | Bacitracin resistance (BACI) | + |
| 47 | Novobiocin resistance (NOVO) | + |
| 50 | Growth in 6.5% NaCl (NC 6.5) | + |
| 52 | D-mannitol (dMAN) | − |
| 53 | D-mannose (dMNE) | + |
| 54 | Methyl-B-D-glucopyranoside (MBdG) | + |
| 56 | Pullulan (PUL) | − |
| 57 | D-raffinose (dRAF) | − |
| 58 | O/129 resistance (comp. vibrio) (O129R) | − |
| 59 | Salicin (SAL) | − |
| 60 | Saccharose/sucrose (SAC) | + |
| 62 | D-trehalose (dTRE) | + |
| 63 | Arginine dihydrolase 2 (ADH2s) | + |
| 64 | Optochin resistance (OPTO) | + |
| Treatment | Number of pregnant females | Number of implantation sites | Number of viable fetuses | Total number of resorption sites |
| Group A | 19/20 | 9.96 ± 1.83∗ | 9.85 ± 1.67∗∗ | 4∗ |
| Group B | 18/20 | 9.19 ± 1.05∗ | 8.73 ± 1.12∗∗ | 5 |
| Group C (control) | 17/10 | 7.17 ± 0.60 | 6.23 ± 1.05 | 6 |
| Characteristic | No. patients % | Direction of PHB | P value | |
| CON, n = 112 (%) | ECC, n = 160 (%) | |||
| Gender | 0.812 | |||
| Male | 165 (60.7) | 67 (59.8) | 98 (61.3) | |
| Female | 107 (39.3) | 45 (40.2) | 62 (38.7) | |
| Age(yrs) | 0.965 | |||
| ≤ 60 | 121 (44.5) | 50 (44.6) | 71 (44.4) | |
| > 60 | 151 (55.5) | 62 (55.4) | 89 (55.6) | |
| Location | 0.816 | |||
| Colon | 141 (51.8) | 59 (52.7) | 82 (51.3) | |
| Rectum | 131 (48.2) | 53 (47.3) | 78 (48.7) | |
| Differentiation | 0.009 | |||
| Well | 120 (44.1) | 60 (53.6) | 60 (37.5) | |
| Moderate | 152 (55.9) | 52 (46.4) | 100 (62.5) | |
| TNM tumor stage | 0.000 | |||
| I | 32 (11.8) | 22 (19.6) | 10 (6.3) | |
| II | 125 (45.9) | 56 (50.0) | 69 (43.1) | |
| III | 109 (40.1) | 33 (29.5) | 76 (47.5) | |
| IV | 6 (2.2) | 1 (0.9) | 5 (3.1) | |
| LN metastasis | 0.024 | |||
| Negative | 191 (70.2) | 87 (77.7) | 104 (65.0) | |
| Positive | 81 (29.8) | 25 (22.3) | 56 (35.0) | |
| Dis. Metastasis | 0.000 | |||
| Negative | 167 (61.4) | 101 (90.2) | 66 (41.2) | |
| Positive | 105 (38.6) | 11 (9.8) | 94 (58.8) | |
| Status | 0.000 | |||
| Censored | 180 (66.2) | 102 (91.1) | 78 (48.7) | |
| Death | 92 (33.8) | 10 (8.9) | 82(51.3) | |
| Survival time | 0.000 | |||
| ≤ 60 months | 131 (48.2) | 34 (30.4) | 97 (60.6) | |
| > 60 months | 141 (51.8) | 78 (69.6) | 63 (39.4) |
| Variables | Unit | Univariate analysis | Multivariate analysis | ||||
| OR | 95 % CI | P value | aOR | 95 % CI | P value | ||
| Age | /5 years | 1.01 | 0.99–1.03 | 0.14 | – | – | – |
| Employed | Yes/no | 1.45 | 0.99–2.12 | 0.05 | – | – | – |
| Nationality | Ivoirian/non-ivoirian | 1.33 | 0.75–2.36 | 0.32 | – | – | – |
| Marital status | Married/single | 1.64 | 1.10–2.42 | 0.03 | – | – | – |
| Divorced/single | 1.47 | 0.87–2.46 | – | – | |||
| Living conditions | Moderate vs bad | 1.74 | 0.98–3.11 | 0.002 | 1.91 | 1.04–3.51 | 0.003 |
| Best vs bad | 2.61 | 1.47–4.65 | 2.74 | 1.50–5.01 | |||
| Smoker | Yes/no | 1.65 | 0.46–5.94 | 0.43 | – | – | – |
| Alcohol use | Yes/no | 1.09 | 0.75–1.58 | 0.63 | – | – | – |
| Contraceptive | Yes/no | 0.93 | 0.46–1.86 | 0.86 | – | – | – |
| WHO stage | 2 vs 1 | 0.69 | 0.45–1.06 | 0.007 | 0.76 | 0.49–1.20 | 0.03 |
| 3 vs 1 | 0.32 | 0.14–0.70 | 0.37 | 0.17–0.82 | |||
| HBP(≥140/90 mmHg) | Yes/no | 8.62 | 3.38–22.00 | 0.0001 | 9.06 | 3.42–24.02 | 0.0001 |
| CD4 count | 350–500 vs ≤350 | 1.17 | 0.74-1.85 | 0.41 | – | – | – |
| >500 vs ≤350/mm3 | 1.37 | 0.85–2.20 | – | – | – | ||
| Viral load | /1 log10 copies/ml | 0.90 | 0.77–1.04 | 0.16 | – | – | – |
| Hemoglobin ≥95 g/dL | Yes/no | 3.12 | 1.65–5.90 | 0.0004 | 3.20 | 1.63–6.28 | 0.0007 |
| HyperTG | Yes/no | 3.32 | 0.73–15.00 | 0.11 | – | – | – |
| LDL >4.13 mmol/L | Yes/no | 1.67 | 1.00–2.79 | 0.04 | – | – | – |
| Hyperglycemia | Yes/no | 1.22 | 0.11–13.64 | 0.86 | – | – | – |
| Gene | Nucleotide (%) a | Amino acid (%) b |
| Pol 1a | 92.5 | 93.2 |
| Pol 1ab | 92.9 | 95.0 |
| Spike | 94.2 | 94.2 |
| Envelope | 87.2 | 91.0 |
| Membrane | 89.0 | 91.2 |
| Nucleocapsid | 86.7 | 87.1 |
| Gene | ORFs | |
| A. nidulans | A. niger | |
| palA | AN4351 | 119792 |
| palB | AN0256 | 171058 |
| palC | AN7560 | 48740 |
| palF | AN1844 | Not found* |
| palH | AN6886 | 120044 |
| palI | AN4853 | 52449 |
| vps32/snf7 | AN4240 | 136905 |
| pacC | AN2855 | 47049 |
| Variable | Category | Frequency | Percent |
| Distance of health institution | < 1 h | 100 | 13.9 |
| ≥ 1 h | 622 | 86.2 | |
| Accessibility of pharmacy | Yes | 198 | 27.4 |
| No | 524 | 72.6 | |
| Presence of health profession in the family | Yes | 56 | 7.2 |
| No | 666 | 92.8 | |
| Presence of medication at home | Yes | 105 | 14.5 |
| No | 617 | 85.5 | |
| Previous experience of SMP | Yes | 402 | 55.7 |
| No | 320 | 44.3 | |
| Peer/family pressure | Yes | 226 | 31.3 |
| No | 496 | 68.7 | |
| Member of health insurance | Yes | 448 | 62.0 |
| No | 274 | 38.0 |
| Group | Dose (mg/kg) | Malondialdehyde (MDA, nmol/mg pro) | Superoxidase Dismutase (SOD, U/mg pro) | Total Antioxidant Capacity (T-AOC, U/mg pro) | Glutathione Peroxidase (GSH-PX, U/mg pro) | Catalase (CAT, U/mg pro) |
| NC | 1.40 ± 0.18 | 383.26 ± 15.34 | 4.30 ± 0.23 | 213.22 ± 15.56 | 51.07 ± 3.78 | |
| MC | 3.09 ± 0.18 ** | 280.17 ± 33.59 ** | 2.46 ± 0.22 ** | 147.68 ± 19.88 ** | 23.79 ± 3.91 ** | |
| LNT | 1 | 2.06 ± 0.14 **## | 368.63 ± 27.40 ## | 4.11 ± 0.14 ## | 211.75 ± 22.31 ## | 34.72 ± 3.13 **## |
| AHG | 1 | 2.81 ± 0.17 **# | 283.71 ± 13.60 ** | 2.89 ± 0.26 ** | 156.36 ± 25.89 ** | 24.60 ± 1.81 ** |
| 5 | 2.17 ± 0.13 **## | 322.16 ± 27.94 ** | 3.58 ± 0.25 ## | 191.47 ± 18.69 *# | 43.43 ± 2.39 *## | |
| 10 | 1.60 ± 0.10 ## | 385.12 ± 25.21 ## | 4.31 ± 0.15 ## | 220.12 ± 30.57 ## | 53.19 ± 2.73 ## |
| TotalN = 171 | Nonoperative treatmentN = 102 | Surgical treatmentN = 69 | |
| Age (years) | 49.7 ± 16.8 (52.0, 18–100) | 48.3 ± 16.0 (52.0, 18–85) | 51.7 ± 17.6 (52.0, 18–100) |
| 18–64 | 142 (83.0) | 89 (87.3) | 53 (76.8) |
| 65–74 | 22 (12.9) | 10 (9.8) | 12 (17.4) |
| 75–84 | 3 (1.8) | 2 (2.0) | 1 (1.4) |
| 85–94 | 3 (1.8) | 1 (1.0) | 2 (2.9) |
| ≥95 | 1 (0.6) | 0 (0.0) | 1 (1.4) |
| Sex | |||
| Male | 74 (43.3) | 42 (41.2) | 32 (46.4) |
| Female | 97 (56.7) | 60 (58.8) | 37 (53.6) |
| Marital status | |||
| Partner | 129 (75.4) | 77 (75.5) | 52 (75.4) |
| No partner | 30 (17.5) | 19 (18.6) | 11 (15.9) |
| Missing | 12 (7.0) | 6 (5.9) | 6 (8.7) |
| Educational level | |||
| Low education: high school or less | 58 (33.9) | 38 (37.3) | 20 (29.0) |
| High education: additional education after high school | 96 (56.1) | 54 (52.9) | 42 (60.9) |
| Missing | 17 (9.9) | 10 (9.8) | 7 (10.1) |
| Anatomical location of fracture | |||
| Toe | 25 (14.6) | 25 (24.5) | 0 (0.0) |
| Ankle/foot | 98 (57.3) | 69 (67.6) | 29 (42.0) |
| Lower leg/knee | 20 (11.7) | 7 (6.9) | 13 (18.8) |
| Upper leg/hip | 28 (16.4) | 1 (1.0) | 27 (39.1) |
| Name | Oligonucleotide (5′ to 3′) |
| C286A Forward | GCT TTG ATT CTT GCA GTT GCC ATT GCA GTC AAC AGT CG |
| C286A Reverse | CGA CTG TTG ACT GCA ATG GCA ACT GCA AGA ATC AAA GC |
| C286S Forward | GCT TTG ATT CTT GCA GTT TCC ATT GCA GTC AAC AGT CG |
| C286S Reverse | CGA CTG TTG ACT GCA ATG GAA ACT GCA AGA ATC AAA GC |
| C295A Forward | CAG TCG AAG AAG GGC TGG GCA GAA GAA AAA GC |
| C295A Reverse | GCT TTT TCT TCT GCC CAG CCC TTC TTC GAC TG |
| Control | Low P | Moderate P | High P | P-values | |
| N resorption proficiency (mg g−1) | |||||
| D. angustifolia | 3.70(0.09)b | 5.58(0.26)a | 5.69(0.23)a | 5.87(0.41)a | 0.002 |
| G. spiculosa | 4.38(0.24)c | 5.11(0.22)bc | 6.00(0.23)ab | 6.14(0.16)a | 0.001 |
| P resorption proficiency (mg g−1) | |||||
| D. angustifolia | 0.70(0.04)c | 1.25(0.01)b | 1.27(0.03)b | 1.45(0.02)a | <0.001 |
| G. spiculosa | 0.72(0.03)b | 1.45(0.03)a | 1.51(0.03)a | 1.53(0.03)a | <0.001 |
| N resorption efficiency (%) | |||||
| D. angustifolia | 48.8(1.9) | 47.0(1.1) | 44.1(1.1) | 48.1(1.7) | 0.210 |
| G. spiculosa | 58.6(1.5) | 58.6(1.4) | 57.0(1.8) | 58.0(2.6) | 0.921 |
| P resorption efficiency (%) | |||||
| D. angustifolia | 57.9(1.6)a | 48.0(2.7)b | 46.3(0.6)b | 50.7(0.6)ab | 0.004 |
| G. spiculosa | 65.6(1.5)a | 49.5(1.8)b | 48.5(0.6)b | 48.8(1.0)b | <0.001 |
| Race/ethnicity | All ages | Age ≥ 18 years | ||||||||
| Prevalence | Adjusted odds ratio1 | Prevalence | Adjusted odds ratio2 | |||||||
| % | SE | OR | 95% CI | % | SE | OR | 95% CI | |||
| Non-Hispanic White | 8.22 | 0.03 | 1.00 | Reference | 8.45 | 0.03 | 1.00 | Reference | ||
| Mexican | 22.69 | 0.16 | 1.70 | 1.66 | 1.75 | 24.69 | 0.17 | 1.64 | 1.60 | 1.69 |
| Puerto Rican | 10.14 | 0.24 | 0.78 | 0.73 | 0.82 | 11.32 | 0.27 | 0.76 | 0.72 | 0.81 |
| Cuban | 12.61 | 0.39 | 1.16 | 1.06 | 1.27 | 12.90 | 0.41 | 1.17 | 1.06 | 1.28 |
| Central/South American | 21.98 | 0.34 | 1.42 | 1.35 | 1.50 | 23.62 | 0.37 | 1.33 | 1.26 | 1.40 |
| Other Hispanics | 12.75 | 0.33 | 1.11 | 1.04 | 1.20 | 13.80 | 0.36 | 1.11 | 1.03 | 1.19 |
| Non-Hispanic Black | 13.11 | 0.08 | 1.07 | 1.05 | 1.09 | 14.01 | 0.09 | 1.05 | 1.03 | 1.07 |
| American Indian/AN | 20.01 | 0.34 | 1.84 | 1.75 | 1.93 | 20.84 | 0.36 | 1.84 | 1.75 | 1.94 |
| Asian Indian | 13.14 | 0.57 | 1.23 | 1.09 | 1.38 | 13.84 | 0.61 | 1.39 | 1.24 | 1.57 |
| Chinese | 7.56 | 0.32 | 0.78 | 0.69 | 0.87 | 7.83 | 0.34 | 0.83 | 0.74 | 0.94 |
| Filipino | 7.81 | 0.34 | 0.80 | 0.72 | 0.89 | 7.95 | 0.35 | 0.86 | 0.77 | 0.97 |
| Japanese | 2.28 | 0.26 | 0.47 | 0.35 | 0.63 | 2.26 | 0.26 | 0.50 | 0.37 | 0.66 |
| Korean | 13.31 | 0.67 | 1.12 | 0.96 | 1.29 | 13.73 | 0.70 | 1.23 | 1.06 | 1.42 |
| Vietnamese | 10.47 | 0.51 | 0.63 | 0.56 | 0.72 | 10.59 | 0.53 | 0.65 | 0.57 | 0.73 |
| Cambodian | 13.97 | 1.33 | 0.63 | 0.49 | 0.82 | 14.64 | 1.44 | 0.63 | 0.49 | 0.82 |
| Bangladeshi | 20.09 | 3.37 | 0.98 | 0.60 | 1.60 | 20.92 | 3.68 | 1.05 | 0.63 | 1.76 |
| Pakistani | 25.13 | 1.98 | 1.60 | 1.23 | 2.08 | 27.30 | 2.17 | 1.98 | 1.51 | 2.59 |
| Hmong | 10.43 | 1.59 | 0.35 | 0.24 | 0.51 | 10.06 | 1.68 | 0.36 | 0.25 | 0.53 |
| Laotian | 13.45 | 1.60 | 0.65 | 0.48 | 0.88 | 14.41 | 1.71 | 0.65 | 0.48 | 0.89 |
| Thai | 8.95 | 1.62 | 0.46 | 0.28 | 0.74 | 9.47 | 1.72 | 0.47 | 0.29 | 0.77 |
| Other Asians | 12.45 | 0.92 | 0.80 | 0.66 | 0.96 | 13.40 | 1.01 | 0.80 | 0.66 | 0.96 |
| Native Hawaiian | 9.96 | 1.13 | 0.91 | 0.67 | 1.24 | 10.55 | 1.20 | 0.86 | 0.62 | 1.17 |
| Samoan | 14.36 | 2.48 | 1.12 | 0.76 | 1.64 | 14.79 | 2.61 | 1.08 | 0.72 | 1.63 |
| Guamanian | 8.82 | 2.37 | 1.00 | 0.58 | 1.73 | 8.99 | 2.46 | 0.84 | 0.47 | 1.48 |
| Other Pacific Islanders | 25.86 | 3.50 | 1.47 | 0.92 | 2.35 | 25.94 | 3.64 | 1.33 | 0.82 | 2.16 |
| All other groups | 14.29 | 0.22 | 1.19 | 1.14 | 1.24 | 16.61 | 0.26 | 1.20 | 1.15 | 1.25 |
| Domain 1: Skills for Chronic Condition Self-Management | Domain 2: Skills for Self-Advocacy and Health Care Utilization |
| Do you fill a prescription if you need to? | Do you fill out the medical history form, including a list of your allergies? |
| Do you know what to do if you are having a bad reaction to your medications? | Do you keep a calendar or list of medical and other appointments? |
| Do you pay or arrange payments for your medications? | Do you tell the doctor or nurse what you are feeling? |
| Do you take medications correctly and on your own? | Do you ask questions of the doctor, nurse or clinic staff? |
| Do you reorder medications before they run out? | Do you make a list of questions before the doctor’s visit? |
| Do you call the suppliers when there is a problem with the equipment? | Do you request the accommodations & support you need at school or work? |
| Do you order medical equipment before they run out? | Do you apply for a job or work or vocational services? |
| Do you arrange payment for the medical equipment and supplies? | Do you get financial help with school or work? |
| Do you call the doctor’s office to make an appointment? | Do you help plan or prepare meals/food? |
| Do you call the doctor about unusual changes in your health? | Do you help keep home/room clean or clean up after meals? |
| Do you apply for health insurance if you lose your current coverage? | Do you use neighborhood stores and services? |
| Do you know what your health insurance covers? | Do you use community support services or advocacy services when you need them? |
| Do you manage your money and budget household expenses? | |
| Do you reorder medications before they run out? |
| Bachaur | Gangatiri | Kherigarh | Kenkatha | Ponwar | Shahabadi | Purnea | Mewati | Gaolao | Hariana | Ongole | |
| 0.000 | Bachaur | ||||||||||
| 0.008 | 0.000 | Gangatiri | |||||||||
| 0.009 | 0.010 | 0.000 | Kherigarh | ||||||||
| 0.008 | 0.009 | 0.009 | 0.000 | Kenkatha | |||||||
| 0.010 | 0.012 | 0.009 | 0.007 | 0.000 | Ponwar | ||||||
| 0.032 | 0.031 | 0.032 | 0.034 | 0.032 | 0.000 | Shahabadi | |||||
| 0.032 | 0.033 | 0.032 | 0.032 | 0.031 | 0.033 | 0.000 | Purnea | ||||
| 0.101 | 0.101 | 0.101 | 0.091 | 0.097 | 0.081 | 0.094 | 0.000 | Mewati | |||
| 0.052 | 0.057 | 0.054 | 0.050 | 0.051 | 0.042 | 0.050 | 0.062 | 0.000 | Gaolao | ||
| 0.105 | 0.106 | 0.106 | 0.102 | 0.106 | 0.091 | 0.102 | 0.087 | 0.068 | 0.000 | Hariana | |
| 0.212 | 0.210 | 0.213 | 0.213 | 0.212 | 0.203 | 0.206 | 0.257 | 0.201 | 0.261 | 0.000 | Ongole |
| Cytokines | Cellular type | Production type | Median | Minimum | Maximum | 1th quartile | 3th quartile |
| TNF-α | Monocyte | Basal | 0.0 | 0.0 | 24.4 | 0.0 | 0.0 |
| LPS | 246.6 | 34.5 | 1486.5 | 182.8 | 97.6 | ||
| PBMC | Basal | 2.5 | 0.0 | 19.0 | 0.0 | 10.4 | |
| LPS | 341.6 | 70.8 | 1165.8 | 270.3 | 728.7 | ||
| IL-6 | Monocyte | Basal | 2.6 | 0.0 | 68.1 | 0.0 | 8.9 |
| LPS | 175.8 | 50.5 | 282.0 | 138.3 | 186.1 | ||
| PBMC | Basal | 0.0 | 0.0 | 123.2 | 0.0 | 6.4 | |
| LPS | 139.6 | 0.0 | 266.6 | 116.7 | 218.2 | ||
| IL-1β | Monocyte | Basal | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 |
| LPS | 69.6 | 15.3 | 173.7 | 37.5 | 173.7 | ||
| PBMC | Basal | 0.0 | 0.0 | 1.0 | 0.0 | 0.0 | |
| LPS | 17.9 | 0.0 | 113.8 | 0.0 | 31.5 | ||
| CXCL-8 | Monocyte | Basal | 173.1 | 48.7 | 288.8 | 130 | 240.1 |
| LPS | 279.5 | 177.3 | 297.7 | 252.3 | 290.9 | ||
| PBMC | Basal | 144.8 | 64.0 | 215.1 | 118.6 | 185.4 | |
| LPS | 229.8 | 218.4 | 305.4 | 219.8 | 303.0 | ||
| MCP-1 | Monocyte | Basal | 6.4 | 0.0 | 190.5 | 0.0 | 39.8 |
| LPS | 48.2 | 0.0 | 241.2 | 0.0 | 148.4 | ||
| PBMC | Basal | 25.9 | 5.9 | 412.4 | 12.2 | 97.5 | |
| LPS | 85.0 | 0.0 | 415.3 | 29.1 | 172.7 | ||
| TGF-β | Monocyte | Basal | 621.2 | 621.1 | 621.4 | 621.1 | 621.3 |
| LPS | 621.2 | 621.0 | 621.6 | 621.1 | 621.2 | ||
| PBMC | Basal | 51.7 | 8.9 | 220.5 | 25.8 | 130.9 | |
| LPS | 567.2 | 110.2 | 690.5 | 223.1 | 587.9 | ||
| IL-10 | Monocyte | Basal | 0.0 | 0.0 | 5.9 | 0.0 | 0.0 |
| LPS | 149.3 | 33.8 | 654.8 | 55.4 | 323.8 | ||
| PBMC | Basal | 0.0 | 0.0 | 11.8 | 0.0 | 0.0 | |
| LPS | 129.1 | 47.0 | 274.1 | 102.7 | 195.6 |
| Simulation set up | Time | Memory | |
| Genome Simulationa | One subclone with 100 SVs | 0.98 h | 9.1 Gb |
| One subclone with 200 SVs | 1.34 h | 9.9 Gb | |
| One subclone with 300 SVs | 1.73 h | 11.6 Gb | |
| Two subclones with 100 SVs | 1.03 h | 9.5 Gb | |
| Three subclones with 100 SVs | 1.28 h | 10.2 Gb | |
| Read generationb | Mixing reads from 2 subclones and 1 normal genome (392 M reads) | 2.76 h | 6.2 Gb |
| GC-bias Introduction (130 M reads) | 4.10 h | 2.5 GB |
| Compound | kα | kβ | kγ | Nα | Nβ | N1,9 | N2,8 | No | Nm | Np | N | EHOMO | ELUMO | ΔEHOMO-LUMO | D |
| Penta-CDDs | |||||||||||||||
| 1,2,3,4,6 | 4.48 × 10−14 | 9.83 × 10−13 | 5.07 × 10−12 | 3 | 2 | 1 | 1 | 3 | 2 | 1 | 5 | −0.267 | −0.028 | 0.240 | 3.14 |
| 1,2,3,4,7 | 4.09 × 10−14 | 6.84 × 10−13 | 7.14 × 10−12 | 2 | 3 | 1 | 1 | 3 | 2 | 1 | 5 | −0.265 | −0.028 | 0.237 | 1.70 |
| 1,2,3,6,7 | 1.34 × 10−13 | 2.34 × 10−13 | 6.10 × 10−12 | 2 | 3 | 1 | 1 | 3 | 1 | 0 | 5 | −0.266 | −0.028 | 0.238 | 1.51 |
| 1,2,3,6,8 | 2.05 × 10−13 | 1.09 × 10−12 | 7.71 × 10−12 | 2 | 3 | 1 | 2 | 2 | 2 | 0 | 5 | −0.267 | −0.029 | 0.238 | 1.12 |
| 1,2,3,6,9 | 1.10 × 10−13 | 6.93 × 10−13 | 4.24 × 10−12 | 3 | 2 | 2 | 1 | 2 | 1 | 1 | 5 | −0.269 | −0.028 | 0.240 | 2.49 |
| 1,2,3,7,8 | 1.49 × 10−13 | 1.24 × 10−15 | 5.21 × 10−12 | 1 | 4 | 1 | 2 | 3 | 1 | 0 | 5 | −0.265 | −0.028 | 0.237 | 1.06 |
| 1,2,3,7,9 | 1.66 × 10−13 | 7.56 × 10−13 | 6.46 × 10−12 | 2 | 3 | 2 | 1 | 2 | 2 | 0 | 5 | −0.267 | −0.029 | 0.238 | 1.84 |
| 1,2,3,8,9 | 1.01 × 10−13 | 5.26 × 10−13 | 6.51 × 10−12 | 2 | 3 | 2 | 2 | 3 | 1 | 0 | 5 | −0.266 | −0.028 | 0.238 | 3.18 |
| 1,2,4,6,7 | 3.66 × 10−14 | 1.98 × 10−12 | 5.72 × 10−12 | 3 | 2 | 1 | 1 | 2 | 1 | 1 | 5 | −0.268 | −0.030 | 0.239 | 1.39 |
| 1,2,4,6,8 | 2.38 × 10−13 | 2.50 × 10−12 | 1.17 × 10−11 | 3 | 2 | 1 | 2 | 1 | 2 | 1 | 5 | −0.267 | −0.029 | 0.238 | 1.12 |
| 1,2,4,6,9 | 7.33 × 10−16 | 1.56 × 10−12 | 4.79 × 10−12 | 4 | 1 | 2 | 1 | 1 | 1 | 2 | 5 | −0.271 | −0.030 | 0.241 | 1.51 |
| 1,2,4,7,8 | 7.27 × 10−14 | 5.78 × 10−13 | 4.89 × 10−12 | 2 | 3 | 1 | 2 | 2 | 1 | 1 | 5 | −0.267 | −0.030 | 0.238 | 0.93 |
| 1,2,4,7,9 | 8.16 × 10−14 | 2.05 × 10−12 | 7.50 × 10−12 | 3 | 2 | 2 | 1 | 1 | 2 | 1 | 5 | −0.270 | −0.031 | 0.239 | 1.02 |
| 1,2,4,8,9 | 3.71 × 10−14 | 1.12 × 10−12 | 6.03 × 10−12 | 3 | 2 | 2 | 2 | 2 | 1 | 1 | 5 | −0.268 | −0.030 | 0.238 | 2.41 |
| Hexa-CDDs | |||||||||||||||
| 1,2,3,4,6,7 | 1.60 × 10−14 | 2.54 × 10−13 | 6.16 × 10−12 | 3 | 3 | 1 | 1 | 4 | 2 | 1 | 6 | −0.270 | −0.033 | 0.237 | 2.26 |
| 1,2,3,4,6,8 | 1.10 × 10−13 | 8.46 × 10−13 | 7.87 × 10−12 | 3 | 3 | 1 | 2 | 3 | 3 | 1 | 6 | −0.271 | −0.034 | 0.237 | 1.19 |
| 1,2,3,4,6,9 | 7.74 × 10−16 | 7.82 × 10−13 | 4.45 × 10−12 | 4 | 2 | 2 | 1 | 3 | 2 | 2 | 6 | −0.273 | −0.034 | 0.239 | 2.36 |
| 1,2,3,4,7,8 | 6.63 × 10−14 | 9.51 × 10−16 | 5.04 × 10−12 | 2 | 4 | 1 | 2 | 4 | 2 | 1 | 6 | −0.269 | −0.033 | 0.236 | 0.19 |
| 1,2,3,6,7,8 | 2.56 × 10−13 | 1.15 × 10−15 | 6.27 × 10−12 | 2 | 4 | 1 | 2 | 4 | 2 | 0 | 6 | −0.270 | −0.033 | 0.237 | 0.00 |
| 1,2,3,6,7,9 | 1.07 × 10−13 | 6.23 × 10−13 | 6.05 × 10−12 | 3 | 3 | 2 | 1 | 3 | 2 | 1 | 6 | −0.272 | −0.034 | 0.237 | 0.97 |
| 1,2,3,6,8,9 | 1.20 × 10−13 | 5.56 × 10−13 | 6.32 × 10−12 | 3 | 3 | 2 | 2 | 3 | 2 | 1 | 6 | −0.272 | −0.034 | 0.237 | 1.71 |
| 1,2,3,7,8,9 | 1.46 × 10−13 | 1.13 × 10−15 | 6.19 × 10−12 | 2 | 4 | 2 | 2 | 4 | 2 | 0 | 6 | −0.269 | −0.033 | 0.237 | 2.01 |
| 1,2,4,6,7,9 | 6.30 × 10−16 | 6.19 × 10−13 | 6.07 × 10−12 | 4 | 2 | 2 | 1 | 2 | 2 | 2 | 6 | −0.274 | −0.036 | 0.238 | 0.00 |
| 1,2,4,6,8,9 | 6.55 × 10−16 | 1.22 × 10−12 | 5.86 × 10−12 | 4 | 2 | 2 | 2 | 2 | 2 | 2 | 6 | −0.274 | −0.036 | 0.238 | 1.02 |
| Hepta-CDDs | |||||||||||||||
| 1,2,3,4,6,7,8 | 7.21 × 10−14 | 9.28 × 10−16 | 5.71 × 10−12 | 3 | 4 | 1 | 2 | 5 | 3 | 1 | 7 | −0.273 | −0.038 | 0.236 | 0.95 |
| 1,2,3,4,6,7,9 | 6.81 × 10−16 | 4.15 × 10−13 | 5.41 × 10−12 | 4 | 3 | 2 | 1 | 4 | 3 | 2 | 7 | −0.276 | −0.039 | 0.237 | 1.06 |
| OCDD | |||||||||||||||
| 1,2,3,4,6,7,8,9 | 7.95 × 10−16 | 7.51 × 10−16 | 5.98 × 10−12 | 4 | 4 | 2 | 2 | 6 | 4 | 2 | 8 | −0.277 | −0.043 | 0.235 | 0.00 |
| Self-report risk assessment | Positive ADHD screen % (n) | Negative ADHD screen % (n) | Χ2 (df = 1) | Odds ratio (95% confidence interval) |
| Any illness or injury, or any other medical condition? | 51.3 (20) | 31.7 (45) | 5.10* | 2.27 (1.10 to 4.66) |
| Taking, supposed to be taking, or need any tablets/medication? | 19.5 (8) | 15.6 (22) | 0.35 | 1.31 (0.54 to 3.21) |
| Consumed alcohol in the last 24 hours? | 28.2 (11) | 26.8 (38) | 0.03 | 1.08 (0.49 to 2.37) |
| Dependent on drugs or any other substances? | 25.6 (10) | 9.2 (13) | 7.50** | 3.42 (1.37 to 8.57) |
| Ever tried to harm yourself? | 23.1 (9) | 7.7 (11) | 7.32** | 3.57 (1.36 to 9.39) |
| Experiencing any mental health problems or depression? | 23.1 (9) | 6.4 (9) | 9.35** | 4.37 (1.60 to 11.94) |
| Require any help with reading/writing? | 10.3 (4) | 2.8 (4) | 3.96 | 3.91 (0.93 to 16.44) |
| Custody officer risk assessment | ||||
| Detainee appears to be injured or unwell? | 20.5 (8) | 11.3 (16) | 2.22 | 2.02 (0.79 to 5.14) |
| Detainee is in need of a Doctor or other Health Care Professional? | 20.0 (6) | 11.3 (13) | 1.58 | 1.96 (0.68 to 5.69) |
| Appears to have taken/be under the influence of alcohol/drugs/any other substance? | 23.1 (9) | 12.8 (18) | 2.55 | 2.05 (0.84 to 5.01) |
| Detainee has indications of self harm? | 17.9 (7) | 5.7 (8) | 6.03* | 3.64 (1.23 to 10.77) |
| Cancer site | Mediastinal-both | Mediastinal-both & Supra-both | Mediastinal-both & Supra-left | Mediastinal-left |
| Breast | ||||
| 3DCRT | 0.86 | 0.84 | 0.85 | 0.91 |
| VMAT | 2.05 | 1.82 | 1.89 | 1.93 |
| Lung | ||||
| 3DCRT | 0.76 | 0.80 | 0.78 | 0.74 |
| VMAT | 1.29 | 1.11 | 1.17 | 1.55 |
| Esophagus | ||||
| 3DCRT | 0.94 | 0.98 | 1.06 | 0.90 |
| VMAT | 1.01 | 1.12 | 1.15 | 1.00 |
| Stomach | ||||
| 3DCRT | 0.92 | 0.91 | 0.92 | 0.93 |
| VMAT | 0.93 | 0.93 | 0.93 | 0.92 |
| Thyroid | ||||
| 3DCRT | 0.89 | 0.61 | 0.62 | 0.93 |
| VMAT | 0.88 | 0.67 | 0.79 | 0.93 |
| Bone sarcoma | ||||
| 3DCRT | 0.88 | 0.87 | 0.82 | 0.88 |
| VMAT | 0.62 | 0.58 | 0.60 | 0.63 |
| Soft tissue sarcoma | ||||
| 3DCRT | 0.89 | 0.83 | 0.83 | 0.90 |
| VMAT | 0.75 | 0.65 | 0.69 | 0.78 |
| All cancers | ||||
| 3DCRT | 0.82 | 0.82 | 0.82 | 0.86 |
| VMAT | 1.59 | 1.36 | 1.43 | 1.63 |
| Images | Positive | Negative |
| 200 | 195 | 5 |
| Trait | Region | SNP | Closest gene | P value | Alleles ancestral>derived |
| Hair shape | 1q21 | rs11803731 | 3 × 10−12 | A>T | |
| Hair shape | 2q12 | rs3827760 | 3 × 10−119 | A>G | |
| Hair shape | 10p14 | rs17143387 | GATA3 | 4 × 10−8 | T>G |
| Hair shape | 16p11 | rs11150606 | 7 × 10−9 | T>C | |
| Beard thickness | 2q12 | rs365060 | EDAR | 1 × 10−15 | G>C |
| Beard thickness | 4q12 | rs4864809 | LNX1 | 1 × 10−8 | A>G |
| Beard thickness | 6q21 | rs6901317 | PREP | 4 × 10−8 | G>T |
| Beard thickness | 7q31 | rs117717824 | FOXP2 | 1 × 10−8 | G>T |
| Eyebrow thickness | 3q22 | rs112458845 | FOXL2 | 4 × 10−10 | G>A |
| Monobrow | 2q36 | rs2218065 | PAX3 | 5 × 10−8 | A>G |
| Hair greying | 6p25 | rs12203592 | IRF4 | 3 × 10−13 | C>T |
| Hair colour | 5p13 | rs183671 | SLC45A2 | 2 × 10−59 | T>G |
| Hair colour | 6p25 | rs12203592 | IRF4 | 1 × 10−13 | C>T |
| Hair colour | 11q14 | rs598952 | TYR | 2 × 10−8 | T>A |
| Hair colour | 15q13 | rs12913832 | HERC2/OCA2 | 5 × 10−104 | A>G |
| Hair colour | 15q21 | rs1426654 | SLC24A5 | 1 × 10−18 | G>A |
| Balding | 10q22 | rs2814331 | GRID1 | 4 × 10−9 | C>T |
| Balding | Xq12 | rs4258142 | AR/EDA2R | 2 × 10−8 | C>T |
| Flexion angle and side | Involved | 95% Confidence intervals | Uninvolved | 95% Confidence intervals | P value |
| Torque at 30 degrees | 1.09 | 0.87–1.31 | 1.17 | 0.98–1.36 | P = 0.45 |
| Torque at 60 degrees | 1.75 | 1.4–2.1 | 2.09 | 1.77–2.41 | P = 0.08 |
| Intra-nuclear body | GO Term | Description | E-Value |
| Nucleolus | GO:0042254 | Ribosome biogenesis and assembly | 1.80E-19 |
| GO:0022613 | Ribonucleoprotein complex biogenesis and assembly | 3.30E-15 | |
| GO:0016072 | rRNA metabolic process | 3.30E-14 | |
| GO:0006364 | rRNA processing | 3.30E-14 | |
| GO:0009059 | Macromolecule biosynthetic process | 2.90E-08 | |
| GO:0043228 | Non-membrane-bound organelle | 3.30E-08 | |
| GO:0043232 | Intracellular non-membrane-bound organelle | 3.30E-08 | |
| GO:0006412 | Translation | 5.70E-08 | |
| GO:0009058 | Biosynthetic process | 1.20E-06 | |
| PML nuclear body | GO:0006950 | Response to stress | 6.10E-09 |
| GO:0006974 | Response to DNA damage stimulus | 1.70E-08 | |
| GO:0009719 | Response to endogenous stimulus | 2.30E-08 | |
| GO:0050896 | Response to stimulus | 4.00E-07 | |
| GO:0006281 | DNA repair | 4.40E-05 | |
| GO:0042770 | DNA damage response, signal transduction | 5.90E-05 | |
| GO:0007049 | Cell cycle | 1.40E-03 | |
| GO:0006464 | Protein modification process | 1.60E-03 | |
| GO:0022402 | Cell cycle process | 2.70E-03 | |
| Nuclear Speckle | GO:0016071 | mRNA metabolic process | 1.20E-61 |
| GO:0006397 | mRNA processing | 4.80E-61 | |
| GO:0008380 | RNA splicing | 1.20E-58 | |
| GO:0005681 | Spliceosome | 1.90E-38 | |
| GO:0006396 | RNA processing | 5.80E-34 | |
| GO:0030529 | Ribonucleoprotein complex | 1.90E-26 | |
| GO:0003723 | RNA binding | 2.00E-25 | |
| GO:0016070 | RNA metabolic process | 1.70E-06 | |
| GO:0000377 | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 4.10E-06 | |
| GO:0000398 | Nuclear mRNA splicing, via spliceosome | 4.10E-06 |
| Condition or therapy | No. (%) | BRS (ms/mmHg) | p value for interaction |
| Hypertension | |||
| Yes | 68 (72) | 8.5 ± 4.4 | 0.056 |
| No | 26 (28) | 10.4 ± 4.6 | |
| Hyperlipidemia | |||
| Yes | 83 (88) | 8.8 ± 4.4 | 0.424 |
| No | 11 (12) | 10.0 ± 5.8 | |
| Smoking | |||
| Yes | 30 (32) | 9.9 ± 4.5 | 0.177 |
| No | 64 (68) | 8.5 ± 4.5 | |
| Sulfonylurea use | |||
| Yes | 25 (27) | 7.1 ± 3.2 | 0.015 |
| No | 69 (73) | 9.7 ± 4.8 | |
| Insulin use | |||
| Yes | 12 (13) | 9.7 ± 5.6 | 0.556 |
| No | 82 (87) | 8.9 ± 4.4 | |
| RAAS inhibitor use | |||
| Yes | 34 (36) | 8.6 ± 4.8 | 0.284 |
| No | 60 (64) | 9.2 ± 4.4 | |
| Calcium-channel blocker use | |||
| Yes | 32 (34) | 8.5 ± 4.8 | 0.258 |
| No | 62 (66) | 9.2 ± 4.4 | |
| Beta-blocker use | |||
| Yes | 5 (5) | 8.4 ± 3.7 | 0.788 |
| No | 89 (95) | 9.0 ± 4.6 | |
| Statin use | |||
| Yes | 28 (30) | 9.0 ± 5.0 | 0.138 |
| No | 66 (70) | 9.0 ± 4.4 |
| Model | Buc | Ind | Poo | Dis | Rec | Sub | All | STR (%) | Int | Cod | Tra | Sup | Com | Upd | USE (%) | Group |
| TCM | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | 0 | 0 | 0 | 0 | 0 | 1 | 16.7 | B |
| CARBINE | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 28.6 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | B |
| Dewar | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 28.6 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | B |
| FORPRO1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 28.6 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | B |
| HARVCAR | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 28.6 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | B |
| CBMFPS1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 28.6 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | B |
| Karjala | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 57.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | C |
| FORCAR1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 28.6 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | B |
| GORCAM | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 28.6 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | B |
| FORPRO2 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 85.7 | 1 | 1 | 0 | 0 | 0 | 0 | 33.3 | C |
| Winjum | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 28.6 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | B |
| CBMFPS2 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 42.9 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | C |
| CO2FIX1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 28.6 | 1 | 0 | 0 | 0 | 0 | 0 | 16.7 | B |
| CBMFPS3 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 85.7 | 0 | 0 | 1 | 1 | 0 | 1 | 50.0 | A |
| Edinbu | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | B |
| CO2FIX2 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 42.9 | 1 | 0 | 0 | 0 | 0 | 0 | 16.7 | C |
| EFISCEN | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 71.4 | 1 | 1 | 1 | 1 | 0 | 0 | 66.7 | A |
| FORCAR2 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 71.4 | 0 | 1 | 0 | 0 | 0 | 0 | 16.7 | C |
| XYLOIKO | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 57.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | C |
| CO2FIX3 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 71.4 | 1 | 1 | 1 | 1 | 1 | 0 | 83.3 | A |
| Perez‐G | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 28.6 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | B |
| White | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 28.6 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | B |
| Dias1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | B |
| HWPIPCC | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 42.9 | 1 | 1 | 0 | 0 | 0 | 0 | 33.3 | C |
| Werne1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 14.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | B |
| Green | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 71.4 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | C |
| CAMFor | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 57.1 | 1 | 1 | 1 | 0 | 0 | 0 | 50.0 | A |
| Frankfu | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 28.6 | 1 | 0 | 0 | 0 | 0 | 0 | 16.7 | B |
| Erikss | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 42.9 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | C |
| Dias2 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 28.6 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | B |
| Seidl | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 71.4 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | C |
| WOODCII | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 85.7 | 0 | 1 | 1 | 0 | 0 | 1 | 50.0 | A |
| FORC‐ON | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 42.9 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | C |
| COT | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 100.0 | 1 | 0 | 1 | 1 | 0 | 1 | 66.7 | A |
| Profft | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 85.7 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | C |
| Pingoud | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 28.6 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | B |
| Werne2 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 71.4 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | C |
| C‐HWP | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 14.3 | 1 | 0 | 0 | 0 | 0 | 1 | 33.3 | B |
| NFCMARS | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 71.4 | 0 | 1 | 1 | 1 | 0 | 1 | 66.7 | A |
| Pukkala | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 57.1 | 1 | 0 | 0 | 0 | 0 | 1 | 33.3 | C |
| WoodCar | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 28.6 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | B |
| CAPSIS | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 85.7 | 1 | 1 | 1 | 0 | 1 | 1 | 83.3 | A |
| BC‐HWP | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 71.4 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | C |
| LANDCAR | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 85.7 | 1 | 0 | 0 | 0 | 0 | 0 | 16.7 | C |
| Earles | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 42.9 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | C |
| Klein | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 57.1 | 0 | 1 | 0 | 0 | 0 | 0 | 16.7 | C |
| PRESTO | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 71.4 | 1 | 1 | 0 | 1 | 0 | 0 | 50.0 | A |
| Pilli | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | B |
| Höglmei | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 57.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | C |
| Genes | ID | adj.P-val | logFC |
| Downregulated genes | |||
| GPI | 208308_s_at | 0.023 | −1.44282 |
| MLXIP | 202519_at | 0.023 | −1.32908 |
| TPP1 | 200742_s_at | 0.023 | −1.26717 |
| NEU1 | 208926_at | 0.023 | −1.21158 |
| ACTN1 | 208636_at | 0.023 | −1.20938 |
| LAMP1 | 201551_s_at | 0.040 | −1.14585 |
| MYOF | 211864_s_at | 0.027 | −1.14455 |
| GLB1 | 201576_s_at | 0.037 | −1.13821 |
| NFKB1 | 209239_at | 0.044 | −1.13729 |
| ACP2 | 202767_at | 0.043 | −1.08902 |
| M6PR | 200900_s_at | 0.047 | −1.06069 |
| HGSNAT | 218017_s_at | 0.023 | −1.05619 |
| Upregulated genes | |||
| UTP14A | 221098_x_at | 0.026 | 1.00982 |
| KLHL23 | 213610_s_at | 0.023 | 1.02244 |
| EFCAB11 | 210525_x_at | 0.023 | 1.02378 |
| NUCKS1 | 217802_s_at | 0.025 | 1.03147 |
| FIP1L1 | 221007_s_at | 0.023 | 1.03372 |
| MBD4 | 214048_at | 0.023 | 1.03480 |
| PPFIBP1 | 203735_x_at | 0.023 | 1.03706 |
| INHBC | 207688_s_at | 0.026 | 1.04053 |
| PPARA | 210771_at | 0.023 | 1.04131 |
| EZR | 217234_s_at | 0.038 | 1.04663 |
| CDC42BPA | 214464_at | 0.023 | 1.05413 |
| INVS | 211054_at | 0.023 | 1.06234 |
| BMP2K | 37170_at | 0.026 | 1.06702 |
| RREB1 | 203704_s_at | 0.045 | 1.07460 |
| DMP1 | 217067_s_at | 0.023 | 1.07594 |
| Level of Confidence | Low | Medium | High |
| Studies | Gessner et al. (1997-b) | Akaeda et al. (1998) | Gessner et al. (1997-a) |
| Prakash et al. (1971) | Bond and Medcoff (1958) | Knaack et al. (2016) | |
| Rodrigue et al. (1990) | Garcia et al. (2004) | - | |
| Sharifzadeh et al. (1991) | Garcia et al. (2005) | - | |
| Tennant et al. (1955) | Gessner and Middaugh (1995) | - | |
| Turnbull et al. (2013) | Langeland et al. (1984) | - | |
| - | Popkiss et al. (1979) | - |
| Source | Allograft | Time from transplant | Risk factors | Presentation | Diagnostic test | Treatment | Outcome |
| Schaeffer et al. [9] | Heart | 2 months | Travel to southeastern US | Perforated colon | BAL examination | Thiabendazole × 15 daysIvermectin × 15 days | Death |
| El Masry and O'Donnell [10] | Heart | 41 days | From Kentucky | Respiratory distress | Alveolar tissue onautopsy | None | Death |
| Mizuno et al. [11] | Heart/kidney | 28 days | From Florida | Respiratory distress | Autopsy findings | None | Death |
| Roxby et al. [8] | Heart | 2 months | Immigrantfrom Ethiopia | DyspneaAbdominal painNausea | Sputumexamination | Oralivermectin | Death |
| Brügemann et al. [12] | Heart | 6 weeks | AbdominalpainAnorexiaNausea | Skin biopsy | Oral ivermectin × 15 daysAlbendazole oral × 10 days | Successfultreatment | |
| Grover et al. [13] | Heart | 4 weeks | From SoutheasternUS | Nauseavomiting | Duodenalbiopsy | Ivermectin | Death |
| Before | 8 hours | 24 hours | 48 hours | 5 days |
| 23 ± 4 | 401 ± 27 | 383 ± 1 | 272 ± 9 | 130 ± 14 |
| sEPCRMedian [25/75] | Malaria patients161.1 [124.4/213.4]N = 76 | Non-malaria patients130.6 [109.5/165.5]N = 67 | Villages238.0 [178.0/292.4]N = 71 | |||
| H1 vs. Hx | 150.3[135.0/200.6]N = 20P = 0.6 | 165.6[123.5/215.0]N = 56 | 115.6[108.9/131.8]N = 19P = 0.09 | 133.2[109.8/208.8 N = 48 | 208[173.0/247.0]N = 17P = 0.09 | 259.0[196.5/297.5]N = 54 |
| H2 vs. Hx | 160.3[123.9/216.3]N = 66P = 0.9 | 163.0[128.9/195.2]N = 10 | 126.7(108.9/154.6]N = 63P = 0.06 | 215.3[191.2/228.6]N = 4 | 247.0[178.0/294.0]N = 61P = 1.0 | 221.5[1855.0/276.5]N = 10 |
| H3 vs. Hx | 193.2[169.1/268.0]N = 16P = 0.009 | 153.3[122.6/208.2]N = 60 | 236.7[197.6/288.6]N = 13P < 0.001 | 119.4[105.3/139.7]N = 54 | 493.0[361.0/628.4]N = 6P = 0.007 | 232.0[178.0/284.5]N = 65 |
| H4 vs. Hx | 156.6[120.6/203.0]N = 10P = 0.7 | 161.1[125.4/213.6]N = 66 | 131.2[120.6/169.4]N = 9P = 0.7 | 128.7[109.5/159.6]N = 58 | 231.3[194.0/283.0]N = 19P = 0.8 | 248.0[177.8/298.6]N = 52 |
| Item | First sensation threshold | Defecation urge threshold | Pain detection threshold | |||||||||||||||
| Before Treatment | After Treatment | Difference | Before Treatment | After Treatment | Difference | Before Treatment | After Treatment | Difference | ||||||||||
| Mean ± S.E | 95% CI | Mean ± S.E | 95% CI | Mean ± S.E | 95% CI | Mean ± S.E | 95% CI | Mean ± S.E | 95% CI | Mean ± S.E | 95% CI | Mean ± S.E | 95% CI | Mean ± S.E | 95% CI | Mean ± S.E | 95% CI | |
| Moxibustion group (n = 15) | 22.27 ± 2.052 | [21.13,23.40] | 22.67 ± 0.63 | [21.32,24.0] | 0.40 ± 0.81 | [−1.34,2.14] | 40.07 ± 3.23 | [33.13,47.00] | 63.47 ± 2.01▲ | [59.15,67.78] | 23.40 ± 2.88★ | [17.23,29.57] | 89.07 ± 5.01 | [78.33,99.81] | 113.6 ± 7.51● | [97.48,129.72] | 24.53 ± 5.78○ | [12.14,36.92] |
| Control group (n = 13) | 22.31 ± 3.351 | [20.28,24.33] | 21.69 ± 1.17 | [19.14,24.2] | −0.62 ± 1.5 | [−0.43,2.80] | 41.31 ± 1.89 | [37.19,45.42] | 44.15 ± 1.55 | [40.78,47.58] | 2.85 ± 1.68 | [−0.80,6.50] | 89.62 ± 2.85 | [83.41,95.82] | 93.46 ± 2.67 | [87.64,99.28] | 3.85 ± 2.84 | [−2.33,10.02] |
| Gene | HCT116 | BxPC-3 | A427 | ||||||
| Slope | Intercept | R2 | Slope | Intercept | R2 | Slope | Intercept | R2 | |
| 18S | 0.09 | 0.16 | 0.98 | 0.14 | -0.41 | 1.00 | 0.11 | -0.16 | 0.94 |
| ACTB | 0.06 | 0.42 | 0.92 | 0.10 | -0.03 | 0.94 | 0.06 | 0.41 | 0.99 |
| ATUB | 0.10 | -0.01 | 0.96 | 0.14 | -0.41 | 0.99 | 0.10 | -0.01 | 0.95 |
| B2M | 0.10 | -0.03 | 0.92 | 0.10 | 0.03 | 0.92 | 0.07 | 0.34 | 0.92 |
| GAPDH | 0.08 | 0.27 | 0.94 | 0.10 | 0.02 | 0.98 | 0.08 | 0.22 | 0.98 |
| HPRT | 0.09 | 0.08 | 0.94 | 0.10 | 0.05 | 0.86 | 0.08 | 0.16 | 0.96 |
| POLR2L | 0.06 | 0.4 | 0.98 | 0.06 | 0.43 | 0.92 | 0.04 | 0.60 | 0.97 |
| PSMB6 | 0.07 | 0.35 | 0.97 | 0.09 | 0.14 | 0.99 | 0.05 | 0.53 | 0.99 |
| RPLP0 | 0.09 | 0.09 | 0.94 | 0.11 | -0.07 | 0.99 | 0.06 | 0.33 | 0.97 |
| Age | Females (%) | Males (%) | Total (%) |
| <30 | 16 (3.5) | 23 (1.6) | 39 (2.0) |
| 30–49 | 314 (68.0) | 704 (48.0) | 1018 (52.8) |
| 50–60 | 92 (19.9) | 268 (18.3) | 360 (18.7) |
| >60 | 40 (8.6) | 470 (32.1) | 510 (26.5) |
| Total | 462 (100) | 1465 (100) | 1927 (100) |
| Predicting from Overt Victimization | Predicting from Relational Victimization | ||||||||
| CBCL Externalizing | CBCL Internalizing | CBCL Externalizing | CBCL Internalizing | ||||||
| ∆R2 | β | ∆R2 | β | ∆R2 | β | ∆R2 | β | ||
| Step 1 | 0.02 | 0.03 | 0.02 | 0.03 | |||||
| Age | −0.12 | 0.18 | −0.12 | 0.18 | |||||
| Step 2 | 0.11 | 0.13 | 0.11 | 0.13 | |||||
| Child Fearful Bias | 0.21 | 0.07 | 0.21 | 0.07 | |||||
| Parent Fearful Bias | −0.02 | −0.10 | −0.02 | −0.10 | |||||
| Parent TAS DIF | 0.32 * | 0.36 ** | 0.32 * | 0.36 ** | |||||
| Step 3 | 0.00 | 0.04 | 0.01 | 0.10 * | |||||
| Perceived Impairment | 0.02 | −0.22 | −0.14 | −0.37 * | |||||
| Step 4 | 0.13 * | 0.10 * | 0.08 | 0.09 | |||||
| Child-reported Victimization | −0.09 | −0.10 | −0.01 | −0.12 | |||||
| Parent-reported Victimization | 0.40 ** | 0.34 * | 0.31* | 0.35 * |
| Symbola | Protein | Process | Alteration/disease |
| ADCYAP1R1 | Adenylate cyclase-activating polypeptide receptor (PAC1) | Signaling pathway | Decreased second messenger |
| CASP3 | Caspase 3 | Protease | Apoptosis. Alzheimer’s disease |
| CCND1 | G1/S-specific cyclin-D1 | Interact with tumor suppressor protein Rb | Abnormal cell cycle G1/S transition |
| CNN1 | Calporin (actin binding protein; fimbrin type) | Actin associated protein | Abnormal cohesion between parental centrioles |
| CREB1 | cAMP-responsive element binding protein 1 | Transcription factor | Altered development. ASD |
| CREM | cAMP-responsive element modulator | Transcription factor modulating CREB | Altered development. ASD |
| CTNNB1 | β-catenin | Regulates the coordination of cell–cell adhesion and gene transcription | Altered asymmetric cell division, epithelial-to-mesenchymal transition. ASD |
| DYRK1A | Dual specificity tyrosine-phosphorylation- regulated kinase 1A | Nuclear signaling | Abnormal cell proliferation and may be involved in brain development. ASD |
| GNB1L | Guanine nucleotide-binding protein subunit β-like protein 1 | Six WD40 repeat-containing protein | Abnormal cell cycle progression. Schizophrenia. ASD |
| FLT1 | Vascular endothelial growth factor receptor 1 | Protein kinase | Abnormal control of cell proliferation and differentiation. ASD |
| HIST1H1T | Histone H1t | Compaction of chromatin | Abnormal cell cycle and differentiation |
| HSD11B2 | Corticosteroid 11-β-dehydrogenase isozyme 2 | Hydrolysis of cortisol | Cortisol induction of growth-inhibition and/or pro-apoptosis embryonic development |
| MAPK1 | Mitogen-activated protein kinase 1 (ERK2) | CREB1 phosphorylation signaling pathway | ASD |
| RGS3 | Regulator of G-protein signaling 3 | Ephrin-B signaling pathway | Early cell cycle exit and precocious differentiation |
| Harmonic (n = 39) | Control (n = 40) | p-value | |
| Total volume (ml) | |||
| Univariate | 2908 ± 2453 | 3898 ± 5791 | 0.382 |
| Multivariate-adjusted | 2864 ± 715 | 3941 ± 706 | 0.293 |
| Duration of draining (days) | |||
| Univariate | 23 ± 14 | 28 ± 15 | 0.195 |
| Multivariate-adjusted | 24 ± 2 | 27 ± 2 | 0.290 |
| KEGG pathway | p value | Number of DEGs found in the KEGG pathway | Ratio (%) |
| Pathways in cancer | 2.1e-4 | 9 | 10.1 |
| Cytokine-cytokine receptor interaction | 2.1e-3 | 7 | 7.9 |
| Basal cell carcinoma | 2.9e-3 | 4 | 4.5 |
| Retinol metabolism | 3.3e-2 | 3 | 3.4 |
| Hedgehog signaling pathway | 3.5e-2 | 3 | 3.4 |
| Underlying Diagnosis | All Diagnoses | |||
| Median | 95% UI | Median | 95% UI | |
| Adults | 66.5 | (65.9, 66.9) | 75.9 | (75.4, 76.3) |
| Children | 38.5 | (37.0, 40.0) | 64.0 | (61.4, 66.3) |
| Neonates | 54.3 | (52.2, 55.6) | 58.9 | (56.9, 60.5) |
| Indices and Its Statements a | Total Sample n = 1107 | Bottom Tertile n = 355/339 | Middle Tertile n = 424/417 | Upper Tertile n = 328/351 | p-Value |
| Perceived health concerns | |||||
| Health Concern Index b | 6.9 (3.7) | 3.0 (0.7) | 6.6 (0.9) | 11.6 (2.3) | <0.0001 |
| I am concerned about gaining weight | 3.1 (1.9) | 1.0 (0.5) | 3.6 (1.5) | 4.6 (1.2) | <0.0001 |
| I am concerned about the risk of high blood pressure | 2.0 (1.4) | 1.0 (0.3) | 1.5 (0.7) | 3.7 (1.3) | <0.0001 |
| I am concerned about the risk of coronary heart disease | 1.8 (1.3) | 1.0 (0.3) | 1.4 (0.8) | 3.3 (1.4) | <0.0001 |
| Perceived nutrition concerns | |||||
| Nutrition Concern Index c | 17.1 (6.6) | 10.0 (1.7) | 16.1 (1.9) | 25.1 (4.2) | <0.0001 |
| I am not concerned about getting a lot of salt in my food (re-coded) | 3.7 (1.5) | 3.4 (1.8) | 3.8 (1.4) | 3.7 (1.4) | 0.1617 |
| I am concerned about food additives in my food | 2.6 (1.5) | 1.4 (0.9) | 2.7 (1.4) | 3.5 (1.4) | <0.0001 |
| I am concerned about getting a lot of sugar in my food | 2.4 (1.6) | 1.1 (0.7) | 2.1 (1.2) | 4.2 (1.2) | <0.0001 |
| I am concerned about getting a lot of fat in my food | 2.3 (1.6) | 1.0 (0.4) | 2.0 (1.3) | 4.0 (1.3) | <0.0001 |
| I am concerned about getting sufficient energy in my food | 2.2 (1.5) | 1.1 (0.5) | 2.2 (1.3) | 3.2 (1.5) | <0.0001 |
| I am concerned about getting a lot of cholesterol in my food | 2.1 (1.5) | 1.0 (0.3) | 1.7 (1.0) | 3.6 (1.3) | <0.0001 |
| I am concerned about getting many calories | 1.9 (1.3) | 1.0 (0.5) | 1.7 (1.0) | 2.9 (1.5) | <0.0001 |
| Pathways | Genes | Descriptions | TPM | NOISeq | RT-qPCR | |||
| P. humilis | P. major | Log2FC | P-adj | Log2FC | P | |||
| Wnt | WNT5A | Protein Wnt-5a | 48.06 | 148.61 | −1.63 | 0.00E+00 | – | – |
| PRICKLE1 | Prickle-like protein 1 | 14.86 | 55.20 | −1.89 | 2.75E-06 | −0.17 | 1.10E-01 | |
| WIF1*† | Wnt inhibitory factor 1 | 7.28 | 57.05 | −2.97 | 8.87E-06 | −3.28 | 5.30E-06 | |
| NFATC3 | Nuclear factor of activated T-cells, cytoplasmic 3 | 8.98 | 39.30 | −2.13 | 9.47E-05 | – | – | |
| FZD4 | Frizzled-4 | 16.67 | 89.95 | −2.43 | 1.54E-04 | – | – | |
| LEF1 | Lymphoid enhancer-binding factor 1 | 60.50 | 143.01 | −1.24 | 1.77E-04 | – | – | |
| FRZB* | Secreted frizzled-related protein 3 | 71.32 | 150.58 | −1.08 | 3.47E-04 | −3.23 | 4.12E-05 | |
| DAAM2 | Disheveled-associated activator of morphogenesis 2 | 2.48 | 15.04 | −2.60 | 3.47E-04 | – | – | |
| CCND1 | G1/S-specific cyclin-D1 | 24.35 | 69.13 | −1.51 | 4.18E-04 | – | – | |
| PRKACB | cAMP-dependent protein kinase catalytic subunit beta | 34.22 | 73.42 | −1.10 | 4.97E-04 | – | – | |
| MAPK/FGF | FGF17 | Fibroblast growth factor 17 | 45.91 | 0.38 | 6.91 | 0.00E + 00 | 0.50 | 4.18E-01 |
| FGF13*† | Fibroblast growth factor 13 | 11.33 | 3.71 | 1.61 | 4.21E-04 | 7.37 | 1.23E-08 | |
| STK3 | Serine/threonine-protein kinase 38 | 11.70 | 40.72 | −1.80 | 4.64E-04 | – | – | |
| OCD | NFATC1* | Nuclear factor of activated T-cells, cytoplasmic 1 | 5.82 | 39.32 | −2.76 | 1.60E-08 | −3.21 | 2.16E-05 |
| ITGB3*† | Integrin beta-3 | 0.76 | 6.43 | −3.08 | 8.57E-05 | −5.49 | 1.21E-06 | |
| Notch | HES5 | Transcription factor HES-5 | 117.76 | 17.23 | 2.77 | 3.11E-04 | 0.22 | 6.83E-01 |
| Calcium | CACNA1G | Voltage-dependent T-type calcium channel subunit alpha-1G | 4.28 | 14.60 | −1.77 | 5.79E-04 | – | – |
| Variable | Mean (range) or no. (%) |
| Total operative time (mins) | 204.94 (180–300) |
| Docking time (mins) | 9.06 (5–30) |
| Undocking time (mins) | 5 (2–10) |
| Time for esophageal mobilization (mins) | 104.08 (80–170) |
| Estimated blood loss (ml) | 86.75 (50–200) |
| Lymphnode yield (no.) | 18.36 (13–24) |
| ICU stay (days) | 1 (1–3) |
| Hospital stay (days) | 10.37 (10–13) |
| Nil by mouth (days) | 9.40 (8–12) |
| Conversion (no.) | Nil |
| Margin positivity (no.) | 2 (2.41) |
| Adjuvant chemotherapy (no.) | 15 (18.07) |
| Complications (no.) | |
| Dysphagia for solids | 6 (7.23) |
| Pleural effusion | 3 (3.61) |
| Aspiration pneumonia | 1 (1.20) |
| Recurrent palsy | 2 (2.41) |
| Anastomotic leak | 3 (3.61) |
| Chyle leak | 1 (1.20) |
| Port site metastasis | 1 (1.20) |
| Surgical site infection | 1 (1.20) |
| Sepsis | 1 (1.20) |
| Group A (n = 162) | Group B (N = 89) | p-value | |
| Median (IQR) age, years | 67 (61–72) | 68 (60–71) | 0.846 |
| Median (IQR) PSA. ng/ml | 8.10 (6.05–14.00) | 8.59 (5.65–12.32) | 0.997 |
| Median IQR) f/t PSA-ratio,% | 12 (9–17) | 13 (9–19) | 0.309 |
| Median (IQR) prostate volume, ml | 48 (35–60) | 50 (37–70) | 0.087 |
| Suspicous DRE, n (%) | 23 (14%) | 26 (29%) | 0.007 |
| No. of prior biopsies, n (%) | |||
| Primary biopsy | 53 (33%) | 41 (46%) | 0.041 |
| 1 | 59 (36%) | 28 (32%) | 0.489 |
| 2 | 33 (20%) | 13 (15%) | 0.308 |
| ≥3 | 17 (10%) | 7 (8%) | 0.655 |
| Localization of lesions with maximum PI-RADS on mpMRI, n (%) | |||
| Apex | 72 (44%) | 35 (39%) | 0.505 |
| Midgland | 43 (27%) | 32 (36%) | 0.149 |
| Base | 47 (29%) | 22 (25%) | 0.555 |
| Anterior | 45 (28%) | 28 (32%) | 0.563 |
| Median (IQR) no. of lesions per patient | 1 (1–2) | 1 (1–2) | 0.451 |
| Maximum diameter of lesions (mm) | 14 (10–17) | 13 (10–18) | 0.885 |
| Mean (SD) of cores taken per patient | 13.7 (±1.6) | 13.2 (±1.2) | 0.009 |
| Mean (SD) TBs per patient | 3.8 (±1.5) | 3.4 (±0.9) | 0.031 |
| Maximum mpMRI Score, n (%)a | |||
| PI-RADS 3 | 31 (19%) | 8 (9%) | 0.044 |
| PI-RADS 4 | 83 (51%) | 43 (48%) | 0.693 |
| PI-RADS 5 | 48 (30%) | 38 (43%) | 0.051 |
| Background characteristics | Frequency | Percentage | |
| Sex | Female | 298 | 73.2 |
| Male | 109 | 26.8 | |
| Age | 18-24 | 75 | 18.4 |
| 25-34 | 178 | 43.8 | |
| 35-44 | 87 | 21.4 | |
| 45-54 | 36 | 8.8 | |
| 55+ | 31 | 7.6 | |
| Marital status | Married | 335 | 82.3 |
| Single | 48 | 11.8 | |
| Divorced | 16 | 3.9 | |
| Widowed | 8 | 2.0 | |
| Educational level | Illiterate | 45 | 11.0 |
| Grade 1-8 | 111 | 27.3 | |
| Grade 9.12 | 120 | 29.5 | |
| College and above | 131 | 32.2 | |
| Religion | Protestant | 268 | 65.8 |
| Orthodox | 88 | 21.6 | |
| Muslim | 27 | 6.6 | |
| Catholic | 24 | 5.9 | |
| Occupation | Gov’t employee | 139 | 34.2 |
| House wife | 137 | 33.7 | |
| Merchant | 59 | 7.6 | |
| Daily laborer | 31 | 14.5 | |
| Others* | 41 | 10.1 |
| Pearson correlation | Secondary structure and interactions | |||
| Target | Guide strand (intra-) | Guide strand (inter-) | ||
| Complete database | R | 0.16 | 0.13 | 0.12 |
| Significance | <10−100 | 1.1 × 10−72 | 2.89 × 10−56 | |
| Dataset with duplex stability −35 ≤ ΔG ≤ −25 kcal/mol | R | – | 0.045 | – |
| Significance | n.s. | 0.0018 | n.s. |
| Method | ASEF | nu-SVR | Deep CNN | Our method |
| fps | 66.7 | 0.82 | 8.3 | 10.5 |
| Odds ratio | 95% CI | |
| Age | 1.04 | 1.01 to 1.07 |
| Site of infection: | ||
| Lung | 1 | |
| Abdomen | 1.55 | 0.66 to 3.70 |
| Catheter | 0.72 | 0.15 to 3.43 |
| Urinary tract | 0.10 | 0.01 to 0.78 |
| Others | 0.70 | 0.25 to 1.94 |
| Chronic alcohol abuse | 3.20 | 0.90 to 11.42 |
| Acquisition in hospital | 2.03 | 0.98 to 4.36 |
| SOFA score day 1 (failure): | ||
| Haematological | 3.20 | 0.92 to 9.92 |
| Cardiovascular | 2.78 | 1.37 to 5.64 |
| Neurological | 2.39 | 0.76 to 7.48 |
| Renal | 1.97 | 0.73 to 5.27 |
| Liver | 1.67 | 0.46 to 6.08 |
| Lung | 1.65 | 0.81 to 3.36 |
| ΔSOFA (3-1) | 1.32 | 1.13 to 1.34 |
| APACHE II Score | 1.02 | 0.97 to 1.08 |
| Pre ICU stay (days) | 0.99 | 0.97 to 1.02 |
| € | Reference/data source | |
| Visit practice nurse (€/minute) | 0.85 | Vektis, information centre on costs and quality of health care in the Netherlands, established by health care insurers. |
| Mean salary costs men (€/hour) | 32.49 | Manual Hakkaart-van Roijen et al. [18] |
| Mean salary costs women (€/hour) | 25.94 | Manual Hakkaart-van Roijen et al. [18] |
| Transportation costs per visit | 3.44 | 1.1 km * €0.20/km (back and forth: €0.44) + €3 parking costs, based on the manual of Hakkaart-van Roijen et al. [18] |
| Weighing scale | 45 | Mean price according to the “Consumentenbond” (Dutch consumers organisation) |
| Pedometer | 40 | Mean price according to “thuisvergelijken.nl” (website with reviews on web shops) |
| Blood pressure device | 120 | Mean price according to “bloeddrukmetershop.nl” |
| Food diary and step diary | 5 | Price according to “weightwatchers.nl” |
| Medication | variable | 2012 prices according to “medicijnkosten.nl”, site of the College of Health Insurances |
| Characteristics | Patientsn = 85 |
| Age | 66 (range 43-87) |
| Hypertension | 34 (39%) |
| Hormone replacement therapy | 21 (24%) |
| Obesity (BMI ≥ 30) | 19 (22.3%) |
| Histology: | |
| Endometrioid adenocarcinoma | 73 (86%) |
| Adenosquamous adenocarcinoma | 1 (1%) |
| Serous papillary adenocarcinoma | 5 (6%) |
| Clear cell adenocarcinoma | 5 (6%) |
| Carcinosarcoma | 1 (1%) |
| Preoperative histological grade on biopsy | |
| 1 | 41 (48.2%) |
| 2 | 22 (25.8%) |
| 3 | 11 (12.9%) |
| NP | 11 (12.9%) |
| Model – Variables | Odds Ratios for eGFR < 75(95% Confidence Interval)n = 51 events | P interaction (APOL1x SES measure) | Odds Ratios for Elevated ACR(95% Confidence Interval) n = 21 events | P interaction (APOL1x SES measure) | ||
| High-risk versus Low-riskAPOL1variants | Low SES versus Higher SES Group | High-risk versus Low-riskAPOL1variants | Low SES versus Higher SES Group | |||
| Additive Models | ||||||
| APOL1, Education | 1.60 (1.00, 2.57) | 1.95 (1.50, 2.54) | 0.4 | 3.89 (2.28, 6.63) | 1.68 (0.34, 8.23) | 0.823 |
| APOL1, Employment | 2.06 (1.53, 2.78) | 4.64 (3.40, 6.33) | 0.017* | 3.12 (1.73, 5.63) | 1.32 (0.83, 2.08) | 0.894 |
| APOL1, Health Insurance | 1.92 (1.27, 2.90) | 1.00 (0.53, 1.89) | 0.662 | 3.04 (1.65, 5.60) | 0.56 (0.14, 2.28) | **could not be determined |
| APOL1, Regular Health Care Source | 1.91 (1.15, 3.17) | 0.54 (0.31, 0.94) | 0.871 | 3.09 (1.56, 6.13) | 0.64 (0.14, 2.86) | **could not be determined |
| ConditionN(%)Median(IQR) | ||||
| All | Experimental (n = 58) | SOC+ (n = 70) | p-value | |
| Product use for IVP in the prior month | ||||
| Water | ||||
| No | 10 (7.8%) | 5 (8.6%) | 5 (7.1%) | |
| Yes | 118 (92.2%) | 53 (91.4%) | 65 (92.9%) | 0.755a |
| Soap | ||||
| No | 39 (30.5%) | 22 (37.9%) | 17 (24.3%) | |
| Yes | 89 (69.5%) | 36 (62.1%) | 53 (75.7%) | 0.095 |
| Cloth, sponge or a rag | ||||
| No | 33 (47.1%) | 27 (46.6%) | 33 (47.1%) | |
| Yes | 68 (53.1%) | 31 (53.4%) | 37 (52.9%) | > 0.999 |
| Traditional medicines | ||||
| No | 91 (71.1%) | 43 (74.1%) | 48 (68.6%) | |
| Yes | 37 (28.9%) | 15 (25.9%) | 22 (31.4%) | 0.489 |
| Herbs or flowers from outdoors | ||||
| No | 103 (80.5%) | 46 (79.3%) | 57 (81.4%) | |
| Yes | 25 (19.5%) | 12 (20.7%) | 13 (18.6%) | 0.763 |
| Lemon | ||||
| No | 115 (89.3%) | 52 (89.7%) | 63 (90.0%) | |
| Yes | 13 (10.2%) | 6 (10.3%) | 7 (10.0%) | > 0.999 |
| Salt | ||||
| No | 117 (91.4%) | 54 (93.1%) | 63 (90.0%) | |
| Yes | 11 (8.6%) | 4 (6.9%) | 7 (10.0%) | 0.753a |
| Vinegar | ||||
| No | 124 (96.9%) | 56 (96.6%) | 68 (97.1%) | |
| Yes | 4 (3.1%) | 2 (3.4%) | 2 (2.9%) | 0.848a |
| Laboratory parameters | ||||
| Abnormal vaginal flora | ||||
| No | 30 (23.4%) | 16 (27.6%) | 14 (20.0%) | |
| Yes | 98 (76.6%) | 42 (72.4%) | 56 (80.0%) | 0.213 |
| Bacterial vaginosis | ||||
| No | 47 (36.7%) | 24 (41.4%) | 23 (32.9%) | |
| Yes | 81 (63.3%) | 34 (58.6%) | 47 (67.1%) | 0.319 |
| Plasma HIV RNA | ||||
| Undetectable | 100 (78.1%) | 46 (79.3%) | 54 (77.1%) | |
| Detectable | 28 (21.9%) | 12 (20.7%) | 16 (22.9%) | 0.768 |
| CVL HIV RNA | ||||
| Undetectable | 108 (84.4%) | 50 (86.2%) | 58 (82.9%) | |
| Detectable | 20 (15.6%) | 8 (13.8%) | 12 (17.1%) | 0.603 |
| Lower genital tract cytokines | ||||
| IL-6 (n = 68; Exp = 35, SOC+ = 33) | 289.9 (258.0) | 306.3 (313.7) | 282.6 (249.1) | 0.944 |
| IL-8 (n = 68; Exp = 35, SOC+ = 33) | 332.5 (1781.9) | 380.11 (1311.9) | 227.5 (2285.5) | < 0.001 |
| Exposure (exposure contrast) | n | ABI < 0.9 | ABI > 1.3 | ||
| NO2 (25 μg/m3) | |||||
| Model 1a | 2,698 | 0.65 | (0.28, 1.52) | 1.91 | (1.09, 3.33) |
| Model 2b (possible intermediates) | 2,600 | 0.72 | (0.29, 1.75) | 1.98 | (1.09, 3.6) |
| Traffic load in a 100 m bufferc (7,200,000 veh-m/day) | |||||
| Model 1 | 2,698 | 0.92 | (0.37, 2.3) | 1.89 | (1.1, 3.26) |
| Model 2 (possible intermediates) | 2,600 | 1.02 | (0.4, 2.61) | 1.89 | (1.07, 3.34) |
| Traffic intensity in nearest street (15,000 veh/day) | |||||
| Model 1 | 2,698 | 0.47 | (0.16, 1.41) | 1.6 | (1.08, 2.38) |
| Model 2 (possible intermediates) | 2,600 | 0.48 | (0.16, 1.46) | 1.7 | (1.13, 2.57) |
| veh, vehicle. aEstimates adjusted by model 1: sex, age,sex–age interaction, smoking status, education, and marital status.bEstimates adjusted by model 2: sex, age, sex–age interaction, smokingstatus, education, marital status, BMI, HDL, waist circumference,systolic and diastolic blood pressure, weekly energy expenditure inphysical activity during leisure time (tertiles), adherence toMediterranean diet, plausibility of reported diet, medication treatment,and percentage of persons with low education at the census-tract level.cModels for traffic load were additionally adjusted for occupationalstatus. |
| Section | Award 1 point if |
| Selection bias (3 pts.) | |
| Goal and inclusion | Goal of the study is stated and study explicitly states the inclusion criteria |
| Selection of patients | Selective recruitment of patients can be ruled out |
| Patient characteristics | Study reports the age range and mean age and states the distribution of men and women |
| Outcome bias (3 pts.) | |
| Definition of subsidence | Definition of subsidence, classification, and radiological tools to measure subsidence were stated |
| Clinical outcome | Clinical outcome was systematically evaluated in correlation to subsidence |
| Preoperative status | Preoperative status was stated for comparison with postoperative status |
| Follow-up bias (2 pts.) | |
| Follow-up period | Follow-up range, period, and mean were given: |
| • If yes and prospective study: 2 points | |
| • If yes and retrospective study: 1 point | |
| • If no, but loss to follow-up < 20%: 1 point | |
| • If too little information: 0 points | |
| Other bias (3 pts.) | |
| Clinical evaluation | Evaluation was done independently from treating physician |
| Radiologic evaluation | Evaluation was done by an independent party, blinded to clinical results |
| Independence | Independence is explicitly stated, conflict of interest can be ruled out |
| Total (11 points) |
| Erosion Ratio (%) | σ3 (MPa) | |||||
| 0.36 | 0.72 | 1.44 | 2.88 | 5.76 | 11.52 | |
| 0.0 | 333 | 688 | 1290 | 1332 | 2663 | 3590 |
| 3.0 | 229 | 688 | 688 | 917 | 1086 | 1101 |
| 6.5 | 235 | 356 | 356 | 938 | 1147 | 1131 |
| 10.0 | 184 | 369 | 491 | 590 | 851 | 786 |
| 15.0 | 195 | 382 | 389 | 523 | 516 | 594 |
| Students, N = 65 | Mothers, N = 63 | |||
| Pre | Post | Pre | Post | |
| Cervical cancer is caused by HPV infection? | 46% | 100% | 86% | 97% |
| Cervical cancer is genetic? | 51% | 63% | 71% | 81% |
| All HPV infections lead to cervical cancer? | 75% | 49% | 89% | 76% |
| Cervical cancer is decreasing in recent years? | 83% | 92% | 100% | 98% |
| Cervical cancer is preventable? | 72% | 97% | 70% | 78% |
| Cervical cancer is asymptomatic usually in early stage? | 65% | 97% | 98% | 98% |
| Early detection of cervical cancer might save one’s life? | 85% | 92% | 95% | 97% |
| HPV is sexually transmitted? | NA | NA | 91% | 97% |
| If vaccinated, you don’t need to be screened? | NA | NA | 98% | 97% |
| Screening test should be done regularly? | NA | NA | 92% | 95% |
| HPV vaccination can prevent cervical cancer | NA | NA | 95% | 95% |
| Safe sex (steady partner, use of condoms) can prevent cervical cancer | NA | NA | 75% | 89% |
| Pap test can prevent cervical cancer | NA | NA | 94% | 95% |
| Healthy lifestyle (ie., regular exercise, disciplined lifestyle, healthy diet) can prevent cervical cancer | NA | NA | 11% | 11% |
| AS | Rett | MWS | FOXG1 | KS | PMS | PHS | CS | CDKL5 | MEF2C | ARTX | |
| Microcephaly | + | + | + | + | + | + | + | + | + | + | |
| Seizure | + | + | + | + | + | + | + | + | + | ||
| Speech impairment | + | + | + | + | + | + | + | + | + | + | |
| Ataxia | + | + | + | + | + | ||||||
| Stereotypical hand movements | +/− | + | + | + | + | + | |||||
| Tremulous/jerky limb movements | + | ||||||||||
| Happy predisposition | + | + | + | + | + | ||||||
| Abnormal MRI | + | + | + | + | + | ||||||
| Hyperventilation/apnea episode | + | + | |||||||||
| Sleep disturbances | + | + | + | + | + | ||||||
| Hirschsprung disease | + | ||||||||||
| Lack of purposeful hand use | + | ||||||||||
| Prominent jaw/chin | + | + | |||||||||
| Wide mouth | + | + | + | ||||||||
| Upturned ear lobes | + | ||||||||||
| Genital anomalies | + | + | |||||||||
| Congenital heart disease | + | + | + | ||||||||
| Developmental regression | + | + | + | ||||||||
| Others | In female only | Mild overgrowth | Persistent finger pad Constipation | In male only | In male only HbH in blood smear |
| Variable | Response options | Total motorcycle riders | Non-helmet user | ||
| Number | % | Number | % | ||
| Helmet use experiences and attitudes | |||||
| Been in accident before | No | 12,649 | 66.6 | 5,479 | 43.5 |
| Yes | 6,349 | 33.4 | 2,890 | 45.7 | |
| Rider status when in accident | Rider | 4,557 | 75.7 | 2,146 | 47.2 |
| Passenger | 1,370 | 22.8 | 601 | 44.1 | |
| Pedestrian | 93 | 1.5 | 37 | 39.8 | |
| Have you ever used a helmet before | No | 7,600 | 40.2 | 5,925 | 52.6 |
| Yes | 11,290 | 59.8 | 2,395 | 31.7 | |
| Perceived danger of not using a helmet | No | 4,720 | 25.0 | 2,008 | 42.7 |
| Yes | 14,175 | 75.0 | 6,316 | 44.7 | |
| Aware of danger of not using a helmet | Low | 840 | 4.4 | 425 | 50.7 |
| Moderate | 7,525 | 39.8 | 3,328 | 44.4 | |
| High | 10,544 | 55.8 | 4,580 | 43.6 | |
| Perceived risk about being caught by the police because of not using a helmet | High risk | 7,788 | 41.3 | 3,602 | 46.4 |
| Moderate risk | 7,411 | 39.3 | 3,271 | 44.3 | |
| Low risk | 2,078 | 11.0 | 855 | 41.3 | |
| No risk | 1,595 | 8.5 | 584 | 36.7 | |
| Ever been caught by police because of not using a helmet | No | 8,918 | 52.8 | 3,839 | 38.6 |
| Yes | 9,983 | 47.2 | 4,483 | 50.4 | |
| Exposure to road safety awareness (RSA) campaign | |||||
| Heard advertising campaign on RSA | No | 3,066 | 16.1 | 1,428 | 46.9 |
| Yes | 15,926 | 83.9 | 6,938 | 43.7 | |
| RTI campaign on radio or TV | Never | 2,476 | 13.2 | 1,198 | 48.5 |
| Not often | 10,253 | 54.5 | 4,391 | 43.0 | |
| Frequently | 5,493 | 29.2 | 2,409 | 44.0 | |
| Not sure | 587 | 3.1 | 272 | 46.4 | |
| Talking to others about RSA in the media | Never | 7,729 | 40.8 | 3,789 | 49.2 |
| Ever | 7,600 | 40.1 | 3,031 | 40.0 | |
| Not sure | 3,620 | 19.1 | 1,533 | 42.6 | |
| How feel about RSA media | Not like | 1,119 | 5.9 | 560 | 50.0 |
| Like a little bit | 11,676 | 61.7 | 5,148 | 44.3 | |
| Like very | 5,173 | 27.3 | 2,205 | 42.7 | |
| much | 955 | 5.0 | 433 | 45.4 | |
| Not sure | |||||
| Follows the TV news report on RSA statistics | Never | 2,614 | 13.8 | 1,256 | 48.2 |
| Not often | 9,841 | 52.0 | 4,415 | 45.0 | |
| Frequently | 5,552 | 29.3 | 2,244 | 40.6 | |
| Not sure | 912 | 4.8 | 436 | 48.2 |
| Conventional CPB | Mini-CPB | P value | |||
| Patients (no.) | 22 | 22 | |||
| Women/men (no.) | 4/18 | 2/20 | 0.66 | ||
| Age (years) | 68 | (63–71) | 69 | (66–74) | 0.57 |
| Body mass index | 28.5 | (25.3–32) | 26.5 | (25–31.3) | 0.38 |
| Acetylsalicylic acid (no.) | 21 | 21 | |||
| Beta blockers (no.) | 21 | 20 | |||
| ACE inhibitors (no.) | 16 | 18 | 0.72 | ||
| Statins (no.) | 21 | 20 | |||
| Diabetes mellitus (no.) | 4 | 6 | 0.72 | ||
| COPD (no.) | 3 | 4 | |||
| Prior myocardial infarction (no.) | 12 | 9 | 0.37 | ||
| Leukocytes (cells ×109/L) | 7.5 | (6.8–8.5) | 7.1 | (6.3–8.8) | 0.8 |
| Ejection fraction (%) | 64.5 | (51.3–69.8) | 60 | (48.5–69.5) | 0.35 |
| Cluster ID | #sequences | #non-redundant sequences | Description |
| CAM_CL_2057 | 20,508 | 24 | Reverse transcriptase (HIV) |
| CAM_CL_1132 | 18,882 | 1,406 | Cytochrome c oxidase subunit I |
| CAM_CL_2568 | 15,405 | 6,091 | ABC transporter |
| CAM_CL_4367 | 15,228 | 771 | Cytochrome b |
| CAM_CL_49 | 14,751 | 7,389 | Short-chain dehydrogenase |
| CAM_CL_3510 | 13,255 | 5,173 | Immunoglobulin |
| CAM_CL_2630 | 13,140 | 3,297 | Envelope glycoprotein |
| CAM_CL_160 | 13,054 | 3,897 | Kinases |
| CAM_CL_4556 | 12,403 | 6,345 | Response regulator |
| CAM_CL_481 | 12,078 | 5,477 | Transcription regulator |
| Cell line | dCK activity | dGK activity | ||||
| 48 h | 72 h | Quiescence | 48 h | 72 h | Quiescence | |
| pmol/min/mg | pmol/min/mg | |||||
| C1 | 19.3 ± 0.8 | 13.6 ± 0.6 | 7.3 ± 0.1 | 0.31 ± 0.02 | 0.31 ± 0.06 | 0.61 ± 0.18 |
| C2 | 17.1 ± 0.2 | 12.9 ± 0.2 | 5.8 ± 0.2 | 0.20 ± 0.02 | 0.41 ± 0.03 | 0.43 ± 0.02 |
| P1 | 14.8 ± 0.9 | 10.7 ± 0.4 | 9.5 ± 0.3 | ≤0.01 | 0.03 ± 0.01 | 0.02 ± 0.00 |
| P2 | 14.5 ± 0.2 | 13.5 ± 0.1 | 8.1 ± 1.4 | 0.04 ± 0.01 | 0.05 ± 0.00 | ≤0.01 |
| P3 | 16.5 ± 0.3 | 11.4 ± 0.2 | 8.0 ± 1.2 | 0.04 ± 0.01 | 0.16 ± 0.01 | ≤0.01 |
| Dependant Variable | Worse-than-Dead | Euthanasia | ||
| Coefficient | Standard Error | Coefficient | Standard Error | |
| Third Level Education | −0.155 | (0.167) | −0.077 | (0.255) |
| Age Group (Base: 18–35) | ||||
| 36–45 | 0.304 | (0.207) | 0.328 | (0.32) |
| 46–60 | 0.471* | (0.228) | 0.318 | (0.42) |
| 61+ | 1.168*** | (0.274) | 0.585 | (0.489) |
| Male | −0.298 | (0.17) | −0.113 | (0.251) |
| Married/Living as Married | −0.158 | (0.204) | −0.07 | (0.303) |
| Dependants Under 18 (Y/N) | −0.098 | (0.208) | 0.412 | (0.359) |
| Visual Analogue Scale | 0.004 | (0.006) | −0.012 | (0.008) |
| Experienced a serious illness | −0.287 | (0.264) | −0.765* | (0.3) |
| In favour of Legalisation of Euthanasia (see scenario in Fig. 1) | 1.003* | (0.394) | – | – |
| Religiosity (Base: A few times a year or less) | ||||
| Monthly | – | – | −0.454 | (0.318) |
| Weekly | – | – | −1.369*** | (0.328) |
| Mobility (Base: No Problems) | ||||
| Slight problems | 0.194 | (0.114) | – | – |
| Moderate problems | 0.326** | (0.109) | – | – |
| Severe problems | 0.476*** | (0.12) | – | – |
| Unable | 0.419*** | (0.112) | – | – |
| Self-care (Base: No Problems) | ||||
| Slight problems | 0.263* | (0.128) | – | – |
| Moderate problems | 0.34* | (0.131) | – | – |
| Severe problems | 0.528*** | (0.143) | – | – |
| Unable | 0.444*** | (0.102) | – | – |
| Usual Activities (Base: No Problems) | ||||
| Slight problems | 0.304* | (0.134) | – | – |
| Moderate problems | 0.477** | (0.156) | – | – |
| Severe problems | 0.443*** | (0.118) | – | – |
| Unable | 0.335*** | (0.091) | – | – |
| Paid/Discomfort (Base: No Problems) | ||||
| Slight problems | 0.253* | (0.116) | – | – |
| Moderate problems | 0.182 | (0.116) | – | – |
| Severe problems | 0.614*** | (0.111) | – | – |
| Extreme problems | 0.852*** | (0.138) | – | – |
| Anxiety/Depression (Base: No Problems) | ||||
| Slight problems | 0.221 | (0.128) | – | – |
| Moderate problems | 0.313* | (0.14) | – | – |
| Severe problems | 0.867*** | (0.159) | – | – |
| Extreme problems | 0.858*** | (0.133) | – | – |
| Constant | −3.331*** | (0.626) | 2.05** | (0.748) |
| Rhoa | −0.801* | (0.402) | ||
| Number of observationsa | 1600 | |||
| Number of clustersa | 160 |
| Clinical trial | Number of patients | Experimental arm | Control arm | Overall/annual fracture incidence | References |
| ATAC | 9366 | Anastrozole | Tamoxifen | Overall: 11 vs. 7.7%Annual: 2.93 vs. 1.90% | [57, 58] |
| IBIS II bone sub-study | 1410 | Anastrozole | Placebo | Annual: 1.37 vs. 1.26% | [100] |
| BIG 1.98 | 4895 | Letrozole | Tamoxifen | Overall: 9.3 vs. 6.5%Annual: 2.71 vs. 1.872% | [59] |
| MA-17 | 5187 | Letrozole | Placebo | Overall: 3.6 vs. 2.9% | [60] |
| IES | 4274 | Exemestane | Tamoxifen | Overall: 7 vs. 5%Annual: 2.01 vs. 1.60% | [61] |
| ABCSG-18 | 3420 | AI + denosumab | AI + placebo | Overall: 5 vs. 9.6% | [107] |
| Instrument | Baseline | Follow-up |
| SCAN [38] | x | |
| PANSS [41] | x | x |
| Insight Scale [39] | x | x |
| Early Signs Scale [40] | x | x |
| DUP [42] | x | |
| PAS [44] | x | |
| Encounter Form [45] | x |
| How detected | % of total |
| Test recommended by general practitioners | 27.1 |
| Sexual partner tracing | 21.7 |
| Voluntary testing | 12.1 |
| Blood donors | 9.7 |
| HIV test done in hospitals | 8.9 |
| Persons with other sexually transmitted infections | 8.3 |
| Pregnant women | 1.6 |
| Other | 10.6 |
| Total | 100% (n = 4276) |
| Gender | NO. examined | NO. positive | Prevalence (%) |
| Male | 52 | 9 | 17.31 |
| Female | 140 | 11 | 7.86 |
| Total | 192 | 20 | 10.42 |
| Objective | Activity |
| Training To understand the nutrient content and ingredients in processed and fast food and make a homemade burger | ‘Ready, steady, cook’. Demonstration used a fast food burger recipe to illustrate poor quality of ‘fast food’. Peer supporters then made their own burger for lunch (meat or vegetarian) to demonstrate the difference in ingredients |
| To taste different fruit and vegetables | ‘Taste trial’. Fresh fruit and vegetables were plated. Peer supporter volunteers were blindfolded and asked to guess the name of the fruit or vegetable they had tried, and describe the taste and texture |
| To emphasize the range of physical activity options | ‘A-Z’. Peer supporters were asked to think of a physical activity beginning with each letter of the alphabet |
| To understand what sedentary behaviour is and its health implications | ‘Before and after’ role plays. Sedentary behaviour (before) changed to active behaviour (after), e.g. taking the lift changed to walking the stairs |
| To consider barriers to physical activity and think of solutions | ‘Barrier wall’. A wall of cardboard box ‘bricks’ was constructed. Peer supporters were asked to think of barriers to physical activity, which were written onto the bricks. Peer supporters who thought of solutions to barriers were allowed to remove the relevant brick until the wall was demolished |
| To develop communication skills for their role | ‘Role play’. Peer supporters improvised conversations with their peers based on key messages about physical activity or healthy eating |
| To use goal setting to change health behaviour | ‘Goal setting’. Peer supporters set themselves a small challenge in relation to physical activity or healthy eating. This was revisited at the follow-up sessions |
| Support ‘follow-up sessions’ | |
| To understand the salt, sugar, fat and fibre content of various foods | A game of top trump cards. Cards display different food products. The winning card has the ‘healthiest’ level of a selected ingredient, e.g. salt, sugar, fat or fibre |
| To remind peer supporters of the importance of breakfast | A morning session with a discussion about how to make healthy choices at breakfast during which volunteers serve breakfast to their peers |
| To evaluate health promotion posters | Peer supporters complete jigsaws of current health promotion posters relating to physical activity and healthy eating, and discuss which they consider would have the greatest impact on their peers |
| To experience physical activity | Physical activity sessions including skipping, circus skills and Frisbee |
| RA | AS | HC | P | |
| HAT (ng/h/mg) | ||||
| (mean ± SEM) | 126.8 ± 16.4 | 68.2 ± 8.1 | 111.3 ± 15.5 | RA vs HC:NS* |
| AS vs HC: p=0.05* | ||||
| HDAC (pmol/min/mg) | ||||
| (mean ± SEM) | 3915.9 ±790.3 | 1984.6 ± 249.0 | 4778.9 ± 752.3 | RA vs HC:NS* |
| AS vs HC: p=0.01* | ||||
| Ratio HDAC/HAT | ||||
| (mean ± SEM) | 49.1 ± 16.7 | 35.6 ± 6.9 | 65.4 ± 16.7 | NS* |
| HAT + TSA (ng/h/mg) | ||||
| (mean ± SEM) | 153.2 ± 30.3 | 81.2 ± 9.9 | 112.6 ± 21 | HAT vs HAT + TSA**:HC:NS |
| RA: NS AS: NS | ||||
| HAT + Sirt (ng/h/mg) | ||||
| (mean ± SEM) | 113.1 ± 14.0 | 71.9 ± 6.2 | 107.9 ± 15.9 | HAT vs HAT+ Sirt** HC:NS |
| RA: p = 0.01 | ||||
| AS: NS | ||||
| HDAC + TSA (pmol/min/mg) | ||||
| (mean ± SEM) | 2457.1± 316.4 | 2134.2 ± 426.3 | 3450.6 ± 709.1 | HDAC vs HDAC + TSA** HC:NS |
| RA: NS AS: NS | ||||
| HDAC + Sirt (pmol/min/mg) | ||||
| (mean ± SEM) | 2440.6 ± 446.4 | 1975.4 ± 313.2 | 2341.6 ± 242.7 | HDAC vs HDAC + Sirt** |
| HC: p = 0.07 | ||||
| RA: NS AS: NS |
| Path | Mediator | Coeff. | SE | t | p |
| Interaction variable to mediators | Identity Compatibility | 0.12 | 0.04 | 2.93 | 0.00 |
| Identity Expression | 0.08 | 0.04 | 2.29 | 0.02 | |
| Mediators to outcome variable | Identity Compatibility | 0.24 | 0.12 | 1.96 | 0.05 |
| Identity Expression | 0.26 | 0.10 | 2.49 | 0.01 |
| Variable | B | SE | Wald | P value | Odds ratio | 95 % confidence interval for EXP(B) | |
| Lower limit | Upper limit | ||||||
| Percentage of monocytes expressing PD-L1 | 1.943 | 0.745 | 6.811 | 0.009 | 6.981 | 1.622 | 30.041 |
| Lymphocytes | 0.088 | 0.794 | 0.012 | 0.912 | 1.092 | 0.230 | 5.173 |
| SOFA score | 1.550 | 0.687 | 5.091 | 0.024 | 4.713 | 1.226 | 18.117 |
| SAPS II | 1.558 | 0.723 | 4.646 | 0.031 | 4.749 | 1.152 | 19.584 |
| Number of comorbidities | 1.887 | 0.726 | 6.761 | 0.009 | 6.598 | 1.591 | 27.352 |
| Constant | −4.133 | 0.918 | 20.256 | 0.000 | 0.016 |
| Psychological and other health measures (Denominatora) | n = 609 |
| HADs anxiety subscale (607) | |
| Normal | 316 (52.1) |
| Mild/possible case | 120 (19.8) |
| Probable/moderate/severe case | 171 (28.2) |
| HADs depression subscale (609) | |
| Normal | 392 (64.4) |
| Mild/possible case | 119 (19.5) |
| Probable/moderate/severe case | 98 (16.1) |
| Pain self-efficacy score (593), mean (SD) | 34.1 (14.6) |
| Illness perceptions questionnaire-short form (IPQ-R) | |
| Timeline-‘back/leg pain will last for a long time (agree or strongly agree) (609) | 345 (56.7) |
| Personal control-‘what I do can determine whether back/leg pain gets better (agree or strongly agree) (605) | 367 (60.7) |
| Identity score (0–7) (584), mean (SD) | 5.9 (1.3) |
| General Health (608) | |
| Excellent/very good | 146 (24.0) |
| Good | 241 (39.5) |
| Fair | 172 (28.3) |
| Poor | 50 (8.2) |
| Co-morbiditiesb(609) | |
| None | 371 (60.9) |
| One other health problem | 158 (25.9) |
| Two or more other health problems | 80 (13.1) |
| EQ—5D—3L summary index (590) | 0.44 (0.32) |
| Patient’s parameters | Low (n = 82) | High (n = 79) | P value |
| Sex, male/female | 44/38 | 54/25 | 0.075 |
| Median age, years (range) | 51.5 (10–87) | 61 (17–93) | 0.009 |
| Median WBC, × 109/L (range) | 7.7 (1.0–185.4) | 31.1 (0.3–528.0) | 0.004 |
| Median hemoglobin, g/L (range) | 75 (40–133) | 78.5 (32–144) | 0.144 |
| Median platelets, × 109/L (range) | 42 (5–447) | 33 (3–399) | 0.262 |
| Median BM blasts, % (range) | 44 (3.0–94.5) | 43 (1–99) | 0.339 |
| Karyotype classification | 0.010 | ||
| Favorable | 29 (35%) | 14 (18%) | |
| Intermediate | 37 (45%) | 55 (70%) | |
| Poor | 12 (15%) | 9 (11%) | |
| No data | 4 (5%) | 1 (1%) | |
| Karyotype | 0.048 | ||
| Normal | 28 (34%) | 42 (54%) | |
| t(8;21) | 7 (9%) | 5 (6%) | |
| t(16;16) | 0 (0%) | 1 (1%) | |
| t(15;17) | 22 (27%) | 8 (10%) | |
| t(9;22) | 0 (0%) | 1 (1%) | |
| + 8 | 3 (4%) | 4 (5%) | |
| − 5/5q− | 1 (1%) | 2 (3%) | |
| − 7/7q− | 1 (1%) | 0 (0%) | |
| Complex | 10 (12%) | 6 (8%) | |
| Others | 6 (7%) | 9 (11%) | |
| No data | 4 (5%) | 1 (1%) | |
| Gene mutation | |||
| CEBPA (+/−) | 10/66 | 7/61 | 0.617 |
| NPM1 (+/−) | 6/70 | 11/57 | 0.195 |
| FLT3-ITD (+/−) | 6/70 | 13/55 | 0.053 |
| c-KIT (+/−) | 4/72 | 1/67 | 0.370 |
| N/K-RAS (+/−) | 4/72 | 8/60 | 0.228 |
| IDH1/2 (+/−) | 2/74 | 6/62 | 0.149 |
| DNMT3A (+/−) | 2/74 | 9/59 | 0.025 |
| U2AF1 (+/−) | 3/73 | 3/65 | 1.000 |
| SRSF2 (+/−) | 3/75 | 4/66 | 0.708 |
| SETBP1 (+/−) | 1/77 | 1/69 | 1.000 |
| CR (+/−) | 40/35 | 22/52 | 0.005 |
| The Akershus Birth Cohort Study | All woman who gave birth in Norway in 2010 | |
| Mean maternal age | 31.3 years | 30.2 years |
| First time mothers | 48.9 % | 42.6 % |
| Smoking during pregnancy | 6.6 % | 7.2 % |
| Single women | 1.1 % | 9.1 % |
| Elective caesarean section | 5.0 % | 6.5 % |
| Cut-off | Mean score(95%CI) | All(n = 497) | Male(n = 217) | Female(n = 280) | 65+(n = 242) | 75+(n = 201) | 90+(n = 54) |
| ≥5 | 6.91 (6.67-7.15) | 202 (40.6%) | 69 (31.8%) | 133 (47.5%) | 99 (40.9%) | 82 (40.8%) | 21 (38.9%) |
| ≥6 | 7.57 (7.33-7.81) | 150 (30.2%) | 51 (23.5%) | 99 (35.4%) | 71 (29.3%) | 62 (30.8%) | 17 (31.5%) |
| ≥7 | 8.19 (7.94-8.44) | 108 (21.7%) | 33 (15.2%) | 75 (26.8%) | 52 (21.5%) | 43 (21.4%) | 13 (24.1%) |
| ≥8 | 8.97 (8.68-9.26) | 65 (13.0%) | 21 (9.6%) | 44 (15.7%) | 32 (13.2%) | 23 (11.4%) | 10 (18.5%) |
| Vitamin D | Vitamin D | Dyslipidemia | Overweight | |||||
| deficiency | Insufficiency | |||||||
| Adjusted | P | Adjusted | P | Adjusted | P | Adjusted | P | |
| OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | |||||
| GCrs2282679 T > G | ||||||||
| TT | 1 | 1 | 1 | 1 | ||||
| TG- GG | 3.53 (1.38 - 9.80) | 0.008 | 2.34 (1.15 - 4.90) | 0.02 | 0.41 (0.21 - 0.84) | 0.01 | 1.60 (0.70 – 3.36) | 0.20 |
| GCrs2298849 T > C | ||||||||
| CC - TC | 1 | 1 | 1 | 1 | ||||
| TT | 3.40 (1.46 - 7.89) | 0.004 | 0.82 (0.51 - 1.31) | 0.41 | 0.67 (0.40 - 1.11) | 0.12 | 1.76 (1.04 - 2.98) | 0.04 |
| NADSYN1rs12785878 G > T | ||||||||
| TT - GT | 1 | 1 | 1 | 1 | ||||
| GG | 1.72 (0.69 - 4.24) | 0.54 | 1.80 (1.12 - 2.87) | 0.01 | 1.72 (1.04 - 2.86) | 0.03 | 1.02 (0.62 - 1.69) | 0.93 |
| Patellar dislocation N = 51 | Group ANonoperatively treated patientsn = 33 | Group BPatients treated operatively during acute phasen = 7 | Group CPatients treated operatively due to recurrence n = 11 |
| Girls : boys | 16 : 17 | 4 : 3 | 9 : 2 |
| Age at injury (years)a | 13.5 ± 1.3 | 12.6 ± 2.3 | 13.3 ± 1.5 |
| Follow-up time (years)a | 7.7 ± 1.5 | 7.0 ± 1.4 | 7.3 ± 1.5 |
| Trochlear dysplasia | 67% (22 of 33) | 83% (5 of 6) | 64% (7 of 11) |
| Patella alta | 33% (11 of 33) | 33% (2 of 6) | 38% (3 of 8) |
| Subjective knee functiona | |||
| KOOS subscales at follow-upb | |||
| (i) Pain (M = 92, F = 92) | 90 ± 14 | 92 ± 8 | 86 ± 9 |
| (ii) Symptoms (M = 87, F = 89) | 82 ± 14 | 82 ± 11 | 78 ± 12 |
| (iii) Function in daily living (M = 94, F = 95) | 94 ± 12 | 97 ± 4 | 93 ± 6 |
| (iv) Sports and recreation (M = 85, F = 86) | 77 ± 24 | 79 ± 15 | 66 ± 17 |
| (v) Quality of life (M = 85, F = 84) | 69 ± 20 | 76 ± 19 | 60 ± 14 |
| Kujala score at follow-upc | 84 ± 10 | 84 ± 7 | 75 ± 15 |
| Objective knee functiona | |||
| Peak torque/body weight | |||
| (i) Extension (90 degr/s) | 187.2 ± 59.5 | 195.6 ± 57.4 | 157.9 ± 63.2 |
| M: 220 ± 43 | M: 242 ± 50 | M: 231 ± 30 | |
| F: 152 ± 56 | F: 161 ± 34 | F: 142 ± 57 | |
| (ii) Flexion (90 degr/s) | 106.3 ± 34.4 | 103.6 ± 31.7 | 113.8 ± 57.6 |
| M: 128 ± 26 | M: 124 ± 36 | M: 208 ± 77 | |
| F: 83 ± 27 | F: 88 ± 20 | F: 93 ± 26 | |
| (iii) H/Q ratioe | 0.58 ± 0.16 | 0.54 ± 0.12 | 1.03 ± 1.30 |
| LSI, peak torque in extensionf | 86 ± 17% | 89 ± 15% | 81 ± 32% |
| 30 s mini squat test injured sideg | 35 ± 15 | 36 ± 18 | 34 ± 13 |
| LSI, 30 s mini-squat testf | 93 ± 21% | 97 ± 8% | 99 ± 32% |
| Redislocation after latest treatmenth | 67% (22 of 33) | 43% (3 of 7) | 18% (2 of 11) |
| Aspira-aA | Tecnis ZCB00 | p value | |
| UDVA (logMAR) | 0.14 ± 0.13 | 0.12 ± 0.15 | 0.25 |
| CDVA (logMAR) | 0.07 ± 0.09 | 0.04 ± 0.09 | 0.22 |
| Sphere ∆ (D) | −0.22 ± 0.67 | −0.50 ± 0.52 | 0.29 |
| Depth of focus (D) | 0.61 ± 0.33 | 0.65 ± 0.29 | 0.74 |
| Corneal asphericity with a pupil size of 4 mm | 0.19 ± 0.24 | 0.26 ± 0.16 | 0.19 |
| DVH analysis: H (MCTPS, RBE = 1.1) - H (TPS, RBE = 1.1) | |||||||||
| Patient | ROI | D5 | D10 | D20 | D33 | D50 | D66 | D75 | D95 |
| A | PTV | 2,0 | 1,7 | 1,2 | 0,9 | 0,6 | 0,0 | 0,0 | -3,2 |
| Temporal lobe left | -4,1 | −2,3 | 0,0 | 0,6 | 0,9 | 0,6 | 0,6 | 0,0 | |
| Temporal lobe right | −6,7 | −3,8 | −4,4 | −1,7 | −1,5 | −1,7 | −2,0 | −0,3 | |
| Brain stem | −0,9 | −2,0 | −1,7 | −1,5 | −0,6 | 0,0 | −0,3 | 0,0 | |
| Optical system | −3,5 | −4,9 | −7,5 | −9,9 | −8,1 | −5,2 | −1,2 | 0,0 | |
| B | PTV | 1,5 | 0,9 | 0,3 | 0,6 | 0,3 | 0,3 | 0,3 | −1,8 |
| Optic nerve left | −0,9 | −1,5 | −0,3 | 0,3 | −0,3 | 0,0 | 0,0 | −0,3 | |
| Chiasma | 1,5 | 1,2 | 0,3 | −1,8 | −2,1 | 0,6 | 2,1 | 2,1 | |
| Optic nerve right | 2,1 | 1,8 | 0,9 | −0,9 | −0,6 | 0,9 | 0,6 | 0,0 | |
| Brain stem | −3,0 | −5,1 | −9,0 | −5,4 | 1,5 | 3,6 | 2,7 | 0,9 | |
| C | PTV | 0,6 | 0,6 | 0,0 | 0,3 | 0,3 | 0,6 | 0,6 | −0,9 |
| Optic nerve (right) | 1,2 | 1,5 | 1,2 | 0,6 | 0,9 | 0,9 | 0,9 | 1,8 | |
| Chiasma | 0,3 | 0,0 | −2,7 | −9,0 | −3,9 | −5,4 | −0,3 | −0,3 | |
| Brain stem | −9,6 | −7,2 | −1,5 | 0,9 | 0,3 | 0,0 | 0,0 | −0,3 | |
| D | PTV | 2,0 | 1,7 | 1,4 | 0,6 | 0,3 | 0,3 | 0,3 | 1,1 |
| Eye (left) | 1,4 | 2,2 | 3,4 | 3,6 | 3,6 | 3,1 | 2,8 | 1,4 | |
| Optic nerve (left) | −3,1 | −2,5 | −2,5 | −0,8 | 2,8 | 3,4 | 2,8 | 0,8 |
| Number of persons | Mean age (range) in years | Males/females | Smokers (non-/NA/current /ex)a | Steroid treatment (no/NA/yes)a | Non-steroidal anti-inflammatory drug (no/NA/yes)a | Mean duration of symptoms (range) in monthsb | |
| Group I | 6 | 71 (65–78) | 3/3 | 4/1/0/1 | 5/1/0 | 6/0/0 | 11 (1–24) |
| Group II | 12 | 68 (42–85) | 5/7 | 5/1/1/5 | 5/1/6 | 2/2/8 | 62 (12–150) |
| Group III | 11 | 56 (40–73) | 5/6 | 4/0/1/6 | 7/3/1 | 4/5/2 | 9 (2–18) |
| Controls | 10 | 42 (20–59) | 5/5 | 6/0/4/0 | |||
| Radiation accident victims | 3 | 38 (27–48) | 2/1 | Estimated protracted dose [10]: 2.7; 0.5; 1.0 Gy |
| Interface | Process (μm) | Supply (V) | ENOB (bits) | Area (mm2) | Power (μW) | BW (kHz) | FOM (pJ/conv) |
| [28] | 0.16 | 1.2 | 12.5 | 0.15 | 10.3 | 1.25 | 8300 |
| [29] | 0.09 | 1.0 | 10.4 | N/A | 3.0 | 1.56 | 1.4 |
| [30] | 0.35 | 3.0 | 9.3 | 0.09 | 54.0 | 12.60 | 3.4 |
| [32] | 0.32 | 3.0 | 9.8 | 0.52 | 84.0 | 2.60 | 4.5 |
| [34] | 0.18 | 0.5 | 7.2 | 0.01 | 1.1 | 2.34 | 1.6 |
| This work | 0.18 | 0.8 | 7.4 | 0.01 | 0.8 | 2.17 | 1.5 |
| Cut-off | Sensitivity | Specificity | Positive predictive value | Negative predictive value | |
| CRP (mg/L) | ≥28 | 100.00 | 97.37 | 97.40 | 100.00 |
| Fibrinogen (mg/dL) | ≥480 | 89.47 | 92.11 | 91.90 | 89.70 |
| IL-6 (pg/mL) | ≥105.8 | 76.32 | 94.74 | 93.50 | 80.00 |
| ESR (mm/h) | ≥42 | 73.68 | 84.21 | 82.40 | 76.20 |
| WBC (103 μ/L) | ≥11.6 | 71.05 | 90.70 | 87.10 | 78.00 |
| DNA amount [μg] | Plus reagent [μl] | Ratio lipid to DNA | Quality | Cells in suspension | Fluor. intensity | Transfection efficiency [%] |
| 0.25 | 0.25 | 1.0:1 | 1 | 0 | + | 0.6 |
| 2.0:1 | 2 | 0 | + | 0.5 | ||
| 2.5:1 | 2 | 0 | + | 3.1 | ||
| 3.0:1 | 2 | 0 | + | 3.8 | ||
| 4.0:1 | 4 | 0 | ++ | 26 | ||
| 0.5 | 0.5 | 1.0:1 | 2 | 0 | + | 2.6 |
| 2.0:1 | 4 | 1 | + | 26 | ||
| 2.5:1 | 3 | 1 | ++ | 50 | ||
| 3.0:1 | 5 | 2 | ++ | 52 | ||
| 0.5 | 1.0 | 2.5:1 | 4 | 1 | ++ | 24 |
| 3.0:1 | 4 | 2 | ++ | 45 | ||
| 0.75 | 0.75 | 1.0:1 | 4 | 0 | ++ | 28 |
| 2.0:1 | 5 | 1 | ++ | 37 | ||
| 2.5:1 | 5 | 1 | ++ | 28 | ||
| 3.0:1 | 5 | 1 | ++ | 21 |
| Primary outcome measures | Generic quality of life | SF-36 |
| Functional health status | FIM | |
| Secondary outcome measures | Anxiety and depression | HADS |
| Cognitive functioning | MMSE | |
| Extent to which individual ADL treatment goals are met | COPM | |
| Note: Costs will be assessed using the PRODISQ, a cost questionnaire and hospital database data |
| Age (years) | Influenza A | Influenza B | ||||
| Positive | Equivocal | Negative | Positive | Equivocal | Negative | |
| <3 | 13.0 (9) | 5.8 (4) | 81.1 (56) | 14.5 (10) | 5.8 (4) | 79.7 (55) |
| 3–4 | 9.7 (6) | 6.4 (4) | 83.9 (52) | 25.8 (16) | 4.8 (3) | 69.3 (43) |
| 4–5 | 14.9 (7) | 8.5 (4) | 76.6 (36) | 27.7 (13) | 10.6 (5) | 61.7 (29) |
| 5–6 | 18.7 (9) | 6.2 (3) | 75.0 (36) | 33.3 (16) | 14.6 (7) | 52.1 (25) |
| 6–12.5 | 24.1 (14) | 10.3 (6) | 65.5 (38) | 58.6 (34) | 13.8 (8) | 27.6 (16) |
| All | 15.8 (45) | 7.4 (21) | 76.7 (218) | 31.3 (89) | 9.5 (27) | 59.1 (168) |
| 2011 | 2012 | 2013 | 2014 | 2015 | ||||||
| Odds Ratio (95% CI) | Odds Ratio (95% CI) | Odds Ratio (95% CI) | Odds Ratio (95% CI) | Odds Ratio (95% CI) | ||||||
| Model 4 | ||||||||||
| women (ref) | - | 1 | 1 | 1 | 1 | |||||
| men | - | 0.99 (0.68–1.46) | ns | 1.08 (0.71–1.64) | ns | 1.57 (1.03–2.39) | * | 1.21 (0.81–1.81) | ns | |
| 20–29 | - | 1 | 1 | 1 | 1 | |||||
| 30–39 | - | 1.73 (0.81–3.67) | ns | 1.19 (0.54–2.63) | ns | 2.12 (0.97–4.65) | ns | 2.24 (0.98–5.15) | ns | |
| 40–49 | - | 1.82 (0.84–3.94) | ns | 2.30 (1.02–5.19) | * | 2.56 (1.16–5.66) | * | 2.62 (1.17–5.89) | * | |
| 50–59 | - | 2.53 (1.19–5.34) | * | 2.80 (1.26–6.23) | * | 3.41 (1.55–7.51) | ** | 2.55 (1.16–5.61) | * | |
| 60 or over | - | 3.39 (1.70–6.77) | *** | 2.76 (1.36–5.61) | ** | 3.80 (1.91–7.55) | *** | 4.02 (1.96–8.25) | *** | |
| mountainous area (ref) | - | 1 | 1 | 1 | 1 | |||||
| central area | - | 0.69 (0.38–1.23) | ns | 0.57 (0.28–1.16) | ns | 0.85 (0.45–1.59) | ns | 0.60 (0.32–1.13) | ns | |
| coastal area other than EOAs | - | 0.90 (0.45–1.78) | ns | 0.57 (0.25–1.28) | ns | 0.90 (0.44–1.84) | ns | 0.57 (0.28–1.16) | ns | |
| EOAs | - | 0.90 (0.34–2.36) | ns | 0.89 (0.29–2.80) | ns | 0.98 (0.38–2.52) | ns | 0.75 (0.26–2.17) | ns | |
| Q1 (relief regarding regional disasters) | - | 1.02 (0.66–1.58) | ns | 0.95 (0.61–1.48) | ns | 1.02 (0.67–1.55) | ns | 1.10 (0.73–1.65) | ns | |
| Q2 (relief regarding of radiation) | - | 0.70 (0.44–1.10) | ns | 1.53 (0.92–2.56) | ns | 1.35 (0.85–2.15) | ns | 1.06 (0.69–1.61) | ns | |
| Q3 (familiarity with the medical service) | - | 1.10 (0.67–1.80) | ns | 1.76 (1.06–2.91) | * | 1.16 (0.70–1.92) | ns | 1.52 (0.88–2.63) | ns | |
| Q4 (familiarity with the welfare service) | - | 1.49 (0.97–2.28) | ns | 1.40 (0.87–2.26) | ns | 1.92 (1.21–3.06) | ** | 1.18 (0.72–1.94) | ns | |
| Q5 (evaluation of prefectural reconstruction) | - | 1.36 (0.78–2.36) | ns | 1.00 (0.55–1.82) | ns | 0.68 (0.41–1.11) | ns | 0.80 (0.52–1.23) | ns | |
| Q6 (bonds with other local people) | - | 0.93 (0.62–1.39) | ns | 1.94 (1.26–3.00) | ** | 1.09 (0.71–1.66) | ns | 1.46 (0.97–2.21) | ns |
| Variable | Coefficient | Standard error | P-value | Relative risk (95% CI) |
| Disease-free survival | ||||
| AST (>50 IU/L) | 0.381 | 0.136 | 0.016 | 1.379 (1.062 to 1.789) |
| Liver cirrhosis | 0.296 | 0.119 | 0.043 | 1.292 (1.009 to 1.654) |
| Perioperative transfusion | 0.301 | 0.118 | 0.008 | 1.386 (1.090 to 1.763) |
| Multiple tumors | 0.553 | 0.134 | 0.013 | 1.564 (1.097 to 2.230) |
| Microvascular invasion | 0.382 | 0.128 | < 0.001 | 1.604 (1.255 to 2.050) |
| Edmondson-Steiner grade III to IV | 0.321 | 0.131 | 0.014 | 1.379 (1.066 to 1.784) |
| Overall survival | ||||
| Serum albumin (≤3.5 g/dL) | 0.587 | 0.166 | < 0.001 | 1.798 (1.298 to 2.490) |
| Platelet count (≤100,000/mm3) | 0.442 | 0.167 | 0.008 | 1.557 (1.122 to 2.161) |
| Perioperative transfusion | 0.477 | 0.140 | 0.001 | 1.610 (1.224 to 2.118) |
| Perioperative morbidity | 0.353 | 0.143 | 0.013 | 1.423 (1.076 to 1.883) |
| Tumor size (>3 cm) | 0.313 | 0.154 | 0.043 | 1.367 (1.010 to 1.850) |
| Multiple tumors | 0.679 | 0.147 | < 0.001 | 1.973 (1.478 to 2.633) |
| Macrovascular invasion | 0.581 | 0.227 | 0.011 | 1.789 (1.145 to 2.793) |
| Edmondson-Steiner grade III to IV | 0.419 | 0.147 | 0.004 | 1.521 (1.141 to 2.028) |
| 12-month falls recall | Daily calendar | ||
| Falls, N (%) | No falls, N (%) | ||
| Falls | 692 (77%) | 70 (6%) | 762 |
| No falls | 206 (23%) | 1128 (94%) | 1334 |
| 898 | 1198 | 2096 |
| Inclusion criteria | Exclusion criteria |
| Age ≥ 18 years | History of previous major hepatic surgery (i.e. more than three liver segments) or biliary major surgery (except gall-bladder surgery by laparoscopy if more than 6 months previously) |
| Patients with liver metastases requiring a hepatectomy of ≥ 2 segments | Patients with cirrhosis or sinusoidal obstruction syndrome with portal hypertension |
| Eastern Cooperative Oncology Group performance status ≤ 1 | Pregnant women |
| Adequate bone marrow and liver function at baseline (defined by platelet count ≥ 100 × 109/L, and haemoglobin of ≥ 9 g/dL, and total bilirubin ≤ 1.5 × upper limit of normal, and transaminases ≤ 5× upper limit of normal) | |
| Recovered from prior anti-neoplasic treatment-related toxicity (grade <2 persistent treatment-related toxicity as per Common Terminology Criteria for Adverse Events v4 are accepted | |
| Willingness for follow-up visits | |
| Covered by a medical insurance | |
| Signed and dated informed consent indicating that the patient has been informed of all aspects of the trial prior to enrolment |
| First comprehension test(n = 30) | Second comprehension test(n = 35) | |
| Items | Patients reporting difficulties in understanding items (%) | Patients reporting difficulties in understanding items (%) |
| 4 | 6.7 | 0 |
| 9 | 6.7 | 0 |
| 15 | 0 | 5.7 |
| Patients reporting difficulties in understanding questions (%) | Patients reporting difficulties in understanding questions (%) | |
| Demographic 1 | 30.0 | 0 |
| Demographic 3 | 13.3 | 0 |
| Demographic 4 | 6.7 | 0 |
| Variable | β | Std error | p-value | Exp β | 95% CI for exp β |
| Age | 0.003 | 0.016 | 0.856 | 0.997 | 0.996–1.029 |
| Literate | –0.248 | 0.482 | 0.607 | 0.781 | 0.304–2.008 |
| NYHA | 0.236 | 0.510 | 0.664 | 1.266 | 0.446–3.440 |
| SBP | 0.002 | 0.008 | 0.809 | 1.002 | 0.986–1.018 |
| Creatinine | 0.272 | 0.793 | 0.732 | 1.312 | 0.227–6.209 |
| Congestion score | 0.005 | 0.019 | 0.012 | 1.007 | 0.976–1.021 |
| 1 | F 5′-TATAGGTACCAATTTATGGCAGTCATTA-3′ | Amplification |
| 2 | R 5′-ATATGAGCTCGCTGGCCCGTGGCTGGAT-3′ | |
| 3 | S 5′-GTCCTTTTCTAGTGTATTGTGTTTGTTAATATTTG-3′ | A→G |
| 4 | Compl 5′-CAAATATTAACAAACACAATACACTAGAAAAGGAC-3′ | |
| 5 | S 5′-GCTCCCACTAATGTGGTATTTAACTTTTGAAAGATCTTTAG-3′ | NFκB (−1537) |
| 6 | Compl 5′-CTAAAGATCTTTCAAAAGTTAAATACCACATTAGTGGGAGC-3′ | |
| 7 | S 5′-GCTTTAAATAATTCTACAATATTTTGTGTATTTTGC-3′ | HNF-3 |
| 8 | Compl 5′-GCAAAATACACAAAATATTGTAGAATTATTTAAAGC-3′ | |
| 9 | S 5′-CAGAAAATATCGGTAATAAAAAAAGTTAAAGATCTTC-3′ | Pou-IV |
| 10 | Compl 5′-GAAGATCTTTAACTTTTTTTATTACCGATATTTTCTG-3′ | |
| 11 | S 5′-GGAGGCTCCCTCCCCCCCCTCCAGCGC-3′ | Sp1 (−236) |
| 12 | Compl 5′-GCGCTGGAGGGGAGGGAGGGAGCCTCC-3′ | |
| 13 | S 5′-GACCCGGCGCAGCACACCAACCGCGAGCAGAAC-3′ | Ets |
| 14 | Compl - 5′-GTTCTGCTCGCGGTTGGTGTGCTGCGCCGGGTC-3′ | |
| 15 | S 5′-CGCTGCGGGCGCTTGCTGCCAGAACCTTG-3′ | Sp1 (−124) |
| 16 | Compl 5′-CAAGGTTCTGGCAGCAAGCGCCCGCAGCG-3′ | |
| 17 | S 5′-CTTAAAGCACAGCCCATCACAGTTTTCATCCAGC-3′ | NFκB (−40) |
| 18 | Compl 5′-GCTGGATGAAAACTGTGATGGGCTGTGCTTTAA-3′ |
| Kappa | % Agreement | Interpretation (Landis and Koch [21]) | |
| DSM-IV | |||
| BN | 0.66 | 99% | Substantial |
| BED | 0.46 | 92% | Moderate |
| EDNOS | 0.55 | 86% | Moderate |
| DSM-5 | |||
| BN | 0.66 | 99% | Substantial |
| BED | 0.42 | 91% | Moderate |
| OSFED | |||
| Sub-BED | 0.48 | 96% | Moderate |
| PD | −0.01 | 97% | Poor |
| NES | 0.14 | 91% | Poor |
| Other | 0.59 | 94% | Moderate |
| Home | Number of Occupant | Baby Age | Shared Room | Average Temp. of the Environment |
| Home 1 | 3 | 8 months | No | 21° |
| Home 2 | 5 | 10 months | Yes | 22.5° |
| Home 3 | 4 | 14 months | No | 19° |
| Home 4 | 3 | 3 months | No | 20.5° |
| Home 5 | 6 | 9 months | Yes | 24.5° |
| Analyte | LOD a (μg/mL) | LOQ b (μg /mL) | Rec. c (%) | ME d (%) | Conc. Range e (μg /mL) | (r2) f |
| retinol | 0.002 | 0.005 | 102.6 ± 8.9 | 108.5 ± 9.1 | 0.005–10 | 0.990 |
| 25-hydroxycholecalciferol | 0.003 | 0.011 | 92.0 ± 3.2 | 87.3 ± 1.4 | 0.011–5 | 0.995 |
| retinol acetate | 0.002 | 0.008 | 103.4 ± 1.5 | 95.1 ± 1.7 | 0.008–10 | 0.995 |
| α-tocotrienol | 0.113 | 0.376 | 99.0 ± 5.3 | 89.9 ± 3.4 | 0.376–5 | 0.992 |
| cholecalciferol | 0.005 | 0.018 | 102.9 ± 2.9 | 89.6 ± 1.3 | 0.018–10 | 0.998 |
| astaxanthin | 0.001 | 0.003 | 102.3 ± 2.6 | 100.1 ± 3.3 | 0.003–1 | 0.995 |
| lutein | 0.008 | 0.028 | 86.1 ± 1.4 | 91.0 ± 2.0 | 0.028–10 | 0.992 |
| zeaxanthin | 0.422 | 1.406 | 86.2 ± 2.2 | 86.9 ± 3.2 | 1.406–10 | 0.992 |
| cantaxanthin | 0.002 | 0.006 | 100.1 ± 2.5 | 103.5 ± 8.0 | 0.006–1 | 0.992 |
| E-β-apo-8′-carotenal | 0.003 | 0.010 | 103.6 ± 2.1 | 100.4 ± 1.4 | 0.010–10 | 0.994 |
| cryptoxanthin | 0.244 | 0.812 | 104.8 ± 3.2 | 94.0 ± 2.3 | 0.812–10 | 0.993 |
| 13-Z-β-carotene | 0.056 | 0.187 | 100.6 ± 2.0 | 87.8 ± 1.0 | 0.187–10 | 0.992 |
| α-carotene | 0.022 | 0.073 | 104.2 ± 5.4 | 102.8 ± 3.9 | 0.073–5 | 0.994 |
| β-carotene | 0.041 | 0.138 | 101.1 ± 2.2 | 95.7 ± 5.3 | 0.138–5 | 0.999 |
| 9-Z-β-carotene | 0.293 | 0.975 | 97.4 ± 6.7 | 91.5 ± 2.4 | 0.975–10 | 0.996 |
| 5-Z-lycopene | 0.189 | 0.631 | 104.6 ± 8.2 | 96.5 ± 3.3 | 0.631–10 | 0.998 |
| Variables | Unadjusted odds ratio (95% CI) | P-value | Adjusted odds ratio (95% CI) | P-value |
| Age* | ||||
| 6-19 (reference) | ||||
| 20-39 | 2.87 (1.98,4.16) | 0.001 | 1.85 (1.00,3.43) | 0.050 |
| 40-59 | 2.75 (1.67,4.52) | 0.001 | 1.83 (1.03,3.25) | 0.042 |
| Sex | ||||
| Males (reference) | ||||
| Females | 1.36 (1.09,1.69) | 0.011 | 1.47 (1.10,1.97) | 0.015 |
| Immigrant status | ||||
| Non-Immigrant (reference) | ||||
| Immigrant | 1.15 (0.76,1.75) | 0.479 | 1.43 (1.05,1.95) | 0.028 |
| Education | ||||
| > High school (reference) | ||||
| < High school | 0.63 (0.39,1.04) | 0.068 | 0.65 (0.05,0.82) | 0.002 |
| Employment status | ||||
| Full-time employed (reference) | ||||
| Part-time employed | 1.01 (0.52,1.97) | 0.964 | 1.37 (0.85,2.22) | 0.176 |
| Unemployed | 0.83 (0.66,1.05) | 0.104 | 1.23 (0.96,1.57) | 0.094 |
| Income | ||||
| Higher (reference) | ||||
| Upper middle | 2.05 (1.58,2.66) | 0.001 | 1.61 (1.25,2.08) | 0.002 |
| Lower middle | 3.74 (2.49,5.60) | 0.001 | 2.95 (1.69,5.15) | 0.001 |
| Lower | 4.21 (2.73,6.50) | 0.001 | 2.64 (1.59,4.38) | 0.001 |
| Insurance | ||||
| Private (reference) | ||||
| Public | 1.81 (0.99,3.30) | 0.054 | 1.21 (0.49,2.97) | 0.655 |
| None | 3.08 (2.39,3.99) | 0.001 | 2.35 (1.62,3.40) | 0.001 |
| Self-reported oral health | ||||
| Good to excellent (reference) | ||||
| Fair to poor | 4.11 (3.18,5.3) | 0.001 | 3.04 (2.34,3.94) | 0.001 |
| Oral health | ||||
| D (decayed teeth) | 1.09 (1.02,1.17) | 0.018 | 1.20 (1.13,1.28) | 0.001 |
| M (missing teeth) | 1.04 (0.99,1.10) | 0.140 | 1.07 (1.05,1.1) | 0.001 |
| Sl no. P.I. | year | State/UT | Setting | Age group | N | Prev. (%) |
| 1. Jiloha [72] | 1981 | Haryana | rural | 5-12 | 715 | 20.7 |
| Used questionnaire (t) and reporting questionnaire for children (p), clinical interview. Diagnosis was made as per ICD-9. | ||||||
| 2. Devsigamani [22] | 1990 | TN | urban | 8-12 | 755 | 33.7 |
| Rutter B scale was used as a screening instrument and diagnosis was made as per ICD- 9 after clinical interview. | ||||||
| 3. Mehta [74] | 1997 | WB | rural | 8-10 | 8-10 | 460 |
| Rutter B scale (Hindi adaptation), Malin’s test of verbal intelligence, VSMS, Gessell’s drawing test were used. Diagnosis was made as per DSM-III-R. | ||||||
| 4. Banerjee [75] | 1997 | WB | rural | 8-10 | 460 | 33.33 |
| Rutter’s B scale was used as screening instrument and ICD-9 was used to make the diagnosis | ||||||
| 5. Gupta [73] | 2001 | Punjab | urban | 9-11 | 957 | 45.6 |
| Rutter’s B scale was used as screening instrument and ICD-10 was used to make the diagnosis | ||||||
| 6. Malhotra [76] | 2002 | Chandigarh | urban | 4-11 | 963 | 6.33 |
| Rutter B scale, pre-school behaviour checklist, Childhood Psychopathology Measurement Schedule was used. Diagnosis was made as per ICD-10. | ||||||
| 7. Bansal [77] | 2011 | Punjab | urban | 10-15 | 982 | 20.2 |
| Childhood Psychopathology Measurement Schedule was used and Diagnosis was made as per ICD-10. |
| BUN(mg/dL) | Creatinine(mg/dL) | Na+(mEq/L) | K+(mEq/L) | Cl−(mEq/L) | HCO3−(mEq/L) | |
| Saline/Control | 24.7 ± 1 | 0.25 ± 0 | 147.3 ± 1 | 3.8 ± 0 | 94.1 ± 1 | 22.7 ± 0 |
| BC-NE | 40.1 ± 1* | 0.45 ± 0 | 135.8 ± 5 | 7.9 ± 1* | 90.7 ± 4 | 23.7 ± 0 |
| BC-S | 44.3 ± 3* | 0.53 ± 0* | 132.5 ± 4* | 10.3 ± 2* | 89.5 ± 3 | 18.5 ± 2 |
| No. of lines | Common genes | Mean expression | Median expression |
| 1 | 47 | 131.28 | 8.05 |
| 2 | 70 | 16.34 | 3.93 |
| 3 | 64 | 190.57 | 2.51 |
| 4 | 104 | 11.32 | 2.17 |
| 5 | 107 | 5.58 | 1.48 |
| 6 | 155 | 24.31 | 1.26 |
| 7 | 348 | 4.52 | 1.10 |
| 8 | 975 | 28.30 | 0.85 |
| 9 | 31909 | 19.93 | 3.65 |
| Year | Total sniffers | Sniffer prevalence rate per 1000 population | ||
| Median | Inter-quartile range | Range (Min-Max) | ||
| 2006 | 604 | 141.6 | 70.1–180.0 | 31.4–307.3 |
| 2008 | 265 | 10.4 | 0–71.4 | 0–196.9 |
| 2012 | 93 | 3.7 | 0–11.1 | 0–186.6 |
| 2014 | 66 | 5.5 | 0–20.8 | 0–48.5 |
| PDB | Ag size | Epitope prediction | Random | ||||||
| EpiPred | DiscoTope 2.0 | ||||||||
| Precision (%) | Recall (%) | MCC | Precision (%) | Recall (%) | MCC | Precision (%) | Recall (%) | ||
| 4hj0 | 92 | 32 | 90 | 0.27 | 0 | 0 | 0.0 | 29 | 50 |
| 1tzh | 94 | 1 | 6 | 0.04 | 73 | 87 | 0.72 | 12 | 25 |
| 4am0 | 96 | 13 | 70 | 0.09 | 33 | 20 | 0.19 | 14 | 60 |
| 2ih3 | 97 | 16 | 64 | 0.08 | 0 | 0 | 0.0 | 15 | 27 |
| 4i77 | 97 | 23 | 55 | 0.0 | 0 | 0 | 0.0 | 21 | 31 |
| 3q1s | 113 | 19 | 81 | 0.15 | 0 | 0 | 0.0 | 20 | 37 |
| 1p2c | 129 | 0 | 0 | 0.0 | 100 | 5 | 0.0 | 39 | 32 |
| 4ht1 | 131 | 5 | 14 | 0.05 | 0 | 0 | 0.0 | 28 | 44 |
| 3ab0 | 136 | 33 | 73 | 0.34 | 0 | 0 | 0.0 | 33 | 52 |
| 1v7m | 145 | 26 | 77 | 0.29 | 0 | 0 | 0.0 | 9 | 16 |
| 4g3y | 148 | 3 | 8 | 0.04 | 100 | 17 | 0.33 | 11 | 25 |
| 2vxt | 156 | 4 | 9 | 0.04 | 47 | 36 | 0.3 | 14 | 23 |
| 3u9p | 169 | 31 | 100 | 0.47 | 6 | 5 | 0.0 | 8 | 15 |
| 3o2d | 178 | 32 | 64 | 0.28 | 0 | 0 | 0.0 | 9 | 16 |
| 1fns | 196 | 0 | 0 | 0.0 | 100 | 7 | 0.0 | 33 | 11 |
| 3ma9 | 197 | 0 | 0 | 0.0 | 0 | 0 | 0.0 | 21 | 33 |
| 3rvv | 223 | 25 | 93 | 0.39 | 15 | 17 | 0.07 | 6 | 15 |
| 3raj | 230 | 0 | 0 | 0.0 | 0 | 0 | 0.0 | 24 | 21 |
| 1nfd | 239 | 7 | 23 | 0.04 | 92 | 70 | 0.75 | 10 | 15 |
| 3i50 | 273 | 0 | 0 | 0.0 | 0 | 0 | 0.0 | 1 | 6 |
| 3gjf | 276 | 15 | 66 | 0.2 | 5 | 11 | 0.05 | 6 | 15 |
| 3liz | 329 | 26 | 68 | 0.34 | 0 | 0 | 0.0 | 10 | 15 |
| 3pgf | 358 | 2 | 4 | 0.0 | 0 | 0 | 0.0 | 13 | 18 |
| 3zkm | 375 | 32 | 88 | 0.46 | 0 | 0 | 0.0 | 11 | 15 |
| 3r1g | 381 | 37 | 100 | 0.57 | 0 | 0 | 0.0 | 7 | 9 |
| 4jr9 | 409 | 19 | 85 | 0.34 | 46 | 50 | 0.46 | 4 | 11 |
| 4ene | 442 | 0 | 0 | 0.0 | 0 | 0 | 0.0 | 1 | 5 |
| 3o0r | 449 | 8 | 70 | 0.19 | 0 | 0 | 0.0 | 2 | 14 |
| 3t3p | 453 | 0 | 0 | 0.0 | 25 | 4 | 0.0 | 4 | 6 |
| 1n8z | 581 | 0 | 0 | 0.0 | 0 | 0 | 0.0 | 6 | 5 |
| Floors | 0 | 1 | 2 | 3 | 4 | 5 |
| Real floor altitude (m) | 0 | 5.3 | 10.68 | 15.05 | 19.47 | 24.41 |
| Estimated floor altitude (m) | 0 | 4.81 | 10.03 | 14.48 | 18.86 | 23.74 |
| Error | 0 | 0.48 | 0.65 | 0.57 | 0.61 | 0.66 |
| Family | Sire | Dam | M | F | M:F | LG5-14 Y p | LG13 Y p | LG13 W p | System |
| RAD 1 | 1 | 1 | 12 | 12 | 0.50 | 0.6843 | NI | 0.0001 | LG13 ZW |
| RAD 2 | 2 | 2 | 9 | 8 | 0.53 | 0.0023 | 0.6199 | 1 | LG5-14 XY |
| 1 | 1 | 1 | 10 | 36 | 0.22 | 0.1639 | NI | 0.0012 | LG13 ZW |
| 2 | 3 | 3 | 8 | 8 | 0.50 | 0.0087 | NI | 0.0001 | LG13 ZW |
| 3 | 3 | 3 | 9 | 8 | 0.53 | 0.3469 | NI | 0.0152 | LG13 ZW |
| 4 | 4 | 4 | 6 | 26 | 0.19 | NI | NI | 0.0192 | LG13 ZW |
| 5 | 5 | 5 | 4 | 6 | 0.40 | 1 | 0.5714 | 0.0048 | LG13 ZW |
| 6 | 6 | 6 | 4 | 10 | 0.29 | 0.2208 | 1 | 0.015 | LG13 ZW |
| 7 | 6 | 7 | 10 | 9 | 0.53 | 0.1534 | NI | 0.009 | LG13 ZW |
| 8 | 7 | 8 | 2 | 13 | 0.13 | 1 | 0.0128 | NI | LG13 XY |
| 9 | 7 | 9 | 16 | 22 | 0.42 | 0.72 | 0.0001 | 0.752 | LG13 XY |
| 10 | 8 | 10 | 12 | 14 | 0.46 | 0.0001 | 0.2177 | 1 | LG5-14 XY |
| 11 | 8 | 11 | 12 | 10 | 0.55 | 0.003 | 0.0092 | 0.6914 | LG5-14 XY |
| 12 | 8 | 12 | 15 | 11 | 0.58 | 0.0001 | 0.4283 | 0.4279 | LG5-14 XY |
| 13 | 8 | 13 | 12 | 7 | 0.63 | 0.0002 | 0.3261 | 0.3498 | LG5-14 XY |
| 14 | 8 | 14 | 4 | 2 | 0.67 | 0.0667 | 0.4 | 1 | LG5-14 XY |
| 15 | 9 | 15 | 12 | 10 | 0.55 | 0.0015 | 0.3246 | 0.1312 | LG5-14 XY |
| 16 | 9 | 16 | 13 | 8 | 0.62 | 0.0237 | NI | 0.2031 | LG5-14 XY |
| 17 | 9 | 17 | 15 | 8 | 0.65 | 0.0083 | 0.2213 | NI | LG5-14 XY |
| 18 | 10 | 18 | 11 | 5 | 0.69 | 0.0256 | 0.5962 | 1 | LG5-14 XY |
| 19 | 11 | 19 | 5 | 4 | 0.56 | 0.444 | 0.0079 | NI | LG13 XY + LG5-14 XY |
| 20 | 12 | 20 | 9 | 11 | 0.45 | 1 | 1 | 0.1789 | Unknown |
| 21 | 6 | 21 | 12 | 26 | 0.32 | 0.6792 | 0.2305 | NI | Unknown |
| 22 | 13 | 22 | 7 | 9 | 0.44 | 0.3024 | 0.1262 | 0.3147 | Unknown |
| 23 | 13 | 23 | 14 | 17 | 0.45 | 1 | 1 | 0.4809 | Unknown |
| 24 | 13 | 24 | 20 | 23 | 0.47 | 0.3652 | 0.7619 | 0.0755 | Unknown |
| 25 | 13 | 25 | 22 | 20 | 0.52 | 0.3783 | 0.0414 | 1 | Unknown |
| Cognitive domain | Age group | Standardised mean difference (95% CI) | Number of participants/studies | Heterogeneity - I2 test |
| Attention & concentration | Children aged 6-18 | 0.62 (0.26 to 0.98)* | 132/2 (4 arms)** | 0% |
| Pre-menopausal women | 0.53 (-0.06 to 1.12) | 47/1 | Not relevant | |
| Intelligence | Children aged 6-18 | 0.02 (-0.22 to 0.27) | 2289/4 (9 arms)** | 82% |
| Pre-menopausal women | 0.62 (0.15 to 1.10)* | 76/2 | 0% | |
| Memory | Children aged 6-18 | 0.33 (-0.19 to 0.85) | 132/2 (4 arms)** | 35% |
| Pre-menopausal women | 0.09 (-0.31 to 0.50) | 123/3 | 18% | |
| Psychomotor | Children aged 6-18 | 0.19 (-0.17 to 0.54) | 132/2 (4 arms)** | 0% |
| Pre-menopausal women | 0.09 (-0.32 to 0.50) | 123/3 | 21% | |
| Scholastic aptitude | Children aged 6-18 | 0.03 (-0.63 to 0.69) | 1799/3 (6 arms)** | 96% |
| Pre-menopausal women | 0.77 (-0.08 to 1.62) | 25/1 | Not relevant |
| Marshall score | n (%) |
| 1 No visible intracranial pathology | 14 (13) |
| 2 Cisterns present with midline shift 0-5 mm; no high or mixed density lesion > 25 ml. | 36 (32) |
| 3 Cisterns compressed or absent with midline shift 0-5 mm. | 43 (39) |
| 4 Midline shift > 5 mm;or surgically evacuated lesion;and non-evacuated high or mixed density lesion >25 ml | 18 (16) |
| Index | Source | df | F | P |
| Sward height | W | 1,12 | 3.26 | 0.096 |
| G | 1,12 | 49.33 | <0.001* | |
| W × G | 1,12 | 0.64 | 0.438 | |
| Sward coverage | W | 1,12 | 0.95 | 0.348 |
| G | 1,12 | 15.86 | 0.002* | |
| W × G | 1,12 | 0.11 | 0.751 | |
| Plant litter mass | W | 1,12 | 1.06 | 0.323 |
| G | 1,12 | 35.61 | <0.001* | |
| W × G | 1,12 | 12.17 | 0.004* | |
| N in graminoids | W | 1,12 | 4.01 | 0.068 |
| G | 1,12 | 60.13 | <0.001* | |
| W × G | 1,12 | 0.53 | 0.483 | |
| Larval growth rate | W | 1,12 | 2.76 | 0.122 |
| G | 1,12 | 25.38 | <0.001* | |
| W × G | 1,12 | 2.71 | 0.126 | |
| Pupal weight | Sex | 1,155 | 343.92 | <0.001* |
| W | 1,155 | 2.10 | 0.149 | |
| G | 1,155 | 33.29 | <0.001* | |
| W × G | 1,155 | 0.001 | 0.983 | |
| Potential fecundity | W | 1,77 | 2.33 | 0.131 |
| G | 1,77 | 21.06 | <0.001* | |
| W × G | 1,77 | 0.01 | 0.931 | |
| Overwintering survival rate | W | 1,12 | 0.001 | 0.977 |
| G | 1,12 | 2.27 | 0.158 | |
| W × G | 1,12 | 0.20 | 0.666 | |
| Pupal density | W | 1,12 | 0.97 | 0.345 |
| G | 1,12 | 33.51 | <0.001* | |
| W × G | 1,12 | 1.44 | 0.254 | |
| Reduction in AGB | W | 1,12 | 2.48 | 0.142 |
| G | 1,12 | 163.30 | <0.001* | |
| W × G | 1,12 | 7.33 | 0.019* | |
| Reduction in graminoid cover | W | 1,12 | 0.42 | 0.530 |
| G | 1,12 | 91.35 | <0.001* | |
| W × G | 1,12 | 2.83 | 0.119 |
| Condition | Rest | Exercise | Recovery | |
| IL-2 | Normoxia | 2.80 ± 0.93 | 4.62 ± 1.62 | 4.40 ± 3.13 |
| Hypoxia | 1.74 ± 1.18 | 3.14 ± 1.30 | 0.73 ± 0.54 | |
| Hypoxia + Carbo | 0.14 ± 0.20 | 0.39 ± 0.54 | 3.60 ± 4.65 a,b | |
| IL-4 | Normoxia | 1.39 ± 1.08 | 0.63 ± 0.48 | 0.42 ± 0.24 |
| Hypoxia | 0.84 ± 0.94 | 0.41 ± 0.24 | 1.39 ± 2.42 | |
| Hypoxia + Carbo | 0.63 ± 0.30 | 0.38 ± 0.20 | 0.52 ± 0.48 | |
| IL-2/IL-4 | Normoxia | 3.50 ± 0.3 | 11.25 ± 7.82 | 13.11 ± 11.54 |
| Hypoxia | 3.49 ± 0.24 | 9.20 ± 5.37 | 2.06 ± 2.05 | |
| Hypoxia + Carbo | 0.21 ± 0.22 c,d | 1.25 ± 1.75 | 11.84 ± 15.38 a,b |
| Variable | B coefficient | HR | CI 95% | P value |
| Risk factors | ||||
| TLS | 0.509 | 1.663 | 1.124–2.462 | 0.011 |
| LFT ≥2.5 UNL | 0.490 | 1.663 | 1.147–2.325 | 0.007 |
| Protective factors | ||||
| Early CR | −1.227 | 0.293 | 0.204–0.421 | 0.0001 |
| Allogenic HSCT | −0.709 | 0.492 | 0.292–0.828 | 0.008 |
| Platelets | −0.004 | 0.996 | 0.995–0.998 | 0.0001 |
| Study site | Latitude | Longitude |
| Aimi (Ai) | 35°20.9′ N | 133°24.2′ E |
| Nawa (Nw) | 35°30.0′ N | 133°30.5′ E |
| Nakayama (Nk) | 35°30.7′ N | 133°33.9′ E |
| Akasaki (Ak) | 35°27.8′ N | 133°38.3′ E |
| Tohaku (Th) | 35°29.3′ N | 133°39.2′ E |
| Kurayoshi (Ku) | 35°23.4′ N | 133°44.7′ E |
| Togo (Tg) | 35°28.0′ N | 133°55.1′ E |
| Yura (YuA, YuB)* | 35°28.5′ N | 133°44.5′ E |
| Otsuka (Ot) | 35°29.0′ N | 134°09.1′ E |
| Kawahara (Ka) | 35°23.5′ N | 134°11.2′ E |
| Koge (Ko) | 35°24.5′ N | 134°19.9′ E |
| Fukube (Fu) | 35°32.4′ N | 134°15.4′ E |
| n(%) | ||
| Frontal | Left | 4 (15%) |
| Right | 4 (15%) | |
| Temporal | Left | 3 (11%) |
| Right | 0 (0%) | |
| Parieto‐occipital | Left | 1 (3.8%) |
| Right | 2 (7.7%) | |
| Cerebellar | Left | 3 (12%) |
| Right | 5 (19%) | |
| Vermis | 3 (12%) | |
| Brain stem | 1 (3.8%) |
| n Pla a 2 | nPhl p 4 | nJugr2 | ||||
| nPla a 2 | nPla a 2 + rPla a 1 | nPhl p 4 | nPhl p 4 +Phl p1/Phl p 5/Phl p 6/Phl p 11 | nJugr2 | nJug r2 + rJugr1 | |
| Mean sIgE levels (ISU) | 1.94 | 4.6 | 0.75 | 1.49 | 0.19 | 1.10 |
| U Mann–Whitney sig. | 0.00 | 0.00 | 0.00 |
| Characteristic | Pneumonia | ||
| Probable Non-bacterial (n = 49) | Probable Bacterial (n = 54) | P Valuea | |
| Age, mean (SD), mo | 19 (10.5) | 17.4 (11.6) | .14 |
| Male sex, % | 50% | 51% | .90 |
| Weight-for-age z score, mean (SD) | −1.03 (1.10) | −1.37 (1.21) | .24 |
| Respiratory rate, mean (SD), respirations/min | 57.0 (12.0) | 62.6 (9.8) | .007 |
| Oxygen saturation, mean (SD), % | 96.3 (2.64) | 92.84 (7.09) | <.01 |
| WBC count, mean (SD), ×109/L | 10.1 (6.42) | 23.7 (10.6) | <.01 |
| Hemoglobin, mean (SD), g/dL | 10.3 (1.53) | 8.65 (1.74) | <.01 |
| Molecular marker concentration, median (IQR) [No.] | |||
| Lpc-2, ng/mL | [42] 81.7 (45.7–109) | [45] 282 (155–365) | <.001 |
| CRP, μg/mL | [41] 175 (182–278) | [47] 283 (142–350) | <.001 |
| vWF, mU/mL | [34] 810 (647–1201) | [45] 1514 (1205–2036) | <.001 |
| TRa | Pathway name | Known pathway genes | Genes clustered with the TRb | TRE | Ref |
| betI (B1590) | glycine betaine synthesis | betABTI | betABTI | choline | [21] |
| catR (A2107) | benzoate degradation | catABCR | catABCR | cis, cis-muconate | [22] |
| cymR (A3550) | p-cumate catabolism | cymAaAbAcAdBCDEFHG | cymAaAbAcAd─CDE─ ─ ─ | p-cumate | [23] |
| cysB (A2466) | sulfur metabolism | cysABPTWA | cysABPTW | N-acetyl-serine | [24] |
| glpR (A0643) | glycerol metabolism | glpABCDKFR | glp─ ─ ─DKFR | glycerol-3-phosphate | [25] |
| hpaR (B2027) | hydroxyphenylacetate catabolism | hpaGEDFHIR | hpaGEDFHIR | 4-hydroxy-phenylacetate | [26] |
| kynR (A0736) | oxidative tryptophan degradation | kynABU | kynABU | L-kynurenine | [27] |
| hutC (A2946) | histidine degradation | hutHUIFGC | hutHUIFGC | urocanate | [28, 29] |
| rcoM (A2142) | carbon monoxide oxidation | coxBCMSLDEFGHIK | cox ─ ─SMLDE ─G ─ ─ ─ | carbon monoxide | [30] |
| modEB2851) | molybdate transport | modABCDE | modABC─E | molybdenum | [31] |
| Compounds | Content (μg/g of dry plant material weight) | Approximate RT (min) | ||
| MTa | MGa | MOKa | ||
| phenolic acids | ||||
| Hydroxyphenyl acetic acid | 914.26 ± 3.42 | 2053.42 ± 532.2 | ndb | 2.425 |
| gallic acid | 723.19 ± 4.1 | 744.72 ± 12.1 | 2780.57 ± 492.1 | 6.0 |
| syringic acid | 119.31 ± 4.2 | 148.45 ± 33.3 | - | 14.35 |
| Ferulic acid | 250.18 ± 3.2 | 41.64 ± 6.2 | 4657.94 ± 840.1 | 24.66 |
| Methyl galate | Nd | 229.84 ± 99.2 | nd | 3.61 |
| Vanillic acid | 1189.39 ± 973.3 | 614.72 ± 41.2 | nd | 15.96 |
| Hydroxybis | 132.2 ± 0.3 | 5581.77 ± 531.7 | nd | 3.69 |
| flavonoids | ||||
| Tyrosin | 5013.06 ± 934.1 | 59.48 ± 3.9 | nd | 5.85 |
| flavone | 128.6 ± 0.4 | 65.65 ± 9.6 | 5512.01 ± 372.2 | 9.16 |
| Vanillin | 1079.26 ± 57.1 | 126.08 ± 15.8 | nd | 17.56 |
| (+)- Catechin hydrate | 18.01 ± 0.22 | 4.9 ± 0.7 | nd | 19.68 |
| Rutin | 609.62 ± 0.6 | 88.54 ± 2.8 | nd | 23.65 |
| Variables | Tertiles of plasma manganese concentrations (μg/L) | ||
| 1 (Lowest) ≤ 4.21 μg/L | 2 4.21–6.84 | 3 (Highest) ≥ 6.84 μg/L | |
| n(NGT/T2D) | 538/780 | 541/377 | 535/457 |
| Crude | 2.08 (1.75, 2.47) | 1 | 1.23 (1.02, 1.47) |
| Model 1 | 2.08 (1.73, 2.49) | 1 | 1.28 (1.05, 1.55) |
| Model 2 | 2.15 (1.75, 2.63) | 1 | 1.54 (1.23, 1.92) |
| Model 3 | 1.89 (1.53, 2.33) | 1 | 1.56 (1.23, 1.97) |
| Model 1, adjusted for age, sex, and body mass index. Model 2, adjusted for Model 1, current smoking status, current alcohol drinking status, physical activity, family history of diabetes, and hypertension. Model 3, adjusted for Model 2, plasma iron, plasma copper, and plasma selenium. |
| TBI + PCD (N = 19) | Control (N = 17) | Significance | |
| Mean age in years (SD) | 32.00 (9.04) | 30.94 (7.48) | F1,35 = 0.14, p = 0.72 |
| Mean BMI (SD) | 29.30 (3.76) | 31.65 (4.82) | F1,35 = 2.03, p = 0.16 |
| Gender, % (No) | N/A | ||
| Male | 100.0% (19) | 100.0% (17) | |
| Race, % (No) | χ2 = 4.22, p = 0.52 | ||
| Caucasian | 73.8% (14) | 58.8% (10) | |
| Mixed | 15.8% (3) | 11.8% (2) | |
| All other | 10.4% (2) | 19.4% (5) | |
| Rank, % (No) | χ2 = 0.97, p = 0.62 | ||
| Lower enlisted | 57.9% (11) | 58.8% (10) | |
| Senior NCO | 36.8% (7) | 35.3% (6) | |
| Officer | 5.2% (1) | 5.9% (1) | |
| Sleep diagnoses, % (No) | χ2 = 2.79, p = 0.43 | ||
| OSA | 10.5% (2) | 5.9% (1) | |
| Insomnia | 31.6% (8) | 23.5% (4) | |
| OSA + insomnia | 31.5% (6) | 58.8% (10) | |
| None | 15.8% (3) | 11.8% (2) | |
| Depression severity (QIDS) | 9.6 (5.1) | 8.7 (4.8) | F1,35 = 2.42, p = 0.10 |
| PTSD severity (PCL-M) | 32.05 (18.8) | 29.90 (15.1) | F1,35 = 2.31, p = 0.14 |
| Prescribed medications, % yes (no) | 36.8% (6) | 41.2% (7) | χ2 = 1.51, p = 0.51 |
| SSRI | 15.8% (3) | 11.8% (2) | |
| Prazosin | 21.1% (4) | 17.6% (3) | |
| Anti-hypertensive | 15.8% (3) | 23.5% (4) |
| Factors | Syphilis infection(n=77) | HCV infection (n=30) | Unprotected sex | ||||||
| % | OR(95% CI) | AOR(95% CI) | % | OR(95% CI) | AOR(95% CI) | % | OR(95% CI) | AOR(95% CI) | |
| Gender | |||||||||
| Male | 7.9 | 1.0 | 1.0 | 3.9 | 1.0 | 37.6 | 1.0 | 1.0 | |
| Female | 17.5 | 2.5(1.5-4.2)** | 2.8(1.2-6.5)* | 2.8 | 0.7(0.2-2.0) | 53.3 | 3.0(1.8-5.1)** | 2.9(1.7-4.9)** | |
| Education | |||||||||
| Middle school or lower | 9.5 | 1.0 | 2.9 | 1.0 | 58.5 | 3.7(2.3-5.9)** | 3.4(2.0-5.5)** | ||
| High school or higher | 9.7 | 1.0(0.6-1.7) | 5.2 | 1.8(0.9-3.8) | 27.4 | 1.0 | 1.0 | ||
| Had ever injected | |||||||||
| Yes | 8.7 | 0.9(0.4-1.9) | 9.8 | 3.6(1.6-8.1)** | 2.7(1.1-6.5)* | 44.0 | 0.8(0.4-1.7) | ||
| No | 9.7 | 1.0 | 2.9 | 1.0 | 1.0 | 50.3 | 1.0 | ||
| Had ever sex with regular sex partners in last year | |||||||||
| Yes | 8.8 | 0.1(0.1-0.6)** | 0.2(0.1-0.6)** | 3.6 | |||||
| No | 42.9 | 1.0 | 0.0 | ||||||
| Had ever sex with commercial sex partners in last year | |||||||||
| Yes | 11.6 | 1.7(1.0-2.7)* | 2.0(1.0-3.9)* | 3.1 | 0.7 (0.5-1.2) | ||||
| No | 7.3 | 1.0 | 1.0 | 4.5 | 1.0 | ||||
| Ever received intervention | |||||||||
| Yes | 10.8 | 1.0 | 3.8 | 1.0 | 34.1 | 1.0 | 1.0 | ||
| No | 9.3 | 0.9(0.5-1.6) | 3.7 | 1(0.4-2.6) | 53.8 | 2.3(1.4-3.7)** | 2.1(1.2-3.6)* | ||
| HCV infection | |||||||||
| Yes | 36.7 | 6.2(2.8-13.6)** | 12.1(4.1-20.3)** | 42.9 | 0.9(0.4-1.9) | ||||
| No | 8.5 | 1.0 | 1.0 | 45.4 | 1.0 | ||||
| Syphilis | |||||||||
| Yes | 14.3 | 6.2(2.8-13.6)** | 8.0(3.5-18.0)** | 56.2 | 3.0(1.8-5.1)** | 4.2(2.4-7.4)** | |||
| No | 2.6 | 1.0 | 27.9 | 1.0 | 1.0 |
| Avg Wait Time | Std. Dev | Avg % of | Std. Dev | |
| in Hours | Patient center | |||
| Monday | 0.7609 | 0.0104 | 4.50 % | 0.0029 |
| Tuesday | 0.7284 | 0.0109 | 5.13 % | 0.0033 |
| Wednesday | 0.6218 | 0.0088 | 3.22 % | 0.0026 |
| Thursday | 0.5672 | 0.0080 | 3.23 % | 0.0026 |
| Friday | 0.5127 | 0.0073 | 3.38 % | 0.0027 |
| Saturday | 0.3954 | 0.0057 | 2.12 % | 0.0022 |
| Sunday | 0.3858 | 0.0050 | 1.84 % | 0.0020 |
| Outcome | Improved | Deteriorated | No change | N |
| Caregiver burden (ZBI) | 0 | 4 | 13 | 17 |
| Hopefulness (HHI) | 3 | 8 | 6 | 17 |
| Anxiety (HADS) | 2 | 0 | 15 | 17 |
| Depression (HADS) | 1 | 1 | 15 | 17 |
| Group | Gender (male/ female) | Age (year) | Disease course (year) | BMI (kg/m2) | FBG (mmol/l) | HbA1c (%) | TC (mmol/l) | LDL-C (mmol/l) | FPG (mmol/l) | TG (mmol/l) | BUN (mmol/l) | FINS (mIU/l) | Cr (μmol/l) | HOMA-IR |
| Control | 60/55 | 48.53 ± 7.26 | / | 22.82 ± 2.33 | 4.74 ± 0.75 | 4.30 ± 0.42 | 4.13 ± 0.88 | 3.21 ± 0.55 | 5.02 ± 0.68 | 1.45 ± 0.44 | 4.89 ± 1.17 | 5.50 ± 0.88 | 58.82 ± 7.65 | 1.25 ± 0.37 |
| NDR | 34/31 | 47.76 ± 8.05 | 4.16 ± 1.21* | 22.67 ± 1.98 | 7.12 ± 0.68* | 6.25 ± 0.58* | 4.25 ± 1.02 | 3.26 ± 0.61 | 5.31 ± 0.73 | 1.48 ± 0.32 | 5.26 ± 1.34 | 5.66 ± 1.02 | 59.07 ± 7.88 | 1.37 ± 0.43 |
| BDR | 32/41 | 48.83 ± 7.13 | 9.13 ± 2.54*† | 23.06 ± 1.85 | 7.25 ± 0.84* | 7.02 ± 0.66*† | 4.32 ± 0.94 | 3.30 ± 0.63 | 6.17 ± 0.75*† | 1.51 ± 0.34 | 5.33 ± 1.38 | 5.71 ± 1.14 | 61.55 ± 8.39 | 1.60 ± 0.50*† |
| PDR | 28/23 | 50.75 ± 10.18 | 13.58 ± 3.82*†‡ | 23.13 ± 2.02 | 7.33 ± 1.05* | 8.16 ± 0.79*†‡ | 4.43 ± 1.08 | 3.38 ± 0.72 | 6.86 ± 0.96*†‡ | 1.55 ± 0.45 | 5.41 ± 1.71 | 5.78 ± 1.21 | 62.43 ± 10.06 | 1.81 ± 0.62*† |
| Intracerebral hemorrhage | Ischemic stroke | |||||
| mRS ≤2* (n = 23) | mRS > 2 (n = 20) | P | mRS ≤2* (n = 82) | mRS > 2 (n = 81) | P | |
| Age (years) | 54.2 ± 12.9 | 66.8 ± 13.9 | 0.004 | 62.6 ± 14.0 | 68.3 ± 12.4 | 0.007 |
| Male | 15 (65.2) | 13 (65) | 1.000 | 64 (78.0) | 47 (58.0) | 0.007 |
| Body mass index (kg/m2) | 25.1 ± 3.1 | 22.6 ± 3.8 | 0.023 | 25.9 ± 3.8 | 25.5 ± 3.7 | 0.528 |
| Diabetes mellitus | 8 (34.7) | 2 (10.0) | 0.076 | 30 (36.6) | 37 (45.7) | 0.267 |
| Hypertension | 21 (91.3) | 18 (90.0) | 1.000 | 53 (64.6) | 66 (81.5) | 0.021 |
| Hyperlipidemia | 3 (13.0) | 6 (30.0) | 0.263 | 25 (30.5) | 28 (34.6) | 0.618 |
| Atril fibrillation | 1 (4.3) | 1 (5.0) | 1.000 | 17 (20.7) | 25 (30.9) | 0.155 |
| History of stroke | 3 (13.0) | 4 (20.0) | 0.687 | 10 (12.2) | 26 (32.1) | 0.002 |
| WBC (103/μl) | 10.2 ± 4.4 | 10.3 ± 2.8 | 0.860 | 8.3 ± 2.8 | 9.3 ± 4.0 | 0.050 |
| Hemoglobin | 14.9 ± 1.3 | 13.0 ± 4.4 | 0.057 | 14.6 ± 3.7 | 13.9 ± 1.9 | 0.173 |
| Glucose (mg/dl) | 137.3 ± 59.2 | 113.5 ± 32.3 | 0.117 | 145.5 ± 61.9 | 148.8 ± 55.8 | 0.723 |
| Creatinine (mg/dl) | 1.2 ± 0.7 | 1.1 ± 0.4 | 0.492 | 1.2 ± 1.0 | 1.3 ± 0.9 | 0.356 |
| NIHSS | 9.7 ± 5.5 | 17.6 ± 7.6 | <0.001 | 5.1 ± 5.8 | 13.1 ± 7.4 | <0.001 |
| Systolic blood pressure (mmHg) | 184.1 ± 44.5 | 190.1 ± 38.2 | 0.640 | 157.9 ± 31.8 | 160.8 ± 32.7 | 0.565 |
| HA < 48 hours (ng/ml) | 202.7 ± 134.1 | 310.1 ± 225.9 | 0.061 | 195.9 ± 164.0 | 226.0 ± 242.6 | 0.356 |
| HA 48 to 72 hours (ng/ml) | 271.1 ± 226.8 | 879.6 ± 1594.7 | 0.077 | 206.1 ± 304.2 | 379.2 ± 698.0 | 0.053 |
| Level of BCPOd (%) | P value | ||||||
| Parameter | 0 | 4 | 8 | SEM | Overall | Linear | Quadratic |
| C14:0, myristic | 6.67a | 5.70b | 5.04c | 0.53 | 0.048 | 0.049 | 0.395 |
| C16:0, palmitic | 27.06 | 27.05 | 24.22 | 1.18 | 0.170 | 0.334 | 0.104 |
| C16:1n-7, palmitoleic | 3.49 | 3.44 | 2.74 | 0.44 | 0.409 | 0.461 | 0.266 |
| C18:0, stearic | 26.10 | 25.28 | 24.42 | 2.56 | 0.898 | 0.814 | 0.693 |
| C18:1n-9, oleic | 19.97b | 18.98b | 26.30a | 2.42 | 0.050 | 0.044 | 0.377 |
| C18:1 trans-11 Vaccenic | 3.48 | 4.27 | 4.87 | 0.73 | 0.422 | 0.569 | 0.239 |
| CLA cis-9 trans-11 | 1.30 | 1.51 | 1.20 | 0.22 | 0.612 | 0.337 | 0.841 |
| CLA trans-10 cis-12 | 1.54 | 2.08 | 1.72 | 0.39 | 0.618 | 0.521 | 0.463 |
| C18:2n-6, linoleic | 3.63 | 3.65 | 3.53 | 0.53 | 0.986 | 0.878 | 0.953 |
| C18:3n-3, linolenic | 1.56 | 1.44 | 1.71 | 0.23 | 0.712 | 0.417 | 0.952 |
| C20:4n-6, arachidonic | 1.89 | 1.62 | 2.13 | 0.52 | 0.784 | 0.491 | 0.980 |
| C20:5n-3, eicosapentaenoic | 1.87c | 2.78b | 2.91c | 0.39 | 0.043 | 0.011 | 0.051 |
| C22:5n-3, eicosapentaenoic | 1.42 | 1.67 | 2.11 | 0.42 | 0.501 | 0.458 | 0.365 |
| C22:6n-3, docosahexanoic | 1.92 | 1.87 | 2.29 | 0.52 | 0.824 | 0.574 | 0.804 |
| Total FA (mg/g of fat) | 842.23 | 925.87 | 982.87 | 160.09 | 0.827 | 0.804 | 0.577 |
| FA sums and ratios | |||||||
| ∑SFA | 59.83 | 58.03 | 54.09 | 3.24 | 0.402 | 0.353 | 0.328 |
| ∑MUFA | 26.95 | 26.69 | 33.90 | 6.62 | 0.169 | 0.113 | 0.299 |
| ∑PUFA | 15.12 | 16.61 | 17.60 | 1.61 | 0.437 | 0.563 | 0.606 |
| ∑n-3 | 7.013 | 7.76 | 9.028 | 0.86 | 0.268 | 0.307 | 0.205 |
| ∑n-6 | 6.22 | 5.27 | 5.653 | 0.76 | 0.696 | 0.730 | 0.442 |
| n-6:n-3 | 0.89 | 0.68 | 0.69 | 0.09 | 0.195 | 0.921 | 0.074 |
| UFA:SFA | 0.70 | 0.91 | 0.77 | 0.11 | 0.411 | 0.317 | 0.317 |
| PUFA:SFA | 0.23 | 0.25 | 0.26 | 0.03 | 0.790 | 0.782 | 0.535 |
| Desaturase and elongase indices | |||||||
| ID16 | 11.42 | 11.28 | 10.12 | 0.87 | 0.711 | 0.418 | 0.111 |
| ID18 | 43.35 | 42.88 | 51.85 | 2.99 | 0.612 | 0.234 | 0.516 |
| Elongation Index (EI) | 60.13 | 59.74 | 65.29 | 3.03 | 0.875 | 0.324 | 0.198 |
| Items | MS1 T1 | M2 T1 | p | Ms1 T2 | MS2 T2 | p | MS3 T3 | MS4 T3 | p |
| How important are the following factors in considering your career in medicine? | |||||||||
| Opportunities to make a difference in people’s lives | 4.89 | 4.83 | NS | 4.88 | 4.83 | NS | 4.71 | 4.66 | NS |
| Intellectual climate | 4.41 | 4.52 | NS | 4.41 | 4.47 | NS | 4.23 | 4.13 | NS |
| Desire to do primary care | 3.04 | 2.74 | .062 | 3.03 | 2.75 | .074 | 3.04 | 2.88 | NS |
| Availability of jobs | 3.55 | 3.86 | .032* | 3.54 | 3.84 | .44* | 4.26 | 3.90 | .025* |
| Job security | 3.80 | 4.03 | .099 | 3.80 | 4.00 | NS | 4.40 | 4.30 | NS |
| Opportunity to help patients who are socially disadvantaged | 4.71 | 3.89 | .034* | 4.15 | 3.90 | .051* | 3.84 | 3.51 | .060 |
| Desire to serve my community | 4.42 | 4.32 | NS | 4.39 | 4.33 | NS | 4.23 | 3.66 | <.001* |
| High income potential | 2.82 | 3.36 | <.001** | 2.82 | 3.32 | <.001** | 3.45 | 3.25 | NS |
| Job satisfaction | 4.76 | 4.75 | NS | 4.77 | 4.77 | NS | 4.84 | 4.78 | NS |
| Status of physicians | 2.69 | 2.97 | .088 | 2.65 | 2.86 | NS | 2.84 | 2.80 | NS |
| How important are the following factors in considering your choice for a specialty? | |||||||||
| Income expectations for the specialty | 2.81 | 3.27 | .002** | 2.76 | 3.23 | .001** | 3.43 | 3.15 | NS |
| Amount of education debt I have | 2.81 | 3.04 | NS | 2.83 | 2.99 | NS | 3.30 | 3.09 | NS |
| Ability to balance my work life with my family responsibilities | 4.37 | 4.62 | .013* | 4.38 | 4.60 | .026* | 4.53 | 4.44 | NS |
| Content of the specialty | 4.69 | 4.70 | NS | 4.71 | 4.69 | NS | 4.59 | 4.70 | NS |
| Competitiveness of the specialty | 3.13 | 3.07 | NS | 3.11 | 3.06 | NS | 2.91 | 2.74 | NS |
| Options for fellowship training associated with the specialty | 3.25 | 3.47 | NS | 3.24 | 3.40 | NS | 3.51 | 3.58 | NS |
| Length of residency training associated with the specialty | 3.18 | 3.44 | .080 | 3.17 | 3.48 | .040* | 3.48 | 2.98 | .008** |
| The lifestyle of the specialty I am considering | 4.20 | 4.42 | .066 | 4.20 | 4.38 | NS | 4.36 | 4.16 | NS |
| Prestige of the specialty I am considering | 2.20 | 2.49 | .042* | 2.17 | 2.42 | .072 | 2.41 | 2.59 | NS |
| Career workshops and courses | 2.66 | 2.53 | NS | 2.63 | 5.47 | NS | 2.71 | 2.36 | .054* |
| Opportunities to do research in this specialty | 2.58 | 2.42 | NS | 2.57 | 2.38 | NS | 3.37 | 3.10 | NS |
| Opportunities to provide care to underserved populations | 3.43 | 3.28 | NS | 3.41 | 3.28 | NS | 3.37 | 3.10 | NS |
| Attitudes toward primary care | |||||||||
| I would like to become a primary care doctor in the future. | 3.12 | 2.97 | NS | 3.11 | 3.13 | NS | 3.13 | 2.62 | .024* |
| I am more interested in learning the skills required for my chosen specialty rather than a general set | 2.79 | 2.82 | NS | 2.75 | 2.69 | NS | 2.69 | 3.45 | <.001* |
| Primary care knowledge is useful for all medical students. | 4.75 | 4.68 | NS | 4.75 | 4.70 | NS | 4.70 | 4.75 | NS |
| Primary care should be a patient’s first contact with the health care system. | 4.39 | 4.36 | NS | 4.38 | 4.68 | NS | 4.68 | 4.47 | .060 |
| Medical interviewing is a fundamental tool for all medical students to learn. | 4.89 | 4.83 | NS | 4.92 | 4.87 | .062 | 4.87 | 4.88 | NS |
| Preventative care knowledge is essential for all medical students to learn. | 4.83 | 4.53 | <.000** | 4.85 | 4.70 | <.001** | 4.70 | 4.67 | NS |
| It is essential that medical students learn how to best communicate with patients | 4.89 | 4.86 | NS | 4.91 | 4.89 | NS | 4.89 | 4.87 | NS |
| Primary care doctors mostly manage chronic health problems. | 3.26 | 3.79 | <.001** | 3.25 | 3.89 | <.001** | 3.89 | 3.81 | NS |
| It is impossible to be an expert in such a wide field as primary care | 2.69 | 3.0 | .035* | 2.69 | 2.97 | .016* | 2.97 | 3.31 | 0.76 |
| Primary care is not very intellectually stimulating | 1.90 | 2.22 | .010* | 1.91 | 2.47 | .014* | 2.47 | 2.58 | NS |
| Primary care doctors have a large work overload. | 3.63 | 3.95 | .006** | 3.63 | 4.15 | .005** | 4.15 | 4.05 | NS |
| Primary care doctors are poorly valued by the rest of the medical profession. | 3.48 | 3.76 | 0.22* | 3.49 | 3.78 | .033* | 3.78 | 3.77 | NS |
| A primary care doctor is clinically competent to provide most of the health care an individual may | 3.96 | 3.99 | NS | 3.94 | 4.36 | NS | 4.36 | 4.36 | NS |
| Stigma | Medication adherence | Total | Statistics | |||
| Non adherent | Adherent | |||||
| f | % | f | % | |||
| No perceived stigma | 8 | 9.2 | 79 | 90.8 | 87 | χ2 = 0.497 |
| Experienced stigma | 7 | 13.0 | 47 | 87.0 | 54 | p = 0.481 |
| Total | 15 | 10.6 | 126 | 89.4 | 141 | - |
| Model | Parameters | True value | Mean estimation | Estimated error |
| Three-way model | ||||
| Case I | G-C/M-C/M-G | 0.2 | 0.23 | 0.04 |
| Case II | G-C/M-C/M-G | 0.3 | 0.31 | 0.05 |
| Case III | G-C/M-C/M-G | 0.4 | 0.40 | 0.05 |
| Independent model | ||||
| Case I | G-C/M-C | 0.2 | 0.22 | 0.04 |
| Case II | G-C/M-C | 0.3 | 0.31 | 0.05 |
| Case III | G-C/M-C | 0.4 | 0.43 | 0.04 |
| Causal model | ||||
| Case I | G-C/M-G | 0.2 | 0.23 | 0.04 |
| Case II | G-C/M-G | 0.3 | 0.31 | 0.05 |
| Case III | G-C/M-G | 0.4 | 0.41 | 0.04 |
| microRNA model | ||||
| Case I | M-C | 0.2 | 0.22 | 0.04 |
| Case II | M-C | 0.3 | 0.30 | 0.04 |
| Case III | M-C | 0.4 | 0.39 | 0.05 |
| Univariate OR (95 % CI)a | p valueb | Multivariate aOR (95 % CI) | p value | |
| Sociodemographic | ||||
| Intercept | – | – | 4.78 (0.98, 23.41) | 0.054 |
| Age: per 5-year increase | 0.85 (0.77, 0.94) | <0.001 | 0.90 (0.81, 1.00) | 0.057 |
| Male | 1.58 (1.07, 2.31) | 0.020 | 1.26 (0.78, 2.04) | 0.343 |
| Born in Canada | 1.09 (0.62, 1.91) | 0.764 | – | – |
| Province of enrolment | – | – | – | – |
| British Columbia | Ref. | Ref. | Ref. | Ref. |
| Ontario | 0.50 (0.31, 0.81) | 0.005 | 0.74 (0.43, 1.27) | 0.275 |
| Quebec | 0.45 (0.30, 0.65) | <0.001 | 0.42 (0.27, 0.67) | <0.001* |
| Otherc | 0.24 (0.07, 0.84) | 0.025 | 0.49 (0.14, 1.73) | 0.265 |
| Aboriginal | 1.75 (1.08, 2.82) | 0.022 | 1.12 (0.58, 2.13) | 0.759 |
| Heterosexual | 1.52 (1.07, 2.16) | 0.019 | 1.12 (0.73, 1.70) | 0.605 |
| Living aloned | 1.44 (1.09, 1.89) | 0.010 | 1.31 (0.92, 1.87) | 0.128 |
| Without a fixed addressd | 2.19 (1.16, 4.14) | 0.016 | 1.19 (0.50, 2.84) | 0.689 |
| Recent changes in housing situatione | 1.44 (1.06, 1.95) | 0.021 | 1.11 (0.73, 1.68) | 0.635 |
| Recent incarceratione | 1.96 (1.14, 3.36) | 0.015 | 1.11 (0.59, 2.08) | 0.749 |
| Socioeconomic | ||||
| Employmentd | 0.34 (0.24, 0.49) | <0.001 | 0.55 (0.35, 0.87) | 0.010* |
| Average personal monthly income ($ CAD): per $100 increasee | 0.96 (0.93, 0.99) | 0.012 | 0.98 (0.97, 0.99) | 0.001* |
| More than high school education | 0.45 (0.30, 0.66) | <0.001 | 0.72 (0.45, 1.13) | 0.155 |
| Behavioral | ||||
| Recent injection drug usee | 2.79 (2.02, 3.85) | <0.001 | 1.98 (1.33, 2.96) | <0.001* |
| Marijuana used | 1.82 (1.37, 2.42) | <0.001 | 1.41 (0.99, 2.01) | 0.060 |
| Cigarette used | 1.67 (1.18, 2.35) | 0.004 | 0.98 (0.65, 1.50) | 0.940 |
| Alcohol used | 1.28 (0.97, 1.67) | 0.077 | 1.21 (0.84, 1.75) | 0.301 |
| 1.55 (1.06, 2.25) | 0.023 | 1.21 (0.75, 1.94) | 0.433 | |
| Trading away foode,f | 5.99 (3.53, 10.16) | <0.001 | 5.23 (2.53, 10.81) | <0.001* |
| Clinical | ||||
| Taking cARTd | 0.52 (0.31, 0.88) | 0.015 | 0.68 (0.36, 1.29) | 0.237 |
| Self-described health state—visual analogue scale (0–100): per 5-point increased | 0.93 (0.89, 0.96) | <0.001 | 0.98 (0.94, 1.02) | 0.242 |
| Therapy for drug addictione | 1.16 (0.79, 1.71) | 0.452 | – | – |
| Recent depressive symptoms (CES-D-10) (in the past week) | 2.78 (2.06, 3.74) | <0.001 | 2.11 (1.48, 3.01) | <0.001* |
| Unmet healthcare needse | 2.25 (1.55, 3.26) | <0.001 | 1.55 (0.93, 2.57) | 0.091 |
| Participant | TTD (Months) | FIGO stage | First attributions of illness symptoms | ||||||||
| Retained condom | Intestinal worms | Genital infections (syphilis, gonorrhoea and Candida) | Menstrual problems (Menopause and other menstrual abnormalities) | Uterine swelling | No clue on cause | HIV and/or its complications | Cervical cancer | Other serious illness | |||
| P10 | 2 | 3B | X | ||||||||
| P11 | 2 | 1A | X | ||||||||
| P7 | 3 | 1A | X | ||||||||
| P8 | 3 | 1B | X | ||||||||
| P4 | 4 | 1B | X | ||||||||
| P3 | 7 | 4A | X | ||||||||
| P15 | 10 | 3B | X | ||||||||
| P18 | 10 | 2A | X | ||||||||
| P9 | 19 | 2A | X | ||||||||
| P16 | 21 | 3B | X | ||||||||
| P13 | 24 | 3A | X | ||||||||
| P12 | 26 | 2A | X | ||||||||
| P2 | 30 | 1B | X | ||||||||
| P5 | 39 | 2B | X | ||||||||
| P6 | 72 | 3B | X | ||||||||
| P14 | 72 | 2B | X | ||||||||
| P17 | 72 | 3B | X | x | |||||||
| P1 | Missing | 140 | X |
| PI-RADS v2 score | |||||
| 1n = 22 | 2n = 11 | 3n = 55 | 4n = 97 | 5n = 30 | |
| Insignificant PCa, n (%) | 3 (13.6%) | 0 (0%) | 2 (3.6%) | 12 (12.4%) | 1 (3.3%) |
| Significant PCa, n (%) | 4 (18.2%) | 1 (9.1%) | 6 (10.9%) | 64 (66.0%) | 24 (80.0%) |
| Total PCa, n (%) | 7 (31.8%) | 1 (9.1%) | 8 (14.5%) | 76 (78.3%) | 25 (83.3%) |
| GeneID | Product Name | Locus | AMX* | CTC* | ENR* |
| 1244239 | ImpA | impA | -0.52 | -0.53 | 4.55 |
| 1244433 | DNA-binding protein Fis | fis | ns | ns | 1.41 |
| 1244528 | LexA repressor | lexA | ns | 1.60 | 9.87 |
| 1244611 | Hypothetical protein PM1264 | - | -0.78 | -0.57 | ns |
| 1244637 | Transcriptional repressor protein MetJ | metJ | -0.53 | -0.74 | -0.80 |
| 1244659 | Hypothetical protein PM1312 | - | -0.56 | -0.68 | -0.31 |
| 1244737 | DNA-directed RNA polymerase subunit alpha | rpoA | ns | -0.77 | 1.27 |
| 1244795 | Hypothetical protein PM1448 | - | -0.81 | -0.70 | 1.29 |
| 1244828 | Hypothetical protein PM1481 | - | -0.53 | -0.51 | -0.51 |
| 1244993 | Hypothetical protein PM1646 | - | -0.62 | ns | -0.70 |
| 1245061 | Hypothetical protein PM1714 | - | -0.74 | -0.91 | ns |
| 1245083 | DNA-directed RNA polymerase subunit beta' | rpoC | ns | -0.76 | -0.87 |
| 1245184 | ATP-dependent helicase HepA | hepA | -0.77 | -0.77 | 1.69 |
| 1245314 | DNA-binding transcriptional activator GutM | gutM | -0.55 | -0.69 | -0.62 |
| 1243539 | Hypothetical protein PM0192 | recJ | -0.77 | -0.79 | 1.24 |
| 1243679 | Hypothetical protein PM0332 | recN | ns | ns | 11.54 |
| 1243758 | DNA-dependent helicase II | uvrD | ns | ns | 4.26 |
| 1243814 | DNA polymerase IV | dinP | -0.76 | -0.83 | 1.83 |
| 1244020 | Hypothetical protein PM0673 | - | -0.63 | -0.81 | -0.47 |
| 1244323 | Holliday junction DNA helicase B | ruvB | ns | -0.78 | 2.37 |
| 1244324 | Holliday junction DNA helicase motor protein | ruvA | ns | ns | 3.39 |
| 1244459 | DeaD | deaD | -0.78 | -0.72 | -0.67 |
| 1244499 | DNA repair protein RadC | radC | -0.52 | -0.60 | -0.65 |
| 1244507 | DNA polymerase III subunit beta | dnaN | ns | ns | 1.41 |
| 1244526 | Primosomal replication protein N | priB | ns | ns | 1.67 |
| 1244563 | DNA polymerase III subunit delta | holA | ns | -0.88 | 1.38 |
| 1244666 | MutY | mutY | -0.68 | -0.86 | 1.17 |
| 1244774 | RecQ | recQ | -0.86 | -0.84 | 1.11 |
| 1244823 | DNA gyrase subunit B | gyrB | ns | 1.36 | 1.45 |
| 1245063 | NAD-dependent DNA ligase LigA | ligA | -0.84 | 1.08 | 1.56 |
| 1245164 | Recombinase A | recA | ns | ns | 9.96 |
| 1245177 | DNA mismatch repair protein | mutS | -0.87 | -0.78 | 1.50 |
| 1245268 | ATP-dependent RNA helicase RhlB | rhlB | -0.73 | -0.83 | 1.07 |
| 1245298 | Excinuclease ABC subunit A | uvrA | -0.78 | ns | 2.57 |
| 1243785 | Hypothetical protein PM0438 | ftsH | -0.94 | -0.80 | 1.13 |
| 1244083 | Hypothetical protein PM0736 | DnaK | ns | -0.74 | 1.50 |
| 1244087 | Hypothetical protein PM0740 | dnaJ | -0.74 | -0.79 | 1.29 |
| 1245051 | ClpB | clpB | -0.66 | ns | 2.14 |
| 1245095 | ATP-dependent protease ATP-binding subunit | hslU | -0.70 | ns | 2.58 |
| 1245163 | Recombination regulator RecX | recX | -0.54 | -0.78 | 6.44 |
| Variable | Average interitem covariance | Number of items in the scale | Scale reliability coefficient |
| Distance | 0.448 | 6 | 0.748 |
| Positive | 0.309 | 3 | 0.563 |
| Demands | 1.024 | 4 | 0.852 |
| Fragment | Size (bp) | Primer sequences (5'-3') |
| NC1 | 2573 | FP: GATCCTGGGCCCCACATCCATCCTC |
| RP: GATCGAATTCGCCCGGGAGGCCAGGGTCG | ||
| NC2 | 524 | FP: GATCGAATTCGGCGAGAAGGGAGAAGCTGC |
| RP: GATCAAGCTTTCAGTCCTGGGCAGTACCTGT |
| Heavy Metal | Arsenic (47) | Cadmium (34) | Mercury (30) | Lead (29) |
| Year | 2012 (16), 2011 (16) | 2009 (4), 2013 (4), 2014 (4) | 2016 (9), 2013 (5), 2015 (5) | 2016 (5), 2002 (4), 2006 (3), 2013 (3) |
| Product category | feed materials (18), pet food (12) | feed additives (10), feed materials (9), animal nutrition (obsolete) (7) | feed materials (13), pet food (9) | animal nutrition (obsolete) (8), feed materials (7), feed additives (6), feed for food-producing animals (obsolete) (5) |
| Notifying country | Italy (10), Germany (8), Belgium (7), Austria (5), United Kingdom (5) | Belgium (8), Germany (4), Norway (4) | Italy (14), Spain (5), Germany (4) | Netherlands (6), Germany (5), Belgium (4) |
| Origin country | Thailand (11), Poland (5) | China (8), Spain (4) | Thailand (10), Russia (5), Spain (4) | Netherlands (5), Spain (4), Turkey (3) |
| Notification basis | official control on the market (21), border control—consignment detained (12), company’s own check (11) | company’s own check (14), official control on the market (14) | official control on the market (14), border control—consignment detained (12) | company’s own check (12), official control on the market (10) |
| Notification type | alert (13), border rejection (12), information for follow-up (11) | information (12), information for follow-up (11) | border rejection (12), information for follow-up (10) | alert (9), information for follow-up (9), information (8) |
| Distribution status | no distribution (11), distribution restricted to notifying country (8), distribution to other member countries (8), information on distribution not (yet) available (7) | distribution on the market (possible) (10), distribution to other member countries (10), distribution restricted to notifying country (8) | product not (yet) placed on the market (11), distribution restricted to notifying country (7), no distribution from notifying country (6) | (not specified) (7), distribution on the market (possible) (6), distribution to other member countries (6), distribution restricted to notifying country (5) |
| Risk decision | undecided (37) | undecided (25) | not serious (18) | undecided (21) |
| Action taken | re-dispatch (8), withdrawal from the market (7), destruction (4), informing recipients (4), official detention (4) | withdrawal from the market (7), (not specified) (4), official detention (4), seizure (3) | re-dispatch (6), import not authorized (5), official detention (5), withdrawal from the market (5) | (not specified) (7), return to consignor (4), withdrawal from the market (4) |
| Location | Annual average hourly NO2 (μg/m3) based on the LUR estimate | ||||
| percent | min | max | mean | sd | |
| Residences | 100 | 6 | 56 | 28 | 8 |
| freeway/highway/arterial/ramp | 17 | 15 | 56 | 34 | 9 |
| Collector | 17 | 2 | 56 | 26 | 8 |
| local/strata/lane | 66 | 2 | 56 | 26 | 8 |
| Rural | 0.2 | 11 | 39 | 19 | 5 |
| Name | First protein | Second protein | Sequence of the fusion helix | ||
| 3,305 | Protein A | mbp3–16 | 266* | QCAREAAREAAACD | 13* |
| 3,306 | mbp3–16 | Protein A | 133 | QCAREAAAREAACN | 217 |
| 3,307 | Protein A | mbp3–16 | 263 | NCAQEAAAREAACD | 13 |
| 3,308 | mbp3–16 | Protein A | 129 | ACILQAAAREAACN | 217 |
| 3,309 | Protein A | mbp3–16 | 266 | QCAREAAARDLGCK | 17 |
| 3,310 | mbp3–16 | Protein A | 133 | QCAREAAAREANCE | 219 |
| 3,311 | mbp3–16 | Protein A | 132 | LCKNKAQQAAFYCI | 227 |
| 3,312 | mbp3–16 | Protein A | 125 | NCRLAAILAKNKCQ | 220 |
| 3,313 | Protein A | mbp3–16 | 259 | ACKLNAAQALGRCL | 18 |
| 3,315 | Protein A | mbp3–16 | 260 | ACLNAAQAALGRCL | 18 |
| 4,254 | Protein A | mbp3–16 | 260 | KCLNDALGAKLLCA | 21 |
| 4,256 | Protein A | mbp3–16 | 260 | KCLNDAQAAKLLCA | 21 |
| 4,257 | Protein A | mbp3–16 | 259 | ACKLNAAQALGRCL | 18 |
| 4,258 | Protein A | mbp3–16 | 259 | ACKLNAAQAAGRCL | 18 |
| 4,260 | Protein A | mbp3–16 | 261 | KCNDAAARALLECA | 22 |
| 4,261 | Protein A | mbp3–16 | 261 | KCNDAALGAKLLCA | 21 |
| 4,262 | Protein A | mbp3–16 | 261 | KCNDAAAGAKLLCA | 21 |
| 6,758 | Protein A | Calmodulin | 260 | KCLNDAEQIAEFCE | 15 |
| 6,759 | Protein A | Calmodulin | 260 | KCLNDEQIAEFKCA | 16 |
| 6,760 | Protein A | Calmodulin | 259 | ACKLNAQIAEFKCA | 16 |
| 6,761 | Protein A | Calmodulin | 260 | KCLNDAQAAAEECI | 10 |
| Number of filled prescriptions | Switching between different statins | ||||||||
| ≥ 2 filled statin prescriptions | No switches | 1-3 switches | |||||||
| N | Mean (%) | 95% CI | N | Mean (%) | 95% CI | N | Mean (%) | 95% CI | |
| Entire study population | |||||||||
| Simvastatin users with generic substitution | 94525 | 90.1 | 89.9-90.3 | 93572 | 86.9 | 86.0-87.8 | 7423 | 83.1 | 82.0-84.1 |
| Simvastatin users with active decline of generic substitution | 697 | 79.8 | 84.7-86.8 | 533 | 68.1 | 56.4-79.9 | 268 | 80.2 | 74.6-85.7 |
| Simvastatin users not exposed to generic substitution | 2911 | 52.5 | 76.6-83.0 | 5651 | 49.3 | 45.7-52.9 | 1292 | 75.9 | 73.4-78.5 |
| Atorvastatin users | 6616 | 85.8 | 50.9-54.0 | 6172 | 79.6 | 76.2-83.1 | 1359 | 67.0 | 64.6-69.5 |
| Those with generic substitution | |||||||||
| Generic substitution at first purchase | 57844 | 88.7 | 88.4-89.1 | 59175 | 83.7 | 83.0-84.4 | 5139 | 80.7 | 79.6-81.8 |
| Generic substitution later on | 36681 | 92.2 | 91.8-92.5 | 34297 | 92.4 | 91.4-93.4 | 2284 | 88.4 | 86.8-90.1 |
| Methylation probe | Distance from MEG3 TSS | Correlation with 14q32 prognostic miRNAs | Number of miRNAs | Overlap with CTCF binding site |
| cg1656 | 1326 | None | None | Near site (in promoter) |
| cg0928 | 775 | 0.466 (0.596 to 0.404) | 7 | In site (in promoter) |
| cg2583 | 156 | 0.459 (0.528 to 0.396) | 3 | Near site (in promoter) |
| cg05711 | −218 | −0.561 | 1 | Near site (within gene body) |
| cg1537 | −628 | −0.443 (−0.408 to −0.631) | 13 | Near site (within gene body) |
| cg1510 | −1264 | 0.546 (0.621 to 0.428) | 2 | Near site (within gene body) |
| cg0429 | −1968 | −0.283 (−0.554 to −0.552) | 10 | Not in site (within gene body) |
| tRF5 | Anticodon | ELISA status | SE | P-value | |
| Negative (RPM)a | Positive (RPM)a | ||||
| tRF5-Ala | CGC | 616 | 494 | 31 | 0.0081 |
| tRF5-Glu | CTC | 2584 | 1492 | 306 | 0.0155 |
| tRF5-Gly | TCC | 65 | 148 | 21 | 0.0082 |
| tRF5-Lys | CTT | 3800 | 6933 | 534 | 0.0002 |
| tRF5-Lys | TTT | 728 | 1193 | 113 | 0.0057 |
| tRF5-Pro | TGG | 78 | 118 | 10 | 0.0093 |
| tRF5-SelCys | UGA | 4.9 | 13.7 | 1.9 | 0.0020 |
| tRF5-Thr | TGT | 6.4 | 8.2 | 0.6 | 0.0499 |
| tRF5-Val | CAC | 11,409 | 15,104 | 1275 | 0.0468 |
| Variable | non-MetS | MetS | Entire sample | p value* |
| Demographical information | ||||
| N | 1194 | 783 | 1977 | |
| Age years | 59.8 ± 8.85 | 61.56 ± 8.37 | 60.5 ± 8.71 | <0.001 |
| Gender male, % | 409 (34.25 %) | 258 (32.95 %) | 667 (33.74 %) | 0.396 |
| Height cm | 161.5 ± 7.89 | 161.48 ± 7.79 | 161.49 ± 7.85 | 0.942 |
| Weight kg | 60.41 ± 9.78 | 67.69 ± 10.5 | 63.3 ± 10.68 | <0.001 |
| SBP mmHg | 122.61 ± 17.33 | 135.52 ± 18.34 | 127.71 ± 18.82 | <0.001 |
| DBP mmHg | 77.82 ± 9.38 | 82.8 ± 9.38 | 79.79 ± 9.69 | <0.001 |
| Medical history, % | ||||
| Smoking yes | 182 (15.24 %) | 122 (15.58 %) | 304 (15.38 %) | 0.773 |
| HTN yes | 371 (31.07 %) | 557 (71.14 %) | 928 (46.94 %) | <0.001 |
| DM yes | 112 (9.39 %) | 307 (39.21 %) | 419 (21.2 %) | <0.001 |
| CAN yes | 173 (14.49 %) | 190 (24.27 %) | 363 (18.36 %) | <0.001 |
| Laboratory assays | ||||
| FPG mmol/L | 5.01 ± 1.27 | 6.19 ± 2.16 | 5.48 ± 1.78 | <0.001 |
| PBG mmol/L | 6.63 ± 2.87 | 9.08 ± 4.02 | 7.6 ± 3.58 | <0.001 |
| FINS uml/L | 6.07 ± 10.53 | 9.07 ± 14.08 | 7.26 ± 12.16 | <0.001 |
| TC mmol/L | 5.31 ± 0.96 | 5.33 ± 1.07 | 5.32 ± 1 | 0.603 |
| TG mmol/L | 1.35 ± 0.66 | 2.26 ± 1.14 | 1.71 ± 0.99 | <0.001 |
| HDL mmol/L | 1.46 ± 0.32 | 1.2 ± 0.26 | 1.36 ± 0.33 | <0.001 |
| LDL mmol/L | 3.18 ± 0.76 | 3.21 ± 0.8 | 3.19 ± 0.78 | 0.212 |
| SCr μmol/L | 76.56 ± 28.72 | 79.14 ± 22.9 | 77.58 ± 26.59 | 0.003 |
| UA μmol/L | 265.96 ± 78.37 | 302.66 ± 87.82 | 280.51 ± 84.17 | <0.001 |
| HRV indices | ||||
| HR bpm | 71.57 ± 9.92 | 73.96 ± 10.34 | 72.52 ± 10.16 | <0.001 |
| TP ms2 | 938.73 ± 728.92 | 788.78 ± 668.07 | 879.34 ± 709.16 | <0.001 |
| LF ms2 | 210.37 ± 219.54 | 164.72 ± 189.4 | 192.29 ± 209.3 | <0.001 |
| HF ms2 | 203.82 ± 241.68 | 155.52 ± 183.24 | 184.69 ± 221.63 | <0.001 |
| LF/HF | 1.67 ± 2.05 | 1.74 ± 1.87 | 1.7 ± 1.98 | 0.307 |
| SNP | ||||
| rs9340799 | 237 (19.97 %) | 147 (19.08 %) | 384 (19.62 %) | 0.495 |
| Variable | Multivariate analysis (DFS) | Multivariate analysis (OS) | ||
| P-value | HR (95%CI) | P-value | HR (95%CI) | |
| AJCC stage (I/II vs. III/IV) | 0.037* | 2.621 (1.011–6.668) | 0.029* | 2.915 (1.113–7.634) |
| N stage (N0 vs. N1 + N2) | 0.043* | 2.354 (1.027–5.395) | 0.033* | 2.785 (1.086–7.141) |
| M stage (M0 vs. M1) | 0.049* | 3.649 (1.008–13.214) | 0.035* | 2.465 (1.067–5.696) |
| Vascular invasion (Yes vs. No) | 0.038* | 2.488 (1.051–5.891) | 0.024* | 2.945 (1.151–7.535) |
| TIMP1 expression (Negative vs. Positive) | 0.027* | 2.603 (1.115–6.077) | 0.013* | 2.907 (1.254–6.737) |
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | |
| First time TB diagnosis | 1995 | 1992 | 1985 | 2001 |
| Immigration Date | August-97 | July-97 | March-92 | March-03 |
| Duration between TB and MDR TB diagnosis | 2 years | 5 years | 12 years | 2 years |
| Duration between MDR TB and XDR TB diagnosis | 2 years | 5 years | 1.3 years | concurrent |
| Duration between XDR TB diagnosis and end of antituberculous drug therapy in Germany | 2.4 years | 1.9 years | 2 years | 2.5 years |
| Overall length of inhospital treatment in Germany | 4.5 years | 6 years | 6 years | 11 months |
| Outcome | treatment failure | cure | death | cure |
| Last sputum cultures | positive | negative | positive | negative |
| Radiologic signs of activity | present | not present | present | not present |
| Known transmission of XDR strain to contacts | no | no | no | no |
| p-value | |
| MicroRNA | (Hypoxia vs Normoxia) |
| ambi_miR_8488 | 0.00038 |
| hsa_miR_152 | 0.00064 |
| ambi_miR_13232 | 0.00137 |
| hsa_miR_193b | 0.00161 |
| hsa_miR_26a | 0.00204 |
| ambi_miR_2537 | 0.00460 |
| hsa_miR_512_5p | 0.01019 |
| mmu_miR_431 | 0.01033 |
| hsa_miR_23a | 0.01074 |
| ambi_miR_7036 | 0.01075 |
| hsa_miR_210 | 0.01103 |
| hsa_miR_125a | 0.01483 |
| ambi_miR_10594 | 0.01708 |
| hsa_miR_188 | 0.01969 |
| hsa_miR_27b | 0.02119 |
| hsa_miR_191 | 0.02243 |
| hsa_miR_30d | 0.02262 |
| hsa_miR_339 | 0.02339 |
| hsa_miR_200b | 0.02427 |
| hsa_miR_23b | 0.02885 |
| hsa_miR_452_AS | 0.03012 |
| hsa_miR_491 | 0.03651 |
| hsa_miR_30a_5p | 0.03778 |
| hsa_miR_30c | 0.04013 |
| rno_miR_333 | 0.04207 |
| ambi_miR_562 | 0.04695 |
| hsa_miR_213 | 0.04702 |
| hsa_miR_206 | 0.04786 |
| DHA source | Frequency, n |
| Salmon | 6 |
| Herring | 5 |
| Tuna | 4 |
| Cod | 3 |
| Brook trout | 3 |
| Trout | 2 |
| Carp | 1 |
| Sardines | 1 |
| Haddock | 1 |
| Grouper | 1 |
| Pike | 1 |
| White fish | 1 |
| Fish sticks (contains minced pollock) | 3 |
| Crustaceans | 3 |
| Caviar | 1 |
| Site | MPM | AF | BU | HE | HY | LE | RA | XE | Unk |
| Djorse | Pos | 12 | 10 | 4 | |||||
| Otuaplem | Pos | 4 | 10 | 1 | 2 | 12 | |||
| Sarpeiman | Pos | 1 | 13 | 8 | |||||
| Seduase | Pos | 9 | |||||||
| Achiaman | Pos | 18 | 1 | ||||||
| Kwashikuma | Pos | 16 | 48 | 3 | 1 | ||||
| Weija | Pos |
| Cigarette | Erg % | LPS % |
| Newport Menthol | 4.45 | 3.36 |
| Camel Turkish Royal | 9.90 | 6.18 |
| Pall Mall | 13.3 | 6.01 |
| Kool | 9.30 | 4.26 |
| Parliament Lights | 10.00 | 3.00 |
| Liggett Select Full Flavor | 8.57 | 3.99 |
| University of Kentucky | 10.86 | 6.30 |
| Trait | Reference |
| Agronomic traits | |
| Yield and yield parameters | Nath and Alam (2002) |
| Pod characters | Swamy et al. (2006) |
| Seed dormancy | Wang et al. (2012) |
| Early maturity | Upadhyaya et al. (2006) |
| Resistance to diseases and insect pests | |
| Early leaf spot (Cercospora arachidicola Hori) | Singh et al. (1997), Holbrook and Isleib (2001) |
| Late leaf spot [Phaeoisariopsis personata (Berk. & Curt.) Van Arx] | Singh et al. (1997, 2003), Holbrook and Isleib (2001), Li et al. (2012) |
| Leaf rust (Puccinia arachidis Spegazzini) | Singh et al. (1997, 2003) |
| Aflatoxin contamination (Aspergillus spp.) | Singh et al. (1997), Whitaker et al. (2004) |
| Stem and pod rot (Sclerotium rolfsii) | Singh et al. (1997), Gorbet et al. (2004) |
| Bacterial wilt resistance (Ralstonia solanacearum) | Singh et al. (1997) |
| Root-knot nematode (Meloidogyne spp.) | Holbrook and Isleib (2001) |
| Tomato spotted wilt virus (TSWV) | Li et al. (2012) |
| Groundnut rosette disease (GRD) | Subrahmanyam et al. (1998) |
| Kalahasty malady (Tylenchorhynchus brevilineatus) | Mehan et al. (1993) |
| Insect pests | Amin et al. (1985), Harish et al. (2012) |
| Abiotic stress tolerance | |
| Drought tolerance | Upadhyaya (2005), Jogloy et al. (2009), Balota et al. (2012) |
| Heat | Ntare et al. (2001) |
| Cold | Upadhyaya et al. (2009) |
| Salinity | Singh et al. (2008) |
| Aluminum toxicity | Boshou et al. (2000) |
| Nitrogen fixation tolerant to soil drying | Devi et al. (2010) |
| Quality parameters and others | |
| Nutritional quality | Wang et al. (2010), Upadhyaya et al. (2012) |
| Traits for confectionary uses | Dwivedi et al. (1994), Dwivedi and Nigam (2005) |
| Root hairs on roots and gynophores that enhance phosphorus uptake | Wissuwa and Ae (2001) |
| Phosphorus (P) uptake | Wissuwa and Ae (1998) |
| Clinical data | Dengue | Non-dengue | OR(95%CI) | ||
| N | % | N | % | ||
| History: | |||||
| Exhaustion | 68 | 98.6 | 69 | 95.8 | |
| Myalgia | 64 | 92.8 | 67 | 93.1 | |
| Headache | 60 | 87.0 | 64 | 87.7 | |
| Lumbar pain | 59 | 85.5 | 59 | 81.9 | |
| Anorexia | 55 | 79.7 | 55 | 75.3 | |
| Retro-orbital pain | 49 | 71.0 | 44 | 60.3 | |
| Taste disorder | 47 | 70.1 | 36 | 52.2 | 2.15 (1.06–4.36) |
| Nausea | 45 | 65.2 | 40 | 54.8 | |
| Arthralgia | 44 | 63.8 | 43 | 58.9 | |
| Photophobia | 38 | 55.9 | 35 | 47.9 | |
| Chills | 33 | 47.8 | 42 | 57.5 | |
| Dizziness | 33 | 47.8 | 34 | 46.6 | |
| History of rash | 30 | 44.1 | 14 | 19.2 | 3.33 (1.56–7.07) |
| Cough | 25 | 36.2 | 26 | 35.6 | |
| Diarrhea | 25 | 36.2 | 18 | 24.7 | |
| Vomiting | 22 | 31.9 | 17 | 23.6 | |
| Itching | 21 | 31.3 | 13 | 18.6 | |
| Abdominal pain | 21 | 30.4 | 31 | 42.5 | |
| Coryza | 20 | 29.0 | 21 | 28.8 | |
| Sore throat | 16 | 23.2 | 27 | 37.0 | |
| Nasal congestion | 14 | 20.9 | 17 | 24.6 | |
| History of bleeding | 12 | 17.4 | 6 | 8.2 | |
| Earache | 11 | 16.2 | 5 | 6.9 | |
| Hoarseness | 11 | 16.2 | 9 | 12.5 | |
| Dyspnea | 10 | 14.5 | 7 | 9.7 | |
| Physical exam: | |||||
| Rash | 48 | 71.6 | 31 | 45.6 | 3.02 (1.48–6.16) |
| Conjunctival redness | 38 | 55.9 | 20 | 29.0 | 3.10 (1.53–6.29) |
| Lymph node enlargement | 33 | 50.8 | 14 | 20.6 | 3.98 (1.86–8.53) |
| Dehydration | 24 | 35.3 | 16 | 23.2 | |
| Pharyngeal erythema | 15 | 22.4 | 21 | 31.3 | |
| Pallor | 11 | 16.4 | 15 | 21.7 | |
| Petechiae | 9 | 13.4 | 4 | 5.9 | |
| Hepatomegaly | 7 | 10.4 | 5 | 7.4 | |
| Splenomegaly | 5 | 7.5 | 5 | 7.2 |
| Number | Age at diagnosis | Disease duration | Anti-CCP-positive | RF-positive | |
| (years) | (years) | (%) | (%) | ||
| RA <1 year | 144 | 54 | 0.8 | 70 | 68 |
| RA >5 years | 59 | 48 | 11 | 87 | 75 |
| AS | 88 | 34 | 10 | 1 | nd |
| PsA | 30 | 41 | 6 | 3 | nd |
| SLE | 21 | 37 | 8 | 5 | nd |
| SSC | 20 | 51 | 0.5 | 5 | nd |
| Healthy | 50 | nd | nd | 0 | nd |
| Pathology | Human FXTAS | CGG knock-in mouse |
| CGG trinucleotide repeat length | 55 to 199 CGG repeat length, repeat instability | 70 to 300 CGG repeats, modest repeat instability |
| Elevated FMR1 mRNA expression | Increased 2- to 8-fold | Increased 1.5- to 3-fold |
| Fragile X mental retardation protein levels | Reduced in several brain regions | Reduced in several brain regions |
| Motor impairments | Tremor/ataxia, postural sway, parkinsonism | Impaired on rotarod and ladder rung task |
| Cognitive Impairments | Poor working memory, anxiety, depression, social phobia | Spatial memory deficits, altered anxiety-like behaviors |
| Intranuclear inclusions | Neurons and astrocytes, highly correlated with CGG repeat length, frequency increases with age | Neurons and astrocytes, related to length of CGG repeat, frequency increases with age |
| Any quantity fills | Single bottle gills of 2.5 mL | |||
| Method of imputing days supply | Sensitivity | Specificity | Sensitivity | Specificity |
| Medication possession | ||||
| Unadjusted days supply | 56% | 63% | 47% | 79% |
| 2.0-2.1 Variable Factor* | 60% | 60% | 53% | 77% |
| 2.0 Constant Factor/45 | ||||
| Minimum† | 61% | 60% | 54% | 77% |
| Days covered | ||||
| Unadjusted days supply | 53% | 68% | 43% | 99% |
| 2.0-2.1 Variable Factor* | 67% | 69% | 61% | 90% |
| 2.0 Constant Factor/45 | ||||
| Minimum† | 70% | 70% | 65% | 90% |
| Trial | Design | No. of Participants | Women % | Mean Age | Suppl. (Y) | Follow-up (Y) | BC, mg | Vit A μg | Vit C mg | Vit E mg | Selenium μg |
| AREDS [62] 2001 | 2x2 | 4757 | 56 | 68 | 6.3 | 6.3 | 15 | 500 | 400 | ||
| ARMDS [63] 1996 | Parallel | 71 | 7 | 72 | 1.5 | 1.5 | 72 | 750 | 165 | 50 | |
| Allsup et al [64], 2004 | Parallel | 164 | 63 | 83 | 0.15 | 0.5 | 800 | 120 | 60 | 60 | |
| Avenell et al [65], 2005 | Parallel | 910 | 47 | 72 | 1 | 1 | 800 | 60 | 10 | ||
| Boaz et al [66], 2000 | Parallel | 196 | 31 | 65 | 1.42 | 1.42 | 537 | ||||
| Brown et al [67], 2001 | 2x2 | 160 | 13 | 53 | 3 | 3 | 25 | 1000 | 537 | 100 | |
| Chylack et al [68], 2002 | Parallel | 297 | 59 | 68 | 3 | 3 | 18 | 750 | 600 | ||
| Collins et al [69], 2003 | 2x2 | 52 | 2 | 67 | 0.5 | 2.5 | 400 | ||||
| Cook et al [70], 2007 | 2x2x2 | 8171 | 100 | 61 | 9.4 | 9.4 | 25 | 500 | 221 | ||
| Correa et al [71], 2000 | 2x2x2 | 976 | 54 | 51 | 6 | 6 | 30 | 2000 | |||
| Desnuelle et al [72], 2001 | Parallel | 288 | 45 | 64 | 1 | 1 | 1000 | ||||
| Garbagnati et al [73], 2009 | Parallel | 72 | 35 | 65 | 1 | 1 | 19 | 240 | 290 | ||
| Girodon et al [74], 1999 | 2x2 | 725 | 74 | 84 | 2 | 2 | 6 | 120 | 15 | 100 | |
| Goodman et al [75], 2004 | Parallel | 18314 | 34 | 58 | 4 | 10 | 30 | 7500 | |||
| Graat et al [76], 2002 | 2x2 | 652 | 50 | N/A | 1 | 1 | 1.2 | 600 | 60 | 210 | 25 |
| Graf et al [77], 2005 | Parallel | 160 | 35 | 58 | 1.5 | 1.5 | 5000 | ||||
| Green et al [78], 1999 | 2x2 | 1621 | 56 | 49 | 4.5 | 4.5 | 30 | ||||
| Greenberg et al [79], 1990 | Parallel | 1805 | 30 | N/A | 5 | 5 | 50 | ||||
| Greenberg et al [80], 1994 | 2x2 | 864 | 21 | 61 | 4 | 4 | 25 | 1000 | 400 | ||
| Grieger et al [81], 2009 | Parallel | 115 | 65 | NA | 0.5 | 0.5 | 3 | 75 | 12,2 | ||
| Hennekens et al [82], 1996 | 2x2 | 22071 | 0 | 53 | 12 | 12.9 | 25 | ||||
| Hercberg et al [83], 2010 | Parallel | 13017 | 61 | 49 | 7.54 | 7.54 | 6 | 120 | 30 | 100 | |
| Hodis et al [84], 2002 | Parallel | 353 | 52 | 56 | 3 | 3 | 364 | ||||
| Jacobson et al [85], 2000 | Parallel | 112 | 42 | 42 | 0.5 | 0.5 | 12 | 500 | 268 | ||
| Lee et al [86], 2005 | 2x2 | 39876 | 100 | 55 | 10.1 | 10.1 | 25 | 221 | |||
| Li et al [87], 1993 | Parallel | 3318 | 56 | 54 | 6 | 6 | 15 | 3000 | 180 | 54 | 50 |
| Lippman et al [88], 2008 | 2x2 | 35533 | 0 | 62 | 5.5 | 5.5 | 400 | 200 | |||
| Liu et al [89], 2007 | Parallel | 763 | 68 | 85 | 1.6 | 1.6 | 16 | 400 | 80 | 44 | 20 |
| Lonn et al [90], 2005 | 2x2 | 9541 | 27 | 66 | 4.5 | 7 | 294 | ||||
| Magliano et al [91], 2006 | Parallel | 409 | 55 | 63 | 4 | 4 | 336 | ||||
| Manuel-y-Keenoy et al [92], 2004 | Parallel | 24 | 14 | 51 | 0.5 | 4.5 | 503 | ||||
| Marras et al [93], 2005 | 2x2 | 800 | 34 | 61 | 2.6 | 13 | 2000 | ||||
| McNeil et al [94], 2004 | Parallel | 1193 | 56 | 66 | 4 | 4 | 500 | ||||
| Meydani et al [95], 2004 | Parallel | 617 | 73 | 84 | 1 | 1 | 182 | 100 | |||
| Mezey et al [96], 2004 | Parallel | 51 | 33 | 48 | 0.25 | 1 | 1000 | ||||
| Milman et al [97], 2008 | Parallel | 1434 | 52 | 69 | 1.5 | 1.5 | 268 | ||||
| Moon et al [98], 1997 | Parallel | 2297 | 30 | 63 | 3.8 | 3.8 | 7500 | ||||
| Mooney et al [99], 2005 | Parallel | 284 | 45 | 37 | 1.25 | 1.25 | 500 | 364 | |||
| HPS [100] 2002 | 2x2 | 20536 | 25 | N/A | 5 | 5 | 20 | 250 | 600 | ||
| Murphy et al [101], 1992 | Parallel | 109 | N/A | N/A | 0.003 | 0.25 | 667 | ||||
| Pike et al [102], 1995 | Parallel | 47 | 72 | 69 | 1 | 1 | 800 | 90 | 45 | ||
| Plummer et al [103], 2007 | Parallel | 1980 | 53 | NA | 3 | 3 | 18 | 750 | 600 | ||
| Prince et al [104], 2003 | Cross-over | 61 | 92 | 58 | 0.25 | 0.25 | 3 | 150 | 50 | 75 | |
| Richer et al [105], 2004 | Parallel | 61 | 4 | 75 | 1 | 1 | 9 | 750 | 1500 | 413 | 200 |
| Salonen et al [106], 2003 | 2x2 | 520 | 51 | N/A | 6 | 6 | 250 | 182 | |||
| Sesso et al [107], 2008 | 2x2x2 | 14641 | 0 | 64 | 8 | 8 | 25 | 1050 | 560 | 182 | 20 |
| Stephens et al [108], 1996 | Parallel | 2002 | 16 | 62 | 1.4 | 1.4 | 403 | ||||
| Tam et al [109], 2005 | Parallel | 39 | 100 | 46 | 0.23 | 2.67 | 500 | 661 | |||
| Virtamo et al [110], 2003 | 2x2 | 29133 | 0 | 57 | 6.1 | 14.1 | 20 | 50 | |||
| Waters et al [111], 2002 | 2x2 | 423 | 100 | 65 | 3 | 3 | 1000 | 800 | |||
| White et al [112], 2002 | Parallel | 100 | 42 | 63 | 0.23 | 0.23 | 1000 | 200 | |||
| Witte et al [113], 2005 | Parallel | 32 | N/A | N/A | 0.75 | 0.75 | 800 | 500 | 400 | 50 | |
| Wluka et al [114], 2002 | Parallel | 136 | 45 | 64 | 2 | 2 | 368 |
| Variable | Blood component | ||||
| Plasma | P-PRP+NID | P-PRG | PPP+NID | PPG | |
| (n=40) | (n=40) | (n=40) | (n=40) | (n=40) | |
| Total protein -TP- (mg/mL)* | 45.9 (4.4)a | 49.5 (6.2)b | 46.1 (4.5) | 46.4 (5.0) | 45.5 (5.5) |
| TGF-β1 (pg/mL) | 1114.3 (457.7)c | 3192.7 (1395.3)d | 2555.5 (1069.4)d | 1714.3 (496.3) | 1508.0 (445.9) |
| TGF-β1 (pg/mg of TP) | 24.4 (11.2)c | 64.9 (29.5)d | 56.0 (24.3)d | 37.2 (11.2) | 33.3 (10.5) |
| PDGF-BB (pg/mL) | 158.1 (281.0)c | 1259.7 (418.6)d | 1228.8 (418.0)d | 601.8 (339.3) | 611.7 (295.9) |
| PDGF-BB (pg/mg of TP) | 3.5 (6.5)c | 25.5 (8.7)d | 27.2 (10.8)d | 13.2 (7.9) | 13.6 (7.3) |
| Haplotype | Case | Control | P-value |
| 2-2-1-2-1-1 | 6.115 | 6.69 | 0.2675 |
| 2-2-1-2-1-2 | 0.9372 | 0 | 0.308 |
| 2-2-1-2-3-1 | 0.6905 | 0 | 0.9992 |
| 2-2-1-4-1-1 | 828.9 | 834 | 0.8783 |
| 2-2-1-4-1-2 | 9.433 | 10.21 | 0.8322 |
| 2-2-1-4-3-1 | 57.67 | 113 | 3.747E-05 |
| 2-2-1-4-3-2 | 1.007 | 0 | 0.3188 |
| 2-2-3-2-1-1 | 12.98 | 6.27 | 0.3267 |
| 2-2-3-2-1-2 | 0 | 0.6707 | 1 |
| 2-2-3-2-3-1 | 1.204 | 0 | 1 |
| 2-2-3-4-1-1 | 0.867 | 1.918 | 0.3793 |
| 2-2-3-4-1-2 | 15.44 | 19.16 | 0.7131 |
| 2-2-3-4-3-1 | 30.39 | 43.74 | 0.2237 |
| 2-2-3-4-3-2 | 2.114 | 0.9249 | 0.609 |
| 2-4-1-4-1-1 | 1.627 | 3.416 | 0.365 |
| 2-4-3-2-1-2 | 0.8596 | 2.21 | 0.6195 |
| 2-4-3-4-1-1 | 1.591 | 13.85 | 0.002506 |
| 2-4-3-4-1-2 | 137.2 | 122.5 | 0.4528 |
| 2-4-3-4-3-1 | 0 | 2.456 | 0.01213 |
| 3-2-1-2-1-1 | 1.148 | 0.6285 | 0.7064 |
| 3-2-1-4-1-1 | 85.07 | 64.9 | 0.07011 |
| 3-2-1-4-1-2 | 1.305 | 0.2028 | 0.3483 |
| 3-2-1-4-3-1 | 3.732 | 0 | 0.3045 |
| 3-2-3-2-1-1 | 295.5 | 334.6 | 0.1975 |
| 3-2-3-2-1-2 | 7.775 | 4.195 | 0.2888 |
| 3-2-3-2-3-1 | 4.929 | 8.097 | 0.1492 |
| 3-2-3-4-1-1 | 5.902 | 0.8962 | 0.06286 |
| 3-2-3-4-1-2 | 48.69 | 19.48 | 0.0004034 |
| 3-2-3-4-3-1 | 1114 | 1153 | 0.3141 |
| 3-2-3-4-3-2 | 5.975 | 2.85 | 0.2993 |
| 3-4-1-4-1-1 | 1.055 | 4.961 | 0.1278 |
| 3-4-1-4-1-2 | 1.301 | 2.3 | 0.6549 |
| 3-4-1-4-3-1 | 1.013 | 0 | 0.3212 |
| 3-4-1-4-3-2 | 0 | 0.6906 | 0.09517 |
| 3-4-3-2-1-1 | 7.049 | 1.218 | 0.3176 |
| 3-4-3-2-1-2 | 12.86 | 31.44 | 0.008042 |
| 3-4-3-4-1-1 | 17.34 | 20.11 | 0.555 |
| 3-4-3-4-1-2 | 2422 | 2309 | 0.02225 |
| 3-4-3-4-3-1 | 0 | 12.7 | 0.004522 |
| Stage dose and route | Patients, n (active:placebo) |
| SAD stage dose, route (cohort) | |
| 0.3 IV (A) | 4:1 |
| 1.0 IV (B) | 4:1 |
| 1.0 SC (C) | 4:1 |
| 3.0 IV (D) | 4:1 |
| 3.0 SC (E) | 4:1 |
| 5.0 IV (F) | 4:1 |
| MAD stage dose, route (cohort) | |
| 1.0 SC (G) | 8:2 |
| 3.0 SC (H) | 16:4 |
| 5.0 IV (I) | 4:1 |
| Adsorption Concentration (mol/L) | 10−3 | 10−2 | 10−1 |
| Absorbance | 1.004 | 0.860 | 0.377 |
| Drug concentration | 0.125 × 10−3 | 0.106 × 10−2 | 0.045 × 10−1 |
| The remaining amount of R6G in 20 mL solution (mg) | 1.198 | 10.189 | 42.589 |
| The amount of added magnetic particles (g) | 0.001 | 0.01 | 0.1 |
| The amount of the adsorbed drug (mg) | 0.239 | 4.085 | 101.114 |
| The amount of the adsorbed drug by 1.0 g particles (mg) | 239.0 | 408.5 | 1011.1 |
| DNA Binding Factor | No. of Bound Genes in the Genome | No. of Bound Genes in hESCs | No. of Bound POLR3G-Dependent Genes | Hypergeometric Test p Value | Adjusted p Value (Benjamini-Hochberg) |
| NANOG | 25,071 | 1,668 (12.2%) | 166 (16.3%) | 3.64 × 10−5 | 2.19 × 10−4 |
| KLF4 | 3,793 | 1,116 (8.2%) | 105 (10.3%) | 4.55 × 10−4 | 1.36 × 10−3 |
| SOX2 | 5,682 | 467 (3.4%) | 49 (4.8%) | 6.57 × 10−3 | 1.31 × 10−2 |
| EP300 | 3,093 | 280 (2.1%) | 37 (3.6%) | 9.08 × 10−3 | 1.36 × 10−2 |
| POU5F1 | 3,889 | 1,524 (11.1%) | 123 (12.1%) | 1.74 × 10−1 | 2.09 × 10−1 |
| POLR3A | 389 | 40 (0.3%) | 3 (0.3%) | 5.81 × 10−1 | 5.81 × 10−1 |
| M | SD | Range | |
| Townsend disability score | 2.4 | 1.38 | 0–4 |
| Social resources (LSNS-6) | 15.4 | 5.90 | 0–30 |
| Cognitive impairment (MMSE) | 26.9 | 3.02 | 8–30 |
| Loneliness | 1.0 | 1.18 | 0–6 |
| Livron 6 loci (without Pwalt_Te39) | Aouste 7 loci | ||
| Ne - LDNe | 892 (243 - Infinite) | -1470 (585 - Infinite) | |
| Ne - ONeSAMP | Run 1 | 186 (103-327) | 533 (202-1995) |
| Run 2 | 182 (93-314) | 1209 (434-5855) | |
| Run 3 | 142 (83-260) | 1844 (557-10265) |
| Overall | Monotherapy | Part of double combination therapy | Part of triple combination therapy | |
| Amikacin | 17.3 | 15.7 | 19.4 | 9.5 |
| Meropenem | 11.8 | 7.2 | 10.8 | 26.2 |
| Piperacillin-tazobactam | 11.2 | 27.7 | 6.3 | 4.8 |
| Ampicillin | 10.1 | 1.2 | 14.0 | 7.1 |
| Gentamicin | 9.2 | 3.6 | 13.1 | 0 |
| Cefotaxime | 5.8 | 15.7 | 3.2 | 0 |
| Fluconazole | 4.9 | 2.4 | 4.1 | 14.3 |
| Ciprofloxacin | 3.8 | 4.8 | 4.1 | 0 |
| Vancomycin | 3.5 | 1.2 | 4.1 | 4.8 |
| Ceftriaxone | 2.6 | 4.8 | 2.3 | 0 |
| Colistin | 2.3 | 0 | 2.7 | 4.8 |
| Levofloxacin | 2.0 | 2.4 | 2.3 | 0 |
| Cefoperazone Sulbactam | 3.2 | 0 | 4.5 | 2.4 |
| Amphotericin B/Amphotericin B liposomal | 1.7 | 2.4 | 1.4 | 2.4 |
| Cefoperazone | 1.4 | 1.2 | 1.4 | 2.4 |
| Section | Number of infants with indicators for OPD | Frequency distribution (%) |
| A. Functioning of physiological subsystems? | 2 | 10 |
| B. State of alertness during feeding† | - | - |
| C. Stress cues during feeding | 15 | 75 |
| D. Movement and muscle tone screening | 4 | 20 |
| E. Oral peripheral examination | 8 | 40 |
| F. Clinical feeding and swallowing evaluation | 14 | 70 |
| Diagnosis of OPD | 9 | 45 |
| Day from onset of fever | Day of defervescence | Total fluid intake in ml | IV fluids in ml | ||||||||
| DHF group | DF group | P value* | DHF group | DF group | P value* | ||||||
| Mean | SD | Mean | SD | Mean | SD | Mean | SD | ||||
| D2 | D-3 | 2123 | 492 | 2314 | 1449 | 0.706 | 1113 | 308 | 1053 | 678 | 0.810 |
| D3 | D-2 | 2733 | 1457 | 2158 | 833 | 0.135 | 1464 | 612 | 1245 | 476 | 0.198 |
| D4 | D-1 | 2846 | 1250 | 2798 | 1164 | 0.851 | 1648 | 523 | 1537 | 460 | 0.290 |
| D5 | D0 | 2981 | 1247 | 2754 | 1071 | 0.268 | 1857 | 609 | 1563 | 531 | 0.004 |
| D6 | D + 1 | 3139 | 880 | 2812 | 966 | 0.032 | 1889 | 541 | 1512 | 417 | <0.001 |
| D7 | D + 2 | 3154 | 913 | 2918 | 884 | 0.129 | 1870 | 555 | 1533 | 422 | <0.001 |
| D8 | D + 3 | 2791 | 690 | 2979 | 936 | 0.255 | 1589 | 487 | 1599 | 494 | 0.920 |
| D9 | D + 4 | 2762 | 598 | 2825 | 762 | 0.782 | 1449 | 543 | 1583 | 503 | 0.494 |
| D10 | D + 5 | 2281 | 639 | 2957 | 1163 | 0.152 | 1310 | 617 | 1583 | 514 | 0.377 |
| Variables | Total n (%) | Boys n (%) | Girls n (%) |
| Alcohol use & bullying others | 15 (2.2) | 13 (4.0) | 2 (0.6) |
| Alcohol use & sexual activity | 12 (1.8) | 11 (3.4) | 1 (0.3) |
| Early sexual intercourse & sexual activity | 10 (1.5) | 6 (1.8) | 4 (1.1) |
| Alcohol use & cigarette use | 9 (1.3) | 4 (1.2) | 5 (1.4) |
| Sexual activity & bullying others | 4 (0.6) | 3 (0.9) | 1 (0.3) |
| Tablets use & bullying others | 3 (0.4) | 3 (0.9) | 0 (0.0) |
| Cigarette use & sexual activity | 5 (0.7) | 2 (0.6) | 3 (0.8) |
| Cigarette use & bullying others | 4 (0.6) | 3 (0.9) | 1 (0.3) |
| Alcohol use & tablets use | 2 (0.3) | 2 (0.6) | 0 (0.0) |
| Alcohol use & cigarette use & sexual activity | 12 (1.8) | 5 (1.5) | 7 (2.0) |
| Alcohol use & sexual activity & bullying others | 10 (1.5) | 8 (2.4) | 2 (0.6) |
| Alcohol use & early sexual intercourse & sexual activity | 9 (1.3) | 6 (1.8) | 3 (0.8) |
| Alcohol use & cigarette use & bullying others | 6 (0.9) | 4 (1.2) | 2 (0.6) |
| Early sexual intercourse & sexual activity & bullying others | 5 (0.7) | 4 (1.2) | 1 (0.3) |
| Alcohol use & tablets use & bullying others | 2 (0.3) | 0 (0.0) | 2 (0.6) |
| Cigarette use & early sexual intercourse & sexual activity | 3 (0.4) | 1 (0.3) | 2 (0.6) |
| Cigarette use & sexual activity & bullying others | 1 (0.1) | 1 (0.3) | 0 (0.0) |
| Cigarette use & tablets use & bullying others | 2 (0.3) | 0 (0.0) | 2 (0.6) |
| Cigarette & alcohol & early sexual intercourse & sexual activity | 5 (0.7) | 5 (1.5) | 0 (0.0) |
| Cigarette & early sexual intercourse & sexual activity & bullying | 2 (0.3) | 2 (0.6) | 0 (0.0) |
| Cigarette & Alcohol & early sexual intercourse & bullying others | 1 (0.1) | 1 (0.3) | 0 (0.0) |
| Alcohol use & early sexual intercourse & sexual activity & bullying | 1 (0.1) | 1 (0.3) | 0 (0.0) |
| Cigarette & alcohol & early sex & sexual activity & bullying others | 5 (0.7) | 4 (1.2) | 1 (0.3) |
| Cigarette & alcohol & tablets & early sex & sexual activity | 1 (0.1) | 0 (0.0) | 1 (0.3) |
| Cigarette & alcohol & tablets & early sex & sexual activity & bullying | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| All | Age 35-59 years | Age 60-74 years | ||||||||||
| eGFR (mL/min/1.73 m2) | eGFR (mL/min/1.73 m2) | eGFR (mL/min/1.73 m2) | ||||||||||
| Coeff. | HR at more adverse level* | p-value | Coeff. | HR at more adverse level* | p-value | Coeff. | HR at more adverse level* | p-value | ||||
| Allcausemortality | ||||||||||||
| Classicalriskfactorsadjusted | -0.0025 | 0.97 | 0.6829 | 0.0181 | 1.18 | 0.3290 | -0.0178 | 0.81 | 0.0020 | |||
| Incident cardiovascular disease | ||||||||||||
| Classicalriskfactorsadjusted | -0.0020 | 0.98 | 0.8030 | 0.0262 | 1.28 | 0.2063 | -0.0162 | 0.83 | 0.0451 |
| Gene symbol | Gene full name | Fold regulation | p-value |
| TLR2 | Toll-like receptor 2 | −30.20 | 0.02 |
| IL1A | Interleukin 1, alpha | −7.85 | 0.01 |
| LTB | Lymphotoxin beta (TNF superfamily, member 3) | −5.80 | 0.02 |
| IL23A | Interleukin 23, alpha subunit p19 | −5.67 | 0.01 |
| TLR4 | Toll-like receptor 4 | −4.03 | 0.01 |
| CCL7 | Chemokine (C-C motif) ligand 7 | −3.78 | 0.00 |
| CXCL3 | Chemokine (C-X-C motif) ligand 3 | −3.66 | 0.02 |
| CXCR2 | Chemokine (C-X-C motif) receptor 2 | −3.55 | 0.02 |
| TLR1 | Toll-like receptor 1 | −3.31 | 0.01 |
| IL15 | Interleukin 15 | −3.23 | 0.00 |
| CCR1 | Chemokine (C-C motif) receptor 1 | −2.91 | 0.03 |
| IL18 | Interleukin 18 | −2.49 | 0.00 |
| IL10 | Interleukin 10 | −2.20 | 0.05 |
| IL1R1 | Interleukin 1 receptor, type I | −2.02 | 0.01 |
| LY96* | Lymphocyte antigen 96 (MD-2) | 2.49 | 0.01 |
| Intervention N = 392 | Comparison N = 394 | ||
| Birth interval (months) | |||
| Mead (SD) | 40.0 (30) | 38.1 (26) | F 0.89, p 0.35; unequal variance in birth interval |
| Missing | (2) | (1) | |
| Birth weight | |||
| Mean (SD) | 3403 (509) | 3500 (504) | Difference -97 g |
| Missing data | (3) | (2) | |
| Low birth weight (<2500 g) | 25/393 | 14/394 | OR (exact) 1.85 [0.91, 3.91] |
| Birth weight <10thpercentile* | 40/378 (11%) | 31/382(8%) | OR (exact) 1.14 [0.55, 2.38] |
| Low birth weight | |||
| <1000 g | 6 | 0 | |
| 1000–1499 | 3 | 0 | |
| 1500–1999 | 7 | 2 | |
| 2000–2499 | 9 | 12 | |
| All with birth weight (≥ 2,500 g | 367 | 380 | |
| Missing data | (3) | (2) | |
| All births | 395 | 396 | |
| Gestation | |||
| Mean (SD) | 39.3 (2.2) | 39.5 (1.5) | |
| Preterm birth (<37 weeks) | 24 (6%) | 17 (4%) | OR (exact) 1.44 (0.73, 2.91) |
| Preterm birth | |||
| 20–27 weeks | 4 | 0 | |
| 28–31 weeks | 6 | 1 | |
| 32–36 weeks | 14 | 16 | |
| All with gestations ≥ 37 weeks | 366 | 374 | |
| Missing data | (2) | (3) | |
| All gestations | 392 | 394 |
| Plasmid | Description | Source |
| pRL446 | Elhai and Wolk, 1988 | |
| pMD18T | TA cloning vector | TaKaRa clonetech |
| pMD18Tslr1670 | This study | |
| pMD18Tslr1670KmR | Construction Δslr1670 | This study |
| pXT323 | Construction ΔglpK | This study |
| Number of patients (%) | |
| Histology | |
| Non-small cell lung cancer | 56 (88%) |
| Other | 6 (9%) |
| No pathology | 2 (3%) |
| Dose schedule | |
| 6 Gy × 5 fractions | 2 (3%) |
| 8 Gy × 5 fractions | 7 (11%) |
| 9 Gy × 5 fractions | 1 (1.5%) |
| 10 Gy × 5 fractions | 10 (16%) |
| 10.5 Gy × 5 fractions | 7 (11%) |
| 12 Gy × 4 fractions | 17 (27%) |
| 18 Gy* × 3 fractions | 19 (29%) |
| Other | 1 (1.5%) |
| Tumor size | |
| ≤ 3 cm | 36 (56%) |
| >3 cm | 28 (44%) |
| SBRT indication | |
| Refused surgery | 7 (11%) |
| Medically inoperable | 47 (73%) |
| Surgically incurable | 10 (16%) |
| Location | |
| Central | 23 (36% |
| Peripheral | 41 (64%) |
| n | TAC M (SE) | Activity counts/min M (SE) | MVPA percentage M (SE) | Lifestyle percentage M (SE) | Light percentage M (SE) | Sedentary percentage M (SE) | Wear time M (SE) | |
| High OA men | 252 | 410,694 (10,303) | 465.6 (11.0) | 5.1 (0.2) | 15.6 (0.4) | 32.6 (0.3) | 46.7 (0.5) | 891.5 (9.4) |
| High OA women | 37 | 337,066 (32,206) | 388.1 (39.2) | 3.2 (0.7) | 13.4 (1.6) | 35.4 (1.8) | 48.0 (2.8) | 876.2 (16.0) |
| p-value | 0.004 | 0.005 | <0.001 | 0.033 | 0.118 | 0.371 | 0.75 | |
| Intermediate OA men | 175 | 346,091 (8743) | 390.6 (10.7) | 3.7 (0.2) | 13.3 (0.5) | 31.1 (0.5) | 51.9 (0.8) | 897.5 (9.5) |
| Intermediate OA women | 125 | 279,822 (10,002) | 326.7 (11.1) | 2.1 (0.2) | 11.8 (0.5) | 34.5 (0.8) | 51.4 (1.2) | 863.9 (7.6) |
| p-value | <0.001 | <0.001 | <0.001 | 0.092 | <0.001 | 0.554 | 0.018 | |
| Low OA men | 207 | 317,172 (9801) | 359.4 (9.3) | 3.9 (0.2) | 10.5 (0.5) | 26.3 (0.8) | 59.2 (1.1) | 890.4 (8.0) |
| Low OA women | 316 | 258,408 (4913) | 295.8 (5.0) | 2.3 (0.1) | 9.1 (0.2) | 30.6 (0.2) | 57.9 (0.4) | 880.4 (4.8) |
| p-value | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | 0.227 | 0.373 |
| Variable | ML score (95% CI)a | MEWS (95% CI)b | Difference (95% CI for difference)c | P value |
| Cardiac arrest within 72 hours after presentation | ||||
| Area under ROC curve | 0.781 | 0.680 | 0.101 (0.006 to 0.197) | 0.037 |
| Sensitivity | 81.4 | 74.4 | 7.0 (-11.1 to 21.9) | 0.581 |
| Specificity | 72.3 | 54.2 | 18.1 (14.3 to 22.0) | < 0.001 |
| Positive predictive value | 12.5 (9.0 to 17.1) | 7.4 (5.3 to 10.3) | < 0.001 | |
| Negative predicting value | 98.8 (97.5 to 99.4) | 97.8 (95.9 to 98.8) | 0.133 | |
| Likelihood ratio (+)d | 2.94 (2.46 to 3.52) | 1.62 (1.34 to 1.96) | ||
| Death after admissione | ||||
| Area under ROC curve | 0.741 | 0.693 | 0.048 (-0.023 to 0.119) | 0.185 |
| Sensitivity | 69.8 | 74.4 | -4.7 (-16.7 to 7.4) | 0.572 |
| Specificity | 73.9 | 55.7 | 18.2 (14.3 to 22.2) | < 0.001 |
| Positive predictive value | 21.5 (16.9 to 26.9) | 14.7 (11.5 to 18.4) | < 0.001 | |
| Negative predicting value | 96.0 (94.1 to 97.3) | 95.5 (93.2 to 97.1) | 0.608 | |
| Likelihood ratio (+)d | 2.67 (2.23 to 3.20) | 1.68 (1.45 to 1.94) |
| Prospective cohort | Fixed effects (all) | Fixed effects (worked > 41 h) | Fixed effects (worked >48 h) | |
| N | 5910 | 18,221 | 5889 | 1631 |
| Long working hours (>48 h) | 1% | 9% | 28% | 100% |
| Semi-long hours (41–48 h) | 6% | 31% | 96% | 86% |
| Short sickness absence | 73% | 64% | 64% | 52% |
| Long sickness absence | 23% | 14% | 14% | 13% |
| Extra-long sickness absence | 12% | 6% | 6% | 5% |
| Age | 45 (SD 12) | 42 (SD 12) | 43 (SD 12) | 44 (SD 11) |
| Salary | 506,685 (SD 160094) | 649,470 (SD 369401) | 746,052 (SD 438982) | 887,558 (SD 479854) |
| Female | 67% | 71% | 58% | 43% |
| Temporary contract | 16% | 32% | 38% | 45% |
| Multiple jobholders | 3% | 5% | 5% | 6% |
| Norwegian | 92% | 92% | 92% | 91% |
| Other Nordic | 3% | 4% | 4% | 4% |
| Other western | 2% | 2% | 2% | 3% |
| Non Western | 2% | 2% | 2% | 2% |
| Physician | 11% | 16% | 37% | 67% |
| Nurse | 30% | 32% | 27% | 12% |
| Other patient-related | 20% | 22% | 14% | 10% |
| Administration/management | 23% | 17% | 10% | 6% |
| Kitchen/cleaning/orderly | 6% | 4% | 5% | 0% |
| Other operations | 6% | 4% | 4% | 2% |
| Other | 6% | 5% | 3% | 2% |
| Dawn | Michelle | |||
| State PCL-5 TRASC* | Pre | Post | Pre | Post |
| #1: Flashbacks of traumatic events | 3 | 3 | 0 | 2 |
| #2: Altered sense of time | 3 | 3 | 0 | 0 |
| #3: Marked loss of emotional feeling | 2 | 4 | 0 | 0 |
| #4: Feeling what you are experiencing is not real | 3 | 3 | 0 | 0 |
| #5: Out of body experience | 2 | 2 | 0 | 0 |
| #6: Feeling like a part of your body is not your own | 2 | 2 | 0 | 0 |
| #7: Identity confusion | 1 | 2 | 1 | 0 |
| #8: Divided or multiple senses of self | 3 | 2 | 3 | 1 |
| #9: Loss of time | 3 | 2 | 0 | 0 |
| #10: Hearing voices | 0 | 0 | 0 | 0 |
| Antinuclear antibodies | P1 | P2 |
| Anti-nRNP/SM | 3+, 2+, 2+ | 3+, 2+, 1+ |
| Anti-SM | N, N, N | 2+, 1+, N |
| Anti-SSA | 3+, 3+, 3+ | 3+, 3+, 3+ |
| Anti-RO-52 | N, N, N | 3+, 3+, 3+ |
| Anti-SSB | N, N, N | 1+, N, N |
| Anti-SCOL-70 | N, N, N | N, N, N |
| Anti-JO-1 | N, N, N | N, N, N |
| Anti-CENP B | N, N, N | N, N, N |
| Anti-dsDNA | 3+, 2+, 2+ | 1+, N, N |
| Anti-nucleosome | 3+, 3+, 3+ | N, N, N |
| Anti-histone | 3+, 1+, 1+ | N, N, N |
| Anti-ribosomal P | N, N, N | 3+, 3+, 2+ |
| ACA | N, N, N | N, N, N |
| Question | Number | % |
| Blood on your tooth brush during brushing may be a sign of: | ||
| 1. Gum disease | 57 | 95.0 |
| 2. Tooth decay | 2 | 3.3 |
| 3. I don’t know | 1 | 1.7 |
| What should you do when you see blood on your toothbrush? | ||
| 1. Stop brushing | 1 | 1.7 |
| 2. Stop brushing the area that is bleeding | 4 | 6.7 |
| 3. Continue brushing | 22 | 36.7 |
| 4. See a dentist | 33 | 55.0 |
| 5. I don’t know what to do | 0 | 0 |
| Group | Biopsy | Reaction | |||
| 0 | I | II | III | ||
| Dercum | Painful abdomen (n = 41) | 11 (27) | 14 (34) | 16 (39) | - |
| Painful knee (n = 47) | 11 (23) | 21 (45) | 14 (30) | 1 (2) | |
| Non-painful area (n = 28) | 8 (29) | 14 (50) | 6 (21) | - | |
| Obese controls | Abdomen (n = 41) | 12 (29) | 15 (37) | 12 (29) | 2 (5) |
| Knee (n = 41) | 10 (24) | 13 (32) | 16 (39) | 2 (5) | |
| Normal weight controls | Knee (n = 11) | 6 (55) | 5 (45) | - | - |
| Differences between groups (p-value) | |||||
| Dercum vs. Obese controls - abdomen | 0.022 | ||||
| Dercum vs. Obese controls - knee | 0.33 | ||||
| Dercum vs. Normal weight controls - knee | 0.81 | ||||
| Obese vs. Normal weight controls - knee | < 0.001 | ||||
| Dercum - painful abdomen vs. Dercum - non-painful abdomen1 | 0.4 | ||||
| Dercum - painful knee vs. Dercum - non-painful knee2 | 0.5 |
| Coiling [n (%)] | Clipping [n (%)] | P | |
| Deteriorated | 2 (10.5) | 7 (38.9) | 0.1900 |
| Unchanged | 4 (21.1) | 2 (11.1) | |
| Improved | 13 (68.4) | 9 (50.0) |
| Group 1 | Group 2 | P value | |
| (n = 19) | (n = 7) | ||
| Age (years), mean ± SD | 29.4 ± 10.8 | 26.6 ± 9.2 | 0.549a |
| BMI (kg/m2), mean ± SD | 20.5 ± 3.4 | 20.0 ± 2.1 | 0.693a |
| Side, n (%) | |||
| left | 6 (31.6) | 3 (42.9) | 0.945b |
| right | 13 (68.4) | 4 (57.1) | |
| Quadrant, n (%) | |||
| up-out | 8 (42.1) | 2 (28.6) | 0.454b |
| up-in | 6 (31.6) | 3 (42.9) | |
| low-in | 3 (15.8) | 0 (0.0) | |
| low-out | 2 (10.5) | 2 (28.6) | |
| Depth (mm), mean ± SD | 15.3 ± 3.9 | 15.9 ± 3.6 | 0.710a |
| Basal volume (mL), median (range) | 1.82 (0.35–5.95) | 8.14 (1.53–10.39) | 0.0140c |
| Color flow Doppler pattern (%) | |||
| 0 | 8 (42.1) | 2 (28.5) | 0.194b |
| I | 8 (42.1) | 1 (14.3) | |
| II | 2 (10.5) | 3 (42.9) | |
| III | 1 (5.3) | 1(14.3) |
| Study | Intact +ve/−ve | Circumcised +ve/−ve | Odds ratio | 95% confidence interval | Exact odds ratio | Exact 95% confidence interval |
| Agot | 207/237 | 184/210 | 1.00 | 0.76–1.31 | 0.9968 | 0.7525–1.3206 |
| Bailey | 58/118 | 65/79 | 0.60 | 0.38–0.94 | 0.5984 | 0.3657–0.9654 |
| Burundi | 48/1612 | 22/864 | 1.17 | 0.70–1.95 | 1.1693 | 0.6870–2.0486 |
| Bwayo | 88/88 | 376/383 | 1.02 | 0.73–1.41 | 1.0186 | 0.7238–1.4336 |
| Gray et al. [44]* | 156/4443 | 33/875 | 0.92 | 0.64–1.36 | 0.9310 | 0.6312–1.4097 |
| Gray et al. [163]* | 503/3967 | 97/728 | 0.93 | 0.64–1.36 | 0.9516 | 0.7528–1.2123 |
| Lavreys | 47/48 | 297/354 | 1.17 | 0.76–1.80 | 1.1668 | 0.7404–1.8383 |
| Newell | 77/1279 | 58/588 | 0.61 | 0.43–0.87 | 0.6105 | 0.4222–0.8866 |
| Seed | 236/358 | 136/107 | 0.52 | 0.38–0.70 | 0.5159 | 0.3790–0.7095 |
| Tyndall | 86/92 | 311/321 | 0.96 | 0.69–1.35 | 0.9649 | 0.6818–1.3646 |
| Warner | 2316/2849 | 14352/21054 | 1.19 | 1.12–1.26 | 1.1925 | 1.1239–1.2653 |
| Random effects summary effect: | 0.8902 | 0.7277–1.0891 |
| Patient | Tumor site | T stage | N stage | M stage |
| 1 | Oral cavity | 1 | 0 | 0 |
| 2 | Oral cavity | 4a | 2b | 0 |
| 3 | Oral cavity | 4a | 2c | 0 |
| 4 | Oropharynx | 2 | 0 | 0 |
| 5 | Oropharynx | 2 | 2b | 0 |
| 6 | Oropharynx | 3 | 2b | 0 |
| 7 | Oropharynx | 4a | 0 | 0 |
| 8 | Oropharynx | 4a | 2c | 0 |
| 9 | Oropharynx | 4a | 2c | 1 |
| 10 | Hypopharynx | 3 | 2b | 0 |
| Variable | Idealistic Distortion | χ2 | p Value | ||||
| Lown (%) | Averagen (%) | Highn (%) | Very Highn (%) | ||||
| Place of Residence | Urban | 3 (0.5) | 189 (29.3) | 318 (49.3) | 135 (20.9) | 5.314 | 0.105 |
| Rural | 13 (1.5) | 243 (27.5) | 420 (47.6) | 207 (23.4) | |||
| Job | Employed | 4 (1.8) | 63 (27.9) | 113 (50) | 46 (20.4) | 1.98 | 0.58 |
| Housewife | 12 (0.9) | 369 (28.3) | 625 (48) | 296 (22.7) | |||
| Education | Illiterate | 1 (2.6) | 7 (18.4) | 24 (63.2) | 6 (15.8) | 10.55 | 0.31 |
| Below diploma | 10 (1.4) | 212 (29.7) | 332 (46.6) | 159 (22.3) | |||
| High school Diploma | 2 (0.4) | 141 (29.1) | 232 (47.9) | 109 (22.5) | |||
| Higher Education | 3 (1) | 72 (24.6) | 150 (51.2) | 68 (23.2) | |||
| Spouse’s Education | Illiterate | 0 (0) | 0 (0) | 4 (80) | 1 (20) | 11.99 | 0.214 |
| Below diploma | 11 (1.5) | 220 (29.7) | 334 (45.1) | 175 (23.6) | |||
| High school Diploma | 1 (0.6) | 54 (31) | 87 (50) | 32 (18.4) | |||
| Higher Education | 4 (0.7) | 158 (25.9) | 313 (51.4) | 134 (22) | |||
| Spouse’s Job | Unemployed | 2 (4.8) | 18 (42.9) | 18 (42.9) | 4 (9.5) | 12.40 | 0.006 |
| Employed | 14 (0.9) | 414 (27.9) | 720 (48.5) | 338 (27.7) | |||
| Income | Less than 100$ | 7 (1.7) | 105 (25.4) | 197 (47.6) | 105 (25.4) | 12.68 | 0.048 |
| 100-300$ | 7 (0.8) | 237 (27.5) | 431 (50.1) | 186 (21.6) | |||
| More than 300$ | 2 (0.8) | 90 (35.6) | 110 (43.5) | 51 (20.2) | |||
| Fertility Status | Fertile | 10 (1) | 288 (28.3) | 503 (49.5) | 216 (21.2) | 2.75 | 0.433 |
| Infertile | 6 (1.2) | 144 (28.2) | 235 (46) | 126 (24.7) |
| BMI | Associated UK 1990 centile2 | ||
| Boys | Girls | ||
| (a) Classify their children as currently overweight | |||
| 7 yearsb | 23.1 | 99 | 99 |
| 12 years | 24.4 | 99 | 97 |
| 15 years | 29.1 | 99 | 99 |
| (b) Express concern that their children will become overweight in the future | |||
| 7 yearsb | 17.1 | 81 | 75 |
| 12 years | 20.3 | 88 | 79 |
| 15 years | 24.1 | 94 | 91 |
| All groups (average) | ≥ 9 years (average) | < 9 years (average) | P value (t test) | |
| Resource consumption | ||||
| Hospitalized | 158 (12.4%) | 96 (10.7%) | 62 (16.4%) | |
| Length of stay (hospitalization days) | 4.1 | 4.0 | 4.3 | 0.003 |
| Consultations (N) | 3.2 | 3.0 | 3.5 | 0.0006 |
| Workdays lost | 2.1 | 2.2 | 1.9 | 0.0036 |
| School days missed | 4.9 | 4.9 | 4.9 | 0.078 |
| Nonhospitalized | 1,121 (87.6%) | 805 (89.3%) | 316 (83.6%) | |
| Consultations (N) | 2.4 | 2.4 | 2.4 | |
| Workdays lost | 0.4 | 0.3 | 0.6 | |
| School days missed | 1.7 | 1.7 | 1.7 | |
| All episodes* | 1,279 | 901 | 378 | |
| Length of stay(hospitalization days) | 0.5 | 0.4 | 0.7 | |
| Consultations (N) | 2.5 | 2.5 | 2.6 | |
| Workdays lost | 0.6 | 0.5 | 0.8 | |
| School days missed | 2.1 | 2.0 | 2.3 |
| Plasma characteristics | β coefficient (S.E.) | Pvalue |
| Neurocognitive impairment | −0.03 (0.16) | 0.859 |
| Gender, male | −0.48 (0.23) | 0.042 |
| Current CD4+ count, per 50 copies | −0.04 (0.02) | 0.021 |
| Detectable HIV VL | 0.37 (0.16) | 0.021 |
| IL-10, per 10 units | 0.18 (0.10) | 0.061 |
| Characteristics | n (%) |
| Symptom occurrence (%) | |
| Mean (range) | 61 (21-100) |
| Incubation time (hr) | |
| Mean (range) | 2 (1-15) |
| Clinical symptoms2 | |
| Diarrhea | 78 (82.9) |
| Vomiting | 78 (82.9) |
| Abdominal pain | 60 (63.8) |
| Nausea | 56 (59.5) |
| Chillness | 55 (58.5) |
| Fever | 35 (37.2) |
| Headache | 6 (6.0) |
| Final clinical outcome | Number (%) of patients |
| Favorable (44 hips) | |
| Excellent | 19 (32.8) |
| Good | 25 (43.1) |
| Unfavorable (14 hips) | |
| Fair | 4 (6.9) |
| Poor | 10 (17.2) |
| Total | 58 (100) |
| Traits/gene transcripts | BTN1A1 | SCD | LPL | GPAM | ACACA | LPIN |
| CMY60 (kg) | 0.43 | 0.48 | 0.40 | 0.65* | 0.22 | 0.19 |
| TDMY (kg) | 0.17 | 0.28 | 0.16 | 0.36 | 0.13 | 0.12 |
| FPCTDMY (kg) | 0.20 | 0.32 | 0.26 | 0.47 | 0.21 | 0.19 |
| Fat percent | 0.20 | 0.18 | 0.43 | 0.49 | 0.38 | 0.34 |
| SNF percent | −0.30 | −0.37 | −0.41 | 0.00 | −0.57 | −0.56 |
| Protein percent | −0.23 | −0.54 | −0.37 | −0.03 | −0.56 | −0.54 |
| Lactose percent | −0.36 | −0.65* | −0.49 | −0.19 | −0.67* | −0.65* |
| Cropping pattern | SGS | NGS | ||||||
| HF | MF | LF | Mean | HF | MF | LF | Mean | |
| MZ-CP within row | 1.92 | 1.71 | 1.30 | 1.65 | 1.92 | 1.73 | 1.01 | 1.56 |
| MZ-CP 1:1 rows | 1.51 | 1.32 | 1.01 | 1.28 | 1.45 | 1.23 | 0.85 | 1.17 |
| MZ-CP 2:2 rows | 1.27 | 1.13 | 0.97 | 1.12 | 1.41 | 1.20 | 0.73 | 1.11 |
| Sole cowpea | 2.84 | 2.52 | 1.37 | 2.24 | 2.73 | 1.82 | 1.15 | 1.90 |
| Mean | 1.89 | 1.67 | 1.16 | 1.57 | 1.88 | 1.49 | 0.94 | 1.44 |
| SED (arrangement) | 0.09 | 0.09 | ||||||
| SED (fertility) | 0.07 | 0.11 | ||||||
| SED (interaction) | 0.15 | 0.17 | ||||||
| MZ-SB within row | 3.45 | 3.42 | 2.96 | 3.27 | 3.51 | 2.09 | 1.26 | 2.28 |
| MZ-SB 1:1 rows | 3.17 | 2.77 | 2.76 | 2.90 | 2.37 | 1.51 | 0.88 | 1.59 |
| MZ-SB 2:2 rows | 2.97 | 2.77 | 2.65 | 2.80 | 2.35 | 1.39 | 0.92 | 1.55 |
| Sole soybean | 5.84 | 6.10 | 5.60 | 5.85 | 4.90 | 2.67 | 1.69 | 3.09 |
| Mean | 3.86 | 3.76 | 3.49 | 3.70 | 3.28 | 1.92 | 1.19 | 2.13 |
| SED (arrangement) | 0.19 | 0.14 | ||||||
| SED (fertility) | n.s. | 0.21 | ||||||
| SED (interaction) | n.s. | 0.29 | ||||||
| MZ-GN within row | 1.17 | 0.86 | 0.89 | 0.97 | 0.87 | 0.81 | 0.66 | 0.78 |
| MZ-GN 1:1 rows | 0.86 | 0.88 | 0.79 | 0.84 | 0.76 | 0.68 | 0.56 | 0.66 |
| MZ-GN 2:2 rows | 0.94 | 0.87 | 0.87 | 0.90 | 0.76 | 0.69 | 0.60 | 0.69 |
| Sole groundnut | 1.79 | 1.74 | 1.52 | 1.68 | 1.40 | 1.17 | 0.87 | 1.14 |
| Mean | 1.19 | 1.09 | 1.02 | 1.10 | 0.94 | 0.84 | 0.67 | 0.82 |
| SED (arrangement) | 0.11 | 0.05 | ||||||
| SED (fertility) | n.s | 0.05 | ||||||
| SED (interaction) | n.s. | 0.08 |
| Disease | EC50 (95% CI) [pM] | Max. spec. lysis [%] | Antigen Density [molecules/cell] | |||
| CD19 | CD33 | |||||
| B cell lines | SEM | Pre-B ALL | 12 (8 – 18) | 58.7 | 50,000 ± 17,000 | < 100 |
| BV173 | Pre-B ALL | 3 (1 – 6) | 61.0 | 60,000 ± 11,000 | 4,500 ± 800 | |
| Raji | Burkitt's lymphoma | 42 (18 – 98) | 60.8 | 31,000 ± 19,000 | 650 ± 100 | |
| ARH77 | Plasma cell leukemia | 460 (179 – 1,177) | 39.4 | 3,000 ± 2,000 | < 100 | |
| AML cell lines | MOLM-13 | AML-M5a | 100 (58 – 173) | 42.3 | 0 | 32,000 ± 6,500 |
| THP-1 | AML-M5 | 2,442 (1,105 – 5,311) | 14.6 | 0 | 17,000 ± 4,000 | |
| Patient samples | ALL | 39 (9 – 165) | 72.9 | n.d | n.d. | |
| MPAL(NOS) | 72 (63 – 84) | 46.6 | 8,500 ± 3,000 | 300 | ||
| B-CLL | 101 (1 – 44,550) | 99.2 | n.d. | n.d. |
| Variable | Value | Effect | S.E. | CI | 95% |
| Mother's BMI | 4 points increment | 0.85 | 0.12 | 0.62 | 1.08 |
| Age (Mother) | 5 years increment | 0.73 | 0.17 | 0.41 | 1.06 |
| Time studying per day (hours) | 6 hrs increment | 0.83 | 0.15 | 0.53 | 1.13 |
| Time in sport activities per day (hours) | 3 hrs increment | -0.43 | 0.18 | -0.77 | -0.08 |
| Time in front of TV per day | ≤ 1 h vs. 1-2 hrs | -2.09 | 0.36 | -2.8 | -1.38 |
| >2 hrs vs. 1-2 hrs | -0.26 | 0.29 | -0.83 | 0.3 | |
| Municipality income (low vs. high) | 1.82 | 0.28 | 1.26 | 2.37 |
| Items | n (%) | Male (n = 32) | Female (n = 35) |
| Knowledge about worm infection: | |||
| Heard about liver fluke “san tap” or “pha yat bai mai nai tap” | 34 (50.7) | 34.4 | 65.7 |
| How to get infection with O. viverrini: | |||
| Eating raw vegetables | 3 (4.5) | 3.1 | 5.7 |
| Not maintaining good personal hygiene: hand washing, nail clipping, unclean environment | 8 (11.9) | 15.6 | 11.4 |
| Eating any raw food: meat, snail, shrimp | 29 (43.3) | 34.4 | 51.4 |
| Eating raw fish dishes (Koi Pa, Lap Pa Nuew) | 8 (11.9) | 12.5 | 11.4 |
| Heard about roundworm | 52 (77.6) | 84.4 | 71.4 |
| How to get infection with roundworm: | |||
| It just occurs in our body | 2 (2.9) | 0 | 5.7 |
| Eat any raw: meat, fish, shrimp, vegetables | 7 (10.4) | 15.6 | 5.7 |
| Not maintaining good personal hygiene: not hand washing before eating, not clipping nails, flies touching our food, drinking dirty water | 16 (23.9) | 18.7 | 28.6 |
| Heard about hookworm | 3 (4.5) | 6.2 | 2.8 |
| Do not know | 3 (4.5) | 6.2 | 2.8 |
| Heard about whipworm | 2 (2.9) | 6.2 | 0 |
| Do not know | 2 (2.9) | 6.2 | 0 |
| Heard about tapeworm | 33 (49.3) | 46.9 | 51.4 |
| Eating raw food | 8 (11.9) | 21.9 | 2.8 |
| Eating raw fish dishes | 33 (49.3) | 53.1 | 45.7 |
| Perceptions of latrine use: | |||
| Village will not be dirty | 15 (22.4) | 34.4 | 11.4 |
| Flies do not touch our food anymore | 4 (5.9) | 12.5 | 0 |
| Prevention of diseases/no transmission of diseases | 10 (14.9) | 18.8 | 11.4 |
| Animals will not eat human faeces | 6 (8.9) | 0 | 17.1 |
| Convenience (not getting wet from rain, convenience during the night and when sick) | 13 (19.4) | 6.2 | 31.4 |
| Perceived liver fluke as health problem in community | 6 (8.9) | 12.5 | 5.7 |
| Practices personal hygiene: | |||
| Hand washing before eating | 31 (46.3) | 31.2 | 60.0 |
| Saying that most of people in village do not wash hands with soap | 10 (14.9) | 0 | 28.6 |
| Perceptions of personal hygiene: | |||
| Hands will be clean if we wash hands before eating | 10 (14.9) | 0 | 28.6 |
| We will be healthy if we wash hands before eating | 3 (4.5) | 9.4 | 0 |
| We can not get any worm infections or diseases if we wash our hands before eating | 20 (29.9) | 28.1 | 31.4 |
| Deworming in community: | |||
| Getting dewormed | 37 (55.2) | 75.0 | 37.1 |
| Treatment of tapeworm with traditional medicine | 19 (28.3) | 43.7 | 14.3 |
| Treatment with modern medicine | 18 (26.9) | 31.2 | 22.8 |
| Treatment of roundworm using modern medicine | 2 (2.9) | 2.9 | 0 |
| Intervention Mean(SE) | Control Mean(SE) | Estimated Intervention Effect Mean (95%CI) | p-value from GEE model | |
| Pre-intervention mean score | 7.71 (0.11) | 7.48 (0.09) | ||
| Post-intervention mean score | 3.63 (0.26) | 4.24 (0.27) | ||
| Pre-post difference | 4.08 (0.23) | 3.24 (0.30) | 0.84 (0.10; 1.58) | 0.03 |
| Pre-post difference adjusted for number of physician visits | 4.10 (0.18) | 3.25(0.27) | 0.85 (0.21 ;1.48) | 0.01 |
| Predictors | OR | P value | 95% CI | |
| Lower | Upper | |||
| Right side operation | 2.37 | <0.001 | 1.52 | 3.70 |
| Male | 2.66 | <0.001 | 1.65 | 4.28 |
| Pleural adhesion | 1.76 | 0.005 | 1.18 | 2.62 |
| BMI < 25.5 kg/m2 | 1.72 | 0.02 | 1.08 | 2.75 |
| Reference | Author | Article | Published in journal | Year published | nsubjects | nteeth | Study design |
| [6] | Pogrel et al. | “Coronectomy: a technique to protect the inferior alveolar nerve” | J Oral Maxillofac Surg | 2004 | 41 | 50 | Prospective cohort |
| [7] | Renton et al. | “A randomised controlled clinical trial to compare the incidence of injury to the inferior alveolar nerve as a result of coronectomy and removal of mandibular third molars” | Br J Oral Maxillofac Surg | 2005 | 128 | 94 | Randomized controlled trial |
| [8] | Pogrel | “An update on coronectomy” | J Oral Maxillofac Surg | 2009 | Not available | 450 | Prospective cohort |
| [9] | Leung and Cheung | “Safety of coronectomy versus excision of wisdom teeth: a randomized controlled trial” | Oral Surg Oral Med Oral Pathol Oral Radiol Endod | 2009 | 231 | 171 | Randomized controlled trial |
| [10] | Hatano et al. | “Clinical evaluations of coronectomy (intentional partial odontectomy) for mandibular third molars using dental computed tomography: a case-control study” | J Oral Maxillofac Surg | 2009 | 220 | 102 | Case control study |
| [11] | Dolanmaz et al. | “A preferable technique for protecting the inferior alveolar nerve: coronectomy” | J Oral Maxillofac Surg | 2009 | 43 | 47 | Prospective cohort |
| [12] | Cilasun et al. | “Coronectomy in patients with high risk of inferior alveolar nerve injury diagnosed by computed tomography” | J Oral Maxillofac Surg | 2011 | 120 | 175 | Prospective cohort |
| [13] | Leung and Cheung | “Coronectomy of the lower third molar is safe within the first 3 years” | J Oral Maxillofac Surg | 2012 | 98 | 135 | Prospective cohort |
| Astaxanthin Content mg/g | C 2 | G 3 | F 4 | E 5 | U 6 | R 7 |
| 0 | 4304.24 ± 177.48 a | 612.47 ± 95.0 a | 1027.15 ± 105.80 a | 120.56 ± 14.02 a | 182.17 ± 14.02 a | 2361.89 ± 146.96 b |
| 3 | 4413.37 ± 151.21 a | 678.24 ± 107.11 a | 1079.89 ± 77.55 a | 141.24 ± 23.59 a | 186.47 ± 13.59 a | 2327.53 ± 139.19 b |
| 6 | 4315.56 ± 147.14 a | 845.24 ± 125.24 a,b | 1024.54 ± 86.78 a | 155.73 ± 16.10 a | 196.59 ± 16.10 a | 2093.46 ± 170.37 a,b |
| 9 | 4532.36 ± 284.82 a | 1048.12 ± 76.37 b | 1263.78 ± 97.73 a | 221.47 ± 31.68 b | 201.21 ± 21.68 a | 1797.78 ± 114.54 a |
| 12 | 4557.24 ± 147.97 a | 1175.11 ± 92.45 b | 1243.45 ± 107.73 a | 233.45 ± 21.68 b | 214.53 ± 21.68 a | 1690.70 ± 114.54 a |
| DEG_Set | Annotated | COG | GO | KEGG | KOG | Pfam | Swiss-Prot | eggNOG | Nr |
| FD1/FD2 | 1825 | 573 | 981 | 603 | 959 | 1355 | 1230 | 1676 | 1795 |
| FD2/FD3 | 1753 | 607 | 995 | 587 | 928 | 1369 | 1255 | 1638 | 1731 |
| FD1/FD3 | 2658 | 741 | 1455 | 835 | 1306 | 1993 | 1858 | 2463 | 2615 |
| MD1/MD2 | 2038 | 667 | 1094 | 716 | 1068 | 1505 | 1317 | 1881 | 1957 |
| MD2/MD3 | 518 | 158 | 323 | 189 | 231 | 422 | 398 | 485 | 510 |
| MD1/MD3 | 3002 | 926 | 1696 | 1049 | 1556 | 2231 | 2055 | 2801 | 2916 |
| Tear location | Autograft | Allograft |
| Near femoral attachment | 14 | 2 |
| Near tibial attachment | 1 | 2 |
| Mid-substance | 1 | 4 |
| Stretched | 2 | 2 |
| No graft seen | 1 | 1 |
| Possible answers | |
| How often do you use wikipedia as an information source in general? | |
| Never | |
| 1-5x/week | |
| Daily | |
| 1-5x/month | |
| How often do you use Wikipedia as an information source in your medical studies? | |
| Never | |
| 1-5x/week | |
| Daily | |
| 1-5x/month | |
| Given that you read a medical article on Wikipedia, do you draw any criteria to evaluate its quality? (Multiple answer possible) | |
| I compare it to my knowledge | |
| Number of references | |
| Authors are well-known | |
| High number of revisions | |
| Date of latest revision | |
| I compare it to specific literature | |
| I discuss the content with my colleagues/teachers | |
| I do not draw any criteria | |
| I trust my gut feeling | |
| Given that you find incorrect information, what do you do? | |
| I correct the error | |
| I am not familiar how to correct articles | |
| I know how to correct articles but leave the entry unaltered | |
| I draw attention to the false information in any other way |
| ODI item | No sick-leave for PGP | Sick-leave for PGP | E.S. | p |
| Pain intensity | 2.30 (0.84) | 2.33 (0.88) | 0.039 | =.954 |
| Personal care | 0.90 (1.11) | 0.94 (1.14) | 0.033 | =.889 |
| Lifting | 1.40 (1.21) | 1.90 (1.29) | 0.395 | =.044 |
| Walking | 0.96 (1.01) | 1.44 (0.97) | 0.483 | =.011 |
| Sitting | 0.96 (1.00) | 1.46 (0.87) | 0.528 | =.003 |
| Standing | 1.50 (1.33) | 2.00 (1.22) | 0.392 | =.031 |
| Sleeping | 1.12 (0.85) | 1.48 (1.03) | 0.379 | =.113 |
| Sex | 1.18 (1.41) | 1.23 (1.49) | 0.037 | =.969 |
| Social function | 1.26 (1.27) | 1.33 (1.31) | 0.056 | =.677 |
| Travelling | 0.92 (1.12) | 1.25 (1.23) | 0.280 | =.180 |
| Anda | Sør‐Gjæslingan | |||
| Oceanic | Coastal | Oceanic | Coastal | |
| Habitat | ||||
| Intrinsic | 0.000 | 0.929 | ||
| Weather | 1.000 | 0.153 | ||
| Time | 1.000 | 0.030 | ||
| Commuting | ||||
| Intrinsic | 0.998 | 0.669 | 0.834 | 0.010 |
| Weather | 0.002 | 0.323 | 0.991 | 0.999 |
| Time | 1.000 | 0.700 | 0.010 | 0.000 |
| Foraging | ||||
| Intrinsic | 0.300 | 0.950 | 0.237 | 1.000 |
| Weather | 0.697 | 0.999 | 0.421 | 0.000 |
| Time | 0.916 | 0.008 | 0.151 | 1.000 |
| Resting | ||||
| Intrinsic | 1.000 | 1.000 | 0.933 | 0.171 |
| Weather | 0.000 | 0.000 | 0.995 | 0.613 |
| Time | 1.000 | 1.000 | 0.003 | 0.894 |
| Behavior | ||||
| Intrinsic | 0.766 | 0.873 | 0.668 | 0.394 |
| Weather | 0.233 | 0.441 | 0.802 | 0.537 |
| Time | 0.972 | 0.569 | 0.055 | 0.631 |
| Variable | Odds ratio | 95%confidence interval |
| Guideline-recommended vancomycin dosing | 0.91 | 0.53-1.56 |
| Vancomycin duration > 15 days | 3.65 | 2.16-6.17 |
| Weight greater than 100 kilograms | 2.08 | 1.18-3.67 |
| Pitt Bacteremia Score of four or greater | 3.80 | 2.17-6.63 |
| Vancomycin trough greater than 20 mcg/ml | 2.51 | 1.28-4.92 |
| Age greater than 52 years | 2.40 | 1.38-4.15 |
| Intensive care unit resident | 3.64 | 2.15-6.18 |
| Concomitant nephrotoxin | 2.08 | 1.24-3.49 |
| Male gender | 1.04 | 0.56-1.57 |
| Charlson comorbidity index 5 or greater | 1.14 | 0.57-2.27 |
| Baseline serum creatinine greater than 1.0 mg/dL | 0.94 | 0.56-1.57 |
| GEO ID | Sample count (case:control) | Platform | Sample source | Tissue |
| GSE14359 | 18: 2 | GPL96 [HG-U133A] Affymetrix Human Genome U133A Array | in vivo | Bone, lung |
| GSE16102 | 48: 6 | GPL96 [HG-U133A] Affymetrix Human Genome U133A Array | in vivo | Bone |
| GSE12865 | 12: 2 | GPL6244 [HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array | in vivo | Bone |
| GSE11414 | 4: 2 | GPL6244 [HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array | in vitro | Bone |
| GSE42352 | 103:15 | GPL10295 Illumina human-6 v2.0 expression beadchip (using nuIDs as identifier) | in vivo/in vitro | Bone |
| GSE36001 | 19: 6 | GPL6102 Illumina human-6 v2.0 expression beadchip | in vitro | Bone |
| GSE32964 | 35: 1 | GPL6947 Illumina HumanHT-12 V3.0 expression beadchip | in vivo | Bone |
| GSE30807 | 1: 1 | GPL570 [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array | in vitro | Bone |
| Gene | Primer sequences | Amplicon length | Annealing temperature |
| MBD-1 | 5' TCTGGTTGCCAAGGTCCAAA 3'5' ACATCCATCTTCCCTTCCCGA 3' | 122bp | 61°C |
| vimentin | 5' TGGAAGAGAACTTTGCCGTTG 3'5' AAGGTGACGAGCCATTTCCTC 3' | 101bp | 60°C |
| GRP78 | 5' CACCAATGACCAGAATCGCCT 3'5' CAATGCGCTCCTTGAGCTTT 3' | 101bp | 60°C |
| Conjugate | N | F0, RFU | Fenz, RFU | Fmax |
| BSA-FITC(Voss et al.) | 25 | - | - | 3450 |
| KLH-sCy5 | 380-750 | 6.25 | 1140 | 18100 |
| BSA-sCy5 | 6.7 | 2.37 | 1680 | 70800 |
| rhBChE-sCy5 | 30 | 6.17 | 1750 | 28300 |
| BSA-sCy7 | 6.5 | 1.8 | 660 | 36500 |
| rhBChE-sCy7 OFF | 32 | 2.71 | 597 | 21900 |
| rhBChE-sCy7 ON | 1 | 50 | 50.05 | 0.1 |
| AE or laboratory abnormality | n (%) | |||
| Grade 1/2 | Grade 3 | Grade 4 | Any grade | |
| Non-hematologic AEs of any cause occurring in ≥ 15% of patients | ||||
| Fatigue/asthenia | 33 (55) | 12 (20) | 0 | 45 (75) |
| Diarrhea | 33 (55) | 3 (5) | 0 | 36 (60) |
| Stomatitis, oral discomfort, and related oral syndromes | 29 (48) | 3 (5) | 0 | 32 (53) |
| Dysgeusia | 27 (45) | 0 | 0 | 27 (45) |
| Hypertension | 18 (30) | 8 (13) | 0 | 26 (43) |
| Skin and subcutaneous tissue disorders | 25 (42) | 0 | 0 | 25 (42) |
| Vomiting | 19 (32) | 2 (3) | 0 | 21 (35) |
| Dyspepsia | 20 (33) | 0 | 0 | 20 (33) |
| Epistaxis | 18 (30) | 2 (3) | 0 | 20 (33) |
| Nausea | 20 (33) | 0 | 0 | 20 (33) |
| Headache | 17 (28) | 2 (3) | 0 | 19 (32) |
| Decreased appetite | 14 (23) | 4 (7) | 0 | 18 (30) |
| Dry skin | 14 (23) | 1 (2) | 0 | 15 (25) |
| Ejection fraction decreased | 10 (17) | 3 (5) | 1 (2) | 14 (23) |
| Abdominal pain | 11 (18) | 0 | 0 | 11 (18) |
| Hand–foot syndrome and related disorders | 8 (13) | 3 (5) | 0 | 11 (18) |
| Pyrexia | 11 (18) | 0 | 0 | 11 (18) |
| Weight decreased | 11 (18) | 0 | 0 | 11 (18) |
| Constipation | 10 (17) | 0 | 0 | 10 (17) |
| Left ventricular dysfunction | 8 (13) | 2 (3) | 0 | 10 (17) |
| Insomnia | 8 (13) | 1 (2) | 0 | 9 (15) |
| Dyspnea | 8 (13) | 1 (2) | 0 | 9 (15) |
| Hematologic laboratory abnormalities | ||||
| Leukopenia | 46 (77) | 4 (7) | 1 (2) | 51 (85) |
| Anemia | 46 (77) | 2 (3) | 0 | 48 (80) |
| Neutropenia | 36 (60) | 9 (15) | 1 (2) | 46 (77) |
| Lymphopenia | 36 (60) | 6 (10) | 1 (2) | 43 (72) |
| Thrombocytopenia | 34 (57) | 6 (10) | 3 (5) | 43 (72) |
| Topic | Sub-Topic | Positive Feedback |
| Usability | Utilization | “Both the motor and cognitive tasks were easy.” |
| Learning | “There was no problem in learning the use of the system.” | |
| Pleasantness | “The 3D glass was not uncomfortable.”“The environment was beautiful.”“The cycle-ergometer was manageable.” | |
| Sense of Presence | Spatial Presence | “The feeling was to be in the real park.”“I had the feeling of being suspended.” “The environment was relaxing.” |
| Engagement | “I was focused on the task.”“I think I’ve been pedaling for 5 min.”“I forget you (the examiners) were here too.” | |
| Realism | “The environment was realistic.” | |
| Cyber Sickness | Physical side-effects | None present side effect like cyber-sickness or nausea |
| Expectations | “This system could be useful for several types of patients.”“I think it’s easier to train with this tool.” |
| Outdoor exposure from 10 am-4 pm corrected for protective factors (years; fifths) | ||||||
| < 0.073* | 0.073 – 0.190 | 0.191 – 0.428 | 0.429 – 0.800 | > 0.800 | Trend test (p-value)‡ | |
| Pure nuclear (No. of cases = 100) | ||||||
| OR§ | 1 | 2.37 | 3.36 | 2.02 | 3.19 | 0.05 |
| (95% CI) | (0.88, 6.38) | (1.32, 8.54) | (0.75, 5.44) | (1.24, 8.21) | ||
| Pure cortical (No. of cases = 40) | ||||||
| OR§ | 1 | 0.55 | 0.58 | 0.51 | 0.29 | 0.09 |
| (95% CI) | (0.18, 1.71) | (0.20, 1.72) | (0.16, 1.67) | (0.78, 1.09) | ||
| Pure posterior (No. of cases = 62) | ||||||
| OR§ | 1 | 0.76 | 1.01 | 0.58 | 0.57 | 0.23 |
| (95% CI) | (0.27, 2.12) | (0.40, 2.56) | (0.21, 1.62) | (0.20, 1.60) | ||
| Outdoor exposure from 10 am-4 pm (years; fifths) | ||||||
| < 0.312* | 0.312 – 0.612 | 0.613 – 0.968 | 0.969 – 1.428 | > 1.428 | Trend test (p-value) | |
| Pure nuclear (No. of cases = 100) | ||||||
| OR§ | 1 | 2.22 | 1.28 | 1.86 | 3.68 | 0.01 |
| (95% CI) | (0.88, 5.61) | (0.47, 3.52) | (0.70, 4.91) | (1.50, 9.01) | ||
| Pure cortical (No. of cases = 40) | ||||||
| OR§ | 1 | 0.50 | 0.47 | 0.12 | 0.67 | 0.28 |
| (95% CI) | (0.17, 1.44) | (0.16, 1.42) | (0.03, 0.55) | (0.22, 2.00) | ||
| Pure posterior (No. of cases = 62) | ||||||
| OR§ | 1 | 0.42 | 0.62 | 0.42 | 0.57 | 0.09 |
| (95% CI) | (0.15, 1.16) | (0.24, 1.60) | (0.15, 1.14) | (0.22, 1.45) |
| Boys (N = 3,256) | Girls (N = 3,158) | |||
| n | % | n | % | |
| Age | ||||
| 9 | 476 | 14.6 | 482 | 15.3 |
| 10 | 479 | 14.7 | 489 | 15.5 |
| 11 | 473 | 14.5 | 475 | 15.0 |
| 12 | 473 | 14.5 | 479 | 15.2 |
| 13 | 454 | 13.9 | 426 | 13.5 |
| 14 | 453 | 13.9 | 400 | 12.7 |
| 15 | 448 | 13.8 | 407 | 12.9 |
| School Type | ||||
| Government | 2,403 | 73.8 | 2,335 | 73.9 |
| Catholic | 655 | 20.1 | 677 | 21.4 |
| Independent | 198 | 6.1 | 146 | 4.6 |
| SES | ||||
| Low | 310 | 9.7 | 272 | 8.8 |
| Medium-low | 1,230 | 38.5 | 1,197 | 38.6 |
| Medium-high | 914 | 28.6 | 886 | 28.6 |
| High | 742 | 23.2 | 748 | 24.1 |
| Weight status* | ||||
| Under/acceptable weight | 2,899 | 89.0 | 2,778 | 88.0 |
| Overweight | 301 | 9.2 | 335 | 10.6 |
| Obese | 56 | 1.7 | 45 | 1.4 |
| Parental Exercise | ||||
| Both parents active | 553 | 18.4 | 630 | 21.5 |
| Mother active only | 518 | 17.3 | 537 | 18.3 |
| Father active only | 627 | 20.9 | 565 | 19.3 |
| Both parents inactive | 1,303 | 43.4 | 1,196 | 40.9 |
| Incomplete data | 255 | 7.8 | 230 | 7.3 |
| Number of sports | ||||
| 0 sport | 184 | 5.7 | 230 | 7.3 |
| 1 sport | 586 | 18.0 | 691 | 21.9 |
| 2 sports | 881 | 27.1 | 857 | 27.1 |
| 3 sports | 740 | 22.7 | 658 | 20.8 |
| 4 sports | 484 | 14.9 | 404 | 12.8 |
| 5 sports | 235 | 7.2 | 187 | 5.9 |
| 6 sports | 146 | 4.5 | 131 | 4.2 |
| Synthesis feature | Traditional systematic review | Critical interpretive synthesis |
| Research question | • A research question is developed a priori and is not changed during the course of the research study. | • A compass question is developed, which can evolve over the course of the research study, in a transparent manner. |
| Literature search | • Exhaustive literature search | • Exhaustive literature search but can purposively sample literature outside of original search parameters |
| Article selection | • Static inclusion and exclusion criteria are applied to search results; | • Inclusion and exclusion criteria are iteratively refined to reflect the evolving compass questions (often through successive pilot testing of the criteria using small batches of references with the final criteria applied to all search results); |
| • Included articles are empirical studies and often consist only of a small number of specific methodological designs (e.g., RCT, CCT, observational studies); and | • Included articles can consist of both empirical and non-empirical (e.g., editorials, essays) analyses that offer insight into the topic under investigation (i.e., articles are not limited to those that meet certain design or quality criteria); and | |
| • All relevant articles meeting inclusion criteria and minimum quality standard are included in the analysis. | • A purposive sample of eligible articles is typically selected based on the unique insights they can provide to the topic under investigation. | |
| Quality rating of articles | • Quality ratings are usually applied to all articles included in a systematic review and used to help interpret the findings. | • Relevance ratings are applied to articles, not quality ratings (i.e., articles are rated on their ability to answer the compass question). |
| Synthesis | • Data is extracted from all studies meeting the inclusion criteria using an a priori approach; and | • Data is extracted from a purposive sample of studies using an analytic framework where the constructs are iteratively revised and reapplied to the included papers to ensure the constructs are grounded in the data; and |
| • Findings are synthesized either quantitatively (i.e., in a meta-analysis) or qualitatively, which typically involves reporting findings from studies according to the pre-defined outcomes of interest. | • The analytical constructs that emerged from the iterative analysis are used to derive an explanatory framework. |
| Model for total tibial cartilage volume | r2 | p Value for Δ r2 compared with the specified model | ΔF with addition to the model (p value for ΔF is the same as for Δr2) |
| Bone area only (+) | 0.14 | < 0.001 | N/A |
| Bone area (+) age (-) | 0.21 | < 0.001 compared with bone area only | 14.84 |
| Bone area (+) age (-) smoking, alcohol | 0.22 | 0.43 compared with bone area and age | 0.86 |
| Bone area (+) age (-) smoking, alcohol, BMI | 0.22 | 0.53 compared with bone area, age, smoking and alcohol | 0.39 |
| Bone area (+) age (-) smoking, alcohol, ln hsCRP (-) | 0.28 | < 0.001 compared with bone area, age, smoking, alcohol | 13.15 |
| Bone area (+) age (-) smoking, alcohol, BMI ln hsCRP(-) | 0.28 | < 0.001 compared with bone area age smoking alcohol | 7.23 (both variables added together); if BMI added first, ΔF = 0.43 (p for ΔF = 0.51) followed by lnCRP ΔF = 13.99, (p for ΔF < 0.001); if ln CRP added first, ΔF = 13.15, (p for ΔF < 0.001) followed by BMI ΔF = 1.28, (p for ΔF = 0.26) |
| No COPD | COPD | COPD/CHF | |||
| Number of beneficiaries | 1,319,680 | 245,958 | 118,617 | ||
| As % of all beneficiaries | 84.30% | 15.70% | 7.60% | ||
| Personal Characteristics | |||||
| Females, % | 59.70% | 54.50% | 55.10% | ||
| Age (yrs), mean (sd) | 75.8 (7.3) | 77.4 (7.2) | 78.9 (7.4) | ||
| Medicare-Disabled/ESRD, % | 7% | 14% | 16% | ||
| Bottom quartile household income,% | 24% | 30% | 31% | ||
| Comorbidities | |||||
| Diabetes | 21.00% | 33.60% | 44.70% | ||
| CHF | 17.80% | 48.20% | 100.00% | ||
| Ischemic heart disease | 35.50% | 65.40% | 84.60% | ||
| Atrial fibrillation | 9.60% | 20.60% | 36.00% |
| Author | Cell line name | Species | Location |
| Hishikawa et al. [61] | SP cells | Mouse | Renal interstitial space |
| Challen et al. [62] | SP cells | Mouse | Proximal tubules |
| Inowa et al. [30] | SP cells | Human | Not identified |
| Dekel et al. [33] | Sca1+ cells | Mouse | Nontubular |
| Gupta et al. [34] | MRPCs | Rat | Renal tubules |
| Maeshima et al. [4, 35] | LRC cells | Rat | Renal tubular cells |
| Oliver et al. [63] | Slow-cycling cells | Mouse, rat | Renal papilla |
| Bussolati et al. [36, 39] | CD133+ CD24+ cells | Human | Bowman's capsule, inner medullary papilla, S3 segment of proximal tubules, interstitium |
| Sallustio et al. [37, 38] | CD133+ CD24+ cells | Human | Tubules, glomerulus |
| Sagrinati et al. [64] | CD133+ CD24+ cells | Human | Bowman's capsule |
| Lindgren et al. [65] | CD133+ CD24+ cells | Human | Renal proximal tubules |
| Kitamura et al. [41] | KS cells | Rat | S3 segment of proximal tubules |
| Classification | Co-biased as At | Biased as At and Aa | Co-biased as Aa |
| Occurrence | 219 | 302 | 325 |
| Expected | 173.1 | 419.2 | 253.7 |
| P300 | N400 & N100 | ||
| Amplitude (X)/Latency (L) | BVS Score | Amplitude (X)/Latency (L) | BVS Score |
| X > μ −σ | 5 | X < μ + σ | 5 |
| L < μ + σ | L < μ + σ | ||
| μ − 1.5σ < X < μ −σ | 4 | μ + 1.5σ > X > μ + σ | 4 |
| μ + 1.5σ > L > μ + σ | μ + 1.5σ > L > μ + σ | ||
| μ − 2σ < X < μ − 1.5σ | 3 | μ + 2σ > X > μ + 1.5σ | 3 |
| μ + 2σ > L > μ + 1.5σ | μ + 2σ > L > μ + 1.5σ | ||
| μ − 2.5σ < X < μ − 2σ | 2 | μ + 2.5σ > X > μ + 2σ | 2 |
| μ + 2.5σ > L > μ + 2σ | |||
| μ + 2.5σ > L > μ + 2σ | |||
| X < μ − 2.5σ | 1 | X > μ + 2.5σ | 1 |
| L > μ + 2.5σ | |||
| L > μ + 2.5σ |
| Formulation | n |
| Drug type | |
| Caffeine | 0.60 |
| Acetaminophen | 0.66 |
| Theophylline | 0.71 |
| Salicylic acid | 0.73 |
| Indomethacin | 0.98 |
| Cross-linker | |
| 1:2 | 1.24 |
| 1:4 | 1.25 |
| Genotype calling | ||||||||||||
| Read | Read mapping | Reference TR mapping | Unmodified TR | Homozygous VNTR | Heterozygous VNTR† | |||||||
| Set | Sen | Spec | Sen | Spec | Sen | Spec | Sens | Spec | PPV | Sens | Spec | PPV |
| 454 Exact (avg. 261 nt) | 97.5% | 99.6% | 96.9% | 99.2% | 97.7% | 100%* | 95.8% | 100%* | 96.3% | 84.2% | 100%* | 91.6% |
| 454 Errors (avg. 261 nt) | 90.1% | 99.5% | 94.7% | 99% | 93.7% | 99.9% | 91.9% | 100%* | 91.8% | 76.6% | 100%* | 85.8% |
| Illumina Exact (100 nt) | 94.5% | 99.5% | 96.8% | 99.6% | 95.0% | 100%* | 93.6% | 100%* | 98.1% | 83.1% | 100%* | 86.5% |
| Illumina Errors (100 nt) | 70.4% | 97.7% | 78.1% | 97.4% | 67.6% | 100%* | 64.8% | 100%* | 94.2% | 47.3% | 100%* | 74.5% |
| Time point | |||||
| Parameter (unit) | Baseline | BL 10 ml∙kg− 1 | BL 20 ml∙kg− 1 | BL 30 ml∙kg− 1 (haemorrhagic shock) | Resuscitation |
| MAP (mmHg) | 117 (108; 122) | 80 (74; 98) | 44 (37; 72) | 33 (30; 38)* | 93 (76; 100) |
| HR (1∙min−1) | 86 (85; 94) | 98 (84; 108) | 107 (77; 118) | 107 (92; 131) | 128 (112; 139)* |
| CI (L∙min−1∙m− 2) | 2.5 (2.2; 2.7) | 1.5 (1.4; 1.6) | 1.2 (1.0; 1.9) | 1.1 (0.8; 1.2) | 3.0 (2.7; 3.8)# |
| CVP (mmHg) | 3 (1; 10) | 6 (3; 9) | 2 (0; 11) | 0 (0; 6) | 5 (1; 9) |
| SVI (ml∙m−2) | 20 (22; 41) | 17 (15; 23) | 13 (9; 18) | 11 (6; 21) | 24 (22; 24) |
| Retinal microcirculation (OCT-A) | |||||
| Flow densityWF (%) | 44.7 (40.3; 50.5) | 44.1 (36.5; 49.7) | 38.7 (22.2; 44.1) | 34.5 (32.8; 40.4)* | 46.9 (41.7; 50.7)# |
| Flow densityCentral (%) | 45.2 (36.7; 48.6) | 43.4 (34.3; 46.4) | 39.2 (21.3; 42.2)§ | 32.5 (32.2; 40.0)§ | 48.6 (38.4; 50.3) |
| Electrochemical Aptasensors Applied for Food Safeguard | ||||
| Analyte | Matrix | Method details | Linear range and LOD | Reference |
| Salmonella Typhimurium | Pork | EIS based on AuNPs and GO | 2.4–2.4 × 103 CFU/mL, 3 CFU/mL | [17] |
| Staphylococcus aureus | Pig Skin | Potentiometry using SWCNT | 800 CFU/mL | [18] |
| Lysozyme | wine | Aptamer–antibody diazonium coupling, DPV | 5 fM–5 nM, 4.3 fM | [21] |
| Ochratoxin A | cocoa beans | Anti-OTA-aptamer on SPCE, EIS | 0.15–2.5 ng/mL, 0.15 ng/mL | [22] |
| Aflatoxin M1 | Milk | Hexaethyleneglycol modified aptamers on SPE, EIS | 2–150 ng/L, 1.15 ng/mL | [23] |
| Aflatoxin B1 | Alcoholic beverage | MB-tagged aptamer on SPCE, hexamethylenediamine and carbodiimide, DPV | 0.05–6.0 ng/mL, 0.05 ng/mL | [6] |
| Kanamycin | Milk | Aptamer on SPCE, EIS | 1.2–75 ng/mL, 0.11 ng/mL | [25] |
| Item | Budget share | Expenditure | Prices | ||
| Cigarettes | Alcohol | Betel nuts | |||
| 1.0062 | -0.6517 | -0.2503 | -0.1041 | ||
| Cigarettes | 0.439 | ||||
| (4.708)** | (-6475)** | (-2.842)** | (-2.526)** | ||
| 0.8104 | -0.1881 | -0.5871 | -0.0351 | ||
| Alcohol | 0.401 | ||||
| (2.433)** | (-1.247) | (-4.407)** | (-0.546) | ||
| 1.4578 | -0.4840 | -0.3476 | -0.6261 | ||
| Betel nuts | 0.160 | ||||
| (1.116) | (-0.857) | (-0.857) | (-2.481)** |
| Demographic variables | N* | % | Demographic variables | N* | % | ||
| Sex | Male | 110 | 24.6 | Age in years | 21-30 | 92 | 20.6 |
| Female | 338 | 75.4 | 31-40 | 152 | 33.9 | ||
| Marital status | Married | 386 | 86.2 | 41-50 | 161 | 35.9 | |
| Others | 62 | 13.8 | >50 | 43 | 9.6 | ||
| Occupation | Administrative staff | 43 | 9.6 | Years worked | ≤5 | 84 | 18.8 |
| General practitioner | 138 | 30.9 | 6-10 | 55 | 12.3 | ||
| Public health physician | 105 | 23.4 | 11-15 | 57 | 12.7 | ||
| Nurse | 122 | 27.2 | 16-20 | 66 | 14.7 | ||
| Other | 40 | 8.9 | ≥21 | 186 | 41.5 | ||
| Working hours (per week) | ≤40 | 212 | 47.3 | Monthly income (RMB) | <2000 | 186 | 41.5 |
| 41-48 | 140 | 31.3 | 2000-2999 | 194 | 43.3 | ||
| 49-56 | 62 | 13.8 | 3000- 3999 | 58 | 12.9 | ||
| >56 | 34 | 7.6 | ≥4000 | 10 | 2.3 | ||
| Title | Senior | 88 | 19.6 | Educational background | High school or below | 92 | 20.5 |
| Middle | 190 | 42.4 | Junior college | 185 | 41.3 | ||
| Junior | 144 | 32.1 | College and above | 171 | 38.2 | ||
| No title | 26 | 5.9 |
| Open abdominal wall hernia repair | Laparoscopic abdominal wall hernia repair | |
| Hematoma | 6 % | 1 % |
| Seroma | 4 % | 3 % |
| Visceral lesions | 0 | 0 |
| Sub-occlusion | 0 | 0 |
| Respiratory infections | 1 % | 0 |
| Infections of prosthesis | 0 | 0 |
| Fascial necrosis | 0 | 0 |
| Postop. Pain (6 mesi) | 3 % | 1 % |
| Recurrence | 7 % | 4 % |
| Mortality | 0 | 0 |
| Pearson Correlation (r) with Sleep Quality Scale (-) | ||||
| Study 1056 | Study 1077 | |||
| r | p-value | r | p-value | |
| Average Daily Diary Pain Numeric Rating Scale (-) | 0.64 | <0.001 | 0.58 | <0.001 |
| MOS Sleep Scales | ||||
| Sleep Disturbance (-) | 0.45 | <0.001 | 0.42 | <0.001 |
| Snoring (-) | 0.01 | 0.884 | 0.00 | 0.993 |
| Awaken Short of Breath or with Headache (-) | 0.21 | <0.001 | 0.14 | <0.001 |
| Quantity of Sleep (+) | -0.31 | <0.001 | -0.34 | <0.001 |
| Sleep Adequacy (+) | -0.21 | <0.001 | -0.32 | <0.001 |
| Somnolence (-) | 0.11 | 0.004 | 0.15 | <0.001 |
| Isolate ID | Laccase (4thday) | Lipase (3rdday) | Cellulase (3rdday) | Source of isolation | Depth (m) |
| PKU F1 | - | + | + | Seawater | 0 |
| PKU F2 | + | - | + | Seawater | 0 |
| PKU F3 | + | ++ | ++ | Seawater | 0 |
| PKU F4 | ++ | + | + | Seawater | 0 |
| PKU F5 | - | ++ | - | Sediment | 0 |
| PKU F6 | - | - | + | Seawater | 0 |
| PKU F7 | ++ | + | ++ | Sediment | 0 |
| PKU F8 | - | + | ++ | Sediment | 0 |
| PKU F9 | - | ++ | ++ | Sediment | 0 |
| PKU F10 | + | - | - | Sediment | 0 |
| PKU F11 | + | ++ | +++ | Seawater | 10 |
| PKU F12 | - | ++ | ++ | Seawater | 10 |
| PKU F13 | - | ++ | +++ | Seawater | 0 |
| PKU F14 | ++ | +++ | ++ | Seawater | 0 |
| PKU F15 | + | - | - | Seawater | 10 |
| PKU F16 | +++ | +++ | ++ | Seawater | 5 |
| PKU F17 | - | ++ | + | Seawater | 10 |
| PKU F18 | +++ | + | +++ | Seawater | 0 |
| PKU F19 | - | + | - | Seawater | 0 |
| PKU F20 | ++ | ++ | ++ | Seawater | 0 |
| PKU F21 | + | ++ | - | Seawater | 0 |
| PKU F22 | - | +++ | ++ | Seawater | 0 |
| PKU Y1 | - | ++ | + | Seawater | 0 |
| PKU Y2 | - | + | ++ | Seawater | 0 |
| PKU Y3 | - | ++ | + | Seawater | 10 |
| PKU Y4 | - | + | ++ | Seawater | 0 |
| PKU Y5 | - | ++ | ++ | Seawater | 10 |
| PKU Y6 | - | ++ | ++ | Seawater | 5 |
| PKU Y7 | - | - | ++ | Seawater | 0 |
| PKU Y8 | - | +++ | +++ | Seawater | 0 |
| PKU Y9 | - | ++ | ++ | Seawater | 10 |
| Patient | Age | Clinical stage | Histologic type | Tumor size | Estrogen receptor (ER) | Progesterone receptor (PR) | Her2 status | Molecular classification |
| A | 50 yr | T2N1M0 (grading: IIB) | Ductal infiltrating | 3 cm | (−) | (−) | (+) | Her2+ |
| B | 59 yr | T3N0M0 (grading: IIB) | Ductal infiltrating | 5 cm | (+) | (+) | (+) | Luminal B |
| C | 41 yr | T2N1M0 (grading: IIB) | Ductal infiltrating | 4 cm | (+) | (+) | (−) | Luminal A |
| MiRs | Expression levels | mRNA targets | Cell types | Refs | miR classification |
| Diabetic retinopathy | |||||
| miR-146a | Down | Fibronectin | HUVECs | [103] | I, A, O |
| miR-146b-3p | Down | ADA2 | Vitreous of diabetes patients, macrophages | [79] | O |
| miR-200b | Down | VEGF | HUVEC | [104] | O, A |
| miR-195 | Up | SIRT1 | HRECs, HMECs | [105] | A, O |
| Diabetic nephropathy | |||||
| miR-192 | Up | ZEB 1/2 | Glomeruli from renal biopsies | [106] | O |
| miR-377 | Up | Pak1, Sod1/2 | NHMCs | [107] | O, A |
| miR-29a/b/c | Down | Col1, Col4 | h. conditionally immortalized podocyte | [108] | O |
| miR-21 | Up | PTEN, RAS40 | hMCs | [91] | O, I, A |
| Up | TIMP3 | human kidney biopsy | [92] | ||
| miR-155 | Up | h. kidney biopsy, HRGECs | [109] | I, O, A | |
| miR-146a | Up | h. kidney biopsy, HRGECs | [109] | I, A, O | |
| miR-215 | Down | SIP1/ZEB2 | h. conditionally immortalized podocytes | [110] | O |
| miR-135a | Up | TRPC1 | kidney tissues, HMC | [111] | O |
| Macrovascular diabetic complications | |||||
| miR-16 | Down | Cox-2 | THP-1 monocytes | [112] | O |
| miR-503 | Up | Ccne1-Cdc25A | HUVEC, HMVEC | [102] | O, A |
| miR-133 | Down | Rho-A, Cdc42 | h. embryos/fetuses cardiac cells | [113] | I, A |
| miR-223 | Up | Glut4 | Left ventricular biopsies | [114] | I, O, A |
| miR-221 | Up | C-kit | HUVEC | [115] | O, A |
| miR-492 | Down | Resistin | HUVEC | [116] | O, A |
| Total, n | Proactive care, n (%)* or mean (SD) | Usual care, n (%) or mean (SD) | p value | |
| All participants | 1077 | 525 | 552 | – |
| Demographic characteristics: | ||||
| Age (years) | 57.4 (10.5) | 57.2 (10.3) | 57.6 (10.8) | 0.47 |
| Race | ||||
| White | 572 (58.4) | 260 (55.0) | 312 (61.6) | 0.20 |
| Black | 340 (29.0) | 178 (31.2) | 162 (27.1) | |
| Hispanic | 85 (5.8) | 43 (6.2) | 42 (5.4) | |
| Other | 80 (6.8) | 44 (7.7) | 36 (5.9) | |
| Gender | ||||
| Male | 1017 (94.1) | 504 (95.7) | 513 (92.6) | 0.045 |
| Marital status | ||||
| Married | 521 (50.0) | 250 (50.0) | 271 (50.1) | 0.98 |
| Socioeconomic status: | ||||
| Income ($) | ||||
| < 10,000 | 203 (18.9) | 98 (19.0) | 105 (18.9) | 0.91 |
| 10,000–20,000 | 334 (32.4) | 170 (33.4) | 164 (31.6) | |
| 20,001–40,000 | 311 (31.3) | 146 (31.2) | 165 (31.4) | |
| ≥ 40,001 | 172 (17.4) | 81 (16.5) | 91 (18.1) | |
| Social and environmental pressures: | ||||
| Home smoking rules | ||||
| Not allowed anywhere | 473 (48.6) | 227 (48.3) | 246 (48.9) | 0.58 |
| Allowed some places/times | 241 (22.3) | 113 (21.7) | 128 (23.7) | |
| Allowed anywhere | 295 (28.7) | 151 (30.1) | 144 (27.4) | |
| Friends who smoke | ||||
| None | 167 (16.5) | 85 (16.7) | 82 (16.3) | 0.96 |
| < half | 328 (32.7) | 149 (31.5) | 179 (33.7) | |
| About half | 213 (21.7) | 104 (22.0) | 109 (21.5) | |
| > half | 179 (18.0) | 92 (18.8) | 87 (17.3) | |
| All | 119 (11.2) | 59 (11.1) | 60 (11.2) | |
| People important to me want me to quit smoking | ||||
| Strongly disagree to neutral | 125 (13.2) | 47 (10.1) | 78 (16.0) | 0.031 |
| Somewhat agree | 198 (19.3) | 99 (19.7) | 99 (18.9) | |
| Strongly agree | 671 (67.5) | 332 (70.3) | 339 (65.1) | |
| Smoking behaviors: | ||||
| Cigarettes per day | ||||
| ≤ 10 | 517 (46.7) | 244 (45.3) | 273 (48.0) | 0.67 |
| 11–20 | 398 (38.9) | 201 (40.4) | 197 (37.7) | |
| ≥ 21 | 138 (14.4) | 67 (14.4) | 71 (14.4) | |
| Time to first cigarette, min | ||||
| ≥ 31 | 375 (33.6) | 172 (32.5) | 203 (34.5) | 0.75 |
| 6–30 | 518 (50.1) | 259 (50.5) | 259 (49.8) | |
| < 5 | 172 (16.3) | 88 (17.0) | 84 (15.7) | |
| Quit in past 12 months | ||||
| Yes | 866 (80.6) | 414 (80.0) | 452 (81.1) | 0.66 |
| Longest quit length | ||||
| Never quit | 55 (4.7) | 30 (5.5) | 25 (4.1) | 0.11 |
| < 1 month | 260 (24.2) | 140 (26.4) | 120 (22.2) | |
| 1–6 months | 313 (28.9) | 155 (29.8) | 158 (28.2) | |
| > 6 months | 441 (42.2) | 194 (38.4) | 247 (45.6) |
| Altitude | 1st Hb (g/dL) | 2nd Hb (g/dL) | GA 1st Hb (weeks) | GA 2nd Hb (weeks) | Gestational age (weeks) | Birthweight (g) | ||||||
| X ± SD | X ± SD | X ± SD | X ± SD | X ± SD | X ± SD | |||||||
| Low | 12.1 | 0.80 | 11.4 | 1.34 | 17.2 | 8.2 | 36 | 11.6 | 38.9 | 1.76 | 3262 | 512 |
| Moderate | 12.7 | 0.90 | 12.5 | 1.43 | 19.4 | 8.36 | 36.7 | 4.6 | 38.8 | 2.07 | 3123 | 529 |
| High | 13.0 | 0.88 | 12.9 | 1.40 | 20.6 | 8.3 | 37.3 | 3.9 | 38.8 | 1.89 | 3095 | 489 |
| P | <0.05 | <0.05 | <0.05 | <0.05 | <0.05 | |||||||
| Total | 12.4 | 0.91 | 11.9 | 1.52 | 18.3 | 8.4 | 36 | 4.5 | 38.9 | 1.83 | 3206 | 515 |
| Reference Subjects | Test Subjects | ||||||
| RTP | W1 | W2 | L | W1 | W2 | L | LSD |
| M1 | 15.0 | 24.8 | 14.3 | 14.7 | 25.3 | 14.4 | 0.59 |
| M2 | 15.0 | 24.8 | 14.3 | 15.6 | 24.9 | 14.4 | 0.62 |
| M3 | 15.0 | 24.8 | 14.3 | 15.2 | 25.2 | 14.6 | 0.54 |
| M4 | 15.0 | 24.8 | 14.3 | 15.3 | 25.0 | 14.0 | 0.47 |
| M5 | 15.0 | 24.8 | 14.3 | 14.6 | 24.9 | 13.8 | 0.65 |
| M6 | 15.1 | 27.2 | 16.5 | 15.3 | 27 | 15.6 | 0.94 |
| M7 | 15.1 | 27.2 | 16.5 | 14.1 | 26.7 | 16.2 | 1.16 |
| F1 | 14.6 | 24.9 | 13.8 | 15.1 | 24.1 | 13.9 | 0.95 |
| F2 | 14.6 | 24.9 | 13.8 | 14.7 | 25.3 | 14.4 | 0.73 |
| F3 | 14.6 | 24.9 | 13.8 | 14.9 | 24.0 | 13.5 | 0.99 |
| F4 | 14 | 26.1 | 16 | 14.1 | 26.7 | 16.2 | 0.64 |
| F5 | 14 | 26.1 | 16 | 14.7 | 26 | 16.2 | 0.73 |
| F6 | 14 | 26.1 | 16 | 14.3 | 26.9 | 15.3 | 1.10 |
| F7 | 15.1 | 27.2 | 16.5 | 15.8 | 26.8 | 16.9 | 0.90 |
| F8 | 15.1 | 27.2 | 16.5 | 15 | 27.2 | 15.7 | 0.81 |
| Measure | A. Single-task | B. Dual-task | C. Dual-task cost | |||||||
| r | F | p | r | F | p | r | F | p | ||
| I. Monthly means | MD | −0.34 | 2.41 | 0.138 | −0.32 | 2.11 | 0.163 | 0.02 | 0.01 | 0.931 |
| MV | 0.04 | 0.03 | 0.870 | 0.06 | 0.07 | 0.799 | −0.05 | 0.05 | 0.824 | |
| AREA | −0.27 | 0.55 | 0.468 | −0.18 | 0.57 | 0.460 | −0.06 | 0.06 | 0.813 | |
| fC | 0.43 | 4.17 | 0.056 | 0.29 | 1.59 | 0.223 | −0.18 | 0.58 | 0.457 | |
| FD | −0.05 | 0.05 | 0.827 | −0.12 | 0.24 | 0.629 | −0.12 | 0.24 | 0.631 | |
| II. Day-to-day variability | MD | −0.48 | 5.51 | 0.031 | −0.45 | 4.47 | 0.049 | 0.08 | 0.13 | 0.723 |
| MV | 0.18 | 0.61 | 0.446 | 0.16 | 0.50 | 0.491 | −0.17 | 0.51 | 0.485 | |
| AREA | −0.25 | 1.15 | 0.297 | −0.47 | 5.03 | 0.038 | −0.06 | 0.06 | 0.804 | |
| fC | 0.46 | 4.91 | 0.040 | 0.26 | 1.33 | 0.265 | −0.27 | 1.40 | 0.252 | |
| FD | 0.21 | 0.84 | 0.371 | 0.05 | 0.04 | 0.842 | 0.00 | 0.00 | 0.992 |
| I. Site 1 (n = 4 writers with 10 letters each) | |||
| Item | GP | Specialist | p |
| History | 4.04 ± 1.0 | 4.16 ± 0.95 | NS |
| Physical Examination | 4.34 ± 0.90 | 4.23 ± 0.98 | NS |
| Impression | 4.12 ± 0.90 | 4.14 ± 1.0 | NS |
| Plan | 4.21 ± 0.85 | 4.21 ± 0.99 | NS |
| Brevity | 3.87 ± 0.94 | 4.25 ± 0.87 | 0.003 |
| Clarity | 4.00 ± 1.1 | 4.14 ± 1.0 | NS |
| Format | 3.98 ± 1.1 | 4.01 ± 1.0 | NS |
| Educational Value | 4.02 ± 0.95 | 3.90 ± 0.90 | NS |
| Global rating | 4.04 ± 0.96 | 3.92 ± 0.97 | NS |
| Overall score | 36.45 ± 7.36 | 36.97 ± 7.85 | NS |
| II Site 2 (n = 5 writers with 10 letters each) | |||
| Item | GP | Specialist | p |
| History | 3.88 ± 1.1 | 4.40 ± 0.72 | 0.0001 |
| Physical Examination | 3.90 ± 0.97 | 4.45 ± 0.71 | <0.0001 |
| Impression | 4.00 ± 1.0 | 4.08 ± 0.96 | NS |
| Plan | 4.14 ± 0.90 | 4.18 ± 0.87 | NS |
| Brevity | 3.64 ± 1.2 | 3.83 ± 0.90 | NS |
| Clarity | 3.931 ± .0 | 4.03 ± 0.91 | NS |
| Format | 3.63 ± 1.1 | 3.68 ± 0.67 | NS |
| Educational Value | 4.00 ± 1.0 | 3.38 ± 1.1 | <0.0001 |
| Global rating | 3.88 ± 0.93 | 3.74 ± 0.91 | NS |
| Overall score | 34.97 ± 7.70 | 35.79 ± 5.19 | NS |
| Putative gene | SNP (bp) | Nucleotides | AA residual |
| Lp1-SST | 871 | TCA→GCA | Y/D |
| 1,087 | GCC→TCC | A/S | |
| 1,091 | GTC→GCC | V/A | |
| 1,116 | GAC→GAG | D/E | |
| 1,124 | CTG→CCG | L/P | |
| Lp6G-FFT | 835 | GTC→ATC | V/I |
| 938 | TAC→TTC | Y/F | |
| LpCAT | 1,093 | GTG→ATG | V/M |
| LpACO1 | 469 | CCG→TCG | P/S |
| CRC | CRC (interaction) | BC | BC (interaction) | |||||
| coeff | pval | coeff | pval | coeff | pval | coeff | pval | |
| Person level | ||||||||
| Age < 50 (reference 50–64) | 0.306 | 0.000 | 0.306 | 0.000 | 0.040 | 0.000 | 0.040 | 0.000 |
| Age 65–74 | −0.105 | 0.000 | −0.105 | 0.000 | −0.255 | 0.000 | −0.255 | 0.000 |
| Age 75+ | −0.051 | 0.000 | −0.051 | 0.000 | −0.139 | 0.000 | −0.139 | 0.000 |
| Female (reference male) | 0.040 | 0.000 | 0.040 | 0.000 | . | . | . | . |
| Black (reference white) | 0.079 | 0.000 | 0.079 | 0.000 | 0.386 | 0.000 | 0.386 | 0.000 |
| Race all other (reference white) | 0.008 | 0.363 | 0.008 | 0.399 | 0.136 | 0.000 | 0.136 | 0.000 |
| County level | ||||||||
| Percentage of population < age 65, with no health insurance | 0.005 | 0.000 | 0.007 | 0.016 | 0.003 | 0.002 | 0.005 | 0.031 |
| Average distance traveled by Medicare beneficiary to cancer screening provider | 0.002 | 0.037 | 0.002 | 0.041 | 0.000 | 0.532 | 0.000 | 0.519 |
| Screening rate (percent of area FFS Medicare population utilizing screening) | −0.036 | 0.000 | −0.037 | 0.000 | −0.027 | 0.000 | −0.027 | 0.000 |
| Managed care penetration (percentage of area insured population in managed care plans) | 0.101 | 0.033 | 0.103 | 0.039 | −0.284 | 0.000 | −0.285 | 0.000 |
| State level | ||||||||
| State Policy (1 = yes, 0 = no) `Direct Access Specialist' | −0.055 | 0.004 | −0.271 | 0.000 | −0.053 | 0.001 | −0.009 | 0.841 |
| Cross level interaction | ||||||||
| < 65 Pop uninsured * state policy interaction | . | . | 0.013 | 0.000 | . | . | −0.003 | 0.288 |
| Variance Components | ||||||||
| Level 1 * (individual) | 3.2899 | 3.2899 | 3.2899 | 3.2899 | ||||
| Level 2 (county) | 0.02497 | 0.02484 | 0.01450 | 0.01447 | ||||
| Level 3 (state) | 0.00074 | 0.00065 | 0.00018 | 0.00017 |
| Good perceived health status | Poor perceived health status | |||||||||
| Variables | n | Prev. | Bivar OR | Mvar OR | 95% CI | n | Prev. | Bivar OR | Mvar OR | 95% CI |
| Age | ||||||||||
| 15-34 | 64 | 11.2 | 1 | 1 | 13 | 29.3 | 1 | 1 | ||
| 35-54 | 86 | 14.9 | 1.4 | 1.41 | 0.94-2.11 | 42 | 32.2 | 1.14 | 1.11 | 0.43-2.87 |
| 55-64 | 47 | 26.6 | *2.89 | 2.84 | 1.69-4.77 | 50 | 40.5 | 1.64 | 1.87 | 0.70-4.97 |
| > = 65 | 91 | 36.6 | *4.62 | 3.42 | 1.81-6.46 | 183 | 51.1 | *2.51 | 3.13 | 1.13-8.63 |
| Total | 288 | 18.3 | 288 | 43.9 | ||||||
| Social class | ||||||||||
| I-II | 58 | 17.6 | 1 | 1 | 22 | 50.4 | 1 | 1 | ||
| III | 86 | 18.5 | 1.06 | 0.94 | 0.64-1.38 | 52 | 44.3 | *0.78 | 0.67 | 0.32-1.39 |
| IV-V | 121 | 16.8 | 0.94 | 0.93 | 0.63-1.37 | 188 | 42.2 | *0.71 | 0.65 | 0.33-1.27 |
| Employment status | ||||||||||
| Salaried employees | 107 | 15.2 | 1 | 1 | 42 | 48.1 | 1 | 1 | ||
| Housewifes | 81 | 13.2 | 0.85 | 0.90 | 0.59-1.38 | 133 | 38.1 | *0.66 | 1.10 | 0.63-1.91 |
| Unemployed women | 19 | 18.4 | *1.26 | 1.44 | 0.80-2.56 | 3 | 20.0 | *0.27 | 0.52 | 0.14-1.85 |
| Retired women | 57 | 26.4 | *2.06 | 1.63 | 0.88-3.04 | 88 | 56.1 | *1.37 | 0.99 | 0.51-1.93 |
| Students | 21 | 27.1 | *2.07 | 0.85 | 0.48-1.52 | 4 | 66.7 | *2.15 | 1.59 | 0.37-6.87 |
| Type of PHC | ||||||||||
| PCR 1984-93 | 50 | 18.2 | 1 | 1 | 73 | 49.4 | 1 | 1 | ||
| PCR 1994-98 | 53 | 13.6 | *0.71 | 0.76 | 0.48-1.20 | 61 | 42.4 | *0.75 | 0.74 | 0.45-1.22 |
| No PCR | 101 | 20.3 | 1.14 | 1.22 | 0.81-1.83 | 110 | 42.3 | *0.74 | 0.85 | 0.54-1.32 |
| Mutual or private | 53 | 16.6 | 0.89 | 0.80 | 0.49-1.30 | 32 | 43.7 | *0.79 | 0.69 | 0.36-1.31 |
| No usual PHC | 29 | 15.5 | *0.82 | 0.81 | 0.47-1.41 | 8 | 26.9 | *0.37 | 0.44 | 0.15-1.27 |
| Variable | n (%) |
| Quality of provider (n = 285) | |
| Licensed pharmacist | 16 (5.6) |
| Pharmacist assistant | 36 (12.6) |
| Auxiliary | 233 (81.8) |
| Sex (n = 285) | |
| Females | 216 (75.8) |
| Males | 69 (24.2) |
| Years of experience (n = 285) | |
| ≤2 | 66 (23.2) |
| 2–5 | 115 (40.4) |
| 5–10 | 58 (20.3) |
| >10 | 46 (16.1) |
| Variable | Total | N | % |
| Mode of spread of HIV/AIDS* | |||
| Sexual intercourse | 206 | 203 | 98.5 |
| Blood transfusion | 206 | 188 | 91.3 |
| Unsterile instrument | 206 | 199 | 96.6 |
| MTCT | 206 | 179 | 87.7 |
| Other (spiritual) | 206 | 33 | 15.0 |
| Mother to child transmission | |||
| Possible | 206 | 190 | 92.2 |
| Not possible | 206 | 1 | 0.5 |
| Don’t know | 206 | 15 | 7.3 |
| Mode of mother –to-child transmission* | |||
| In the womb (intrauterine) | 190 | 179 | 94.2 |
| During delivery | 190 | 154 | 81.1 |
| Through breastfeeding | 190 | 187 | 98.4 |
| MTCT preventable? | |||
| Preventable | 206 | 182 | 88.3 |
| Not preventable | 206 | 8 | 3.8 |
| Don’t know | 206 | 15 | 7.2 |
| Means of PMTCT* | |||
| Giving ART | 182 | 176 | 96.7 |
| Avoiding breastfeeding | 182 | 162 | 89.0 |
| C/S delivery | 182 | 69 | 37.9 |
| Antiretrovials* | |||
| Drug to prevent transmission to baby | 206 | 58 | 28.2 |
| Drug to cure HIV | 206 | 78 | 37.9 |
| Drug to prevent death from HIV/AIDS | 206 | 147 | 71.4 |
| Drug to prolong lives | 206 | 184 | 89.3 |
| Works effectively with optimal adherence | 206 | 200 | 97.6 |
| Non-syndromic Robin sequence (ns-RS) | Non-syndromic cleft palate (ns-CP) | Chi-square Test (two-sided) | |||
| N | % | N | % | P | |
| Total number of patients | 115 | 100 | 191 | 100 | |
| Males/females | 49/66 | 42.6/57.4 | 86/105 | 45.0/55.0 | |
| Tooth agenesis (excl. 3rd molars) | 55 | 47.8 | 57 | 29.8 | < 0.001 |
| Maxilla | 28 | 24.3 | 31 | 16.2 | 0.082 |
| Mandibulaa | 45 | 39.1 | 39 | 20.4 | < 0.001 |
| Right dental quadrants (q1, q4) | 42 | 36.5 | 43 | 22.5 | 0.008 |
| Left dental quadrants (q2, q3) | 50 | 43.4 | 42 | 22.0 | < 0.001 |
| In males | 18/49 | 36.7 | 28/86 | 32.6 | 0.622 |
| In femalesb | 37/66 | 56.0 | 30/105 | 28.6 | < 0.001 |
| Never smokers N = 25 | COPDGene N = 2098 | SPIROMICS N = 1117 | p-value (SPIROMICS vs COPDGene) (current and former smokers) | |
| Age (years) | 57.5 (7) | 65.8 (8.9) | 62.7 (9) | < 10−04 |
| Gender Male | 36.0% | 50.9% | 51.9% | 0.6931 |
| Race | ||||
| White | 100.0% | 71.2% | 74.9% | |
| Black | 0.0% | 28.4% | 20.8% | |
| Other | 0.0% | 0.0% | 4.3% | |
| Current Smoker | 0% | 34.7% | 40.5% | 0.0009 |
| BMI (kg/m2) | 25.7 (4.2) | 28.8 (6.3) | 28.2 (5.4) | 0.0028 |
| ATS Smoking, pack-years | 0 (0) | 45.1 (24) | 47.6 (24.7) | 0.0054 |
| FEV1 (% predicted) | 105.5 (12) | 76.1 (25.6) | 76.1 (28.7) | 0.9906 |
| FEV1/FVC | 0.8 (0) | 0.7 (0.2) | 0.6 (0.2) | < 10−04 |
| BODE Index | 0.2 (0.4) | 1.3 (1.7) | 1.5 (2) | 0.0084 |
| SGRQ | 2.7 (3.5) | 23.6 (21.1) | 32 (21.2) | < 10−04 |
| Emphysema (% LAA < −950 HU) | 1 (1.3) | 6.5 (10.2) | 7.3 (10.4) | 0.0386 |
| Chronic Bronchitis (%) | 4% | 15.2% | 20.9% | < 10−04 |
| Duration of participation in study (years) | NA | 6.7 (1.2) | 2.2 (0.9) | < 10−04 |
| Decline in FEV1 (ml/year) | NA | −38.1 (53.4) | −48.5 (144.1) | 0.0416 |
| Exacerbations (#/year) | 0 (0) | 0.3 (0.8) | 0.5 (1.0) | < 10−04 |
| Never Smoker | 100% | 0% | 0% | |
| Spirometry category | ||||
| PRISm | 0% | 10.4% | 0% | |
| Control Smoker | 0% | 41.5% | 49.3% | |
| GOLD 1 | 0% | 9.3% | 7.9% | |
| GOLD 2 | 0% | 20.4% | 17.5% | |
| GOLD 3 | 0% | 12.2% | 18.1% | |
| GOLD 4 | 0% | 5.8% | 7.1% |
| Beads Type | Beads Size (μm; n = 50) | Encapsulation yield (%; n = 15) | Viability (log CFU/mL, n = 4) |
| I + 5% GT | 344.19 ± 1 | 37.14 ± 0.4 | 9.28 ± 0.3 |
| I + 10% GT | 339.1.6 ± 1 | 35.33 ± 0.7 | 9.36 ± 0.2 |
| B + 5% GT | 329.36 ± 1 | 37.18 ± 0.4 | 9.39 ± 0.3 |
| B +10% GT | 331.25 ± 1 | 36.15 ± 0.7 | 9.43 ± 0.4 |
| I | 325.14 ± 0.5 | 38.24 ±0.5 | 9.34 ± 0.3 |
| B | 321.08 ± 0.9 | 37.24 ±0.8 | 9.24 ± 0.4 |
| 10% GT | 318.23 ± 1 |
| Variables | Total | Fasting triglycerides | P-value | |
| <1.2 mmol/L (N = 103) | ≥2 mmol/L (N = 226) | |||
| Biochemical markers | ||||
| hs-CRP (mg/L) | 3.2 ± 4.1 | 3.5 ± 4.5 | 3.1 ± 3.9 | 0.440 |
| Leucocyte count (109/L) | 6.5 ± 1.6 | 6.2 ± 1.5 | 6.6 ± 1.6 | 0.048 |
| Neutrophil count (109/L) | 3.8 ± 1.2 | 3.6 ± 1.1 | 3.9 ± 1.2 | 0.041 |
| Neutrophil/lymphocyte ratio | 2.2 ± 1.1 | 2.1 ± 1.0 | 2.2 ± 1.1 | 0.530 |
| Fasting blood glucose (mmol/L) | 6.1 ± 2.2 | 5.7 ± 1.9 | 6.3 ± 2.3 | 0.025 |
| Hemoglobin A1C (%) | 6.9 ± 1.4 | 6.7 ± 1.3 | 6.9 ± 1.4 | 0.149 |
| D-dimer (ug/mL) | 0.4 ± 0.5 | 0.4 ± 0.6 | 0.4 ± 0.4 | 0.252 |
| Fibrinogen (g/L) | 3.1 ± 0.8 | 3.1 ± 0.8 | 3.1 ± 0.9 | 0.644 |
| Endothelin-1 (fmol/ml) | 0.6 ± 0.3 | 0.6 ± 0.3 | 0.6 ± 0.3 | 0.587 |
| Alkaline phosphatase (IU/L) | 63.5 ± 18.6 | 62.0 ± 20.1 | 64.2 ± 17.9 | 0.318 |
| Uric acid (mmol/L) | 338.3 ± 78.9 | 314.9 ± 75.9 | 348.9 ± 78.1 | 0.000 |
| Creatinine (umol/L) | 76.3 ± 15.6 | 74. 4 ± 14.0 | 77.2 ± 16.2 | 0.138 |
| Lipid profile | ||||
| Total cholesterol (mmol/L) | 4.0 ± 1.0 | 3.5 ± 0.8 | 4.2 ± 1.1 | 0.000 |
| LDL-C (mmol/L) | 2.4 ± 0.9 | 2.1 ± 0.7 | 2.5 ± 0.9 | 0.000 |
| HDL-C (mmol/L) | 1.1 ± 0.3 | 1.1 ± 0.3 | 1.0 ± 0.3 | 0.002 |
| Lipoprotein (a) (mg/L) | 244.4 ± 244.5 | 267.9 ± 218.9 | 233.6 ± 254.9 | 0.237 |
| apoA(g/L) | 1.4 ± 0.3 | 1.4 ± 0.3 | 1.4 ± 0.3 | 0.477 |
| apoB(g/L) | 1.0 ± 0.3 | 0.9 ± 0.2 | 1.1 ± 0.3 | 0.000 |
| TG/HDL-C index | 1.7 ± 1.3 | 0.8 ± 0.3 | 2.2 ± 1.3 | 0.000 |
| Non-HDL-C (mmol/L) | 2.9 ± 0.9 | 2.4 ± 0.7 | 3.1 ± 0.9 | 0.000 |
| LDL-C/HDL-C ratio | 2.3 ± 0.8 | 1.9 ± 0.7 | 2.4 ± 0.8 | 0.000 |
| Parameters | Control group (n = 61) n (%) | Patient group (n = 66) n (%) | P |
| Fatigue | 36 (59) | 59 (92.4) | <0.001 |
| Presence of RBD | 3 (4.9) | 8 (12.1) | 0.001 |
| PSQI | 35 (57.4) | 46 (69.7) | >0.05 |
| Depression | 25 (41) | 62 (93.9) | <0.001 |
| Presence of RLS | 10 (16.4) | 45 (68.1) | <0.001 |
| SKM | CSM | |
| Concentration (nmol/g SKM protein) | Concentration (nmol/g CSM protein) | |
| Laminin | 2.20 ± 0.22 | N/A |
| α-Dystroglycan | 89.72 ± 15.04 | 692.67 ± 57.39 |
| Dystrophin | 2.20 ± 0.07 | 16.11 ± 0.69 |
| Ratio | Lam : αDG : Dys = 1 : 41 : 1 | αDG : Dys = 43 : 1 |
| Frailty status | Overall | Not frail (CFS 1–4) | Frail (CFS 5–9) | p-value |
| Number of admissions | 308 (100%) | 143 (46.4%) | 165 (53.6%) | |
| Age | 84 [82–87] | 82 [81–86] | 85 [82–88] | < 0.001 |
| Male | 164 (50%) | 79 (55.2%) | 75 (45.5%) | 0.09 |
| APACHE II | 18 [12–26] | 15 [12–25] | 19 [12–26] | 0.18 |
| SAPS II | 39 [29.5–51] | 37 [29–48] | 42 [30–55] | 0.17 |
| SOFA Score | 6 [3–10] | 6 [3–9] | 7 [4–10] | 0.016 |
| Cause of admission | ||||
| Acute medical | 162 (52.6%) | 58 (40.6%) | 104 (63%) | < 0.001 |
| Acute surgery | 16 (5.2%) | 8 (5.6%) | 8 (4.8%) | 0.77 |
| Trauma | 33 (10.7%) | 14 (9.8%) | 19 (11.5%) | 0.63 |
| Elective surgery | 97 (31.5%) | 63 (44.1%) | 34 (20.6%) | < 0.001 |
| ICU length of stay (days) | 3.1 [1.1–8.1] | 2.9 [1–7] | 3.4 [1.4–9.5] | 0.21 |
| Use of life sustaining treatments | ||||
| Non-invasive ventilation | 104 (33.8%) | 48 (33.6%) | 56 (33.9%) | 0.95 |
| Mechanical ventilation | 141 (45.8%) | 59 (41.3%) | 82 (49.7%) | 0.14 |
| Vasoactive drugs | 189 (61.4%) | 82 (57.3%) | 107 (64.8%) | 0.18 |
| Renal replacement therapy | 59 (19.2%) | 26 (18.2%) | 33 (20%) | 0.69 |
| Treatment withheld | 41 (13.3%) | 11 (7.7%) | 30 (18.2%) | 0.01 |
| Treatment withdrawn | 36 (11.7%) | 10 (7%) | 26 (15.8%) | 0.02 |
| ICU mortality | 53 (17.3%) | 16 (11.3%) | 37 (22.4%) | 0.01 |
| 30-day mortality | 84 (31.2%) | 23 (18.4%) | 61 (42.4%) | < 0.001 |
| Group 1 | Group 2 | Group 3 | Group 4 | TOTAL | ||
| Number of animals | 6 | 7 | 7 | 7 | 27 | |
| Number of tumours | 12 | 14 | 14 | 14 | 54 | |
| Weight (g) | Mean | 30 | 29 | 29 | 29 | 29 |
| Range | 28–33 | 27–32 | 28–31 | 28–31 | 27–33 | |
| Tumour size (mm3) | Mean | 100 | 95 | 97 | 96 | 97 |
| Range | 26–181 | 25–165 | 40–271 | 39–182 | 25–271 | |
| Treatment given | vehicle | 5Gy + vehicle | FGFR inhibitor | FGFR inhibitor + 5 Gy |
| LPS | IL1A | IL1β | IL6 | IL8 | iNOS |
| ng/mL | Expression, a.u. | Expression, a.u. | Expression, a.u. | Expression, a.u. | Expression, a.u. |
| 0 | 1 ± 3.25 | 1 ± 1.82 | 1 ± 1.54 | 1 ± 1.41 | 1 ± 3.14 |
| 50 | 194 ± 2.77* | 317 ± 1.63* | 99 ± 1.48* | 26 ± 1.8* | 882 ± 2.46* |
| 100 | 265 ± 2.33* | 465 ± 1.78* | 155 ± 1.4* | 46 ± 1.36* | 1128 ± 2.3* |
| 500 | 315 ± 2.35* | 755 ± 1.68* | 47 ± 2.67* | 18 ± 1.98* | 1596 ± 2.46* |
| 1000 | 247 ± 2.38* | 498 ± 1.78* | 98 ± 1.6* | 11 ± 1.61* | 1489 ± 2.37* |
| 2500 | 338 ± 2.35* | 729 ± 1.57* | 224 ± 2.32* | 20 ± 3.33* | 1438 ± 2.25* |
| PGM-High | PGM-Low | |
| MiSeq-High | 2864925 | 44534 |
| MiSeq-Low | 394 | 115 |
| Special stain/IHC | Squamous cell carcinoma | Adenocarcinoma |
| CK7 | −/+ | + |
| p63 | + | − |
| CK5/6 | + | − |
| TTF-1 | − | +/− |
| Height for age | Male No % | Female No % |
| Stunted | 38 (7.9) | 14 (2.9) |
| Normal | 443 (92.1) | 465 (97.1) |
| Total | 481 (100) | 479 (100) |
| t-TATI(f*i) | s-TATI(μg/L) | ||||||
| Pre RT | After RT(OP) | Before RT | After RT | ||||
| Age at OP | |||||||
| R | -0,007 | 0,114 | 0,586 | 0,453 | |||
| p | 0,970 | 0,474 | < 0,001* | 0,001* | |||
| n | 33 | 42 | 56 | 51 | |||
| Gender | |||||||
| R | -0,214 | -0,406 | 0,011 | -0,167 | |||
| p | 0,232 | 0,008* | 0,94 | 0,241 | |||
| n | 33 | 42 | 52 | 51 | |||
| Disease stage | |||||||
| R | 0,066 | 0,330 | 0,057 | 0,338 | |||
| p | 0,720 | 0,033* | 0,703 | 0,021* | |||
| n | 31 | 42 | 47 | 46 | |||
| Vascular invasion | |||||||
| R | 0,204 | -0,062 | -0,165 | -0,053 | |||
| p | 0,262 | 0,695 | 0,268 | 0,725 | |||
| n | 32 | 42 | 47 | 36 | |||
| s-kreatinin drafted preOP | |||||||
| R | 0,170 | 0,038 | 0,369 | 0,302 | |||
| p | 0,346 | 0,812 | 0,011* | 0,041* | |||
| n | 33 | 41 | 47 | 46 |
| Risk factor | Odds ratio | 95 % CI | P value |
| −1SD of BMI | 1.2 | 0.6–2.3 | 0.562 |
| +1SD of age | 4.5 | 1.9–13.0 | 0.001 |
| +1SD of NTX | 1.9 | 0.9–4.1 | 0.073 |
| +1SD of BAP | 0.7 | 0.3–1.4 | 0.442 |
| −1SD of L2–4 BMD | 8.2 | 2.9–34.4 | <0.001 |
| −1SD of total BMD | 4.5 | 2.0–13.3 | 0.001 |
| −1SD of neck BMD | 7.2 | 2.6–28.8 | <0.001 |
| −1SD of troch BMD | 9.6 | 3.0–51.2 | 0.001 |
| Control | MT | Cell 1 | Cell 2 | MT-Diff | Diff-Cell1 | Diff-Cell2 |
| CGC | 13.33 | 8.5 | 8.66 | 6.33 | 4.66 | 6.5 |
| GO | 72.33 | 33.66 | 41.5 | 47.66 | 43.16 | 29.5 |
| Oncogenic | 7.66 | 3 | 3.33 | 10.33 | 10.33 | 4.83 |
| Breast & Prostate | ||||||
| CGC | 14.66 | 8.33 | 10 | 2.66 | 3.33 | 1.83 |
| GO | 77.5 | 70.66 | 64.83 | 18.16 | 25.66 | 18.33 |
| Oncogenic | 8.66 | 4.33 | 5.16 | 2.66 | 2.5 | 2.5 |
| Prostate | ||||||
| CGC | 15 | 10.16 | 10.33 | 3.33 | 2.33 | 3.83 |
| GO | 82.33 | 85.83 | 88.66 | 23 | 26.83 | 18.5 |
| Oncogenic | 11 | 8.33 | 7.66 | 3 | 4.5 | 3.16 |
| THE BPRS SCALE Assessment of each item: EMOTION | ||||||
| GROUP | CONTOL | |||||
| T0 | T4 | Diff. | T0 | T4 | Diff, | |
| Thought disorganization | 2,56 | 2,00 | -0,56 | 2,34 | 2,18 | -0,16 |
| Emotional flattening | 3,24 | 2,24 | -7,00 | 2,80 | 2,61 | -0,79 |
| Emotional withdrawal | 3,37 | 2,34 | -7,03 | 3,18 | 2,80 | -0,38 |
| Delayed motor skills | 2,53 | 1,42 | -1,11 | 2,13 | 1,85 | -0,28 |
| Tension | 3,48 | 2,16 | -1.32 | 3,10 | 2,55 | -0,55 |
| Lack of compliance | 2,11 | 1,29 | -0,82 | 1,98 | 1,56 | -0,42 |
| Excitement | 1,63 | 1,11 | -0,52 | 1,99 | 1,44 | -0,55 |
| Distractibility | 2,38 | 1,40 | -0.98 | 2,30 | 1,80 | -0,50 |
| Motor skill hyperactivity | 1,59 | 1,06 | -0,53 | 1,76 | 1,32 | -0,44 |
| Artificial behavior | 1,89 | 1,24 | -0,65 | 1,92 | 1,67 | -0,25 |
| TOTAL Assessment | 24,80 | 16,27 | -8,53 | 23,47 | 19,77 | -3,70 |
| Tumor samples | IRX1 | NOL4 | Age (years) | Gender | Race | Smoking | Alcohol | Tumor anatomic site | Overall stage |
| 1 | N | N | 67 | M | C | Yes | Yes | Nasal floor | 2 |
| 2 | Y | Y | 57 | M | C | Yes | Yes | Larynx | 2 |
| 3 | N | N | 61 | M | C | No | No | Neck | 3 |
| 4 | Y | Y | 60 | F | C | Yes | Yes | Larynx | 4 |
| 5 | Y | Y | 55 | M | A | Yes | Yes | Larynx | 2 |
| 6 | Y | Y | 54 | M | C | No | Yes | Oropharynx | 4 |
| 7 | Y | N | 64 | M | A | Yes | Yes | Hypopharynx | 3 |
| 8 | Y | Y | 55 | F | A | Yes | No | Oral cavity | 1 |
| 9 | N | Y | 80 | M | C | Yes | No | Oral cavity | NA |
| 10 | Y | Y | 54 | F | C | No | Oral | cavity | 4 |
| 11 | Y | Y | 62 | M | C | Yes | Yes | Oropharynx | 4 |
| 12 | Y | Y | 72 | M | C | Yes | Yes | Hypopharynx | 3 |
| 13 | Y | Y | 42 | M | C | Yes | No | Larynx | 2 |
| 14 | Y | Y | 66 | M | C | Yes | No | Oropharynx | 4 |
| 15 | Y | Y | 74 | M | C | Yes | Larynx | 2 | |
| 16 | Y | Y | 58 | M | A | Yes | Yes | Oropharynx | 4 |
| 17 | Y | Y | 56 | F | C | Yes | Yes | Oral cavity | 2 |
| 18 | Y | Y | 43 | M | C | Yes | Yes | Oropharynx | 4 |
| 19 | Y | Y | 68 | M | C | Yes | Yes | Oropharynx | 4 |
| 20 | Y | Y | 63 | M | A | Yes | Oral cavity | NA | |
| 21 | Y | Y | 64 | F | C | No | Yes | Oral cavity | 3 |
| 22 | N | Y | 88 | M | C | Yes | Yes | Oral cavity | NA |
| 23 | Y | Y | 42 | M | C | Yes | No | Oral cavity | 3 |
| 24 | Y | Y | 51 | M | C | Yes | Yes | Larynx | 4 |
| 25 | Y | Y | 80 | M | C | No | Yes | Neck | NA |
| 26 | Y | Y | 58 | M | C | Yes | Yes | Larynx | 3 |
| 27 | Y | Y | 71 | M | C | Yes | Yes | Neck | NA |
| 28 | Y | Y | 48 | M | C | Yes | Yes | Oropharynx | 4 |
| 29 | Y | Y | 61 | M | C | Yes | No | Maxillary sinus | 1 |
| 30 | Y | Y | 77 | M | C | No | No | Salivary gland | NA |
| 31 | Y | Y | 67 | M | C | Larynx | 3 | ||
| 32 | Y | Y | 36 | M | C | Yes | No | Oral cavity | 4 |
| 33 | Y | Y | 74 | F | C | No | Yes | Maxillary sinus | 4 |
| Year | |||
| Indicator | 1995 | 2000 | 2005 |
| Received any prenatal care *** | 42.4 | 54.1 | 71.4 |
| CI by Education | 0.41 (0.396 0.424) | 0.39 (0.378 0.402) | 0.41 (0.402 0.418) |
| CI by Wealth index | 0.50 (0.486 0.514) | 0.37 (0.358 382) | 0.45 (0.442 0.458) |
| Received regular prenatal care (4+ visits)*** | 31.0 | 40.7 | 61.3 |
| CI by Education | 0.49 (0.474 0.506) | 0.44 (0.426 0.454) | 0.39 (0.382 0.398) |
| CI by Wealth index | 0.60 (0.584 0.616) | 0.42 (0.404 0.436) | 0.49 (0.482 0.498) |
| Received tetanus injection before birth*** | 73.1 | 78.0 | 80.7 |
| CI by Education | -0.15 (-0.162 -0.138) | -0.14 (-0.148 -0.132) | -0.21 (-0.216 -0.204) |
| CI by Wealth index | -0.22 (-0.234 -0.206) | -0.23 (-0.240 -0.220) | -0.36 (-0.368 -0.352) |
| Told about pregnancy complications*** | - | 26.0 | 36.7 |
| CI by Education | - | 0.11 (0.083 0.137) | 0.12 (0.104 0.136) |
| CI by Wealth index | - | 0.07 (0.041 0.099) | 0.15 (0.132 0.168) |
| Given iron supplement during pregnancy*** | - | 43.6 | 64.7 |
| CI by Education | - | 0.23 (0.212 0.248) | 0.17 (0.162 0.178) |
| CI by Wealth index | - | 0.23 (0.212 0.248) | 0.22 (0.200 0.240) |
| Independent variables | Adjusted | |
| OR (95 % CI) | P-value | |
| Sex | ||
| Male | 1.08 (0.68 – 1.72) | 0.73 |
| Female (Ref.) | ||
| Age | ||
| ≤35 years | 2.71 (1.14 – 6.46) | 0.024 |
| ≥36 years (Ref.) | ||
| Nationality | ||
| Yemeni | 0.69 (0.35 – 1.35) | 0.28 |
| Foreign (Ref.) | ||
| University | ||
| Yemeni | 0.71 (0.33 – 1.52) | 0.39 |
| Foreign (Ref.) | ||
| Referral | ||
| Yes | 0.78 (0.41 – 1.50) | 0.47 |
| No (Ref.) |
| Participant | Age | Sex | Diagnosis | CARS |
| 1 | 14 | Male | ASD | 42 |
| 2 | 14 | Male | ASD | 33 |
| 3 | 13 | Male | ASD | 43.5 |
| 4 | 16 | Male | ASD | 39 |
| 5 | 20 | Male | ASD | 36 |
| 6 | 13 | Male | ASD | 38 |
| Study patients | n | Children | Adults | HLA DQ2/DQ8 | IgA-tTG/EMA | Atrophy grade at diagnosis (Marsh criteria) | |
| Celiac patients | aCD-patient | 2 | 1 | 1 | + | + | II-III |
| GFD-patient | 2 | 1 | 1 | + | + | II-III | |
| Non-Celiac patients | GP-patient | 2 | 1 | 1 | +/- | - (*) | M.M |
| Type of data | Data source | Detail of data to be collected | Time point(s) |
| Non-participant observation of training sessions | Observation, training sessions | •Observation of the training and care home-based sessions will allow recording of content and delivery of training, length of sessions, number of attendees. Also, identification of possible issues for follow-up in semi-structured interviews in the case study care homes | Each session |
| Non-participant observation of care home-based sessions | Observation, care home-based sessions | A selected number of sessions throughout the programme (approximately 30% of the total) | |
| Documentary analysis | Patient Safety Collaborative Programme Board | •All documents relating to the programme will be analysed to provide information about programme planning, content and delivery | Throughout the programme |
| Focus groups | Care home staff participating in the programme (2 groups of 6–8 staff at each time point) | •What has been learned by participation in the programme, how learning has been applied to individuals’ practice, barriers and facilitators to implementing change in the care home, perceptions of best/worst features of the programme, suggestions for improvement | 6, 12 and 18 months |
| Semi-structured interviews | CCG managers and programme facilitators (n = 6) | •Experience of running the programme, perceived barriers to safety-related change in care homes, best/worst features of the programme, suggestions for improvement | Months 6, 12 and 24 |
| Semi-structured interviews in four case study care homes | Staff and care home managers (participants and non-participants in the programme) (n = 6 to 8 in each of the four case study sites at each time point) | •What has been learned, how learning has been applied to individuals’ practice, barriers and facilitators to implementing change in the care home, changes made to safety-related processes at the care home level, extent and type of collaboration across care homes | 12 and 24 months |
| Controls | PD patients | AR | TD | |
| n | 20 | 20 | 10 | 10 |
| Mean age (SD; range) | 66.0 (9.1; 43–85) | 66.25 (9.0; 42–84) | 66.3 (5.9; 58–79) | 66.2 (11.7; 42–84) |
| Gender ratio: male/female | 10/10 | 11/9 | 5/5 | 6/4 |
| Time symptom onset in years (SD) | 6.27 (4.4) | 6.75 (5.0) | 5.78 (3.8) | |
| Unified Parkinson Disease Rating Scale (UPDRS) | 34.6 (17.4) | 30.4 (13.2) | 38.8 (20.6) | |
| Subtype ratio | 1.1 (0.7) | 0.5 (0.2)** | 1.7 (0.6)** | |
| Addenbrooke's Cognitive Examination-Revised (ACE-R) | 88.4 (15.0) | 91.3 (7.5) | 85.6 (20.1) | |
| Barratt Impulsiveness Scale (BIS) | 0.5 (0.1) | 0.5 (0.1) | 0.5 (0.1) | |
| l-dopa equivalence units | 393.8 (339.0) | 375.4 (268.2) | 412.2 (412.2) | |
| Whole brain volume in mm3 (SD) | 1235.3 (146.2) | 1230.4 (102.1) | 1193.3 (101.1) | 1267.4 (93.5) |
| Intracranial volume mm3 (SD) | 1647.7 (201.5) | 1705.1 (140.6) | 1678.1 (153.8) | 1732.0 (128.4) |
| Whole brain MT (SD) | 0.833 (0.14) | 0.848 (0.09) | 0.835 (0.08) | 0.861 (0.09) |
| Whole brain R2* (SD) | 22.4 (0.9) | 22.9 (2.0) | 23.1 (2.5) | 22.8 (1.6) |
| Original version | Translated version |
| Is there a view of the outside from corridors? (include internal courtyard) | Are there external views from different parts of the circulation space? (including internal courtyard) |
| Are there external views from different parts of the circulation space? |
| Water (mL) | Starch (g) | Urea (g) | Borate (g) | Reaction temp. (°C) | Stirring rate (rpm) |
| 1000 | 50 | 15 | 2.5 | 80 | 600 ± 5 |
| 1000 | 50 | 15 | 3.5 | 80 | 600 ± 5 |
| 1000 | 50 | 15 | 4.5 | 80 | 600 ± 5 |
| Growth Medium | 2,4-D (mg/L) | NAA (mg/L) | Kinetin (mg/L) | |
| Alfalfa (M. sativa ssp. Varia A2) | MS | 1 | - | 0.2 |
| Arabidopsis (A. thaliana ecotype Columbia) | MS | - | 0.5 | 0.05 |
| Grape (V. berlandieri × V. rupestris cv. 'Richter 110') | MS | - | 1 | 0.2 |
| Maize (Z. mays, cv. H1233) | N6 M (LP40) | 0.5 | - | - |
| Rice (O. sativa ssp. japonica cv. 'Unggi 9' | G1 | 1 | - | - |
| Tobacco (N. tabacum cv. Petit Havana SR1) | MS | - | 1 | 0.2 |
| Calculated peak sizes# | ||||||
| Dye | Oligonucleotide | Fragment length | Mean | StdDev | Min | Max |
| TET | PRNP_154R | 92 bp | 89.16 | 0.12 | 88.91 | 89.70 |
| PRNP_154H | 96 bp | 92.13 | 0.09 | 91.98 | 92.45 | |
| PRNP_171Q | 146 bp | 142.91 | 0.12 | 142.67 | 143.48 | |
| PRNP_171R | 150 bp | 148.05 | 0.18 | 146.72 | 148.42 | |
| PRNP_171H | 154 bp | 153.13 | 0.72 | 152.31 | 153.74 | |
| FAM | PRNP_154R | 92 bp | 89.56 | 0.13 | 89.36 | 89.84 |
| PRNP_154H | 96 bp | np | np | np | np | |
| PRNP_171Q | 146 bp | 143.29 | 0.11 | 143.13 | 143.48 | |
| PRNP_171R | 150 bp | np | np | np | np | |
| PRNP_171H | 154 bp | np | np | np | np |
| Total cells | Eosinophils | Neutrophils | Lymphocytes | Macrophages | |
| Control | 8.91 ± 1.17 | 0.00 ± 0.00 | 0.05 ± 0.00 | 0.19 ± 0.01 | 8.37 ± 1.57 |
| OVA | 74.64 ± 12.60 * | 9.08 ± 2.20 * | 2.12 ± 0.52 * | 4.51 ± 1.43 * | 58.41 ± 10.05 * |
| OVA + OVA323-339 | 63.64 ± 8.07 # | 4.58 ± 0.86 # | 1.03 ± 0.15 | 3.06 ± 0.52 | 55.59 ± 9.91 |
| OVA + MAPs | 43.32 ± 5.64 § | 1.02 ± 0.16 § | 0.92 ± 0.16 | 0.86 ± 0.11 § | 40.24 ± 6.29 |
| Chromosome - RNA | ||||||
| Positive | Negative | |||||
| Dataset | Overlap | Enrichment | p-value | Overlap | Enrichment | p-value |
| GO Process | 238 | 1.50 | 2.76E-12 | 393 | 1.66 | 9.55E-29 |
| SGD Phenotype | 59 | 2.73 | 8.45E-12 | 135 | 4.19 | 9.35E-44 |
| Positive Genetic | 20 | 23.82 | 7.29E-21 | 3 | 2.39 | 0.13 |
| Synthetic Sick | 2 | 1.30 | 0.67 | 49 | 21.35 | 1.44E-46 |
| Chromosome - Signalling | ||||||
| Positive | Negative | |||||
| Dataset | Overlap | Enrichment | p-value | Overlap | Enrichment | p-value |
| GO Process | 56 | 1.39 | 5.98E-03 | 121 | 1.30 | 1.12E-03 |
| SGD Phenotype | 10 | 1.40 | 2.50E-01 | 67 | 4.07 | 2.13E-22 |
| Positive Genetic | 3 | 13.48 | 1.56E-03 | 2 | 3.90 | 0.09 |
| Synthetic Sick | 0 | 0.00 | 1.00 | 24 | 19.98 | 3.06E-23 |
| RNA - Signalling | ||||||
| Positive | Negative | |||||
| Dataset | Overlap | Enrichment | p-value | Overlap | Enrichment | p-value |
| GO Process | 65 | 2.03 | 5.97E-09 | 162 | 2.25 | 7.63E-26 |
| SGD Phenotype | 33 | 5.07 | 1.87E-14 | 88 | 6.02 | 7.13E-42 |
| Positive Genetic | 16 | 71.81 | 1.19E-24 | 2 | 4.00 | 0.09 |
| Synthetic Sick | 1 | 2.40 | 0.34 | 54 | 57.77 | 1.98E-74 |
| Handle | Functionality | Comfort | Freedom of movement |
| Scissors handle A | 4.4 ± 1.8 | 3.8 ± 1.7 | 4.1 ± 1.5 |
| Scissors handle B | 5.0 ± 1.4 | 4.6 ± 1.4 | 4.9 ± 1.3 |
| In-line handle | 4.0 ± 1.6 | 4.6 ± 1.5 | 4.7 ± 1.6 |
| Pistol grip A | 5.3 ± 1.4 | 5.3 ± 1.4 | 5.0 ± 1.3 |
| Pistol grip B | 4.5 ± 1.8 | 4.6 ± 1.7 | 4.4 + 1.6 |
| Variation | Purpose of the variation and ideas for the debriefing discussions |
| Include observers. | • Include an outside view on the processes during the conduct into the debriefing. What does such an outside view contribute to the analysis of the conduct of Hand-it-on?• Prepare participants for the observer role during scenarios and debriefings. What is helpful feedback to colleagues after a simulation scenario? |
| Vary the objects. | • Use objects where there is something at stake for those who handle them. When handling a full glass of water there is a different “risk” for the person handling the water than when handing on a pen. Where are own risks during the care for patients? How do they impact the actions of those involved?• Use objects that are difficult to manipulate (e.g., a thin thread). They can be used to focus on technical skills and psychomotoric challenges in combination with keeping an overview of parallel tasks. How does the requirement to concentrate on handling this object impact the overview of the situation? |
| Vary the direction in which the objects should be passed and/or include more tasks. | • This variation can challenge improvement plans between two rounds of Hand-it-on. How are the intentions to implement changes (work as imagined) impacted by the practicalities of the work system (work as done)?• Discuss the impact of work procedures and personal preferences on their implementation. How do changes in procedures impact the patient care? |
| Separate one or more participants while giving the details of the instruction. Let the first few rounds run without them and include those participants only then. | • Discuss the integration of new colleagues into a department. How are they introduced to the tasks they are supposed to do? How are they welcomed on a social and emotional level? What influences their integration (think about time pressure, work-load, or structured introduction programs)? Are there differences in the introduction between the two departments in the variation for large groups (See Fig. 1b)?• Discuss the importance of knowing about the history of discussions in a department. How do people understand a situation if they know only parts of its development and did not have any prior practice of the task?• Discuss working with people who might not have been part of forming the current routines, norms, values and beliefs. How does the shared understanding of those impact the task and social level? How does it feel to accept the features of the work system if you were not a part in forming them? |
| Include “hidden” instructions for briefed role players. You could ask them to frequently “drop” objects or to not concentrate on the process, causing delays. Remember to reveal the hidden instructions during the debriefing to protect your role player. They would not like to come across as “obstructive” or “unable” in reality. | • Discuss how the group reacted to such a “low” performer. How can a work team or an organization deal with a worker who does not perform to standards? How would a team identify such a person in the first place? What would impact the reaction to such a worker? Is there a difference in how you treat people who you like vs. those you do not get along with? How does it feel to observe this person? How does it feel to be this person? What do patients think about the low performer? |
| Include “stressors” such as loud music, noise, or the threat of moving the organization to a different country. | • Discuss the impact of such disturbances and ask participants to draw connections to real life. How do different operation room settings with their lighting, temperature or noise conditions impact performance?• Explore the differences in the experience and in handling of such stressors between the individuals involved. Who is disturbed by such external factors, who can deal with them easily? What are the coping strategies? |
| PG group | Control group | 95% CI | p-value | |
| Wound closure ) | n = 32 | n = 41 | ||
| Second day postoperatively | 0 | 0 | – | |
| Third day postoperatively | 7 | 6 | 7% (–11% to 25%) | 0.5 |
| Fourth day postoperatively | 7 | 13 | –9% (–30% to 10%) | 0.4 |
| Wound closure | n = 36 | n = 46 | ||
| 2 weeks postoperatively | 4 | 16 | –24% (–41% to 7%) | 0.02 |
| Drop in Hb, mean (SD) | n = 50 | n = 52 | ||
| mmol/L | –1.58 (0.63) | –1.75 (0.58) | 0.16 (–0.07 to 0.4) | 0.2 |
| Pain at rest, median (range) | n = 50 | n = 52 | ||
| At inclusion | 3 (1–5) | 3 (1–5) | 0.8 | |
| 6 weeks | 2 (1–5) | 2 (1–5) | 0.08 | |
| 3 months | 2 (1–5) | 2 (1–5) | 0.8 | |
| Pain during walking, median (range) | n = 50 | n = 52 | ||
| At inclusion | 4 (1–5) | 4 (1–5) | 0.4 | |
| 6 weeks | 2 (1–5) | 2 (1–5) | 0.07 | |
| 3 months | 2 (1–5) | 2 (1–5) | 0.9 | |
| Use of pain medication, median (range) | n = 50 | n = 52 | ||
| At inclusion | 2 (1–5) | 2 (1–5) | 0.5 | |
| 6 weeks | 2 (1–5) | 2 (1–5) | 0.9 | |
| 3 months | 2 (1–5) | 2 (1–5) | 0.1 | |
| WOMAC score, mean (range) | n = 50 | n = 52 | ||
| At inclusion | 45 (8–76) | 44 (14–74) | ||
| 6 weeks | 26 (3–76) | 24 (0–65) | 0 (–8 to 8) | 0.7 |
| 3 months | 25 (0–76) | 21 (0–66) | –3 (–6 to 1) | 0.4 |
| ROM, mean (SD) | n = 32 | n = 36 | ||
| Second day postoperatively | 53 (14) | 50 (17) | ||
| Third day postoperatively | 68 (13) | 65 (16) | ||
| Fourth day postoperatively | 72 (13) | 73 (14) | 0.7 | |
| ROM, mean (SD) | n = 34 | n = 45 | ||
| 2 weeks postoperatively | 91 (13) | 89 (13) | ||
| 6 weeks postoperatively | 99 (11) | 100 (13) | ||
| 3 months postoperatively | 102 (12) | 101 (12) | 0.9 |
| CLSI Guidelines | EUCAST Guidelines | |||||||||||||||
| Disk content (μg) | 2006 | 2007 | 2008 | 2010 | 2011 | 2012 | Disk content (μg) | 2013 | 2014 | |||||||
| 11/8 | 23/8 | 6/8 | 5/5 | 14/12 | 22/4 | 10/4 | 26/3 | 6/6 | 30/9 | 20/12 | 23/1 | 23/1a | 11/9a | |||
| Drug | ||||||||||||||||
| Ofloxacin | 5 | S | S | NT | NT | NT | NT | NT | 0 | NT | NT | NT | NT | NT | NT | NT |
| Pipercillin/ Tazobactum | 100/10 | S | S | S | S | S | S | S | 36 | S | S | S | S | S | R | S |
| Ceftazidime | 30 | S | S | S | S | S | S | S | 10 | S | S | S | S | S | S | S |
| Tobramycin | 10 | S | S | S | S | S | S | S | 10 | S | S | S | S | S | S | S |
| Ciprofloxacin | 5 | NT | S | NT | S | S | S | S | 5 | S | S | S | S | S | S | S |
| Amikacin | 30 | NT | S | NT | NT | NT | NT | NT | 30 | NT | NT | NT | NT | NT | NT | NT |
| Aztreoman | 30 | NT | S | NT | NT | NT | NT | S | 30 | S | I | I | I | I | I | I |
| Colistin (E-Test) | 10 | NT | S | NT | NT | NT | NT | NT | 10 | NT | NT | S | S | S | S | S |
| Imipenem | 10 | NT | S | NT | NT | NT | NT | NT | 10 | NT | NT | NT | NT | NT | NT | NT |
| Meropenem | 10 | NT | S | S | S | S | S | S | 10 | S | S | S | S | S | S | S |
| Enterobacteria phage | Accession no. | Genome size (bp) | Coverage (×) | No. of CDSsa | No. of tRNAs |
| RB3 | KM606994 | 168,402 | 2,831 | 273 | 10 |
| RB5 | KM606995 | 168,394 | 3,449 | 271 | 10 |
| RB6 | KM606996 | 168,394 | 1,474 | 271 | 10 |
| RB7 | KM606997 | 168,395 | 6,985 | 272 | 10 |
| RB9 | KM606998 | 168,395 | 2,826 | 272 | 10 |
| RB10 | KM606999 | 168,401 | 2,798 | 272 | 10 |
| RB27 | KM607000 | 165,179 | 2,966 | 271 | 10 |
| RB33 | KM607001 | 166,007 | 3,355 | 274 | 8 |
| RB55 | KM607002 | 168,896 | 259 | 272 | 8 |
| RB59 | KM607003 | 168,966 | 3,158 | 276 | 8 |
| RB68 | KM607004 | 168,401 | 3,187 | 276 | 9 |
| Case | Constant Error (m/s) | Amplitude of White Noise |
| Case1 | 0 | 0 |
| Case2 | 1 | 0 |
| Case3 | 0 | 0.1 |
| Case4 | 1 | 0.1 |
| Medium(dielectric constant) | Dipole Moment (D) |
| Gas | 2.98 |
| Water (78.3) | 5.13 |
| DMSO (46.8) | 4.50 |
| Acetonitrile (35.7) | 4.53 |
| n-Octanol (9.9) | 4.54 |
| Chloroform (4.7) | 3.96 |
| Carbon tetrachloride (2.2) | 3.46 |
| Tumor type | Site of sample collection a | Metastatic disease | Ki67 index, % |
| Ileal carcinoid | Retro-peritoneal LN (m) | Yes | <2 |
| Ileal carcinoid | Ileum (p) | Yes | <2 |
| Ileal carcinoid | Ileum (p) | Yes | <2 |
| Ileal carcinoid | Ileum (p) | Yes | <2 |
| Ileal carcinoid | Ovary (m) | Yes | 40 |
| Ileal carcinoid | Retro-peritoneal LN (m) | Yes | 5 |
| Ileal carcinoid | Ileum (p) | No | <2 |
| Ileal carcinoid | Muscle (m) | Yes | <2 |
| Ileal carcinoid | Ileum (p) | Yes | <2 |
| Ileal carcinoid | Ileum (p) | No | <2 |
| Ileal carcinoid | Ileum (p) | Yes | <2 |
| N-F pancreatic NET | Pancreas (p) | No | <2 |
| N-F pancreatic NET | Pancreas (p) | No | 5 |
| Functioning pancreatico-duodenal NETs | |||
| Gastrinoma | Retro-peritoneal LN (m) | Yes | 5 |
| Glucagonoma | Retro-peritoneal LN (m) | Yes | <2 |
| Glucagonoma | pancreas (p) | Yes | 5 |
| Glucagonoma | Pancreas (p) | Yes | 50 |
| Glucagonoma/Somatostatinoma | Pancreas (p) | No | <2 |
| Somatostatinoma | Pancreas (p) | Yes | <2 |
| Somatostatinoma | Papilla Vatery (p) | No | <2 |
| Pheochromocytoma | Adrenal medulla (p) | No | <2 |
| Pheochromocytoma | Adrenal medulla (p) | <2 | |
| Pheochromocytoma | Adrenal medulla (m) | Yes | <2 |
| Pheochromocytoma | Adrenal medulla (p) | No | 10 |
| Pheochromocytoma | Adrenal medulla (p) | <2 | |
| Pheochromocytoma | Adrenal medulla (p) | Yes | 5 |
| Pheochromocytoma | Adrenal medulla (p) | No | <2 |
| Pheochromocytoma | Adrenal medulla (p) | No | 25 |
| Paraganglioma | Retroperitoneum (p) | No | <2 |
| NE colon carcinoma | Colon (p) | Yes | 50 |
| NE colon carcinoma | Colon (p) | Yes | 85 |
| NE colon carcinoma | Colon (p) | Yes | <2 |
| NE colon carcinoma | Liver (m) | Yes | 5 |
| Gastric NET, type 3 | Corpus (p) | No | 5 |
| Variable | Group | N | % |
| Aeitiology | HSVa | 38 | 18.18 |
| ADEMb | 23 | 11 | |
| VZVc | 12 | 5.74 | |
| MTBd | 10 | 4.78 | |
| ANTe | 8 | 3.83 | |
| Other | 34 | 16.27 | |
| Viral | 22 | 10.53 | |
| Bacterial | 12 | 5.74 | |
| Unknown | 84 | 40.19 | |
| Gender | Male | 114 | 54.54 |
| Age: Categorical | Age ≤ 10 | 55 | 26.32 |
| 10 < Age ≤35 | 55 | 26.32 | |
| 35 < Age ≤55 | 42 | 20.1 | |
| Age >55 | 50 | 23.92 | |
| Age: Continuous | 33.29 ± 25.64 (0,87)* | ||
| Region | South West | 17 | 8.13 |
| London | 86 | 41.15 | |
| North West | 106 | 50.72 | |
| Duration of illness | 58.88 ± 71.39 (3,535)* | ||
| Length of stay** | 49.01 ± 67.01(2,521)* |
| Gene ID | Illumina sequencing | QRT-PCR | KO description |
| comp139796_c2 | −53.83a | −138.82 | chalcone synthase |
| comp78650_c0 | −26.86 | −80.31 | flavonol synthase |
| comp129681_c0 | −3.78 | −9.73 | hydroxymethyl glutaryl CoA synthase |
| comp106407_c0 | −10.00 | −25.62 | 3-hydroxy-3-methylglutaryl-coenzyme A reductase |
| comp140511_c0 | −3.30 | −5.73 | Dammarenediol-II synthase |
| comp126977_c0 | −6.04 | −4.79 | glycosyltransferase |
| comp141084_c0 | −2.13 | −6.34 | glycosyltransferase |
| comp140248_c0 | 6.98b | 19.41 | glutathione S-transferase |
| comp117631_c0 | 8.19 | 25.85 | glutathione S-transferase |
| comp128853_c0 | 2.05 | 63.56 | myb proto-oncogene protein, plant |
| comp128641_c0 | 2.32 | 2.17 | myb proto-oncogene protein, plant |
| comp66279_c0 | 3.55 | 2.63 | myb proto-oncogene protein, plant |
| comp128496_c0 | 5.93 | 8.83 | myb proto-oncogene protein, plant |
| comp77739_c0 | 8.52 | 8.26 | myb proto-oncogene protein, plant |
| comp109390_c0 | 6.71 | 5.20 | heat shock transcription factor, other eukaryote |
| comp141438_c1 | 5.22 | 9.27 | heat shock 90 kDa protein |
| comp142366_c1 | 6.33 | 4.68 | heat shock 70 kDa protein |
| comp141020_c0 | 7.02 | 21.39 | heat shock 70 kDa protein |
| comp134360_c1 | 12.85 | 9.71 | heat shock 70 kDa protein |
| comp134360_c0 | 13.58 | 20.37 | heat shock 70 kDa protein |
| Compound | IC50 (μM) | ||||
| HL-60 | SMMC-7721 | A-549 | MCF-7 | SW480 | |
| 2 | >40 | >40 | >40 | >40 | >40 |
| 3 | 17.6 | 20.8 | 24.1 | 23.0 | >40 |
| 4 | >40 | 35.9 | 17.4 | >40 | >40 |
| 5 | 15.2 | 18.6 | 21.2 | 17.1 | 12.8 |
| 6 | 17.6 | 18.6 | 17.2 | 21.4 | 30.1 |
| 7 | 16.0 | 29.3 | 23.1 | 16.9 | 11.8 |
| 8 | 18.4 | >40 | 30.6 | 21.6 | 34.2 |
| DDP a | 3.1 | 10.2 | 9.1 | 17.5 | 12.0 |
| arabinose | galactose | glucose | xylose | mannose | sucrose | |
| sugar maple | not detected | not detected | 1231 | not detected | not detected | not detected |
| aspen | 13.4 | 0.6 | 1.4 | 3.5 | 2.5 | 0.98 |
| spalted aspen | not detected | 3.3 | 10.1 | 15.8 | 12.6 | 12.1 |
| tree of heaven | 29.2 | 110 | 133.5 | 14.2 | not detected | 1.9 |
| Site | Latitude | Longitude | Elevation(m) | Land Cover | Site Size |
| Dayekou | 38.5337°N | 100.2502°E | 2835.2 | Coniferous Forest | 2 km × 2 km |
| Yingke | 38.8571°N | 100.4103°E | 1519.1 | Cropland (corn) | 2 km × 2 km |
| Hulunber | 49.3533°N | 120.1246°E | 650 | Meadow steppe | 3 km × 3 km |
| Jingyuetan | 44.1172°N | 125.3615°E | 190 | Cropland (corn) | 3 km × 3 km |
| ROI | Cohen’s d | s.e. | P-value | I2 | N voxels |
| Average FA | −0.42 | 0.042 | 4.5 × 10−24 | 34.65 | 112 889 |
| ACR | −0.40 | 0.045 | 9.19 × 10−19 | 43.83 | 3129 |
| CC | −0.40 | 0.045 | 8.36 × 10−19 | 42.51 | 7318 |
| BCC | −0.39 | 0.045 | 2.51 × 10−18 | 43.24 | 3173 |
| GCC | −0.37 | 0.042 | 1.24 × 10−18 | 35.22 | 1834 |
| ALIC | −0.37 | 0.046 | 2.27 × 10−15 | 46.30 | 1510 |
| CR | −0.33 | 0.040 | 3.16 × 10−17 | 27.89 | 7344 |
| FXST | −0.32 | 0.042 | 8.28 × 10−14 | 36.39 | 706 |
| FX | −0.31 | 0.045 | 6.76 × 10−12 | 43.25 | 222 |
| PTR | −0.31 | 0.035 | 1.99 × 10−18 | 11.78 | 1987 |
| SS | −0.30 | 0.040 | 4.91 × 10−14 | 30.34 | 1294 |
| SFO | −0.29 | 0.054 | 3.96 × 10−8 | 59.68 | 193 |
| CGC | −0.27 | 0.045 | 2.95 × 10−9 | 42.87 | 594 |
| PCR | −0.25 | 0.036 | 2.39 × 10−12 | 15.76 | 1437 |
| SCC | −0.22 | 0.048 | 4.39 × 10−6 | 50.94 | 2311 |
| SLF | −0.22 | 0.040 | 5.61 × 10−8 | 29.17 | 3503 |
| EC | −0.21 | 0.040 | 1.41 × 10−7 | 31.01 | 2896 |
| IC | −0.18 | 0.042 | 1.80 × 10−5 | 36.25 | 4781 |
| UNC | −0.16 | 0.033 | 8.78 × 10−6 | 4.18 | 125 |
| SCR | −0.15 | 0.034 | 6.91 × 10−6 | 7.84 | 2778 |
| RLIC | −0.13 | 0.041 | 0.0021 | 33.10 | 1496 |
| IFO | −0.11 | 0.038 | 0.0035 | 22.70 | 88 |
| CGH | −0.11 | 0.041 | 0.0082 | 33.73 | 524 |
| CST | −0.04 | 0.038 | 0.24 | 24.20 | 167 |
| PLIC | 0.04 | 0.046 | 0.37 | 46.20 | 1775 |
| 24-h group | 7-d group | Re-exposure group | ||||||||||
| AMS+(n = 190) | AMS-(n = 71) | t | P | AMS+ ( n = 26) | AMS-( n = 73) | t | P | AMS+ ( n = 48) | AMS-( n = 46) | t | P | |
| [Hb] (g/L) | 145.77 ± 12.04 | 146.55 ± 15.24 | -0.432 | 0.666 | 175.38 ± 10.82 | 169.33 ± 11.77 | 2.299 | 0.024* | 187.06 ± 12.69 | 183.46 ± 9.99 | -1.527 | 0.130 |
| RBC (1012) | 4.57 ± 0.39 | 4.62 ± 0.40 | -0.990 | 0.323 | 5.23 ± 0.35 | 5.12 ± 0.41 | 1.225 | 0.223 | 5.81 ± 0.72 | 5.62 ± 0.45 | -1.519 | 0.132 |
| HCT (L/L) | 41.29 ± 3.08 | 41.48 ± 3.83 | -0.398 | 0.691 | 47.91 ± 2.69 | 46.24 ± 3.15 | 2.419 | 0.017* | 54.34 ± 6.93 | 52.72 ± 4.36 | -1.358 | 0.178 |
| MCV (fl) | 90.77 ± 5.48 | 89.58 ± 8.49 | 1.331 | 0.184 | 91.87 ± 2.81 | 90.71 ± 5.21 | 1.085 | 0.281 | 93.64 ± 4.30 | 93.86 ± 3.66 | 0.268 | 0.789 |
| MCH (pg) | 31.96 ± 2.19 | 31.70 ± 2.59 | 0.797 | 0.426 | 33.54 ± 1.23 | 33.16 ± 2.36 | 0.777 | 0.439 | 32.39 ± 2.66 | 32.69 ± 2.11 | 0.600 | 0.550 |
| MCHC (g/L) | 352.34 ± 7.60 | 352.51 ± 9.48 | -0.144 | 0.886 | 365.50 ± 5.53 | 365.86 ± 10.79 | -0.164 | 0.870 | 346.52 ± 25.32 | 348.78 ± 19.57 | 0.483 | 0.630 |
| Diagnosis | All patients (n) | RF+(n) | Patients with early disease (<12 months) (n) | RF+(n) |
| Rheumatoid arthritis | 160 | 129 | 52 | 39 |
| Undifferentiated monoarhtritis | 13 | 4/11a | 8b | 2/6a |
| Undifferentiated oligoarthritis | 9 | 2 | 4b | 1 |
| Undifferentiated polyarthritis | 7 | 2 | 5c | 1 |
| Juvenile idiopathic arthritis | 9 | 4 | 0 | 0 |
| Adult Still's disease | 1 | 0 | 0 | 0 |
| Undifferentiated spondylarthritis | 4 | 0 | 2 | 0 |
| Psoriatic arthritis | 12 | 0 | 2 | 0 |
| Ankylosing spondylitis | 1 | 0 | 0 | 0 |
| Ulcerative colitis | 2 | 0/1d | 1 | 0 |
| Undifferentiated systemic inflammatory disease with arthritis | 1 | 0 | 0 | 0 |
| Systemic lupus erythematosus | 3 | 0 | 1 | 0 |
| Cutaneous PAN with arthritis | 1 | 0 | 0 | 0 |
| Osteoarthritis | 4 | 4 | 1 | 1 |
| Healthy individuals | 10 | ND | NA | NA |
| Sum | 237 | 141 | 76 | 42 |
| Bacterial Luciferase (Lux) | Green Fluorescent Protein (GFP) | ||
| V. fischeri | [16] | E. coli | [17] |
| Various toxins | Various toxins | ||
| Bacteriophage | [18] | E. coli | [19] |
| Pathogenic Bacteria | L-arabinose | ||
| Saccharomyces cerevisiae | [20] | Yeast | [21] |
| Androgenic compounds | DNA damage | ||
| E. coli | [22] | E. coli | [23] |
| Nalidixic Acid | Arsenic | ||
| E. coli | [24] | Bacillus sp. | [14] |
| Various stressors | Arsenic/Zinc | ||
| HEK293 mammalian cell line | [25] | Firefly Luciferase (Luc) | |
| Whole animal imaging | E. coli | [26] | |
| Gene expression | |||
| E. coli | [27] | ||
| Polycyclic aromatic hydrocarbons | E. coli | [28] | |
| Benzene | |||
| Alcaligenes eutrophus | [29] | ||
| Heavy metals | E. coli | [30] | |
| Various toxins | |||
| Pseudomonas putida | [31] | ||
| Microbial volatile organics | Aequorin | ||
| E. coli | [32] | ||
| Pseudomonas fluorescens | [33] | Calcium | |
| Naphthalene/salicylate | |||
| B Cells | [34] | ||
| E. coli | [35] | Pathogenic Bacteria | |
| DNA damaging agents |
| Patient age | Total | |||
| Younger than 60 years | Older than 60 years | |||
| Low risk | 12 | 41 | 53 | |
| Goasguen score | Intermediate risk | 9 | 48 | 57 |
| Total | 21 | 89 | 110 |
| Beneficiary-related features | Men (n = 198) | Women (n = 117) | Total (n = 315) | ||||
| Number | (%) | Number | (%) | Number | (%) | ||
| Aspects of life | |||||||
| Working, attending school, or performing housework | 159 | (82.4%) | 92 | (81.4%) | 251 | (82.0%) | |
| Home care | 28 | (14.5%) | 18 | (15.9%) | 46 | (14.6%) | |
| Hospitalization or admission | 6 | (3.1%) | 3 | (2.7%) | 9 | (2.9%) | |
| Not known | 5 | — | 4 | — | 9 | — | |
| Visit status | |||||||
| Primarily inpatient | 9 | (4.7%) | 1 | (1.0%) | 10 | (3.4%) | |
| Half inpatient/half outpatient | 12 | (6.3%) | 8 | (7.6%) | 20 | (6.8%) | |
| Primarily outpatient | 170 | (89.0%) | 96 | (91.4%) | 266 | (89.9%) | |
| Other or not known | 7 | — | 12 | — | 19 | — | |
| Physical-disability certification and grade | |||||||
| Not certified | 148 | (75.1%) | 92 | (78.6%) | 240 | (76.4%) | |
| Grade 1 | 42 | (21.3%) | 17 | (14.5%) | 59 | (18.8%) | |
| Grade 2–5 | 7 | (3.6%) | 8 | (6.8%) | 15 | (4.8%) | |
| Not known | 1 | — | 0 | — | 1 | — | |
| Care-requirement certification status | |||||||
| Needing care or support | 8 | (4.1%) | 7 | (6.5%) | 15 | (5.0%) | |
| No need for care or support | 185 | (95.9%) | 100 | (93.5%) | 285 | (95.0%) | |
| Not known | 5 | — | 10 | — | 15 | — | |
| Self-rated clinical course as compared with previous year | |||||||
| Worse | 52 | (28.3%) | 29 | (27.4%) | 81 | (27.9%) | |
| Unchanged | 109 | (59.2%) | 69 | (65.1%) | 178 | (61.4%) | |
| Improved or cured | 23 | (12.5%) | 8 | (7.5%) | 31 | (10.7%) | |
| Other or not known | 14 | — | 11 | — | 25 | — |
| Cohorts | |||||
| Parameter | All | LRC | BHS | ERA | LSADT |
| N | 1156 | 620 | 271 | 185 | 80 |
| Females % | 44 | 33 | 66 | 33 | 70 |
| Age (years) | |||||
| Baseline | 38 ± 15 | 30 ± 1 | 31 ± 5 | 58 ± 10 | 75 ± 2 |
| Follow-up | 50 ± 14 | 43 ± 1 | 43 ± 4 | 68 ± 10 | 86 ± 2 |
| Follow-up duration | 12.1 ± 1.7 | 13.0 ± 0.8 | 12.4 ± 1.8 | 9.5 ± 0.5 | 10.8 ± 0.0 |
| LTL (kb) | |||||
| Baseline | 7.06 ± 0.81 | 7.34 ± 0.67 | 7.22 ± 0.73 | 6.45 ± 0.56 | 5.85 ± 0.60 |
| Follow-up | 6.73 ± 0.77 | 7.00 ± 0.63 | 6.83 ± 0.72 | 6.23 ± 0.54 | 5.51 ± 0.64 |
| LTL attrition (bp/year) | 27.3 ± 16.8 | 25.7 ± 14.8 | 32.2 ± 17.8 | 23.6 ± 15.6 | 31.2 ± 24 |
| BMI (Kg/m2) | |||||
| Baseline | 25.7 ± 4.8 | 24.8 ± 3.7 | 27.0 ± 6.7 | 26.5 ± 4.2 | 26.5 ± 4.1 |
| Follow-up | 27.6 ± 5.4 | 27.2 ± 4.6 | 29.8 ± 7.3 | 26.8 ± 4.3 | 24.9 ± 3.7 |
| Difference | 1.88 ± 3.14 | 2.36 ± 2.62 | 2.76 ± 3.73 | 0.33 ± 1.66 | −1.60 ± 3.62 |
| Smoking (%) | |||||
| Baseline | 31 | 37 | 31 | 15 | 23 |
| Follow-up | 23 | 28 | 22 | 10 | 11 |
| Section | Global rating questions used | MID improvement | Specificity | Sensitivity | MID deterioration | Specificity | Sensitivity |
| Activity | Global health, Impairment, Walking | 6 | 0.25–0.65 | 0.10–0.67 | 10 | 0.36–0.72 | 0.39–0.70 |
| 7 | 0.29–0.86 | 0.12–0.75 | 11 | 0.44–0.78 | 0.33–0.78 | ||
| 8 | 0.28–0.86 | 0.13–0.75 | 25 | 0.42–0.72 | * | ||
| Participation | Global health, Impairment, Participation | 16 | 0.47–0.90 | 0.50 | 15 | 0.44–0.9 | 0.22–0.78 |
| 17 | 0.45–0.88 | 0.67 | 17 | 0.43–0.91 | 0.40–0.80 | ||
| 20 | 0.45–0.89 | 0.50 | 22 | * | * | ||
| Balance | Balance | 1 | 0.46, 0.69 | 0.13, 0.15 | 2 | 0.42, 0.69 | 0.42, 0.42 |
| 2 | 0.48, 0.68 | 0.10, 0.21 | 3 | 0.49, 0.72 | 0.5, 0.67 | ||
| 3 | 0.49–0.71 | 0.13, 0.25 | 4 | * | * | ||
| Total score | Global health, Participation Impairment | 16 | 0.44–0.97 | 0.11–0.66 | 16 | 0.26–0.65 | 0.17–0.68 |
| 20 | 0.47–0.95 | 0.14–0.80 | 18 | 0.29–0.65 | 0.21–0.67 | ||
| 25 | 0.47–0.95 | 0.20–0.80 | 22 | 0.29–0.64 | 0.25–0.75 |
| MiMix [21] | Minimum Information required for reporting a Molecular Interaction experiment |
| It relies on PSI-MI [22] controlled vocabularies for terms, and its purpose is providing a checklist of the information to be supplied when describing experimental molecular interaction data. It is a module developed within the framework of the MIAPE guidelines. | |
| MIAPE [23] | Minimum Information About a Proteomics Experiment |
| It provides guidance modules for reporting the use of proteomics techniques such as gel electrophoresis and mass spectrometry, and has been developed and proposed to encourage collection and integration of these kinds of data. | |
| MIAME [24] | Minimum Information About a Microarray Experiment |
| It is used to submit fully compliant datasets, to enable the interpretation of the experimental results unambiguously and, potentially, to reproduce the study. | |
| MIRIAM Registry [25] | Minimum Information Required in the Annotation of Models |
| Created for defining the meta-information needed to ensure the re-usability of computational models of biological processes. It aims to maintain, unambiguously and perennially, the identifiers regarding the biomedical domain. The registry retrieves the identifiers in the form of URIs, and provides the http://www.Identifiers.org resolver online service, for their generation. |
| Clinical Outcome Measure | Natural course mean pp/y (95% CI) P-value | Treatment course mean pp/y (95% CI) P-value | Difference* mean pp/y (95% CI) P- value | |||
| MRC sumscore Total study population (N = 69, M = 558) | 1.4 (0.8 to 2.1) | <0.001 | ||||
| MRC sumscorePatients with pre-ERT + ERT follow-up (N = 49, M = 523) | −1.2 (−2.1 to −0.4) | 0.006 | 2.1 (1.2 to 3.0) | <0.001 | 3.3 (1.9 to 4.7) | <0.001 |
| HHD sumscore Total study population (N = 64, M = 503) | 4.0 (2.5 to 5.6) | <0.001 | ||||
| HHD sumscore Patients with pre-ERT + ERT follow-up (N = 42, M = 435) | −2.8 (−4.2 to −1.3) | <0.001 | 5.1 (3.0 to 7.3) | <0.001 | 7.9 (5.0 to 10.7) | <0.001 |
| QMFT score Total study population (N = 69, M = 553) | 0.7 (−0.2 to 1.7) | 0.14 | ||||
| FVC in upright position Total study population (N = 62, M = 475) | 0.1 (−1.0 to 1.1) | 0.92 | ||||
| FVC in upright position Patients with pre-ERT + ERT follow-up (N = 46, M = 480) | −2.0 (−3.1 to −0.8) | 0.001 | −0.2 (−1.6 to 1.2) | 0.76 | 1.8 (−0.2 to 3.7) | 0.08 |
| FVC in supine position Total study population (N = 54, M = 411) | −1.1 (−2.1 to −0.1) | 0.03 | ||||
| FVC in supine position Patients with pre-ERT + ERT follow-up (N = 42, M = 436) | −1.8 (−2.9 to −0.7) | 0.002 | −1.0 (−2.3 to 0.3) | 0.12 | 0.8 (−0.9 to 2.4) | 0.38 |
| Variable, n (%) | Fatal outcomes | Univariate analysis | Multivariable analysis | |||||
| Yes (n = 69) | No (n = 117) | OR | 95 % CI | P-value | OR | 95 % CI | P-value | |
| Demographics | ||||||||
| Male gender | 34(49.3) | 49(41.9) | 1.3 | 0.7–2.4 | 0.361 | |||
| Mean age, years (range) | 27.1(20.4–33.8) | 26.9(21.6–32.3) | 0.489 | |||||
| Newborns (0–28 days) | 16(23.2) | 10(8.5) | 3.2 | 1.4–7.5 | 0.008 | 4.5 | 2.4–37.8 | 0.025 |
| P remature babies | 9(13.0) | 5(4.3) | 3.4 | 1.1–9.9 | 0.042 | |||
| Children (1 month–17 years) | 17(24.6) | 54(46.1) | 2.6 | 1.4–5.0 | 0.005 | |||
| Adults (up to 17 years) | 36(52.2) | 53(45.3) | 1.3 | 0.7–2.4 | 0.448 | |||
| Comorbidity | ||||||||
| Sickle cell disease | 6(8.7) | 11(0.5) | 0.5 | 0.3–2.5 | 1 | |||
| Malnutrition | 4(5.8) | 13(11.1) | 0.5 | 0.5–1.5 | 0.296 | |||
| AIDS | 3(4.3) | 7(5.9) | 0.7 | 0.2–2.6 | 0.747 | |||
| Diagnostic at admission | ||||||||
| Gastroenteritis | 6(8.7) | 19(16.2) | 0.5 | 0.2–1.3 | 0.184 | |||
| Respiratory disease | 18(26.1) | 17(14.5) | 2.1 | 0.9–4.3 | 0.079 | |||
| Meningitis | 11(15.9) | 4(3.4) | 5.3 | 1.7–16.6 | 0.004 | 2.3 | 1.5–4.9 | <0.0001 |
| Tuberculosis | 2(2.8) | 4(3.4) | 0.8 | 0–4.1 | 1 | |||
| Cancer | 12(20.3) | 4(3.4) | 5.9 | 1.9–18.3 | 0.002 | 2.7 | 1.6–6.6 | 0.001 |
| Neurologic disorder | 8(11.5) | 24(20.5) | 0.5 | 0.2–1.2 | 0.159 | |||
| Invasive procedure | ||||||||
| Surgical intervention | 15(21.7) | 21(17.9) | 1.3 | 0.6–2.6 | 0.567 | |||
| Parenteral nutrition | 15(21.7) | 15(12.8) | 1.9 | 0.9–4.1 | 0.148 | |||
| Mechanical ventilation | 28(40.5) | 17(14.5) | 3.9 | 1.9–7.9 | 0.0002 | 6.1 | 3.1–124.6 | 0.040 |
| Central venous catheter | 53(76.8) | 66(56.4) | 2.6 | 1.3–4.9 | 0.007 | |||
| Urinary catheter | 14(20.3) | 36(30.8) | 0.6 | 0.3–1.1 | 0.128 | |||
| ESBL Production | 52(75.4) | 58(49.6) | 3.1 | 1.6–5.9 | <0.0001 | 5.3 | 3.1–19.9 | 0.008 |
| Type of infection | ||||||||
| Bloodstream infection | 31(44.9) | 38(32.5) | 1.7 | 0.9–3.1 | 0.116 | |||
| Urinary tract infection | 18(26.1) | 49(41.9) | 0.5 | 0.2–0.9 | 0.039 | |||
| Meningitidis | 7(10.1) | 2(1.7) | 6.5 | 1.5–25.7 | 0.014 | |||
| Surgical site infection | 9(13.0) | 15(12.8) | 1.0 | 0.4–2.4 | 1 | |||
| Respiratory infection | 4(6.8) | 8(7.7) | 0.8 | 0.2–2.7 | 1 | |||
| Inadequate antibiotherapy prescription | 49(71.0) | 62(52.9) | 2.3 | 1.2–4.3 | 0.013 | |||
| Mean time to infection, days, (95 % CI) | 5.9(4.3–7.5) | 7.3(5.4–9.3) | 0.838 |
| Collection day | Total no. of females | No. of parous females | Daily parity rate |
| 1 | 98 | 67 | 0.55 |
| 2 | 128 | 86 | 0.67 |
| 3 | 90 | 66 | 0.69 |
| 4 | 31 | 25 | 0.70 |
| 5 | 9 | 6 | 0.70 |
| 6 | 42 | 37 | 0.72 |
| 7 | 28 | 18 | 0.71 |
| 8 | 18 | 17 | 0.72 |
| 9 | 52 | 43 | 0.73 |
| 10 | 58 | 43 | 0.73 |
| 11 | 22 | 18 | 0.74 |
| 12 | 11 | 6 | 0.73 |
| 13 | 13 | 8 | 0.73 |
| 14 | 47 | 31 | 0.72 |
| 15 | 13 | 9 | 0.72 |
| 16 | 16 | 10 | 0.72 |
| 17 | 5 | 4 | 0.72 |
| 18 | 31 | 21 | 0.72 |
| 19 | 47 | 32 | 0.72 |
| 20 | 39 | 27 | 0.71 |
| 21 | 27 | 23 | 0.72 |
| 22 | 50 | 38 | 0.72 |
| Totals | 875 | 635 | na |
| Reduced transversal palatal diameter N (%) | Skeletal class II | Cross-byte | Atipic swallowing | |
| N (%) | N (%) | N (%) | ||
| Atopic SDB subjects | 39/60 (65%) | 24/60 (40%) | 21/60 (35%) | 54/60 ( 90%) |
| Non atopic SDB subjects | 44/50 (88%) | 24/50 (48%) | 15/50 (30%) | 47/50 (94%) |
| p | P<0.05 (*) | n.s. | n.s. | n.s. |
| Axis | Conditions | Mean | SD | SEM (95% CI) | ICC (95% CI) | P value | |
| X | Anterior (+)/Posterior (−) | BL | 0.9 | 1.3 | 0.07 (0.04 to 0.52) | 0.994 (0.975 to 0.998) | 0.01a |
| ST | 0.09 | 0.9 | 0.23 (0.04 to 0.86) | 0.816 (0.259 to 0.954) | |||
| SR | 2.3 | 2.2 | 0.05 (0.01 to 0.28) | 0.999 (0.997 to 0.100) | |||
| Y | Superior (+)/Inferior (−) | BL | 0.7 | 1.7 | 0.02 (0.01 to 0.18) | 0.100 (0.998 to 0.100) | 0.048a |
| ST | 0.6 | 1.7 | 0.02 (0.01 to 0.07) | 0.100 (0.999 to 0.100) | |||
| SR | −1.9 | 5.0 | 0.04 (0.01 to 0.31) | 0.100 (0.999 to 0.100) | |||
| Z | Lateral (−)/Medial (+) | BL | −2.5 | 1.9 | 0.04 (0.01 to 0.16) | 0.100 (0.999 to 0.100) | 0.001a |
| ST | −2.6 | 2.1 | 0.02 (0.01 to 0.08) | 0.100 (0.100 to 0.100) | |||
| SR | −5.4 | 1.2 | 0.03 (0.01 to 0.15) | 0.999 (0.996 to 0.100) |
| Days | Activities | Detail |
| Day 1 | Orientation | Briefing on pharmacy operation and services |
| Discussion about the objective of the session | ||
| Daily work schedule, including learning clinical skills and responding to symptoms | ||
| Day 2 | Observation | Pharmacy layout |
| Arrangement of drugs in pharmacy (outlet and store) | ||
| Types of medicines available | ||
| Requirements for medication storage | ||
| Day 3 | Store management | Storage of drugs according to their volume of use |
| First-in/first-out method | ||
| Day 4 and day 5 | Pharmaceutical care for the community | Management of chronic and long-term health problems though pharmacy |
| Responding to symptoms in community pharmacy | ||
| Dealing with special health issues | ||
| Proper information about family planning methods | ||
| Health screening | ||
| Day 6 | Counselling skills | Basic counselling skills |
| Counselling for stigmatized patients | ||
| Use of pharmacological and non-pharmacological approaches during counselling | ||
| Day 7 | Practical skills | Use of medical devices |
| Applying methods of physical examination | ||
| Day 8 | Business plan | Drug selection criteria and drug procurement activities |
| Inventory management | ||
| Break-even point analysis | ||
| Legal procedure for establishing a community pharmacy | ||
| Day 9 | Waste management | Handling of damaged and expired drugs |
| Disposal of wastage | ||
| Day 10 | Medicine information source | Use of available information sources in pharmacy |
| Development of informational material by the pharmacy such as leaflets, booklets, and other materials for educational purposes | ||
| Day 11 | ADR reporting and pharmacovigilance | Determination of ADR by various assessment scales |
| Reporting of ADR to regional pharmacovigilance center | ||
| Day 12 | Future prospects | Potential for community pharmacy-managed services in the Nepalese context |
| Variable | Diabetes Patients (n=218) | Non-Diabetes (n=734) | P value |
| Operative time (min) (mean±SD) | 434±81 | 422±76 | 0.014 |
| Aortic cross clamp time (min) (mean±SD) | 82±25 | 83±30 | 0.351 |
| No. of coronary grafts (%) | 0.143 | ||
| One | 3.7 | 4.1 | |
| Two | 16.5 | 19.6 | |
| Three | 79.8 | 75.5 | |
| ≥Four | 0 | 0.8 |
| Predictor Variables | B | β | sr2 | t | p |
| Age | .02 | .01 | .00 | .36 | .72 |
| Income | -.36 | -.05 | -.11 | -2.06 | .04* |
| Education | -.26 | -.02 | -.03 | -.85 | .39 |
| History of Depression | -.02 | -.01 | -.00 | -.23 | .82 |
| History of Abuse | .26 | .06 | .00 | 2.22 | .03* |
| History of Miscarriage/Abortion | -.46 | -.03 | -.05 | -1.03 | .34 |
| Antenatal Anxiety | 2.15 | .32 | .06 | 9.46 | .00*** |
| Major Life Events | .97 | .07 | .00 | 2.55 | .01* |
| Negative Cognitive Style | .04 | .11 | .00 | 2.68 | .00** |
| Self-Esteem | -.43 | -.34 | -.33 | -6.46 | .00*** |
| Social Support | -1.86 | -.18 | -.19 | -3.71 | .00*** |
| R = .88 | |||||
| R2 = .78*** | |||||
| Adjusted R2 = .77 | |||||
| Standard Error = 4.30 |
| Security Level | NISTP192-SHA256 | NISTP224-SHA256 | NISTP224-SHA224 | NISTP384-SHA256 | NISTP384-SHA384 | ||||||||||
| CB | Xn | i7 | CB | Xn | i7 | CB | Xn | i7 | CB | Xn | i7 | CB | Xn | i7 | |
| Sign w/o Certificate a | 1.39 | 0.19 | 0.06 | 1.77 | 0.26 | 0.12 | 1.76 | 0.26 | 0.16 | 6.32 | 0.85 | 0.36 | 6.21 | 0.85 | 0.39 |
| Sign with Certificate a | 1.44 | 0.20 | 0.07 | 1.83 | 0.27 | 0.08 | 1.81 | 0.27 | 0.09 | 6.39 | 0.86 | 0.42 | 6.31 | 0.86 | 0.38 |
| Encrypt w/o Certificate b | 6.57 | 0.92 | 0.29 | 8.58 | 1.28 | 0.42 | 8.65 | 1.27 | 0.40 | 42.88 | 5.25 | 1.79 | 42.82 | 5.29 | 1.79 |
| Encrypt with Certificate b | 6.58 | 0.93 | 0.30 | 8.62 | 1.29 | 0.40 | 8.68 | 1.28 | 1.18 | 42.93 | 5.29 | 1.78 | 42.87 | 5.30 | 1.92 |
| Sign & Encrypt w/o Certificate c | 8.01 | 1.13 | 0.38 | 10.42 | 1.54 | 0.51 | 10.47 | 1.54 | 0.60 | 49.35 | 6.12 | 2.10 | 49.21 | 6.12 | 2.21 |
| Sign & Encrypt with Certificate c | 8.06 | 1.14 | 0.39 | 10.55 | 1.56 | 0.78 | 10.54 | 1.55 | 0.53 | 49.43 | 6.17 | 2.11 | 49.29 | 6.14 | 2.12 |
| Region | Ergot limit in cereal grains for humans (ppm) | Ergot limit in animal feed (ppm) | Other comments |
| Australia and New Zealand | 0.05 | N/A | 0–0.1% (T) |
| Canada | 0–0.05 | 0.10–0.33 | Varies with grade of wheat |
| European Union | 0.05 | 0.10 | – |
| Switzerland | 0.02 | N/A | 0.05 limit on cereals destined for milling |
| Japan | 0.04 | N/A | – |
| United Kingdom | Zero tolerance | 0.001 | – |
| United States | 0.3 (W, R) | 0.3 (W, R) | 0.1% (B, O, T) |
| First story (Aladdin’s Lamp) | Second story (The Three Little Pigs) | Third story (Adopting a Star) | ||||
| Moral | No moral | Moral | No moral | Moral | No moral | |
| TB | 37 | 13 | 24 | 26 | 32 | 18 |
| PC-NoIA | 16 | 34 | 31 | 19 | 21 | 29 |
| PC-IA | 20 | 30 | 8 | 42 | 11 | 39 |
| χ2 = 19.51 | χ2 = 22.82 | χ2 = 18.04 | ||||
| p < 0.001 | p < 0.001 | p < 0.001 |
| Participant Patients | Age | Gender | Lesion location | Hemi-paretic side | Etio-logy | Time since lesion (days) | ARAT (max = 57) | Max. grip force (kg) affected\\non-affected | % max. grip force (%) | Moberg Pick-Up Test (s) affected\\non-affected | Mono-filaments (g) affected\\non-affected |
| 1 | 76 | F | Right precentral gyrus and right lenticular nucleus | left | H | 36 | 57 | 12\\16 | 75 | 16\\12 | 0.4\\0.4 |
| 2 | 49 | M | Left parieto-occipital cortex, intra-ventricular and corpus callosum | right | H | 120 | 57 | 42\\39 | 100 | 25\\13 | 0.4\\0.07 |
| 3 | 25 | M | Right temporo-parietal cortex | left | H | 330 | 32 | 15/44 | 34 | 60\\13 | 0.07\\0.07 |
| 4 | 68 | F | Left fronto-parietal cortex | right | I | 19 | 57 | 11/15 | 73 | 19\\14 | 0.07\\0.4 |
| 5 | 46 | M | Right sylvian and subdural hematoma | left | I | 165 | 51 | 12/26 | 46 | 50\\30 | 0.4\\0.4 |
| 6 | 68 | M | Left sylvian | right | I | 315 | 40 | 18/37 | 49 | 60\\22 | 0.07\\0.4 |
| 7 | 40 | M | Left thalamus | right | H | 75 | 40 | 6/43 | 14 | 51\\21 | 0.07\\0.4 |
| 8 | 64 | M | Left pons | right | I | 40 | 57 | 38/30 | 100 | 32\\24 | 0.4\\0.4 |
| 9 | 50 | F | Left precentral cortex and left semi-oval center | right | I | 210 | 56 | 19/24 | 79 | 13\\12 | 0.4\\0.4 |
| 10 | 65 | M | Left pons | right | I | 180 | 57 | 17/39 | 43 | 26\\17 | 0.4\\0.4 |
| Patients | 55.1 (±15.7) | 3 F/7M | 149 (±112) | 50.4 (±9.4) | 31.3 (±10.7) | 61.3 (±28.5) | 35.2 (±18.3) | 0.33 (±0.14) | |||
| Mean (±SD) | \\19.0 (±11.7) | \\17.8 (±6.2) | \\0.27 (±0.18) | ||||||||
| Controls Mean (±SD) | 52.9 (±17.4) | 4 F/6 M | 35.1 (±11.4) | 14.3 (±1.9) | 0.14 (±0.14) |
| Treatment (n = 5) | Dose (mg/kg) | Onset of sleep (min) | Duration of sleep (min) |
| Control | – | 32.80 ± 7.03 | 128.20 ± 19.79 |
| Hibiscus tiliaceus leaves | 500 | 16.40 ± 1.03* | 133.40 ± 13.87* |
| Hibiscus tiliaceus barks | 500 | 13.80 ± 2.08* | 101.40 ± 12.54* |
| Category | Survey question |
| Awareness items | Do you know what colorectal cancer is? |
| Do you know what a colon polyp is? | |
| Do you know what a cancer screening test is? | |
| Do you know the different types of screening tests available for colorectal cancer? | |
| Do you know what the following tests are: | |
| Fecal Occult Blood Test (FOBT)/ Stool Blood Test? | |
| Colonoscopy? | |
| Sigmoidoscopy? | |
| Do you know where you can obtain screening tests for colorectal cancer? | |
| Knowledge items | Do you think a diet low in fat and high in fiber helps decrease the risk for developing colorectal cancer? |
| Do you think physical activity decreases the risk of developing colorectal cancer? | |
| Do you think the risks for developing colorectal cancer increases after the age of 50? | |
| Do you think most patients survive colorectal cancer if it is found early and removed? | |
| Do you think you ONLY need colorectal cancer screening if you are having any symptoms? | |
| Behavioral intention to obtain colorectal cancer screening | Do you plan on talking to your doctor about cancer of the colon and rectum in the future? |
| Do you plan on getting screened for cancer of the colon and rectum in the future? | |
| Behavioral intentions to promote colorectal cancer education | How likely are you to talk about colorectal cancer with your: |
| Parents | |
| Grandparents | |
| Relatives (aunts, uncles, cousins) | |
| Peers (friends, colleagues, etc.) | |
| Community members | |
| Individuals at risk (50+ years of age, family history, etc.) |
| Characteristics | Preoperative with plasmapheresis group (PPG) N (33) | Preoperative without plasmapheresis group (NPPG) N (53) | P value |
| Male, n (%) | 8 (24.2) | 17 (32.1) | 0.475 |
| Age (years), (mean ± SD) | 44.2 ± 11.6 | 44.0 ± 15.3 | 0.933 |
| Underlying disease (DM or HT or dyslipidemia) | 17 (51.5) | 30 (56.6) | 0.663 |
| Osserman classification | 0.611 | ||
| I | 2 (6.1) | 5 (9.4) | 0.703 |
| IIA | 6 (18.2) | 14 (26.4) | 0.440 |
| IIB | 21 (63.6) | 31 (58.5) | 0.658 |
| III | 4 (12.1) | 3 (5.7) | 0.421 |
| History of myasthenic crisis at any time | 16 (48.5) | 12 (22.6) | 0.018 |
| History of myasthenic crisis within one month before surgery | 7 (21.2) | 1 (1.9) | 0.005 |
| History of plasmapheresis within one month before surgery | 11 (33.3) | 5 (9.4) | 0.009 |
| Ocular involvement | 15 (45.5) | 25 (47.2) | 1.000 |
| Neck muscle motor power (mean ± SD) | 4.5 ± 0.7 | 4.8 ± 0.4 | 0.025 |
| Upper extremities motor power (mean ± SD) | 4.4 ± 0.7 | 4.7 ± 0.5 | 0.009 |
| lower extremities motor power (mean ± SD) | 4.3 ± 0.8 | 4.7 ± 0.5 | 0.004 |
| Respiratory involvement | 6 (18.2) | 1 (1.9) | 0.012 |
| Bulbar involvement | 13 (39.4) | 6 (11.3) | 0.003 |
| Mestinon use | 33 (100) | 47 (88.7) | 0.078 |
| Dose of mestinon (mg/day) (mean ± SD) | 238.2 ± 132.0 | 204.9 ± 88.1 | 0.179 |
| Prednisolone use | 30 (91.0) | 48 (91.0) | 1.000 |
| Dose of prednisolone (mg/day) (mean ± SD) | 36.0 ± 19.8 | 29.3 ± 14.9 | 0.094 |
| Azathioprine use | 16 (48.5) | 21 (39.6) | 0.503 |
| Dose of Azathioprine (mg/day) (mean ± SD) | 65.6 ± 22.1 | 73.8 ± 28.0 | 0.342 |
| FVC (mean ± SD) | 1503.3 ± 304.7 | 2552.9 ± 221.5 | 0.019 |
| Probability of receiving treatment (propensity score)* | 0.53 ± 0.32 | 0.26 ± 0.15 | <0.001 |
| Gene symbol | Gene name & function | Fold change | p-value |
| ompC | Outer membrane protein C porin - permeability | 0.97 | NS |
| ompF | Outer membrane protein F porin - permeability | 0.14 | < .001 |
| micF | Anti-sense RNA - negative regulation of OmpF translation | 2.27 | < .001 |
| marA | Multiple antibiotic resistance (mar) protein A - transcription activator of mar regulon | 2.01 | < .001 |
| marB | mar protein B | 2.22 | < .001 |
| marR | mar operon repressor | 1.80 | .003 |
| soxS | Regulatory protein SoxS - superoxide response regulon | 0.37 | < .001 |
| acrA | Acriflavine resistance protein A - antibiotic and bile resistance | 1.89 | < .001 |
| acrB | Acriflavine resistance protein B - antibiotic and bile resistance | 2.21 | < .001 |
| acrR | Acriflavine resistance protein R –transcription regulator | 2.83 | < .001 |
| yceE | Multidrug resistance protein - antibiotic and bile resistance | 2.04 | .002 |
| yojI | Drug (microcin) efflux pump | 2.49 | < .001 |
| Multiplex PCR assay | Biochemical test | TOTAL | |
| Nitrate positive | Nitrate negative | ||
| Nitrate positive | 133 | 5 | 138 |
| Nitrate negative | 5 | 205 | 210 |
| Total | 138 | 210 | 348 |
| Characteristic variables | Number | Weighting % | (95% CI) |
| Gender | |||
| Male | 958 | 48.4 | (47.4–49.4) |
| Female | 6355 | 51.6 | (50.6–52.6) |
| Age (years) | |||
| <17 | 3649 | 29.3 | (25.7–33.2) |
| 17–18 | 6695 | 55.4 | (51.0–59.6) |
| >18 | 1969 | 15.3 | (12.4–18.7) |
| Hometown | |||
| Shanghai | 6290 | 49.8 | (46.8–52.9) |
| Sanming | 3027 | 24.3 | (21.4–27.5) |
| Beihai | 2996 | 25.9 | (23.2–28.7) |
| School type | |||
| Model senior high school | 2371 | 19.0 | (16.0–22.5) |
| Common senior high school | 8053 | 64.0 | (60.5–67.4) |
| Vocational high school | 1889 | 16.9 | (14.6–19.6) |
| Average monthly income per person (CNY*) | |||
| <1500 | 3982 | 32.7 | (31.3–34.1) |
| 1500-2500 | 5281 | 42.5 | (41.4–43.6) |
| >2500 | 3050 | 24.8 | (23.7–25.9) |
| Experience of premarital sex | |||
| Yes | 552 | 4.5 | (4.1–5.5) |
| No | 11761 | 95.4 | (95.0–95.9) |
| Condom use in sexual debut | |||
| Yes | 132 | 25.0 | (21.2–29.1) |
| No | 420 | 75.0 | (70.9–78.8) |
| Consistent condom use | |||
| Yes | 65 | 11.6 | (9.1–14.7) |
| No | 487 | 89.5 | (85.0–90.3) |
| Group | N | WBC (×109/L) | PMN (%) |
| control | 14 | 6.38±1.23 | 24.22±5.11 |
| model | 11 | 13.52±2.86** | 56.24±6.37** |
| DSQ | 13 | 8.60±2.86## | 37.25±4.22## |
| LVX | 13 | 9.29±1.80## | 35.44±6.42## |
| Categories | Search terms |
| Participants | (child OR children OR adolescent* OR pediatric*OR paediatric*) AND |
| Disease | (sleeplessness OR ‘chronic insomnia’ ORinsomniac OR insomnia OR insomni* OR ‘sleep initiation andmaintenance disorders’) AND |
| Interventions | (CBT OR ‘cognitive behavioural therapy’ OR‘cognitive behavioral therapy’ OR ‘cognitive behaviortherapy’ OR ‘cognitive behavioural therapies’ OR ‘cognitivebehavioral therapies’ OR ‘cognitive behavior therapies’ OR‘cognitive analytic therapy’ OR ‘sleep hygiene’ OR ‘stimuluscontrol’ OR ‘relaxation’ OR ‘relaxation therapy’ OR‘relaxation techniques’ OR ‘behavior modification’ OR‘behavior therapy’ OR ‘cognitive therapy’ OR ‘imagery’ OR‘biofeedback’ OR ‘counseling’ OR ‘family therapy’ OR‘psychoanalytic therapy’ OR ‘psychotherapy’) |
| Categories of neuropsychiatric services | Total cost AED (%) | Average cost per visit paid by patient AED (US $) (%) | Average cost per visit paid by insurance AED (US $) (%) | Average cost per visit AED (US $) (%) |
| Psychiatry | 12,337,182 (44 %) | 151 ($41) (34 %) | 300 ($82) (66 %) | 451 ($123) (100 %) |
| Neurology | 7908,970 (28 %) | 75 ($20) (14 %) | 458 ($132) (86 %) | 533 ($145) (100 %) |
| Psychotherapy | 7810,044 (28 %) | 335 ($91) (67 %) | 165 ($45) (33 %) | 500 ($136) (100 %) |
| Total | 28,056,196 (100 %) | 181 ($49) (37 %) | 304 ($83) (63 %) | 485 ($132) (100 %) |
| Primer name | Sequence | Used to generate data for figure: |
| IAP-F [8] | 5′-ATAATCTGCGCATGAGCCAAGG-3′ | 1 |
| IAP-R [8] | 5′-AGGAAGAACACCACAGACCAGA-3′ | 1 |
| Tagln F | 5′-GCATAAGAGGGAGTTCACAGACA-3′ | 3, 4, S11 |
| Tagln R | 5′-GCCTTCCCTTTCTAACTGATGATC-3′ | 3, 4, S11 |
| Myh11 F | 5′-CAGTTGGACACTATGTCAGGGAAA-3′ | 3, 4, S11 |
| Myh11 R | 5′-ATGGAGACAAATGCTAATCAGCC-3′ | 3, 4, S11 |
| 1F [33] | 5′-GCGCCAGTCATCCGATAGACT-3′ | S2 |
| K1R [33] | 5′-AAGGCTTTATTGGGAACACG-3′ | S2 |
| MoA 5 bbone | 5′-GCGCCAGTCCTCCGATTGAC-3′ | S13 |
| XMRV adapt MoA | 5′ -TGAGAACGCTGGACTTTCCATC | S13 |
| 5bbone R | GATGTTAGGCCATTAAGGAG-3′ | |
| XMRV adapt MoA | 5′-AACTCCTCCGGCCGGAACAGC | S13 |
| env F | ATGAGACAGCGGACCCGGACT-3′ | |
| MoA adapt XMRV | 5′-GAAACTGAATAAAATCTTTTAT | S13 |
| env R | GGCTCGTACTCTATAGGCTT-3′ | |
| MoA adapt XMRV | 5′-GAAGAAGTGGAATCACGTGA | S13 |
| 3bbone F | ATAGATAAAATAAAAGATTTTA-3′ | |
| MoA 3bbone R | 5′-TGCAACTGCAAG | S13 |
| AGGGTTTATTGG-3′ | ||
| XMRV 5bbone F | 5′-GCGCCAGTCCTCCGATTGAC-3′ | S14 |
| MoA adapt XMRV | 5′-CTCCTTAATGGCCTAACATCG | S14 |
| env F | ATGGAAAGTCCAGCGTTCTCA-3′ | |
| MoA adapt XMRV | 5′-GAAACTGAATAAAATCTTTTA | S14 |
| env R | TGGCTCGTACTCTATAGGCTT-3′ | |
| XMRV adapt MoA | 5′-TAAAATCTTTTATTTTATCTA | S14 |
| env R | TTCACGTGATTCCACTTCTTC-3′ | |
| XMRV 3bbone F | 5′-AAGCCTATAGAGTACGAGCCA | S14 |
| TAAAAGATTTTATTCAGTTTC-3′ | ||
| XMRV 3bbone R | 5′-TTGCAAACAGCAAAAGGCTTT-3′ | S14 |
| XPR1 F [35] | 5′- TAATTCAGAAGAATCAGGAATT-3′ | S16 |
| XPR1 R [35] | 5′-CGAGTGACCTCGTTCTTTG-3′ | S16 |
| Health Unit | Health Region Peer Groupa | Land area (km2) | Population density (persons/km2)(Census, 2011) | Populationage 65+ (% of total)(Census, 2011) | Visible minorities (% of population)(NHS, 2011) |
| North Bay Parry Sound District | Sparsely populated urban-rural mix | 16,801 | 7.4 | 19% | 1.7% |
| Simcoe Muskoka District | Moderately populated urban centres | 8736 | 58 | 16% | 4% |
| York Region | Highly populated urban centres | 1762 | 586.0 | 12% | 43% |
| Initial pH | pH range | ΔpH |
| 5.1 | 5.1–3.7 | 1.4 |
| 6.0 | 6.0 –3.8 | 2.2 |
| 7.0 | 7.0 –3.9 | 3.1 |
| 7.9 | 7.9–4.0 | 3.9 |
| Performance Parameter | Mean (SD) | Z statistic | ρ – value | |
| Group A (n = 6) | Group B (n = 10) | |||
| P1 | 8.2 (0.85) | 9.4 (0.14) | −0.617 | 0.077* |
| P2 | 8.1 (1.07) | 9.3 (0.99) | −4.934 | 0.035* |
| P3 | 14.0 (5.06) | 7.0 (1.25) | −4.904 | 0.015* |
| P4 | 5.8 (2.13) | 4.2 (0.85) | −3.047 | 0.042* |
| P5 | 1.0 (0.49) | 0.7 (0.05) | −3.297 | 0.021* |
| P6 | 549.6 (35.06) | 436.2 (14.25) | −5.751 | 0.028* |
| KNH (%) | AKUH (%) | |||||||||
| Attitude statements | SA | A | U | D | SD | SA | A | U | D | SD |
| A computer increases costs by increasing the nurses workload | 5.2 | 11 | 4.5 | 35.5 | 43.9 | 16.3 | Nil | 2.3 | 23.3 | 55.8 |
| Costs of health care are likely to increase because of computers | 8.4 | 18.8 | 4.6 | 34.4 | 33.8 | 18.2 | 4.6 | 29.6 | 34.1 | 2.3 |
| The time spent using a computer is out of proportion to the benefits | 5.9 | 9.2 | 9.9 | 32.2 | 42.8 | 7.3 | 2.4 | 36.6 | 41.5 | 13.6 |
| Computers represent a violation of patient privacy | 6.7 | 17.3 | 8 | 31.3 | 36.7 | 17.1 | 14.6 | 22 | 34.2 | 12.2 |
| Only one person at a time can use a computer terminal and, therefore, staff efficiency is inhibited. | 16.2 | 27.9 | 10.4 | 26.6 | 18.2 | 27.3 | 9.1 | 15.9 | 20.5 | 12.2 |
| Computerization of nursing data offers nurses a remarkable opportunity to improve patient care | 49.7 | 35.5 | 2.6 | 5.2 | 6.5 | 40.9 | 29.6 | 22.7 | 6.8 | 27.3 |
| Computers contain too much personal data to be used in an area as open as a nursing station | 14.7 | 27.6 | 5.1 | 30.1 | 22.4 | 11.6 | 20.9 | 4.7 | 44.2 | 18.6 |
| Computers can cause nurses to give less time to quality nursing care | 8.3 | 11.5 | 6.4 | 35.3 | 38.5 | 14 | 14 | 4.7 | 14 | 53.5 |
| If I had my way, nurses would never have to use computers | 4 | 4.6 | 4 | 15.1 | 72.4 | 4.7 | 4.7 | 2.3 | 16.3 | 72.1 |
| Computers should only be used in the financial department | 4.6 | 0.7 | 2.6 | 17.7 | 73.9 | 4.9 | 2.4 | 2.4 | 9.8 | 80.5 |
| Computers make nurses jobs easier | 51.7 | 31.1 | 6 | 7.3 | 4 | 60.5 | 25.6 | 7 | 4.7 | 2.3 |
| Paperwork for nurses can be reduced greatly by the use of computers | 69.9 | 20.9 | 5.2 | 1.3 | 2.6 | 56.8 | 29.6 | 2.3 | 9.1 | 2.3 |
| Orientation for new employees takes longer because of computers | 7.1 | 8.4 | 11.7 | 38.3 | 34.4 | 4.7 | 11.6 | 9.3 | 37.2 | 37.2 |
| Nursing data cannot be manipulated using computers | 13.6 | 23.9 | 9.7 | 27.1 | 25.8 | 12.2 | 26.8 | 4.9 | 36.6 | 19.5 |
| Computers save steps and allow the nursing staff to become more efficient | 43.5 | 35.7 | 6.5 | 10.4 | 3.9 | 47.7 | 29.6 | 2.3 | 13.6 | 6.8 |
| The more computers in an institution, the less number of jobs for employees | 21.8 | 25 | 10.9 | 24.4 | 18 | 29.6 | 22.7 | 6.8 | 20.5 | 20.5 |
| Increased computer use will allow nurses more time to give patient care | 45.3 | 26 | 9.3 | 14 | 5.3 | 37.8 | 29.7 | 8.1 | 16.2 | 8.1 |
| Because of computers, nurses will face more law suits | 9.5 | 15.5 | 12.2 | 29.1 | 33.8 | 3 | 15.2 | 9.1 | 36.4 | 36.4 |
| Computers can cause a decrease in communication between hospital departments | 7.3 | 11.3 | 6.7 | 28.7 | 46 | 16.7 | 16.7 | Nil | 30.6 | 36.1 |
| Confidentiality will be sacrificed by patient records being computerized | 14 | 17.3 | 6 | 33.3 | 29.3 | 32.4 | 27 | 2.7 | 18.9 | 18.9 |
| Fungicide concentration (kg ha−1) | Tebuconazole | Copper hydroxide |
| 0.0 | 260 ± 2.47f (100) | 260 ± 1.85f (100) |
| 1.0 | 410 ± 0.68d (157) | 420 ± 2.68e (161) |
| 2.5 | 750 ± 2.81c (288) | 650 ± 2.31c (250) |
| 5.0 | 920 ± 2.46a (353) | 800 ± 0.82a (307) |
| 7.5 | 820 ± 2.46b (315) | 740 ± 0.97b (284) |
| 10.0 | 380 ± 1.48e (146) | 350 ± 0.62d (134) |
| Epitope | Start position | Combined score |
| FIEYCNHCY | 64 | 2.4978 |
| FRYEFTAPF | 56 | 2.0697 |
| RYEFTAPFI | 57 | 1.6395 |
| ESLLHQASW | 19 | 1.2675 |
| SFVTDLEKY | 44 | 1.1582 |
| Cellulase | Percentage of mass/area remove | Film swelling | |
| RT | Topt | ||
| Cel9A | 5 | 11 | No |
| Cel9A-CBM | 12 | 32 | Yes |
| Cel5A | 1 | 4 | No |
| Cel5A-CBM | 16 | 35 | Yes |
| SNP reference | Chromosome | Genotype association χ2 P value | Permutation test P value |
| rs17163819 | 2 | 2.587 * 10-150 | 0.0042 |
| rs10894818 | 12 | 1.751 * 10-120 | 0.0046 |
| rs582397 | 3 | 1.089 * 10-82 | 0.0022 |
| rs7596121 | 3 | 5.212 * 10-60 | 0.0022 |
| rs16898558 | 6 | 1.718 * 10-52 | 0.0046 |
| rs996877 | 13 | 1.566 * 10-44 | 0.0036 |
| rs9387380 | 7 | 2.315 * 10-34 | 0.011 |
| rs940153 | 9 | 1.032 * 10-33 | 0.0040 |
| rs1456222 | 4 | 1.544 * 10-33 | 0.0048 |
| rs1572075 | 5 | 1.474 * 10-23 | 0.0040 |
| rs7192563 | 17 | 2.862 * 10-18 | 0.0030 |
| rs17765376 | 15 | 3.277 * 10-18 | 0.0058 |
| rs9532645 | 14 | 1.26 * 10-16 | 0.0028 |
| rs10751815 | 11 | 1.036 * 10-15 | 0.0014 |
| rs6975106 | 8 | 3.207 * 10-13 | 0.0028 |
| OPINIONS ABOUT USE OF MORPHINE | GP AGREEMENT (%) | HP AGREEMENT (%) | % DIFFERENCE GP - HP | P-Value |
| It means that it is serious (GP n = 171; HP n = 399) | 96 (56,1) | 37 (9,3) | 46,8 | 0,000* |
| There is a risk to develop dependency (GP n = 171; HP n = 405) | 70 (41.0) | 6 (1,5) | 39,5 | 0,000* |
| There is a risk of delirium or euphoria (GP n = 171; HP n = 405) | 68 (39.8) | 18 (4,4) | 35,4 | 0,000* |
| It does diminish the surviving period (GP n = 171; HP n = 407) | 61 (35,7) | 13 (3,2) | 32,5 | 0,002* |
| There is a risk of somnolence or sedation (PG n = 170; PS n = 403) | 74 (43,5) | 123 (30,5) | 13,0 | 0,000* |
| It can lead to increasing doses (GP n = 170; HP n = 403) | 85 (50,0) | 105 (26,1) | 23,9 | 0,000* |
| It is a sign of limited life expectancy (GP n = 171 - HP n = 409) | 47 (27,5) | 4 (1,0) | 26,5 | 0,000* |
| It increases legal risks in relation to other medication (GP n = 171; HP n = 407) | 85 (49,7) | 229 (56,3) | -6,6 | 0,149 |
| There is a risk of discrimination (PG n = 169; PS n = 397) | 33 (19,5) | 10 (2,5) | 17,0 | 0,000* |
| Genotypes | ||||
| GG | GA | AA | P | |
| N = 141 | 32 | 78 | 31 | |
| New coronary lesion (mean) | 0.34 ± 0.48 | 0.38 ± 0.49 | 0.26 ± 0.45 | 0.462 |
| Subjects with new coronary lesions (%) | 11 (34.3) | 30 (38.4) | 8 (25.8) | 0.265 |
| New coronary occlusions (mean) | 0.03 ± 0.18 | 0.08 ± 0.27 | 0.06 ± 0.25 | 0.678 |
| Subjects with new coronary occlusions (%) | 1 (3.1) | 6 (7.7) | 2 (6.5) | 0.209 |
| Average final MLD (mm) | 1.54 ± 0.40 | 1.62 ± 0.41 | 1.59 ± 0.39 | 0.657 |
| Change in MLD (mm) | -0.09 ± 0.25 | -0.11 ± 0.23 | -0.11 ± 0.25 | 0.928 |
| Website (n = 24) | JawboneTM/UP app (n = 23) | F2F (group) (n = 19) | F2F (1-2-1) (n = 22) | Facebook group (n = 24) | Food & nutrient report (n = 24) | GymstickTM (n = 23) | TEMPlateTM dinner disc (n = 16) | |
| Provided me with useful information about healthy eating | 4.0 ± 0.6 | 3.2 ± 1.0 | 4.1 ± 0.6 | 4.5 ± 0.7 | 3.8 ± 0.8 | 4.4 ± 0.9 | NA | 3.9 ± 0.9 |
| Provided me with useful information about exercise | 4.2 ± 0.6 | 3.9 ± 0.9 | 4.2 ± 0.9 | 4.2 ± 0.8 | 3.7 ± 0.8 | NA | NA | NA |
| Provided me with useful information about stress | 3.7 ± 0.7 | 3.0 ± 0.9 | 3.6 ± 0.8 | 4.0 ± 0.9 | 3.5 ± 0.8 | NA | NA | NA |
| Helped me to attain my goals | 3.6 ± 0.8 | 3.8 ± 0.9 | 3.9 ± 1.0 | 4.0 ± 0.9 | 3.7 ± 0.9 | 4.1 ± 1.0 | 3.7 ± 1.0 | 3.3 ± 0.9 |
| Motivated me | 3.5 ± 0.9 | 4.1 ± 0.7 | 4.3 ± 0.7 | 4.0 ± 0.8 | 3.6 ± 0.8 | 4.0 ± 0.9 | 3.5 ± 1.0 | 3.3 ± 1.1 |
| Made me feel accountable | 3.3 ± 0.9 | 4.0 ± 1.0 | 3.8 ± 0.9 | 4.1 ± 0.8 | 3.5 ± 1.0 | 4.2 ± 0.9 | 3.6 ± 1.0 | 3.2 ± 0.9 |
| Was easy to use/navigate | 4.3 ± 0.6 | 4.0 ± 0.9 | NA | NA | 4.2 ± 0.8 | NA | 3.8 ± 1.0 | 3.5 ± 1.2 |
| Content was easy to understand | 4.3 ± 0.4 | 4.1 ± 0.7 | 4.4 ± 0.6 | 4.4 ± 0.6 | 4.2 ± 0.8 | 4.1 ± 0.9 | NA | NA |
| Was visually appealing | 4.0 ± 0.7 | 4.0 ± 0.9 | NA | NA | 3.8 ± 0.8 | 3.9 ± 0.9 | NA | 3.4 ± 0.9 |
| Was supportive in answering any queries/questions | NA | NA | 4.5 ± 0.7 | 4.5 ± 0.6 | 3.7 ± 0.8 | NA | NA | NA |
| Satisfaction | 4.0 ± 0.6 | 4.2 ± 1.1 | 4.1 ± 0.8 | 4.3 ± 0.8 | Not asked | 4.2 ± 0.8 | 4.0 ± 0.9 | 3.0 ± 0.9 |
| Prevalence % | |||
| Beijing urban (1) | Beijing rural (2)b | Hong Kong (3)b | |
| Male | |||
| 65–74 | 108 (8.88 %) | 4 (1.29 %)1 | 99 (7.36 %)2 |
| 75–84 | 202 (18.33 %) | 6 (7.19 %)1 | 90 (15.80 %)2 |
| 85+ | 22 (19.30 %) | 0 (0 %) | 9 (21.40 %) |
| Female | |||
| 65–74 | 342 (14.89 %) | 24 (6.59 %)1 | 223 (17.61 %)1,2 |
| 75–84 | 362 (24.69 %) | 16 (12.62 %)1 | 164 (27.12 %)2 |
| 85+ | 41 (32.80 %) | 1 (33.33 %) | 20 (34.39 %) |
| Total | |||
| 65–74 | 450 (12.81 %) | 28 (4.53 %)1 | 322 (12.91 %)2 |
| 75–84 | 564 (21.96 %) | 22 (10.05 %)1 | 254 (20.94 %)2 |
| 85+ | 63 (26.36 %) | 1 (13.84 %) | 29 (26.69 %) |
| City | As | Cr | Ni | Cd | Co | Reference |
| Hezhang, China | 4.9 × 10−4 | 3.1 × 10−6 | 2.2 × 10−7 | 1.8 × 10−9 | 4.6 × 10−8 | This study |
| Zhuzhou, China | 1.1 × 10−6 | 3.2 × 10−8 | 6.9 × 10−9 | 8.5 × 10−8 | 3.2 × 10−8 | [58] |
| Huludao, China | 2.4 × 10−8 | [7] | ||||
| Beijing, China | 2.4 × 10−8 | 2.0 × 10−7 | 2.1 × 10−9 | 9.5 × 10−10 | 5.6 × 10−9 | [31] |
| Nanjing, China | 3.9 × 10−8 | 7.2 × 10−10 | 3.1 × 10−10 | 2.3 × 10−9 | [21] | |
| Shiraz, Iran | 1.1 × 10−8 | 8.3 × 10−8 | [30] | |||
| Luanda, Angola | 7.7 × 10−6 | 5.7 × 10−8 | 4.6 × 10−10 | 3.9 × 10−10 | 1.5 × 10−9 | [32] |
| Database | Search strategy | |
| Embase | #1 | ‘headache*’:ti,ab OR ‘cephalgia*’:ti,ab OR ‘cephalalgia*’:ti,ab OR ‘cranialgia*’:ti,ab OR ‘head ache*’:ti,ab OR ‘cephalodynia*’:ti,ab OR ‘cephalea*’:ti,ab OR ‘cerebral pain’:ti,ab OR ‘head pain’:ti,ab OR ‘eye pain’:ti,ab |
| #2 | ‘neuroimaging’:ti,ab OR ‘brain imaging’:ti,ab OR ‘tomography’:ti,ab OR ‘mri’:ti,ab OR ‘magnetic resonance imaging’:ti,ab OR ‘mr imaging’:ti,ab OR ‘nmr imaging’:ti,ab | |
| #3 | #1AND #2 | |
| Restrict to humans | #4 | #3 AND ‘human’/de |
| Filter by type of study | #5 | #4 AND (‘clinical study’/de OR ‘clinical trial’/de OR ‘cohort analysis’/de OR ‘comparative study’/de OR ‘controlled clinical trial’/de OR ‘controlled study’/de OR ‘family study’/de OR ‘major clinical study’/de OR ‘medical record review’/de OR ‘observational study’/de OR ‘prospective study’/de OR ‘randomized controlled trial’/de OR ‘retrospective study’/de OR ‘systematic review’/de) |
| Antibiotic name | MSO(central government | MCD | CG1 | CG2 | CPA(Delhi state government) |
| Azithromycin cap/tab | No rate available | 6.31 | No rate available | 9.45 | No rate available |
| Ceftriaxone injection | 14.99 | 18.28 | 16.46 | 15.50 | 8.50 |
| Erythromycin Stearate | 1.43 | 1.32 | 2.04 | 1.68 | 0.85 |
| cap/tab | |||||
| Gentamicin eye drops | No rate available | 0.61 | 0.81 | 1.21 | 0.58 |
| Gentamicin injection | No rate available | 1.40 | 1.53 | 2.49 | 1.52 |
| Roxithromycin cap/tab | 1.04 | 1.29 | No rate available | No rate available | 0.74 |
| miRNA Migr. / Inv. / Met. | Targets | Cells / Tissue | Expression | Function | Reference |
| miR-17 family (20a, 20b) | TGFßR2 | A549/CDDP | down | TGFßR2 suppressor, reverses CDDP-resistance and suppresses metastases | [81] |
| miR-21 | PTEN | Serum, NSCLC cells | up | Promotes migration, invasion and metastasis | [9] |
| mir-26b | PTEN | NSCLC tissue, NSCLC cells | down | Regulates NSCLC migration and CDDP-chemosensitivity | [78] |
| miR-27a | RKIP | A549/CDDP | up | Regulates EM-transition and CDDP-resistance | [82] |
| miR-98 | PAK1 | NSCLC tissue, A549/PAR | down | Inversely regulates PAK1, inhibits migration and invasion | [51] |
| miR-182 | PDCD4 | A549 cells | up | Induces resistance to CDDP by targeting PDCD4 | [84] |
| miR-200c | n. d. | NSCLC cell lines (n=9) | down | Inversely correlates with aggressive, invasive and chemoresistant phenotype | [8] |
| miR-206 | MET | NSCLC tissue, A549/CDDP, H1299/CDDP | down | Inhibits CDDP-resistance via MET dependent PI3K/AKT/mTOR pathways | [80] |
| miR-217 | KRAS | NSCLC tissue, A549/PAR | down | Inhibits proliferation, migration and invasion, promotes apoptosis and sensitivity to CDDP | [79] |
| DNA damage response | |||||
| miR-17/miR-92 families | TGFßR2, CDKN1A, RAD21 | A549/CDDP | down | Influence CDDP-resistance by synergistic and combined regulation of their target genes | [127] |
| miR-33b-3p | P21WAF1 | A549/CDDP | up | Impairs the DNA damage response | [128] |
| miR-92 | |||||
| miR-138 | ERCC1 | A549/CDDP | up | Negatively regulates ERCC1 expression | [38] |
| miR-155 | APAF-1 | NSCLC tissue, A549/PAR | up | Inhibits sensitivity to CDDP via negative regulation of Apaf-1 | [37] |
| miR-509-3-5p | PLK1 | CDDP-treated A549/PAR | down | Tumor suppressor, causes aberrant mitosis and anti-proliferative effects by suppressing PLK1 | [20] |
| miR-630 | ATM, H2AX, p53 | A549/PAR CDDP-treated | up | Blocks DNA-damage response | [13] |
| Drug uptake | |||||
| miR-15b | PEBP4 | A549/CDDP, NSCLC tissue | up | Suppresses PEBP4 expression and contribute to CDDP-resistance | [129] |
| miR-31-p | Dicer | A549 cells | n. d. | Enhances sensitivity to CDDP by repressing Dicer | [130] |
| miR-34a | PEBP4, MYCN | A549/PAR | up | Modulates CDDP-sensitivity in NSCLC cells by regulating PEBP4 expression | [131] |
| miR-106a | ABCA1 | A549/CDDP | up | Induces CDDP-resistance by targeting ABCA1 and inhibiting apoptosis | [68] |
| miR-148b | DNMT1 | A549/CDDP, SPC-A1/CDDP | down | Influence CDDP-sensitivity, cell viability and apoptosis | [57] |
| miR-181a | PTEN | A549/CDDP | up | Regulates epithelial-mesenchymal transition and metastatic properties of NSCLC cells | [46] |
| miR-185-5p | ABCC1 | A549/CDDP | down | Promotes CDDP-induced apoptosis by suppressing ABCC1 | [69] |
| miR-495 | ATP7A | NSCLC tissue, A549/CDDP | down | Negatively regulates ATP7A and modulates CDDP-induced apoptosis | [70] |
| miR-503 | FANCA | NSCLC tissue, A549/CDDP | down | Regulates CDDP-resistance by targeting FANCA | [102] |
| AC- | AC+ | |
| 2.5 Gy/fraction | 94 (A1) | 83 (A3) |
| 2.0 Gy/fraction | 142 (A2) | 114 (A4) |
| Gene ID | Log2 (RPKMOXR/RPKMWT) | Description | ||
| 0 h | 6 h | 24 h | ||
| Catalase (CAT) | ||||
| Os06t0727200-01 | 0.79 | 1.36 ** | 0.79 | catalase isozyme B (EC 1.11.1.6) |
| Ascorbate peroxidase (APX) | ||||
| Os04t0602100-01 | −1.77 * | −2.21 * | −1.34 * | l-ascorbate peroxidase |
| Peroxiredoxin (PrxR) | ||||
| Os06t0196300-01 | −1.64 * | −0.49 | 0.77 | similar to peroxiredoxin Q |
| Glutathione S-transferase (GST) | ||||
| Os04t0435500-01 | −0.72 | −1.03 * | −0.15 | glutathione S-transferase, c-terminal-like domain containing protein |
| Os10t0530500-01 | −1.42 * | −1.78 * | −2.0 * | similar to glutathione-S-transferase |
| Peroxidase superfamily protein | ||||
| Os07t0677200-01 | −0.04 | 2.81 ** | 0.64 | peroxidase |
| Os07t0677400-00 | −1.47 * | −0.28 | −0.02 | peroxidase. |
| Os04t0688100-01 | 0.45 | 2.21 ** | 0.18 | peroxidase (EC 1.11.1.7) |
| Os04t0688100-02 | 0.79 | 1.87 ** | 0.58 | peroxidase (EC 1.11.1.7) |
| Os04t0688500-01 | 0.9 | 2.72 ** | 1.21 ** | peroxidase (EC 1.11.1.7) |
| Os10t0109300-01 | 0.35 | 1.94 ** | 0.17 | similar to peroxidase (EC 1.11.1.7) |
| Os01t0263300-01 | 0.44 | 1.42 ** | −0.6 | similar to peroxidase 72 precursor (EC 1.11.1.7) |
| Os01t0962700-01 | 0.47 | 1.11 ** | −0.16 | similar to peroxidase 12 precursor (EC 1.11.1.7) |
| Os01t0963000-01 | 1.01 ** | 4.55 ** | 1.38 ** | similar to peroxidase BP 1 precursor |
| Os06t0547400-01 | 0.73 | 1.76 ** | 1.03 ** | similar to peroxidase P7 (EC 1.11.1.7) |
| Os06t0695500-01 | 0.01 | 2.19 ** | −0.44 | similar to peroxidase 16 precursor (EC 1.11.1.7) |
| Os04t0688300-01 | 1.02 ** | 3.24 ** | 1.77 ** | Haem peroxidase, plant/fungal/bacterial family protein. |
| Os01t0326300-01 | −0.07 | 1.92** | 0.24 | Haem peroxidase, plant/fungal/bacterial family protein. |
| Os06t0521500-01 | 1.26 ** | 3.09 ** | 0.82 | Haem peroxidase family protein. |
| Os06t0306300-01 | 0.42 | 1.94 ** | 0 | Haem peroxidase domain containing protein. |
| Os02t0684400-01 | 0.24 | 1.33 ** | 0 | similar to OXS3 (OXIDATIVE STRESS 3) |
| Dehydrogenase/reductase | ||||
| Os04t0531900-01 | 0.62 | 1.05 ** | −0.07 | short-chain dehydrogenase/reductase SDR domain-containing protein |
| Os11t0484500-01 | 0.31 | −0.76 | −1.23 * | similar to 6-phosphogluconate dehydrogenase |
| 50 years + | Female | Male | Total | |||
| N | % | n | % | N | % | |
| Circulatory system diseases | 29 | 27.6 | 19 | 18.6 | 48 | 23.2 |
| Tuberculosis | 7 | 6.7 | 10 | 9.8 | 17 | 8.2 |
| Malaria | 8 | 7.6 | 8 | 7.8 | 16 | 7.7 |
| Intestinal infectious diseases (diarrhea) | 3 | 2.9 | 6 | 5.9 | 9 | 4.3 |
| Malignant neoplasms | 5 | 4.8 | 3 | 2.9 | 8 | 3.9 |
| Traffic accidents | 2 | 1.9 | 5 | 4.9 | 7 | 3.4 |
| Acute respiratory infections (pneumonia) | 4 | 3.8 | 3 | 2.9 | 7 | 3.4 |
| HIV | 4 | 3.8 | 1 | 1.0 | 5 | 2.4 |
| Diabetes Mellitus | 1 | 1.0 | 4 | 3.9 | 5 | 2.4 |
| Digestive system | 1 | 1.0 | 3 | 2.9 | 4 | 1.9 |
| Intentional self-harm | 2 | 1.9 | 1 | 1.0 | 3 | 1.4 |
| Accidental drowning and sub. | 0 | 0.0 | 2 | 2.0 | 2 | 1.0 |
| Rabies | 1 | 1.0 | 0 | 0.0 | 1 | 0.5 |
| Mental and behavioural disorders | 0 | 0.0 | 1 | 1.0 | 1 | 0.5 |
| Infections of the skin and subcutaneous tissue | 0 | 0.0 | 1 | 1.0 | 1 | 0.5 |
| Injury of unspecified body region | 1 | 1.0 | 0 | 0.0 | 1 | 0.5 |
| Exposure to unspecified electric current | 1 | 1.0 | 0 | 0.0 | 1 | 0.5 |
| Sepsis | 0 | 0.0 | 1 | 1.0 | 1 | 0.5 |
| Asthma | 0 | 0.0 | 1 | 1.0 | 1 | 0.5 |
| Unknow (R95-R99) | 1 | 1.0 | 6 | 5.9 | 7 | 3.4 |
| Indeterminate | 35 | 33.3 | 27 | 26.5 | 62 | 30.0 |
| Total | 105 | 102 | 207 |
| Device | Structure | Thickness (nm) | a (nm) | n | λ (nm) | s (μm) | η |
| A1 | YIG/Ti/Co | 20/1/25 | 200 | 2, 4 | 100 | 30 | 95% |
| A2 | YIG/Ti/Co | 20/1/25 | 180 | 2, 4, 6 | 60 | 30 | 106% |
| A3 | YIG/Ti/Co | 20/1/50 | 180 | 4 | 90 | 60 | 61% |
| A4 | YIG/Al2O3/Co | 20/7/30 | 600 | 14, 16 | 75 | 30 | 11%a |
| B1 | YIG/Ti/Ni | 20/2/20 | 600 | 4, 6, 8, 10 | 120 | 30 | 21% |
| C1 | YIG/Ti/CoFe | 20/1/50 | 200 | 2, 4, 6, 8 | 50 | 15 | 98% |
| C2 | YIG/Al2O3/CoFe | 20/25/50 | 200 | 2, 4 | 100 | 15 | 41% |
| Sample | Superoxide Anion Generation (Inh %) | Elastase Release (Inh %) | ||
| A-EtOH | 90.1 ± 5.3 | ** | 85.3 ± 0.8 | ** |
| A-BuOH | 93.9 ± 8.3 | ** | 77.6 ± 2.4 | ** |
| A-Water | 11.4 ± 1.6 | * | 2.7 ± 4.1 | – |
| A-EtOAc | 94.8 ± 5.6 | ** | 85.4 ± 1.8 | ** |
| A-Hexane | 103.4 ± 1.8 | ** | 80.2 ± 4.0 | ** |
| A-MeOH | 96.5 ± 8.0 | ** | 90.4 ± 6.0 | ** |
| AM1 | 54.5 ± 5.7 | ** | 99.2 ± 2.3 | ** |
| AM2 | 68.7 ± 5.0 | ** | 47.5 ± 5.3 | ** |
| AM3 | 105.9 ± 3.4 | ** | 86.8 ± 2.0 | ** |
| AM4 | 100.7 ± 8.1 | ** | 70.9 ± 1.0 | ** |
| AM5 | 102.6 ± 1.5 | ** | 93.5 ± 3.7 | ** |
| AM6 | 102.4 ± 2.0 | ** | 99.3 ± 2.3 | ** |
| E50 | E60 | E70 | |
| Total clean reads | 57,050,205 | 60,029,490 | 61,295,544 |
| Total clean nucleotides | 11,410,041,000 | 12,005,898,000 | 12,259,308,800 |
| Total trinity transcripts | 61,057 | 342,255 | 192,448 |
| Total trinity components | 49,282 | 279,928 | 158,626 |
| Contig N50 | 1379 | 1159 | 825 |
| Median contig length | 536 | 352 | 279 |
| Average contig | 909 | 695 | 536 |
| Total assembled bases | 55,473,630 | 237,734,046 | 103,165,360 |
| Percent GC (%) | 48 | 51 | 47 |
| Q20 percentage (%) | 98 | 98.4 | 98.6 |
| OD values | Biofilm formation |
| ≤ODc | Non |
| 2 × ODc ≤ OD > ODc | Weak |
| 4 × ODc ≤ OD > 2 × ODc | Moderate |
| >4 × ODc | High |
| Scale | Subscale | M | SD | Extreme negative responders (%)a |
| Marcus | Prognosis for recovery (recovery) | 3.01 | 1.37 | — |
| Alcoholism and character defect (character defect) | 2.59 | 1.22 | — | |
| Social status of the alcoholic (social status) | 2.91 | 1.02 | — | |
| Alcoholism as an illness (illness) | 3.13 | 1.67 | 4.2 | |
| Seaman-Mannello | Personal/professional satisfaction (satisfaction) | 3.17 | 1.27 | 12.5 |
| Inclination to identify (“helpable”) | 4.17 | .982 | — | |
| Personal attitudes toward drinking (personal drinking) | 4.56 | 1.15 | — | |
| SAAPPQ | Work satisfaction (satisfaction) | 3.66 | 1.11 | 8.2 |
| Role adequacy | 4.04 | 1.33 | 4.1 | |
| Role legitimacy | 4.87 | 1.14 | 2.0 | |
| Task specific self-esteem (self-esteem) | 4.96 | 1.22 | 16.7 | |
| I want to work with drinkers (desire) | 3.40 | 1.23 | 14.3 | |
| Pessimism is the most attitude to take toward drinkers (pessimism) | 2.85 | 1.40 | 2.0 |
| Patients | ||||
| 1 | 2 | 3 | 4 | |
| Management | ||||
| Operation | No | Resection and IVC PTFE Patch | Resection and primary repair | Resection and IVC Vein Patch |
| Chemotherapy | Yes | No | No | No |
| Adjuvant therapy | None | Radiotherapy | None | Radiotherapy |
| Histological grade | High | High | High | High |
| Complications | ||||
| Limb oedema | NA | No | No | No |
| Venous insufficiency | NA | No | No | No |
| Other | None | No | CVA | No |
| Follow-up | ||||
| Recurrence | - | No | Yes (5 months) | No |
| Status | Dead | Dead | Dead | Alive |
| Survival | 36 months | 30 months | 7 months | 16 months |
| Baseline/outcome measure | Questionnaire | Survey administration times | |||
| Baseline | Time 1 | Time 2 | |||
| (after referral for abnormal screen) | (within 3 months ofnegativediagnosis) | (within 3 months ofpositivediagnosis) | (3 months after treatment initiation) | ||
| Health literacy | Rapid Estimate of Adult Literacy in Medicine[25] | X | |||
| Comorbid conditions that may alter risk of mortality | Charlson Comorbidity Index[24] | X | |||
| Anxiety and stress | Perceived Stress Scale[26] | X | |||
| Perceived functional support | Medical Outcomes Study-Social Support Survey[27] | X | |||
| Predisposition for fatalistic attitudes directed at health | Wallston Multi-Dimensional Locus of Control[28] | X | X | ||
| Distrust towards health care system | Health Care System Distrust[29] | X | X | X | |
| Patient engagement in own health care | *Communication and Attitudinal Self-Efficacy - General[30] | X | |||
| Patient engagement in own cancer care | *Communication and Attitudinal Self-Efficacy - Cancer[30] | X | |||
| Subjective distress related to a specific event | *Impact of Events[31] | X | X | X | |
| Satisfaction with cancer-related care | *Patient Satisfaction with Care[32] | X | X | X | |
| Satisfaction with patient navigation services | Patient Satisfaction with Navigator[33] | X | X | X |
| Clusters | ||||
| The comprehensive | The theoretician | The minimalist | The structural | |
| South American sample areas | 14,1 | 7 | 31 | 47.9 |
| European sample areas | 24 | 49.5 | 25 | 1,5 |
| Total | 21.4 | 38.4 | 26.6 | 13.7 |
| Resection margin | Recurrence rate No. patients (%) | Surgery and radiotherapy No. (%) | Surgery alone No. (%) |
| R0 | 5/16 (31) | 2/4 (50) | 3/12 (25) |
| R1 | 30/47 (64) | 27/36 (75) | 3/11 (27) |
| R2 | 11/20 (55) | 9/14 (64) | 2/6 (33) |
| R3 | 7/13 (54) | 5/7 (71) | 2/6 (33) |
| RX | 7/14 (50) | 5/7 (71) | 2/7 (29) |
| Phase | Morphology | Secondary phase | |
| 1,098 K/8 h | |||
| Undoped | Rutile | Nanorod | - |
| 0.5% Co | Rutile | Nanorod | - |
| 1% Co | Rutile | Nanorod | - |
| 3% Co | Rutile | Nanorod | - |
| 5% Co | Rutile + anatase | Nanoparticle | - |
| 10% Co | Rutile | Nanoparticle + nanorod | CoTiO3 (nanoflakes) |
| 1% Co-doped | |||
| 1,098 K/8 h | Rutile | Nanorod | - |
| 1,173 K/8 h | Rutile | Nanorod | - |
| 2 h/1,098 K | Rutile | Nanorod | - |
| 8 h/1,098 K | Rutile | Nanorod | - |
| 16 h/1,098 K | Rutile | Nanorod | - |
| 5% Co-doped | |||
| 1,098 K/8 h | Rutile + anatase | Nanoparticle | - |
| 1,173 K/8 h | Rutile | Nanoparticle | - |
| 2 h/1,098 K | Rutile + anatase | Nanoparticle | - |
| 8 h/1,098 K | Rutile + anatase | Nanoparticle | - |
| 16 h/1,098 K | Rutile | Nanoparticle | Co2P4O12 |
| Men (n = 123) | Women (n = 169) | Total (n = 292) | |
| Non-smokers, n (%) | 47 (38.2) | 74 (43.8) | 121 (41.4) |
| Ever-smokers, n (%) | 76 (61.8) | 95 (56.2) | 171 (58.6) |
| 1 positive SPT reaction, n (%) | 55 (50.0) | 63 (44.7) | 118 (47.0) |
| ≥6 positive SPT reactions, n (%) | 10 (9.1) | 5 (3.5) | 15 (6.0) |
| Allergic rhinoconjunctivitis (ARC), n (%) | 40 (32.5) | 71 (42.0) | 111 (38.0) |
| Family history of asthma, n (%) | 17 (13.8) | 36 (21.3) | 53 (18.2) |
| Physician-diagnosed asthma, n (%) | 7 (5.7) | 6 (3.6) | 13 (4.5) |
| Asthma medication ever, n (%) | 21 (17.1) | 31 (18.3) | 52 (17.8) |
| Asthma medication past 12 months, n (%) | 9 (7.3) | 13 (7.7) | 22 (7.5) |
| Question number | Question |
| 1. | Please tell me all about your rotator cuff tear/shoulder? (follow up questions to find out when and and how the tear happened and obtain narrative history from participant). |
| 2. | Please tell me about how your shoulder tear affected/affects you? (follow up questions to explore impact upon activities of daily living, work, leisure, relationships, emotional impact, and to explore symptoms). |
| 3. | Are you right or left handed? (follow up to explore dominance, unilateral or bilateral shoulder problems, “how is your other shoulder?”). |
| 4. | Please tell me anything else you’d like to tell me about your shoulder and how the tear had affected you? |
| Event | Grade 1 (0) | Grade 2 (1–2) | Grade 3 (3–6) | Grade 4 (> 6) | Na |
| Head lifting (n) | 153 (88.4%) | 5 (2.9%) | 4 (2.3%) | 6 (3.5%) | 5 (2.9%) |
| Paddling (one limb) (n) | 159 (91.9%) | 8 (4.6%) | 1 (0.6%) | 0 | 5 (2.9%) |
| Paddling (several limbs) (n) | 152 (87.9%) | 5 (2.9%) | 8 (4.6%) | 3 (1.7%) | 5 (2.9%) |
| Kicking (one limb) (n) | 161 (93.1%) | 5 (2.9%) | 1 (0.6%) | 1 (0.6%) | 5 (2.9%) |
| Kicking (several limbs) (n) | 162 (93.6%) | 4 (2.3%) | 2(1.2%) | 0 | 5 (2.9%) |
| Pull up (one limb) (n) | 136 (78.6%) | 23 (13.3%) | 9 (5.2%) | 0 | 5 (2.9%) |
| Pull up (several limbs) (n) | 154 (89.0%) | 13 (7.5%) | 1 (0.6%) | 0 | 5 (2.9%) |
| Focused eye movement (n) | 114 (65.9%) | 11 (6.4%) | 6 (3.5%) | 1 (0.6%) | 41 (23.7%) |
| Spontaneous blinking (n) | 49 (28.3%) | 32 (18.5%) | 24 (13.9%) | 27 (15.6%) | 41 (23.7%) |
| Ear movement (n) | 131 (75.7%) | 8 (4.6%) | 1 (0.6%) | 0 | 33 (19.1%) |
| Tail movement (n) | 87 (50.3%) | 34 (19.7%) | 14 (8.1%) | 10 (5.8%) | 28 (16.2%) |
| Nose Movement (n) | 132 (76.3%) | 3 (1.7%) | 0 | 0 | 38 (22.0%) |
| Mouth Movement (n) | 124 (71.7%) | 8 (4.6%) | 3 (1.7%) | 1 (0.6%) | 37 (21.4%) |
| Groaning (stimulus-associated) (n) | 96 (55.5%) | 28 (16.2%) | 24 (13.9%) | 25 (14.5%) | 0 |
| Vocalisation (n) | 108 (62.4%) | 17 (9.8%) | 21 (12.1%) | 27 (15.6%) | 0 |
| Generic name | Trade name | Number of cases of monotherapy |
| Losartan | Nu-lotan® | 214 |
| Valsartan | Diovan® | 266 |
| Telmisartan | Micardis® | 185 |
| Candesartan | Blopress® | 458 |
| Olmesartan | Olmetec® | 192 |
| Parameter | Level 1 | Level 2 | Level 3 | Level 4 | Level 5 |
| 100-OD (% sat.) | ≤10 | ≤20 | ≤30 | ≤50 | >50 |
| BOD5 (O2 mg/L) | <2.5 | ≤4 | ≤8 | ≤15 | >15 |
| COD (O2 mg/L) | <5 | ≤10 | ≤15 | ≤25 | >25 |
| NH4 (N mg/L) | <0.03 | ≤0.10 | ≤0.50 | ≤1.50 | >1.50 |
| NO3 (N mg/L) | <0.3 | ≤1.5 | ≤5.0 | ≤10.0 | >10.0 |
| Total phosphorous (P mg/L) | <0.07 | ≤0.15 | ≤0.30 | ≤0.60 | >0.60 |
| Escherichia coli (UFC/100/mL) | <100 | ≤1.000 | ≤5.000 | ≤20.000 | >20.000 |
| Score to be attributed for each analysed parameter (75° percentile of the monitoring period) | 80 | 40 | 20 | 10 | 5 |
| Pollution level expressed by the LIM | 480–560 | 240–475 | 120–235 | 60–115 | <60 |
| Re-revision diagnosis | UKA to UKA minor | UKA to UKA major | UKA to TKA | TKA to TKA | ||||
| n | % | n | % | n | % | n | % | |
| Loosening/lysis | 17 | 46 | 27 | 52 | 63 | 46 | 34 | 42 |
| Infection | 2 | 5.4 | 5 | 9.6 | 19 | 14 | 25 | 31 |
| Pain | 6 | 16.2 | 6 | 11.5 | 18 | 13 | 8 | 9.9 |
| Patello femoral pain | 1 | 2.7 | 1 | 1.9 | 9 | 6.5 | 3 | 3.7 |
| Progression of disease | 2 | 5.4 | 7 | 14 | 3 | 2.2 | ||
| Other | 9 | 24.3 | 6 | 12 | 26 | 19 | 11 | 13 |
| Total | 37 | 100 | 52 | 100 | 138 | 100 | 81 | 100 |
| Diagnosis in MRI | Specific abnormalities in MRI | N | Total number (%) |
| Abnormal MRI | 13 (52%) | ||
| Hepatic dysmorphia | Included lobulation of liver surface | 3 | 3 (12%) |
| Included first-segment hypertrophy | 0 | ||
| Portal hypertension | Included splenomegaly | 5 | 5 (20%) |
| Included portal vein dilatation | 2 | ||
| Included splenic vein dilatation | 1 | ||
| Isolated biliary abnormalities | Intrahepatic | 1 | 1 (4%) |
| Extrahepatic | 0 | ||
| Hepatic dysmorphia and portal hypertension | 0 | 0 (0%) | |
| Hepatic dysmorphia and biliary abnormalities | Included lobulation of liver surface and intrahepatic abnormalities | 1 | 1 (4%) |
| Portal hypertension and biliary abnormalities | Included portal vein hypertrophy and intrahepatic abnormalities | 1 | 1 (4%) |
| Hepatic dysmorphia, portal hypertension, and biliary abnormalities | Included splenomegaly, lobulation of liver surface, first-segment hypertrophy, and intrahepatic and extrahepatic abnormalities | 2 | 2 (8%) |
| Normal MRI | 12 (48%) | ||
| Total | 25 (100%) |
| Variable | OR [95%CI] | P value |
| Steroids before ICU stay | 0.77 [0.17-3.49] | 0.74 |
| Steroids during ICU stay | ||
| No Steroid | 5.64 [0.70-45.5] | |
| Low Dose Steroid | 1 | 0.02 |
| High Dose Steroids | 9.33 [1.97-44.3] | |
| SAPS II per point | 1.04 [1.01-1.08] | 0.01 |
| Underlying disease | ||
| Hematological disease | 1 | |
| Other | 4.06 [1.19-13.09] | 0.03 |
| Shock | 20.31 [6.45-63.9] | <0.001 |
| Male | Female | |||||
| C | NC | p-value | C | NC | p-value | |
| Dietary component | ||||||
| Energy (kJ) | 9665 | 9863 | 0.1573 | 7238 | 7408 | 0.0684 |
| Nutrients | ||||||
| Carbohydrates (%E) | 42.8 | 43.4 | 0.1154 | 42.3 | 43.8 | <0.0001 * |
| Total Sugars (%E) | 18.1 | 18.7 | 0.0789 | 19.2 | 19.9 | 0.0209 |
| Free Sugar (%E) | 9.2 | 10.7 | <0.0001 * | 9.2 | 10.3 | <0.0001 * |
| Total Fat (%E) | 30.5 | 30.3 | 0.5978 | 31.1 | 31.3 | 0.4329 |
| Saturated Fat (%E) | 11.9 | 12.0 | 0.4937 | 11.9 | 12.2 | 0.1099 |
| MUFA (%E) | 11.8 | 11.6 | 0.2112 | 11.9 | 11.9 | 0.8910 |
| PUFA (%E) | 4.7 | 4.6 | 0.1968 | 5.0 | 5.0 | 0.5831 |
| Protein (%E) | 19.5 | 17.9 | <0.0001 * | 19.9 | 18.1 | <0.0001 * |
| Sodium (mg) | 2838 | 2677 | 0.0005 * | 2112 | 2062 | 0.0979 |
| Fibre (%E) | 2.2 | 2.1 | 0.2967 | 2.3 | 2.4 | 0.0613 |
| Food Groups | ||||||
| Discretionary Foods (%E) | 33.7 | 34.4 | 0.307 | 30.4 | 30.6 | 0.8011 |
| Grains and Cereals (serves) | 5.0 | 5.2 | 0.0912 | 3.7 | 3.9 | 0.0011 |
| Meat and Alternatives (serves) | 2.2 | 2.1 | 0.3305 | 1.7 | 1.6 | 0.0139 |
| Dairy and alternatives (serves) | 1.7 | 1.4 | <0.0001 * | 1.5 | 1.3 | <0.0001 * |
| Fruit (serves) | 1.7 | 1.5 | 0.0496 | 1.4 | 1.5 | 0.0474 |
| Vegetables (serves) | 2.9 | 3.2 | 0.0013 | 2.8 | 3.0 | 0.0034 |
| Variablea | HR (95% CI) | P |
| Bowel obstruction/perforation (positive vs negative) | 4.118 (2.270-7.471) | <.001 |
| Lymphovascular invasion (positive vs negative) | 1.766 (1.156-2.697) | .009 |
| Five-gene molecular signature (high-risk vs low-risk for 36-mo recurrence) | 1.644 (1.035-2.610) | .035 |
| Subject | R (mean ± std. deviation) |
| 1 | 0.8084 ± 0.0140 |
| 2 | 0.7605 ± 0.1104 |
| 3 | 0.7915 ± 0.0147 |
| 4 | 0.8045 ± 0.0173 |
| 5 | 0.7970 ± 0.0204 |
| % Coronary Vasoreactive Change with IHE vs. Coronary Wall Measure: | % area change | % velocity change | % flow change |
| Healthy: Mean Coronary Wall Thickness | R = -0.17 | R = 0.02 | R = -0.02 |
| P = 0.46 | P = 0.93 | P = 0.92 | |
| Healthy: Eccentricity Index | R = 0.18 | R = 0.08 | R = 0.14 |
| P = 0.46 | P = 0.74 | P = 0.56 | |
| CAD: Mean Coronary Wall Thickness | R = -0.54 | R = -0.11 | R = -0.34 |
| P = 0.001 | P = 0.51 | P = 0.05 | |
| CAD: Eccentricity Index | R = -0.60 | R = -0.06 | R = -0.27 |
| P = 0.0002 | P = 0.75 | P = 0.13 |
| Survey Data | Model 1–30 min/day | Model 2–60 min/day | Model 3 – KKD | |||||
| Active vs Inactive | Moderately Active vs Inactive | |||||||
| Fixed effect (95% CI) | P value | Fixed effect (95% CI) | P value | Fixed effect (95% CI) | P value | Fixed effect (95% CI) | P value | |
| Study Condition | ||||||||
| Comparison (PEI) | Referent | <.0001 | Referent | <.0001 | Referent | 0.23 | Referent | 0.32 |
| Intervention (Manitoba) | 2.24 (1.88, 2.66) | 1.32 (1.16, 1.50) | 1.16 (0.91,1.48) | 1.13 (0.89, 1.45) | ||||
| Time | ||||||||
| Baseline | Referent | Referent | Referent | Referent | ||||
| Follow-up | 0.79 (0.65, 0.95) | 0.01 | 0.95 (0.82, 1.10) | 0.49 | 1.13 (0.84, 1.51) | 0.41 | 1.15 (0.86, 1.52) | 0.35 |
| Condition*Time Interaction | 1.13 (0.92, 1.39) | 0.24 | 0.92 (0.78, 1.07) | 0.26 | 0.63 (0.47, 0.85) | 0.0021 | 0.82 (0.61, 1.11) | 0.20 |
| Grade | ||||||||
| 9 | Referent | Referent | Referent | Referent | ||||
| 10 | 0.91 (0.82, 1.00) | 0.05 | 0.91 (0.86, 0.97) | 0.0016 | 0.84 (0.75, 0.93) | 0.0008 | 0.92 (0.82, 1.02) | 0.12 |
| 11 | 0.75 (0.68, 0.82) | <.0001 | 0.73 (0.69, 0.77) | <.0001 | 0.58 (0.52, 0.64) | <.0001 | 0.81 (0.73, 0.90) | <.0001 |
| 12 | 0.66 (0.60, 0.73) | <.0001 | 0.68 (0.64, 0.72) | <.0001 | 0.52 (0.47, 0.57) | <.0001 | 0.80 (0.72, 0.89) | <.0001 |
| Sex | ||||||||
| Female | Referent | <.0001 | Referent | < .0001 | Referent | < .0001 | Referent | <.0001 |
| Male | 1.87 (1.74, 2.00) | 1.88 (1.80, 1.95) | 2.26 (2.10, 2.43) | 1.29 (1.20, 1.39) | ||||
| BMI status | ||||||||
| Healthy weight | Referent | 0.0007 | Referent | 0.0006 | Referent | < .0001 | Referent | 0.20 |
| Overweight or obese | 0.88 (0.81, 0.95) | 0.92 (0.88, 0.97) | 0.85 (0.78, 0.92) | 0.95 (0.87, 1.03) |
| GOLD II | GOLD III | GOLD IV | Total | |
| (n = 12) | (n = 21) | (n = 10) | (n = 43) | |
| Short acting bronchodilator | 75.0% | 80.9% | 80.0% | 79.1% |
| Combined LABA with steroid | 58.3% | 61.9% | 70.0% | 62.8% |
| Antibiotics | 58.3% | 61.9% | 60.0% | 60.5% |
| Expectorants | 50% | 52.4% | 70.0% | 55.8% |
| Combined ≥2 bronchodilators | 50.% | 76.2% | 70.0% | 67.4% |
| Long acting bronchodilator | 16.7% | 9.5% | 20.0% | 14.0% |
| Anti-tussive | 8.3% | 47.6% | 10.0% | 27.9% |
| Chinese traditional medicine | 8.3% | 19.1% | 20.0% | 16.3% |
| Oral corticosteroids | 0.0% | 14.3% | 0.0% | 7.0% |
| ICS | 0.0% | 0% | 10.0% | 2.3% |
| Adipokine | Study time point | Media alone | Stimulated | P values | |
| Adipsin | Pre-int | Mean (SEM) | 3.83 (2.12) | 4.74 (3.89) | 0.743 (ns) |
| Range | 0–23.14 | 0–57.72 | |||
| Post-int | Mean (SEM) | 103.40 (48.23) | 92.73 (48.59) | 0.132 (ns) | |
| Range | 0–661.30 | 0–651.00 | |||
| MCP-1 | Pre-int | Mean (SEM) | 16.19 (5.12) | 33.22 (13.63) | 0.093 (ns) |
| Range | 0–57.54 | 0–199.90 | |||
| Post-int | Mean (SEM) | 199.80 (183.30) | 179.20 (166.00) | 0.264 (ns) | |
| Range | 0–2,398 | 0–2,170 | |||
| IL-1β | Pre-int | Mean (SEM) | 0.59 (0.54) | 16.37 (5.25) | 0.009 |
| Range | 0–8.17 | 0–52.37 | |||
| Post-int | Mean (SEM) | 41.26 (30.94) | 16.57 (11.54) | 0.447 (ns) | |
| Range | 0–401.60 | 0–152.20 | |||
| IP-10 | Pre-int | Mean (SEM) | 0.73 (0.33) | 1.30 (0.61) | 0.225 (ns) |
| Range | 0–4.28 | 0–7.67 | |||
| Post-int | Mean (SEM) | 30.97 (28.74) | 9.89 (7.62) | 0.338 (ns) | |
| Range | 0–375.70 | 0–101.00 | |||
| CXCL8 | Pre-int | Mean (SEM) | 175.80 (104.20) | 523.40 (191.30) | 0.018 |
| Range | 0–1,610 | 7.07–2,422 | |||
| Post-int | Mean (SEM) | 810.60 (395.90) | 961.10 (480.10) | 0.226 (ns) | |
| Range | 0–4,738 | 17.27–6,130 | |||
| IL-6 | Pre-int | Mean (SEM) | 3.69 (3.56) | 23.89 (12.82) | 0.056 (ns) |
| Range | 0–53.43 | 0–187.40 | |||
| Post-int | Mean (SEM) | 218.60 (208.80) | 15.71 (6.24) | 0.342 (ns) | |
| Range | 0–2,723 | 0–64.81 | |||
| Resistin | Pre-int | Mean (SEM) | 89.80 (53.89) | 101.70 (60.39) | 0.204 (ns) |
| Range | 0–747.20 | 0–790.70 | |||
| Post-int | Mean (SEM) | 304.60 (110.40) | 251.10 (101.80) | 0.049 | |
| Range | 14.03–1,320 | 12.98–1,262 | |||
| TNF-α | Pre-int | Mean (SEM) | 1.28 (1.02) | 71.44 (26.68) | 0.021 |
| Range | 0–15.42 | 0–350.90 | |||
| Post-int | Mean (SEM) | 394.20 (393.10) | 18.35 (6.57) | 0.360 (ns) | |
| Range | 0–5,111 | 0–64.89 |
| Grade | Normal group | Osteoarthritis group | |||||||||
| 12 F | 39 F | 43 M | 42 M | 49 F | 54 F | 55 M | 58 F | 65 F | 66 F | 70 F | |
| Transverse section | 0 | 0 | 0 | 2 | 2 | 3 | 3 | 1 | 3 | 4 | 4 |
| Longitudinal section | 0 | 0 | 0 | 3 | 1 | 3 | 3 | 1 | 4 | 4 | 4 |
| Averagea | 0 | 0 | 0 | 2.5 | 1.5 | 3 | 3 | 1 | 3.5 | 4 | 4 |
| Variable | Comparison used in rate ratio | Rate ratio (other death/HIV/TB death) | 95% Confidence interval (p value) |
| Sex | Male/female | 1.12 | 0.99–1.27 (0.077) |
| Country of origin | South Africa/Mozambique | 0.85 | 0.75–0.98 (0.023) |
| Residence status | Temporary/permanent | 1.05 | 0.91–1.21 (0.493) |
| Distance from Bhubezi(km) | Greater than 5 km/5 km or less | 1.02 | 0.86–1.20 (0.842) |
| SEP quintiles | Quintiles 2–5/quintile 1 | 0.95 | 0.81–1.11 (0.503) |
| Mean level of household education | Greater than 7 years/7 years or less | 0.93 | 0.82–1.06 (0.294) |
| ABRA system delayed closure system | |
| Pros | Cons |
| ABRA abdominal wall closure can restore lost abdominal domain and achieve complete repair of the musculofascial support of the abdominal wall, achieving primary closure. The sutures can be tightened at sequential dressings, preventing fascial retraction | ABRA abdominal wall closure requires two to three interventions in operation room under general anesthesia |
| No skin grafts required when using ABRA | ABRA system need a normal skin of 5–6 cm around the abdominal wound (in order to place the elastomers) |
| Reduction in the numbers of days to any closure | The possibility to need to be used in conjunction with another dressing system |
| The changes of VAC system and time in nurse and surgery cares are more expensive than ABRA system | There is no active removal of the fluids. So if the peritonitis is still active a dressing system with 24–48 h re-interventions could be the best option |
| Origin | Prenatal | Delivery room |
| Greek | 34/2467 (1.4%) | 3/174 (1.7%) |
| Albanian | 20/227 (8.8%) | 6/61 (9.8%) |
| Others* | 11/135 (8.1%) | 2/27 (7.4%) |
| Total | 65/2829 (2.3%)** | 11/262 (4.2%)** |
| Study characteristics | Nepal trial* | Bangladesh trial | Pakistan trial |
| Type of study | Cluster RCT | Cluster RCT | 2 × 2 factorial design cluster RCT |
| No. clusters (average size) | 413 (700) | 133 (4100) | 187 (1000) |
| Sample size total | 15,123 | 29,760 | 9,741 |
| Average sample size per group | ~ 5,050 | ~ 9,900 | ~ 4,850 |
| Duration of trial | Nov 2002 to Mar 2005 | Jun 2007 to Sep 2009 | Jan 2008 to Jun 2009 |
| Overall NMR | 32/1000 | 36/1000 | 30/1000 |
| % of home births | 92 % | 93 % | 80 % |
| Inclusion criteria | All live births in the study area | All live births in the study area | All live births in the study area were included except those who were born in hospitals. |
| Exclusion criteria | Not met within 10 days after birth | Didn’t receive intervention within 7 days after birth | Not met within 3 days after birth. Babies with congenital anomalies |
| Comparison group | Dry cord care | Dry cord care | Dry cord care |
| Intervention groups | 1.Multiple CHX2.Soap/H2O | 1.Multiple CHX2.Single CHX | 1.Multiple CHX2.Handwashing (HW)3.CHX + HW |
| CHX concentration | 4.0 % | 4.0 % | 4.0 % |
| Participants recruiters | Local female worker | CHWs | CHWs |
| Intervention providers | Local project staff | Village health worker | TBA to caretaker |
| Outcome assessors | (Nonmedical) field workers | CHWs | CHWs |
| Basic interventions to all babies/mothers | CDK, FE/FA, TT, promotion of ANC/ENC | CDK. FE/FA, promotion of TT, ANC, birth preparedness, ENC | Basic component of ENC as promoted by Ministry of Health |
| Primary outcomes | Omphalitis, neonatal mortality | Omphalitis, neonatal mortality | Omphalitis, neonatal mortality |
| Follow up days | 1, 2, 3, 4, 6, 8, 10, 12, 14, 21, 28 | 1,3,6,9,15,28 | 1,3,5,7,14,28 |
| WHO guidelinea | Swiss TPH guidelinea | |||
| Trichuris trichiura | Ascaris lumbricoides | Trichuris trichiura | Ascaris lumbricoides | |
| Total number of Kato-Katz thick smears (positive/negative) | 1,445 (1,189/256) | 1,445 (297/1,148) | 1,445 (1,189/256) | 1,445 (297/1,148) |
| 1. No. of Kato-Katz thick smears with difference in FECs (%) | 345 (23.9%) | 148 (10.2%) | 97 (6.7%) | 108 (7.5%) |
| 2. No. of Kato-Katz thick smears with differences in presence/absence of helminth eggs (%) | 51 (3.5%) | 32 (2.2%) | 51 (3.5%) | 32 (2.2%) |
| 3. No. of Kato-Katz thick smears with difference in FECs (%) among samples with egg counts | 345 (29.0%) | 148 (49.8%) | 97 (8.2%) | 108 (36.4%) |
| 4. No. of Kato-Katz thick smears with differences in presence/absence of helminth eggs (%) among samples with egg counts | 51 (4.3%) | 32 (10.8%) | 51 (4.3%) | 32 (10.8%) |
| 1. and/or 2. (%) | 381 (26.4%) | 164 (11.4%) | 145 (10.0%) | 130 (9.0%) |
| No. of Kato-Katz thick smears with discrepancies according to respective guidelineb (%) | 345 (23.9%) | 164 (11.4%) | 145 (10.0%) | 130 (9.0%) |
| 3. and/or 4. and proportion as percentage (%) among Kato-Katz thick smears with positive egg counts | 381 (32.0%) | 164 (55.2%) | 145 (12.2%) | 130 (43.8%) |
| No. of Kato-Katz thick smears with discrepancies according to respective guidelineb (%) among Kato-Katz thick smears with positive egg counts | 345 (29.0%) | 148 (49.8%) | 145 (12.2%) | 130 (43.8%) |
| Biologics | Pooled incremental efficacy | 6-month incremental cost-effectiveness ratio | ||||
| Base case | Best case | Worst case | Base case | Best case | Worst case | |
| Etanercept | 58% | 71% | 45% | $30,954 | $25,287 | $39,897 |
| Adalimumab | 56% | 59% | 52% | $23,980 | $22,760 | $25,824 |
| Infliximab | 69% | 76% | 63% | $28,587 | $25,954 | $31,310 |
| Ustekinumab 45 mg | 58% | 64% | 51% | $28,943 | $26,229 | $32,915 |
| Ustekinumab 90 mg | 62% | 66% | 58% | $54,151 | $50,869 | $57,886 |
| Architecture | DeepLab without CRF (Chen et al., 2014) | FCN (Long et al., 2015) | U-Net (Ronneberger et al., 2015) | DeconvNet (Noh et al., 2015) | |
| Side length of receptive field | 44 | 52 | 46 | 44 | |
| Dice | train | 0.60 | 0.66 | 0.71 | 0.71 |
| val | 0.55 | 0.60 | 0.64 | 0.62 | |
| test | 0.48 | 0.50 | 0.52 | 0.55 | |
| m#FP | train | 10.35 | 11.73 | 7.86 | 8.32 |
| val | 11.51 | 13.30 | 8.95 | 10.08 | |
| test | 12.81 | 16.44 | 12.85 | 11.78 | |
| m#FN | train | 4.80 | 2.96 | 2.35 | 2.19 |
| val | 4.91 | 4.00 | 3.92 | 4.03 | |
| test | 5.22 | 3.88 | 3.99 | 3.99 | |
| mSFP | train | 7.23 | 8.40 | 9.56 | 8.60 |
| val | 7.29 | 8.66 | 9.10 | 8.69 | |
| test | 8.25 | 9.92 | 11.50 | 10.14 | |
| mSFN | train | 3.34 | 2.03 | 2.17 | 1.80 |
| val | 6.53 | 5.84 | 6.20 | 5.11 | |
| test | 4.08 | 3.66 | 4.17 | 3.58 | |
| DR | train | 0.97 | 0.99 | 0.99 | 0.99 |
| val | 0.98 | 0.99 | 0.99 | 0.97 | |
| test | 0.93 | 0.94 | 0.94 | 0.94 |
| All suicide | Firearm suicide | Nonfirearm suicide | |||||||
| IRR* | 95% CI | P-value | IRR* | 95% CI | P-value | IRR* | 95% CI | P-value | |
| Crude analyses | |||||||||
| NonTCA^:TCA ratio | 0.85 | (0.76, 0.95) | 0.0040 | 0.69 | (0.57, 0.84) | 0.0002 | 1.07 | (0.96, 1.18) | 0.2270 |
| Multivariate analyses | |||||||||
| Household firearm ownership | 1.29 | (1.18, 1.40) | <.0001 | 1.67 | (1.49, 1.88) | <.0001 | 1.04 | (0.94, 1.16) | 0.4441 |
| NonTCA^:TCA ratio | 1.02 | (0.91, 1.14) | 0.7462 | 1.05 | (0.90, 1.22) | 0.5392 | 1.02 | (0.89, 1.17) | 0.8198 |
| % Population living in urban area | 1.09 | (1.01, 1.19) | 0.0293 | 1.14 | (1.02, 1.27) | 0.0211 | 1.08 | (0.98, 1.20) | 0.1407 |
| Median income | 0.99 | (0.95, 1.02) | 0.4770 | 0.97 | (0.93, 1.02) | 0.2758 | 1.01 | (0.96, 1.07) | 0.6421 |
| Unemployment rate | 1.01 | (0.98, 1.03) | 0.6227 | 0.99 | (0.96, 1.03) | 0.6932 | 1.01 | (0.98, 1.05) | 0.5231 |
| Low-income countries | Middle-income countries | High-income countries | |
| Number of global countries where data is < 5% gross monthly income | 5 | 78 | 46 |
| % of subscriptions with broadband speeds 10 mbps or higher | 7 | 50 | 75 |
| Variable | RBHS group (n = 36) | Control group (n = 38) | Pvalue |
| Composite outcome (any morbid event) | 1 (2.8) | 5 (13.1) | 0.20 |
| Morbid eventsa | |||
| Infection | 0 (0%) | 1 (2.8%) | 0.20 |
| Thrombotic | 1 (2.8%) | 2 (5.3%) | 0.87 |
| Renal | 1 (2.8%) | 2 (5.3%) | 0.87 |
| Respiratory | 0 (0%) | 0 (0%) | NS |
| Stroke | 0 (0%) | 0 (0%) | NS |
| Myocardial infarction | 0 (0%) | 0 (0%) | NS |
| Country | Acronym of the Study | Year of Recruitment | Age Class | n | GM | 50p | 95p | Reference |
| Italy | SEpiAs | 2010 | 20–44 | 271 | 8.76 | 7.78 | 86.28 | [49] |
| Germany | GerES-III | 1998 | 18–6925–69 | 47414052 | 3.923.87 | 4.14.0 | 18.919.3 | [90,91] |
| France | ENNS | 2006–2007 | 18–3918–74 | 4441500 | 4.073.75 | 4.494.03 | 10.7210.68 | [92] |
| France | ENNS | 2006–2007 | 18–74 | 3015 | 3.75 | nr | nr | [83] |
| USA | NHANES | 2009–20102011–2012 | >20 years | 20201724 | 6.75.6 | 5.955.15 | 23.217.6 | [57] |
| Data Set | Original | Global Median | Quantile | Cyclic Loess | IS.Median | Invariant Set |
| PSD | 4.18% (1.96%) | 2.15% (1.41%) | 1.97% (1.12%) | 2.12% (1.39%) | 3.09% (1.51%) | 1.99% (1.29%) |
| CSP | 4.04% (2.82%) | 3.47% (2.75%) | 2.85% (2.03%) | 3.26% (2.16%) | NA | 3.29% (2.43%) |
| S. Pyogene | 3.05% (2.78%) | 3.47% (2.84%) | 2.34% (2.02%) | 2.85% (3.15%) | 3.12% (3.32%) | 2.69% (2.74%) |
| Clinical indicators | OR (95 % CI) | p-value | Multivariable OR (95 % CI) | p-value |
| LDL-C goal attainment | ||||
| LDL-C ≥ 100 mg/dL | 1.00 | 1.00 | ||
| LDL-C 70–99 mg/dL | 0.75 (0.36–1.58) | 0.448 | 0.67 (0.35–1.30) | 0.240 |
| LDL-C < 70 mg/dL | 0.55 (0.33–0.91) | 0.019 | 0.43 (0.27–0.69) | <0.001 |
| Revascularization | 0.32 (0.17–0.63) | 0.001 | 0.44 (0.24–0.81) | 0.009 |
| eGFR < 60 mL/min/1.73 m2 | 3.24 (2.74–3.82) | <0.001 | 2.46 (2.21–2.75) | <0.001 |
| Male gender | 1.25 (0.79–1.96) | 0.337 | 1.85 (1.29–2.66) | 0.001 |
| Age (year) | 1.03 (1.01–1.04) | <0.001 | 1.00 (0.99–1.03) | 0.258 |
| Hypertension | 2.39 (1.20–4.73) | 0.013 | 1.66 (0.70–3.95) | 0.249 |
| ACEI/ARB | 0.53 (0.35–0.81) | 0.003 | 0.72 (0.49–1.06) | 0.101 |
| Diabetes mellitus | 2.09 (0.67–6.50) | 0.202 | 1.56 (0.52–4.73) | 0.428 |
| Follow-up time (day)a | 1.00 (1.00–1.00) | 0.908 | 1.00 (1.00–1.00) | 0.890 |
| Function | Gene | Accession no.∗ | Chromosome | |
| T. aestivum | Ae. umbellulata | |||
| Protein biosynthesis | ||||
| HMW glutenins | Glu-1Ax1 | X61009 | 1A | 1U |
| Glu-1Ax2 | M22208.2 | 1A | 1U | |
| Glu-B1-1b | X13927.3 | 1B | 1U | |
| Glu-1D-1d | X12928.5 | 1D | 1U | |
| Glu-D1-2b | X12929.2 | 1D | 1U | |
| X03041.1 | 1D | 1U | ||
| Glu-1Ux | AF476961.1 | – | 1U | |
| Glu-1Uy | AF476962.1 | – | 1U | |
| LMW glutenins | AB062868.1 | 1D | 1U | |
| AB062872.1 | 1D | 1U | ||
| JX163862.1 | 1B | 1U | ||
| HM055909.1 | 1DS | 1U | ||
| Y17845.1 | 1BS | 1U | ||
| U86026.1 | 1DS | 1U | ||
| X13306.1 | 1DS | 1U | ||
| AB062875.1 | 1DS | 1U | ||
| U86028.1 | 1DS | 1U | ||
| X07747.1 | 1AS | 1U | ||
| AB062873.1 | 1DS | 1U | ||
| γ-Gliadins | Group/pattern/subgroup | |||
| C10/C10-P1/SG-1 | AJ937838.1 | 1DS | 1U | |
| C9/C9-P2/SG-2 | AF234646.1 | 1DS | 1U | |
| C9/C9-P3/SG-3 | FJ006638.1 | 1DS | 1U | |
| C9/C9-P4/SG-4 | FJ006605.1 | 1DS | 1U | |
| C9/C9-P4/SG-6 | AF234647.1 | 1BS | 1U | |
| C9/C9-P4/SG-7 | FJ006596.1 | 1DS | 1U | |
| C8/C8-P5/SG-8 | AF175312.1 | 1DS | 1U | |
| C8/C8-P5/SG-9 | AF120267.1 | 1DS | 1U | |
| C8/C8-P5/SG-12 | AF234649.1 | 1DS | 1U | |
| C8/C8-P5/SG-13 | AF234643.1 | 1AS | 1U | |
| C7/C7-P6/SG-14 | AJ416336.1 | 1DS | 1U | |
| C7/C7-P7/SG-15 | M16064.1 | 1DS | 1U | |
| α-Gliadins | AJ133612.1 | 6AS | 1U | |
| DQ166377.1 | 6AS | 1U | ||
| K03074.1 | 2BS | 1U | ||
| M11075.1 | 6AS | 1U, 2U | ||
| U08287.1 | 6AS | 1U, 3U | ||
| X01130.1 | 6AS | 1U, 3U | ||
| U50984.1 | 6AS | 1U, 3U | ||
| X02539.1 | 6AS | 1U, 3U |
| RDP (n = 7) | LDP (n = 21) | P value | |
| Mean operative time (min) | 368 | 210 | 0.0002 |
| Mean blood loss (mL) | 200 | 250 | 0.451 |
| Transfusion (no. of patients) (%) | 0 | 0 | |
| Conversion (no. of patients) (%) | 0 | 0 | |
| Reverse operation (no. of patients) (%) | 0 | 1 (4.7)a | |
| Mean postoperative stay (days) | 8.7 | 10.6 | 0.004 |
| Complications (no. of patients) (%) | 2 (28.6) | 7 (33.3) | 0.815 |
| Grade, Clavien classification | II (1), III (1) | I (5), II (1), III (1) | |
| Hospital costs ($) | 10,125 | 6921 | 0.0002 |
| Group | Drug | Frequency | Percent (n/N) b |
| β-lactam | 26 | 28.9 (26/90) | |
| Penicillin | PenicillinG | 11 | 29.0 (11/27) |
| Ampicillin | 12 | 32.4 (12/26) | |
| Cephalosporin | Cephalothin | 1 | 2.7 (1/37) |
| Ceftiofur | 1 | 2.7 (1/37) | |
| Combination | Amoxicillin/Clavulanic acid | 1 | 2.7 (1/37) |
| Tetracycline | Doxycycline | 1 | 2.7 (1/37) |
| Fluoroquinolone | 6 | 8.6 (6/70) | |
| Enrofloxacin | 3 | 7.9 (3/35) | |
| Orbifloxacin | 3 | 7.9 (3/35) | |
| Aminoglycoside | 4 | 3.6 (4/110) | |
| Gentamicin | 1 | 2.7 (1/37) | |
| Amikacin | 1 | 2.7 (1/37) | |
| Kanamycin | 2 | 5.3 (2/36) | |
| Potentiated sulfonamide | Sulfamethoxazole/trimethoprim | 4 | 10.5 (4/34) |
| Amphenicols | Chloramphenicol | 2 | 5.2 (2/36) |
| Lincosamides | Clindamycin | 13 | 34.2 (13/25) |
| Aminoglycoside-lincosamide | Lincospectin | 12 | 31.6 (12/26) |
| Macrolide | Tylosin | 2 | 5.3 (2/36) |
| Group | Dose (mg/kg) | Mean Fasting Blood Sugar Level (mM) | |||
| 0 min | 30 min | 60 min | 120 min | ||
| NC | – | 4.32 ± 0.88 | 13.65 ± 1.24 | 8.94 ± 1.47 | 4.89 ± 0.95 |
| MC | – | 16.04 ± 2.15 ** | 48.65 ± 3.29 ** | 42.32 ± 4.18 ** | 32.74 ± 2.82 ** |
| 100-CPOP | 100 | 14.42 ± 2.07 # | 42.82 ± 2.81 ## | 33.54 ± 3.23 ## | 25.06 ± 2.67 ## |
| 200-CPOP | 200 | 12.36 ± 1.52 ## | 33.98 ± 3.61 ## | 24.77 ± 2.75 ## | 18.91 ± 2.03 ## |
| 400-CPOP | 400 | 10.49 ± 1.84 ## | 28.46 ± 3.05 ## | 19.35 ± 2.36 ## | 14.36 ± 1.42 ## |
| Glyburide | 25 | 8.37 ± 1.26 ## | 22.16 ± 2.19 ## | 14.82 ± 1.63 ## | 10.55 ± 1.34 ## |
| Animal ID | Sex | Mb (kg) | SL (cm) | G (cm) | [Hct] | N | fR (breaths ⋅ min-1) | ||
| Air | Water | Air | Water | ||||||
| Tt19 | M | 294 | 256 | 142 | 54 | 104 | 17 | 3.9 | 4.7 |
| Tt20 | M | 282 | 261 | 142 | 54 | 222 | 29 | 5.8 | 9.7 |
| Tt21 | F | 173 | 238 | 144 | 57 | 166 | 33 | 6.1 | 9.6 |
| Tt22 | M | 282 | 251 | 144 | 59 | 127 | 24 | 4.4 | 3.0 |
| Mean | 258 ± 57 | 252 ± 10 | 143 ± 1 | 56 ± 2 | 155 ± 52 | 26 ± 7 | 5.1 ± 1.0 | 6.7 ± 3.4 |
| Predictor | 1 year | 2 years | ||||||
| Unadjusted OR (95% CI) | p Value | Adjusted OR (95% CI) | p Value | Unadjusted OR (95% CI) | p Value | Adjusted OR (95% CI) | p Value | |
| HAQ score | 1.84 (1.12 to 3.01) | 0.02 | 1.87 (1.11 to 3.15) | 0.02 | 1.47 (0.94 to 2.29) | 0.09 | 1.42 (0.89 to 2.26) | 0.14 |
| Type | CVID (n = 34) | IgGSD (n = 398) | Value of P |
| B∗07 | 29.4 (10) | 22.9 (91) | 0.3866 |
| B∗08 | 38.2 (13) | 25.4 (101) | 0.1025 |
| B∗13 | 0 | 4.3 (17) | 0.2414 |
| B∗14 | 2.9 (1) | 9.0 (36) | 0.1874 |
| B∗15 | 11.8 (4) | 14.1 (56) | 0.4757 |
| B∗18 | 8.8 (3) | 7.3 (29) | 0.4708 |
| B∗27 | 2.9 (1) | 6.8 (27) | 0.3322 |
| B∗35 | 8.8 (3) | 14.1 (56) | 0.2888 |
| B∗37 | 2.9 (1) | 2.3 (9) | 0.5634 |
| B∗38 | 8.8 (3) | 2.8 (11) | 0.0891 |
| B∗39 | 0 | 3.5 (14) | 0.1681 |
| B∗40 | 17.7 (6) | 8.8 (35) | 0.0894 |
| B∗41 | 0 | 1.0 (4) | 0.7196 |
| B∗44 | 44.1 (15) | 30.2 (120) | 0.0917 |
| B∗45 | 0 | 2.3 (9) | 0.4747 |
| B∗47 | 0 | 1.0 (4) | 0.7196 |
| B∗48 | 0 | 0.3 (1) | 0.9213 |
| B∗49 | 0 | 3.8 (15) | 0.2863 |
| B∗50 | 0 | 2.8 (11) | 0.3705 |
| B∗51 | 14.7 (5) | 8.3 (33) | 0.1673 |
| B∗52 | 0 | 2.5 (10) | 0.4366 |
| B∗53 | 2.9 (1) | 1.3 (5) | 0.3903 |
| B∗55 | 0 | 3.5 (14) | 0.3116 |
| B∗56 | 0 | 1.3 (5) | 0.6624 |
| B∗57 | 2.9 (1) | 7.0 (28) | 0.3127 |
| B∗58 | 0 | 0.5 (2) | 0.8486 |
| B∗60 | 0 | 1.3 (5) | 0.6624 |
| B∗62 | 2.9 (1) | 0.5 (2) | 0.2185 |
| Study Cohort | Number | Percentages |
| Women | 36 | 34 |
| Men | 71 | 66 |
| Mean Age 64.7 years | ||
| (Range 31–95 years) | ||
| Clinical Neuropathic Syndrome | ||
| MNM | 1 | 1 |
| DLRPN | 35 | 33 |
| DSPN | 71 | 66 |
| Histological Severity of Neuropathy | ||
| Normal | 1 | 1 |
| Mild | 17 | 16 |
| Moderate | 54 | 50 |
| Severe | 35 | 33 |
| Teased Fiber/Semithin Section Analysis | ||
| Normal | 1 | 1 |
| Axonopathy | 45 | 65 |
| Myelinopathy | 23 | 35 |
| Cellular Response | ||
| Perivasculitis | 26 | 23 |
| Microvasculitis | 3 | 3 |
| Necrotizing arteritis | 3 | 3 |
| Complement Immunofluorescence | ||
| C3 deposition | 70 | 67 |
| C5b-9 | 65 | 62 |
| Other Findings | ||
| Onion bulb formation | 10 | 9 |
| Epineurial vascular thrombosis | 5 | 5 |
| Type | Strain/ Transgeneb | Main patternc | Myoepithelial differentiationd | EMT (%)e | K1 | K5 | K6 | K8/18 | K10 | K14 | K17 | FLG | IVL | LOR | THH | SMA | VIM |
| Simple | FVB-Myc | Glandular | 6/9 | 4/9 (<1%) | + | + | + | ++ | + | ||||||||
| FVB-Notch4 | Glandular | 0/6 | 0 | + | + | + | |||||||||||
| C57BL6/J-Tag | Glandular | 1/5 | 0 | + | + | + | |||||||||||
| BALB/cJ (mostly) | Papillary, 1 cell thick | 2/6 | 0 | + | + | ++ | ++ | ++ | |||||||||
| C57BL6/J-Tag | Papillary | 0/4 | 0 | + | + | + | |||||||||||
| FVB-Myc | Solid | 1/4 | 3/4 (<1%) | + | + | + | |||||||||||
| FVB-Neu | Solid | 0/10 | 0 | ||||||||||||||
| Complex | FVB and B6D2-Tgfa | Macrocyst | 6/8 | 0 | + | + | +++ | + | + | + | |||||||
| FVB and B6D2-Tgfa | Lactation plaque | 3/3 | 0 | ++ | + | +++ | ++ | + | + | ||||||||
| BALB/cJ | Adenomyoepithelioma | 5/5 | 0 | + | +++ | ++ | ++ | +++ | ++ | ||||||||
| BALB/cJ (mostly) | Adenoacanthoma | 7/7 | 0 | ++ | ++ | ++ | ++ | ++ | +++ | +++ | ++ | ++ | + | + | + | ||
| C3H/HeJ | Microacinar | 8/8 | 0 | ++ | + | ++ | ++ | + | |||||||||
| BALB/cJ, C3H/HeJ | Papillary, 2 cells thick | 2/2 | 0 | ++ | ++ | + | ++ | ++ | +++ | ||||||||
| C3H/HeJ | Type P tumor | 9/9 | 0 | ++ | + | ++ | ++ | ++ | + | +++ | |||||||
| FVB-Wnt1 | Type P tumor | 6/6 | 0 | ++ | ++ | +++ | ++ | ++ | + | + | ++ | ||||||
| B6SJL-Wnt1 | Type P tumor | 7/7 | 0 | + | + | + | ++ | + | ++ | ||||||||
| EMT | C57BL6/J-Tag | Glandular with EMT | 2/3 | 3/3 (6%) | +++ | +++ | ++ | ++ | + | ||||||||
| FVB-Myc | Glandular with EMT | 4/6 | 6/6 (20%) | + | + | ++ | ++ | ++ | + | + | |||||||
| PL/J and SJL/J | Glandular with EMT | 4/4 | 4/4 (38%) | ++ | + | +++ | ++ | ++ | + | ++ | ++ | ||||||
| FVB-Hras | Solid with EMT | 3/4 | 3/4 (<1%) | + | ++ | + | + | + |
| HAA intake | ||||
| Low | Moderate | High | Pinteraction | |
| NAT2-imputed phenotype | ||||
| Rapid or intermediate acetylator | ||||
| Cases/Controls | 92/124 | 100/116 | 132/93 | |
| OR (95% CI)a | 1.00 | 1.17 (0.84–1.65) | 1.85 (1.34–2.56) | |
| Slow acetylator | ||||
| Cases/Controls | 8/7 | 8/8 | 11/3 | |
| OR (95% CI) | 1.43 (0.50–4.12) | 1.21 (0.56–2.60) | 5.29 (2.37–11.80) | 0.004 |
| CYP1A1 | ||||
| AA | ||||
| Cases/controls | 51/87 | 68/82 | 88/63 | |
| OR (95% CI) | 1.00 | 1.46 (0.95–2.24) | 2.41 (1.61–3.63) | |
| GA + GG | ||||
| Cases/controls | 49/44 | 40/42 | 55/33 | |
| OR (95% CI) | 2.05 (1.19–3.63) | 1.72 (1.07–2.76) | 2.86 (1.83–4.47) | < 0.001 |
| CYP1A2 | ||||
| CC | ||||
| Cases/controls | 7/17 | 14/17 | 13/13 | |
| OR (95% CI) | 1.00 | 2.05 (0.73–5.77) | 2.65 (0.97–7.29) | |
| CA + AA | ||||
| Cases/controls | 93/114 | 94/107 | 130/83 | |
| OR (95% CI) | 2.17 (0.85–5.59) | 2.34 (0.93–5.92) | 4.01 (1.60–10.05) | 0.003 |
| EORTC QLQ-C30 subscales | Item | Baseline | 2 weeks post-RT | ||||||
| IG (n = 89) | CON (n = 89) | IG (n = 89) | CON (n = 89) | ||||||
| Mean(SD) | Mean(SD) | tvalue | pvalue | Mean(SD) | Mean(SD) | tvalue | pvalue* | ||
| Functioning scales | |||||||||
| Physical functioning PF | 1-5 | 77.23(10.19) | 78.91(10.81) | −1.067 | 0.288 | 79.70(9.80) | 75.36(9.71) | 2.970 | 0.003 |
| Role functioning RF | 6,7 | 59.55(24.48) | 58.28(24.49) | 0.347 | 0.729 | 59.18(24.23) | 57.45(21.01) | 0.507 | 0.613 |
| Emotional functioning EF | 21-24 | 72.57(12.51) | 70.77(14.71) | 0.874 | 0.383 | 74.18(11.43) | 66.03(14.00) | 4.251 | <0.001 |
| Cognitive functioning CF | 20,25 | 80.71(11.48) | 81.27(11.46) | −0.327 | 0.744 | 81.09(12.36) | 78.58(10.01) | 1.489 | 0.138 |
| Social functioning SF | 26,27 | 75.00(13.82) | 73.43(12.31) | 0.802 | 0.424 | 74.35(10.67) | 71.33(11.88) | 1.782 | 0.076 |
| Global health status QL | 29,30 | 61.31(13.23) | 58.43(12.78) | 1.48 | 0.141 | 58.80(12.20) | 51.12(12.82) | 4.092 | <0.001 |
| Symptom scales and/or items | |||||||||
| Fatigue FA | 10,12,18 | 28.05(14.75) | 28.63(13.38) | −0.276 | 0.783 | 29.20(11.86) | 32.93(13.78) | −1.938 | 0.054 |
| Nausea/vomiting NV | 14,15 | 11.05(11.50) | 9.74(9.99) | 0.812 | 0.418 | 14.61(12.26) | 15.92(10.93) | −0.753 | 0.452 |
| Pain PA | 9,19 | 31.46(13.86) | 30.52(14.70) | 0.437 | 0.662 | 28.84(15.64) | 30.90(16.77) | −0.847 | 0.398 |
| Dyspnea DY | 8 | 12.36(16.19) | 14.79(16.56) | −0.992 | 0.323 | 11.98(16.08) | 12.36(16.95) | −0.151 | 0.880 |
| Insomnia SL | 11 | 29.21(22.37) | 30.71(21.45) | −0.456 | 0.649 | 27.71(20.25) | 34.08(20.71) | −2.074 | 0.040 |
| Appetite loss AP | 13 | 23.03(22.96) | 25.09(22.63) | −0.603 | 0.547 | 26.78(21.26) | 28.84(23.13) | −0.618 | 0.537 |
| Constipation CO | 16 | 16.85(20.18) | 16.10(20.17) | 0.248 | 0.805 | 18.73(19.43) | 20.97(19.71) | −0.766 | 0.445 |
| Diarrhea DI | 17 | 10.86(19.32) | 9.36(15.88) | 0.565 | 0.573 | 13.11(17.13) | 12.36(18.38) | 0.281 | 0.779 |
| Financial difficulties FI | 28 | 62.17(29.38) | 61.42(29.26) | 0.170 | 0.865 | 68.17(30.11) | 67.04(28.65) | 0.255 | 0.799 |
| HUS-STEMI I | HUS-STEMI II | ||
| n = 194 | n = 306 | ||
| % | % | p | |
| Mean age, mean (SD) years | 64.8 (12.9) | 64.3 (14.0) | 0.920 |
| Age > 75 years | 23.7 | 26.1 | 0.542 |
| Male sex | 64.9 | 69.0 | 0.352 |
| Diabetes | 15.5 | 19.6 | 0.240 |
| Current smoker | 35.6 | 39.0 | 0.449 |
| Hypertension | 63.4 | 53.3 | 0.026 |
| Dyslipidemia | 44.8 | 41.5 | 0.462 |
| Renal dysfunction | 1.5 | 4.2 | 0.094 |
| AMI | 18.6 | 10.8 | 0.014 |
| Stroke | 8.8 | 6.5 | 0.354 |
| CABG | 4.1 | 5.2 | 0.573 |
| PCI | 9.8 | 13.4 | 0.227 |
| ASA | 23.2 | 26.8 | 0.367 |
| P2Y12 inhibitor | 2.1 | 3.9 | 0.250 |
| Warfarin | 9.3 | 8.8 | 0.863 |
| Anterior infarct | 46.8 | 53.6 | 0.143 |
| Killip class 2--4 | 12.4 | 18.0 | 0.096 |
| Admission at regular hours | 41.5 | 40.8 | 0.888 |
| Category | All Respondents (n = 769) | Nurses (n = 527) | Physicians (n = 238) |
| 1 Lack of timea | 33.0% (254) | 27.3% (144) | 46.2% (110) |
| 2 Behaviours attributed to women living with abuse | 21.5% (165) | 19.9% (105) | 25.2% (60) |
| 3 Lack of traininga | 16.4% (126)b | 20.9% (110) | 5.5% (13) |
| 4 Language/cultural practicesa | 15.5% (119)c | 18.4% (97) | 8.8% (21) |
| 5 Partner presencea | 14.0% (108) | 19.5% (103) | 2.1% (5) |
| 6 Lack of resourcesa | 13.0% (100) | 10.4% (55) | 18.9% (45) |
| 7 Lack of space/privacya | 8.2% (63) | 11.2% (59) | 1.7% (4) |
| 8 Discomfort with topic | 4.6% (35) | 4.7% (25) | 4.2% (10) |
| 9 Lack of practitioner knowledge of resources | 2.6% (20) | 2.7% (14) | 2.5% (6) |
| CHEK2 mutation type | Controls(n = 1,026)a | Allelic frequency in controls | Cases(n = 1,014)a | Allelic frequency in cases | P value | OR | 95% CI |
| Any CHEK2 mutation | 4 | 0.39% | 16 | 1.58% | 0.0065 | 4.15 | (1.38 to 12.50) |
| CHEK2 deleterious mutations | 3 | 0.29% | 15 | 1.48% | 0.0042 | 5.18 | (1.49 to 18.00) |
| Chr | SNP | Position | Minor allele/major allele | Association p-value | Allelic OR (95% CI) | Bonferroni adjusted p-value | BH-false discovery rate p-value | Interaction (ADD × sex) p-value |
| 1 | rs865682 | 223,080,777 | A/G | 4.545 × 10-6 | 0.39(0.26-0.60) | 0.16 | 0.16 | - |
| 2 | rs12477038 | 201,518,282 | G/A | 1.038 × 10-5 | 0.47(0.33-0.66) | 0.41 | 0.25 | 0.09 |
| 3 | rs6775137 | 193,649,851 | A/C | 2.124 × 10-5 | 0.65(0.53-0.79) | 0.70 | 0.70 | - |
| 4 | rs512244 | 12,775,151 | G/A | 8.362 × 10-8 | 2.2(1.7-3.0) | 0.002 | 0.002 | 0.14 |
| 5 | rs7726943 | 67,854,337 | G/A | 2.991 × 10-6 | 0.62(0.50-0.76) | 0.09 | 0.09 | 0.21 |
| 6 | rs660895 | 32,685,358 | G/A | 8.346 × 10-24 | 3.4(2.7-4.3) | 2.642 × 10-19 | 2.642 × 10-19 | 5.263 × 10-45 |
| 7 | rs17470799 | 100,768,534 | A/G | 6.937 × 10-6 | 0.4(0.27-0.60) | 0.18 | 0.12 | 1.0 |
| 8 | rs966561 | 6,642,801 | A/G | 6.817 × 10-5 | 0.68(0.56-0.82) | 1.0 | 0.54 | 0.93 |
| 9 | rs306772 | 121,171,909 | A/G | 3.559 × 10-5 | 1.7(1.3-2.1) | 0.83 | 0.40 | 0.09 |
| 10 | rs7072006 | 133,595,618 | A/G | 5.309 × 10-6 | 0.48(0.35-0.67) | 0.13 | 0.13 | 0.78 |
| 11 | rs761453 | 31,834,576 | A/G | 3.867 × 10-5 | 0.61(0.48-0.77) | 0.91 | 0.46 | 0.52 |
| 12 | rs2283275 | 2,054,821 | G/A | 4.362 × 10-6 | 0.59(0.47-0.74) | 0.10 | 0.10 | 0.98 |
| 13 | rs17086849 | 28,064,399 | A/G | 3.158 × 10-6 | 0.56(0.44-0.72) | 0.06 | 0.06 | 0.94 |
| 14 | rs12885166 | 92,195,035 | A/C | 1.139 × 10-5 | 1.6(1.3-1.9) | 0.18 | 0.18 | 0.45 |
| 15 | rs11857639 | 71,424,825 | A/G | 1.083 × 10-5 | 0.39(0.25-0.61) | 0.16 | 0.16 | 1.0 |
| 16 | rs1076251 | 73,326,313 | A/C | 6.524 × 10-6 | 0.59(0.46-0.74) | 0.10 | 0.10 | 0.21 |
| 17 | rs1039519 | 3,394,664 | G/A | 7.11 × 10-5 | 1.52(1.2-1.9) | 0.90 | 0.60 | - |
| 18 | rs2174899 | 72,420,808 | G/A | 3.671 × 10-5 | 0.57(0.44-0.75) | 0.54 | 0.54 | - |
| 19 | rs9630874 | 57,619,851 | A/C | 1.27 × 10-5 | 0.31(0.17-0.54) | 0.10 | 0.10 | 0.51 |
| 20 | rs1182531 | 57,826,397 | A/C | 4.314-6 | 0.56(0.43-0.71) | 0.05 | 0.05 | 0.17 |
| 21 | rs12626622 | 31,981,460 | A/G | 2.063 × 10-4 | 1.8(1.3-2.4) | 1.0 | 0.52 | 0.20 |
| 22 | rs3830104 | 35,033,124 | G/A | 3.974 × 10-5 | 2.3(1.5-3.5) | 0.29 | 0.21 | 0.73 |
| T1 | T2 | T3 | P for trend | |
| Men (n) | 679 | 659 | 542 | |
| Age (yr) | 58.1 ± 10.6 | 54.5 ± 10.3 | 51.9 ± 9.4 | <0.001 |
| Weight (kg) | 68.9 ± 10.7 | 74.5 ± 11.0 | 80.0 ± 11.8 | <0.001 |
| BMI (kg/m2) | 26.5 ± 3.9 | 26.2 ± 3.9 | 26.0 ± 3.8 | 0.048 |
| Abdominal obesity (%) | 55.2 | 62.2 | 66.2 | <0.001 |
| Hypercholesterolemia (%) | 61.9 | 61.2 | 57.0 | 0.093 |
| Low HDL-C (%) | 61.7 | 63.6 | 63.5 | 0.501 |
| Hypertriglyceridemia (%) | 54.4 | 61.5 | 55.3 | 0.616 |
| Hypertension (%) | 33.4 | 26.8 | 24.8 | <0.001 |
| Diabetes (%) | 18.6 | 17.9 | 13.8 | 0.037 |
| Smoking (% current) | 22.6 | 28.2 | 28.9 | 0.011 |
| Family history of CVD (%) | 11.5 | 14.6 | 13.5 | 0.267 |
| Women (n) | 795 | 725 | 710 | |
| Age (yr) | 55.7 ± 9.6 | 52.9 ± 8.9 | 49.8 ± 8.2 | <0.001 |
| Weight (kg) | 65.1 ± 11.2 | 70.0 ± 11.1 | 74.6 ± 11.5 | <0.001 |
| BMI (kg/m2) | 29.4 ± 5.0 | 29.1 ± 4.6 | 28.7 ± 4.3 | 0.003 |
| Abdominal obesity (%) | 57.2 | 60.2 | 60.0 | 0.261 |
| Hypercholesterolemia (%) | 80.1 | 73.9 | 69.8 | <0.001 |
| Low HDL-C (%) | 32.8 | 37.8 | 41.1 | <0.001 |
| Hypertriglyceridemia (%) | 62.3 | 61.2 | 56.3 | 0.020 |
| Hypertension (%) | 38.2 | 35.5 | 23.3 | <0.001 |
| Diabetes (%) | 21.2 | 23.3 | 15.9 | 0.314 |
| Smoking (% current) | 2.5 | 2.5 | 5.4 | 0.003 |
| Family history of CVD (%) | 19.3 | 18.9 | 16.8 | 0.220 |
| Menopause (%) | 66.8 | 58.2 | 45.5 | <0.001 |
| Polysaccharide(s) | Source(s) | Animals | Dose/day | Duration | CNS tests performed | Significant effects | Reference |
| Alpha-glucan (isolichenan) | Cetrariella islandica | 5-week-old ♂ Std-ddY mice treated with 30% ethanol p.o. 20 minutes before learning trial | 100, 200, or 400 mg/kg p.o. once | 30 minutes before learning trial | Passive avoidance step through and step down | All doses reversed ethanol impaired fear memory acquisition; no effects on mice without ethanol exposure | 18 |
| ♂ Wistar rats receiving daily i.c.v. injections of A-beta peptide from day 7 to day 4 | 100 or 200 mg/kg p.o. | 8 days | Morris water maze | 100 mg/kg reversed A-beta-induced spatial memory deficits; no effects on rats without A-beta peptide pretreatment | 18 | ||
| Arabinoxylan; beta-glucan | Triticum aestivum L.; Hordeum vulgare L. | ♂ Sprague–Dawley rats with bilateral common carotid artery occlusion | 20 mg/kg p.o. | Days 8–14 post-surgery; testing on days 22–26 post-surgery | Morris water maze; immunohistochemistry and western blot (GFAP, MBP); Luxol fast blue and hematoxylin staining | Both treatments reversed ischemia-induced spatial memory deficits; arabinoxylan prevented loss of MBP in corpus callosum | 20 |
| Pectin | Citrus [peel] | 9–11-week-old C56BL/6J mice injected i.p. with 100 μg/kg LPS | 10% pectin diet | 6–8 weeks post-weaning | Social exploratory behavior of a novel juvenile mouse | Faster recovery from LPS-induced social withdrawal compared with 5% cellulose diet | 19 |
| Polysaccharide fraction: PSF (no characterization provided) | Panax ginseng | Adult ♂ Wistar rats | 4, 20, or 40 mg/kg i.p. | 10 days | Conditioned Active Escape Response | All doses differentially improved indications of learning and memory | 22 |
| Alpha-glucan (FPS) | Fu Zi (Aconitum carmichaeli Debx) | 8–11-week-old ♂ C57BL/6 mice | 5 to 400 mg/kg i.p. | Varied with assay: 30 minutes, 6 hours, or 1–4 weeks | BrdU labeling; forced swim; open-field; novelty-suppressed feeding; chronic social defeat stress; monoamine levels in the frontal cortex; ELISA and Western blot (BDNF) | 10–400 mg/kg doses increased newborn neurons in the DG; 50 and 100 mg/kg produced AD effects (similar to imipramine); 100 mg/kg increased BDNF expression in the hippocampus; AD and neurogenesis effects were blocked by co-injection with K252a (trkB inhibitor) | 23 |
| Quartile 1 | Quartile 2 | Quartile 3 | Quartile 4 | Ptrend | |
| TyG | |||||
| Range | <8.16 | 8.16 to 8.47 | 8.48 to 8.81 | ≥8.82 | |
| No. of cases | 18 | 35 | 52 | 88 | |
| No. of person-years | 8740.50 | 8526.83 | 8529.25 | 8399.50 | |
| Incidence ratea | 2.06 | 4.10 | 6.10 | 10.48 | <0.001 |
| Unadjusted model | 1 (ref) | 2.36 (1.33–4.16) | 3.58 (2.09–6.12) | 6.30 (3.78–10.50) | <0.001 |
| Multivariable adjusted model 1b | 1 (ref) | 2.38 (1.17–4.85) | 3.71 (1.89–7.29) | 5.54 (2.87–10.71) | <0.001 |
| Multivariable adjusted model 2c | 1 (ref) | 2.49 (1.22–5.08) | 3.89 (1.98–7.65) | 5.69 (2.94–11.01) | <0.001 |
| Multivariable adjusted model 3d | 1 (ref) | 2.48 (1.20–5.11) | 3.77 (1.83–7.79) | 5.30 (2.21–12.71) | <0.001 |
| TyG-D | |||||
| Range | <−0.27 | −0.27 to 0 | 0.01 to 0.31 | ≥0.32 | |
| No. of cases | 41 | 39 | 30 | 83 | |
| No. of person-years | 8520.00 | 9747.08 | 7373.00 | 8556.00 | |
| Incidence ratea | 4.81 | 4.00 | 4.07 | 9.70 | <0.001 |
| Unadjusted model | 1 (ref) | 0.95 (0.58–1.55) | 1.15 (0.68–1.93) | 2.19 (1.41–3.39) | <0.001 |
| Multivariable adjusted model 1b | 1 (ref) | 0.92 (0.52–1.63) | 1.09 (0.59–2.03) | 2.51 (1.50–4.19) | <0.001 |
| Multivariable adjusted model 2c | 1 (ref) | 0.92 (0.52–1.64) | 1.10 (0.59–2.05) | 2.52 (1.51–4.22) | <0.001 |
| Multivariable adjusted model 3d | 1 (ref) | 1.14 (0.63–2.09) | 1.54 (0.80–2.99) | 3.91 (2.22–6.87) | <0.001 |
| Characteristic | HES APCa | Englandb |
| Finished consultant episodes | 18731964 | |
| Admissions | 15892434 | |
| Admission type | ||
| Emergency | 5615707 (30.0) | |
| Waiting list | 6119234 (32.7) | |
| Planned | 2154564 (11.5) | |
| Other | 2002929 (10.7) | |
| Sex | ||
| Male | 8359362 (44.6) | 26773200 (49.3) |
| Female | 10370245 (55.4) | 27543400 (50.7) |
| Gender unknown | 2357 (0.01) | – |
| Age | ||
| 0 years | 1013476 (5.4) | 664183 (1.2) |
| 1–4 years | 454461 (2.4) | 2766774 (5.1) |
| 5–14 years | 568902 (3.0) | 6245420 (11.5) |
| 15–24 years | 1167439 (6.2) | 6837371 (12.6) |
| 25–34 years | 1880715 (10.0) | 7425591 (13.7) |
| 35–44 years | 1573273 (8.4) | 7103408 (13.1) |
| 45–54 years | 1986116 (10.6) | 7635651 (14.1) |
| 55–64 years | 2319214 (12.4) | 6100512 (11.2) |
| 65–74 years | 3013044 (16.1) | 5162873 (9.5) |
| 75–84 years | 2941250 (15.7) | 3099319 (5.7) |
| 85+ years | 1711354 (9.1) | 1275516 (2.3) |
| Missing | 102720 (0.5) |
| miRNAs | Expression in lung cancer | Cellular processes affected and targets | Reference |
| Let-7 family | Decreased | (i) Cell proliferation (KRAS, MYC, and HMGA2) | [28–30] |
| (ii) miRNA maturation Dicer mediated | [31] | ||
| (iii) Cell-cycle regulation (CDC25A, CDK6, and cyclin D2) | [32] | ||
| mir-34 family | Decreased | (i) Transcriptionally activated by p53 | [40] |
| (ii) TRAIL-induced cell death and cell proliferation (BCL-2, MET, and PDGFR-α/β) | [41–43] | ||
| mir-21 | Increased | (i) Apoptosis, cellular proliferation, and migration (TPM1, PDCD4, and PTEN) | [50–53] |
| (ii) TKI-treatment resistance | [54] | ||
| mir-17/92a cluster | Increased | (i) Transcriptionally regulated by c-MYC | [60] |
| (ii) Cellular proliferation and cancer development (PTEN, HIF-1a CL2L11, CDKNA, and TSP-1) | [57, 61–63] | ||
| mir-15a/16 cluster | Decreased | Cell cycle regulation (cyclin D1, D2 and E1) | [66, 67] |
| mir-200 family | Decreased | Promotion of EMT and metastasization(ZEB transcription factors,CDH-1, and vimentin) | [68–73] |
| miRNA-29 family | Decreased | Epigenetic regulation of gene expression (DNMT-3A and DNMT-3B) | [74] |
| mir-221/mir-222 | Increased | (i) TRAIL resistance and cellular migration (PTEN and TIMP3) | [75, 76] |
| (ii) Transcriptionally regulated by EGFR and MET and gefitinib resistance (BIM and APAF1) | [77] | ||
| mir-548 | Decreased | Tumor cell growth (CCND, ERBB2, DMNT3A, and DNMT3B) | [78] |
| SL2 clinical data | SL1 clinical data | p-value | |||
| Pre 24 hour | Pilot trial (+) | Post 24 hour | Pilot trial (+) | SL1 vs. SL2 | |
| Number of patients: | 9 | 9 | 9 | 9 | / |
| Total hours: | / | 194 h | / | 215 h | / |
| Number of BG measurements: | 46 | 91 | 44 | 205 | / |
| BG median [IQR] (mg/dL): | 155.5 [124.0 - 171.0] | 134.0 [117.2 - 150.8] | 136.5 [115.0 - 159.5] | 136.0 [122.5 - 158.0] | 0.27(*) |
| % BG within 80–100 mg/dL | 8.7 | 3.3 | 6.82 | 3.4 | 1.00 |
| % BG within 100–140 mg/dL | 10.9 | 54.9 | 43.18 | 50.7 | 0.53 |
| % BG within 140–180 mg/dL | 50.0 | 33.0 | 36.36 | 37.1 | 0.51 |
| % BG ≥ 180 mg/dL | 19.6 | 7.7 | 9.09 | 8.3 | 1.00 |
| % BG < 90 mg/dL | 19.6 | 3.3 | 11.4 | 2.0 | 0.44 |
| % BG < 80 mg/dL | 10.9 | 1.1 | 4.55 | 0.5 | 0.52 |
| % BG < 40 mg/dL | 0.0 | 0.0 | 0.0 | 0.0 | 1.00 |
| Number of patients < 40 mg/dL | 0 | 0 | 0 | 0 | / |
| Median insulin rate [IQR] (U/h): | / | 2.0 [1.0 - 2.5] | / | 1.5 [0.5 - 3.4] | 0.92(*) |
| Median glucose rate [IQR] (g/h): | / | 0.0 [0.0 - 5.4] | / | 7.4 [2.0 - 11.2] | 0.00(*) |
| Fatty acid | Name | Percentage in EVOO | mg FAME/g sample |
| C16:0 | Palmitic acid | 11,27 | 125,41 |
| C16:1n7 | Palmitoleic acid | 0,86 | 9,56 |
| C17:0 | Margaric acid | 0,04 | 0,46 |
| C18:0 | Stearic acid | 3,85 | 42,81 |
| C18:1n7c | Cis-Vaccenic acid | 2,42 | 26,92 |
| C18:1n9c | Oleic acid | 75,99 | 845,97 |
| C18:2n6c | Linoleic acid | 4,2 | 46,74 |
| C18:3n3 | α-Linolenic acid | 0,61 | 6,81 |
| C20:0 | Arachidic acid | 0,4 | 4,46 |
| C20:1n9 | Cis-11 eicosenoic acid | 0,22 | 2,42 |
| C22:0 | Behenic acid | 0,1 | 1,14 |
| C24:0 | Lignoceric acid | 0,05 | 0,544 |
| Selected phenolic compounds (STP) | μg/g sample | ||
| Hydroxytyrosol | 9,31 | ||
| p-coumaric acid | 0,14 | ||
| Oleuropein | n.d. |
| Covariate | χ2 | P-value | Hazard ratio | 95% CI |
| Adjacent involvement (with vs. without) | 11.841 | 0.001 | 2.295 | 1.430-3.683 |
| Mitotic rate (> = 5/50 HPF vs. <5/50 HPF) | 8.895 | 0.003 | 2.406 | 1.351-4.284 |
| Risk grade (high risk vs. non-high risk) | 26.129 | <0.001 | 11.794 | 4.579-30.379 |
| Assessment | Group | Mean value (95% confidence interval) | Paired t test | 1-way ANCOVA | |
| PRE | POST | P (Cohen’s d) | P (Partial η2) | ||
| FMAfull score | Clinic | 13.75 (8.09–19.41) | 30.31 (23.88–36.75) | 0.000 ( − 1.45)*** | 0.550 (0.012) |
| Lab | 17.50 (9.95–25.05) | 30.88 (23.92–37.83) | 0.000 ( − 1.46)*** | ||
| FMAshoulder/elbow | Clinic | 10.31 (6.28–14.34) | 20.31 (16.18–24.44) | 0.000 ( − 1.35)*** | 0.782 (0.003) |
| Lab | 12.44 (7.25–17.63) | 21.06 (16.16–25.97) | 0.000 ( − 1.18)*** | ||
| FMAwrist/hand | Clinic | 3.44 (1.37–5.51) | 10.00 (7.52–12.48) | 0.000 ( − 1.36)*** | 0.333 (0.032) |
| Lab | 5.06 (2.34–7.78) | 9.81 (6.75–12.87) | 0.000 ( − 1.35)*** | ||
| ARAT | Clinic | 3.81 (− 0.30 to 7.92) | 14.50 (9.56–19.44) | 0.000 ( − 1.22)*** | 0.175 (0.063) |
| Lab | 11.69 (5.66–17.72) | 18.06 (11.43–24.69) | 0.000 ( − 1.44)*** | ||
| FIM | Clinic | 56.63 (52.05–61.20) | 62.13 (59.41–64.84) | 0.004 ( − 0.86)** | Nil |
| Lab | 58.50 (51.53–65.47) | 60.00 (53.39–66.61) | 0.161 ( − 0.37) | ||
| MASFinger | Clinic | 1.70 (1.32–2.08) | 0.95 (0.68–1.22) | 0.000 (1.12)*** | 0.622 (0.009) |
| Lab | 1.34 (0.81–1.87) | 0.91 (0.52–1.31) | 0.085 (0.46) | ||
| MASWrist | Clinic | 1.65 (1.18–2.12) | 0.91 (0.56–1.26) | 0.001 (0.97)*** | 0.443 (0.020) |
| Lab | 1.10 (0.77–1.43) | 0.80 (0.45–1.15) | 0.075 (0.48) | ||
| MASElbow | Clinic | 1.91 (1.54–2.28) | 1.18 (0.82–1.53) | 0.001 (1.08)*** | 0.892 (0.001) |
| Lab | 1.21 (0.77–1.66) | 0.76 (0.40–1.12) | 0.013 (0.71)* |
| Validation against our test | Validation against the test in literature | |||
| The current experiment (n = 8) | Predicted value | Hashemi et al.’s experiment (n > 4) | Predicted value | |
| High density | 2015 ± 95.7 N | 2028.8 N | 2132.5 ± 119.3 N | 2028.8 N |
| Low density | 657 ± 69.4 N | 607 N | 688.2 ± 91.4 N | 607 N |
| n | % | |
| Gender | ||
| Male | 432 | 49.3 |
| Female | 444 | 50.7 |
| Ethnicity | ||
| White | 536 | 61.2 |
| Non-white | 340 | 38.8 |
| Education | ||
| Less than college | 421 | 48.1 |
| Some college or higher | 455 | 51.9 |
| Household income | ||
| Less than $20,000 | 506 | 57.8 |
| $20,000 or more | 370 | 42.2 |
| Marital status | ||
| Single | 665 | 75.9 |
| Married/living with partner | 211 | 24.1 |
| Insurance | ||
| Managed care (HMO, PPO) | 241 | 27.5 |
| Medicare | 364 | 41.6 |
| Veterans Affairs Medical Center | 41 | 4.7 |
| State Medicaid (MediCal for CA residents) | 350 | 40.0 |
| No health insurance | 61 | 7.0 |
| Don't know | 16 | 1.8 |
| Employment | ||
| Employed full time | 129 | 14.7 |
| Employed part time | 163 | 18.6 |
| Student | 29 | 3.3 |
| Retired | 70 | 8.0 |
| Not employed | 484 | 55.3 |
| Atypical Medication | ||
| On a atypical medication | 628 | 71.7 |
| Mean | SD | |
| Age | 43.03 | 11.80 |
| Number of comorbidities | 1.27 | 1.30 |
| Variable | ROSC | No ROSC | P value |
| Paramedics with prior OHCA case volume ≥ 15 (%) | 24.5 | 22.7 | <0.01 |
| Male gender (%) | 60.1 | 63.2 | 0.01 |
| Non-Caucasian (%) | 31.7 | 29.8 | 0.09 |
| Age in years (mean, ± SD) | 65.7 | 67.4 | <0.01 |
| Shockable rhythm (%) | 38.9 | 21.2 | <0.01 |
| Layperson/first responder CPR (%) | 51.8 | 36.3 | <0.01 |
| EMS response time in minutes (mean, ± SD) | 7.7 | 8.9 | <0.01 |
| Component | Score | Definition |
| Physical Activity | ||
| 0 | No exercise | |
| 1 | 1–149 min of moderate exercise or 1–74 min of vigorous exercise/week | |
| 2 | 150+ minutes of moderate exercise or 75+ minutes of vigorous exercise/week | |
| Dieta | ||
| 0 | 0–1 components of healthy diet | |
| 1 | 2–3 components of healthy diet | |
| 2 | 4–5 components of healthy diet | |
| Glucose | ||
| 0 | ≥126 mg/dL fasting | |
| 1 | 100–125 mg/dL fasting or treated to <100 mg/dL | |
| 2 | <100 mg/dL fasting, unmedicated | |
| Blood Pressure | ||
| 0 | Systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg | |
| 1 | Systolic blood pressure 120–139 mmHg or diastolic blood pressure 80–89 mmHg or treated to <120/80 mmHg | |
| 2 | <120/80 mmHg, unmedicated | |
| BMI | ||
| 0 | ≥30 kg/m2 | |
| 1 | 25.0–29.99 kg/m2 | |
| 2 | <25.0 kg/m2 | |
| Cholesterol | ||
| 0 | ≥240 mg/dL | |
| 1 | 200–239 mg/dL or treated to <200 mg/dL | |
| 2 | <200 mg/dL, unmedicated | |
| Smoking | ||
| 0 | Current smoker | |
| 1 | Former smoker, quit ≤12 months ago | |
| 2 | Never smoker or quit >12 months ago |
| Cancer type | Reference |
| Breast | Fernandez et al. (19), Gazit et al. (20) |
| Prostate | Daneshmand et al. (23), Fu et al. (24) |
| Gastric | Song et al. (26) |
| Ovarian | Huang, LW et al. (25) |
| Endometrial | Bifulco et al. (31), Calí et al. (32) |
| Hepatocellular | Su et al. (27); Shuda (28) |
| Esophageal | Langer et al. (29) |
| Fibrosarcoma | Jamora et al. (35) |
| Glioma | Pyrko et al. (34) |
| Melanoma | Zhuang et al. (33) |
| Lung | Lin et al. (21), Koomagi et al. (22) |
| Renal | Fu et al. (30) |
| LN | |||||
| CD63 | |||||
| Number of patients, n (%) | Positive, n | Negative, n | P-value | ||
| MDR1 | Positive | 11 (22.9) | 11 | 0 | |
| Negative | 37 (77.1) | 16 | 21 | P < 0.05 |
| Capsules | Spectrophotometric method | Fluorimetric method | ||||
| Recovery (%) ± SD(a) | F value(b) | t value(b) | Recovery (%) ± SD(a) | F value(b) | t value(b) | |
| Prozac | 99.9 ± 1.4 | 1.68 | 1.17 | 99.7 ± 1.6 | 2.38 | 3.00 |
| Pluzac | 100.1 ± 1.3 | 2.62 | 1.27 | 99.2 ± 1.5 | 1.58 | 2.91 |
| Salipax | 99.8 ± 1.3 | 1.00 | 1.10 | 100.8 ± 1.8 | 1.60 | 2.18 |
| Flutin | 100.1 ± 1.6 | 1.64 | 1.27 | 100.1 ± 1.3 | 0.19 | 1.12 |
| Octozac | 99.8 ± 1.2 | 2.35 | 2.13 | 99.4 ± 1.5 | 1.49 | 2.47 |
| Age (Years) | Height (cm) | Weight (kg) | |
| CFS | 43 ± 4.6 | 164 ± 7.3 | 73 ± 21.2 |
| Control | 43 ± 6.5 | 167 ± 7.0 | 70 ± 16.7 |
| General health | Conditions and symptoms | Infections | |
| ‘Type 1’ | |||
| 1a: Emerging female excess | General health – Past year General health – Past month | High temperature Rash | Eye infection Ear infection |
| 1b: Increasing female excess | Earache Stomach-ache Headache Lice/scabies | Cold sores Urinary infection | |
| 1c: Disappearing male excess | Breathlessness | ||
| ‘Type 2’ | |||
| 2a: Consistent female excess | Health-related days off school | Constipation Eczema | Tonsillitis/laryngitis Cold Worm infections |
| 2b: Consistent no sex difference | Vomiting Cough Ear discharge Food/drink allergies Non-food/drink allergies | Chicken pox Influenza | |
| 2c: Consistent male excess | Wheezing Asthma Hay fever | Chest infection | |
| ‘Type 3’ | |||
| 3a: Emerging male excess | Pain in arms/legs | ||
| 3b: Increasing male excess | Diarrhoea |
| Sample | ZKR a_S1 b | ZKR_S2 b | ZKR_S3 b | QXR c_S1 | QXR_S2 | QXR_S3 |
| Raw reads | 100,481,781 | 99,812,614 | 99,445,825 | 100,002,793 | 99,887,525 | 99,071,615 |
| Clean reads | 95,660,601 | 94,297,177 | 90,539,959 | 97,386,913 | 97,460,159 | 91,414,542 |
| Filtering rate | 93.26% | 92.81% | 90.31% | 95.51% | 95.85% | 91.25% |
| Q30 | 92.25% | 91.40% | 95.96% | 94.52% | 95.74% | 96.03% |
| Total mapped reads | 87,463,758 (91.41%) | 87,557,832(92.85%) | 83,122,460(91.81%) | 89,812,801(92.22%) | 90,465,752(92.82%) | 83,950,965(91.84%) |
| Multiple mapped | 10,182,952(10.65%) | 11,506,609(12.20%) | 11,988,424(13.24%) | 10,370,562(10.65%) | 11,019,503(11.30%) | 13,298,066(14.53%) |
| Uniquely mapped | 77,280,806(80.77%) | 76,051,223(80.65%) | 71,134,037(78.56%) | 79,442,240(81.58%) | 79,446,249(81.52%) | 70,652,899(77.31%) |
| Reads map to ‘+’ | 38,609,153(40.35%) | 37,967,782(40.26%) | 35,526,529(39.24%) | 39,685,378(40.75%) | 39,665,757(40.70%) | 35,482,024(38.82%) |
| Reads map to ‘−’ | 38,671,654(40.42%) | 38,083,441(40.39%) | 35,607,508(39.33%) | 39,756,861(40.83%) | 39,780,492(40.82%) | 35,170,875(38.49%) |
| Cross-linked polyurethane | Macrodiols | Diisocyanate | Chain extender | State at room temperature | Tg (°C) | Tm (°C) |
| CPU 1 | PCEG 1 | HDI | TMP | Hard | −45 | 46 |
| CPU 2 | PCEG 2 | HDI | TMP | Frangibility | −48 | 44 |
| CPU 3 | PCEG 3 | HDI | TMP | Elasticity | −51 | 38 |
| Striatal Regionψ | PD (n = 65) | Healthy Controls (n = 27) | F(1,91) | p | Effect size |
| Normalized Caudate | 0.416% (0.400 – 0.433) | 0.468% (0.443 – 0.493) | 11.38 | 0.001 | −0.80 |
| Normalized Putamen | 0.422% (0.405 – 0.440) | 0.459% (0.432 – 0.442) | 5.22 | 0.03 | −0.52 |
| Gender effectsψ | Male (n = 67) | Female (n = 25) | F(1,91) | p | Effect size |
| Normalized Caudate | 0.423% (0.407 – 0.439) | 0.461% (0.435 – 0.487) | 6.2 | 0.02 | −0.59 |
| Normalized Putamen | 0.425% (0.408 – 0.442) | 0.456% (0.429 – 0.483) | 3.8 | 0.05 | −0.47 |
| Caudate sub-regionsζ | PD (n = 58) | Healthy Controls (n = 25) | F(1,82) | p | Effect size |
| Normalized Head | 0.351% (0.338 – 0.363) | 0.381% (0.363 – 0.399) | 7.4 | 0.008 | −0.66 |
| Normalized Body | 0.071% (0.064 – 0.077) | 0.078% (0.070 – 0.086) | 2.0 | 0.16 | −0.32 |
| Cognitively normal comparison* | PD normal cognition (n = 41) | Healthy Controls (n = 27) | F(1,67) | p | Effect size |
| Normalized Caudate | 0.424% (0.401 – 0.446) | 0.470% (0.442 – 0.497) | 6.0 | 0.02 | −0.65 |
| Normalized Putamen | 0.429% (0.406 – 0.453) | 0.465% (0.437 – 0.494) | 3.9 | 0.05 | −0.48 |
| Aerobe genomes | Anaerobe genomes | Facultative genomes | ||||||||||
| Predictions | Aerobe | 137 | 87 | % | Aerobe | 6 | 6 | % | Aerobe | 43 | 44 | % |
| Anaerobe | 3 | 2 | % | Anaerobe | 95 | 88 | % | Anaerobe | 21 | 21 | % | |
| Facultative | 17 | 11 | % | Facultative | 7 | 6 | % | Facultative | 34 | 35 | % |
| Male to female ratio is 432(73%): 160(27%) | ||
| Characteristics | Cases (n = 296) | Controls (n = 296) |
| n* (%) | n* (%) | |
| Marital status | ||
| - Married | 227 (76.69%) | 251 (84.80%) |
| Family type | ||
| - Nuclear family | 207 (70.61%) | 175 (59.12%) |
| - Extended family | 87 (29.39%) | 121 (40.88%) |
| Socioeconomic status | ||
| - Lowest | 91 (30.74%) | 85 (28.72%) |
| - Middle | 145 (48.99%) | 165 (55.74%) |
| - Upper | 60 (20.27%) | 46 (15.54%) |
| Occupation | ||
| - Salaried workers | 29 (9.8%) | 23 (7.77%) |
| - Daily wages laborer | 31 (10.47%) | 36 (12.16%) |
| - Not working | 236 (79.73%) | 237(80.07%) |
| House ownership | ||
| - Shared accommodation | 15 (5.07%) | 11 (3.72%) |
| - On rent | 122 (41.21%) | 114 (38.51%) |
| - Own house | 159 (53.72%) | 171 (57.77%) |
| Illiterate | 150 (50.68%) | 160 (54.05%) |
| H/o smoking | 21 (7.09%) | 20 (6.76%) |
| H/o high cholesterol | 16 (5.41%) | 12 (4.05%) |
| H/o exercise | 51 (17.23%) | 35 (11.83%) |
| Past h/o depression | 49 (16.55%) | 41 (13.85%) |
| Annotation type | Content | Elements involved |
| Curatorial | Meta annotation referring annotations commented on by a curator. Each annotated value can be accepted, rejected and discussed | All elements of the curated annotation |
| Batch | Meta annotation linking identical annotations referring to different annotated records | All elements of the linked annotation(s) |
| CuratorialBatch | Meta annotation referring to all curated annotations of a Batch and its annotation type. Each annotated value can be accepted, rejected or commented by the curator for all annotations linked by the referred Batch | All elements of the curated BatchAnnotations |
| Outcome | Persons with symptomatic RHOA (n = 718), mean (s.d.) | Persons with EOA (n = 80), mean (s.d.) | Adjusted mean differencea (95% CI) |
| Female, n (%) | 442 (62) | 67 (84) | 22.2 (13.4, 31.0) |
| Age, years | 66.1 (8.1) | 69.2 (7.8) | 3.1 (1.3, 5.0) |
| BMI, kg/m2 | 29.3 (5.1) | 28.7 (5.1) | −0.6 (−1.7, 0.6) |
| AUSCAN pain | 6.6 (4.2) | 8.0 (4.2) | 1.3 (0.3, 2.3) |
| AUSCAN stiffness | 1.1 (0.9) | 1.5 (1.0) | 0.3 (0.1, 0.6) |
| AUSCAN function | 10.4 (8.1) | 13.8 (8.0) | 2.3 (0.4, 4.2) |
| AIMS-2 pain subscale | 3.8 (2.3) | 4.7 (2.6) | 0.8 (0.3, 1.4) |
| AIMS-2 hand/finger function | 2.2 (2.1) | 3.1 (2.4) | 0.8 (0.2, 1.3) |
| AIMS-2 impact subscale | 2.2 (2.1) | 2.6 (2.2) | 0.5 (−0.05, 1.0) |
| Power grip, lbs | 50.7 (25.6) | 37.4 (18.9) | −3.0 (−7.1, 1.1) |
| Pulp pinch, lbs | 10.3 (4.1) | 8.4 (2.7) | −0.3 (−1.0, 0.4) |
| GAT | 31.8 (12.9) | 32.3 (9.8) | −0.7 (−4.7, 3.4) |
| SF-12 PCS | 37.6 (11.8) | 37.0 (11.3) | 0.5 (−2.4, 3.4) |
| SF-12 MCS | 50.4 (10.8) | 53.0 (9.3) | 2.9 (0.2, 5.5) |
| MHQ aesthetics subscale | 72.2 (20.5) | 52.2 (23.7) | −17.6 (−22.8, −12.5) |
| Eikelboom morphotypea | Taxonomy | Classification | ||||
| Phylum | Class | Order | Family | Genus | ||
| 0092 (30) | RDPb | Chloroflexi | Anaerolineae | Anaerolineales | Anaerolineaceae | |
| Greengenesc | Chloroflexi | Anaerolineae | DRC31 | |||
| SILVAd | Chloroflexi | Ardenticatenia | ||||
| MiDASe | Chloroflexi | Ardenticatenia | 419 | 2-1 | B45 | |
| 0803 (27) | RDP | Chloroflexi | Caldilineae | Caldilineales | Caldilineaceae | Caldilinea |
| Greengenes | Chloroflexi | Anaerolineae | Caldilineales | Caldilineaceae | Caldilinea | |
| SILVA | Chloroflexi | Caldilineae | Caldilineales | Caldilineaceae | ||
| MiDAS | Chloroflexi | Caldilineae | Caldilineales | Caldilineaceae | P2CN44 | |
| 0914 (31) | RDP | Chloroflexi | Caldilineae | Caldilineales | Caldilineaceae | |
| Greengenes | Chloroflexi | Anaerolinea | SHA-20 | |||
| SILVA | Chloroflexi | |||||
| MiDAS | Chloroflexi | SJA-15 | 1-20 | 1-20 | Ca. Sarcinathrix | |
| 1851 (28, 32) | RDP | Chloroflexi | Chloroflexia | Chloroflexales | Chloroflexineae | Roseiflexus |
| Greengenes | Chloroflexi | Chloroflexi | Roseiflexales | Kouleothrixaceae | Kouleothrix | |
| SILVA | Chloroflexi | Chloroflexia | Chloroflexales | Roseiflexaceae | Roseiflexus | |
| MiDAS | Chloroflexi | Chloroflexia | Chloroflexales | Roseiflexaceae | Kouleothrix |
| Variables | Codes | ||
| −1 | 0 | +1 | |
| Frying temperature (°C) | 140 | 150 | 160 |
| Frying time (min) | 2 | 3 | 4 |
| Level of BSCF (%) | 20 | 30 | 40 |
| Thickness (mm) | 2 | 3 | 4 |
| Material | Element type | Constitutive relation | Material properties |
| Bony structures | |||
| Vertebral cortical bone, endplates, and posterior cortical bone | 8 Nodes brick element (C3D8) | Isotropic, elastic | E = 12,000 MPa ν = 0.3 |
| Vertebral cancellous bone and posterior cancellous bone | 8 Nodes brick element (C3D8) | Isotropic, elastic | E = 100 MPa ν = 0.2 |
| Ligaments | Elastic modulus MPa (strain %) | ||
| Anterior longitudinal | Tension-only, truss elements (T3D2) | Hypoelastic | 7.8 (<12%), 20.0 (>12%) ν = 0.3 |
| Posterior longitudinal | Tension-only, truss elements (T3D2) | Hypoelastic | 10.0 (<11%), 20.0 (>11%) ν = 0.3 |
| Ligamentum flavum | Tension-only, truss elements (T3D2) | Hypoelastic | 15.0 (<6.2%), 19.5 (>6.2%) ν = 0.3 |
| Intertransverse | Tension-only, truss elements (T3D2) | Hypoelastic | 10.0 (<18%), 58.7 (>18%) ν = 0.3 |
| Interspinous | Tension-only, truss elements (T3D2) | Hypoelastic | 10.0 (<14%), 11.6 (>14%) ν = 0.3 |
| Supraspinous | Tension-only, truss elements (T3D2) | Hypoelastic | 8.0 (<20%), 15.0 (>20%) ν = 0.3 |
| Capsular | Tension-only, truss elements (T3D2) | Hypoelastic | 7.5 (<25%), 32.9 (>25%) ν = 0.3 |
| Intervertebral disk | |||
| Nucleus pulposus | 8 Nodes brick element (C3D8) | Isotropic, elastic | E = 2 MPa ν = 0.499 |
| Annulus fibrosus | 8 Nodes brick element (C3D8) | Hyperelastic anisotropic (HGO) | Table 2 |
| Apophyseal joints | GAPUNI elements | Non-linear soft contact | Pressure overclosure = 12,000 MPa |
| Men | Women | |||||||||||||
| Model 0 | Model 1 | Model 2 | Model 0 | Model 1 | Model 2 | Model 3b | ||||||||
| OR | OR | OR | OR | OR | OR | OR | ||||||||
| Intercept | 0.21 | *** | 0.07 | *** | 0.07 | *** | 0.18 | *** | 0.08 | *** | 0.09 | *** | 0.09 | *** |
| (1) Individual variablesa | ||||||||||||||
| Education Level (ref. University Studies) | ||||||||||||||
| Illiterate, no diploma, or primary education | 1.41 | *** | 1.40 | *** | 1.67 | *** | 1.70 | *** | 1.71 | *** | ||||
| Lower Secondary | 1.21 | ** | 1.20 | ** | 1.35 | *** | 1.37 | *** | 1.38 | *** | ||||
| Upper Secondary | 1.19 | * | 1.19 | ** | 1.28 | ** | 1.30 | *** | 1.26 | ** | ||||
| Higher technical education | 1.04 | 1.04 | 1.26 | * | 1.26 | * | 1.25 | * | ||||||
| (2) Period Variables | ||||||||||||||
| Period (ref. 2006) | ||||||||||||||
| 2009 | 1.01 | 1.04 | 1.05 | 0.94 | 0.93 | |||||||||
| 2011 | 1.13 | * | 0.96 | 1.14 | ** | 0.99 | 1.00 | |||||||
| Change in real GDP growth rate | 1.01 | 0.95 | 0.94 | |||||||||||
| Change in low work intensity indicator | 1.04 | ** | 0.99 | 0.97 | ||||||||||
| (3) Context Variables | ||||||||||||||
| Mean real GDP growth rate | 0.96 | 0.98 | 0.97 | |||||||||||
| Mean low work intensity indicator | 1.02 | * | 1.04 | ** | 1.04 | ** | ||||||||
| (1) Education level* (2) Period Variables | ||||||||||||||
| Illiterate, no diploma, or primary education* Change in Low work intensity indicator | 1.03 | + | ||||||||||||
| Variance | ||||||||||||||
| Region | 0.013 | (0.013) | 0.025 | (0.023) | 0.019 | (0.019) | 0.054 | (0.030) | 0.066 | (0.048) | 0.026 | (0.028) | 0.030 | (0.028) |
| Period | 0.034 | (0.019) | 0.016 | (0.020) | 0.010 | (0.012) | 0.007 | (0.007) | 0.005 | (0.007) | 0.006 | (0.007) | 0.005 | (0.007) |
| VPC | ||||||||||||||
| Regionb | 0.4 % | 0.8 % | 0.6 % | 1.6 % | 2.0 % | 0.8 % | 0.9 % | |||||||
| Periodc | 1.0 % | 0.5 % | 0.3 % | 0.2 % | 0.1 % | 0.2 % | 0.2 % | |||||||
| VPC at higher levels (Region + Period) | 1.4 % | 1.2 % | 0.9 % | 1.8 % | 2.1 % | 1.0 % | 1.1 % | |||||||
| DIC: | 8762.19 | 7419.424 | 7412.147 | 8950.835 | 7963.463 | 7964.03 | 7960.65 | |||||||
| Units: Region | 17 | 17 | 17 | 17 | 17 | 17 | 17 | |||||||
| Units: Period | 51 | 51 | 51 | 51 | 51 | 51 | 51 | |||||||
| Units: Individuals | 21,260 | 21,052 | 21,052 | 26,182 | 25,919 | 25,919 | 25,919 |
| Frequency | |||
| Current employment | Not working as nurses | Total | |
| 1994 | 18 | 5 | 23 |
| 1995 | 13 | 5 | 18 |
| 1996 | 15 | 6 | 21 |
| 1997 | 23 | 2 | 25 |
| 2001 | 20 | 4 | 24 |
| 2002 | 22 | 3 | 25 |
| 2005 | 23 | 3 | 26 |
| 2006 | 16 | 0 | 16 |
| 2007 | 19 | 2 | 21 |
| 2009 | 20 | 1 | 21 |
| 2011 | 11 | 1 | 12 |
| Total | 200 | 33 | 233 |
| LFI strip test | DAS ELISA (OD) | ||
| Pig 77 | Swap 1 | + | 1.717 |
| Swap 2 | + | 1.3 | |
| Swap 3 | + | 0.307 | |
| Pig 78 | Swap 1 | + | 0.604 |
| Pig 79 | Swap 1 | + | 1.589 |
| Swap 2 | + | 0.833 | |
| Swap 3 | + | 2.04 | |
| Pig 80 | Swap 1 | + | 3.079 |
| Swap 2 | + | 3.372 | |
| Swap 3 | + | 2.713 | |
| Swap 4 | + | 2.918 |
| Causes of pulmonary hypertension in ICU | Causes of RV failure in ICU |
| 1) PAH (for example, preexisting PAH; PoPH (8.5% ESLD) | 1) RV Pressure overload, pulmonary hypertension, any cause |
| 2) Elevated LAP: RV pressure overload (left-sided myocardial infarction/cardiomyopathy; mitral regurgitation; pulmonary stenosis) | 2) Reduced RV contractility |
| 3) PH due to hypoxia: acute (for example, ARDS)/preexisting lung disease (for example, COPD, IPF) | RV infarction; sepsis; RV cardiomyopathy; myocarditis; pericardial disease; LVAD; after CPB; after cardiac surgery/transplantation |
| 4) Thromboembolic (for example, acute PE; chronic (CTEPH); other causes of emboli (AFE, air, cement) | 3) RV-volume overload |
| 5) Mechanical (for example, increased Pplat - IPPV | Cardiac causes: tricuspid and pulmonary regurgitation; intracardiac shunts |
| Gene | 5′–3′ sequence |
| P5CS1 | F‐GTAGACGACGACGACGATAATG |
| R‐ACTGCTGTCCCAACCTTAAC | |
| P5CS2 | F‐GGTGCTGAGGTGGGAATAAG |
| R‐ACTTGTCCCTTTCCTCTCATTATC | |
| P5CR | F‐GAGGAGTAGCTGCTGGTTTAC |
| R‐CCTGGATGCTTCCCAGTTT | |
| OAT | F‐TGCTTGAGCTTGAAGGAGAG |
| R‐GATCCATCTCGGAGTTCATCAG | |
| PDH1 | F‐AGCAGCTCATGGAAGGATTC |
| R‐GGGTTGGAGGATTGTGTCTT | |
| PDH2 | F‐GCGTAGAACACGCTGAAGA |
| R‐GCTTAAGTGAGACGAAGGTAGG | |
| P5CDH | F‐AGGATGCACGCTCATCTAAC |
| R‐CCAGCATATGTAGTCCCATTCA | |
| GAPDH | F‐TTGTTGTTGAGTCCACTG |
| R‐CTTGTATTCCTTCTCGTTGA |
| First quartile | Third quartile | |
| Shortwave radiation | 164.97 (1.41)* | 141.35(1.14) |
| HDD | 134.62(1.22) | 168.11(1.39) |
| Snowfall | 135.04(1.24) | 163.66(1.42) |
| Rainfall | 164.69 (1.60) | 131.82(1.32) |
| Permitted air emissions | 142.96(1.09) | 149.01(1.12) |
| Acres of land used to grow crops | 142.09(1.29) | 157.14(1.53) |
| Author | Country | Year | Type of study | Patients | Control | Cut off (pmol/L) | TP | FP | FN | TN | SEN | SPE |
| Moore RG et al. [5] | USA | 2008 | prospective/retrospective | 171 | 156 | / | 78 | 8 | 93 | 148 | 46 | 95 |
| Zanotti L et al. [6] | Italy | 2012 | retrospective | 193(152 + 41) | 125 | 51 | 152 | 19 | 41 | 106 | 79 | 85 |
| 64 | 127 | 6 | 66 | 119 | 66 | 95 | ||||||
| Angioli R et al. [7] | Italy | 2013 | prospective | 101(95 + 6) | 103 | 70 | 60 | 0 | 41 | 103 | 59 | 100 |
| 150 | 36 | 0 | 65 | 103 | 36 | 100 | ||||||
| Omer Bet al. [8] | Turkey | 2013 | prospective l | 64(54 + 10) | 94(60 + 34) | 60 | 48 | 32 | 16 | 62 | 75 | 66 |
| Bignotti E et al. [9] | Italy | 2011 | prospective | 138(109 + 29) | 76 | / | 92 | 4 | 46 | 72 | 67 | 95 |
| Zhang, Ai-min et al. [10] | China | 2012 | prospective | 124 | 206(97 + 109) | / | 51 | 10 | 73 | 196 | 41 | 95 |
| Total | 791 | 760 |
| Training description | Related themes |
| 1. Video: Invite for the workshop and foundational information on Rx for Change and systematic reviews | Need for knowledgeDiversity in delivery |
| 2. Face-to-face workshop (1 hour) | Didactic presentation: Need for knowledgeHands on skills training: Need for skill development in navigating the database and integrating evidence into decision-making, tailoringDiscussion: Knowledge and skillsHandouts: Need for knowledge, variety in delivery methods |
| 3. Post-training remindersDelivery: Emailed at 1 and 3 months post-workshopContent: Cues and/or reminders regarding the database’s use, value, updates, and navigation tips | Routine habits |
| Motif | Number of matches |
| P. pastoris AT-ACS | 15 |
| P. pastoris GC-ACS | 1 |
| S. cerevisiae 11 bp ACS | 11 |
| S. cerevisiae 17 bp ACS | 6 |
| Characteristic | Overall | AKI | No AKI | |||
| N | % | N | % | N | % | |
| N | 14,651 | 1966 | (13.4% of cohort) | 12,685 | (86.6% of cohort) | |
| Age in years (median & IQR) | 69 | (54–78) | 73 | (63–81) | 68 | (53–78) |
| Female | 8317 | (56.8) | 1011 | (51.4) | 7306 | (57.6) |
| Residential care | 433 | (3.0) | 111 | (5.6) | 322 | (2.5) |
| Deprived home locationa | 1215 | (8.3) | 169 | (8.6) | 1046 | (8.2) |
| Rural home location | 4014 | (27.4) | 551 | (28.0) | 3463 | (27.3) |
| Emergency hospital admission | 8689 | (59.3) | 1580 | (80.4) | 7109 | (56.0) |
| Medical specialty admission | 7203 | (49.2) | 1336 | (68.0) | 5867 | (46.3) |
| Critical care admission | 1288 | (8.8) | 529 | (26.9) | 759 | (6.0) |
| Intensive care admission | 428 | (2.9) | 276 | (14.0) | 152 | (1.2) |
| Length of hospital stay in days (median & IQR) | 3 | (1–9) | 14 | (7–31) | 2 | (1–7) |
| Cancer | 1011 | (6.9) | 201 | (10.2) | 810 | (6.4) |
| Cardiac failure | 668 | (4.6) | 181 | (9.2) | 487 | (3.8) |
| Cerebrovascular disease | 613 | (4.2) | 124 | (6.3) | 489 | (3.9) |
| Dementia | 150 | (1.0) | 30 | (1.5) | 120 | (0.9) |
| Diabetes | 917 | (6.3) | 255 | (13.0) | 662 | (5.2) |
| Liver disease | 189 | (1.3) | 49 | (2.5) | 140 | (1.1) |
| Myocardial infarction | 735 | (5.0) | 182 | (9.3) | 553 | (4.4) |
| Neurologic disease | 76 | (0.5) | 20 | (1.0) | 56 | (0.4) |
| Peptic disease | 304 | (2.1) | 66 | (3.4) | 238 | (1.9) |
| Peripheral vascular disease | 487 | (3.3) | 140 | (7.1) | 347 | (2.7) |
| Pulmonary disease | 836 | (5.7) | 199 | (10.1) | 637 | (5.0) |
| Rheumatic disease | 312 | (2.1) | 68 | (3.5) | 244 | (1.9) |
| Baseline (pre-episode) eGFR (median & IQR) | 66.8 | (53.0–88.2) | 75.3 | (53.9–91.8) | 65.8 | (52.9–87.3) |
| Post-episode eGFRb | ||||||
| ≥60 | 9004 | (61.5) | 955 | (48.6) | 8049 | (63.5) |
| 45–59 | 3369 | (23.0) | 444 | (22.6) | 2925 | (23.1) |
| 30–44 | 1733 | (11.8) | 374 | (19.0) | 1359 | (10.7) |
| <30 | 545 | (3.7) | 193 | (9.8) | 352 | (2.8) |
| Intra-episode background change in eGFRc | ||||||
| >30% rise | 1135 | (7.7) | 67 | (3.4) | 1068 | (8.4) |
| 10%–30% rise | 2069 | (14.1) | 120 | (6.1) | 1949 | (15.4) |
| No change | 7654 | (52.2) | 517 | (26.3) | 7137 | (56.3) |
| 10%–30% fall | 2990 | (20.4) | 757 | (38.5) | 2233 | (17.6) |
| >30% fall | 803 | (5.5) | 505 | (25.7) | 298 | (2.3) |
| Post-episode proteinuriad | ||||||
| Untested | 13069 | (89.2) | 1550 | (78.8) | 11519 | (90.8) |
| Normal | 753 | (5.1) | 136 | (6.9) | 617 | (4.9) |
| Abnormal | 829 | (5.7) | 280 | (14.2) | 549 | (4.3) |
| AKI stage | ||||||
| 0 | 12685 | (86.6) | n/a | – | 12685 | (100.0) |
| 1 | 1355 | (9.2) | 1355 | (68.9) | n/a | – |
| 2 | 410 | (2.8) | 410 | (20.9) | n/a | – |
| 3 | 201 | (1.4) | 201 | (10.2) | n/a | – |
| Prior AKI episodes | 1358 | (9.3) | 356 | (18.1) | 1002 | (7.9) |
| Variables | Total cohort | Tsunami group | Radiation group | p valuea |
| Physical examination | ||||
| Body weight (kg) | 58.5 (52.0–66.0) | 57.9 (52.6–65.9) | 59.5 (51.9–66.3) | n.s. |
| BMI (kg/m2) | 24.2 (22.4–26.1) | 24.2 (22.1–26.3) | 24.3 (22.6–26.0) | n.s. |
| High BMI | 32 (16.2) | 17 (15.7) | 15 (16.7) | n.s. |
| Waist circumference (cm) | 86.5 (81.9–92.5) | 86.0 (81.2–92.5) | 87.0 (82.3–92.5) | n.s. |
| High waist circumference | 83 (41.5) | 45 (41.7) | 38 (41.3) | n.s. |
| Systolic blood pressure (mmHg) | 132 (124–146) | 131 (124–144) | 134 (126–148) | n.s. |
| High systolic blood pressure | 102 (51.0) | 54 (50.0) | 48 (52.2) | n.s. |
| Diastolic blood pressure (mmHg) | 80 (70–84) | 76 (70–84) | 80 (76–86) | 0.002 |
| High diastolic blood pressure | 48 (24.0) | 22 (20.4) | 26 (28.3) | n.s. |
| Laboratory examination | ||||
| HbA1c (%) | 5.5 (5.4–5.9) | 5.5 (5.4–5.9) | 5.5 (5.2–5.8) | n.s. |
| High HbA1c | 62 (31.0) | 37 (34.3) | 25 (27.2) | n.s. |
| HDL cholesterol (mmol/L) | 1.47 (1.22–1.76) | 1.53 (1.27–1.81) | 1.42 (1.14–1.69) | 0.02 |
| Low HDL cholesterol | 19 (9.5) | 6 (5.6) | 13 (14.3) | 0.04 |
| LDL cholesterol (mmol/L) | 3.08 (2.64–3.62) | 3.05 (2.59–3.59) | 3.13 (2.57–3.66) | n.s. |
| High LDL cholesterol | 48 (24.1) | 23 (21.3) | 25 (27.5) | n.s. |
| Triglyceride (mmol/L) | 1.00 (0.75–1.57) | 1.02 (0.72–1.54) | 1.00 (0.78–1.69) | n.s. |
| High triglyceride | 46 (23.1) | 23 (21.3) | 23 (25.3) | n.s. |
| Treatment status | ||||
| Periodic clinic visits for chronic metabolic diseases | 102 (51.0) | 50 (46.3) | 52 (56.5) | n.s. |
| Disease for periodic clinic visits | ||||
| Hypertension | 89 (44.5) | 43 (39.8) | 46 (50.0) | n.s. |
| Dyslipidemia | 16 (8.0) | 7 (6.5) | 9 (9.8) | |
| Diabetes | 12 (6.0) | 4 (3.7) | 8 (8.7) | |
| Hyperuricemia | 3 (1.5) | 0 (0.0) | 3 (3.3) | |
| Cardiovascular | 11 (5.5) | 4 (3.7) | 7 (7.6) | |
| Medication for chronic metabolic diseases | 97 (48.5) | 45 (41.7) | 52 (56.5) | 0.04 |
| Chromosomal arm | Total no. informative SNPs with LOH | No. informative SNPs with LOH and CN = 1 (fraction) | No. informative SNPs with LOH and CN = 2 (fraction) | No. informative SNPs with LOH and CN = 3 or 4 (fraction) |
| 1p | 10,576 | 2,930 (0.28) | 6,522 (0.62) | 1,124 (0.11) |
| 1q | 8,366 | 459 (0.05) | 7,674 (0.92) | 233 (0.03) |
| 2p | 11,321 | 371 (0.03) | 10,770 (0.95) | 180 (0.02) |
| 2q | 23,115 | 3,015 (0.13) | 18,939 (0.82) | 1,161 (0.05) |
| 3p | 27,593 | 15,335 (0.56) | 12,064 (0.44) | 194 (0.01) |
| 3q | 7,256 | 41 (0.01) | 4,168 (0.57) | 3,047 (0.42) |
| 4p | 12,223 | 4,771 (0.39) | 7,452 (0.61) | 0 (0) |
| 4q | 28,105 | 9,142 (0.33) | 17,905 (0.64) | 1,958 (0.04) |
| 5p | 1,315 | 0 (0) | 1,259 (0.96) | 56 (0.04) |
| 5q | 16,537 | 7,744 (0.47) | 8,777 (0.53) | 16 (0) |
| 6p | 5,622 | 342 (0.06) | 4,870 (0.87) | 410 (0.07) |
| 6q | 3,365 | 165 (0.05) | 2,773 (0.82) | 427 (0.13) |
| 7p | 7,389 | 9 (0) | 5,491 (0.74) | 1,889 (0.26) |
| 7q | 8,001 | 151 (0.02) | 6,452 (0.74) | 1,398 (0.17) |
| 8p | 8,803 | 1,580 (0.18) | 6,234 (0.71) | 989 (0.11) |
| 8q | 17,321 | 47 (0) | 4,633 (0.27) | 12,641 (0.74) |
| 9p | 18,292 | 2,772 (0.15) | 13,333 (0.73) | 2,187 (0.12) |
| 9q | 31,400 | 1,965 (0.06) | 27,212 (0.87) | 2,223 (0.07) |
| 10p | 2,739 | 472 (0.17) | 2,063 (0.75) | 204 (0.07) |
| 10q | 14,651 | 1,728 (0.12) | 12,075 (0.82) | 848 (0.06) |
| 11p | 9,391 | 2,367 (0.25) | 6,902 (0.73) | 122 (0.01) |
| 11q | 17,377 | 5,116 (0.29) | 10,422 (0.60) | 1,839 (0.11) |
| 12p | 5,229 | 156 (0.03) | 3,251 (0.62) | 1,822 (0.34) |
| 12q | 6,794 | 67 (0.01) | 5,980 (0.88) | 747 (0.11) |
| 13q | 35,648 | 5,897 (0.17) | 25,964 (0.73) | 3,787 (0.11) |
| 14q | 10,931 | 1,484 (0.14) | 7,446 (0.68) | 2,001 (0.18) |
| 15q | 10,194 | 685 (0.07) | 8,313 (0.82) | 1,196 (0.12) |
| 16p | 1,395 | 111 (0.08) | 1,284 (0.92) | 0 (0) |
| 16q | 3,127 | 1 (0) | 2,832 (0.91) | 294 (0.09) |
| 17p | 7,719 | 324 (0.04) | 6,939 (0.90) | 456 (0.06) |
| 17q | 16,328 | 38 (0) | 14,754 (0.90) | 1,536 (0.09) |
| 18p | 2,596 | 488 (0.19) | 1,147 (0.44) | 961 (0.37) |
| 18q | 9,978 | 3,108 (0.31) | 6,838 (0.69) | 32 (0) |
| 19p | 1,069 | 1 (0) | 1,065 (1.00) | 3 (0) |
| 19q | 3,505 | 932 (0.27) | 2,482 (0.71) | 91 (0.03) |
| 20p | 1,278 | 0 (0) | 229 (0.18) | 1,049 (0.82) |
| 20q | 1,773 | 60 (0.03) | 1,677 (0.95) | 36 (0.02) |
| 21q | 9,444 | 3,825 (0.41) | 5,599 (0.59) | 20 (0) |
| 22q | 4,177 | 621 (0.15) | 3,274 (0.80) | 222 (0.05) |
| Range (fraction SNPs with LOH) | 0-0.56 | 0.18-1.00 | 0-0.82 | |
| Median (fraction SNPs with LOH) | 0.05 | 0.71 | 0.05 | |
| Global average (fraction SNPs with LOH) | 0.19 | 0.70 | 0.11 |
| Driers | Appearance | Odor | Taste | Flavor | Texture | Palability | Acceptability | Shelf-life (1–30 days) |
| Plastic | Attractive | Pleasant | Fair | Fair | Hard | Good | Moderate | Long |
| Mosquito net | Attractive | Pleasant | Good | Good | Very hard | Good | High | Long |
| Glass | Very attractive | Pleasant | Very good | Very good | Very hard | Good | Very high | Longer |
| Aluminum | Attractive | Pleasant | Good | Good | Very hard | Good | High | Longer |
| Glass with black stone | Very attractive | Very pleasant | Very good | Very good | Very hard | Very good | Very high | Longest |
| Open-sun drying (control) | Not attractive | Not pleasant | Fair | Fair | Hard | Fair | Low | Not long |
| Condition | EGL | ESL | LSL | ESL (n.a.) | LSL (n.a.) |
| correct | 94.7 (0.9) | 92.0 (1.2) | 82.5 (2.6) | 92.0 (1.6) | 82.1 (3.5) |
| semantics | 97.6 (0.8) | 94.2 (1.2) | 94.5 (1.8) | 93.1 (3.4) | 84.1 (5.9) |
| syntax | 95.5 (1.9) | 77.3 (4.2) | 80.5 (4.5) | 27.8 (11.6) | 34.3 (10.6) |
| Opioids | Crystalloid | Colloid | P value |
| Fentanyl (mcg) | 25 (0.0–100) | 25 (0.0–75.0) | 0.52 |
| Pethidine (mg) | 10.3 (23.7) | 4.9 (16.2) | 0.17 |
| Rescue Anti-emetics | |||
| Number of Patients Requiring Rescue | |||
| Anti-emetics N(%) | 9 (16.9) | 5 (5.3) | 0.37 |
| Time of Anti-emetic administration. N (%) | |||
| 0–30 min | 2 (3.6) | 3 (5.3) | 0.98 |
| 30 min–2 hrs | 5 (9.1) | 2 (3.5) | 0.42 |
| 2–24 hrs | 3 (5.7) | 0 (0.0) | 0.22 |
| Sl. no | Hydrophobic substrates | Emulsification index (%) | |
| 24 h | 168 h | ||
| 1 | n-Hexadecane | 25.19 ± 0.12 | 22.58 ± 0.11 |
| 2 | Sunflower oil | 33.33 ± 0.87 | 5.26 ± 0.53 |
| 3 | Motor oil | 62.26 ± 0.32 | 60.00 ± 0.12 |
| 4 | Diesel | 25.00 ± 0.25 | 5.00 ± 0.43 |
| 5 | Crude oil | 100.00 ± 0.32 | 83.33 ± 0.23 |
| Procedure | Number |
| Abdominal aortic aneurysm repair | 1 |
| Abdominoperineal resection | 1 |
| Atrial septal defect closure | 2 |
| Bronchoscopy | 1 |
| Coronary artery bypass grafting | 2 |
| Cardiac ablation | 1 |
| Cardiac catheterization | 3 |
| Inadvertent air bolus via IV line | 1 |
| Central vascular access | 9 |
| Endoscopic Retrograde Cholangio-Pancreatography (ERCP) | 1 |
| Hysteroscopy | 1 |
| Laparoscopic liver resection | 2 |
| Necrotic bowel resection | 1 |
| Endovascular neurointervention | 2 |
| Neurosurgery (open procedures) | 11 |
| Pacemaker placement | 1 |
| Spinal surgery | 2 |
| Transarterial chemoembolization (TACE) | 1 |
| Cardiac valve replacement | 4 |
| Varicose vein injection | 2 |
| Base | P30 | P60 | ||
| Brachial systolic blood pressure (mmHg) | Before | 117 ± 13 | 116 ± 8 | 116 ± 8 |
| After | 117 ± 10 | 116 ± 11 | 119 ± 12 | |
| Brachial mean arterial blood pressure (mmHg) | Before | 90 ± 10 | 92 ± 9 | 92 ± 9 |
| After | 91 ± 8 | 89 ± 9 | 92 ± 10 | |
| Brachial diastolic blood pressure (mmHg) | Before | 73 ± 10 | 73 ± 9 | 71 ± 7 |
| After | 70 ± 8 | 71 ± 8 | 74 ± 9 | |
| Brachial pulse pressure (mmHg) | Before | 44 ± 8 | 43 ± 7 | 45 ± 7 |
| After | 47 ± 7 | 45 ± 8 | 46 ± 8 | |
| Carotid systolic blood pressure (mmHg) | Before | 109 ± 5 | 107 ± 3 | 107 ± 3 |
| After | 109 ± 4 | 106 ± 4 | 110 ± 4 | |
| Carotid pulse pressure (mmHg) | Before | 37 ± 3 | 34 ± 2 | 36 ± 2 |
| After | 39 ± 3 | 35 ± 2 | 36 ± 3 | |
| Heart rate (bpm) | Before | 58 ± 7 | 62 ± 5 | 60 ± 5 |
| After | 56 ± 6 | 60 ± 7a | 60 ± 8 | |
| β‐stiffness (U) | Before | 7.4 ± 3.9 | 6.6 ± 3.5 | 6.9 ± 4.0 |
| After | 6.2 ± 3.0b | 5.6 ± 2.8a,b | 6.2 ± 2.7 |
| Climate/geography‡ | PC1 | PC2 | PC3 | DRYWT | HT | HEAD | LFRATIO | LFCOL | LFPUB | HABIT | AWNS | GERM |
| MAT | 0.08 | −0.20 | 0.48 | 0.09 | 0.09 | −0.40 | 0.53 | −0.16 | 0.07 | 0.05 | −0.18 | 0.03 |
| MWMT | −0.14 | −0.18 | 0.47 | −0.14 | 0.00 | −0.40 | 0.55 | −0.31 | 0.15 | 0.14 | −0.32 | 0.17 |
| MCMT | 0.31 | −0.05 | 0.31 | 0.29 | 0.25 | −0.14 | 0.29 | 0.10 | −0.05 | −0.03 | 0.17 | −0.12 |
| TD | −0.42 | −0.14 | 0.20 | −0.40 | −0.22 | −0.27 | 0.30 | −0.40 | 0.19 | 0.17 | −0.47 | 0.27 |
| MAP | 0.35 | 0.19 | −0.47 | 0.31 | 0.10 | 0.15 | −0.48 | 0.25 | −0.39 | −0.41 | 0.26 | 0.06 |
| MSP | 0.37 | 0.19 | −0.50 | 0.32 | 0.09 | 0.18 | −0.51 | 0.26 | −0.43 | −0.48 | 0.27 | 0.00 |
| AHM | −0.35 | −0.23 | 0.54 | −0.27 | −0.12 | −0.24 | 0.63 | −0.32 | 0.34 | 0.38 | −0.28 | 0.02 |
| SHM | −0.36 | −0.30 | 0.48 | −0.30 | −0.20 | −0.33 | 0.58 | −0.32 | 0.39 | 0.37 | −0.29 | 0.04 |
| FFP | 0.20 | −0.32 | 0.18 | 0.13 | −0.05 | −0.43 | 0.24 | −0.11 | 0.04 | −0.22 | −0.20 | −0.06 |
| PAS | 0.01 | 0.20 | −0.53 | −0.01 | −0.07 | 0.21 | −0.50 | 0.08 | −0.31 | −0.21 | 0.13 | 0.20 |
| ELEV | −0.26 | 0.29 | −0.33 | −0.29 | 0.04 | 0.43 | −0.39 | 0.04 | 0.00 | 0.17 | 0.23 | 0.07 |
| LAT | 0.36 | −0.34 | 0.00 | 0.38 | −0.17 | −0.33 | 0.08 | 0.15 | −0.01 | −0.38 | −0.20 | −0.24 |
| LON | −0.06 | 0.03 | −0.14 | −0.08 | −0.01 | −0.10 | −0.18 | −0.11 | −0.18 | −0.13 | −0.22 | 0.20 |
| SCC (n = 395) | AC (n = 95) | p-value | |
| Male | 317(80.3) | 71(74.7) | 0.23 |
| Age | |||
| < 60 | 195(49.4) | 32(33.7) | 0.006 |
| 60-69 | 118(29.9) | 26(27.4) | |
| 70- | 82(20.8) | 37(38.9) | < 0.0001 |
| G3+4 | 192(48.6) | 61(64.2) | 0.02 |
| T1-2 | 94(25.5) | 17(20.5) | 0.33 |
| T3 | 201(50.9) | 51(53.7) | n.s. |
| T4 | 73(18.5) | 15(15.8) | n.s. |
| N+ | 198(50.1) | 48(50.5) | n.s. |
| M1 | 83(22.0) | 28(32.2) | 0.04 |
| Treatment | P | |||
| LNG-IUD | NETA | |||
| n (%) | n (%) | |||
| Initial Mens | HMB | 30 (%100) | 30 (%100) | 1,000 |
| 3-6. months Mens | ● HMB | 2 (%7,1) | 4 (%20) | 0,218 |
| Spotting | 18 (%64,3) | 6 (%30) | 0,0,019* | |
| ●Amenorrhea | 2 (%7,1) | 1 (%5) | 1,000 | |
| Normal Cycle | 3 (%10,7) | 7 (%35) | 0,041* | |
| ●Oligomenorrhea | 3 (%10,7) | 2 (%10) | 1,000 | |
| HMB Spotting | 1 (%3,7)7 (%25,9) | 5 (%27,8)4 (%22,2) | 0,031*0,777 | |
| Amenorrhea | 12 (%44,4) | 1 (%5,6) | 0,006** | |
| ●Normal Cycle | 2 (%7,4) | 6 (%33,3) | 0,045* | |
| ●Oligomenorrhea | 5 (%18,5) | 2 (%11,1) | 0,684 |
| Population | Genomic region | Number of windows | MinimumPperm | RefSeq genes | |||||
| ID | Name | Cluster | Chr | Begin (bp) | End (bp) | Length (bp) | |||
| ITU | Telugu | A | 10 | 132,953,074 | 133,048,305 | 95,232 | 189 | 0.013 | TCERG1L |
| PJL | Punjabi | A | 13 | 20,001,572 | 20,181,691 | 180,120 | 28 | 0.044 | TPTE2 |
| Component | M. indicus | R. oryzae |
| Biomass (g/L) | 4.7 ± 0.2 | 4.0 ± 0.1 |
| Biomass yield (g/g sugars consumed) | 0.25 ± 0.01 | 0.28 ± 0.00 |
| Protein 1 | 0.40 ± 0.01 | 0.51 ± 0.07 |
| Total lipids 1 | 0.098 ± 0.011 | 0.044 ± 0.007 |
| AIM 2 yield 1 | 0.31 ± 0.01 | 0.34 ± 0.01 |
| Raw meats | Cooked meats | |||||
| Fatty acidsA | DCCOC | DCCOM | DCCOH | DCCOC | DCCOM | DCCOH |
| MC (%) | 70.7 ± 0.6 | 72.0 ± 0.6 | 72.3 ± 0.5 | 61.6 ± 1.0 | 59.7 ± 1.6 | 59.4 ± 1.7 |
| IMF (%) | 3.5 ± 0.4 | 3.7 ± 0.6 | 2.9 ± 0.3 | 5.5 ± 0.6 | 5.0 ± 0.6 | 4.7 ± 0.6 |
| ∑FA | 3203 ± 379.3 | 3421 ± 520.3 | 2628 ± 273.6 | 5030 ± 591.9 | 4565 ± 527.7 | 4264 ± 554.7 |
| 14:0 | 55.4 ± 10.7 | 55.7 ± 12.4 | 37.2 ± 5.0 | 113.5 ± 21.9 | 59.6 ± 11.1 | 59.7 ± 7.8 |
| 16:0 | 722.6 ± 88.5 | 769.4 ± 129.2 | 549.1 ± 57.8 | 1139.0 ± 129.0 | 956.1 ± 116.2 | 890.7 ± 119.6 |
| 18.0 | 537.2 ± 81.1 | 606.6 ± 98.5 | 434.7 ± 53.9 | 834.5 ± 109.5 | 833.6 ± 11.9 | 726.7 ± 102.2 |
| 16:1ω7c | 41.0 ± 5.4 | 39.6 ± 7.5 | 26.9 ± 2.9 | 71.6 ± 12.4 | 49.2 ± 6.8 | 45.5 ± 7.0 |
| 18:1ω9c | 1188 ± 179.2 | 1258 ± 205.3 | 928.5 ± 106.9 | 1880 ± 240.8 | 1693 ± 221.7 | 1561 ± 210.6 |
| 18:1ω7c | 58.9 ± 5.4 | 64.3 ± 8.5 | 59.4 ± 4.9 | 83.5 ± 8.8 | 86.5 ± 9.6 | 87.9 ± 13.3 |
| 18:1ω7t | 50.1 ± 8.8 | 57.9 ± 12.8 | 58.5 ± 7.5 | 103.8 ± 26.0 | 88.1 ± 14.5 | 108.6 ± 16.9 |
| 18:2ω6 (LA) | 148.1 ± 11.2 | 182.2 ± 22.1 | 165.4 ± 16.8 | 221.6 ± 17.9 | 256.2 ± 28.0 | 231.6 ± 28.3 |
| 18:3ω3 (ALA) | 27.6 ± 4.2 | 32.8 ± 4.7 | 33.1 ± 4.1 | 49.0 ± 9.0 | 47.7 ± 5.5 | 48.7 ± 7.6 |
| 20:4ω6 (ARA) | 43.8 ± 4.1 | 43.0 ± 4.9 | 46.8 ± 2.4 | 59.2 ± 8.8 | 66.5 ± 7.9 | 62.7 ± 7.7 |
| 20:5ω3 (EPA) | 17.9 ± 1.6b | 16.1 ± 1.4b | 21.0 ± 2.0a | 21.4 ± 2.2 | 24.2 ± 1.8 | 28.1 ± 4.0 |
| 22:6ω3 (DHA) | 6.1 ± 1.3 | 3.9 ± 0.5 | 7.2 ± 0.7 | 7.2 ± 0.8 | 7.6 ± 0.8 | 10.0 ± 1.9 |
| 22:5ω3 (DPA) | 14.2 ± 1.5 | 14.2 ± 1.2 | 16.3 ± 0.8 | 20.7 ± 2.2 | 23.5 ± 2.0 | 23.2 ± 2.9 |
| ∑SFA | 1453 ± 170.6 | 1562 ± 254.9 | 1137 ± 130.2 | 2292 ± 265.8 | 2031 ± 252.2 | 1853 ± 242.9 |
| ∑MUFA | 1448 ± 202.1 | 1527 ± 246.9 | 1164 ± 128.4 | 2307 ± 309.8 | 2055 ± 267.1 | 1951 ± 259.1 |
| ∑PUFA | 301.8 ± 19.2 | 331.2 ± 34.5 | 326.9 ± 25.5 | 430.5 ± 33.3 | 479.3 ± 43.7 | 460.8 ± 54.9 |
| ∑CLA | 12.8 ± 2.1 | 12.5 ± 1.9 | 9.7 ± 1.0 | 17.6 ± 1.4 | 15.9 ± 2.1 | 18.1 ± 3.0 |
| ∑ω6 | 208.2 ± 14.1 | 238.9 ± 27.1 | 226.0 ± 19.6 | 298.6 ± 26.5 | 343.0 ± 36.5 | 314.4 ± 36.9 |
| ∑ω3 | 70.0 ± 6.0 | 69.7 ± 6.4 | 80.3 ± 7.1 | 101.9 ± 8.7 | 106.3 ± 6.2 | 113.9 ± 15.4 |
| EPA + DHA | 24.0 ± 2.9ab | 20.0 ± 1.6b | 28.2 ± 2.7a | 28.6 ± 2.7 | 31.7 ± 2.4 | 38.1 ± 5.9 |
| P/S | 0.2 ± 0.0 | 0.2 ± 0.0 | 0.3 ± 0.0 | 0.2 ± 0.0 | 0.3 ± 0.0 | 0.3 ± 0.0 |
| 6/3 | 3.1 ± 0.2 | 3.5 ± 0.3 | 2.9 ± 0.2 | 3.0 ± 0.3 | 3.2 ± 0.2 | 2.8 ± 0.2 |
| IA | 0.5 ± 0.0 | 0.5 ± 0.0 | 0.5 ± 0.0 | 0.6 ± 0.0 | 0.5 ± 0.0 | 0.5 ± 0.0 |
| IT | 1.2 ± 0.1 | 1.3 ± 0.1 | 1.1 ± 0.0 | 1.3 ± 0.0 | 1.2 ± 0.0 | 1.1 ± 0.0 |
| h/H | 1.9 ± 0.1 | 2.0 ± 0.1 | 2.1 ± 0.0 | 1.8 ± 0.1 | 2.1 ± 0.1 | 2.1 ± 0.1 |
| α | EP selection | Leuk1 | Lung1 | Leuk2 | SRBCT | Breast | Lung2 | DLBCL | Cancers | GCM | Average |
| No adjustment | Formula (11) | 94.12 | 84.38 | 93.33 | 95.00 | 90.00 | 100.00 | 90.00 | 81.08 | 60.87 | 87.64 |
| 0.01 | Formula (11) | 94.12 | 84.38 | 93.33 | 100 | 90.00 | 97.02 | 90.00 | 90.54 | 63.04 | 89.16 |
| 0.05 | Formula (11) | 94.12 | 84.38 | 100 | 100 | 93.33 | 98.51 | 90.00 | 90.54 | 71.74 | 91.40 |
| 0.05 | Mean | 94.12 | 84.38 | 100 | 100 | 93.33 | 97.01 | 90.00 | 90.54 | 71.74 | 91.24 |
| Gene (total SNPs) | SNP | Minor allele frequency | BODE score | Post-BD FEV1 | Maximum work | USCD SOBQ score |
| GSTP1 (7) | rs6120205' genomic | 0.083 | 0.003 | |||
| rs112278843' genomic | 0.073 | 0.003 | 0.02 | |||
| SFTPB (5) | --* | |||||
| SERPINE2 (22) | rs6436449 intron | 0.17 | 0.07 | 0.09 | ||
| EPHX1 (19) | rs3753658 promoter | 0.10 | 0.008 | 0.02 | ||
| rs1877724 intron | 0.26 | 0.04 | ||||
| rs2234922 His139Arg | 0.19 | 0.02 | 0.05 | |||
| rs1051741 exon, synon. | 0.11 | 0.09 | 0.01 | |||
| rs3600633' genomic | 0.38 | 0.07 | 0.05 | |||
| rs22925583' genomic | 0.11 | 0.09 | 0.03 | |||
| rs10096683' genomic | 0.10 | 0.08 | ||||
| TGFB1 (11) | rs2241712 promoter | 0.32 | 0.07 | |||
| rs8110090 intron | 0.05 | 0.09 | ||||
| rs8179181 intron | 0.26 | 0.06 | ||||
| rs129810533' genomic | 0.15 | 0.06 | ||||
| rs129809423' genomic | 0.15 | 0.05 |
| Date of DNA extraction | OTUs | Abundance (%) |
| 17 July 2014 | Aerococcus | 14 |
| Dermabacteraceae | 12 | |
| Micrococcus | 10 | |
| Enhydrobacter | 9 | |
| Leuconostoc | 6 | |
| Kocuria | 6 | |
| Actinomyces | 6 | |
| 25 March 2015 | Methylobacterium komagatae | 65 |
| Ruminococcaceae | 11 | |
| Methylobacterium | 6 | |
| 26 March 2015 | Methylobacterium komagatae | 67 |
| Methylobacterium | 6 |
| Aboriginal and/or Torres Strait Islander | Non-Indigenous Australian | P value | |
| N = 174 | N = 1210 | ||
| Age (years) | 37.4 | 65.1 | <0.001 |
| (Median (IQR)) | (26.9 – 49.1) | (55.5 – 72.8) | |
| Sex (% female) | 67.2 | 64.0 | 0.411 |
| (95% CI) | (59.7 – 74.2) | (61.3 – 66.8) | |
| Concomitant CABG | 9.8 | 22.9 | <0.001 |
| (%, 95% CI) | (5.8 – 15.2) | (20.6 – 25.4) | |
| Area of residence | |||
| Remote and very remote | 54.1 | 1.6 | <0.001 |
| (% RA category 3 & 4, 95% CI) | (46.3 – 61.7) | (1.0 – 2.4) | |
| Inner and outer regional | 39.5 | 33.3 | 0.108 |
| (% RA category 1 & 2, 95% CI) | (32.2 – 47.3) | (30.7 – 36.1) | |
| Major city | 6.4 | 65.1 | <0.001 |
| (%, 95% CI) | (3.2 – 11.2) | (62.3 – 67.8) | |
| Pre-surgery comorbidities | |||
| Diabetes | 24.3 | 19.8 | 0.167 |
| (%, 95% CI) | (18.1 – 31.4) | (17.5 – 22.1) | |
| Elevated Creatinine | 2.9 | 2.7 | 0.912 |
| (% Cr > =200 μmol/L) (95% CI) | (0.9 – 6.6) | (1.9 – 3.8) | |
| Chronic kidney disease (% eGFR < 60 mL/min/1.73 m2) | 14.4 | 33.5 | <0.001 |
| (95% CI) | (9.5 – 20.5) | (30.8 – 36.2) | |
| Hypertension | 37.0 | 55.3 | <0.001 |
| (%, 95% CI) | (29.8 – 44.7) | (52.4 – 58.1) | |
| Previous smoking | 64.2 | 51.0 | <0.001 |
| (%, 95% CI) | (56.5 – 71.3) | (48.2 – 53.9) | |
| Current smoking | 55.4 | 19.7 | <0.001 |
| (%, 95% CI) | (45.7 – 64.8) | (16.7 – 23.1) | |
| Pre-operative status | |||
| NYHA classes III & IV | 47.1 | 53.1 | 0.138 |
| (%, 95% CI) | (39.5 – 54.8) | (50.3 – 56.0) | |
| Atrial fibrillation | 33.3 | 41.6 | 0.039 |
| (%, 95% CI) | (26.4 – 40.9) | (38.8 – 44.4) | |
| LVEF >45% | 83.9 | 84.7 | 0.784 |
| (%, 95% CI) | (77.6 – 89.0) | (82.6 – 86.7) | |
| LVEF 30 – 45% | 11.5 | 10.8 | 0.792 |
| (%, 95% CI) | (7.2 – 17.2) | (9.1 – 12.7) | |
| LVEF <30% | 3.4 | 2.1 | 0.249 |
| (%, 95% CI) | (1.3 – 7.4) | (1.3 – 3.1) | |
| Previous procedures | |||
| Valve surgery | 16.1 | 13.1 | 0.287 |
| (%, 95% CI) | (11.0 – 22.4) | (11.3 – 15.2) | |
| PBV | 29.5 | 19.5 | 0.124 |
| (%, 95% CI) | (16.8 – 45.2) | (15.3 – 24.3) |
| Diabetic children | School children | ||||||||
| Scale | No.items | F | d.f | p-value | |||||
| n | mean ± SD | α | n | mean ± SD | |||||
| PedsQLTM 4.0 Generic | |||||||||
| Core Scales | |||||||||
| Child self-report | |||||||||
| Total score | 23 | 94 | 67.98 ± 14.03 | 0.87 | 200 | 78.21+13.23 | 33.33 | (1,292) | < 0.001 |
| Physical health | 8 | 94 | 69.18 ± 17.05 | 0.77 | 200 | 80.06+15.02 | 29.34 | (1,292) | < 0.001 |
| Emotional functioning | 5 | 94 | 59.84 ± 20.41 | 0.71 | 200 | 69.17+19.60 | 13.93 | (1,292) | < 0.001 |
| Social functioning | 5 | 94 | 76.78 ± 18.19 | 0.73 | 200 | 78.62+18.25 | 1.69 | (1,292) | 0.194 |
| School functioning | 5 | 94 | 65.79 ± 18.23 | 0.73 | 200 | 83.90+16.59 | 52.54 | (1,292) | < 0.001 |
| Psychosocial health | 15 | 94 | 67.34 ± 14.72 | 0.82 | 200 | 77.23+14.36 | 26.15 | (1,292) | < 0.001 |
| Parent proxy-report | |||||||||
| Total score | 23 | 94 | 67.03 ± 12.83 | 0.83 | 200 | 74.79+16.22 | 14.91 | (1,292) | < 0.001 |
| Physical health | 8 | 94 | 67.42 ± 16.50 | 0.73 | 200 | 76.00+20.11 | 12.03 | (1,292) | 0.001 |
| Emotional functioning | 5 | 94 | 58.63 ± 18.48 | 0.73 | 200 | 68.02+21.09 | 16.37 | (1,292) | < 0.001 |
| Social functioning | 5 | 94 | 75.16 ± 18.63 | 0.71 | 200 | 81.30+20.90 | 2.99 | (1,292) | 0.085 |
| School functioning | 5 | 94 | 66.65 ± 19.24 | 0.72 | 200 | 73.12+20.68 | 5.61 | (1,292) | 0.019 |
| Psychosocial health | 15 | 94 | 66.81 ± 13.81 | 0.79 | 200 | 74.15+16.59 | 12.13 | (1,292) | 0.001 |
| PedsQLTM 3.0 Diabetic | |||||||||
| Module | |||||||||
| Child self-report | |||||||||
| Diabetes symptoms | 11 | 94 | 59.21 ± 14.46 | 0.74 | - | - | - | - | - |
| Treatment barriers | 4 | 94 | 58.38 ± 21.51 | 0.67 | - | - | - | - | - |
| Treatment adherence | 7 | 94 | 60.18 ± 18.12 | 0.78 | - | - | - | - | - |
| Worry | 3 | 94 | 56.47 ± 23.35 | 0.71 | - | - | - | - | - |
| Communication | 3 | 94 | 61.08 ± 27.34 | 0.76 | - | - | - | - | - |
| Parent proxy-report | |||||||||
| Diabetes symptoms | 11 | 94 | 58.57 ± 13.62 | 0.73 | - | - | - | - | - |
| Treatment barriers | 4 | 94 | 53.53 ± 21.03 | 0.68 | - | - | - | - | - |
| Treatment adherence | 7 | 94 | 57.60 ± 15.99 | 0.71 | - | - | - | - | - |
| Worry | 3 | 94 | 56.91 ± 23.01 | 0.72 | - | - | - | - | - |
| Communication | 3 | 94 | 60.99 ± 25.69 | 0.70 | - | - | - | - | - |
| Overall Injury Risk (RP1) 1 | Ankle Injury Severity (RP2) 1 | Knee Injury Severity (RP3) 1 | Injuries Are Preventable (OE1) 2 | FIFA 11+ Prevents Injuries (OE2) 2 | I Understand the FIFA 11+ (TSE1) 3 | I Can Use the FIFA 11+ (TSE2) 3 | Intention to Use the FIFA 11+ (INT) 4 | |
| RP1 | 1.00 | - | - | - | - | - | - | - |
| RP2 | 0.68 * | 1.00 | - | - | - | - | - | - |
| RP3 | 0.80 * | 0.79 * | 1.00 | - | - | - | - | - |
| OE1 | 0.70 * | 0.74 * | 0.78 * | 1.00 | - | - | - | - |
| OE2 | −0.34 | 0.06 | −0.16 | −0.18 | 1.00 | - | - | - |
| TSE1 | 0.17 | 0.17 | 0.53 | 0.00 | −0.25 | 1.00 | - | - |
| TSE2 | 0.06 | 0.18 | 0.46 | −0.07 | −0.13 | 0.96 * | 1.00 | - |
| INT | 0.09 | 0.13 | 0.55 | 0.13 | −0.24 | 0.84 * | 0.89 * | 1.00 |
| Number of patients | Percentage | |
| OCD Group | 135 | 75.4% |
| Non-OCD anxiety disorders group | 44 | 24.6% |
| Rupintrivir concn (μM) at final passage or control treatment | Clone no. | Mean EC50 ± SDa (μM) | Fold change in sensitivityb | Amino acid substitution(s) in protease |
| 20 | 1 | 14.3 ± 1.7 | 10.9 | A105V/I109V |
| 2 | 12.3 ± 1.2 | 9.4 | A105V/I109V | |
| 3 | 15.3 ± 1.1 | 11.7 | A105V/I109V | |
| 15 | 1 | 8.5 ± 1.9 | 6.5 | A105V/I109V |
| 2 | 14.3 ± 1.3 | 10.9 | A105V/I109V | |
| 3 | 6.9 ± 1.7 | 5.3 | I109V | |
| 10 | 1 | 6.6 ± 2.4 | 5.0 | I109V |
| 2 | 6.3 ± 2.3 | 4.8 | I109V | |
| 3 | 5.9 ± 1.3 | 4.5 | I109V | |
| DMSO | 1.3 ± 0.2 | 1.0 |
| Variable | Number (%) | BAIa score n (%) | p-value* | |
| <22 | ≥22 | |||
| Age (years) | 0.493 | |||
| 10–19 | 208(18.2) | 174(83.7) | 34(16.3) | |
| 20–29 | 858(75.2) | 727(84.7) | 131(15.3) | |
| ≥ 30 | 75(6.6) | 67(89.3) | 8(10.7) | |
| Body mass index (Kg/m2) | 0.718 | |||
| < 25.0 | 986(86.4) | 838(85.0) | 148(15.0) | |
| ≥ 25.0 | 155(13.6) | 130(83.9) | 25(16.1) | |
| Marital status | 0.481 | |||
| Unmarried | 1018(89.2) | 861(84.6) | 157(15.4) | |
| Married | 123(10.8) | 107(87.0) | 16(13.0) | |
| Educational level | 0.655 | |||
| ≤ high school | 882(77.3) | 746(84.6) | 136(15.4) | |
| ≥ college | 259(22.7) | 222(85.7) | 37(14.3) | |
| Smoking habit | 0.014 | |||
| Non-smoker | 769(67.4) | 669(87.0) | 100(13.0) | |
| Ex-smoker | 146(12.8) | 117(80.1) | 29(19.9) | |
| Current smoker | 226(19.8) | 182(80.5) | 44(19.5) | |
| Risky drinkingb | 0.006 | |||
| No | 935(81.9) | 806(86.2) | 129(13.8) | |
| Yes | 206(18.1) | 162(78.6) | 44(21.2) | |
| Regular exercise | 0.674 | |||
| < 3 times per week | 904(79.2) | 769(79.4) | 135(78.0) | |
| ≥ 3 times per week | 237(20.8) | 199(20.6) | 38(22.0) | |
| Shift work | 0.145 | |||
| No | 75(6.5) | 68(90.7) | 7(9.3) | |
| Yes | 1066(93.5) | 900(84.4) | 166(15.6) | |
| Job tenure (years) | 0.306 | |||
| < 1 | 274(24.0) | 232(84.7) | 42(15.3) | |
| 1–3 | 286(25.1) | 237(82.9) | 49(17.1) | |
| 4–6 | 273(23.9) | 228(83.5) | 45(16.5) | |
| ≥ 7 | 308(27.0) | 271(88.0) | 37(12.0) | |
| PSQIc score | <0.001 | |||
| < 6 | 450(39.4) | 421(93.6) | 29(6.4) | |
| ≥ 6 | 691(60.6) | 547(79.2) | 144(20.8) |
| Type | % Miss in positive | % Miss in random |
| All features | 83% | 85% |
| Gene expression | 15–27% | 24–43% |
| GO | 39–66% | 40–54% |
| Barriers to carrying out PU | Risk assessment number (%) | Documentation number (%) | Prevention number (%) |
| Total number of respondents | 194 (100) | 194 (100) | 194 (100) |
| Lack of time | 32 (23.7) | 46 (34.1) | 33 (24.4) |
| Unstable patient | 17 (12.6) | 16 (11.9) | 24 (17.8) |
| Lack of training, resources, equipment, guidelines | 26 (19.3) | 0 (0) | 22 (16.3) |
| Short staffed | 33 (24.4) | 30 (22.2) | 20 (14.8) |
| Lack of knowledge | 13 (9.6) | 14 (10.4) | 19 (14.1) |
| Lack of aids | 0 (0) | 15 (11.1) | 14 (10.4) |
| Unable to assess | 9 (6.7) | 0 (0) | 13 (9.6) |
| Problem with assessment tool | 9 (6.7) | 21 (15.6) | 0 (0) |
| Forget | 0 (0) | 13 (9.6) | 0 (0) |
| Lack of equipment | 18 (13.3) | 10 (7.4) | 0 (0) |
| Patient un-cooperative/too ill | 20 (14.8) | 0 (0) | 0 (0) |
| Label | Volume | t-value | Peak activation (LPI) | ||
| x | y | z | |||
| Left Thalamus | 342 | 3.92 | -9 | 6 | 12 |
| Right Inferior Parietal Lobule | 208 | 3.67 | 57 | −57 | 39 |
| Left Superior Medial Gyrus | 184 | 3.65 | 3 | 36 | 42 |
| Left Precuneus | 179 | 3.59 | 3 | −69 | 48 |
| Right Middle Frontal Gyrus | 137 | 3.64 | 33 | 15 | 60 |
| Left Angular Gyrus | 113 | 3.51 | −57 | −54 | 30 |
| Left Middle Frontal Gyrus | 96 | 3.69 | −24 | 15 | 60 |
| Left Middle Frontal Gyrus | 90 | 3.48 | −45 | 51 | -3 |
| Sites | Gender | Lt(cm) | Lf(cm) | Wt(g) | Wg(g) | GSI |
| Reference (A1) | Female | 29.85 ± 2.72* | 26.29 ± 2.98* | 283.45 ± 57.34* | 7.936 ± 0.361 | 2.68 ± 0.26* |
| Male | 28.85 ± 2.81* | 27.29 ± 2.21* | 281.25 ± 37.54* | 5.434 ± 0.251 | 1.58 ± 0.12* | |
| Harbor (A2) | Female | 20.88 ± 3.22 | 19.45 ± 2.74 | 108.50 ± 77.90 | 0.629 ± 0.447 | 0.08 ± 0.063 |
| Male | 18.28 ± 8.72 | 16.25 ± 2.92 | 105.31 ± 55.60 | 0.129 ± 0.047 | 0.02 ± 0.013 |
| Characteristic | Prevalence | Incidence | ||||
| No. | % | Weighteda (%) | No. | % | Weighteda (%) | |
| Age group | ||||||
| 0–24 | 160,382 | 26.9 | 33.8 | 166,840 | 28.0 | 34.7 |
| 25–34 | 91,435 | 15.3 | 14.9 | 89,597 | 15.0 | 15.1 |
| 35–44 | 99,582 | 16.7 | 18.3 | 102,999 | 17.3 | 18.5 |
| 45–54 | 93,763 | 15.7 | 13.9 | 90,667 | 15.2 | 13.4 |
| 55–64 | 80,155 | 13.4 | 10.5 | 78,075 | 13.1 | 10.2 |
| 65–74 | 44,840 | 7.5 | 5.5 | 43,245 | 7.3 | 5.3 |
| 75–84 | 22,200 | 3.7 | 2.6 | 20,585 | 3.5 | 2.4 |
| ≥85 | 4,179 | 0.7 | 0.5 | 3,703 | 0.6 | 0.4 |
| Sex | ||||||
| Men | 300,192 | 50.3 | 51.1 | 299,725 | 50.3 | 51.1 |
| Women | 296,344 | 49.7 | 48.9 | 295,986 | 49.7 | 48.9 |
| Ethnicity | ||||||
| Han | 521,343 | 87.4 | 91.8 | 518,151 | 87.0 | 91.4 |
| Other | 75,193 | 12.6 | 8.2 | 77,560 | 13.0 | 8.6 |
| Education, n (%) | ||||||
| Primary school | 248,916 | 41.7 | 39.6 | 245,192 | 41.2 | 38.9 |
| Middle school | 294,209 | 49.3 | 49.0 | 294,193 | 49.4 | 49.2 |
| College and higher | 51,730 | 8.7 | 11.2 | 51,721 | 8.7 | 11.3 |
| Missing | 1,681 | 0.3 | 0.2 | 4,605 | 0.8 | 0.5 |
| Marital status, n (%) | ||||||
| Married | 391,160 | 65.6 | 60.9 | 391,124 | 65.7 | 61.2 |
| Single | 116,817 | 19.6 | 24.0 | 115,438 | 19.4 | 23.8 |
| Widowed | 32,734 | 5.5 | 4.2 | 32,731 | 5.5 | 4.2 |
| Other | 53,735 | 9.0 | 10.6 | 51,402 | 8.6 | 10.2 |
| Missing | 2,090 | 0.4 | 0.2 | 5,016 | 0.8 | 0.6 |
| Occupation, n (%) | ||||||
| Students | 108,978 | 18.3 | 23.1 | 105,510 | 17.7 | 22.4 |
| Worker | 45,021 | 7.5 | 8.7 | 45,004 | 7.6 | 8.8 |
| Farmer | 271,068 | 45.4 | 38.6 | 270,916 | 45.5 | 38.8 |
| Employee | 46,676 | 7.8 | 9.8 | 46,674 | 7.8 | 9.9 |
| Entrepreneurs | 52,518 | 8.8 | 10.2 | 52,516 | 8.8 | 10.2 |
| Retiree or homemaker | 66,169 | 11.1 | 8.7 | 66,145 | 11.1 | 8.7 |
| other | 4,439 | 0.7 | 0.7 | 4,356 | 0.7 | 0.7 |
| Missing | 1,667 | 0.3 | 0.2 | 4,590 | 0.8 | 0.5 |
| Place of residence | ||||||
| Urban | 248,570 | 47.4 | 52.9 | 248,090 | 47.4 | 52.8 |
| Rural | 347,966 | 52.6 | 47.1 | 347,621 | 52.6 | 47.2 |
| Geographic location | ||||||
| Eastern China | 201,354 | 33.8 | 40.7 | 201,196 | 33.8 | 40.7 |
| Central China | 239,735 | 40.2 | 32.0 | 239,288 | 40.2 | 32.0 |
| Western China | 155,447 | 26.1 | 27.3 | 155,227 | 26.1 | 27.3 |
| HPV genotype | Age (Years)Frequency (%) | Total Frequency (%) | |||
| < 40 | 40–49 | 50–59 | > 60 | ||
| 6 | 0 (0%) | 0 (0%) | 1 (100.0%) | 0 (0%) | 1 (100%) |
| 16 | 7 (6.3%) | 27 (24.3%) | 42 (37.9%) | 35 (31.5%) | 111 (100%) |
| 18 | 1 (4.5%) | 7 (31.8%) | 6 (27.3%) | 8 (36.4%) | 22 (100%) |
| 31 | 0 (0%) | 1 (50.0%) | 0 (0%) | 1 (50.0%) | 2 (100%) |
| 33 | 0 (0%) | 1 (25.0%) | 0 (0%) | 3 (75.0%) | 4 (100%) |
| 35 | 0 (0%) | 1 (50.0%) | 1 (50.0%) | 0 (0%) | 2 (100%) |
| 39 | 0 (0%) | 0 (0%) | 0 (0%) | 1 (100.0%) | 1 (100%) |
| 45 | 0 (0%) | 2 (33.3%) | 2 (33.3%) | 2 (33.3%) | 6 (100%) |
| 52 | 1 (50.0%) | 0 (0%) | 0 (0%) | 1 (50.0%) | 2 (100%) |
| 56 | 0 (0%) | 0 (0%) | 2 (50.0%) | 2 (50.0%) | 4 (100%) |
| 68 | 0 (0%) | 0 (0%) | 1 (100.0%) | 0 (0%) | 1 (100%) |
| 16 + 18 | 1 (33.3%) | 0 (0%) | 1 (33.3%) | 1 (33.3%) | 3 (100%) |
| 16 + 39 | 0 (0%) | 0 (0%) | 0 (0%) | 1 (100.0%) | 1 (100%) |
| 16 + 45 | 0 (0%) | 0 (0%) | 2 (100.0%) | 0 (0%) | 2 (100%) |
| 16 + 51 | 0 (0%) | 0 (0%) | 1 (100.0%) | 0 (0%) | 1 (100%) |
| 16 + 52 | 0 (0%) | 1 (0%) | 0 (0%) | 0 (0%) | 1 (100%) |
| 31 + 52 | 0 (0%) | 1 (0%) | 0 (0%) | 0 (0%) | 1 (100%) |
| Variables | Resource | Year | Operating institution |
| The number of general hospitals (per 100,000 persons) | Survey of Medical Institutions, | 2002 | Ministry of Health, Labor and welfare |
| The number of beds in hospital (per 100,000 persons) | Hospital Report | 2002 | Ministry of Health, Labor and welfare |
| Ratio of daily occupied beds in general hospital | Hospital Report | 2002 | Ministry of Health, Labor and welfare |
| The number of families in which the elderly were living alone (per 100 households with person 65 years or older) | Population Census | 2002 | Ministry of Public Management, Home Affairs, Posts and Telecommunications |
| Dwelling rooms (per dwelling) | Population Census | 2002 | Ministry of Public Management, Home Affairs, Posts and Telecommunications |
| Health service facilities for the elderly (per 100,000 persons 65 years old and over) | Survey of Institutions and Establishment for long-term care | 2002 | Ministry of Health, Labor and welfare |
| Data set name | Number of patients | Microarray type | Outcome |
| Chin [72] | 130 | Affymetrix GeneChip Human Genome U133A Array Set | Disease specific survival (Event = death from breast cancer) |
| Miller [73] | 251 | Affymetrix GeneChip Human Genome U133 Array Set | Disease specific survival (Event = death from breast cancer) |
| Pittman [74] | 158 | Affymetrix GeneChip Human Genome U95av2 Array Set | Overall survival (Even t = death from breast cancer) |
| B | Se | |
| Intercept | 0.23 | 0.16 |
| Quality aspects: | ||
| Total quality score | 0.75 | 0.19 |
| Adjustment for confounders at study level | -2.34 | 0.81 |
| Culturally adjusted questionnaire | -1.83 | 0.52 |
| Study characteristics: | ||
| Country US | 1.67 | 0.60 |
| Publication year | -0.00 | 0.04 |
| Adjustment confounders outcome level | -0.00 | 0.41 |
| Sample size majority reference group | 0.00 | 0.00 |
| Sample size immigrant groups | -0.00 | 0.00 |
| Length of reference period of use | -0.15 | 0.26 |
| Background immigrant groups a | ||
| European | 1.69 | 0.92 |
| African | 0.14 | 0.77 |
| Asian | 0.92 | 0.56 |
| (South/central) American | 0.23 | 0.60 |
| Variance study levelb | 0 | 0 |
| Variance outcome level | 0.92 | 0.09 |
| Impact Category- | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 | Group 6 |
| Non-renewable, fossil | 0.224 | 0.219 | 0.215 | 0.212 | 0.207 | 0.198 |
| Renewable, biomass | 1.04 | 1.04 | 1.04 | 1.04 | 1.04 | 1.04 |
| *Others | 0.012 | 0.012 | 0.012 | 0.012 | 0.011 | 0.011 |
| Total | 1.28 | 1.27 | 1.27 | 1.26 | 1.26 | 1.25 |
| Sample no. | TDS (mg/L) | pH | Conductivity (Ds/m) | |||
| Before desalination | After desalination | Before desalination | After desalination | Before desalination | After desalination | |
| Sample A-B | 320 | 40 | 7.60 | 7.32 | 1 | 0.10 |
| Active ROM Excursion | Dominant arm | Non Dominant arm | |
| MSD | MSD | P-value | |
| CAD (cm) | 25.38 ± 3.67 | 24.70 ± 3.56 | <0.001* |
| FLX (°) | 165.56 ± 7.76 | 164.52 ± 9.33 | <0.001* |
| ER0 (°) | 76.46 ± 11.98 | 74.56 ± 11.65 | <0.001* |
| IR 90° Abduction (°) | 54.72 ± 13.35 | 58.35 ± 11.96 | <0.001* |
| ER 90° Abduction (°) | 98.81 ± 10.88 | 95.30 ± 10.15 | <0.001* |
| ARC (°) | 153.53 ± 16.47 | 153.65 ± 14.58 | 0.804 |
| Passive ROM Excursion | Dominant arm | Non Dominant arm | |
| MSD | MSD | P-value | |
| CAD (cm) | 23.31 ± 3.49 | 22.59 ± 3.42 | <0.001* |
| FLX (°) | 170.55 ± 7.68 | 169.79 ± 9.44 | 0.009* |
| ER0 (°) | 82.28 ± 12.34 | 80.48 ± 11.73 | <0.001* |
| IR 90° Abduction (°) | 58.91 ± 14.04 | 62.43 ± 12.80 | <0.001* |
| ER 90° Abduction (°) | 104.64 ± 10.83 | 100.55 ± 9.81 | < 0.001* |
| ARC (°) | 163.56 ± 17.41 | 162.99 ± 15.65 | 0.251 |
| PFAS n = 1,566 | Men (n = 956) β (95% CI) | All women (n = 958) β (95% CI) | Premenopausal women (n = 590) β (95% CI) | Postmenopausal women (n = 368) β (95% CI) |
| PFOA | ||||
| Q1 | Referent | Referent | Referent | Referent |
| Q2 | 0.011 (–0.021, 0.043) | –0.025 (–0.052, 0.002) | –0.028 (–0.060, 0.003) | –0.022 (–0.077, 0.033) |
| Q3 | –0.013 (–0.053, 0.028) | –0.002 (–0.039, 0.034) | 0.014 (–0.031, 0.060) | –0.024 (–0.083, 0.035) |
| Q4 | 0.004 (–0.035, 0.043) | –0.028 (–0.058, 0.001) | –0.019 (–0.056, 0.018) | –0.041 (–0.098, 0.016) |
| ln-PFOA | 0.001 (–0.025, 0.022) | –0.017 (–0.033, –0.001) | –0.012 (–0.030, 0.007) | 0.020 (–0.049, 0.010) |
| PFOS | ||||
| Q1 | Referent | Referent | Referent | Referent |
| Q2 | –0.036 (–0.077, 0.006) | 0.001(–0.019, 0.019) | –0.005 (–0.028, 0.018) | –0.005 (0.087, 0.077) |
| Q3 | –0.027 (–0.063, 0.009) | –0.001 (–0.025, 0.025) | –0.005 (–0.028, 0.017) | –0.001 (–0.082, 0.080) |
| Q4 | –0.046 (–0.078, –0.015) | –0.034 (–0.059, –0.009) | –0.001 (–0.029, 0.029) | –0.062 (0.134, 0.009) |
| ln-PFOS | –0.013 (–0.024, –0.002) | –0.016(–0.029, –0.002) | –0.001 (–0.015, 0.015) | –0.033 (–0.049, –0.017) |
| PFHxS | ||||
| Q1 | Referent | Referent | Referent | Referent |
| Q2 | –0.002 (–0.042, 0.038) | –0.008 (–0.039, 0.023) | –0.004 (–0.042, 0.033) | –0.025 (–0.100, 0.050) |
| Q3 | –0.004 (–0.031, 0.023) | 0.001 (–0.025, 0.027) | 0.010 (–0.018, 0.038) | –0.017 (–0.092, 0.058) |
| Q4 | –0.013 (–0.052, 0.025) | –0.018 (–0.051, 0.016) | –0.010 (–0.039, 0.018) | –0.026 (–0.104, 0.051) |
| ln-PFHxS | –0.009 (–0.024, 0.006) | –0.005 (–0.018, 0.008) | –0.001 (–0.015, 0.013) | –0.005 (–0.024, 0.013) |
| PFNA | ||||
| Q1 | Referent | Referent | Referent | Referent |
| Q2 | –0.010 (–0.058, 0.037) | –0.020 (–0.066, 0.027) | –0.023 (–0.073, 0.027) | –0.013 (–0.087, 0.060) |
| Q3 | –0.004 (–0.035, 0.028) | –0.001 (–0.029, 0.029) | 0.001 (–0.035, 0.038) | –0.009 (–0.078, 0.060) |
| Q4 | 0.009 (–0.022, 0.039) | –0.023 (–0.051, 0.005) | –0.005 (–0.049, 0.040) | –0.046 (–0.103, 0.012) |
| ln-PFNA | –0.005 (–0.021, 0.018) | –0.014 (–0.032, 0.003) | –0.005 (–0.025, 0.016) | –0.025 (–0.049, –0.001) |
| aAdjusted for age (continuous) and age categories (12–20, 21–50, ≥ 50 years), ethnicity, BMI, serum cotinine, physical activity, milk consumption, and blood lead concentration. |
| Smoking status | GOLD stage | H. influenzae | |||||||
| Current smoker n = 15 | Ex-smoker n = 29 | p* | II n = 15 | III+IV n = 29 | p* | No n-12 | Yes = n = 12 | p* | |
| IL-6(pg/ml) | |||||||||
| induced | 17.2(5.7-36.2) | 16.7(4.0-43.2) | 0.63 | 16.7(4.5-67.8) | 19.4(5.2-36.2) | 0.78 | 20.7(10.9-49.0) | 17.8(1.3-28.6) | 0.16 |
| spontaneous | 10.2(3.0-29.5) | 21.5(5.8-48.2) | 0.22 | 15.6(2.2-64.9) | 13.8(4.45.8) | 0.79 | 32.2(22.4-75.38) | 12.0(2.6-18.8) | 0.01 |
| IL-8(pg/ml) | |||||||||
| induced | 505.4(161.3-805.9) | 517.0(193.3-1257.2) | 0.54 | 233.4(170.0-1257.2) | 529.0(224.5-1156.0) | 0.37 | 277.6(170.0-649.0) | 655.49(274.70-832.70) | 0.32 |
| spontaneous | 221.0(165.4-674.4) | 405.0(173.2-891.8) | 0.42 | 210.1(112.7-844.1) | 546.3(174.7-891.8) | 0.18 | 336.9(210.1-734.2) | 570.4(265.8-1141.4) | 0.23 |
| IP-10(pg/ml) | |||||||||
| induced | 216.5(130.9-826.2) | 624.3(289.9-1844.9) | 0.08 | 232.5(175.2-748.3) | 600.8(216.7-1844.9) | 0.20 | 477.5(175.2-2554.8) | 696.1(56.0-1574.1) | 0.85 |
| spontaneous | 345.6(124.9-716.5) | 461.0(237.5-1361.7) | 0.14 | 354.5(129.7-780.1) | 448(237.5-1202.0) | 0.33 | 491.9(285.2-2269.7) | 582.7(180.0-1093.0) | 0.42 |
| TNF-α(pg/ml) | |||||||||
| induced | 0.4(0-1.9) | 1.5(0-4.8) | 0.34 | 0.00(0.00-2.5) | 1.6(0-4.2) | 0.14 | 2.3(0.0-5.1) | 3.2(0.7-24.3) | 0.24 |
| spontaneous | 0.9(0-3.2) | 3.3(0.3-7.4) | 0.20 | 0.5(0.0-4.5) | 2.4(0.8-7.4) | 0.18 | 6.43.7-14.0 | 7.9(2.1-173.9) | 0.69 |
| IL-18(pg/ml) | |||||||||
| induced | 9.0(0.9-19.3) | 8.4(4.1-25.6) | 0.58 | 10.6(2.4-14.9) | 6.3(4.1-25.6) | 0.91 | 5.04(0.0-13.6) | 4.2(0.6-10.1) | 1.0 |
| spontaneous | 2.9(0.5-14.8) | 14.8(8.3-31.7) | 0.01 | 8.8(1.0-15.1) | 14.6(3.5-29.8) | 0.24 | 10.4(5.0-13.9) | 7.0(2.7-25.2) | 0.45 |
| MIG(pg/ml) | |||||||||
| induced | 332.2(30.1-661.7) | 806.3(110.5-1391.4) | 0.15 | 121.8(41.2-897.0) | 661.7(110.5-1314.3) | 0.27 | 157.8(43.3-1714.8) | 677.1(179.0-961.8) | 0.54 |
| spontaneous | 208.5(31.7-385.8) | 626.8(222.6-2031.7) | 0.03 | 280.4(69.8-1537.1) | 383.4(205.3-1941.6) | 0.47 | 1473.0 (438.8-4392.9) | 740.5(384.6-2088.3) | 0.33 |
| Hemodynamic variable | T0 | T1 | T2 | p value |
| HR, beats.min−1 | 96 (72,5 to 105.5) | 93 (71.5 to 103.5) | 91.5 (72.5 to 102.5) | 0.067 |
| PAM, mmHg | 76.5 (71 to 83,6) | 85 (76 to 90.5)a,b | 81 (72.5 to 92) | <0.001* |
| PAPm, mmHg | 25 (21 to 27) | 28 (26 to 30)a,b | 26 (24 to 29)c | <0.001* |
| PCWP, mmHg | 12 (9.5 to 14) | 14 (12 to 17)a,b | 14 (10 to 14.2) | <0.001* |
| CVP, mmHg | 10 (7.7 to 11.2) | 12 (9.7 to 13)a,b | 10 (8 to 11) | <0.001* |
| CI, l.min−2.m−2 | 3.4 ± 0.9 | 3.9 ± 0.9a,b | 3.5 ± 1.0 | <0.001* |
| SVRI, dyn.sec.cm−5 m2 | 1,576 (1,390 to 1,966) | 1,427 (1,229 to 1,867)a | 1,555 (1,290 to 2,229) | 0.013* |
| PVRI, dyn.sec.cm−5 m2 | 311 (241 to 375) | 262 (225 to 319)a | 302 (265 to 403)c | <0.001* |
| SvO2,% | 71 (67.8 to 78.6) | 73.1 (68.1 to 78.8) | 71.9 (68.1 to 78.4) | 0.356 |
| D (A-v)O2, mL/dL | 3.5 (3.0 to 4.0) | 3.3 (2.7 to 3.8)a | 3.3 (2.9 to 3.9) | 0.043* |
| DO2, mL.m−1.m−2 | 450 ± 127 | 489 ± 125a,b | 456 ± 137 | <0.001* |
| VO2, mL.m−1.m−2 | 118 ± 28 | 126 ± 29a | 116 ± 31 | 0.03* |
| Lactate, mmol.L | 1.9 (1.2 to 2.4) | 1.55 (1.05 to 2.45)a,b | 1.95 (1.15 to 2.27) | 0.002* |
| Hb, g/dL | 10 (8.8 to 10,9) | 8.9 (8.1 to 10.5)a | 9.6 (8.6 to 10.9)c | <0.001* |
| VTIAo, cm | 18.3 ± 3.62 | 21.21 ± 4.49a,b | 20.4 ± 4.63 | <0.001* |
| E/A | 1.05 ± 0.27 | 1.1 ± 0.31 | 1.11 ± 0.3 | 0.232 |
| E/e’ | 5.17 (4.36 to 6.42) | 6.27 (4.24 to 6.7) | 5.65 (4.82 to 7.35) | 0.657 |
| Qva/Qt | 25.3 (22.5 to 33) | 26 (22.2 to 32.6) | 27.5 (22.5 to 32.6) | 0.307 |
| Strategy | Life time Cost $ | Life time incremental cost$ | Life years gain | Incremental life years gain | Cost effectiveness ($) | Incremental Cost Effectiveness ratio (ICER $) | % change from base case ICER |
| Undiscounted | |||||||
| no-ART | 265(86–1148) | 2.3(1.95–2.73) | 114(38–504) | ||||
| ART | 2479(1214–4828) | 2215(771–4635) | 9.4(8.67–10.05) | 7.1(6.24–7.83) | 265(130–513) | 314(111–654) | |
| Discounted at 3% | |||||||
| no-ART | 247(80–1008) | 2.2(1.83–2.56) | 114(37–471) | ||||
| ART | 2028(1000–3868) | 1780(577–3710) | 7.7(7.15–8.18) | 5.5(4.85–6.13) | 265(131–508) | 325(106–680) | 3.5 |
| eGFR | Urinary protein | Systolic blood pressure | ||||
| B* | p value | B* | p value | B* | p value | |
| Complement system components | ||||||
| Complement C1q subcomponent subunit C | − | 0.3 | + | 0.2 | + | 0.5 |
| Complement C1r subcomponent | − | 0.003 | + | 0.5 | + | 0.02 |
| Complement C1s subcomponent | − | 0.005 | + | 0.7 | + | 0.003 |
| Complement C3 | − | 0.3 | − | 0.5 | + | 0.2 |
| Complement C4-B | − | 0.2 | + | 0.9 | + | 0.05 |
| Complement C5 | − | 0.04 | − | 0.3 | + | 0.02 |
| Complement C6 | − | 0.03 | − | 0.3 | + | 0.09 |
| Complement C7 | − | 0.06 | − | 0.5 | + | 0.2 |
| Complement C8 alpha chain | − | 0.03 | − | 0.4 | + | 0.05 |
| Complement C8 beta chain | − | 0.02 | − | 0.2 | + | 0.004 |
| Complement C8 gamma chain | − | 0.1 | + | 0.6 | + | 0.4 |
| Complement C9 | − | 0.01 | − | 0.24 | + | 0.01 |
| Complement system regulators | ||||||
| Clusterin | − | 0.02 | − | 0.3 | + | 0.1 |
| Complement factor H | − | 0.1 | − | 0.5 | + | 0.02 |
| Complement factor H-related protein 1 | − | 0. 4 | − | 0.8 | + | 0.1 |
| Complement factor H-related protein 2 | + | 0.9 | − | 0.9 | + | 0.5 |
| Complement factor H-related protein 5 | − | 0.3 | − | 0.5 | + | 0.5 |
| Complement receptor type 1 | + | 0.07 | + | 0.9 | − | 0.4 |
| C4b-binding protein alpha chain | − | 0.06 | − | 0.4 | + | <0.001 |
| Total number of isolates N = 973 | Proportion of T2 isolates n (%) | Univariate analysis | Multivariable analysis | |||
| Zone | **OR (95% CI) | p-value | OR (95% CI) | *p-value | ||
| South West | 313 | 172 (55.0) | Ref. | Ref. | ||
| Kampala | 278 | 112 (40.3) | 1.9 (1.34-2.79) | 0.004 | 1.8 (1.23-2.53) | 0.005 |
| Eastern | 89 | 22 (23.6) | 1.9 (0.76-4.79) | 1.57 | 1.9 (0.8-4.43) | 0.122 |
| South East | 36 | 7 (19.4) | 1.7 (1.26-2.35) | 0.001 | 1.8 (1.25-2.62) | 0.003 |
| North East | 59 | 28 (44.1) | 1.9 (1.27-2.73) | 0.030 | 1.8 (1.23-2.53) | 0.001 |
| North | 28 | 10 (35.7) | 0.8 (0.58-1.08) | 0.137 | 1.0 (0.69-1.45) | 0.980 |
| North West | 66 | 20 (30.3) | 0.5 (0.27-1.10) | 0.295 | 0.73 (2.05-2.78) | 0.113 |
| Western | 104 | 53 (51.0) | 1.5 (0.22-1.61) | 0.134 | 1.6 (0.89-2.78) | 0.546 |
| Phase | Normothermia | Hypothermia | Mortality | |||
| Male | Female | Male | Female | Total | n | |
| 1 | 23 | 20 | 7 (14%) | 43 | ||
| 2 | 14 | 17 | 15 | 16 | 2 (3%)a | 62 |
| 3 | 3 | 4 | 3 | 5 | 1 (6.25%) | 15 |
| Skewed Distributions | Approximately Symmetric Distributions | |||||
| Number of Factors | 1 | 2 | 3 | 1 | 2 | 3 |
| China | 993 | 7 | 0 | 0 | 1000 | 0 |
| India | 62 | 938 | 0 | 0 | 932 | 18 |
| Mexico | 894 | 106 | 0 | 0 | 1000 | 0 |
| Russian Federation | 6 | 994 | 0 | 0 | 1000 | 0 |
| South Africa | 1000 | 0 | 0 | 0 | 396 | 604 |
| Ghana | 587 | 413 | 0 | 0 | 0 | 1000 |
| Property | Clarified Juice | UV Treatment |
| pH | 3.74 ± 0.01 a | 3.54 ± 0.03 b |
| Malic acid eq. (mg/mL) | 6.19 ± 0.04 a | 6.06 ± 0.04 a |
| °Brix | 17.97 ± 0.06 a | 18.05 ± 0.07 a |
| Ascorbic acid (ppm) | 119.22 ± 5.04 a | 121.16 ± 0.75 a |
| TEAC (mM) | 10.99 ± 0.16 a | 9.85 ± 0.96 c |
| Gallic acid eq. (mg/L) | 343.17 ± 1.02 a | 346.02 ± 5.04 a |
| Hue | 81.37 ± 0.59 a | 87.57 ± 0.51 b |
| Chroma | 3.29 ± 1.21 a | 5.10 ± 1.32 a |
| Time Between Ultrasound and MRI | PC VIPR Pressure (mmHg) | Ultrasound Pressure (mmHg) | Stenosis (%) | |
| No Repair | 7 days | 16.3 | 42** | 32.8 |
| 5 months | 32.3 | 33.8 | 26.2 | |
| 6 days | 16.3 | 23.4 | 18.4 | |
| Post Repair | 17 months | 5.5 | 0* | 11.1 |
| 1 month | 6.6 | 0* | 6.9 | |
| 3 months | 26.6 | 35.1 | 30.1 | |
| 2 years | -1.6 | 0* | 24.8 |
| Training set (n = 86) | Validation set (n = 42) | |
| Error rate (%) | 9.1 | 16.7 |
| Sensitivity (%) | 97.5 | 93.3 |
| Specificity (%) | 74.8 | 58.3 |
| AUC | 0.93 | 0.89 |
| Name | Function | Primer Sequence (5' to 3') | Tm (°C) | Product Length | Amplified Region |
| SIRT2 | RT-PCR | CAACCTGGAGAAATACCGTCTT | 61.0 | 166 bp | 400–565 |
| CAGTCCTTTTTCCTTCAGCAG | |||||
| β-actin | Reference | CACCAACTGGGACGACAT | 61.0 | 202 bp | 320–521 |
| ATACAGGGACAGCACAGC | |||||
| RPS9 | Reference | CCTCGACCAAGAGCTGAAG | 61.0 | 64 bp | 128–191 |
| CCTCCAGACCTCACGTTTGTTC | |||||
| GAPDH | Reference | CCAACGTGTCTGTTGTGGAT | 61.0 | 80 bp | 778–857 |
| CTGCTTCACCACCTTCTTGA | |||||
| Primer A | 3'UTR region amplification | ACCCCTGACCTCACCAAAT | 56.5 | 549 bp | 19411–19959 |
| GCACCTTTCAGCACTCTTC | |||||
| Primer B | 3'UTR region amplification | ACCCCTGACCTCACCAAAT | 62.3 | 138 bp | 19411–19548 |
| CCTGTGGCCCCCTGAGCAGTTAGAGTCTAG |
| Data set name | Description |
| LIVER CANCER [46] | Microarrays: 181; Probes: 6,605; K = 2Samples and Class: 76 normal; 105 tumorConfiguration: (ngr = 8, ngc = 4, nsr = 27, nsc = 28)http://genome-www5.stanford.edu/cgi-bin/publication/viewPublication.pl?pub_no=107 |
| LYMPHOMA [47] | Microarrays: 81; Probes: 6,850; K = 3Samples and Class: 29 normal, 43 diffuse large B-cell lymphoma (DLBCL); 9 follicular lymphoma (FL)Configuration: (ngr = 4, ngc = 4, nsr = 24, nsc = 24); (ngr = 8, ngc = 4, nsr = 24, nsc = 24)http://genome-www5.stanford.edu/cgi-bin/publication/viewPublication.pl?pub_no=79 |
| RENAL CELL CARCINOMA [48] | Microarrays: 38; Probes: 13,608; K = 4Samples and Class: 3 normal; 26 clear cell carcinoma (CCC); 5 granular cell carcinoma (GCC);4 papillary carcinoma (PC)Configuration: (ngr = 8, ngc = 4, nsr = 27, nsc = 28)http://genome-www5.stanford.edu/cgi-bin/publication/viewPublication.pl?pub_no=210 |
| GASTRIC CARCINOMA [49] | Microarrays: 130; Probes: 15,541; K = 2Samples and Class : 28 normal; 102 tumorConfiguration: (ngr = 12, ngc = 4, nsr = 30, nsc = 32); (ngr = 12, ngc = 4, nsr = 29, nsc = 32); (ngr = 12, ngc = 4, nsr = 30, nsc = 30)http://genome-www5.stanford.edu/cgi-bin/publication/viewPublication.pl?pub_no=232 |
| LUNG CANCER [50] | Microarrays: 60; Probes: 20,601; K = 5Samples and Class: 6 normal; 35 adenocarcinoma (AC); 11 squamous cell carcinoma (SCC); 4 large cell lung cancer (LCLC); 4 small cell lung cancer (SCLC)Configuration: (ngr = 8, ngc = 4, nsr = 27, nsc = 28)http://genome-www5.stanford.edu/cgi-bin/publication/viewPublication.pl?pub_no=100 |
| Clinical characteristics | LINE-1 methylation ratio by age and sex-adjusted | ||
| B | 95% CI | P | |
| HbA1c (%) | 0.043 | 0.034 to 0.052 | < 0.001 |
| FBG (mmol/l) | 0.063 | 0.048 to 0.077 | < 0.001 |
| TC (mmol/L) | −0.016 | −0.024 to −0.009 | < 0.001 |
| TG (mmol/L) | 0.001 | −0.005 to 0.008 | 0.685 |
| HDL-C (mmol/L) | −0.005 | −0.008 to −0.003 | < 0.001 |
| LDL-C (mmol/L) | −0.019 | −0.025 to −0.012 | < 0.001 |
| ApoA1 (g/l) | −0.002 | −0.005 to 0.000 | 0.053 |
| ApoB (g/l) | −0.004 | −0.006 to −0.001 | 0.006 |
| Hcy (μmol/l) | −0.251 | −0.579 to 0.077 | 0.132 |
| SBP (mmhg) | −0.245 | −0.512 to 0.021 | 0.071 |
| DBP (mmhg) | −0.018 | −0.173 to 0.138 | 0.824 |
| BMI | 0.008 | −0.039 to 0.056 | 0.732 |
| Total(n = 1889) | Male | Female | P | |
| WC ≥90 cm in men and ≥80 cm in women, n (%) | 278 (14.7) | 85 (11.2) | 193 (17.1) | <0.001 |
| SBP ≥130 mm Hg or DBP ≥85 mm Hg or hypertensive treatment, n (%) | 1064 (56.3) | 406 (53.4) | 658 (58.3) | <0.05 |
| HDL-c <40 mg/dL in men and <50 mg/dL in women, n (%) | 264 (14.0) | 123 (16.2) | 141 (12.5) | <0.05 |
| TG ≥150 mg/dL, n (%) | 226 (12.0) | 100 (13.2) | 126 (11.2) | 0.19 |
| FPG ≥100 mg/dL or diabetes treatment, n (%) | 432 (22.9) | 202 (26.6) | 230 (20.4) | <0.05 |
| Ingenuity canonical pathways | p-value | Ratio | Molecules | |
| A | TREM1 signaling | 2.71 × 10-11 | 1.69 × 10-1 | IL8, CXCL3, ICAM1, CD40, GRB2, IL10, TLR8, CASP1, IL1B, FCGR2B, NFKB1, TNF |
| Hepatic fibrosis/hepatic stellate cell activation | 8.32 × 10-11 | 1.10 × 10-1 | CXCL3, IL8, IL4R, CCR5, ICAM1, CD40, MYL6, IL10, IL6R, IL1B, IFNGR1, CCL5, NFKB1, TNF, CCR7, IL4 | |
| IL-10 signaling | 3.82 × 10-9 | 1.41 × 10-1 | TRAF6, SOCS3, FOS, IL4R, CCR5, MAPK14, IL10, IL1B, FCGR2B, NFKB1, TNF | |
| IL-12 signaling and production in macrophages | 6.87 × 10-9 | 8.97 × 10-2 | IL10, MAF, IFNGR1, NFKB1, IRF1, TRAF6, FOS, MAPK14, CD40, ZNF668, NOS2, TNF, PRKD3, IL4 | |
| IL-17A signaling in gastric cells | 3.33 × 10-8 | 2.80 × 10-1 | IL8, FOS, MAPK14, CCL20, CCL5, NFKB1, TNF | |
| B | Role of cytokines in mediating communication between immune cells | 8.88 × 10-7 | 7.27 × 10-2 | IL8, IFNB1, IL13, IL4 |
| Communication between innate and adaptive immune cells | 6.73 × 10-6 | 3.67 × 10-2 | IL8, IFNB1, CCR7, IL4 | |
| Airway inflammation in asthma | 1.81 × 10-5 | 3.33 × 10-1 | IL13, IL4 | |
| Remodeling of epithelial adherens junctions | 1.08 × 10-4 | 4.41 × 10-2 | ACTR3, MAPRE1, CLIP1 | |
| Prolactin signaling | 1.5 × 10-4 | 3.75 × 10-2 | SOCS3, FOS, IRF1 |
| Univariable | Multivariable | |||||
| Odds ratio | Confidential interval | p value | Odds ratio | Confidential interval | p value | |
| Age | 0.98 | 0.95–1.03 | 0.63 | 1.02 | 0.96–1.10 | 0.49 |
| Initial rhythm (VF and pulseless VT/asystole and PEA) | 1.47 | 0.51–4.22 | 0.46 | 1.42 | 0.32–6.27 | 0.64 |
| Location(out/in) | 1.17 | 0.42–3.26 | 0.64 | 10.0 | 1.35–75.0 | 0.01 |
| CPR duration | 1.02 | 0.99–1.05 | 0.22 | 1.08 | 1.01–1.12 | 0.02 |
| pH | 25.2 | 1.24–509 | 0.03 | 247 | 4.16–15,000 | < 0.01 |
| Lactate clearance (high/low) | 5.3 | 1.67–16.8 | 0.01 | 7.10 | 1.71–29.5 | < 0.01 |
| Parameter | Total | With ≥ 2-year complete follow-up | ||
| Female | Male | Female | Male | |
| Number of patients | 802 | 526 | 463 | 313 |
| Number of knees | 1069 | 716 | 574 | 397 |
| Proportion right knees | 51.7% | 49.4% | 51.4% | 49.4% |
| Patient age, mean (range) years | 71.9 (39–95) | 70.9 (44–96) | 73.3 (50–94) | 71.6 (48–95) |
| Body mass index mean (range) kg/m2 | 33.2 (18–76) | 32.3 (8–79) | 32.6 (18–62) | 32.0 (8–57) |
| Diagnosis | ||||
| Osteoarthritis | 97.5% | 98.6% | 97.4% | 98.7% |
| Rheumatoid arthritis | 1.6% | 0.8% | 1.9% | 1.0% |
| Avascular necrosis | 0.6% | 0.3% | 0.4% | 0.3% |
| Osteonecrosis | 0.1% | 0.0% | 0.2% | 0.0% |
| Posttraumatic arthritis | 0.1% | 0.1% | 0.2% | 0.0% |
| Others | 0.2% | 0.1% | 0.0% | 0.0% |
| Length-of-stay, mean (range) days | 2.5 (1–18) | 2.2 (1–22) | 2.4 (1–10) | 2.1 (1–11) |
| Follow-up, mean (range) years | 2.4 (0.7–7.2) | 2.4 (0.8–6.9) | 2.9 (2–7.2) | 2.9 (2–6.9) |
| Parameters | Negative control | Standardmisoprostol 100 μg/kg | Test-ITDFME 125 mg/kg | Test-IITDFME250 mg/kg | Test-IIITDFME500 mg/kg |
| Catalase | 2.89 ± 0.11 (0.27) | 4.09 ± 0.18 (0.44)b | 3.86 ± 0.12 (0.49)a | 3.94 ± 0.20 (0.49)a | 4.23 ± 0.38 (0.94)b |
| Malondialdehyde | 7.11 ± 0.30 (0.74) | 2.69 ± 0.23 (0.57)c | 5.64 ± 0.29 (0.73)b | 4.94 ± 0.16 (0.40)c | 3.58 ± 0.24 (0.60)c |
| Mucin content | 0.52 ± 0.06 (0.15) | 1.07 ± 0.11 (0.27)b | 0.95 ± 0.15 (0.37)a | 1.15 ± 0.10 (0.24)b | 1.89 ± 0.11 (0.29)c |
| Nonprotein sulphhydryl concentration | 2.31 ± 0.18 (0.45) | 4.55 ± 0.17 (0.42)c | 3.00 ± 0.19 (0.47)b | 3.07 ± 0.09 (0.24)b | 4.98 ± 0.00 (0.23)c |
| Superoxide dismutase | 2.75 ± 0.35 (0.86) | 5.99 ± 0.31 (0.78)c | 2.44 ± 0.30 (0.74)ns | 4.05 ± 0.23 (0.57)a | 4.07 ± 0.24 (0.59)a |
| Total protein content | 342.5 ± 4.09 (10.03) | 313.2 ± 3.22 (7.91)c | 321.7 ± 4.68 (11.47)b | 316.5 ± 5.50 (13.49)b | 251.7 ± 4.15 (10.17)c |
| Ulcer index | 10 ± 0.28 (0.70) | 4.50 ± 0.42 (1.04)c | 7.08 ± 0.58 (1.42)c | 4.00 ± 0.36 (0.89)c | 1.50 ± 0.46 (1.14)c |
| Time points | Bowel movement frequency, mean ± SD, episodes per wk | Stool consistency, mean ± SD, BSFS grade | ||||
| PEG | PEG + PM | P | PEG | PEG + PM | P | |
| Enrollment | 2.5 ± 1.1 | 2.3 ± 0.7 | 0.344 | 2.6 ± 0.6 | 2.5 ± 0.7 | 0.395 |
| 2-week follow-up visit | 5.9 ± 1.3 | 5.4 ± 1.4 | 0.168 | 4.2 ± 0.5 | 3.9 ± 1.0 | 0.271 |
| 4-week follow-up visit | 6.3 ± 0.9 | 6.0 ± 1.2 | 0.659 | 4.4 ± 0.5 | 4.1 ± 0.6 | 0.267 |
| 8-week follow-up visit | 6.3 ± 0.9 | 6.3 ± 1.0 | 0.924 | 4.2 ± 0.5 | 4.2 ± 0.5 | 0.857 |
| Variants | AA change | Novel | Exon | Sift Prediction | Polyphen Prediction | MAF (%) | ||||
| Score | Prediction | Score | Prediction | Control | PS | PSE | ||||
| +21059 C/T | 333A > T | Yes | 5 | 0.28 | Tolerated | 0 | Benign | 0 | 0.5 | 0 |
| +21029 C/G | 323A > P | Yes | 5 | 0.08 | Tolerated | 0.476 | Possibly damaging | 0.5 | 0 | 0 |
| rs2296651 | 267S > F | No | 4 | 0.31 | Tolerated | 0.88 | Probably damaging | 0.9 | 0.9 | 2.3 |
| +18885 A/G | 256 M > T | Yes | 4 | 0 | Damaging | 0.839 | Possibly damaging | 0 | 0 | 0.5 |
| +18131 A/G | 222 L > S | Yes | 3 | 0 | Damaging | 0.637 | Possibly damaging | 0 | 0 | 0.5 |
| rs202213974 | 200 V > M | No | 3 | 0 | Damaging | 0.819 | Possibly damaging | 0 | 0 | 0.5 |
| +11121 G/C | 131 L > V | Yes | 2 | 0.23 | Tolerated | 0.484 | Possibly damaging | 0.5 | 0 | 0 |
| rs148467625 | 88I > T | No | 1 | 0.57 | Tolerated | 0.072 | Benign | 0.5 | 0.5 | 0 |
| Original value | HNR-I | HNR-II | HNR-III | HNR-IV | HNR-V | HNR-VI | Total |
| 1-10 | O/13 | 15/30 | 20/27 | 0/1 | 11/11 | 15/20 | |
| 10-20 | O/21 | 1/41 | 5/21 | 0/21 | 0/3 | 0/0 | 6/107§ |
| ≥20 | 0/16 | 0/16 | 0/21 | 0/16 | 0/23 | 0/26 | 0/118 |
| Total | 0/50 | 16/87 | 25/69 | 0/38 | 11/37 | 15/46 | 67/327 |
| ICGA | FA | |||||||||
| No. | Age | Sex | R/L | Cell/Flare | SRD | Optic disc hyperemia | Fuzzy choroidal vessels | Hypofluorescent dark dots | Pinpoints Hyperfluorescence | Pleocytosis |
| 1 | 34 | F | L | + | − | − | + | + | − | + |
| 2 | 56 | F | R | − | + | + | + | + | + | + |
| L | − | + | + | + | + | + | ||||
| 3 | 31 | F | R | − | + | + | + | + | + | + |
| L | + | + | + | + | + | + | ||||
| 4 | 43 | F | R | + | + | + | + | + | + | + |
| 5 | 57 | F | R | + | + | + | + | + | + | + |
| L | + | − | + | + | + | − | ||||
| 6 | 24 | M | R | − | + | + | + | + | + | + |
| 7 | 44 | M | R | − | − | + | + | + | − | + |
| 8 | 46 | F | R | + | − | + | + | + | − | − |
| 9 | 64 | M | R | + | + | + | + | + | + | + |
| L | + | + | + | + | + | + | ||||
| 10 | 15 | M | R | + | + | + | + | + | + | + |
| L | + | − | + | unknown | + | − |
| Supernatant | Colorimetric | HPLC | Difference |
| 1 | 3.8 | 3.3 | 0.5 |
| 2 | 13 | 12.7 | 0.3 |
| 3 | 12.3 | 11.7 | 0.6 |
| 4 | 2.2 | 3 | −0.8 |
| 5 | 12.7 | 13.7 | −1.0 |
| 6 | 10.6 | 11.2 | −0.6 |
| 7 | 0.9 | 1.1 | −0.2 |
| 8 | 14.8 | 13.9 | 0.9 |
| 9 | 3.9 | 3.9 | 0.0 |
| d (average on difference) | 0.03 | ||
| sd (standard deviation of difference) | 0.7 |
| Item NO. | PF | EF | SF | SchF |
| PF | ||||
| QOL1 | .42 | .21 | .30$ | .26 |
| QOL2 | .44 | .18 | .33$ | .28 |
| QOL3 | .53 | .14 | .26 | .29 |
| QOL4 | .39 | .13 | .31$ | .22 |
| QOL5 | .13 | .21$ | .07 | |
| QOL6 | .48 | .21 | .26 | .21 |
| QOL7 | .45 | .25 | .19 | .21 |
| QOL8 | .43 | .32$ | .23 | .19 |
| EF | ||||
| QOL9 | .16 | .17 | .25$ | |
| QOL10 | .25 | .51 | .25 | .19 |
| QOL11 | .16 | .25$ | .16 | |
| QOL12 | .25$ | .39***$ | .29***$ | |
| QOL13 | .22***$ | .34***$ | .32***$ | |
| SF | ||||
| QOL14 | .33***$ | .32***$ | . | .29***$ |
| QOL15 | .31$ | .28 | .45 | .23 |
| QOL16 | .25 | .27 | .46 | .30 |
| QOL17 | .23 | .31 | .47 | .47$ |
| QOL18 | .22 | .22 | .39 | .37$ |
| SchF | ||||
| QOL19 | .27 | .33 | .36 | .52 |
| QOL20 | .26 | .41 | .39 | .55 |
| QOL21 | .24 | .32 | .38 | .53 |
| QOL22 | .30 | .14 | .33 | .56 |
| QOL23 | .30 | .19 | .36 | .57 |
| Potential operon (r value) | Gene ID | Putative or predicted function | Reference (s) |
| Iron uptake or heme synthesis | |||
| yfeABCD operon* (r > 0.91) | YPO2439-2442 | Transport/binding chelated iron | yfeABCD [54] |
| hmuRSTUV operon (r > 0.90) | YPO0279-0283 | Transport/binding hemin | hmuRSTUV [55] |
| ysuJIHG* (r > 0.95) | YPO1529-1532 | Iron uptake | - |
| sufABCDS* (r > 0.90) | YPO2400-2404 | Iron-regulated Fe-S cluster assembly? | - |
| YPO1854-1856* (r > 0.97) | YPO1854-1856 | Iron uptake or heme synthesis? | - |
| Sulfur metabolism | |||
| tauABCD operon (r > 0.90) | YPO0182-0185 | Transport/binding taurine | tauABCD [56] |
| ssuEADCB operon (r > 0.97) | YPO3623-3627 | Sulphur metabolism | ssu operon [57] |
| cys operon (r > 0.92) | YPO3010-3015 | Cysteine synthesis | - |
| YPO1317-1319 (r > 0.97) | YPO1317-1319 | Sulfur metabolism? | - |
| YPO4109-4111 (r > 0.90) | YPO4109-4111 | Sulfur metabolism? | - |
| Urea uptake and urease activation | |||
| ure operon* (r > 0.96) | YPO2665-2672 | Pathogenicity | ure [58, 59] |
| Stress response and adaptation | |||
| dnaKJ operon (r = 0.97) | YPO0468-0469 | Chaperones, chaperonins, heat shock | dnaKJ [60, 61] |
| hslUV operon (r = 0.97) | YPO0105-0106 | Adaptions and atypical conditions | hslUV [62] |
| katY-cybCB operon* (r > 0.90) | YPO3319-3321 | Detoxification and electron transport | - |
| psp operon (r > 0.90) | YPO2349-2351 | Adaptions and atypical conditions | psp operon [63] |
| Ribosome constituents | |||
| rps-rpm-rpl operon (r > 0.90) | YPO0209-0235 | Ribosomal protein synthesis and modification | rps-rpm-rpl operon [64] |
| Energy metabolism | |||
| sdh-suc operon* (r > 0.92) | YPO1109-1116 | Tricarboxylic acid cycle | sdhCDAB [65] |
| cyo operon (r > 0.94) | YPO3164-3168 | Aerobic respiration | cyoABCDE [55] |
| nap operon (r > 0.94) | YPO3036-3040 | Electron transport | nap operon [66] |
| atp operon (r > 0.93) | YPO4120-4128 | ATP-proton motive force | atpIBEFHAGDC [67] |
| ace operon* (r > 0.90) | YPO3724-3726 | Glyoxylate bypass | aceBAK [68] |
| nuo operon* (r > 0.92) | YPO2543-2555 | Aerobic respiration | nuo operon [69] |
| Degradation and transport/binding of amino acids | |||
| pro operon* (r > 0.92) | YPO2645-2647 | Transport/binding amino acids and amines | proVWX [70] |
| ast operon (r > 0.90) | YPO1962-1966 | Degradation of amino acids | astCADBE [71] |
| gln operon* (r > 0.91) | YPO2512-2514 | Transport/binding amino acids and amines | glnHPQ [72] |
| others | |||
| YPO1994-1996* (r > 0.98) | YPO1994-1996 | Unknown | - |
| YPO0881-0884 (r = 0.99) | YPO0881-0884 | Chemotaxis and mobility? | - |
| YPO1087-1088 (r = 0.99) | YPO1087-1088 | Phage-related functions and prophage | - |
| YPO0623-0628* (r > 0.94) | YPO0623-0628 | Unknown | - |
| mur operon (r > 0.95) | YPO0550-0553 | Murein sacculus and peptidoglycan | - |
| idn operon (r = 0.96) | YPO2539-2540 | Degradation of carbon compounds | - |
| fad operon* (r = 0.95) | YPO3766-3767 | Degradation of small molecule | - |
| glg operon (r > 0.90) | YPO3938-3942 | Synthesis and modification of cytoplasmic polysaccharides | glg operon [73] |
| YPO3838-3839 (r = 0.92) | YPO3838-3839 | Unknown | - |
| YPO0408-0409* (r = 0.97) | YPO0408-0409 | Unknown | - |
| YPO1516-1517 (r = 0.90) | YPO1516-1517 | Unknown | - |
| YPCD1.15c-1.17c (r > 0.98) | YPCD1.15c-1.17c | Unknown | - |
| yscGHIJK operon* (>0.90) | YPCD1.55-1.57 | T3SS constituents | - |
| YPPCP1.08c-1.09c (r = 0.97) | YPPCP1.08c-1.09c | Unknown | - |
| Variable | Male | Female | Overall | ||||||
| % active | 95% CI | p value | % active | 95% CI | p value | % active | 95% CI | p value | |
| Age (years) | |||||||||
| 18–20 | 23.1 | 16.3–31.2 | .24a | 5.5 | 2.2–10.9 | .65a | 14.5 | 10.5–19.4 | .11a |
| 21–24 | 29.5 | 22.5–36.3 | 6.8 | 3.2–12.5 | 19.6 | 15.3–24.5 | |||
| Monthly family income (BDT)* | |||||||||
| ≤20,000 | 25.0 | 16.4–35.4 | .33a | 3.7 | 0.1–1.9 | .99b | 20.0 | 13.1–28.5 | .20a |
| 20,001–40,000 | 33.3 | 23.9–43.9 | 5.8 | 1.6–14.2 | 21.6 | 15.5–28.7 | |||
| 40,001–70,000 | 21.4 | 13.2–31.7 | 6.8 | 2.5–14.3 | 14.0 | 9.1–20.0 | |||
| > 70,000 | 26.7 | 14.6–41.9 | 6.9 | 2.3–15.5 | 14.5 | 8.7–22.2 |
| Age Group | Boys | Girls | ||||||
| WC/Ht percentile | WC/Ht percentile | |||||||
| < 97th | 97-100th | < 97th | 97-100th | |||||
| 6-9 yr | n | 40 | 154 | 14 | 142 | |||
| Systolic BP < 130 mmHg | 2/40 | (5.0) | 10/154 | (6.5) | 0/1 | (0.0) | 9/142 | (6.3) |
| Dyastolic BP < 85 mmHg | 2/40 | (5.0) | 8/154 | (5.2) | 1/14 | (7.1) | 11/142 | (7.8) |
| BS < 5.6 mM | 7/40 | (17.5) | 31/154 | (20.1) | 0/14 | (0.0) | 17/142 | (12.0) |
| TG < 1.7 mM | 0/40 | (0.0) | 10/154 | (6.5) | 0/14 | (0.0) | 5/142 | (3.5) |
| HDL-C <1.03 mM | 0/40 | (0.0) | 4/154 | (2.6) | 0/14 | (0.0) | 5/142 | (3.5) |
| Two or more metabolic risk factors | 0/40 | (0.0) | 7/154 | (4.6) | 0/14 | (0.0) | 2/142 | (1.4) |
| 10-12 yr | n | 78 | 83 | 38 | 78 | |||
| Systolic BP < 130 mmHg | 11/78 | (14.1) | 15/83 | (18.1) | 2/15 | (13.3) | 10/59 | (17.0) |
| Dyastolic BP < 85 mmHg | 6/78 | (7.7) | 14/83 | (16.9) | 0/15 | (0.0) | 5/59 | (8.5) |
| BS < 5.6 mM | 17/78 | (21.8) | 20/83 | (24.1) | 4/15 | (26.7) | 11/59 | (18.6) |
| TG < 1.7 mM | 3/78 | (3.9) | 12/83 | (14.5) | 2/15 | (13.3) | 3/59 | (5.1) |
| HDL-C <1.03 mM | 0/78 | (0.0) | 6/83 | (7.2) | 1/15 | (6.7) | 0/59 | (0.0) |
| Two or more metabolic risk factors | 4/78 | (5.1) | 12/83 | (14.5) | 2/15 | (13.3) | 1/59 | (1.7) |
| Actual positive | Actual negative | |
| Predicted positive | TP | FP |
| Predicted negative | FN | TN |
| NS | HA | RD | P | ||
| NS | – | −0.431** | 0.207* | −0.128 | |
| HA | −0.431** | – | 0.009 | −0.165 | |
| RD | 0.207* | 0.009 | – | −0.088 | |
| P | −0.128 | −0.165 | −0.088 | – | |
| NS | NS1 | NS2 | NS3 | NS4 | |
| NS | – | 0.551** | 0.652** | 0.715** | 0.640** |
| NS1 | 0.551** | – | −0.006 | 0.335** | 0.151 |
| NS2 | 0.652** | −0.006 | – | 0.294** | 0.357** |
| NS3 | 0.715** | 0.335** | 0.294** | – | 0.239* |
| NS4 | 0.640** | 0.151 | 0.357** | 0.239* | – |
| HA | HA1 | HA2 | HA3 | HA4 | |
| HA | – | 0.869** | 0.799** | 0.826** | 0.750** |
| HA1 | 0.869** | – | 0.712** | 0.658** | 0.544** |
| HA2 | 0.799** | 0.712** | – | 0.583** | 0.442** |
| HA3 | 0.826** | 0.658** | 0.583** | – | 0.457** |
| HA4 | 0.750** | 0.544* | 0.442** | 0.457** | – |
| RD | RD1 | RD2 | RD3 | ||
| RD | – | 0.672** | 0.804** | 0.466** | |
| RD1 | 0.672** | – | 0.253* | 0.070 | |
| RD2 | 0.804** | 0.243* | – | 0.220* | |
| RD3 | 0.466** | 0.070 | 0.220* | – |
| Clinical source | Total strains | ZOT positivity | Exotoxin 9 positivity | GSI | GSII |
| CD | 29 | 72.41 | 72.41 | 10.34 | 89.66 |
| Gastroenteritis | 31 | 70.97 | 51.61 | 35.48 | 64.52 |
| Lymphocytic colitis | 1 | 100 | 100 | 0 | 100 |
| Collagenous colitis | 3 | 33.33 | 100 | 33.33 | 66.67 |
| Bloody diarrhoea | 8 | 100 | 37.5 | 50 | 50 |
| Periodontal disease | 1 | 100 | 100 | 100 | 0 |
| Healthy | 11 | 72.73 | 63.64 | 27.27 | 72.73 |
| UC | 4 | 25 | 50 | 50 | 50 |
| All | 88 | 71.59 | 60.22 | 28.41 | 71.59 |
| Anterior segment pathology | Number of eyes |
| Cornea diseases | |
| Mucopolysaccharidosis | 4 |
| Keratoconus | 3 |
| Anterior segment congenital condition | |
| Mesoectodermal dysgenesis | 2 |
| Sclerocornea | 1 |
| Congenital glaucoma | 2 |
| Microphthalmia | 3 |
| Keratoglobus | 1 |
| Ocular trauma | |
| Self-sealing corneal penetrating injury | 1 |
| Anterior segment surgery | |
| Cornea transplant and glaucoma drainage tube | 1 |
| Glaucoma drainage tube | 1 |
| Iridocorneal angle abnormalities | |
| Anterior synechiae post-uveitis | 1 |
| Neovascular glaucoma | 2 |
| Synechia associated to ciliary body lesion | 1 |
| Intermediate Uveitis | 2 |
| Ocular surface lesions | |
| Corneoscleral dermoid | 1 |
| Discussed with an HIV nurse practitioner | Discussed with an HIV care medical doctor | Discussed at the HIV care visit | |||||||
| Never | Sometimes | Regularly | Never | Sometimes | Regularly | Never | Sometimes | Regularly | |
| Topics that patients wanted to discuss | % (n) | % (n) | % (n) | % (n) | % (n) | % (n) | % (n) | % (n) | % (n) |
| STI-related symptoms | 20 (12) | 52 (30) | 28 (16) | 25 (15) | 61 (36) | 14 (8) | 18 (11) | 55 (33) | 27 (16) |
| Information on STIs | 24 (13) | 48 (26) | 28 (15) | 23 (12) | 57 (30) | 21 (11) | 13 (7) | 52 (28) | 35 (19) |
| Sexual problems | 17 (8) | 58 (28) | 25 (12) | 37 (17) | 50 (23) | 13 (6) | 13 (6) | 57 (27) | 30 (13) |
| Safe sex information | 14 (6) | 60 (25) | 26 (11) | 20 (8) | 59 (24) | 22 (9) | 14 (6) | 52 (22) | 34 (14) |
| Relationship and sex | 11 (4) | 67 (24) | 22 (8) | 23 (8) | 60 (21) | 17 (6) | 11 (4) | 61 (22) | 28 (10) |
| Negative sexual experiences | 25 (5) | 60 (12) | 15 (3) | 58 (11) | 37 (7) | 5 (1) | 25 (5) | 60 (12) | 15 (3) |
| Contraception | 18 (3) | 47 (8) | 35 (6) | 13 (2) | 69 (11) | 19 (3) | 6 (1) | 59 (10) | 35 (6) |
| Pregnancy | 11 (1) | 71 (5) | 14 (1) | 0 | 100 (8) | 0 | 0 | 88 (7) | 12 (1) |
| Age | Discharge type | Single duct? | Initial surgery | Initial histology | Final histology | Treatment |
| 32 | Fresh blood | Yes | Micro | DCIS | Intermediate grade DCIS | Mx + ANS + recon |
| 43 | Fresh blood | No | TDE | DCIS | Extensive intermediate grade DCIS | Mx + ANS + recon |
| 51 | Fresh blood/serous | Yes | TDE | DCIS | High grade DCIS | Mx + ANS |
| 58 | Fresh blood | Yes | TDE | IDC | 3 mm grade 3 IDC + extensive DCIS | Mx + ANC + recon |
| 60 | Fresh blood | Yes | Micro | DCIS | High grade DCIS | Mx + ANS |
| 68 | Fresh blood | Yes | TDE | IDC | 3 mm grade 2 IDC + DCIS | Mx + ANC |
| 69 | Fresh blood | Yes | Micro | DCIS | Multifocal intermediate grade DCIS | Mx + ANS |
| 72 | History of fresh blood; serous discharge identified, dipstick +++ for blood | Yes | TDE | IDC | 10 mm grade 2 IDC + DCIS | Mx+ ANC |
| 74 | Altered blood | Yes | TDE | IDC | 10 mm grade 2 IDC + widespread DCIS | Mx and ANC |
| 78 | Fresh blood | Yes | TDE | DCIS | Multifocal intermediate grade DCIS | Simple Mx |
| 88 | Fresh blood | Yes | TDE | DCIS | Low grade DCIS | Simple Mx |
| Nonretreatment Group B | Retreatment Group A | |
| (N = 106) | (N = 125) | |
| Age, years | ||
| Mean (SD) | 61.4 (10.00) | 60.8 (10.39) |
| Gender, N (%) | ||
| Female | 62 (58.5) | 74 (59.2) |
| Male | 44 (41.5) | 51 (40.8) |
| Body mass index, kg/m2 (mean ± SD) | 28.4 (4.06) | 28.3 (4.05) |
| Kellgren-Lawrence Score - Study Knee [N (%)] | ||
| Grade 1 | 11 (10.4) | 10 (8.0) |
| Grade 2 | 46 (43.4) | 42 (33.6) |
| Grade 3 | 49 (46.2) | 73 (58.4) |
| WOMAC pain subscores - Study Knee (mean) | 68.1 | 69.0 |
| Subtype | OMIM ID | Causative gene | HGNC ID | Cytogenetic location | Inheritance |
| FHL1 | 267700 | HPLH1a | HGNC:23824 | 9q21.3 - q22 | AR |
| FHL2 | 603553 | PRF1 | HGNC:9360 | 10q22.1 | AR |
| FHL3 | 608898 | UNC13D | HGNC:23147 | 17q25.1 | AR b |
| FHL4 | 603552 | STX11 | HGNC:11429 | 6q24.2 | AR |
| FHL5 | 613101 | STXBP2 | HGNC:11445 | 19p13.2 | AR b |
| XLP1 | 308240 | SH2D1A | HGNC:10820 | Xq25 | XLR |
| XLP2 | 300635 | XIAP | HGNC:592 | Xq25 | XLR |
| Clinical symptoms | PCNSL(NO of patients) | GBM(NO of patients) |
| Organic brain syndrome | 22 | 12 |
| Signs of intracranial hypertension | 16 | 23 |
| Paresis | 16 | 19 |
| Vertigo | 12 | 13 |
| Phatic disorder | 11 | 14 |
| Visual disturbances | 7 | 3 |
| Cranial nerve dysfunction other than visual disturbance | 5 | 0 |
| Fatigue | 4 | 7 |
| Dysesthesia or hypesthesia | 4 | 1 |
| Seizure | 1 | 9 |
| Description | Unit | n | Abbreviation |
| Milk yield | l/day | 285 | dMY |
| FMI per visit | kg/visit | 13,908 | vFMI |
| Feeding duration per visit | s/visit | 13,908 | vFdur |
| FMI (fresh matter intake) | kg/day | 311 | dFMI |
| Feeding time | min/day | 311 | dFtime |
| Feeding frequency | visits/day | 311 | dFfreq |
| Mean FMI per visit | kg/visit | 311 | mvFMI |
| Mean feeding duration per visit | s/visit | 311 | mvFdur |
| Daily feeding rate | g/min | 311 | dFR |
| Cow feeding rate | g/min | 16 | cFR |
| Rumination duration per event | min/event | 7,697 | eRUMdur |
| Rumination time | min/day | 311 | dRUMtime |
| Rumination frequency | events/day | 311 | dRUMfreq |
| Mean rumination duration | min/event | 311 | meRUMdur |
| Characteristicsa | Cases(n = 1760) | Controls(n = 2481) |
| No. (%) | No. (%) | |
| Age (years)* | ||
| 18-49 | 368(20.9) | 265(10.7) |
| 50-59 | 412(23.4) | 690(27.8) |
| 60-69 | 646(36.7) | 998(40.2) |
| 70+ | 334(19.0) | 528(21.3) |
| Sex | ||
| Males | 935(53.1) | 1357(54.7) |
| Females | 825(46.9) | 1124(45.3) |
| Province of residence | ||
| NL | 488(27.7) | 651(26.2) |
| ON | 1272(72.3) | 1830(73.8) |
| BMIb (kg/m2)* | ||
| Underweight(< 18.5) | 23(1.3) | 22(0.9) |
| Normal(18.5-24.9) | 595(33.8) | 930(37.5) |
| Overweight (25-29.9) | 748(42.5) | 1069(43.1) |
| Obese(≥ 30) | 394(22.4) | 460(18.5) |
| Physical activity (METs/weekb)* | ||
| 0 - 7.4 | 465(26.4) | 595(24.0) |
| 7.4 - 22.4 | 348(19.8) | 633(25.5) |
| 22.4 - 53.0 | 429(24.4) | 633(25.5) |
| > 53.0 | 518(29.4) | 620(25.0) |
| Family history of CRC* | ||
| No | 1582(89.9) | 2337(94.2) |
| Yes | 178(10.1) | 144(5.8) |
| Reported any colon screening procedure* | ||
| No | 1500(85.2) | 1861(75.0) |
| Yes | 260(14.8) | 620(25.0) |
| Regular use of NSAIDb* | ||
| No | 1163(66.1) | 1439(58.0) |
| Yes | 597(33.9) | 1042(42.0) |
| Education attainment* | ||
| High school graduate or less | 884(50.2) | 1042(42.0) |
| Technical school/some college/university | 540(30.7) | 866(34.9) |
| Bachelor's degree/graduate degree | 336(19.1) | 573(23.1) |
| Household income ($CAN)* | ||
| < 12,000 | 109(6.2) | 154(6.2) |
| 12,000-29,999 | 507(28.8) | 573(23.1) |
| 30,000-49,999 | 547(31.1) | 777(31.3) |
| ≥ 50,000 | 597(33.9) | 977(39.4) |
| Downregulated Pathways | Fat | Liver | Muscle | Comments |
| Steroid Biosynthesis | Q; EQ | Target of Statins | ||
| Phagocytosis/ leukocyte extravasation | EQ | Innate Immune Response | ||
| EIF2 signaling | Q; EQ | Stress Response | ||
| Mitochondrial dysfunction | Q | Associated with disease | ||
| eIF4/p70S6K signaling | Q; EQ | Insulin Signaling | ||
| Oxidative phosphorylation | Q; EQ | Energy Production | ||
| PPARα/RXRα activation | Q | Gene Expression |
| Termamyl | |||
| Parameter | Model (5) versus model (1) | Model (6) versus model (1) | Model (7) versus model (1) |
| vmax | t value = −2.874 | t value = −3.214 | t value = −3.327 |
| P value = 0.045* | P value = 0.032* | P value = 0.029* | |
| D.F. = 4 | D.F. = 4 | D.F. = 4 | |
| KM | t value = −1.921 | t value = −1.873 | t value = −1.683 |
| P value = 0.127 | P value = 0.134 | P value = 0.168 | |
| D.F. = 4 | D.F. = 4 | D.F. = 4 | |
| San Super | |||
| Parameter | Model (5) versus model (1) | Model (6) versus model (1) | Model (7) versus model (1) |
| vmax | t value = −2.582 | t value = −2.053 | t value = −3.179 |
| P value = 0.061 | P value = 0.109 | P value = 0.033* | |
| D.F. = 4 | D.F. = 4 | D.F. = 4 | |
| KM | t value = −1.982 | t value = −1.895 | t value = −1.778 |
| P value = 0.118 | P value = 0.131 | P value = 0.150 | |
| D.F. = 4 | D.F. = 4 | D.F. = 4 | |
| BAN | |||
| Parameter | Model (5) versus model (1) | Model (6) versus model (1) | Model (7) versus model (1) |
| vmax | t value = −2.301 | t value = −2.182 | t value = −2.089 |
| P value = 0.083 | P value = 0.094 | P value = 0.105 | |
| D.F. = 4 | D.F. = 4 | D.F. = 4 | |
| KM | t value = −0.689 | t value = −0.638 | t value = −0.577 |
| P value = 0.529 | P value = 0.558 | P value = 0.595 | |
| D.F. = 4 | D.F. = 4 | D.F. = 4 |
| Health Care Providers | |||||
| Unqualified providers (UQP) | Yes | Qualified Providers (QP) | Yes | ||
| n* | % | n | % | ||
| Village doctor | 416 | 92.7 | Public | ||
| Drug stores | 341 | 75.9 | Upazila Health Complex | 136 | 30.3 |
| Self-medication | 302 | 67.3 | Union Health/Satellite Clinic | 100 | 22.3 |
| FWA/FWV/Nurses | 161 | 35.9 | Private | ||
| Medical assistant | 39 | 8.7 | Private clinic | 160 | 35.5 |
| Homeopath | 158 | 35.2 | Paramedics | 266 | 59.1 |
| Spiritual treatment | 94 | 20.9 | |||
| Folk medicine | 142 | 31.6 | |||
| *n=number |
| No CAD (%) (n = 15) | CAD (%) (n = 38) | |
| Hypertension (blood pressure > 140/90 mmHg or on antihypertensive therapy) | 60 | 97 |
| Increased abdominal circumference (male > 92 cm, females > 88 cm) | 33.3 | 79.1 |
| Abnormal glucose tolerance | 0 | 55.26 |
| Raised triglycerides (> 1.7 mmol/l) | 26.7 | 50 |
| Low HDL cholesterol (men < 1.0 mmol/l, women < 1.3 mmol/l) | 33.33 | 42.10 |
| Raised LDL cholesterol (> 3 mmol/l) | 13.33 | 42.10 |
| Cigarette smoking/previous smokers | 20 | 62.5 |
| Mean CIMT (mm) | 0.998 | 1.13 |
| Increased CIMT (> 0.8 mm) | 53 | 76 |
| (N = 24) | Distance from the bladder neck | Distance from the echolucent urethral lumen | |
| [mm] | % of urethral length | [mm] | |
| Mean | 19.43 | 64.9% | 3.13 |
| Median | 19.00 | 64.5% | 3.30 |
| Std. dev. | 3.19 | 6.9% | 0.94 |
| Parameter | Control (n=56) | Oil refinery workers (n=56) | p-value |
| Age (years) | 30.02±1.76 | 35.20±1.62 | 0.320 |
| Height (cm) | 174±0.93 | 170.75±0.83 | 0.100 |
| Weight (kg) | 80.25±2.68 | 78.36±1.55 | 0.543 |
| FVC (lit) | 5.21±0.15 | 4.76±0.20 | 0.083 |
| FEV1 (lit/sec) | 3.99±0.14 | 3.08±0.16 | 0.0001 |
| FEV1/FVC (%) | 76.66±2.01 | 67.19±3.15 | 0.013 |
| PEF (lit/ sec) | 6.89±0.34 | 4.80±0.37 | 0.0001 |
| FEF 25% (lit/sec) | 6.39±0.33 | 4.45±0.36 | 0.0001 |
| FEF 50% (lit/sec) | 4.62±0.25 | 3.65±0.28 | 0.012 |
| FEF 75% (lit/sec) | 2.24±0.16 | 1.92±0.15 | 0.151 |
| Response options for doctors and researchersb | ||||||||
| Benefit | Harm | |||||||
| A great deal | Quite a lot | Only a little | No benefit or harm | Only a little | Quite a lot | A great deal | ||
| Criteria for doctors and researchers | ||||||||
| 1. Significant discussiona or other intervention that presumably reduces other health care use | x | |||||||
| 2. Need to contact child welfare | x | |||||||
| 3. Some referrals to secondary care | x | x | ||||||
| 4. Doctor’s role irreplaceable by nurse | x | |||||||
| 5. Presumably reduced concernb | x | |||||||
| 6. Some significant discussionsb | x | |||||||
| 7. Nurse could have replaced the doctor | x | |||||||
| 8. No significant harm as consequence of unhandled concerns | x | |||||||
| 9. Suspicion that interaction failed or suspicion of no progress in care | x | |||||||
| 10. The interaction failed or here was no progress in care | x | |||||||
| 11. Suspicion of negative PREM or refusal of school doctor services in the future and no progress in care | x | |||||||
| PREM question | ||||||||
| How much benefit or harm did you perceive from the school doctor’s health check? | I don’t know | |||||||
| Response options for parents | x | x | x | x | x | x | x | x |
| Response options for children | x | x | x | x | x |
| Source | A lot | A fair amount | A little | Almost none |
| Chicago City Health Department | 9.5 | 21.4 | 33.3 | 35.7 |
| Chicago Housing Authority | 9.5 | 14.3 | 23.8 | 52.4 |
| Doctor | 19.1 | 14.3 | 21.4 | 45.2 |
| Friends and relatives | 31.0 | 14.3 | 28.6 | 26.2 |
| Illinois Department of Health | 16.7 | 19.1 | 21.4 | 42.9 |
| Newspaper | 21.4 | 21.4 | 40.5 | 16.7 |
| People for Community Recovery (PCR) | 45.2 | 21.4 | 21.4 | 11.9 |
| Private industry, such as Waste Management or Ford Motor Company | 9.5 | 7.1 | 19.1 | 64.3 |
| Radio | 21.4 | 14.3 | 21.4 | 42.9 |
| Television | 31.0 | 28.6 | 33.3 | 7.1 |
| U.S. Environmental Protection Agency | - | 40.5 | 28.6 | 30.9 |
| University/College scientists | 4.8 | 26.2 | 33.3 | 35.7 |
| Species | Whole wing | Red band | ||||
| t | df | p | t | df | p | |
| H. erato phyllis | 0.46 | 57.18 | .65 | 0.30 | 52.82 | .77 |
| H. besckei | 0.76 | 52.34 | .45 | −4.10 | 47.80 | .0002a |
| H. melpomene burchelli | 0.39 | 32.86 | .70 | −2.00 | 40.40 | .05a |
| H. melpomene nanna | 0.39 | 48.31 | .70 | −3.22 | 50.28 | .002a |
| Appendix I: Key Economic Variables | Reference/Data Source | |
| ECONOMIC | ||
| Annual Discount Rate | 3% | 27 |
| Exchange Rate: Shekels to USD (2005) | 4.35 | 12 |
| Per capita GDP (USD 2003) | $16,497 | 12 |
| Training Staff | ||
| Number of Clinics in Israel | 3000 | MOH Statistical Dept. |
| Staff per clinic receiving training | 2 | Ashkelon Project |
| Full Days Training in initial year | 2 | Ashkelon Project |
| Days training in subsequent years | 1 | Ashkelon Project |
| Cost per ticipant-day of training course | $100 | Ashkelon Project |
| Tele-management & Operational costs per patient. | $60 | Ashkelon Project |
| Nurse/GP guidance per patient in first year of program | $230 | Ashkelon Project |
| Unit Care Costs | ||
| Ambulatory visit to Nurse or Nutritionist | $7.83 | 15 mins visit & 5 mins secretarial time |
| Ambulatory GP visit | $11.37 | 15 mins GP & 5 mins secretarial time |
| Cost of OPV | $99.14 | 25% of general hospital cost (30) |
| General Hospital Cost per day | $397 | 30 |
| ICU cost per day | $1,586 | estimated as four times general per diem cost (30) |
| Rehabilitation Hospital Cost per day | $238.85 | 30 |
| Home Physiotherapy Visit | $38.53 | 30 |
| Devices and Procedure costs | ||
| Stent | $202 | Barzelai Hospital Accounts Dept. |
| Cypher | $2,989 | Barzelai Hospital Accounts Dept. |
| Diagnostic Catheterisation | $2,464 | 30 |
| Restenosis | $9,701 | 30, includes 1 day in ICU & 3 days in cardiac ward |
| Average cost of Catheterisation with Stent or cypher | $6,925 | 30 |
| CABG operation | $12,740 | 30 |
| TPA | $1,800 | 30 estimated as four times general per diem cost |
| PRS Streptokinaise | $81 | 31 |
| Kidney Transplant Cost | $39,132 | 30 |
| Haemodialysis cost | $313 | 30 |
| Peritonea dialysis cost | $136 | 30 |
| % receiving haemodialysis | 88.8% | 20 |
| Average annual Dialysis Cost | $46,041 | 30 |
| Drug Costs | ||
| Post-MI or stroke drugs per day per patient- Males | $1.92 | 14 |
| Post-MI or stroke drugs per day per patient- Females | $1.79 | 14 |
| Post-UAP drugs per day per patient- Males | $1.92 | 14 |
| Post-UAP drugs per day per patient- Females | $1.79 | 14 |
| Correct preventive medication per day | $0.92 | 14, Ace inhibitor, Aspirin & Statin |
| Inadequate preventive medication per day | $0.31 | 14, Assumed only 1 correct drug taken |
| First author (public year) [Reference] | Experimental animal | Inoculum spores | Inoculation route | Outcome | Results |
| Kawai (2012) [2] | 4-5-d old ddY mouse | Kudoa septempunctata | Oral | Bowel movements and FAR | Showing diarrheagenic activity (11/17) and significantly higher FAR |
| Ahn (2015) [6] | 6-wk old BALB/c mice | Kudoa septempunc-tata | Oral | Bowl movements and histo-pathological examination | No significant diarrhea (0/32) and histopathologic changes (0/24) |
| Jang (2016) [7] | 4-5-d old ddY mouse | Kudoa septempunc-tata | Oral | Bowel movements and FAR | No watery stool form (0/20) and no significant variations in FAR |
| Guo (2015) [8] | 4-5-d old BALB/c suckling mice | Myxobolus hongh-uensis | Oral | Bowel movements, FAR, and histopathology | No significant change of FAR, no abnormal stool form (0/25) and no evidence of inflammation (0/25) |
| AMR | AMR + PLR | Total | ||||
| Stage | Age (SD)/No. | F/M (Ratio) | Age (SD)/No. | F/M (Ratio) | Age (SD)/No. | F/M (Ratio) |
| I | 52 (9)/37 | 30/7 (4.3) | 55 (10)/12 | 11/1 (11)* | 53 (9)/49 | 41/8 (5.1) |
| II | 58 (11)/163 | 123/40 (3.1) | 59 (11)/47 | 43/4 (10.8)* | 58 (11)/210 | 166/44 (3.8) |
| III | 64 (8)/170 | 147/23 (6.4) | 63 (5)/37 | 32/5 (6.4) | 64 (7)/207 | 179/28 (4.6) |
| IV | 62 (7)/36 | 30/6 (5.0) | 66 (1)/3 | 3/0 (NA)* | 62 (7)/39 | 33/6 (5.5) |
| Total | 60 (9)/406 | 330/76 (4.3) | 64 (11)/99 | 89/10 (8.9)* | 60 (10)/505 | 419/86 (4.9) |
| p<0.0001, R2=0.15 | p=0.019, R2=0.07 | p<0.0001, R2=0.13 |
| MIGS ID | Property | Term |
| MIGS-31 | Finishing quality | High quality draft |
| MIGS-28 | Libraries used | IonTorrent 100 bp and 400 bp single end reads |
| MIGS-29 | Sequencing platforms | IonTorrent PGM |
| MIGS-31.2 | Fold coverage | 110× |
| MIGS-30 | Assemblers | Newbler 2.6, MIRA 3.9.18, Sequencher 5.0.1 |
| MIGS-32 | Gene calling method | Prodigal |
| Locus Tag | M670 | |
| Genbank ID | JJRY00000000 | |
| Genbank Date of Release | 2014-06-16 | |
| GOLD ID | Gi0050495 | |
| BIOPROJECT | PRJNA209301 | |
| Project relevance | Environmental, co-denitrification | |
| MIGS 13 | Source Material Identifier | LMG 28302 |
| Clinicopathological features | GPx3 expression level (n) | |||
| Number | Down regulated | Non-down regulated | P | |
| Sex | 0.210 | |||
| Male | 92 | 43 | 49 | |
| Female | 21 | 13 | 8 | |
| Age | 0.926 | |||
| Younger than 55 | 57 | 28 | 29 | |
| Older than 55 | 56 | 28 | 28 | |
| pTNM stagea | 0.024 * | |||
| Early stage (1-2) | 29 | 9 | 20 | |
| Advanced stage (3-4) | 83 | 46 | 37 | |
| Venous infiltration | 0.043 * | |||
| Absent | 47 | 18 | 29 | |
| Present | 66 | 38 | 28 | |
| Tumor sizea | 0.462 | |||
| Less than 5 cm | 47 | 25 | 22 | |
| More than 5 cm | 65 | 30 | 35 | |
| Tumor Nodulesa | 0.448 | |||
| Less than 3 | 83 | 39 | 44 | |
| More than 3 | 29 | 16 | 13 | |
| HBsAg | 0.794 | |||
| Negative | 13 | 6 | 7 | |
| Positive | 100 | 50 | 50 | |
| AFP levela | 0.006 * | |||
| Lower than 20 ng/mL | 45 | 15 | 30 | |
| Higher than 20 ng/mL | 67 | 40 | 27 | |
| One year recurrencea | 0.038* | |||
| Recurrence | 42 | 27 | 15 | |
| Non-recurrence | 62 | 27 | 35 | |
| Five year recurrencea | 0.019* | |||
| Recurrence | 62 | 36 | 26 | |
| Non-recurrence | 43 | 15 | 28 |
| n | 1 (<=0.90) | 2 (0.91–1.07) | 3 (1.08–1.27) | 4 (>1.27) | P trend | |
| Frailty | 30 | 1.00 | 4.27 (0.66–27.60) | 1.27 (0.22–7.74) | 1.90 (0.36–9.88) | 0.887 |
| Pre-frailty | 79 | 1.00 | 0.81 (0.30–2.24) | 0.60 (0.23–1.56) | 1.64 (0.50–5.35) | 0.648 |
| Weight loss | 16 | 1.00 | 0.93 (0.18–4.78) | 1.03 (0.20–5.31) | 0.43 (0.09–2.18) | 0.394 |
| Exhaustion | 43 | 1.00 | 2.02 (0.66–6.18) | 1.10 (0.34–3.48) | 1.76 (0.63–4.94) | 0.428 |
| Low hand grip strength | 76 | 1.00 | 0.86 (0.33–2.28) | 0.34 (0.13–0.88)* | 0.70 (0.27–1.79) | 0.182 |
| Slow walking speed | 43 | 1.00 | 5.66 (1.17–27.42)* | 2.13 (0.48–9.58) | 4.19 (0.94–18.71) | 0.188 |
| Low physical activity | 39 | 1.00 | 0.90 (0.30–2.66) | 0.43 (0.14–1.36) | 0.37 (0.12–1.13) | 0.021* |
| Medicine | MIC (mg/L) |
| AMPH-B | 0.5 |
| 5-FC | <=0.12 |
| MCZ | 0.12 |
| FLCZ | 0.25 |
| ITCZ | 0.06 |
| MCFG | 0.12 |
| VRCZ | <=0.015 |
| CFC | WCM | MRC | SSC | RF | OMCR | |
| AOM | 65.6 | 65.5 | 61.0 | 76.2 | 80.3 | 90.0 |
| OME | 56.7 | 58.2 | 65.3 | 72.8 | 79.1 | 89.1 |
| NOE | 71.4 | 69.0 | 83.9 | 58.3 | 69.4 | 93.2 |
| Accuracy | 63.6 | 63.6 | 68.2 | 70.0 | 77.1 | 89.9 |
| Population | Frequency (%) | Number of subjects | Reference |
| African American | 20 | 50 | [48] |
| African American | 36 | 85 | [49] |
| African American | 34 | 93 | [152] |
| Tanzanians | 36 | 95 | [153] |
| Malawians | ∧31 (15) | 26 | [60] |
| Ghanaians | 46 | 42 | [152] |
| Ghanaians | 25 | 800 | [78] |
| Ethiopians | ∧45.5 (8.7) | 262 | [45] |
| Ivory coast | 38 | 41 | [152] |
| Sierra Leone | 36 | 52 | [152] |
| Senegal | 60 | 10 | [152] |
| Guinea | 48 | 21 | [152] |
| West Africa | 42 | 166 | [152] |
| West Africa | 50 | 153 | [49] |
| Yoruba (Ibadan, Nigeria) | 35 | 78 | [49] |
| South Africa | ∧41 (23) | 80 | [154] |
| Xhosa (South Africa) | ∧∧17 | 109 | [155] |
| CMA (South Africa) | ∧∧9 | 67 | [155] |
| Botswana | 36.6 | 101 | [156] |
| Zimbabwe | 49 | 71 | [76] |
| Uganda | 35.6 | 121 | [63] |
| Uganda | 29 | 7 males | [13] |
| Mozambique | 7 | 78 | [14] |
| Study | n | n COPD patients | n controls | Age (mean ± SD) | FEV1 (L) (mean ± SD) | FEV1/FVC% (mean ± SD) | Pack-years (mean ± SD) | %Current smoker | % Female |
| Qiu et al.[23] | 1085 | 620 | 325 | 57.3 ± 8.1 | N/A | 54.4 ± 19.8 | 41.7 ± 26.2 | 36.5 | 45.6 |
| 369 | 181 | 109 | 47.5 ± 7.1 | N/A | 54.3 ± 21.1 | 28.7 ± 23.6 | 27.9 | 64 | |
| Bell et al. [22] | 172 | N/A | N/A | 57.2 ± 8.2 | 2.46 ± 0.46 | N/A | N/A | 15.1a | 100 |
| Lepeule et al. [25] | 756 | 81 + 42b | N/A | 73.3 ± 6.7 | 2.50 ± 0.6 | N/A | 20.5 ± 25.7 | 4 | 0 |
| Lange et al. [26] | 663 | 107 | N/A | 72.7 ± 6.7 | 2.70 ± 0.64 | 75 ± 8 | 30.6 ± 24.8 | 7 | 0 |
| Marioni et al. [21] | 1091 | N/A | N/A | 69.8 ± 0.78 | 2.36 ± 0.69 | N/A | N/A | N/A | 50.4 |
| Wielscher et al. [24] | 204 | 42 | 27 healthy +34 GOLD grade 0 | 53.4± 13.4c | N/A | N/A | N/A | N/A | 23.2d |
| Cultivar | TDZ/BA concentration | No. of explants | % of explants producing massive shoots/budsx(mean ± standard error) |
| Accent Red | 1 μM TDZ + 0 μM BA (IM1) | 121 | 20.5 ± 6.4 A |
| 2.3 μM TDZ + 1.8 μM BA (IM2) | 121 | 66.5 ± 6.4 B | |
| 1 μM TDZ + 2.2 μM BA (IM3) | 119 | 42.6 ± 6.4 C | |
| Salmon | 1 μM TDZ + 0 μM BA (IM1) | 65 | 59.5 ± 5.3 A |
| Picote | 2.3 μM TDZ + 1.8 μM BA (IM2) | 68 | 80.1 ± 4.6 B |
| 1 μM TDZ + 2.2 μM BA (IM3) | 65 | 43.9 ± 5.3 A |
| FST | mAIC | vAIC | mPr | ||
| Clusters 3 & 4 | F (202) | 0.028 | 0.476 | 20.05 | 0.031 |
| M (179) | 0.028 | −0.537 | 17.20 | 0.033 | |
| P-value | 0.991 | 0.012 | 0.261 | 0.255 | |
| Cluster 2 | F (71) | 0.061 | 0.706 | 11.64 | 0.115 |
| M (52) | 0.076 | −0.964 | 22.15 | 0.137 | |
| P-value | 0.617 | 0.024 | 0.025 | 0.001 | |
| Cluster 1 | F (61) | 0.020 | 0.541 | 17.19 | 0.099 |
| M (44) | 0.013 | −0.750 | 35.52 | 0.252 | |
| P-value | 0.931 | 0.144 | 0.033 | 0.000 |
| SITE | ||||||
| NHA, n (%) | UATH, n (%) | MCHO, n (%) | GHA, n (%) | FMCK, n (%) | AKTH, n (%) | |
| SCREENED, 5190 | 1979 (38.1) | 1792 (34.5) | 539 (10.4) | 352 (6.8) | 393 (7.6 %) | 135 (2.6) |
| HIV Positive = 3212, n (%) | 1563 (48.7) | 1431 (44.6) | 15 (0.4) | 39 (1.2) | 130 (4.0) | 35 (1.1) |
| HIV Negative = 1978, n (%) | 416 (21.0) | 361 (18.3) | 524 (26.5) | 313 (15.8) | 263 (13.3) | 100 (5.1) |
| INCLUDED IN STUDY, 177 | 102 (57.6) | 48 (27.1) | 8 (4.5) | 14 (8.0) | 5 (2.8) | 0 (0.0) |
| HIV Positive = 120, n (%) | 79 (65.8) | 38 (31.7) | 1 (0.8) | 2 (1.7) | 0 (0.0) | 0 (0.0) |
| HIV Negative = 57, n (%) | 32 (40.3) | 10 (18.5) | 7 (12.3) | 12 (21.1) | 5 (8.8) | 0 (0.0) |
| RECURRENCE, 29 | 13 (44.8) | 13 (44.8) | 1 (3.5) | 2 (6.9) | 0 (0.0) | 0 (0.0) |
| HIV Positive = 22, n (%) | 12 (54.5) | 10 (45.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| HIV Negative =7, n (%) | 1 (14.3) | 3 (42.8) | 1 (14.3) | 2 (28.6) | 0 (0.0) | 0 (0.0) |
| Men (N = 2389) | Women (N = 2328) | ||||||
| n | % | %w | n | % | %w | p | |
| Covariates in 2006 | |||||||
| Age (years) | ns | ||||||
| <30 | 286 | 11.97 | 17.94 | 257 | 11.04 | 17.64 | |
| 30-39 | 701 | 29.34 | 31.71 | 647 | 27.79 | 28.57 | |
| 40-49 | 832 | 34.83 | 32.79 | 866 | 37.20 | 33.26 | |
| ≥50 | 570 | 23.86 | 17.56 | 558 | 23.97 | 20.53 | |
| Occupation | *** | ||||||
| Managers/professionals | 401 | 16.80 | 16.66 | 318 | 13.67 | 11.86 | |
| Associate professionals/technicians | 602 | 25.22 | 25.71 | 648 | 27.85 | 26.38 | |
| Clerks/service workers | 327 | 13.70 | 17.30 | 1121 | 48.17 | 50.24 | |
| Manual workers | 1057 | 44.28 | 40.13 | 240 | 10.31 | 11.53 | |
| Living alone | 528 | 22.10 | 20.30 | 678 | 29.12 | 23.70 | * |
| Presence of child(ren) under 3 y | 289 | 12.10 | 14.88 | 200 | 8.59 | 10.67 | *** |
| Low social support outside work | 626 | 26.20 | 26.43 | 739 | 31.74 | 29.81 | * |
| Life events during childhood (one or more) | 1077 | 45.08 | 45.80 | 1122 | 48.20 | 48.73 | ns |
| Life events 2002–2006 (one or more) | 207 | 8.67 | 8.49 | 252 | 10.83 | 10.76 | * |
| Occupational factors in 2006 | |||||||
| Psychosocial work factors | |||||||
| High psychological demands | 998 | 41.77 | 41.80 | 840 | 36.08 | 35.66 | *** |
| Low decision latitude | 780 | 32.65 | 35.15 | 728 | 31.27 | 32.49 | ns |
| Low social support | 565 | 23.65 | 23.95 | 506 | 21.74 | 21.93 | ns |
| Low reward | 716 | 29.97 | 31.12 | 732 | 31.44 | 31.64 | ns |
| Emotional demands | 740 | 30.98 | 33.43 | 1084 | 46.56 | 46.45 | *** |
| Role conflict | 1084 | 45.37 | 46.86 | 1066 | 45.79 | 45.43 | ns |
| Ethical conflict | 857 | 35.87 | 35.92 | 654 | 28.09 | 27.86 | *** |
| Tensions with the public | 959 | 40.14 | 41.83 | 1080 | 46.39 | 46.75 | ** |
| Job insecurity | 520 | 21.77 | 22.22 | 468 | 20.10 | 21.10 | ns |
| Work-life imbalance | 750 | 31.39 | 32.64 | 693 | 29.77 | 29.83 | ns |
| Working time/hours | |||||||
| Long working hours | 1008 | 42.19 | 42.41 | 523 | 22.47 | 21.94 | *** |
| Night work | 595 | 24.91 | 25.77 | 230 | 9.88 | 10.44 | *** |
| Shift work | 414 | 17.33 | 17.96 | 322 | 14.26 | 15.35 | * |
| Low predictability | 794 | 33.24 | 34.19 | 526 | 22.59 | 23.66 | *** |
| Physical work factors | |||||||
| Biomechanical exposure | 1040 | 45.53 | 42.89 | 718 | 30.84 | 32.38 | *** |
| Physical exposure | 1242 | 51.99 | 49.63 | 597 | 25.64 | 26.33 | *** |
| Chemical exposure | 1104 | 46.21 | 44.07 | 579 | 24.87 | 26.56 | *** |
| Mental disorders in 2010 | |||||||
| MDD | 61 | 2.55 | 2.53 | 114 | 4.90 | 4.75 | *** |
| GAD | 66 | 2.76 | 2.81 | 120 | 5.15 | 4.58 | ** |
| The Value of L (mm) | Strength of the Alternating Magnetic Field (A/m) | Compensation Ratio of Vpp | fL (kHz) | fn(kHz) | Relative Tolerance |
| 20 | 6892 | 1.11 | - | 172 | - |
| 25 | 7299 | 1.05 | 160 | 138 | 13.7% |
| 30 | 7499 | 1.02 | 140 | 115 | 17.8% |
| 40 | 7651 | 1 | 100 | 86 | 14% |
| IM | GS | OBGY | Ped | Psy | OS | EM | Total | ||
| History Taking | Min | 2 | 0 | 0 | 1 | 1 | 0 | 0 | 5 |
| Max | 30 | 30 | 10 | 16 | 20 | 10 | 10 | 85 | |
| Mean | 13.9 | 8.6 | 3.1 | 4.9 | 5.7 | 1.9 | 2.6 | 40.5 | |
| SD | 5.5 | 5.5 | 2.7 | 2.7 | 3.0 | 2.0 | 1.7 | 14.9 | |
| Physical Exam | Min | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Max | 30 | 20 | 10 | 16 | 12 | 20 | 10 | 85 | |
| Mean | 12.9 | 7.9 | 2.5 | 4.5 | 3.6 | 1.7 | 2.3 | 35.4 | |
| SD | 5.4 | 5.2 | 2.6 | 2.7 | 3.4 | 2.3 | 1.6 | 14.3 |
| Manner of intent a,b | Total N (%) | Mean | Std. Dev. | Min | Max |
| Total firearm deaths | 5,660 (100) | 138.1 | 43.5 | 67 | 243 |
| Accidental | 164 (2.9) | 4 | 3.2 | - | 11 |
| Suicide a | 5,025 (88.8) | 122.6 | 40 | 57 | 212 |
| Homicide a | 432 (7.6) | 10.5 | 4.7 | 2 | 24 |
| Event of undetermined intent a | 34 (0.6) | 0.8 | 0.9 | - | 3 |
| Legal investigation. | - (-) | - | - | - | - |
| Operation of war c | 5 (0.1) | 0.1 | 0.3 | - | 1 |
| MALE | |||||
| Total firearm deaths | 5,334 (100) | 130.1 | 40.2 | 64 | 221 |
| Accidental | 158 (3.0) | 3.9 | 3.1 | - | 11 |
| Suicide a | 4,863 (91.2) | 118.6 | 37.9 | 54 | 199 |
| Homicide a | 276 (5,2) | 6.7 | 3.6 | 1 | 15 |
| Event of undetermined intent a | 32 (0.6) | 0.8 | 0.9 | - | 3 |
| Legal investigation | - (-) | - | - | - | - |
| Operation of war c | 5 (0.1) | 0.1 | 0.3 | - | 1 |
| FEMALE | |||||
| Total firearm deaths | 326 (100) | 8 | 4.1 | 1 | 22 |
| Accidental | 6 (1.8) | 0.2 | 0.4 | - | 1 |
| Suicide a | 162 (49.7) | 4 | 2.7 | - | 13 |
| Homicide a | 156 (47.9) | 3.8 | 2.3 | - | 10 |
| Event of undetermined intent a | 2 (0.6) | 0.1 | 0.2 | - | 1 |
| Legal investigation | - (-) | - | - | - | - |
| Operation of war c | - (-) | - | - | - | - |
| Dapagliflozin N = 10 227 | DPP‐4 inhibitor N = 30 681 | Standardized differencea | |
| Age, years (s.d.) | 61 (11.1) | 60.8 (12.4) | 0.017 |
| Sex (Female) | 4196 (41.0) | 12 391 (40.4) | 0.011 |
| First GLD, years (s.d.) | 6.5 (4.1) | 6.5 (4.1) | 0.009 |
| CV disease | 2356 (23.0) | 6970 (22.7) | 0.006 |
| Myocardial infarction | 730 (7.1) | 2183 (7.1) | 0.001 |
| Stroke | 566 (5.5) | 1699 (5.5) | 0.000 |
| Unstable angina | 286 (2.8) | 900 (2.9) | 0.007 |
| Heart failure | 485 (4.7) | 1440 (4.7) | 0.002 |
| Atrial fibrillation | 879 (8.6) | 2549 (8.3) | 0.008 |
| Chronic kidney disease | 219 (2.1) | 626 (2.0) | 0.006 |
| Microvascular complications | 1497 (14.6) | 4449 (14.5) | 0.003 |
| Cancer | 850 (8.3) | 2624 (8.6) | 0.007 |
| Metformin | 8522 (83.3) | 25 705 (83.8) | 0.010 |
| Sulphonylurea | 2668 (26.1) | 7920 (25.8) | 0.005 |
| GLP‐1RAs | 798 (7.8) | 2309 (7.5) | 0.008 |
| Thiazolidinediones | 148 (1.4) | 416 (1.4) | 0.006 |
| Insulin | 3105 (30.4) | 8920 (29.1) | 0.023 |
| Short‐acting | 1124 (11.0) | 3307 (10.8) | 0.006 |
| Intermediate‐acting | 1504 (14.7) | 4358 (14.2) | 0.012 |
| Premixed insulin | 813 (7.9) | 2350 (7.7) | 0.009 |
| Long‐acting | 1044 (10.2) | 3062 (10.0) | 0.006 |
| CV disease preventive drugs | 8702 (85.1) | 26 041 (84.9) | 0.005 |
| Low‐dose aspirin | 3497 (34.2) | 10 434 (34.0) | 0.003 |
| Statins | 6457 (63.1) | 19 405 (63.2) | 0.002 |
| Antihypertensives | 7483 (73.2) | 22 255 (72.5) | 0.012 |
| Loop diuretics | 1364 (13.3) | 4036 (13.2) | 0.004 |
| Aldosteron antagonists | 441 (4.3) | 1303 (4.2) | 0.003 |
| Warfarin | 527 (5.2) | 1530 (5.0) | 0.006 |
| Receptor P2Y12 antagonists | 471 (4.6) | 1351 (4.4) | 0.008 |
| Variable | Premetformin | Postmetformin | Change | P-value |
| Median (Q1, Q3) | Median (Q1, Q3) | Median (Q1, Q3) | ||
| Insulin receptor | 4.5 (3, 6) | 4 (2, 5) | 0 (−1, 0) | 0.0375 |
| OCT1 | ND | 7 (6, 7) | ND | ND |
| Cytoplasmic p-Akt (S473) | 6 (5.5, 7) | 3 (3, 5) | −2 (−3, −1) | <0.0001 |
| Nuclear p-Akt (S473) | 4 (2, 5.5) | 3 (2, 4.5) | 0 (−2, 1) | 0.206 |
| Overall p-Akt (S473) | 5 (4, 6) | 3.5 (2.5, 4.5) | −1.5 (−2.5, −0.2) | 0.0001 |
| p-ERK (T202/Y204) | 7 (6, 7) | 4 (3, 6) | −2 (−4, 0) | <0.0001 |
| p-AMPK (T172) | 7 (5.2, 7) | 5 (4, 6) | −1.5 (−3, 0) | 0.0034 |
| p-ACC (S79) | 5 (4, 6) | 4 (3, 5) | −1 (−2, 1) | 0.0193 |
| Gene Description | Unigene | Gene Bank | Function |
| Cadherin 5, type 2, VE-cadherin | Hs.76206 | NM_001795 | Plays an important role in cell adhesion and is crucial for vessel growth and maturation. |
| Collagen, type XVIII, alpha 1 | Hs.517356 | NM_030582 | Component of extra-cellular matrix (ECM) that is important for tissue organization. |
| Collagen, type IV, alpha 3 | Hs.570065 | NM_000091 | |
| Integrin, alpha V | Hs.436873 | NM_002210 | Cell adhesion molecules that plays a key role in tumor growth, angiogenesis and metastasis. |
| Integrin, beta 3 | Hs.218040 | NM_000212 | |
| Hepatocyte growth factor | Hs.396530 | NM_000601 | Stimulates tumor cell motility, invasion and angiogenesis and its receptor is a tyrosine kinase encoded by c-met. |
| Ephrin-A3 | Hs.516656 | NM_004952 | Ephrins are cell-membrane-bound ligands for Eph receptor tyrosine kinases and regulate a variety of developmental processes. |
| Platelet-derived growth factor alpha polypeptide | Hs.645488 | NM_002607 | Stimulates endothelial cell proliferation. |
| Epidermal growth factor | Hs.419815 | NM_001963 | An EGFR ligand, regulates cell growth, proliferation and differentiation. |
| Neuropilin 2 | Hs.471200 | NM_003872 | Receptor for VEGF and semaphorin (SEMA) and is involved in angiogenesis and neuronal guidance. |
| Ephrin-B2 | Hs.149239 | NM_004093 | An Eph ligand, promotes cell attachment, cell-adhesion, migration, capillary tube formation and tumor angiogenesis. |
| Jagged 1 | Hs.224012 | NM_000214 | A notch ligand, it regulates a transmembrane ligand-receptor signaling pathway involved in the regulation of endothelial cell differentiation. |
| Tumor necrosis factor, alpha-induced protein 2 | Hs.525607 | NM_006291 | A cytokine mainly produced by macrophages causes apoptotic cell death, cellular proliferation, differentiation and inflammation. |
| TEK tyrosine kinase, endothelial | Hs.89640 | NM_000459 | Helps in vascular maturation, maintenance of integrity and remodeling. |
| Transforming growth factor, alpha | Hs.170009 | NM_003236 | Binds to EGFR and is involved in tumorigenesis. |
| Vascular endothelial growth factor C | Hs.435215 | NM_005429 | Involved in angiogenesis and lymphangiogenesis. |
| Original data | Secret data | XOR result |
| 0 | 0 | 0 |
| 0 | 1 | 1 |
| 1 | 0 | 1 |
| 1 | 1 | 0 |
| Studies | BCC + | SCC + (control) |
| Karahan, et al. [16] | 20/20 | 0/20 |
| Fan, et al. [28] | 51/51 | - |
| Krahl & Sellheyer [29] | 28/28 | - |
| Ishida, et al. [30] | 20/20 | - |
| Filho, et al. [31] | 20/20 | - |
| Mashhood, et al. [32] | 29/29 | 0/11 |
| Tan & Sunjaya [9] | 23/23 | - |
| Kirzhner & Jakobiec [33] | 13/13 | - |
| Dasgeb, et al. [24] | 24/24 | 1/11 (weak positive) |
| Patil, et al. [12] | 9/9 | - |
| Sellheyer, et al. [34] | 17/17 | 0/75 |
| Ansai, et al. [35] | 30/31 | - |
| BerEP4 positive | 284 | 1 |
| Ber EP4 negative | 1 | 116 |
| Total | 285 | 117 |
| Sensitivity | 284/285 × 100 = 99.6% | |
| Specificity | 116/117 × 100 = 99.2% | |
| Positive predictive value | 284/285 × 100 = 99.6% | |
| Negative predictive value | 116/117 × 100 = 99.1% |
| Code | Name | Classification algorithm(s) used |
| CAS | Chinese Academy of Sciences | Naïve Bayes, Support Vector Machine |
| CBC | CapitalBio Corporation, China | k-Nearest Neighbor, Support Vector Machine |
| Cornell | Weill Medical College of Cornell University | Support Vector Machine |
| FBK | Fondazione Bruno Kessler, Italy | Discriminant Analysis, Support Vector Machine |
| GeneGo | GeneGo, Inc. | Discriminant Analysis, Random Forest |
| GHI | Golden Helix, Inc. | Classification Tree |
| GSK | GlaxoSmithKline | Naïve Bayes |
| NCTR | National Center for Toxicological Research, FDA | k-Nearest Neighbor, Naïve Bayes, Support VectorMachine |
| NWU | Northwestern University | k-Nearest Neighbor, Classification Tree, Support VectorMachine |
| SAI | Systems Analytics, Inc. | Discriminant Analysis, k-Nearest Neighbor, Machine Learning,Support Vector Machine, Logistic Regression |
| SAS | SAS Institute, Inc. | Classification Tree, Discriminant Analysis, LogisticRegression, Partial Least Squares, Support VectorMachine |
| Tsinghua | Tsinghua University, China | Classification Tree, k-Nearest Neighbor, Recursive FeatureElimination, Support Vector Machine |
| UIUC | University of Illinois, Urbana-Champaign | Classification Tree, k-Nearest Neighbor, Naïve Bayes,Support Vector Machine |
| USM | University of Southern Mississippi | Artificial Neural Network, Naïve Bayes, SequentialMinimal Optimization, Support Vector Machine |
| ZJU | Zejiang University, China | k-Nearest Neighbor, Nearest Centroid |
| Not at all | A little bit | Moderately | Quite a bit | Extremely | No/inappropriate answer | Total | ||||||||
| n | % | n | % | n | % | n | % | n | % | n | % | n | % | |
| Any reminder brought back feelings about it | 63 | 21.6 | 117 | 40.1 | 63 | 21.6 | 25 | 8.6 | 15 | 5.1 | 9 | 3.1 | 292 | 100 |
| I had trouble staying asleep | 206 | 70.5 | 37 | 12.7 | 28 | 9.6 | 8 | 2.7 | 1 | 0.3 | 12 | 4.1 | 292 | 100 |
| Other things kept making me think about it | 189 | 64.7 | 58 | 19.9 | 24 | 8.2 | 6 | 2.1 | 6 | 2.1 | 9 | 3.1 | 292 | 100 |
| I felt irritable and angry | 234 | 80.1 | 38 | 13.0 | 7 | 2.4 | 4 | 1.4 | 0 | 0.0 | 9 | 3.1 | 292 | 100 |
| I avoided letting myself get upset when I thought about it or was reminded of it | 145 | 49.7 | 91 | 31.2 | 24 | 8.2 | 17 | 5.8 | 5 | 1.7 | 10 | 3.4 | 292 | 100 |
| I thought about it when I didn't mean to | 133 | 45.5 | 100 | 34.2 | 31 | 10.6 | 14 | 4.8 | 3 | 1.0 | 11 | 3.8 | 292 | 100 |
| I felt as if it hadn't happened or wasn't real | 199 | 68.2 | 46 | 15.8 | 21 | 7.2 | 5 | 1.7 | 1 | 0.3 | 20 | 6.8 | 292 | 100 |
| I stayed away from reminders about it | 197 | 67.5 | 53 | 18.2 | 15 | 5.1 | 7 | 2.4 | 3 | 1.0 | 17 | 5.8 | 292 | 100 |
| Pictures about it popped into my mind | 193 | 66.1 | 59 | 20.2 | 14 | 4.8 | 8 | 2.7 | 3 | 1.0 | 15 | 5.1 | 292 | 100 |
| I was jumpy and easily startled | 172 | 58.9 | 63 | 21.6 | 24 | 8.2 | 11 | 3.8 | 9 | 3.1 | 13 | 4.5 | 292 | 100 |
| I tried not to think about it | 152 | 52.1 | 67 | 22.9 | 34 | 11.6 | 18 | 6.2 | 7 | 2.4 | 14 | 4.8 | 292 | 100 |
| I was aware that I still had a lot of feelings about it,but I didn't deal with them | 165 | 56.5 | 62 | 21.2 | 26 | 8.9 | 17 | 5.8 | 6 | 2.1 | 16 | 5.5 | 292 | 100 |
| My feelings about it were kind of numb | 162 | 55.5 | 70 | 24.0 | 35 | 12.0 | 6 | 2.1 | 2 | 0.7 | 17 | 5.8 | 292 | 100 |
| I found myself acting or feeling as though I was back at that time | 214 | 73.3 | 42 | 14.4 | 17 | 5.8 | 4 | 1.4 | 1 | 0.3 | 14 | 4.8 | 292 | 100 |
| I had trouble falling asieep | 212 | 72.6 | 38 | 13.0 | 14 | 4.8 | 10 | 3.4 | 4 | 1.4 | 14 | 4.8 | 292 | 100 |
| I had waves of strong feelings about it | 192 | 65.8 | 53 | 18.2 | 22 | 7.5 | 9 | 3.1 | 5 | 1.7 | 11 | 3.8 | 292 | 100 |
| I tried to remove it from my memory | 201 | 68.8 | 42 | 14.4 | 21 | 7.2 | 9 | 3.1 | 4 | 1.4 | 15 | 5.1 | 292 | 100 |
| I had trouble concentrating | 226 | 77.4 | 40 | 13.7 | 9 | 3.1 | 3 | 1.0 | 1 | 0.3 | 13 | 4.5 | 292 | 100 |
| Reminders of it caused me to have physical reactions,such as sweating,trouble breathing,nausea,or a pounding heart | 227 | 77.7 | 38 | 13.0 | 12 | 4.1 | 4 | 1.4 | 0 | 0.0 | 11 | 3.8 | 292 | 100 |
| I had dreams about it | 246 | 84.2 | 28 | 9.6 | 4 | 1.4 | 1 | 0.3 | 0 | 0.0 | 13 | 4.5 | 292 | 100 |
| I felt watchful or on-guard | 112 | 38.4 | 92 | 31.5 | 41 | 14.0 | 20 | 6.8 | 14 | 4.8 | 13 | 4.5 | 292 | 100 |
| I tried not to talk about it | 187 | 64.0 | 54 | 18.5 | 22 | 7.5 | 11 | 3.8 | 5 | 1.7 | 13 | 4.5 | 292 | 100 |
| Sample 1 | Sample 2 | |
| Control Slide | 41 | 52 |
| Splashing device | 29 | 34 |
| Variable | OAK and controlpreinterventionb | OAK | Control | Difference in change between groups | |||||
| 8weeks | 6months | 8weeks | 6months | Preinterventionto 8 weeks | 95%CI | Preintervention to 6 months | 95% CI | ||
| TUG (score)c | 12 (0) | 10 (0.2) | 10 (0.2) | 11 (0.2) | 11 (0.2) | -1.3 | -1.81 to -0.86 | -0.72 | -1.35 to -0.08 |
| Muscle Strength (kg) | |||||||||
| Left quadriceps | 18.9 (0) | 20.3 (0.5) | 19.6 (0.7) | 18.6 (0.5) | 18.1 (0.7) | 1.65 | 0.34 to 2.95 | 1.58 | -0.31 to 3.47 |
| Right quadriceps | 18.0 (0) | 19.6 (0.5) | 18.9 (0.7) | 17.8 (0.5) | 18.2 (0.7) | 1.79 | 0.33 to 3.24 | 0.66 | -1.37 to 2.69 |
| Left hamstringc | 8.0 (0) | 10.1 (0.3) | 9.5 (0.4) | 8.6 (0.3) | 8.79 (0.4) | 1.47 | 0.63 to 2.30 | 0.74 | -0.31 to 1.79 |
| Right hamstringc | 7.6 (0) | 10.2 (0.3) | 9.8 (0.4) | 8.4 (0.3) | 8.7 (0.4) | 1.80 | 0.89 to 2.70 | 1.18 | 0.06 to 2.29 |
| Range of motion (°) | |||||||||
| Left knee flexionc | 125 (0) | 126 (0.8) | 126 (0.9) | 123 (0.8) | 123 (0.9) | 2.80 | 0.58 to 5.02 | 2.26 | -0.32 to 4.86 |
| Right knee flexion | 123 (0) | 123 (0.9) | 121 (0.9) | 121 (0.9) | 121 (0.9) | 1.56 | -0.90 to 4.02 | 0.02 | -2.53 to 2.57 |
| Left knee extensionc | -4 (0) | -4 (0.3) | -4 (0.5) | -4 (0.3) | -3 (0.5) | 0.1 | -0.72 to 0.88 | -1.39 | -2.71 to -0.06 |
| Right knee extensionc | -4 (0) | -4 (0.3) | -5 (0.5) | -5 (0.3) | -3 (0.5) | 0.9 | -0.03 to 1.78 | -1.18 | -2.63 to 0.26 |
| Variable | n (%) |
| Sex | |
| Female | 330 (53.9%) |
| Male | 282 (46.1%) |
| Age (years) | |
| 10 - 14 | 305 (49.8%) |
| 15 - 19 | 307 (50.2%) |
| District of residence | |
| Kigoma | 107 (17.5%) |
| Kilombero | 131 (21.4%) |
| Rufiji | 176 (28.8%) |
| Ulanga | 198 (32.3%) |
| Groups for Comparions | Dependent Variables | Degrees of freedom | Chi-square | p |
| Control (n=14) | TBARs (nmol/g) | 3 | 3.87 | 0.28 |
| STZ (n=12) | SOD (U/mg) | 3 | 6.40 | 0.09 |
| P+STZ (n=12) | CAT (K/g) | 3 | 5.98 | 0.11 |
| STZ+P (n=13) | GSH-Px (U/mg) | 3 | 3.46 | 0.33 |
| Scenario 4 - health, Work Cover & employment data linked by researchers | |
| Consent justifications | No consent justifications |
| Consent provides protection against potential impact of research (10)a | Acceptable practice because of the benefits (5) |
| Access to identifiable data by researchers requires consent (9) | The findings are presented in de-identified form (3) |
| Practical considerations of obtaining consent from thousands (3) | |
| Consent required when researchers do the linkage (7) | Acceptable due to cost and time constraints involved when obtaining consent (2) |
| Consent is required when other spheres of life (apart from health) are involved (7) | Consent lowers research participation rates (2) |
| Opt-out consent would result in more participants being involved (6) | Low participation rates impact on quality of research (2) |
| Consent required because of lack of separation of tasks (4) | The information is already there so it should just be used without consent (2) |
| People have right to choose (4) | |
| Researchers may disclose information to third party (2) | Researchers are not interested in specific cases (2) |
| Someone on the research team may know the research participants (2) | Strict measures/guidelines provide protection (2) |
| To ensure people are not upset/do not object (2) | Getting consent could have detrimental effect on participants (1) |
| No need for consent if data linkage organisation is trustworthy (1) | |
| Opt-in consent captures the people who really want to participate (2) | Researchers will not use information obtained without consent to harm participants (1) |
| Having the option to consent is good (2) | |
| Information belongs to people (1) | Provided that the linkage organisation was involved so that tasks are separated (1) |
| People want to control their information (1) | |
| Researchers using identifiable information without consent is intrusive (1) | Researchers will be dealing with de-identified data eventually (1) |
| Acceptable depending on study (1) | |
| Consent required when participants are experiencing mental health issues, as they may not welcome people delving into their affairs at that point in their lives (1) | Consent would have been given at data collection point (1) |
| Information given to WorkCover can be shared with researchers, as it was given confidentially (1) | |
| Consent should be sought for all research (1) | Retrospective use of data does not require consent (1) |
| Consent should be sought at initial point of data collection (1) | People have inflated view of how interesting they are to others (1) |
| Collecting this kind of information without consent may not be legal (1) | |
| It is very good to obtain consent if it is simple to do so (1) |
| Dose-volume data | |||||
| Swallowing structure | Dmean (Gy) Mean ± SD (range) | Dmax (Gy) Mean ± SD (range) | V60 (%) Mean ± SD (range) | V65 (%) Mean ± SD (range) | V70 (%) Mean ± SD (range) |
| PCM | 66.03 ± 2.19 (63.17 - 69.96) | 72.69 ± 1.62 (69.92 - 74.85) | 89.24 ± 9.20 (73.27 - 99.92) | 64.75 ± 22.79 (20.19 - 90.38) | 27.91 ± 21.83 (0.00-65.33) |
| SPCM | 68.35 ± 2.66 (63.29 - 71.65) | 72.66 ± 1.64 (69.92 - 74.85) | 99.14 ± 1.64 (94.98 - 100.00) | 81.35 ± 26.41 (24.37 - 100.00) | 37.66 ± 30.09 (0.00-83.03) |
| MPCM | 65.30 ± 2.77 (61.28 - 69.62) | 67.69 ± 2.60 (64.23 - 72.03) | 97.63 ± 6.43 (79.56 - 100.00) | 51.33 ± 45.38 (0.00 - 100.00) | 4.80 ± 11.93 (0.00-37.40) |
| IPCM | 59.96 ± 4.09 (50.39 - 63.35) | 65.86 ± 3.18 (61.27 - 71.83) | 58.50 ± 34.43 (2.35 - 100.00) | 12.09 ± 19.33 (0.00-48.71) | 0.62 ± 1.97 (0.00-6.22) |
| BOT | 52.85 ± 13.03 (36.80 - 68.08) | 70.02 ± 2.79 (65.36 - 74.00) | 62.38 ± 32.78 (15–99.55) | 34.12 ± 31.63 (0.01-90.03) | 5.54 ± 11.05 (0.00-34.86) |
| Larynx | 62.55 ± 5.76 (50.56 - 68.07) | 70.43 ± 2.97 (64.45 - 73.54) | 74.92 ± 28.33 (29.27 - 100.00) | 52.05 ± 31.83 (0.00-89.83) | 9.52 ± 12.30 (0.00-32.72) |
| PES | 50.97 ± 3.22 (46.09 - 57.15) | 53.78 ± 4.76 (47.11 - 61.75) | 2.08 ± 4.40 (0.00 - 11.10) | 0.00 | 0.00 |
| Variable | Univariate | Multivariate | ||
| Odds ratio (95%CI) | p value | Odds ratio (95%CI) | p value | |
| Age | 0.998(0.980-1.016) | 0.829 | ||
| Sex | 1.033(0.549-1.943) | 0.921 | ||
| Diabetes mellitus | 0.932(0.547-1.588) | 0.797 | ||
| Prior MI | 1.869 (0.781-9.178) | 0.092 | 1.745 (0.752-8.644) | 0.495 |
| LVEF | 0.995 (0.968-1.022) | 0.702 | ||
| Time from symptom onset to PPCI | 1.021 (1.008-1.208) | 0.094 | 1.002 (0.979-1.195) | 0.553 |
| Creatinine | 1.007 (0.997-1.017) | 0.194 | ||
| Neutrophil count | 1.016 (0.935-1.104) | 0.704 | ||
| Hemoglobin | 0.998 (0.986-1.010) | 0.780 | ||
| Lymphocyte count | 1.019 (0.886-1.173) | 0.790 | ||
| Monocyte count | 2.429 (1.022-5.776) | 0.045 | 3.107 (1.199-7.052) | 0.020 |
| Breed | Samples | GG | GA | AA | Freq. A | Exp GG | Exp GA | Exp AA |
| Abyssinian* | 1955 | 1476 | 465 | 14 | 0.126 | 1493 | 431 | 31 |
| Abyssinian (UK) | 36 | 28 | 8 | 0 | 0.11 | 29 | 7 | 0 |
| American Bobtail | 10 | 10 | 0 | |||||
| American SH | 51 | 51 | 0 | |||||
| American Wirehair | 11 | 11 | 0 | |||||
| Australian Mist (UK) | 27 | 27 | 0 | |||||
| Balinese | 39 | 39 | 0 | |||||
| Bengal* | 1340 | 925 | 390 | 25 | 0.164 | 936 | 368 | 36 |
| Bengal (UK) | 1210 | 827 | 354 | 29 | 0.17 | 834 | 341 | 35 |
| Birman | 187 | 187 | 0 | |||||
| British SH | 966 | 966 | 0 | |||||
| British SH (UK) | 43 | 43 | 0 | |||||
| Burmese | 118 | 118 | 0 | |||||
| Burmilla | 38 | 38 | 0 | |||||
| Cornish Rex | 46 | 46 | 0 | |||||
| Devon Rex | 186 | 186 | 0 | |||||
| Domestic SH/LH | 76 | 62 | 13 | 1 | 0.099 | 62 | 13 | 1 |
| Egyptian Mau | 36 | 27 | 9 | 0 | 0.1 | 28 | 8 | 1 |
| Exotic LH | 91 | 91 | 0 | |||||
| Exotic SH | 645 | 644 | 1 | 0 | 0.0008 | 644 | 1 | 0 |
| Himalayan | 601 | 601 | 0 | |||||
| Korat | 41 | 41 | 0 | |||||
| La Perm | 56 | 40 | 16 | 0 | 0.14 | 41 | 14 | 1 |
| Maine Coon | 118 | 103 | 15 | 0 | 0.064 | 104 | 14 | 0 |
| Munchkin | 19 | 19 | 0 | |||||
| Norwegian Forest Cat | 13 | 10 | 3 | 0 | 0.1 | 10 | 3 | 0 |
| Ocicat | 69 | 69 | 0 | |||||
| Oriental LH | 48 | 48 | 0 | |||||
| Oriental SH | 337 | 336 | 1 | 0 | 0.001 | 336 | 1 | 0 |
| Persian | 2226 | 2217 | 9 | 0 | 0.002 | 2217 | 9 | 0 |
| Ragamuffin | 20 | 20 | 0 | |||||
| Ragdoll | 1063 | 1063 | 0 | |||||
| Russian Blue | 14 | 14 | 0 | |||||
| Savannah Cat | 11 | 10 | 1 | 0 | 0.05 | 10 | 1 | 0 |
| Scottish Fold | 68 | 68 | ||||||
| Selkirk Rex | 124 | 124 | ||||||
| Siamese | 457 | 457 | ||||||
| Siberian Cat | 377 | 360 | 16 | 1 | 0.024 | 359 | 18 | 0 |
| Singapura | 150 | 88 | 55 | 7 | 0.23 | 89 | 53 | 8 |
| Singapura (UK) | 168 | 60 | 77 | 31 | 0.414 | 58 | 81 | 29 |
| Somali | 633 | 527 | 104 | 2 | 0.0853 | 530 | 99 | 5 |
| Somali (UK) | 65 | 49 | 14 | 2 | 0.14 | 48 | 16 | 1 |
| Sphynx | 248 | 248 | ||||||
| Turkish Angora | 31 | 31 | ||||||
| Unreported | 111 | 98 | 13 | 0 | 0.059 | 99 | 12 | 0 |
| Total | 14179 | 12503 | 1564 | 112 | 0.063051 | 12447 | 1675 | 56 |
| Demographic data and diagnoses | IPC + sevoflurane (N = 20) | IPC (N = 20) |
| Age (years) | 68 ± 12 | 68 ± 11 |
| Height (cm) | 170 ± 11 | 170 ± 8 |
| Weight (kg) | 77 ± 17 | 75 ± 9 |
| Male/female | 14/6 | 13/7 |
| Body-Mass-Index (BMI; kg.m-2) | 27 ± 5 | 26 ± 3 |
| Ankle-Brachial-Index (ABI)* | 0.58 ± 0.18 | 0.56 ± 0.05 |
| Side of surgery (right/left) | 13 (65%)/7 (35%) | 6 (30%)/14 (70%) |
| Fontaine grade (I/IIa/IIb/III/IV/V) | 0/3/14/1/2 (0%/15%/70%/5%/10%) | 0/5/14/0/1 (0%/25%/70%/0%/10%) |
| Obesity | 5 (25%) | 1 (5%) |
| Alcohol abuse | 1 (5%) | 1 (5%) |
| History of stroke | 4 (20%) | 1 (5%) |
| Diabetes mellitus | 6 (30%) | 5 (25%) |
| Hyperlipidaemia | 14 (70%) | 12 (60%) |
| Hypertonia | 18 (90%) | 17 (85%) |
| Hyperuricaemia | 1 (5%) | 5 (25%) |
| Coronary heart disease | 9 (45%) | 6 (30%) |
| Renal insufficiency | 4 (20%) | 1 (5%) |
| Smoking | 9 (45%) | 10 (50%) |
| Characteristics of children | Number of children (%) | Mean per year/per team (min/max) | Median per year/per team (P25/P75) |
| Age of children | |||
| 0–1 y | 885 (25%) | ||
| 1–10 y | 1689 (47%) | ||
| 11–20 y | 879 (24%) | ||
| > 20 y | 116 (3%) | 144 (43–240) | 144 (103–196) |
| Total of children: 3607 (100%) | |||
| Pathologies | |||
| Haematology/Oncology | 1816 (50%) | ||
| Neurology-/Degenerative/Metabolic | 989 (27%) | ||
| Other (Neonatology/Gastroenterology/Respiratory) | 849 (23%) | ||
| Total: 3654 (100%) | |||
| Curative/Palliative Patients | |||
| Curative patients | 2540 (70%) | 102 (1–181) | 105 (82–135) |
| Palliative patients | 910 (25%) | 36 (10–86) | 23 (20–58) |
| Undefined | 157 (5%) | ||
| Total: 3607 (100%) | |||
| Referral of new patients | |||
| From originating hospital | 1848 (51%) | ||
| External hospital | 108 (3%) | ||
| Total new patients | 2056 (54%) | ||
| Total: 3607 (100%) | |||
| Length follow-up (children who died) | 226 days/child (1–4612 days) | 32 days/child (21–201 days) | |
| < 120 days | 272 (64%) | ||
| 121–240 days | 65 (15%) | ||
| 241–400 days | 31 (7%) | ||
| > 401 days | 60 (14%) | ||
| Total: 428 (100%) | |||
| Location of death | |||
| Hospital | 200 (47%) | 8 (2–22) | 6 (6–10) |
| Home | 221 (51%) | 9 (1–22) | 9 (3–16) |
| Others (respite care home, others) | 7 (2%) | 18 (3–32) | 19 (12–26) |
| Total: 428 (100%) |
| Acoustic lens properties | |
| Excitation center frequency [MHz] | 100 |
| Max PRF [kHz] | 100 |
| Gain [dB] | 40 |
| Sampling rate [MSamples/s] | 400 |
| Focal resolution [μm] | 10 |
| Aperture [μm] | 950 |
| Aperture angle [°] | 55 |
| Working distance [μm] | 900 |
| N | |
| Treatment interruption for reasons other than PD | 5 |
| Death for reason other than GBM | 1 |
| No measurable disease at time of randomization | 6 |
| No imaging available for central review | 4 |
| Total | 16 |
| Behaviors | Scores | ||
| 1 | 2 | 3 | |
| Target: Cat touches a plastic chopstick or trainer’s finger with its nose | Stretching neck toward target | Purposeful movement towards target, but no touch; or touches with face but not nose | Actual contact with nose |
| Spin (in either direction): Cat turns body in a circle | Head follows or <90 degree turn | Spins approximately 91–270 degrees | Spins approximately 271–360 degrees |
| Sit: Cat assumes a sitting position, with hind-end on floor and front paws touching the floor, in a weight-bearing stance | Some hind-end crouching | Hind-end on floor or in close proximity and/or front paws go up | Front paws on floor and hind-end contact with floor |
| High-five: Cat touches a trainer’s hand with a front paw | Any degree of front paw lift (one or both paws) | Movement towards hand with just one paw | Purposeful hand contact with one paw |
| Risk group | N (%) | SE (%) | SP(%) | PPV (%) | NPV (%) | ICG-R (%) |
| (95% CI) | (95% CI) | (95% CI) | (95% CI) | |||
| 1 | 162 (58.7) | 100 | 0 | 5 | ||
| 2 | 84 (30.4) | 85.2 (72.9-93.4) | 69.4 (62.9-75.4) | 40.4 (31.3-49.9) | 95.1 (90.5-97.8) | 29 |
| 3 | 30 (10.9) | 40.7 (27.6-55.0) | 96.4 (93.0-98.4) | 73.3 (54.1-87.7) | 87.0 (82.1-90.9) | 73 |
| Odds ratio (95 % confidence interval) | P-value | |
| Age | 1.0 (0.9–1.1) | 0.11 |
| Race | ||
| African American | 1.3 (0.6–3.0) | 0.47 |
| Other | 1.2 (0.7–2.3) | 0.49 |
| At least one previous prostate biopsy | 0.7 (0.3–1.3) | 0.26 |
| Abnormal Digital Rectal Exam | 30.5 (11.8–92.2) | <0.001 |
| Family history of prostate cancer | 3.5 (1.8–6.8) | <0.001 |
| Prostate-specific antigen (ng/mL)a | 4.4 (3.3–5.9) | <0.001 |
| Sarcosine uM in 20uL seruma | 1.1 (0.7–1.8) | 0.64 |
| Intervention group | Control group | ||||||
| Baseline (%) | End of study (%) | PValue | Baseline (%) | End of study (%) | Pvalue | Intervention vs control ( P value) | |
| Krece plus questionnaire | |||||||
| Breakfast | 99.2 | 98.2 | 0.11 | 99.8 | 99.2 | 0.18 | 0.50 |
| Dairy product at breakfast | 91.9 | 92.3 | 0.72 | 95.4 | 93.0 | 0.08 | 0.09 |
| Cereals at breakfast | 68.3 | 72.9 | 0.01 | 74.8 | 74.5 | 0.89 | 0.13 |
| Pastry at breakfast | 17.5 | 15.3 | 0.17 | 16.2 | 15.1 | 0.62 | 0.70 |
| Daily fruit or natural juice | 70.9 | 72.9 | 0.30 | 78.1 | 78.9 | 0.95 | 0.59 |
| Fruit, second per day | 38.3 | 42.6 | 0.03 | 38.4 | 37.6 | 0.78 | 0.14 |
| Dairy product, second per day | 81.9 | 80.6 | 0.43 | 85.9 | 84.2 | 0.4 | 0.81 |
| Vegetables, daily | 68.9 | 72.6 | 0.04 | 72.7 | 73.8 | 0.67 | 0.42 |
| Vegetables, >1 per day | 25.7 | 32.0 | 0.001 | 23.2 | 26.9 | 0.13 | 0.50 |
| Fish, regularly | 73.9 | 74.8 | 0.65 | 76.10 | 74.3 | 0.4 | 0.35 |
| Fast food, >1 per week | 7.9 | 8.9 | 0.41 | 7.9 | 8.7 | 0.63 | 0.92 |
| Legumes >1 per week | 75.5 | 75.2 | 0.85 | 76.9 | 70.9 | 0.01 | 0.06 |
| Candy >1 per day | 12.9 | 12.0 | 0.52 | 11.6 | 9.9 | 0.32 | 0.68 |
| Pasta or rice, daily | 57.3 | 57.9 | 0.80 | 59.9 | 62.2 | 0.37 | 0.58 |
| Cooking with olive oil at home | 96.6 | 97.4 | 0.32 | 97.1 | 97.9 | 0.38 | 0.85 |
| AVall questionnaire | |||||||
| Before leaving home | |||||||
| Dairy products | 84.3 | 82.4 | 0.20 | 86.6 | 83.8 | 0.15 | 0.65 |
| Pastry | 3.9 | 2.4 | 0.005 | 2.8 | 2.6 | 0.15 | 0.50 |
| Cereals | 37.6 | 38.2 | 0.87 | 38.4 | 39.7 | 0.83 | 0.94 |
| Fresh fruit or natural juice | 20.9 | 20.6 | 0.07 | 18.8 | 18.5 | 0.21 | 0.93 |
| Sandwich | 23.9 | 25.2 | 0.45 | 19.1 | 22.1 | 0.93 | 0.69 |
| Juice packaged/soft drinks | 9.6 | 7.2 | 0.93 | 8.4 | 8.9 | 0.32 | 0.46 |
| Break (Midmorning) | |||||||
| Dairy products | 17.3 | 12.7 | 0.79 | 13.7 | 10.1 | 0.29 | 0.51 |
| Pastry | 3.8 | 1.7 | <0.001 | 4.1 | 2.2 | 0.002 | 0.95 |
| Cereals | 6.5 | 5.6 | 0.68 | 5.2 | 4.7 | 0.45 | 0.71 |
| Fresh fruit or natural juice | 12.5 | 12.7 | 0.59 | 12.2 | 15.5 | 0.05 | 0.18 |
| Sandwich | 45.5 | 49.2 | 0.09 | 43.3 | 48.3 | 0.08 | 0.71 |
| Juice packaged/soft drinks | 11.4 | 6.1 | 0.67 | 9.9 | 12.8 | 0.48 | 0.41 |
| Position | Mutation | Run1 | Run2 b | Highest of 2 run (95 CI) |
| 21 | M41L(A->C) | 0.02% | 0.01% | 0.02% (0.01 to 0.03) |
| 94 | K65R(A->G) a | 0.31% | 0.09% | 0.31(0.19 to 0.42) |
| 99 | D67W(G->A) | 0.07% | 0.02% | 0.07% (0.01 to 0.13) |
| 109 | K70R(A->G) | 0.09% | 0.06% | 0.09% (0.03 to 0.16) |
| 120 | L74V(T->G) | 0.02% | 0.00% | 0.02% (0.00 to 0.01) |
| 198 | L90I(T->A) | 0.00% | 0.00% | 0.00% (0.00 to 0.03) |
| 209 | K103N(A->C) | 0.02% | 0.01% | 0.02% (0.01 to 0.03) |
| 210 | K103N(A->T) | 0.02% | 0.02% | 0.02% (0.01 to 0.03) |
| Seed 05 | Seed 07 | Seed 08 | Seed 09 | Leaf | Root | Stem | All tissues | |
| BUSCO (%): | ||||||||
| Completeness | 86 | 76 | 79 | 83 | 74 | 84 | 84 | 83 |
| Duplicated | 18 | 18 | 19 | 20 | 18 | 18 | 17 | 24 |
| Fragmented | 5 | 16 | 13 | 9 | 13 | 7 | 8 | 10 |
| Missing | 7 | 7 | 7 | 7 | 11 | 7 | 7 | 5 |
| RMBT to themselves: | ||||||||
| % mapped | 86.1 | 96.3 | 87.6 | 86.6 | 88.8 | 85.6 | 86.2 | 90.9 |
| % properly paired | 75.9 | 87.5 | 76.6 | 75.9 | 81.0 | 76.8 | 77.9 | 80.1 |
| % singletons | 3.8 | 1.3 | 3.4 | 3.7 | 3.4 | 3.9 | 3.6 | 3.2 |
| Total bp | 16,523,554 | 17,276,866 | 17,753,884 | 17,041,720 | 13,759,496 | 23,850,824 | 14,396,240 | 120,602,584 |
| RMBT to Full: | ||||||||
| % mapped | 95.5 | 96.3 | 96.0 | 95.4 | 97.2 | 94.5 | 97.4 | 95.9 |
| % properly paired | 86.2 | 87.5 | 87.4 | 86.3 | 89.9 | 86.2 | 89.0 | 87.3 |
| % singletons | 1.4 | 1.3 | 1.3 | 1.5 | 1.0 | 1.4 | 1.0 | 1.3 |
| Total bp | 16,523,554 | 17,276,866 | 17,753,884 | 17,041,720 | 13,759,496 | 23,850,824 | 14,396,240 | 120,602,584 |
| In-person workshop group (n = 25) | Patients and caregivers in in-person workshop (n = 18) | Online wiki-inspired group (n = 26) | Patients and caregivers in online wiki-inspired group (n = 19) | |
| Age | ||||
| 18–39 years | 3 (12) | 1 (5.6) | 4 (15.4) | 4 (21.1) |
| 40–64 years | 14 (56) | 9 (50) | 16 (61.5) | 9 (47.4) |
| ≥ 65 years | 8 (32) | 8 (44.4) | 6 (23.1) | 6 (31.6) |
| Sex | ||||
| Male | 13 (52) | 11 (61.1) | 11 (42.3) | 9 (47.4) |
| Female | 12 (48) | 7 (38.9) | 15 (57.7) | 10 (52.6) |
| Role | ||||
| Patient | 12 (48) | 12 (66.7) | 11 (42.3) | 11 (57.9) |
| Caregiver | 6 (24) | 6 (33.3) | 8 (30.8) | 8 (42.1) |
| Health Care Provider | 6 (24) | - | 6 (23.1) | - |
| Policymaker | 1 (4) | - | 1 (3.8) | - |
| Marital Status | ||||
| Married | 22 (88) | 16 (88.9) | 19 (73.1) | 13 (68.4) |
| Common Law | 1 (4) | 0 (0) | 2 (7.7) | 1 (5.3) |
| Divorced/Separated | 2 (8) | 2 (11.1) | 0 (0) | 0 (0) |
| Single | 0 (0) | 0 (0) | 3 (11.5) | 3 (15.8) |
| Not Indicated | 0 (0) | 0 (0) | 2 (7.7) | 2 (10.5) |
| Employment Status | ||||
| Full-time | 14 (56) | 8 (44.4) | 12 (46.2) | 6 (31.6) |
| Part-time or casual | 2 (8) | 1 (5.6) | 2 (7.7) | 1 (5.3) |
| Retired | 9 (36) | 9 (50) | 10 (38.5) | 10 (52.6) |
| Unemployed | 0 (0) | 0 (0) | 1 (3.8) | 1 (5.3) |
| Not Indicated | 0 (0) | 0 (0) | 1 (3.8) | 1 (5.3) |
| Highest Level of Education | ||||
| Some High School | 0 (0) | 0 (0) | 1 (3.8) | 1 (5.3) |
| High School Graduate | 4 (16) | 4 (22.2) | 3 (11.5) | 3 (15.8) |
| College Diploma | 4 (16) | 3 (16.7) | 8 (30.8) | 8 (42.1) |
| University Degree | 17 (68) | 11 (61.1) | 12 (46.2) | 5 (26.3) |
| Not Indicated | 0 (0) | 0 (0) | 2 (7.7) | 2 (10.5) |
| Taxon, area, location | Code | N | Date | Coordinates |
| Clupea pallasii | ||||
| NW Pacific & Bering Sea | ||||
| Sea of Japan | JAP | 24 | 2005 | 48.40°N, 141.94°E |
| Sea of Okhotsk, Taui Bay | OKH | 37 | 5.2005 | 59.40°N, 150.12°E |
| 31.8.2007 | 59.18°N, 149.05°E | |||
| Bering Sea, Togiak Bay | BER | 48 | 58°N, 160°W | |
| NE Pacific | ||||
| Gulf of Alaska, Kodiak Bay | KOD | 27 | 57°N, 154°W | |
| Washington | WAS | 28 | 2009 | 48°N, 125°W |
| Pacific, Total | 164 | |||
| Pechora Sea | ||||
| Chesha Bay, Yarnei River | CHE | 21 | 16.6.2010 | 67.78°N, 45.99°E |
| Indiga Bay, near Svyatoi Nos | IND | 21 | 20.6.2010 | 67.87°N, 48.58°E |
| White Sea | ||||
| Mezen Bay, West Kanin | MEZ | 24 | 16.6.2010 | 67.20 N, 43.49 E |
| Dvina Bay, Yandovaya Inlet | YAN | 36+5 | 5.2001; 15.6.2010 | 64.66°N, 39.82°E |
| Onega Bay, Kolezhma Inlet | KLZ | 21 | 11.5.2001 | 64.30°N, 35.91°E |
| Onega Bay, Kii Island | KIY | 12 | 18.5.2001 | 64.00°N, 37.90°E |
| Gulf of Kandalaksha, Chupa Inlet* | CHP | 10 | 19.4.2001 | 66.30°N, 33.47°E |
| Gulf of Kandalaksha, Chupa Inlet | CHU | 23 | 30.8.1994 | 66.30°N, 33.47°E |
| Gulf of Kandalaksha, Kolvitsa* | KOL | 38 | 30.4.2010 | 67.04°N, 32.55°E |
| Gulf of Kandalaksha, Umba | UMB | 32 | 16.6.2010 | 66.65°N, 34.25°E |
| Norwegian Sea | ||||
| Balsfjord | BLS | 39 | 28.4.2009 | 69.27°N, 19.28°E |
| European C. pallasii, Total | 282 | |||
| Clupea harengus | ||||
| NW Atlantic, Canada | CAN | 26 | 10.3.2010 | 47°N, 47°E |
| Norwegian Sea | NOR | 26 | 2010 | 72°N, 16°E |
| Baltic Sea, Bothnian Sea | BOT | 30 | 2009 | 62°N, 19°E |
| Total C. harengus | 85 | |||
| Total, both species | 528 |
| Parameter | Reference value | Day 1 | Day 1 | Day 2 | Day 2 | Day 3 | Day 3 | Day 5 | Day 7 | Day 8 | Day 15 |
| 12:02 | 22:58 | 05:47 | 21.38 | 07:42 | 18:10 | 09:45 | 10:42 | 08:08 | 12:21 | ||
| BUN | 9.0-20.0 mg/dl | 25 | 21 | 21 | NM | 12 | 9 | 4 | 6 | 8 | 14 |
| Creatinine | −1.1 mg/dl | 1.64 | 1.15 | NM | NM | 0.87 | 1.00 | 0.74 | 0.80 | 0.84 | 0.81 |
| GFR | >90 ml/min/1.73 m | 42 | 63 | NM | NM | 87 | 74 | 104 | 95 | 90 | 94 |
| Sodium | 136.0-145.0 mmol/l | 130 | 129 | 132 | 132 | 138 | 136 | 137 | 140 | 140 | 139 |
| Potassium | 3.3-5.1 mmol/l | 1.1 | 1.6 | 1.5 | 1.4 | 1.7 | 2.8 | 4.5 | 5.4 | 4.9 | 5.0 |
| Chloride | 98.0-106.0 mmol/l | 90 | 92 | 97 | 98 | 101 | 97 | 100 | NM | NM | 99 |
| Calcium | 2.1-2.7 mmol/l | 2.66 | 2.0 | 2.0 | 2.0 | 2.1 | 2.0 | 2.1 | NM | NM | 2.8 |
| pH | 7.33-7.42 | 7.549 | 7.514 | 7.468 | 7.454 | 7.357 | 7.453 | 7.467 | NM | NM | 7.371 |
| HCO3- | 22-26 mmol/l | 31.4 | 28.6 | 29.0 | 28.4 | 25.3 | 30.9 | 33.3 | NM | NM | 29.0 |
| PCO2 | 38-42 mmHg | 36.1 | 34.2 | 40.9 | 42.3 | 52.1 | 48.0 | 35.7 | NM | NM | 57.0 |
| CK | −144.0 U/l | 15966 | 13143 | 11570 | NM | 9882 | 12043 | 5703 | 1867 | 1070 | 102 |
| Leukocytes | 4.0-9.0/nl | 18.1 | NM | NM | NM | 9.5 | 8.9 | NM | NM | 5.5 | 5.9 |
| Erythrocytes | 4.0-5.2/pl | 5.19 | NM | NM | NM | 3.28 | 3.48 | NM | NM | 3.54 | 3.55 |
| Hemoglobin | 12.0-16.0 g/dl | 16.6 | NM | NM | NM | 10.4 | 11.2 | NM | NM | 11.4 | 12.1 |
| Hematocrit | 38.0-48.0% | 42.7 | NM | NM | NM | 27.8 | 29.6 | NM | NM | 35.0 | 35.2 |
| Characteristic | Distribution |
| Sex [n (%)] | |
| Female | 117 (12%) |
| Male | 848 (88%) |
| Age [mean (range)] | 37 (18 – 67) |
| Transmission Risk Factor [n (%)] | |
| MSM, not IDU | 567 (59) |
| IDU | 189 (20) |
| Heterosexual | 160 (17) |
| Other/Unknown | 49 (5) |
| Race/Ethnicity [n (%)] | |
| Black | 139 (14) |
| Hispanic | 193 (20) |
| White | 559 (58) |
| Other/Unknown | 74 (8) |
| Prior Antiretroviral Treatment [n (%)] | |
| Experienced | 571 (59) |
| Naive | 394 (41) |
| Absolute CD4 [mean (std dev)] | 233 (337) |
| log10 HIV Plasma Viral Load [mean (std dev)] | 4.6 (1.7) |
| Age | Parameter | Group | Mean | SD | t | p |
| 3 years | P1 | Control | 95.40 | 16.98 | 3.013 | <0.01 |
| Experimental | 81.30 | 12.22 | ||||
| N1 | Control | 168.40 | 32.10 | 3.908 | <0.01 | |
| Experimental | 134.60 | 21.57 | ||||
| P2 | Control | 235.90 | 36.67 | 5.008 | <0.01 | |
| Experimental | 183.55 | 28.98 | ||||
| N2 | Control | 296.80 | 38.38 | 3.695 | <0.01 | |
| Experimental | 256.85 | 29.40 | ||||
| 4 years | P1 | Control | 79.38 | 16.40 | 0.893 | >0.05 |
| Experimental | 84.05 | 17.69 | ||||
| N1 | Control | 147.61 | 36.61 | 0.152 | >0.05 | |
| Experimental | 149.20 | 27.40 | ||||
| P2 | Control | 205.55 | 49.03 | 0.185 | >0.05 | |
| Experimental | 208.45 | 47.14 | ||||
| N2 | Control | 259.27 | 44.72 | 0.699 | >0.05 | |
| Experimental | 270.30 | 51.64 | ||||
| 5 years | P1 | Control | 70.40 | 13.70 | 0.580 | >0.05 |
| Experimental | 72.95 | 14.11 | ||||
| N1 | Control | 120.68 | 31.36 | 0.367 | >0.05 | |
| Experimental | 123.95 | 23.91 | ||||
| P2 | Control | 154.30 | 36.84 | 0.840 | >0.05 | |
| Experimental | 163.10 | 28.98 | ||||
| N2 | Control | 217.90 | 34.87 | 0.683 | >0.05 | |
| Experimental | 211.80 | 19.46 |
| Estimate | Std. Error | Wald | Df. | Sig. | 95 % Confidence Interval | |||
| Lower Bound | Upper Bound | |||||||
| Threshold | One visit last year | 16.691 | 1.861 | 80.423 | 1 | 0 | 13.043 | 20.339 |
| 2 visits last year | 17.705 | 1.86 | 90.604 | 1 | 0 | 14.059 | 21.35 | |
| Distance | −0.051 | 0.047 | 1.163 | 1 | 0.281 | −0.143 | 0.041 | |
| Family Size | 0.005 | 0.09 | 0.004 | 1 | 0.953 | −0.171 | 0.181 | |
| Age | <20 | 0.446 | 0.517 | 0.744 | 1 | 0.388 | −0.567 | 1.459 |
| 20–34 | 0.025 | 0.376 | 0.004 | 1 | 0.947 | −0.713 | 0.762 | |
| 35–44 | 0.161 | 0.388 | 0.173 | 1 | 0.678 | −0.599 | 0.921 | |
| >45 | 0a | . | . | 0 | . | . | . | |
| House income | 2000–4000 | −0.34 | 0.537 | 0.401 | 1 | 0.527 | −1.392 | 0.712 |
| 4001–6000 | 0.217 | 0.538 | 0.163 | 1 | 0.686 | −0.838 | 1.272 | |
| 6001–8000 | −0.005 | 0.506 | 0 | 1 | 0.992 | −0.997 | 0.986 | |
| 8001–10000 | −0.06 | 0.558 | 0.011 | 1 | 0.915 | −1.154 | 1.034 | |
| >10001 | 0a | . | . | 0 | . | . | . | |
| Education | Less High school | 0.47 | 0.44 | 1.143 | 1 | 0.285 | −0.392 | 1.332 |
| High school | 0.295 | 0.381 | 0.599 | 1 | 0.439 | −0.452 | 1.042 | |
| Collage degree | 0a | . | . | 0 | . | . | . | |
| Gender | Male | −0.92 | 0.387 | 5.658 | 1 | 0.017 | −1.678 | −0.162 |
| Female | 0a | . | . | 0 | . | . | . | |
| Transportation | Always | −0.69 | 0.576 | 1.433 | 1 | 0.231 | −1.82 | 0.44 |
| Occasionally | −0.857 | 0.797 | 1.155 | 1 | 0.282 | −2.419 | 0.706 | |
| Sometimes | −0.405 | 0.531 | 0.582 | 1 | 0.446 | −1.446 | 0.636 | |
| Never | 0a | . | . | 0 | . | . | . |
| Patients | Cancer classification | Clinical stage |
| 1 | Adenocarcinoma | cT2N + M0, Stage III |
| 2 | Adenocarcinoma | cT3N + M0, Stage III |
| 3 | Adenocarcinoma | cT3N + M0, Stage III |
| 4 | Adenocarcinoma | cT3N0M0, Stage II |
| 5 | Adenocarcinoma | cT3N + M0, Stage III |
| 6 | Adenocarcinoma | cT3N + M0, Stage III |
| 7 | Adenocarcinoma | cT3N + M0, Stage III |
| Variable | CGC n =12 | CyGC n = 20 | P ^ |
| Baseline | |||
| Insulin (pmol/L) | 64.59 ± 17.36 | 53.48 ± 18.75 | 0.12 |
| HOMA-IR | 2.2 ± 0.79 | 1.73 ± 0.79 | 0.11 |
| HOMA (β-cell) | 112.8 ± 47.8 | 113.3 ± 63.2 | 0.98 |
| Insulin, follow-up week (pmol/L) | |||
| 1 | 105.56 ± 66.67 | - | - |
| 2 | 125.70 ± 75.01 | - | - |
| 3 | 142.37 ± 57.64 | 106.95 ± 59.73 | 0.11 |
| 4 | 154.87 ± 88.20 | - | - |
| 5 | 156.96 ± 86.81 | - | - |
| 6 | 169.46 ± 109.73 | 125.70 ± 73.62 | 0.19 |
| 8 | 129.87 ± 68.75 | - | - |
| 9 | - | 120.15 ± 70.84 | - |
| 12 | - | 96.53 ± 40.28 | - |
| Insulin (pmol/L) [n] | |||
| With DM1 | 63.20 ± 15.97 | 61.46 ± 20.14 | 0.88 |
| Without DM2 | 66.67 ± 21.32 | 51.39 ± 18.75 | 0.15 |
| P value (1 vs. 2) | 0.75 | 0.39 | - |
| HOMA-IR | |||
| With DM3 | 2.20 ± 0.74 | 2.14 ± 0.96 | 0.91 |
| Without DM4 | 2.21 ± 0.94 | 1.62 ± 0.75 | 0.17 |
| P value (3 vs.4) | 0.99 | 0.35 | - |
| HOMA- β-cell | |||
| With DM5 | 98.8 ± 21.9 | 135.3 ± 102 | 0.36 |
| Without DM6 | 132 ± 68.9 | 107 ± 53.1 | 0.40 |
| p value (5 vs.6) | 0.24 | 0.45 | - |
| MMII† pmol/L(%) | |||
| With DM [week]7 | 145.84(231%) [6] | 154.18(251%) [9] | 0.76 |
| Without DM [week]8 | 82.64 (116%) [4] | 56.25 (111%) [6] | 0.37 |
| p value (7 vs. 8) | 0.02* | 0.01* | - |
| NOPES score | ≥1 | ≥2 | ≥3 |
| Sensitivity (%) | 98.7 | 68.9 | 24.3 |
| Specificity (%) | 14.1 | 59.2 | 95.1 |
| Validity index (%) | 38.4 | 62 | 74.8 |
| Positive predictive value (%) | 31.6 | 40.5 | 66.7 |
| Negative predictive value (%) | 96.3 | 82.6 | 75.8 |
| Youden Index | 0.13 | 0.28 | 0.19 |
| Prevalence of BE (%) | 31.6 | 40.8 | 66.7 |
| ANC | ALC | CD3Count | CD3% | CD4Count | CD4% | CD8Count | CD4% | CD4/CD8ratio | CD19Count | CD19% | ||
| Serum iron (mg/dl) | p | 0.02* | 0.08 | 0.5 | 0.14 | 0.5 | 0.001* | 0.05 | 0.19 | 0.002* | 0.02* | 0.69 |
| r | 0.27 | −0.2 | −0.07 | 0.17 | 0.08 | 0.5 | −0.22 | −0.14 | 0.35 | −0.27 | −0.05 |
| Plant | Material | Shoot Weight | Lead Concentration | Lead Uptake |
| (a) | (b) | (c = a × b) | ||
| (mg box−1 DW) | (μg g−1 DW) | (μg box−1 DW) | ||
| Barley | +HAP | 410 ± 90 | 7 ± 2 | 2.7 ± 0.2 |
| −HAP | 240 ± 40 | 90 ± 70 | 18 ± 13 | |
| p value | 0.1513 | 0.2964 | 0.2867 | |
| Hairy vetch | +HAP | 700 ± 100 | 9 ± 1 | 6.1 ± 1.2 |
| −HAP | 244 ± 24 | 24 ± 7 | 5.5 ± 1.3 | |
| p value | 0.0014 ** | 0.1005 | 0.7530 |
| Clinical Dosage | Flow Rate | Volume and Syringe Size | |
| Loading Dose | 4 g MgSO4 over 20 min | 60 mL/h | 20 mL in a single 20 mL syringe |
| Maintenance Dose | 1 g/h MgSO4 for 24 h | 5 mL/h | 120 mL in two 60 mL syringes |
| EE | EK | P value | |
| Mean (95% CI) | Mean (95% CI) | ||
| n males/n females | 934/934 | 40/42 | - |
| Triglycerides (mmol/L) | 1.94 (1.90, 1.99) | 1.61 (1.44, 1.80) | 0.001 |
| Cholesterol (mmol/L) | 4.86 (4.82, 4.90) | 4.88 (4.69, 5.08) | 0.889 |
| LDL-cholesterol (mmol/L) | 2.77 (2.73, 2.80) | 2.87 (2.70, 3.04) | 0.237 |
| HDL-cholesterol (mmol/L) | 1.05 (1.04, 1.06) | 1.10 (1.05, 1.16) | 0.081 |
| BMI (kg/m2) | 35.90 (35.87, 35.93) | 35.91 (35.78, 36.03) | 0.940 |
| Weight (kg) | 100.55 (100.21, 100.90) | 101.51 (99.88, 103.17) | 0.264 |
| Waist Circumference (cm) | 115.03 (114.69, 115.37) | 116.73 (115.11, 118.37) | 0.043 |
| Glucose (mmol/L) | 8.38 (8.28, 8.49) | 8.02 (7.56, 8.51) | 0.154 |
| HbA1c | 7.18 (7.14, 7.23) | 7.00 (6.79, 7.22) | 0.113 |
| SBP (mm/Hg) | 129.12 (128.31, 129.93) | 124.88 (121.23, 128.64) | 0.031 |
| DBP (mm/Hg) | 69.38 (68.98, 69.79) | 67.55 (65.71, 69.43) | 0.062 |
| Triglycerides (mmol/L) on subjects not receiving lipid lowering medication | 1.91 (1.85, 1.98)(n = 771) | 1.54 (1.31, 1.80)(n = 36) | 0.007 |
| Characteristics | Study population N=253 | |||
| ST (n=88) | ART- naïve (n=96) | EC (n=19) | HS (n=50) | |
| Age (years) [Mean ± SD (range)] | 48.4±9.4 (29-81) | 39.2±9.2 (23-58) | 49.0±7.1 (40-62) | 45.0±9.9 (19-64) |
| Male [n (%)] | 73 (83%) | 76 (79%) | 9 (47%) | 35 (70%) |
| Risk factors: | ||||
| Men Who Have Sex with Men [n (%)] | 59 (67%) | 58 (60%) | 6 (32%) | NA |
| Heterosexual [n (%)] | 15 (17%) | 22 (23%) | 10 (53%) | NA |
| Endemic [n (%)] | 11 (13%) | 12 (13%) | 2 (11%) | NA |
| Injection drug users [n (%)] | 3 (3%) | 4 (4%) | 1 (5%) | NA |
| Time since HIV-1 diagnosis (years) [Mean ± SD (range)] | 10.1±5.5 (2-24) | 4.2±5.2 (0-23) | 13.1±4.1 (4-20) | NA |
| CD4 T-cell count (cells/μL) [Mean ± SD range)] | 531.3±267.4 (37-1282) | 416.1±189.2 (3-1110) | 617.8±209.4 (417-1341) | 812.6±273.0(281-1559) |
| CD8 T-cell count (cells/μL)[Mean ± SD (range)] | 785.8±332.6 (153-2013) | 761.9±365.2 (237-1933) | 559.7±307.0 (162-1198) | 390.9±188.5 (95-843) |
| CD4:CD8 ratio [Mean ±SD (range)] | 0.75±0.42 (0.08-2.06) | 0.64±0.38 (0.01-12.09) | 1.35±0.61 (0.35-2.72) | 2.45±0.96 (0.38-4.34) |
| VL (log10copies/mL) [Mean ±SD (range)] | < 1.6 | 4.0±0.87 (1.73-6.35) | < 1.6 | NA |
| Time of undetectable VL (years)[Mean ± SD (range)] | 3.64±2.7 (1-10) | NA | 12.8±7.0 (7-20) | NA |
| Time since start of ART (years) [Mean ± SD (range)] | 8.1±4.7 (1-20) | NA | NA | NA |
| Collection$ | LR loci | ER loci | RatioER/LR | P value |
| P{EP} | 10.6 (273) | 42.3 (1,738) | 4.0 | 1.8E-135 |
| P{EPgy2} | 17.5 (452) | 56.6 (2,325) | 3.2 | 2.0E-153 |
| P{GT1} | 3.0 (78) | 6.7 (274) | 2.2 | 5.4E-13 |
| P{SUPor-P} | 11.9 (307) | 31.2 (1,281) | 2.6 | 5.8E-69 |
| PBac{PB} | 22.0 (566) | 40.7 (1,674) | 1.9 | 1.9E-50 |
| PBac{RB} | 18.4 (473) | 41.7 (1,714) | 2.3 | 1.9E-75 |
| Mi{ET1} | 27.6 (710) | 20.6 (847) | 0.7 | 9.7E-15 |
| Selected set | 12.2 (313) | 46.4 (1,908) | 3.8 | 5.1E-144 |
| Genomic size, Mb | 25.8 | 41.1 |
| Direct | Indirect | |
| Medical | Medical consultations (Ch-P)c | d |
| Skills training (Ch) | ||
| Parent training (P) | ||
| Day-care treatment (Ch) | ||
| Hospitalization (Ch) | ||
| Medication (Ch-P) | ||
| Non-medical | Remedial teaching at school (Ch) | Agency for child welfare (Ch) |
| Weekend care (Ch) | Police (Ch) | |
| Care after school (Ch) | Special education (Ch) | |
| Diet (Ch) | Productivity losses | |
| Absenteeism (P) | ||
| Presenteeism (P) |
| Amino acid | Casein | Jinyan-No.13 | Bayou-No.8 | Baiyan-No.2 | Dingyou-No.8 | Baiyan-No.8 |
| Asparagine | 71.3 | 82.6 | 78 | 123.3 | 83.5 | 59.9 |
| Threonine | 40.5 | 33.9 | 32.5 | 52.9 | 34.2 | 25.0 |
| Serine | 50.4 | 47.4 | 44.9 | 74.8 | 46.5 | 34.8 |
| Glutamine | 244.7 | 253.7 | 246.5 | 392.7 | 261.0 | 192.8 |
| Glycine | 18.4 | 50.0 | 48.7 | 80.2 | 50.3 | 37.2 |
| Alanine | 31.6 | 48.9 | 46.1 | 76.5 | 48.7 | 35.6 |
| Cystine | 16.5 | 39.2 | 35.9 | 58.6 | 36.3 | 27.6 |
| Valine | 60.3 | 56.8 | 55.6 | 88.2 | 57.3 | 42.9 |
| Methionine | 27.7 | 14.7 | 15.9 | 22.0 | 16.7 | 12.9 |
| Isoleucine | 50.3 | 38.9 | 39 | 61.0 | 40.8 | 29.8 |
| Leucine | 96.1 | 77.6 | 76.4 | 124.1 | 80.0 | 60.4 |
| Tyrosine | 52.7 | 39.7 | 43.1 | 69.3 | 41.3 | 36.7 |
| Lysine | 77.9 | 59.5 | 57.7 | 96.3 | 58.3 | 45.8 |
| Histidine | 26.2 | 41.4 | 38.9 | 64.3 | 40.9 | 30.3 |
| Arginine | 33.5 | 30.3 | 29.7 | 47.3 | 30.5 | 22.8 |
| Phenylalanine | 48.7 | 62.6 | 66.3 | 104.8 | 68.6 | 51.2 |
| Proline | 104.1 | 48.4 | 48.9 | 85.0 | 52.2 | 38.6 |
| Lysine/arginin | 2.33 | 0.66 | 0.59 | 0.61 | 0.60 | 0.59 |
| Methionin/glycine | 1.51 | 0.29 | 0.33 | 0.27 | 0.33 | 0.35 |
| Attributes | Levels |
| Cervical cancer risk | 0, 2, 4 in 1,000 |
| Genital wart risk | 0, 50, 100 in 1,000 |
| Common side effect e.g. mild fever, little pain | 2, 6, 10, 14 in 100 |
| Costs for 3 doses of HPV vaccinea | 0 Baht, 5,000 Baht, 10,000 Baht |
| Laparoscopic surgery | Preoperative intraabdominal adhesions evaluation scores | Success rate | χ2 | P value | RR |
| LC (n = 118) | ≤ 3 points, n = 62 | 96.8%(60/62) | 59.70 | 0.001 | 3.38a |
| >3 points, n = 56 | 28.6%(16/56) | ||||
| LCBDE+LC (n = 171) | ≤ 3 points, n = 59 | 84.7%(50/59) | 53.41 | 0.001 | 3.27b |
| >3 points, n = 112 | 25.9%(29/112) |
| Variable | No. (%) |
| Age at admission (days) | |
| 21–90 | 8,168 (42.7) |
| 91–180 | 5,819 (30.5) |
| 181–270 | 3,196 (16.7) |
| 271–365 | 1,926 (10.1) |
| Gestation (weeks) | |
| 37 1/7–44 | 16,049 (84.0) |
| 34 1/7–37 | 2,035 (10.7) |
| 29 1/7–34 | 789 (4.1) |
| 25–29 | 236 (1.2) |
| Sex | |
| Male | 11,277 (59.7) |
| Female | 7,832 (40.3) |
| Ethnicity | |
| Hispanic | 12,373 (64.8) |
| Non-Hispanic | 6,393 (33.5) |
| Unknown | 343 (1.7) |
| Recorded respiratory/cardiac conditions of newborn | |
| Respiratory distress syndrome | 609 (3.2) |
| Bronchopulmonary dysplasia | 85 (0.4) |
| Pulmonary anomalies | 63 (0.3) |
| Any pulmonary disease | 678 (3.6) |
| Cardiac anomalies | 505 (2.6) |
| Payment source | |
| MediCal | 11,673 (61.1) |
| Private insurance/HMO/PPO | 6,670 (34.9) |
| Other | 766 (4.0) |
| Both sexes - all age groups | Males - all age groups | Females - all age groups | ||||||||||
| Year | Mid-year population | Total deaths from 4 NCDsa | Death ratea | ASMR | Mid-year population | Total deaths from 4 NCDs | Death rate | ASMR | Mid-year population | Total deaths from 4 NCDs | Death rate | ASMR |
| 2001 | 18,797,000b | 41,808 | 2.2 | 2.1 | 9359,000b | 25,526 | 2.7 | 4.8 | 9438,000b | 16,282 | 1.7 | 3.7 |
| 2002 | 18,921,000 | 42,485 | 2.2 | 1.4 | 9,350,000 | 25,963 | 2.8 | 3.7 | 9,571,000 | 16,522 | 1.7 | 2.1 |
| 2003 | 19,173,083 | 45,350 | 2.4 | 1.5 | 9,475,000 | 27,358 | 2.9 | 3.9 | 9,698,083 | 17,992 | 1.8 | 2.3 |
| 2004 | 19,433,360 | 47,856 | 2.5 | 1.6 | 9,676,883 | 28,798 | 3.0 | 4.0 | 9,756,478 | 19,058 | 1.9 | 2.4 |
| 2005 | 19,643,474 | 49,013 | 2.5 | 1.6 | 9,782,497 | 29,488 | 3.0 | 4.0 | 9,860,977 | 19,525 | 1.9 | 2.4 |
| 2009 | 20,476,000 | 60,880 | 3.0 | 1.8 | 10,174,000 | 34,830 | 3.4 | 4.4 | 10,302,000 | 26,050 | 2.5 | 3.0 |
| 2010 | 20,675,000 | 62,565 | 3.0 | 1.8 | 10,273,000 | 35,584 | 3.5 | 4.4 | 10,402,000 | 26,981 | 2.6 | 3.0 |
| Procedure | Percent Agreeing quite or very important. |
| ACLS/CPR | 91 |
| Central Venous Catheter Insertion | 93 |
| Paracentesis | 90 |
| Endotracheal Intubation | 89 |
| Lumbar Puncture | 89 |
| Thoracentesis | 87 |
| Arterial access and blood gases | 82 |
| Ambulatory ECG | 79 |
| Cardioversion | 77 |
| Exercise Stress Testing | 77 |
| Hemodynamic Monitoring | 76 |
| Temporary Pacemaker Insertion | 75 |
| Mechanical Ventilation | 75 |
| Transthoracic Pacing | 71 |
| Arthrocentesis | 70 |
| Bone Marrow Aspiration and Biopsy | 60 |
| Chest Tube Insertion | 58 |
| Venipuncture | 50 |
| Variable | Frequency in complete baseline sample | Frequency in complete 1-year follow-up sample | Frequency at 1-year follow-up among those who had valid MVPA and travel mode data | |||
| N (%) | N (%) | N (%) | ||||
| Sex | n=2064 | n=913 | n=812 | |||
| Boy | 926 | (45) | 374 | (41) | 333 | (41) |
| Girl | 1,138 | (55) | 539 | (59) | 479 | (59) |
| Ethnicity | n=1914 | n=885 | n=794 | |||
| White | 1841 | (96) | 857 | (97) | 770 | (97) |
| Other | 73 | (4) | 28 | (3) | 24 | (3) |
| Urban/rural status | n=2023 | n=902 | n=802 | |||
| Hamlet and isolated dwelling | 142 | (7) | 73 | (8) | 67 | (8) |
| Village | 506 | (25) | 248 | (28) | 219 | (27) |
| Town and fringe | 575 | (28) | 275 | (30) | 244 | (30) |
| Urban >10 k | 800 | (40) | 306 | (34) | 272 | (34) |
| Parent education status | n=1882 | n=877 | n=786 | |||
| None | 140 | (7) | 53 | (6) | 45 | (6) |
| GCSE or equivalent | 963 | (51) | 454 | (52) | 405 | (51) |
| A-levels or equivalent | 468 | (25) | 204 | (23) | 186 | (24) |
| Degree or postgraduate degree | 311 | (17) | 166 | (19) | 150 | (19) |
| Travel mode | n=2053 | n=913 | n=812 | |||
| Bicycle | 189 | (9) | 73 | (8) | 59 | (7) |
| Bus or train | 127 | (6) | 62 | (7) | 57 | (7) |
| Car | 923 | (45) | 357 | (39) | 322 | (40) |
| Foot | 814 | (40) | 421 | (46) | 374 | (46) |
| PATIENT | SIZE AND POSITION OF CHROMOSOME 15 DELETION | ADDITIONAL CHROMOSOME ABERRATION | SEX | CLEFT PALATE | HEART DEFECT | DEVELOPMENTAL DELAY | FACIES ANOMALIES | ADDITIONAL ABNORMALITIES |
| Present case | del(15)(q14) (submicroscopic, 1,6 Mb) | t(1;13)(p31.1;q13),t(3;19)(p23;p12), t(9;15)(p23;q14),t(14;18)(q22;p11.23) | M | + | - | + | + | - |
| Chen et al., 2008 | del(15)(q14) (submicroscopic, 5,6 Mb) | - | M | + | VSD | + | + | Epilepsy; speech and language disorder |
| Brunetti-Pierri et al., 2008 case 1 | del(15)(q14) (submicroscopic, 4,2 Mb) | - | M | + (Bifid uvula) | + | + | + | Bilateral inguinal hernias, autistic spectrum behavior |
| Brunetti-Pierri et al., 2008 case 2 | del(15)(q13-q14) (submicroscopic, 8,9 Mb) | - | F | - | + | + | + | Hypotonia,feeding difficulties |
| Erdogan et al., 2007 | del(15)(q14) (submicroscopic, 5,3 Mb) | - | F | + | ASD | + | + | Low-set ears, OFC 3rd percentile |
| Galan et al., 1991 | del(15)(q12-q14) | - | M | + (Bifid uvula) | Pulmonary valve stenosis | + | + | Right cryptorchidism, hearing deficency |
| Tonk et al., 1995 | del(15)(q12-q14) | - | M | + | VSD, PDA, ischemic cardiomyopathy | + | + | Large fontanelles, hearing deficency |
| Autio et al., 1988 | del(15)(q13-q15) | - | M | + | ASD | + | + | Cryptorchidism, kidney defect, corpus callosum agenesis |
| Herva and Vuorinen, 1980 | del(15)(q12-q14) | Mosaic with 46, XY | M | - | VSD, hypoplastic pulmonary artery, atretic tricuspid valve | Died at 7 days | + | Cryptorchidism |
| Pauli et al., 1983 | del(15)(pter-q15) | del(11)(q25-qter) | M | + (Bifid uvula) | VSD | + | + | Cryptorchidism, unilateral renal ptosis |
| Windpassinger et al., 2003 | del(15)(pter-q14) | del(3)(qter) | M | - | Persistent foramen ovale, PDA | + | + | Cryptorchidism, clubfeet, strabismus |
| Kucerova et al., 1979 | del(15)(pter-q15) | del(3)(pter-p25) | M | - | - | + | + | Cryptorchidism |
| Duckett and Roberts, 1981 | del(15)(pter-q14or15) | Trisomy 13(pter-q32 or 33) | F | + (Bifid uvula) | VSD, ASD, PDA, transposition of great vessels | Died at 14 hr | + | Microphthalmia, tracheo-oesophageal fistula |
| Ming et al., 1977 | del(15)(pter-q21) | del(6)(q27-qter) | F | + | - | Died at 3 days | + | Microphthalmia |
| Schwartz et al., 1985 | del(15)(pter-q14) | del(22)(pter-q13.2) | M | - | Coarctation of aorta, PDA | + | + | Cleft alveolar ridge, hydronephrosis |
| Matsumura et al., 2003 | del(15)(pter-q14) | Trisomy 22q | M | - | PDA | + | + | Renal failure, cryptorchidism |
| Treatment-naïve (n = 42) | Previously treated (n = 270) | All(N = 312) | |
| All adverse events, n (%) | 18 (42.9) | 70 (25.9) | 88 (28.2) |
| Treatment-related, n (%) | 11 (26.2) | 37 (13.7) | 48 (15.4) |
| Oculara | 11 (26.2) | 37 (13.7) | 48 (15.4) |
| Ocular hyperemia | 6 (14.3) | 12 (4.4) | 18 (5.8) |
| Dark circles under the eyes | 0 | 6 (2.2) | 6 (1.9) |
| Eye pruritus | 1 (2.4) | 4 (1.5) | 5 (1.6) |
| Decreased lacrimation | 1 (2.4) | 4 (1.5) | 5 (1.6) |
| Eye allergy | 1 (2.4) | 2 (0.7) | 3 (1.0) |
| Ocular discomfort | 1 (2.4) | 1 (0.4) | 2 (0.6) |
| Eye pain | 1 (2.4) | 0 | 1 (0.3) |
| Serious | 0 | 0 | 0 |
| Leading to discontinuation, n (%) | 6 (14.3) | 15 (5.6) | 21 (6.7) |
| Comfortable | Natural | Soothed | |
| Forest area | 4.00 ± 0.60 | 4.63 ± 0.63 | 3.63 ± 0.91 |
| Urban area | 0.13 ± 0.40 | −2.00 ± 0.53 | 0.00 ± 0.53 |
| p-value | 0.006 ** | 0.006 ** | 0.010 * |
| Non-financial COI terms | n (%) |
| Personal relationship | 29 (54) |
| Other | 21 (39) |
| Non-financial COI | 18 (33) |
| Professional | 15 (28) |
| Academic competition | 12 (22) |
| Personal opinion | 10 (19) |
| Academic | 9 (17) |
| Intellectual passion | 9 (17) |
| Religious views | 8 (15) |
| Political | 8 (15) |
| Personal | 8 (15) |
| Intellectual | 7 (13) |
| Ideological | 7 (13) |
| Competing loyalties | 5 (9) |
| Advocacy groups/institutional advocacy | 5 (9) |
| Institutional | 3 (6) |
| Legal relationship | 3 (6) |
| Governmental | 1 (2) |
| Polymorphisms | Subgroup | Heterogeneity | Test of association | |||
| OR (95% CI) | P Value | Model | I2 (%) | P Value | ||
| Donor | ||||||
| rs1800469 | Overall | 0.56 (0.32-0.98) | 0.04 | F | 10 | 0.34 |
| Caucasian | 0.95 (0.40-2.25) | 0.12 | F | 0 | 0.50 | |
| Asian | 0.38 (0.18-0.80) | 0.01 | F | 0 | 0.52 | |
| HLA-matched | 0.23 (0.04-1.32) | 0.10 | F | 0 | 0.80 | |
| rs1800470 | Overall | 0.65 (0.46-0.94) | 0.02 | F | 0 | 0.47 |
| Caucasian | 0.70 (0.47-1.06) | 0.09 | F | 0 | 0.37 | |
| Recipient | ||||||
| rs1800469 | Overall | 0.73 (0.63-0.85) | <0.0001 | F | 7 | 0.37 |
| Caucasian | 0.51 (0.22-1.18) | 0.12 | F | 0 | 0.78 | |
| Asian | 0.74 (0.63-0.86) | 0.0001 | F | 42 | 0.18 | |
| HLA-matched | 0.32 (0.08-1.27) | 0.11 | F | 0 | 0.99 | |
| rs1800470 | Overall | 1.28 (0.81-2.01) | 0.29 | F | 0 | 0.72 |
| Caucasian | 1.32 (0.80-2.17) | 0.28 | F | 0 | 0.44 |
| Variables | Management outcomes | COR (95 % CI) | AOR (95 % CI) | P-value | |
| Favorable [N] | Unfavorable [N] | ||||
| Age | |||||
| <14 years | 52 | 8 | 0.287(0.11–0.76) | 0.99(0.11–2.13) | 0.998 |
| 14–24 years | 21 | 7 | 0.62(0.21–1.79) | 0.59(0.109–3.21) | 0.543 |
| 25–34 years | 32 | 12 | 0.70(0.28–1.74) | 0.86(0.23–3.17) | 0.828 |
| 35–44 years | 27 | 5 | 0.34(0.11–1.08) | 0.35(0.08–1.48) | 0.158 |
| 45–55 years | 45 | 9 | 0.64(0.242–1.73) | 0.28(0.07–1.08) | 0.066 |
| >55 years | 28 | 15 | 1 | 1 | |
| Occupation | |||||
| Farmer | 64 | 26 | 1 | 1 | |
| Merchant | 18 | 7 | 0.95(0.35–2.56) | 1.93(0.56–6.56) | 0.291 |
| House wife | 14 | 13 | 2.28(0.94–5.52) | 3.28(0.97–11.11) | 0.056 |
| Student | 18 | 1 | 0.14(0.02–1.07) | 0.97(1.87–2.61) | 0.998 |
| Governmental employer | 23 | 2 | 0.21(0.05–0.97) | 0.14(0.02–1.09) | 0.061 |
| Duration of illness | |||||
| ≤24 h | 101 | 18 | 0.39(0.21–0.74) | 0.49(0.25–0.97) | 0.014* |
| >24h | 85 | 38 | 1 | 1 | |
| Intra-operative finding | |||||
| Gangrenous SBV | 9 | 9 | 1 | 1 | |
| Gangrenous SV | 8 | 10 | 1.25(0.33–4.63) | 1.95(0.34–10.95) | 0.447 |
| Adhesion & bands | 28 | 14 | 0.50(0.16–1.54) | 5.90(0.72–4.80) | 0.098 |
| Viable SBV | 29 | 2 | 0.07(0.01–0.37) | 0.08(0.01–0.95) | 0.046* |
| Viable SV | 34 | 7 | 0.21(0.06–0.71) | 0.17(0.03–0.88) | 0.035* |
| Intussusceptions | 49 | 7 | 0.14(0.04–0.48) | 0.49(0.07–3.22) | 0.460 |
| Colonic Cancer | 8 | 4 | 0.50(0.11–2.27) | 0.27(0.04–1.64) | 0.157 |
| Hernia | 8 | 1 | 0.12(0.01–1.216) | 0.12(0.01–1.65) | 0.114 |
| Illiosigmoidal knot | 4 | 1 | 0.25(0.023–2.69) | 1.40(0.04–43.13) | 0.844 |
| Intra-operative procedure done | |||||
| Resection& Anastomosis | |||||
| Yes | 63 | 35 | 3.02(1.61–5.69) | 3.05(1.04–8.94) | 0.041* |
| No | 109 | 21 | 1 | 1 | |
| Adhesion release | |||||
| Yes | 33 | 9 | 0.83(0.37–1.86) | 0.09(0.01–0.69) | 0.020* |
| No | 139 | 47 | 1 | 1 | |
| Manual Reduction | |||||
| Yes | 41 | 2 | 0.12(0.02–0.52) | 0.15(0.03–0.68) | 0.014* |
| No | 131 | 54 | 1 | 1 | |
| Hospital stay | |||||
| ≤ 7 days | 117 | 3 | 0.03(0.01–0.11) | 0.05(0.01–0.16) | 0.001* |
| >7 days | 69 | 53 | 1 | 1 |
| Lambertian Scattering | Epidermis | Dermis | Veins | Phalanx | Proximal Phalanx | Digital Arteries |
| Reflectance | 32% | 26% | 34% | 47% | 26% | 53% |
| Transmittance | 68% | 74% | 66% | 53% | 74% | 47% |
| Mazabuka | Kafue | ||||
| (Total = 273) | (Total = 361) | ||||
| % | (n) | % | (n) | p-value | |
| Sex of head of family | |||||
| Male | 84 | (226) | 92 | (327) | 0.003 |
| Females | 16 | (43) | 8 | (30) | |
| Age of caretaker (years) | |||||
| <19 | 15 | (41) | 14 | (51) | 0.96 |
| 20-29 | 59 | (161) | 59 | (212) | |
| 30-39 | 22 | (60) | 23 | (83) | |
| 40-59 | 3.3 | (9) | 4 | (14) | |
| Caretaker-child relationship | |||||
| Mother | 98.2 | (268) | 99 | (357) | 0.368 |
| Other | 1.8 | (5) | 1 | (4) | |
| Marital status | |||||
| Married | 81.8 | (220) | 85 | (308) | 0.265 |
| Widowed | 4.1 | (11) | 2 | (8) | |
| Divorced | 3 | (8) | 2 | (8) | |
| Separated | 1.1 | (3) | 2 | (8) | |
| Single | 10 | (27) | 7 | (25) | |
| Educational level-caretaker | |||||
| None | 5.2 | (14) | 11 | (38) | <0.001 |
| Primary | 50.6 | (137) | 67 | (239) | |
| Secondary | 38 | (103) | 23 | (81) | |
| Tertiary | 6.3 | (17) | 0 | (1) | |
| Age distribution of the children | |||||
| <6 months | 28 | (76) | 31 | (111) | |
| 6 – 11 months | 26.2 | (71) | 30 | (107) | |
| >12 months | 45.8 | (124) | 39 | (140) |
| Diagnosis | Number OFSO patients | First line OFSO | Salvage OFSO |
| Chronic frontal sinusitis | 23 | 7/23 (30%) | 16/23 (70%) |
| Frontal sinus mucocele | 11 | 8/11 (72%) | 3/11 (28%) |
| Total inflammatory frontal sinus disease patients | 34 | 15/34 (44%) | 19/34 (56%) |
| Systematic name or TIGR identifier | Description |
| Tc00.1047053506811.120 | Hypothetical protein 1 (HYPO1) |
| UP|Q9NIQ8 (Q9NIQ8) | Mucin-like protein |
| UP|Q72DX6 (Q72DX6) | Sensor histidine kinase |
| UP|Q25325 (Q25325) | Heat shock protein 70-related protein |
| UP|Q7TPK7 (Q7TPK7) | Ac2-048 |
| UP|Q9XY95 (Q9XY95) | Neurotrophin |
| UP|H2A_TRYCR (P35066) | Histone H2A |
| UP|RL29_DROME (Q24154) | 60S ribosomal protein L29 (L43) |
| UP|RS6_LEIMA (Q9NE83) | 40S ribosomal protein S6 |
| PDB|1II2_A.0|17942708| | 1II2_A Chain A, Crystal Structure Of Phosphoenolpyruvate Carboxykinase (Pepck) |
| UP|O48239 (O48239) | Cytochrome b (Fragment) |
| gb|L22334.1|TRBS3RRBN | 5.8S ribosomal RNA, internal transcribed spacers 1–7, and 28S ribosomal RNA |
| Attributes | Format |
| Date | MM/DD/YY |
| Time | (H) H:MM (military time) |
| Count | Number of cars measured for the previous five minutes |
| Beginning event time | HH:MM:SS (military) |
| Ending event time | HH:MM:SS (military) |
| Away team | — |
| Game attendance | — |
| W/L score | — |
| Subject | Age | Weight | Height | BMI | FSH |
| No. | (y) | (kg) | (m) | (kg/m2) | (IU/L) |
| 1 | 52 | 57.00 | 1.60 | 22.27 | 49.20 |
| 2 | 53 | 52.50 | 1.53 | 22.43 | 48.50 |
| 3 | 54 | 54.00 | 1.51 | 23.68 | 33.50 |
| 4 | 54 | 60.00 | 1.56 | 24.65 | 49.40 |
| 5 | 56 | 48.50 | 1.45 | 23.07 | 38.60 |
| 6 | 56 | 42.00 | 1.44 | 20.25 | 68.50 |
| 7 | 49 | 58.50 | 1.66 | 21.23 | 128.20 |
| 8 | 55 | 58.00 | 1.53 | 24.78 | 68.80 |
| 9* | 57 | 48.50 | 1.50 | 21.56 | 101.00 |
| 10 | 62 | 60.50 | 1.60 | 23.63 | 53.33 |
| 11 | 59 | 49.00 | 1.51 | 21.50 | 40.79 |
| 12 | 62 | 48.00 | 1.42 | 23.81 | 63.49 |
| Mean | 55.75 | 53.04 | 1.53 | 22.74 | 61.94 |
| SD | 3.70 | 5.63 | 0.07 | 1.37 | 26.43 |
| IE >10% | AI >10% | ||||||
| Absent(n = 55) | Present(n = 14) | P | Absent(n = 48) | Present(n = 21) | P | ||
| Pathology | Restrictive | 29 (53) | 10 (71) | 0.24 | 24 (50) | 15 (71) | 0.12 |
| Obstructive | 26 (47) | 4 (29) | 24 (50) | 6 (29) |
| Total population (R2 = 0.69*) | Type 1 (R2 = 0.73*) | Type 2 (R2 = 0.66*) | ||||
| Covariate | ß | p-value | ß | p-value | ß | p-value |
| Systolic blood pressure (mmHg) | 0.301 | < 0.001 | 0.442 | < 0.001 | 0.233 | 0.001 |
| Low eGFR (ml/min/1.73 m2) | 0.131 | 0.007 | 0.009 | 0.909 | 0.150 | 0.024 |
| Low stress-corrected MWS (%) | 0.239 | < 0.001 | 0.493 | < 0.001 | 0.156 | 0.017 |
| Isovolumic relaxation time (ms) | 0.170 | 0.001 | 0.180 | 0.041 | 0.155 | 0.016 |
| LV mass/height2.7 | 0.187 | 0.001 | 0.091 | 0.284 | 0.189 | 0.008 |
| Circumferential end-systolic stress (dyne/cm2) | –0.584 | < 0.001 | –0.682 | < 0.001 | –0.602 | < 0.00 |
| Male gender | 0.083 | 0.065 | –0.009 | 0.905 | 0.123 | 0.051 |
| Characteristic | Community level (n=32) | Patch level (n=62) |
| Communities in cattle corridor (percent) | 59.7% | – |
| Perceived patch condition (percent) | ||
| Bad | 9.80% | |
| Average | 42.70% | |
| Good | 47.50% | |
| Patch usage by community members (percent) | 40% | 30% |
| Area of communal grazing land (hectares)* | 24 | 6 |
| Grazing lands with use restrictions (percent)* | 8.06% |
| Bentonite symbol | Grain size distribution, % | ||||
| 0.5–1 μm | 1–5 μm | 5–10 μm | 10–50 μm | 50–100 μm | |
| B | 4.1 | 13.4 | 20.4 | 30.6 | 31.5 |
| BP1 | 3.5 | 10.6 | 18.3 | 33.2 | 34.4 |
| BP2 | 2.6 | 9.3 | 17.4 | 31.8 | 38.9 |
| Practice Visitor as: | Assessor | Expert/Educator | Facilitator | Interpreter |
| Whose role is: | External assessment against standards. | Knowledge and skill transfer. | Consensus building to achieve group view. | Helping practice teams decide what and how they would like to improve. |
| Based upon: | Historical competence. | Best practice. | A template for process. | Practice based issues. |
| Controlling: | Outcome. | Outcome and process. | Process. | Neither outcome nor process, simply participation. |
| Theoretical basis: | Systems. | Systems and organisational development. | Organisational development. | Complexity. |
| Examples: | Accreditation systems. | Outreach project to set up systems for chronic disease management. | Maturity Matrix. | Action research. |
| Parameters | overall(n = 1447) | cf-PWV ≥12(n = 571) | cf- PWV < 12(n = 876) | P value |
| Age (year) | 61.30 ± 11.4 | 65.59 ± 10.9 | 52.46 ± 11.5 | <0.001 |
| Male [n (%)] | 601(41.53) | 270(47.28) | 331(37.78) | <0.001 |
| BMI | 25.41 ± 3.32 | 25.41 ± 3.28 | 25.26 ± 4.17 | 0.583 |
| Systolic BP(mmHg) | 128.7 ± 17.7 | 135.38 ± 18.37 | 124.37 ± 15.93 | <0.001 |
| Diastolic BP(mmHg) | 77.11 ± 10.26 | 77.00 ± 10.92 | 77.18 ± 9.82 | 0.762 |
| Fasting glucose (mmol/L) | 5.39 ± 1.65 | 5.63 ± 1.87 | 5.21 ± 1.35 | <0.001 |
| 2-HpBG(mmol/L) | 6.96 ± 1.11 | 7.71 ± 1.10 | 6.47 ± 1.23 | <0.001 |
| Triglyceride(mmol/L) | 1.80 ± 1.24 | 1.92 ± 1.27 | 1.74 ± 1.24 | 0.017 |
| Total cholesterol (mmol/L) | 5.01 ± 0.93 | 5.02 ± 0.97 | 5.01 ± 0.89 | 0.845 |
| HDL2-C (mg/dL) | 29.85 ± 9.13 | 29.69 ± 9.44 | 30.05 ± 9.08 | 0.593 |
| HDL3-C (mg/dL) | 20.98 ± 4.22 | 20.62 ± 4.12 | 21.42 ± 4.38 | 0.006 |
| HDL cholesterol (mmol/L) | 1.34 ± 0.42 | 1.30 ± 0.43 | 1.37 ± 0.41 | 0.247 |
| LDL cholesterol (mmol/L) | 2.91 ± 0.71 | 2.96 ± 0.73 | 2.87 ± 0.69 | 0.030 |
| Waist-hip ratio | 0.87 ± 0.05 | 0.88 ± 0.06 | 0.86 ± 0.0.07 | <0.001 |
| eGFR (ml/min) | 94.2 ± 14.3 | 88.18 ± 14.19 | 98.63 ± 12.45 | <0.001 |
| Current smoking [n (%)] | 380(26.26) | 175(30.65) | 205(23.40) | <0.001 |
| Hypertension [n (%)] | 755(52.17) | 418(73.20) | 337(38.47) | <0.001 |
| Diabetes mellitus [n (%)] | 302(20.87) | 183(24.22) | 119(18.45) | <0.001 |
| Component | Consumers (n = 347) | Non-consumers (n = 17,220) | p-value |
| Calories, kcal | 2250 ± 652 | 2190 ± 11 | n.s.3 |
| Total fats (g) | 92.0 ± 1.6 | 82.9 ± 0.3 | <0.0001 |
| Monounsaturated fat (g) | 36.3 ± 0.6 | 30.7 ± 0.1 | <0.0001 |
| Polyunsaturated fat (g) | 19.5 ± 0.5 | 17.4 ± 0.1 | <0.0001 |
| Carbohydrates (g) | 250 ± 4.2 | 266 ± 0.9 | <0.001 |
| Dietary fiber (g) | 21.5 ± 0.8 | 15.8 ± 0.2 | <0.0001 |
| Vitamin E, as α-tocopherol (mg) | 9.0 ± 0.4 | 7.3 ± 0.1 | 0.0001 |
| Vitamin K, μg | 141 ± 13 | 95.5 ± 1.9 | 0.0013 |
| Magnesium (mg) | 328 ± 7.9 | 290 ± 1.8 | <0.0001 |
| Potassium (mg) | 3133 ± 56.9 | 2710 ±13.7 | <0.0001 |
| Sodium (mg) | 3359 ± 67.6 | 3491 ±12.3 | n.s. |
| Variable | Anemic | Non-anemic | P-value |
| Dietary intake (n = 336) | (n = 118) | (n = 218) | |
| Iron (mg/day) | 1.2 ± 1.0 | 1.3 ± 0.9 | 0.746 |
| Zinc (mg/day) | 1.8 ± 0.6 | 2.0 ± 0.5 | 0.299 |
| Vitamin A (μg/day) | 66.7 ± 24.5 | 75.3 ± 27.3 | 0.227 |
| Serum concentration (n = 55) | (n = 21) | (n = 34) | |
| Iron (μg/L) | 881.2 ± 449.9 | 1227.9 ± 566.4 | 0.014 |
| Zinc (μg/L) | 610.0 ± 107.8 | 679.4 ± 117.1 | 0.027 |
| Retinol (μmol/L) | 0.5 ± 0.1 | 0.8 ± 0.1 | <0.001 |
| Fatigue factor:Eigenvalue=3.357% variance=30.52 | DB factor:Eigenvalue=1.50% variance=13.62 | RT:Eigenvalue=1.33% variance=12.14 | |
| Drive late at night | 0.774 | ||
| Drive after prolonged work | 0.774 | ||
| Drive for long periods | 0.734 | ||
| Drive when tired | 0.638 | ||
| Drive with a cold | 0.470 | ||
| Lapses of concentration | 0.794 | ||
| Speeding | 0.747 | ||
| Miss warning signs | 0.687 | ||
| Hostility to others | 0.434 | ||
| Risks at work | 0.865 | ||
| Risks outside work | 0.860 |
| Variable | Control factor | Coded value | Uncoded value |
| x1 | Coating weigh gain | −0.6566 | 9.0302 |
| x2 | Duration of coating | 0.5152 | 29.8176 |
| x3 | Amount of plasticizer | 1 | 120 |
| Pretreatments | Weighted average degree of polymerization |
| Untreated Solka-Floc cellulose (control) | 1, 110 |
| Dilute acid | 260 |
| Dilute acid/Fe2+ | 150 |
| All (n = 55) | Ultrasound-defined active synovitis | P valuea | ||
| Yes (n = 25) | No (n = 30) | |||
| Activin A | 6,556 (3,012 to 10,887) | 9,186 (4,846 to 12,297) | 4,175 (2,450 to 10,255) | 0.086 |
| ANG | 7,670 (6,206 to 10,496) | 8,009 (6,729 to 10,816) | 6867 (5,861 to 9,421) | 0.119 |
| ANG-1 | 32,622 (28,287 to 36,705) | 34,343 (28,615 to 39,515) | 31,066 (27,977 to 35,834) | 0.210 |
| ANG-2 | 726.4 (595.8-1014.8) | 881 (670 to 1,072) | 702 (536 to 869) | 0.038 |
| Angiostatin | 37,409 (30,333 to 48,183) | 34,326 (28,123 to 46,416) | 39,648 (34,243 to 49,152) | 0.111 |
| ANGPTL4 | 15,120 (6,450 to 6,464) | 1,374 (606 to 6,030) | 2,294 (7,450 to 7,713) | 0.630 |
| bFGF | 314 (268 to 492) | 384 (288 to 675) | 295 (265 to 318) | 0.007 |
| CXCL16 | 849 (739 to 1,311) | 907 (774 to 1,214) | 848 (682 to 1,454) | 0.967 |
| ENA-78 | 1,186 (813 to 1,746) | 1,146 (871 to 1,664) | 1,241 (780 to 1,886) | 0.927 |
| GRO | 9,570 (7,592 to 12,000) | 10,724 (8,644 to 12,000) | 9,284 (7,050 to 12,000) | 0.350 |
| IL-17 | 10 (0 to 27) | 13 (5 to 32) | 7 (0 to 25) | 0.141 |
| IL-17 F | 288 (57 to 4,888) | 344 (59 to 3,351) | 204 (58 to 4,980) | 0.872 |
| IL-18 | 589 (395 to 1,066) | 741 (463 to 1,224) | 514 (341 to 890) | 0.066 |
| IL-20 | 259 (92 to 836) | 422 (145 to 924) | 234 (68 to 727) | 0.098 |
| IL-23 | 249 (176 to 431) | 257 (219 to 699) | 240 (166 to 323) | 0.098 |
| IL-33 | 14 (4 to 73) | 17 (4 to 69) | 11 (4 to 83) | 0.866 |
| IL-6 | 149 (93 to 290) | 177 (106 to 317) | 136 (91 to 226) | 0.136 |
| IL-8 | 30 (21 to 62) | 42 (21 to 64) | 26 (22 to 46) | 0.366 |
| MMP-2 | 2,738 (1,941 to 4,050) | 3,762 (2,294 to 5,574) | 2,404 (1,915 to 3,263) | 0.027 |
| MMP-9 | 28,180 (21,104 to 34,808) | 27,370 (23,526 to 34,009) | 29,008 (17,682 to 35,779) | 0.940 |
| PlGF | 288 (148 to 979) | 453 (192 to 1,357) | 237 (117 to 721) | 0.043 |
| SDF-1 | 280 (117 to 1,554) | 750 (164 to 3,305) | 165 (84 to 1,006) | 0.035 |
| TGF-β1 | 1,453 (809 to 2,252) | 1,741 (1,065 to 2,424) | 1,196 (649 to 2,053) | 0.089 |
| Tie-1 | 5,099 (1,647 to 19,737) | 6,841 (1,896 to 31,161) | 4,039 (1,556 to 12,210) | 0.112 |
| Tie-2 | 14,735 (6,215 to 32,401) | 20,559 (7,426 to 47,483) | 11,436 (4,101 to 26,744) | 0.317 |
| TNFα | 6,755 (4,460 to 12,112) | 6,755 (4,539 to 12,869) | 6,362 (4,379 to 10,507) | 0.465 |
| VEGF | 1,193 (815 to 1,990) | 1,193 (871 to 2,178) | 1,193 (810 to 1,911) | 0.609 |
| VEGFR-1 | 485 (308 to 881) | 634 (366 to 1,001) | 471 (278 to 723) | 0.204 |
| VEGFR-2 | 1,014 (713 to 1,918) | 1,096 (869 to 1,807) | 1,005 (679 to 1,937) | 0.149 |
| VEGF-D | 32,097 (17,815 to 227,618) | 63,480 (26,776 to 600,000) | 27,545 (12,517 to 76,119) | 0.018 |
| Treatment | Jumps (#) | SEp | p-Value | Percent Reduction (%) |
| NOTH | 11.1 | 1.94 | <0.01 | 79.3 |
| H2O | 2.3 | |||
| NOTA | 7.8 | 1.94 | 0.03 | 79.5 |
| ANH | 1.6 | |||
| NOTS | 8.6 | 1.94 | 0.01 | 84.9 |
| AND1 | 1.3 | |||
| NOTI | 6.1 | 1.94 | 0.07 | 82.0 |
| AND2 | 1.1 |
| Depressive disorders | Anxiety disorders | |||||
| Hypertension (-) | Hypertension (+) | P-value | Hypertension (-) | Hypertension (+) | P-value | |
| Total | 89 | 6 | 67 | 11 | ||
| Maternal age | ||||||
| < 35 years | 32 | 4 | 0.29 | 49 | 6 | 0.14 |
| ≥ 35 years | 57 | 2 | Reference | 18 | 5 | Reference |
| Parity | ||||||
| Nulliparity | 53 | 4 | Reference | 41 | 7 | Reference |
| Multiparity | 40 | 2 | 0.97 | 26 | 4 | 0.85 |
| Medication | ||||||
| No | 23 | 2 | Reference | 30 | 4 | Reference |
| Yes | 64 | 4 | 0.91 | 32 | 2 | 0.67 |
| Self-interruption | 2 | 0 | 0.32 and 0.23* | 5 | 5 | 0.03 and < 0.01* |
| Economic problems | ||||||
| No | 85 | 6 | Reference | 56 | 10 | Reference |
| Yes | 4 | 0 | 0.6 | 11 | 1 | 0.87 |
| 15 centromere Profile | Delete-one jackknife† | ||||||
| Chr | # aligned | # pass filters | First Cen | First FP | # pass filters | First Cen | First FP |
| 1 | 230,107 | 6 | 0.778‡ | 0.317 | 5 | 0.745 | 0.303 |
| 2 | 813,073 | 34 | 0.849 | 0.401 | 23 | – | 0.420 |
| 3 | 316,509 | 8 | 0.822‡ | 0.388 | 7 | 0.571 | 0.426 |
| 4§ | 1,531,822 | – | – | – | 31 | – | 0.394 |
| 5 | 576,763 | 51 | 0.807 | 0.611¶ | 48 | – | 0.625¶ |
| 6 | 270,050 | 14 | 0.726‡ | 0.389 | 13 | 0.723 | 0.306 |
| 7 | 1,090,829 | 33 | 0.756‡ | 0.450 | 32 | 0.707 | 0.466 |
| 8 | 562,532 | 7 | 0.459‡ | 0.346 | 4 | – | 0.293 |
| 9 | 439,777 | 11 | 0.493 | 0.375 | 2 | – | −0.092 |
| 10 | 745,640 | 22 | 0.626‡ | 0.402 | 19 | 0.579 | 0.357 |
| 11 | 666,705 | 23 | 0.634‡ | 0.407 | 15 | – | 0.326 |
| 12 | 1,078,066 | 48 | 0.742‡ | 0.430 | 47 | 0.698 | 0.453 |
| 13 | 924,320 | 48 | 0.873‡ | 0.491 | 53 | 0.847 | 0.498 |
| 14 | 784,222 | 23 | 0.778‡ | 0.398 | 16 | 0.748 | 0.384 |
| 15 | 1,091,180 | 21 | 0.796 | 0.457 | 11 | – | 0.420 |
| 16 | 947,955 | 32 | 0.764‡ | 0.455 | 23 | 0.464 | 0.478 |
| Median** | 764,931 | 22.5 | 0.760 | 0.402 | 17.5 | 0.518 | 0.407 |
| Number of Cancer Patients Treated2 | |||||||
| Study Site | Total PopulationService Area1 | Breast | Colorectal | Prostate | Lung | Other | TOTAL |
| Billings Clinic, Montana | 283,828 | 186 | 133 | 207 | 150 | 753 | 1,429 |
| Christiana Hospital, Delaware | 571,322 | 533 | 258 | 367 | 447 | 1258 | 2,863 |
| Hartford Hospital, Connecticut | 1,054,456 | 544 | 217 | 479 | 280 | 1075 | 2,595 |
| Our Lady of the Lake Regional Medical Center, Louisiana | 672,319 | 362 | 250 | 365 | 539 | 1075 | 2,591 |
| St. Joseph's/Candler, Georgia | 385,242 | 227 | 124 | 87 | 253 | 366 | 1,057 |
| St. Joseph's, Orange, California | 2,432,932 | 385 | 147 | 118 | 149 | 728 | 1,527 |
| Sanford USD Medical Center, South Dakota | 489,576 | 187 | 147 | 139 | 177 | 586 | 1,236 |
| Spartanburg Regional Hospital, South Carolina | 353,757 | 244 | 136 | 193 | 253 | 553 | 1,379 |
| Ascension Health, based in Missouri: St. Vincent Indianapolis Hospital, Indianapolis, Indiana | 1,951,252 | 573 | 219 | 182 | 287 | 1934 | 3,195 |
| Columbia St. Mary's Hospital, Milwaukee Wisconsin | 685,066 | 417 | 157 | 227 | 169 | 692 | 1,662 |
| Seton Family of Hospitals, Austin, Texas | 1,544,670 | 371 | 171 | 58 | 300 | 1132 | 2,032 |
| Catholic Health Initiatives, based in Colorado: Penrose-St. Francis Health Services, Colorado Springs, Colorado | 477,263 | 208 | 156 | 197 | 110 | 552 | 1,223 |
| St. Joseph Medical Center, Towson, Maryland | 633,814 | 205 | 128 | 155 | 124 | 463 | 1,078 |
| CHI Nebraska coordinated regional program: Good Samaritan Hospital, Kearney, Nebraska | 205,994 | 87 | 67 | 95 | 77 | 227 | 553 |
| St. Elizabeth Regional Medical Center, Lincoln, Nebraska | 256,939 | 215 | 114 | 39 | 87 | 317 | 772 |
| St. Francis Medical Center, Grand Island, Nebraska | 106,724 | 104 | 106 | 82 | 59 | 208 | 559 |
| TOTAL | 12,105,154 | 4848 | 2530 | 2990 | 3461 | 11919 | 25,751 |
| Low blood pressure criteria | |||||
| SBP < 110 mmHg | SBP < 100 mmHg | SBP < 95 mmHg | SBP < 90 mmHg | ||
| Odds ratio (95% CI) | |||||
| Crude Model | 1.07 (0.91 to 1.26) | 1.33 (1.14 to 1.56)*** | 1.57 (1.28 to 1.93)*** | 2.07 (1.43 to 2.98)** | |
| Covariates | |||||
| Model I | Age, Sex, BMI, Total cholesterol level | 1.01 (0.85 to 1.20) | 1.26 (1.06 to 1.49)** | 1.44 (1.17 to 1.78)*** | 1.87 (1.24 to 2.65)** |
| Model II | Model I + Household income, Educational level, Marital status | 1.10 (0.92 to 1.32) | 1.34 (1.13 to 1.59)*** | 1.50 (1.21 to 1.87)*** | 1.81 (1.26 to 2.77)** |
| Model III | Model II + Current smoking status, Alcohol intake | 1.07 (0.89 to 1.29) | 1.35 (1.13 to 1.62)*** | 1.51 (1.19 to 1.90)*** | 1.81 (1.17 to 2.77)** |
| Model IV | Model III + Sex*Age | 1.03 (0.85 to 1.24) | 1.29 (1.08 to 1.55)** | 1.44 (1.14 to 1.82) ** | 1.71 (1.11 to 2.62) * |
| Model V | Model IV + DM, Stroke, MI/Angina pectoris, Depression | 1.04 (0.86 to 1.26) | 1.25 (1.04 to 1.50)* | 1.43 (1.13 to 1.81) ** | 1.74 (1.14 to 2.68) * |
| Species | Year | Captures | Odds ratio of capture on pipeline | |
| On pipeline | Off pipeline | |||
| D. ordii | 1997 | 35 | 106 | 1.663 |
| 1998 | 57 | 116 | 2.473 | |
| 1999–2001 | 21 | 21 | 5.037 | |
| P. flavescens | 1997 | 0 | 27 | 0 |
| 1998 | 5 | 44 | 0.572 | |
| 1999–2001 | 13 | 75 | 0.873 |
| Variable | Frequency (%) |
| Sex | |
| Male | 138 (76.7) |
| Female | 42 (23.3) |
| Age (years) | |
| < 10 | 13 (7.2) |
| 11-20 | 42 (23.3) |
| 21-30 | 49 (27.2) |
| 31-40 | 54 (30.0) |
| 41-50 | 15 (8.3) |
| 51-60 | 7 (3.9) |
| Left targets | Central targets | Right targets | ||||
| Session | 1 | 2 | 1 | 2 | 1 | 2 |
| Accuracy (%) | ||||||
| L-PA | 99.64 ± 0.36 | 98.93 ± 1.07 | 98.93 ± 0.57 | 99.29 ± 0.49 | 99.64 ± 0.36 | 100.00 ± 0.00 |
| R-PA | 98.21 ± 1.00 | 99.29 ± 0.49 | 100.00 ± 0.00 | 99.29 ± 0.71 | 96.79 ± 1.62 | 99.64 ± 0.36 |
| Neutral | 100.00 ± 0.00 | 98.21 ± 1.79 | 99.64 ± 0.36 | 99.29 ± 0.49 | 99.64 ± 0.36 | 98.57 ± 1.10 |
| Reaction time (ms) | ||||||
| L-PA | 388 ± 24 | 399 ± 17 | 383 ± 24 | 385 ± 17 | 379 ± 23 | 403 ± 19 |
| R-PA | 408 ± 15 | 416 ± 19 | 397 ± 15 | 403 ± 15 | 401 ± 13 | 414 ± 15 |
| Neutral | 375 ± 10 | 404 ± 14 | 360 ± 10 | 383 ± 14 | 365 ± 9 | 396 ± 10 |
| Variables | Rs2910164 (Cases/Controls) | Crude OR (95% CI) | P | Adjusted ORa (95% CI) | Pa | |||
| CC | CG/GG | |||||||
| N | % | N | % | |||||
| Age, yr | ||||||||
| ≤59 (median) | 202/217 | 34.9/35.6 | 376/393 | 65.1/64.4 | 1.03 (0.81-1.30) | 0.822 | 1.04 (0.82-1.32) | 0.769 |
| >59 (median) | 195/203 | 35.6/34.6 | 352/383 | 64.4/65.4 | 0.96 (0.75-1.22) | 0.723 | 0.95 (0.74-1.22) | 0.677 |
| Gender | ||||||||
| Males | 291/284 | 36.4/34.4 | 509/542 | 63.6/65.6 | 0.92 (0.75-1.12) | 0.401 | 0.93 (0.76-1.14) | 0.496 |
| Females | 106/136 | 32.6/36.8 | 219/234 | 67.4/63.2 | 1.20 (0.88-1.64) | 0.253 | 1.19 (0.86-1.63) | 0.291 |
| Smoking status | ||||||||
| Never | 249/214 | 36.3/35.1 | 437/396 | 63.7/64.9 | 0.95 (0.76-1.19) | 0.649 | 0.97 (0.77-1.22) | 0.764 |
| Former | 6/39 | 35.3/32.5 | 11/81 | 64.7/67.5 | 0.88 (0.30-2.56) | 0.819 | 1.10 (0.36-3.36) | 0.872 |
| Current | 142/167 | 33.6/35.8 | 280/299 | 66.4/64.2 | 1.10 (0.84-1.45) | 0.495 | 1.09 (0.82-1.44) | 0.560 |
| Drinking status | ||||||||
| Never | 309/300 | 36.1/35.3 | 546/551 | 63.9/64.7 | 0.96 (0.79-1.17) | 0.702 | 0.97 (0.80-1.19) | 0.771 |
| Ever | 88/120 | 32.6/34.8 | 182/225 | 67.4/65.2 | 1.10 (0.79-1.55) | 0.569 | 1.10 (0.79-1.55) | 0.572 |
| Pack-years | ||||||||
| 0 | 249/214 | 36.3/35.1 | 437/396 | 63.7/64.9 | 0.95 (0.76-1.19) | 0.649 | 0.96 (0.76-1.21) | 0.726 |
| ≤25 (mean) | 72/130 | 31.7/36.6 | 155/225 | 68.3/63.4 | 1.24 (0.87-1.77) | 0.226 | 1.20 (0.84-1.73) | 0.322 |
| >25 (mean) | 76/76 | 35.8/32.9 | 136/155 | 64.2/67.1 | 0.88 (0.59-1.30) | 0.514 | 0.97 (0.64-1.46) | 0.877 |
| Tumor site | ||||||||
| GCA | 110/420 | 36.1/35.1 | 195/776 | 63.9/64.9 | 0.96 (0.74-1.25) | 0.756 | 0.96 (0.74-1.25) | 0.752 |
| NGCA | 287/420 | 35.0/35.1 | 533/776 | 65.0/64.9 | 1.01 (0.83-1.21) | 0.957 | 1.01 (0.84-1.22) | 0.901 |
| Treatment | N | Mean survival ± SE | 95% CI |
| Nonsurgical | 533 | 67 ± 3 months | 62–72 |
| Surgical | 751 | 87 ± 4 months | 80–95 |
| Overall | 1284 | 83 ± 3 months | 78–88 |
| Parasite density | Sample size (n) | Positives | Detection rate |
| <200 | 16 | 14 | 87.50% |
| 200-1999 | 77 | 76 | 98.70% |
| >2000 | 229 | 229 | 100% |
| DDS | SDDS | ||
| Food group | Note | Food group | Note |
| All starch staples | With a threshold of 10 g | Refined grains and cereals | With a threshold of 10 g |
| Other cereals and grains | With a threshold of 10 g | ||
| Starch tubers and roots | With a threshold of 10 g | ||
| Vitamin A-rich vegetables & fruit | With a threshold of 10 g | Vitamin A-rich dark-green leafy vegetables | With a threshold of 10 g |
| Vitamin A-rich deep yellow/orange/red vegetables | With a threshold of 10 g | ||
| Vitamin A-rich fruits | With a threshold of 10 g | ||
| All other fruits | With a threshold of 10 g | Vitamin C-rich vegetables | With a threshold of 10 g |
| All other vegetables | With a threshold of 10 g | Vitamin C-rich fruits | With a threshold of 10 g |
| All other fruits & vegetables | With a threshold of 10 g | ||
| All legumes & nuts | With a threshold of 10 g | All legumes & nuts | With a threshold of 10 g |
| Oil and fat | With a threshold of 2 g | Oil and fat | With a threshold of 2 g |
| Meat, poultry, fish | With a threshold of 10 g | Meat, poultry, fish | With a threshold of 10 g |
| Organ meat | With a threshold of 10 g | ||
| All dairy | With a threshold of 10 g | All dairy | With a threshold of 10 g |
| Eggs | With a threshold of 10 g | Eggs | With a threshold of 10 g |
| Other food | Exclude calculation | Desserts, candy, sugar-sweetened beverages and Puffing Food | With a threshold of 10 g |
| Other food | With a threshold of 10 g |
| Estimated effect on baseline physical activity (minutes per day) | Estimated effect on physical activity trajectories (minutes per day per semester) | |||
| Fixed effect | P value | Fixed Effect | P value | |
| Student Characteristics | ||||
| Gender | ||||
| Female | −12.5 (2.04) | <0.0001 | 0.596 (0.598) | 0.3194 |
| Male | Referent | Referent | ||
| Baseline physical activity | ||||
| Low | −47.7 (1.50) | <0.0001 | 7.11 (0.707) | <0.0001 |
| Moderate | −25.8 (1.51) | <0.0001 | 4.20 (0.719) | <0.0001 |
| High | Referent | Referent | ||
| BMI status | ||||
| Overweight or obese | 1.92 (3.21) | 0.5512 | −0.785 (0.901) | 0.3894 |
| Healthy weight | Referent | Referent | ||
| Missing | 1.88 (2.35) | 0.4252 | −0.0527 (0.657) | 0.9362 |
| School neighbourhood characteristics | ||||
| School location | ||||
| Rural | −10.6 (2.25) | <0.0001 | 1.49 (0.658) | 0.0234 |
| Urban | Referent | Referent | ||
| Socioeconomic status | ||||
| Low | −9.09 (2.27) | <0.0001 | 1.75 (0.664) | 0.0086 |
| High | Referent | Referent |
| Link with violence | |
| Antisocial | |
| Social norms | No specific reference within literature. |
| Deceitfulness | No specific reference within literature. |
| Impulsivity | Related to more violent assaults [41].Did not directly predict aggression once emotional dysregulation was controlled for [40].Impulsivity related to history of persistent violence [27] |
| Aggressiveness | Disturbed batterers more physically aggressive [7].Aggressiveness related to ASPD and NPD diagnoses. In BPD aggressiveness linked to poor impulse control. [19]. |
| Reckless | Related to more violent assaults [41]. |
| Irresponsibility | No specific reference within literature. |
| Lack remorse | No specific reference within literature. |
| Borderline | |
| Avoid abandonment | Avoidant attachment predicted severity of physical partner violence mediated by interpersonal difficulties [31].Female offenders have greater number of traumatic experiences and less secure attachment styles [22].ASPD and BPD diagnoses mediated path between by avoidant attachment intimate partner violence [34]. |
| Unstable relationships | See ‘Avoid Abandonment’. |
| Identity disturbance | No specific reference within literature. |
| Impulsivity | See ‘Impulsivity’ under Antisocial diagnosis. |
| Suicidal behavior | No specific reference within literature. |
| Affective instability | Emotional Dysregulation predicted physical assault [40]. |
| Emptiness | No specific reference within literature. |
| Anger | Impulsivity predicted physical aggression and trait anger. Trait anger mediates relationship between impulsivity and physical aggression. [42]. |
| Paranoid ideation | Disturbed batterers higher levels of paranoid ideation [7]. |
| Narcissistic | |
| Grandiose | Link between experience grandiose delusions and serious violence. Stronger link to violence when associated with elation or anger [49]. |
| Fantasies of success | No specific reference within literature. |
| Is “special” | See ‘Grandiose’. |
| Excessive admiration | No specific reference within literature. |
| Sense of entitlement | Evidence of inflated sense of entitlement linked to violent offenders. When violated more likely to be violent [18] |
| Exploitative | No specific reference within literature. |
| Lacks empathy | Violent offenders have reduced ability to recognise facial emotions [41].Poor perspective taking exacerbated anger arousal [9].Violent offender have poorer empathy [7]. |
| Envious | No specific reference within literature. |
| Arrogant | No specific reference within literature. |
| Number | DPW + SVM | DPW | DTW + SVM | DTW | ||||||||
| PR | SE/RE | F1 | PR | SE/RE | F1 | PR | SE/RE | F1 | PR | SE/RE | F1 | |
| 0 | 96.72 | 100.00 | 98.33 | 98.15 | 89.83 | 93.81 | 93.10 | 91.53 | 92.31 | 96.36 | 89.83 | 92.98 |
| 1 | 86.15 | 94.92 | 90.32 | 96.30 | 88.14 | 92.04 | 95.08 | 98.31 | 96.67 | 96.61 | 96.61 | 96.61 |
| 2 | 98.28 | 96.61 | 97.44 | 98.33 | 100.00 | 99.16 | 94.83 | 93.22 | 94.02 | 98.21 | 93.22 | 95.65 |
| 3 | 96.67 | 98.31 | 97.48 | 100.00 | 96.61 | 98.28 | 95.08 | 98.31 | 96.67 | 96.61 | 96.61 | 96.61 |
| 4 | 98.00 | 83.05 | 89.91 | 81.82 | 91.53 | 86.40 | 87.72 | 84.75 | 86.21 | 77.05 | 79.66 | 78.33 |
| 5 | 100.00 | 98.31 | 99.15 | 100.00 | 96.61 | 98.28 | 98.31 | 98.31 | 98.31 | 98.28 | 96.61 | 97.44 |
| 6 | 95.16 | 100.00 | 97.52 | 91.67 | 93.22 | 92.44 | 92.19 | 100.00 | 95.93 | 83.10 | 100.00 | 90.77 |
| 7 | 89.47 | 86.44 | 87.93 | 85.07 | 96.61 | 90.48 | 90.57 | 81.36 | 85.71 | 87.72 | 84.75 | 86.21 |
| 8 | 98.33 | 100.00 | 99.16 | 96.72 | 100.00 | 98.33 | 95.08 | 98.31 | 96.67 | 96.61 | 96.61 | 96.61 |
| 9 | 94.92 | 94.92 | 94.92 | 94.44 | 86.44 | 90.27 | 94.83 | 93.22 | 94.02 | 94.55 | 88.14 | 91.23 |
| Avg. | 95.37 | 95.25 | 95.22 | 94.25 | 93.90 | 93.95 | 93.68 | 93.73 | 93.65 | 92.51 | 92.20 | 92.24 |
| St dev. | 4.33 | 5.91 | 4.23 | 6.27 | 4.81 | 4.38 | 2.94 | 6.34 | 4.41 | 7.35 | 6.45 | 6.05 |
| Patients (n) | Coverage (106 reads) | Cassette exons | Competing 5′ splice sites | Competing 3′ splice sites | Retained introns | Constitutive introns | Constitutive junctions | Retained intron ratio | |
| Acute myeloid leukemia | 169 | 75 (8) | 1,219 | 326 | 377 | 973 | 6,239 | 841 | 4.74 (1.2) |
| Bladder | 18 | 56 (14) | 894 | 170 | 211 | 296 | 552 | 456 | 1.83 (2.2) |
| Breast | 104 | 72 (17) | 1,052 | 210 | 268 | 266 | 612 | 569 | -2.01 (2.1) |
| Colon | 37 | 58 (18) | 597 | 165 | 200 | 307 | 376 | 291 | 3.44 (2.6) |
| Endometrium | 21 | 35 (16) | 619 | 171 | 180 | 296 | 370 | 312 | 0.48 (2.4) |
| Head and neck | 40 | 81 (26) | 829 | 153 | 202 | 115 | 290 | 418 | 0.82 (1.7) |
| Kidney (chromophobe) | 25 | 82 (12) | 941 | 184 | 228 | 207 | 481 | 484 | 1.65 (1.4) |
| Kidney (renal clear cell) | 71 | 80 (16) | 729 | 149 | 194 | 143 | 380 | 380 | 1.42 (1.7) |
| Kidney (renal papillary cell) | 30 | 85 (20) | 730 | 155 | 220 | 184 | 440 | 408 | 1.51 (2.1) |
| Liver | 50 | 70 (15) | 413 | 90 | 117 | 106 | 200 | 206 | 0.82 (2.1) |
| Lung (adenocarcinoma) | 51 | 43 (28) | 517 | 115 | 141 | 176 | 277 | 233 | 0.20 (2.6) |
| Lung (squamous cell) | 50 | 83 (31) | 1,068 | 190 | 252 | 236 | 609 | 547 | 0.44 (2.0) |
| Prostate | 43 | 75 (11) | 607 | 133 | 185 | 130 | 358 | 337 | 1.44 (2.4) |
| Stomach | 30 | 105 (21) | 1,048 | 200 | 302 | 206 | 886 | 884 | 0.99 (1.7) |
| Rectum | 8 | 53 (14) | 680 | 123 | 172 | 310 | 390 | 314 | 4.30 (2.3) |
| Thyroid | 58 | 83 (11) | 533 | 132 | 177 | 174 | 488 | 332 | 0.66 (2.4) |
| Characteristic | Ranking from electronic survey | Ranking from paper survey |
| Impact on care | 1 | 2 |
| Strength of supporting evidence | 2 | 1 |
| Local health needs of patients/clients | 3 | 3 |
| Costs associated with new ways of working | 4 | 4 |
| Local expertise | 5 | 5 |
| Meeting minimum standards | 6 | 6 |
| National or local priority | 7 | 7 |
| Property | Explanation |
| Citation-related properties | |
| occursInChecklist | Reference to a species checklist |
| auctorumYear | The year of original publication |
| completeAuctorumString | Author name(s) expressed according |
| to the established practices of taxonomy | |
| Name-related properties | |
| hasNonvalidName | Expresses synonyms, homonyms |
| and orthographic variants of a valid | |
| scientific name | |
| hasVernacularName | The common name equivalents for |
| the scientific names | |
| hasNomenclaturalCode | Specifies the set of rules that are applied |
| (ICN [55] or ICZN [56]) | |
| hasVernacularNameStatus | Expresses whether a common name is |
| accepted or an alternative one | |
| rdf:type | Expresses the hierarchical level in |
| a classification. The ranks are obtained | |
| from TDWG Taxon Rank LSID Ontology [57]. | |
| Every taxon is an instance of a specific | |
| taxonomic rank and the class | |
| TaxonInChecklist (Figure 3). |
| Attention | Memory | ||||||||
| MMSE | SDMT | SRT | RBMT | EMC | |||||
| Completing rate | Correct rate | SPS | ‘Belonging’ | ‘Appointment’ | ‘Pictures’ | ‘Date’ | |||
| Bag use | 0.06 | −0.29 | −0.28 | −0.41 | 0.31 | −0.5 | −0.65* | 0.11 | 0.52 |
| List use | −0.69* | −0.5 | −0.63 | −0.71* | −0.67* | −0.73* | −0.34 | −0.59 | 0.76* |
| Forward movement | −0.31 | −0.43 | −0.62 | −0.34 | 0.09 | −0.56 | −0.53 | −0.3 | 0.01 |
| Correct purchases | 0.18 | 0.39 | 0.05 | 0.48 | 0.47 | 0.09 | 0.16 | 0.67* | 0.26 |
| Total time | −0.6 | −0.80** | −0.89** | −0.71* | −0.37 | −0.88** | −0.45 | −0.52 | 0.52 |
| Item* | Affirmative responses (%)** | Item calibration*** | SE**** | Item infit | Item outfit |
| AD1 Worried food would run out | 48.7 | 3.45 | 0.078 | 0.76 | 1.85 |
| AD2 Food ran out; did not have money for more | 53.1 | 2.86 | 0.085 | 0.95 | 1.47 |
| AD3 Could not afford to eat nutritious meal | 50.9 | 3.17 | 0.081 | 0.97 | 4.20 |
| AD4 Cut size of meal or skipped meal | 26.7 | 5.90 | 0.077 | 1.03 | 1.80 |
| AD5 Ate less than thought he/she should | 21.3 | 6.58 | 0.084 | 0.90 | 1.62 |
| AD6 Hungry but did not eat | 13.2 | 7.93 | 0.101 | 0.76 | 0.81 |
| AD7 Lost weight | 10.3 | 8.60 | 0.113 | 1.09 | 2.03 |
| AD8 Did not eat for whole day | 7.2 | 9.51 | 0.134 | 1.05 | 1.14 |
| Mean | 6.00 | ||||
| Standard deviation | 2.44 | ||||
| Discrimination parameter | 1.00 | ||||
| Number of cases***** | 2,003 | 1,241 | 1,241 | 1,241 | 1,241 |
| FDC (n = 54) | ST (n = 49) | p-value | |
| Age, mean ± SD | 45 ± 8.7 | 46.2 ± 9.5 | NS |
| Asian ethnicity, n (%)a | 51 (94.4) | 40 (81.6) | NS |
| Male gender, n (%) | 52 (96.3) | 41 (83.7) | NS |
| Weight (kg), mean ± SDb | 59.2 ± 9.8 | 61.7 ± 12.3 | NS |
| Weight bands, nb | |||
| < 35 kg | 0 | 0 | − |
| 35–54 kg | 13 | 9 | NS |
| > 54 kg | 25 | 25 | NS |
| Height (cm), mean ± SDc | 165.2 ± 7.8 | 164.1 ± 8 | NS |
| Smokers, n (%) | 19 (35.2) | 13 (26.5) | NS |
| Hypertension, n (%) | 11 (20.4) | 15 (30.6) | NS |
| Vitamin D level, mean ± SDd | 19.5 ± 22.5 | 19.2 ± 8.5 | NS |
| HbA1c, mean ± SD | 10.6 ± 2.5 | 10.8 ± 2.1 | NS |
| AFB load, n (%) | |||
| 1+ | 10 (18.5) | 4 (8.2) | NS |
| 2+ | 19 (35.2) | 16 (32.7) | NS |
| 3+ | 21 (38.9) | 27 (55.1) | NS |
| Anti-TB dose (mg/kg), mean ± SD | |||
| Isoniazid | 4.8 ± 0.5 | 5 ± 0.9 | NS |
| Rifampin | 9.6 ± 1.1 | 9.6 ± 1.4 | NS |
| Pyrazinamide | 25.6 ± 2.6 | 24 ± 2.8 | 0.011 |
| Ethambutol | 17.5 ± 2 | 18.1 ± 4.1 | NS |
| Patients received metformin, n (%) | 38 (70.4) | 34 (69.4) | NS |
| Items (n) | Mean (SD) | Median (range) | Cronbach's alpha | MIIC | Test–retest* | |
| PCL-5 subscales | ||||||
| Intrusion | 5 | 0.9 (1.3) | 0.0 (0–6) | 0.57 | 0.23 | 0.58** |
| Avoidance | 2 | 0.5 (1.1) | 0.0 (0–6) | 0.74 | 0.73 | 0.49** |
| Cognition and mood | 7 | 2.5 (3.2) | 1.0 (0–14) | 0.78 | 0.34 | 0.63*** |
| Arousal and reactivity | 6 | 1.7 (2.5) | 0.0 (0–9) | 0.77 | 0.40 | 0.77*** |
| PCL-5 total | 20 | 5.5 (7.1) | 2.0 (0–28) | 0.90 | 0.32 | 0.66*** |
| Item 1 | 0.52 (0.70) | 0.0 (0–3) | ||||
| Item 2 | 0.03 (0.18) | 0.0 (0–1) | ||||
| Item 3 | 0.10 (0.43) | 0.0 (0–3) | ||||
| Item 4 | 0.18 (0.30) | 0.0 (0–1) | ||||
| Item 5 | 0.10 (0.35) | 0.0 (0–2) | ||||
| Item 6 | 0.35 (0.77) | 0.0 (0–4) | ||||
| Item 7 | 0.13 (0.38) | 0.0 (0–2) | ||||
| Item 8 | 0.34 (0.65) | 0.0 (0–3) | ||||
| Item 9 | 0.31 (0.74) | 0.0 (0–3) | ||||
| Item 10 | 0.60 (0.91) | 0.0 (0–4) | ||||
| Item 11 | 0.47 (0.78) | 0.0 (0–3) | ||||
| Item 12 | 0.19 (0.51) | 0.0 (0–2) | ||||
| Item 13 | 0.32 (0.65) | 0.0 (0–3) | ||||
| Item 14 | 0.23 (0.56) | 0.0 (0–3) | ||||
| Item 15 | 0.23 (0.46) | 0.0 (0–2) | ||||
| Item 16 | 0.08 (0.34) | 0.0 (0–2) | ||||
| Item 17 | 0.45 (0.86) | 0.0 (0–4) | ||||
| Item 18 | 0.31 (0.53) | 0.0 (0–2) | ||||
| Item 19 | 0.26 (0.54) | 0.0 (0–2) | ||||
| Item 20 | 0.34 (0.75) | 0.0 (0–4) | ||||
| Mothers (n = 42) | Fathers (n = 20) | |||||
| Mean (SD) | Mean (SD) | p-value | ||||
| Intrusion | 1.0 (1.3) | 0.7 (1.2) | ns | |||
| Avoidance | 0.5 (0.9) | 0.6 (1.4) | ns | |||
| Cognition and mood | 2.5 (3.0) | 2.3 (3.7) | ns | |||
| Arousal and reactivity | 1.8 (2.6) | 1.5 (2.1) | ns | |||
| PCL-5 total | 5.8 (7.0) | 4.9 (7.3) | ns |
| Characteristics | Experimental mean (SD) | Control mean (SD) | p | F |
| Age (Years) | 69.95 (6.73) | 73.20 (6.48) | 0.13 | 2.36 |
| Education (Years) | 13.37 (3.27) | 12.85 (3.36) | 0.62 | 0.23 |
| MMSE | 28.31 (1.00) | 27.75 (1.48) | 0.17 | 1.92 |
| Information | 18.42 (2.61) | 16.95 (3.06) | 0.11 | 2.58 |
| Groups | Normoglycemic(n = 10) | Hyperglycemic(n = 10) | Hyperglycemic + vitamin C (n = 9) |
| Sperm number in the cauda epididymis (×106) | 111.00 [90.00 - 131.00] a | 40.16 [33.05 - 71.00] b | 43.00 [42.63 - 73.80] ab |
| Sperm transit time in the cauda (days) | 3.43 [3.30 - 4.65] a | 1.56 [1.25 - 2.70] b | 2.14 [1.72 - 2.88] ab |
| Plant | Feedstock | Volume of AD digesters (m3) | Dry matter content in digesters (%) | Organic loading in digesters (kg/day⋅m3) | Methane content in biogas (%) | Installed CHP power (kW) | Electricity generation (MWh/year) | Electricity consumption (MWh/year) | Heat generation (MWh/year) | Heat consumption by AD (MWh/year) |
| Plant 1 | • Pig slurry• Tomato peel and seeds• Maize silage | 1650 | 8.7 | 0.92 | 52.8 | 230 | 1945 | 173 | 2549 | 809 |
| Plant 2 | • Pig slurry• Maize silage | 2250 | 10.6 | 1.07 | 52.6 | 300 | 2429 | 206 | 3184 | 814 |
| Plant 3 | • Pig slurry• Maize silage• Maize ear silage | 2000 | 9.7 | 0.98 | 52.7 | 300 | 2505 | 276 | 3514 | 799 |
| Plant 4 | • Maize silage | 2 × 2750 | 10.7 | 3.40 | 52.1 | 999 | 7972 | 717 | 8771 | 2505 |
| Plant 5 | • Cow slurry | 1850 | 8.5 | 0.58 | 56.0 | 100 | 781 | 86 | 1095 | 547 |
| Medicine | MIC (mg/L) |
| AMPH-B | 0.25 |
| 5-FC | <=0.12 |
| MCZ | 0.06 |
| FLCZ | 8 |
| ITCZ | 0.12 |
| MCFG | <=0.015 |
| VRCZ | 0.25 |
| Men (n = 98) | Women (n = 139) | |||||||
| CCsa | Same category | Same and adjacent category | Extreme category | CCsa | Same category | Same and adjacent category | Extreme category | |
| Energyb | 0.58 | 34 | 71 | 0 | 0.59 | 37 | 81 | 1 |
| Water content | 0.43 | 33 | 70 | 1 | 0.64 | 42 | 79 | 1 |
| Protein | 0.53 | 46 | 72 | 2 | 0.47 | 33 | 78 | 4 |
| The sum of amino acid residues | 0.58 | 31 | 80 | 0 | 0.56 | 33 | 75 | 3 |
| Total fat | 0.49 | 33 | 73 | 1 | 0.55 | 40 | 75 | 1 |
| Total fat in % energyb | 0.50 | 23 | 57 | 5 | 0.59 | 29 | 66 | 2 |
| Saturated fatty acid | 0.49 | 34 | 67 | 2 | 0.56 | 39 | 78 | 2 |
| Monounsaturated fatty acid | 0.50 | 34 | 66 | 0 | 0.46 | 39 | 69 | 1 |
| Polyunsaturated fatty acid | 0.46 | 36 | 63 | 1 | 0.42 | 36 | 67 | 3 |
| n-3 PUFA | 0.50 | 27 | 72 | 0 | 0.49 | 36 | 74 | 2 |
| n-6 PUFA | 0.45 | 35 | 65 | 0 | 0.42 | 33 | 69 | 4 |
| Triacylglycerol equivalents | 0.49 | 32 | 72 | 1 | 0.54 | 38 | 74 | 2 |
| Cholesterol | 0.61 | 36 | 80 | 1 | 0.51 | 35 | 74 | 2 |
| Carbohydrate | 0.60 | 44 | 77 | 1 | 0.61 | 36 | 81 | 1 |
| Total dietary fiber | 0.58 | 46 | 77 | 2 | 0.61 | 40 | 75 | 1 |
| Water soluble fiber | 0.56 | 50 | 77 | 1 | 0.59 | 34 | 73 | 1 |
| Water insoluble fiber | 0.58 | 41 | 77 | 2 | 0.61 | 43 | 73 | 1 |
| Sodium | 0.58 | 39 | 78 | 1 | 0.60 | 37 | 78 | 1 |
| Potassium | 0.68 | 43 | 82 | 0 | 0.61 | 34 | 79 | 2 |
| Calcium | 0.61 | 38 | 78 | 0 | 0.49 | 34 | 73 | 3 |
| Magnesium | 0.67 | 41 | 80 | 1 | 0.63 | 37 | 80 | 1 |
| Phosphorus | 0.61 | 35 | 72 | 0 | 0.47 | 30 | 72 | 1 |
| Iron | 0.75 | 46 | 90 | 1 | 0.61 | 41 | 82 | 2 |
| Zinc | 0.66 | 38 | 80 | 1 | 0.47 | 40 | 74 | 4 |
| Copper | 0.69 | 43 | 82 | 0 | 0.59 | 45 | 82 | 0 |
| Manganese | 0.61 | 45 | 80 | 1 | 0.68 | 50 | 84 | 1 |
| Iodine | 0.44 | 40 | 71 | 2 | 0.42 | 32 | 68 | 3 |
| Selenium | 0.59 | 37 | 78 | 1 | 0.36 | 33 | 64 | 3 |
| Chromium | 0.50 | 31 | 72 | 2 | 0.47 | 28 | 68 | 3 |
| Molybdenum | 0.68 | 41 | 83 | 0 | 0.57 | 40 | 77 | 2 |
| Retinol | 0.41 | 47 | 73 | 3 | 0.45 | 41 | 70 | 4 |
| α-carotene | 0.53 | 43 | 71 | 1 | 0.66 | 39 | 80 | 0 |
| β-carotene | 0.55 | 40 | 76 | 0 | 0.64 | 37 | 78 | 1 |
| Cryptoxanthin | 0.46 | 30 | 69 | 1 | 0.53 | 32 | 78 | 1 |
| Beta carotene equivalents | 0.55 | 41 | 76 | 0 | 0.61 | 42 | 74 | 0 |
| Retinol equivalents | 0.50 | 41 | 77 | 4 | 0.60 | 41 | 78 | 2 |
| Vitamin D | 0.57 | 33 | 72 | 1 | 0.53 | 36 | 76 | 2 |
| α-tocopherol | 0.57 | 44 | 74 | 2 | 0.52 | 35 | 71 | 2 |
| β-tocopherol | 0.51 | 35 | 72 | 3 | 0.45 | 37 | 68 | 4 |
| γ-tocopherol | 0.37 | 27 | 65 | 3 | 0.50 | 36 | 71 | 2 |
| δ-tocopherol | 0.49 | 41 | 73 | 1 | 0.56 | 45 | 76 | 1 |
| Vitamin K | 0.60 | 40 | 79 | 1 | 0.56 | 39 | 75 | 2 |
| Vitamin B1 | 0.56 | 37 | 72 | 1 | 0.57 | 38 | 73 | 1 |
| Vitamin B2 | 0.66 | 38 | 85 | 1 | 0.41 | 35 | 71 | 4 |
| Niacin | 0.65 | 43 | 78 | 0 | 0.64 | 42 | 80 | 2 |
| Vitamin B6 | 0.65 | 43 | 77 | 0 | 0.69 | 39 | 81 | 1 |
| Vitamin B12 | 0.63 | 41 | 82 | 1 | 0.56 | 35 | 76 | 2 |
| Folate | 0.74 | 43 | 85 | 0 | 0.59 | 37 | 76 | 0 |
| Pantothenic acid | 0.60 | 40 | 79 | 1 | 0.44 | 34 | 70 | 2 |
| Biotin | 0.66 | 43 | 74 | 0 | 0.61 | 37 | 76 | 1 |
| Vitamin C | 0.71 | 37 | 86 | 1 | 0.60 | 32 | 69 | 0 |
| Daidzein | 0.52 | 38 | 80 | 3 | 0.65 | 43 | 77 | 0 |
| Genistein | 0.52 | 39 | 79 | 1 | 0.64 | 47 | 79 | 0 |
| Ethanol | 0.89 | 64 | 97 | 0 | 0.85 | 61 | 93 | 0 |
| Median | 39 | 77 | 1 | 37 | 75 | 2 |
| Q1 | Q2 | Q3 | Q4 | |||||
| (Pre) | (Pos) | (Pre) | (Pos) | (Pre) | (Pos) | (Pre) | (Pos) | |
| Min | 1 | 3 | 1 | 3 | 1 | 3 | 1 | 3 |
| Max | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Median | 1 | 5 | 1 | 5 | 1 | 5 | 1 | 5 |
| P | < 0.0001 | < 0.0001 | < 0.0001 | < 0.0001 |
| Diagnosis | Intervention | Number of Patients | Reference |
| Evidence from Pediatric Studies | |||
| msk pain/soft tissue injury | analgesic | 17 | Clark 2003[10] |
| Asthma exacerbation | inhaled β-agonist | 12 | Travers 2001[11] |
| radial fracture | reduction & cast | 10 | McLauchlan 2002[12] |
| otitis media | PO antibiotics | 10 | Kozyrskyj 2000[13] |
| dehydration (failed PO rehydration) | IV rehydration | 6 | Atherly-John 2002[14] |
| bronchiolitis | salbutamol | 6 | Kellner 2000[15] |
| dehydration | PO rehydration | 5 | Atherly-John 2002[14] |
| urinary tract infection | PO antibiotics | 5 | Hoberman 1999[16] |
| constipation | suppository/enema | 5 | Dashshan 1999[17] |
| laceration | sutures | 4 | Barnett 1998[18] |
| croup | PO steroids | 4 | Ausejo 2000[19] |
| suspected occult bacteremia | IM/IV antibiotics | 3 | Bass 1993[20] |
| tonsillitis | PO antibiotics | 3 | Del Mar 2000[21] |
| urticaria | cetirizine | 2 | Simons 2000[22] |
| Kawasaki Syndrome | IVIG & ASA | 2 | Newburger 1986[23] |
| alcohol intoxication | intubation | 2 | Gausche-Hill 2000[24] |
| generalized tonic-clonic seizure in known epileptic | increase clobazam dose | 1 | Booth 1998[25] |
| radial head subluxation | reduction by hyperpronation | 1 | Macias 1998[26] |
| epistaxis | silver nitrate | 1 | Ruddy 1991[27] |
| behavior problems | referral for counselling | 1 | Dishion 1995[28] |
| bronchiolitis | racemic epinephrine | 1 | Menon 1995[29] |
| viral conjunctivitis | polysporin ointment | 1 | Isenberg 2002[30] |
| laceration | tissue glue | 1 | Barnett 1998[18] |
| constipation | polyethylene glycol | 1 | Dashshan 1999[17] |
| dog bite | IV antibiotics & debridement | 1 | Medeiros 2001[31] |
| burn | delayed graft | 1 | Desai 1991[32] |
| reflux esophagitis | conservative reflux measures | 1 | Craig 2004[33] |
| pain (following MVC trauma) | morphine infusion | 1 | Hendrickson 1990[34] |
| reflux esophagitis | ranitidine | 1 | Cucchiara 1993[35] |
| varicella zoster | supportive care | 1 | Klassen 2002[36] |
| atopic dermatitis | hydrocortisone cream | 1 | Alonso 1999[37] |
| meningitis exposure (H flu) | PO antibiotics | 1 | Daum 1981[38] |
| dislocated patella | relocation under sedation | 1 | Nikku 1997[39] |
| Evidence from Adult Studies | |||
| migraine headache | metoclopramide | 3 | Colman 2003[40] |
| proximal humerus fracture | cast & sling | 3 | Gibson 2003[41] |
| ankle fracture | cast | 2 | Phillips 1985[42] |
| gastritis | antacids | 1 | Moayyedi 2003[43] |
| clavicle fracture | sling | 1 | Andersen 1987[44] |
| prozac overdose (2 hours previous) | supportive care | 1 | Yeates 2000[45] |
| tibial fracture | internal fixation | 1 | Wyrsch 1996[46] |
| epididymitis | PO antibiotics | 1 | Redfern 1984[47] |
| panic attack | sublingual short-acting benzodiazepine | 1 | Dunner 1986[48] |
| aphthous ulcers | viscous lidocaine | 1 | Saxen 1997[49] |
| fracture T12 vertebrae | T11–12 instrumentation & fusion | 1 | Shen 2001[50] |
| aggression | haloperidol & lorazepam | 1 | Gillies 2001[51] |
| tibial fracture | reduction & cast | 1 | Abdel-Salem 1991[52] |
| acetaminophen overdose | N-acetylcysteine | 1 | Brok 2002[53] |
| gastrostomy tube fell out | insertion of foley catheter | 1 | Kadakia 1994[54] |
| increased intracranial pressure | mannitol | 1 | Schierhout 2003[55] |
| migraine headache | NSAID | 1 | Bussone 1999[56] |
| Category/name | Function | Change (x-fold) |
| Cellular defense | ||
| HSP27 | Protein stabilisation | ++ |
| Apoptosis/degeneration | ||
| Cathepsin Z | Lysosomal proteolysis | ++ |
| Proliferation | ||
| Annexin | Growth factor | ++ |
| Migration | ||
| Cofilin | Actin turnover | +++ |
| Tropomodulin 3 | Actin turnover | ++++++ |
| CLIM1 | Actin kinase adaptor | ++++++ |
| Galectin | Cell to cell interaction | ++ |
| β-Hexosaminidase β-subunit | Glycosidasis | ++++++ |
| Metabolism | ||
| Pyruvate kinase 3 | Glycolysis | − |
| Enolase 1 | Glycolysis | − |
| Nuclear transport | ||
| Ran-binding protein 1 | RanGAP activity | ++ |
| elF5A | Cofactor in nuclear export | ++++++ |
| Translation | ||
| CRHSP-24 | Translation regulating protein | ++++++ |
| Patient | Location of sample | Size of sample(Average;mm2) | Number of samples taken |
| P01 | Central and peripheral | 30 | 3 |
| P02 | Central | 24 | 4 |
| P03 | Central | 40 | 3 |
| P04 | Central and peripheral | 20 | 4 |
| P05 | Central | 24 | 3 |
| P06 | Central | 80 | 3 |
| P07 | Central and peripheral | 66 | 2 |
| P08 | Central and peripheral | 72 | 3 |
| Foot complication | Alln (% (95% CI)) | Diabetesn (% (95% CI)) | Nondiabetesn (% (95% CI)) | p value |
| Participants | 733 | 172 | 561 | |
| Foot complication(s)a | 336 (46.0% (42.4–49.7)) | 112 (65.5% (58.1–72.2) | 224 (40.1% (36.2–44.3)) | <0.001∗ |
| Multiple foot complicationsb | 175 (23.9% (20.9–27.1)) | 66 (38.6% (31.6–46.1)) | 109 (19.5% (16.4–23.0)) | <0.001∗ |
| Previous foot diseasec | 81 (11.1% (9.0–13.6)) | 38 (22.1% (16.5–28.9)) | 43 (7.7% (5.7–10.2)) | <0.001∗ |
| Previous amputation | 30 (4.1% (2.9–5.8)) | 16 (9.3% (5.7–14.7)) | 14 (2.5% (1.4–4.2))) | <0.001∗ |
| Previous foot ulcer | 72 (9.8% (7.9–12.2) | 35 (20.3% (15.0–27.0)) | 37 (6.6% (4.8–9.0))) | <0.001∗ |
| Peripheral arterial disease | 153 (21.0% (18.2–24.1)) | 60 (35.1% (28.3–42.5)) | 93 (16.7% (13.8–20.0)) | <0.001∗ |
| Peripheral neuropathy | 160 (22.0% (19.1–25.1)) | 74 (43.3% (36.1–50.8)) | 86 (15.4% (12.6–18.6)) | <0.001∗ |
| Foot deformity | 158 (22.4% (19.5–25.6)) | 51 (30.5% (24.0–37.9)) | 107 (19.9% (16.7–23.5)) | 0.004∗ |
| All patientsN= 14 | Survivorsn= 7 | Nonsurvivorsn= 7 | Pvalue | |
| Characteristics at ICU admission | ||||
| Age | 32 (22–51) | 23 (21–44) | 48 (30–58) | 0.14 |
| Male sex | 8 | 4 | 4 | 1.00 |
| CCI | 2 (2–2) | 2 (2–2) | 2 (2–4) | 0.48 |
| SAPS II | 51 (42–65) | 56 (43–63) | 45 (39–68) | 0.90 |
| Prior allogeneic stem cell transplantation | 4 | 0 | 4 | <0.01 |
| Days from diagnosis of HM to ECMO | 87 (6–907) | 0 ((−1)–116) | 759 (69–1,228) | 0.04 |
| Days from ICU admission to ECMO | 2 (0–3) | 1 (0–2) | 3 (1–11) | 0.08 |
| Days from intubation to ECMO | 2 (1–5) | 1 (0–2) | 3 (1–9) | 0.17 |
| Characteristics at ECMO baseline | ||||
| SOFA score | 12 (11–13) | 12 (12–19) | 12 (11–15) | 0.79 |
| Lung injury score | 3.3 (3.3–3.7) | 3.3 (2.3–3.7) | 3.5 (3.3–3.8) | 0.09 |
| PaO2/FiO2 ratio | 60 (53–65) | 63 (51–106) | 60 (48–61) | 0.44 |
| pH | 7.29 (7.23–7.37) | 7.29 (7.23–7.39) | 7.37 (7.21–7.46) | 0.52 |
| PaCO2, mm Hg | 49 (43–59) | 41 (38–49) | 55 (48–72) | 0.05 |
| Lactate, mM | 2.2 (1.6–4.8) | 3.8 (1.6–7.1) | 2.0 (1.0–5.0) | 0.34 |
| Hemoglobin, g/dl | 9.4 (8.8–10.4) | 9.4 (8.6–10.5) | 9.8 (8.4–10.4) | 0.90 |
| Leukocytes, G/L | 6.0 (2.5–12.6) | 11.0 (3.6–17.0) | 5.6 (2.0–12.8) | 0.34 |
| Platelets, G/L | 38 (30–113) | 64 (29–201) | 35 (10–88) | 0.21 |
| Prothrombin time, % | 70 (43–74) | 50 (18–72) | 73 (64–78) | 0.22 |
| Fibrinogen, mg/dl | 436 (220–522) | 473 (160–627) | 421 (294–531) | 1.00 |
| Etiology of ARF determineda | 7 | 5 | 2 | 0.29 |
| Clinical diagnosis of pneumonia | 10 | 3 | 7 | 0.07 |
| Characteristics during ECMO | ||||
| Venoarterial ECMO | 3 | 3 | 0 | 0.19 |
| Duration of ECMO therapy, days | 8.5 (4–16) | 4 (3–9) | 10 (7–28) | 0.08 |
| Diagnosis of HM on ECMO | 4 | 4 | 0 | 0.07 |
| Chemotherapy on ECMO | 5 | 4 | 1 | 0.27 |
| Vasopressors | 14 | 7 | 7 | na |
| Hemofiltration | 5 | 2 | 3 | 1.00 |
| Major bleeding events | 5 | 1 | 4 | 0.27 |
| Number of packed red blood cell units | 8 (4–14) | 4 (3–8) | 14 (6–27) | 0.02 |
| Number of platelet concentrates | 5 (1–17) | 2 (0–5) | 23 (14–26) | 0.01 |
| Outcome | ||||
| ICU LOS, days | 22 (14–42) | 22 (21–77) | 18 (11–40) | 0.12 |
| Hospital LOS, days | 56 (44–101) | 63 (49–110) | 45 (15–133) | 0.46 |
| ICU and hospital survival, n (%) | 7 (50%) |
| Sham-vehicle (pg/mL) | Sham-EFX (pg/mL) | TBI-vehicle (pg/mL) | TBI-EFX (pg/mL) | TBI-vehicle vs. TBI-EFX | |||||
| Ipsilateral | Contralateral | Ipsilateral | Contralateral | Ipsilateral | Contralateral | Ipsilateral | Contralateral | % decrease (ipsilateral side) | |
| Pro-inflammatory cytokines | |||||||||
| IL-1α | 5.75 ± 0.87 | 5.17 ± 0.22 | 5.53 ± 0.81 | 3.83 ± 0.88 | 40.41 ± 5.14*** | 3.27 ± 0.63 | 13.55 ± 2.65** | 1.32 ± 0.77 | 33 |
| IL-1β | 45.14 ± 2.89 | 37.68 ± 2.43 | 56.58 ± 9.43 | 34.77 ± 3.25 | 382.88 ± 64.66*** | 33.98 ± 1.57 | 148.97 ± 25.50** | 29.82 ± 1.72 | 39 |
| IL-2 | 26.47 ± 0.75 | 24.84 ± 0.70 | 23.48 ± 0.50 | 22.89 ± 1.57 | 27.55 ± 4.42 | 21.55 ± 0.62 | 23.44 ± 1.64 | 20.46 ± 0.64 | ns |
| IL-6 | 2.65 ± 0.33 | 1.76 ± 0.23 | 14.00 ± 8.89 | 3.21 ± 0.71 | 150.18 ± 21.25*** | 4.34 ± 0.64 | 41.97 ± 10.25** | 1.86 ± 0.51 | 28 |
| IL-12 | 8.87 ± 0.29 | 8.54 ± 0.38 | 7.50 ± 0.24 | 7.50 ± 0.95 | 7.41 ± 0.26 | 6.95 ± 0.38 | 6.95 ± 0.20 | 7.10 ± 0.20 | ns |
| TNF-α | 5.34 ± 0.35 | 1.30 ± 0.14 | 5.93 ± 0.36 | 4.48 ± 0.84 | 16.34 ± 1.71*** | 5.24 ± 0.62 | 9.91 ± 1.28** | 5.91 ± 0.70 | 60 |
| GM-CSF | 2.49 ± 0.67 | 2.24 ± 0.49 | 2.06 ± 0.26 | 1.52 ± 0.29 | 1.20 ± 0.22 | 1.15 ± 0.17 | 1.07 ± 0.27 | 1.36 ± 0.14 | ns |
| Anti-inflammatory cytokines | |||||||||
| IL-4 | 2.86 ± 0.13 | 2.50 ± 0.08 | 3.20 ± 0.53 | 2.85 ± 0.51 | 4.19 ± 0.78 | 2.54 ± 0.05 | 3.65 ± 0.72 | 2.32 ± 0.13 | ns |
| IL-5 | 11.22 ± 0.24 | 10.74 ± 0.24 | 7.93 ± 0.31 | 6.72 ± 1.71 | 9.34 ± 0.63 | 9.24 ± 0.89 | 9.30 ± 1.18 | 9.00 ± 1.13 | ns |
| IL-10 | 25.99 ± 1.60 | 24.13 ± 1.67 | 19.94 ± 2.04 | 19.66 ± 4.35 | 35.29 ± 4.98 | 17.52 ± 2.82 | 28.48 ± 2.45 | 23.12 ± 0.83 | ns |
| Macrophage-attracting chemokines | |||||||||
| MIP-1α | 1.71 ± 1.01 | 0.04 ± 0.04 | 2.64 ± 1.3 | 0.00 ± 0.00 | 90.42 ± 25.47*** | 0.00 ± 0.00 | 36.99 ± 4.51* | 0.24 ± 0.21 | 41 |
| MCP-1 | 7.50 ± 1.97 | 4.30 ± 0.63 | 12.82 ± 5.16 | 4.25 ± 0.64 | 93.82 ± 21.66*** | 5.53 ± 0.97 | 53.00 ± 7.45* | 6.34 ± 1.55 | 56 |
| Enrichment score+ | Protein count (%) | Protein ID | P value | ||
| Biological process | Regulation of response to external stimulus | 2.3 | 3 (27.27) | AHSG, C3, HRG | 4.69e-3 |
| Cellular iron ion homeostasis | 2.13 | 3 (27.27) | HAP, HPX, TF | 1.81e-4 | |
| Iron ion homeostasis | 2.13 | 3 (27.27) | HAP, HPX, TF | 2.45e-4 | |
| Cellular di-, tri-valent inorganic cation homeostasis | 2.13 | 3 (27.27) | HAP, HPX, TF | 9.34e.3 | |
| Di-, tri-valent inorganic cation homeostasis | 2.13 | 3 (27.27) | HAP, HPX, TF | 1.03e-2 | |
| Cellular cation homeostasis | 2.13 | 3 (27.27) | HAP, HPX,TF | 1.16e-2 | |
| Molecular function | Endopeptidase inhibitor activity | 2.3 | 3 (27.27) | AHSG,C3, HRG | 3.32e-3 |
| Peptidase inhibitor activity | 2.3 | 3 (27.27) | AHSG, C3, HRG | 3.69e-3 | |
| Enzyme inhibitor activity | 2.3 | 3 (27.27) | AHSG, C3, HRG | 1.11e-2 | |
| Cellular component | Extracellular region | 8.11 | 11 (100) | A1BG, AHSG, APOA1, AZGP1, C3, FGG, HAP, HPX, HRG, LRG1, TF | 2.66e-11 |
| Secretory granule | 2.31 | 4 (36.36) | APOA1, FGG, HRG, TF | 3.06e-4 | |
| Cytoplasmic membrane-bounded vesicle | 2.31 | 4 (36.36) | APOA1, FGG, HRG, TF | 7.58e-3 | |
| Membrane-bounded vesicle | 2.31 | 4 (36.36) | APOA1, FGG, HRG, TF | 8.29e-3 | |
| Cytoplasmic vesicle | 2.31 | 4 (36.36) | APOA1, FGG, HRG, TF | 1.16e-2 |
| Assessment | |||||
| Outcomes | Measures | t1 | t2 | t3 | t4 |
| Self-management competence (primary outcome) | Health education impact questionnaire heiQ, German version [29]. Subscales Self-monitoring and insight, Skill and technique acquisition | X | X | X | X |
| Kansas City Cardiomyopathy Questionnaire KCCQ, German version [30]. Subscale self-efficacy | X | X | X | X | |
| Determinants of behavior: | |||||
| Intention, action and coping planning, action control | HAPA-scales [31,32] | X | X | X | X |
| Medication beliefs | Beliefs about Medicine Questionnaire BMQ-D [33], German version | X | X | X | X |
| Self-management behavior: | |||||
| Symptom control | Questionnaire will be developed by our research group | X | --- | X | X |
| Physical activity | Godin Leisure-Time Exercise Questionnaire [34], German modified version | X | --- | X | X |
| Medication adherence | Medication Adherence Report Scale MARS-D, German version [35] | X | --- | X | X |
| Health-related quality of life (disease specific) | Kansas City Cardiomyopathy Questionnaire KCCQ, German version [30] | X | X | X | X |
| Treatment satisfaction | Short questionnaire developed by our research group [36] | --- | X | --- | --- |
| Year of birth | DHS | Masakacohort | Rakaicohort | |||||||
| 1988 | 1995 | 2001 | 2006 | Total | Median AFS† | N | Median AFS | N | Median AFS | |
| 1950–9 | 1158 | 1171 | 777 | 360 | 3466 | 15.9 | 581 | 16.6 | 1039 | 15.9 |
| 1960–9 | 1948 | 2273 | 1604 | 1553 | 7378 | 16.1 | 1030 | 16.8 | 2196 | 16.0 |
| 1970–9 | 947 | 3199 | 2805 | 2497 | 9448 | 16.4 | 1768 | 17.0 | 5606 | 16.6 |
| 1980–9 | 0 | 131 | 2060 | 3366 | 5557 | 17.1 | 3235 | 17.5 | 4853 | 16.5 |
| 1990–94 | 0 | 0 | 0 | 755* | 755* | – | 829 | 16.9 | 0 | – |
| Total | 4053 | 6774 | 7246 | 8531 | 26604 | 16.4 | 7443 | 17.1 | 13694 | 16.4 |
| Hypermethylated | Hypomethylated | |
| n | 3925 | 4615 |
| CpG island location | CpG islands | Non-CGI |
| Genomic location | TSS, 1st exon | Gene body, outside genes |
| Associated genes | 1832 | 2057 |
| GO function terms | 36 | 27 |
| GO process terms | 265 | 53 |
| Canonical pathways (IPA) | 19 | 3 |
| Transcription factors | 24 | 1 |
| DNA binding consensus sequence | Putative binding site found in putative ATRX promoter | Biological roles | References | |
| 5'UTR of ATRX (+215 to +1) | ||||
| YY1(+38 to +29) | SNCCATNTT | CGCCATTTT | Activator/repressor involved in neural development with roles in the testis and meiosis | [35,36] |
| ATRX promoter region | ||||
| Inr element(-2 to +3) | CTTNACC | CTTAACC | Binds to basal transcription factor TFIID | [19] |
| CCAAT boxes(-2 to +3)(-38 to -34)(-69 to -65) | CCAAT | CCAAT | Binds NF-Y, C/EBP, GATA1, NF-E3 | [42] |
| E2F(-6 to -1) | TTTGGCGC | ATTGGCGC | Family of TFs that regulate mitosis, apoptosis, DNA repair, development and differentiation | [52] |
| CREB(-122 to -117) | TGACGTCA | CGACGTCA | Mediation of basal and PKA-inducible transcription | [65] |
| HNF4(-173 to -168) | TGACCT | TGACCT | Liver factor involved in liver development and digestive function | [66] |
| CR1 | ||||
| STAT5B(-963 to -956) | TTCN3GAA | TTCAAGAA | Involved in immune response, erythropoesis and mammary development | [67] |
| CP2(-1017 to -1003) | A/TCTGG-CNRGN6CNRS | CTATT-CCAGN6GCAG | Regulates transcription of SRY. Initially shown to bind murine alpha-globin gene | [50] |
| E2F (-796 to -791) | TTTGGCGC | TTTGGCTG | See E2F above | [52] |
| CR2 | ||||
| HNF6(-1413 to -1408) | GAATCA | GAAGCY | Liver factor involved in regulation of HNF4 and pancreatic precursor cells | [68] |
| CR3 | ||||
| FOXJ2/NKX2-5(-12720 to -12714) | TNAAGTG | TTAAGTA | Involved in regulation of cardiogenesis | [69] |
| Titer of serum from one sheep infected intrapulmonarily with 300.000 TCID 50 of virus K796 | Virus strains | ||
| K796 | 10B | 7W | |
| Serum 13 months after infection with K796 | 128 | 16 | 8 |
| Serum 3 years after infection with K796 | 256 | 32 | 16 |
| Titer of serum from one naturally infected sheep in Cyprus | 16 | 128 | 128 |
| Gene ID | Gene Product Description | Hilltop | Valley bottom |
| PF3D7_1121600 | circumsporozoite-related antigen (CRA) | 0.12 (0.05 - 0.19) | 0.51 (0.39 - 0.63) |
| PF3D7_1035700 | duffy binding-like merozoite surface protein (DBLMSP) | 0.11 (0.05 - 0.17) | 0.92 (0.33 - 1.51) |
| PF3D7_0108700 | secreted ookinete protein, putative (PSOP24) | 0.13 (0.01 - 0.25) | 0.93 (0.41 - 1.44) |
| PF3D7_0206900.1 | merozoite surface protein 5 (MSP5) | 0.08 (0.05 - 0.11) | 0.51 (0.26 - 0.76) |
| PF3D7_0501800 | chromosome assembly factor 1 (CAF1), residues 692-1,239 | 0.09 (0.03 - 0.15) | 0.47 (0.26 - 0.67) |
| PF3D7_0815500 | conserved Plasmodium protein | 0.05 (0.03 - 0.07) | 0.34 (0.17 - 0.51) |
| PF3D7_1014100 | conserved Plasmodium protein | 0.14 (0.02 - 0.25) | 0.92 (0.33 - 1.51) |
| PF3D7_0207000 | merozoite surface protein 4 (MSP4), residues 1-164 (exon 1) | 0.16 (0.01 - 0.30) | 0.49 (0.38 - 0.60) |
| PF3D7_1002000 | Plasmodium exported protein (hyp2) | 0.07 (0.01 - 0.12) | 0.33 (0.19 - 0.47) |
| PF3D7_0619000.1 | conserved Plasmodium protein | 0.05 (0.01 - 0.09) | 0.37 (0.14 - 0.61) |
| PF3D7_1100800 | Maurer's cleft two transmembrane protein (MC-2TM) | 0.10 (0.04 - 0.16) | 0.45 (0.21 - 0.68) |
| PF3D7_1134000 | heat shock protein 70 (Hsp70-3) | 0.13 (0.05 - 0.22) | 0.40 (0.26 - 0.55) |
| Traits/Disease | No. of Putative Associations |
| Conduct disorder (case status) * | 11 |
| Ischemic stroke | 11 |
| Atrial fibrillation/atrial flutter* | 10 |
| Permanent tooth development* | 10 |
| Conduct disorder (symptom count)* | 9 |
| Primary tooth development (time to first tooth eruption)* | 8 |
| Cleft lip* | 7 |
| Primary tooth development (number of teeth)* | 5 |
| Alcoholism (alcohol dependence factor score)* | 4 |
| Plasma coagulation factors* | 3 |
| Vitamin D insufficiency* | 3 |
| Vitamin D levels* | 2 |
| Atrial fibrillation* | 1 |
| Nonsyndromic cleft lip with or without cleft palate* | 1 |
| Plasma levels of Protein C* | 1 |
| Total | 86 |
| Sentence duration | N | Plaque index | Tartar index | Total OHI | |||
| Mean | SD | Mean | SD | Mean | SD | ||
| Till 1 year | 68 | 1.56 | 0.76 | 0.51 | 0.63 | 2.07 | 1.20 |
| 1–5 years | 26 | 1.23 | 0.43 | 0.23 | 0.43 | 1.46 | 0.65 |
| Over 5 years | 6 | 1.00 | 0.00 | 0.00 | 0.00 | 1.00 | 0.00 |
| Total | 100 | 1.44 | 0.69 | 0.41 | 0.59 | 1.85 | 1.10 |
| Kruskal–Wallis test | P < 0.05 | P < 0.05 | P < 0.05 |
| HbB Genotype | Numbers (87)a | G6PD Genotype | Numbers (84)a | 68 Status | 126 Status | Deduced Phenotypeb |
| 68–126 | ||||||
| AA | 75 (86%) | VV-NNc | 51 (61%) | Wildtype | Wildtype | G6PD B |
| SS | 0 | VV-DDd | 8 (10%) | Wildtype | Mutant | G6PD A |
| AS | 12 (14%) | M-De | 6 (7%) | Mutant | Mutant | G6PD A- |
| AC | 0 | VM-ND | 10 (12%) | Single Mutant | Single Mutant | G6PD A |
| CC | 0 | VV-ND | 8 (9%) | Wildtype | Single Mutant | G6PD A |
| SC | 0 | VM-DD | 1 (1%) | Single Mutant | Mutant | G6PD A |
| No PCR-product | 3 | No PCR-product | 6 |
| Age | 65 – 74 | 75 – 84 | ≥ 85 | |||
| Vaccinated | yes | no | yes | no | yes | no |
| 2003 Influenza season | ||||||
| Deaths/100 000 | 491 | 706 | 2235 | 2270 | 7224 | 7317 |
| Reduction (95% CI) p | 31% (0,44–1,07) < 0.1 | 2% (0,79–1,22) < 0.9 | 1% (0,81–1,20) < 0.9 | |||
| Non-influenza season | ||||||
| Deaths/100 000 | 610 | 767 | 2440 | 2332 | 6677 | 7580 |
| Reduction (95% CI) p | 21% (0,53–1,18) < 0.6 | - 5% (0,85–1,28) < 0.9 | 12% (0,72–1,07) < 0.2 | |||
| 2004 Influenza season | ||||||
| Deaths/100 000 | 973 | 837 | 2012 | 2566 | 8401 | 8974 |
| Reduction (95% CI) p | - 16% (0,85–1,59) < 0.4 | 22% (0,62–0,97) < 0.03 | 7% (0,78–1,12) < 0.4 | |||
| Non-influenza season | ||||||
| Deaths/100 000 | 730 | 646 | 2028 | 2214 | 7667 | 8171 |
| Reduction (95% CI) p | - 12% (0,79–1,65) < 0.5 | 9% (0,72–1,15) < 0.5 | 7% (0,77–1,13) < 0.5 | |||
| 2005 Influenza season | ||||||
| Deaths/100 000 | 502 | 882 | 2144 | 2829 | 6979 | 8882 |
| Reduction (95% CI) p | 43% (0,40–0,82) < 0.002 | 25% (0,62–0,92) < 0.01 | 23% (0,64–0,92) < 0.01 | |||
| Non-influenza season | ||||||
| Deaths/100 000 | 698 | 813 | 1761 | 2188 | 6942 | 7676 |
| Reduction (95% CI) p | 14% (0,61–1,20) < 0.4 | 20% (0,64–1,0) < 0.06 | 11% (0,73–1,08) < 0.3 |
| Variable | % increase (95% CI) |
| Age | |
| 35-64 years | 1.48 (0.28, 2.70) |
| 65-74 years | 1.54 (0.34, 2.75) |
| 75-84 years | 1.59 (0.42, 2.77) |
| ≥ 85 years | 1.51 (0.34, 2.70) |
| Education | |
| ≤ 8 years | 1.53 (0.26, 2.83) |
| 9-12 years | 1.54 (0.39, 2.70) |
| 13-16 year | 1.56 (0.36, 2.77) |
| 17 years or more | 1.46 (0.13, 2.80) |
| Marital status | |
| Never Married | 1.54 (0.32, 2.78) |
| Married or separated | 1.51 (0.34, 2.69) |
| Widowed | 1.57 (0.41, 2.74) |
| Divorced | 1.49 (0.21, 2.79) |
| Race | |
| White & non Hispanic | 1.54 (0.39,2.70) |
| Black | 1.47 (0.12,2.84) |
| Indian | 1.26 (-7.46,10.81) |
| Hispanic | 1.33 (-0.87,3.59) |
| Asian or Pacific | 1.63 (-0.21,3.50) |
| Others | 0.93 (-19.24,26.15) |
| Hispanic | |
| Hispanic | 1.54 (0.39,2.69) |
| Non Hispanic | 1.53 (-0.43,3.52) |
| White | |
| White | 1.54 (0.39,2.69) |
| Non white | 1.52 (0.23,2.83) |
| Gender | |
| Male | 1.55 (0.39,2.72) |
| Female | 1.53 (0.37,2.69) |
| Population per km2 * | |
| Low | 1.5 (0.32,2.69) |
| Medium | 1.54 (0.38,2.71) |
| High | 1.57 (0.38,2.78) |
| Household income* | |
| Low | 1.58 (0.39,2.79) |
| Medium | 1.51 (0.36,2.68) |
| High | 1.56 (0.37,2.76) |
| Percent poverty* | |
| Low | 1.47 (0.3,2.66) |
| Medium | 1.55 (0.4,2.72) |
| High | 1.58 (0.37,2.8) |
| Rape NOS | Gang Rape | Sexual Slavery | Combined Gang Rape and Sexual Slavery | |||||
| Number | Percent | Number | Percent | Number | Percent | Number | Percent | |
| Physical: | ||||||||
| Pelvic pain | 53 | 24.2 | 139 | 23.0 | 3 | 6.0 | 25 | 21.0 |
| Lumbar pain | 24 | 11.0 | 72 | 11.9 | 0 | 0 | 16 | 13.4 |
| Abdominal pain | 22 | 10.0 | 41 | 6.8 | 1 | 2.0 | 6 | 5.0 |
| Pregnancy | 12 | 5.5 | 13 | 2.1 | 20 | 40.0 | 17 | 14.3 |
| Malaise | 10 | 4.6 | 44 | 7.3 | 1 | 2.0 | 6 | 5.0 |
| Vaginal discharge | 10 | 4.6 | 36 | 6.0 | 1 | 2.0 | 8 | 6.7 |
| Vaginal itching | 9 | 4.1 | 25 | 4.1 | 1 | 2.0 | 8 | 6.7 |
| Abnormal menses | 10 | 4.6 | 26 | 4.3 | 1 | 2.0 | 6 | 5.0 |
| Generally unwell | 5 | 2.3 | 24 | 4.0 | 0 | 0 | 5 | 4.2 |
| Social: | ||||||||
| Loss of possessions | 55 | 25.1 | 147 | 24.3 | 10 | 20.0 | 19 | 16.0 |
| Loss of child/spouse | 13 | 5.9 | 75 | 12.4 | 2 | 4.0 | 21 | 17.6 |
| Spousal abandonment | 6 | 2.7 | 43 | 7.1 | 3 | 6.0 | 10 | 8.4 |
| Loss of other family | 2 | 0.91 | 15 | 2.5 | 0 | 0 | 9 | 7.6 |
| Loss of home | 1 | 0.46 | 9 | 1.5 | 0 | 0 | 1 | 0.84 |
| Psychological: | ||||||||
| Anxiety about rape | 53 | 24.2 | 154 | 25.5 | 18 | 36 | 31 | 26.1 |
| Anxiety about spousal abandonment | 6 | 2.7 | 38 | 6.3 | 4 | 8 | 9 | 7.6 |
| Concern about STIs | 25 | 11.4 | 76 | 12.6 | 4 | 8 | 19 | 16.0 |
| Concern about HIV | 14 | 6.4 | 56 | 9.3 | 4 | 8 | 13 | 10.9 |
| General health concerns | 16 | 7.3 | 66 | 10.9 | 7 | 14 | 9 | 7.6 |
| Grief about loss of spouse | 9 | 4.1 | 40 | 6.6 | 1 | 2 | 10 | 8.4 |
| Grief about loss of child/children | 8 | 3.7 | 25 | 4.1 | 0 | 0 | 3 | 2.5 |
| Key inclusion and exclusion criteria | Orchard et al. [7] | Meisser et al. [8] | Noehren et al. [11] | Ferber et al. [12] | Phinyonmark et al. [20] | Foch et al. [21] | Foch and Milner [22] | Foch and Milner [23] | Grau et al. [24] | Hein et al. [25] | Miller et al. [26]a | Miller et al. [27]a | Noehren et al. [28] | |
| 1 | Clear definition of location of pain was reported | ✓ | ✓ | X | ✓ | ✓ | ✓ | X | X | ✓ | ✓ | X | X | ✓ |
| 2 | Reports a typical history of ITBS with symptoms consistent to the condition | ✓ | X | X | ✓ | ✓ | ✓ | X | X | ✓ | ✓ | X | ✓ | ✓ |
| 4 | Diagnosis was confirmed by a medical practitioner/physiotherapist/ trainer | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| 4 | A positive clinical test (Obers/Nobles)/ palpation | ✓ | ✓ | X | X | ✓ | X | X | X | ✓ | ✓ | X | ✓ | ✓ |
| 5 | No previous knee surgery | ✓ | X | ✓ | ✓ | ✓ | X | ✓ | ✓ | ✓ | ✓ | ✓ | X | ✓ |
| 6 | No internal derangement or other sources of lateral knee pain present | ✓ | ✓ | ✓ | ✓ | ✓ | X | ✓ | ✓ | ✓ | ✓ | ✓ | X | ✓ |
| 7 | No previous spine or lower limb injury | ✓ | ✓ | ✓ | ✓ | ✓ | X | X | ✓ | ✓ | ✓ | ✓ | X | ✓ |
| Criteria’s Met | 7 | 5 | 4 | 6 | 7 | 3 | 3 | 4 | 7 | 7 | 4 | 3 | 7 |
| Ordinary light | Infrared ray light | |
| ICG-positive nodedetection | 28/36(78 %) | 36/36 |
| The number ofICG-positive nodes | 3.4 ± 3.7*(0 to 16)+ | 9.2 ± 5.9*(2 to 25)+ |
| Lymph nodemetastasis sensitivity | 1/5(20 %) | 5/5(100 %) |
| Test | Day 0 (admission) | Day 13 (discharge) |
| Coxsackie A9 (NT) | 8 Units | 16 Units |
| Coxsackie B1 (NT) | 16 Units | 32 Units |
| Coxsackie B2 (NT) | <4 Units | <4 Units |
| Coxsackie B3 (NT) | 32 Units | 64 Units |
| Coxsackie B4 (NT) | <4 Units | <4 Units |
| Coxsackie B5 (NT) | <4 Units | <4 Units |
| Coxsackie B6 (NT) | <4 Units | <4 Units |
| Characteristic | Female | Male | Total |
| n of subjects | 14 | 14 | 28 |
| Gender (M/F) % | 50/50 | ||
| Age (years) | 23 (23, 23) | 20.5 (19, 21.25) | 21.75 ± 1.92 |
| Height (cm) | 158 ± 7.34 | 170.3 ± 7.30 | 164.1 ± 9.53 |
| Body weight (kg) | 59.16 ± 8.79 | 72.61 ± 11.47 | 65.89 ± 12.14 |
| BMI (kg/m2) | 23.67 ± 2.57 | 25.04 ± 3.28 | 24.36 ± 2.97 |
| Waist circumference (cm) | 76.57 ± 6.98 | 85.96 ± 8.20 | 81.27 ± 8.87 |
| Waist-to-hip ratio | 0.78 ± 0.05 | 0.85 ± 0.04 | 0.82 ± 0.06 |
| Glycemia (mg/dL) | 83.57 ± 5.87 | 82.64 ± 9.90 | 83.11 ± 8.00 |
| Total cholesterol (mg/dL) | 168.1 ± 33.76 | 172.6 ± 27.78 | 170.3 ± 30.43 |
| Triglycerides (mg/dL) | 89 (72.5, 161.5) | 92.5 (65.75, 126.5) | 92.50 (69.50, 153.8) |
| Who Would Use the App? | When Would They Use the App? | How Useful Is an App? | What Should Be in the App? | Who or How Should It Be Advertised to Users? |
| Parents of children ages 0–6First time momsParents about to switch their child to a new seatCaregiversFamilyBabysittersDads say they are less likely to use it but moms say dads would use it a lot | Before the baby is bornWhen buying a new seat (process) or about to switch seatsExternal caregiver installingFirst time installation with new seatWhen looking for car seat check pointsTroubleshootingIn need of non-installation factoids/frequently asked questions (expiration dates) | AdvantagesOn the go informationSimple to useAccessibleProvides direct infoEasier to readVisual assistanceDisadvantagesSome preferred websiteApps may be difficult to navigateUnfamiliarity with appsNot useful when installing—“keep checking your phone” | Car seat check locator and appointment schedulerWhat seat fit best in the carHow to install in different types of carsConsumer product reviewsCar seat laws and policiesTypes of car seats for height, weight, and ageFAQ’s, safety myths vs. factsExpiration datesTravelingOnline forum (social tools)Search functionMultiple languagesSpanishVideos and imagesTroubleshooting info and tools—inch and pinch test | Who:Not manufacturersDoctors in officeCHOPInsurance companiesSafekids WorldwideHow:No brochuresParent magazinesWebsite of CRS companiesPoster in waiting roomPrenatal and parenting classes |
| Organizational | Socio-cultural | Intrinsic |
| Motivators | ||
| • Opportunities for higher qualifications | • Respect | • Serving people |
| • Good working and hygienic conditions | • Social rewards | • Work interest |
| • Personal safety | • Career growth | |
| • Good professional experience | • Ability to support oneself and family | |
| • Good pay | • Autonomy | |
| • Financial incentives other than pay | • Empowerment | |
| Demotivators | ||
| • Less pay | • Disrespect | • Less career growth |
| • Poor working and hygienic conditions | • Poor interpersonal relations | • Inability to support oneself and family |
| • Fewer opportunities for higher qualifications | • Less social rewards | |
| • Less personal safety | • Less personal and social time | |
| • Heavy work load | ||
| • Long duty hours | ||
| • Resource unavailability | ||
| • Fewer promotion opportunities | ||
| • Poor supervision |
| Cost variable | Source | Unit cost in public system (Dollar) | Unit cost in private system (Dollar) |
| Medical visit | |||
| Public | Hospital accounts department/DMA | 5* | 125 (range 100-150) |
| Medication | |||
| Pain killer | Central Medical Store | 0.05/500 mgx2×3=0.30** | 2.00 |
| ORS | Central Medical Store | 0.75/packx3=2.25 | 4.5×3=13.5 |
| Antibiotics | Central Medical Store | 0.03/250 mgx3×3×5=1.35*** | 8.00 |
| Gravol | Central Medical Store | 0.05/50 mgx4×2=0.4**** | 2.00 |
| Loperamide | Private dispensary | 0.50/2 mgx2=1.0***** | 2.00 |
| IV fluid (0.9% sodium solution) | Central Medical Store | 3.42/litre | |
| Testing of stool specimens | Billing department, PMH | 20.00 | |
| Loss of working days | |||
| Caregiver service | Labour standard order (Minimum wage) | 28.75/day | |
| Duration of illness | Population survey | 2 days (Median value) |
| Neuroprotectant | n (%*) |
| Edaravone | 95 (8.4) |
| Ganglioside GM1 | 29 (2.6) |
| Cattle encephalon glycoside and ignotin | 112 (9.9) |
| Cinepazide | 56 (5.0) |
| Citicholine | 334 (29.6) |
| Other† | 198 (17.5) |
| Unspecified | 321 (28.4) |
| Self-rated spiritual health | Ideators (%) | Non-ideators (%) | χ2 | p-Value |
| Excellent OR good | 117 (49.37) | 2713 (85.10) | 196.23 | <.0001 |
| Fair OR poor OR uncertain | 120 (50.63) | 475 (14.90) |
| Variable | Controls (n = 73) | Participants (n = 73) | p valuea |
| Lipoprotein subclassb | |||
| VLDL and chylomicron particle concentrations (nmol/L) | |||
| Total VLDL and chylomicron particles | 82.0 ± 45.3 | 87.5 ± 39.6 | 0.15 |
| Large VLDL and chylomicron particles | 4.6 ± 6.3 | 8.2 ± 6.8 | < 0.01c |
| Medium VLDL particles | 38.1 ± 28.5 | 39.7 ± 25.7 | 0.50c |
| Small VLDL particles | 39.3 ± 19.9 | 39.7 ± 17.2 | 0.90 |
| LDL particle concentrations (nmol/L) | |||
| Total LDL particles | 1253 ± 367 | 1437 ± 477 | 0.01 |
| Large LDL particles | 337 ± 211 | 251 ± 218 | < 0.01c |
| Intermediate LDL particles | 45.8 ± 38.5 | 72.6 ± 50.2 | < 0.01c |
| Small LDL particles | 870 ± 434 | 1113 ± 478 | < 0.01 |
| HDL particle concentrations (μmol/L) | |||
| Total HDL particles | 34.7 ± 6.7 | 32.1 ± 5.6 | 0.01 |
| Large HDL particles | 6.4 ± 3.5 | 4.6 ± 3.4 | < 0.01 |
| Medium HDL particles | 5.2 ± 4.9 | 5.9 ± 4.8 | 0.25c |
| Small HDL particles | 23.1 ± 7.0 | 21.7 ± 5.8 | 0.17 |
| Mean particle sizes (nm) | |||
| VLDL size | 50.6 ± 9.0 | 55.6 ± 10.4 | < 0.01 |
| LDL size | 20.7 ± 0.9 | 20.2 ± 0.8 | < 0.01 |
| HDL size | 8.9 ± 0.4 | 8.6 ± 0.3 | < 0.01 |
| Physiological variablesd | |||
| Age | 60.0 ± 7.8 | 60.3 ± 8.0 | 0.79 |
| Body mass index (kg/m2) | 28.2 ± 3.7 | 34.0 ± 7.0 | < 0.01 |
| Systolic blood pressure (mm Hg) | 133 ± 17 | 136 ± 17 | 0.12c |
| Diastolic blood pressure (mm Hg) | 78.9 ± 9.2 | 80.8 ± 9.8 | 0.50c |
| HDL-cholesterol (mg/dl) | 50.5 ± 13.7 | 43.7 ± 13.1 | < 0.01c |
| LDL-cholesterol (mg/dl) | 111 ± 33 | 111 ± 39 | 0.64c |
| Total cholesterol (mg/dl) | 191 ± 42 | 193 ± 47 | 0.82 |
| Triglycerides (mg/dl) | 148 ± 100 | 189 ± 99 | < 0.01 |
| Physical fitness (Bruce score) | 10.4 ± 2.8 | 6.6 ± 2.2 | < 0.01 |
| Framingham risk (× 100) | 7.4 ± 6.8 | 10.7 ± 8.5 | 0.02c |
| Regular expression method | Term voting method | |||
| TOTAL terms | 98435 | 100% | 98435 | 100% |
| Selected set | 13755 | 14% | 13755 | 14% |
| Excluded set | 84680 | 86% | 84680 | 86% |
| Sample of excluded | 3140 | 100% | ||
| Wrong (false negative) | 49 | 1.6% | ||
| Correct (true negative) | 3091 | 98.4% | ||
| Proportionate number of bona fide terms in excluded set | 1321 | |||
| Sample of included | 2070 | 100% | 2287 | 100% |
| Wrong (false positive) | 1538 | 74.3% | 1974 | 86.3% |
| Correct (true positive) | 532 | 25.7% | 313 | 13.7% |
| Probable number of bona fide terms in selected set | 3535 | 1883 | ||
| Recall | 0.728 | |||
| Precision | 0.257 | 0.137 |
| N = 301 | Total | Emotional | Physical | Active Coping | Passive Coping |
| Range | 47.19 | 44.85 | 49.89 | 49.08 | 47.95 |
| Minimum | 26.63 | 31.07 | 20.44 | 25.04 | 24.91 |
| Maximum | 72.82 | 75.92 | 70.33 | 74.13 | 72.86 |
| Percentile | |||||
| 25 | 42.53 | 42.04 | 43.52 | 42.51 | 42.98 |
| 50 | 50 | 50 | 50 | 50 | 50 |
| 75 | 56.70 | 56.80 | 56.92 | 57.48 | 56.88 |
| Target gene | Forward primer (5′ to 3′) | Reverse primer (5′ to 3′) | Source |
| Mad2 | GAGTTCTTCTCATTCGGCATCA | CCAATCTTTCAGTTGTTCCACC | PrimerBank |
| Bub1 | TGCTGCACAACTTGCGTCTAC | TCAACGCCCAACTCTGCCT | PrimerBank |
| APC | CCAACAAGGCTACGCTATGC | ATCTGCTCGCCAAGACAAAT | PrimerBank |
| β-actin | ATCATGTTTGAGACCTTCAACA | CATCTCTTGCTCGAAGTCCA | PrimerBank |
| Comparison | BC1 vs BC2 | BC1 vs BC3 | BC2 vs BC3 | |
| Successful Calls for Both | SNPs | 134128046 | 134063768 | 134107787 |
| % | 99.241 | 99.194 | 99.226 | |
| Concordant Calls (All) | SNPs | 134109060 | 134036623 | 134095792 |
| % | 99.986 | 99.980 | 99.991 | |
| Concordant Calls (Hom) | SNPs | 98050788 | 97992008 | 98016851 |
| % | 99.989 | 99.983 | 99.993 | |
| Concordant Calls (Het) | SNPs | 36058272 | 36044165 | 36078941 |
| % | 99.977 | 99.970 | 99.985 |
| Inner cortical width of thoracic pedicles (mm) | No. of thoracic pedicles instrumented | No. of thoracic pedicles accurately instrumented | Accuracy (%) |
| 0–1.0 | 194 | 68 | 35.05 |
| 1.1–2.0 | 176 | 115 | 65.34 |
| 2.1–3.0 | 352 | 304 | 86.36 |
| ≥3.1 | 376 | 339 | 90.16 |
| Total | 1098 | 826 | 75.23 |
| EDA-Q items (18 items) | Corresponding DISCO items (17 items) | DISCO variables |
| Obsessively resists and avoids ordinary demands | Lack of co-operation | LACKCOP |
| Has difficulty complying unless carefully presented | ||
| Is driven by the need to be in charge | Using age peers as mechanical aids, bossy and domineering | CPEERAD* |
| Tells other children how to behave | ||
| Finds everyday pressures intolerably stressful | Anxiety | ANXIETY |
| Mimics adult mannerisms and styles | Repetitive acting out roles | CTROL* |
| Shows little shame or embarrassment | Behaviour in public places | BEHAPUB |
| Embarrassing remarks in public | REMARK | |
| Good at getting around others | Apparently manipulative behaviour | MANBEH* |
| Unaware of differences between self and authority figures | Awareness of own identity | CIDENT* |
| Attempts to negotiate better terms with adults | ||
| If pressurised to do things, may have a ‘meltdown’ | Temper tantrums | TEMPER |
| Mood changes rapidly | Changeable mood | MOODCH |
| Knows what to do or say to upset specific people | Difficulties with other people | DIFPEOP |
| Blames or targets a particular person | Harassment of others | HARAS* |
| Blaming other people | BLAME* | |
| Denies behaviour, even when caught red-handed | Fantasising, lying, cheating, stealing | LYING* |
| Outrageous behaviour to get out of doing something | Socially shocking behaviour | SHOCK* |
| Extreme emotional responses to small events | Inappropriate sociability (rapid, inexplicable changes from loving to aggression) | CINAPP* |
| Social interaction has to be on his/her own terms | One-sided social approaches | CONESID |
| SA-test (reaction time (msec) | ||
| Active diet | Control diet | |
| time 0 | 1320 ± 20 | 1320 ± 21 |
| 45 min | 1219 ± 19 | 1230 ± 21 |
| 120 min | 1182 ± 21 | 1202 ± 23 |
| Treatment-naïve cancer patients (n= 555) | |
| Age, years (IQR) | 62 (52-71) |
| Male gender, n (%) | 227 (41%) |
| BMI kg/m2, (IQR) | 25.0 (22.6–28.4) |
| Comorbidities | |
| Known CAD, n (%) | 28 (5%) |
| Heart Failure, n (%) | 38 (7%) |
| Diabetes mellitus, n (%) | 43 (8%) |
| Arterial Hypertension, n (%) | 250 (45%) |
| CKD, n (%) | 31 (6%) |
| COPD, n (%) | 113 (20%) |
| Cancer disease stage* | |
| Stage 1, n (%) | 96 (17%) |
| Stage 2, n (%) | 50 (9%) |
| Stage 3, n (%) | 108 (19%) |
| Stage 4, n (%) | 183 (33%) |
| Hepatic involvement | |
| Primary hepatic, biliary tract or pancreatic malignoma, n (%) | 27 (5%) |
| Hepatic metastases, n (%) | 51 (10%) |
| Laboratory parameters | |
| GFR, mL/min/1.73 m2 (IQR) | 74.5 (63.7–86.0) |
| BUN, mg/dl (IQR) | 15 (12-19) |
| BChE, kU/l (IQR) | 7.31 (6.10–8.40) |
| AST (GOT), U/l (IQR) | 24 (19–31) |
| ALT (GPT), U/l (IQR) | 22 (16–32) |
| GGT, U/l (IQR) | 32 (21–63) |
| Bilirubin, mg/dl (IQR) | 0.58 (0.44-0.79) |
| Albumin, g/l (IQR) | 43.0 (40.0–45.4) |
| CRP, mg/dl (IQR) | 0 (0-1) |
| SAA, μg/ml (IQR) | 8 (4-26) |
| IL-6, pg/ml (IQR) | 2 (2–3) |
| Time points of measurements | IOP | ONSD | |
| T0 | Patient awake in supine position before induction of anaesthesia | X | - |
| T1 | 20 min after induction of general anaesthesia in supine position | X | X |
| T2 | After insufflation of the abdomen with CO2 in supine position | X | X |
| T3 | After 30 min in 45° Trendelenburg position with the abdomen still insufflated with CO2 | X | X |
| T4 | Control of Santorini’s plexus in 45° Trendelenburg position with CO2 still insufflated | X | X |
| T5 | Anaesthetised before awakening in supine position | X | X |
| Proteins present in all 8 Mimiviridae genomes | |||
| CLS10031 | A1L transcription factor VLTF-2 | CLS10052 | Proliferating cell nuclear antigen |
| CLS10071 | A2L transcription factor VLTF-3 | CLS10035 | protein disulfide Isomerase/thioredoxin family |
| CLS10199 | asnB, asparagine synthetase B | CLS10216 | putative DNA-directed RNA polymerase II subunit N |
| CLS10039 | capsid protein | CLS10047 | replication factor C small subunit |
| CLS10262 | D5-like helicase-primase | CLS10049 | replication factor C small subunit |
| CLS10015 | DEAD/SNF2-like helicase or ATP-dependent RNA helicase | CLS10258 | ribonuclease H |
| CLS10089 | DNA directed RNA polymerase subunit L | CLS10041 | ribonuclease III |
| CLS10259 | DNA mismatch repair ATPase MutS | CLS10130 | ribonucleosidediphosphatereductase large subunit |
| CLS10104 | DNA polymerase elongation subunit family B | CLS10252 | ribonucleosidediphosphatereductase small subunit |
| CLS10201 | DNA topoisomerase IB | CLS10028 | TATA-box-binding protein |
| CLS10230 | DNA topoisomerase II | CLS10057 | Transcription factor S-II (TFIIS)-domain-containing protein |
| CLS10090 | DNA-dependent RNA polymerase subunit Rpb9/M | CLS10055 | transcription initiation factor IIB |
| CLS10250 | DNA-directed RNA polymerase subunit 5 (RPB5) | CLS10011 | ubiquitin-conjugating enzyme E2 |
| CLS10261 | DNA-directed RNA polymerase subunit 6 | CLS10214 | Ulp1-like protease |
| CLS10076 | DNA-directed RNA polymerase subunit alpha | CLS10066 | VV A18-like helicase |
| CLS10053 | DNA-directed RNA polymerase subunit beta | CLS10068 | VV A32 virion packaging ATPase |
| CLS10249 | DNA-directed RNA polymerase subunit E’ (RPB7) | CLS10218 | YqaJ-like viral recombinase |
| CLS10024 | Erv1 / Alr family oxidoreductase | CLS10212 | hypothetical protein |
| CLS10221 | eukaryotic translation initiation factor 4E-like protein | CLS10222 | hypothetical protein |
| CLS10086 | FtsJ-like methyltransferase | CLS10233 | hypothetical protein |
| CLS10030 | Holliday junction resolvase | CLS10236 | hypothetical protein |
| CLS10056 | metallopeptidase WLM | CLS10032 | hypothetical protein |
| CLS10219 | mRNA capping enzyme | CLS10043 | hypothetical protein |
| CLS10088 | NUDIX hydrolase | CLS10046 | hypothetical protein |
| CLS10224 | poxvirus poly(A) polymerase catalytic subunit-like protein | CLS10070 | hypothetical protein |
| CLS10253 | probable ubiquitin carboxyl-terminal hydrolase | CLS10081 | hypothetical protein |
| Genes missing in one or two OLPG genomes but present in all the other Mimiviridae genomes | |||
| CLS10059 | AAA family ATPase | CLS10009 | Lon domain protease |
| CLS10021 | chaperone protein DnaJ | CLS10033 | patatin-like phospholipase |
| CLS10022 | chaperone protein DnaJ | CLS10072 | Prolyl 4-hydroxylase |
| CLS10082 | heat shock 70 kDa protein | CLS10091 | thymidylate synthase |
| CLS10042 | hypothetical protein | CLS10010 | XRN 5'-3' exonuclease |
| MMSE Non-demented | MMSE Demented | EMSE Non-demented | EMSE Demented | |
| Below 5th pcntle (MMSE cut-point = 21, EMSE cut-point = 41) | 618 (3%) | 622 (73%) | 810 (5%) | 474 (77%) |
| Below 10th pcntle (MMSE cut-point = 23, EMSE cut-point = 45) | 1443 (8%) | 707 (84%) | 1676 (10%) | 524 (88%) |
| Below -1 SD (MMSE cut-point = 23.1, EMSE cut-point = 44.5) | 2075 (13%) | 739 (90%) | 1676 (10%) | 524 (88%) |
| Below -2 SD (MMSE cut-point = 12.9, EMSE cut-point-24.5) | 5 (0%) | 229 (24%) | 36 (0%) | 125 (19%) |
| Trial centre | Trial arm | Questionnaire type | ||||
| Standard | Mini | Mini-mini | Total by study arm | Total by site | ||
| Bristol | Control (%) | 54 (31) | 6 (30) | 9 (50) | 69 (33) | |
| IPB+ (%) | 56 (32) | 6 (30) | 6 (33) | 68 (32) | ||
| IPB only (%) | 63 (36) | 8 (40) | 3 (17) | 74 (35) | ||
| Total (%) | 173 (82) | 20 (9) | 18 (9) | 211 (28) | ||
| Newcastle | Control (%) | 38 (33) | 9 (29) | 5 (36) | 52 (32) | |
| IPB+ (%) | 40 (35) | 10 (32) | 4(29) | 54 (34) | ||
| IPB only (%) | 38 (33) | 12 (39) | 5 (36) | 55 (34) | ||
| Total (%) | 116 (72) | 31(19) | 14 (9) | 161 (21) | ||
| Norwich | Control (%) | 65 (38) | 9 (43) | 4 (44) | 78 (39) | |
| IPB+ (%) | 48 (28) | 7 (33) | 3 (33) | 58 (29) | ||
| IPB only (%) | 57 (34) | 5 (24) | 2 (22) | 64 (32) | ||
| Total (%) | 170 (85) | 21 (10) | 9 (5) | 200 (27) | ||
| Nottingham | Control (%) | 51 (36) | 1 (8) | 9 (39) | 61 (34) | |
| IPB+ (%) | 47 (33) | 7 (54) | 5 (22) | 59 (33) | ||
| IPB only (%) | 45 (32) | 5 (39) | 9 (39) | 59 (33) | ||
| Total (%) | 143 (80) | 13 (7) | 23 (13) | 179 (24) | ||
| Total by questionnaire type (%) | 602 (80) | 85 (11) | 64 (9) | 751 (100) |
| Variable | WAI | |||
| Status | Mean | S.D | P-value | |
| Body mass index (kg/m2) | ≥ 25 (n= 393) | 41.65 | 6.72 | 0.031 |
| < 25 (n= 283) | 42.66 | 4.88 | ||
| Smoking | Yes (n= 153) | 40.27 | 6.80 | < 0.001 |
| No (n= 523) | 42.60 | 5.71 | ||
| Physical activity (MET.min/week) | Low (≤ 600) (n= 261) | 40.63 | 6.71 | < 0.001 |
| Moderate(600-3000)(n= 206) | 42.53 | 5.47 | ||
| High (> 3000) (n= 209) | 43.42 | 5.28 |
| Subchondral bone volume | Subchondral bone migration area | |||
| Pearson's r | P value | Pearson's r | P value | |
| Weeks | 0.799 | <0.001 | 0.799 | <0.001 |
| Gross appearance | 0.865 | 0.001 | 0.923 | <0.001 |
| Histology | 0.649 | 0.059 | 0.520 | 0.152 |
| Country | Study type | Phase | n | Primary objective | Major findings |
| Thailand | HNV, PK and tolerability | 1 | 24 | PK and bio-availability of AS and MQ; administered separately and as a coformulation to healthy volunteers and patients | No difference was seen in the bio-equivalence of MQ in the two formulations; although a difference was seen for AS/DHA, this was not concluded to be clinically relevant[20] |
| PK, efficacy and safety | 2 | 50 | Population PK model of new dosage regime of MQ with AS in loose combination over three days | Splitting the 25 mg/kg dose of MQ into three doses of 8 mg/kg improved oral bio-availability compared to the conventional split-dose regimen results. New regimen was well tolerated and with an equivalent therapeutic response[21] | |
| PK, efficacy and safety | 2b | 50 | Safety and PK of ASMQ FDC vs non-fixed AS+MQ against multi-drug resistant falciparum malaria in adults | FDC well-tolerated with broadly similar PK profiles to non-fixed AS plus MQ[22]. The observed slowing of heart rate was best explained by malaria resolution[23] | |
| Efficacy and safety | 3 | 500 | ASMQ FDC with separate tablets in adults and children with uncomplicated multidrug-resistant falciparum malaria | Cure rates were 91.9% for the FDC after 63 days, with a lower incidence of vomiting compared to those in the loose tablets group[24] | |
| Myanmar | Competitive Effectiveness | 4 | 808 | Effectiveness of five artemisinin combination regimens with or without PQ in uncomplicated falciparum malaria | ASMQ provided the greatest post-treatment suppression of malaria after 63 days, with the addition of PQ substantially reducing transmission potential of malaria[25] |
| India | Efficacy and safety | 3 | 77 | PCR corrected cure rate of ASMQ FDC in adult patients with uncomplicated falciparum malaria | Mean parasite clearance time of 48 hours |
| Brazil | Intervention study: PK Efficacy and safety | 3b/4 | 23,845 | Effectiveness of ASMQ FDC in reducing malaria transmission in the Juruá valley | Early detection of malaria and treatment with ASMQ FDC was feasible and efficacious, significantly reduced the incidence and morbidity of falciparum malaria[26] |
| Outcome and complication | No. (%) |
| Mortality | 6 (14.2%) |
| 30 day | 2 (4.8%) |
| 1 year | 1 (2.4%) |
| 5 years | 2 (4.8%) |
| Complications | |
| Grade I | 14 (33.3%) |
| Grade II | 2 (4.8%) |
| Grade IIIa | 4 (9.5%) |
| Grade IIIb | 2 (4.8%) |
| Grade IV | 3 (7.1%) |
| Massive intraoperative bleeding and edema. | 2 (4.8%) |
| Wound infection | 4 (9.5%) |
| New hemiparesis, sensory changes | 4 (9.5%) |
| New cranial nerve palsy | 7 (16.7%) |
| Deep vein thrombosis. | 1 (2.4%) |
| Discharge location | 42 (100%) |
| Home ± rehabilitation | 24 (57.1%) |
| Rehabilitation center | 14 (33.3%) |
| Convalescence hospital | 2 (4.8%) |
| Hospital persist | 2 (4.8%) |
| Karnofsky score at 1 year | (n = 38) |
| > 70 | 23 (60.5%) |
| < 70 | 15 (39.5%) |
| Karnofsky score at 5 years | (n = 34) |
| > 70 | 20 (58.8%) |
| < 70 | 14 (41.2%) |
| Ordered by socioeconomic variableb | Male | Female | ||
| Prevalencec | Times/dayd | Prevalencec | Times/dayd | |
| Based on ranges. n = 24e | ||||
| Reason for extreme rates | 1.06 | 1.26 | 1.26 | 6.00 |
| Difference of extreme rates | 4.53 | 0.11 | 17.16 | 0.45 |
| Prevalence attributable to population | −3.44 | −0.13 | 1.69 | −0.07 |
| Prevalence attributable to population (%) | −4.39 | −44.00 | 2.49 | 45.28 |
| Based on disparity or dispersion. n = 33 | ||||
| Pearcy-Keppel | 0.57 | 2.29 | 0.66 | 1.23 |
| Pearcy-Keppel (Adjusted A) | 28.02 | 0.21 | 25.34 | 0.08 |
| Variance between groups (VEG) | 60.14 | 0.02 | 105.35 | 0.01 |
| Variance between groups (VEGA) | 0.77 | 0.05 | 1.55 | 0.05 |
| Based on disproportionality and concentration. n = 24 | ||||
| Gini | 0.05 | 0.22 | 0.08 | 0.25 |
| Concentration | 0.01 | 0.12 | −0.01 | −0.05 |
| Based on regression models. n = 24 | ||||
| Coefficient β | 0.12 | −0.00 | 0.24 | 0.00 |
| Coefficient of determination | 0.00 | 0.00 | 0.02 | 0.11 |
| Inequality of slope | 3.23 | 0.22 | −3.16 | −0.05 |
| Inequality of Pamuk or relative | 0.04 | 0.73 | 0.05 | 0.28 |
| Inequality of Kunst and Mackenbach | 1.04 | 1.53 | 1.05 | 1.33 |
| Dimensional inequality | 3.23 | 0.49 | 1.04 | 1.29 |
| Based on the concept of entropy. n = 33 | ||||
| Kullback-Liebler (Z) | 0.01 | 0.09 | 0.01 | 0.11 |
| Hoover or dissimilitudes (Z) | 0.04 | 0.15 | 0.06 | 0.17 |
| Theil (Z) | 0.01 | 0.08 | 0.01 | 0.11 |
| Pollutant | Concentration | Averaging period | Permitted exceedences each year |
| Cuprum [μ/m3] | 0,6 μg/m3 | 1 year | n/a |
| PM10 | 40 μg/m3 | 1 year | n/a |
| Lead (Pb) | 0,35 μg/m3 | 1 year | n/a |
| Publication | Zona pellucida breach | Embryonic stage | No of ET | Pregnancies conceived | Intervention | Outcome | ||
| ICSI | Assisted hatching | Embryo biopsy | ||||||
| Salat-Baroux et al., 1994 | No | No | No | Cleavage | 4 | MCTA triplets | Reduction | DCDA miscarriage |
| DCDA twins | ||||||||
| Belaisch-Allart et al., 1995 | No | No | No | Cleavage | 3 | MCTA triplets | Nil | Delivery ?weeks |
| Yakin et al., 2001 | Yes | No | No | Blastocyst | 3 | MCTA triplets | Reduction | DCDA delivery 36 weeks |
| DCDA twins | ||||||||
| Ghulmiyyah et al., 2003 | Yes | Yes | No | Blastocyst | 2 | MCTA triplets | Nil | CS at week 31 |
| Ulug et al., 2004 | Yes | Yes | No | Cleavage | 3 | MCTA triplets | Reduction | Singleton CS at week 38 |
| Singleton | ||||||||
| Yes | Yes | No | Cleavage | 3 | MCTA triplets | Nil | CS at week 34 | |
| Unger et al., 2004 | Yes | No | No | Blastocyst | 2 | MCTA triplets | Reduction | Ongoing MCDA pregnancy 22 weeks |
| MCDA twins | ||||||||
| Zikopoulos et al., 2004 | Yes | No | No | Blastocyst | 2 | MCTA triplets | Reduction | Ongoing MCDA pregnancy 20 weeks |
| MCDA twins | ||||||||
| Risquez et al., 2004 | Yes | Yes | No | Cleavage | 1 | MCTA triplets | Nil | Ongoing pregnancy |
| 16 weeks | ||||||||
| Jain et al., 2004 | No | No | No | Blastocyst | 2 | MCTA triplets | Nil | Ongoing pregnancy 7 weeks |
| Henne et al., 2005 | No | No | No | Blastocyst | 2 | MCTA triplets | Termination | |
| Yanaihara et al., 2007 | No | No | No | Blastocyst | 1 | MCTA triplets | Termination | |
| Lee et al., 2008 | Yes | No | No | Blastocyst | 1 | MCTA triplets | Nil | CS at 33 weeks |
| Faraj et al., 2008 | No | No | No | Blastocyst | 1 | MCTA triplets | Nil | CS at 32 weeks |
| Pantos et al., 2004 | Yes | Yes | No | Day 4 | 3 | MCTA triplets | Reduction | Singleton CS at 38 weeks |
| singleton | ||||||||
| Haimov-Kochman et al., 2009 | Yes | No | Yes | Day 4 | 3 | MCTA triplets | Reduction | Singleton delivery at 38 weeks |
| singleton | ||||||||
| Liu et al., 2010 | No | No | No | Cleavage | 2 | MCQA | Nil | Miscarriage |
| Gurunath et al., 2015 | No | No | No | Blastocyst | 2 | MCTA | Termination | |
| Saravelos et al., 2015 | Yes | No | Yes | Day 4 | 1 | MCQA | Reduction | MCDA CS at 35 + 6 weeks |
| No | No | No | Blastocyst | 1 | MCTA | Reduction | Ongoing MCDA pregnancy |
| Location and day | Central station | Adjacent to patient |
| John Radcliffe Hospital Adult ICU weekday | 58.4 dB | 59.7 dB |
| John Radcliffe Hospital Adult ICU weekend | 59.1 dB | 59.5 dB |
| Royal Berkshire Hospital ICU weekday | 58.7 dB | 59.9 dB |
| Royal Berkshire Hospital ICU weekend | 57.7 dB | 58.5 dB |
| Wycombe General Hospital ICU weekday | 52.4 dB | 55.4 dB |
| Wycombe General Hospital ICU weekend | 51.3 dB | 54.1 dB |
| John Radcliffe Neurosciences ICU weekday | 58.0 dB | 58.8 dB |
| Churchill Hospital Adult ICU weekend | 55.7 dB | 55.4 dB |
| Gene ID | Description | Lineagea | dN/dS | ||||
| A | B | C | D | E | |||
| YDR197W | Mitochondrial translational activator of the COB mRNA | B | 0.078 | 1.472 | 0.092 | 0.088 | 0.131 |
| YER174C | Hydroperoxide and superoxide- radical responsive glutathione- dependent oxidoreductase | B | 0.086 | 1.243 | 0.033 | 0.102 | 0.044 |
| YFR041C | telomere maintenance | B | 0.132 | 1.138 | 0.054 | 0.111 | 0.071 |
| YGL119W | Protein required for ubiquinone (coenzyme Q) biosynthesis and for respiratory growth | B | 0.045 | 4.607 | 0.044 | 0.073 | 0.078 |
| YMR006C | glycerophospholipid metabolism | C | 0.060 | 0.036 | 2.788 | 0.060 | 0.052 |
| YPL248C | galactose metabolism; DNA- dependent regulation of transcription | C | 0.175 | 0.240 | 1.078 | 0.145 | 0.170 |
| Code | Before wetting | After wetting | Increased by |
| CH | 220 μm | 410 μm | 46.34% |
| MCG | 225 μm | 310 μm | 27.42% |
| F | 240 μm | 440 μm | 45.45% |
| MF | 300 μm | 380 μm | 21.05% |
| Vol. | Class | Macrogametocyte | k-1 | Round stage | k-2 | Ookinete | k-3 | Oocyst | K |
| Anopheles dirus | |||||||||
| 11 | HIGH | 2978.0 | * | 3.23 | 1.96 | 32.69 | 1.40 | 1.30 | 3.36 |
| 15 | 1242.0 | 1.63 | 29.27 | 0.00 | 31.37 | 0.00 | 59.50 | 1.63 | |
| 2 | 812.9 | 1.12 | 61.05 | 0.21 | 37.69 | 0.35 | 17.00 | 1.68 | |
| 5 | 416.3 | * | 42.39 | 0.33 | 192.58 | 0.65 | 42.70 | 0.98 | |
| 6 | 358.6 | 1.38 | 15.08 | 0.17 | 10.15 | 0.63 | 2.40 | 2.18 | |
| 1 | 332.8 | 1.44 | 12.20 | 0.00 | 13.43 | 0.00 | 25.10 | 1.44 | |
| 13 | 277.7 | 0.85 | 39.33 | 0.52 | 11.88 | 0.77 | 2.00 | 2.14 | |
| 3 | 233.3 | 1.37 | 10.02 | 0.00 | 14.03 | 0.00 | 85.80 | 1.37 | |
| 14 | 96.1 | * | 6.71 | 0.77 | 16.20 | 0.00 | 61.70 | 0.77 | |
| 12 | 56.6 | 1.20 | 3.54 | 0.08 | 2.96 | 0.00 | 10.60 | 1.28 | |
| 8 | LOW | 804.4 | 2.15 | 5.70 | 0.77 | 0.15 | 0.06 | 0.00 | 2.98 |
| 7 | 165.5 | 0.93 | 19.63 | 1.17 | 1.32 | 0.25 | 0.30 | 2.35 | |
| 10 | 138.8 | 2.06 | 0.23 | 0.09 | 0.00 | 0.00 | 0.10 | 2.15 | |
| 4 | 101.8 | 1.58 | 2.70 | 0.34 | 1.23 | 0.14 | 0.60 | 2.06 | |
| 9 | 34.7 | 1.54 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.54 | |
| Average Losses | 1.44 (27-fold) | 0.43 (3-fold) | 0.28 (2-fold) | 1.86 (72-fold) | |||||
| Anopheles minimus | |||||||||
| 15 | HIGH | 485.9 | 1.57 | 12.96 | 0.18 | 8.57 | 0.00 | 10.7 | 1.75 |
| 2 | 318.0 | 0.97 | 33.91 | 0.34 | 15.48 | ND | ND† | ND | |
| 13 | 108.6 | 0.43 | 40.54 | 0.67 | 8.66 | 1.34 | 0.4 | 2.44 | |
| 14 | 37.6 | 0.67 | 8.06 | 0.00 | 11.17 | 0.40 | 4.4 | 1.07 | |
| 12 | 22.2 | 0.83 | 3.32 | 0.52 | 1.00 | 0.19 | 0.3 | 1.54 | |
| 8 | LOW | 314.7 | 1.60 | 7.89 | 0.70 | 0.76 | 0.25 | 0 | 2.55 |
| 7 | 64.8 | 0.35 | 29.18 | 0.83 | 4.32 | 0.64 | 0 | 1.82 | |
| 10 | 54.3 | 1.73 | 0.00 | 0.00 | 0.00 | ND | ND | ND | |
| 9 | 13.6 | 1.03 | 0.37 | 0.14 | 0.00 | 0.00 | 0 | 1.17 | |
| Average Losses | 1.02 (10 -fold) | 0.33 (2-fold) | 0.40 (2-fold) | 1.76 (58-fold) | |||||
| Anopheles sawadwongporni | |||||||||
| 15 | HIGH | 518.3 | 1.51 | 15.92 | 0.34 | 7.26 | 0.58 | 1.9 | 2.43 |
| 2 | 339.2 | 1.00 | 34.23 | 0.54 | 9.98 | ND | ND | ND | |
| 13 | 115.9 | 1.35 | 5.13 | 0.56 | 1.42 | ND | ND | ND | |
| 3 | 97.4 | 1.08 | 8.08 | 0.24 | 4.67 | ND | ND | ND | |
| 14 | 40.1 | 0.67 | 8.61 | 0.04 | 7.82 | 1.05 | 0.7 | 1.76 | |
| 12 | 23.6 | 1.15 | 0.76 | 0.18 | 0.15 | 0.06 | 0 | 1.39 | |
| 8 | LOW | 335.7 | 2.48 | 0.12 | 0.05 | 0.00 | ND - | ND | ND |
| Average Losses | 1.27 (19-fold) | 0.38 (2-fold) | 0.35 (2-fold) | 1.83 (68-fold) |
| Simulated Ontario Illness Attack Rates by the Percentage of Adults 53+ Years Old with Pre-existing Immunity1 | Calibrated Attack Rates (AR) | |||||
| Age | 30% | 50% | 70% | Age | AR | |
| 0–4 | 30.6% | 31.0% | 30.8% | 0–4 | 29.5% | |
| 5–13 | 53.8% | 55.0% | 55.2% | 5–18 | 55.9% | |
| 14–17 | 56.0% | 57.1% | 57.3% | |||
| 18–22 | 48.9% | 49.7% | 49.7% | 19–52 | 40.8% | |
| 23–52 | 39.6% | 39.8% | 39.3% | |||
| 53–64 | 21.7% | 15.3% | 8.8% | 53–59 | 14.3% | |
| 65+ | 19.1% | 13.2% | 7.5% | 60+ | 11.0% | |
| Overall | 36.8% | 35.4% | 33.5% | Overall | 34.1% |
| Author | Sample size | +936C/T | −1154G/A | |||||||||||
| C | T | CC | CT | TT | HWE | G | A | GG | GA | AA | HWE | |||
| Rueda et al. (2005) | Case | 53 | – | – | – | – | – | 77 | 29 | 26 | 25 | 2 | ||
| Control | 226 | – | – | – | – | – | 320 | 132 | 118 | 84 | 24 | 0.13 | ||
| Liu et al. (2007) | Case | 155 | 90 | – | – | – | – | – | ||||||
| Control | 195 | 150 | – | – | – | – | – | |||||||
| Zhang et al. (2007) | Case | 1849 | – | – | – | – | – | 2018 | 1680 | 539 | 940 | 370 | ||
| Control | 1798 | – | – | – | – | – | 1937 | 1659 | 515 | 907 | 376 | 0.00 | ||
| Li et al. (2007) | Case | 200 | 285 | 115 | 125 | 35 | 40 | – | – | – | – | – | ||
| Control | 100 | 154 | 46 | 70 | 14 | 16 | 0.00 | – | – | – | – | – | ||
| Li et al. (2009) | Case | 150 | 190 | 110 | 51 | 88 | 11 | – | – | – | – | – | ||
| Control | 120 | 180 | 60 | 67 | 46 | 7 | 0.80 | – | – | – | – | – | ||
| Kim et al. (2011) | Case | 991 | 1604 | 378 | 642 | 320 | 29 | 1619 | 363 | 674 | 271 | 46 | ||
| Control | 494 | 824 | 164 | 344 | 136 | 14 | 0.89 | 815 | 173 | 339 | 137 | 18 | 0.37 | |
| Fu et al. (2011) | Case | 147 | 249 | 45 | 106 | 37 | 4 | 227 | 67 | 86 | 55 | 6 | ||
| Control | 131 | 218 | 44 | 90 | 38 | 3 | 0.66 | 194 | 68 | 69 | 56 | 6 | 0.20 | |
| Yu et al. (2012) | Case | 420 | 573 | 267 | 172 | 229 | 19 | – | ‐ | – | – | – | ||
| Control | 456 | 706 | 206 | 267 | 172 | 17 | 0.09 | – | – | – | – | – | ||
| Fontanella et al. (2013) | Case | 200 | 350 | 50 | 153 | 44 | 3 | – | – | – | – | – | ||
| Control | 200 | 348 | 52 | 151 | 46 | 3 | 0.81 | – | – | – | – | – | ||
| Zhang et al. (2014) | Case | 68 | 114 | 22 | 48 | 18 | 2 | – | – | – | – | – | ||
| Control | 118 | 196 | 40 | 81 | 34 | 3 | 0.80 | – | – | – | – | – |
| Child demographics | Maternal psychopathology | |||
| Maternal Abuse Group | Age, M ± SD | Sex, % female | PTSD, M ± SD | Depression, M ± SD |
| Physical Childhood Abuse | ||||
| Low (n = 22) | 8.9 ± 2.0 | 54.5 | 11.5 ± 11.0 | 17.3 ± 10.0 |
| High (n = 11) | 10.7 ± 2.0* | 45.5 | 22.3 ± 13.9* | 28.5 ± 14.7* |
| Emotional Childhood Abuse | ||||
| Low (n = 24) | 8.9 ± 2.1 | 54.2 | 11.9 ± 10.7 | 16.7 ± 9.7 |
| High (n = 9) | 11.1 ± 1.4* | 44.4 | 23.7 ± 15.0* | 32.2 ± 13.6** |
| Sexual Childhood Abuse | ||||
| Low (n = 17) | 8.6 ± 2.2 | 52.9 | 7.7 ± 7.9 | 14.8 ± 8.5 |
| High (n = 16) | 10.4 ± 1.8* | 50.0 | 22.7 ± 12.8** | 27.7 ± 13.3** |
| Enthalpy of desolvation, ΔdesolvH (kJ mol−1) from DSC | Enthalpy of desolvation, ΔdesolvH (kJ mol−1) calculated from equation 4 | |
| Atorvastatin (ATC) | - | |
| Solvate- I (ATC + 0.5 Isopropyl alcohol) | 24.20 | 25.93 |
| Solvate- II (ATC + THF) | 51.47 | 57.17 |
| Solvate- III (ATC + Ethanol) | 44.69 | 34.39 |
| Solvate- IV (ATC + 0.5 t-butanol) | 78.85 | 78.31 |
| Solvate- V (ATC + methanol) | 26.27 | 26.70 |
| Solvate-VI (ATC + 1 Acetone +0.5 Ethanol) | 56.74 | 52.01 |
| Solvate-VII (ATC + 0.5 Ethanol + Water) | 104.64 | 103.96 |
| Solvate- VIII (ATC + 1- butanol) | 28.56 | 31.81 |
| Behavioral trait | |
| Time spent in predator channel (proportion) | 0.44 ± 0.01n = 11 |
| Direct approaches toward predator (proportion) | 0.32 ± 0.03n = 11 |
| Startle responses | 0.52 ± 0.06n = 11 |
| Number of freezes | 0.99 ± 0.15n = 11 |
| Relative swimming activity | 0.17 ± 0.01n = 11 |
| Analyte | FNa | FP | ||||
| Original result (total) | Discrepant investigation outcomeb | Original result (total) | Discrepant investigation outcome | |||
| RP2 confirmed (TN) | RP2 unconfirmed (FN) | RP2 confirmed (TP) | RP2 unconfirmed (FP) | |||
| Viruses | ||||||
| Adenovirus | 4 | 1 | 3 | 48 | 40 | 8 |
| Coronavirus 229E | 1 | 1 | 0 | 5 | 0 | 5 |
| Coronavirus HKU1 | 0 | 12 | 3 | 9 | ||
| Coronavirus NL63 | 0 | 10 | 3 | 7 | ||
| Coronavirus OC43 | 8 | 2 | 6c | 5 | 2 | 3 |
| Human metapneumovirus | 2 | 2 | 0 | 8 | 6 | 2 |
| Human rhinovirus/enterovirus | 11 | 6 | 5 | 77 | 33 | 44 |
| Influenza virus A | 0 | 0 | ||||
| H1 | 0 | 0 | ||||
| H1-2009 | 0 | 0 | ||||
| H3 | 0 | 0 | ||||
| Influenza virus B | 0 | 2 | 2 | 0 | ||
| Middle East respiratory syndrome coronavirus (MERS-CoV) | 0 | 0 | ||||
| Parainfluenza virus 1 | 0 | 1 | 0 | 1 | ||
| Parainfluenza virus 2 | 1 | 1 | 0 | 8 | 5 | 3 |
| Parainfluenza virus 3 | 2 | 0 | 2 | 10 | 4 | 6 |
| Parainfluenza virus 4 | 0 | 7 | 1 | 6 | ||
| Respiratory syncytial virus | 1 | 1 | 0 | 24 | 8 | 16 |
| Bacteria | ||||||
| Bordetella parapertussis (IS1001) | 1 | 0 | 1 | 0 | ||
| Bordetella pertussis (ptxP) | 1 | 0 | 1 | 1 | 1 | 0 |
| Chlamydia pneumoniae | 0 | 1 | 1 | 0 | ||
| Mycoplasma pneumoniae | 1 | 0 | 1 | 5 | 5 | 0 |
| Total | 33 | 14 | 19 | 224 | 114 | 110 |
| Clinical profile | Asthmatics (all subject) | AIA | ATA |
| N | 592 | 163 | 429 |
| Age of first medical examination (mean (range)) | 46.15 (15.40-77.88) | 43.13 (17.22-72.73) | 47.30 (15.40-77.88) |
| Height (cm) | 160.78 ± 8.63 | 161.72 ± 8.69 | 160.42 ± 8.39 |
| Weight (kg) | 62.81 ± 10.84 | 61.25 ± 10.38 | 63.40 ± 10.97 |
| Fall rate (%) | 9.27 ± 13.24 | 24.63 ± 16.11 | 3.54 ± 4.85 |
| Blood eosinophil (%) | 6.01 ± 5.73 | 5.96 ± 5.21 | 6.03 ± 5.92 |
| FVC %, predicted | 88.54 ± 14.08 | 90.35 ± 14.04 | 87.85 ± 14.05 |
| FEV1 %, predicted | 90.54 ± 16.97 | 87.58 ± 16.94 | 91.66 ± 16.87 |
| PC20, methacholine (mg/ml) | 6.43 ± 8.67 | 5.02 ± 7.83 | 6.91 ± 8.90 |
| Total IgE (IU/ml)* | 156 (62, 394) | 164 (78, 357) | 154 (53, 416) |
| Sex (male/female) | 206/386 | 59/104 | 147/282 |
| Current Smoker (%) | 27.70 | 21.47 | 30.07 |
| Positive rate of skin test (%) | 56.42 | 52.76 | 57.81 |
| Survivors(n = 45) | Nonsurvivors(n = 43) | |
| Age (mean ± SD) | 42 (35-50) | 38 (29-46) |
| Male gender (%) | 36 (80%) | 31 (72%) |
| Location before ICU (ward, %) | 24 (53%) | 29 (67%) |
| Performance status 3 or 4 | 1 (0-2) | 2 (1-3) |
| CD4 count <50 mm3 (%) | 20 (44%) | 21 (49%) |
| Length of time from AIDS diagnosis | 39 (2-92) | 50 (2-85) |
| Recent (<3 months) AIDS diagnosis | 13 (29%) | 13 (30%) |
| HAART use | 20 (44%) | 20 (46%) |
| SAPS II expanded (points) | 44 (37-54) | 54 (46-67)b |
| SOFA D1 (points) | 4 (1-7) | 7 (4-10)b |
| Mechanical ventilation | 17 (38%) | 36 (84%)b |
| Use of vasopressors on day 1 | 6 (13%) | 15 (30%)a |
| Renal support | 3 (7%) | 13 (30%)b |
| Severe sepsis/septic shock (%) | 15 (33%) | 29 (67%)b |
| ICU length of stay (days) | 9 (5-17) | 10 (4-14) |
| Hospital length of stay (days) | 24 (12-58) | 15 (10-24)a |
| Characteristics | Correlation coefficient (r) | P value | ||
| AA | SS | AA | SS | |
| Age | −0.752 | −0.744 | 0.000 | 0.000 |
| BMI | 0.120 | 0.386 | 0.241 | 0.000 |
| Subischial leg length | −0.922 | −0.919 | 0.000 | 0.000 |
| Sitting height | −0.728 | −0.670 | 0.000 | 0.000 |
| Weight | −0.565 | −0.700 | 0.000 | 0.000 |
| Variable | β | SE | Ventricular septal defects (yes vs. no) | P value | |
| Odds ratio | 95% confidence interval | ||||
| NBL | −0.37 | 0.12 | 0.69 | 0.55 to 0.87 | 0.001 |
| UA PI | 2.09 | 0.32 | 8.10 | 4.31 to 15.21 | <0.0001 |
| MCA PI | −1.37 | 0.38 | 0.25 | 0.12 to 0.54 | <0.0001 |
| RSV group A | RSV group B | |||
| Global | Dadaab | Global | Dadaab | |
| Period (years) | 2006-11 | 2007-11 | 2006-11 | 2007-11 |
| Total Sequences@ | 649 | 182 | 504 | 108 |
| Overall % Genetic distance | 6.9 | 1.4 | 4.7 | 2.4 |
| Sequences Unique (%)* | 338 (52.1) | 39 (21.4) | 361(71.6) | 24 (22.2) |
| Number of genotypes identified | 2 | 2 | 4 | 1 |
| Technique | N | TP | TN | FN | k | Sensitivity | Specify% | Specify% | PPV% | NPV% | Accuracy% |
| 4D-TRAK | 52 | 42 | 6 | 1 | 3 | 0.91 | 93.33 | 85.71 | 96.67 | 66.67 | 92.31 |
| 3D-TOF-MRA | 52 | 45 | 6 | 1 | 0 | 0.95 | 100.00 | 85.71 | 97.83 | 100 | 98.08 |
| Pupil size (mm) | n | Nurses’ estimationsa (mm) | Pupillometer measurementsa (mm) | P value | Spearman's coefficient (95 % CI) | P value |
| <2 | 61 | 2 (2–2) | 1.8 (1.6–1.8) | 0.057 | 0.39 (0.15–0.59) | 0.002 |
| 2–4 | 232 | 3 (2–3) | 2.8 (2.5–3.3) | 0.005 | 0.44 (0.33–0.54) | <0.001 |
| >4 | 113 | 4 (3–5) | 4.9 (4.4–5.6) | <0.001 | 0.37 (0.19–0.51) | 0.001 |
| All | 406 | 3 (2–4) | 3.0 (2.3–4.3) | <0.001 | 0.75 (0.71–0.79) | <0.001 |
| Full cohort | Matched cohort | ||||
| Totala | AKIa | non-AKIa | AKIa | non-AKIa | |
| Clinical features | n = 1,030 | n = 287 | n = 743 | n = 257 | n = 257 |
| Pre-operative characteristics | |||||
| Male gender | 750 (72.8) | 209 (72.8) | 541 (72.8) | 190 (73.9) | 189 (73.5) |
| Age (years), mean (IQR) | 65.8 (59 to 75) | 70.0 (64 to 78) | 64.1 (58 to 73) | 69.4 (63 to 77) | 69.3 (65 to 76) |
| Smoker | |||||
| Present | 487 (47.3) | 147 (51.2) | 340 (45.8) | 130 (50.6) | 129 (50.2) |
| Never | 357 (34.7) | 88 (30.7) | 269 (36.2) | 82 (31.9) | 83 (32.3) |
| Previous | 186 (18.1) | 52 (18.1) | 134 (18.0) | 45 (17.5) | 45 (17.5) |
| BMI (kg/m2) | |||||
| <25 | 287 (27.9) | 85 (29.6) | 202 (27.2) | 72 (28.0) | 63 (24.5) |
| 25 to 30 | 425 (41.3) | 110 (38.3) | 315 (42.4) | 103 (40.0) | 100 (38.9) |
| >30 | 318 (30.9) | 92 (32.1) | 226 (30.4) | 82 (31.9) | 94 (36.6) |
| Previous ischemic peripheral disease | 57 (5.5) | 19 (6.6) | 38 (5.1) | 17 (6.6) | 13 (5.1) |
| Previous stroke | 104 (10.1) | 37 (12.9) | 67 (9.0) | 32 (12.5) | 29 (11.3) |
| Previous myocardial infarction | 256 (24.9) | 66 (23.0) | 190 (25.6) | 63 (24.5) | 65 (25.3) |
| History of arrhythmias | 154 (15.0) | 60 (20.9) | 94 (12.7) | 49 (19.1) | 51 (19.8) |
| Diabetes mellitus | 166 (16.1) | 58 (20.2) | 108 (14.5) | 50 (19.5) | 55 (21.4) |
| Dyslipidemia | 570 (55.3) | 156 (54.3) | 414 (55.7) | 141 (54.9) | 147 (57.2) |
| Hypertension | 585 (56.8) | 166 (57.8) | 419 (56.4) | 146 (56.8) | 153 (59.5) |
| Normal <140 and <90b | 455 (44.2) | 121 (42.2) | 324 (43.6) | 111 (43.2) | 104 (40.5) |
| Grade I 140 to 159 or 90 to 99b | 306 (29.7) | 80 (27.9) | 226 (31.4) | 70 (27.2) | 91 (23.7) |
| Grade II 160 to 179 or 100 to 109b | 189 (18.4) | 61 (21.3) | 128 (17.2) | 56 (21.8) | 42 (16.3) |
| Grade III > =180 or > =110b | 90 (8.7) | 25 (8.7) | 65 (8.8) | 20 (7.8) | 20 (7.8) |
| Charlson comorbidity index | |||||
| Low (score 0) | 396 (38.5) | 91 (31.7) | 305 (41.5) | 86 (33.5) | 91 (35.0) |
| Medium (score 1 to 2) | 456 (44.3) | 135 (47.0) | 321 (43.2) | 119 (46.3) | 112 (43.6) |
| High (score >3) | 178 (17.3) | 61 (21.3) | 117 (15.7) | 52 (20.2) | 54 (21.0) |
| Baseline creatinine (μmol/L), mean (IQR) | 85.0 (68 to 98) | 94.2 (73 to 109) | 81.4 (66 to 92) | 90.9 (72 to 107) | 91.3 (73 to 105) |
| euroSCORE, mean (IQR)c | 5.2 (3 to 7) | 6.4 (4 to 8) | 4.7 (3 to 7) | 6.1 (4 to 8) | 6.1 (4 to 8) |
| Low risk (score 0 to 2) | 199 (19.3) | 30 (10.5) | 169 (22.8) | 30 (11.7) | 28 (10.9) |
| Medium risk (score >2 to 5) | 369 (35.8) | 82 (28.6) | 287 (38.6) | 78 (30.4) | 81 (31.5) |
| High risk (score >5) | 462 (44.9) | 175 (70.0) | 287 (38.6) | 149 (58.0) | 148 (57.6) |
| Surgical procedure characteristics | |||||
| Type of surgery | |||||
| Valved | 313 (30.4) | 84 (29.3) | 229 (30.8) | 77 (30.0) | 78 (30.4) |
| CABG | 372 (36.1) | 85 (29.6) | 287 (38.6) | 80 (31.1) | 71 (27.6) |
| Valve and CABG | 158 (15.3) | 59 (20.6) | 99 (13.3) | 51 (19.8) | 54 (17.1) |
| Othere | 187 (18.2) | 59 (20.6) | 128 (17.2) | 49 (19.1) | 54 (17.1) |
| Extra corporal circulation | 910 (88.4) | 255 (88.9) | 655 (88.2) | 227 (88.3) | 223 (86.8) |
| n | Mean | Std. Deviation | |
| FRACTURE STRENGTH | 80 | 1016.6670 | 171.58485 |
| 1997 | 2012 | |
| Subconjunctival hemorrhage | 92 (28.75%) | 133 (27.42%) |
| Conjunctivitis | 108 (33.75%) | 153 (31.75%) |
| Keratitis | 20 (6.25%) | 32 (6.60%) |
| Eyelid-related disorders | 61 (19.06%) | 79 (16.29%) |
| Contact lens-related disorders | 39 (12.19%) | 87 (17.94%) |
| Total | 320 (100%) | 485 (100%) |
| Season | Entry∗ | Grain yield (t ha−1) (±SEM) | Number holes/plant (±SEM) | % Stem height tunnelled (±SEM) |
| 1 | Bt | 6.4 ± 0.4ab | 0.4 ± 0.3a | 0.7 ± 0.3a |
| Non-Bt | 5.7 ± 0.4ab | 2.7 ± 0.3c | 3.8 ± 0.3c | |
| Checks | 5.0 ± 0.5a | 2.8 ± 0.5c | 5.0 ± 0.4d | |
| 2 | Bt | 11.7 ± 0.4d | 1.7 ± 0.3b | 0.1 ± 0.3a |
| Non-Bt | 7.2 ± 0.4bc | 4.0 ± 0.3d | 3.9 ± 0.3c | |
| Checks | 5.9 ± 0.5ab | 4.9 ± 0.5d | 4.8 ± 0.4d | |
| 3 | Bt | 11.0 ± 0.4d | 0.03 ± 0.3a | 0.07 ± 0.3a |
| Non-Bt | 6.9 ± 0.4ab | 1.5 ± 0.3b | 2.1 ± 0.3b | |
| Checks | 7.0 ± 0.5bc | 2.1 ± 0.5b | 3.4 ± 0.4c | |
| Mean entry | Bt | 9.7 ± 0.2c | 0.7 ± 0.2a | 0.3 ± 0.1a |
| Non-Bt | 6.9 ± 0.2b | 2.8 ± 0.2b | 3.7 ± 0.1b | |
| Checks | 6.0 ± 0.3a | 3.3 ± 0.2c | 4.7 ± 0.2c | |
| Mean season | 1 | 5.8 ± 0.2a | 2.0 ± 0.2b | 3.3 ± 0.2b |
| 2 | 8.3 ± 0.2b | 3.6 ± 0.2c | 3.1 ± 0.2b | |
| 3 | 8.4 ± 0.2b | 1.2 ± 0.2a | 2.3 ± 0.2a |
| Spot no. | Identity | MW (Da) | GenBank acc. no. | FC |
| 1 | Ser/Thr-specific protein phosphatase 2A A regulatory subunit β isoform (Medicago sativa subsp.×varia) | 65161.6 | AAG29594 | 0.647 |
| 2 | Pyruvate kinase (Lactuca sativa) | 56174.9 | ABS87384 | 0.481 |
| 3 | Branched-chain amino acid aminotransferase, putative (Ricinus communis) | 45159.9 | XP_002530599 | 0.541 |
| 4 | Glucose-6-phosphate isomerase (Zea mays) | 68403.5 | NP_001147983 | 1.837 |
| 5 | Actin (Phaseolus acutifolius) | 33121.3 | AAZ95077 | 2.277 |
| 6 | Dehydrin (Phaseolus vulgaris) | 22955.6 | AAB00554 | 2.048 |
| 7 | Dehydrin (Phaseolus vulgaris) | 22955.6 | AAB00554 | 1.846 |
| 8 | Lactoylglutathione lyase, putative/glyoxalase I, putative (Arabidopsis thaliana) | 20830.4 | NP_001030996 | 2.414 |
| 9 | Dehydrin (Phaseolus vulgaris) | 22955.6 | AAB00554 | 2.438 |
| 10 | Dehydrin (Phaseolus vulgaris) | 22955.6 | AAB00554 | 1.625 |
| Dorsal | Ventral | |||||||||||||||
| 1 (pSN) | 2 (pSN) | 3 (aSN) | 4 (aSN) | 5 (aSN) | A (pSN) | B (pSN) | C (aSN) | |||||||||
| L | R | L | R | L | R | L | R | L | R | L | R | L | R | L | R | |
| pHipp | −0.05 | −0.06 | −0.06 | −0.06 | 0.02 | −0.01 | 0.08 | 0.06 | 0.13 | 0.12 | 0 | 0.01 | 0.08 | 0.06 | 0.08 | 0.11 |
| aHipp | −0.03 | −0.03 | −0.08 | −0.07 | 0.06 | 0.02 | 0.13 | 0.11 | 0.22 | 0.20 | 0.03 | 0.07 | 0.11 | 0.09 | 0.12 | 0.15 |
| Day | Haematocrit | Haemoglobin | ||||
| Control | Group A | Group B | Control | Group A | Group B | |
| 0 | 28.3 ± 3.7 | 28.2 ± 3.7 | 28.4 ± 2.8 | 9.2 ± 1.3 | 9.3 ± 1.2 | 9.2 ± 0.9 |
| 3 | 27.9 ± 3.7 | 26.7 ± 5.0 | 28.2 ± 3.7 | 9.1 ± 1.3 | 9.0 ± 1.1 | 9.1 ± 1.2 |
| 7 | 28.4 ± 4.1 | 28.4 ± 3.7 | 29.5 ± 4.0 | 9.1 ± 1.4 | 9.2 ± 1.2 | 9.5 ± 1.3 |
| 10 | 28.8 ± 4.5 | 29.4 ± 4.1 | 30.3 ± 4.2* | 9.4 ± 1.6 | 9.6 ± 1.2 | 9.7 ± 1.4 |
| 14 | 28.8 ± 4.5 | 30.8 ± 4.5 | 32.3 ± 5.4* | 9.4 ± 1.4 | 10.0 ± 1.5 | 10.3 ± 1.9* |
| 21 | 29.4 ± 6.2 | 31.9 ± 5.0 | 36.5 ± 6.3* † | 9.7 ± 2.0 | 10.3 ± 1.7 | 11.3 ± 2.1* |
| 28 | 30.4 ± 4.5 | 33.3 ± 5.3 | 37.5 ± 5.8* † | 9.9 ± 1.5 | 10.6 ± 1.9 | 11.6 ± 1.9* |
| Index | Segment | L | Nopt1 | Index | Segment | L | Nopt1 | Index | Segment | L | Nopt1 |
| 1 | B1 ↔ B2 | 8.1 | 10 | 31 | T8 ↔ T9 | 18.8 | 27 | 61 | H9 ↔ H10 | 50.8 | 75 |
| 2 | B1 ↔ B6 | 73.5 | 91 | 32 | T8 ↔ T18 | 12.9 | 18 | 62 | H9 ↔ H14 | 70.4 | 104 |
| 3 | B1 ↔ H1 | 56.9 | 87 | 33 | T9 ↔ T10 | 10.6 | 15 | 63 | H10 ↔ H11 | 24.3 | 35 |
| 4 | B2 ↔ B3 | 19.5 | 24 | 34 | T9 ↔ T17 | 22.5 | 33 | 64 | H10 ↔ H13 | 32 | 47 |
| 5 | B2 ↔ H4 | 36.8 | 56 | 35 | T10 ↔ T11 | 13.9 | 20 | 65 | H11 ↔ H12 | 45.8 | 67 |
| 6 | B3 ↔ B4 | 10.5 | 13 | 36 | T10 ↔ T16 | 18.9 | 27 | 66 | H12 ↔ H13 | 42.6 | 62 |
| 7 | B3 ↔ H5 | 36.3 | 55 | 37 | T11 ↔ T12 | 14.8 | 21 | 67 | H12 ↔ H20 | 96.5 | 143 |
| 8 | B4 ↔ B5 | 11.3 | 14 | 38 | T11 ↔ T15 | 34.6 | 51 | 68 | H13 ↔ H14 | 37.5 | 55 |
| 9 | B4 ↔ H6 | 23.5 | 36 | 39 | T12 ↔ T13 | 38.6 | 57 | 69 | H13 ↔ H21 | 85.2 | 126 |
| 10 | B5 ↔ B6 | 7.8 | 9 | 40 | T13 ↔ T14 | 9.8 | 14 | 70 | H14 ↔ H15 | 65.8 | 97 |
| 11 | B5 ↔ B7 | 12.6 | 19 | 41 | T13 ↔ T15 | 6 | 8 | 71 | H14 ↔ H28 | 71.9 | 106 |
| 12 | B6 ↔ B8 | 12 | 18 | 42 | T14 ↔ T15 | 12.6 | 18 | 72 | H15 ↔ H17 | 21.1 | 30 |
| 13 | B7 ↔ B8 | 6.7 | 10 | 43 | T14 ↔ H16 | 33.1 | 47 | 73 | H15 ↔ H28 | 82 | 121 |
| 14 | B7 ↔ T2 | 29.2 | 45 | 44 | T15 ↔ T16 | 21.3 | 31 | 74 | H16 ↔ H17 | 17.9 | 26 |
| 15 | B7 ↔ H6 | 13.7 | 21 | 45 | T16 ↔ T17 | 37.6 | 56 | 75 | H16 ↔ H18 | 29.8 | 43 |
| 16 | B8 ↔ T1 | 24.4 | 37 | 46 | T16 ↔ H19 | 62.1 | 89 | 76 | H17 ↔ H18 | 23.6 | 34 |
| 17 | T1 ↔ T2 | 7.3 | 10 | 47 | T17 ↔ T18 | 12.5 | 18 | 77 | H18 ↔ H19 | 35.5 | 52 |
| 18 | T1 ↔ T6 | 39.2 | 58 | 48 | H1 ↔ H2 | 16.7 | 24 | 78 | H20 ↔ H22 | 15.8 | 23 |
| 19 | T2 ↔ T4 | 23.8 | 35 | 49 | H1 ↔ H3 | 13.1 | 19 | 79 | H20 ↔ H23 | 14 | 20 |
| 20 | T2 ↔ T5 | 27.9 | 41 | 50 | H2 ↔ H3 | 20.1 | 29 | 80 | H21 ↔ H22 | 20.9 | 30 |
| 21 | T3 ↔ T4 | 11.2 | 16 | 51 | H2 ↔ H11 | 35.2 | 51 | 81 | H21 ↔ H25 | 36.1 | 53 |
| 22 | T3 ↔ T12 | 7.2 | 10 | 52 | H3 ↔ H4 | 13.7 | 19 | 82 | H22 ↔ H24 | 14 | 20 |
| 23 | T3 ↔ H8 | 31.8 | 45 | 53 | H4 ↔ H5 | 25.1 | 36 | 83 | H23 ↔ H24 | 19.4 | 28 |
| 24 | T4 ↔ T5 | 19 | 28 | 54 | H4 ↔ H10 | 48.7 | 71 | 84 | H23 ↔ H26 | 40.8 | 60 |
| 25 | T4 ↔ H7 | 29.5 | 42 | 55 | H5 ↔ H6 | 26.7 | 39 | 85 | H24 ↔ H25 | 18.7 | 27 |
| 26 | T5 ↔ T6 | 12.6 | 18 | 56 | H5 ↔ H9 | 32.8 | 48 | 86 | H24 ↔ H26 | 25.2 | 37 |
| 27 | T5 ↔ T8 | 36.7 | 54 | 57 | H6 ↔ H7 | 26.3 | 38 | 87 | H25 ↔ H27 | 25.7 | 37 |
| 28 | T6 ↔ T7 | 19.4 | 28 | 58 | H7 ↔ H8 | 25.1 | 36 | 88 | H25 ↔ H28 | 81.4 | 120 |
| 29 | T7 ↔ T8 | 17.6 | 25 | 59 | H8 ↔ H9 | 26.6 | 39 | 89 | H26 ↔ H27 | 13.4 | 19 |
| 30 | T7 ↔ T18 | 22.6 | 33 | 60 | H8 ↔ H16 | 85.5 | 126 |
| CS-cineCMR | 3D-HR-CMR(ref) | Diff | Diff [%] | |
| Volume [ml] | Volume [ml] | Volume [ml] | ||
| Patient 1 | 62.5 | 59.0 | 3.5 | 5.7 % |
| Patient 2 | 61.5 | 71.0 | −9.5 | −14.3 % |
| Patient 3 | 395.0 | 397.0 | −2.0 | −0.5 % |
| Variable | Overall | 0–5 years (n = 145) | 6–10 years (n = 36) | 11–15 years (n = 13) |
| Weight-for-Height z-score | ||||
| < −2 (%) | 45 (31.5) | 45 (31.5) | N/A | N/A |
| ≥ 2 (%) | 98 (68.5) | 98 (68.5) | N/A | N/A |
| Median WHZ (IQR) | n = 143; −0.89 (−2.46,0.10) | n = 143; −0.89 (−2.46,0.10) | N/A | N/A |
| Weight-for-age z-score | ||||
| < −2 (%) | 77 (42.5) | 65 (44.8) | 12 (33.3) | N/A |
| ≥ 2 (%) | 104 (57.5) | 80 (55.2) | 24 (66.7) | N/A |
| Median WAZ (IQR) | n = 181; −1.69 (−3.07,-0.69) | n = 145; −1.83 (−3.36,-0.62) | n = 36; −1.54 (−2.17,-0.77) | N/A |
| Height-for-age z-score | ||||
| < −2 (%) | 88 (45.4) | 70 (48.3) | 14 (38.9) | 4 (30.8) |
| ≥ 2 (%) | 106 (54.6) | 75 (51.7) | 22 (61.1) | 9 (69.2) |
| Median HAZ (IQR) | n = 194; −1.67 (−3.21,-0.51) | n = 145; −1.91 (−3.34,-0.58) | n = 36; −1.62 (−2.47,-0.52) | n = 13; −0.93 (−2.57,-0.47) |
| BMI for age z-score | ||||
| < −2 (%) | 53 (27.3) | 46 (31.7) | 4 (11.1) | 3 (23.1) |
| ≥ 2 (%) | 141 (72.7) | 99 (68.3) | 32 (88.9) | 10 (76.9) |
| Median BMIZ (IQR) | n = 194; −0.72 (−2.21,0.17) | n = 145; −0.74 (−2.41,0.33) | n = 36; −0.61 (−1.53,-0.15) | n = 13; −0.81 (−1.89,0.29) |
| Study sites | Sampling units (classes of listed educational institutions below, wards of Village Development Committee (VDCa )) | Sampling unit population | Sample size (i.e. number of respondents) | Sample size (%) |
| Bachhayauli | Class 12, Jhuwani Higher Secondary School, Bachhayauli 09, Chitwan | 33 (10 students, 23 teachers)b | 25 (10 students, 15 teachers) | 76 |
| Ward number 3, Bachhayauli VDCa, Chitwan | 148 household headsc | 25 (household heads) | 17 | |
| Baghauda | Bachelor’s degree of Business Studies, 1st year, Madi Multiple Campus, Tribhuvan University, Baghauda 03, Chitwan | 44 (24 students, 20 teachers)b | 25 (10 students, 15 teachers) | 57 |
| Ward number 5, Baghauda VDCa, Chitwan | 87 household headsc | 25 (household heads) | 29 | |
| Meghauli | Class 11 and 12, Janaki Higher Secondary School, Telauli, Meghauli 05, Chitwan | 60 (28 students, 32 teachers)b | 25 (10 students, 15 teachers) | 42 |
| Ward number 6, Meghauli VDCa, Chitwan | 43 household headsc | 25 (household heads) | 58 | |
| Total | 415 | 150 (30 students, 45 teachers, 75 villagers) | 36 |
| Women (n = 203) | Men (n = 161) | Overall (N = 364) | |
| Number (%) by age (years) | |||
| 25–44 | 90 (46.0) | 76 (49.1) | 16 (47.8) |
| 45–64 | 113 (54.0) | 85 (50.9) | 198 (52.2) |
| Number (%) by education | |||
| < Tertiarya | 127 (77.9) | 99 (76.3) | 226 (77.2) |
| Tertiarya | 76 (22.1) | 62 (23.7) | 138 (22.8) |
| Anthropometry | |||
| Mean BMI (Kg/m2) | 30.3 (29.0, 31.6) | 27.1 (26.0, 28.2) | 28.7 (27.9, 29.6) |
| Mean waist circ (cm) | 94.7 (91.9, 97.4) | 92.4 (89.7, 95.1) | 93.6 (91.9, 95.2) |
| % overweight (BMI ≥ 25) | 73.9 (64.1, 81.8) | 57.9 (47.2, 67.9) | 66.0 (58.4, 72.9) |
| % obese (BMI ≥ 30) | 46.4 (38.4, 54.6) | 25.3 (19.0, 32.8) | 36.0 (30.8, 41.5) |
| Blood pressure | |||
| Systolic BP (mm Hg) | 124.4 (121.6, 127.2) | 130.5 (127.4, 133.7) | 127.3 (125.3, 129.4) |
| Diastolic BP (mm Hg) | 78.1 (76.1, 80.0) | 79.5 (77.1, 81.8) | 78.7 (77.3, 80.2) |
| % reported hypertension | 25.8 (17.8, 36.0) | 14.4 (9.6, 21.0) | 20.4 (15.5, 26.3) |
| % total hypertension | 35.5 (27.5, 44.4) | 32.7 (23.2, 43.8) | 34.1 (27.7, 41.2) |
| Glucose | |||
| Fasting (mmol/l) | 5.5 (5.2, 5.8) | 5.4 (5.2, 5.6) | 5.4 (5.3, 5.6) |
| % reported diabetes | 9.9 (5.7, 16.5) | 9.0 (5.0, 15.6) | 9.4 (6.6, 13.3) |
| % all diabetes | 15.1 (9.8, 22.5) | 10.9 (6.1, 18.7) | 13.1 (9.6, 17.6) |
| Referral hospitals | District hospitals | Health centers | Private clinics | Kigali | Other regions | All facilities/all regions | |
| Average number of PAC cases per year per facility | |||||||
| From incidence study (2009)a | 484 | 200 | 37 | 75 | 100 | 44 | 57 |
| Percent of PAC cases with specific complications | |||||||
| Incomplete abortion | 73.2% | 70.8% | 78.1% | 78.9% | 70.3% | 79.1% | 76.0% |
| Sepsis | 6.1% | 12.5% | 12.8% | 18.0% | 17.6% | 10.4% | 13.0% |
| Shock | 5.2% | 14.9% | 8.1% | 2.5% | 7.2% | 9.7% | 8.8% |
| Lacerations | 4.9% | 1.5% | 0.0% | 0.0% | 1.7% | 0.2% | 0.8% |
| Perforations | 10.7% | 0.3% | 1.0% | 0.6% | 3.2% | 0.6% | 1.5% |
| Total | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Number of PAC cases with rare complicationsb | |||||||
| Number per 1000 | 9.3 | 2.5 | 0.1 | 0.0 | 3.0 | 3.0 | 1.4 |
| Percent of PAC patients treated as inpatients | |||||||
| Incomplete abortion | 76.7% | 90.0% | 95.2% | 21.7% | 51.7% | 97.6% | 81.1% |
| Sepsis | 100.0% | 97.8% | 98.1% | 55.0% | 80.6% | 97.6% | 91.5% |
| Shock | 100.0% | 100.0% | 84.0% | 99.5% | 92.6% | 91.2% | 91.7% |
| Lacerations | 73.3% | 100.0% | 100.0% | 83.3% | 87.1% | 100.0% | 95.4% |
| Perforations | 100.0% | 100.0% | 100.0% | 83.3% | 92.9% | 100.0% | 97.4% |
| All Complications | 81.6% | 92.6% | 94.7% | 30.0% | 63.5% | 97.1% | 83.8% |
| Percent of all admissions that are PAC casesc | |||||||
| Percent of all cases | 1.24% | 2.76% | 0.87% | 0.77% | 0.88% | 1.32% | 1.17% |
| Estimated number of PAC cases annually (2012) due to induced abortion | |||||||
| Incomplete abortion | 700 | 4000 | 7700 | 1500 | 3000 | 11 000 | 13 900 |
| Sepsis | 100 | 700 | 1200 | 300 | 900 | 1400 | 2300 |
| Shock | 100 | 800 | 800 | 0 | 500 | 1200 | 1700 |
| Lacerations | 0 | 100 | 0 | 0 | 100 | 0 | 100 |
| Perforations | 100 | 0 | 100 | 0 | 100 | 100 | 200 |
| All complications | 1000 | 5600 | 9800 | 1900 | 4600 | 13 700 | 18 300 |
| parameter | apo-Spr1654 | Spr1654/PLP | Spr1654/PMP |
| data collection statistics | |||
| resolution (Å) (range) | 30.0–1.9 (2.0–1.9) | 29.7–2.2 (2.3–2.2) | 29.8–2.4 (2.5–2.4) |
| space group | P1211 | P1211 | P1211 |
| cell dimensions for a, b, c (Å) | 79.3, 100.0, 110.4 | 79.0, 99.3, 107.6 | 78.9, 99.6, 108.1 |
| α, β, γ (°) | 90.0, 97.7, 90.0 | 90.0, 97.7, 90.0 | 90.0, 97.5, 90.0 |
| no. reflectionsa | |||
| observed | 348 605 (35 719) | 169 716 (16 002) | 213 232 (19 470) |
| unique | 130 980 (13 145) | 79 389 (7743) | 64 471 (6344) |
| mean I/σ(I) | 10.9 (2.3) | 6.4 (2.0) | 7.4 (2.0) |
| completeness (%) | 97 | 95 | 99 |
| Rmerge (%) | 6.3 (44.4) | 9.8 (50.1) | 15.1 (61.6) |
| B-factor from Wilson plot (Å2) | 23.5 | 21.8 | 21.3 |
| refinement statisticsb | |||
| Rcryst (%) | 23.6 (33.4) | 23.8 (32.6) | 24.2 (31.4) |
| Rfree (%) | 26.5 (37.1) | 28.8 (35.9) | 28.5 (34.1) |
| no. non-hydrogen atoms | |||
| total | 13 277 | 13 383 | 12 804 |
| protein | 12 564 | 12 506 | 12 533 |
| ligands | None | 60 | 64 |
| water | 713 | 817 | 207 |
| average B-factor values | |||
| total | 28.3 | 23.6 | 25.4 |
| protein (Å2) | 28.2 | 23.7 | 25.6 |
| ligands (Å2) | None | 24.9 | 25.3 |
| solvent (A°2) | 29.8 | 18.9 | 15.6 |
| RMSD from ideal geometry | |||
| bond length (Å) | 0.014 | 0.012 | 0.011 |
| bond angle (°) | 1.6 | 1.53 | 1.52 |
| Ramachandran plot | |||
| % of residues in preferred regions | 100 | 100 | 100 |
| % of residues in disallowed regions | 0 | 0 | 0 |
| First examiner | Hand | Thyroid | Eye lens | Chest | No. of Film | Exposure time (min) | X-ray tube location |
| Present study | 27.0 | 5.0 | 3.0 | 6.0 | 2.5 | 2.4 | Overcouch |
| Buls et al [14] | 0.64 | 0.45 | 0.55 | nd | 4 | 6.0 | Overcouch |
| Naidu et al. [9]* | NR | 0.2 | 0.04 | NR | 4.6 | 5.9 | Overcouch |
| Sulieman et al. [3] | 27.2 | 5.4 | 3.8 | 6.2 | 2.6 | 2.9 | Overcouch |
| Oztas et al. [10] | 20.0 | 2.0 | 82.0 | NR | 1.7 | 5.7 | undercouch |
| Population n | Age (years)/avg ± SD range | Mass (kg)/Avg ± SD range | Stature (m)/Avg ± SDr ange | BMI/Avg ± SD range |
| 10(f = 3, m = 7) | 35.8 ± 8.822–53 | 53.6 ± 10.444–73 | 1.60 ± 0.091.45–1.75 | 20.7 ± 3.116.4–25.9 |
| Parameter | Pre-control | Post-control | Pre-transport | Post-transport |
| Vital signs | ||||
| Temperature (°C) | 26.86 ± 0.06 | 26.35 ± 0.07 | 27.77 ± 0.06 | 25.63 ± 0.33 |
| Heart rate (beats/min) | 52.80 ± 1.25 | 51.60 ± 1.05 | 55.00 ± 1.74 | 48.00 ± 1.35 |
| Respirations (breaths/min) | 4.85 ± 0.59 | 3.93 ± 0.34 | 3.03 ± 0.38 | 4.40 ± 0.41 |
| Timing parameters (min; measured from time of first disturbance) | ||||
| Bleeding time | 1.94 ± 0.08 | 3.05 ± 0.35 | 2.33 ± 0.36 | 1.36 ± 0.18 |
| Handling time | 11.98 ± 0.72 | 9.63 ± 0.53 | Not recorded | Not recorded |
| CG4 lag time | 2.54 ± 0.50 | 1.52 ± 0.14 | 2.19 ± 0.26 | 2.52 ± 0.39 |
| CG8 lag time | 7.01 ± 0.81 | 5.24 ± 0.14 | 5.69 ± 0.22 | 6.07 ± 0.39 |
| Haematological data | ||||
| Heterophils (%) | 64.87 ± 1.97 | 68.93 ± 2.49 | 63.87 ± 2.69 | 71.80 ± 3.69 |
| Lymphocytes (%) | 32.47 ± 1.73 | 29.00 ± 2.41 | 34.60 ± 2.68 | 26.27 ± 3.52 |
| Monocytes (%) | 1.93 ± 0.32 | 1.33 ± 0.21 | 1.27 ± 0.25 | 1.53 ± 0.27 |
| Eosinophils (%) | 0.73 ± 0.18 | 0.67 ± 0.23 | 0.27 ± 0.12 | 0.40 ± 0.21 |
| Heterophils (cells/μl) | 2877 ± 202.6 | 3789 ± 570.4 | 3784 ± 458.0 | 5045 ± 1109.9 |
| Lymphocytes (cells/μl) | 1412 ± 87.9 | 1466 ± 152.2 | 1873 ± 141.8 | 1386 ± 125.9 |
| Monocytes (cells/μl) | 85 ± 15.8 | 63 ± 10.6 | 75 ± 18.0 | 92 ± 17.2 |
| Eosinophils (cells/μl) | 33 ± 8.4 | 26 ± 8.2 | 14 ± 6.5 | 17 ± 9.8 |
| Funcats | Number of genes assigned an InterAct class | Number of InterAct class 0000 genes | p-value |
| All funcats | 3,447 | 1,089 | - |
| Metabolism | 496 | 120 | 6.0 × 10-4 |
| Protein synthesis | 218 | 55 | 2.6 × 10-2 |
| Energy | 125 | 21 | 1.34 × 10-4 |
| Factor | Coefficients | Standard error | t-value | P value |
| Intercept | −249.9 | 80.11 | −3.120 | 0.02059 |
| Yeast extract (La) | 41.53 | 12.19 | 3.405 | 0.01440 |
| Yeast extract (Qb) | −3.236 | 0.7220 | −4.482 | 0.004182 |
| Cu2+ (L) | 2.071 | 0.4551 | 4.550 | 0.003890 |
| Cu2+ (Q) | −0.0060 | 0.00116 | −5.483 | 0.001539 |
| Ferulic acid (L) | 106.7 | 34.13 | 3.127 | 0.02040 |
| Ferulic acid (Q) | −28.68 | 6.498 | −4.414 | 0.004501 |
| Characteristics | No. of errors | % |
| Gender | ||
| Male | 860 | 64.5 |
| Female | 473 | 35.5 |
| Total | 1333 | 100 |
| Age group | ||
| Less than 1 year | 593 | 44.5 |
| 1-3 years | 249 | 18.7 |
| 4-6 years | 167 | 12.5 |
| 7-9 years | 43 | 3.2 |
| 10-12 years | 281 | 21.1 |
| Total | 1333 | 100 |
| Administration route | ||
| Intravenous | 669 | 50.2 |
| Oral | 342 | 25.7 |
| Inhalation | 222 | 16.6 |
| Topical | 60 | 4.5 |
| Subcutaneous | 24 | 1.8 |
| Intramuscular | 16 | 1.2 |
| Total | 1333 | 100 |
| Location | ||
| PICU | 452 | 33.9 |
| Pediatric wards | 881 | 66.1 |
| Total | 1333 | 100 |
| Drugs: | n | % |
| Adefovir | 1 | 1.9 |
| Boceprevir | 1 | 1.9 |
| Entecavir | 9 | 17.3 |
| Interferon | 4 | 7.7 |
| Pegylated interferon | 9 | 17.3 |
| Lamivudine | 4 | 7.7 |
| Ribavirin | 13 | 25.0 |
| Telapravir | 1 | 1.9 |
| Tenofovir | 10 | 19.2 |
| Total | 52 | 100 |
| Liver | Total Modules | Counter-Intuitive Modules | % Total |
| 1 | 88 | 20 | 22.73 |
| 2 | 143 | 52 | 36.36 |
| 3 | 147 | 67 | 45.58 |
| 4 | 117 | 41 | 35.04 |
| 5 | 191 | 57 | 29.84 |
| 6 | 102 | 30 | 29.41 |
| 7 | 170 | 91 | 53.53 |
| 8 | 143 | 90 | 62.94 |
| 9 | 141 | 68 | 48.23 |
| Average | 40.41 | ||
| Stdev | 13.03 |
| Variables | Entire sample (100%) | Multiple sclerosis§ (46%) | Depressive disorders (32%) | Psychotic and other disorders (22%)* | Statistics (Pearson’s χ2 or ANOVA) |
| Gender, % | p < .0001 | ||||
| Women | 68 | 78 | 66 | 56 | |
| Men | 32 | 22 | 34 | 44 | |
| Age, years (Mean, standard deviation) | 41 ± 13 | 43 ± 11 | 41 ± 14 | 38 ± 13 | F = 5.2; p = .006 |
| Family status, % | p < .0001 | ||||
| Married | 58 | 56 | 50 | 67 | |
| With partner, not married | 22 | 17 | 34 | 21 | |
| Divorced | 11 | 19 | 0 | 0 | |
| Single | 10 | 8 | 16 | 12 | |
| Educational level, % | p = .007 | ||||
| Through Grade 9 | 24 | 22 | 26 | 26 | |
| Through Grade 10 | 33 | 33 | 37 | 31 | |
| High school diploma | 38 | 36 | 37 | 41 | |
| Other | 5 | 9 | 0 | 1 | |
| Spiritual/religious self-categorization, % | n.s. | ||||
| R + S + (religious and spiritual) | 15 | 12 | 16 | 18 | |
| R + S- (religious, not spiritual) | 21 | 19 | 24 | 21 | |
| R-S + (not religious but spiritual) | 15 | 16 | 14 | 14 | |
| R-S- (neither religious nor spiritual) | 50 | 54 | 47 | 46 | |
| Engagement in spiritual activities (0–100)** | |||||
| Existential practices | 54 ± 25 | 43 ± 11 | 60 ± 23 | 62 ± 22 | F = 23.2; p < .0001 |
| Humanistic practices | 65 ± 19 | 65 ± 19 | 66 ± 16 | 65 ± 20 | F = 0.1; n.s. |
| Religious practices | 26 ± 24 | 22 ± 24 | 31 ± 25 | 27 ± 23 | F = 5.1; p = .007 |
| Spiritual (MB) practices | 19 ± 22 | 21 ± 24 | 15 ± 17 | 19 ± 21 | F = 2.6; n.s. |
| Gratitude/Awe | 42 ± 24 | 44 ± 22 | 38 ± 25 | 43 ± 25 | F = 2.2; n.s. |
| Life satisfaction Sum Score (BMLSS-10) (0-100) | 54.6 ± 22.3 | 69.1 ± 17.1 | 42.5 ± 15.6 | 42.5 ± 20.7 | F = 123.1; p < .0001 |
| Life Satisfaction Subdimensions (0–6) | |||||
| Family life | 3.62 ± 1.83 | 4.60 ± 1.45 | 2.83 ± 1.55 | 2.84 ± 1.84 | F = 66.0; p < .0001 |
| Friendships | 3.70 ± 1.73 | 4.49 ± 1.43 | 3.03 ± 1.64 | 3.06 ± 1.73 | F = 46.7; p < .0001 |
| Work situation | 2.82 ± 1.96 | 3.69 ± 1.72 | 2.30 ± 1.75 | 2.18 ± 1.98 | F = 28.2; p < .0001 |
| Myself | 2.81 ± 1.80 | 4.00 ± 1.40 | 1.82 ± 1.44 | 1.88 ± 1.53 | F = 121.5; p < .0001 |
| Where I live | 4.01 ± 1.64 | 4.55 ± 1.42 | 3.50 ± 1.61 | 3.62 ± 1.71 | F = 22.1; p < .0001 |
| Life in general | 3.32 ± 1.69 | 4.39 ± 1.20 | 2.21 ± 1.37 | 2.32 ± 1.66 | F = 142.6; p < .0001 |
| Financial situation | 3.24 ± 1.83 | 3.93 ± 1.55 | 2.82 ± 1.76 | 2.59 ± 1.92 | F = 29.6 ; p < .0001 |
| Future prospects | 2.92 ± 1.60 | 3.64 ± 1.29 | 2.22 ± 1.49 | 2.43 ± 1.66 | F = 43.5; p < .0001 |
| Health situation | 2.45 ± 1.62 | 3.20 ± 1.49 | 1.89 ± 1.39 | 1.77 ± 1.47 | F = 50.3; p < .0001 |
| Abilities to deal withDaily life activities | 3.07 ± 1.62 | 4.03 ± 1.33 | 2.29 ± 1.26 | 2.24 ± 1.47 | F = 94.8; p < .0001 |
| IOP | Visual acuity | ||||||||
| Patient code | Gender | Age Dx | Diagnosis | Gly326Ser | RE | LE | RE | LE | Surgical procedure |
| G62 | Male | 59/65 | OHT/POAG | yes | 30 | 30 | 20/40 | 20/40 | Trabeculectomy LE |
| 01A | Female | 65 | Blind by POAG | yes | ptosis | 20 | HM | HM | - |
| 03A | Female | 63 | OHT with tendency to angle closure | yes | 26 | 20 | 20/30 | 20/30 | Iridotomy |
| 24A | Male | 72 | Advanced POAG | yes | 26 | 26 | HM | 20/40 | - |
| 05A | Male | 75 | Pseudo exfoliation Glaucoma | no | 25 | 17 | - | 20/40 | Trabeculectomy, cataract surgery |
| 08A | Male | 76 | POAG | no | 22 | 23 | 20/50 | 20/40 | Trabaculoplasty |
| Single-Task | Dual-Task | ||
| 200ms before and after HSa | Frontal plane | 0.9529±0.029 | 0.9270±0.044 * |
| Sagittal plane | 0.9505±0.042 | 0.9373±0.046 | |
| Transverse plane | 0.8530±0.150 | 0.8539±0.140 | |
| HS-TOb | Frontal plane | 0.9396±0.042 | 0.91150.092 |
| Sagittal plane | 0.9842±0.019 | 0.9825±0.022 | |
| Transverse plane | 0.9228±0.092 | 0.9274±0.072 |
| Test type | Dataset | Threshold | P-value |
| Unpaired two sample | Aging—old vs. young | 0.0537 | 0.0363 |
| 0.1074 | 0.0023 | ||
| 0.1609 | 8.45 × 10−4 | ||
| 0.2144 | 4.15 × 10−4 | ||
| 0.3208 | 1.40 × 10−4 | ||
| 0.4264 | 3.00 × 10−5 | ||
| 0.6349 | 0 | ||
| 0.8476 | 0 | ||
| 1 | 1 | ||
| Connectome Leipzig | 0.0535 | 0.4387 | |
| 0.1069 | 0.3073 | ||
| 0.1604 | 0.2436 | ||
| 0.2138 | 0.1864 | ||
| 0.3206 | 0.1765 | ||
| 0.4277 | 0.1066 | ||
| 0.6395 | 0.4672 | ||
| 0.8505 | 0.0828 | ||
| 1 | 1 | ||
| Paired two sample | Aging—rest vs. MS | 0.0533 | 2.00 × 10−5 |
| 0.1067 | 1.50 × 10−5 | ||
| 0.1599 | 3.00 × 10−5 | ||
| 0.2131 | 3.50 × 10−5 | ||
| 0.3193 | 2.50 × 10−5 | ||
| 0.4243 | 5.50 × 10−5 | ||
| 0.6321 | 3.10 × 10−4 | ||
| 0.8411 | 2.50 × 10−4 | ||
| 1 | 1 | ||
| Aging—rest vs. visual | 0.0535 | 9.80 × 10−5 | |
| 0.107 | 2.00 × 10−5 | ||
| 0.1604 | 5.00 × 10−6 | ||
| 0.2138 | 5.00 × 10−6 | ||
| 0.3202 | 0 | ||
| 0.4251 | 5.00 × 10−6 | ||
| 0.633 | 2.50 × 10−6 | ||
| 0.8415 | 2.00 × 10−6 | ||
| 1 | 1 |
| cis-acting | trans-acting | |
| KS p-value 10-6 - 10-15 | 4,484 | 646 |
| KS p-value 10-15 - 10-30 | 5,311 | 500 |
| Correlation with BMI z-score1) | |||||
| Without MS | With MS | P2) | WHO | CDC | |
| Number of participants (%) | 185 (75.2) | 61 (24.8) | - | - | - |
| Females, n (%) | 97 (52.4) | 25 (41.0) | 0.141 | - | - |
| Pubertal Stage (pre-pub (%))3) | 30 (16.2) | 8 (13.1) | 0.684 | - | - |
| Age (years) | 12.7 ± 1.8 | 13.4 ± 2.1 | 0.017 | 0.057 | 0.122 |
| Height (cm) | 158.5 ± 8.9 | 162.8 ± 9.9 | 0.002 | 0.189** | 0.277** |
| Weight (kg) | 78.0 (68.0-89.0) | 90.2 (76.0-113.5) | <0.001 | 0.673** | 0.726** |
| BMI (kg/m2) | 30.55 (28.15-34.08) | 34.52 (30.20-39.14) | <0.001 | 0.848** | 0.865** |
| BMI z-score (CDC) | 2.20 ± 0.29 | 2.43 ± 0.31 | <0.001 | 0.933** | - |
| BMI z-score (WHO) | 3.00 ± 0.62 | 3.51 ± 0.86 | <0.001 | - | 0.933** |
| Waist circumference (cm) | 99.0 (91.8-106.5) | 105.0 (96.5-118.0) | <0.001 | 0.736** | 0.778** |
| Waist / Height | 0.630 ± 0.066 | 0.668 ± 0.081 | 0.002 | 0.794** | 0.783** |
| Blood pressure | |||||
| Systolic (mmHg)4) | 116 ± 12 | 135 ± 13 | <0.001 | 0.323** | 0.360** |
| Diastolic (mmHg)4) | 63 ± 8 | 70 ± 12 | 0.001 | 0.267** | 0.218** |
| Lipid profile | |||||
| TG (mg/dl) | 71.0 (53.1-100.6) | 126.7 (81.5-181.5) | <0.001 | 0.186** | 0.185** |
| HDLc (mg/dl) | 43.0 (38.3-49.0) | 35.0 (32.0-38.4) | <0.001 | −0.215** | −0.223** |
| TC (mg/dl) | 150.8 (134.5-174.0) | 164.0 (142.0-189.2) | 0.038 | 0.105 | 0.084 |
| LDLc (mg/dl) | 92.0 (76.0-109.8) | 101.0 (83.5-119.4) | 0.055 | 0.145* | 0.126* |
| Glucose metabolism | |||||
| Glucose (mg/dl) | 83.0 (77.0-89.6) | 88.0 (80.0-93.8) | 0.005 | 0.043 | 0.046 |
| Insulin (μU/ml) | 15.9 (12.2-22.1) | 23.3 (14.6-33.3) | <0.001 | 0.421** | 0.440** |
| HOMA-IR | 3.18 (2.43-4.52) | 4.94 (3.34-7.06) | <0.001 | 0.410** | 0.429** |
| Inflammatory mediator | |||||
| CRP (mg/l)5) | 1.61 (0.84-4.05) | 2.30 (1.00-4.59) | 0.072 | 0.326** | 0.302** |
| Parameter | Correct | ||
| Study 1, No. (%) | Study, No. (%) | p | |
| Registration of insertion date | 337 (42.3) | 339 (50.1) | 0.003 |
| Registration of daily surveillance | 779 (97.7) | 660 (98.2) | 0.52 |
| Registration of dressing change date | 322 (41.2) | 328 (49.1) | 0.003 |
| Registration of set replacement date | 74 (45.4) | 65 (43.3) | 0.71 |
| Use of connectors (split-septum) in all hubs | 660 (83.7) | 615 (92.2) | <0.001 |
| Characteristics | LGSOCNo. of patients (%) | HGSOCNo. of patients (%) | p values |
| All cases | 25 | 55 | |
| Mean Age, years (± SEM) | 49.8 ± 3.0 | 56.8 ± 1.5 | 0.03 |
| Type of primary surgery | |||
| Cytoreduction | 25 | 55 | – |
| Residual tumor after primary surgery (cm) | |||
| 0 | 22 | 36 | 0.06# |
| < 1 | 3 | 14 | |
| > 1 | 0 | 5 | |
| FIGO Stage | |||
| I/II | 10 (40) | 8 (15) | 0.01 |
| III/IV | 15 (60) | 47 (85) | |
| Primary chemotherapy | |||
| None | 3 (12) | 1 (1.8) | 0.08§ |
| Platinum/paclitaxel | 17 (68.0) | 48 (87.3) | |
| Platinum-based | 4 (16.0) | 5 (9.1) | |
| Other | 1 (4) | 1 (1.8) |
| p-Nephrin | Nck (with p-Nephrin) | Nck (with p-TIR) | N-WASP | |
| Null hypothesis | Single Exp. | Single Exp. | Single Exp. | Single Exp. |
| Alternate hypothesis | Double Exp. | Double Exp. | Double Exp. | Double Exp. |
| p value | <0.0001 | <0.0001 | <0.0001 | <0.0001 |
| Conclusion (alpha = 0.05) | Reject null hypo. | Reject null hypo. | Reject null hypo. | Reject null hypo. |
| Preferred model | Double Exp. | Double Exp. | Double Exp. | Double Exp. |
| F (DFn, DFd) | 64.16 (2282) | 47.33 (2635) | 46.72 (2379) | 48.64 (2379) |
| 2014 | 2014+>2 HR | 2015 | 2015+>2 HR | |||||
| HR | VHR | HR | VHR | HR | VHR | HR | VHR | |
| N | 166 | 37 | 131 | 72 | 100 | 103 | 65 | 138 |
| % | 82% | 18% | 64.5% | 35.5% | 49% | 51% | 32% | 68% |
| 4y bDFS % (95% CI) | 89 (82–93) | 83 (66–92) | 89 (82–93) | 84 (73–91) | 90 (82–95) | 85 (75–91) | 92 (80–97) | 85 (78–90) |
| 4y MFS % (95% CI) | 90 (84–94) | 83 (63–93) | 92 (84–96) | 85 (72–92) | 93 (85–97) | 85 (75–92) | 93 (78–98) | 87 (80–92) |
| 4y CSS % (95% CI) | 100 | 92 (70–98) | 100 | 95 (82–99) | 100 | 97 (88–99) | 100 | 98 (91–99) |
| 4y OS % (95% CI) | 96 (92–99) | 85 (64–94) | 98 (93–100) | 87 (74–94) | 96 (89–99) | 92 (83–96) | 100 | 91 (84–96) |
| Day | Parameter | Reference§ | HFE mean | LFE mean | P-value |
| 0 | Cholesterol (mg/dL) ♦ | 80–120 | 112.33 ± 20.6 | 122.22 ± 25.9 | 0.1904 |
| Triglycerides (mg/dL)○ | 0–14 | 14.51 ± 5.6 | 12.62 ± 5.2 | 0.1675 | |
| Globulin (g/dL)○ | 3.00–3.48 | 3.71 ± 0.5 | 3.51 ± 0.4 | 0.1045 | |
| AST (U/L)○ | 78–132 | 82.25 ± 16.9 | 78.50 ± 42.8 | 0.5606 | |
| ALT (U/L)○ | 11–40 | 20.25 ± 6.8 | 21.20 ± 5.0 | 0.6058 | |
| GGT (U/L)♦ | 6.1–17.4 | 17.35 ± 5.1 | 18.15 ± 4.7 | 0.6084 | |
| ALP (U/L)○ | 0–488 | 308.25 ± 89.4 | 322.35 ± 115.7 | 0.4818 | |
| Albumin (g/dL)♦ | 3.03–3.55 | 2.78 ± 0.2 | 2.82 ± 0.2 | 0.4793 | |
| Protein (g/dL)○ | 6.74–7.46 | 6.49 ± 0.5 | 6.33 ± 0.4 | 0.1894 | |
| 70 | Cholesterol (mg/dL)♦ | 80–120 | 123.15 ± 26.5 | 147.45 ± 17.7 | 0.0017* |
| Triglycerides (mg/dL)○ | 0–14 | 11.61 ± 4.6 | 12.63 ± 3.4 | 0.6455 | |
| Globulins (g/dL)○ | 3.00–3.48 | 3.41 ± 0.4 | 3.41 ± 0.3 | 0.5074 | |
| AST (U/L)○ | 78–132 | 86.50 ± 12.6 | 82.30 ± 13.7 | 0.2179 | |
| ALT (U/L)○ | 11–40 | 29.05 ± 5.2 | 28.45 ± 3.5 | 0.3149 | |
| GGT (U/L)○ | 6.1–17.4 | 15.25 ± 5.2 | 18.95 ± 3.3 | 0.0150* | |
| ALP (U/L)♦ | 0–488 | 443.30 ± 96.8 | 382.30 ± 143.2 | 0.6560 | |
| Albumin (g/dL)○ | 3.03–3.55 | 3.03 ± 0.2 | 3.07 ± 0.1 | 0.2284 | |
| Protein (g/dL)○ | 6.74–7.46 | 6.44 ± 0.4 | 6.48 ± 0.3 | 0.9892 |
| Talairach coordinates | |||||||
| Hemisphere | BA | x | y | z | Volume (mm3) | Mean t | |
| REGION OF ACTIVATION | |||||||
| Medial frontal gyrus | Left/Right | 6/8 | 5 | 18 | 43 | 2590 | 5.40 |
| Anterior insula | Right | 13 | 41 | 18 | 5 | 4015 | 5.67 |
| Anterior insula | Left | 13 | −30 | 18 | 5 | 1153 | 5.13 |
| Dorsolateral prefrontal gyrus | Right | 9/10 | 38 | 42 | 27 | 888 | 4.94 |
| Precentral gyurs | Right | 9 | 43 | 26 | 34 | 1262 | 5.10 |
| Middle frontal gyrus | Right | 9 | 45 | 12 | 36 | 2422 | 5.18 |
| Middle frontal gyrus | Left | 9 | −41 | 29 | 37 | 67 | 4.72 |
| Middle temporal gyrus | Right | 21 | 56 | −25 | −5 | 191 | 4.86 |
| Inferior parietal lobe | Right | 40 | 48 | −44 | 37 | 2744 | 5.42 |
| Inferior parietal lobe | Left | 40 | −46 | −37 | 41 | 595 | 5.05 |
| Precuneus | Right | 7 | 10 | −68 | 39 | 299 | 5.01 |
| Nucleus caudatus | Right | 13 | 8 | 12 | 224 | 5.38 | |
| Thalamus | Right | 10 | −12 | 10 | 113 | 4.82 | |
| Thalamus | Left | −7 | −16 | 9 | 131 | 5.01 | |
| REGION OF DEACTIVATION | |||||||
| Anterior cingulate gyrus | Left/Right | 32 | −2 | 36 | −3 | 3226 | −5.23 |
| Superior frontal gyrus | Left | 8 | −17 | 26 | 45 | 315 | −4.90 |
| Posterior cingulate gyrus | Left/Right | 30 | −2 | −53 | 20 | 560 | −5.21 |
| Variable | Rater | Group activity | Control | t | df | p (two-tailed) | Effect size | ||
| Mean | SD | Mean | SD | ||||||
| 'Engagement' | TR | 3.55 | 1.41 | 2.72 | 1.96 | 4.84 | 92 | 0.000 | 0.71 |
| Observer | 3.73 | 1.35 | 3.31 | 1.7 | 3.43 | 96 | 0.001 | 0.49 | |
| Positive mood | TR | 2.48 | 1.07 | 1.76 | 1.28 | 6.04 | 91 | 0.000 | 0.89 |
| Observer | 1.52 | 1.07 | 1.24 | 1.29 | 3.12 | 96 | 0.002 | 0.45 | |
| Asleep | TR | 1.14 | 1.62 | 1.87 | 2.15 | −3.87 | 89 | 0.000 | −0.58 |
| Observer | 1.19 | 1.63 | 1.48 | 2.09 | −1.94 | 94 | 0.056 | −0.28 |
| Protein | BQ00140 [49473701] | BQ00720 [49473755] | BQ03880 [49474026] | BQ12030 [49474691] | BQ07670 [49474353] | BQ11900 [49474679] |
| Length | 222 | 83 | 198 | 91 | 336 | 172 |
| Bra. jap. | 5e-18 (1.10) | 2e-09 (1.08) | 2e-20 (0.97) | 2e-07 (1.05) | 5e-46 (1.06) | 1e-17 (0.98) |
| Rho. pal. | 3e-14 (1.11) | 3e-09 (1.06) | 2e-18 (0.97) | 1e-07 (1.37) | - | - |
| Agr. tum. | 5e-13 (1.06) | 6e-11 (1.02) | 1e-26 (0.98) | 2e-12 (1.03) | 7e-66 (0.97) | 2e-24 (1.37) |
| Sino. meli. | 3e-20 (1.00) | 2e-13 (1.02) | 7e-23 (0.98) | 2e-14 (0.98) | 5e-62 (1.02) | - |
| Bru. mel. | 9e-39 (0.98) | 4e-19 (1.04) | 1e-38 (0.97) | 3e-13 (0.54) | 8e-70 (0.96) | 2e-26 (1.02) |
| Bru. suis | 4e-39 (0.98) | 4e-19 (0.96) | 1e-38 (1.03) | 6e-20 (0.99) | 8e-70 (0.98) | 6e-27 (0.98) |
| Meso. loti | 3e-25 (1.07) | 2e-13 (1.18) | 1e-25 (0.98) | 4e-16 (0.99) | 2e-67 (0.95) | 1e-26 (1.03) |
| Meso. sp. | 7e-18 (1.06) | 2e-13 (1.02) | 2e-25 (0.98) | 2e-14 (1.02) | 3e-61 (0.93) | 7e-31 (1.02) |
| B. henselae | 1e-92 (0.97) | 6e-43 (1.00) | 5e-92 (1.00) | 2e-39 (1.00) | e-158 (1.01) | 3e-81 (1.00) |
| B. Quintana | e-127 (1.00) | 4e-43 (1.00) | e-107 (1.00) | 1e-43 (1.00) | 0.0 (1.00) | 1e-91 (1.00) |
| Non – Rizobiale | Bdell. bacter. 0.25 (1.77) | Sil. sp. 0.46 (0.82) | Vibrio fischeri 0.005 (2.49) | St. pyogenes 0.12 (0.86) | St. agalactiae 0.38 (2.65) | Croc. watsonii 6.1 (2.85) |
| B. subtilis | S. aureus | A. niger | S. cerevisiae | |
| (a) Activity per full feces sample | ||||
| Feces producer (FP) | P = 0.440 | P = 0.098 | P = 0.005 | P <0.0001 |
| Mother-offspring interactions (MO) | P = 0.808 | P = 0.104 | P = 0.342 | P = 0.051 |
| FP : MO | P = 0.553 | P = 0.934 | P = 0.068 | P = 0.215 |
| (b) Activity per mg of feces | ||||
| Feces producer (FP) | P <0.0001 | P = 0.008 | P = 0.095 | P = 0.080 |
| Mother-offspring interactions (MO) | P = 0.813 | P = 0.575 | P = 0.052 | P = 0.078 |
| FP : MO | P = 0.812 | P = 0.731 | P = 0.037 | P = 0.089 |
| Disease stage | Number of patients | HU, IFN or combination pretreatment months from diagnosis median (range) | Months on imatinib median (range) | WBC x109/L PB median (range) PLT x109/L PB median (range) | Blasts in PB (%) median (range) | Ph+ cells (%) median (range) | BCR-ABL (%) median (range) | BCR-ABL KD mutation Number of patients |
| Dg | 13 | NA | NA | 67 (22-457) | 2 (1-5) | 100 | 132 (61-312) | NA |
| 481 (130-824) | ||||||||
| AP/BC | 12 | 24 (2-106) | 24 (8-55) | 34 (1.17-147) | 18 (8-76) | 100 | 510 (103-2500) | 3 |
| 81 (14-562) | ||||||||
| Hr | 15 | 18 (1-66) | 22 (10-54) | 16 (6-28) | 10; 12 | 100 (32-100) | 80 (23-827) | 15 |
| 448 (71-1779) | ||||||||
| TF | 14 | 14 (1-68) | 18 (12-67) | Phy | 0 | 100 (40-100) | 32 (11-91) | 4 |
| Phy | ||||||||
| MMR | 16 | 3 (1-11) | 16 (7-24) | Phy | 0 | 0 | 0.02 (0.001-0.1) | NA |
| Phy |
| threshold | Geuvadis data | GenoExp data | ||||||
| Lasso | ENET | LMM | BSLMM | Lasso | ENET | LMM | BSLMM | |
| 0.05 | 2252 | 2262 | 2447 | 2567 | 1785 | 1414 | 1560 | 1758 |
| 0.10 | 1144 | 1145 | 1145 | 1266 | 831 | 788 | 734 | 826 |
| 0.20 | 420 | 422 | 383 | 466 | 315 | 309 | 276 | 323 |
| 0.30 | 161 | 162 | 152 | 178 | 156 | 148 | 124 | 160 |
| 0.40 | 75 | 75 | 65 | 76 | 70 | 70 | 56 | 70 |
| 0.50 | 33 | 33 | 25 | 32 | 36 | 32 | 27 | 37 |
| 0.60 | 14 | 14 | 12 | 14 | 25 | 21 | 20 | 24 |
| Influenza, Tdap, HZ vaccines (2014) | Influenza, Tdap, HZ, pneumococcal vaccines (2014) | |
| Aged 60-64 years | Aged ≥65 years | |
| % (95% CI) | % (95% CI) | |
| Overall complianceb | 6.61 (5.94, 7.28) | 11.21 (9.51, 12.91) |
| Compliance by state: | ||
| California | 5.51 (2.39, 12.17) | 13.53 (9.14, 19.57) |
| Colorado | 9.52 (6.69, 13.38) | 14.82 (11.46, 18.96) |
| Georgia | 6.12 (3.78, 9.75) | 6.02 (3.81, 9.38) |
| Massachusetts | 6.78 (4.80, 9.51) | 10.32 (7.75, 13.61) |
| Mississippi | 4.13 (1.61, 10.21) | 2.99 (1.53, 5.77) |
| Rhode Island | 5.60 (3.95, 7.89) | 9.43 (6.93, 12.72) |
| Tennessee | 4.35 (2.24, 8.27) | 7.71 (5.15, 11.39) |
| Texas | 7.76 (5.14, 11.56) | 10.34 (6.89, 15.26) |
| Vermont | 14.40 (10.74, 19.05) | 18.26 (14.48, 22.76) |
| Virginia | 7.60 (5.53, 10.36) | 10.63 (7.96, 14.06) |
| Dictionary | Token features | Linguistic features | Semantic features | ||
| TUI | CUI | ||||
| Baseline I | X | ||||
| Baseline II | X | ||||
| Experiment I | X | X | X | ||
| Experiment II | X | X | X | X | |
| Experiment III | X | X | X | X |
| First author, [Ref] year, country | Study design | No. of case/controls (cohort) | Exposure category | Risk estimates (95% CI) | Adjustment for confounders | ||||
| Age | BMI | Parity | HRT | OC use | |||||
| Neill et al. [15], 2013, Australia | Population-based case-control | 1398/740 | Ever vs. Never≥ 2 week vs. Never | 1.19 (0.86−1.65)0.77 (0.41−1.45) | √ | √ | √ | √ | √ |
| Setiawan et al. [16], 2012, USA | Cohort | 620/64000 | Ever vs. Never≥ 6 years vs. Never | 0.96 (0.81−1.13)0.80 (0.61−1.06) | √ | √ | √ | √ | √ |
| Walter et al. [17], 2011, USA* | Cohort | 214/32059 | Ever vs. Never≥4 d/week and ≥ 4 years vs. Never | 1.05 (0.72−1.54)0.99 (0.48−2.01) | √ | √ | × | √ | × |
| Bodelon et al. [18], 2009, USA | Population-based case-control | 410/356 | Ever vs. Never≥ 10 years vs. Never | 1.11 (0.70−1.77)1.80 (0.91−3.56) | √ | √ | × | √ | × |
| Viswanathan et al. [19], 2008, USA* | Cohort | 747/82971 | Ever vs. Never≥ 6–7 d/weeks vs. Never | 1.11 (0.70−1.77)0.86 (0.57−1.30) | × | √ | √ | √ | √ |
| Moysich et al. [20], 2005, USA | Hospital-based case-control | 427/427 | Ever vs. Never≥ 10 years vs. Never | 0.96 (0.60−1.54)0.49 (0.15−1.60) | √ | √ | √ | × | × |
| Friis et al. [21], 2002, Denmark | Cohort | 58/26272 | Ever vs. Never | 1.10 (0.80−1.40) | × | × | × | × | × |
| Resistance pattern | N |
| Double drugs | |
| MNZ + LVX | 12 (28.6) |
| MNZ + CAM | 3 (7.1) |
| Triple drugs | |
| CAM + MNZ + LVX | 5 (11.9) |
| Gene name | AGI code | Forward primer sequence | Reverse primer sequence |
| ACL5 | At5g19530 | ACCGTTAACCAGCGATGCTTT | CCGTTAACTCTCTCTTTGATTC |
| XTH3 | At3g25050 | GTGTTTTTGTAGTAACGTTATGG | GGTTGGATTGAACCAAAGCAA |
| VND6 | At5g62380 | ATGGAAAGTCTCGCACACAT | CTCTTCCACATAACTCTTGG |
| VND7 | At1g71930 | CGATGCATCAATATGGCAAC | AGGGAAGCATCCAAGAGAAT |
| CNA | At1g52150 | GGTATTTGCTGATTCATGAGC | ATGGTTTACACTTGACAGAGC |
| ATHB8 | At4g32880 | AGCGTTTCAGCTAGCTTTTGAG | CAGTTGAGGAACATGAAGCAGA |
| MP/ARF5 | At1g19850 | GATGATCCATGGGAAGAGTT | TAAGATCGTTAATGCCTGCG |
| TMO5L1 | At1g68810 | CACCACCAAAACGGATAAAG | CGTTTTGAGACGCATAGCTT |
| PIN1 | At1g73590 | CTTAGCACTGCGGTGATATT | TTGCTGAGCTCCTACTTAAG |
| PIN6 | At1g77110 | CTATCGTACAGGCTGCTCTA | CTCCTCAAGAACAACTCTTA |
| YUC2 | At4g13260 | ATGTGGCTAAAGGGAGTGAA | AACTTGCCAAATCGAAACCC |
| IRT1 | At4g19690 | GTCTAATCACTCTAGCCATTGA | TGTATACTCAGCCTGGAGGA |
| PXY/TDR | At5g61480 | CGGTTACATTGCACCAGAAT | GCTTGTACACAACAACGCAA |
| SAC51 | At5g64340 | AATTGCCAGGCTGAGTACTT | GACCGACCTACTATATCCTT |
| ACT8 | At1g49240 | GTGAGCCAGATCTTCATTCGTC | TCTCTTGCTCGTAGTCGACAG |
| Culprit plaque | Totals | |||
| Acute rupture | Healing rupture | Stable plaque | ||
| N | 51 | 5 | 16 | 72 |
| Age, years ± SD | 52 ± 11 | 52 ± 10 | 48 ± 8 | 51 ± 11 |
| Men: women | 47:4 | 5:0 | 14:2 | 66:6 |
| White:Black | 38:13 | 3:2 | 12:4 | 53:19 |
| Heart weight, g ± SD | 504 ± 127 | 605 ± 125 | 466 ± 87 | 511 ± 134 |
| Diabetic | 9 | 0 | 1 | 10 |
| Hypertensive | 13 | 4 | 5 | 22 |
| Hypercholesterolemic | 25 | 3 | 9 | 37 |
| Smokers | 26 | 3 | 7 | 36 |
| Number of plaques studied | 100* | 7 | 28 | 135 |
| Acute ruptures | 61 | 0 | 0 | 61 |
| Healing ruptures | 8 | 0 | 0 | 15 |
| Thin cap FA | 20 | 7 | 11 | 31 |
| FA | 11 | 0 | 17 | 28 |
| Sr. no. | Type of fertilizer | Alpha track densities (Tcm−2d−1) root lower stem upper stem | Leaves | Fruit | AM ± SE* | ||
| 1. | WF | 9.9 | 2.5 | 1.9 | 1.6 | 3.1 | 3.8 ± 1.5 |
| 2. | CDM | 11.8 | 3.3 | 2.7 | 2.4 | 3.8 | 4.8 ± 1.7 |
| 3. | DAP | 20.9 | 5.8 | 4.9 | 4.4 | 6.6 | 8.5 ± 3.2 |
| 4. | NPK | 16.3 | 3.8 | 3.6 | 3.4 | 4.7 | 6.3 ± 2.5 |
| 5. | SSP | 15.2 | 4.7 | 3.8 | 3.3 | 4.9 | 6.5 ± 2.2 |
| 6. | PF | 20.2 | 5.3 | 4.4 | 4.3 | 5.8 | 7.9 ± 3.1 |
| 7. | ZnSO4 | 18.5 | 4.7 | 3.8 | 3.6 | 5.3 | 7.2 ± 2.8 |
| 8. | URA | 13.3 | 3.8 | 3.3 | 3.1 | 4.7 | 5.7 ± 1.9 |
| 9. | OF | 12.9 | 3.1 | 3.1 | 0.9 | 4.2 | 5.2 ± 1.9 |
| Integration Block | Frame Rate (frames per second) |
| L&K C 9 × 9 Integration Block | 0.3 |
| L&K C 9 × 9 SIB | 0.9 |
| L&K C 9 × 9 SIB | 3.6 |
| L&K ASM 9 × 9 SIB and propagation | 11.9 |
| L&K C 5 × 5 Integration Block | 1.3 |
| L&K C 5 × 5 SIB | 3.3 |
| L&K C 5 × 5 SIB and propagation | 8.9 |
| L&K ASM 5 × 5 SIB and propagation | 28.8 |
| Characteristics | N | % |
| Median age, years (range) | 62.1 (21.1–79.7) | |
| Male / Female | 65/44 | 59.6/40.4 |
| Median Karnofsky performance status (range) | 70 (30–90) | |
| Extent of surgery | ||
| - Complete resection | 82 | |
| - Partial resection | 27 | 24.8 |
| Radiotherapy | 84 | 77.1 |
| Median OS, months (range) | 13.2 (1.5–141.4) | |
| Median PFS, months (range) | 7.9 (0.9–132.4) |
| Variables | N | Connexin 43 expression | p value | |||
| - | + | ++ | +++ | |||
| Total, n (%) | 243 | 148 (60.9) | 22 (9.1) | 45 (18.5) | 28 (11.5) | |
| Age (years) | ||||||
| < 70 | 132 (54.3) | 74 (50.0) | 20 (90.9) | 20 (44.4) | 18 (64.3) | 0.21 |
| ≥ 70 | 111 (45.7) | 74 (50.0) | 2 (9.1) | 25 (55.6) | 10 (35.7) | |
| BMI (kg/m2) | ||||||
| ≤ 25 | 136(56.0) | 83 (56.1) | 8 (36.4) | 19 (42.2) | 26 (92.9) | 0.29 |
| > 25 | 107(44.0) | 65 (43.9) | 14 (63.6) | 26 (57.8) | 2 (7.1) | |
| Prostate Volume (ml) | ||||||
| ≤ 35 | 136(56.0) | 92 (62.2) | 6(27.3) | 22(48.9) | 16 (57.1) | 0.07 |
| > 35 | 107(44.0) | 56 (37.8) | 16 (72.7) | 23 (51.1) | 12 (42.9) | |
| PSA level (ng/ml) | ||||||
| < 10 | 141 (58.0) | 69 (46.6) | 5 (22.7) | 44 (97.8) | 23 (82.1) | <0.001 |
| ≥ 10 | 102 (42.0) | 79 (53.4) | 17 (77.3) | 1 (2.2) | 5 (17.9) | |
| Gleason Score | ||||||
| 2-6 | 134 (55.1) | 67 (45.3) | 15 (68.2) | 29 (64.4) | 23 (82.1) | <0.001 |
| 7 | 70 (28.8) | 46 (31.1) | 5 (22.7) | 14 (31.1) | 5 (17.9) | |
| 8-10 | 39 (16.0) | 35 (23.6) | 2 (9.1) | 2 (4.4) | 0 (0) | |
| pT stage | ||||||
| T1 | 89 (36.6) | 32 (21.6) | 15 (68.2) | 25 (55.6) | 17 (60.7) | <0.001 |
| T2 | 130 (53.5) | 94 (63.5) | 6 (27.3) | 19 (42.2) | 11 (39.3) | |
| T3 | 24 (9.9) | 22 (14.9) | 1 (4.5) | 1 (2.2) | 0 (0) | |
| Extracapsular extension | ||||||
| Yes | 15 (6.2) | 14 (9.5) | 1 (4.5) | 0 (0) | 0 (0) | 0.007 |
| No | 228 (93.8) | 134 (90.5) | 21 (95.5) | 45 (100) | 28 (100) | |
| Seminal vesicle invasion | ||||||
| Yes | 11 (4.5) | 10 (6.8) | 1 (4.5) | 0 (0) | 0 (0) | 0.028 |
| No | 232 (95.5) | 138 (93.2) | 21 (95.5) | 45 (100) | 28 (100) | |
| Positive surgical margin | ||||||
| Yes | 37 (15.2) | 28 (18.9) | 7 (31.8) | 2 (4.4) | 0 (0) | 0.007 |
| No | 206 (84.8) | 120 (81.1) | 15 (68.2) | 43 (95.6) | 28 (100) |
| A) Factors differentiating those who do / do not recover during follow up | Odds ratio (95% CI) | p-value | Interpretation |
| Ethnicity(Caucasian vs non-Caucasian) | 14.19 (2.52, 122.63) | 0.007 | Non-Caucasians – less likely to recover from proteinuria |
| eGFR | 1.04 (1.02, 1.08) | 0.007 | Low eGFR at proteinuria onset - less likely to recover |
| Azathioprine use | 0.093 (0.01, 0.78) | 0.044 | Use of Azathioprine at proteinuria onset – less likely to recover |
| Haematological involvement | 0.13 (0.03, 0.53) | 0.007 | Haematological involvement – less likely to recover |
| Cardiorespiratory involvement | 11.22 (1.57, 107.54) | 0.022 | Cardiorespiratory involvement - more likely to recover |
| B) Factors influencing time to recovery from proteinuria | HR (95% CI) | p-value | |
| Age (years) | 1.38 (1.1, 1.8) | 0.007 | Younger patients - less likely to recover |
| eGFR | 1.0 (1.0, 1.1) | 0.036 | Lower eGFR - less likely to recover |
| Haematological involvement | 0.3 (0.1, 0.8) | 0.016 | Haematological involvement - less likely to recover |
| Original EpiPen | New-look EpiPen | Anapen | |
| Step 1: Remove safety caps | Form a fist around EpiPen and remove gray safety cap | Form a fist around EpiPen and pull off blue safety release | 1. Pull off black needle shield |
| 2. Pull off gray safety cap from red button | |||
| Step 2: Place against thigh | Place black end against outer mid thigh (with or without clothing) | Place orange end against outer mid thigh (with or without clothing) | Place needle end firmly against outer mid-thigh (with or without clothing) |
| Step 3: Push and inject | Push down hard until a click is heard or felt and hold in place for 10 seconds | Push down hard until a click is heard or felt and hold in place for 10 seconds | Press red button so it clicks and hold in place for 10 seconds. |
| Step 4: Remove and massage site | Remove EpiPen and do not touch needle. Massage injection site for 10 seconds | Remove EpiPen. Massage injection site for 10 seconds. | Remove Anapen and do not touch needle. Massage injection site for 10 seconds. |
| Shared by: | C. graminicola | Shared by: | C. sublineola | ||
| OrthoMCL | RBH | OrthoMCL | RBH | ||
| CgramCsubChigg | 9281 | 9264 | Cgram:Csub:Chigg | 9323 | 9252 |
| Cgram:Csub | 1015 | 1018 | Csub:Cgram | 1036 | 1057 |
| Cgram:Chiggs | 473 | 560 | Csub:Chiggs | 333 | 500 |
| Cgram only | 134 | 1164 | Csub only | 456 | 2502 |
| Not Characterized | 1103 | 0 | Not Characterized | 2163 | 0 |
| Total | 12006 | 12006 | Total | 13311 | 13311 |
| Pathways | Infection related | Pathways in |
| pathways | cancer | |
| Gene No. | 1082 | 326 |
| Overlap between pathways in cancer and infection related pathways | 169 | |
| Hum-Mtb targeted Human proteins Overlap with HP-PPI targeted human proteins | 204 | 29 |
| Overlap of the three datasets | 20 |
| n = 58 | Mean ± SD | Quartiles25%50%75% |
| Leptin (ng/mL) | 18.4 ± 9.3 | 10.5 |
| 16.5 | ||
| 24.7 | ||
| Total adiponectin (μg/mL) | 23.1 ± 8.3 | 7.9 |
| 11.5 | ||
| 14.1 | ||
| Leptin/adiponectin ratio (LAR) | 0.9 ± 0.6 | 0.9 |
| 1.5 | ||
| 2.8 | ||
| HMWA (μg/mL) | 3.5 ± 1.4 | 2.4 |
| 3.4 | ||
| 4.4 | ||
| Leptin/HMWA ratio | 7.3 ± 9.5 | 3.0 |
| 5.1 | ||
| 8.0 |
| Allele | Study | Proportions of alleles | Adjusted‡ odds ratios of AD (95% CI, p) | |
| Controls | AD | |||
| HLA-B7 | Previous† | 10/112 | 26/110 | 3.1 (1.2–8.0, 0.02) |
| Replication | 32/286 | 46/282 | 1.9 (1.03–3.4, 0.04) | |
| All | 42/398 | 72/392 | 2.3 (1.4–3.7, 0.001) | |
| HLA-Cw*0702 | Previous† | 14/112 | 28/108 | 2.7 (1.1–6.3, 0.03) |
| Replication | 34/286 | 48/282 | 1.7 (0.95–2.9, 0.08) | |
| All | 48/398 | 76/390 | 2.0 (1.3–3.1, 0.003) |
| Space group | P21 |
| Unit cell dimensions | |
| a (Å) | 42.2 |
| b (Å) | 64.3 |
| c (Å) | 48.6 |
| β (°) | 102.1 |
| Number of molecules in the unit cell | 2 |
| Resolution range (Å) | 36.0 - 1.2 |
| The range of the highest shell | 1.24 - 1.20 |
| Total number of measured reflections | 727277 |
| Number of unique reflections | 62459 |
| Rsym (%) | 5.0(22.1) |
| I/σ(I) | 17.8(3.6) |
| Completeness of data (%) | 98.5(87.1) |
| Rcryst (%) | 15.8 |
| Rfree (%) 5% of reflections | 18.6 |
| Protein atoms | 2101 |
| Water oxygen atoms | 434 |
| Phosphate ion atoms (1) | 5 |
| Atoms from PEG | 40 |
| R.m.s.d in bond lengths (Å) | 0.008 |
| R.m.s.d in bond angles (°) | 1.2 |
| R.m.s.d in torsion angles (°) | 16.8 |
| B-factors (Å2) | |
| B-factor from Wilson plot (Å2) | 12.3 |
| Mean B-factor for main chain atoms (Å2) | 11.2 |
| Mean B-factor for side chain and water atoms (Å2) | 19.2 |
| Mean B-factor for all atoms(Å2) | 15.8 |
| Ramachandran's φ, ψ map | |
| Residues in the most favoured regions (%) | 90.4 |
| Residues in the additionally allowed regions (%) | 9.3 |
| Residues in the generously allowed regions (%) | 0.3 |
| PDB ID | 3MU7 |
| General Information | All patients | Participants | Unwilling participants | |
| Mainland China | Hong Kong | Hong Kong | ||
| Sex | ||||
| Male | 20 (47.62) | 15 (50) | 5 (41.67) | 0 (0) |
| Female | 22 (52.38) | 15 (50) | 7 (58.33) | 3 (100) |
| Age | ||||
| Average | 57.59 | 56 | 59.17 | 78.33 |
| Range | 24–91 | 24–79 | 42–91 | 74–82 |
| Marital status | ||||
| Single | 2 (4.76) | 0 (0) | 2 (16.67) | 0 (0) |
| Married | 38 (90.48) | 30 (100) | 8 (66.66) | 2 (67) |
| Widowed | 2 (4.76) | 0 (0) | 2 (16.67) | 1 (33) |
| Education | ||||
| Illiteracy | 8 (19.05) | 6 (20) | 2 (16.67) | 1 (33) |
| Primary school | 13 (30.95) | 12 (30) | 1 (8.33) | 1 (33) |
| Secondary school | 2 (4.76) | 2 (6.67) | 0 (0) | 0 (0) |
| High school | 14 (33.33) | 9 (30) | 5 (41.67) | 1 (33) |
| University or above | 5 (11.91) | 1 (3.33) | 4 (33.33) | 0 (0) |
| Primary Disease Site | ||||
| Head and neck | 5 (11.9) | 1 (3.33) | 4 (33.33) | 1 (33) |
| Lung | 12 (28.57) | 11 (36.67) | 1 (8.33) | 1 (33) |
| Breast | 3 (7.14) | 1 (3.33) | 2 (16.67) | 0 (0) |
| Gynecological | 6 (14.29) | 5 (16.67) | 1 (8.33) | 0 (0) |
| Liver | 5 (11.9) | 5 (16.67) | 0 (0) | 0 (0) |
| Upper GI (Esophagus, stomach and spleen) | 5 (11.9) | 3 (10) | 2 (16.67) | 0 (0) |
| Lower GI(Colon) | 3 (7.14) | 2 (6.67) | 1 (8.33) | 0 (0) |
| Other | 3 (7.14) | 2 (6.67) | 1 (8.33) | 1 (33) |
| Stage of cancer | ||||
| III | 5 (11.9) | 1 (3.33) | 4 (33.33) | 0 (0) |
| IV | 37 (88.1) | 29 (96.67) | 8 (66.67) | 3 (100) |
| Other chronic diseases | 26 (61.9) | 20 (66.67) | 6 (50) | 2 (67) |
| Level of pain | ||||
| Average | 5.81 | 5.9 | 5.58 | 7 |
| Range | 2–8 | 2–8 | 5–8 | 5–8 |
| KPS score | ||||
| Average | 70 | 69 | 72.5 | 70 |
| Range | 40–90 | 40–90 | 60–80 | 60–80 |
| EBF | PBF | EBF | PBF | EBF | PBF | |
| 1 | 45 | 68 | 96 | 98 | 51 | 30 |
| 2 | 12 | 46 | 90 | 92 | 78 | 46 |
| 3 | 7 | 30 | 81 | 84 | 74 | 54 |
| 4 | 3 | 14 | 70 | 73 | 67 | 59 |
| 5 | 1 | 6 | 62 | 65 | 61 | 59 |
| 6 | 0 | 3 | 52 | 55 | 52 | 52 |
| 7 | 0 | 42 | 45 | 45 | ||
| 8 | 33 | 35 | ||||
| 9 | 23 | 25 | ||||
| 10 | 12 | 13 | ||||
| 11 | 5 | 6 | ||||
| 12 | 0 | 0 |
| Outcome parameter | Instrument | Hypotheses | To be filled out by |
| Psychosocial functioning (inclusion criteria) | Global assessment of functioning[14] | II | Psychiatrist |
| Psychopathology | Brief Psychiatric Rating Scale (BPRS)[15] | II | Psychiatrist |
| Patient | |||
| Life satisfaction | 11 point scale from the German Socioeconomic Panel[16] | II | Patient |
| Functional impairment | WHO-Disability Assessment Scale (WHO-DAS II)[17] | II | Patient |
| Substance misuse | Alcohol Use und Drug Use Scale (AUS, DUS)[18] | II | Patient |
| Medical adherence | Medical Adherence Rating Scale (MARS)[19] | II | Patient |
| Patient satisfaction with medical care1 | Patient Assessment of Chronic Care (PACIC)[20] | III | Patient |
| Service use1,2 | Client Sociodemographic and Service Receipt Inventory (CSSRI)[21] | I+IV | Practice assistant |
| Gene Symbol | Log2(Fold Change) | P Value | Adjusted P Value | Gene Symbol | Log2(Fold Change) | P Value | Adjusted P Value |
| GUCY1A2 | 6.94 | 3.17E–10 | 3.79E–06 | TSPAN5 | 1.67 | 3.87E–05 | 2.07E–02 |
| LINC00844 | 6.03 | 1.25E–04 | 3.42E–02 | APBB2 | 1.67 | 4.39E–05 | 2.22E–02 |
| GRIN3A | 5.65 | 1.68E–10 | 3.79E–06 | HMGCS1 | 1.65 | 1.55E–04 | 3.57E–02 |
| PTGER4 | 5.31 | 9.09E–05 | 2.99E–02 | CASP4 | 1.62 | 5.73E–05 | 2.52E–02 |
| LUM | 4.63 | 1.75E–04 | 3.78E–02 | C2orf76 | 1.53 | 2.27E–04 | 4.19E–02 |
| NPR3 | 4.27 | 7.19E–05 | 2.73E–02 | WWC3 | 1.5 | 1.06E–04 | 3.16E–02 |
| STXBP6 | 3.88 | 6.79E–05 | 2.66E–02 | AQP3 | 1.47 | 3.08E–04 | 4.82E–02 |
| NR5A2 | 3.41 | 9.43E–07 | 2.86E–03 | PARP9 | 1.46 | 7.36E–05 | 2.75E–02 |
| GABRA1 | 3.33 | 2.36E–04 | 4.21E–02 | PPAP2A | 1.45 | 3.26E–04 | 4.87E–02 |
| NUDT11 | 3.25 | 2.93E–06 | 5.01E–03 | STX19 | 1.43 | 1.17E–05 | 1.09E–02 |
| ADAM7 | 3.25 | 6.20E–07 | 2.12E–03 | EIF4E3 | 1.42 | 1.19E–05 | 1.09E–02 |
| SHISA9 | 3.08 | 1.20E–07 | 6.55E–04 | ZFY | 1.4 | 3.34E–04 | 4.87E–02 |
| CCDC68 | 3.06 | 1.46E–07 | 6.63E–04 | NEDD4L | 1.39 | 3.47E–04 | 4.89E–02 |
| PRR16 | 3 | 9.53E–05 | 3.04E–02 | MTHFD2L | 1.37 | 1.99E–05 | 1.47E–02 |
| NLGN1 | 2.92 | 2.17E–04 | 4.18E–02 | RIT1 | 1.3 | 3.55E–04 | 4.92E–02 |
| PCDHB6 | 2.84 | 2.95E–04 | 4.71E–02 | SRPK2 | 1.26 | 1.96E–04 | 3.87E–02 |
| PRKAR2B | 2.63 | 1.28E–05 | 1.09E–02 | GABARAPL1 | 1.22 | 2.95E–04 | 4.71E–02 |
| PPP1R3D | 2.51 | 1.43E–04 | 3.51E–02 | CEP192 | 1.19 | 1.80E–05 | 1.40E–02 |
| ERO1LB | 2.49 | 5.89E–06 | 8.94E–03 | TLE4 | 1.19 | 1.43E–04 | 3.51E–02 |
| KATNAL1 | 2.39 | 3.41E–04 | 4.87E–02 | TMEM87A | 1.18 | 3.64E–05 | 2.03E–02 |
| SYTL4 | 2.36 | 1.81E–04 | 3.78E–02 | SLC44A2 | 1.15 | 3.16E–04 | 4.85E–02 |
| PKIB | 2.34 | 8.16E–06 | 9.42E–03 | ELF4 | 1.15 | 3.39E–04 | 4.87E–02 |
| ZDHHC14 | 2.24 | 6.12E–05 | 2.65E–02 | CDC42SE2 | 1.13 | 3.37E–04 | 4.87E–02 |
| PTPRJ | 2.23 | 4.49E–05 | 2.23E–02 | OSTM1 | 1.11 | 3.09E–04 | 4.82E–02 |
| RERG | 2.18 | 1.45E–05 | 1.20E–02 | KCTD16 | 1.09 | 1.23E–04 | 3.40E–02 |
| FAM105A | 2.06 | 1.67E–04 | 3.78E–02 | PTPRK | 1.08 | 1.31E–04 | 3.42E–02 |
| ST8SIA1 | 2 | 2.92E–05 | 1.80E–02 | BMPR2 | 1.08 | 9.59E–05 | 3.04E–02 |
| COBLL1 | 1.94 | 1.46E–04 | 3.54E–02 | JKAMP | 1.07 | 3.28E–04 | 4.87E–02 |
| MIA2 | 1.86 | 2.69E–04 | 4.51E–02 | EIF1AY | 1.07 | 3.40E–04 | 4.87E–02 |
| FAM49A | 1.82 | 7.42E–06 | 9.42E–03 | FAM115A | 1.06 | 3.13E–04 | 4.85E–02 |
| ZNF697 | 1.81 | 2.60E–05 | 1.69E–02 | CREM | 1.06 | 1.81E–04 | 3.78E–02 |
| ZNF124 | 1.79 | 2.08E–05 | 1.49E–02 | JADE1 | 1.04 | 6.44E–05 | 2.66E–02 |
| FBXO6 | 1.76 | 2.25E–04 | 4.19E–02 | SAE1 | 1.04 | 3.41E–04 | 4.87E–02 |
| GLYATL2 | 1.76 | 8.12E–05 | 2.91E–02 | SHANK2 | 1.03 | 1.33E–04 | 3.42E–02 |
| RND3 | 1.74 | 2.08E–04 | 4.06E–02 | ZMIZ1 | 1.02 | 3.20E–04 | 4.87E–02 |
| ZNF275 | 1.7 | 5.03E–05 | 2.37E–02 | UPP1 | 1.01 | 1.26E–05 | 1.09E–02 |
| Groups | High fat diet a (%) | Others | Dietary energy contributions a(Kcal/100 g pellet) |
| Normal | 0 | 100% normal rat pellet | 335 |
| High fat diet | 50 | 50% normal rat pellet | 548 |
| 50% Germinated brown rice | 50 | 50% germinated brown rice | 554 |
| Low dose OE | 100 | 100 mg/kg/day OE | 554 |
| High dose OE | 100 | 200 mg/kg/day OE | 554 |
| Characteristic | Number (percentage)a |
| Age group (in years) | |
| 15 – 29 | 2137 (48.4) |
| 30 – 44 | 1475 (33.4) |
| 45 – 59 | 808 (18.3) |
| Marital status | |
| Never married | 1267 (28.7) |
| Currently married | 2671 (60.5) |
| Widow or divorcee | 482 (10.9) |
| Place of residence | |
| Rural | 1864 (42.2) |
| Urban | 2556 (57.8) |
| Religion | |
| Christians | 3096 (70.0) |
| Muslims | 755 (17.1) |
| Others | 569 (12.9) |
| Level of education | |
| No school | 540 (12.2) |
| Primary | 1573 (35.6) |
| Secondary/higher | 2306 (52.2) |
| Wealth index | |
| Low | 1456 (32.9) |
| Middle | 1463 (33.1) |
| High | 1501 (34.0) |
| Number of lifetime sex partners | |
| 0 – 5 | 1937 (43.8) |
| 6 – 95 | 2473 (56.0) |
| Age at first sexual intercourse | |
| ≤ 17 years | 2192 (49.6) |
| > 17 years | 2215 (50.1) |
| Predictor | B | SE B | B | p |
| Univariate Relationships | ||||
| Age | 0.01 | 0.01 | 0.27 | 0.05 |
| Gender | -0.10 | 0.18 | -0.07 | 0.60 |
| Hours to enrolment | 0.00 | 0.00 | 0.07 | 0.62 |
| Hypertension | -0.06 | 0.17 | -0.05 | 0.73 |
| Atrial fibrillation | 0.19 | 0.22 | 0.12 | 0.40 |
| Hypercholesterolaemia | -0.20 | 0.22 | -0.12 | 0.37 |
| Diabetes | 0.02 | 0.20 | 0.02 | 0.90 |
| Smoking history | -0.09 | 0.17 | -0.07 | 0.60 |
| Aetiology | -0.03 | 0.06 | -0.06 | 0.66 |
| Clinical syndrome | -0.43 | 0.08 | -0.61 | 0.00 |
| Systolic blood pressure | 0.00 | 0.00 | 0.00 | 0.99 |
| Diastolic blood pressure | 0.00 | 0.01 | -0.07 | 0.58 |
| NIHSS score | 0.56 | 0.20 | 0.36 | 0.01 |
| Modified Rankin | 0.00 | 0.00 | 1.10 | 0.28 |
| Modified Barthel | -0.01 | 0.00 | -0.36 | 0.01 |
| Glucose | 1.52 | 0.84 | 0.25 | 0.08 |
| Homocysteine | 0.01 | 0.52 | 0.00 | 0.99 |
| Hs-CRP | 0.56 | 0.12 | 0.55 | 0.00 |
| Fibrinogen | 0.10 | 0.07 | 0.20 | 0.16 |
| E-Selectin | -0.09 | 0.29 | -0.04 | 0.75 |
| von Willebrand factor activity | 0.00 | 0.00 | 2.26 | 0.03 |
| F2-Isoprostanes | 0.04 | 0.31 | 0.02 | 0.89 |
| Lesion area | 0.73 | 0.08 | 0.77 | 0.00 |
| Final multivariate model | ||||
| Hs-CRP | 0.42 | 0.07 | 0.41 | 0.00 |
| Lesion area | 0.65 | 0.07 | 0.69 | 0.00 |
| Risk factor/Preventive practice | ||||
| Total (n = 186) | University of Colombo (n = 86) | University of Kelaniya (n = 100) | P value* | |
| Family history of osteoporosis | 60 (32.3) | 32 (37.2) | 28 (28.0) | 0.19 |
| Female sex | 177 (95.2) | 81 (94.2) | 96 (96.0) | 0.56 |
| Old age | 105 (56.4) | 54 (62.8) | 51 (51.0) | 0.11 |
| Premature menopause | 14 (7.5) | 4 (4.7) | 10 (10.0) | 0.17 |
| Smoking | 28 (15) | 17 (19.8) | 11 (11.0) | 0.10 |
| Physical activity ( Weight bearing exercises) | 75 (40.3) | 25 (29.1) | 50 (50.0) | < 0.01 |
| Daily calcium requirement from food | 84 (45.2) | 41 (29.1) | 43 (43.0) | 0.52 |
| Sources of calcium | 119 (63.9) | 70 (81.4) | 49 (49.0) | <0.01 |
| Hormone therapy after menopause | 45 (24.2) | 22 (25.6) | 23 (23.0) | 0.44 |
| Test | True positive (sensitivity) | False negative (1 − sensitivity) | True negative (specificity) | False positive (1 − specificity) | Total |
| Criteria | HPHPA > 101.5 mmol/mol creatinine | ||||
| Control | 61 (98.4%) | 1 (1.6%) | 62 | ||
| ASDs | 45 (72.6%) | 17 (27.4%) | 62 | ||
| Criteria | 3HPA > 45.2 mmol/mol creatinine | ||||
| Control | 62 (100%) | 0 (0%) | 62 | ||
| ASDs | 18 (29%) | 44 (71%) | 62 | ||
| Criteria | 3HHA > 14.8 mmol/mol creatinine | ||||
| Control | 60 (96.8%) | 2 (3.2%) | 62 | ||
| ASDs | 21 (33.9%) | 41 (66.1%) | 62 | ||
| Criteria | Prediction probability > 0.65 (based on the three metabolites) | ||||
| Control | 98.4% | 1.6% | |||
| ASDs | 90.3% | 9.7% |
| No. components in analysis | Best component(s) | Accuracy |
| One | H2BK5ac at TSS | 0.72 |
| Two | H2BK5ac at TSS-1 | 0.74 |
| H2BK5ac at TSS-2 | ||
| Three | H2BK5ac at TSS-1 | 0.75 |
| H2BK5ac at TSS-2 |
| Correlation coefficients | |||
| EQ VAS score | EQ-5D index-G | EQ-5D index-UK | |
| LSAS | |||
| _total score | -0.20* | -0.22* | -0.24* |
| _anxiety | -0.21* | -0.23* | -0.25* |
| _avoidance | -0.17* | -0.19* | -0.21* |
| BDI score | -0.44* | -0.44* | -0.47* |
| SPAI score | -0.24* | -0.31* | -0.33* |
| SPAI No. 22 score | -0.18* | -0.16* | -0.17* |
| Factors | n | x ± s | F | P | |
| size (cm) | < 6.0 | 41 | 2.880 ± 1.643 | ||
| ≥ 6.0 | 48 | 3.762 ± 1.966 | 4.916 | 0.029* | |
| site | lower | 48 | 3.656 ± 2.042 | ||
| middle | 19 | 3.286 ± 1.824 | |||
| upper | 16 | 2.129 ± 0.956 | 3.101 | 0.031* | |
| total | 6 | 4.260 ± 0.784 | |||
| Borrmann type | 1/2 | 15 | 2.063 ± 0.789 | 7.320 | 0.008* |
| 3/4 | 74 | 3.584 ± 1.914 | |||
| Depth of invassion | T2/3 | 25 | 2.612 ± 1.270 | 6.154 | 0.015* |
| T4 | 64 | 3.684 ± 1.995 | |||
| infiltrating pattern | INFα/β | 34 | 2.306 ± 1.093 | 21.579 | < 0.001* |
| INFγ | 55 | 4.036 ± 1.956 | |||
| differentiation | Well/moderate | 31 | 2.114 ± 1.147 | 23.782 | < 0.001* |
| poor | 58 | 3.979 ± 1.858 | |||
| Lymphatic/venous invasion | – | 54 | 3.362 ± 2.208 | 0.004 | 0.947 |
| + | 35 | 3.389 ± 1.179 | |||
| TNM Node classification (7th) | N0 (0) | 27 | 1.916 ± 1.066 | 21.219 | < 0.001* |
| N1(1–2) | 23 | 3.258 ± 1.324 | |||
| N2 (3–6) | 21 | 3.670 ± 1.524 | |||
| N3 (≥ 7) | 18 | 5.359 ± 1.864 |
| EDX | ||||
| positive | negative | total | ||
| Ultrasound | positive | 13 (48.1) | 4 (14.8) | 17 (63.0) |
| negative | 0 (0.0) | 10 (37.0) | 10 (37.0) | |
| total | 13 (48.1) | 14 (51.9) | 27 (100) |
| Cell source | Stimulus | ||||
| None | PMA | HC plasma | iBD plasma | aBD plasma | |
| Neutrophils | |||||
| gp91-phox | |||||
| HC | 23.98 ± 11.55 | 399.71 ± 47.86a | 148.26 ± 29.29 | 261.27 ± 32.52b | 271.33 ± 44.23b |
| iBD | 19.66 ± 11.23 | 402.00 ± 71.57a | 156.95 ± 31.23 | 291.87 ± 45.39b | 297.35 ± 22.48b |
| aBD | 32.68 ± 17.61 | 464.71 ± 48.45a | 139.05 ± 32.75 | 277.88 ± 41.76b | 278.64 ± 39.95b |
| p22 | |||||
| HC | 20.93 ± 11.40 | 453.04 ± 70.51a | 139.25 ± 31.37 | 262.56 ± 36.43b | 281.02 ± 53.86b |
| iBD | 23.72 ± 12.25 | 438.87 ± 52.98a | 132.62 ± 17.28 | 279.12 ± 38.67b | 282.62 ± 35.75b |
| aBD | 38.82 ± 24.88 | 422.75 ± 64.76a | 152.78 ± 9.32 | 288.74 ± 30.77b | 314.94 ± 40.60b |
| p40 | |||||
| HC | 22.73 ± 9.96 | 377.33 ± 115.38a | 165.77 ± 33.20 | 279.88 ± 38.13b | 299.00 ± 49.97b |
| iBD | 42.43 ± 7.36 | 453.37 ± 77.82a | 133.37 ± 16.08 | 279.00 ± 50.57b | 293.12 ± 31.47b |
| aBD | 28.85 ± 12.85 | 475.42 ± 79.97a | 160.71 ± 20.86 | 274.71 ± 55.96b | 253.00 ± 36.56b |
| p47 | |||||
| HC | 22.16 ± 9.23 | 383.05 ± 69.88a | 132.90 ± 38.84 | 247.97 ± 92.38b | 280.63 ± 59.20b |
| iBD | 35.68 ± 22.66 | 447.75 ± 41.11a | 151.53 ± 29.26 | 274.12 ± 50.08b | 270.12 ± 56.07b |
| aBD | 21.04 ± 7.94 | 400.00 ± 57.01a | 141.27 ± 34.16 | 282.12 ± 16.01b | 293.00 ± 50.48b |
| p67 | |||||
| HC | 32.78 ± 13.00 | 487.36 ± 93.67a | 162.11 ± 32.10 | 288.44 ± 42.48b | 296.11 ± 55.36b |
| iBD | 36.61 ± 15.39 | 396.50 ± 57.82a | 145.12 ± 30.69 | 289.50 ± 46.72b | 266.12 ± 54.21b |
| aBD | 26.42 ± 9.91 | 425.42 ± 50.71a | 160.00 ± 22.37 | 296.71 ± 42.42b | 274.57 ± 39.45b |
| Monocytes | |||||
| gp91-phox | |||||
| HC | 29.75 ± 16.20 | 412.02 ± 68.52a | 154.13 ± 19.00 | 355.05 ± 107.18b | 421.50 ± 78.28b |
| iBD | 16.43 ± 5.38 | 415.43 ± 60.54a | 148.00 ± 33.64 | 318.06 ± 17.94b | 330.40 ± 15.98b |
| aBD | 22.41 ± 8.09 | 468.62 ± 30.17a | 149.41 ± 26.47 | 263.51 ± 50.51b | 282.71 ± 50.99b |
| p22 | |||||
| HC | 21.37 ± 12.57 | 486.14 ± 82.35a | 157.44 ± 40.22 | 267.42 ± 34.51b | 281.82 ± 39.82b |
| iBD | 23.00 ± 14.07 | 442.61 ± 44.55a | 157.41 ± 30.28 | 281.65 ± 35.56b | 283.66 ± 43.68b |
| aBD | 27.25 ± 21.68 | 414.80 ± 33.12a | 129.20 ± 15.01 | 272.47 ± 29.72b | 235.70 ± 53.94b |
| p40 | |||||
| HC | 28.21 ± 10.94 | 467.00 ± 67.57a | 147.22 ± 25.00 | 286.11 ± 37.36b | 273.77 ± 53.97b |
| iBD | 54.53 ± 6.55 | 560.12 ± 74.73a | 142.25 ± 30.90 | 259.25 ± 42.82b | 289.25 ± 35.70b |
| aBD | 45.62 ± 9.24 | 468.75 ± 78.34a | 137.00 ± 25.80 | 290.37 ± 31.87b | 301.25 ± 44.61b |
| p47 | |||||
| HC | 27.45 ± 11.87 | 387.52 ± 45.42a | 155.84 ± 17.92 | 246.52 ± 37.54b | 263.57 ± 60.32b |
| iBD | 23.56 ± 15.99 | 416.77 ± 49.75a | 118.50 ± 27.70 | 278.71 ± 35.03b | 286.70 ± 49.01b |
| aBD | 29.49 ± 23.42 | 427.37 ± 63.68a | 160.71 ± 24.88 | 264.12 ± 21.63b | 262.01 ± 38.54b |
| p67 | |||||
| HC | 27.09 ± 17.14 | 453.77 ± 62.69a | 160.44 ± 27.99 | 272.55 ± 42.45b | 275.22 ± 46.01b |
| iBD | 29.01 ± 12.42 | 420.12 ± 71.30a | 140.37 ± 26.73 | 281.75 ± 38.49b | 303.75 ± 48.17b |
| aBD | 29.41 ± 12.61 | 447.00 ± 67.93a | 142.50 ± 34.80 | 249.75 ± 39.07b | 269.50 ± 33.04b |
| Materials | E. coli (G−) | S. aureus (G+) | S. enterica (G−) | M. luteus (G+) | P. multocida (G−) | Cytospora sp. | P. piricola | F. oxysporum f. sp. cucumebrium |
| C3-3-2-2 a | 0.46 | - b | 0.46 | - | 0.46 | 0.46 | 0.94 | - |
| hurgadacin | 0.46 | 3.75 | 0.94 | >3.75 | 0.46 | >3.75 | 0.94 | >3.75 |
| MBBC predictions | Actual numbers | ||||||
| genome size | 3524796 | 2315047 | 1745685 | 2274392 | NA | 2249085 | NA |
| relative abundance | 11.25% | 16.87% | 23.33% | 48.55% | 14.12% | 16.67% | 69.21% |
| k-mer coverage | 4.48 | 10.24 | 18.78 | 30 | 8.28 | 10.49 | 18.49 |
| Category | N animals | Mean (l milk) | Std |
| Top sixth | 16 | 39.7 | 9.3 |
| Worse sixth | 16 | −29.0 | 5.2 |
| Top twelfth | 8 | 47.2 | 8.1 |
| Worse twelfth | 8 | −32.5 | 5.5 |
| Group | Case number (n) | TNF-α | IL-6 | ||
| Before treatment | After treatment | Before treatment | After treatment | ||
| Treatment group | 45 | 209.34±45.15 | 81.37±14.92 | 65.91±12.73 | 16.39±10.23 |
| Control group | 45 | 211.78±43.09 | 124.78±32.09 | 65.98±11.62 | 34.28±13.01 |
| t | 0.293 | 31.983 | 0.078 | 12.733 | |
| P | 0.11 | 0.00 | 0.25 | 0.00 |
| Prior beliefs | ||||
| Postreading conclusions, n (%) | Appropriate | Inappropriate | Unsure | Total |
| Appropriate | 163 (80.3%) | 70 (47.0%) | 62 (45.3%) | 295 (60.4%) |
| Inappropriate | 39 (19.2%) | 74 (49.7%) | 33 (24.1%) | 146 (29.8%) |
| Did not understand | 1 (0.5%) | 5 (3.3%) | 42 (30.7%) | 48 (9.8%) |
| Total | 203 (100%) | 149 (100%) | 137 (100%) | 489 (100%) |
| I (1998) | II (2001) | III (2005) | IV (2007–2009) | V (2010–2012) | VI (2013–2014) | P value | β coefficient | p for trend | ||
| Men | Age, years | 42.2 (0.32) | 45.7 (0.38) | 42.8 (0.44) | 43.8 (0.25) | 44.8 (0.28) | 45.6 (0.32) | <0.01 | 0.30 | 0.01 |
| BMI, kg/m2 | All | 23.2 (0.07) | 23.7 (0.07) | 24.0 (0.08) | 24.0 (0.05) | 24.1 (0.05) | 24.2 (0.06) | <0.01 | 0.12 | <0.01 |
| 20–39 years | 23.1 (0.10) | 23.6 (0.11) | 23.7 (0.14) | 24.0 (0.08) | 24.2 (0.10) | 24.3 (0.11) | <0.01 | 0.17 | <0.01 | |
| 40–59 years | 23.7 (0.09) | 24.1 (0.09) | 24.4 (0.11) | 24.4 (0.06) | 24.3 (0.06) | 24.6 (0.08) | <0.01 | 0.07 | <0.01 | |
| ≥60 years | 22.0 (0.13) | 23.0 (0.17) | 23.4 (0.18) | 23.3 (0.09) | 23.5 (0.08) | 23.5 (0.08) | <0.01 | 0.12 | <0.01 | |
| WC, cm | All | 82.8 (0.20) | 84.4 (0.19) | 83.7 (0.23) | 84.2 (0.15) | 84.2 (0.16) | 84.2 (0.16) | <0.01 | 0.03 | 0.65 |
| 20–39 years | 81.2 (0.28) | 82.6 (0.29) | 81.4 (0.37) | 82.7 (0.23) | 82.9 (0.27) | 83.1 (0.29) | <0.01 | 0.30 | <0.01 | |
| 40–59 years | 85.1 (0.25) | 86.0 (0.25) | 86.0 (0.28) | 85.4 (0.19) | 85.0 (0.19) | 85.0 (0.22) | <0.01 | −0.29 | <0.01 | |
| ≥60 years | 82.2 (0.41) | 85.0 (0.46) | 85.1 (0.55) | 85.0 (0.26) | 85.2 (0.25) | 84.8 (0.28) | <0.01 | −0.04 | 0.74 | |
| Women | Age, years | 43.3 (0.39) | 45.6 (0.39) | 44.6 (0.41) | 45.9 (0.26) | 47.0 (0.26) | 47.8 (0.35) | <0.01 | 0.70 | <0.01 |
| BMI, kg/m2 | All | 23.1 (0.06) | 23.4 (0.07) | 23.3 (0.09) | 23.2 (0.05) | 23.3 (0.06) | 23.2 (0.06) | <0.01 | −0.05 | 0.03 |
| 20–39 years | 22.2 (0.08) | 22.2 (0.09) | 22.2 (0.12) | 22.1 (0.08) | 22.1 (0.09) | 22.1 (0.10) | 0.33 | −0.03 | 0.32 | |
| 40–59 years | 24.1 (0.09) | 24.2 (0.10) | 24.2 (0.12) | 23.8 (0.06) | 23.9 (0.07) | 23.5 (0.08) | <0.01 | −0.18 | <0.01 | |
| ≥60 years | 23.8 (0.12) | 24.3 (0.16) | 24.3 (0.14) | 24.3 (0.08) | 24.3 (0.08) | 24.3 (0.09) | <0.01 | −0.01 | 0.90 | |
| WC, cm | All | 78.0 (0.21) | 78.8 (0.23) | 77.9 (0.26) | 78.4 (0.18) | 78.1 (0.17) | 77.5 (0.20) | <0.01 | −0.24 | <0.01 |
| 20–39 years | 74.2 (0.23) | 74.3 (0.25) | 73.8 (0.34) | 74.4 (0.23) | 73.7 (0.25) | 73.7 (0.28) | <0.01 | −0.14 | 0.12 | |
| 40–59 years | 80.7 (0.30) | 80.3 (0.31) | 79.8 (0.33) | 79.6 (0.21) | 79.3 (0.22) | 77.6 (0.23) | <0.01 | −0.60 | <0.01 | |
| ≥60 years | 83.2 (0.38) | 84.5 (0.43) | 83.4 (0.43) | 83.8 (0.26) | 83.2 (0.23) | 82.6 (0.29) | <0.01 | −0.41 | <0.01 |
| Characteristic | Confirmed HCV-InfectedRaw Frequency (n = 467) | Confirmed HCV-InfectedWeighted Mean (SD) or Proportion | ||
| All HCV Patients | Thrombocytopenia Population1(n = 43) | Non-Thrombocytopenia Population1(n = 422) | ||
| Age at screening (yrs), mean (SD) | 467 | 46.7 (15.5) | 55.3 (22.5) | 46.0 (12.7) |
| Male gender, % | 293 | 61.7 | 73.4 | 61.2 |
| Weight (kg), mean (SD) | 451 | 78.2 (22.5) | 78.0 (23.3) | 78.3 (22.6) |
| Race/ethnicity, % | 467 | |||
| White | 190 | 65.7 | 21.6 | 20.0 |
| Black/African-American | 160 | 20.1 | 56.3 | 66.4 |
| Hispanic | 103 | 10.9 | 19.3 | 10.3 |
| Other | 14 | 3.3 | 2.9 | 3.3 |
| Annual Household income, % | 433 | |||
| Below $20,000 | 185 | 36.3 | 39.5 | 35.6 |
| $20,000 - $74,999 | 204 | 50.1 | 47.1 | 50.7 |
| Above $75,000 | 44 | 13.6 | 13.4 | 13.7 |
| Ever used marijuana or hashish, %1 | 124 | 87.4 | 100.0 | 88.0 |
| Times received health care over past 12 months, % | 467 | 43 | 422 | |
| None | 83 | 16.5 | 13.0 | 16.9 |
| 1-3 times | 162 | 35.6 | 39.7 | 34.9 |
| More than 4 times | 222 | 47.9 | 47.3 | 48.3 |
| Alcohol use (drinks/day over past year), mean (SD) | 270 | 4.4 (3.7) | 4.1 (2.9) | 4.4 (3.7) |
| Albumin (g/dL), mean (SD) | 456 | 4.2 (0.4) | 3.7 (1.01) | 4.2 (0.4) |
| ALT (u/L), mean (SD) | 456 | 52.2 (60.9) | 81.5 (93.6) | 50.0 (56.5) |
| AST (u/L), mean (SD) | 456 | 47.2 (49.7) | 84.6 (46.7) | 44.2 (48.5) |
| Blood urea nitrogen (mg/dL), mean (SD) | 456 | 12.1 (6.4) | 13.9 (11.1) | 12.0 (5.3) |
| Total calcium (mg/dL), mean (SD) | 456 | 9.4 (0.5) | 9.1 (0.7) | 9.5 (0.5) |
| Creatinine (mg/dL), mean (SD) | 346 | 0.9 (0.3) | 1.0 (0.6) | 0.9 (0.3) |
| Iron (ug/dL), mean (SD) | 456 | 108.9 (58.0) | 138.9 (61.7) | 106.9 (57.2) |
| Bilirubin (umol/L), mean (SD) | 456 | 13.1 (7.6) | 19.3 (13.1) | 12.6 (6.9) |
| Total protein (g/dL), mean (SD) | 456 | 7.4 (0.8) | 7.3 (0.9) | 7.4 (0.9) |
| Globulin (g/dL), mean (SD) | 456 | 3.3 (0.8) | 3.6 (0.7) | 3.2 (0.8) |
| Hemoglobin (g/dL), mean (SD) | 465 | 14.9 (2.1) | 14.5 (2.2) | 14.9 (2.1) |
| Fasting glucose (mg/dL), mean (SD)2 | 91 | 107.7 (38.9) | 105.6 (21.2) | 108.0 (42.8) |
| Fasting insulin (uU/mL), mean (SD)2 | 86 | 13.3 (12.3) | 26.4 (33.9) | 11.5 (12.7) |
| White blood cell count (1000 cells/uL), mean (SD) | 465 | 7.3 (3.2) | 5.4 (2.3) | 7.4 (3.2) |
| Platelet count | 465 | 257.6 (87.7) | 112.0 (31.2) | 269.5 (76.0) |
| Thrombocytopenia, % | 465 | |||
| < 150 × 109/L | 43 | 7.6 | 100 | 0 |
| < 125 × 109/L | 25 | 4.5 | 59.4 | 0 |
| < 100 × 109/L | 12 | 2.0 | 26.7 | 0 |
| < 75 × 109/L | 7 | 0.8 | 10.7 | 0 |
| Host species | Pooled estimate | Heterogeneity | |||
| p (95% CI) | Z-p | I2 | Q-p | Q/df | |
| Ruminants† | 7.47 (4.75,11. 58) | 0.000 | 73.4 | 0.000 | 3.76 |
| Cattle | 7.07 (2.05,16.17) | 0.000 | 89.1 | 0.000 | 9.17 |
| Sheep | 8.41 (4.77,14.42) | 0.000 | 39.9 | 0.189 | 1.67 |
| Goats | 9.01 (3.88, 19.62) | 0.000 | 69.4 | 0.038 | 3.27 |
| Pigs | 43.81 (38.89,48.85) | 0.000 | 0.0 | 0.680 | 0.09 |
| Inflammatory reaction signs | SDE group | IRDE group | |||
| SS | SLE | RA | Total | ||
| Conjunctival congestion ratio | 32.2%a | 69.3% | 78.5% | 63.1% | 70.3%a |
| Conjunctival papillary hyperplasia ratio | 27.5%b | 52.4% | 61.8% | 50.8% | 55.0%b |
| Conjunctival follicular hyperplasia ratio | 16.3%c | 36.8% | 40.4% | 39.2% | 38.8%c |
| Secretion ratio | 12.6%d | 10.1% | 13.6% | 10.6% | 11.4%d |
| Time Interval | VN-NP Telemedicine Algorithm (mean and standard deviation, minutes) |
| Onset to Door | 32.3 ± 20.5 |
| Onset to Call | 42.8 ± 21.2 |
| Onset to Lab | 110.5 ± 12.0 |
| Onset to Decision | 112.6 ± 31.1 |
| Onset to rt-PA | 159.0 ± 8.5 |
| Door to Call | 19.6 ± 18.7 |
| Door to Consent | 39.8 ± 26.0 |
| Door to Lab | 75.0 ± 32.4 |
| Door to Neuro Exam | 54.2 ± 15.1 |
| Door to CT Reading | 78.2 ± 23.4 |
| Door to Decision | 69.6 ± 9.6 |
| Call to Consent | 21.0 ± 10.8 |
| Call to Neuro Exam | 31.5 ± 11.5 |
| Call to Decision | 53.2 ± 9.0 |
| Consent to Neuro Exam | 9.0 ± 16.8 |
| Consent to Decision | 30.7 ± 19.3 |
| Consent to rt-PA | 67.0 ± 30.5 |
| Decision to rt-PA | 45.5 ± 21.9 |
| SED | Significance | |||||||
| Year 1 | Year 2 | Year 3 | Treatment | Year | Treatment | Year | Interaction | |
| Livera | ||||||||
| Treated | ||||||||
| No.b | 11/15 | 4/14 | 2/12 | |||||
| Concentration | 7.45 (56) | 4.36 (19) | — (45) | 1.67 | 1.58 | NS | * | NS |
| Control | ||||||||
| No. | 13/14 | 7/19 | 2/16 | |||||
| Concentration | 10.57 (112) | 7.30 (53) | — (265) | |||||
| Kidney fat | ||||||||
| Treated | ||||||||
| No. | 1/15 | 0/14 | 2/12 | |||||
| Concentration | — (45) | — (ND) | — (134) | |||||
| Control | ||||||||
| No. | 6/15 | 3/18 | 3/16 | |||||
| Concentration | — (77) | — (96) | — (29) | |||||
| Musclea | ||||||||
| Treated | ||||||||
| No. | 0/15 | 10/13 | 9/12 | |||||
| Concentration | — (ND) | 14.83 (220) | 31.76 (1,009) | 3.78 | 3.78 | * | NS | # |
| Control | ||||||||
| No. | 0/15 | 19/19 | 11/15 | |||||
| Concentration | — (ND) | 42.8 (1,832) | 26.3 (692) |
| Parasite forms | IC50 (μM) | Time (h) | SI |
| Epimastigotes (Y strain) | 255.15 ± 32.6 | 24 | >15 |
| Metacyclic trypomastigotes (Dm28c) | 191.8 ± 10.5 | 24 | >21 |
| Bloodstream trypomastigotes (Y strain) | 259.4 ± 6.1 | 24 | >16 |
| Intracellular amastigotes (Y strain) | 188.2 ± 47.5 | 48 | >21 |
| Algorithm for feature selection | Average sensitivity for 5-fold cross validation (%) | Average specificity for 5-fold cross validation (%) |
| FDAFSA | 84 | 86 |
| RTPFSGA | 94 | 59 |
| PromoBot[FDAFSA + RTPFSGA] | 89 | 86 |
| Factors | Criteria | Comment |
| Sea level height in tsunami, tide level in storm surge, flood level | >2.5 m | Unsuitable |
| 2.5–1.5 m | Neutral | |
| <1.5 m | Suitable | |
| Geological environment | Geologically inappropriate areas and near-fault region | Unsuitable |
| Others | Suitable | |
| Distance from gas stations, natural gas fueling stations, high voltage lines, and power plants | <50 m | Unsuitable |
| 50–100 m | Neutral | |
| >100 m | Suitable | |
| Distance from dangerous goods warehouse | <500 m | Unsuitable |
| 500–1000 m | Neutral | |
| >1000 m | Suitable | |
| Distance from high pressure gas pipelines | <25 m | Unsuitable |
| 25–50 m | Neutral | |
| >50 m | Suitable | |
| Terrain slope | >30° | Unsuitable |
| 15–30° | Neutral | |
| >15° | Suitable | |
| Distance from waters | 0–30 m | Neutral |
| >30 m | Suitable | |
| Terrain elevation | <1.5 m | Neutral |
| >1.5 m | Suitable | |
| Distance from heritage conservation areas | 0–30 m | Neutral |
| >30 m | Suitable | |
| Distance from waste treatment stations | <100 m | Neutral |
| >100 m | Suitable |
| Clinical trial | Median age | Range | ≥75 years | PS 2 | Visceral metastases |
| TROPIC | 68 | 62–73 | 18% | 7% | 25% |
| COU-AA-301 | 69 | 42–95 | 28% | 10% | 11% (liver metastases) |
| AFFIRM | 69 | 41–92 | 25% | 8.5% | 23.2% |
| n: 78 | % | ||
| Working status at the time of admission | Yes | 68 | 87.2 |
| No | 10 | 12.8 | |
| Sector of work | Industry | 17 | 21.8 |
| Service | 61 | 78.2 | |
| Total duration of work (month) Mean ±SD (min - max) | 34.6±51 (1-156) |
| Season | Response | Predictor variables | θ | SE | P-value |
| Dry | Frequency of occurrence | Distance to permanent water | -2.49E-04 | 1.11E-04 | <0.05 |
| (Distance to permanent water)2 | 4.67E-08 | 2.18E-08 | <0.05 | ||
| Distance to rangerpost/lodge | 1.66E-05 | 9.30E-06 | <0.1 | ||
| Wooded grassland | 2.31E-01 | 1.18E-01 | <0.1 | ||
| Dry | Average biomass | Distance to rangerpost/lodge | -7.91E-05 | 1.79E-05 | <0.0001 |
| Wet | Frequency of occurrence | Distance to water | 5.04E-04 | 2.02E-04 | <0.05 |
| (Distance to water)2 | -3.42E-07 | 1.10E-07 | <0.01 | ||
| Distance to rangerpost/lodge | -5.44E-05 | 7.88E-06 | <0.0001 | ||
| Wooded grassland | -1.60E-01 | 9.81E-02 | <0.2 | ||
| Dense woodland | -4.61E-01 | 2.05E-01 | <0.05 | ||
| Wet | Average biomass | Distance to rangerpost/lodge | -5.18E-05 | 1.77E-05 | <0.01 |
| Open grassland | 1.37E + 00 | 2.16E-01 | <0.0001 | ||
| Open woodland | 1.60E + 00 | 4.23E-01 | <0.001 |
| Type of samples collected | Personal breathing zone mass concentrations (μg/m3) | Study |
| Estimated inhalable mass | 0.7 - 53 | Maynard et al. 2004 [21] |
| Total gravimetric mass | N.D. - 331.7 | Han et al. 2008 [19] |
| Total gravimetric mass | 7.8 - 320.8 | Lee et al. 2010 [20] |
| Total carbon-inhalable size fraction | 64-1094 | Methner et al. 2010 [25] |
| Elemental carbon- inhalable size fraction | N.D. - 38 | Methner et al. 2012 [24] |
| Elemental carbon- inhalable size fraction | N.D. - 7.86 | Dahm et al. 2012 [23] |
| Elemental carbon- respirable size fraction | 45 - 80 | Birch et al. 2011 [22] |
| Culture (MGIT + LJ) | ||||
| Positive | Negative | Total | ||
| Magnetic bead FM (with blinded re-checking of discrepants) | ||||
| Positive | 76 | 12 | 88 | |
| Negative | 31 | 163 | 194 | |
| Total | 107 | 175 | 282 | |
| Sensitivity, %(95% CI) | 71.0%(61.5 - 79.4) | |||
| Specificity, %(95% CI) | 93.1%(88.3 - 96.4) | |||
| Overall accuracy, %(95% CI) | 84.8%(80.0-88.7) | |||
| PPV, %(95% CI) | 86.4%(77.4-92.8) | |||
| NPV, %(95% CI) | 84.0%(80.0-88.7) |
| uHR (95% CI) | p | aHR (95% CI) | p | ||
| Clinical malaria | LvM | 0.56 (0.34–0.94) | 0.028 | 0.64 (0.38–1.09) | 0.1 |
| LvH | 0.12 (0.05–0.28) | <0.0001 | 0.15 (0.06–0.35) | <0.0001 | |
| High-density parasitemia | LvM | 0.80 (0.50–1.30) | 0.37 | 0.94 (0.58–1.53) | 0.804 |
| LvH | 0.26 (0.13–0.49) | <0.0001 | 0.35 (0.18–0.70) | 0.003 |
| Adjusted odds of treatment success (cure/completed) vs. failure/relapse(N = 1,302)OR (95% CI) | Adjusted odds of treatment success (cure/completed) vs. failure/relapse/death(N = 1,483)OR (95% CI) | Adjusted odds of treatment success (cure/completed) vs. failure/relapse/death/lost to follow-up(N = 1,864)OR (95% CI) | |
| HIV | |||
| No | 1.7 (0.9; 3.4) | 2.7 (1.7; 4.2) | 2.3 (1.6; 3.4) |
| Yes | Reference | Reference | Reference |
| Regimen | |||
| Standardized | 2.7 (1.8; 3.9) | 1.4 (1.1; 1.9) | 1.0 (0.8; 1.3) |
| Individualized | Reference | Reference | Reference |
| First DR-TB episode | |||
| Yes | 8.8 (5.7; 13.5) | 5.4 (3.8; 7.7) | 2.1 (1.1; 4.1) |
| No | Reference | Reference | Reference |
| AFB positive | |||
| No | 4.2 (2.1; 8.2) | 2.1 (1.4; 3.1) | 2.1 (1.5; 2.8) |
| Yes | Reference | Reference | Reference |
| Bilateral disease | – | ||
| No | 1.4 (1.1.; 1.9) | 1.3 (1.1; 1.6) | |
| Yes | Reference | Reference | |
| Number of previous regimens | – | – | 0.4 (0.2; 0.7) |
| Diabetes | – | – | |
| No/Unknown | 0.7 (0.5; 0.9) | ||
| Yes | Reference | ||
| Macro-region | – | ||
| North | 0.9 (0.3; 2.2) | 0.9 (0.5; 1.5) | – |
| Northeastern | 0.2 (0.1; 0.5) | 0.4 (0.4; 0.7) | |
| Centre-West | 0.4 (0.1; 1.8) | 1.0 (0.4; 2.6) | |
| Southeastern | 0.4 (0.2; 0.8) | 0.7 (0.5; 1.1) | |
| South | Reference | Reference |
| Universe | Registered users of the private area of Company XX’s website who had used this service at least once |
| Sampling procedure | By means of a structured survey accessed online |
| Sample | 23,223 |
| Scope | Spain |
| Real sample | 4,178 |
| Sampling error | ±1.05% |
| Level of confidence | 95% (Z = 1.96) |
| Maximum variance allowed | P = q = 50% |
| Fieldwork | June/July 2016 |
| Parameter | Control | CHD | IS | PCHD | PIS |
| Number | 622 | 579 | 546 | - | - |
| Male/female | 446/176 | 431/148 | 394/152 | 0.286 | 0.862 |
| Age, years | 61.68 ± 11.99 | 62.23 ± 10.56 | 62.87 ± 12.34 | 0.403 | 0.097 |
| BMI, kg/m2 | 22.64 ± 3.20 | 23.89 ± 3.22 | 23.39 ± 3.49 | <0.001 | <0.001 |
| Systolic blood pressure, mmHg | 127.39 ± 19.77 | 133.05 ± 23.29 | 147.63 ± 22.16 | <0.001 | <0.001 |
| Diastolic blood pressure, mmHg | 81.28 ± 13.08 | 79.15 ± 14.20 | 83.73 ± 12.97 | 0.007 | 0.001 |
| Pulse pressure, mmHg | 46.11 ± 18.27 | 53.90 ± 17.50 | 63.89 ± 17.92 | <0.001 | <0.001 |
| Cigarette smoking, n (%) | 248 (39.9) | 250 (43.2) | 227 (41.6) | 0.245 | 0.554 |
| Alcohol consumption, n (%) | 267 (42.9) | 134 (23.1) | 152 (27.8) | <0.001 | <0.001 |
| TC, mmol/l | 4.99 ± 1.06 | 4.53 ± 1.19 | 4.52 ± 1.14 | <0.001 | <0.001 |
| TG, mmol/l | 1.00 (0.71) | 1.36 (0.94) | 1.36 (0.92) | <0.001 | <0.001 |
| HDL-C, mmol/l | 1.90 ± 0.50 | 1.14 ± 0.033 | 1.23 ± 0.40 | <0.001 | <0.001 |
| LDL-C, mmol/l | 2.77 ± 0.78 | 2.71 ± 1.00 | 2.70 ± 0.89 | 0.272 | 0.163 |
| TC/HDL-C | 2.77 ± 1.26 | 4.22 ± 1.84 | 3.96 ± 1.44 | <0.001 | <0.001 |
| ApoA1, g/l | 1.41 ± 0.27 | 1.04 ± 0.52 | 1.03 ± 0.22 | <0.001 | <0.001 |
| ApoB, g/l | 0.90 ± 0.21 | 0.91 ± 0.27 | 0.89 ± 0.24 | 0.713 | 0.455 |
| ApoA1/ApoB | 1.65 ± 0.52 | 1.38 ± 2.48 | 1.25 ± 0.58 | 0.009 | <0.001 |
| Type II diabetes mellitus, n (%) | 25 (4.0) | 95 (16.3) | 124 (22.3) | <0.001 | <0.001 |
| Hypertension, n (%) | 180 (28.7) | 298 (51.0) | 272 (49.0) | <0.001 | <0.001 |
| Sex | No. (%) | Age | No. (%) | Source | No. (%) | MRSA/MSSA |
| Male | 401 (66.0%) | 14–24 | 43 (7.1%) | Respiratory | 410 (67.4%) | 321/89 (78.3%/21.7%) |
| Female | 207 (34.0%) | 25–34 | 56 (9.2%) | Skin/soft tissue | 86 (14.1%) | 31/55 (36.0%/64.0%) |
| 35–44 | 63 (10.4%) | Other sterile body fluids | 64 (10.5%) | 37/27 (57.8%/42.2%) | ||
| 45–54 | 81(13.3%) | Blood | 27 (4.4%) | 12/15 (44.4%/55.6%) | ||
| 55–64 | 92 (15.1%) | Urine | 21 (3.6%) | 13/8 (61.9%/38.1%) | ||
| 65–74 | 96 (15.8%) | |||||
| 75–84 | 72 (11.8%) | |||||
| ≥85 | 105 (17.3%) |
| Territory | Northwest Territories (NT) | Nunavut | Nunavik | ||||
| Region | NT (all) | ISR only | Nunavut (all) | Kitikmeot | Kivalliq | Qikiqtani | Nunavik |
| LRTI admissions (n) | 41 | 3 | 305 | 70 | 89 | 146 | 167 |
| Average cost per LRTI hospitalization | |||||||
| Medical evacuation, average(range) | $7,865(0–$35,517) | $20,859($18,924–$23,273) | $12,086($0–38,494) | $19,378($14,000–$38,494) | $10,151($2,776–$20,846) | $9,770(0–$34,441) | $5,681(0–$25,18) |
| All transportation average(range) | $8,285($0–36,913) | $22,000($19–924–24,564) | $13,392($0–41,175) | $21,086($15,211–41,175) | $11,377($3,448–2,250) | $10,392(0–$36,902) | $6,121(0–$26,667) |
| Inpatient costs Average(range) | $25,7,839($4,680–$344,108) | $14,820($11,700–$187,20) | $27,753($1,253–$1,130, 112) | $34,097($3,510–$219,708) | $48,851($2,609–$1,130, 112) | $27,281($2,132–$808,323) | $14,724($1,253–$338,688) |
| All costs | $36,542 | $38,629 | $55,265 | $57,535 | $63,686 | $40,873 | $23,203 |
| Total costs for all LRTI hospitalizations | |||||||
| Total transportation cost (%) | $339,674 (22.7) | $65,967 (54.9) | $4,084,596 (26.1) | $1,476,019 (36.6) | $1,012,527 (17.9) | $1,596,050 (26.7) | $1,022,264 (26.4) |
| Total inpatient costs (%) | $1,060,782 (70.8) | $44,460 (37.0) | $10,717,638 (68.4) | $2,386,803 (59.3) | $4,347,741 (76.7) | $3,983,094 (66.7) | $2,458,896 (63.5) |
| Physician fees (%) | $81,576 (5.4) | $5,431 (4.5) | $681,784 (4.4) | $148,741 (3.7) | $217,638 (3.8) | $315,405 (5.3) | $331,020 (8.5) |
| ER and accommodation (%) | $16,200 (1.1) | $5,431 (3.6) | $178,951 (1.1) | $15,900 (0.4) | $90,151 (1.6) | $72,900 (1.8) | $62,701 (1.6) |
| All costs | $1,498,232 | $120,189 | $15,662,968 | $4,027,463 | $5,668,056 | $5,967,449 | $3,874,881 |
| Average cost per live birth | $1,412 | $690 | $12,132 | $22,375 | $14,608 | $8,254 | $10,333 |
| GA at delivery | Stillborn | Live born | ||
| n | % | n | % | |
| <37 weeks | 17 | 85 | 27 | 82 |
| 37–42 weeks | 3 | 15 | 5 | 15 |
| >42 weeks | 0 | 0 | 1 | 3 |
| Sensor Response | Body Movement | |
| Abnormal | Normal | |
| Detection | 48 | 3 |
| No detection | 0 | 45 |
| Baseline characteristics | Medial central femoral condyle | Medial central tibial plateau | Both areas (medial compartment) | Joint space width (mm) | ||||
| P value | P value | P value | P value | |||||
| Age | -0.13 | 0.18 | -0.07 | 0.49 | -0.11 | 0.26 | -0.05 | 0.58 |
| Gender | 0.12 | 0.24 | 0.08 | 0.41 | 0.11 | 0.26 | 0.04 | 0.66 |
| Body mass index | -0.21 | 0.03 | -0.21 | 0.03 | -0.23 | 0.02 | -0.07 | 0.48 |
| Alcohol | 0.02 | 0.86 | 0.02 | 0.82 | 0.02 | 0.82 | 0.18 | 0.06 |
| Smoking | 0.74 | 0.45 | 0.09 | 0.36 | 0.09 | 0.35 | 0.06 | 0.55 |
| SF-36 | -0.14 | 0.14 | -0.03 | 0.79 | -0.09 | 0.34 | -0.05 | 0.61 |
| WOMAC total | -0.05 | 0.61 | -0.02 | 0.82 | 0.02 | 0.88 | 0.08 | 0.41 |
| WOMAC subscale | ||||||||
| Pain | 0.10 | 0.30 | 0.05 | 0.58 | 0.09 | 0.38 | 0.14 | 0.14 |
| Stiffness | 0.04 | 0.68 | -0.07 | 0.46 | -0.06 | 0.52 | -0.0005 | 0.99 |
| Function | -0.05 | 0.62 | -0.03 | 0.76 | 0.01 | 0.92 | 0.08 | 0.42 |
| Patient global | 0.04 | 0.65 | 0.12 | 0.90 | 0.03 | 0.75 | -0.0004 | 0.99 |
| Joint space width (mm) | 0.29 | 0.003 | -0.28 | 0.03 | 0.32 | 0.001 | -- | -- |
| Meniscal extrusion | -0.31 | 0.001 | -0.26 | 0.007 | -0.32 | 0.001 | -0.16 | 0.11 |
| Severe meniscal extrusion | -0.33 | 0.001 | -0.40 | 0.0001 | -0.41 | 0.0001 | -0.16 | 0.10 |
| Medial meniscal tear | -0.26 | 0.006 | -0.11 | 0.25 | -0.21 | 0.03 | -0.32 | 0.001 |
| Severe medial meniscal tear | -0.36 | 0.0001 | -0.29 | 0.003 | -0.36 | 0.0001 | -0.32 | 0.001 |
| Lateral meniscal tear | 0.21 | 0.03 | 0.05 | 0.60 | 0.15 | 0.13 | -0.09 | 0.33 |
| Severe lateral meniscal tear | 0.07 | 0.49 | 0.04 | 0.65 | 0.06 | 0.52 | 0.16 | 0.11 |
| Bone hypersignal | -0.26 | 0.008 | -0.23 | 0.02 | -0.27 | 0.005 | -0.11 | 0.25 |
| Bone hypersignal in the medial compartment | -0.11 | 0.23 | -0.10 | 0.30 | -0.12 | 0.21 | -0.03 | 0.76 |
| Bone hypersignal in the lateral compartment | -0.32 | 0.001 | -0.31 | 0.001 | -0.35 | 0.0001 | -0.13 | 0.17 |
| Changes in selected clinical variables at 24 months | Medial central femoral condyle | Medial central tibial plateau | Both areas (medial compartment) | Joint space narrowing | ||||
| P value | P value | P value | P value | |||||
| SF-36 | 0.07 | 0.44 | 0.12 | 0.23 | 0.11 | 0.27 | 0.10 | 0.31 |
| WOMAC total | -0.05 | 0.58 | -0.10 | 0.31 | -0.09 | 0.38 | -0.23 | 0.02 |
| WOMAC subscale | ||||||||
| Pain | -0.15 | 0.12 | -0.21 | 0.03 | -0.21 | 0.03 | -0.29 | 0.002 |
| Stiffness | 0.02 | 0.85 | -0.03 | 0.74 | 0.009 | 0.93 | -0.18 | 0.07 |
| Function | -0.04 | 0.68 | -0.07 | 0.45 | -0.06 | 0.51 | -0.23 | 0.02 |
| Patient global | -0.17 | 0.08 | -0.17 | 0.08 | -0.19 | 0.05 | -0.02 | 0.83 |
| Joint space narrowing | 0.40 | 0.003 | 0.21 | 0.003 | 0.34 | <0.0001 | -- | -- |
| Model | Genotype | Controls | OHSS | OR (95% CI) | P-value |
| Codominant | G/G | 61 (39.4%) | 9 (47.4%) | 1 | 0.064 |
| G/T | 74 (47.7%) | 5 (26.3%) | 0.35 (0.10, 1.19) | ||
| T/T | 20 (12.9%) | 5 (26.3%) | 1.70 (0.46, 6.34) | ||
| Dominant | G/G | 61 (39.4%) | 9 (47.4%) | 1 | 0.320 |
| G/T-T/T | 94 (60.6%) | 10 (52.6%) | 0.59 (0.21, 1.65) | ||
| Recessive | G/G-G/T | 135 (87.1%) | 14 (73.7%) | 1 | 0.110 |
| T/T | 20 (12.9%) | 5 (26.3%) | 2.79 (0.82, 9.47) | ||
| Overdominant | G/G-T/T | 81 (52.3%) | 14 (73.7%) | 1 | 0.027 |
| G/T | 74 (47.7%) | 5 (26.3%) | 0.30 (0.10, 0.93) |
| Characteristic | Percent |
| Race | |
| White | 15 |
| African American | 85 |
| Maternal smoking at time of pregnancy | |
| No | 44 |
| Yes | 56 |
| Breast-fed | |
| Yes | 6 |
| No | 94 |
| No. of older siblings | |
| 0 | 25 |
| 1 | 25 |
| ≥ 2 | 50 |
| Maternal height (cm) | |
| 144–155.9 | 29 |
| 156–165.9 | 54 |
| 166–181 | 17 |
| Maternal prepregnancy BMI (kg/m2) | |
| 16–19.9 | 21 |
| 20–24.9 | 47 |
| 25–29.9 | 23 |
| 30–44 | 9 |
| Maternal age at menarche (years) | |
| 8–11 | 21 |
| 12 | 29 |
| 13 | 25 |
| ≥ 14 | 26 |
| Maternal age at enrollment in CPP (years) | |
| 13–19 | 23 |
| 20–24 | 36 |
| 25–29 | 23 |
| 30–42 | 18 |
| Family SEI at time of pregnancy | |
| 0–2.5 | 17 |
| 2.6–5.0 | 59 |
| ≥ 5.1 | 24 |
| Suicidal ideation | Depressive symptoms | Loneliness | |||||||
| B | SE | β | B | SE | β | B | SE | β | |
| STEP 1 | |||||||||
| Size of the discrepancy | 0.03 | 0.01 | 0.35** | 0.35 | 0.13 | 0.26** | 0.09 | 0.14 | 0.06 |
| Direction of the discrepancy | 0.03 | 0.01 | 0.22* | 0.65 | 0.19 | 0.33** | 0.43 | 0.20 | 0.21* |
| STEP 2 | |||||||||
| Size of the discrepancy* | 0.04 | 0.02 | 0.53* | 0.75 | 0.27 | 0.59** | 0.79 | 0.29 | 0.61** |
| Direction of the discrepancy |
| Raman reporter | λmax (nm) | λ0(nm) | Reference |
| Carboxyfluorescein (FAM) | 494 | 514.5 | [85] |
| Rhodamine 6 G (R6G) | 524 | 514.5, 532 | [85–88] |
| TRITC-DHPE | 540 | 514.5 | [89] |
| Carboxy-X-rhodamine (ROX) | 585 | 514.5, 632.8 | [85] |
| BIODIPY TR-X | 588 | 632.8 | [85] |
| Crystal violet (CV) | 590 | 514.5, 647.1 | [86, 90] |
| Malachite green (MG) | 618 | 632.8 | [91] |
| Malachite green isothiocyanate (MGITC) | 625 | 632.8 | [91] |
| Methylene blue | 570–760∤ | 785 | [92, 93] |
| Cy5.5 | 683 | 632.8 | [85] |
| 3,3′-diethylthiatricarbocyanine iodide (DTTC) | 765 | 785 | [94] |
| Group | Mean increase (106 × cm/s) | SEM | P-value |
| Control | 5.3962 | ±0.4043 | <0.001 |
| Lithium 0.2 mmol/L | 2.9419 | ±0.1747 | <0.001 |
| Lithium 0.4 mmol/L | 3.9716 | ±0.3881 | <0.001 |
| Relationship to patient | N (%)i |
| Wife/partner | 444 (86.4) |
| Other relative | 13 (2.2) |
| Friend | 2 (0.3) |
| Other | 22 (3.7) |
| Age (years) | |
| < 54 | 68 (11.4) |
| 55-64 | 190 (31.9) |
| 65-74 | 225 (37.8) |
| 75+ | 96 (16.1) |
| Overall health | |
| Very good | 154 (25.9) |
| Good | 280 (47.1) |
| Fair | 118 (19.8) |
| Poor | 18 (3.0) |
| Very poor | 5 (0.8) |
| Ethnicity | |
| White British/Irish | 562 (94.5) |
| South Asian | 3 (0.5) |
| African/Caribbean | 5 (0.8) |
| Other | 0 (0) |
| Current situation | |
| Employed | 136 (22.9) |
| Retired | 388 (65.2) |
| Other | 35 (5.9) |
| Current or most recent occupation | |
| Professional | 136 (22.9) |
| Managerial | 51 (8.6) |
| Clerical | 164 (27.6) |
| Technical/craft | 7 (1.2) |
| Manual/service | 82 (13.8) |
| Methods | Negative effects | Number of published papers (PubMed 1975–2015) | |
| In vivo human studies | Biomonitoring methodsCorrelation studiesCross-sectional studiesPlasma/urine determinations (ELISA, GC/MS,HPLC, LC/MS) | General toxicityReproduction and developmentNeurodevelopment and neuroendocrine systemImmune systemCardiovascular systemMetabolism (diabetes, weight gain, obesity)GenotoxicityCarcinogenicity | 442 |
| In vivo animal studies (mice, rats, monkeys) | Prenatal exposureNeonatal exposureAdult animals | Immune systemMetabolism (glucose intolerance, hyper- insulinaemia, diabetes, weight gain, hyper- tryglyceridemia)CancerReproduction and development | 565 |
| Element | Summer | Winter | ||||
| Average | Min | Max | Average | Min | Max | |
| Ag | 0.42 | 0.2 | 0.9 | 0.31 | 0.1 | 0.5 |
| Al | 3800 | 200 | 14000 | 1800 | 400 | 8500 |
| As | 2 | 0.5 | 9 | 3 | 0.2 | 15 |
| Ba | 4 | 2 | 8 | 13 | 3 | 57 |
| Br | 14 | 3 | 51 | 5 | 0.4 | 18 |
| Ca | 2400 | 300 | 5800 | 1800 | 300 | 2500 |
| Cd | 0.9 | 0.2 | 4 | 0.9 | 0.2 | 5 |
| Ce | 1 | 0.09 | 3 | 0.7 | 0.1 | 4 |
| Cl | 1300 | 300 | 9300 | 1400 | 200 | 5400 |
| Co | 0.4 | 0.05 | 2.1 | 0.3 | 0.04 | 2.4 |
| Cr | 6 | 1 | 12 | 9 | 1 | 21 |
| Cs | 0.2 | 0.01 | 1.9 | 0.3 | 0.01 | 1.6 |
| Eua | 0.15 | 0.02 | 0.22 | 0.11 | 0.02 | 0.24 |
| Fe | 1850 | 600 | 4800 | 1500 | 350 | 4100 |
| Hfa | 91 | 21 | 320 | 75 | 11 | 250 |
| Hg | 0.64 | 0.1 | 1.6 | 0.45 | 0.1 | 1.5 |
| I | 6 | 2 | 12 | 4 | 3 | 9 |
| K | 930 | 100 | 3400 | 490 | 50 | 2800 |
| Laa | 12 | 1 | 38 | 7 | 0.9 | 25 |
| Mg | 1490 | 100 | 3500 | 950 | 100 | 1500 |
| Mn | 52 | 12 | 98 | 37 | 10 | 85 |
| Mo | 3.4 | 0.4 | 12 | 2.8 | 0.2 | 11 |
| Na | 2500 | 300 | 9800 | 1530 | 200 | 5200 |
| Ni | 5.5 | 1 | 19 | 4 | 1 | 15 |
| Pb | 42 | 12 | 157 | 54 | 15 | 250 |
| Rb | 5 | 1 | 18 | 6 | 1 | 24 |
| Sb | 8 | 0.5 | 17 | 9 | 0.4 | 31 |
| Sca | 45 | 14 | 120 | 51 | 12 | 135 |
| Se | 0.7 | 0.1 | 1.3 | 0.6 | 0.1 | 1.6 |
| Ta | 0.02 | 0.01 | 0.09 | 0.03 | 0.01 | 1.1 |
| Tb | 0.048 | 0.009 | 0.32 | 0.035 | 0.005 | 0.42 |
| Tha | 200 | 22 | 510 | 180 | 19 | 460 |
| Ti | 250 | 50 | 930 | 124 | 100 | 630 |
| Tl | 1.2 | 0.3 | 6 | 1.7 | 0.5 | 9 |
| U | 0.3 | 0.02 | 0.9 | 0.2 | 0.03 | 0.8 |
| V | 15 | 1 | 34 | 21 | 5 | 49 |
| Zn | 130 | 25 | 290 | 180 | 40 | 640 |
| Zr | 45 | 5 | 75 | 39 | 7 | 61 |
| Characteristic | n | % |
| Sex | ||
| Female | 1150 | 48.4 |
| Male | 1078 | 54.6 |
| Age | ||
| ≤15 | 572 | 26.8 |
| 16 | 593 | 27.8 |
| 17 | 457 | 21.4 |
| ≥18 | 514 | 24.1 |
| Grade | ||
| 9-10 | 1299 | 60.4 |
| 11-12 | 851 | 39.5 |
| Income per capita (Euros) | ||
| Lowest (0–200 TL) (0–97 Euros) | 479 | 30.7 |
| Lowest middle (201–400 TL) (98–193 Euros) | 555 | 35.6 |
| Upper middle (401–600 TL) (194–290 Euros) | 216 | 13.8 |
| Highest (601 TL +) (291 Euros and over) | 311 | 19.9 |
| Social class | ||
| Blue collar/Unemployed | 956 | 46.9 |
| Self Employed | 444 | 21.8 |
| Employer | 170 | 8.3 |
| White collar/Manager | 468 | 23.0 |
| Mother’s Education | ||
| Illiterate/Only literate | 139 | 6.4 |
| Primary (5 years) | 908 | 41.7 |
| Secondary (8 years) | 370 | 17.0 |
| High school (11 years) | 426 | 19.6 |
| University (13+ years) | 332 | 15.3 |
| School Type | ||
| Trade high school | 285 | 13.3 |
| Technical high school for girls | 212 | 9.9 |
| Standard high school | 558 | 26.0 |
| Industrial technical high school | 489 | 22.7 |
| Anatolian/Science/Private high school | 606 | 28.2 |
| Mobile phone utilization | ||
| Yes | 2005 | 92.0 |
| No | 175 | 8.0 |
| Document type | Diagnosis | Signs/symptoms | Diagnosis or symptoms |
| DMH consult notes | 11 (44%) | 13 (52%) | 13 (52%) |
| Physician notes | 1 (.06%) | 8 (32%) | 8 (32%) |
| Discharge summary | 4 (16%) | 11 (44%) | 11 (44%) |
| Nursing Notes | - | 14 (56%) | 14 (56%) |
| ICD-9 diagnosis code | 7 (28%) | - | 7 (28%) |
| Unique veterans including DMHC notes | 14 (56%) | 16 (64%) | 16 (64%) |
| Unique veterans excluding DMHC notes | 9 (36%) | 16 (64%) | 16 (64%) |
| Number | Average bleeding volume (ml) | Average exposure time (min) | |
| Group A | 34 | 8.2 ± 2.3 | 3.2 ± 2.1 |
| Group B | 32 | 6.8 ± 1.2 | 2.8 ± 1.7 |
| Group C | 36 | 15.4 ± 1.3 | 3.6 ± 2.5 |
| Year | PPP* Euro [60], own calculation] | Inflation[61] | |
| Australia | 2007 | 1.719532906 | 0.98 |
| Canada | 1998 | 1.202424923 | 0.85 |
| USA | 1993 | 0.99786743 | 0.78 |
| Germany | 2008 | 1 | 1 |
| Odds ratio | P | |
| Oxygen treatment | 4,27 | <0,01 |
| Systolic BP < 100 | 3,28 | <0,01 |
| Heart rate > 110 | 2,14 | <0,01 |
| Respiratory rate > 22 | 2,71 | <0,01 |
| SpO2 < 94 % | 1,67 | <0,01 |
| Predictor variables | Regression Type | R2[1] | SSE [2] | Significance F (p<0.05) p value [3] | Model Validation [criterion] | ΔAIC [4] | Preferred model of regression [criterion] |
| FT4 | Linear | 0.004 | 2728.62 | 0.6533 | Reject model [3] | -2.61 | Polynomial [1,2,4] |
| Polynomial | 0.09 | 2501.08 | 0.1026 | Reject model [3] | |||
| Pretreatment period | Linear | 0.07 | 2539.30 | 0.0502 | Reject model [3] | -23.88 | Polynomial [1,2,4] |
| Polynomial | 0.43 | 1558.26 | <0.0001 | Accept model [3] | |||
| CO | Linear | 0.35 | 1763.9 | <0.0001 | Accept model [3] | -9.54 | Polynomial [1,2,4] |
| Polynomial | 0.48 | 1418.57 | <0.0001 | Accept model [3] | |||
| Age | Linear | 0.48 | 1411.17 | <0.0001 | Accept model [3] | -9.08 | Polynomial [1,2,4] |
| Polynomial | 0.58 | 1144.82 | <0.0001 | Accept model [3] | |||
| Systolic BP/24h | Linear | 0.81 | 497.04 | <0.0001 | Accept model [3] | -0.09 | Polynomial [1,2,4] |
| Polynomial | 0.83 | 477.79 | <0.0001 | Accept model [3] | |||
| PVR | Linear | 0.84 | 427.39 | <0.0001 | Accept model [3] | -5.39 | Polynomial [1,2,4] |
| Polynomial | 0.86 | 371.74 | <0.0001 | Accept model [3] |
| Protein name | Corresponding gene name | Primers: Forward (F) & Reverse (R) |
| Caspase 3 | CASP3 | F: 5’-CGGAAGCAGTGCAGACGCGG-3’ |
| R: 5’-GCTGCGAGCACTCACGAAACTCTTC-3’ | ||
| Bcl-2 | BCL2 | F: 5’-TCAACCGGGAGATGTCGCCCC-3’ |
| R: 5’-ACAAAGGCATCCCAGCCTCCGTT-3’ | ||
| Bax | BAX | F: 5’-AAACTGGTGCTCAAGGCCC-3’ |
| R: 5’-TGAGGAGTCTCACCCAACCA-3’ | ||
| Cytochrome c | CYCS | F: 5’-ATGGTCTCTTTGGGCGGAAG-3’ |
| R: 5’-CTCCCCAGATGATGCCTTTGT-3’ | ||
| Collagen I | COL1A1 | F: 5’-ACGAAGACATCCCACCAATC-3’ |
| R: 5’-AGATCACGTCATCGCACAAC-3’ | ||
| Collagen III | COL3A1 | F: 5’-GCCTCCCGGAAGTCAAGGAGAAAG-3’ |
| R: 5’-CTTTAGGACCGGGGAAGCCCATG-3’ | ||
| αSMA | αSMA | F: 5’-CTGCTGAGCGTGAGATTGTC-3’ |
| R: 5’-CTCAAGGGAGGATGAGGATG-3’ | ||
| GAPDH | GAPDH | F:5’-TCTTTTGCGTCGCCAGCCGAG-3’ |
| R:5’-TGACCAGGCGCCCAATACGAC-3’ |
| Side of Surgery | |||
| Baseline INVOS | Left surgery | Right surgery S | P |
| Left baseline INVOS | 67.96 ± 7.30 | 65.91 ± 8.80 | NS |
| Right baseline INVO | 66.24 ± 6.85 | 65.66 ± 8.99 | NS |
| Soluble mediator | Ex-smokers | Smokers |
| BAL | ||
| SLPI (ng/ml) | 156 (72-386) | 87 (48-154) |
| M-CSF (pg/ml) | 150 (150-159) | 571 (150-927) |
| IL-6 (pg/ml) | 6 (6-6) | 6 (6-6) |
| IL-8 (pg/ml) | 83 (43- 193) | 64 (37-122) |
| Sputum | ||
| SLPI (ng/ml) | 5897 (4406-8628) | 6643 (4321-8862) |
| Elafin (ng/ml) | 44 (20-102) | 44 (12-101) |
| IL-6 (pg/ml) | 23 (10-36) | 30 (11-58) |
| IL-8 (pg/ml) | 3454 (1178-5212) | 2571 (805-5900) |
| Ingredients | Content (%) | Nutrients (3) | |
| Corn | 64.5 | Digestible Energy, MJ/kg | 13.81 |
| Whey powder | 5.0 | Crude Protein (%) | 19.82 |
| Soybean meal | 23.0 | Calcium (%) | 0.70 |
| Fish meal | 5.0 | Total Phosphorus (%) | 0.64 |
| L-Lysine HCl | 0.2 | Lysine (%) | 1.22 |
| CaHPO4 | 0.7 | Sulfur Amino Acid (%) | 0.65 |
| Pulverized Limestone | 0.3 | Threonine (%) | 0.75 |
| NaCl | 0.3 | Trptophan (%) | 0.22 |
| Premix (2) | 1.0 | ||
| Total | 100.0 |
| Source organ | Adult maleMBq-h/MBq | SD | Adult femaleMBq-h/MBq | SD |
| Brain | 3.43E-02 | 3.18E-03 | 3.90E-02 | 1.17E-02 |
| Red marrow | 1.37E-03 | 8.13E-04 | 1.40E-03 | 4.67E-04 |
| Liver | 6.52E + 00 | 1.45E + 00 | 6.62E + 00 | 9.05E-01 |
| Pancreas | 7.96E-02 | 9.12E-03 | 9.02E-02 | 1.41E-04 |
| Kidneys | 2.06E-01 | 5.52E-02 | 2.49E-01 | 6.93E-02 |
| LLI | 5.01E-01 | 1.38E-01 | 4.78E-01 | 1.01E-01 |
| SI | 3.30E-01 | 9.08E-02 | 3.14E-01 | 6.62E-02 |
| ULI | 6.27E-01 | 1.73E-01 | 5.98E-01 | 1.26E-01 |
| Remainder | 9.75E + 00 | 1.34E + 00 | 9.57E + 00 | 1.35E + 00 |
| Strategy | Questionnaire A communitiesn = 6,987 | Questionnaire A physiciansn = 3,013 | MIKADOn = 202 | Schoolsn = 32,000 | Total42,202 |
| Response (n (%)) | 1,012 (15) | 887 (29) | 104 (51) | 1,540 (5) | 3543 (8) |
| Primary caregiver responder: | |||||
| - Mother (n (%)) | 843 (83) | 757 (85) | 87 (84) | 1,244 (81) | 2,931 (83) |
| - Father (n (%)) | 158 (16) | 120 (14) | 14 (14) | 271 (18) | 563 (16) |
| - Other (n (%)) | 11 (1) | 10 (1) | 3 (3) | 25 (2) | 49 (1) |
| Age of children (mean (SD)) | 6.2 (4.1) | 7.6 (4.2) | 9.2 (2.3) | 8.1 (2.5) | 7.5 (3.6) |
| Age of mother (mean (SD)) | 38.9 (6.3) | 40.3 (5.6) | Not asked | 39.8 (5.1) | 39.8 (5.7)c |
| Highest parental educationa | |||||
| - Low (n (%)) | 31 (3) | 41 (5) | 23 (22) | 41 (3) | 136 (4) |
| - Middle (n (%)) | 268 (27) | 262 (30) | 50 (48) | 405 (29) | 985 (28) |
| - High (n (%)) | 404 (40) | 454 (51) | 28 (27) | 730 (45) | 1,616 (46) |
| - Academic (n (%)) | 300 (30) | 126 (14) | 3 (3) | 332 (22) | 761 (21) |
| - Other (n (%)) | 0 | 0 | 32 (2) | 32 (1) | |
| - Missing (n (%)) | 9 (1) | 4 (1) | 13 (0) | ||
| Active smoking of both parents (n (%))b | 306 (16) | 257 (15) | 141 (70) | 507 (17) | 1,211 (34) |
| Active smoking at least one parent per family (n (%)) | 250 (25) | 210 (24) | 104 (100) | 390 (25) | 954 (27) |
| Smoking in the presence of the child (n (%)) | 131 (13) | 135 (15) | 104 (100) | 141 (9) | 511 (14) |
| Wheezing ever (n (%)) | 283 (28) | 255 (29) | 29 (28) | 478 (31) | 1,045 (29) |
| Wheezing in the past 12 months (n (%)) | 144 (14) | 114 (13) | 7 (7) | 229 (15) | 494 (14) |
| Asthma diagnosis (n (%))c | 66 (13) | 65 (12) | 0 | 161 (11) | 292 (8) |
| Respiratory tract infection in the past 12 months (n (%)) | 413 (41) | 278 (31) | Not asked | 567 (37) | 1,258 (37)d |
| Asthma in the first degree relative (n (%)) | 258 (26) | 215 (24) | 104 (100) | 423 (28) | 1,000 (28) |
| DM, g/kg | g/kg, DM basis | ||||||
| Crude protein | Ether extract | Crude ashes | NDF | ADF | Starch | ||
| Experimental diets | |||||||
| LP HD | 929 | 229 | 120 | 66 | 83 | 27 | 464 |
| HP HD | 935 | 304 | 140 | 82 | 109 | 27 | 364 |
| HP LD | 938 | 303 | 124 | 123 | 111 | 33 | 338 |
| Undigested residues | |||||||
| LP HD | - | 159 | 35.7 | 215 | 539 | 175 | 41.4 |
| HP HD | - | 174 | 47.2 | 259 | 481 | 124 | 28.7 |
| HP LD | - | 212 | 24.4 | 339 | 411 | 125 | 9.0 |
| Coping | T1 | T2 | Within group | Effect size | ||||
| Mean | SD | Mean | SD | df | t | |||
| Active coping | NET-R | 3.40 | 1.07 | 5.40 | 1.35 | 9 | 3.87** | 1.57 |
| Reframing | NET | 4.40 | 1.90 | 5.50 | 2.01 | 9 | 2.91* | 0.54 |
| NET-R | 4.70 | 1.64 | 6.70 | 1.42 | 9 | 2.68* | 1.25 | |
| Planning | NET | 4.40 | 1.65 | 6.00 | 2.00 | 9 | 2.28* | 0.84 |
| Religion | WL | 4.30 | 2.06 | 4.80 | 2.30 | 9 | 3.00* | 0.22 |
| Self-distraction | NET-R | 6.90 | 1.20 | 7.90 | 0.32 | 9 | 3.87** | 1.09 |
| Content (no of questions) | Correct answers | Low risk1) | Moderate risk2) | High risk3) |
| Gen. Pharmacology (3) | 82% | 56% | 39% | 5% |
| Effect (3) | 80% | 56% | 41% | 3% |
| Side effects (3) | 81% | 59% | 34% | 7% |
| Formulations (2) | 41% | 14% | 45% | 42% |
| Interactions (1) | 60% | 22% | 68% | 10% |
| Generics (2) | 81% | 68% | 25% | 7% |
| Pharmacology (14) | 74% | 50% | 39% | 11% |
| Regulations (2) | 59% | 46% | 29% | 25% |
| Storage (4) | 33% | 21% | 51% | 27% |
| Dispensation (4) | 60% | 48% | 28% | 24% |
| Administration (4) | 63% | 49% | 23% | 28% |
| Drug management (14) | 53% | 40% | 33% | 26% |
| Conversion of units (7) | 76% | 61% | 29% | 10% |
| Dose-quantity-strength (4) | 92% | 73% | 24% | 3% |
| Infusions (2) | 84% | 57% | 40% | 4% |
| Dilutions (1) | 55% | 25% | 68% | 8% |
| Drug dose calculations (14) | 80% | 61% | 32% | 7% |
| Totalt (42) | 69% | 50% | 35% | 15% |
| Case(N = 14) | Control(N = 14) | |||||||
| Factor | n | Baseline | Endpoint | P value | n | Baseline | Endpoint | P value |
| ESS Total | 8 | 11.1 ± 4.9 | 8.4 ± 5.9 | 0.042 | 12 | 9.8 ± 6.2 | 9.0 ± 4.5 | 0.40 |
| FSS Total | 8 | 27.3 ± 13.1 | 21.3 ± 11.0 | 0.21 | 12 | 30.5 ± 11.5 | 28.2 ± 11.2 | 0.35 |
| ISI Total | 8 | 15.7 ± 3.0 | 7.8 ± 4.4 | 0.002 | 12 | 15.3 ± 3.0 | 12.2 ± 5.5 | 0.033 |
| UPDRS1b Total | 8 | 9.8 ± 4.0 | 6.9 ± 3.1 | 0.004 | 12 | 9.7 ± 1.8 | 8.6 ± 2.4 | 0.037 |
| UPDRS1b Modified | 8 | 5.4 ± 3.4 | 4.4 ± 2.1 | 0.35 | 12 | 5.4 ± 1.7 | 4.8 ± 1.6 | 0.77 |
| UPDRS2 total | 8 | 12.6 ± 7.9 | 12.3 ± 6.3 | 0.93 | 12 | 10.9 ± 7.1 | 10.6 ± 8.4 | 0.99 |
| PDQ Total | 7 | 14.4 ± 4.4 | 13.7 ± 3.7 | 0.53 | 11 | 15.6 ± 5.8 | 13.1 ± 3.8 | 0.73 |
| PHQ9 Total | 8 | 7.8 ± 5.1 | 3.5 ± 4.5 | 0.005 | 12 | 7.5 ± 4.2 | 5.4 ± 3.3 | 0.17 |
| pirs20 Total | 8 | 9.1 ± 2.4 | 5.0 ± 2.3 | <0.001 | 12 | 9.2 ± 2.1 | 7.4 ± 3.9 | 0.14 |
| EQ5D Index | 8 | 0.75 ± 0.15 | 0.71 ± 0.17 | 0.24 | 12 | 0.79 ± 0.13 | 0.77 ± 0.17 | 0.55 |
| Name | Accession |
| IAI39 | NC_011750.1 |
| SMS-3-5 | NC_010498.1 |
| E2348/69 | NC_011601.1 |
| 536 | NC_008253.1 |
| UTI89 | NC_007946.1 |
| S88 | NC_011742.1 |
| CFT073 | NC_004431.1 |
| UMN026 | NC_011751.1 |
| Sakai | NC_002695.1 |
| EDL933 | NC_002655.2 |
| S. dysenteriae 197 | NC_007606.1 |
| S. sonnei 046 | NC_007384.1 |
| S. boydii 3083 | NC_010658.1 |
| E24377A | NC_009801.1 |
| IAI1 | NC_011741.1 |
| TY-2482 | AFOG00000000 |
| 55989 | NC_011748.1 |
| SE11 | NC_011415.1| |
| H.I.8. | AFDY00000000 |
| 2009 | NC_013353.1 |
| 11128 | NC_013364.1 |
| 1368 | NC_013361.1 |
| S. flexneri 2457T | NC_004741.1 |
| 53638 | NZ_AAKB00000000 |
| HS | NC_009800.1 |
| ATCC 8739 | NC_010468.1 |
| BL21 | NC_012947.1 |
| K12 MG1655 | NC_000913.2 |
| K12 W3110 | AC_000091.1 |
| BW2952 | NC_012759.1 |
| Covariate | RMS error | 95% CI | p value |
| Distance from Camera (cm) | |||
| 150 | 0.13 | 0.12 - 0.14 | |
| 200 | 0.15 | 0.14- 0.16 | |
| 247 | 0.20 | 0.19 - 0.21 | |
| p<0.001 | |||
| Marker status | |||
| All active | 0.15 | 0.14 - 0.16 | |
| Minimum active | 0.17 | 0.16 - 0.18 | |
| p=0.03 | |||
| Patient Tracker distance (cm) | |||
| 20 | 0.17 | 0.16-0.18 | |
| 30 | 0.17 | 0.16-0.18 | |
| 40 | 0.14 | 0.13-0.15 | |
| p = 0.36 |
| Atypical antipsychotics | Typical antipsychotics | Alternatives |
| Clozapine | Haloperidol | Individual therapy |
| Risperidone | Loxapine | Family therapy |
| Olanzapine | Molindone | Skill building and psychoeducation |
| Clinical presentation and Symptoms | |||||
| GIST localization | GI bleeding | Abdominal pain | Acute abdomen | Palpable mass | Asymptomatic |
| Gastric | 8 | 11 | - | 2 | 6 |
| Duodenal | 2 | 1 | - | - | - |
| Jejunal | 1 | 1 | 2 | 1 | 2 |
| Small bowel | 2 | 1 | 3 | 1 | 1 |
| Rectal | 1 | 2 | - | - | - |
| Esophageal | - | 1 | - | - | - |
| EGIST | - | 1 | - | 1 | - |
| Code | Value | % age | Description |
| J | 190 | 9.3 | Translation, ribosomal structure and biogenesis |
| A | 0 | 0.0 | RNA processing and modification |
| K | 144 | 7.1 | Transcription |
| L | 102 | 5.0 | Replication, recombination and repair |
| B | 0 | 0.0 | Chromatin structure and dynamics |
| D | 31 | 1.5 | Cell cycle control, cell division, chromosome partitioning |
| V | 52 | 2.6 | Defense mechanisms |
| T | 56 | 2.8 | Signal transduction mechanisms |
| M | 105 | 5.2 | Cell wall/membrane biogenesis |
| N | 14 | 0.7 | Cell motility |
| U | 21 | 1.0 | Intracellular trafficking and secretion |
| O | 57 | 2.8 | Posttranslational modification, protein turnover, chaperones |
| C | 60 | 2.9 | Energy production and conversion |
| G | 177 | 8.7 | Carbohydrate transport and metabolism |
| E | 132 | 6.5 | Amino acid transport and metabolism |
| F | 90 | 4.4 | Nucleotide transport and metabolism |
| H | 79 | 3.9 | Coenzyme transport and metabolism |
| I | 66 | 3.2 | Lipid transport and metabolism |
| P | 79 | 3.9 | Inorganic ion transport and metabolism |
| Q | 25 | 1.2 | Secondary metabolites biosynthesis, transport and catabolism |
| R | 133 | 6.5 | General function prediction only |
| S | 108 | 5.3 | Function unknown |
| - | 434 | 21.3 | Not in COGs |
| Parameters | At start of CRRT | During dialysis period |
| Creatinine, mg/dl | 2.7 ± 1.3 | |
| eGFR, CKD-EPI | 24.7 ml/minute | |
| Cystatin C, mg/dl | 3.2 ± 1.1 | |
| GFR, cystatin C | 17.7 ml/minute | |
| Bilirubin, mg/dl | 9.5 ± 10.6 | 7.9 ± 6.8 |
| Albumin, g/L | 24.7 ± 7.0 | 25.0 ± 4.1 |
| Cholinesterase, ×1000 IE/L | 2.8 ± 1.7 | 2.6 ± 1.2 |
| ICG-PDR | 7.6 ± 5.8 | 9.9 ± 6.3 |
| MELD score | 29.8 ± 5.1 |
| Questions about physical activity counseling | Possible answers |
| Relevance | |
| It is important that physical activity programs for the community are offered by the health system. | (a) Strongly disagree (b) Disagree (c) Agree (d) Strongly agree |
| Viability of offering physical activity programs at primary health care units. | (a) Yes (b) No |
| Priority in offering physical activity programs in health units. | (a) Yes (b) No |
| Who is the main health professional responsible for promoting physical activity in the unit? | (a) Physician (b) Nurse (c) Physical education professional (d) Nutritionist (e) Physiotherapist (f) Others |
| What difficulties do you face with regard to physical activity counseling? | (a) Lack of knowledge (b) Lack of time (c) Lack of places for physical activity practice nearby the unit (d) Others |
| Physical activity assessment | |
| Do you usually ask about the physical activity level of your patients? | (a) Yes (b) No |
| If so, what method do you employ? | (a) General questions about engagement in physical activity (b) Specific questions about sedentary time (c) Questions about duration, type and intensity of activities (d) Standardized questionnaires (e) Other method |
| Knowledge about physical activity guidelines | |
| How do you rate your knowledge about the current recommendations on physical activity for health? | (a) Know enough (b) Would like to learn more (c) Have insufficient knowledge |
| What is the minimum number of days per week that individuals should perform of physical activity of moderate intensity in order to achieve health benefits? | __ days per week |
| On these days, what is the minimum time recommended to obtain health benefits? | __ __ __ minutes |
| How should moderate-intensity physical activity be performed to have a positive impact on health? | (a) One bout per day (b) Can be done in 2–3 bouts per day |
| What is the minimum number of days per week that individuals should perform of physical activity of vigorous intensity in order to achieve health benefits? | __ days per week |
| On these days, what is the minimum time recommended to achieve health benefits? | __ __ __ minutes |
| How should vigorous-intensity physical activity be performed to have a positive impact on health? | (a) One bout per day (b) Can be done in 2–3 bouts per day |
| People can combine moderate-intensity activities (e.g. walking) with vigorous-intensity activities (e.g. running) for meeting physical activity guidelines? | (a) Strongly disagree (b) Disagree (c) Agree (d) Strongly agree |
| Enzyme | Extension rate (nt/s) | Processivity (nt) | Kd [DNA] (nM) |
| Taq (wt) | 50 | 20 | 102 |
| Taq 42 | 85 | 20 | 2.75 |
| Taq 1C2 | ND | ND | 1.9 |
| E507K | 85 | 20 | 1.1 |
| G59W | ND | ND | 91.6 |
| p value | OR | 95% CI | ||
| Lower | Upper | |||
| Gender | 0.422 | 1.171 | 0.797 | 1.722 |
| Age | 0.107 | 1.017 | 0.996 | 1.038 |
| ECOG PS | 0.901 | 1.022 | 0.721 | 1.449 |
| Tumor focality | 0.058 | 1.504 | 0.986 | 2.294 |
| Glasgow Prognostic Score | < 0.01 | 1.539 | 1.241 | 1.908 |
| Symbol | Entrez Gene ID | Description |
| AHRR | 57491 | Aryl-hydrocarbon receptor repressor |
| AKR1C3 | 8644 | Aldo-keto reductase family 1, member C3 |
| AXIN2 | 8313 | Axin2 |
| BCL6 | 604 | B-cell CLL/lymphoma 6 |
| BIRC3 | 330 | Baculoviral IAP repeat containing 3 |
| CARD15 | 64127 | Nucleotide-binding oligomerization domain containing 2 |
| CAT | 847 | Catalase |
| CCL5 | 6352 | Chemokine (C-C motif) ligand 5 |
| CCNH | 902 | Cyclin H |
| FTHFD | 10840 | Aldehyde dehydrogenase 1 family, member L1 |
| GATA3 | 2625 | GATA binding protein 3 |
| GSTM3 | 2947 | Glutathione S-transferase mu 3 (brain) |
| HSD17B4 | 3295 | Hydroxysteroid (17-beta) dehydrogenase 4 |
| IGF1R | 3480 | Insulin-like growth factor 1 receptor |
| IL1A | 3552 | Interleukin 1, alpha |
| INSR | 3643 | Insulin receptor |
| MASP1 | 5648 | Mannan-binding lectin serine peptidase 1 (C4/C2 activating component of Ra-reactive factor) |
| MBD2 | 8932 | Methyl-CpG binding domain protein 2 |
| MMP1 | 4312 | Matrix metallopeptidase 1 (interstitial collagenase) |
| MYBL2 | 4605 | V-myb myeloblastosis viral oncogene homolog (avian)-like 2 |
| NEDD5 | 4735 | Septin 2 |
| OPRM1 | 4988 | Opioid receptor, mu 1 |
| PARP4 | 143 | Poly (ADP-ribose) polymerase family, member 4 |
| PGR | 5241 | Progesterone receptor |
| PIM1 | 5292 | Pim-1 oncogene |
| RERG | 85004 | RAS-like, estrogen-regulated, growth inhibitor |
| TNKS | 8658 | Tankyrase, TRF1-interacting ankyrin-related ADP-ribose polymerase |
| TP53I3 | 9540 | Tumor protein p53 inducible protein 3 |
| XPC | 7508 | Xeroderma pigmentosum, complementation group C |
| Variable | SCI dogs (n = 44) | Healthy control dogs (n = 21) |
| Dogs | ||
| Median age | 5.75 years | 3 years |
| MFS at admission | 2.5 | N/A |
| TSCIS at admission | 6 | N/A |
| Injury to anesthesia time | 36.5 h | N/A |
| Sex characteristics | ||
| Female intact | 4 (9 %) | 0 (0 %) |
| Female spayed | 18 (41 %) | 3 (14 %) |
| Male intact | 8 (18 %) | 5 (24 %) |
| Male neutered | 14 (32 %) | 13 (62 %) |
| Breeds | ||
| Dachshund | 34 (76 %) | 0 (0 %) |
| Labrador retriever | 0 (0 %) | 7 (33 %) |
| Mixed breed | 4 (9 %) | 5 (24 %) |
| Injuries | ||
| T12–13 | 6 (14 %) | N/A |
| T13–L1 | 13 (30 %) | N/A |
| L1–L2 | 5 (11 %) | N/A |
| L2–L3 | 8 (18 %) | N/A |
| Other thoracic | 8 (18 %) | N/A |
| Other lumbar | 4 (9 %) | N/A |
| Treatments | ||
| Non-steroidal anti-inflammatory drugs | 17 (39 %) | 0 (0 %) |
| Glucocorticoids | 14 (32 %) | 0 (0 %) |
| Both | 3 (<1 %) | 0 (0 %) |
| Measurement | Juvenile | n | Adult | n | p |
| LVAWd (mm) | 0.61 ± 0.09 | 15 | 0.74 ± 0.14 | 15 | 0.005 |
| LVAWs (mm) | 0.85 ± 0.13 | 15 | 1.08 ± 0.18 | 15 | < 0.001 |
| LVIDd (mm) | 2.84 ± 0.20 | 15 | 3.56 ± 0.19 | 15 | < 0.001 |
| LVIDs (mm) | 1.96 ± 0.21 | 15 | 2.44 ± 0.28 | 15 | < 0.001 |
| LVPWd (mm) | 0.59 ± 0.15 | 15 | 0.64 ± 0.13 | 15 | ns |
| LVPWs (mm) | 0.81 ± 0.17 | 15 | 0.88 ± 0.19 | 15 | ns |
| EF (%) | 59.63 ± 9.05 | 15 | 59.91 ± 8.15 | 15 | ns |
| FS (%) | 30.76 ± 6.15 | 15 | 31.45 ± 5.63 | 15 | ns |
| IVSd (mm) | 0.41 ± 0.08 | 15 | 0.47 ± 0.15 | 15 | ns |
| IVSs (mm) | 0.50 ± 0.13 | 15 | 0.62 ± 0.25 | 15 | ns |
| RVIDd (mm) | 1.08 ± 0.15 | 7 | 1.42 ± 0.19 | 11 | 0.001 |
| RVIDs (mm) | 0.65 (0.31) | 7 | 0.89 (0.21) | 11 | ns |
| RVAWd (mm) | 0.50 ± 0.11 | 7 | 0.32 ± 0.08 | 11 | 0.001 |
| RVAWs (mm) | 0.66 ± 0.16 | 7 | 0.57 ± 0.13 | 11 | ns |
| Variable | Value |
| Body length (from snout to vent) (cm) | 45.07 ± 2.83 |
| Length of tail (cm) | 6.07 ± 0.85 |
| Length of left vas deferens from testis to vent (cm) | 15.30 ± 1.21 |
| Length of right vas deferens from testis to vent (cm) | 11.74 ± 1.003 |
| Weight of right testis (mg) | 123.07 ± 16.01 |
| Weight of left testis (mg) | 93.07 ± 17.02 |
| Volume of right testis (mL) | 0.12 ± 0.03 |
| Volume of left testis (mL) | 0.06 ± 0.01 |
| Length of right testis (mm) | 21.77 ± 3.70 |
| Length of left testis (mm) | 16.69 ± 3.95 |
| Week of Induction | IOL CD | Expt mgmt CD | AOR (95% CI)† | Spontaneous Labor CD |
| 38 weeks | 11.9% | 13.3% | 1.80 (1.29 – 2.53) | 7.0%* |
| 39 weeks | 14.3% | 15.0% | 1.39 (1.08 – 1.80) | 9.1%* |
| 40 weeks | 20.4% | 19.0% | 1.27 (1.00 – 1.62) | 10.9%* |
| 41 weeks | 24.3% | 26.0% | 1.26 (0.99 – 1.61) | 14.9%* |
| Posterior vs anterior | Anterior half, Vg1-like | ||||||
| Gene symbol | Probe ID | Fold change | p Value | Rank | Fold change | p Value | Rank |
| ADMP | Gga.354.1.S1_at | 13.095 | 0.0080 | 1 | 3.771 | 0.0686 | 2 |
| PITX2 | Gga.3398.2.S1_a_at | 9.586 | 0.0001 | 2 | 2.162 | 0.0069 | 8 |
| PITX2 | Gga.3398.1.S1_a_at | 8.528 | 0.0001 | 3 | 2.429 | 0.0087 | 4 |
| THPO | GgaAffx.21801.1.S1_at | 7.398 | 0.0009 | 4 | 2.272 | 0.0267 | 7 |
| ST6-GAL2 | Gga.14379.1.S1_at | 6.896 | 0.0744 | 5 | 2.506 | 0.0003 | 3 |
| T | Gga.3772.1.S1_a_at | 6.388 | 0.0867 | 6 | 5.544 | 0.0251 | 1 |
| PKDCC | Gga.12157.1.S1_at | 5.618 | 0.0006 | 7 | 1.572 | 0.2048 | 33 |
| PITX2 | Gga.3398.1.S1_at | 5.263 | 0.0030 | 8 | 2.320 | 0.0026 | 6 |
| MIXL1 | Gga.426.1.S1_s_at | 5.197 | 0.0160 | 9 | 2.378 | 0.0185 | 5 |
| n/a | Gga.2705.1.S1_at | 5.019 | 0.00002 | 10 | 1.415 | 0.0237 | 63 |
| GDF3 | Gga.4324.2.S1_a_at | 4.309 | 0.00006 | 11 | 1.710 | 0.0062 | 21 |
| PMEPA1 | Gga.6268.1.S1_at | 4.141 | 0.0805 | 12 | 2.032 | 0.0103 | 12 |
| PMEPA1 | GgaAffx.12721.1.S1_at | 3.777 | 0.0007 | 13 | 1.745 | 0.0003 | 19 |
| TBX6 | Gga.466.1.S1_at | 3.694 | 0.0004 | 14 | 2.030 | 0.0210 | 13 |
| FGF8 | Gga.661.1.S1_at | 3.277 | 0.0052 | 15 | 1.690 | 0.0859 | 22 |
| Ovoinhibitor | Gga.6976.1.S1_at | 3.213 | 0.0015 | 16 | 1.467 | 0.0633 | 50 |
| ELK3 | Gga.4498.1.S1_s_at | 3.094 | 0.0096 | 17 | 1.503 | 0.0010 | 43 |
| LITAF | Gga.3383.1.S2_at | 3.066 | 0.0031 | 18 | 1.670 | 0.0110 | 25 |
| LITAF | Gga.3383.1.S1_at | 2.895 | 0.0019 | 19 | 1.822 | 0.0027 | 17 |
| n/a | Gga.13092.1.S1_at | 2.823 | 0.0025 | 20 | 1.406 | 0.0284 | 66 |
| Ever diagnosed with asthmaa(N = 5,646) | Wheeze in past 12 monthsb(N = 5,647) | Ever diagnosed with bronchitisc(N = 7,114) | ||||
| No. cases | OR (95% CI) | No. cases | OR (95% CI) | No. cases | OR (95% CI) | |
| Gas stove used with ventilation | ||||||
| No | 263 | 1 Ref. | 555 | 1 Ref. | 184 | 1 Ref. |
| Yes | 224 | 0.68 (0.45, 1.04) | 458 | 0.62 (0.44, 0.89)* | 128 | 0.61 (0.38, 0.98)* |
| Gas stove used for heating | ||||||
| Yes | 382 | 1 Ref. | 795 | 1 Ref. | 239 | 1 Ref. |
| No | 105 | 0.56 (0.34, 0.94)* | 218 | 0.57 (0.38, 0.85)* | 73 | 1.12 (0.66, 1.92) |
| Extract | Total saponina | Rg1 | Re | Rd |
| Content (%) | Content (%) | Content (%) | Content (%) | |
| GTS | 66.9 ± 1.5 | 4.9 ± 0.2 | 3.4 ± 0.1 | 1.6 ± 0.1 |
| Partition | Resolution1 | TE MAFFT2 | TE BAli-Phy2 | Protein coding |
| rRNA MAFFT | 95% | 0.287 | 0.264 | 0.309 |
| rRNA BAli-Phy | 95% | 0.272 | 0.221 | 0.261 |
| CAD | 91% | 0.339 | 0.329 | 0.207 |
| EFF1 | 79% | 0.434 | 0.440 | 0.404 |
| EFF2 | 67% | 0.403 | 0.416 | 0.419 |
| POL | 77% | 0.438 | 0.458 | 0.415 |
| CO1 | 74% | 0.384 | 0.381 | 0.358 |
| Morphology | 91% | 0.292 | 0.298 | 0.362 |
| Variable | Carotid Score | m-IMT | Left Ventricular Mass |
| Age | r = 0.53p < 0.01 | r = 0.46p < 0.01 | - |
| Weight | - | - | r = 0.53p < 0.01 |
| Height | - | - | r = 0.38p < 0.05 |
| Body Mass Index | - | - | - |
| Waist Circumference | - | - | r = 0.57p < 0.001 |
| Systolic BP | - | - | - |
| Diastolic BP | - | - | - |
| Pulse Pressure | - | - | - |
| Heart Rate | - | - | - |
| Total Cholesterol | - | - | - |
| HDL Cholesterol | - | - | - |
| Total/HDL Ratio | - | - | - |
| Triglycerides | - | - | - |
| Glucose | - | - | - |
| Insulin | - | - | - |
| Creatinine | - | - | - |
| Uric acid | - | - | - |
| Progetto CuoreScore | r = 0.55p < 0.001 | r = 0.36p < 0.05 | - |
| Progetto CuoreScore – Logarithm | r = 0.54p < 0.01 | r = 0.43p < 0.05 | - |
| MCF-7 | MDA-MB-231 | |
| SSTR1 | ++ | +++ |
| SSTR2 | +++ | ++ |
| SSTR3 | + | + |
| SSTR4 | ++++ | ++++ |
| SSTR5 | + | + |
| Characteristic | Coefficient (95% CI) | p-value |
| Treatment regimen | 0.04 | |
| Prophylaxis | 10.0 (0.7, 19.3) | |
| On-demand | reference | |
| Chronic painb | 0.03 | |
| Moderate to severe | −10.0 (−19.2, −0.8) | |
| None to mild | reference |
| Subgroups | HR | 95% CI | P Value |
| Patients with diabetes mellitus | 0.36 | 0.14 to 0.90 | 0.03 |
| Patients without diabetes mellitus | 0.74 | 0.41 to 1.33 | 0.32 |
| Patients with hypertension | 0.57 | 0.36 to 0.92 | 0.02 |
| Patients with hyperlipidemia | 0.93 | 0.38 to 2.27 | 0.89 |
| Patients with normal lipids | 0.47 | 0.26 to 0.83 | 0.009 |
| Patients with prior myocardial infarction | 1.36 | 0.30 to 6.1 | 0.70 |
| Patients with no prior myocardial infarction | 0.57 | 0.35 to 0.94 | 0.02 |
| Patients with major cardiac adverse events | 0.30 | 0.08 to 1.13 | 0.07 |
| Patients with no major cardiac adverse events | 0.59 | 0.36 to 0.97 | 0.04 |
| baseline n (%) | six months n (%) | |
| Nightly pain | 75 (34.7%) | 68 (31.5%) |
| (38 (50.7%) persistent)b | ||
| Unbearable pain | 29 (13.4%) | 34 (15.7%) |
| (17 (58.6%) persistent) | ||
| Pain when changing position | 88 (40.7%) | 83 (38.4%) |
| (57 (64.8%) persistent) | ||
| Pain when walking | 45 (20.8%) | 44 (20.4%) |
| (23 (51.1%) persistent) | ||
| Pain when standing | 49 (22.7%) | 41 (19.0%) |
| (17 (34.7%) persistent) | ||
| Constant pain | 50 (23.1%) | 47 (21.8%) |
| (33 (66.0%) persistent) | ||
| Pain when stair climbing | 7 (3.2%) | 3 (1.4%) |
| (1 (14.3%) persistent) | ||
| Pain when sitting | 89 (41.2%) | 66 (30.6%) |
| (44 (49.4%) persistent) |
| Assaysb | Sensitivity (%) | Specificity (%) | Accuracy (%) | LR+c | LR−d | DORe | ROC analysis, AUC (95% CI) |
| WB PCRf (95% CI) | 73 (54–86) | 92 (76–98) | 82.7 | 9.5 | 0.3 | 32.7 | |
| Serum PCR (95% CI) | 65 (46–81) | 79 (60–91) | 72.0 | 3.1 | 0.4 | 7.3 | |
| GM (95% CI) | 68 (47–84) | 80 (61–91) | 74.5 | 3.4 | 0.4 | 8.5 | 0.77 (0.62–0.91) |
| BDG (95% CI) | 46 (27–65) | 100 (86–100) | 74.5 | >455 | 0.6 | >827.3 | 0.82 (0.70–0.95) |
| Serum/WB PCR | 91/33 | 65/100 | 77/68 | 2.6/>330 | 0.1/0.7 | 18.6/>495 | 0.84 (0.72–0.96) |
| BDG/WB PCR | 86/24 | 91/100 | 89/64 | 9.6/>240 | 0.2/0.8 | 48/>300 | 0.90 (0.79–1.00) |
| GM/WB PCR | 100/33 | 78/96 | 89/66 | 4.5/8.3 | <0.001/0.7 | >4500/11.8 | 0.91 (0.81–1.00) |
| BDG/serum PCR | 76/33 | 74/100 | 75/68 | 2.9/>330 | 0.3/0.7 | 9.7/>471 | 0.79 (0.66–0.93) |
| GM/serum PCR | 90/43 | 61/96 | 75/70 | 2.3/10.8 | 0.2/0.6 | 11.5/18 | 0.82 (0.70–0.95) |
| GM/BDG | 81/38 | 83/100 | 82/70 | 4.8/>380 | 0.2/0.6 | 24/>613 | 0.85 (0.73–0.97) |
| WB PCR/GM/BDG | 100/67/14 | 78/96/100 | 89/82/59 | 4.5/16.8/>140 | <0.001/0.3/0.9 | >5000/57/>156 | 0.95 (0.88–1.00) |
| Serum PCR/GM/BDG | 100/48/33 | 61/96/100 | 80/73/68 | 2.6/12/>330 | <0.002/0.5/0.7 | >1300/24/>471 | 0.88 (0.79–0.98) |
| WB/serum PCR/BDG | 90/71/10 | 65/100/100 | 77/86/57 | 2.6/>710/>100 | 0.2/0.3/0.9 | 13/>2367/>111 | 0.90 (0.81–1.00) |
| WB/serum PCR/GM | 100/81/14 | 57/91/100 | 77/86/59 | 2.3/9/>140 | <0.002/0.2/0.9 | >187/45/>156 | 0.92 (0.84–1.00) |
| All four assays | 100/91/44/10 | 57/91/100/100 | 77/91/73/57 | 2.3/10.4/>429/>950 | <0.001/0.1/0.6/0.9 | >2300/104/>751/>1044 | 0.95 (0.90–1.00) |
| NSR (n = 361) | AF (n = 81) | p | |
| Before surgery | |||
| LV end diastolic dimension (mm) | 56.6 ± 10.8 | 55.0 ± 10.9 | 0.375 |
| LV end systolic dimension (mm) | 38.4 ± 9.2 | 38.7 ± 9.9 | 0.863 |
| LV ejection fraction (%) | 62.7 ± 10.0 | 58.9 ± 14.1 | 0.026 |
| LA antero-posterior dimension (AP) (mm) | 50.7 ± 8.7 | 53.1 ± 6.9 | 0.080 |
| LA medio-lateral dimension (ML) (mm) | 56.2 ± 10.6 | 58.6 ± 9.9 | 0.339 |
| LA supero-inferior dimension (SI) (mm) | 62.4 ± 9.7 | 60.4 ± 9.1 | 0.372 |
| LA volume index (ml/m2)a | 58.4 ± 24.9 | 62.9 ± 22.8 | 0.399 |
| TR grade | 0.4 ± 0.8 | 1.2 ± 1.1 | 0.005 |
| Estimated PAP | 39.2 ± 17.5 | 44.5 ± 18.4 | 0.252 |
| After surgery | |||
| LV end diastolic dimension (mm) | 48.9 ± 5.3 | 50.1 ± 8.9 | 0.126 |
| LV end systolic dimension (mm) | 33.8 ± 5.8 | 35.9 ± 10.8 | 0.015 |
| LV ejection fraction (%) | 60.9 ± 9.5 | 57.2 ± 13.8 | 0.006 |
| LA AP dimension (mm) | 42.9 ± 6.0 | 50.7 ± 8.1 | < .001 |
| LA ML dimension (mm) | 50.3 ± 6.8 | 56.3 ± 7.5 | < .001 |
| LA SI dimension (mm) | 57.3 ± 27.5 | 61.8 ± 8.2 | 0.172 |
| LA AP change (mm) | 7.7 ± 8.4 | 4.1 ± 7.9 | 0.011 |
| LA ML change (mm) | 6.7 ± 10.4 | 3.4 ± 10.1 | 0.197 |
| LA SI change (mm) | 7.4 ± 9.0 | 1.3 ± 8.3 | 0.005 |
| LA volume index (ml/m2) | 37.9 ± 12.6 | 52.1 ± 15.6 | < .001 |
| LA volume change (ml/m2) | 20.5 ± 21.3 | 10.8 ± 23.4 | 0.041 |
| LA volume change % | 28.1 ± 27.9 | 9.5 ± 36.8 | < .001 |
| MDPG of the MV (mmHg) | 3.5 ± 1.4 | 3.9 ± 1.5 | 0.023 |
| Residual mitral regurgitation | 0.337 | ||
| No | 352 (97.5%) | 77 (95.1%) | |
| Trivial | 8 (2.2%) | 3 (3.7%) | |
| More than grade I | 1 (0.3%) | 1 (1.2%) | |
| TR grade | 0.3 ± 0.6 | 1.0 ± 1.0 | < 0.001 |
| Estimated PAP | 26.4 ± 6.6 | 29.8 ± 7.1 | 0.001 |
| TAP or TVR | 33 (7.5%) | 6 (1.4%) | 0.828 |
| • | ‘I would prefer to see the same consultant in hospital, as I trust her already and would find it hard to build the same level of trust with someone else’ |
| • | ‘Continuity of care- New consultant may not read all information or interpret it differently’ |
| • | ‘A relationship of trust with your own consultant takes time to build and could never be done with a stranger that you meet now and again’ |
| • | ‘I’d prefer the above mainly for comfort and familiarity. I’ve shared my condition and stories enough times; having to repeat everything is pointless and counterproductive. It feels like an exercise in futility’ |
| • | ‘Continuity of care. I feel it would be best for me to have my care managed by someone who is familiar with me and can compare my symptoms with when I am well’ |
| • | ‘Over the past 5 years, I have had annual review as an outpatient and have seen a few different psychiatrists each time. I would prefer to be seen by one psychiatrist and also if admitted to hospital to see the same one’ |
| • | ‘Seeing the same doctor means you do not have to repeat your illness every time as this can be upsetting’ |
| • | ‘On one hand having the same consultant might give a sense of security. On the other hand, a different consultant having slightly different experiences, may also be a good thing-My personal view is that I would rather choose to have the same consultant’ |
| Medium | Score | |
| Ham's F-12 | +10% FCS | 180 |
| DMEM/Ham's F-12 (1:1) | +10% FCS | 170 |
| Medium199 | +10% FCS | 165 |
| DMEM | +10% FCS | 165 |
| McCoy's 5A | +10% FCS | 140 |
| Author, Year, Citation | Sample size* | Respondents who reported the PtDA was balanced.n (%) | Did the PtDA include side-by-side display of evidence? | Did the PtDA include any side-by-side display? |
| Mathieu, Barratt et al., 2010 [14] | 117 | 66 (57%) | no | no |
| Smith, Trevena et al., 2010 [15] | 334 | 160 (48%) | no | no |
| Griffith, Fichter et al., 2008 [6] | 106 | 17 (16%) | unclear | unclear |
| Spunt, Deyo et al., 1996 [16] | 239 | 133 (56%) | unclear | unclear |
| Anderson, Carter et al., 2011 [17] | 19 | 17 (89%) | no | yes |
| Watson, Hewitson et al., 2006 [18] | 468 | 439 (94%) | no | yes |
| Drake, Engler-Todd et al., 1999 [19] | 38 | 27 (71%) | yes | yes |
| Lalonde, O’Connor et al., 2004 [20] | 16 | 13 (80%) | yes | yes |
| van Tol-Geerdink, Stalmeier et al., 2006 [21] | 150 | 142 (95%) | yes | yes |
| van Tol-Geerdink, Leer et al., submitted [22] | 153 | 147 (96%) | yes | yes |
| Position of the tapes | at 3 months after surgery | at 6 months after surgery | at one year after surgery |
| Proximal third of the urethra | 3,92 % | 9,81 % | 9,81 % |
| The middle third of the urethra | 88,23 % | 82,35 % | 82,35 % |
| Distal third | 7,84 % | 7,84 % | 7,84 % |
| Semester | Nominees | Non-nominees | ||
| Weekday | Weekend | Weekday | Weekend | |
| Semester 1 | 97 | 63 | 28 | 8 |
| Semester 2 | 303 | 144 | 42 | 13 |
| Variables | CSS | OS | ||||
| HR | 95%CI | p-Value | HR | 95%CI | p-Value | |
| Age (continuous variable) | 1.037 | 1.027–1.048 | <0.001 | 1.041 | 1.032–1.049 | <0.001 |
| Race | ||||||
| Non-Hispanic White | 1 | 1 | ||||
| Non-Hispanic Black | 0.478 | 0.245–0.932 | 0.030 | 0.698 | 0.444–1.098 | 0.119 |
| Hispanic (all Races) | 0.881 | 0.581–1.336 | 0.550 | 0.898 | 0.643–1.255 | 0.529 |
| Other | 0.312 | 0.100–0.977 | 0.046 | 0.403 | 0.179–0.904 | 0.027 |
| Tumor grade | ||||||
| Well differentiated | 1 | 1 | ||||
| Moderately differentiated | 0.937 | 0.646–1.358 | 0.730 | 0.972 | 0.719–1.314 | 0.853 |
| Poorly/undifferentiated | 0.852 | 0.570–1.272 | 0.433 | 0.879 | 0.635–1.217 | 0.436 |
| Tumor size (continuous variable) | 1.013 | 1.009–1.018 | <0.001 | 1.012 | 1.008–1.016 | <0.001 |
| Number of PLNs (n) | ||||||
| 1 | 1 | 1 | ||||
| 2 | 1.408 | 1.007–1.969 | 0.046 | 1.156 | 0.879–1.521 | 0.3 |
| ≥3 | 2.367 | 1.753–3.197 | < 0.001 | 2.208 | 1.744–2.796 | <0.001 |
| Number of RLNs (n) | ||||||
| 7–10 | 1 | 1 | ||||
| 1–6 | 1.588 | 1.113–2.266 | 0.011 | 1.335 | 1.008–1.767 | 0.044 |
| 11–16 | 0.782 | 0.530–1.153 | 0.215 | 0.712 | 0.527–0.961 | 0.027 |
| 17–45 | 0.962 | 0.653–1.416 | 0.844 | 0.817 | 0.603–1.107 | 0.192 |
| Adjuvant radiotherapy | ||||||
| No | 1 | 1 | ||||
| Yes | 0.806 | 0.612–1.062 | 0.126 | 0.721 | 0.580–0.895 | 0.003 |
| Chemotherapy | ||||||
| No/unknown | 1 | 1 | ||||
| Yes | 0.917 | 0.688–1.222 | 0.556 | 0.744 | 0.584–0.947 | 0.016 |
| 6 months | 12 months | |||||
| Characteristics | n/N (%) | RR | 95%CI | n/N (%) | RR | 95%CI |
| Minority | ||||||
| No | 593/627 (94.6%) | 481/513 (93.8%) | ||||
| Yes | 546/662 (82.5%) | 0.87 | 0.84-0.91 | 402/487 (82.5%) | 0.88 | 0.84-0.92 |
| Family composition | ||||||
| One child | 533/589 (90.5%) | 436/478 (91.2%) | ||||
| Two children | 474/532 (89.1%) | 0.98 | 0.95-1.02 | 351/400 (87.8%) | 0.96 | 0.92-1.01 |
| More than 3 children | 138/174 (79.3%) | 0.88 | 0.81-0.95 | 102/128 (79.7%) | 0.87 | 0.80-0.96 |
| Child’s health insurance | ||||||
| Public | 733/793 (92.4%) | 583/645 (90.4%) | ||||
| Other | 397/486 (81.7%) | 0.88 | 0.84 - 0.93 | 295/348 (84.8%) | 0.94 | 0.89-0.99 |
| Mother’s age | ||||||
| ≤20 | 43/89 (48.3%) | 26/54 (48.1%) | ||||
| 21-30 | 552/613 (90.0%) | 1.86 | 1.50-2.31 | 436/495 (88.1%) | 1.83 | 1.38-2.42 |
| 31-40 | 500/541 (92.4%) | 1.91 | 1.54-2.37 | 385 / 415 (92.8%) | 1.93 | 1.46-2.54 |
| ≥41 | 50/52 (96.2%) | 1.99 | 1.59-2.48 | 42 / 42 (100.0%) | NA | NA-NA |
| Father’s age | ||||||
| ≤20 | 23/46 (50.0%) | 11/26 (42.3%) | ||||
| 21-30 | 284/350 (81.1%) | 1.62 | 1.21-2.18 | 231/279 (82.8%) | 1.96 | 1.25-3.08 |
| 31-40 | 626/661 (94.7%) | 1.89 | 1.42-2.53 | 472/515 (91.7%) | 2.17 | 1.38-3.40 |
| ≥41 | 205/229 (89.5%) | 1.79 | 1.34-2.40 | 170/181 (93.9%) | 2.22 | 1.41-3.48 |
| Mother’s education | ||||||
| Illiterate | 57/111 (51.4%) | 28/71 (39.4%) | ||||
| < high school | 180/225 (80.0%) | 1.56 | 1.29-1.89 | 132/163 (81.0%) | 2.05 | 1.52-2.77 |
| High school | 538/567 (94.9%) | 1.85 | 1.54-2.22 | 425/450 (94.4%) | 2.39 | 1.79-3.20 |
| >high school | 355/377 (94.2%) | 1.83 | 1.53-2.20 | 29/307 (94.5%) | 2.40 | 1.79-3.20 |
| Father’s education | ||||||
| Illiterate | 49/102 (48.0%) | 29/66 (43.9%) | ||||
| < high school | 180/219 (82.2%) | 1.71 | 1.39-2.11 | 119/154 (77.3%) | 1.76 | 1.32-2.34 |
| High school | 609/646 (94.3%) | 1.96 | 1.60-2.40 | 499/529 (94.3%) | 2.15 | 1.63-2.82 |
| >high school | 276/292 (94.5%) | 1.97 | 1.60-2.41 | 214/228 (93.9%) | 2.14 | 1.62-2.81 |
| Mother’s occupation | ||||||
| Unemployed | 422/519 (81.3%) | 332/406 (81.8%) | ||||
| Blue collar Worker | 11/15 (73.3%) | 0.90 | 0.66-1.23 | 8/11 (72.7%) | 0.89 | 0.62-1.28 |
| Public sector employee | 98/99 (99.0%) | 1.22 | 1.16-1.27 | 84/84 (100.0%) | NA | NA-NA |
| Private sector employee | 297/311 (95.5%) | 1.17 | 1.12-1.23 | 240/245 (98.0%) | 1.20 | 1.14-1.26 |
| Father’s occupation | ||||||
| Unemployed | 167/207 (80.7%) | 118/160 (73.8%) | ||||
| Worker | 204/266 (76.7%) | 0.95 | 0.87-1.04 | 163/201 (81.1%) | 1.10 | 0.98-1.23 |
| Public sector employee | 114/125 (91.2%) | 1.13 | 1.04-1.23 | 99/99 (100.0%) | NA | NA-NA |
| Private sector employee | 426/436 (97.7%) | 1.21 | 1.13-1.30 | 342/359 (95.3%) | 1.29 | 1.17-1.42 |
| Age group | |||||
| Baseline characteristic | Overall cohort (n=41,088) | >50 years (n=2591) | 15 to 50 years (n=38,497) | p-value (>50 vs 15 to 50 years) | |
| Age (years) | Median (IQR) | 34 (29, 40) | 53 (51, 57) | 33 (29, 38) | N/A |
| Sex n (%) | Female | 19,891 (48.4) | 1225 (47.3) | 18,666 (48.5) | 0.24* |
| Male | 21,184 (51.6) | 1365 (52.7) | 19,819 (51.5) | ||
| Not available | 13 (0.0) | 1 (0.0) | 12 (0.0) | ||
| WHO Stage n (%) | 1 | 3722 (9.1) | 180 (7.0) | 3542 (9.2) | <0.01* |
| 2 | 3951 (9.6) | 277 (10.7) | 3674 (9.5) | ||
| 3 | 20,549 (50.0) | 1435 (55.6) | 19,114 (49.7) | ||
| 4 | 12,057 (29.3) | 635 (24.6) | 11,422 (29.7) | ||
| Not available | 809 (2.0) | 64 (2.5) | 745 (1.9) | ||
| Baseline CD4 n (%) | <200 | 16,038 (39.0) | 882 (34.0) | 15,156 (39.4) | 0.65* |
| 200 to 499 | 5832 (14.2) | 313 (12.1) | 5519 (14.3) | ||
| 500 + | 679 (1.7) | 32 (1.2) | 647 (1.7) | ||
| Not available | 18,539 (45.1) | 1364 (52.6) | 17,175 (44.6) | ||
| BMI n (%) | <18.5 | 15,258 (37.1) | 882 (34.0) | 14,376 (37.3) | <0.01* |
| 18.5 to 25 | 14,201 (34.6) | 897 (34.6) | 13,304 (34.6) | ||
| >25 | 1399 (3.4) | 123 (4.8) | 1276 (3.3) | ||
| Not available | 10,230 (24.9) | 689 (26.6) | 9541 (24.8) | ||
| Region n (%) | Africa | 9156 (22.3) | 801 (30.9) | 8355 (21.7) | <0.01 |
| Asia | 31,698 (77.1) | 1781 (68.7) | 29,917 (77.7) | ||
| Europe | 234 (0.6) | 9 (0.4) | 225 (1.0) | ||
| Duration of ART (years) | Median (IQR) | 1.7 (0.6, 3.4) | 1.4 (0.6, 2.9) | 1.7 (0.6, 3.5) | <0.01 |
| Test | Strain H-6 | Alteromonas macleodii |
| Starch hydrolysis | + | + |
| Catalase | + | + |
| H2S production | + | + |
| Gelatin hydrolysis | + | + |
| Indole test | – | 0 |
| Methyl-red test | – | + |
| Voges-Proskauer test | – | – |
| Citrate utilization | – | 0 |
| Arginine utilization | + | 0 |
| Phenylalanine utilization | – | 0 |
| Glucose utilization | + | + |
| Lactose utilization | + | + |
| Sucrose utilization | + | + |
| Gram reaction | G− | G− |
| Polymorphism | Cachexia n = 61 (%) | Noncachexia n = 64 (%) | χ2 | P |
| IL-8 −251 A/T | 1.224 | .542 | ||
| AA | 12 (19.7) | 8 (12.5) | ||
| AT | 34 (55.7) | 38 (59.4) | ||
| TT | 15 (24.6) | 18 (28.1) | ||
| A allele | 58 (47.5) | 54 (42.2) | 0.724 | .395 |
| T allele | 64 (52.5) | 74 (57.8) | ||
| IL-8 +781 C/T | 9.315 | .009 | ||
| CC | 13 (21.3) | 27 (42.2) | ||
| CT | 29 (47.5) | 29 (45.3) | ||
| TT | 19 (31.2) | 8 (12.5) | ||
| C allele | 55 (45.1) | 83 (64.8) | ||
| T allele | 67 (54.9) | 45 (35.2) | 9.864 | .002 |
| 2004 | 2005 | ||||||
| dry season | rainy season | global | dry season | rainy season | global | ||
| Data | Mean | 0.390 | 0.311 | 0.351 | 0.166 | 0.212 | 0.190 |
| SD& | 0.385 | 0.260 | 0.330 | 0.241 | 0.257 | 0.250 | |
| Kriging model | Ordinary | Ordinary | Ordinary | Ordinary | Universal | Ordinary | |
| Transform data | No | No | No | No | No | No | |
| Trend Removal | No | No | No | No | Yes | No | |
| Searching Neighborhood | Radius (m) | 9924.7 | 9509.9 | 9509.9 | 9924.7 | 9509.9 | 9924.7 |
| Angle | 0 | 0 | 0 | 0 | 0 | 0 | |
| Prediction error measurements | Mean | 0.021 | 0.005 | 0.012 | 0.005 | 0 | -0.0004 |
| MSE# | 0.435 | 0.302 | 0.338 | 0.157 | 0.113 | 0.102 | |
| Average Stand. Error | 0.4 | 0.282 | 0.308 | 0.144 | 0.11 | 0.102 | |
| SMSE$ | 1.09 | 1.074 | 1.098 | 1.088 | 1.015 | 1.006 |
| Medical Costs | Costs per Hypoglycemia Event | Costs per Cardiovascular Events | Weight Gain Costs (transition costsa) | Total Costs (without transition costsa) | |
| Metformin monotherapy | $24 | $0 | $141 | $0 | $165 |
| Metformin+DPP-4i | $3524 | $0 | $330 | $0 | $3854 |
| Metformin+DPP-4i + Basal insulin | $7170 | $1 | $366 | $0 | $7537 |
| Metformin+SU | $40 | $4 | $441 | $148 | $486 |
| Metformin+SU + Basal insulin | $3686 | $1 | $366 | $0 | $4054 |
| Agricultural sector | Specific application areas | References |
| Agronomy/Horticulture | Crop protection | [2,33] |
| Cultivar selection & discrimination | [34,35,44] | |
| Pesticide detection | [33,45–48] | |
| Plant cell culture | [36] | |
| Biotechnology processes | Monitoring | [49,50] |
| Botany | Floral odors | [37] |
| Plant identification | [30] | |
| Plant volatiles detection | [30,38,39] | |
| Taxonomic determinations | [30] | |
| Cell culture | Plant growth | [36] |
| Chemistry | Chemical detection & identification | [51] |
| Classification | [52,53] | |
| Ecology | Niche roles in ecosystem | [30] |
| Plant and animal species identification | [30] | |
| Entomology | Detect insects or induced plant volatiles | [54–56] |
| Insect identification and plant damage | [57–61] | |
| Environmental hazards | Ecosystem management | [30] |
| Explosive vapors | [62–64] | |
| Health hazards monitoring | [5,65–70] | |
| Toxic gas detection | [71–77] | |
| Water contamination detection | [78–81] | |
| Food production | Chemical contaminants | [82] |
| Microbial pathogens or toxins | [83,84] | |
| Forestry/Silviculture | Classify/identify wood types | [30,85] |
| Forest health protection | [2,86] | |
| Forest management | [30] | |
| Industrial Processes | Process monitoring control | [87,88] |
| Formulation development | [89] | |
| Quality control | [90] | |
| Microbiology | Discrimination of strains | [91–95] |
| Identification of microbes | [96] | |
| Microbial growth phases | [97] | |
| Pathogen detection | [98] | |
| Toxin production | [99] | |
| Monitoring | Enzyme and protein activity | [100] |
| Humidity | [101,102] | |
| Immunoglobulin levels | [103] | |
| Oxygen levels | [104] | |
| Plant volatiles | [39] | |
| Physiological conditions | Disease effects on plant physiology | [31,32] |
| Fruits | [105] | |
| Plant Pathology | Crop protection against bioterrorism | [2] |
| Disease detection and monitoring | [2,106–112] | |
| Host identification | [30,85] | |
| Host physiology (pathogenesis effects) | [31,32,105] | |
| Host resistance | [113] | |
| Pathogen identification | [2,106] | |
| Post-harvest decay or rot detection | [114–118] | |
| Wood decay fungi | [2,86,96,119,120] | |
| Wood decay types | [2,86] | |
| Waste management | Monitoring malodorous emissions | [23,121–125] |
| Wood science | Wood identifications | [30,85,126] |
| Pathways | Map B | No. of genes | No. of TFs |
| 00010: Glycolysis/gluconeogenesis | Carbohydrate metabolism | 57 | 14 |
| 00500: Starch and sucrose metabolism | Carbohydrate metabolism | 32 | 12 |
| 00520: Amino sugar and nucleotide sugar metabolism | Carbohydrate metabolism | 48 | 20 |
| 00620: Pyruvate metabolism | Carbohydrate metabolism | 39 | 22 |
| 00030: Pentose phosphate pathway | Carbohydrate metabolism | 25 | 14 |
| 00630: Glyoxylate and dicarboxylate metabolism | Carbohydrate metabolism | 18 | 30 |
| 00250: Alanine, aspartate and glutamate metabolism | Amino acid metabolism | 32 | 22 |
| 00290: Valine, leucine and isoleucine biosynthesis | Amino acid metabolism | 11 | 30 |
| 00310: Lysine degradation | Amino acid metabolism | 43 | 26 |
| 00230: Purine metabolism | Nucleotide metabolism | 152 | 24 |
| 00590: Arachidonic acid metabolism | Lipid metabolism | 77 | 21 |
| 00591: Linoleic acid metabolism | Lipid metabolism | 40 | 13 |
| 00100: Steroid biosynthesisa | Lipid metabolism | 18 | 17 |
| 00670: One carbon pool by folate | Metabolism of cofactors and vitamins | 17 | 26 |
| 00790: Folate biosynthesisa | Metabolism of cofactors and vitamins | 11 | 28 |
| 00900: Terpenoid backbone biosynthesisa | Metabolism of terpenoids and polyketides | 13 | 22 |
| 00604: Glycosphingolipid biosynthesis-ganglio seriesa | Glycan biosynthesis and metabolism | 15 | 19 |
| 00534: Glycosaminoglycan biosynthesis-heparan sulfate | Glycan biosynthesis and metabolism | 24 | 25 |
| Contig_ID | Log2_Fold_change | AdjP_value | 2C FPKM | 2 T FPKM | E-value | Protein families |
| c32642_g1_i1 | -3.614 | 0.0009 | 3.1 | 0.3 | 0 | Glycosyltransferase 8 family, Glycogenin subfamily |
| c38916_g2_i3 | -3.232 | 0.0097 | 2.9 | 0.3 | 1.00E-83 | Cyclin family, Cyclin AB subfamily |
| c44152_g1_i2 | -2.667 | 0.0177 | 3.8 | 0.6 | 0 | Cyclic nucleotide-gated cation channel family |
| c37946_g1_i2 | -2.916 | 0.0244 | 4.1 | 0.6 | 1.00E-132 | MAD2 family |
| c43673_g1_i5 | -2.574 | 0.0313 | 4.8 | 0.8 | 0 | Cytochrome P450 family |
| c44152_g1_i1 | -2.545 | 0.0818 | 3.1 | 0.6 | 0 | Cyclic nucleotide-gated cation channel family |
| c24995_g1_i1 | -2.173 | 0.1794 | 2.8 | 0.7 | 0 | WD repeat CDC20/Fizzy family |
| c25920_g1_i1 | -2.094 | 0.2470 | 3.7 | 0.9 | 6.00E-162 | NA |
| c33730_g1_i3 | -1.879 | 0.3855 | 2.3 | 0.7 | 6.00E-96 | HSF family, Class A subfamily |
| WC | BMI | PBF | HDL | Triglyceride | LDL | SBP | DBP | |
| Females | ||||||||
| 8 year old cohort | <.05 | <.05 | <.05 | <.05 | <.05 | |||
| 11 year old cohort | <.05 | <.05 | <.05 | <.05 | <.05 | |||
| 14 year old cohort | <.05 | <.05 | ||||||
| Males | ||||||||
| 8 year old cohort | <.05 | <.05 | <.05 | |||||
| 11 year old cohort | <.05 | <.05 | <.05 | <.05 | <.05 | <.05 | ||
| 14 year old cohort | <.05 | <.05 | <.05 | <.05 | <.05 | <.05 |
| Causes of death | Number of deathsn (%) | Cause-Specific Mortality Rate (per 1000 people) |
| Ch. X – Diseases of the respiratory system, J00-J99 | 282 (37.1) | 3187 |
| Ch. IX – Diseases of the circulatory system, I00-I99 | 197 (25.9) | 2227 |
| Ch. V – Mental and behavioural disorders, F00-F99 | 81 (10.7) | 916 |
| Ch. VI – Diseases of the nervous system, G00-G99 | 59 (7.8) | 669 |
| Ch. I – Certain infectious and parasitic diseases, A00-B99 | 33 (4.3) | 373 |
| Ch. XVIII – Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified, R00-R99 | 28 (3.7) | 317 |
| Ch. XI – Diseases of the digestive system, K00-K93 | 16 (2.1) | 181 |
| Ch. II – Neoplasms, C00-D48 | 15 (2) | 170 |
| Ch. IV – Endocrine, nutritional and metabolic diseases, E00-E90 | 14 (1.8) | 158 |
| Ch. XIV – Diseases of the genitourinary system, N00-N99 | 10 (1.3) | 113 |
| Ch. XVII – Congenital malformations, deformations and chromosomal abnormalities, Q00-Q99 | 9 (1.2) | 102 |
| Ch. XX – External causes of morbidity and mortality, V01-Y98 | 8 (1.1) | 90 |
| Ch. III – Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism, D50-D89 | 3 (0.4) | 34 |
| Ch. XIX – Injury, poisoning and certain other consequences of external causes, S00-T98 | 3 (0.4) | 34 |
| Ch. XIII – Diseases of the musculoskeletal system and connective tissue, M00-M99 | 2 (0.3) | 23 |
| Ch. XII – Diseases of the skin and subcutaneous tissue, L00-L99 | 0 (0) | NA |
| Ch. XVI - Certain conditions originating in the perinatal period, P00-P96 | 0 (0) | NA |
| Case | Measure | Improvement | Execution time | ||
| Standard | Scout | Standard | Scout | ||
| I | Average | 47.36% | 57.21% | 2.0065 | 1.2346 |
| Stdev | 0.2443 | 0.3037 | 1.8070 | 0.7588 | |
| Observations | 480 | 480 | 480 | 480 | |
| z-score | −5.5393 | 8.6285 | |||
| P value | 0.0000 | 0.0000 | |||
| II | Average | 62.99% | 81.34% | 839.9745 | 741.0001 |
| Stdev | 0.3015 | 0.4073 | 295.65 | 338.65 | |
| Observations | 160 | 160 | 160 | 160 | |
| z-score | −4.5795 | 2.7849 | |||
| P value | 0.0000 | 0.0054 |
| Sample ID | ARW742C (TGg>TGt/c)ddPCRNEB Phusion® Preamplification | ARW742C (TGg>TGt/c)ddPCRInvitrogenTM PlatinumTM SuperFiTM Preamplification | ||||
| Mutant Droplet Count | Wild-type Droplet Count | Percent Mutant | Mutant Droplet Count | Wild-type Droplet Count | Percent Mutant | |
| JHU Pt 3 | 4 | 25067 | 0.016 | 38 | 33611 | 0.113 |
| JHU Pt 7 | 0 | 19753 | 0.000 | 0 | 15958 | 0.000 |
| PreamplifiedWild-type Genomic DNA | 0 | 17573 | 0.000 | 0 | 37069 | 0.000 |
| PreamplifiedNo Template Control | 0 | 0 | 0.000 | 0 | 0 | 0.000 |
| Non-AmplifiedWild-type Genomic DNA | 0 | 31225 | 0.000 | 0 | 31225 | 0.000 |
| Non-AmplifiedAR W742C Mutant Control DNA | 10602 | 0 | 100 | 10602 | 0 | 100 |
| Non-AmplifiedNo Template Control | 0 | 0 | 0.000 | 0 | 0 | 0.000 |
| Line | Ca (%) | K (%) | Mg (%) | P (%) | N (%) | S (%) | B (mg/kg) | Cu (mg/kg) | Fe (mg/kg) | Mn (mg/kg) | Mo (mg/kg) | Na (mg/kg) | Zn (mg/kg) |
| 243 | 2.2 | 1.4 | 0.5 | 0.2 | 1.3 | 0.5 | 126 | 8.0 | 54.9 | 52.5 | 1.9 | 5386 | 16.4 |
| 56F | 2.7 | 1.6 | 0.5 | 0.2 | 1.5 | 0.8 | 131 | 8.2 | 59.4 | 51.4 | 1.1 | 6234 | 16.8 |
| 56N | 2.6 | 1.4 | 0.5 | 0.3 | 1.5 | 0.7 | 145 | 7.9 | 57.9 | 49.9 | 1.3 | 5317 | 16.3 |
| DESF | 1.3 | 1.3 | 0.3 | 0.2 | 1.5 | 0.6 | 148 | 7.6 | 56.1 | 44.8 | 1.3 | 4970 | 15.3 |
| DESN | 1.9 | 1.3 | 0.3 | 0.2 | 1.4 | 0.5 | 144 | 8.2 | 48.5 | 51.4 | 1.4 | 51.4 | 16.6 |
| MDF | 1.5 | 1.3 | 0.4 | 0.2 | 1.7 | 0.5 | 125 | 7.5 | 46.9 | 55.3 | 1.2 | 3926 | 15.9 |
| MDN | 2.8 | 2.4 | 0.6 | 0.2 | 2.2 | 0.9 | 148 | 7.6 | 60.4 | 87.8 | 1.2 | 4936 | 15.4 |
| SGF | 1.4 | 2.5 | 0.6 | 0.2 | 1.6 | 0.4 | 82 | 8.0 | 41.4 | 61.9 | 1.3 | 4711 | 15.9 |
| SGN | 1.6 | 2.5 | 0.4 | 0.2 | 1.8 | 0.4 | 68 | 7.8 | 47.5 | 55.9 | 1.3 | 4627 | 14.3 |
| STVF | 1.5 | 1.1 | 0.3 | 0.1 | 2.3 | 0.4 | 81 | 7.7 | 50.1 | 68.5 | 1.4 | 4627 | 14.4 |
| STVN | 1.7 | 1.3 | 0.7 | 0.3 | 2.8 | 0.9 | 85 | 7.9 | 64.8 | 110.0 | 1.3 | 6350 | 14.3 |
| LSD | 0.16 | 0.09 | 0.04 | 0.02 | 0.15 | 0.08 | 5 | 0.43 | 2.9 | 3.6 | 0.15 | 360 | 0.6 |
| Domain | Principal cause | Number of patients |
| Neuromuscular | Parkinsonism syndrome | 3 |
| Unexplained Ataxia | 2 | |
| Lower extremity weakness | 7 | |
| Sensory | Dizziness or vertigo | 2 |
| Visual impairment | 4 | |
| Peripheral neuropathy | 3 | |
| Orthopedics | Osteoarthritis (including foot problems) | 8 |
| Hip problems or deformity | 6 | |
| CV causes* | Orthostatic hypotension | 2 |
| Postprandial hypotension | 1 | |
| Vasovagal syndrome | 2 | |
| Carotid sinus hypersensitivity | 1 |
| RECIST | CHOI | mCHOI | MASS | |
| Progressive disease (MASS unfavourable response) | Increase in sum of longest target lesion diameters >20%.orDevelopment of new lesions.orUnequivocal non-target lesion progression. | Increase in lesion sizea > 10%.orDevelopment of new lesions.orNew or enlarging intratumoral nodule. | Increase in lesion sizea > 10%.orDevelopment of new lesions.orNew or enlarging intratumoral nodule. | Increase in lesion sizea > 20% without central necrosis.orDevelopment of new lesions.orNew intratumoral enhancing components. |
| Partial response (MASS favourable response) | >30% decrease in sum of longest target lesion diameters. | Decrease in target lesion CT enhancement (Hounsfield units) >15% or size >10% | Decrease in target lesion CT enhancement (Hounsfield units) >15% and size >10% | Decrease in lesion size >20%, central necrosis or reduction in attenuation >40 Hounsfield units |
| Complete response | Disappearance of all target lesions and resolution of lymphadenopathy (<10 mm). | Disappearance of all target lesions | Disappearance of all target lesions | Disappearance of all target lesions |
| Stable disease (MASS indeterminate response) | None of the above | None of the above | None of the above | None of the above |
| Indicator bacteria | Station | N | Mean | Std. Deviation | Minimum | Maximum |
| Total coliform (MPN/100 ml) | 1 | 6 | 112.07 | 600 | 920 | |
| 2 | 6 | 1220 | 184.93 | 920 | 1400 | |
| 3 | 6 | 1000 | 161.12 | 680 | 1100 | |
| 4 | 6 | 1050 | 168.99 | 750 | 1200 | |
| 5 | 6 | 1800 | 328.00 | 1200 | 2200 | |
| 6 | 6 | 1750 | 339.76 | 1100 | 2000 | |
| 7 | 6 | 885 | 111.23 | 660 | 950 | |
| 8 | 6 | 1400 | 247.54 | 920 | 1600 | |
| Average | 48 | 1238.12 | 206.7 | 853.75 | 1421.25 | |
| Fecal coliform (MPN/100 ml) | 1 | 6 | 15.57 | 79 | 120 | |
| 2 | 6 | 165 | 8.07 | 160 | 180 | |
| 3 | 6 | 111.17 | 17.11 | 94 | 140 | |
| 4 | 6 | 143.33 | 20.15 | 110 | 170 | |
| 5 | 6 | 213.33 | 72.67 | 110 | 330 | |
| 6 | 6 | 193.33 | 43.29 | 140 | 260 | |
| 7 | 6 | 107.17 | 16.29 | 79 | 130 | |
| 8 | 6 | 170 | 38.14 | 110 | 230 | |
| Average | 48 | 150.875 | 28.91125 | 110.25 | 195 | |
| Pseudomonas (MPN/100 ml) | 1 | 6 | 1.22 | 3 | 6 | |
| 2 | 6 | 8.50 | 2.07 | 5 | 11 | |
| 3 | 6 | 6.33 | 2.16 | 3 | 9 | |
| 4 | 6 | 7.33 | 2.58 | 4 | 11 | |
| 5 | 6 | 13.00 | 2.28 | 11 | 17 | |
| 6 | 6 | 11.00 | 1.414 | 9 | 13 | |
| 7 | 6 | 4.83 | 1.169 | 3 | 6 | |
| 8 | 6 | 10.33 | 1.966 | 7 | 12 | |
| Average | 48 | 8.227 | 1.857 | 5.625 | 10.625 | |
| HPC (CFU/ml) | 1 | 6 | 89.443 | 1000 | 1250 | |
| 2 | 6 | 1841.67 | 724.166 | 1100 | 2800 | |
| 3 | 6 | 1350.00 | 420.095 | 940 | 1850 | |
| 4 | 6 | 1743.33 | 406.776 | 1350 | 2500 | |
| 5 | 6 | 2358.33 | 941.497 | 1500 | 3500 | |
| 6 | 6 | 2173.33 | 344.770 | 1890 | 2700 | |
| 7 | 6 | 1248.33 | 217.754 | 970 | 1610 | |
| 8 | 6 | 2078.33 | 302.815 | 1640 | 2400 | |
| Average | 48 | 1742.91 | 430.914 | 1298.75 | 2326.25 |
| Whole sample size (N = 47) | Placebo | Perilla | Placebo | Perilla | |||||||
| Run In | Intake week 1-2 | Intake week 3-4 | p value (ANOVA) | Run In | Intake week 1-2 | Intake week 3-4 | p value (ANOVA) | Delta week 3-4 to run in | Delta week 3-4 to run in | Comparison between groups (95% CI) | |
| Bloating | 1.45 | 1.44 | 1.2 | 0.0733 | 1.42 | 1.28 | 0.98 | 0.0003 | -0.25 | -0.44 | -0.194 to 0.562 |
| SD | 0.74 | 0.72 | 0.77 | 0.81 | 0.64 | 0.78 | 0.71 | 0.56 | |||
| Passage of gas | 1.47 | 1.57 | 1.37 | 0.2284 | 1.6 | 1.5 | 1.3 | 0.0264 | -0.10 | -0.30 | -0.177 to 0.577 |
| SD | 0.66 | 0.53 | 0.62 | 0.77 | 0.62 | 0.74 | 0.62 | 0.66 | |||
| GI rumbling | 1.51 | 1.33 | 1.18 | 0.0635 | 1.64 | 1.27 | 1.09 | 0.0014 | -0.33 | -0.55 | -0.251 to 0.685 |
| SD | 0.86 | 0.91 | 0.83 | 0.85 | 0.6 | 0.81 | 0.71 | 0.87 | |||
| Feeling of fullness | 1.08 | 1.05 | 0.83 | 0.0987 | 1.03 | 0.84 | 0.67 | 0.0152 | -0.24 | -0.36 | -0.288 to 0.515 |
| SD | 0.8 | 0.59 | 0.62 | 0.77 | 0.63 | 0.63 | 0.64 | 0.72 | |||
| Abdominal discomfort | 1.15 | 1.06 | 0.84 | 0.0345 | 1.25 | 0.92 | 0.71 | 0.0004 | -0.31 | -0.54 | -0.156 to 0.621 |
| SD | 0.93 | 0.84 | 0.81 | 0.86 | 0.61 | 0.74 | 0.55 | 0.75 |
| k-spaced AA pairs | ||||||||
| Feature representation | Composition Vector | PSI-BLAST profile | Binary Encoding | adjacent pairs (dipeptides) | 1-spaced pairs | ...... | p-spaced pairs | Total |
| Number of features | 20 | 315 | 380 | 400 | 400 | ...... | 400 | 400(p+1) |
| Haplotype | Cases (percentage) | Controls (percentage) | OR (95% CI)a |
| z1 G-G-T-T-A | 1,250 (49.4) | 1,691 (48.2) | 1.00 (reference) |
| z2 G-G-T-C-A | 435 (17.2) | 667 (19.0) | 0.84 (0.72–0.98) |
| z3 G-C-T-T-A | 403 (15.9) | 544 (15.5) | 0.99 (0.85–1.17) |
| z4 C-G-G-C-A | 358 (14.1) | 507 (14.5) | 0.92 (0.79–1.09) |
| z5 C-G-G-C-G | 53 (2.1) | 63 (1.8) | 1.16 (0.78–1.72) |
| Global p = 0.15 |
| Ingredient | Herb medicine | Object | Stimulus | Role | related pathway |
| 1, 6-di-O-caffeoyl-β-D-glucopyranoside | Callicarpa nudiflora Hook | Platelet | ADP, AA | αIIbβ3, 5-HT, TXA2, platelet aggregation↓ | PI3K/Akt/GSK3β, RhoA |
| Atractylenolide | Atractylodes macrocephala | Platelet | ADP, collagen, thrombin | platelet aggregation and secretion↓ | p38, PI3K/Akt |
| Andrographolide | Andrographis paniculata | Platelet | Collagen | platelet aggregation, Ca2+, TxB2↓ | eNOS/NO/sGC/cGMP, PI3K/Akt/p38/cPLA2, PLCγ2/DAG/PKC |
| platelet aggregation, Ca2+↓ | eNOS/NO/sGC/cGMP, p38/ROS/IKKβ/NF-κB/ERK2 | ||||
| Gomisin J | Schisandra chinensis | EC | None | eNOS, NO↑ | Ca2+/CaMI, PI3K/Akt |
| β-Elemene | Curcuma Wenyujin | EC | None | eNOS, NO↑ | PI3K/Akt |
| Puerarin | Pueraria lobata | EC | TNF-α | eNOS, NO↑ | ER/PI3K/Akt, CaMKII/AMPK |
| Tanshinone IIA | Salvia miltiorrhiza Bunge | Macrophage | Ox-LDL | TF↓ | ROS/NF-κB |
| Platelet | None | Platelet activation↓ | ERα/PI3K/Akt | ||
| Platelet | ADP | Platelet activation↓ | ERK-2 | ||
| Xuezhikang | Red yeast rice | Macrophage | Ox-LDL | TF↓, SOD↑ | NOX/ROS/ERK1/2/NF-κB |
| Gypenoside XLIX | Gynostemma pentaphyllum | Macrophage | LPS | TF↓ | PPAR-α |
| Salvianolic acid B | Salvia miltiorrhiza Bunge | EC | TNF-α | PAI-1↓ | ERK1/2/AP-1 (NF-κB) |
| Incremental cost | Incremental effect | ICER | |||||
| Mean; (95% bootstrap CI) | Mean; (95% bootstrap CI) | ||||||
| CBT versus TAU | |||||||
| Completers (N=152) | |||||||
| QALY (EQ-5D) | −2,061.9 | −3,168.9 | −954.9 | 0.01 | −0.00 | 0.03 | CBT dominant |
| EQ VAS | −2,073.2 | −3,179.8 | −966.6 | 6.19 | 3.63 | 8.75 | CBT dominant |
| ITT (N=168) | |||||||
| QALY (EQ-5D) | −2,158.8 | −3,357.1 | −960.5 | 0.02 | −0.00 | 0.03 | CBT dominant |
| EQ VAS | −2,163.9 | −3,363.8 | −964.0 | 6.33 | 3.62 | 9.07 | CBT dominant |
| PPA (N=154) | |||||||
| QALY (EQ-5D) | −2,368.9 | −3,599.1 | −1,138.6 | 0.02 | −0.00 | 0.03 | CBT dominant |
| EQ VAS | −2,372.4 | −3,604.8 | −1,140.0 | 6.58 | 3.83 | 9.33 | CBT dominant |
| CBT versus RPT | |||||||
| Completers (N=152) | |||||||
| QALY (EQ-5D) | −2,386.9 | −3,485.4 | −1,288.3 | 0.01 | −0.00 | 0.03 | CBT dominant |
| EQ VAS | −2,393.9 | −3,495.2 | −1,292.6 | 3.52 | 1.13 | 5.90 | CBT dominant |
| ITT (N=168) | |||||||
| QALY (EQ-5D) | −2,304.7 | −3,326.6 | −1,282.7 | 0.01 | −0.00 | 0.03 | CBT dominant |
| EQ VAS | −2,307.8 | −3,331.4 | −1,284.2 | 3.61 | 1.08 | 6.15 | CBT dominant |
| PPA (N=154) | |||||||
| QALY (EQ-5D) | −2,550.3 | −3,624.9 | −1,475.7 | 0.01 | −0.00 | 0.03 | CBT dominant |
| EQ VAS | −2,552.7 | −3,631.5 | −1,473.9 | 3.93 | 1.35 | 6.51 | CBT dominant |
| RPT versus TAU | |||||||
| Completers (N=152) | |||||||
| QALY (EQ-5D) | 324.9 | −894.8 | 1,544.7 | −0.00 | −0.02 | 0.01 | TAU dominant |
| EQ VAS | 320.7 | −894.3 | 1,535.6 | 2.67 | 0.56 | 4.79 | 120 |
| ITT (N=168) | |||||||
| QALY (EQ-5D) | 145.9 | −1,150.7 | 1,442.5 | 0.00 | −0.01 | 0.02 | 79,071 |
| EQ VAS | 143.9 | −1,150.8 | 1,438.6 | 2.72 | 0.42 | 5.02 | 53 |
| PPA (N=154) | |||||||
| QALY (EQ-5D) | 181.4 | −1,127.9 | 1,490.7 | 0.00 | −0.01 | 0.02 | 137,161 |
| EQ VAS | 180.3 | −1,127.3 | 1,487.9 | 2.65 | 0.36 | 4.94 | 68 |
| Flavonoid | NGF | GDNF | BDNF |
| Flavanones | |||
| Alpinetin | +++ | ++ | + |
| Hesperidin | — | + | — |
| Naringenin | — | — | — |
| Naringin | — | +++ | — |
| Neohesperidin | — | ++ | — |
| Flavones | |||
| Apigenin | — | ++ | — |
| Baicalein | — | — | — |
| Luteolin | ++++ | ++++ | ++ |
| Tangeretin | ++ | — | — |
| Wogonin | — | — | — |
| Aurones | |||
| Sulfuretin | — | ++ | — |
| Dihydrochalcones | |||
| Phloretin | — | — | — |
| Flavonols | |||
| Silybin | ++++ | — | + |
| Chalcones | |||
| Cardamonin | + | ++ | — |
| Isoflavones | |||
| Calycosin | +++ | ++++ | +++ |
| Calycosin-7-O-glc | +++ | ++ | — |
| Daidzein | — | — | — |
| Formononetin | — | — | — |
| Genistein | ++++ | ++++ | ++ |
| Genistin | — | — | — |
| Puerarin | + | +++ | — |
| Flavones | |||
| (−)-Catechin | — | — | + |
| (−)-Epicatechin | — | — | — |
| Flavonols | |||
| Fisetin | +++ | — | + |
| Galangin | — | ++ | — |
| Hyperin | — | — | — |
| Icariin | — | — | + |
| Isorhamnetin | ++++ | ++++ | +++ |
| Kaempferol | + | + | + |
| Quercetin | — | + | — |
| RNFG | — | ++ | — |
| 173-estradiol | ++++ | ++++ | +++ |
| Variables | N | Case/Control | OR(95%CI) PhP | OR(95%CI) PhP | OR(95%CI) PhP | OR(95%CI) PhP | OR(95%CI) PhP |
| M-allele vs. W-allele | MW vs. WW | MM vs. WW | MM+MW vs. WW | MM vs. MW+WW | |||
| rs3740199 | |||||||
| Total | 5 | 1405/2531 | 1.02(0.93-1.12)0.538 0.726 | 1.03(0.87-1.21)0.811 0.743 | 1.03(0.85-1.25)0.527 0.758 | 1.03(0.88-1.20)0.631 0.714 | 1.00(0.86-1.17)0.630 0.967 |
| Ethnicity | |||||||
| Asian | 4 | 1242/2316 | 1.02(0.92-1.13)0.379 0.709 | 1.03(0.88-1.22)0.680 0.703 | 1.04(0.85-1.27)0.370 0.722 | 1.03(0.88-1.21)0.473 0.679 | 1.00(0.84-1.19)0.461 0.989 |
| Caucasian | 1 | 163/215 | - | - | - | - | - |
| Source of control | |||||||
| HB | 3 | 517/579 | 1.03(0.87-1.21)0.213 0.771 | 1.03(0.77-1.38)0.470 0.829 | 1.05(0.75-1.48)0.209 0.764 | 1.04(0.79-1.36)0.285 0.792 | 0.99(0.75-1.31)0.277 0.944 |
| PB | 2 | 888/1952 | 1.01(0.90-1.14)0.914 0.822 | 1.03(0.84-1.24)0.780 0.802 | 1.02(0.81-1.29)0.849 0.868 | 1.03(0.85-1.23)0.805 0.791 | 1.01(0.83-1.22)0.973 0.922 |
| Sex | |||||||
| Male | 3 | 264/993 | 1.49(0.95-2.34)0.053 0.086 | 1.44(1.02-2.04)0.906 0.040 | 2.09(0.82-5.33)0.066 0.122 | 1.46(1.05-2.03)0.420 0.025 | 1.60(0.76-3.39)0.034 0.220 |
| Female | 3 | 824/1159 | 0.96(0.84-1.09)0.554 0.531 | 0.91(0.73-1.13)0.574 0.389 | 0.94(0.72-1.23)0.537 0.648 | 0.92(0.75-1.13)0.516 0.417 | 0.98(0.79-1.21)0.637 0.836 |
| rs1278279 | 2 | 316/379 | 1.08(0.84-1.38)0.964 0.543 | 1.26(0.91-1.73)0.935 0.158 | 0.88(0.47-1.62)0.995 0.671 | 1.19(0.88-1.61)0.950 0.265 | 0.80(0.44-1.47)0.995 0.474 |
| rs1871054 | 2 | 316/379 | 1.85(1.49-2.30)0.984 <0.001 | 1.12(0.75-1.67)0.824 0.592 | 2.81(1.84-4.27)0.964 <0.001 | 1.68(1.16-2.43)0.887 0.006 | 2.61(1.89-3.60)0.897 <0.001 |
| rs1044122 | 2 | 316/379 | 0.95(0.77-1.18)0.838 0.665 | 1.05(0.75-1.48)0.978 0.759 | 0.87(0.55-1.37)0.803 0.543 | 1.01(0.73-1.39)0.948 0.972 | 0.84(0.56-1.26)0.767 0.394 |
| Gene ID | ENSEMBL Gene ID | Gene name | Base Mean | Fold Change (log2) | p-adj |
| VIM | ENSECAG00000004216 | vimentin | 101,873.95 | 0.49 | 0.0846 |
| LUM | ENSECAG00000018248 | lumican | 93,834.08 | 1.21 | 0.0000 |
| EEF1A1 | ENSECAG00000020363 | eukaryotic translation elongation factor 1 alpha 1 | 80,865.77 | 0.35 | 0.4978 |
| FN1 | ENSECAG00000000701 | fibronectin 1 | 76,204.43 | − 0.03 | 0.9131 |
| COL3A1 | ENSECAG00000024769 | collagen type III alpha 1 | 71,782.03 | −0.28 | 0.3120 |
| COL1A2 | ENSECAG00000024740 | collagen type I alpha 2 | 68,527.63 | 0.03 | 0.9444 |
| ACTG1 | ENSECAG00000018600 | actin gamma 1 | 67,827.73 | 0.59 | 0.1648 |
| DCN | ENSECAG00000020413 | decorin | 66,957.05 | 0.72 | 0.0000 |
| CLU | ENSECAG00000007010 | clusterin | 60,592.80 | 0.54 | 0.3689 |
| CTSK | ENSECAG00000019087 | cathepsin K | 50,743.84 | −0.01 | 0.9822 |
| PSAP | ENSECAG00000021672 | prosaposin | 42,671.36 | −0.71 | 0.0123 |
| COL6A3 | ENSECAG00000020887 | collagen type VI alpha 3 chain | 39,357.71 | −0.81 | 0.0000 |
| AHNAK | ENSECAG00000014229 | AHNAK nucleoprotein | 32,777.16 | −1.03 | 0.0004 |
| TPT1 | ENSECAG00000018348 | tumor protein, translationally-controlled 1 | 32,069.02 | 0.86 | 0.0000 |
| RPL4 | ENSECAG00000023179 | ribosomal protein L4 | 28,412.14 | 0.55 | 0.0555 |
| ANXA1 | ENSECAG00000015794 | annexin A1 | 28,358.48 | 1.22 | 0.0000 |
| HSP90AA1 | ENSECAG00000018948 | heat shock protein 90 alpha family class A member 1 | 27,249.39 | 0.36 | 0.5410 |
| ASPN | ENSECAG00000007047 | asporin | 27,102.67 | 1.44 | 0.0000 |
| EIF4G2 | ENSECAG00000014700 | eukaryotic translation initiation factor 4 gamma 2 | 25,563.63 | 1.26 | 0.0000 |
| HSPA8 | ENSECAG00000013510 | heat shock protein family A (Hsp70) member 8 | 23,372.98 | −0.02 | 0.9496 |
| HTRA1 | ENSECAG00000009990 | HtrA serine peptidase 1 | 23,322.81 | −0.18 | 0.7559 |
| APP | ENSECAG00000021011 | amyloid beta precursor protein | 21,959.94 | −0.08 | 0.7687 |
| CLTC | ENSECAG00000019077 | clathrin heavy chain | 21,758.80 | 0.44 | 0.1597 |
| CTNNB1 | ENSECAG00000006949 | catenin beta 1 | 21,082.51 | 0.57 | 0.0512 |
| FAP | ENSECAG00000011790 | fibroblast activation protein alpha | 20,454.17 | 1.72 | 0.0000 |
| Treatment category | |
| Cat I | Treatment for new patients with first-line anti-TB drugs (2 months of INH, RIF, EMB, PZA/4 months of INH, RIF) |
| Cat II | Re-treatment regimen with first-line anti-TB drugs (2 months of STR, INH, RIF, EMB, PZA/1 month of INH, RIF, EMB, PZA/3 months of INH, RIF, EMB) |
| New | A patient who has never had treatment for TB or who has taken anti-TB drugs for <1 month |
| Close contact | Close contacts of MDR-TB patients who develop active TB |
| Failure | A patient previously treated for TB who is started on a re-treatment regimen after previous treatment has failed |
| Relapse | A patient who was previously declared cured or treatment completed and is diagnosed with bacteriologically-positive (sputum smear or culture) TB |
| Standard MDR-TB regimen | 6 months of AMK, PZA, LFX, ETH, DCS/18 months of PZA, LFX, ETH, DCS a |
| PT (n = 21) | ST (n = 23) | p value | ||
| Global score | Baseline | 26.0 ± 11.2 | 29.7 ± 9.8 | 0.256† |
| After training | 25.7 ± 10.6 | 24.5 ± 7.7 | 0.678† | |
| Follow-up | 23.9 ± 10,0 | 21.8 ± 8.1 | 0.465† | |
| Pain | Baseline | 46.2 ± 19.3 | 50.2 ± 23.3 | 0.538† |
| After training | 41.2 ± 23.6 | 35.7 ± 22.0 | 0.425† | |
| Follow-up | 38.8 ± 23.3 | 29.6 ± 24.0 | 0.203† | |
| Physical function | Baseline | 16.2 ± 10.2 | 20.1 ± 10.4 | 0.210† |
| After training | 14.0 ± 9.7 | 13.8 ± 8.1 | 0.943† | |
| Follow-up | 12.8 ± 8.4 | 10.9 ± 6.2 | 0.382† | |
| Social function | Baseline | 18.4 ± 15.2 | 20.3 ± 11.3 | 0.625† |
| After training | 16.3 ± 12.8 | 16.0 ± 10.1 | 0.924† | |
| Follow-up | 17.7 ± 12.9 | 17.1 ± 10.4 | 0.864† | |
| Health perception | Baseline | 50.0 ± 19.0 | 57.6 ± 15.5 | 0.151† |
| After training | 49.2 ± 21.1 | 47.5 ± 11.6 | 0.743† | |
| Follow-up | 44.4 ± 15.2 | 49.3 ± 17.4 | 0.334† | |
| Mental function | Baseline | 31.5 ± 11.6 | 34,3 ± 12.0 | 0.434† |
| After training | 38.8 ± 9.3 | 37.7 ± 7.7 | 0.678† | |
| Follow-up | 34.4 ± 10.3 | 32.9 ± 11.6 | 0.645† |
| Contact Stress, GPa | Rolling Time, h | Rolling Speed, rpm | Condition |
| 2.5 | 12, 24 | 1000 | dry |
| 3.0 |
| Effect size | Point estimatefreqpost mean post median | Percentile bootstrap | Bias-corrected bootstrap | Bayesian equal-tail credibilityintervals | Bayesian HPD credibilityintervals |
| Medps | 0.1080.1050.106 | [0.059, 0.183] | [0.046, 0.161] | [0.054, 0.154] | [0.052, 0.151] |
| Proportion | 0.4110.4120.378 | [0.193, 1.055] | [0.190, 0.950] | [0.163, 0.853] | [0.153, 0.734] |
| Ratio | 0.697−0.5260.598 | [−1.986, 4.915] | [0.137, 5.213] | [0.186, 3.308] | [0.133, 2.484] |
| Segmental LV wall | Endocardial (%) | Middle (%) | Epicardial (%) | |||||||
| Preoperative | Postoperative | P-value | Preoperative | Postoperative | P-value | Preoperative | Postoperative | P-value | ||
| Apical 4-CH view | Lateral | −15.38 ± 7.90 | −8.55 ± 6.58 | <0.001 | −12.64 ± 6.77 | −6.70 ± 5.42 | <0.001 | −10.61 ± 5.99 | −5.32 ± 4.62 | <0.001 |
| Septum | −13.95 ± 7.32 | −10.77 ± 7.19 | 0.026 | −11.27 ± 6.15 | −9.01 ± 6.08 | 0.054 | −9.25 ± 5.33 | −7.71 ± 5.29 | 0.119 | |
| Apical 3-CH view | Anteroseptum | −15.75 ± 7.72 | −8.03 ± 7.10 | <0.001 | −12.28 ± 6.28 | −6.35 ± 5.89 | <0.001 | −9.65 ± 5.26 | −5.13 ± 5.00 | <0.001 |
| Posterior | −17.33 ± 6.88 | −10.97 ± 8.21 | <0.001 | −14.01 ± 6.05 | −8.84 ± 6.87 | <0.001 | −11.46 ± 5.44 | −7.21 ± 5.88 | 0.001 | |
| Apical 2-CH view | Anterior | −15.49 ± 7.07 | −7.51 ± 7.46 | <0.001 | −12.55 ± 6.42 | −5.85 ± 6.16 | <0.001 | −10.31 ± 5.96 | −4.64 ± 5.20 | <0.001 |
| Inferior | −17.34 ± 7.38 | −12.90 ± 8.69 | 0.009 | −13.89 ± 6.26 | −10.40 ± 7.22 | 0.013 | −11.18 ± 5.44 | −8.49 ± 6.15 | 0.020 |
| Screening | Randomization | 3 monthlyFU | 6 monthlyFU | End of study | |
| 25(OH)D3 serum levels | X | X(when 25(OH)D3 levels >80 ng/ml and study drug temporarily interrupted) | X | ||
| Blood sample for DNA analysis | X | ||||
| Hemoglobin, Hematocrit | X | X | |||
| WBC count and differentiation | X | X | X | ||
| RBC count | X | X | |||
| Platelet count | X | X | |||
| Renal function (creatinine) | X | X | |||
| Liver function (AF, ALT, gamma-GT, LDH) | X | X | |||
| Serum calcium | X | X | X | ||
| Serum phosphate | X | X | X | ||
| Albumin | X | X | |||
| 24 h urine calcium | X |
| Author, date | No. Participants = n | Avg age at start | Cast changed | Avg days in casts - ‘fast’ group | Tenotomy rate | Follow up | Comment |
| Morecuende, 2005 | 230(non-random) | Not stated | 5 days | 30 | 85% | Study ran over 11 years | Older study, NR sample |
| Harnett, 2011 | 40(RCT) | 21 days | 3 / week | 16 | 79% | Min 6 mthsAve 8 mths | Youngest children |
| Xu, 2011 | 26(RCT) | 92 days | 2 / week | 20.6 | 87% | 2–6 years | Manipulation time of 2 min |
| Ullah, 2014 | 28(RCT) | 18 weeks | 2 / week | 23.3 | 80% | Not reported | |
| Elgohary, 2015 | 41(RCT) | 11 weeks (SD 7) | 2 / week | 18.1 (SD 3) | 91% | 12–48 mths | Relapse rate 15% both groups |
| RCT data summary | RCTsn = 135 | 11 weeks | 2/week | 19.5 days | 84% average | 1 year(3 RCTs) | Young infants, 2 min. Stretch |
| Variable | Coefficient | S.E. | p-value | OR | 95%CI |
| Intercept | -5.21 | 4.44 | - | - | - |
| Mains water to the farmhouse | -8.56 | 1.25 | < 0.0001 | 0.0002 | 1.64E-5 : 2.22E-3 |
| Number of positive samples | 0.30 | 0.07 | 0.0002 | 1.36 | 1.19 : 1.56 |
| Y coordinate (1 km) | 0.014 | 0.006 | 0.026 | 1.014 | 1.0027 : 1.026 |
| Bacteria | Methanogens | |||||
| Community | Similarity | Pseudo- F | P-value | Similarity | Pseudo- F | P-value |
| Treatment effect | 4.54 | 0.007 | 9.06 | 0.003 | ||
| Pairwise comparisons | ||||||
| CON versus CHI | 59.5 | 2.33 | 0.046 | 76.0 | 1.09 | 0.360 |
| CON versus IVY | 73.9 | 1.62 | 0.118 | 62.4 | 3.10 | 0.024 |
| CHI versus IVY | 60.1 | 2.17 | 0.048 | 60.7 | 7.00 | 0.003 |
| Code Level 3 | Label level 3 | Assigned land use type |
| 111 | Continuous urban fabric | Urban |
| 112 | Discontinuous urban fabric | Urban |
| 121 | Industrial or commercial units | Urban |
| 122 | Road and rail networks and associated land | Urban |
| 123 | Port areas | Urban |
| 124 | Airports | Urban |
| 131 | Mineral extraction sites | Urban |
| 132 | Dump sites | Urban |
| 133 | Construction sites | Urban |
| 141 | Green urban areas | Urban |
| 142 | Sport and leisure facilities | Urban |
| 211 | Non-irrigated arable land | Arable |
| 212 | Permanently irrigated land | Arable |
| 213 | Rice fields | Arable |
| 221 | Vineyards | Arable |
| 222 | Fruit trees and berry plantations | Arable |
| 223 | Olive groves | Arable |
| 231 | Pastures | Grassland |
| 241 | Annual crops associated with permanent crops | Arable |
| 242 | Complex cultivation patterns | Arable |
| 243 | Land principally occupied by agriculture, with significant areas of natural vegetation | Grassland |
| 244 | Agro-forestry areas | Forest |
| 311 | Broad-leaved forest | Forest |
| 312 | Coniferous forest | Forest |
| 313 | Mixed forest | Forest |
| 321 | Natural grasslands | Grassland |
| 322 | Moors and heathland | Grassland |
| 323 | Sclerophyllous vegetation | Grassland |
| 324 | Transitional woodland-shrub | Forest |
| 333 | Sparsely vegetated areas | Grassland |
| Variables | Crude ORs | Model 1 | Model 2 | Model 3 |
| Older Ages: Age ≥ 80 | 1.74 (1.28, 2.36) * | 1.29 (0.93, 1.80) | 1.26 (0.91, 1.75) | |
| Living Alone | 1.66 (1.26, 2.19) * | 1.27 (0.91, 1.78) | 1.31 (0.93, 1.85) | |
| Low Education | 1.94 (1.49, 2.51) * | 1.63 (1.24, 2.16) * | 1.60 (1.21, 2.12) * | |
| Not Married | 1.67 (1.34, 2.09) * | 1.28 (0.95, 1.72) | 1.24 (0.92, 1.67) | |
| Male | 0.82 (0.66, 1.02) | 1.11 (0.85, 1.46) | 1.13 (0.86, 1.48) | |
| Pct. Residential | 1.01 (1.00, 1.02) * | 1.01 (1.00, 1.02) * | 1.01 (1.00, 1.02) * | |
| Pct. Vegetation | 1.00 (0.998, 1.01) | 1.00 (0.996, 1.01) | 1.00 (0.995, 1.01) | |
| Avg Build Height | 1.00 (0.99, 1.00) | 0.98 (0.96, 0.99) * | 0.98 (0.96, 0.99) * | |
| Std Build Height | 1.01 (0.999, 1.02) | 1.03 (1.01, 1.04) * | 1.03 (1.01, 1.04) * |
| Function | P-value | No. of Genes |
| Cellular movement | 2.10E-35 to 3.60E-05 | 584 |
| Cell death | 1.99E-30 to 3.56E-05 | 853 |
| Cellular development | 2.08E-29 to 3.43E-05 | 730 |
| Cellular growth and proliferation | 3.01E-28 to 2.40E-05 | 912 |
| Cellular assembly and organization | 1.24E-15 to 3.32E-05 | 460 |
| Food Groups | Factor I Meat–Instant Food Dietary Pattern | Factor II Vege–Seafood Dietary Pattern | Factor III Cereal–Dairy Dietary Pattern |
| Milk | −0.174 | 0.047 | 0.597 |
| Dairy products | 0.038 | 0.058 | 0.634 |
| Eggs | 0.471 | 0.131 | 0.154 |
| Meat | 0.552 | 0.265 | −0.037 |
| Organ meats | 0.313 | 0.127 | 0.036 |
| Legumes/soy products | 0.331 | 0.354 | 0.146 |
| Seafood | 0.312 | 0.400 | 0.070 |
| Light-colored vegetables | −0.055 | 0.815 | 0.078 |
| Dark-colored vegetables | −0.084 | 0.841 | 0.080 |
| Fruit | −0.063 | 0.440 | 0.355 |
| Vegetables with oil/dressing | 0.278 | 0.569 | −0.053 |
| Rice/flour products | 0.295 | −0.011 | 0.521 |
| Whole grains | −0.039 | 0.089 | 0.441 |
| Root crops | 0.126 | 0.241 | 0.397 |
| Refined dessert | 0.327 | 0.226 | −0.079 |
| Jam/honey | 0.317 | −0.066 | 0.453 |
| Sugary drinks | 0.524 | −0.173 | 0.154 |
| Rice/flour cooked in oil | 0.405 | 0.011 | 0.238 |
| Deep-fried food | 0.674 | 0.111 | −0.030 |
| Instant noodle | 0.397 | −0.115 | −0.009 |
| Processed food | 0.611 | 0.051 | 0.053 |
| Sauce | 0.549 | 0.076 | −0.035 |
| Algorithm | TP (%) | FN (%) | FP (%) | SE (%) | +P (%) | Threshold values | ||
| THR1 | THR2 | THR3 | ||||||
| Proposed | 100 | 0.32 | 0 | 99.78 | 100 | MAbeat+α | W2 | NA |
| algorithm | ||||||||
| AF1 | 69.5 | 7.5 | 30.5 | 90.25 | 69.5 | 0.31 | 0.0001 | -0.001 |
| AF2 | 0.018 | 0.27 | 99.98 | 6.25 | 0.018 | 0.21 | 0.75 | NA |
| AF3 | 0 | 0 | 100 | NaN | 0 | 62 | NA | NA |
| FD1 | 0.27 | 2.8 | 99.73 | 8.79 | 0.27 | 0.099 | NA | NA |
| FD2 | 0 | 0 | 100 | NaN | 0 | 150 | NA | NA |
| DF1 | 0 | 0 | 100 | NaN | 0 | 21 | NA | NA |
| DF2 | 48.8 | 14.2 | 51.2 | 77.46 | 48.8 | 1 | 0.06 | NA |
| FS1 | 2.42 | 0.3 | 97.58 | 88.97 | 2.42 | 154.5 | NA | NA |
| FS2 | 42.46 | 6.9 | 57.54 | 86.02 | 42.46 | 0.55 | 0.47 | NA |
| Cases | sCD157 <31.02 ng/ml | sCD157 ≥31.02 ng/ml | P value* | |
| MPM, n | 61 | 30 | 31 | |
| Age at diagnosis, y | 0.062 | |||
| mean ± SD | 73.07 ± 10,46 | 77.39 ± 6.76 | ||
| median (range) | 73.50 (52–94) | 79.00 (61–89) | ||
| Sex | 0.106 | |||
| Male | 40 | 23 | 17 | |
| Female | 21 | 7 | 14 | |
| Histologic subtype | 0.951 | |||
| Epithelioid | 47 | 23 | 24 | |
| Sarcomatoid | 5 | 3 | 2 | |
| Biphasic | 2 | 1 | 1 | |
| NOSa | 7 | 3 | 4 | |
| Cytology | 0.359 | |||
| negative | 21 | 13 | 8 | |
| positive | 21 | 9 | 12 | |
| suspicious | 19 | 8 | 11 | |
| PMNb (n = 54) | 0.516 | |||
| <10 cells × 10 (HPF, 200×)c | 36 | 17 | 19 | |
| 10–50 cells × 1 (HPF, 200×) | 14 | 8 | 6 | |
| >50 cells × 10 (HPF, 200×) | 4 | 1 | 3 | |
| CD157 expression in biopsy tissues (n = 29) | 0.06 | |||
| H-score <110 | 11 | 8 | 3 | |
| H-score ≥110 | 18 | 6 | 12 | |
| Follow-up (n = 54) | 0.005 | |||
| DODd | 43 | 17 | 26 | |
| AWDe | 11 | 10 | 1 |
| Partition number | Cluster number | BRCA1 | BRCA2 | Number of genes selected |
| 1 | 1 | 0 | 4 | 80 |
| 2 | 7 | 4 | ||
| 2 | 1 | 7 | 4 | 110 |
| 2 | 0 | 4 | ||
| 3 | 1 | 5 | 3 | 73 |
| 2 | 2 | 5 | ||
| 4 | 1 | 6 | 0 | 61 |
| 2 | 1 | 8 |
| miRNA name | PTC | N | P‐value | Fold change |
| Upregulated | ||||
| miR‐221‐5p | 10.35 ± 3.68 | 2.88 ± 1.15 | <0.001 | 3.91 ± 1.36 |
| miR‐222‐5p | 7.80 ± 1.18 | 3.44 ± 0.73 | <0.001 | 2.35 ± 0.52 |
| miR‐34a‐5p | 7.45 ± 1.22 | 2.21 ± 1.43 | <0.001 | 2.94 ± 0.74 |
| miR‐146b‐5p | 10.39 ± 2.97 | 1.7 ± 0.35 | <0.001 | 6.11 ± 1.02 |
| miR‐21‐5p | 8.03 ± 2.77 | 3.26 ± 0.67 | <0.001 | 2.53 ± 0.84 |
| miR‐31‐5p | 6.52 ± 0.98 | 2.93 ± 0.39 | <0.001 | 2.12 ± 0.47 |
| Downregulated | ||||
| miR‐181‐5p | 3.91 ± 1.32 | 7.40 ± 2.21 | <0.001 | 2.00 ± 0.51 |
| miR‐138‐5p | 4.00 ± 1.55 | 7.05 ± 1.99 | <0.001 | 1.76 ± 0.36 |
| Single methods | Combined method | ||||
| Case | Histology (Lauren) | IHC (Score) | SISH (≥ 2.0/< 2.0) | IHC (Score) | SISH (≥ 2.0/< 2.0) |
| 6693 | i | 2+ | ≥2.0 | 3+ | ≥2.0 |
| 9924 | i | 2+ | <2.0 | 1+ | <2.0 |
| 20209 | i | 2+ | ≥2.0 | 3+ | ≥2.0 |
| 1057 | d | 3+ | <2.0 | 2+ | <2.0 |
| pN0 and pN1 | pN2 and pN3 | p-value | |
| Percentage of positive tumors cells | 47.12 +/- 29,.3 | 55.62 +/- 26.33 | 0.068 |
| Staining intensity | 1.22 +/- 0.82 | 1.43 +/- 0.75 | 0.036* |
| Variables | Name and source of the original scales and items | α | Items (n) |
| Socio-demographic factorsa | 18 | ||
| Health behaviour | |||
| Physical activity | Health Questionnaire age 18–64 years [29] | – | 1 |
| Dietary habits | Food Frequency Questionnaire [30] | – | 15 |
| Smoking | Health Questionnaire age 18–64 years [7] | – | 2 |
| Alcohol consumption | AUDIT-C [31, 32] | – | 3 |
| Health status | |||
| General health status | Survey in vocational schools in Bielefeld [36] | – | 1 |
| Diseases and complaints | Work Ability Index – Questionnaire [33] | – | 6 |
| Self-efficacy | Self-efficacy scale [24] | 0.85 | 10 |
| Irritation | Irritation scale [22] | 0.88 | 8 |
| Occupational situation and prospects | |||
| Job satisfaction | COPSOQ: German standard version [23, 34] | 0.81 | 7 |
| Job strain and prospects | Additional questions (e.g., taking into account the current work situation, do you want to stay in this profession for the next five years?) | – | 3 |
| Coefficient | Standard Error | P-value | |
| HIV-infected | |||
| For Log IP-10 | |||
| Gender | 0.153 | 0.101 | 0.131 |
| Age | 0.005 | 0.005 | 0.250 |
| Weight | 0.002 | 0.003 | 0.554 |
| Co-morbidity | -0.078 | 0.098 | 0.423 |
| For log sCD14 | |||
| Gender | 0.074 | 0.056 | 0.196 |
| Age | 0.002 | 0.002 | 0.575 |
| Weight | 0.002 | 0.003 | 0.947 |
| Co-morbidity | -0.003 | 0.055 | 0.963 |
| HIV-uninfected | |||
| For Log IP-10 | |||
| Gender | -0.098 | 0.148 | 0.508 |
| Age | -0.007 | 0.008 | 0.318 |
| Weight | 0.005 | 0.009 | 0.594 |
| For log sCD14 | |||
| Gender | -0.074 | 0.057 | 0.196 |
| Age | -0.001 | 0.002 | 0.575 |
| Weight | 0.001 | 0.003 | 0.947 |
| PROCEDURE | ONCOLOGIC RESULTS | ||
| RARC* | equivalent lymph node yields | comparable overall and recurrence-free survival | similar positive surgical margins in ≤ T2 disease |
| RAPN§ | comparable margin status | equivalent local recurrence rates | |
| RALNU# | studies with long-term follow-up are needed |
| Comorbidity | ICD codes | |
| Heart failure | ICD-8: | 427, 428 |
| ICD-10: | I42, I50, I110, J819 | |
| Ischaemic heart disease | ICD-8: | 411, 412, 413, 414 |
| ICD-10: | I20, I23, I24, I25, | |
| Anemia | ICD-8: | 280-285 |
| ICD-10: | D60-D69 | |
| Cancer | ICD-8: | 140-209 |
| ICD-10: | C00-C97 | |
| Chronic obstructive pulmonary disease | ICD-8: | 490, 491, 492 |
| ICD-10: | J42, J44 | |
| Atrial fibrillation | ICD-8: | 427.4 |
| ICD-10: | I48 | |
| Acute myocardial infarction | ICD-8: | 410 |
| ICD-10: | I21, I22 | |
| Peripheral arterial disease | ICD-8: | 443 |
| ICD-10: | I70, I74 | |
| Diabetes | ICD-8: | 250 |
| ICD-10: | E10-E14 | |
| Hypertension | ICD-8: | 400, 401 |
| ICD-10: | I109, I119, !959, I270, I951 |
| Group Examined (ICD-9 Code) | 0 μg Organic-Hg (%) (Reference Dose) | 12.5 μg Organic-Hg (%) | 25 μg Organic-Hg (%) | 37.5 μg Organic-Hg (%) | Odds Ratio per μg Organic-Hg (95% CI) (p-value) |
| Febrile Seizure Cases (780.3) | 218 (5.2) | 60 (1.4) | 3432 (81.5) | 499 (11.9) | 1 (0.993–1.003) (0.53) |
| Controls | 2858 (3.4) | 981 (1.1) | 74,102 (87.1) | 7,171 (8.4) | |
| Failure to Thrive Cases (783.4) | 322 (8.3) | 106 (2.7) | 3028 (77.6) | 444 (11.4) | 0.98 (0.97–0.98) (<0.001) |
| Controls | 3270 (3.4) | 1096 (1.2) | 82,425 (86.5) | 8458 (8.9) | |
| Cerebral Degeneration Cases (330.xx or 331.xx) | 92 (14.2) | 13 (2.0) | 483 (74.7) | 59 (9.1) | 0.95 (0.94–0.96) (<0.001) |
| Controls | 5148 (3.8) | 1558 (1.1) | 116,038 (85.4) | 13,145 (9.7) |
| Advantages | Shortcomings |
| Available anywhere on the earth in any weather conditions for outdoor measurements at no cost | High cost of professional equipment |
| Tri-dimensional positioning with centimeter accuracy (Real Time Kinematics, RTK mode) | Not fully validated for gait analysis yet |
| No space restriction: freedom in the path selection, including uphill/downhill locomotion. | Limited time windows (2–4 h per day) |
| Free living conditions, i.e close to real life | One body segment measured only (head): Because of mandatory constant satellite access, the antenna must not be obstructed by body parts. |
| Unlimited number of consecutive strides: limited only by the memory capacity of the receiver and the duration of the batteries. | Outdoor analysis: difficult to standardize environmental conditions (weather, terrain). |
| Not fully miniaturized (cumbersome antenna). |
| Operation (Pipette-dependence modea) | Purpose | Details | |||
| PF | 1 | Input (I-mode) | Liquid charging into MMV wells | Figure 1c | |
| 2 | Output (O-mode) | a. Transfer | Complete ejection of liquid in wells | Figure 1b and Additional file 6: Figure S5 | |
| b. Washing | |||||
| 3 | Square transfer (S-mode) | Fractional volume transfer | Additional file 2: Figure S1 | ||
| 4 | Z-direction transfer (Z-mode) | Normal transfer of liquid into wells | Figure 1b and Additional file 5: Figure S4 | ||
| 5 | X-direction transfer (X-mode) | Division of liquid in all wells | Additional file 7: Figure S6 | ||
| 6 | Magnetic beads transfer (M-mode) | a. Beads recovery | Beads recovery | Additional file 8: Figure S7 | |
| b. Division of liquid | Division of liquid in all wells | Additional file 9: Figure S8 | |||
| 7 | Filtering (F-mode) | Filter-selective transfer | Figure 2a | ||
| PD | 8 | Pipette-dependent transfer (P-mode) | a. Manual | Manual transfer of liquid or beads | Additional file 10: Figure S9 |
| b. Robotic | Robotic transfer of liquid or beads | Additional file 3: Figure S2 |
| Gene | Sequence (5′-3′) | Product size (bp) |
| IL-6 | For: CCTGACCCAACCACAAATGC | 646 |
| Rev: CCTTAAAGCTGCGCAGAATGA | ||
| IL-8 | For: CTTTCCACCCCAAATTTATCAAAG | 264 |
| Rev: AGAGCTCTCTTCCATCAGAAAGCT | ||
| GAPDH | For: ACACCCACTCCTCCACCTTT | 199 |
| Rev: TAGCCAAATTCGTTGTCATACC |
| Before SS exposure on PND59 | After SS exposure on PND59 | |||
| Group | RL | Cdyn | RL | Cdyn |
| GD7 SS | 1.12 ± 0.11 | 0.053 ± 0.014 | 1.18 ± 0.19 | 0.046 ± 0.016 |
| GD7 FA | 1.04 ± 0.13 | 0.058 ± 0.016 | 1.11 ± 0.11 | 0.054 ± 0.017 |
| PND2 SS | 1.01 ± 0.09 | 0.065 ± 0.011 | 1.09 ± 0.13 | 0.053 ± 0.012 |
| PND2 FA | 0.94 ± 0.12 | 0.069 ± 0.016 | 1.03 ± 0.15 | 0.059 ± 0.007 |
| PND21 SS | 1.08 ± 0.05 | 0.062 ± 0.008 | 1.02 ± 0.10 | 0.069 ± 0.011 |
| PND21 FA | 1.01 ± 0.08 | 0.067 ± 0.007 | 0.96 ± 0.12 | 0.072 ± 0.014 |
| EAPs for sensing | ||
| pros | cons | |
| ionic EAPs | ||
| conducting polymers | chemical stability, miniaturization, facile fabrication process, low-cost, low-weight, biocompatibility, soft, multiformable (sheet, film, tubular, trilayer), response to mechanical, electrical, chemical and thermal stimulation | insufficient adhesion onto substrate, fragile upon mechanical and thermal loading |
| ionic polymer–metal composites | low-weight, biocompatibility, miniaturization, soft, large produced voltage signal, sensitive to large bending deformation, ability to work in wet environments | hysteresis, sensitive to moisture and temperature during operation, operation limited to low temperature due to liquid electrolyte, slow response |
| carbon nanotubes | high surface area to volume, high sensitivity, miniaturization, directional mechanical and electrical properties | expensive, slow response, difficult to control intrinsic properties during fabrication |
| electronic EAPs | ||
| dielectric elastomers | large sensing range, low-cost, light-weight, stability in many working cycles, and capability as self-sensing actuators | defect-sensitive, rare for stress measurement, not sensitive to compression in normal direction, may be affected by temperature |
| liquid-crystal elastomers | potential for high strain changes, potential high sensitivity to strain | complex and expensive synthesis and processing of the materials |
| piezoelectric polymers | wide bandwidth, fast electromechanical response, relatively low-power requirements, high generative forces | relatively low output performance originating from charge dissipation. Some materials need to be stretched and poled to gain higher output |
| Model | Regression coefficient | [95% CI] | p |
| Intercept | -17.15 | [-18.94;-14.86] | - |
| Distance | -3.21 | [-6.17;-1.74] | 0.021 |
| Biotope | |||
| Clear water | 0 | - | - |
| Rush wetland | 0.92 | [-0.64;3.03] | 0.25 |
| Rice field | 17.67 | [15.38;19.45] | 0.005 |
| Reeds | 14.48 | [-0.12;16.59] | 0.084 |
| Marshes with Scirpus | 17.50 | [14.99;19.24] | 0.009 |
| Drug resistant plasmid Name | Antimicrobial drug | Drug resistance plasmid MIC (ug/ml) | Empty vector MIC (ug/ml) | Fold increase |
| pAMP | ampicillin | 16 | 4 | 4 |
| pAMP | piperacillin | 3 | 2 | 1.5 |
| pAMP | cefotaxime | <.25 | <.25 | 0 |
| pAMP | ceftazidime | <.5 | <.5 | 0 |
| pAMP | cefepime | 0.064 | 0.094 | 0.68 |
| pAMP | Aztreonam | 0.19 | 0.125 | 1.5 |
| pAMP | Imipenem | 0.25 | 0.25 | 0 |
| pCIP | ciprofloxacin | 0.125 | <0.002 | >62.5 |
| pCIP | levofloxacin | 0.38 | 0.012 | 31.7 |
| pCIP | Ampicillin | 6 | 4 | 1.5 |
| pCIP | piperacillin | 3 | 2 | 1.5 |
| pCIP | ceftazidime | <.5 | <.5 | 0 |
| pCIP | cefotaxime | <.25 | <.25 | 0 |
| pCIP | cefepime | 0.125 | 0.094 | 1.3 |
| pCIP | Imipenem | 0.25 | 0.25 | 0 |
| pTMP | trimethoprim | >32 | 0.124 | >258 |
| pTMP | trimethoprim- sulfamethoxazole | 0.5 | 0.064 | 7.8 |
| pAZT | Aztreonam | 12 | 0.125 | 96 |
| pAZT | cefepime | 1 | 0.094 | 10.6 |
| pAZT | ceftazidime | 16 | 0.5 | 32 |
| pAZT | piperacillin | 12 | 2 | 6 |
| pSXT | trimethoprim-sulfamethoxazole | 1 | 0.064 | 15.6 |
| pSXT | trimethoprim | >32 | 0.125 | >256 |
| pPRP:1B | ciprofloxacin | 0.125 | 0.016 | 7.8 |
| pPRP:1B | levofloxacin | 0.25 | 0.047 | 5.3 |
| Primers | Sequences | Denaturation | annealing | Cycles | PCR products |
| HGF: ForwardReverse | 5'-CAGAGGGACAAAGGAAAAGAA-3'5'-GCAAGTGAATGGAAGTCCTTTA-3' | 94°C, 15s | 58°C, 60s | 40 | 167 bp |
| KGF: ForwardReverse | 5'-GAACAAGGAAGGAAAACTCTATGCAA-3'5'-AAGTGGGCTGTTTTTTGTTCTTTCT-3' | 94°C, 15s | 60°C, 60s | 40 | 201 bp |
| HGF-R: ForwardReverse | 5'-GTTTACTTGTTGCAAGGGAGAAGACT-3'5'-TAGGGTGCCAGCATTTTAGCA-3' | 94°C, 15s | 58°C, 60s | 40 | 88 bp |
| KGF-R: ForwardReverse | 5'-TTAAGCAGGAGCATCGCATTG-3'5'-AACATCCAGGTGGTACGTGTGAT-3' | 94°C, 15s | 60°C, 60s | 40 | 151 bp |
| Ubiquitin-c: ForwardReverse | 5'-CACTTGGTCCTGCGCTTGA-3'5'-TTTTTTGGGAATGCAACAACTTT-3' | 94°C, 15s | 60°C, 60s | 40 | 105 bp |
| Base value | Esmolol group (n = 75) | Control group (n = 76) | t/χ2 | P |
| Male, n (%) | 54 (72.0) | 53 (69.7) | 0.094 | 0.760 |
| APACHE-II score, mean ± standard deviation | 24.20 ± 7.66 | 25.46 ± 7.83 | −0.999 | 0.319 |
| HR, mean ± standard deviation | 125.04 ± 13.28 | 127.21 ± 13.88 | −0.982 | 0.328 |
| MAP, mean ± standard deviation | 74.71 ± 7.28 | 75.89 ± 6.61 | −1.051 | 0.295 |
| CVP, mean ± standard deviation | 12.45 ± 3.16 | 11.99 ± 3.35 | 0.881 | 0.380 |
| IS, mean ± standard deviation | 10.99 ± 2.08 | 11.11 ± 1.81 | −0.374 | 0.709 |
| Lac, mean ± standard deviation | 8.98 ± 3.09 | 9.74 ± 4.05 | −1.301 | 0.195 |
| P(va)CO2, mean ± standard deviation | 9.54 ± 3.89 | 10.12 ± 3.52 | −0.947 | 0.345 |
| ScvO2, mean ± standard deviation | 0.77 ± 0.06 | 0.78 ± 0.06 | −0.537 | 0.592 |
| Inter-rater | Intra-rater | ||||
| FT | ROl | FT | ROl | ||
| L4 (N=103) | FA R/L | 0.89/0.89 | 0.68/0.54 | 0.79/0.83 | 0.78/0.78 |
| ADC R/L | 0.96/0.93 | 0.85/0.85 | 0.87/0.93 | 0.96/0.86 | |
| L5 (N=127) | FA R/L | 0.96/0.95 | 0.65/0.77 | 0.93/0.93 | 0.69/0.79 |
| ADC R/L | 0.96/0.96 | 0.82/0.93 | 0.96/0.95 | 0.88/0.90 | |
| S1 (N=135) | FA R/L | 0.96/0.98 | 0.85/0.90 | 0.96/0.95 | 0.77/0.87 |
| ADC R/L | 0.96/0.93 | 0.92/0.95 | 0.98/0.98 | 0.97/0.96 |
| Virus | Dilution | Virus isolation | Real time RT-PCR | CT |
| WEEV | 10-1 | 4/4 | + | 15.25 |
| 10-2 | 4/4 | + | 18.29 | |
| 10-3 | 4/4 | + | 22.02 | |
| 10-4 | 4/4 | + | 25.49 | |
| 10-5 | 4/4 | + | 29.28 | |
| 10-6 | 2/4 | + | 32.79 | |
| 10-7 | 0/4 | + | 36.03 | |
| 10-8 | 0/4 | - | ||
| TCID50: 106/0.1 ml | ||||
| EEEV | 10-1 | 4/4 | + | 11.37 |
| 10-2 | 4/4 | + | 16.25 | |
| 10-3 | 4/4 | + | 18.54 | |
| 10-4 | 4/4 | + | 22.03 | |
| 10-5 | 4/4 | + | 27.35 | |
| 10-6 | 2/4 | + | 30.18 | |
| 10-7 | 1/4 | + | 34.79 | |
| 10-8 | 0/4 | + | 37.59 | |
| TCID50: 106.25/0.1 ml |
| True/False item | Correct answer | % correct* | True/False item | Correct answer | % correct* |
| HIV/AIDS KNOWLEDGE | OVERDOSE KNOWLEDGE | ||||
| When a couple decides that they are ONLY going to have sex with each other, they no longer need to use condoms to prevent HIV. | F | 66.9 (62.1, 71.8) | Causing physical pain will help keep someone who is overdosing conscious or alive. | F | 36.9 (31.9, 41.9) |
| The fewer sex partners you have in your life, the less likely you are to get HIV. | T | 66.0 (61.2, 70.9) | Fatal ODs are more likely to happen when people use alone. | T | 89.5 (86.4, 92.6) |
| People can still transmit the HIV/AIDS virus even if they test negative for the virus. | T | 45.2 (40.1, 50.3) | People are more likely to have an OD if they use soon after getting out of a government center, prison, or detoxification program. | T | 84.8 (81.1, 88.5) |
| Most people who have HIV know they have it. | F | 52.1 (46.9, 57.2) | Most heroin OD deaths happen very quickly, in less than 15 minutes after taking the drugs. | F | 9.8 (6.7, 12.8) |
| HEPATITIS KNOWLEDGE | It is easy to tell the difference between a “heavy nod” and a heroin overdose. | F | 10.1 (7.0, 13.2) | ||
| Hepatitis can cause liver cancer. | T | 72.1 (67.5, 76.7) | Sweating and anxiety are signs of a heroin OD. | F | 58.0 (52.9, 63.1) |
| HIV is easier to transmit than hepatitis. | F | 46.4 (41.3,51.6) | Injecting water can slow or reverse the effects of an opioid overdose | F | 30.5 (25.7, 35.2) |
| You will be able to recognize if any individual is infected with hepatitis. | F | 40.9 (35.8, 46.0) | Someone who is overdosing should be immediately placed on their back. | F | 18.3 (14.3, 22.3) |
| Most people infected with hepatitis know that they have the disease. | F | 46.4 (41.2, 51.6) | Naloxone is a medication for reversing the effects of a heroin OD. | T | 47.7 (42.4, 53.0) |
| Drinking alcohol worsens the course of hepatitis C. | T | 84.2 (80.4, 87.9) | Naloxone must be injected into a vein. | F | 26.9 (22.2, 31.7) |
| You are more likely to get hepatitis B than hepatitis C by having unprotected sex. | T | 54.3 (49.1, 49.4) | Naloxone will reverse a stimulant overdose. | F | 24.8 (20.3, 29.4) |
| Productivity software | Microsoft Office |
| Endnote | |
| Toolbook Runtime (with modules) | |
| Medical Software (Anatomy) | A.D.A.M |
| Anatomy TV | |
| Grant's Atlas of Dynamic Human Anatomy | |
| Netter | |
| Imaging Modalities | |
| D.A.R.T.O.S. | |
| Medical Software (Biochemistry) | Buffers |
| Clustal X | |
| Cn3D | |
| Genedoc | |
| Graphpad Prism | |
| Growcyt | |
| Hypercell 98 | |
| Image J | |
| Interactive biochemistry | |
| NjPlot | |
| Protein explorer | |
| Protein purification lab | |
| RasMol 2.6 | |
| Spectrophotmetry | |
| Swiss PDB Viewer | |
| Trace | |
| Medical Software (Nutrition and Dietetics) | FoodWorks |
| SERV v5.5e | |
| Medical Software (Pharmacology) | Pharma-Cal-Ogy |
| Medical Software (Physiology) | Acid Base |
| Exercise Physiology |
| Number | Scenario |
| 1 | Human papilloma virus positive state |
| 2 | Cervical intraepithelial neoplasia grade I |
| 3 | Cervical intraepithelial neoplasia grade II/III |
| 4 | Cervical cancer requiring simple or radical hysterectomy |
| 5 | Cervical cancer requiring radical hysterectomy and subsequent radiotherapy (and chemotherapy) |
| 6 | Cervical cancer requiring chemoradiation therapy |
| 7 | Cervical cancer requiring chemotherapy without surgery |
| 8 | Condyloma (genital warts [condyloma acuminatum]) |
| District | Locality (n) | Seroprevalence % (proportion) | 95% C.I. | P-value |
| Charsadda | Ataki (38) | 36.8 (14/38) | 21.8–54.0 | Χ2 = 7.63 |
| Batagram (29) | 55.2 (16/29) | 35.7–73.6 | P = 0.106 | |
| Penda Khel (63) | 50.8 (32/63) | 37.9–63.6 | ||
| Sarderi (31) | 38.7 (12/31) | 21.8–57.8 | ||
| Torenzai (32) | 65.6 (21/32) | 46.8–81.4 | ||
| Peshawar | Ganjkohati (56) | 32.1 (18/56) | 20.3–46.0 | χ2 = 9.39 |
| Badabir (40) | 22.5 (9/40) | 10.8–38.5 | P = 0.024 | |
| Pandu (50) | 40.0 (20/50) | 26.4–54.8 | ||
| Ring Road (54) | 14.8 (8/54) | 6.6–27.1 | ||
| Total | 38.2 (150/393) | 33.3–43.2 |
| Parameter | HMA All Lines (n = 88) | First-Line HMA (n = 41) | First-Line ICT (n = 122) | p-Value First-Line HMA vs. ICT |
| Median age at diagnosis, years | 69 | 73 | 60 | 0.1698 |
| (min–max) | (28–88) | (44–88) | (20–86) | |
| Male gender, n (%) | 54 (61) | 26 (63) | 88 (72) | 0.3919 |
| BM blasts at start of treatment | ||||
| Median | 22 | 22 | 24 | 0.8576 |
| Mean (Standard Deviation) | 25.8 (17.2) | 25.8 (15.9) | 27.1 (15.8) | |
| Unknown, n (%) | 12 (14) | 2 (5) | 6 (5) | |
| Hemoglobin at start of treatment, n (%) | ||||
| ≤10 g/dL | 55 (63) | 32 (78) | 32/64 (50) | 1.00 |
| Pts. with unknown hemoglobin | 3 (3) | 0 (0) | 71 (58) | |
| Median WBC count at start of treatment, ×109/L (min–max) | 2.35 | 2.42 | 1.81 | 0.7294 |
| (0.1–32.3) | (0.6–24.0) | (0.2–23.9) | ||
| Neutrophil count at start of treatment, n (%) | ||||
| ≤ 0.5 × 109/L | 34 (39) | 18 (44) | 18/57 (31) | 0.7326 |
| Pts. with unknown neutrophil count | 5 (6) | 1 (2) | 79 (65) | |
| Platelet count at start of treatment, n (%) | ||||
| ≤50 × 109/L | 54 (61) | 24 (69) | 62 (51) | 0.8673 |
| Unknown | 3 (3) | 0 (0) | 10 (8) | |
| AML subtype, n (%) | ||||
| Primary | 66 (75) | 35 (85) | 81 (66) | 0.4373 |
| Secondary | 11 (13) | 4 (10) | 17 (14) | |
| Unknown | 11 (13) | 2 (5) | 24 (20) | |
| MRC cytogenetic risk group, n (%) | ||||
| Good risk | 1 (1) | 0 (0) | 0 (0) | 0.6943 |
| Intermediate risk | 39 (44) | 17 (42) | 51 (42) | |
| Poor risk | 45 (51) | 22 (54) | 53 (43) | |
| Unknown | 3 (3) | 2 (5) | 18 (15) |
| Molecular Category | TGFβ Sub-Family Pathway 1 | BMP Sub-Family Pathway |
| Ligands | TGFβs, ActivinsGDF8/9/10/11, BMP3, Nodal | BMP2/4/5/6/7/8/9/10, GDF1/3/5/6/7, MIS |
| Type II receptors | TβRII, ActRIIA, ActRIIB | BMPRII, ActRIIA, ActRIIB |
| Type I receptors | ALK4, TβRI (ALK5), ALK7 | ALK1/2, BMPR1A (ALK3), BMPR1B (ALK6) |
| R-Smad | Smad2/3 | Smad1/5/8 |
| Co-Smad | Smad4 | Smad4 |
| I-Smad | Smad7 | Smad6/7 |
| Comparison | p value | r value |
| Quads Strength and TWT | ||
| Baseline | 0.003 | -0.688 |
| Week 6 | 0.003 | -0.697 |
| Week 12 | 0.005 | -0.662 |
| Quads Strength and TST | ||
| Baseline | 0.008 | -0.626 |
| Preoperative | 0.020 | -0.552 |
| Week 6 | 0.009 | -0.618 |
| Week 12 | 0.001 | -0.776 |
| Quads Strength and TCT | ||
| Preoperative | 0.032 | -0.508 |
| WOMAC-Pain and TCT | ||
| Baseline | 0.047 | 0.464 |
| WOMAC-Function and TWT | ||
| Baseline | 0.034 | 0.252 |
| SF36-Physical Health and TWT | ||
| Baseline | 0.009 | -0.623 |
| Week 12 | 0.041 | -0.481 |
| SF36-Physical Health and TST | ||
| Preoperative | 0.039 | -0.487 |
| SF36-Mental Health and TCT | ||
| Week 12 | 0.026 | -0.528 |
| FMF | |||
| Rheumatic diseases (+) | Rheumatic diseases (–) | ||
| n = 26 | n = 166 | p | |
| Male/female | 4/22 | 79/87 | 0.002 |
| Age at onset (years), mean ± SD | 39.3 ± 15.8 | 29.0 ± 16.8 | 0.006 |
| Fever | 24 (92.3 %) | 160 (96.4 %) | 0.296 |
| Frequencies of febrile attack (per month), mean ± SD | 1.01 ± 0.59 | 1.06 ± 0.96 | 0.523 |
| Duration of fever attack (days), mean ± SD | 3.0 ± 2.2 | 3.8 ± 4.1 | 0.359 |
| Abdominal pain | 3 (11.5 %) | 74 (44.6 %) | 0.001 |
| Thoracic pain | 4 (15.4 %) | 47 (28.3 %) | 0.165 |
| Arthritis | 21 (80.8 %) | 87 (52.4 %) | 0.007 |
| Erysipelas-like erythema | 3 (11.5 %) | 31 (18.7 %) | 0.281 |
| AA amyloidosis | 0 | 7 (4.2 %) | 0.355 |
| Family history of periodic fever | 1 (3.8 %) | 38 (22.9 %) | 0.025 |
| MicroRNA | Location | Model | Response | References |
| miR-200c | Upstream | db/db T2DM | Increase aorta endothelial dysfunction | [101] |
| miR-320 | Upstream | High glucose treated HUVECs | Reduced expression of ET-1, VEGF, and FN | [102] |
| miR-133a | Upstream | STZ-induced diabetes | Prevent cardiac fibrosis | [103] |
| miR-1 and 6 | Up stream | STZ-induced diabetes and high glucose treated NRVCs | Increase cardiomyocyte apoptosis | [104] |
| Uncorrected T2Prep‐IR BOOST | Motion Corrected T2Prep‐IR BOOST | |||
| RCA | Length (cm) | 7.03 ± 1.50 | 8.58 ± 2.27 | P < 0.02 |
| %VS (4 cm) | 36.54 ± 8.63 | 48.31 ± 6.71 | P < 0.001 | |
| %VS (tot) | 37.96 ± 8.63 | 48.82 ± 4.63 | P < 0.001 | |
| LAD | Length (cm) | 4.82 ± 3.78 | 7.92 ± 4.16 | P < 0.02 |
| %VS (4 cm) | 32.92 ± 16.08 | 48.82 ± 6.51 | P < 0.005 | |
| %VS (tot) | 32.42 ± 15.15 | 48.12 ± 6.63 | P < 0.005 |
| Site/size | Mean | StDev | Min | Med | Max |
| EF >100 | 0.02615 | 0.02849 | 0 | 0.0159 | 0.10568 |
| EF >50 < 100 | 1.02039 | 0.02286 | 0 | 0.01761 | 0.07789 |
| EF <50 | 0.04478 | 0.03933 | 0 | 0.04559 | 0.124 |
| SE >100 | *0.1589 | 0.03933 | 0.00677 | 0.131 | 0.4524 |
| SE >50 < 100 | *0.2121 | 0.167 | 0.0124 | 0.1976 | 0.6228 |
| SE <50 | *0.7170 | 0.477 | 0.0352 | 0.755 | 1.654 |
| I >100 | 0.01564 | 0.02594 | 0 | 0.0124 | 0.11683 |
| I >50 < 100 | 0.02883 | 0.03709 | 0 | 0.02067 | 0.15578 |
| I <50 | 0.093 | 0.1135 | 0 | 0.0671 | 0.4284 |
| Expression in A549 | |||||
| Parental (fold) | Senescent RNA-seq (fold) | Senescent RT-PCR (fold) | Revertant RNA-seq (fold) | Revertant RT-PCR (fold) | |
| NPTX1 | 1 | 23 | 40 | 4 | 6 |
| IGF2 | 1 | 13 | 12 | 4.1 | 3.5 |
| HAPLN3 | 1 | 10 | 38 | 2.8 | 7.4 |
| CHAC1 | 1 | 25 | 22 | 4.2 | 2.7 |
| BST2 | 1 | 207 | 62 | 10 | 1.5 |
| C15orf48 | 1 | 207 | 9 | 10 | 2.5 |
| NIPAL4 | 1 | 64 | 25 | 4.2 | 2.2 |
| AGT | 1 | 185 | 98 | 7.4 | 3 |
| SPATA18 | 1 | 10 | 19 | 1.8 | 2 |
| PIK3R2 | 1 | 6 | 9 | 1.9 | 3.6 |
| MT1X | 1 | 9 | 9 | 1.9 | 1.8 |
| PAQR7 | 1 | 7 | 6 | 2.3 | 1.7 |
| GJA1 | 1 | 5 | 10 | 2.4 | 3.2 |
| LAPTM5 | 1 | 26 | 168 | 2.4 | 3.7 |
| SP5 | 1 | 16 | 30 | 2.4 | 2.6 |
| COL20A1 | 1 | 11 | 16 | 2.4 | 2.4 |
| NAP1L3 | 1 | 43 | 48 | 2.5 | 2 |
| FBXL21 | 1 | 28 | 14 | 2.5 | 3.5 |
| Tmem26 | 1 | 88 | 28 | 2.5 | 3.3 |
| CST1 | 1 | 7 | 11 | 2.8 | 4 |
| SNAI2 | 1 | 25 | 74 | 2.8 | 5.3 |
| TEN1 | 1 | 5 | 2 | 2.9 | 1.7 |
| DYDC2 | 1 | 15 | 9 | 3 | 2 |
| ZNF841 | 1 | 15 | 5 | 3 | 1.6 |
| AMOT | 1 | 7 | 28 | 3 | 6.2 |
| BARX1 | 1 | 13 | 15 | 3 | 3.2 |
| ABCA8 | 1 | 6 | 8 | 3 | 3.2 |
| AIM1L | 1 | 10 | 12 | 3.2 | 2.5 |
| CDRT4 | 1 | 6 | 3 | 3.2 | 1.3 |
| SLC2A3 | 1 | 18 | 14 | 3.3 | 2.5 |
| CPE | 1 | 5 | 7 | 3.6 | 4.4 |
| TRO145 | 1 | 30 | 19 | 3.9 | 1.4 |
| HOXD10 | 1 | 11 | 4 | 5 | 1.9 |
| PIP | 1 | 53 | 36 | 5.6 | 1.1 |
| EMB | 1 | 5 | 6 | 6.5 | 4.9 |
| SERPINB4 | 1 | 26 | 2 | 7.9 | 1.6 |
| QPRT3 | 1 | 119 | 24 | 20 | 2.7 |
| SLC7A4 | 1 | 714 | 4 | 340 | 1 |
| IFI44 | 1 | 395 | 4324 | 3 | 18 |
| Cheese sample | Area assessed | a value at 144 days |
| Control | Top | −2.22 |
| Side | −2.17 | |
| Base | −2.32 | |
| Center | −2.38 | |
| Exp1 | Top | −2.21 |
| Side | −2.28 | |
| Base | −2.21 | |
| Center | −1.95 | |
| Exp2 | Top | −2.18 |
| Side | −2.16 | |
| Base | −2.10 | |
| Center | −1.34b | |
| Exp3 | Top | −2.14 |
| Side | −2.35 | |
| Base | −2.13 | |
| Center | −1.82 |
| Low Rate | Medium Rate | High Rate | p-value | |
| Countries with implemented screening programmes | 22% (2/9) | 67% (6/9) | 89% (8/9) | 0.014 |
| Countries with guidelines for screening | 11% (1/9) | 78% (7/9) | 78% (7/9) | 0.005 |
| Reported obstetric complications or near misses | ||||
| Independent variables | Eclampsia | Hemorrhage | Sepsis | Obstructed labor |
| (n = 324) | (n = 4,945) | (n = 3,120) | (n = 2,847) | |
| Odds ratio | Odds ratio | Odds ratio | Odds ratio | |
| Biological factors | ||||
| Age 18–35 years (ref) | ||||
| Age <18 years | 1.35*** | 1.20*** | 1.18*** | 1.27*** |
| Age >35 years | 1.34*** | 1.27*** | 1.19* | 1.21*** |
| Parity 1–2 (ref) | ||||
| Nulliparity | 1.13** | 1.10** | 1.14** | 1.30*** |
| Parity >2 | 1.12 | 1.09 | 1.05 | 1.10 |
| No previous stillbirth or miscarriage (ref) | ||||
| Adverse obstetric history | 1.18*** | 1.06** | 1.12** | 1.14*** |
| MUAC ≥ 21.5 cm (ref) | ||||
| MUAC < 21.5 cm | 1.04 | 1.12* | 1.16* | 1.05 |
| Socioeconomic factors | ||||
| Wealth index – Lowest quartile (ref) | ||||
| Wealth index - 2nd quartile | 1.00 | 1.01 | 1.02 | 1.00 |
| Wealth index - 3rd quartile | 1.01 | 1.02 | 1.00 | 1.00 |
| Wealth index - Highest quartile | 1.00 | 1.03 | 1.05 | 1.02 |
| Maternal illiteracy (ref) | ||||
| Maternal literacy | 1.01 | 1.01 | 1.04 | 1.03 |
| Psychosocial factors | ||||
| Both partners wanted pregnancy (ref) | ||||
| Only one partner wanted pregnancy | 1.02 | 1.06 | 1.08 | 1.07 |
| Neither partner wanted pregnancy | 1.02 | 1.40*** | 1.37*** | 1.28*** |
| Swollen joints | Tender joints | |||||
| 32JC- (n = 760) | 28JC-/32JC+ (n = 38) | p | 32JC- (n = 1,120) | 28JC-/32JC+ (n = 102) | p | |
| SDAI | 6.45 | 8.93 | 0.03 | 7.95 | 10.91 | 0.00 |
| DAS28 | 2.65 | 2.92 | 0.11 | 2.65 | 2.97 | 0.00 |
| C-reactive protein (mg/dl) | 1.25 | 1.43 | 0.56 | 1.38 | 1.52 | 0.42 |
| Pain (mm VAS) | 23 | 36 | 0.00 | 20 | 34 | 0.00 |
| Patient global (mm VAS) | 22 | 39 | 0.00 | 21 | 35 | 0.00 |
| Physician global (mm VAS) | 17 | 19 | 0.51 | 12 | 25 | 0.00 |
| Outcome variable | ESeC 1 | ESeC 2 | ESeC 3 | p |
| ESS score | 9.24±5.27 | 9.41±4.9 | 8.92±5.2 | 0.645 |
| Median (IQR) | 8.5 (5-12) | 9 (6-13) | 8 (5-12) | |
| Missing data | 1 (1) | 2 (2.9) | 4 (3.5) | 0.485 |
| AHI | 39.81±27.01 | 50.51±30.43 | 41.94±24.26 | 0.059 |
| Median (IQR) | 31.7(16.7-63.5) | 45 (24-78.6) | 39.3 (22-64.4) | |
| AHI groups | ||||
| <15 | 23 (23.2) | 6 (8.6) | 18 (15.9) | 0.133 |
| 15-29.9 | 23 (23.2) | 19 (27.1) | 24 (21.2) | |
| ≥30 | 53 (53.5) | 45 (64.3) | 71 (62.8) |
| Supernatant conditions | Protein concentration (mg/mL) | Degradation (%) |
| Culture supernatant | 0.24 ± 0.03 | 50.48 ± 2.40 |
| Super filtered culture supernatant a | 1.22 ± 0.04 | 73.84 ± 1.65 |
| Boiled culture supernatant | 0.12 ± 0.02 | 52.24 ± 1.74 |
| Full follow-up scenario | Early mortality scenario | ||
| ....Hazard ratio (95 % CI)... | |||
| cART | Yes | 0 · 41 (0 · 18, 0 · 92) | 0 · 28 (0 · 16, 0 · 49) |
| No | 1 · 0 | 1 · 0 | |
| Cotrimoxazole | Yes | 0 · 06 (0 · 01, 0 · 26) | 0 · 02 (0 · 01, 0 · 07) |
| No | 1 · 0 | 1 · 0 | |
| TB cure | Yes | 0 · 38 (0 · 18, 0 · 84) | 0 · 66 (0 · 38, 01 · 13) |
| No | 1 · 0 | 1 · 0 |
| Variables | AEP monitor group (n= 19) | RSS monitor group (n= 18) | P |
| Median number of propofol dosage adjustment | 6 [5-7] | 3 [2-3.8] | <0.001 |
| Time to the first adjustment of the propofol dosage (second) | 137 [117.5-200.5] | 466 [376.5-553.5] | <0.001 |
| Propofol dosage during examination (μg⋅kg-1⋅min-1) | 43.5 [28.5-49.3] | 24.2 [15.5-32.4] | 0.025 |
| Fentanyl dosage during examination (μg⋅kg-1⋅hr-1) | 2.5 [1.8-3.1] | 2.7 [1.9-3.4] | 0.679 |
| Percentage of propofol dosage change compared with the baseline dose (%) | 93.5 [48.4-172.3] | 39.5 [30.4-53.9] | 0.011 |
| Percentage of time at sedation target (%) | 51.3 [47.0-63.5] | 15.4 [9.5-23.5] | <0.001 |
| Percentage of AAI levels greater than 40 during examination (%) | 35.3 [27.1-51.5] | 84.5 [76.5-90.4] | 0.033 |
| Patients with significant hypotension (MAP less than 60 mmHg) (%) | 2 (10.5) | 0 (0) | 0.154 |
| Duration of FB examination (min) | 29 [27-32] | 30 [28-32] | 0.860 |
| EMG (dB) | 18 [16-23.5] | 20 [17-25] | 0.751 |
| Total (n = 1998) | ORN/CIT | PRO/CIT | ORN/ARG | Arginine Bioavailability § |
| TG (mg/dL) φ | 0.062 * | 0.149 | 0.027 * | −0.026 |
| HDLC (mg/dL) φ | −0.051 * | −0.056 | −0.088 * | 0.110 * |
| FBG (mg/dL) φ | 0.051 * | 0.134 | −0.002 * | 0.021 |
| SBP (mmHg) | 0.020 | 0.038 | 0.021 | −0.029 |
| DBP (mmHg) | 0.041 | 0.035 * | 0.054 | −0.051 * |
| TC (mg/dL) | 0.010 | 0.028 * | −0.048 | 0.074 * |
| LDLC (mg/dL) | −0.017 | −0.022 | −0.043 | 0.044 |
| AST (IU/L) φ | 0.114 * | −0.005 * | 0.170 | −0.107 * |
| ALT (IU/L) φ | 0.097 * | 0.079 * | 0.054 * | −0.025 |
| Background characteristics | Total % |
| Total 85 participants | |
| Age in years | |
| ≥20 | 7.7 |
| 21-30 yrs | 37.2 |
| 31-40 yrs | 14.1 |
| 41-50 yrs | 9 |
| ≤ 50 | 3.8 |
| Missing data | 28 |
| Education | |
| Illiterate | 26.9 |
| 1 to 5 yrs | 6.4 |
| 6 to 10 yrs | 35.9 |
| ≤ 12 yrs | 11.6 |
| Missing data | 19.2 |
| Place of last birth | |
| No child | 1.3 |
| Pregnant | 3.8 |
| Home | 30.8 |
| Govt | 15.4 |
| Private | 26.9 |
| Missing data | 21.8 |
| Number of children | |
| No child | 7.1 |
| Pregnant | 9.0 |
| 1 child | 14.1 |
| 2 children | 24.7 |
| 3 to 4 children | 38.5 |
| more than 4 children | 4.7 |
| missing data | 1.3 |
| SNP | Gene | SNP vs. IC50 | SNP vs. Expression | Expression vs. IC50 | |||||||||
| rsID | Chr | Position | Region | MAF | Probeset | Gene symbol | Chr | R value | P value | R value | P value | R value | P value |
| rs2290344 | 15 | 53407088 | Coding | 0.253 | 205452_at | PIGB | 15 | 0.339 | 1.75E-05 | −0.340 | 1.06E-08 | −0.212 | 5.31E-03 |
| rs2290344 | 15 | 53407088 | Coding | 0.253 | 242760_x_at | PIGB | 15 | 0.339 | 1.75E-05 | −0.301 | 4.81E-07 | −0.294 | 8.98E-05 |
| rs4774760 | 15 | 53376504 | 5′-upstream | 0.416 | 205452_at | PIGB | 15 | 0.326 | 3.63E-05 | −0.283 | 2.48E-06 | −0.212 | 5.31E-03 |
| rs4774760 | 15 | 53376504 | 5′-upstream | 0.416 | 242760_x_at | PIGB | 15 | 0.326 | 3.63E-05 | −0.240 | 6.85E-05 | −0.294 | 8.98E-05 |
| rs8024695 | 15 | 53426597 | Intron | 0.285 | 205452_at | PIGB | 15 | 0.321 | 5.00E-05 | −0.326 | 4.60E-08 | −0.212 | 5.31E-03 |
| rs8024695 | 15 | 53426597 | Intron | 0.285 | 242760_x_at | PIGB | 15 | 0.321 | 5.00E-05 | −0.282 | 2.56E-06 | −0.294 | 8.98E-05 |
| rs12050587 | 15 | 53414820 | Intron | 0.450 | 205452_at | PIGB | 15 | 0.305 | 1.23E-04 | −0.246 | 4.54E-05 | −0.212 | 5.31E-03 |
| rs28668016 | 15 | 53398725 | 5′-UTR | 0.365 | 205452_at | PIGB | 15 | 0.304 | 1.31E-04 | −0.346 | 5.97E-09 | −0.212 | 5.31E-03 |
| rs28668016 | 15 | 53398725 | 5′-UTR | 0.365 | 242760_x_at | PIGB | 15 | 0.304 | 1.31E-04 | −0.274 | 5.28E-06 | −0.294 | 8.98E-05 |
| rs11636687 | 15 | 53392444 | 5′-upstream | 0.421 | 205452_at | PIGB | 15 | 0.302 | 1.53E-04 | −0.287 | 2.22E-06 | −0.212 | 5.31E-03 |
| rs7174876 | 15 | 53406853 | Intron | 0.423 | 205452_at | PIGB | 15 | 0.284 | 4.06E-04 | −0.261 | 1.64E-05 | −0.212 | 5.31E-03 |
| Treatment | Target:Control Ratio | |||||
| 24 Hour | 48 Hour | |||||
| MT1-MMP ± SEM | MMP-11 ± SEM | 18S rRNA ± SEM | MT1-MMP ± SEM | MMP-11 ± SEM | 18S rRNA ± SEM | |
| Control | 1.00 ± 0.02 | 1.00 ± 0.02 | 1.00 ± 0.02 | 1.00 ± 0.08 | 1.00 ± 0.04 | 1.00 ± 0.05 |
| Collagen I | 1.00 ± 0.08 | 1.38 ± 0.18 | 0.90 ± 0.04 | 0.84 ± 0.06 | 1.20 ± 0.10 | 0.94 ± 0.04 |
| Collagen IV | 1.10 ± 0.06 | 1.65 ± 0.08 | 0.58 ± 0.06 | 1.00 ± 0.08 | 1.45 ± 0.12 | 0.60 ± 0.05 |
| Collagen V | 1.04 ± 0.10 | 1.65 ± 0.08 | 0.60 ± 0.06 | 0.90 ± .004 | 1.80 ± 0.10 | 0.56 ± 0.02 |
| Con-A | 1.20 ± 0.14 | 0.66 ± 0.12 | 0.78 ± 0.08 | 0.95 ± 0.08 | 0.85 ± 0.10 | 0.80 ± 0.04 |
| TGF-β | 0.90 ± 0.06 | 0.56 ± 0.06 | 0.60 ± 0.02 | 0.84 ± 0.08 | 0.75 ± 0.05 | 0.64 ± 0.08 |
| Fibronectin | 1.07 ± 0.12 | 0.71 ± 0.08 | 0.58 ± 0.02 | 0.95 ± 0.32 | 0.95 ± 0.07 | 0.64 ± 0.04 |
| IL-1β | 1.34 ± 0.02 | 0.65 ± 0.04 | 0.55 ± 0.02 | 1.45 ± 0.16 | 1.86 ± 0.20 | 0.55 ± 0.03 |
| IL-2 | 0.88 ± 0.20 | 0.66 ± 0.08 | 0.50 ± 0.02 | 0.96 ± 0.04 | 1.50 ± 0.10 | 0.56 ± 0.06 |
| IL-6 | 1.03 ± 0.04 | 0.72 ± 0.04 | 0.65 ± 0.02 | 0.75 ± 0.06 | 1.15 ± 0.12 | 0.60 ± 0.02 |
| Indicator | Mean 1 | Mean 2 | SD 1 | SD 2 | p | Error | |
| 1 | 15.38 mm | 15.59 mm | 7.52 | 7.51 | −0.94 | 0.34 | 0.97 |
| 2 | 60.95 mm | 60.71 mm | 7.69 | 7.75 | 1.45 | 0.15 | 0.76 |
| 3 | 15.03° | 15.17° | 4.23 | 4.07 | — | 0.19 | 0.48 |
| GD | HT | |||||
| Tx (n = 28) | Ct (n = 16) | P value | Tx (n = 39) | Ct (n = 17) | P value | |
| Age (year) | 36.2 ± 14.19 | 37.24 ± 10.26 | 0.156 | 41.40 ± 13.76 | 43.82 ± 12.48 | 0.168 |
| Gender (male/female) | 14/28 | 6/16 | 0.492 | 11/39 | 7/17 | 0.254 |
| BMI (kg/m2) | 21.11 ± 2.46 | 22.94 ± 3.16 | 0.061 | 23.13 ± 3.57 | 22.83 ± 4.01 | 0.071 |
| SBP (mmHg) | 117.87 ± 12.26 | 114.55 ± 11.43 | 0.112 | 120.25 ± 15.24 | 114.27 ± 17.64 | 0.057 |
| DBP (mmHg) | 76.47 ± 10.23 | 78.58 ± 9.15 | 0.135 | 86.08 ± 13.44 | 77.98 ± 10.21 | 0.106 |
| HR (/min) | 88.53 ± 5.82 | 86.89 ± 4.53 | 0.171 | 75.42 ± 9.32 | 78.36 ± 8.34 | 0.770 |
| FT3 (pmol/L) | 9.52 ± 7.53 | 8.96 ± 1.43 | 0.308 | 3.39 ± 1.01 | 3.42 ± 1.12 | 0.640 |
| FT4 (pmol/L) | 23.01 ± 17.26 | 25.93 ± 10.46 | 0.112 | 11.83 ± 3.64 | 10.47 ± 3.59 | 0.318 |
| TSH (μIU/L) | 0.07 ± 0.13 | 0.09 ± 0.17 | 0.451 | 10.94 ± 6.52 | 9.75 ± 7.21 | 0.522 |
| TPO-Ab (IU/mL) | 659.28 ± 585.89 | 672.39 ± 463.51 | 0.086 | 820.51 ± 372.45 | 829.39 ± 388.29 | 0.455 |
| TG-Ab (IU/mL) | — | — | — | 547.8 ± 331.45 | 593.28 ± 273.65 | 0.383 |
| TR-Ab (IU/mL) | 34.51 ± 17.97 | 31.16 ± 11.46 | 0.128 | — | — | — |
| CD3+ (%) | 66.98 ± 9.40 | 67.62 ± 8.36 | 0.196 | 69.56 ± 8.57 | 67.62 ± 8.36 | 0.146 |
| CD4+ (%) | 38.30 ± 5.37 | 36.96 ± 2.29 | 0.227 | 34.47 ± 6.74 | 33.96 ± 4.29 | 0.238 |
| CD8+ (%) | 21.93 ± 4.46 | 21.98 ± 6.56 | 0.348 | 29.07 ± 7.06 | 28.98 ± 6.54 | 0.074 |
| CD4+/CD8+ ratio | 1.86 ± 0.66 | 1.89 ± 0.79 | 0.105 | 1.23 ± 0.55 | 1.19 ± 0.68 | 0.089 |
| AS | FA | SS | AC | EF | WO | CLDQ | |
| PF | 0.597 | 0.762 | 0.691 | 0.744 | 0.636 | 0.438 | 0.756 |
| RP | 0.643 | 0.717 | 0.646 | 0.667 | 0.614 | 0.480 | 0.735 |
| BP | 0.662 | 0.763 | 0.702 | 0.686 | 0.660 | 0.475 | 0.776 |
| GH | 0.595 | 0.614 | 0.563 | 0.546 | 0.586 | 0.538 | 0.676 |
| VT | 0.648 | 0.846 | 0.727 | 0.608 | 0.798 | 0.560 | 0.825 |
| SF | 0.667 | 0.799 | 0.759 | 0.697 | 0.726 | 0.536 | 0.825 |
| RE | 0.572 | 0.702 | 0.589 | 0.568 | 0.666 | 0.496 | 0.708 |
| MH | 0.598 | 0.778 | 0.655 | 0.524 | 0.824 | 0.506 | 0.771 |
| CNVs | Copy numbers | Related genes | Related pathways |
| rs2002594; rs1986617 | 1 | FAM162A | Mitochondrial apoptotic cascades |
| rs10517547; rs10517548; rs2122642; rs2345041; rs1823535; rs1823536; rs1470724 | 1 | LPHN3 | G-protein-coupled-receptor proteolysis |
| rs764223 | 1 | PGAM1 | Glycolysis/gluconeogenesis; metabolism of carbohydrates |
| rs137964; rs10483201 | 1 | GRAP2 | T cell receptor signaling pathway |
| rs10491333 | 4 | HLA-DQB1 | Antigen processing and presentation |
| rs2895201 | 4 | SPTLC1 | Sphingolipid metabolism |
| rs1988981; rs1321555; rs1358815; rs1964875; | 4 | PRIM2 | Purine and pyrimidine metabolism; telomere maintenance |
| rs3797819; rs10515399; rs1896582; rs1366081; rs9326759 | 4 | FER | Adherens junction |
| rs342597; rs10507638; rs10507639 | 3 | DIAPH3 | Regulation of actin cytoskeleton |
| rs10520675; rs10520671; rs7167737; rs1948066; rs10520673; rs965313 | 3 | NTRK3 | MAPK pathway |
| rs6816712; rs2911940; rs10517654; rs10517655; rs7662187; rs10517658 | 3 | PDGFC | Cytokine-cytokine receptor interaction; Focal adhesion; Gap junction |
| rs855858; rs855860; rs10489736 | 3 | ROR1 | transmembrane receptor protein tyrosine kinase signaling pathway |
| rs2912 | 3 | GAB2 | Fc epsilon RI signaling pathway |
| rs10491050; rs7092874; rs7904118 | 3 | SORCS1 | neuropeptide signaling pathway |
| rs10485060; rs9322451; rs1852629 | 3 | OPRM1 | Neuroactive ligand-receptor interaction |
| rs1060447; rs4919231; rs1932796; rs716838; rs2169462; rs10509722 | 3 | HPSE2 | Glycosaminoglycan degradation |
| Gene symbol | Description | Position (Mb) | MiRNA | Packages |
| RNF111 | Ring Finger Protein 111 | 6.32–6.36 | miR-142-3p | Targetscan |
| TCF12 | transcription factor 12 | 6.90–7.00 | miR-142-5p | MIRDB, TargetscanPicTar |
| ARPP19 | cAMP–regulated phosphoprotein, 19 kDa | 8.23–8.24 | miR-142-5p | Targentscan |
| MYO5A | myosin VA (heavy chain 12, myoxin) | 8.24–8.33 | miR-142-3p | Targentscan |
| MAPK6 | Mitogen–Activated Protein Kinase 6 | 8.42– 8.45 | miR-142-5p | Targentscan |
| Compounds | Bradykinin a | Renin substrate tetra-decapeptide a | ||
| S/N | Sig. Int. | S/N | Sig. Int. | |
| 1 | 711 | 56530 | 551 | 47162 |
| 2 | 540 | 23276 | 423 | 23276 |
| 3 | 547 | 61687 | 228 | 23778 |
| 4 | 447 | 64184 | 205 | 50958 |
| 5 | 965 | 179163 | 579 | 39417 |
| 6 | 612 | 73058 | 450 | 40258 |
| 7 | 403 | 98986 | 586 | 132521 |
| 8 | 710 | 105850 | 689 | 68272 |
| 9 | 148 | 254785 | 435 | 32688 |
| 10 | 250 | 38696 | 411 | 59285 |
| 11 | 568 | 129858 | 361 | 80878 |
| 12 | 524 | 157277 | 360 | 144048 |
| 13 | 548 | 58187 | 620 | 105141 |
| 14 | 520 | 131703 | 668 | 127967 |
| 15 | 612 | 17858 | 402 | 55811 |
| 16 | 369 | 24724 | 463 | 65700 |
| 17 | 250 | 57522 | 432 | 81912 |
| 18 | 332 | 101983 | 299 | 61957 |
| 19 | 294 | 55402 | 200 | 13615 |
| 20 | 286 | 13022 | 514 | 14110 |
| 21 | 244 | 53297 | 446 | 36294 |
| 22 | 427 | 88683 | 642 | 101135 |
| 23 | 455 | 85541 | 650 | 53205 |
| 24 | 328 | 11451 | 519 | 81163 |
| 25 | 850 | 16992 | 574 | 85517 |
| 26 | 402 | 14593 | 436 | 79334 |
| 27 | 370 | 26798 | 444 | 66542 |
| 28 | 202 | 10398 | 221 | 13736 |
| 29 | 727 | 115238 | 309 | 124664 |
| 30 | 708 | 10452 | 125 | 16030 |
| 31 | 806 | 89386 | 66 | 18759 |
| HCCA | 832 | 86824 | 792 | 147702 |
| Variable | Number | Percentage |
| Intravenous drug users | 20 | 5.8 |
| Surgery | 144 | 41.6 |
| Blood transfusion | 40 | 11.6 |
| Transplantation | 1 | 0.3 |
| History of hepatitis in the family | 186 | 53.8 |
| Uterine curettage | 12 | 11.9a |
| Dialysis | 13 | 3.8 |
| Dental manipulation | 292 | 84.4 |
| Tattoo | 54 | 15.6 |
| Ear Piercing | 91 | 26.3 |
| Circumcision | 243 | 99.2b |
| High-risk sex | 6 | 1.7 |
| Phlebotomy | 60 | 17.3 |
| Variables | Univariate analysis | Model 1 | Model 2 | |||||
| HR (95%CI) | p value | HR (95%CI) | p value | HR (95%CI) | p value | |||
| Age (years) | 1.1 (1.0-1.1) | 0.011 | 1.0 (1.0-1.1) | 0.191 | 1.0 (1.0-1.1) | 0.195 | ||
| Sex (1 = male, 2 = female) | 0.7 (0.4-1.1) | 0.130 | 0.5 (0.3-1.1) | 0.089 | 0.7 (0.3-1.3) | 0.262 | ||
| TC (mmol/L) | 1.3 (1.0-1.7) | 0.087 | 1.2 (0.9-1.7) | 0.161 | 1.2 (0.9-1.6) | 0.213 | ||
| Elevated WC | 3.1 (1.9-5.3) | < 0.001 | ||||||
| Elevated TG | 2.3 (1.3-4.0) | 0.004 | ||||||
| Elevated BP | 1.9 (1.1-3.2) | 0.017 | 1.5 (0.8-2.5) | 0.172 | ||||
| Reduced HDL-C | 1.4 (0.9-2.4) | 0.142 | 1.8 (1.1-3.0) | 0.032 | ||||
| Smoking | 1.4 (0.9-2.3) | 0.169 | 1.5 (0.8-2.8) | 0.226 | 1.5 (0.8-2.7) | 0.251 | ||
| HTGW | 3.8 (2.2-6.5) | < 0.001 | 3.9 (2.2-7.0) | < 0.001 | ||||
| MetS | 3.4 (2.0-5.9) | < 0.001 | 3.7 (2.1-6.6) | < 0.001 |
| Perprotocol | Intention to treat | |||
| Odds ratio (95% CI) | P value | Odds ratio (95% CI) | P value | |
| Age | ||||
| <60 years old | 1.0 (referent) | 1.0 (referent) | ||
| ≥60 years old | 1.33 (0.61–2.92) | 0.478 | 1.16 (0.55–2.47) | 0.696 |
| Gender | ||||
| Male | 1.0 (referent) | 1.0 (referent) | ||
| Female | 1.14 (0.53–2.46) | 0.737 | 1.18 (0.57–2.44) | 0.648 |
| Resident area | ||||
| Urban | 1.0 (referent) | 1.0 (referent) | ||
| Rural | 1.49 (0.65–3.42) | 0.342 | 1.12 (0.53–2.37) | 0.775 |
| Endoscopic finding | ||||
| With peptic ulcer | 1.0 (referent) | 1.0 (referent) | ||
| Without peptic ulcer | 1.05 (0.48–2.26) | 0.909 | 1.05 (0.51–2.16) | 0.900 |
| Treatment | ||||
| CAR | 1.0 (referent) | 1.0 (referent) | ||
| LAcR | 2.67 (1.22–5.84) | 0.014* | 2.57 (1.24–5.33) | 0.011* |
| σ (MPa) | STD | λ | STD | |
| SV- Longitudinal | 5.38 | 0.6 | 1.32 | 0.04 |
| SV- Circumferential | 2.61 | 0.67 | 1.55 | 0.06 |
| UV- Longitudinal | 1.65 | 0.11 | 1.33 | 0.04 |
| UV- Circumferential | 0.97 | 0.19 | 1.90 | 0.16 |
| Platform | System | Applications | |||||||||||
| IMU | GPS | LIDAR | Camera | DG payload weights | Cost | Large area | Small area | Mobility | Weather limitation | DG accuracy (3DRMS) | Cyber city | Rapid Disaster Relief | |
| Fixed wing aircraft | Tactical grade | Geodetic grade | Yes | Digital/film | > 50 kg | High | Yes | Yes | Low | High | < 20 cm | Yes | Low |
| Helicopter | Tactical grade | Geodetic grade | Yes | Digital | > 50 kg | High | No | Yes | Low | High | < 20 cm | Yes | Low |
| UAV | MEMS | L1 phase | Yes | Digital | < 25 kg | Low | No | Yes | High | Low | < 50 cm | Yes | High |
| UAV Helicopter | MEMS | L1 phase | Yes | Digital | < 10 kg | Low | No | Yes | High | Low | < 50 cm | Yes | High |
| N voxels | Gray Matter | White Matter | CSF | MD | axial | FA | FW | radial | |
| CSF | 117049 | 0.1321 ± 0.2485 | 0.0044 ± 0.0423 | 0.7580 ± 0.2926 | 0.0018 ± 0.0009 | 0.0022 ± 0.0011 | 0.2046 ± 0.1257 | 0.4511 ± 0.2221 | 0.0015 ± 0.0008 |
| Gray matter | 256549 | 0.7724 ± 0.2988 | 0.1024 ± 0.2260 | 0.1206 ± 0.2451 | 0.0009 ± 0.0004 | 0.0011 ± 0.0004 | 0.2208 ± 0.1053 | 0.2302 ± 0.1050 | 0.0008 ± 0.0003 |
| White matter | 162773 | 0.1119 ± 0.2301 | 0.8808 ± 0.2417 | 0.0055 ± 0.0483 | 0.0007 ± 0.0002 | 0.0010 ± 0.0003 | 0.4226 ± 0.1441 | 0.1397 ± 0.0519 | 0.0005 ± 0.0002 |
| Left Hippocampus | 1359 | 0.8438 ± 0.2672 | 0.0368 ± 0.1349 | 0.1176 ± 0.2425 | 0.0011 ± 0.0004 | 0.0013 ± 0.0005 | 0.2265 ± 0.0919 | 0.2734 ± 0.1055 | 0.0009 ± 0.0003 |
| Right Hippocampus | 1457 | 0.8541 ± 0.2610 | 0.0287 ± 0.1135 | 0.1153 ± 0.2435 | 0.0011 ± 0.0004 | 0.0013 ± 0.0005 | 0.2248 ± 0.0895 | 0.2734 ± 0.1079 | 0.0009 ± 0.0004 |
| Left MOG middle occipital gyrus | 2659 | 0.6734 ± 0.3550 | 0.1602 ± 0.2997 | 0.1601 ± 0.2873 | 0.0010 ± 0.0004 | 0.0012 ± 0.0005 | 0.2101 ± 0.1020 | 0.2562 ± 0.1217 | 0.0009 ± 0.0004 |
| Right MOG middle occipital gyrus | 2263 | 0.6738 ± 0.3535 | 0.1454 ± 0.2868 | 0.1650 ± 0.2829 | 0.0010 ± 0.0004 | 0.0012 ± 0.0005 | 0.2145 ± 0.0964 | 0.2514 ± 0.1085 | 0.0009 ± 0.0003 |
| Left PCgG posterior cingulate gyrus | 1877 | 0.6969 ± 0.3493 | 0.0877 ± 0.2133 | 0.2120 ± 0.3323 | 0.0009 ± 0.0004 | 0.0011 ± 0.0004 | 0.2052 ± 0.0952 | 0.2551 ± 0.1095 | 0.0009 ± 0.0003 |
| Right PCgG posterior cingulate gyrus | 1648 | 0.7383 ± 0.3210 | 0.1020 ± 0.2264 | 0.1571 ± 0.2851 | 0.0009 ± 0.0003 | 0.0011 ± 0.0004 | 0.2109 ± 0.0925 | 0.2411 ± 0.1024 | 0.0008 ± 0.0003 |
| Left Cerebellum White Matter | 4948 | 0.1392 ± 0.2664 | 0.8237 ± 0.3130 | 0.0351 ± 0.1613 | 0.0007 ± 0.0004 | 0.0011 ± 0.0005 | 0.4411 ± 0.1507 | 0.1454 ± 0.1007 | 0.0006 ± 0.0003 |
| Right Cerebellum White Matter | 4847 | 0.1114 ± 0.2261 | 0.8635 ± 0.2663 | 0.0232 ± 0.1201 | 0.0007 ± 0.0003 | 0.0011 ± 0.0004 | 0.4468 ± 0.1464 | 0.1409 ± 0.0853 | 0.0005 ± 0.0003 |
| Left SPL superior parietal lobule | 5225 | 0.4955 ± 0.3931 | 0.1335 ± 0.2805 | 0.3621 ± 0.4095 | 0.0012 ± 0.0006 | 0.0014 ± 0.0006 | 0.1998 ± 0.1109 | 0.3220 ± 0.1774 | 0.0011 ± 0.0006 |
| Right SPL superior parietal lobule | 5249 | 0.4720 ± 0.3950 | 0.1138 ± 0.2588 | 0.4024 ± 0.4178 | 0.0012 ± 0.0006 | 0.0014 ± 0.0006 | 0.1946 ± 0.1034 | 0.3375 ± 0.1779 | 0.0011 ± 0.0006 |
| Left Pallidum | 559 | 0.0347 ± 0.0905 | 0.9609 ± 0.0963 | 0.0012 ± 0.0059 | 0.0007 ± 0.0001 | 0.0010 ± 0.0001 | 0.4009 ± 0.1427 | 0.1375 ± 0.0397 | 0.0005 ± 0.0001 |
| Right Pallidum | 564 | 0.0253 ± 0.0744 | 0.9700 ± 0.0816 | 0.0014 ± 0.0064 | 0.0007 ± 0.0001 | 0.0010 ± 0.0001 | 0.4259 ± 0.1499 | 0.1334 ± 0.0401 | 0.0005 ± 0.0001 |
| Left PP planum polare | 893 | 0.6095 ± 0.3765 | 0.0095 ± 0.0515 | 0.3775 ± 0.3801 | 0.0012 ± 0.0005 | 0.0014 ± 0.0006 | 0.1715 ± 0.0639 | 0.3357 ± 0.1390 | 0.0011 ± 0.0005 |
| Right PP planum polare | 783 | 0.5859 ± 0.3846 | 0.0048 ± 0.0288 | 0.4054 ± 0.3861 | 0.0013 ± 0.0006 | 0.0015 ± 0.0007 | 0.1688 ± 0.0584 | 0.3628 ± 0.1516 | 0.0012 ± 0.0005 |
| Factors | ANC | Delivery | ||||
| N = 315 | N = 315 | |||||
| AOR (95% CI) | P-value* | P-value** | AOR (95% CI) | P-value* | P-value** | |
| Age group of women: ref. = Teens | <0.001 | 0.002 | ||||
| Young adults | 2.12 (1.18,3.79) | 0.01 | 1.54 (0.81,2.93) | 0.2 | ||
| Adults | 3.14 (1.76,5.63) | <0.001 | 2.9 (1.56,5.38) | <0.001 | ||
| Ethnicity of women: ref. = Indigenous Non-Indigenous | 1.77 (1.11,2.83) | 0.02 | 0.02 | 1.71 (1.04,2.8) | 0.03 | 0.03 |
| Referral status: ref. = Referred Not referred | 3.77 (1.27,11.15) | 0.02 | 0.006 |
| Recipient | Donor | |
| Male (%) | 37 (74%) | 36 (72%) |
| Female (%) | 13 (26%) | 14 (28%) |
| Age (yrs) | 51.3 ± 11.1 (16 - 67) | 53.2 ± 17.2 (19 - 86) |
| BMI (kg/m2) | 25.7 ± 4.73 (16.6 - 42.9) | 24.3 ± 3.3 (16.0- 31.0) |
| MELD | 21 ± 10.4 (6 - 40) | |
| RRT before TPL (%) | 8 (16%) | |
| HRS before TPL (%) | 17 (34%) | |
| SAPS II | 30 ± 19 (0 - 91) | |
| Creatinine (μmol/l) | 121 ± 117 (40 - 814) | |
| Hematocrit (%) | 31.4 ± 7.6 (18.8 - 49.6) | |
| Platelets (103/μl) | 106 ± 65 (33 - 324) | |
| INR | 1.5 ± 0.6 (0.9 - 4.3) | |
| Bilirubin (μmol/l) | 148 ± 198 (5 - 875) | |
| Etiology of liver disease | ||
| HCV (%) | 17 (34%) | |
| HBV (%) | 3 (6%) | |
| HCC (%) | 10 (20%) | |
| Alcoholic liver cirrhosis (%) | 6 (12%) | |
| Cholangiocarcinoma (%) | 2 (4%) | |
| Others1 (%) | 12 (24%) | |
| Cadaveric Donor (%) | 44 (88%) | |
| Living Donor (%) | 6 (12%) | |
| Extended donor graft criteria (%) | 16 (32%) |
| No. of points | ||
| Risk factor | SITS SICH risk score | Extended risk score |
| Aspirin + clopidogrel | 3 | 3 |
| Aspirin monotherapy | 2 | 2 |
| NIHSS ≥13 | 2 | 2 |
| NIHSS 7-12 | 1 | 1 |
| Blood glucose ≥180 mg/dL | 2 | 2 |
| Age ≥72 y | 1 | 1 |
| Systolic blood pressure ≥146 mm Hg | 1 | 1 |
| Weight ≥95 kg | 1 | 1 |
| Onset-to-treatment time ≥180 min | 1 | 1 |
| History of hypertension | 1 | 1 |
| Total anterior circulation infarct | N/A | 3 |
| Maximal total points | 12 | 15* |
| Variable | Level of knowledge | COR (95% CI) | AOR (95% CI) | |
| Adequate | Inadequate | |||
| Age | ||||
| 15–24 | 53 (57%) | 40 (43%) | 4.711 (2.022, 10.976) | 1.253 (0.364, 4.319) |
| 25–35 | 115 (64.2%) | 64 (35.8%) | 6.389 (2.870, 14.221) | 2.740 (1.000, 7.502) |
| 36–45 | 31 (54.4%) | 26 (45.6%) | 4.239 (1.715, 10.476) | 1.950 (0.678, 5.606) |
| >45 | 9 (22%) | 32 (78%) | 1.00 | 1.00 |
| Marital status | ||||
| Married | 190 (59.6%) | 129 (40.4%) | 1.00 | 1.00 |
| Single | 6 (31.6%) | 13 (68.4%) | 0.313 (0.116, 0.846) | 0.548 (0.104, 2.893) |
| Widowed | 2 (20%) | 8 (80%) | 0.170 (0.035, 0.812) | 0.498 (0.054, 4.580) |
| Divorced | 10 (45.5%) | 12 (54.5%) | 0.566 (0.237, 1.348) | 0.685 (0.169, 2.768) |
| Educational status | ||||
| Illiterate | 87 (40.1%) | 130 (59.9%) | 1.00 | 1.00 |
| Primary (1–8) | 32 (57.1%) | 24 (42.9%) | 1.992 (1.099, 3.612) | 5.384 (2.008, 14.435)∗ |
| Secondary and above | 89 (91.6%) | 8 (8.4%) | 16.624 (7.676, 36) | 11.769 (3.527, 39.275)∗ |
| Occupational status | ||||
| Housewife | 123 (50.8%) | 119 (49.2%) | 1.00 | 1.00 |
| Government emp∗ | 61 (98.4%) | 1 (1.6%) | 59.016 (8.051, 432.587) | 5.037 (0.516, 49.207) |
| Private employee | 5 (41.7%) | 7 (58.3%) | 0.691 (0.213, 2.238) | 0.245 (0.036, 1.680) |
| Daily laborer | 10 (28.6%) | 25 (71.4%) | 0.387 (0.178, 0.840) | 0.208 (0.054, 0.810)∗ |
| Merchant | 9 (64.3%) | 5 (35.7%) | 1.741 (0.567, 5.347) | 0.441 (0.113, 1.728) |
| Farmer | 2 (40%) | 3 (60%) | 0.644 (0.243, 3.952) | 0.379 (0.186, 1.962) |
| Number of children | ||||
| 1-2 | 149 (63.1%) | 87 (36.9%) | 1.00 | 1.00 |
| 3-4 | 55 (46.6%) | 63 (53.4%) | 0.510 (0.326, 0.798) | 1.141 (0.560, 2.322) |
| >4 | 4 (25%) | 12 (75%) | 0.195 (0.061, 0.622) | 0.609 (0.138, 2.688) |
| Information about diarrhea | ||||
| No information | 6 (12.8%) | 41 (87.2%) | 0.088 (0.036, 0.213) | 0.139 (0.054, 0.354)∗ |
| Have information | 202 (62.5%) | 121 (37.5%) | 1.00 | 1.00 |
| IL-1 | IL-6 | TNF-α | IL-10 | TGF-β1 | |
| pg/mg | |||||
| NC | 10.3 ± 1.2 * | 12.5 ± 2.1 * | 20.7 ± 2.3 * | 265.8 ± 17.9 | 16.4 ± 1.8 |
| SS24 | 92.6 ± 4.5 | 1275.6 ± 18.3 | 80.4 ± 3.4 | 235.8 ± 4.1 | 12.8 ± 1.6 |
| SA24 | 44.3 ± 2.6 # | 662.3 ± 13.5 # | 42.9 ± 1.9 # | 367.8 ± 9.2 # | 55.3 ± 2.6 # |
| SS48 | 83.2 ± 5.4 | 834.3 ± 17.3 | 67.8 ± 3.6 | 214.2 ± 5.6 | 16.6 ± 5.6 |
| SA48 | 32.3 ± 2.3 # | 385.4 ± 12.8 # | 38.8 ± 3.2 # | 229.4 ± 7.7 | 22.4 ± 3.4 |
| Treatment | Flume number | Field name |
| Sustainable intensification | 6 | Golden Rove |
| Increased use of legumes | 8 | Higher Wyke Moor and Middle Wyke Moor (reseeding in 2013) |
| 11 | Dairy East | |
| Planned reseeding | 10 | Lower Wheaty |
| 15 | Longlands East (reseeding in 2013) |
| Characteristics | Count (%) |
| Sociodemographic | |
| Gender | |
| Male | 98 (65.3) |
| Female | 52 (34.7) |
| Age (years) | |
| 20–30 | 80 (53.3) |
| 31–40 | 48 (32.0) |
| 41–50 | 22 (14.7) |
| Education level | |
| Vocational school | 58 (38.7) |
| Diploma or equivalent | 62 (41.3) |
| Bachelor degree or higher | 30 (20.0) |
| Monthly income (Baht) | |
| <9000 | 96 (64.0) |
| ≥9000 | 54 (36.0) |
| Behavioral | |
| Smoke cigarettes | |
| No | 70 (46.7) |
| Yes | 80 (53.3) |
| Drink alcohol | |
| No | 86 (57.3) |
| Yes | 64 (42.7) |
| Variable | PIK3CA mutations (n = 113) | PIK3CA amplification (n = 131) | ||||
| Yes | No | P | Yes | No | P | |
| No.of patients | 8 | 105 | 88 | 43 | ||
| Gender | ||||||
| Male | 5 | 82 | 0.57 | 68 | 34 | 0.82 |
| Female | 3 | 23 | 20 | 9 | ||
| Age, years | ||||||
| Mean | 55.5 | 59.1 | 0.47 | 58.6 | 61.4 | 0.25 |
| SD | 19.8 | 12.7 | 13.3 | 12.1 | ||
| Tumor localization | ||||||
| gastric cardia | 0 | 26 | 0.98 | 23 | 12 | 0.66 |
| gastric body | 5 | 24 | 22 | 12 | ||
| gastric antrum | 3 | 55 | 43 | 19 | ||
| Tumor size (cm3) | ||||||
| ≤ 3 | 3 | 35 | 0.68 | 29 | 14 | 0.88 |
| 3-5 | 3 | 35 | 32 | 15 | ||
| > 5 | 2 | 35 | 27 | 14 | ||
| Differentiation | ||||||
| well/moderate | 1 | 44 | 0.21 | 33 | 23 | 0.08 |
| poor/undifferentiation | 7 | 61 | 55 | 20 | ||
| Tumor invasion | ||||||
| T1 | 2 | 14 | 0.96 | 9 | 5 | 0.59 |
| T2 | 0 | 17 | 15 | 8 | ||
| T3 | 6 | 72 | 62 | 30 | ||
| T4 | 0 | 2 | 2 | 0 | ||
| TNM stage | ||||||
| I | 2 | 27 | 0.91 | 20 | 10 | 0.86 |
| II | 1 | 14 | 15 | 6 | ||
| III | 5 | 58 | 49 | 25 | ||
| IV | 0 | 6 | 4 | 2 | ||
| Residual tumor | ||||||
| Yes | 1 | 12 | 1.00 | 12 | 2 | 0.10 |
| No | 7 | 93 | 76 | 41 | ||
| Lymph node metastasis (LNM) | ||||||
| Yes | 5 | 65 | 1.00 | 57 | 24 | 0.32 |
| No | 3 | 40 | 31 | 19 | ||
| No. of LNM | ||||||
| N0 | 3 | 40 | 0.63 | 31 | 19 | 0.20 |
| N1 (1-6) | 4 | 36 | 32 | 16 | ||
| N2 (7-15) | 1 | 23 | 20 | 7 | ||
| N3 (≥ 16) | 0 | 6 | 5 | 1 | ||
| Survival status | ||||||
| Dead | 3 | 53 | 0.73 | 51 | 15 | 0.01* |
| Alive | 5 | 52 | 37 | 28 |
| Parametric | Nonparametric | ||
| Misacylation | |||
| COVE | 68* | 55 | |
| resCOVE | 64 | 64 | |
| Spacer | 55 | 64 | |
| Usage | 38 | 48 | |
| COVERes COVE | |||
| Spacer | 46 | 46 | |
| 64 | 73* | ||
| Usage | 67 | 62 | |
| 57 | 52 | ||
| Spacer | Usage | 55 | 55 |
| Processing | Misacylation | 82*/46 | |
| COVE | 82*/82* | ||
| res COVE | 55/55 | ||
| Mis-COVE | 82*/46 | 64/55 | |
| Mis-res COVE | 73*/55 | 64/55 | |
| Mis-Usage | 55/20 | 64/30 | |
| COVE-Usage | 55/90* | 55/80* | |
| Res COVE-Usage | 46/80* | 46/70 |
| Age/sex | Comorbidity | Site | Culture source | Therapy | Outcome |
| 75/F | Syringomyelia | L leg | Tissue | Antibiotics, debridement | Survived |
| 80/F | None | R leg | Tissue | Antibiotics, debridement | Survived (skin graft) |
| 49/F | None | L ankle | Tissue | Antibiotics, debridement | Survived |
| 75/M | None | R leg | Tissue | Antibiotics, debridement | Survived |
| 71/M | None | L foot | Skin/bulla | Antibiotics, debridement | Survived (skin graft) |
| 59/M | Not stated | R leg | Skin/blister | Antibiotics, debridement | Died |
| 64/F | Diabetes mellitus | Both legs | Tissue | Antibiotics | Died |
| 65/F | Rheumatoid arthritis | R arm | Blood/tissue | Antibiotics, amputation | Died |
| 52/M | Diabetes mellitus | R leg | Tissue | Antibiotics, debridement | Survived |
| 52/M | Diabetes mellitus | R leg | Tissue | Antibiotics, debridement | Survived |
| 59/M | Hairy-cell leukemia | L leg | Blood/tissue | Antibiotics, debridement | Survived |
| 58/M | Cirrhosis | L leg | Tissue | Antibiotics, debridement | Died |
| 49/F | Rheumatoid arthritis | R leg | Blood/skin | Antibiotics | Died |
| 48/M | None | R leg | Tissue | Antibiotics, debridement | Survived |
| 77/F | Rheumatoid arthritis | R leg | Tissue/blood | Antibiotics | Died |
| 2/M | Vascular/lymphatic malformation | Perineum | Tissue/stool | Antibiotics, debridement | Survived |
| Outcome | All births | |||
| n | Rate | OR (95% CI) | AORa (95% CI) | |
| Umbilical artery pH < 7.10 | ||||
| Occiput posterior | 56 | 5.5 | 1.48 (1.12–1.96) | 1.28 (0.93–1.74) |
| Occiput anterior | 733 | 3.8 | reference | reference |
| Metabolic acidaemia | ||||
| Occiput posterior | 2 | 0.2 | 1.15 (0.28–4.80) | 0.64 (0.08–5.04) |
| Occiput anterior | 33 | 0.2 | reference | reference |
| Apgar score < 7 at 5 min | ||||
| Occiput posterior | 20 | 1.5 | 2.18 (1.37–3.47) | 1.84 (1.11–3.05) |
| Occiput anterior | 188 | 0.7 | reference | reference |
| Neonatal care | ||||
| Occiput posterior | 38 | 2.9 | 1.87 (1.33–2.62) | 1.68 (1.17–2.42) |
| Occiput anterior | 420 | 1.6 | reference | reference |
| Composite morbidityb | ||||
| Occiput posterior | 47 | 3.6 | 1.87 (1.38–2.54) | 1.66 (1.19–2.31) |
| Occiput anterior | 520 | 2.0 | reference | reference |
| Ages (years) | Mild/NVI | Low vision | Blindness | Total VI (%) | |||
| 0 | 1 | 2 | 3 | 4 | 5 | ||
| 6–18 | 20.8 | 1.8 | 0.3 | 0.8) | 1.5 | 0.0 | 4.3 |
| 19–35 | 18.8 | 2.5 | 0.0 | 0.8) | 1.3 | 1.8 | 6.3 |
| 36–59 | 15.5 | 5.0 | 0.0 | 1.0) | 2.5 | 1.0 | 9.5 |
| ≥ 60 | 9.3 | 7.8 | 0.3 | 1.8) | 4.3 | 1.8 | 15.8 |
| Total | 64.3 | 17.0 | 0.5 | 4.3 | 9.5 | 4.5 | 35.8 |
| Material | Scaffold Preparation | Shape and Structure of the Scaffold | Mechanical Properties of the Scaffold | Ref. |
| Collagen | Freeze drying | Sponges L = 11, 23 or 51 mm94% porosity, pore size = 62 μm | For L = 23 mm spec. EM = 0.02 MPaLinear Stiffness = 0.05 N/mmMaximum Stress = 0.005 MPa | [38,39] |
| Collagen/Chondroitin Sulfate | Sponge pore size = 53 μm | Linear Stiffness = 0.025 N/mm | [87] | |
| Collagen/Chondroitin Sulfate | Isotropic sponge pore size = 87 μmAnisotropic pore sizes = 55, 152, 243 μm | ND | [51,55] | |
| Collagen | Extrusion | EDC Crosslinked fiber diameter = 215 μmEDC/EDGE Crosslink diameter = 137 μm | Fiber diameter 215 μm → EM = 19.3 MPaFiber diameter 137 μm → EM = 46.2 MPa | [52,53] |
| Collagen | ELAC | Collagen thread diameter = 50–100 μm | ND | [33] |
| Collagen | Woven collagen scaffold with 81% of porosity | Stiffness = 23.8 N/mm | [34] | |
| PLGA | Electrospinning | Random nanofibers = 568 nmAligned fibers = 320, 680 and 1800 nm | Random nanofibers → EM = 107 MPaAligned fibers → EM = 341–510 MPa | [105,106] |
| PLLA | Aligned nanofiber diameter = 430 nmRandom nanofiber diameter = 450 nm | Aligned nanofibers → Stiffness = 3.48 N/mm; EM = 22.76 MPaRandom nanofibers → Stiffness = 0.07 N/mm; EM = 0.63 MPa | [30] | |
| PLDLLA | Crimped fiber diameter = 880 nmAmplitude = 5.2 μmWavelength = 46 μm | Crimped fiber Modulus = 3 MPa | [54] | |
| PEEUR | Aligned or random fiberdiameters <1 μm, 1–2 μm or >2 μm | EM = 4.2–9.2 MPa | [45,46] | |
| PCL | Yarned made of twisted aligned fibers (200 μm diameter) | UTS = 17 MPaEM = 30 MPa | [35] | |
| P(LLA-CL)/Collagen | Fiber diameter = 643 nmFinal yarn thickness = 150 μmPore size = 28.5 μm | Yarns EM = 2 MPaUltimate deformation = 250% | [107] | |
| PLGA | Knitting | Scaffold with 3 yarns. 20 filaments/yarn25 μm diameter of filament + electrospun nanofibers | Initial failure load = 56.3 NInitial Elastic Stiffness = 5.80 N/mmInitial toe region Stiffness = 0.34 N/mm | [36] |
| Silk | Combined knitted silk fibers and silk sponge pores size from 20 to 100 μm | Maximum Tensile Load = 252 NTensile Stiffness = 40 N/mm | [37] | |
| Silk/Collagen | Combined knitted silk scaffold and freeze dryed collagen sponge | Failure force = 21.65 N | [97] |
| Demographic characteristics | Sampled frequency, n (%) | Weight misperception frequency, n (%) |
| Sexa | ||
| Female | 2003 (44.5) | 426 (21.4) |
| Male | 2380 (55.5) | 900 (39.1) |
| Race/ethnicityb | ||
| American Indian/Alaskan Native | 50 (0.6) | 17 (30.7) |
| Asian | 111 (2.2) | 33 (20.8) |
| Hispanic/Latino | 1672 (25.3) | 457 (28.3) |
| Multiple Race/Ethnicities Non-Hispanic | 223 (5.1) | 67 (23.3) |
| Native Hawaiian/other Pacific Islander | 29 (0.6) | 8 (37.2) |
| Non-Hispanic black or African American | 479 (14.5) | 202 (41.0) |
| Non-Hispanic white | 1819 (51.8) | 542 (31.0) |
| Grade in schoolc | ||
| 9th | 1120 (26.4) | 376 (35.6) |
| 10th | 1129 (26.6) | 357 (30.7) |
| 11th | 1152 (24.3) | 330 (30.2) |
| 12th | 982 (22.7) | 263 (27.7) |
| Factors | Univariate analysis | Multivariate analysis | ||
| Hazard ratio (95% CI) | P value | Hazard ratio (95% CI) | P value | |
| DDA1 | 2.747 (1.405–5.372) | 0.003 | 0.005 | |
| Gender | 0.578 (0.267–1.248) | 0.163 | 0.345 | |
| Age | 1.586 (0.851–2.958) | 0.147 | 0.309 | |
| Type | 0.847 (0.462–1.552) | 0.59 | 0.844 | |
| Tumour size | 2.185 (1.189–4.015) | 0.012 | 0.012 | |
| Positive LN number | 2.094 (1.112–3.944) | 0.022 | <0.001 | |
| AJCC stage | 4.42 (2.257–8.656) | <0.001 | 4.281 (2.186–8.384) | <0.001 |
| Histological grade | 1.142 (0.574–2.272) | 0.706 | 0.996 |
| Men (n = 58) | Women (n = 65) | ANOVA | F | p | |
| Bench press | |||||
| Pre | 68.7 ± 16.0§ | 29.2 ± 6.3 | Group | 378.14 | < 0.001 |
| Post | 79.8 ± 15.4§* | 36.9 ± 6.9* | Time | 820.58 | < 0.001 |
| Δ% | +16.2 | +26.4 | Interaction | 27.42 | < 0.001 |
| Arm curl | |||||
| Pre | 40.0 ± 7.0§ | 21.7 ± 3.8 | Group | 358.12 | < 0.001 |
| Post | 45.5 ± 6.8§* | 26.6 ± 4.1* | Time | 547.01 | < 0.001 |
| Δ% | +13.8 | +22.6 | Interaction | 2.29 | 0.132 |
| Task | Group description | Activity of group 1 higher that group 2 | Activity of group 1 low that group 2 | Reference |
| Tactile stimulation | PD patients (1) vs. healthy control volunteers | R. primary sensory, R. motor cortex, R. supplementary motor area, B. caudate, B. precuneus, B. occipital visual cortex, L. and M. temporal gyrus | (23) | |
| Time perception task | PD patients (1) vs. healthy control volunteers and medical patients (2) | Precuneus (after long stimuli) | (26) | |
| Gambling | Non-Pathological gamblers whit PD (1) vs. Pathological gamblers with PD (2) | B. anterior cingulate cortex, M. and S. frontal gyri, precuneus, R. I. parietal lobule, ventral striatum | (24) | |
| Imaginary gait | PD patients experiencing freezing (1) vs. PDs not experiencing freezing (2) | R. globus pallidus, R. supplementary motor area, R. mesencephalic locomotor region, R. cerebellum, B. anterior insula, B. ventral striatum, B. pre-supplementary motor area, L. sub-thalamic nucleaus | (28, 29) | |
| Hand movement | PD patients with (1) and without (2) mirror movements syndrome | R. dorsolateral prefrontal cortex, M. prefrontal cortex, Pre-supplementary motor area, Occipital Cortex | B. insula, B. posterior cingulate cortex, L inferior frontal cortex | (27) |
| Balloon analog risk task | PD patients with an impulse-control disorder (1) vs. PD patients without and impulse-control disorder (2) | R. ventral striatum | (25) | |
| Speech | PD patients (1) vs. healthy control volunteers | Primary orofacial sensorimotor cortex | (20) | |
| Saccade | PD patients (1) vs. healthy control volunteers | Frontal and supplementary eye fields | L. and R. cerebellum contralateral motor cortex | (22) |
| Finger tapping | PD patients (1) vs. healthy control volunteers | Putamen, supplementary motor area | R. prefrontal cortex, R. caudate | (21) |
| Motor nerve conduction | |||
| Nerve | Latency | Amplitude | Conduction velocity |
| Median R (wrist) | 8.9 ms | 1.3 mV | |
| Median R (elbow) | 18.5 ms | 0.8 mV | 24 m/s |
| Ulnar R (wrist) | 4.4 ms | 6.9 mV | |
| Ulnar R (below elbow) | 10.4 ms | 5.7 mV | 38 m/s |
| Ulnar R (above elbow) | 13.4 ms | 3.3 mV | 33 m/s |
| Tibial R (ankle) | 6.2 ms | 3.4 mV | |
| Tibial R (popliteal fossa) | 23.1 ms | 0.7 mV | 24 m/s |
| R-cases (n = 20) | 6mo-cases (n = 19)a | TST+ (n = 9) | TST− (n = 18) | |
| Median age, years (range) | 31.5 (17–65) | 30 (18–69) | 42 (20–65) | 22.5 (16–51) |
| Female sex, n (%) | 5 (25) | 6 (23) | 8 (89) | 14 (78) |
| FflV + , n (%) | 1 (5) | 1 (5) | 0 | 0 |
| Smear gradeb | ||||
| 3, n (%) | 7 (35) | 4 (21.1) | N/A | N/A |
| 2, n (%) | 6 (30) | 6 (31.6) | N/A | N/A |
| l, n (%) | 6 (30) | 7 (36.8) | N/A | N/A |
| neg, n (%) | 1 (5) | 2 (10.5) | N/A | N/A |
| Chest X-ray gradec | ||||
| 3, n (%) | 14 (70) | 14 (73.7) | N/A | N/A |
| 2, n (%) | 5 (25) | 5 (26.3) | N/A | N/A |
| l, n TO | 1 (5) | 0 | N/A | N/A |
| No. of abnormalities | ||||||
| Abnormality | Arctic | Innoko | Kenai | Tetlin | Yukon Delta | Total |
| Eye abnormality | ||||||
| Anophthalmia (missing eye) | 0 | 2 | 12 | 6 | 0 | 20 |
| Unpigmented iris (black eye) | 0 | 15 | 118 | 20 | 1 | 154 |
| Microphthalmia (small eye) | 0 | 0 | 1 | 1 | 0 | 2 |
| Othera | 0 | 2 | 6 | 2 | 0 | 10 |
| Skeletal injuryb | ||||||
| Brachydactyly (short digits) | 2 | 0 | 7 | 0 | 2 | 11 |
| Ectrodactyly (missing digits) | 1 | 1 | 4 | 3 | 0 | 9 |
| Ectromelia (partial limb) | 0 | 0 | 44 | 6 | 0 | 50 |
| Limb crushed | 0 | 0 | 14 | 1 | 2 | 17 |
| Otherc | 0 | 2 | 2 | 0 | 0 | 4 |
| Skeletal malformation | ||||||
| Amelia (missing limb) | 0 | 1 | 31 | 3 | 0 | 35 |
| Anteversion (twisted long bones) | 0 | 0 | 9 | 0 | 0 | 9 |
| Brachygnathia (short jaw) | 1 | 4 | 6 | 0 | 0 | 11 |
| Microcephaly (shrunken head or blunt snout) | 0 | 0 | 4 | 0 | 0 | 4 |
| Micromelia (shrunken limb or limb element) | 5 | 3 | 126 | 17 | 3 | 154 |
| Polymelia (extra limb) | 0 | 0 | 1 | 0 | 0 | 1 |
| Polydactyly (extra digits) | 2 | 0 | 2 | 0 | 0 | 4 |
| Scoliosis or lordosis (curved spine) | 0 | 0 | 2 | 0 | 0 | 2 |
| Cutaneous fusion (skin webbing) | 0 | 0 | 3 | 0 | 0 | 3 |
| Syndactyly (digits fused) | 0 | 0 | 11 | 2 | 0 | 13 |
| Taumelia (bone bridge or triangle) | 0 | 0 | 4 | 0 | 0 | 4 |
| Skeletal unknown origin | ||||||
| Kinked tail | 0 | 0 | 3 | 0 | 0 | 3 |
| Brachydactyly (short digits) | 0 | 1 | 27 | 1 | 2 | 31 |
| Ectrodactyly (missing digits) | 0 | 0 | 26 | 3 | 0 | 29 |
| Ectromelia (partial limb) | 7 | 12 | 90 | 14 | 2 | 125 |
| Otherd | 0 | 2 | 5 | 0 | 0 | 7 |
| Overall | ||||||
| Eye total | 0 | 19 | 137 | 29 | 1 | 186 |
| Injury total | 3 | 3 | 71 | 10 | 4 | 91 |
| Malformation total | 8 | 8 | 199 | 22 | 3 | 240 |
| Unknown origin total | 7 | 15 | 151 | 18 | 4 | 195 |
| Total abnormalities | 18 | 45 | 558 | 79 | 12 | 712 |
| Total abnormal individuals | 12 | 39 | 450 | 68 | 7 | 576 |
| Total individuals examined | 615 | 1,309 | 5,716 | 1,146 | 482 | 9,268 |
| Percent individuals abnormal | 2.0% | 3.0% | 7.9% | 5.9% | 1.5% | 6.2% |
| Source | Minerals | Vitamins | ||||||
| Fe (%) | Na (%) | Se (%) | Riboflavin (%) | Thiamin (%) | B12 (%) | Niacin (%) | Folic acid (%) | |
| Red meat* | 14.5 | 13.9 | 25.5 | 16.4 | 5.4 | 50.6 | 32.6 | 4.4 |
| White meat | 2.9 | 4.5 | 5.2 | 5.5 | 1.5 | 4.1 | 11.5 | 4.6 |
| Cereals | 6.39 | 6.89 | 8.4 | 4.8 | 10.2 | 0 | 4.1 | 21.6 |
| Legumes | 2.7 | 0.9 | 0.3 | 0.8 | 1.2 | 0 | 0.29 | 7.1 |
| Fish and seafood | 4.4 | 5.2 | 35.1 | 2.3 | 1.0 | 35.1 | 13.9 | 1.7 |
| White bread | 56.6 | 52.1 | 41.8 | 60.7 | 73.3 | 10.2 | 33.9 | 47.9 |
| Vegetables | 12.4 | 16.5 | 1.4 | 9.5 | 7.4 | 0 | 3.6 | 16.2 |
| pCR prediction(n = 488) | ||||
| Prediction evaluation* | PPV (SD) | NPV (SD) | Sensitivity (SD) | Specificity (SD) |
| Unsupervised clustering | ||||
| BRmet50 | 93(14) | 34(3) | 58(3) | 83(0.6) |
| PMID18271932Sig33 | 92(3) | 32(5) | 53(6) | 83(6) |
| Anthracycline-taxane Centroid | ||||
| BRmet50 | 89(6) | 27(0.6) | 40(5) | 83(6) |
| PMID18271932Sig33 | 77(4) | 20(3) | 29(1) | 67(0.5) |
| SNP ID | Chr 16 position sequence | Sequence | Type | Amino acid change |
| rs200158701 | 70680854(+) | CCATGC/TCCCGG | mis | PS |
| rs192337001 | 70680866(+) | GCTTCA/CCCTGG | mis | TP |
| rs139133476 | 70688459(+) | CCTTGG/CCGTGG | mis | AG |
| rs142890682 | 70688461(+) | TTGGCG/ATGGCC | mis | MV |
| rs118062333 | 70690511(+) | AACACT/CACTTC | mis | HY |
| rs200597979 | 70690960(+) | GGGCCA/GCCCAT | mis | HR |
| rs8046424 | 70690989(+) | AGGTGC/GAGACG | mis | QE |
| rs187166563 | 70693576(+) | CCCAGA/GGCCAA | mis | EG |
| rs142214904 | 70693626(+) | GCTTCC/TGGGTC | mis | RW |
| rs7206509 | 70693945(+) | GCCAAG/CTCCTC | mis | TS |
| rs201277640 | 70693984(+) | GTATGC/TGGCCA | mis | AV |
| rs202122982 | 70694001(+) | TGTACC/TCTCCG | mis | PS |
| rs148286339 | 70694011(+) | GCCCCC/TGTGGT | mis | PL |
| rs141513638 | 70694056(+) | GAGGCC/TGGTCA | mis | PL |
| rs112639369 | 70694073(+) | AGGGCG/AAGGGC | mis | KE |
| rs1444643201 | 70694076(+) | GCGAGG/AGCCTC | mis | SG |
| rs367851338 | 70693627(+) | CTTCCA/GGGTCA | mis | QR |
| rs368143418 | 70690933(+) | TGAGTC/TGGTGC | mis | SL |
| rs374665339 | 70690963(+) | CCACCC/TATCCT | mis | PL |
| rs368923655 | 70691023(+) | CCTCAC/TGGTGA | mis | TM |
| rs368367274 | 70693597(+) | GGTGCA/GGCCCA | mis | QR |
| rs200891924 | 70693560(+) | TGTCCC/ATCTTG | mis | IL |
| rs372998917 | 70694041(+) | CTCCAC/TGGGCT | mis | TM |
| rs370436386 | 70690927(+) | TGCCAC/TTGAGT | mis | TL |
| rs144427482 | 70690571(+) | CCAACG/ATCACC | mis | IV |
| rs201108464 | 70693569(+) | TGAATG/ACCCCA | mis | TA |
| rs144144426 | 70690541(+) | GTGTGC/TCTTAC | mis | PS |
| rs377411431 | 70690885(+) | CGAGCG/TGGAGC | mis | RL |
| rs369011177 | 70680875(+) | GGCTGC/TGCTGT | mis | RC |
| rs145782768 | 70693979(+) | TTGCAG/CTATGC | mis | HQ |
| rs201784459 | 70694005(+) | CCCTCC/TGCCCC | mis | PL |
| rs200488835 | 70693655(+) | TCCTGC/GTGTAA | mis | CW |
| rs3813904 | 70680744(+) | TGACTG/CAGTGA | ese | |
| rs3813905 | 70680850(+) | ACCACC/GATGCC | ese | |
| rs4985556 | 70694000(+) | CTGTAC/ACCTCC | ese |
| Groups | Total cholesterol | LDL-C | HDL-C | TG | HbA1c | FBG |
| r Pearson | r Pearson | r Pearson | r Pearson | r Pearson | r Pearson | |
| Ox-LDL of normoalbuminurics | −0.07 | −0.085 | −0.25 | −0.21 | −0.024 | −0.220 |
| Ox-LDL of microalbuminurics | −0.086 | −0.2 | −0.28 | 0.28 | −0.379 | 0.36 |
| Ox-LDL of macroalbuminurics | −0.148 | 0.066 | 0.001 | −0.139 | −0.136 | −0.129 |
| Ox-LDL of first degree relatives | −0.26 | 0.21 | −0.029 | 0.26 | 0.03 | −0.093 |
| Ox-LDL of control group | 0.49 | 0.33 | 0.092 | 0.05 | 0.057 | −0.37 |
| Survivors(n = 90) | Former prisoners(n = 83) | Statistics | Descendants of survivors(n = 97) | Descendants of former prisoners(n = 90) | Statistics | |
| Gender % (n) | ||||||
| Male | 28.9 (26) | 90.2 (74) | χ2(1,172) = 66.4*** | 43.3 (42) | 50.5 (46) | n.s. |
| Female | 71.1 (64) | 9.8 (8) | 56.7 (55) | 49.5 (45) | ||
| Age | 51.6 (10.3, 30–77) | 53.9 (7.9, 34–81) | n.s. | 21.1 (5.9, 13–31) | 21.6 (5.8, 13–31) | |
| Marital Status % (n) | ||||||
| Single | 4.5 (4) | 1.2 (1) | n.s. | 91.8 (89) | 85.7 (78) | n.s. |
| Married | 38.9 (35) | 82.9 (68) | χ2(3,172) = 34.6*** | 6.2 (6) | 13.2 (12) | n.s. |
| Divorced/ Separated | 3.3 (3) | 4.9 (4) | n.s. | 2.0 (2) | 1.1 (1) | n.s. |
| Widowed | 53.3 (48) | 11.0 (9) | χ2(3,172) = 34.7*** | - | - | |
| Number of children M (SD, range) | 6.0 (2.76, 1–13) | 6.8 (2.63, 2–16) | U = 2971.5* | 0.3 (1.03, 0–5) | 0.3 (0.92, 0–6) | n.s. |
| Years of Schooling M (SD, range) | 5.2 (3.48, 0–14) | 3.7 (3.28, 0–14) | U = 2811.5** | 6.71 (3.18, 0–16) | 5.42 (3.02, 0–17) | U = 3251.0** |
| Highest degree obtained % (n) | ||||||
| No degree | 48.9 (44) | 61.0 (50) | n.s. | 39.2 (38) | 58.2 (53) | χ2(2,188) = 6.8** |
| Primary School | 46.7 (42) | 35.4 (29) | n.s. | 45.4 (44) | 34.1 (31) | n.s. |
| Secondary School | 4.4 (4) | 3.6 (3) | n.s. | 15.4 (15) | 7.7 (7) | n.s. |
| Possessions % (n) | ||||||
| House | 93.3 (84) | 98.8 (81) | n.s. | n.a. | n.a. | |
| Agricultural Field | 80.0 (72) | 96.3 (79) | χ2(1,172) = 10.7*** | n.a. | n.a. | |
| Monthly Income M (SD, range) | 2922.2 (6849.5, 0–41.000) | 3695.1 (6051.6, 0–35.000) | n.s. | n.a. | n.a. | |
| Social Integration | ||||||
| Number of friends M (SD, range) | 4.3 (4.0, 0–20) | 4.9 (3.7, 0–20) | n.s. | 4.3 (4.5, 0–25) | 4.6 (3.6, 0–20) | n.s. |
| Community activities % (n) | 94.4 (85) | 92.7 (76) | n.s. | n.a | n.a. | |
| Memberships in cooperatives M (SD, range) | .7 (.8, 0–3) | .7 (.9, 0–5) | n.s. | n.a. | n.a. | |
| Family members lost in 1994 M (SD, range) | 14 (1.6, 0–70) | 3 (.4, 0–24) | U = 1032.5*** | n.a. | n.a. | |
| Displacement due to genocide % (n) | 98.9 (89) | 82.9 (68) | U = 13.7*** | n.a. | n.a. | |
| Destination of displacement % (n) | n.a. | n.a. | ||||
| Same district | 75.5 (68) | 15.9 (13) | χ2(1,172) = 61.4*** | n.a. | n.a. | |
| Other district (Bugesera, Kibuye) | 23.3 (21) | 59.8 (49) | χ2(1,172) = 23.6*** | n.a. | n.a. | |
| Foreign country (DRC) | - | 7.3 (6) | χ2(1,172) = 6.8** | n.a. | n.a. | |
| Years spent in prison M (SD, range) | n.a. | 8.5 (4.4, .2-15.7) | n.a. | n.a. |
| SSA | ST | t1(h) | μe | STD | ξ | STD | γ | t1(h) | μe | STDa | ξ | STD | γ |
| 3.37 | 53.95 | 6 | −3.12 | −0.05 | −31.92 | −0.04 | 48.93 | 36 | −2.38 | 1.79 | −24.26 | 1.81 | 51.69 |
| 46.09 | −3.35 | −0.67 | −34.44 | −0.66 | 49.41 | −2.55 | 1.31 | −26.23 | 1.32 | 50.39 | |||
| 42.78 | −3.44 | −0.81 | −35.29 | −0.81 | 46.25 | −2.72 | 0.98 | −27.88 | 0.98 | 47.87 | |||
| 36.07 | −3.14 | −0.39 | −32.20 | −0.38 | 39.87 | −2.84 | 0.35 | −29.13 | 0.36 | 45.02 | |||
| 3.73 | 53.95 | −3.21 | −0.61 | −32.94 | −0.60 | 47.53 | −2.52 | 1.12 | −25.86 | 1.11 | 50.20 | ||
| 46.09 | −3.06 | −0.31 | −31.41 | −0.31 | 46.38 | −2.70 | 0.59 | −27.72 | 0.58 | 47.55 | |||
| 42.78 | −3.27 | −0.51 | −33.58 | −0.51 | 46.58 | −2.77 | 0.74 | −28.42 | 0.74 | 47.85 | |||
| 36.07 | −3.44 | −0.70 | −35.27 | −0.69 | 44.72 | −2.94 | 0.53 | −30.22 | 0.53 | 45.27 | |||
| 4.44 | 53.95 | −3.22 | −0.34 | −33.02 | −0.34 | 49.32 | −2.72 | 0.89 | −27.92 | 0.89 | 49.70 | ||
| 46.09 | −3.32 | −1.01 | −32.92 | −0.76 | 48.91 | −2.31 | 1.49 | −23.76 | 1.45 | 48.48 | |||
| 42.78 | −3.48 | −0.90 | −35.71 | −0.90 | 49.18 | −2.54 | 1.44 | −26.04 | 1.43 | 46.55 | |||
| 36.07 | −3.37 | −0.62 | −34.56 | −0.62 | 44.43 | −2.61 | 1.27 | −26.82 | 1.25 | 44.71 | |||
| 3.37 | 53.95 | 12 | −3.21 | −0.29 | −32.98 | −0.30 | 52.01 | 48 | −3.85 | −1.88 | −39.67 | −1.91 | 47.25 |
| 46.09 | −3.25 | −0.44 | −33.40 | −0.41 | 50.09 | −3.81 | −1.82 | −38.90 | −1.74 | 44.89 | |||
| 42.78 | −3.33 | −0.54 | −34.17 | −0.54 | 47.59 | −3.72 | −1.50 | −38.14 | −1.50 | 44.06 | |||
| 36.07 | −3.22 | −0.60 | −33.12 | −0.61 | 47.74 | −3.67 | −1.70 | −37.61 | −1.69 | 43.98 | |||
| 3.73 | 53.95 | −2.94 | 0.06 | −30.19 | 0.06 | 53.88 | −3.23 | −0.66 | −33.19 | −0.66 | 48.11 | ||
| 46.09 | −2.99 | −0.13 | −30.69 | −0.13 | 49.52 | −3.20 | −0.66 | −32.86 | −0.66 | 46.40 | |||
| 42.78 | −3.20 | −0.32 | −32.80 | −0.32 | 50.05 | −3.32 | −0.62 | −34.09 | −0.63 | 43.18 | |||
| 36.07 | −3.13 | 0.06 | −32.18 | 0.06 | 45.05 | −3.85 | −1.72 | −39.51 | −1.71 | 41.96 | |||
| 4.44 | 53.95 | −3.35 | −0.66 | −34.36 | −0.66 | 51.21 | −3.10 | −0.05 | −31.83 | −0.05 | 46.33 | ||
| 46.09 | −3.09 | −0.45 | −31.77 | −0.48 | 51.94 | −2.92 | −0.01 | −29.94 | −0.04 | 45.21 | |||
| 42.78 | −3.49 | −0.93 | −35.82 | −0.93 | 49.04 | −3.26 | −0.37 | −33.47 | −0.36 | 43.56 | |||
| 36.07 | −3.13 | −0.03 | −32.10 | −0.02 | 46.65 | −3.37 | −0.63 | −34.62 | −0.63 | 42.30 | |||
| 3.37 | 53.95 | 24 | −2.70 | 0.98 | −27.68 | 0.98 | 49.02 | 72 | −3.31 | −0.54 | −34.01 | −0.55 | 46.95 |
| 46.09 | −2.48 | 1.49 | −25.47 | 1.50 | 46.44 | −3.03 | 0.12 | −31.71 | 0.00 | 45.34 | |||
| 42.78 | −2.41 | 1.74 | −24.79 | 1.73 | 44.92 | −3.06 | 0.14 | −31.39 | 0.13 | 44.44 | |||
| 36.07 | −2.38 | 1.49 | −24.48 | 1.48 | 44.03 | −2.64 | 0.85 | −27.11 | 0.85 | 44.18 | |||
| 3.73 | 53.95 | −2.95 | 0.05 | −30.26 | 0.05 | 50.16 | −2.95 | 0.05 | −30.25 | 0.05 | 45.17 | ||
| 46.09 | −2.67 | 0.66 | −27.41 | 0.66 | 47.68 | −2.99 | −0.14 | −30.71 | −0.14 | 44.97 | |||
| 42.78 | −3.07 | −0.01 | −31.54 | −0.01 | 46.01 | −2.78 | 0.72 | −28.47 | 0.73 | 44.21 | |||
| 36.07 | −3.06 | 0.24 | −31.39 | 0.24 | 44.18 | −2.52 | 1.58 | −25.87 | 1.58 | 42.71 | |||
| 4.44 | 53.95 | −2.79 | 0.73 | −28.62 | 0.72 | 49.98 | −3.31 | −0.58 | −33.99 | −0.57 | 45.78 | ||
| 46.09 | −2.85 | 0.15 | −29.61 | 0.04 | 47.20 | −2.98 | −0.16 | −30.59 | −0.20 | 45.65 | |||
| 42.78 | −2.97 | 0.36 | −30.51 | 0.35 | 45.17 | −2.96 | 0.40 | −30.32 | 0.40 | 44.97 | |||
| 36.07 | −3.15 | −0.08 | −32.31 | −0.07 | 45.21 | −3.08 | 0.09 | −31.64 | 0.09 | 44.60 |
| ABFAB | FBC | FPH | Total | |
| Women who stopped breastfeeding before 6 months | n = 65 | n = 7 | n = 14 | n = 86 |
| Stopped bf before mastitis | 5 | 1 | 2 | 8 |
| Stopped within 3 wks | 29 | 2 | 5 | 36* |
| Stopped between 3 and 26 wks | 31 | 4 | 7 | 42 |
| Women breastfeeding at 6 months | n = 70 | n = 19 | n = 31 | n = 120 |
| Mastitis in previous 3 wks | 2 | 0 | 0 | 2 |
| Mastitis > 3 wks earlier | 68 | 19 | 31 | 118 |
| Total women with mastitis | 206 |
| Patients | Controls | OR* | 95%CI | OR** | 95%CI | |
| rs117813469 | ||||||
| GG | 186 | 198 | ||||
| GC/CC | 28 | 15 | 2.25 | (1.14-4.46) | 2.12 | (1.09-4.14) |
| rs130005507 | ||||||
| CC | 160 | 158 | ||||
| CG/GG | 54 | 55 | 0.98 | (0.63-1.53) | 0.97 | (0.63-1.5) |
| rs11305133 | ||||||
| AA | 191 | 197 | ||||
| AG/GG | 23 | 16 | 1.67 | (0.84-3.34) | 1.54 | (0.79-3.02) |
| rs150877473 | ||||||
| CC | 188 | 192 | ||||
| CG/GG | 26 | 21 | 1.49 | (0.79-2.81) | 1.34 | (0.72-2.49) |
| rs188801636 | ||||||
| AA | 190 | 191 | ||||
| AG/GG | 23 | 19 | 1.40 | (0.72-2.72) | 1.28 | (0.67-2.45) |
| rs77111769 | ||||||
| TT | 184 | 194 | ||||
| TC/CC | 30 | 19 | 1.82 | (0.98-3.41) | 1.74 | (0.94-3.23) |
| rs142764723 | ||||||
| TT | 189 | 189 | ||||
| TC/CC | 25 | 24 | 2.53 | (1.33-4.82) | 2.32 | (1.24-4.34) |
| rs149306391 | ||||||
| GG | 188 | 193 | ||||
| GC/CC | 26 | 20 | 1.58 | (0.83-3.02) | 1.44 | (0.77-2.71) |
| rs373417600 | ||||||
| GG | 199 | 202 | ||||
| GC/CC | 15 | 11 | 1.58 | (0.69-3.64) | 1.47 | (0.65-3.29) |
| Pencil | Oil-pastel | Gouache | F(2,98) | |
| (M/SD) | (M/SD) | (M/SD) | ||
| RSA | 6.23 (± 1.07) | 5.90 (± 0.98) | 6.01 (± 1.09) | 3.58∗ |
| ΔRSA | -0.11 (± 0.57) | -0.49 (± 0.62) | -0.33 (± 0.65) | 5.97∗∗ |
| CSI | 2.85 (± 0.14) | 3.04 (± 0.13) | 2.83 (± 0.13) | 0.017 |
| ΔCSI | -0.29 (± 1.02) | 0.08 (± 1.06) | -0.15 (± 0.85) | 7.41∗∗ |
| Protein ID | Orthologs | Potential functions |
| Wolco1| 166770 | STE20 | Growth, virulence, and sclerotial formation |
| Wolco1| 43954 | STE11 | Growth, virulence, and sclerotial formation |
| Wolco1| 150169 | STE7 | Growth, virulence, and sclerotial formation |
| Wolco1| 75024 | MKK2 | Regulate MAPK signaling pathway |
| Wolco1| 144702 | PBS2 | Regulate MAPK signaling pathway |
| Wolco1| 135363 | BCK1 | Regulate MAPK signaling pathway |
| Wolco1| 121529 | CLA4 | Pathogenicity, mycelial growth and conidial morphology |
| Group A†(n = 255) | Group B‡(n = 41) | p-value | |
| Mean sUA level (mg/dL) | 4.69 ± 1.08 | 7.61 ± 0.95 | < 0.001 |
| F/U time (months) | 73.0 ± 42.2 | 62.0 ± 46.8 | 0.134 |
| Initial eGFR (mL/min/1.73 m2) | 82.0 ± 19.6 | 52.2 ± 27.4 | < 0.001 |
| Final eGFR (mL/min/1.73 m2) | 75.6 ± 27.9 | 48.3 ± 31.7 | < 0.001 |
| ΔeGFR (mL/min/1.73 m2/yr) | −0.29 ± 4.22 | −1.87 ± 3.30 | 0.026 |
| ΔeGFR (%/yr) | −0.72 ± 6.03 | −6.23 ± 9.84 | 0.001 |
| ESRD progression, n (%) | 14 (5.4%) | 14 (34.1%) | < 0.001 |
| HPV type | Baseline (n = 1759) | Follow-up (n = 85) | ||
| N | Prevalence (%) | N | Persistence (%) | |
| Any type | 152 | 8.64 | 29/85 | 34.12 |
| High-risk | 131 | 7.45 | 25/73 | 34.25 |
| HPV16 | 33 | 1.88 | 7/17 | 41.18 |
| HPV18 | 16 | 0.91 | 5/8 | 62.50 |
| HPV26 | 3 | 0.17 | 0/0 | - |
| HPV31 | 5 | 0.28 | 0/0 | - |
| HPV33 | 10 | 0.57 | 1/4 | 25.00 |
| HPV39 | 15 | 0.85 | 1/7 | 14.29 |
| HPV45 | 2 | 0.11 | 0/2 | 0.00 |
| HPV51 | 3 | 0.17 | 1/2 | 50.00 |
| HPV52 | 29 | 1.65 | 2/13 | 15.38 |
| HPV56 | 2 | 0.11 | 1/1 | 100.00 |
| HPV58 | 19 | 1.08 | 7/15 | 46.67 |
| HPV59 | 2 | 0.11 | 2/2 | 100.00 |
| HPV66 | 1 | 0.06 | 0/1 | 0.00 |
| HPV68 | 7 | 0.40 | 0/4 | 0.00 |
| Low-risk | 29 | 1.65 | 4/16 | 25.00 |
| HPV6 | 9 | 0.51 | 0/6 | 0.00 |
| HPV11 | 1 | 0.06 | 0/0 | - |
| HPV40 | 1 | 0.06 | 0/0 | - |
| HPV53 | 1 | 0.06 | 0/1 | 0.00 |
| HPV55 | 2 | 0.11 | 0/0 | - |
| HPV61 | 13 | 0.74 | 4/8 | 50.00 |
| HPV82 | 4 | 0.23 | 0/1 | 0.00 |
| Individual subject characteristics | Prognostic factors | |
| Age | Confirmatory | |
| Gender | Exploratory | |
| Height, weight, body mass index | Exploratory | |
| Ethnicity/race | Exploratory | |
| Lifestyle factors | ||
| Participation in sports activities or physical fitness level | Exploratory | |
| Smoking | Exploratory | |
| Alcohol use | Exploratory | |
| Sociodemographic characteristics | ||
| Marital status | Exploratory | |
| Level of education | Exploratory | |
| Income | Exploratory | |
| Employment status | Exploratory | |
| Nature and severity of the low back pain | ||
| Duration of the low back pain | Confirmatory | |
| Non-specific | Exploratory | |
| Radiation | Exploratory | |
| Previous low back pain treatment received | Exploratory | |
| Comorbidities, e.g., diabetes, heart disease | ||
| Presence of comorbidities | Exploratory | |
| Number of comorbidities | Exploratory | |
| Category of comorbidities | Exploratory | |
| Type of treatment | Manipulation, mobilization, combination | |
| Psychosocial factors | e.g., Back Depression Inventory, Fear Avoidance Beliefs Questionnaire | Confirmatory |
| Treatment preference/ expectation | e.g., preference for treatment, previous experience with treatment, expectation to final improvement, self-efficacy scale/beliefs | Confirmatory |
| Systems | Plot area (m2) | Gradient (°) | Aspect | Agro type (by Chinese system) | Bulk density (g cm−3) | pH | OM (g kg−1) | TN (g kg−1) | AN (g kg−1) | TP (g kg−1) | AP (g kg−1) |
| S1 | 56 | 6.3 | NE36° | Purple soil | 1.26 | 7.81 | 29.12 | 1.38 | 0.104 | 0.78 | 0.022 |
| S2 | 54 | 4.7 | NE98° | 1.31 | 7.78 | 25.36 | 1.44 | 0.118 | 0.78 | 0.015 | |
| S3 | 52 | 5.8 | NE60° | 1.48 | 6.11 | 39.66 | 2.44 | 0.166 | 0.36 | 0.001 |
| B | SE | Significance | |
| (Constant) | −0.57 | 0.05 | |
| City of residence | 0.25 | 0.06 | 0.000* |
| Smoker(s) present in the home | 0.12 | 0.07 | 0.073 |
| Year | No. of Samples | No. of Positive | Positive Rate (%) | Influenza A Virus | Influenza B Virus | ||
| H1N1 | H3N2 | pdm H1N1 | |||||
| 2006 | 1290 | 145 | 11.24 | 103 (71.03%) | 6 (4.14%) | 0 (0%) | 36 (24.83%) |
| 2007 | 1223 | 113 | 9.24 | 2 (1.77%) | 109 (96.46%) | 0 (0%) | 2 (1.77%) |
| 2008 | 1230 | 56 | 4.56 | 31 (55.36%) | 19 (33.93%) | 0 (0%) | 6 (10.71%) |
| 2009 | 2359 | 401 | 17.00 | 37 (9.23%) | 129 (32.17%) | 209 (52.12%) | 26 (6.48%) |
| 2010 | 1821 | 128 | 7.03 | 0 (0%) | 31 (24.22%) | 49 (38.28%) | 48 (37.50%) |
| 2011 | 864 | 26 | 3.01 | 0 (0%) | 3 (11.54%) | 11 (42.31%) | 12 (46.15%) |
| 2012 | 866 | 24 | 2.77 | 0 (0%) | 6 (25.00%) | 0 (0%) | 18 (75.00%) |
| 2013 | 1658 | 69 | 4.16 | 0 (0%) | 18 (26.09%) | 33 (47.83%) | 18 (26.09%) |
| 2014 | 1983 | 186 | 9.38 | 0 (0%) | 95 (51.08%) | 60 (32.26%) | 31 (16.67%) |
| Total | 13,294 | 1148 | 8.64 | 173 (15.07%) | 416 (36.24%) | 362 (31.53%) | 197 (17.16%) |
| Total, n= 1781 | Wild-type KRAS, n= 1416 | Mutant KRAS, n= 365 | P | |
| No. of associated alterations | ||||
| Median (range) | 0 (0-9) | 0(0-9) | 1(1-9) | <0.0001 |
| >2 | 118 | 81(6%) | 37 (10%) | 0.0025 |
| Type of associated alterations | ||||
| PI3KCA | 162/1386 (12%) | 118/1203 (10%) | 44/183 (24%) | <0.0001 |
| P53 | 184/510 (36%) | 155/427 (36%) | 29/83 (35%) | 0.87 |
| PTEN | 132/1040 (13%) | 111/881 (13%) | 21/159 (13%) | 0.83 |
| BRAF | 77/1370 (6%) | 76/1139 (7%) | 1/231 (0.4%) | 0.0002 |
| EGFR | 54/1205 (5%) | 49/1022 (5%) | 5/183 (3%)* | 0.21 |
| MET | 41/951(4%) | 32/786 (4%) | 9/165 (5.5%) | 0.43 |
| Tumor Response as per RECIST v1.1 | Arm A, N = 3 | Arm B, N = 5 |
| Number of patients | Number of patients | |
| CR | 0 | 0 |
| PR | 0 | 0 |
| SD | 1 | 2 |
| PD | 2 | 3 |
| Number of eligible patients | 420 | Type of procedure |
| Primary procedures | 196 | Aesthetic |
| n = 378 | 131 | Aesthetic and functional |
| 51 | Functional | |
| Revision procedures | 31 | Aesthetic |
| n = 42 | 9 | Aesthetic and functional |
| 2 | Functional |
| Incubation medium [Fe] (mM) | Measured MR relaxation times | Cell function assays | ||
| T1 (ms) | T2 (ms) | Viability (%) | Proliferation (%) | |
| 0 | 2166 ± 135 | 85.7 ± 9.0 | 100 ± 14 | 100 ± 18 |
| 0.0036 | 1263 ± 193 | 16.1 ± 2.6 | 96 ± 19 | 92 ± 8 |
| 0.009 | 828 ± 127 | 12.6 ± 0.6 | 96 ± 15 | 96 ± 19 |
| 0.018 | 613 ± 65 | 11.3 ± 0.6 | 95 ± 13 | 89 ± 12 |
| 0.036 | 630 ± 60 | 10.9 ± 0.5 | 86 ± 16 | 84 ± 15 |
| No. | % | |
| Gender | ||
| Male | 59 | 54.13 |
| Female | 50 | 45.87 |
| Chemotherapy | ||
| Gemcitabine alone | 41 | 37.61 |
| Gemcitabine combined with other drugs* | 68 | 62.39 |
| Primary pancreas tumor | ||
| Head | 50 | 45.87 |
| Body or tail | 35 | 32.11 |
| Unknown | 24 | 22.02 |
| Stage of disease | ||
| Locally advanced | 10 | 9.17 |
| Metastatic | 70 | 64.22 |
| Unknown | 29 | 26.61 |
| Distant metastasis | ||
| Liver | 50 | 71.43 |
| Lung | 2 | 2.86 |
| bone | 4 | 5.71 |
| Abdomen | 5 | 7.14 |
| Characteristic | Number (n) | Percentage (%) | |
| Gender | Male | 155 | 55 |
| Female | 127 | 45 | |
| Gestational age (weeks) | 28–36 | 115 | 41 |
| ≥37–42 | 168 | 59 | |
| Postnatal age at measurement | ≤24 h | 9 | 3 |
| 2 days | 54 | 19 | |
| 3 days | 84 | 30 | |
| 4 days | 73 | 25 | |
| 5–10 days | 58 | 21 |
| Ash sample | Fraction | Total | Total independent measurment | ||||
| Water soluble | Acid soluble/exchangeable | Reducible | Oxidizable | Entrapped in parent matter | |||
| A | 0.0008 | 0.004 | 0.01 | 0.201 | 0.359 | 0.575 | 0.499 |
| B | 0.0007 | 0.005 | 0.02 | 0.159 | 0.365 | 0.550 | 0.520 |
| C | 0.0016 | 0.004 | 0.01 | 0.146 | 0.257 | 0.419 | 0.441 |
| D | 0.0016 | 0.004 | 0.01 | 0.187 | 0.335 | 0.538 | 0.442 |
| Blank | 0.00008 | 0.0001 | 0.0008 | 0.0001 | 0.0003 | 0.0014 | |
| Average | 0.0012 | 0.004 | 0.0125 | 0.173 | 0.329 | 0.520 | 0.471 |
| SD | 0.0004 | 0.001 | 0.005 | 0.025 | 0.049 | 0.046 | |
| Percent of Total Tl | 0.23 | 0.77 | 2.4 | 33.27 | 63.27 |
| Variable | Adjusted odds ratio (95% CI) | SE |
| CGPA | 15.27 [6.28, 27.11]∗∗∗ | 0.88 |
| Age <30 years | 0.31 [0.06, 1.63] | 0.85 |
| Male gender | 1.13 [0.50, 2.55] | 0.42 |
| Home residence (ref = rural) | ||
| Semiurban | 1.49 [0.41, 5.37] | 0.65 |
| City/urban | 1.44 [0.38, 5.42] | 0.68 |
| Father highly educated | 0.56 [0.21, 1.49] | 0.49 |
| Mother highly education | 1.23 [0.55, 2.76] | 0.41 |
| Entered nursing with WASSCE | 0.32 [0.04, 2.63] | 1.08 |
| Nursing was a first career of choice | 0.50 [0.21, 1.19] | 0.45 |
| Read science in formal school | 1.2 [0.5, 2.6] | 0.40 |
| Gene names | RS | Gene names | RS | Gene names | RS |
| KRT19 | 1.6 | PTGES2 | 0.4 | BCL7C | 0.2 |
| BARD1 | 1.6 | PREX2 | 0.4 | ZNF18 | 0.2 |
| MST1R | 1.5 | USP1 | 0.4 | PGLS | 0.2 |
| S100A14 | 1.2 | EHF | 0.4 | CNTN4 | 0.2 |
| LGALS1 | 1.2 | ADM | 0.4 | BACH1 | 0.2 |
| RNF168 | 1.1 | GRM4 | 0.4 | ZFPL1 | 0.2 |
| TFF1 | 1 | SHFM1 | 0.4 | MAGED2 | 0.1 |
| SPEN | 1 | EMP3 | 0.4 | TMEM43 | 0.1 |
| WDR18 | 0.9 | PTGES | 0.3 | GALNT5 | 0.1 |
| RRAS | 0.9 | TRAF1 | 0.3 | HMX1 | 0.1 |
| PLEK2 | 0.8 | NAMPT | 0.3 | RASSF6 | 0.1 |
| CD248 | 0.8 | BCL2L12 | 0.3 | PFN1 | 0.1 |
| RHBDL2 | 0.8 | MAML1 | 0.3 | SLC16A7 | 0.1 |
| CAPN5 | 0.7 | USP24 | 0.3 | ZBTB40 | 0.1 |
| S100A16 | 0.7 | AMHR2 | 0.3 | MAGED4 | 0.1 |
| CDC6 | 0.6 | PSMG3 | 0.3 | PIF1 | 0.1 |
| ENDOG | 0.6 | NFE2L2 | 0.3 | MBTPS1 | 0.1 |
| GNG2 | 0.6 | RAPH1 | 0.3 | HDAC4 | 0.1 |
| CLDN18 | 0.6 | TSHZ2 | 0.2 | VASN | 0.1 |
| RNF169 | 0.5 | RNF146 | 0.2 | PSME3 | 0.1 |
| NR3C1 | 0.5 | NFIL3 | 0.2 | AMN | 0.1 |
| TMC8 | 0.5 | SPINK1 | 0.2 | ERCC1 | 0.1 |
| AKT1S1 | 0.5 | OSTM1 | 0.2 | BRD9 | 0.1 |
| KLK10 | 0.5 | ESRRG | 0.2 | B4GALNT1 | 0.1 |
| SLC2A1 | 0.5 | XRCC3 | 0.2 | PLEKHG5 | 0.1 |
| ANTXR1 | 0.4 | SLC4A7 | 0.2 | ARHGAP33 | 0.1 |
| CHSY1 | 0.4 | DPH1 | 0.2 | CYP24A1 | 0.1 |
| ELAC1 | 0.4 |
| SNP-database region | ||||
| Scan-statistic region | Inter-gene | Within-gene | Regions detected only by scan statistic | Total no. regions |
| Non-gene scan statistic | 33 (8)a | 0 | 72 (12) | 105 (20) |
| Gene scan statistic | 10 (7) | 38 (17) | 87 (20) | 135 (44) |
| Total | 43 (15) | 38 (17) | 159 (32) | 240 (64) |
| Reference | Country | Study design | Sample size | Data source/sample type | Results | |
| [30] | China | The 5th Chinese National Nutrition and Health Survey (2010–2012) | 2111 | Questionnaire of dietary Mn intake | Men | A decreased risk of MetS with higher Mn intake. |
| Women | An increased risk of MetS with higher Mn intake. | |||||
| MetS components | Mn intake was inversely associated with abdominal obesity and hypertriacylglycerolaemia in men, but positively associated with low HDL-cholesterol in both men and women. | |||||
| [31] | Korea | The Korea National Health and Nutrition Examination Survey (2007–2008) | 5136 | Questionnaire of dietary Mn intake | Men | No difference |
| Women/MetS components | The women subjects with high blood pressure showed significantly lower intake of Mn than did control subjects. | |||||
| [32] | China | Cross-sectional study | Cases: 221 Controls: 329 | Questionnaire of dietary Mn intake | Men/women | A lower risk of developing MetS in the second, third, and highest quintiles of Mn intake with respect to the lowest quintile after adjusting age, sex, and energy intake. |
| MetS components | Daily intake of Mn was decreased with the increasing number of MetS components. | |||||
| [5] | Poland | Cross-sectional study | 313 (men aged 50–75 years) | Serum (Mn level) | Significant positive correlations (Mn–BMI, Mn–abdominal circumference, Mn–waist-to-hip ratio, Mn–insulin, Mn–HOMA-IR), but no correlation with MetS. | |
| [33] | Korea | The Korea National Health and Nutrition Examination Survey (2008) | 1405 | Whole blood (Mn level) | No difference | |
| Urine (Mn level) | No difference |
| Theme | Number of mode-sensitive* items of total number of items | Median (and maximum)odds ratio among mode-sensitive items |
| Health behaviour | ||
| Medicine | 0/3 | - |
| Smoking habits | 0/1 | - |
| Self assessments | ||
| Self-esteem | 8/9 | 1.57 (2.57) |
| Well-being | 9/11 | 1.55 (2.20) |
| Depression | 3/6 | 2.12 (2.21) |
| Stress | 12/15 | 1.67 (2.44) |
| Total | No education | Primary | Secondary | Some college or more | Ratio: No ed vs. Some college or more | |
| Diabetes | ||||||
| 1998 | 3.72 (3.62, 3.83) | 3.88 (3.65,4.12) | 3.99 (3.84,4.14) | 2.81 (2.48,3.13) | 2.86 (2.52,3.20) | 1.30 |
| 2003 | 4.52 (4.41, 4.64) | 5.22 (4.93, 5.51) | 4.70 (4.56, 4.85) | 3.70 (3.43, 3.97) | 3.47 (3.16, 3.79) | 1.30 |
| 2008 | 5.54 (5.43, 5.65) | 6.30 (5.99, 6.60) | 5.93 (5.78. 6.09) | 4.64 (4.40, 4.89) | 4.12 (3.83, 4.40) | 1.34 |
| 2013 | 6.76 (6.39, 7.13) | 8.11 (7.03, 9.19) | 7.70 (7.10, 8.30) | 5.46 (4.71, 6.21) | 4.58 (3.73, 5.42) | 1.48 |
| overall change | 3.04 | 4.23 | 3.71 | 2.65 | 1.72 | |
| Hypertension | ||||||
| 1998 | 19.94 (19.68, 20.20) | 23.97 (23.33, 24.62) | 20.33 (20.03,20.63) | 15.70 (15.08, 16.31) | 13.80 (13.14, 14.46) | 1.44 |
| 2003 | 21.36 (21.12, 21.60) | 25.36 (24.67, 26.04) | 22.57 (22.28, 22.86) | 16.18 (15.67, 16.70) | 15.81 (15.22, 16.39) | 1.35 |
| 2008 | 22.10 (21.88, 22.33) | 26.22 (25.55, 26.89) | 23.73 (23.44, 24.03) | 18.12 (17.71, 18.53) | 16.71 (16.20, 17.22) | 1.32 |
| 2013 | 22.54 (21.93, 23.16) | 25.28 (23.46, 27.10) | 24.96 (23.96, 25.96) | 19.81 (18.57, 21.04) | 19.10 (17.62, 20.58) | 1.18 |
| overall change | 2.60 | 1.31 | 4.63 | 4.11 | 5.30 | |
| Heart problems | ||||||
| 1998 | 6.95 (6.78, 7.11) | 8.26 (7.88,8.63) | 7.07 (6.87,7.27) | 5.60 (5.17,6.04) | 4.24 (3.84,4.65) | 1.64 |
| 2003 | 6.13 (5.99, 6.26) | 7.03 (6.70, 7.36) | 6.50 (6.33, 6.68) | 4.39 (4.10, 4.69) | 4.53 (4.18, 4.89) | 1.35 |
| 2008 | 5.82 (5.70, 5.94) | 6.76 (6.44, 7.09) | 6.26 (6.10, 6.42) | 4.60 (4.36, 4.84) | 4.10 (3.83, 4.38) | 1.42 |
| 2013 | 4.20 (3.87, 4.53) | 4.82 (4.00, 5.63) | 4.70 (4.18, 5.23) | 3.38 (2.71, 4.05) | 3.43 (2.55, 4.31) | 1.22 |
| overall change | −2.75 | −3.44 | −2.37 | −2.22 | −0.81 |
| Risk of bias | Applicability concerns concerns | ||||||
| First author, year | Patient selection | Index test | Reference standard | Flow and timing | Patient selection | Index test | Reference standard |
| Beldame, 2011 [23] | ? | + | + | - | + | + | + |
| Boeree, 1991 [24] | - | ? | + | + | + | + | + |
| Decker, 1988 [33] | ? | + | ? | - | + | + | + |
| Harilainen, 1987 [25] | + | ? | ? | - | + | + | + |
| Katz, 1986 [26] | - | + | ? | + | + | + | + |
| Lee, 1988 [27] | - | + | ? | - | + | + | + |
| Lucie, 1984 [28] | - | + | ? | - | + | + | + |
| Mulligan, 2011 [29] | + | + | ? | ? | + | + | + |
| Noyes, 1980 [30] | - | ? | + | - | ? | + | + |
| Richter, 1996 [34] | - | + | ? | + | + | + | + |
| Schwartz, 1997 [35] | - | + | + | + | + | + | + |
| Tonino, 1986 [31] | - | + | ? | ? | + | + | + |
| Wagemakers, 2010 [19] | + | + | + | + | + | + | + |
| Wong, 1999 [32] | + | ? | ? | + | + | + | + |
| Tumor stage | N | (%) |
| Non-invasive carcinoma | 24 | 8.7 |
| Invasive carcinoma | ||
| T1 | 176 | 61.9 |
| T2 | 63 | 22.1 |
| T3 | 9 | 3.0 |
| T4 | 8 | 3.0 |
| Unknown | 4 | 1.3 |
| Nodal status | ||
| N0 | 187 | 65.8 |
| ≥N1 | 93 | 32.7 |
| Unknown | 4 | 1.5 |
| Metastases/recurrence | 29 | 10.4 |
| Treatment | ||
| Surgery | ||
| BET | 224 | 78.9 |
| Mastectomy | 55 | 19.4 |
| No surgery | 5 | 1.7 |
| SN biopsy | 128 | 45.2 |
| Axillary lymph node dissection | 117 | 41.5 |
| Chemotherapy | ||
| Neoadjuvant | 24 | 8.4 |
| Adjuvant | 122 | 42.8 |
| Irradiation | 233 | 81.9 |
| Hormonal therapy | 218 | 76.9 |
| Relationship | ||
| Single | 16 | 5.7 |
| Married/living with partner | 172 | 60.5 |
| Divorced/widowed | 79 | 27.8 |
| Unknown | 17 | 6 |
| Education | ||
| Compulsory | 121 | 42.2 |
| Post-compulsory | 149 | 52.8 |
| University level | 14 | 5.0 |
| Employment | ||
| Employed | 77 | 27.1 |
| Retired | 86 | 30.3 |
| Homemaker/unemployed | 88 | 31.0 |
| Unknown | 33 | 11.6 |
| Primers | 5′–3′ sequence (bp) | |
| Primers for 3′-RACE PCR | ||
| Kiss1-F | CGCCACAAGCGGCCAAGAAG | |
| Kiss2-F | AGGGCCACATTTCCTGCCGACT | |
| Primers for 5′-RACE PCR | ||
| Kiss1-R | CCCGCTTCTTGGCCGCTTGT | |
| Kiss2-R | CCGAACGGATTGCGGTTGAATTTG | |
| Primers for qPCR | ||
| Kiss1-F | GGTCTCTTAGGTACACCCCGT | This study |
| Kiss1-R | ACAGCTCCTCGCTCATTTG | |
| Kiss2-F | ACGGACGACTCAGGTTCTCT | This study |
| Kiss2-R | GCCCTCGATTTCACTGTCTT | |
| actin-F | AGTATTTGCGCTCGGGTG | Aroua et al. (27) |
| actin-R | CAGCCTTCCTTCCTGGGT | |
| lhβ-F | TCACCTCCTTGTTTCTGCTG | Aroua et al. (27) |
| lhβ-R | TAGCTTGGGTCCTTGGTGATG | |
| fshβ-F | TCTCGCCAACATCTCCATC | Aroua et al. (27) |
| fshβ-R | AGAATCCTGGGTGAAGCACA | |
| gnrh-r1a-F | TGGTCATGAGTTGCTGCTACA | Penaranda et al. (25) |
| gnrh-r1a-R | AGACACCCCTCTCCGTCTTT | |
| gnrh-r1b-F | TCGTCACGCTCTACGTTGTC | Penaranda et al. (25) |
| gnrh-r1b-R | AGGCAGGACTCTCCACCTTT | |
| gnrh-r2-F | TCACCTTCTCCTGCCTCTTC | Penaranda et al. (25) |
| gnrh-r2-R | TTGGAAGATGCCTTCCCTTT |
| Accession ID | Amplicon Size | Primers used |
| α ENaC-wt | 325 bp | Sense: 5'-TCATGCTGCTACGCCGGTTCC-3' |
| Antisense:5'-TCCATCAGTTTACAAGGGAG-3' | ||
| α ENaC a | 266 bp | Sense: 5'-CAGAGCTCCTGGGGGCGCCTT-3' |
| Antisense: 5'-TCCTTCTGTCACGATGGTCA-3' | ||
| α ENaC-b | 278 bp | Sense: 5'-GGATGATGGTGGCTTCAACT-3' |
| Antisense: 5'-ACACCCAGGAGCTCTGCTTT-3' | ||
| α ENaC-c | 59 bp | Sense: 5'-GCTCCTGGGTGTGATCAACTA-3' |
| Antisense: 5'-AAAGAAGGTGGTGGGGATGT-3' | ||
| 59 bp | Sense: 5'-GGATGATGGTGGCTTCAACT-3' | |
| Antisense: 5'-AAAGAAGGTGGTGGGGATGT-3' | ||
| α ENaC-d | 99 bp | Sense: 5'-CCACGCGTCCGAAGAAAC-3' |
| Antisense:5'-AAAGAAGGTGGTGGGGATGT-3' | ||
| 99 bp | Sense: 5'-CCACGCGTCCGAAGAAACTG-3' | |
| Antisense:5'-TAAAGAAGGTGGTGGGGATG-5' | ||
| CK479583 | 767 bp | Sense: 5'-GCCCCAGCAGGGCATGACCC-3' |
| Antisense: 5'-CTAGAGTAGCATAGGCAGGT-3' | ||
| CK475461 | 814 bp | Sense: 5'-TCCAAGTATACACAGCAGGT-3' |
| Antisense: 5'-TACAGGAGTCAGGCTGTGAG-3' | ||
| CK364785 | 764 bp | Sense: 5'-GGGGCTATTGCTATTATAAA-3' |
| Antisense:5'-CCACACAGAGGGCTCGGCGGG-3' | ||
| CK475819 | 748 bp | Sense: 5'-GATTCCCGGGATCTTGGA-3' |
| Antisense: 5'-AGGCTGACCATCGTGACAG-3' | ||
| CB690980 | 376 bp | Sense: 5'-CCACGCGTCCGAAGAAAC-3' |
| Antisense: 5'-AAAGAAGGTGGTGGGGATGT-3' | ||
| Pgk | 263 bp | Sense: 5'-GCTGCAGAACTCAAATCTCT-3' |
| Antisense:5'-TGTGTGCAGTCCCAAAAGCA-3' |
| Powders Prepared with Different Process Control Agents | Crystallite Size (nm) | Lattice Constant (Å) | Strain (%) |
| None | 11.8 | 3.1636 | 0.688 |
| Ethanol | 24.2 | 3.1549 | 0.483 |
| Stearic acid | 14.7 | 3.1648 | 0.590 |
| Region | States | Frequency | IAQ Practice Indexb | Schools with index ≥ 70 (%) |
| 1 | Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont | 25 | 71.8 | 64 |
| 2 | New Jersey, New York, Puerto Rico,c U.S. Virgin Islandsc | 28 | 71.9 | 57 |
| 3 | Delaware, Maryland, Pennsylvania, Virginia, West Virginia, District of Columbia | 21 | 77.0 | 71 |
| 4 | Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee | 46 | 64.4 | 41 |
| 5 | Illinois, Indiana, Michigan, Minnesota, Ohio, Wisconsin | 87 | 73.0 | 60 |
| 6 | Arkansas, Louisiana, New Mexico, Oklahoma, Texas | 40 | 70.7 | 60 |
| 7 | Iowa, Kansas, Missouri, Nebraska | 15 | 66.7 | 53 |
| 8 | Colorado, Montana, North Dakota, South Dakota, Utah, Wyoming | 13 | 66.3 | 54 |
| 9 | Arizona, California, Hawaii, Nevada, Pacific Islands,c Tribal Nations subject to U.S. law | 27 | 70.1 | 56 |
| 10 | Alaska, Idaho, Oregon, Washington | 16 | 77.1 | 81 |
| Zone | 2008 NBS* Est. U5sfrom 2002 Census | U5s Registered | LLINs delivered† | LLINS issued‡ (%) | U5s not receiving an LLIN** |
| Tanga | 288,185 | N/A†† | 402,448 | 380,458(94.5) | 0‡‡ |
| South | 333,571 | 403,594 | 469,644 | 435,112 (92.6) | 3,456 |
| Lake | 1,457,439 | 1,925,372 | 2,107,000 | 2,047,889 (97.2) | 65,618 |
| West Lake | 1,609,747 | 1,691,854 | 1,745,682 | 1,662,302 (95.2) | 155,523 |
| South West | 782,563 | 766,291 | 793,696 | 789,586 (99.4) | 68,859 |
| Southern Highlands | 464,119 | 514,414 | 562,112 | 554,433 (98.6) | 22,922 |
| Central | 844,157 | 984,985 | 1,065,748 | 1,052,750 (98.7) | 92,397 |
| Northern | 476,131 | 540,785 | 586,720 | 567,348 (96.6) | 43,190 |
| Coast | 966,171 | 1,153,715 | 1,311,987 | 1,263,560 (96.3) | N/A |
| Total | 7,222,083 | 7.981,010 | 9,045,037 | 8,753,438 (96.7) | 451,965 |
| County | Pre-treatment | Post-treatment | ||
| Number of schools | Number of children | Number of schools | Number of children | |
| Bomet | 1 | 108 | 1 | 103 |
| Bungoma | 1 | 108 | 1 | 105 |
| Busia | 2 | 214 | 2 | 210 |
| Homa Bay | 1 | 108 | 1 | 102 |
| Kakamega | 2 | 212 | 2 | 213 |
| Kisii | 1 | 105 | 1 | 103 |
| Kisumu | 3 | 312 | 3 | 313 |
| Kwale | 3 | 317 | 3 | 316 |
| Mombasa | 1 | 98 | 1 | 108 |
| Narok | 2 | 215 | 2 | 214 |
| Taita Taveta | 1 | 102 | 1 | 91 |
| Overall | 18 | 1899 | 18 | 1878 |
| Patient 1 | Patient 2 | Patient 3 | |
| Origin | Dominican Republic | Haiti | Haiti |
| Age (years) | 25 | 52 | 41 |
| Sex (W/M) | W | W | M |
| Date of diagnosis (and onset of symptoms) | December 2014 | January 2015 | December 2014 |
| Time in Guadeloupe | 1 year | 10 years | Several years |
| Initial symptoms | Generalized seizure | Generalized seizure | Ischemic stroke and tonic-clonic seizuresa |
| Number of colloidal cysts | 1 | 5 | 0 |
| Number of vesicular cysts | 1 | 1 | 0 |
| Number of calcified cerebral cysts | 3 | 9 | 30 |
| T. solium antibodies in serum (ELISA) | Negative | Negative | Negative |
| T. solium antibodies in CSF (EITB) | Negative | Positive | Not done |
| Screening for taeniasis in index case | Negative | Negative | Negative |
| Screening for taeniasis in household | Negative | Negative | Negative |
| Treatment | Albendazole + Steroids + Valproic acid | Albendazole + Praziquantel + Steroids + Levetiracetam | Surgical removala + Albendazole + Steroids + Valproic acid |
| Seizure recurrence in the first 6 months after treatment | Several | Multiple episodes in the first months after tapering steroids | No recurrence |
| Domain | APH | PPH | Eclampsia |
| Initial assessment & diagnosis | Per vaginum examination (34%) | Exploring the uterus for blood clots (39%) | Weight (4%) |
| Swelling on body parts related to severe anemia (8%), blurred vision related to night blindness (1%) | |||
| Diagnosed eclampsia as pre eclampsia or pregnancy induced hypertension (26%) | |||
| First line management | Antibiotic (12%) | Alternate drugs mentioned: | Diazepam (5%) |
| Ergometrine (34%) | |||
| Iron folic acid (11%) | Misoprostol (15%) | Diazepam with MgSO4 (3%) | |
| Misoprostol and ergometrine (<1%) | Unindicated drugs mentioned: | Antibiotics (5%) | |
| Injection Tranexamic acid (1%), | Anti hypertensive (6%) | ||
| Antibiotics (21%) | |||
| Ironfolicacid (11%) Calcium and multivitamin (9%) | |||
| Vaginal packing (1%) | |||
| Advice | Dietary advice and regular ANC (12%) | Dietary advice and regular ANC (20%) | Regular ANC (3% ) |
| Perceived APH is caused by sexual activity or lifting weight; hence advised bed rest | New born care, Early breast feeding | ||
| And Family planning (1%) |
| Pt nr. | Max IAP | Macroscopy | Microscopy | Outcome |
| 1 | 22 | Autopsy findings: Focal ischemia on serosal and mucosal side of small bowel | Mucosa of jejunum and colon almost completely disappeared | Died 2 days after admission to the ICU |
| 7 | 24 | Full necrosis of the sigmoid | Transmural ischemic necrosis sigmoid | Died 67 days after decompression due to bleeding complications caused by pancreatitis |
| 8 | 26 | Dubious signs of ischemia of terminal ileum | Segmental chronic and acute inflammation with perforation; concordant with ischemic enteritis | Died 40 days after decompression due to sepsis and MOF |
| 9 | 27 | Firm necrosis of the jejunum | Severe transmural ischemic enteritis | Discharge to ward 134 days after decompression |
| 10 | 27 | Only necrotic remains of the sigmoid colon | Transmural necrosis | Died 13 days after decompression due to sepsis and MOF |
| 11 | 29 | Full black necrosis of small and large intestine | Not available | Died several hours after decompression, after withdrawal of treatment |
| 12 | 32 | Marbled aspect of left liver lobe | Not available | Died 47 days after decompression, due to sepsis and MOF |
| 13 | 32 | Patchy and full ischemia of the terminal ileum; full ischemia of cecum and left colon | ischemia ileum, cecum and left colon | Discharge to ward 16 days after decompression |
| Parameters | Score | |
| Acuteness of the first cry | Absent | 0 |
| Present | 2 | |
| Burst rhythmicity | Absent | 0 |
| Present | 2 | |
| Constancy of the crying intensity | Absent | 0 |
| Intermediate | 1 | |
| Constant | 2 |
| Part 1 (n = 104) | Part 2 (n = 56) | |
| Breed [number (%) of cats] | ||
| Domestic shorthair cat | 85 (81.6) | 46 (82.1) |
| Maine coon | 6 (5.7) | 3 (5.4) |
| Norwegian | 4 (3.8) | 3 (5.4) |
| Oriental | 3 (2.9) | 2 (3.6) |
| Chartreux | 2 (2.8) | 1 (1.8) |
| Birman | 1 (0.9) | 1 (1.8) |
| Siamese | 1 (0.9) | – |
| Turkish Angora Cat | 1 (0.9) | – |
| British Shorthair | 1 (0.9) | – |
| Gender [number (%) of cats] | ||
| Sexually intact female | – | – |
| Spayed female | 40 (38.8) | 21 (37.5) |
| Sexually intact male | 4 (3.8) | 4 (7.1) |
| Castrated male | 60 (57.6) | 31 (55.4) |
| Age (in years) | ||
| Mean age ± SD | 7.26 ± 4.0 | 7.47 ± 4.3 |
| Viral status [number (%) of cats] | ||
| Tested for feline immunodeficiency virus (FIV) | 89/104 (85.4) | 49/56 (87.5) |
| FIV positive | 12/89 (13.5) | 6/49 (12.2) |
| Feline leukemia virus positive | 0/89 (0) | 0/49 (0) |
| Tested for FHV | 80/104 (76.8) | 43/56 (76.8) |
| FHV positive | 14/80 (17.5) | 7/43 (16.3) |
| Feeding Practices | Age of Introduction of Complementary Foods | |
| <17 Weeks n (%) | ≥17 Weeks n (%) | |
| Total | 395 (62.5) | 237 (37.5) |
| Explanations given for introducing solid foods | ||
| Baby hungry | 203 (51.4) | 118 (49.8) |
| Baby old enough | 105 (26.6) | 56 (23.6) |
| Poor baby weight gain | 50 (12.7) | 35 (14.8) |
| Maternal illness | 23 (5.8) | 22 (9.3) |
| Other reason | 14 (3.5) | 6 (2.5) |
| Type of food infant was initially given: | ||
| Baby cereal | 244 (61.7) | 145 (61.2) |
| Pureed or mashed fruit or vegetables | 77 (19.5) | 36 (15.2) |
| Pureed or mashed meat or fish | 33 (8.4) | 12 (5.1) |
| Baby food manufacturers | 27 (6.8) | 25 (10.5) |
| Yoghurt | 5 (1.3) | 11 (4.6) |
| Other food type | 9 (2.3) | 8 (3.4) |
| Was it difficult to introduce solid foods? | ||
| Yes | 298 (75.4) | 115 (48.5) |
| No | 97 (24.6) | 122 (51.5) |
| Explanations given for difficulty in introducing solid foods | ||
| Mother uncertain about weaning | 34 (8.6) | 29 (12.2) |
| Infant would only accept certain solids and not others | 145 (36.7) | 112 (47.3) |
| Infant preferred drinks to food | 166 (42.0) | 87 (36.7) |
| Infant experienced choking or vomiting | 37 (9.3) | 4 (1.7) |
| Other reason | 13 (3.4) | 5 (2.1) |
| Infant took ≥30 min to finish a meal? | ||
| Yes | 144 (36.5) | 56 (23.6) |
| No | 251 (63.5) | 181 (76.4) |
| Meals a day | ||
| 1 | 168 (42.5) | 35 (14.8) |
| 2 | 147 (37.2) | 138 (58.2) |
| 3 or more | 80 (20.3) | 64 (27.0) |
| Was salt added to the infant’s solid food? | ||
| Yes | 123 (31.1) | 143 (60.3) |
| No | 272 (68.9) | 94 (39.7) |
| Was sugar added to the infant’s solid food? | ||
| Yes | 87 (22.0) | 79 (33.3) |
| No | 308 (78.0) | 158 (66.7) |
| Which foods did mothers avoid giving to their infants? | ||
| Any poultry, seafood or other meat | 227 (57.5) | 76 (32.1) |
| Eggs or other dairy products | 104 (26.3) | 37 (15.6) |
| Vegetables (salad) | 387 (98.0) | 188 (79.3) |
| Fruit (fresh) | 338 (85.6) | 201 (84.8) |
| Nuts | 395 (100.0) | 237 (100.0) |
| Honey | 387 (98.0) | 189 (79.7) |
| Processed foods | 312 (79.0) | 175 (73.8) |
| Chocolate or other sweets | 277 (70.1) | 107 (45.1) |
| High salt content foods | 86 (21.8) | 56 (23.6) |
| High sugar content foods | 157 (39.7) | 98 (41.4) |
| High fat content foods | 203 (51.4) | 186 (78.5) |
| Other foods | 47 (11.9) | 36 (15.2) |
| Explanations given for not giving particular foods | ||
| The infant dislikes them | 127 (32.2) | 112 (47.3) |
| Heath reasons (allergies/adverse reactions) | 91 (23.0) | 23 (9.7) |
| Food was not cooked at home | 47 (11.9) | 41 (17.3) |
| Concern about choking | 89 (22.5) | 33 (13.9) |
| Infant is still too young | 25 (6.3) | 19 (8.0) |
| Other reason | 16 (4.1) | 9 (3.8) |
| Right Knee | Left Knee | |||||||
| Before | After | P | Effect size | Before | After | P | Effect size | |
| KIN (n = 16) | 6.9 ± 1.9 (5.0 – 10.0) | 2.3 ± 2.7a (0.0 – 8.0) | 0.0001 | 0.70 | 7.0 ± 2.1 (4.0 – 10.0) | 2.4 ± 2.8a (0.0 – 7.0) | 0.0008 | 0.68 |
| TENS (n = 12) | 8.0 ± 1.5 (6.0 – 10.0) | 2.6 ± 2.9a (0.0 – 7.5) | 0.0001 | 0.76 | 5.6 ± 2.7 (0.0 – 10.0) | 2.3 ± 2.5a (0.0 – 9.0) | 0.004 | 0.53 |
| US (n = 12) | 6.6 ± 3.0 (0.0 – 10.0) | 4.5 ± 3.7a (0.0 – 10.0) | 0.009 | 0.41 | 7.3 ± 2.3 (4.0 – 10.0) | 3.8 ± 3.1 (0.0 – 7.0) | 0.054 | 0.54 |
| Positive keywords | Negative keywords | |
| BTE | mould, be34, map, gp, 92, audio, inf, be52, ref, staff, reqd, be36, contact | fta, reshel, appt, it, nn, nfa, 2001, rev, lacquer, hn, km, imp, review, 2000 |
| ITE | fta, reshel, appt, it, nn, nfa, 2001, rev, lacquer, hn, km, imp, review, 2000, nh, vent, progress, aid, dt, taken | mould, be34, map, gp, 92, audio, inf, be52, ref, staff, reqd, be36, contact, tri, n, order |
| A. Regions from first iteration analyses | ||||||||
| Degree of damage to each ROI | Analysis with Fuzzy images | Analysis with Binary images | ||||||
| Group | Temporal ROI | Frontal ROI | n | Impaired | Not impaired | n | Impaired | Not impaired |
| Frontal (1) | ≤ 25% | ≥ 75% | 68 | 18 | 50 | 77 | 19 | 58 |
| Temporal (2) | ≥ 75% | ≤ 25% | 23 | 10 | 13 | 25 | 11 | 14 |
| Both (3) | ≥ 75% | ≥ 75% | 71 | 48 | 23 | 63 | 45 | 18 |
| Partial (4) | 74%−26% | 74%−26% | 70 | 13 | 57 | 50 | 13 | 37 |
| Neither (5) | ≤ 25% | ≤ 25% | 127 | 9 | 118 | 144 | 10 | 134 |
| B. Regions from second iteration analyses | ||||||||
| Analysis with Fuzzy images | Analysis with Binary images | |||||||
| Degree of damage of Putamen ROI | n | Impaired | Not Impaired | n | Impaired | Not Impaired | ||
| Putamen damaged (> 25%) | 13 | 3 | 10 | 26 | 5 | 21 | ||
| Putamen preserved (≤ 25%) | 114 | 6 | 108 | 118 | 5 | 113 |
| Age | Southern Coastal plain(Yoto) | Central Plateaux(Ogou) | Northern Savannah(Tone) | |||||||
| mo | 2004% | 2005% | RR (95%CI) | 2004% | 2005% | RR (95%CI) | 2004% | 2005% | RR (95%CI) | |
| Hb <8 g/dL | <18 | 23.9 | 24.3 | 1.01 (0.73-1.41) | 35.0 | 16.2 | 0.46 (0.33-0.64) | 38.8 | 31.7 | 0.82 (0.65-1.02) |
| ≥18 | 15.2 | 9.4 | 0.62 (0.44-0.88) | 17.4 | 9.4 | 0.54 (0.37-0.79) | 14.5 | 15.7 | 1.08 (0.78-1.49) | |
| Malarial anaemia | <18 | 15.0 | 19.8 | 1.31 (0.86-2.01) | 23.2 | 8.6 | 0.37 (0.24-0.58) | 28.6 | 28.9 | 1.01 (0.75-1.37) |
| ≥18 | 10.8 | 7.7 | 0.71 (0.48-1.05) | 13.6 | 7.4 | 0.54 (0.33-0.90) | 9.7 | 12.8 | 1.32 (0.89-1.95) | |
| Clinical malaria | <18 | 5.9 | 3.4 | 0.59 (0.27-1.27) | 10.0 | 3.9 | 0.38 (0.19-0.76) | 11.4 | 10.4 | 0.91 (0.62-1.34) |
| ≥18 | 9.5 | 4.9 | 0.51 (0.35-0.75) | 8.9 | 7.3 | 0.83 (0.54-1.28) | 10.7 | 9.4 | 0.89 (0.59-1.33) | |
| Any parasitaemia | <18 | 39.6 | 50.4 | 1.27 (1.02-1.59) | 49.1 | 44.1 | 0.90 (0.75-1.07) | 39.4 | 49.0 | 1.24 (1.05-1.47) |
| ≥18 | 64.1 | 71.3 | 1.11 (1.00-1.24) | 71.1 | 68.1 | 0.96 (0.83-1.11) | 70.7 | 74.5 | 1.05 (0.94-1.19) | |
| High parasitaemia | <18 | 32.2 | 24.8 | 0.77 (0.48-1.24) | 45.5 | 22.2 | 0.49 (0.33-0.71) | 43.2 | 40.1 | 0.93 (0.67-1.28) |
| ≥18 | 30.4 | 26.4 | 0.87 (0.68-1.11) | 36.0 | 28.0 | 0.78 (0.58-1.05) | 31.5 | 36.2 | 1.15 (0.90-1.47) |
| + | − | |
| NEURAL ACTIVITY | ||
| Spontaneous activity | ||
| Electro-physiology | Basta and Ernst (90), Jastreboff and Sasaki (87), and Manabe et al. (91) | Ma et al. (92) |
| Metabolicmarkers | Paul et al. (93) | Wallhausser-Franke et al. (94) |
| Burst firing | Chen and Jastreboff (88) | |
| Auditory-evoked activity | Ma et al. (92) and Sun et al. (95) | |
| NEUROTRANSMISSION | ||
| Excitation | ||
| NMDA | Hu et al. (96) and Hwang et al. (97, 98) | |
| Inhibition | ||
| GABAA | Bauer et al. (99) (GABAA affinity) | Bauer et al. (99) (GABAA binding sites) and Zou and Shang (100) |
| GAD65 | Bauer et al. (99) | |
| GAD67 | Zou and Shang (100) | |
| GlyR | Lu et al. (102) | |
| Serotonin | Liu et al. (101) | Wang et al. (103) |
| GENE EXPRESSION | ||
| Arg3.1/arc | Hu et al. (96) | |
| Egr-1 | Hu et al. (96) | |
| c-FOS | Wu et al. (104) | Mahlke and Wallhausser-Franke (105) |
| INFLAMMATORY MARKERS | ||
| COX-2 | Hwang et al. (97) | |
| IL1β | Hwang et al. (98, 106) | |
| TNFα | Hwang et al. (98, 106) |
| Baseline | HD | H60 | S60 | ||||
| PEG-albumin | HES | PEG-albumin | HES | PEG-albumin | HES | ||
| Hematocrit (%) | 46.4 ± 1.4 | 26.4 ± 0.9*b | 31.6 ± 1.1* | 18.2 ± 0.4*† | - | 18.1 ± 0.5*† | - |
| PaO2 (mmHg) | 58.9 ± 8.7 | 59.5 ± 11.3b | 69.6 ± 7.0 | 100.0 ± 12.8*† | - | 121.0 ± 14.3*†‡ | - |
| PaCO2 (mmHg) | 59.1 ± 10.1 | 59.7 ± 5.0 | 51.1 ± 5.3 | 45.3 ± 12.9 | - | 36.1 ± 8.1*† | - |
| pH arterial | 7.388 ± 0.030 | 7.387 ± 0.036 | 7.349 ± 0.025 | 7.251 ± 0.076*† | - | 7.109 ± 0.047*†‡ | - |
| BE (mmol/l) | 5.5 ± 1.9 | 5.3 ± 2.3 | 1.8 ± 1.8* | -8.2 ± 2.8*† | - | -18.0 ± 4.7*† | - |
| N = 134 | (%) | |
| Food reactions | ||
| Gastro-intestinal symptoms | 67 | (50) |
| OAS – Oral Allergy Syndrome | 63 | (47) |
| Difficulty breathing | 53 | (40) |
| Skin symptoms | 50 | (37) |
| Anaphylaxis | 20 | (15) |
| Eye-nose symptoms | 19 | (14) |
| Food reactions during the last 12 months | 60 | (45) |
| Allergic diseases | 100 | (75) |
| Rhino conjunctivitis | 69 | (52) |
| Eczema | 64 | (48) |
| Asthma | 44 | (33) |
| Additional allergy/hypersensitivity | 95 | (71) |
| Additional family member with food hypersensitivity | 78 | (58) |
| Parent(s) | 49 | (37) |
| Sibling(s) | 45 | (34) |
| Cases (%) | Controls (%) | ||
| Gender | |||
| Male | 463 (58%) | 423 (53%) | |
| Female | 334 (42%) | 370 (47%) | |
| Age group (years) | |||
| 20-49 | 150 (19%) | 208 (26%) | |
| 50-59 | 194 (24%) | 169 (21%) | |
| 60-69 | 214 (27%) | 206 (26%) | |
| 70+ | 239 (30%) | 210 (26%) | |
| Ethnicity | |||
| Caucasian | 625 (78%) | 613 (77%) | |
| Asian | 80 (10%) | 90 (11%) | |
| South Asian | 29 (4%) | 37 (5%) | |
| Mixed/Other | 36 (5%) | 34 (4%) | |
| Unknown/Refused | 27 (3%) | 19 (2%) | |
| Pathology | |||
| B-cell lymphomas | |||
| DLBCL | 210 (26%) | - | |
| FL1 | 138 (17%) | - | |
| FL2/FL3 | 78 (10%) | - | |
| MZL/MALT | 92 (12%) | - | |
| MCL | 47 (6%) | - | |
| SLL/CLL | 43 (5%) | - | |
| LPL | 42 (5%) | - | |
| MISC BCL | 71 (9%) | - | |
| T-cell lymphomas | |||
| MF | 40 (5%) | - | |
| PTCL | 29 (4%) | - | |
| MISC TCL | 7 (1%) | - | |
| Total | 797 (100%) | 793 (100%) |
| Number of airlines | |
| Pre-boarding arrangements | |
| • Request a food “buffer zone” | 5 |
| • No “buffer zone” | 3 |
| • Request “allergen-free meal” | 1 |
| • Pre-boarding to wipe down seats and table trays | Yes 4 |
| No 1 | |
| • Buffer zone for fragrance sensitivity | 2 |
| • Announcements to inform customers there is a peanut or tree-nut allergic passenger on board or that peanut products will not be served | Yes 4 |
| No 7 | |
| Free snack policy on peanut/nut/sesame | |
| • Serving peanuts | Yes 2 |
| No 11 | |
| • Serving nuts and sesameaw | Yes 8 |
| No 1 | |
| • First class warmed nuts | 3 |
| Gluten-free meals | Yes 11 |
| No 1 | |
| Lactose-free meals | 1 |
| Shellfish served | Yes 4 |
| No 3 | |
| Fish served | Yes 6 |
| No 1 | |
| Buffer zones for passengers allergic to pets | 5 |
| Risk category | Criteria | Age to commence screening | Screening Test | Screening frequency (years) |
| Average-risk(Age-only) | Age 50–74 years | 50 | FOBT | 2 |
| Sigmoidoscopy | 5 | |||
| Colonoscopy | 10 | |||
| Moderate-risk(FamilyHx) | Family history of CRC in 1 first-degree relative ≥60 years | 40 | FOBT | 2 |
| Sigmoidoscopy | 5 | |||
| Colonoscopy | 10 | |||
| Family history of CRC in 1 first-degree relative < 60 years | 40b | Colonoscopy | 5 | |
| Family history of CRC in 2 or more relatives | ||||
| High-risk (PersonalHx) | Personal history of a bowel conditionc | 40d | Colonoscopy | 5 |
| Highest-risk (Family/PersonalHx) | Personal history of a bowel condition and family history of CRC |
| Targeted Gene | Primer | Sequence (5′–3′) |
| ALDOA | Forward | ATGCCCTACCAATATCCAGC |
| Reverse | GACAGCCCATCCAACCCT | |
| CDC20 | Forward | GGCACCAGTGATCGACACATTCGCAT |
| Reverse | GCCATAGCCTCAGGGTCTCATCTGCT | |
| CCNB2 | Forward | GCGTTGGCATTATGGATCG |
| Reverse | TCTTCCGGGAAACTGGCTG | |
| CDC45 | Forward | TGGACTGCACACGGATCT |
| Reverse | AACCTGGCTGCGGTATAG | |
| TK1 | Forward | TGGCTGTCATAGGCATCGAC |
| Reverse | CCAGTGCAGCCACAATTACG | |
| β-Actin | Forward | AGCGAGCATCCCCCAAAGTT |
| Reverse | GGGCACGAAGGCTCATCATT |
| Resistance pattern to the NARMS antimicrobial panel | % of isolates with resistance profile (no.) | Plasmid profile groups detected (no.)a | Species of isolates with plasmids (no.) | PFGE patterns |
| STR, FIS, TET, SXT | 33% (14) | II, X(3), VIII | S. sonnei (4), S. flexneri | III, V, VI, IX, X |
| AMP, STR, FIS, TET, SXT | 14% (6) | II(4), VI | S. sonnei (5) | I, IV, VII, VIII, XI, XII |
| AMP, CHL, STR, FIS, TET | 10% (4) | none | none | |
| AMP, CHL, TET | 7% (3) | VII | S. flexneri 3a | XX, XXIII, XV |
| AMP, CHL, STR, FIS, TET, SXT | 7% (3) | IV(2), V | S. flexneri 3a (2), S. sonnei | |
| TET | 5% (2) | I, IV | S. flexneri 1b (2) | XIX |
| AMP, CHL, FIS, TET | 5% (2) | IV(2) | S. flexneri 2a (2) | XVII |
| CHL, STR, FIS, TET, SXT | 5% (2) | V(2) | S. flexneri 1c (2) | XV |
| AMP, CHL, FIS, TET, SXT | 2% (1) | IV | S. flexneri 2a | XVIII |
| AMP, KAN, STR, FIS | 2% (1) | IV | S. sonnei | XIII |
| CHL, FIS, TET, SXT | 2% (1) | III | S. flexneri Y var. | XXIV |
| AMP, CHL, STR, TET | 2% (1) | IX | S. flexneri 1b | XIV |
| AMP, STR, FIS, SXT | 2% (1) | IX | S. sonnei | |
| AMC, AMP, GEN, STR, FIS | 2% (1) | IV | S. flexneri |
| Disability in 2012 (%) | |||||
| All n (%) | No FOF in 2012 | Having FOF in 2012 | |||
| No FOF in 2010 | Having FOF in 2010 | No FOF in 2010 | Having FOF in 2010 | ||
| Prevalence of Disability in 2012†† | 21.2 | 7.1 | 21.1 | 24.7 | 49.0 |
| Age group | ** | * | ** | ** | |
| 70–74 | 7.6 | 2.9 | 8.6 | 8.9 | 28.9 |
| 75–79 | 18.3 | 6.9 | 27.8 | 23.4 | 38.4 |
| 80–84 | 32.9 | 14.3 | 19.1 | 36.2 | 53.8 |
| 85 and over | 56.0 | 30.0 | 42.9 | 58.6 | 73.1 |
| Marital status and living arrangement | ** | * | * | ** | |
| No spouse & Living alone | 17.1 | 4.8 | 9.2 | 26.1 | 37.5 |
| No spouse & living with others | 35.1 | 13.6 | 37.7 | 33.9 | 63.0 |
| Living with spouse only | 14.0 | 4.3 | 18.8 | 16.7 | 42.5 |
| Living with spouse & others | 16.2 | 7.5 | 16.0 | 17.4 | 46.2 |
| Education | ** | ||||
| Elementary school or less | 22.8 | 7.8 | 21.7 | 25.9 | 50.5 |
| Middle school | 11.1 | 3.1 | 22.2 | 20.0 | 28.6 |
| High school or more | 8.5 | 3.8 | 0 | 9.1 | 33.3 |
| Having disability in 2010 †† | ** | ** | ** | ** | ** |
| No | 11.4 | 4.6 | 13.1 | 15.2 | 28.4 |
| Yes | 64.4 | 33.8 | 47.8 | 74.4 | 81.3 |
| Having fall history in 2010 | |||||
| No | 20.4 | 6.9 | 20.1 | 25.0 | 49.2 |
| Yes | 38.0 | 22.2 | 33.3 | 14.3 | 47.5 |
| Number of chronic disease in 2010 | |||||
| None | 21.2 | 6.9 | 22.0 | 26.7 | 50.9 |
| One or more | 21.2 | 8.6 | 16.1 | 17.3 | 41.9 |
| Cognitive function in 2010 †† | |||||
| Normal (K-MMSE ≥ 24) | 9.4 ** | 6.2 | 2.9 | 9.6 | 32.1 |
| Mild impairment (18 ≤ K-MMSE ≤ 23) | 15.4 | 4.3 | 13.8 | 20.8 | 36.5 |
| Severe impairment (K-MMSE ≤ 17) | 38.1 | 12.5 | 35.7 | 44.6 | 61.8 |
| Visual function in 2010 † | ** | * | |||
| Good | 16.7 | 7.2 | 16.2 | 17.4 | 49.4 |
| Bad | 28.1 | 6.9 | 26.0 | 35.4 | 48.7 |
| Auditory function in 2010 | * | ** | |||
| Good | 17.4 | 6.2 | 17.9 | 21.8 | 43.4 |
| Bad | 43.4 | 18.5 | 32.6 | 39.0 | 65.6 |
| Fear-induce activity avoidance †† | ** | * | * | ||
| No | 11.3 | 6.5 | 19.6 | 13.0 | 34.8 |
| Yes | 34.1 | 9.4 | 25.0 | 29.3 | 52.4 |
| Frequency of meeting friends | ** | * | * | ** | |
| Less than several times a year or none | 41.4 | 13.0 | 36.4 | 40.5 | 66.3 |
| Once or twice a month | 21.2 | 6.7 | 15.8 | 39.1 | 57.6 |
| Everyday | 16.5 | 6.4 | 16.9 | 19.1 | 40.3 |
| Depressive symptoms †† | ** | * | * | ** | |
| No | 12.6 | 6.2 | 14.7 | 15.9 | 33.3 |
| Yes (CES-D10 score ≥ 10) | 34.6 | 9.7 | 30.1 | 34.2 | 59.6 |
| Putative fox feces | Locations | |||
| Number of samples | Positive samples (%) | Number of locations | Positive locations (%) | |
| Anatolia | 186 | 7 (3.8) | 59 | 3 (5.1) |
| Thrace | 219 | 1 (0.5) | 114 | 1 (0.9) |
| Total | 405 | 8 (1.9) | 173 | 4 (2.3) |
| Characteristics | No. of patients | Expression of CIP2A | Pvalue | |
| Low, n (%) | High, n (%) | |||
| Age | ||||
| ≤45 | 130 | 48 (50) | 82 (45) | 0.39 |
| >45 | 150 | 48 (50) | 102 (55) | |
| Sex | ||||
| Male | 208 | 72 (75) | 136 (74) | 0.84 |
| Female | 72 | 24 (25) | 48 (26) | |
| WHO type | ||||
| I + II | 10 | 2 (2) | 8 (6) | 0.50 |
| III | 270 | 94 (98) | 176 (94) | |
| VCA-IgA | ||||
| < 1:80 | 41 | 16 (17) | 25 (14) | 0.49 |
| ≥ 1:80 | 239 | 80 (83) | 159 (86) | |
| EA-IgA | ||||
| < 1:10 | 68 | 24 (25) | 44 (24) | 0.84 |
| ≥ 1:10 | 212 | 72 (75) | 140 (76) | |
| T Stage | ||||
| T1-T2 | 137 | 55 (57) | 82 (45) | 0.04 |
| T3-T4 | 143 | 41 (43) | 102 (55) | |
| N Stage | ||||
| N0-N1 | 173 | 61 (64) | 112 (61) | 0.66 |
| N2-N3 | 107 | 35 (36) | 72 (39) | |
| TNM Stage | ||||
| I-II | 86 | 40 (42) | 46 (25) | <0.01 |
| III-IV | 194 | 56 (58) | 138 (75) | |
| Locoregional failure | ||||
| Yes | 38 | 11 (11) | 27 (15) | 0.46 |
| No | 242 | 85 (89) | 157 (85) | |
| Distant metastasis | ||||
| Yes | 63 | 11 (11) | 52 (28) | <0.01 |
| No | 217 | 85 (89) | 132 (72) | |
| Death | ||||
| Yes | 67 | 14 (15) | 53 (29) | 0.01 |
| No | 213 | 82 (85) | 131 (71) |
| Early differentiation | Intermediate differentiation | Terminal differentiation | |
| Phenotypic markers | |||
| CD28 | ++ | +/− | – |
| CD27 | ++ | +/− | – |
| CD45RA | ++ | +/− | +/− |
| CCR7 | ++ | + | – |
| CD62L | ++ | + | – |
| CD57 | – | +/− | ++ |
| KLRG1 | – | +/− | ++ |
| Other NKR (KIR, NKG2, and CD56) | – | +/− | ++ |
| Functional features | |||
| Proliferation | ++ | + | – |
| Telomerase activity | ++ | + | – |
| Telomeres | +++ | ++ | + |
| Cytotoxicity | – | + | ++ |
| Cytokine secretion (TNF-α, IFN-γ) | – | + | ++ |
| Signaling pathways | |||
| TCR signaling | + | ++ | +/− |
| IL-2 signaling | + | ++ | +/− |
| Pi3K–AKT–mTOR signaling | + | ++ | +/− |
| p38MAPK activation | – | – | + |
| Amendment | Concentration | mNa | Effectiveness |
| Aldrich Humic Acid | 1 mg C L-1 | 0.7(0) | LS |
| 5 mg C L-1 | 0.3(6) | LS | |
| 10 mg C L-1 | 0.3(7) | LS | |
| IHSS Humic Acid | 1 mg C L-1 | 0.8(4) | LS |
| 5 mg C L-1 | 0.1(7) | LS | |
| 10 mg C L-1 | 0.1(9) | LS | |
| IHSS Fulvic Acid | 1 mg C L-1 | 0.7(7) | LS |
| 5 mg C L-1 | 0.1(9) | LS | |
| 10 mg C L-1 | 0.1(7) | LS | |
| MCC water | ∼ 5 mg C L-1* | <0.1 | NR |
| SR lake water | ∼ 10 mg C L-1* | 0.8(6) | LS |
| Variable | HBV | % | Odds ratio | p |
| Year | Positive/Total | (95% CI) | ||
| 2001* | 52/552 | 9.42 | 3.31 (2.40-4.57) | < 0.01 |
| 2010 | 269/8,840 | 3.04 |
| Chromosome | AntiSMASH | SMURF | Unique NP |
| I | 1 | 1 | 1 |
| II | 3 | 1 | 4 |
| III | 4 | 4 | 5 |
| IV | 3 | 1 | 4 |
| V | 6 | 6 | 7 |
| VI | 8 | 6 | 8 |
| VII | 7 | 6 | 7 |
| Total | 32 | 25 | 36 |
| n (%) | |
| Primary clinical composite diagnoses | |
| Anterior cruciate ligament injury | 8 (5) |
| Meniscal injury | 36 (20) |
| Patellofemoral Pain Syndrome | 45 (25) |
| Osteoarthritis | 79 (44) |
| Other knee diagnoses | 11 (6) |
| Imaging findings and diagnoses | |
| Osteoarthritis | 96 (56) |
| K-L Grade 1 | 14 (15) |
| K-L Grade 2 | 36 (38) |
| K-L Grade 3 | 19 (20) |
| K-L Grade 4 | 13 (14) |
| Meniscal tears (n) | 54 (32) |
| Medial meniscus | 49 (91) |
| Lateral meniscus | 8 (15) |
| Anterior cruciate ligament tears | 16 (9) |
| Complete | 6 (37) |
| Partial | 8 (50) |
| Unclear | 2 (13) |
| Posterior cruciate ligament tear | 1 (1) |
| Soleus tear | 1 (1) |
| Hamstring tendinopathy | 2 (1) |
| Medial collateral ligament tear | 1 (1) |
| 0d | 3d | 6d | 9d | 12d | 15d | 18d | 21d | 24d | 27d | 30d | 33d | 36d | 39d | 42d | 45d | 48d | 51d | 54d | 57d | 60d | 63d | ≥ 66d | |
| # of CTGR-SPs | 214 | 211 | 221 | 194 | 154 | 135 | 131 | 127 | 125 | 128 | 125 | 127 | 136 | 157 | 157 | 163 | 163 | 163 | 163 | 187 | 190 | 198 | 217 |
| # of longest CTGR-SPs | 28 | 25 | 25 | 82 | 37 | 17 | 17 | 14 | 10 | 13 | 13 | 7 | 10 | 157 | 157 | 163 | 163 | 163 | 163 | 187 | 190 | 198 | 217 |
| Maximal length of CTGR-SPs | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| # of genes in CTGR-SPs | 136 | 134 | 136 | 134 | 127 | 124 | 123 | 121 | 120 | 121 | 119 | 121 | 125 | 132 | 132 | 132 | 132 | 132 | 132 | 136 | 136 | 136 | 136 |
| # of genes in longest CTGR-SPs | 3 | 3 | 3 | 15 | 10 | 9 | 9 | 9 | 7 | 8 | 5 | 5 | 4 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 |
| # of gene pairs in lonest CTGR-SPs | 21 | 19 | 19 | 59 | 26 | 16 | 16 | 14 | 10 | 12 | 10 | 10 | 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| -Log(p-value)†† | 1.26 | 1.37 | 1.37 | 0.70 | 0.00 | 0.00 | 0.00 | 0.00 | 0.86 | 0.86 | 0.65 | 0.53 | 0.40 | - | - | - | - | - | - | - | - | - | - |
| Part of Intestine | Control group | Pomegranate treated group | Sodium.butyrate treated group | |||
| Non-everted (μg) | Everted (μg) | Non-everted (μg) | Everted (μg) | Non-everted (μg) | Everted (μg) | |
| Duodenum | 12.4±0.14 | 13.1±0.2 | 7.07± 1.0 | 12.29±0 .7 | 11.9±1.0 † | 15.5±0.3 |
| Jejunum | 13.3±0.66 | 15.2±0.2 | 8.96±0 .32 | 11.87±0.3 | 13.4±0 .4† | 14.3±0.3 |
| Ileum | 9.97±0.77 | 17.1±0.3 | 7.97±0.05 | 14.82 ±0.4 | 10.3±0.8 | 16.8±0.8† |
| Colon | 9.57±0.48 | 14.0±0.2 | 6.85±0.7 | 9.89±0.1 | 9.7±1.2† | 14.5±0.3† |
| Discharged | Expired | |
| 32 | 18 | |
| Tracheostomy | 26.5 | 23.5 |
| 1.141 | 1.30 | |
| 21 | 29 | |
| Non Tracheostomy | 26.5 | 23.5 |
| 1.141 | 1.30 |
| BRCA1 | BRCA2 | Non-BRCA1/2 | |
| All males in kConFab registry | 429 | 339 | 19137 |
| Breast Cancers | 5 (1.2%) | 35 (10.3%) | 78 (0.4%) |
| Pathology Available | 3 | 25 | 32 |
| Patients with HPA | Gender | Age | Mechanism of trauma | Liver injury grade* | Symptoms of HPA | Blood transfusion |
| 1 | Female | 25 | Blunt | 2 | No | No |
| 2 | Male | 20 | Blunt | 2 | Yes | Yes |
| 3 | Male | 45 | Blunt | 2 | No | No |
| 4 | Male | 9 | Blunt | 3 | No | No |
| 5 | Male | 30 | Blunt | 3 | Yes | Yes |
| 6 | Female | 42 | Blunt | 4 | No | No |
| 7 | Male | 42 | Blunt | 4 | No | No |
| Age groups of Males/females | Quantity of interviewees |
| 50-60 (10 males) | 10 |
| 63-69 (20 males/5 females) | 25 |
| 70-75 (10 male hakims/7 females) | 17 |
| 75-80 (8 female) | 8 |
| Gene a | Region | Size | Inc b | AT% | AT-Skew c | GC-Skew | Start Codon | Stop Codon | Anticodon |
| cox1 | 1–1539 | 1539 | 1 | 64.39 | −0.322 | 0.263 | ATG | TAA | - |
| trnL2 | 1542–1606 | 65 | 2 | 70.77 | −0.087 | 0.474 | - | - | TAA |
| cox2 | 1607–2270 | 664 | 0 | 68.67 | −0.197 | 0.202 | ATT | T- e | - |
| trnK | 2271–2340 | 70 | 0 | 71.43 | 0.000 | −0.100 | - | - | CTT |
| trnD | 2347–2408 | 62 | 6 | 66.13 | −0.171 | 0.333 | - | - | GTC |
| atp8 | 2418–2564 | 147 | 9 | 62.59 | −0.217 | 0.273 | ATA | TAA | - |
| atp6 | 2558–3208 | 651 | −7 | 71.27 | −0.388 | 0.241 | ATT | TAG | - |
| trnE | 3233–3293 | 61 | 24 | 72.13 | 0.000 | 0.059 | - | - | TTC |
| trnF | 3301–3363 | 63 | 7 | 76.19 | 0.292 | 0.067 | - | - | GAA |
| nad5 | 3364–5023 | 1660 | 0 | 73.13 | 0.137 | −0.166 | ATA | T- | - |
| trnH | 5024–5084 | 61 | 0 | 81.97 | 0.040 | 0.455 | - | - | GTG |
| nad4 | 5086–6366 | 1281 | 1 | 69.95 | −0.007 | −0.179 | ATA | TAG | - |
| nad4L | 6363–6659 | 297 | −4 | 76.77 | −0.018 | −0.246 | ATG | TAA | - |
| trnT | 6661–6724 | 64 | 1 | 76.56 | −0.102 | 0.333 | - | - | TGT |
| trnP | 6723–6784 | 62 | −2 | 72.58 | 0.111 | −0.059 | - | - | TGG |
| nad6 | 6816–7250 | 435 | 31 | 70.57 | −0.270 | 0.328 | ATA | TAA | - |
| cob | 7250–8383 | 1134 | −1 | 64.90 | −0.351 | 0.186 | ATG | TAA | - |
| trnS2 | 8384–8439 | 56 | 0 | 80.36 | −0.067 | 0.273 | - | - | TGA |
| nad1 | 8450–9359 | 910 | 10 | 72.86 | 0.005 | −0.198 | ATT | T- | - |
| trnL1 | 9360–9422 | 63 | 0 | 84.13 | 0.132 | 0.200 | - | - | TAG |
| rrnL | 9423–10612 | 1190 | 0 | 77.23 | 0.134 | −0.055 | - | - | - |
| rrnS | 10707–11435 | 729 | 94 | 75.99 | 0.022 | 0.074 | - | - | - |
| trnN | 11483–11548 | 66 | 47 | 78.79 | 0.115 | 0.143 | - | - | ATT |
| trnQ | 11553–11623 | 71 | 4 | 87.32 | 0.000 | −0.111 | - | - | TTG |
| trnV | 11617–11680 | 64 | −7 | 73.44 | −0.021 | 0.059 | - | - | TAC |
| trnR | 11678–11742 | 65 | −3 | 73.85 | −0.042 | 0.059 | - | - | TCG |
| trnA | 11744–11805 | 62 | 1 | 75.81 | −0.021 | 0.200 | - | - | TGC |
| nad3 | 11806–12159 | 354 | 0 | 72.60 | −0.276 | 0.052 | ATT | TAA | - |
| trnG | 12161–12222 | 63 | 1 | 82.54 | −0.038 | 0.273 | - | - | TCC |
| cox3 | 12223–13009 | 786 | 0 | 66.92 | −0.198 | 0.115 | ATG | TAA | - |
| trnS1 | 13025–13086 | 62 | 15 | 61.29 | −0.263 | 0.083 | - | - | TCT |
| CR d | 13087–13961 | 875 | 0 | 66.86 | −0.050 | 0.117 | - | - | - |
| trnM | 13962–14028 | 67 | 0 | 77.61 | 0.077 | −0.067 | - | - | CAT |
| nad2 | 14029–15003 | 975 | 0 | 68.72 | −0.287 | 0.279 | ATA | TAA | - |
| trnW | 15002–15064 | 63 | −2 | 82.54 | 0.077 | 0.091 | - | - | TCA |
| trnY | 15063–15124 | 60 | −2 | 86.67 | 0.154 | 0.500 | - | - | GTA |
| trnC | 15125–15187 | 63 | 0 | 92.06 | 0.138 | 0.200 | - | - | GCA |
| Branch and Terminal Node Number and Description | N | AT% | Mean Distance | |
| Node | Suburban branch | |||
| 1. | Front porch > 0.83, driveways < 0.83, sidewalks > 0.67 | 136 | 7 4,8,9,11,12 | 1366.45 2,4–12 |
| 2. | Blank walls > 0.26, front porch < 0.83, driveways < 0.83, sidewalks > 0.67 | 39 | 23 8,9,11,12 | 688.55 1,4,5,11,12 |
| 3. | Blank walls < 0.26, front porch < 0.83, driveways < 0.83, sidewalks > 0.67 | 8 | 75 | 1245.7412 |
| Urban branch | ||||
| 4. | Zebra crosswalks < 0.03, driveways > 0.83, sidewalks > 0.67 | 137 | 23 1,8,9,11,12 | 1123.83 1,2,6–12 |
| 5. | Traffic/pedestrian signals > 0.44, zebra crosswalks > 0.03, driveways > 0.83, sidewalks > 0.67 | 60 | 25 8,9,11,12 | 1105.56 1,2,6–12 |
| 6. | Curb cut < 0.91, decorative sidewalks > 0.21, zebra crosswalks > 0.03, driveways > 0.83, sidewalks > 0.67 | 31 | 29 9,11,12 | 464.75 1,4,5,7,8,10,12 |
| 7. | Sidewalk buffer > 0.93, curb cut > 0.91, decorative sidewalks > 0.21, traffic/pedestrian signals < 0.44, zebra crosswalks > 0.03, driveways > 0.83, sidewalks > 0.67 | 24 | 42 1,2 | 739.21 1,4–6,9,11,12 |
| 8. | Sidewalk buffer < 0.93, curb cut > 0.91, decorative sidewalks > 0.21, traffic/pedestrian signals < 0.44, zebra crosswalks > 0.03, driveways > 0.83, sidewalks > 0.67 | 14 | 79 1,2,4,5 | 739.6 1,4–6,9,11,12 |
| 9. | Decorative sidewalks < 0.21, traffic/pedestrian signals < 0.44, zebra crosswalks > 0.03, driveways > 0.83, sidewalks > 0.67 | 26 | 77 1,2,4–6 | 401.25 1,4,5,7,8,10,12 |
| Alley branch | ||||
| 10. | Crosswalks < 0.14, convenient to cross segment < 0.15, sidewalks > 0.67 | 18 | 39 1,2 | 774.1 1,4–6,9,11,12 |
| 11. | Crosswalks > 0.14, convenient to cross segment < 0.15, sidewalks > 0.67 | 18 | 78 1,2,4–6 | 297.85 1,2,4,5,7,8,10 |
| 12. | Convenient to cross segment > 0.15, sidewalks < 0.67 | 25 | 100 4,8,9,11,12 | 137.18 1–10 |
| Number (%) of patients | |||||
| with PE (N = 107) | without PE (N = 7175) | total (N = 7282) | P* | ||
| Metabolic syndrome | yes | 26 (2.7) | 932 (97.3) | 958 | 0.001 |
| no | 81 (1.3) | 6243 (98.7) | 6324 | ||
| Number of metabolic syndrome components | 0 | 16 (0.85) | 1872 (99.15) | 1888 | <0.003 |
| 1 | 31 (1.24) | 2469 (98.76) | 2500 | ||
| 2 | 34 (1.76) | 1902 (98.24) | 1936 | ||
| 3 | 21 (2.64) | 775 (97.36) | 796 | ||
| 4 | 5 (3.09) | 157 (96.91) | 162 | ||
| Individual components of metabolic syndrome | |||||
| body mass index | <30 kg/m2 | 38 (0.9) | 3966 (99.1) | 4004 | <0.001 |
| ≥30 kg/m2 | 69 (2.1) | 3209 (97.9) | 3278 | ||
| dyslipidemia | 26 (2.7) | 932 (97.3) | 958 | 0.169 | |
| hypertension | 68 (1.8) | 3806 (98.2) | 3874 | 0.032 | |
| dysglycemia | 19 (2.1) | 867 (97.9) | 886 | 0.099 |
| # Gene ID Gene Description |
| AKAP11 A-kinase anchor protein 11 2 |
| AKR1A1 alcohol dehydrogenase 3 |
| ATP5O ATP synthase subunit O, mitochondrial precursor 4 |
| C1orf109 hypothetical protein LOC54955 5 |
| C2orf29 hypothetical protein LOC55571 6 |
| C9orf123 transmembrane protein C9orf123 7 |
| CDK9 cell division protein kinase 9 8 |
| CHSY1 chondroitin sulfate synthase 1 9 |
| CKAP2L cytoskeleton-associated protein 2-like 10 |
| CLINT1 clathrin interactor 1 11 |
| DUSP2 dual specificity protein phosphatase 2 12 |
| DUSP6 dual specificity protein phosphatase 6 isoform 13 |
| HSPC157 hypothetical LOC29092 14 |
| KIAA0427 CBP80/20-dependent translation initiation factor 15 |
| LDHA L-lactate dehydrogenase A chain isoform 5 16 |
| LOC100188949 hypothetical LOC100188949 17 |
| LOC285456 hypothetical LOC285456 18 |
| LSM14B protein LSM14 homolog B 19 |
| MAX protein max isoform a 20 |
| MRPS18A 28S ribosomal protein S18a, mitochondrial 21 |
| MTF2 metal-response element-binding transcription 22 |
| NAIF1 nuclear apoptosis-inducing factor 1 23 |
| NDUFA10 NADH dehydrogenase [ubiquinone] 1 alpha 24 |
| POMP proteasome maturation protein 25 |
| PSMA6 proteasome subunit alpha type-6 26 |
| RBM16 putative RNA-binding protein 16 27 |
| RBM38 RNA-binding protein 38 isoform a 28 |
| RPN1 dolichyl-diphosphooligosaccharide--protein 29 |
| SEPHS2 selenide, water dikinase 2 30 |
| SIRPG signal-regulatory protein gamma isoform 1 31 |
| SPRED2 sprouty-related, EVH1 domain-containing protein 32 |
| TFRC transferrin receptor protein 1 33 |
| TMEM18 transmembrane protein 18 34 |
| TRIP13 thyroid receptor-interacting protein 13 isoform 35 |
| TXN2 thioredoxin, mitochondrial precursor 36 |
| UBE2D2 ubiquitin-conjugating enzyme E2 D2 isoform 1 37 |
| ZFAT zinc finger protein ZFAT isoform 1 38 |
| ZNF212 zinc finger protein 212 39 |
| ZNF683 zinc finger protein 683 |
| Part | Number of sub-parts | Number of guidance points |
| Leadership | 8 | 93 |
| Policy and strategy | 5 | 43 |
| People management | 6 | 60 |
| Resources | 7 | 54 |
| Processes | 4 | 29 |
| Customer and society results | 2 | 43 |
| People results | 2 | 36 |
| Contractor results | 2 | 33 |
| Key performance results | 2 | 19 |
| Total | 38 | 410 |
| Variable | N (92,082) | % (100.0) | |
| Age (years) | 30–39 | 20,069 | 21.8 |
| 40–49 | 23,377 | 25.4 | |
| 50–59 | 19,776 | 21.5 | |
| 60–69 | 15,954 | 17.3 | |
| ≥70 | 12,906 | 14.0 | |
| Smoking status | Non-smoking | 21,147 | 23.0 |
| Smoking | 70,935 | 77.0 | |
| Current smoking | 43,088 | 46.8 | |
| Ex smoking | 27,847 | 30.2 | |
| Period of smoking (Years) | Non-smoking | 21,147 | 23.0 |
| 0–9 | 7531 | 8.0 | |
| 10–19 | 20,384 | 22.1 | |
| 20–29 | 19,845 | 21.6 | |
| 30–39 | 12,645 | 13.7 | |
| 40–49 | 7150 | 7.8 | |
| ≥50 | 3509 | 3.8 | |
| Physician-diagnosed stroke | Yes | 2380 | 2.6 |
| No | 89,699 | 97.4 | |
| Physician-diagnosed myocardial infarction | Yes | 1387 | 1.5 |
| No | 90,695 | 98.5 | |
| Physician-diagnosed hypertension | Yes | 19,040 | 20.7 |
| No | 72,985 | 79.3 | |
| Physician-diagnosed diabetes | Yes | 7991 | 8.7 |
| No | 84,050 | 91.3 |
| Nutridrink | Impact | Return to Nutridrink | p | |
| Body weight (kg) | 57 ± 5.8 | 57 ± 5.9 | 58 ± 5.8 | NS |
| Systolic BP (mmHg) | 115 ± 11 | 110 ± 7 | 117 ± 11 | 0.012 |
| Diastolic BP (mmHg) | 69 ± 9 | 64 ± 8 | 69 ± 9 | 0.03 |
| Heart rate (pulse/min) | 88 ± 15 | 77 ± 17 | 80 ± 14 | 0.002 |
| BMI (kg/m2) | 18.8 ± 1.7 | 18.9 ± 1.6 | 19 ± 1.6 | NS |
| Variable | Overall | Girls | Boys | p-Value |
| N (%) | N (%) | N (%) | (Chi-Square Test) | |
| Physical activity level | ||||
| Sedentary | 98 (36.8) | 48 (41.0) | 50 (33.6) | 0.252 |
| Moderate | 60 (22.6) | 28 (23.9) | 32 (21.5) | |
| Vigorous | 108 (40.6) | 41 (35.0) | 67 (45.0) | |
| MVPA (moderate and vigorous) | 168 (63.2) | 69 (59.0) | 99 (66.4) | |
| Activity type | ||||
| Sports games | 8 (3.0) | 0 (0) | 8 (5.4) | 0.019 * |
| Active games | 22 (8.3) | 5 (4.3) | 17 (11.4) | |
| Sedentary activities | 37 (13.9) | 18 (15.4) | 19 (12.8) | |
| Locomotion | 39 (14.7) | 20 (17.1) | 19 (12.8) | |
| Activities on playground equipment | 160 (60.2) | 74 (63.3) | 86 (57.7) | |
| Group size | ||||
| Alone (without other persons) | 63 (23.8) | 26 (22.4) | 37 (24.8) | 0.712 |
| Small (2 to 4 persons) | 186 (70.2) | 84 (72.4) | 102 (68.5) | |
| Medium (5 to 9 persons) | 14 (5.3) | 5 (4.3) | 9 (6.0) | |
| Large (10 and more persons) | 2 (0.8) | 1 (0.9) | 1 (0.7) | |
| Usage of playground equipment | Fisher’s exact test | |||
| Things to hang from | 14 (5.3) | 6 (5.1) | 8 (5.4) | 1 |
| Things to slide down | 33 (12.5) | 10 (8.6) | 23 (15.5) | 0.095 |
| Things to climb up | 30 (11.3) | 15 (12.8) | 15 (10.1) | 0.560 |
| Things to climb through | 3 (1.1) | 0 (0) | 3 (2.0) | 0.258 |
| Things to stand/walk on | 15 (5.7) | 11 (9.4) | 4 (2.7) | 0.030 * |
| Swings | 44 (16.6) | 24 (20.5) | 20 (13.5) | 0.138 |
| Carousels | 8 (3.0) | 5 (4.3) | 3 (2.0) | 0.308 |
| See-saws | 4 (1.5) | 1 (0.9) | 3 (2.0) | 0.633 |
| Playing fields | 8 (3.0) | 2 (1.7) | 6 (4.0) | 0.472 |
| Sandpits | 18 (6.8) | 11 (9.4) | 7 (4.7) | 0.147 |
| Characteristics | n£ | Mean | SD | Median | p-value |
| Ethnicity | 0.7011* | ||||
| White | 1756 | 110.7 | 56 | 106.9 | |
| Non-white | 433 | 109.3 | 56 | 107.3 | |
| Age (years) | 0.5204* | ||||
| ≤ 29 | 1254 | 109.9 | 56.9 | 106.4 | |
| > 29 | 935 | 111.1 | 54.8 | 107.4 | |
| Parity | 0.0342* | ||||
| Nullipara | 1168 | 107.7 | 55.5 | 106.1 | |
| ≥ 1 | 1021 | 113.4 | 56.4 | 107.5 | |
| Gestational age (US) | < 0.0001** | ||||
| 13 | 18 | 18.3 | 6.9 | 18.7 | |
| 14 | 43 | 23.3 | 7.5 | 23.4 | |
| 15 | 59 | 27.2 | 8.1 | 26.5 | |
| 16 | 60 | 39.5 | 13.5 | 35.8 | |
| 17 | 61 | 44.1 | 17.0 | 41.7 | |
| 18 | 60 | 45.3 | 18.1 | 41.4 | |
| 19 | 62 | 69.3 | 21.3 | 66.2 | |
| 20 | 110 | 67.9 | 22.1 | 64.4 | |
| 21 | 102 | 81.6 | 32.1 | 76.6 | |
| 22 | 91 | 86.7 | 33.2 | 80.7 | |
| 23 | 82 | 95.5 | 35.1 | 87.1 | |
| 24 | 60 | 115.2 | 35.0 | 115.6 | |
| 25 | 59 | 113.5 | 37.6 | 114.3 | |
| 26 | 62 | 120.2 | 37.2 | 120.9 | |
| 27 | 62 | 125.6 | 36.8 | 128.9 | |
| 28 | 92 | 137.0 | 51.3 | 136.9 | |
| 29 | 80 | 137.3 | 48.4 | 133.6 | |
| 30 | 91 | 141.1 | 49.8 | 125.3 | |
| 31 | 103 | 142.0 | 50.9 | 137.4 | |
| 32 | 101 | 142.0 | 51.3 | 132.7 | |
| 33 | 95 | 135.2 | 56.5 | 126.8 | |
| 34 | 102 | 137.9 | 44.0 | 136.0 | |
| 35 | 121 | 141.5 | 49.4 | 136.1 | |
| 36 | 102 | 135.6 | 45.7 | 130.4 | |
| 37 | 99 | 134.2 | 48.4 | 129.0 | |
| 38 | 94 | 134.7 | 50.7 | 121.7 | |
| 39 | 59 | 137.6 | 44.6 | 144.8 | |
| 40 | 59 | 151.9 | 52.0 | 143.3 |
| Independent variables | Model 1 | Model 2 | Model 3 |
| Health-related risk factors | |||
| Medical conditions (index) | −0.134*** | −0.052*** | −0.036* |
| Mobility difficulties (index) | −0.273*** | −0.115*** | −0.079*** |
| Activity limitations (index) | −0.504*** | −0.196*** | −0.168*** |
| Sociodemographic variables | |||
| Age (cont.) | −0.104*** | ||
| Language: Swedish (ref. Finnish and others) | 0.068*** | ||
| Gender: female (ref. male) | 0.056*** | ||
| Civil status: partnership (ref. single) | 0.052*** | ||
| Income: high (ref. low) | 0.062*** | ||
| Education: high (ref. low education) | 0.083*** | ||
| Country: Sweden (ref. Finland) | −0.015 | ||
| n | 5435 | 5435 | |
| Adjusted R square | 0.071 | 0.101 |
| β | 95% CI | p value | ||
| Intercept | -4.64 | -8.93; -0.35 | ||
| Group (Reference: controls) | NSCLC | 1.63 | 0.75; 2.51 | 0.0004 |
| Gender (Reference: male) | Female | 0.22 | -0.66; 1.10 | 0.6210 |
| Age | [10 years] | 0.45 | -0.10; 1.00 | 0.1058 |
| Smoking status (Reference: never) | Ever | -0.42 | -1.94; 1.10 | 0.5848 |
| Test Type | 5-Option Version (n = 25) | 2-Option Version (n = 37) | ||
| Without OPC | With OPC* | Without OPC | With OPC** | |
| FOBT | 21% | 17% | 32% | 54% |
| Sigmoidoscopy | 4% | 8% | - | - |
| FOBT & Sigmoidoscopy | 21% | 21% | - | - |
| Colonoscopy | 46% | 42% | 68% | 41% |
| Barium Enema | 4% | 8% | - | - |
| No Screening | 4% | 4% | - | 5% |
| Parameter | GM (CV %)a | GMR (90% CI)a | ||
| Pre-moringa | Post-moringa | Post/Pre | P | |
| AUC0–12h (h*μg/mL) | 94.17 (25.24) | 100.44 (27.65) | 1.07 (1.00–1.14) | 0.131 |
| C12h (μg/mL) | 7.30 (25.85) | 7.55 (28.56) | 1.03 (0.92–1.16) | 0.702 |
| Cmax,ss (μg/mL) | 9.92 (26.93) | 10.57 (29.62) | 1.06 (0.98–1.16) | 0.261 |
| Overall | Chronic kidney disease at baseline | p values | ||
| (n = 162) | Present (n = 25) | Absent (n = 137) | ||
| Male sex (n, %) | 89, 55 | 12, 48 | 77, 56 | 0.45 |
| Smokers (n, %) | 53, 33 | 6, 24 | 47, 3 | 0.30 |
| Age (years) | 62 ± 10 | 69 ± 9 | 61 ± 10 | 0.000 |
| BMI (kg/m2) | 24.2 ± 3.7 | 25.3 ± 4.0 | 24.0 ± 3.6 | 0.10 |
| Waist circumference (cm) | 87.0 ± 10.0 | 88.8 ± 7.7 | 86.7 ± 10.3 | 0.35 |
| Duration of diabetes (years) | 9.7 ± 7.2 | 12.8 ± 8.0 | 9.1 ± 7.0 | 0.02 |
| Treatment of diabetes; diet/OHA/insulin (n, %) | 53/81/28, 33/50/17 | 4/14/7, 16/56/28 | 49/67/21, 36/49/15 | 0.10 |
| Hypertension; CCB/RASi/diuretics (n, %) | 56/68/7, 35/42/4 | 18/17/5, 72/68/20 | 38/51/2, 28/37/1 | 0.000 |
| HbA1c (%) | 7.0 ± 0.8 | 7.2 ± 0.8 | 7.0 ± 0.9 | 0.25 |
| Fasting PG (mg/dL) | 125 ± 23 | 125 ± 24 | 126 ± 22 | 0.86 |
| Postbreakfast PG (mg/dL) | 154 ± 48 | 162 ± 51 | 152 ± 48 | 0.37 |
| CV-HbA1c (%) | 6.7 ± 5.7 | 6.8 ± 4.5 | 6.7 ± 5.9 | 0.96 |
| Total cholesterol (mg/dL) | 188 ± 21 | 178 ± 26 | 190 ± 20 | 0.012 |
| LDL cholesterol (mg/dL) | 112 ± 22 | 104 ± 24 | 113 ± 22 | 0.06 |
| HDL cholesterol (mg/dL) | 55 ± 15 | 50 ± 12 | 56 ± 16 | 0.06 |
| Fasting TG (mg/dL) | 114 ± 51 | 132 ± 73 | 111 ± 45 | 0.06 |
| Postbreakfast TG (mg/dL) | 145 ± 62 | 167 ± 80 | 141 ± 57 | 0.06 |
| Serum creatinine (mg/dL) | 0.8 ± 0.2 | 1.0 ± 0.3 | 0.7 ± 0.1 | 0.000 |
| eGFR (mL/min/1.73 m2) | 76 ± 16 | 51 ± 9 | 80 ± 13 | 0.000 |
| ΔeGFR (mL/min/1.73 m2/year) | −1.1 ± 2.9 | −1.2 ± 2.4 | −1.1 ± 3.0 | 0.93 |
| Uric acid (mg/dL) | 5.2 ± 1.3 | 5.7 ± 1.3 | 5.1 ± 1.2 | 0.03 |
| Systolic BP (mmHg) | 128 ± 12 | 131 ± 12 | 128 ± 12 | 0.20 |
| CV-systolic BP (%) | 8.1 ± 2.2 | 8.4 ± 2.1 | 8.0 ± 2.2 | 0.41 |
| Diastolic BP (mmHg) | 72 ± 6 | 69 ± 5 | 73 ± 7 | 0.02 |
| Urinary ACR (mg/g) | 86 ± 327 | 233 ± 531 | 59 ± 268 | 0.014 |
| log ACR | 1.3 ± 0.6 | 1.7 ± 0.8 | 1.2 ± 0.5 | 0.001 |
| Leucocyte count (103/μL) | 5.8 ± 1.5 | 6.1 ± 1.3 | 5.7 ± 1.5 | 0.19 |
| Maximum IMT (mm) | 1.0 ± 0.3 | 1.1 ± 0.4 | 1.0 ± 0.3 | 0.14 |
| Mean IMT (mm) | 0.8 ± 0.2 | 0.9 ± 0.2 | 0.8 ± 0.2 | 0.26 |
| ACR ≥ 30 mg/g (n, %) | 53, 33 | 12, 48 | 41, 30 | 0.08 |
| Hierarchy Depth | PPStream | PPTV | QQLive | PPfilm | UUSee | All |
| 1 | 19.12% | 3.20% | 15.95% | 8.34% | 3.25% | 14.72% |
| 2 | 80.87% | 44.69% | 9.34% | 43.35% | 85.64% | 50.76% |
| 3 | 0.014% | 52.11% | 17.50% | 48.31% | 11.11% | 27.42% |
| 4 | 0.00% | 0.004% | 57.22% | 0.003% | 0.00% | 7.09% |
| 5 | 0.00% | 0.00% | 0.0003% | 0.00% | 0.00% | 0.002% |
| Time from onset of illness | Signs/symptoms | Drug exposure | Laboratory values | ||||
| ALT | ALP | Total bilirubin | Direct bilirubin | Misc. | |||
| −5 | Sore throat | Amoxicillin started | |||||
| 0 | Fever, anorexia, dysphagia, neck swelling, and cervical lymphadenopathy | Ceftriaxone and vancomycin started | |||||
| 3–5 | Worsening of neck swelling | Ceftriaxone and vancomycin discontinued, and ampicillin/sulbactam and steroid started | |||||
| 5–10 | Diarrhea | Ampicillin/sulbactam and steroid discontinued, and clindamycin and probiotics started | |||||
| 10 | Fever, headache, dizziness, chest pain on coughing, and dark urine. Hepatosplenomegaly, RUQ tenderness | Clindamycin switched to ampicillin/sulbactam | 406 | 404 | 3.0 | 2.7 | |
| 16–23 | Generalized maculopapular rash and pruritus | Ampicillin/sulbactam | 152 | 737 | 8.8 | ||
| 25–30 | Abdominal pain, vomiting. Hepatomegaly | Ampicillin/sulbactam | 124 | 780 | 9.9 | AST 130 | |
| 48 | Chest pain, fatigue, pruritus, acholic stools, and jaundice | 138 | 713 | 13.4 | 8.8 | Cholesterol 1044, GGT 347, | |
| 53 | Increasing pruritus, anorexia | 117 | 651 | 12.7 | 8.5 | GGT 294 | |
| 67 | Anorexia, pruritus | 48 | 493 | 12.6 | 8.7 | GGT 77 | |
| 83 | Anorexia | 83 | 497 | 8.3 | 5.5 | GGT 273 | |
| 111 | No anorexia | 51 | 670 | 2.3 | 1.2 | GGT 507 |
| Inclusion criteria | Exclusion criteria |
| Original research articles referring to noninvasive modalities or minimally invasive techniques to accelerate orthodontic tooth movementAnimal studies | Randomized clinical trialsArticles dealing with highly invasive proceduresArticles referring to use of biochemical or drugs to accelerate tooth movementMicroimplants or frictionless brackets as a modality to reduce treatment duration Reviews, interviews, and discussions |
| GP* | Combinations* | |
| OR (95% CI)† | OR (95% CI)† | |
| Age | 1.00 (0.99-1.02) | 1.00 (0.98-1.02) |
| Man | 1.00 | 1.00 |
| Woman | 1.24 (0.84-1.85) | 1.17 (0.83-1.65) |
| Normal weight (BMI < 25 kg/m2) | 1.00 | 1.00 |
| Overweight (BMI 25-29.99 kg/m2) | 1.35 (0.81-2.26) | 1.71 (1.09-2.68) |
| Obese (BMI ≥ 30 kg/m2) | 1.72 (1.00-2.93) | 1.62 (1.00-2.62) |
| Lowest quintile of deprivation | 1.00 | 1.00 |
| Highest quintile of deprivation | 1.00 (0.57-1.74) | 0.98 (0.59-1.61) |
| Living in rural areas | 1.00 | 1.00 |
| Living in urban areas | 2.40 (1.14-5.04) | 1.18 (0.71-1.97) |
| Pain in both hips and knees | 1.00 | 1.00 |
| Pain in hips only | 0.96 (0.56-1.66) | 0.96 (0.59-1.57) |
| Pain in knees only | 1.03 (0.67-1.59) | 1.17 (0.80-1.72) |
| Pain severity | 1.28 (1.13-1.44) | 1.48 (1.34-1.64) |
| Not anxious/depressed | 1.00 | 1.00 |
| Anxious/depressed | 0.88 (0.58-1.33) | 1.04 (0.73-1.49) |
| No mobility problems | 1.00 | 1.00 |
| Mobility problems | 2.62 (1.64-4.17) | 2.77 (1.83-4.20) |
| 0-1 other health problems | 1.00 | 1.00 |
| 2 health problem areas | 1.60 (0.84-3.05) | 1.31 (0.76-2.28) |
| 3 health problem areas | 1.76 (0.93-3.34) | 1.15 (0.66-2.01) |
| 4 or more health problem areas | 1.28 (0.66-2.48) | 1.26 (0.73-2.18) |
| Area | Parameter estimate (SE) | t‐Value (P‐value) for parameter difference from zero | t‐Values (P‐values) for differences of least squares means | ||||
| Garbage | Light | Lawn | Other modified | Natural | |||
| Garbage | 2.92 (0.52) | 5.61 (<0.0001) | 2.66 (0.08) | 4.34 (<0.01)b | 4.11 (<0.01)b | 5.61 (<0.0001)b | |
| Under lights | 1.47 (0.60) | 2.46 (0.01) | 0.96 (0.87) | 1.37 (0.65) | 2.46 (0.12) | ||
| Lawn | 0.89 (0.58) | 1.54 (0.13) | 0.48 (0.99) | 1.54 (0.54) | |||
| Other modified | 0.60 (0.63) | 0.94 (0.35) | 0.94 (0.88) | ||||
| Natural | 0a |
| Sample Name | Raw Reads | Clean Reads | Clean Bases | Total Mapped | Error Rate (%) | Q20 (%) | Q30 (%) | GC Content (%) |
| O2-treated_1 | 12,984,364 | 12,920,255 | 0.65 G | 12,360,505 (95.67%) | 0.01 | 97.9 | 94.07 | 43.13 |
| O2-treated_2 | 11,192,761 | 11,131,963 | 0.56 G | 10,740,908 (96.49%) | 0.01 | 98.84 | 96.07 | 43.38 |
| HCl-treated_1 | 13,670,896 | 13,598,605 | 0.68 G | 13,068,581 (96.1%) | 0.01 | 97.92 | 94.13 | 43.44 |
| HCl-treated_2 | 13,595,227 | 13,514,169 | 0.68 G | 12,993,548 (96.15%) | 0.01 | 98.64 | 95.87 | 45.03 |
| Non-treated_1 | 12,361,440 | 12,313,326 | 0.62 G | 11,827,559 (96.05%) | 0.01 | 97.91 | 94.12 | 43.15 |
| Non-treated_2 | 12,559,734 | 12,506,248 | 0.63 G | 11,993,516 (95.9%) | 0.01 | 98.16 | 94.66 | 43.5 |
| Locus | Primer sequences (5′–3′) | Primer sequences (5′–3′) |
| b50 | F: AACAATCCAGGAGTGGCAATC | R: ACAAGCGAAGATCGTCTCATC |
| b35 | F: CGTTCAGTCACCAGCAAGG | R: GAGGGAAGCAGGGAGAGC |
| b38 | F: TAATCCCTCAATGGCTCTTTTC | R: GAGAAGGATACGAATTGACAGG |
| b40 | F:TGTATAGAACTGAGTAAATGATTG | R: CAACTTTCTTAAACCACTTTCG |
| b43 | F: CGAGCCTTCTTCTTCTTCTGG | R: GCAAGCAATACGGACAGTAGG |
| c03 | F:CGTGAAAATAGTGATATGTGTG | R: ACTGTAACAATCAAGAAGAAACC |
| c07 | F:GCCACAGCCGAGGAAGAG | R: TCTCATCACCACCACCTTAGG |
| b27 | F: AGCCAGGTTCCAGAAGTCC | R: CATAATCACAAAGTCTCGGTTCC |
| b28 | F: TCCCACCACGGACTACTG | R: AACCACCATCATCATCATCATC |
| b11 | F: GCGGAGGCTTAATTTGCTTTG | R: ACTCAATACATACACGGCACTAG |
| b16 | F: ACCTCTACGGACCTCTTCTTC | R: CATAACATAACATGACACACAAGC |
| b24 | F: GAGCCAGAGCCAGGTTCC | R: ACAAAGTCTCGGTTCCTTACAC |
| b34 | AATAGAATGTGGAGGCGATAGAG | R: AAACCATAAATCAACTACCGAACC |
| b64 | F: CTTGAGATACAGCCTTCCATTAG | R: CACACCTCGCTTCCCTTG |
| c17 | F:GAAACTATTTCCACCAACAAAG | R: ACACACATTCCTACACACC |
| b57 | F: CGGATATGGTGGAGGTTATGC | R: CAGAACGACGACGACGAC |
| b65 | F: ACGAACCACAACACAGAGAG | R: ACGAGGGAACACCAGAGAG |
| c18 | F:AAGCCGAGCGTGAAGAAG | R: ACACACAGAAAGAACACAAGAC |
| b53 | F: GGCTCAAGTTTGCTCATAGATTC | R: CGGCTTCGCTTTAGGATTTG |
| b56 | F: CGGTCTGTGGATACGAATGG | R: GACGACGACGACGATGATG |
| c10 | F:AGTGCGGAGATAACTGTTC | R: GGCTACTTTATTCTAAACCAAAC |
| Phases | Contacted | Screening1a | Screening2b | Screening3c | Successfully recruited | |
| IG | CG | |||||
| Run-in | 214 | 184 (86) | 106 (50) | 109 (51) | 50 (23) | 50 (23) |
| Main | 488 | 378 (78) | 306 (63) | 300 (62) | 140 (29) | 140 (29) |
| TOTAL | 702 | 562 (80) | 412 (59) | 409 (58) | 190 (27) | 190 (27) |
| Study characteristics | WBC | Monocytes | Neutrophils | Lymphocytes | Neutrophil to lymphocyte ratio | Reference | |||||||
| Population | FU | Size (n) | Risk [95% CI] | p | Risk [95% CI] | p | Risk [95% CI] | p | Risk [95% CI] | p | Risk [95% CI] | p | |
| PCI | <1 | 309 | 1.2 [1.0–1.3]b | * | (27) | ||||||||
| PCI | 1–6 | 1,425 | 4.8 [1.3–16.8] | n.s. | 1.7 [1.0–2.9] | n.s. | 5.7 [1.6–19.6] | n.s. | 5.6 [1.6–19.8] | ** | (40) | ||
| PCI | >6–36 | 83 | 14.7 [2.7–80.7] | ** | (29) | ||||||||
| UAP/NSTEMI | >6–36 | 280 | 1.4 [0.6–2.9] | n.s. | (41) | ||||||||
| CAD | >6–36 | 1,246 | 2.0 [1.3–3.1] | ** | (36) | ||||||||
| CAD | >6–36 | 422 | 5.3 [1.2–24.1] | n.s. | 6.4 [1.4–28.8] | n.s. | 5.5 [1.2–24.7]c | n.s. | 4.2 [1.4–12.4]a | n.s. | 8.1 [1.4–46.6] | * | (38) |
| PCI | >6–36 | 1,046 | 1.9 [1.3–3.0] | * | (44) | ||||||||
| UAP/NSTEMI | >36 | 275 | 1.7 [1.1–2.5] | * | (34) | ||||||||
| PCI | >36 | 1,425 | 1.7 [1.0–2.7] | n.s. | 2.0 [1.2–3.4] | * | 2.0 [1.2–3.3] | n.s. | 0.6 [0.4–0.9] | n.s. | 3.0 [1.8–5.0] | *** | (40) |
| Second-level category | n (%) |
| b140 attention functions | 149 (85) |
| b130 energy and drive functions | 127 (73) |
| b147 psychomotor functions | 124 (71) |
| b760 control of voluntary movement functions | 114 (65) |
| b164 higher-level cognitive functions | 106 (61) |
| b152 emotional functions | 90 (51) |
| b126 temperament and personality functions | 64 (37) |
| b125 dispositions and intra-personal functions | 58 (33) |
| b144 memory functions | 55 (31) |
| b117 intellectual functions | 31 (18) |
| b156 perceptual functions | 31 (18) |
| b134 sleep functions | 30 (17) |
| b180 experience of self and time functions | 26 (15) |
| b235 vestibular functions | 19 (11) |
| b735 muscle tone functions | 15 (9) |
| b260 proprioceptive functions | 14 (8) |
| b160 thought functions | 12 (7) |
| b210 seeing functions | 12 (7) |
| b230 hearing functions | 11 (6) |
| b110 consciousness functions | 10 (6) |
| b122 global psychosocial functions | 10 (6) |
| b163 basic cognitive functions | 10 (6) |
| b114 orientation functions | 9 (5) |
| b167 mental functions of language | 9 (5) |
| b280 sensation of pain | 9 (5) |
| b330 fluency and rhythm of speech functions | 9 (5) |
| b765 involuntary movement functions | 9 (5) |
| b176 mental function of sequencing complex movements | 8 (5) |
| b265 touch function | 8 (5) |
| b270 sensory functions related to temperature and other stimuli | 8 (5) |
| Total | Asp299Asp | Asp299Gly | P | |
| n (%) | 138 | 125 (90.6) | 13 (9.4) | |
| Oro-Hypopharyngeal SCC; n (%) | 37 | 34 (91.9) | 3 (8.1) | 0.76 |
| Laryngeal SCC; n (%) | 101 | 90 (89.1) | 11 (10.9) | |
| Mean age ± SD [years] | 61 ± 10 | 60 ± 10 | 63 ± 13 | 0.66 |
| Median follow up [months] (range)# | 50 (0-129) | 52 (0-129) | 42 (8-98) | 0.37 |
| Sex (male/female); n | 119/19 | 106/19 | 13/0 | 0.21 |
| Smoking; n (%) | 124 (89.8) | 112 (89.6) | 12 (92.3) | 1.00 |
| Mean pack years ± SD | 45 ± 25 | 45 ± 24.6 | 50 ± 29.6 | 0.62 |
| Primary therapy | 0.02 | |||
| Surgery alone; n (%) | 61 | 57 (45.6) | 4 (30.8) | |
| Surgery + RCT§; n (%) | 54 | 51 (40.8) | 3 (23.1) | |
| Primary RCT§; n (%) | 23 | 17 (13.6) | 6 (46.1) | |
| AJCC stage | 0.53 | |||
| I; n (%) | 25 | 22 (17.6) | 3 (23.1) | |
| II; n (%) | 33 | 30 (24.0) | 3 (23.1) | |
| III; n (%) | 25 | 22 (17.6) | 3 (23.1) | |
| IVA; n (%) | 50 | 47 (37.6) | 3 (23.1) | |
| IVB; n (%) | 3 | 2 (1.6) | 1 (7.6) | |
| IVC; n (%) | 2 | 2 (1.6) | 0 (0.0) | |
| Grade | 0.32 | |||
| 1; n (%) | 9 | 7 (5.6) | 2 (15.4) | |
| 2; n (%) | 96 | 87 (69.6) | 9 (69.2) | |
| 3-4; n (%) | 25 | 23 (18.4) | 2 (15.4) |
| Total number | Gleason grade group 1 | Gleason grade group 2 | Gleason grade group 3 | Gleason grade group 4 | Gleason grade group 5 | |
| N° of primary tumors | 60 | 12 | 12 | 12 | 12 | 12 |
| N° of CD44v8-10 | 24 | 3 | 3 | 5 | 6 | 5 |
| % positive tumors | 40% | 25% | 25% | 42% | 50% | 42% |
| Boys | Girls | |||||
| Verbal abuse | Threat of violence | Physical assault | Verbal abuse | Threat of violence | Physical assault | |
| Verbal abuse | 1.00 | 1.00 | ||||
| Threat of violence | 0.35* | 1.00 | 0.34* | 1.00 | ||
| Physical assault | 0.27* | 0.52* | 1.00 | 0.23* | 0.36* | 1.00 |
| Clinical setting | ||
| Barrier | HTN & eGFR ≥ 60 (%) | HTN & eGFR < 60 (%) |
| No impact on management | 37 | 24 |
| Limited time/more urgent patient issues | 25 | 20 |
| Not recommended by guidelines | 25 | 11 |
| Cost | 13 | 9 |
| Poor patient adherence | 5 | 5 |
| Progression to PID | Fraction progressing, % (95% CI)* | Cumulative incidence of PID after one year, % (95% CI)† | Akaike’s Information Criterion‡ | |
| Control group | Intervention group | |||
| Data | ||||
| Results from RCT | 1.9 (1.2 to 2.9) | 1.3 (0.7 to 2.1) | ||
| Model | ||||
| Immediate progression | 8.3 (5.7 to 11.0) | 1.6 (1.1 to 2.1) | 1.6 (1.1 to 2.1) | 13.3 |
| Constant progression | 9.9 (6.8 to 13.0) | 1.7 (1.2 to 2.3) | 1.5 (1.0 to 1.9) | 12.1 |
| Progression at the end | 10.0 (6.8 to 13.1) | 1.7 (1.2 to 2.3) | 1.5 (1.0 to 1.9) | 12.1 |
| Fc γ IIA genotype | Mild (<8) | Moderate (8–18) | Severe (>18) |
| R131/R131 (n = 16) | 2 | 4 | 10 |
| R131/H131 (n = 54) | 10 | 26 | 18 |
| H131/H131 (n = 10) | 0 | 10 | 0 |
| Total (n = 80) | 12 (15%) | 40 (50%) | 28 (35%) |
| Pharmacologic intervention title: ‘Vitamins C and E for prevention of pre-eclampsia in women with type 1 diabetes (DAPIT): a randomized placebo-controlled trial’ [28] | Non-pharmacologic intervention title: ‘Treatment of childhood obesity by retraining eating behaviour: randomized controlled trial’ [29] | |
| Active ingredients | Vitamins C and E | Not reported |
| Comparator | Placebo | Not reported |
| Health condition | Pre-eclampsia | Obesity |
| Eligibility criteria | Women with type 1 diabetes | Children |
| Objective | Prevention of pre-eclampsia | Retraining eating behaviour |
| Trial design | Randomized controlled trial | Randomized controlled trial |
| Item | N-free | Soybean meal | Rapeseed meal | Canola meal |
| Ingredients (%) | ||||
| Corn starch | 56.50 | 44.79 | 32.34 | 37.94 |
| Soybean meal (44 %) | - | 52.24 | - | - |
| Rapeseed meal (35 %) | - | - | 65.57 | - |
| Canola meal (38 %) | - | - | - | 59.78 |
| Sucrose | 20.00 | - | - | - |
| Glucose | 20.00 | - | - | - |
| Choline chloride (50 %) | 0.05 | 0.05 | 0.05 | 0.05 |
| TCP | 1.68 | 1.13 | 0.65 | 0.74 |
| Limestone | 0.62 | 0.64 | 0.24 | 0.34 |
| Salt | 0.30 | 0.30 | 0.30 | 0.30 |
| Mineral premix1 | 0.30 | 0.30 | 0.30 | 0.30 |
| Vitamin premix2 | 0.30 | 0.30 | 0.30 | 0.30 |
| Chromic oxide | 0.25 | 0.25 | 0.25 | 0.25 |
| Total | 100.00 | 100.00 | 100.00 | 100.00 |
| Chemical composition (%) | ||||
| ME (kcal/kg) | 3,509 | 3,391 | 2,904 | 3,125 |
| CP | - | 23.00 | 23.00 | 23.00 |
| Calcium | 0.70 | 0.70 | 0.70 | 0.70 |
| Available phosphorus | 0.32 | 0.32 | 0.32 | 0.32 |
| Lysine | - | 1.44 | 1.31 | 1.18 |
| Met + Cys | - | 0.66 | 1.08 | 0.76 |
| Matrix Mechanical Characteristics that Impact Cell or Tissue Function |
| • Pore size and morphology (Chan et al., 2008); [142] |
| • Elasticity (Janson et al., 2015); [131] |
| • Stiffness (Xia et al., 2017); [143] |
| • Hydration degree (Wu et al., 2006); [140] |
| Name | SNP | Primer | Product length (bp) | Primer sequence (5’→3’) |
| rs17576 | A/G | Forward | CAATTCACCCTCCCGCACTC | |
| Reverse | 222 | GGAAGATGAATGGAAACTGG | ||
| rs2250889 | C/G | Forward | GTATTTGTTCAAGGATGGGTG | |
| Reverse | 367 | AGACGTTTCGTGGGTTAT |
| Material | Tested | Ref. |
| Boron nitride, BN | Tested, in use, high efficiency, low erosion (0.02 mm3/C at 300 V) | 131, 139, 140 |
| Borosil, BN + SiO2 | Tested, in use, high efficiency, low wear | 131, 141 |
| Alumina, Al2O3 | Tested, medium efficiency, low erosion (0.01 mm3/C at 300 V) | 139, 141 |
| Silicon carbide, SiC | Tested, medium efficiency, medium erosion | 131 |
| Graphite | Tested, low efficiency, high erosion | 65 |
| Nanocrystalline diamond | Tested, high efficiency, low erosion | 131, 142 |
| CVD diamond | Tested for wear, lower erosion | 63 |
| Ultra-BN, uBN | Tested, high efficiency, very low wear | New result |
| HAZ | WAZ | |||
| Coefficient | Percent of ∆ | Coefficient | Percent of ∆ | |
| Raw gap, ∆ | .379 | 100.00 | .248 | 100.00 |
| Of which: | ||||
| Explained | .234 | 61.7 | .164 | 66.3 |
| Unexplained | .145 | 38.3 | .083 | 33.7 |
| Sub-scale | Attitudinal items | Surgeon (n=41) | Anaesthetist (n= 33) | Nurse (n=33) | |||
| Mode | IQR | Mode | IQR | Mode | IQR | ||
| There is little difference between the surgical checklist at GUH and the WHO surgical checklist. | 3 | 2 | 1 | 3.25 | 2 | 2.75 | |
| Norms | The complete checklist is used for every procedure in every theatre at UHG. | 2 | 3 | 1 | 3 | 5 | 1 |
| The complete checklist is used for every procedure in which I am involved in theatre. | 5 | 1.5 | 1 | 3 | 5 | 1 | |
| When the checklist is being carried out, everyone in theatre stops what they are doing and listens until it is completed. | 1 | 3 | 1 | 1 | 1 | 1.5 | |
| Sometimes sections of the checklist are not completed.* | 4 | 2 | 4 | 2 | 4 | 1 | |
| The individual who signs the checklist personally ensures that the relevant steps have been completed. | 5 | 1.5 | 4 | 2 | 4 | 1 | |
| Impact on teamwork & safety | I believe that failing to use the checklist is poor professional practice. | 5 | 1 | 5 | 1 | 5 | 0 |
| I believe using the checklist reduces the likelihood of human error. | 5 | 0.75 | 5 | 1 | 5 | 0 | |
| I believe using the checklist improves patient safety. | 5 | 0.5 | 5 | 1 | 5 | 0 | |
| I believe using the checklist improves teamwork in theatre. | 5 | 1 | 5 | 1 | 5 | 1 | |
| The use of the checklist should be mandatory for every case. | 5 | 1 | 5 | 1 | 5 | 0 | |
| Support | Surgical personnel support the use of the checklist. | 5 | 1 | 4 | 1 | 5 | 5 |
| Anaesthetic personnel support the use of the checklist. | 4 | 2 | 4 | 1 | 5 | 4 | |
| Nursing staff support the use of the checklist. | 5 | 0 | 4 | 1 | 5 | 5 | |
| Senior theatre personnel support the use of the checklist. | 5 | 2 | 4 | 1 | 5 | 5 | |
| Junior theatre personnel support the use of the checklist. | 5 | 1 | 4 | 1 | 5 | 5 | |
| Management support the use of the checklist. | 5 | 2 | 5 | 1 | 5 | 5 | |
| Initiate | I have initiated the use of the checklist in the past. | 5 | 2 | 1 | 3 | 5 | 0 |
| I intend to initiate the use of the checklist in the future. | 5 | 1 | 3 | 1.75 | 5 | 0 | |
| Barriers | The requirement for signatures. | 4 | 2.5 | 5 | 3 | 5 | 1 |
| Lack of assertiveness of staff. | 4 | 2 | 4 | 2.5 | 4 | 1 | |
| Lack of time. | 4 | 2 | 4 | 2.75 | 4 | 1 | |
| Lack of training. | 4 | 2 | 4 | 2 | 4 | 1.5 | |
| The lack of an electronic version of the checklist. | 3 | 2 | 5 | 3 | 3 | 2 |
| Research problem | Tool/Instrument | Authors |
| Nausea and vomiting | Nausea Vomiting Pregnancy QOL (NVP QOL) | [8] Canada |
| Pregnancy Unique Questionnaire Emesis (PUQE) | [9] Canada, [10] Canada | |
| McGill nausea questionnaire | [11] Canada | |
| Rhodes’ scores (RI) | [12] Canada | |
| Short form – 36 (SF-36) | [13] China | |
| SF-12, NVP specific QOL | [14] Canada | |
| NVPQOL, SF-36, SCL90 | [15] USA | |
| Irritable bladder | Incontinence Impact Questionnaire (IIQ), Urogenital Distress Inventory (UDI) | [6] Netherlands |
| Incontinence Questionnaire Short Form (ICIQ-SF) | [16] Turkey | |
| Back pains | Nottingham Health Profile (NHP) Disability Rating Index (DRI) | [17] Sweden |
| Pregnancy Mobility Index (PMI) | [18] Netherlands | |
| WHOQOL-BREF | [19] Turkey | |
| Anxiety and depression | Finnish modification of SF of the beck depression inventory and anxiety | [20] Finland |
| Hospital Anxiety and Depression Scale (HADS) | [21] Sweden | |
| EPDS, SF-36v2 | [22] China | |
| WHOQOL-BREF, EPDS | [23] Austria |
| Laboratory site | Samples (n) | Number of devices (n) | Runs per day (n) | Approximately overall time requirement | ||
| Sprinter XL | EUROPattern | Screening | Titer | |||
| Houston, TX, USA | 141 | 1 | 1 | 1 | 1 | 06:00 h |
| Tampa, FL, USA | 134 | 1 | 1 | 1 | 1 | 06:10 h |
| Dallas, TX, USA | 187 | 1 | 1 | 1 | 1 | 06:40 h |
| Phoenix, AZ, USA | 231 | 1 | 1 | 1 | 1 | 07:10 h |
| Birmingham, AL, USA | 236 | 2 | 2 | 2 | 1 | 06:30 h |
| Burlington, NC, USA | 471 | 2 | 2 | 2 | 2 | 07:10 h |
| Dublin, OH, USA | 330 | 2 | 2 | 2 | 2 | 07:10 h |
| Raritan, NJ, USA | 568 | 3 | 3 | 3 | 3 | 07:05 h |
| School | Arm allocationa | Number of girls in school | Provided consent (n, %) | Enrolled in intervention (n, %) | Provided baseline data (n, %) | Mean weekly attendance during intervention (n, %) | |
| Questionnaire | Accelerometerb | ||||||
| 1 | A | 106 | 43 (40.6) | 30 (28.3) | 30 (100) | 28 (93.3) | 15.4 (51.3) |
| 2 | A | 100 | 43 (43.0) | 30 (30.0) | 30 (100) | 29 (96.7) | 24.8 (82.6) |
| 3 | A | 112 | 42 (37.5) | 30 (26.8) | 30 (100) | 30 (100) | 25.9 (86.3) |
| 4 | B | 112 | 57 (50.9) | - | 30 (100) | 30 (100) | - |
| 5 | C | 83 | 44 (53.0) | - | 30 (100) | 29 (96.7) | - |
| 6 | C | 101 | 41 (40.6) | - | 30 (100) | 27 (90) | - |
| 7 | B | 179 | 48 (26.8) | - | 30 (100) | 30 (100) | - |
| Characteristic | β | Standard error | P |
| Baseline | -5.169 | 1.388 | 0.000 |
| Proband breast cancer diagnosis ≤35 years | 2.791 | 1.379 | 0.043 |
| Proband breast cancer diagnosis 36-39 years | 2.248 | 1.365 | 0.100 |
| Proband breast cancer diagnosis 40-49 years | 1.763 | 1.355 | 0.193 |
| Proband breast cancer diagnosis 50-59 years | 1.065 | 1.354 | 0.431 |
| Proband bilateral breast cancer at any age | 1.036 | 0.462 | 0.025 |
| Proband ovarian cancer at any age | 0.238 | 1.469 | 0.871 |
| Proband triple-negative breast cancer at any age | 1.323 | 0.331 | 0.000 |
| For each relative with cancer: | |||
| First degree, breast cancer diagnosis ≤39 years | 0.950 | 0.369 | 0.010 |
| First degree, breast cancer diagnosis 40-49 years | 1.450 | 0.386 | 0.000 |
| First degree, breast cancer diagnosis 50-59 years | 1.445 | 0.450 | 0.001 |
| First degree, breast cancer diagnosis 60+ years | 0.207 | 0.646 | 0.749 |
| First degree, ovarian cancer at any age | 2.556 | 0.769 | 0.001 |
| Second degree, breast cancer diagnosis at any age | 0.359 | 0.272 | 0.187 |
| Second degree, ovarian cancer diagnosis at any age | 1.861 | 0.832 | 0.025 |
| Normal thyroid (n.4) | Hyperplasia/Benign nodules (n.5) | Thyroid carcinoma (n.7) | |
| Video intensity UCAIGg | |||
| Video intensity difference | 11.3 (9.4-14.7) | 12.2 (8.5-19.6) | 19.4 (11.4-22.6) |
| Video intensity UCAVEGFR2 | |||
| Video intensity difference | 10.9 (10.3-14.9) | 13.3 (10.8-15.8) | 30.1 (25.1-35.6)* § |
| Mechanism of action | Drugs | Trial (reference) | Study population | Benefits | Common severetoxicities | |
| Apoptosis | PARP inhibitors | Olaparib | Phase II (127) | Recurrent/metastatic adult ES (failure to prior CH), n = 12 patients | NO responses SD: 4 patients, TTP: 5.7 weeks | No significant toxicities |
| Heat shock protein inhibitors | Retaspimycin (Hsp-90 INH) | Phase I (128) | Metastatic and/or unresectable STS, n = 54 patients | PR: 2 patients (proof of clinical activity) | Grade 3–4:Fatigue Nausea and vomiting Headache Artharalgia | |
| Proteaseome inhibitor | Bortezomib | Phase II (129) | Metastatic OS, ES, RMS, and STS with no prior treatment for advanced disease, n = 25 patients | Lack of benefit (trial prematurely closed) | Grade 3–4:Neuropathy Asthenia Myalgias | |
| MDM2 inhibitor | RG7112 | Proof of mechanism study (130) | WDLS or DDLS with MDM2 amplification receive RG7112 prior to surgery, n = 20 patients | SD: 14 patients, IHQ: activation of p53 pathway | Grade 3–4Neutropenia Thrombocytopenia | |
| Phase I (131) | Phase I trial with extension cohort for sarcoma patients, n = 30 (sarcoma patients) | Metabolic responses (PET-CT) IHQ: activation of p53 (MDM2-independent) | Grade 3–4 Cytopenias | |||
| PI3K-AKT-mTOR pathway inhibitors | Ridaforolimus (mTOR INH) | Phase II (132) | Pre-treated advanced bone and STS, n = 212 patients | RR: 1.9%, clinical benefit: 28.8% | Grade 3–4Fatigue Stomatitis Hypertriglyceridemia Anemia Thrombocytopenia | |
| Phase III (133) | Advanced bone and STS with clinical benefit to previous CH were randomized to maintenance Ridaforolimus or Placebo, n = 711 patients | Improvement in PFS (17.7 weeks with Ridaforolimus vs. 14.6 weeks with Placebo, HR: 0.72, p: 0.001) | Similar to previous study | |||
| Everolimus (mTOR INH) | Phase II (134) | Pre-treated advanced bone and STS, n = 41 patients | Poor clinical activity | Grade 3–4Hyperglicemia Stomatitis Pain Asthenia | ||
| Anti-angiogenic therapy | Sorafenib (VEGFR2, VEGFR3, PDGFR, and c-Kit INH) | Phase II (135) | Pre-treated advanced STS, n = 101 patients | RR: 14.5%, SD: 32.9% (leiomyosarcoma better PFS) | Grade 3–4Fatigue Diarrhea Hand–foot Syndrome Nausea and vomiting | |
| Pazopanib (VEGFR-1, VEGFR-2, VEGFR-3, PDGFR, and c-Kit INH) | Phase III (136) | Pre-treated non-adipocytic STS randomized to PAZOPANIB vs. PLACEBO, n = 369 patients | Improvement in PFS (4.6 months with PAZOPANIB vs. 1.6 months with Placebo, HR: 0.31, p < 0.0001) | Grade 3–4Asthenia Hypertension Anorexia Alteration of transaminases | ||
| Mitotic catastrophe | CDK inhibitors | Palbociclib (CDK4 and CDK6 INH) | Phase II (137) | WDLS or DDLS with CDK4 amplification and pRb expression | 66% of patients free of PD at 12 weeks | Grade 3–4Anemia Neutropenia Thrombocytopenia |
| Sample | L / cov | Compression rates | |||||
| Assembltrie | Assembltrie (corrected) | Orcom | BEETL | Mince | k-Path | ||
| SRR554369 | 100/25 | 0.369 | 0.345 | 0.518 | 1.133 | 0.484 | 0.673 |
| SRR327342 | 63/80 | 0.272 | 0.291 | 0.304 | 0.986 | 0.312 | 0.384 |
| MH0001.081026 | 44/NA | 0.781 | 0.758 | 0.804 | 1.785 | 0.786 | 2.545 |
| SRR870667 | 108/20 | 1.821 | 1.733 | 0.884 | 1.287 | 0.735 | 0.707 |
| ERR174310 | 101/7 | 0.701 | 0.570 | 0.686 | 1.493 | 0.746 | 0.797 |
| ERP001775 | 101/20 | 0.350 | 0.322 | 0.364 | N/A | N/A | N/A |
| Sim. T. cacao | 108/19 | 0.538 | 0.479 | 0.667 | N/A | N/A | N/A |
| NA12878 | 101/7 | 0.444 | N/A | 0.650 | N/A | N/A | N/A |
| Library | total reads | reads length(bp) | Total mapped | mapped% | mapped pairs | mapped paired% | Mapped genes* |
| T1 | 23,708,937 | 101 | 33,274,003 | 70.17% | 15,623,535 | 65.90% | 15,594 |
| N1 | 16,433,264 | 101 | 18,224,025 | 55.45% | 8,108,072 | 49.34% | 16,245 |
| T2 | 46,059,548 | 101 | 38,593,916 | 83.79% | 18,494,595 | 80.31% | 17,549 |
| N2 | 40,830,844 | 101 | 34,288,810 | 83.98% | 16,370,875 | 80.19% | 17,584 |
| Flg22-responsive genes* | Light-responsive genes** | Overlap genes | P-value*** | |||
| Flg22-induced light-dependent genes | 3579 | (flg22-up) | 2576 | (light-dependent) | 536 | 8.790e-24 |
| Flg22-induced light-repressed genes | 3579 | (flg22-up) | 2161 | (light-repressed) | 239 | 1.084e-05 |
| Flg22-repressed light-dependent genes | 4159 | (flg22-down) | 2576 | (light-dependent) | 359 | 2.599e-04 |
| Flg22-repressed light-repressed genes | 4159 | (flg22-down) | 2161 | (light-repressed) | 370 | 0.15 |
| Patient No. | Ethnicity | Biochemical findings | Phenotype | ACADS genotype | ||||
| C4a | C4/C2a | C4/C3a | C4/C8a | EMAb | ||||
| 1 | R | 1.53 | 0.21 | 1.35 | 40.38 | N/A | microcephaly, DD/ID, marked hypotonus, horizontal nystagmus | c.310_312delGAG/c.310_312delGAG |
| 9 | R | N/A | N/A | N/A | N/A | 634 | DD/ID, apnoic pause, bleeding into the adrenal glands in the neonatal age, hypoglycaemia | |
| 10 | R | 1.44 | 0.05 | 0.81 | 30.64 | 363 | central hypotonus with acral hypertonus, laryngomalatia | |
| 12 | R | 1.07 | 0.07 | 1.07 | 40.75 | 146 | epilepsy, hypotonus, irritability, cerebral palsy, pectus carinatum, kyphoscoliosis | |
| 14 | R | 0.97 | 0.08 | 0.61 | 59.6 | 1070 | recurrent sepsis, MAC, hepatosplenomegaly, severe hepatopathy along with gastroenteritis | |
| 15 | C | 2.77 | 0.11 | 3.26 | 60.23 | 169 | mild MAC in neonatal age, at age 2 yo - DD/ID, hypotonus, at age 3 yo – without DD/ID | |
| 17 | R | N/A | N/A | N/A | N/A | 329 | severe DD/ID, parents consanguinity, MAC, brother – DD/ID with no biochemical positivity to SCADD | |
| 23 | R | 1.19 | 0.07 | 0.57 | 129 | 322 | hypoglycaemia, elevated CK | |
| 24 | R | 1.00 | 0.10 | 0.53 | 60.88 | N/A | mild MAC | |
| 25 | R | 1.90 | 0.14 | 1.98 | 52.34 | 657 | DD | c.310_312delGAG/c.1138C>T |
| 32 | R | N/A | N/A | N/A | N/A | 306 | prematurity, severe DD/ID, quadruparesis, recurrent hypoglycaemia | |
| 33 | R | N/A | N/A | N/A | N/A | 965 | DD/ID(milder than brother - patient No. 32) | |
| 35 | R | 1.52 | 0.08 | 0.94 | 77.08 | 433 | mild hepatomegaly, hyperammonemia, MAC | |
| 52 | N/A | 0.61 | 0.06 | 5.28 | 10.18 | N/A | DD/ID c | c.310_312delGAG/c.625G>A |
| 53 | R | 1.20 | 0.07 | 0.72 | 17.93 | 135 | short stature, ophtalmoplegia (first sign – suspicion for congenital myasthenia), hypomimic facies, severe kyphoscoliosis, DD/ID, cachexia, hypotonus, respiratory failure, diffuse brain edema, coma vigile (high suspicion for other unknown neuromuscular disease) | |
| 54 | R | N/A | N/A | N/A | N/A | 71 | epilepsy | |
| 55 | R | 0.44 | 0.03 | 0.19 | 50.42 | 54 | recidivating granulomatous hepatopathy with hepatomegaly, mild hypertonus, mild DD/ID, epilepsy, apnoic pauses | |
| 56 | R | 0.86 | 0.03 | 0.41 | 21.15 | 110 | recurrent seizures |
| Non-surgical n = 261 | Bariatric surgery n = 301 | Adjusted for gender/age/BMI | ||||
| Range | Mean (SD) | Mean (SD) | F | P | ηp2 | |
| Family obesity | ||||||
| - parent/sibling + as a child | 0–2 | 1.0 (0.7) | 1.3 (0.7) | 8.98 | <0.01 | 0.017 |
| - partner + own children | 0–2 | 0.7 (0.7) | 0.7 (0.6) | 0.01 | 0.93 | |
| Current behavior | ||||||
| Unhealthy eating habits | ||||||
| - Total | 1–5 | 2.4 (0.7) | 2.5 (0.7) | 0.73 | 0.39 | |
| - Snacking between meals | 1–5 | 3.0 (0.9) | 3.1 (1.0) | 0.82 | 0.37 | |
| - Snacking on sweets | 1–5 | 2.8 (1.0) | 2.8 (1.0) | 1.13 | 0.29 | |
| - Drinking soda drinks | 1–5 | 2.6 (1.4) | 3.0 (1.4) | 6.71 | <0.01 | 0.012 |
| - Night time eating | 1–5 | 1.3 (0.7) | 1.2 (0.6) | 3.57 | 0.11 | |
| Physical activity MET-minutes/week | 0–14,958 | 2292.5 (2445.3) | 1844.2 (2290.6) | 3.96 | <0.05 | 0.008 |
| Alcohol use | 1–9 | 4.5 (1.8) | 4.0 (1.7) | 2.12 | 0.14 | |
| Self-monitoring of weight | 1–7 | 3.1 (1.5) | 2.7 (1.5) | 3.70 | 0.06 | |
| Dieting history | ||||||
| % yrs. Dieting | 0–88 | 47.6 (20.1) | 53.9 (17.4) | 11.93 | <0.001 | 0.023 |
| # organized diet programs | 0–25 | 2.7 (2.9) | 3.6 (4.1) | 7.31 | <0.01 | 0.014 |
| # 3 day diets past year | 0–25 | 2.5 (4.2) | 3.2 (4.6) | 1.07 | 0.30 | |
| # lost >10 kg | 0–12 | 3.1 (2.8) | 4.2 (3.4) | 8.36 | <0.01 | 0.017 |
| Diet strategies | ||||||
| -Total | 0–11 | 4.0 (2.3) | 4.9 (2.3) | 13.75 | <0.001 | 0.025 |
| - Less fat/carbs/sweets | 0–3 | 1.6 (1.1) | 1.8 (1.0) | 1.28 | 0.26 | |
| - Skipping meals/eat less/fasted | 0–3 | 1.3 (0.9) | 1.5 (0.9) | 6.89 | <0.01 | 0.013 |
| - Use laxatives/ vomiting/diet drugs/diuretic drugs | 0–4 | 0.6 (0.8) | 1.0 (0.9) | 16.75 | <0.001 | 0.030 |
| GeneID | Gene Description | miRNAs | miRDB (target score) | TargetScan (Context + Percentile) |
| ABHD3 | Abhydrolase domain containing 3 | miR-1244, miR-130a, miR-205 | 74, > 85 | 84 |
| CCNJ | Cyclin J | miR-205-5p | 90 | 98 |
| CHAMP1/ZNF828 | Chromosome alignment maintaining phosphoprotein 1 | miR-7-5p, miR-378a-3p | 60-96 | 96 |
| MYB | v-Myb myeloblastosis viral oncogene homolog (avian) | miR-15b-5p, miR-16-5p | 74 | 96 |
| PIK3CD | Phosphoinositide-3-kinase, catalytic, delta polypeptide | miR-7-5p | 94 | 91 |
| VEGFA | Vascular endothelial growth factor A | miR-205, miR-15b | 79 | 97 |
| FGD4 | RhoGEF and PH domain containing 4 | miR-17, miR-106a, miR-20a | 100 | 98 |
| SPOPL | Speckle-type POZ protein-like | miR-9-3p | 97 | 97 |
| RAB9B | RAB9B, member RAS oncogene family | miR-15b-5p, miR-16-5p, miR-130a-3P, miR-9-5p | 67-86 | 67-86 |
| EGFR | Epidermal growth factor receptor | miR-7 | 81 | 93 |
| E2F1 | E2F transcription factor 1 | miR-205, miR-17, miR-20b | 77 | 80 |
| DOK4/IRS-5 | Docking protein 4 | miR-205 | N/A | 94 |
| Diagnosis | n |
| Breast cancer | 200 |
| Glioma | 144 |
| Cervical carcinoma | 117 |
| Meningioma | 72 |
| Pituary adenoma | 50 |
| Cerebral lymphoma | 49 |
| Prague | 4 cities | |||||||
| CAPI | CAWI | CAPI | CAWI | |||||
| coeff. | s.e. | coeff. | s.e. | coeff. | s.e. | coeff. | s.e. | |
| α | 2.26 | 0.312 | 1.25 | 0.268 | 0.97 | 0.217 | 0.70 | 0.222 |
| β | −0.00056 | 4.95E-05 | −0.00033 | 3.99E-05 | −0.00054 | 3.68E-05 | −0.00051 | 3.64E-05 |
| δ | 0.095 | 0.0158 | 0.123 | 0.0312 | 0.083 | 0.0232 | 0.055 | 0.0256 |
| N of obs. | 1,365 | 1,840 | 2,585 | 2,635 | ||||
| VSL (mill Euro) | 4.02 | 3.85 | 1.79 | 1.37 |
| Food resource referrals - 2016 | |
| Pediatrics clinic | 438 |
| Internal medicine clinic | 140 |
| Family medicine clinic | 246 |
| Emergency department | 55 (25 Attending Physicians, 22 Resident Physicians, 8 Physician Assistants) |
| Psychiatry clinic | 52 |
| Reference | Sample number | Histotype | Results |
| Sawabata et al. (17) | 9 | NSCLC | CTC-positive in 4/9 patients. No recurrence after surgery |
| Bevilacqua et al. (19) | 5 | SCLC | CTC have a role in SCLC patients diagnosis |
| Tanaka et al. (20) | 150 | NSCLC and SCLC | CTC well differentiate stage I from stage IV tumors |
| Hou et al. (21) | 50 | SCLC | CTCs ≥ 2 in 86%. Higher CTC number → shorter OS. CTC-positive decreased after CT (60%) |
| Naito et al. (22) | 51 | SCLC | CTCs detected in 68.6, 26.5, and 67.6% at B, post-CT, and R, respectively. CTCs > 8 → worse OS |
| Hiltermann et al. (23) | 59 | SCLC | Median CTCs at B = 6 and 63 in localized and metastatic disease, respectively. CTCs decrease after CT → strong predictor of OS |
| Normanno et al. (24) | 60 | SCLC | CTCs identified in 90% at B and associated to involved organs. CTC reduction higher than 89% after CT → better OS |
| Hou et al. (25) | 97 | SCLC | CTCs present in 85%. CTCs ≥ 50 at B → worse OS. Failure of CTC to decrease <50 after CT → worse prognosis |
| Krebs et al. (26) | 101 | NSCLC | CTC number at B higher in stage IV than stage III (60 and 27, respectively).CTCs number → prognostic factor for PFS and predictor of OS after first cycle of CT |
| Hirose et al. (27) | 33 | NSCLC | CTCs positive in 36.4 and 15.2% had five or more CTCs before CT. Positive CTCs patients → progressive disease |
| Punoose et al. (28) | 41 | NSCLC | CTCs identified in 78% at B. CTC decrease during CT → longer PFS |
| Muinelo-Romay et al. (29) | 43 | NSCLC | CTCs detected in 41.9%. CTCs ≥ 5 → shorter PFS and OS. CTC decrease after second cycle of CT → higher response and better PFS and OS |
| Isobe et al. (30) | 24 | NSCLC | CTCs detected in 33.3%. EGFR mutations in cfDNA: 25%. EGFR mutation rate in cfDNA higher when CTCs ≥ 2 |
| Swennenhuis et al. (31) | 10 | NSCLC and SCLC | DNA isolation and sequencing from a single CTC |
| B | S.E. | Wald | p | OR | 95% CI | ||
| Min | Max | ||||||
| Predisposing characteristics | |||||||
| Single-parent family | 1.142 | 0.403 | 8.040 | 0.005 | 3.132 | 1.423 | 6.894 |
| Not seeking health information actively | 0.620 | 0.223 | 7.724 | 0.005 | 1.860 | 1.201 | 2.880 |
| Enabling characteristics | |||||||
| Financial status (Able to meet basic needs as reference) | 7.776 | 0.020 | |||||
| Just to meet basic needs | 0.422 | 0.263 | 2.570 | 0.109 | 1.524 | 0.912 | 2.553 |
| Cannot meet basic needs | 0.959 | 0.344 | 7.760 | 0.005 | 2.610 | 1.329 | 5.125 |
| Need | |||||||
| Perceived health status (Excellent as reference) | 8.473 | 0.037 | |||||
| Good | 0.114 | 0.273 | 0.176 | 0.675 | 1.121 | 0.657 | 1.914 |
| Fair | 0.606 | 0.305 | 3.930 | 0.047 | 1.832 | 1.007 | 3.334 |
| Poor | 1.827 | 0.868 | 4.431 | 0.035 | 6.217 | 1.134 | 34.075 |
| Constant | −1.479 | 0.299 | 24.413 | 0.001 | 0.228 |
| ASRV | DGRV | ACRV | IIRV | PVRV | FV3 | SSTIV | CH8/96 | ESV/ECV | RTV | TRV | |
| ASRV | 98.0 | 99.6 | 96.4 | 98.0 | 99.6 | 99.4 | 98.2 | 96.4 | 98.2 | 98 | |
| DGRV | 98.8 | 98.4 | 96.0 | 97.6 | 98.4 | 98.6 | 97.8 | 96 | 99.0 | 97.6 | |
| ACRV | 100 | 98.8 | 96.8 | 98.4 | 100 | 99.8 | 98.6 | 96.8 | 98.6 | 98.4 | |
| IIRV | 95.8 | 96.4 | 95.8 | 96.8 | 96.8 | 97.0 | 98.2 | 100 | 96.2 | 96.8 | |
| PVRV | 98.2 | 98.2 | 98.2 | 95.2 | 98.4 | 98.6 | 97.8 | 96.8 | 97.8 | 100 | |
| FV3 | 100 | 98.8 | 100 | 95.8 | 98.2 | 99.8 | 98.6 | 96.8 | 98.6 | 98.4 | |
| SSTIV | 99.4 | 99.4 | 99.4 | 96.4 | 98.8 | 99.4 | 98.8 | 97.0 | 98.8 | 98.6 | |
| CH8/96 | 97.6 | 97.6 | 97.6 | 98.2 | 97.0 | 97.6 | 98.2 | 98.2 | 98. 0 | 97.8 | |
| ESV/ECV | 95.8 | 96.4 | 95.8 | 100 | 95.2 | 95.8 | 96.4 | 98.2 | 96.2 | 96.8 | |
| RTV | 98.8 | 100 | 98.8 | 96.4 | 98.2 | 98.8 | 99.4 | 97.6 | 96.4 | 97.8 | |
| TRV | 98.2 | 98.2 | 98.2 | 95.2 | 100 | 98.2 | 98.8 | 97.0 | 95.2 | 98.2 |
| Characteristic | Lifestyle | Preventive screening | Choosing treatments | Choosing specialists | Choosing medications | Diagnostic testing |
| OR [95% CI] | OR [95% CI] | OR [95% CI] | OR [95% CI] | OR [95% CI] | OR [95% CI] | |
| Gender | ||||||
| Male | Ref | Ref | Ref | Ref | Ref | Ref |
| Female | 1.21 [0.97, 1.53] | 1.10 [0.90, 1.36] | 1.44 [1.17, 1.78] | 1.46 [1.19, 1.79] | 1.18 [0.96, 1.44] | 1.14 [0.93, 1.39] |
| Age | ||||||
| 18–30 | Ref | Ref | Ref | Ref | Ref | Ref |
| 31–40 | 1.08 [0.75, 1.55] | 1.30 [0.92, 1.83] | 0.95 [0.67, 1.35] | 0.97 [0.68, 1.36] | 1.02 [0.72, 1.44] | 1.12 [0.79, 1.59] |
| 41–50 | 1.10 [0.77, 1.58] | 1.25 [0.89, 1.75] | 0.99 [0.71, 1.39] | 0.92 [0.66, 1.28] | 1.06 [0.76, 1.48] | 1.21 [0.87, 1.70] |
| 51–60 | 2.03 [1.37, 3.00] | 2.05 [1.45, 2.89] | 1.63 [1.15, 2.30] | 1.69 [1.21, 2.36] | 1.38 [0.98, 1.93] | 1.80 [1.29, 2.52] |
| 61–70 | 1.65 [1.13, 2.41] | 2.06 [1.44, 2.94] | 1.49 [1.04, 2.14] | 1.81 [1.29, 2.55] | 1.35 [0.95, 1.92] | 2.09 [1.47, 3.00] |
| 71–80 | 1.86 [1.07, 3.22] | 2.57 [1.57, 4.20] | 1.46 [0.93, 2.31] | 1.84 [1.16, 2.95] | 1.12 [0.71, 1.77] | 2.33 [1.49, 3.64] |
| 80+ | 1.49 [0.70, 3.17] | 1.29 [0.69, 2.45] | 1.18 [0.61, 2.28] | 2.05 [1.02, 4.11] | 1.30 [0.67, 2.53] | 2.83 [1.44, 5.58] |
| Ethnicity | ||||||
| White | Ref | Ref | Ref | Ref | Ref | Ref |
| Black | 0.87 [0.60, 1.26] | 0.77 [0.55, 1.07] | 0.81 [0.58, 1.13] | 1.03 [0.74, 1.43] | 0.67 [0.48, 0.93] | 0.86 [0.61, 1.21] |
| Asian or Pacific Islander | 0.92 [0.42, 2.00] | 0.53 [0.27, 1.05] | 0.45 [0.26, 0.81] | 0.59 [0.28, 1.23] | 0.47 [0.25, 0.89] | 0.83 [0.42, 1.63] |
| Other | 1.22 [0.79, 1.88] | 1.07 [0.71, 1.62] | 1.61 [1.04, 2.50] | 1.49 [0.99, 2.23] | 1.42 [0.94, 2.13] | 1.80 [1.19, 2.72] |
| Income | ||||||
| <$15,000 | Ref | Ref | Ref | Ref | Ref | Ref |
| $15,000–$34,999 | 0.87 [0.58, 1.30] | 1.21 [0.83, 1.77] | 1.22 [0.84, 1.76] | 1.41 [0.98, 2.03] | 0.91 [0.63, 1.33] | 0.97 [0.67, 1.41] |
| $35,000–$49,999 | 1.09 [0.69, 1.73] | 1.09 [0.72, 1.66] | 1.05 [0.69, 1.59] | 1.17 [0.77, 1.78] | 0.96 [0.63, 1.45] | 0.77 [0.51, 1.18] |
| $50,000+ | 0.98 [0.67, 1.45] | 1.12 [0.78, 1.61] | 0.97 [0.68, 1.39] | 1.42 [0.99, 2.04] | 0.93 [0.65, 1.34] | 0.95 [0.66, 1.37] |
| Missing | 1.43 [0.82, 2.49] | 2.16 [1.29, 3.60] | 1.14 [0.71, 1.85] | 2.59 [1.58, 4.24] | 1.36 [0.81, 2.26] | 1.43 [0.87, 2.35] |
| Education | ||||||
| High school or less | Ref | Ref | Ref | Ref | Ref | Ref |
| Some college | 1.47 [1.12, 1.95] | 1.24 [0.96, 1.59] | 1.12 [0.87, 1.44] | 1.15 [0.89, 1.47] | 0.92 [0.71, 1.18] | 1.00 [0.78, 1.28] |
| College graduate | 1.70 [1.23, 2.40] | 1.60 [1.18, 2.15] | 1.63 [1.21, 2.19] | 1.24 [0.92, 1.65] | 1.03 [0.78, 1.37] | 1.02 [0.76, 1.37] |
| Graduate school | 1.99 [1.28, 3.11] | 1.57 [1.06, 2.31] | 2.54 [1.71, 3.79] | 1.57 [1.08, 2.28] | 1.17 [0.81, 1.68] | 0.92 [0.63, 1.32] |
| Patient activation | ||||||
| Level 1 | Ref | Ref | Ref | Ref | Ref | Ref |
| Level 2 | 1.33 [0.86, 2.08] | 1.62 [1.08, 2.44] | 1.06 [0.70, 1.60] | 1.13 [0.74, 1.70] | 1.47 [0.97, 2.22] | 0.92 [0.61, 1.38] |
| Level 3 | 1.42 [0.95, 2.12] | 1.65 [1.14, 2.38] | 1.05 [0.71, 1.54] | 1.25 [0.86, 1.83] | 1.53 [1.04, 2.24] | 1.04 [0.71, 1.51] |
| Level 4 | 2.13 [1.43, 3.18] | 2.02 [1.41, 2.91] | 1.50 [1.00, 2.13] | 1.17 [0.81, 1.71] | 1.82 [1.25, 2.66] | 1.31 [0.97, 2.05] |
| Self-rated health | ||||||
| Poor | 1.35 [0.62, 2.93] | 1.80 [0.88, 3.66] | 1.39 [0.68, 2.82] | 2.93 [1.51, 5.69] | 1.51 [0.73, 3.13] | 1.95 [0.95, 4.00] |
| Fair | 1.41 [0.88, 2.28] | 1.13 [0.73, 1.74] | 0.99 [0.64, 1.52] | 1.22 [0.81, 1.85] | 0.91 [0.59, 1.41] | 0.82 [0.53, 1.25] |
| Good | 1.37 [0.93, 2.03] | 0.80 [0.56, 1.12] | 0.89 [0.62, 1.26] | 0.87 [0.62, 1.23] | 0.81 [0.57, 1.15] | 0.67 [0.48, 0.95] |
| Very good | 1.40 [0.95, 2.05] | 0.87 [0.61, 1.23] | 1.03 [0.73, 1.45] | 1.09 [0.78, 1.52] | 0.85 [0.60, 1.19] | 0.79 [0.56, 1.11] |
| Excellent | Ref | Ref | Ref | Ref | Ref | Ref |
| Chronic conditions | ||||||
| 0 | Ref | Ref | Ref | Ref | Ref | Ref |
| 1 | 0.99 [0.74, 1.34] | 1.17 [0.90, 1.55] | 1.17 [0.88, 1.54] | 0.95 [0.72, 1.25] | 1.19 [0.98, 1.69] | 0.98 [0.74, 1.29] |
| 2+ | 1.34 [0.99, 1.82] | 1.32 [1.00, 1.72] | 1.36 [1.04, 1.79] | 1.16 [0.90, 1.51] | 1.62 [1.25, 2.11] | 1.14 [0.88, 1.49] |
| Antibiotic class | Multidrug-resistant (n = 226) | Non-multidrug-resistant (n = 514) | P-value |
| Aminoglycosides | 226 (29.2%) | 505 (91.1%) | <0.001 |
| Antipseudomonal carbapenems | 226 (15.0%) | 508 (84.6%) | <0.001 |
| Antipseudomonal cephalosporins | 226 (26.5%) | 504 (93.7%) | <0.001 |
| Antipseudomonal fluoroquinolones | 222 (21.5%) | 502 (88.4%) | <0.001 |
| Antipseudomonal penicillins + | 221 (22.2%) | 502 (89.0%) | <0.001 |
| β-lactamase inhibitors | |||
| Monobactams | 158 (13.9%) | 208 (81.2%) | <0.001 |
| Phosphonic acids | 86 (40.7%) | 105 (81.0%) | <0.001 |
| Polymyxins | 159 (97.5%) | 215 (92.1%) | 0.025 |
| Variable | No. of missing data |
| Expenditure | 2 |
| Family support | 2 |
| MBI at admission | 10 |
| WHOQOL-BREF at admission | 15 |
| Number of joints with limited ROM at admission | 50 |
| MBI at discharge | 8 |
| WHOQOL-BREF at discharge | 12 |
| Number of joints with limited ROM at discharge | 18 |
| Work status after discharge | 4 |
| Name | Forward | Reverse | Accession number | Transcripts length (base pairs) | Primer efficiency (%) |
| Housekeeping gene study | |||||
| Actb | agccatgtacgtagccatcc | accctcatagatgggcacag | NM_031144.3 | 115 | 100.8 |
| Gapdh | gtgatgctggtgctgagta | gcggaaggggcggagatg | NM_017008.4 | 115 | 77.2 |
| Hmbs | aggatgggcaactgtacctg | aactgtgggtcatcctctgg | NM_013168.2 | 130 | 85.1 |
| Hprt1 | gcagactttgctttccttgg | agaggtccttttcaccagca | NM_012583.2 | 79 | 86.3 |
| Ppia | catcctgaagcatacaggtc | catccagccactcagtctt | NM_017101.1 | 107 | 98.7 |
| Ppib | caagacctcctggctagacg | ttctccaccttccgtaccac | NM_022536.2 | 81 | 87.6 |
| Rpl13a | gatgaacaccaacccgtctc | atcccatccaacaccttgag | NM_173340.2 | 141 | 90.5 |
| Sdha | cgagatccgtgaaggaagag | ctctgagatcccaggcagac | NM_130428.1 | 109 | 90.0 |
| Gene expression study | |||||
| Ppiba | caagacctcctggctagacg | ttctccaccttccgtaccac | NM_022536.2 | 81 | 98.9 |
| Rpl13aa | gatgaacaccaacccgtctc | atcccatccaacaccttgag | NM_173340.2 | 141 | 98.9 |
| Adamts4 | aactccctgttccccagact | tagcttcagggccaggtaga | NM_023959.1 | 271 | 91.4 |
| Mmp9 | cactgtaactgggggcaact | cacttcttgtcagcgtcgaa | NM_031055.1 | 150 | 103.8 |
| Plat | tctgccgcccactgctttg | cgaatgtctgctcctcctctcc | NM_013151.2 | 103 | 106.7 |
| Serpin1 | atgaggctggtggcatctac | gatcagctgtggtttgagca | NM_053779.1 | 131 | 99.8 |
| Timp1 | ggttccctggcataatctga | atggctgaacagggaaacac | NM_053819.1 | 99 | 101.2 |
| Timp3 | gctgtgcaactttgtggaga | aattgcaacccaggtggtag | NM_012886.2 | 86 | 93.6 |
| Response | Medical n = 779 | Dental n = 347 | P value | ||
| Mean (SD) | Med (IOR) | Mean (SD) | Med (IQR) | ||
| My muscles become tense | 1.88 (0.89) | 2.0 (1) | 1.99 (0.88) | 2.0 (1) | 0.027 |
| My breathing rate increases | 1.85 (0.90) | 2.0 (1) | 1.72 (0.85) | 1.0 (1) | 0.030 |
| I perspire | 1.53 (0.81) | 1.0 (1) | 1.50 (0.77) | 1.0 (1) | 0.616 |
| I feel nauseated and sick to my stomach | 1.48 (0.79) | 1.0 (1) | 1.27 (0.60) | 1.0 (0) | 0.000 |
| My heart beats faster | 2.07 (0.99) | 2.0 (2) | 1.83 (0.86) | 2.0 (1) | 0.000 |
| genes percontig | number ofcontigs | contigs perscaffold | number ofscaffolds | Vitis genes perdeleted block | number ofdeletions |
| 1 | 1699 | 1 | 469 | 1 | 2253 |
| 2 | 612 | 2 | 181 | 2 | 548 |
| 3 | 337 | 3 | 121 | 3 | 167 |
| 4 | 210 | 4 | 80 | 4 | 36 |
| 5 | 140 | 5 | 67 | 5 | 23 |
| 6 | 107 | 6 | 29 | 6 | 8 |
| 7 | 91 | 7 | 25 | 7 | 5 |
| 8 | 55 | 8 | 19 | 8 | 1 |
| 9 | 38 | 9 | 27 | 9 | 1 |
| 10 | 36 | 10 | 10 | 10 | 0 |
| >10 | 289 | >10 | 59 | >10 | 3 |
| total: 14033 | 3614 | total: 3614 | 1087 | total: 4267 | 3045 |
| Number of OTU | The Mean Proportion of OTUs in the Group (%) | ||||||
| Taxon | Moderate exposure | Low exposure | Moderate exposure a | Low exposure a | p-value a | Odds ratio b | 95% CI b |
| Actinobacteria /Actinomyces | 912 | 906 | 5.5% | 5.0% | 0.90 | 0.96 | 0.87–1.06 |
| Actinobacteria /Rothia | 326 | 415 | 1.6% | 2.4% | 0.15 | 0.75 | 0.64–0.87 |
| Bacteroidetes /Porphyromonas | 609 | 640 | 2.7% | 3.7% | 0.46 | 0.91 | 0.81–1.02 |
| Bacteroidetes /Prevotella | 2344 | 2497 | 14.4% | 12.7% | 0.80 | 0.89 | 0.83–0.94 |
| Bacteroidetse /Prevotellaceae | 202 | 484 | 0.9% | 2.4% | 0.19 | 0.39 | 0.33–0.47 |
| Firmicutes | 353 | 251 | 1.7% | 1.3% | 0.45 | 1.35 | 1.14–1.59 |
| Firmicutes /Bacilli | 3910 | 3884 | 19.1% | 21.2% | 0.62 | 0.95 | 0.91–1.00 |
| Firmicutes /Gemella | 712 | 552 | 4.0% | 3.1% | 0.76 | 1.24 | 1.11–1.39 |
| Firmicutes /Lactobacillales | 347 | 267 | 1.8% | 1.4% | 0.63 | 1.25 | 1.06–1.47 |
| Firmicutes /Streptococcus | 865 | 478 | 6.0% | 2.3% | 0.11 | 1.76 | 1.57–1.97 |
| Firmicutes /Veillonella | 1269 | 1217 | 8.0% | 6.3% | 0.52 | 1.00 | 0.92–1.08 |
| Fusobacteria /Fusobacterium | 540 | 713 | 2.6% | 4.0% | 0.11 | 0.72 | 0.64–0.80 |
| Fusobacteria /Leptotrichia | 810 | 744 | 4.1% | 3.5% | 0.74 | 1.04 | 0.94–1.15 |
| Proteobacteria /Gammaproteobacteria | 964 | 969 | 4.6% | 5.3% | 0.64 | 0.95 | 0.86–1.04 |
| Proteobacteria /Neisseria | 493 | 317 | 2.2% | 1.8% | 0.65 | 1.50 | 1.29–1.73 |
| Proteobacteria /Neisseriaceae | 2930 | 3190 | 14.6% | 19.8% | 0.43 | 0.86 | 0.82–0.91 |
| Proteobacteria/Pasteurellaceae | 1311 | 542 | 6.2% | 3.5% | 0.34 | 2.39 | 2.15–2.64 |
| Primers | Sequences | Nucleotide position |
| First round | ||
| Sense | 5′-TTCATACAGTAACGCCCAGC-3′ | 259–278 |
| Antisense | 5′-GCAACTACAGGGATTGTAAGGG-3′ | 808–829 |
| Second round | ||
| Sense | 5′GCCTTGTGTTTCTATGTTTGC-3′ | 277–297 |
| Antisense | 5′GCATCCATACATTCTGCGAG-3′ | 786–805 |
| (% completing step correctly) (n = 15) | |||||
| Description of step | End of traininga | 7 months post trainingb | Most common error(s) | ||
| 1 | Work surface disinfected with alcohol | - | - | Not applicable due to change in training protocol. | |
| 2 | Assembles all required equipment | 87 | 100 | ||
| 3 | S | Put on new pair of gloves | 93 | 93 | |
| 4 | Check expiry date of RDT packet | 67 | 80 | Did not check. | |
| 5 | Check desiccant sachet is dry | 100 | 67 | Did not check. | |
| 6 | Write client name on cassette | 80 | 93 | ||
| 7 | Place cassette on level surface | 100 | 100 | ||
| 8 | S | Clean finger with alcohol swab | 93 | 93 | |
| 9 | Allow finger to dry before pricking | 100 | 93 | ||
| 10 | S | Use sterile lancet to prick finger | 93 | 93 | Set down sterile lancet onto surface after removing cap |
| 11 | Puncture side of ball of the 3rd or 4th finger | 100 | 73 | Punctured vertically (i.e. perpendicular to the tip) | |
| 12 | S | Dispose of lancet immediately after pricking finger | 100 | 87 | Used lancet, then set down onto work surface |
| 13 | Wipes away initial blood from finger | 100 | 93 | ||
| 14 | A | Uses blood collection device correctly | 100 | 100 | |
| 15 | A | Correctly transfer blood to cassette using tool | 100 | 100 | |
| 16 | S | Dispose of blood collection tool immediately | 100 | 87 | Left blood collection device inserted into sample well. |
| 17 | A | Dispenses correct volume of buffer | 87 | 60 | Too much buffer added. |
| 18 | A | Start the timer immediately after adding buffer | 87 | 60 | Did not record time. |
| 19 | Dispose of non-sharps safely | 93 | 100 | ||
| 20a | A | States the correct time to read RDT (RDT test sheet) | 100 | - | |
| 20b | A | Waits correct time before reading RDT result | - | 27 | Waited <5 minutes before reading result. |
| 21 | A | Reads test results correctly c | 80 | 100 | |
| 22 | T | Completes correct sections of treatment register | 87 | 93 | |
| 23 | T | Selects appropriate AL dose based on weight | 87 | 100 | Did not record time. |
| 24 | T | Selects appropriate paracetamol dose | 60 | 93 | |
| 25 | T | Selects correct Parent Information sheet for AL dose | 67 | 40 | |
| 26 | T | States correct time for 2nd dose of AL to be taken | 47 | 40 | Did not complete information sheet, provided counselling verbally only |
| Intervention | n | Duration | % of analyzed time |
| Respiratory support via mask | 46 | 8.8 (1.5-28.5) min | 46.9 (15.8-97.6)b |
| Sustained inflations | 15 | 8.5 (1.8–13.8) s | 2.6(0.2-8.4)c |
| Mechanical ventilation | 7 | 53.1 (6.9-128.5) s | 11.6(0.5-69.8)c |
| Suctioning | 31 | 34.6 (0.9-153.6) s | 3.2(0.1-8.7)b |
| CPAP prior to nasopharyngeal tube | 12 | 22.6 (10-39.4) minc | |
| Stabilization prior to transport | 22 | 27.3 (11.7-50) mind |
| Patients with total lipid profile | All patients (n = 2,009) | Very high risk* (n = 1,649) | High Risk (n = 58) | Moderate risk (n = 214) | Low Risk (n = 88) |
| LDL-C not at target [%]† | 61.8 | 69.5 | 56.9 | 29.0 | Δ |
| Low HDL-C (<1.0 [men]/1.2 [women] mmol/L) [%] | 55.5 | 58.4 | 36.2 | 47.2 | 33.0 |
| Elevated TG (>1.7 mmol/L) [%] | 48.5 | 51.1 | 37.9 | 36.4 | 37.5 |
| All patients | (n = 2,181) | (n = 1,801) | (n = 59) | (n = 224) | (n= 97) |
| LDL-C not at target [%]†,‡ | 61.5 | 69.5 | 56.9 | 29.0 | Δ |
| Low HDL-C (<1.0 [men]/1.2 [women] mmol/L) [%]‡ | 56.8 | 59.8 | 37.3 | 47.8 | 33.7 |
| Elevated TG (>1.7 mmol/L) [%]§ | 46.7 | 48.6 | 37.3 | 37.5 | 39.6 |
| Year | Month | BMI | Treatment | Dose | Performance status |
| 2011 | 31.2 | ||||
| 2013 | Feb | 29.4 | FLOX C1 | Oxaliplatin: 150 mg Fluorouracil: 950 mg Calciumfolinat: 110 mg | 0 |
| March | 28.7 | FLOX C2 | Oxaliplatin: 140 mg Fluorouracil: 900 mg Calciumfolinat: 100 mg | 1 | |
| April | 27.8 | FLOX C3 | Oxaliplatin: 120 mg Fluorouracil: 720 mg Calciumfolinat: 100 mg | 1 | |
| June | 29.2 | Capecitabine | 500mgx1 | 1-2 | |
| July | Capecitabine/ Bevacizumab C1 | 500 mg × 2/ 350 mg | 1-2 | ||
| Aug | Capecitabine/ Bevacizumab C2 | 500 mg × 2/ 350 mg | 0-1 | ||
| Capecitabine/ Bevacizumab C3 | 500 mg × 2/ 350 mg | ||||
| Sept | Capecitabine/ Bevacizumab C4 | 500 mg × 2/ 350 mg | |||
| Capecitabine/ Bevacizumab C5 | 500 mg × 2/ 350 mg | ||||
| Oct | 29.8 | Capecitabine/ Bevacizumab C6 | 500 mg × 2/ 350 mg | 0-1 | |
| Capecitabine/ Bevacizumab C7 | 500 mg × 2/ 350 mg | ||||
| 2014 | Jan | 31.2 | 0 |
| Disc level | Overall | Men | Women |
| L1-L2 | 21.9 ± 3.8 | 21.6 ± 3.9 | 22.1 ± 3.8 |
| L2-L3 | 24.0 ± 4.5 | 24.4 ± 4.6 | 23.7 ± 4.5 |
| L3-L4 | 26.2 ± 5.5 | 26.5 ± 5.0 | 26.0 ± 5.7 |
| L4-L5 | 26.9 ± 6.5 | 27.0 ± 6.1 | 26.8 ± 6.8 |
| L5-S1 | 27.9 ± 8.2 | 27.4 ± 8.6 | 28.0 ± 8.0 |
| Placebo yoghurt group | Plant stanol yoghurt group | pb | |||||
| Baseline | Intervention | Change (%) | Baseline | Intervention | Change (%) | ||
| Total cholesterol (mg/dl) | 233.4 ± 26.83 | 235.0 ± 23.75 | 1.2 ± 8.11 | 241.1 ± 25.81 | 232.0 ± 22.12 | −3.4 ± 7.60 | 0.007* |
| LDL cholesterol (mg/dl) | 154.5 ± 21.16 | 154.1 ± 18.58 | 0.5 ± 10.65 | 157.9 ± 26.40 | 147.7 ± 24.41 | −5.8 ± 10.90 | 0.005* |
| HDL cholesterol (mg/dl) | 51.2 ± 11.36 | 50.6 ± 11.62 | −0.9 ± 10.76 | 50.1 ± 14.35 | 49.6 ± 15.79 | −1.2 ± 8.87 | 0.524 |
| Triglycerides (mg/dl) | 138.5 ± 66.41 | 151.6 ± 66.45 | 19.8 ± 53.75 | 165.9 ± 99.42 | 174.0 ± 84.62 | 11.2 ± 27.05 | 0.606 |
| VLDL cholesterol (mg/dl) | 27.7 ± 13.27 | 30.3 ± 13.26 | 19.8 ± 53.60 | 33.1 ± 19.88 | 34.8 ± 16.92 | 11.3 ± 27.06 | 0.596 |
| Non-HDL cholesterol (mg/dl) | 182.2 ± 24.54 | 184.4 ± 20.86 | 2.0 ± 12.98 | 191.0 ± 28.24 | 182.5 ± 26.45 | −4.2 ± 10.73 | 0.005* |
| Apolipoprotein A-I (mg/dl) | 155.9 ± 20.50 | 154.3 ± 19.28 | −0.8 ± 6.02 | 152.7 ± 26.12 | 154.4 ± 33.25 | 1.4 ± 13.17 | 0.602 |
| Apolipoprotein B (mg/dl) | 122.1 ± 19.92 | 121.1 ± 20.28 | −0.4 ± 8.72 | 128.2 ± 20.09 | 121.0 ± 19.18 | −5.0 ± 11.81 | 0.076 |
| Lipoprotein-a (mg/dl) | 27.8 ± 26.86 | 29.3 ± 27.78 | 4.1 ± 18.13 | 35.8 ± 31.18 | 32.6 ± 29.39 | −2.8 ± 25.36 | 0.094 |
| Center 1Southeast | Center 2Southeast | Center 3Southeast | Center 4Southeast | Center 5South | Center 6Northeast | Center 7Center-West | Total | |
| DR-absent | 109 (60.6 %) | 118 (45.9 %) | 71 (41.0 %) | 31 (32.6 %) | 89 (49.4 %) | 82 (50.3 %) | 108 (49.5 %) | 608 (48.0 %) |
| DR-NP mild | 35 (19.4 %) | 91 (35.4 %) | 53 (30.6 %) | 33 (34.7 %) | 44 (24.4 %) | 42 (25.8 %) | 54 (24.8 %) | 352 (27.8 %) |
| DR-NP moderate | 10 (5.6 %) | 12 (4.7 %) | 5 (2.9 %) | 6 (6.3 %) | 8 (4.4 %) | 4 (2.5 %) | 7 (3.2 %) | 52 (4.1 %) |
| DR-NP severe | 8 (4.4 %) | 9 (3.5 %) | 4 (2.3 %) | 0 (0.0 %) | 3 (1.7 %) | 4 (2.5 %) | 6 (2.8 %) | 34 (2.7 %) |
| DR-proliferative | 14 (7.8 %) | 20 (7.8 %) | 29 (16.8 %) | 18 (19.0 %) | 27 (15.0 %) | 22 (13.5 %) | 29 (13.3 %) | 159 (12.6 %) |
| DR-impossible | 4 (2.2 %) | 7 (2.7 %) | 11 (6.4 %) | 7 (7.4 %) | 9 (5.0 %) | 9 (5.5 %) | 14 (6.4 %) | 61 (4.8 %) |
| Total retinopathy | 180 (100 %) | 257 (100 %) | 173 (100 %) | 95 (100 %) | 180 (100 %) | 163 (100 %) | 218 (100 %) | 1266 (100 %) |
| MAC-apparently absent | 141 (78.3 %) | 201 (78.2 %) | 137 (79.2 %) | 72 (75.8 %) | 144 (80.0 %) | 124 (76.1 %) | 161 (73.9 %) | 980 (77.4 %) |
| MAC-apparenlty present | 32 (17.8 %) | 42 (16.4 %) | 14 (8.1 %) | 13 (13.7 %) | 18 (10.0 %) | 25 (15.3 %) | 35 (16.1 %) | 179 (14.1 %) |
| MAC-impossible | 7 (3.9 %) | 14 (5.4 %) | 22 (12.7 %) | 10 (10.5 %) | 18 (10.0 %) | 14 (8.6 %) | 22 (10.1 %) | 107 (8.5 %) |
| Total maculopathy | 180 (100 %) | 257 (100 %) | 173 (100 %) | 95 (100 %) | 180 (100 %) | 163 (100 %) | 218 (100 %) | 1266 (100 %) |
| 11/15/13 | 11/20/13 | 1/8/14 | 5/26/14 | |
| Total T (2–45 ng/dL) | 337 | 281 | 230 | 288 |
| Free T (0.1–6.4 pg/mL) | 41.2 | 42.4 | 55.4 | |
| DHEA (<1185 mcg/dL) | 117 | |||
| DHEA‐S (24–278 mcg/dL) | 92 | |||
| Estradiol (5–38 pg/mL) | 23 | |||
| FSH (0–14 mIU/mL) | 86.5 | |||
| LH (0–14 mIU/mL) | 42.7 | |||
| 17‐hydroxyprogesterone (<51 ng/dL) | 26 | |||
| Prolactin (<20 ng/mL) | 8 | |||
| ACTH (6–50 pg/dL) | 9 |
| Model | R2 | AIC | ∆AIC | Model parameters | Parameter estimate |
| Climate variables only – Above 1300 m | |||||
| 1 | 0.50 | −217.3 | 0 | Precipitation – 6 month lag | −0.56 |
| Precipitation – 4 mo. Lag | 0.37 | ||||
| 2 | 0.48 | −215.6 | 1.7 | Precipitation – 6 mo. Lag | −1.4 |
| Mean temperature – 0 mo. lag | 0.83 | ||||
| Climate and crop variable – Above 1300 m | |||||
| 1 | 0.69 | −232.3 | 0 | Maize/Millet harvest – 0 mo. lag | 0.47 |
| Nut harvest – 4 mo. Lag | 0.53 | ||||
| 2 | 0.68 | −231.0 | 1.3 | Maize/Millet harvest – 0 mo. lag | 0.51 |
| Bean harvest – 4 + 5 mo. Lag | 0.51 |
| Indexes | T1 | T2 | CK |
| CH4 : O2 | 90:10 | 99:1 | – |
| Dissolved O2 (mg l−1) | 3.96 ± 0.09 | 0.24 ± 0.01 | – |
| Methane oxidation activity (μmol g VSS−1 day−1) | 640.16 ± 88.76 | 354.21 ± 45.62 | – |
| Denitrification activity (μmol g VSS−1 day−1) | |||
| Nitrite consumption rate | 68.39 ± 2.90 | 46.50 ± 6.19 | 28.03 ± 1.59 |
| Nitrate consumption rate | 25.50 ± 2.33 | 13.18 ± 2.07 | 5.02 ± 1.78 |
| Formaldehyde (μg l−1) | 355.00 ± 7.07 | 405.00 ± 7.07 | 19.50 ± 0.71 |
| Citrate (μg l−1) | 350.00 ± 14.14 | 320.00 ± 14.14 | 55.00 ± 7.07 |
| Acetate (μg l−1) | 130.00 ± 21.21 | 150.00 ± 0.00 | 17.2 ± 2.12 |
| Formate (μg l−1) | 24.70 ± 0.71 | 27.20 ± 1.41 | 0.6 ± 0.14 |
| Methanol (μg l−1) | 0.50 ± 0.00 | 0.55 ± 0.07 | 0.15 ± 0.07 |
| Constructs | mutation | XMRV p53 | XMRV p58 |
| pVP62 (WT) | None | + | + |
| pVP62Δgg0 | _ to A (nt 372) | - | - |
| pVP62Δgg1 | C to AT (nt 382) | - | - |
| pVP62Δgg2 | T to C (nt 370) | + | - |
| pVP62Δgg3 | T to C (nt 341) | - | + |
| pVP62Δgg4 | T to G (nt 354) | - | + |
| Observed | Poisson | Neg. Bin | ZIP | ZINB | PLH | NBLH |
| 1705 | 183 | 1704 | 1705 | 1705 | 1705 | 1705 |
| HAZ or HAZ Difference | Boys | Girls | ||
| FPC1 Score b | Adj-FPC2 Scorec | FPC1 Scoreb | Adj-FPC2 Scorec | |
| HAZ at enrollment | −0.849 | 0.292 | −0.971 | −0.136d |
| HAZ at 6 months | −0.940 | 0.100e | −0.982 | −0.179d |
| HAZ at 12 months | −0.996 | −0.304 | −1.000 | −0.350 |
| HAZ at 18 months | −0.980 | −0.427 | −0.992 | −0.459 |
| HAZ at 24 months | −0.979 | −0.425 | −0.990 | −0.467 |
| Change of HAZ %tiles from birth to age 24 months | −0.156d | −0.919 | −0.047e | −0.794 |
| Change of HAZ %tiles between age 6 and 18 months | −0.062e | −0.905 | −0.028e | −0.787 |
| Oil | Soybean oil | Soybean oil | Soybean oil | Salmon oil | Salmon oil | Salmon oil | ANOVA (P) | ||
| Vitamin E (mg/kg) | 25 | 250 | 2500 | 25 | 250 | 2500 | Vitamin E | Oil | Vitamin E x oil |
| Initial weight (g) | 314 ± 16 | 314 ± 15 | 313 ± 14 | 314 ± 14 | 313 ± 14 | 314 ± 14 | 0.99 | 0.98 | 0.99 |
| Final weight (g) | 428 ± 25 | 435 ± 22 | 434 ± 26 | 442 ± 21 | 438 ± 26 | 440 ± 19 | 0.96 | 0.18 | 0.71 |
| Body weight gain (g/d) | 114 ± 22 | 122 ± 13 | 120 ± 17 | 128 ± 13 | 124 ± 18 | 126 ± 14 | 0.91 | 0.058 | 0.50 |
| Diet intake (g/d) | 24.0 ± 1.3 | 24.6 ± 1.4 | 24.9 ± 1.3 | 25.7 ± 0.9 | 25.1 ± 1.5 | 25.2 ± 1.7 | 0.82 | 0.008 | 0.18 |
| Feed/gain ratio (g/g) | 5.9 ± 1.6 | 5.5 ± 0.5 | 5.7 ± 0.7 | 5.5 ± 0.6 | 5.5 ± 0.5 | 5.4 ± 0.4 | 0.71 | 0.25 | 0.60 |
| Maternal support | Paternal support | |
| Physical activity | ||
| All children | 0.37** | 0.36** |
| Boys | 0.31** | 0.26* |
| Girls | 0.45** | 0.45** |
| Fruit and vegetable consumption | ||
| All children | 0.35** | 0.13 |
| Boys | 0.26* | 0.25 |
| Girls | 0.46** | 0.05 |
| Patients | Uniform orthogonal grid | Uniform tetrahedron mesh | Nonuniform tetrahedron mesh |
| H&N01 | |||
| Number of vertices | 936 | 992 | 1,007 |
| NCC | 0.8327 | 0.8358 | 0.8460 |
| NRMSE | 0.4988 | 0.4938 | 0.4792 |
| H&N02 | |||
| Number of vertices | 1,040 | 990 | 1,000 |
| NCC | 0.9036 | 0.9122 | 0.9134 |
| NRMSE | 0.4182 | 0.4116 | 0.4084 |
| H&N03 | |||
| Number of vertices | 980 | 1,000 | 998 |
| NCC | 0.8470 | 0.8471 | 0.8482 |
| NRMSE | 0.4748 | 0.4743 | 0.4722 |
| H&N04 | |||
| Number of vertices | 1,001 | 1,000 | 1,000 |
| NCC | 0.7756 | 0.7806 | 0.8111 |
| NRMSE | 0.5841 | 0.5817 | 0.5567 |
| H&N05 | |||
| Number of vertices | 980 | 1,000 | 995 |
| NCC | 0.7565 | 0.7690 | 0.7843 |
| NRMSE | 0.6278 | 0.6092 | 0.5712 |
| Kessounou South | Malanville North | Allada South | Kandi North | |||||
| Distance to water for washing nets | < 0.05 km | > 5.0 km | ||||||
| Assessment visit | T12 | T18 | T12 | T18 | T12 | T18 | T12 | T18 |
| n of nets found with any hole (s) | 219 | 210 | 294 | 260 | 178 | 133 | 241 | 208 |
| n (%) of nets with ‘rip in the fabric’ | 158 (72) | 142 (68) | 279 (95) | 248 (95) | 133 (75) | 114 (86) | 219 (91) | 178 (86) |
| CI 95% | 65.87-77.66 | 61.02-73.58 | 91.75-96.88 | 92.11-97.34 | 67.86-80.54 | 78.76-90.66 | 86.57-93.89 | 80.16-89.71 |
| n (%) of nets with ‘rip in the seam’ | 4 (2) | 5 (2) | 3 (1) | 5 (2) | 10 (6) | 3 (2) | 9 (4) | 16 (8) |
| CI 95% | 00.71-04.60 | 01.02-05.45 | 00.35-02.96 | 00.82-04.42 | 03.08-10.03 | 00.77-06.42 | 01.98-06.94 | 04.79-12.13 |
| n (%) of nets with ‘burn holes’ | 52 (24) | 62 (29) | 9 (3) | 6 (2) | 26 (14) | 11 (8) | 12 (5) | 9 (4) |
| CI 95% | 18.59-29.80 | 23.77-36.02 | 01.62-05.71 | 01.06-04.94 | 10.17-20.54 | 04.68-14.20 | 02.87-08.50 | 02.29-08.02 |
| n (%) of nets chewing by rodent | 5 (2) | 2 (1) | 3 (1) | 1 (1) | 9 (5) | 5 (4) | 1 (0) | 5 (2) |
| CI 95% | 00.98-05.23 | 00.26-03.41 | 00.35-02.96 | 00.07-02.15 | 02.68-09.33 | 01.62-08.50 | 00.07-02.31 | 01.03-05.50 |
| Standard method | Locally-based method | Total | |
| Period of facility assessments | March-April, 2010 | July-August, 2010 | March-August, 2010 |
| Number of survey teams used | 1 | 24 | 25 |
| All unique facilities assessed | 11 | 24 | 24 |
| Sub-Health Center | 2 | 6 | 6 |
| Basic Health Centers | 8 | 16 | 16 |
| Comprehensive Health Centers | 1 | 2 | 2 |
| All patients observed/interviewed | 94 | 216 | 310 |
| All health workers interviewed | 30 | 64 | 94 |
| Category | AML with inv(16) (n = 27) | AMML without inv(16) * (n = 10) | Other types of AML * (n = 22) |
| Strong | 20 | 1 | 7 |
| Weak/Focal | 5 | 3 | 3 |
| Negative | 2 | 6 | 12 |
| Age (years) | Male | Female | ||
| n | % | n | % | |
| 7 | 4 | 40 | 4 | 40 |
| 8 | 6 | 60 | 3 | 30 |
| 9 | 0 | 0 | 3 | 30 |
| Total | 10 | 100 | 10 | 100 |
| RQCD1 mutant | RQCD1 WT | ||||||
| Mutation | n | % | n | % | OR | 95%CI | p-value |
| BRAF | |||||||
| WT | 17 | 59 | 448 | 65 | 1 | ||
| V600E | 7 | 24 | 193 | 28 | 1.0 | 0.4, 2.3 | 0.9 |
| V600K | 5 | 17 | 44 | 6 | 3.0 | 1.1, 8.5 | 0.04 |
| NRAS** | |||||||
| WT | 90 | 91 | 1 | ||||
| Mutant | 10 | 9 | 0.7 | 0.2, 2.5 | 0.6 |
| Fatty acids | CB diets | SF diets |
| Palmitic (16:0) | 26.3 | 7.9 |
| Palmitoleic (16:1) | 0.2 | 0.1 |
| Stearic (18:0) | 29.0 | 2.3 |
| Oleic (18:1n-9) | 31.6 | 12.5 |
| Linoleic (18:2n-6) | 10.5 | 75.3 |
| α-Linolenic (18:3n-3) | 1.2 | 1.1 |
| SFAs1 | 56.4 | 10.7 |
| MUFAs2 | 31.9 | 12.9 |
| PUFAs | 11.7 | 76.4 |
| PUFA/SFA ratio | 0.21 | 7.14 |
| n-6/n-3 ratio | 8.8 | 68.5 |
| Relative UI | 0.57 | 1.67 |
| Variable | Hazards ratio | 95% CI* | P value |
| Age (>45.89 vs. ≤45.89) | 3.14 | 1.58–6.25 | 0.001 |
| Clinical stage (III-IV vs. I-II) | 3.27 | 1.00–10.67 | 0.050 |
| Relapse (Yes vs. No) | 5.97 | 3.10–11.49 | 0.000 |
| p53R2 expression (High vs. Low) | 0.39 | 0.18–0.85 | 0.018 |
| Number of patients (%) (N = 36) | |
| Age | |
| Median (range) | 58 (21–74) |
| ≥ 65 years | 10 (27.8%) |
| Sex | |
| Male | 33 (91.7%) |
| Female | 3 (8.3%) |
| Hepatocellular carcinoma etiology | |
| Hepatitis B | 26 (72.2%) |
| Hepatitis C | 1 (2.8%) |
| Alcoholic cirrhosis | 8 (22.2%) |
| Other | 1(2.8%) |
| Metastastic sites | |
| Lung | 22 (61.1%) |
| Lymph node | 11 (30.6%) |
| Bone | 9 (25.0%) |
| Other | 11 (30.6%) |
| ECOG PS | |
| 0 | 23 (63.9%) |
| 1 | 13 (36.1%) |
| 2 | 0 (0.0%) |
| Any prior therapy | |
| Sorafenib | 31 (86.1%) |
| Locoregional therapya | 31 (86.1%) |
| AFP | |
| < 200 ng/mL | 22 (61.1%) |
| ≥ 200 ng/mL | 14 (38.9%) |
| PIVKA | |
| < 400 mAU/mL | 17 (47.2%) |
| ≥ 400 mAU/mL | 19 (52.8%) |
| Name | P-value | Number of molecules |
| Molecular and Cellular Functions | ||
| Cell Death and Survival | 2.53 × 10−24 to 1.36 × 10−3 | 405 |
| Cellular Growth and Proliferation | 3.37 × 10−24 to 1.36 × 10−3 | 414 |
| Cellular Movement | 5.41 × 10−13 to 1.36 × 10−3 | 236 |
| Gene Expression | 8.14 × 10−11 to 1.20 × 10−3 | 247 |
| Cellular Development | 1.13 × 10−10 to 1.36 × 10−3 | 328 |
| Physiological System Development and Function | ||
| Cardiovascular System Development and Function | 4.17 × 10−12 to 1.20 × 10−3 | 125 |
| Organismal Development | 3.96 × 10−11 to 1.22 × 10−3 | 92 |
| Tissue Development | 3.68 × 10−8 to 1.22 × 10−3 | 163 |
| Tumor Morphology | 3.84 × 10−7 to 1.20 × 10−3 | 117 |
| Connective Tissue Development and Function | 8.52 × 10−6 to 1.24 × 10−3 | 40 |
| Confinement | CNVR | VMR | Total |
| Free Roaming | 1441 | 4812 | 6253 |
| Presented by owner | 20 | 631 | 651 |
| Total | 1461 | 5443 | 6904 |
| Database | # Of Genes in Database | Last Updated 1 | Database Source |
| ShortBRED VF 2 | 26,187 | July 2017 | https://huttenhower.sph.harvard.edu/shortbred |
| ShortBRED AR 3 | 932 | July 2017 | https://huttenhower.sph.harvard.edu/shortbred |
| Virulence Factor DataBase (VFDB) | 30,246 | February 2018 | http://www.mgc.ac.cn/VFs/main.htm |
| Comprehensive Antibiotic Resistance Database (CARD) | 2514 | February 2018 | https://card.mcmaster.ca/download |
| No. | Antibiotic | Abbr. | Concentration (μg) | Class |
| 1. | Amikacin | AK | 30 | Aminoglycosides |
| 2. | Amoxicillin/clavulanic acida | AMC | 30 | 3rd generation penicillins |
| 3. | Ampicillin | AMP | 10 | Aminoglycosides |
| 4. | Aztreonam | ATM | 30 | Monobactams |
| 5. | Cefamandole | MA | 30 | 2nd generation cephalosporins |
| 6. | Cefepime | FEP | 30 | 4th generation cephalosporins |
| 7. | Cefotaximea | CTX | 30 | 3rd generation cephalosporins |
| 8. | Cefoxitin | FOX | 30 | 3rd generation cephalosporins |
| 9. | Ceftazidimea | CAZ | 30 | 3rd generation cephalosporins |
| 10. | Cefalotin | KF | 30 | 3rd generation cephalosporins |
| 11. | Cefazolin | KZ | 30 | 1st generation cephalosporins |
| 12. | Ciprofloxacin | CIP | 5 | Chinolons |
| 13. | Gentamicin | CN | 10 | Aminoglycosides |
| 14. | Netilmicin | NET | 30 | Aminoglycosides |
| 15. | Piperacillin | PRL | 100 | 4th generation penicillins |
| 16. | Piperacillin/tazobactam | TZP | 110 | 4th generation penicillins |
| 17. | Tetracycline | TE | 30 | Tetracyclines |
| 18. | Ticarcyillin | TIC | 75 | 4th generation penicillins |
| 19. | Tobramycin | TOB | 10 | Aminoglycosides |
| 20. | Trimethoprim/sulfamethoxazole | SXT | 25 | Sulfonamides |
| Variable | Diabetes case ascertainment cohort n (%) | Comorbidity case ascertainment cohort n (%) |
| Age group | ||
| < 65 years | 1518 (6.5) | 300 (7.2) |
| 65 – 74 years | 2090 (9.0) | 554 (13.2) |
| 75 – 84 years | 7187 (31.0) | 1517 (36.3) |
| 85+ years | 12422 (53.5) | 1812 (43.3) |
| Sex | ||
| Female | 14795 (63.7) | 2547 (60.9) |
| Male | 8422 (36.3) | 1636 (39.1) |
| Charlson comorbidity index | ||
| 0 | 7947 (34.2) | 1108 (26.5) |
| 1-2 | 9467 (40.8) | 1552 (37.1) |
| 3+ | 5803 (25.0) | 1523 (36.4) |
| Income quintile | ||
| Q1 (Lowest) | 5400 (23.3) | 1097 (26.2) |
| Q2 | 4814 (20.7) | 887 (21.2) |
| Q3 | 5639 (24.3) | 983 (23.5) |
| Q4 | 4072 (17.5) | 693 (16.6) |
| Q5 (Highest) | 3143 (13.5) | 500 (12.0) |
| Missing | 149 (0.6) | 23 (0.5) |
| Residence location | ||
| Rural | 11796 (50.8) | 2197 (52.5) |
| Urban | 11209 (48.3) | 1932 (46.2) |
| Missing | 212 (0.9) | 54 (1.3) |
| Facility affiliation | ||
| Affiliated | 6834 (29.4) | 1160 (27.7) |
| Amalgamated | 14412 (62.1) | 2686 (64.2) |
| Contract | 1968 (8.5) | 334 (8.1) |
| Facility type | ||
| Special care home | 20002 (90.5) | 3787 (90.5) |
| Other facility | 2215 (9.5) | 396 (9.5) |
| Diabetes prevalence (%) | 6298 (27.1) | 4183 (100.0) |
| Stakeholders’ designation | Number of participants |
| Mobile phone programming company | 1 |
| Clinicians | 4 |
| Community health workers | 4 |
| Research team | 4 |
| District health management teams | 10 |
| Total | 23 |
| CHP per subject | Number of subjects (%) | Number of conditions | CHP/subj average | Column-% | |
| 0 = MM0 | 17,273 | (19.7) | 0 | 0 | 0 |
| 1 = MM1 | 14,328 | (16.3) | 14,328 | 1 | 4.7 |
| 2 = MM2 | 12,762 | (14.5) | 25,524 | 2 | 8.4 |
| 3 = MM3 | 10,350 | (11.8) | 31,050 | 3 | 10.3 |
| 4-5 = MM4-5 | 14,199 | (16.2) | 62,939 | 4.4 | 20.8 |
| 6-10 = MM6-10 | 14,365 | (16.4) | 107,314 | 7.5 | 35.4 |
| 11+ = MM11+ | 4,560 | (5.2) | 61,653 | 13.5 | 20.4 |
| Total | 87,837 | (100,1) | 302,808 | 3.4 | 100 |
| N = 3520 | Total number of women | % | 95% CIs |
| Given information during pregnancy (Told about pregnancy complications or told where to go for pregnancy complications or advised to use a skilled birth attendant) | |||
| Yes | 2,872 | 81.6 | 78.5 to 84.4 |
| Iron tablets/syrup taken | |||
| Yes | 3,214 | 91.3 | 89.3 to 93.0 |
| Given intestinal parasite drugs | |||
| Yes | 2,250 | 63.9 | 60.8 to 66.9 |
| Two or more tetanus injections given | |||
| Yes | 3,033 | 86.2 | 84.2 to 87.9 |
| Blood pressure measured | |||
| Yes | 3,043 | 86.4 | 83.9 to 88.6 |
| Blood sample taken | |||
| Yes | 1,595 | 45.3 | 41.8 to 48.9 |
| Urine sample taken | |||
| Yes | 1,968 | 55.9 | 52.4 to 59.3 |
| Received all seven ANC components | |||
| 854 | 24.3 | 21.6 to 27.2 |
| Early events in the disease course | EDSS outcome in patients with long term follow-up (≥ 100 months)(median, range; N) | p-level |
| Motor symptoms at first myelitis*Sensory symptoms at first myelitis* | 7 (1.5-10; 29)5.25 (2-9; 16) | p < 0.04§ |
| Motor symptoms at onsetSensory symptoms at onset | 8.25 (5.5-10; 8)4 (2-6.5; 5) | p < 0.007§ |
| Tetraparesis at first myelitis*Motor symptoms other than tetraparesis at first myelitis* | 8.25 (7-10; 8)6 (1.5-10; 21) | p < 0.003§ |
| > 1 myelitis attacks during the first year1 myelitis attack during the first year | 8 (2.5-10; 7)5.5 (2-8.5; 11) | p < 0.035§ |
| 18S+28S vs. 18S+28S | 18S+28S vs. cox1+cox3 | 18S+28S vs. tufA | cox1+cox3 vs. 18S+28S | cox1+cox3 vs. cox1+cox3 | cox1+cox3 vs. tufA | tufA vs. 18S+28S | tufA vs. cox1+cox3 | tufA vs. tufA | |
| BP | 0.989 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| KH | 1 | 0.021 | 0.04 | 0 | 1 | 0 | 0 | 0 | 1 |
| SH | 1 | 0.021 | 0.04 | 0 | 1 | 0 | 0 | 0 | 1 |
| WSH | 1 | 0.032 | 0.04 | 0 | 1 | 0 | 0 | 0 | 1 |
| AU | 0.994 | 0 | 0 | 0 | 0.235 | 0 | 0 | 0 | 0.235 |
| ln | −3114.161 | −3217.96 | −3192.395 | −3213.426 | −2301.843 | −2819.113 | −1822.457 | −1667.534 | −1259.645 |
| Parameter | Estimate | SE | T | i |
| Intercept | 0.974 | 0.261 | 3.736 | <0.001 |
| Species | −2.028 | 0.369 | −5.500 | <0.001 |
| Acc.Temp | −0.057 | 0.018 | −3.231 | 0.001 |
| Species × Acc.Temp | 0.111 | 0.025 | 4.419 | <0.001 |
| Toxicity | Number of Patients Reporting Toxicity by Gradea(N = 24 total toxicities) | Total | ||||
| 1 | 2 | 3 | 4 | 5 | ||
| Pain | 2 | 7 | 0 | 0 | 0 | 9 |
| Fatigue | 2 | 0 | 0 | 0 | 0 | 2 |
| Pneumonia | 0 | 1 | 1 | 0 | 0 | 2 |
| Pneumothorax | 0 | 2 | 0 | 0 | 0 | 2 |
| Atrial Fibrillation (uncontrolled) | 0 | 0 | 0 | 1 | 0 | 1 |
| Dyspnea | 1 | 0 | 0 | 0 | 0 | 1 |
| Respiratory failure | 0 | 0 | 0 | 1 | 0 | 1 |
| Post-Operative Bleeding | 1 | 0 | 0 | 0 | 0 | 1 |
| Broncho-pleural Fistula | 0 | 1 | 0 | 0 | 0 | 1 |
| Generalized Weakness | 1 | 0 | 0 | 0 | 0 | 1 |
| Nausea | 0 | 1 | 0 | 0 | 0 | 1 |
| Vomiting | 0 | 1 | 0 | 0 | 0 | 1 |
| Anorexia | 1 | 0 | 0 | 0 | 0 | 1 |
| Variables (Percentage) | |
| No. patients | 74 |
| Age (years) | |
| Mean | 59.8 ± 15.6 |
| Median | 62 |
| Sex (female/male) | 53/47 |
| Mechanically ventilated | 84 |
| Oxygen by | |
| Mask | 9 |
| Nasal tube | 7 |
| Central venous line | 76 |
| Intra-arterial catheter | 92 |
| Peripheral venous line | 87 |
| Vasopressor/inotropic drugs | 53 |
| APACHE II score | 20 ± 8.1 |
| Duration of transfer (min) | 51.3 ± 19.1 |
| Reason transfer | |
| Logistic | 20 |
| Advanced therapy | 80 |
| IQ | Working memory | Inhibitory control | Emotion recognition | |
| Working memory | .39 | |||
| Inhibitory control | .21 | .11 | ||
| Emotion recognition | −.16 | −.11 | −.09 | |
| ADHD hyperactive-impulsive | −.16 | −.13 | −.07 | .09 |
| ADHD inattentive | −.21 | −.19 | −.12 | .09 |
| Social cognition | −.14 | −.11 | −.05 | .10 |
| Pragmatic language | −.25 | −.18 | −.06 | .08 |
| Group (n = 5) | Tumor volume(mm3) | Inhibitory Rate (%) | Tumor weight (g) | Inhibitory Rate (%) |
| control | 2531.78 ± 153.25 | 1.194 ± 0.10 | ||
| Tet (40 mg/kg) | 1243.00 ± 55.19*** | 50.90 | 0.641 ± 0.06*** | 46.31 |
| Tet(120 mg/kg) | 493.06 ± 145.63*** | 80.52 | 0.298 ± 0.09*** | 75.04 |
| Parameter | Base case (male, female) | Age 55 years | Age 60 years |
| Threshold | Threshold | ||
| First aseptic revision rate (early) | 1.31%, 1.13% | Robust | Robust |
| First aseptic revision rate (late) | 0.61%, 0.63% | Robust | Robust |
| First infection revision rate (early) | 0.20%, 0.17% | Robust | Robust |
| First infection revision rate (late) | 0.09% | Robust | Robust |
| End-stage osteoarthritis [1] | USD 12,815 | Robust | Robust |
| Initial post-THA (365 days) | USD 38,965 | USD 123,700 (female)USD 170,100 (male) | USD 78,800 (female)USD 116,900 (male) |
| Productivity | Varies by age and gender | 26% of base (female)20% of base (male) | 41% of base (female)28% of base (male) |
| Characteristics | Mean (SD) | n (%) |
| Gender | ||
| Male | 162 (47.5) | |
| Female | 179 (52.5) | |
| Marital Status | ||
| Single | 20 (5.9) | |
| Married | 257 (75.3) | |
| Others | 64 (18.8) | |
| Current Smoker | ||
| Yes | 75 (22) | |
| No | 266 (78) | |
| Education | ||
| Less than secondary school | 243 (71.3) | |
| Diploma | 45 (13.2) | |
| Bachelor or higher | 51 (15.5) | |
| Diabetes Treatment | ||
| Insulin | 96 (28.2) | |
| Oral tablet | 165 (48.4) | |
| Insulin + Oral tablet | 78 (23.4) | |
| Blood Sugar Self-Monitoring | ||
| Yes | 300 (88) | |
| No | 41 (12) | |
| Age (yr) | 55.2 (12.9) | |
| Body Mass Index | 29.7 (5.6) | |
| Household members | 4 (2.4) | |
| Income (USD) | 630 (425) | |
| Duration of illness (years) | 11.3 (9.2) | |
| Glycated Hemoglobin | 7.9 (1.9) | |
| No. of Cigarettes/ day | 4.4 (10.1) |
| Filtering Criteria | Number of SNPs Excluded | Number of SNPs Remaining |
| None | 0 | 2,740,205 |
| Multiple Variants hits | 33,917 | 2,706,288 |
| Heterozygous and Bias* | 2,111,439 | 594,849 |
| Flanking Sequence** | 5,482 | 589,367 |
| Candidate SNPs | 589,367 |
| Total cost | Medical cost | Drug cost | |
| Crude cost change – binary indicator | |||
| Chronic users | 20,161**(18,775–21,547) | 10,925**(9637–12,213) | 9236**(8841–9632) |
| Concomitant users | 16,666**(15,893–17,439) | 11673**(10,954–12,392) | 4993**(4772–5214) |
| Opioid disorder | 15,026**(13,306–16,746) | 11,974**(10,377–13,571) | 3051**(2559–3544) |
| Adjusted cost change (with covariates and weighting) – binary indicator | |||
| Chronic users | 6216**(5678–6754) | 281(−123 to 795) | 5935**(5808–6063) |
| Concomitant users | 637*(134–1140) | -1036**(−1518 to −553) | 1673**(1546–1799) |
| Opioid disorder | 1558**(1039–2076) | 671**(161–1181) | 887**(809–964) |
| Crude cost change (one level increase in severity) – severity level (0–3) | |||
| Severity of chronic users | 8845**(8205–9486) | 4523**(3928–5119) | 4322**(4139–4505) |
| Severity of concomitant users | 7343**(6987–7700) | 4959**(4628–5291) | 2384**(2282–2486) |
| Severity of opioid disorder | 6206**(5390–7022) | 4880**(4123–5637) | 1326**(1093–1560) |
| Adjusted cost change (with covariates: one level increase in severity) – severity level (0–3) | |||
| Severity of chronic users | 3337**(2695–3978) | 263(−344 to 869) | 3074**(2887–3261) |
| Severity of concomitant users | 1209**(840–1579) | 315(−34 to 664) | 895**(787–1002) |
| Severity of opioid disorder | 1136*(206–2067) | 809(−70 to 1688) | 328*(56–599) |
| Patients with dementia N = 1059 | Comparison patients N = 5543 | |||
| Non-Osteoporosis group | N | % | N. | % |
| Total | ||||
| Non-osteoporosis | 177 | 16.71 | 768 | 13.86 |
| Crude HR (95% CI) | 1.36 (1.15- 1.60)* | 1.00 | ||
| Adjusted HR (95% CI) | 1.35 (1.11- 1.64)* | 1.00 | ||
| Hip fracture | ||||
| Non-osteoporosis | 84 | 7.93 | 242 | 4.37 |
| Crude HR (95% CI) | 2.04 (1.59- 2.62)* | 1.00 | ||
| Adjusted HR (95% CI) | 1.84 (1.37- 2.46)* | 1.00 | ||
| Wrist fracture | ||||
| Non-osteoporosis | 34 | 3.21 | 142 | 2.56 |
| Crude HR (95% CI) | 1.32 (0.87- 1.99) | 1.00 | ||
| Adjusted HR (95% CI) | 1.48 (0.93- 2.43) | 1.00 | ||
| Vertebral fracture | ||||
| Non-osteoporosis | 48 | 4.53 | 335 | 6.04 |
| Crude HR (95% CI) | 0.86 (0.64- 1.17) | 1.00 | ||
| Adjusted HR (95% CI) | 0.88 (0.62- 1.25) | 1.00 |
| Congenital Malformation | Count of Exposures | ||||
| Number of dyads | Fathers (max/individual = 3) | Mothers (max/individual = 2) | |||
| Cases | Controls | Cases | Controls | ||
| Multifactorial conditions with morphologic anomalies (excluding hip) | 97 | 42 | 27 | 23 | 20 |
| Hip dysplasia and dislocation | 20 | 16 | 4 | 13 | 2 |
| Cancer type | Mechanism | Agent | Phase |
| Melanoma | Anti-CTLA-4 | Ipilimumab | FDA approved |
| Melanoma | Anti-PD-1 | Nivolumab | Phase III |
| Melanoma | Anti-PD-1 | Pembrolizumab | FDA approved |
| Melanoma | Adoptive cell therapy | Phases I-II | |
| Melanoma | Peptide Vaccine | Melan-A peptides | Phases I-II |
| Melanoma | Autologous DC vaccine | Phases I-II | |
| Melanoma | Whole tumor cell vaccine | Phases I-II | |
| NSCLC | Peptide vaccine | EGFR peptide | Phase III |
| NSCLC | Anti-CTLA-4 | Ipilimumab | Phase III |
| NSCLC | Anti-PD-1 | Nivolumab | Phase II |
| Item | Never | Seldom (< 1/month) | Occasionally (1 to 3 times/month) | Often (1 to 2 times/week) | Frequently (≥3 times/week) |
| N (%) | N (%) | N (%) | N (%) | N (%) | |
| Applied to patient care | 0 (0) | 3 (14) | 7 (33) | 8 (38) | 3 (14) |
| Reinforced by senior residents and faculty | 0 (0) | 4 (19) | 12 (57) | 5 (24) | 0 (0) |
| Drug | Target | Rat study standard findings | Human clinical findings | MMtox prediction |
| Captopril | Kidney | Yes | Yes | Yes (∗) |
| Lisinopril | Kidney | Yes | Yes | Yes (∗) |
| Cyclosporin A | Kidney | Yes | Yes | Yes |
| Doxorubicin | Kidney | Yes | Yes | Yes |
| Phenytoin | Kidney | No | No | No |
| Captopril | Liver | No | Yes | Yes |
| Cyclosporin A | Liver | Yes | Yes | Yes |
| Doxorubicin | Liver | Yes | Yes | Yes |
| Lisinopril | Liver | No | No | No |
| Phenytoin | Liver | No | Yes | Yes |
| Cyclosporin A | Anemia | Yes | Yes | Yes |
| Doxorubicin | Anemia | Yes | Yes | Yes |
| Captopril | Bone marrow | Yes | Yes | Yes |
| Lisinopril | Platelet | Yes | Yes | Yes |
| Test Material/Chemical | Experimental Model | Findings | Reference |
| Xanthigen (brown marine algae fucoxanthin + pomegranate seed oil) | Mouse 3T3-L1 preadipocytes | ↓ accumulation of lipid droplets in adipocytes;↓ protein levels of key adipogenesis transcription factors: PPARγ, CCAAT/enhancer binding protein (C/EBP) β, and C/EBPδ & fatty acid synthase;↑ NAD+-dependent histone deacetylases (SIRT1) and activated AMP-activated protein kinase (AMPK) signaling in differentiated 3T3-L1 adipocytes. | [63] |
| Brown seaweed extract (10% fucoxanthin) | Human adipose-derived stem cells | ↓ ROS;Silencing of palmitic acid-induced long non-coding RNAs (lncRNAs) resulted in the decrease in lipid droplet accumulation | [57] |
| Fucoxanthin-rich wakame (Undaria) lipids (WL) | Mouse (Type 2 diabetes/obese model) | ↓ body weight and white adipose weight;↓ plasma levels of leptin;↑ mRNA expression of β3-adrenergic receptor (Adrb3) in WAT and glucose transporter 4 (GLUT4) mRNA in skeletal muscle tissues | [45] |
| Fucoxanthin & Fucoxanthinol | Mouse (Type 2 diabetes/obese model) | Improved glucose tolerance;↓ TNF-γ and MCP-1 expression in WAT | [48] |
| Capsule containing omega-3 PUFA-rich scallop phospholipids (PL) with incorporation of Undaria lipids (UL) containing fucoxanthin | Mouse | ↓ body weight and WAT weight;↑ UCP1 and mRNA expression of UCP1 in epididymal fat | [53] |
| Fucoxanthin (pure chemical) | Mouse | ↓ IL-1β, TNF-α, iNOS, and COX-2, and suppressed maleic dialdehyde (MDA) and infiltration of polymorphonuclear cells (PMN) | [47] |
| Petalonia binghamiae extract containing fucoxanthin | Mouse | ↓ body weight gain, adipose tissue weight and cell size, fatty droplet accumulation in the liver, and serum triacylglycerol level;↓ phosphorylation of AMP-activated protein kinase (AMPK) and acetyl-CoA carboxylase (ACC) in epididymal adipose tissue | [58] |
| Fucoxanthin (isolated from dried Undaria pinnatifida) | Mouse | ↓ plasma triacylglycerols with a concomitant;↑ fecal lipids;↓ hepatic lipid contents;↓ activity of the hepatic lipogenic enzymes, glucose-6-phosphate dehydrogenase, malic enzyme, fatty acid synthase and phosphatidate phosphohydrolase;↑ activity of β-oxidation;↑ plasma HDL-cholesterol concentrations;↓ glucose and HbA1c | [51] |
| Fucoxanthin oil (1% fucoxanthin) + conjugated linolenic acid (CLA) | Rat | ↓ triacylglycerol and leptin levels;↑ mRNA expression of adiponectin, adipose triacylglycerol lipase and carnitine palmitoyltransferase 1A | [50] |
| Xanthigen (brown marine algae fucoxanthin + pomegranate seed oil) | Human subjects | ↓ body weight, waist circumference, body and liver fat content, liver enzymes (NAFLD group only), serum triacylglycerols and C-reactive protein | [62] |
| Variable | HR* (95% CI) | p value |
| Age | 1.04 (1.01–1.07) | 0.014 |
| Loss of Hemoglobin | 1.23 (1.03–1.47) | 0.023 |
| Biopsy proven rejection | 2.4 (1.41–4.0) | 0.001 |
| Scale | Measures |
| Physical Component | |
| Physical functioning (PF) | Limitations in physical activities due to health problems |
| Role-physical (RP) | Limitations in usual daily activities due to health problems |
| Bodily pain (BP) | Pain experienced due to health problems |
| General health (GH) | General health perceptions |
| Vitality (VT) | Self-perceived energy and fatigue |
| Mental Component | |
| Social functioning (SF) | Limitations in social activities due to physical or emotional problems |
| Role-emotional (RE) | Limitations in usual daily activities due to emotional problems |
| Mental health (MH) | Perceived well-being and the presence of any psychological distress |
| Risk factors | Univariate analysis | Multivariate analysis | ||||
| HR | p-value | 95% CI | HR | p-value | 95% CI | |
| Lucat1 expression | 1.155 | 0.000** | 1.082-1.233 | 1.124 | 0.002** | 1.043-1.211 |
| Age | 1.695 | 0.002** | 1.220-2.354 | 1.488 | 0.018* | 1.070-2.070 |
| Grade | 2.421 | 0.000** | 1.692-3.463 | 1.489 | 0.040* | 1.017-2.179 |
| Stage | 4.308 | 0.000** | 3.046-6.095 | 2.466 | 0.000** | 1.624-3.744 |
| M | 4.765 | 0.000** | 3.424-6.632 | 2.299 | 0.000** | 1.564-3.380 |
| T | 3.597 | 0.000** | 2.588-5.001 | |||
| N | 2.821 | 0.002** | 1.484-5.365 | |||
| Recurrence | 2.407 | 0.000** | 1.745-3.319 | |||
| Gender | 1.022 | 0.896 | 0.737-1.418 |
| Parameters | Proposed Sensor | XTE-190 |
| Operational mode | Absolute | Absolute |
| Pressure range | 2 MPa | 1.7 MPa |
| Compensated temperature range | +20–220 °C | +25–232 °C |
| Sensitivity (10 V power supply) | 210 mV/100 kPa | 8 mV/100 kPa |
| Thermal zero shift Thermal sensitivity shift | ±1.2%FS/100F ±1.2%/100F | ±1%FS/100F ±1%/100F |
| Total accuracy in compensation temperature range | ±2%FS | ±1.5%FS |
| Syntax Score Category | Low(<22)(n=83) | Intermediate(23-32)(n=36) | High(>32) p(n=21) | p |
| Age (years), meanMinimum-Maximum95% CI | 65.843-97(63.6-67.9) | 70.346-87(66.8-73.8) | 66.9 47-83(62.8-71.1) | 0.074 |
| Sex (male) | 77 (92.77%) | 32 (88.89%) | 21 (100%) | 0.291 |
| Smoker | 32 (38.55%) | 10 (27.77%) | 8 (38.1%) | 0.514 |
| Hyperlipidemia | 47 (56.62%) | 28 (77.78%) | 8 (38.1%) | 0.010 |
| Hypertension | 50 (60.24%) | 30 (83.33%) | 12 (57.14%) | 0.034 |
| Diabetes mellitus | 27 (32.53%) | 13 (36.11%) | 6 (28.57%) | 0.839 |
| Family History | 22 (26.5%) | 7 (19.44%) | 2 (9.52%) | 0.222 |
| Overweight | 9 (10.84%) | 1 (2.77%) | 2 (9.52%) | 0.348 |
| CAD | 21 (25.3%) | 7 (19.44%) | 4 (19.04%) | 0.708 |
| Type of cells | Bladder cancer cell line | ||||||
| T24 | RT4 | 5637 | SW780 | UMUC3 | HT1376 | TSSCUP | |
| Unsorted | 0/10 | 0/10 | 0/10 | 0/10 | 0/10 | 0/10 | 0/10 |
| CD44high | 7/10 | 5/10 | 3/10 | 3/10 | 5/10 | 2/10 | 5/10 |
| CD44low | 0/10 | 0/10 | 0/10 | 0/10 | 0/10 | 0/10 | 0/10 |
| Mechanical incremental steps compression | ||
| Compression factor | Intraparticle porosity | Voidage space |
| (λ) | (εp) | (ε) |
| 0.00 | 0.63 | 0.41 |
| 0.02 | 0.60 | 0.39 |
| 0.05 | 0.63 | 0.36 |
| 0.10 | 0.62 | 0.33 |
| 0.15 | 0.60 | 0.31 |
| Group | Treatment | Sham |
| Men/women (number of patients) | 3/17 | 4/16 |
| Age (years) | 43.5 ± 11.07 | 43.55 ± 7.82 |
| Headache history (years) | 15.25 ± 8.37 | 18.75 ± 9.98 |
| Baseline VAS | 7.75 ± 0.96 | 7.45 ± 0.88 |
| Baseline headache duration (days/month) | 21.05 ± 3.36 | 19.65 ± 3.66 |
| Baseline MIDAS score | 63.05 ± 19.89 | 63.60 ± 16.59 |
| Furosemide | Placebo | |||||||||||||||
| PEFR | FEV1.0 | PEFR | FEV 1.0 | |||||||||||||
| Study (year) | Baseline airflow | SD | Post-treatment airflow | SD | Baseline airflow | SD | Post-treatment airflow | SD | Baseline airflow | SD | Post-treatment airflow | SD | Baseline airflow | SD | Post-treatment airflow | SD |
| Alshehri and colleagues, 2005 [5] | 59.0 | 22.0 | 84.9 | 14.0 | 58.5 | 14.5 | 80.2 | 13.9 | 57.2 | 25.4 | 80.7 | 17.4 | 56.7 | 17.3 | 77.8 | 19.1 |
| Nuhoğlu and colleagues, 2006 [3] | 178 | 65.9 | 222 | 66.1 | N/A | N/A | 183 | 51.7 | 218 | 60.3 | N/A | N/A | ||||
| Baseline airflow | SD | Net airflow improvement above baseline | SD | Baseline airflow | SD | Net airflow improvement above baseline | SD | Baseline airflow | SD | Net airflow improvement above baseline | SD | Baseline airflow | SD | Net airflow improvement above baseline | SD | |
| González-Sánchez and colleagues, 2002 [4] | N/A | N/A | 0.820 | 0.460 | 0.910 | 0.067 | N/A | N/A | 0.850 | 0.340 | 0.980 | 0.078 | ||||
| Nannini and colleagues, 1992 [1] | 147 | 68.0 | 269 | 89.7 | N/A | N/A | 234 | 82.0 | 316 | 56.2 | N/A | N/A | ||||
| Ono and colleagues, 1997 [6] | 171 | 20.0 | 205 | 45.1 | 1.18 | 0.13 | 178 | 25.0 | 198 | 21.3 | 1.32 | 0.74 | N/A | |||
| Pendino and colleagues, 1998 [2] | 200 | 71.0 | 426 | 98.0 | N/A | N/A | 209 | 68.0 | 337 | 73.2 | N/A | N/A |
| Determinants | Food-hygiene practice | Diarrhea | ||
| % | Unadjusted OR (95% CI) | Adjusteda OR (95% CI) | ||
| All children | Poor | 11 | 1.15 (0.51–2.60) | 1.33 (0.57–3.14) |
| Better | 9 | 1.00 | 1.00 | |
| p-value | 0.73 | 0.51 | ||
| Stratified by age group | ||||
| ≤ 2 y (n = 93) | Poor | 23 | 2.63 (0.78–8.89) | 4.55 (1.08–19.10)* |
| Better | 10 | 1.00 | 1.00 | |
| p-value | 0.12 | 0.04* | ||
| > 2 y (n = 181) | Poor | 5 | 0.55 (0.17–1.78) | 0.62 (0.18–2.14) |
| Better | 9 | 1.00 | 1.00 | |
| p-value | 0.32 | 0.38 |
| MODEL | χ2/df | GFI | AGFI | NFI | IFI | CFI | RMR | RMSEA |
| Experience value | 2.0-5.0 | >0.90 | >0.90 | >0.90 | >0.90 | >0.90 | <0.10 | <0.08 |
| Model RT(Total sample) | 4.557 | 0.908 | 0.897 | 0.904 | 0.912 | 0.911 | 0.053 | 0.077 |
| Model RW(Wuhan) | 4.693 | 0.904 | 0.893 | 0.900 | 0.908 | 0.909 | 0.058 | 0.077 |
| Model RS(Shiyan) | 3.370 | 0.911 | 0.902 | 0.906 | 0.912 | 0.912 | 0.050 | 0.076 |
| Model RJ(Jingmen) | 4.187 | 0.905 | 0.893 | 0.903 | 0.910 | 0.911 | 0.054 | 0.077 |
| Specific Production (μmol/min/mg) | |||
| Substrate | Product | Monohydroxy Fatty Acid | Dihydroxy Fatty Acid |
| Palmitoleic acid (16:1Δ9Z) | 8-HHME | 9.6 ± 0.2 | NA |
| Oleic acid (18:1Δ9Z) | 8-HOME | 9.0 ± 0.1 | NA |
| Linoleic acid (18:2Δ9Z,12Z) | 8-HODE, 8,11-DiHODE | 10.8 ± 0.1 | 1.4 ± 0.0 |
| Conjugated linoleic acid (18:2Δ9E,12E) | NA | NA | NA |
| α-Linolenic acid (18:3Δ9Z,12Z,15Z) | 8-HOTrE, 8,11-DiHOTrE | 14.9 ± 0.0 | 1.1 ± 0.0 |
| γ-Linolenic acid (18:3Δ6Z,9Z,12Z) | NA | NA | NA |
| Eicosadienoic acid (20:2Δ11Z,14Z) | NA | NA | NA |
| Dihomo-γ-linolenic acid (20:3Δ8Z,11Z,14Z) | NA | NA | NA |
| Arachidonic acid (20:4Δ5Z,8Z,11Z,14Z) | NA | NA | NA |
| Docosapentaenoic acid (22:5Δ7Z,10Z,13Z,16Z,119Z) | NA | NA | NA |
| Docosahexaenoic acid (22:6Δ4Z,7Z,10Z,13Z,16Z,19Z) | NA | NA | NA |
| Up-Regulated Genes | Down-Regulated Genes | ||
| Gene Symbol | Gene Name | Gene Symbol | Gene Name |
| APOLD1 | Apolipoprotein L domain containing 1 | AMD1 | S-adenosylmethionine decarboxylase 1 |
| Atrogin-1 | F-box protein 32/Atrogin-1 | AMIGO2 | Adhesion molecule with Ig-like domain 2 |
| BCL6 | B-cell CLL/lymphoma 6 | ATP13A3 | ATPase type 13A3 |
| BTG1 | B-cell translocation gene 1 | BAG2 | BCL2-associated athanogene 2 |
| C1orf183 | Chromosome 1 open reading frame 183 | BDNF | Brain-derived neurotrophic factor |
| C1orf63 | Chromosome 1 open reading frame 63 | BIRC3/cIAP2 | Baculoviral IAP repeat-containing 3 |
| CCNG2 | Cyclin G2 | CCL2 | Chemokine (C-C motif) ligand 2 |
| CLK1 | CDC-like kinase 1 | CCND1 | Cyclin D1 |
| CTGF | Connective tissue growth factor | CYP1B1 | Cytochrome P450 subfamily I polypeptide 1 |
| DDIT3/CHOP | DNA-damage-inducible transcript 3 | DCK | Deoxycytidine kinase |
| EIF1/SUI1 | Eukaryotic translation initiation factor 1 | DIO2 | Deiodinase, iodothyronine, type II |
| GADD45B | Growth arrest and DNA-damage-inducible β | DKFZP686E2158 | Hypothetical protein LOC643155 |
| ID1 | Inhibitor of DNA binding 1 | DKK1 | Dickkopf homolog 1 (Xenopus laevis) |
| ID2B | Striated muscle contraction regulatory prot. | DSCR1 | Down syndrome critical region gene 1 |
| IRF7 | Interferon regulatory factor 7 | EDN1 | Endothelin 1 |
| KIF1B | Kinesin family member 1B | F3 | Coagulation factor III |
| KLF6 | Kruppel-like factor 6 | FGF2 | Fibroblast growth factor 2 |
| KLHL24 | Kelch-like 24 | FST | Follistatin |
| LOC85028 | PNAS-123 | G0S2 | Putative lymphocyte G0/G1 switch gene |
| MIR | Myosin regulatory light chain interacting prot. | GABPB2 | GA binding protein transcription factor, β2 |
| MT1E | Metallothionein 1E | GBP1 | Guanylate binding protein 1 |
| PCMTD1 | Protein-L-isoaspartate O-methyltransferase | GBP3 | Guanylate binding protein 3 |
| PHLDA1 | Pleckstrin homology-like domain family A | GLIPR1 | Glioma pathogenesis-related protein |
| PNPLA8 | Patatin-like phospholipase domain 8 | GPR19 | G protein-coupled receptor 19 |
| RNU2 | RNA, U2 small nuclear | GRIK1 | Glutamate receptor, ionotropic, kainate 1 |
| SAT | Spermine N1-acetyltransferase | GRO3 | GRO3 oncogene |
| STK31 | Serine/threonine kinase 31 | IGFBP5 | Insulin-like growth factor binding protein 5 |
| TAF9 | TAF9 RNA polymerase II | IL7R | Interleukin 7 receptor |
| TIEG | TGFβ inducible early growth response | ISG20L1 | Interferon stimulated exonuclease |
| TXNIP | Thioredoxin interacting protein | LOC57090 | HRPAP20 short form |
| ZBTB1 | Zinc finger and BTB domain containing 1 | LTV1 | LTV1 homolog (S. cerevisiae) |
| cDNA DKFZp564C2063 | MAT2A | Methionine adenosyltransferase II, alpha | |
| MMP3 | Matrix metalloproteinase 3 | ||
| NAV3 | Neuron navigator 3 | ||
| NCOA7 | Nuclear receptor coactivator 7 | ||
| NOLA1 | Nucleolar protein family A, member 1 | ||
| NTF3 | Neurotrophin 3 | ||
| NXT1 | NUTF-like export factor1 | ||
| PAK1IP1 | PAK1 interacting protein 1 | ||
| PLAU | Plasminogen activator, urokinase | ||
| PPIF | Peptidylprolyl isomerase F (cyclophilin F) | ||
| PTRH2 | Peptidyl-tRNA hydrolase 2 | ||
| PTX3 | Pentaxin-related gene | ||
| RGS20 | Regulator of G-protein signalling 20 | ||
| SC4MOL | Sterol-C4-methyl oxidase-like | ||
| SFRS3 | Splicing factor, arginine/serine-rich 3 | ||
| SGNE1 | Secretory granule, neuroendocrine protein 1 | ||
| SNK | Serum-inducible kinase | ||
| STC2 | Stanniocalcin 2 | ||
| TNFRSF11B | Tumor necrosis factor receptor 11b (OPG) | ||
| TRIM16 | Tripartite motif-containing 16 | ||
| TSLP | Thymic stromal lymphopoietin | ||
| cDNA FLJ11812 fis, clone HEMBA1006364 |
| Annotation | Figure 1A* | S. pneumoniae TIGR4 | S. pneumoniae G54 | S. mitis B6 | S. oralis Uo5 | S. gordonii V288 | S. sanguinis SK36 |
| Regulator | 1 | SP1674 | SPG1583 | smi0612 | SOR0560 | SGO0127 | SSA0081 |
| Hypothetical protein | 2 | - | - | smi0610 | SOR0559 | SGO0126 | SSA0080 |
| N-acetylmannosamine kinase | 3 | SP1675 | SPG1584 | smi0609 | SOR0558 | SGO0125 | SSA0079 |
| N-acetylneuraminate lyase | 4 | SP1676 | SPG1585 | smi0608 | SOR0557 | SGO0124 | SSA0078 |
| hypothetical protein | 5 | SP1677 | SPG1586 | smi0607 | SOR0556 | - | - |
| hypothetical protein | 6 | SP1679 | - | - | - | - | - |
| hypothetical protein | 7 | SP1680 | SPG1588 | smi0606 | SOR0555 | - | - |
| satA ABC transporter permease | 8 | SP1681 | SPG1589 | smi0605 | SOR0553 | - | - |
| satB ABC transporter permease | 9 | SP1682 | SPG1590 | smi0604 | SOR0552 | - | - |
| satC ABC transporter substrate-binding protein | 10 | SP1683 | SPG1591 | smi0603 | SOR0550 | - | - |
| PTS system, IIBC components | 11 | SP1684 | SPG1592 | - | - | - | - |
| NanE, ManAc-6P 2-epimerase | 12 | SP1685 | SPG1593 | smi0602 | SOR0549 | SGO0118 | SSA0071 |
| oxidoreductase | 13 | SP1686 | SPG1594 | - | - | SGO0123 | SSA0077 |
| NanB neuraminidase | 14 | SP1687 | SPG1595 | - | - | - | - |
| ABC transporter permease | 15 | SP1688 | SPG1596 | - | - | SGO0122 | SSA0076 |
| ABC transporter permease | 16 | SP1689 | SPG1597 | - | - | SGO0121 | SSA0075 |
| ABC transporter substrate-binding protein | 17 | SP1690 | SPG1598 | - | - | SGO0120 | SSA0074 |
| hypothetical protein | 18 | SP1691 | SPG1599 | - | - | SGO0119 | SSA0073 |
| NanA neuraminidase | 19 | SP1693 | SPG1600 | smi0601 | SOR0548 | - | - |
| Acetyl xylan esterase | 20 | SP1694 | SPG1601 | smi0600 | SOR0547 | - | SSA0070 |
| Age (year) | BMI (kg/m2) | Size of Tumor (mm) | Number of Tumor | ||
| Urine HER2/neu | r | -0.014 | -0.022 | 0.277 | -0.057 |
| p | 0.897 | 0.843 | 0.068 | 0.711 | |
| Urinary HER2/neu/ Urinary Creatinine | r | 0.178 | 0.122 | 0.108 | -0.070 |
| p | 0.105 | 0.269 | 0.483 | 0.649 | |
| Serum HER2/neu | r | -0.073 | -0.102 | -0.056 | 0.172 |
| p | 0.512 | 0.363 | 0.722 | 0.277 |
| sRNA id | Start | End | Length(nucleotides) | Flanking gene id | Strand* | Expression pattern | Relative copy numbers | Primers | |
| Start | End | ||||||||
| sRNA1 | 2840862 | 2840921 | ~60 | BC2880/BC2881 | <>< | ↓↑↓ | 54 | 2840862 | 2840921 |
| sRNA2 | 1502573 | 1502638 | ~66 | BC1553/BC1554 | <>< | ↓↑↓ | 38 | 1502576 | 1502635 |
| sRNA3 | 5024909 | 5024970 | ~62 | BC5122/BC5123 | <>< | ↓↑↓ | 36 | 5024910 | 5024969 |
| sRNA4 | 3372000 | 3372189 | ~190 | BC3408/BC3409 | <>< | ↓↑↓ | 181 | 3372130 | 3372189 |
| sRNA5 | 4261246 | 4261455 | ~210 | BC4317/BC4318 | <>< | ↓↑↓ | 41 | 4261395 | 4261454 |
| sRNA6 | 4219221 | 4219336 | ~116 | BC4271/BC4272 | <>< | ↓↑↓ | 56 | 4219276 | 4219335 |
| sRNA7 | 4040528 | 4040740 | ~213 | BC4070/BC4071 | <>< | ↓↑↓ | 169 | 4040679 | 4040738 |
| sRNA8 | 525752 | 526136 | ~385 | BC0547/BC0548 | ><> | ↓↑↓ | 142 | 526073 | 526132 |
| sRNA9 | 1106401 | 1106863 | ~463 | BC1124/BC1125 | ><> | ↓↑↓ | 44 | 1106797 | 1106856 |
| sRNA10 | 1381925 | 1382221 | ~297 | BC1419/BC1420 | ><> | ↓↑↓ | 183 | 1382156 | 1382215 |
| sRNA11 | 5372154 | 5372598 | ~445 | BC5447/BC5448 | <>< | ↓↑↓ | 42 | 5372540 | 5372599 |
| sRNA12 | 4790423 | 4791589 | ~1167 | BC4864/BC4865 | <>< | ↓↑↓ | 19 | 4791428 | 4791487 |
| sRNA13 | 3802805 | 3802907 | ~103 | BC3824/BC3825 | <>< | ↓↑↓ | 16 | 38028445 | 3802904 |
| sRNA14 | 3121534 | 3121698 | ~165 | BC3151/BC3152 | <>< | ↓↑↓ | 12 | 3121639 | 3121698 |
| Cell line class | S:MI | S:MER | MER:MI | Significant predictive relationships |
| HMEC | <0.0001** | 0.006** | 0.0120* | S→MER, MER→MI, and S→MI |
| BL | 0.5996 | 0.5954 | 0.1659 | N/A |
| LumB | 0.0041* | 0.4769 | <0.0001** | MER→MI, S→MI |
| CL | 0.4827 | 0.3758 | 0.0051* | MER→MI |
| Her2E | 0.0706 | 0.3090 | 0.1309 | N/A |
| cluster α | hybrid | cluster β | |
| Lineage 1 | 80 | 0 | 1 |
| Lineage 2 | 22 | 7 | 82 |
| PCMP Samples | Sample 1# | Sample 2# | Sample 3# | Sample 4# | Sample 5# | Sample 6# | Sample 7# | Sample 8# | Sample 9# |
| AP percentage (%) | 0 | 2.5 | 5 | 7.5 | 10 | 12.5 | 15 | 17.5 | 20 |
| Heat transfer coefficient (W/m2·K) | 2.38 | 2.42 | 2.59 | 2.68 | 2.84 | 2.98 | 3.05 | 3.11 | 3.24 |
| Guliver coding System | Total sample | NL | IT | UK | BE |
| Category | |||||
| Non-verbal behaviour | 69.1 | 74.4 | 90.0 | 59.0 | 62.6 |
| Structuring | 86.0 | 94.1 | 92.3 | 68.5 | 89.8 |
| Summarizing | 84.2 | 97.8 | 78.0 | 71.4 | 87.1 |
| Patient involvement | 71.7 | 97.3 | 76.7 | 71.1 | 72.3 |
| Speaking peculiarities | 27.7 | 23.1 | 41.7 | 17.9 | 36.8 |
| Task-oriented attitude | 95.6 | 95.9 | 99.6 | 92.2 | 95.3 |
| Collecting information | 74.8 | 81.7 | 89.4 | 63.5 | 69.5 |
| Giving information | 91.4 | 86.7 | 100 | 87.9 | 92.8 |
| Providing solution | 95.3 | 100 | 97.2 | 73.3 | 97.0 |
| Affective-oriented attitude | 97.2 | 95.3 | 100 | 95.1 | 97.9 |
| Total | 86.6 | 86.7 | 93.8 | 78.6 | 87.8 |
| Grade 1 | Grade 2 | Grade 3 | Total | |
| Group 1 | 18 (47.3%) | 15 (39.5%) | 5 (13.2%) | 38 |
| Group 2 | 16 (44.4%) | 13 (36.1%) | 7 (19.4%) | 36 |
| Characteristic | Boys | Girls | ||
| OR | 95% CI | OR | 95% CI | |
| Secondhand Smoke Exposure in Household (/None) | - | - | - | - |
| 1–2 Days | 1.00 | 0.88–1.14 | 1.41 | 1.07–1.86 |
| ≥3 Days | 1.96 | 1.78–2.17 | 2.86 | 2.34–3.49 |
| Family Smoking Status (/No) | - | - | - | - |
| Yes | 1.36 | 1.24–1.49 | 1.60 | 1.31–1.95 |
| Father | 1.16 | 1.07–1.26 | 0.92 | 0.77–1.09 |
| Mother | 1.84 | 1.52–2.22 | 2.46 | 1.87–3.24 |
| Siblings | 2.07 | 1.83–2.35 | 2.49 | 2.01–3.10 |
| Grandparents | 1.20 | 1.02–1.42 | 2.59 | 2.02–3.31 |
| Friends’ Smoking Status (/No) | - | - | - | - |
| Some | 3.64 | 2.98–4.44 | 6.51 | 4.40–9.64 |
| Most/all | 22.82 | 18.70–27.85 | 81.43 | 55.49–119.51 |
| Witnessed Smoking at School (/No) | - | - | - | - |
| Yes | 1.94 | 1.77–2.12 | 1.90 | 1.58–2.28 |
| Variable | Placebo (n = 25) | Telotristat ethyl | |||||
| 250 mg tid (n = 25) | 500 mg tid (n = 25) | ||||||
| Mean (s.d.) | Mean (s.d.) | P | 95% CL | Mean (s.d.) | P | 95% CL | |
| BM frequency | |||||||
| Change from baseline in BM frequency averaged over 12 weeks, counts/day | 0.05 (0.33) | −0.45 (0.69) | − | − | −0.60 (0.72) | − | − |
| Arithmetic mean treatment difference | − | −0.50 | − | −0.81 to −0.19 | −0.65 | − | −0.96 to −0.33 |
| Hodges–Lehmann estimator | − | −0.45 | 0.004 | −0.72 to −0.17 | −0.54 | <0.001 | −0.79 to −0.25 |
| Stool consistency | |||||||
| Change from baseline in stool consistency averaged over 12 weeks (Bristol Stool Form scale) | 0.01 (0.41) | −0.20 (0.70) | – | – | −0.60 (0.86) | – | – |
| Arithmetic mean treatment difference | − | −0.20 | – | −0.53 to 0.13 | −0.60 | – | −0.99 to −0.22 |
| Hodges–Lehmann estimator | − | −0.20 | 0.09 | −0.45 to 0.02 | −0.39 | 0.009 | −0.82 to −0.12 |
| Flushing | |||||||
| Change from baseline in daily cutaneous flushing episodes averaged over 12 weeks, counts/day | −0.33 (1.22) | −0.06 (0.98) | – | – | 0.11 (2.10) | – | – |
| Arithmetic mean treatment difference | − | 0.27 | – | −0.36 to 0.90 | 0.45 | – | −0.53 to 1.42 |
| Hodges–Lehmann estimator | − | 0.11 | 0.67 | −0.17 to 0.61 | 0.02 | 0.58 | −0.28 to 0.62 |
| Abdominal pain | |||||||
| Change from baseline in abdominal pain averaged over 12 weeks, 11-point numeric rating scale | −0.06 (0.78) | −0.23 (0.97) | – | – | 0.03 (0.77) | – | – |
| Arithmetic mean treatment difference | − | −0.17 | – | −0.67 to 0.33 | 0.09 | – | −0.35 to 0.53 |
| Hodges–Lehmann estimator | − | 0.06 | 0.61 | −0.42 to 0.33 | 0.14 | 0.66 | −0.39 to 0.51 |
| Rescue short-acting SSA use | |||||||
| Change from baseline in rescue short-acting SSA use averaged over 12 weeks, counts/day | −0.01 (0.14) | −0.07 (0.35) | – | – | 0.01 (0.10) | – | – |
| Arithmetic mean treatment difference | − | −0.05 | – | −0.20 to 0.10 | 0.02 | – | −0.05 to 0.09 |
| Hodges–Lehmann estimator | − | 0.00 | 0.45 | 0.00–0.00 | 0.000 | 0.98 | 0.00–0.00 |
| Performance Statistics | Total(n = 1053) | Initial surgery-MR interval ≤ 36 months(n = 709) | Initial surgery-MR interval > 36 months(n = 344) | p value |
| Cancer detection rate for MRIa | 6.7 (7/1053) | 1.4 (1/709) | 17.4 (6/344) | 0.006 |
| Abnormal interpretation rate for MRI | 84/1053 (8.0%)c | 51/709 (7.2%) | 33/344 (9.6%) | 0.184 |
| Cancer detection rate for intramammary lesionsb | 3.8 (4/1053) | 1.41 (1/709) | 8.7 (3/344) | 0.105 |
| Abnormal interpretation rate for intramammary lesions | 76/1053 (7.2%) | 49/709 (6.9%) | 27/344 (7.8%) | 0.612 |
| PPV1 | 4/76 (5.3%) | 1/49 (2.0%) | 3/27 (11.1%) | 0.125 |
| PPV3 | 3/19 (15.8%) | 1/10 (10.0%) | 2/9 (22.2%) | 0.582 |
| Sensitivity | 3/4 (75.0%) | 1/1 (100%) | 2/3 (66.7%) | > 0.999 |
| Specificity | 1031/1049 (98.3%) | 698/708 (98.6%) | 333/341 (97.6%) | 0.199 |
| Men | Women | ||
| Change from baseline value | P value | ||
| HR (beats/min) | 47 ± 12 | 38 ± 10 | 0.20 |
| MAP (mmHg) | −31 ± 9 | −33 ± 8 | 0.45 |
| SAP (mmHg) | −54 ± 7 | −48 ± 8 | 0.29 |
| DAP (mmHg) | −18 ± 5 | −18 ± 7 | 0.78 |
| SV (mL) | −57 ± 8 | −41 ± 4 | 0.006 |
| Q (L/min) | −1.6 ± 0.7 | −1.4 ± 0.4 | 0.32 |
| TPR (mmHg/L/min) | 6.2 ± 3.9 | 9.2 ± 1.8 | 0.10 |
| RRIHF (Vagal Index) | 1229 ± 1118 | 1155 ± 769 | 0.44 |
| BRS | 16.4 ± 3.8 | 18.7 ± 5.3 | 0.53 |
| SAP-MSNA coherence (arbitrary units) | 0.05 ± 0.14 | −0.39 ± 0.28 | 0.03 |
| SAP LF (mmHg2) | 27.5 ± 19 | 16.2 ± 6 | 0.09 |
| Gene Title and Abbreviation (The GENE Database) | Percent Change |
| OPRM1, 1 opioid receptor, mu 1 | +1294 |
| TP73, 2 tumor protein p73 | +938 |
| KCND1, 3 potassium voltage-gated channel, Shal-related subfamily, member 1 | +845 |
| SLC8A2, 4 solute carrier family 8 (sodium/calcium exchanger), member 2 | +737 |
| CNTNAP2, 5 contactin associated protein-like 2 | +581 |
| STMN3, 6 stathmin-like 3 | +500 |
| LPHN3, 7 latrophilin 3 | +494 |
| ANGPT1, 8 angiopoietin 1 | +487 |
| SYN3, 9 synapsin III | +478 |
| DPP6,10 dipeptidyl-peptidase 6 | +448 |
| PITX3, 221 paired-like homeodomain 3 | −541 |
| NOTCH3, 222 notch 3 | −547 |
| DLGAP1, 223 discs, large homolog-associated protein 1 | −547 |
| SLIT1, 224 slit homolog 1 | −553 |
| BSN, 225 bassoon (presynaptic cytomatrix protein) | −563 |
| CELSR1, 226 cadherin, EGF LAG seven-pass G-type receptor 1 | −647 |
| CACNB4, 227 calcium channel, voltage-dependent, beta 4 subunit | −672 |
| NDN, 228 necdin homolog (mouse) | −729 |
| EDNRB, 229 endothelin receptor type B | −768 |
| CHRM2, 230 cholinergic receptor, muscarinic 2 | −1049 |
| Prognostic factor/parameter | N evt/N pts | Univariate analysis (n=108) | Multivariate analysis (n=99) | ||
| HR [95% CI] | p-Value (Wald) | HR [95% CI] | p-Value (Wald) | ||
| Smoker status | |||||
| Never | 7/11 | 1 | 1 | ||
| Former/current | 76/95 | 1.8 [0.9-4.0] | 0.12 | 2.1 [0.8-5.1] | 0.11 |
| Performance Status | |||||
| 0-1 | 65/85 | 1 | 1 | ||
| >1 | 16/19 | 1.8 [1.0-3.1] | 0.039 | 1.6 [0.9-2.9] | 0.12 |
| Primary size tumor | 80/103 | 1.0 [0.99-1.01] | 0.70 | 1.0 [0.99-1.01] | 0.97 |
| Adrenal metastasis | |||||
| No | 49/91 | 1 | 0.21 | 1 | 0.01 |
| Yes | 11/17 | 1.5 [0.8-2.9] | 2.2 [1.2-4.0] | ||
| Liver metastasis | |||||
| No | 51/93 | 1 | 0.38 | 1 | 0.67 |
| Yes | 9/15 | 1.4 [0.7-2.8] | 1.2 [0.6-2.2] | ||
| Coarse (2.2) | |||||
| Entropy | 84/108 | 1.2 [0.7-2.1] | 0.59 | - | - |
| Coarse (2.8) | |||||
| Entropy | 84/108 | 1.2 [0.8-1.8] | 0.37 | - | - |
| Coarse (3.3) | |||||
| Entropy | 84/108 | 1.2 [0.9 - 1.6] | 0.18 | 1.1 [0.8-1.5] | 0.65 |
| Relative risk reduction | ||||||
| 20% | 24% | 28% | 32% | 35% | ||
| Control event rate | 25% | 0.49 | 0.68 | 0.84 | 0.93 | 0.97 |
| 27% | 0.54 | 0.73 | 0.87 | 0.95 | 0.98 | |
| 30% | 0.61 | 0.80 | 0.92 | 0.98 | 0.99 | |
| 33% | 0.68 | 0.85 | 0.95 | 0.99 | 1.00 | |
| 35% | 0.72 | 0.89 | 0.99 | 1.00 | 1.00 |
| Predicted change in hazard for one unit change in variable | Significance (P) | |
| HADS anxiety | 1.012 (0.39–2.58) | 0.98 |
| HADS depression | 0.82 (0.22–3.05) | 0.76 |
| PANAS negative affect | 1.07 (0.33–3.47) | 0.90 |
| Mood rating scale | 1.20 (0.48–3.0) | 0.68 |
| FACT C FW | 0.56 (0.16–1.89) | 0.81 |
| FACT C AC | 0.37 (0.16–0.89) | 0.02 |
| TNM | 4.35 (1.93–9.8) | <0.001 |
| N | Minimum | Maximum | Mean | Std. Deviation | |
| IL- 17 B | 24 | 18.258 | 31.605 | 23.63281 | 3.553243 |
| IL-10 B | 24 | .00 | 112.43 | 13.8533 | 28.72131 |
| IL-17 P | 24 | 21.009 | 33.020 | 24.97380 | 3.595384 |
| IL-10 P | 24 | 1.75 | 229.83 | 60.1112 | 59.13965 |
| WBC | 24 | 2.3 | 30.6 | 10.296 | 5.5273 |
| RBC | 24 | 3.16 | 5.17 | 3.9788 | .53680 |
| HCT | 24 | 28.4 | 46.5 | 36.192 | 4.7277 |
| PLT | 24 | 87 | 658 | 283.71 | 117.411 |
| HB | 24 | 9 | 16 | 12.02 | 1.675 |
| GR% | 24 | 43.5 | 93.8 | 71.912 | 10.7272 |
| MONO% | 24 | .8 | 30.6 | 9.846 | 6.6490 |
| LYMPH% | 24 | 1.4 | 32.1 | 17.308 | 7.5535 |
| AGE | 24 | 37 | 74 | 60.42 | 10.270 |
| GENDER | 24 | 1 | 2 | 1.63 | .495 |
| AGEgroup | 24 | 1 | 3 | 2.50 | .659 |
| primary1 | 24 | 1 | 2 | 1.63 | .495 |
| TYPE_3_UN | 24 | 1 | 3 | 2.04 | .624 |
| chemo1yes | 24 | 0 | 1 | .58 | .504 |
| Valid N (listwise) | 24 |
| Author, Year [Reference] | Study Design | StudyPopulationParticipantsAgeBMIHealth Status | Intervention and Doses | Duration Weeks | Observed Effects |
| Pol, 2013 [28] | Meta-analysis of 26 RCTs | 2060 M/F18–70 years18.5–35.8 kg/m2Healthy | Whole grain (mean dose: 84.1 g/day)vs. refined grain | 2–16 | = BW↓ body fat: −0.48%vs.refined grain |
| Kim, 2016 [29] | Meta-analysis of 21 RCTs | 940 M/F47–57 years27.6–31.4 kg/m2Metabolic syndrome | Dietary pulses (mean dose: 142 g/day)vs. control | 4–12 | ↓ BW: −0.34 kgvs.control |
| Mytton, 2014 [30] | Meta-analysis of 8 RCTs | 1026 M/F30–75 years23.7–37.8 kg/m2Healthy | High fruit and vegetablesvs. low fruit and vegetables consumption(mean dose difference in vegetables and fruit consumptionbetween arms 133 g/day) | 4–52 | ↓ BW: −0.54 kgvs.low fruit and vegetables |
| Thompson, 2017 [31] | Meta-analysis of 12 RCTs | 609 M/F20–70 years25–35 kg/m2Healthy | Soluble fibre supplementation (mean dose: 18.5 g/day)vs. control | 2–17 | ↓ BMI: −0.84 kg↓ BW: −2.52 kg↓ body fat: −0.41%vs.control |
| Year | High-risk owned dogs | Pets |
| Positive/Total (%) | Positive/Total (%) | |
| 2011 | 7/196 (3.6) | 8/811 (1.0) |
| 2012 | 10/502 (2.0) | 9/561 (1.6) |
| 2013 | 10/415 (2.4) | – |
| 2014 | 3/209 (1.4) | – |
| 2015 | 4/200 (2.0) | – |
| 2016 | 3/200 (1.5) | – |
| Totala | 37/1,722 (2.1) | 17/1,372 (1.2) |
| Assembler | Number of scaffolds | Longest scaffold (kb) | Longest scaffold corr. (kb) | N50 (kb) | Err. | N50 corr. (kb) | LAP |
| Human chromosome 14, starting from Velvet assembly | |||||||
| Before | 1,081 | 4,628 | 263 | 1,190 | 9,156 | 27 | −138.765779 |
| After | 1,634 | 1,046 | 265 | 347 | 8,049 | 27 | −138.632657 |
| REAPR | 17,727 | 153 | 81 | 36 | 4,607 | 14 | −162.869192 |
| Human chromosome 14, starting from ALLPATHS assembly | |||||||
| Before | 129 | 81,640 | 14,918 | 81,640 | 34 | 7,652 | −111.288806 |
| After | 139 | 81,640 | 14,918 | 81,640 | 33 | 7,652 | −111.287938 |
| REAPR | 858 | 977 | 146 | 190 | 4,230 | 17 | −168.024865 |
| *1/*1 (n = 229) | *1/*2 + *2/*2 (n = 148) | P‐value | |
| Lesion vessel number | NS | ||
| 1 (n, %) | 55 (24%) | 39 (26.4%) | |
| 2 (n, %) | 69 (30.1%) | 43 (29.1%) | |
| 3 (n, %) | 105 (45.9%) | 66 (44.6%) | |
| Lesion vessel | |||
| LM (n, %) | 23 (10%) | 27 (18.2%) | .033 |
| LAD (n, %) | 184 (80.3%) | 124 (83.8%) | NS |
| LCX (n, %) | 146 (63.8%) | 90 (60.8%) | NS |
| RCA (n, %) | 167 (72.9%) | 98 (66.2%) | NS |
| Revascularization (n, %) | 187 (81.7%) | 130 (87.8%) | NS |
| Revascularization vessel >1 (n, %) | 112 (48.9%) | 81 (54.7%) | NS |
| TIMI3 grade after PCI (n, %) | 219 (95.6%) | 139 (93.9%) | NS |
| Variable | Possible score range | Group | Number | Baseline Mean (SD) | Number | Month 3 Mean (SD) | Mean change (SD) | t-test (p-value) a |
| Self-management knowledgeb | 0–27 | Intervention | 51 | 21.1 (2.8) | 51 | 23.1 (2.7) | 2.0 (3.4) | .337 |
| Control | 49 | 19.4 (3.0) | 47 | 21.1 (2.5) | 1.7 (2.6) | |||
| Self-efficacy for HF self-managementc | 0–100 | Intervention | 51 | 44.9 (24.7) | 51 | 59.7 (17.3) | 14.8 (26.0) | .034 |
| Control | 49 | 49.2 (22.9) | 47 | 53.8 (24.0) | 5.2 (25.5) | |||
| Patient activation (PAM Rasch scaled scores) d | 0–100 | Intervention | 51 | 57.3 (19.2) | 50 | 69.1 (16.7) | 11.7 (21.3) | .069 |
| Control | 48 | 56.6 (18.6) | 47 | 61.4 (18.2) | 5.7 (18.5) | |||
| Self-management strategies (RSCB) e | 0–145 | Intervention | 50 | 86.8 (19.3) | 51 | 115.7 (19.6) | 28.9 (23.0) | <.0005 |
| Control | 49 | 91.9 (19.9) | 47 | 97.6 (22.6) | 5.6 (22.3) |
| Repeat type | Structured | Unstructured | ||||
| RONN | DISOPRED | IUPRED | RONN | DISOPRED | IUPRED | |
| E | 3 | 13 | 10 | 97 | 87 | 90 |
| P | 6 | 5 | 5 | 94 | 95 | 95 |
| A | 32 | 23 | 63 | 68 | 77 | 37 |
| S | 4 | 6 | 16 | 96 | 94 | 84 |
| L | 100 | 97 | 100 | 0 | 3 | 0 |
| G | 11 | 8 | 14 | 89 | 92 | 86 |
| Q | 13 | 3 | 14 | 87 | 97 | 86 |
| Setting | Results of simulations | ||||||
| Methods (Effect measures) | βX | Mean of estimates (Ratio scale) | Bias (Log scale) | Empirical standard error | Mean squared error | Mean standard error | Coverage (%) |
| SCCS (IRR) | log(1.0) | 0.99 | -0.0125 | 0.1354 | 0.0185 | 0.1335 | 95.1 |
| CCO (OR) | 1.00 | -0.0005 | 0.2084 | 0.0434 | 0.2116 | 96.1 | |
| SSA (ASR) | 0.99 | -0.0005 | 0.2373 | 0.0563 | 0.2454 | 96.3 | |
| SCCS (IRR) | log(3.0) | 2.99 | -0.0030 | 0.0791 | 0.0063 | 0.0777 | 94.7 |
| CCO (OR) | 3.04 | 0.0121 | 0.18 | 0.0309 | 0.1732 | 94.8 | |
| SSA (ASR) | 3.04 | 0.0119 | 0.2016 | 0.0408 | 0.2003 | 95.2 | |
| SCCS (IRR) | log(10.0) | 9.98 | -0.0019 | 0.0438 | 0.0019 | 0.0446 | 95.5 |
| CCO (OR) | 10.30 | 0.0295 | 0.1663 | 0.0285 | 0.1604 | 94.4 | |
| SSA (ASR) | 9.97 | -0.0026 | 0.1834 | 0.0336 | 0.1817 | 94.7 |
| mRNA | Primersa |
| MMP-13 | Fw: 5'-TTGGTCAGATGTGACACCTCRv: 5'-ATCGGGAAGCATAAAGTGGC |
| Cathepsin K | Fw: 5'-AGGTGGATGAAATCTCTCGGRv: 5'-TTCTTGAGTTGGCCCTCCAG |
| 5-LOX | Fw: 5'-TGCGTTCCAGTGACTTCCACRv: 5'-CTCTGCACCATCTGCACGTG |
| ADAMTS-4 | Fw: 5'-TACTACTATGTGCTGGAGCCRv: 5'-AGTGACCACATTGTTGTATCC |
| ADAMTS-5 | Fw: 5'-GGCATCATTCATGTGACACRv: 5'-GCATCGTAGGTCTGTCCTG |
| GAPDH | Fw: 5'-AGGCTGTGGGCAAGGTCATCRv: 5'-AAGGTGGAAGAGTGGGTGTC |
| Population | GO ID | Gene ontology term | Genes under GO term | Related environmental stressor(s) | Reference |
| Kuroilers | GO:0060584 | Regulation of prostaglandin-endoperoxide synthase activity | EDN2, EDN1 | Oxidative stress/Pathogen | Lee et al. 2007 [89] |
| GO:0007631 | Feeding behavior | HCRTR2, HTR1B, GRIN1, NPY1R, ASIP | Nutrient stress | UniProt [67], Jenuth 2000 [69, 77] | |
| GO:0032693 | Negative regulation of interleukin-10 production | TRIB2, IL-12B | Pathogen | UniProt [67], Jenuth 2000 [69, 77] | |
| GO:0051341 | Regulation of oxidoreductase activity | ACVR2A, EDN2, EDN1, SNCA | Oxidative stress/Pathogen | UniProt [67], Jenuth 2000 [69, 77], Lee et al. 2007 [89] | |
| GO:0007618 | Mating | ACVR2A, SERPINE2, GRIN1 | Survival Behavior | UniProt [67], Jenuth 2000 [69, 77] | |
| GO:0016627 | Oxidoreductase activity, acting on the CH-CH group of donors | IVD, CPOX, ACAD9, DHCR24 | Oxidative/Environmental Stress | UniProt [67], Jenuth 2000 [69, 77], Lee et al. 2007 [89] | |
| GO:0006950 | Response to stress | ENTPD1, ETFDH, WNT5A CHID1, RBBP5, NEDD4, NSMCE2, GLP1R, STX2, LEAP2, RAB23, DEAF1, TNFSF11, PPP2R5C, DRD4, ZC3HAV1, CDH8, PPAP2B, GTF2H5, MCPH1, EDN1, FAM175B, GCLM, JAK1, UBXN2A, MID1, BATF, CPEB2, IL12B, PIK3AP1, SOX2, SNCA, CITED2, CHAC1, DTL, HIPK3, NOS1, STT3B, PDIA4, SBNO2, NUAK1, CDC7, SERPINE2, ULK1, MASP2, WFS1, DHCR24, PRKD1 | Oxidative/Metabolic/Environmental Stress | UniProt [67], Puvadolpirod et al. 2000 [48], Li et al. 2011 [70], Yen et al. 2014 [90] | |
| GO:0080134 | Regulation of response to stress | WNT5A, CHID1, PIK3AP1, IL12B, STX2, SNCA, HIPK3, TNFSF11, ZC3HAV1, PPAP2B, SBNO2, NUAK1, MCPH1, EDN1, SERPINE2, ULK1, WFS1, MID1 | Oxidative/Metabolic/Environmental Stress | UniProt [67], Puvadolpirod et al. 2000 [48], Li et al., 2011, Yen et al., 2014 | |
| GO:0033554 | Cellular response to stress | WNT5A, RBBP5, BATF, CPEB2, NEDD4, NSMCE2, SNCA, CHAC1, CITED2, DTL, HIPK3, RAB23, TNFSF11, PPP2R5C, PDIA4, GTF2H5, NUAK1, FAM175B, EDN1, CDC7, ULK1, WFS1, UBXN2A, MID1, PRKD1 | Oxidative/Metabolic/Environmental Stress | UniProt [67], Puvadolpirod et al. 2000 [48] | |
| GO:0045859 | Regulation of protein kinase activity | TNFSF11, DRD4, WNT5A, TGFBR2, RAPGEF2, PDGF, PIK3CA, KIAA1199, LATS2, IL12B, EDN1, PAQR3, SNCA, GTPBP4, HIPK3 | Oxidative/Metabolic/Environmental Stress | UniProt [67], Jenuth 2000 [69, 77] | |
| GO:0003100 | Regulation of systemic arterial blood pressure by endothelin | EDN2, EDN1 | Oxidative/Metabolic Stress | Endemann et al. 2004 [20], Gomez et al. 2007 [21] | |
| GO:0048010 | Vascular endothelial growth factor receptor signaling pathway | FIGF, NEDD4, GRB10, PRKD1 | Oxidative/Metabolic Stress | Koch et al., 2012 [57] | |
| GO:0004674 | Protein serine/threonine kinase activity | CDC42BPB, DCLK1, TGFBR3, TGFBR2, PRKCA, LATS2, ACVR2A, NUAK1, CDC7, ULK1, CDC2L1, HIPK3, VRK1, PRKD1 | Oxidative/Metabolic/Environmental Stress | UniProt [67], Evans et al. 2002 [46], Perkins et al. 2007 [55], Salminen et al. 2008 [87], Tam et al., 2012 [88] | |
| GO:0009628 | Response to abiotic stimulus | GPR65, GRIN1, CASP8, IL12B, CPEB2, SOX2, NEDD4, TNFRSF8, CITED2, DTL, ER81, NOS1, DEAF1, CNGA2, CDH8, MME, GTF2H5, HR1B, SERPINE2, EDN1, FAM175B | Oxidative/Metabolic/Environmental Stress | Mashaly et al. 2004 [92], Mujahid et al. 2005 [16] | |
| GO:0004672 | Protein kinase activity | CDC42BPB, DCLK1, PRKCA, HIPK3, VRK1, ROR1, TRIB2, TGFBR3, TGFBR2, LATS2, ACVR2A, NUAK1, CDC7, ULK1, CDC2L1, PEAK1, JAK1, RPS6KC1, PRKD1 | Oxidative/Metabolic/Environmental Stress | UniProt [67], Jenuth 2000 [69, 77] |
| Source | F ratio | p |
| Method | 7.377 | 0.013 |
| Method × group | 0.373 | 0.547 |
| Task | 35.697 | 0.000 |
| Task × group | 0.030 | 0.865 |
| Hemisphere | 0.310 | 0.583 |
| Hemisphere × group | 0.692 | 0.414 |
| Method × task | 4.838 | 0.039 |
| Method × task × group | 0.005 | 0.945 |
| Method × hemisphere | 0.047 | 0.831 |
| Method × hemisphere × group | 0.042 | 0.839 |
| Task × hemisphere | 0.035 | 0.853 |
| Task × hemisphere × group | 0.207 | 0.653 |
| Method × task × hemisphere | 0.009 | 0.924 |
| Method × task × hemisphere × group | 0.123 | 0.730 |
| Solvents | SC16-Lu | TC18-Lu | TC16-Lu | TC14-Lu | TC12-Lu |
| Acetone | I | I | G (1.5) | I | PS |
| Aniline | S | G (2.0) | G (2.0) | G (1.5) | PS |
| Toluene | PS | PS | I | PS | PS |
| Pyridine | S | S | G (2.0) | S | S |
| Isopropanol | PS | G (2.5) | G (2.0) | PS | PS |
| Cyclopentanone | PS | G (2.0) | G (1.5) | PS | PS |
| Cyclohexanone | PS | PS | G (2.0) | PS | PS |
| Nitrobenzene | S | G (2.0) | G (2.0) | G (2.0) | PS |
| n-Butanol | PS | G (2.5) | G (2.0) | PS | PS |
| Ethanolamine | G (2.0) | PS | I | S | PS |
| n-Butyl acrylate | PS | PS | S | PS | PS |
| 1,4-Dioxane | PS | G (2.5) | G (2.0) | S | PS |
| Petroleum ether | S | G (2.0) | S | S | PS |
| Ethyl acetate | PS | PS | S | PS | PS |
| Dichloromethane | PS | S | S | S | S |
| THF | I | PS | S | PS | PS |
| DMF | PS | G (2.0) | G (1.5) | G (1.5) | S |
| DMSO | G (2.5) | PS | I | G (2.0) | PS |
| Ethanol | PS | G (2.0) | G (2.0) | PS | PS |
| Benzene | PS | PS | I | S | PS |
| Tetrachloromethane | PS | PS | PS | S | S |
| Acetonitrile | PS | PS | PS | PS | PS |
| Methanol | PS | PS | S | PS | PS |
| n-Pentanol | PS | G (2.5) | G (2.0) | PS | PS |
| Cyclopentanol | PS | G (2.0) | S | PS | PS |
| Formaldehyde (aq.) | PS | PS | PS | PS | PS |
| Biocatalyst | S/B | RS% | Xyl% | Glc% | Useful results | |
| 1 | TL-xylanase | 3.3 | 23.5 | 2.26 | 8.6 | xylobiose 3.3 g/L |
| pentasaccharide 1 (Figure 2), 2 g/L | ||||||
| 2 | TM-xylanase | 2.6 | 38 | 0 | 0 | - |
| 3 | CFE-TT | 3.5 | 90 | 19.2 | 16.9 | - |
| 4 | CFE-TT | 1.2 | 100 | 28.6 | 6.8 | - |
| 5 | CFE-TT | 3.5 | 20 | 8.7 | 7.8 | tetrasaccharide 2 (Figure 2) 2.64 g/L |
| 6 | CFE-TN | 1.2 | 75 | 40.5 | 15.2 | see Figure 3 |
| 7 | ES-GTM1b | 13.5 | 73.5 | 26.5 | 0 | see Figure 3 |
| 8 | ES-GTM1a | 36.3 | 63.1 | 9.85 | 0 | see Figure 3 |
| Comment | ||||||
| 9 | TM-xylanase | 7.7 | Formation of mono and dixylosylated acceptor | |||
| 10 | CFE-TN | 1.2 | Formation of mono and dixylosylated acceptor | |||
| 11 | ES-GTM1 | 13.5 | Formation of mono, di and trixylosylated acceptor | |||
| 12 | CFE-TT | 3.5 | Formation of mono and dixylosylated acceptor |
| Reason for hysterectomy | Number of women with vaginal bleeding | Odds ratio (95% CI) | ||
| Supracervical abdominal hysterectomy | Fibroids | Yes | 16 | 0.66 (0.16, 2.71)* |
| No | 3 | |||
| Heavy bleeding | Yes | 11 | 1.28 (0.49, 3.35)* | |
| No | 8 | |||
| Pain and/or endometriosis | Yes | 5 | 1.37 (0.43, 4.32)* | |
| No | 14 | |||
| Supracervical laparoscopic hysterectomy | Fibroids | Yes | 33 | 0.47 (0.23, 0.93)* |
| No | 24 | |||
| Heavy bleeding | Yes | 41 | 4.07 (1.32, 12.57)* | |
| No | 16 | |||
| Pain and/or endometriosis | Yes | 23 | 0.41 (0.20, 0.85)* | |
| No | 34 |
| Module | Module hub genes | Module membership | LPS log2FC | DE FDR |
| module I | BIRC3 | 0.97 | 1.26 | 1.89e-12 |
| module I | VPS37A | 0.95 | 0.53 | 3.97e-9 |
| module I | STARD13 | 0.94 | 0.80 | 1.01e-4 |
| module I | SOD2 | 0.94 | 1.75 | 8.83e-16 |
| module I | SLC1A2 | 0.94 | 2.83 | 3.62e-18 |
| module I | ARHGEF3 | 0.94 | 0.53 | 3.39e-8 |
| module I | TTC25 | 0.94 | 0.84 | 5.30e-8 |
| module I | SLC39A14 | 0.93 | 1.80 | 2.80e-12 |
| module I | ENSECAG00000002023, superoxide dismutase | 0.93 | 1.79 | 5.69e-16 |
| module I | TREX1 | 0.93 | 0.85 | 2.25e-7 |
| module II | VAT1 | 0.95 | −1.13 | 1.68e-16 |
| module II | SDC3 | 0.94 | −2.27 | 1.16e-9 |
| module II | FCGRT | 0.94 | −1.39 | 1.42e-10 |
| module II | SLC46A1 | 0.94 | −1.80 | 8.21e-18 |
| module II | NAAA | 0.94 | −0.94 | 2.53e-20 |
| module II | CSF1R | 0.93 | −1.54 | 1.43e-11 |
| module II | MAN2B1 | 0.93 | −0.44 | 5.77e-10 |
| module II | ARRB1 | 0.92 | −1.03 | 3.19e-9 |
| module II | GAMT | 0.92 | −2.40 | 3.77e-19 |
| module II | S100A4 | 0.92 | −1.10 | 4.29e-12 |
| Comparator | Correlation [95% CI] with UCEIS | Correlation [95% CI] with Modified Baron Scorea |
| Full MCS+ [including endoscopy] | 0.86 [0.83, 0.88] | N/Ab |
| Partial MCS [excluding endoscopy] | 0.82 [0.79, 0.85] | 0.77 [0.61, 0.88] |
| Stool frequency subscore | 0.76 [0.72, 0.80] | 0.73 [0.53, 0.85] |
| Rectal bleeding subscore | 0.82 [0.78, 0.85] | 0.74 [0.54, 0.85] |
| Both stool frequency and rectal bleeding | 0.81 [0.77, 0.84] | 0.77 [0.58, 0.87] |
| Patient functional assessment subscore | 0.76 [0.71, 0.79] | 0.52 [0.24, 0.72] |
| Modified Baron scorea | 0.78 [0.74, 0.81] | - |
| Vials with FA detectedn (%) | Vials without FAn (%) | |
| Infundibulae or surface structures on sections | 376 (72.6) | 94 (18.1) |
| No infundibulae or surface structures on sections | 0 (0.0) | 48 (9.3) |
| Image number | Proposed method (e1) | Method proposed by Zhang (e2) | ||||
| 7 | 14 | 20 | 7 | 14 | 20 | |
| 1 | 0.050 | 0.021 | 0.011 | 0.041 | 0.034 | 0.012 |
| 2 | 0.047 | 0.032 | 0.027 | 0.025 | 0.029 | 0.039 |
| 3 | 0.061 | 0.011 | 0.034 | 0.037 | 0.028 | 0.019 |
| 4 | 0.103 | 0.028 | 0.018 | 0.031 | 0.051 | 0.027 |
| 5 | 0.032 | 0.036 | 0.012 | 0.028 | 0.047 | 0.014 |
| 6 | 0.098 | 0.040 | 0.019 | 0.029 | 0.013 | 0.009 |
| 7 | 0.057 | 0.035 | 0.017 | 0.037 | 0.018 | 0.015 |
| 8 | 0.046 | 0.022 | 0.020 | 0.035 | 0.024 | 0.020 |
| 9 | 0.039 | 0.023 | 0.025 | 0.041 | 0.015 | 0.034 |
| 10 | 0.049 | 0.039 | 0.020 | 0.022 | 0.022 | 0.009 |
| Average error | 0.058 | 0.0287 | 0.0203 | 0.0326 | 0.0281 | 0.0198 |
| Variable | Number | % |
| Age, mean ± SD | 69.0 ± 10.2 | |
| Sex | ||
| Male | 159 | 70.7 |
| Female | 66 | 29.3 |
| Histology | ||
| Adenocarcinoma | 139 | 61.5 |
| Squamous cell | 67 | 30.1 |
| NSCLC-NOS | 10 | 4.4 |
| Pleomorphic | 5 | 2.2 |
| Adenosquamous | 4 | 1.8 |
| Pathological stage | ||
| IA | 78 | 34.5 |
| IB | 53 | 23.9 |
| IIA | 23 | 10.2 |
| IIB | 24 | 10.6 |
| IIIA | 36 | 15.9 |
| IIIB/IV | 11 | 4.9 |
| Total population | Consumers only | Percentiles of intake among consumers | ||||
| N = 8,861 | n = 2,310 | |||||
| Gender | Mean ± SE | Pct. | Mean ± SE | 25th ± SE | 50th ± SE | 75th ± SE |
| Combined | 50.3 ± 1.8 | 23.8 | 210.0 ± 3.8 | 109.4 ± 3.0 | 468.6 ± 4.7 | 259.3 ± 6.8 |
| Male | 59.2 ± 2.7a | 24.5 | 235.6 ± 5.3a | 118.3 ± 4.1 | 192.2 ± 2.0 | 286.9 ± 8.3 |
| Female | 41.4 ± 2.1b | 23.1 | 177.4 ± 5.0b | 94.6 ± 3.8 | 147.9 ± 7.4 | 227.7 ± 7.7 |
| Sample a | Molar Composition b (Relative %, mol/mol) | Molar Ratio c | |||||
| Ara | Gal | Glc | Xyl | GlcA | GlcA/Xyl | Ara/Xyl | |
| H2 | 11.25 ± 0.2 | 4.60 ± 0.1 | 22.01 ± 0.1 | 58.30 ± 0.0 | 3.59 ± 0.1 | 0.06 | 0.19 |
| H24 | 6.48 ± 0.1 | 0.59 ± 0.0 | 2.87 ± 0.2 | 86.93 ± 0.0 | 3.30 ± 0.0 | 0.03 | 0.07 |
| Microorganisms | Isolation Sites | Applications | Enzyme | Reference |
| Pseudoalteromonas haloplanktis | Antarctica | Starch conversion; detergent | Amylase Endo-amylase | [106] |
| Zunongwangia profunda | Deep-sea, China | Starch conversion; detergent | Alpha-amylase | [107] |
| Martelella mediterranea | Lake Martel, Spain | cellulose conversion; detergent | Beta-glucosidase | [22] |
| Desulfotalea psychrophila | Marine sediments, Antarctica | Agriculture; food; pharmaceutical industries | Esterase | [108] |
| Pseudoalteromonas haloplanktis | Marine Antarctic | Detergent | Lipase | [98] |
| Psychrobacter sp. wp37 | Deep-sea sediments, West Pacific | Detergent | Lipase | [109] |
| Microorganisms | EPS-Structure and Chemical Composition 1 | Applications and Activity | Reference | |
| Pseudomonas sp. ID1 | Carbohydrates 33.8% (Glc 17.0%, Gal 8.6%, Fuc 8.2%)/Uronic acids 2.4%/Proteins 2.8% | Cryo-protection and emulsifying activities | [110] | |
| Pseudomonas strain CAM025 | Glc/GalA/Rha/Gal Molar ratios: 1:0.5:0.1:0.08 | Cryo-protection and trace metal binding | [110] |
| Indicator |
| A Ratio of native Dutch within total population: both parents were born in the Netherlands |
| B Ratio of Moroccan origin within total population: person or at least one parent was born in Morocco |
| C Ratio of Turkish origin within total population: person or at least one parent was born in Turkey |
| D Ratio of Surinamese origin within total population: person or at least one parent was born in Surinam |
| E Ratio of Antillean origin within total population: person or at least one parent was born in the Netherlands Antilles |
| C | C + WGP | HF | HF + WGP | |
| Glucose in plasma (mg/dL) | 94.8 ± 1.8 | 88.3 ± 3.0 | 104.3 ± 2.8* | 91. ± 2.84 |
| Triglycerides in plasma (mg/mL) | 92.4 ± 6.8 | 108.8 ± 4.2 | 140.7 ± 11.2* | 122.1 ± 7.8 |
| Insulin in plasma (μU/mL) | 7.6 ± 1.5 | 5.8 ± 0.6 | 912.2 ± 1.3* | 8.9 ± 0.7 |
| Systolic arterial pressure (mmHg) | 108.8 ± 4.4 | 110.6 ± 2.1 | 115.0 ± 1.7 | 112.2 ± 1.8 |
| Body weight (g) | 515.8 ± 22.6 | 519.1 ± 17.9 | 514.0 ± 22.4 | 528.9 ± 21.8 |
| Heart weight (g) | 1.43 ± 0.05 | 1.46 ± 0.06 | 1.50 ± 0.05 | 1.56 ± 0.09 |
| Variable | Group on-pump (n = 146) | Group off-pump (n = 92) | P Value |
| Clinical demographics | |||
| Age (y) | 65 ± 8 | 63 ± 9 | 0.0749 |
| Female sex | 25 (17.1%) | 12(13.0%) | 0.398 |
| Coronary risk factors | |||
| Hypertension | 95(65.1%) | 59(64.1%) | 0.883 |
| Diabetes | 122(83.6%) | 76(82.6%) | 0.080 |
| Hyperlipidemia | 64(43.8%) | 55(59.8%) | 0.017 |
| Smoking | 67(45.9%) | 41(44.6%) | 0.842 |
| Peripheral vascular disease | 28(19.2%) | 15(16.6%) | 0.575 |
| Previous renal impairment | 8(5.5%) | 4(4.3%) | 0.698 |
| Cerebrovascular accident | 3(2.1%) | 13(14.1%) | 0.000 |
| COPD | 6(4.1%) | 22(23.9%) | 0.000 |
| Calcified ascending aorta | 4(2.7%) | 45(48.9%) | 0.000 |
| Cardiac profile | |||
| Previous myocardial infarction | 93(63.7%) | 55(62.2%) | 0.544 |
| Unstable angina | 106(72.6%) | 68(73.9%) | 0.824 |
| previous PCI | 23(15.8%) | 15(16.3%) | 0.910 |
| Mean ejection fraction | 0.58 ± 0.12 | 0.56 ± 0.11 | 0.1974 |
| Poor ejection fraction(<0.35) | 15(10.3%) | 9(9.8%) | 0.902 |
| Left main disease | 29(19.8%) | 17(18.5%) | 0.792 |
| RCA Critical stenosis > 90% | 81(55.5%) | 89(96.7%) | 0.000 |
| Number of diseased vessels | 3.5 ± 0.5 | 3.4 ± 0.6 | 0.1689 |
| Characteristics | Total population |
| n = 3807 | |
| Gender | |
| Male | 42.1 % |
| Age (years) | |
| Mean (SD) | 78 (7.68) |
| Range | 65–102 |
| Number of chronically used drugs | |
| Median (IQR) | 9 (7–11) |
| Mean (SD) | 9.54 (3.40) |
| Range | 5–27 |
| Number of DRPs | |
| Median (IQR) | 2 (1–4) |
| Mean (SD) | 3.00 (2.26) |
| Range | 1–26 |
| (-)crystal packing | biological interactions(+) | ||||||
| support level | range of support ratios | ||||||
| -INF | -2 | 1 | 2 | 3 | > = 4 | INF | |
| -INF | (-2.5,-1.5] | (-1.5,1.5) | [1.5,2.5) | [2.5,3.5) | [3.5,7.5) | INF | |
| 2 | 13 | 0 | 152 | 0 | 0 | 0 | 1144 |
| 3 | 0 | 3 | 0 | 38 | 0 | 0 | 207 |
| 4 | 0 | 0 | 0 | 0 | 13 | 0 | 40 |
| > = 5 | 0 | 0 | 0 | 1 | 7 | 6 | 23 |
| Total | 13 | 3 | 152 | 39 | 20 | 6 | 1414 |
| Total group (n = 270) | Subgroup (n = 141) | |
| Haemoglobin (g/dl) | 13.1 ± 0.9 | 13.2 ± 0.9 |
| Haematocrit (%) | 39.2 ± 2.7 | 39.2 ± 2.8 |
| Mean Corpuscular Volume (fl.) | 87.2 ± 5.0 | 86.9 ± 5.0 |
| Serum Ferritin (ng/ml) | 25.1 ± 21.3 | 25.5 ± 16.9 |
| Serum Transferrin (mg/dl) | 307.5 ± 54.1 | 311.5 ± 56.7 |
| Serum iron (μg/dl) | 81.7 ± 37.5 | 80.0 ± 36. |
| Transferrin saturation (%) | 19.4 ± 10.2 | 18.8 ± 8.7 |
| Layers | Attacks |
| Physical layer | Jamming, Node tampering |
| Link layer/medium access control | Collision, exhaustion, and unfairness |
| Network and routing layer | Neglect and greed, homing, misdirection, spoofing, replaying, routing-control traffic or clustering messages |
| Transport layer | Flooding and De-synchronization |
| Application layer | Overwhelming sensors, reprogramming attack |
| ADC: SUVmax | SQC: SUVmax | |||||
| Factor | Low | High | Pvalue | Low | High | Pvalue |
| Pleural invasion | 0.027 | 0.064 | ||||
| No | 19 | 19 | 17 | 9 | ||
| Yes | 2 | 12 | 1 | 5 | ||
| Vascular invasion | 0.042 | 0.735 | ||||
| No | 17 | 16 | 9 | 6 | ||
| Yes | 4 | 15 | 9 | 8 | ||
| Nodal status | 0.016 | 0.365 | ||||
| N0 | 21 | 23 | 16 | 10 | ||
| N1 + 2 | 0 | 8 | 2 | 4 | ||
| Cox-2 expression | 0.001 | 0.473 | ||||
| Negative | 13 | 5 | 12 | 7 | ||
| Positive | 8 | 26 | 6 | 7 | ||
| Ki-67 expression | 0.011 | 0.087 | ||||
| Negative | 15 | 11 | 11 | 4 | ||
| Positive | 6 | 20 | 7 | 10 | ||
| VEGF expression | 0.003 | 0.999 | ||||
| Negative | 12 | 5 | 9 | 7 | ||
| Positive | 9 | 26 | 9 | 7 |
| Accession | Hydroxycinnamic Acids | ORAC | DPPH | TRC | NO Inhibition |
| S. muricatum | |||||
| 37-A | 5 | 2 | 4 | 2 | 1 |
| El Camino | 3 | 4 | 5 | 4 | 5 |
| Puzol | 2 | 3 | 2 | 5 | 2 |
| Valencia | 1 | 5 | 3 | 3 | 4 |
| S. caripense | |||||
| E-7 | 4 | 1 | 1 | 1 | 3 |
| Region | Diseased animals | Apparently healthy animals | Total | |||
| Number of isolates as detected from 16SrRNA | Positive for SeM gene | Number of isolates as detected from 16SrRNA | Positive for SeM gene | Number of isolates as detected from 16SrRNA | Positive for SeM gene | |
| R.S. Pura | 4 | 0 | 1 | 0 | 5 | 0 |
| Katra | 12 | 2 | 3 | 0 | 15 | 2 |
| Total | 16 | 2 | 4 | 0 | 20 | 2 |
| Brain region | Hemisphere | NVtxs | Size (mm2) | X | Y | Z | Max | CWP | |
| Group comparisons | |||||||||
| HC > CD | Superior temporal gyrus | R | 338 | 154.4 | 64 | −37 | 13 | 3.5 | 0.001 |
| CD > HC | None significant at CWP ≤ 0.001 | ||||||||
| CO-CD > AO-CD and vice-versa | None at CWP ≤ 0.001 | ||||||||
| Correlation with CU traits in the CD group | |||||||||
| Negative correlation | Lingual gyrus | L | 399 | 168.9 | −22 | −54 | −2 | 4.3 | 0.0007 |
| Positive correlation | None at CWP ≤ 0.001 | ||||||||
| Correlation with lifetime CD symptoms in the CD group | |||||||||
| Negative correlation | Inferior parietal lobule | R | 344 | 184.6 | 45 | −64 | 32 | 3.5 | 0.0002 |
| Positive correlation | Inferior frontal gyrus (pars opercularis) | R | 297 | 169.5 | 47 | 25 | 20 | 3.2 | 0.0007 |
| NHI Code | Treatment | (n = 13,261) | % |
| 45010C | Supportive individual psychotherapy | 2117 | 16.0 |
| 45087C | Re-educative individual psychotherapy-adult | 1578 | 11.9 |
| 45088C | Re-educative individual psychotherapy: 6–15 years old | 127 | 1.0 |
| 45100C | Behavior modification assessment | 49 | 0.4 |
| 45013C | Intensive individual psychotherapy-adult | 34 | 0.3 |
| 45016C | Supportive group psychotherapy | 33 | 0.2 |
| 45094C | Re-educative group psychotherapy | 24 | 0.2 |
| 45022C | Activity therapy (day) | 24 | 0.2 |
| 45043C | Biofeedback therapy | 14 | 0.1 |
| 45089C | Re-educative individual psychotherapy-under 6 years old | 12 | 0.1 |
| 45095C | Special Occupational therapy | 10 | 0.1 |
| 45090C | Intensive individual psychotherapy: 6–15 years old | 7 | 0.1 |
| All patients | L5/S1 herniations with high iliac crest | Herniations with scoliosis | Herniation with calcification | |
| No. of patients in category | 209 | 29 | 25 | 31 |
| Excellent or good n (%) | 200 (95.7) | 29 (100) | 25 (100) | 30 (96.8) |
| Fair n (%) | 6 (2.9) | 0 (0) | 0 (0) | 1 (3.2) |
| Poor n (%) | 3 (1.4) | 0 (0) | 0 (0) | 0 (0) |
| RL | AP | SI | Net | |
| Range | 0-0.85 | 0-1.83 | 0-1.96 | 0.10-2.01 |
| Average (Right shoulder) | 0.22 | 0.36 | 0.35 | 0.55 |
| Average (Left shoulder) | 0.26 | 0.48 | 0.27 | 0.60 |
| Average net | 0.58 |
| F508del | Sex | Male | Female | Chi-square | p-value |
| -/- | G/G | 8 (53.3%) | 7 (46.7%) | 0.257 | 0.613 |
| G/T and T/T | 15 (45.5%) | 18 (54.5%) | |||
| F508del/- | G/G | 13 (48.1%) | 14 (51.9%) | 0.931 | 0.335 |
| G/T and T/T | 20 (60.6%) | 13 (39.4%) | |||
| F508del/F508del | G/G | 5 (41.7%) | 7 (58.3%) | 0.018 | 0.893 |
| G/T and T/T | 11 (44%) | 14 (54%) | |||
| F508del | Diabetes | No | Yes | ||
| -/- | G/G | 12 (80%) | 3 (20%) | 0.01 | 0.919 |
| G/T and T/T | 26 (81.3%) | 6 (18.8%) | |||
| F508del/- | G/G | 19 (70.4%) | 8 (29.6%) | 2.652 | 0.103 |
| G/T and T/T | 28 (87.5%) | 4 (12.5%) | |||
| F508del/F508del | G/G | 8 (66.7%) | 4 (33.3%) | 1.437 | 0.231 |
| G/T and T/T | 21 (84%) | 4 (16%) | |||
| F508del | Meconium ileus | No | Yes | ||
| -/- | G/G | 15 (100%) | - | 1.455 | 0.228 |
| G/T and T/T | 30 (90.9%) | 3 (9.1%) | |||
| F508del/- | G/G | 22 (81.5%) | 5 (18.5%) | 0.067 | 0.795 |
| G/T and T/T | 26 (78.8%) | 7 (21.2%) | |||
| F508del/F508del | G/G | 10 (83.3%) | 2 (16.7%) | 0.566 | 0.452 |
| G/T and T/T | 18 (72%) | 7 (28%) | |||
| F508del | Age | ≤ 154 months | > 154 months | ||
| -/- | G/G | 4 (26.7%) | 11 (73.3%) | 0.032 | 0.857 |
| G/T and T/T | 8 (24.2%) | 25 (75.8%) | |||
| F508del/- | G/G | 15 (55.6%) | 12 (44.4%) | 0.297 | 0.586 |
| G/T and T/T | 16 (48.5%) | 17 (51.5%) | |||
| F508del/F508del | G/G | 9 (75%) | 3 (25%) | 1.009 | 0.315 |
| G/T and T/T | 22 (88%) | 3 (12%) |
| Study reference | Study design | Reported inclusion/exclusion criteria | Reported double blind | Reported clinically-labeled products | Reported sample power estimation | Reported adverse events | Reported study completion ratio | Overall quality factor scores |
| Study 2 from Lloyd et al. 1999 [8] | Randomized Parallel group | 1 | 1 | 1 | 1 | 0 | 1 | 5/6 |
| Study 1 from Lloyd et al. 1999 [8] | Randomized Parallel group | 1 | 1 | 1 | 0 | 0 | 1 | 4/6 |
| Study 1 from Ostrom et al. 2002 [7] | Randomized Crossover | 0 | 1 | 1 | 0 | 0 | 1 | 3/6 |
| Study 2 from Ostrom et al. 2002 [7] | Randomized Crossover | 1 | 1 | 1 | 0 | 0 | 1 | 4/6 |
| Borschel et al. 2012 [11] | Randomized Parallel group | 1 | 1 | 1 | 1 | 1 | 1 | 6/6 |
| Borschel et al. 2014 [10] | Randomized Parallel group | 1 | 1 | 1 | 1 | 1 | 1 | 6/6 |
| Leite et al. 2013 [9] | Randomized Crossover 1 | 1 | 1 | 0 | 1 | 1 | 1 | 5/6 |
| Nelson et al. 1996 [6] | Randomized Crossover | 0 | 0 | 1 | 0 | 1 | 1 | 3/6 |
| Nelson et al. 1998 [5] | Randomized Crossover | 0 | 1 | 1 | 0 | 1 | 1 | 4/6 |
| With tumor thrombus | P | Without tumor thrombus | P | |
| OR(%95 CI) | OR (%95 CI) | |||
| AFP, ng/mL (> 20 vs. ≤ 20) | 1.1 (0.9, 1.3) | 0.479 | 1.1 (0.7, 1.7) | 0.746 |
| Tumor size, cm (> 5 vs. ≤ 5) | 1.7 (1.4, 2.0) | <0.001* | 0.9 (0.6, 1.5) | 0.717 |
| Tumor number (> 3 vs. ≤ 3) | 1.0 (0.8, 1.3) | 0.992 | 1.3 (0.8, 2.1) | 0.328 |
| Tumor location (more than one vs. one lobe) | 1.0 (0.8, 1.2) | 0.673 | 2.1 (1.5, 3.0) | <0.001* |
| Tumor capsule (absent vs. present) | 1.1 (0.9, 1.3) | 0.261 | 1.0 (0.7, 1.5) | 0.928 |
| Tumor differentiate (III-IV vs. I-II) | 1.2 (1.0, 1.4) | 0.071 | 1.1 (0.8, 1.6) | 0.610 |
| No | A | B | C | D | extract weight(%)y1 | TTC(%)y2 | score z |
| 1 | 1 | 1 | 1 | 1 | 56.76 | 22.54 | 73.79 |
| 2 | 1 | 2 | 2 | 2 | 69.10 | 24.97 | 85.14 |
| 3 | 1 | 3 | 3 | 3 | 73.18 | 30.92 | 98.65 |
| 4 | 2 | 1 | 2 | 3 | 72.14 | 31.63 | 99.44 |
| 5 | 2 | 2 | 3 | 1 | 34.94 | 26.04 | 68.46 |
| 6 | 2 | 3 | 1 | 2 | 64.81 | 24.73 | 82.34 |
| 7 | 3 | 1 | 3 | 2 | 62.08 | 30.09 | 91.09 |
| 8 | 3 | 2 | 1 | 3 | 65.58 | 28.54 | 89.99 |
| 9 | 3 | 3 | 2 | 1 | 52.24 | 24.25 | 74.56 |
| K1 | 257.58 | 264.32 | 246.12 | 216.81 | |||
| K2 | 250.24 | 243.59 | 259.14 | 258.57 | |||
| K3 | 255.64 | 255.55 | 258.20 | 288.08 | |||
| k1 | 85.86 | 88.11 | 82.04 | 72.27 | |||
| k2 | 83.41 | 81.20 | 86.38 | 86.19 | |||
| k3 | 85.21 | 85.18 | 86.07 | 96.03 | |||
| R | 2.45 | 6.91 | 4,34 | 23.76 |
| WT | +/- | -/- | |
| Early-stage seizure | 0 | + | ++ |
| Myoclonic jerks | 0 | +* | 0 |
| Clonic seizure | 0 | −* | −− |
| Repetitive jumping | 0 | (+) | ++ |
| Social preference | 0 | (+) | ++ |
| Ultrasonic vocalization | 0 | (−)* | −− |
| Nest building | 0 | − | −− |
| Acoustic startle response | 0 | − | −− |
| Prepulse inhibition | 0 | (−) | −− |
| Cue test (fear conditioning) | 0 | (−) | −− |
| Up-regulated miRNAs | Fold-change | P |
| miR-7 | 10.91 | 0.005 |
| miR-196b | 7.67 | 0.030 |
| miR-424 | 6.75 | 0.008 |
| miR-18b | 6.67 | 0.002 |
| miR-223 | 6.31 | 0.003 |
| miR-130b | 5.18 | 0.005 |
| Statement | Depression Vignette | Depression/Suicidal Vignette | Early Schizophrenia Vignette | Chronic Schizophrenia Vignette |
| Person could snap out of the problem | ||||
| Australian | 24.7 (21.7%–27.9%) | 22.7 (19.9%–25.7%) | 18.3 (15.6%–21.3%) | 17.9 (15.0%–21.2%) |
| Japanese | 47.2 * d (42.8%–51.6%) | 49.4 * d (45.0%–53.8%) | 41.2* (36.9%–45.5%) | 36.4 * a,b (32.2%–40.6%) |
| Problem is a sign of personal weakness | ||||
| Australian | 13.4 (11.0%–16.2%) | 16.9 (14.4%–19.6%) | 19.3 (16.6%–22.4%) | 14.0 (11.7%–16.7%) |
| Japanese | 45.4* (41.0%–49.8%) | 45.0* (40.6%–49.4%) | 46.6* (42.2%–51.0%) | 46.0* (41.6%–50.4%) |
| Problem is not a real medical illness | ||||
| Australian | 14.6 (12.3%–17.1%) | 15.2 (13.0%–17.8%) | 14.9 (12.7%–17.4%) | 13.9 (11.7%–16.6%) |
| Japanese | 40.2* (35.9%–44.5%) | 38.4* (34.1%–42.7%) | 31.4* (27.3%–35.5%) | 35.8* (31.6%–40.0%) |
| People with this problem are dangerous | ||||
| Australian | 11.9 c,d (9.8%–14.3%) | 18.3 c (15.7%–21.2%) | 24.9 a,b (22.2%–27.8%) | 22.5 a (19.6%–25.7%) |
| Japanese | 14.6 d (11.5%–17.7%) | 16.0 d (12.8%–19.2%) | 20.4 d (16.9%–23.9%) | 37.6 * a,b,c (33.3%–41.9%) |
| Avoid people with this problem | ||||
| Australian | 6.9 (5.3%–9.0%) | 4.7 (3.5%–6.4%) | 4.9 (3.6%–6.6%) | 5.2 (3.9%–7.0%) |
| Japanese | 7.8 d (5.4%–10.2%) | 5.8 c,d (3.7%–7.9%) | 11.8 *,b (9.0%–14.6%) | 17.8 * a,b (14.4%–21.2%) |
| People with this problem are unpredictable | ||||
| Australian | 42.2 c,d (38.8%–45.6%) | 51.1 c,d (47.6%–54.5%) | 67.1 a,b (63.9%–70.1%) | 67.5 a,b (64.1%–70.7%) |
| Japanese | 18.6 * c,d (15.2%–22.0%) | 20.0 * c,d (16.5%–23.5%) | 31.0 * a,b,d (26.9%–35.1%) | 45.6 * a,b,c (41.2%–50.0%) |
| If I had this problem I wouldn't tell anyone | ||||
| Australian | 17.0 c,d (14.5%–19.9%) | 21.5 d (18.8%–24.3%) | 26.7 a (23.8%–29.8%) | 31.1 a,b (28.1%–34.3%) |
| Japanese | 26.8 * d (22.9%–30.7%) | 24.8 c,d (21.0%–28.6%) | 35.0 b (30.8%–39.2%) | 37.2 a,b (32.9%–41.5%) |
| I would not employ someone with this problem | ||||
| Australian | 21.6 d (19.2%–24.3%) | 22.5 d (19.8%–25.4%) | 24.8 (22.0%–27.9%) | 32.4 a,b (29.2%–35.8%) |
| Japanese | 38.6 * d (34.3%–42.9%) | 38.6 * d (34.3%–42.9%) | 47.6 * d (43.2%–52.0%) | 61.2 * a,b,c (56.9%–65.5%) |
| I would not vote for a politician with this problem | ||||
| Australian | 30.1 d (26.9%–33.4%) | 32.5 d (29.4%–35.8%) | 35.3 d (32.2%–38.5%) | 45.7 a,b,c (42.5%–49.0%) |
| Japanese | 58.0 * d (53.7%–62.3%) | 53.8 * d (49.4%–58.2%) | 58.0 * d (53.7%–62.3%) | 73.8 * a,b,c (69.9%–77.7%) |
| OR (95% CI) | ||
| Pregnancy outcome (n) | Unadjusted | Adjusteda |
| Term [≥ 37 weeks (923)] | ||
| All preterm [< 37 weeks (101)] | 1.1 (0.6–2.2) | 1.55 (0.7–2.9) |
| Moderately preterm [35–36 weeks (57)] | 0.3 (0.1–1.4) | 0.4 (0.1–1.9) |
| Very preterm [< 35 weeks (44)] | 2.4 (1.1–5.1) | 3.0 (1.3–6.7) |
| Targeted agent | Chemotherapy | N | RR | PFS (months) | OS (months) | Reference |
| Cetuximab | Irinotecan and FU | 49 | 42% | 8.6 | 16.6 | Kanzler et al. [11] |
| Bevacizumab | Docetaxel, FU and cisplatin | 44 | 67% | 12 | 16.2 | Kelsen et al. [12] |
| Cetuximab | Irinotecan and oxaliplatin | 51 | 60% | 6 | 9.5 | Woell et al. [13] |
| ID | Protein change | aNucleotide change | Mutation type | dPolyPhen-2 | eSIFT | Predicted function | Mutant ratio |
| 777T | Y249X | 747T>A | nonsense | Loss of function | 0.91 | ||
| 869T | G869E | 2606G>A | missense | damaging | damaging | Damaging | 0.51 |
| 163T | C911F | 2732G>T | missense | damaging | tolerated | Uncertain | 0.49 |
| 324T | S947C | 2840C>G | missense | benign | damaging | Uncertain | 0.61 |
| 970T | P226RfsX4 | 677_693del17 | frameshift | Loss of function | 0.19 | ||
| 981T | P226RfsX4 | 677_693del17 | frameshift | Loss of function | 0.23 | ||
| 1278T | F1250del | 3747_3749del | in-frame del | Uncertain | 0.14 | ||
| bACCMESO1 | V132EfsX3 | 395_399del5 | frameshift | Loss of function | |||
| cNYU695 | K674SfsX73 | 2020delA | frameshift | Loss of function |
| Johnsen Score | Parameters | Area Under the Curve | Std. Error | Asymptotic Sig. | Asymptomic 95% Confidence Interval | ||
| Lower Bound | Upper Bound | ||||||
| Left Testis | ≥8 | Testis Volume | 0.796 | 0.034 | 0.000 | 0.729 | 0.863 |
| TT | 0.544 | 0.043 | 0.308 | 0.459 | 0.629 | ||
| ≤7 | age | 0.546 | 0.043 | 0.290 | 0.461 | 0.631 | |
| PRL | 0.587 | 0.043 | 0.044 | 0.503 | 0.671 | ||
| FSH | 0.627 | 0.042 | 0.003 | 0.545 | 0.710 | ||
| LH | 0.561 | 0.043 | 0.156 | 0.477 | 0.645 | ||
| E2 | 0.688 | 0.042 | 0.000 | 0.605 | 0.771 | ||
| Right Testis | ≥8 | Testis Volume | 0.791 | 0.035 | 0.000 | 0.721 | 0.860 |
| age | 0.556 | 0.043 | 0.193 | 0.472 | 0.641 | ||
| LH | 0.552 | 0.043 | 0.231 | 0.467 | 0.636 | ||
| TT | 0.574 | 0.043 | 0.085 | 0.491 | 0.658 | ||
| ≤7 | PRL | 0.547 | 0.043 | 0.274 | 0.463 | 0.632 | |
| FSH | 0.537 | 0.044 | 0.395 | 0.451 | 0.623 | ||
| E2 | 0.716 | 0.039 | 0.000 | 0.641 | 0.792 |
| No. | Age | Gender | BSA (m2) | MSKCC risk | Metastatic sites | Prior therapy |
| 1 | 70 | Female | 1.298 | Intermediate | Lung, Lymph nodes | None |
| 2 | 58 | Female | 1.446 | Favorable | Abdominal wall, Lung, liver | None |
| 3 | 56 | Male | 1.929 | Intermediate | Lung | Interferon |
| 4 | 79 | Male | 1.710 | Favorable | Pancreas, Contralateral kidney | None |
| 5 | 62 | Male | 1.893 | Favorable | Pleura | None |
| 6 | 64 | Male | 1.659 | Intermediate | Lung | None |
| Dependent variable: 2009 performance score | |||||
| (1) | (2) | (3) | (4) | (5) | |
| Private | −6.212 | −7.030 | −7.026 | −5.548 | −5.311 |
| (3.651)* | (3.615)* | (3.506)** | (3.556) | (3.505) | |
| Weifang | 5.578 | 6.234 | 6.313 | 6.368 | 6.994 |
| (2.273)** | (2.137)*** | (1.999)*** | (2.351)*** | (2.223)*** | |
| Private*Weifang | 7.480 | 7.585 | 7.273 | 6.789 | 6.035 |
| (3.940)* | (3.885)* | (3.709)* | (3.874)* | (3.809) | |
| Clinic space (m2) | 0.007 | −0.000 | 0.000 | ||
| (0.004)* | (0.001) | (0.001) | |||
| Value of fixed assets | −0.023 | −0.007 | −0.007 | ||
| (0.014) | (0.008) | (0.007) | |||
| Number of beds | 0.296 | 0.330 | 0.352 | 0.248 | 0.277 |
| (0.280) | (0.267) | (0.249) | (0.268) | (0.264) | |
| Number of staff members | 0.206 | 0.147 | 0.120 | 0.362 | 0.323 |
| (0.194) | (0.168) | (0.158) | (0.205)* | (0.179)* | |
| Dummy for medical insurance appointed health stations | −0.407 | −0.852 | −1.135 | ||
| (3.047) | (2.932) | (3.059) | |||
| Dummy for implementing the policy of separating prescribing from dispensing | 1.939 | −0.754 | 0.604 | ||
| (2.608) | (2.229) | (2.226) | |||
| Constant | 70.534 | 72.637 | 72.083 | 70.907 | 70.283 |
| (3.793)*** | (3.755)*** | (2.693)*** | (3.770)*** | (2.910)*** | |
| Observations | 90 | 100 | 106 | 92 | 94 |
| Adjusted R-squared | 0.16 | 0.18 | 0.21 | 0.15 | 0.18 |
| Sequence | Faster adaptation for the lens of period 1 (immediate or few hours) | No difference | Faster adaptation for the lens of period 2 (immediate or few hours) | TOTAL |
| N | N | N | N | |
| New-generation lens then older-generation lens | 14 | 35 | 12 | 61 |
| Older-generation lens then new-generation lens | 5 | 39 | 19 | 63 |
| TOTAL | 19 | 74 | 31 | 124 |
| Outcomes | Lifestyle intervention group n = 27a | Close follow-up group n = 27 | p valueb |
| Total weight gain (kg) | 11.4 ± 6.0 | 13.9 ± 5.1 | NS |
| Weight at the end of pregnancy ( kg) | 88.6 ± 14.4 | 84.1 ± 11.3 | NS |
| Fasting glucose (mmol/l) | 4.6 ± 0.4 | 4.4 ± 0.3 | NS |
| OGTT 1-hour glucose (mmol/l) | 6.9 ± 1.7 | 6.9 ± 1.7 | NS |
| OGTT 2-hour glucose (mmol/l) | 6.1 ± 1.4 | 6.0 ± 1.2 | NS |
| Area under the curve (mmol/l/2 h) | 12.3 ± 2.4 | 12.1 ± 2.2 | NS |
| Gestational diabetes | 3 (11.1) | 1 (3.7) | NS |
| Insulin therapy | 0 | 0 | NS |
| Obese non-diabetic(n = 138) | Obese diabetic(n = 92) | p | |
| Physical and clinical characteristics | |||
| Age (years) | 45.76 ± 9.91 | 48.28 ± 8.17 | 0.16 |
| Gender (M/F) | 71/67 | 49/43 | 0.44 |
| BMI (kg/m2) | 33.82 ± 3.47 | 33.55 ± 2.94 | 0.59 |
| PBF (%) | 38.20 ± 5.35 | 37.02 ± 4.95 | 0.54 |
| Waist (cm) | 106.02 ± 12.00 | 108.88 ± 8.75 | 0.053 |
| Hip (cm) | 115.06 ± 12.64 | 113.96 ± 12.40 | 0.97 |
| Resting HR (beats/min) | 76.67 ± 11.01 | 86.01 ± 11.68 | <0.0001 |
| SBP (mmHg) | 120.92 ± 13.04 | 121.88 ± 11.92 | 0.64 |
| DBP (mmHg) | 78.13 ± 8.58 | 78.70 ± 6.16 | 0.28 |
| VO2 Max (mL/kg/min) | 17.57 ± 4.70 | 15.89 ± 4.10 | 0.04 |
| WBC10 | 6.65 ± 1.89 | 7.54 ± 1.91 | 0.0003 |
| Metabolic markers | |||
| Cholesterol (mmol/L) | 5.21 ± 0.89 | 5.05 ± 1.16 | 0.22 |
| HDL (mmol/L) | 1.22 ± 0.36 | 1.11 ± 0.33 | 0.027 |
| LDL (mmol/L) | 3.35 ± 0.85 | 3.16 ± 1.24 | 0.09 |
| TG (mmol/L) | 1.45 ± 0.95 | 2.10 ± 1.74 | 0.0002 |
| Glucose (mmol/L) | 5.43 ± 0.47 | 9.82 ± 3.85 | <0.0001 |
| HbA1c (%) | 5.76 ± 0.49 | 8.70 ± 1.93 | <0.0001 |
| Insulin (ng/mL) | 3.82 ± 1.94 | 4.22 ± 2.04 | 0.26 |
| HOMA-IR | 0.96 ± 0.55 | 1.60 ± 0.88 | <0.0001 |
| C-peptide (g/mL) | 1.88 ± 1.13 | 1.87 ± 1.25 | 0.91 |
| Glucagon (ng/mL) | 0.16 ± 0.04 | 0.18 ± 0.05 | 0.11 |
| GIP (ng/mL) | 0.76 ± 0.55 | 0.92 ± 0.61 | 0. 13 |
| GLP-1 (ng/mL) | 0.27 ± 0.05 | 0.29 ± 0.04 | 0.002 |
| Leptin (ng/mL) | 9.10 ± 6.25 | 8.66 ± 3.99 | 0.74 |
| Inflammatory markers | |||
| IL-1b (pg/L) | 8.29 ± 3.28 | 7.82 ± 1.94 | 0.96 |
| IL-6 (pg/mL) | 17.30 ± 6.24 | 17.16 ± 4.87 | 0.71 |
| IL-10 (pg/mL) | 28.47 ± 20.05 | 33.02 ± 27.87 | 0.50 |
| IP-10 (pg/mL) | 571 ± 418 | 689 ± 617 | 0.54 |
| TNF-α (pg/mL) | 127 ± 40 | 123 ± 31 | 0.65 |
| hsCRP (μg/mL) | 5.38 ± 3.91 | 6.36 ± 4.52 | 0.24 |
| Working countries | Health problems suffered during last 12 month | Total | |
| Yes (%) | No (%) | ||
| Qatar | 120 (58.5) | 85 (41.5) | 205 |
| Saudi Arabia | 74 (54.0) | 63 (46.0) | 137 |
| United Arab Emirates | 37 (56.1) | 29 (43.9) | 66 |
| Total | 231 (56.6) | 177 (43.4) | 408 |
| Working countries | Accident at the work place | Total | |
| Yes (%) | No (%) | ||
| Qatar | 47 (22.9) | 158 (77.1) | 205 |
| Saudi Arabia | 36 (26.3) | 101 (73.7) | 137 |
| United Arab Emirates | 19 (28.8) | 47 (71.2) | 66 |
| Total | 102 (25.0) | 306 (75.0) | 408 |
| Univariate logistic regression | Multivariable logistic regression | |||
| Variable | OR (95% CI) | p-value | OR (95% CI) | p-value |
| Year | ||||
| For every 1-year increase | 1.11 (1.02 – 1.20) | 0.01 | 1.12 (1.02 – 1.24) | 0.02 |
| Site | ||||
| Lung | 1.00 | Referent | 1.00 | Referent |
| Breast | 1.38 (0.82 – 2.33) | 0.22 | 1.34 (0.70 – 2.56) | 0.38 |
| Liver/colorectal/stomach | 0.66 (0.34 – 1.27) | 0.21 | 0.52 (0.24 – 1.10) | 0.09 |
| Funding | ||||
| Not for profit/Mixed | 1.00 | Referent | 1.00 | Referent |
| Industry | 3.63 (2.00 – 6.58) | <.0001 | 3.54 (1.85 – 6.78) | 0.0001 |
| Not specified | 0.88 (0.44 – 1.79) | 0.73 | 0.95 (0.45 - 2.03) | 0.90 |
| Multi-center | ||||
| No | 1.00 | Referent | 1.00 | Referent |
| Yes | 1.24 (0.77 – 2.00) | 0.38 | 0.91 (0.52 – 1.58) | 0.74 |
| Placebo-controlled | ||||
| No | 1.00 | Referent | 1.00 | Referent |
| Yes | 3.08 (1.57 – 6.07) | 0.001 | 2.57 (1.19 – 5.54) | 0.02 |
| Treatment type | ||||
| Basic/Limited | 1.00 | Referent | 1.00 | Referent |
| Enhanced/Maximal | 1.11 (0.68 – 1.82) | 0.68 | 0.61 (0.32 – 1.16) | 0.13 |
| Treatment aim | ||||
| Adjuvant | 1.00 | Referent | 1.00 | Referent |
| Both | 3.67 (1.48 – 9.06) | 0.005 | 5.12 (1.81 – 14.48) | 0.002 |
| Metastatic | 3.38 (1.75 – 6.55) | 0.0003 | 4.00 (1.90 – 8.43) | 0.0003 |
| Supportive measures | 2.67 (0.91 – 7.79) | 0.07 | 1.21 (0.35 – 4.17) | 0.76 |
| Design | ||||
| Factorial/multiple arms | 1.00 | Referent | 1.00 | Referent |
| Simple 2 arm | 0.96 (0.49 – 1.90) | 0.91 | 0.73 (0.34 – 1.58) | 0.43 |
| Ethics | ||||
| Not documented | 1.00 | Referent | 1.00 | Referent |
| Documented | 1.36 (0.73 – 2.54) | 0.33 | 0.76 (0.37 – 1.56) | 0.45 |
| Studies | n | Procedures | Mean age ± SD (yr) (min–max) | Described complication | % found in each study | Equivalent % in our cohort |
| Sury et al., 1999 [3] | 1155 | MRI | N/A | Failure | 5 | 2.3 |
| Beebe et al., 2000 [9] | 572 | MRI | 5 ± 4(2 mo–14 yo) | Inadequate sedation | 7.9 | 7.3 |
| Total | 20.1 | 22 | ||||
| Malviya et al., 1997 [1] | 1140 | MRI (48%) CT (27%) Cardiac (22%) | 3 ± 3.7 | Inadequate sedationFailureDesaturation ≤90% | 13.23.785.5 | 82.35.77 |
| Total | 6.52 | 22 | ||||
| Lightdale et al., 2009 [11] | 5045 | Imaging (81%) | 3.3 (1.4–6.4) | Serious adverse events*FailureDesaturation§ | 1.921.170.57 | 02.30 |
| Haque and Fadoo, 2010 [12] | 499 | Oncology | 4.2 (6 mo–14 yo) | Desaturation¥Apnea | 2.40.6 | 5.770 |
| Cravero et al., 2006 [13] | 30037 | Imaging (60%) Oncology (9%) GI (6%) | 0–6 mo : 6% 6 mo–2 yo : 23% 2–8 yo : 47% 8 yo+ : 29% | Desaturation ≤90%Apnea | 1.570.24 | 5.770 |
| Cravero et al., 2009 [10] | 49836 | Imaging (60%) Oncology (14%) GI (11%) | 0–6 mo : 2% 6–12 mo : 6% 1-2 yo : 12% 2–4 yo : 21% 4–8 yo : 28%8 yo+ : 29% | Desaturation ≤90% for 30 sApnea | 1.545.75 | 5.770 |
| Lavoie, 2012 | 448 | Imaging (41%) GI (10%) | 4.1 ± 4.3 (1 mo–18 yo) | FailureDesaturation ≤90%ApneaMajor complication | 2.35.7700 | ———— |
| Method | Temporal resolution | Measure | Span of interest | General functionality | Hypothesized emotion-related functionality | |
| ERP | Higher (as low as 1 ms) | Amplitude fluctuations evoked by stimulus | Short (∼1 s) | Early (e.g., P1, N1, N170) | Perceptual feature extraction | Early selective attention to affective stimuli |
| Middle (e.g., P2, N2) | Executive control, selective attention | Retrieving concept knowledge for evaluation of affective state | ||||
| Late (e.g., P3, N4, Late Positive Potential) | Semantic processing, memory, evaluation | Using concept knowledge for evaluation of affective state | ||||
| ERD/ERS | Lower [few multiple of ERPs (Knösche and Bastiaansen, 2002)] | Decrease or increase of induced power in given frequency band | Long (1 s∼) | Activation or suppression of cortical activity. Alpha band oscillation is related to the access to concept knowledge. Gamma band is associated with processing of affective stimuli. |
| Odds ratio (95% confidence interval) | P value | |
| Age | 1.04 (1.01-1.07) | 0.0022 |
| BMI | 0.98 (0.93-1.03) | 0.4578 |
| Female sex | 0.79 (0.47-1.34) | 0.3952 |
| DR | 1.71 (1.03-2.85) | 0.0366 |
| Hypertension | 1.78 (1.05-3.00) | 0.0300 |
| Dyslipidaemia | 1.16 (0.71-1.89) | 0.5505 |
| Smoking | 2.17 (1.13-4.14) | 0.0109 |
| eGFR | 1.00 (0.99-1.01) | 0.3345 |
| UAE | 0.99 (0.99-1.00) | 0.6397 |
| Cavus | Neutral | Planus | P-value | |
| N (female) | 53 (5) | 184 (34) | 711 (133) | |
| AHF (mm/kN) | 13.2 ± 7.4 | 14.8 ± 7.4 | 16.6 ± 7.4 | 0.0001 a,c |
| ΔFoot Length (mm) | 4.8 ± 2.6 | 4.3 ± 2.2 | 3.6 ± 2.1 | <.0001 a,c |
| Climate model | Seasonal mean temperature (oC) | Seasonal cumulated rainfall (mm) | ||||
| 2030 | 2050 | 2070 | 2030 | 2050 | 2070 | |
| ACCESS1-0 | 14.3 ± 1.7 | 15.1 ± 1.8 | 16.1 ± 1.9 | 230.8 ± 89.9 | 213.2 ± 88.8 | 207.6 ± 84.1 |
| ACCESS1-3 | 14.5 ± 1.8 | 15.4 ± 1.9 | 16.5 ± 2.0 | 220.4 ± 88.9 | 185.4 ± 74.6 | 151.0 ± 62.9 |
| bcc-csm1-1 | 14.2 ± 1.7 | 14.8 ± 1.8 | 15.8 ± 1.8 | 222.6 ± 85.8 | 219.2 ± 84.7 | 193.0 ± 80.1 |
| bcc-csm1-1-m | 14.8 ± 1.8 | 15.3 ± 1.8 | 16.1 ± 1.8 | 224.3 ± 91.3 | 217.0 ± 83.7 | 210.6 ± 83.9 |
| BNU-ESM | 14.3 ± 1.8 | 15.2 ± 1.8 | 16.7 ± 1.8 | 262.5 ± 102.3 | 233.4 ± 91.1 | 175.3 ± 67.9 |
| CanESM2 | 14.5 ± 1.9 | 15.4 ± 2.0 | 16.7 ± 2.0 | 210.3 ± 82.4 | 203.9 ± 81.2 | 190.6 ± 74.8 |
| CCSM4 | 14.3 ± 1.8 | 15.1 ± 1.7 | 16.1 ± 1.7 | 230.9 ± 89.9 | 238.0 ± 93.8 | 230.4 ± 92.3 |
| CESM1-BGC | 14.4 ± 1.8 | 15.0 ± 1.8 | 16.1 ± 1.8 | 245.2 ± 96.0 | 247.7 ± 94.6 | 224.3 ± 87.7 |
| CESM1-CAM5 | 14.4 ± 1.8 | 15.1 ± 1.8 | 16.5 ± 1.9 | 235.5 ± 92.1 | 219.0 ± 87.4 | 208.2 ± 82.0 |
| CESM1-WACCM | 14.3 ± 1.7 | 15.1 ± 1.7 | 15.8 ± 1.7 | 231.4 ± 90.6 | 227.9 ± 89.6 | 229.5 ± 90.8 |
| CNRM-CM5 | 14.0 ± 1.7 | 14.8 ± 1.8 | 15.5 ± 1.8 | 220.1 ± 87.6 | 215.6 ± 87.5 | 216.8 ± 85.6 |
| CSIRO-Mk3-6-0 | 14.1 ± 1.8 | 14.9 ± 1.9 | 15.9 ± 2.0 | 198.9 ± 80.6 | 181.5 ± 74.4 | 150.7 ± 64.8 |
| FGOALS-g2 | 14.1 ± 1.8 | 14.6 ± 1.9 | 15.0 ± 1.8 | 212.2 ± 84.5 | 212.5 ± 86.5 | 254.5 ± 107.2 |
| FIO-ESM | 14.2 ± 1.7 | 15.0 ± 1.7 | 16.2 ± 1.7 | 232.6 ± 90.9 | 235.7 ± 92.1 | 219.7 ± 86.1 |
| GFDL-CM3 | 14.1 ± 1.9 | 14.9 ± 2.0 | 16.2 ± 2.2 | 213.1 ± 83.5 | 190.6 ± 78.3 | 153.8 ± 66.3 |
| GFDL-ESM2G | 14.0 ± 1.8 | 14.7 ± 1.9 | 15.4 ± 1.9 | 215.0 ± 88.5 | 197.5 ± 82.4 | 186.9 ± 80.4 |
| GFDL-ESM2M | 14.3 ± 1.9 | 14.8 ± 2.0 | 15.7 ± 2.1 | 188.1 ± 76.2 | 165.7 ± 70.0 | 147.4 ± 62.9 |
| GISS-E2-H | 14.0 ± 1.8 | 15.0 ± 1.7 | 15.9 ± 1.8 | 229.8 ± 89.0 | 225.5 ± 89.3 | 212.8 ± 86.3 |
| GISS-E2-H-CC | 14.0 ± 1.7 | 14.8 ± 1.7 | 15.5 ± 1.7 | 233.2 ± 93.2 | 223.0 ± 91.9 | 227.4 ± 92.5 |
| GISS-E2-R | 14.1 ± 1.7 | 14.8 ± 1.8 | 15.5 ± 1.8 | 252.6 ± 97.7 | 239.6 ± 93.8 | 242.7 ± 95.6 |
| GISS-E2-R-CC | 14.2 ± 1.8 | 15.0 ± 1.8 | 15.9 ± 1.8 | 228.4 ± 89.1 | 221.2 ± 87.5 | 214.7 ± 84.4 |
| HadGEM2-AO | 14.1 ± 1.8 | 14.9 ± 1.8 | 16.0 ± 1.9 | 230.8 ± 91.3 | 216.0 ± 87.2 | 200.2 ± 79.1 |
| HadGEM2-CC | 14.5 ± 1.7 | 15.3 ± 1.8 | 16.1 ± 1.9 | 219.5 ± 86.9 | 210.8 ± 83.3 | 199.3 ± 80.5 |
| HadGEM2-ES | 14.5 ± 1.7 | 15.4 ± 1.8 | 16.4 ± 1.9 | 231.9 ± 91.3 | 204.6 ± 80.0 | 177.7 ± 71.3 |
| inmcm4 | 13.9 ± 1.8 | 14.5 ± 1.8 | 15.2 ± 1.9 | 246.7 ± 97.3 | 240.0 ± 94.9 | 220.0 ± 86.2 |
| IPSL-CM5A-LR | 14.5 ± 1.8 | 15.4 ± 1.9 | 16.6 ± 1.9 | 208.7 ± 86.4 | 199.9 ± 83.1 | 180.9 ± 74.6 |
| IPSL-CM5A-MR | 14.5 ± 1.8 | 15.4 ± 1.9 | 16.9 ± 1.9 | 198.5 ± 79.2 | 192.1 ± 76.9 | 159.4 ± 66.1 |
| IPSL-CM5B-LR | 14.1 ± 1.8 | 14.8 ± 1.9 | 15.8 ± 1.9 | 224.0 ± 87.7 | 210.2 ± 81.9 | 201.2 ± 79.2 |
| MIROC5 | 14.1 ± 1.8 | 14.7 ± 1.8 | 15.4 ± 1.9 | 234.0 ± 90.5 | 221.4 ± 86.2 | 230.9 ± 90.7 |
| MIROC-ESM | 14.1 ± 1.6 | 14.8 ± 1.6 | 15.8 ± 1.7 | 242.2 ± 96.4 | 251.1 ± 103.2 | 229.3 ± 100.3 |
| MIROC-ESM-CHEM | 14.1 ± 1.6 | 14.8 ± 1.6 | 15.8 ± 1.6 | 249.6 ± 100.3 | 251.3 ± 102.5 | 229.2 ± 97.5 |
| MRI-CGCM3 | 13.9 ± 1.7 | 14.6 ± 1.6 | 15.3 ± 1.7 | 227.5 ± 88.9 | 224.3 ± 93.4 | 220.1 ± 93.1 |
| NorESM1-M | 14.0 ± 1.7 | 14.8 ± 1.7 | 15.5 ± 1.7 | 230.1 ± 91.5 | 221.3 ± 91.3 | 233.9 ± 103.2 |
| Changes in WHtR*1¶ | Changes in weight*2 [kg] | Changes in BMI percentiles*3 | ||||
| (n = 1252) | (n = 1251) | (n = 1250) | ||||
| B (SE) | p-value | B (SE) | p-value | B (SE) | p-value | |
| Skipping breakfast | 0.50 (0.19) | 0.007** | 0.39 (0.12) | <0.001*** | 2.01 (0.90) | 0.027* |
| Soft drinks > 1 time per week | -0.01 (0.15) | 0.966 | -0.08 (0.09) | 0.385 | -0.75 (0.70) | 0.282 |
| Screen media > 1 h/day | 0.29 (0.16) | 0.074 | 0.19 (0.10) | 0.054 | 0.70 (0.78) | 0.373 |
| Urea Concentration (M) | Mn Content (%) | ||||||
| 5 | 10 | 20 | 40 | 60 | 80 | 100 | |
| 0.5 | 4.59 | 1.66 | 3.386 | 0.896 | 3.808 | 3.585 | 2.488 |
| 1.0 | 3.089 | 0.685 | 2.964 | 0.136 | 2.739 | 1.973 | 2.385 |
| 2.0 | 2.732 | 2.439 | 2.135 | 0.085 | 2.256 | 2.244 | 2.403 |
| Clinical Features | MBD5-specific mutation20,22–24 | 2q23.1 Deletion20,22–24 | Case in this study | ||
| Number | Percentage | Number | Percentage | +, present; - absent | |
| Neurological | |||||
| Development delay | 20/21 | 95% | 53/55 | 96% | + |
| Language impairment | 12/21 | 57% | 38/55 | 69% | + |
| Seizure | 11/21 | 52% | 32/55 | 58% | + |
| Infantile spasms | 0/21 | 0 | 0/55 | 0 | + |
| Infantile hypotonia | 4/21 | 19% | 23/55 | 41% | + |
| Growth/Endocrine | |||||
| Short stature | 5/21 | 24% | 25/55 | 45% | - |
| Local hirsutism | 0/21 | 0 | 4/55 | 7% | - |
| Craniofacial abnormalities | |||||
| Coarse face | 0/21 | 0 | 3/55 | 5% | + |
| Broad forehead | 3/21 | 14% | 4/55 | 7% | + |
| Microcephaly | 1/21 | 5% | 26/55 | 47% | +(<2SD) |
| Synophrys | 2/21 | 9% | 10/55 | 18% | +mild |
| Nasal abnormalities | 7/21 | 33% | 35/55 | 64% | + |
| Open mouth | 3/21 | 14% | 23/55 | 42% | + |
| Downturned corners of the mouth | 3/21 | 14% | 17/55 | 31% | + |
| Macroglossia or protruding tongue | 2/21 | 9% | 6/55 | 11% | - |
| Dental abnormalities | 4/21 | 19% | 13/55 | 24% | |
| Skeletal abnormalities | + | ||||
| Small hands and feet | 1/21 | 5% | 23/55 | 42% | + |
| Clinodactyly, 5th finger | 2/21 | 9% | 22/55 | 40% | + |
| Brachydactyly | 0/21 | 0 | 13/55 | 24% | + |
| Short fifth digit of hands/feet | 1/21 | 5% | 14/55 | 25% | + |
| Absent hallux | 0/21 | 0 | 0/55 | 0 | + |
| Behaviors | - | ||||
| Autistic feature | 13/21 | 62% | 44/55 | 80% | + |
| Sleep disturbance | 5/21 | 24% | 17/55 | 31% | ND |
| Self-injurious behavior | 2/21 | 9% | 17/55 | 31% | + |
| Other | - | ||||
| Cardiovascular abnormalities | 1/21 | 5% | 4/55 | 7% | - |
| Urogenital abnormalities | 1/21 | 45% | 1/55 | 2% | - |
| Dementia can be cured through divine healing, such as through prayer | People with dementia should be placed in ‘homes’ | |||||
| B | β | t | B | β | t | |
| Age | 0.013 | 0.013 | 0.333 | 0.134 | 0.141 | 3.495*** |
| Gender | −0.029 | −0.012 | −0.377 | −0.024 | −0.011 | −0.328 |
| Ethnic | 0.069 | 0.051 | 1.546 | 0.022 | 0.018 | 0.520 |
| Religion | −0.057 | −0.286 | −8.938*** | −0.002 | −0.012 | −0.377 |
| Education | 0.034 | 0.063 | 1.610 | −0.029 | −0.058 | −1.427 |
| Multiple R=0.301 | Multiple R=0.186 | |||||
| R2=0.091 | R2=0.034 | |||||
| Adjusted R square=0.086 | Adjusted R square=0.029 | |||||
| F=18.810*** | F=6.730*** |
| Domains of quality of life d | |||||
| Characteristics | Physical Mean (SD) | Psychological Mean (SD) | Social Mean (SD) | Environmental Mean (SD) | Global Mean (SD) |
| Diagnosis | |||||
| Stroke | 41.26 (15.49)*** | 40.47 (15.31)*** | 51.04 (17.37)*** | 46.04 (17.41)*** | 45.2 (23.14)*** |
| Non-stroke | 67.45 (15.69) | 64.76 (17.19) | 71.25 (15.03) | 61.71 (15.26) | 65.46 (18.58) |
| Gender | |||||
| Male | 61.99 (19.38)*** | 61.09 (19.97)*** | 68.15 (17.98)*** | 60.35 (17.86)*** | 62.36 (21.51)*** |
| Female | 55.25 (19.95) | 51.9 (19.28) | 60.59 (18.25) | 52.33 (16.41) | 54.78 (22.60) |
| Education a | |||||
| Low | 54.84 (19.31)*** | 53.24 (18.50)*** | 61.87 (17.66)*** | 52.59 (16.18)*** | 55.45 (21.83)*** |
| High | 68.93 (17.83) | 65.59 (21.56) | 71.42 (18.85) | 66.63 (17.25) | 67.20 (21.49) |
| Income b | |||||
| Low | 54.46 (18.45)*** | 51.15 (19.01)*** | 61.41 (17.61)*** | 51.20 (16.43)*** | 54.78 (22.02)*** |
| High | 62.15 (20.42) | 61.05 (19.98) | 66.98 (18.82) | 60.69 (17.43) | 61.83 (22.14) |
| Psychological stress c | -0.339 *** | -0.247 *** | -0.231 *** | -0.245 *** | -0.284 *** |
| No cancer | Cancer | Total | |
| Mammogram (+) | 20 | 10 | 32 |
| Mammogram (−) | 21 | 1 | 21 |
| Total | 41 | 11 | 52 |
| Measure | Sn = 91 % | Sp = 51 % |
| HtMM | |||||||
| Normalized jerk | |||||||
| Dominant | Nondominant | ||||||
| Young adults | Middle aged | Senior | All | Young adults | Middle aged | Senior | All |
| R = 0.75p < 10–6 | R = 0.84p < 10–5 | R = 0.79p < 10–5 | R = 0.80p < 10–17 | R = 0.75p < 10–6 | R = 0.65p = 0.002 | R = 0.67p < 10–3 | R = 0.71p < 10–12 |
| Acceleration coefficient of periodicity | |||||||
| Dominant | Nondominant | ||||||
| Young adults | Middle aged | Senior | All | Young adults | Middle aged | Senior | All |
| R = −0.43p = 0.010 | R = −0.63p = 0.004 | R = −0.66p < 10–3 | R = −0.61p < 10–8 | R = −0.61p < 10–3 | R = −0.36p = 0.135 | R = −0.47p = 0.022 | R = −0.51p < 10–5 |
| Group | Ace genotype | Presence | Absence | Total | X2 | p | X2 | p | OR (CI 5-95%) |
| Without taking CFTR mutation into account | I/I | 8 | 64 | 72 | 8.654 | 0.013 | 0.468 | 0.498 | 0.699 (0.319 – 1.534) |
| I/D | 9 | 74 | 82 | 0.814 | 0.182 | 0.651 (0.304 – 1.394) | |||
| D/D | 8 | 16 | 24 | 8,653 | 0.003 | 4.509 (1.513 – 10.89) | |||
| No identified CFTR mutation | I/I | 3 | 18 | 21 | 0.530 | 0.767 | 0.003 | 1.29 | 1.056 (0.188 - 5.925) |
| I/D | 2 | 16 | 18 | 0.204 | 1.00 | 0.656 (0.107 - 4.041) | |||
| D/D | 1 | 3 | 4 | 0.438 | 0.93 | 2.267 (0.196 - 26.27) | |||
| One CFTR mutation identified class I, II or III | I/I | 2 | 20 | 22 | 5.539 | 0.063 | 1.248 | 0.466 | 0.383 (0.069 - 2.117) |
| I/D | 2 | 18 | 20 | 0.787 | 0.629 | 0.463 (0.084 - 2.562) | |||
| D/D | 4 | 5 | 9 | 6.834 | 0.027 | 7.6 (1.43 - 40.38) | |||
| Two CFTR mutation identified class I, II or III | I/I | 3 | 26 | 29 | 0.511 | 0.774 | 0.084 | 1.07 | 0.8077 (0.193 - 3.387) |
| I/D | 5 | 40 | 45 | 0.039 | 1.10 | 0.875 (0.234 - 3.275) | |||
| D/D | 2 | 9 | 11 | 0.495 | 0.764 | 1.833 (0.335 - 10.02) |
| Diabetes | Gender | n | Box-counting FD (GrayScale) | ||
| Mean FD | 95% CI | p† | |||
| No | Female | 71 | 2.4203 | 2.4164 - 2.4242 | 0.052 |
| Male | 95 | 2.4251 | 2.4217 - 2.4284 | ||
| Yes | Female | 12 | 2.4308 | 2.4214 - 2.4402 | |
| Male | 11 | 2.4499 | 2.4401 - 2.4598 |
| CHD group (n = 45) | Healthy group (n = 15) | P value | |
| Age | 59.24 ± 7.87 | 57.53 ± 4.47 | 0.304 |
| Gender (male/female) | 33/12 | 7/8 | 0.058 |
| Predictor | Digit span backward | Letter-number sequencing | ||||||
| Df | F-value | p-value | η2p | Df | F-value | p-value | η2p | |
| Group | 1 | 0.56 | 0.46 | 0.11 | 1 | 0.64 | 0.43 | 0.10 |
| Score | 1 | 3.45 | 0.07 | 0.15 | 1 | 7.55 | 0.01 | 0.04 |
| Group X Score | 1 | 0.10 | 0.75 | 0.00 | 1 | 0.82 | 0.37 | 0.00 |
| Residuals | 33 | 33 |
| No FamPlex | With FamPlex | |||||
| Rank | Entity Text | Count | % of Total | Entity Text | Count | % of Total |
| 1 | NF-kappaB | 18,381 | 3.78 | PKCzeta | 222 | 0.24 |
| 2 | ERK1/2 | 6137 | 1.26 | RANTES | 176 | 0.19 |
| 3 | mTORC1 | 2753 | 0.57 | DC | 169 | 0.18 |
| 4 | NFkappaB | 2425 | 0.50 | LDL | 168 | 0.18 |
| 5 | c-Jun | 2369 | 0.49 | IgE | 152 | 0.17 |
| 6 | antigen | 1724 | 0.35 | SDF-1-alpha | 141 | 0.15 |
| 7 | PDGF | 1626 | 0.33 | receptor | 128 | 0.14 |
| 8 | IKK | 1542 | 0.32 | beta1 integrin | 127 | 0.14 |
| 9 | c-Src | 1362 | 0.28 | p38alpha | 126 | 0.14 |
| 10 | histone H3 | 1347 | 0.28 | CD4+ | 124 | 0.14 |
| 2008 | 2009 | 2010 | 2011 | |||||||||
| Province | Cattle | Goats | Sheep | Cattle | Goats | Sheep | Cattle | Goats | Sheep | Cattle | Goats | Sheep |
| Limpopo | 2.33 | 0.02 | ||||||||||
| Gauteng | 12.60 | 91.97 | 0.38 | 8.56 | ||||||||
| Mpumalanga | 23.89 | 1.98 | 3.38 | 11.77 | ||||||||
| Kwazulu-Natal | 7.22 | |||||||||||
| Northwest | 4.54 | 1.45 | 0.68 | 24.11 | ||||||||
| Free State | 17.22 | 29.38 | 187.97 | |||||||||
| Eastern Cape | 1.16 | 0.99 | 6.50 | 1.58 | 3.81 | 26.67 | ||||||
| Northern Cape | 5.07 | 8.22 | 344.18 | 0.06 | 120.99 | |||||||
| Western Cape | 38.69 | 15.49 | 12.54 | 2.16 | 108.18 | 25.45 |
| Gene | Disease | Mode of inheritance | Stroke mechanism |
| GAL | Fabry's disease | X-linked | Large-artery disease and small-vessel disease |
| NOTCH3 | CADASIL | AD | Small-vassel disease |
| HBB | Sickle-cell disease | AR | Large-artery disease, small-vessel disease, haemodynamic insufficiency |
| CBS and others | Homocystinuria | AR | Large-artery disease, cardioembolism, small-vessel disease, arterial dissection |
| mtDNA | MELAS | Maternal | Complex (microvascular and neuronal factors) |
| FBN1 | Marfan syndrome | AD | Cardioembolism and arterial dissection |
| COL3A1 | Ehlers-Danlos syndrome type IV | AD | Arterial dissection |
| ABCC6 | Pseudoxanthoma elasticum | AR | Large-artery disease and small-vessel disease |
| Fungi | Minimum fungicidal concentrations of ethanol extract of Cleome gynandra in mg/ml | Controls | ||||||||
| 0.5 | 0.25 | 0.125 | 0.0625 | 0.0313 | 0.0156 | 0.00781 | 0.00391 | −ve ctrl | + ctrl | |
| Mc | Nfgo | Fgo | Fgo | Fgo | Fgo | Fgo | Fgo | Fgo | Fgo | Nfgo |
| Tm | Nfgo | Fgo | Fgo | Fgo | Fgo | Fgo | Fgo | Fgo | Fgo | Nfgo |
| Tr | Nfgo | Nfgo | Nfgo | Fgo | Fgo | Fgo | Fgo | Fgo | Fgo | Nfgo |
| Testing completed | N (%) |
| Actionable | 92 (65%) |
| Not actionable or informative | 35 (25%) |
| Informative | 11 (8%) |
| No reportable results | 2 (1%) |
| Test failed | 1 (< 1%) |
| Escala de risco de sangramento RIETE modificada | |
| Variável | Pontos |
| Hemorragia maior recente (< 1 mês) | 2 |
| Creatinina > 1,2 mg/dL | 1,5 |
| Anemia | 1,5 |
| Câncer | 1 |
| Idade > 75 anos | 5 |
| Risco baixo: 0; Risco intermediário: 1-4; Risco alto: > 4 |
| Percentage reporting ‘never’ undertaking measure for reducing risk of violence | ||||
| M | F | N | Significance χ2 | |
| Check patient notes in advance | 52 | 37 | 620 | p<.001 |
| Leave door ajar when seeing certain patients | 80 | 67 | 604 | p<.001 |
| Accompanied when seeing certain patients | 70 | 64 | 610 | p<.05 |
| Accompanied on visits to certain patients | 77 | 65 | 610 | p<.005 |
| Leaving visit schedule with someone | 48 | 25 | 618 | p<.001 |
| Carry personal alarm | 95 | 77 | 583 | p<.001 |
| Attended self‐defence course | 94 | 85 | 590 | p<.005 |
| Pt | Chromosome | Probes/libraries | Band localization | Genomic Localization (bp) (hg19) |
| 1 | 8 | AML1/ETOaWCP 1b | designed for t(8;21)Whole chromosome paint library | – |
| 2 | 2 | WCP 2bCTD-2314L14cCTD-2599D22cALKdCTD-3028D11 cCTD-2232H14cCTD-2566H13cCTD-2532N8cCTD-2371H10cCTD-2382F21cCTD-2052G24cCTD-3058K15c | Whole chromosome paint library2p23.32p23.22p23.2–23.12p23.12p22.22p22.2–22.12p21.32p21.12p16.32p152p15–14 | 27,436,476–27,577,216 bp29,678,603–29,819,833 bp-31,532,615–31,667,611 bp36,717,490–36,828,693 bp38,563,970–38,725,504 bp42,157,290–42,301,116 bp46,582,036–46,715,607 bp48,326,711–48,434,143 bp61,463,234–61,600,608 bp64,034,477–64,232,972 bp |
| 8 | WCP 8bAML1/ETOaCTD-2341G19cCTD-2246G22cCTD-3245G9cCTD-2330N9c | Whole chromosome paint library designed for t(8;21)8q21.138q21.38q21.38q21.3 | -83,886,651–83,982,215 bp87,885,140–87,980,460 bp91,740,722–91,959,017 bp92,778,106–92,922,619 bp |
| FIRST GENE (REFSEQ ACCESSION NUMBER) | FIRST GENE (AHR BINDING SITES) | FIRST GENE (BINDING SITES OF OTHER TFS) | SECOND GENE (REFSEQ ACCESSION NUMBER) | SECOND GENE (AHR BINDING SITES) | SECOND GENE (BINDING SITES OF OTHER TFS) |
| NM_003928 | - | - | NM_015582 | n.d.* | n.d.* |
| NM_005334 | - | NFKB | NM_003492 | 1 | ATF3, SP2 |
| NM_001643 | - | PPARG2 | NM_032174 | 1 | - |
| NM_021642 | 1 | - | NM_002155 | - | NFKB |
| NM_005807 | - | - | NM_003292 | - | SP2 |
| NM_006623 | - | - | NM_005518 | - | PPARG2 |
| NM_002061 | 1 | SP2 | NM_000350 | - | - |
| NM_144631 | 2 | RFXANK | NM_002707 | 1 | PPARG2 |
| NM_005911 | - | SP2, PPARG2 | NM_000821 | 1 | PPARG2 |
| NM_016467 | - | PPARG2 | NM_000534 | - | NFKB |
| NM_022173 | 1 | - | NM_016297 | 1 | RFXANK, SP2 |
| NM_006590 | 1 | - | NM_000542 | - | NRF1, PPARG2 |
| NM_005141 | - | - | NM_000508 | - | - |
| NM_000508 | - | - | NM_000509 | - | - |
| NM_007104 | - | - | NM_003214 | 1 | SP2 |
| NM_138446 | 1 | - | NM_006547 | - | BHLHB2 |
| NM_003235 | - | - | NM_006748 | - | - |
| NM_001261 | - | NFKB | NM_004957 | - | PBX1, SP2 |
| NM_005564 | - | NFKB | NM_024112 | - | SP2 |
| NM_005489 | - | SP2 | NM_001261 | - | - |
| NM_004376 | - | NFKB | NM_015960 | - | PPARG2 |
| NM_005271 | 5 | BHLHB2 | NM_019054 | 3 | - |
| NM_001572 | - | SP2, NFKB | NM_021924 | 1 | SP2 |
| NM_052854 | - | SP2 | NM_003646 | - | SP2, PPARG2 |
| NM_006169 | - | RFXANK | NM_019021 | 1 | PPARG2 |
| NM_021640 | - | - | NM_015665 | - | NFKB |
| NM_003348 | 1 | - | NM_014050 | - | - |
| NM_002937 | - | PPARG2 | NM_001145 | - | - |
| NM_006599 | - | NFKB, BHLHB2 | NM_000903 | 1 | NRF1 |
| NM_003562 | 1 | RFXANK | NM_015528 | 1 | NFKB, RFXANK |
| NM_002544 | 1 | - | NM_006495 | - | - |
| NM_018952 | - | NFKB, RFXANK | NM_004502 | 2 | RFXANK, BHLHB2 |
| NM_007292 | 2 | NFKB, BHLHB2 | NM_001258 | - | PPARG2 |
| NM_005359 | - | - | NM_016626 | 1 | SP2 |
| NM_032377 | - | RFXANK | NM_001611 | 2 | BHLHB2, PPARG2 |
| NM_018270 | 2 | - | NM_007346 | - | RFXANK, BHLHB2 |
| NM_002626 | 2 | SP2 | NM_004928 | 1 | SP2 |
| Plant Part | Subject of Study | Effect | Reference |
| ethyl acetate extract of the leaves | lung A549 cancer cells | mitochondrial-mediated apoptosis, cell cycle arrest at G1 phase | [83] |
| ethyl acetate extract of the leaves | colon HT-29 and HCT-116 cancer cells | mitochondrial-mediated apoptosis, cell cycle arrest at G1 phase, suppression of migration and invasion | [84] |
| water extract of the leaves | rat’s prostate | reduction of prostate size | [86] |
| ethanolic extract of the leaves | breast tissues of mice | prevention of DMBA-induced DNA damage | [87] |
| ethanolic extract of the leaves | DMBA/croton oil induced mice skin papillomagenesis | suppression of tumor initiation and promotion | [88] |
| ethanolic extract of the leaves | DMH induced colon cancer | reduction of ACF formation | [89] |
| ethanolic extract of the leaves | K562 chronic myeloid leukemia cells | induction of apoptosis | [85] |
| leaves boiled in water | metastatic breast cancer | stabilization of disease | [90] |
| ethyl acetate of the leaves | azoxymethane induced colon cancer | reduction of ACF formation | [91] |
| ethyl acetate of the leaves | colon HT-29 cancer cells | bioassay-guided isolation of annomuricin E and its apoptosis inducing effect | [91] |
| Number | Gender | Age | Treatment | Diagnosis of infection | Bacterial etiology | Days of infection detected after TACE and/or RFA | PCT on day of fever | Peak PCT within 7 days | Outcome of infection |
| 1 | M | 57 | TACE | Cholecystitis | Bile, E. hirae | 4 | 2.58 | 2.58 | Cured |
| 2 | M | 83 | TACE | Pneumonia | — | 5 | 0.72 | 0.72 | Cured |
| 3 | M | 55 | TACE | UTI | — | 4 | 0.23 | 2.40 | Cured |
| 4 | M | 75 | TACE | Bacteremia, primary | Blood, E. coli | 2 | 1.55 | 1.70 | Cured |
| 5 | M | 79 | TACE | UTI | — | 3 | 1.19 | 1.19 | Cured |
| 6 | M | 73 | TACE | Pneumonia | Sputum, E. coli | 7 | 0.21 | 0.24 | Cured |
| 7 | F | 77 | Sequential TACE/RFA | Liver abscess | Blood, E. casseliflavus | 7 | 0.16 | 0.59 | Transferred to another hospital |
| 8 | M | 71 | TACE | Bacteremia, cholangitis | Blood, E. gallinarum | 1 | 0.15 | 0.55 | Cured |
| 9 | F | 65 | RFA | Bacteremia, RFA site cutaneous abscess | Blood, S. aureus | 1 | 0.08 | 0.17 | Cured |
| Type of Gholonj | Traditional term | Type of obstruction | Pathology |
| Inflammatory Gholonj | Gholonj-e-varami | Non mechanical | Inflammation in the intestinal wall or surrounding organs |
| Secretory Gholonj | Gholonj-e-balghami | Non mechanical | Accumulation of mucoid Phlegm in lumen of intestine |
| Flatulency Gholonj | Gholonj-e-reehi | Non mechanical | High gas accumulation in the lumen of intestine |
| Fecal Gholonj | Gholonj-e-sofli | Mechanical | Accumulation of fecal masses |
| Parasitic Gholonj | Gholonj-e-doodi | Mechanical | Aggregation of worms in the lumen of intestine |
| Torsion Gholonj | Gholonj-e-eltevaee | Mechanical | Intestinal torsion or bowel herniation |
| TGF-β1 Release | BDNF Release | |||||||
| LPS | E. coli | V. vulnificus | E. coli | V. vulnificus | ||||
| (ng/mL) | (pg/mL) | n1 | (pg/mL) | n1 | (pg/mL) | n1 | (pg/mL) | n1 |
| 0 | 319.7 ± 50.1 | 3 | 319.7 ± 50.1 | 3 | 0 | 2 | 0 | 2 |
| 0.1 | 424.3 ± 40.3 | 3 | 386 ± 16.0 | 2 | 5.1 ± 4.4 | 2 | 1.4 ± 0.8 | 2 |
| 1 | 363.3 ± 36 | 3 | 419 ± 66.9 | 3 | 18.4 ± 14.9 | 2 | 10.2 ± 6.2 | 2 |
| 10 | 318.7 ± 73.2 | 3 | 358 ± 50.1 | 3 | 6.9 ± 3.9 | 2 | 6.5 ± 5.5 | 2 |
| 100 | 333.3 ± 58.6 | 3 | 310 ± 51.6 | 3 | 6.6 ± 3.0 | 2 | 9.1 ± 4.7 | 2 |
| 1000 | ND | 352 ± 55.5 | 3 | ND | 7.5 ± 7.5 | 2 | ||
| 10,000 | ND | 613 ± 58.7 | 3 | ND | 0 ± 0 | 2 | ||
| 100,000 | ND | 973.5 ± 264.5 * | 2 | ND | 2.05 ± 2.05 | 2 |
| Characteristics | Orifice involved (n=138) | Non-Orifice involved (n=1221) | Total (n=1359) | P | |
| Age (Mean ± SD) | 65.1±10.5 | 63.4±11.7 | 63.5±11.6 | 0.087 | |
| Follow-up, months (mean ± IQR)* | 45.5 (9–68) | 47.1 (9–70) | 46.9 (9–69) | 0.721 | |
| No. Gender (%) | |||||
| M | 119 (86.2) | 1095 (89.7) | 1214 (89.3) | 0.214 | |
| F | 19 (13.8) | 126 (10.3) | 145 (10.7) | ||
| No.TCC tumor grade (%) | |||||
| G1 | 47 (34.1) | 493 (40.4) | 540 (39.7) | ||
| G2 | 36 (26.1) | 286 (23.4) | 322 (23.7) | 0.067 | |
| G3 | 40 (29.0) | 248 (20.3) | 288 (21.2) | ||
| Unspecified | 15 (10.8) | 194 (15.9) | 209 (15.4) | ||
| No.TCC Tumor stage (%) | |||||
| Ta | 47 (34.1) | 349 (28.6) | 396 (29.1) | ||
| T1 | 59 (42.8) | 520 (42.6) | 579 (42.6) | 0.565 | |
| ≥T2 | 32 (23.2) | 302 (24.7) | 334 (24.6) | ||
| Unspecified | – | 50 (4.1) | 50 (3.7) | ||
| Carsinoma in situ (CIS)(%) | |||||
| CIS at initial diagnosis | 6 (4.3) | 42 (3.4) | 48 (3.5) | 0.584 | |
| CIS progression | 3 (2.2) | 22 (1.8) | 25 (1.8) | 0.758 | |
| Total CIS | 9 (6.5) | 64 (5.2) | 73 (5.3) | ||
| No. Tumor size (%) | |||||
| Tumor < 3 cm | 35 (25.4) | 348 (28.5) | 383 (28.2) | ||
| Tumor ≥ 3 cm | 94 (68.1) | 755 (61.8) | 849 (62.5) | 0.305 | |
| Unspecified | 9 (6.5) | 118 (9.7) | 127 (9.3) | ||
| No. Tumor number (%) | |||||
| Solitary | 99 (71.7) | 728 (59.6) | 827 (60.9) | ||
| Multiple | 36 (26.1) | 479 (39.2) | 515 (37.9) | 0.003 | |
| Unspecified | 3 (2.2) | 14 (1.1) | 17 (1.2) | ||
| Hydronephrosis (initial diagnosis)(%) | |||||
| Hydronephrosis±Atrophic kidney | 46 (33.3) | 170 (13.9) | 216 (15.9) | 0.0001 | |
| Presence of UTUC (%) | |||||
| Synchronous | 14 (10.1) | 8 (0.7) | 22 (1.6) | 0.0001 | |
| Metachronous* | 7 (5.3) | 11 (0.9) | 18 (1.4) |
| E/MPa | μ | α | K/MPa | |
| Theory values | 2157 | 0.2 | 0.165872 | 0.875726 |
| Identified values by GA | 2135 | 0.182 | 0.171365 | 0.853471 |
| Relative error of computing results for GA (%) | 1.02 | 9 | 3.31 | 2.54 |
| Identified values by FGA | 2140 | 0.182 | 0.168442 | 0.853532 |
| Relative error of computing results for FGA (%) | 0.79 | 9 | 1.55 | 2.54 |
| Identified values by IGA | 2143 | 0.188 | 0.167812 | 0.854621 |
| Relative error of computing results for IGA (%) | 0.65 | 6 | 1.17 | 2.41 |
| TOOL | COHORT CHARACTERISTICS | |||||
| Disease | Number | Age (years) | Time since diagnosis/transplant | Race & gender | Country of validation | |
| TRAQ [4] | Chronic diseases | 192 | 16-26 (mean: 19.7) | NR | 64% white, 56% female | USA |
| UNCTRxANSITION [17] | Chronic diseases | NR | 12-22 | NR | NR | USA |
| Self-management skills assessment guide [16] | Chronic diseases | 49 | 11-19 (mean: 15.6) | NR | 86% Caucasian | Canada |
| SCIS [8] | CF (with pancreatic insufficiency) | 76 patients, 70 parents | 4-17 (mean: 11.2) | NR | 94% white | USA |
| Readiness questionnaire [9] | CF | 36 | NR | NR | NR | Canada |
| RTQ [10] | Renal transplant | 48 patients, 32 parents | 15-21 (mean: 18.6) | 5.73 y | 58% white, 29% black, 10% Hispanic | USA |
| TRS [2] | Liver transplant | 71 patients, 58 parents | 11-20 (mean: 15.6) | 1-19 y (mean: 9.4 y) | 56% female | USA |
| RCBRS [13] | T1DM | 69 | 12-17 (mean: 14.2) | >6 months (mean: 5.49) | 87% Caucasian | USA |
| McPherson et al. [14] | Sickle cell disease | 69 | 14-21 | NR | 43% female | USA |
| TRQ [15] | HIV | 65 | 9-25 (mean: 15.8) | 1-17 years (mean: 10.5) | 44% female, 45% Caucasian | USA |
| Phase II study | |||||||||
| Patient | Treatment group | Visit | |||||||
| BL | C2D1 | C3D1 | C4D1 | D85 | D180 | D360 | ET | ||
| 1 | Lipegfilgrastim | Neg | Neg | Neg | Neg | Pos | NA | NA | NA |
| 2 | Lipegfilgrastim | NA | NA | NA | NA | NA | NA | Pos | NA |
| 3 | Lipegfilgrastim | Pos | Pos | Pos | Pos | Pos | Pos | Pos | NA |
| 4 | Lipegfilgrastim | Pos | Pos | Pos | Pos | Pos | Pos | Neg | NA |
| 5 | Lipegfilgrastim | Pos | Pos | NA | NA | NA | Pos | Pos | Neg |
| 6 | Lipegfilgrastim | Pos | NA | NA | NA | NA | NA | NA | NA |
| 7 | Lipegfilgrastim | Pos | NA | NA | NA | NA | NA | NA | NA |
| 8 | Lipegfilgrastim | Pos | NA | NA | NA | NA | NA | Neg | NA |
| 9 | Lipegfilgrastim | Pos | NA | NA | NA | NA | NA | NA | NA |
| 10 | Pegfilgrastim | NA | NA | NA | NA | Pos | NA | NA | NA |
| 11 | Pegfilgrastim | Pos | NA | NA | NA | NA | NA | NA | NA |
| 12 | Pegfilgrastim | Pos | NA | NA | NA | NA | NA | NA | NA |
| Phase III study | |||||||||
| Patient | Treatment group | Visit | |||||||
| S | BL | C2D1 | C3D1 | C4D1 | D85 | D180 | D360 | ||
| 13 | Lipegfilgrastim | NA | NA | NA | NA | NA | NA | Pos | Pos |
| 14 | Lipegfilgrastim | NA | Pos | Pos | Pos | Pos | Neg | Neg | Neg |
| 15 | Lipegfilgrastim | NA | Pos | Pos | Neg | Neg | Neg | Neg | Neg |
| 16 | Lipegfilgrastim | NA | Pos | NA | NA | NA | NA | NA | NA |
| 17 | Pegfilgrastim | NA | NA | NA | NA | NA | NA | NA | Pos |
| 18 | Pegfilgrastim | NA | Pos | NA | NA | NA | NA | NA | NA |
| 19 | Pegfilgrastim | Pos | NA | NA | NA | NA | NA | NA | NA |
| 20 | Pegfilgrastim | NA | Pos | NA | NA | NA | NA | NA | NA |
| 21 | Pegfilgrastim | NA | Pos | NA | NA | NA | NA | NA | NA |
| 22 | Pegfilgrastim | NA | Pos | Neg | NA | NA | NA | NA | NA |
| 23 | Pegfilgrastim | NA | Pos | NA | NA | NA | NA | NA | NA |
| Birth Weight for Gestational Age | Dietary Pattern | |||||
| Cereals, Eggs, and Cantonese Soups | Dairy | Fruits, Nuts, and Cantonese Desserts | Meats | Vegetables | Varied | |
| (n = 1026) | (n = 1020) | (n = 799) | (n = 1066) | (n = 1383) | (n = 1160) | |
| SGA (n, %) | 89 (8.7) | 80 (7.8) | 54 (6.8) | 86 (8.1) | 94 (6.8) | 102 (6.1) |
| Crude OR (95% CI) | 1.00 (Reference) | 0.90 (0.65-1.23) | 0.76 (0.54-1.08) | 0.92 (0.68-1.26) | 0.77 (0.57-1.04) | 0.69 (0.51-0.93) * |
| Adjusted OR (95% CI) 1 | 1.00 (Reference) | 0.89 (0.65-1.22) | 0.80 (0.56-1.14) | 0.94 (0.69-1.28) | 0.78 (0.58-1.06) | 0.75 (0.56-1.01) |
| Adjusted OR (95% CI) 2 | 1.00 (Reference) | 0.90 (0.66-1.23) | 0.77 (0.54-1.09) | 0.92 (0.68-1.26) | 0.77 (0.57-1.04) | 0.69 (0.51-0.93) * |
| Adjusted OR (95% CI) 3 | 1.00 (Reference) | 0.89 (0.65-1.23) | 0.72 (0.50-1.03) | 0.94 (0.69-1.29) | 0.76 (0.56-1.04) | 0.70 (0.52-0.95) * |
| Adjusted OR (95% CI) 4 | 1.00 (Reference) | 0.87 (0.63-1.21) | 0.76 (0.53-1.10) | 0.95 (0.69-1.30) | 0.77 (0.56-1.05) | 0.77 (0.57-1.04) |
| LGA (n, %) | 103 (10.0) | 106 (10.4) | 96 (12.0) | 87 (8.2) | 147 (10.6) | 194 (11.7) |
| Crude OR (95% CI) | 1.00 (Reference) | 1.04 (0.78-1.38) | 1.22 (0.91-1.64) | 0.80 (0.59-1.07) | 1.07 (0.82-1.39) | 1.19 (0.92-1.53) |
| Adjusted OR (95% CI) 1 | 1.00 (Reference) | 1.03 (0.78-1.38) | 1.17 (0.87-1.57) | 0.78 (0.58-1.06) | 1.04 (0.80-1.36) | 1.11 (0.86-1.43) |
| Adjusted OR (95% CI) 2 | 1.00 (Reference) | 1.03 (0.77-1.37) | 1.21 (0.90-1.62) | 0.79 (0.59-1.07) | 1.08 (0.82-1.41) | 1.19 (0.93-1.54) |
| Adjusted OR (95% CI) 3 | 1.00 (Reference) | 1.04 (0.77-1.36) | 1.22 (0.90-1.64) | 0.77 (0.57-1.04) | 1.06 (0.81-1.38) | 1.17 (0.91-1.51) |
| Adjusted OR (95% CI) 4 | 1.00 (Reference) | 1.01 (0.75-1.35) | 1.14 (0.84-1.54) | 0.75 (0.56-1.02) | 1.03 (0.79-1.36) | 1.10 (0.85-1.42) |
| mRNA co-expression MET vs. | ALL Stage | Stage I-II | Stage III-IV | |||
| Pearson's Correlation | p-value | Pearson's Correlation | p-value | Pearson's Correlation | p-value | |
| ALDH1A1 | 0.06 | 0.008 | 0.05 | 0.058 | -0.03 | 0.736 |
| ALDH1A3 | 0.22 | <0.001 | 0.21 | <0.001 | 0.40 | <0.001 |
| CD44 | 0.02 | 0.381 | 0.01 | 0.857 | 0.04 | 0.637 |
| CD133 | 0.30 | <0.001 | 0.31 | <0.001 | 0.40 | <0.001 |
| KLF4 | 0.10 | <0.001 | 0.11 | <0.001 | 0.12 | 0.181 |
| MYC | 0.14 | <0.001 | 0.15 | <0.001 | 0.17 | 0.055 |
| NANOG | -0.04 | 0.064 | -0.02 | 0.560 | 0.01 | 0.895 |
| NOTCH1 | 0.17 | <0.001 | 0.16 | <0.001 | 0.43 | <0.001 |
| NOTCH3 | 0.06 | 0.010 | 0.02 | 0.449 | 0.22 | 0.017 |
| OCT4 | 0.02 | 0.325 | 0.00 | 0.888 | 0.35 | <0.001 |
| SOX2 | 0.00 | 0.882 | 0.01 | 0.730 | -0.05 | 0.609 |
| STAT3 | -0.03 | 0.156 | -0.05 | 0.078 | -0.05 | 0.558 |
| BMI1 | -0.16 | <0.001 | -0.17 | <0.001 | -0.20 | 0.023 |
| Main objectives of participating in the training | n | % |
| To learn about psychosomatic medicine/biopsychosocial models | 28 | 25% |
| To learn didactical teaching methods (such as interactive learning and presenting lectures) | 23 | 20% |
| To acquire practical skills for daily clinical practice (such as communication, role playing, patient interviewing, family interviewing, and creating genograms) | 18 | 16% |
| To learn about doctor-patient communication skills | 12 | 11% |
| To improve patient management | 9 | 8% |
| To learn about the diagnosis and treatment of specific psychosomatic disorders | 8 | 6% |
| To address administrative and sustainability issues in the curriculum | 5 | 4% |
| To learn how to use Balint group methods | 5 | 4% |
| To share experiences with other doctors/acquire more self-experience | 4 | 3% |
| Other | 2 | 2% |
| Intervention, n = 114 | Comparison, n = 60 | |||
| IPV status | n | % | n | % |
| 0 | 9 | 8 | 6 | 10 |
| 3–6 | 11 | 10 | 2 | 3 |
| ≥ 7 | 93 | 82 | 48 | 80 |
| Missing | 1 | 1 | 4 | 7 |
| When partner last inflicted abuse | ||||
| Abused in last 12 months(n = 121) | ||||
| 0 | 1 | 1 | 0 | 0 |
| 3–6 | 3 | 4 | 1 | 2 |
| ≥ 7 | 76 | 95 | 39 | 95 |
| Missing | 0 | 0 | 1 | 2 |
| Abused>12 months ago (n = 33) | ||||
| 0 | 4 | 20 | 3 | 23 |
| 3–6 | 3 | 15 | 0 | 0 |
| ≥ 7 | 13 | 65 | 8 | 62 |
| Missing | 0 | 0 | 2 | 15 |
| A partner has never abused me(n = 15) | ||||
| 0 | 4 | 36 | 2 | 50 |
| 3–6 | 2 | 18 | 1 | 25 |
| ≥ 7 | 4 | 36 | 0 | 0 |
| Missing | 1 | 9 | 1 | 25 |
| Depressed (EPDS ≥ 13) | ||||
| No | 32 | 28 | 26 | 43 |
| Yes | 81 | 71 | 33 | 55 |
| Missing | 1 | 1 |
| Item | Patient Ratings | Clinician Ratings | ||||
| Localized | Metastatic | Total | Nurse | Physician | Total | |
| PAIN | ||||||
| I have pain | 2.4 | 1.8 | 2.1 | 3.8 | 4.0 | 3.9 |
| Pain interfered with my daily activities | 2.0 | 1.8 | 1.9 | 3.8 | 3.2 | 3.5 |
| I have pain in my back | 2.0 | 1.1 | 1.5 | 2.4 | 2.6 | 2.5 |
| I have discomfort or pain in my stomach area | 1.7 | 1.8 | 1.8 | 2.6 | 1.8 | 2.2 |
| BREATHING | ||||||
| I have been short of breath | 0.7 | 2.5 | 1.7 | 3.8 | 3.0 | 3.3 |
| WEAKNESS | ||||||
| I have felt weak | 2.2 | 2.8 | 2.5 | 4.0 | 3.6 | 3.8 |
| MOOD | ||||||
| I worry that my condition will get worse | 3.0 | 3.1 | 3.1 | 3.6 | 2.4 | 3.0 |
| I have emotional ups and downs | 2.6 | 2.2 | 2.4 | 3.6 | 1.6 | 2.6 |
| I feel depressed | 2.6 | 2.0 | 2.3 | 3.6 | 1.8 | 2.7 |
| I am able to enjoy life2 | 2.2 | 2.8 | 2.5 | 3.8 | 3.0 | 3.4 |
| SLEEP | ||||||
| I have had trouble sleeping | 2.5 | 2.1 | 2.3 | 3.6 | 2.4 | 3.0 |
| WEIGHT LOSS | ||||||
| I am losing weight | 1.4 | 2.0 | 1.7 | 3.5 | 3.6 | 3.6 |
| COGNITIVE | ||||||
| I have difficulty remembering things | 1.6 | 1.6 | 1.6 | 3.5 | 2.0 | 2.7 |
| I have trouble concentrating | 1.7 | 2.1 | 1.9 | 3.5 | 2.0 | 2.7 |
| FATIGUE | ||||||
| I feel fatigued | 2.3 | 2.0 | 2.2 | 3.8 | 3.8 | 3.8 |
| I have a lack of energy | 2.4 | 2.5 | 2.5 | 3.8 | 3.2 | 3.4 |
| I feel tired | 2.3 | 2.1 | 2.2 | 3.8 | 3.0 | 3.3 |
| I have trouble starting things because I am tired | 1.7 | 2.1 | 1.9 | 3.0 | 2.0 | 2.5 |
| I have trouble finishing things because I am tired | 1.9 | 2.4 | 2.2 | 3.0 | 2.0 | 2.5 |
| APPETITE | ||||||
| I have lacked appetite | 1.5 | 1.9 | 1.7 | 3.6 | 3.6 | 3.6 |
| I have a good appetite3 | 2.5 | 3.1 | 2.8 | 3.0 | 3.4 | 3.2 |
| INCONTINENCE (BOWEL OR BLADDER) | ||||||
| I have control of my bowels4 | 2.4 | 2.5 | 2.5 | 2.2 | 1.6 | 1.9 |
| I have trouble moving my bowels | 1.6 | 1.3 | 1.5 | 3.6 | 2.2 | 2.9 |
| I urinate more frequently than usual5 | 1.7 | 1.7 | 1.7 | 2.2 | 1.6 | 1.9 |
| I have difficulty urinating | 1.6 | 1.2 | 1.4 | 2.4 | 1.6 | 2.0 |
| OTHER SYMPTOMS | ||||||
| I have had chills | 1.4 | 1.8 | 1.6 | 3.4 | 2.6 | 3.0 |
| I have had fevers | 1.3 | 1.5 | 1.4 | 3.8 | 3.0 | 3.4 |
| I have had sweats6 | 1.2 | 1.1 | 1.1 | 3.8 | 3.2 | 3.5 |
| I feel lightheaded | 1.6 | 1.7 | 1.6 | 2.8 | 2.6 | 2.7 |
| I am bothered by blood in my urine7 | n/a | n/a | n/a | 2.0 | 2.8 | 2.4 |
| Target genes | Primers |
| MMP1 | Forward primer: 5′-aagccatcacttaccttgcact-3′ |
| Reverse primer: 5′-tcagagaccttggtgaatgtca-3′ | |
| MMP9 | Forward primer: 5′-ctggagacctgagaaccaa-3′ |
| Reverse primer: 5′-actgctcaaagcctccacaaga-3′ | |
| β-Actin | Forward primer: 5′-ctccatcctggcctcgctgt-3′ |
| Reverse primer: 5′-gctgtcaccttcaccgttcc-3′ |
| Metal | SQGs (mg/kg)-Freshwater Sediment (Upstream) | Percentage of Samples Exceeding SQGs (%) | |||
| TEL | PEL | <TEL | TEL-PEL | >PEL | |
| Cu | 35.7 | 197 | 80.0 | 16.0 | 4.00 |
| Zn | 123 | 315 | 80.0 | 8.00 | 12.0 |
| Cr | 37.3 | 90.0 | 32.0 | 44.0 | 24.0 |
| Ni | 18.0 | 35.9 | 16.0 | 68.0 | 16.0 |
| Pb | 35.0 | 91.3 | 96.0 | 4.0 | 0.00 |
| Cd | 0.60 | 3.53 | 96.0 | 4.00 | 0.00 |
| Metal | SQGs (mg/kg)-Marine Sediment (Downstream) | Percentage of Samples Exceeding SQGs (%) | |||
| TEL | PEL | <TEL | TEL-PEL | >PEL | |
| Cu | 18.7 | 108 | 73.3 | 20.0 | 6.67 |
| Zn | 124 | 271 | 93.3 | 0.00 | 6.67 |
| Cr | 52.3 | 160 | 73.3 | 26.7 | 0.00 |
| Ni | 15.9 | 42.8 | 46.7 | 53.3 | 0.00 |
| Pb | 30.2 | 112 | 86.7 | 13.3 | 0.00 |
| Cd | 0.68 | 4.21 | 93.3 | 6.67 | 0.00 |
| Hue | Saturation | Value | Red | Green | Blue | Grey | |
| Low Resolution Normalised Images | |||||||
| Expert 1 | 90.8% | 82.5% | 85.8% | 85.8% | 87.0% | 87.0% | 90.8% |
| Expert 2 | 91.0% | 82.8% | 84.5% | 84.5% | 86.3% | 86.3% | 90.0% |
| Expert 3 | 91.0% | 80.3% | 87.5% | 87.5% | 89.3% | 88.8% | 92.5% |
| Expert 4 | 91.8% | 84.0% | 84.3% | 84.3% | 86.0% | 86.0% | 89.8% |
| High Resolution Normalised Images | |||||||
| Expert 1 | 83.3% | 75.0% * | 85.8% | 87.8% | 87.3% | 87.5% | 87.3% |
| Expert 2 | 84.5% | 74.8% * | 86.0% | 87.5% | 87.5% | 86.3% | 87.5% |
| Expert 3 | 85.0% | 75.3% * | 87.5% | 88.5% | 89.5% | 87.8% | 89.5% |
| Expert 4 | 82.3% | 74.0% * | 83.8% | 85.8% | 85.3% | 86.0% | 85.3% |
| Factor | Cronbach’s α | Item-to-subscale correlation | Subscale-to-total correlation |
| 1 Psychological expression | 0.92 | 0.58–0.75 | 0.92 |
| 2 Changes in self and family | 0.82 | 0.49–0.62 | 0.73 |
| 3 Physical symptoms | 0.81 | 0.31–0.64 | 0.80 |
| 4 Social and family connectedness | 0.73 | 0.30–0.73 | 0.39 |
| 5 Fatalism | 0.88 | 0.67–0.84 | 0.39 |
| 6 Religion and faith | 0.64 | 0.17–0.66 | 0.02 |
| 7 Self-query | 0.62 | 0.27–0.47 | 0.59 |
| 8 Coping style | 0.59 | 0.34–0.50 | 0.12 |
| Transobturator Sling | Single-Incision Sling | p value | |
| Preoperative daily pads usage (mean) | 4.45±0.82 (3-6) | 4.25±0.78 (3-6) | p=0.495 |
| Postoperative daily pads usage (mean) | 0.30±0.57 (0-2) | 0.55±0,68 (0-2) | p=0.192 |
| Postoperatively, the number of patients with | 15 / 20 | 11 / 20 | p=0.190 |
| no pad usage (n / all patients) | |||
| Subjective cure rates | 75% | 55% | p=0.190 |
| Treatment options | Mean cost per child in A$2010-2011 (95%CI) | Mean number of QALYs (95%CI) | Mean incremental number of QALYs vs no treatment | ICER |
| No treatment | 0 | 11.57 | - | - |
| (10.24; 13.06) | ||||
| Non-directive counselling | 2125 | 12.59 | 1.02 | 2083 |
| (1927; 2335) | (11.62; 13.57) | |||
| TF-CBT only | 2097 | 12.85 | 1.28 | 1638 |
| (1904; 2302) | (11.98; 13.74) | |||
| TF-CBT + SSRI (sertraline) | 2271 | 12.92 | 1.35 | 1682 |
| (2070; 2478) | (12.01; 13.78) |
| Total dust | Respirable crystalline silica dust | |
| Long-term average exposure (mg/m3) | ||
| Mean (SD) | 6.1 (4.8) | 0.27 (0.19) |
| Median (min.–max.) | 4.8 (0–36.7) | 0.22 (0–1.16) |
| Highest exposure ever* (mg/m3) | ||
| Mean (SD) | 23.5 (11.6) | 0.73 (0.34) |
| Median (min.–max.) | 23.8 (0–65.8) | 0.74 (0–1.95) |
| Cumulative exposure (mg/m3-year) | ||
| Mean (SD) | 226.4 (171.0) | 7.32 (5.22) |
| Median (min.–max.) | 183.7 (0–861.7) | 6.20 (0–26.6) |
| Exposure duration (years) | ||
| Mean (SD) | 27.8 (7.4) | |
| Median (min.–max.) | 27.8 (1.1–46.4) |
| Qigong | Exercise therapy | Study population | |
| Mean (±SD) | Mean (±SD) | Mean (±SD) | |
| N = 10 8 female, 2 male | N = 10 8 female, 2 male | N = 122 107 female, 25 male | |
| Age (years) | 40.6 (±10.3) | 44.6 (±9.3) | 45.6 (±10.7) |
| VAS baseline (mm) | 60.1 (±13.1) | 56.5(±12.2) | 56.2 (±14.1) |
| Pain duration (years) | 3.9 (±1.2) | 3.1 (±1.6) | 3.2 (±1.6) |
| Stage | OS | |
| HR(95% CI) | P-value‡ | |
| T2 | ||
| RT+Surg Vs Surg | 1.085(0.745-1.581) | 0.671 |
| Surg+RT Vs Surg | 0.776(0.400-1.507) | 0.454 |
| T3 | ||
| RT+Surg Vs Surg | 0.615(0.475-0.797) | 0.000*** |
| Surg+RT Vs Surg | 0.597(0.387-0.921) | 0.020* |
| General descriptives | ∑ Tot. | Sand | Canopy-forming algae | Seagrass aboveground | Seagrass belowground |
| Traditional numerical variables | |||||
| # of species | 36 | 17 | 26 | 29 | 23 |
| # of species only in one habitat | 10 | 2 | 4 | 3 | 1 |
| # of species found in all habitats | 13 | ||||
| Abundance dm-3 (Mean ± SD) | 18.4±11.5 | 2733.8±1624.8 | 5974.7±4154.3 | 110.0±44.2 | |
| Functional variables | |||||
| # of modalities expressed (Total) | 55 | 51 | 55 | 54 | 53 |
| # of modalities (Mean ±SD) | 44.3±3.1 | 48.5±1.8 | 50.6±3.4 | 51.7±1.1 | |
| # of species per modality (Mean) | 2.4 | 3.7 | 4.5 | 4.2 |
| Shift admitted | p value | ||
| Day | Night | ||
| Mortality (%) | 3.5 | 4.3 | 0.57 |
| ICU admission (%) | 2.2 | 3.2 | 0.32 |
| Mean length of stay (days) | 5.1 | 5.7 | 0.18∗ |
| Readmission, 30 days (%) | 8.1 | 7.1 | 0.60 |
| Need for surgery (%) | 43.5 | 39.6 | 0.26 |
| Bivariate Correlations | |||||||||
| M | SD | 1 | 2 | 3 | 4 | 5 | 6 | 7 | |
| DERS total | 83.76 | 25.80 | _ | ||||||
| DBT Skills Use | 1.92 | .40 | -.36** | _ | |||||
| Dysfunctional Coping | 1.61 | .55 | .69** | .03 | _ | ||||
| SRP Subscales: | |||||||||
| Interpersonal manipulation | 1.96 | .69 | .26* | -.27* | .26* | _ | |||
| Callous affect | 1.91 | .68 | .35* | -.24* | .43* | .63** | _ | ||
| Erratic lifestyle | 2.18 | .72 | .39** | -.14 | .44** | .52** | .70** | _ | |
| Criminal tendencies | 1.29 | .39 | .27* | -.13 | .29* | .51** | .57** | .56** | _ |
| Knowledge | Tick check frequency | |||||
| β | S.E. | pvalue | βa | S.E. | pvalue | |
| (Intercept) | 0.522 | 0.265 | 0.049 | −0.034 | 0.241 | 0.886 |
| t2 (reference: t1) | 1.430 | 0.310 | 0.000 | 0.599 | 0.252 | 0.017 |
| Leaflet (reference: game) | 0.232 | 0.337 | 0.499 | 0.624 | 0.305 | 0.052 |
| Control group (reference: game) | 0.032 | 0.330 | 0.924 | 1.040 | 0.305 | 0.002 |
| Knowing somebody with Lyme | 0.604 | 0.178 | 0.001 | 0.710 | 0.178 | 0.000 |
| Having had lectures on ticks | 0.535 | 0.184 | 0.004 | 0.215 | 0.176 | 0.222 |
| t2aLeaflet | 0.735 | 0.409 | 0.072 | −0.601 | 0.291 | 0.039 |
| t2aControl | −0.532 | 0.335 | 0.112 | −0.347 | 0.298 | 0.244 |
| t2aKnowing somebody with Lyme | −0.022 | 0.316 | 0.946 | −0.270 | 0.253 | 0.286 |
| t2aHaving had lectures on ticks | −0.380 | 0.289 | 0.188 | 0.035 | 0.241 | 0.883 |
| Haplotype | Honduras (n = 77) | Nicaragua (n = 33) | ||
| Number of samples | Frequency | Number of samples | Frequency | |
| I | 22 | 0.29 | 9 | 0.27 |
| II | 2 | 0.03 | 0 | 0 |
| III | 1 | 0.01 | 1 | 0.03 |
| IV | 2 | 0.03 | 0 | 0 |
| V | 6 | 0.08 | 0 | 0 |
| VI | 1 | 0.01 | 0 | 0 |
| VII | 7 | 0.09 | 1 | 0.03 |
| VIII | 1 | 0.01 | 0 | 0 |
| IX | 5 | 0.06 | 6 | 0.18 |
| X | 1 | 0.01 | 0 | 0 |
| XI | 1 | 0.01 | 0 | 0 |
| XII | 1 | 0.01 | 0 | 0 |
| XIII | 5 | 0.06 | 0 | 0 |
| XIV | 1 | 0.01 | 0 | 0 |
| XV | 1 | 0.01 | 0 | 0 |
| XVI | 7 | 0.09 | 2 | 0.06 |
| XVII | 1 | 0.01 | 0 | 0 |
| XVIII | 6 | 0.08 | 0 | 0 |
| XIX | 1 | 0.01 | 0 | 0 |
| XX | 2 | 0.03 | 0 | 0 |
| XXI | 1 | 0.01 | 0 | 0 |
| XXII | 1 | 0.01 | 0 | 0 |
| XXIII | 1 | 0.01 | 1 | 0.03 |
| XXIV | 0 | 0 | 1 | 0.03 |
| XXV | 0 | 0 | 12 | 0.36 |
| Origin | Region | Isolate serial number | Total number of isolates | Number of genotypes | Number of polymorphic loci | Polymorphic loci (%) |
| Rich Kser Wallal | Rich Errachidia | 7 | 1 | - | - | - |
| Rich Kser Aït Said | Rich Errachidia | 20 | 1 | - | - | - |
| Rich Kser Tabia | Rich Errachidia | 27; 30 | 2 | - | 5 | 13.51 |
| Demnate | Demnate | 42 | 1 | - | - | - |
| Ziz Kser Bouya Jerf | Jerf Erfoud | 57-58 | 2 | - | 6 | 16.22 |
| Jerf | Jerf Erfoud | 66 | 1 | - | - | - |
| Erfoud Hay Lagmbita | Jerf Erfoud | 76-80; 88 | 6 | 6 | 20 | 54.05 |
| Erfoud Masoudia | Jerf Erfoud | 91-92 | 2 | - | 5 | 13.51 |
| Errachidia Aïne Zerka | Rich Errachidia | 116-117 | 2 | - | 9 | 24.32 |
| Toudra Tinghir | Tinghir | 119; 121 | 2 | - | 14 | 37.84 |
| Ziz Errachidia | Ziz | 122 | 1 | - | - | - |
| Over all | - | - | 21 | 21 | 35 | 94.59 |
| 1st set | 1st set CV | 2nd set | 2st set CV | SDw | CV (%) | ICC | |
| Rrs5 (kPa/L/sec) | 1.11 ± 0.24 | 8.04 ± 11.9 | 1.10 ± 0.18 | 7.68 ± 4.0 | 0.37 | 4.64 | 0.88 (0.76–0.94) |
| Rrs10 (kPa/L/sec) | 0.90 ± 0.17 | 5.33 ± 2.70 | 0.90 ± 0.13 | 5.88 ± 4.05 | 0.31 | 4.29 | 0.87 (0.74–0.94) |
| Xrs5 (kPa/L/sec) | −0.43 ± 0.12 | 10.4 ± 5.74 | −0.41 ± 0.10 | 14.0 ± 7.74 | 0.29 | 5.78 | 0.81 (0.61–0.91) |
| Xrs10 (kPa/L/sec) | −0.23 ± 0.06 | 11.7 ± 6.01 | −0.25 ± 0.09 | 14.4 ± 8.44 | 0.31 | 10.35 | 0.73 (0.46–0.87) |
| AX (kPa/L) | 3.62 ± 1.36 | 11.2 ± 6.70 | 3.28 ± 1.28 | 14.4 ± 10.08 | 0.98 | 11.21 | 0.85 (0.71–0.93) |
| Rf (Hz) | 22.0 ± 2.0 | 4.90 ± 2.81 | 21.6 ± 2.2 | 4.64 ± 4.47 | 1.37 | 3.36 | 0.76 (0.52–0.88) |
| HCC parameters | Number of patients | miR-940 (−) | miR-940 (+) | χ2 | P |
| Gender | |||||
| Male | 38 | 31 | 7 | 0.515 | 0.473 |
| Female | 8 | 5 | 3 | ||
| Age | |||||
| ≥50 years old | 36 | 29 | 7 | 0.080 | 0.777 |
| <50 years old | 10 | 7 | 3 | ||
| Etiology | |||||
| HBV+ | 38 | 30 | 8 | 0.000 | 1.000 |
| HBV− | 8 | 6 | 2 | ||
| Cirrhosis | |||||
| Positive | 37 | 31 | 6 | 1.934 | 0.164 |
| Negative | 9 | 5 | 4 | ||
| AFP (ng/mL) | |||||
| ≥400 | 29 | 22 | 7 | 0.021 | 0.885 |
| <400 | 17 | 14 | 3 | ||
| Tumor size | |||||
| ≥5 cm | 26 | 21 | 5 | 0.012 | 0.913 |
| <5 cm | 20 | 15 | 5 | ||
| TNM stage | |||||
| I-II | 25 | 18 | 7 | 0.584 | 0.445 |
| III-IV | 21 | 18 | 3 | ||
| Edmondson grade | |||||
| I-II | 22 | 13 | 9 | 7.076 | 0.008∗∗ |
| III-IV | 24 | 23 | 1 | ||
| Tumor microsatellite or multiple tumors | |||||
| Yes | 20 | 19 | 1 | 4.217 | 0.040∗ |
| No | 26 | 17 | 9 | ||
| Vascular invasion | |||||
| Yes | 15 | 15 | 0 | 4.432 | 0.035∗ |
| No | 31 | 21 | 10 | ||
| Recurrence and metastasis | |||||
| Yes | 29 | 26 | 3 | 4.313 | 0.038∗ |
| No | 17 | 10 | 7 |
| Target protein or pathway | Drug | CHIKV IC50 (μM) | WST-1 IC50 (μM) | Therapeutic index |
| Fatty acid synthesis | TOFA | 0.15 | > 60* | NT |
| Orlistat | 0.82 | 8.67 | 10.57 | |
| Cerulenin | 3 | 7.57 | 2.53 | |
| vATPase | Bafilomycin | 0.000334 | 0.003* | NT |
| CLK1 | AnnH18 | 1.02 | 9.19 | 9.04 |
| AnnH14 | 1.55 | 10.55 | 6.79 | |
| KH-CB19 | 3.36 | 10.93 | 3.26 | |
| KAT5 | (15:3)-Anacardic acid | 0.58 | 2.68 | 4.65 |
| Calmodulin signalling | TAE684 | 0.15 | 2.07 | 14.28 |
| Pimozide | 0.28 | 19.18 | 69.75 | |
| Perphenazine | 0.63 | 24.23 | 38.28 | |
| 6-Hydroxyflavone | 2.6 | > 60 | NT | |
| Prenylamine | 2.39 | 16.53 | 6.91 | |
| Felodipine | 3.24 | 12.08 | 3.73 | |
| FLT4 | Alsterpaullone | 0.002 | 44.38* | NT |
| Pazopanib | 0.13 | 1.32* | NT | |
| Axitinib | 0.3 | 0.34* | NT | |
| Tivozanib | 0.8 | 8.34* | NT | |
| Sorafenib | 1.11 | 18.24 | 16.42 | |
| Linifanib | 2.15 | > 60 | NT |
| Country | Year | Sample size | Age range | Both genders | Male | Female |
| Southern China | 2008 | 446 | 55 | 19.1% | 14.5% | 24.4% |
| Taiwan [10] | 2000 | 1937 | 65+ | 32.5% | 30.1% | 34.9% |
| Japan [11] | 2006 | 572 | 55-75 | 45.8% | 41.7% | 52.5% |
| Australia [12] | 2001 | 1263 | 65+ | 43% | 35% | 52% |
| New Zealand [13] | 1997 | 814 | 65+ | 36.1% | 24.7% | 43.7% |
| Indonesia [14] | 1996 | 204 | 60-75 | 25.0% | 24.7% | 25.2% |
| Korea [15] | 2000 | 2188 | 50+ | 30.2% | 28.5% | 30.7% |
| Malaysia [16] | 2005 | 60 | 50+ | 83.1% | NA | NA |
| Name BRE | 5′ primer (5′-3′) | 3′ primer (5′-3′) | size (bp) |
| 7–13 | GATGAGCTCATGCGAAAGTGAAGGTGGTCCCCAG | TGAAGATCTAGCAAGGAGGAACTGGAGATGTCA | 1278 |
| 9–13 | GAGCTCTCGAACCTCTCTTTCCTATCTC | AGATCTAGCAAGGAGGAACTGGAGATGTCA | 695 |
| 10–13 | GAGCTCTGGAGCTGAGCCTGGAGAGAAG | AGATCTAGCAAGGAGGAACTGGAGATGTCA | 530 |
| 12–13 | GAGCTCTAGGCCATCAGACAGCTCTGAG | AGATCTAGCAAGGAGGAACTGGAGATGTCA | 127 |
| 9 | GAGCTCTCGAACCTCTCTTTCCTATCTC | AGATCTCTTCTCTCCAGGCTCAGCTCCA | 189 |
| 9–10 | GAGCTCTCGAACCTCTCTTTCCTATCTC | AGATCTCCCTCATCTCTCCTTGCAGCT | 253 |
| 9–11 | GAGCTCTCGAACCTCTCTTTCCTATCTC | AGATCTAGGCCCTCAAATTCCTCAGAG | 348 |
| Age (years) | Male [positive/total (%)] | Female [positive/total (%)] | Total [positive/total (%)] |
| 17-27 | 7/452 (1.54) | 10/585 (1.7) | 17/1037 (1.63) |
| 28-36 | 4/326 (1.22) | 7/365 (1.91) | 11/691 (1.59) |
| 37-53 | 6/137 (4.37) | 8/293 (2.73) | 14/430 (3.25) |
| 54-79 | 5/180 (2.77) | 5/350 (1.42) | 10/530 (1.88) |
| Total | 22/1095 (2.0) | 30/1593 (1.88) | 52/2688 (1.93) |
| Characteristics | PA group (N = 145) | Non-PA group (N = 79) | P value |
| Age, years (mean ± SD) | 67.6 ± 11.7 | 65.0 ± 12.6 | 0.128 |
| Sex (male/female) | 94 (64.8%)/51 (35.2%) | 54 (68.4%)/25 (31.6%) | 0.659 |
| Body mass index (kg/m2) | 21.6 ± 2.7 | 21.8 ± 2.7 | 0.538 |
| Aims (preoperative/palliative) | 82 (56.6%)/63 (43.4%) | 44 (55.7%)/35 (44.3%) | 1.000 |
| Diabetes mellitus | 21 (14.5%) | 11 (13.9%) | 1.000 |
| WBC (×1000), (/mm3) | 8.1 ± 3.2 | 7.5 ± 2.7 | 0.198 |
| ANC (×1000), (/mm3) | 5.8 ± 3.0 | 5.2 ± 2.5 | 0.124 |
| CRP∗ (mg/dL) | 4.6 ± 6.6 | 2.4 ± 3.4 | 0.001 |
| Potassium (mEq/L) | 3.9 ± 0.5 | 3.9 ± 0.8 | 0.556 |
| Abdominal pain | 112 (77.2%) | 54 (68.4%) | 0.154 |
| Abdominal tenderness∗ | 66 (45.5%) | 22 (27.8%) | 0.010 |
| Degree of obstruction (total/subtotal) | 42 (29.0%)/103 (71.0%) | 19 (24.1%)/60 (75.9%) | 0.530 |
| Mechanical ileus∗ | 80 (55.2%) | 24 (27.8%) | <0.001 |
| Carcinomatosis peritonei | 18 (12.4%) | 7 (8.9%) | 0.509 |
| Obstruction site | 0.857 | ||
| Ascending colon | 3 (2.1%) | 2 (2.5%) | |
| Hepatic flexure | 8 (5.5%) | 5 (6.3%) | |
| Transverse colon | 3 (2.1%) | 0 (0.0%) | |
| Splenic flexure | 7 (4.8%) | 5 (6.3%) | |
| Descending colon | 8 (5.5%) | 5 (6.3%) | |
| Rectosigmoid colon | 116 (80.0%) | 62 (78.5%) |
| Outcomes | Group | LS mean ± SEa | Differenceb (95 % CI) | P-value |
| Primary outcome | ||||
| Total VSCs | ||||
| 10 min | Test | 0.115 ± 0.078 | −0.246 | 0.002 |
| Placebo | 0.362 ± 0.081 | (−0.395 to 0.098) | ||
| 30 min | Test | 0.173 ± 0.086 | −0.136 | 0.199 |
| Placebo | 0.309 ± 0.090 | (−0.348 to 0.075) | ||
| Secondary outcomes | ||||
| H2S | ||||
| 10 min | Test | −0.085 ± 0.083 | −0.349 | < 0.001 |
| Placebo | 0.263 ± 0.086 | (−0.506 to 0.192) | ||
| 30 min | Test | 0.056 ± 0.080 | −0.171 | 0.066 |
| Placebo | 0.226 ± 0.084 | (−0.353 to 0.012) | ||
| CH3SH | ||||
| 10 min | Test | −0.635 ± 0.129 | −0.044 | 0.747 |
| Placebo | −0.591 ± 0.134 | (−0.321 to 0.233) | ||
| 30 min | Test | −1.070 ± 0.141 | −0.265 | 0.163 |
| Placebo | −0.806 ± 0.149 | (−0.641 to 0.112) |
| Dependent variable | Independent variable | Estimate | Standard error | 95% CI | P |
| SF-BP | Migraine (yes vs. no) | −8.93 | 1.40 | −6.20 to −11.67 | <0.001 |
| HAMD (one-point increment) | −1.20 | 0.10 | −1.00 to − 1.40 | <0.001 | |
| HADS-A (one-point increment) | −0.59 | 0.19 | −0.22 to −0.96 | <0.01 | |
| Educational years (one-year increment) | 0.90 | 0.29 | 1.47 to 0.32 | <0.01 | |
| PS | Migraine (yes vs. no) | 1.33 | 0.23 | 1.78 to 0.89 | <0.001 |
| HAMD (one-point increment) | 0.19 | 0.02 | 0.22 to 0.16 | <0.001 | |
| HADS-A (one-point increment) | 0.12 | 0.03 | 0.18 to 0.06 | < 0.001 | |
| Educational years (one-year increment) | −0.13 | 0.05 | −0.03 to −0.23 | 0.01 | |
| Married (yes vs. no) | 0.53 | 0.21 | 0.95–0.12 | 0.01 | |
| Age (one-year increment) | 0.03 | 0.01 | 0.05 to 0.004 | 0.02 | |
| Anxiety disorders (yes vs. no) | 0.52 | 0.24 | 1.00 to 0.05 | 0.03 |
| Coal samples | Atomic concentration of elements/% | (O/C) ratio/% | ||||
| C 1s | O 1s | N 1s | S 2p | Elemental analysis | XPS analysis | |
| Beizao lignite | 80.34 | 18.22 | 1.44 | / | 20.61 | 22.68 |
| Daliuta long flame coal | 84.37 | 14.17 | 0.94 | 0.52 | 16.02 | 16.80 |
| Yushuwan gas coal | 87.68 | 11.5 | 0.82 | / | 12.03 | 13.12 |
| Xinjulong fat coal | 89.11 | 8.88 | 1.72 | 0.29 | 7.15 | 9.97 |
| Wugou coking coal | 88.41 | 9.08 | 1.83 | 0.68 | 5.50 | 10.27 |
| Yangquan anthracite | 89.18 | 9.05 | 1.34 | 0.43 | 2.52 | 10.15 |
| Variable | N | R Pearson Correlation | Level of significance |
| Organizational culture and organizational commitment | 165 | 0.419 | 0.027 |
| Variable | b | Wald | OR | 95% CI for OR |
| Unreasonable illegitimate Tasks | 0.53* | 6.69 | 1.69 | [1.14–2.52] |
| Role Conflict | 0.08 | 0.33 | 1.08 | [0.83–1.40] |
| Control over Work Pace | −0.44** | 15.48 | .64 | [0.52–0.80] |
| Exhaustion | 0.59** | 11.24 | 1.81 | [1.28–2.55] |
| Administrative Tasks | 0.004 | 0.55 | 1.00 | [0.99–1.02] |
| Gender | 0.02 | 0.006 | 1.02 | [0.69–1.50] |
| Age | −0.07 | 0.93 | [0.85–1.02] | |
| -2log likelihood 619.37**Cox & Snell R2 .107Nagelkerke R2 .144 |
| RSV | Influenza A (H1N1) virus |
| Age <6 months | Age <5 years |
| History of prematurity | Chronic lung disease |
| Chronic lung disease | Congenital heart disease |
| Congenital heart disease | Immunocompromised conditions |
| Viral coinfection |
| Group | Sub group | Gender | Age (years ± SD) | Verbal memory (score ± SD) | O&M (years ± SD) |
| Gamers | Early blind | 4 m/4 f | 24.00 ± 6.76 | 81.13 ± 15.29 | 14.25 ± 7.78 |
| Late blind | 5 m/2 f | 29.86 ± 7.34 | 72.43 ± 18.16 | 1.0 ± 0.00* | |
| Subgroup totals/means | 9 m/6 f | 26.73 ± 7.42 | 77.07 ± 16.69 | 8.07 ± 8.78 | |
| Directed navigators | Early blind | 4 m/3 f | 28.29 ± 9.05 | 87.86 ± 6.82 | 10.43 ± 9.91 |
| Late blind | 4 m/3 f | 31.71 ± 10.45 | 83.43 ± 11.49 | 1.0 ± 0.00* | |
| Subgroup totals/means | 8 m/6 f | 30.00 ± 9.56 | 85.64 ± 9.36 | 5.71 ± 8.32 | |
| Controls | Early blind | 2 m/2 f | 21.00 ± 2.94 | 88.75 ± 7.37 | 14.25 ± 1.71 |
| Late blind | 0 m/3 f | 33.33 ± 9.71 | 89.33 ± 6.03 | 14.00 ± 5.29 | |
| Subgroup totals/means | 2 m/5 f | 26.29 ± 8.90 | 89.00 ± 6.27 | 14.14 ± 3.29 | |
| Totals/means | 20 m/18 f | 27.92 ± 8.51 | 82.72 ± 13.25 | 8.33 ± 8.24 |
| Sensory neurons in the DRGs | BL40 | GB30 |
| Large-sized neuron | 58 (10.78%) | 149 (17.21%) |
| Medium-sized neuron | 222 (41.26%) | 357 (41.22%) |
| Small-sized neuron | 258 (47.96%) | 360 (41.57%) |
| Number | Percent | ||
| Gender | Female | 379 | 90.9 |
| Male | 38 | 9.1 | |
| Country | Australia | 396 | 94.9 |
| New Zealand | 21 | 5.1 | |
| Age (years) | 21-30 | 23 | 5.5 |
| 31-40 | 84 | 20.1 | |
| 41-50 | 156 | 37.4 | |
| 51-60 | 141 | 33.8 | |
| 60+ | 13 | 3.1 | |
| Length of Time Working in Haemodialysis | <1 year | 11 | 2.6 |
| 1-2 years | 22 | 5.3 | |
| 3-5 years | 70 | 16.8 | |
| 6-10 years | 116 | 27.8 | |
| 11-15 years | 94 | 22.5 | |
| 16-20 years | 41 | 9.8 | |
| >20 years | 63 | 15.1 | |
| Nursing Classification | Registered Nurse (RN) | 406 | 97.4 |
| Enrolled Nurse (EN) | 11 | 2.6 | |
| Highest Nursing Qualification | Certificate in Nursing | 85 | 20.4 |
| Diploma in Nursing | 56 | 13.4 | |
| Undergraduate Degree | 74 | 17.7 | |
| Postgraduate Certificate/Diploma | 170 | 40.8 | |
| Masters/Doctorate | 32 | 7.7 | |
| Work Location | Metropolitan | 177 | 42.4 |
| Regional | 144 | 34.5 | |
| Rural | 85 | 20.4 | |
| Remote | 11 | 2.6 | |
| Type of Unit | In-Center | 187 | 44.8 |
| Satellite | 202 | 48.4 | |
| Home | 28 | 6.7 |
| Inclusion criteria | Exclusion criteria |
| Women < 40 years old | Women who conceived the fetus using artificial methods including in-vitro fertilization or intrauterine insemination |
| Aboriginal ancestry | Women carrying more than one fetus |
| Pregnant with singleton | Surrogate mothers |
| Women who suffer from severe chronic medical conditions including active cancer, severe infectious diseases including HIV, hepatitis B or C, or who are VDRL positive |
| Variable | Points |
| Age >80 years | 1 |
| History of cancer | 1 |
| History of heart failure or chronic lung disease | 1 |
| Pulse rate ≥110 bpm | 1 |
| Systolic blood pressure <100 mmHg | 1 |
| Oxygen saturation <90 % on room air | 1 |
| Variables | Knowledgeable | COR 95 % CI | AOR 95 % CI | |
| Yes | No | |||
| Sex | ||||
| Male | 229 | 281 | 2.07 (1.55, 2.78) | 1.89 (1.36, 2.61)** |
| Female | 207 | 367 | 1 | 1 |
| Age (years) | ||||
| 18–25 | 191 | 101 | 5.14 (3.18, 8.26) | 2.42 (1.33, 4.40)* |
| 26–35 | 150 | 85 | 4.78 (2.92,7.80) | 2.06 (1.13, 3.73)* |
| 36–45 | 64 | 66 | 2.63 (1.54, 4.49) | 1.38 (0.75, 2.54) |
| > 45 | 31 | 84 | 1 | 1 |
| Educational status | ||||
| Non formal education | 18 | 84 | 1 | 1 |
| Primary school (1–8th) | 30 | 36 | 3.89 (1.93, 7.85) | 2.93 (1.39, 6.17)* |
| Secondary (9–12th) | 147 | 90 | 7.62 (4.30, 13.5) | 3.33 (1.68, 6.60)** |
| Certificate & above | 241 | 126 | 8.93 (5.14, 15.5) | 4.39 (2.29, 8.39)** |
| Source of information | ||||
| Television | 355 | 246 | 0.64 (0.38, 1.07) | 1.03 (0.60, 1.76) |
| Radio | 29 | 67 | 0.19 (0.10, 0.37) | 0.37 (0.19, 0.75)* |
| Newspaper/Internet | 52 | 23 | 1 | 1 |
| Geometric mean | 95th percentile | |||||||
| DEP | DEHP | DEP | DEHP | |||||
| Population group | MEP | MEHP | MEHHP | MEOHP | MEP | MEHP | MEHHP | MEOHP |
| 289 adults (Blount et al. 2000b) | 345 (11.4) | 3.0 (0.5) | ND | ND | 2,610 (86.6) | 15.2 (3.3) | ND | ND |
| 2,536 persons 6 to > 20 years of age (Silva et al. 2004a) | 163 (5.4) | 3.12 (0.7) | ND | ND | 1,950 (64.7) | 18.5 (4.0) | ND | ND |
| 2,772 persons 6 to > 20 years of age (CDC 2005) | 167 (5.5) | 3.99 (0.9) | 18.8 (2.1) | 12.6 (2.2) | 1,860 (61.7) | 32.8 (7.1) | 147 (16.8) | 87.5 (15.6) |
| 85 children and adults (Koch et al. 2003c)a | 165b (5.5) | 12.4b (2.7) | 57.2b (6.5) | 41.7b (7.4) | 673 (22.2) | 34.7 (7.5) | 143 (16.3) | 106 (18.9) |
| Description of framework objectives | |
| 1. | Surveillance to develop shared operational definitions and determinants of mental illness |
| 2. | Epidemiological research into determinants and protective factors for mental health and their relationships to chronic diseases |
| 3. | Prevention research to determine the importance of mental illness/health as factors in public health promotion and prevention |
| 4. | Communication to develop culturally, linguistically, and developmentally appropriate educational products |
| 5. | Education of Health Professionals including the development of appropriate education plans for professional audiences |
| 6. | Program Integration Support at various jurisdictional levels |
| 7. | Policy Integration that involves the development of policies at all government levels for all audiences and stakeholders |
| 8. | Systems to Promote Integration such as establish systems integration to promote program and policy integration across multiple infrastructures |
| Parameter† | Minimum | Maximum | Mean | Standard deviation |
| TK | 6 | 73 | 47.47 | 12.7 |
| LL | 2 | 67 | 39.62 | 12.4 |
| TT | 0 | 21 | 7.08 | 4.9 |
| LT | 0 | 24 | 12.09 | 5.9 |
| PT | 0 | 27 | 10.32 | 6.5 |
| PI | 4 | 70 | 45.37 | 10.7 |
| SS | 13 | 55 | 35.37 | 8.1 |
| Outcome | Regression coefficient(95%CI) | |
| Publication year | Type of fractures | |
| Blood loss | − 0.02 (− 0.11, 0.08) | − 0.70 (− 2.04, 0.64) |
| Operation time | − 0.32 (− 0.10, 0.04) | − 0.22 (− 1.28, 0.83) |
| Scale | Fatigue description |
| 1 | No such feeling |
| 2 | Negligible feeling |
| 3 | Some feeling |
| 4 | Clear feeling |
| 5 | Strong feeling |
| 6 | Very strong feeling |
| 7 | Extremely strong feeling |
| C/N0 | 25 dB-Hz | 30 dB-Hz | 35 dB-Hz | 40 dB-Hz | |
| Standard Receiver | Optimal Bandwidth | 15 Hz | 22 Hz | 28 Hz | 35 Hz |
| Tracking Error of the PLL in Optimal Bandwidth | 28 deg. | 15 deg. | 9 deg. | 7 deg. | |
| Dynamic Stress Noise Proportion (BPLL = 20 Hz) | 8% | 14% | 21% | 28% | |
| Ultra-tightly Integrated GNSS/INS Receiver | Optimal Bandwidth | 7 Hz | 9 Hz | 13 Hz | 25 Hz |
| Tracking Error of the PLL in Optimal Bandwidth | 20 deg. | 12 deg. | 8 deg. | 6 deg. | |
| Dynamic Stress Noise Proportion (BPLL = 20 Hz) | <1% | <1% | <1% | <1% |
| Variable | Time to report to hospital | P-value | |||
| Less than one week | One week and above | COR*(95 %CI#) | AOR**(95% CI) | ||
| Age of the child | |||||
| - Less than 5 years | 28(17.2) | 10(9.6) | 0.062 | 0.47(0.21-1.04) | |
| - Five to ten years | 62(38.0) | 38(36.5) | 0.409 | 0.80(0.47-1.36) | |
| - More than 10 years | 73(44.8) | 56(53.8) | 1 | 1 | |
| Sex of the child | |||||
| - Male | 28(17.2) | 37(35.6) | 0.001 | 2.66(1.50-4.70) | 2.40(1.34-4.31) |
| - Female | 135(82.8) | 67(64.4) | 1 | 1 | 1 |
| Previous history of abuse | |||||
| - Yes | 20(12.3) | 25(24.0) | 0.010 | 2.26(1.18-4.33) | 1.88(0.96-3.68) |
| - No | 143(87.7) | 79(76.0) | 1 | 1 | 1 |
| Place of residence | |||||
| - Addis Ababa | 140(85.9) | 89(85.6) | 0.539 | 0.89(0.48-2.93) | |
| - Out of Addis Ababa | 23(14.1) | 15(14.4) | 1 | 1 | |
| Is the abuser known to the child? | |||||
| - Yes | 113(69.3) | 82(78.8) | 0.057 | 1.64(0.92-2.93) | |
| - No | 50(30.7) | 22(21.2) | 1 | 1 |
| 2006 | 2007 | 2008 | ||||
| N | % | N | % | N | % | |
| United States | 1,025 | 1,021 | 658 | |||
| Any SSM | 24.4 | 33.0 | 48.8 1 | |||
| NRT | 19.5 | 16.5 | 22.2 | |||
| Bupropion | 4.8 | 3.4 | 4.3 | |||
| Varenicline | 0.4 | 13.7 | 21.7 1 | |||
| United Kingdom | 903 | 843 | 704 | |||
| Any SSM | 31.9 | 36.3 | 36.6 1 | |||
| NRT | 29.8 | 32.7 | 29.1 | |||
| Bupropion | 1.9 | 1.1 | 2.0 | |||
| Varenicline | 0.0 | 2.0 | 4.41 | |||
| Canada | 975 | 927 | 676 | |||
| Any SSM | 31.1 | 32.3 | 45.7 1 | |||
| NRT | 26.8 | 24.1 | 24.6 | |||
| Bupropion | 4.8 | 5.5 | 5.5 | |||
| Varenicline | 0.0 | 2.3 | 14.8 1 | |||
| Australia | 1,119 | 999 | 697 | |||
| Any SSM | 31.5 | 35.3 | 45.6 1 | |||
| NRT | 26.0 | 29.8 | 24.5 | |||
| Bupropion | 5.2 | 5.1 | 5.6 | |||
| Varenicline | 0.0 | 0.12 | 14.5 1 |
| Characteristic | Number (%) |
| Male (n = 412) | 220 (53) |
| Role in ED (n = 419) | |
| Attending | 207 (49) |
| Resident | 170 (41) |
| Advanced practice provider | 42 (10) |
| Years working in ED (n = 417) | |
| < 1 year | 52 (13) |
| > 1 – < 5 years | 164 (39) |
| > 5 – < 10 years | 53 (13) |
| > 10 – < 20 years | 85 (20) |
| > 20 years | 63 (15) |
| Location of ED* (n = 420) | |
| Rural | 8 (2) |
| Suburban | 24 (6) |
| Urban | 410 (98) |
| ED practice setting* (n = 420) | |
| Academic | 409 (97) |
| Community | 71 (17) |
| VA/military | 16 (4) |
| Prior therapeutic OA use (n=420) | 265 (63) |
| Tissue | Content of poncirin (mg/g FW) |
| flavedo | 0.15 ± 0.01 |
| albedo | 1.37 ± 0.09 |
| segment membrane | 0.52 ± 0.01 |
| juice sac | 0.07 ± 0.01 |
| Problem | Possible Reason | Solution |
| Genome is not fragmented after sonication. | Buffer condition is not adaptable for sonication. | Purify the DNA. We used QIAGEN PCR Purification Kit, eluted in EB to have it work. |
| Nothing is visible on the gel after 1 hr electrophoresis during library generation. | When the starting amount of DNA is small or there is significant DNA loss during the process for various reasons, it is possible that the DNA is smeared over a wide range after an hour of electrophoresis and not visible on the gel. | It is good to check the gel to see if the DNA is present after ~10 min run when the DNA is not smeared at a wide range.Even though nothing is visible, it is highly possible that the DNA is still present. Proceed to the next step regardless and see if PCR amplifies anything. |
| Cannot collect ~400 ul after the stripping step. | Gasket slide was re-used.The array slide was lifted up too quickly.Different buffer was used for the 95C stripping process. | Do not re-use the gasket slide.The solution can be flushed to a collection boat and collected.When using multi-array slides like 2×105 K, 4×44 K or 8×15 K, it is still possible to run the capture protocol as indicated. After the stripping, the array slide should be slowly lifted up to prevent contamination. The solution tends to stay within the gaskets. |
| Not enough DNA amplified after the first stripping. | Stripping was not efficient. | Another stripping process can be done and checked if there were left over genomic fragments hybridized on the probes. Since it does not matter if the stripped solution contains contaminants as long as the contaminants do not have adapters ligated at the end, it is possible to thoroughly continue the stripping process until no products get amplified. |
| Dietary Intake Adequacy Based on Mean Adequacy Ratio (MAR) | Minimum Dietary Diversity | Minimum Meal Frequency | Minimum Acceptable Diet | Consumption of Iron-Rich/Fortified Food |
| Odds Ratio (95% CI) | ||||
| b MAR > 0.6 (more than 60.0%) | 11.10 (3.09, 39.87), p = 0.000 | 6.70 (1.44, 31.16), p = 0.015 | 4.03 (1.17, 13.87), p = 0.027 | 2.73 (0.45, 16.48), p = 0.273 |
| 0.5 < a MAR ≤ 0.6 (50.1%–60.0%) | 5.49 (1.35, 22.22), p = 0.017 | 1.60 (0.35, 7.30), p = 0.544 | 2.96 (0.75, 11.67), p = 0.121 | 1.33 (0.20, 9.00), p = 0.768 |
| ScheduleTreatment day (TD)Time point (T) | T0 (Screening, baseline and prediagnosis tests) | T1 (Treatment and discharge) | T2 3M | T3 6M | T4 12M | Withdrawal | ||||||
| TD 1* | TD 2 | TD 3 | TD 4 | TD 5 | Rescue therapy† | Discharge | ||||||
| Screening with diagnostic algorithm and core investigations including physical examination | X | |||||||||||
| Patient information and informed consent | X | |||||||||||
| Eligibility form | X | |||||||||||
| Registration form | X | |||||||||||
| Prediagnosis tests—for example, MRI and AQP4 | X | |||||||||||
| Randomisation | X | |||||||||||
| Biobank samples | X | X | ||||||||||
| ASIA Impairment Score (A-E) | X | X | X | X | P | X | ||||||
| ASIA Motor and Sensory Score | X | X | X | X | S | X | ||||||
| Neurostatus scoring (Kurtzke functional systems and EDSS) | X | X | X | S | X | |||||||
| 8–12 years EQ-5D-Y | X | X | S | X | ||||||||
| ≥13 years EQ-5D-5L | X | X | S | X | ||||||||
| ≥13 years SCI QoL Basic data set | X | S | X | |||||||||
| CSRI | X | S | X | |||||||||
| ≥13 years SCI Bladder | T | X | ||||||||||
| ≥13 years SCI Bowel | T | X | ||||||||||
| 5–7 years Peds QL | T | X | ||||||||||
| 2–4 years Peds QL | T | X | ||||||||||
| Treatment form | X | |||||||||||
| Concomitant medications | X | X | X | X | ||||||||
| Discharge form | X | |||||||||||
| Rescue therapy form (if needed)† | X | |||||||||||
| Relapse form (at any time point if needed)† | X | X | X | X | ||||||||
| Adverse events‡ | X | X | X | X | X | |||||||
| Study Status Form | X | X | X | |||||||||
| Withdrawal form (at any time point)† | X |
| Study | Number of patients | Follow-up (days) | Baseline comparison | Adverse event | Outcomes measure (primary/secondary) | Treatment group dosage | Types of stroke |
| Cai et al. 2000 [29] | 256 | 14 | Y | N | TER, CSS | XNJ 30–60 mL/d + CWM | IS |
| Chen et al. 2004a [30] | 100 | 14 | Y | N | TER | XNJ 20 mL/d + CWM | IS |
| Chen et al. 2004b [31] | 70 | 14 | Y | N | TNF-α, IL-6, IL-1, ESSS | XNJ 40 mL/d + CWM | ICH |
| Chen 2013 [32] | 202 | 21 | Y | Y | NIHSS, IL-9 | XNJ 30 mL/d + CWM | ICH |
| Lei 2013 [33] | 120 | 28 | Y | Y | TER | XNJ 20 mL/d + CWM | ICH |
| Li 2011 [34] | 118 | 14 | Y | N | TNF-α, IL-6, NIHSS | XNJ 40 mL/d + CWM | ICH |
| Liu and Bai 2004 [35] | 70 | 14 | Y | N | TNF-α, IL-6, IL-8, ESSS | XNJ 40 mL/d + CWM | ICH/IS |
| Ming et al. 2010 [36] | 91 | 21 | Y | N | ESS, | XNJ 20 mL/d + CWM | ICH |
| Wang 2013 [37] | 155 | 14 | Y | N | TER | XNJ 20 mL/d + CWM | ICH/IS/SAH |
| Wei and Li 2009 [13] | 120 | 28 | Y | Y | TER, CSS | XNJ 10 mL/d + CWM | ICH |
| Zhang et al. 2012 [38] | 65 | 14 | Y | N | NIHSS | XNJ 20 mL/d + CWM | IS |
| Zhang et al. 2013 [39] | 63 | 14 | Y | N | NIHSS | XNJ 20 mL/d + CWM | IS |
| Zhou et al. 2005 [40] | 84 | 28 | Y | N | TER | XNJ 20 mL/d + CWM | ICH |
| No Bone Graft(n = 18) | Bone Graft(n = 29) | p value | |
| Pain severity, neck | 10.37 | 17.01 | 0.139 |
| Pain severity, arm | 7.22 | 6.44 | 0.628 |
| Functional disability | 18.78 | 21.01 | 0.877 |
| Psychological distress | 19.14 | 38.37 | 0.024 |
| Physical symptoms other than neck/arm pain | 12.96 | 18.07 | 0.344 |
| Healthcare utilisation | 24.44 | 22.07 | 0.415 |
| CA-AKI and RIFLE (n = 14) | CA-AKI (n = 9) | Only RIFLE (n = 31) | No CA-AKI (n = 95) | P value | |
| Age (years) | 73 [61–80] | 60 [48–67] | 68 [57–75] | 63 [55–71] | 0.08 |
| Sex (male/female) | 10/4 | 6/3 | 22/9 | 55/40 | 0.55 |
| ICU admission diagnosis (medical/surgical) | 11/3* | 7/2 | 29/2* | 77/18 | 0.41 |
| APACHE II score | 26 [20–30]* | 21 [17–28] | 18 [11–26] | 20 [14–23] | 0.04 |
| Weight (kg) | 80 [74–90] | 72 [60–88] | 84 [75–95]* | 75 [65–86] | 0.05 |
| Diabetes mellitus (%) | 4 (29) | 2 (22) | 9 (29) | 26 (27) | 0.98 |
| Nephrotoxic drugs | 5 (36) | 4 (44) | 14 (45) | 43 (45) | 0.92 |
| Cardiovascular risk factors (%) | 11 (79) | 6 (75) | 23 (74) | 65 (68) | 0.86 |
| Need for renal replacement (%) | 3 (21)* | 0 (0) | 3 (10)* | 0 (0) | <0.001 |
| Length of ICU stay (days) | 15 [12–18] | 10 [6–19] | 8 [5–21] | 12 [8–23] | 0.42 |
| ICU mortality (%) | 9 (64)* | 3 (33) | 9 (29) | 14 (15) | <0.001 |
| Haematocrit (%) | 32 .2 [29.2–40.2] | 28.5 [24.8–33.0] | 32.1 [26.9–40.8] | 30.6 [27.1–36.6] | 0.37 |
| Urea (mg/dL) | 50 [42–57] | 40 [31–54] | 40 [32–60] | 44 [32–58] | 0.57 |
| Creatinine (mg/dL) | 1.18 [1.00–1.40]* | 0.80 [0.45–1.10] | 0.98 [0.74–1.18] | 0.84 [0.62–1.08] | 0.03 |
| MDRD mL/min/1.73 m2 | 52 [46–71] | 80 [66–173] | 76 [52–92] | 82 [59–128] | 0.06 |
| Patients with creatinine ≥1.5 mg/dL | 1 (9 %) | 1 (14 %) | 4 (12.9 %) | 9 (9.5 %) | 0.93 |
| pH | 7.37 [7.30–7.42] | 7.42 [7.27–7.48] | 7.36 [7.30–7.42] | 7.42 [7.33–7.46] | 0.08 |
| BE (meq/L) | −2 [−6–2] | 1 [−3–7] | −1 [−4–0] | 1 [−2–5] | 0.08 |
| HCO3 (mmoL/L) | 22.9 [20.7–25.2] | 25.0 [23.5–31.4] | 24.0 [21.4–27.8] | 25.7 [22.0–30.3] | 0.29 |
| Na (mEq/L) | 140 [136–142] | 138 [134–140] | 139 [137–143] | 140 [137–143] | 0.19 |
| CPK (UI/mL) | 171 [91–854] | 203 [11–376] | 199 [49–604] | 117 [44–348] | 0.32 |
| CRP (mg/dL) | 15.6 [6.6–22.8] | 8.7 [3.6–17.3] | 7.4 [0.5–13.0] | 9.3 [2.5–18.4] | 0.13 |
| Lactate (mmol/L) | 1.0 [0.6–1.3] | 0.6 [0.5–0.9] | 0.4 [0.4–0.8] | 0.5 [0.5–0.7] | 0.11 |
| Nephropathy prevention (%) | 2 (14.2) | 0 (0) | 6 (19.4) | 21 (22) | 0.41 |
| Mean blood pressure before CM (mmHg) | 80 [64–94] | 70 [62–87] | 84 [74–91] | 81 [71–94] | 0.51 |
| Mean blood pressure at 6 h (mmHg) | 72 [66–88] | 72 [60–79] | 77 [68–88] | 81 [71–96] | 0.10 |
| Mean blood pressure at 12 h (mmHg) | 73 [64–74]* | 74 [68–80] | 74 [69–79] | 79 [70–88] | 0.02 |
| Mean blood pressure at day 1 (mmHg) | 71 [65–74]* | 76 [69–80] | 74 [68–83] | 85 [74–97] | <0.001 |
| Mean blood pressure at day 2 (mmHg) | 67 [64–77]* | 74 [68–77]* | 79 [71–86]* | 90 [79–98] | <0.001 |
| Mean blood pressure at day 3 (mmHg) | 76 [69–88]* | 71 [65–85]* | 77 [69–88]* | 88 [77–100] | <0.001 |
| CVP before CM (mmHg) | 10 [6–14] | 13 (11–14] | 10 [8–11] | 9 [5–11] | 0.14 |
| Maximal vasopressor dose on the day of CM (mcg/kg/min) | 0.12 [0.00–0.20]* vs no | 0.00 [0.00–0.15] | 0.04 [0.00–0.12] | 0.00 [0.00–0.00] | 0.004 |
| Maximal vasopressor dose, day 1 (mcg/kg/min) | 0.10 [0.05–0.40]* | 0.00 [0.00–0.06] | 0.00 [0.00–0.06] | 0.00 [0.00–0.00] | <0.001 |
| Maximal vasopressor dose, day 2 (mcg/kg/min) | 0.19 [0.00–0.40]* | 0.00 [0.00–0.04] | 0.00 [0.00–0.08] | 0.00 [0.00–0.00] | <0.001 |
| Maximal vasopressor dose, day 3 (mcg/kg/min) | 0.15 [0.00–0.30]* | 0.00 [0.00–0.09] | 0.00 [0.00–0.01] | 0.00 [0.00–0.00] | <0.001 |
| Doses of CM (ml/kg) | 1.54 [1.47–5.38] | 1.64 [1.33–1.85] | 1.53 [1.17–1.61] | 1.60 [1.21–1.85] | 0.32 |
| Diuretics on day of CM injection (%) | 1 (9 %) | 5 (71 %)* | 3 (12 %) | 7 (13 %) | <0.001 |
| Fluid intake, day 0 (ml) | 3015 [2200–3885] | 2495 [1774–3030] | 2600 [2058–3516] | 2830 [2124–3814] | 0.65 |
| Fluid intake, day 1 (ml) | 3371 [2125–4184] | 3371 [2125–4184] | 3085 [2005–3748] | 2865 [2098–3676] | 0.49 |
| Fluid intake, day 2 (ml) | 3069 [1786–3780] | 2090 [1730–3369] | 2810 [2186–3124] | 2550 [1949–3395] | 0.78 |
| Fluid intake, day 3 (ml) | 2640 [1738–3811] | 2750 [1820–3308] | 2285 [1628–3103] | 2465 [1690–3360] | 0.63 |
| Step | (min) Time | (W) Power | Temp. (°C) |
| 1 | 15 | 450 | 195 |
| 2 | 2.0 | 0 | 190 |
| 3 | 10 | 300 | 195 |
| 4 | 15 | 350 | 195 |
| Locality | Taxon | Site | Latitude | Longitude | Depth (m) | No. of tube fragments* |
| Antarctic | Sclerolinum sp. | Hook Ridge Site 1 | −62.1969 | −57.2975 | 1174 | 686* |
| Hook Ridge Site 2 | −62.1924 | −57.2783 | 1054 | 87* | ||
| Kemp Caldera | −59.6948 | −28.35 | 1432 | 95* | ||
| Arctic | S. contortum | Loki’s Castle CG2009 | 73.5662 | 8.1585 | 2357 | 33* |
| Loki’s Castle CG2008 | 73.5662–73.5683 | 8.1585–8.1563 | - | 8* | ||
| HMMV CG2010 | 71.9975–71.9999 | 14.7329–14.7316 | 1262 | 1* | ||
| HMMV VICKING 2006 | 72.0013 | 14.7225 | 1270 | 50+ | ||
| GoM | S. contortum | Walker Ridge WR269 | 26.6833 | −91.65 | 1954 | 21* |
| Data source | # of annotated exons | # of mapped exon | ||||
| Ensembl-rheMac2 | GASS | RefSeq -rheMac3 | Ensembl-rheMac2 | GASS | RefSeq-rheMac3 | |
| SRR299127 | 122,454 | 146,364 | 45,540 | 16,696(13.63%) | 24,001 (16.40%) | 9,341(20.51%) |
| SRR832953 | 108,940(88.96%) | 131,393(89.77%) | 43,398(95.29%) | |||
| SRR594464 | 94,115(76.85%) | 102,831(70.25%) | 40.291(88.47%) |
| ID | Gender | Age | TNM | Tumor sublocation | Chemotherapy | Volume (cm3) | Mean planned PG dose (Gy) | Xerostomia NTCP (%) [23, 24] | ||||
| CTV70 | ILP | CLP | ILP | CLP | ILP | CLP | ||||||
| 1 | M | 77 | T4N0 | Tonsil | Cetuximab | 45.2 | 52.1 | 48.6 | 30.2 | 31.1 | 27.1 | 28.9 |
| 2 | F | 61 | T2N2 | Base of tongue | CDDP | 26.3 | 31.1 | 27.5 | 31.4 | 26 | 29.7 | 19.1 |
| 3 | M | 70 | T3N2c | Oropharynx | CDDP | 181.5 | 24.9 | 20.7 | 37.9 | 31.1 | 45.1 | 29.1 |
| 4 | F | 66 | T2N2c | Oropharynx | Cetuximab | 107.2 | 27.8 | 23.4 | 32.9 | 27.9 | 33.1 | 22.5 |
| 5 | M | 57 | T3N0 | Velum | CDDP | 62.4 | 20.7 | 18 | 28.1 | 27.8 | 23 | 22.3 |
| 6 | M | 67 | T3N2c | Base of tongue | CDDP | 156.2 | 24.5 | 22.7 | 30.8 | 29.4 | 25.4 | 22.1 |
| 7 | M | 52 | T4N2a | Tonsil | Cetuximab | 165.1 | N/A | 21.6 | N/A | 28.7 | N/A | 24 |
| 8 | M | 67 | T4N1 | Base of tongue | CDDP | 139.3 | 22 | 19.3 | 30.7 | 29.2 | 28 | 25 |
| 9 | F | 65 | T3N3 | Base of tongue | CDDP | 237.5 | 23.9 | 20.2 | 42.4 | 31.1 | 56.1 | 29 |
| 10 | F | 65 | T4N3 | Oropharynx | CDDP | 257.9 | N/A | 24.5 | N/A | 35.2 | N/A | 38.5 |
| 11 | M | 50 | T4N2c | Oropharynx | CDDP | 434.5 | N/A | 17.7 | N/A | 36.3 | N/A | 41.1 |
| 12 | M | 53 | T3N0 | Base of tongue | CDDP | 14.4 | 16.6 | 23.3 | 41.3 | 24.2 | 53.6 | 16.3 |
| 13 | M | 73 | T3N2c | Oropharynx | Cetuximab | 147 | 29.4 | 29.2 | 54.6 | 32.2 | 82.1 | 31.4 |
| 14 | M | 56 | T3N0 | Epiglottic | Cetuximab | 14 | 22.8 | 29.2 | 19.7 | 9.2 | 10.3 | 2.7 |
| 15 | M | 75 | T2N2a | Oropharynx | Cetuximab | 76.3 | 20.3 | 22.4 | 29.4 | 29.1 | 25.6 | 25 |
| 16 | M | 57 | T3N0 | Oropharynx | CDDP | 46.5 | 23.8 | 31.2 | 32.1 | 31.2 | 29.3 | 31.3 |
| 17 | M | 64 | T3N2c | Epiglottic | CDDP | 109.8 | 23.5 | 15.6 | 39.6 | 17.3 | 49.3 | 7.8 |
| 18 | M | 55 | T1N2b | Tonsil | CDDP | 31 | 20.2 | 20.8 | 25.7 | 23.63 | 18.7 | 15.3 |
| 19 | M | 65 | T4N0 | Velum | CDDP | 10.1 | 23.7 | 25.3 | 28.6 | 28.2 | 24 | 23.2 |
| 20 | M | 56 | T4N2b | Pharyngeal wall | CDDP | 150 | 32.4 | 26.8 | 45 | 24.4 | 62.8 | 16.6 |
| Recalling and understanding (part A) | Applying (part B) | Total (part A & B) | ||||||||
| N | M | SD | Min–max | M | SD | Min–max | M | SD | Min–max | |
| Pre-test | 7 | 3.07 | 1.26 | 1–5 | 0.86 | 0.69 | 0–2 | 3.93 | 1.16 | 3–6 |
| Post-test | 7 | 5.07 | 1.15 | 4–7 | 1.57 | 0.98 | 0–3 | 6.64 | 1.27 | 5–9 |
| Follow-up | 7 | 5.14 | 1.56 | 4–8 | 1.29 | 0.95 | 0–3 | 6.43 | 2.16 | 5–11 |
| Farm | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| nr. of samples | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| nr. of PRM/sample | 50 | 50-100 | 100 | 50 | 50 | 50 | 50-100 | 50-100 |
| layers on the farm | No | Yes | Yes | Yes | Yes | Yes | Yes | No |
| nr. of layers on the farm | 0* | 6,000 | 12,000 | 15,000 | 20,000 | 18,000 | 16,000 | 0 |
| Salmonella PCR | + | + | - | - | - | - | - | + |
| Percentage agree or strongly agree (n = 37) | |
| Knowledge translation was hampered by a lack of incentives for KTE activities within organisations that conduct health systems and policy research (HSPR) | 38 |
| Organisations that conduct HSPR made available financial and human resources to assist with KTE activities | 24 |
| Organisations that conduct HSPR were not seen as a credible source of research | 14 |
| 2012 (N = 18,558) | 2006 (N = 12,443) | 2000 (N = 9,049) | 1994 (N = 8,864) | |||||
| Age group | Male (%) | Female (%) | Male (%) | Female (%) | Male (%) | Female (%) | Male (%) | Female (%) |
| <30 | 13.59 | 15.31 | 15.48 | 16.71 | 15.05 | 16.99 | 13.47 | 14.68 |
| 31–44 | 11.26 | 13.46 | 10.70 | 12.43 | 11.40 | 13.08 | 13.19 | 14.77 |
| 45–60 | 10.56 | 14.65 | 10.70 | 14.66 | 9.15 | 12.06 | 10.1 | 12.92 |
| 61–74 | 4.89 | 9.45 | 4.40 | 8.71 | 6.27 | 10.86 | 6.0 | 9.7 |
| ≥75 | 1.79 | 5.05 | 1.49 | 4.71 | 1.12 | 4.02 | 1.12 | 4.06 |
| Total (%) | 42.08 | 57.92 | 42.78 | 57.22 | 42.99 | 57.01 | 43.87 | 56.13 |
| Household size (mean) | 4.26** | 4.35^ | 4.04^^ | 3.41* | ||||
| Working status (employed %) | 56.16 | 54.25 | 49.52 | 54.66 | ||||
| Adult equivalent household mean income (roubles) per montha | ||||||||
| Male (head) | 7,690.00 | 5,290.00 | 2,730.00 | 4,280.00 | ||||
| Female (head) | 7,360.00 | 4,990.00 | 2,510.00 | 4,080.00 | ||||
| Asset-holding (%) | ||||||||
| All durable assetsb but no car or tractor | 88.23 | 65.19 | 77.74 | 68.19 | ||||
| All durable assets with car and/or tractor | 11.42 | 30.92 | 19.31 | 29.28 | ||||
| Positive wealth groupc (%) | 89.87 | 86.64 | 90.71 | 92.73 | ||||
| Living standard (access to all publiclyprovided services) % | 95.25 | 91.69 | 86.81 | 83.36 | ||||
| Geography of residence (%) | ||||||||
| Urban | 68.06 | 68.79 | 65.12 | 70.23 | ||||
| Rural | 31.94 | 31.21 | 34.88 | 29.77 |
| ID code | Sex | Age (Years) | Time in facility (Years) | Staff position | |||
| Dyads | |||||||
| Dyad 1 | |||||||
| Resident | R1 | F | 84 | 6 | |||
| Family | F1 | F | 55 | ||||
| Dyad 2 | |||||||
| Resident | R2 | F | 79 | 1.5 | |||
| Family | F2 | F | 56 | ||||
| Dyad 3 | |||||||
| Resident | R3 | M | 89 | 1 | |||
| Family | F3 | F | 43 | ||||
| Dyad 4 | |||||||
| Resident | R4 | F | 84 | 2 | |||
| Family | F4 | M | 53 | ||||
| Dyad 5 | |||||||
| Resident | R5 | F | 89 | 3 | |||
| Family | F5(a) | F | 57 | ||||
| Family | F5(b) | M | 62 | ||||
| Staff | |||||||
| Staff 1 | S1 | F | 54 | Lifestyle manager | |||
| Staff 2 | S2 | F | 41 | Personal Care Worker | |||
| Staff 3 | S3 | F | 50 | Care Manager | |||
| Staff 4 | S4 | F | - | Personal Care Worker | |||
| Staff 5 | S5 | F | 60 | Enrolled Nurse | |||
| Staff 6 | S6 | F | 52 | Diversional Therapist | |||
| Staff 7 | S7 | F | 30 | Endorsed Enrolled Nurse |
| Mitochondrial abnormality | MS | CFS | PD | AUT | MDD | Schiz | BPD |
| Ultrastructural abnormalities in mitochondria | + | ++ | + | + | + | +++ | + |
| Evidence to shift in energy production via glycolysis | + | ++ | ++ | ++ | ++ | ++ | |
| Mitochondrial dysfunction in peripheral immune cells | + | ++ | ++ | ++ | ++ | ++ | + |
| Mitochondria DNA damage | + | ++ | |||||
| Damage to the electron transport chain | ++ | +++ | + | ++ | + | ||
| High lactate in brain or cerebrospinal fluid | + | + | + | + | + | ++ | + |
| Bioenergetic impairment Skeletal muscle | +++ | + | |||||
| Decreased mitochondrial membrane potential | + | + |
| T1 | T2 | T3 | T4 | T5 | |
| Case 1 | |||||
| SNA | 82.7 | 82.6 | 81.3 | 81.7 | 81.8 |
| SNB | 68.0 | 68.7 | 70.1 | 70.2 | 71.4 |
| ANB | 14.7 | 13.8 | 11.3 | 11.5 | 10.4 |
| SN-Pog | 65.8 | 70.1 | 69.1 | 69.1 | 70.6 |
| SN-Mp | 60.2 | 51.1 | 52.3 | 52.1 | 54.0 |
| SN-Occ | 26.3 | 27.1 | 27.3 | 27.8 | 32.3 |
| Interincisal | 115.6 | 115.5 | 123.1 | 126.3 | 129.6 |
| L1-Mp | 89.0 | 97.5 | 92.9 | 90.8 | 91.2 |
| Case 2 | |||||
| SNA | 74.7 | 74.2 | 74.5 | 74.1 | 73.7 |
| SNB | 63.9 | 62.6 | 66.4 | 67.6 | 70.3 |
| ANB | 10.9 | 11.6 | 8.1 | 6.5 | 3.3 |
| SN-Pog | 64.4 | 66.6 | 66.8 | 67.7 | 71.0 |
| SN-Mp | 53.4 | 52.1 | 51.0 | 49.0 | 49.1 |
| SN-Occ | 19.6 | 29.0 | 29.3 | 24.4 | 23.5 |
| Interincisal | 99.9 | 122.3 | 120.4 | 105.3 | 117.3 |
| L1-Mp | 95.8 | 101.0 | 100.4 | 95.7 | 93.2 |
| Case 3 | |||||
| SNA | 86.7 | 86.1 | 86.3 | 86.2 | 86.0 |
| SNB | 72.0 | 70.0 | 74.7 | 73.8 | 77.2 |
| ANB | 14.7 | 16.1 | 11.6 | 12.4 | 8.8 |
| SN-Pog | 69.4 | 72.5 | 73.2 | 72.6 | 76.4 |
| SN-Mp | 54.5 | 52.4 | 50.1 | 52.0 | 48.6 |
| SN-Occ | 18.4 | 24.3 | 23.5 | 24.0 | 25.3 |
| Interincisal | 106.2 | 113.5 | 115.2 | 117.4 | 115.4 |
| L1-Mp | 95.0 | 97.3 | 93.0 | 91.4 | 96.4 |
| Age/Gender | Experience in Using EPW | Type of Disabilities | ||
| Motor | Cognition | |||
| User I | 60-year-old male | Yes | Lower body amputation by diabetes | Low cognition/reflexes by dementia |
| User II | 48-year-old female | Yes | Amyotrophic lateral sclerosis | - |
| User III | 32-year-old female | Yes | Cerebral palsy | - |
| User IV | 73-year-old male | Yes | Lack of strength | Weak senile dementia |
| User V | 28-year-old female | Yes | Spinal cord injury | - |
| Group | EPG | Egg reduction rate (%) |
| PBS (n = 5) | 76.60 ± 7.427 | – |
| B.s-CotC (n = 5) | 74.80 ± 8.194 | – |
| Oral (n = 5)a | 39.60 ± 3.945** | 48.30 |
| Injected (n = 5)b | 37.40 ± 3.647** | 51.20 |
| Diagnosis | 12 to 14 years old | 15 to 17 years old |
| (n = 9) | (n = 7) | |
| ADHD | 3 | 1 |
| ODD | 2 | |
| MDD | 2 | |
| PTSD | 1 | |
| Social phobia | 1 | |
| ADHD/DBD | 2 | |
| ADHD/ODD | 1 | |
| ADHD/MDD | 2 | |
| ADHD/PTSD/ODD | 1 |
| Characteristic | Classification of chronic malnutrition | Test statistic | |
| Normal % [95 % confidence interval] | Stunted % [95 % confidence interval] | ||
| Religion of mother | |||
| Christianity | 81.8 [CI: 78.7 – 84.6] | 18.2 [CI: 15.4 – 21.3] | χ2 = 9.4 p = 0.038 |
| Islam | 76.2 [CI: 72.3 – 79.7] | 23.8 [CI: 20.3 – 27.7] | |
| ATR | 75.4 [CI: 68.5 – 81.2] | 24.6 [CI: 18.8 – 31.5] | |
| Age of child (months) | |||
| 6-8 | 90.6 [CI: 86.2– 93.7] | 9.4 [CI: 6.3 – 13.8] | χ2 = 31.0 p <0.001 |
| 9-23 | 76.3 [CI: 73.6– 78.7] | 23.7 [CI: 21.3 – 26.4] | |
| Gender of child | |||
| Male | 75.5 [CI: 72.4 – 78.3] | 24.5 [CI: 21.7 – 27.6] | χ2 = 11.5 , p = 0.001 |
| Female | 81.7 [CI: 78.6 – 84.5] | 18.3 [CI: 15.5 – 21.4] | |
| Characteristic | Classification of chronic malnutrition | Test statistic | |
| Normal | Stunted | ||
| Household wealth index | |||
| Low | 77.9 [CI: 75.4 – 80.2] | 22.1 [CI: 19.8 – 24.6] | χ2 = 5.5 , p = 0.01 |
| High | 87.5 [CI: 80.2 – 92.4] | 12.5 [CI: 7.6 – 19.8] | |
| Salt Iodine Content | χ2 = 8.7 , p = 0.03 | ||
| 0 ppm | 76.6 [CI: 73.4 – 79.6] | 23.4 [CI: 20.4 – 26.6] | |
| Less than 15 ppm | 78.0 [CI: 74.2 – 81.4] | 22.0 [CI: 18.6 – 25.8] | |
| ≥15 ppm | 84.6 [CI: 79.3 – 88.7] | 15.4 [CI: 11.3 – 20.7] | |
| CWC Attendance | |||
| 1-2 | 76.3 [CI: 72.1 – 80.0] | 23.7 [CI: 20.0 – 27.9] | χ2 = 6.7 , p = 0.03 |
| 3-4 | 80.6 [CI: 77.5 – 83.4] | 19.4 [CI: 16.6 – 22.5] | |
| 4+ | 94.7[CI: 80.8 – 98.7] | 5.3[CI: 1.3 – 19.2] | |
| Maternal Educational level | |||
| None | 77.2 [CI: 74.4 – 79.8] | 22.8 [CI: 20.2 – 25.6] | χ2 = 5.6 , p = 0.04 |
| Low | 81.2 [CI: 77.1 – 84.7] | 18.8 [CI: 15.3 – 22.9] | |
| High | 85.3 [CI: 77.5 – 90.7] | 14.7 [CI: 9.3 – 22.5] | |
| ANC Attendance | |||
| <4 times | 72.2 [CI: 66.9 – 76.9] | 27.8 [CI: 23.1 – 33.1] | χ2 = 12.3 , p = 0.003 |
| ≥4 times | 80.3 [CI: 77.4 – 82.8] | 19.7 [CI: 17.2 – 22.6] | |
| Timing of first complementary food at 6 months | |||
| No | 748 (77.0) | 224 (23.0) | χ2 = 5.4 , p = 0.02 |
| Yes | 752 (81.3) | 173 (18.7) |
| Genus/subgenus | Species | No. of unique conotoxin precursors | No. of unique mature toxins | No. of gene superfamilies | No. of cysteine frameworks | Most abundant gene superfamily and frequencya | Main diet summarized from [29, 42] |
| Puncticulis | arenatus | 326 | 256 | 36 | 31 | O1, (20.3 %) | eunicids, nereids, capitellids |
| Californiconus | californicus | 185 | 164 | 30 | 21 | O1, (20.1 %) | molluscs, polychaetes, fish |
| Virroconus | coronatus | 331 | 286 | 32 | 30 | O1, (19.6 %) | eunicids, capitellids |
| Virroconus | ebraeus | 75 | 69 | 27 | 23 | M, (31.9 %) | eunicids, nereids |
| Stephanoconus | imperialis | 70 | 66 | 20 | 19 | P, (16.7 %) | amphinomids |
| Lividoconus | lividus | 244 | 204 | 31 | 25 | O1, (10.7 %) | enteropneusts, terebellids |
| Conus | marmoreus | 81 | 69 | 14 | 16 | M, (26.1 %) | gastropods |
| Lividoconus | quercinus | 97 | 78 | 25 | 23 | O1, (15.4 %) | enteropneusts, sabellids |
| Rhizoconus | rattus | 102 | 89 | 28 | 30 | con-ikot-ikot, (18 %) | eunicids |
| Harmoniconus | sponsalis | 401 | 338 | 35 | 29 | O1, (28.1 %) | eunicids, nereids |
| Strategoconus | varius | 198 | 168 | 29 | 24 | M, (10.7 %) | polychaetes |
| Virgiconus | Virgo | 113 | 78 | 25 | 21 | O1, (24.4 %) | terebellids |
| Customers-Suppliers vignettes | Employees-Suppliers vignettes | Employees-Environment vignettes | ||||||||||
| Effect | SE | LL95%CI | UL95%CI | Effect | SE | LL95%CI | UL95%CI | Effect | SE | LL95%CI | UL95%CI | |
| −1SD | 0.20 | 0.09 | 0.06 | 0.40 | 0.27 | 0.18 | −0.07 | 0.63 | −0.21 | 0.100 | −0.46 | −0.06 |
| Mean | 0.37 | 0.08 | 0.22 | 0.55 | 0.46 | 0.10 | 0.27 | 0.68 | −0.15 | 0.07 | −0.32 | −0.04 |
| +1SD | 0.59 | 0.14 | 0.36 | 0.91 | 0.59 | 0.17 | 0.30 | 0.99 | −0.05 | 0.10 | −0.29 | 0.14 |
| Symptoms | EG | YG | P |
| Heartburn | 1.6 ± 0.89 | 2.8 ± 0.76 | <0.05 |
| Acid regurgitation | 1.6 ± 0.98 | 2.4 ± 0.91 | <0.05 |
| Solid food dysphagia | 1.7 ± 0.78 | 0.6 ± 0.22 | <0.05 |
| Chest pain | 1.7 ± 0.84 | 1.5 ± 0.89 | >0.05 |
| Respiratory complication | 1.9 ± 1.06 | 1.1 ± 0.47 | <0.05 |
| Norm Method | % Correct | Sensitivity | Specificity | Between-mean array correlation (after normalization) | Between array coefficient of variation (after normalization) | Confounding index (after normalization) |
| SGM-Log2 | 0.709 | 0.411 | 0.782 | 0.931 | 0.105 | 0.985 |
| Quantile 75 | 0.511 | 0.647 | 0.478 | 0.996 | 0.807 | 0.989 |
| Mean | 0.488 | 0.705 | 0.434 | 0.993 | 0 | 0.989 |
| Minimum Mean | 0.488 | 0.705 | 0.434 | 0.993 | 0 | 0.989 |
| Sum | 0.488 | 0.705 | 0.434 | 0.993 | 0 | 0.989 |
| Z Trans | 0.476 | 0.647 | 0.434 | 0.992 | −30.447 | 0.989 |
| 5%–95% Adjust | 0.465 | 0.882 | 0.362 | 0.991 | 0.252 | 0.989 |
| Global Mean Adjust | 0.465 | 0.705 | 0.405 | 0.902 | 0 | 0.989 |
| Max1, Min0 | 0.465 | 0.882 | 0.362 | 0.991 | 0.258 | 0.989 |
| Quantile 90 | 0.465 | 0.647 | 0.42 | 0.991 | 0.265 | 0.989 |
| Quantile 95 | 0.465 | 0.647 | 0.42 | 0.991 | 0.265 | 0.989 |
| Quantile 99 | 0.465 | 0.647 | 0.42 | 0.991 | 0.265 | 0.989 |
| SGM-Square Root Trans | 0.441 | 0.941 | 0.318 | 0.961 | 0.372 | 0.988 |
| No Norm | 0.43 | 1 | 0.289 | 0.902 | 0.862 | 0.989 |
| Trimmed Mean 10–90 | 0.418 | 0.764 | 0.333 | 0.987 | 0.767 | 0.989 |
| Trimmed Mean 1–99 | 0.418 | 0.764 | 0.333 | 0.987 | 0.767 | 0.989 |
| Trimmed Mean 5–95 | 0.418 | 0.764 | 0.333 | 0.987 | 0.767 | 0.989 |
| Median Mean | 0.406 | 1 | 0.26 | 0.557 | 2.067 | 0.989 |
| Quantile 25 | 0.406 | 1 | 0.26 | −0.721 | −10.2 | 1.018 |
| SGM-Cond Log Trans | 0.36 | 1 | 0.202 | 0.966 | 0.886 | 1.026 |
| Quantile 50 | 0.36 | 0.941 | 0.217 | 0.622 | 2.417 | 0.989 |
| Trimmed Mean 25–75 | 0.36 | 0.941 | 0.217 | 0.768 | 1.915 | 0.989 |
| Median | 0.348 | 0.941 | 0.202 | 0.694 | 2.2 | 0.989 |
| Cases | Deaths | |
| Cervical cancer | 1344 | 492 |
| CIN2+ | 4528 | – |
| CIN1 | 2532 | – |
| Vaginal cancer | 14 | 4 |
| Vulvar cancer | 20 | 6 |
| Anal cancer females | 242 | 75 |
| Anal cancer males | 79 | 34 |
| Genital warts females | 33,091 | – |
| Genital warts males | 24,258 | – |
| Total | 66,108 | 611 |
| Herd-level performance indicators | Semesters | |||||||
| Jan-Jun 2009 | Jul-Dec 2009 | Jan-Jun 2010 | Jul-Dec 2010 | Jan-Jun 2011 | Jul-Dec 2011 | Jan-Jun 2012 | ||
| (n = 710) | (n = 620) | (n = 726) | (n = 636) | (n = 747) | (n = 632) | (n = 591) | ||
| 1 | Average daily milk production per cow (L/day/cow) | 29.08 (±5.46) | 27.44 (±4.54) | 29.23 (±4.52) | 27.05 (±4.57) | 29.16 (±4.69) | 27.33 (±4.60) | 29.32 (±4.69) |
| 2 | Average milk protein content (%) | 3.43 (±0.19) | 3.43 (±0.16) | 3.39 (±0.14) | 3.4 (±0.28) | 3.36 (±0.14) | 3.43 (±0.18) | 3.42 (±0.15) |
| 3 | Average milk fat content (%) | 3.65 (±0.33) | 3.73 (±0.32) | 3.67 (±0.31) | 3.71 (±0.43) | 3.61 (±0.32) | 3.68 (±0.32) | 3.72 (±0.30) |
| 4 | Average number of lactations per cow (no.) | 2.37 (±0.30) | 2.36 (±0.30) | 2.34 (±0.28) | 2.34 (±0.27) | 2.33 (±0.27) | 2.33 (±0.28) | 2.33 (±0.28) |
| 5 | Average lactation length (days) | 200.75 (±34.37) | 203.41 (±37.20) | 203.42 (±38.30) | 203.83 (±38.73) | 198.8 (±33.28) | 195.03 (±32.89) | 198.89 (±31.81) |
| 6 | Average calving-to-conception interval (days) | 163.65 (±34.65) | 167.28 (±38.08) | 164.03 (±38.36) | 166.25 (±38.95) | 159.34 (±34.71) | 158.44 (±34.60) | 157.5 (±34.46) |
| 7 | Average number of inseminations per pregnancy (no.) | 2.38 (±0.63) | 2.36 (±0.66) | 2.43 (±0.74) | 2.47 (±0.76) | 2.39 (±0.78) | 2.34 (±0.71) | 2.36 (±0.69) |
| 8 | Average number of inseminations per pregnancy in primiparous cows (no.) | 2.36 (±0.83) | 2.36 (±0.89) | 2.44 (±0.88) | 2.48 (±0.98) | 2.42 (±0.95) | 2.32 (±0.87) | 2.39 (±0.84) |
| 9 | Average number of inseminations per pregnancy in multiparous cows (no.) | 2.39 (±0.71) | 2.35 (±0.67) | 2.42 (±0.81) | 2.48 (±0.84) | 2.37 (±0.86) | 2.35 (±0.77) | 2.33 (±0.77) |
| 10 | Average number of inseminations per pregnancy leading to a registered newborn (no.)a | 0.66 (±0.58) | 0.81 (±0.73) | 0.67 (±0.64) | 0.79 (±0.75) | 0.67 (±0.63) | 0.76 (±0.74) | 0.65 (±0.61) |
| 11 | Total number of registered newborns (no.)b | 5.04 (±4.18) | 4.47 (±3.69) | 5.34(±4.37) | 4.74 (±3.80) | 5.34 (±4.38) | 4.71 (±4.22) | 4.98 (±3.69) |
| 12 | Number of cows per farm (no.) | 70.27 (±45.49) | 70.54 (±48.23) | 70.67 (±48.17) | 71.52 (±50.00) | 72.72 (±49.51) | 73.73 (±52.68) | 64.65 (±22.36) |
| 13 | Cows’ average age (months) | 46.19 (±5.98) | 46.66 (±6.67) | 46.61 (±6.38) | 46.73 (±5.98) | 46.69 (±5.16) | 46.77 (±5.18) | 46.85 (±5.85) |
| 14 | Average length of dry period (days) | 76.78 (±59.67) | 76.03 (±66.95) | 74.16 (±41.76) | 74.15 (±38.01) | 70.1 (±20.19) | 67.96 (±13.57) | 67.09 (±14.23) |
| 15 | Proportion of pregnant primiparous cows (%) | 44.63 (±14.18) | 45.74 (±15.34) | 43.79 (±15.59) | 45.96 (±15.99) | 46.53 (±15.82) | 46.48 (±16.22) | 44.84 (±16.07) |
| 16 | Proportion of pregnant multiparous cows (%) | 41.66 (±13.53) | 42.21 (±14.07) | 40.4 (±14.93) | 43.13 (±14.41) | 42.62 (±13.76) | 42.42 (±14.75) | 40.72 (±14.92) |
| 17 | Proportion of artificial inseminations (%) | 91.67 (±20.39) | 91.48 (±21.35) | 91.61 (±22.42) | 89.95 (±25.04) | 89.02 (±26.32) | 89.62 (±25.56) | 89.65 (±25.39) |
| 18 | Proportion of culled cows (%) | 2.54 (±3.09) | 3.04 (±3.18) | 2.27 (±2.29) | 2.83 (±2.55) | 2.37 (±2.40) | 2.85 (±2.74) | 2.31 (±2.35) |
| 19 | Cows’ average age at first delivery (months) | 27.15 (±4.04) | 27.87 (±6.67) | 28.17 (±6.71) | 31.32 (±39.57) | 21.07 (±12.97) | 20.9 (±12.00) | 19.25 (±12.88) |
| Drink tea | Term (n) | Preterm (n = 1019) | Moderate preterm (n = 833) | Very preterm (n = 186) | Medically indicated (n = 338) | Spontaneous (n = 681) | |||||
| No. | OR(95 % CI) | No. | OR(95 % CI) | No. | OR(95 % CI) | No. | OR(95 % CI) | No. | OR(95 % CI) | ||
| Never | 8403 | 900 | 1 | 733 | 1 | 167 | 1 | 295 | 1 | 605 | 1 |
| Ever | 757 | 119 | 1.36(1.09–1.69) | 100 | 1.41(1.12–1.79) | 19 | 1.05(0.64–1.72) | 43 | 1.24(0.85–1.83) | 76 | 1.41(1.09–1.83) |
| Before pregnancy | 680 | 107 | 1.39(1.10–1.75) | 91 | 1.47(1.15–1.87) | 16 | 1.01(0.59–1.73) | 36 | 1.24(0.82–1.88) | 71 | 1.49(1.14–1.94) |
| During pregnancy ever | 377 | 69 | 1.38(1.04–1.83) | 55 | 1.37(1.00–1.87) | 14 | 1.34(0.75–2.39) | 33 | 1.76(1.13–2.76) | 36 | 1.19(0.83–1.72) |
| Before pregnancy only | 380 | 50 | 1.33(0.97–1.83) | 45 | 1.47(1.05–2.05) | 5 | 0.66(0.27–1.65) | 10 | 0.62(0.30–1.28) | 40 | 1.67(1.18–2.36) |
| Before and during pregnancy | 300 | 57 | 1.45(1.06–1.98) | 46 | 1.47(1.05–2.06) | 11 | 1.35(0.71–2.58) | 26 | 1.92(1.17–3.15) | 31 | 1.29(0.87–1.92) |
| During pregnancy only | 77 | 12 | 1.10(0.57–2.14) | 9 | 1.01(0.48–2.13) | 3 | 1.30(0.38–4.42) | 7 | 1.25(0.48–3.28) | 5 | 0.78(0.30–2.03) |
| Antimicrobial agents | Breakpoint for resistance (mg/L) | % Resistant | Range (mg/L) | MIC50 (mg/L) | MIC90 (mg/L) |
| Imipenem | ≥8 | 100 | 8–128 | 32 | 64 |
| Meropenem | ≥8 | 99 | 4–128 | 32 | 64 |
| Amikacin | ≥64 | 87 | 0.5 – > 512 | >512 | >512 |
| Ciprofloxacin | ≥4 | 100 | 32 – > 512 | >512 | >512 |
| Colistin | ≥4 | 5 | 0.125–16 | 0.5 | 1 |
| Tigecycline | - | - | ≤0.125–16 | 1 | 8 |
| Year | 2006 | 2007 | 2008 | 2009 |
| Export | 9,762 | 9,975 | 9,630 | 9,496 |
| Import | 7,288 | 6,956 | 5,763 | 4,683 |
| Net export | 2,474 | 3,019 | 3,867 | 4,813 |
| Cohorta | Claimantsb | |||||
| Odd Ratio* | 95 % Confidence Interval | Odd Ratio* | 95 % Confidence Interval | |||
| Top cost percentile during 2010 | ||||||
| Top 1 Percentile | 0.99 | 0.84 | 1.15 | 1.66c | 1.42 | 1.94 |
| Top 5 Percentile | 0.8c | 0.74 | 0.85 | 1.34c | 1.25 | 1.43 |
| Incremental Effect on PMPY | -$323.08 | -$345.54 | -$278.07 | $494.72 | $461.63 | $526.01 |
| Top cost percentile during 2011 | ||||||
| Top 1 Percentile | 1.17c | 1.01 | 1.37 | 1.80c | 1.55 | 2.10 |
| Top 5 Percentile | 0.96 | 0.89 | 1.02 | 1.47c | 1.37 | 1.57 |
| Incremental Effect on PMPY | -$88.22 | -$133.59 | -$42.84 | $831.80 | $763.38 | $879.21 |
| Top cost percentile during 2010 and 2011 combined | ||||||
| Top 1 Percentile | 1.11 | 0.97 | 1.27 | 1.60c | 1.40 | 1.84 |
| Top 5 Percentile | 0.89c | 0.84 | 0.95 | 1.29c | 1.25 | 1.41 |
| Incremental Effect on PMPY | -$411.44 | -$491.53 | -$348.55 | $647.10 | $570.87 | $703.56 |
| Mean of self-monitored FPG values from preceding 3 days | Adjust of nocturnal basal insulin dosage (IU/day) |
| <90 mg/dL (5.0 mmol/L) | −1 |
| 90-130 mg/dL (5.0-7.2 mmol/L) | No adjustment |
| >130 mg/dL (7.2 mmol/L) | +2 |
| Mean of self-monitored pre-dinner values from preceding 3 days | Adjust of diurnal basal insulin dosage (IU/day) |
| <90 mg/dL (5.0 mmol/L) | −2 |
| 90-130 mg/dL (5.0-7.2 mmol/L) | No adjustment |
| >130 mg/dL (7.2 mmol/L) | +2 |
| Mean of self-monitored postprandial values from preceding 3 days | Adjust of prandial insulin dosage (IU/day) |
| <90 mg/dL (5.0 mmol/L) | −1 |
| 90-180 mg/dL (5.0-10.0 mmol/L) | No adjustment |
| >180 mg/dL (10.0 mmol/L) | +1 |
| EV71 vaccine candidates | Adjuvant formulated | Total IgG titers | Western blot | Virus neutralization titer | ||||
| VP1-43 | VP2-28 | rVP1 | rVP2 | rVP3 | EV71 (B4 E59) | CVA16 (N5079) | ||
| VP1-43 | Alum | 1/3200 | ++ | <1/8 | <1/8 | |||
| VP1-43 | CFA/IFA | 1/6400 | +++ | 1/32 | <1/8 | |||
| VP2-28 | Alum | 1/200 | − | <1/8 | <1/8 | |||
| VP2-28 | CFA/IFA | 1/1600 | + | <1/8 | <1/8 | |||
| VP1-43/VP2-28 | CFA/IFA | 1/6400 | 1/800 | +++ | + | 1/32 | <1/8 | |
| rVP1 | Alum | 1/6400 | +++ | <1/8 | <1/8 | |||
| rVP1 | CFA/IFA | 1/12800 | +++ | 1/128 | <1/8 | |||
| rVP2 | Alum | <1/100 | +++ | <1/8 | <1/8 | |||
| rVP2 | CFA/IFA | 1/200 | +++ | 1/8 | <1/8 | |||
| rVP3 | Alum | ++ | <1/8 | <1/8 | ||||
| rVP3 | CFA/IFA | +++ | 1/8 | <1/8 | ||||
| EV71-VLP | PBS | 1/1600 | <1/100 | ++ | ++ | ++ | 1/64 | <1/8 |
| EV71-VLP | Alum | 1/6400 | <1/100 | ++ | ++ | ++ | 1/128 | <1/8 |
| EV71-VLP | CFA/IFA | 1/12800 | <1/100 | +++ | +++ | ++ | 1/160 | <1/8 |
| 2 μg of inactivated | ||||||||
| EV71 virion | PBS | 1/6400 | <1/100 | +++ | +++ | ++ | 1/64 | <1/8 |
| EV71 virion | Alum | 1/12800 | <1/100 | +++ | +++ | ++ | 1/640 | <1/8 |
| 5 μg of inactivated | ||||||||
| EV71 virion | Alum | 1/12800 | <1/100 | +++ | +++ | +++ | 1/2560 | <1/8 |
| System | Prosthetic crown | |
| 8 mm | 13 mm | |
| Neodent | 31.43 ±15.44Aa | 28.13 ± 12.66Aa |
| Bicon | 26.18 ± 13.00Ba | 30.92 ± 14.89Aa |
| Number of patients (percentage of sample in parentheses) | |
| Age | |
| <=60 years | 1743 (65.1%) |
| >60 years | 936 (34.9%) |
| Gender | |
| Female | 1439 (53.7%) |
| Male | 1240 (46.3%) |
| Body mass index | |
| <=25 kg/m2 | 309 (11.5%) |
| >25 to < =30 kg/m2 | 1003 (37.4%) |
| = > 30 kg/m2 | 1367 (51.0%) |
| Smoking status | |
| Current smoker | 464 (17.3%) |
| Ex-smoker | 301 (11.2%) |
| Non-smoker | 1914 (71.4%) |
| Country | |
| Eastern European countries | 1763 (65.8%) |
| Western-central European countries | 916 (34.2%) |
| miR-155 copy no. | Age | DD | ESR | CRP | TJS | SJS | |
| Age | −0.239 | ||||||
| (−0.58, 0.18) | |||||||
| 0.260 | |||||||
| DD | −0.064 | 0.464 | |||||
| (−0.45, 0.34) | (0.07, 0.73) | ||||||
| 0.766 | 0.022 | ||||||
| ESR | 0.546 | −0.136 | −0.108 | ||||
| (0.18, 0.77) | (−0.51, 0.28) | (−0.49, 0.30) | |||||
| 0.006 | 0.526 | 0.615 | |||||
| CRP | 0.186 | −0.169 | −0.095 | 0.672 | |||
| (−0.23, 0.54) | (−0.53, 0.25) | (−0.48, 0.32) | (0.36, 0.84) | ||||
| 0.384 | 0.429 | 0.659 | 0.000 | ||||
| TJS | 0.631 | −0.035 | 0.127 | 0.261 | 0.197 | ||
| (0.30, 0.82) | (−0.43, 0.37) | (−0.29, 0.50) | (−0.15, 0.60) | (−0.22, 0.55) | |||
| 0.001 | 0.872 | 0.555 | 0.218 | 0.356 | |||
| SJS | 0.503 | −0.232 | −0.301 | 0.565 | 0.472 | 0.529 | |
| (0.12, 0.75) | (−0.58, 0.18) | (−0.62, 0.11) | (0.21, 0.78) | (0.08, 0.73) | (0.16, 0.76) | ||
| 0.012 | 0.276 | 0.152 | 0.004 | 0.020 | |||
| DAS28 | 0.728 | −0.193 | −0.055 | 0.759 | 0.600 | 0.781 | 0.803 |
| (0.46, 0.87) | (−0.55, 0.22) | (−0.44, 0.35) | (0.51, 0.88) | (0.26, 0.80) | (0.55, 0.90) | (0.59, 0.93) | |
| 0.000 | 0.366 | 0.797 | 0.000 | 0.002 | 0.000 | 0.000 |
| Intrathecal morphine (n = 50) | Epidural analgesia (n = 50) | P | |
| Patients with complications | 8 (16%) | 11 (22%) | .59 |
| Biloma | 1 (2%) | 1 (2%) | .89 |
| Hepatic insufficiency | 2 (4%) | 3 (6%) | .88 |
| Wound infection | 3 (6%) | 4 (8%) | .73 |
| Pleural effusion | 1 (2%) | 2 (4%) | .78 |
| Pneumonia | — | 1 (2%) | — |
| Urinary tract infection | 1 (2%) | — | — |
| Positive likelihood ratio (95% CI) | Negative likelihood ratio (95% CI) | |
| Serial ECG & ST monitoring N = 690 | 5.4 (3.0 to 9.8) | 0.801 (0.696 to 0.922) |
| Initial CK-MB(mass) N = 687 | 20.9 (11.3 to 38.5) | 0.579 (0.464 to 0.722) |
| Delayed CK-MB(mass) N = 601 | 31.7 (17.0 to 58.9) | 0.373 (0.261 to 0.534) |
| Delta CK-MB(mass) N = 601 | 153.1 (37.6 to 623.5) | 0.444 (0.327 to 0.602) |
| Any positive CK-MB(mass) N = 601 | 28.1 (16.9 to 46.7) | 0.291 (0.194 to 0.435) |
| Troponin T > = 0.1 ng/ml N = 686 | ~25* | ~0* |
| Troponin T > = 0.03 ng/ml N = 686 | 281.5 (70.4 to 1126) | 0.104 (0.049 to 0.221) |
| Molar ratio | Vitamin K recovery (%) | Lipid recovery (%) | Loading capacity (w %) | Size (nm) |
| 0.22 | 98.4 ± 2.8 | 96.3 ± 0.4 | 5.0 ± 0.2 | 11.0 ± 1.4 |
| 0.44 | 91.3 ± 2.0 | 89.5 ± 4.1 | 9.9 ± 0.2 | 19 ± 6 |
| 0.88 | 42.6 ± 1.5 | 41.1 ± 3.9 | 18.4 ± 0.5 | 44 ± 5 |
| TGC | CGC | Overall event rates (%) | M-H pooled RR | Heterogeneity | ||||||
| Events | Studies | N+(%) | Total | N+(%) | Total | RR/ SMD (95%CI) | p | I2(%) | p | |
| Infection | [1, 15–27] | 231(9.4%) | 2464 | 392(15.8%) | 2488 | 12.6% | 0.586(0.504, 0.680) | <0.001 | 3.9 | 0.407 |
| Sepsis | [1, 19, 20, 23, 25, 26] | 48(2.7%) | 1753 | 82(4.7%) | 1763 | 3.7% | 0.594(0.418, 0.842) | 0.003 | <0.001 | 0.945 |
| Pneumonia | [19, 20, 23–26] | 22(2.0%) | 1079 | 31(2.9%) | 1078 | 2.5% | 0.692(0.400, 1.196) | 0.187 | <0.001 | 0.511 |
| Urinary tract infection | [19, 20, 23, 25, 30] | 36(3.6%) | 988 | 43(4.4%) | 980 | 4.0% | 0.843(0.548, 1.297) | 0.437 | <0.001 | 0.682 |
| Wound infection | [19, 20, 22–27] | 54(4.6%) | 1186 | 86(7.2%) | 1188 | 6.1% | 0.620(0.422, 0.910) | 0.015 | 18.8 | 0.287 |
| Short-term mortality | [1, 14–22, 24, 27] | 85(3.8%) | 2233 | 122(5.4%) | 2259 | 4.6% | 0.692(0.527, 0.909) | 0.008 | <0.001 | 0.769 |
| Any mortality | [1, 14–27] | 159(6.3%) | 2514 | 204(8.0%) | 2539 | 7.2% | 0.792(0.653, 0.960) | 0.018 | <0.001 | 0.738 |
| Neurological dysfunction | [14, 18, 22, 24, 26] | 8(1.1%) | 752 | 18(2.4%) | 761 | 1.7% | 0.499(0.219, 1.137) | 0.098 | <0.001 | 0.651 |
| Acute renal failure | [1, 22, 24, 26] | 46(3.3%) | 1413 | 78(5.4%) | 1439 | 4.3% | 0.610(0.359, 1.038) | 0.068 | 16.0 | 0.312 |
| Hypoglycemia | [1, 16–20, 22–24, 27] | 467(22.3%) | 2097 | 233(11.0%) | 2118 | 16.6% | 3.145(1.928, 5.131) | <0.001 | 81.4 | <0.001 |
| Severe hypoglycemia | [15, 16, 19–21, 24, 26] | 34(2.8%) | 1207 | 8(0.7%) | 1210 | 1.7% | 3.821(1.796, 8.127) | <0.001 | <0.001 | 0.894 |
| ICU stay | [1, 15, 16, 18, 23, 26, 27] | −0.428(−0.833, −0.022) | 0.039 | 96.6 | <0.001 | |||||
| Mechanical ventilation | [1, 15, 16, 18, 23, 26, 27] | −0.275(−0.695,0.146) | 0.201 | 96.9 | <0.001 | |||||
| LOS | [15, 16, 18–20, 26, 27] | −0.233(−0.496,0.030) | 0.082 | 85.4 | <0.001 |
| Results of TST | Results of T.SPOT.TB | |||
| Negative | Positive | Indeterminate | Total | |
| Negative | 79 | 3 | 4 | 86 |
| Positive | 4 | 2 | 0 | 6 |
| Total | 83 | 5 | 4 | 92 |
| Controls | Offspring | |||
| Beta ± SE † | P-value* | Beta ± SE† | P-value* | |
| PC (O-34:3) | 0.037 ± 0.322 | 0.909 | 0.034 ± 0.369 | 0.927 |
| PC (O-34:1) | −0.384 ± 0.303 | 0.206 | −0.124 ± 0.236 | 0.600 |
| PC (O-36:3) | 0.015 ± 0.372 | 0.969 | −0.352 ± 0.372 | 0.345 |
| PC (O-36:2) | 0.029 ± 0.386 | 0.940 | −0.718 ± 0.428 | 0.094 |
| PE (38:6) | −0.900 ± 0.680 | 0.186 | 0.602 ± 0.652 | 0.356 |
| SM (d18:1/14:0) | −0.051 ± 0.278 | 0.854 | 0.524 ± 0.288 | 0.069 |
| SM (d18:1/15:0) | −0.368 ± 0.296 | 0.215 | 0.408 ± 0.274 | 0.136 |
| SM (d18:1/16:0) | −0.049 ± 0.221 | 0.825 | 0.344 ± 0.185 | 0.064 |
| SM (d18:1/17:0) | −0.118 ± 0.329 | 0.719 | −0.002 ± 0.448 | 0.996 |
| SM (d18:1/18:2) | −0.589 ± 0.404 | 0.146 | 0.093 ± 0.341 | 0.786 |
| SM (d18:1/21:0) | −0.058 ± 0.319 | 0.855 | 0.418 ± 0.315 | 0.186 |
| SM (d18:1/23:1) | −0.169 ± 0.283 | 0.550 | 0.682 ± 0.226 | 0.003 |
| SM (d18:1/23:0) | 0.197 ± 0.255 | 0.440 | 0.630 ± 0.238 | 0.008 |
| TG (52:1) | −0.050 ± 0.691 | 0.942 | 1.40 ± 0.632 | 0.027 |
| TG (54:7) | −0.672 ± 0.786 | 0.393 | 1.24 ± 0.637 | 0.052 |
| TG (54:6) | −0.360 ± 0.793 | 0.650 | 1.86 ± 0.690 | 0.005 |
| TG (56:7) | −0.686 ± 0.727 | 0.346 | 1.10 ± 0.656 | 0.094 |
| TG (56:6) | −0.699 ± 0.609 | 0.252 | 1.18 ± 0.537 | 0.028 |
| TG (57:2) | −0.779 ± 0.633 | 0.219 | 0.828 ± 0.544 | 0.129 |
| Criteria/Quantitative description | Score |
| Background blood/clot | |
| Large amount; great compromise in diagnosis | 0 |
| Moderate amount; diagnosis possible | 1 |
| Minimal; diagnosis | 2 |
| Amount of cellular material | |
| Minimal to absent; diagnosis not possible | 0 |
| Sufficient for diagnosis | 1 |
| Abundant; diagnosis possible | 2 |
| Degree of cellular degeneration | |
| Degeneration marked; diagnosis impossible | 0 |
| Degeneration moderate; diagnosis possible | 1 |
| Degeneration minimal; diagnosis obvious | 2 |
| Degree of cellular trauma | |
| Marked; diagnosis impossible | 0 |
| Moderate; diagnosis possible | 1 |
| Minimal; diagnosis obvious | 2 |
| Retention of appropriate architecture | |
| Minimal to absent; non-diagnostic | 0 |
| Moderate; some preservation of, e.g., follicle, papillae, acini, etc. | 1 |
| Excellent architectural display closely reflecting histology; diagnosis obvious | 2 |
| Strains with Stable ST | ||||||
| Patient | ST of the first CoS strain isolated | Sample type | Sample type of first clinical CoS | ST of CoR strain isolated | Sample type | Time to switch from CoR to CoS (days) |
| 1 | 554 | SRS | Arterial catheter | - | bronchial aspirate | 36 |
| 2 | 512 | SRS | skin swab | - | urine | 26 |
| 3 | 307 | SRS | skin swab | - | skin swab | 42 |
| 4 | 512 | SRS | skin swab | - | SRS | 123 |
| 5 | 512 | SRS | drainage fluid | - | drainage fluid | 28 |
| 6 | 512 | urine | urine | - | urine | 17 |
| 7 | 512 | SRS | bronchial aspirate | - | SRS | 74 |
| 8 | 1543 | SRS | - | - | SRS | 50 |
| 9 | 512 | SRS | bronchial aspirate | - | bronchial aspirate | 31 |
| 10 | 512 | SRS | bronchial aspirate | - | bronchial aspirate | 6 |
| 11 | 554 | SRS | - | - | bronchial aspirate | na |
| 12 | 512 | SRS | bronchial aspirate | - | blood | 24 |
| 13 | 258 | SRS | urine | - | urine | 8 |
| Median | ||||||
| 29.5 days | ||||||
| Switched ST | ||||||
| Patient | ST of the first CoS strain isolated | Sample type | Sample type of first clinical CoS | ST of CoR strain isolated | Sample type | Time to switch from CoR to CoS (days) |
| 14 | 15 | SRS | urine | 512 | SRS | 167 |
| 15 | 554 | urine | urine | 512 | SRS | 67 |
| 16 | 2581 | SRS | skin swab | 512 | SRS | 34 |
| 17 | 554 | SRS | arterial catheter | 1733 (554 SLV) | drainage fluid | 54 |
| Median: | ||||||
| 60.5 days |
| Variants | Haplotype | Haplotype frequency | OR (95% CI) | P value | |
| Case (n = 350) | Control (n = 350) | ||||
| eNOS 4 and eNOS 7 | bG | 0.5550 | 0.7912 | 0.33 (0.23–0.46) | 0.000∗ |
| aT | 0.0650 | 0.0112 | 6.08 (1.97–20.99) | 0.002∗ | |
| aG | 0.1850 | 0.1288 | 1.55 (1.00–2.39) | 0.048∗ | |
| bT | 0.1950 | 0.0688 | 3.28 (1.95–5.52) | 0.000∗ | |
| eNOS 4 and eNOS T786C | bT | 0.5775 | 0.6794 | 0.64 (0.47–0.89) | 0.006∗ |
| bC | 0.1725 | 0.1806 | 0.94 (0.63–1.42) | 0.843 | |
| aT | 0.1925 | 0.1106 | 1.89 (1.21–2.96) | 0.004∗ | |
| aC | 0.0575 | 0.0294 | 2.17 (0.96–5.02) | 0.07 | |
| eNOS 7 and eNOS T786C | GT | 0.5698 | 0.7268 | 0.50 (0.36–0.69) | 0.000∗ |
| GC | 0.1702 | 0.1932 | 0.86 (0.57–1.28) | 0.47 | |
| TT | 0.2002 | 0.0632 | 3.73 (2.19–6.38) | 0.000∗ | |
| TC | 0.0598 | 0.0168 | 3.66 (1.38–10.26) | 0.006∗ |
| Classifier | PSGO-TRN | PSGO-TST | ORI-TRN | ORI-TST | ORIRW-TRN | ORIRW-TST | Mean |
| SCMPSP | 83.82 | 71.54 | 77.78 | 62.60 | 81.8 | 64.38 | 66.17 |
| SVM-AAC | 85.45 | 78.85 | 71.36 | 50.61 | 71.20 | 57.30 | 62.25 |
| SVM-DPC | 83.33 | 72.31 | 68.94 | 69.11 | 67.30 | 61.37 | 67.60 |
| SVM-AAindex | 79.19 | 75.38 | 71.40 | 71.03 | 71.36 | 71.14 | 72.52 |
| J48-AAC | 68.50 | 73.84 | 64.24 | 63.41 | 68.21 | 49.79 | 62.35 |
| J48-DPC | 63.20 | 61.92 | 55.25 | 51.22 | 55.70 | 59.44 | 57.53 |
| J48-AAindex | 65.03 | 70.38 | 62.50 | 62.02 | 61.46 | 68.09 | 66.83 |
| Bayers-AAC | 67.92 | 69.20 | 64.65 | 63.00 | 65.00 | 65.02 | 65.74 |
| Bayers-DPC | 65.41 | 67.31 | 58.28 | 57.32 | 58.80 | 60.73 | 61.79 |
| Bayes-AAindex | 66.09 | 64.62 | 62.70 | 60.30 | 62.73 | 57.11 | 60.68 |
| Mean | 72.79 | 70.54 | 65.71 | 61.06 | 66.37 | 61.44 |
| Factor | IRR (95% CI) | |
| Unadjusted | Adjusted | |
| Gender | ||
| Female | 1.00 | 1.00 |
| Male | 0.53 (0.45-0.61) | 0.53 (0.45-0.61) |
| Age (years) | ||
| 0-40 | 0.90 (0.71-1.12) | 0.87 (0.69-1.09) |
| 40-55 | 1.00 | 1.00 |
| 55-70 | 0.80 (0.67-0.96) | 0.78 (0.65-0.94) |
| > 70 | 0.27 (0.21-0.34) | 0.25 (0.19-0.32) |
| Region | ||
| Stockholm | 1.00 | 1.00 |
| North | 0.57 (0.40-0.83) | 0.66 (0.46-0.94) |
| South-east | 1.04 (0.78-1.39) | 1.13 (0.84-1.51) |
| South | 1.23 (0.97-1.58) | 1.38 (1.08-1.77) |
| Uppsala/Örebro | 1.00 (0.78-1.27) | 1.19 (0.93-1.52) |
| West | 1.37 (1.07-1.74) | 1.49 (1.17-1.89) |
| Abroad | 0.78 (0.25-2.47) | 0.46 (0.15-1.44) |
| Cause of renal disease | ||
| Diabetes | 1.00 | 1.00 |
| Nephrosclerosis | 1.02 (0.75-1.39) | 1.56 (1.14-2.13) |
| Glomerulonephritis | 2.22 (1.75-2.80) | 2.30 (1.80-2.94) |
| Adult polycystic kidney disease | 2.17 (1.65-2.87) | 1.88 (1.42-2.50) |
| Pyelonephritis | 2.60 (1.90-3.56) | 2.54 (1.85-3.48) |
| Other | 1.22 (0.98-1.60) | 1.30 (1.00-1.68) |
| Years with functioning transplant | ||
| 0 | 1.00 | 1.00 |
| 0 > and < 1 | 1.32 (1.03-1.68) | 1.59 (1.23-2.04) |
| ≥ 1 and < 3 | 3.22 (2.56-4.06) | 0.71 (0.56-0.89) |
| ≥ 3 | 1.00 (0.79-1.27) | 0.24 (0.19-0.30) |
| Word-pairs | Sentences | Oddball | Mean per task | ||
| Ignore task | M | 32.55 | 55.99 | 46.89 | 45.15 |
| SD | 22.08 | 56.99 | 40.52 | 42.66 | |
| Passive task | M | 72.91 | 80.01 | 89.39 | 80.77 |
| SD | 47.24 | 58.11 | 55.82 | 53.34 | |
| Focused task | M | 73.76 | 85.98 | 83.71 | 81.15 |
| SD | 46.09 | 59.84 | 54.37 | 52.98 |
| liver | spleen | caecum | |
| (log CFU/g of tissue) | |||
| wt | 4.97 ± 2.22 | 5.52 ± 2.47 | 4.19 ± 2.49 |
| ΔSPI1 | 5.10 ± 1.12 | 5.79 ± 1.07 | 4.18 ± 1.15 |
| ΔSPI2 | 0.25 ± 0.43* | 0.56 ± 0.50* | 2.05 ± 1.49 |
| ΔSPI3 | 5.13 ± 0.19 | 6.19 ± 0.36 | 3.79 ± 0.02 |
| ΔSPI4 | 4.83 ± 1.42 | 5.60 ± 1.36 | 2.97 ± 1.75 |
| ΔSPI5 | 3.52 ± 1.79 | 4.29 ± 2.32 | 2.90 ± 1.40 |
| SPI1o | 0.33 ± 0.47* | 0.33 ± 0.47* | 2.20 ± 1.59 |
| SPI2o | 5.29 ± 0.87 | 5.82 ± 1.07 | 3.76 ± 0.77 |
| SPI3o | 0.00 ± 0.00* | 0.00 ± 0.00* | 0.33 ± 0.47* |
| SPI4o | 0.00 ± 0.00* | 0.00 ± 0.00* | 1.68 ± 2.38 |
| SPI5o | 0.00 ± 0.00* | 0.00 ± 0.00* | 1.07 ± 1.51* |
| ΔSPI1-5 | 0.00 ± 0.00* | 0.00 ± 0.00* | 1.06 ± 1.50* |
| Area | WT TA (o) | SOD TA (o) | WT TA (i) | SOD TA (i) | WT Soleus | SOD Soleus |
| #Dock vesicles/μm AZ | 5.11 ± 0.65 | 4.91 ± 0.65 | 5.67 ± 0.97 | 4.62 ± 0.96 | 5.99 ± 0.63 | 4.55 ± 0.62 |
| #Vesicles/μm2 terminal | 55.00 ± 7.60 | 55.83 ± 7.58 | 54.94 ± 7.59 | 53.96 ± 7.47 | 65.65 ± 6.80 | 54.77 ± 6.72 |
| #Junctional folds/μm AZ | 1.60 ± 0.10 | 1.60 ± 0.10 | 1.45 ± 0.14 | 1.27 ± 0.13 | 1.12 ± 0.11 | 0.95 ± 0.11 |
| Junctional fold length (nm) | 683.48 ± 22.58 | 598.26 ± 21.93 | 617.28 ± 36.08 | 562.52 ± 32.82 | 595.13 ± 32.98 | 553.27 ± 31.78 |
| Junctional fold diameter (nm) | 65.24 ± 2.90 | 67.60 ± 2.88 | 72.014 ± 4.46 | 65.26 ± 4.27 | 79.06 ± 4.43 | 73.02 ± 4.30 |
| General Practitioner Visits | Specialist Visits | |||||
| Variables | Chinese N (% of 746) | White N (% of 711) | P-Value | Chinese N (% of 485) | White N (% of 637) | P-Value |
| Satisfied with physician care | ||||||
| Very Satisfied | 158 (21.2) | 420 (59.1) | 0.0001 | 140 (28.9) | 364 (57.1) | 0.0001 |
| Satisfied | 392 (52.5) | 240 (33.8) | 226 (46.6) | 181 (28.4) | ||
| Neither | 153 (20.5) | 30 (4.2) | 89 (18.4) | 33 (5.2) | ||
| Dissatisfied | 33 (4.4) | 17 (2.4) | 20 (4.1) | 25 (3.9) | ||
| Very Dissatisfied | 5 (0.7) | 2 (0.3) | 7 (1.4) | 23 (3.6) | ||
| Unsure | 5 (0.7) | 2 (0.3) | 3 (0.6) | 11 (1.7) | ||
| Definitely trust physician enough to always follow physician advice | ||||||
| Yes Definitely | 443 (59.4) | 424 (59.6) | 0.606 | 326 (67.2) | 400 (62.8) | 0.003 |
| Yes, to some extent | 267 (35.8) | 242 (34) | 131 (27) | 158 (24.8) | ||
| No | 29 (3.9) | 37 (5.2) | 21 (4.3) | 62 (9.7) | ||
| Unsure | 7 (0.9) | 8 (1.1) | 7 (1.4) | 17 (2.7) | ||
| Definitely felt physician had adequate experience | ||||||
| Yes Definitely | 330 (44.2) | 586 (82.4) | 0.0001 | 285 (58.8) | 538 (84.5) | 0.0001 |
| Yes, to some extent | 361 (48.4) | 103 (14.5) | 153 (31.5) | 67 (10.5) | ||
| No | 41 (5.5) | 12 (1.7) | 28 (5.8) | 19 (3) | ||
| Unsure | 14 (1.9) | 10 (1.4) | 19 (3.9) | 13 (2) | ||
| Definitely felt enough time was spent with physician | ||||||
| Yes Definitely | 252 (33.8) | 524 (73.7) | 0.0001 | 212 (43.7) | 404 (63.4) | 0.0001 |
| Yes, to some extent | 335 (44.9) | 132 (18.6) | 187 (38.6) | 155 (24.3) | ||
| No | 149 (20) | 52 (7.3) | 81 (16.7) | 68 (10.7) | ||
| Unsure | 10 (1.3) | 3 (0.4) | 5 (1) | 10 (1.6) | ||
| Definitely felt comfortable asking physician questons | ||||||
| Yes Definitely | 549 (73.6) | 637 (89.6) | 0.0001 | 343 (70.7) | 494 (77.6) | 0.001 |
| Yes, to some extent | 173 (23.2) | 61 (8.6) | 108 (22.3) | 85 (13.3) | ||
| No | 19 (2.5) | 13 (1.8) | 26 (5.4) | 49 (7.7) | ||
| Unsure | 4 (0.7) | 0 (0) | 8 (1.6) | 9 (1.4) | ||
| Definitely understood physician explanation and advice | ||||||
| Yes Definitely | 567 (76) | 667 (93.8) | 0.0001 | 278 (57.3) | 516 (81) | 0.0001 |
| Yes, to some extent | 156 (20.9) | 41 (5.8) | 157 (32.4) | 99 (15.5) | ||
| No | 18 (2.4) | 2 (0.3) | 49 (10.1) | 16 (2.5) | ||
| Unsure | 5 (0.7) | 1 (0.1) | 1 (0.2) | 6 (0.9) | ||
| Definitely felt physician listened carefully | ||||||
| Yes Definitely | 473 (63.4) | 585 (82.3) | 0.0001 | 289 (59.6) | 456 (71.6) | 0.0001 |
| Yes, to some extent | 238 (31.9) | 112 (15.8) | 167 (34.4) | 121 (19) | ||
| No | 31 (4.2) | 14 (2) | 21 (4.3) | 50 (7.8) | ||
| Unsure | 4 (0.5) | 0 (0) | 8 (1.6) | 10 (1.6) |
| Cost in CDN dollars Mean (SD) | |
| Total Cost | $49,923 (45,773) |
| Total Indirect Cost | $13,566 (12,625) |
| Total Direct Cost | $36,358 (33,501) |
| Direct Costs per costing Category | |
| Health Professionals | $2600 (4787) |
| Imaging | $1069 (1428) |
| Lab | $1923 (1709) |
| Nursing | $16,378 (16,735) |
| Operating room | $1192 (1819) |
| Surgical Implants | $907 (2821) |
| Post anaesthesia care unit | $307 (590) |
| Pharmacy | $3273 (4157) |
| Special Care Unit | $7502 (16,929) |
| Endoscopy | $72 (223) |
| Food Services | $1134 (1247) |
| Variables | Mean ± SD | Range |
| Age (yr) | 21.5 ± 2.6 | 18.0~25.0 |
| Height (cm) | 175.5 ± 6.0 | 167.0~185.0 |
| Weight (kg) | 94.9 ± 12.9 | 79.3~117.4 |
| BMI (kg/m2) | 30.7 ± 2.6 | 27.4~34.3 |
| LBM (kg) | 74.4 ± 8.7 | 62.1~90.9 |
| FM (kg) | 16.4 ± 5.8 | 9.7~27.0 |
| FM (%) | 17.0 ± 4.4 | 12.3~25.6 |
| Variables | Quartile 1 | Quartile 2 | Quartile 3 | Quartile 4 | P value |
| Demographics | |||||
| (n = 4,970) | (n = 1,347) | (n = 1,356) | (n = 1,150) | (n = 1,117) | |
| Age, in years | 56.5 (8.6) | 59.7 (9.3) | 63.4 (9.3) | 67.8 (9.6) | <0.0001 |
| Male | 511 (38%) | 647 (48%) | 621 (54%) | 591 (53%) | <0.0001 |
| Female | 836 (62%) | 709 (52%) | 529 (46%) | 526 (47%) | <0.0001 |
| Caucasian | 453 (33%) | 505 (37%) | 484 (42%) | 501 (45%) | <0.0001 |
| Chinese | 234 (17%) | 172 (13%) | 129 (11%) | 116 (10%) | <0.0001 |
| African | 384 (29%) | 359 (26%) | 257 (22%) | 274 (25%) | <0.003 |
| Hispanic | 276 (20%) | 320 (24%) | 280 (24%) | 226 (20%) | <0.024 |
| Medical history | |||||
| HTN | 425 (32%) | 491 (36%) | 524 (46%) | 669 (60%) | <0.0001 |
| Diabetes | 142 (11%) | 120 (9%) | 95 (8%) | 155 (14%) | <0.0001 |
| Current smokers | 158 (12%) | 165 (12%) | 151 (13%) | 157 (14%) | <0.31 |
| Renal disease (self-report) | 20 (1.5%) | 17 (1.3%) | 31 (2.7%) | 45 (4.0%) | 0.0001 |
| Laboratory/clinical parameters | |||||
| Creatinine mg/dL | 0.84 (0.2) | 0.91 (0.2) | 0.97 (0.2) | 1.13 (0.5) | <0.0001 |
| GFR MDRD mL/min/1.73 m2 | 91.8 (16.0) | 84.0 (14.2) | 78.4 (13.5) | 67.8 (16.0) | <0.0001 |
| Systolic BP, mm Hg | 121.2 (20.2) | 123.8 (20.0) | 126.7 (21.0) | 131.4 (22.9) | <0.0001 |
| Diastolic BP, mm Hg | 71.5 (10.5) | 72.3 (10.2) | 72.0 (9.9) | 71.6 (10.6) | 0.19 |
| Body mass index Kg/m2 | 26.7 (4.8) | 27.5 (4.7) | 28.2 (4.9) | 28.8 (5.2) | <0.0001 |
| Body surface area m2 | 1.80 (0.2) | 1.85 (0.2) | 1.87 (0.2) | 1.88 (0.2) | <0.0001 |
| Medications | |||||
| Antihypertensive meds | 322 (24%) | 414 (31%) | 421 (37%) | 598 (54%) | <0.0001 |
| Beta-blockers | 70 (5%) | 86 (6%) | 110 (10%) | 157 (14%) | <0.0001 |
| ACE inhibitors | 107 (8%) | 113 (8%) | 122 (11%) | 199 (18%) | <0.0001 |
| ARB | 23 (2%) | 41 (3%) | 30 (3%) | 67 (6%) | <0.0001 |
| Calcium channel blockers | 127 (9%) | 146 (11%) | 145 (13%) | 174 (16%) | <0.0001 |
| Thiazide diuretics | 47 (3%) | 70 (5%) | 79 (7%) | 126 (11%) | <0.0001 |
| Loop diuretics | 10 (1%) | 11 (1%) | 15 (1%) | 40 (4%) | <0.0001 |
| Factor | Univariable HR | p-value | Multivariable HR (95% CI) | p-value |
| Monitoring randomisation | ||||
| LCM | 1.00 | - | 1.00 | - |
| CDM | 1.07 | 0.45 | 1.11 (0.93 - 1.35) | 0.25 |
| Gender | ||||
| Male | 1.00 | - | 1.00 | - |
| Female | 0.80 | 0.02 | 0.79 (0.65 - 0.95) | 0.01 |
| Initial ART | ||||
| TDF | 1.00 | <0.0001 | 1.00 | <0.0001 |
| NVP | 0.49 | - | 0.48 (0.38 - 0.62) | - |
| ABC | 1.18 | - | 1.27 (1.02 - 1.59) | - |
| TB in 12 months prior to enrolment | 1.13 | 0.26 | 1.07 (0.86 - 1.33) | 0.52 |
| Age (per 10 years older) | 0.73 | <0.0001 | 0.73 (0.64 - 0.84) | <0.0001 |
| Baseline CD4 (per 100 cells/mm3 higher) | 0.60 | <0.0001 | 0.64 (0.54 - 0.75) | <0.0001 |
| Baseline viral load (log10 copies/mL) | 1.02 | 0.84 | 1.01 (0.84 - 1.22) | 0.89 |
| Adherence in previous 48 weeksa (per 10% higher) | 0.89 | <0.0001 | 0.89 (0.84 - 0.94) | <0.0001 |
| Method | Planar objects | Real feet | Main disadvantages |
| Accuracy/Repeatibility | Static/Dynamic | ||
| Coudert et al.[13] | NA/NA | NA/NA | Technique requires spraying foot with paint or adding sock |
| Jezersek & Mazina [14] | 0.2 mm/NA | 0.4 mm/NA | The system requires several specialized camera-projector-mirror systems |
| Jezersek et al.[16] | 0.5 mm/NA | NA/NA | Similar to Jezersek & Mazina, the system requires expensive specialized equipment |
| Kouchi et al.[17] | 0.5 mm/NA | 2.0 mm/NA | System only measures 4 cross-section areas of the foot, which need to be manually marked on the foot surface |
| Schmeltzpfenning et al.[18] | NA/NA | NA/NA | Camera-projector systems work sequentially thus reducing the acquisition frequency |
| Mochimaru et al.[20] | NA/NA | NA/NA | Matching random pattern is computationally expensive and can create unpredictable errors |
| Yoshida & Kouchi [21] | NA/NA | 4.0 mm/NA | System uses one generic model for all foot reconstructions; shape deformations during walking cannot be fully accounted by the generic model |
| Liu et al.[22] | 0.25 mm/NA | NA/NA | System provides good visual results, but lacks proper experiments with real feet |
| Blenkinsopp et al.[25] | NA/NA | NA/NA | Reconstruction is based on painted artifacts on the foot surface |
| CFS | Healthy | |
| (n = 55) | (n = 30) | |
| Age (y) | 35.4 ± 1.1 | 36.1 ± 1.6 |
| Male | 20 | 11 |
| Female | 35 | 19 |
| α-MSH (pg/mL) | 17.9 ± 1.0 | 14.5 ± 1.0* |
| Response to endotoxin administration | Clinical | Autonomic | Immune | |||
| Outcome expectancies | Flu-like symptoms (T90) | Epinephrine (T0) | IL-10 (T60) | TNF-α (T90) | IL-6 (T120) | IL-8 (T120) |
| Generalized outcome expectancies | ||||||
| Optimism (LOT-R) | −.38 | .76** | .60* | −.32 | −.26 | −.32 |
| Neuroticism (BFI) | .10 | −.32 | −.09 | .27 | .22 | .11 |
| Specific outcome expectancies | −.71** | .28 | .33 | .00 | .16 | −.15 |
| Surfactant | Drug loaded | Comments | References |
| Brij 35, 78, 98, and 700 | Atenolol, timolol, betaxololcyclosporine A | Significantly increased the corneal permeability.Significantly increased bioavailability of ophthalmic drugs by using contact lenses. | [52, 76] |
| Polysorbate 80, polyoxyl 40 stearate, and polyoxyl 60 hydrogenated castor oil | Cyclosporine A | Improve ocular CsA penetration and are clinically useful in the treatment of immune-mediated ophthalmic diseases. | [71] |
| Pluronic F127 | Pilocarpine | Enhanced miotic response to a single instillation of pilocarpine eye drops compared to an aqueous solution of the drug. | [68] |
| Polysorbates 60 and 80 and Brij 35 | Gentamicin sulphate | Effective in the prolongation of drug release from the ocular delivery and observed no irritancy on albino rabbits. | [72] |
| Polysorbate 20 | Cyclopentolate | Promoted ocular absorption. | [23, 25] |
| Solulan C-24 and span 60 | Timolol maleate | Treatment of ocular hypotensive activity. Exhibited sustained controlled ocular drug delivery. | [45, 46] |
| Spans 20, 40, 60, and 80 | Acyclovir | Effective for the treatment of herpes simplex keratitis. | [67] |
| Acetazolamide | Effective in enhancing the bioavailability of drug and lowered the intraocular pressure. | [43, 45, 73] | |
| Brimonidine tartrate | Improved bioavailability and increased precorneal residence time.Decreased the intraocular pressure for a prolonged period of time and nonirritant effect | [77–80] | |
| Naltrexone hydrochloride | Possessed better ocular tolerability and less ocular irritation. | [74] | |
| Fluconazole | Improved permeability as compared to marketed formulation and nonirritant effect. | [25] | |
| Flupirtine maleate | Improved the low corneal permeability for effective management of trigeminal neuralgia. | [75] | |
| Diclofenac sodium | Nonirritant and safe vesicular system for the effective ocular drug delivery. | [68] | |
| Levofloxacin. | Efficient in prolonging the drug release with reduced side effects. | [69] |
| Expression | Gene_Symbol | LogFC | Adjusted p value |
| Upregulated | Grin2c | 2.272 | 4.27E−06 |
| Ccnb3 | 3.243 | 4.27E−06 | |
| Usp51 | 1.702 | 4.45E−06 | |
| Slc1a3 | 1.443 | 6.34E−06 | |
| Kcnk1 | 2.774 | 6.34E−06 | |
| Bmp3 | 2.764 | 9.74E−06 | |
| Rbm44 | 1.846 | 1.14E−05 | |
| Plppr5 | 2.010 | 1.85E−05 | |
| Phex | 1.977 | 1.85E−05 | |
| Nell1 | 2.368 | 2.00E−05 | |
| AI593442 | 1.477 | 2.00E−05 | |
| Ooep | 0.828 | 2.00E−05 | |
| Trpc6 | 1.628 | 2.00E−05 | |
| Dkk1 | 1.730 | 2.00E−05 | |
| Downregulated | Lef1 | − 1.677 | 2.90E−06 |
| Elf1 | − 1.300 | 4.79E−06 | |
| Jph1 | − 1.674 | 5.47E−06 | |
| Zfhx4 | − 2.183 | 6.34E−06 | |
| S1pr3 | − 1.209 | 8.30E−06 | |
| Slc20a2 | − 1.031 | 9.06E−06 | |
| Pdgfc | − 1.073 | 9.20E−06 | |
| Wbp4 | − 1.221 | 9.74E−06 | |
| Robo1 | − 1.536 | 1.12E−05 | |
| Dgkh | − 1.183 | 1.12E−05 | |
| Mpped2 | − 1.873 | 1.14E−05 | |
| Dnajc15 | − 1.661 | 1.24E−05 | |
| Atp10a | − 1.118 | 1.85E−05 | |
| Slc6a15 | − 2.051 | 1.85E−05 |
| Intention to quit | Quitting smoking | |||||
| OR | 95 % CI | OR | 95 % CI | |||
| Province (Hanoi vs Nam Dinh) | 0.47*** | 0.34 | 0.67 | 0.50* | 0.23 | 1.08 |
| Location (Urban vs Rural) | 1.44 | 0.90 | 2.31 | |||
| Duration of MMT (month) | 1.00 | 0.99 | 1.02 | 0.99 | 0.95 | 1.03 |
| Outpatient service use last 12 months (yes vs no) | 1.98*** | 1.44 | 2.72 | |||
| # of drug rehabilitation | 1.03 | 0.98 | 1.07 | |||
| Religion (vs cult of ancestors) | ||||||
| Buddhism | 2.72* | 0.84 | 8.78 | |||
| Occupation (vs unemployed) | ||||||
| Other jobs | 1.41 | 0.87 | 2.28 | |||
| Age (vs 18–<25) | ||||||
| 35–<40 | 2.63** | 1.30 | 5.30 | |||
| ≥45 | 0.51*** | 0.34 | 0.78 | |||
| Marital status (vs single) | ||||||
| Live with spouse | 1.23 | 0.91 | 1.67 | |||
| Income quintile (vs poorest) | ||||||
| Rich | 0.78 | 0.56 | 1.09 | |||
| Having pain/discomfort (yes vs no) | 0.41 | 0.12 | 1.43 | |||
| HIV status (vs negative) | ||||||
| Positive | 0.58** | 0.34 | 0.99 | |||
| Body mass index (vs underweight) | ||||||
| Normal | 1.47 | 0.86 | 2.52 | |||
| Level of nicotine dependence (vs very low) | ||||||
| Low | 0.31** | 0.12 | 0.81 | |||
| Moderate | 0.22** | 0.05 | 0.97 | |||
| High | 0.37** | 0.13 | 1.04 | |||
| Very high | 0.22** | 0.05 | 0.99 | |||
| Year of smoking | 0.95** | 0.91 | 1.00 |
| Testosterone groupn = 49 | Placebo groupn = 51 | Difference between groupsa | P valueb | |
| Fat mass, kg | ||||
| Week 0–10 | –7.9 (–9.7 to –6.1)* | –7.5 (–9.4 to –5.7)* | –0.4 (–3.0 to 2.2) | 0.78 |
| Week 0–56 | –9.4 (–11.3 to –7.5)* | –6.5 (–8.5 to –4.5)* | –2.9 (–5.7 to –0.2) | 0.04 |
| Fat mass, % | ||||
| Week 0–10 | –3.8 (–4.9 to –2.6)* | –3.0 (–4.3 to –1.8)* | –0.7 (–2.4 to 1.0) | 0.40 |
| Week 0–56 | –5.7 (–6.9 to –4.5)* | –2.9 (–4.3 to –1.6)* | –2.8 (–4.6 to –1.0) | 0.003 |
| Lean mass, kg | ||||
| Week 0–10 | –3.9 (–5.3 to –2.6)* | –4.8 (–6.2 to –3.5)* | 0.9 (–1.0 to 2.8) | 0.36 |
| Week 0–56 | –0.6 (–2.0 to 0.8) | –4.0 (–5.5 to –2.5)* | 3.4 (1.3 to 5.5) | 0.002 |
| VAT area, mm2 | ||||
| Week 0–10 | –7688 (–9333 to –6044)* | –6590 (–8267 to –4912)* | –1099 (–3448 to 1251) | 0.36 |
| Week 0–56 | –7223 (–8921 to –5526)* | –4545 (–6383 to –2708)* | –2678 (–5180 to –176) | 0.04 |
| Body weight, kg | ||||
| Week 0–10 | –12.0 (–14.5 to –9.5)* | –13.5 (–16.0 to –11.0)* | 1.5 (–2.0 to 5.1) | 0.40 |
| Week 0–56 | –11.4 (–13.9 to –8.8)* | –10.9 (–13.6 to –8.1)* | –0.5 (–4.3 to 3.3) | 0.80 |
| Documentation practice | Description | Number of sites |
| Paper-based documentation | Documentation on a structured paper-based template and later scanned into the EHR in pdf format. No entries of vital signs were done in the EHR. | 2 Sites |
| Mixed Documentation | Done on a paper-based template and later transferred into a digital EHR template. | 3 sites |
| Digital documentation | Documentation on a digital template | 4 sites |
| Variable | Number | % of total | % male | % female | |
| Patients | 64,179 | 100.0 | 63.6 | 36.4 | |
| Age (year) | |||||
| ≤21 | 59,928 | 93.4 | 91.7 | 96.3 | |
| 22–28 | 3,656 | 5.7 | 7.3 | 2.9 | |
| ≥29 | 595 | 0.9 | 1.0 | 0.8 | |
| Education | |||||
| Elementary | 63 | 0.1 | 0.1 | 0.0 | |
| High school | 59,578 | 92.8 | 90.5 | 96.9 | |
| Post-high school | 4,415 | 6.9 | 9.1 | 2.9 | |
| Unknown | 123 | 0.2 | 0.2 | 0.2 | |
| Ethnicity | |||||
| Israel | 4,853 | 7.6 | 8.4 | 6.1 | |
| Asia + Africa + Ethiopia | 30,215 | 47.1 | 45.2 | 50.3 | |
| West | 15,329 | 23.9 | 24.6 | 22.7 | |
| Former Soviet Union | 8,187 | 12.8 | 13.3 | 11.9 | |
| Unknown | 5,595 | 8.7 | 8.6 | 9.0 | |
| Country of birth | |||||
| Israel | 50,726 | 79.0 | 78.4 | 80.1 | |
| Asia, Africa | 1,298 | 2.0 | 2.4 | 1.5 | |
| West | 1,861 | 2.9 | 3.1 | 2.6 | |
| Former Soviet Union | 6,776 | 10.6 | 10.8 | 10.1 | |
| Unknown | 3,518 | 5.5 | 5.3 | 5.8 |
| Study | Patients (#) | SRS median total dose/fx | Follow-up median, range (months) | Tumor size median, range (cc) | Prior irradiation Dose, median, range (Gy) | Toxicity | Complete Response Rate | Overall survival |
| Voynov et al. [13] | 22 | 24/1-8 | 19, 11-40* | 19.1, 2.5-140.3 | 97.8, 70.1-190.3 (BED10) | No Grade 4+ | - | 22% at 2-yrs |
| Heron et al. [15] | 25 | 25-44/5 | NS | 44.8, 4.2-217 | 66-69.2 | No Grade 3+ | 8.6% | 18% at 1-yr |
| Roh et al. [14] | 36 | 30/3-5 | 17.3 | 22.6, 0.2-114.9 | 70.2, 39.6-134.4 | No Grade 4+ 36% Grade 3 | 42.9% | 52.1% at 1-yr, 30.9% at 2-yrs |
| Rwigema et al. [23] | 85 | 35/1-5 | 6, 1.3-39 | 25.1, 2.5-162 | 70, 32-170.7 | No Grade 4+ 4.7% Grade 3 | 34% | 48% at 1-yr, 16% at 2-yrs |
| Sulman et al. [31] | 78§ | IMRT 60 Gy | 25, 0-81 | 64.1, 2.9-425.4 | 60, 16-75 | 20% severe Including 1% Grade 5 | - | 58% at 2-yrs |
| Siddiqui et al. [25] | 44§† | 13-18/1 or 36-48/5-8 | 6.8, 1.5-48 | 15.5, 1.7-155‡ | 63.5, 50.4-74‡ | 6.7% Grade 3‡ 9% Grade 4‡ | 31% | 38.1% at 1-yr 14.3% at 2-yrs |
| Unger et al. [24] | 65 | 30/2-5 | 16* | 75, 7-276 | 67, 32-120 | 11% Grade 4+ | 54% | 41% at 2-yrs |
| Current Study | 22 (14 N-, 8 N+) | 33.7/2-5 | 24, 4-39 | 24.5, 3.4-74.4 | 40-65 | No Grade 4+ 22.7% Grade 3 | 45.4% (N- 64.3%, N+ 12.5%) | N- 78.6% at 2-yrs N+ 12.5% at 2-yrs |
| Country | Natural forest cover (1000 ha) | Loss (1000 ha) | Coverage % | Annual deforestation rate (%) | |||||
| 1990 | 2000 | 2005 | 2010 | 1990–2010 | 2000 | 1990–2000 | 2000–2005 | 2005–2010 | |
| Burundi | 289 | 112 | 103 | 103 | 186 | 3.7 | −6.1 | −6.12 | −0.8 |
| Ethiopia | 14,623 | 13,214 | 12,509 | 11,785 | 2838 | 4.2 | −1.0 | −0.96 | −1.08 |
| Kenya | 3470 | 3370 | 3320 | 3270 | 200 | 30.0 | −0.3 | −0.29 | −0.30 |
| Madagascar | 13,461 | 12,850 | 12,548 | 12,138 | 1323 | 20.2 | −0.5 | −0.45 | −0.55 |
| Rwanda | 70 | 62 | 62 | 62 | 8 | n.a | −1.1 | −1.14 | 0 |
| Tanzania | 41,345 | 37,262 | 35,215 | 33,188 | 8157 | 43.9 | −1.0 | −0.99 | −1.09 |
| Uganda | 4717 | 3837 | 3398 | 2937 | 1780 | 21.0 | −1.9 | −1.87 | −2.35 |
| HospitalVolume | No. ofhospitals inJapan | No. of beds in Japan (Ni) | No. of beds in DPCparticipating hospitals (ni) | No. of intussusceptionfrom July to December(Xi) | Estimated No. of cases per year(Yi) | |||
| 2007 | 2008 | 2007 | 2008 | 2007 | 2008 | |||
| < 400 beds(i = 1) | 7,001 | 566,658 | 138,979 | 119,853 | 86 | 97 | 701 (597-806) | 917 (788-1046) |
| 400 - < 600beds (i = 2) | 466 | 175,715 | 98,050 | 89,627 | 176 | 169 | 631 (565-697) | 663 (592-733) |
| 600 - < 800beds (i = 3) | 161 | 88,870 | 54,351 | 49,740 | 98 | 78 | 320 (276-365) | 278 (235-322) |
| > 800 beds(i = 4) | 95 | 78,995 | 50,245 | 50,245 | 97 | 71 | 305 (262-348) | 223 (187-260) |
| Total | 7,723 | 910,238 | 341,625 | 309,465 | 457 | 415 | 1,957 (1743-2216) | 2,081 (1802-2361) |
| Markers | Afreq | Families | S | E(s) | Z | p-values |
| rs4366301 | C:0.831G:0.169 | 169169 | 213.00125.00 | 233.00105.00 | -2.8722.872 | 0.0040.004 |
| rs11585959 | C:0.243T:0.757 | 216216 | 123.00309.00 | 141.00291.00 | -2.1992.199 | 0.0280.028 |
| rs1322784 | G:0.369A:0.631 | 242242 | 206.00278.00 | 202.50281.50 | -0.3920.392 | 0.6950.695 |
| rs6668845 | G:0.332A:0.668 | 244244 | 172.00316.00 | 193.00295.00 | -2.3262.326 | 0.0200.020 |
| rs10864698 | A:0.330G:0.670 | 242242 | 175.00309.00 | 191.50292.50 | -1.8311.831 | 0.0670.067 |
| rs872624 | G:0.345A:0.655 | 232232 | 168.00296.00 | 180.00284.00 | -1.3721.372 | 0.1700.170 |
| rs821616 | A:0.881T:0.119 | 130130 | 186.0074.00 | 181.5078.50 | 0.728-0.728 | 0.4670.467 |
| Materials | Melting | Solidification | |||||
| Onset temperature (°C) | End temperature (°C) | Enthalpy (J/g) | Onset temperature (°C) | End temperature (°C) | Enthalpy (J/g) | ||
| FS TD-CA PCM | 0 cycling | 18.90 | 24.24 | 100.50 | 14.16 | 9.18 | 99.70 |
| 500 cycling | 18.47 | 23.34 | 98.70 | 14.66 | 9.53 | 96.40 | |
| 1000 cycling | 18.12 | 22.90 | 96.30 | 15.40 | 10.18 | 94.50 | |
| FS TD-LA PCM | 0 cycling | 24.53 | 30.18 | 90.20 | 24.92 | 19.88 | 88.70 |
| 500 cycling | 23.62 | 29.69 | 87.60. | 25.93 | 20.67 | 86.40 | |
| 1000 cycling | 23.22 | 29.28 | 85.70 | 26.23 | 21.12 | 85.10 | |
| FS TD-MA PCM | 0 cycling | 33.15 | 37.75 | 128.60 | 30.72 | 27.63 | 125.70 |
| 500 cycling | 32.81 | 37.28 | 125.30 | 31.11 | 28.00 | 123.40 | |
| 1000 cycling | 32.65 | 37.04 | 123.50 | 31.72 | 28.55 | 121.70 |
| Variable | Totaln (%) | Normaln (%) | Anemia1n (%) | X2 | P | |
| Occupation | ||||||
| Mixed farming | 351 (36.2) | 266 (75.8) | 85 (24.2) | 21.7 | 0.001 | |
| Livestock | 33 (3.4) | 14 (42.4) | 19 (57.6) | |||
| Trade | 125 (12.9) | 85 (68.0) | 40 (32.0) | |||
| Civil servant | 154 (15.9) | 108 (70.1) | 46 (29.9) | |||
| Factory worker | 26 (2.7) | 15 (57.7) | 11 (42.3) | |||
| Handicraft | 40 (4.1) | 29 (72.5) | 11 (27.5) | |||
| None(housewife) | 241 (24.8) | 158 (65.6) | 83 (34.4) | |||
| Type of family planning | ||||||
| None | 521 (53.7) | 353 (67.8) | 168 (32.2) | 15.8 | 0.003 | |
| Pills | 146 (15.1) | 109 (74.7) | 37 (25.3) | |||
| IUCD | 7 (0.7) | 5 (71.5) | 2 (28.5) | |||
| Injection | 285 (29.4) | 203 (71.2) | 82 (28.8) | |||
| Others (condom) | 25 (2.6) | 9 (36.0) | 16 (64.0) | |||
| Type of illnesses2 | ||||||
| Pneumonia | 39 (4.0) | 25 (64.1) | 14 (35.9) | 16.7 | 0.001 | |
| Malaria | 42 (4.3) | 26 (61.9) | 16 (38.1) | |||
| Chronic illnesses3 | 45 (4.6) | 20 (44.4) | 25 (55.6) | |||
| None | 844 (87.0) | 604 (71.6) | 240 (28.4) | |||
| Intestinal parasites | ||||||
| Present | 837 (86.3) | 620 (74.1) | 217 (25.9) | 3.07 | 0.07 | |
| Absent | 163 (13.7) | 123 (75.5) | 40 (24.5) | |||
| Vegetable consumption daily | ||||||
| Once a day or more | 567 (58.5) | 451 (79.5) | 116 (24.5) | 16.6 | 0.001 | |
| Less than once a day | 403 (41.5) | 274 (68.0) | 129 (32.0) | |||
| Meat consumption weekly | ||||||
| Once a week or more | 194 (20.0) | 116 (59.8) | 78 (40.2) | 13.6 | 0.001 | |
| Less than once a week | 776 (80.0) | 349 (45.0) | 427 (55.0) |
| Total | Woman | Man | |
| Total thyroidectomy | 166 | 125 (75.3)∗ | 41 (24.7) |
| Pyramidal lobe present | 109 (65.7) | 82 (65.6) | 27 (65.9) |
| Pyramidal lobe absent | 57 (34.3) | 43 (34.4) | 14 (34.1) |
| Parameters | Control group | 500 mg/kg·b·wt (A) | 1000 mg/kg·b·wt (B) | 2000 mg/kg·b·wt (C) |
| Number of examined fetuses | 15 | 15 | 15 | 15 |
| Impairment of skull ossification | — | 3 (20%) | 5 (33.33%) | 8 (53.33%) |
| Absence or dislocation of sternebrae | — | 2 (13.33%) | 3 (20%) | 5 (33.33%) |
| Reduction or absence of caudal vertebrae | — | 5 (33.33%) | 6 (40%) | 10 (66.67%) |
| Absence of digit's bone of fore limb | — | 3 (20%) | 4 (26.67%) | 9 (60%) |
| Absence of digit's bone of hind limb | — | 2 (12.33%) | 3 (20%) | 7 (46.67%) |
| Absence of some metatarsal bone | — | 3 (20%) | 4 (26.67%) | 6 (40%) |
| Absence of some metacarpal bone | — | 2 (12.33%) | 4 (26.67%) | 5 (33.33%) |
| Criteria | Total n | Normosmic | Hyposmic | Anosmic |
| TOAST criteria | ||||
| Large artery atherosclerosis | 11 | 7 | 2 | 2 |
| Cardioembolism | 21 | 14 | 4 | 3 |
| Small vessel occlusion | 14 | 7 | 4 | 3 |
| Stroke of other determined etiology | 1 | 1 | 0 | 0 |
| Stroke of undetermined etiology | 26 | 11 | 11 | 4 |
| OCPS criteria | ||||
| PACI | 37 | 18 | 11 | 8 |
| POCI | 12 | 9 | 2 | 1 |
| TACI | 4 | 2 | 1 | 1 |
| LACI | 20 | 11 | 7 | 2 |
| Variable | Response | Surgeon 1 | Surgeon 2 | P |
| Operative time, no previous abdominal surgery | N, Mean ± SD | 59, 45.6 ± 12.9 | 13, 73.2 ± 13.6 | < 0.001 |
| Operative time, previous abdominal surgery | N, Mean ± SD | 43, 44.0 ± 12.6 | 2, 115.5 ± 2.1 | 0.019 |
| Region | Control | Autism | t-value | P |
| Amygdala | 3.93 ± 0.64 | 3.69 ± 0.57 | 0.58 | 0.58 |
| Caudate nucleus | 4.28 ± 0.47 | 4.56 ± 0.62 | 0.67 | 0.52 |
| Cerebellum | 1.07 ± 0.10 | 1.25 ± 0.068 | 3.17 | 0.016 |
| Cingulate | 4.33 ± 0.43 | 4.42 ± 0.23 | 0.42 | 0.68 |
| Entorhinal area | 1.78 ± 0.71 | 2.75 ± 0.59 | 2.19 | 0.065 |
| Frontal lobe | 4.11 ± 0.39 | 4.28 ± 0.22 | 0.87 | 0.41 |
| Fusiform gyrus | 3.86 ± 0.49 | 3.69 ± 0.52 | 0.47 | 0.65 |
| Globus pallidus | 1.12 ± 0.14 | 1.28 ± 0.15 | 1.58 | 0.16 |
| Hippocampus | 3.74 ± 0.67 | 3.66 ± 0.52 | 0.21 | 0.84 |
| Insula | 4.58 ± 0.62 | 4.49 ± 0.51 | 0.22 | 0.83 |
| Occipital lobe | 3.22 ± 0.39 | 3.35 ± 0.15 | 0.79 | 0.46 |
| Paracentral gyrus | 2.89 ± 0.44 | 3.36 ± 0.32 | 1.83 | 0.11 |
| Parahippocampus | 3.25 ± 0.09 | 3.55 ± 0.40 | 1.22 | 0.26 |
| Parietal lobe | 3.93 ± 0.36 | 4.10 ± 0.14 | 1.08 | 0.32 |
| Precentral gyrus | 3.55 ± 0.38 | 3.86 ± 0.12 | 1.89 | 0.10 |
| Precuneus | 3.87 ± 0.24 | 4.19 ± 0.20 | 2.13 | 0.071 |
| Postcentral gyrus | 3.44 ± 0.22 | 3.82 ± 0.20 | 2.60 | 0.036 |
| Putamen | 3.90 ± 0.54 | 4.18 ± 0.33 | 0.91 | 0.39 |
| Temporal lobe | 4.23 ± 0.57 | 4.23 ± 0.30 | 0.02 | 1.00 |
| Thalamus | 2.43 ± 0.28 | 2.50 ± 0.29 | 0.37 | 0.72 |
| Ventral striatum | 4.75 ± 0.66 | 5.10 ± 0.50 | 0.89 | 0.40 |
| \"0\" + EC | \"0\" + NEC | p | |
| Number of cycles | 50 | 39 | |
| Maternal age (mean ± SD) | 30.3 ± 4.0 | 31.6 ± 3.4 | >0.5 |
| Total number of embryos transferred | 75 | 75 | |
| Mean ± SD embryos/cycle | 1.5 ± 0.5 | 1.9 ± 0.5 | 0.000 |
| Biochemical pregnancies | 30 | 17 | |
| bPR (%) | 60 | 44 | >0.5 |
| Clinical pregnancies | 28 | 12 | |
| cPR (%) | 56 | 31 | 0.020 |
| Number of gestational sacs by US | 32 | 20 | |
| IR (%) | 43 | 27 | 0.038 |
| Current study | Previous studies | ||||
| SSCa | Position 1 | Position 2 | Position 1 | Position 2 | Trait |
| 1 | 181,896,016 | 186,896,016 | 105,873,529 | 290,457,491 | teat number [39] |
| 165,580,236 | 257,944,209 | nonfunctional nipples [41] | |||
| 183,913,205 | 184,015,342 | total number born [48] | |||
| 183,913,205 | 184,015,342 | total number born alive [48] | |||
| 184,917,301 | 185,121,617 | corpus luteum number [36] | |||
| 185,717,517 | 185,784,945 | corpus luteum number [36] | |||
| 2 | 138,703,617 | 143,703,617 | 116,028,974 | 145,137,405 | corpus luteum number [36] |
| 139,963,748 | 140,963,748 | 138,002,690 | 142,235,710 | nonfunctional nipples [41] | |
| 141,775,934 | 142,775,934 | 139,070,668 | 139,947,117 | age at puberty [43] | |
| 139,359,663 | 150,135,089 | nonfunctional nipples [42] | |||
| 139,525,787 | 139,963,748 | mummified pigs [20] | |||
| 139,841,202 | 139,989,204 | corpus luteum number [36] | |||
| 140,050,554 | 140,262,094 | total number born [20] | |||
| 140,443,704 | 140,934,348 | teat number [40] | |||
| 3 | 5,484,217 | 6,484,217 | 1,456,046 | 130,209,174 | teat number [39] |
| 6,342,416 | 7,342,416 | 4,571,903 | 82,495,610 | corpus luteum number [37] | |
| 6 | 154,583,417 | 157,083,417 | 19,536,155 | 157,765,593 | teat number [39] |
| 7 | 34,743,041 | 35,743,041 | 8,014,191 | 92,220,281 | corpus luteum number [38] |
| 10,763,543 | 117,929,721 | teat number [39] | |||
| 11,136,187 | 116,028,974 | corpus luteum number [36] | |||
| 16,365,408 | 42,509,154 | age at puberty [7] | |||
| 34,692,239 | 35,120,284 | total number born [44] | |||
| 34,692,239 | 35,120,284 | total number born alive [44] | |||
| 34,692,239 | 35,120,284 | litter weight, total [44] | |||
| 9 | 70,252,726 | 71,252,726 | 39,568,811 | 138,751,051 | corpus luteum number [37] |
| 13 | 139,777,016 | 142,277,016 | 5,836,383 | 188,271,972 | nonfunctional nipples [41] |
| 140,304,656 | 142,804,656 | 18,268,056 | 206,704,152 | corpus luteum number [38] | |
| 91,625,750 | 145,083,047 | embryo weight [45] | |||
| 141,246,965 | 141,992,388 | age at puberty [43] | |||
| 14 | 8,423,533 | 13,423,533 | 12,814,009 | 12,929,926 | total number born [20] |
| 141,048,490 | 143,548,490 | 141,246,965 | 141,992,388 | age at puberty [43] |
| Organs | %ID/g | |||||
| 4 h | 24 h | 120 h | ||||
| 131I-prohy | CA4P + 131I-prohy | 131I-prohy | CA4P + 131I-prohy | 131I-prohy | CA4P + 131I-prohy | |
| Blood | 4.43 ± 0.14 | 4.75 ± 0.65 | 0.66 ± 0.08 | 0.74 ± 0.03 | 0.06 ± 0.01 | 0.09 ± 0.02* |
| Thyroid | 0.47 ± 0.03 | 1.14 ± 0.07** | 0.08 ± 0.02 | 0.36 ± 0.02** | 0.12 ± 0.03 | 0.25 ± 0.11 |
| Lung | 2.71 ± 0.23 | 2.64 ± 0.23 | 1.68 ± 0.16 | 1.27 ± 0.40 | 0.20 ± 0.04 | 0.26 ± 0.08 |
| Heart | 1.26 ± 0.11 | 1.61 ± 0.13* | 0.54 ± 0.16 | 0.32 ± 0.02 | 0.24 ± 0.07 | 0.12 ± 0.02* |
| liver | 5.60 ± 0.38 | 5.84 ± 0.40 | 2.13 ± 0.38 | 1.88 ± 0.24 | 0.70 ± 0.10 | 0.75 ± 0.08 |
| Spleen | 2.48 ± 0.06 | 2.98 ± 0.46 | 1.05 ± 0.08 | 0.74 ± 0.10* | 0.31 ± 0.01 | 0.38 ± 0.05 |
| Kidney | 2.61 ± 0.29 | 2.75 ± 0.09 | 1.22 ± 0.13 | 1.24 ± 0.19 | 0.13 ± 0.01 | 0.19 ± 0.02* |
| Stomach | 0.74 ± 0.14 | 1.14 ± 0.27 | 0.44 ± 0.08 | 0.47 ± 0.09 | 0.07 ± 0.01 | 0.14 ± 0.02* |
| Muscle | 0.45 ± 0.15 | 0.38 ± 0.01 | 0.10 ± 0.02 | 0.15 ± 0.05 | 0.02 ± 0.00 | 0.06 ± 0.01** |
| Bone | 1.57 ± 0.11 | 1.34 ± 0.11 | 0.26 ± 0.06 | 0.40 ± 0.14 | 0.10 ± 0.01 | 0.09 ± 0.01 |
| Small intestine | 2.36 ± 0.24 | 2.20 ± 0.40 | 0.28 ± 0.15 | 0.33 ± 0.03 | 0.09 ± 0.01 | 0.11 ± 0.03 |
| Larger intestine | 1.23 ± 0.09 | 1.70 ± 0.31 | 0.33 ± 0.12 | 0.54 ± 0.08 | 0.06 ± 0.01 | 0.15 ± 0.05* |
| Necrotic Tumor | 1.99 ± 0.29 | 3.01 ± 0.35* | 2.96 ± 0.34 | 3.87 ± 0.38* | 1.45 ± 0.31 | 2.14 ± 0.19* |
| Viable Tumor | 2.16 ± 0.71 | 3.05 ± 0.38 | 1.26 ± 0.31 | 1.48 ± 0.04 | 0.51 ± 0.02 | 0.41 ± 0.09 |
| Age, sex | NOAC | Lesion | Prescription (month) | BARC | Other factors |
| Upper GI | |||||
| 92 F | D | Gastric ulcer | 11 | 3a | PPI (-) |
| 96 F | R | Gastric ulcer | 42 | 3a | PPI (-) |
| 63 M | R | Duodenal ulcer | 29 | 3b | PPI (-) |
| 74 M | R | Gastric ulcer | 32 | 3a | PPI (-) |
| 83 F | A | Gastric ulcer | 16 | 3a | PPI (-) |
| 84 M | A | Ulcers/o | 12 | 3a | PPI (-), steroid |
| 72 M | A | Duodenal ulcer | 25 | 3b | PPI (-), operation |
| Lower GI | |||||
| 78 M | D | Ileal erosion | 23 | 3a | DAPT |
| 80 M | D | Colon diverticulosis | 7 | 3a | - |
| 72 F | R | Colon vascular ectasia | 8 | 3a | NSAID, steroid |
| 75 M | R | Post EMR for colon polyp | 24 | 3a | LDA |
| 85 F | A | Colon diverticulosis | 3 | 3b | NSAID |
| Parameter or measurement | July | Aug | Sept | Oct | Nov | Dec |
| OPD attendances | 14,940 | 15,354 | 10,927 | 13,265 | 9,561 | 10,737 |
| Presumed malaria | 8,041 | 7,733 | 5,844 | 6,576 | 5,430 | 5,412 |
| (%)* | (40%) | (41%) | (40%) | (37%) | (42%) | (40%) |
| Anti-malaria prescriptions | 5,143 | 5,550 | 3,815 | 4121 | 3,486 | 3,814 |
| RDT-negative treated | 871 | 1,056 | 787 | 828 | 585 | 534 |
| % RDT negatives | 35.0 | 34.4 | 33.9 | 29.4 | 27.3 | 29.0 |
| treated as malaria(CI) | (20-50) | (19-50) | (23-45) | (19-40) | (15-39) | (19-39) |
| Risk ratio^ | 0.71[0.53-0.96] | 0.60[0.58-0.63] | 0.64[0.48-0.87] | 0.59[0.42-083] | 0.68[0.50-0.92] | 0.67[0.46-0.97] |
| p-value | 0.029 | <0.001 | 0.008 | 0.004 | 0.023 | 0.05 |
| Order | Reading | Location (x, y) |
| 1 | 1 | (1.5, 3.0) |
| 2 | 4 | (3.0, 3.3) |
| 3 | 4 | (2.8, 1.9) |
| 4 | 5 | (2.3, 0.9) |
| 5 | 3 | (4.3, 0.4) |
| 6 | 5 | (5.8, 1.3) |
| 7 | 6 | (5.4, 2.9) |
| 8 | 7 | (4.3, 4.0) |
| 9 | 3 | (2.2, 4.4) |
| 10 | 2 | (3.7, 5.7) |
| 11 | 10 | (6.3, 4.7) |
| CMM | SCC | |||
| Events/Pyr1 | OR (95% CI) | Events/Pyr | OR (95% CI) | |
| Sex | ||||
| Female | 2058/173 679 | 1.00 ref | 1893/81 108 | 1.00 ref |
| Male | 1938/115 144 | 1.51 (1.41,1.63) | 3719/94 533 | 1.90 (1.79,2.01) |
| Age2 | ||||
| < 40 years | 80/31 862 | 1.00 ref | 19/3020 | 1.00 ref |
| 40-59 years | 807/106 669 | 2.89 (2.29,3.65) | 222//17 362 | 2.28 (1.42,3.66) |
| ≥ 60 years | 3109/147 183 | 6.67 (5.31,8.39) | 5371/155 259 | 4.62 (2.93,7.29) |
| Residential region3 | ||||
| North | 275/23 927 | 1.00 ref | 419/15 325 | 1.00 ref |
| Mid | 703/54 955 | 1.09 (0.95,1.26) | 1124/37 786 | 1.09 (0.98,1.23) |
| South | 3018/209 941 | 1.20 (1.06,1.36) | 4069/122 530 | 1.20 (1.08,1.33) |
| Calendar period2 | ||||
| < 1965 | 6/2959 | 1.00 ref | 35/4411 | 1.00 ref |
| 1965-1974 | 71/13 448 | 3.01 (1.30,6.98) | 168/10 542 | 2.51 (1.73,3.64) |
| 1975-1984 | 276/34 380 | 4.92 (2.15,11.24) | 438/22 580 | 3.61 (2.50,5.20) |
| 1985-1994 | 913/69 763 | 7.80 (3.43,17.34) | 1281/40 225 | 6.46 (4.52,9.24) |
| 1995-2004 | 1707/112 983 | 8.88 (3.91,20.17) | 2364/64 765 | 7.76 (5.44,11.1) |
| ≥ 2004 | 1023/55 290 | 10.52 (4.63,23.9) | 1326/33 118 | 8.73 (6.10,12.5) |
| Educational level4 | ||||
| ≤ Primary | 63/5193 | 1.00 ref | 178/6203 | 1.00 ref |
| Secondary | 1285/85 407 | 0.80 (0.61,1.04) | 2514/82 333 | 0.60 (0.50,0.71) |
| Some college | 1293/85 733 | 0.79 (0.60,1.05) | 1577/46 489 | 0.60 (0.50,0.72) |
| ≥ College degree | 1355/112 490 | 0.80 (0.61,1.05) | 1343/40 616 | 0.61 (0.51,0.74) |
| Marital status3 | ||||
| Not married | 1089/84 671 | 1.00 ref | 2161/72 265 | 1.00 ref |
| Married | 2907/204 152 | 1.02 (0.94,1.10) | 3451/103 376 | 1.01 (0.95,1.08) |
| Parental status4 | ||||
| No children | 881/68 530 | 1.00 ref | 1692/56 884 | 1.00 ref |
| Children | 3115/220 293 | 0.91 (0.84,0.99) | 3920/118 757 | 0.93 (0.87,0.99) |
| Income (annual)3 | ||||
| $ 05 | 1586/81 524 | 1.00 ref | 3982/113 773 | 1.00 ref |
| $ 80–9 999 | 679/57 594 | 0.83 (0.75,0.91) | 715/24 518 | 0.85 (0.78,0.92) |
| $ 10 000–19 999 | 514/50 340 | 0.68 (0.61,0.75) | 300/12 099 | 0.76 (0.67,0.85) |
| $ 20 000–39 999 | 713/57 131 | 0.75 (0.68,0.82) | 334/13 692 | 0.65 (0.58,0.74) |
| $ ≥ 40 000 | 504/42 234 | 0.65 (0.58,0.73) | 281/11 559 | 0.59 (0.51,0.67) |
| New | ||||
| Risk Factor | Adjusted Odds Ratio | 95% Confidence Interval | P-value | |
| Any family member suffering from hepatitis B & C | Yes | 14.5 | 9.5-22.1 | 0.001 |
| No | Reference | |||
| Dental extract/filling/scaling | Yes | 1.9 | 1.4-2.7 | 0.001 |
| No | Reference | |||
| Blood transfusion | Yes | 2.9 | 1.2-7.3 | 0.017 |
| No | Reference | |||
| History of IV/IM injection/year | None | Reference | ||
| < 5/year | 2.1 | 1.3-3.4 | 0.003 | |
| ≥/year | 5.8 | 3.5-9.6 | 0.001 |
| Case | Age | Gender | HSCT source | Underlying disease | Interval between HSCT and CM analysis (mo) | Interval between DE onset and CM analysis (mo) | Interval between HSCT and DE onset (mo) | DE severity level | CC | Clinically affected cGVHD organs |
| 1 | 57 | Male | PBSC | ML | 17 | 1 | 16 | 3 | - | Eye, Skin |
| 2 | 47 | Male | PBSC | AML | 19 | 6 | 13 | 4 | + | Eye, Skin, Mouth, Liver |
| 3 | 50 | Male | PBSC | MM | 12 | 1 | 11 | 4 | + | Eye, Mouth |
| 4 | 47 | Female | BM | MM | 43 | 1 | 42 | 4 | + | Eye, Mouth |
| 5 | 38 | Female | BM | AML | 12 | 0 | 12 | 2 | - | Eye |
| 6 | 57 | Male | BM | MDS | 14 | N.A. | N.A. | 3 | + | Eye |
| 7 | 51 | Male | BM | CML | 120 | 48 | 72 | 2 | - | Eye |
| 8 | 46 | Female | PBSC | MM | 116 | 108 | 8 | 2 | - | Eye |
| 9 | 55 | Male | PBSC | AML | 25 | 17 | 8 | 4 | + | Eye, Skin |
| SNP rsID | Marker name | Amino acid change | Chromosome | Cytoband | P-values |
| rs4149015 | SLCO1B1 c.-11187G > A | Promoter | 12 | p12.2 | 0.0001 |
| rs1060253 | SLC7A5 c.∗438C > G | 3′UTR | 16 | q24.2 | 0.0005 |
| rs4149117 | SLCO1B3 c.334G > T | A112S | 12 | p12.2 | 0.0021 |
| rs7311358 | SLCO1B3 c.699A > G | I233M | 12 | p12.2 | 0.0021 |
| rs2053098 | SLCO1B3 c.1557G > A | A519A | 12 | p12.2 | 0.0021 |
| rs4149056 | SLCO1B1 c.521T > C | V174A | 12 | p12.1 | 0.0090 |
| Active partitions MIC values (μg/ml) | Reference antibioticsMIC values (μg/ml) | ||||
| CSBt | CSEA | Amox | Gent | Vanc | |
| Gram – bacteria | |||||
| Escherichia coli T20A2 | NA | NA | S | R | R |
| Pseudomonas aeruginosa T41 | NA | NA | R | S | R |
| Pseudomonas aeruginosa ATCC9027 | NA | NA | R | S | R |
| Gram + bacteria | |||||
| Dermabacter hominis T47A7 | 312 | 625 | R | S | S |
| Dermabacter hominis T49B5 | 312 | 625 | S | S | S |
| Corynebacterium striatum T40A3 | NA | NA | R | R | S |
| Corynebacterium striatum T46C1 | NA | NA | S | S | S |
| Enterococcus faecalis T37B1 | NA | NA | S | S | S |
| Enterococcus faecalis T47A16 | NA | NA | R | S | S |
| Streptococcus agalactiae T53A4 | NA | NA | R | R | R |
| Staphylococcus aureus T2510 | 312 | 625 | R | S | S |
| Staphylococcus aureus T281 | NA | NA | R | S | S |
| Staphylococcus aureus 8143 | 312 | 625 | S | S | S |
| Staphylococcus aureus 8148 | 312 | 625 | R | S | S |
| Staphylococcus aureus 8142 | NA | NA | R | S | S |
| Staphylococcus aureus T61 | NA | NA | R | S | S |
| Staphylococcus aureus T21 | 312 | 625 | R | S | S |
| Staphylococcus aureus T11 | NA | NA | R | S | S |
| Staphylococcus aureus T306 | 312 | 625 | S | S | S |
| Staphylococcus aureus T26A4 | 625 | 625 | R | S | S |
| Staphylococcus epidermidis T151 | NA | NA | R | R | S |
| Staphylococcus epidermidis T19A1 | NA | NA | S | S | R |
| Staphylococcus capitis T21A3 | NA | NA | S | S | S |
| Staphylococcus capitis T29A2 | NA | NA | S | S | S |
| Staphylococcus pettenkoferi T282 | NA | NA | S | S | S |
| Staphylococcus pettenkoferi T33 | NA | NA | R | S | S |
| Staphylococcus saprophyticus 8237 | NA | NA | S | S | S |
| Staphylococcus lugdunensis T36A1 | NA | NA | S | S | S |
| Staphylococcus lugdunensis T47B2 | NA | NA | S | S | S |
| Credit Points(Score) | Class | Premium Reduction | Number of LouisianaParishes | |
| (SFHA) | Non-SFHA | |||
| 4500+ | 1 | 45% | 10% | 0 |
| 4000–4499 | 2 | 40% | 10% | 0 |
| 3500–3999 | 3 | 35% | 10% | 0 |
| 3000–3499 | 4 | 30% | 10% | 0 |
| 2500–2999 | 5 | 25% | 10% | 0 |
| 2000–2499 | 6 | 20% | 10% | 3 |
| 1500–1999 | 7 | 15% | 5% | 2 |
| 1000–1499 | 8 | 10% | 5% | 8 |
| 500–999 | 9 | 5% | 5% | 2 |
| 0–499 | 10 | 0% | 0% | 1 |
| Rest | ΔActive standing | ΔHandgrip | ||||
| T1D | CON | T1D | CON | T1D | CON | |
| Heart rate (bpm) | 59 (12) | 58 (16) | +20* (13) | +26* (16) | +22* (16)‡ | +27* (21)† |
| Breathing frequency (Hz) | 0.19 (0.12)‡ | 0.20 (0.18) | +0.03* (0.03)‡ | 0.00 (0.08) | +0.08* (0.08)‡ | +0.05*(0.11) |
| Blood pressure | ||||||
| Systolic (mmHg) | 118 (18) | 121 (22) | +4.4 (11) | −5.0 (24) | +40* (20)§ | +41* (23) |
| Diastolic (mmHg) | 66 (8) | 65 (7) | +11* (9) | +7.6* (12) | +26* (16)§ | +29* (9) |
| Species | ||||
| Habitat characteristics | An. arabiensis | An. chrysti | An. cinereus | An. demeilloni |
| Correlation | ||||
| pH | −0.2 | 0.0 | 0.1 | −0.2 |
| Temperature (0 C) | 0.3* | −0.1 | 0.2 | −0.3* |
| Depth (cm) | −0.6** | 0.2 | 0.0 | 0.2 |
| Differences of means (medians) | ||||
| Substrate | ||||
| Muddy | 1.9 (0.0)** | 52.5(25.8)* | 19.2 (2.3) | 15.8 (14.3) |
| Sandy | 61.5 (23.3) | 17.7 (4.1) | 54.1 (12.5) | 16.7 (4.2) |
| Turbidity | ||||
| Low | 39.5 (2.5) | 31.1 (7.7) | 42.2 (7.5) | 15.9 (5.0) |
| Medium | 1.1(1.1) | 40.9(40.9) | 0.0 | 23.9 (24.0) |
| Surface debris | ||||
| Present | 38.0 (2.2) | 32.4 (8.7) | 42.2 (7.5) | 15.0 (5.1) |
| Absent | 30.3 (30.3) | 17.7 (17.7) | 0.0 | 42.1 (42.1) |
| Surface Algae | ||||
| Present | 38.6 (2.2) | 32.2 (8.9) | 41.1 (7.4) | 16.7 (7.6) |
| Absent | 0.0 | 8.6 (8.6) | 2.9 (2.9) | 0.0 |
| Metals | Cu | Zn | As | Hg | Pb | Cd | Cr |
| Cu | 1 | ||||||
| Zn | –0.256 | 1 | |||||
| As | 0.194 | 0.467** | 1 | ||||
| Hg | 0.725** | –0.389** | 0.124 | 1 | |||
| Pb | 0.658** | –0.032 | 0.306 | 0.648** | 1 | ||
| Cd | –0.039 | 0.491** | 0.511** | –0.002 | 0.148 | 1 | |
| Cr | 0.286 | 0.102 | 0.233 | 0.214 | 0.011 | –0.066 | 1 |
| SNV | bp | Conserved Regiona | P-Valueb | Allelesc | MAFd | Unaffected | Scoliosis | Kyphoscoliosis | |||||||
| rs114080324 | 2947499 | Yes | 0.116 | G/A | 0.006 | GG | GG | GG | — | GG | AG | AG | AG | AG | AG |
| rs183225473 | 3045672 | No | 0.039 | G/C | 0.006 | GG | GG | GG | CG | GG | CG | CG | CG | CG | CG |
| rs10068728 | 3045983 | Yes | 0.034 | T/G | 0.27 | TT | TT | TT | TG | TT | — | TG | TG | TG | TG |
| rs146531224 | 3046004 | No | 0.039 | G/A | 0.006 | GG | GG | GG | AG | GG | AG | AG | AG | AG | AG |
| rs117273909 | 3182971 | Yes | 0.039 | C/T | 0.005 | CC | CC | CC | CT | CC | CT | CT | CT | CT | CT |
| rs111916055 | 3187995 | No | 0.034 | A/G | 0.028 | AA | AA | AA | AG | AA | — | AG | AG | AG | AG |
| Novel | 3188045 | No | 0.083 | T/G | NA | TT | TT | TT | AT | TT | — | AT | AT | — | AT |
| rs16871553 | 3269602 | No | 0.029 | C/T | 0.109 | TT | TT | TT | CT | TT | CT | CT | CT | CT | — |
| rs73733752 | 3278780 | No | 0.039 | A/G | 0.03 | AA | AA | AA | AG | AA | AG | AG | AG | AG | AG |
| Variables | All | Physicians | Nurses | |||
| % | N | % | N | % | N | |
| Gender | ||||||
| Male | 29.5 | 156 | 56.6 | 103 | 15.3 | 53 |
| Female | 70.5 | 373 | 43.4 | 79 | 84.7 | 294 |
| Age (years) | ||||||
| ≤30 | 44.1 | 233 | 26.9 | 49 | 53.2 | 184 |
| 31 to 40 | 31.1 | 164 | 31.9 | 58 | 30.6 | 106 |
| >40 | 24.8 | 131 | 41.2 | 75 | 16.2 | 56 |
| Skin color | ||||||
| White | 63.9 | 338 | 67.6 | 123 | 62.0 | 215 |
| Others | 36.1 | 191 | 32.4 | 59 | 38.0 | 132 |
| Specialization degree in Public or Family Health | ||||||
| Yes | 10.8 | 57 | 9.3 | 17 | 11.5 | 40 |
| No | 89.2 | 447 | 90.7 | 165 | 88.5 | 307 |
| Time since the last academic degree (years) | ||||||
| <5 | 68.3 | 359 | 50.8 | 92 | 77.4 | 267 |
| 5 to 10 | 15.4 | 81 | 14.4 | 26 | 15.9 | 55 |
| >10 | 16.3 | 86 | 34.8 | 63 | 6.7 | 23 |
| Working hours per week | ||||||
| <40 | 30.6 | 161 | 45.6 | 82 | 22.8 | 79 |
| ≥40 | 69.4 | 365 | 54.4 | 98 | 77.2 | 267 |
| Working time at the health care unit (years) | ||||||
| ≤1 | 37.9 | 198 | 49.7 | 90 | 31.7 | 108 |
| 2 to 5 | 43.9 | 229 | 32.0 | 58 | 50.1 | 171 |
| >5 | 18.2 | 95 | 18.3 | 33 | 18.2 | 62 |
| Patients attending per week | ||||||
| ≤80 | 54.0 | 271 | 29.2 | 52 | 67.6 | 219 |
| 80 to 160 | 33.7 | 169 | 50.0 | 89 | 24.7 | 80 |
| >160 | 12.3 | 62 | 20.8 | 37 | 7.7 | 25 |
| Total | 100 | 529 | 100 | 182 | 100 | 347 |
| Variable | Cases 2002–2008 (N = 1064) | Cases 2013–2015 | P | ||||
| Total cases N = 990 | Anterior N = 530 | Intermediate N = 74 | Panuveitis N = 226 | Posterior N = 160 | |||
| Median age at presentation years (IQR) | 40 (26–55) | 44 (29–57)* | 45 (32–59) | 26 (15–46) | 45 (30–58) | 42 (29–55) | <0.001 |
| Gender | 0.300 | ||||||
| Male | 481 (45) | 403 (41)* | 204 (38) | 36 (49) | 93 (41) | 70 (44) | |
| Female | 583 (55) | 587 (59) | 326 (62) | 38 (51) | 133 (59) | 90 (56) | |
| Site | <0.001 | ||||||
| Unilateral | 825 (78) | 499 (50)* | 364 (69) | 13 (18) | 57 (25) | 65 (41) | |
| Bilateral | 239 (22) | 491 (50) | 166 (31) | 61 (82) | 169 (75) | 95 (59) | |
| Granulomatous | <0.001 | ||||||
| Yes | 553 (52) | 545 (55) | 312 (59) | 13 (18) | 147 (65) | 73 (46) | |
| No | 511 (48) | 445 (45) | 218 (41) | 61 (82) | 79 (35) | 87 (54) | |
| Non-Italian ethnicity | 31 (3) | 106 (11)* | 43 (8) | 6 (8) | 44 (19) | 13 (8) | <0.001 |
| Has a specific diagnosis | 787 (74) | 759 (77) | 404 (76) | 45 (61) | 177 (78) | 133 (84) | 0.002 |
| Infectious etiology | 257 (24) | 301 (30)* | 173 (43) | 3 (7) | 68 (38) | 57 (43) | <0.001 |
| Systemic disease | na | 259 (26) | 114 (21) | 12 (16) | 110 (49) | 23 (14) | <0.001 |
| Total number of patients(n = 376) | |
| Trials | |
| Ludman [27] | 40 (11%) |
| Crimi [28] | 76 (20%) |
| Garcia-Dorado [30] | 177 (47%) |
| White [29] | 83 (22%) |
| Randomization | |
| Intervention | 191 (51%) |
| Placebo | 185 (49%) |
| Age | 59 ± 12 |
| Sex — male | 193 (51%) |
| Risk factors | |
| Smoking | 221 (59%) |
| Hypertension | 166 (44%) |
| Dyslipidemia | 117 (31%) |
| Diabetes Mellitus | 55 (15%) |
| Family history of CAD | 72 (19%) |
| Pre-infarct angina | 108 (29%) |
| Onset to balloon time/min | 215 ± 97 |
| Artery involved | |
| LAD | 211 (56%) |
| RCA | 71 (19%) |
| Cx | 94 (25%) |
| TIMI flow pre-PPCI | |
| 0 | 365 (97%) |
| 1 | 11 (3%) |
| Rentrop collateral flow | |
| 0 | 287 (76%) |
| 1 | 61 (16%) |
| 2 | 28 (7%) |
| TIMI flow post-PPCI | |
| 1 | 1 (1%) |
| 2 | 43 (11%) |
| 3 | 330 (88%) |
| CMR details | |
| LVEDV | 154 ± 36 |
| LVESV | 78 ± 31 |
| LVEF | 50 ± 11 |
| MI size/%LV | 22 ± 11 |
| AAR/%LV | 33 ± 12 |
| MI size/%AAR | 64 ± 21 |
| MVO/% | 111 (53%) |
| Probe Set ID | Gene Title | Gene Symbol | FC in tumors | GO biological function |
| 99104_at | adiponectin, C1Q and collagen domain containing | Adipoq | -21.75 | Lipid metabolism, Organic acid metabolism |
| 99671_at | adipsin | Adn | -35.98 | |
| 98924_at | ADP-ribosyltransferase 3 | Art3 | -2.55 | |
| 92537_g_at | adrenergic receptor, beta 3 | Adrb3 | -2.88 | |
| 102327_at | amine oxidase, copper containing 3 | Aoc3 | -3.66 | Cell adhesion |
| 96785_at | ankyrin repeat domain 47 | Ankrd47 | -2.04 | |
| 104761_at | anthrax toxin receptor 2 | Antxr2 | -1.60 | |
| 160375_at | carbonic anhydrase 3 | Car3 | -20.83 | |
| 101539_f_at | carboxylesterase 3 | Ces3 | -4.06 | Lipid metabolism, Organic acid metabolism |
| 102016_at | cell death-inducing DFFA-like effector c | Cidec | -4.79 | |
| 95415_f_at | complement component 1, r subcomponent | C1r | -2.64 | |
| 92224_at | C-type lectin domain family 3, member b | Clec3b | -5.87 | |
| 96346_at | cysteine dioxygenase 1, cytosolic | Cdo1 | -9.76 | Organic acid metabolism |
| 93996_at | cytochrome P450, family 2, subfamily e, polypeptide 1 | Cyp2e1 | -3.54 | |
| 96742_at | dermatopontin | Dpt | -5.06 | Cell adhesion |
| 103031_g_at | dynamin 1 | Dnm1 | -2.21 | |
| 92535_at | early B-cell factor 1 | Ebf1 | -1.81 | |
| 100567_at | fatty acid binding protein 4, adipocyte | Fabp4 | -2.31 | |
| 92441_at | fibroblast activation protein | Fap | -2.27 | |
| 101991_at | flavin containing monooxygenase 1 | Fmo1 | -3.20 | |
| 93040_at | FXYD domain-containing ion transport regulator 1 | Fxyd1 | -2.69 | |
| 93750_at | gelsolin | Gsn | -5.43 | |
| 102373_at | glutamyl aminopeptidase | Enpep | -2.86 | |
| 99108_s_at | growth hormone receptor | Ghr | -1.99 | |
| 92833_at | histidine ammonia lyase | Hal | -2.25 | Organic acid metabolism |
| 95546_g_at | insulin-like growth factor 1 | Igf1 | -2.07 | |
| 103904_at | insulin-like growth factor binding protein 6 | Igfbp6 | -4.34 | |
| 92366_at | laminin, alpha 2 | Lama2 | -3.25 | Cell adhesion |
| 103083_at | lipase, hormone sensitive | Lipe | -2.46 | Lipid metabolism |
| 160083_at/95611_at | lipoprotein lipase | Lpl | -5.18 | Lipid metabolism |
| 93353_at | lumican | Lum | -9.33 | |
| 97520_s_at | neuronatin | Nnat | -5.92 | |
| 100120_at | nidogen 1 | Nid1 | -2.19 | Cell adhesion |
| 160481_at | phosphoenolpyruvate carboxykinase 1, cytosolic | Pck1 | -2.61 | Lipid metabolism, Organic acid metabolism |
| 102763_at | plasma membrane associated protein, S3-12 | MGI:1929709 | -8.13 | |
| 93826_at | protein phosphatase 2, regulatory subunit B (B56), alpha isoform | Ppp2r5a | -1.43 | |
| 102366_at | resistin | Retn | -10.89 | |
| 97835_at | retinoic acid receptor responder (tazarotene induced) 2 | Rarres2 | -6.19 | |
| 96047_at | retinol binding protein 4, plasma | Rbp4 | -4.08 | |
| 104445_at | RIKEN cDNA 4631408O11 gene | 4631408O11Rik | -5.20 | |
| 101861_at | sarcoglycan, epsilon | Sgce | -1.62 | |
| 102707_f_at | serine (or cysteine) peptidase inhibitor, clade A, member 3C | Serpina3c | -1.94 | |
| 97429_at | SNF related kinase | Snrk | -1.65 | |
| 92582_at | solute carrier family 1 (neutral amino acid transporter), member 5 | Slc1a5 | -1.94 | |
| 160320_at | sorbin and SH3 domain containing 1 | Sorbs1 | -2.74 | Cell adhesion |
| 94056_at/94057_g_at | stearoyl-Coenzyme A desaturase 1 | Scd1 | -2.76 | Lipid metabolism, Organic acid metabolism |
| 103087_at | sulfotransferase family 1A, phenol-preferring, member 1 | Sult1a1 | -1.68 | Lipid metabolism |
| 103568_at | sushi-repeat-containing protein | Srpx | -2.84 | |
| 104280_at | synuclein, gamma | Sncg | -4.63 | |
| 102916_s_at/161907_s_at | tenascin XB | Tnxb | -4.73 | Cell adhesion |
| 160547_s_at | thioredoxin interacting protein | Txnip | -2.83 | |
| 99052_at | zinc finger homeobox 1a | Zfhx1a | -1.63 |
| Studies groups | No of reports | Relative risk (95% CI) | Heterogeneity | P for test | |
| P value | I2 (%) | ||||
| Total | 22 | 0.86 (0.78–0.92) | 0.001 | 54.9% | 0.002 |
| Tumour subtype | |||||
| Glioma | 16 | 0.94 (0.88–0.99) | 0.003 | 57.0% | 0.042 |
| Meningioma | 1 | 0.97 (0.64–1.47) | 0.880 | ||
| Glioblastoma | 5 | 0.78 (0.63–0.95) | 0.883 | 0.0% | 0.014 |
| Study design | |||||
| Case–control | 19 | 0.88 (0.78–0.95) | 0.000 | 60.3% | < 0.001 |
| Cohort | 3 | 0.93 (0.85–0.98) | 0.686 | 0.0% | 0.013 |
| No of participants | |||||
| ≥ 10 000 | 17 | 0.87 (0.78–0.91) | 0.000 | 66.0% | 0.003 |
| < 10 000 | 5 | 0.91 (0.85–0.97) | 0.155 | 46.3% | < 0.001 |
| No of cases | |||||
| ≥ 1000 | 11 | 0.83 (0.73–0.94) | 0.162 | 24.2% | 0.005 |
| < 1000 | 11 | 0.90 (0.81–0.98) | 0.001 | 65.8% | 0.013 |
| Study quality | |||||
| Score ≥ 7 | 20 | 0.88 (0.78–0.98) | 0.002 | 54.6% | 0.007 |
| Score < 7 | 2 | 0.74 (0.67–0.82) | 0.448 | 0.0% | < 0.001 |
| STX | Okadaic Acid, DTXS | Domoic Acid | ||||
| (PSP) | (DSP) | (ASP) | ||||
| Sampling Date | Multi SPR | ELISA | Multi SPR | ELISA | Multi SPR | ELISA |
| 24.07.2011 | − | − | − | − | − | − |
| 08.08.2011 | − | − | − | + | − | − |
| 22.08.2011 | − | + | − | + | − | − |
| 04.10.2011 | − | + | − | + | − | + |
| 20.10.2011 | + | + | − | + | − | + |
| Vitamin D Status | IOM | Endocrine Society |
| Deficiency | <12 ng/mL (30 nmol/L) | <20 ng/mL (50 nmol/L) |
| Insufficiency | 12–20 ng/mL (30–50 nmol/L) | 21–29 ng/mL (52.5–72.5 nmol/L) |
| Sufficiency | >20 ng/mL (50 nmol/L) | >30 ng/mL (75 nmol/L) |
| Toxicity | >50 ng/mL (125 nmol/L) | >150 ng/mL (375 nmol/L) |
| Clinical characteristics | Genotype | OR (95% C.I.)* | P | Allele | OR (95% C.I.) | P | |||
| TT | CT | CC | T | C | |||||
| Tumor size | |||||||||
| <5 cm | 106 | 83 | 18 | 1.00 (Reference) | 295 | 119 | 1.00 (Reference) | ||
| 5-10 cm | 104 | 79 | 21 | 0.99 (0.66-1.49) | 0.963 | 287 | 121 | 0.96 (0.70-1.31) | 0.773 |
| ≥10 cm | 30 | 21 | 5 | 1.10 (0.58-2.07) | 0.753 | 81 | 31 | 1.05 (0.65-1.73) | 0.825 |
| Tumor stages | |||||||||
| 1a | 26 | 32 | 6 | 1.00 (Reference) | 84 | 44 | 1.00 (Reference) | ||
| 1b | 20 | 14 | 2 | 1.83 (0.74-4.54) | 0.150 | 54 | 18 | 1.57 (0.79-3.16) | 0.169 |
| 2a | 23 | 14 | 4 | 1.87 (0.78-4.47) | 0.121 | 60 | 22 | 1.43 (0.74-2.75) | 0.251 |
| 2b | 34 | 33 | 5 | 1.31 (0.63-2.74) | 0.439 | 101 | 43 | 1.23 (0.72-2.12) | 0.426 |
| 3a | 30 | 19 | 6 | 1.75 (0.79-3.88) | 0.129 | 79 | 31 | 1.33 (0.74-2.41) | 0.305 |
| 3b | 37 | 24 | 10 | 1.59 (0.76-3.34) | 0.182 | 98 | 44 | 1.17 (0.68-2.00) | 0.553 |
| 3c | 59 | 41 | 9 | 1.72 (0.88-3.38) | 0.086 | 159 | 59 | 1.41 (0.86-2.32) | 0.151 |
| 4 | 85 | 80 | 15 | 1.31 (0.73-2.43) | 0.363 | 250 | 110 | 1.19 (0.76-1.87) | 0.425 |
| Degree of differentiation | |||||||||
| Low | 215 | 179 | 39 | 1.00 (Reference) | 609 | 257 | 1.00 (Reference) | ||
| Medium | 94 | 74 | 17 | 1.05 (0.73-1.50) | 0.792 | 262 | 108 | 1.02 (0.73-1.35) | 0.863 |
| High | 5 | 4 | 1 | 14 | 6 | ||||
| Lymphatic metastasis | |||||||||
| 0 | 69 | 69 | 13 | 1.00 (Reference) | 207 | 95 | 1.00 (Reference) | ||
| 1 | 55 | 39 | 9 | 1.36 (0.80-2.32) | 0.228 | 149 | 57 | 1.20 (0.80-1.81) | 0.360 |
| 2 | 60 | 39 | 10 | 1.46 (0.86-2.46) | 0.137 | 159 | 59 | 1.24 (0.83-1.85) | 0.279 |
| 3a | 67 | 46 | 11 | 1.40 (0.80-2.42) | 0.169 | 180 | 68 | 1.21 (0.83-1.79) | 0.302 |
| 3b | 26 | 26 | 9 | 0.88 (0.46-1.68) | 0.684 | 78 | 44 | 0.81 (0.51-1.44) | 0.360 |
| All | Gadopentetat (Magnevist) | Gadoteracid (Dotarem) | Gadobenat (Multihance) | Gadotbutrol (Gadovist) | Gadoteridol (Prohance) | Gadodiamide (Omniscan) | Other* | |
| All | 45 | 20 | 5 | 3 | 9 | 2 | 3 | 3 |
| Age (years, mean) | 51.9 | 50.8 | 48.2 | 68.0 | 49.6 | 38.0 | 62.0 | 56.0 |
| SD | 16.5 | 18.1 | 19.0 | 4.6 | 16.1 | 14.1 | 4.0 | 13.0 |
| Median | 54.0 | 54.0 | 53.0 | 69.0 | 42.0 | 38.0 | 62.0 | 56.0 |
| Range | 16-77 | 16-74 | 25-69 | 63-72 | 31-77 | 28-48 | 58-66 | 43-69 |
| Sex | ||||||||
| Male (%) | 62.2 | 75.0 | 60.0 | 33.3 | 44.4 | 50 | 66.7 | 66.7 |
| Contrast dose (ml, mean) | 20.6 | 22.5 | 24.8 | 13.7 | 13.2 | 14.3 | 20.0 | 23.0 |
| SD | 8.3 | 7.5 | 8.8 | 3.2 | 4.3 | 17.0 | 8.0 | 11.5 |
| Median | 20.0 | 22.5 | 28.0 | 15.0 | 14.0 | 28.0 | 20.0 | 27.0 |
| Range | 7-40 | 7-36 | 10-32 | 10-16 | 10-21 | 16-40 | 12-28 | 10-32 |
| Category of reaction | ||||||||
| Mild | 43 | 18 | 5 | 3 | 9 | 2 | 3 | 3 |
| Moderate | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Severe | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Symptoms | ||||||||
| Allergic shock | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cardiac arrest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dyspnoea | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bronchospasm | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Nausea | 10 | 3 | 0 | 1 | 2 | 0 | 2 | 2 |
| Vomiting | 6 | 3 | 0 | 0 | 0 | 0 | 2 | 1 |
| Warmth | 3 | 2 | 0 | 1 | 0 | 0 | 0 | 0 |
| Headache | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Dizziness | 5 | 3 | 0 | 0 | 0 | 0 | 2 | 0 |
| Altered taste | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Itching | 9 | 2 | 1 | 1 | 4 | 1 | 0 | 0 |
| Flushing | 10 | 2 | 1 | 1 | 6 | 0 | 0 | 0 |
| Chills | 2 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Sweats | 3 | 2 | 0 | 0 | 1 | 0 | 0 | 0 |
| Rash/Hives | 15 | 4 | 4 | 2 | 2 | 2 | 1 | 0 |
| Swelling of eye/face | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Anxiety | 6 | 6 | 0 | 0 | 0 | 0 | 0 | 0 |
| Treatment | ||||||||
| Observation | 30 | 14 | 3 | 2 | 5 | 1 | 2 | 3 |
| Antihistamines | 18 | 4 | 3 | 2 | 4 | 1 | 3 | 1 |
| Steroids | 14 | 3 | 1 | 2 | 3 | 2 | 3 | 0 |
| Adrenaline | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gene Symbol | Primary Sertoli cell signal (normalized) | hS1 cell signal (normalized) | Log2 FC (hS1 vs. Control) |
| GDNF | 2.7378905 | 4.001061 | 1.2631705 |
| BMP4 | 7.070616 | 10.179245 | 3.108629 |
| BMP6 | 2.913889 | 6.345799 | 3.43191 |
| LIF | 8.199608 | 9.237209 | 1.037601 |
| FGF2 | 7.0719824 | 10.704937 | 3.6329546 |
| SOX9 | 1.4255941 | 1.4340813 | 0.0084872 |
| WT1 | 2.236927 | 2.0595062 | –0.1774208 |
| GATA4 | 10.017227 | 9.562365 | –0.4548 |
| GATA1 | 2.7784665 | 2.5375004 | –0.2409661 |
| kcat/KM(M−1 s−1) | C3 | C5 | C8 | iso C5 | |
| GEO179 | 0.9±0.02 | 100±15 | 1,200±130 | 41±1.2 | Discovered |
| GEO195 | 2.4±0.1 | 200±14 | 1,400±160 | 8±0.3 | Discovered |
| GEO175 | 0.51±0.02 | 48±3.7 | 17,000±2,700 | 3.3±0.2 | Discovered |
| GEO175 L376T_T240S | 0.27±0.02 | 30±7.2 | 1,100±160 | 1.6±0.1 | Designed |
| 1OVM | 32±0.5 | 2,100±420 | 80,000±4,300 | 1,300±130 | Native |
| 2VBI | 5,700±1,400 | 52±1.8 | 14±0.8 | 1.8±0.1 | Native |
| 3FZN | 5.4±0.1 | 1,700±110 | 350±30 | 110±10 | Native |
| 1ZPD | 8,200±545 | 140±5.6 | 19±2 | 0.33±0.01 | Native |
| 1OZF | n.d. | 0.53±0.04 | n.d. | 17±0.9 | Native |
| Native KIVD | 42±0.6 | 9,500±470 | 32,000±5,500 | 14,000±1,100 | Native |
| KIVD_VLV | 0.71±0.07 | 1.3±0.2 | 2,800±860 | 0.24±0.02 | Designed |
| kcat (s−1) | |||||
| GEO179 | n.d. | 0.47±0.03 | 0.32±0.01 | 0.39±0.01 | |
| GEO195 | n.d. | 0.49±0.01 | 0.56±0.02 | 0.072±0.001 | |
| GEO175 | n.d. | 0.97±0.04 | 10.1±0.6 | n.d. | |
| GEO175 L376T_T240S | n.d. | 0.28±0.04 | 3.4±0.2 | n.d. | |
| 1OVM | 0.2±0.01 | 1±0.1 | 1.7±0.1 | 7.8±0.4 | |
| 2VBI | 25±2.6 | n.d. | 0.051±0.01 | 0.025±0.001 | |
| 3FZN | n.d. | 4.7±0.1 | 1.3±0.1 | 0.52±0.02 | |
| 1ZPD | 46.7±1.4 | 0.95±0.02 | 0.021±0.001 | n.d. | |
| 1OZF | n.d. | n.d. | n.d. | 0.03±0.001 | |
| Native KIVD | n.d. | 14.3±0.2 | 7±0.3 | 61±2.1 | |
| KIVD_VLV | n.d. | 0.013±0.001 | 0.5±0.03 | n.d. | |
| KM (mM) | |||||
| GEO179 | n.d. | 4.6±0.6 | 0.27±0.03 | 9.4±0.2 | |
| GEO195 | n.d. | 2.5±0.2 | 0.4±0.04 | 9.1±0.3 | |
| GEO175 | n.d. | 20±1.3 | 0.58±0.09 | n.d. | |
| GEO175 L376T_T240S | n.d. | 10±2 | 3.1±0.4 | n.d. | |
| 1OVM | 7.5±0.1 | 0.5±0.1 | 0.021±0.001 | 6.1±0.6 | |
| 2VBI | 4.3±1.0 | n.d. | 3.6±0.2 | 14±0.5 | |
| 3FZN | n.d. | 2.7±0.2 | 3.8±0.3 | 4.9±0.3 | |
| 1ZPD | 5.7±0.3 | 7.1±0.3 | 1.2±0.1 | n.d. | |
| 1OZF | n.d. | n.d. | n.d. | 1.8±0.1 | |
| Native KIVD | n.d. | 1.5±0.1 | 0.21±0.04 | 4.5±0.3 | |
| KIVD_VLV | n.d. | 10±1 | 0.18±0.05 | n.d. |
| No | Expression system | SAK Productivity [mg/Lbroth] | Cultivation system | Volume [L] | SAK - glycosylation [Yes/No] | Reference |
| 1 | E. coli | > 50 | (not defined) | 2.7 | No | [8] |
| 2 | E. coli | > 175 | Fermenter | 10-15 | No | [19] |
| 3a | B. subtilis | 140 | Shake flask | 0.25 | No | [20] |
| 3b | B. subtilis | 337 | Fermenter | 2 | No | [20] |
| 4a | P.pastoris | 110 | Fermenter | < 5 | Partially yes | [13] |
| 4b | E. coli | 300-400 | Shake flask | 0.1 | No | [13] |
| 5 | E. coli | 2800 | Fermenter | 2 | No | [21] |
| 6 | P.pastoris | ~ 1000 | Shake flask (w/o -tunicamycin) | 0.05 | Yes | [17] |
| 7 | P.pastoris | Shake flask (w - tunicamycin) | 0.05 | No | [17] | |
| 8 | H. polymorpha | ~ 1100 | Fermenter | 80 | No | - |
| Length of training (months) | Total hours of training | Year |
| 22 | 2996 | 1989 |
| 23 | 3672 | 1996 |
| 19.5 | 2719 | 2001 |
| 23 | 3341 | 2007 |
| Provinces | No. of samples | ||||
| Bovine | Ovine | Caprine | Buffalo | Camel | |
| Tehran | 274 | 100 | 53 | 165 | 33 |
| Isfahan | 188 | 76 | 148 | 70 | 81 |
| Kerman | 83 | 152 | 102 | 25 | 70 |
| Khorasan | 75 | 197 | 139 | 112 | 30 |
| Total | 620 | 525 | 442 | 372 | 214 |
| Number of strain/strain code | Species | Biofilm | Cefoxitin resistance |
| 65/ MSSE 65 | S.epidermidis | black (+) | S |
| 62/ MRSE 62 | S.epidermidis | black (+) | R |
| 93/ MSSH 93 | S.haemolyticus | bordeaux (−) | S |
| 89/MRSH 89 | S.haemolyticus | bordeaux (−) | R |
| ATCC 12493 | S. aureus | very black (+) | R |
| Country | Seroprevalence of HCV in general population [1, 63] (%) | Seroprevalencea of HCV in HIV patients (%) |
| Argentina | 1.9 | 29.9 |
| Brazil | 1.4 | 18.9 |
| Chile | 0.8 | 2.6 |
| Colombia | 1.0 | 0.8 |
| Cuba | 1.8 | 12.9 |
| Mexico | 1.0 | 12.1 |
| Peru | 1.0 | 4.3 |
| Puerto Rico | 6.3 | 5.2 |
| Venezuela | 0.9 | 0.7 |
| Variable | AQP4(−) NEBLs patients (n=16) | AQP4(+) NEBLs patients (n=37) | P values |
| Serum analysis | |||
| CRP (mg/l) | 1.81 ± 0.65 | 3.01 ± 1.01 | 0.371 |
| ESR (mm/H) | 17.19 ± 2.22 | 15.24 ± 12.24 | 0.57 |
| C3 (g/l) | 1.16 ± 0.20 | 1.14 ± 0.30 | 0.838 |
| C4 (g/l) | 0.29 ± 0.16 | 0.22 ± 0.07 | 0.772 |
| CH50 (U/ml) | 49.50 ± 10.30 | 44.43 ± 11.52 | 0.136 |
| Person Characteristics | SfW N = 314 | Control N = 59 | P-Values |
| Female patients, n (%) | 180 (57.3) | 30 (50.8) | 0.3574 |
| Agea, yrs, (± SD) | 41.2 (± 11.97) | 39.9 (± 12.55) | 0.4532 |
| Weighta, kg, (± SD) | 93.5 (± 20.88) | 87.6 (± 18.53) | 0.0437* |
| Heighta, cm, (± SD) | 171.6 (± 9.43) | 171.8 (± 9.35) | 0.8765 |
| BMIa, kg/m2, (± SD) | 31.7 (± 6.48) | 29.6 (± 5.33) | 0.0173* |
| Waist circumferencea, cm, (± SD) | 107.5(± 18.52) | 105.9 (± 18.90) | 0.5544 |
| Waist circumference Sensitivity analysisa, cm (± SD) | 106.4 (± 16.37) | 103.5(± 13.89) | 0.2115 |
| 15D total score a, (± SD) | 0.814 (± 0.12) | 0.857(± 0.09) | 0.0085* |
| SWN total score a, (± SD) | 80.5 (± 15.97 | 87.9 (± 18.35) | 0.0016* |
| Clinical Characteristics | |||
| Psychiatric Diagnosis | 0.0627 | ||
| Schizophrenia n (%) | 163 (51.9) | 40 (67.8) | |
| Bipolar Disorder n (%) | 28 (8.9) | 5 (8.5) | |
| Other n (%) | 123 (39.2) | 14 (23.7) | |
| Time since diagnosisa, b, yrs, (± SD) | 9.47 (9.68) | 11.36 (12.27) | 0.1911 |
| CGI-S total scorea, (± SD) | 4.1 (± 0.99) | 3.4 (± 1.59) | < 0.0001 |
| Psychotropic medication | |||
| Atypical antipsychotics n (%) c | 203 (64.6) | 46 (78.0) | |
| Antidepressants n (%) | 124 (39.5) | 12 (20.3) | |
| Typical Antipsychotics n (%) | 70 (22.3) | 14 (23.7) |
| Group | ||
| STZ + DMH | STZ + DMH + MET | |
| N | 13 | 15 |
| Tumor-bearing rats | 11 | 9 |
| Tumor incidence (%) | 84.62 | 60.00 |
| Number of tumors | 40 | 20 |
| Average tumor number | 3.1 ± 0.45 | 1.3 ± 0.37* |
| Average tumor number of tumor-bearing rats | 3.6 ± 0.28 | 2.2 ± 0.36* |
| Volume of tumors (mm3) | 94.8 ± 19.77 | 30.9 ± 8.19* |
| Inhibition of colorectal tumor (%) | 29.08 |
| Study design | Study | Comment |
| Survey | National TB epidemiological survey 200217 | 45% (121/272) of patients having interrupted or suspended treatment due to financial difficulty |
| Zhang 200712 | 9% of households with TB suspects (2308) or patients defaulted due to financial burden | |
| Xu 200920 | 16% (13/82) of non-adherence patients interrupted treatment because of high medical costs of the treatment | |
| Ai 201022 | 2% of patients who interrupted treatment (43) because of financial difficulty | |
| Cohort | Jackson 200611 | 3% (5/159) was too poor to begin treatment |
| Sun 200723 | Patients who were charged high medical cost were more likely to interrupt treatment than patients having lower medical costs |
| Control | NASH | HFD | HFr | |
| Liver weight (g) | 18.9 ± 3.4# | 32.7 ± 7.9*†‡ | 16.5 ± 2.5# ‡ | 23.1 ± 4.4#† |
| Fasting plasma glucose (mM)b | 6.4 ± 0.2#†‡ | 7.2 ± 0.2* | 7.5 ± 0.1* | 7.16 ± 0.2* |
| Fasting plasma insulin (pM)b | 560.6 ± 79.5 | 486.7 ± 93.7 | 603.0 ± 43.7 | 695.8 ± 83.7 |
| Plasma β-hydroxybutyrate (μmol/L) | 38.4 ± 4.2† | 64.0 ± 5.3† | 115.4 ± 16.8*#‡ | 38.4 ± 2.8† |
| Plasma leptin (ng/mL) | 3283.3 ± 1035.2† | 3803.0 ± 1341.1† | 9366.6 ± 2052.8*#‡ | 2638.0 ± 808.5† |
| Plasma TG (mmol/L) | 1.6 ± 0.2‡ | 1.7 ± 0.1‡ | 1.5 ± 0.1‡ | 3.9 ± 0.5*#† |
| Plasma FFA (mmol/L) | 0.3 ± 0.1 | 0.4 ± 0.03 | 0.4 ± 0.02 | 0.3 ± 0.02 |
| Plasma Cholesterol (mmol/L) | 2.1 ± 0.1 | 2.5 ± 0.1 | 2.1 ± 0.1 | 2.3 ± 0.2 |
| Plasma HDL-C (mmol/L) | 1.3 ± 0.1 | 1.0 ± 0.1 | 1.3 ± 0.1 | 1.1 ± 0.1 |
| Jejunal MCP-1 (ng/mL)a | 45.3 [36.3; 55.3] | 58.1 [48.5; 69.6] | 49.5 [40.1; 60.5] | 56.4 [48.1; 65.5] |
| Jejunal TNF-α (ng/mL)a | 179.9 [129.3; 247.7] | 87.6 [61.7; 125.5] | 171.1 [76.1; 384.6] | 213.2 [112.4; 404.3] |
| Adipose tissue MCP-1 (ng/mL)a | 14.8 [13.4; 16.5] | 14.1 [11.9; 16.8]‡ | 14.2 [11.3; 17.7]‡ | 25.6 [15.2; 42.6]#† |
| Adipose tissue TNF-α (ng/mL)a | 15.4 [14.4; 16.4] | 16.1 [14.3; 18.2] | 15.4 [13.6; 18.2] | 16.2 [14.6; 18.0] |
| Study | Year published | n | MC/SC | Patients | EN/PN | Gln adm | Daily gln dose | Length of treatment* | Treatment benefit |
| Andrews [53] | 2011 | 502 | MC | General ICU | EN+PN | iv | 10-20 g | 5 (1-10) | None |
| Beale [29] | 2008 | 55 | SC | General ICU | EN | enteral | 40 g | <10 | Morbidity |
| Conejero [46] | 2002 | 84 | MC | General ICU | EN | enteral | 35 g | 10 (7-25) | Morbidity |
| Garrel [47] | 2003 | 41 | SC | Burns | EN | enteral | 26 g | 30 ± 17 | Mortality |
| Goeters [14] | 2002 | 95 | MC | General ICU | EN+PN | iv | 0.2 g/kg | 17 ± 11 | Mortality |
| Griffiths [15] | 1997 | 84 | SC | General ICU | PN | iv | 25 g | 6 (2-91) | Mortality |
| Hall [48] | 2003 | 363 | SC | General ICU | EN | enteral | 11-27 g | 10 (6-16) | None |
| Houdijk [30] | 1998 | 72 | SC | Trauma | EN | enteral | 27 g | 12 ± 6 | Morbidity |
| Jones [49] | 1999 | 50 | SC | General ICU | EN | enteral | 18 (11-21) g | 11 (3-47) | Morbidity |
| Wernerman [17] | 2011 | 284 | MC | General ICU | EN+PN | iv | 0.28 g/kg | 12 (4-47) | Mortality |
| Zhou [50] | 2003 | 40 | SC | Burns | EN | enteral | 0.35 g/kg | 12 | Morbidity |
| Timing of initial post-discharge outpatient follow up | ||||
| Casesn | ≤3 daysn (%) | >3 daysn (%) | p-value | |
| Low-risk* | ||||
| Short-stay† | 34 | 22 (65) | 12 (35) | 0.29 |
| Longer-stay | 44 | 22 (50) | 22 (50) | |
| Higher-risk | ||||
| Short-stay | 21 | 17 (81) | 4 (19) | 0.04 |
| Longer-stay | 74 | 39 (53) | 35 (47) |
| Nomenclature | Amino acids | Chromosome | Intracellular localization |
| Zm2G012631_T01 | 699 | II | Nucleus and mitochondrial matrix space |
| Zm2G112165_T01 | 698 | II | Nucleus and mitochondrial matrix space |
| Zm2G069651_T01 | 699 | II | Nucleus and mitochondrial matrix space |
| Zm5G833699_T01 | 714 | V | Nucleus and mitochondrial matrix space |
| Zm2G141931_T01 | 804 | II | Endoplasmic reticulum and vacuole |
| Zm2G141931_T03 | 710 | II | Endoplasmic reticulum and vacuole |
| Zm2G399073_T02 | 1001 | II | Endoplasmic reticulum |
| Zm2G399073_T03 | 808 | II | Endoplasmic reticulum |
| Zm2G141931_T04 | 667 | II | Endoplasmic reticulum |
| Zm2G002220_T01 | 793 | II | Chloroplast stroma and chloroplast thylakoid membrane |
| Zm5G813217_T01 | 758 | V | Nucleus and chloroplast stroma |
| Zm5G813217_T03 | 708 | V | Nucleus and mitochondrial matrix space |
| Clinical and laboratory parameters | Pharmacokinetic parameters 1,2(number of data points) | |||||
| Kβ | T1/2β | MRTiv | CLCEF | Vβ | VSS | |
| Weight | 0.08 | -0.05 | -0.04 | -0.34 | -0.42** | -0.47** |
| (28) | (28) | (28) | (28) | (28) | (28) | |
| Age | -0.65** | 0.58* | 0.61* | -0.75** | -0.50** | -0.34 |
| (28) | (28) | (28) | (28) | (28) | (28) | |
| Proteins | 0.52* | -0.27 | -0.28 | 0.24 | -0.13 | -0.29 |
| (26) | (26) | (26) | (26) | (26) | (26) | |
| Albumin | 0.63* | -0.31 | -0.32 | 0.21 | -0.27 | -0.43** |
| (26) | (26) | (26) | (26) | (26) | (26) | |
| Hemoglobin | 0.07 | 0.06 | 0.07 | -0.42** | -0.58** | -0.59** |
| (28) | (28) | (28) | (28) | (28) | (28) | |
| Na+ | -0.11 | 0.01 | -0.01 | 0.17 | 0.38 | 0.38 |
| (28) | (28) | (28) | (28) | (28) | (28) | |
| Creatinine | -0.78** | 0.91* | 0.91* | -0.69** | -0.31 | -0.19 |
| (27) | (27) | (27) | (27) | (27) | (27) | |
| CLCr | 0.79* | -0.81** | -0.82** | 0.88* | 0.51* | 0.35 |
| (27) | (27) | (27) | (27) | (27) | (27) | |
| pCO2 | 0.28 | -0.41 | -0.42** | 0.03 | -0.14 | -0.20 |
| (23) | (23) | (23) | (23) | (23) | (23) | |
| HCO3 | 0.33 | -0.42** | -0.41 | -0.05 | -0.27 | -0.33 |
| (23) | (23) | (23) | (23) | (23) | (23) | |
| Cefepime dose (mg/kg) | 0.19 | -0.17 | -0.17 | 0.57* | 0.51* | 0.53* |
| (28) | (28) | (28) | (28) | (28) | (28) |
| Age, years | N | Point prevalence of SRH | ||||||
| Fine(excellent, very good,or good) | Excellent | Very good | Good | Fair | Poor | Invalid response | ||
| Men | ||||||||
| 20–29 | 51 | 92% | 33% | 12% | 47% | 6% | 0% | 2% |
| 30–39 | 106 | 88% | 25% | 21% | 42% | 8% | 1% | 4% |
| 40–49 | 122 | 89% | 28% | 16% | 45% | 9% | 0% | 2% |
| 50–59 | 189 | 79% | 14% | 15% | 50% | 10% | 2% | 9% |
| 60–69 | 354 | 69% | 12% | 15% | 42% | 12% | 1% | 18% |
| 70–79 | 264 | 60% | 10% | 8% | 42% | 14% | 2% | 23% |
| ≥80 | 92 | 59% | 10% | 11% | 38% | 13% | 2% | 26% |
| Total | 1,178 | 72% | 15% | 14% | 44% | 11% | 1% | 15% |
| Women | ||||||||
| 20–29 | 62 | 77% | 24% | 15% | 39% | 13% | 3% | 6% |
| 30–39 | 224 | 85% | 23% | 24% | 39% | 8% | 2% | 5% |
| 40–49 | 179 | 81% | 15% | 21% | 45% | 12% | 1% | 7% |
| 50–59 | 267 | 79% | 12% | 17% | 50% | 10% | 1% | 10% |
| 60–69 | 407 | 65% | 11% | 11% | 43% | 13% | 2% | 21% |
| 70–79 | 315 | 56% | 7% | 11% | 38% | 14% | 3% | 26% |
| ≥80 | 101 | 58% | 3% | 14% | 42% | 15% | 2% | 25% |
| Total | 1,555 | 70% | 12% | 15% | 43% | 12% | 2% | 16% |
| Compartment | Local** | Distant** | ||||||||||
| sp† | sh†° | cb | ais | ? | n (∑) | sp† | sh†° | cb^ | ais | ? | n (∑) | |
| Abs. N° | 22 | 47 | 0 | 0 | 5 | 74 | 15 | 56 | 3 | 0 | 5 | 79 |
| % | 29.7 | 63.5 | 0.0 | 0.0 | 6.8 | (100) | 19.0 | 70.9 | 3.8 | 0.0 | 6.3 | (100) |
| cDNA | No. of isolates | Characteristics |
| NIK | 58 | N terminal deletion |
| CD30 | 3 | Full length |
| LT-βR | 2 | Cytoplasmic region |
| RIP2 | 1 | Full length |
| Cardiac syncope vs non-cardiac syncopen = 142 | Cardiac syncope vs chest pain control groupn = 147 | |||||
| Patient characteristics | Cardiac syncopen = 49 | Non-cardiacsyncopen = 93 | P-value | Cardiac syncopen = 49 | Chest paincontrol groupn = 98 | P-value |
| Age, years | 60 ± 13 | 54 ± 12 | 0.002 | 60 ± 13 | 60 ± 12 | 0.810 |
| Male gender | 32 (65) | 57 (61) | 0.716 | 32 (65) | 64 (65) | >0.999 |
| BMI, kg/m2 | 26 ± 3 | 26 ± 4 | 0.365 | 26 ± 3 | 27 ± 4 | 0.116 |
| Systolic Blood Pressure, mm Hg | 143 ± 20 | 140 ± 21 | 0.349 | 143 ± 20 | 144 ± 16 | 0.990 |
| Diastolic Blood Pressure, mm Hg | 81 ± 13 | 83 ± 13 | 0.396 | 81 ± 13 | 78 ± 9 | 0.140 |
| Active smoking | 19 (39) | 27 (29) | 0.256 | 19 (39) | 38 (39) | >0.999 |
| Diabetes mellitus II | 3 (6) | 4 (4) | 0.693 | 3 (6) | 5 (5) | >0.999 |
| Family history of CAD | 16 (33) | 43 (46) | 0.152 | 16 (33) | 27 (28) | 0.566 |
| PROCAM risk score | 9 (4–21)a | 7 (2–16)b | 0.131 | 9 (4–21)a | 8 (3–16) | 0.280 |
| Sample | pH | Temp (°C) | Conductivity (μS cm−1) | dO2 (%) | TSS (mg L−1) | PO4 (μM) | NH4 (μM) | NO2 + NO3 (μM) | Partic P (μM) | Rainfall (mm) | V rich |
| 6-3_0830 | 7.19 | 21.4 | 479.2 | 23.5 | 125.1 | 0.29 | 13.58 | BDL | 0.40 | 0 | 12 |
| 6-3_1330 | 6.60 | 26.2 | 122.4 | 58.0 | 88.4 | 1.05 | 5.43 | 11.2 | 3.39 | 28.4 | 6 |
| 6-4_0930 | 6.76 | 21.8 | 127.3 | 45.0 | 55.0 | 1.57 | 5.62 | 10.5 | 2.26 | 5.6 | 4 |
| 6-4_1700 | 6.50 | 23.5 | 136.7 | 30.1 | 45.5 | 1.86 | 6.13 | 5.48 | 2.11 | 0 | 6 |
| 6-5_0930 | 6.65 | 20.9 | 143.9 | 26.6 | 44.0 | 1.86 | 7.12 | 6.65 | 1.93 | 0 | 7 |
| 6-5_1800 | 6.70 | 21.9 | 154.1 | 19.2 | 43.3 | 2.05 | 7.19 | 7.76 | 1.95 | 0 | 7 |
| 6-6_0940 | 6.74 | 20.9 | 168.1 | 33.1 | 29.1 | 1.52 | 6.39 | 4.76 | 1.73 | 0 | 13 |
| 6-6_1500 | 6.40 | 22.7 | 173.9 | 33.7 | 30.4 | 1.52 | 5.73 | 4.32 | 1.90 | 0 | 14 |
| 6-7_0930 | 6.10 | 21.9 | 109.8 | 77.0 | 23.6 | 9.04 | 3.71 | 5.60 | 1.83 | 36.6 | 15 |
| 6-7_1500 | 6.24 | 20.9 | 87.9 | 83.2 | 144.4 | 3.86 | 5.03 | 19.0 | 3.58 | 34.5 | 6 |
| 6-8_1300 | 6.40 | 24.0 | 105.7 | 48.2 | 213.1 | 7.38 | 3.67 | 8.31 | 6.96 | 61.2 | 7 |
| 6-9_1500 | 6.27 | 27.1 | 96.7 | 31.4 | 86.5 | 4.90 | 1.80 | 6.20 | 2.77 | 0 | 6 |
| 6-10_0930 | 6.53 | 23.5 | 101.5 | 25.0 | 198.9 | 5.00 | 4.29 | 4.27 | 7.13 | 0 | 11 |
| 6-11_0920 | 6.04 | 22.9 | 124.1 | 23.0 | 70.8 | 4.62 | 1.91 | 5.98 | 2.82 | 40.4 | 6 |
| 6-11_1500 | 5.98 | 27.5 | 130.3 | 28.0 | 90.3 | 4.90 | 2.20 | 2.49 | 3.67 | 0 | 6 |
| 6-12_0930 | 6.10 | 21.8 | 132.0 | 17.8 | 92.7 | 3.71 | 1.84 | 2.88 | 3.29 | 0 | 6 |
| 6-12_1430 | 6.54 | 26.2 | 136.2 | 33.4 | 73.3 | 3.52 | BDL | 2.27 | 3.98 | 0 | 8 |
| 6-13_0930 | 6.47 | 22.4 | 142.1 | 28.6 | 166.0 | 2.81 | 3.89 | 1.77 | 6.38 | 0 | 8 |
| 6-13_1520 | 6.50 | 34.0 | 152.9 | 38.0 | 124.5 | 1.38 | BDL | 0.06 | 7.00 | 0 | 10 |
| 6-14_0920 | 6.82 | 18.2 | 177.1 | 28.0 | 86.2 | 2.62 | 2.42 | 0.06 | 3.98 | 11.4 | 7 |
| 6-14_1500 | 6.72 | 21.0 | 178.9 | 32.1 | 64.8 | 3.33 | 2.31 | 1.11 | 3.26 | 0 | ND |
| 7-16_1010 | 6.17 | 24.4 | 127.2 | 28.6 | 63.7 | 3.5 | 2.5 | 5.5 | 2.60 | 0 | ND |
| 7-16_1330 | 6.08 | 26.4 | 127.5 | 31.2 | 58.6 | 2.9 | 2.8 | 5.0 | 2.70 | 0 | ND |
| 7-17_1010 | 6.09 | 24.6 | 162.6 | 34.2 | 43.3 | 3.7 | 1.1 | 3.7 | 4.29 | 0 | ND |
| 7-17_1330 | 6.02 | 28.7 | 156.2 | 52.4 | 68.0 | 2.5 | 2.1 | 3.1 | 4.15 | 0 | ND |
| 7-18_1010 | 6.61 | 24.5 | 211 | 48.0 | 68.0 | 6.2 | 5.1 | 2.5 | 7.08 | 0 | 7 |
| 7-18_1330 | 5.33 | 26.8 | 198.6 | 48.0 | 41.4 | 2.0 | 0.7 | 2.2 | 3.43 | 0 | 7 |
| 7-19_1010 | 5.80 | 23.1 | 302.3 | 32.0 | 52.0 | 2.1 | 2.0 | 1.2 | 6.07 | 0 | 8 |
| 7-19_1330 | 5.08 | 24.9 | 294.2 | ND | 53.4 | 1.2 | 1.5 | 1.7 | 3.52 | 0 | 6 |
| Main mindfulness instruction | General guidance points | Contemplative movement | Mindful movement |
| Awareness of sensations | Bodily sensations as objects for the attention (sensations related to autonomic response, skeletal and muscular aspects, pressure, tactile and visceral, proprioception, kinematics) | √ | √ |
| Awareness of the present moment (PM) | PM attributes of body, movement sensations, and breath | Implicit | √ |
| PM attribute of mental experience, e.g., emphasis on staying with the present moment (not getting lost in past or future thinking) | Not usually | ||
| Awareness of attention | Deliberate awareness of the ways in which to move, shift, narrow, and widen the focus of attention to aspects of body and movement. Commentary on the quality of the attention (vivid, dull, agitated, stable, striving) | Not usually | √ |
| Awareness of mind-wandering | Acknowledgment and suggested management of mind-wandering | Not usually | √ |
| Awareness of intention (on purpose) | Purposeful, deliberate engagement with the intention to move the body, pay attention, be present, mindful | Can be (e.g., Tai Chi, Feldenkrais, continuum movement) | √ |
| Awareness of non-judgment | A deliberate attitude of acceptance and gentleness to mental and physical phenomena. For example, psychological responses to learning new movements (frustration, elation, irritation, pride) | Implicit and in relation to the physical body rather than the mind | √ |
| Markers | Markers in the DG | Markers in the SVZ | |||
| Ki67 | DCX | Prox1 | SOX2 | Dlx2 | |
| BrdU | - | F(1,5) = 11.2, r = 0.83 p = 0.020 (AIE, P57) | - | - | F(1,5) = 9.9, r = 0.82 p = 0.025 (Control, P95) |
| - | F(1,6) = 10.0, r = 0.79 | - | - | - | |
| p = 0.020 (AIE, P95) | |||||
| SOX2 | F(1,5) = 13.3, r = 0.85 p = 0.015 (AIE, P57) | - | - | N/A | - |
| DCX | - | N/A | - | - | F(1,6) = 6.9, r = 0.73 p = 0.04 (AIE, P95) |
| Activated caspase-3 | F(1,5) = 11.5, r = 0.83, p = 0.020 (AIE, P57) | - | - | F(1,6) = 14.9, r = 0.85 p = 0.008 (AIE, P95) | - |
| - | F(1,6) = 8.3, r = 0.76 p = 0.028 (AIE, P95) | F(1,6) = 7.5, r = 0.75 p = 0.034 (AIE, P95) | - | - |
| Compounds of hydrocarbon | Mean | SD |
| Pars 1 dispersant | 0.126 | 0.082 |
| Pars 2 dispersant | 0.055 | 0.049 |
| Gamlen dispersant | 0.011 | 0.004 |
| Crude oil | 0.072 | 0.046 |
| Pars 1 dispersant + petroleum | 0.156 | 0.098 |
| Pars 2 dispersant + petroleum | 0.104 | 0.087 |
| Gamlen dispersant + petroleum | 0.115 | 0.067 |
| Categorical variables | ||||
| Consented to participate n = 43 (37%) | Declined to participate n = 73 (63%) | All (n = 116) | P-value χ2 test | |
| First degree relative with diabetes mellitus | ||||
| No | 22 (35%) | 41 (65%) | 63 | 0.601 |
| Yes | 21 (40%) | 32 (60%) | 53 | |
| Smoker | ||||
| Past | 17 (41%) | 25 (59%) | 42 | 0.790 |
| Current | 7 (39%) | 11 (61%) | 18 | |
| Never | 19 (34%) | 37 (66%) | 56 | |
| Meets daily exercise requirements | ||||
| No | 5 (31%) | 11 (69%) | 16 | 0.604 |
| Yes | 38 (38%) | 62 (62%) | 100 | |
| Meets daily fruit and vegetable requirements | ||||
| No | 0 | 3(100%) | 3 | 0.178 |
| Yes | 43 (38%) | 70 (62%) | 113 | |
| Insulin use during pregnancy | ||||
| No | 33 (46%) | 38 (54%) | 71 | 0.008 95% CI (7.5, 41) |
| Yes | 10 (22%) | 35 (77%) | 45 | |
| IFG at follow-up | ||||
| No | 34 (36%) | 61 (64%) | 95 | 0.544 |
| Yes | 12 (57%) | 9 (43%) | 21 | |
| IGT at follow-up | ||||
| No | 41 (38%) | 68 (62%) | 109 | 0.631 |
| Yes | 2 (29%) | 5 (71%) | 7 |
| Variable | Manipur n = 41 | Nagaland n = 33 | Total n = 74 |
| Average age (range) | 33 yrs (23–46) | 32 yrs (20–52) | 32.5 yrs (20–52) |
| Average length of widowhood (range) | 4.5 yrs (3 mth-12.8 yrs) | 4.2 yrs (1 mth-11 yrs) | 4.3 yrs (1 mth-12.8 yrs) |
| Average no. children (range) | 2.2 (1–4) | 2.7 (0–7) | 2.4 (0–7) |
| Ethnicity – n (%) | |||
| Naga | 2 (5) | 26 (79) | 28 (38) |
| Meitei | 26 (63) | 0 | 26 (35) |
| Other | 11 (27) | 7 (21) | 18(24) |
| Missing | 2 (5) | 0 | 2 (3) |
| Religion – n (%) | |||
| Christian | 14 (34) | 30 (91) | 44 (59) |
| Hindu | 25 (61) | 2 (6) | 27 (37) |
| Muslim | 0 | 1 (3) | 1 (1) |
| Missing | 2 (5) | 0 | 2 (3) |
| Employment – n (%) | |||
| Employed | 2 (5) | 10 (30) | 12 (16) |
| Unemployed | 37 (90) | 23 (70) | 60 (81) |
| Missing | 2 (5) | 0 | 2 (3) |
| Education – n (%) | |||
| None | - | 7 (21) | 7 (9) |
| Primary | 5 (12) | 1 (3) | 6 (8) |
| Secondary | 15 (37) | 24 (73) | 39 (53) |
| Tertiary | 21 (51) | 1 (3) | 22 (30) |
| Taxonomy Level | Method | V1V2 Region | |
| CST = 0.8 | CST = 0.5 | ||
| Species | BLCA | 0.570 | 0.716 |
| Kraken | 0.589 | 0.589 | |
| MEGAN | 0.544 | 0.544 | |
| RDP | 0.490 | 0.613 | |
| SPINGO | 0.486 | 0.562 | |
| Genus | BLCA | 0.729 | 0.79 |
| Kraken | 0.694 | 0.694 | |
| MEGAN | 0.745 | 0.745 | |
| RDP | 0.643 | 0.708 | |
| SPINGO | 0.605 | 0.650 | |
| Family | BLCA | 0.814 | 0.832 |
| Kraken | 0.777 | 0.777 | |
| MEGAN | 0.869 | 0.869 | |
| RDP | 0.775 | 0.805 | |
| SPINGO | NA | NA |
| Baseline | One month after treatment | Three month after treatment | |
| PLI | |||
| Adults | 0.195 ± 0.311a | 0.610 ± 0.512* | 0.780 ± 0.531* |
| Adolescents | 0.491 ± 0.367 | 0.637 ± 0.444* | 0.899 ± 0.490* |
| Total | 0.345 ± 0.292 | 0.680 ± 0.463* | 0.876 ± 0.462* |
| SBI | |||
| Adults | 0.253 ± 0.412 | 1.123 ± 0.503* | 1.119 ± 0.148* |
| Adolescents | 0.278 ± 0.457 | 0.993 ± 0.492* | 1.002 ± 0.481* |
| Total | 0.283 ± 0.505 | 0.976 ± 0.0.484* | 0.984 ± 0.0.496*,# |
| PD | |||
| Adults | 0.056 ± 0.122a | 1.188 ± 0.164* | 1.047 ± 0.148* |
| Adolescents | 1.015 ± 0.101 | 1.190 ± 0.172* | 1.021 ± 0.104* |
| Total | 1.020 ± 0.103 | 1.178 ± 0.180 | 1.100 ± 0.0.142*,# |
| Stages | Classification | Macroscopic appearance | Oocyte size (μm) | GSI range | ||
| Testes | Ovary | F | M | |||
| I | Immature | Small, flat, translucent to whitish, poorly developed, with reduced fringes. | Small, transparent to translucent and not very voluminous. Oocyte not visible with naked eye. | 209.61-592.78 (447.30 ± 99.42)a | <10.9 | <2.0 |
| II | Develop | Whitish with voluminous fringes. | Large orange-pale, oocytes may be visible through the ovary tunic. | 528.37-867.10 (711.24 ± 63.21)b | 11.0-18.9 | 2.5-5.5 |
| III | Mature | Very large, firm, white in colour. | Very large occupying part of the abdominal cavity. Yellow oocyte turgescency. | 604.15-894.33 (780.59 ± 50.71)c | 19.0-23.9 | 5.6-8.0 |
| IV | Ripe | Full developed, turgid fringes, milky-whitish in colour. Milt run out of the fish. | Occupying the entire abdominal cavity. Ovulated oocytes can be fully expelled from the oviduct with gentle pressure. | 725.27-991.81 (844.09 ± 57.59)d | >24.0 | > 8.0 |
| V | Spent | Bloody and flaccid fringes. | Flaccid, red-brown or bloody in colour. Few remaining large oocytes observed, and smaller size oocytes may be seen. | 227.64-770.82 (447.38 ± 139.02)a | 2.5-10.9 | 1.5-3.0 |
| Biotype | Human | Mouse |
| LincRNA | 13245 | 6473 |
| Antisense | 10980 | 3612 |
| TEC | 1072 | 2759 |
| Sense_intronic | 984 | 294 |
| Retained_intron | 517 | 294 |
| Processed_transcript | 368 | 980 |
| Sense_overlapping | 310 | 50 |
| 3prime_overlapping_ncRNA | 34 | 3 |
| Pseudogene | 20 | 24 |
| Bidirectional_promoter_lncRNA | 11 | 118 |
| Non_coding | 3 | 0 |
| Macro_lncRNA | 1 | 2 |
| Total | 27545 | 14609 |
| FAF (%) | NIA(%) | |||||
| hypoFAF | mixedFAF | hyperFAF | hypoNIA | mixedNIA | hyperNIA | |
| Detached area (N = 10) | 10 | 20 | 70 | 30 | 20 | 50 |
| Leakage spot (N = 13) | 23.1 | × | 76.9 | 92.3 | × | 7.7 |
| Window defect area (N = 8) | 12.5 | 12.5 | 75 | 62.5 | 32.5 | 0 |
| Overall image (N = 17) | 17.6 | 11.8 | 70.6 | 58.8 | 17.6 | 23.5 |
| PED (N = 22) | 63.6 | × | 36.4 |
| VAS Measurea | M | SD | 95% Confidence Interval | Response Range | |
| Mechanism | Acceptance, equality, and non-judgment | 80.1 | 20.7 | [76.83, 83.34] | 0–100 |
| Dignity and self-worth | 77.3 | 21.5 | [73.88, 80.65] | 1–100 | |
| Reduced experience of stigma | 83 | 20.1 | [79.78, 86.15] | 10–100 | |
| Independence and self-efficacy | 81 | 19.8 | [77.79, 84.04] | 8–100 | |
| Relationship to others and reduced isolation | 74 | 23.8 | [70.02, 77.63] | 0–100 | |
| Sense of connection and belonging | 79 | 21.9 | [75.20, 82.24] | 0–100 | |
| Outcome | |||||
| Feeling better and at peace | 74 | 23 | [70.31, 77.55] | 0–100 | |
| Personhood | 83 | 18.9 | [80.00, 85.93] | 0–100 | |
| Skills Acquired | 75 | 23.6 | [71.53, 79.05] | 0–100 |
| Type of strategies | Strategies Medicines | NCMS (China) | National Health Insurance (Ghana) | Jamkesmas (Indonesia) | Seguro Popular (Mexico) |
| Selection | Formulary | ✓ | ✓ | ✓ | ✓ |
| Cost sharing for medicines included in the formulary | ✓ | ✗ | ✗ | ✗ | |
| Generic substitution | ✗ | ✓ | ✗ | ✗ | |
| Procurement | Medicines prices negotiation or rebates | ✓ | ✗c | ✓ | (✓) |
| Bulk procurement | ✓ | ✓ | ✓ | ✓ | |
| Generic reference pricing | ✗ | ✓ | ✗a | ✓ | |
| Contracting | Fee for service for prescribers | ✓ | |||
| Fixed salary for prescribersa | ✓ | ✓a | ✓ | ||
| Fixed reimbursement rates for medicines | ✓ | ✓ | ✗ | ✗ | |
| Preferred provider network (accreditation) | ✗ | ✓ | ✓ | ✓ | |
| Utilization | Standard treatment guidelines | (✓) | ✓ | ✓ | ✓ |
| Payment for performance | (✓) | ✗ | ✗ | ✗ | |
| Separation of prescribing and dispensing | ✓ | ✓ | ✓ | ✓ | |
| Disease management programs | ✓ | No info | ✓ | ✓ | |
| Monitoring and evaluation | User satisfaction monitoring | ✗ | ✗ | ✗ | ✓ |
| Medicines purchasing monitoring | ✓b | ✓ | ✓ | ||
| Prescription monitoring | ✗ | ✗ | ✗ | ✗ |
| Type of epilepsy | No. of patients Males/females | Age ranges | Recording length ranges (mins) | No. of electrodes |
| General epilepsy | 7/1 | 30–45 | 20–30 | 22 |
| Uncompressed | 192 k MP-3 | 96 k MP-3 | ||||
| Method I | Method II | Method I | Method II | Method I | Method II | |
| IDR | 99.1% | 99.7% | 98.9% | 99.7% | 99.0% | 99.7% |
| FAR | 1.5% | 0.2% | 1.9% | 0.2% | 1.6% | 0.2% |
| FRR | 0.3% | 0.4% | 0.2% | 0.4% | 0.3% | 0.6% |
| ACC | 98.7% | 99.5% | 98.5% | 99.5% | 98.6% | 99.4% |
| Independent predictor | Subgroup comparisons | Parameter estimate | 95% CI | p Value |
| Patient expectation of change | Completely recover | 0 | ||
| Much improve | 5.21 | 1.80 to 8.61 | 0.003 | |
| Slightly improve | 12.43 | 8.20 to 16.67 | <0.001 | |
| No change/worse | −0.94 | −8.53 to 6.66 | 0.809 | |
| Pain self-efficacy | −0.36 | −0.50 to −0.22 | <0.001 | |
| Number of additional health problems | None | 0 | ||
| One | 3.52 | 0.30 to 6.75 | 0.032 | |
| Two or more | 6.62 | 1.48 to 9.75 | 0.008 | |
| Anxiety or depression | None | 0 | ||
| Moderate | 2.19 | −0.99 to 5.37 | 0.177 | |
| Extreme | 12.02 | 1.49 to 22.56 | 0.025 | |
| Frequency of pain medication | None/occasional | 0 | ||
| Most/every day/night | 3.85 | 0.61 to 7.09 | 0.020 | |
| Most strenuous exercise | None | 0 | ||
| Mild | −5.53 | −10.32 to −0.74 | 0.024 | |
| Moderate | −8.98 | −13.86 to −4.11 | <0.001 | |
| Strenuous | −6.82 | −12.17 to −1.47 | 0.013 | |
| Difference between passive and active abduction | 0.07 | 0.004 to 0.142 | 0.038 | |
| Change during scapular facilitation | Yes | 0 | ||
| No | 4.93 | 2.13 to 7.74 | 0.001 | |
| Severity of pain at rest | 1.89 | 1.26 to 2.51 | <0.001 | |
| Duration of shoulder symptoms (weeks) | 0.02 | 0.01 to 0.03 | 0.002 | |
| Paraesthesia in the arm | No | 0 | ||
| Yes | −10.08 | −18.73 to −1.43 | 0.022 | |
| Current employment status | Employed | 0 | ||
| Retired | 2.96 | 0.10 to 6.02 | 0.058 | |
| Unemployed | 14.30 | 7.72 to 20.87 | <0.001 |
| Aripiprazole | SE | SoC | SE | |||
| Total | N = 164 | 16.21 | 1.12 | N = 162 | 10.01 | 1.13 |
| Interpersonal relationships | N = 164 | 6.34 | 0.48 | N = 162 | 4.23 | 0.48 |
| Instrumental role | N = 162 | 3.14 | 0.31 | N = 161 | 1.75 | 0.31 |
| Intrapsychic foundation | N = 164 | 5.54 | 0.42 | N = 162 | 3.33 | 0.42 |
| Common activities | N = 164 | 1.11 | 0.12 | N = 162 | 0.73 | 0.12 |
| Residual symptoms | N = 164 | 6.65 | 0.5 | N = 162 | 4.05 | 0.5 |
| Platoons | Bangolo | Danané | Kahin | Logoualé | Guezon | BleniMéhouin | Dieouzon | Zoukougbeu | Blotile | Duekoue |
| 1 | 15 | 3 | 0.5 | |||||||
| 2 | 14 | 2 | 2 | 2 | ||||||
| 3 | 4 | 4 | 10 | |||||||
| 4 | 10 | 4 | 4 | |||||||
| 5 | 15 | 3 |
| Characteristics | Male (n = 26) (mean ± SD)a | Female (n = 24) (mean ± SD)a |
| Continuous variable | ||
| Age (years) | 28.2 ± 3.18 | 30.4 ± 3.67 |
| Prepregnant body mass index (kg/m2) | 22.0 ± 3.43 | 22.8 ± 4.24 |
| Gestational age (weeks) | 39.0 ± 1.50 | 38.7 ± 1.49 |
| Baby birth weight (g) | 3,251 ± 382 | 2,958 ± 393 |
| Baby birth length (cm) | 51.6 ± 2.59 | 50.9 ± 2.63 |
| Baby head circumference (cm) | 33.9 ± 1.23 | 33.0 ± 1.46 |
| Placental weight (g) | 629 ± 141 | 579 ± 184 |
| Fat content of placenta (%) | 0.74 ± 0.12 | 0.77 ± 0.084 |
| Categorical variable | ||
| Cigarette smoking, n (%) | 1 (3.85) | 2 (8.33) |
| Passive smoking, n (%) | 13 (50.0) | 11 (45.8) |
| Alcohol drinking, n (%) | 0 (0.0) | 0 (0.0) |
| Potential dioxin-exposed occupation, n (%) | 0 (0.0) | 0 (0.0) |
| Gene | Position TGFBR1 TGFBR2 gene | HGVS names | Protein position | Number of patients | rsSNP number |
| TGFBR1 | Exon 1 | c.68_76delCGGCGGCG | p.Ala23Ala | 4 | rs11466445 |
| IVS 7 + 24 | c.1255 + 24 G > A | 2 | rs334354 | ||
| TGFBR2 | IVS 3 + 7 | c.338 + 7 A > G | 2 | rs1155705 | |
| IVS 5-4 | c.455-4 T > A | 3 | rs11466512 | ||
| Exon 4 | c.458delA | p.Lys153 | 8 | rs79375991 |
| Subject | Question |
| Directions | How would you make the directions more clear/easy to understand? |
| What does \"in the past month\" mean to you? | |
| When you see \"the past month\", what days did you include? | |
| Items | In your own words, what do you think this question is asking? |
| What does this question mean to you? What did you think of when answering this question? | |
| Was this question easy to understand? Are there any specific words that are difficult to understand? | |
| How would you change the words to make it more clear? | |
| Was this item hard to answer? If yes, why? | |
| How did you choose your answer? | |
| Domains | In your own words, what do you think this group of questions is asking about? |
| How do you think these items are related? | |
| Are there any questions that do not belong in this group? | |
| ResponseChoices | What do you think about the response choices? |
| How would you make the response choices clearer or easier to understand? | |
| OverallAssessment | Are there things that we forgot to ask about that you think are important? |
| Overall thoughts/opinions of the questionnaire? | |
| Anything you would change in the questionnaire as a whole? |
| Parameter | NL | HC | MS | Units |
| count | 211 ± 10 | 216 ± 13 | 217 ± 11 | x103/μl |
| ßTG | 51.7 ± 2.2 | 55.6 ± 2.3 | 52.3 ± 2.8 | pg/ml |
| PF4 | 16.6 ± 2.4 | 18.9 ± 2.7 | 18.6 ± 2.5 | pg/ml |
| TXB2 | 7.4 ± 1.3 | 12.8 ± 2.3* | 10.7 ± 1.9* | pg/ml |
| PS PGI2 | 0.96 ± 0.09 | 1.82 ± 0.51* | 1.65 ± 0.22* | ng/ml |
| SI | 2.9 ± 0.4 | 4.1 ± 0.6* | 6.8 ± 2.2* | % |
| WU | 0.95 ± 0.02 | 0.86 ± 0.04* | 0.78 ± 0.06* | % |
| retention | 88.4 ± 3.2 | 87.1 ± 3.7 | 89.0 ± 3.8 | % |
| migration | 386 ± 21 | 397 ± 26 | 391 ± 22 | mm2 |
| Parameters | PC1 | PC2 | R2 | p-Value | |
| Tide (m) | −0.8349 | 0.5504 | 0.01 | 0.894 | |
| Sediment Temperature (°C) | −0.4182 | 0.9084 | 0.01 | 0.931 | |
| Salinity (ppt) | −0.3844 | −0.9232 | 0.01 | 0.782 | |
| pH | 0.5676 | 0.8233 | 0.02 | 0.461 | |
| Ammonia | −0.4668 | −0.8844 | 0.01 | 0.698 | |
| Nitrate | −1.0000 | −0.0023 | 0.02 | 0.449 | |
| Nitrite | 0.8412 | −0.5408 | 0.02 | 0.326 | |
| Sulfide | 0.9900 | 0.1414 | 0.02 | 0.352 | |
| Group | 1 | −0.1079 | −0.1349 | 0.41 | 0.001 |
| 2 | 0.4435 | 0.1412 | |||
| 3 | 0.0883 | 0.6255 | |||
| 4 | 0.4232 | 0.4104 | |||
| 5 | −0.0277 | 0.3129 | |||
| Vegetation Zone | JS | 0.0159 | −0.1705 | 0.07 | 0.131 |
| SAL | −0.0235 | −0.0705 | |||
| SS | −0.0573 | −0.0658 | |||
| S | 0.0731 | 0.1548 | |||
| T | 0.0402 | 0.0563 |
| References | Period of sample collection | Year of publication | Study area | Age of participants |
| Chandenier et al. [20] | 1993 | 1995 | Brazzaville, Niari, Kouilou, Pool | 6–10 years |
| Durand et al. [21] | 1998 | 2003 | Pointe-Noire | No limit |
| Nsimba et al. [22] | 1999–2002 | 2004 | Brazzaville, Pointe-Noire | 0.5–<5 years |
| Nsimba et al. [23] | 1999–2002 | 2005 | Brazzaville, Pointe-Noire | 0.5–<5 years |
| Mayengue et al. [24] | 2003 | 2005 | Brazzaville | ≤5 years |
| Ndounga et al. [25] | 2003–2004 | 2007 | Brazzaville | <5 years |
| Ndounga et al. [13] | 2003–2006 | 2008 | Brazzaville | No limit |
| Van den Broek et al. [26] | 2004 | 2006 | Kindamba | 0.5–<5 years |
| Mayengue et al. [27] | 2005 | 2011 | Brazzaville | No limit |
| Ndounga et al. [28] | 2005 | 2013 | Brazzaville | No limit |
| Pradine et al. [29] | 2005–2006 | 2006 | Pointe-Noire | 1.4–17 years |
| Tsumori et al. [11] | 2005–2006 | 2011 | Brazzaville, Gamboma, Pointe-Noire | No limit |
| Oguike et al. [19] | 2005–2006 | 2011 | Brazzaville, Gamboma, Pointe-Noire | No limit |
| Moyen et al. [14] | 2006 | 2010 | Brazzaville | ≤15 years |
| Ndounga et al. [30] | 2006 | 2012 | Brazzaville | 0.5–10 years |
| Murai et al. [31] | 2006 | 2015 | Brazzaville, Gamboma, Pointe-Noire | No limit |
| Mita et al. [32] | 2006 | 2016 | Brazzaville, Gamboma, Pointe-Noire | No limit |
| Culleton et al. [12] | 2007 | 2009 | Pointe-Noire | No limit |
| Koekemoer et al. [33] | 2009 | 2011 | Boutoto | Not applicable |
| Koukouikila-Koussounda et al. [15] | 2010 | 2012 | Brazzaville | <10 years |
| Ibara-Okabande et al. [34] | 2010–2011 | 2012 | Brazzaville | <10 years |
| Ndounga et al. [35] | 2010–2011 | 2015 | Brazzaville | <10 years |
| Ossou-Nguiet et al. [18] | 2011 | 2013 | Brazzaville | 0.4–14 years |
| Mbongo et al. [17] | 2011–2013 | 2015 | Brazzaville | 15–39 years |
| Ntoumi et al. [9] | 2011–2012 | 2013 | Brazzaville, Pointe-Noire | ≤15 years |
| Koukouikila-Koussounda et al. [36] | 2012–2013 | 2015 | Brazzaville | 12–44 years |
| Ntoumi et al. [16] | 2012–2013 | 2016 | Brazzaville | 12–44 years |
| Singana et al. [10] | 2012–2013 | 2016 | Owando | <12 years |
| Category | Repbase TEs | TE proteins | de novo | Combined TEs | ||||
| Length (bp) | % of genome | Length (bp) | % of genome | Length (bp) | % of genome | Length (bp) | % of genome | |
| DNA | 25,035,683 | 1.43 | 6,450,126 | 0.37 | 56,943,252 | 3.26 | 70,663,766 | 4.04 |
| LINE | 124,676,466 | 7.13 | 132,747,210 | 7.60 | 191,015,014 | 10.93 | 213,508,152 | 12.22 |
| SINE | 20,281,741 | 1.16 | - | 0.00 | 54,941,907 | 3.14 | 57,180,364 | 3.27 |
| LTR | 7,613,766 | 0.44 | 17,931,338 | 1.03 | 16,104,019 | 0.92 | 28,021,391 | 1.60 |
| Other | 24,327 | 0.00 | - | 0.00 | - | 0.00 | 24,327 | 0.00 |
| Unknown | 761,119 | 0.04 | - | 0.00 | 283,563,847 | 16.23 | 284,276,315 | 16.27 |
| Total | 174,011,206 | 9.96 | 157,050,977 | 8.99 | 627,828,869 | 35.93 | 657,625,603 | 37.63 |
| n = 1450 | Cluster 1n = 385 | Cluster 2n = 431 | Cluster 3n = 243 | Cluster 4n = 391 |
| Severity∧ | ||||
| (i) Moderate | 23.8 | 25.3 | 31.2 | 49.4 |
| (ii) Severe | 16.8 | 9.1 | 8.2 | 23.1 |
| Asthma∧ | 11.2 | 32.1 | 28.3 | 5.8 |
| Pollen allergy∧ | 78.5 | 36.3 | 11.3 | 87.4 |
| House dust mite allergy∧ | 18.8 | 33.5 | 32.1 | 51.5 |
| Total IgE∗ | 138 (129) | 89 (87) | 116 (98) | 221 (167) |
| FeNO∗∗ | 35 (22) | 69 (54) | 54 (34) | 36 (15) |
| SAR | SEM | |||
| Coef. | z-Value | Coef. | z-Value | |
| Household car ownership | 0.35⁎⁎⁎ | 5.58 | 0.22⁎⁎⁎ | 3.42 |
| Prop. of people going to work by public transport | 0.39⁎ | 2.56 | 0.42⁎⁎ | 2.92 |
| Prop. of people who are economically active | 0.78⁎ | 2.57 | 1.07⁎⁎⁎ | 3.85 |
| Prop. of white | 0.22 | 1.93 | 0.22⁎ | 2.06 |
| Median age | 0.01⁎⁎⁎ | 3.91 | 0.02⁎⁎⁎ | 7.00 |
| Prop. of households classified as deprived | − 0.01 | − 0.06 | − 0.19 | − 0.98 |
| Fuel poverty | − 0.004 | − 0.84 | − 0.002 | − 0.45 |
| Regions | ||||
| London | Reference case | |||
| East Midlands | 0.29⁎⁎⁎ | 4.93 | 0.02 | 0.32 |
| East of England | 0.11⁎ | 2.10 | 0.02 | 0.44 |
| North East | 0.11 | 1.65 | 0.03 | 0.51 |
| North West | 0.09 | 1.70 | − 0.09 | − 1.41 |
| South East | 0.10⁎ | 2.01 | 0.04 | 0.73 |
| South West | 0.13⁎ | 2.20 | 0.06 | 1.00 |
| West Midlands | 0.13⁎ | 2.21 | − 0.10 | − 1.53 |
| Yorkshire and the Humber | 0.20⁎⁎⁎ | 3.40 | 0.03 | 0.55 |
| Constant | − 0.39 | − 1.00 | − 0.83⁎ | − 2.33 |
| λ | − 55.35⁎⁎⁎ | − 3.64 | ||
| ρ | 550.47⁎⁎⁎ | 30.75 | ||
| Statistics | ||||
| N | 320 | 320 | ||
| Log-likelihood | 247.75 | 278.91 | ||
| AIC | − 459.49 | − 521.81 |
| S. No. | Allergen | Mouse MHC class I | Mouse MHC class II | Human MHC class I | Human MHC class II |
| 1 | Asp f1 | 148–156 (VIYTYPNKV) | 147–155 (RVIYTYPNK) | ||
| 9–23 (LLAATAVSVLAAPSP) | 9–17 (LLAATAVSV) | 1–15 (MVAIKNLFLLAATAV) | |||
| 2 | Asp f2 | 5–19 (LRLAVLLPLAAPLVA) | 9–17 (VLLPLAAPL) | 4–18 (LLRLAVLLPLAAPLV) | |
| 3 | Asp f5 | 318–332 (LSFKYPYSVSSSPPS) | 316–324 (SSLSFKYPY) | 308–322 (LNNYRPSSSSLSFKY) | |
| 319–333 (SFKYPYSVSSSPPSS) | 314–322 (SSSSLSFKY) | 305–319 (PSYLNNYRPSSSSLS) | |||
| 4 | Asp f17 | 93–108 (DKFVAANAGGTVYED) | 98–106 (AANAGGTVY) | ||
| 5 | Asp f34 | 75–89 (IQDGSLYLYAASATP) | 74–82 (YIQDGSLYL) |
| Patient sizes | Typical nasal trumpet sizes (Fr) |
| Large man | 34, 30 |
| Medium man | 32, 28 |
| Small man | 30, 28 |
| Large woman | 32, 28 |
| Medium woman | 30, 28 |
| Small woman | 28, 26 |
| LN-ER/PR+Her2- status | LN+ER/PR-Her2+ status | |||
| Relapse | No relapse | Relapse | No relapse | |
| Number of patients | 12 | 81 | 39 | 51 |
| Age in year | 53.25±14.27 | 51.07±10.06 | 47.77±9.10 | 46.41±8.35 |
| Time to relapse (months) | 23.83±8.29 | - | 17.59±10.38 | - |
| Pre-/post-menopausal | 5/7 | 45/36 | 17/22 | 28/23 |
| Tumor size (mm) | 1.90±0.67 | 2.34±1.16 | 3.92±1.82 | 3.2±1.47 |
| Family carcinoma history +/- | 6/6 | 21/60 | 25/14 | 15/36 |
| Stage I/IIa/IIb/III | 8/2/2/0 | 46/29/6/0 | 6/14/9/10 | 17/23/7/4 |
| Her2+/++/+++ | - | - | 14/20/5 | 23/19/9 |
| ER content ≤30%/31%-60%/>60% | 3/4/5 | 12/34/35 | - | - |
| PR content ≤30%/31%-60%/>60% | 4/0/8 | 8/30/43 | - | - |
| PCNA content - / ≤30%/31%-60%/>60% | 1/1/2/8 | 7/7/27/40 | 0/3/23/13 | 6/7/23/15 |
| P53 content - / ≤30%/31%-60%/>60% | 8/3/1/0 | 59/12/2/1 | 15/0/7/17 | 25/1/12/13 |
| Lymph node <4/4-9/>9 | - | - | 16/13/10 | 34/12/5 |
| Radiation/no radiation | 12/0 | 81/0 | 39/0 | 51/0 |
| Adjuvant therapy: hormonal (tamoxifen) | 12/0 | 81/0 | 0/39 | 0/51 |
| Group | Water storage (24 hours) | Thermocycling (10,000 cycles) |
| NC | 20.18 (2.01)c | 20.68 (4.60)b |
| SBU | 27.33 (2.81)b | 22.49 (4.11)b∗ |
| PC | 30.50 (3.40)a | 28.77 (3.52)a |
| True Phylo | QuartetS | QuartetA | QuartetM | Quartet-Net | Neighbor-Net | Neighbor-Joining | |||||||||||||
| Split | Wei | Split | Wei | BV | Split | Wei | BV | Split | Wei | BV | Split | Wei | BV | Split | Wei | BV | Split | Wei | BV |
| ab | 1 | ab | 1.08 | 100 | ab | 1.09 | 100 | ab | 1.12 | 100 | ab | 1.08 | 100 | ab | 0.76 | 80 | ab | 0.41 | 56 |
| abc | 4 | abc | 4 | 100 | abc | 4 | 100 | abc | 4 | 100 | abc | 4 | 100 | abc | 4 | 100 | abc | 4 | 100 |
| abd | 1 | abd | 1.03 | 100 | abd | 1.03 | 100 | abd | 1.03 | 100 | abd | 1.02 | 100 | abd | 1.32 | 50 | |||
| abcd | 4 | abcd | 3.99 | 100 | abcd | 3.99 | 100 | abcd | 3.99 | 100 | abcd | 3.99 | 100 | abcd | 4.17 | 100 | abcd | 3.97 | 100 |
| abce | 1 | abce | 1.01 | 100 | abce | 1.02 | 100 | abce | 1.01 | 100 | abce | 1.01 | 100 | abce | 0.86 | 46 | |||
| abcg | 1 | abcg | 1.03 | 100 | abcg | 1.03 | 100 | abcg | 1.03 | 100 | abcg | 1.02 | 100 | abcg | 0.89 | 54 | |||
| aefg | 1 | aefg | 1.02 | 100 | aefg | 1.03 | 100 | aefg | 1.02 | 100 | aefg | 1.02 | 100 | aefg | 1.39 | 50 | |||
| abcde | 1 | abcde | 1.08 | 100 | abcde | 1.09 | 100 | abcde | 1.12 | 100 | abcde | 1.07 | 100 | abcde | 0.76 | 67 | abcde | 0.39 | 46 |
| abcdg | 1 | abcdg | 1.07 | 100 | abcdg | 1.08 | 100 | abcdg | 1.11 | 100 | abcdg | 1.07 | 100 | abcdg | 0.71 | 68 | abcdg | 0.39 | 54 |
| abceg | 2 | abceg | 2.07 | 100 | abceg | 2.09 | 100 | abceg | 2.12 | 100 | abceg | 2.07 | 100 | abceg | 2.36 | 47 | |||
| acefg | 2 | acefg | 2.06 | 100 | acefg | 2.07 | 100 | acefg | 2.11 | 100 | acefg | 2.06 | 100 | acefg | 2.23 | 8 | |||
| adefg | 1 | adefg | 1.08 | 100 | adefg | 1.09 | 100 | adefg | 1.12 | 100 | adefg | 1.07 | 100 | adefg | 0.76 | 73 | adefg | 0.43 | 44 |
| a | 10 | a | 10.31 | 100 | a | 10.15 | 100 | a | 10.17 | 100 | a | 10.43 | 100 | a | 10.07 | 100 | a | 9.42 | 100 |
| b | 6 | b | 6.25 | 100 | b | 6.11 | 100 | b | 6.07 | 100 | b | 6.33 | 100 | b | 7.62 | 100 | b | 7.15 | 100 |
| c | 10 | c | 10.26 | 100 | c | 10.11 | 100 | c | 10.12 | 100 | c | 10.38 | 100 | c | 10.05 | 100 | c | 9.40 | 100 |
| d | 4 | d | 4.21 | 100 | d | 4.06 | 100 | d | 4.08 | 100 | d | 4.26 | 100 | d | 6.02 | 100 | d | 6.82 | 100 |
| e | 10 | e | 10.28 | 100 | e | 10.14 | 100 | e | 10.16 | 100 | e | 10.41 | 100 | e | 10.12 | 100 | e | 9.43 | 100 |
| f | 6 | f | 6.25 | 100 | f | 6.11 | 100 | f | 6.06 | 100 | f | 6.34 | 100 | f | 7.22 | 100 | f | 7.11 | 100 |
| g | 10 | g | 10.31 | 100 | g | 10.16 | 100 | g | 10.18 | 100 | g | 10.44 | 100 | g | 10.14 | 100 | g | 9.47 | 100 |
| ac | 0.08 | 99 | abdfg | 0.04 | 15 | ||||||||||||||
| abcdf | 0.08 | 97 | ag | 0.04 | 13 | ||||||||||||||
| acdeg | 0.02 | 74 | ae | 0.03 | 12 | ||||||||||||||
| acdef | 0.03 | 66 | abdef | 0.04 | 10 | ||||||||||||||
| ae | 0.04 | 65 | |||||||||||||||||
| abdeg | 0.03 | 65 | |||||||||||||||||
| ag | 0.04 | 64 | |||||||||||||||||
| abdfg | 0.04 | 64 | |||||||||||||||||
| acdfg | 0.02 | 62 | |||||||||||||||||
| abdef | 0.04 | 59 | |||||||||||||||||
| af | 0.03 | 58 |
| 6-8 h postoperative >20% | 66-72 h postoperative >20% | |||||
| Sevoflurane | Xenon | P-value | Sevoflurane | Xenon | P-value | |
| DS | 5 (26) | 2 (11) | 0,405 | 5 (28) | 3 (21) | 1 |
| DSST | 4 (21) | 3 (17) | 1 | 1 (6) | 0 (0) | 1 |
| TMT A | 4 (21) | 4 (22) | 1 | 1 (6) | 6 (43) | 0,027 |
| TMT B | 4 (21) | 6 (33) | 0,476 | 3 (17) | 0 (0) | 0,238 |
| Alertness RT | 5 (26) | 4 (22) | 1 | 2 (12) | 2 (14) | 1 |
| Alertness VR | 0 (0) | 2 (11) | 0,23 | 1 (6) | 1 (7) | 1 |
| Divided Attention RT | 2 (11) | 1 (6) | 1 | 1 (6) | 2 (14) | 0,576 |
| Divided Attention VR | 1 (6) | 1 (6) | 1 | 2 (12) | 0 (0) | 0,488 |
| Visual Scanning RT | 7 (37) | 3 (17) | 0,269 | 4 (25) | 2 (14) | 0,657 |
| Visual Scanning VR | 3 16) | 3 (17) | 1 | 3 (19) | 2 (14) | 1 |
| Working Memory RT | 3 (16) | 4 (22) | 0,693 | 5 (31) | 3 (21) | 0,689 |
| Working Memory VR | 5 (26) | 5 (28) | 1 | 1 (6) | 0 (0) | 1 |
| Reaction Change RT | 3 (16) | 1 (6) | 0,608 | 0 (0) | 0 (0) | - |
| Reaction Change VR | 0 (0) | 2 (13) | 0,202 | 0 (0) | 1 (8) | 0,433 |
| Unadjusted OR | 95% CI | Adjusted OR | 95% CI | P-value | |
| Adherence history: | |||||
| poor at least once vs optimal | 1.34 | (0.81, 2.17) | 1.30 | (0.78, 2.10) | 0.30 |
| non-response at least once vs optimal | 1.99 | (1.01, 3.63) | 1.98 | (1.00, 3.62) | 0.03 |
| missing at least once vs optimal | 3.26 | (1.65, 5.96) | 3.60 | (1.80, 6.65) | <0.001 |
| Pre-ART WHO disease stage | |||||
| stage 2 | 1(ref) | 1(ref) | 0.8 | ||
| stage 3 | 1.08 | (0.61, 2.02) | 1.02 | (0.57, 1.91) | |
| stage 4 | 1.48 | (0.76, 2.92) | 1.19 | (0.60, 2.41) | |
| Pre-ART CD4 cell count | |||||
| 0-49 | 1.69 | (0.88, 3.51) | 1.43 | (0.72, 3.07) | |
| 50-99 | 1.27 | (0.61, 2.77) | 1.18 | (0.55, 2.61) | |
| 100-149 | 1.07 | (0.49, 2.41) | 1.01 | (0.45, 2.29) | |
| 150-199 | 1(ref) | 1(ref) | 0.6 | ||
| Pre-ART Body mass index | |||||
| <20 | 1.35 | (0.82, 2.18) | 1.31 | (0.79, 2.14) | |
| 20-27 | 1(ref) | 1(ref) | 0.5 | ||
| >27 | 1.37 | (0.59, 2.79) | 1.33 | (0.57,2.77) | |
| Age at ART initiation groups | |||||
| 18-35 | 1(ref) | 1(ref) | 0.9 | ||
| 35-50 | 0.84 | (0.53, 1.35) | 0.92 | (0.57, 1.50) | |
| 50+ | 0.89 | (0.31, 2.09) | 1.03 | (0.35, 2.48) | |
| Sex | |||||
| Female vs Male | 1.23 | (0.76, 2.04) | 1.31 | (0.79, 2.22) | 0.3 |
| Time since ART initiation in years | |||||
| ≤2 | 1(ref) | 1(ref) | 0.06 | ||
| 2-3 | 0.37 | (0.17, 0.73) | 0.40 | (0.18, 0.79) | |
| 3-4 | 0.57 | (0.30, 1.04) | 0.60 | (0.31, 1.10) | |
| 4-5 | 0.49 | (0.24, 0.93) | 0.47 | (0.23, 0.91) | |
| >5 | 0.76 | (0.34, 1.54) | 0.65 | (0.29, 1.34) |
| Full Sample | Sibling Subsample | Non-Sibling Subsample | ||||
| (1) | (2) | (3) | (4) | (5) | (6) | |
| Food | Nutrient-Rich Food Groups | Food | Nutrient-Rich Food Groups | Food | Nutrient-Rich Food Groups | |
| LNS | 0.068* | 0.069* | 0.070 | 0.059 | 0.060 | 0.068 |
| (0.036) | (0.038) | (0.058) | (0.066) | (0.046) | (0.047) | |
| Z-Score of Maternal Height | −0.006 | −0.004 | −0.026 | −0.040 | 0.016 | 0.023 |
| (0.019) | (0.019) | (0.036) | (0.039) | (0.022) | (0.022) | |
| LNS*Z-Score of Maternal Height | 0.031 | 0.035 | 0.119 | 0.170* | -0.013 | -0.025 |
| (0.039) | (0.042) | (0.076) | (0.089) | (0.046) | (0.048) | |
| N | 1089 | 1111 | 394 | 403 | 695 | 708 |
| Overall R2 | 0.094 | 0.089 | 0.165 | 0.144 | 0.062 | 0.065 |
| Coefficient | Robust Std.Err. | P > |z| | 95% confidence interval | ||
| Constant | -5.6968 *** | 0.8729 | 0.000 | -7.4076 | -3.9859 |
| Cholera cases | 0.0001 *** | 0.00001 | 0.000 | 0.0001 | 0.0002 |
| Water cover | -12.5607 *** | 1.5875 | 0.000 | -15.6721 | -9.4492 |
| Observations | 15 | ||||
| Log pseudolikelihood | -84.2818 |
| Sample ID | Organ | Related microorganism | GenBank accession no. | Similarity % |
| 12Ue0622 | Placenta | Not interpretable | – | – |
| 12Ue1119 | Placenta | Chlamydia abortus | Z49871 | 100 |
| 12Ue1503 | Placenta | Uncultured Chlamydiales bacteriumclone HE210023biof | JX083111 | 99.3 |
| 12Ue1510 | Placenta | Chlamydia abortus | NR_036834 | 100 |
| 13Ue0490 | Placenta | Chlamydia abortus | Z49871 | 94.7 |
| 13Ue0499 | Placenta | Not interpretable | – | – |
| 13Ue0815 | Placenta | Chlamydiales bacterium cvE71 | JF706724 | 96 |
| 13Ue0857 | Placenta | Chlamydia abortus | Z49871 | 100 |
| 13Ue1009 | Placenta | Chlamydia abortus | Z49871 | 99.3 |
| 13Ue1293 | Placenta | Chlamydia abortus | Z49871 | 100 |
| 13Ue1359 | Placenta | Chlamydia abortus | Z49871 | 100 |
| 14A0078 | Placenta | Chlamydia abortus | Z49871 | 98.5 |
| 15A0068 | Placenta | Chlamydia abortus | Z49871 | 90.8 |
| 15A0076 | Placenta | Not interpretable | – | – |
| 15A0078 | Placenta | Chlamydia abortus | Z49871 | 99.5 |
| 15A0079 | Placenta | Chlamydia abortus | Z49871 | 99.8 |
| 15A0080 | Placenta | Chlamydia abortus | Z49871 | 99.5 |
| 15A0082 | Placenta | Chlamydia abortus | Z49871 | 96.2 |
| 15A0087 | Placenta | Uncultured Chlamydiales bacteriumclone P-9 | AF364575 | 97 |
| 15A0091 | Placenta | Chlamydia abortus | Z49871 | 92 |
| 15A0092 | Placenta | Chlamydia abortus | Z49871 | 100 |
| 15A0093 | Placenta | Chlamydia abortus | Z49871 | 90.8 |
| 15A0096 | Placenta | Chlamydia abortus | Z49871 | 99.5 |
| 15A0096 | Abomasal content | Chlamydia abortus | Z49871 | 99.5 |
| 15A0099 | Placenta | Not interpretable | – | – |
| 15A0104 | Placenta | Chlamydia abortus | Z49871 | 100 |
| 15A0107 | Placenta | Not interpretable | – | – |
| 15A0111 | Placenta | Chlamydia abortus | Z49871 | 99.5 |
| 15A0113 | Placenta | Chlamydia abortus | Z49871 | 100 |
| 15A0114 | Placenta | Chlamydia abortus | Z49871 | 99.5 |
| 15A0117 | Placenta | Not interpretable | – | – |
| 15A0118 | Placenta | Chlamydia abortus | Z49871 | 96.8 |
| 15A0121 | Placenta | Chlamydia abortus | Z49871 | 98.1 |
| 15A0122 | Placenta | Chlamydia abortus | Z49871 | 97.6 |
| 15A0126 | Abomasal content | Not interpretable | – | – |
| 15A0129 | Placenta | Not interpretable | – | – |
| 15A0137 | Placenta | Not interpretable | – | – |
| 15A0148 | Placenta | Not interpretable | – | – |
| 15A0155 | Placenta | Parachlamydia acanthamoebae strain Bn9 | NR_026357 | 90.3 |
| 15A0160 | Placenta | Not interpretable | – | – |
| 15A0172 | Placenta | Not interpretable | – | – |
| λ | Combined t-test | Linear regression | Combined Wilcoxon | Combined BWS |
| 0 | 0.056 | 0.053 | 0.073 | 0.669 |
| 0.05 | 0.075 | 0.057 | 0.094 | 0.703 |
| 0.1 | 0.182 | 0.087 | 0.200 | 0.832 |
| 0.15 | 0.402 | 0.141 | 0.412 | 0.939 |
| 0.2 | 0.701 | 0.212 | 0.687 | 0.988 |
| 0.25 | 0.911 | 0.298 | 0.893 | 0.999 |
| Out-of-hours GP services | EDs | |||
| Usual care | UCC | Usual care | UCC | |
| All employees | 12 | 12 | 3 | 3 |
| Physicians | 19 | 20 | 7 | 12 |
| Support staff member | 33 | 32 | 4 | 4 |
| Vision | Number of patients | Percent |
| 6/6–6/18 | 8 | 16 |
| <6/18–6/60 | 12 | 24 |
| <6/60–3/60 | 9 | 18 |
| <3/60–1/60 | 12 | 24 |
| <1/60–PL | 7 | 14 |
| No PL | 2 | 4 |
| Total | 50 | 100 |
| Controls | Welders | P value | |
| (n = 21) | (n = 21) | ||
| Mean age (years ± SD) | 58.6 ± 10.8 | 58.5 ± 10.7 | ns |
| Gender | |||
| Female | 6 (28.6%) | 1 (4.8%) | 0.038 |
| Male | 15 (71.4%) | 20 (95.2%) | ns |
| Tobacco smoking | |||
| Smoking status | ns | ||
| Current smokers | 9 (43.0%) | 6 (28.6%) | |
| Former smokers | 9 (43.0%) | 12 (57.1%) | |
| Never smokers | 3 (14.0%) | 3 (14.3%) | |
| Cumulative consumption (P-Y ± SD) | 24.6 ± 29.0 | 22.2 ± 15.2 | ns |
| Age at onset (years ± SD) | 16.8 ± 3.4 | 18.3 ± 4.2 | ns |
| Age at cessation (years ± SD) | 51.6 ± 14.0 | 48.8 ± 11.2 | ns |
| Duration (years ± SD) | 32.6 ± 16.7 | 33.7 ± 10.3 | ns |
| Duration since cessation (years ± SD) | 5.7 ± 9.3 | 8.2 ± 10.4 | ns |
| Welding fumes exposure | - | ||
| Positive occupational questionnaire | 0 | 21 | |
| Age at onset (years ± SD) | - | 19.9 ± 7.6 | |
| Age at cessation (years ± SD) | - | 48.2 ± 9.9 | |
| Duration (years ± SD) | - | 27.0 ± 9.2 | |
| Duration since cessation (years ± SD) | - | 9.2 ± 10.4 |
| Age | Quebec, Geometric Mean (95th Percentile) | Ontario, Geometric Mean (95th Percentile) |
| 4 | 0.03 (0.13) | 0.06 (0.17) |
| 8 | 0.02 (0.05) | 0.05 (0.12) |
| SASIn = 123–124 | Non-SASIn = 5514–5515 | Totaln = 5635–5639 | |||||
| Mean | SD | Mean | SD | Mean | SD | p value | |
| Anxiety | 9.6 | 5.5 | 4.6 | 3.9 | 4.7 | 4.0 | <.001 |
| Depression | 12.4 | 6.2 | 5.0 | 4.4 | 5.2 | 4.6 | <.001 |
| Anger | 9.0 | 5.7 | 4.0 | 4.0 | 4.2 | 4.1 | <.001 |
| Post-traumatic stress | 14.0 | 6.4 | 6.1 | 4.9 | 6.2 | 5.1 | <.001 |
| Dissociation | 12.9 | 6.2 | 5.9 | 4.8 | 6.0 | 4.9 | <.001 |
| Sexual concerns | 4.8 | 3.9 | 2.2 | 2.4 | 2.6 | 2.5 | <.001 |
| First Contact (Admission) | Second contact (Discharge) | Third Contact (Community- based phase) | Defaulted & Loss to follow-up | |
| Children’s Sex (%) | ||||
| Male | 46 | 46.2 | 47 | 44 |
| Female | 54 | 53.8 | 53 | 56 |
| Children’s Age, months (%) | ||||
| 6–11 | 38.7 | 33.9 | 25 | 32 |
| 12–23 | 45.3 | 49.2 | 55 | 46 |
| 24–35 | 12 | 14.4 | 14 | 16 |
| 36+ | 4 | 2.5 | 6 | 6 |
| Mother’s religion(%) | ||||
| Hindu | 29.3 | 30.5 | 30 | 28 |
| Muslim | 6 | 5.1 | 6 | 4 |
| Sarna | 54 | 56.8 | 55 | 60 |
| Others | 10.7 | 7.6 | 9 | 8 |
| Mother’s caste(%) | ||||
| SC | 9.3 | 11 | 10 | 10 |
| ST | 68 | 70.3 | 71 | 72 |
| OBC | 15.3 | 14.4 | 14 | 12 |
| General | 7.4 | 4.2 | 5 | 6 |
| Mother’s age (%) | ||||
| 18–25 | 46.7 | 47.5 | 47 | 42 |
| 26–30 | 24 | 22.9 | 24 | 26 |
| 31+ | 29.3 | 29.7 | 29 | 32 |
| Mother’s education (%) | ||||
| No schooling | 67.3 | 66.1 | 66 | 70 |
| 1–8 | 26.1 | 29 | 29 | 28 |
| 9+ | 6.6 | 5.2 | 5 | 2 |
| Total children and mothers | 150 | 116 | 100 | 50 |
| 1st author and year | N | ALD | HBV or HCV | Cryptogenic | ALD + HCV | Miscellaneous |
| Krowka 1999 | 14 | 1 | 1 | 3 | 3 | 1 HCC + HCV, 1 sarcoidosis,2 PBC, 1 Budd Chiari, 1 AIH |
| Hoeper 2005 | 11 | 7 | 1 | 0 | 2 | 1 biliary atresia |
| Reichenberger 2006 | 14 | 7 | 3 | 3 PBC, 1 Budd Chiari | ||
| Sussman 2006 | 8 | 4 | 1 | 2 | 1 | |
| Fix 2007 | 35 | 7 | 9 | 3 | 10 | 1 HIV, 2 HCC, 2 PBC, 1 AIH |
| Hoeper 2007 (bosentan) | 18 | 11 | 3 | 1 | 0 | 1 PVT, 2 AIH |
| Hoeper 2007 (iloprost) | 13 | 6 | 2 | 0 | 0 | 1 biliary duct atresia, 4 AIH |
| Gough and White 2009 | 11 | 4 | 2 | 0 | 4 | 1 ALD + NASH |
| Hemnes 2009 | 13 | 1 | 8 | 0 | 0 | 1 PBC |
| Melgosa 2010 | 13 | 2 | 7 | 0 | 0 | 1 hemochromatosis, 2 PBC, 1 portal vein thrombosis |
| Halank 2011 | 13 | 8 | 1 | 3 | 0 | 1 PBC |
| Hollatz 2012 | 11 | 5 | 1 | 0 | 3 | 1 ALD + NASH + PBC, 1 biliary atresia |
| Savale 2013 | 34 | 20 | 4 | 3 | 6 PVT, 1 AIH | |
| Total | 83 (40%) | 43 (20%) | 12 (5%) | 26 (12%) | 41 (20%) |
| Food Item | Copacabana | Bertioga | Itacimirim | Pântano do Sul | Vitória sland | TOTAL |
| Algae | 1 | 1 | ||||
| Anything | 3 | 3 | 3 | 7 | 1 | 17 |
| Bonito | 1 | 4 | 1 | 1 | 1 | 8 |
| Crabs | 1 | 2 | 1 | 2 | 6 | |
| Crustacean | 2 | 2 | ||||
| Deteriorated fish/meat | 1 | 5 | 7 | 13 | ||
| Fish | 2 | 15 | 8 | 2 | 27 | |
| Meat | 1 | 1 | ||||
| Mouse/snake | 1 | 1 | ||||
| Octopus | 2 | 1 | 3 | |||
| Sardine | 3 | 6 | 2 | 2 | 1 | 14 |
| Shrimp | 1 | 2 | 3 | |||
| Small mollusks | 4 | 1 | 5 | |||
| Squid | 3 | 3 | 6 | |||
| Interviews | 10 | 11 | 15 | 11 | 2 | 49 |
| Process | Tool | Parameters | Subject database |
| Screening of rRNAs | BLASTALL | -p blastn –e 1e-3 –f T – b 1 –v 1 –M BLOSUM62 | |
| Identification of tRNAs | tRNA scan SE | -b G | |
| ORF calling | MetaGene Annotator | -m | |
| Known protein identification | BLASTALL | -p blastp –e 1e-1 –F T – b 50 –v 50 –M BLOSUM 62 | UNIREF 100 |
| Environmental Protein Identification | BLASTALL | -p blastp –e 1e-1 –F T –b 50 –v 50 –M BLOSUM62 | MGOL |
| S/P value | Mean | S.D. | Minimum | Maximum | |
| Group 2 | Positive | 1.46 | 0.66 | 0.42 | 3.01 |
| Negative | 0.13 | 0.13 | 0.00 | 0.37 | |
| Group 3 | 0.01 | 0.02 | 0.00 | 0.20 | |
| Group 4 | 0.06 | 0.07 | 0.00 | 0.39 | |
| Group 5 | Negative | 0.07 | 0.06 | 0.00 | 0.31 |
| Positive n = 2 | - | - | 0.64 | 2.22 |
| Sociodemographic | Total N = 70 | |
| N | (%) | |
| Gender of the respondent | ||
| Female | 54 | 77 |
| Type of the respondent | ||
| Compound members | 55 | 79 |
| Compound manager | 15 | 21 |
| Age of the respondent | ||
| 19–35 year | 38 | 54 |
| Above 36 year | 32 | 46 |
| Education of the respondent | ||
| No education | 25 | 36 |
| Primary | 21 | 30 |
| Secondary | 17 | 24 |
| Above secondary | 7 | 10 |
| Occupation of the respondent | ||
| Housewife | 54 | 77 |
| School teacher | 1 | 1 |
| Business | 12 | 17 |
| Service | 3 | 4 |
| Simplex Assay | Multiplex Assay | |||||
| CHIKV | DENV | Leptospira | CHIKV | DENV | Leptospira | |
| Slope | −3.13 | −3.19 | −3.25 | −3.41 | −3.15 | −3.37 |
| Efficiency | 2.09 | 2.06 | 2.03 | 1.96 | 2.08 | 1.98 |
| Databases | Contents |
| National Eye Institute: NEI Bank Project | Transcriptome profiling for different tissues of the eye for a variety of different species including mouse and human |
| Mouse Retina Serial Analysis of Gene Expression (SAGE) | Gene expression data from the embryonic and postnatal mouse retina. |
| Scripps Friedlander Gene Expression | Expression of retinal transcripts for the mouse retina during eight different postnatal stages. |
| Retinal Information Network | Mapped loci and cloned genes associated with inherited retinal disease. |
| Retinal International Website | Series of databases listing: retinal diseases, mutations affecting the eye, current animal models, and known proteins involved in retinal disease. |
| GENSTAT: Retina Project | Cell specific labeling in the retina using BAC transgenic mice. |
| Retina Central | Integrated platform for gene related information regarding the adult mammalian retina |
| Hormone | Quantity of studies | Normal response | Blunted response | Exacerbated response |
| Cortisol | 26 (65.0%) | 18 (69.2%) | 8 (30.8%) | - |
| Total T | 18 (45.0%) | 14 (77.8%) | 3 (16.7%) | 1 (5.9%) |
| GH | 13 (32.5%) | 7 (53.8%) | 5 (38.4%) | 1 (7.8%) |
| T/C | 10 (25.0%) | 5 (50.0%) | 4 (40.0%) | 1 (10.0%) |
| ACTH | 10 (25.0%) | 6 (60.0%) | 4 (40.0%) | - |
| Plasma catecholamines | 9 (22.5%) | 4 (44.4%) | 4 (44.4%) | 1 (11.1%) |
| Insulin | 8 (20.0%) | 6 (75.0%) | 2 (25.0%) | - |
| LH | 8 (20.0%) | 7 (87.5%) | 1 (12.5%) | - |
| Prolactin | 6 (15.0%) | 4 (66.7%) | 2 (33.3%) | - |
| FSH | 6 (15.0%) | 5 (83.3%) | 1 (16.7%) | - |
| IGF-1 | 5 (12.5%) | 3 (60.0%) | 1 (20.0%) | 1 (20.0%) |
| Aldosterone | 5 (12.5%) | 1 (20.0%) | 2 (40.0%) | 2 (40.0%) |
| Free T | 3 (7.5%) | 1 (33.3%) | 1 (33.3%) | 1 (33.3%) |
| T4 | 2 (5.0%) | 2 (100%) | - | - |
| T3 | 2 (5.0%) | 2 (100%) | - | - |
| NUC | 2 (5.0%) | - | 2 (100%) | - |
| Salivary C | 2 (5.0%) | - | 2 (100%) | - |
| Salivary T | 2 (5.0%) | 1 (50.0%) | 1 (50.0%) | - |
| NUC | 2 (5.0%) | 1 (50.0%) | 1 (50.0%) | - |
| IGFBP-3 | 2 (5.0%) | 1 (50.0%) | 1 (50.0%) | - |
| IGF-1/IGFBP-3 | 2 (5.0%) | 2 (100%) | - | - |
| SHBG | 1 | 1 | - | - |
| DHEA-S | 1 | 1 | - | - |
| Peptide F | 1 | 1 | - | - |
| Fertility | 1 | - | 1 | - |
| Beta-2 muscle receptors | 1 | - | 1 | - |
| Level | Discovery phase | Improvement phase |
| Heritability | ||
| 0.25 | 0.033 (0.012, 0.056)a | 0.098 (−0.005, 0.200)a |
| 0.50 | 0.045 (0.020, 0.072)b | 0.130 ( 0.014, 0.232)b |
| Genotyping platform | ||
| GBS10x@10K | 0.029 (0.011, 0.049)a | 0.098 (−0.014, 0.210)a |
| GBS1x@100K | 0.050 (0.030, 0.072)b | 0.130 ( 0.031, 0.232)b |
| Number of phenotyped seeds per landrace | ||
| 1 | 0.035 (0.013, 0.061)a | 0.109 (−0.008, 0.219)a |
| 3 | 0.040 (0.014, 0.069)b | 0.116 ( 0.008, 0.223)b |
| 5 | 0.042 (0.017, 0.071)c | 0.117 ( 0.009, 0.224)b |
| Number of selected landraces | ||
| 40 | 0.042 (0.016, 0.072)a | 0.115 ( 0.003, 0.220)a |
| 80 | 0.036 (0.013, 0.063)b | 0.113 ( 0.001, 0.226)a |
| Number of tested seeds per selected landrace | ||
| 10 | 0.038 (0.014, 0.066)a | 0.113 (−0.004, 0.228)a |
| 20 | 0.040 (0.014, 0.068)b | 0.114 ( 0.000, 0.218)a |
| 40 | 0.041 (0.015, 0.070)c | 0.114 ( 0.009, 0.222)a |
| Number of phenotyped synthetic seeds | ||
| 0 | / | 0.069 (−0.020, 0.166)a |
| 20 | / | 0.116 ( 0.016, 0.213)b |
| 40 | / | 0.131 ( 0.036, 0.229)c |
| 60 | / | 0.139 ( 0.038, 0.244)d |
| Immune cells | Enriched genes | References |
| All T cells | Human: CD3G, CD3D, TRA, CD6, CD5, NPDC1, CD28, CAMK4, GFI1, GATA3, SH2D1A, TRB, TNFRSF25, NK4, TACTILE, BCL11B, CD3E, INPP4B, MAL, NPDC1, ITM2A, ITK, LCK, NFATC3, RORA, MGC19764, TCF7, ZAP70, LEF1, SPOCK2, PRKCQ, SATB1, RASGRP1, LRIG1, DPP4, CD3Z, PDE4D, FYN, WWP1, LAT, DUSP16, KIAA0748, CDR2, STAT4, FLT3LG, IL6ST | 78–79 |
| CD8+T cells | Human: FCGBP, C1ORF21, PHEMX, KLRG1, ZNF145, ADRB2, DUSP2, IL2RB, CCL5, GZMC, TBX21, CCL4L, GZMH, PRF1, GNLY, CST7, GPR56, KLRC1, S100B, D12S2489E, CD8B1, CD8A | 79, 81, 82 |
| T regulatory cells | Human: AKAP2, ANXA2, C8FW, CALM2, CDH13, ENTPD1, EPSTI1, F5, GBP2, GBP5, HS3ST3B1, HSPCA, ICA1, LAIR2, LGALS3, LOC51191, MKP-7, NINJ2, P53DINP1, PMAIP1, PTPLA, GPR2, HLA-DMA, HLA-DPA1, HLA-DPB1, HLA-DQB1, HLA-DRA, HLA-DRB4, HLA-DRB5, HPGD, PTT1, SAT, SHMT2, TMOD3, TNFRSF6, VIL2, LRRC32, CHAC1, EGR1, PYCR1, IL13, C3AR1, ZBED2, IL10, GAB3, NR4A1, IL1R2, ULBP1, IL17F, EIF4EBP1, RGS16, BCAT1, VEGFA, GIMAP1, GPR44, GPT2, PSPH, NLN, MS4A3, UCK2, TNIP3, TNFRSF9, IL7R, NR4A3, CSGALNA, CT1, SLC43A1, ZBTB32, SCFD2, HK2, C17ORF96, C1ORF186, LYZ, SFXN4, CYP1B1, SLC7A5, C17ORF58, SLC4A5, CD52, KLRB1, S100A4, POLA1, SLC7A1, ATPBD4, UBXN8, CASP8, FAIM3, IL12RB2, MPP7, ZNF831, BNIP3L, LRP8, UTRN, SOCS3, LY9, EVI2B, SFXN3, TNFRSF4, ING4, BLM, TNFSF11, SLFN5, CCR8, CD244, MYO1F, HOMER1, ATF3, AGPAT4, CTH, JAKMIP1, TFRC, RPL26L1, MICAL1, GPRASP1, TMX4, FYB, ZNF792, WDR4, HUWE1, CD83, TRIB2, LARP1B, SLC38A5, AUH, CTPS, CYTH1, APOL3, CHD6, IL1R1, LPCAT4, CITED2, DUSP4, SSBP2, LAYN, ZFAND2B, PIK3R1, GCNT4, PPP3CA, TIMP1, SIRPG, CCR3, PTP4A3, SERINC5, MAGOHB, GIMAP4, KLHL24, CCNG2, WDR70, MYBL1, CNPY4, TIMM8A, CCDC28A, MNAT1, MS4A2, GZMB, E2F5, HIBCH, C9ORF91, NHP2, CDC25B, VDR, CSF1, GPATCH4, NFKBID, TMCO7, EHBP1, FAM173B, FARS2, FLVCR2, NPM3, PNPO, P2RY8, TMEM63A, MXI1, MRTO4, SESN2, C1ORF38, STK38, SLC6A6, ALG14, LXN, TNFRSF18, ACSS1, UBA7, MTSS1, PSMA6, FAM8A1, RAB31, TNRC6B, SESN1, CEP68, LAPTM5, PLAGL2, LRRC33, EIF2B3, URB2, DDX21, ITGA4, RGS2, RORC, IFNAR2, CSDA, SORL1, LRRC37B, IL10RA, PRKACB, CBWD1, SMAD3, C1ORF96, FCER1A, HSP90AB1, EMG1 | 83–87 |
| B cells | Human: PSEN2, FZD5, PLEKHF2, SIDT2, MTPN, TUBB6, FLJ21127, SMC6L1, KIAA1026, NUP88, GNA12, RNTRE, GSTZ1, RFX5, XYLT1, GL012, EPB41L2, LOC51760, SCRN1, PTD008, CYB561D2, SCAP2, MMP11, ERDJ5, TTC7A, PMAIP1, GARNL4, TMEPAI, SH3BP5, EDD, UCP4, EVI5L, PIK3C2B, SMAD3, LHFPL2, LOC57228, GM2A, HRK, ZNF207, LOC92497, F5, DMXL1, CLIC4, PRCP, DKFZP434C0328, STRBP, PHF16, JUP, TEAD2, PPP3CA, CNR2, ATP5B, ABCA1, BMF, ZCCHC7, KIAA0274, SLC22A3, SPI1, AMFR, ANXA4, EBF, ITPR1, HIST1H2BK, COPS3, COL14A1, SAV1, APOBEC3B, CCNG2, STAG3, LOC348938, POLD4, TBC1D1, MK2S4, APG4A, DAPP1, TNFRSF18, HERPUD1, POU2F2, ADK, CKIP-1, ACTA2, PARP14, MTSS1, DTX1, DDR1, RRAS2, RNF141, SYPL, SSPN, CORO1C, NFKBIE, CHD7, SP140, WDR34, BTNL9, ATP6V0A1, UROS, HLA-DOA, C22ORF13, IFI27, JMJD2B, WEE1, ODC1, KIAA0746, WDR11, SYNGR2, FOXP1, BLR1, MYO1E, MYBL2, GYLTL1B, SETBP1, KLF1, INPPL1, LOC54103, ZNF154, MHC2TA, CD24, ARHGEF3, BIRC3, TRIM56, HLA-DPB1, UVRAG, CD38, PEA15, FLJ10697, TLR10, ARHGAP10, HLA-DRA, SHMT2, LGALS9, FLJ10853, CEBPB, PRICKLE1, LCP21, CR1, KLHL14, TLR7, C20ORF72, HLA-DQB2, CORO1A, PRKCEHECW2, FLJ25604, TRIM26, FBXO41, GCNT1, LRMP, UBE2J1, IGKV3D, PCCA, GLDC, CYSLTR1, BTLA, NET5, HLA-DPA1, BLNK, CD79B, TM4SF8, TFEB, CD11ORF24,ADRBK2, CDKN2A, RIPK2, STX7, NCF4, SRGAP2, SLC2A5, CTSZ, AIM2, TCF4, TPD52, MAP3K8, MOBKL2B, HLA-DOB, IFIT3, MGC24039, BRD4, RALGPS2, SEMA4B, BSG,IGKC, HLA-DRB6, FUBP1, UNC84B, IFNGR2, HSPA5, HLA-DRB5, MARCKS, KYNU, PACAP, RHOBTB2, FLJ12363, TMED8, FGD2, FBXO10, IL4R, CD1C, MGC50844,MRPL49, CTSH, LYN, WASPIP, C3ORF6, EGR1, IGKV15, SPAP1, CHERP, IGHG3, ADAM28, HLA-DMA, HLA-DMB, PALM2-AKAP2, CD86, LAF4, LOC283663, FREB,DKFZP586A0522, UREB1, IGLL1, HLA-DQA2, KIAA1219, PLCG2, MARCH-1, BCNP1, PNOC, CD20, PSCD1, BCL11A, VPS28, SWAP70, SYK, BCL7A, NAP1L, TEM6, BTK,RAB30, FCGR2B, STAT6, BRDG1, LOC201895, ITGB1, CD74, CORO2B, VPREB3, HSPC182, MGC15619, RHOH, IGHA, CYBASC3, KIAA0125, RAM2, CD83, FCRH1, FLII,SNX10, IGHG1, EPHX1, FLJ10979, GTPAP, IGLL3, E2F5, TNFRSF17, BLK, FLJ00332, SNX2, CD200, HLA-DQB1, TRIO, CYBB, PIK3AP1, IRF4, CD22, BACE2, IGJ, PAX5,RGS13, TCL1A, MEF2C, C13ORF18, POU2AF1, HHEX, IRF8, BANK1, OSBPL10, SLC2A1, NCF1, IGL@, IGLC2, SPAP1, IGHG3, HLA-DMA, HLA-DMB, CD79A, HSPA6, IGHD,KIAA0476, SLC7A7, NKG7, CD19, SAMD9, LY86, SPIB, NAPSB, RNASE6, IGHM, LY64, CD72, IRTA2, CD1D, HLA-DQA1, SAS, CTSH, LYN, WASPIP, C3ORF6, EGR1, FREB,DKFZP586A0522 | 88, 79, 89 |
| Resting NK cells | Human: IL18RAP, PRF1, GZMH, TKTL1 | 90–92 |
| Macrophages | aMurine: Pecr, Tmem195, Ptplad2, 1810011H11Rik, Fert2, Tlr4, Pon3, Mr1, Arsg, Fcgr1, Camk1, Pld3, Tpp1, Ctsd, Pla2g15, Lamp2, Pla2g4a, MerTK, Tlr7, Cd14, Tbxas1, Fcgr3, Fgd4, Sqrdl, Csf3r, Plod1, Tom1, Myo7a, A930030A15Rik, Sepp1, Glul, Cd164, Tcn2, Dok3, Ctsl, Tspan14 | 93–95 |
| M1 macrophages | aMurine: Cd38, Cfb, Slfn4, H2-Q6, Fpr1, Slfn1, Gpr18, Ccrl2, Fpr2, Cxcl10, Mpa2IOasl1, Tlr2, Ms4a4c, LOC100503664, Irak3, Hp, Itgal, Herc6, Cd300lf, Isf20, Pstpip2, Cp, Isg15, Herc6, Probe, 1452408_at, Ifi44, E030037K03, Rik, Saa3, Ifit1, Marco, F11r, Rsad2, Ddx60, Pilr1, Cpd, Gngt2, Mx1, Pyhin1, Epb4.1l3, Slfn8, Arhgap24, Nfkbiz, Gbp6, Stat1, Zpb1, D14Erd668e, Ddx58, Tuba4a, H2-T10, Ebi3, Fam176b, Xaf1, Stat2, Sepx1, Ifit2 | 96 |
| M2 macrophages | aMurine: Ptgs1, Egr2, Olfm1, Flrt2, P2ry1, Vwf, Amz1, Tmem158, Tiam1, Rhoj, Mmp9, Mrc1, Bcar3, Il6st, Tanc2, Mmp12, Tcfec, Clec71, Matk, Myc, Clec10a, Atp6v0a1, Lmna, Chst7, Atp6v0d2, Emp2, Socs6, Atp6v0a1, Plk2, Ptpla | 96 |
| Classical monocytes | Human: S100A12, ALOX5AP, PAD14, NRG1, MCEMP1, THBS1, CRISPLD2, F13A1, MOSC1, CYP27A1, CD163, QPCT, ADAM19, ASGR2, RNASE4, ALDH1A1, EDG3, PROK2, CLEC4D, S100A9, OSM, CSPG2, GALS2, ANG, VNN2, EBI2, UTS2, RPPH1, MGST1, IL8, CCR2, SELL, DYSF, MT1F, CD14, RANSE6, CSF3R, STAB1, CYP1B1, ADHFE1, PLA2G7, MMP25, ZNF395, SLC2A3, EGR1, CMTM2, CD9 | 97, 98 |
| Intermediate monocytes | Human: GFRA2, NKG7, PLVAP, PLAC8, MARCKSL1, E2F2, G8P4, CLEC10A, SCD, COTL1, SLC29A1, DDIT4, TGM2, LILRA3, ATF5, GPA33, C1QC, EVA1, MERTK, MGLL, DDEFL1, MARCO, NR1H3, FBP1, ACP2, GBP1, GPBAR1, SASH1, OLFM1, TIMP1, HLA-DOA, CAMK1, POUFUT1, EPB4IL3, H19, ZNF703, SNX5, CLEC10, AK-ALPHA-1, DPB1, DHRS9, MTHFD2, RGL1, PRDM1, FADS1, SLC2A8, CSK, ISOC2, CD300C, FGD2 | 97, 98 |
| Nonclassical monocytes | Human: C1QA, HES4, CDKN1C, C1QB, RHOC, CLEC4F, ADA, TAGLN, TCF7L2, CD798, CTSL, SFTPD, ABI3, SETBP1, FGFRL1, CD798, SPRED1, SNFT, EVL, MTSS1, SH2D1B, CYFIP2, NELF, STS-1, SIGLEC10, CKS1B, PTP4A3, LYPD2, SIDT2, INSIG1, LTB, PAPSS2, ABCC3, CASP5, VOM1, HSPB1, GNGT2, HMOX1, RRAS, RNF122, CDH23, FMNL2, RGS12, SGGB3A1, FER1L3, CALML4, IFITM3, CKB, CEACAM3, IFITM1 | 97, 98 |
| Mature DC’s | Human: ACCL5, CXCL10, CCR7, IL15, IF127, IF144L, IFIH1, IFIT1, MX1, ISG15, ISG20, IRF7, GBP4, DUSP5, NFKB1A, ATF3, TNFSF10, IL6, IL8, IL7R, CCL4, TNFA1P6, IFIT3, OASL, GBP1, HES4, CYP27B1, RIPK2, TNFRSF9, SOD2, CD38, CD44, CD80, CD83, CD86, INDO MT2A, TRAF1, GADD45B, MT1M, MTIP2, BIRC3, USP18, TUBB2A, CCL8, EBI3, IFITM1, MT1B, MT1E, MT1G, MT1H, GADD45A, CD200, LAMP3, RGS1, SAT1 | 99, 100 |
| Monocyte-derived DC’s | Human: CD1A, CD1B, CD1C, CD23A, MRC1, CD36, HLA-DQA, HLA-DP light chain, HLA-DG protein 41, RIL, RAP1GAP, CCND2, DUSP5, PPIC, STAC, PRKACB, TRIB2, SHB | 99–101 |
| Mature neutrophils | Human: ALPL, IL8RB, FCGR3B, SEMA3C, HM74, SOD2, FCGR3A, IL-8, STHM, IL8RA, FCGR2A, CSF3R, NCF2, AOAH | 102, 103 |
| Immature neutrophils | Human: AZU1, ELA2, BPI, LCN2, MPO, CTSG, MMP8, DEFA4, DEFA3, CAMP, X-CGD | 103–105 |
| Gene | Primer name | Primer sequence |
| C8J_0133 | C8J0133-F | TATTGCTGGGCATAGGAAAGG |
| C8J0133-R | TCTAGCAGCTTCTCTTGGAGTA | |
| C8J_0398 | C8J0398-F | GCAACATCTACCGTGATGCTAA |
| C8J0398-R | ACATATCTACAATCCACCAAATCCA | |
| C8J_0648 | C8J0648-F | GTATCAGCAGACATAAGACAAGG |
| C8J0648-R | TGCTTTCTTCTAGGTACTCTTTATC | |
| C8J_1333 | C8J1333-F | TGAGCTTGCACAAGATGATACC |
| C8J1333-R | GCACCAGAATACAAACCCTTCT | |
| C8J_1342 | C8J1342-F | GTTGATTTAGTGGCAGTTGGTG |
| C8J1342-R | CTCTTTCTACTGCTCCTTGAATACT | |
| C8J_1423 | C8J1423-F | AAATTTATGCGCGTGCTTT |
| C8J1423-R | AACTATGCCACCAAGCAAA | |
| C8J_1619 | C8J1619-F | CCAAAGTGGATAGTATTGCAAGAATTAG |
| C8J1619-R | GACGACTTAAAGAACTTGAAACTGG | |
| frdA | qfrdA-F | GTGTGCCTTGGACTAGAGTTAC |
| qfrdA-R | CTGCGATATAGCAAGTTCTCCA | |
| ccpA-2 | qccpA-2-F | GTGGTATCATTTCTTGTAATACCTGTC |
| qccpA-2-R | TGATGAGGATTTGCTGTCCAT | |
| racR | qracR-F | ACGGATACAGCGTTTCAAGAG |
| qracR-R | ACTCTTAAGCGACCGATGATAAC | |
| flhB | qflhB-F | GGAAGGAGATCCTCAGGTTAAAG |
| qflhB-R | GCATAATGCGTTGGGTTTGT | |
| kpsM | qkpsM-F | TGTGGAACCTTTAAGAACTTTGC |
| qkpsM-R | AAGCAAAGGACGAGGAGTTAG | |
| cmeB | qcmeB-F | GCCATAGGGATCGTTGTAGATG |
| qcmeB-R | CTATCCAAGCGATGCAAGAAGT | |
| 16S rRNA | 16S-qF | AGAGATGCATTAGTGCCTTCGGGA |
| 16S-qR | ACTAAGGATAAGGGTTGCGCTCGT |
| City(project) | Activities described in final report | |
| Birmingham(Walking Revolution) | Led walks to the park for key stage 2 pupils at one city primary schoolPledge cards for individualsThemed walksCommunity Street AuditsSmall grants fundWalking ChampionsSocial media workStrategic work to share learning | |
| Cambridge(Walk Local) | Promotion of Walk4Life and WfH campaigns (various media), maps and community walks. 7 walks with 108 participantsWalk to work week activities with 17 employersHealth walks in 3 medical centres. 27 participantsBeat the Street piloted in 4 primary schools. 890 participants (3 week intervention)Weekly buggy walks / wild play with young parents and children under 5 years of age. 230 attendances | |
| Leeds and Bradford(Best foot forward) | Themed walksCommunity Street AuditsSmall grants fundTendering delivery to local community organisationsSocial media workStrategic work to share learning3 million steps social reward scheme involved388 people who walked over 15 Million steps in Spring 2015. | |
| Manchester(Get Active) | Active Oldham Outdoors Project:26 Level 1 health walks with 143 participants14 new volunteer walk leadersCapital funding from Public health to improve walking infrastructure in 9 parksActive Trafford Greenspace Project:20 led walks with 278 participants23 new volunteer walk leaders3 GP Surgeries piloting ‘walk prescribing’ or other methods of promoting walking to patients.3 Workplace Walk led walks events held5 new Workplace Walks mapped and promotedBridgewater Canal Walks Project:22 recreational themed walks with 74 participantsSelf-led walking trailPartnership working with a community Leisure TrustFour week Walking FestivalEast Manchester Moving:23 led walks with 163 participants10 led cycle rides with 96 participants8 volunteer action days24 volunteers trained as volunteer walk leaders | Salford Ranger team project:1 new self-guided walking route11 additional recreational walks with 107 participants12 volunteers trained as walk leaders12 led cycle rides with 108 participantsStockport Walkaday Walks Project:13 additional walks with 217 participants4 new volunteer walk leadersTameside Active Outdoors Project:4 new health walks with 30 participants18 new volunteer walk leaders1 new patient from new exercise referral programme5 new self-guided walking routes in production – Proposed launch in 2016The Green Corridor Project:9 led health walks with 91 new participants.5 volunteers trained as walk leaders |
| Norwich(Walk to) | Group walking champions led walks including 1 km group walk for people with a learning disabilityPledge cards for individualsCommunity Street Audit (1)Small grants fundBeat the Streets project for school children: 1890 participatedSocial media workStrategic work to share learningHealth walks: 185 walks, 12 volunteers and 154 new participantsBeat the Street: 1890 participatedTravel plans: numbers not reported |
| Risk factor | OR Esteghamati et al. | OR Harati et al. (18) | Adjusted OR - Harati et al. (18) | OR - Valdez et al. (21) | Adjusted OR - Valdez (21) |
| IFG | - | 8.3 (4.2–16.5) | 7.4 (3.6–15.0) | 11.5 (5.6–23.6) | 8.4 (3.1–23) |
| IGT | - | 7.1 (5.1–9.8) | 5.9 (4.2–8.4) | 6.7 (3.4–13.3) | 4.7 (1.9–11.7) |
| IFG + IGT | - | 42.2 (25.8–75.7) | 42.2 (23.8–74.9) | 45.6 (15.8–131.4) | 45.6 (15.8–131.4) |
| General Obesity | 2.04(2.48-1.66) | 4.0 (2.7–5.8) | 2.3 (1.5–3.6) | 6.1 (2–18.8) | - |
| Central Obesity | 1.97(1.61-2.33) | 1.4 (1.3–1.5) | 1.9 (1.4–2.6) | - | - |
| Hypercholesterolemia | 1.99(1.61-2.45) | - | - | 1.6 (0.8–3) | - |
| Hypertriglyceridemia | 2.75(2.14-3.53) | 2.0 (1.5–2.6) $ | 1.4 (1.1–1.9) | 4.8 (2.2–10.4) | - |
| Low HDL | 1.19(0.97-1.46) | 1.4 (1.0–1.9) | - | 2.9 (1.5–5.6) | - |
| Hypertension | - | 1.9 (1.4–2.6) | - | 4 (2.1–7.9) | - |
| Physical Inactivity | 1.5(1.24-1.82) | - | - | 2.7 (1.4–5.1) |
| Bacteria | Oral n/N (%) | Vaginal n/N (%) | P value |
| Gardnerella vaginalis | 24/30 (80%) | 16/22 (73%) | .43 |
| Megasphaera spp. | 12/22 (55%) | 5/15 (33%) | .38 |
| Leptotrichia/Sneathia | 6/18 (33%) | 5/11 (45%) | .76 |
| Atopobium vaginae | 11/21 (52%) | 9/17 (53%) | .85 |
| BVAB1 | 0/11 (0%) | 1/5 (20%) | .29 |
| BVAB2 | 3/18 (17%) | 1/9 (11%) | .30 |
| BVAB3 | 1/6 (17%) | 1/3 (33%) | .66 |
| Reference | Nr studies included | Nr subjects included | Pooled effect size (95% CI) | |
| Metabolic dysregulation | ||||
| Metabolic syndrome | Pan et al. 20121[22] | 29 | 155,333 | OR = 1.42 (1.28 to 1.57) |
| Abdominal obesity | Xu et al. 20111[57] | 15 | 34,832 | OR = 1.38 (1.22 to 1.57) |
| Immuno-inflammatory dysregulation | ||||
| C-Reactive Protein | Howren et al. 20091[58] | 49 | 51,234 | d = 0.15 (0.10 to 0.21) |
| Interleukin-6 | 61 | 24,837 | d = 0.25 (0.18 to 0.31) | |
| Interleukin-1β | 14 | 756 | d = 0.35 (0.03 to 0.67) | |
| Interleukin-1RA | 9 | 1,214 | d = 0.25 (0.04 to 0.46) | |
| Interleukin-6 | Dowlati et al. 20102[59] | 16 | 892 | MD = 1.8 pg/mL (1.2 to 2.3) |
| TNF-α | 13 | 788 | MD = 4.0 pg/mL (2.2 to 5.7) | |
| Interleukin-1β | 9 | 533 | MD = -1.6 pg/mL (-3.6 to 0.4) | |
| Soluble Interleukin-2R | Liu et al. 20122[60] | 8 | 596 | MD = 0.56 pg/mL (0.28 to 0.84) |
| Interleukin-6 | 18 | 923 | MD = 0.68 pg/mL (0.44 to 0.92) | |
| TNF-α | 15 | 995 | MD = 0.55 pg/mL (0.13 to 0.99) | |
| Interleukin-1β | 10 | 580 | MD = -0.53 pg/mL (-1.36 to 0.31) | |
| Autonomic dysregulation | ||||
| Heart rate variability | Rottenberg, 20072[61] | 13 | 686 | d = 0.33 (0.18 to 0.49) |
| Heart rate variability | Kemp et al. 20102[62] | 14 | 726 | Hedges’ g = -0.21 (-0.40 to -0.02)4 |
| HPA-axis dysregulation | ||||
| Higher cortisol 3 | Stetler and Miller 20111[63] | 354 | 18,374 | d = 0.60 (0.54 to 0.66) |
| Higher ACTH | 96 | 3,812 | d = 0.28 (0.16 to 0.41) | |
| Higher CRH | 16 | 888 | d = -0.53 (-1.71 to 0.65) | |
| Saliva morning cortisol | Knorr et al. 20101[64] | 20 | 2,318 | MD = 2.6 nmol/l (1.0 to 4.2) |
| Saliva evening cortisol | 10 | 1,617 | MD = 0.3 nmol/l (0.03 to 0.5) |
| Gene | BMPR1A | SMAD4 | PTEN | STK11 |
| Name | Bone morphogenetic protein receptor, type Ia | Mothers against decapentaplegic, drosophila, homolog of, 4 | Phosphatase and tensin homologue | Serine/threonine protein kinase 11 |
| Function of the protein | receptor | signalling protein | phosphatase | kinase |
| MIM | *601299 | *600993 | *601728 | *602216 |
| Chromosome | 10q22.3 | 18q21 | 10q23.31 | 19q13.3 |
| Size | 168.5 kbp | 38.5 kbp | 108 kbp | 23 kbp |
| Exons | 13 | 11 | 9 | 10 |
| Amino acids | 532 | 552 | 403 | 433 |
| Transcript (bp) | 3613 | 8365 | 9007 | 3276 |
| Mass of protein | 60 kDa | 60 kDa | 47 kDa | 48.6 kDa |
| All | ≤ 40 years | > 40 years | |
| Variables | (n = 641) | (n = 150) | (n = 491) |
| Age, years (SD) | 49 (13.0) | 31 (7.2) | 55 (8.6) |
| Female, n (%) | 280 (44) | 50 (33) | 230 (47) |
| BMI (SD) | 27 (4.4) | 26 (4.2) | 28 (4.5) |
| Symptom onset, n (%) | |||
| Developed slowly over time | 208 (32) | 29 (19) | 179 (36) |
| Developed as a result of | |||
| less severe incident | 260 (41) | 51 (34) | 209 (43) |
| severe incident | 173 (27) | 70 (47) | 103 (21) |
| Duration of symptoms, n (%) | |||
| 0–3 months | 129 (20) | 41 (27) | 88 (18) |
| 4–6 months | 181 (28) | 24 (16) | 157 (32) |
| 7–12 months | 135 (21) | 31 (21) | 104 (21) |
| 13–24 months | 94 (15) | 20 (13) | 74 (15) |
| Longer than 24 months | 102 (16) | 34 (23) | 68 (14) |
| KOOS subscale scores, mean (SD) | |||
| Pain | 54.9 (18) | 58.9 (20) | 53.6 (18) |
| Symptoms | 60.0 (19) | 60.6 (19) | 59.8 (18) |
| ADL | 63.7 (19) | 69.8 (20) | 61.8 (19) |
| Sport/Rec | 26.3 (22) | 31.1 (23) | 24.9 (21) |
| QOL | 41.6 (15) | 40.2 (16) | 42.0 (15) |
| Type of surgery, no. (%) | |||
| Resection | 600 (94) | 118 (79) | 482 (98.) |
| Repair | 33 (5.1) | 24 (16) | 9 (1.8) |
| Both | 8 (1.2) | 8 (5.3) | 0 (0.0) |
| Variable | Cases (n=110) | Controls (n=110) |
| Average age at blood collection, years (SD) | 44.2 (7.3) | 44.2 (7.2) |
| Average age at cancer diagnosis, years (SD) | 55.9 (8.6) | n/a |
| Average time from blood collection to diagnosis, years (SD) | 12.6 (5.1) | n/a |
| Date of blood collection, median, calendar years (range) | 1990 (1986-1991) | 1990 (1986-1991) |
| Date of birth, median, calendar years (range) | 1948 (1923-1955) | 1948 (1923-1955) |
| Male sex, number (%) | 82 (74.5%) | 82 (74.5%) |
| Average sample storage time in freezer, years (SD) | 24.7 (1.5) | 24.7 (1.5) |
| Blood collection to glioblastoma diagnosis, number/time period | ||
| 0–5 years | 8 | n/a |
| 5–10 years | 26 | n/a |
| 10–15 years | 35 | n/a |
| 15–20 years | 37 | n/a |
| >20 years | 4 | n/a |
| Subject area | Frequency | % N = 8619 a |
| Medicine | 5406 | 62.7 |
| Immunology and Microbiology | 3075 | 35.7 |
| Biochemistry, Genetics and Molecular Biology | 1681 | 19.5 |
| Pharmacology, Toxicology and Pharmaceutics | 533 | 6.2 |
| Agricultural and Biological Sciences | 407 | 4.7 |
| Veterinary | 283 | 3.3 |
| Multidisciplinary | 234 | 2.7 |
| Social Sciences | 179 | 2.1 |
| Chemistry | 170 | 2.0 |
| Environmental Science | 133 | 1.5 |
| Nursing | 123 | 1.4 |
| Participants | Non-participants or not included in analysis | ||||||
| Baseline characteristics | Missing values | Followed-up n = 2166 (49.4%) | Not followed-up Alive/Unknown/DM status missing n = 1814 (41.3%) | p-value* | Deceased n = 408 (9.3%) | p-value** | |
| Age in years, mean (SD) | 0 | 62.7 (9.4) | 62.6 (10.4) | 0.84 | 71.6 (12.8) | <0.001 | |
| Systolic BP in mmHg, mean (SD) | 12 | 139.5 (23.5) | 140.8 (24.8) | 0.16 | 147.4 (30.3) | <0.001 | |
| Diastolic BP in mmHg , mean (SD) | 12 | 82.6 (13.0) | 83.3 (13.6) | 0.19 | 82.7 (16.5) | 0.94 | |
| Random Blood Glucose, mean (SD) | 92 | 5.1 (2.3) | 5.3 (2.3) | 0.12 | 5.7 (3.7) | <0.001 | |
| Sex, % (n) | Female | 0 | 1025 (47.3%) | 841 (46.4%) | 0.59 | 236 (57.8%) | <0.001 |
| Male | 1141 (52.7%) | 973 (53.6%) | 172 (42.2%) | ||||
| BMI, % (n) | Underweight (<18.5 kg/m2) | 42 | 267 (12.4%) | 250 (14.0%) | 0.52 | 99 (25.0%) | <0.001 |
| Normal (18.5–24.99 kg/m2) | 1091 (50.5%) | 882 (49.2%) | 199 (50.3%) | ||||
| Overweight (25–29.99 kg/m2) | 506 (23.4%) | 419 (23.4%) | 66 (16.7%) | ||||
| Obese (30 + kg/m2) | 295 (13.7%) | 240 (13.4%) | 32 (8.1%) | ||||
| Vision status impaired (<6/12 better eye), % (n) | Normal | 17 | 1985 (91.7%) | 1635 (90.8%) | 0.36 | 306 (75.4%) | <0.001 |
| Impaired | 180 (8.3%) | 165 (9.2%) | 100 (24.6%) | ||||
| Tribe, % (n) | Kikuyu | 0 | 1393 (64.3%) | 1079 (59.5%) | <0.001 | 283 (69.4%) | 0.09 |
| Kalenjin | 540 (24.9%) | 380 (20.9%) | 92 (22.5%) | ||||
| Other | 233 (10.8%) | 355 (19.6%) | 33 (8.1%) | ||||
| Education, % (n) | None | 1 | 193 (8.9%) | 204 (11.3%) | 0.03 | 26 (6.4%) | <0.001 |
| Primary | 687 (31.7%) | 588 (32.4%) | 179 (43.9%) | ||||
| Secondary | 1069 (49.4%) | 806 (44.5%) | 174 (42.6%) | ||||
| Higher | 217 (10.0%) | 215 (11.9%) | 29 (7.1%) | ||||
| Residence, % (n) | Rural | 0 | 1636 (75.5%) | 1014 (55.9%) | <0.001 | 302 (74.0%) | 0.59 |
| Urban | 530 (24.5%) | 800 (44.1%) | 106 (26.0%) | ||||
| SES Quartile, % (n) | Lower | 22 | 514 (23.8%) | 442 (24.5%) | 0.01 | 136 (33.3%) | 0.003 |
| Middle lower | 591 (27.4%) | 404 (22.4%) | 96 (23.5%) | ||||
| Middle upper | 557 (25.8%) | 438 (24.3%) | 97 (23.8%) | ||||
| Upper | 495 (22.9%) | 517 (28.7%) | 79 (19.4%) | ||||
| Smokers, % (n) | Never | 0 | 1503 (69.4%) | 1322 (72.9%) | 0.007 | 255 (62.5%) | 0.02 |
| Former | 163 (7.5%) | 145 (8.0%) | 33 (8.1%) | ||||
| Current | 500 (23.1%) | 347 (19.1%) | 120 (29.4%) | ||||
| Alcohol, % (n) | Never | 5 | 882 (40.8%) | 704 (38.9%) | 0.10 | 117 (28.7%) | <0.001 |
| Former | 942 (43.6%) | 772 (42.6%) | 221 (54.2%) | ||||
| Current | 339 (15.7%) | 336 (18.5%) | 70 (17.2%) |
| Variability of U6 and miR-99b as reference assays | ||||
| hsa-miR-99b | U6 | |||
| P-value | C of V | P-value | C of V | |
| Nucleus accumbens | 0.69 | 0.40 | 0.024* | 0.71 |
| EDL | 0.64 | 0.22 | 0.13 | 0.86 |
| Soleus | 0.23 | 0.23 | 0.09 | 0.21 |
| 3 months | |||||
| ΔDAS28 | ΔDAS28-CRP | ΔSDAI | ΔCDAI | ||
| ΔSUV (12 joints) | r | 0.615* | 0.696* | 0.652* | 0.662* |
| p | 0.009 | 0.002 | 0.005 | 0.004 | |
| ΔSUV (8 joints) | r | 0.61* | 0.723* | 0.637* | 0.64* |
| p | 0.009 | 0.001 | 0.006 | 0.006 | |
| 6 months | |||||
| ΔDAS28 | ΔDAS28-CRP | ΔSDAI | ΔCDAI | ||
| ΔSUV (12 joints) | r | 0.775* | 0.828* | 0.686* | 0.711* |
| p | <0.001 | <0.001 | 0.002 | 0.001 | |
| ΔSUV (8 joints) | r | 0.749* | 0.775* | 0.623* | 0.686* |
| p | 0.001 | <0.001 | 0.008 | 0.002 |
| Variables | Low CHO | Low fat | P* |
| Males/females | 25/24 | 25/26 | |
| Energy (Cal) | 1114 ± 22.5 | 1138 ± 26.0 | N.S. |
| Carbohydrate (%) | 45 ± 0.6 | 57 ± 0.9 | <0.001 |
| Total fat (%) | 35 ± 0.8 | 28 ± 0.9 | <0.001 |
| Saturated fat (%) | 10 ± 0.5 | 9 ± 0.4 | <0.02 |
| Protein (%) | 20 ± 0.5 | 15 ± 0.6 | N.S |
| Cholesterol (g) | 163 ± 13.1 | 103 ± 9.1 | <0.001 |
| Fiber (g) | 14 ± 0.6 | 16 ± 0.8 | <0.02 |
| Test | Observed | Predicted | Difference |
| 1 | 4,084.05 | 3,996.40 | 87.64 |
| 2 | 4,108.22 | 4,040.57 | 67.65 |
| 3 | 4,140.16 | 4,101.24 | 38.92 |
| 4 | 4,023.51 | 4,019.85 | 3.66 |
| 5 | 4,113.16 | 4,047.87 | 65.29 |
| 6 | 3,950.07 | 4,050.91 | −100.84 |
| 7 | 4,058.73 | 4,085.59 | −26.85 |
| 8 | 4,054.97 | 4,062.27 | −7.30 |
| 9 | 4,046.38 | 4,007.67 | 38.71 |
| 10 | 3,997.07 | 3,989.82 | 7.25 |
| 11 | 4,044.88 | 3,969.98 | 74.89 |
| 12 | 4,062.20 | 4,042.23 | 19.97 |
| 13 | 4,062.67 | 3,994.71 | 67.95 |
| 14 | 4,009.57 | 3,974.33 | 35.23 |
| 15 | 3,957.41 | 3,962.92 | −5.51 |
| 16 | 4,036.46 | 4,036.31 | 0.15 |
| 17 | 3,983.54 | 3,970.58 | 12.96 |
| 18 | 4,011.42 | 3,993.93 | 17.49 |
| 19 | 3,932.03 | 3,951.91 | −19.88 |
| 20 | 3,980.49 | 4,035.48 | −54.99 |
| 21 | 4,065.07 | 4,054.47 | 61.22 |
| 22 | 4,024.33 | 4043.60 | −19.28 |
| 23 | 4,025.92 | 4,020.54 | 5.38 |
| 24 | 4,020.02 | 4,024.04 | −4.02 |
| 25 | 4,016.88 | 4,005.85 | 11.03 |
| 26 | 4,051.08 | 3,996.01 | 55.06 |
| 27 | 4,058.55 | 3,987.99 | 70.57 |
| 28 | 4,051.18 | 4,018.28 | 32.90 |
| 29 | 4,088.96 | 4,036.06 | 52.90 |
| 30 | 4,087.01 | 4,028.30 | 58.71 |
| 31 | 4,121.96 | 4,017.35 | 104.61 |
| 32 | 4,084.62 | 4,055.96 | 28.66 |
| 33 | 4,002.90 | 4,050.52 | −47.62 |
| 34 | 3,979.24 | 4,014.76 | −35.52 |
| 35 | 4,003.71 | 4,022.21 | −18.50 |
| 36 | 4,066.90 | 4,022.56 | 44.34 |
| 37 | 3,934.52 | 4,003.62 | −69.10 |
| 38 | 4,041.55 | 4,038.95 | 2.59 |
| 39 | 4,029.50 | 4,062.03 | −32.54 |
| 40 | 3,991.01 | 4,031.85 | −40.84 |
| SD* | 49.74 | 32.93 | |
| RSD※* | 46.75 | ||
| P-value | 0.16 |
| Name | Species | Activity against | Cytotoxic activity | Anticancer activity | Reference |
| Sesquin | Vigna sesquipedalis | MCF-7 and M1 | Not tested | Yes | [44] |
| Limenin | Phaseolus limensis | L1210 and M1 | Not tested | Yes | [41] |
| Lunatusin | Phaseolus lunatus | MCF-7rabbit reticulocyte | Yes | Yes | [45] |
| Purple pole defensin | Phaseolus vulgaris cv. “Extra-long Purple Pole bean” | HepG2, MCF7, HT-29, and SiHa | No | Yes | [46] |
| Coccinin | Phaseolus coccineus cv. “Major” | HL60 and L1210 | No | Yes | [47] |
| Phaseococcin | Phaseolus coccineus | L1210 and HL60 | No | Yes | [48] |
| γ-Thionin | Capsicum chinense | HeLa | No | Yes | [49] |
| NaD1 | Nicotiana alata | U937 | Not tested | Yes | [67] |
| Mitogenic defensin | Phaseolus vulgaris | MCF-7, murine splenocytes | Yes | Yes | [68] |
| Vulgarinin | Phaseolus vulgaris | MCF-7, L1210, and M1 | Not tested | Yes | [69] |
| Cloud bean defensin | Phaseolus vulgaris cv. cloud bean | L1210 and MBL2 | Not tested | Yes | [70] |
| Nepalese | Phaseolus angularis | L1210, MBL2 | Not tested | Yes | [71] |
| Gymnin | Gymnocladus chinensis Baill | M1, HepG2, and L1210 | Not tested | Yes | [72] |
| Odds ratio | 95% CI | p-value | |
| Aortic valve replacement | 4.36 | 2.68–7.07 | < 0.001 |
| Chronic heart failure | 1.81 | 1.10–2.99 | < 0.001 |
| EuroSCORE (per point) | 1.10 | 1.03–1.17 | < 0.001 |
| Age (per year) | 1.05 | 1.03–1.07 | < 0.001 |
| Pulse feature | Frequency | Proportion of the total (%) |
| Rate | ||
| Normal | 33 | 76.7 |
| Slow | 1 | 2.3 |
| Fast | 6 | 14.0 |
| Uneven | 2 | 4.6 |
| Left pulse | ||
| Slippery | 15 | 34.9 |
| Thin | 15 | 34.9 |
| Soft/weak | 23 | 53.5 |
| Wiry | 22 | 51.2 |
| Right pulse | ||
| Slippery | 18 | 41.9 |
| Thin | 19 | 44.2 |
| Soft/Weak | 25 | 58.1 |
| Wiry | 15 | 34.9 |
| Groups | Mean ± SD | Median | Minimum | Maximum |
| C | 71.34 ± 26.74 | 88.12 | 36.91 | 99.07 |
| P-Ch 0 | 116.73 ± 62.94 | 97.37 | 59.17 | 302.61 |
| P-Ch A | 126.67 ± 32.79 | 122.19 | 79.46 | 177.40 |
| P-Ch B | 180.51 ± 68.74 | 171.58 | 47.69 | 343.53 |
| P-Ch C | 231.26 ± 80.51 | 228.85 | 108.28 | 398.34 |
| Station Name | CLS | MIP | ALN | CIS | CIRS | CUC | STA |
| Ejin Banner | 0.86–0.93 | 0.18–0.25 | 0.22–0.28 | 0.44–0.56 | 0.18–0.26 | 0.10–0.15 | 0.30–0.39 |
| Mazongshan | 0.80–0.90 | 0.16–0.29 | 0.20–0.27 | 0.47–0.54 | 0.19–0.26 | 0.12–0.14 | 0.32–0.36 |
| Yumenzhen | 0.83–0.96 | 0.18–0.27 | 0.24–0.29 | 0.48–0.55 | 0.17–0.27 | 0.09–0.14 | 0.30–0.41 |
| Dingxin | 0.79–0.98 | 0.18–0.26 | 0.21–0.28 | 0.50–0.54 | 0.22–0.27 | 0.08–0.15 | 0.32–0.38 |
| Jinta | 0.81–0.94 | 0.20–0.24 | 0.25–0.26 | 0.46–0.57 | 0.18–0.27 | 0.10–0.15 | 0.33–0.37 |
| Jiuquan | 0.80–0.94 | 0.17–0.28 | 0.22–0.27 | 0.46–0.55 | 0.23–0.25 | 0.09–0.16 | 0.31–0.36 |
| Gaotai | 0.85–0.95 | 0.18–0.27 | 0.20–0.29 | 0.49–0.53 | 0.22–0.28 | 0.10–0.14 | 0.30–0.37 |
| Alxa Right Banner | 0.82–0.93 | 0.18–0.27 | 0.23–0.26 | 0.48–0.58 | 0.18–0.27 | 0.11–0.15 | 0.32–0.36 |
| Tuole | 0.80–0.96 | 0.20–0.25 | 0.21–0.26 | 0.45–0.55 | 0.23–0.26 | 0.10–0.15 | 0.34–0.37 |
| Yeniugou | 0.80–0.93 | 0.18–0.27 | 0.23–0.28 | 0.47–0.56 | 0.19–0.25 | 0.12–0.14 | 0.30–0.38 |
| Zhangye | 0.87–0.92 | 0.15–0.22 | 0.22–0.32 | 0.48–0.58 | 0.21–0.25 | 0.09–0.15 | 0.33–0.36 |
| Qilian | 0.78–0.92 | 0.20–0.25 | 0.19–0.29 | 0.49–0.52 | 0.18–0.27 | 0.11–0.14 | 0.31–0.38 |
| Shandan | 0.83–0.96 | 0.18–0.28 | 0.22–0.28 | 0.47–0.53 | 0.22–0.25 | 0.10–0.16 | 0.32–0.37 |
| Yongchang | 0.81–0.95 | 0.18–0.27 | 0.20–0.30 | 0.48–0.53 | 0.20–0.25 | 0.12–0.15 | 0.34–0.36 |
| Range | 0.78–0.98 | 0.15–0.29 | 0.19–0.32 | 0.45–0.58 | 0.17–0.28 | 0.08–0.16 | 0.30–0.41 |
| Sequence | QP | Level 0 | Level 1 | Level 2 | Level 3 |
| FourPeople | 22 | 49.48 | 24.79 | 22.13 | 3.60 |
| 27 | 66.59 | 16.50 | 15.19 | 1.71 | |
| 32 | 74.69 | 11.88 | 12.46 | 0.98 | |
| 37 | 79.57 | 8.78 | 11.15 | 0.50 | |
| Johnny | 22 | 51.30 | 26.48 | 19.91 | 2.31 |
| 27 | 68.30 | 17.63 | 13.26 | 0.81 | |
| 32 | 76.74 | 11.87 | 10.95 | 0.44 | |
| 37 | 82.57 | 7.58 | 9.59 | 0.25 | |
| Vidyo1 | 22 | 48.94 | 26.55 | 21.07 | 3.44 |
| 27 | 65.94 | 18.27 | 14.51 | 1.27 | |
| 32 | 74.66 | 13.12 | 11.66 | 0.55 | |
| 37 | 80.34 | 9.35 | 10.07 | 0.24 | |
| Average | 68.26 | 16.07 | 14.33 | 1.34 |
| Cases (number, %) | NLR (number) | P value | PLR (number) | P value | |||
| <3.5 | ≥3.5 | <150 | ≥150 | ||||
| Gender | 0.143 | 0.473 | |||||
| Female | 72 (14.9) | 51 | 21 | 42 | 30 | ||
| Male | 411 (85.1) | 254 | 157 | 221 | 190 | ||
| Age (years) | 0.305 | 0.804 | |||||
| ≤60 | 273 (56.5) | 167 | 106 | 150 | 123 | ||
| >60 | 210 (43.5) | 138 | 72 | 113 | 97 | ||
| Tumor length | <0.001 | <0.001 | |||||
| ≤3 | 138 (28.6) | 117 | 21 | 95 | 43 | ||
| >3 | 345 (71.4) | 188 | 157 | 168 | 177 | ||
| Tumor location | 0.101 | 0.561 | |||||
| Upper | 27 (5.6) | 12 | 15 | 15 | 12 | ||
| Middle | 247 (51.1) | 156 | 91 | 140 | 107 | ||
| Lower | 209 (43.3) | 137 | 72 | 108 | 101 | ||
| Vessel involvement | 0.121 | 0.729 | |||||
| Negative | 407 (84.3) | 263 | 144 | 223 | 184 | ||
| Positive | 76 (15.7) | 42 | 34 | 40 | 36 | ||
| Perineural invasion | 0.862 | 0.882 | |||||
| Negative | 390 (80.7) | 247 | 143 | 213 | 177 | ||
| Positive | 93 (19.3) | 58 | 35 | 50 | 43 | ||
| Differentiation | 0.021 | 0.038 | |||||
| Well | 71 (14.7) | 42 | 29 | 38 | 33 | ||
| Moderate | 323 (66.9) | 217 | 106 | 187 | 136 | ||
| Poor | 89 (18.4) | 46 | 43 | 38 | 51 | ||
| Depth of invasion | <0.001 | 0.003 | |||||
| T1 | 87 (18.0) | 81 | 6 | 63 | 24 | ||
| T2 | 80 (16.6) | 54 | 26 | 41 | 39 | ||
| T3 | 265 (54.9) | 154 | 111 | 134 | 131 | ||
| T4 | 51 (10.5) | 16 | 35 | 25 | 26 | ||
| Nodal metastasis | <0.001 | <0.001 | |||||
| Negative | 274 (56.7) | 199 | 75 | 169 | 105 | ||
| Positive | 209 (43.3) | 106 | 103 | 94 | 115 |
| Case 1 | Case 2 | Case 3 | Case 4 | Case 5 | Case 6 | Case 7 | Our patient | |
| T4 μg/dL | 1 | 0.9 | 0.23 | 0.43 | 1.8 | 1 | < 1 | 1.8 |
| TSH μU/mL | ? | 0.34 | 1.9 | 1.4 | 0.39 | 2.9 | 1.49 | 3.9 |
| FSH IU/L | 0.3 | 1.6 | 1 | 0.58 | 2.9 | 1.07 | 7.43 | 3.6 |
| LH IU/L | 0.8 | 1.1 | 1.6 | 0.18 | 0.74 | 1.07 | 0.75 | 0.6 |
| PRL μg/L | - | - | - | - | 2.8 | 1 | 1.9 | 2.8 |
| Cortisol μg/dL | 4 | - | 0.7 | < 1 | 5.8 | < 1 | 6.6 | 20 |
| GH μg/L | 0.3 | 0.08 | - | < 0.05 | < 0.25 | < 0.25 | 0.24 | - |
| ACTH ng/mL | - | < 1 | 12 | < 10 | - | - | - | - |
| Clinical / laboratory characteristic | Number of patients (of n = 99) |
| Altered level of consciousness | 99 |
| Fever | 93 |
| Headache | 54 |
| Seizures | 58 |
| Prodromal symptoms | 77 |
| Focal neurological signs | 44 |
| Cerebellar signs | 12 |
| Extrapyramidal signs | 6 |
| Neuropsychiatric symptoms | 21 |
| Cerebrospinal fluid | |
| Protein >40 mg/dl | 22 |
| CSF:plasma glucose ratio < 30% | 39 |
| Pleocytosis | 26 |
| Gram stain positivity | 0 |
| Bacterial culture positivity | 0 |
| S100β ≥0.13 μg/Ln = 10 (8.47%) | S100β <0.13 μg/Ln = 108 (91.53%) | p value | |
| Age | |||
| ≥55 | 3 (30%) | 64 (59.26%) | 0.099 |
| < 55 | 7 (70%) | 44 (40.74%) | |
| PR | |||
| + ve | 8 (80%) | 87 (80.56%) | 1.00 |
| –ve | 2 (20%) | 21 (19.44%) | |
| HER2 | |||
| + ve | 3 (30%) | 52 (51.49%) | 0.097 |
| –ve | 7 (70%) | 49 (48.51%) | |
| Node | |||
| + ve | 2 (22.22%) | 43 (47.25%) | 0.162 |
| –ve | 7 (77.78%) | 48 (52.75%) | |
| Grade | |||
| ≥3 | 4 (40%) | 26 (24.07%) | 0.273 |
| <3 | 6 (60%) | 82 (75.93%) | |
| Size | |||
| ≥20 mm | 7 (100%) | 81 (96.43%) | 1.00 |
| < 20 mm | – | 3 (3.57%) | |
| Recurrence | |||
| + ve | 5 (50%) | 17 (15.74%) | 0.019(r = +0.245) |
| –ve | 5 (50%) | 91 (84.26%) |
| Implementation unit | No. of pools | Average pool size | No. of An. gambiae processed | No. of An. gambiae collected | % of An. gambiae processed | Positive | 95% CI |
| Cinkasse | 166 | 15.9 | 2646 | 2782 | 95.1 | 0 | 0–0.073 |
| Kpendjal | 172 | 14.5 | 2495 | 2807 | 88.9 | 0 | 0–0.077 |
| Tone | 291 | 13.9 | 4050 | 5283 | 76.7 | 0 | 0–0.047 |
| Total | 629 | 14.6 | 9191 | 10,872 | 84.5 | 0 | 0–0.021 |
| Subjects (n = 35) | |
| Age (yrs) | 22.6 ± 3.5 |
| Height (cm) | 177.1 ± 7.1 |
| Weight (kg) | 77.0 ± 11.0 |
| Time period | Findings | |
| 1 | Any time-point | Brain death. |
| 2 | <24 h from ROSC | Early myoclonus status# and bilateral absence of N20 peak on SSEP after rewarming. |
| 3 | 72 h after rewarming | GCS-M 1–2 and bilateral absence of N20 peak on SSEP performed 48–72 hours after rewarming, or later. |
| 4 | 72 h after rewarming | A treatment refractory status epilepticus* and GCS-M 1–2. |
| Response rate | p value | Local control rate | p value | Disease-free survival | p value | Overall survival | p value | |
| Algorithm | 0.008 | 0.879 | 0.408 | 0.311 | ||||
| RAT group | 77.3% | 94.1% | 43.8% | 38.9% | ||||
| MC group | 100.0% | 90.9% | 21.5% | 67.1% | ||||
| Tumor origin | 0.309 | 0.367 | <0.001 | 0.088 | ||||
| Lung cancer | 93.8% | 88.5% | 38.2% | 62.2% | ||||
| Metastasis | 80.0% | 100.0% | 10.0% | 50.0% | ||||
| RT dose | 0.571 | 0.132 | ||||||
| 48–50 Gy | 100.0% | 83.3% | n/a | n/a | ||||
| 60 Gy | 87.2% | 94.1% | n/a | n/a | ||||
| Tumor size | 0.143 | 0.629 | ||||||
| ≤3 cm | 83.3% | 95.7% | n/a | n/a | ||||
| >3 cm | 100.0% | 83.3% | n/a | n/a |
| Percentage of biobanks which get specimens from... | n | % |
| Direct from individuals donating them | 343 | 75 |
| Residual specimens acquired from clinical care in hospitals, clinical laboratories, or pathology departments | 261 | 57 |
| Research | 60 | 13 |
| Residual specimens from public health departments or programs | 19 | 4 |
| Vendors | 8 | 2 |
| Organ/body donation organization | 7 | 2 |
| Other repositories | 7 | 2 |
| Other | 6 | 1 |
| Orphaned collections | 4 | 1 |
| Strategy | Intervention | Comments |
| Formulary restriction | Only certain agents available for use | Effective, minimal effort to maintain, usurps prescriber autonomy, ‘squeezing the balloon’ |
| Pre-authorization | Certain agents available if specific criteria are met | Effective, allows education, requires designated call person, creates tension between prescriber and stewardship program, clinician may circumvent the system |
| Audit and feedback | Review of ordered antimicrobials or culture results | Customizable, educational, maintains prescriber autonomy, recommendations specific to clinical situation, optional, time intensive, requires reviewer with broad knowledge |
| Guidelines/clinical pathways | Development of institution specific recommendations for management of specific disease states | Ability to standardize practice and meet quality measures; customized to institutional needs, resources and formulary, compliance usually not mandatory; perception of ‘cookbook medicine’ |
| Education | Education to clinicians regarding appropriate antimicrobial use | Alters behavioral patterns, improves compliance with guidelines, decreased misuse, poor efficacy of passive education, diminishing effect over time, rotation of personal means repeated education needed |
| Biomarkers | Use of laboratory information (procalcitonin, etc.) to assist in therapy decisions | Objective marker, well validated in certain situations, must be used with overall patient evaluation, false positive and negative results can occur, clinicians must be able to interpret to use correctly |
| Antibiotic cycling | Scheduled removal and substitution of antimicrobial or class | May decrease resistance rates, compliance difficult due to patient allergies, national guidelines, and adverse events |
| Combination therapy | Use of two or more agents to prevent resistance and improve clinical outcomes | Evidence for improvement in clinical outcomes is variable, minimal data to support decrease in resistance, increased risk of allergy and toxicity, increased cost |
| Streamlining/de-escalation | Narrowing of broad spectrum therapy when no pathogen isolated or targeting of pathogen isolated | Decreases antimicrobial use and costs, allows narrowest effective therapy if culture data available, possible under-treatment if no culture data acquired, treatment of colonizers |
| Dose optimization | Use of pharmacokinetic-pharmacodynamic (PK-PD) parameters to optimize dosing | Improves likelihood of achieving PK-PD targets, may allow use of agents against resistant pathogens, may decrease selection of resistant strains, some data improves clinical outcomes, requires expertise and time, may be limited by microbiologic data available (MIC), limited data on clinical outcomes |
| Computerized decision support | Use of information technology to assist clinicians in antimicrobial decision making | Can be integrated into EHR, integrates local data for customized recommendations, requires significant technology and personnel input to set up, alert fatigue, requires constant updating |
| IV to oral conversion | Agents with excellent oral bioavailability are switched from IV to oral | Decreases cost and need for IV access, may decrease length of stay, only certain agents have excellent oral bioavailability |
| Total (overall) | Mediastinal radiotherapy | p value† | ||
| Yes (n = 52) | No (n = 82) | |||
| Fractional shortening, % | 33.3 (30.4, 36.1) | 33.3 (30.6, 36.0) | 33.1 (29.9, 36.1) | 0.948 |
| Fractional shortening < 27% | 7 (5.2) | 5 (9.6) | 2 (2.4) | NA |
| Ejection fraction, % | 61.1 (58.0, 63.6) | 60.7 (57.6, 63.4) | 61.2 (58.1, 64.0) | 0.457 |
| Ejection fraction < 55% | 8 (6.0) | 5 (9.6) | 3 (3.7) | NA |
| GLS, % | 18.0 (17.0, 20.0) | 18.0 (16.0, 19.5) | 19.0 (17.0, 20.0) | 0.040 |
| GLS ≤ 16% | 31 (23.1) | 19 (36.5) | 12 (14.6) | 0.036 |
| GLS (APLAX), % | 18.0 (16.0, 20.0) | 17.0 (15.0, 19.0) | 19.0 (17.0, 21.0) | 0.023 |
| GLS (A4C), % | 18.0 (16.0, 20.0) | 17.0 (15.0, 19.0) | 18.0 (17.0, 20.0) | 0.010 |
| GLS (A2C), % | 19.0 (17.0, 21.0) | 19.0 (16.5, 20.0) | 19.0 (17.0, 21.0) | 0.279 |
| GLS rate, 1/s | 1.1 (1.0, 1.2) | 1.1 (1.0, 1.2) | 1.1 (1.0, 1.2) | 0.995 |
| GRS, %∗∗ | 42.1 (31.1, 53.7) | 42.1 (26.5, 55.2) | 42.0 (31.9, 51.4) | 0.843 |
| GRS rate, 1/s∗∗ | 2.2 (1.9, 2.7) | 2.3 (1.9, 2.9) | 2.2 (1.9, 2.7) | 0.086 |
| GCS, %∗∗ | 17.3 (15.2, 19.7) | 16.1 (14.5, 19.7) | 17.6 (16.0, 19.7) | 0.086 |
| GCS rate, 1/s∗∗ | 1.5 (1.3, 1.8) | 1.5 (1.3, 1.9) | 1.4 (1.3, 1.8) | 0.058 |
| LV mass/BSA, g/m2 | 64.3 (55.9, 72.1) | 63.1 (56.9, 69.2) | 65.4 (55.6, 74.3) | 0.099 |
| Mitral E/A ratio | 1.5 (1.2, 1.8) | 1.3 (1.0, 1.6) | 1.6 (1.3, 1.9) | 0.005 |
| Septal e′, cm/s | 10.4 (8.8, 12.3) | 9.3 (8.3, 11.2) | 11.6 (9.8, 12.6) | 0.003 |
| Days post CD instillation | Reactors | |
| PC (GC mL−1) | TDC (GC mL−1) | |
| 0.25 | 7.4 | 7.3 |
| 1 | 5.7 | 6.2 |
| 2 | 4.4 | 5.1 |
| 3 | ND | ND |
| 4 | ND | ND |
| 5 | ND | ND |
| 6 | ND | ND |
| 7 | ND | ND |
| 8 | ND | ND |
| 9 | ND | 6.0 |
| 10 | ND | 6.0 |
| 11 | ND | 6.4 |
| 12 | ND | 6.9 |
| 13 | ND | 7.1 |
| 14 | ND | 7.5 |
| 15 | ND | 7.8 |
| 16 | ND | 7.8 |
| Variable | Pre-study | Post-study | Treatment interaction p-value |
| Saliva IgA concentration (μg . mL-1) | 0.461 | ||
| Low | 333 ± 181 | 314 ± 152 | |
| Medium | 292 ± 143 | 302 ± 151 | |
| High | 315 ± 159 | 289 ± 158 | |
| Saliva protein IgA concentration (μg . mg-1) | 0.675 | ||
| Low | 471 ± 162 | 484 ± 156 | |
| Medium | 444 ± 170 | 419 ± 155 | |
| High | 535 ± 224 | 499 ± 187 | |
| Saliva IgA secretion rate (μg . min-1) | 0.476 | ||
| Low | 173 ± 135 | 220 ± 163 | |
| Medium | 185 ± 118 | 233 ± 129 | |
| High | 207 ± 118 | 212 ± 74 |
| Variable | Univariate analysis | Multivariate analysis | |||||
| OR | 95% CI | p-value | Adjusted OR | 95% CI | p-value | ||
| Age, per 10 years older | 2.93 | 1.24-6.91 | 0.014 | 3.07 | 1.22-7.74 | 0.017 | |
| Female | 0.96 | 0.20-4.52 | 0.073 | 2.22 | 0.33-14.7 | 0.409 | |
| Body mass index, per 5 kg/m2 increase | 1.71 | 0.62-4.69 | 0.300 | ||||
| Non-white ethnicity | 0.22 | 0.04-1.55 | 0.092 | - | - | - | |
| Risk | Men who have sex with men | 1* | - | - | - | - | - |
| Heterosexual | 0.25 | 0.15-1.14 | 0.134 | - | - | - | |
| Intravenous drug use | 0.67 | 0.13-3.45 | 0.629 | - | - | - | |
| Prior AIDS-defining condition | 3.35 | 0.87-13.0 | 0.080 | 3.02 | 0.56-16.2 | 0.198 | |
| Antiretroviral treatment | 1.24 | 0.31-4.96 | 0.764 | 0.71 | 0.13-4.01 | 0.699 | |
| CD4 cell count, per 50 cells/μL increase | 0.86 | 0.70-1.04 | 0.123 | - | - | - | |
| CD4 cell count ≥200 versus < 200 cells/μL | 0.41 | 0.11-1.46 | 0.168 | 0.46 | 0.10-2.05 | 0.306 | |
| CD8 cell count, per 50 cells/μL increase | 1.01 | 0.96-1.05 | 0.740 | - | - | - | |
| Extrapulmonary versus pulmonary TB | 1.22 | 0.34-4.32 | 0.759 | - | - | - |
| Gene set = G | Centroid set = C | ||||||
| Data set | S | D | j | Description | cj0 | cj1 | vjP |
| Colon cancer | Swirl | 1 | 1772 | myosin heavy chain | 44 | 125 | 61 |
| 249 | desmin | 1958 | 467 | 793 | |||
| 1582 | p cadherin | 53 | 174 | 83 | |||
| 1423 | myosin reg light chain 2 | 763 | 196 | 213 | |||
| 745 | ORF, xq terminal portion | 188 | 226 | 179 | |||
| Leukemia 1 | Swirl | 1 | 3532 | glutathione S-transferase | 37 | 1460 | 569 |
| Medulloblastoma | Swirl | 1 | 977 | zinc finger protein HZfq | 38 | -102 | 87 |
| Prostate cancer | Swirl | 1 | 8850 | cDNA DKFZp564A072 | 24 | 215 | 110 |
| Leukemia 2 | Swirl | 1 | 8828 | HLA class II alpha | 785 | 41345 | 7280 |
| Genotypes | pvalue | ||
| (n=1394,100%) | AA(n=1223) | AG+GG(n=171) | |
| Age(years) | 59.9 ± 10.1 | 59.5 ± 10.8 | 0.62 |
| Gender,female(%) | 40.6 | 37.4 | 0.42 |
| Race/color(%) | |||
| White | 65.0 | 74.9 | |
| Intermediate | 29.8 | 23.4 | 0.02 |
| Black | 5.2 | 1.8 | |
| Hypertension(%) | 70.0 | 68.4 | 0.68 |
| Diabetes(%) | 31.2 | 27.5 | 0.33 |
| Hyperlipidemia(%) | 57.2 | 71.3 | 0.002 |
| Statin use(%) | 28.0 | 30.5 | 0.61 |
| Smokers(%) | 35.6 | 38.0 | 0.44 |
| Body mass index(Kg/m2) | 27.7 ± 4.8 | 27.6 ± 4.9 | 0.99 |
| Total cholesterol(mg/dL) | 228 ± 49 | 237 ± 46 | 0.05 |
| LDL-C(mg/dL) | 147 ± 44 | 155 ± 39 | 0.11 |
| HDL-C(mg/dL) | 42 ± 12 | 42 ± 10 | 0.82 |
| Triglycerides(mg/dL) | 183 ± 130 | 179 ± 108 | 0.75 |
| Systolic blood pressure(mmHg) | 149 ± 34 | 152 ± 39 | 0.61 |
| Diastolic blood pressure(mmHg) | 82 ± 15 | 84 ± 15 | 0.29 |
| Ejection fraction(%) | 60.6 ± 14.4 | 56.8 ± 17.7 | 0.07 |
| Coronary lesions(%) | 79.6 | 88.9 | 0.004 |
| Extension score | 2.1 ± 1.6 | 2.6 ± 1.7 | <0.001 |
| Severity score | 1.5 ± 1.2 | 1.9 ± 1.3 | <0.001 |
| Gensini score | 19.7 ± 28.2 | 25.7 ± 32.0 | 0.05 |
| Codes | Oil (%) | Surfactant and cosurfactant (3 : 1) | Water (%) | Permeation flux |
| (Tween 80 and isopropyl alcohol, %) | (μg/cm2/hour)b | |||
| Oleic acid | ||||
| F-1 | 25 | 60 | 15 | 0.090 ± 0.001 |
| F-2 | 20 | 65 | 15 | 0.146 ± 0.001 |
| F-3 | 15 | 75 | 10 | 0.186 ± 0.002 |
| F-4 | 10 | 82 | 8 | 0.199 ± 0.002 |
| Isopropyl myristate | ||||
| F-5 | 25 | 60 | 15 | 0.229 ± 0.002 |
| F-6 | 20 | 65 | 15 | 0.233 ± 0.002 |
| F-7 | 15 | 75 | 10 | 0.257 ± 0.003 |
| F-8 | 10 | 82 | 8 | 0.284 ± 0.003 |
| n = 30 | 30/15 | Valsalva | E/I | VLF | LF | HF | Total espectrum | |
| Age | r | 0.155 | −0.245 | −0.190 | −0.029 | −0.128 | −0.275 | −0.181 |
| p | 0.412 | 0.191 | 0.313 | 0.876 | 0.499 | 0.142 | 0.337 | |
| BMI | r | 0.034 | −0.182 | −0.447 | −0.201 | −0.315 | −0.436 | −0.405 |
| p | 0.860 | 0.335 | 0.013 | 0.287 | 0.090 | 0.016 | 0.026 | |
| Fasting glycemia | r | −0.204 | −0.184 | −0.253 | −0.488 | −0.313 | −0.259 | −0.311 |
| p | 0.280 | 0.330 | 0.178 | 0.006 | 0.093 | 0.167 | 0.095 | |
| A1c | r | −0.400 | −0.190 | −0.310 | −0.460 | −0.525 | −0.326 | −0.434 |
| p | 0.029 | 0.315 | 0.096 | 0.010 | 0.003 | 0.079 | 0.017 | |
| Basal Insulin | r | −0.432 | −0.358 | −0.610 | −0.501 | −0.590 | −0.645 | −0.583 |
| p | 0.017 | 0.052 | 0.000 | 0.005 | 0.001 | 0.000 | 0.001 | |
| HOMA-IR | r | −0.439 | −0.362 | −0.591 | −0.543 | −0.561 | −0.598 | −0.555 |
| p | 0.015 | 0.049 | 0.001 | 0.002 | 0.001 | 0.000 | 0.001 | |
| Leptin | r | 0.537 | 0.312 | 0.291 | 0.338 | 0.339 | 0.379 | 0.364 |
| p | 0.002 | 0.094 | 0.119 | 0.067 | 0.067 | 0.039 | 0.048 | |
| ACR | r | −0.514 | −0.200 | −0.356 | −0.627 | −0.374 | −0.276 | −0.477 |
| p | 0.004 | 0.289 | 0.053 | 0.000 | 0.042 | 0.140 | 0.008 | |
| Total cholesterol | r | −0.259 | −0.021 | −0.262 | −0.103 | −0.193 | −0.145 | −0.156 |
| p | 0.167 | 0.913 | 0.161 | 0.589 | 0.306 | 0.444 | 0.411 | |
| HDL-c | r | 0.366 | 0.248 | 0.301 | 0.313 | 0.198 | 0.199 | 0.221 |
| p | 0.046 | 0.186 | 0.106 | 0.092 | 0.294 | 0.292 | 0.240 | |
| LDL-c | r | −0.259 | 0.058 | −0.214 | −0.027 | −0.079 | −0.123 | −0.077 |
| p | 0.184 | 0.769 | 0.275 | 0.892 | 0.688 | 0.532 | 0.698 | |
| Triglycerides | r | −0.632 | −0.261 | −0.674 | −0.470 | −0.548 | −0.420 | −0.539 |
| p | 0.000 | 0.163 | 0.000 | 0.009 | 0.002 | 0.021 | 0.002 |
| Features analysed | P. aeruginosa pangenome |
| Genomes | 181 |
| Total genes | 1,117,803 |
| Average genome size | 6175 genes |
| Pangenome size (non-redundant genes) | 16,820 |
| Core genome | 2503 genes |
| Accessory genome | 9108 genes |
| Unique genes | 5209 |
| Average unique genes/strain | 16 |
| Gene families under positive selection | 233 |
| Whole sample | 18- 30 years old sample | |||||
| Support | PCOS (%) | Control (%) | Χ2 (p) | PCOS (%) | Control (%) | Χ2 (pcp |
| Husband/partnera | 116 (76) | 37 (58) | 2.42 (0.120) | 52 (74) | 14 (42) | 8.83 (0.003) |
| Friends | 93 (61) | 30 (47) | 1.82 (0.178) | 46 (66) | 22 (67) | 0.01 (0.931) |
| Parents | 86 (56) | 24 (38) | 3.45 (0.063) | 49 (70) | 21 (64) | 0.27 (0.604) |
| Other family* | 77 (50) | 19 (30) | 5.00 (0.025) | 42 (60) | 14 (42) | 3.18 (0.075) |
| Children*a | 65 (42) | 16 (25) | 4.31 (0.038) | 15 (21) | 2 (6) | 8.33 (0.004) |
| Health care profs | 42 (27) | 14 (22) | 0.51 (0.475) | 22 (31) | 8 (24) | 0.89 (0.345) |
| Co-workers | 40 (26) | 13 (20) | 0.78 (0.376) | 24 (34) | 9 (27) | 0.80 (0.370) |
| Physical activity instructors | 40 (26) | 14 (22) | 0.33 (0.564) | 25 (36) | 10 (30) | 0.55 (0.460) |
| Myself | 9 (6) | 4 (6) | 0.00 (1.00) | 5 (7) | 4 (12) | 1.32 (0.251) |
| Other | 4 (3) | 0 (0) | - | 2 (3) | 0 (0) | - |
| Exercise friends/team | 2 (1) | 2 (3) | - | 2 (3) | 0 (0) | - |
| No one | 1 (1) | 1 (2) | - | 0 (0) | 1 (3) | - |
| Pets | 1 (1) | 1 (2) | - | 1 (1) | 0 (0) | - |
| 15th postoperative day | 30th postoperative day | |||||||
| Treatment group | Control group | F value | P value | Treatment group | Control group | F value | P value | |
| First voiding desire (mL) | 190.22 ± 12.77186.92–193.52 | 198.52 ± 16.33194.30–202.74 | 3.722 | 0.002 | 184.88 ± 10.98182.05–187.72 | 191.25 ± 14.44187.52–194.98 | 2.136 | 0.008 |
| MCC (mL) | 370.92 ± 13.06367.54–374.29 | 362.57 ± 13.46359.09–366.04 | 0.01 | 0.001 | 384.97 ± 15.73380.90–389.03 | 372.92 ± 14.46369.18–376.65 | 0.534 | <0.001 |
| Maximal flow rate (mL/sec) | 8.07 ± 1.757.62–8.52 | 6.42 ± 2.405.80–7.04 | 6.573 | <0.001 | 13.52 ± 2.4112.89–14.14 | 10.70 ± 3.139.89–11.51 | 6.38 | <0.001 |
| PVR (mL) | 92.52 ± 10.3789.84–95.20 | 100.53 ± 17.2896.07–105.00 | 7.058 | 0.003 | 86.05 ± 10.1683.42–88.68 | 94.85 ± 11.8291.80–97.90 | 0.054 | <0.001 |
| BC (mL/cmH2O) | 22.27 ± 2.8121.54–22.99 | 20.03 ± 4.0119.00–21.07 | 5.237 | 0.001 | 28.22 ± 5.5926.77–29.66 | 24.32 ± 4.7723.08–25.55 | 0.046 | <0.001 |
| Parameters | Group | Before | After | Before versus after | Group comparison | ||
| Median | 25–75 percentile | Median | 25–75 percentile | p value∗ | p value∗∗ | ||
| Stool Hp antigen | L. gasseri group | 1.45 | 0.38–2.38 | 1.17 | 0.48–2.13 | 0.588 | 0.958 |
| Placebo group | 1.22 | 0.38–2.83 | 1.24 | 0.44–2.50 | 0.584 | ||
| UBT | L. gasseri group | 19.4 | 10.4–35.0 | 21.9 | 11.1–31.2 | 0.395 | 0.516 |
| Placebo group | 19.6 | 10.3–36.7 | 19.9 | 10.3–32.8 | 0.958 | ||
| PGI/PGII | L. gasseri group | 2.6 | 2.1–3.5 | 2.7 | 2.1–3.6 | 0.537 | 0.414 |
| Placebo group | 2.7 | 2.0–3.9 | 2.7 | 2.1–3.7 | 0.604 | ||
| PGI | L. gasseri group | 61.0 | 45.2–76.5 | 63.3 | 48.5–79.6 | 0.006 | 0.497 |
| Placebo group | 59.2 | 42.0–74.5 | 62.3 | 43.9–77.0 | 0.018 | ||
| PGII | L. gasseri group | 21.4 | 16.4–32.5 | 22.5 | 16.1–35.1 | 0.012 | 0.725 |
| Placebo group | 20.6 | 16.9–27.5 | 24.3 | 16.4–29.8 | 0.003 |
| Class | Drug name | n11 | n1+ | ROR (95%CI) | IC (95%CI) |
| GLP-1-RAs | (ALL) | 36 | 429 | 5.61* (3.95–7.96) | 2.17* (1.66–2.67) |
| dulaglutide | 1 | 20 | 3.08 (0.41–23.04) | 0.56 (−1.57–2.70) | |
| exenatide | 19 | 122 | 11.08* (6.75–18.18) | 2.70* (2.00–3.41) | |
| liraglutide | 15 | 278 | 3.39* (2.00–5.74) | 1.49* (0.74–2.24) | |
| lixisenatide | 1 | 12 | 5.32 (0.69–41.28) | 0.71 (− 1.48–2.91) | |
| DPP-4-Is | (ALL) | 31 | 3276 | 0.54 (0.37–0.77) | -0.81 (− 1.34 – −0.29) |
| alogliptin | 1 | 345 | 0.17 (0.02–1.20) | − 1.77 (−3.82–0.28) | |
| anagliptin | 0 | 72 | – | – | |
| linagliptin | 4 | 332 | 0.71 (0.26–1.91) | −0.40 (−1.71–0.90) | |
| omarigliptin | 0 | 2 | – | – | |
| saxagliptin | 0 | 70 | – | – | |
| sitagliptin | 16 | 1181 | 0.80 (0.48–1.31) | −0.30 (−1.01–0.41) | |
| teneligliptin | 0 | 98 | – | – | |
| trelagliptin | 1 | 19 | 3.25 (0.43–24.39) | 0.58 (−1.56–2.72) | |
| vildagliptin | 9 | 1189 | 0.44 (0.23–0.85) | −1.07 (−2.00 – −0.15) |
| N (%) | |
| Median age at diagnosis (range) | 63 (20–92) |
| Histological subtype | |
| High-grade serous | 90 (92.7) |
| High-grade endometrioid | 5 (5.2) |
| Clear cell | 2 (2.1) |
| FIGO stage at diagnosis | |
| I | 7 (7.2) |
| II | 4 (4.1) |
| III | 73 (75.3) |
| IV | 13 (13.4) |
| ER-status | |
| Positive | 50 (51.5) |
| Negative | 1 (1) |
| Unknown | 46 (47.4) |
| PR-status | |
| Positive | 20 (20.1) |
| Negative | 11 (11.3) |
| Unknown | 66 (68) |
| Primary Surgery status | |
| Complete debulking | 37 (38.1) |
| Suboptimal debulking (>1 cm residual disease) | 44 (45.3) |
| No surgery | 16 (16.5) |
| Platinum-sensitivity | |
| Platinum-sensitive | 39 (40) |
| Platinum-resistant | 58 (60) |
| Number of lines of prior chemotherapy | |
| 1 | 18 (18.6) |
| 2 | 15 (15.5) |
| 3 | 21 (21.6) |
| 4 | 17 (17.5) |
| 5 | 10 (10.3) |
| ≥ 6 | 16 (16.5) |
| Variable | Breakpoint-Specific PCR | Concordance, % | |||
| CN1 | CN2+ | Fail | Total | ||
| Sequence read depth: Thailand | |||||
| CN1 | 57 (22a) | 13 (13) | 1 | 71 | ... |
| CN2+ | 0 | 17 (7) | 0 | 17 | ... |
| Total | 57 | 30 | 1 | 88 | 85 |
| qPCR: Thailand | |||||
| CN1 | 33 (11b) | 3 (2) | 1 | 37 | ... |
| CN2+ | 1 (0) | 9 (4) | 1 | 11 | ... |
| Total | 34 | 12 | 2 | 48 | 91 |
| qPCR: Indonesia | |||||
| CN1 | 25 | 0 | 2 | 27 | ... |
| CN2+ | 0 | 0 | 0 | 0 | ... |
| Total | 25 | 0 | 2 | 27 | 100 |
| Gene | Mesor | Amplitude | Acrophase ZT (h) |
| C57 ND | |||
| Bmal1 | 0.61 ± 0.04 | 0.44 ± 0.05 | 23.58 ± 0.09 |
| Cry1 | 0.93 ± 0.01 | 0.51 ± 0.04 | 19.22 ± 0.12 |
| Per2 | 1.39 ± 0.08 | 0.64 ± 0.08 | 10.77 ± 0.08 |
| Rev-erb α | 2.23 ± 0.14 | 2.08 ± 0.19 | 7.75 ± 0.01 |
| PPAR α | 7.34 ± 0.16 | 6.83 ± 0.29 | 12.1 ± 0.03 |
| PPAR γ | 1.25 ± 0.05 | 0.68 ± 0.05 | 15.55 ± 0.03 |
| ROR α | — | — | — |
| RXR X | — | — | — |
| Sirt1 | 7.24 ± 0.24 | 7.18 ± 0.28 | 6.33 ± 0.01 |
| ApoE-KO | |||
| Bmal1 | 0.30 ± 0.03∗∗ | 0.13 ± 0.03∗∗ | 23.27 ± 0.15 |
| Cry1 | — | — | — |
| Per2 | 0.66 ± 0.01∗∗ | 0.57 ± 0.09 | 13.41 ± 0.06∗∗ |
| Rev-erb α | 2.99 ± 0.08∗∗ | 2.58 ± 0.22∗ | 10.96 ± 0.02∗∗ |
| PPAR α | 11.27 ± 0.20∗∗ | 7.71 ± 0.10∗∗ | 12.68 ± 0.01 |
| PPAR γ | — | — | — |
| ROR α | — | — | — |
| RXR α | — | — | — |
| Sirt1 | 15.27 ± 0.73∗∗ | 9.60 ± 0.97∗∗ | 6.10 ± 0.02 |
| ApoE-KO LD/DL | |||
| Bmal1 | — | — | — |
| Cry1 | — | — | — |
| Per2 | 0.42 ± 0.05∗∗## | 0.18 ± 0.03∗∗## | 10.28 ± 0.09## |
| Rev-erb α | 2.16 ± 0.18∗## | 2.01 ± 0.36# | 11.12 ± 0.03∗∗ |
| PPAR α | 13.81 ± 0.33∗∗## | 6.70 ± 0.05 | 12.03 ± 0.02 |
| PPAR γ | — | — | — |
| ROR α | 2.01 ± 0.04 | 0.84 ± 0.05 | 4.79 ± 0.02 |
| RXR α | 1.52 ± 0.04 | 0.44 ± 0.02 | 2.29 ± 0.07 |
| Sirt1 | 13.12 ± 0.10∗∗# | 7.47 ± 0.18 | 5.84 ± 0.01 |
| Yield (%) | ||||||||||||
| Entry | Catalyst | Additive (equiv.) | Solvent | Temp.(K) | O2 (MPa) | Time (h) | FDCA | DFF | HFCA | FFCA | Comments | Reference |
| 1 | Ru(OH)x/CeO2 | — | Water | 413 | 0.25 | 6 | 38 | 12 | 50 | — | Reuse (3 times) | [173] |
| 2b | Ru(OH)x/MgAl2O4 | — | Water | 413 | 0.5 | 18 | 56 | 4 | 30 | — | Reuse (4 times), leaching (Mg: 0.9%, Ru: 0.02%) | [174] |
| 3c | Ru(OH)x/La2O3 | — | [EMIm] [OAc] | 373 | 3 | 5 | 48 | — | 12 | — | Leaching (9.9%) | [175] |
| 4 | Au/CeO2 | NaOH (4) | Water | 338 | Flow (1) | 8 | >99 | — | — | — | Au/CeO2: reuse (3 times), leaching (no) | [176] |
| Au/TiO2 | NaOH (4) | Water | 338 | Flow (1) | 8 | >99 | — | — | — | [176] | ||
| 5 | Pt/C | NaOH (2) | Water | 295 | 0.68 | 6 | 79 | — | 21 | — | Pt/C: reuse (3 times), | [177] |
| Pd/C | NaOH (2) | Water | 295 | 0.68 | 6 | 71 | — | 29 | — | Au/C: leaching (no) | [177] | |
| Au/C | NaOH (2) | Water | 295 | 0.68 | 6 | 8 | — | 92 | — | [177] | ||
| 6 | Au/hydrotalcite | — | Water | 368 | Flow (0.1) | 7 | >99 | — | — | — | Reuse (3 times), leaching (no) | [178] |
| 7d | Au/TiO2 | HTFA (18–21) | AcOH | 403 | 1 | 3 | — | — | — | 78 | — | [179] |
| 8 | Au/HY zeolite | NaOH (4) | Water | 333 | 0.3 | 6 | >99 | — | — | — | Reuse (4 times) | [180] |
| 9 | Ru/C | — | Water | 383 | 2 | — | — | 29 | — | <1 | Reuse (5 times, decrease in activity), leaching (no) | [181] |
| 10e | Ag/OMS-2 | — | IPA | 438 | 1.5 (air) | 6 | — | 99 | — | — | Reuse (6 times) | [182] |
| 11 | Au–Cu/TiO2 | NaOH (4) | Water | 368 | 1 | 4.5 | 95 | — | 5 | — | Reuse (5 times), leaching (≤2% after 5th reuse) | [183] |
| 12 | Pt–Bi/C | NaHCO3 (4) | Water | 373 | 4 (air) | 6 | 98 | — | 1 | — | Reuse (5 times), leaching (<0.5%) | [184] |
| 13f | Au8Pd2/AC | NaOH (2) | Water | 333 | 0.3 | 2 | 99 | — | 1 | — | Reuse (5 times), leaching (no) | [185] |
| 14 | Au–Pd/CNT | — | Water | 373 | 0.5 | 12 | 94 | — | — | 2 | Reuse (6 times) | [186] |
| Antimicrobial | MIC (μg/ml) |
| Nisin A | 12.5 |
| Nisin V | 6.25 |
| M21A | 6.25 |
| Citric Acid | 2340 |
| 99% cinnamaldehyde | 625 |
| Lactoferrin | >2500 |
| Sodium acetate | 250,000 |
| Sodium benzoate | 25,000 |
| Carvacrol | 310 |
| Potassium sorbate | 37,500 |
| Nisaplin® | 393 |
| Variable | Presence of hypertension | P-value* | |
| Yes (n = 398) | No (n = 460) | ||
| Age (yrs) | 61.2 (9.3) | 58.6 (10.2) | <0.0001 |
| Height (m) | 1.56 (0.08) | 1.56 (0.07) | 0.779 |
| Weight (kg) | 57.6 (13.5) | 55.9 (12.9) | 0.06 |
| Body mass index (Kg/m2) | 23.6 (5.3) | 22.8 (4.6) | 0.019 |
| Waist circumference (cm) | 85.9 (12.6) | 83.5 (12.7) | 0.006 |
| Waist to Hip ratio | 0.88 (0.07) | 0.87 (0.06) | 0.011 |
| Systolic blood pressure (mmHg) | 158.4 (19.7) | 118.6 (12.8) | <0.0001 |
| Diastolic blood pressure (mmHg) | 91.4 (14.1) | 70.9 (9.3) | <0.0001 |
| Fasting blood glucose (mmol/L) | 4.6 (1.5) | 4.6 (1.8) | 0.989 |
| Total cholesterol (mmol/L)† | 4.6 (0.8) | 4.6 (0.9) | 0.972 |
| Current density | 44 mA g−1 (mAh g−1) | 110 mA g−1 (mAh g−1) | 220 mA g−1 (mAh g−1) | 660 mA g−1 (mAh g−1) | 1320 mA g−1 (mAh g−1) | Retention rate (%) |
| Pristine | 229 | 194 | 170 | 134 | 101 | 44.1 |
| Composite 0.5 | 260 | 228 | 203 | 164 | 123 | 47.3 |
| Composite 2.0 | 287 | 253 | 225 | 179 | 151 | 52.6 |
| Composite 5.0 | 276 | 243 | 215 | 174 | 145 | 52.5 |
| Number of region | Color | Maximum number of correctly sequenced syllables | Minimum number of correctly sequenced syllables |
| 1 | dark red | 90 | 75 |
| 2 | red | 74 | 61 |
| 3 | light red | 60 | 45 |
| 4 | light blue | 44 | 31 |
| 5 | blue | 30 | 15 |
| 6 | dark blue | 14 | 0 |
| EZ Metric Endpoint | Weighting factor |
| 24 hpf mortality | 1.0 |
| 120 hpf mortality | 0.95 |
| Heart malformation | 0.12 |
| Brain malformation | 0.12 |
| Yolk sac edema | 0.1 |
| Notochord malformation | 0.08 |
| Curved axis | 0.08 |
| Trunk malformation | 0.06 |
| Delayed developmental progression | 0.06 |
| Occluded circulation | 0.04 |
| Eye malformation | 0.04 |
| Jaw malformation | 0.04 |
| Lack of spontaneous movement | 0.04 |
| Somite malformation | 0.02 |
| Motility | 0.02 |
| Lack of touch response | 0.02 |
| Snout malformation | 0.02 |
| Otic malformation | 0.02 |
| Caudal/pectoral fin malformation | 0.02 |
| Atypical pigmentation | 0.02 |
| Atypical swim bladder inflation | 0.02 |
| Total | RCRC | LCRC | ||
| N (%) | N (%) | N (%) | P value | |
| Patient Number | 901 (100.0) | 136 (100.0) | 765 (100.0) | |
| Gender | ||||
| Male | 557 (61.8) | 74 (54.4) | 483 (63.1) | .0536 |
| Female | 344 (38.2) | 62 (45.6) | 282 (36.9) | |
| Mean age at treatment (years) | ||||
| Mean (SD) | 59.95 (12.02) | 61.39 (11.91) | 59.70 (12.02) | .0992 |
| Median (min, max) | 60 (22, 96) | 61 (22, 96) | 60 (26, 90) | |
| Age group (years) | ||||
| <50 | 163 (18.1) | 18 (13.2) | 145 (19.0) | .2256 |
| 50-64 | 420 (46.6) | 64 (47.1) | 356 (46.5) | |
| 65+ | 318 (35.3) | 54 (39.7) | 264 (34.5) | |
| Histology | ||||
| Mucinous adenocarcinoma | 36 (4.0) | 15 (11.0) | 21 (2.7) | < .0001 |
| Non-mucinous adenocarcinoma | 836 (92.8) | 115 (84.6) | 721 (94.2) | |
| Others | 29 (3.2) | 6 (4.4) | 23 (3.0) | |
| Grade | ||||
| 1 | 43 (4.8) | 5 (3.7) | 38 (5.0) | .0002 |
| 2 | 689 (76.5) | 90 (66.2) | 599 (78.3) | |
| 3 | 93 (10.3) | 28 (20.6) | 65 (8.5) | |
| Undifferentiated or Unknown | 76 (8.4) | 13 (9.6) | 63 (8.2) | |
| Stage at diagnosisa | ||||
| I-III | 396 (44.0) | 64 (47.1) | 332 (43.4) | .4281 |
| IV | 505 (56.0) | 72 (52.9) | 433 (56.6) | |
| Cetuximab combination with chemotherapy | 893 (99.1) | 135 (99.3) | 758 (99.1) | |
| Chemotherapy after end of cetuximab | 495 (54.9) | 61 (44.9) | 434 (56.7) | |
| Death | 747 (82.9) | 121 (89.0) | 626 (81.8) | |
| Follow-up (months) | ||||
| Mean (SD) | 13.0 (8.6) | 10.1 (8.0) | 13.5 (8.6) | |
| Median (min, max) | 11.5 (0.1, 39.4) | 8.1 (1.2, 34.8) | 12.5 (0.1, 39.4) |
| Parameter | Symbol | Nominal value |
| Maximal firing rate | Qmax | 250 s−1 |
| Average spike-threshold | θ | 15 mV |
| Spike-threshold deviation | σ | 3.3 mV |
| Synaptic decay rate | α | 50 s−1 |
| Synaptic rise rate | β | 200 s−1 |
| Synaptic strength from e to e neurons | νee | 1 mV s |
| Synaptic strength from i to e neurons | νei | −1.8 mV s |
| Synaptic strength from s to e neurons | νes | 3.2 mV s |
| Synaptic strength from i to i neurons | νii | −1.8 mV s |
| Synaptic strength from e to i neurons | νie | 1 mV s |
| Synaptic strength from s to i neurons | νis | 3.2 mV s |
| Synaptic strength from r to s neurons | νsr | −0.8 mV s |
| Synaptic strength from e to s neurons | νse | 2.2 mV s |
| Synaptic strength from s to r neurons | νrs | 0.6 mV s |
| Synaptic strength from e to r neurons | νre | 1.6 mV s |
| Average noise level | νsnφn | 2.0 mV |
| Noise standard deviation | σn | 0.2 mV |
| Cortico-thalamic delay | τ | 0.04 s |
| Cortical damping rate | γ | 100 s−1 |
| Han | Uygur | |||||||||||||||||
| Total | Men | Women | Total | Men | Women | |||||||||||||
| CAD | Control | P value | CAD | Control | P value | CAD | Control | P value | CAD | Control | P value | CAD | Control | P value | CAD | Control | P value | |
| Number (n) | 389 | 411 | 294 | 224 | 95 | 187 | 293 | 408 | 210 | 205 | 83 | 203 | ||||||
| Age (years) | 58.73 ± 7.32 | 57.82 ± 8.53 | 0.502 | 59.82 ± 8.24 | 58.52 ± 8.43 | 0.332 | 58.21 ± 6.37 | 59.76 ± 6.76 | 0.052 | 56.97 ± 5.58 | 55.93 ± 5.59 | 0.086 | 56.57 ± 8.33 | 54.96 ± 9.06 | 0.09 | 54.20 ± 3.89 | 52.30 ± 4.83 | 0.076 |
| BMI (kg/m2) | 27.62 ± 3.71 | 28.23 ± 2.74 | 0.428 | 26.63 ± 1.72 | 26.34 ± 1.75 | 0.201 | 30.63 ± 1.78 | 30.17 ± 2.23 | 0.069 | 32.34 ± 7.20 | 28.11 ± 4.37 | <0.001* | 31.45 ± 6.84 | 28.48 ± 3.98 | <0.001* | 32.97 ± 7.40 | 26.73 ± 5.41 | <0.001* |
| Pulse(beats/min) | 73.82 ± 10.23 | 73.13 ± 10.01 | 0.673 | 74.24 ± 10.52 | 73.76 ± 10.23 | 0.324 | 73.13 ± 9.24 | 72.45 ± 8.53 | 0.802 | 74.59 ± 10.92 | 76.56 ± 7.93 | 0.38 | 73.49 ± 11.20 | 74.76 ± 8.45 | 0.732 | 76.91 ± 9.74 | 80.38 ± 5.17 | 0.339 |
| Glu (mmol/L) | 6.12 ± 2.34 | 5.28 ± 1.67 | <0.001* | 5.63 ± 1.68 | 5.42 ± 1.45 | 0.036* | 6.48 ± 3.12 | 5.42 ± 1.59 | <0.001* | 6.60 ± 2.78 | 5.24 ± 2.38 | <0.001* | 6.21 ± 2.64 | 5.20 ± 2.55 | <0.001* | 7.31 ± 3.25 | 5.37 ± 2.41 | <0.001* |
| TG (mmol/L) | 1.97 ± 1.22 | 1.82 ± 1.76 | 0.978 | 1.74 ± 0.87 | 1.58 ± 0.69 | 0.284 | 2.23 ± 1.64 | 1.62 ± 1.18 | 0.254 | 1.83 ± 1.25 | 1.76 ± 1.35 | 0.435 | 1.77 ± 0.99 | 1.83 ± 1.50 | 0.638 | 2.10 ± 2.07 | 1.70 ± 1.24 | 0.061 |
| TC (mmol/L) | 4.35 ± 1.08 | 4.12 ± 0.74 | 0.262 | 4.35 ± 1.17 | 4.26 ± 0.82 | 0.431 | 4.62 ± 1.23 | 4.52 ± 0.85 | 0.873 | 4.24 ± 1.08 | 4.15 ± 0.98 | 0.34 | 4.18 ± 1.06 | 4.13 ± 0.97 | 0.565 | 4.50 ± 1.15 | 4.17 ± 0.97 | 0.037* |
| HDL (mmol/L) | 1.14 ± 0.23 | 1.26 ± 0.31 | 0.054 | 1.12 ± 0.26 | 1.19 ± 0.47 | 0.672 | 1.15 ± 0.36 | 1.33 ± 0.24 | 0.528 | 0.98 ± 0.13 | 1.01 ± 0.12 | 0.142 | 0.97 ± 0.31 | 0.98 ± 0.25 | 0.738 | 1.044 ± 0.20 | 1.04 ± 0.10 | 0.702 |
| LDL (mmol/L) | 2.53 ± 0.79 | 2.16 ± 0.85 | <0.001* | 2.62 ± 0.84 | 2.56 ± 0.68 | 0.005* | 2.58 ± 1.02 | 2.24 ± 0.58 | <0.001* | 2.86 ± 0.86 | 2.59 ± 0.97 | <0.001* | 2.90 ± 0.84 | 2.56 ± 0.99 | <0.001* | 2.84 ± 0.87 | 2.72 ± 0.89 | 0.356 |
| EH (%) | 59.32 | 47.63 | 0.023* | 62.31 | 43.34 | <0.001* | 57.27 | 51.22 | 0.031* | 42.68 | 18.42 | <0.001* | 34.35 | 20.01 | <0.001* | 51 | 16.53 | <0.001* |
| DM (%) | 27.23 | 13.56 | <0.001* | 22.74 | 15.03 | <0.001* | 31.18 | 12.26 | <0.001* | 26.71 | 12.84 | <0.001* | 21.53 | 7.73 | <0.001* | 30.69 | 17.95 | <0.001* |
| Smoke (%) | 58.48 | 31.43 | <0.001* | 87.59 | 56.38 | <0.001* | 12.13 | 3.62 | 0.002* | 33.15 | 17.97 | <0.001* | 63.73 | 34.9 | <0.001* | 5.63 | 1.23 | 0.023* |
| Type 1 (n=641) | Type 2 (n=10039) | |||||
| Without retinopathyn=540 | With Retinopathyn=101 | p-value | Without retinopathyn=7484 | With Retinopathyn=2555 | p-value | |
| Age(years) | 24.59±11.68 | 31.14±13.28 | 0.000 | 52.16±10.55 | 54.06±9.61 | 0.000 |
| Sex (M/F) | 232 / 308(43.0% / 57.0%) | 45 / 56(44.6% / 55.4%) | 0.767 | 2322 / 5162(31.0% / 69.0%) | 947 / 1608(37.1% / 62.9%) | 0.000 |
| BMI | 22.16±6.48 | 24.96±7.20 | 0.000 | 27.98±5.67 | 28.22±5.94 | 0.066 |
| W.C(cm) | 88.32±15.21 | 84.74±16.47 | 0.035 | 93.11±11.99 | 91.52±11.61 | 0.000 |
| SBP(mmHg) | 128.48±15.04 | 141.53±26.74 | 0.000 | 125.40±14.99 | 137.29±22.94 | 0.000 |
| DBP(mmHg) | 76.94±8.57 | 79.50±7.98 | 0.006 | 83.11±9.88 | 83.88±10.12 | 0.001 |
| RBS(mg/dl) | 240.39±85.50 | 302.33±122.52 | 0.000 | 221.85±84.88 | 283.90±115.40 | 0.000 |
| All homes | Box-shaped, Metal-roofed | Round-shaped, Thatch-roofed | ||
| ACH | Mean (SD) | Mean (SD) | Mean (SD) | p-value |
| Closed | 3 (2.9) | 3 (2.7) | 3 (3.3) | 0.50 |
| Windows Open | 9 (7.1) | 13 (8.1) | 5 (2.9) | 0.01 |
| Windows & Door | 20 (13.1) | 27 (9.7) | 13 (12.8) | 0.01 |
| Open | ||||
| *TB Risk (10h exposure) | ||||
| Closed | 55.4 (27.8) | 58.3 (24.7) | 52.5 (31.5) | 0.62 |
| Windows Open | 21.5 (14.1) | 24.7 (18.1) | 18 (8.4) | 0.32 |
| Windows & Door | 9.6 (4.7) | 8.9 (3.6) | 10 (5.6) | 0.44 |
| Open |
| Gene set/pathway | NTk q value | NEk q value |
| Regulation of cell growth (GO:0001558) | 0.0 | 0.0 |
| Nuclear pore complex (GO:0046930) | 0.0 | 0.03 |
| Negative regulation of cellular metabolism (GO:0031324) | 0.0 | 0.04 |
| Chromatin remodeling (GO:0016568) | 0.0 | 0.055 |
| PI3K-AKT signaling pathway (humanpaths) | 0.0 | 0.1 |
| Histone acetyltransferase binding (GO:0035035) | 0.0 | 0.2 |
| cAMP/Ca2+ signaling (humanpaths) | 0.0 | 0.3 |
| Spliceosome complex (GO:0005681) | 0.0 | 0.9 |
| Rainy season 2009 | Dry season 2010 | P-values | Total | |
| Sensitivity% | 56.4 | 20.7 | < 0.001 | 52.9 |
| Specificity% | 72.4 | 97.3 | < 0.001 | 85.5 |
| PPV% | 67.5 | 43.3 | < 0.001 | 66.1 |
| NPV% | 62 | 92.5 | < 0.001 | 77.2 |
| P-values | < 0.001 | < 0.001 | < 0.001 |
| No. of individuals with genotype (%) | ||||||
| Population and disease | No. | VariantAllele Frequency (%) | Ser/Ser | Ser/Leu | Leu/Leu | P valuea |
| Ghana, delivering women | ||||||
| P. falciparum positive | 541 | 0.1 | 540 (99.8) | 1 (0.2) | 0 (0) | 0.49 |
| P. falciparum negative | 554 | 0 | 554 (100) | 0 (0) | 0 (0) | |
| Germany | ||||||
| Sepsis patients | 223 | 18.1 | 170 (76.2) | 43 (19.3) | 10 (4.5) | 0.19 |
| Controls | 188 | 19.2 | 138 (74.4) | 48 (25.5) | 2 (1.1)b | |
| Bangladesh | ||||||
| Leprosy patients | 263 | 16.3 | 186 (70.7) | 68 (25.9) | 9 (3.4) | 0.22 |
| Controls | 280 | 17.2 | 188 (67.1) | 88 (31.5) | 4 (1.4) | |
| Turkey | 0.11 | |||||
| Leprosy patients | 60 | 10.8 | 47 (78) | 13 (21) | 0 (0) | |
| Controls | 100 | 6.5 | 88 (88) | 11 (11) | 1 (1) |
| Healthy | Milder fibrosis | Significant fibrosis | Early Cirrhosis | |
| Number | 42 | 24 | 32 | 12 |
| Age (Mean ± SD) | 32.9 ± 9.2 | 37.4 ± 12.4 | 34.4 ± 11.7 | 38.5 ± 14.4 |
| Gender (Male/Female) | 42/0 | 22/2 | 28/4 | 10/2 |
| 14–16 weeks | 22–24 weeksc | 30–32 weeks | 36–38 weeksc | 5 year. follow-up | ||||||
| Uni | Multi | Uni | Multi | Uni | Multi | Uni | Multi | Uni | Multi | |
| Age | −0.02 | −0.01 | −0.03 | −0.13* | −0.12* | −0.01 | ||||
| BMI | 0.70*** | 0.53*** | 0.68*** | 0.50*** | 0.61*** | 0.38*** | 0.61*** | 0.50*** | 0.73*** | 0.56*** |
| Paritya | 0.05 | 0.02 | −0.01 | −0.08 | −0.14** | 0.04 | ||||
| Smokingb | 0.16* | 0.15* | 0.09 | 0.18** | 0.01 | |||||
| Systolic BP | 0.26*** | 0.20** | 0.22*** | 0.25*** | 0.28*** | |||||
| CRP | 0.25*** | 0.32*** | 0.28*** | 0.20*** | 0.32*** | |||||
| Insulin sensitivity | −0.60*** | −0.32*** | −0.61** | −0.35*** | −0.61*** | −0.24* | −0.50*** | −0.37*** | −0.61*** | −0.29*** |
| Insulin resistance | 0.56*** | 0.53*** | 0.59*** | 0.28* | 0.48*** | 0.56*** | ||||
| Β-cell function | −0.39*** | −0.38*** | −0.33*** | 0.20** | −0.18*** | 0.17** | −0.45*** | |||
| R-square | 0.56 | 0.55 | 0.49 |
| GEO ID | Description |
| GSE43559 (gene expression) | |
| GSM1065332 | PGC E13 F3-Control biological rep1 |
| GSM1065333 | PGC E13 F3-Control biological rep2 |
| GSM1065334 | PGC E13 F3-Vinclozolin biological rep1 |
| GSM1065335 | PGC E13 F3-Vinclozolin biological rep2 |
| GSM1065336 | PGC E16 F3-Control biological rep1 |
| GSM1065337 | PGC E16 F3-Control biological rep2 |
| GSM1065338 | PGC E16 F3-Vinclozolin biological rep1 |
| GSM1065339 | PGC E16 F3-Vinclozolin biological rep2 |
| GSE59510 (promoter methylation) | |
| GSM1438556 | E16-Vip2/Cip2 |
| GSM1438557 | E13-Vip2/Cip1 |
| GSM1438558 | E13-Vip1/Cip1 |
| GSM1438559 | E16-Vip1/Cip1 |
| GSM1438560 | E16-Vip2/Cip1 |
| GSM1438561 | E13-Vip2/Cip2 |
| Variables | Total cholesterol<150 mg/dL(n = 68) | Total cholesterol>150 mg/dL(n = 97) |
| Age in years | 39.8 ± 7.9 | 41.1 ± 7.2 |
| Men | 72% | 68% |
| Women | 28% | 32% |
| Black | 65% | 55% |
| Hispanic | 33% | 29% |
| White | 0% | 16% |
| Annual income | ||
| Less than $10,000 | 89% | 88% |
| $11,000-$20,000 | 9% | 10% |
| More than $20,000 | 2% | 2% |
| Cigarette smoker | 81% | 80% |
| Hazardous alcohol use | 64% | 48% |
| Drug use | 42% | 39% |
| Albumin in mg/dl | 4.0 ± 0.4 | 4.1 ± 0.5 |
| Body mass index in kg/m2 | 26.2 ± 6.2 | 27.4 ± 6.7 |
| Number of years diagnosed with HIV | 9.7 ± 6.6 | 8.7 ± 5.6 |
| Class 1 (n = 16) | Class 2 (n = 30) | P-value | |
| Age (years), mean ± SD | 64.38 ± 11.32 | 61.50 ± 6.26 | 0.186 |
| Men, n (%) | 16 (100%) | 27 (90%) | 0.542 |
| Neurological symptoms*, n (%) | 6 (37.5%) | 18 (60%) | 0.217 |
| Hypertension, n (%) | 9 (56.3%) | 13 (43.3%) | 0.538 |
| Diabetes mellitus, n (%) | 3 (18.8%) | 9 (30.0%) | 0.498 |
| Hypercholesterolemia, n (%) | 9 (56.3%) | 18 (60.0%) | 1.000 |
| Current smoker, n (%) | 8 (50.5%) | 19 (63.3%) | 0.531 |
| EG mean (SD) | CG mean (SD) | |
| H1: General self-care managementa | ||
| Baseline | 46.19 (13.13) | 46.31 (8.97) |
| 1 month | 50.57 (4.89) | 50.76 (6.73) |
| H2: Self-care specific to HFa | ||
| Baseline | 49.37 (20.37) | 46.25 (14.50) |
| 1 month | 75.23 (10.60) | 69.48 (16.66) |
| H3: Perceived competence to manage HFa | ||
| Baseline | 20.13 (4.08) | 19.06 (5.30) |
| 1 month | 23.29 (3.27) | 23.85 (4.02) |
| H4: Behavioral Questionnaire of the Elderly-Health activities | ||
| H4a A-motivationb | ||
| Baseline | 7.88 (3.98) | 5.87 (3.46) |
| 1 month | 4.14 (2.18) | 6.08 (3.64) |
| H4b: External extrinsic motivationb | ||
| Baseline | 13.00 (4.77) | 15.13 (4.73) |
| 1 month | 16.29 (6.40) | 13.85 (5.32) |
| H4c: Internal extrinsic motivationa | ||
| Baseline | 16.65 (2.93) | 16.38 (3.16) |
| 1 month | 19.29 (1.77) | 17.54 (3.23) |
| H4d: Intrinsic motivationa | ||
| Baseline | 11.13 (5.58) | 9.63 (4.26) |
| 1 month | 10.86 (7.55) | 9.77 (5.48) |
| H5: Family Care Climate Questionnaire-Patient versiona | ||
| Baseline | 57.56 (7.97) | 60.19 (5.24) |
| 1 month | 61.86 (6.63) | 62.46 (6.57) |
| H6: Family Care Climate Questionnaire-Family versiona | ||
| Baseline | 58.13 (4.94) | 57.94 (6.69) |
| 1 month | 60.21 (4.93) | 57.85 (6.45) |
| Characteristic | Notifying hospitals | Cardiac arrests/eligible for donation | p value | OR (95 % CI) |
| Total, n (%) | 27 (100) | 141/465 (30.3) | ||
| Hospital beds, n (%) | ||||
| < 150 beds | 10 (37.0) | 29/62 (46.7) | 0.002 | 2.28 (1.32; 3.93) |
| 150–250 beds | 10 (37.0) | 65/217 (29.9) | 0.87 | |
| > 250 beds | 7 (25.9) | 47/186 (25.2) | 0.053 | 0.66 (0.44; 1.0) |
| ICU beds, n (%) | ||||
| < 5 % | 5 (18.5) | 44/131 (33.5) | 0.33 | |
| 5–10 % | 15 (55.6) | 89/294 (30.3) | 0.97 | |
| > 10 % | 7 (25.9) | 14/39 (35.8) | 0.43 | |
| Teaching, n (%) | ||||
| Yes | 15 (55.6) | 101/329 (30.7) | 0.78 | |
| No | 12 (44.4) | 40/136 (29.4) | ||
| Trauma referral center, n (%) | ||||
| Yes | 15 (55.6) | 112/354 (31.6) | 0.27 | |
| No | 12 (44.4) | 29/111 (26.1) | ||
| Transplant center, n (%) | ||||
| Yes | 6 (22.2) | 44/211 (20.8) | <0.001 | 0.42 (0.28; 0.65) |
| No | 21 (78.8) | 97/254 (38.1) | ||
| Onsite training, n (%) | ||||
| Yes | 8 (29.7) | 69/238 (28.9) | 0.52 | |
| No | 19 (70.3) | 72/227 (31.7) | ||
| Transplant coordination unit connected to the ICU, n (%) | ||||
| Yes | 17 (63.0) | 113/394 (18.2) | 0.07 | 0.61 (0.36; 1.04) |
| No | 10 (37.0) | 28/70 (25.9) | ||
| Public administration, n (%) | ||||
| Yes | 22 (81.5) | 137/433 (31.6) | 0.02 | 3.23 (1.11; 9.41) |
| No | 5 (18.5) | 4/31 (12.3) |
| Factors | Odds ratio | 95% confidence interval |
| Nicardipine vs. labetalol | 2.73 | 1.113-6.698 |
| Female | 3.311 | 1.36-8.064 |
| No history of stroke | 5.38 | 1.565-18.468 |
| Strains | Clinical signs first evident | No. leisions/total | Mortalitye | Main clinical signs | Salient gross lesions |
| SPF chickens | |||||
| Herts/33 | 2 dpi | 12/12 | 8/8 | severe depression, lethargy, ruffled feathers, eyelid edema, diarrhea, open-mouth breathing | Spleen, Atr; Intestene, Hem; Proventriculus, Hem; Pancreas, Nec; Thymus, Hem; Larynx and trachea, Hem; |
| ZJ1 | 2 dpi | 12/12 | 8/8 | severe depression, lethargy, ruffled feathers, eyelid edema, diarrhea, open-mouth breathing | Spleen, Nec; Intestene, Hem + Nec; Proventriculus, Hem; Pancreas, Nec; Thymus, Hem; Larynx and trachea, Hem; |
| JS-5-05-Go | 2 dpi | 12/12 | 8/8 | ||
| XJ-2/97 | 2 dpi | 12/12 | 8/8 | ||
| JS-3-05-Ch | 2 dpi | 12/12 | 8/8 | ||
| Geese | |||||
| Herts/33 | 4 dpi | 12/12 | 4/8 | morderate depression, diarrhea, crouch, nasal discharge, eyelid edema | Spleen, Atr; Intestene, Hem, Proventriculus, Ed + Hem; Pancreas, Nec;Thymus, Hem; Larynx and trachea, Hem; |
| ZJ1 | 3 dpi | 12/12 | 5/8 | morderate to severe depression, diarrhea, crouch, nasal discharge, eyelid edema | Spleen, Nec; Intestene, Hem + Nec; Proventriculus, Ed + Hem; Pancreas, Nec; Thymus, Hem; Larynx and trachea, Hem; |
| JS-5-05-Go | 3 dpi | 12/12 | 6/8 | ||
| XJ-2/97 | 3 dpi | 12/12 | 5/8 | ||
| JS-3-05-Ch | 3 dpi | 12/12 | 6/8 |
| Source | Sum of squares | Degree of freedom | Mean2 | F value | P > F | Coefficient estimate |
| Block | 46.37 | 2 | 23.19 | |||
| Model | 2905.88 | 14 | 207.56 | 8.47 | 0.0002 | |
| A | 37.50 | 1 | 37.50 | 1.53 | 0.2379 | 1.25 |
| B | 2.30 | 1 | 2.30 | 0.094 | 0.7643 | −0.31 |
| C | 153.30 | 1 | 153.30 | 6.26 | 0.0265 | 2.53 |
| D | 1053.35 | 1 | 1053.35 | 42.99 | <0.0001 | −6.62 |
| A2 | 0.15 | 1 | 0.15 | 6.258E-3 | 0.9381 | 0.08 |
| B2 | 181.64 | 1 | 181.64 | 7.41 | 0.0174 | 2.57 |
| C2 | 634.40 | 1 | 634.40 | 25.89 | 0.0002 | 4.81 |
| D2 | 624.94 | 1 | 624.94 | 25.51 | 0.0002 | 4.77 |
| AB | 2.81 | 1 | 2.81 | 0.11 | 0.7405 | −0.42 |
| AC | 32.23 | 1 | 32.23 | 1.32 | 0.2721 | −1.42 |
| AD | 1.72 | 1 | 1.72 | 0.070 | 0.7951 | −0.33 |
| BC | 0.020 | 1 | 0.020 | 8.178E-4 | 0.9776 | 0.04 |
| BD | 359.40 | 1 | 359.40 | 14.67 | 0.0021 | −4.74 |
| CD | 60.63 | 1 | 60.63 | 2.47 | 0.1397 | −1.95 |
| Residuals | 318.51 | 13 | 24.50 | |||
| Lack of Fit | 299.05 | 10 | 29.91 | 4.61 | 0.1175 | |
| Pure error | 19.46 | 3 | 6.49 | |||
| Cor total | 3270.76 | 29 |
| PKS/NRPS | LuxRI | Bacteriocin | Siderophore | Terpene | Ectoine | |
| Leisingera sp. ANG-Vp | 1 | 1 | 0 | 1 | 0 | 1 |
| Leisingera sp. ANG-M1 | 1 | 1 | 0 | 0 | 0 | 1 |
| Leisingera sp. ANG1 | 1 | 1 | 0 | 1 | 0 | 0 |
| Leisingera sp. ANG-DT | 1 | 1 | 0 | 1 | 0 | 0 |
| Leisingera sp. ANG-S | 1 | 1 | 0 | 1 | 0 | 0 |
| Leisingera sp. ANG-S3 | 1 | 1 | 0 | 1 | 0 | 0 |
| Leisingera sp. ANG-M6 | 1 | 1 | 0 | 1 | 0 | 0 |
| Leisingera sp. ANG-S5 | 1 | 1 | 0 | 1 | 0 | 0 |
| Leisingera sp. ANG-M7 | 1 | 1 | 0 | 1 | 0 | 0 |
| Ruegeria sp. ANG-R | 1 | 2 | 3 | 0 | 0 | 1 |
| Ruegeria sp. ANG-S4 | 2 | 2 | 3 | 0 | 0 | 0 |
| Tateyamaria sp. ANG-S1 | 0 | 1 | 2 | 1 | 1 | 0 |
| A | Fixed effect | Random effect | % variances | |||||||||||
| M | D | Y | G | G×M | G×D | G×Y | G | G×M | G×D | G×Y | Res | h2b | ||
| NDVI | x | x | - | x | x | - | - | 35 | 19 | - | - | 46 | 0.62 | |
| sdNDVI | x | x | - | x | x | - | - | 21 | 8 | - | - | 71 | 0.50 | |
| VARI | x | x | - | x | x | x | - | 23 | 6 | 9 | - | 61 | 0.77 | |
| sdVARI | x | x | - | x | x | x | - | 9 | 5 | 10 | - | 76 | 0.56 | |
| SRPI | x | x | - | x | x | x | - | 19 | 18 | 4 | - | 59 | 0.60 | |
| sdSRPI | x | x | - | x | x | x | - | 17 | 8 | 5 | - | 70 | 0.69 | |
| TsTa | x | x | - | x | x | x | - | 15 | 18 | 5 | - | 62 | 0.55 | |
| sdTsTa | x | x | - | x | x | x | - | 7 | 9 | 4 | - | 79 | 0.49 | |
| WDI | x | x | - | x | x | x | - | 11 | 7 | 5 | - | 76 | 0.59 | |
| sdWDI | x | x | - | x | x | x | - | 3 | 6 | 6 | - | 85 | 0.31 | |
| TCSA | x | - | x | x | x | - | - | 51 | 15 | - | - | 34 | 0.76 | |
| NbFr | x | - | x | x | - | - | x | 25 | - | - | 37 | 37 | 0.52 | |
| BmFr | x | - | x | x | x | - | x | 12 | 8 | - | 32 | 49 | 0.31 | |
| B | Fixed effect | Random effect | % variances` | |||||||||||
| M | D | Y | G | G×M | G×D | G×Y | G | G×M | G×D | G×Y | Res | h2b | ||
| NDVI_DI | - | x | - | x | - | - | - | 44 | - | - | - | 56 | 0.61 | |
| sdNDVI_DI | - | x | - | x | - | - | - | 19 | - | - | - | 81 | 0.32 | |
| VARI_DI | - | x | - | x | - | - | - | 19 | - | - | - | 81 | 0.33 | |
| sdVARI_DI | - | x | - | x | - | x | - | 13 | - | 8 | - | 79 | 0.62 | |
| SRPI_DI | - | x | - | x | - | - | - | 35 | - | - | - | 65 | 0.52 | |
| sdSRPI_DI | - | x | - | x | - | x | - | 17 | - | 7 | - | 75 | 0.70 | |
| TsTa_DI | - | x | - | x | - | - | - | 34 | - | - | - | 66 | 0.50 | |
| sdTsTa_DI | - | x | - | x | - | x | - | 19 | - | 14 | - | 67 | 0.70 | |
| WDI_DI | - | x | - | x | - | - | - | 17 | - | - | - | 83 | 0.29 | |
| sdWDI_DI | - | x | - | x | - | - | - | 9 | - | - | - | 91 | 0.17 | |
| TCSA_DI | - | - | x | x | - | - | - | 35 | - | - | - | 65 | 0.52 | |
| NbFr_DI | - | - | x | x | - | - | x | 13 | - | - | 1 | 86 | 0.38 | |
| BmFr_DI | - | - | x | x | - | - | - | 17 | - | - | - | 83 | 0.29 |
| Veterinary rating of pet owner compliance in endemic regions | ||||||
| Number clinics responding (% responding) | ||||||
| Excellent | Good | Reasonable | Poor | Non-compliant | Responders | |
| France | 10 (21) | 7 (15) | 19 (40) | 4 (9) | 7 (15) | 47 |
| Spain | 0 (0) | 21 (51) | 17 (41) | 3 (7) | 0 (0) | 41 |
| Italy | 26 (24) | 76 (71) | 2 (2) | 3 (3) | 0 (0) | 107 |
| Total | 36 (18) | 104 (53) | 38 (19) | 10 (5) | 7 (4) | 195 |
| Gene features | Clinical covariates | Samples | |
| UPP | 44,928 | 21 | 251 |
| MAINZ | 22,283 | 21 | 200 |
| TransBig | 22,283 | 21 | 198 |
| VDX | 22,283 | 21 | 344 |
| TCGA | 19,420 | 5 | 3096 |
| Valuables (n) | AR positive (n, %) | B | SE | p-value | OR (95% CI) |
| Gender | −1.627 | 0.680 | 0.017* | 0.197(0.052–0.745) | |
| Male (70) | 42 (60) | ||||
| Female (19) | 7 (36.8) | ||||
| Fuhrman Gradea | 0.003* | ||||
| 1 (17) | 14 (82.4) | ||||
| 2 (42) | 26 (61.9) | −1.789 | 0.884 | 0.043 | 0.167 (0.030–0.945) |
| 3 (23) | 7 (30.4) | −3.615 | 1.080 | 0.001 | 0.027 (0.003–0.224) |
| 4 (7) | 2 (28.8) | −4.559 | 1.428 | 0.001 | 0.010 (0.001–0.172) |
| pT stageb | 0.123 | ||||
| T1 (54) | 31 (57.4) | ||||
| T2 (9) | 4 (44.4) | −1.350 | 0.878 | 0.124 | 0.259 (0.046–1.449) |
| T3 (23) | 12 (52.2) | 1.296 | 0.745 | 0.082 | 3.655 (0.848–15.754) |
| T4 (3) | 2 (62.7) | 22.420 | 15921.320 | 0.999 | 5.459E9 (0.000) |
| Pulmonary metastasis | 1.904 | 0.842 | 0.024* | 6.711 (1.289–34.929) | |
| No (76) | 39 (51.3) | ||||
| Yes (13) | 10 (76.9) | ||||
| Lymphatic metastasis | −21.410 | 15921.320 | 0.999 | 0.000 (0.000) | |
| No (80) | 47 (58.8) | ||||
| Yes (9) | 2 (22.2) | ||||
| Constant | 7.174 | 3980.330 | 0.999 | 1304.430 |
| PDB ID | Ligand | Proc. Snap. (%) | TOP10 (%) | TOP20 (%) | TOP30 (%) | TOP100 (%) | TOP200 (%) |
| 1P44 | GEQ | 48.92 | 100.00 | 95.00 | 93.00 | 86.00 | 86.00 |
| 2B35 | TCL | 50.67 | 80.00 | 55.00 | 60.00 | 75.00 | 80.00 |
| 2B36 | 5PP | 50.97 | 60.00 | 70.00 | 66.00 | 67.00 | 73.00 |
| 2B37 | 8PS | 49.72 | 60.00 | 60.00 | 60.00 | 78.00 | 79.50 |
| 2H7I | 566 | 52.33 | 80.00 | 90.00 | 83.00 | 79.00 | 78.00 |
| 2H7L | 665 | 50.62 | 100.00 | 100.00 | 100.00 | 98.00 | 98.00 |
| 2H7M | 641 | 47.75 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| 2H7N | 744 | 50.65 | 100.00 | 100.00 | 100.00 | 97.00 | 97.00 |
| 2H7P | 468 | 49.84 | 90.00 | 95.00 | 83.00 | 82.00 | 82.00 |
| 3FNE | 8PC | 52.46 | 90.00 | 90.00 | 93.00 | 90.00 | 88.00 |
| 3FNH | JPJ | 47.89 | 100.00 | 100.00 | 100.00 | 96.00 | 93.00 |
| 2NSD | 4PI | 53.61 | 100.00 | 95.00 | 96.00 | 97.00 | 96.00 |
| Average | - | 50.45 | 88.83 | 87.50 | 86.17 | 87.08 | 87.54 |
| Patients with NTG (n = 24) | Controls (n = 24) | |
| Age (years) | 66.7 ± 10.2 | 67.2 ± 11.6 |
| Male | 9 (37.5%) | 9 (37.5%) |
| Female | 15 (62.5%) | 15 (62.5%) |
| Smoking | 13 (54.2%) | 11 (45.8%) |
| Body-mass index (kg/m2) | 26.8 ± 2.3 | 25.9 ± 2.4 |
| Neck circumference (cm) | 34.61 ± 2.43 | 33.26 ± 3.78 |
| Carriers of the class S allele | Non-carriers of the class S allele | |||||
| Arsenic exposure, μg/L | Controls n (%) | Patients n (%) | Multivariate-adjusted OR (95% CI) | Controls n (%) | Patients n (%) | Multivariate-adjusted OR (95% CI) |
| Lanyang cohorta | ||||||
| ≤ 10 | 13 (6.8) | 7 (3.9) | 1.0 (referent) | 5 (7.7) | 2 (2.8) | 1.0 (referent) |
| 10.1-50 | 7 (3.7) | 5 (2.8) | 1.57 (0.33-7.38) | 3 (4.6) | 4 (5.6) | 8.64 (0.70-106.82) |
| 50.1-100 | 66 (34.6) | 64 (36.0) | 2.90 (1.02-8.27)* | 21 (32.3) | 24 (33.3) | 4.04 (0.64-25.76) |
| 100.1-300 | 60 (31.4) | 61 (34.3) | 2.90 (1.00-8.35)* | 19 (29.2) | 20 (27.8) | 4.47 (0.69-29.19) |
| > 300 | 45 (23.6) | 41 (23.0) | 2.39 (0.81-7.05) | 17 (26.2) | 22 (30.6) | 3.97 (0.62-25.57) |
| Trend test | 1.12 (0.91-1.38) | 1.13 (0.81-1.57) | ||||
| LMN cohortb | ||||||
| ≤ 300 | 39 (32.8) | 10 (12.4) | 1.0 (referent) | 13 (28.9) | 2 (5.6) | 1.0 (referent) |
| 300-750 | 43 (36.1) | 36 (44.4) | 2.04 (0.75-5.57) | 22 (48.9) | 20 (55.6) | 1.13 (0.16-7.95) |
| > 750 | 37 (31.1) | 35 (43.2) | 2.20 (0.79-6.10) | 10 (22.2) | 14 (38.9) | 4.65 (0.66-32.94) |
| Trend test | 1.39 (0.86-2.25) | 2.65 (1.03-6.82)* |
| Outcome | Model A | Model B | Model C |
| BMI z-score increment | |||
| LMW metabolites | 0.07 (0.02, 0.13)* | 0.03 (–0.03, 0.09) | 0.03 (–0.03, 0.09) |
| HMW metabolites | –0.003 (–0.05, 0.05) | –0.01 (–0.06, 0.04) | –0.01 (–0.06, 0.04) |
| DEHP metabolites | –0.01 (–0.06, 0.04) | –0.02 (–0.07, 0.03) | –0.01 (–0.06, 0.03) |
| Overweight OR | |||
| LMW metabolites | 1.08 (0.97, 1.19) | 1.01 (0.90, 1.14) | 1.01 (0.90, 1.13) |
| HMW metabolites | 0.97 (0.86, 1.10) | 0.96 (0.85, 1.08) | 0.96 (0.86, 1.09) |
| DEHP metabolites | 0.95 (0.84, 1.08) | 0.95 (0.84, 1.06) | 0.95 (0.85, 1.07) |
| Obesity OR | |||
| LMW metabolites | 1.12 (0.99, 1.25) | 1.02 (0.89, 1.16) | 1.02 (0.90, 1.17) |
| HMW metabolites | 1.02 (0.89, 1.17) | 1.03 (0.88, 1.20) | 1.04 (0.89, 1.22) |
| DEHP metabolites | 1.01 (0.88, 1.16) | 1.02 (0.88, 1.19) | 1.04 (0.89, 1.20) |
| Model A adjusts only for urinary creatinine; model B alsoincludes sex, poverty–income ratio, parental education, serum cotinine,age, and race/ethnicity category; model C includes model B covariatesplus caloric intake and television watching. All associations are withthe natural log of the phthalate metabolite concentration. Resultsrepresent increase in odds of BMI z-score per unit log increase inphthalate metabolite. *p < 0.05. |
| RT-PCR negative | RT-PCR positive | p-valuea | Single ARI | Multiple ARI | p-value | |
| DSS, mean | 8.83 | 13.83 | 0.000 | 13.57 | 14.51 | 0.243 |
| Fever n/total (%) | 37/103 (35.9) | 243/457 (53.2) | 0.002 | 173/331 (52.3) | 70/126 (55.6) | 0.529 |
| Admission n/total, (%) | 74/103 (71.8) | 342/457 (74.8) | 0.530 | 252/331 (76.1) | 90/126 (71.4) | 0.300 |
| LOS (days) | 2.99 | 3.95 | 0.003 | 4.02 | 3.76 | 0.432 |
| Oxygen supply (days) | 0.85 | 1.98 | 0.000 | 1.99 | 1.96 | 0.912 |
| Nebulizer therapy (days) | 1.03 | 1.19 | 0.227 | 1.10 | 1.46 | 0.140 |
| Antibiotics (days) | 1.56 | 2.32 | 0.041 | 2.19 | 2.67 | 0.190 |
| Gene | Exon | Tag-seq | ||||
| Log2 FC | Adj. P-val. | MDL | Log2 FC | Adj. P-val. | MDL | |
| TCL1A | 6.976 | <0.001 | 4.5% | 10.069 | <0.001 | 1.9% |
| HLA-DRA | 6.135 | <0.001 | 12.6% | 9.541 | <0.001 | 4.0% |
| CD74 | 5.891 | 0.001 | 5.0% | 10.077 | <0.001 | 2.0% |
| C13orf18 | 6.801 | <0.001 | 6.1% | 7.401 | 0.008 | 7.9% |
| ARHGDIB | 6.188 | <0.001 | 9.7% | 7.349 | 0.008 | 15.4% |
| CKB | −5.573 | 0.002 | NA | −9.526 | <0.001 | NA |
| LCP1 | 7.108 | <0.001 | 7.4% | 6.087 | 0.029 | 27.4% |
| CD52 | 5.63 | 0.002 | 9.1% | 7.209 | 0.010 | 16.9% |
| FHL1 | −5.736 | 0.001 | NA | −6.229 | 0.028 | NA |
| UCHL1 | −5.212 | 0.006 | NA | −7.714 | 0.005 | NA |
| APBB1IP | 5.408 | 0.003 | 18.4% | 6.267 | 0.028 | 25.5% |
| GLUL | −5.323 | 0.004 | NA | −6.592 | 0.012 | NA |
| CD79A | 6.132 | <0.001 | 4.8% | 5.858 | 0.033 | 33.1% |
| GCET2 | 5.347 | 0.004 | 14.8% | 6.129 | 0.029 | 45.2% |
| CD79B | 4.682 | 0.020 | 7.3% | 8.077 | 0.003 | 7.7% |
| ELF1 | 5.07 | 0.008 | 6.9% | 6.977 | 0.012 | 12.7% |
| CPNE3 | −5.036 | 0.009 | NA | −6.304 | 0.028 | NA |
| CD53 | 6.122 | <0.001 | 9.0% | 5.392 | 0.049 | 47.4% |
| AMOT | −5.189 | 0.006 | NA | −6.044 | 0.029 | NA |
| ST6GAL1 | 5.254 | 0.005 | 5.8% | 5.858 | 0.028 | 18.8% |
| ETS1 | 5.299 | 0.005 | 18.8% | 5.781 | 0.036 | 26.6% |
| CNN3 | −4.618 | 0.023 | NA | −6.066 | 0.029 | NA |
| MS4A1 | 4.435 | 0.037 | 13.9% | 5.977 | 0.029 | 37.9% |
| MYB | 5.117 | 0.007 | 14.5% | 5.392 | 0.049 | 31.8% |
| APP | −4.419 | 0.039 | NA | −5.858 | 0.033 | NA |
| PTPRC | 4.799 | 0.015 | 66.4% | 5.392 | 0.049 | 67.7% |
| BANK1 | 4.677 | 0.020 | 35.5% | 5.426 | 0.049 | 42.6% |
| ACSL5 | 4.685 | 0.020 | 29.3% | 5.392 | 0.049 | 64.8% |
| BCL6 | 4.366 | 0.044 | 21.2% | 5.524 | 0.046 | 50.2% |
| EBF1 | 4.34 | 0.046 | 15.1% | 5.392 | 0.049 | 77.7% |
| Features for Event Detection | Results | Ref |
| Spatio-temporal of Markov Random Field (MRF) for motion vectors and object tracking | Overall success rate is 94.6% for horizontal and vertical traffic | [110] |
| Discrete Cosine Transform (DCT) coefficient feature vector with traffic detections using Gaussian mixture HMM | HMM classifier correctly detected 91% to 94% under different illumination situations | [107] |
| Spatio-temporal motion trajectories using MRF | Able to detect accidents at a very high recall rate, which is more than 90% | [114] |
| Blob tracker using Kalman filter | Results reported that the percentage of falsely classified vehicle modes was about 3% | [100] |
| Extracted features: shape, position, motion and track object using Kalman filter | Correctly classify five types of vehicle behavior and pedestrians with 86% to 96% accuracy | [105] |
| Motion trajectories and hierarchical clustering | Half total error rate (HTER) = 11% and area under the curve (AUC) > 0.8 | [109] |
| Motion trajectories; velocities of motion vector | The accuracy increases up to 95%, tested on two video clips (277 frame sequences) | [116] |
| Target trajectories with context free grammar (CFG) representations | Results reported using (1) stochastic CFG, TP = 86%, TN = 14%; (2) HMM, TP = 55%, TN = 45% | [117] |
| Optical flow and K-means clustering | Only visual sample results; no empirical analysis | [102] |
| Local motion patterns to initialize the Gaussian mixture model (GMM) | Accuracy of detection measured = 83.23%, and the error rate is 16.77% | [113] |
| Motion trajectories and C-means clustering | Results reported that the false rejection rate (FRR) = 6%, and the false acceptance rate (FAR) = 8.3% | [111] |
| Track target trajectories and learn rules using grammar representations | The accuracy increased from 73% to 98.6% when tested on five traffic sub-events with different parsing parameters, θ and ω | [94] |
| Lane tracking using particle swarm optimization (PSO) particle filters (PF) | Results indicated that particle filter output is smoother than the PSO-PF algorithm | [103] |
| The pair of parameters | R Spearman | p |
| Number of metastases & WBC | 0.795611 | 0.000000 |
| Number of metastases & LYM | 0.785315 | 0.000000 |
| Number of metastases & MON | 0.788080 | 0.000000 |
| Number of metastases & GRA | 0.755175 | 0.000001 |
| Number of metastases & MCV | 0.632756 | 0.000102 |
| Number of metastases & MCH | 0.515611 | 0.002525 |
| Cell Category | All Features (k = 5) | P-Fuzzy (k = 4) | Q-Fuzzy (k = 4) | ||||||
| Precision | Recall | F1 Score | Precision | Recall | F1 Score | Precision | Recall | F1 Score | |
| Normal superficial | 0.83 | 0.86 | 0.84 | 0.95 | 0.91 | 0.93 | 0.95 | 0.95 | 0.95 |
| Normal intermediate | 0.82 | 0.74 | 0.78 | 0.89 | 0.84 | 0.86 | 0.89 | 0.89 | 0.89 |
| Normal columnar | 0.63 | 0.67 | 0.65 | 0.65 | 0.72 | 0.68 | 0.61 | 0.74 | 0.67 |
| Carcinoma in situ | 0.74 | 0.83 | 0.78 | 0.81 | 0.87 | 0.84 | 0.84 | 0.90 | 0.87 |
| Light dysplastic | 0.83 | 0.78 | 0.81 | 0.88 | 0.94 | 0.91 | 0.89 | 0.97 | 0.93 |
| Moderate dysplastic | 0.69 | 0.85 | 0.76 | 0.83 | 0.96 | 0.89 | 0.89 | 0.96 | 0.93 |
| Severe dysplastic | 0.79 | 0.62 | 0.70 | 0.86 | 0.65 | 0.74 | 0.88 | 0.61 | 0.72 |
| Branch | Free-ratio | 2-ratio | |||
| dN/dS | Bootstrap | dN/dS | 2ΔL | P | |
| A | 0.024 | 91 | 0.021 | 3.167 | 0.0751 |
| B | 0.057 | 80 | 0.056 | 1.064 | 0.3024 |
| C | 0.080 | 96 | 0.049 | 1.550 | 0.2131 |
| D | 0.129 | 68 | 0.023 | 2.224 | 0.1359 |
| E | 0.365 | 61 | 0.002 | 1.746 | 0.1864 |
| F | 0.049 | 100 | 0.051 | 0.726 | 0.3942 |
| G | 0.013 | 100 | < 0.001 | 7.951 | 0.0048# |
| H | 0.022 | 100 | 0.018 | 3.961 | 0.0466 |
| I | 0.085 | 73 | 0.019 | 0.342 | 0.5588 |
| J | 0.853 | 41 | > 999 | 11.627 | 0.0006**,## |
| K | 0.094 | 100 | 0.116 | 0.087 | 0.7680 |
| L | 0.131 | 100 | 0.141 | 0.399 | 0.5278 |
| M | 0.112 | 100 | 0.172 | 0.412 | 0.5212 |
| N | 0.613 | 62 | > 999 | 4.752 | 0.0293 |
| O | > 999 | 97 | > 999 | 6.263 | 0.0123 |
| P | 0.303 | 77 | > 999 | 5.772 | 0.0163 |
| Q | 0.177 | 100 | 0.237 | 2.696 | 0.1006 |
| R | 0.017 | 99 | 0.027 | 1.360 | 0.2435 |
| S | 0.087 | 100 | 0.077 | 0.146 | 0.7022 |
| T | 0.173 | 97 | 0.180 | 0.280 | 0.5964 |
| U | 0.177 | 90 | 0.214 | 0.447 | 0.5039 |
| V | 0.029 | 100 | 0.029 | 3.183 | 0.0744 |
| W | 0.171 | 85 | 0.073 | 0.100 | 0.7524 |
| X | 3.860 | 59 | > 999 | 3.589 | 0.0582 |
| Y | 0.740 | 58 | > 999 | 8.385 | 0.0038# |
| Z | 2.148 | 47 | 17.722 | 1.898 | 0.1683 |
| AA | 0.016 | 93 | 0.027 | 0.665 | 0.4148 |
| AB | 0.451 | 54 | 8.852 | 1.815 | 0.1779 |
| AC | 0.072 | 98 | 0.137 | 0.050 | 0.8228 |
| AD | 0.074 | 100 | 0.056 | 0.836 | 0.3605 |
| AE | 0.027 | 100 | 0.025 | 2.859 | 0.0909 |
| AF | 0.091 | 95 | 0.102 | 0.000 | 0.9929 |
| AG | 0.073 | 100 | 0.106 | 0.005 | 0.9447 |
| AH | 0.046 | 100 | 0.055 | 1.221 | 0.2691 |
| AI | 0.039 | 100 | 0.024 | 2.779 | 0.0955 |
| AJ | < 0.001 | 99 | < 0.001 | 10.084 | 0.0015*,## |
| AK | 0.236 | 95 | 0.287 | 1.944 | 0.1632 |
| AL | > 999 | 90 | > 999 | 4.708 | 0.0300 |
| AM | 0.366 | 70 | 0.581 | 2.098 | 0.1475 |
| AN | 0.266 | 94 | 0.361 | 3.621 | 0.0570 |
| AO | 0.382 | 71 | 0.982 | 1.682 | 0.1947 |
| AP | 0.188 | 81 | 0.080 | 0.241 | 0.6235 |
| AQ | 0.713 | 53 | > 999 | 3.275 | 0.0703 |
| Characteristics | Private health facilities | Public health facilities | p value |
| Frequency (%) | Frequency (%) | ||
| Location | |||
| Urban | 194/241 (81) | 25/52 (48) | <0.01* |
| Rural | 47/241 (19) | 27/52 (52) | 0.02* |
| Level of facility | |||
| Health centre II | 31/52 (59.6) | ||
| Health centre III | – | 16/52 (30.8) | – |
| Health centre IV | 3/52 (5.8) | ||
| Hospital | 2/52 (3.8) | ||
| Type of facility | Ownership | ||
| Drug shop | 170/241 (71) | Government 39/52 (75) | |
| Private clinic | 59/241 (24) | Private for profit 6/52 (12) | – |
| Pharmacy | 12/241 (5) | Private not for profit 7/52 (13) | |
| Drug shop/private clinic registered | – | ||
| Yes | 191/241 (79) | – | |
| No | 50/241 (21) | ||
| Days when facility is open | |||
| Monday to friday | 241/241 (100) | 53/53 (100) | – |
| Saturdays | 232/241 (96) | 49/53 (92.4) | |
| Sundays | 191/241 (79) | 39/53 (74) | |
| Number of Children with fever seen on atypical day | Median 4 (IQR 3) | Median 8 (IQR 6) | |
| Children with cough seen on atypical day | Median 5 (IQR 7) | Median 10 (IQR 11) | |
| Children with diarrhoea seen on atypical day | Median 2 (IQR 2) | Median 3 (IQR 3) | |
| Patients’ register present | |||
| Yes | 93/241 (39) | 53/53 (100) | <0.01* |
| No | 148/241 (61) | – |
| OS | PFS | LRRFS | ||||
| Overall, mo (95% CI) | 1-year, % | Overall, mo (95% CI) | 1-year, % | Overall, mo (95% CI) | 1-year, % | |
| TRT | 17.7 (14.1-18.8) | 57.9 | 9.8 (8.4–11.3) | 45.9 | 16.2 (13.5–24.9) | 72.6 |
| Non-TRT | 11.3 (9.8–12.7) | 27.3 | 6.3 (5.0–7.0) | 9.3 | 6.3 (5.6–7.0) | 10.2 |
| P | <0.001 | – | <0.001 | – | <0.001 | – |
| ERT | 16.4 (13.4–18.4) | 66.2 | 8.0 (7.0–9.0) | 34.2 | 25.3 (21.5–27.9) | 69.8 |
| LRT | 14.5 (12.2–17.0) | 60.5 | 11.7 (9.1–13.4) | 44.1 | 19.2 (13.1–23.1) | 63.8 |
| P | 0.272 | – | 0.226 | – | 0.498 | – |
| Outcome | LMWH (D or E) vs. Control | SE | P-Value | Impact on Risk |
| Both drugs vs. placebo | 0.50 (0.40 - 0.61) | <0.001 | ↓by 50% | |
| RR difference between drugs (E vs. D) | 0.23 (i.e. 12%) | 0.25 | 0.36 | NS |
| European trial | 0.33 | 0.49 | 0.50 | NS |
| Global trial | 0.20 | 0.58 | 0.73 | NS |
| LMWH dosing1 | -0.09 | 0.53 | 0.87 | NS |
| LMWH treatment duration2 | -0.21 | 0.31 | 0.51 | NS |
| Year of publication | 0.04 | 0.04 | 0.34 | NS |
| Both drugs vs. placebo | 1.19(0.39 - 3.55) | 0.76 | NS | |
| Risk difference between Drugs (E vs. D) | -0.94 | 1.25 | 0.45 | NS |
| Both drugs vs. placebo | 1.13 (0.36 - 3.53) | 0.83 | NS | |
| RR difference between Drugs (E vs. D) | -0.85 | 2.0 | 0.48 | NS |
| Both drugs vs. placebo | 0.72 (0.22-2.34) | 0.59 | NS | |
| RR difference between Drugs (E vs. D) | 0.22 | 1.28 | 0.86 | NS |
| Both drugs vs. UH | 0.83 (0.66-1.05) | 0.12 | NS | |
| RR difference between drugs (E vs. D) | -0.24 (i.e. - 22%) | 0.61 | 0.66 | NS |
| Both drugs vs. UH | 0.70 (0.35-1.38) | 0.30 | NS | |
| RR difference between Drugs (E vs. D) | NA | |||
| Both drugs vs. UH | 0.61 (0.21-1.77) | 0.36 | NS | |
| RR difference between Drugs (E vs. D) | 0.56 | 1.53 | 0.71 | NS |
| Both drugs vs. UH | 0.59 (0.12-3.1) | 0.53 | NS | |
| RR difference between Drugs (E vs. D) | NA |
| Quality indicators of colonoscopy | Patients included in primary analysis1 | Patients included in secondary analysis2 | Recommended | Provincial endoscopist performance, 2015 |
| Cecal intubation rate, % | 98 | 97 | ≥ 95 | 97 - 99 |
| PR, screening, men % | 36 | 45 | - | 34 - 50 |
| PR, screening, women % | 34 | 34 | - | 34 - 50 |
| ADR, screening, men, % | 25 | 40 | ≥ 25 | - |
| ADR, screening, women, % | 19 | 30 | ≥ 15 | - |
| Inadequate bowel preparation, % | 7 | 6 | ≤ 10 | 3 - 7 |
| Withdrawal time3 (SD) | 6 (5) | 6 (5) | 6-7 | - |
| Complications | ||||
| Bleeding rate, % | 0.0 | 0.0 | ≤ 0.1 | 0.1 - 0.5 |
| Bowel perforation rate, % | 0.0 | 0.0 | ≤ 0.1 | 0.1 - 0.8 |
| Other rate, % | 0.0 | 0.0 | - | - |
| Risk Factor | Wald χ2 | P | OR | 95% C.I |
| BMI | 30.73 | <0.01 | 0.80 | 0.74-0.87 |
| C602A | 5.69 | <0.01 | 7.58 | 1.53-11.97 |
| T1559C | 6.12 | <0.05 | 6.77 | 1.07-1.83 |
| Height | 9.51 | <0.01 | 1.07 | 1.02-1.11 |
| Weight | 27.93 | <0.01 | 0.92 | 0.90-0.95 |
| Respondent profile (%) | Child profile (%) | ||
| Relationship to child | Sex | ||
| Mother | 67.3 | Male | 53.8 |
| Father | 15.7 | Female | 46.2 |
| Grandmother | 15.7 | Age group (years) | |
| Grandfather | 1.2 | 1-2 | 32.7 |
| Occupation | 3-5 | 32.9 | |
| PMEB | 28.7 | 6-10 | 34.4 |
| Other white collar | 19.7 | Race | |
| Blue collar | 7.4 | Chinese | 64.4 |
| Housewife | 37.6 | Malay | 16.7 |
| Unemployed | 2.9 | Indian/other | 18.9 |
| Other | 3.7 | ||
| Education | |||
| None | 2.0 | ||
| Primary | 13.3 | ||
| Secondary | 37.3 | ||
| Tertiary (polytechnic) | 19.7 | ||
| Tertiary (university) | 27.8 |
| ZOI (mm)a | MIC (μg/mL) | MBC (μg/mL) | ||||
| Microorganisms | Eugenol | Isoeugenol | Eugenol | Isoeugenol | Eugenol | Isoeugenol |
| Gram-positive | ||||||
| S. aureus | 12.7 ± 0.6 cB | 20.8 ± 0.6 bA | 625.0 | 312.5 | 625.0 | 312.5 |
| B. subtilis | 15.3 ± 0.7 bcB | 21.3 ± 2.1 bA | 625.0 | 312.5 | 625.0 | 312.5 |
| L. monocytogenes | 22.3 ± 1.4 aB | 26.0 ± 1.5 aA | 625.0 | 312.5 | 625.0 | 312.5 |
| Gram-negative | ||||||
| E. coli | 17.1 ± 1.2 bA | 18.0 ± 1.8 bA | 312.5 | 312.5 | 312.5 | 312.5 |
| S. typhimurium | 20.1 ± 1.0 aA | 21.2 ± 1.2 bA | 625.0 | 312.5 | 625.0 | 312.5 |
| S. dysenteriae | 17.0 ± 1.0 bA | 18.3 ± 1.2 bA | 312.5 | 312.5 | 312.5 | 312.5 |
| Item 1 | Item 2 | Item 3 | Proprioceptive drift | |||||
| Block 1 | Block 2 | Block 1 | Block 2 | Block 1 | Block 2 | Block 1 | Block 2 | |
| Periodic | 1.68 (0.36) | 1.59 (0.39) | 1.86 (0.25) | 2.05 (0.26) | 1.86 (0.27) | 1.81 (0.18) | 1.81 (0.87) | 3.02 (0.79) |
| Non-Periodic | 1.59 (0.35) | 0.95 (0.86) | 2.14 (0.23) | 1.64 (0.31) | 1.95 (0.25) | 1.55 (0.28) | 1.73 (0.81) | 3.41 (0.92) |
| Asynchronous | −0.77 (0.47) | −0.73 (0.49) | −0.82 (0.39) | −0.82 (0.39) | −0.55 (0.45) | −0.5 (0.31) | 0.11 (0.88) | 1.41 (0.51) |
| Promoter | Line name | Replica | Total plant # | Total GUS+ | Total GUS− | %GUS+ |
| pLeExt1 | 3 | 18 | 18 | 0 | 100 | |
| LIG31A-19 | 2 | 11 | 11 | 0 | 100 | |
| LIG26-7 | 2 | 11 | 9 | 2 | 81.82 | |
| pAtCortex | 3 | 13 | 13 | 0 | 100 | |
| CoG29-1 | 2 | 10 | 10 | 0 | 100 | |
| CoG5b-23 | 2 | 10 | 0 | 10 | 0 | |
| pAtE29 | 3 | 15 | 15 | 0 | 100 | |
| 29G7-32 | 2 | 15 | 15 | 0 | 100 | |
| pAtS13 | 3 | 14 | 14 | 0 | 100 | |
| 13G3b-100 | 2 | 11 | 11 | 0 | 100 | |
| pAtS18 | 3 | 19 | 19 | 0 | 100 | |
| XG2C-7 | 2 | 10 | 0 | 10 | 0 | |
| pCaMV35S | 2 | 11 | 11 | 0 | 100 | |
| SG19b-5 | 2 | 10 | 0 | 10 | 0 | |
| Control vector | NEG15B-5 | 3 | 18 | 0 | 18 | 0 |
| Model | Odds ratio | 95% CI | p-value | |
| 1 Sex (male vs female) | 1.9 | 0.9 - 4.2 | 0.10 | |
| Age (yrs) | 1.06 | 1.01 - 1.12 | 0.03 | |
| 2 Sex (male vs female) | 1.8 | 0.8 - 4.1 | 0.13 | |
| Age (yrs) | 1.07 | 1.01 - 1.14 | 0.02 | |
| Prophylaxis (yes/no) | 0.5 | 0.2 - 1.0 | 0.06 | |
| 3 Sex (male vs female) | 4.1 | 1.2 - 14.4 | 0.03 | |
| Age (yrs) | 1.03 | 0.94 - 1.12 | 0.54 | |
| Prophylaxis (yes/no) | 0.3 | 0.1 - 1.1 | 0.07 | |
| LET | 101 | 18 - 583 | <0.0001 | |
| 4 Sex (male vs female) | 3.8 | 1.07 - 13.4 | 0.04 | |
| Age (yrs) | 1.03 | 0.95 - 1.13 | 0.46 | |
| Prophylaxis (yes/no) | 0.3 | 0.1 - 1.1 | 0.07 | |
| LET | 75 | 11 - 495 | <0.0001 | |
| Dipslide | 1.6 | 0.5 - 5.4 | 0.46 |
| Personal | Community–related | Service-related |
| • Age | • Presence of and links to NHCs | • Training |
| • Gender | • Distance between CHW and TBA families | • Experience |
| • Education | • Distances among , CHW and rural health center | • Supervision and support by relevant community and health system structures |
| • Socio-economic status | • Payment or in-kind compensation | |
| • Language | • Motivation | |
| • Tribal affiliation | • Availability of means of transport (e.g. bicycle) | |
| • Religion | • Possession of a cell phone | |
| •Employment | • Availability of various supplies and drugs that the CHW and TBA might need to provide the defined services | |
| • Membership in an association |
| Physiotherapist | Patient | |||||
| Timing of data collection | Before training | At follow-up | ||||
| Measurements | Questionnaire | Questionnaire | Observation video/audio | Assessing patient files | Reflection report | Questionnaire |
| 1a. To what extent is the PSG performed as intended? | ||||||
| Performance and recording of the PSG steps | X | X | ||||
| Patients’ involvement in the PSG | X | |||||
| 1b. How satisfied are patients about the PSG? | ||||||
| Patients’ satisfaction with the PSG | X | |||||
| 1c. What are physiotherapists’ experiences with the PSG? | ||||||
| Physiotherapists’ experiences with the PSG | X | |||||
| 2. Did the physiotherapists’ intention to use the PSG, the actual use of the PSG, and their client-centred competences improve after training? | ||||||
| Intention to use the PSG | X | X | ||||
| Actual use of the PSG | X | X | ||||
| Client-centred competences | X | X |
| Food Group | Factors | B | β | P-value |
| Grain | ||||
| Activity | 0.334 | 0.235 | 0.018 | |
| Tobacco use | −0.866 | −0.168 | 0.090 | |
| Vegetable | ||||
| Age | −0.038 | −0.192 | 0.057 | |
| Diet related chronic disease | −0.353 | 0.164 | 0.033 | |
| Fruit | ||||
| Education level | 0.164 | 0.177 | 0.079 | |
| Diet related chronic disease | −0.326 | −0.173 | 0.085 | |
| Dairy | ||||
| Gender | 0.410 | 0.262 | 0.006 | |
| Rural/urban | −0.257 | −0.180 | 0.059 | |
| Meat/Beans | ||||
| No statistically significant model |
| amales | afemales | b | SD | r2 | p-value | |
| LVEDV (ml) | 77.5 | 67.8 | 1.380 | 0.0426 | 0.98 | <0.00005 |
| LVESV (ml) | 29.7 | 26.1 | 1.370 | 0.0647 | 0.95 | <0.005 |
| LVSV (ml) | 47.4 | 41.7 | 1.394 | 0.0500 | 0.97 | <0.0005 |
| LVCO (ml/min) | 3890 | 3622 | 1.062 | 0.0727 | 0.89 | ns |
| LVM (g) | 53 | 45.2 | 1.304 | 0.0475 | 0.97 | <0.00005 |
| Papillary muscle (g) | 1.9 | 1.6 | 1.451 | 0.0976 | 0.85 | <0.05 |
| RVEDV (ml) | 83.8 | 72.7 | 1.469 | 0.0499 | 0.97 | <0.0001 |
| RVESV (ml) | 35.3 | 30.2 | 1.559 | 0.0737 | 0.95 | <0.005 |
| RVSV (ml) | 48.2 | 42.1 | 1.407 | 0.0524 | 0.97 | <0.0005 |
| RVCO (ml/min) | 3947.3 | 3658.3 | 1.076 | 0.0783 | 0.88 | ns |
| RVM (g) | 16.7 | 14.9 | 1.331 | 0.0605 | 0.95 | <0.01 |
| 95% Confidence Interval | ||||
| Odds Ratio | Low | High | P value | |
| Race/ethnicity | ||||
| White | Reference | |||
| African American | 1.34 | 0.88 | 2.05 | .17 |
| Hispanic | 0.92 | 0.57 | 1.47 | .73 |
| Other | 0.82 | 0.53 | 1.25 | .35 |
| Graduated college | 1.09 | 0.92 | 1.31 | .32 |
| Employed | 0.88 | 0.73 | 1.07 | .21 |
| Prescription coverage | 1.49 | 1.22 | 1.82 | < .001 |
| Income ($25,000 unit) | 1.08 | 1.01 | 1.15 | .04 |
| Out-of-pocket spending on prescriptions as a proportion of income | 2.42 | 1.21 | 4.84 | .01 |
| Cost cutting actions | 0.95 | 0.77 | 1.16 | .60 |
| Ask for generic | 1.06 | 0.90 | 1.24 | .48 |
| Children in home | 0.92 | 0.81 | 1.05 | .21 |
| Marital status | ||||
| Married | reference | reference | reference | |
| Single | 1.49 | 1.02 | 2.20 | .04 |
| Divorced/separated | 1.11 | 0.91 | 1.36 | .31 |
| Widowed | 1.20 | 0.97 | 1.50 | .10 |
| Treatment regimens | Main results | References no. |
| 1. Heatstroke rats received intravenous or intracerebroventricular injection of HUCBCs | MSCs attenuate cerebral ischemic damage by reducing overproduction of TNF‐α, IL‐1β, and IL‐6, but stimulating production of IL‐10. | Chen et al. (2005) Chen et al. (2006) Liu et al. (2009) |
| 2. Heatstroke rats received intravenous injection of HICBC‐derived CD34+ cells | MSCs reduce cerebral ischemic damage by reducing overproduction of both TNF‐α and ICAM‐1, but stimulating production of IL‐10. | Hwang et al. (2008) Chen et al. (2007) Tseng et al. (2014) |
| 3. Heatstroke rats received subcutaneous injection of granulocyte‐colony stimulating factor | The factor attenuates cerebral ischemic damage by reducing overproduction of both TNF‐α and ICAM‐1, but stimulating production of IL‐10, EPSs, GDNF, and VEGF. | Yung et al. (2011) |
| 4. Heatstroke mice received intravenous injection of human dental pulp‐derived stem cells or HUCBCs | MSCs attenuate cerebral ischemic damage by reducing overproduction of TNF‐α, intercellular adhesion molecule 1, and oxidative damage markers, but promoting both hypothalamo–pituitary–adrenocortical axis activity and IL‐10 production. | Tseng et al. (2014) Tseng et al. (2015) |
| Polymer type | Applications | Reference |
| Bio-PE | Plastics bags, milk and water bottles, food packaging films, toys | Vona et al. 1965; Aamer et al. 2008 |
| Bio-PE and blends | Agricultural mulch films | Kasirajan and Ngouajio 2012 |
| EC name | definition | gene name | Microarray available | ORF |
| 4.1.2.13 | Fructose-bisphosphate aldolase | fbaI | x | Ot01g03020 |
| fbaI | x | Ot03g00610 | ||
| fbaII | x | Ot10g01490 | ||
| 3.1.3.11 | Fructose-1,6-bisphosphatase | x | Ot03g00330 | |
| x | Ot14g01140 | |||
| 5.3.1.1 | Triosephosphate isomerase | x | Ot09g00080 | |
| 5.3.1.9 | Glucose-6-phosphate isomerase | x | Ot11g02980 | |
| 5.4.2.2 | phosphoglucomutase | x | Ot15g02630 | |
| 2.7.7.27 | ADP-glucose pyrophosphorylase | AGPLU1 | Ot07g03280 | |
| agpsu1 | x | Ot07g02930 | ||
| agplu2 | Ot20g00490 | |||
| 2.4.1.21 | Soluble Starch synthase | SSIII-C | Ot06g03410 | |
| SSIII-B | x | Ot13g01250 | ||
| SSII | x | Ot16g02790 | ||
| SSI | x | Ot13g01230 | ||
| SSIII-A | x | Ot16g01560 | ||
| 2.4.1.242 | Granul-bound starch synthase | gbssI | x | Ot06g03200 |
| 2.4.1.18 | Starch branching enzyme | SBEII(?) | x | Ot03g00840 |
| SBEI | x | Ot04g04110 | ||
| 2.4.1.1 | starch phosphorylase | Ot11g00280 | ||
| x | Ot04g02110 | |||
| SPho1 | Ot11g01020 | |||
| 2.4.1.25 | disproportionating enzyme | DPE1 | x | Ot02g05750 |
| Ot11g02290 | ||||
| Ot11g02300 | ||||
| 3.2.1.1 | α-amylase | Aamy1 | x | Ot16g00380 |
| x | Ot02g05490 | |||
| Aamy2 | x | Ot10g00260 | ||
| Aamy3 | x | Ot07g02010 | ||
| 3.2.1.2 | β-amylase | x | Ot02g06980 | |
| Bamy2 | x | Ot03g03190 | ||
| bamy1 | Ot03g03170 | |||
| 3.2.1.68 | Isoamylase (debranching enzyme) | dbe1 (Isa1) | x | Ot14g02550 |
| Isa2 | Ot02g07230 | |||
| dbeII (Isa3) | x | Ot12g00310 | ||
| 3.2.1.142 | Pullulanase | spu | x | Ot01g03030 |
| 2.7.9.4 | α-glucan, water dikinase (GWD) | SR1-A | x | Ot13g01510 |
| R1 C | Ot16g02370 | |||
| Ot04g04170 | ||||
| Glucose transporter | Ot03g05590 | |||
| Glucose transporter | Ot14g01870 | |||
| Glucose transporter | Ot08g01260 | |||
| Maltose transporter | MEX1 | x | Ot09g03160 |
| Variable | Males | Females | ||
| F | p < 0.05 | F | p < 0.05 | |
| Right hand | ||||
| FRR1 | 0.349 | 0.706 | 0.658 | 0.519 |
| FRR2 | 0.158 | 0.854 | 1.672 | 0.190 |
| FRR3 | 1.928 | 0.148 | 1.413 | 0.245 |
| FRR4 | 2.258 | 0.107 | 5.845 | * 0.003 |
| FRR5 | 5.926 | * 0.003 | 5.103 | * 0.007 |
| a–b rc R | 16.648 | * 0.000 | 31.573 | * 0.001 |
| b–c rc R | 1.032 | 0.358 | 2.327 | 0.096 |
| c–d rc R | 8.923 | * 0.000 | 11.064 | * 0.001 |
| atd R | 3.378 | * 0.036 | 4.335 | * 0.014 |
| Left hand | ||||
| FRL1 | 0.139 | 0.870 | 0.103 | 0.903 |
| FRL2 | 1.336 | 0.265 | 0.143 | 0.867 |
| FRL3 | 0.198 | 0.821 | 1.930 | 0.147 |
| FRL4 | 2.547 | 0.080 | 3.522 | * 0.031 |
| FRL5 | 1.697 | 0.185 | 1.256 | 0.287 |
| a–b rc L | 21.277 | * 0.000 | 26.045 | * 0.001 |
| b–c rc L | 5.405 | * 0.005 | 4.574 | * 0.011 |
| c–d rc L | 7.666 | * 0.001 | 7.460 | * 0.001 |
| atd L | 7.914 | * 0.000 | 8.487 | * 0.001 |
| Perioperative morbidity (10 days) | Px2 test | ||||
| No | Yes | ||||
| N | % | N | % | ||
| Gender | |||||
| Male | 36 | 59.0 | 25 | 41.0 | 0.752 |
| Female | 11 | 55.0 | 9 | 45.0 | |
| Age (years) , mean (SD) | 79.3(4.0) | 78.9(3.2) | 0.650** | ||
| Age (years) | |||||
| <77 | 14 | 60.9 | 9 | 39.1 | 0.895 |
| 77-80 | 17 | 54.8 | 14 | 45.2 | |
| >80 | 16 | 59.3 | 11 | 40.7 | |
| BMI, mean (SD) | 25.6(2.9) | 25.5(3.7) | 0.873** | ||
| Urinary diversion | |||||
| Ileal conduit | 22 | 56.4 | 17 | 43.6 | 0.724* |
| S-pouch | 4 | 80.0 | 1 | 20.0 | |
| Cutaneous ureterostomy | 21 | 56.8 | 16 | 43.2 | |
| pT (TNM system) | |||||
| pTis | 3 | 25.0 | 9 | 75.0 | 0.070 |
| pT1 to pT2b | 17 | 60.7 | 11 | 39.3 | |
| pT3a to pT3b | 18 | 62.1 | 11 | 37.9 | |
| pT4a to pT4b | 9 | 75.0 | 3 | 25.0 | |
| Nodes (TNM system) | |||||
| 0 | 34 | 56.7 | 26 | 43.3 | 0.675 |
| 1-2 | 13 | 61.9 | 8 | 38.1 | |
| Hospital stay, mean (SD) | 13.7(8.4) | 12.1(5.4) | 0.334** | ||
| Charlson score | |||||
| ≤6 | 39 | 56.5 | 30 | 43.5 | 0.511 |
| >6 | 8 | 66.7 | 4 | 33.3 |
| n | % | |
| Disease stage | ||
| Indeterminate | 32 | 64 |
| Advanced (cardiomyopathy) | 13 | 26 |
| No data | 5 | 10 |
| Treatment history* | ||
| Received etiological treatment | 40 | 80 |
| Benznidazole | 19 | 47.5 |
| Nifurtimox | 17 | 42.5 |
| Benznidazole and nifurtimox | 4 | 10 |
| Discontinued treatment (side effects) | 6 | 15 |
| Untreated | 10 | 20 |
| Due to advancement of the disease | 5 | 50 |
| Other (patient declined or unable) | 5 | 50 |
| Race/ethnicity comparisons | |||||
| Treatment type | OverallN = 600% (SE) | WhiteN = 417% (SE) | BlackN = 135% (SE) | HispanicN = 108% (SE) | χ2 (p†) |
| Narcotics/cocaine/alcoholicsAnonymous or any 12 step meeting | 62.64 (2.62) | 60.86 (3.08)a | 79.67 (4.36)a | 54.19 (6.98) | 11.34 (.005) |
| Private physician, psychiatrist, psychologist, social worker, or other professional | 55.07 (2.45) | 57.63 (2.95)a, b | 39.45 (4.93)a | 54.86 (6.19)b | 7.94 (.024) |
| Drug/alcohol rehabilitation program | 51.45 (2.67) | 49.93 (3.07)a | 65.85 (4.45)a | 44.59 (7.55) | 8.45 (.019) |
| Drug/alcohol detoxification ward/clinic | 39.18 (2.74) | 38.33 (2.98) | 48.03 (5.36) | 34.37 (7.33) | 3.56 (.177) |
| Outpatient clinic, including outreach and day/partial patient program | 36.66 (2.47) | 34.36 (2.87)a, b | 54.74 (5.36)a | 31.35 (5.36)b | 10.65 (.007) |
| Inpatient ward of psychiatric/general hospital or community mental health program | 31.02 (2.10) | 28.51 (2.41) | 39.75 (5.16) | 40.26 (7.27) | 5.46 (.072) |
| Emergency room because of medicine/drug use | 23.35 (1.86) | 22.44 (2.14) | 22.01 (4.41) | 32.90 (8.26) | 1.38 (.506) |
| Family services or other social service agency | 21.69 (2.13) | 20.29 (2.49) | 27.07 (5.27) | 26.20 (6.26) | 2.03 (.368) |
| Clergyman, priest, or rabbi because of medicine/drug use | 20.31 (1.89) | 18.27 (2.25) | 32.77 (4.80) | 20.53 (5.54) | 6.15 (.053) |
| Halfway house because of medicine/drug use | 12.56 (1.71) | 11.75 (1.92) | 17.15 (4.60) | 13.10 (4.05) | 1.30 (.526) |
| Other agency or professional | 11.75 (1.51) | 10.06 (1.81) | 20.03 (3.99) | 14.68 (3.79) | 5.16 (.084) |
| Employment assistance program (EAP) | 9.49 (1.47) | 9.45 (1.80) | 13.95 (3.52) | 3.73 (1.97) | 6.14 (.053) |
| Crisis center because of medicine/drug use | 6.37 (1.46) | 5.82 (1.68) | 11.07 (3.91) | 4.54 (2.02) | 2.05 (.364) |
| Methadone maintenance program | 5.28 (1.10) | 4.40 (1.20) | 8.92 (2.65) | 7.74 (3.46) | 3.47 (.185) |
| Variable | Men N = 52 | Women N = 87 |
| Mean (SD) | Mean (SD) | |
| Duration of arthritis* (years) | 4.8 (2.9) | 5.6 (2.8) |
| Median (IQR) | Median (IQR) | |
| Number of swollen joints | 2.0 (1.0, 8.0) | 5.0 (2.0, 11.0) |
| Number of tender joints | 5.0 (2.0, 8.5) | 6.0 (2.0, 15.0) |
| Number of both swollen and tender joints | 1.0 (0.0, 3.5) | 2.0 (0.0, 5.0) |
| Larsen score1 | 27.5 (13.0,31.0) | 11.0 (1.0, 21.0) |
| HAQ score (0–3) | 0.5 (0.1, 1.1) | 0.8 (0.4, 1.3) |
| % | % | |
| Rheumatoid factor + ve | 39.1 | 33.8 |
| Erosions1 | 75.0 | 56.5 |
| Satisfied ARA RA criteria (4/7 definition) | 22.9 | 45.8 |
| Satisfied ARA RA criteria (tree definition) | 41.7 | 60.2 |
| Steroid use for at least 3 months | 5.8 | 17.2 |
| Small-voxel correct | Small-voxel not correct | p value | |
| Malignant lymph nodes (n = 148) | |||
| Standard-voxel correct | 112 | 1 | < 0.001 |
| Standard-voxel not correct | 20 | 15 | |
| Benign lymph nodes (n = 61) | |||
| Standard-voxel correct | 42 | 12 | 0.04 |
| Standard-voxel not correct | 3 | 4 | |
| All lymph nodes (n = 209) | |||
| Standard-voxel correct | 154 | 13 | 0.13 |
| Standard-voxel not correct | 23 | 19 |
| Health Outcome | Total (N = 460) | Urban Parañaque (N = 250) | Rural Tagum (N = 210) | p-value |
| Ultrasound findings (%) | ||||
| Normal scans | 68.3 | 62.4 | 75.2 | < 0.01 |
| Abnormal scans | 31.7 | 37.6 | 24.8 | |
| Maternal deaths possibly averteda (%) | ||||
| Normal | 93.7 | 91.2 | 96.6 | 0.02 |
| Abnormal placentation | ||||
| Low lying | 2.4 | 2.4 | 2.4 | |
| Placenta previa | 1.3 | 2.0 | 0.5 | |
| Fetal malpresentation | ||||
| Transverse | 2.6 | 4.4 | 0.5 | |
| Neonatal deaths possibly avertedb (%) | ||||
| Normal | 74.6 | 71.2 | 78.6 | 0.02 |
| Fetal malpresentation | ||||
| Breech | 24.1 | 26.8 | 20.9 | |
| Oligohydramnios | 0.2 | 0.0 | 0.5 | |
| Polyhydramnios | 0.4 | 0.8 | 0.0 | |
| Twinsc | 1.3 | 2.4 | 0.0 |
| ShamN = 8 | MIN = 10 | MI-VIN = 9 | MI-VLN = 9 | |
| Heart rate (bpm) | 346 ± 16 | 378 ± 7 | 350 ± 9 | 361 ± 12 |
| LVESP (mmHg) | 117 ± 4 | 109 ± 3 | 108 ± 3 | 109 ± 4 |
| LVEDP (mmHg) | 6.2 ± 0.8 | 9.6 ± 1.6* | 9.8 ± 1.3* | 7.4 ± 0.5 |
| SBP (mmHg) | 115 ± 3 | 111 ± 2 | 110 ± 3 | 113 ± 3 |
| DBP (mmHg) | 87 ± 2 | 86 ± 2 | 85 ± 2 | 84 ± 2 |
| dPdtmax (mmHg/s) | 8744 ± 435 | 7245 ± 436 | 6908 ± 396 | 7952 ± 484 |
| dPdtmin (mmHg/s) | -9363 ± 268 | -6419 ± 466* | -6592 ± 613* | -7077 ± 380* |
| Cumulative no. with a newly detected HPV infection (cumulative%) | |||||
| 6 months | 12 months | 24 months | 36 months | P value for log-rank test | |
| HIV-negative women | |||||
| Total sample: | |||||
| Cryotherapy arm (n = 271) | 15 (5.5) | 21 (7.9) | 25 (9.7) | 28 (11.2) | 0.0004 |
| Control arm (n = 269) | 17 (6.3) | 30 (11.5) | 45 (18.0) | 59 (24.8) | |
| Sexual activity reported during 1 month prior to enrolment or at 1 or 6 months after enrollment: | |||||
| Cryotherapy arm (n = 238)a | 13 (5.5) | 18 (7.7) | 22 (9.7) | 25 (11.3) | 0.002 |
| Control arm (n = 236)b | 16 (6.8) | 27 (11.8) | 42 (19.4) | 56 (27.2) | |
| No sexual activity reported during 1 month prior to enrollment and at 1 and 6 months after enrollment: | |||||
| Cryotherapy arm (n = 31)a | 2 (6.5) | 3 (10.4) | 3 (10.4) | 3 (10.4) | 0.96 |
| Control arm (n = 29)b | 1 (3.5) | 3 (10.3) | 3 (10.3) | 3 (10.3) | |
| HIV-positive women | |||||
| Total sample: | |||||
| Cryotherapy arm (n = 38) | 9 (23.7) | 16 (42.1) | 19 (50.8) | 20 (53.7) | 0.8 |
| Control arm (n = 34)c | 7 (20.6) | 14 (42.8) | 15 (46.6) | 16 (50.5) | |
| Sexual activity reported during 1 month prior to enrollment or at 1 or 6 months after enrollment: | |||||
| Cryotherapy arm (n = 33) | 8 (24.2) | 12 (36.4) | 15 (46.4) | 16 (49.8) | 0.65 |
| Control arm (n = 29)c | 7 (24.1) | 14 (49.4) | 15 (54.0) | 15 (54.0) | |
| No sexual activity reported during 1 month prior to enrollment and at 1 and 6 months after enrollment: | |||||
| Cryotherapy arm (n = 5) | 1 (20.0) | 4 (80.0) | 4 (80.0) | 4 (80.0) | 0.08 |
| Control arm (n = 3) | 0 | 0 | 0 | 0 |
| Incentive | Study design (N) | Year(s) data collection | Relevant outcome measures | Healthcare quality |
| Western New York Physician Incentive Program (WNY-P4P) [16] | Pre-post testExperimental group: patients (n = 624) whose physicians (n = 21) participated in P4P schemeControl group: sample of diabetic patients from health plan | 2002-2003 | • Quality of care based on a composite score which was based on process and outcome measures. | • Average of physician's composite scores increased 48% (baseline to end of project).• 13 out of 21 physicians improved their average composite score enough to earn some level of financial reward.• Of the 8 physicians not receiving reward, 6 improved their composite score. |
| Integrated Healthcare Association Pay-for-performance Program (IHA-P4P) [30] | Cross-sectional analysis of linked 2006 clinical performance scores from IHA-P4P and survey data from the 2nd National Study of Physician Organizations among 108 California physician organizations. | 2006 | • Association between clinical performance and the use of chronic management processes• Association between clinical performance and electronic medical record capabilities• Association between clinical performance and participation in external quality improvement initiatives. | • Physician organizations investing more heavily in care management processes (e.g. patient registries, physician reminders and feedback, patient reminders and education) may achieve better performance scores.• Use of organized quality improvement efforts (e.g. participation in QI program) may be associated with increased delivery of recommended care processes, which in the context of the study translated into better performance on the clinical measures that were rewarded in the P4P scheme. |
| Practice Incentive Program Diabetes Incentive (PIP-DI) [38] | Retrospective study based on dataset from BEACH study (data from 100 consecutive encounters of 1000 GPs that are yearly randomly selected. Each encounter contains data on up to 4 problems treated, drugs prescribed, treatments conducted, referrals written and pathology).N = 12187: | April 2002-March 2007 from | • Percentage of patients that received a glycosylated haemoglobin blood test during GP consult | • PIP-DI increased probability of a HbA1c test being ordered by 20 percentage points.• For patients from Aboriginal and Torres Straight Islander background the increase was more than 35 percentage points. |
| Practice Incentive Program Diabetes Incentive (PIP-DI) [37] | Descriptive study based on semi structured face-to-face interviews (22 GP practices) | 2003 | • Implementation of components of diabetes cycle of care | • Financial incentives may promote better clinical management. GPs claiming incentives were more likely to comply with all requirements than GPs that did not claim incentives. |
| External incentives (including financial incentives). [39] | Cross-sectional study: telephone survey among 1104 physician organizations (PO) with 20 or more physicians | 2000-2001 | • Extent of use of organized CMPs on the basis of summary measure: PO care management index, external incentives (bonus from health plans, public recognition, better contracts with health plans) quality reporting to outside organization (HEDIS data, clinical outcome data, results of quality improvement projects, patient satisfaction data), IT use | • External incentives and clinical IT were most strongly associated with CMP use.• Use of the most strongly associated incentives (public recognition and better contracts for healthcare quality) was associated with use of 1.3 and 0.7 additional CMPs (significant).• Receiving a bonus for scoring well on quality of care measures was not significantly associated with CMP use. |
| Resource | Mean frequency per patient | Price per item (in euro) | |
| 10 Most frequent resource items | |||
| 1 | Tissue obtainment (microbiology and clinical chemistry) | 18.1 | 13.73 |
| 2 | Antibodies against any pathogen by using complement fixation test of haemagglutination inhibition essay | 10.4 | 4.84 |
| 3 | General ward nursing (one day) | 9.4 | 375.00 |
| 4 | Sodium | 8.2 | 1.76 |
| 5 | Potassium | 8.2 | 1.76 |
| 6 | Creatinine | 6.6 | 1.76 |
| 7 | Glucose | 6.4 | 1.76 |
| 8 | Leukocytes | 6.1 | 1.76 |
| 9 | C-reactive protein | 6.0 | 4.84 |
| 10 | Urea | 5.9 | 1.76 |
| 10 Most expensive resource items | |||
| 1 | Intensive care unit nursing (one day) | 0.6 | 1,730.00 |
| 2 | Surgical treatment of thorax empyema | 0.2 | 1,084.75 |
| 3 | Laryngoscopy | 0.0 | 999.00 |
| 4 | Microbiological determination on isolated DNA/RNA | 0.0 | 867.61 |
| 5 | General ward nursing (one day) | 9.4 | 375.00 |
| 6 | Flexible bronchoscopy | 0.2 | 209.25 |
| 7 | DNA/RNA amplification (qualitative) | <0.1 | 208.60 |
| 8 | Computer tomography of thorax | 0.2 | 195.83 |
| 9 | Immunopathologic research | <0.1 | 109.57 |
| 10 | Computer tomography airways | <0.1 | 160.01 |
| Model | Data | Description | Section with model details |
| M1 | Aggregate data only | Aggregates the IPD and includes observational data through random effects on change from baseline 6MWD | 2.1 |
| M2 | Aggregate and IPD | Extends M1 to combine aggregate data and IPD | 2.2 |
| M3 | Aggregate and IPD | Extends M2 to include covariate adjustments on change from baseline 6MWD | 2.3 |
| M4 | Aggregate and IPD | Extends M3 to include interactions between treatment effect and covariates | 2.4 |
| S1 | Aggregate and IPD | Same as M4 but SE in observational studies are inflated by a factor of 10 to downweight their evidence | 3.3 |
| S2 | Aggregate and IPD | Same as M4 but constructed a control arm for observational studies where all patients assumed to deteriorate by 25 m from baseline in 6MWD | 3.4 |
| Vegetarian | Omnivorous | p Value | |
| Overall Energy intake (kJ/day) | 4988 (3531–6387) | 5528 (5021–6428) | 0.15 |
| Protein (g/day) | 42.5 (32.7–59.2) | 71.1 (61.3–77) | 0.0003 |
| Iron intake (g/day)) | 8.1 | 8.4 | 0.56 |
| Carbohydrate (g/day) | 129.1 (106.5–154.4) | 144.6 (133.5–167) | 0.21 |
| Starch (g/day) | 76.5 (47.5–95.1) | 74.0 (54.1–88.0) | 0.78 |
| Sugars (g/day) | 56.0 (44.2–72.1) | 75.3 (64.2–92.3) | 0.02 |
| Dietary fibre (g/day) | 20.9 (13.9–26.7) | 16.5 (13.5–19.6) | 0.13 |
| Glycaemic Index | 51.5 (49.0–52.1) | 49.1 (46.7–52.6) | 0.40 |
| Saturated fatty acids (g/day) | 13.9 (11.3–23.8) | 21.5 (17.4–26.5) | 0.04 |
| Monounsaturated fatty acids (g/day) | 18.0 (10.6–23.8) | 18.9 (16.4–23.5) | 0.53 |
| Polyunsaturated fatty acids (g/day) | 11.6 (9.1–15.8) | 6.5 (5.0–8.6) | 0.006 |
| α-Linoleic acid (g/day) | 0.97 | 0.63 | 0.16 |
| Linoleic acid (g/day) | 10.4 | 5.7 | 0.008 |
| Arachidonic acid (g/day) | 0.02 | 0.05 | 0.05 |
| EPA (g/day) | 0.003 | 0.078 | 0.002 |
| DHA (g/day) | 0.01 | 0.17 | 0.002 |
| Representation of compound | K | Prediction accuracy for each class (%) | |
| Networking triads (SN) | Non-networking triads (SP) | ||
| SMILES | 3 | 92.67 | 92.03 |
| 5 | 89.79 | 92.92 | |
| Graph | 3 | 95.34 | 99.48 |
| 5 | 94.18 | 99.48 |
| SA1 | SA2 | SA3 | SA4 | |
| Erel (eV) | 0.00 | 0.17 | 0.52 | 0.53 |
| Eads (eV) | 2.64 | 2.47 | 2.12 | 2.11 |
| Step edge | ||||
| Ṡ̇̇Au (Å) | 3.12 (× 2) | 2.54 | ||
| –CṄ̇̇Au (Å) | 2.18 | 2.56 | 2.31 | 2.34 |
| Terrace | ||||
| Ṡ̇̇Au (Å) | 3.34 | 3.33 | 3.61 | 3.69 |
| –CṄ̇̇Au (Å) | 3.17 | 2.36 | 2.68 | 3.14 |
| Parameters | Group A† | Group B† | Total† |
| Ht | 40.69 ± 0.80 | 41.27 ± 0.65 | 40.98 ± 0.51 |
| WBC | 8,821.00 ± 498.54 | 8,170.00 ± 400.25 | 8,501.02 ± 320.98 |
| PLT | 260,200 ± 15,850 | 302,414 ± 24,537 | 280,949 ± 14,643 |
| PT | 13.39 ± 0.41 | 12.57 ± 0.24 | 12.99 ± 0.25 |
| PTT | 33.8 ± 0.90 | 33.83 ± 1.25 | 33.6 ± 0.76 |
| INR | 1.06 ± 0.04 | 1.01 ± 0.02 | 1.04 ± 0.02 |
| Fibrinogen | 496.97 ± 24.63 | 471.28 ± 26.55 | 484.34 ± 18.01 |
| D-dimers | 0.84 ± 0.18 | 0.84 ± 0.21 | 0.84 ± 0.14 |
| Urea | 38.13 ± 2.15 | 37.76 ± 3.03 | 37.95 ± 1.83 |
| Crea | 0.94 ± 0.04 | 0.98 ± 0.05 | 0.96 ± 0.03 |
| SGOT | 21.13 ± 1.60 | 27.52 ± 3.05 | 24.27 ± 1.74 |
| SGPT | 29.33 ± 8.22 | 37.93 ± 6.84 | 33.56 ± 5.35 |
| Total Protein | 7.27 ± 0.10 | 7.36 ± 0.14 | 7.31 ± 0.08 |
| Albumin | 4.00 ± 0.10 | 4.16 ± 0.13 | 4.07 ± 0.8 |
| Total Bil | 0.61 ± 0.09 | 0.63 ± 0.06 | 0.62 ± 0.05 |
| Direct Bil | 0.11 ± 0.02 | 0.12 ± 0.01 | 0.11 ± 0.01 |
| Category | Example | Concept | Global theme |
| Locus of control | Improve mental health | Additive | Resilience |
| Removing negative friendships | Subtractive | ||
| Autonomy | Internal | ||
| Success of peers | External | ||
| Increase physical activity | Additive | Self-management | |
| Eating out less | Subtractive | ||
| Goal setting | Internal | ||
| Access to gym | External |
| QLQ-C30 | QLQ-BR23 | |||
| Then-test | Post-test | Then-test | Post-test | |
| Baseline | 359 (94.2%) | 357 (93.7%) | ||
| After surgery | 347 (91.1%) | 347 (91.1%) | 347 (91.1%) | 346 (90.8%) |
| 3 months | 339 (90.0%) | 342 (89.8%) | 355 (87.9%) | 340 (89.2%) |
| 6 months | 314 (82.4%) | 322 (84.5%) | 313 (82.1%) | 322 (84.5%) |
| Reactor Type | Anodic Supporting Materials | Cathode Materials | Power Density (mW m−2) | Comparision to Pt/C or Bare Materials | Ref. |
| 250 mL double chambers | Graphite granule | Pt/C | 1470 ± 10 | - | [35] |
| 250mL double chambers | Graphite granule | Co3O4/N doped graphene | 1340 ± 10 | Comparable to Pt/C | [35] |
| 6 mL single chamber | Carbon paper | Co/Fe/N/CNTs | 751 | 1.5 times > Pt/C | [36] |
| 80 mL double chamber | Carbon fiber | N-doped CNTs on C cloth | 1600 ± 50 | 12.8% > Pt/C | [37] |
| Single chamber | Carbon felts | Fe–N-functionalized graphene | 1149.8 | 2.1 times > Pt/C | [38] |
| Single chamber | Carbon cloth | Graphene supported Pt–Co | 1378 | Comparable to Pt/C | [39] |
| Sediment MFCs | Graphite felt | Polyaniline-Graphene nanosheets | 99 | 116 times > Graphite | [40] |
| Double chamber | - | N/S co-doped carbon nanosheets | 1500 | Comparable to Pt/C | [41] |
| 15 mL sediment single chamber | MWNT coating Graphite | MWNT coating Graphite | 214.7 ± 9.9 | 1.6 times higher than that of bare graphite | [42] |
| Single chamber | Carbon cloth | Graphene/poly(3,4-ethylenedioxythiophene)/Fe3O4 | 3525 | 8.2 times > Carbon cloth | [43] |
| Double chamber | Carbon brush | N-doped Graphene/CoNi alloy encased within bamboo-like CNTs | 2000 | Comparable to Pt/C | [44] |
| 210 mL double chamber | Carbon paper | CNTs/Polypyrrole | 113.5 | Comparable to Pt/C | [45] |
| Single chamber | Graphite fiber brush | Ag/Fe/N/C | 1791 | 1.5 times > Pt/C | [46] |
| 20 mL single chamber | N-Ni-carbon nanofibers | N-doped polymer-Ni–carbon nanofibers | 1690 ± 30 | - | [47] |
| 1.5 L single chamber | Carbon fiber | Co-doped Carbon nanofibers | 92 | Stable more than 6000 h | [48] |
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | ||
| Pumps | M | 36.86 | 36.15 | 35.68 | 36.72 | 35.77 | 36.66 | 38.94 | 36.95 |
| SD | 14.95 | 8.80 | 5.59 | 6.36 | 5.37 | 4.22 | 7.25 | 3.28 | |
| Total of pumps | M | 1105.88 | 1082.88 | 1070.25 | 1101.50 | 1073.13 | 1099.81 | 1168.31 | 1108.56 |
| SD | 448.60 | 266.08 | 167.83 | 190.78 | 161.24 | 126.74 | 217.46 | 98.30 | |
| Adjusted pumps | M | 43.49 | 42.46 | 43.39 | 43.39 | 42.12 | 42.04 | 44.53 | 43.09 |
| SD | 21.29 | 13.96 | 10.14 | 8.23 | 8.61 | 4.04 | 7.06 | 5.65 | |
| Total of adjusted pumps | M | 763.81 | 825.25 | 821.19 | 860.06 | 823.44 | 859.94 | 824.13 | 842.38 |
| SD | 183.96 | 121.06 | 100.71 | 138.70 | 94.21 | 106.56 | 199.06 | 101.34 | |
| Win trials | M | 20.25 | 20.63 | 19.50 | 20.25 | 20.19 | 20.50 | 18.56 | 19.75 |
| SD | 5.98 | 4.27 | 2.99 | 3.79 | 3.73 | 2.07 | 3.92 | 2.65 | |
| Loss trials | M | 9.75 | 9.38 | 10.50 | 9.75 | 9.81 | 9.50 | 11.44 | 10.25 |
| SD | 5.98 | 4.27 | 2.99 | 3.79 | 3.73 | 2.07 | 3.92 | 2.65 | |
| Total earning | M | 20.60 | 27.71 | 28.16 | 30.40 | 28.17 | 30.45 | 23.64 | 28.33 |
| SD | 16.90 | 10.91 | 5.46 | 9.99 | 7.32 | 7.58 | 23.35 | 8.38 | |
| Adjusted pumps following a win | M | 43.77 | 42.10 | 44.38 | 41.77 | 42.71 | 42.74 | 43.00 | 44.57 |
| SD | 22.59 | 12.67 | 10.60 | 7.77 | 8.22 | 3.93 | 13.62 | 7.13 | |
| Adjusted pumps following a loss | M | 45.14 | 43.00 | 41.90 | 44.86 | 42.03 | 41.83 | 45.42 | 40.78 |
| SD | 20.48 | 14.81 | 12.03 | 10.18 | 12.02 | 7.51 | 11.51 | 7.00 | |
| Reaction time (ms) | M | 287.57 | 218.84 | 205.47 | 185.03 | 197.53 | 156.00 | 177.29 | 182.28 |
| SD | 169.47 | 134.49 | 131.79 | 106.42 | 118.61 | 53.43 | 51.77 | 77.43 |
| NaCl (n = 12) | TCA (n = 9) | p | ||
| direct treatment response | no response | 8 | 2 | |
| partial response, not satisfactory | 1 | 0 | ||
| partial response, satisfactory | 2 | 1 | ||
| complete resolution of symptoms | 1 | 6 | ||
| 0.015* | ||||
| mean severity of pain in the past week (95% CI) | 4.3 (2.3-6.3) | 1.3 (0.3-2.9) | ||
| mean rank | 13.1 | 7.4 | 0.031§ | |
| mean Dutch AIMS-2-HFF (95% CI) | 2.7 (1.9-3.6) | 1.9 (0.7-3.2) | ||
| mean rank | 12.4 | 8.2 | 0.112§ | |
| patient perceived improvement | much worse | 0 | 0 | |
| worse | 2 | 0 | ||
| not better not worse | 6 | 2 | ||
| better | 1 | 1 | ||
| much better | 3 | 6 | ||
| 0.047* |
| Feature combination | S1 | S2 | S3 | S4 | S5 | S6 | S7 |
| Mean & slope | 95.6 | 97.4 | 94.9 | 97.1 | 96.6 | 96.0 | 95.6 |
| Mean & peak | 96.9 | 98.5 | 98.1 | 98.7 | 97.9 | 98.4 | 98.4 |
| Mean & variance | 98.0 | 98.4 | 98.1 | 97.7 | 98.2 | 96.4 | 98.2 |
| Slope & peak | 95.4 | 92.3 | 95.9 | 96.1 | 95.5 | 90.2 | 92.7 |
| Slope & variance | 97.9 | 98.4 | 97.7 | 98.2 | 98.0 | 97.0 | 98.0 |
| Peak & variance | 98.1 | 97.9 | 97.4 | 97.2 | 98.0 | 97.4 | 98.4 |
| Peak & skewness | 92.8 | 89.0 | 84.2 | 94.1 | 91.6 | 88.5 | 84.7 |
| Mean & skewness | 92.0 | 94.0 | 90.6 | 92.8 | 89.8 | 88.7 | 92.7 |
| Slope & skewness | 90.8 | 88.0 | 88.2 | 90.7 | 90.0 | 91.6 | 90.6 |
| Kurtosis & skewness | 54.5 | 55.7 | 53.6 | 55.6 | 56.2 | 55.7 | 51.6 |
| Variance & skewness | 98.4 | 98.5 | 97.6 | 98.4 | 97.2 | 97.0 | 98.0 |
| Peak & kurtosis | 90.1 | 88.5 | 81.4 | 94.1 | 87.8 | 87.5 | 84.9 |
| Mean & kurtosis | 90.1 | 93.5 | 89.0 | 91.6 | 90.7 | 89.8 | 91.5 |
| Slope & kurtosis | 91.3 | 88.1 | 88.2 | 90.0 | 90.6 | 91.9 | 90.3 |
| Variance & kurtosis | 98.4 | 98.4 | 97.1 | 97.4 | 97.6 | 96.6 | 95.5 |
| Total group n = 72 | Controls n = 36 | CVD patients n = 36 | p value | |
| Characteristics | ||||
| Age (years) | 60 ± 7 | 59 ± 7 | 61 ± 6 | 0.41 |
| Body height (cm) | 178 ± 7 | 180 ± 7 | 176 ± 6 | 0.011 |
| Body mass (kg) | 81 ± 11 | 81 ± 11 | 81 ± 12 | 0.98 |
| Body Mass Index (kg/m2)a | 25.3 [23.6 to 27.0] | 24.9 [23.3 to 26.9] | 25.6 [24.2 to 27.9] | 0.20 |
| Mean arterial pressure (mmHg)a | 97 [91 to 105] | 100 [93 to 106] | 94 [90 to 100] | 0.035 |
| Diastolic blood pressure (mmHg)a | 79 [75 to 88] | 83 [77 to 91] | 77 [73 to 82] | 0.011 |
| Systolic blood pressure (mmHg) | 131 [123 to 142] | 136 [124 to 142] | 128 [120 to 139] | 0.19 |
| Cardiovascular medication use | ||||
| Anticoagulant (n) | - | 35 (97%) | ||
| Antihypertensive agents (n) | - | 29 (81%) | ||
| Lipid lowering agents (n) | - | 32 (89%) | ||
| Vascular measurements | ||||
| Radial strain (%)a | 4.2 [3.2 to 6.5] | 4.2 [3.2 to 6.4] | 4.8 [3.6 to 6.5] | 0.50 |
| Circumferential strain (%)a | −10.0 [−13.6 to −6.5] | −10.2 [−14.9 to −7.0] | −8.8 [−13.2 to −6.2] | 0.29 |
| Distensibilitya | 0.27 [0.19 to 0.37] | 0.27 [0.20 to 0.35] | 0.29 [0.18 to 0.40] | 0.77 |
| Central pulse wave velocitya | 8.0 [6.8 to 10.1] | 7.8 [6.5 to 10.0] | 8.0 [7.2 to 10.2] | 0.22 |
| Intima to media thickness (mm)a | 0.72 [0.61 to 0.78] | 0.68 [0.58 to 0.76] | 0.76 [0.68 to 0.80] | 0.023 |
| After the Onset | |||||
| Value | Std.Error | df | t-value | p-value | |
| (Intercept) | 22.00 | 3.37 | 4553 | 6.53 | <0.0001 |
| AUT | 16.58 | 4.90 | 26 | 3.39 | 0.0023 |
| Dataset | Arrays (Drugs) | Unique Drugs | Exp. Blockers (Unique) | LQT Drugs (Unique) |
| CMap Build 02 | 7,056 (6,100) | 1,309 | 324 (61) | 284 (54) |
| HT-HG-U133A | 6,029 (5,242) | 1,219 | 271 (60) | 234 (52) |
| Batch Correction | 5,454 (4,754) | 1,145 | 253 (60) | 222 (52) |
| Non-Silent Drugs | 2,119 (1,419) | 673 | 88 (37) | 76 (35) |
| Merge Replicates | - | 673 | 62 (37) | 57 (35) |
| Variable | Aromatherapy group | Control group | p-value |
| Standard deviation and mean of mothers' age (year) | 26.43±3.216 | 26.60±3.406 | 0.768 |
| Educationhigh school and loweruniversity degree | 79.4%20.6% | 82.5%17.5% | 0.967 |
| ProfessionHousewifeWorking | 79.4%20.6% | 82.5%17.5% | 0.650 |
| Husband's Educationhigh school and loweruniversity degree | 84.2%15.8% | 87.3%12.7% | 0.895 |
| Husband's professionUnemployedFree workemploee | 14.3%69.8%15.9% | 12.7%69.8%17.5% | 0.948 |
| Standard deviation and mean of pregnancy age(week) | 38.30±0.978 | 38.08±1.067 | 0.225 |
| Wanted pregnancy | 79.4% | 82.5% | 0.650 |
| Receiving prenatal careYesNo | 92.5%4.8% | 96.8%3.2% | 0.650 |
| Type of childbirthNormal vaginal deliveryCesarian section | 98.4%1.6% | 96.8%3.2% | 0.561 |
| Standard deviation and mean ofcontraction length in 3-4 cm dilatation | 44.08±0.703 | 43.94±0.759 | 0.275 |
| Standard deviation and mean of contraction length in 5-7 cm dilatation | 47.40±0.493 | 47.27±0.447 | 0.133 |
| Standard deviation and mean of contraction length in8-10 cm dilatation | 49.44±0.501 | 49.43±0.499 | 0.859 |
| Standard deviation and mean of contraction frequency during 10 minutes in 3-4 cm dilatation | 2.27±0.447 | 2.27±0.447 | 1.000 |
| Standard deviation and mean of contraction frequency during 10 minutes in 5-7 cm dilatation | 3.16±0.368 | 3.22±0.419 | 0.368 |
| Standard deviation and mean of contraction frequency during 10 minutes in 8-10 cm dilatation | 3.81±0.396 | 3.73±0.447 | 0.294 |
| Variables Separated by Category 1 | Number of Responses/Number Total | Number Relative (%) |
| Lives near areas of vegetation | ||
| Yes | 449/478 | 93.9 * |
| No | 29/478 | 6.1 |
| Destination of Household Waste | ||
| Garbage truck | 288/478 | 60.3 * |
| Local dump site | 6/478 | 1.3 |
| Garbage truck and other destinations | 184/478 | 38.5 |
| Lives near open-air garbage dump | ||
| Yes | 366/478 | 76.6 * |
| No | 112/478 | 23.4 |
| Disposal of domestic sewage | ||
| Mossoró River | 213/478 | 44.6 * |
| Sanitation system | 181/478 | 37.9 |
| Sink | 70/478 | 14.6 |
| Sink and Mossoró River | 8/478 | 1.7 |
| Unknown | 6/478 | 1.3 |
| Vegetation around residence | ||
| Fruit trees | 135/478 | 28.2 |
| Other types of vegetation | 166/478 | 34.7 |
| Does not have vegetation | 177/478 | 37.0 |
| Presence of mosquitoes in house | ||
| Yes | 412/478 | 86.2 * |
| No | 66/478 | 13.8 |
| Increase in mosquitoes in the rainy season | ||
| Yes | 399/478 | 83.5 * |
| No | 79/478 | 16.5 |
| Repellent plants/insecticides used near home | ||
| Yes | 15/478 | 3.1 |
| No | 463/478 | 96.9 * |
| Inhibitor/control media | Isotonic RME (± S.E.) | Hypotonic RME (± S.E.) | Mean % of area change (± S.E.) | Translocation |
| Untreated control | 28.77 (6.78) | 78.84 (1.84)* | 145.19 (1.11)* | Yes |
| Non-specific kinase inhibitor (hypericin) | 21.85 (6.80) | 38.22 (5.58) | 103.50 (2.05) | No |
| PKC (Myr-PKCi) | 27.27 (4.73) | 55.28 (3.97)* | 141.00 (2.05)* | Yes |
| PKA (Myr-PKAi) | 25.62 (5.16) | 33.66 (6.62) | 102.97 (5.21) | No |
| Calcium-free media | 26.69 (6.03) | 32.16 (4.48) | 111.60 (1.92) | No |
| Calmodulin inhibitor (trifluoperazine) | 27.23 (7.11) | 31.40 (5.91) | 108.61 (5.47) | No |
| Calmodulin inhibitor (W7) | 16.86 (8.43) | 22.11 (8.14) | 110.31 (14.21) | No |
| Group | IC50 (μmol/L) | RR |
| EST1 siRNA | 34.63 ± 1.29* | 2.35 |
| Negative control siRNA | 86.18 ± 5.29 | 0.94 |
| Control untransfected | 81.37 ± 6.34 | 1.00 |
| IBTR | DFS | OS | |||||
| 5-year | Adjusteda HR (95% CI) | 5-year (%) | Adjusteda HR (95% CI) | 5-year (%) | 10-year (%) | Adjusteda HR (95% CI) | |
| Negative margins and primary BCS only (n = 7820)b | 163 (2.3%) | 0.76 (0.43–1.35) | 89.2 | 0.81 (0.63–1.04) | 93.1 | 82.9% | 1.07 (0.85–1.34) |
| Focally positive margins | |||||||
| Primary BCS only (n = 492)b | 13 (2.9%) | Reference | 86.0 | Reference | 92.7 | 81.1 | Reference |
| Primary BCS + re-excision (n = 586)c | 6 (1.1%) | 0.30 (0.11–0.82) | 87.1 | 0.83 (0.59–1.17) | 92.1 | 82.1 | 1.17 (0.87–1.59) |
| By BCS (n = 268)b | 3 (1.3%) | 0.39 (0.11–1.38) | 90.7 | 0.66 (0.42–1.06) | 94.8 | 86.0 | 1.01 (0.68–1.49) |
| By mastectomy (n = 318)d | 3 (1.0%) | 0.23 (0.06–0.89) | 84.0 | 0.98 (0.66–1.47) | 89.9 | 78.7 | 1.34 (0.93–1.91) |
| Extensively positive margins and primary BCS + re-excision (n = 1535)e | 40 (2.9%) | 0.75 (0.37–1.51) | 84.7 | 0.97 (0.72–1.31) | 91.8 | 81.1 | 1.22 (0.94–1.59) |
| Strain | Growth rate | min Nar | max Nar | Distance to WT | p-value | q-value | Method |
| (h−1) | (mmol/gDCW/h) | (mmol/gDCW/h) | (mmol/gDCW/h) | ||||
| wild type | 0.50 | 0 | 0 | ||||
| ΔackAΔmetY | 0.32 | 0 | 0.50 | 400 | 0.0742 | 0.0779 | OptKnock a |
| ΔptaΔilvA_ile | 0.20 | 0 | 0.50 | 404 | 0.2432 | 0.1197 | |
| ΔptaΔmetY | 0.32 | 0 | 0.50 | 400 | 0.2342 | 0.1197 | |
| ΔackAΔilvA_ile | 0.20 | 0 | 0.50 | 404 | 0.4139 | 0.1285 | |
| ΔackAΔmetY | 0.32 | 0 | 0.50 | 400 | 0.3656 | 0.1285 | |
| ΔsdhCABΔddh | 0.21 | 0 | 0.50 | 545 | 0.5443 | 0.1285 | OptKnock |
| ΔmdhΔpyc | 0.23 | 0 | 0.49 | 39 | 0.5377 | 0.1285 | screening |
| ΔpycΔzwf | 0.13 | 0 | 0.50 | 565 | 0.8300 | 0.1285 | |
| ΔpycΔopcA | 0.13 | 0 | 0.50 | 565 | 0.8580 | 0.1285 | |
| ΔpycΔgnd | 0.13 | 0 | 0.50 | 565 | 0.8784 | 0.1285 | |
| ΔpycΔrpe | 0.16 | 0 | 0.50 | 441 | 0.7986 | 0.1285 | |
| ΔpycΔtkt_1 | 0.15 | 0 | 0.50 | 532 | 0.8553 | 0.1285 | |
| ΔpycΔtal | 0.15 | 0 | 0.50 | 532 | 0.8940 | 0.1285 | |
| ΔpycΔtkt_2 | 0.17 | 0 | 0.50 | 413 | 0.8340 | 0.1285 | |
| ΔpycΔpmmB | 0.19 | 0 | 0.17 | 47 | 0.7249 | 0.1285 |
| Predicted Variables (Y) | Variable Selection (Variables Left in the Model with p < 0.05) | Prediction Equations (Test Model: Y = a + b1x1 + b2x2) | Model R2 Value | RSD a | p Value |
| Carbohydrate fraction profiles | |||||
| CA4 (% CHO) | Ratio of structural CHO to total CHO left in the model | Y = −41.04 + 99.32 A_StCHO/A_CHO ratio | 0.77 | 1.00 | 0.022 |
| CB1 (% CHO) | H_1415 left in the model | Y = −6.91 + 355.77 H_1415 | 0.70 | 0.97 | 0.038 |
| CB3 (% CHO) | H_895 left in the model | Y = 42.57 − 4338.00 H_895 | 0.91 | 0.64 | 0.004 |
| Total digestible nutrients | |||||
| tdNDF (% DM) | A_non-STCHO left in the model | Y = 21.84 − 83.78 A_non-STCHO | 0.88 | 0.28 | 0.006 |
| Overall (n = 93) | Dentist (n = 54) | Dental hygienist (n = 22) | Medical (n = 17) | |
| Asking smoking status | 66.9 (36.2) | 68.5 (36.3)* | 46.4 (32.3) | 88.2 (27.2) ** |
| Advise to quit | 43.9 (36.5) | 43.3 (36.4) | 30.9 (25.6) | 62.4 (42.8)* |
| Assess willingness to make a quit attempt | 22.5 (28.3) | 23.3 (28.9) | 22.2 (23.1) | 20.0 (33.5) |
| Assist in quit attempt | 17.3 (25.2) | 14.6 (21.0) | 19.1 (21.6) | 23.5 (39.0) |
| Kinase | Activity % | Kinase | Activity % | Kinase | Activity % |
| CK2α2β2 | 10 | PKCa | 95 | TAK1 | 107 |
| CK2α | 42 | IRAK4 | 95 | CDK9-Cyclin T1 | 108 |
| PIM3 | 62 | HIPK3 | 96 | RSK1 | 108 |
| MLK3 | 63 | JNK3 | 96 | MPSK1 | 108 |
| CK1δ | 72 | IGF-1R | 96 | RSK2 | 108 |
| BRK | 72 | VEG-FR | 96 | DDR2 | 109 |
| PLK1 | 75 | IRAK1 | 97 | EPH-A2 | 110 |
| MST2 | 77 | MAPKAP-K2 | 97 | MNK1 | 110 |
| MST4 | 78 | PAK5 | 97 | PKCγ | 110 |
| CHK2 | 80 | IKKe | 97 | CHK1 | 111 |
| MKK1 | 81 | GSK3b | 98 | OSR1 | 111 |
| TrkA | 81 | DYRK1A | 98 | JNK2 | 112 |
| PKBb | 81 | MAPKAP-K3 | 98 | STK33 | 112 |
| CAMK1 | 82 | MSK1 | 99 | NEK6 | 112 |
| MKK2 | 82 | AMPK (hum) | 99 | IKKb | 112 |
| ABL | 82 | SYK | 99 | EIF2AK3 | 112 |
| PDK1 | 83 | PDGFRA | 99 | p38g MAPK | 114 |
| MAP4K3 | 84 | LKB1 | 99 | MKK6 | 114 |
| MLK1 | 84 | p38a MAPK | 99 | ZAP70 | 114 |
| PIM1 | 85 | HIPK2 | 99 | p38b MAPK | 114 |
| FGF-R1 | 85 | HER4 | 100 | CSK | 114 |
| MAP4K5 | 86 | MARK2 | 100 | TTBK1 | 115 |
| PAK6 | 87 | TTBK2 | 100 | Aurora A | 115 |
| TIE2 | 88 | EPH-B2 | 101 | TAO1 | 115 |
| MNK2 | 88 | TTK | 101 | MEKK1 | 115 |
| SIK2 | 89 | ULK2 | 101 | MELK | 116 |
| MARK3 | 89 | WNK1 | 101 | SRPK1 | 117 |
| YES1 | 89 | ERK8 | 102 | EPH-B3 | 117 |
| GCK | 90 | PINK | 102 | PRK2 | 118 |
| ERK1 | 90 | PKCz | 102 | PIM2 | 120 |
| TESK1 | 90 | PAK4 | 102 | IRR | 120 |
| PKBa | 91 | JAK2 | 102 | ASK1 | 120 |
| DYRK2 | 91 | MARK4 | 103 | p38d MAPK | 120 |
| SGK1 | 91 | BRSK1 | 103 | PKA | 121 |
| CK1γ2 | 91 | PRAK | 103 | CDK2-Cyclin A | 121 |
| S6K1 | 91 | RIPK2 | 103 | Lck | 122 |
| CLK2 | 91 | TBK1 | 103 | HIPK1 | 123 |
| SmMLCK | 92 | DYRK3 | 104 | BTK | 125 |
| JNK1 | 92 | NUAK1 | 104 | EPH-A4 | 126 |
| ULK1 | 92 | NEK2a | 105 | TLK1 | 126 |
| Aurora B | 93 | SIK3 | 105 | MST3 | 126 |
| DAPK1 | 93 | ROCK 2 | 105 | IR | 128 |
| ERK2 | 94 | MINK1 | 105 | TGFBR1 | 130 |
| CAMKKb | 94 | ERK5 | 106 | TSSK1 | 131 |
| EF2K | 94 | EPH-B1 | 106 | EPH-B4 | 132 |
| BRSK2 | 95 | PAK2 | 106 | ||
| PKD1 | 95 | MARK1 | 106 | ||
| Src | 95 | PHK | 107 |
| Operator | Sagittal* (degrees) | Coronal** (degrees) | Horizontal*** (degrees) |
| A | 24.8 (7.2) | 0.9 (2.8) | -2.3 (4.4) |
| B | 25.4 (8.0) | 3.3 (2.2) | -1.2 (3.8) |
| C | 26.8 (7.6) | 1.2 (3.9) | -2.8 (4.1) |
| Grading | Description |
| 0 | No apparent EB extravasation |
| 1 | A small amount of EB extravasation within the cerebral cortex |
| 2 | Flake dispersion of EB at the lateral ventricle or hippocampal layer |
| 3 | Massive EB extravasation in the brain tissue |
| LBI | Peak method* | |||
| ≥ LLQ | ≥ LLD | |||
| Min | Max | Min | Max | |
| Oxford qPCR | 97,608** | 1,396,941** | 33,768 | 1,396,941 |
| UW large volume qRT-PCR | 37,800 | 1,855,630 | 37,800 | 1,855,630 |
| Participant | Form of feedback | Total number |
| General practitioner | One-on-one interview | 4 |
| GP registrar | Focus group | 1 group with 14 attendees |
| General practitioner | Focus group | 3 groups (3 GPs, 4 GPs, 4 GPs) |
| Healthcare consumer representative | One-on-one interview | 5 |
| Representative bodies for chronic illness | One-on-one interview | 2 |
| Dietician | One-on-one interview | 1 |
| Psychologist | One-on-one interview | 1 |
| Total—38 |
| Lead Author | Year | Journal | Detection Rate | Accuracy Rate | Sensitivity Rate | False Negative Rate | Negative Predictive Value | Upstaging Rate |
| Saha (a)[47] | 2000 | Ann Surg Oncol | 99 | 96 | 91 | 9 | Ns | 18 |
| Wiese (a)[48] | 2000 | Arch Pathol Lab Med | 99 | 96 | 91 | 9 | ns | ns |
| Waters (b)[49] | 2000 | Am Surg | 91 | 100 | 100 | 0 | 100 | 6 |
| Bilchik (c)[50] | 2001 | J Clin Oncol | 100 | 100 | 100 | 0 | 100 | 50 |
| Paramo (d)[51] | 2001 | Am J Surg | 71 | 100 | 100 | 0 | 100 | 11 |
| Wood (a)+(c)[52] | 2001 | Ann Surg Oncol | 96 | 95 | 88 | 12 | ns | 25 |
| Wood (c)[53] | 2001 | Surg Endosc | 100 | 100 | 100 | 0 | 100 | 9 |
| Saha (a)+(c)[54] | 2001 | Ann Surg Oncol | 98 | 96 | 90 | 10 | 95 | 14 |
| Esser [55] | 2001 | Dis Colon Rectum | 58 | 94 | 67 | 33 | 94 | 7 |
| Bendavid [56] | 2002 | J Surg Oncol | 90 | 94 | 95 | 5 | 91 | 42 |
| Paramo (d)[57] | 2002 | Ann Surg Oncol | 82 | 98 | 93 | 7 | 97 | 11 |
| Wood (c)[58] | 2002 | J GastroInt Surg | 97 | 95 | 92 | 8 | ns | 24 |
| Bilchik (c)[59] | 2002 | Eur J Cancer | 97 | 95 | 91 | 5 | ns | 24 |
| Kitagawa [60] | 2002 | Dis Colon Rectum | 91 | 92 | 82 | 18 | 88 | ns |
| Feig (e)[61] | 2002 | Am J Surg | 98 | 79 | 38 | 62 | 76 | 8 |
| Broderick-Villa [62] | 2002 | Cancer J | 92 | 79 | 50 | 50 | 73 | 0 |
| Tsioulias (c)[63] | 2002 | Am Surg | 100 | 93 | 67 | 33 | ns | 15 |
| Nastro [64] | 2002 | Tumori | 75 | 100 | 100 | 0 | 100 | ns |
| Bilchik (c)[65] | 2003 | Cancer Control | 100 | 93 | 91 | 9 | ns | 14 |
| Cox [66] | 2003 | Curr Surg | 100 | 100 | 100 | 0 | 100 | 29 |
| Bilchik (c)[67] | 2003 | J Clin Oncol | 96 | 96 | 92 | 8 | ns | 29 |
| Turner (c)[68] | 2003 | Archives Path | 82 | 92 | 87 | 13 | ns | 29 |
| Trocha (a)+(c)[69] | 2003 | J GastroInt Surg | 98 | 95 | 84 | 16 | 93 | 21 |
| Veihl [70] | 2003 | World J Surg | 87 | 78 | 50 | 22 | 71 | 11 |
| Levine (b)[71] | 2003 | J GastroInt Surg | 92 | ns | 50 | ns | 86 | ns |
| Saha (a)[72] | 2004 | Dis Colon Rectum | 99 | ns | 88 | 12 | ns | 13 |
| Dan (a)[73] | 2004 | Arch Surg | 99 | 96 | 86 | 16 | ns | 5 |
| Braat [21] | 2004 | Eur J Surg Oncol | 94 | 97 | 80 | 20 | 92 | 3 |
| Bertoglio [74] | 2004 | J Surg Oncol | 95 | 92 | 78 | 22 | 88 | ns |
| Read [75] | 2004 | Dis Colon Rectum | 79 | 97 | 25 | 75 | ns | 3 |
| Patten (e)[76] | 2004 | Cancer | 98 | 89 | 83 | 17 | 76 | 20 |
| Bertagnolli [77] | 2004 | Ann Surg | 92 | 80 | 46 | 54 | 75 | 0 |
| Saha (a)[78] | 2004 | Ann Surg Oncol | 100 | 95 | 84 | 16 | 93 | 5 |
| Saha (a)[79] | 2004 | Semin Oncol | 100 | 96 | 92 | 8 | ns | 13 |
| Bembenek (f)[80] | 2005 | World J Surg | 85 | ns | 92 | 8 | 95 | 26 |
| Codnignola [81] | 2005 | JJ Clin Oncol | 100 | ns | 72 | 28 | 70 | 37 |
| Dahl [82] | 2005 | Eur J Surg Oncol | 100 | 92 | 83 | 17 | 91 | ns |
| Bilchik (a)+(c)[83] | 2006 | Arch Surg | 100 | 95 | 88 | 12 | ns | 23 |
| Tuech [84] | 2006 | Eur J Surg Oncol | 97 | 94 | 91 | 9 | ns | ns |
| Saha (a)[85] | 2006 | Am J Surg | 98 | 96 | 90 | 10 | 93 | ns |
| Kelder (g)[86] | 2006 | Scand J Gastroenterol | 97 | 93 | 86 | 14 | 89 | 33 |
| Thomas (b)[87] | 2006 | Am Surg | 93 | 20 | 46 | 54 | 73 | 5 |
| Covarelli [88] | 2006 | Am Surg | 95 | 95 | 86 | 14 | ns | 8 |
| Kelder (g)[89] | 2007 | Int J Col Dis | 97 | 96 | 89 | 11 | 93 | ns |
| Bianchi [90] | 2007 | Surg End | 100 | 95 | 83 | 17 | 94 | 9 |
| Murawa [91] | 2007 | Acta Chir Belg | 93 | 84 | 83 | 17 | ns | 8 |
| Bembenek (f)[92] | 2007 | Ann Surg | 85 | 86 | 54 | 46 | 80 | 21 |
| Sandrucci [93] | 2007 | J Surg Oncol | 100 | 91 | 92 | 9 | ns | 11 |
| Tiffet [94] | 2007 | Dis Colon Rectum | 92 | 81 | 80 | 20 | 74 | ns |
| Lim (e)[95] | 2008 | Ann Surg Oncol | 99 | 83 | 59 | 41 | 78 | ns |
| Kusano [96] | 2008 | Digestive Surgery | 88.5 | 82.6 | 33 | 67 | 81 | ns |
| Quadros [97] | 2008 | J Surg Oncol | 91 | 80 | 67 | 33 | 67 | 25 |
| Antibiotic | MBEC (−Streptokinase) (mg/L) | MBEC (+Streptokinase) (mg/L) |
| Daptomycin | 1024 | 1024 |
| Daptomycin + rifampicin | 64 | <4 |
| Vancomycin | 128 | 64 |
| Vancomycin + rifampicin | 64 | 4 |
| Variable | First assessment | Second assessment | p value | ||
| Mean | 95% CI | Mean | 95% CI | ||
| Adjusted age | 10.9 | 10.1–10.7 | 19.9 | 19.1–20.7 | <0.001 |
| Cognitive | 92.8 | 89.5–96.1 | 93.2 | 89.3–97.1 | 0.874 |
| Language | 103.0 | 99.7–106.2 | 94.6 | 91.7–97.5 | 0.001 |
| Motor | 95.2 | 92.2–98.3 | 100.1 | 97.9–102.4 | 0.004 |
| Item | Brucellosis | Leptospirosis | ||
| Cases (%) | 95% CI | Cases (%) | 95% CI | |
| Season | ||||
| Spring | 170 (26.1) ** | 22.2-29.5 | 32 (2.8) | 1.9-3.8 |
| Summer | 207 (31.8) ** | 28.2-35.4 | 80 (6.9) | 5.4-8.4 |
| Autumn | 156 (24.0) | 20.7-27.3 | 940 (84.5) ** | 79.3-83.7 |
| Winter | 118 (18.1) ** | 15.1-21.1 | 101 (8.8) | 7.2-10.4 |
| Total | 651 | 1,153 | ||
| Region | ||||
| Eastern | 256 (39.3) | 35.1-43.1 | 775 (67.2) ** | 64.5-69.9 |
| Western | 321 (49.3) ** | 45.5-53.1 | 325 (28.2) | 25.6-30.8 |
| Central | 67 (10.3) ** | 8.0-12.6 | 51 (4.4) | 3.2-5.6 |
| Jeju-Island | 7 (1.1) | 0.3-1.9 | 2 (0.2) | - |
| Total | 651 | 1,153 |
| Operator\\device | 1 | 2 |
| 1 | SEN = 75% | SEN = 68% |
| SPC = 82% | SPC = 61% | |
| 2 | SEN = 68% | SEN = 58% |
| SPC = 59% | SPC = 70% |
| Stimulation | Overexpressed in BCG-vaccinated infants | Median fold change | Under-expressed in BCG-vaccinated infants | Median fold change |
| Mtb lysate | IL-2, IFNγ, IL-13, IL-1α, IP-10, IL-6 | >10 | ||
| Flt-3L, IL-8, IL-1Rα, IL-12p40, IL-10, MCP-3 | 5–10 | |||
| MIP-1α, IL-5, TNFα, VEGF, MIP-1β, GM-CSF, IL-7, IL-17, IFNα2, eotaxin | 2–5 | |||
| CD40L, TNFβ, fractalkine, FGF- 2, TGFα | 1–2 | |||
| Pam3Cys | IL-10, epidermal growth factor (EGF) | 5–10 | ||
| Platelet-derived growth factor (PDGF)-AB/BB, sCD40L, MIP-1α | 2–5 | |||
| IL-12p40, IL-6, MCP-3, IL-7, eotaxin | 1–2 | |||
| Candida albicans | EGF, IL-6, PDGF-AB/BB, MCP-3 | 2–5 | IL-2, IL-13, IL-17, IP-10 | 0.2–0.5 |
| Staphylococcus aureus | EGF, IL-6 | 2–5 | ||
| PDGF-AB/BB | 1.7 | |||
| Escherichia coli | EGF | 2.8 | GM-CSF, GRO | 0.2–1.0 |
| Lipopolysaccharide | IL-8 | 1.7 | GM-CSF, GRO | 0.2–1.0 |
| GI name | tRNA gene (gene_ID) | GI-left end | GI-right end | GI-length (bp) | GC% | duplication length (bp) | gene_ID of integrase |
| BJ6TGI01 | trnR-CCG (BJ6T08940) | 911,924 | 937,940 | 26,017 | 55.7 | 50 | BJ6T08690 |
| BJ6TGI02 | trnR-ACG (BJ6T12260) | 1,307,833 | 1,310,731 | 2,899 | 62.7 | 18 | - |
| BJ6TGI03 | trnE-CTC (BJ6T19770) | 2,046,607 | 2,146,757 | 100,151 | 59.7 | 48 | BJ6T20830 |
| BJ6TGI04 | trnK-CTT (BJ6T30200) | 3,118,227 | 3,192,248 | 74,022 | 59.5 | 46 | BJ6T31070 |
| BJ6TGI05 | trnK-CTT (BJ6T30200) | 3,192,295 | 3,236,376 | 44,082 | 60.9 | 46 | BJ6T31620 |
| BJ6TGI06 | trnK-CTT (BJ6T30200) | 3,236,423 | 3,322,375 | 85,953 | 59.0 | 46 | - |
| BJ6TGI07 | trnK-CTT (BJ6T30200) | 3,322,421 | 3,326,439 | 4,019 | 58.6 | 45 | BJ6T32590 |
| BJ6TGI08 | trnT-TGT (BJ6T43300) | 4,371,641 | 4,428,687 | 57,047 | 58.8 | 47 | BJ6T42570 |
| BJ6TGI09 | trnS-TGA (BJ6T51900) | 5,251,688 | 5,269,566 | 17,879 | 58.4 | 14 | BJ6T51650 |
| BJ6TGI10 | trnN-GTT (BJ6T53120) | 5,380,012 | 5,394,916 | 14,905 | 59.3 | 53 | BJ6T52900 |
| BJ6TGI11 | trnQ-TTG (BJ6T71420) | 7,326,115 | 7,332,736 | 6,622 | 62.7 | 47 | - |
| BJ6TGI12 | trnQ-TTG (BJ6T71420) | 7,332,777 | 7,363,200 | 30,424 | 62.1 | 39 | - |
| BJ6TGI13 | trnI-CAT (BJ6T75390) | 7,790,844 | 7,797,321 | 6,478 | 61.1 | 48 | - |
| BJ6TGI14 | trnI-CAT (BJ6T82220) | 8,494,412 | 8,539,486 | 45,075 | 58.5 | 49 | BJ6T82530 |
| BJ6TGI15 | trnI-CAT (BJ6T82220) | 8,539,534 | 8,591,258 | 51,725 | 59.5 | 47 | BJ6T82650 |
| Fucans | Total sugar (%) | Sulfate (%) | Sulfate/Total sugar (%/%) | Proteins (%) | Molar ratio | |||||
| Fuc | Gal | Glc | Man | Xyl | Gluc A | |||||
| F0.5v | 89.1 | 14.1 | 0.16 | 0.1 | 1.0 | 2.0 | 0.3 | 0.5 | 0.7 | 0.9 |
| F0.7v | 70.0 | 17.8 | 0.25 | 0.3 | 1.0 | 3.0 | 0.4 | 0.6 | 1.5 | 2.2 |
| F1.0v | 65.0 | 19.0 | 0.29 | 0.5 | 1.0 | 1.9 | 0.2 | 0.5 | 0.8 | 1.5 |
| F1.3v | 68.2 | 14.5 | 0.21 | 0.1 | 1.0 | 2.4 | 0.3 | 0.2 | 0.6 | 0.5 |
| F1.5v | 61.3 | 15.4 | 0.25 | 0.1 | 1.0 | 1.6 | 0.2 | 0.4 | 1.3 | 1.9 |
| F2.0v | 64.3 | 16.0 | 0.25 | 0.7 | 1.0 | 1.8 | 0.2 | 0.4 | 1.6 | 2.2 |
| Genotype | Overall colorectal cancer cases (n = 387) vs. controls (1,536) | Colon cancer (n = 169) vs. controls (1,536) | Rectum cancer (n = 218) vs. controls (1,536) | |||||||||
| Crude OR (95% CI) | P | Adjusted ORa (95%CI) | P | Crude OR (95% CI) | P | Adjusted ORa (95% CI) | P | Crude OR (95% CI) | P | Adjusted ORa (95% CI) | P | |
| Additive model | 0.67 (0.43–1.04) | 0.072 | 0.67 (0.43–1.04) | 0.073 | 0.55 (0.27–1.09) | 0.086 | 0.54 (0.27–1.08) | 0.083 | 0.76 (0.45–1.31) | 0.324 | 0.77 (0.45–1.32) | 0.335 |
| Homozygote model | 0.77 (0.09–6.60) | 0.810 | 0.77 (0.09–6.82) | 0.814 | 1.75 (0.20–15.03) | 0.612 | 1.80 (0.21–15.73) | 0.596 | – | – | – | – |
| Dominant model | 0.68 (0.44–1.04) | 0.077 | 0.68 (0.44–1.05) | 0.078 | 0.59 (0.31–1.15) | 0.120 | 0.59 (0.30–1.14) | 0.117 | 0.76 (0.45–1.31) | 0.324 | 0.77 (0.45–1.32) | 0.335 |
| Recessive model | 0.80 (0.09–6.87) | 0.839 | 0.80 (0.09–7.07) | 0.838 | 1.84 (0.21–12.85) | 0.579 | 1.89 (0.22–16.57) | 0.566 | – | – | – | – |
| mRNA | Primer |
| Mouse B2m | Fwd 5′-ACCGTCTACTGGGATCGAGA-3′ |
| Rev 5′-TGCTATTTCTTTCTGCGTGCAT-3′ | |
| Mouse Rpl13a | Fwd 5′-AGAAGCAGATCTTGAGGTTACGG-3′ |
| Rev 5′-GTTCACACCAGGAGTCCGTT-3′ | |
| Mouse Aqp5 | Fwd 5′-CTTGTGGGGATCTACTTCACCG-3′ |
| Rev 5′-AAGTAGAGGATTGCAGCCAGG-3′ | |
| Mouse T1α | Fwd 5′-TCACCCCAATAGAGATGGCTTG-3′ |
| Rev 5′-GGGCAAGTTGGAAGCTCTCTT-3′ | |
| Mouse Rage | Fwd 5′-CACAGGCTCTGTGGGTGAG-3′ |
| Rev 5′-TTCAGCTCTGCACGTTCCTC-3′ | |
| Mouse Con43 | Fwd 5′-TCCTTTTCCTTTGACTTCAGCCTC-3′ |
| Rev 5′-TCTGAAAATGAAGAGCACCGACA-3′ | |
| Mouse Sftpc | Fwd 5′-GGAGCACCGGAAACTCAGAA-3′ |
| Rev 5′-GGAGCCGCTGGTAGTCATAC-3′ |
| Base case ICER calculations | Threshold analysis*: probability of cost-effective at alternative values of willingness to pay for a QALY(%) | ||||||||
| Mean total cost (£) | Incremental cost (£) | Mean QALY | Incremental QALY | ICER (£/QALY) | £10,000 | £20,000 | £30,000 | £50,000 | |
| Fluid loading | 10,373 | 0.3527 | 84.4 | 86.5 | 89.4 | 92.0 | |||
| Fluid control | 11,739 | -1,366 | 0.3175 | 0.0352 | Dominated | 15.6 | 13.5 | 10.6 | 8.0 |
| Adjusted differences(95% CI; P-value)* | -2,047(-6,947 to 2,854; P = 0.413) | 0.0431(-0.0171 to 0.1033; P = 0.161) |
| Name | Sequence | Genome Position* | Expected Size (bp) | Reference |
| p20F | 5' ACAATATGCGAGCTTACTTTA 3' | 17691–17710 | 555 | [18] |
| p20R | 5' AACCTACACGCAAGATGGA 3' | 18229–18246 | ||
| p23F | 5' GTCTCTCCATCTTGCGGTGTAG 3' | 18224–18244 | 733 | [30] |
| p23R | 5' CAATCAGATGAAGTGGTG3' | 18941–18957 | ||
| p25F | 5' TGAATTATGGACGACGAAAC 3' | 16079–16097 | 676 | |
| p25R | 5' TCAACGTGTGTTGAATTTCCC 3' | 16736–16755 |
| Plant material | Deposit number | Deposit location | Name of herbarium |
| Piper aduncum | 10,480 | INPA1 | INPA herbarium |
| Piper tuberculatum | 6,797 | IFAM2 | EAFM herbarium |
| Piper hispidum | 6,796 | IFAM | EAFM herbarium |
| Piper marginatum | 6,798 | IFAM | EAFM herbarium |
| Piper callosum | 6,794 | IFAM | EAFM herbarium |
| Piper hispidinervum | IFAM | EAFM herbarium | |
| Piper sp. | IFAM | EAFM herbarium |
| Source | P | 95% CI | |
| Model | 0.005 | Odds Ratio | |
| Diabetes Mellitus | 0.017 | 1.823 | 1.111–2.99 |
| Male Gender | 0.048 | 0.616 | 0.381–0.998 |
| Chronic Heart Failure | 0.058 | 1.974 | 0.972–4.009 |
| Chronic Renal Failure | 0.083 | 1.727 | 0.928–3.215 |
| MDH/Community | 0.125 | 1.561 | 0.879–2.774 |
| Alcohol abuse | 0.217 | 0.288 | 0.032–2.62 |
| Age ≥ 65 | 0.26 | 1.01 | 0.993–1.027 |
| Liver disease | 0.413 | 0.491 | 0.085–2.846 |
| Lung disease | 0.75 | 1.106 | 0.595–2.056 |
| Ischaemic Heart Disease | 0.944 | 1.022 | 0.559–1.869 |
| Annual drug expenses (USD) (n = 116), mean ± SD | T | p value | |
| Preoperative | 660.08 ± 426.05 | 14.877 | <0.001 |
| Postoperative 1 year | 65.12 ± 138.23 | ||
| Difference in expenses | 594.96 ± 430.74 |
| ICD-10 code | Criteria for Appropriate Antibiotic Prescription |
| H65 Nonsuppurative otitis mediaH66 Suppurative and nonspecified otitis media | H65 must meet both conditions: presence of Acute Bilateral Otitis media AND age < 2H65 or H66 with presence of otorrhea |
| J01 Acute sinusitis | Must meet all conditions: Fever of >38C°, purulent discharge and facial pain |
| JO2 Acute pharyngitisJO3 Acute tonsillitis | Must meet 3 of the following CENTOR criteria: Presence of tonsilar exudate Presence of painful anterior cervical lymphadenopathy or lymphadenitis Fever (> 38°) Absence of cough |
| JOO Acute nasopharyngitis [common cold]JO1 Acute sinusitisJO2 Acute pharyngitisJO3 Acute tonsillitisJO4 Acute laryngitis and tracheitisJO5 Acute obstructive laryngitis [croup] and epiglotitisJO6 Acute upper respiratory infections of multiple and unspecified sitesJ10 Influenza due to other identified influenza virusJ11 Influenza due to unidentified influenza virus | Must meet any of the following criteria: Presence of one or more of the following comorbidities: Cardiac, Pulmonary, Renal, Hepatic, Neuromuscular, Immunosuppression, Cystic Fibrosis, Diabetes Mellitus.- OR Age < 2 years old AND history of prematurityOR Age > 65 years old AND presence of cough AND two or more of the following:▪ Hospitalized in 2014▪ Diabetes mellitus▪ History of cardiac arrest▪ Current use of corticosteroidsOR Age > 80 years old AND presence of cough AND one or more of the following:▪ Hospitalized in 2014▪ Diabetes mellitus▪ History of cardiac arrest▪ Current use of corticosteroids |
| Control | JOAG | AOAG | |||||
| N (%) | N (%) | OR (95%CI) | P* | N (%) | OR (95%CI) | P* | |
| Non-smoker | 55 (43.7) | 14 (41.2) | 4.33 (0.12-5.84 × 105) | 0.692 | 31 (33.7) | 1.03 (0.52-2.08) | 0.925 |
| Smoker | 71 (56.3) | 16 (58.8) | 61 (66.3) |
| Preparedness | Female | Male |
| Personal: | ||
| Yes | 8 | 19 |
| No | 11 | 7 |
| Uncertain | 3 | 4 |
| Community: | ||
| Yes | 5 | 5 |
| No | 11 | 15 |
| Uncertain / Improving | 0 | 6 |
| Filtered times | Repeat | Contigs (kb) | Accuracy (%) | Genome coverage (%) | |||||
| TRC | CNRC | NNC | N50 | Max | CN-accuracy | Rep-accuracy | C-accuracy | ||
| 1 | 11 | Appendix | 801 | 0.3 | 2.3 | 100 | 66.8 | 100 | 53.4 |
| 2 | 12 | Appendix | 418 | 1.8 | 7.6 | 100 | 82.1 | 100 | 101.9 |
| 3 | 13 | Appendix | 1025 | 0.3 | 2.3 | 100 | 68 | 100 | 77.4 |
| Synchronous combined surgery (n = 25) (35.7%) | Synchronous “bowel first” (n = 14) (20%) | Metachronous (n = 31) (44.3%) | Total (n = 70) | p value | |
| Age (years, range) | 68 (34–85) | 75 (46–82) | 70 (52–85) | 69.5 (34–85) | 0.730 |
| Sex (n, %) | 0.683 | ||||
| Male | 15 (60%) | 9 (64.3%) | 16 (51.6%) | 40 (57.1%) | |
| Female | 10 (40%) | 5 (35.7%) | 15 (48.4%) | 30 (42.9%) | |
| Bowel obstruction (n, %) | 5 (20%) | 7 (50%) | 7 (22.6%) | 19 (27.1%) | 0.097 |
| Site of primary tumor (n, %) | 0.343 | ||||
| Right colon | 8 (32%) | 2 (14.3%) | 11 (35.5%) | 21 (30%) | |
| Left colon | 17 (68%) | 12 (85.7%) | 20 (64.5%) | 49 (70%) | |
| CHT before liver surgery | 2 (8%) | 11 (78.6%) | 20 (64.5%) | 33 (47%) | <0.0001 |
| Characteristics | Range | |
| No. of patients | 1085 | |
| Age, mean (SD) | 44.72(12.12) | 13-82 |
| No. of women (%) | 846(77.97%) | |
| Educational degree | Primary school | 85 |
| Junior high | 60 | |
| Senior high | 211 | |
| College | 576 | |
| Post-graduate | 153 |
| Variable | HIV-negative | HIV-infected, | HIV-infected, |
| Proportion (%) | control | ART-naive | on ART |
| Median [IQR] | (number = 153) | (number = 151) | (number = 150) |
| Female | 94 (61.4%) | 89 (58.9%) | 115 (76.7%) |
| Age (in years) | 38 [32 to 46] | 37 [32 to 44] | 40 [38 to 47] |
| Education level | |||
| Incomplete primary | 27 (17.7%) | 25 (16.6%) | 30 (20.0%) |
| Complete primary | 82 (53.6%) | 98 (64.9%) | 94 (62.7%) |
| Secondary and above | 44 (28.8%) | 28 (18.5%) | 26 (17.3%) |
| Work type | |||
| Manual | 109 (71.2%) | 114 (75.5%) | 105 (70.0%) |
| Office | 44 (28.8%) | 37 (24.5%) | 45 (30.0%) |
| Vigorous work | 15 (9.8%) | 21 (13.9%) | 33 (22.0%) |
| Mode of transportation | |||
| Walking or bicycle | 130 (85.0%) | 110 (72.9%) | 117 (78.0%) |
| Motorized vehicle | 23 (15.0%) | 41 (27.1%) | 33 (22.0%) |
| Ease of Living Indexa | |||
| Low | 86 (56.2%) | 94 (62.3%) | 81 (54.0%) |
| Middle | 20 (13.1%) | 24 (15.9%) | 26 (17.3%) |
| Higher | 47 (30.7%) | 33 (21.9%) | 43 (28.7%) |
| Ever smoking | 6 (3.9%) | 16 (10.6%) | 10 (6.7%) |
| Current smoker | 5 (3.3%) | 4 (2.7%) | 0 |
| Fruit and vegetables servings/week | 6 [4-12] | 8 [5-12] | 9 [6 to 13] |
| Sugary drinks/day | 1 [0.5 to 2] | 1 [0.5 to 2] | 1 [1 to 2] |
| Current alcohol use | |||
| None | 119 (77.8%) | 120 (79.5%) | 136 (90.7%) |
| < once/week | 19 (12.4%) | 16 (10.6%) | 8 (5.3%) |
| ≥ once/week | 15 (9.8%) | 15 (9.9%) | 6 (4.0%) |
| Body Mass Index (BMI) in kg/m2 | 23.8 [22.3 to 25.8] | 22 [20.2 to 24.3] | 23.7 [21.5 to 27.9] |
| BMI <18.5 | 5 (3.3%) | 18 (11.9%) | 4 (2.7%) |
| BMI 18.5 to 25 | 104 (68.0%) | 113 (74.8%) | 80 (53.3%) |
| BMI 25 to 30 | 33 (21.6%) | 9 (6.0%) | 45 (30.0%) |
| BMI >30 | 11 (7.2%) | 11 (7.3%) | 21 (14.0%) |
| Waist-hip ratio | 0.84 [0.82 to 0.87] | 0.84 [0.80 to 0.89] | 0.87 [0.82 to 0.91] |
| Central obesityb | 44 (29.1%) | 56 (37.1%) | 78 (52.0%) |
| Diabetes mellitus | 0 | 1 (0.7%) | 1 (0.7%) |
| Current CD4 T-cell count in cells/μL | NA | 215 [150 to 321] | 378 [263 to 521] |
| Nadir CD4 T-cell count in cells/μL | NA | 209 [120 to 302] | 118.5 [68 to 196] |
| ART duration (months) | NA | NA | 56 [31 to 68] |
| Protease inhibitor use | NA | NA | 18 (12.0%) |
| N | Mean ± SD | Median | IQR | Range | β ± SE (p) | ||
| a) | Persisted to 2nd year | 23 | 0·110 ± 0·068 | 0·105 | 0·061–0·139 | 0·026–0·308 | 2·9 ± 3·7 (0·44) |
| Did not persist | 80 | 0·098 ± 0·060 | 0·089 | 0·065–0·117 | 0·000–0·301 | ||
| b) | Both adults survived | 42 | 0·093 ± 0·067 | 0·082 | 0·048–0·117 | 0·000–0·308 | −3·7 ± 3·4 (0·29) |
| One or both adults died | 61 | 0·106 ± 0·058 | 0·097 | 0·069–0·118 | 0·000–0·301 | ||
| c) | Did not divorce | 23 | 0·110 ± 0·068 | 0·105 | 0·061–0·139 | 0·026–0·308 | −9·9 ± 5·8 (0·09) |
| Divorced | 19 | 0·073 ± 0·061 | 0·081 | 0·033–0·096 | 0·000–0·254 | ||
| d) | Persisted to 3rd year | 5 | 0·159 ± 0·026 | 0·147 | 0·142–0·169 | 0·136–0·200 | t = −5·9 (0·001) |
| Did not persist | 11 | 0·071 ± 0·031 | 0·067 | 0·047–0·093 | 0·031–0·117 | ||
| e) | Persisted to next year | 28 | 0·118 ± 0·065 | 0·115 | 0·067–0·147 | 0·026–0·308 | 6·2 ± 3·4 (0·08) |
| Did not persist | 91 | 0·095 ± 0·058 | 0·086 | 0·061–0·115 | 0·000–0·301 |
| Mean (mm) | Standard Deviation (mm) | |
| Study I | 0.43 | 3.54 |
| Study II | ‐1.77 | 5.23 |
| Variable | Event | PYs | Rate | Crude HR (95% CI) | Adjusted HR (95% CI) |
| Comparison cohort | 191 | 44535 | 42.89 | ref | ref |
| OSA without treatment | 62 | 6018 | 103.02 | 2.41 (1.81–3.21) | 2.15 (1.60–2.88) |
| OSA with surgery only | 7 | 1407 | 49.75 | 1.15 (0.54–2.45) | 1.53 (0.72–3.29) |
| With pharyngeal surgery | 5 | 858 | 58.25 | 1.34 (0.55–3.27) | 1.86 (0.76–4.56) |
| With nasal surgery | 2 | 549 | 36.45 | 0.84 (0.21–3.38) | 1.14 (0.28–4.62) |
| OSA with CPAP only | 27 | 2712 | 99.55 | 2.34 (1.56–3.50) | 1.65 (1.09–2.49) |
| OSA with multiple modality | 5 | 972 | 51.46 | 1.16 (0.48–2.82) | 1.25 (0.51–3.04) |
| Cox regression | Crude analysis | Adjusted analysis | ||
| Variable | RR | 95% CI | RR | 95% CI |
| Sex | ||||
| Female | 1 | 1 | ||
| Male | 1.48 | 0.80-2.74 | 1.50 | 0.81-2.79 |
| Age | 1.03* | 1.01-1.05 | 1.03* | 1.01-1.05 |
| Suicide prevention team | ||||
| No | 1 | 1 | ||
| Yes | 0.76 | 0.41-1.39 | 0.85 | 0.46-1.57 |
| Previous attempt | ||||
| No | 1 | |||
| One | 1.56 | 0.72-3.39 | ||
| Several | 0.93 | 0.47-3.95 | ||
| Aftercare referrals | ||||
| Others | 1 | 1 | ||
| Out-patient | 0.72 | 0.38-1.35 | 0.88 | 0.64-1.21 |
| Alcohol misuse | ||||
| No | 1 | |||
| Yes | 1.07 | 0.51-2.23 | ||
| Marital status | ||||
| Others | 1 | |||
| Married/cohabitant | 1.28 | 0.67-2.48 | ||
| Employment | ||||
| Employed | 1 | |||
| Unemployed/disabled | 1.48 | 0.57-3.81 | ||
| Student/pupil | 0.57 | 0.16-2.05 | ||
| Others | 2.82* | 1.19-6.66 |
| Lysis entity in exponential phase [%] | 73 ± 0.3 |
| Lysis delay after induction [min] | 55 |
| Doubling time [min] | 66.1 ± 1.7 |
| Doubling time of negative control [min] | 65.9 ± 0.6 |
| Effects (% Substitution) | Peak 1 (cP) | Trough 1 (Nm) | Break Down | Final Visc 3 (cP) | Setback (cP) | Peak Time (min) | Pasting Temp (°C) | |||||||
| Mean | SD 2 | Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD | |
| DDGS (%) | ||||||||||||||
| 0 | 1532.0 a | 309.27 | 839.33 a | 360.90 | 692.66 a | 91.41 | 3243.83 a | 1968.38 | 2404.50 a | 1648.26 | 5.93 a | 0.56 | 86.13 a | 10.18 |
| 10 | 1208.17 b | 133.12 | 613.33 b | 181.97 | 594.83 b | 56.79 | 2152.50 b | 959.03 | 1539.17 b | 785.28 | 5.53 b | 0.29 | 85.21 a | 8.59 |
| 20 | 1017.50 b | 72.70 | 548.83 b | 23.49 | 468.66 c | 65.91 | 1561.00 b | 322.52 | 1012.17 b | 317.90 | 5.33 b | 0.04 | 88.36 a | 1.77 |
| SSL (%) | ||||||||||||||
| 0 | 1121.67 b | 71.48 | 474.33 b | 59.53 | 647.33 a | 98.98 | 993.50 b | 250.70 | 519.16 b | 233.97 | 5.25 b | 0.05 | 79.15 b | 8.99 |
| 2 | 1233.33 ab | 221.02 | 661.33 ab | 163.97 | 572.00 b | 106.28 | 2676.50 a | 1089.27 | 2015.17 a | 935.38 | 5.65 a | 0.35 | 89.30 a | 0.75 |
| 5 | 1402.67 a | 423.11 | 865.83 a | 311.94 | 536.83 b | 132.10 | 3287.33 a | 1418.14 | 2421.50 a | 1132.29 | 5.88 a | 0.51 | 91.25 a | 2.02 |
| Gene | Primer sequence |
| Collagen II | Forward primer 5′‐GCTCCCAGAACATCACCTACCA‐3′Reverse primer 5′‐ACAGTCTTGCCCCACTTACCG‐3′ |
| Aggrecan | Forward primer 5′‐AGGTCGTGGTGAAAGGTGTTGTG‐3′Reverse primer 5′‐TGGTGGAAGCCATCCTCGTAG‐3′ |
| Sox‐9 | Forward primer 5′‐CGAGCCGGACCTCAAGAAG‐3′Reverse primer 5′‐ GCACCAGCGTCCAGTCGTA‐3′ |
| Collagen X | Forward primer 5′‐GCCCTTCTGCTGCTAGTGTCTTT‐3′Reverse primer 5′‐TGTGTCTTGGTGTTGGGTTGTG‐3′ |
| GAPDH | Forward primer 5′‐AAGGTCGGAGTGAACGGATTTG‐3′Reverse primer 5′‐CGTGGGTGGAATCATACTGGAAC‐3′ |
| Plant species | Degree of inhibition |
| Andrographis paniculata | +++ |
| Momordica charantia | ++ |
| Cymbopogn citratus | + |
| Ocimum sanctum | + |
| Citrus limon | - |
| Pelargonium citrosum | - |
| HCV Genotype | Modified Multiplex PCR Method (Genotype Specific Primers) | INNO-LiPA HCV II (Line Probe Assay) | ||
| Isolates, No. | Percentage | Isolates, No. | Percentage | |
| 1a | 1 | 1.37 | 1 | 1.37 |
| 1b | 1 | 1.37 | 1 | 1.37 |
| 3a | 3 | 4.11 | 3 | 4.11 |
| 4 | 65 | 89.04 | 38 | 52.05 |
| 4a | - | - | 2 | 2.74 |
| 4c/4d | - | - | 18 | 24.66 |
| 4e | - | - | 5 | 6.85 |
| 4h | - | - | 4 | 5.48 |
| Not Genotyped | 3 | 4.11 | 1 | 1.37 |
| Total | 73 | 100 | 73 | 100 |
| Characteristics | Frequency | Percentage |
| Sex | ||
| Male | 482 | 53.8 |
| Female | 414 | 46.2 |
| Religion | ||
| Christianity | 888 | 99.1 |
| Islam | 6 | 0.7 |
| Traditional African Religion | 2 | 0.2 |
| Parental Background | ||
| Father dead | 80 | 8.9 |
| Mother dead | 32 | 3.6 |
| One or both parents dead | 106 | 11.8 |
| Parents alive but divorced | 23 | 2.6 |
| Parents deprivation | 129 | 14.4 |
| Father smokes | 62 | 6.9 |
| Mother smokes | 3 | 0.3 |
| Father takes alcohol | 306 | 34.2 |
| Mother takes alcohol | 130 | 14.5 |
| Sample | Wild type CHO-S crude protein extract | pcDNA: trp-21-472-cA transfected CHO-S cell crude protein extract | ||||
| Replicates | 1 | 2 | 3 | 1 | 2 | 3 |
| 0 min | 0.203 | 0.205 | 0.202 | 0.205 | 0.208 | 0.206 |
| 5 mins | 0.196 | 0.199 | 0.194 | 0.173 | 0.179 | 0.175 |
| 10 mins | 0.184 | 0.188 | 0.180 | 0.140 | 0.147 | 0.143 |
| 15 mins | 0.179 | 0.182 | 0.176 | 0.101 | 0.106 | 0.104 |
| 20 mins | 0.170 | 0.173 | 0.168 | 0.093 | 0.098 | 0.095 |
| Parameters | Hazard ratio | 95% confidence interval | P value |
| 5-year-DFS | |||
| EZH2 | 2.287 | 1.137-4.602 | 0.020 |
| pT | 2.244 | 1.076-4.678 | 0.013 |
| pN | 2.532 | 1.292-4.961 | 0.007 |
| 5-year-OS | |||
| EZH2 | 2.182 | 0.940-5.064 | 0.069 |
| pT | 2.395 | 0.997-5.365 | 0.051 |
| pN | 2.471 | 1.138-5.364 | 0.022 |
| Variable | Men (n = 21) | Women (n = 19) | Total (n = 40) | |
| Glucose (mg/dL) | Week 0 | 103.3 ± 5.0 | 96.4 ± 3.3 | 99.8 ± 3.0 |
| Week 12 a | 91.3 ± 2.1 | 89.8 ± 2.3 | 90.5 ± 1.5 | |
| Insulin (μU/mL) | Week 0 | 9.2 ± 1.1 | 6.0 ± 0.5 | 7.6 ± 0.7 |
| Week 12 a | 5.5 ± 0.8 | 3.5 ± 0.3 | 4.5 ± 0.5 | |
| Leptin (ng/mL) | Week 0 | 13.6 ± 1.7 | 84.7 ± 17.7 | 45.4 ± 9.8 |
| Week 12 a | 6.6 ± 1.3 | 22.9 ± 3.5 | 13.9 ± 2.1 | |
| Adiponectin (ng/mL) | Week 0 | 16.1 ± 2.1 | 27.8 ± 5.3 | 21.7 ± 2.9 |
| Week 12 | 15.7 ± 1.6 | 27.3 ± 4.3 | 21.2 ± 2.3 |
| Mixture | Compressive Strength (MPa) * | ||||
| 3 Days | 7 Days | 14 Days | 28 Days | 90 Days | |
| C-0.45-N | 30.74 0.77 | 41.93 0.67 | 49.17 1.40 | 56.93 0.81 | 65.98 0.92 |
| C-0.45-H | 34.79 0.63 | 45.82 0.89 | 54.43 0.17 | 61.72 1.67 | 69.73 0.42 |
| C-0.45-SCM | 40.76 0.68 | 48.95 0.16 | 57.28 0.81 | 64.43 1.85 | 73.48 1.17 |
| 10FA-0.45-N | 31.77 2.41 | 43.44 0.81 | 50.50 0.40 | 58.08 1.15 | 67.13 0.94 |
| 10FA-0.45-H | 33.68 0.25 | 46.45 1.27 | 53.45 0.20 | 60.51 1.54 | 69.33 1.27 |
| 10FA-0.45-SCM | 35.83 0.95 | 49.26 0.39 | 56.17 0.85 | 62.48 0.67 | 71.53 1.31 |
| 20FA-0.45-N | 21.33 0.16 | 29.21 0.55 | 35.88 0.69 | 43.24 0.10 | 53.29 1.14 |
| 20FA-0.45-H | 23.73 0.47 | 32.64 1.40 | 40.51 0.32 | 49.11 1.37 | 56.98 0.87 |
| 20FA-0.45-SCM | 29.21 0.75 | 35.07 0.29 | 42.77 1.83 | 52.62 0.58 | 61.67 1.24 |
| 40FA-0.45-N | 14.25 0.26 | 21.68 0.34 | 27.11 0.32 | 31.42 1.16 | 41.47 0.83 |
| 40FA-0.45-H | 16.50 0.50 | 22.96 0.31 | 28.96 2.01 | 33.71 0.77 | 44.18 1.23 |
| 40FA-0.45-SCM | 18.56 0.23 | 25.39 1.25 | 30.69 0.37 | 36.83 1.43 | 46.88 0.87 |
| 60FA-0.45-N | 13.18 1.15 | 19.78 0.93 | 26.17 0.82 | 30.87 1.34 | 40.24 0.52 |
| 60FA-0.45-H | 15.65 0.78 | 21.29 0.64 | 27.82 1.04 | 32.19 0.90 | 42.78 0.89 |
| 60FA-0.45-SCM | 17.24 1.39 | 24.61 0.75 | 29.94 0.44 | 35.61 0.32 | 45.31 0.59 |
| Groups | Dose (TCID50) 1 mL | Survival rate (day post infection) | Mortality (%) | ||||||||
| 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | |||
| PRV FJ-2012 | 106 | 4/4 | 4/4 | 3/4 | 3/4 | 2/4 | 2/4 | 1/4 | 1/4 | 0/4 | 100 |
| Cohabitation | DMEM | 2/2 | 2/2 | 2/2 | 2/2 | 2/2 | 2/2 | 1/2 | 1/2 | 1/2 | 50 |
| Control | DMEM | 4/4 | 4/4 | 4/4 | 4/4 | 4/4 | 4/4 | 4/4 | 4/4 | 4/4 | 0 |
| Supplementary addition of L- proline (mM) | 0 | 1 | 2 | 4 | 8 | 12 |
| Hyp (g/L) | 2.28 | 2.81 | 3.25 | 6.72 | 5.56 | 6.32 |
| Treatment | Open dentinal tubules (N/mm2) (N=20) | Diameter of tubules (μm) (N=20) | ||
| Old root | Young root | Old root | Young root | |
| Citric acid | 122 (14) | 152 (19) | 2.0 (0.1) | 1.7 (0.2) |
| EDTA | 161 (22) | 140 (17) | 2.3 (0.1) | 1.7 (0.2) a |
| Control | 147 (10) | 159 (24) | 1.6 (0.2) | 1.9 (0.2) |
| SOUND CATEGORY | DESCRIPTION |
| Mouth | Crunching a hard candy |
| Kissing | |
| Gargling | |
| Crunching chips | |
| Finishing a beverage with a straw | |
| Hand | Ripping a sheet of paper |
| Unrolling scotch tape | |
| Zipping a zipper | |
| Opening a soda can | |
| Crushing a soda can | |
| Environmental | Train passing by |
| Howling wind | |
| Waves breaking on the shore | |
| Electric discharge | |
| Water dripping | |
| Hand control (Fuzzy) | Crumple can |
| Open can | |
| Zip | |
| Scotch | |
| Paper | |
| Mouth control (Fuzzy) | Kiss |
| Candy | |
| Chips | |
| Gargle | |
| Straw |
| DNA sequence | A | T | G | C | G | A | C | C | C | T... |
| xA(k): | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| xC(k): | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 0 |
| xG(k): | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| xT(k): | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Antigen | Antibody | Crude IRR (95%CI) | P-value | Age-adjusted IRR | P-value | |
| MSP3 | ||||||
| IgG2* | (coded as log(2)) | 0.74 (0.57, 0.98) | 0.04 | 0.85 (0.63, 1.15) | 0.29 | |
| IgG4 | < detection limit | 1 | 0.01 | 1 | 0.20 | |
| < median | 0.45 (0.21, 0.95) | 0.56 (0.26, 1.19) | ||||
| ≥ median | 0.47 (0.28, 0.79) | 0.68 (0.40, 1.15) | ||||
| MSP119 | ||||||
| IgG2* | (coded as log(2)) | 0.62 (0.45, 0.86) | < 0.01 | 0.836 (0.606, 1.157) | 0.275 | |
| IgG4* | (coded as log(2)) | 1.07 (0.95, 1.21) | 0.25 | 0.838 (0.608, 1.159) | 0.278 | |
| GLURP | ||||||
| IgG2* | (coded as log(2)) | 0.65 (0.49, 0.86) | < 0.01 | 0.79 (0.58, 1.08) | 0.13 | |
| IgG4* | (coded as log(2)) | 0.94 (0.81, 1.08) | 0.37 | 1.01 (0.87, 1.16) | 0.94 | |
| AMA1 | ||||||
| IgG2 | < detection limit | 1 | 0.18 | 1 | 0.54 | |
| < median | 1.80 (0.86, 3.78) | |||||
| ≥ median | 1.78 (0.90, 3.51) | |||||
| IgG4 | < detection limit | 1 | 0.19 | 1 | 0.54 | |
| < median | 0.96 (0.47, 1.93) | |||||
| ≥ median | 0.62 (0.36, 1.07) |
| CEER | Reverse Phase Protein Array | PhosphoFlow | ELISA | |
| Sample Protein Requirement | Native proteins | Denatured proteins | Fixed proteins | Native or Fixed proteins |
| Minimum Cell Requirement (Assay Sensitivity) | 1 cell | 2500~15000 cells | 1 × 104~1 × 106 cells | 150 to 300 cells |
| Multiplex Format | One sample, multiple analytes | Multiple samples, one analyte | One sample, multiple analytes (limited) | Multiple samples, one analyte |
| Assay Specificity | • High | • Low | • Low | • Medium |
| Advantages of Assay | • Simultaneous analysis of multiple analytes (e.g. selected analytes of a signaling pathway) on a single sample.• Suitable for clinical samples of rare cells as well as limited solid tissue samples. | • Simultaneous analysis of multiple samples for a single analyte.• Suitable for samples of cells or solid tissue. | • Detection of target molecules within a cell population in one sample.• Suitable for blood sample analysis. | • High throughput. |
| Disadvantages of Assay | • Screening compatible antibody sets for each target. | • Need to print each sample; not suitable for applications in clinical samples from individual patients.• Cross reaction of detector antibody. | • Not suitable for rare cell analysis or solid tissue samples.• Requires a large number of cells.• Requires samples in single cell suspension, limiting its use. | • Low sensitivity requires large numbers of cells.• Not suitable for rare cell analysis. |
| Sensitivity | Specificity | Positive Predictive Value | Negative Predictive Value | |
| PF/other1(PF gametocytaemia considered negative for PF) | 89.1[85.5-91.8] | 97.6[96.5-98.4] | 93.8[90.8-95.9] | 95.2[94.2-96.8] |
| PF/other2(PF gametocytaemia considered positive for PF) | 85.1[81.3-88.2] | 96.1[94.7-97.2] | 90.6[87.3-93.2] | 93.6[91.9-95.0] |
| PF mono-infection1(PF gametocytaemia considered negative for PF) | 95.6[87.7-98.5] | - | - | - |
| PF mono-infection2(PF gametocytaemia considered positive for PF) | 86.7[79.9-91.4] | - | - | - |
| PV mono-infection1(PV gametocytaemia considered negative for PV) | 91.0[86.5-94.1] | - | - | - |
| PV mono-infection2(PV gametocytaemia considered positive for PV) | 88.4[83.7-91.9] | - | - | - |
| ORF | Gene | Identification | Genotype used in this study |
| F17A2.5 | ceh-40 | Homeodomain protein (Extradenticle ortholog) | ceh-40(ok740) X |
| K10B4.6 | cwn-1 | Putative Wnt ligand | cwn-1(ok546) II |
| D1081.2 | unc-120 | MADS domain TF | unc-120(st364) I |
| B0304.1 | hlh-1 | bHLH TF | hlh-1(cc561) II |
| C44C10.8 | hnd-1 | Hand bHLH TF | hnd-1(q740) X |
| F35G12.6 | mab-21 | Highly conserved novel protein | mab-21(bx53)III; him-5(e1490)V |
| F11C1.6 | nhr-25 | Nuclear hormone receptor | +/szT1 [lon-2(e678)] I; nhr-25(jm2389)/szT1 X |
| Y75B8A.2 | nob-1 | Homeodomain TF (posterior Hox paralog) | nob-1(ct223) dpy-18(e364) unc-25(e156) III; eDp6 (III;f) |
| K02B9.4 | elt-3 | GATA TF | elt-3(gk121) X |
| T07C4.2 | tbx-8 | T-box TF (Brachyury) | tbx-8(ok656) III |
| M142.4 | vab-7 | Homeobox TF (even-skipped subfamily) | vab-7(e1562) III |
| T07C4.6 | tbx-9 | T-box TF (Brachyury) | Mutant not available |
| C55C2.1 | Zinc-finger TF | Mutant not available | |
| C38D4.6 | pal-1 | Homeobox TF (cad subfamily) | pal-1(ct224) dpy-17(e164) ncl-1(e1865) unc-36(e251) III; sDp3(f:III); lin-2(e1309) X |
| W09C2.1 | elt-1 | GATA TF | elt-1(zu180) unc-43(e408)/unc-24(e138) dpy-20(e1282) IV |
| F18A1.2 | lin-26 | Zinc-finger TF | lin-26(n156) II |
| T28F12.2 | unc-62 | Meis-class homeodomain (Homothorax ortholog) | unc-62(e644) V |
| C28C12.7 | spp-10 | Predicted prosaposin | Mutant not available |
| R02D3.1 | Dehydrogenase | Mutant not available | |
| C09D4.2 | Uncharacterized | Mutant not available | |
| R07C3.11 | Uncharacterized | Mutant not available | |
| T22B7.3 | Uncharacterized | Mutant not available | |
| C46H11.2 | Uncharacterized | Mutant not available | |
| ZK1307.1 | Uncharacterized | Mutant not available | |
| C01G6.1 | aqp-2 | Aquaporin | Mutant not available |
| T27D12.1 | Sodium/phosphate transporter | Mutant not available |
| Variables | R | p-Value ** |
| Socioeconomic | ||
| Age (years) | 0.125 | 0.243 |
| Schooling (years) | 0.118 | 0.267 |
| Per capita income (real) | −0.080 | 0.441 |
| Water supply | 0.061 | 0.565 |
| Garbage collection | 0.008 | 0.935 |
| Sewer connect to the public network or existence of septic tank | 0.162 | 0.128 |
| Basic sanitation | 0.226 | 0.033 |
| Obstetric | ||
| Parity (number of pregnancies) | −0.125 | 0.243 |
| Trimester at the time of blood collection | −0.317 | 0.002 |
| Nutritional | ||
| Pre-gestational nutritional status (BMI/age) * | 0.276 | 0.008 |
| Gestational nutritional status (BMI) * | 0.246 | 0.019 |
| Infection (CRP ≥ 5 mg/L) | −0.068 | 0.527 |
| Nutrient intake | ||
| Vitamin A (μg) * | 0.046 | 0.666 |
| Zinc (mg) * | 0.048 | 0.654 |
| Iron (mg) * | 0.001 | 0.986 |
| Summary of progress with IRS and ITNs | MIS 2006 | MIS 2008 | MIS 2010 |
| Percentage of households receiving indoor residual spraying (IRS) in the previous 12 months among all households | 9.5 | 14.9 | 23.1 |
| Percentage of household members who slept under an ITN the previous night | 19 | 34 | 42 |
| Percentage of households covered by at least one ITN or recent IRS | 43.2 | 68.3 | 72.9 |
| Percentage of households covered by at least one ITN or recent IRS | 43 | 68 | 73 |
| Percentage of children ages 0–59 months who slept under an ITN the previous night | 24 | 41 | 50 |
| Percentage of children ages 0–59 months with malaria parasitaemia | 22 | 10 | 16 |
| Factors | |||
| Self-assessment item | 1 | 2 | 3 |
| 1) Obtain a medical history that is relevant to the patient's complaint | 0.83 | ||
| 2) Perform a clinical examination that is targeted at the patient's chief complaint | 0.72 | 0.39 | |
| 3) Obtain a psychosocial history from the patient | 0.67 | 0.33 | |
| 4) Announce bad news (e.g., an unfavorable prognosis) | 0.61 | 0.32 | |
| 5) Make sure that an illiterate patient understands the treatment of his chronic disease (e.g., hypertension, depression, etc.) | 0.52 | 0.43 | |
| 6) Explain the reason for refusing an unjustified treatment or investigation to patient who requests it | 0.52 | ||
| 7) Discuss advantages and risks of unconventional therapies with a patient who uses them | 0.48 | ||
| 8) Discuss a patient's religious preferences and constraints regarding his treatment | 0.73 | ||
| 9) Communicate the importance of medical treatment to a patient who believes that his illness is due to supernatural causes | 0.65 | ||
| 10) Explore the migratory trajectory and possible traumatic experiences of an asylum seeker | 0.68 | ||
| 11) Work effectively with a professional interpreter | 0.65 | ||
| 12) Orient an immigrant patient without papers toward appropriate medical and social services | 0.47 | 0.41 | |
| 13) Perform a physical examination of a Muslim woman who wears a veil | 0.79 | ||
| 14) Ask questions and give information to the husband of a patient, if she requests it | 0.76 |
| Group | nNOS activity (nmol/min/mg) | MDA nmol/g/wet tissue | GSH nmol/g/wet tissue |
| Control | 0.604 ± 0.04 | 3.55 ± 0.20 | 1.68 ± 0.15 |
| Cocaine | 0.935 ± 0.14* | 4.65 ± 0.32* | 0.94 ± 0.10* |
| 7-NI | 0.360 ± 0.07* | 3.50 ± 0.10 | 1.59 ± 0.10 |
| 7-NI + cocaine | 0.535 ± 0.10+ | 3.68 ± 0.15+ | 1.55 ± 0.08+ |
| Parameters | Base-case | Range (min—max) | Reference |
| Thai birth cohort population | 782,129 | – | (19) |
| Incidence of haemophilus influenzae type b (Hib) meningitis in <1 year old | 0.000137 | 0.000038–0.000236 | (14, 20) |
| Incidence of Hib meningitis in ≥1 to <5 years olda | 0.000046 | 0.000038–0.000054 | |
| Incidence of Hib pneumonia in <5 years | 0.000959 | 0.000266–0.001652 | (21)b |
| Incidence of Hib NPNM in population <5 years old | 0.000025 | 0.000007–0.000043 | (1)c |
| Case-fatality ratio of Hib meningitis | |||
| Estimate based on real-world evidence of national database (base-case analysis) | 0.029 | 0.018–0.040 | NHSOd |
| Estimate from published article | 0.099 | 0.049–0.149 | (22) |
| Case-fatality ratio of Hib pneumonia | |||
| Estimate based on real-world evidence of national database (base-case analysis) | 0.019 | 0.012–0.026 | NHSOd |
| Estimate from published article | 0.020 | 0.010–0.030 | (1) |
| Case-fatality ratio of Hib NPNM | |||
| Estimate based on real-world evidence of national database (base-case analysis) | 0.050 | 0.022–0.078 | NHSOd |
| Estimate from published article | 0.010 | 0.005–0.015 | (1) |
| Probability of hearing loss after recovery from Hib meningitis | 0.111 | 0.055–0.167 | |
| Probability of epilepsy after recovery from Hib meningitis | 0.050 | 0.025–0.075 | (23) |
| Probability of developmental deficit after recovery from Hib meningitis | 0.083 | 0.041–0.125 | |
| Risk ratio of mortality compared to general population | |||
| Hearing loss | 1.075 | 1.010–1.140 | |
| Epilepsy | 1.005 | 1.000–1.010 | (24) |
| Developmental deficit | 6.165 | 5.160–7.170 |
| Annual average | Primary care utilisation | 95% confidence interval | Reduction | |||||
| Low (n = 6987) | Medium (n = 5926) | High (n = 1271) | Low | Medium | High | Medium | High | |
| Hospitalisations per person | ||||||||
| Diabetes | 5 (1421) | 1.1 (1892) | 1 (772) | 4.87-5.11 | 1.06-1.16 | 0.89-1.04 | 78% | 80% |
| IHD | 5.9 (612) | 2.3 (626) | 1.5 (340) | 5.69-6.08 | 2.22-2.47 | 1.34-1.6 | 61% | 75% |
| COPD | 3.4 (572) | 1.3 (657) | 1 (322) | 3.27-3.58 | 1.18-1.35 | 0.92-1.15 | 62% | 71% |
| Renal Disease | 7.7 (1143) | 1.2 (1923) | 1.1 (826) | 7.54-7.87 | 1.16-1.26 | 1.06-1.2 | 84% | 86% |
| Hypertension | 4 (1433) | 1.1 (1986) | 0.9 (832) | 3.92-4.13 | 1.07-1.16 | 0.88-1.01 | 73% | 78% |
| PAHs | ||||||||
| Diabetes | 2.7 | 0.6 | 0.5 | 2.6-2.78 | 0.6-0.67 | 0.48-0.59 | 76% | 80% |
| IHD | 4 | 1.5 | 0.9 | 3.8-4.12 | 1.43-1.63 | 0.84-1.05 | 63% | 78% |
| COPD | 2 | 0.8 | 0.8 | 1.93-2.17 | 0.76-0.9 | 0.66-0.86 | 60% | 60% |
| Renal Disease | 3.4 | 0.5 | 0.6 | 3.31-3.53 | 0.5-0.57 | 0.54-0.65 | 85% | 82% |
| Hypertension | 2.3 | 0.7 | 0.5 | 2.19-2.35 | 0.64-0.71 | 0.49-0.6 | 70% | 78% |
| Deaths (per 100) | ||||||||
| Diabetes | 3.23 | 0.99 | 0.80 | 2.92-3.53 | 0.85-1.14 | 0.59-1 | 69% | 75% |
| IHD | 4.71 | 1.76 | 1.61 | 4.16-5.26 | 1.42-2.09 | 1.17-2.04 | 63% | 66% |
| COPD | 5.08 | 1.96 | 2.04 | 4.48-5.68 | 1.62-2.31 | 1.54-2.54 | 61% | 60% |
| Renal Disease | 4.21 | 1.18 | 1.06 | 3.82-4.59 | 1.02-1.34 | 0.83-1.29 | 72% | 75% |
| Hypertension | 3.11 | 1.28 | 0.97 | 2.82-3.41 | 1.12-1.44 | 0.75-1.19 | 59% | 69% |
| YLLs | ||||||||
| Diabetes | 1.00 | 0.24 | 0.20 | 0.99-1.02 | 0.23-0.24 | 0.19-0.21 | 76% | 80% |
| IHD | 1.47 | 0.46 | 0.39 | 1.44-1.5 | 0.44-0.47 | 0.37-0.41 | 69% | 73% |
| COPD | 1.32 | 0.41 | 0.44 | 1.29-1.35 | 0.39-0.42 | 0.41-0.46 | 69% | 67% |
| Renal Disease | 1.30 | 0.28 | 0.25 | 1.28-1.32 | 0.27-0.28 | 0.24-0.27 | 78% | 81% |
| Hypertension | 0.89 | 0.30 | 0.23 | 0.87-0.9 | 0.29-0.31 | 0.22-0.24 | 66% | 74% |
| Clinical features | FA | XP | CS | TTD |
| Cancer | + | + | - | - |
| Skin pigmentation | + | + | - | ± |
| Developmental delay | + | - | + | + |
| Neurological defects | ± | ± | + | + |
| Operational Mode | bits/s | kbits/sol | Power(mW) | Energy/sol(mWh) |
| Nominal (1sps during 5 min each hour) | 112 | 806.4 | 0.25 | 0.5 |
| In-flight calibration (1sps during 15 min each week) | 112 | 14.4 | 500 | 17.8 |
| Total | - | 820.8 | - | 18.3 |
| Surgery Type (# of Patients) Ref. | Prognostic Value (Y/N/Insignificant) | Remarks |
| General/vascular surgery (143)39 | Insignificant | Suggested conducting randomized control trial |
| Spine (268)40 | Yes | |
| General orthopedic (723)41 | No | SAS did not predict 30-day major complications after general orthopedic surgery |
| Radical cystectomy (155)42 | Yes | |
| General surgery (2,125)43 | Yes | |
| Laparotomy (218)44 | Yes | |
| Non-cardiac surgeries (5,909)45 | Yes | |
| General and vascular surgeries (224)46 | Yes | |
| General, vascular, and orthopedic surgeries (223)47 | Yes | SAS uncorrelated with orthopedic patients who had major events |
| Renal mass excision (886)48 | Yes | |
| High-risk intra-abdominal surgeries (355)49 | Yes | SAS was significantly predictive but weakly discriminative for adverse events |
| No. (%) of participants from | ||||
| Eastern Croatia | Central Croatia | Southern Croatia | Croatia | |
| pH≥7.3 | 75 (64.1) | 144 (58.3) | 167 (68.7) | 386 (63.6) |
| pH<7.3 | 42 (35.9) | 103 (41.7) | 76 (31.3) | 221 (36.4) |
| All | 117 (19.3) | 247 (40.7) | 243 (40.0) | 607 (100.0) |
| Asset index items | Scoring factors | % of distribution in the sample | Most poor (%) | Least poor (%) |
| Refrigerator | 0.382 | 48.4 | 0 | 100 |
| Radio | 0.231 | 65.8 | 41.1 | 91 |
| Television | 0.368 | 47.5 | 0 | 40 |
| Stove | 0.357 | 59.2 | 0 | 98 |
| Phone | 0.329 | 43.7 | 0 | 40 |
| Car | 0.161 | 7.3 | 0 | 21 |
| Drinking water(Piped inside the house) | 0.379 | 45.4 | 0 | 55 |
| Type of toilet( Flush toilet) | 0.358 | 48.2 | 0 | 41 |
| Cooking fuel(Using electricity for cooking) | 0.36 | 35.4 | 0 | 43 |
| Molecular function term | % Coverage | p-value | FDR (%) |
| catalytic activity | 43 | 1.32E-04 | 0.22 |
| nucleotide binding | 14 | 1.27E-05 | 0.02 |
| purine nucleotide binding | 13 | 4.74E-05 | 0.08 |
| purine ribonucleotide binding | 12 | 1.49E-05 | 0.02 |
| ribonucleotide binding | 12 | 1.49E-05 | 0.02 |
| RNA binding | 11 | 1.60E-09 | 2.71E-06 |
| structural molecule activity | 10 | 4.34E-12 | 7.36E-09 |
| structural constituentof ribosome | 9 | 4.38E-22 | 7.43E-19 |
| GTP binding | 3 | 7.43E-06 | 0.01 |
| guanyl nucleotide binding | 3 | 7.43E-06 | 0.01 |
| guanyl ribonucleotide binding | 3 | 7.43E-06 | 0.01 |
| oxidoreductase activity, acting on CH-OH group of donors | 3 | 4.66E-05 | 0.08 |
| translation regulator activity | 3 | 8.71E-07 | 1.48E-03 |
| oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor | 3 | 1.10E-04 | 0.19 |
| translation factor activity, nucleic acid | 3 | 2.14E-07 | 3.62E-04 |
| GTPase activity | 2 | 2.39E-03 | 3.98 |
| rRNA binding | 2 | 8.85E-11 | 1.50E-07 |
| snoRNA binding | 2 | 8.58E-09 | 1.45E-05 |
| ligase activity, forming aminoacyl-tRNA and related compounds | 2 | 1.33E-06 | 2.25E-03 |
| ligase activity, forming carbon- oxygen bonds | 2 | 1.33E-06 | 2.25E-03 |
| aminoacyl-tRNA ligase activity | 2 | 1.33E-06 | 2.25E-03 |
| RNA helicase activity | 2 | 4.29E-05 | 0.07 |
| ATP-dependent RNA Helicase activity | 2 | 9.12E-07 | 1.54E-03 |
| RNA-dependent ATPase activity | 2 | 9.12E-07 | 1.54E-03 |
| translation initiation factor activity | 1 | 4.61E-04 | 0.78 |
| No. of pts. | Spearmen-Rho | p-value | |
| Quality of life | |||
| Health status | 111 | 0.882 | 0.000 |
| ICIQ (1) | 111 | −0.211 | 0.027 |
| IPSS (2) | 104 | −0.204 | 0.037 |
| Urethral D30 (3) | |||
| Volume of prostate | 162 | −0.326 | 0.000 |
| IPSS at survey | |||
| IPSS (preimplant) | 103 | 0.287 | 0.003 |
| Seed dislocation/loss | |||
| V100 (4) | 163 | −0.262 | 0.001 |
| D90 (5) | 163 | −0.190 | 0.015 |
| INTAKE24 Geometric Mean | Interview Geometric Mean | Ratio of Geometric Mean | Limits of Agreement | ||
| Lower | Upper | ||||
| Energy (kJ) | 6681.7 | 6823.9 | 0.97 | 0.52 | 1.82 |
| Carbohydrate (g) | 234.2 | 236.0 | 0.99 | 0.52 | 1.88 |
| NSP (g) | 9.1 | 9.6 | 0.94 | 0.45 | 1.98 |
| Fat (g) | 52.3 | 55.8 | 0.92 | 0.43 | 1.96 |
| Fat (%) | 29.5 | 31.0 | 0.95 | 0.63 | 1.42 |
| Saturated Fat (g) | 19.2 | 20.5 | 0.92 | 0.39 | 2.17 |
| Protein (g) | 52.4 | 52.4 | 0.99 | 0.47 | 2.11 |
| NMES (g) | 89.3 | 85.3 | 1.07 | 0.28 | 4.05 |
| NMES (%) | 22.4 | 20.8 | 1.10 | 0.32 | 3.75 |
| Alcohol (g) | 0.01 | 0.01 | 0.95 | 0.29 | 3.10 |
| Vitamin C (mg) | 104.3 | 96.7 | 1.09 | 0.44 | 2.71 |
| Iron (mg) | 8.1 | 8.3 | 0.98 | 0.45 | 2.11 |
| Calcium (mg) | 713.9 | 705.8 | 1.00 | 0.46 | 2.18 |
| Wheat in OSR (in 2000) | Infectivity of Soil (% roots)a | Take-All in Spring | Take-All in Summer | Take-All Index (0–100) | Grain Yield (t ha−1) | ||
| Total(% plants) | No. Roots(plant−1) | Total (% plants) | Mod. (% plants)b | ||||
| None | −2.55 (0.1) | −1.56 (3.8) | 0.07 | −1.73 (2.5) | −2.44 (0.3) | 1.0 | 8.20 |
| Destroyed early | −2.78 (0.0) | −1.81 (2.1) | 0.06 | −1.75 (2.4) | −2.24 (0.6) | 1.7 | 8.56 |
| Destroyed late | −2.03 (1.2) | −1.61 (3.4) | 0.06 | −1.81 (2.1) | −2.45 (0.2) | 0.7 | 8.31 |
| Not destroyed | −1.92 (1.6) | −1.12 (9.1) | 0.25 | −1.37 (5.5) | −2.09 (1.0) | 3.5 | 8.46 |
| SED (21 d.f.) | 0.274 | 0.231 | 0.068 | 0.263 | 0.148 | 1.36 | 0.286 |
| Organism | Release version | Coverage depth | Genome size (Mbp) | Scaffolds numbers | EST Size (Mbp) | EST numbers |
| Aq | v1.0 | ~8X | 143 | 3,579 | 42 | 63,542 |
| Ta | v1.0 | ~8.1X | 107 | 1,415 | 8 | 11,498 |
| Nv | v1.0 | ~7.8X | 356 | 10,804 | 133 | 163,314 |
| Ct | v1.0 | ~7.9X | 334 | 21,042 | 119 | 209,323 |
| Lg | v1.0 | ~8.9X | 360 | 4,475 | 203 | 252,091 |
| Bf | v2.0 | ~8.1 X | 522 | 398 | 234 | 334,502 |
| System | Manifestation |
| Digestive system | Burning throat, nausea, vomiting, abdominal pain, abdominal distension |
| Nervous system | Dizziness, vertigo, dysarthria, dysphagia, blurred vision, diplopia, drooping eyelids, mydriasis, miosis, absence of pupillary light reflex, gait ataxia, fatigue, convulsion, numbness, restlessness, loss of consciousness |
| Respiratory system | Chest tightness, tachypnea, bradypnea, shortness of breath, irregular breathing, respiratory arrest, cyanosis |
| Circulatory system | Palpitation, bradycardia, tachycardia, cardiac arrest, decrease of blood pressure |
| Entry Plasmidsa | Applications |
| pL1R5-BGHpA-empty | 1. The TALEN Entry plasmid pairs can be used for |
| pL1R5-CAG-EGFP-T2A-TALEN-NN-BGHpA | TALEN functional tests. |
| pL1R5-CAG-EGFP-T2A-TALEN-NI-BGHpA | 2. The TALEN Entry plasmids contain EGFP or |
| pL1R5-CAG-EGFP-T2A-TALEN-NG-BGHpA | mCherry reporters, which can be used for |
| pL1R5-CAG-EGFP-T2A-TALEN-HD-BGHpA | monitoring transfection efficiency and cell sorting. |
| 3. Through LR recombination, the TALEN pairs can | |
| pL5L2-empty | be transferred to pPB-DEST or pPB-Puro-DEST or |
| pL5L2-EF1α-mCherry-T2A-TALEN-NN | other destination vectors. |
| pL5L2-EF1α-mCherry-T2A-TALEN-NI | 4. TALENs in pL1R5-BGHpA vectors together with |
| pL5L2-EF1α-mCherry-T2A-TALEN-NG | pL5L2 empty vector can be recombined into |
| pL5L2-EF1α-mCherry-T2A-TALEN-HD | pAd/PL-DEST to produce adenoviruses with CAG |
| EGFP. Alternatively the reverse insertion of | |
| pL5L2-CAG-mCherry-T2A-TALEN-NN | TALENs in pL5L2 vectors together with pL1R5 - |
| pL5L2-CAG-mCherry-T2A-TALEN-NI | BGHpA empty vector can be recombined into |
| pL5L2-CAG-mCherry-T2A-TALEN-NG | pAd/PL-DEST to produce adenoviruses with EF1α |
| pL5L2-CAG-mCherry-T2A-TALEN-HD | mCherry or CAG-mCherry. |
| Gene | Primers | Sequence |
| PRP8 | Forward | TCATGGCTGCGTCTGAAGTA |
| Reverse | GGCTCAAACCCTTCCGATAG | |
| MET18 | Forward | TGCTGGAAGTTGTCGTTGC |
| Reverse | TCGTTTTTGGAGAGGTGGTC | |
| CTT1 | Forward | GATTCCGTTCTACAAGCCAGAC |
| Reverse | GGAGTATGGACATCCCAAGTTTC | |
| CTA1 | Forward | CCAACAGGACAGACCCATTC |
| Reverse | TTACCCAAAACGCGGTAGAG |
| Species | # of Strains | Genome size (Mb) | GC content (%) |
| Fungi (Kingdom) | |||
| Ascomycota (Phylum) | |||
| Pezizomycotina (Subphylum) | |||
| Aspergillus fumigatus | 2 | 29.3 ± 0.1 | 49.672 ± 0.178 |
| Aspergillus niger | 2 | 35.6 ± 2.3 | 50.365 ± 0.012 |
| Coccidioides immitis | 4 | 28.3 ± 0.7 | 46.529 ± 0.514 |
| Coccidioides posadasii | 11 | 27.2 ± 0.9 | 46.839 ± 0.537 |
| Histoplasma capsulatum | 5 | 36.2 ± 4.7 | 43.400 ± 1.859 |
| Paracoccidioides brasiliensis | 3 | 30.7 ± 2.0 | 43.868 ± 0.930 |
| Fusarium graminearuma | 2 | 36.6 | 48.283 |
| Saccharomycotina (Subphylum) | |||
| Candida albicans | 2 | 14.4 ± 0.1 | 33.462 ± 0.010 |
| Saccharomyces cerevisiae | 3 | 11.9 ± 0.3 | 38.252 ± 0.090 |
| Saccharomyces bayanus | 2 | 11.7 ± 0.3 | 40.196 ± 0.011 |
| Saccharomyces mikataeb | 2 | 11.1 ± 0.5 | 37.920 ± 0.315 |
| Basidiomycota (Phylum) | |||
| Agricomycotina (Subphylum) | |||
| Cryptococcus neoformans | 4 | 19.2 ± 0.2 | 48.251 ± 0.316 |
| Ustilaginomycotina (Subphylum) | |||
| Ustilago maydis | 2 | 19.7 ± 0.0 | 53.995 ± 0.045 |
| Chytridiomycota (Phylum) | |||
| Batrachochytrium dendrobatidis | 2 | 24.1 ± 0.3 | 39.261 ± 0.011 |
| Chloroplastida (Kingdom) | |||
| Charophyta (Phylum) | |||
| Oryza sativa | 2 | 399.2 ± 38.4 | 43.530 ± 0.046 |
| Vertebrata (Phylum) | |||
| Vertebrata (Phylum) | |||
| Homo sapiens | 4 | 3,052.2 ± 409.3 | 40.878 ± 0.042 |
| Complication | Evisceration Incidence/% | Enucleation Incidence/% | P value (Fisher’s exact test) |
| No complication | 30/71.4 | 16/61.5 | 0.43 |
| Wound dehiscence | 4/9.5 | 3/11.5 | 1.00 |
| Implant exposure | 2/4.8 | 1/3.8 | 1.00 |
| Implant extrusion | 1/2.4 | 2/7.7 | 0.55 |
| Implant migration | 0/0 | 1/3.8 | 0.38 |
| Infection | 2/4.8 | 1/3.8 | 1.00 |
| Deep superior sulcus | 3/7.1 | 2/7.7 | 1.00 |
| Total | 42/100 | 26/100 |
| Female | |||||||
| Genotype | wt/wt | KO/KO | |||||
| Treatment | Vehicle | AngII | Δ | Vehicle | AngII | Δ | |
| Aorta | HR (bpm) | 515.6 ± 8.0 | 512.3 ± 7.1 | − 3.3 | 504.4 ± 6.8 | 503.6 ± 3.6 | − 0.8 |
| SP (mmHg) | 109.3 ± 3.3 | 135.5 ± 4.1* | 26.2 | 119.7 ± 6.3 | 130.9 ± 3.7 | 11.2 | |
| DP (mmHg) | 78.1 ± 2.3 | 83.7 ± 2.5 | 5.6 | 83.1 ± 2.8 | 86.8 ± 2.4 | 3.7 | |
| MAP (mmHg) | 88.5 ± 2.6 | 101 ± 2.8* | 12.5 | 95.3 ± 3.9 | 101.5 ± 2.7 | 6.2 | |
| PP (mmHg) | 31.2 ± 1.2 | 51.8 ± 3.0* | 20.6 | 36.6 ± 3.6 | 44.0 ± 2.2 | 7.4 | |
| LV | HR (bpm) | 500.9 ± 8.2 | 500.4 ± 2.2 | − 0.5 | 514.0 ± 9.6 | 508.9 ± 4.8 | − 5.1 |
| SP (mmHg) | 106.5 ± 3.1 | 128.8 ± 1.5* | 22.3 | 112.9 ± 4.7 | 126.4 ± 2.6* | 13.5 | |
| EDP (mmHg) | 6.4 ± 0.5 | 7.0 ± 1.1 | 0.6 | 5.3 ± 0.3 | 8.7 ± 1.1* | 3.4 | |
| dP/dT max (mmHg/s) | 9799 ± 860.0 | 10,998 ± 426.2 | 1199 | 11,343 ± 745 | 12,455 ± 383.9 | 1112 | |
| dP/dT min (mmHg/s) | − 9019 ± 853.7 | − 9253 ± 584.0 | − 234 | − 9262 ± 470.2 | − 9718 ± 330.8 | − 456 | |
| Morphometry | Body weight (g) | 21.2 ± 0.3 | 22.3 ± 0.3 | 1.1 | 23.3 ± 0.5 | 22.3 ± 0.3 | −1.0 |
| Tibia length (mm) | 16.1 ± 0.1 | 16.1 ± 0.1 | 0 | 16.4 ± 0.1 | 16.4 ± 0.1 | 0 | |
| HW:TL (mg/mm) | 6.5 ± 0.1 | 8.1 ± 0.2* | 1.6 | 6.8 ± 0.1 | 8.2 ± 0.2* | 1.4 | |
| LVW:TL (mg/mm) | 4.6 ± 0.1 | 6.0 ± 0.2* | 1.4 | 4.9 ± 0.1 | 6.2 ± 0.1* | 1.3 | |
| RVW:TL (mg/mm) | 1.4 ± 0.0 | 1.4 ± 0.0 | 0 | 1.4 ± 0.0 | 1.4 ± 0.0 | 0 | |
| Lung:TL (mg/mm) | 9.9 ± 0.4 | 9.5 ± 0.3 | − 0.4 | 9.3 ± 0.5 | 9.7 ± 0.4 | 0.4 |
| Epigenetic Process | Target | Function |
| DNA Methylation | DNA in cell or viral epigenome | Typically silence genes |
| Nucleosome Location | Cellular and Viral Chromatin | Nucleosome position controls access to DNA sequences |
| Histone Modification | Cellular and Viral Chromatin | Histone acetylation and methylation on H3K4/H3K36 association with activation of transcription, methylation on H3K9 and H3K27 is associated with repression, methylation of H4K20 could result in either activation or repression |
| Histone Variants | Cellular and Viral Chromatin | Not yet well understood for viruses |
| miRNA | Cellular and Viral Chromatin | Modify gene expression at the level of translation |
| Chromosomes | % Aneuploidy (loss, gain) | |||
| Healthy brain | AT | AD | Schizo | |
| 1 | 0.5 (0.3, 0.2) | 2.8 (1.7, 1.1) | 0.7 (0.3, 0.4) | 1.8 (0.9, 0.9) |
| 7 | 0.7 (0.3, 0.4) | 1.5 (0.6, 0.8) | NA | NA |
| 8 | 1.0 (0.3, 0.7) | 2.8 (0.8, 2.0) | NA | NA |
| 9 | 1.2 (0.5, 0.7) | 1.3 (0.6, 0.7) | NA | NA |
| 11 | 0.8 (0.4, 0.3) | 3.1 (1.5, 1.5) | 1.1 (0.7, 0.4) | NA |
| 16 | 0.7 (0.1, 0.6) | 2.8 (0.4, 2.5) | NA | NA |
| 17 | 2.2 (0.4, 1.8) | 2.4 (1.2, 1.2) | 7.7 (0.5, 7.2) | NA |
| 18 | 0.9 (0.5, 0.4) | 2.5 (1.2, 1.2) | 1.0 (0.5, 0.4) | 0.5 (NR, 0.5) |
| 21 | 2.5 (1.3, 1.3) | NA | 10.7 (4.1, 6.6) | NA |
| X | 0.7 (0.3, 0.4) | 1.8 (0.3, 1.5) | 1.9 (0.7, 1.2) | 1.2 (NR, 1.2) |
| Y | 0.2 (0.1, 0.1) | 0.6 (0.0, 0.6) | NA | NA |
| Different techniques | NESP for single pulse | Ave. NESP for orthogonal pulses |
| Seventh derivative Gaussian pulse [35] | 46% | - |
| Hermite Gaussian Functions [20] | 65% | 65% |
| PM algorithm [10] | 72.41% | - |
| SOCP based FIR filter [14] | 79% | 77.5% |
| SOCP based FIR filter [13] | 92.16% | 59.26% |
| Proposed UWB pulse | 98.7% | 98.7% |
| KPs | Aqueous cells | Aqueous flare | Vitreous cells | |||||||||
| Patient number | 0 | 1 | 3 | 0 | 1 | 3 | 0 | 1 | 3 | 0 | 1 | 3 |
| 1 | +++ | ++ | ± | +++ | ++ | + | +++ | ++ | + | ++ | + | ± |
| 2 | +++ | + | − | ++ | + | − | +++ | + | + | − | − | − |
| 3 | +++ | ++ | − | ++ | + | − | ++ | + | − | − | − | − |
| 4 | ++ | + | − | ++ | + | − | ++ | + | − | + | ± | − |
| 5 | +++ | ++ | ± | +++ | + | ± | +++ | ++ | ± | ++ | + | + |
| 6 | ++ | + | + | ++ | + | − | ++ | + | − | − | − | − |
| Placing State | Other Experiment Settings |
| Static | Running the whole ARS |
| Static | Only running Sensors |
| Static | Running the ARS without activity recognition and result processing |
| Static | Running the ARS without result processing |
| Static | The phone on standby |
| Shaker | Running the whole ARS |
| Shaker | Only running Sensors |
| Shaker | Running the ARS without activity recognition and result processing |
| Shaker | Running the ARS without result processing |
| Shaker | The phone on standby |
| Lower UTI | Control | P value | |
| (n = 13) | (n = 24) | ||
| Leucocyte count (G/l) | 8.6 ± 3.3 | 6.43 ± 2.1 | NS |
| [7.4 (3.4)] | [5.6 (3.3)] | ||
| hsCRP (mg/L) | 2.9 ± 1.7 | 3.5 ± 2.3 | NS |
| [2.28 (2.81)] | [3.3 (2.5)] | ||
| PCT (ng/ml) | 0.05 ± 0 | 0.06 ± 0.02 | NS |
| [0.05 (0)] | [0.05 (0)] | ||
| IL −6 (pg/ml) | 22.5 ± 1.6 | 3.1 ± 1.6 | <0.001 |
| [5.8 (41.9)] | [2.8 (2)] | ||
| CPP (pg/ml) | 2253 ± 1323 | 224 ± 109 | <0.001 |
| [1757 (1403)] | [209 (141)] |
| Method | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 |
| A.RANKING ORDER UNDER ALL STRESS(BETTER-GOOD-AVERAGE) | |||||||||
| geNorm | MAP/UBC | FHP | EF 1-α | CGS1 | PPK | ATPase | eif4A | DPE2 | |
| NormFinder | UBC | MAP | EF 1-α | FHP | CGS1 | PPK | eif4A | ATPase | DPE2 |
| BestKeeper | MAP | UBC | FHP | PPK | CGS1 | EF 1-α | ATPase | eif4A | DPE2 |
| Δct method | UBC | MAP | FHP | EF 1-α | CGS1 | ATPase | eif4A | PPK | DPE2 |
| Comprehensive ranking | UBC | MAP | FHP | EF 1-α | CGS1 | PPK | ATPase | eif4A | DPE2 |
| B.RANKING ORDER UNDER DEHYDRATION STRESS (BETTER-GOOD-AVERAGE) | |||||||||
| geNorm | CGS1/FHP | PPK | UBC | MAP | EF 1-α | eif4A | DPE2 | ATPase | |
| NormFinder | UBC | CGS1 | FHP | MAP | EF 1-α | PPK | eif4A | DPE2 | ATPase |
| BestKeeper | CGS1 | FHP | PPK | UBC | MAP | EF 1-α | DPE2 | ATPase | eif4A |
| Δct method | UBC | CGS1 | FHP | MAP | PPK | EF 1-α | eif4A | ATPase | DPE2 |
| Comprehensive ranking | CGS1 | UBC | FHP | PPK | MAP | EF 1-α | eif4A | DPE2 | ATPase |
| C.RANKING ORDER UNDER TEMPERATURE STRESS (BETTER-GOOD-AVERAGE) | |||||||||
| geNorm | MAP/ATPase | EF 1-α | UBC | CGS1 | FHP | PPK | DPE2 | eif4A | |
| NormFinder | UBC | MAP | CGS1 | EF 1-α | ATPase | FHP | DPE2 | PPK | eif4A |
| BestKeeper | MAP | ATPase | UBC | CGS1 | PPK | EF 1-α | FHP | DPE2 | eif4A |
| Δct method | UBC | MAP | ATPase | EF 1-α | CGS1 | FHP | DPE2 | PPK | eif4A |
| Comprehensive ranking | MAP | UBC | CGS1 | ATPase | EF 1-α | FHP | PPK | DPE2 | eif4A |
| System | Effect | Manifestation |
| Renal | Renal vein compression, cortical arteriolar compression | Oliguria, rising creatinine |
| Pulmonary | Upward pressure on diaphragm, decreased compliance and functional residual capacity, increased air way resistance | Hypoxia, hypercarbia, elevated airway pressure, decreased tidal volume |
| Cardiovascular | Decreased venous return, increased afterload | Decreased cardiac output |
| Cerebral | Increased intrathoracic pressure with decreased cerebral venous outflow | Elevated Intra Cranial Pressure |
| Splanchnic | Decreased perfusion of liver and intestine | Metabolic acidosis, bowel ischemia |
| Ever Delirium (n = 125) | Never Delirium (n = 135) | p-value | |
| Characteristic | |||
| Mean age (± 1 SD; years) | 56 (± 18) | 49 (± 17) | 0.002 |
| Male | 62 (50%) | 67 (50%) | 1.0 |
| No. of Caucasians | 99 (79%) | 115 (85%) | 0.25 |
| APACHE II score, median (IQR) | 15 (10–21) | 11 (6–16) | <0.001 |
| Charlson co-morbidity index, median (IQR) | 4 (2–7) | 3 (1–6) | 0.079 |
| Diagnostic category for ICU admission (%)b | |||
| Pulmonary | 29 | 40 | |
| Gastrointestinal | 20 | 21 | |
| Metabolic | 22 | 18 | |
| Cardiac | 7 | 9 | |
| Hematology/oncology | 5 | 4 | |
| Neurologic | 5 | 3 | |
| Renal | 9 | 2 | |
| Other | 3 | 3 |
| Function-based screening | Sequence-based screening | SIGEX | |
| Screening principle | • Detecting changes by enzymatic reactions (e.g. halo formation around the colonies) | • PCR or Southern hybridization based on the DNA sequence consensus | • Trapping the operon induced by a substrate and sorting using FACS |
| Advantages | • Secures a complete form of gene or gene cluster required for desired traits• Potentially obtains completely novel genes. | • Overcomes the limitations of the heterologous expression | • Fast and economical• Any substrates that can be introduced into cytoplasm can be used in its native forms. |
| Disadvantages | • Must satisfy the expression conditions (transcription, translation, folding, secretion) in heterologous hosts | • Requires a database and analyses of the DNA sequence consensus.• Does not guarantee the acquisition of complete forms of genes or gene clusters. | • Sensitive to the orientation of the genes with desired traits• Cannot use substrates that do not migrate to cytoplasm• Sensitive to the initial FACS setting |
| Examples | antibiotics [9, 19-22], genes involved antibiotic resistance [9, 23, 24], agarases [15], amidases [13], amylases [15, 21, 25, 26], esterase/lipases [8, 15, 21, 27, 28], xylanases [29], 4-hydoxybutyrate dehydrogenase [30] alcohol oxidoreductases [14], pectate lyases [31] | amylases [26], polyketide synthases [32, 33] | Benzoate-degratative or catechol degradative operon, P450 enzyme [16] |
| Instrument | FAST Year 1 | GDS Year 1 | CDR-GS Year 1 |
| AQ Year 1 | 0.84 | 0.78 | 0.74 |
| FAQ Year 1 | 0.83 | 0.77 | 0.75 |
| MMSE Year 1 | -0.59 | -0.64 | -0.65 |
| Group | AGEs | p Value | sRAGE | p Value |
| Control group | 16.89 ± 2.98 | 0.001 | 3.01 ± 1.53 | 0.0001 |
| 16.82 (11.1) | 3 (3.8) | |||
| All Hemodialysis groups | 18.92 ± 4.1517.9 (20.2) | 8.23 ± 2.349.3 (9.6) | ||
| Diabetic HD | 19.3 ± 4.69 | 0.001 * | 8.97 ± 1.53 | 0.0001 *,# |
| 18.5 (18) | 9.6 (6.52) | |||
| Non-diabetic HD | 18.75 ± 3.8917.8 (17.1) | 7.89 ± 2.579.23 (9.6) | ||
| Control | 16.89 ± 2.9916.82 (11.1) | 3.01 ± 1.533 (3.8) | ||
| CVD | 19.49 ± 4.34 | 0.24 | 9.03 ± 1.54 | 0.003 |
| 17.9 (18) | 9.68 (6.43) | |||
| Non-CVD | 18.6 ± 4.0317.9 (17.9) | 7.77 ± 2.598.3 (9.6) | ||
| Hemodialysis sub-groups | ||||
| DM+CVD+ (1) | 18.55 ± 5.23 | 0.011 ′′ | 8.97 ± 1.85 | 0.015 ′′ |
| 17.24 (18) | 9.77 (6.4) | |||
| DM+CVD− (2) | 20.09 ± 4.0321.03 (13.9) | 8.97 ± 1.159.1 (2.77) | ||
| DM−CVD+ (3) | 20.25 ± 3.3819.6 (9.6) | 9.09 ± 1.279.68 (3.83) | ||
| DM−CVD− (4) | 18.13 ± 3.9516.98 (17.1) | 7.39 ± 2.818.3 (9.6) |
| odds ratio | 95% CI | p-value | |
| Age, years (mean ± SD) | 1.01 | 0.88–1.15 | 0.920 |
| Education, years (mean ± SD) | 1.02 | 0.88–1.21 | 0.778 |
| Gender, female (%) | 3.33 | 0.68–18.62 | 0.146 |
| 1st CDR-SB | 0.90 | 0.63–1.28 | 0.573 |
| 1st MMSE | 1.00 | 0.82–1.22 | 0.962 |
| Cilostazol use | 0.51 | 0.12–1.99 | 0.331 |
| ApoE ε4(+),n (%) | 0.39 | 0.07–1.92 | 0.248 |
| Items | single | multiple | ||||
| OR | 95% CI | P | OR | 95% CI | P | |
| Sing songs with your child | 1.82a | 1.10–3.01 | 0.0204 | 1.71a | 1.01–2.89 | 0.0475 |
| Gender | 2.74a | 1.10–6.82 | 0.0303 | 2.73a | 1.04–7.18 | 0.0416 |
| Siblings | 1.47 | 0.62–3.47 | 0.3799 | 1.70 | 0.68–4.22 | 0.2536 |
| Family type | 0.98 | 0.27–3.49 | 0.9722 | 0.89 | 0.22–3.70 | 0.8735 |
| Mother’s age | 0.49 | 0.21–1.17 | 0.1067 | 0.60 | 0.20–1.81 | 0.3631 |
| Mother’s education | 0.86 | 0.59–1.24 | 0.4141 | 0.85 | 0.56–1.29 | 0.4560 |
| Mother’s occupation | 0.77 | 0.33–1.76 | 0.5276 | 0.75 | 0.31–1.84 | 0.5340 |
| Father’s age | 0.62 | 0.32–1.19 | 0.1490 | 0.68 | 0.27–1.71 | 0.4093 |
| Father’s education | 1.05 | 0.79–1.39 | 0.7451 | 0.97 | 0.68–1.38 | 0.8496 |
| Family’s economic status | 1.38 | 0.88–2.15 | 0.1600 | 1.50 | 0.99–2.52 | 0.1239 |
| H-L test (P) | — | 0.3878 |
| Pathology | Young | AdV | 1 mo post DSB | 2 mo post DSB | Old |
| Karyomegaly | 1.62±0.38 | 2.27±0.14 | 3.00±0* | 2.25±0.25 | 4.00±0** |
| Intranuclear inclusions | 0±0 | 0.09±0.10 | 0.38±0.13# | 0.38±0.13# | 3.00±0** |
| Lobular infiltrates | 0.38±0.24 | 0.81±0.26 | 1.63±0.13* | 1.38±0.24 | 3.67±0.33** |
| Portal infiltrates | 1.12±0.12 | 0.90±0.09 | 1.25±0.15* | 1.25±0.25 | 2.33±0.66* |
| EMH | 0±0 | 0±0 | 0.75±0.25* | 0.25±0.25 | 2.33±0.66* |
| Lipofuscin | 0.37±0.12 | 0.20±0.13 | 0.25±0.14 | 0±0 | 2.0±0.29* |
| Program | 50 | 150 | 250 |
| B-TBLASTN | 0.458 ± 0.004 | 0.478 ± 0.002 | 0.484 ± 0.001 |
| S-TBLASTN | 0.454 ± 0.004 | 0.471 ± 0.002 | 0.478 ± 0.001 |
| C-TBLASTN | 0.455 ± 0.004 | 0.474 ± 0.002 | 0.481 ± 0.001 |
| Classifier | Accuracy (%) | Recall rate (%) | F1 measure | Time (s) |
| EEG | 94.2 | 92.8 | 93.7 | 0.01 |
| Skeleton | 93.8 | 93.4 | 93.8 | 0.01 |
| Skeleton-EEG | 94.7 | 94.6 | 94.2 | 0.01 |
| Integrated | 96.5 | 96.4 | 96.2 | 0.01 |
| Group | Cases, n | In-stent restenosis, n (%) | Angina, n (%) | Myocardial infarction, n (%) | Heart failure, n (%) | Revascularization (unchanged number), n (%) | All-cause mortality, n (%) | MACE events, n (%) | Medical costs, RMB |
| CR | 1020 | 121 (11.9) | 307 (30.1) | 18 (1.7) | 67 (6.5) | 142 (13.9) | 12 (1.2) | 173 (17) | 62,100 |
| FR | 856 | 111 (12.9) | 246 (28.7) | 19 (2.2) | 84 (9.8) | 111 (12.9) | 15 (1.8) | 248 (29) | 83,200 |
| PR | 433 | 63 (14.6) | 191 (44.1) | 12 (2.8) | 93 (21.4) | 98 (22.8) | 17 (3.9) | 290 (67) | 66,900 |
| Interval from calving | ||||
| 50-70 | 71-100 | 101- | Total | |
| Parity | ||||
| 0 | 27.3 (22) | |||
| 1 | 25.0 (8) | 10.7 (28) | 25.0 (8) | 15.9 (44) |
| 2-5 | 18.2 (11) | 16.9 (59) | 25.0 (12) | 18.3 (82) |
| 6- | 25.0 (4) | 40.0 (10) | 50.0 (2) | 37.5 (16) |
| Total | 21.7 (23) | 17.5 (97) | 27.3 (22) |
| Probable |
| Probable CVID |
| Male or female patient who has a marked decrease of IgG (at least 2 SD below the mean for age) and a marked decrease in at least one of the isotypes IgM or IgA, and fulfils all of the following criteria: |
| ∙ Onset of immunodeficiency at >2 years of age |
| ∙ Absent isohemagglutinins and/or poor response to vaccines |
| ∙ Defined causes of hypogammaglobulinemia have been excluded |
| Possible CVID |
| Male or female patient who has a marked decrease (at least 2 SD below the mean for age) in at least one of the major isotypes (IgM, IgG, and IgA) and fulfils all of the following criteria: |
| 1. Onset of immunodeficiency at >2 years of age |
| 2. Absent isohemagglutinins and/or poor response to vaccines |
| 3. Defined causes of hypogammaglobulinemia have been excluded |
| Affymetrix ID | FoldΔ | GenBank | Gene | Gene Description |
| 1384944_at | 43.3 | BE116855 | Bcl11b | B-cell leukemia/lymphoma 11B (predicted) |
| 1370041_at | 11.7 | NM_053440 | Stmn2 | stathmin-like 2 |
| 1378776_at | 6.8 | BE097103 | Pou6f1 | POU domain, class 6, transcription factor 1 |
| 1368411_a_at | 4.6 | X74211 | Mtap2 | microtubule-associated protein 2 |
| 1391019_at | 3.4 | BF285698 | Slitrk1 | SLIT and NTRK-like family, member 1 (predicted) |
| 1377308_a_at | 3.4 | BF398408 | Neurotrophic tyrosine kinase, receptor, type 3 | |
| 1368097_a_at | 3.4 | NM_053865 | Rtn1 | reticulon 1 |
| 1369765_at | 3.3 | NM_022384 | Ascl1 | achaete-scute complex homolog-like 1 (Drosophila) |
| 1371618_s_at | 3.3 | AI229029 | Tubb3 | tubulin, beta 3 |
| 1370043_at | 3.3 | NM_031753 | Alcam | activated leukocyte cell adhesion molecule |
| 1372299_at | 3.0 | AI013919 | Cdkn1c | cyclin-dependent kinase inhibitor 1C (P57) |
| 1368261_at | 2.7 | NM_053817 | Nrxn3 | neurexin 3; hypothetical gene supported by NM_053817 |
| 1395357_at | 2.7 | BG672052 | Map1b | microtubule-associated protein 1b |
| 1390671_at | 2.7 | AI044666 | Igf1r | Insulin-like growth factor 1 receptor |
| 1373683_at | 2.7 | AI230396 | Fyn | fyn proto-oncogene |
| 1387200_at | 2.6 | NM_021770 | Olig1 | oligodendrocyte transcription factor 1 |
| 1392477_at | 2.6 | AI059914 | Etv1 | ets variant gene 1 (predicted) |
| 1367918_at | 2.5 | NM_031066 | Fez1 | fasciculation and elongation protein zeta 1 (zygin I) |
| 1387274_at | 2.5 | NM_012943 | Dlx5 | distal-less homeobox 5 |
| 1388015_at | 2.4 | U04998 | Ptprz1 | protein tyrosine phosphatase, receptor-type, Z polypept. 1 |
| 1379693_at | 2.4 | AI409154 | Robo2 | Roundabout 2 (Drosophila) |
| 1395986_at | 2.3 | BF391439 | Slit2 | slit homolog 2 (Drosophila) |
| 1388419_at | 2.3 | AW915005 | CDK5 regulatory subunit associated protein 2 | |
| 1369213_at | 2.3 | NM_017345 | neural cell adhesion molecule L1 | |
| 1379526_at | 2.3 | BG374506 | Mbp | Myelin basic protein |
| 1387424_at | 2.2 | NM_012884 | Cntn2 | contactin 2 |
| 1370124_at | 2.2 | NM_053968 | Mt3 | metallothionein 3 |
| 1368148_at | 2.2 | NM_012610 | Ngfr | nerve growth factor receptor (TNFR superfamily, mem 16) |
| 1381215_at | 2.2 | AA900967 | PREDICTED: similar to Numbl protein [Rattus norvegicus] | |
| 1368472_at | 2.1 | NM_031320 | Celsr3 | cadherin EGF LAG seven-pass G-type receptor 3 |
| 1396150_at | 2.1 | AW917275 | Cldn1 | claudin 1 |
| 1374403_at | 2.1 | BF412072 | Efnb1 | ephrin B1 |
| 1382205_at | 2.1 | AW527509 | Transcribed locus | |
| 1386948_at | 2.0 | NM_012987 | Nes | Nestin |
| 1368879_a_at | 2.0 | AF413212 | Gnao | guanine nucleotide binding protein, alpha o |
| G6PD Status | Parasite density/log10 μl | Hb (g/dl) | HCT (%) | MCV (fl) | MCH (pg) | MCHC (%) |
| Normal | 2.97 ± 1.22 | 12.44 ± 2.70 | 37.86 ± 8.609 | 85.51 ± 6.68 | 26.87 ± 5.58 | 31.98 ± 2.50 |
| Deficient | 1.64 ± 1.55 | 14.15 ± 3.50 | 43.13 ± 10.54 | 85.75 ± 5.84 | 28.12 ± 4.92 | 32.43 ± 1.43 |
| p-value | 0.000 | 0.006 | 0.005 | 0.834 | 0.201 | 0.149 |
| Variables | Adjusted odds ratio | 95 % confidence interval | P |
| Previous-day aPTTa | |||
| ≥46 and ≤55 s | 2.03 | 0.68–6.10 | 0.30 |
| ≥56 and ≤69 s | 1.32 | 0.41–4.27 | 0.47 |
| ≥70 s | 3.24 | 1.11–9.44 | 0.03 |
| Previous-day anticoagulation | 0.21 | 0.06–0.52 | <0.01 |
| Daily lowest corporeal temperature | 1.79 | 1.20–2.66 | <0.01 |
| APACHE III score | 1.03 | 1.01–1.04 | <0.01 |
| Protein identification | Accession number (UniProtKB/TrEMBL) | Spot | Fold | Mascot score | Sequence coverage (%) | Peptide number | Molecular mass (kDA) | pI |
| gSG6 SP | Q9BIH5_ANOGA | 794 | 1.8 | 14 | 45.22 | 14 | 13.1 | 5.49 |
| gSG1b SP | Q9BIH6_ANOGA | 1197 | 1.6 | 59 | 46.23 | 59 | 43.6 | 7.58 |
| Long form D7 SP | Q7PJ76_ANOGA | 1144 | 1.4 | 15 | 40.19 | 15 | 35.6 | 5.90 |
| SG5 SP | Q9BIH7_ANOGA | 1228 | 2.0 | 15 | 29.22 | 15 | 38.2 | 6.47 |
| 1229 | 1.6 | 14 | 29.52 | 14 | ||||
| TRIO protein SP | Q8WR22_ANOGA | 819 | 1.4 | 12 | 31.46 | 12 | 43.7 | 6.46 |
| 1228 | 2.0 | 21 | 36.83 | 21 | ||||
| 1229 | 1.6 | 15 | 29.41 | 15 | ||||
| 1239 | 1.4 | 25 | 40.15 | 25 |
| Men | Women | |||||
| Non-NAFLD | NAFLD | P | Non-NAFLD | NFALD | P | |
| N | 311 | 214 | 876 | 610 | ||
| Age, yr | 56 (44–64) | 57 (44–66) | 0.723 | 51 (41–61) | 59 (51–64) | <0.001 |
| Blood lead level, μg/dL | 5.12 (3.30–6.90) | 5.65 (4.00–7.76) | 0.006 | 4.24 (2.80–6.24) | 4.80 (3.20–6.94) | <0.001 |
| Blood cadmium level, μg/dL | 0.15 (0.05–0.32) | 0.21 (0.08–0.36) | 0.017 | 0.14 (0.05–0.31) | 0.16 (0.06–0.31) | 0.295 |
| ALT, U/L | 19.0 (15.0–26.0) | 24.0 (18.0–34.0) | <0.001 | 15.0 (12.0–20.0) | 18.0 (15.0–25.0) | <0.001 |
| Educational level, % | 0.380 | 0.001 | ||||
| <High School | 76.0 | 77.9 | 83.9 | 90.5 | ||
| High school | 15.4 | 16.8 | 10.7 | 7.5 | ||
| >High School | 8.6 | 5.3 | 5.4 | 2.0 | ||
| Waist circumference, cm | 76.5 (72.0–83.0) | 86.0 (82.0–92.0) | <0.001 | 72.0 (68.0–78.0) | 83.0 (77.0–89.0) | <0.001 |
| Body mass index, kg/m2 | 22.5 (20.8–24.5) | 26.1 (23.8–28.0) | <0.001 | 22.4 (20.4–24.4) | 26.0 (24.2–28.4) | <0.001 |
| LDL-cholesterol, mmol/L | 2.67 (2.26–3.09) | 2.92 (2.46–3.38) | <0.001 | 2.63 (2.24–3.09) | 2.97 (2.54–3.43) | <0.001 |
| HDL-cholesterol, mmol/L | 1.39 (1.18–1.58) | 1.22 (1.08–1.40) | <0.001 | 1.51 (1.32–1.71) | 1.39 (1.23–1.58) | <0.001 |
| Triglycerides, mmol/L | 1.10 (0.86–1.49) | 1.66 (1.19–2.35) | <0.001 | 1.06 (0.81–1.46) | 1.48 (1.08–2.14) | <0.001 |
| Total-cholesterol, mmol/L | 4.84 (4.25–5.41) | 5.09 (4.56–5.68) | 0.001 | 4.87 (4.33–5.48) | 5.27 (4.58–5.93) | <0.001 |
| Diabetes, % | 9.7 | 15.0 | 0.002 | 5.4 | 19.7 | 0.001 |
| Current smoker, % | 47.1 | 49.0 | 0.681 | 1.8 | 2.3 | 0.524 |
| Study and reference | Pack-years of smoking | |
| Controls (N) | COPDs (N) | |
| Bergen cohort from Pillai et al [26] | 19 ± 13*(810) | 32 ± 19*(823) |
| Copenhagen City Heart Study from Kaur-Knudsen et al [25] | NR | NR |
| COPDGene study from Kim et al [24] | 52 ± 29*(335) | 37 ± 19*(507) |
| COPACETIC cohort from Lambrechts et al [23] | 38.0 (28.0-46.2) (295) | 38.7 (29.7-49.5)(161) |
| LEUVEN cohort from Lambrechts et al [25] | 42.3 (30.0-50.5) (184) | 40.0 (30.0-57.0) (475) |
| NETT/NAS cohorts from Pillai et al [26] | 40 ± 28*(472) | 66 ± 30*(389) |
| New Zealand study from Young et al [27] | 40 ± 19*(488) | 47 ± 20*(458) |
| Variable category | Characteristics | n (%) |
| Sex | Male | 90 (51.7) |
| Female | 84 (48.3) | |
| Age category | < 30 | 21 (12.1) |
| 30–60 | 114 (65.5) | |
| > 60 | 39 (22.4) | |
| Level of educational | Illiterate | 60 (34.5) |
| Primary education | 74 (42.5) | |
| Secondary education | 35 (20.1) | |
| College and above | 5 (2.9) | |
| Marital status | Single | 14 (8.0) |
| Married | 142 (81.6) | |
| Divorced/separated | 18 (10.3) | |
| Regular follow up | No | 74 (42.5) |
| Yes | 100 (57.5) | |
| Family support | Yes | 63 (36.2) |
| No | 111 (63.8) | |
| Duration of diabetes treatment (years) | < 5 | 53 (30.5) |
| 5–10 | 35 (20.1) | |
| > 10 | 86 (49.4) | |
| Co-morbidity | Yes | 90 (51.7) |
| No | 84 (48.3) | |
| Type of co-morbidity | Hypertension | 71 (78.9) |
| Ischemic heart disease (IHD) | 10 (11.1) | |
| Hypertension + IHD | 5 (5.6) | |
| CKD | 2 (2.2) | |
| Others | 2 (2.2) | |
| Diabetic complications | Yes | 71 (40.8) |
| No | 103 (59.2) | |
| Type of diabetic complication | Neuropathy | 31 (43.7) |
| Retinopathy | 10 (14.1) | |
| Retinopathy + Neuropathy | 28 (39.4) | |
| Retinopthy + Neuropathy + Nephropathy | 2 (2.8) |
| Brand name | Manufacturing country | Manufacturing date | Expiring date |
| Ciprocin 500 | Bangladesh | September 2015 | September 2017 |
| Beuflox 500 | Bangladesh | June 2015 | May 2017 |
| Neofloxacin 500 | Bangladesh | August 2015 | August 2018 |
| Ciprox 500 | Bangladesh | August 2015 | August 2018 |
| Quinox 500 | Bangladesh | February 2015 | February 2018 |
| Flontin 500 | Bangladesh | September 2015 | September 2018 |
| Floxabid 500 | Bangladesh | May 2015 | May 2018 |
| Cipro A 500 | Bangladesh | March 2015 | March 2018 |
| Ciprozid DS 500 | Bangladesh | June 2015 | June 2018 |
| Rocipro 500 | Bangladesh | April 2015 | April 2018 |
| Compounds | Street | Alley | Relative Difference a (%) | Wilcoxon p-Value b | Correlation Coefficient c |
| Σ8PAHsemivolatile | 20.59 (24.00 ± 15.49) | 17.46 (20.81 ± 14.04) | 16 | 0.002 | 0.93 *** |
| Pyrene | 0.89 (0.94 ± 0.34) | 0.83 (0.89 ± 0.33) | 7 | 0.198 | 0.90 *** |
| Phe | 15.50 (18.32 ± 12.35) | 12.63 (15.40 ± 10.98) | 21 | 0.001 | 0.94 *** |
| 1-MEPH | 0.58 (0.68 ± 0.41) | 0.55 (0.64 ± 0.41) | 5 | 0.109 | 0.94 *** |
| 2-MEPH | 1.14 (1.32 ± 0.80) | 1.07 (1.24 ± 0.78) | 6 | 0.064 | 0.90 *** |
| 3-MEPH | 1.27 (1.47 ± 0.93) | 1.18 (1.39 ± 0.90) | 7 | 0.084 | 0.94 *** |
| 9-MEPH | 0.81 (0.94 ± 0.59) | 0.78 (0.93 ± 0.62) | 4 | 0.363 | 0.96 *** |
| 1,7-DMEPH | 0.10 (0.13 ± 0.09) | 0.10 (0.12 ± 0.09) | 0 | 0.975 | 0.81 *** |
| 3,6-DMEPH | 0.18 (0.21 ± 0.11) | 0.18 (0.20 ± 0.11) | 0 | 0.470 | 0.82 *** |
| Σ8PAHnonvolatile | 1.32 (1.61 ± 1.04) | 1.10 (1.37 ± 0.94) | 18 | 0.011 | 0.90 *** |
| BaA | 0.08 (0.10 ± 0.07) | 0.08 (0.10 ± 0.07) | 0 | 0.363 | 0.89 *** |
| Chry | 0.16 (0.19 ± 0.11) | 0.15 (0.18 ± 0.11) | 6 | 0.683 | 0.93 *** |
| BbFA | 0.31 (0.40 ± 0.26) | 0.24 (0.31 ± 0.21) | 25 | 0.002 | 0.83 *** |
| BkFA | 0.07 (0.10 ± 0.07) | 0.06 (0.08 ± 0.05) | 15 | 0.064 | 0.90 *** |
| BaP | 0.07 (0.09 ± 0.08) | 0.07 (0.10 ± 0.09) | 0 | 0.470 | 0.93 *** |
| BghiP | 0.40 (0.48 ± 0.32) | 0.29 (0.37 ± 0.27) | 32 | 0.004 | 0.91 *** |
| IP | 0.19 (0.23 ± 0.16) | 0.18 (0.22 ± 0.15) | 5 | 0.056 | 0.97 *** |
| Daha | 0.03 (0.03 ± 0.02) | 0.02 (0.02 ± 0.01) | 40 | 0.019 | 0.61 *** |
| All subjects [n (%)] | Subjects assessed as unexposed or probably exposed to TCE [n (%)] | |||
| Characteristics | Controls (n = 982) | Cases (n = 1,189) | Controls (n = 566) | Cases (n = 644) |
| Age at reference date (years) | ||||
| < 35 | 53 (5.4) | 68 (5.7) | 44 (7.8) | 56 (8.7) |
| 35–44 | 98 (10.0) | 153 (12.9) | 51 (9.0) | 83 (12.9) |
| 45–54 | 185 (18.8) | 261 (22.0) | 100 (17.7) | 115 (17.9) |
| 55–64 | 230 (23.4) | 316 (26.6) | 136 (24.0) | 174 (27.0) |
| ≥ 65 | 416 (42.4) | 391 (32.9) | 235 (41.5) | 216 (33.5) |
| Sex | ||||
| Female | 458 (46.6) | 523 (44.0) | 238 (42.1) | 284 (44.1) |
| Male | 524 (53.4) | 666 (56.0) | 328 (58.0) | 360 (55.9) |
| Race | ||||
| White | 787 (80.1) | 1,014 (85.3) | 452 (79.9) | 541 (84.0) |
| African American | 132 (13.4) | 91 (7.7) | 75 (13.3) | 56 (8.7) |
| Other | 63 (6.4) | 84 (7.1) | 39 (6.9) | 47 (7.3) |
| Study center | ||||
| Detroit | 144 (14.7) | 209 (17.6) | 79 (14.0) | 109 (16.9) |
| Iowa | 273 (27.8) | 352 (29.6) | 153 (27.0) | 181 (28.1) |
| Los Angeles | 273 (27.8) | 310 (26.1) | 157 (27.7) | 178 (27.6) |
| Seattle | 292 (29.7) | 318 (26.8) | 177 (31.3) | 176 (27.3) |
| Years of education | ||||
| < 12 | 97 (9.9) | 118 (9.9) | 46 (8.1) | 63 (9.8) |
| 12–15 | 584 (59.5) | 734 (61.7) | 335 (59.2) | 376 (58.4) |
| ≥ 16 | 301 (30.7) | 336 (28.3) | 185 (32.7) | 204 (31.7) |
| Missing | 0 (0.0) | 1 (0.1) | 0 (0.0) | 1 (0.1) |
| Year of first employment | ||||
| < 1950 | 239 (24.3) | 247 (20.8) | 131 (23.1) | 126 (19.6) |
| 1950–1959 | 274 (27.9) | 290 (24.4) | 153 (27.0) | 161 (25.0) |
| 1960–1969 | 225 (22.9) | 284 (23.9) | 118 (20.9) | 131 (20.3) |
| 1970–1979 | 154 (15.7) | 233 (19.6) | 91 (16.1) | 119 (18.5) |
| ≥ 1980 | 90 (9.1) | 135 (11.4) | 73 (12.9) | 107 (16.6) |
| NHL histologic typea | ||||
| Diffuse large B-cell | 366 (30.8) | 211 (32.8) | ||
| Follicular | 293 (24.6) | 146 (22.7) | ||
| Small lymphocytic lymphoma/chronic lymphocytic leukemia | 141 (11.9) | 79 (12.3) | ||
| Other or not otherwise specified | 389 (32.7) | 208 (32.4) |
| Information | Number of bits |
| Outgoing neighbours | 4 |
| Hash function number | 3 |
| Quotient value | 33 |
| (α/β)x = 2 Gy | (α/β)x = 10 Gy | ||||||
| Patient | Model | minRBE | maxRBE | meanRBE | minRBE | maxRBE | meanRBE |
| 1 | LEMDt = 10 Gy | 1.10 | 1.70 | 1.19 | 1.05 | 1.34 | 1.09 |
| 2 | 1.17 | 1.41 | 1.22 | 1.05 | 1.19 | 1.10 | |
| 1 | LEMDt = 40 Gy | 1.15 | 1.90 | 1.27 | 1.05 | 1.45 | 1.12 |
| 2 | 1.22 | 1.57 | 1.30 | 1.09 | 1.26 | 1.13 | |
| 1 | WED | 1.20 | 1.64 | 1.24 | 1.10 | 1.26 | 1.11 |
| 2 | 1.22 | 1.42 | 1.27 | 1.10 | 1.19 | 1.12 | |
| 1 | CAR | 1.20 | 1.60 | 1.27 | |||
| 2 | 1.23 | 1.43 | 1.28 |
| Inclusion | Exclusion |
| Severe illness requiring intensive care | Substituted hypothyroidism (E03.0, E03.1, E03.3 E03.9, E89.0) or substitution in case of thyroid carcinoma (C73) |
| Stay of at least 24 hours at the ICU | Hyperthyroidism treated with thyrostatic agents and exhibiting a TSH level not below the reference region (E05.0 E05.9, E06.2) |
| Manifest AIDS disease (B24) | |
| Pregnancy |
| Variables | Coefficient (95 % CI) | ||||
| Gamma | Linear | Quantile | |||
| Quantile 0.25 | Quantile 0.50 | Quantile 0.75 | |||
| Age | 0.15 (0.14, 0.17) | 0.15 (0.13, 0.17) | 0.11 (0.09, 0.12) | 0.14 (0.12, 0.16) | 0.18 (0.16, 0.21) |
| Marital statusa | |||||
| With partner | 0.59 (0.28, 0.90) | 0.60 (0.26, 0.93) | 0.43 (0.16, 0.79) | 0.54 (0.23, 0.85) | 0.76 (0.39, 1.14) |
| Race/colourb | |||||
| Brown | −0.96 (−1.51, −0.42) | −0.97 (−1.53, −0.41) | −0.43 (−0.98, 0.12) | −0.89 (−1.65, −0.14) | −1.63 (−2.30, −0.96) |
| White | −1.19 (−1.71, −0.68) | −1.23 (−1.76, −0.70) | −0.73 (−1.21, −0.25) | −1.28 (−2.03, −0.53) | −1.86 (−2.50, −1.22) |
| Mother’s schoolingc | |||||
| 9–11 years | 0.21 (−0.13, 0.56) | 0.21 (−0.17, 0.58) | −0.10 (−0.40, 0.20) | 0.27 (−0.09, 0.62) | 0.21 (−0.19, 0.61) |
| 12 or more years | 0.69 (0.26, 1.12) | 0.80 (0.34, 1.26) | 0.42 (0.02, 0.81) | 0.34 (−0.09, 0.76) | 0.78 (0.13, 1.43) |
| Domestic overloadd | |||||
| High | 0.60 (0.27, 0.94) | 0.63 (0.28, 0.98) | 0.43 (0.11, 0.74) | 0.61 (0.23, 0.99) | 0.89 (0.48, 1.31) |
| Years worked at night | 0.03 (0.01, 0.06) | 0.03 (0.01, 0.06) | 0.00 (−0.03, 0.02) | 0.03 (−0.01, 0.06) | 0.04 (0.01, 0.07) |
| Self-rated healthe | |||||
| Poor | 1.52 (1.20, 1.85) | 1.62 (1.28, 1.97) | 1.12 (0.79, 1.45) | 1.50 (1.12, 1.87) | 1.75 (1.32, 2.19) |
| Consumption of fried foodf | |||||
| 1–3×/month | 1.00 (0.41, 1.58) | 1.06 (0.42, 1.71) | 0.93 (0.26, 1.61) | 0.90 (0.25, 1.55) | 0.99 (0.02, 1.96) |
| 1–3×/week | 1.22 (0.64, 1.80) | 1.27 (0.62, 1.91) | 0.86 (0.20, 1.52) | 0.95 (0.28, 1.63) | 1.24 (0.24, 2.24) |
| 4–6×/week | 1.41 (0.71, 2.11) | 1.61 (0.84, 2.37) | 1.02 (0.30, 1.74) | 1.20 (0.38, 2.02) | 1.55 (0.45, 2.65) |
| Daily | 1.50 (0.69, 2.32) | 1.42 (0.53, 2.30) | 0.82 (0.13, 1.51) | 1.01 (0.17, 1.84) | 2.14 (0.99, 3.29) |
| Physical inactivityg | |||||
| Yes | 0.75 (0.42, 1.80) | 0.80 (0.43, 1.15) | 0.45 (0.17, 0.74) | 0.78 (0.46, 1.10) | 0.88 (0.49, 1.27) |
| BMI at age 20 years | 0.93 (0.88, 0.99) | 0.90 (0.81, 0.91) | 0.84 (0.78, 0.90) | 0.97 (0.92, 1.03) | 1.09 (1.03, 1.16) |
| Group A | Group B | |
| Symptoms score (NIH-CPSI questionnaire 0–43) (±S.D.) | ||
| Baseline | 21.85 ± 5.23 | 22.56 ± 5.78 |
| 2 months | 12.00 ± 4.34 | 5.23 ± 2.76 |
| 4 months | 10.48 ± 4.14 | 4.11 ± 2.32 |
| 6 months | 13.26 ± 4.88 | 3.67 ± 1.98 |
| Pain score (NIH-CPSI questionnaire 0–21) (±S.D.) | ||
| Baseline | 11.65 ± 3.23 | 12.00 ± 2.78 |
| 2 months | 6.20 ± 2.35 | 2.13 ± 1.90 |
| 4 months | 5.82 ± 2.10 | 1.65 ± 1.17 |
| 6 months | 8.06 ± 2.81 | 1.25 ± 0.99 |
| Urinary score (NIH-CPSI questionnaire 0–10) (±S.D.) | ||
| Baseline | 4.65 ± 2.11 | 4.26 ± 2.28 |
| 2 months | 2.35 ± 1.35 | 1.34 ± 0.89 |
| 4 months | 2.10 ± 1.15 | 1.11 ± 0.89 |
| 6 months | 2.65 ± 1.44 | 1.01 ± 0.76 |
| Symptoms (%) | ||
| Baseline | 76 (100) | 77 (100) |
| 2 months | 15 (19.7) | 7 (9) |
| 4 months | 18 (23.7) | 7 (9) |
| 6 months | 20 (26.3) | 5 (6.5) |
| QoL (NIH-CPSI questionnaire 0–12) (±S.D.) | ||
| Baseline | 5.76 ± 2.44 | 5.66 ± 2.39 |
| 2 months | 2.89 ± 1.68 | 1.85 ± 1.00 |
| 4 months | 2.60 ± 1.43 | 1.66 ± 0.95 |
| 6 months | 3.09 ± 1.74 | 1.40 ± 0.94 |
| Candidates | Anatomical evidence to ARC or Kiss1 neurons | ICV or electrophysiology studies | Receptors expressed in Kiss1 neurons | Physiological relevance |
| Agouti-related peptide/neuropeptide Y (AgRP/NPY) | AgRP neurons formed synaptic connections with Kiss1ARC neurons (mice) (135) | Channel rhodopsin-assisted mapping indicated AgRP neurons formed inhibitory synaptic connections with Kiss1ARC neurons (mice) (135) | Npy1r, Npy2r and Npy5r (82) | Chemogenetic activation of AgRP neurons inhibited fertility in vivo (135) |
| Arginine vasopressin (AVP) | AVP-immunoreactive fibers in close apposition with Kiss1RP3V neurons (hamsters) (32) | AVP-stimulated Kiss1RP3V neurons (105) | Avp1r in Kiss1RP3V neurons (32, 105) | Circadian AVP signaling on Kiss1RP3V neurons is facilitated by estrogen during LH surge (32, 105) |
| Corticotropin-releasing hormone (CRH) | Close appositions of CRH-immunoreactive fibers and Kiss1 neurons (125) | 1. Central administration of CRH suppressed LH secretion in rats (117).2. CRH stimulated LH and increased GnRH pulse amplitude in sheep (118, 119) | CRHR (125) | Possible regulator of GnRH secretion in stress-induced reproductive disorders |
| Dynorphin (DYN) | DYN-immunoreactive fibers in close apposition with Kiss1ARC neurons (rats and sheep) (171, 172) | ICV injection of dynorphin in adult male rats suppressed LH secretion (71) | Oprk1 or KOR (39, 59, 73) | Inhibitory |
| Ghrelin | 1. ICV administration inhibited LH secretion (rats and sheep) (143, 144).2. Ghrelin acts on a subset of Kiss1ARC neurons and estradiol increases the sensitivity of these neurons to ghrelin signals (mice) (147) | Ghsr or GHSR1A (147) | Inhibitory | |
| Leptin | ICV leptin treatment to fasted adult rats increased LH pulse frequency, amplitude, and mean levels (140) | Lepr (83, 141) | Kiss1 neurons are indirect target of leptin during puberty onset (142) | |
| Neurokinin B (NKB) | NKB-immunoreactive fibers in close apposition with Kiss1ARC neurons (rats and sheep) (65, 172) | NKB increased action potential firing of Kiss1ARC neurons via activation of NK3R (57–59) | NK1 tachykinin receptor (NK1R), NK2R and NK3R (58) | Stimulatory |
| Pituitary adenylate cyclase-activating peptide (PACAP) | Channel rhodopsin-assisted mapping indicated PACAP neurons from the PMV synapses onto Kiss1 neurons (mice) (81) | 1. ICV administered PACAP depressed plasma LH amplitude and pulse frequency in gonadectomized ewes (75).2. PACAP elevated the plasma LH levels in male rats (76).3. PMV PACAP neurons formed stimulatory synapses with Kiss1 neurons (mice) (81) | Adcyap1r1 (81, 82) | Critical for ovulatory cycling and fertility in females, acts as permissive role for leptin or nutritional regulation of reproductive function (81) |
| Proopiomelanocortin/Cocaine- and amphetamine-regulated transcript | Appositions between α-MSH fibers and Kiss1ARC neurons (rats and sheep) (131, 134) | Central alpha-MSH can stimulate or inhibit LH secretion in rats (129, 130) | MC4R (134) | Kiss1ARC neurons relay the stimulatory effects of melanocortin signaling onto the reproductive axis during puberty (134) |
| Relaxin-3 | Dense relaxin-3-immunoreactive fibers projecting to the ARC (mice) (103) | ICV administration of human relaxin-3 in adult male rats stimulated LH secretion (102) | Rxfp 1 (82) | Stimulatory |
| RFamide-related peptide-3 (RFRP-3) | RFRP-3-immunoreactive fibers contacted Kiss1 neurons (mice and rats) (33, 90) | 1. ICV RFRP-3 injection inhibits LH secretion in rats (91, 92), whereas it had no effects (97) in ewes.2. Stimulates LH secretion in male hamsters (94, 95), but inhibits LH release in females (87, 93) | Gpr147 or Npffr1 (33, 90) | Primary central target for the inhibitory action of melatonin signal on reproductive function (98) |
| Somatostatin (SST) | Appositions between SST-immunoreactive fibers and Kiss1 neurons (sheep) (85) | Inhibits episodic LH secretion during anestrus in sheep (84). | Sstr1, 2, 3, and 5 (82) | Inhibitory |
| Substance P (SP) | SP-immunoreactive fibers in close apposition with Kiss1ARC neurons (monkey) (70) | 1. ICV administration of SP showed increased LH release (67).2. SP activates Kiss1ARC neurons (58) | Tacr1 or NK1R (68) | Stimulatory; critical in sustaining reproductive capabilities in female mice (66) |
| Body Site | TPS Technique | Energy |
| Brain | 3D | 6 MV, 6 MV FFF |
| Brain | IMRT, VMAT | 6 MV |
| Whole Brain | 3D | 6 MV |
| Head and Neck bilateral | 3D, IMRT, VMAT | 6 MV |
| Lung ‐ Left upper lobe | 3D, IMRT | 6 MV |
| Peak a | Carotenoid | tR b (min) | λmax c (nm) | % III/II | % AB/AII | [M + H]+ (m/z) | MS/MS fragment ions (positive mode) (m/z) | [M − H]− (m/z) | MS/MS fragment ions (negative mode)(m/z) |
| 26 | crustaxanthin | 7.9 | 422, 449, 476 | 40 | 0 | 601 | 583 [M + H − 18]+, 565 d [M + H − 18 − 18]+, 547 [M + H − 18-18-18]+, 509 [M + H − 92]+ | 599 | 581 [M − 18]−, 563 [M − 18 − 18]−, 545 [M − 18 − 18 − 18]−, 507 [M − 92]−, 493 [M − 106]− |
| 27 | crustaxanthin | 8.5 | 422, 449, 476 | 35 | 0 | 601 | 583 [M + H − 18]+, 565 [M + H − 18 − 18]+, 547 d [M + H − 18 − 18 − 18]+, 509 [M + H − 92]+ | 599 | 581 [M − 18]−, 563 [M − 18 − 18]−, 545 [M − 18 − 18 − 18]−, 507 [M − 92]− |
| 28 | cis-crustaxanthin | 9.0 | 337, 422, 449, 476 | 40 | 6 | 601 | 583 [M + H − 18]+, 565 [M + H − 18 − 18]+, 547 [M + H − 18 − 18 − 18]+, 509 [M + H − 92]+ | 599 | 581 [M − 18]−, 563 [M − 18 − 18]−, 545 [M − 18 − 18 − 18]−, 507 [M − 92]− |
| 29 | cis-crustaxanthin | 9.3 | 337, 420, 444, 470 | 20 | 39 | 601 | 583 [M + H − 18]+, 565 [M + H − 18 − 18]+, 547 [M + H − 18 − 18 − 18]+, 509 [M + H − 92]+ | 599 | 581 [M − 18]− |
| Characteristic | Variable | Case |
| Gender | Male | 24165 |
| Female | 19825 | |
| Site | Colon | 23563 |
| Rectal | 20427 | |
| Colon | Proximal | 7588 |
| Distal | 7305 | |
| unknown | 8670 | |
| Pathologic classification | Adenocarcinoma | 30845 |
| Mucinous carcinoma | 1716 | |
| Other types | 1014 | |
| unknown | 10415 |
| MetS present (n = 37) | MetS absent (n = 38) | p | |
| Age (years) | 47 ± 6 | 40 ± 8 | <0.001 |
| Body mass index (kg/m2) | 30.9 (24.2-42.5) | 23.4 (17.6-29.8) | <0.001 |
| Waist circumference (cm) | 107.0 (94.0-135.0) | 87.0 (71.0-93.5) | <0.001 |
| Height (cm) | 180 ± 6 | 180 ± 6 | 0.665 |
| Current smokers (N, %) | 13 (35) | 4 (10) | 0.014 |
| Systolic blood pressure (mmHg) | 132 ± 14 | 115 ± 10 | <0.001 |
| Diastolic blood pressure (mmHg) | 88 ± 9 | 74 ± 6 | <0.001 |
| Total cholesterol (mmol/L) | 5.25 ± 0.74 | 4.38 ± 0.80 | <0.001 |
| Low-density lipoprotein cholesterol (mmol/L) | 3.25 ± 0.71 | 2.52 ± 0.67 | <0.001 |
| High-density lipoprotein cholesterol (mmol/L) | 1.02 ± 0.26 | 1.50 ± 0.40 | <0.001 |
| Triglycerides (mmol/L) | 2.20 (0.65-6.26) | 0.72 (0.35-1.57) | <0.001 |
| fP-glucose (mmol/L) | 5.8 (4.6-6.9) | 5.0 (4.4-6.0) | <0.001 |
| fS-insulin (mU/L) | 9.3 (3.3-36.9) | 2.9 (0.9-7.7) | <0.001 |
| HOMA-IR index | 2.6 (0.8-8.0) | 0.6 (0.2-2.0) | <0.001 |
| Myocardial triglyceride content (%) | 0.90 (0.31-2.33) | 0.43 (0.14-1.39) | <0.001 |
| Epicardial fat (mm2) | 838 (385-1753) | 518 (251-1129) | <0.001 |
| Pericardial fat (mm2) | 1905 (615-6131) | 562 (66-1582) | <0.001 |
| Sample | Source | UId | Sex | Age | Mutation | |||
| nt change | aa change | domain affected | type of mutation | |||||
| RTT1 | HBTRC | 4315 | F | 11 | c.763C>T | R255X | TRD-NLS | Nonsense |
| RTT3 | HBTRC | 4422 | F | 12 | c.808C>T | R270X | TRD-NLS | Nonsense |
| RTT4 | TICHR | NB | F | 18 | c.473C>T | T158M | MBD | Missense |
| RTT5 | TICHR | KB | F | 11 | c.316C>T | R106W | MBD | Missense |
| RTT6 | TICHR | BC | F | 21 | c.808C>T | R270X | TRD-NLS | Nonsense |
| RTT9 | BCM | 93-244 | F | 4 | c.750insC | P251fs | TRD | Frameshift/Truncation |
| CON4 | NSWTRC | 88210 | F | 43 | ||||
| CON5 | NSWTRC | 88295 | F | 42 | ||||
| CON6 | NSWTRC | 88365 | F | 31 | ||||
| CON7 | NSWTRC | 88304 | F | 43 | ||||
| CON8 | NSWTRC | 9092 | F | 46 | ||||
| CON10 | NSWTRC | 12862 | F | 52 |
| Question | HCW category Total, (%) | ||||
| MDs (n = 20) | Nurses (n = 77) | PA (n = 4) | Overall (n = 101) | χ2, p-value | |
| Whether facility is equipped to handle EVD cases | 2.66, 0.62 | ||||
| Yes | 4 (3.96) | 21 (20.79) | 1 (0.99) | 26 (25.74) | |
| No | 14 (13.86) | 39 (38.61) | 2 (1.98) | 55 (54.46) | |
| I don’t know | 2 (1.98) | 17 (16.83) | 1 (0.99) | 10 (19.80) | |
| Whether health staff agrees to be isolated or not | 4.69, 0.321 | ||||
| Yes | 19 (18.81) | 75 (74.26) | 4 (3.96) | 98 (97.03) | |
| No | 0 (0) | 2 (1.98) | 0 (0) | 2 (1.98) | |
| Maybe | 1 (0.99) | 0 (0) | 0 (0) | 1 (0.99) | |
| Willingness to attend to an EVD patient | 8.03, 0.09 | ||||
| Yes | 9 (8.91) | 36 (35.64) | 0 (0) | 45 (44.55) | |
| No | 6 (5.94) | 25 (24.75) | 4 (3.96) | 35 (34.65) | |
| Maybe | 5 (4.95) | 16 (15.84) | 0 (0) | 21 (20.79) | |
| Whether health staff is adequately trained or not | 0.98, 0.614 | ||||
| Yes | 1 (0.99) | 8 (7.92) | 0 (0) | 9 (8.91) | |
| No | 19 (18.81) | 69 (68.32) | 4 (3.96) | 92 (91.09) | |
| Confidence level in handling an EVD suspected patient | 13.09, 0.11 | ||||
| No confidence | 3 (2.97) | 15 (14.85) | 1 (0.99) | 19 (18.81) | |
| Little confidence | 10 (9.90) | 13 (12.87) | 1 (0.99) | 24 (23.76) | |
| Confident | 3 (2.97) | 29 (28.71) | 1 (0.99) | 33 (32.67) | |
| Very confident | 3 (2.97) | 15 (14.85) | 0 (0.99) | 18 (17.82) | |
| Extremely confident | 1 (0.99) | 5 (4.95) | 1 (0.99) | 7 (6.93) |
| Cohort 1* - ELISA studies | Cohort 2** - proteomic studies | |||||
| Characteristics | CIS → CIS | CIS → CDMS | Pvalues | CIS → CIS | CIS → CDMS | Pvalues |
| n | 27 | 29 | - | 18 | 18 | - |
| Age (years)a | 28.1 (9.6) | 27.4 (6.3) | 0.724 | 31.7 (7.3) | 30.2 (5.9) | 0.308 |
| Female/male (% female) | 20/7 (74.1) | 20/9 (69.0) | 0.672 | 13/5 (72.2) | 13/5 (72.2) | 1 |
| Follow-up time (years)a | 8.2 (4.2) | 8.6 (3.3) | 0.819 | 6.1 (3.6) | 8.8 (2.7) | 0.098 |
| Clinical presentation | ||||||
| Optic neuritis | 15 (55.6) | 8 (27.6) | 0.206 | 9 (50.0) | 3 (16.7) | 0.152 |
| Brainstem | 4 (14.8) | 7 (24.1) | 2 (11.1) | 5 (27.8) | ||
| Spinal | 5 (18.5) | 8 (27.6) | 3 (16.7) | 6 (33.3) | ||
| Others | 3 (11.1) | 6 (20.7) | 4 (22.2) | 4 (22.2) | ||
| CSF cellsb | 0.5 (0-5.0) | 2.0 (0-9.0) | 0.337 | 0 (2.4-3.5) | 4.0 (0-11.5) | 0.059 |
| Proteins (mg/dL)b | 33.0 (24.0-43.0) | 37.0 (26.8-57.3) | 0.391 | 32.5 (23.7-41.5) | 29.5 (24.0-51.8) | 0.705 |
| Variable | Definition |
| Taxonomic class | Within this example we adopt the designation of taxonomic Specification from the NCBI's taxonomy database [63]. |
| Injection.chemical | The chemical molecule injected into the brain of an animal as part of a tract-tracing experiment. These reagents are not confined to a specific type of chemical simply have the property of when injected into brain tissue, they are taken up and transported along axons by active processes in neurons. Early examples of these include tritiated amino acids [64], Horseradish peroxidase (HRP) [65] and notably Phaseolus Leuco-Agglutinin [66]. Tracer chemicals include fluorescent dyes and beads and even include more exotic materials such as viruses and Cholera Toxin. See [17,67-71] for reviews of the general and specialized methods used. |
| Injection.location | This refers to the extent of the complete injection site expressed in terms of its spatial relationships to identified brain structures from the Swanson atlas [32] and encoded into the neuroanatomical nomenclature specified from the BAMS system [72] |
| Mapped location | Similarly to Injection.location, this refers to the spatial extent of an individual region of labeling (judged by the scientist reporting the study to be relatively homogeneous) expressed in terms of its spatial relationships to named neuroanatomical terms from the BAMS ontology [72] |
| Labeling.type | A simple categorization of the part of the neuron that is labeled. This is a nominal data element with possible values 'cellular' (denoting that the neuronal cell bodies were labeled), ' fibers' (denoting that axonal fibers were labeled), or 'terminals' (denoting that axonal fibers with characteristics of a terminal region were labeled, including heavy branching and the presence of boutons). |
| Labeling.density | A simple, seven point ordinal scale with the following categories (in order): 'no label', 'very sparse label, 'sparse label', 'sparse/moderate label', 'moderate label', 'moderate/dense label' and 'dense label'. We also include an additional category to denote that labeling is present but with an unknown density. |
| Preoperative model | Postoperative model | Intra-ICU model | |
| (Constant) | 1.26 | 0.44 | 1.82 |
| Expected session time (min) | 1.10 (1.01–1.21) | ||
| Patient age (per decade) | 1.16 (1.06–1.28) | 1.20 (1.09–1.31) | 1.09 (1.02–1.17) |
| FEV1 (l) | 0.91 (0.81–1.03) | 0.85 (0.75–0.96) | |
| Gastroesophageal reflux disease (yes/no) | 1.46 (1.14–1.89) | 1.53 (1.19–1.96) | |
| Vascular comorbidity (yes/no) | 1.29 (1.01–1.66) | 1.32 (1.03–1.69) | |
| Neurological comorbidity (yes/no) | 1.74 (1.24–2.43) | 1.82 (1.31–2.53) | |
| Previous chemotherapy (yes/no) | 0.81 (0.68–0.97) | ||
| Previous radiotherapy (yes/no) | 0.78 (0.63–0.97) | ||
| Transthoracic approach (yes/no) | 2.13 (1.74–2.62) | 1.79 (1.44–2.24) | 1.21 (1.05–1.40) |
| Reconstruction using colon (yes/no) | 1.56 (1.05–2.30) | 1.52 (1.03–2.23) | |
| Observed session time (min) | 1.07 (0.98–1.16) | ||
| Volume administration of colloids (liter) | 1.14 (1.01–1.29) | ||
| Absolute intraoperative blood loss (l) | 0.94 (0.87–1.02) | ||
| Absolute intraoperative urine production (l) | 1.12 (0.99–1.25) | ||
| Epidural analgesia administration (yes/no) | 0.83 (0.69–1.01) | ||
| Respiratory minute volume (l) | 1.09 (1.04–1.15) | 1.05 (1.01–1.09) | |
| Positive end-expiratory pressure (cmH2O) | 1.03 (0.99–1.07) | ||
| Chylothorax surgical complication (yes/no) | 1.31 (0.96–1.79) | ||
| Anastomosis leakage complication (yes/no) | 1.83 (1.47–2.28) | ||
| Other complication (yes/no) | 1.71 (1.38–2.10) | ||
| Pulmonary nonsurgical complication (yes/no) | 1.97 (1.72–2.26) | ||
| Myocardial infarction (yes/no) | 1.54 (0.93–2.56) | ||
| Infection (yes/no) | 1.61 (1.25–2.07) | ||
| Other nonsurgical complication (yes/no) | 1.41 (1.22–1.62) | ||
| Multiple r2 | 21% | 25% | 56% |
| Optimism | 6% | 9% | 11% |
| Optimism corrected r2 | 15% | 17% | 45% |
| Variable, n (%) | n=841* |
| Gender (female) n=821* | 689 (83.9) |
| Age: n= 819* | |
| >−25 | 88 (10.7) |
| 25-35 | 172 (21.0) |
| 35-45 | 215 (26.3) |
| 45-55 | 205 (25.0) |
| 55-< | 139 (17.0) |
| Born not in Sweden, n=819* | 389 (47.5) |
| Profession: n=798* | |
| Health care staff | 678 (85.0) |
| Administrative staff | 49 (6.1) |
| Food staff | 15 (1.9) |
| Others: | 56 (7.0) |
| Concentration | EAC Control | PST 200 mg/kg | 5-FU 20 mg/kg | PST + 5-FU |
| Tumor volume (mL) | 9.7 ± 0.2 | 4.4 ± 0.34*** | 3.3 ± 0.6*** | 2.9 ± 0.29*** |
| Body weight (g) | 34.91 ± 1.9 | 30.8 ± 1.2** | 26.21 ± 2.3** | 25.12 ± 2.7** |
| PCV (mL) | 3 ± 0.45 | 1.2 ± 0.1*** | 0.8 ± 0.1*** | 0.6 ± 0.2*** |
| Mean survival time (Days) | 20 ± 1 | 33 ± 2*** | 44 ± 0.57*** | 56 ± 1*** |
| % Increase in life span (ILS) | — | 65 ± 1*** | 120 ± 2*** | 180 ± 1*** |
| Tumor cell count (106 cells/mL) | 173 ± 0.43 | 51 ± 0.36*** | 29 ± 0.5*** | 25 ± 0.36*** |
| Percentage of viable cells | 92 ± 1 | 70 ± 2*** | 64 ± 0.57** | 60 ± 1** |
| Percentage of nonviable cells | 8 ± 1 | 30 ± 0.57*** | 36 ± 1*** | 40 ± 2*** |
| Hb (G%) (12.2–16.2) gm/dL | 7.2 ± 0.8 | 9.8 ± 1* | 12 ± 1.4*** | 14 ± 1.9*** |
| RBC (Million/cmm) (7–12.5) × 106/mm3 | 2.7 ± 0.4 | 3.6 ± 0.9ns | 4.3 ± 1.3ns | 5.1 ± 1.6** |
| TC (c/mm) (5100–11600) | 18800 ± 100 | 11100 ± 50*** | 8500 ± 75*** | 8000 ± 60*** |
| Platelets (/cmm) (160000–410000) | 115000 ± 450 | 170000 ± 525*** | 200000 ± 550*** | 230000 ± 490*** |
| Comparison | CYP19A1 vs. RORA* | A2BP1 vs. RORA | ITPR1 vs. RORA | NLGN1 vs. RORA |
| Correlation coefficient | 0.99 | 0.83 | 0.72 | 0.81 |
| P val (2-tailed) | 0.03 | 0.38 | 0.49 | 0.39 |
| R2 | 0.99 | 0.69 | 0.52 | 0.66 |
| Characteristic | N (%) |
| Sex | |
| Male | 58 (61.1) |
| Female | 36 (38.8) |
| Missing | 1 (1.1) |
| Work-place | |
| Ministry of Health | 15 (15.7) |
| Tertiary/referral hospital | 32 (33.7) |
| University | 27 (28.4) |
| NGO | 20 (21.1) |
| Missing | 1 (1.1) |
| Training completed | |
| Bachelor of medicine/MD | 59 (62.1) |
| Postgraduate training/MMED | 8 (8.4) |
| MS/MPH | 12 (12.6) |
| PhD | 2 (2.1) |
| *Other | 13 (13.7) |
| Missing | 1(1.1) |
| Current training | |
| Postgraduate training/MMED | 17 (18.9) |
| MS/MPH | 16 (16.8) |
| PhD in a health related field (e.g. epidemiology or Health Services Research) | 23 (24.2) |
| **Other | 38 (40.0) |
| Missing | 1 (1.1) |
| RA-UIP | IPF | Controls | p-value | |
| Telomere length | 0.663(1.476, 11.548) | 1.118 (0.747, 9.867) | 1.876 (0.038, 3.221) | 0.170 |
| Risk Factors | Odds Ratio for Anti-HEV IgM, 95% CI | P value† | Odds Ratio for Anti-HEV IgG, 95% CI | P valueγ |
| CD4+ count >200cells/μl | 5.109 [1.624–16.070] | 0.005* | 0.67 [.333–1.36] | 0.273 |
| Anti HCV Positive status | 0.018 [0.006–0.056] | <0.001* | 5.35 [2.44–11.69] | <0.001* |
| Residing in Kathmandu Valley | 44.31 [14.507–135.353] | <0.001* | 37.73 [20.98–67.87] | <0.001* |
| HIV viral load > 3log cps/ml | 3.045 [1.25–7.39] | <0.001* | 4.43 [1.67–11.73] | 0.001* |
| ID # | Age (yr) | Sex | RBT (w) | Symptoms | HP | ED | GH | PU | AD | RD |
| 1 | 5.9 | M | 4 | Severe | ||||||
| 2 | 13.4 | M | 3 | Arthralgia | Mild | |||||
| 3 | 5.4 | M | 6 | + | + | Severe | ||||
| 4 | 5.4 | M | 3 | Severe | ||||||
| 5 | 10.8 | F | 3 | Abdominal pain | + | Moderate | ||||
| 6 | 10.6 | M | 9 | + | Severe | + | ||||
| 7 | 7.9 | F | 3 | + | Severe | + | ||||
| 8 | 12.0 | F | 6 | + | + | Severe | + | |||
| 9 | 7.7 | F | 12 | Abdominal pain, arthralgia, | + | Moderate | ||||
| 10 | 9.1 | M | 3 | Abdominal pain, arthralgia, | + | + | + | Severe | + | |
| 11 | 9.2 | M | 2 | Arthralgia | + | Severe |
| Demographic category | N (%) | |
| N | 1184 | |
| Age (m,sd) | 66.6 (10.8) | |
| Age | ||
| 18-45 | 45 (3.8) | |
| 46-60 | 281 (23.7) | |
| 61-70 | 394 (33.3) | |
| 71-80 | 346 (29.3) | |
| 81+ | 114 (9.7) | |
| Gender | ||
| Male | 720 (60.9) | |
| Marital status | ||
| Single | 118 (10.0) | |
| Married/partner | 891 (75.2) | |
| Divorced | 74 (6.3) | |
| Widowed | 99 (8.4) | |
| Length of time with diabetes | ||
| < 5 years | 612 (51.7) | |
| > = 5 years | 572 (48.3) | |
| Diabetes management | ||
| Diet | 321 (27.1) | |
| Tablets | 711 (60.1) | |
| Insulin | 148 (12.5) | |
| Health status | ||
| Diabetes related complications | None | 710 (61.3) |
| One or more | 448 (38.7) | |
| Feet | 257 (21.7) | |
| Eyes | 266 (22.5) | |
| Kidneys | 66 (5.6) | |
| Other health complications | None | 216 (18.5) |
| One or more | 952 (81.5) | |
| Arthritis | 503 (43.2) | |
| Hypertension | 513 (44.1) | |
| High cholesterol | 588 (50.5) | |
| Heart conditions | 108 (11.4) | |
| Depression/anxiety | 207 (17.8) | |
| EQ-5D index score | 0.652 (0.32) | |
| SF-6D index score | 0.693 (0.16) | |
| DHP-18 PD | 17.93 (20.5) | |
| BA | 21.53 (19.31) | |
| DE | 35.93 (23.04) | |
| Change in health baseline-follow up | ||
| Health improvement | 186 (15.9) | |
| No change | 717 (61.7) | |
| Health deterioration | 260 (22.4) |
| Parameter | Value |
| General assumptions for the facility | |
| rBuChE production level | 25 kg rBuChE/year (bulk) |
| rBuChE doses per year | 62,500 doses/year at 400 mg/dose |
| Downstream Recovery/purification yield | 20% |
| Annual operating days | 330 days |
| rBuChE production in plants following infiltration/incubation | 125 kg rBuChE/year |
| Batch cycle time (time between start of new infiltration batches) | 7 days |
| Batches per year | 47 |
| Base case rBuChE expression level | 500 mg/kg FW at ~7 days after infiltration |
| Facility lifetime | 15 years |
| Depreciation | Straight line over 10 years, 5% direct fixed capital salvage |
| Working capital | 30 days of labor, materials, utilities, waste treatment |
| Lab/QC/QA costs | 2% of total labor costs for plant growth and agroinfiltration sections, 15% of total labor costs for recovery and purification section |
| Start-up/validation costs | 5% direct fixed capital |
| Assumptions for indoor plant growth section | |
| Mass per plant at 5 weeks | 0.02 kg FW/plant |
| Tray size | 4 ft × 4 ft |
| Number of plants per tray | 256 |
| Tobacco seed cost | $0.001/seed |
| Age at infiltration | 4 weeks |
| Total number of plant batches in inventory | 5 batches (just seeded, 1 wk old, 2 wk old, 3 wk old, 4 wk old—ready to infiltrate, 5 wk old—infiltrated, incubated and ready to harvest) |
| Total number of plants in inventory | ~1.3 million |
| Total plant growth area | 83,320 ft2 total, or 10 levels with 8,332 ft2 footprint |
| LED fixture costs | $40/ft2 plant growth area (including capital cost factors for plant growth area as shown in Table 2) |
| LED energy costs | 20 W/ft2 |
| Assumptions for Agrobacterium production, vacuum infiltration, and plant incubation section | |
| Agro “loading”—mass of recombinant Agrobacterium to mass of plant tissue | 0.00001 kg dry weight (dw) bacteria/kg FW plant biomass |
| Agrobacterium biomass density at 12 hours of culture | 2.6 g dw/L = 0.0026 kg dw/L |
| Inoculum density used in seed train | 1% V/V |
| Dilution factor between agroinfiltration solution and agrobacterial production fermentor | 78 |
| Percent weight change in plant tissue following vacuum agroinfiltration | 30% |
| Trays processed per vacuum chamber (30 ft) per day | 336 trays/chamber/day |
| “Excess” Agrobacterium solution used | 87% of total infiltration solution |
| Incubation time for infiltrated plants | ~7 days |
| Assumptions for the rBuChE recovery and purification section | |
| Overall yield in downstream processes | 20% |
| Harvesting rate | 3 trays/minute |
| IEX chromatography | |
| Binding capacity | 20 mg/mL |
| Resin cost | $1,839/L |
| Number of reuse cycles | 100 |
| Affinity chromatography | |
| Binding capacity | 3 mg/mL |
| Resin cost | $10,000/L |
| Number of reuse cycles | 30 |
| Overall | Ability to access to NSP syringes‡ | χ2-test | Venue stratification | χ2-test | |||||
| <40% | 40-70% | >70% | (χ2, p-value) | MDC | Community | NSP | (χ2, p value) | ||
| N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | |||
| Used drugs in the last 30 days (n = 402)* | |||||||||
| Yes | 398 (99.0) | 139 (97.9) | 55 (100) | 204 (99.5) | 74 (94.9) | 171 (100) | 153 (100) | ||
| No | 4 (1.0) | 3 (2.1) | 0 (0) | 1 (0.5) | 2.89, p = 0.236 | 4 (5.1) | 0 (0) | 0 (0) | 16.782, p < 0.001† |
| Frequency of injecting drugs in the last 30 days (n = 392) | |||||||||
| <1 times / day | 41 (10.5) | 12 (8.8) | 4 (7.4) | 25 (12.4) | 7 (9.6) | 19 (11.1) | 15 (10.1) | ||
| 1-2 times / day | 220 (56.1) | 68 (50.0) | 21 (38.9) | 131 (64.9) | 37 (50.7) | 109 (63.7) | 74 (50.0) | ||
| 3-5 times / day | 115 (29.3) | 46 (33.8) | 28 (51.9) | 41 (20.3) | 22 (30.1) | 39 (22.8) | 54 (36.5) | ||
| >6 times / day | 16 (4.1) | 10 (7.4) | 1 (1.9) | 5 (2.5) | 29.439, p < 0.001† | 7 (9.6) | 4 (2.3) | 5 (3.4) | 15.236, p = 0.019† |
| Times of repeated use per needle/syringe before disposal in the last 30 days (n = 389) | |||||||||
| 0 | 4 (1.0) | 0 (0) | 3 (5.9) | 1 (0.5) | 0 (0) | 0 (0) | 4 (2.7) | ||
| 1 | 248 (63.8) | 81 (58.7) | 26 (51.0) | 141 (70.5) | 49 (66.2) | 111 (65.7) | 88 (60.3) | ||
| 2-5 | 131 (33.7) | 54 (39.1) | 22 (43.1) | 55 (27.5) | 21 (28.4) | 57 (33.7) | 53 (36.3) | ||
| 6-9 | 1 (0.3) | 1 (0.7) | 0 (0) | 0 (0) | 1 (1.4) | 0 (0) | 0 (0) | ||
| ≥10 | 5 (1.3) | 2 (1.4) | 0 (0) | 3 (1.5) | 6.84, p = 0.033† | 3 (4.1) | 1 (0.6) | 1 (0.7) | 0.151, p = 0.927 |
| Average ± SD | 1.62 ± 1.32 | 1.80 ± 1.45 | 1.55 ± 0.86 | 1.52 ± 1.31 | 1.93 ± 2.00 | 1.54 ± 1.05 | 1.56 ± 1.13 | ||
| Shared syringes in the last 30 days (n = 400) | |||||||||
| Yes | 35 (8.8) | 23 (16.3) | 7 (12.7) | 5 (2.5) | 15 (19.5) | 4 (2.3) | 16 (10.5) | ||
| No | 365 (91.2) | 118 (83.7) | 48 (87.3) | 199 (97.5) | 21.326, p < 0.001† | 62 (80.5) | 167 (97.7) | 136 (89.5) | 20.507, p < 0.001† |
| Number of times shared syringes in the last 30 days (n = 29) | |||||||||
| 1 | 10 (34.5) | 9 (45.0) | 1 (16.7) | 0 (0) | 8 (66.7) | 0 (0) | 2 (15.4) | ||
| 2-5 | 16 (55.2) | 9 (45.0) | 5 (83.3) | 2 (66.7) | 4 (33.3) | 3 (75.0) | 9 (69.2) | ||
| ≥6 | 3 (10.3) | 2 (10.0) | 0 (0) | 1 (33.3) | 4.83, p = 0.090 | 0 (0) | 1 (25.0) | 2 (15.4) | 5.780, p = 0.056 |
| Average ± SD | 4.28 ± 6.85 | 4.15 ± 7.37 | 2.17 ± 0.98 | 9.33 ± 9.29 | 1.55 ± 0.93 | 6.75 ± 8.85 | 5.92 ± 8.78 | ||
| Number of sharing partners in the last 30 days (n = 31) | |||||||||
| 1 | 10 (31.3) | 5 (22.7) | 5 (71.4) | 0 (0) | 4 (28.6) | 1 (25.0) | 5 (35.7) | ||
| 2-5 | 20 (62.5) | 15 (68.3) | 2 (28.6) | 3 (100) | 9 (64.3) | 3 (75.0) | 8 (57.1) | ||
| 6-9 | 1 (3.1) | 1 (4.5) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (7.1) | ||
| ≥10 | 1 (3.1) | 1 (4.5) | 0 (0) | 0 (0) | 6.73, p = 0.035† | 1 (7.1%) | 0 (0) | 0 (0) | 0.594, p = 0.743 |
| Average ± SD | 2.53 ± 1.98 | 2.82 ± 2.26 | 1.43 ± 0.79 | 3.00 ± 0.0 | 2.64 ± 2.50 | 2.25 ± 0.96 | 2.85 ± 1.99 | ||
| Maximum number of group sharing partners in the last 30 days (n = 32) | |||||||||
| 1 | 2 (6.3) | 1 (4.5) | 1 (14.3) | 0 (0) | 1 (7.1) | 0 (0) | 1 (7.1) | ||
| 2-5 | 28 (87.5) | 20 (90.9) | 5 (71.4) | 3 (100) | 13 (92.9) | 4 (100) | 11 (78.6) | ||
| 6-9 | 2 (6.3) | 1 (4.5) | 1 (14.3) | 0 (0) | 3.19, p = 0.203 | 0 (0) | 0 (0) | 2 (14.3) | 0.867, p = 0.648 |
| Average ± SD | 2.94 ± 1.68 | 2.86 ± 1.42 | 3.00 ± 2.71 | 3.33 ± 0.58 | 2.50 ± 0.76 | 2.50 ± 0.58 | 3.50 ± 2.35 |
| Feature | Restenosis group (n = 74) | Non-restenosis group (n = 91) | P |
| Age (years) | 65.4 ± 8.6 | 64.7 ± 8.0 | 0.583 |
| Male, n (%) | 52 (70.2) | 60 (65.9) | 0.553 |
| BMI (kg/m2) | 24.8 ± 3.6 | 24.1 ± 3.2 | 0.184 |
| Hypertension, n (%) | 19 (25.7) | 22 (24.2) | 0.825 |
| Hyperlipidemia, n (%) | 15 (20.3) | 17 (18.7) | 0.797 |
| Renal dysfunction, n (%) | 10 (13.5) | 11 (12.1) | 0.785 |
| Diabetes, n (%) | 21 (28.4) | 6 (6.6) | <0.001 |
| Smoking, n (%) | 59 (79.7) | 27 (29.7) | <0.001 |
| Drinking, n (%) | 33 (44.6) | 40 (44.0) | 0.935 |
| SBP (mmHg) | 137.8 ± 22.3 | 133.6 ± 21.5 | 0.221 |
| DBP (mmHg) | 73.4 ± 9.8 | 72.6 ± 7.7 | 0.558 |
| HDL-C (mmol/L) | 1.1 ± 0.3 | 1.2 ± 0.3 | 0.177 |
| LDL-C (mmol/L) | 3.0 ± 0.5 | 2.5 ± 0.3 | <0.001 |
| Blood sugar, (mmol/L) | 6.3 ± 2.0 | 5.4 ± 1.8 | <0.001 |
| Stent mean diameter (mm) | 7.4 ± 1.0 | 6.6 ± 1.0 | <0.001 |
| With SD (n = 165) | Without SD (n = 35) | P | |
| No (%) | No (%) | ||
| Gender (n = 200) | 0.04 | ||
| Women (n = 100) | 88 (88.0) | 12 (12.0) | |
| Men (n = 100) | 77 (77.0) | 23 (23.0) | |
| Age groups (years) | 0.13 | ||
| 30-39 | 15(68.2) | 7(31.8) | |
| 40-49 | 74(82.2) | 16(17.8) | |
| 50-59 | 76(86.4) | 12(13.6) | |
| Diabetes status | 0.35 | ||
| Controlled | 80(80.0) | 20(20.0) | |
| Uncontrolled | 85(85.0) | 15(15.0) | |
| Duration of diabetes (years) | 0.64 | ||
| 10-14 | 130(81.2) | 30(18.8) | |
| 15-19 | 27(87.1) | 4(12.9) | |
| 20-25 | 8(88.8) | 1(11.2) | |
| Hypertension | 0.31 | ||
| Yes | 19(90.5) | 2(9.5) | |
| No | 146(81.6) | 33(18.4) | |
| Type of diabetes | 0.04* | ||
| Type 1 | 18 (100.0) | 0.00 | |
| Type 2 | 147(80.8) | 35(19.2) |
| Value | Alternative Indicator | |
| Waist circumference | * >94 cm in males, >80 cm in females** >102 cm in males, >88 cm in females | |
| Raised blood pressure | Systolic ≥130 and/or diastolic ≥85 mm Hg | Treatment of previously diagnosed hypertension |
| Raised FPG | ≥100 mg/dL (5.6 mmol/L) | Previously diagnosed of T2DM |
| Raised TG | >150 mg/dL (1.7 mmol/L) | Specific pharmacological treatment |
| Reduced HDL-C | <40 mg/dL (1.0 mmol/L) in males<50 mg/dL (1.3 mmol/L) in females | Specific pharmacological treatment |
| Probe Set | z-score | DMFS | Gene Symbol | Gene Title |
| 208905_at | 4.29 | - | CYCS | cytochrome c, somatic |
| 204817_at | 3.73 | - | ESPL1 | extra spindle poles like 1 |
| 38158_at | 3.41 | - | ESPL1 | extra spindle poles like 1 |
| 204947_at | 3.04 | - | E2F1 | E2F transcription factor 1 |
| 201111_at | 3.04 | - | CSE1L | CSE1 chromosome segregation 1-like |
| 201636_at | 2.97 | - | FXR1 | fragile X mental retardation, autosomal homolog 1 |
| 220048_at | 2.82 | - | EDAR | ectodysplasin A receptor |
| 210766_s_at | 2.75 | - | CSE1L | CSE1 chromosome segregation 1-like |
| 221567_at | 2.66 | - | NOL3 | nucleolar protein 3 (apoptosis repressor with CARD domain) |
| 213829_x_at | 2.65 | - | TNFRSF6B | tumor necrosis factor receptor superfamily, member 6b, decoy |
| 201112_s_at | 2.57 | - | CSE1L | CSE1 chromosome segregation 1-like |
| 212353_at | 2.51 | - | SULF1 | sulfatase 1 |
| 208822_s_at | 2.47 | - | DAP3 | death associated protein 3 |
| 209462_at | 2.37 | - | APLP1 | amyloid beta (A4) precursor-like protein 1 |
| 203005_at | 2.29 | - | LTBR | lymphotoxin beta receptor (TNFR superfamily, member 3) |
| 202731_at | 4.01 | + | PDCD4 | programmed cell death 4 |
| 206150_at | 3.57 | + | TNFRSF7 | tumor necrosis factor receptor superfamily, member 7 |
| 202730_s_at | 3.18 | + | PDCD4 | programmed cell death 4 |
| 209539_at | 3.14 | + | ARHGEF6 | Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6 |
| 212593_s_at | 3.07 | + | PDCD4 | programmed cell death 4 |
| 204933_s_at | 2.96 | + | TNFRSF11B | tumor necrosis factor receptor superfamily, member 11b |
| 209831_x_at | 2.43 | + | DNASE2 | deoxyribonuclease II, lysosomal |
| 203187_at | 2.38 | + | DOCK1 | dedicator of cytokinesis 1 |
| 210164_at | 2.34 | + | GZMB | granzyme B |
| Connecticut (n = 631 visits) % | Washington (n = 1186 visits) % | |
| Gender | ||
| female | 76 | 74 |
| Age | ||
| Median | 43 years | 42 years |
| 0–15 years | 12.8 | 10.9 |
| 16–34 years | 16.4 | 20.9 |
| 35–64 years | 63.0 | 58.5 |
| 65 years+ | 7.8 | 9.7 |
| Race | ||
| White | 97 | 96 |
| Smoking status: | ||
| non-smokers | 95 | 94 |
| Type of major problema | ||
| Acute problem | 22 | 23 |
| Chronic problem, routine | 53 | 56 |
| Chronic problem, flare up | 20 | 18 |
| Pre/post-surgery/injury | 1 | 1 |
| Non-illness care | 5 | 6 |
| Primary reason for visitb | ||
| Fatigue | 6.1 | 6.0 |
| Headache | 4.4 | 3.8 |
| Back symptoms | 4.4 | 6.5 |
| Skin rashes | 4.2 | 2.5 |
| Menopausal symptoms | 3.7 | 2.0 |
| Bowel function changes | 3.5 | 2.0 |
| Anxiety or Depression | 3.2 | 5.1 |
| Allergies to food, milk | 3.0 | 3.6 |
| Sinus symptoms | 2.8 | <2 |
| Upper respiratory symptoms | 2.6 | <2 |
| Cough | 2.4 | <2 |
| Neck symptoms | 2.3 | 3.3 |
| Infectious disease | 2.2 | <2 |
| Ear infection symptoms | 2.2 | <2 |
| Abdominal pain/cramps | 2.2 | 2.7 |
| Menstrual problems | <2 | 2.1 |
| Diagnosis by naturopathic physicianc | ||
| Menopausal disorders | 4.9 | 3.1 |
| Allergies | 4.6 | 6.3 |
| Back conditions | 3.5 | 5.8 |
| Fibromyalgia | 3.0 | 2.0 |
| Sinusitis | 2.9 | <2 |
| Fatigue | 2.4 | 2.7 |
| Headache | 2.2 | 3.1 |
| Upper respiratory infections | 2.0 | <2 |
| Neck conditions | <2 | 3.3 |
| Depression | <2 | 2.6 |
| Asthma | <2 | 2.2 |
| Anxiety | <2 | 2.1 |
| Dermatitis | <2 | 2.0 |
| New patients | 22 | 22 |
| Payment | ||
| Private insurance | 60 | 43 |
| Worker's compensation | 0 | 3 |
| Personal injury | 0 | 3 |
| Self-pay | 37 | 48 |
| Other | 3 | 3 |
| Scopus | Query | Research in: | Items found |
| #1 | “Sensory integration” OR “multisensory integration” OR “crossmodal integration” OR “cross-modal integration” OR “intersensory integration” OR “multimodal integration” OR “crossmodal illusion*” OR “cross-modal illusion*” OR multisensory OR crossmodal OR cross-modal OR “crossmodal sensory integration” OR “cross-modal sensory integration” OR “multisensory interaction*” | Article Title, Abstract, Keywords | 11,005 |
| #2 | Measurement* OR Test* OR performance OR assessment* OR “Test development” OR “task performance” OR “disability evaluation” OR “Feasibility studies” OR validity OR reliability OR study* OR results* | Article Title, Abstract, Keywords | 14,411,633 |
| #3 | Combine #1 AND #2 | 5127 | |
| #4 | Limit to (Humans OR human) AND (Limit to (DOCTYPE, article)) | 3241 | |
| #5 | Limit to (“aged”, “aging”) | 394 | |
| #6 | Exclude (“Speech perception”, “Speech Perception”, “Speech”) | 351 | |
| #7 | Exclude (“Alzheimer Disease”, “Alzheimer disease”, “Parkinson Disease”, “Parkinson disease”, “Aphasia”, “Dementia”, “Disease severity”, “Brain damage”, “Brain injury”, “Stroke”, “Neglect”, “Brain damage, chronic”, “Cerebrovascular accident”, “Cognition disorders”, “Neurologic disease”, “Schizophrenia”) | 308 |
| Therapeutic Strategy | Gene/System | Strong Points | Weak Points |
| Tumor Suppressor gene | p53 | Altered gene in a high percentage of OC.The use of Gendicine (a recombinant human Ad-p53) has been approved in the treatment of OC in China. Several clinical trials are currently ongoing. | Not useful in cells with a normal p53 gene.No therapeutic benefit in the first clinical trials due to the use of a wrong delivery system. |
| WWOX | Promising results in vivoInhibition of proliferation and promotion of apoptosis in OCSC. | It has not been evaluated in clinical trials in OC. | |
| Oncofactor inhibition strategies | EGFR | Gene widely studied in cancer.Its use increases the sensitivity to chemotherapy | It has not been evaluated in vivo or in clinical trials in OC. |
| CLDN3 | Several strategies of silencing have been studied in OC (siRNA and shRNA).Promising results in vivo, with inhibition of malignant ascites formation. | It has not been evaluated in clinical trials in OC. | |
| Suicide gene therapy | HVS-TK | Strategy widely studied in gene therapy for cancer.Several clinical trials are currently ongoing.Promising results in vivo and in clinical trials.Bystander effect. | Not phase 2 or 3 clinical trials published. |
| DT-A | Promising results in vivo, with minimal cytotoxicity. | It has not been evaluated in clinical trials in OC. | |
| Antiangiogenic gene therapy | VEGFRs | Promising results in vivo, with inhibition of ascities formation.Synergist effect in combination with chemotherapy. | It has not been evaluated in clinical trials in OC.The work showed increased proliferation of tumour cells with the use of VEGFR2 and Ti2 in combination with PTX and carboplatin. |
| Endostatin | Promising results in vivo.Clinical trials have been carried out in other types of cancer. | Transient expression due to humoral immune response if adenovirus is used as delivery system.It has not been evaluated in clinical trials in OC. | |
| Genetic immunopotentiation | IL-12 | Potent immune-modulatory properties and ability to inhibit tumour angiogenesis.Promising results in vivo.Several clinical trials are currently ongoing or have been completed.It has showed to be safe and feasible in phase I trials. | Poor clinical benefits in the completed phase II trial. |
| CAR-T cell | Possibility of target any specific tumour antigen.Promising preliminary results in clinical trials in OC. | Important side effects caused in patients. | |
| Multi-Drug Resistance | MDR1 | Several strategies have been developed to knockdown it.Its silencing enhances sensitivity to anticancer drugs.Promising results in vivo. | It has not been evaluated in clinical trials in OC. |
| Survivin | Several strategies targeting this gene have been developed, including combined therapy with anticancer drugs. Promising results in vivo. | It has not been evaluated in clinical trials in OC. | |
| Oncolytic virotherapy | VSV | Can be genetically designed to deliver therapeutic genes.A phase I trial is currently ongoing. | Neurotoxicity and Induction of neutralizing antibodies.IFN response intact in most OC cells, blocking virus replication. |
| RGB Only | NIR Only | Early Fusion | Late Fusion |
| 0.816 | 0.797 | 0.799 | 0.838 |
| Physical activity in leisure time (hours per week) | Women | Men | ||||
| Adjustment for age | Additional adjustmenta | Adjustment for age | Additional adjustmenta | |||
| Total | 9616 | 9199 | 8452 | 8130 | ||
| Light | Hard | Score | RR (95 % CI) | RR (95 % CI) | RR (95 % CI) | RR (95 % CI) |
| <1 | 0 | 1 | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| ≥1 | 0 | 2 | 0.94 (0.83–1.05) | 0.97 (0.86–1.09) | 0.96 (0.82–1.13) | 1.03 (0.87–1.21) |
| <1b | 3 | 0.92 (0.81–1.05) | 0.99 (0.87–1.13) | 0.88 (0.75–1.03) | 0.96 (0.82–1.14) | |
| 1–2 | 4 | 0.81 (0.71–0.93) | 0.89 (0.77–1.03) | 0.71 (0.60–0.85) | 0.81 (0.68–0.97) | |
| ≥3 | 5 | 0.94 (0.77–1.14) | 1.05 (0.86–1.27) | 0.85 (0.70–1.03) | 0.96 (0.79–1.17) | |
| P, categorical effect | 0.045 | 0.36 | 0.001 | 0.06 | ||
| P, linear effectc | 0.016 | 0.46 | 0.001 | 0.07 | ||
| P, quadratic effectd | 0.39 | 0.56 | 0.33 | 0.69 |
| Material | E1/3/ρ (GPa1/3/(Mg/m3)) | η |
| Cast iron | 0.63 | 1.2 × 10−3–1.7 × 10−3 |
| Steel | 0.77 | 6.0 × 10−4–1.0 × 10−3 |
| Al alloys | 1.50 | 2.0 × 10−4–4.0 × 10−4 |
| Mg alloys | 1.90 | 1.0 × 10−3–1.0 × 10−2 |
| Al corrugated sandwich | 2.52 | 1.0 × 10−3–1.0 × 10−2 |
| Al foams | 2.67 | 4.0 × 10−3–1.0 × 10−2 |
| CFRP (unidirectional) | 4.00 | 1.5 × 10−3–3.0 × 10−3 |
| Lactate (μm) | ||||||
| d-Lactate | l-lactate | |||||
| Cell line | Plus methylglyoxal | Minus methylglyoxal | Net | Plus methylglyoxal | Minus methylglyoxal | Net |
| T. brucei | ||||||
| Procyclics | 22 ± 3 | 10 ± 2 | 12 | 148 ± 7 | 24 ± 3 | 124 |
| Bloodstream forms | 68 ± 9 | 50 ± 2 | 18 | 355 ± 42 | 134 ± 18 | 221 |
| pLew100–luciferase | ||||||
| Procyclics | 17 ± 2 | 9 ± 1 | 8 | 134 ± 12 | 19 ± 2 | 115 |
| Bloodstream forms | 59 ± 2 | 48 ± 3 | 11 | 329 ± 26 | 118 ± 21 | 211 |
| pLew100–TcGLO1 | ||||||
| Procyclics | 57 ± 4a | 19 ± 2 | 38 | 122 ± 9 | 22 ± 2 | 100 |
| Bloodstream forms | 183 ± 24a | 71 ± 5 | 112 | 308 ± 14 | 105 ± 8 | 203 |
| Characteristics | Study group (N= 19) | Control group (N= 19) | p-value |
| Fertilization rate | 95.33% | 84.4% | 0.11 |
| cleavage rate | 89.56% | 87.74% | 0.76 |
| Implantation rate | 17.64% | 7.4% | 0.14 |
| Chemical pregnancy rate/cycle [n (%)] | 8 (47.1%) | 3 (16.7%) | 0.07 |
| Clinical pregnancy rate/cycle [n (%)] | 7 (41.2%) | 3 (16.7%) | 0.14 |
| Ongoing pregnancy rate [n (%)] | 6 (85.7%) | 3 (100%) | 1 |
| Clinical abortion rate [n (%)] | 2 (11.8%) | 0 (0%) | 0.22 |
| Brightness | Contrast | Entropy | Clarity | |
| Original image | 57.15 | 311.36 | 6.29 | 38.21 |
| IEABPM | 77.42 | 441.67 | 10.18 | 59.83 |
| IIEABPM | 79.26 | 487.82 | 14.01 | 73.85 |
| Sex (n) | Age (years) | Side (n) | ||||
| Female | Male | Median | Range | Right | Left | |
| total | 8 | 8 | 34 | 20–76 | 11 | 5 |
| Variable | r | P-value |
| Age, years | 0.023 | 0.400 |
| Gender | 0.031 | 0.359 |
| Course of disease, years | 0.267 | 0.002 |
| SBP, mmHg | 0.429 | <0.001 |
| DBP, mmHg | 0.438 | <0.001 |
| BMI, kg/m2 | 0.204 | 0.013 |
| HbA1c, % | 0.179 | 0.025 |
| FBG, mmol/l | 0.164 | 0.037 |
| TG, mmol/l | 0.208 | 0.011 |
| TC, mmol/l | 0.156 | 0.044 |
| HDL-C, mmol/l | −0.194 | 0.020 |
| LDL-C, mmol/l | 0.193 | 0.021 |
| VLDL-C, mmol/l | 0.168 | 0.036 |
| apoCIII, μg/ml | 0.501 | <0.001 |
| Concomitant conditions | Number | Percent |
| Heart disease | 37 | 33.9 |
| Current smokers | 36 | 33.0 |
| Diabetes mellitus | 26 | 23.9 |
| Osteoarthritis | 24 | 22.0 |
| Previous cancer | 22 | 20.2 |
| Peripheral arterial disease | 19 | 17.4 |
| Kidney disease | 17 | 13.8 |
| Gout/chondrocalcinosis | 15 | 13.8 |
| Alcohol abuse | 13 | 11.9 |
| Lung disease | 12 | 11.0 |
| Oral corticosteroids | 10 | 9.2 |
| Skin ulceration | 10 | 9.2 |
| Eschars | 9 | 8.2 |
| Liver disease | 7 | 6.4 |
| Rheumatoid arthritis and other inflammatory rheumatic disease | 7 | 6.4 |
| Intra-articular corticosteroids | 3 | 2.8 |
| Intravenous drug abuse | 2 | 1.8 |
| Total specimen length (cm) | |
| Cook | 4.73 |
| Boston Scientific | 2.98 |
| Olympus | 4.26 |
| Covidien | 5.07 |
| Trucut | 1.55 |
| Boys | Girls | P-value | |||||||
| n | HBP | HNBP | HT | n | HBP | HNBP | HT | ||
| Fourth graders (age 9–10 years) | |||||||||
| SBP | 661 | 53 (8.0) | 51 (7.7) | 2 (0.3) | 636 | 46 (7.2) | 42 (6.6) | 4 (0.6) | 0.603 |
| DBP | 661 | 72 (10.9) | 68 (10.3) | 4 (0.6) | 636 | 73 (11.5) | 61 (9.6) | 12 (1.9) | 0.792 |
| SBP and/or DBP | 661 | 105 (15.9) | 100 (15.1) | 5 (0.8) | 636 | 100 (15.8) | 85 (13.4) | 15 (2.4) | 0.939 |
| Seventh graders (age 12–13 years) | |||||||||
| SBP | 566 | 28 (4.9) | 28 (4.9) | 0 (0.0) | 522 | 24 (4.6) | 24 (4.6) | 0 (0.0) | 0.887 |
| DBP | 566 | 42 (7.4) | 42 (7.4) | 0 (0.0) | 522 | 41 (7.9) | 38 (7.3) | 3 (0.6) | 0.820 |
| SBP and/or DBP | 566 | 63 (11.1) | 63 (11.1) | 0 (0.0) | 522 | 56 (10.8) | 53 (10.2) | 3 (0.6) | 0.846 |
| Round | Positive Selection (+) | PCR Cycles | Negative Selection (–) | PCR Cycles |
| 1 | Immobilized Target (IT) 24 h | 9 | – | – |
| 2 | IT 18 h | 15 | BSA Immobilized Negative Target (INT) 22 h | 16 |
| 3 | IT 13 h | 13 | BSA INT 26 h | 17 |
| 4 | IT 7 h | 18 | Exotoxin A INT 22 h | 16 |
| 5 | IT 3 h | 11 | Exotoxin A INT 26 h | 15 |
| 6 | IT 30 min | 17 | BSA INT 24 h | 12 |
| 7 | IT 5 min, Competitive Elution with 1 mg/mL free alpha toxin, 5 min | 17 | IT 5 min, Competitive Elution with 1 mg/mL free BSA, 5 min | 16 |
| 8 | IT 5 s, Competitive Elution with 1 mg/mL free alpha toxin, 5 s | 15 | IT 5 s, Competitive Elution with 20 μg/mL free exotoxin a, 6 h | 13 |
| 9 | IT 5 s, Competitive Elution with 10 μg/mL free alpha toxin, 5 s | 12 | IT 5 s, Competitive Elution with 20 μg/mL free cholera toxin, 6 h | 13 |
| 10 | IT 5 s, Competitive Elution with 5 μg/mL free alpha toxin, 5 s | 12 | IT 5 s, Competitive Elution with 20 μg/mL free toxin B, 6 h | 13 |
| 11 | IT 5 s, Competitive Elution with 2.5 μg/mL free alpha toxin, 5 s | 19 | IT 5 s, Competitive Elution with 20 μg/mL free BSA, 24 h | 7 |
| 12 | IT 5 s, Competitive Elution with 1 μg/mL free alpha toxin, 5 s | 10 | – | – |
| No. a | Protein name b | Cdc | No. | Protein name | Cbd | No. | Protein name | Cce |
| 175 | EGFR | 0.411 | 166 | PGH2 | 0.177 | 207 | KPCA | 0.500 |
| 149 | ADRB1 | 0.404 | 234 | PP2BA | 0.109 | 126 | MK01 | 0.496 |
| 156 | BKRB2 | 0.404 | 207 | KPCA | 0.093 | 232 | MK03 | 0.496 |
| 170 | DRD1 | 0.404 | 252 | HCD2 | 0.082 | 234 | PP2BA | 0.496 |
| 194 | ACM3 | 0.404 | 126 | MK01 | 0.082 | 175 | EGFR | 0.447 |
| 195 | ACM2 | 0.404 | 232 | MK03 | 0.082 | 149 | ADRB1 | 0.445 |
| 197 | ACM5 | 0.404 | 175 | EGFR | 0.069 | 156 | BKRB2 | 0.445 |
| 198 | ACM1 | 0.404 | 282 | TYRO | 0.049 | 170 | DRD1 | 0.445 |
| 209 | 5HT2C | 0.404 | 192 | AOFA | 0.036 | 194 | ACM3 | 0.445 |
| 210 | 5HT2A | 0.404 | 261 | ADH1B | 0.027 | 195 | ACM2 | 0.445 |
| E-learning group | Non-e-learning group | ||||||
| n | Mean rate | SD | n | Mean rate | SD | ||
| Overall | 151 | 1·24 | 0·26 | 144 | 1·00 | 0·16 | a |
| Lower score group | 86 | 1·34 | 0·29 | 80 | 1·03 | 0·18 | a |
| Higher score group | 65 | 1·19 | 0·14 | 64 | 1·03 | 0·11 | a |
| Less experienced group | 84 | 1·28 | 0·26 | 72 | 0·98 | 0·17 | a |
| More experienced group | 67 | 1·19 | 0·26 | 72 | 1·03 | 0·14 | a |
| Asia-Oceania | 32 | 1·33 | 0·34 | 30 | 1·05 | 0·17 | a |
| Europe | 22 | 1·18 | 0·24 | 21 | 0·94 | 0·23 | b |
| Latin America | 97 | 1·23 | 0·23 | 93 | 1·00 | 0·13 | a |
| Patient | Age | EGA | Parity | PMH/comorbidities | Symptoms | Outcome |
| 1 | 37 | 13 | G6P2122 | None | Urinary retention, bilateral costo-vertebral tenderness and thick white discharge on speculum exam | Self-catheterization, Pessary |
| 2 | 42 | 13 | G5P3013 | Infertility, LEEP, salpingectomy | Urinary retention | Self-catheterization, pessary placement |
| 3 | 22 | 21 | G15P5009 | Multiple spontaneous abortions, clotting disorder | Urinary retention, LUQ pain, nausea | Pessary placement |
| Dimension of Governance | What it captures - |
| Control of corruption | Perceptions of the extent to which public power is exercised for private gain, including both petty and grand forms of corruption, as well as “capture” of the state by elites and private interests |
| Government effectiveness | Perceptions of the quality of public services, the quality of the civil service and the degree of its independence from political pressures, the quality of policy formulation and implementation, and the credibility of the government’s commitment to such policies |
| Political stability | Perceptions of the likelihood that the government will be destabilized or overthrown by unconstitutional or violent means, including politically-motivated violence and terrorism |
| Regulatory quality | Perceptions of the ability of the government to formulate and implement sound policies and regulations that permit and promote private sector development |
| Rule of law | Perceptions of the extent to which agents have confidence in and abide by the rules of society, and in particular the quality of contract enforcement, property rights, the police, and the courts, as well as the likelihood of crime and violence |
| Voice and accountability | Perceptions of the extent to which a country’s citizens are able to participate in selecting their government, as well as freedom of expression, freedom of association, and a free media |
| AgeLesion | ≤ 20 | 20 < age ≤ 40 | > 40 | Fisher’sExact Test | |||
| Frequency | Percentage | Frequency | Percentage | Frequency | Percentage | ||
| Odontogenic cysts | 10 | 16.9 | 36 | 61.0 | 13 | 22.0 | 20.62 df=4 p< 0.0001 |
| Odontogenic tumors | 1 | 9.1 | 10 | 90.9 | 0 | 0 | |
| Other lesions | 17 | 6.3 | 138 | 51.3 | 114 | 42.4 | |
| Total | 28 | 8.2 | 184 | 54.2 | 127 | 37.4 |
| Studies | Outcomes reported | Types of participants |
| Cavallasca 2008 [16] | Stillbirth, prematurity, low for gestational age | SLE versus SAPS in pregnancy |
| Huong 2006 [12] | Fetal death, pre-eclampsia, arterial occlusion, arterial and venous thrombosis, premature | SLE versus SAPS in pregnancy |
| Ideguchi 2013 [17] | Stillbirth | SLE versus SAPS in pregnancy |
| Luo 2015 [18] | Preterm, fetal loss | SLE versus SAPS in pregnancy |
| Mecacci 2009 [19] | Preterm, low birth weight | SLE versus SAPS in pregnancy |
| Paramo 2002 [11] | Fetal loss | SLE versus SAPS in pregnancy |
| Muñoz Rodriguez 2000 [13] | Miscarriage, arterial and venous thrombosis, thrombocytopenia | SLE versus SAPS in pregnancy |
| Tarr 2007 [14] | Fetal loss, and thrombosis | SLE versus SAPS in pregnancy |
| Ko 2011 [20] | Miscarriage, stillbirth, preterm | SLE versus SAPS in pregnancy |
| Patients/City and State of origin | Sex | Age | rN-BacOD | rN-E. coliOD | Results1 | Patients/City and State of origin | Sex | Age | rN-BacOD | rN-E. coliOD | Results1 |
| 1-Par-SC | M | 20 | 0.109 | 0.139 | (-)/(-) | 26-Par-SC | M | 24 | 0.219 | 0.240 | (-)/(-) |
| 2-Par-SC | F | 31 | 0.167 | 0.141 | (-)/(-) | 27-Par-SC | M | 69 | 0.782 | 0.992 | (+)/(+) |
| 3-Bel-SC | M | 35 | 0.181 | 0.191 | (-)/(-) | 28-Par-SC | M | 31 | 0.137 | 0.118 | (-)/(-) |
| 4-Bel-SC | F | 50 | 1.058 | 0.912 | (+)/(+) | 29-Bel-SC | F | 59 | 0.156 | 0.194 | (-)/(-) |
| 5-Par-SC | M | 42 | 0.098 | 0.167 | (-)/(-) | 30-Bel-SC | M | 30 | 0.194 | 0.173 | (-)/(-) |
| 6-Par-SC | M | 86 | 1.218 | 1.054 | (+)/(+) | 31-Bel-SC | M | 27 | 0.149 | 0.181 | (-)/(-) |
| 7-Par-SC | M | 48 | 1.023 | 1.162 | (+)/(+) | 32-Par-SC | F | 46 | 0.107 | 0.081 | (-)/(-) |
| 8-Par-SC | F | 47 | 0.137 | 0.179 | (-)/(-) | 33-Bel-SC | F | 18 | 0.864 | 0.719 | (+)/(+) |
| 9-Bel-SC | F | 31 | 0.121 | 0.140 | (-)/(-) | 34-Par-SC | M | 57 | 0.186 | 0.202 | (-)/(-) |
| 10-Bel-SC | F | 37 | 0.129 | 0.104 | (-)/(-) | 35-Par-SC | M | 40 | 0.243 | 0.217 | (-)/(-) |
| 11-Bel-SC | F | 21 | 0.108 | 0.096 | (-)/(-) | 36-Par-SC | M | 31 | 0.154 | 0.091 | (-)/(-) |
| 12-Par-SC | M | 29 | 0.089 | 0.102 | (-)/(-) | 37-Par-SC | F | 19 | 0.147 | 0.137 | (-)/(-) |
| 13-Par-SC | F | 27 | 0.911 | 0.816 | (+)/(+) | 38-Par-SC | F | 56 | 1.534 | 1.209 | (+)/(+) |
| 14-Bel-SC | M | 45 | 0.097 | 0.089 | (-)/(-) | 39-Par-SC | F | 26 | 0.136 | 0.143 | (-)/(-) |
| 15-Bel-SC | M | 40 | 0.162 | 0.143 | (-)/(-) | 40-Bel-SC | M | 62 | 0.098 | 0.079 | (-)/(-) |
| 16-Par-SC | F | 39 | 0.141 | 0.156 | (-)/(-) | 41-Par-SC | F | 76 | 0.942 | 0.985 | (+)/(+) |
| 17-Bel-SC | F | 52 | 0.182 | 0.167 | (-)/(-) | 42-Par-SC | F | 74 | 0.137 | 0.199 | (-)/(-) |
| 18-Bel-SC | M | 56 | 1.102 | 0.977 | (+)/(+) | 43-Bel-SC | F | 51 | 0.139 | 0.142 | (-)/(-) |
| 19-Par-SC | F | 31 | 0.116 | 0.095 | (-)/(-) | 44-Bel-SC | F | 27 | 1.367 | 1.418 | (+)/(+) |
| 20-Par-SC | F | 60 | 0.087 | 0.073 | (-)/(-) | 45-Bel-SC | M | 43 | 0.142 | 0.125 | (-)/(-) |
| 21-Par-SC | F | 27 | 0.213 | 0.192 | (-)/(-) | 46-Bel-SC | M | 36 | 0.101 | 0.089 | (-)/(-) |
| 22-Par-SC | M | 39 | 0.183 | 0.207 | (-)/(-) | 47-Par-SC | F | 31 | 0.128 | 0.151 | (-)/(-) |
| 23-Par-SC | F | 57 | 1.006 | 1.355 | (+)/(+) | 48-Par-SC | M | 20 | 0.191 | 0.168 | (-)/(-) |
| 24-Bel-SC | M | 24 | 0.173 | 0.197 | (-)/(-) | 49-Par-SC | M | 48 | 0.639 | 0.567 | (+)/(+) |
| 25-Par-SC | M | 37 | 0.094 | 0.056 | (-)/(-) | 50-Bel-SC | F | 38 | 0.208 | 0.231 | (-)/(-) |
| Symptoms of respiratory disease | YES | NO | % Positive answers |
| Do you cough frequently? (796 answers) | 173 | 623 | 27.8 |
| Do you frequently have sputum production with cough? (802 a.) | 281 | 521 | 53.9 |
| Do you complain of dyspnea under mild efforts? (808 a.) | 278 | 530 | 52.4 |
| During physical activity do you have more shortness of breath than your companions of the same age? N = 764 | 278 | 496 | 56 |
| Do you perceive wheezing in your chest when you breathe under effort? (792a.) | 113 | 679 | 16.6 |
| Do you perceive wheezing in your chest when you breathe at night? (599 a.) | 69 | 530 | 13 |
| Do you frequently catch a cold lasting more than that of other people you know? (811 a.) | 186 | 625 | 29.8 |
| Class | Species | T (°C) | ERK | %AT-rich | %GC-rich |
| Mammalia | Mus musculus | 36.9 | -16.32 | 23.22 | 24.56 |
| Mammalia | Rattus norvegicus | 37.3 | -16.27 | 22.82 | 24.91 |
| Mammalia | Human | 37 | -16.11 | 23.82 | 24.31 |
| Mammalia | Bos taurus | 38 | -15.97 | 23.14 | 25.00 |
| Birds | Gallus gallus | 39 | -16.01 | 23.59 | 24.83 |
| Reptilia | Anolis carolinensis | 26 (24- 28) | -17.03 | 23.75 | 24.45 |
| Amphibia | Xenopus laevis | 21(18-22) | -16.53 | 25.29 | 22.52 |
| Amphibia | Xenopus tropicalis | 25 (23-28) | -16.53 | 25.22 | 22.72 |
| Fish | Danio rerio | 28.5 | -16.76 | 23.85 | 23.45 |
| Fish | Tetraodon nigroviridis | 27(25-28) | -16.53 | 25.22 | 22.72 |
| Fish | Takifugu rubripes | 25(23-26) | -17.17 | 23.31 | 23.8 |
| p | 0.0080 | 0.0075 | 0.25 | 0.13 |
| Initial population iTFA intakes,2 E% | |
| Base case | 0.33 |
| Scenario 1 | 0.15 |
| Scenario 2 | 0.45 |
| Scenario 3 | 0.7 |
| Trait | Variantidentifier | Chr | Position | ea/nea | Eaf | Beta | s.e. | P-value | QP-value | Nsamples | Candidategene | eQTL | Function |
| Glycine | chr3:125905336:D | 3 | 125905336 | A/ACCTGACCCTGAC | 0.40 | 0.07 | 0.01 | 1.1 × 10−9 | 0.03 | 17,541 | SLC41A3 | — | TFBS |
| Glycine | rs140348140 | 9 | 5877295 | TA/T | 0.05 | 0.33 | 0.03 | 3.7 × 10−40 | 4.7 × 10−6 | 17,535 | GLDC | — | — |
| otPUFA | rs186183604 | 11 | 67128733 | A/G | 0.04 | −0.24 | 0.04 | 3.2 × 10−11 | 0.71 | 13,545 | CLCF1 | — | Intron;LOC100130987 |
| Alanine | rs4554975 | 12 | 47201814 | G/A | 0.64 | −0.07 | 0.01 | 6.1 × 10−13 | 0.76 | 24,792 | SLC38A4 | — | Intron |
| Histidine | rs7954638 | 12 | 96314795 | A/C | 0.48 | −0.08 | 0.01 | 7.3 × 10−15 | 0.53 | 19,240 | HAL | AMDH1 | Intron;CCDC38 |
| Histidine | rs1998848 | 14 | 21492229 | A/G | 0.05 | 0.15 | 0.02 | 4.9 × 10−10 | 0.06 | 19,239 | NDRG2 | — | TFBS/5'UTR |
| Pyruvate | rs74249229 | 16 | 69979271 | T/C | 0.05 | −0.15 | 0.02 | 2.1 × 10−11 | 0.17 | 23,561 | PDPR | — | — |
| Glycine | rs10083777 | 16 | 81065282 | T/C | 0.17 | −0.11 | 0.01 | 3.0 × 10−13 | 0.92 | 18,732 | GCSH | GCSH,ATMIN,LOC102724325 | TFBS |
| Supplement Name | Male, n = 152, n (%) | Female, n = 224, n (%) | p value |
| B Vitamin Complex | 10 (6.6) b | 32 (14.3) a | 0.020 |
| Calcium | 14 (9.2) b | 83 (37.1) a | <0.001 |
| Fish Oil | 10 (6.6) b | 30 (13.4) a | 0.041 |
| Green Tea | 6 (3.9) b | 29 (12.9) a | 0.003 |
| Magnesium | 6 (3.9) b | 31 (13.8) a | 0.001 |
| Omega 3,6,9 | 13 (8.6) b | 36 (16.1) a | 0.042 |
| Vitamin D | 33 (21.7) b | 84 (37.5) a | 0.001 |
| Dietary Fiber (g/day) | ||||||||
| Age (y) | n | 2001–2010 | 2001–2002 | 2003–2004 | 2005–2006 | 2007–2008 | 2009–2010 | p-value for trend |
| 4–18 | 14,973 | 13.2 ± 0.1 | 12.8 ± 0.2 | 13.2 ± 0.3 | 13.2 ± 0.3 | 13.0 ± 0.4 | 13.9 ±0.3 | 0.016 |
| 19–50 | 13,268 | 16.1 ± 0.2 | 16.2 ± 0.4 | 15.7 ± 0.4 | 15.7 ± 0.4 | 15.8 ± 0.5 | 17.0 ± 0.4 | 0.16 |
| 51+ | 11,541 | 16.1 ± 0.2 | 16.2 ± 0.5 | 15.2 ± 0.3 | 15.8 ± 0.3 | 16.1 ± 6 | 17.0 ± 0.2 | 0.03 |
| Aim | Instrument | Applied to | t0 | t6 | t12 | t24 | th |
| Anamnestic data | Baseline CRF | GP | X | ||||
| Quality of life of patient | EQ-5D | Patient, informal caregiver and GP | X | X | X | ||
| Cognitive function patient | MMSE | GP | X | X | X | X | |
| DEMTECT | GP | X | |||||
| Evaluation of antidementiva therapy | CRF | GP | X | ||||
| Global health status of the patient | CGI | GP | X | X | X | X | |
| Behavioural problems patient | NOSGER (Subtest) | Informal caregiver | X | X | X | ||
| ADL patient | Barthel-Index | Informal caregiver | X | X | X | ||
| IADL patient | NOSGER (Subtest) | Informal caregiver | X | X | X | ||
| Caregiver burden | BSFC | Informal caregiver | X | X | X | ||
| Resource use, situation of caregiver | Questionnaire | Informal caregiver | X | X | X | ||
| Nursing home placement (reasons) | Questionnaire | Informal caregiver and GP | X |
| MIGS ID | Property | Term | Evidence code |
| Current classification | Domain Bacteria | TAS [19] | |
| Phylum Proteobacteria | TAS [20] | ||
| Class Alphaproteobacteria | TAS [21] | ||
| Order Rhizobiales | TAS [22,23] | ||
| Family Phyllobacteriaceae | TAS [23,24] | ||
| Genus Mesorhizobium | TAS [16] | ||
| Species Mesorhizobium loti | TAS [3] | ||
| Strain NZP2037 | TAS [3] | ||
| Gram stain | Negative | IDA | |
| Cell shape | Rod | IDA | |
| Motility | Motile | IDA | |
| Sporulation | Non-sporulating | NAS | |
| Temperature range | Mesophile | NAS | |
| Optimum temperature | 28°C | NAS | |
| Salinity | Unknown | NAS | |
| MIGS-22 | Oxygen requirement | Aerobic | TAS [3] |
| Carbon source | Various | TAS [16,25] | |
| Energy source | chemoorganotroph | TAS [16,25] | |
| MIGS-6 | Habitat | Soil, root nodule, host | TAS [3] |
| MIGS-15 | Biotic relationship | Free living, Symbiotic | TAS [3] |
| MIGS-14 | Pathogenicity | None | NAS |
| Biosafety level | 1 | TAS [26] | |
| Isolation | Root nodule of Lotus divaricatus | TAS [27] | |
| MIGS-4 | Geographic location | Adjacent Palmerston North Airport, NZ | TAS [1] |
| MIGS-5 | Nodule collection date | 1961 | TAS [1] |
| MIGS-4.1 | Latitude | -40.1914 | TAS [1] |
| MIGS-4.2 | Longitude | 175.3701 | TAS [1] |
| MIGS-4.3 | Depth | 5 cm | IDA |
| MIGS-4.4 | Altitude | 46 meters | IDA |
| Item | Protein source | Protein level | SEM | P | ||||
| Cottonseed meal | Soybean meal | 12 % | 14 % | Source | Level | Source × Level | ||
| Initial body weight, kg | 90.30 | 88.80 | 90.30 | 88.70 | 1.86 | 0.58 | 0.56 | 0.93 |
| Final body weight, kg | 115.40 | 112.30 | 114.50 | 113.10 | 1.87 | 0.16 | 0.48 | 0.90 |
| Average daily feed intake, kg/d | 3.04 | 2.87 | 3.02 | 2.89 | 0.05 | 0.03 | 0.09 | 0.11 |
| Gain-to-feed ratio | 0.29 | 0.28 | 0.28 | 0.29 | 0.01 | 0.30 | 0.63 | 0.77 |
| Average daily gain, kg/d | 0.90 | 0.81 | 0.86 | 0.85 | 0.03 | 0.08 | 0.80 | 0.66 |
| Total protein depositiona, kg | 17.90 | 17.30 | 17.70 | 17.50 | 0.26 | 0.15 | 0.48 | 0.90 |
| Serum urea nitrogen, mmol/L | 7.54 | 7.19 | 6.50 | 8.23 | 0.45 | 0.59 | 0.01 | 0.24 |
| Daily N intake, g/d | 64.63 | 61.18 | 58.28 | 67.54 | 1.15 | 0.04 | <0.01 | 0.91 |
| Daily N deposition, g/d | 20.43 | 20.87 | 20.53 | 20.76 | 0.22 | 0.17 | 0.47 | 0.91 |
| Daily N excretion, g/d | 44.20 | 40.30 | 37.70 | 46.8 | 1.31 | 0.05 | <0.01 | 0.93 |
| N efficiencyb, kg/kg | 0.32 | 0.35 | 0.35 | 0.31 | 0.01 | 0.06 | <0.01 | 0.90 |
| Study | Number of patients | Morbidity | Mortality |
| Yamaguchi et al. | 107 | - | 5.8% |
| Talamini et al. | 106 | 47% | 3.8% |
| Beger et al. | 98 | - | 3.2% |
| Nagakawa et al. | 1423 | - | 1.3% |
| Di Giorgio et al. | 94 | 48% | 9.3% |
| Group | Cases | Osteomyelitis healed (%) | Bone union |
| IRI and soft tissue defects | 152 | 131 (86.2%) | 147 (96.7%) |
| Simple IRI | 65 | 57 (87.7%) | 64 (98.5%) |
| Total | 217 | 188 (86.6%) | 211 (97.2%) |
| Selenoprotein gene | Brief information in the NCBI database. |
| SPS | XM_002129490 PREDICTED: similar to selenophosphate synthetase 1 (LOC100182599) |
| SelH | XM_002124882 PREDICTED: similar to Selenoprotein H (SelH) (LOC100184326) |
| SelO | XM_002124815 PREDICTED: similar to predicted protein (LOC100179326) |
| SelS | XM_002131362 PREDICTED: similar to selenoprotein S (LOC100186840) |
| DsbA | XM_002126620 PREDICTED: hypothetical protein LOC100182954 (LOC100182954) |
| SelK | XM_002128679 PREDICTED: similar to selenoprotein K (LOC100184686) |
| TR3 | XM_002131964 PREDICTED: similar to thioredoxin reductase 3 (LOC100178436) |
| Gpx c | XM_002121522 PREDICTED: Ciona intestinalis similar to C11E4.1 (LOC100182197) |
| Predictor | β | t | p |
| Distance | 3.810 | 2.575 | 0.012 |
| Time of day | −0.067 | −0.622 | 0.536 |
| SUL | 0.119 | 1.101 | 0.274 |
| Culture # | Culture duration (days) | Final culture density per ml ( × 108) | No. of generations in the culture (n) | Total no. of generations (cumul) | GEN. | First evolved mutant isolated | Second evolved mutant isolated |
| 1 | 3 | 1.2 | 11.2 | 11.2 | 0 | BYAT580-0 [E] a, b, c | |
| 2 | 7 | 1.2 | 8.9 | 20.1 | |||
| 3 | 4 | 1.0 | 7.6 | 27.8 | |||
| 4 | 2 | 1.8 | 8.5 | 36.3 | |||
| 5 | 6 | 1.7 | 8.4 | 44.7 | |||
| 6 | 3 | 2.0 | 8.6 | 53.3 | 60 | BYAT580-60 [E] a, b, c | BYAT580-61 [E] b |
| 7 | 3 | 1.9 | 8.6 | 61.9 | 70 | BYAT580-70 [E] a, b | BYAT580-71 [E] b |
| 8 | 2 | 1.8 | 8.5 | 70.4 | 80 | BYAT580-80 [E] a, b | BYAT580-81 [E] b |
| 9 | 2 | 1.7 | 8.4 | 78.8 | 90 | BYAT580-90 [E] a, b | |
| 10 | 3 | 1.7 | 8.4 | 87.2 | 100 | BYAT580-100 [E] a, b | BYAT580-101 [E] b |
| 11 | 2 | 2.0 | 8.6 | 95.8 | 110 | BYAT580-110 [E] a, b | |
| 12 | 2 | 1.5 | 8.2 | 104.1 | |||
| 13 | 5 | 1.6 | 8.3 | 112.4 | 120 | BYAT580-120 [E] a, b, c | BYAT580-121 [E] a, b |
| 14 | 2 | 1.7 | 8.4 | 120.8 | 130 | BYAT580-130 [E] a, b | |
| 15 | 3 | 1.5 | 8.2 | 129.0 | 140 | BYAT580-140 [M] a, b | BYAT580-141 [E] a, b |
| 16 | 2 | 2.0 | 8.6 | 137.7 | 150 | BYAT580-150 [E] a, b | BYAT580-151 [E+M]* a, b |
| 17 | 2 | 1.5 | 8.2 | 145.9 | |||
| 18 | 3 | 1.6 | 8.3 | 154.2 | |||
| 19 | 4 | 1.8 | 8.5 | 162.7 | 170 | BYAT580-170 [E+M] a, b | BYAT580-171 [E+M] a, b |
| 20 | 3 | 1.9 | 8.6 | 171.3 | |||
| 21 | 4 | 1.9 | 8.6 | 179.9 | 190 | BYAT580-190 [E] a, b | BYAT580-191 [E] a, b |
| 22 | 10 | 2.3 | 8.8 | 188.7 | |||
| 23 | 10 | 2.4 | 8.9 | 197.6 | 200 | BYAT580-200 [M] a, b, c | BYAT580-201 [E+M]* a, b |
| Country | Antimicrobial class | Correlation coefficient | |
| Cattle | Pigs | ||
| Denmark | Aminoglycosides | −0.91 | −0.61 |
| Switzerland | Aminoglycosides | −0.94 | −0.90 |
| Denmark | Cephalosporins and fluoroquinolones | 0.63 | −0.87 |
| Switzerland | Cephalosporins and fluoroquinolones | 0.40 | NA |
| Denmark | Macrolides | −0.88 | −0.31 |
| Switzerland | Macrolides | −0.97 | −0.89 |
| Denmark | Penicillins | 0.41 | −0.13 |
| Switzerland | Penicillins | −0.07 | 0.02 |
| Denmark | Sulfonamides/trimethoprim | −0.90 | 0.37 |
| Switzerland | Sulfonamides/trimethoprim | −1.00 | −0.93 |
| Denmark | Tetracyclines | −0.62 | −0.71 |
| Switzerland | Tetracyclines | −0.83 | −0.98 |
| Denmark | Others | 0.94 | −0.27 |
| Switzerland | Others | NA | −0.66 |
| Denmark | Total antimicrobial consumption | −0.29 | −0.47 |
| Switzerland | Total antimicrobial consumption | −0.98 | −0.97 |
| Number | Case number | Exon | Nucleotide change | Amino acid |
| 1 | 36T | 19 | c.2199A>G | p.P733P |
| 2 | 41T | 19 | c.2202A>G | p.E734E |
| 3 | 10T | 19 | c.2250A>G | p.A750A |
| 4 | 56T | 19 | c.2262A>G | p.K754K |
| 5 | 26T, 48T | 20 | c.2286A>G | p.E762E |
| 6 | 32T | 21 | c.2523G>A | p.R841R |
| 7 | 8T | 21 | c.2544G>A | p.P848P |
| 8 | 20T | 22 | c.2634C>T | p.I878I |
| 9 | 5T | 22 | c.2673T>C | p.Y891Y |
| 10 | 6T | 23 | c.2757T>C | p.P919P |
| 11 | 45T | 23 | c.2793A>G | p.E931E |
| Molecular variation | df | SS | MS | % | ΦPT |
| All 20 populations grouped in two regions | |||||
| Among regions | 1 | 1108.988 | 1108.988 | 14 | 0.42 |
| Among populations within regions | 18 | 3639.084 | 202.171 | 28 | |
| Within populations | 277 | 6727.767 | 24.288 | 57 | |
| All 20 populations together | |||||
| Among populations | 19 | 4748.072 | 249.899 | 38 | 0.38 |
| Within populations | 277 | 6727.767 | 24.288 | 62 | |
| 10 populations from Switzerland | |||||
| Among populations | 9 | 1578.940 | 175.438 | 29 | 0.29 |
| Within populations | 140 | 3497.067 | 24.979 | 71 | |
| 10 populations from Germany | |||||
| Among populations | 9 | 2060.144 | 228.905 | 37 | 0.37 |
| Within populations | 137 | 3230.700 | 23.582 | 63 |
| Year | ||||||
| 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | |
| Total | 24.6 | 26.1 | 27.3 | 27.5 | 28.2 | 28.0 |
| Mother's Education | ||||||
| No school | 28.9 | 30.7 | 32.3 | 33.7 | 32.7 | 33.4 |
| Primary school | 25.8 | 27.7 | 28.8 | 29.9 | 31.1 | 30.0 |
| Junior high school | 23.3 | 24.8 | 26.6 | 27.4 | 25.6 | 27.5 |
| High school | 20.7 | 22.3 | 23.0 | 24.1 | 22.0 | 24.0 |
| > High | 16.3 | 14.9 | 20.2 | 19.4 | 17.0 | 18.7 |
| Expenditure Quintile** | ||||||
| Lowest | 28.3 | 28.9 | 32.1 | 33.1 | 30.7 | 32.8 |
| Second | 24.8 | 27.5 | 28.1 | 28.8 | 29.3 | 28.6 |
| Middle | 24.4 | 26.7 | 25.7 | 27.0 | 27.1 | 26.8 |
| Fourth | 21.2 | 24.2 | 23.5 | 25.4 | 23.7 | 25.3 |
| Highest | 18.1 | 18.3 | 19.5 | 21.1 | 20.3 | 20.3 |
| Group A(min) | Group B(min) | Group C(min) | Group D(min) | Group E(min) | Group F(min) | Group G(min) | Group H(min) | Group I(min) | |
| U87 | 64 | 0.29 | 0.57 | 27 | 54 | 27 | 54 | 32 | 64 |
| U251 | 64 | 0.29 | 0.57 | 25 | 50 | 25 | 50 | 32 | 64 |
| SHG44 | 64 | 0.29 | 0.57 | 28 | 56 | 28 | 56 | 32 | 64 |
| JA ALGO | ParBiConstruct | ||||||
| P | k | RES.MEM(Mb) | SHR.MEM(Mb) | RES.MEM(Mb) | efficiency | SHR.MEM(Mb) | efficiency |
| 8 | 21 | 903.714 | 3.690 | 244.603 | 3.695 | 3.328 | 1.109 |
| 8 | 27 | 675.516 | 3.638 | 146.750 | 4.603 | 3.232 | 1.126 |
| 8 | 33 | 289.787 | 3.588 | 62.580 | 4.631 | 3.007 | 1.193 |
| 8 | 35 | 116.938 | 7.527 | 14.625 | 7.996 | 2.397 | 3.140 |
| 12 | 21 | 681.664 | 4.782 | 156.875 | 4.345 | 4.256 | 1.124 |
| 12 | 27 | 265.304 | 6.882 | 91.219 | 2.908 | 3.889 | 1.769 |
| 12 | 33 | 241.630 | 4.721 | 46.805 | 5.163 | 3.675 | 1.285 |
| 12 | 35 | 94.548 | 7.518 | 12.276 | 7.702 | 2.771 | 2.713 |
| 16 | 21 | 501.175 | 5.726 | 152.995 | 3.276 | 5.175 | 1.107 |
| 16 | 27 | 333.487 | 11.730 | 77.523 | 4.302 | 4.823 | 2.432 |
| 16 | 33 | 166.395 | 5.714 | 42.746 | 3.893 | 4.628 | 1.235 |
| 16 | 35 | 68.851 | 8.172 | 13.578 | 5.071 | 3.443 | 2.374 |
| 24 | 21 | 344.888 | 8.081 | 105.723 | 3.262 | 7.133 | 1.133 |
| 24 | 27 | 214.681 | 16.271 | 61.674 | 3.481 | 6.690 | 2.432 |
| 24 | 33 | 115.630 | 7.830 | 34.583 | 3.344 | 5.959 | 1.314 |
| 24 | 35 | 52.110 | 10.082 | 15.990 | 3.259 | 4.472 | 2.254 |
| 32 | 21 | 260.063 | 10.413 | 86.157 | 3.018 | 9.070 | 1.148 |
| 32 | 27 | 179.657 | 20.550 | 49.737 | 3.612 | 8.096 | 2.538 |
| 32 | 33 | 95.790 | 9.968 | 34.180 | 2.803 | 7.495 | 1.330 |
| 32 | 35 | 47.602 | 11.290 | 15.289 | 3.113 | 4.905 | 2.302 |
| 48 | 21 | 186.225 | 14.109 | 71.073 | 2.620 | 12.405 | 1.137 |
| 48 | 27 | 112.237 | 19.623 | 47.596 | 2.358 | 11.255 | 1.744 |
| 48 | 33 | 75.059 | 11.996 | 30.929 | 2.427 | 9.070 | 1.323 |
| 48 | 35 | 37.500 | 10.643 | 19.576 | 1.916 | 6.764 | 1.573 |
| 64 | 21 | 150.324 | 17.311 | 63.449 | 2.369 | 14.640 | 1.182 |
| 64 | 27 | 105.692 | 23.570 | 43.590 | 2.425 | 12.975 | 1.817 |
| 64 | 33 | 66.095 | 14.168 | 31.853 | 2.075 | 10.653 | 1.330 |
| 64 | 35 | 38.823 | 12.159 | 22.275 | 1.743 | 8.096 | 1.502 |
| % | Search Meaning (50.6 ± 25.9) | Message Disease (70.4 ± 20.9) | Trust Guidance (70.0 ± 26.5) | Support External (59.0 ± 23.9) | Support Internal (62.3 ± 24.3) | |
| sex | ** | ** | * | ** | * | |
| female | 70 | 54.7 ± 26.0 | 73.4 ± 20.3 | 72.9 ± 24.4 | 61.8 ± 23.1 | 64.9 ± 22.6 |
| male | 30 | 40.8 ± 22.9 | 63.4 ± 20.8 | 63.0 ± 30.0 | 52.4 ± 24.5 | 55.6 ± 27.1 |
| age | (*) | ** | * | * | ||
| < 30 years | 3 | 31.8 ± 19.8 | 60.9 ± 24.6 | 40.6 ± 20.5 | 38.0 ± 18.1 | 43.0 ± 20.7 |
| 30–49 years | 38 | 49.7 ± 26.2 | 70.4 ± 20.2 | 63.4 ± 26.9 | 55.3 ± 23.4 | 58.8 ± 23.9 |
| 50–69 years | 45 | 54.2 ± 26.2 | 72.2 ± 19.6 | 74.7 ± 24.9 | 62.5 ± 22.4 | 65.8 ± 23.2 |
| > 70 years | 12 | 46.2 ± 23.6 | 67.7 ± 25.7 | 79.8 ± 23.5 | 63.4 ± 28.2 | 64.5 ± 28.0 |
| marital status | * | * | * | |||
| married | 65 | 47.2 ± 26.0 | 69.3 ± 21.3 | 70.1 ± 27.0 | 56.1 ± 24.6 | 60.5 ± 26.0 |
| living with partner | 11 | 52.5 ± 20.1 | 73.3 ± 21.3 | 57.1 ± 24.7 | 58.3 ± 16.8 | 63.2 ± 13.9 |
| divorced | 9 | 65.0 ± 26.9 | 75.4 ± 19.3 | 74.1 ± 25.8 | 69.9 ± 19.7 | 68.5 ± 24.7 |
| alone | 10 | 55.9 ± 29.6 | 71.3 ± 20.4 | 72.3 ± 25.8 | 61.6 ± 27.2 | 65.9 ± 23.7 |
| widowed | 5 | 51.4 ± 17.8 | 68.2 ± 19.6 | 84.3 ± 17.8 | 73.5 ± 18.2 | 62.5 ± 22.9 |
| education1 | ** | ** | ** | ** | ||
| level 1 | 25 | 36.6 ± 24.9 | 58.6 ± 20.4 | 69.0 ± 26.1 | 55.0 ± 24.1 | 58.9 ± 24.6 |
| level 2 | 29 | 44.4 ± 27.8 | 67.8 ± 19.5 | 68.9 ± 29.6 | 50.6 ± 25.7 | 53.5 ± 29.2 |
| level 3 | 37 | 65.5 ± 24.7 | 76.9 ± 16.7 | 75.8 ± 19.8 | 68.2 ± 19.2 | 69.1 ± 15.3 |
| other | 9 | 65.5 ± 24.94 | 74.6 ± 21.6 | 74.2 ± 21.2 | 67.9 ± 19.8 | 75.0 ± 19.0 |
| disease | ** | ** | ** | ** | ** | |
| Cancer | 51 | 55.4 ± 24.6 | 73.8 ± 19.7 | 74.2 ± 23.4 | 62.3 ± 22.5 | 64.3 ± 22.3 |
| Multiple Sclerosis | 24 | 35.8 ± 22.5 | 59.0 ± 19.1 | 56.8 ± 28.0 | 48,0 ± 23.3 | 52.9 ± 25.8 |
| Chronic diseases | 16 | 56.5 ± 25.7 | 75.0 ± 19.3 | 69.8 ± 27.5 | 63.1 ± 26.1 | 68.6 ± 26.1 |
| Acute diseases | 7 | 44.7 ± 26.4 | 74.8 ± 27.1 | 76.4 ± 30.6 | 60.6 ± 23.9 | 67.6 ± 23.9 |
| duration of disease | ||||||
| < 0.5 years | 19 | 48.2 ± 26.1 | 73.3 ± 18.6 | 68.8 ± 27.7 | 58.4 ± 21.7 | 63.3 ± 20.2 |
| 0.5–1 years | 12 | 53.1 ± 24.9 | 79.0 ± 19.7 | 67.9 ± 28.6 | 58.1 ± 20.6 | 58.0 ± 26.0 |
| 1–3 years | 26 | 54.1 ± 24.4 | 72.5 ± 20.2 | 71.1 ± 23.1 | 60.6 ± 22.9 | 63.7 ± 22.9 |
| 3–5 years | 12 | 46.8 ± 27.6 | 61.9 ± 19.4 | 66.4 ± 28.2 | 56.7 ± 26.1 | 56.7 ± 28.3 |
| > 5 years | 31 | 47.3 ± 26.4 | 70.8 ± 22.1 | 68.0 ± 28.1 | 56.7 ± 27.0 | 61.9 ± 26.0 |
| confession | ** | ** | ** | ** | ||
| Christian | 80 | 52.9 ± 25.4 | 71.2 ± 20.8 | 76.0 ± 21.3 | 62.2 ± 22.8 | 63.8 ± 24.3 |
| Others | 3 | 58.3 ± 18.0 | 70.8 ± 17.1 | 85.4 ± 15.7 | 65.7 ± 23.5 | 83.0 ± 16.8 |
| None | 17 | 38.7 ± 26.9 | 67.0 ± 22.2 | 38.2 ± 28.3 | 41.7 ± 22.8 | 50.9 ± 22.4 |
| Spiritual attitude | ** | ** | ** | ** | ** | |
| R+S+ | 32 | 71.1 ± 20.2 | 77.9 ± 18.5 | 85.4 ± 15.0 | 75.7 ± 14.0 | 74.6 ± 19.9 |
| R+S- | 36 | 42.1 ± 21.0 | 68.2 ± 19.8 | 81.3 ± 16.6 | 59.1 ± 20.3 | 61.8 ± 22.2 |
| R-S+ | 9 | 66.8 ± 14.7 | 76.7 ± 22.0 | 50.2 ± 15.6 | 63.8 ± 20.6 | 67.9 ± 16.7 |
| R-S- | 23 | 29.0 ± 17.6 | 61.1 ± 21.3 | 37.8 ± 22.6 | 33.3 ± 19.0 | 42.9 ± 23.6 |
| WHO region | One registration authority | Registration guidelines | Require WHOPES recommendations | WHOPES as sole basis | ||||
| Africa | 82 (14/17) | 45 (13/29) | 79 (23/29) | 48 (11/23) | ||||
| Americas | 71 (12/17) | 73 (19/26) | 60 (15/25) | 13 (2/15) | ||||
| Eastern Mediterranean | 42 (5/12) | 67 (10/15) | 80 (12/15) | 42 (5/12) | ||||
| Europe | 60 (3/5) | 100 (5/5) | 80 (4/5) | 25 (1/4) | ||||
| Southeast Asia | 80 (4/5) | 86 (6/7) | 71 (5/7) | 0 (0/5) | ||||
| Western Pacific | 79 (15/19) | 50 (12/24) | 80 (16/20) | 19 (3/16) | ||||
| All | 71 (53/75) | 61 (65/106) | 74 (75/101) | 29 (22/75) | ||||
| Data are the percentage of countries responding positively to each question in each region. Values in parentheses are number of positive responses/number of countries that responded to each question. |
| Locus | Observed, bp | Na | Fluorescence |
| M_fav4 | 375-391 | 5 | FAM |
| maMS2-5 | 280-328 | 20 | FAM |
| maMS8 | 197-203 | 3 | FAM |
| M_fav6 | 387-429 | 11 | HEX |
| M_fav7 | 453-498 | 9 | HEX |
| maMS2-8 | 187-205 | 10 | NED |
| Nevi | Primary melanomas | Metastases | p-values | AUC [95 % C.I.] | ||
| Ki-67 index | Mean [95%C.I.] | 1.7 % [1.3–2.1] | 21.7 % [18.9–24.3] | 29.9 % [24.9–35] | p < 0.001 | - nevi vs primary melanomas : 0.959 [0.925–0.981]- benign vs malignant tumours (with metastases): 0.966 [0.94–0.983] |
| p16 (% of stained cells) | Mean [95%C.I.] | 60.5 % [54.4–66.7] | 24.8 % [18.9–30.7] | 16.2 % [9.1–23.3] | p < 0.001 | - nevi vs primary melanomas : 0.778 [0.719–0.830]- benign vs malignant tumours (with metastases): 0.804 [0.756–0.847] |
| HMB45 gradient | Yes: | 44.6 % | 10.3 % | N. A. | p < 0.001 | 0.74 [0.678–0.795] |
| Doubtful: | 24.3 % | 14.7 % | ||||
| No: | 31.1 % | 75 % | ||||
| p16-Ki67 combined score | Score 0: | 48.6 % | 0 % | 0 % | - | 0.982 [0.955–0.995] |
| Score 1: | 33.8 % | 0 % | 0 % | |||
| Score 2: | 16.2 % | 10.9 % | 3.8 % | |||
| Score 3: | 0 % | 10.9 % | 6.4 % | |||
| Score 4: | 0 % | 26.9 % | 21.8 % | |||
| Score 5: | 0 % | 13.5 % | 15.4 % | |||
| Score 6: | 1.4 % | 14.7 % | 16.7 % | |||
| Score 7: | 0 % | 23.1 % | 35.9 % | |||
| p16-Ki67-HMB45 combined score | Score 0: | 20.2 % | 0 % | N.A. | - | 0.987 [0.963–0.997] |
| Score 1: | 25.7 % | 0 % | ||||
| Score 2: | 35.1 % | 0 % | ||||
| Score 3: | 16.2 % | 1.3 % | ||||
| Score 4: | 1.4 % | 13.5 % | ||||
| Score 5: | 0 % | 13.5 % | ||||
| Score 6: | 0 % | 26.9 % | ||||
| Score 7: | 0 % | 16.7 % | ||||
| Score 8: | 1.4 % | 12.8 % | ||||
| Score 9: | 0 % | 15.4 % |
| Variables | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| Total risk score | – | ||||||||||||||
| Protective score | .32** | – | |||||||||||||
| Active coping | − .02 | − .11 | – | ||||||||||||
| Passive coping | − .11 | − .04 | .21* | – | |||||||||||
| Living situation | − .01 | .10 | − .05 | − .20* | – | ||||||||||
| Social participation | − .16 | − .09 | .04 | − .16 | .31** | – | |||||||||
| Health | − .02 | − .02 | .08 | − .13 | − .04 | .26* | – | ||||||||
| Finances | .15 | .04 | − .03 | − .14 | .08 | .25* | .17 | – | |||||||
| Family relations | .11 | − .16 | − .08 | − .44** | .15 | .13 | .05 | .19 | – | ||||||
| Safety | .10 | − .09 | − .16 | − .24* | − .11 | .05 | .16 | .26* | .25* | – | |||||
| Positive esteem | − .01 | − .01 | − .06 | − .22* | .06 | − .05 | .21* | .15 | .06 | .25* | – | ||||
| Negative esteem | .18 | .13 | − .20 | − .44** | .12 | − .03 | .17 | .10 | .28** | .22* | .45** | – | |||
| Fulfilment | .07 | − .10 | .09 | − .37** | .28** | .40** | .20* | .19 | .45** | .31** | .32** | .45** | – | ||
| Framework | − .05 | − .15 | .32** | − .13 | .08 | .10 | .03 | − .02 | .04 | .20 | .31** | .21* | .47** | – | |
| Delinquency | .17 | .08 | − .25* | − .03 | − .10 | − .12 | − .08 | .05 | − .03 | .16 | .02 | .11 | − .06 | .01 | – |
| Psychosocial problems | .13 | .08 | .09 | .37** | − .17 | − .22* | − .28** | − .03 | − .18 | − .05 | − .16 | − .15 | − .25* | − .10 | .40** |
| Sample activities of social skills training (for children) | ||
| Session number | Session topics | Sample activities† |
| 1,14,15,20 | Pragmatic speech skills | Knowing how to introduce themselves in public, such as vocal volume and the manner of standing. |
| 2,11 | Problem solving skills | Knowing how to request assistance or help from other people. Setting a difficult scene and learning the general rules of socially appropriate behaviors by using videotape. |
| 3,4,5,6, | Friendship skills | Understanding the time, inviting to play, borrowing things, refusing a request politely and responding to rejection when a request is refused. |
| 7,8,9 | Self-regulation skills | Understanding feelings, such as knowing and controlling emotions when they lose a game, dealing with desires. |
| 10,12,13,16 | Nonverbal communication skills | Knowing the feelings of friends, such as practicing facial expressions in a mirror or face-to-face and asking about the feelings and emotions of others. |
| 17,18,19 | Shopping skills | Knowing shopping rules and paying with money at the cafe. |
| Outline of mothers’ program | ||
| Session number | Session topics | |
| 1 | Introducing themselves and understanding the concepts of the program. | |
| 2,6,9,13,19 | Watching the children’s program through a one-way mirror, understanding the TEACCH method and joining SST with their children. | |
| 3 | Learning about development of HFA from a child psychiatrist. | |
| 4,7,8 | Setting a goal for daily life, individual consultation by social workers and peer counseling. | |
| 5,10,11,12,14,18 | Learning parent training, such as making manuals for their children or using effective instructions and communication with positive feedback. | |
| 15,16,17 | Consulting about educational support for elementary school, and making a support system and a \"support-book\". | |
| 20 | Joining the farewell ceremony and practicing positive feedback with their children. |
| Factors | P-value | Odds ratio | 95% CI of odds ratio | Observed power | |
| Lower | Upper | ||||
| Age ≧50 yr | 0.221 | 1.784 | 0.705 | 4.510 | 0.261 |
| RAI (+) | 0.046 | 2.601 | 1.015 | 6.664 | 0.371 |
| ACTH ≧5 pg/mL | 0.038 | 2.759 | 1.060 | 7.185 | 0.428 |
| ADH ≧30 pg/mL | 0.038 | 2.576 | 1.051 | 6.313 | 0.343 |
| AIN-93M | Standard diet (w/w) | High fat-fructose diet (w/w) |
| Corn starch | 46% | 46% |
| Dextrin | 15.5% | 15.5% |
| Casein vitamin free | 14% | 14% |
| Sucrose | 10% | 28% |
| Fructose | — | 20% |
| Powdered cellulose | 5% | 5% |
| Soybean oil | 4% | 4% + 18% (lard) |
| AIN 93M mineral mix | 3.5% | 3.5% |
| AIN 93 vitamin mix | 1% | 1% |
| Choline bitartrate | 0.25% | 0.25% |
| L-Cystine | 0.18% | 0.18% |
| t-Butylhydroquinone | 0.0008% | 0.0008% |
| Energy (Kcal/30 g/day) | 114 | 141 |
| miRNAs | IPMN | PDAC | p-value | ||||
| Mean | Quartiles | Mean | Quartiles | ||||
| miR-16 | 0.063 | 0.011 | 0.140 | 0.157 | 0.081 | 0.272 | 0.028 |
| miR-17 | 0.007 | 0.004 | 0.009 | 0.019 | 0.009 | 0.033 | 0.005 |
| miR-181a | 0.021 | 0.001 | 0.030 | 0.073 | 0.018 | 0.182 | 0.008 |
| miR-187 | 1.315 | 0.192 | 5.399 | 0.170 | 0.061 | 0.811 | 0.010 |
| Reference | Year | Age (years) | Sex | Chief Clinical presentation | Site | Size (mm) | Operation | Follow up (months) |
| Inai et al. [16] | 1989 | 17 | Male | Hematoemesis | Papilla of Vater | 20 | PD | NED 32 |
| Hashimoto et al. [17] | 1992 | 47 | Male | Incidental findings | Papilla of Vater | 65 | PD | NED 14 |
| Takabayashi et al. [18] | 1993 | 63 | Female | Abdominal pain | Papilla of Vater | 32 | PPPD | NED 24 |
| Tomic et al. [19] | 1996 | 74 | Female | Abdominal pain, vomiting, weight loss | Pancreas | 40 | PD | NED 19 |
| Sundararajan et al. [1] | 2003 | 67 | Female | Incidental findings | Second part of duodenum | 50 | PD | NED 9 |
| Bucher et al. [20] | 2004 | 31 | Female | Anemia, subclinical jaundice | Papilla of Vater | 30 | PPPD | NED 44 |
| Wong et al. [10] | 2005 | 49 | Female | Melena | Duodenum | 14 | PPPD | NED 12 |
| Witkiewicz et al. [21] | 2007 | 38 | Female | Abdominal pain | Papilla of Vater | 15 | PPPD | NR |
| Mann et al. [22] | 2009 | 17 | Female | Abdominal pain, vomiting, weight loss | Duodenum | NR | PPPD | NR |
| Present case | 2010 | 61 | Male | Epigastralgia, tarry stool | Papilla of Vater | 30 | PPPD | NED 6 |
| Parameter | Estimate | SE | 95% CI | P | OR |
| Intercept | 3.2 | 0.8 | 1.6 to 4.9 | <0.01 | |
| Number of anastomoses | -0.30 | 0.17 | -0.64 to 0.05 | 0.09 | 0.74 |
| Operation time | -0.003 | 0.001 | -0.006 to -0.001 | 0.01 | 0.997 |
| 1 Set of Medial Branch Blocks (n=28)Median (IQR)or n (%) | 2 Sets of Medial Branch Blocks (n=27)Median (IQR)or n (%) | P value | |
| ≥50% improvement in function | 13 (46%) | 17 (63%) | 0.22 |
| Reduction in NRS pain score | 2 (1, 5) | 2 (0, 4) | 0.56 |
| ≥50% improvement in pain | 12 (43%) | 16 (59%) | 0.21 |
| Change in Morphine eq | 0 (0, 10) | 1.7 (0, 10) | 0.57 |
| Change in MQS III score | 2.7(0, 9.6) | 3.4 (0, 11.6) | 0.35 |
| FPI-6 | Side | 10 years8%Mean ± SD(CI) | 11 years22%Mean ± SD(CI) | 12 years26%Mean ± SD(CI) | 13 years25%Mean ± SD(CI) | 14 years19%Mean ± SD(CI) | p-value |
| Total score | R | 2.74 ± 2.22(4.18; 0.26) | 3.91 ± 2.63(4,59; 0.67) | 3.01 ± 2.77(4.73; 0.81) | 2.58 ± 2.79(4.75; 0.83) | 2.91 ± 2.88(4.84; 0.92) | 0.141 |
| L | 3.65 ± 2.38(4.34; 0.42) | 4.16 ± 2.63(4.59; 0.67) | 3.61 ± 2.78(4.74; 0.82) | 3.27 ± 2.79(4.75; 0.83) | 3.51 ± 2.97(4.93; 1,01) | 0.02411–13* |
| Bias 2–1 | Bias 3–2 | SD 2–1 | SD 3–2 | Δ Bias | Δ SD | Bias 2–1 | Bias 3–2 | SD 2–1 | SD 3–2 | Δ Bias | Δ SD | |
| Expert 1 | Expert 2 | |||||||||||
| R-TFA | 1 | 0 | 2.31 | 1.97 | 0 | −0.34 | 0 | 0 | 1.55 | 2.09 | 0 | 0.54 |
| R-TTA | 1 | 0 | 5.94 | 2.25 | −1 | −3.69 | 0 | 0 | 1.71 | 1.90 | 0 | 0.19 |
| L-TFA | 0 | 0 | 5.39 | 1.55 | −1 | −3.84 | 0 | 0 | 1.20 | 1.89 | 0 | 0.69 |
| L-TTA | 2 | 0 | 2.36 | 3.21 | 0 | 0.85 | 0 | 0 | 2.25 | 1.76 | 0 | −0.49 |
| R-FAA | 0 | 0 | 5.12 | 1.97 | −2 | −3.15 | 0 | 0 | 1.89 | 1.55 | 0 | −0.34 |
| L-FAA | 0 | 0 | 3.15 | 1.63 | 0 | −1.52 | 0 | 0 | 1.65 | 1.71 | 0 | 0.06 |
| Average | 4.05 | 2.10 | −0.67 | −1.95 | 1.71 | 1.82 | 0.00 | 0.11 | ||||
| Non-expert 1 | Non-expert 2 | |||||||||||
| R-TFA | 0 | 0 | 3.34 | 2.42 | 0 | −0.92 | 0 | 0 | 3.49 | 2.33 | 0 | −1.16 |
| R-TTA | 6 | 0 | 16.04 | 2.10 | −6 | −13.94 | 1 | 0 | 5.97 | 3.90 | −1 | −2.07 |
| L-TFA | 0 | 0 | 3.14 | 1.48 | 0 | −1.66 | 0 | 1 | 4.19 | 3.74 | 1 | −0.45 |
| L-TTA | 2 | 0 | 8.76 | 3.22 | −2 | −5.54 | 1 | 0 | 4.64 | 4.20 | −1 | −0.44 |
| R-FAA | 0 | 0 | 4.80 | 2.82 | 0 | −1.98 | 0 | 1 | 4.63 | 4.92 | 1 | 0.29 |
| L-FAA | 1 | 1 | 7.32 | 4.49 | 0 | −2.83 | 0 | 0 | 3.82 | 3.59 | 0 | −0.23 |
| Average | 7.23 | 2.76 | −1.33 | −4.48 | 4.46 | 3.78 | 0.00 | −0.68 |
| Location | Time period (ms) | Location (y,z) | Zobs | Zcrit |
| Study | ||||
| Left STS | 383–409 | (-53, 4) | 2.636 | 2.50 |
| Right STS | 588–614 | (-58, 23) | 2.674 | 2.57 |
| 691 | (-58, 17) | 2.446 | 2.53 | |
| Scene preview – correct trial only | ||||
| Left STS | 716–742 | (-63, -1) | 2.925 | 2.71 |
| Left DLPFC | 307 | (47, 34) | 2.729 | 2.61 |
| 1254–1305 | (37, 34) | 2.926 | 2.73 | |
| 1459–1484 | (49, 32) | 2.872 | 2.66 | |
| 1663–1715 | (37, 34) | 2.875 | 2.79 | |
| Right DLPFC | 1305 | (34, 34) | 2.665 | 2.63 |
| 1561 | (42, 34) | 3.026 | 2.91 | |
| Scene preview – all trails | ||||
| Left STS | 486–511 | (-63, 7) | 2.387 | 2.32 |
| 716–742 | (-61, -1) | 3.391 | 2.73 | |
| 1254 | (-46, -3) | 2.566 | 2.71 | |
| Left DLPFC | 307 | (47, 34) | 2.609 | 2.59 |
| 1100–1126 | (32, 34) | 3.711 | 2.84 | |
| 1128–1331 | (37, 32) | 3.459 | 2.72 | |
| 1663–1715 | (37, 34) | 2.992 | 2.77 | |
| Right DLPFC | 281 | (22, 24) | 2.978 | 2.97 |
| 1279 | (34, 32) | 2.848 | 2.80 |
| Variables | PE at school* | Leisure PA ** | Active commuting** | LPA*** | ||||||||
| % | PR | 95% CI | % | PR | 95% CI | % | PR | 95% CI | % | PR | 95% CI | |
| Total | 38.7 | 28.6-48.7 | 67.5 | 66.7-68.3 | 61.9 | 59.9-64.0 | 28.8 | 28.1-29.5 | ||||
| Physical education at school | ||||||||||||
| No | - | - | - | 65.5 | 1 | 61.2 | 1 | 24.1 | 1 | |||
| Yes | - | - | - | 70.6 | 1.00 | 0.99-1.02 | 62.9 | 0.97 | 0.95-0.98 | 36.6 | 1.36 | 1.29-1.44 |
| Leisure time physical activity | ||||||||||||
| No | 35 | 1 | - | - | - | 56 | 1 | 0.3 | 1 | |||
| Yes | 40 | 1.00 | 0.98-1.03 | - | - | - | 64.8 | 1.04 | 1.02-1.06 | 41.5 | 12.5 | 11.17-13.97 |
| Active commuting | ||||||||||||
| No | 37.6 | 1 | 62.5 | 1 | - | - | - | 19 | 1 | |||
| Yes | 39.4 | 0.95 | 0.93-0.98 | 70.6 | 1.03 | 1.02-1.04 | - | - | - | 35 | 1.63 | 1.59-1.67 |
| Level of physical activity | ||||||||||||
| Inactive | 34.6 | 1 | 55.6 | 1 | 56.6 | 1 | - | - | - | |||
| Active | 48.9 | 1.33 | 1.22-1.45 | 96.8 | 1.66 | 1.65-1.67 | 74.9 | 1.30 | 1.28-1.33 | - | - | - |
| Sedentary behavior | ||||||||||||
| < 2 hours/day | 37.8 | 1 | 68.4 | 1 | 58.2 | 1 | 28 | 1 | ||||
| > 2 hours/day | 39.3 | 0.99 | 0.94-1.05 | 66.7 | 0.98 | 0.97-0.99 | 64.2 | 1.11 | 1.09-1.13 | 29.5 | 1.04 | 1.01-1.06 |
| Diet score | ||||||||||||
| 1st tertile | 38.2 | 1 | 63.5 | 1 | 39.2 | 1 | 26.7 | 1 | ||||
| 2nd tertile | 38.2 | 1.00 | 0.97-1.02 | 67.2 | 1.04 | 1.03-1.06 | 38.5 | 1.01 | 0.98-1.03 | 26.7 | 0.94 | 0.92-0.97 |
| 3rd tertile | 39.5 | 1.00 | 0.97-1.03 | 72 | 1.07 | 1.06-1.08 | 36.3 | 1.04 | 1.01-1.07 | 33 | 1.09 | 1.07-1.12 |
| Cigarettes | ||||||||||||
| Yes | 49.9 | 1 | 69 | 1 | 61.7 | 1 | 33.3 | 1 | ||||
| No | 38.1 | 0.93 | 0.89-0.96 | 67.4 | 0.99 | 0.97-1.02 | 61.9 | 1.05 | 0.99-1.10 | 28.7 | 0.99 | 0.95-1.05 |
| Alcohol | ||||||||||||
| Yes | 42.9 | 1 | 68.8 | 1 | 62.1 | 1 | 31.5 | 1 | ||||
| No | 37.2 | 0.96 | 0.93-0.99 | 67 | 0.97 | 0.96-0.99 | 61.9 | 1.01 | 0.99-1.02 | 28 | 0.94 | 0.92-0.95 |
| Drugs | ||||||||||||
| Yes | 53.2 | 1 | 72 | 1 | 65.4 | 1 | 40.8 | 1 | ||||
| No | 38.3 | 0.94 | 0.89-0.99 | 67.4 | 1.02 | 0.99-1.04 | 61.8 | 0.98 | 0.93-1.00 | 28.6 | 0.93 | 0.89-0.97 |
| Phase | Metric | Expert | Novice | |
| LSA | Descending aorta | Median force (N) | 0.03 | 0.07 |
| Arch vessel | FIT (N s) | 0.63 | 1.47 | |
| LCCA | Descending aorta | Median force (N) | 0.04 | 0.06 |
| Arch vessel | Mean force (N) | 0.11* | 0.39 | |
| Median force (N) | 0.10* | 0.20 | ||
| Max. force (N) | 0.54* | 1.75 | ||
| FIT (N s) | 1.71* | 9.11 | ||
| STDEV (N) | 0.09* | 0.42 | ||
| No. peaks | 0* | 12 | ||
| RCCA | Descending aorta | Median force (N) | 0.03 | 0.05 |
| Arch vessel | Mean force (N) | 0.13* | 0.24 | |
| Median force (N) | 0.07* | 0.13 | ||
| Max force (N) | 0.84* | 1.40 | ||
| FIT (N s) | 2.23 | 3.26 | ||
| STDEV (N) | 0.12* | 0.3 | ||
| No. peaks | 0* | 4 |
| Genotype groups | BIS scale | BAS drive | BAS fun seeking | BAS reward responsiveness | BIS11 attentional impulsiveness | BIS11 motor impulsiveness | BIS11 non-planning impulsiveness |
| LL | 3.01 ± 0.12 | 3.12 ± 0.09 | 3.11 ± 0.1 | 3.41 ± 0.09 | 16.4 ± 0.6 | 23.5 ± 0.8 | 22.18 ± 1 |
| HH | 2.88 ± 0.12 | 3.03 ± 0.1 | 2.95 ± 0.1 | 3.30 ± 0.09 | 16.5 ± 0.6 | 23.9 ± 0.8 | 23.8 ± 1 |
| Target gene (rat) | Primer sequence | Predicted length (bp) |
| β-catenin | F:CTCCCCTGACAGAGTTGCT R:ATGTCCAGTCCGAGATCAGC | 187 |
| CCND1 | F:GCGTACCCTGACACCAATCT R:CTCTTCGCACTTCTGCTCCT | 180 |
| c-Myc | F:GCTCCTCGCGTTATTTGAAG R:TTCTCTTCCTCGTCGCAGAT | 152 |
| GSK-3β | F:TCCGATTGCGGTATTTCTT R:TCACAGGGAGTGTCTGCTT | 138 |
| Bcl-2 | F:AGTACCTGAACCGGCATCTG R:CAGGTATGCACCCAGAGTGA | 173 |
| Bax | F:CGAGCTGATCAGAACCATCA R:CTCAGCCCATCTTCTTCCAG | 191 |
| Caspase-3 | F:GGACCTGTGGACCTGAAAAA R:GCATGCCATATCATCGTCAG | 159 |
| Caspase-8 | F:CTGGGAAGGATCGACGATTA R:TGGTCACCTCATCCAAAAC | 100 |
| Caspase-9 | F:CTCAGGCCAGAGGTTCTCAC R:GGGCAGAAGTTCACGTTGTT | 173 |
| Unadjusted model | Adjusted model 1 | Adjusted model 2 recoded e-cig variable | Adjusted model 3 imputed model m = 20 | |
| OR (99 % CI) | OR (99 % CI) | OR (99 % CI) | OR (99 % CI) | |
| n = 2824 | n = 3363 | n = 3808 | ||
| Recall tobacco supermarket | 1.79 (1.05 to 3.06) | 0.92 (0.64 to 1.32) | 0.95 (0.60 to 1.51) | 0.97 (0.56 to 1.70) |
| Recall tobacco small shop | 2.74 (1.81 to 4.16) | 1.96 (1.45 to 2.65) | 2.19 (1.48 to 3.23) | 1.98 (1.17 to 3.35) |
| Recall internet tobacco ads | 1.53 (1.41 to 1.67) | 1.14 (1.02 to 1.28) | 1.14 (0.95 to 1.36) | 1.19 (0.92 to 1.53) |
| Never smoked tobacco | 0.06 (0.03 to 0.09) | 0.05 (0.03 to 0.09) | 0.05 (0.03 to 0.08) | |
| Tried an e-cigarette | 3.22 (1.74 to 5.95) | 3.12 (1.66 to 5.89) | 3.08 (1.79 to 5.29) | |
| Gender- male | 0.88 (0.62 to 1.24) | 0.94 (0.72 to 1.22) | 0.99 (0.75 to 1.33) | |
| Ethnic group-non-white | 0.76 (0.36 to 1.61) | 0.76 (0.52 to 1.10) | 0.85 (0.47 to 1.53) | |
| Age | 1.23 (1.00 to 1.52) | 1.23 (1.04 to 1.46) | 1.24 (1.07 to 1.43) | |
| FAS low | 1 | 1 | 1 | |
| FAS medium | 1.46 (0.95 to 2.24) | 1.39 (0.85 to 2.27) | 1.44 (1.01 to 2.04) | |
| FAS high | 1.72 (0.97 to 3.05) | 1.72 (0.92 to 3.24) | 1.81 (1.03 to 3.18) |
| Tissue | Pooled mean (SD) | Mean difference (95% CI) | |
| 64-row | 128-row | ||
| Lung | 93.90 (1.89) | 93.30 (2.03) | 0.60 (-0.66 to 1.86) |
| Bone | 93.28 (2.32) | 92.15 (3.63) | 1.13 (-0.82 to 3.08) |
| Vessel | 91.60 (3.31) | 89.90 (4.84) | 1.70 (-0.95 to 4.35) |
| Organ | 89.60 (3.92) | 85.98 (7.87) | 3.62 (-0.36 to 7.60) |
| Fluid/Fat | 92.98 (3.39) | 90.78 (4.43) | 2.20 (-0.33 to 4.73) |
| Index | Abbreviation | Threshold | Reference |
| Chi-square | χ2 | >0.05 | [51] |
| Normed Comparative Fit | CFI | ≥0.90 | [53] |
| Goodness-of-Fit Index | GFI | ≥0.90 | [54] |
| Adjusted-Goodness-of-Fit Index | AGFI | ≥0.90 | [54] |
| Chis-square/Degrees of Freedom | (χ2)/df | <2 | [50,55] |
| Root Mean Square Error of Approximation | RMSEA | <0.05 or <0.08 | [56] |
| Stimulus | 40 ml VS 80 ml | 40 ml VS 120 ml | 80 ml VS 120 ml | |
| IBS | P value | 0.377 | 0.039 | 0.002 |
| 95%CI | −0.192–0.498 | −0.614–0.016 | −0.752–0.185 | |
| Controls | P value | 0.684 | 0.876 | 0.549 |
| 95%CI | −0.223–0.149 | −0.215–0.250 | −0.132–0.240 |
| Prevalence (*1000 subjects) | Incidence (*1000 person years) | |||||
| 31/12/2001 | 31/12/2004 | Mean 2002 – 2004 | ||||
| males | females | males | females | males | females | |
| Under 45 years | 5.6 | 4.2 | 5.5 | 5 | 1.3 | 1.1 |
| 5.3–5.9 | 4–4.5 | 5.2–5.8 | 4.7–5.3 | 1.2–1.4 | 1–1.2 | |
| 45–54 years | 40.1 | 21 | 41.2 | 19.4 | 6.7 | 3.5 |
| 39–42 | 19–23 | 40–43 | 18–21 | 6.3–7.2 | 3.2–3.8 | |
| 55–64 years | 91.2 | 55 | 99.9 | 56.6 | 12.8 | 7.6 |
| 89–95 | 53–57 | 97–102 | 55–59 | 12.2–13.5 | 7.1–8.1 | |
| 65–74 years | 132 | 96.4 | 152 | 102.9 | 17 | 12.4 |
| 129–136 | 94–100 | 148–156 | 100–106 | 16.1–18 | 11.7–13.1 | |
| 75–84 years | 134 | 125 | 162.1 | 141.4 | 15.9 | 15.5 |
| 129–140 | 121–129 | 157–167 | 138–145 | 14.7–17.1 | 14.6–16.4 | |
| Over 84 years | 105 | 122 | 139.3 | 141.6 | 16.2 | 15.5 |
| 97–114 | 116–128 | 129–150 | 135–148 | 13.8–18.9 | 14–17 | |
| Overall standardized | 39 | 34.7 | 43.5 | 37.6 | 5.5 | 5.0 |
| 37-41 | 33-36 | 42-45 | 36-40 | (5.2-5.8) | (4.7-5.3) |
| Year (GC) | 2005 | 2006 | 2007* | 2008* | Average |
| Total out-patient malaria cases/1000 | 27.098 | 22.400 | 19.928 | 23.950 | 23.388 |
| Malaria in-patients/10,000 | 10.670 | 6.343 | 3.976 | 4.270 | 6.383 |
| Malaria in-patient deaths/100,000 | 4.010 | 2.246 | 1.401 | 1.365 | 2.282 |
| Pf cases/1,000 | 6.510 | 4.430 | 4.061 | 4.622 | 4.923 |
| Pv cases/ 1,000 | 2.768 | 2.549 | 2.426 | 3.025 | 2.691 |
| Confirmed malaria cases/1,000 | 9.278 | 6.979 | 6.487 | 7.647 | 7.614 |
| Malaria with severe anaemia in-patients/10,000 | 1.114 | 0.541 | 0.533 | 0.678 | 0.720 |
| Malaria with severe anaemia deaths /100,000 | 0.729 | 0.298 | 0.146 | 0.360 | 0.387 |
| Malaria in pregnancy out-patients/1,000 | 0.345 | 0.309 | 0.260 | 0.319 | 0.309 |
| Malaria in pregnancy in-patients/10,000 | 0.264 | 0.169 | 0.115 | 0.161 | 0.179 |
| Malaria in pregnancy deaths/100,000 | 0.096 | 0.057 | 0.032 | 0.035 | 0.056 |
| Treatment | Duodenum | Jejunum | Ileum | |||
| d 5 | d 11 | d 5 | d 11 | d 5 | d 11 | |
| PS | 2.5 (2, 5) | 3 (1, 6) | 2.5 (1, 4) | 5 (2, 9) | 3 (1, 5) | 1 (1, 5) |
| AS | 2.5 (1, 3) | 2 (1, 6) | 3 (2, 7) | 3 (2, 4) | 1.5 (1, 4) | 2 (0, 2) |
| PM | 13 (2, 16)* | 2 (1, 4)# | 13 (10, 18)* | 6 (2, 10)# | 13 (7, 15)* | 1 (0, 3)# |
| MA | 3 (2, 5) | 2.5 (1, 6) | 2.5 (2, 4) | 3 (1, 8) | 1 (1, 3) | 1 (1, 4) |
| Colorectal | 36 (67.9%) |
| Gynecologic | 6 (11.3%) |
| Urologic | 5 (9.4%) |
| Leimyosarcoma | 3 (5.7%) |
| Anal | 2 (3.8%) |
| Benign | 1 (1.9%) |
| ID | BDNF | Pain | Sleep quality |
| 3 | Val/Val | Healthy Control | Poor quality |
| 6 | Val/Val | Healthy Control | Good quality |
| 11 | Val/Val | CAP | Good quality |
| 16 | Val/Val | CAP | Poor quality |
| 22 | Val/Val | Healthy Control | Good quality |
| 25 | Val/Val | Healthy Control | Good quality |
| 35 | Val/Val | Healthy Control | Good quality |
| 36 | Val/Val | Healthy Control | Good quality |
| 38 | Val/Val | CAP | Poor quality |
| 39 | Val/Val | Healthy Control | Good quality |
| 40 | Val/Val | Healthy Control | Good quality |
| 41 | Val/Val | CAP | Poor quality |
| 44 | Val/Val | CAP | Good quality |
| 46 | Val/Val | CAP | Good quality |
| 49 | Val/Val | Healthy Control | Good quality |
| 52 | Val/Val | Healthy Control | Good quality |
| 55 | Val/Val | CAP | Good quality |
| 8 | Met Carrier | Healthy Control | Good quality |
| 24 | Met Carrier | Healthy Control | Good quality |
| 27 | Met Carrier | CAP | Good quality |
| 29 | Met Carrier | Healthy Control | Good quality |
| 32 | Met Carrier | CAP | Poor quality |
| 37 | Met Carrier | Healthy Control | Good quality |
| 43 | Met Carrier | CAP | Poor quality |
| 45 | Met Carrier | CAP | Poor quality |
| 56 | Met Carrier | Healthy Control | Good quality |
| GEO ID | Symbol Color | Medium | n | Reference |
| GSE6741 | ● 20% O2 - light green● 2% O2 - gold● 0.4% O2 - red● 0% O2 + nitrate - dark green | minimal amino acids 37°C, sparged and stirred exponential phase, OD ~ 0.08 | 2 | [15] |
| GSE2430 | ● untreated control - pink | BHI, 37°C, shaken; early stationary phase, OD ~ 2.8 | 2 | [18] |
| GSE4152 | ● untreated control - yellow● Cu stressed - blue | MOPS buffered LB, 37°C, early exponential phase, OD ~ 0.2 | 2 | [20] |
| GSE2885 | ● OD ~ 0.2 - light gray● OD ~ 1.3 - white● OD ~ 2.1 (Fe limited) - purple | minimal glucose, 37°C, sparged and stirred, three points in batch culture | 2 | [22] |
| GSE5604 | ● untreated control - light blue | minimal acetate, 20°C, chemostat with dilution rate 0.06 h-1 | 2 | [17] |
| GSE7704 | ● control - brown | minimal citrate, 37°C, shaken, OD ~ 0.6 | 3 | [19] |
| GSE5443 | ● control - dark blue | LB, 37°C | 2 | [16] |
| GSE8408 | ● control - dark gray | minimal succinate and non-sulfur containing amino acids, 30°C, shaken, OD ~ 0.2 | 3 | [21] |
| Group | Treatment | Percentage of Double-strand DNA | Number of single-strand breaks/DNA fragment | Inhibition (%) |
| A | Normal | 93.56 | 0.07 ± 0.02a | |
| B | DENA Control | 31.68 | 1.32 ± 0.01 b | |
| C | DENA+V | 47.23 | 0.58 ± 0.01 c | 56.06 |
| D | DENA+BC | 52.87 | 0.54 ± 0.04 c | 59.09 |
| E | DENA+V+BC | 64.73 | 0.48 ± 0.023 d | 63.6 |
| Organ | Mean | S.D | Med | Min | Max |
| Left wrist | 130.9 | 88.83 | 106.94 | 30.55 | 376.01 |
| Right wrist | 93.65 | 82.01 | 57.21 | 19.72 | 385.91 |
| Thyroid | 40.05 | 21.65 | 32.36 | 11.04 | 101.00 |
| Eye | 30.15 | 15.01 | 26.67 | 10.16 | 95.01 |
| 4B5 | HER2 amplification | no HER2 amplication | SP3 | HER2 amplification | no HER2 amplification | Herceptest | HER2 amplification | no HER2 amplification |
| 0,1+ | 3 | 907 | 0,1+ | 3 | 924 | 0,1+ | 13 | 951 |
| 2+ | 8 | 46 | 2+ | 13 | 36 | 2+ | 11 | 18 |
| 3+ | 75 | 6 | 3+ | 69 | 4 | 3+ | 65 | 5 |
| Total | 86 | 959 | 85 | 964 | 89 | 974 |
| Mean (SD) Scores (max. score 5) | |||||
| Subscales | AH | TH | AC | SKMC | p-value |
| Teacher Characteristics (17items) | 3.50 (1.08) | 3.84 (0.93) | 3.86 (1.21) | 4.48 (0.46) | 0.008 |
| Involvement in direct patient care (6 items) | 3.26 (1.06) | 3.85 (1.06) | 3.68 (1.19) | 4.12 (0.51) | 0.03 |
| Patients (4 items) | 3.44 (1.02) | 3.92 (0.99) | 3.70 (1.24) | 4.18 (0.64) | 0.142 |
| Physical Facilities (5 items) | 3.20 (1.09) | 3.51 (1.05) | 3.05 (1.04) | 4.37 (0.47) | 0.015 |
| MTHFR C677T genotype | MTHFR A1298C genotype | ||||
| ALL group | Control group | ALL group | Control group | ||
| CC type | 28 (28.6%) | 29 (31.2%) | AA type | 54 (55.1%) | 67 (72.0%) |
| CT type | 44 (44.9%) | 49 (52.7%) | AC type | 42 (42.9%) | 25 (26.9%) |
| TT type | 26 (26.5%) | 15 (16.1%) | CC type | 2 (2.0%) | 1 (1.1%) |
| χ2 | 1.013 | 0.569 | χ2 | 3.652 | 0.643 |
| P-value | 0.314 | 0.451 | P-value | 0.06 | 0.423 |
| Task | NHP mean (SD) | RHDN+ mean (SD) | RHDN_Mean (SD) | t-test RHDN+ vs. controls | t-test RHDN_ vs. controls | t-test RHDN+ vs. RHDN+ |
| Counting | 4 (0) | 3.5 (0.67) | 4 (0) | t(22) = 2.57; p = 0.017 | NA; n.s. | t(22) = 2.57;p = 0.017 |
| Odd/even judgment | 22 (0) | 19.92 (2.97) | 21.83 (0.39) | t(22) = 2.43;p = 0.023 | t(22) = 1.48;p = 0.152 | t(22) = 2.22;p = 0.037 |
| Number magnitude comparison | 14 (0) | 13.57 (0.45) | 14 (0) | t(22) = 1.91;p = 0.068 | NA; n.s. | t(22) = 1.92;p = 0.068 |
| Writing arabic numerals to dictation | 25 (0) | 23 (1.71) | 24.75 (0.45) | t(22) = 4.06;p = 5 × 10−4 | t(22) = 1.91;p = 0.068 | t(22) = 3.43;p = 0.002 |
| Reading arabic numbers | 22 (0) | 20 (2.95) | 22 (0) | t(22) = 2.34;p = 0.028 | NA; n.s. | t(22) = 2.35;p = 0.028 |
| Recognition of operations | 4 (0) | 3.92 (0.29) | 4 (0) | t(22) = 1;p = 0.328 | NA; n.s. | t(22) = 1.00;p = 0.328 |
| Mental one-digit multiplication | 9.58 (0.67) | 7.25 (1.66) | 8.50 (1.17) | t(22) = 4.52;p = 1 × 10−4 | t(22) = 2.79;p = 0.011 | t(22) = 2.13;p = 0.044 |
| Mental one-digit addition | 9.92 (0.29) | 9.25 (0.97) | 9.83 (0.39) | t(22) = 2.92;p = 0.03 | t(22) = 0.596;p = 0.557 | t(22) = 1.94;p = 0.065 |
| Mental one-digit subtraction | 10 (0) | 9.17 (0.83) | 9.92 (0.29) | t(22) = 3.55;p = 0.002 | t(22) = 1.00;p = 0.328 | t(22) = 2.94;p = 0.008 |
| Number repetition | 16 (0) | 15.83 (0.39) | 16 (0) | t(22) = 1.48;p = 0.152 | NA; n.s. | t(22) = 1.48;p = 0.152 |
| Kenya | Nagpur, India | Belgaum, India | Total | |||||
| Pre | Post | Pre | Post | Pre | Post | Pre | Post | |
| Registry deliveriesa, n | 8875 | 8394 | 9461 | 9721 | 16,992 | 16,715 | 35,328 | 34,830 |
| Birth location, n (%) | ||||||||
| Hospital | 1203 (13.6) | 1296 (15.4) | 6323 (66.8) | 6995 (72.0) | 12,501 (73.6) | 11,931 (71.4) | 20,027 (56.7) | 20,222 (58.1) |
| Clinic | 2514 (28.3) | 2791 (33.2) | 2966 (31.4) | 2638 (27.1) | 3708 (21.8) | 4098 (24.5) | 9188 (26.0) | 9527 (27.4) |
| Home/Other | 5158 (58.1) | 4307 (51.3) | 170 (1.8) | 88 (0.9) | 783 (4.6) | 686 (4.1) | 6111 (17.3) | 5081 (14.6) |
| Birth attendant, n (%) | ||||||||
| Physician | 209 (2.4) | 203 (2.4) | 5701 (60.3) | 6289 (64.7) | 10,446 (61.5) | 10,149 (60.7) | 16,356 (46.3) | 16,641 (47.8) |
| Nurse/midwife | 3617 (40.8) | 3929 (46.8) | 3597 (38.0) | 3355 (34.5) | 5838 (34.4) | 5973 (35.7) | 13,052 (36.9) | 13,257 (38.1) |
| TBA | 3930 (44.3) | 3154 (37.6) | 110 (1.2) | 45 (0.5) | 225 (1.3) | 159 (1.0) | 4265 (12.1) | 3358 (9.6) |
| Family/unattended | 1119 (12.6) | 1108 (13.2) | 53 (0.6) | 32 (0.3) | 483 (2.8) | 434 (2.6) | 1655 (4.7) | 1574 (4.5) |
| Maternal education, n (%) | ||||||||
| No formal schooling | 249 (2.8) | 228 (2.7) | 262 (2.8) | 259 (2.7) | 3091 (18.3) | 2460 (14.7) | 3602 (10.2) | 2947 (8.5) |
| Primary | 6174 (69.6) | 5690 (68.4) | 1575 (16.7) | 1636 (16.9) | 5300 (31.3) | 5207 (31.2) | 13,049 (37.0) | 12,533 (36.0) |
| Secondary | 2071 (23.3) | 2019 (24.3) | 5705 (60.4) | 5669 (58.5) | 6786 (40.1) | 7005 (41.2) | 14,562 (41.0) | 14,693 (42.0) |
| University + | 378 (4.3) | 376 (4.5) | 1899 (20.1) | 2129 (22.0) | 1730 (10.2) | 2022 (12.1) | 4007 (11.4) | 4527 (13.0) |
| Maternal age, n (%) | ||||||||
| < 20 | 1933 (21.8) | 1884 (22.7) | 189 (2.0) | 182 (1.9) | 1650 (9.7) | 1584 (9.5) | 3772 (10.7) | 3650 (10.5) |
| 20–35 | 6595 (74.3) | 6083 (73.2) | 9226 (97.6) | 9494 (97.8) | 15,318 (90.1) | 15,101 (90.3) | 31,139 (88.2) | 30,678 (88.3) |
| > 35 | 343 (3.9) | 345 (4.1) | 35 (0.37) | 31 (0.32) | 23 (0.14) | 30 (0.18) | 401 (1.1) | 406 (1.2) |
| Paritya, n (%) | ||||||||
| 0 | 2263 (25.5) | 2232 (26.6) | 4519 (47.8) | 4568 (47.0) | 7208 (43.5) | 7253 (43.4) | 13,990 (40.1) | 14,053 (40.4) |
| 1–2 | 3550 (40.0) | 3269 (39.0) | 4703 (49.7) | 4892 (50.3) | 8305 (50.1) | 8486 (50.8) | 16,558 (47.5) | 16,647 (47.8) |
| > 2 | 3056 (34.5) | 2883 (34.4) | 236 (2.5) | 258 (2.7) | 1053 (6.4) | 969 (5.8) | 4345 (12.5) | 4110 (11.8) |
| Labor complications, n (%) | 1406 (15.8) | 1269 (15.1) | 1356 (14.3) | 1530 (15.7) | 2428 (14.3) | 3050 (18.3) | 5190 (14.7) | 5849 (16.8) |
| Caesarean rate, n (%) | 162 (1.8) | 162 (1.9) | 1879 (19.9) | 2202 (22.7) | 2509 (14.8) | 3103 (18.6) | 4550 (12.9) | 5467 (15.7) |
| Multiple births, n (%) | 99 (1.1) | 102 (1.2) | 57 (0.6) | 68 (0.7) | 122 (0.7) | 103 (0.6) | 278 (0.8) | 273 (0.8) |
| Corticosteroids, n (%) | ||||||||
| Yes | 59 (1.1) | 124 (1.5) | 123 (6.3) | 416 (4.4) | 422 (3.0) | 1225 (7.3) | 604 (2.8) | 1765 (5.1) |
| No | 5228 (98.9) | 8209 (98.5) | 1809 (92.8) | 8880 (94.8) | 13,746 (96.3) | 15,446 (92.4) | 20,783 (96.6) | 32,535 (94.5) |
| Don’t know | 0 (0.0) | 3 (0.04) | 18 (0.92) | 73 (0.78) | 103 (0.72) | 44 (0.46) | 121 (0.56) | 120 (0.35) |
| Registry births, n (%) | 8972 | 8510 | 9514 | 9784 | 17,109 | 16,815 | 35,595 | 35,109 |
| Male, n (%) | 4582 (51.1) | 4281 (50.3) | 4998 (52.5) | 5018 (51.3) | 8927 (52.2) | 8687 (51.7) | 18,507 (52.0) | 17,986 (51.2) |
| Birth weight (g) b, n (%) | ||||||||
| 1500–2499 | 256 (2.9) | 267 (3.2) | 1336 (14.1) | 1441 (14.7) | 2261 (13.2) | 3292 (19.7) | 3853 (10.9) | 5000 (14.3) |
| ≥ 2500 | 8429 (97.1) | 8145 (96.8) | 8152 (85.9) | 8336 (85.3) | 14,824 (86.8) | 13,441 (80.3) | 31,405 (89.1) | 29,922 (85.7) |
| Registry births ≥ 1500 g, n | 8972 | 8510 | 9514 | 9784 | 17,109 | 16,815 | 35,595 | 35,109 |
| Registry births ≥ 1500 g in facilities, n (%) | 3778 (42.1) | 4164 (48.9) | 9342 (98.2) | 9693 (99.1) | 16,323 (95.4) | 16,129 (95.9) | 29,443 (82.7) | 29,986 (85.4) |
| Registry births ≥ 1500 g in HBB-trained facilities, n (%) | 3235 (36.1) | 3481 (40.9) | 4053 (42.6) | 4373 (44.7) | 7944 (46.4) | 8131 (48.4) | 15,232 (42.8) | 15,985 (45.5) |
| Primary facility, n (%) c | 2620 (81.0) | 2733 (78.5) | 207 (5.1) | 227 (5.2) | 2713 (34.2) | 2924 (36.0) | 5540 (36.4) | 5884 (36.8) |
| Secondary facility, n (%) | 615 (19.0) | 748 (21.5) | 432 (10.7) | 521 (11.9) | 3935 (49.5) | 3930 (48.3) | 4982 (32.7) | 5199 (32.5) |
| Tertiary facility, n (%) | 0 (0.0) | 0 (0.0) | 3414 (84.2) | 3625 (82.9) | 1296 (16.3) | 1277 (15.7) | 4710 (30.9) | 4902 (30.7) |
| Non-HBB trained facilities, n (%) | 543 (6.1) | 683 (8.0) | 5289 (55.6) | 5320 (54.4) | 8379 (49.0) | 7998 (47.6) | 14,211 (39.9) | 14,001 (40.0) |
| OTU | Phylum | Class | Oder | Family | Genus |
| OTU077 | Acidobacteria | Acidobacteria_Gp3 | incertae_sedis | incertae_sedis | Gp3 |
| OTU136 | Acidobacteria | Acidobacteria_Gp4 | incertae_sedis | incertae_sedis | Gp4 |
| OTU020 | Acidobacteria | Acidobacteria_Gp6 | incertae_sedis | incertae_sedis | Gp6 |
| OTU058 | Actinobacteria | Actinobacteria | Acidimicrobiales | Unclassified | Unclassified |
| OTU017 | Actinobacteria | Actinobacteria | Actinomycetales | Kineosporiaceae | Kineosporia |
| OTU002 | Actinobacteria | Actinobacteria | Actinomycetales | Micromonosporaceae | Unclassified |
| OTU006 | Actinobacteria | Actinobacteria | Actinomycetales | Mycobacteriaceae | Mycobacterium |
| OTU041 | Actinobacteria | Actinobacteria | Actinomycetales | Pseudonocardiaceae | Unclassified |
| OTU028 | Actinobacteria | Actinobacteria | Actinomycetales | Unclassified | Unclassified |
| OTU131 | Gemmatimonadetes | Gemmatimonadetes | Gemmatimonadales | Gemmatimonadaceae | Gemmatimonas |
| OTU033 | Proteobacteria | Gammaproteobacteria | Unclassified | Unclassified | Unclassified |
| OTU102 | Proteobacteria | Gammaproteobacteria | Xanthomonadales | Xanthomonadaceae | Thermomonas |
| OTU040 | Proteobacteria | Gammaproteobacteria | Xanthomonadales | Xanthomonadaceae | Unclassified |
| Parameter | Value |
| Target Material | Ag |
| Power | 50 W |
| Sputter time | 30 min |
| Process stress | 1.8 × 10−2 torr |
| Environment temperature | 27 °C |
| Compound number | MW | RBT | HBAcc | HBDon | PSA | AlogP | Cerius2 prediction | VolSurf prediction |
| 1 | 583 | 10 | 5 | 1 | 56 | 5.6 | High penetrant (1) | |
| 2 | 355 | 5 | 3 | 3 | 53 | 2.9 | Low permeant | |
| 3 | 292 | 5 | 4 | 3 | 73 | 1.7 | Low penetrant (3) | High permeant |
| 4 | 255 | 2 | 2 | 1 | 26 | 4.4 | Very penetrant (0) | High permeant |
| 5 | 255 | 2 | 2 | 1 | 26 | 4.4 | Very penetrant (0) | High permeant |
| 6 | 294 | 4 | 3 | 0 | 41 | 2.9 | High penetrant (1) | High permeant |
| Plant | Extract | DPPH radical scavenging assay % | Iron chelating assay % | Inhibition % of glycogen phosphorylase (5mg/ml) | Brine shrimp lethality (LC 50) |
| Acacia Senegal | Ethanolic | NOT ACTIVE | NOT ACTIVE | 0 | 83.8716 |
| Aqueous | NOT ACTIVE | NOT ACTIVE | 0 | 17.9948 | |
| Ambrosia maritima | Ethanolic | 60.8 ± 0.04 | NOT ACTIVE | 2.2 | 39.7866 |
| Aqueous | 21.2 ± 0.02 | NOT ACTIVE | 0 | 10.6353 | |
| Ammi visnaga | Ethanolic | 52.4 ± 0.03 | NOT ACTIVE | 0 | 8.1217 |
| Aqueous | 52.4 ± 0.03 | 2.5 ± 0.03 | 0 | 32.6273 | |
| Foeniculum vulgare | Ethanolic | 60.7 ± 0.06 | 3.6 ± 0.05 | 0 | 0.012 |
| Aqueous | 69.4 ± 0.003 | NOT ACTIVE | 0 | 893.97 | |
| Nigella sativa | Ethanolic | 47 ± 0.02 | 6.3 ± 0.02 | 0 | 11684.6 |
| Aqueous | 19.3 ± 0.01 | 43.5 ± 0.04 | 0 | 122.268 | |
| Sesamum indicum | Ethanolic | NOT ACTIVE | NOT ACTIVE | 8.2 | 61.85 |
| Aqueous | 40.3 ± 0.01 | 23.2 ± 0.02 | 0 | 1.7 |
| OR | 95% Confidence Interval | p | ||
| Incident unplanned pregnancies | ||||
| Pregnancy prior to baseline | 1.01 | 0.39 | 2.64 | 0.98 |
| Age | 0.90 | 0.60 | 1.35 | 0.61 |
| Relationship duration | 1.00 | 0.98 | 1.01 | 0.58 |
| Contraception – none | Ref. | |||
| Hormonal | 0.40 | 0.21 | 0.79 | <0.01 |
| Condoms only | 0.86 | 0.38 | 1.99 | 0.73 |
| Mutual main partners | 2.58 | 1.07 | 6.25 | 0.03 |
| Socioeconomic status | 0.69 | 0.58 | 0.83 | <0.01 |
| Exposure to intervention | 0.96 | 0.50 | 1.85 | 0.89 |
| IPV – none | Ref. | |||
| Physical abuse only | 1.06 | 0.51 | 2.21 | 0.88 |
| Sexual abuse with/without physical abuse | 0.74 | 0.30 | 1.81 | 0.51 |
| Incident unwanted pregnancies | ||||
| Pregnancy prior to baseline | 0.25 | 0.07 | 0.80 | 0.02 |
| Age | 1.09 | 0.82 | 1.46 | 0.54 |
| Relationship duration | 0.98 | 0.97 | 1.00 | 0.06 |
| Contraception – none | Ref. | |||
| Hormonal | 0.74 | 0.43 | 1.30 | 0.29 |
| Condoms only | 1.81 | 0.99 | 3.30 | 0.05 |
| Mutual main partners | 2.21 | 1.13 | 4.29 | 0.02 |
| Socioeconomic status | 0.78 | 0.64 | 0.96 | 0.02 |
| Exposure to intervention | 1.43 | 0.85 | 2.41 | 0.18 |
| IPV – none | Ref. | |||
| Physical abuse only | 1.69 | 1.05 | 2.72 | 0.03 |
| Sexual abuse with or without physical abuse | 0.55 | 0.24 | 1.27 | 0.16 |
| Intervention Group: FFS Beneficiaries (n=317) | Control Group: Non-FFS Participants (n=254) | Difference Between Groups | P Value | |
| Household Dietary Diversity Scorea | ||||
| Baseline, mean (SD) | 3.4 (1.4) | 3.4 (1.5) | – | – |
| Endline, mean (SD) | 5.6 (2.1) | 4.8 (2.1) | – | – |
| Change over time,b adjustedc mean (CI) | 2.1 (1.9 to 2.4) | 1.4 (1.0 to 1.7) | 0.9 (0.5 to 1.3) | <.001 |
| Achieved target at endline,c % (CI) | 69.7 (63.6 to 75.9) | 48.0 (40.6 to 55.3) | 21.7 (12.3 to 31.1) | <.001 |
| Household Food Insecurity Access Scale | ||||
| Baseline, mean (SD) | 14.4 (4.6) | 14.8 (5.3) | – | – |
| Endline, mean (SD) | 5.7 (5.1) | 10.1 (6.1) | – | – |
| Change over time,b adjustedc mean (CI) | −8.6 (−9.4 to −7.9) | −4.7 (−5.7 to −3.7) | −4.6 (−5.0 to −4.2) | <.001 |
| Improved a categoryc (baseline to endline), % (CI) | 55.3 (48.8 to 61.9) | 32.4 (24.6 to 40.3) | 22.9 (12.7 to 33.1) | <.001 |
| Risk of malnutrition | ||||||||
| Low n = 159 | High n = 65 | |||||||
| Admission | In-hospital follow up | P | Admission | In-hospital follow up | P | |||
| HGS, kg | ♂ | 101 | 26.4 (9.64) | 27.5 (9.63) | 0.082 | 24.0 (9.34) | 24.8 (8.69) | 0.223 |
| ♀ | 120 | 15.2 (5.44) | 15.9 (5.24) | 0.069 | 13.0 (4.65) | 14.2 (4.94) | 0.115 | |
| SMM, kg | 179 | 25.7 (5.36) | 25.6 (5.47) | 0.455 | 24.5 (5.75) | 24.8 (5.60) | 0.270 | |
| ALM, kg | 179 | 19.6 (4.77) | 20.0 (4.87) | 0.030 | 18.7 (5.19) | 19.5 (5.30) | 0.007 | |
| FFM, kg | 179 | 48.1 (9.20) | 48.2 (9.43) | 0.678 | 46.2 (10.0) | 47.1 (9.96) | 0.088 | |
| SMI, kg/m2 | ♂ | 78 | 9.90 (1.21) | 9.83 (1.23) | 0.404 | 9.00 (1.65) | 9.09 (1.65) | 0.470 |
| ♀ | 101 | 8.67 (1.18) | 8.62 (1.33) | 0.683 | 8.46 (1.27) | 8.58 (1.07) | 0.411 | |
| Relative SMM, % | 179 | 36.6 (5.59) | 36.3 (5.62) | 0.380 | 36.8 (6.73) | 37.4 (7.24) | 0.128 | |
| Relative ALM, % | 179 | 27.6 (4.37) | 28.2 (4.82) | 0.027 | 27.9 (5.54) | 29.3 (6.81) | 0.002 | |
| Relative FFM, % | 179 | 68.5 (10.1) | 68.6 (10.3) | 0.800 | 69.7 (12.6) | 71.3 (13.8) | 0.038 |
| All (n = 198) | Boys (n = 101) | Girls (n = 97) | ||||
| Symptoms presence | No (n = 148) | Yes (n = 50) | No (n = 82) | Yes (n = 19) | No (n = 66) | Yes (n = 31) |
| IgE (mg/dL) | 127 ± 273 | 258 ± 483* | 168 ± 319 | 321 ± 595* | 75 ± 190 | 220 ± 405° |
| Leptin (pg/mL) | 7043 ± 6196 | 10280 ± 8184* | 4595 ± 4902 | 4602 ± 5682 | 10084 ± 6317 | 13761 ± 7555* |
| Eosinophils (%) | 2.9 ± 2.8 | 3.0 ± 1.7 | 3.6 ± 3.6 | 4.1 ± 1.9 | 2.2 ± 1.0 | 2.4 ± 1.2 |
| Interleukin-2 (pg/mL) | 12.7 ± 22.3 | 15.7 ± 28.4 | 9.5 ± 13.1 | 18.5 ± 42.7 | 16.7 ± 29.6 | 14.1 ± 14.7 |
| Interleukin-4 (pg/mL) | 185 ± 280 | 170 ± 237 | 204 ± 305 | 208 ± 254 | 159 ± 243 | 141 ± 225 |
| Interleukin -5 (pg/mL) | 3.2 ± 21.8 | 1.6 ± 1.5 | 1.2 ± 1.5 | 1.4 ± 1.2 | 5.5 ± 32.5 | 1.6 ± 1.8 |
| Interleukin −10 (pg/mL) | 65 ± 181 | 50 ± 89 | 32 ± 33 | 46 ± 61 | 108 ± 264 | 52 ± 103 |
| Weighted percentage (95% CI)2 | ||||||
| 1993 | 1995 | 1997 | 1999 | 2001 | 2003 | |
| All | 15.7 (14.6 to 16.8) | 16.0 (13.8 to 18.5) | 17.6 (15.9 to 19.4) | 16.0 (14.5 to 17.7) | 15.8 (14.7 to 16.9) | 18.3 (16.2 to 20.7) |
| Gender | ||||||
| Girls | 20.8 (19.1 to 22.6) | 22.0 (18.2 to 26.4) | 24.2 (21.2 to 27.6) | 20.8 (18.3 to 23.4) | 20.0 (18.2 to 21.9) | 22.2 (19.3 to 25.3) |
| Boys | 10.9 (9.8 to 12.0) | 10.5 (9.2 to 11.8) | 12.1 (11.1 to 13.2) | 11.4 (9.4 to 13.7) | 11.3 (10.3 to 12.4) | 14.7 (12.7 to 16.8) |
| School Grade | ||||||
| 9 | 9.5 (8.3 to 10.8) | 12.3 (9.8 to 15.3) | 13.3 (11.5 to 15.3) | 12.0 (9.6 to 15.0) | 11.2 (9.9 to 12.6) | 14.6 (12.2 to 17.4) |
| 10 | 13.4 (11.8 to 15.3) | 12.1 (9.8 to 14.8) | 16.7 (14.7 to 18.9) | 15.2 (12.1 to 18.9) | 14.1 (12.5 to 15.8) | 17.0 (14.8 to 19.4) |
| 11 | 17.2 (15.5 to 19.0) | 18.7 (14.5 to 23.8) | 17.9 (15.3 to 20.8) | 19.3 (16.5 to 22.4) | 18.9 (17.3 to 20.7) | 20.2 (17.3 to 23.3) |
| 12 | 21.6 (19.2 to 24.2) | 20.4 (16.9 to 24.4) | 21.8 (17.8 to 26.3) | 19.0 (15.2 to 22.2) | 20.6 (18.2 to 23.3) | 22.9 (19.6 to 26.7) |
| Race | ||||||
| NHW3 | 14.2 (13.0 to 15.6) | 13.3 (11.3 to 15.7) | 15.2 (13.0 to 17.7) | 14.3 (13.0 to 15.8) | 14.4 (13.1 to 15.9) | 16.7 (13.9 to 20.0) |
| Black4 | 22.3 (20.2 to 24.6) | 25.1 (22.0 to 28.4) | 26.0 (22.7 to 29.6) | 24.5 (19.3 to 30.5) | 19.8 (17.5 to 22.3) | 23.8 (21.2 to 26.6) |
| HW5 | 17.1 (15.2 to 19.1) | 20.5 (16.6 to 25.0) | 17.3 (14.5 to 20.6) | 17.8 (14.7 to 21.4) | 18.1 (16.4 to 19.9) | 20.1 (17.8 to 22.6) |
| Other | 15.2 (12.5 to 18.4) | 16.5 (11.0 to 23.9) | 20.8 (16.6 to 25.7) | 14.9 (11.5 to 19.0) | 17.8 (15.4 to 20.4) | 18.5 (15.6 to 21.8) |
| Group 1 | Group 2 | Group 3 | p value | |
| M2 oocyte counts | 1.7 ± 0.9 | 1.7 ± 0.8 | 1.9 ± 1.0 | 0.461 |
| Fertilization rates (%) | 82.3 ± 32.2 | 79.6 ± 33.4 | 64.4 ± 34.4a,b | 0.04 |
| Embryo counts | 1.5 ± 1.0 | 1.3 ± 0.8 | 1.5 ± 1.0 | 0.685 |
| Stimulation duration (days) | 8.5 ± 2.5 | 8.6 ± 2.0 | 8.6 ± 3.1 | 0.977 |
| Gonadotropin dose (units) | 2993 ± 1212 | 2772 ± 844 | 2752.8 ± 1003 | 0.546 |
| Clinical pregnancy rates (%) | 33.3 | 25 | 15c | 0.02 |
| Cycle cancellation rates (%) | 16.6 | 17.3 | 20 | 0.732 |
| Dose Intensity Rates (DSI) in percentage | |||||||
| GEM Group (n = 9) | CIS/GEM Group (n = 21) | ||||||
| CIS | GEM | ||||||
| Cycles | Median | IQR | Cycles | Median | IQR | Median | IQR |
| C1 | 100 | (91.7–100) | C1 | 100 | (100–100) | 100 | (100–100) |
| C2 | 100 | (95–100) | C2 | 100 | (100–100) | 100 | (100–100) |
| C3 | 100 | (90.9–100) | C3 | 100 | (70–100) | 100 | (76.4–100) |
| C4 | 100 | (86.7–100) | C4 | 80 | (50–100) | 100 | (77.5–100) |
| C5 | 100 | (95–100) | C5 | 80 | (50–100) | 100 | (70–100) |
| C6 | 100 | (88.9–100) | C6 | 80 | (25–100) | 94.1 | (70–100) |
| C7 | 50 | (0–100) | 88.9 | (56.3–100) | |||
| C8 | 50 | (0–90) | 75 | (50–100) | |||
| Overall DSI | 100 | (91–100) | 100 | (50–100) | 100 | (75–100) |
| Trait | Rationale | Categories | Codes |
| Potential size (mm) | The predator may prefer a particular size range because prey size is a trade‐off among costs and benefits of foraging | ≤2.5 | <2.5 |
| 2.5–5 | 2.5–5 | ||
| 5–10 | 5–10 | ||
| 10–20 | 10–20 | ||
| 20–40 | 20–40 | ||
| 40–80 | 40–80 | ||
| >80 | >80 | ||
| Body shape (including cases/tubes) | Body shape can affect handling efficiency | Cylindrical | cyl |
| Spherical | sph | ||
| Conical | con | ||
| Flattened | flat | ||
| Body flexibility (including cases/tubes) | Higher body flexibility may be preferred because it compromises lower handling time | None | f.no |
| Weak | f.weak | ||
| High | f.high | ||
| Concealment | Prey concealment (colored patterns, accessories) may reduce vulnerability to predation | Fixed accessory (nets, retreats) | net |
| Movable accessory (cases, tubes) | case | ||
| Solidly colored | c.sol | ||
| Variable | c.var | ||
| Patterned | c.patt | ||
| Morphological defenses | Morphological defenses may reduce vulnerability to predation | Cerci, silk, spine | def.sp |
| None | def.no | ||
| Locomotion and substrate relation | Crawlers, burrowers and attached organisms may be more vulnerable to predation because the fish foraging preferences (benthic) | Surface swimmer | surf.s |
| Full water swimmer | wat.s | ||
| Crawler | craw | ||
| Burrower | burw | ||
| Interstitial | int | ||
| Attached | att | ||
| Tendency to drift in the water column | Drift tendency may increase vulnerability to predation | None | d.no |
| Weak | d.weak | ||
| Medium | d.med | ||
| High | d.high | ||
| Diel drift behavior | Nocturnal drift may reduce vulnerability to predation because foraging efficiency can decrease with a decrease in luminosity | None | none |
| Nocturnal | noct | ||
| Dawn | dawn | ||
| Daylight | d.light | ||
| Twilight | t.light | ||
| Agility | High agility may increase encounter rate with the predator, increasing prey vulnerability to predation | None (sluggish) | a.no |
| Weak | a.weak | ||
| High | a.high | ||
| Movement frequency | Continuous movement may increase vulnerability to predation because it may reduce hunting time | Continuous | cont |
| Discontinuous | disc | ||
| Trajectory on the bottom substratum or in the drift | Random trajectory may reduce vulnerability to predation because it may increase hunting time | None | t.no |
| Linear | t.lin | ||
| By random | t.rand | ||
| Oscillatory | t.oscil | ||
| Aggregation tendency | Aggregation may increase vulnerability trough increasing conspicuous to predators, but may be also an antipredator strategy | Weak | ag.weak |
| High | ag.high | ||
| Feeding habits | Habitat use by the predatory fish may affect differently to the potential prey depending on prey feeding habits | Absorber | abs |
| Deposit feeder | dpfd | ||
| Shredder | shrd | ||
| Scraper | scrp | ||
| Filter‐feeder | filt | ||
| Piercer | pier | ||
| Predator | pred | ||
| Parasite | par |
| Author | Study design | Aim of the study | Sample size | Conclusion |
| Dunn M, et al32Michigan,USA 2007 | . Case control | Assessment of OPG in regulatingmechanically induced bone modeling in a rat model of orthodontic toothmovement. | 39 male Sprague-Dawley rats » 9rats without appliances: (3 rats without injections, 3 rats with vehicleand 3 rats with high-dose OPG) » 30 rats with orthodontic forces: (10rats with 0.5 mg/Kg OPG-Fc, 10 rats with 5.0 mg/Kg OPG-Fc and 10 ratswith vehicle) | Local delivery of OPG-Fc inhibitsosteoclastogenesis and tooth movement at targeted dental sites. |
| Keles A, et al31BostonUSA 2007 | Case control | Evaluation of the efficacy ofpamidronateversus osteoprotegerin (OPG) in theinhibition of bone resorption and tooth movement. | 18 C57Bl/6 male mice into 3 groupsof 6 mice: » Control group (vehicle) » 5 mg/kg-1 pamidronate » 10 mg/kg-1OPG | OPG results in a more powerfulinhibitor of osteoclast recruitment and activity than pamidronate, with areduction of osteoclasts number of 95% and tooth movement of 77%. |
| UBS time A | BBS time A | UBS time B | BBS time B | UBS time C | BBS time C | UBS time D | BBS time D | |
| UBS time A | 0.43 | 0.54 | - | 0.56 | - | 0.55 | - | |
| BBS time A | 0.43 | - | - | - | - | - | 0.48 | |
| UBS time B | 0.54 | - | 0.54 | 0.64 | - | 0.56 | - | |
| BBS time B | - | - | 0.54 | 0.42 | 0.63 | 0.41 | 0.50 | |
| UBS time C | 0.56 | - | 0.64 | 0.42 | 0.53 | 0.69 | - | |
| BBS time C | - | - | - | 0.63 | 0.53 | 0.46 | 0.57 | |
| UBS time D | 0.55 | - | 0.56 | 0.41 | 0.69 | 0.46 | 0.54 | |
| BBS time D | - | 0.48 | - | 0.50 | - | 0.57 | 0.54 |
| Pattern | PT (s) | APTT (s) | FIB (g/L) | D-D (ug/ml) |
| Dampness-heat accumulation | 12.25 ± 1.08 | 39.38 ± 6.33 | 3.65 ± 1.08 | 2.30 ± 0.46∗∗ |
| Liver-kidney yin deficiency | 14.34 ± 0.56 | 40.81 ± 4.75 | 2.98 ± 0.35 | 0.65 ± 0.13∗ |
| Qi and yin deficiency | 12.58 ± 0.64 | 42.13 ± 5.05 | 3.41 ± 0.85 | 0.53 ± 0.27∗ |
| Blood-heat bleeding | 13.17 ± 0.78 | 39.13 ± 1.96 | 3.56 ± 0.48 | 2.28 ± 0.76∗∗ |
| Where did you go for the first consultation during the past 30 days | |||
| Categories | Frequency | Percent (%) | |
| Did not access healthcare (1–5) | 1 = Drugs at Home | 32 | 2.4 |
| 2 = Neighbor/Friend | 5 | 0.4 | |
| 3 = Community health worker | 12 | 0.9 | |
| 4 = Homapak drug distributor | 1 | 0.1 | |
| 5 = Ordinary shop | 13 | 1.0 | |
| Accessed healthcare (6–11) | 6 = Drug shop/Pharmacy | 134 | 10.1 |
| 7 = Private clinic | 408 | 30.9 | |
| 8 = Health unit government | 414 | 31.3 | |
| 9 = Health unit NGO | 48 | 3.6 | |
| 10 = Hospital government | 160 | 12.1 | |
| 11 = Hospital NGO | 54 | 4.1 | |
| Did not access healthcare (12, 96) | 12 = Traditional healer | 25 | 1.9 |
| 96 = Other (specify) | 15 | 1.1 | |
| Total | 1,321 | 100 |
| Sample | Sample | Library prep/ | Seq | Anabaena sp. genome | |||||
| date | Seq platform | output | |||||||
| (Gbp) | |||||||||
| N50 | Mean | No. | Max | Total | Unique | ||||
| cov. | contigs | contig | length | core | |||||
| (nt) | (nt) | genes | |||||||
| Anabaena | Dec | Blue | |||||||
| sp. WA102 | 2014 | Pippin/ | 1.13 | 5,715,573 | 50x | 3* | 5,705,437 | 5,807,452 | 104 |
| culture | PacBio | ||||||||
| est. from | Dec | TruSeq/ | |||||||
| Anderson | 2013 | HiSeq2000 | 3.83 | 15,892 | 129x | 819 | 66,878 | 5,698,213 | 105 |
| Lake | 100bp PE | ||||||||
| May 2013 | |||||||||
| WA25 | July | TruSeq/ | Shotgun | ||||||
| 2012/ | HiSeq2000 | 30.1 | metagenome | ||||||
| Anderson | 100bp PE | of surface | - | - | - | - | - | ||
| Lake | lake water | ||||||||
| Anabaena | |||||||||
| sp. AL93 | |||||||||
| culture | Jan | Nextera/ | |||||||
| est. from | 2013 | MiSeq | 1.36 | 46,264 | 149x | 314 | 133,848 | 5,757,055 | 105 |
| American | 250bp PE | ||||||||
| Lake | |||||||||
| 1993 |
| Variables | Adjusted R2 | Beta |
| 0.07 | ||
| Age | 0.19*** | |
| Gender (1 = female, 2 = male) | -0.08 | |
| Employment status (1 = employed, 2 = unemployed) | 0.19*** | |
| Source (1 = internet, 2 = paper) | 0.01 | |
| 0.51 | ||
| Attitude | -0.47**** | |
| Subjective norm | -0.22**** | |
| Perceived control | -0.19*** | |
| Self-efficacy | -0.06 | |
| 0.56 | ||
| Anticipated regret | -0.19*** | |
| Last year, did you have a vaccination for ordinary seasonal flu?, (1 = yes) | -0.04 | |
| Do you intend to have a vaccination for ordinary seasonal flu this year? (1 = yes) | -0.14* | |
| Knowledge | 0.02 | |
| 0.60 | ||
| Perceived susceptibility | 0.01 | |
| Perceived severity | -0.06 | |
| Perceived benefits: | ||
| Vaccination is a good idea because I feel less worried about catching swine flu | 0.07 | |
| Vaccination decreases my chance of getting swine flu or its complications | -0.24*** | |
| If I get vaccinated for swine fu, I will decrease the frequency of having to consult my doctor | -0.12** | |
| Perceived barriers: | ||
| The side-effects of swine flu vaccination interfere with my usual activities | -0.04 | |
| I am scared of needles | 0.05 | |
| I cannot be bothered to get a swine flu vaccination | 0.13*** |
| Radiographs & event forms | Pre-surgery | Surgery | Post-surgery | ||||||||||
| Screening | Enrolment | Baseline | (Day 0) | ≤ 48 hrs Post surgery | D/C | 1 wk (24 hrs-10 ds) | 10 wk (8-12 wks) | 6 mo (5-7 mos) | 9 mo (8-10 mos) | 12 mo (11-13 mos) | 18 mo (17-19 mos) | 24 mo (≥24 mos) | |
| Radiographs | ● | ● | ● | ● | ● | ||||||||
| Screening | ● | ||||||||||||
| Informed consent | ● | ||||||||||||
| Randomization | ● | ||||||||||||
| Baseline | ● | ||||||||||||
| Patient contact | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | |||
| Pre-Op care | ● | ||||||||||||
| Fracture characteristics | ● | ||||||||||||
| Surgical report | ● | ||||||||||||
| Post-Op care | ● | ||||||||||||
| Clinic or telephone follow-up | ● | ● | ● | ● | ● | ● | ● | ||||||
| RS | * | * | * | * | * | * | * | * | |||||
| AE | * | * | * | * | * | * | * | * | * | ||||
| Hospital D/C | ● | * | * | ||||||||||
| Missed | |||||||||||||
| Follow-up | * | * | * | * | * | * | * | ||||||
| Early W/D | * | * | * | * | * | * | * | * |
| Gene | Forward Primer | Reverse Primer | Product Size (bp) |
| AFP | CACTGCTGCAACTCTTCGTA | CTTTGGACCCTCTTCTGTGA | 300 |
| Alb | GACAAGGAAAGCTGCCTGAC | TTCTGCAAAGTCAGCATTGG | 174 |
| Trf | ACCATGTTGTGGTCTCACGA | ACAGAAGGTCCTTGGTGGTG | 135 |
| CPS | AGGATGTCAAGGTGTTTGGC | GCTTAACTAGCAGGCGGATG | 93 |
| β-actin | GACCTCTATGCCAACACAGT | AGTACTTGCGCTCAGGAGGA | 139 |
| Predictor | B | OR [95% CI] | p |
| Detect (DL and DnL) | |||
| Response time | |||
| Accuracy | 0.13 | 1.14 [1.10, 1.18] | <0.001 |
| d' | −0.01 | 0.99 [0.98, 1.01] | 0.40 |
| c | 0.004 | 1.00 [0.99, 1.01] | 0.42 |
| General belief about percentage of images manipulated = High (71–100%) | |||
| Accuracy | 0.16 | 1.18 [1.02, 1.36] | 0.03 |
| d' | 0.09 | 1.09 [0.97, 1.23] | 0.14 |
| c | −0.04 | 0.96 [0.90, 1.03] | 0.25 |
| Gender = Female | |||
| Accuracy | −0.01 | 0.99 [0.86, 1.15] | 0.92 |
| d' | −0.03 | 0.97 [0.86, 1.09] | 0.60 |
| c | −0.01 | 0.99 [0.93, 1.06] | 0.82 |
| Interest in photography = Interested | |||
| Accuracy | 0.17 | 1.19 [1.02, 1.39] | 0.03 |
| d' | 0.04 | 1.04 [0.92, 1.18] | 0.56 |
| c | −0.05 | 0.95 [0.89, 1.02] | 0.18 |
| Frequency of taking photos = Daily/weekly | |||
| Accuracy | −0.01 | 0.99 [0.84, 1.17] | 0.91 |
| d' | −0.07 | 0.93 [0.82, 1.07] | 0.31 |
| c | −0.05 | 0.95 [0.88, 1.02] | 0.18 |
| Locate (DL and nDL) | |||
| Response time | 0.10 | 1.11 [1.08, 1.14] | <0.001 |
| General belief about percentage of images manipulated = High (71–100%) | −0.01 | 0.99 [0.87, 1.12] | 0.84 |
| Gender = Female | −0.10 | 0.91 [0.80, 1.03] | 0.14 |
| Interest in photography = Interested | 0.16 | 1.17 [1.02, 1.34] | 0.02 |
| Frequency of taking photos = Daily/weekly | −0.08 | 0.92 [0.80, 1.06] | 0.27 |
| Detect and locate (DL) | |||
| Response time: detect | 0.17 | 1.19 [1.15, 1.23] | <0.001 |
| Response time: locate | 0.13 | 1.14 [1.11, 1.18] | <0.001 |
| General belief about percentage of images manipulated = High (71–100%) | 0.05 | 1.05 [0.91, 1.20] | 0.51 |
| Gender = Female | −0.13 | 0.88 [0.77, 1.01] | 0.07 |
| Interest in photography = Interested | 0.20 | 1.22 [1.06, 1.41] | 0.01 |
| Frequency of taking photos = Daily/weekly | −0.09 | 0.92 [0.78, 1.07] | 0.28 |
| Male | Female | P-value | |
| Number of patients | 110 | 51 | |
| Age (mean, SD) | 36 (10.3) | 40 (10.0) | 0.013 |
| Age of onset (median, range) | 20 (12–39) | 25 (13–48) | 0.057 |
| Psychiatric hospital admissions (median, range) | 6 (1–24) | 4 (0–20) | 0.091 |
| Suicide attempts (median, range) | 0 (0–6) | 0 (0–5) | 0.674 |
| Years of evolution of disease (median, range) | 13 (0–45) | 11 (0–49) | 0.578 |
| Marital status (N, percentage) | |||
| Single | 95 (87%) | 32 (62%) | 0.002 |
| Married or paired | 7 (6%) | 12 (23%) | |
| Separated or divorced | 8 (7%) | 5 (11%) | |
| Widowed | 0 (0%) | 2 (4%) | |
| Drug abuse (N, percentage) | 81 (74%) | 33 (65%) | 0.246 |
| Red clade | Green clade | Black clade | ||||||||||||||||||||
| CabpIAP | IAP31 | IAP44 | IAP51 | IAP77 | IAP90 | IAP110 | IAP176 | IAP182 | IAP186 | IAP195 | IAP236 | *IAP281Y | IAP268 | IAP506 | IAP655 | IAP1112 | IAP1248 | IAP1252 | IAP1259 | IAP1334 | Average | |
| Mouse 1 | 74 | 52 | 70 | 77 | 60 | 80 | 71 | 69 | 70 | 61 | 70 | 62 | 77 | 77 | 76 | 66 | LOD | 83 | 82 | 88 | 72 | |
| Mouse 2 | 77 | 60 | 77 | 75 | 60 | 71 | 72 | 60 | 71 | 68 | 76 | 68 | 84 | 86 | 70 | 69 | 83 | 77 | 78 | 86 | 73 | |
| Mouse 3 | 81 | 57 | 77 | 78 | 66 | 76 | 72 | 66 | 74 | 55 | 73 | 67 | 76 | 71 | 76 | 68 | 84 | 78 | 84 | LOD | 72 | |
| Mouse 4 | 72 | 61 | 80 | 77 | 65 | 68 | 69 | 56 | 77 | 56 | 54 | 65 | 73 | 82 | 70 | 60 | 89 | 80 | 81 | 86 | 71 | |
| Mouse 5 | 74 | 59 | 71 | 78 | 61 | 80 | 75 | 65 | 70 | 69 | 69 | 63 | 80 | 81 | 70 | LOD | 76 | 78 | 82 | 90 | 73 | |
| Mouse 6 | 76 | 57 | 78 | 74 | 65 | 73 | 71 | 63 | 64 | 67 | 76 | 58 | 64 | 77 | 94 | 76 | 63 | 78 | LOD | 85 | 86 | 72 |
| Mouse 7 | 66 | 62 | 80 | 75 | 61 | 73 | 78 | 54 | 67 | 65 | 64 | 66 | 75 | 75 | 74 | 60 | 85 | 78 | 82 | 86 | 71 | |
| Mouse 8 | 76 | 60 | 75 | 78 | 62 | 72 | 64 | 63 | 71 | 65 | 73 | 60 | 78 | 93 | 70 | 62 | 81 | 79 | 84 | LOD | 72 | |
| Mouse 9 | 67 | 62 | 83 | 73 | 64 | 70 | 67 | 69 | 75 | 69 | 74 | 63 | 67 | 76 | 76 | 74 | 68 | 87 | 83 | 86 | 86 | 73 |
| Mouse 10 | 82 | 62 | 80 | 47 | 68 | 69 | 57 | 57 | 78 | 73 | 65 | 58 | 82 | 92 | 79 | 60 | 84 | 82 | 81 | 91 | 72 | |
| Mouse 11 | 70 | 60 | 87 | 69 | 65 | 71 | 73 | 65 | 70 | 68 | 72 | 54 | 64 | 80 | 76 | 73 | 63 | 87 | 87 | 84 | 90 | 73 |
| Mouse 12 | 48 | 61 | 77 | 70 | 66 | 71 | 57 | 63 | 74 | 71 | 76 | 64 | 61 | 84 | 94 | 75 | 64 | 81 | 82 | 81 | 89 | 72 |
| Mouse 13 | 79 | 64 | 81 | 73 | 64 | 69 | 66 | 67 | 69 | 68 | 75 | 62 | 64 | 80 | 81 | 72 | 66 | LOD | 77 | 84 | 86 | 72 |
| Mouse 14 | 79 | 58 | 79 | 72 | 68 | 76 | 57 | 63 | 69 | 68 | 78 | 71 | 79 | 82 | 77 | 69 | 84 | 84 | 84 | 90 | 74 | |
| Mouse 15 | 74 | 55 | 80 | 75 | 68 | 74 | 71 | 60 | 72 | 66 | 71 | 60 | 81 | 80 | 71 | 64 | 83 | 84 | 85 | 89 | 73 | |
| Mouse 16 | 73 | 56 | 81 | 71 | 70 | 69 | 48 | 60 | 83 | 71 | 75 | 67 | 57 | 83 | 74 | 73 | 66 | 82 | 79 | 85 | 88 | 72 |
| Mouse 17 | 76 | 59 | 71 | 78 | 62 | 78 | 72 | 66 | 66 | 67 | 68 | 65 | 65 | 78 | LOD | 77 | 65 | 82 | 79 | 83 | 91 | 72 |
| mean | 73 | 59 | 78 | 73 | 64 | 73 | 67 | 63 | 72 | 66 | 71 | 63 | 63 | 79 | 82 | 74 | 65 | 83 | 81 | 83 | 88 | 72 |
| median | 74 | 60 | 79 | 75 | 65 | 72 | 71 | 63 | 71 | 68 | 73 | 63 | 64 | 79 | 81 | 74 | 65 | 83 | 80 | 84 | 88 | 72 |
| stdev | 8 | 3 | 4 | 7 | 3 | 4 | 8 | 4 | 5 | 5 | 6 | 4 | 3 | 3 | 8 | 3 | 3 | 3 | 3 | 2 | 2 | 1 |
| min | 48 | 52 | 70 | 47 | 60 | 68 | 48 | 54 | 64 | 55 | 54 | 54 | 57 | 73 | 71 | 70 | 60 | 76 | 77 | 78 | 86 | 71 |
| max | 82 | 64 | 87 | 78 | 70 | 80 | 78 | 69 | 83 | 73 | 78 | 71 | 67 | 84 | 94 | 79 | 69 | 89 | 87 | 86 | 91 | 74 |
| range | 34 | 12 | 17 | 31 | 10 | 12 | 30 | 15 | 19 | 18 | 25 | 18 | 11 | 11 | 24 | 9 | 10 | 13 | 10 | 8 | 5 | 3 |
| Algorithm | Average Error (°) | Average Time (s) |
| Radon transform | 0.17 | 8.61 |
| MBR correction | 0.16 | 1.13 |
| Normal range | Patient 1 | Patient 2 | Patient 3 | |
| Haemoglobin (g/L) | 110–165 | 206 | 201 | |
| Total white cells (×109 cells/L) | 3 · 5–10 · 0 | 8 · 9 | 58 | |
| Neutrophils (×109 cells/L) | 1 · 2–6 · 8 | 5 · 79 | 41 · 8 | |
| Lymphocytes (×109 cells/L) | 1 · 2–3 · 2 | 2 · 76 | 10 · 9 | |
| Platelets (×109 cells/L) | 150–390 | 18 | 162 | |
| Prothrombin time (s) | 12–14 | 24 · 8 | 15 · 9 | |
| Activated partial thromboplastin time (s) | 25–37 | 53 · 1 | 67 · 3 | |
| INR | 0 · 8–1 · 5 | 2 · 52 | 1 · 43 | |
| D-dimer (mg/L) | <0 · 3 | 0 · 2 | 0 · 2 | |
| Urea (mmol/L) | 2 · 5–7 · 5 | 7 · 9 | 14 · 8 | |
| Creatinine (μmol/L) | 44–135 | 161 | 253 | |
| Bilirubin (μmol/L) | 3 · 42–20.5 | 17 · 4 | 61 · 8 | |
| Total protein (g/L) | 60–80 | 30 | 60 | |
| Albumin (g/L) | 35–50 | 23 | 35 | |
| Globulin (g/L) | 25–35 | 7 | 25 | |
| Alanine aminotransferase (U/L) | 0–40 | 35 · 4 | 68 | |
| Aspartate aminotransferase (U/L) | 0–37 | 67 | 479 · 8 | |
| Lactate dehydrogenase (U/L) | 109–245 | 127 | 585 | |
| Creatinine kinase (U/L) | 24–195 | 146 | 9868 | |
| C-reactive protein (mg/L) | 0–10 | 73 | 150 | |
| Glucose (mmol/L) | 3 · 9–6 · 1 | 19 | 5 · 1 | |
| Ka (mmol/L) | 3 · 5–5 · 1 | 2 · 6 | 3 · 03 | |
| Na (mmol/L) | 135–147 | 60 | 114 | |
| Cl (mmol/L) | 95–106 | 40 | 80 | |
| Ca (mmol/L) | 2 · 25–2 · 75 | 1 · 62 | 2 · 09 | |
| Urinalysis | ||||
| PH value | 5 · 0–7 · 0 | 5 · 5 | 5 · 0 | |
| Protein (mg/dl) | 100 | 100 | ||
| Ketone (mg/dl) | 15 | Neg | ||
| Bilirubin (mg/dl) | 0 · 5 | 0 · 5 | ||
| Urobilinogen (mg/dl) | 8 | 4 | ||
| Blood (mg/dl) | Neg | 1 | ||
| Leu (leu/ul) | 75 | Neg | ||
| Bacterial Diagnostic test | ||||
| Microscopy | - | + | + | + |
| RT-PCR | - | + | + | + |
| IHA | - | 1:40 (serum) | 1:2560 (serum) 1:160 (tissue fluid) | 1:800 (serum) |
| rIHA | - | 1:6400 (nasopharyngeal swab) 1:12800 (sputum) | 1:1024 (serum) | 1:5120 (serum) |
| 2009 | 2010 | 2011 | 2012 | 2013 | |
| Percent (+) of all tests run | 12.22% | 15.45% | 12.30% | 13.70% | 13.70% |
| NEW (+) as % of all tests run | 5.90% | 7.86% | 5.60% | 7.01% | 6.10% |
| Profile of a NEW (+) out of ALL new (+)’s | |||||
| Incomplete-vaccination | 86.59% (71/82) | 89.52% (94/105) | 85.92% (61/71) | 86.08% (68/79) | 95.45% (63/66) |
| Full-vaccination | 13.41% (11/82) | 10.48% (11/105) | 14.08% (10/71) | 13.92% (11/79) | 4.55% (3/66) |
| Infection rate (IR) based on vaccine status*: | |||||
| ALL incomplete-vaccination | 16.86% (71/421) | 32.08% (94/293) | 18.32% (61/333) | 23.13% (68/294) | 20.32% (63/310) |
| Complete-vaccination | 1.13% (11/970) | 1.04% (11/1053) | 1.07% (10/933) | 1.32% (11/833) | 0.39% (3/762) |
| Negative infection rate based on vaccine status | |||||
| ALL incomplete-vaccination | 83.14% (350/421) | 67.92% (199/293) | 81.68% (272/333) | 76.87% (226/294) | 79.68% (247/310) |
| Complete-vaccination | 98.87% (959/970) | 98.96% (1042/1053) | 98.93% (923/933) | 98.68% (822/833) | 99.61% (759/762) |
| Chi-square test statistic | 130.95 | 307.01 | 137.89 | 158.56 | 151.47 |
| P-value | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 |
| Preventative fraction (PF) against infection** | 93.29% | 96.76% | 94.16% | 94.29% | 98.08% |
| Risk ratio (RR)*** | 14.92 | 30.85 | 17.12 | 17.52 | 52.10 |
| Compound number | Alkyl substitute | MIC M. tuberculosis (ng/ml) | logP* |
| 10926013 | Methyl | 250 | 1.31 |
| 10926021 | Ethyl | 62 | 1.64 |
| 10926027 | Propyl | 3.7 | 2.11 |
| 10926172 | Butyl | 1.9 | 2.51 |
| 11026100 | Isobutyl | 1.9 | 2.51 |
| 11026142 | 1-Ethylpropyl | 0.37 | 2.99 |
| 11026128 | 1-sec-Butyl | 0.37 | 2.52 |
| 11026129, PBTZ129 | 2-Cyclohexylethyl | 0.19 | 3.52 |
| 11026131 | 1-Methylbutyl | 0.19 | 3.11 |
| 11026134, PBTZ134 | Heptyl | 0.19 | 3.30 |
| 11026137, PBTZ137 | 4-Phenoxybutyl | 1.5 | 3.35 |
| 11026139, PBTZ139 | 4-Phenylbutyl | 0.37 | 4.05 |
| 10926168 | Cyclohexyl | 0.75 | 3.09 |
| 10926169, PBTZ169 | Cyclohexylmethyl | ≤0.19 | 3.20 |
| Score | Reactions |
| − | Negative reaction |
| +? | Doubtful reaction; faint erythema only |
| + | Weak (non-vesicular) positive reaction; erythema, infiltration and possibly papules |
| ++ | Strong (vesicular) positive reaction; erythema, infiltration, papules, vesicles |
| +++ | Extreme positive reaction; bullous reaction |
| IR | Irritant reaction |
| Eligible | Ineligible |
| Sexually active | Unable or unwilling to provide a reliable method of contact for the field team |
| 16 years old or above | Likely to move permanently out of the study area within the next year |
| HIV negative at screening | Likely to have sex more than 14 times a week on a regular basis during the course of following up |
| Willing to undergo regular HIV testing and receive the result before randomization | Using spermicides regularly |
| Willing to undergo regular speculum examinations and genital infection screens | Pregnant or within six weeks postpartum at enrolment |
| Willing to have regular urine pregnancy tests | Had a severe clinical or laboratory abnormality |
| Willing to use study gel as instructed | Requiring referral for assessment of a clinically suspicious cervical lesion |
| Willing to receive health education about condoms | Had treatment to the cervix, or to the womb through the cervix, within 30 days of enrolment |
| Willing and able to give informed consent | Had known latex allergy |
| Participating, or having participated within 30 days of enrolment, in a clinical trial of an unlicensed product, microbicide, barrier method or any other intervention likely to impact on the outcome of this trial | |
| Considered unlikely to be able to comply with the protocol |
| Malaria is caused by: | Total (N = 34) |
| Self1 | |
| Mentioned mosquitoes as cause | 33 (97.1%) |
| Mentioned environmental cause2 | 9 (26.5%) |
| Mentioned bad food/water consumption as cause | 8 (23.5%) |
| Mentioned cold temperatures/rain as cause | 13 (38.2%) |
| Mentioned mosquitoes solely as cause | 15 (44.1%) |
| Mentioned mosquitoes plus additional cause | 18 (52.9%) |
| Mentioned both an accurate and an inaccurate cause | 16 (47.1%) |
| Others | |
| Mentioned mosquitoes as cause | 20 (58.8%) |
| Mentioned environmental cause | 5 (14.7%) |
| Mentioned bad food/water consumption as cause | 6 (17.6%) |
| Mentioned cold temperatures/rain as cause | 6 (17.6%) |
| Mentioned mosquitoes solely as cause | 14 (41.2%) |
| Mentioned mosquitoes plus additional cause | 6 (17.6%) |
| Did not mention moquitoes; mentioned other cause | 9 (26.5%) |
| Did not know cause | 5 (14.7%) |
| Antibody | Type | Dilution | Source |
| Cytokeratin 7 | Rabbit-Monoclonal | 1:100 | Biocare Medical, Concord, CA |
| Cytokeratin 20 | Mouse Monoclonal | 1:200 | Biocare Medical, Concord, CA |
| CDX-2 | Mouse Monoclonal | 1:100 | Biocare Medical, Concord, CA |
| Villin | Mouse Monoclonal | 1:100 | Biocare Medical, Concord, CA |
| β-catenin | Mouse Monoclonal | 1:200 | DAKO, Carpinteria, CA |
| E-cadherin | Mouse Monoclonal | 1:2000 | BD Transduction Labs, San Jose, CA |
| Name | 5′ -3′ | Length |
| PrimerF1 | AGTATCGTTGAGAAGAATCG | 20 |
| PrimerF2 | TATGCTTTCCTGGCGGCGGTAC | 22 |
| PrimerF3 | GAAGGGGAGACAAGCAGATCAA | 22 |
| PrimerF4 | CTGCAAGAGAGGAAAAAGACCA | 22 |
| PrimerF5 | GGAGGGGCAGAGTAGGCAGAAA | 22 |
| PrimerF6 | CCGTTGGCTCGTGGAGAAAGGA | 22 |
| PrimerF7 | TCAGCGGAGATGACTGTGTCGT | 22 |
| PrimerR1 | CCTTCATTTCCTCCTCTTTTGT | 22 |
| PrimerR2 | TGAACGGCTTTTCCTATGGAGT | 22 |
| PrimerR3 | CAAACATCAATCCAACTGCCGA | 22 |
| PrimerR4 | AGTCCATTGGGCATGTGTATGT | 22 |
| PrimerR5 | TCTGCATGAGCATCGGTTCTTC | 22 |
| PrimerR6 | AAATGGTTAGAGCAGAAGGGAA | 22 |
| PrimerR7 | TCTTCCTCACCACCAGCTACAT | 22 |
| Controls | Cases | |||||||
| Medications | % | (n) | % | (n) | Crude OR (95% CI) | ORs (95% CI) adjusted for age and sex | ORs (95% CI) adjusted for age, sex and other risk factors* | ORs (95%CI) adjusted for age, sex, other risk factors* and the use of FRIDs |
| All medications | ||||||||
| 0 medication | 40.7 | (8318) | 28.3 | (130) | 1.00 | (REF) | 1.00 (Ref) | 1.00 (Ref) |
| 1 medication | 12.0 | (2443) | 7.4 | (34) | 0.91 (0.60-1.38) | 0.95 (0.63-1.45) | 1.26 (0.75-2.11) | 1.40 (0.82-2.40) |
| 2 medications | 11.2 | (2283) | 11.7 | (54) | 1.63 (1.14-2.32) | 1.44 (1.01-2.05) | 1.74 (1.10-2.77) | 2.06 (1.16-3.64) |
| 3 medications | 9.8 | (1998) | 9.6 | (44) | 1.58 (1.09-2.31) | 1.34 (0.91-1.95) | 1.50 (0.94-2.41) | 1.83 (0.94-3.57) |
| 4 medications | 8.0 | (1636) | 9.8 | (45) | 1.82 (1.24-2.68) | 1.45 (0.98-2.16) | 1.74 (1.07-2.81) | 2.14 (1.13-4.05) |
| ≥5 medications | 18.4 | (3768) | 33.3 | (153) | 2.58 (1.98-3.36) | 1.79 (1.36-2.35) | 1.53 (1.06-2.21) | 1.92 (1.08-3.41) |
| Variable | Mean (SD) | N | % |
| Age | 37.2 (6.1) | ||
| Marital status | |||
| Married | 231 | 96.3 | |
| Widowed/Divorced | 9 | 3.8 | |
| Education | |||
| Primary | 70 | 29.2 | |
| Secondary | 52 | 21.6 | |
| High school | 78 | 32.5 | |
| University | 40 | 16.7 | |
| History of breast problems | |||
| Yes | 29 | 12.1 | |
| No | 211 | 87.9 | |
| Performing BSE | |||
| Yes (regular* & irregular**) | 76 | 31.7 | |
| No (never done) | 164 | 68.3 |
| Characteristics | Univariate analysis | Multivariate analysis | ||
| HR (95% CI) | P-value* | HR (95% CI) | P-value* | |
| HBP1 IHC | ||||
| Absent/decreased | 1.00 | 1.00 | ||
| Preserved | 0.48 (0.24–0.96) | 0.039 | 0.38 (0.15–0.96) | 0.042 |
| β-catenin nuclear accumulation | ||||
| Yes | 1.00 | 1.00 | ||
| No | 0.49 (0.24–0.99) | 0.047 | 0.38 (0.15–0.96) | 0.041 |
| Smoking habit | ||||
| Non-smoker | 1.00 | 1.00 | ||
| Smoker | 0.66 (0.28–1.57) | 0.348 | 0.58 (0.20–1.72) | 0.326 |
| Tumour type | ||||
| ADC | 1.00 | 1.00 | ||
| SCC | 1.01 (0.73–2.17) | 0.973 | 1.17 (0.38–3.67) | 0.784 |
| Tumour stage | ||||
| Early (I/II) | 1.00 | 1.00 | ||
| Late (III/IV) | 1.58 (0.77–3.26) | 0.213 | 0.68 (0.21–2.26) | 0.532 |
| Lymph node status | ||||
| N0 | 1.00 | 1.00 | ||
| ≥N1 | 2.01 (0.99–4.10) | 0.055 | 3.34 (1.02–10.92) | 0.046 |
| AF Group | Control group | P value | |
| Age (year) | 3/0±69 | 8/0±72 | 0.27 |
| Male | 13 | 13 | |
| Female | 12 | 12 | |
| Low Education (%) | 5/0±25 | 3/0±33 | 0.08 |
| Smoke (%) | 1/0±14 | 2/0±17 | 0.12 |
| BMI | 4/0±26 | 2/0±27 | 0.17 |
| Mutated gene | Expressing neurons+ | Number of turns/min for the 5th minute | p value | |||
| Wild-type control | Mutant | |||||
| 150 mOsm | 400 mOsm | 150 mOsm | 400 mOsm | |||
| gpa-8 | AQR, PQR, URX | 9.58 ± 1.02 (24) | 24.61 ± 1.51 (23) | 7.33 ± 0.85 (21) | 20.67 ± 1.89 (21) | 0.538 |
| gpa-13 | PQR | 7.19 ± 1.13 (16) | 16.13 ± 2.91 (15) | 9.63 ± 2.23 (16) | 21.69 ± 1.98 (16) | 0.467 |
| gcy-1 | URX | 8.19 ± 1.50 (16) | 29.00 ± 1.91 (16) | 5.88 ± 1.01 (16) | 25.31 ± 2.22 (16) | 0.691 |
| gcy-25 | AQR, PQR, URX | 11.07 ± 1.52 (15) | 26.73 ± 2.10 (15) | 8.50 ± 1.10 (16) | 23.13 ± 1.26 (16) | 0.734 |
| gcy-28 | Widely expressed | 9.31 ± 1.76 (16) | 24.63 ± 2.40 (16) | 9.00 ± 1.14 (16) | 32.06 ± 2.18 (16) | 0.049# |
| gcy-32 | AQR, PQR, URX | 11.06 ± 1.80 (16) | 27.60 ± 1.77 (15) | 7.71 ± 0.71 (14) | 25.81 ± 1.61 (16) | 0.622 |
| gcy-33 | AQR, PQR, URX | 10.94 ± 2.24 (16) | 22.88 ± 2.67 (16) | 8.88 ± 1.13 (16) | 18.87 ± 2.34 (15) | 0.655 |
| gcy-34 | AQR, PQR, URX | 7.33 ± 0.84 (15) | 22.94 ± 2.14 (16) | 7.73 ± 1.01 (15) | 20.19 ± 2.37 (16) | 0.377 |
| gcy-35 | AQR, PQR, URX | 9.83 ± 1.39 (23) | 30.08 ± 1.25 (24) | 9.68 ± 1.26 (22) | 28.46 ± 1.40 (24) | 0.578 |
| gcy-36 | AQR, PQR, URX | 9.83 ± 1.39 (23) | 30.08 ± 1.25 (24) | 8.42 ± 1.18 (24) | 27.39 ± 1.99 (23) | 0.665 |
| gcy-37 | AQR, PQR, URX | 9.94 ± 1.25 (16) | 26.69 ± 2.15 (16) | 6.93 ± 0.73 (15) | 21.87 ± 2.14 (15) | 0.592 |
| Line | Independent lines | Individual plants per line | Repetitions per line | Total n of cells | Total n of Golgi bodies |
| STtmd-mRFP/GFP-HDEL | 1 | 5 | 3 | 41 | 332 |
| mRFP-AtCASP/GFP-HDEL | 2 | 7 and 4 | 3 and 2 | 4632 | 388240 |
| mRFP-AtCASP-∆CC/GFP-HDEL | 2 | 6 and 4 | 3 and 2 | 4323 | 456174 |
| Pediatric-onset CD patients | Low BMD | Normal BMD | p-value |
| Z-score<−1 | Z-score ≥−1 | ||
| n=77 | n=46 | n=31 | |
| % | 60% | 40% | |
| NOD2 variant n (%) | 24 (52%) | 10 (32%) | p=0.10 |
| One variant allele | 17 | 5 | p=0.061 |
| Two variant alleles | 7 | 5 | p=0.75 |
| Homozygous variant alleles | 7 | 0 | p=0.037* |
| Gender: female/male in % | 45/55 | 48/52 | p=0.89 |
| Age: y | |||
| mean/SD | 25/12.8 | 24/13.9 | p=0.62 |
| median/interquartile range | 21/17-30 | 19/15-29 | p=0.29 |
| average disease duration/SD | 12.2/11.6 | 11.6/10.8 | p=0.84 |
| Age at diagnosis: y | |||
| mean/SD | 13/3.6 | 12/5.1 | p=0.33 |
| median/interquartile range | 14/11-16 | 13/10-17 | p=0.69 |
| Localization: n (%) | |||
| L1 ileal | 8 (17%) | 9 (29%) | p=0.27 |
| L2 colonic | 8 (17%) | 6 (19%) | p=1.0 |
| L3 ileocolonic | 30 (65%) | 16 (52%) | p=0.25 |
| L4 isolated upper disease | 0 (0%) | 0 (0%) | p=1.0 |
| Upper GI involvement | 15 (33%) | 13 (42%) | p=0.47 |
| Behaviour: n (%) | |||
| B1 non-stricturing/penetrating | 27 (59%) | 20 (65%) | p=0.64 |
| B2 stricturing | 11 (23%) | 6 (19%) | p=0.78 |
| B3 penetrating intern | 6 (13%) | 3 (10%) | p=0.73 |
| B3p penetrating perianal | 9 (19%) | 3 (10%) | p=0.34 |
| Underweight at diagnosis | 14/27 (52%) | 5/22 (32%) | p=0.0453* |
| Underweight in 1y follow-up | 14 (30%) | 2 (6%) | p=0.0113* |
| Short stature | 5 (11%) | 1 (3%) | p=0.39 |
| Treatment: n (%) | |||
| Steroid dependent/refractory | 23 (50%) | 9 (29%) | p=0.10 |
| Azathioprine / MTX | 35 (76%) | 15 (48%) | p=0.016* |
| Anti-TNFα-antibody | 20 (44%) | 7 (26%) | p=0.09 |
| Lipids (abnormal range) | Females | Males | P value * |
| Cholesterol (> 5.0 mmol/L) | 211/313 (67.4%) | 66/ 123 (53.7%) | ≤ 0.01 |
| Triglycerides (> 1.92 mmol/L) | 108/313 (34.5%) | 50/ 123 (40.7%) | ns |
| HDL cholesterol (< 1.00 mmol/L) | 9/199 (4.5%) | 13/72 (18.1%) | ≤ 0.001 |
| LDL cholesterol (> 3.00 mmol/L) | 121/194 (62.4%) | 37/66 (56.1%) | ns |
| Sensor Error | Parameter Value |
| Constant bias of gyroscope | 0.002 (°/h) |
| Constant bias of accelerometer | 1.96 × 10-4 (m/s2) |
| Scale factor error of gyroscope | 5 × 10-6 (°/h)-1 |
| Installation error of gyroscope | 2 × 10-10 (°/h) |
| No. | Mean ± SD | Median (range) | p-Value | |
| Sex | ||||
| Male | 49 | 9.21 ± 7.09 | 7.77 (27.88) | |
| Female | 34 | 7.72 ± 5.21 | 6.40 (19.19) | 0.2966 |
| Residence | ||||
| Rural | 30 | 8.52 ± 6.31 | 7.31 (20.11) | 0.9281 |
| Urban | 53 | 8.65 ± 6.51 | 6.86 (27.42) | |
| Smoking | ||||
| Yes | 32 | 8.75 ± 6.86 | 7.08 (27.42) | |
| No | 51 | 8.5 ± 6.16 | 6.86 (26.96) | 0.8634 |
| Occupation | ||||
| Farmer | 10 | 13.34 ± 8.29 | 11.88 (1.83–28.79) | 0.0827 |
| Housewife | 29 | 7.56 ± 6.05 | 5.94 (0.91–27.88) | |
| Industrial | 19 | 8.68 ± 5.46 | 7.77 (0.91–16.45) | |
| Professional | 25 | 7.84 ± 6.14 | 5.03 (1.37–25.14) |
| Fulfilment of ASAS axSpA criteria | ||||
| SPACE | DESIR | |||
| OR (95% CI) | P- value | OR (95% CI) | P- value | |
| Any PFH | 2.1 (1.4-3.1) | <0.001 | 1.3 (1.0-1.9) | 0.091 |
| AS | 3.3 (2.0-5.3) | <0.001 | 2.1 (1.3-3.3) | <0.001 |
| AAU | 7.4 (2.5-21.7) | <0.001 | 5.0 (1.5-16.7) | 0.009 |
| ReA | 0.6 (0.2-1.9) | 0.421 | 0.3 (0.05-1.5) | 0.132 |
| IBD | 1.1 (0.5-2.2) | 0.798 | 0.8 (0.4-1.6) | 0.521 |
| Psoriasis | 1.2 (0.8-2.0) | 0.388 | 1.2 (0.8-1.8) | 0.464 |
| Group PC(n = 27) | Group VC(n = 27) | p value | |
| Age (year) | 44.4 ± 12.3 | 41.1 ± 100 | NS |
| Weight (kg) | 78.9 ± 8.8 | 79.5 ± 10.3 | NS |
| Gender (M/F) | 20/7 | 22/5 | NS |
| HR (beats/min) | |||
| Pre | 79.7 ± 10.4 | 76.5 ± 12.7 | NS |
| Prone | 78.7 ± 11.0 | 73.1 ± 9.4 | NS |
| Post | 76.1 ± 94 | 74.8 ± 8.2 | NS |
| SAP (mmHg) | |||
| Pre | 133 ± 12.9 | 132 ± 14.5 | NS |
| Prone | 116 ± 13.1 | 117 ± 14.0 | NS |
| Post | 125 ± 11.9 | 123 ± 12.7 | NS |
| MAP (mmHg) | |||
| Pre | 103 ± 13.4 | 103 ± 15.4 | NS |
| Prone | 93.9 ± 13.6 | 94.1 ± 8.5 | NS |
| Post | 92.8 ± 14.1 | 96.2 ± 13.6 | NS |
| Mean Value (m) | |
| Set 1 | 0.2189 ± 0.0003 |
| Set 2 | 0.2117 ± 0.0003 |
| Set 3 | 0.2189 ± 0.0003 |
| Set 4 | 0.2087 ± 0.0003 |
| Discovery method | Predicted validation success (%) | |||
| Infinium | Axiom | |||
| Predictive | Filtering | Predictive | Filtering | |
| BOWTIE2 | 75.7 | 45.6 | 83.3 | 61.7 |
| BWA | 72.1 | 39.7 | 78.5 | 54.6 |
| NEWBLER | 46.8 | 27.3 | 48.9 | 35.5 |
| SWAP454 | 57.0 | 34.6 | 61.8 | 45.9 |
| Gender | Reporting | |
| Plausible Reporters | Non-Plausible Reporters | |
| Female | 57.3% (n = 311) | 46.7% (n = 685) |
| Male | 42.7% (n = 232) | 53.3% (n = 781) |
| Gene name | Accession number | Primer sequences (forward/reverse) | Tm(°C) | Amplication length | Amplification efficacy (%) |
| h2afz | NM_016750 | GTGGACTGTATCTCTGTGAA/GGTTGGTTGGAAGGCTAA | 60 | 89 | 92.1 |
| sdha | NM_023281 | ATTCATTGTCTACTTCTCACT/AGGGTTTATTTGGCTTACA | 58 | 108 | 90.6 |
| tgfb1 | NM_011577 | TATACTGAGACACCTTGG/GTGATAGTCCTGAATAATTTG | 55 | 83 | 97.2 |
| gapdh | NM_008084 | AGTGGCAAAGTGGAGATT/GTGGAGTCATACTGGAACA | 60 | 83 | 91.5 |
| actb | NM_007393 | ATCTTCCGCCTTAATACT/GCCTTCATACATCAAGTT | 56 | 98 | 90.7 |
| sptbn | NM_175836 | TCTAATGGTTACTTGCTTGT/CAATAGTTACAGTGACAGAGA | 55 | 101 | 91.2 |
| ablim | NM_178688 | GTATTCAGTGTTCACAGT/AATAGCATTAACCAGTAAGA | 55 | 106 | 90.1 |
| ywhaz | NM_001253807 | CAGTAGATGGAGAAAGATTTGC/GGGACAATTAGGGAAGTAAGT | 60 | 92 | 93.5 |
| wrnip | NM_030215 | ATGAGTAGGATGCTTGTA/TAACCACCTCCATCTATG | 56 | 130 | 91.6 |
| 18 s | X00686 | CGCCGCTAGAGGTGAAATTCT/CGAACCTCCGACTTTCGTTCT | 60 | 102 | 93.6 |
| Basins | Q and SSC time span | Area (km2) | Characters |
| Da River Basin | 1988–2004monthly | 55000 | No big dam in the upstream before 2004 Main vegetation cover: forest |
| Chiang Sean Basin | 1986–1991monthly | 185,000 | No big dam before 1992 Main vegetation cover: grass and forest |
| Nam Muc Basin | 1997–2006monthly | 2,200 | No big dam existedMain vegetation cover: forest |
| Characteristic | Public | Private | pb | ||
| n | % | n | % | ||
| Maternal age (years) | |||||
| 12–19 | 1,487 | 19.7 | 128 | 5.7 | < 0.001 |
| 20–34 | 5,396 | 71.3 | 1,716 | 76.0 | |
| 35 or more | 683 | 9.0 | 415 | 18.3 | |
| Total | 7,566a | 100 | 2,259 | 100 | |
| Skin colour | |||||
| Indigenous | 25 | 0.3 | 5 | 0.2 | < 0.001 |
| Black | 835 | 11.0 | 95 | 4.2 | |
| Brown | 4,139 | 54.8 | 835 | 36.9 | |
| Oriental | 83 | 1,1 | 30 | 1,3 | |
| White | 2,482 | 32,8 | 1,294 | 57.3 | |
| Total | 7,564a | 100 | 2,259 | 100 | |
| Education | |||||
| Elementary school | 4,172 | 55.3 | 330 | 14.7 | < 0.001 |
| High school | 3,153 | 41.8 | 1,265 | 56.4 | |
| College or more | 220 | 2.9 | 649 | 28.9 | |
| otal | 7,545a | 100 | 2,244a | 100 | |
| Marital status | |||||
| With partner | 5,734 | 75.8 | 1,990 | 88.2 | < 0.001 |
| No partner | 1,832 | 24.2 | 267 | 11.8 | |
| Total | 7,566a | 100 | 2,257a | 100 | |
| Paid work | |||||
| No | 4,790 | 63.3 | 674 | 29.8 | < 0.001 |
| Yes | 2,777 | 36.7 | 1,585 | 70.2 | |
| Total | 7,567a | 100 | 2,259 | 100 | |
| Economic class | |||||
| A or B | 1,376 | 18.3 | 1,416 | 63.5 | < 0.001 |
| C | 4,780 | 63.5 | 770 | 34.5 | |
| D or E | 1,372 | 18.2 | 45 | 2.0 | |
| Total | 7,528a | 100 | 2,231a | 100 | |
| Hospital location | |||||
| Capital | 2,507 | 33.1 | 766 | 33.9 | 0.486 |
| Regional | 5,062 | 66.9 | 1,493 | 66.1 | |
| Total | 7,569 | 100 | 2,259 | 100 | |
| Previous cesarian section | |||||
| No | 2,603 | 34.4 | 350 | 15.5 | < 0.001 |
| Yes | 1,608 | 21.2 | 653 | 28.9 | |
| Primiparae | 3,358 | 44.4 | 1,256 | 55.6 | |
| Total | 7,569 | 100 | 2,259 | 100 | |
| Antenatal complications | |||||
| No | 4,161 | 55.0 | 1,378 | 61.0 | < 0.001 |
| Yes | 3,408 | 45.0 | 881 | 39.0 | |
| Total | 7,569 | 100 | 2,259 | 100 | |
| Labour complications | |||||
| No | 2,312 | 30.5 | 675 | 29.9 | 0.016 |
| Yes | 1,419 | 18.7 | 372 | 16.5 | |
| No labour | 3,838 | 50.8 | 1,212 | 53.6 | |
| otal | 7,569 | 100 | 2,259 | 100 |
| Variable | 2 year | 3 year | 5 year | 10 year | ||||
| Univariate | Multivariate | Univariate | Multivariate | Univariate | Multivariate | Univariate | Multivariate | |
| HR (95% C.I) | HR (95% C.I) | HR (95% C.I) | HR (95% C.I) | HR (95% C.I) | HR (95% C.I) | HR (95% C.I) | HR (95% C.I) | |
| Hb trajectory | ||||||||
| Normal Hb | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. |
| Persisted anemia | 7.8(2.9-21.1)** | 3.4(1.2-10.2)* | 5.6(2.8-11.3)** | 2.9(1.3-6.2)* | 4.9(2.9-8.3)** | 2.4(1.3-4.3)* | 4.2(2.6-6.7)** | 2.2(1.3-3.8)* |
| Improved anemia | 4.0(1.2-13.2)* | 2.1(0.5-8.8) | 2.5(1.0-6.1) | 1.6(0.5-4.5) | 2.7(1.4-5.3)* | 2.0(0.9-4.2) | 2.2(1.2-4.0)* | 1.8(0.9-3.5) |
| Mild anemia | 2.5(0.9-6.6) | 1.5(0.6-4.1) | 1.9(1.0-3.8)* | 1.2(0.60-2.5) | 1.7(0.9-2.7) | 1.0(0.6-1.8) | 1.6(1.0-2.5)* | 1.1(0.7-1.7) |
| Low normal Hb | 1.9(0.8-4.8) | 1.3(0.5-3.4) | 1.5(0.8-2.8) | 1.1(0.6-2.1) | 1.5(0.9-2.3) | 1.0(0.6-1.6) | 1.3(0.9-2.0) | 1.1(0.7-1.6) |
| Control group (n = 26) | UTI group (n = 24) | P | ||
| FDP (μg/ml) | BOD | 1.76 ± 1.11 | 1.84 ± 1.70 | 0.854 |
| POD1 | 6.87 ± 5.19 | 5.04 ± 2.63 | 0.142 | |
| Fbg (mg/dl) | BOD | 307.30 ± 118.49 | 278.15 ± 78.01 | 0.314 |
| POD1 | 329.64 ± 125.57 | 294.70 ± 80.56 | 0.252 | |
| D-dimer (mg/L) | BOD | 0.36 ± 0.42 | 0.37 ± 0.64 | 0.963 |
| POD1 | 2.30 ± 1.96 | 1.57 ± 1.08 | 0.128 | |
| INR | BOD | 1.02 ± 0.08 | 1.01 ± 0.67 | 0.778 |
| POD1 | 1.08 ± 0.11 | 1.11 ± 0.08 | 0.290 |
| Libraries | LS1 mean | Nb. of concordant identifications | LS1 mean of concordant identifications | Nb. of non-concordant identifications | LS1 mean of non -concordant identifications | Mean of the difference between LS1 and LS2 | Max frequency parameter (%) | Nb. of peaks parameter |
| B1 | 1.34 | 449 | 1.58 | 361 | 1.04 | 0.38 | 25 | 70 |
| B1b | 1.34 | 449 | 1.58 | 361 | 1.04 | 0.38 | 25 | 100 |
| B1c | 1.34 | 449 | 1.58 | 361 | 1.04 | 0.38 | 50 | 70 |
| B1d | 1.36 | 473 | 1.60 | 337 | 1.03 | 0.40 | 50 | 100 |
| B1e | 1.34 | 449 | 1.58 | 361 | 1.04 | 0.38 | 75 | 70 |
| B1f | 1.32 | 445 | 1.56 | 365 | 1.03 | 0.36 | 75 | 100 |
| B1g | 1.39 | 473 | 1.63 | 337 | 1.05 | 0.43 | 100 | 70 |
| B1h | 1.39 | 473 | 1.63 | 337 | 1.05 | 0.43 | 100 | 100 |
| B7 | 1.80 | 611 | 1.96 | 199 | 1.30 | 0.53 | 25 | 70 |
| B7g | 1.80 | 595 | 1.96 | 215 | 1.35 | 0.50 | 100 | 70 |
| Months | sAPPβ | APP 110 kDa | Serotonin |
| 7 | |||
| WT | 3780 ± 330 (5)- | 99 ± 8 (5)- | 59 ± 11 (5)- |
| WT Chol | 3600 ± 330 (5) ns | 80 ± 8 (5) ns | 62 ± 11 (4) ns |
| 14 | |||
| WT | 3809 ± 332 (5) | 146 ± 16 (5)- | 70 ± 8 (5)- |
| WT Chol | 2097 ± 909 (4) ns | 180 ± 29 (5) ns | 58 ± 15 (5) ns |
| 20 | |||
| WT | 2077 ± 464 (4) | 76 ± 18 (6) | 640 ± 127 (5)- |
| WT Chol | 868 ± 396 (4) p = 0.09 | 105 ± 33 (5) ns | 529 ± 163 (5) ns |
| Symptom | Median (IQR) | Rank | Low (score 1–3) N (%) | Medium (score 4–7) N (%) | High (score 8–10) N (%) |
| Weight gain | 9 (6–10) | 1 | 74 (12.3) | 145 (24) | 385 (63.7) |
| Insomnia | 8 (5–10) | 2 | 75 (12.4) | 210 (34.8) | 319 (52.8) |
| Moon face | 8 (5–10) | 2 | 125 (20.7) | 149 (24.7) | 330 (54.6) |
| High blood pressure | 8 (4–10) | 4 | 150 (24.8) | 138 (22.8) | 316 (52.3) |
| Reduced bone strength | 8 (4–10) | 4 | 133 (22) | 134 (22.2) | 337 (55.8) |
| Eye disease | 8 (3–10) | 6 | 164 (27.2) | 93 (15.4) | 347 (57.5) |
| Cardiovascular disease | 8 (1–10) | 7 | 216 (35.8) | 56 (9.3) | 332 (55) |
| Diabetes | 8 (1–10) | 7 | 206 (34.1) | 86 (14.2) | 312 (51.7) |
| Infections | 8 (1–10) | 7 | 182 (30.1) | 116 (19.2) | 306 (50.7) |
| Changes in mood | 7 (5–9) | 10 | 110 (18.2) | 239 (39.6) | 255 (42.2) |
| Skin changes | 7 (5–9) | 10 | 109 (18) | 214 (35.4) | 281 (46.5) |
| Palpitations | 7 (4–9) | 12 | 125 (20.7) | 212 (35.1) | 267 (44.2) |
| Indigestion | 6 (3–8) | 13 | 152 (25.2) | 276 (45.7) | 176 (29.1) |
| Acne | 1 (1–6) | 14 | 359 (59.4) | 138 (22.8) | 107 (17.7) |
| Couple no. | Females | Males | ||||||||
| Visits to ANC1 | Visits to CHC2 | Participation in childbirth and parenthood classes | Visit to dental hygienist during pregnancy | Ever visited open pre-school | Visits to ANC | Visits to CHC | Participation in childbirth and parenthood classes | Visit to dental hygienist during pregnancy | Ever visited open pre-school | |
| 1 | Most visits | Most visits | ANC and CHC | No | Yes | Most visits | Sometimes | Only ANC | No | Yes |
| 2 | Most visits | Most visits | Only ANC | No | Yes | Most visits | Sometimes | Only ANC | No | Yes |
| 3 | Most visits | Most visits | Only CHC | No | Yes | Most visits | Most visits | No | No | Yes |
| 4 | Most visits | Most visits | ANC and CHC | Yes | Yes | Most visits | Most visits | Only ANC | Yes | No |
| 5 | Most visits | Most visits | Only ANC | Yes | Yes | Most visits | Most visits | Only ANC | Yes | Yes |
| 6 | Most visits | Most visits | Only CHC | No | Yes | Most visits | Most visits | Only CHC | No | Yes |
| 7 | Most visits | Most visits | Only ANC | No | Yes | Sometimes | Seldom | Only ANC | No | No |
| 8 | Most visits | Most visits | Only ANC | No | Yes | Sometimes | Sometimes | Only ANC | No | Yes |
| 9 | Most visits | Most visits | ANC and CHC | No | Yes | Most visits | Most visits | ANC and CHC | No | Yes |
| 10 | Most visits | Most visits | Only ANC | No | No | Most visits | Most visits | Only ANC | No | No |
| 11 | Most visits | Most visits | ANC and CHC | No | Yes | Sometimes | Sometimes | ANC and CHC | No | Yes |
| 12 | Most visits | Most visits | Only ANC | Yes | Yes | Seldom | Seldom | ANC (once) | No | Yes |
| Total | sea | seb | sec | sed | see | seg | seh | sei | selj | sek | sell | sem | sen | seo | sep | seq | ser | tsst‐1 | |
| Shopping baskets (n = 740) | 46 | 2 | 5 | – | – | – | 14 | 1 | 8 | – | 1 | 3 | 6 | 12 | 10 | 6 | – | – | 8 |
| Percentage | 4.3 | 10.9 | – | – | – | 30.4 | 2.2 | 17.4 | – | 2.2 | 6.5 | 13.0 | 26.1 | 21.7 | 13.0 | – | – | 17.4 |
| Admission appropriateness | Length of stay appropriateness | ||||||
| Yes | No | P Value | Yes | No | P Value | ||
| % (n) | % (n) | % (n) | % (n) | ||||
| Gender | Female | 70.7 (41) | 29.3 (17) | 0.678 | 37.5 (15) | 62.5 (25) | 0.932 |
| Male | 74.1 (43) | 25.9 (15) | 36.6 (15) | 63.4 (26) | |||
| Admitted via the emergency department? | Yes | 68.1 (47) | 31.9 (22) | 0.210 | 40.0 (18) | 60.0 (27) | 0.537 |
| No | 78.7 (37) | 21.3 (10) | 33.3 (12) | 66.7 (24) | |||
| Presented with a neurologically related problem? | Yes | 64.3 (27) | 35.7 (15) | 0.315 | 34.6 (9) | 65.4 (17) | 0.343 |
| No | 73.7 (42) | 26.3 (15) | 46.3 (19) | 53.7 (22) | |||
| Place of residence | Nursing/residential home | 88.0 (22) | 12.0 (3) | 0.049* | 33.7 (7) | 66.7 (14) | 0.683 |
| Own home | 68.1 (62) | 31.9 (29) | 38.3 (23) | 61.7 (37) | |||
| Household members | Lives with others | 69.4 (43) | 30.6 (19) | 0.795 | 54.8 (23) | 45.2 (19) | < 0.001* |
| Lives alone | 66.7 (20) | 33.3 (10) | 5.3 (1) | 94.7 (18) | |||
| Receives home help | Yes | 74.3 (26) | 25.7 (9) | 0.262 | 25.0 (6) | 75.0 (18) | 0.058 |
| No | 62.7 (32) | 37.3 (19) | 50.0 (16) | 50.0 (16) | |||
| Referred to in-patient physiotherapy | Yes | n/a | n/a | n/a | 25.0 (10) | 75.0 (30) | 0.027* |
| No | 48.8 (20) | 51.2 (21) | |||||
| Referred to social services | Yes | n/a | n/a | n/a | 9.1 (1) | 90.9 (10) | 0.039* |
| No | 41.4 (29) | 58.6 (41) | |||||
| Transferred on discharge | Yes | 74.2 (66) | 235.8 (23) | 0.155 | 18.2 (2) | 81.8 (9) | 0.164 |
| No | 57.0 (11) | 42.1 (8) | 40.0 (28) | 60.0 (42) | |||
| Median (IQR) | Median (IQR) | P Value | Median (IQR) | Median (IQR) | P Value | ||
| Age (119) | 71.5(53.3–78.5) | 74.0(59.3–83.0) | 0.177 | 72.5(I62.5-81.0) | 76.0(58.0–83.0) | 0.984 | |
| Number of LTNCs (119) | 1 (1.0–2.0) | 1 (1.0–2.0) | 0.876 | 1 (1.0–2.0) | 1 (1.0–1.0) | 0.016* | |
| Number of presenting complaints (119) | 1 (1.0–2.0) | 1 (1.0–2.0) | 0.829 | 1 (1.0–1.0) | 2 (1.0–2.0) | 0.040* | |
| FIM score (73) (Score range 1–126, 126 indicates no impairment) | 111.0(103.0–120.0) | 113.0(103.0–120.0) | 0.873 | 103.0(96.0–122.0) | 107.0(45.0–115.0) | 0.228 | |
| GDNS (walking) (74) (score range 1–5, 5 indicates no impairment) | 2.0 (1.5–4.0) | 2.0 (0.0–4.0) | 0.616 | 2.5 (0.0–4.0) | 3.5 (2.0–4.0) | 0.194 | |
| GDNS (speech) (74) (score range 1–5, 5 indicates no impairment) | 0.5 (0.0–0.0) | 0.0 (0.0–2.0) | 0.122 | 0.0 (0.0-0.0) | 0.0 (0.0–3.0) | 0.078 | |
| MMSE (49) (score range 1–30, 30 indicates no impairment) | 24.0(23.0–28.5) | 26.0(24.0–28.0) | 0.445 | 24.0(18.5–26.5) | 26.5(23.0–29.0) | 0.119 | |
| Length of stay (119) | 8.0 (4.0–13.0) | 4.0 (2.0–13.0) | 0.063 | 4.0 (2.0–8.0) | 10.0 (5.0–14.0) | < 0.001* |
| Junior | Intermediate | Senior |
| Supports skills acquisition by using Modelling | Support growing independent practice by using Coaching | Fix gaps in competence development by using exploration |
| “...because at this point rather than learning the theory stuff what I want is to acquire clinical abilities and skills when approaching the patients” (Junior Resident #26). | “I think this is the most important one, because it allows me to perform the clinical activities independently whilst receiving supervision and feedback in order to improve the abilities step by step.” (Intermediate Resident #3) | “In this moment my training is almost complete and I think about what am I lacking to face a competitive working market” (Senior Resident # 75). |
| Overcoming deficiencies by using Coaching | Help expand knowledge base and engage in dialogue with supervisor by using Articulation | Help expand knowledge base and engage in dialogue with supervisor by using articulation |
| “I think that in this stage of training it would help me to have more feedback with regard to the quality, pertinence and rationally of my actions” (Resident (Junior) #34) | “Laying the foundations of my actions and exploring my strengths and weaknesses allow me to develop and improve my clinical criterion and my decision-making skills” (Resident (Intermediate) #22) | “In this year I think that one already has enough knowledge and training to show what do you know and what you don’t.” (Senior Resident #24) |
| “At this level of academic training, initial phase, I will be better helped by permanent feedback in order to fix the fails and to strengthen the right choices...” ( Junior Resident #71) | “Because I consider that it motivates you to make your own decisions and it makes you feel important in the patient care” (Intermediate Resident #65) | “It allow us not only to answer questions but also to formulate them” (Senior Resident #54) |
| Encourage participation by creating a Safe Learning Environment | Gain confidence in own performance by not be coerced using a Safe learning environment | |
| “ I think that the supervisor-trainee relationship is very important. If the supervisor creates an environment of trust and respect, it is possible to loose a little bit that formality and rigidity a teacher has and one can ask questions, formulate doubts and even have more security as a student..” (Junior Resident #80) | “...this is the moment to give confidence and respect (to the resident) in terms of what has been taught and modeled, this can only be reflected in a safe learning environment that not coerce our free performance.” (Senior Resident #18) |
| Item | Geniposide | Baicalin | Palmatine | Berberine | Baicalein | Wogonin | |
| HRT | Retention time (tR, min) | 17.39 | 36.02 | 39.54 | 39.75 | 48.29 | 58.33 |
| Amount (μga) | 15.71 ± 0.08 | 8.72 ± 0.41 | 1.10 ± 0.03 | 19.08 ± 0.51 | 3.98 ± 0.02 | 3.50 ± 0.01 |
| Template | Primer/probe (label) | Sequence (5'-3') |
| IS481 | Forward primer | GCCGGATGAACACCCATAAG |
| Reverse primer | GCGATCAATTGCTGGACCAT | |
| Probe (FAM) | CGATTGACCTTCCTACGTC-MGB | |
| IS1001 | Forward primer | AATTGCTGCAAGCCAACCA |
| Reverse primer | CCAGAGCCGTTTGAGTTCGT | |
| Probe (VIC) | ACATAGACCGTCAGCAG-MGB | |
| IS1002 | Forward primer | CTAGGTCGAGCCCTTCTTGTTAAC |
| Reverse primer | GCGGGCAAGCCACTTGTA | |
| Probe (CY5) | CATCGTCCAGTTCTGTTGCATCACCC-BBQ | |
| PhHV | Forward primer | GGGCGAATCACAGATTGAATC |
| Reverse primer | GCGGTTCCAAACGTACCAA | |
| Probe (NED) | TTTTTATGTGTCCGCCACCA-MGB |
| Groups | Bilateral hippocampus transfection | Drug administration via caudal vein |
| Control | No surgery | Saline (10 mL/kg) |
| Sham | Lentiviral | Saline (10 mL/kg) |
| Model | Lentiviral+miR-30e | Saline (10 mL/kg) |
| TSA low | Lentiviral+miR-30e | TSA (10 mL/kg, 1 mg/mL) |
| TSA high | Lentiviral+miR-30e | TSA (10 mL/kg, 2 mg/mL) |
| Session | TAKE 5 | Waist Winners Too |
| 1 | Benefits of losing weight and motivation towards a healthy lifestyle | Introduction to health and weight |
| 2 | Introduction to individualised energy deficit diet and the importance of physical activity | Planning meals |
| 3 | Principles of healthy eating and improving physical activity levels | Food labelling and fats |
| Introduction to physical activity diaries and pedometer | ||
| 4 | Healthy ways to cook, meal planning and shopping lists | Food labelling salt and sugar |
| Emotions and overeating | ||
| 5 | Disadvantages of eating out and take-aways | Shopping, budgeting, snacks, eating out and take-aways |
| Using behaviour change to alter ‘bad habits’ | ||
| 6 | Coping with cravings and evaluating knowledge of physical activity | Alcohol and other drinks |
| 7 | Diet myths and introduction to new ways to motivate participation in physical activity | Benefits of exercise |
| 8 | Relapse prevention | Review |
| 9 | Evaluate success up to now | What have we learned |
| Groups | Body weight (g) | Splenomegaly (g) | Tumor volume (mL) | Packed cell volume (mL) | Viable tumor cell count (×106 cells/mL) |
| Control L5178Y | 30.83 ± 2.41 | 0.23 ± 0.05 | 2.67 ± 1.08 | 1.30 ± 0.49 | 412.62 ± 35.14 |
| L5178Y + Globulin UF | 29.32 ± 2.89 | 0.23 ± 0.11 | 3.00 ± 1.22 | 1.12 ± 0.87 | 286.96 ± 92.84 |
| L5178Y + Glutelin UF | 27.5 ± 1.73 | 0.19 ± 0.02 | 4.20 ± 0.64 * | 1.97 ± 0.60 | 415.80 ± 92.88 |
| L5178Y + Albumin SFD | 28.08 ± 2.38 | 0.20 ± 0.07 | 0.60 ± 0.75 * | 0.50 ± 0.30 * | 750.00 ± 47.03 * |
| L5178Y + Glutelin SFD | 31.06 ± 3.20 | 0.21 ± 0.01 | 3.50 ± 3.46 | 1.02 ± 0.95 | 365.10 ± 223.82 |
| Weather season | Monitoring period | Variable | Soil temperature | Soil moisture |
| Wet season | September 2012 | r = 0.2253 P = 0.1464 | r = 0.1955 P = 0.2091 | |
| November 2012 | r = −0.5169 P = 0.0001 | r = 0.1127 P = 0.4264 | ||
| January 2013 | Soil CO2 emission | r = −0.4829 P = 0.0004 | r = 0.2290 P = 0.1135 | |
| Dry season | April 2013 | r = −0.7431 P = 0.0001 | r = −0.0776 P = 0.5558 | |
| July 2013 | r = −0.5992 P = 0.0001 | r = −0.2299 P = 0.0854 | ||
| Pooling data throughout the wet and dry seasons | r = −0.1119 P = 0.0710 | r = 0.1027 P = 0.0980 |
| Variable | Experimental schools(mean standard error) | Control schools(mean standard error) | t (8) | Cohen's d |
| Screen time | ||||
| Child report (hours/week) | 32.5(0.6) | 31.2(1.0) | .26 | .69 |
| Parent report (hours/week) | 22.8(0.7) | 24.6(0.3) | -2.15a | 1.26 |
| Fruit and vegetable consumption | ||||
| Child report (servings/day) | 4.4(0.2) | 4.2(0.1) | 1.78b | .52 |
| Parent report (servings/week) | 24.9(0.7) | 22.6(0.4) | 2.69a | 1.36 |
| Physical activity | ||||
| Pedometer (steps/day) | 12,250(260) | 11,870(232) | .91 | 1.83 |
| Body mass index | ||||
| Body mass index (kg/m2) | 19.0(0.02) | 19.0(0.03) | .05 | .38 |
| PCOS group | Control group | P | |
| Total macular thickness (μm) | |||
| Central subfield (CSF) | 242.9 ± 19.7 | 241.2 ± 19.8 | 0.7011 |
| Superior inner macula (SIM) | 320.0 ± 15.0 | 323.8 ± 14.1 | 0.2391 |
| Temporal inner macula (TIM) | 305.5 ± 12.3 | 308.6 ± 14.2 | 0.2971 |
| Inferior inner macula (IIM) | 316.3 ± 14.5 | 317.0 ± 21.4 | 0.8651 |
| Nasal inner macula (NIM) | 322.5 ± 15.4 | 322.8 ± 15.5 | 0.9411 |
| Superior outer macula (SOM) | 282.6 ± 15.0 | 285.6 ± 14.6 | 0.3581 |
| Temporal outer macula (TOM) | 260.7 ± 12.6 | 263.5 ± 13.6 | 0.3491 |
| Inferior outer macula (IOM) | 268.9 ± 14.8 | 268.8 ± 15.0 | 0.9801 |
| Nasal outer macula (NOM) | 300.7 ± 14.1 | 299.4 ± 19.6 | 0.7371 |
| Retinal nerve fiber layer (macula, μm) | |||
| Average macular RNFL | 38.6 ± 4.8 | 41.0 ± 9.5 | 0.1681 |
| Superior macular | 33.9 ± 5.2 | 35.2 ± 7.3 | 0.3341 |
| Temporal macular | 52.5 ± 15.0 | 54.2 ± 16.1 | 0.6361 |
| Inferior macular | 33.8 ± 7.2 | 35.6 ± 7.0 | 0.2581 |
| Nasal macular | 35.0 ± 11.3 | 35.2 ± 8.0 | 0.9451 |
| Knowledge | Frequency | Percentage |
| Do you think Condoms can prevent STDs? (N = 581) | ||
| Yes | 443 | 76.2 |
| No | 134 | 23.1 |
| Probably | 4 | 0.7 |
| Can HIV transmit through kissing and sharing equipment(N = 583) | ||
| Yes | 243 | 41.7 |
| No | 307 | 52.6 |
| I don’t know | 33 | 5.7 |
| Is HIV STDs? (N = 491) | ||
| Yes | 440 | 89.6 |
| No | 51 | 10.4 |
| Can HIV transmit through breast feeding (N = 563) | ||
| Yes | 311 | 55.2 |
| No | 252 | 44.8 |
| Know about STDs (N = 576) | ||
| Yes | 510 | 88.45 |
| No | 66 | 11.5 |
| Items | 2010 | 2011 | ||||
| Gaoyou | Pukou | Rudong | Gaoyou | Pukou | Rudong | |
| Outpatient reimbursement rate(%) | ||||||
| Village clinics | 25 | 40 | 25 | 35 | 40 | 30 |
| THCs | 25 | 30 | 20 | 30 | 30 | 25 |
| County-level hospital | 20 | 20 | 15 | 20 | 20 | 20 |
| Yearly maximum payment amount | 500 | 600 | 460 | 600 | 600 | 500 |
| Rural per capita net income (yuan RMB) | 8825 | 11188 | 9120 | 10170 | 13204 | 10500 |
| IVT Macular Thickness | SBT Macular Thickness | p < 0.05 | |
| Baseline | 386.3 ± 12.4 | 384.1 ± 18.9 | 0.721 |
| 1 month | 222.7 ± 13.4 | 220.1 ± 15.1 | 0.625 |
| 3 months | 228.1 ± 10.6 | 231.3 ± 10.9 | 0.580 |
| 6 months | 385.2 ± 11.3 | 235.4 ± 8.7 | 0.001 |
| Number of patients | Interval between uterine surgery and diagnosis of BML | Size or type of uterine myoma | Adjuvant treatment | Outcome (follow-up period) | |
| Rivera et al.[3] | 2 | 11 years | 6 cm | GnRH agonist, tamoxifen, aromatase inhibitor | 5 years |
| 3 years | 22 × 16 × 10 cm, intramural | GnRH agonist tamoxifen, aromatase inhibitor | 2 years | ||
| Egberts et al.[4]. | 1 | 10 years | - | GnRH agonist | 3 years |
| Mogi et al. [31]. | 1 | 7 years | 14 m | GnRH agonist | - |
| Bodner-Alder et al.[32]. | 1 | 1 year | 6 × 7 cm, subserosal | GnRH agonist | 3 months |
| Nasu et al.[10]. | 1 | 10 years | - | Aromatase inhibitor | 15 months |
| Beck et al. [33]. | 1 | 5 years | 10 × 10 cm, 8 × 8 cm subserosal | Progesterone | 1 year |
| Wentling et al. [34]. | 1 | 6 years | 5 cm | Progesterone | 3 years |
| Goyle et al. [11]. | 1 | 5 years | - | progesterone | 3 months |
| Moon et al. [9]. | 1 | - | 6 × 5 cm | observation | 6 months |
| Awonuga et al.[35]. | 2 | 3 years | 21 cm | Observation | - |
| 6 years | Six, ~30 cm (multiple) | Tamoxifen | 2 years | ||
| Ki et al. (this case report) | 4 | None | Small | Observation | 16 years |
| None | 10 × 10 cm | Observation | 3 months | ||
| 7 years | 8 × 8 cm, 5 × 7 cm | Observation | 2 months | ||
| 11 years | 10.5 × 8 cm, subserosal | Observation | 2 years |
| Predictorsa | Level | β | p | 95% Confidence Interval |
| Sex | Male/female | -0.505 | 0.135 | -1.169, 0.158 |
| Living with partner | Yes/no | 0.756 | 0.039† | 0.040, 1.472 |
| Age | Continuous | 0.016 | 0.263 | -0.012, 0.043 |
| Number of hospitalization days | Continuous | 0.007 | 0.386 | -0.009, 0.024 |
| Discharged to nursing home | Yes/no | 1.074 | 0.191 | -0.539, 2.688 |
| Discharged to home | Yes/no | 1.087 | 0.169 | -0.466, 2.640 |
| Stroke type | Ischemic/haemorrhagic | 0.210 | 0.658 | -0.722, 1.142 |
| Stroke location | Left/right | 0.297 | 0.365 | -0.348, 0.942 |
| Diabetes | Yes/no | -0.214 | 0.589 | -0.994, 0.566 |
| Alive within 10-year ref/per | Yes/no | 0.136 | 0.705 | -0.569, 0.640 |
| Explained variance | 0.047 (R2) |
| Isolate no. | Isolate or accession no.a | Organism | Amino acid residue at position corresponding to nonsynonymous mutation: | |
| K137R | P533L | |||
| PF3D7_1343700 | P. falciparum | K168 | P553 | |
| PVX_083080 | P. vivax | K152 | P539 | |
| PKH_121080 | P. knowlesi | K152 | P539 | |
| 1 | PM1A | P. malariae | P | |
| 2 | PM2 | P. malariae | P | |
| 3 | PMS | P. malariae | P | |
| 4 | PM1381 | P. malariae | P | |
| 5 | PM17 | P. malariae | P | |
| 6 | PM18 | P. malariae | P | |
| 7 | PM048 | P. malariae | L | |
| 8 | PM1S | P. malariae | P | |
| 9 | PM4 | P. malariae | P | |
| 10 | PM2848 | P. malariae | P | |
| 11 | PM454 | P. malariae | P | |
| 12 | PM5 | P. malariae | P | |
| 13 | PM1454 | P. malariae | P | |
| 14 | PoW1 | P. ovalewallikeri | K | |
| 15 | PoW21 | P. ovalewallikeri | K | |
| 16 | PoW23 | P. ovalewallikeri | K | |
| 17 | PoC13 | P. ovalecurtisi | K | |
| 18 | PoW20 | P. ovalewallikeri | R |
| Haplotype | Control Freq. | Case Freq. | Coef. | Odds Ratio | 95% CI | Z-Score | P-value |
| Discovery Cohort (363 patients) | |||||||
| TG | 0.33 | 0.21 | 1.00 | (reference) | |||
| CA | 0.39 | 0.42 | 0.42 | 1.52 | (1.05, 2.21) | 2.21 | 0.027 |
| CG | 0.21 | 0.23 | 0.56 | 1.75 | (1.12, 2.72) | 2.46 | 0.014 |
| TA | 0.07 | 0.15 | 1.21 | 3.36 | (1.77, 6.37) | 3.71 | 0.000 |
| Validation Cohort (209 patients) | |||||||
| TG | 0.34 | 0.20 | 1.00 | (reference) | |||
| CA | 0.40 | 0.49 | 0.68 | 1.98 | (1.19, 3.27) | 2.65 | 0.008 |
| CG | 0.18 | 0.23 | 0.75 | 2.11 | (0.99, 4.50) | 1.94 | 0.053 |
| TA | 0.09 | 0.09 | 0.63 | 1.87 | (0.67, 5.23) | 1.20 | 0.230 |
| Material | No. of samples | No. of positives |
| Manure | 114 | 1 |
| Soil | 84 | 0 |
| Silage | 4 | 0 |
| Before pasteurisation | 11 | 3 |
| After pasteurisation | 11 | 0 |
| After digestion | 11 | 0 |
| Peak | Start | RT | End | Height | Area | Area % | AreaSumPercent | BasePeakMz |
| 1 | 0.423 | 0.474 | 0.574 | 1605457 | 7925924 | 20.49 | 5.51 | 150.1117 |
| 2 | 0.641 | 0.691 | 0.741 | 1260173 | 3247945 | 8.4 | 2.26 | 139.0495 |
| 3 | 5.433 | 5.517 | 5.617 | 929895 | 3587468 | 9.27 | 2.5 | 453.3415 |
| 4 | 9.274 | 9.357 | 9.441 | 2115277 | 5968077 | 15.43 | 4.15 | 568.2943 |
| 5 | 9.508 | 9.574 | 9.675 | 1806352 | 5584557 | 14.44 | 3.89 | 383.1507 |
| 6 | 15.853 | 16.054 | 16.438 | 2043093 | 25462871 | 65.83 | 17.72 | 326.377 |
| 7 | 18.024 | 18.108 | 18.225 | 3059381 | 14141487 | 36.56 | 9.84 | 311.1631 |
| 8 | 19.56 | 19.711 | 19.945 | 1145362 | 9522103 | 24.62 | 6.63 | 338.34 |
| 9 | 21.397 | 21.497 | 21.614 | 2927045 | 14662592 | 37.91 | 10.2 | 413.2648 |
| 10 | 24.036 | 24.654 | 25.271 | 1030920 | 38679784 | 100 | 26.91 | 663.451 |
| Characteristic | Entire Cohort (n = 88) | PD-L1 ≥36.5 ∆Ct | PD-L1 < 36.5 ∆Ct | p-Value | PD-L1 IHC ≥ 1% (IC) | PD-L1 IHC < 1% (IC) | p-Value |
| pT-Stage | 0.096 | 0.27 | |||||
| pT2 | 24 (27%) | 13 (28%) | 11 (26%) | 8 (28%) | 16 (27%) | ||
| pT3 | 47 (53%) | 28 (61%) | 19 (45%) | 18 (62%) | 29 (49%) | ||
| pT4 | 17 (20%) | 5 (11%) | 12 (29%) | 3 (10%) | 14 (24%) | ||
| pN-Stage | 0.014 | 0.019 | |||||
| pN0 | 60 (68%) | 36 (78%) | 24 (57%) | 23 (79%) | 37 (63%) | ||
| pN1 | 9 (10%) | 1 (2%) | 8 (19%) | 0 (0%) | 9 (15%) | ||
| pN2 | 19 (22%) | 9 (20%) | 10 (24%) | 6 (21%) | 13 (22%) | ||
| Grading | |||||||
| WHO 1973 | |||||||
| G2 | 4 (5%) | 3 (7%) | 1 (2%) | 0.34 | 2 (7%) | 2 (3%) | 0.47 |
| G3 | 84 (95%) | 43 (93%) | 41 (98%) | 27 (93%) | 57 (97%) | ||
| 0 (0%) | 0 (0%) | 0 (0%) | 1.0 | 0 (0%) | 0 (0%) | 1.00 | |
| WHO 2016 | 88 (100%) | 46 (100%) | 42 (100%) | 29 (100%) | 59 (100%) | ||
| Low grade | |||||||
| High grade | |||||||
| L1 | 50 (57%) | 22 (48%) | 28 (66%) | 0.074 | 13 (45%) | 37 (62%) | 0.11 |
| V1 | 26 (30%) | 11 (24%) | 15 (36%) | 0.23 | 7 (24%) | 19 (32%) | 0.43 |
| Pn1 | 27 (30%) | 17 (37%) | 10 (24%) | 0.18 | 12 (41%) | 15 (25%) | 0.13 |
| Carcinoma in situ | 62 (70%) | 32 (70%) | 30 (71%) | 0.85 | 17 (58%) | 45 (76%) | 0.092 |
| Median age (Min./Max.) | 70.2 (41.3–90.8) | 70.1 (50.7–85.4) | 70.7 (41.3–90.8) | 0.45 | 70.05 (53.6–84.4) | 70.28 (41.3–90.8) | 0.64 |
| Adjuvant platinum-containing chemotherapy | 29 (33%) | 14 (30%) | 15 (36%) | 0.60 | 8 (28%) | 21 (36%) | 0.45 |
| Median survival time (Min./Max.) | 26.6 (0.03–135.7) | 39.7 (0.83–135.7) | 14.53 (0.03–114.83) | 0.0065 | 40.9 (0.08–135.7) | 20.83 (0.03–129.4) | 0.088 |
| Censors: | |||||||
| Alive | 28 (32%) | 18 (39%) | 10 (24%) | 0.12 | 12 (41%) | 16 (27%) | 0.18 |
| Deceased | 60 (68%) | 28 (61%) | 32 (76%) | 0.12 | 17 (59%) | 43 (73%) | 0.18 |
| Tumor specific death | 37 (42%) | 15 (33%) | 22 (52%) | 0.15 | 10 (34%) | 27 (46%) | 0.31 |
| Assembly | k-mer | No. transcripts | Total Mbp | Mean transcript length (bp) | N50 (bp) | RMBT (%) | No. transcripts >1 kb | CEGMA complete/partial (%) |
| (A) ALL READS: 138 MILLION PAIRS | ||||||||
| Oases SK | 39 | 153,729 | 255 | 1662 | 3659 | 92 | 64,243 | n/d |
| Oases MK | 1,208,328 | 2601 | 2153 | 3487 | 96 | 763,694 | n/d | |
| CLC SK | 25 | 220,829 | 145 | 657 | 877 | 86 | 32,545 | n/d |
| CLC MK | 201,432 | 210 | 1042 | 1707 | 95 | 62,038 | n/d | |
| (B) SUB-SAMPLE OF READS: 30 MILLION PAIRS | ||||||||
| Oases SK | 23 | 78,640 | 125 | 1588 | 3144 | 90 | 34,850 | 87.5/98.8 |
| Oases MK | 507,954 | 1014 | 1996 | 3068 | 94 | 319,913 | 92.7/99.6 | |
| CLC SK | 25 | 97,375 | 76 | 781 | 1346 | 87 | 16,121 | 79.8/94.0 |
| CLC MK | 144,789 | 190 | 1315 | 2635 | 95 | 51,516 | 94.8/99.2 | |
| ABySS SK | 35 | 53,368 | 47 | 878 | 1439 | 59 | 12,936 | 33.1/65.3 |
| ABySS MK | 89,457 | 108 | 1204 | 2158 | 87 | 32,797 | 83.5/96.8 |
| Amino Acid | Relative Content (g/100 g) a,b | |
| ACP | CCP | |
| Asp | 5.68 | 5.17 |
| Glu | 10.51 | 11.53 |
| Ser | 3.38 | 3.17 |
| Gly | 19.84 | 21.28 |
| His | 3.27 | 2.97 |
| Thr | 7.90 | 8.51 |
| Ala | 4.09 | 4.68 |
| Pro | 12.47 | 12.18 |
| Arg | 8.61 | 8.47 |
| Tyr | 2.28 | 1.79 |
| Val | 3.06 | 2.90 |
| Met | 1.79 | 1.27 |
| Cys | 2.39 | 2.08 |
| Ile | 4.11 | 3.93 |
| Leu | 0.70 | 0.08 |
| Phe | 9.31 | 9.36 |
| Lys | 0.61 | 0.62 |
| Total | 100.00 | 100.00 |
| Boys | Girls | |
| N = 139 | N = 144 | |
| Mean [percentage] | Mean [percentage] | |
| Migrant families | [79.7%] | [83.0%] |
| Native-born families | [20.3%] | [17.0%] |
| Age | 4.25 (SD 0.88) | 4.25 (SD 0.82) |
| Area of education | ||
| St Gallus | [25.2%] | [30.6%] |
| St Pius | [19.4%] | [14.6%] |
| St Fidelis | [17.3%] | [16.0%] |
| St. Martin | [15.1%] | [17.4%] |
| St. Michael | [23.0%] | [21.4%] |
| Origin of migrant families: | ||
| Asia | [40.2%] | [45.5%] |
| Africa | [40.2%] | [30.3%] |
| Eastern Europe | [15.2%] | [5.1%] |
| Western Europe | [3.3%] | [15.2%] |
| North and South America | [1.1%] | [4%] |
| ILOC | p-value | PLOC | p-value | CLOC | p-value | ||
| Behaviour | OR (95% CI) | OR (95% CI) | OR (95% CI) | ||||
| Cigarette smoking (N=3229 ) | Non-Smoker | 1 | 1 | 1 | |||
| Ex-Smoker | 1.01 (0.95-1.07) | 0.826 | 0.95 (0.89-1.01) | 0.084 | 0.96 (0.91-1.02) | 0.230 | |
| Smoker | 1.01 (0.96-1.06) | 0.778 | 0.97 (0.92-1.02) | 0.165 | 1.09 (1.04-1-15) | 0.001 | |
| Alcohol consumption (N=3271) | Never | 1 | 1 | 1 | |||
| Less than once a week | 1.03 (0.96-1.11) | 0.449 | 1.03 (0.95-1.11) | 0.494 | 0.97 (0.90-1.04) | 0.397 | |
| Once a week | 1.04 (0.97-1-12) | 0.318 | 0.99 (0.92-1.07) | 0.847 | 0.96 (0.89-1.04) | 0.318 | |
| Several times every week | 1.04 (0.97-1-12) | 0.297 | 0.94 (0.87-1.01) | 0.111 | 1.02 (0.95-1.10) | 0.563 | |
| Every day or more | 1.07 (0.93-1.23) | 0.363 | 0.95 (0.82-1.09) | 0.442 | 1.19 (0.97-1.07) | 0.013 | |
| Drug intake (N=3189) | No | 1 | 0.801 | 1 | 0.012 | 1 | 0.319 |
| Yes | 0.99 (0.93-1.06) | 0.92 (0.85-0.98) | 1.04 (0.97-1.11) | ||||
| Weight (N=3154) | Underweight | 0.93 (0.84-1.02) | 0.116 | 1.10 (0.99-1.22) | 0.069 | 0.91 (0.82-1.01) | 0.068 |
| Normal weight | 1 | 1 | 1 | ||||
| Overweight | 0.98 (0.93-1.04) | 0.562 | 1.04 (0.99-1.10) | 0.133 | 1.04 (0.98-1.09) | 0.019 | |
| Physical activity (N=3263) | At least 3 times a week | 1 | 1 | 1 | |||
| 1 to 2 times a week | 0.87 (0.83-0.91) | <0.001 | 1.08 (1.03-1.13) | 0.002 | 1.06 (1.01-1.11) | 0.019 | |
| Less than once a week | 0.86 (0.81-0.91) | <0.001 | 1.07 (1.01-1.13) | 0.026 | 1.12 (1.06-1.18) | <0.001 | |
| Importance of healthy nutrition (N=3281) | Very important | 1 | 1 | 1 | |||
| Somewhat important | 0.89 (0.84-0.94) | <0.001 | 1.02 (0.97-1.08) | 0.458 | 1.04 (0.99-1.10) | 0.140 | |
| Important | 0.79 (0.74-0.84) | <0.001 | 0.96 (0.90-1.02) | 0.135 | 1.10 (1.04-1.17) | 0.001 | |
| Somewhat unimportant | 0.79 (0.72-0.87) | <0.001 | 0.90 (0.82-0.99) | 0.025 | 1.25 (1.14-1.37) | <0.001 | |
| Very unimportant | 0.64 (0.55-0.74) | <0.001 | 0.83 (0.71-0.97) | 0.016 | 1.29 (1.11-1.49) | 0.001 |
| Cluster | Tree distance | q | q+ |
| dro1 | 0.039669 | 0.961108 | 1 |
| dro2 | 0.21 | 0.810584 | 0.849477 |
| dro_anoGam | 0.191225384 | 0.825946 | 0.864839 |
| dro_apiMel | 0.231922 | 0.793008 | 0.8319 |
| dro_triCas | 0.324132615 | 0.723154 | 0.762047 |
| all | 0.3252756 | 0.722328 | 0.761221 |
| PHB/ENR-50 composition | Clay content (wt%) | DSC * | TG-DTG ** | |||||||
| Tg1 (°C) | Tg2 (°C) | Tm (°C) | ∆Hm (J/g) | T10 (°C) | T20 (°C) | T30 (°C) | Tmax1 (°C) | Tmax2 (°C) | ||
| 30/70 | 0 | −18.1 | – | 169.6 | 25.8 | 255.6 | 281.5 | 370.4 | 280.9 | 433.1 |
| 1 | −18.8 | 53.5 | 172.4 | 4.1 | 270.4 | 318.5 | 366.7 | 332.8 | 438.2 | |
| 3 | – | 49.3 | – | – | 296.3 | 366.7 | 403.7 | 310.9 | 432.7 | |
| 5 | – | 60.0 | – | – | 314.8 | 377.8 | 414.8 | 291.0 | 430.7 | |
| 50/50 | 0 | −17.7 | – | 170.2 | 37.5 | 248.2 | 259.3 | 270.4 | 279.1 | 437.8 |
| 1 | – | 60.7 | 172.4 | 9.1 | 266.7 | 281.5 | 307.4 | 313.9 | 431.5 | |
| 3 | – | 57.3 | – | – | 274.1 | 340.7 | 388.9 | 300.0 | 429.5 | |
| 5 | – | 58.6 | – | – | 285.2 | 388.9 | 425.9 | 294.4 | 441.0 | |
| 70/30 | 0 | −19.3 | – | 173.1 | 53.7 | 235.2 | 242.6 | 248.2 | 276.9 | 414.2 |
| 1 | – | 58.0 | 172.8 | 18.3 | 281.5 | 292.6 | 300.0 | 303.6 | 446.7 | |
| 3 | – | 57.4 | 170.0 | 1.9 | 274.1 | 296.3 | 377.8 | 297.9 | 438.7 | |
| 5 | – | 54.3 | – | – | 266.7 | 355.6 | 407.4 | 284.1 | 429.5 |
| Antibiotics Tested | No. (%) Resistant a |
| Cefoxitin (CX) | 34 (20.12%) |
| Cefotaxime (CTX) | 165 (97.63%) |
| Ceftazidime (CAZ) | 154 (91.12%) |
| Cefpodoxime (CPD) | 156 (92.30%) |
| Imipenem (IPM) | 18 (10.65%) |
| Ertapenem (ETP) | 69 (40.82%) |
| Meropenem (MRP) | 53 (31.36%) |
| Ciprofloxacin (CIP) | 27 (15.98%) |
| Aztreonam (AT) | 110 (65.08%) |
| Amox/clav (AMC) | 65 (38.46%) |
| Piperacillin/Tazobactam (TZP) | 69 (40.82%) |
| Smoking groups | Women (n = 1741) | Men (n = 1637) | |||||||
| n | Median | 5th perc. | 95th perc. | n | Median | 5th perc. | 95th perc. | p valuea | |
| Never smokers | 868 | 15.7 | 7.8 | 35.7 | 817 | 19.0 | 9.0 | 44.2 | <0.0001 |
| Former smokers | 581 | 16.3 | 7.6 | 35.6 | 615 | 18.9 | 9.2 | 39.9 | <0.0001 |
| Current smokers | 292 | 10.4b | 4.4 | 29.4 | 205 | 13.2 b | 6.2 | 34.3 | <0.0001 |
| All subjects | 1741 | 15.0 | 6.6 | 35.3 | 1637 | 18.2 | 8.2 | 41.3 | <0.001. |
| Changes between years | Difference in the changes | |||||
| EG | Non EG | Mean | 95% CI | Sig. | ||
| 2003-2005 | ||||||
| HCE as % of total expenditure (%) | −0.528 | 0.458 | −0.987 | −1.651 | −0.398 | Yes |
| Number of self-treatment (#) | −0.991 | −1.094 | 0.103 | −0.157 | 0.359 | No |
| Number of go-to-pharmacy (#) | −0.030 | −0.046 | 0.016 | −0.099 | 0.101 | No |
| Number of private health care utilizations (#) | −0.188 | −0.204 | 0.016 | −0.119 | 0.149 | No |
| Number of CHS utilizations (#) | 0.005 | −0.046 | 0.052 | −0.025 | 0.102 | No |
| Number of DH utilizations (#) | 0.016 | 0.019 | −0.003 | −0.046 | 0.033 | No |
| Number of P/CH utilizations (#) | −0.010 | 0.007 | −0.017 | −0.042 | 0.012 | No |
| Total number of utilizations (#) | −1.199 | −1.365 | 0.167 | −0.249 | 0.545 | No |
| 2005-2007 | ||||||
| HCE as % of total expenditure (%) | −0.065 | 0.222 | −0.287 | −1.066 | 0.560 | No |
| Number of self-treatment (#) | 0.196 | −0.062 | 0.258 | −0.103 | 0.484 | No |
| Number of go-to-pharmacy (#) | 0.209 | 0.182 | 0.027 | −0.083 | 0.123 | No |
| Number of private health care utilizations (#) | 0.014 | 0.021 | −0.007 | −0.164 | 0.066 | No |
| Number of CHS utilizations (#) | 0.016 | 0.030 | −0.013 | −0.111 | 0.053 | No |
| Number of DH utilizations (#) | 0.247 | 0.269 | −0.022 | −0.093 | 0.047 | No |
| Number of P/CH utilizations (#) | 0.034 | −0.005 | 0.039 | 0.016 | 0.075 | Yes |
| Total number of utilizations (#) | 0.716 | 0.434 | 0.282 | −0.350 | 0.690 | No |
| 2003-2007 | ||||||
| HCE as % of total expenditure (%) | −0.588 | 0.640 | −1.227 | −2.312 | −0.724 | Yes |
| Number of self-treatment (#) | −0.797 | −1.165 | 0.368 | 0.067 | 0.663 | Yes |
| Number of go-to-pharmacy (#) | 0.176 | 0.143 | 0.033 | −0.070 | 0.124 | No |
| Number of private health care utilizations (#) | −0.176 | −0.190 | 0.014 | −0.154 | 0.115 | No |
| Number of CHS utilizations (#) | 0.023 | −0.015 | 0.038 | −0.030 | 0.123 | No |
| Number of DH utilizations (#) | 0.262 | 0.280 | −0.018 | −0.088 | 0.043 | No |
| Number of P/CH utilizations (#) | 0.023 | 0.002 | 0.021 | 0.001 | 0.051 | Yes |
| Total number of utilizations (#) | −0.488 | −0.944 | 0.456 | −0.013 | 0.825 | No |
| Crude model 1OR (95 % CI) | Model 2OR (95 % CI) | Model 3OR (95 % CI) | Mediating effect of maternal burden of care(%) | Model 4OR (95 % CI) | Mediating effectof maternal aggressive behavior(%) | |
| Overall problem score P80 | 3.27 (2.11–5.07) | 2.12 (1.30–3.46) | 1.98 (1.21–3.24) | 12.5 % | 1.90 (1.16–3.1 2) | 9 % |
| Conduct problems P80 | 2.25 (1.46–3.48) | 1.75 (1.09–2.81) | 1.63 (1.00–2.62) | 16 % | 1.61 (0.99–2.56) | 6 % |
| Emotional symptoms P80 | 2.13 (1.37–3.34) | 1.54 (0.96–2.47) | 1.42 (0.88–2.28) | 1.41 (0.88–2.28) | ||
| Hyperactivity P80 | 2.28 (1.47–3.53) | 1.76 (1.10–2.82) | 1.75 (1.09–2.82) | 1 % | 1.72 (1.07–2.78) | 4 % |
| Peer problems P80 | 2.55 (1.62–4.01) | 1.63 (0.79–2.73) | 1.61 (0.96–2.70) | 1.60 (0.95–2.70) | ||
| Pro-social P20 | 1.74 (1.08–2.80) | 1.45 (0.87–2.42) | 1.36 (0.81–2.28) | 1.32 (0.79–2.22) | ||
| SMFQ P80 | 2.62 (1.70–4.05) | 1.84 (1.14–2.96) | 1.70 (1.05–2.74) | 17 % | 1.63 (1.01–2.65) | 10 % |
| Generalized anxiety P80 | 1.87 (1.19–2.92) | 1.25 (0.77–2.02) | 1.19 (0.74–1.94) | 1.17 (0.72–1.90) |
| ESI | SRM Transition (m/z→m/z) | Collision | ~tR | ||
| Mycotoxin | (+ or -) | Quantitative | Qualitative | Energy | (min) |
| DON | - | 341.0→265.0 | 341.0→247.0 | 18 | 6.1 |
| HT2 | + | 442.2→263.0 | 442.2→215.0 | 18 | 8.9 |
| T2 | + | 484.2→185.0 | 484.2→305.0 | 18 | 9.3 |
| ZON | - | 317.0→174.5 | 317.0→130.5 | 25 | 10.1 |
| FB1 | + | 722.5→334.4 | 722.5→352.2 | 40 | 9.2 |
| OTA | + | 404.0→239.0 | 404.0→358.4 | 20 | 9.9 |
| FB2 | + | 706.4→336.2 | 706.4→354.2 | 35 | 10.2 |
| Meloxicam (IS) | + | - | 352.0→115.0 | 20 | 8.6/9.1 |
| OTUs | Mucus | Seawater | OTU contribution (%)b | Cumulative contribution (%) |
| Average abundancea | Average abundancea | |||
| Unclassified Pseudoalteromonadaceae | 2,203.67 | 10,112.13 | 21.86 | 21.86 |
| Unclassified Desulfovibrionaceae | 2,253.75 | 158.88 | 6.01 | 27.87 |
| Unclassified Flavobacteriaceae | 1,396.42 | 8.13 | 3.64 | 31.51 |
| Alteromonas | 45.83 | 1,417.5 | 3.58 | 35.1 |
| Ruegeria* | 1,189.92 | 372.75 | 3.28 | 38.38 |
| Vibrio | 276.67 | 1,247.75 | 2.83 | 41.21 |
| Pseudoalteromonas | 1,090.67 | 100.63 | 2.76 | 43.97 |
| Arcobacter | 1,010.17 | 2.38 | 2.64 | 46.61 |
| Unclassified Desulfobulbaceae | 847.92 | 1.25 | 2.22 | 48.82 |
| Unclassified Desulfovibrionaceae | 825.17 | 41.25 | 2.19 | 51.02 |
| Idiomarina | 76.58 | 817.13 | 2.17 | 53.18 |
| Unclassified Rhodobacteraceae | 910.33 | 276.5 | 2.15 | 55.34 |
| Unclassified Hyphomonadaceae | 804.17 | 2.75 | 2.1 | 57.44 |
| Halomonas | 560.92 | 122.13 | 1.64 | 59.08 |
| Thalassospira | 563.33 | 69.25 | 1.56 | 60.64 |
| Alcanivorax | 18.42 | 600.38 | 1.53 | 62.16 |
| Marinobacter | 10.92 | 543.63 | 1.41 | 63.57 |
| Unclassified Vibrionaceae | 613.17 | 153.75 | 1.28 | 64.85 |
| Unclassified Acidaminobacteraceae | 476.67 | 0 | 1.25 | 66.09 |
| Unclassified Flavobacteriaceae | 398.25 | 15.75 | 1.03 | 67.13 |
| Oceanicaulis | 317 | 141.38 | 0.97 | 68.1 |
| Idiomarina | 35.08 | 389 | 0.92 | 69.02 |
| Marinobacter | 0.17 | 334.25 | 0.87 | 69.9 |
| Phylum | ||||
| Proteobacteria | 63.97 | 63.97 | ||
| Firmicutes | 1.25 | 65.22 | ||
| Bacteriodetes | 4.67 | 69.89 |
| Nocardia spp. (no. of strains) | Agreement between 16S and MALDI-TOF MS | No. of strains in the Bruker database |
| High prevalence (n = 25) | ||
| Nocardia abscessus (n = 2) | 2/2 | 2 |
| N. cyriacigeorgica (n = 6) | 5/6 | 16 |
| N. farcinica (n = 8) | 7/8 | 12 |
| N. nova (n = 9) | 5/9 | 2 |
| Total (%) | 19/25 (76.0%) | 32 |
| Intermediate prevalence (n = 20) | ||
| N. brasiliensis (n = 5) | 3/5 | 1 |
| N. carnea (n = 7) | 1/7 | 1 |
| N. otitidiscaviarum (n = 5) | 5/5 | 6 |
| N. transvalensis complex (n = 3) | 0/3 | 1 |
| Total (%) | 9/20 (45%) | 9 |
| Low prevalence (n = 55) | ||
| 22 Nocardia species: | 5/55 | 45 |
| -13 Nocardia species included in Bruker database (n = 28) | 5/23 | 45 |
| -9 Nocardia species not included in Bruker database (n = 27) | 0 | 0 |
| Total (%) | 5/55 (9.1%) | 45 |
| Diagnosis | Indication | Type of procedure |
| HLHS | Trans-isthmus gradient > 20 mmHg | Balloon angioplasty |
| DILV | SVC-LPA 2 mmHg gradient | LPA balloon angioplasty |
| TA | Significant LPA stenosis at X-ray angiography | LPA balloon angioplasty |
| PAIVS | Veno-venous collateral draining into the CS | Embolization |
| TA | Veno-venous collateral draining into the atrium | Embolization |
| Complex 2 ventricles | BTm shunt center opened at previous surgery | Embolization |
| Likelihood | ||||
| Covariate | WHO | Int 1 | Int 2 | Exact |
| Age (centered at 40 in y) | 0.968 (0.966–0.970) | 0.969 (0.967–0.971) | 0.968 (0.967–0.970) | 0.968 (0.967–0.970) |
| Alcohol intake (g/d) | 1.002 (0.999–1.004) | 1.003 (1.001–1.005) | 1.003 (1.001–1.004) | 1.002 (1.001–1.004) |
| Fruit and vegetables | ||||
| High | 1 | 1 | 1 | 1 |
| Low | 0.880 (0.824–0.940) | 0.928 (0.874–0.986) | 0.929 (0.878–0.983) | 0.929 (0.878–0.983) |
| Physical activity | ||||
| High | 1 | 1 | 1 | 1 |
| Moderate | 0.836 (0.774–0.903) | 0.850 (0.792–0.912) | 0.863 (0.808–0.921) | 0.862 (0.808–0.921) |
| Low | 0.695 (0.640–0.756) | 0.743 (0.688–0.802) | 0.769 (0.716–0.827) | 0.769 (0.716–0.826) |
| Education | ||||
| Mandatory | 1 | 1 | 1 | 1 |
| Secondary | 1.095 (0.992–1.209) | 1.252 (1.141–1.373) | 1.256 (1.150–1.371) | 1.254 (1.149–1.369) |
| Tertiary | 1.604 (1.441–1.786) | 1.760 (1.594–1.944) | 1.785 (1.625–1.961) | 1.781 (1.622–1.956) |
| Nationality | ||||
| Swiss | 1 | 1 | 1 | 1 |
| Foreign | 0.785 (0.728–0.848) | 0.832 (0.776–0.893) | 0.810 (0.758–0.864) | 0.809 (0.758–0.864) |
| Region | ||||
| German speaking | 1 | 1 | 1 | 1 |
| French speaking | 1.175 (1.091–1.266) | 1.147 (1.071–1.228) | 1.134 (1.063–1.208) | 1.133 (1.063–1.208) |
| Italian speaking | 1.190 (1.026–1.382) | 1.173 (1.024–1.344) | 1.236 (1.086–1.405) | 1.234 (1.085–1.403) |
| Total | SPM-Free | SPM | P-valuesc | ||||
| Variable | No. | % | No. | % | No. | % | |
| Total patients | 1,292 | 100 | 1,172 | 100 | 120 | 100 | |
| Age | |||||||
| ≤ median (57 years) | 668 | 51.7 | 629 | 53.7 | 39 | 32.5 | < 0.001 |
| > median (57 years) | 624 | 48.3 | 543 | 46.3 | 81 | 67.5 | |
| Sex | |||||||
| Male | 981 | 75.9 | 887 | 75.7 | 94 | 78.3 | 0.518 |
| Female | 311 | 24.1 | 285 | 24.3 | 26 | 21.7 | |
| Ethnicity | |||||||
| Non-Hispanic White | 1,093 | 84.6 | 999 | 85.2 | 94 | 78.3 | 0.050 |
| Other | 199 | 15.4 | 173 | 14.8 | 26 | 21.7 | |
| Smoking | |||||||
| Never | 346 | 26.8 | 321 | 27.4 | 25 | 20.8 | 0.122 |
| Ever | 946 | 73.2 | 851 | 72.6 | 95 | 79.2 | |
| Alcohol | |||||||
| Never | 337 | 26.1 | 310 | 26.4 | 27 | 22.5 | 0.348 |
| Ever | 955 | 73.9 | 862 | 73.6 | 93 | 77.5 | |
| Index Cancer Site | |||||||
| Oral cavity | 420 | 32.5 | 382 | 32.6 | 38 | 31.7 | 0.320 |
| Oropharynx | 575 | 44.5 | 527 | 45.0 | 48 | 40.0 | |
| Larynx/Hypopharynx | 297 | 23.0 | 263 | 22.4 | 34 | 28.3 | |
| Index Cancer Stage | |||||||
| I or II | 327 | 25.3 | 295 | 25.0 | 32 | 26.7 | 0.720 |
| III or IV | 965 | 74.7 | 877 | 75.0 | 88 | 73.3 | |
| Treatment | |||||||
| Surgery only | 230 | 17.8 | 209 | 17.8 | 21 | 17.5 | 0.894 |
| Surgery + Adjuvant Txa | 322 | 24.9 | 289 | 24.7 | 33 | 27.5 | |
| XRTb | 330 | 25.6 | 302 | 25.8 | 28 | 23.3 | |
| XRT + Chemotherapy | 410 | 31.7 | 372 | 31.7 | 38 | 31.7 |
| Equations for lean mass estimation (kg) | Equation number | r2 | Cp | p | RMSE (kg) | |
| M (n = 24) | 0.3BW + 3.0PC/TC – 0.003BW/RTL + 3.51 | 13 | 0.92 | 2.31 | =0.04 | 0.16 |
| F (n = 24) | −0.003BW/RTL + 0.11BL2/R + 0.40 | 14 | 0.83 | 0.45 | =0.04 | 0.17 |
| M and F (n = 48) | 0.2BW + 0.09BL2/R + 0.25 | 15 | 0.85 | 4.72 | =0.0001 | 0.21 |
| 0.04 BW + 0.07 BL2/R – 3.7SFLT + 0.17 | 16 | 0.87 | 2.65 | =0.05 | 0.20 | |
| T0 (n = 16) | 0.4BW + 0.08BL2/R - 0.05 | 17 | 0.86 | 4.23 | =0.05 | 0.22 |
| T1 (n = 16) | 0.3BW + 0.08BL2/R + 0.20 | 18 | 0.87 | 6.40 | =0.02 | 0.17 |
| T2 (n = 16) | 0.3BW – 2.71PC/TC – 0.004BW/RTL + 0.05BL2/R + 2.73 | 19 | 0.97 | 3.09 | =0.02 | 0.10 |
| Variable | OR (95% CI) | p-value |
| With Shared Epitope | 0.7 (0.3–1.3) | 0.25 |
| No Shared Epitope | 0.9 (0.3–2.6) | 0.90 |
| Duration > 10 | 0.9 (0.4–1.9) | 0.75 |
| Duration < 10 | 0.8 (0.3–2.0) | 0.66 |
| Patient Characteristic | Plasmodium knowlesi | Plasmodium vivax | Plasmodium falciparum | P Value |
| Children (age ≤12 y), No. (% total) | 44 (9.1) | 71 (41.3) | 31 (32.3) | <.001 |
| Age, y | ||||
| Median (IQR) | 8 (5–10) | 9 (5–10) | 7 (3–10) | .095 |
| Range | 0.1–12 | 0.67–12 | 1–12 | |
| Male sex, No. (%) | 25 (56.8) | 34 (47.9) | 21 (67.7) | .170 |
| Previous malaria (self-reported), No. (%) | 4 (9.1) | 11 (15.5) | 3 (9.7) | .526 |
| History of chronic disease, No. (%) | 2 (4.5) | 0 | 0 | .095 |
| Days of fever | 5 (3–7) | 5 (3–7) | 4 (3–5) | .751 |
| Symptoms on enrollment, No. (%) | ||||
| Rigors | 29 (65.9) | 55 (77.5) | 14 (45.2) | .006 |
| Headache | 34 (77.3) | 55 (77.5) | 21 (67.7) | .542 |
| Vomiting | 14 (31.8) | 37 (52.1) | 11 (35.5) | .068 |
| Abdominal pain | 19 (43.2) | 9 (12.7) | 9 (29.0) | .001 |
| Diarrhea | 4 (9.1) | 2 (2.8) | 4 (12.9) | .140 |
| Cough | 15 (34.1) | 25 (35.2) | 12 (38.7) | .914 |
| Shortness of breath | 3 (6.8) | 4 (5.6) | 4 (12.9) | .431 |
| Myalgia | 11 (25.0) | 15 (21.1) | 7 (22.6) | .890 |
| Arthralgia | 12 (27.3) | 15 (21.1) | 7 (22.6) | .746 |
| Examination findings on enrollment | ||||
| Temperature, °C | 37.1 (36.8–37.9) | 37.4 (36.8–37.8) | 37.1 (36.8–38) | .647 |
| Fever (≥37.5°C), No. (%) | 17 (38.6) | 33 (46.5) | 12 (38.7) | .634 |
| Systolic blood pressure, mm Hg | 101 (94–109) | 102 (96–110) | 106 (98–112) | .356 |
| Heart rate, beats/min | 104 (93–119) | 105 (94–118) | 117 (96–134) | .688 |
| Respiratory rate, breaths/min | 24 (22–27) | 24 (22–28) | 26 (24–28) | .081 |
| Oxygen saturation, % | 99 (99–100) | 99 (98–100) | 100 (99–100) | .504 |
| Palpable liver, No. (%) | 14 (31.8) | 20 (28.2) | 8 (25.8) | .842 |
| Palpable spleen, No. (%) | 9 (20.5) | 12 (16.9) | 2 (6.5) | .244 |
| Rash, No. (%) | 1 (2.3) | 0 (0) | 1 (3.2) | .360 |
| Parasite count/μL | 1722 (386–4830) | 5967 (1829–13901) | 7392 (1462–36546) | <.001 |
| Parasite count/μL, range | 36–74365 | 109–140500 | 61–635415 | |
| Schizont proportion, mean % (SD) | 3 (7.5) | 1 (4.0) | 0 (0) | .013 |
| Schizont proportion >10%, No. (%) | 3 (6.8) | 1 (1.5) | 0 (0) | .138 |
| Parasite count >20000/μL, No. (%) | 4 (9) | 8 (11) | 12 (39) | .001 |
| Gametocytes present, no./No. (%) | 4/35 (11) | 21/66 (32) | 1/11 (9) | .035 |
| Hemoglobin, g/dL | 10.6 (9.7–11.3) | 10.1 (9.3–11.2) | 10.3 (9.2–11.6) | .726 |
| Anemiaa (baseline), No. (%) | 36 (82) | 56 (79) | 21 (68) | .328 |
| G6PD deficiency present, no./No. (%) | 1/38 (2.6) | 3/69 (4.3) | 1/18 (5.6) | .852 |
| White blood cell count, × 103/μL | 6.1 (5.1–7.5) | 7.1 (5.1–8.6) | 9.2 (6.4–12.7) | .002 |
| Neutrophil count, × 103/μL | 2.7 (2.0–3.5) | 3.3 (2.5–4.8) | 3.8 (2.5–6.8) | .015 |
| Lymphocyte count, × 103/μL | 2.0 (1.4–2.7) | 2.2 (1.6–2.9) | 2.8 (1.7–5.0) | .025 |
| Monocyte count, × 103/μL | 1.1 (0.8–1.4) | 0.9 (0.6–1.3) | 1.2 (0.7–1.4) | .241 |
| Platelet count, × 103/μL | 106 (80–163) | 120 (93–179) | 159 (83–282) | .078 |
| Platelet nadir, × 103/μL | 78 (60–134) | 104 (70–154) | 129 (63–275) | <.001 |
| Platelet nadir, d | 1 (0–1) | 1 (0–1) | 1 (0–1) | 1.000 |
| Thrombocytopenia (platelets <150 × 103/μL), No. (%) | 30 (68) | 46 (65) | 13 (42) | .047 |
| Creatinine, μmol/L | 48 (36–57) | 48 (34–58) | 40 (31–53) | .267 |
| Urea, mmol/L | 3.8 (2.8–4.5) | 3.5 (3.0–4.6) | 3.2 (2.3–4.5) | .167 |
| Sodium, mmol/L | 137 (135–139) | 137 (136–139) | 136 (133–139) | .640 |
| Bilirubin, μmol/L | 11.5 (8.3–15.8) | 9.8 (6.0–14.6) | 11.0 (6.8–19.7) | .474 |
| Glucose, mmol/L | 5.8 (5.1–6.8) | 5.7 (5.0–6.4) | 6.2 (5.6–6.6) | .802 |
| Albumin, g/dL | 35 (31–37) | 34 (28–36) | 32 (29–37) | .644 |
| AST, IU/L | 25 (23–34) | 24 (15–28) | 37 (24–42) | .268 |
| ALT, IU/L | 16 (11–32) | 17 (11–28) | 24 (14–32) | .270 |
| Bicarbonate, mmol/L | 23 (21–25) | 22 (20–26) | 25 (21–26) | .418 |
| Acute kidney injury, No. (%) | 11 (26) | 7 (10) | 10 (32) | .016 |
| Blood culture positiveb, No. (%) | 0/33 (0) | 0/28 (0) | 0/15 (0) | 1.000 |
| Correlatesa | Unadjusted OR | ORa | 95% CI of the ORa | p-Value |
| Vegetarian/low calories diet versus mixed dietb | ||||
| Older age | 1.04 | 1.04 | 0.98–1.11 | 0.168 |
| Income level | 0.012 | |||
| Quartile 1 (reference) | 1.00 | |||
| Quartile 2 | 0.95 | 0.93 | 0.69–1.26 | 0.630 |
| Quartile 3 | 1.01 | 0.94 | 0.68–1.31 | 0.721 |
| Quartile 4 | 1.41 | 1.45 | 1.06–1.99 | 0.021 |
| Body mass index | 0.035 | |||
| Underweight (reference) | 1.00 | |||
| Normal weight | 1.25 | 1.41 | 0.96–2.07 | 0.076 |
| Overweight | 1.30 | 1.45 | 0.90–2.32 | 0.136 |
| Obese | 1.44 | 2.80 | 1.40–5.61 | 0.004 |
| Private versus public university | 1.18 | 1.23 | 0.96–1.57 | 0.099 |
| Higher physical activity level | 0.651 | |||
| No activity (reference) | 1.00 | |||
| Quartile 1 | 1.13 | 1.21 | 0.88–1.64 | 0.237 |
| Quartile 2 | 1.11 | 1.19 | 0.86–1.64 | 0.304 |
| Quartile 3 | 1.12 | 1.05 | 0.76–1.47 | 0.759 |
| Quartile 4 | 1.03 | 1.23 | 0.86–1.75 | 0.260 |
| Female versus male gender | 1.36 | 1.62 | 1.24–2.12 | <0.001 |
| Westernized diet versus mixed dietc | ||||
| Older Age | 0.78 | 0.98 | 0.93–1.04 | 0.534 |
| Income level | 0.468 | |||
| Quartile 1 (reference) | 1.0 | |||
| Quartile 2 | 0.95 | 0.90 | 0.68–1.17 | 0.422 |
| Quartile 3 | 1.21 | 1.06 | 0.80–1.41 | 0.693 |
| Quartile 4 | 1.23 | 1.12 | 0.84–1.49 | 0.458 |
| Body mass index | 0.616 | |||
| Underweight (reference) | 1.00 | |||
| Normal weight | 1.13 | 1.08 | 0.78–1.51 | 0.643 |
| Overweight | 1.25 | 0.96 | 0.63–1.45 | 0.835 |
| Obese | 1.35 | 1.36 | 0.73–2.53 | 0.335 |
| Private versus public university | 1.22 | 1.15 | 0.92–1.43 | 0.214 |
| Higher physical activity level | 0.038 | |||
| No activity (reference) | 1.00 | |||
| Quartile 1 Low physical activity | 0.73 | 0.75 | 0.56–1.00 | 0.046 |
| Quartile 2 moderate Physical activity | 0.74 | 0.63 | 0.47–0.86 | 0.003 |
| Quartile 3 high physical activity | 0.96 | 0.82 | 0.61–1.09 | 0.171 |
| Quartile 4 very high physical activity | 1.19 | 0.86 | 0.63–1.18 | 0.359 |
| Female versus male gender | 0.69 | 0.64 | 0.50–0.80 | <0.001 |
| Species | Family | Origin | Reference |
| Agrotis hephaestaea (Meyrick) | Noctuidae | Endemic | [49] |
| Ethmia nigroapicella (Saalmuller) | Oecophoridae | Adventive | [48] |
| Eudonia sp. | Crambidae | Endemic | [49] |
| Eupithecia monticolens Butler | Geometridae | Endemic | [49] |
| Fletcherana leucoxyla Meyrick | Geometridae | Endemic | [49] |
| Haliophyle euclidias Meyrick | Noctuidae | Endemic | [49] |
| Scotorythra arboricolans Butler | Geometridae | Endemic | [49] |
| Scotorytorythra caryopis Meyrick | Geometridae | Endemic | [48] |
| Scotorythra hecataea Meyrick | Geometridae | Endemic | [49] |
| Scotorythra pauludicola (Butler) | Geometridae | Endemic | [48] |
| Scotorythra rara Butler | Geometridae | Endemic | [49] |
| Scotorythra trapezias Meyrick | Geometridae | Endemic | [48] |
| Scotorythra spp. | Geometridae | Endemic | [49] |
| Spodalea recurvalis (Fabricius) | Crambidae | Adventive | [48] |
| Pseudaletia unipuncta (Haworth) | Noctuidae | Adventive | [48] |
| Spodoptera exempta (Walker) | Noctuidae | Adventive * | [48] |
| Spodoptera mauritia (Boisduval) | Noctuidae | Adventive | [48] |
| Spheretista pleonectes Walsingham | Tortricidae | Endemic | [49] |
| Udea stellata (Butler) | Crambidae | Endemic | [33] |
| No. | Mean | SD | |
| Management: General | |||
| 11 | Different approaches are used on this ward to manage patient aggression and violence. | 1.7 | 0.8 |
| 24 | Patient aggression could be handled more effectively on this ward. | 2.1 | 0.8 |
| Management: Use of medication | |||
| 16 | Medication is a valuable approach for treating aggressive and violent behaviour. | 2.3 | 0.9 |
| 25 | Prescribed medication can in some instances lead to patient aggression and violence. | 2.2 | 0.6 |
| 28 | Prescribed medication should be used more frequently to help patients who are aggressive and violent. | 2.4 | 0.9 |
| Management: Use of seclusion | |||
| 13 | When a patient is violent, seclusion is one of the most effective approaches to use. | 2.7 | 0.9 |
| 15 | The practice of secluding violent patients should be discontinued. | 3.0 | 0.8 |
| 27 | Seclusion is sometimes used more than necessary. | 2.5 | 0.9 |
| Management: Restraint | |||
| 14 | Patients who are violent are often restrained for their own safety. | 2.5 | 0.9 |
| 21 | Physical restraint is sometimes used more than necessary. | 2.4 | 0.9 |
| Management: Non-physical methods | |||
| 18 | Negotiation could be used more effectively when managing aggression and violence. | 1.9 | 0.7 |
| 20 | Expressions of aggression do not always require staff intervention. | 2.5 | 0.8 |
| 22 | Alternatives to the use of containment and sedation to manage patient violence could be used more frequently. | 2.1 | 0.7 |
| 29 | The use of de-escalation is successful in preventing violence. | 1.7 | 0.6 |
| Step | Push node | flow | Received node |
| 1 | S | ∞ | G1 |
| 2 | G1 | 1.83 | G6 |
| 3 | G1 | 0.69 | G3 |
| 4 | G3 | 0.69 | G7 |
| 5 | G6 | 1.83 | T |
| 6 | G7 | 0.69 | T |
| VITBRK2 | Growth characteristics |
| Growth under anaerobic conditions | Negative |
| Gram stain | Positive |
| Shape and growth | Long filamentous |
| Motility | Non-motile |
| Temperature range for growth | 25-37°C |
| Optimum temperature | 28°C |
| Range of pH for growth | 6-8 |
| Growth on MacConky plates | Negative |
| Growth in the presence of NaCl | 2-12 % |
| 2% | Positive |
| 5% | Positive |
| 7% | Positive |
| 9% | Positive |
| 12% | Positive |
| Aerial mass colour | Whitish grey |
| Melanoid pigments | Negative |
| Reverse side pigments | Negative |
| Soluble pigments | Negative |
| Spore chain | Spiral |
| Spore surface | Smooth |
| Arabinose | Positive |
| Xylose | Positive |
| Inositol | Positive |
| Mannitol | Positive |
| Fructose | Positive |
| Rhamnose | Negative |
| Sucrose | Positive |
| Raffinose | Positive |
| Spot no. | Mascot score | ID | Accession no. | Protein name | Mr/PI | SC | Description |
| H3(872) | 88 | FIBB | P02675 | Fibrinogen beta chain | 55/8.5 | 35 | N>P |
| H4(867) | 62 | FIBB | P02675 | Fibrinogen beta chain | 55/8.5 | 26 | N>P |
| H6(1026) | 72 | FIBB | P02675 | Fibrinogen beta chain | 55/8.5 | 29 | N>P |
| H7(1023) | 114 | TCPB | P78371 | T-complex protein 1 subunit beta | 57/6.0 | 41 | N>P |
| G11(1014) | 57 | FIBG | P02679 | Fibrinogen gamma chain | 51/5.3 | 18 | N>P |
| G13(1534) | 63 | SH319 | Q5HYK7 | SH3 domain-containing protein 19 | 86/8.5 | 11 | N>P |
| G15(812) | 61 | RARB | P10826 | Retinoic acid receptor beta | 50/8.0 | 11 | N>P |
| H16(1572) | 57 | GPX1 | P07203 | Glutathione peroxidase 1 | 21/6.1 | 23 | N>P |
| G1(791) | 86 | PDIA3 | P30101 | Protein disulfdte-isomerase A3 | 56/5.9 | 25 | P>N |
| H2(786) | 94 | PDIA3 | P30101 | Protein disulfide-isomerase A3 | 56/5.9 | 30 | P>N |
| G14(1317) | 70 | CAPZB | P47756 | F-actin-capping protein subunit beta | 31/5.3 | 26 | P>N |
| Components and processes | |
| National Performance Indicators | 52 National indicators spanning government priorities |
| • Governance | |
| • Prevention and early intervention, | |
| • Access | |
| • Integration | |
| • Chronic disease management | |
| Compulsory reporting against a subset of national indicators and choice in reporting against local programs | |
| PIs underpinned by a conceptual framework and technical details 4 levels of indicators from processes through to client outcomes | |
| Accreditation | Requirement for all Divisions to become accredited by June 2008 |
| Once accredited, Divisions no longer required to report on governance indicators | |
| Performance Assessment | Performance against indicators is to feed into individual performance appraisal |
| At the national level, analysis and benchmarking support comparison and provide an aggregated picture of performance | |
| Links to rewards (still to be determined) to reward high performance and support improvement |
| lncRNABLACAT1 | |||
| OR | 95% CI | P value | |
| PTC diagnosis | 0.887 | 0.833–0.982 | 0.013* |
| Model 1 | |||
| Lymph node metastasis | |||
| Model 1 | 0.596 | 0.459–0.805 | < 0.001** |
| Model 2 | 0.504 | 0.341–0.798 | 0.005* |
| Naive group | Treated patients | STI patients | |
| Number | 10 | 20 | 15 |
| Genders | |||
| Males | 5 | 8 | 8 |
| Females | 5 | 12 | 6 |
| Transsexuals | 1 | ||
| Mean years old | 42 | 42 | 43 |
| Geographic origin | |||
| Europeans | 5 | 12 | 12 |
| Other/Unknown | 5 | 8 | 3 |
| Mean range follow up | |||
| Yearsa | 4 (range 1 – 11) a | 7.5 (range 1 – 15)a | 6 (range 2 – 7) a |
| CD4+ count | |||
| cells × 106/l | Median 391 (range 109–805) | Median 338 (range 1 – 790) | Median 717 (range 216 – 1356) |
| <200 cells × 106/l (Number) b | 1 | 6 | 0 |
| Plasma HIV-RNA | |||
| Log10 copies/ml | Median 4.8 (range 2.7 – 5.4) | Median 4.4 (range 1.7 – 5.9) | Median 3.2 (range 1.7 – 4.7) c |
| <50 copies/ml (Number)b | 0 | 5 | 3 |
| HIV1-DNA | |||
| Log10 copies/106 CD4 cells | Median 3.0 (range 2.6 – 3.7) | Median 3.3 (range 2.2 – 4.6) | Median 2.9 (range 2.1 – 4.0) |
| <5 copies/PCR (Number) b | 6 | 12 | 5 |
| Attribute | Value | % of totala |
| Genome size (bp) | 4,071,168 | 100 |
| DNA cding region (bp) | 3,565,936 | 87.5 |
| DNA G+C content (bp) | 1,880,879 | 46.1 |
| Total number of genesb | 4095 | n/a |
| RNA genes | 116 | n/a |
| rRNA operons | 10 | n/a |
| Protein-coding genes | 3912 | 100 |
| CDSs with predicted functions | 3170 | 81 |
| Uncharacterized/Hypothetical genes | 742 | 18.1 |
| CDSs assigned to COGs | 3506 | 89.6 |
| CDSs with signal peptides | 302 | 7.7 |
| CDSs with transmembrane helices | 1012 | 25.8 |
| Parametersa | ND | HFD | HFD + ACG | HFD + QHD | HFD + RGZ |
| Body weight (g) | 29.69 ± 2.89 | 45.85 ± 2.23## | 34.69 ± 2.84∗∗ | 32.75 ± 2.66∗∗ | 33.54 ± 2.57∗∗ |
| Food intake (g/day) | 2.60 ± 0.09 | 2.77 ± 0.14 | 2.65 ± 0.10 | 2.62 ± 0.08 | 2.73 ± 0.08 |
| Liver weight (g) | 1.06 ± 0.10 | 2.45 ± 0.14## | 1.35 ± 0.38∗∗& | 1.56 ± 0.45∗∗ | 1.67 ± 0.43∗∗ |
| Liver/body weight ratio | 3.60 ± 0.37 | 5.36 ± 0.30## | 3.95 ± 1.39∗ | 4.78 ± 1.52 | 5.04 ± 1.46 |
| ALT (U/L) | 30.31 ± 7.54 | 91.65 ± 20.78## | 55.18 ± 13.66∗∗ | 71.98 ± 19.55 | 81.68 ± 20.5 |
| AST (U/L) | 20.42 ± 4.26 | 87.83 ± 18.26## | 60.46 ± 13.51∗∗ | 74.84 ± 11.91 | 82.44 ± 16.76 |
| I | II | III | IV | V | X | |||||||
| 4856 | 4858 | 4856 | 4858 | 4856 | 4858 | 4856 | 4858 | 4856 | 4858 | 4856 | 4858 | |
| Function | ||||||||||||
| Exon | ||||||||||||
| Insert | 9,942 | 91 | 16,423 | 334 | 10,263 | 156 | 11,219 | 6 | 8,645 | 112 | 11,106 | 437.11 |
| Deletion | 13825.97 | 78.05 | 17536.07 | 320.82 | 13684.02 | 192.04 | 15121.4 | 5.6 | 13436 | 93.73 | 11907.1 | 309.85 |
| bs | 19107.81 | 4110.87 | 41335.02 | 21232.1 | 19126.52 | 11330.5 | 12926.4 | 173.73 | 45618 | 1944.89 | 11563.6 | 6003.35 |
| syn | 9165.53 | 2406.68 | 19484.52 | 10292 | 7775.01 | 6870.87 | 5243.72 | 106.48 | 23642 | 876.37 | 5839.05 | 3192.57 |
| Total | 42876.05 | 4279.99 | 75293.76 | 21886.6 | 43073.55 | 11679.1 | 39267 | 184.94 | 67698 | 2151.1 | 34576.3 | 6750.32 |
| Intron | ||||||||||||
| Insert | 26409.16 | 435.8 | 20319.57 | 782.81 | 8397.01 | 867.75 | 13536.1 | 16.81 | 19268 | 201.52 | 14540.4 | 459.24 |
| Deletion | 11806.45 | 305.71 | 22268.03 | 648.06 | 26590.53 | 654.37 | 23657.7 | 16.81 | 11769 | 126.54 | 15570.8 | 520.11 |
| bs | 19263.15 | 5281.69 | 31731.94 | 14167.6 | 14306.02 | 10605 | 16828.7 | 173.73 | 36974 | 2371.36 | 14998.3 | 6877.58 |
| Total | 57478.76 | 6023.21 | 74319.54 | 15598.4 | 49293.56 | 12127.2 | 54022.6 | 207.36 | 68011 | 2699.41 | 45109.5 | 7856.92 |
| UTR | ||||||||||||
| Insert | 11495.75 | 695.99 | 21850.5 | 1803.03 | 11507.01 | 1322.96 | 8536.29 | 44.83 | 19789 | 243.7 | 7785.4 | 586.5 |
| Deletion | 24,079 | 852 | 17,675 | 1,655 | 23,325 | 1,046 | 15,487 | 22 | 16,456 | 248 | 18,662 | 580.97 |
| bs | 23457.55 | 6036.22 | 25747.41 | 18421.7 | 15239.02 | 11842.7 | 13658.1 | 263.4 | 31558 | 3791.37 | 10876.7 | 7137.63 |
| Total | 59032.24 | 7584.3 | 65273.15 | 21880.2 | 50071.06 | 14211.2 | 37681.6 | 330.65 | 67802 | 4283.45 | 37324.1 | 8305.1 |
| IG | ||||||||||||
| Insert | 23923.59 | 1144.8 | 28670.08 | 3054.24 | 11351.51 | 1856.42 | 27194.2 | 140.11 | 38432 | 328.05 | 34805.3 | 1593.52 |
| Deletion | 59032.24 | 787.05 | 44814.4 | 2771.91 | 23791.53 | 1593.25 | 58290.7 | 117.69 | 53950 | 313.99 | 49689.2 | 1659.91 |
| bs | 34021.21 | 9997.48 | 54556.66 | 39538.3 | 32966.04 | 20420.6 | 41827.8 | 1333.8 | 84675 | 5740.94 | 43277.7 | 22901.3 |
| Total | 116977.1 | 11929.33 | 128041.2 | 45364.4 | 68109.09 | 23870.2 | 127313 | 1591.6 | 177057 | 6382.99 | 127772 | 26154.7 |
| Suboptimal factors N (%) | All patients | ethnic Dutch | Surinamese/Antillean | 'Other non-western' |
| Education & Counselling | 11 (22.45) | 5 (33.33) | 3 (20.00) | 3 (15,79) |
| Prescriptions & types of inhalation devices | 13 (26.53) | 4 (26.67) | 2 (13.33) | 7 (36,84) |
| Routine follow-ups | 9 (18.37) | 3 (20.00) | 4 (26.67) | 2 (10,53) |
| Referrals and shared care* | 10 (20.41) | 2 (13.33) | 5 (33.33) | 3 (15,79) |
| Patient Compliance & effort undertaken to promote compliance | 4 (8.16) | 1 (6.67) | 1 (6.67) | 2 (10,53) |
| Other | 2 (4.08) | - | - | 2 (10,53) |
| Total number of factors (%) | 49 (100.0) | 15 (30.61) | 15 (30.61) | 19 (38,78) |
| Point | Stress shielding rate in the traditional prosthesis group (η%) | Stress shielding rate in the anatomic prosthesis group (η%) |
| 1 | 18.6 (1.6) | |
| 2 | 21.2 (2.1) | |
| 3 | 24.9 (1.9) | |
| 4 | 19.2 (1.7) | |
| 5 | 25.4 (2.0) | |
| 6 | 36.5 (1.8) | 28.3 (2.4) |
| 7 | 43.6 (2.6) | 31.4 (2.8) |
| 8 | 33.0 (2.9) | 26.3 (2.4) |
| 9 | 38.0 (3.1) | 27.0 (1.2) |
| 10 | 5.6 (0.8) | 3.7 (0.4) |
| 11 | 35.6 (2.3) | 22.7 (1.8) |
| 12 | 29.3 (2.6) | 18.4 (1.9) |
| 13 | 36.1 (2.9) | 18.7 (1.4) |
| 14 | 22.7 (1.8) | 15.1 (1.7) |
| 15 | 25.0 (1.6) | 18.5 (1.2) |
| 16 | 1.5 (0.2) | 1.41 (0.1) |
| 17 | 17.9 (1.9) | 10.3 (0.8) |
| 18 | 12.6 (1.1) | 4.3 (0.3) |
| Exercise | Control | P | ηp2 | |||
| Baseline | PI | Baseline | PI | |||
| MAP (mm Hg) | ||||||
| X | 96 | 90 | 98 | 96 | 0.160 | 0.05 |
| s.d. | 13 | 12 | 14 | 15 | ||
| pDBP (mm Hg) | ||||||
| X | 77 | 73 | 77 | 75 | 0.518 | 0.01 |
| s.d. | 10 | 10 | 9 | 11 | ||
| pSBP (mm Hg) | ||||||
| X | 134 | 125 | 140 | 138 | 0.046a | 0.09 |
| s.d. | 21 | 19 | 27 | 28 | ||
| cSBP (mm Hg) | ||||||
| X | 127 | 118 | 133 | 132 | 0.027a | 0.11 |
| s.d. | 19 | 17 | 26 | 28 | ||
| pPP (mm Hg) | ||||||
| X | 57 | 52 | 62 | 63 | 0.037a | 0.10 |
| s.d. | 14 | 12 | 22 | 24 | ||
| cPP (mm Hg) | ||||||
| X | 49 | 43 | 53 | 55 | 0.011a | 0.14 |
| s.d. | 13 | 10 | 21 | 23 | ||
| pSBP-cSBP (mm Hg) | ||||||
| X | 6.4 | 6.8 | 6.8 | 6.1 | 0.419 | 0.02 |
| s.d. | 4.9 | 3.7 | 4.8 | 4.4 | ||
| AIx (%) | ||||||
| X | 119 | 104 | 102 | 115 | 0.045a | 0.09 |
| s.d. | 47 | 49 | 43 | 67 | ||
| Heart rate (b.p.m.) | ||||||
| X | 59 | 59 | 65 | 62 | 0.406 | 0.02 |
| s.d. | 9 | 12 | 16 | 14 | ||
| DP | ||||||
| X | 7591 | 7429 | 7795 | 8685 | 0.468 | 0.01 |
| s.d. | 2359 | 1985 | 3737 | 3111 |
| All characters | Forrest-only | Jenny-only | ||||
| Audio-visual | Audio-only | Audio-visual | Audio-only | Audio-visual | Audio-only | |
| Dimensional emotion attributesArousalValenceDirection | 0.676 ±0.0060.851 ±0.0040.555 ±0.011 | 0.305 ±0.0780.564 ±0.0440.068 ±0.050 | 0.600 ±0.0080.784 ±0.0060.543 ±0.012 | 0.443 ±0.0780.440 ±0.054-0.059 ±0.072 | 0.688 ±0.0060.858 ±0.0030.576 ±0.012 | 0.330 ±0.0760.598 ±0.0790.053 ±0.145 |
| Emotion categoriesAdmirationAnger/RageCompassionContemptDisappoint.FearFears conf.GloatingGratificationGratitudeHappinessHappy-forHateHopeLovePrideReliefRemorseResentmentSadnessSatisfactionShame | 0.392 ±0.0060.719 ±0.0050.337 ±0.0100.433 ±0.0080.408 ±0.0080.749 ±0.0030.048 ±0.0090.644 ±0.0140.155 ±0.0100.317 ±0.0120.618 ±0.0060.478 ±0.0130.441 ±0.0110.333 ±0.0100.568 ±0.0080.473 ±0.0110.353 ±0.0190.557 ±0.022n/a0.737 ±0.0050.112 ±0.0070.316 ±0.006 | 0.343 ±0.0940.377 ±0.0420.182 ±0.0130.157 ±0.0430.367 ±0.0950.546 ±0.108n/a0.045 ±0.038n/an/a0.289 ±0.107n/a0.097 ±0.0700.217 ±0.0600.396 ±0.0320.156 ±0.054-0.003 ±0.0010.323 ±0.107n/a0.464 ±0.023n/a0.185 ±0.112 | 0.306 ±0.0150.693 ±0.0060.232 ±0.019n/a0.431 ±0.0070.729 ±0.004n/an/a0.242 ±0.0170.267 ±0.0240.561 ±0.0070.408 ±0.0280.478 ±0.0270.202 ±0.0080.472 ±0.0080.536 ±0.0090.505 ±0.028n/an/a0.750 ±0.005n/a0.290 ±0.006 | n/a0.141 ±0.100n/an/a0.456 ±0.1290.504 ±0.072n/an/an/an/a0.381 ±0.060n/an/an/a0.327 ±0.092n/an/a0.453 ±0.364n/a0.522 ±0.006n/a0.034 ±0.036 | n/a0.809 ±0.0070.459 ±0.0180.404 ±0.020n/a0.633 ±0.005n/an/an/a0.165 ±0.0150.738 ±0.005n/an/a0.439 ±0.0260.660 ±0.009n/an/a0.464 ±0.006n/a0.695 ±0.009n/a0.201 ±0.015 | 0.643 ±0.1970.626 ±0.1090.363 ±0.042n/an/a0.392 ±0.013n/an/an/an/a0.532 ±0.108n/an/a0.804 ±0.0520.432 ±0.040n/an/an/an/a0.228 ±0.040n/an/a |
| Emotion onset cuesAudioContextFaceGestureNarratorVerbal | 0.418 ±0.0080.384 ±0.0100.713 ±0.0060.619 ±0.010n/a0.637 ±0.008 | 0.037 ±0.051n/an/an/a0.251 ±0.0470.368 ±0.107 | 0.354 ±0.0130.424 ±0.0110.687 ±0.0100.532 ±0.011n/a0.565 ±0.007 | n/an/an/an/a0.202 ±0.0450.455 ±0.042 | 0.203 ±0.0070.547 ±0.0100.880 ±0.0040.769 ±0.009n/a0.783 ±0.005 | n/an/an/an/a0.578 ±0.2860.626 ±0.168 |
| Domain | SED PAQ | SED ACC | LPA PAQ | LPA ACC | MVPA PAQ | MVPA ACC | ||||||
| Mean (SD) | % (Day) | Mean (SD) | % (Day) | Mean (SD) | % (Day) | Mean (SD) | % (Day) | Mean (SD) | % (Day) | Mean (SD) | % (Day) | |
| Transport (min/day) | 3 (9) | 1 | 13 (6) | 3 | 20 (13) | 11 | 11 (4) | 5 | 2 (7) | 1 | 7 (4) | 7 |
| School time (min/day) | 247 (114) | 52 | 271 (38) | 55 | 50 (41) | 27 | 103 (22) | 53 | 35 (39) | 20 | 41 (14) | 46 |
| Physical education (min/week) | 36 (42) | 1 | 66 (44) | 2 | 17 (50) | 2 | 50 (28) | 4 | 116 (72) | 13 | 39 (23) | 8 |
| Leisure time (min/day) | 183 (94) | 39 | 182 (50) | 37 | 98 (70) | 56 | 56 (16) | 29 | 49 (57) | 30 | 21 (9) | 23 |
| Organized sports activities (min/week) | 56 (39) | 7 | 41 (36) | 4 | 12 (41) | 4 | 37 (27) | 9 | 100 (80) | 35 | 32 (28) | 16 |
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | |
| 1. Playfulness | – | 013 | −001 | 406** | 396** | −295** | 289** | 308** | 361** | 402** |
| 2. Disruptive (SR) | 009 | – | 298** | −299** | 256* | −317** | 043 | 041 | 019 | 283** |
| 3. Disruptive (PR) | −010 | 225* | – | −258* | 097 | −306** | −307** | 046 | 155* | 362** |
| 4. Disruptive (TR) | 018 | 279** | −236* | – | 362** | −405** | −328** | −015 | 313** | 340** |
| 5. Social competence (SR) | 107 | −105 | −102 | 008 | – | −326** | 288** | −014 | 290** | −296** |
| 6. Social competence (TR) | −031 | −287** | −405** | −279** | 284** | – | −264* | −023 | 279* | −311** |
| 7. Social status (PR) | 156* | −104 | −089 | −213* | 062 | −295** | – | 088 | 275* | −288** |
| 8. Class clown (SR) | 019 | 007 | 061 | 245* | 027 | −039 | 068 | – | 296** | 315** |
| 9. Class clown (PR) | 004 | 095 | 273** | 256* | 091 | −088 | 310** | 297** | – | −322** |
| 10. Class clown (TR) | −023 | 276** | 288** | 278** | 046 | −294** | 335** | 023 | −288** | – |
| Position | δH mult (J Hz) | δC mult | HMBC |
| 1 | 195.5, C | 2 | |
| 2 | 3.70, d (2.4) | 68.4, CH | |
| 3 | 3.86, ddd (7.2, 1.9, 1.9) | 72.5, CH | 2, 4, 5 |
| 4 | 1.51, m; 1.24, m | 32.1, CH2 | 2, 3 |
| 5 | 3.42, m; 2.71, t (12.0) | 37.9, CH2 | 3 |
| 6-NH | 8.43, s | ||
| 7 | 168.9, C | 5, 8, 9 | |
| 8 | 5.76, dd (11.4, 2.8) | 124.8, CH | 10 |
| 9 | 6.02, ddd (11.4, 11.4, 2.6) | 141.8, CH | 10 |
| 10 | 3.53, m; 2.09, m | 25.9, CH2 | 8 |
| 11 | 1.35, m | 50.3, CH | 9, 10, 20, 22, 23 |
| 12 | 2.51, m | 43.4, CH | 10, 14 |
| 13 | 5.62, ddd (9.9, 2.8, 2.8) | 129.6, CH | |
| 14 | 5.83, dt (10.0, 2.1) | 131.9, CH | |
| 15 | 1.48, m | 48.4, CH | 13, 14, 19 |
| 16 | 1.29, m | 48.5, CH | 17, 30 |
| 17 | 2.20, m | 34.3, CH | 18, 29, 30 |
| 18 | 2.05, m; 0.63, ddd (11.9, 11.8, 6.8) | 39.9, CH2 | 19, 29 |
| 19 | 1.08, m | 50.4, CH | 14, 18, 21 |
| 20 | 2.00, m | 43.2, CH | 13, 18, 21 |
| 21 | 2.01, m; 1.10, m | 38.1, CH2 | 19, 22, 23 |
| 22 | 2.32, m | 49.6, CH | 21, 23, 24 |
| 23 | 6.47, dd (15.1, 10.0) | 147.8, CH | 21, 22 |
| 24 | 7.30, d (15.2) | 130.4, CH | 22 |
| 25 | 184.7, C | 23, 24 | |
| 26 | 102.8, C | ||
| 27 | 179.9, C | 2 | |
| 28-NH | 8.43, s | ||
| 29 | 0.81, d (6.0) | 18.1, CH3 | 17, 18 |
| 30 | 1.42, m; 1.30, m | 22.7, CH2 | 16, 31 |
| 31 | 0.87, t (7.1) | 13.7, CH3 | 30 |
| Data Type | Control | Cold | Freezing | |||
| Total Reads | Unique Reads | Total Reads | Unique Reads | Total Reads | Unique Reads | |
| Clean reads | 10,823,011 | 4,415,425 | 10,833,023 | 4,746,716 | 10,781,132 | 4,296,444 |
| Rfam | 229,925 | 18,696 | 400,604 | 28,495 | 1,947,224 | 38,460 |
| Transcriptome | 4,933,169 | 1,201,107 | 4,509,305 | 1,232,313 | 3,892,472 | 1,219,439 |
| Known miRNA | 1,597,215 | 24,334 | 1,287,494 | 27,292 | 987,515 | 24,278 |
| Novel miRNA | 172,273 | 1355 | 82,573 | 1121 | 62,290 | 944 |
| Treatment phase | Parameter | Experts | Faesibility study [28] | |||
| Unit | Median | Min | Max | Median | ||
| Positioning | Time patient verification | min | 15 | 10 | 25 | 11.5 |
| Time verification reachability | min | 15 | 7 | 20 | 14.5 | |
| Time target definition | min | 8 | 5 | 15 | n/a | |
| Chance of repositioning | - | 0.30 | 0.10 | 0.75 | n/a | |
| Test | Time to place navigator | min | 2 | 1 | 10 | 1 |
| Time MRI scan | min | 2.5 | 1 | 15 | 2.5 | |
| Time for treatment planning | min | 2 | 1 | 5 | n/a | |
| Time to fill LUT | min | 2.75 | 0 | 5 | n/a | |
| Test sonication and check focal point | min | 3 | 1 | 5 | 4 | |
| Chance of adjustment focal point per coronal plane | - | 0.55 | 0.20 | 0.90 | n/a | |
| Therapeutic | Time therapeutic phase | min | 0.50 | 0.25 | 0.75 | n/a |
| Cooling time after each sonication | min | 3.5 | 1 | 10 | n/a | |
| Chance of abortion per coronal plane | - | 0,10 | 0,05 | 0,20 | n/a | |
| Chance of resonication per coronal plane | - | 0.20 | 0.10 | 0.30 | n/a | |
| Post-treatment | Time clinical ward | min | 240 | 120 | 300 | n/a |
| Chance of complications | - | 0.015 | 0.01 | 0.03 | n/a |
| Symbol | Definition | Theory | Experiment |
| PRR | Packet Reception Rate | Varying | Varying |
| BER | Bit Error Rate | Varying | Varying |
| SNR | Signal to Noise Ratio | Varying | Varying |
| RSSI | Receiver Signal Strength Indicator | Varying | Varying |
| fdata | Date frame size in bits | 272 | 272 |
| fack | ACK frame size in bits | 64 | 64 |
| Eb | The average energy per bit | Varying | Varying |
| N0 | Noise power spectral density | Varying | Varying |
| R | Data bit rate | 1.2 to 152 kbps | 9.6, 20, 38, 76 kbps |
| B | Channel bandwidth | Varying | Varying |
| N | Channel noise power | Varying | Varying |
| k | Boltzmann’s constant | 1.38 × 10−23 J/K | 1.38 × 10−23 J/K |
| T | Effective temperature in Kelvin | Varying | Varying |
| E | Node energy consumption | Varying | Varying |
| n | The number of neighbors | 10 | 1 |
| Pl | Power in listening | 2.85 mA | 2.85 mA |
| Ptx | Power in transmitting | 25.4 mA | 25.4 mA |
| Prx | Power in receiving | 15.1 mA | 15.1 mA |
| tl | Listening time | 11 ms | 11 ms |
| ttone | Polling time | 12 ms | 12 ms |
| α | One hop link reliability requirement | 1 | 1 |
| Prognostic-risk group | Cytogenetic profile alone | Cytogenetic profile and molecular abnormalities |
| Favorable | t(8:21)(q22; q22)inv(16)(p13; 1q22)t(15;17)(q22; q12) | t(8:21)(q22; q22) with no c-KIT mutationinv(16)(p13; 1q22)t(15;17)(q22; q12)Mutated NPM1 without FLT3-ITD (CN-AML)Mutated biallelic CEBPA (CN-AML) |
| Intermediate | CN-AMLt(9;11)(p22; q23)Cytogenetic abnormalities not included in the favorable or adverse prognostic risk groups | t(8:21)(q22;q22) with mutated c-KITCN-AML other than those included in the favorable or adverse prognostic groupt(9;11)(p22; q23)Cytogenetic abnormalities not included in the favorable or adverse prognostic risk groups |
| Adverse | inv(3)(q21q26.2)t(6;9)(p23; q34)11q abnormalities other than t(9;11)−5 or del(5q)−7Complex karyotype | TP53 mutation, regardless of cytogenetic profileCN with FLT3-ITDCN with DNMT3ACN with KMT2A-PTDinv(3)(q21q26.2)t(6;9)(p23;q34)11q abnormalities other than t(9;11)−5 or del(5q)−7Complex karyotype |
| Age Groups (Years) | No. of Samples | Specific activities of DBH (pmol/men/mg protein)a | |
| Normal | Arsenicosis Patient | ||
| Group 1 (10-18) | 9 | 376.4 ± 79.6 | 190.2 ± 57.0b |
| Group 2 (20-40) | 14 | 427.5 ± 60.2 | 348.8 ± 74.7c |
| Group 3 (45-70) | 9 | 399.6 ± 86.7 | 415.7 ± 85.1d |
| Geographical regions and environmental variables | Malkangiri (Non-coastal) | Puri (Coastal) |
| Physical components | ||
| Temperature (Maximum, Minimum) | 47 °C, 11 °C | 36 °C, 13 °C |
| Average yearly rainfall in mm | 1465 | 1586 |
| Natural components | ||
| Height from the sea level in metres | 196 | 6 |
| Forest cover in percentage | 38 | 3 |
| Social components | ||
| Total population in million | 0.61 | 1.69 |
| Population Density per Sq. Km | 106 | 488 |
| Literacy Rate in percentage | 49 | 85 |
| Independent variables | Total N | Children with DHN (%) | PR (95% CI) | P* |
| Age (cont.) | 0.97(0.78 to 1.19) | 0.784 | ||
| Sex | ||||
| (ref.: male) | 26 | 11 (42.3) | 1.00 | 0.923 |
| Female | 22 | 9 (40.9) | 0.97(0.49 to 1.91) | |
| Dental erosion | ||||
| (ref.: absent) | 24 | 6 (25.0) | 1.00 | 0.033 |
| Present | 24 | 14 (58.3) | 2.33(1.07 to 5.09) | |
| Bitter taste | ||||
| (ref.: no) | 39 | 13 (33.3) | 1.00 | 0.004 |
| Yes | 9 | 7 (77.8) | 2.33(1.32 to 4.13) | |
| Temperature of soft drink | ||||
| (ref.: room temperature) | 19 | 9 (47.4) | 1.00 | 0.517 |
| Cold/iced | 29 | 11 (37.9) | 0.80(0.41 to 1.57) | |
| Usual drinking method | ||||
| (ref.: Swallowing immediately) | 39 | 14 (35.9) | 1.00 | 0.054 |
| Holding the beverage in the mouth before swallowing | 9 | 6 (66.7) | 1.86(0.99 to 3.49) | |
| Simplified Oral Hygiene Index (cont.) | 0.47(0.24 to 0.94) | 0.033 |
| Variable | Number of TRBs (n = 43) | Odds ratio† | 95% CI |
| Male | 28 | 1.0 | 0.7-1.4 |
| Age ≥65 years | 6 | 5.3 | 3.7-7.6 |
| Travel region‡ | 7 | 18.4 | 6.9-49.5 |
| Sub-Saharan Africa | 2 | 10.6 | 2.1-53.2 |
| Middle East | 14 | 4.0 | 2.2-7.5 |
| South East Asia |
| Species | Fructose | Mannitol | Sucrose | Trehalose | Total sugars |
| (g/100 g fresh weight) | |||||
| Agaricus bisporus | 0.03 | 5.6 | nd | 0.16 | 5.79 |
| Lentinus edodes | 0.69 | 10.01 | nd | 3.38 | 14.03 |
| Pleurotus ostreatus | 0.01 | 0.54 | nd | 4.42 | 4.97 |
| Pleurotus eryngii | 0.03 | 0.60 | 0.03 | 8.01 | 8.67 |
| Dry powder formulations | |||||
| Agaricus blazei | 0.27 | 60.89 | nd | 5.74 | 66.91 |
| Lentinus edodes | nd | 23.3 | nd | 13.22 | 38.31 |
| Antimicrobial agent | MIC |
| Cefazolin | > 16 |
| Ampicillin/sulbactam | 8 |
| Ceftriaxone | ≦ 0.5 |
| Cefepime | ≦ 0.5 |
| Gentamicin | ≦ 1 |
| Levofloxacin | ≦ 0.25 |
| Imipenem | ≦ 0.5 |
| Meropenem | ≦ 0.5 |
| Piperacillin/tazobactam | ≦ 2 |
| Trimethoprim/sulfamethoxazole | ≦ 5 |
| Clinical analysis | Number | Percentage (%) |
| Clinical phenotype | 212 | |
| DMD | 148 | 69.81% |
| BMD | 52 | 24.53% |
| IMD | 12 | 5.66% |
| Blood test | 190 | |
| Testing for Crn level | 190 | 100% |
| Testing for cystatin C level | 190 | 100% |
| Vignos scale | 187 | |
| Degree (1–6) | 173 | 92.51% |
| Degree (7–9) | 14 | 7.49% |
| Mutation analysis | 195 | |
| Large rearrangements | 136 | 69.74% |
| Smaller mutations | 42 | 21.54% |
| No large rearrangements | 17 | 8.72% |
| Noise type | Noise reduction technique | Noise intensity (dB) | ||||||
| 20 | 18 | 16 | 14 | 12 | 10 | 8 | ||
| Gaussian | Wavelet | 90.71 | 90.00 | 90.36 | 87.86 | 88.57 | 86.07 | 71.79 |
| Contourlet | 89.29 | 88.57 | 87.50 | 87.51 | 78.93 | 65.00 | 44.64 | |
| TV | 87.14 | 89.64 | 86.79 | 85.00 | 72.21 | 37.89 | 25.12 | |
| WVTV | 87.14 | 86.43 | 86.43 | 85.71 | 86.79 | 87.14 | 85.16 | |
| Rayleigh | Wavelet | 90.36 | 89.64 | 89.64 | 91.43 | 89.64 | 87.86 | 88.57 |
| Contourlet | 89.64 | 88.57 | 88.57 | 86.07 | 89.29 | 84.64 | 72.36 | |
| TV | 87.86 | 87.86 | 85.36 | 88.57 | 85.43 | 87.59 | 51.25 | |
| WVTV | 86.43 | 86.79 | 87.86 | 85.00 | 86.79 | 86.07 | 83.57 | |
| Exponential | Wavelet | 90.00 | 90.00 | 88.93 | 88.21 | 88.21 | 88.21 | 77.14 |
| Contourlet | 90.36 | 87.14 | 87.86 | 84.29 | 72.50 | 61.84 | 48.25 | |
| TV | 90.71 | 89.29 | 87.50 | 86.07 | 82.86 | 75.00 | 62.37 | |
| WVTV | 85.71 | 85.36 | 85.36 | 85.71 | 84.29 | 85.57 | 83.93 |
| Swiss Prot Acc. No. | Symbol | Entrez Gene Name | Fold Change | Location | Protein Class |
| P08758 | ANXA5 | annexin A5 | -1.98 | Plasma membrane | transfer/carrier protein |
| Q07507 | DPT | dermatopontin | -2.15 | Extracellular space | extracellular matrix binding protein |
| Q96KK5 | HIST1H2AH | histone cluster 1, H2ah | -2.85 | Nucleus | histone |
| P02545 | LMNA | lamin A/C | -1.85 | Nucleus | structural protein |
| P62937 | PPIA | peptidylprolyl isomerase A (cyclophilin A) | -1.64 | Cytoplasm | isomerase |
| P18124 | RPL7 | ribosomal protein L7 | -1.82 | Cytoplasm | ribosomal protein |
| P62917 | RPL8 | ribosomal protein L8 | -1.76 | Cytoplasm | ribosomal protein |
| Primer | Sequence (5′-3′) |
| FLAG-NS1-F | CAGAATTCTAATGGATTCCAACACTGTG (EcoRI) |
| FLAG-NS1-R | GGGGTACCCACTTCTGACTCAATTGTTC (KpnI) |
| HA-ANXA2-F | GGGGTACCCCGTCTACTGTTCACGAAATCCTG (KpnI) |
| HA-ANXA2-R | GAAGATCTTCGTCATCTCCACCACACAGGTA (BglII) |
| ANXA2-159F | TGGATGAGGTCACCATTGTCA |
| ANXA2-159R | TCAATAGGCCCAAAATCACC |
| GAPDH-F | GGCATCCTGGGCTACACTGA |
| GAPDH-R | TGTTGCTGTAGCCAAATTCGTT |
| Stabilizer | DLC (%) | EE (%) | |
| Abm-NPs-1 | PLGA-b-PEG | 41.46 ± 0.05 | 96.74 ± 0.12 |
| Abm-NPs-2 | PLA-b-PEG | 40.97 ± 0.05 | 95.60 ± 0.11 |
| Abm-NPs-3 | PCL-b-PEG | 40.76 ± 0.03 | 95.10 ± 0.07 |
| All childrena (n = 838) | Female (n = 405) | Male (n = 433) | |
| Frequency (%) | Frequency (%) | Frequency (%) | |
| No. of years of schooling (y) | |||
| 0 | 14 (1.7) | 6 (1.5) | 8 (1.8) |
| 1 | 40 (4.8) | 20 (4.9) | 20 (4.6) |
| 2 | 89 (10.6) | 41 (10.1) | 48 (11.1) |
| 3 | 201 (24.0) | 106 (26.2) | 95 (21.9) |
| 4 | 241 (28.8) | 118 (29.1) | 123 (28.4) |
| 5 | 187 (22.3) | 76 (18.8) | 111 (25.6) |
| 6 | 62 (7.4) | 35 (8.6) | 27 (6.2) |
| 7 | 4 (0.5) | 3 (0.7) | 1 (0.2) |
| Schooling years, categorized | |||
| ≤2 y | 143 (17.1) | 67 (16.5) | 76 (17.6) |
| 3+ y | 695 (82.9) | 338 (83.5) | 357 (82.4) |
| Model 1 | Model 2 | Model 3 | ||||
| Explanatory variables | OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P |
| PTH | 1.69 (1.12–2.56) | 0.013 | 2.25 (1.34–3.78) | 0.002 | 2.62 (1.52–4.53) | 0.001 |
| 25(OH)D | 0.86 (0.62–1.20) | 0.383 | 0.96 (0.65–1.44) | 0.860 | 1.06 (0.69–1.63) | 0.783 |
| Magnesium | 0.02 (0.00–0.15) | <0.001 | 0.04 (0.00–0.47) | 0.010 | 0.22 (0.02–2.54) | 0.224 |
| Transposon | Primer 5'-3' | Tm (°C) |
| IAP-RTF1 | TCAAGGACAGGGTATTGTTG | For reverse transcription |
| IAP-RTR2 | TATTGACGCCCTGGACATCAC | For reverse transcription |
| IAP-PCRF3 | GGGTATTGTTGAGCGTGCGC | 56 |
| IAP-PCRR4 | TCGGGTGAGTCTTTCTGGTAC | 56 |
| MuERV-RTF1 | CAAAGTGGCCATGGTGGTCG | For reverse transcription |
| MuERV-RTR2 | GTACCATATATCGAGCGCTG | For reverse transcription |
| MuERV-PCRF3 | TGCTTGGGCTCAGCAACATGG | 56 |
| MuERV-PCRR4 | GACAGAATGCCTCATCTATCGT | 56 |
| Variable | Deceased patientsn = 91 | Surviving patientsn = 1660 | P value |
| Age [years (mean ± SD)] | 54 ± 17 | 45 ± 15 | <0.0001 |
| Male gender [n (%)] | 46 (51) | 766 (46) | 0.42 |
| SAPS II score, points (mean ± SD) | 69 ± 21 | 36 ± 15 | <0.0001 |
| Mental disorder [n (%)] | |||
| Schizophrenia | 3 (3) | 94 (6) | 0.48 |
| Non-schizophrenia psychiatric disorder | 16 (21) | 218 (13) | 0.04 |
| Depression disorder | 50 (55) | 1008 (60) | 0.27 |
| Bipolar disorder | 12 (13) | 160 (10) | 0.26 |
| Anxiety disorder | 7 (8) | 180 (11) | 0.48 |
| Substance dependence (alcohol and/or drug addiction) | 14 (15) | 478 (29) | 0.003 |
| Transfer from psychiatric hospital or ward [n (%)] | 14 (15) | 116 (7) | 0.003 |
| Psychoactive medication before admission [n (%)] | |||
| None | 9 (10) | 189 (11) | 0.66 |
| Benzodiazepines | 58 (64) | 1138 (68) | 0.33 |
| Neuroleptics | 26 (28) | 471 (28) | 0.97 |
| Antipsychotics other than neuroleptics | 10 (11) | 165 (10) | 0.74 |
| Lithium | 3 (3) | 78 (5) | 0.53 |
| SSRIs | 18 (20) | 402 (24) | 0.33 |
| SNRIs | 1 (1) | 33 (2) | 0.55 |
| Tri- or tetracyclics antidepressants | 11 (12) | 215 (13) | 0.81 |
| MAOIs | 8 (9) | 140 (8) | 0.90 |
| Reason for admission [n (%)] | |||
| Deliberate self-poisoning with psychoactive medications | |||
| Alone | 15 (16) | 1067 (64) | <0.0001 |
| And/or with non-psychoactive medications | 10 (11) | 129 (8) | 0.27 |
| And/or with pesticides, household, or industrial products | 0 (0) | 28 (2) | 0.40 |
| And/or with hanging, drowning, jumping from buildings, or corrosive chemicals ingestion | 13 (14) | 18 (1) | <0.0001 |
| Respiratory failure | 14 (15) | 151 (9) | 0.06 |
| Shock | 15 (16) | 50 (3) | <0.0001 |
| CNS or peripheral disorder | 6 (7) | 76 (6) | 0.31 |
| Metabolic disorder | 1 (1) | 52 (3) | 0.52 |
| Out-of-hospital cardiac arrest | 14 (15) | 4 (0.2) | <0.0001 |
| Acute kidney injury | 0 (0) | 13 (0.5) | 0.99 |
| Non-deliberate psychoactive medication overdose | 2 (2) | 42 (2.5) | 0.99 |
| Miscellaneous | 3 (3) | 30 (2) | 0.24 |
| Chemical pneumonitis and/or aspiration pneumonia [n (%)] | 28 (31) | 451 (27) | 0.45 |
| Organ support in the ICU [n (%)] | |||
| Invasive mechanical ventilation | 91 (100) | 1115 (67) | <0.0001 |
| Vasopressors | 84 (92) | 294 (18) | <0.0001 |
| Renal replacement therapy | 38 (42) | 138 (8) | <0.0001 |
| Acquired infection at any site | 14 (15) | 50 (3) | <0.0001 |
| Overweight* | Body fat (%)+ | Lean body mass (kg)+ | |
| Birth weight (z) | 1.13 (1.03 to 1.25) | 0.03 (−0.26 to 0.32) | 1.66 (1.36 to 1.95) |
| P for trend | 0.01 | 0.8 | <0.001 |
| Ponderal index (z) | 1.12 (1.01 to 1.23) | 0.28 (−0.01 to 0.57) | 0.40 (0.10 to 0.71) |
| P for trend | 0.03 | 0.05 | 0.008 |
| Placental weight (z) | 1.07 (0.97 to 1.18) | 0.02 (−0.28 to 0.31) | 0.99 (0.69 to 1.29) |
| P for trend | 0.2 | 0.9 | <0.001 |
| Max placental diam (z) | 1.04 (0.94 to 1.14) | 0.00 (−0.30 to 0.29) | 0.64 (0.34 to 0.95) |
| p for trend | 0.5 | 1.0 | <0.001 |
| Lesser placental diam (z) | 1.07 (0.97 to 1.18) | 0.09 (−0.20 to 0.39) | 0.69 (0.39 to 1.00) |
| P for trend | 0.2 | 0.5 | <0.001 |
| Placental area (z) | 1.05 (0.95 to 1.15) | 0.05 (−0.24 to 0.34) | 0.69 (0.39 to 0.99) |
| P for trend | 0.4 | 0.7 | <0.001 |
| Comorbidities | ICD-9-CM codes |
| Schizophrenia | 295.XX |
| Bipolar disorder | 296.01, 296.02, 296.03, 296.04, 296.05, 296.06, 296.40, 296.41, 296.42, 296.43, 296.44, 296.45, 296.46, 296.50, 296.51, 296.52, 296.53, 296.54, 296.55, 296.56, 296.60, 296.61, 296.62, 296.63, 296.64, 296.65, 296.66, 296.7, 296.80, 296.89 |
| Major depressive disorder | 296.2X, 296.3X, 311.XX |
| Substance abuse | 296.5x, 303.xx–305.xx |
| Hypertension | 401–405 |
| Hyperlipidemia | 272.2–272.4 |
| Diabetes | 250.XX |
| Chronic obstructive pulmonary disease | 490–496, 500–505, 506.4 |
| Paper | CMR parametersa | Description of aneurysm |
| Contreras et al. [18] | Steady-state free precession | None provided |
| Corti et al. [12] | Turbo field-echo movie reconstruction | Dimensions: 7 × 5 × 3.5 cm2.8 cm ostiumRight ventricular compressionSysto-diastolic filling of the mass consistent with right atrial filling |
| Duran et al. [21] | Not specified | Dimensions: 2.5 × 1.5 cm over the tricuspid valveNeck: 11 mmNo thrombus |
| Guaricci et al. [10] | Not specified | Above tricuspid valve, overlapping with the RV and outflow tract with pulmonary artery |
| Gulati et al. [15] | Cine imaging using balanced steady-state free precession sequence | Mild tricuspid regurgitationNoncontractile, smooth-walled, pyramidal RAA extending anterior to the body of the right atriumPartially separated from the main atrial chamber by a membraneRight atrial volume 118 mL/m2Mild distortion of the RV but no compression |
| Le Ven et al. [22] | Not specified | None provided |
| Sondhi et al. [17] | Not specified | Magnetic resonance imaging of the heart and vessels confirmed the connection of the aneurysm to the RAA and also showed slight compression of the descending thoracic aorta by aneurysm |
| Xu et al. [8] | None described | None provided |
| Chrom | Chrom length | # genes | gene density | # differentially expressed | % differentially expressed | up in ko | down in ko | fraction up in ko |
| 1 | 197195432 | 1272 | 155028 | 412 | 32.4 | 134 | 278 | 0.33 |
| 2 | 181748087 | 1942 | 93588 | 555 | 28.6 | 187 | 368 | 0.34 |
| 3 | 159599783 | 1071 | 149019 | 306 | 28.6 | 98 | 208 | 0.32 |
| 4 | 155630120 | 1410 | 110376 | 402 | 28.5 | 151 | 251 | 0.38 |
| 5 | 152537259 | 1339 | 113919 | 424 | 31.7 | 140 | 284 | 0.33 |
| 6 | 149517037 | 1149 | 130128 | 363 | 31.6 | 120 | 243 | 0.33 |
| 7 | 152524553 | 2026 | 75284 | 426 | 21.0 | 207 | 219 | 0.49 |
| 8 | 131738871 | 1121 | 117519 | 318 | 28.4 | 102 | 216 | 0.32 |
| 9 | 124076172 | 1289 | 96258 | 372 | 28.9 | 129 | 243 | 0.35 |
| 10 | 129993255 | 1042 | 124754 | 319 | 30.6 | 117 | 202 | 0.37 |
| 11 | 121843856 | 1748 | 69704 | 490 | 28.0 | 182 | 308 | 0.37 |
| 12 | 121257530 | 733 | 165426 | 270 | 36.8 | 63 | 207 | 0.23 |
| 13 | 120284312 | 882 | 136377 | 253 | 28.7 | 85 | 168 | 0.34 |
| 14 | 125194864 | 879 | 142429 | 251 | 28.6 | 79 | 172 | 0.31 |
| 15 | 103494974 | 835 | 123946 | 289 | 34.6 | 115 | 174 | 0.40 |
| 16 | 98319150 | 706 | 139262 | 244 | 34.6 | 78 | 166 | 0.32 |
| 17 | 95272651 | 1096 | 86928 | 285 | 26.0 | 125 | 160 | 0.44 |
| 18 | 90772031 | 528 | 171917 | 173 | 32.8 | 37 | 136 | 0.21 |
| 19 | 61342430 | 758 | 80927 | 239 | 31.5 | 89 | 150 | 0.37 |
| x | 166650296 | 965 | 172695 | 160 | 16.6 | 144 | 16 | 0.90 |
| y | 15902555 | 12 | 1325213 | 0 | 0 | |||
| Total A | Average A | Total A | Total A | Average A | ||||
| 6391 | 30.1 | 2238 | 4153 | 0.35 |
| ELISA Antigen Titer after Four iImmunizations * | |||||
| Animal a | Immunogen | Bridging Sheet | gp120-SF162 | gp140DV2-SF162 | E2 Protein |
| Mouse1 | E2-BS1 | 100,000 | <20 | -- | 500,000 |
| Mouse2 | E2-BS1 | 100,000 | <20 | -- | 1,000,000 |
| Mouse3 | E2-BS1 | 50,000 | <20 | -- | 500,000 |
| Mouse4 | E2 | <20 | <20 | -- | 1,000,000 |
| Mouse5 | E2 | <20 | <20 | -- | 1,000,000 |
| Mouse6 | E2 | <20 | <20 | -- | 500,000 |
| Rabbit1 (#E2-BS60 male) | E2-BS1 | 500,000 | 400 b | -- | 1,000,000 |
| Rabbit2 (#E2-BS60 female) | E2-BS1 | 2000 | 200 b | -- | 500,000 |
| Rabbit3 (#E2-BS male) | E2-BS1 | 500,000 | 400 c | -- | 1,000,000 |
| Rabbit4 (#E2-BS female) | E2-BS1 | 150,000 | 20,000 c | -- | 1,000,000 |
| Rabbit5 (#5/76) | E2-BS1 | 100,000 | 5000 c | 3000 c | 500,000 |
| Rabbit6 (#6/76) | E2-BS1 | 100 | <20 | <20 | 75,000 |
| Rabbit7 (#1/76) | E2 | <20 | <20 | <20 | 500,000 |
| Rabbit8 (#3/76) | E2 | <20 | <20 | <20 | 1,000,000 |
| Rabbit9 (#E2-wt female) | E2 | <20 | <20 | -- | 1,000,000 |
| Rabbit10 (#E2-wt male) | E2 | <20 | <20 | -- | 500,000 |
| 2012 | 2013 | 2014 | Overall | |
| Dog vaccination costs for Laoag City | ||||
| Total cost of dog vaccination (PHP) | 1,110,365 | 1,040,485 | 1,054,202 | 3,205,053 |
| Total cost of dog vaccination (USD) | 24,428 | 22,891 | 23,192 | 70,511 |
| Number of dogs vaccinated | 3,476 | 4,527 | 7,513 | 15,516 |
| Cost/dog (USD) | 7.03 | 5.06 | 3.09 | 4.54 |
| Dog vaccination costs for Dingras Municipality | ||||
| Total cost of dog vaccination (PHP) | 591,155 | 751,045 | 648,821 | 1,991,021 |
| Total cost of dog vaccination (USD) | 13,005 | 16,523 | 14,274 | 43,802 |
| Number of dogs vaccinated | 726 | 2,982 | 1,357 | 5,065 |
| Cost/dog (USD) | 17.91 | 5.54 | 10.52 | 8.65 |
| PEP costs for Laoag City | ||||
| Total cost for PEP (PHP) | 2,156,857 | 2,297,622 | 2,755,215 | 7,209,695 |
| Total cost for PEP (USD) | 47,451 | 50,548 | 60,615 | 158,613 |
| Number of PEP doses provided | 2,295 | 2,402 | 3,397 | 8093.13 |
| Number of patients vaccinated | 636 | 726 | 913 | 2,275 |
| Average doses/patient | 3.61 | 3.31 | 3.72 | 3.56 |
| Cost per PEP dose (USD) | 20.68 | 21.05 | 17.85 | 19.60 |
| Cost per patient (USD) | 74.61 | 69.62 | 66.39 | 69.72 |
| PEP provision cost for Dingras Municipality | ||||
| Total cost for PEP (PHP) | 183,976 | 404,390 | 755,128 | 1,343,494 |
| Total cost for PEP (USD) | 4,047 | 8,897 | 16,613 | 29,557 |
| Number of PEP doses provided | 202 | 507 | 1,207 | 1,917 |
| Number of patients vaccinated | 63 | 158 | 382 | 603 |
| Average doses/patient | 3.21 | 3.21 | 3.16 | 3.18 |
| Cost per PEP dose (USD) | 20.01 | 17.54 | 13.76 | 17.11 |
| Cost per patient (USD) | 64.25 | 56.31 | 43.49 | 49.02 |
| Localization sites | No. |
| cytoplasmic | 248 |
| inner membrane | 268 |
| periplasmic | 244 |
| outmembrane | 352 |
| extracellular | 190 |
| cytoplasmic / inner membrane | 14 |
| membrane / periplasmic | 49 |
| outer membrane / extracellular | 76 |
| All sites | 1441 |
| MIF overexpression | Comments | Ref |
| Childhood rhabdomyosarcoma | Human RMS cells express and secrete MIF | [137] |
| Melanoma | MIF levels increase in advanced stages | [18] |
| Uveal melanoma | MIF prevents NK cell-mediated lysis | [138] |
| Gastric cancer | Serum MIF levels increase in advanced stages | [44] |
| Pancreatic ductal adenocarcinoma | Higher MIF levels correlate with poor prognosis | [42] |
| Hepatocellular carcinoma | Serum MIF levels are higher in HCC patientsMIF levels are increaed in tumor compared to adjiacent non tumor tissueMIF levels correlate with TNM | [40] |
| Malignant glioma | MIF levels increase wuth tumor gradeMIF counteract NK cell-mediated lysis | [83] |
| Lung adenocarcinoma | MIF distribution predicts patient prognosis | [38] |
| Non-small cell lung cancer | Higher MIF levels are found in tumor tissue. Higher expression of MIF correlate with poor prognosis | [39] |
| Oral cavity squamous cell carcinoma | Higher MIF levels are assocated to worse prognosis | [41] |
| Head and neck squamous cell carcinoma | Tumor tissue MIF expression and plasma levels correlated with tumor recurrence and metastasis, and overall survival. | [35, 43] |
| Osteosarcoma | MIF levels are increased in the tissue and serum samples of patients and correlate with tumour size, pulmonary metastasis and survival rate | [139] |
| DN | GN | GO | Control | ANOVA | |
| P value | |||||
| AST (IU/L) | 353.7 ± 165.45 | 403.4 ± 169.31 | 363.4 ± 174.53 | 273.0 ± 193.34 | 0.861 |
| ALT (IU/L) | 89.0 ± 37.46 | 102.2 ± 43.10 | 113.5 ± 72.89 | 123.3 ± 70.19 | 0.763 |
| ALP (IU/L) | 183.1a ± 42.44 | 285.1b ± 61.57 | 182.8a ± 25.74 | 175.5a ± 25.08 | 0.000 |
| Glucose (mg/dL) | 145.7 b ± 32.89 | 138.1b ± 19.78 | 144.4b ± 24.59 | 218.8a ± 56.77 | 0.003 |
| Creatinine (mg/dL) | 0.36a ± 0.205 | 0.29b ± 0.147 | 0.49a ± 0.098 | 0.54a ± 0.100 | 0.023 |
| BUN (mg/dL) | 49.4 ± 4.37 | 55.3 ± 10.16 | 50.9 ± 5.16 | 53.2 ± 11.29 | 0.634 |
| TP (g/L) | 57.2 ± 3.06 | 55.3 ± 3.33 | 55.3 ± 5.57 | 59.0 ± 5.22 | 0.440 |
| Albumin (g/L) | 48.5 ± 4.04 | 48.2 ± 3.60 | 49.8 ± 5.27 | 49.8 ± 5.19 | 0.882 |
| LDH (U/L) | 1496 ± 420.7 | 1468 ± 313.3 | 1516 ± 297.3 | 1209 ± 463.5 | 0.481 |
| TG (mg/dL) | 135.4 ± 34.97 | 99.6 ± 30.18 | 117.1 ± 24.63 | 103.4 ± 26.48 | 0.175 |
| Characteristics | Total | nd (%) | Physical activity | |||
| N | COR(95%CI) | P Value | AOR(95%CI) | P value | ||
| Total | 3600 | 3411 (94.7) | ||||
| Age groups | ||||||
| 18–29 | 1346 | 1268 (94.2) | 1.0 | |||
| 30–39 | 1065 | 1015 (95.3) | 1.24 (0.86–1.79) | 0.232 | ||
| 40–49 | 641 | 608 (94.9) | 1.13 (0.74–1.72) | 0.558 | ||
| 50–59 | 414 | 394 (95.2) | 1.21 (0.73–2.00) | 0.455 | ||
| 60+ | 134 | 126 (94.0) | 0.96 (0.45–2.05) | 0.934 | ||
| Education level | ||||||
| No education | 1287 | 1245 (96.7) | 1.0 | |||
| Primary | 2073 | 1950 (94.1) | 0.53 (0.37–0.76) | 0.001 | ||
| Secondary | 240 | 216 (90.0) | 0.30 (0.18–0.51) | <0.001 | ||
| Occupation | ||||||
| Professionals | 82 | 76 (92.7) | 1.0 | 1.0 | ||
| Farming | 2643 | 2588 (97.9) | 3.71 (1.55–8.89) | 0.003 | 2.83 (1.17–6.86)*** | 0.021 |
| Business | 652 | 536 (82.2) | 0.36 (0.15–0.85) | 0.021 | 0.39 (0.16–0.92)*** | 0.032 |
| Skilled work | 73 | 68 (93.2) | 1.07 (0.31–3.67) | 0.910 | 1.04 (0.30–3.60) | 0.942 |
| Unskilled work | 119 | 113 (95.0) | 1.48 (0.46–4.78) | 0.506 | 1.38 (0.42–4.47) | 0.586 |
| Residence | ||||||
| Urban | 1358 | 1223 (90.1) | 1.0 | 1.0 | ||
| Rural | 2240 | 2186 (97.6) | 4.46 (3.23–6.17) | 2.27 (1.59–3.24)*** | < 0.001 | |
| Marital status | ||||||
| Single/never married | 273 | 258 (94.5) | 1.0 | |||
| Married | 3327 | 3153 (94.8) | 1.05 (0.61–1.81) |
| Characteristic | Newly diagnosed (age > 14 years old) | Initial CD4 cell count within one month | Initial CD4 cell count within one year | Initial CD4 cell counts < 200 cell/ul within one year | |||
| n | % | n | % | n | % | ||
| Year of HIV diagnosis | |||||||
| 2006 | 26,027 | 4950 | 19.0 | 9129 | 35.1 | 3901 | 42.7 |
| 2007 | 32,538 | 8856 | 27.2 | 15,621 | 48.0 | 6282 | 40.2 |
| 2008 | 40,690 | 14,475 | 35.6 | 23,979 | 58.9 | 8491 | 35.4 |
| 2009 | 48,163 | 20,327 | 42.2 | 32,083 | 66.6 | 11,321 | 35.3 |
| 2010 | 53,375 | 25,110 | 47.0 | 40,073 | 75.1 | 13,511 | 33.7 |
| 2011 | 67,256 | 35,950 | 53.5 | 54,378 | 80.9 | 18,002 | 33.1 |
| 2012 | 76,716 | 45,550 | 59.4 | 66,064 | 86.1 | 20,444 | 30.9 |
| 2013 | 85,518 | 54,931 | 64.2 | 76,191 | 89.1 | 23,474 | 30.8 |
| 2014 | 97,951 | 64,403 | 65.8 | 86,482 | 88.3 | 25,669 | 29.7 |
| Route of HIV infection | |||||||
| Heterosexual | 333,753 | 183,602 | 55.0 | 264,332 | 79.2 | 96,527 | 36.5 |
| Homosexual | 85,252 | 57,299 | 67.2 | 78,895 | 92.5 | 15,515 | 19.7 |
| Injection drug use | 73,834 | 21,958 | 29.7 | 40,713 | 55.1 | 9168 | 22.5 |
| Sexual contact and injection drug use | 5257 | 1760 | 33.5 | 3257 | 62.0 | 777 | 23.9 |
| Blood or plasma transfusion | 16,767 | 7006 | 41.8 | 11,833 | 70.6 | 7142 | 60.4 |
| Sites of diagnosis | |||||||
| VCT centers | 150,157 | 91,425 | 60.9 | 124,603 | 83.0 | 39,141 | 31.4 |
| Hospitals | 236,047 | 118,702 | 50.3 | 176,834 | 74.9 | 73,114 | 41.3 |
| Detention centers | 43,231 | 12,397 | 28.7 | 23,395 | 54.1 | 3196 | 13.7 |
| others | 98,799 | 52,028 | 52.7 | 79,168 | 80.1 | 15,644 | 19.8 |
| Total | 528,234 | 274,552 | 52.0 | 404,000 | 76.5 | 131,095 | 32.4 |
| Mycotoxin | Correlation Coefficient (r) | Repeatability (RSDr, %) a | Reproducibility (RSDR, %) a | LOD (ng/g) | LOQ (ng/g) | SSE (%) | ||
| 25 ng/g b | 50 ng/g b | 25 ng/g b | 50 ng/g b | |||||
| AOH | 0.998 | 81 (6) | 82 (4) | 84 (8) | 89 (6) | 1.40 | 3.50 | 65 |
| AME | 0.996 | 86 (4) | 89 (7) | 90 (7) | 93 (10) | 1.40 | 3.50 | 80 |
| TEN | 0.995 | 91 (9) | 94 (6) | 94 (15) | 90 (12) | 0.70 | 1.75 | 78 |
| Number of requests | One Tomcat server | Two Tomcat servers | ||
| Mean time (seconds) | Total time (seconds) | Mean time (seconds) | Total time (seconds) | |
| 1 | 1.661 | 1.661 | 1.994 | 1.994 |
| 10 | 1.300 | 13 | 1.200 | 12 |
| 20 | 1.500 | 30 | 1.100 | 22 |
| 30 | 1.400 | 42 | 1.133 | 34 |
| 40 | 1.400 | 56 | 1.250 | 50 |
| 50 | 1.380 | 69 | 1.140 | 57 |
| 60 | 1.367 | 82 | 1.150 | 69 |
| 70 | 1.371 | 96 | 1.157 | 81 |
| 80 | 1.400 | 112 | 1.275 | 102 |
| 90 | 1.489 | 134 | 1.267 | 114 |
| 100 | 1.600 | 160 | 1.170 | 117 |
| Burnout Subscale | Low | Moderate | High |
| Emotional exhaustion | 37 (34%) | 39 (35%) | 34 (31%) |
| Depersonalization | 93 (77%) | 22 (18%) | 6 (5%) |
| Personal accomplishment | 42 (45%) | 26 (28%) | 25 (27%) |
| Gene | Genotype | Time to progression | HR (95% CI) | p | Overall survival | HR (95% CI) | p |
| Median (25%–75%) | Median (25%–75%) | ||||||
| MMP2 | |||||||
| rs243865 | CC | 8.83 (6.43–15.03) | Ref. | 17.43 (10.60–27.27) | Ref. | ||
| CT | 10.17 (6.00–16.33) | 0.88 (0.63–1.22) | 0.437 | 17.47 (9.47–31.17) | 0.96 (0.68–1.36) | 0.826 | |
| TT | 14.97 (8.20–44.57) | 0.54 (0.17–1.75) | 0.305 | 30.00 (22.03–30.00) | 0.44 (0.11–1.81) | 0.255 | |
| CT + TT | 10.20 (6.27–16.33) | 0.85 (0.61–1.18) | 0.334 | 18.07 (9.63–31.17) | 0.92 (0.66–1.30) | 0.653 | |
| rs243849 | CC | 9.87 (6.13–16.67) | Ref. | 19.10 (9.83–28.13) | Ref. | ||
| CT | 8.67 (6.67–14.30) | 1.30 (0.91–1.86) | 0.144 | 16.23 (10.80–29.03) | 1.26 (0.86–1.85) | 0.227 | |
| TT | 7.33 (3.27–11.80) | 2.16 (1.02–4.55) | 0.043 | 17.63 (7.33–36.73) | 1.18 (0.51–2.72) | 0.698 | |
| CT + TT | 8.67 (6.60–14.30) | 1.38 (0.98–1.94) | 0.064 | 16.63 (10.80–30.27) | 1.25 (0.87–1.80) | 0.225 | |
| rs7201 | AA | 9.27 (6.37–16.93) | Ref. | 16.23 (10.63–28.03) | Ref. | ||
| AC | 10.00 (6.73–15.03) | 0.87 (0.61–1.24) | 0.441 | 19.30 (10.80–30.00) | 0.89 (0.62–1.29) | 0.547 | |
| CC | 8.00 (5.50–12.63) | 1.15 (0.73–1.80) | 0.551 | 14.20 (9.23–26.17) | 1.20 (0.74–1.95) | 0.467 | |
| AC + CC | 9.80 (6.43–14.57) | 0.93 (0.67–1.30) | 0.684 | 18.07 (9.63–29.03) | 0.96 (0.67–1.36) | 0.803 | |
| MMP9 | |||||||
| rs17576 | AA | 9.27 (6.13–13.53) | Ref. | 13.57 (9.83–23.90) | Ref. | ||
| AG | 10.73 (6.80–18.47) | 0.84 (0.60–1.17) | 0.303 | 21.20 (12.17–32.53) | 0.72 (0.50–1.03) | 0.070 | |
| GG | 8.50 (6.00–16.67) | 1.17 (0.69–1.98) | 0.558 | 16.63 (8.27–26.60) | 0.96 (0.54–1.68) | 0.881 | |
| AG + GG | 10.00 (6.67–16.90) | 0.89 (0.65–1.23) | 0.478 | 19.30 (11.33–31.17) | 0.76 (0.54–1.06) | 0.106 | |
| rs2250889 | CC | 10.03 (6.73–16.67) | Ref. | 19.10 (11.33–30.00) | Ref. | ||
| CG | 6.07 (4.07–7.90) | 2.32 (1.34–4.03) | 0.003 | 9.23 (4.53–14.20) | 2.52 (1.42–4.46) | 0.002 | |
| rs17577 | GG | 10.00 (6.60–16.33) | Ref. | 18.07 (10.60–28.30) | Ref. | ||
| GA | 8.33 (5.50–14.57) | 1.20 (0.84–1.72) | 0.319 | 17.63 (9.47–32.87) | 0.82 (0.56–1.20) | 0.311 | |
| AA | 8.83 (8.00–19.43) | 1.02 (0.32–3.25) | 0.977 | 13.50 (9.97–25.93) | 1.58 (0.49–5.04) | 0.444 | |
| GA + AA | 8.50 (5.53–14.57) | 1.19 (0.84–1.68) | 0.339 | 17.63 (9.63–32.53) | 0.85 (0.59–1.24) | 0.403 | |
| rs20544 | CC | 7.53 (5.53–11.53) | Ref. | 13.50 (8.13–21.20) | Ref. | ||
| CT | 10.93 (7.37–19.97) | 0.60 (0.40–0.90) | 0.014 | 20.67 (11.33–32.53) | 0.59 (0.39–0.91) | 0.018 | |
| TT | 9.40 (6.27–14.30) | 0.67 (0.43–1.03) | 0.069 | 15.40 (10.80–25.67) | 0.70 (0.44–1.11) | 0.132 | |
| CT + TT | 10.13 (6.73–16.20) | 0.62 (0.43–0.92) | 0.016 | 19.30 (10.80–31.17) | 0.63 (0.42–0.95) | 0.025 | |
| MMP14 | |||||||
| rs1042703 | TT | 9.27 (6.67–16.33) | Ref. | 17.50 (9.97–29.13) | Ref. | ||
| TC | 10.17 (6.27–14.53) | 1.36 (0.94–1.96) | 0.100 | 19.30 (9.47–29.03) | 1.25 (0.87–1.81) | 0.229 | |
| CC | 8.70 (5.13–16.20) | 2.09 (1.06–4.12) | 0.032 | 12.70 (7.07–20.60) | 2.14 (1.12–4.06) | 0.020 | |
| TC + CC | 10.17 (6.03–14.97) | 1.44 (1.01–2.03) | 0.042 | 17.63 (8.30–28.30) | 1.36 (0.97–1.92) | 0.076 | |
| rs1042704 | GG | 9.80 (6.73–14.90) | Ref. | 17.50 (10.80–31.17) | Ref. | ||
| GA | 8.30 (5.70–16.20) | 1.05 (0.74–1.49) | 0.780 | 17.47 (9.10–24.23) | 1.40 (0.98–2.00) | 0.068 | |
| AA | 7.87 (6.00–16.90) | 0.90 (0.45–1.82) | 0.777 | 20.27 (13.57–25.93) | 1.22 (0.59–2.53) | 0.598 | |
| GA + AA | 8.30 (5.93–16.90) | 1.03 (0.74–1.42) | 0.881 | 18.07 (9.63–24.57) | 1.37 (0.97–1.92) | 0.072 | |
| rs743257 | CC | 9.87 (7.07–14.07) | Ref. | 13.50 (9.97–27.27) | Ref. | ||
| CT | 9.40 (5.97–19.43) | 1.08 (0.72–1.64) | 0.700 | 15.40 (6.80–28.13) | 0.98 (0.65–1.49) | 0.931 | |
| TT | 9.70 (6.60–14.53) | 1.15 (0.75–1.76) | 0.535 | 20.17 (12.53–31.17) | 0.87 (0.56–1.36) | 0.544 | |
| CT + TT | 9.43 (6.07–16.33) | 1.11 (0.76–1.63) | 0.588 | 19.30 (9.83–30.27) | 0.93 (0.63–1.37) | 0.722 |
| Gene associated with presence in East Asia clade and absence in USA clade | Antibiotic(s) to which resistance conferred |
| catA | Chloramphenicol |
| ermB | Macrolides, lincosamides, streptogramins B |
| mecA | Beta-lactams |
| tetK | Tetracyclines |
| ant(6)-Ia | Aminoglycosides |
| aph(3)-III | Aminoglycosides |
| Transcript(Primer Name) | Forward Primer | Reverse Primer | Product Size |
| H. E4BP4(HUMANE4BP4-742 & 991) | 5'ATGGGGAATTCTTTCTCTGG3' | 5'CTTTGATCCGGAGCTTGTGT3' | 250 bp |
| M. E4BP4(Mouse E4BP4-742 &1117) | 5'ATGGGAAGCTCTTTCTCCACT3' | 5'TACCCGAGGTTCCATGTTTC3' | 376 bp |
| Bim(BIM 5/6 SENSE & ANTI) | 5'CAGATATGCGCCCAGAGATA3' | 5'ACCAGGCGGACAATGTAAC3' | 163 bp |
| Puma(PUMA SENSE & ANTI) | 5'AAGAGCAAATGAGCCAAACG3' | 5'GCAGAGCACAGGATTCACAG3' | 181 bp |
| β-actin(B-ACTIN-130 SENSE & ANTI) | 5'AGTCCTCTCCCAAGTCCACA3' | 5'CACGAAGGCTCATCATTCAA3' | 130 bp |
| Variable | 18–49 years(n = 263) | 50–64 years(n = 142) | 65+ years(n = 77) | Chi-SquareP-value |
| Exhaustion (% yes) | 139 (52.9%) | 34 (24.0%) | 8 (11.0%) | <0.001 |
| Physical activity (% inactive)a | - | - | - | <0.001 |
| Mobility function (gait speed proxy, % mobility impairment) | 13 (4.9%) | 13 (9.3%) | 7 (9.7%) | <0.001 |
| Unintentional weight loss (% yes) | 127 (48.1%) | 29 (20.1%) | 5 (7.1%) | <0.001 |
| Weak grip strength (% yes) | 33 (12.6%) | 17 (12.2%) | 9 (11.9%) | <0.001 |
| Clinical manifestations | Kidney and ureter stones | Simple kidney stones | Unilateral ureteral calculi | Simple bilateral ureteral calculi | Bladder calculi | Urinary tract stones | Total |
| Anuria | 13 | 1 | 1 | 5 | 1 | 0 | 21 |
| Oliguria | 1 | 0 | 0 | 0 | 1 | 0 | 2 |
| Dysuria | 0 | 0 | 0 | 0 | 0 | 2 | 2 |
| Others | 1 | 0 | 1 | 0 | 1 | 0 | 3 |
| Total | 15 | 1 | 2 | 5 | 3 | 2 | 28 |
| Questions: | T0 Mean ± SD | T1 Mean ± SD |
| Training/learning to use the device is not complicated | 4.67 ± 0.58 | 4.33 ± 0.58 |
| Wearing/adjusting the device is relatively simple | 4.33 ± 0.58 | 4.33 ± 1.15 |
| It was comfortable to exercise with the device | 4.67 ± 0.58 | 4.33 ± 0.58 |
| The usage of the device did not cause considerable pain | 5.00 ± 0.00 | 4.67 ± 0.58 |
| I did not feel excessive fatigue while excessive with the device | 4.00 ± 1.00 | 4.00 ± 1.00 |
| After completing the training period I felt comfortable using the device | 4.67 ± 0.58 | 4.67 ± 0.58 |
| Training with the device diminishes the spasticity in my legs | 5.00 ± 0.00 | 5.00 ± 0.00 |
| I did not have breathing difficulties while training with the device | 5.00 ± 0.00 | 5.00 ± 0.00 |
| I felt improvement in my bowel movement during the training program | 3.33 ± 1.53 | 4.00 ± 1.00 |
| After completing the training I felt safe using the device | 3.00 ± 2.00 | 4.67 ± 0.58 |
| MQ2 Aspect ratio | HD magnet Aspect ratio | Difference | |
| Top & Bottom | 0.204 | 0.123 | –40.7% |
| Middle | 0.203 | 0.081 | –60.9% |
| Left & Right | 0.194 | 0.120 | –38.1% |
| Corners | 0.201 | 0.116 | –42.2% |
| Average | 0.200 | 0.110 | –45.1% |
| Treatment | Total episodes | 1st episode | 2nd and subsequent episodes | |||
| mild | severe | mild | severe | |||
| Total | 781 | 575 (96%) | 22 (4%) | 177 (96%) | 7 (4%) | |
| No treatment | 464 | 59% | 327 (57%) | 11 (44%) | 123 (70%) | 3 (43%) |
| Antimotility agents | 231 | 30% | 178 (31%) | 7 (32%) | 46 (26%) | 0 |
| ORS | 116 | 15% | 92 (16%) | 6 (27%) | 16 (9%) | 2 (29%) |
| Antibiotic | 36 | 5% | 30 (5%) | 1 (5%) | 3 (2%) | 2 (29%) |
| Alternative antidiarrhoeal drugs | 22 | 3% | 18 (3%) | 1 (5%) | 3 (2%) | 0 |
| Visited physician for diarrhoea | 25 | 3% | 18 (3%) | 1 (5%) | 5 (3%) | 1 (14%) |
| ICD Codes/Conditions | Frequency of Admissions | Percentage of Total Admissions | |
| Top Reasons for Primary Admission (<1 YEAR) | |||
| Lower respiratory tract infection | 44 | 40.8 | |
| Lower respiratory tract infection (J22) | 42 | ||
| Bronchiolitis (J21.9) | 2 | ||
| Gastroenteritis | 28 | 25.9 | |
| Infectious gastroenteritis (A09.9) | 27 | ||
| Vomiting (R11) | 1 | ||
| Upper respiratory tract infection | 10 | 9.3 | |
| Otitis media (H66.3, H66.9) | 5 | ||
| Upper respiratory tract infection (J06.9) | 4 | ||
| Croup (J05.0) | 1 | ||
| Genitourinary | Urinary Tract Infection (N39.0) | 5 | 4.6 |
| Injury | Traumatic brain injury (S06.01), head injury (S09.9), fractured femur (S72.9), dog or snake bite (T14.1) | 4 | 3.6 |
| Subtotal admission reason | 92 | 84.2 | |
| Other | 16 | 15.8 | |
| Total Primary admission reason | 108 | 100 | |
| Top Comorbidities at Admission | |||
| Upper respiratory tract infection | H66.3, H66.9, J06.9 | 9 | 33.3 |
| Failure to thrive | R62.8 | 5 | 18.5 |
| Anaemia | D64.9 | 5 | 18.5 |
| Subtotal comorbidities | 19 | 70.3 | |
| Other | 8 | 29.7 | |
| Total comorbidities | 27 | 100 |
| Val/Val n = 60 | Met carriers n = 41 | |
| Age (mean ± SD) (years) | 38.1 ± 8.5 | 39.7 ± 10.7 |
| Gender, males n (%) | 24 (40) | 21 (51) |
| Smoking habit, n (%) | 17 (28) | 12 (29) |
| Number of metabolic syndrome components (number of girls/boys) | HOMA-IR | |
| Girls | Boys | |
| 0 (468/301 girls/boys) | 2.12 (1.53; 2.84) | 1.90 (1.42; 2.61) |
| 1 ( 381/359 girls/boys) | 2.55 (1.80; 3.45) | 2.28 (1.65; 3.11) |
| 2 (174/168 girls/boys) | 2.85 (2.09; 4.37) | 3.19 (2.20; 5.03) |
| 3 (54/76 girls/boys) | 3.60 (2.56; 5.69) | 4.44 (2.88; 6.25) |
| 4 (4/29 girls/boys) | 5.86 (4.90; 9.19) | 6.38 (4.26; 7.98) |
| 5 (0/3 girls/boys) | --- | 7.19 (4.33; 13.93) |
| `Parameter | Time | Placebo (SCG-P) (n = 14) | Cromolyn 20 mg (SCG-20) (n = 14) | Cromolyn 40 mg (SCG-40) (n = 12) | p-value |
| FEV1 | Baseline | 60.07 ± 3.29 | 57.33 ± 3.54 | 67.49 ±2.04 | NS |
| 15 min | 60.56 ± 3.29 | 58.85 ± 3.22 | 66.97 ± 1.99 | NS | |
| 30 min | 60.46 ± 3.27 | 58.41 ± 2.90 | 67.29 ± 2.00 | NS | |
| 60 min | 62.06 ± 3.17 | 59.49 ± 3.40 | 67.97 ± 2.04 | NS | |
| FVC | Baseline | 71.17 ± 3.30 | 70.17 ± 3.23 | 73.45 ±7.40 | NS |
| 15 min | 71.71 ± 3.37 | 71.30 ± 3.23 | 73.75 ±2.52 | NS | |
| 30 min | 71.94 ± 3.24 | 71.22 ±2.63 | 73.02 ± 2.72 | NS | |
| 60 min | 72.77 ± 3.76 | 72.53 ± 2.85 | 74.33 ± 2.61 | NS | |
| PEF | Baseline | 59.19 ±4.91 | 56.02 ± 4.62 | 64.79 ± 2.71 | NS |
| 15 min | 57.85 ± 4.68 | 58.93 ± 4.48 | 65.10 ±3.60 | NS | |
| 30 min | 58.66 ± 5.68 | 58.74 ± 4.51 | 65.50 ±3.40 | NS | |
| 60 min | 58.56 ± 5.23 | 60.69 ± 4.76 | 65.20 ± 3.13 | NS | |
| MEF75% | Baseline | 41.52 ±5.45 | 38.86 ± 4.41 | 54.37 ± 3.21* | S |
| 15 min | 41.87 ± 4.56 | 39.73 ± 4.47 | 52.93 ± 3.38 | - | |
| 30 min | 42.81 ± 3.88 | 38.69 ±3.94 | 52.59 ± 3.55 | - | |
| 60 min | 44.31 ± 3.80 | 38.37 ± 4.17 | 53.91 ± 3.49 | - | |
| MEF50% | Baseline | 34.87 ± 4.89 | 29.96 ± 3.75 | 45.62 ± 3.25* | S |
| 15 min | 33.73 ± 3.79 | 31.67 ± 3.68 | 44.30 ± 2.49 | - | |
| 30 min | 32.78 ± 2.82 | 30.30 ± 3.41 | 44.97 ± 2.58 | - | |
| 60 min | 36.64 ±3.18 | 29.91 ± 3.13 | 45.68 ± 2.63 | - | |
| MEF25% | Baseline | 30.78 ± 4.91 | 24.76 ± 2.64 | 39.76 ± 2.24* | S |
| 15 min | 29.79 ± 4.63 | 26.89 ± 3.31 | 39.80 ± 2.69 | - | |
| 30 min | 27.48 ± 3.48 | 26.25 ± 2.76 | 42.24 ±2.50 | - | |
| 60 min | 30.66 ± 3.95 | 25.22 ± 2.56 | 39.56 ± 2.62 | - |
| Fold Change | Method | Accuracy % | Sensitivity % | PPV % | F-Score % |
| FishersTotal | 70.41% | 70.79% | 91.24% | 79.72% | |
| FishersHousekeeping | 65.60% | 65.22% | 95.05% | 77.36% | |
| 1 | GFOLD | 78.13% | 80.06% | 92.67% | 85.90% |
| Cuffdiff | 11.37% | 6.96% | 100.00% | 13.01% | |
| edgeR | 73.03% | 73.26% | 95.56% | 82.94% | |
| IsoDE-Match | 82.63% | 87.46% | 83.70% | 85.54% | |
| IsoDE-All | 82.22% | 87.17% | 82.82% | 84.94% | |
| FishersTotal | 74.05% | 78.20% | 84.85% | 81.39% | |
| FishersHousekeeping | 76.68% | 73.61% | 93.67% | 82.44% | |
| 1.5 | GFOLD | 79.15% | 79.35% | 90.41% | 84.52% |
| Cuffdiff | 28.43% | 8.60% | 100.00% | 15.85% | |
| edgeR | 80.01% | 79.92% | 92.07% | 85.57% | |
| IsoDE-Match | 78.98% | 86.23% | 84.62% | 85.42% | |
| IsoDE-All | 79.01% | 86.42% | 84.49% | 85.44% | |
| FishersTotal | 78.43% | 81.86% | 82.44% | 82.15% | |
| FishersHousekeeping | 81.20% | 80.00% | 88.21% | 83.90% | |
| 2 | GFOLD | 82.94% | 78.84% | 92.37% | 85.07% |
| Cuffdiff | 40.96% | 10.47% | 100.00% | 18.95% | |
| edgeR | 83.67% | 81.63% | 91.17% | 86.13% | |
| IsoDE-Match | 82.04% | 85.58% | 85.19% | 85.38% | |
| IsoDE-All | 81.20% | 86.74% | 83.07% | 84.87% |
| Application | Method (Sample Size) | ||
| MOAT (240) | Importance Measures (400) | VBD (2000) | |
| Watershed | 15 681 | 27 078 | 150 890 |
| Level Set | 6,825 | 22 696 | 211 912 |
| Variable | OR | CI | p-value |
| Age | 1.15 | 0.86-1.54 | 0.53 |
| Gender | 0.07 | ||
| Male | Ref | ||
| Female | 0.28 | ——0.07-1.13 | |
| Marital status | 0.03 | ||
| Not marries | Ref | ||
| Married | 4.99 | ——1.23-20.24 | |
| Alcohol use, past month | 0.11 | ||
| No | Ref | ||
| Yes | 2.81 | ——0.79-9.98 | |
| Ecstasy use, lifetime | 0.70 | ||
| No | Ref | ||
| Yes | 1.24 | ——0.42-3.70 | |
| Sexually active, lifetime | - | 0.84 | |
| No | Ref | ||
| Yes | 0.84 | —0.19-3.67 | |
| HIV stigmatizing attitude | 0.03 | ||
| Yes | Ref | ||
| No | 0.33 | ——0.12-0.89 | |
| Activity involvement: | |||
| Read fiction literature for entertainment | 1.46 | 1.10-1.99 | 0.02 |
| Go to parties, café, bar or disco in the evening | 1.54 | 1.05-2.24 | 0.03 |
| Pass time with neighborhood friends/neighbors | 1.35 | 1.01-1.82 | 0.05 |
| Variable | Description | Type | Values | Frequency | Percent |
| High Blood Pressure (mmHg) Diastolic Systolic | Blood pressure measured around the arm above the elbow; it detects the amount of pressure in the blood flowing in the vein (in mm of mercury) | Nominal | 1 ≤ 120/80 = Normal | 336 | 77.6 |
| 2 = 120–139/80–89 = Pre-hypertension | 84 | 19.4 | |||
| 3 = 140+/90+ = High Blood Pressure | 13 | 3.0 | |||
| BMI (weight in kg/squared height in meters) | Calculated based on calibrated measurements performed by school nurse | Continuous Ordinal | 0.0–60++ | ||
| 1 ≤ 18.5 Underweight | 76 | 17.6 | |||
| 2 = 18.5–25.0 Normal | 185 | 42.7 | |||
| 3 = 26.0–30.0 | 55 | 12.7 | |||
| Overweight | |||||
| 4 ≥ 30.0 Obese | 117 | 27.0 | |||
| Tobacco Use | Do you smoke | Dichotomous | 1 = Yes | 63 | 14.5 |
| 2 = No | 370 | 85.5 | |||
| Alcohol Use | Do you drink alcoholic beverages? | Dichotomous | 1 = Yes | 127 | 29.3 |
| 2 = No | 306 | 70.7 | |||
| Optimistic Bias | Do you think it is possible that you could develop cardiovascular disease? | Dichotomous | 1 = Yes | 166 | 38.3 |
| 2 = No | 267 | 61.7 |
| Variables | Baseline | Post-treatment |
| OHRQoL scores | ||
| Total score | 16.67 (12.10) | 7.05 (7.16) ** |
| Functional limitation | 1.83 (2.21) | 1.08 (1.48) ** |
| Physical pain | 3.55 (1.81) | 1.52 (1.53) ** |
| Psychological discomfort | 2.59 (2.26) | 0.91 (1.33) ** |
| Physical disability | 2.68 (2.09) | 1.25 (1.49) ** |
| Psychological disability | 2.43 (2.01) | 0.99 (1.27) ** |
| Social disability | 1.67 (1.93) | 0.61 (1.10) ** |
| Handicap | 1.93 (1.96) | 0.69 (1.14) ** |
| Periodontal parameters | ||
| No. of teeth (n) | 26.96 (2.24) | 26.39 (2.71) ** |
| PD (mm) | 3.00 (0.75) | 2.53 (0.65) ** |
| CAL (mm) | 2.66 (1.46) | 2.50 (1.47) * |
| FMBS (%) | 35.07 (23.52) | 19.99 (16.13) ** |
| PD ≥ 4 mm (%) | 25.83 (19.34) | 12.93 (12.74) ** |
| PCR (%) | 56.66 (20.75) | 37.57 (15.51) ** |
| Sample name | Silicon-rich concentration(volume percentage v%) | Sample structure/thickness (nm) |
| SRC80 | 80 | Single layer/approximately 600 |
| SRC70 | 70 | Single layer/approximately 600 |
| SRC60 | 60 | Single layer/approximately 600 |
| SRC50 | 50 | Single layer/approximately 600 |
| SiC | 0 | Single layer/approximately 600 |
| Control subjects | STAMPEDE subjects | Subset of STAMPEDE subjects | STAMPEDE vs CONTROLS | STAMPEDE subset vs controls | |||||||
| Entrez ID | Mean | ST DEV | CV, % | Mean | ST DEV | CV, % | Mean | ST DEV | CV, % | p value | p value |
| A1AG1 | 18.69 | 0.40 | 2.1 | 19.49 | 0.52 | 2.7 | 19.98 | 0.44 | 2.2 | 0.00055429 | 5.95509E-07 |
| A1BG | 18.95 | 0.32 | 1.7 | 19.20 | 0.33 | 1.7 | 19.52 | 0.13 | 0.6 | 0.0001927 | 4.63441E-05 |
| AACT | 17.34 | 0.50 | 2.9 | 17.99 | 0.35 | 2.0 | 18.37 | 0.13 | 0.7 | 0.0010359 | 6.39218E-06 |
| ANT3 | 17.62 | 0.39 | 2.2 | 18.15 | 0.35 | 1.9 | 18.50 | 0.17 | 0.9 | 0.00037815 | 3.80627E-06 |
| HEMO | 18.74 | 0.29 | 1.5 | 19.07 | 0.31 | 1.6 | 19.37 | 0.27 | 1.4 | 2.7297E-05 | 0.000126029 |
| APOA1 | 17.42 | 1.22 | 7.0 | 18.53 | 0.91 | 4.9 | 19.10 | 0.52 | 2.7 | 9.4027E-05 | 0.000842961 |
| APOA2 | 15.72 | 1.26 | 8.0 | 16.65 | 1.18 | 7.1 | 17.09 | 1.08 | 6.3 | 0.00057807 | 0.018670507 |
| PZP | 17.01 | 0.99 | 5.8 | 17.86 | 0.71 | 4.0 | 18.27 | 0.57 | 3.1 | 3.3055E-05 | 0.003711976 |
| A2MG | 16.74 | 0.85 | 5.1 | 17.24 | 0.63 | 3.6 | 17.56 | 0.59 | 3.4 | 1.9526E-05 | 0.024453179 |
| HBA | 16.29 | 1.93 | 11.9 | 17.48 | 1.60 | 9.1 | 18.29 | 1.78 | 9.8 | 1.4869E-05 | 0.025085649 |
| HBB | 15.96 | 1.94 | 12.1 | 17.67 | 1.51 | 8.6 | 18.42 | 1.71 | 9.3 | 7.2466E-06 | 0.006838885 |
| HBD | 16.42 | 2.08 | 12.7 | 17.90 | 1.71 | 9.5 | 18.64 | 2.24 | 12.0 | 5.1691E-07 | 0.014381261 |
| Patients | Sex | Age | pH juice | Sample | Log10 CFU/g or ml | Bifidobacteriaceae species |
| AAG groups (2 of 10 patients) | ||||||
| 1 | F | 60 | 7.84 | Juice | 5.30 | Sca. |
| Corpus | 4.30 | Sca. | ||||
| 2 | M | 33 | 8.11 | Juice | 4.30 | Par. |
| OME groups (7 of 13 patients) | ||||||
| 3 | M | 52 | 7.80 | Antrum | 4.30 | Par. |
| 4 | M | 55 | 6.75 | Antrum | 3.00 | Bif.d. |
| 5 | M | 46 | 8.08 | Juice | 2.69 | Par. |
| Corpus | 4.00 | Par. | ||||
| 6 | F | 44 | 7.41 | Juice | 5.30 | Bif.d.;Par.;Sca. |
| Antrum | 4.07 | Par. | ||||
| Corpus | 4.00 | Par. | ||||
| 7 | F | 70 | 7.83 | Juice | 4.00 | Bif.d.;Par.;Sca. |
| Antrum | 3.60 | Bif.d. | ||||
| 8 | M | 50 | 5.02 | Antrum | 4.00 | Bif.ilon. |
| 9 | F | 43 | 6.48 | Juice | 4.00 | Un.Bif. |
| Date, meal, food item | Exposed | Not exposed | RR | 95% CI | AF | ||||
| ill | not ill | AR (%) | ill | not ill | AR (%) | ||||
| Cohort from units 1 and 9, n = 181 (variable denominator due to missing data), only those with RR>2 shown: | |||||||||
| 5-Aug, lunch, \"light meal\" | 10 | 63 | 15.9 | 9 | 118 | 7.6 | 2.08 | 0.89–4.86 | 28% |
| 5-Aug, afternoon, cake | 17 | 128 | 13.3 | 2 | 53 | 3.8 | 3.52 | 0.84–14.70 | 64% |
| 6-Aug, lunch, \"light meal\" | 11 | 47 | 23.4 | 8 | 134 | 6.0 | 3.92 | 1.68–9.15 | 43% |
| 6-Aug, afternoon, cake | 17 | 125 | 13.6 | 2 | 56 | 3.6 | 3.81 | 0.91–15.93 | 66% |
| 6-Aug, dinner, cold cuts | 16 | 116 | 13.8 | 3 | 65 | 4.6 | 2.99 | 0.91–9.87 | 56% |
| 7-Aug, afternoon, cake | 16 | 125 | 12.8 | 3 | 56 | 5.47 | 2.39 | 0.73–7.87 | 49% |
| Cohort from units 1, 2, 4 and 9, n = 378 (variable denominator due to missing data), all food items shown: | |||||||||
| 5-Aug, afternoon, cake | 38 | 306 | 13.3 | 4 | 70 | 5.7 | 2.17 | 0.80–5.89 | 49% |
| 6-Aug, afternoon, cake | 38 | 303 | 13.3 | 4 | 69 | 5.5 | 2.29 | 0.84–6.21 | 51% |
| 7-Aug, afternoon, cake | 37 | 303 | 12.2 | 5 | 68 | 6.8 | 1.78 | 0.73–4.38 | 39% |
| 6-Aug, lunch, \"light meal\" | 20 | 123 | 16.3 | 22 | 253 | 8.7 | 1.87 | 1.06–3.29 | 22% |
| No. | MCs tot a,b | ANA-a a | ANA-a | DH-ANA-a c | E-ANA-a c | MC-RR | MC-YR | MC-LR | MC-LA | MC-LY | MC-LW | MC-LF | CYN | STX | BMAA |
| 1 | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND |
| 2 | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND |
| 3 | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND |
| 4 | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND |
| 5 | ND | ND | ND | ND | 7.2 | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND |
| 6 | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND |
| 7 | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND |
| 8 | 0.25 (10) | ND | ND | 0.41 | ND | ND | ND | ND | 0.3 (13) | ND | ND | ND | ND | ND | ND |
| 9 | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND |
| 10 | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND |
| 11 | 2.5 (104) | ND | ND | ND | 8.1 | ND | 1.6 (67) | 0.06 (3) | 0.08 (3) | ND | ND | ND | ND | ND | ND |
| 12 | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND |
| 13 | 0.6 (25) | ND | ND | ND | ND | ND | ND | 0.03 (1) | ND | ND | ND | ND | ND | ND | ND |
| 14 | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND |
| 15 | 16.4 (683) | ND | 0.30 (5) | 2.2 | 1.8 | 0.8 (33) | ND | 8.6 (358) | 2.2 (92) | 0.04 (17) | ND | ND | ND | ND | 0.08 |
| 16 | 4.5 (188) | ND | ND | ND | 0.28 | ND | ND | 3.6 (150) | 1.2 (50) | ND | ND | ND | ND | ND | ND |
| 17 | 3.3 (138) | 0.35 (6) | 0.32 (5) | 5.8 | ND | ND | 0.18 (8) | 0.04 (17) | 2.6 (108) | ND | ND | ND | ND | ND | 0.44 |
| 18 | 0.8 (33) | ND | ND | ND | ND | ND | ND | 0.52 (22) | ND | ND | ND | ND | ND | ND | ND |
| Cr | Co | Mo | Al | Ti | C | B | Ni |
| 19.5 | 13.5 | 4.3 | 1.3 | 3 | 0.08 | 0.006 | Bal |
| Name | Thermal Treatment | Surface * (m2/g) | D90 ** (μm) | D50 ** (μm) | D10 ** (μm) | S (%) | N (%) | Fe (%) | Si (%) | Ni (%) | P (ppm) | B (ppm) |
| CNF A | no | 103 | 2.2 | 1.6 | 0.7 | <0.010 | 0.017 | 0.008 | 0.020 | 1.29 | 5.0 | 0.7 |
| CNF B | yes | 61 | 2.2 | 1.9 | 1.6 | <0.010 | 0.016 | 0.023 | 0.012 | 0.070 | 3.8 | 2.0 |
| CNF C | no | 124 | 2.6 | 1.7 | 0.8 | 0.095 | 0.037 | 0.148 | 0.056 | 4.97 | 8.1 | 7.6 |
| CNF D | yes | 56 | 2.5 | 1.5 | 0.6 | <0.010 | 0.012 | 0.002 | 0.004 | 0.036 | 0.3 | 0.3 |
| CB | no | 321 | 6.9 | 3.2 | 1.3 | 0.45 | 0.121 | 0.003 | <0.03 | <0.0003 | 1.1 | <1.0 |
| Course level | |
| Level 1 | Text, images, audio, simple interactivities for content presentation. Template layout |
| Level 2 | Level 1+video and simple animations. Fewer pages with template layout |
| Level 3 | Complex animation, high-fidelity/3D graphics, complex multilevel, and multivariable interaction |
| Underweight (n = 39) | Normal (n = 280) | Overweight (n = 121) | Obese (n = 304) | |||||
| Estimates (SE) | p value | Estimates (SE) | p value | Estimates (SE) | p value | Estimates (SE) | p value | |
| Age (per year) | −0.26 (0.18) | 0.16 | −0.07 (0.08) | 0.37 | −0.07 (0.13) | 0.52 | 0.02 (0.07) | 0.84 |
| Sex (boys versus girls) | 0.23 (0.29) | 0.43 | −0.26 (0.09) | 0.006∗ | −0.49 (0.14) | 0.004∗ | −0.09 (0.10) | 0.34 |
| BMI (per unit) | 0.16 (0.17) | 0.35 | −0.02 (0.03) | 0.42 | 0.06 (0.07) | 0.4 | −0.01 (0.01) | 0.54 |
| Insulin (per SD) | 0.52 (0.73) | 0.48 | 0.16 (0.08) | 0.06 | 0.25 (0.11) | 0.02∗ | 0.15 (0.04) | <0.0001∗ |
| VEGFA (per SD) | 0.16 (0.18) | 0.38 | 0.07 (0.06) | 0.26 | −0.08 (0.12) | 0.53 | 0.10 (0.04) | 0.01∗ |
| IL-12p70 (per SD) | −0.06 (0.13) | 0.66 | −0.07 (0.05) | 0.13 | −0.005 (0.06) | 0.93 | −0.14 (0.05) | 0.01∗ |
| Governorate | 0.12a | <0.0001a,∗ | <0.0001a,∗ | <0.0001a,∗ |
| Grade | Forequarter% | Ribs/Flank% | Rump/Round% | Loin% | T. Coxae (hip)% | T. Ischiadicum (rear)% | Total% |
| 1 | 12.2 | 7.9 | 8.3 | 5.5 | 20.0 | 14.9 | 68.7 |
| 2 | 10.2 | 6.3 | 1.9 | 1.3 | 9.3 | 2.4 | 31.3 |
| Total | 22.4 | 14.1 | 10.1 | 6.8 | 29.3 | 17.3 | 100 |
| Characteristics | HR* (95% CI) | P |
| EGFR CNG | 2.31 (1.44-3.69) | 0.001 |
| HER2 CNG | 1.21 (0.75-1.92) | 0.44 |
| HER3 CNG | 1.36 (0.85-2.15) | 0.19 |
| HER4 CNG | 1.29 (0.82-2.03) | 0.28 |
| Gender | 0.82 (0.52-1.30) | 0.39 |
| Age1 | 1.52 (1.16-1.98) | 0.002 |
| WHO grade2 | 1.92 (1.47-2.48) | 0.001 |
| KPS score3 | 1.38 (0.86-2.21) | 0.18 |
| Recurrence | 44.86 (6.16-327.00) | <0.001 |
| Radiotherapy | 0.47 (0.30-0.75) | <0.001 |
| Chemotherapy | 1.45 (0.92-2.30) | 0.11 |
| Smoking | 1.55 (0.96-2.50) | 0.07 |
| Drinking | 0.84 (0.31-2.30) | 0.73 |
| Epilepsy | 0.41 (0.25-0.66) | <0.001 |
| IDH1 mutations | 0.30 (0.17-0.53) | <0.001 |
| Gene | Location | Length (bp) | ||||
| Exon I | Intron I | Exon II | Intron II | Exon III | ||
| rps12 | LSC | 114 | - | 270 | ||
| ndhB | LSC | 729 | 629 | 780 | ||
| ycf66 | LSC | 106 | 591 | 320 | ||
| rpoC1 | LSC | 423 | 789 | 1614 | ||
| atpF | LSC | 411 | 654 | 135 | ||
| ycf3 | LSC | 126 | 684 | 228 | 739 | 153 |
| clpP | LSC | 69 | 687 | 291 | 483 | 234 |
| rpl2 | LSC | 396 | 637 | 438 | ||
| ndhA | SSC | 556 | 731 | 551 | ||
| trnK-UUU | LSC | 37 | 2272 | 42 | ||
| trnL-UAA | LSC | 38 | 262 | 50 | ||
| trnV-UAC | LSC | 37 | 542 | 37 | ||
| trnI-GAU | IR | 42 | 769 | 35 | ||
| trnA-UGC | IR | 38 | 763 | 35 |
| “At” | “From” | |||||
| Method | M | SD | M | SD | t | P |
| Persuasive Communication | 4.85 | 0.37 | 4.15 | 1.14 | 2.77 | .01 |
| Tailoring | 4.20 | 1.01 | 4.40 | 0.99 | −0.66 | .52 |
| Modeling | 4.30 | 0.66 | 4.55 | 0.69 | −1.56 | .14 |
| Feedback | 4.35 | 0.93 | 4.65 | 0.59 | −1.19 | .25 |
| Reinforcement/Punishment | 3.65 | 1.04 | 4.05 | 0.89 | −2.03 | .06 |
| Facilitation | 4.50 | 0.89 | 4.45 | 1.00 | 0.25 | .80 |
| Consciousness Raising | 4.60 | 0.82 | 4.15 | 1.18 | 1.69 | .11 |
| Direct Experience | 3.70 | 1.22 | 4.10 | 1.07 | −2.18 | .04 |
| Info about others’ approval | 4.35 | 0.88 | 4.05 | 0.76 | 1.19 | .25 |
| Resistance to Social Pressure | 3.30 | 1.13 | 3.60 | 0.88 | −0.88 | .39 |
| Goal Setting | 4.15 | 0.99 | 4.55 | 0.60 | −1.71 | .10 |
| Systems Change | 3.95 | 1.15 | 3.95 | 1.15 | 0.00 | .00 |
| Participatory Problem Solving | 4.25 | 0.72 | 3.90 | 0.91 | 1.44 | .17 |
| Coercion | 1.95 | 1.05 | 2.10 | 1.21 | −0.57 | .58 |
| Advocacy and Lobbying | 4.25 | 0.72 | 2.85 | 1.31 | 4.63 | .00 |
| Technical Assistance | 4.45 | 0.83 | 4.35 | 0.81 | 0.57 | .58 |
| Sense-making | 3.55 | 1.00 | 3.65 | 0.88 | −0.44 | .67 |
| Organ. Diagnosis and Feedback | 4.45 | 0.76 | 3.45 | 1.19 | 3.25 | .00 |
| Team Building | 3.70 | 1.13 | 3.65 | 1.31 | 0.16 | .87 |
| Structural Redesign | 3.45 | 1.15 | 3.70 | 1.13 | −0.69 | .50 |
| Increasing Stakeholder Influence | 3.70 | 1.13 | 3.10 | 1.37 | 1.71 | .10 |
| Social Action | 2.90 | 1.33 | 2.60 | 1.27 | 1.45 | .16 |
| Forming Coalitions | 3.65 | 0.93 | 3.10 | 1.02 | 2.77 | .01 |
| Reporting, Social Planning | 3.70 | 1.03 | 3.20 | 1.11 | 1.88 | .08 |
| Media Advocacy | 3.35 | 1.18 | 2.95 | 1.36 | 1.57 | .13 |
| PML isoform | Wild type | Nuclear import-defective mutant |
| PML I | PML NBs | Early endosomes |
| PML II | Nuclear periphery | Nuclear periphery |
| PML III | PML NBs | Late endosomes/lysosomes |
| PML IV | PML NBs | Late endosomes/lysosomes |
| PML V | PML NBs | Late endosomes/lysosomes |
| PML VII | Late endosomes/lysosomes | Not applicable |
| Species | m | M | N-M | n | Adjusted p-value |
| Dengue virus | 14 | 41 | 55016 | 550 | 0.00E+00 |
| Deer tick virus | 5 | 10 | 55047 | 550 | 8.20E-06 |
| Mycoplasma | 4 | 55 | 55002 | 550 | 0.5073 |
| A-2 plaque virus | 2 | 8 | 55049 | 550 | 0.6017 |
| Phytomyza | 5 | 100 | 54957 | 550 | 0.6325 |
| Orf virus | 6 | 150 | 54907 | 550 | 0.6859 |
| Brevibacterium | 3 | 41 | 55016 | 550 | 0.9211 |
| Gene | Complex | SNP | Major/minor allele | Location | MAF |
| NDUFS2 | I | rs33941127 | C/T | Promoter | T - 0.21 |
| NDUFS2 | I | rs3813623 | G/T | 5′-UTR | T - 0.15 |
| NDUFS2 | I | rs11538340 | C/A | Coding P20T | A - 0.06 |
| NDUFS2 | I | rs11576415 | C/G | Coding P352A | G - 0.09 |
| NDUFS2 | I | rs1136224 | A/G | 3′-UTR | G - 0.17 |
| UQCRB | III | rs7836698 | C/T | 3′-UTR | T - 0.42 |
| UQCRB | III | rs10504961 | C/T | 3′-UTR | T - 0.50 |
| COX5B | IV | rs11904110 | T/C | Promoter | C – 0.06 |
| COX6B1 | IV | rs6510502 | A/C | Promoter | C - 0.13 |
| COX6B1 | IV | rs10420252 | G/A | 5′-UTR | A - 0.10 |
| ATP5C1 | V | rs11255367 | G/A | Promoter | A - 0.12 |
| ATP5C1 | V | rs2802460 | T/C | Promoter | C - 0.26 |
| ATP5C1 | V | rs4655 | T/C | 3′-UTR | C - 0.36 |
| GAPDH | rs7971637 | C/T | Promoter | T - 0.19 | |
| GAPDH | rs1136666 | C/G | 5′-UTR | G - 0.26 | |
| HSPD1 | rs1116734 | C/G | Promoter | G - 0.33 |
| MIGS ID | Property | Term |
| MIGS-31 | Finishing quality | Finished |
| MIGS-28 | Libraries used | Three genomic libraries:two Sanger libraries – 8 kb pMCL200 and fosmid pcc1FOSand one 454 pyrosequece standard library |
| MIGS-29 | Sequencing platforms | ABI3730, 454 GS FLX |
| MIGS-31.2 | Sequencing coverage | 7.1× Sanger; 1.1× pyrosequence pseudo-reads |
| MIGS-30 | Assemblers | Newbler version 1.1.02.15, phrap |
| MIGS-32 | Gene calling method | Prodigal, GenePRIMP |
| INSDC ID | CP001874 | |
| Genbank Date of Release | May 17, 2010 | |
| GOLD ID | Gc01281 | |
| NCBI project ID | 469371 | |
| Database: IMG-GEBA | 2501651196 | |
| MIGS-13 | Source material identifier | DSM 43833 |
| Project relevance | Tree of Life, GEBA |
| Plot properties with increasing accelerator | Mechanistic conclusions |
| PAA saturates to 100% | d is before or at j |
| PAA does not saturate to 100% | d is after j |
| Saturated PAA less than 100% | 1. Equilibrium constant of antagonist at step d is less than that of agonist at step d and d is after j. Product is mostly derived from steps after d.2. Equilibrium constant of antagonist is greater than agonist and d is after j. Product is mostly derived from steps before d. |
| Saturated PAA greater than 100% | 1. Equilibrium constant of antagonist is greater than agonist and d is after j. Product is mostly derived from steps after d.2. Equilibrium constant of antagonist is less than agonist and d is after j. Product is mostly derived from steps before d. |
| PAA increases as linear-fractional function to maximum of 100% | Equilibrium constant of antagonist is less than agonist and d is before or at concentration limiting step (CLS) |
| PAA decreases as linear-fractional function to minimum of 100% | Equilibrium constant of antagonist is greater than agonist and d is before or at CLS |
| PAA is not a linear-fractional function | d is after CLS |
| PP increases | Equilibrium constant of antagonist is less than agonist |
| PP decreases | Equilibrium constant of antagonist is greater than agonist |
| PAA/PP does not change | d is before or at CLS |
| PAA/PP increases | Equilibrium constant of antagonist is greater than agonist and d is after CLS |
| PAA/PP decreases | Equilibrium constant of antagonist is less than agonist and d is after CLS |
| EC50 of PAA as function of receptor number decreases | d is before or at CLS |
| Village HAT status | Intervention participation | Cattle sampled (n) | TBSL + (n) | % TBSL + | SRA + (n) | % SRA + | TV + (n) | % TV + | TC + (n) | % TC + |
| HAT + villages | 956 | 195 | 20.4 | 12 | 1.3 | 0 | 0 | 108 | 11.3 | |
| Unknown | 32 | 5 | 15.6 | 0 | 0 | 0 | 0 | 3 | 9.4 | |
| Intervention | 486 | 89 | 18.3 | 4 | 0.8 | 0 | 0 | 56 | 11.5 | |
| No intervention | 438 | 101 | 23.1 | 8 | 1.8 | 0 | 0 | 49 | 11.2 | |
| HAT - villages | 935 | 147 | 15.7 | 2 | 0.2 | 1 | 0.1 | 123 | 13.2 | |
| Unknown | 27 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 14.8 | |
| Intervention | 558 | 86 | 15.4 | 1 | 0.2 | 1 | 0.2 | 83 | 14.9 | |
| No intervention | 350 | 61 | 17.4 | 1 | 0.3 | 0 | 0 | 36 | 10.3 |
| Variables | Percentages (%) ± SD | Normal Range † | P value |
| Total Carbohydrates | 47.8%* ± 1.70 | 55 - 65% | .000 |
| Total Fat | 35.6%* ± 1.66 | 25 - 35% | .000 |
| Saturated Fat | 16.5%* ± .84 | 7-10% | .000 |
| Monounsaturated Fat | 11.1%* ± .46 | 5-10% | .000 |
| Polyunsaturated Fat | 8.0%* ± .64 | 5-7% | .000 |
| Total Protein | 16.6%* ± .80 | 10 - 15% | .000 |
| Species | Mondragón-Jacobo et al. [11] | Griffith and Porter [13] | This protocol | |||
| DNA yield (ng/μl) | OD ratio 260.280 | DNA yield (ng/μl) | OD ratio 260.280 | DNA yield (ng/μl) | OD ratio 260.280 | |
| 1. Opuntia auberi Pfeiff. | 256 | 1.4 | 423 | 1.7 | 1600 | 1.9 |
| 2. Opuntia decumbens Salm-Dyck | 35 | 1.7 | 30 | 1.9 | 2930 | 1.9 |
| 3. Opuntia delafuentiana Martínez-González et al. | 75 | 1.6 | 56 | 1.9 | 4937 | 1.8 |
| 4. Opuntia depressa Britton and Tose | 95 | 1.9 | 73 | 1.8 | 8755 | 1.9 |
| 5. Opuntia durangensis Britton and Tose | 134 | 1.5 | 123 | 1.7 | 5835 | 1.9 |
| 6. Opuntia ficus-indica Mill. | 34 | 1.8 | 258 | 1.8 | 3829 | 2.0 |
| 7. Opuntia heliabravoana Scheinvar | 198 | 1.6 | 43 | 1.8 | 8743 | 1.8 |
| 8. Opuntia huajuapensis Bravo | 57 | 1.5 | 78 | 1.7 | 1573 | 1.9 |
| 9. Opuntia joconostle F.A.C. Weber | 86 | 1.9 | 196 | 1.0 | 8375 | 1.8 |
| 10. Opuntia lasiacantha Pfeiff. | 67 | 1.7 | 356 | 1.7 | 2943 | 1.9 |
| 11. Opuntia leiascheinvariana Martínez-González | 110 | 1.8 | 98 | 1.9 | 3980 | 1.9 |
| 12. Opuntia leucotricha DC. | 248 | 1.5 | 34 | 1.8 | 3789 | 1.9 |
| 13. Opuntia matudae Scheinvar | 93 | 1.7 | 63 | 1.8 | 7947 | 1.9 |
| 14. Opuntia megacantha Salm-Dyck | 117 | 1.6 | 78 | 1.8 | 7000 | 1.8 |
| 15. Opuntia microdasys Pfeiff. | 44 | 1.5 | 39 | 1.7 | 6578 | 1.9 |
| 16. Opuntia oligacantha Förster | 87 | 1.8 | 70 | 1.9 | 2395 | 1.8 |
| 17. Opuntia olmeca Joel Pérez et al. | 94 | 1.5 | 57 | 1.7 | 9200 | 1.9 |
| Variables | 2009–2010 Pandemic (n = 16) | 2012–2016 Postpandemic (n = 60) | p value |
| Male sex | 8 (50) | 42 (70) | 0.15 |
| Age, years | 43 (32–53) | 60 (50–65) | < 0.001 |
| BMI | 29.7 (24.0–36.1) | 27.1 (24.5–32.4) | 0.55 |
| BMI 30–40 | 6 (37) | 13 (22) | |
| BMI > 40 | 2 (12.5) | 6 (10.2) | 0.4 |
| Chronic underlying disease | 14 (87.5) | 49 (83) | 0.7 |
| Cardiovascular | 1 (6.3) | 24 (40) | 0.015 |
| COPD/asthma | 5 (31,3) | 18 (30.0) | >0.9 |
| Diabetes | 6 (37.5) | 9 (15.0) | 0.07 |
| Malignancy or immuno- suppressive medicationa | 1 (6.3) | 9 (15.0) | 0.7 |
| Epilepsy or other neurological disease | 6 (37.5) | 5 (8.3) | 0.009 |
| APACHE II score on admission | 14 (10–17) | 17 (13–22) | 0.002 |
| SAPS II score on admission | 31 (25–35) | 40 (31–51) | 0.002 |
| SOFA score on admission | 5 (3–7) | 6 (3–9) | 0.31 |
| SOFA score max | 5 (4–9) | 9 (5–12) | 0.03 |
| TISS score | 34 (28–42) | 39 (28–53) | 0.40 |
| LOS in ICU, days | 1.9 (1.1–4.8) | 4.3 (2.3–10.7) | 0.31 |
| LOS in hospital, days | 8.2 (4.6–10) | 13.0 (6.9–23.3) | 0.009 |
| ICU mortality | 0 | 6 (10) | 0.33 |
| Hospital mortality | 0 | 10 (16.7) | 0.11 |
| 6-month mortality | 2 (12.5) | 15 (25) | 0.5 |
| OverallAge range | Transported patients/population | Transport rate(per 1000/year) | Rate ratio (95% CI) |
| 85–99 | 59 570/237 873 | 250 | reference |
| 65–84 | 185 871/2 055 439 | 90 | 2.78 (2.17–3.58) |
| 45–64 | 135 135/3 258 801 | 41 | 6.10 (4.37–8.70) |
| 25–44 | 147 928/4 014 081 | 37 | 6.76 (4.77–9.82) |
| 5–24 | 114 260/2 847 377 | 40 | 6.25 (4.46–8.96) |
| 0–4 | 29 807/476 692 | 63 | 3.97 (3.00–5.32) |
| MalesAge range | Transported patients/population | Transport rate(per 1000/year) | Rate ratio (95% CI) |
| 85–99 | 21 151/72 432 | 292 | reference |
| 65–84 | 95 700/918 229 | 104 | 2.81 (2.24–3.55) |
| 45–64 | 84 491/1 641 695 | 51 | 5.73 (4.24–7.87) |
| 25–44 | 79 809/2 071 599 | 39 | 7.49 (5.35–10.75) |
| 5–24 | 62 777/1 467 004 | 43 | 6.79 (4.92–9.58) |
| 0–4 | 16 889/243 648 | 69 | 4.23 (3.25–5.58) |
| FemalesAge range | Transported patients/population | Transport rate(per 1000/year) | Rate ratio (95% CI) |
| 85–99 | 38 419/165 441 | 232 | reference |
| 65–84 | 90 171/1 137 210 | 79 | 2.94 (2.27–3.84) |
| 45–64 | 50 644/1 617 106 | 31 | 7.48 (5.13–11.27) |
| 25–44 | 68 119/1 942 482 | 35 | 6.63 (4.63–9.75) |
| 5–24 | 51 483/1 380 373 | 37 | 6.27 (4.42–9.13) |
| 0–4 | 12 918/233 044 | 55 | 4.22 (3.13–5.77) |
| Women of reproductive age (20–49 years) | Men (20–59 years) | Adolescent girls (15–19 years) | Adolescent boys (15–19 years) | Caregivers/family members | Total | |
| Kenya | 41 | 23 | 20 | 11 | 17 | 112 |
| Nepal | 40 | 29 | 10 | 10 | 15 | 104 |
| Uganda | 50 | 17 | 24 | 12 | 33 | 136 |
| Total | 131 | 69 | 54 | 33 | 65 | 352 |
| Study | Penetration | Genital contact | Exposure of genitals to child | Attempted penetration | Exploitation: prostitution or pornography |
| TYPE OF ABUSE | |||||
| NIS-1 | 0.3/1,000 | 0.2/1,000 | 0.1/1,000 | ||
| NIS-2 | 0.8/1,000 | 0.9/1,000 | 0.5/1,000 | ||
| CIS-1998 | 0.29/1,000 | 0.82/1,000 | 0.21/1,000 | 0.29/1,000 | 0.1/1,000 |
| Finkelhor et al. (2005) | 4/1,000 | 32/1,000 | 4/1,000 | 18/1,000 |
| Tissue | Number of Genes | Number of Z+ | Number of Z- | AVG (Number of Z+ with H3K4me3) | Number of Expected Z+ | AVG (Number of Z− with H3K4me3) | Number of Expected Z- | χ2P-Value |
| Astrocytes-cerebellar | 12,418 | 5,923 | 6,495 | 5,108 | 4,812.38 | 4,981.5 | 5,277.12 | 3.806E−09 |
| Cardiac fibroblasts | 12,098 | 5,605 | 6,493 | 4,702 | 4,548.21 | 5,115 | 5,268.78 | 0.00185 |
| Cardiac myocytes | 12,098 | 5,605 | 6,493 | 4,920.5 | 4,759.71 | 5,353 | 5,513.79 | 0.00146 |
| Nuclei/field | Central retina | Paracentral retina | Peripheral retina | |||
| Control | Scrapie | Control | Scrapie | Control | Scrapie | |
| Outer nuclearlayer | 5.9 ± 0.7 | 4.7 ± 1.1** | 5.8 ± 0.6 | 4.9 ± 0.8* | 5.3 ± 0.9 | 5.1 ± 1.5 |
| Inner nuclearlayer | 1.5 ± 0.2 | 1.0 ± 0.2** | 1.4 ± 0.2 | 1.0 ± 0.2* | 1.5 ± 0.2 | 1.3 ± 0.4 |
| Ref nr | Authors | Title | Journal | Year of publ |
| 31 | A.Ekström, A.Matthiesen, A.Widström, E.Nissen | Breastfeeding attitudes among counselling health professionals. Development of an instrument to describe breastfeeding attitudes. | Scandinavian Journal of Public Health, 33(5), 353–359. | 2005 |
| 22 | A.Ekström, A.Matthiesen, A.Widström, E.Nissen | Process-oriented Training in Breastfeeding Alters Attitudes to Breastfeeding in Health Professionals. | Scand. J of Public Health, 33(6), 424–431. | 2005 |
| 28 | A.Ekström, A.Matthiesen, A.Widström, E.Nissen | Does Continuity of Care by Well‐Trained Breastfeeding Counselors Improve a Mother’s Perception of Support? | Birth, 33(2), 123-130 | 2006 |
| 15 | A.Ekström, E.Nissen | A mothers’s feelings for her baby are strenghten by excellent breastfeeding counseling and continuity of care. | Peadiatrics, 118(2), e309-e314. | 2006 |
| 27 | A.Ekström, E.Nissen | Process-Oriented Training in Breastfeeding Attitudes and Continuity of Care Improve Mothers Perception of Support. | Health Education Research Trends. Nova Publishers. NY. | 2007 |
| 25 | A.Ekström, K.Guttke, M.Lenz, E.Hertfelt Wahn | Long term effects of professional breastfeeding support - An intervention. | International Journal of Nursing and Midwifery, Vol. 3(8), pp. 109–117. | 2011 |
| 26 | A.Ekström, E.Kylberg E.Nissen, | A process-oriented breastfeeding training for health professionals to promote breastfeeding. | Breastfeeding Medicine. 7(2), 85–92. | 2012 |
| 17 | S.Thorstensson, E.Nissen, A.Ekström | Professional support in pregnancy influence maternal relation to and feelings for the baby after Cesarean birth; an intervention study. | Journal of Nursing & Care 1:112. | 2012 |
| 23 | I.Blixt, L.B.Mårtensson, A.Ekström | Process-oriented training in breast feeding for health professionals decreases breastfeeding challenges. | International Breastfeeding Journal, 9:15 | 2014 |
| 24 | A.Ekström, H.Abrahamsson, R-M.Eriksson L.B.Mårtensson, | Women’s use of nipple shields - its influences on breastfeeding duration after a process oriented education for health professionals. | Breastfeeding Medicine, 9(9), 458-466 | 2014 |
| 2003 | 2009 | 2010 | 2012 | p-trend | |
| Total: | |||||
| PDa (95% CI) | |||||
| Low education | 23.1 (19.4–26.9) | 26.9 (24.4–29.4) | 28.3 (25.9–30.8) | 32.2 (29.0–35.5) | <0.001 |
| Medium education | 12.5 (9.2–15.8) | 12.8 (10.9–14.7) | 13.7 (11.9–15.5) | 14.4 (12.5–16.4) | 0.225 |
| High education (ref.) | 0.0 | 0.0 | 0.0 | 0.0 | |
| SIIb (95% CI) | 0.30 (0.25–0.35) | 0.34 (0.31–0.38) | 0.38 (0.34–0.41) | 0.41 (0.37–0.45) | 0.001 |
| Men: | |||||
| PDa (95% CI) | |||||
| Low education | 22.9 (17.9–28.0) | 26.4 (22.8–30.1) | 29.0 (25.4–32.5) | 33.6 (29.3–37.9) | 0.001 |
| Medium education | 15.6 (10.9–20.3) | 15.1 (12.1–18.1) | 17.6 (14.8–20.5) | 17.8 (15.0–20.6) | 0.299 |
| High education (ref.) | 0.0 | 0.0 | 0.0 | 0.0 | |
| SIIc (95% CI) | 0.30 (0.23–0.38) | 0.36 (0.30–0.41) | 0.39 (0.34–0.44) | 0.44 (0.39–0.49) | 0.004 |
| Women: | |||||
| PDa (95% CI) | |||||
| Low education | 23.2 (17.5–28.9) | 27.3 (23.8–30.8) | 27.7 (24.3–31.1) | 30.7 (25.8–35.6) | 0.041 |
| Medium education | 10.3 (5.4–15.1) | 11.6 (9.1–14.0) | 11.2 (8.9–13.6) | 11.4 (8.7–14.2) | 0.637 |
| High education (ref.) | 0.0 | 0.0 | 0.0 | 0.0 | |
| SIIc (95% CI) | 0.29 (0.22–0.37) | 0.33 (0.29–0.38) | 0.36 (0.32–0.41) | 0.37 (0.32–0.43) | 0.077 |
| Parameter | Total (n = 273)N (%) | Recurrence (n = 81) | Non-recurrence (n = 192) | PRe versus non-re |
| Age (years) | 19.8 ± 3.5 | 19.4 ± 4.3 | 20.1 ± 4.6 | 0.242 |
| Male, n (%) | 221 (81.0%) | 63 (28.5%) | 158 (71.5%) | 0.386 |
| Height (cm) | 173.6 ± 4.7 | 174.3 ± 4.1 | 173.0 ± 4.5 | 0.026 |
| Weight (kg) | ||||
| BMI (kg/m2), n (%) | 59.2 ± 7.3 | 57.1 ± 5.0 | 62.2 ± 6.9 | <0.001 |
| Underweight | 75 (27.5%) | 46 (61.3%) | 29 (38.7%) | |
| Normal | 192 (70.3%) | 34 (17.7%) | 158 (82.3%) | |
| Overweight | 6 (2.2%) | 1 (16.7%) | 5 (83.3%) | |
| Obese | 0 (0%) | 0 (0%) | 0 (0%) | |
| Smoking history, n (%) | 0.850 | |||
| Yes | 19 (7.0%) | 6 (31.6%) | 13 (68.4%) | |
| No | 254 (93.0%) | 75 (29.5%) | 179 (70.5%) | |
| Location of pneumothorax, n (%) | 0.490 | |||
| Right | 145 (53.1%) | 39 (26.9%) | 106 (73.1%) | |
| Left | 126 (46.2%) | 41 (32.5%) | 85 (67.5%) | |
| Bilateral | 2 (0.7%) | 1 (50%) | 1 (50%) | |
| Size of pneumothorax, n (%) | 0.002 | |||
| <50 | 171 (62.6%) | 27 (33.3%) | 137 (71.4%) | |
| ≥50 | 102 (37.4%) | 54 (52.9%) | 48 (47.1%) | |
| Treatment, n (%) | <0.001 | |||
| Non-surgery | 97 (35.5%) | 57 (58.8%) | 40 (41.2%) | |
| Surgery | 176 (64.5%) | 24 (13.6%) | 152 (86.4%) | |
| Overall recurrence rate (year) | ||||
| 1 | 57 (20.9%) | – | – | – |
| 2 | 65 (23.8%) | – | – | – |
| 5 | 81 (28.7%) | – | – | – |
| Two-stage period | Possible counts | Percentages |
| Blastula-early gastrula | (0:0:0) | (0:0:0) |
| Early gastrula-mid gastrula | (4:2:0) | (67:33:0) |
| Mid gastrula-late gastrula | (5:1:0) | (83:17:0) |
| Late gastrula-early planula | (6:1:0) | (86:14:0) |
| Early planula-planula | (5:1:0) | (83:17:0) |
| Planula-late planula | (2:1:0) | (67:33:0) |
| GeneID | Protein description | Pathway | Fold change for transcripts | Fold change for proteins |
| Entcl_0332 | Phosphoenolpyruvate carboxykinase (ATP) (complement(365954..367573)) | Citrate cycle (TCA cycle) | 2.670 | 3.102 |
| Entcl_3179 | UspA domain-containing protein (3394773..3395201) | None given | 3.080 | 2.953 |
| Entcl_4175 | Periplasmic binding protein/LacI transcriptional regulator (complement(4503494..4504456)) | ABC transporters | 2.170 | 2.796 |
| Entcl_3779 | Carbon starvation protein CstA (4066791..4068944) | None given | 2.670 | 2.701 |
| Entcl_1304 | Malic protein NAD-binding (1376647..1378926) | Pyruvate metabolism | 3.770 | 2.490 |
| Entcl_0617 | AI-2 transport system substrate-binding protein (642484..643485) | ABC transporters | 3.180 | 1.780 |
| Entcl_4402 | Periplasmic binding protein/LacI transcriptional regulator (complement(4764359..4765249)) | ABC transporters | 2.020 | 1.704 |
| Entcl_1207 | ABC transporter, substrate-binding protein (complement(1260320..1261303)) | ABC transporters | 2.380 | 1.564 |
| Entcl_2658 | Isocitrate dehydrogenase, NADP-dependent (complement(2808830..2810080)) | Glutathione metabolism | 2.010 | 1.091 |
| Entcl_0176 | D-xylose ABC transporter, periplasmic substrate-binding protein (complement(183475..184470)) | ABC transporters | 2.410 | 1.035 |
| Entcl_3614 | 2-oxo-acid dehydrogenase E1 subunit, homodimeric type (complement(3877006..3879669)) | Glycolysis/Gluconeogenesis | 2.500 | −0.229 |
| Entcl_1941 | Phosphoribosylglycinamide formyltransferase 2 (complement(2053388..2054566)) | Purine metabolism | −2.080 | −0.779 |
| Entcl_1559 | Cytidine deaminase (complement(1657176..1658060)) | Pyrimidine metabolism | −3.710 | −1.169 |
| Entcl_0641 | Cys/Met metabolism pyridoxal-phosphate-dependent protein (complement(670311..671459)) | None given | −2.000 | −1.757 |
| Entcl_3443 | Taurine dioxygenase (complement(3672816..3673664)) | Taurine and hypotaurine metabolism | −14.850 | −2.995 |
| Original = cardio-vascular | Oncology | Psychiatric | Anti-viral | Anti-bacterial/fungal | Monogenetic orphans | |
| Aspect | ||||||
| Starting evidence | ||||||
| In vitro data including animal genetics | 2 | 2 | 1 | 9 | 3 | 2 |
| In vivo data including animal genetics | 3 | 1 | 1 | 1 | 5 | 2 |
| Animal disease models | 3 | 5 | 1 | 1 | 5 | 2 |
| Data from multiple species | 3 | 1 | 1 | 1 | 1 | 2 |
| Human evidence | ||||||
| Genetics | 5 | 5 | 4 | 4 | 4 | 20 |
| Model compounds | 13 | 10 | 26 | 12 | 12 | 2 |
| Clinical trials | 13 | 11 | 26 | 12 | 12 | 10 |
| Biomarkers for efficacy and safety prediction | ||||||
| Biomarker grading | 24 | 28 | 10 | 23 | 22 | 23 |
| Biomarker development | 13 | 17 | 5 | 12 | 11 | 12 |
| Proof-of-mechanism, proof-of-principle and proof of concept testing | ||||||
| Biomarker strategy | 5 | 5 | 7 | 5 | 5 | 5 |
| Surrogate or endpoint strategy | 8 | 2 | 12 | 7 | 7 | 7 |
| Personalized medicine aspects | ||||||
| Disease sub-classification and responder concentration | 3 | 7 | 2 | 9 | 9 | 9 |
| Pharmacogenetics | 5 | 6 | 4 | 4 | 4 | 4 |
| Sum | 100 | 100 | 100 | 100 | 100 | 100 |
| Treatment | Dry leaf yield (t ha−1) | Dry stem yield (t ha−1) | Harvest Index (HI) | |||||||||||||||
| CSIR-IHBT | RHRS | PAU | CSIR-IHBT | RHRS | PAU | CSIR-IHBT | RHRS | PAU | ||||||||||
| 2010 | 2011 | 2010 | 2011 | 2010 | 2011 | 2010 | 2011 | 2010 | 2011 | 2010 | 2011 | 2010 | 2011 | 2010 | 2011 | 2010 | 2011 | |
| Nitrogen Level | ||||||||||||||||||
| N30 | 1.24 | 1.34 | 0.79 | 0.91 | 0.39 | 0.6 | 1.83 | 1.99 | 1.42 | 1.43 | 0.78 | 1.19 | 0.41 | 0.42 | 0.36 | 0.39 | 0.34 | 0.33 |
| N60 | 1.56 | 1.69 | 0.93 | 1.04 | 0.52 | 0.81 | 2.19 | 2.48 | 1.47 | 1.56 | 0.76 | 1.47 | 0.42 | 0.41 | 0.39 | 0.4 | 0.4 | 0.35 |
| N90 | 1.69 | 1.91 | 1.03 | 1.19 | 0.53 | 0.83 | 2.35 | 2.65 | 1.56 | 1.69 | 0.74 | 1.53 | 0.42 | 0.42 | 0.39 | 0.41 | 0.41 | 0.35 |
| SEm(±) | 0.04 | 0.03 | 0.03 | 0.02 | 0.02 | 0.04 | 0.04 | 0.05 | 0.03 | 0.03 | 0.03 | 0.08 | 0.007 | 0.004 | 0.009 | 0.007 | 0.007 | 0.011 |
| CD(P = 0.05) | 0.10 | 0.09 | 0.08 | 0.06 | 0.05 | 0.13 | 0.12 | 0.14 | 0.08 | 0.08 | NS | 0.22 | NS | NS | 0.025 | NS | 0.021 | NS |
| Phosphorus Level | ||||||||||||||||||
| P20 | 1.44 | 1.55 | 0.87 | 1.01 | 0.47 | 0.68 | 1.94 | 2.22 | 1.48 | 1.55 | 0.73 | 1.35 | 0.42 | 0.41 | 0.37 | 0.39 | 0.39 | 0.34 |
| P40 | 1.55 | 1.74 | 0.98 | 1.08 | 0.48 | 0.8 | 2.3 | 2.52 | 1.49 | 1.56 | 0.79 | 1.45 | 0.4 | 0.41 | 0.39 | 0.41 | 0.38 | 0.35 |
| SEm (±) | 0.03 | 0.03 | 0.02 | 0.02 | 0.01 | 0.04 | 0.03 | 0.04 | 0.02 | 0.02 | 0.03 | 0.06 | 0.006 | 0.003 | 0.007 | 0.006 | 0.006 | 0.009 |
| CD(P = 0.05) | 0.08 | 0.07 | 0.06 | 0.05 | NS | 0.11 | 0.10 | 0.12 | NS | NS | NS | NS | 0.016 | NS | 0.020 | 0.016 | NS | NS |
| Potassium Level | ||||||||||||||||||
| K20 | 1.38 | 1.51 | 0.84 | 0.99 | 0.47 | 0.74 | 1.91 | 2.20 | 1.49 | 1.53 | 0.75 | 1.31 | 0.41 | 0.41 | 0.37 | 0.39 | 0.38 | 0.36 |
| K40 | 1.62 | 1.74 | 0.98 | 1.08 | 0.49 | 0.76 | 2.11 | 2.44 | 1.52 | 1.59 | 0.77 | 1.48 | 0.43 | 0.42 | 0.39 | 0.4 | 0.38 | 0.34 |
| K60 | 1.50 | 1.69 | 0.95 | 1.07 | 0.49 | 0.73 | 2.34 | 2.48 | 1.54 | 1.56 | 0.76 | 1.41 | 0.39 | 0.41 | 0.38 | 0.4 | 0.39 | 0.34 |
| SEm (±) | 0.04 | 0.03 | 0.03 | 0.02 | 0.02 | 0.04 | 0.04 | 0.05 | 0.03 | 0.03 | 0.03 | 0.08 | 0.007 | 0.004 | 0.009 | 0.007 | 0.007 | 0.011 |
| CD(P = 0.05) | 0.10 | 0.09 | 0.08 | 0.06 | NS | NS | 0.12 | 0.14 | 0.08 | NS | NS | NS | 0.02 | NS | NS | NS | NS | NS |
| Interaction effect | ||||||||||||||||||
| CD of N × P | NS | NS | NS | NS | NS | NS | 0.16 | 0.20 | NS | NS | NS | NS | NS | NS | NS | NS | NS | NS |
| CD of N × K | 0.18 | 0.16 | NS | NS | NS | NS | 0.20 | NS | NS | NS | NS | NS | 0.04 | NS | NS | NS | NS | NS |
| CD of P × K | NS | NS | NS | NS | NS | NS | 0.16 | NS | NS | NS | NS | NS | 0.03 | NS | NS | NS | NS | NS |
| CD of N × P × K | NS | NS | NS | NS | NS | NS | NS | NS | NS | NS | NS | NS | NS | NS | NS | NS | NS | NS |
| Authors, year of publication | Samples | PIK3CA mutations | Ref. |
| Campbell et al., 2004 | 167 primary epithelial ovarian carcinomas, of which, 40 were samples of EnOC and OCCC and 88 were samples of serous ovarian carcinomas (all coding exons of PIK3CA analyzed) | PIK3CA mutations in 8 (20%) of 40 EnOC and OCCC compared to only 2 (2.3%) of 88 in serous ovarian carcinomas (p = 0.001); mutation or gene amplification of PIK3CA was found in a total of 45% of OCCC and EnOC | [135] |
| Wang et al., 2005 | 109 advanced ovarian carcinomas, including inter alia 2 OCCC and 5 EnOC, as well as 90 serous and 4 mucinous ovarian carcinomas (PIK3CA exon 9 and 20 analyzed) | A total of 4 activating missense PIK3CA mutations in 109 tumors were found (in 1 of 2 OCCC, 1 mucinous and 2 serous ovarian carcinomas) | [136] |
| Levine et al., 2005 | 198 unselected invasive epithelial ovarian carcinomas (exon 9 and 20 analyzed) | PIK3CA mutations in 24 of 198 (12%) ovarian carcinomas (not significantly different between different histological subtypes) | [137] |
| Willner et al., 2007 | 12 OCCC, 26 EnOC and 51 serous ovarian carcinomas | Mutations in 3 of 12 (25%) OCCC, in 3 of 26 (12%) EnOC, but in none of 51 serous ovarian carcinomasPIK3CA gene amplification found in 0/22 EnOC and OCCC compared to 19/94 (20%) in SC | [138] |
| Kuo et al., 2009 | 97 OCCC (18 OCCC with affinity-purified tumor cells from fresh specimen, 69 microdissected tumors from paraffin tissues, 10 tumor cell lines) | PIK3CA mutations in 33% of the 97 OCCC (46% of the 28 affinity-purified OCCC and OCCC cell lines) | [129] |
| Jones et al., 2010 | Whole exome sequencing in 8 OCCC samples and validation in 42 OCCC (including the 8 tumor samples of the discovery cohort) by Sanger sequencing of all exon | Mutations of PIK3CA in 40% of the 42 tumors (a total of 17 mutations), the majority at codons 542, 545, 546 or 1,047 | [2] |
| Yamamoto et al., 2011 | 23 OCCC (sequencing of PIK3CA exons 9 and 20) | PIK3CA mutations in 10 (43%) of 23 OCCC (H1047R mutations in the kinase domain in all cases) | [134] |
| Yamamoto et al., 2012 | 42 OCCC (28 endometriosis-associated cases and 14 clear-cell adenofibroma-associated carcinoma cases (sequencing of exons 9 and 20) | 17 (40%) of the 42 OCCC harboring PIK3CA mutations (majority of them ARID1A-deficient carcinomas (71%), suggesting frequent co-occurrence of mutations in these two genes | [101] |
| Yamamoto et al., 2012 | 90 cases of OCCC (including 42 cases previously examined in [101]; sequencing of PIK3CA exons 9 and 20) | PIK3CA mutations found in 34 (39%) of 88 informative OCCC cases | [102] |
| Rahman et al., 2012 | Mutational analysis of PIK3CA (exons 1, 9, 20) and immunohistochemistry for phospho-AKT and -mTOR in 56 OCCC samples13 ovarian carcinoma cell lines (4 serous, 9 clear cell) for in vitro inhibitor studies | Missense mutations in 16 (28.6%) of 56 OCCC tumor samplesNo correlation of PIK3CA mutations with the immunohistochemical pattern of phosphorylated AKT or mTORNo correlation of PIK3CA mutations with sensitivity to PI3K/AKT/mTOR inhibitors in OCCC cell lines | [139] |
| McConechy et al., 2013 | Select exon capture sequencing in 33 EnOC samples in addition to 307 endometrial endometrioid carcinomas | 12 (40%) of 30 EnOC mutated in PIK3CA. 107 (39%) of 307 low-grade endometrial endometrioid carcinomas mutated in PIK3CA | [140] |
| NLR | PLR | RDW | SCC-Ag | |||||
| Stage | AUC | P value | AUC | P value | AUC | P value | AUC | P value |
| Stage I+IIA | 0.5153 | 0.5112 | 0.5360 | 0.1232 | 0.5150 | 0.5205 | 0.8568 | < 0.0001 |
| Stage IIB | 0.6144 | < 0.0001 | 0.5993 | 0.0004 | 0.5037 | 0.8937 | 0.9554 | < 0.0001 |
| Stage III+IV | 0.7423 | < 0.0001 | 0.6381 | 0.0012 | 0.5612 | 0.1510 | 0.9673 | < 0.0001 |
| Category and Population | Core | Flexible | Odds Ratio | Significance |
| Nonsynonymous mutations in nonmutator populations | 123 | 51 | 2.41 | P < 10−8 |
| Synonymous mutations in nonmutator populations | 10 | 10 | 1.00 | P = 1.0000 |
| Nonsynonymous mutations in mutator populations | 2265 | 2510 | 0.90 | P = 0.1477 |
| Synonymous mutations in mutator populations | 838 | 860 | 0.97 | P = 0.4814 |
| Materials | Elastic modulus | Poisson ratio | Friction coefficient |
| E (MPa) | μ | f | |
| Titanium plate | 110,000 | 0.30 | 0.45 |
| Titanium screw | 110,000 | 0.30 | – |
| Articular cartilage | 11.9–0.48 | 0.40 | 0.0024 ~ 0.24 |
| Cortical bone | 17,000 | 0.3 | 0.4 |
| Cancellous bone | 129 | 0.2 | 0.4 |
| Name | Sequence (5’ --- 3’) | Length (bp) | Tm (° C) |
| flp-14 RT F | GCGAGTCCATGTGTAGCAGCTAAT | 117 | 60 |
| flp-14 RT R | GGGAGATGAAGAACGTTTACTACTTTGCC | ||
| flp-18 RT F | AGGATGACTTATTGCGCCAGGA | 185 | 60 |
| flp-18 RT R | TTCCTTTACCGAATCTGAGCACGC | ||
| 18SrRNA Tobacco RT F | CGCGCGCTACACTGATGTATTCAA | 172 | 60 |
| 18SrRNA Tobacco RT R | TACAAAGGGCAGGGACGTAGTCAA | ||
| 18SrRNAM.incognita RT F | TCAACGTGCTTGTCCTACCCTGAA | 155 | 60 |
| 18SrRNAM.incognita RT R | TGTGTACAAAGGGCAGGGACGTAA |
| Strain | Animal No. | Incidence (%) | Multiplicity a) | |
| FVB/N | total | 16 | 16 (100) | 32.56 ± 3.60 |
| female | 9 | 9 (100) | 28.22 ± 4.46 | |
| male | 7 | 7 (100) | 38.14 ± 5.36 | |
| PWK/Rbrc | total | 10 | 0 (0) | 0 |
| female | 10 | 0 (0) | 0 | |
| male | 10 | 0 (0) | 0 | |
| FVB × PWK | total | 25 | 4 (16) | 0.32 ± 0.8 |
| female | 14 | 4 (28.6) | 0.57 ± 1.01 | |
| male | 11 | 0 (0) | 0 | |
| PWK × FVB | total | 17 | 0 (0) | 0 |
| female | 8 | 0 (0) | 0 | |
| male | 9 | 0 (0) | 0 | |
| (FxP) × F | total | 208 | 123(56.7) | 4.86 ± 0.56 |
| female | 107 | 60(56.1) | 3.45 ± 0.64 | |
| male | 101 | 63(62.4) | 6.34 ± 0.92 |
| 2011 totala | 2011 indoor tanned | 2013 totala | 2013 indoor tanned | Chi-square | P value | |
| Sex | ||||||
| Female | 8,316 | 1420 (17.6%) | 8004 | 882 (11.7%) | 10.2 | 0.002 |
| Male | 7,293 | 442 (6.4%) | 7180 | 276 (3.8%) | 9.64 | 0.002 |
| Combined | 15,609 | 1862 (12%) | 15,184 | 1158 (7.7%) | 11.37 | <0.0001 |
| Grade Level | ||||||
| 8th grade | 6,035 | 332 (5.2%) | 6,186 | 228 (3.3%) | 7.8 | 0.005 |
| 10th grade | 5,389 | 669 (11.9%) | 5,069 | 417 (7.4%) | 8.9 | 0.003 |
| 12th grade | 4,187 | 861 (19.6%) | 3,970 | 516 (12.6%) | 9.1 | 0.003 |
| Race/ethnicity | ||||||
| American Indian | 512 | 58 (9.8%) | 501 | 38 (6.7%) | 1.8 | 0.18 |
| Asian | 462 | 31 (5.9%) | 517 | 33 (6.4%) | 0.53 | 0.82 |
| Black | 399 | 39 (8.1%) | 422 | 23 (4.7%) | 2.35 | 0.13 |
| Hispanic | 2,061 | 146 (6.9%) | 2,347 | 114 (4.5%) | 5.43 | 0.02 |
| Pacific Islander | 415 | 33 (7.1%) | 424 | 26 (5.8%) | 0.32 | 0.57 |
| White | 12,724 | 1,657 (13.3%) | 12,242 | 1,009 (8.5%) | 11.35 | <0.0001 |
| Substance use | ||||||
| Smoked in past 30 days | 823 | 233 (30.6%) | 620 | 126 (19.7%) | 7.53 | 0.006 |
| Did not smoke in past 30 days | 14,701 | 1,625 (11%) | 14,533 | 1,029 (7.2%) | 10.94 | 0.001 |
| Drank alcohol within past 30 days | 1,759 | 464 (26.4%) | 1,387 | 268 (19.2%) | 11.8 | <0.0001 |
| Did not drink within the past 30 days | 13,746 | 1,386 (10.2%) | 13,704 | 876 (6.5%) | 10.92 | 0.0010 |
| Body weight status | ||||||
| Normal weight | 12,655 | 1,620 (12.9%) | 11,255 | 924 (8.3%) | 11.03 | 0.001 |
| Obese (>95th percentile for weight) | 1,068 | 55 (6.1%) | 1123 | 60 (6.3%) | 0.015 | 0.901 |
| Parental education level | ||||||
| <High school | 822 | 81 (11.3%) | 902 | 60 (7.5%) | 2.98 | 0.09 |
| High school graduate | 2,166 | 311 (14.8%) | 2,128 | 217 (10.5%) | 6.17 | 0.01 |
| Some college | 2,657 | 370 (14%) | 2,524 | 227 (8.4%) | 7.36 | 0.007 |
| Bachelor degree | 5,781 | 642 (11.1%) | 5,453 | 387 (7%) | 8.73 | 0.003 |
| Graduate degree | 2,471 | 301 (12%) | 2,457 | 154 (6.7%) | 9.01 | 0.003 |
| Local health district | ||||||
| Bear River | 1,745 | 198 (11.7%) | 1,773 | 134 (7.5%) | 3.34 | 0.07 |
| Central | 1,007 | 163 (15.9%) | 964 | 111 (11.5%) | 2.51 | 0.11 |
| Davis | 1,678 | 200 (13.5%) | 590 | 51 (8.2%) | 4.51 | 0.03 |
| Salt Lake | 3,984 | 393 (10.1%) | 4,197 | 263 (6.6%) | 7.35 | 0.007 |
| Southeast | 559 | 54 (8.3%) | 597 | 57 (9.8%) | 0.45 | 0.49 |
| Southwest | 1,065 | 156 (14%) | 1,290 | 140 (9.7%) | 2.95 | 0.09 |
| Summit | 424 | 50 (11.6%) | 477 | 25 (5.3%) | 4.02 | 0.05 |
| Tooele | 855 | 90 (10.8%) | 993 | 74 (7.8%) | 1.78 | 0.18 |
| Tri-County | 432 | 71 (19.7%) | 433 | 45 (12.3%) | 1.85 | 0.17 |
| Utah County | 2,177 | 274 (11.7%) | 2,427 | 135 (6.7%) | 5.02 | 0.03 |
| Wasatch | 321 | 40 (12.9%) | 278 | 24 (9.5%) | 0.58 | 0.44 |
| Weber-Morgan | 1,364 | 173 (14.5%) | 1,206 | 102 (9.7%) | 2.36 | 0.12 |
| Variable | GPCPa | EPGb | MDc |
| n = 35 | n = 21 | n = 20 | |
| Median; mean (SD) | Median; mean (SD) | Median; mean (SD)) | |
| Age in years | 86.0; 85.0 (7.5) | 87.0; 84.8 (7.2) | 87.5; 88.0 (5.6) |
| Baseline QoLd (EQ-5D score) | 0.33; 0.38 (0.33) | 0.45; 0.46 (0.26) | 0.38; 0.41 (0.33) |
| Baseline functional status (Barthel Index) | 57.0; 55.5 (23.3) | 61.0; 59.8 (19.2) | 60.5; 58.4 (20.9) |
| Baseline cognitive function (SMMSEe score)* | 25.0; 23.3 (5.7) | 19.5; 19.2 (5.8) | 23.5; 23.4 (4.3) |
| Baseline depressive symptoms (GDS-15f score) | 6.0; 5.8 (2.7) | 5.0; 5.6 (2.9) | 4.5; 6.0 (3.6) |
| Body mass index (BMI)g | 22.2; 23.6 (6.5) | 24.0; 24.9 (5.3) | 22.9; 23.9 (5.0) |
| Gender [n,(%) male] | 15 (43) | 12 (57) | 5 (25) |
| n (%) who had a QoLh gain over 12 months | 13 (41) | 7 (41) | 8 (44) |
| n (%) who had died at the end of 12 months | 10 (29) | 6 (29) | 2 (10) |
| Place of death [n (%) in each column] | |||
| Hospital | 6 (60) | 3 (50) | 1 (50) |
| Residential Care/Respite | 4 (40) | 3 (50) | 1 (50) |
| Home/Independent living unit | 0 | 0 | 0 |
| When AD was completedi | |||
| Before admission to TCj | 0 | 17 (81) | 5 (25) |
| During admission to TCj | 35 (100) | 2 (10) | 15 (70) |
| Trial Arm | |||
| Intervention* | 30 (86) | 14 (67) | 9 (45) |
| Usual care* | 5 (14) | 7 (33) | 11 (55) |
| SiteLight | FINDMAP | 3DEX | MIMOP | Mapitope | MIMOX | |
| Coded in | C++ | C++ | VB | PHP | C++ | Perl |
| Operating System | Linux | Not stated | Windows | Platform independent | Windows | Platform independent |
| Interface | Command Line | Not stated | Graphic | Web | Command Line | Web |
| Online Service | no | no | no | available on request | under construction | available |
| Structure Dependent | yes | no | yes | yes/no | yes | yes |
| Rank | Suggestions for solutions to delayed diagnosis in primary care | Total priority score | Type of interventions to decrease delayed diagnosis | Breakdown points in the diagnostic process |
| 1 | To have more rigorous systems in place for communicating abnormal results to patients | 92.3 | Structured-process change | Follow-up |
| 2 | Direct hotlines to specialists to discuss patient problems | 91.4 | Structured-process change | Referral & consultation |
| 3 | Clear referral guidelines and pathways for other common conditions (not just cancer) | 88.4 | Structured-process change | Referral & consultation |
| 4 | Improve handovers | 86.9 | Structured-process change | Referral & consultation |
| 6 | To have “affordable” GP update courses | 86.3 | Educational intervention | Patient-practitioner encounter |
| 5 | Better training of GPs in spotting warning signs of serious conditions, diagnosis that are easily missed and safety netting | 86.3 | Educational intervention | Patient-practitioner encounter |
| 7 | Review of every delayed diagnosis to learn how, why and whether it could be prevented in the future | 85.4 | Additional review & education | NA |
| 8 | Better ways of informing patients that their results are ready and what the next best steps would be | 84.8 | Structured-process change | Follow-up |
| 9 | Training in decision making and reinforcing the concept on ongoing reflection to continuous consideration of differential diagnosis | 84.5 | Educational intervention | Patient-practitioner encounter |
| 10 | Have easier access to secondary care for the patients that GPs are worried about | 83.9 | Structured-process change | Referral & consultation |
| Neural-specific measurements: low-stability mRNAs | |||||
| GO term | Definition | Pvalue | FDR | Count | Fold enrichment |
| 0006351 | Transcription | 4 × 10−10 | 2 × 10−7 | 58 | 2.5 |
| svp, dpn, pros, vvl, grh, gsb, onecut | |||||
| 0030182 | Neuron differentiation | 2 × 10−7 | 4 × 10−5 | 48 | 2.3 |
| chinmo, Dl, tup, Ephrin, Eph, fax, shot | |||||
| 0007067 | Mitosis | 6 × 10−5 | 3 × 10−3 | 21 | 2.9 |
| cycB3, cdc27, Sse, cnn, glu, mts | |||||
| 0018024 | Histone methyltransferase activity | 2 × 10−4 | .02 | 7 | 6.9 |
| G9a, Set1, Set2, Su(z)12, ash1, egg | |||||
| 0006897 | Endocytosis | 4 × 10−3 | .08 | 25 | 1.9 |
| Arpc4, shi, CalpA, pat1, faf, scb, Rac1 | |||||
| 0005840 | Ribosome | 2 × 10−3 | .06 | 21 | 2.0 |
| RpL17, RpL35, mRpL11, mRpS35 | |||||
| Neural-specific measurements: high-stability mRNAs | |||||
| GO term | Definition | Pvalue | FDR | Count | Fold enrichment |
| 0048812 | Neuron projection morphogenesis | 5 × 10−6 | 6 × 10−4 | 33 | 2.4 |
| trc, fusl, Fas2, Appl, Fmr1, otk, ben | |||||
| 0003924 | GTPase activity | 2 × 10−4 | .02 | 17 | 2.9 |
| Rab23, Rab30, Rab11, Rho1, Ras64B | |||||
| 0012501 | Programmed cell death | 2 × 10−3 | .06 | 17 | 2.4 |
| grim, pten, scyl, egr, mod(mdg4) | |||||
| 0004672 | Protein kinase activity | 9 × 10−3 | .24 | 23 | 1.8 |
| CamKI, Cdk4, Ror, ald, aur, nmo, trbl | |||||
| 0019226 | Transmission of nerve impulse | .02 | .25 | 17 | 1.8 |
| CASK, CanB, Dap160, cpx, Sap47 | |||||
| 0051674 | Localization of cell | .01 | .16 | 18 | 1.9 |
| cbl, APC, cortactin, par-6, baz, spri |
| Treatment | ||||
| Variety | Tissue | Control | Mild stress | Severe stress |
| Costal | Needles | DCNC | DCNM | DCNS |
| Wood | DCWC | DCWM | DCWS | |
| Interior | Needles | DINC | DINM | DINS |
| Wood | DIWC | DIWM | DIWS |
| Type of Insurance | Estimated cases in 2005 (a) | Estimated cases in 2005 (b) | Incremental financial burden of moving from OC to LC by government (c) | Household's off-set cost from moving from OC to LC (d) | Net financial burden to society (e) |
| UC | 8,000 | 6,400 | 76,800,000 | 32,000,000 | 44,800,000 |
| CSMBS | 2,000 | 1,600 | 19,200,000 | 8,000,000 | 11,200,000 |
| Total | 10,000 | 8,000 | 96,000,000 | 40,000,000 | 56,000,000 |
| Theme | Balancing between ideality and reality | ||
| Categories | Limitation | Self-regulation | Companionship |
| Subcategories | Insufficiency | Guilt | Belonging |
| Adaptation | Motivation | Pleasure |
| A (n= 1930) | B (n= 1938) | C (n= 1969) | Total (N= 5837) | |
| What would you say was the design of the study? | ||||
| Two separate surveys of student drinking | 323 (17%) | 322 (17%) | 290 (15%) | 935 (16%) |
| Following up a group of student drinkers over time | 1,523 (79%) | 1,515 (78%) | 1,550 (79%) | 4,588 (79%) |
| Other | 84 (4.4%) | 101 (5.2%) | 129 (6.6%) | 314 (5.4%) |
| After completing the survey last month did you think more about your drinking? | ||||
| No | 1357 (70%) | 1407 (73%) | 1357 (69%) | 4121 (71%) |
| Yes | 455 (24%) | 424 (22%) | 500 (25%) | 1379 (24%) |
| Don’t know | 118 (6.1%) | 107 (5.5%) | 112 (5.7%) | 337 (5.8%) |
| After completing the survey last month did you change your drinking? | ||||
| My drinking did not change | 1493 (77%) | 1535 (79%) | 1532 (78%) | 4560 (78%) |
| My drinking decreased | 358 (19%) | 317 (16%) | 363 (18%) | 1038 (18%) |
| My drinking increased | 79 (4.1%) | 86 (4.4%) | 74 (3.8%) | 239 (4.1%) |
| Was this due to taking part in the survey? (Asked of 1038 participants who said their drinking decreased) | ||||
| No | 276 (77%) | 251 (79%) | 288 (79%) | 815 (79%) |
| Yes | 82 (23%) | 66 (21%) | 75 (21%) | 223 (21%) |
| Incidental PTMCs | Non-incidental PTMCs | P value | |
| Number of patients | 274 | 61 | |
| Age at diagnosis | 49.1 ± 12.5 (range 16 – 76) years | 47.9 ± 13.1 (range 18–81) years | 0.485 |
| Gender | 226F (82.5 %) | 38F (62.3 %) | <0.001 |
| 48 M (17.5 %) | 23 M (37.7 %) | ||
| Hyperthyroidism | 46/228 (20.2 %) | 0/61 (0 %) | <0.001 |
| Graves | 21/46 (45.7 %) | 0/0 | – |
| Hashimoto | 42/274 (15.3 %) | 5/61 (8.2 %) | 0.147 |
| Family History | 4/274 (1.5 %) | 1/61 (1.6 %) | 0.917 |
| Singlenodular | 65/274 (23.7 %) | 22/61 (36.1 %) | 0.047 |
| Multinodular | 209/274 (76.3 %) | 39/61 (63.9 %) | |
| Unifocal | 179/274 (65.3 %) | 36/61 (59 %) | 0.352 |
| Multifocal | 95/274 (34.7 %) | 25/61 (40.1 %) | |
| < or = 5 mm | 96/179(53.6 %) | 13/36 (36.1 %) | 0.055 |
| > 5 mm (of unifocal cases) | 83/179 (46.4 %) | 23/36 (63.9 %) | |
| Metastases | 0/274 (0 %) | 0/61 (0 %) | >0.999 |
| Capsule involvement | 21/274 (7.7 %) | 47/61 (77 %) | <0.001 |
| T > 1 and/or N > 0 | 17/274 (6.2 %) | 19/61 (31.1 %) | <0.001 |
| Histological types | 145/274 (52.9 %) CPC | 25/61 (41 %) | 0.091 |
| 53/274 (19.4 %) EFVC | 8/61 (13.1 %) | 0.254 | |
| 36/274 (13.1 %) N-EFVC | 22/61 (36 %) | <0.001 | |
| 37/274 (13.5 %) SVC | 4/61 (6.6 %) | 0.134 | |
| 3/274 (1.1 %) T-CVC | 2/61 (3.3 %) | 0.203 | |
| Total or near total thyroidectomy | 240/274 (87.5 %) | 52/61 (85.2 %) | 0.620 |
| 131I | 202/274 (73.7 %) | 57/61 (93.4 %) | <0.001 |
| Follow up | 10.9 ± 5.4 (range 5–33) years | 9.1 ± 4.3 (range 5–27.5) years | 0.005 |
| Recurrence | 2/274 (0.7 %) | 0/61 (0 %) | 0.503 |
| Persistence | 8/274 (3 %) | 5/61 (8.2 %) | 0.054 |
| Disease free | 264/274 (96.3 %) | 56/61 (91.8 %) | 0.120 |
| Hausa IPAQ-SF | Total (N = 102) | Women (n = 46) | Men (n = 56) |
| ICC (95% CI) | ICC (95% CI) | ICC (95%CI) | |
| Vigorous PA (Min week-1) | 0.73 (0.55-0.84) | 0.44 (-0.19-0.81) | 0.82 (0.67-0.91) |
| Moderate PA (Min week-1) | 0.33 (0.12-0.51) | 0.35 (0.05-0.59) | 0.31 (0.01-0.56) |
| Walking (Min week-1) | 0.56 (0.39-0.69) | 0.43 (0.10-0.67) | 0.63 (0.43-0.71) |
| Total PA (MET-Min week-1) | 0.61 (0.47-0.72) | 0.56 (0.33-0.73) | 0.62 (0.43-0.76) |
| Sitting (Min week-1) | 0.56 (0.43-0.68) | 0.67 (0.48-0.81) | 0.40 (0.15-0.60) |
| Item | Total case number (436) | Normal renal function group (176) | Slight decrease group (141) | Moderate and severe decrease group (119) |
| Gender (male/female) (case) | 322/114 | 118/58 | 100/41 | 104/15 |
| Age (year) | 79 (60, 98) | 67 (63, 85) | 78 (65, 89)a | 81 (71, 98)bc |
| Cardiac function classification (grade) | ||||
| II | 175 (40.1) | 93 (52.8) | 49 (34.8) | 33 (27.7)bc |
| III | 141 (32.3) | 62 (35.2) | 43 (30.5) | 36 (30.3) |
| IV | 120 (27.5) | 21 (11.9) | 49 (34.8)b | 50 (42.0)bd |
| Factors | P | Odds | 95 % CI |
| Age | 0.0875 | 1.27742 | 0.96462–1.69165 |
| DD | 0.3805 | 0.9947 | 0.98294–1.00659 |
| DAS28 | 0.0401 | 0.00284 | 0.00001–0.76627 |
| PSL | 0.3289 | 1.53217 | 0.65064–3.60805 |
| MTX | 0.9742 | 0.98265 | 0.34078–2.83353 |
| Stage | 0.8398 | 0.64611 | 0.00936–44.5802 |
| Class | 0.9247 | 1.18464 | 0.03524–39.8251 |
| Variable | NTUa | TSb | ||
| nc | Percent (SE) | nc | Percent (SE) | |
| Age (years) | ||||
| 12–19 | 752 | 14.9 (0.91) | 104 | 7.16 (0.93) |
| 20–39 | 563 | 28.9 (1.52) | 205 | 44.4 (3.48) |
| 40–59 | 459 | 33.9 (1.56) | 172 | 36.5 (3.32) |
| ≥ 60 | 522 | 22.2 (2.22) | 89 | 12.0 (1.70) |
| Race/ethnicity | ||||
| Mexican American | 628 | 9.41 (1.25) | 78 | 4.88 (1.20) |
| Non-Hispanic black | 558 | 10.3 (2.01) | 178 | 13.5 (2.24) |
| Non-Hispanic white | 942 | 71.1 (2.92) | 275 | 73.8 (3.35) |
| Other Hispanic or other/multi-race | 168 | 9.18 (1.51) | 39 | 7.83 (1.85) |
| Sex | ||||
| Female | 1,288 | 54.9 (0.97) | 248 | 45.7 (2.00) |
| Male | 1,008 | 45.1 (0.97) | 322 | 54.3 (2.00) |
| aNon-tobacco users (NTU): defined for this study as non-smokers with serum cotinine ≤ 10 ng/mL. bTobacco smokers (TS): defined for this study as smokers with serum cotinine > 10 ng/mL, using cigarettes, cigars, or pipes during the last 5 days prior to physical examination. cSample size. |
| n | % | Days | IQR | |
| Six-month mortality | 165 | 35.6% | ||
| ICU mortality | 84 | 17.1% | ||
| Hospital mortality | 132 | 26.9% | ||
| Length of ventilation | 11 | 6–20 | ||
| ICU length of stay | 13 | 7–23 | ||
| Hospital length of stay | 35 | 19–59 | ||
| Destination after discharge | ||||
| Home | 144 | 40.7% | ||
| Other hospital | 80 | 22.6% | ||
| Nursing home | 76 | 21.5% | ||
| Rehabilitation unit | 45 | 12.7% | ||
| Other | 9 | 2.5% |
| Characteristics | SLLP1-positive | SLLP1-negative | Sig. |
| Total (N = 394) | 99 (25.1) | 296 (74.9) | |
| Age at time of sample collection (years) | |||
| ≤60 | 64 (21.1) | 240 (78.9) | 0.001 |
| >60 | 35 (38.9) | 55 (61.1) | |
| BM-infiltrating plasma cells (%) | |||
| <10 | 24 (11.6) | 183 (88.4) | 0.000 |
| 10–30 | 19 (33.3) | 38 (66.7) | |
| ≥30 | 37 (53.6) | 32 (46.4) | |
| Serum paraprotein (g/dL) | |||
| <5 (IgG), <3 (IgA) | 8 (14.3) | 48 (85.7) | 0.061 |
| 5–7 (IgG), 3–5 (IgA) | 7 (24.1) | 22 (75.9) | |
| >7 (IgG), >5 (IgA) | 57 (30.0) | 133 (70.0) | |
| Involved serum free light chains (mg/L) | |||
| ≤100 | 6 (30.0) | 14 (70.0) | 0.129 |
| >100 | 3 (10.0) | 27 (90.0) | |
| Serum albumin (g/dL) | |||
| ≥3.5 | 67 (21.8) | 241 (78.2) | 0.006 |
| <3.5 | 19 (43.2) | 25 (56.8) | |
| β2-microglobulin (mg/L) | |||
| <3.5 | 22 (18.6) | 96 (81.4) | 0.019 |
| ≥3.5 | 18 (35.3) | 33 (64.7) | |
| Serum LDH (U/L) | |||
| ≤300 | 75 (23.0) | 251 (77.0) | 0.082 |
| >300 | 13 (35.1) | 23 (63.9) | |
| Hemoglobin (g/dL) | |||
| >10.0 | 6 (27.3) | 16 (72.7) | 0.043 |
| 9.9–8.5 | 16 (41.0) | 23 (59.0) | |
| <8.5 | 55 (22.4) | 190 (77.6) | |
| Serum calcium (mmol/L) | |||
| ≤2.6 | 79 (22.8) | 267 (77.2) | 0.015 |
| >2.6 | 9 (47.4) | 10 (52.6) | |
| Serum creatinine (mg/dL) | |||
| ≤2.0 | 78 (22.5) | 269 (77.5) | 0.008 |
| >2.0 | 9 (50.0) | 9 (50.0) | |
| Treatment status | |||
| Untreated | 25 (44.6) | 31 (55.4) | 0.003 |
| Chemotherapy | 8 (22.2) | 28 (77.8) | |
| AutoSCT | 19 (29.2) | 46 (70.8) | |
| AlloSCT | 47 (19.9) | 189 (80.1) |
| (a) Results from sham and temporal lobe epilepsy rats after 6 weeks of treatment with NLRP1 siRNA or control siRNA | ||||
| Within 24 h post-stimulation | On the 6th week post-treatment | |||
| Number | Rate (%) | Number | Rate (%) | |
| Sham + Control siRNA | 0/18 | 0 | 0/18 | 0 |
| Sham + NLRP1 siRNA | 0/18 | 0 | 0/18 | 0 |
| TLE + Control siRNA | 18/18 | 100 | 14/18 | 77.8 |
| TLE + NLRP1 siRNA | 18/18 | 100 | 8/18 | 44.4a |
| (b) Results from sham and TLE rats after 6 weeks of treatment with Caspase-1 siRNA or control siRNA | ||||
| Sham + Control siRNA | 0/18 | 0 | 0/18 | 0 |
| Sham + Caspase-1 siRNA | 0/18 | 0 | 0/18 | 0 |
| TLE + Control siRNA | 18/18 | 100 | 14/18 | 77.8 |
| TLE + Caspase-1 siRNA | 18/18 | 100b | 7/18 | 38.9b |
| Men | Women | |||
| TUG | N (#dead) | Seconds, mean (SD) | N (#dead) | Seconds, mean (SD) |
| 1 (quickest) | 128 (58) | 8.2 (1.0) | 125 (46) | 8.4 (1.2) |
| 2 | 80 (52) | 10.1 (0.3) | 138 (52) | 10.5 (0.5) |
| 3 | 69 (38) | 11.0 (0.4) | 120 (50) | 12.4 (0.6) |
| 4 | 89 (60) | 12.8 (1.2) | 90 (46) | 14.6 (0.7) |
| 5 (slowest) | 72 (53) | 19.1 (10.3) | 94 (51) | 23.2 (12.4) |
| Total | 438 (261) | 11.7 (5.6) | 567 (245) | 13.2 (7.1) |
| Sensor Locations | Year 2012 | Year 2013 | |||||||
| March 19 | April 23 | May 30 | July 26 | September 7 | October 19 | December 19 | January 23 | March 10 | |
| 1-1-1 | 42.4 | 42 | 40.5 | 39 | 39.1 | 39.5 | 36.6 | 38.9 | 35.2 |
| 1-1-2 | −32.1 | −29.5 | −31.5 | −30.4 | −31.6 | −31.9 | −34.5 | −34.3 | −35 |
| 1-2-1 | −39.1 | −38.1 | −38.1 | −37.9 | −38.1 | −38.1 | −38.1 | −38.1 | −37.9 |
| 1-2-2 | 41.5 | 40.7 | 40.7 | 40.4 | 40.7 | 40.7 | 40.7 | 38.9 | 41.6 |
| 1-3-1 | −60.5 | −67.6 | −61.9 | −63.9 | −63.4 | −67.2 | −67.7 | −67.4 | −66.6 |
| 1-3-2 | −38.9 | −38.2 | −36.4 | −38.2 | −38.2 | −39.1 | −24 | −38.2 | −38.4 |
| 1-4-1 | −14.6 | −14.4 | −14.9 | −14.7 | −16.1 | −16.8 | −20 | −17.9 | −20.1 |
| 1-4-2 | −44.5 | −42.7 | −43.3 | −44.5 | −44.6 | −46.8 | −48.4 | −47.4 | −48 |
| 1-5-1 | −13.9 | −14.3 | −16.4 | −16.3 | −18 | −17.7 | −19.9 | −17.9 | −22.2 |
| 1-5-2 | 15.9 | 17 | 15.1 | 14.7 | 14.7 | 13.2 | 9.1 | 15.2 | 11.5 |
| 1-6-1 | −81.2 | −79.4 | −80.5 | −81.8 | −81.9 | −83.7 | −85 | −82.4 | −82.5 |
| 1-6-2 | −57.3 | −55.8 | −57.6 | −57.1 | −59 | −60.4 | −61.2 | −61.3 | −63.2 |
| Concentration mIU/ml | Vaccination protection | Vaccination recommendation | Before vaccination | After vaccination |
| <= 30 | No | Basic immunization | 0 | 0 |
| ]30 – 100] | Not surely guaranteed | Booster vaccination | 8 | 0 |
| ]100 – 500] | Existent | Booster vaccination | 29 | 2 |
| ]500 – 1000] | Sufficient | Control in 2 years | 13 | 4 |
| ]1000 – 5000] | Long term | Control in 5–10 years | 41 | 6 |
| > 5000 | Extremely high | Control in 10 years | 9 | 79 |
| Oocyte | 1-cell | 2-cell | 4-cell | 8-cell | Morula | ICM | TE | |
| Mouse embryos* | 14 h | 24–26 h | 36 h | 48 h | 60 h | 72 h | 96 h | 96 h |
| Pig in vivo embryos** | 24 h after estrus | 24 h | 40–45 h | 65–72 h | 84–90 h | 108–115 h | 156–160 h | 156–160 h |
| Pig SCNT embryos*** | In vitro matured | 24 h | 40 h | 65–72 h | 84–90 h | 108–115 h | 156–160 h | 156–160 h |
| Condition | Experiment 1 | Experiment 2 | ||
| 93 Hz | 109 Hz | 217 Hz | 233 Hz | |
| Attend-Low | 4.7 ± 1.6 | 4.8 ± 1.8 | 6.2 ± 1.8 | 6.4 ± 2.1 |
| Attend-High | 4.4 ± 2.2 | 5.2 ± 1.5 | 6.0 ± 2.0 | 6.5 ± 2.5 |
| Attend-Visual (low stream first) | 4.1 ± 2.4 | 5.6 ± 2.2 | 6.1 ± 2.1 | 7.1 ± 2.8 |
| Attend-Visual (high stream first) | 5.5 ± 3.1 | 4.9 ± 1.8 | 5.7 ± 3.3 | 7.1 ± 3.2 |
| Mod. | Mol. exp. | wt (CEN vec) | trm82∆ (CEN TRM82) | trm82∆ (CEN vec) | trm82∆ (CEN trm82-K223L) | trm82∆ (CEN trm82-K223R) |
| 30 °C | ||||||
| m7G | 1 | 0.41 ± 0.04 | 0.34 ± 0.03 | <0.03 | 0.21 ± 0.01 | 0.32 ± 0.04 |
| Ψ | 2 | 2.09 ± 0.06 | 1.94 ± 0.03 | 1.85 ± 0.04 | 1.99 ± 0.07 | 2.06 ± 0.05 |
| Cm | 1 | 0.89 ± 0.09 | 0.92 ± 0.05 | 0.93 ± 0.08 | 0.95 ± 0.03 | 0.93 ± 0.06 |
| Gm | 1 | 0.72 ± 0.01 | 0.76 ± 0.07 | 0.76 ± 0.03 | 0.73 ± 0.08 | 0.75 ± 0.02 |
| m5C | 2 | 1.53 ± 0.06 | 1.64 ± 0.07 | 1.69 ± 0.03 | 1.66 ± 0.06 | 1.59 ± 0.03 |
| m2G | 1 | 0.78 ± 0.02 | 0.83 ± 0.04 | 0.87 ± 0.02 | 0.83 ± 0.04 | 0.82 ± 0.03 |
| 37 °C | ||||||
| m7G | 1 | 0.37 ± 0.03 | 0.21 ± 0.03 | <0.03 | <0.03 | 0.18 ± 0.02 |
| Ψ | 2 | 2.00 ± 0.08 | 1.91 ± 0.06 | 1.87 ± 0.01 | 1.82 ± 0.10 | 1.92 ± 0.01 |
| Cm | 1 | 0.98 ± 0.08 | 1.00 ± 0.14 | 0.91 ± 0.02 | 0.93 ± 0.05 | 0.90 ± 0.04 |
| Gm | 1 | 0.77 ± 0.03 | 0.84 ± 0.02 | 0.91 ± 0.05 | 0.96 ± 0.02 | 0.84 ± 0.02 |
| m5C | 2 | 1.63 ± 0.03 | 1.69 ± 0.02 | 1.79 ± 0.05 | 1.76 ± 0.04 | 1.71 ± 0.02 |
| m2G | 1 | 0.82 ± 0.05 | 0.88 ± 0.02 | 0.90 ± 0.07 | 0.94 ± 0.06 | 0.86 ± 0.02 |
| Period | Total biopsies (n) | Adequate biopsies (n,%) | Suboptimal biopsies (n,%) | Inadequate biopsies (n,%) | Difference in adequacy (%)* | p value |
| 1 | 127 | 40 (31%) | 43 (34%) | 44 (35%) | NA | NA |
| 2 | 432 | 311 (72%) | 54 (13%) | 67 (16%) | +40% (31, 50) | < 0.0001 |
| 3 | 104 | 94 (90%) | 2 (2%) | 8 (8%) | +18% (8, 29) | <0.0001 |
| Input layer | Hidden layer | ||||
| Neuron 1 | Neuron 2 | Neuron 3 | Neuron 4 | Neuron 5 | |
| Bias | −0.756 | −0.715 | −0.521 | 1.154 | −1.304 |
| Awareness | −0.184 | 0.403 | 0.548 | −0.239 | 0.427 |
| Knowledge | −0.489 | 0.276 | −0.009 | 0.063 | 0.107 |
| Skill | 0.394 | −0.090 | 0.420 | −0.561 | 0.332 |
| Attitude | −0.554 | 0.374 | 0.312 | −0.060 | 0.151 |
| Social capital | 0.017 | 0.801 | 0.392 | −0.718 | 0.558 |
| Damage severity | −0.258 | −0.194 | 0.080 | −0.063 | 0.467 |
| Recovery capacity | 0.287 | 0.286 | 0.280 | −0.354 | −0.185 |
| Employment recovery | −0.519 | −0.173 | 0.139 | 0.217 | 0.407 |
| Lakes | Metals | Pb | Cd | Cu | Fe | Mn |
| Futala | BII | 0.14 ± 0.24 | 0.09 ± 0.33 | 0.08 ± 0.83 | 49.0 ± 0.33 | 1.23 ± 0.49 |
| AII | 0.32 ± 0.89 | 0.33 ± 0.58 | 4.40 ± 0.72 | 169.1 ± 0.82 | 2.60 ± 0.67 | |
| Gandhi Sagar | BII | 0.19 ± 0.29 | 0.14 ± 0.51 | 1.23 ± 0.42 | 52.5 ± 0.37 | 2.15 ± 0.23 |
| AII | 0.83 ± 0.76 | 0.47 ± 0.80 | 5.10 ± 0.67 | 189.3 ± 0.61 | 3.60 ± 0.77 | |
| Ambazari | BII | 0.15 ± 0.20 | 0.13 ± 0.62 | 1.70 ± 0.75 | 63.2 ± 0.50 | 1.10 ± 0.59 |
| AII | 0.56 ± 0.34 | 0.25 ± 0.28 | 3.60 ± 0.58 | 177.9 ± 0.10 | 2.90 ± 0.94 | |
| PL** | - | 0.214 | 0.1 | 3.0 | 43.0 | 2.0-9.0 |
| Variables | Recurrence free survival | P | |
| RR | 95% CI | ||
| Ulinastatin administration | 0.149 | 0.063-0.351 | <0.05 |
| TNM | 1.812 | 0.652-5.038 | 0.254 |
| Alcohol consumption | 2.066 | 0.909-4.344 | 0.757 |
| Smoking | 1.088 | 0.534-2.217 | 0.817 |
| Gender | 0.916 | 0.425-1.973 | 0.822 |
| Urine iodine levels n (%) | |||||||
| Age group (yrs) | <20 | 20–49 | 50–149 | 150–249 | 250–499 | 500 | Total |
| <20 | 2 (16.67) | 2 (16.67) | 3 (25.00) | 1 (8.33) | 2 (16.67) | 2 (16.67) | 12 |
| 20–24 | 4 (13.33) | 2 (6.67) | 5 (16.67) | 4 (13.33) | 9 (30.00) | 6 (20.00) | 30 |
| 25–29 | 2 (5.71) | 2 (5.71) | 8 (22.86) | 2 (5.71) | 7 (20.00) | 14 (40.00) | 35 |
| 30–34 | 3 (12.50) | 3 (12.50) | 7 (29.17) | 6 (25.00) | 1 (4.17) | 4 (16.67) | 24 |
| 35–39 | 2 (11.76) | 3 (17.65) | 1 (5.88) | 2 (11.76) | 2 (11.76) | 7 (41.18) | 17 |
| ≥40 | 1 (50.00) | 0 (0.00) | 1 (50.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 2 |
| Occupation | |||||||
| Formal | 0 (0) | 0 (0) | 1 (16.67) | 1 (16.67) | 1 (16.67) | 3 (50) | 6 |
| Non-formal | 11 (12.36) | 9 (10.11) | 19 (21.35) | 11 (12.36) | 15 (16.85) | 24 (26.97) | 89 |
| None | 3 (12.00) | 3 (12.00) | 5 (20.00) | 3 (12.00) | 5 (20.00) | 6 (24.00) | 25 |
| Trimester | |||||||
| First | 2 (7.14) | 4 (14.29) | 8 (28.57) | 2 (7.14) | 5 (17.86) | 7 (25.00) | 28 |
| Second | 7 (11.48) | 6 (9.84) | 11 (18.03) | 5 (8.20) | 12 (19.97) | 20 (32.79) | 61 |
| Third | 5 (16.13) | 2 (6.45) | 6 (19.35) | 8 (25.81) | 4 (12.90) | 6 (19.35) | 31 |
| Use of iodated salt | |||||||
| Yes | 0 (0.00) | 0 (0.00) | 13 (16.25) | 14 (17.50) | 20 (25.00) | 33 (41.25) | 0 |
| No | 14 (35.00) | 12 (30.00) | 12 (30.00) | 1 (2.50) | 1 (2.50) | 0 (0.00) | 0 |
| Calculation (cm−1) | Solid (cm−1) | SERS-Ag (cm−1) | SERS-Au (cm−1) | Assignments |
| 606 (w) | 615 (w) | 626 (w) | 626 (w) | δ(C–C–C)ip δ(S–C–N)ip |
| 748 (m) | 778 (m) | 782 (vs) | 783 (m) | δ(C–H)oop |
| 957 (w) | 985 (w) | 988 (m) | - | υ(C–S) |
| 1000 (m) | 1010 (m) | 1007 (vs) | 1007 (s) | δ(C–H)ip |
| 1139 (w) | 1118 (w) | 1116 (w) | 1116 (w) | δ(C–H)ip |
| 1158 (m) | 1154 (w) | 1147 (m) | 1147 (w) | δ(C–H)ip |
| 1215 (w) | 1255 (m) | 1239 (w) | - | υ ring |
| 1270 (s) | 1277 (s) | 1279 (m) | 1270 (m) | υ ring + δ(C–H)ip |
| 1313 (w) | 1303 (w) | 1322 (m) | 1326 (m) | δ(C–H)ip |
| 1401 (w) | 1403 (w) | 1404 (m) | 1406 (m) | υ(C=C) |
| 1445 (s) | 1456 (s) | 1433 (w) | 1462 (m) | υ(C=N) |
| 1498 (w) | 1492 (w) | 1492 (w) | 1493 (w) | υ(C=C) + δ(N–H)ip |
| 1579 (vs) | 1577 (vs) | 1576 (s) | 1586 (s) | υ(C=N) |
| 1599 (s) | 1591 (s) | - | - | υ(C=N) |
| 1641 (w) | 1623 (w) | 1621 (w) | 1626 (w) | υ(C=N) |
| Genotype | GeneID | log2 ratio | P-value | q-value | Gene description |
| R2 | Comp133037_c0 | 7.0454 | 1.82E-08 | 4.59E-07 | Dehydration-responsive element-binding protein 1A OS = Oryza sativa subsp. japonica GN = DREB1A PE = 2 SV = 1 |
| Comp143318_c0 | 7.4867 | 3.61E-38 | 3.66E-36 | Dehydration-responsive element-binding protein 1H OS = Oryza sativa subsp. japonica GN = DREB1H PE = 3 SV = 1 | |
| Comp155879_c0 | 5.8445 | 0 | 0 | Dehydration-responsive element-binding protein 1A OS = Oryza sativa subsp. indica GN = DREB1A PE = 3 SV = 1 | |
| R3 | Comp133037_c0 | 5.9961 | 1.46E-05 | 0.0003279 | Dehydration-responsive element-binding protein 1A OS = Oryza sativa subsp. japonica GN = DREB1A PE = 2 SV = 1 |
| Comp143318_c0 | 5.5908 | 4.28E-14 | 2.24E-12 | Dehydration-responsive element-binding protein 1H OS = Oryza sativa subsp. japonica GN = DREB1H PE = 3 SV = 1 | |
| Comp155879_c0 | 4.8139 | 2.87E-206 | 2.62E-203 | Dehydration-responsive element-binding protein 1A OS = Oryza sativa subsp. indica GN = DREB1A PE = 3 SV = 1 | |
| R4 | Comp159413_c1 | 4.2154 | 1.47E-06 | 5.96E-05 | Dehydration-responsive element-binding protein 1C OS = Oryza sativa subsp. japonica GN = DREB1C PE = 2 SV = 1 |
| S1 | Comp155879_c0 | 3.1428 | 2.83E-08 | 1.24E-06 | Dehydration-responsive element-binding protein 1A OS = Oryza sativa subsp. indica GN = DREB1A PE = 3 SV = 1 |
| S3 | Comp143318_c0 | 8.4116 | 4.08E-05 | 0.0014065 | Dehydration-responsive element-binding protein 1H OS = Oryza sativa subsp. japonica GN = DREB1H PE = 3 SV = 1 |
| Comp155879_c0 | 5.2997 | 1.58E-66 | 1.62E-63 | Dehydration-responsive element-binding protein 1A OS = Oryza sativa subsp. indica GN = DREB1A PE = 3 SV = 1 | |
| Comp159413_c1 | 3.2936 | 0.0001694 | 0.0049795 | Dehydration-responsive element-binding protein 1C OS = Oryza sativa subsp. japonica GN = DREB1C PE = 2 SV = 1 |
| Complete dataN = 11,920 | Missing dataN = 879 | ||||
| BMI (kg/m2) | Mean (SE) | 27.8 | (0.10) | 28.4 | (0.28) |
| Age (y) | Mean (SE) | 46.2 | (0.28) | 47.8 | (1.2) |
| Sex | (% male) | 46.4% | 43.1% | ||
| Diabetes | (%) | 10.1% | 11.5% | ||
| Poverty index | (%) | ||||
| Poor | 15.4% | 15.2% | |||
| Near poor | 5.6% | 9.1% | |||
| Low income | 14.8% | 17.5% | |||
| Middle income | 29.7% | 33.2% | |||
| High income | 33.1% | 25.0% | |||
| Race | (%) | ||||
| Hispanic | 17.3% | 21.4% | |||
| White | 62.5% | 59.2% | |||
| Black | 12.1% | 13.1% | |||
| Asian | 5.3% | 4.4% | |||
| Other or multiple | 2.9% | 1.9% |
| Analysis* | Left ventricular mass (SD) in grams while on CHD | Left ventricular mass (SD) in grams after conversion to INHD | Change in LVM (SD) in grams | p-value |
| Primary (n = 37) | 219 ± 66 | 186 ± 69 | -32 ± 58 | 0.002 |
| Secondary (n = 31) | 215 ± 71 | 174 ± 62 | -40 ± 56 | 0.0004 |
| Participants’ Smoking and Vaping Use at Time of Interview | Daily | Weekly | Monthly | Total No. of Participants |
| Dual users | ||||
| Smoking status | 5 | 4 | 0 | 9 |
| Vaping status | 3 | 5 | 1 | |
| Smokers | ||||
| Smoking status | 9 | 0 | 0 | 9 |
| Vapers | ||||
| Vaping status | 6 | 1 | 0 | 7 |
| No treatment intensification | Treatment intensification | |
| Age, years, mean (SD) | 52.6 (12.6) | 51.0 (12.4) |
| Sex, n (% female) | 46 (78.9) | 39 (68.4) |
| Treatment arm | ||
| Early remission | 46.2 | 57.2 |
| MTX + SSZ + HCQ + prednisone | 20.9 | 19.9 |
| MTX + adalimumab | 19.1 | 16.0 |
| Out of protocol | 13.8 | 6.7 |
| Symptom duration, weeks, median (IQR) | 20 (9–35) | 19 (9–32) |
| Diagnosed RA, % meeting 2010 ACR/EULAR criteria | 46 (79.2) | 47 (84.5) |
| Anti-citrullinated protein antibodies, % positive | 34 (57.6) | 35 (61.9) |
| Rheumatoid factor, % positive | 33 (58.9) | 34 (63.0) |
| Health Assessment Questionnaire (0–3)a, mean (SD) | 0.78 (0.56) | 0.63 (0.48) |
| Disease Activity Score, mean (SD) | 1.95 (0.23) | 1.99 (0.23) |
| Tender joint count, median (IQR) | 2 (2–4) | 3 (2–4) |
| Swollen joint count, median (IQR) | 0 (0–1) | 1 (0–2) |
| VAS general health (0–100)b, mean (SD) | 31.0 (19.6) | 31.7 (20.3) |
| Erythrocyte sedimentation rate, mm/h, median (IQR) | 15.7 (13.0) | 13.9 (11.2) |
| Zn | Supplemented | Analyzed Zn |
| source | Zn (mg/kg) | content (mg/kg)a |
| Basal diet | 0 | 25.00 |
| ZnO | 8 | 39.18 |
| Bioplex Zn | 8 | 32.64 |
| ZnO | 40 | 68.46 |
| Bioplex Zn | 40 | 70.29 |
| Fifths of observed vegetable intake | ||||||
| 1 | 2 | 3 | 4 | 5 | p‐trendb | |
| Total vegetables, g/day | ≤ 82.8 | >82.8 to ≤ 126.4 | >126.4 to ≤ 182.1 | >182.1 to ≤ 281.6 | >281.7 | |
| Cases, n | 1,526 | 1,451 | 1,457 | 1,549 | 1,053 | |
| HR (95% CI) | 1 ref | 1.04 (0.96–1.12) | 1.01 (0.93–1.09) | 1.07 (0.99–1.16) | 1.04 (0.95–1.14) | 0.4 |
| Adjusted HR (95% CI)a | 1 ref | 1.03 (0.96–1.11) | 0.99 (0.92–1.07) | 1.05 (0.97–1.14) | 1.02 (0.93–1.12) | 0.6 |
| Cruciferous vegetables, g/day | ≤ 3.0 | >3.0 to ≤ 9.2 | >9.2 to ≤ 18.7 | >18.7 to ≤ 36.6 | >36.6 | |
| Cases, n | 1,457 | 1,287 | 1,253 | 1,190 | 1,207 | |
| HR (95% CI) | 1 ref | 1.06 (0.97–1.15) | 1.05 (0.96–1.15) | 1.07 (0.98–1.16) | 1.06 (0.96–1.18) | 0.4 |
| Adjusted HR (95% CI)a | 1 ref | 1.06 (0.97–1.15) | 1.04 (0.95–1.13) | 1.05 (0.96–1.15) | 1.06 (0.96–1.17) | 0.5 |
| Leafy vegetables, g/day | ≤ 1.6 | >1.6 to ≤ 6.0 | >6.0 to ≤ 15.1 | >15.1 to ≤ 36.9 | >36.9 | |
| Cases, n | 1,773 | 1,453 | 1,218 | 1,034 | 916 | |
| HR (95% CI) | 1 ref | 1.03 (0.96–1.11) | 1.09 (1.00–1.18) | 1.04 (0.95–1.14) | 1.09 (0.97–1.22) | 0.3 |
| Adjusted HR (95% CI)a | 1 ref | 1.01 (0.94–1.09) | 1.06 (0.97–1.16) | 1.01 (0.92–1.11) | 1.06 (0.95–1.19) | 0.4 |
| Fruiting vegetables, g/day | ≤ 21.6 | >21.6 to ≤ 36.5 | >36.5 to ≤ 56.3 | >56.3 to ≤ 97.8 | >97.8 | |
| Cases, n | 1,642 | 1,590 | 1,465 | 1,365 | 974 | |
| HR (95% CI) | 1 ref | 1.07 (1.00–1.15) | 1.05 (0.97–1.13) | 1.03 (0.95–1.11) | 1.04 (0.95–1.14) | 0.8 |
| Adjusted HR (95% CI)a | 1 ref | 1.06 (0.99–1.14) | 1.04 (0.96–1.12) | 1.01 (0.94–1.10) | 1.03 (0.94–1.13) | 0.9 |
| Tomatoes, g/day | ≤ 9.0 | >9.0 to ≤ 18.9 | >18.9 to ≤ 30.8 | >30.8 to ≤ 67.3 | >67.3 | |
| Cases, n | 1,612 | 1,540 | 1,443 | 1,480 | 961 | |
| HR (95% CI) | 1 ref | 1.05 (0.97–1.13) | 1.04 (0.96–1.12) | 1.01 (0.93–1.09) | 1.09 (0.98–1.21) | 0.2 |
| Adjusted HR (95% CI)a | 1 ref | 1.04 (0.97–1.12) | 1.03 (0.95–1.11) | 1.00 (0.92–1.08) | 1.08 (0.97–1.20) | 0.2 |
| Root vegetables, g/day | ≤ 3.8 | >3.8 to ≤ 8.9 | >8.9 to ≤ 16.3 | >16.3 to ≤ 35.5 | >35.5 | |
| Cases, n | 1,416 | 1,371 | 1,353 | 1,334 | 1,562 | |
| HR (95% CI) | 1 ref | 1.01 (0.93–1.09) | 1.02 (0.94–1.10) | 1.01 (0.93–1.09) | 1.04 (0.96–1.13) | 0.3 |
| Adjusted HR (95% CI)a | 1 ref | 1.00 (0.92–1.08) | 1.00 (0.92–1.08) | 0.99 (0.92–1.07) | 1.02 (0.94–1.11) | 0.5 |
| AA component | Liquid crystal component | ||||||||
| Compound | XM | A0/nm2 | AC/nm2 | πC/mN·m−1 | CS′/m·N−1 | A0/nm2 | AC/nm2 | πC/mN·m−1 | CS′/m·N−1 |
| N52/AA | 0.1 | 0.20 | 0.16 | 26.0 | 9.6 | 0.24 | 0.22 | 7.5 | 10.0 |
| 0.2 | 0.17 | 0.14 | 26.1 | 9.9 | 0.25 | 0.23 | 7.7 | 10.3 | |
| 0.3 | 0.15 | 0.12 | 26.5 | 9.4 | 0.26 | 0.24 | 7.7 | 10.6 | |
| 0.4 | 0.13 | 0.11 | 25.6 | 9.1 | 0.27 | 0.25 | 7.6 | 10.6 | |
| 0.5 | 0.11 | 0.09 | 25.7 | 10.8 | 0.29 | 0.26 | 7.4 | 12.9 | |
| 0.6 | 0.09 | 0.07 | 25.4 | 11.3 | 0.29 | 0.26 | 7.6 | 12.5 | |
| N53/AA | 0.1 | 0.21 | 0.17 | 26.2 | 8.4 | 0.25 | 0.23 | 2.7 | 20.8 |
| 0.2 | 0.18 | 0.15 | 25.5 | 8.3 | 0.26 | 0.24 | 2.6 | 20.9 | |
| 0.3 | 0.15 | 0.13 | 25.9 | 8.4 | 0.25 | 0.24 | 2.6 | 19.8 | |
| 0.4 | 0.12 | 0.10 | 26.0 | 8.8 | 0.27 | 0.26 | 3.7 | 13.4 | |
| 0.5 | 0.10 | 0.08 | 26.6 | 9.0 | 0.28 | 0.26 | 3.6 | 14.2 | |
| 0.6 | 0.09 | 0.07 | 25.9 | 9.0 | 0.28 | 0.26 | 3.3 | 16.2 | |
| N54/AA | 0.1 | 0.21 | 0.17 | 26.8 | 8.2 | 0.25 | 0.24 | 2.7 | 12.7 |
| 0.2 | 0.18 | 0.15 | 26.8 | 8.2 | 0.25 | 0.25 | 2.7 | 10.5 | |
| 0.3 | 0.16 | 0.13 | 26.8 | 8.2 | 0.29 | 0.25 | 2.7 | 24.6 | |
| 0.4 | 0.15 | 0.11 | 26.4 | 10.4 | 0.26 | 0.26 | 2.6 | 24.2 | |
| 0.5 | 0.13 | 0.10 | 26.4 | 10.7 | 0.31 | 0.28 | 2.6 | 25.7 | |
| 0.6 | 0.11 | 0.08 | 26.5 | 11.1 | 0.32 | 0.29 | 2.5 | 27.0 |
| CKD Patients(N = 201) | Non-CKD(N = 201) | P-value | |
| Age, years | 55.9 ± 9.9 | 52.5 ± 10.0 | < 0.001 |
| Male, % | 55.2 | 45.3 | 0.06 |
| African-American, % | 60.7 | 51.2 | 0.06 |
| Current cigarette smoking, % | 53.7 | 48.8 | 0.32 |
| Alcohol consumption, % | 27.9 | 59.2 | < 0.001 |
| Physical activity ≥twice/week, % | 53.0 | 72.9 | < 0.001 |
| High school education, % | 58.5 | 81.6 | < 0.001 |
| History of CVD, % | 43.7 | 7.0 | < 0.001 |
| History of hypertension, % | 88.1 | 23.9 | < 0.001 |
| History of diabetes, % | 49.3 | 5.5 | < 0.001 |
| History of hypercholesterolemia, % | 65.7 | 30.9 | < 0.001 |
| Use of antihypertensive agents, % | 79.6 | 15.4 | < 0.001 |
| Use of hypoglycemic agents, % | 34.3 | 3.0 | < 0.001 |
| Use of lipid lowering agents, % | 21.9 | 8.9 | < 0.001 |
| Use of aspirin, % | 34.8 | 8.5 | < 0.001 |
| BMI, kg/m2 | 32.2 ± 7.8 | 28.9 ± 6.4 | < 0.001 |
| Systolic BP, mm Hg | 132.2 ± 21.0 | 122.0 ± 14.7 | < 0.001 |
| Diastolic BP, mm Hg | 77.2 ± 13.5 | 77.6 ± 9.4 | 0.77 |
| LDL-cholesterol, mg/dL | 101.8 ± 47.3 | 118.2 ± 30.2 | < 0.001 |
| HDL-cholesterol, mg/dL | 50.3 ± 15.6 | 57.7 ± 18.0 | < 0.001 |
| Fasting plasma glucose, mg/dL | 119.9 ± 46.8 | 103.4 ± 35.4 | < 0.001 |
| C-reactive protein mg/L | 5.3 ± 11.7 | 4.1 ± 8.4 | 0.26 |
| eGFR, mL/min/1.73 m2 | 43.3 ± 19.3 | 96.7 ± 16.8 | < 0.001 |
| Urinary albumin, mg/24 h | 74.5 (12.3, 417.4) | 5.9 (4.1, 11.4) | < 0.001 |
| Percentage of practice that reflects use of guidelines by referrers | Number of responses | Percentage of respondents |
| <20% | 2 | 4% |
| 20–39% | 5 | 7% |
| 40–59% | 10 | 4% |
| 60–79% | 12 | 22% |
| 80–100% | 26 | 47% |
| Term | Definition |
| Energy | A property of the matter expressed in calories; 1 Calorie (kcal) is the energy needed to increase the temperature of 1 kg of water by 1 °C. |
| Energy expenditure (EE) | Sum of internal heat produced (endogenous energy production) and external work. The internal heat produced is mainly a sum of basal metabolic rate (BMR) and of the thermic effect of food. It is measured by indirect calorimetry. Importantly, equations used to estimate EE cannot be considered as actual EE. |
| Energy requirement | Energy from essential nutrients necessary to maintain energy homeostasis. In health, its magnitude depends mainly on age, gender, and physical activity level; in illness, many other factors influence it. |
| Endogenous energy production | Energy that is produced from internal resources (glucose, proteins, and lipids) that are degraded to produce adenosine triphosphate (ATP). The endogenous glucose production (glycogenolysis and gluconeogenesis) is the first to be activated during fasting to provide it to glucose-dependent organs. In acute illness, endogenous glucose production is increased, but the magnitude and duration of this activation is variable. |
| Extrinsic energy provision | Includes nutrition and energy-containing medications or fluids administered to patients for non-nutritional purposes. |
| Energy target | Target for extrinsic energy provision, prescribed by physicians and expressed in kcal/day. Often the target is set to match actual energy expenditure (full target). |
| Fasting | Complete interruption of feeding: different patterns are possible, such as intermittent fasting, which is now considered a promising weight-loss strategy [4]. |
| Full feeding | Delivery of energy to completely cover equation-estimated target or measured EE: as equations are inexact, only the latter enables a real appreciation of the level of delivery in relation to actual EE. |
| Nutrient restriction | Reduction of a particular or total nutrient intake without causing malnutrition or biological changes known to shorten animal life span [5]. The reduction can be relative to the subject’s previous intake before intentionally restricting calories, or relative to an average person of similar body type. |
| Hypocaloric feeding | Feeding below target, or feeding to a target that is deliberately below estimated target or measured EE. Term used to describe feeds with an energy density of ≤1 kcal/mL. |
| Overfeeding | Feeding quantities of energy that exceed 110% of measured EE. |
| Timing of feeding interventions | |
| - Early | 48 h after intensive care (ICU) admission |
| - Intermediate | Days 3 to 7 after ICU admission |
| - Late | Beyond the first week in the ICU |
| Vitamin B12 Intake | Model 1 (Unadjusted) | Model 2 (Adjusted) | ||
| Total (μg/day) | <148 pmol/L (n = 125) | p | <148 pmol/L (n = 125) | p |
| <1.87 | 1.00 (ref.) | - | 1.00 (ref.) | - |
| 1.87–2.88 | 0.70 (0.42, 1.18) | 0.180 | 0.57 (0.32, 1.01) | 0.056 |
| 2.88–4.40 | 0.60 (0.35, 1.02) | 0.057 | 0.50 (0.28, 0.92) | 0.026 |
| >4.40 | 0.53 (0.31, 0.92) | 0.024 | 0.40 (0.21, 0.76) | 0.005 |
| Meat and Meat products (μg/day) | <148 pmol/L (n = 118) | p | <148 pmol/L (n = 118) | p |
| <0.35 | 1.00 (ref.) | - | 1.00 (ref.) | - |
| 0.35–1.03 | 0.72 (0.42, 1.24) | 0.236 | 0.69 (0.38, 1.25) | 0.220 |
| 1.03–2.10 | 0.84 (0.50, 1.44) | 0.533 | 0.78 (0.43, 1.42) | 0.422 |
| >2.10 | 0.55 (0.31, 0.98) | 0.043 | 0.41 (0.20, 0.81) | 0.010 |
| Fish and Fish products (μg/day) | <148 pmol/L (n = 43) | p | <148 pmol/L (n = 43) | p |
| <0.46 | 1.00 (ref.) | - | 1.00 (ref.) | - |
| 0.46–1.06 | 0.61 (0.23, 1.65) | 0.331 | 0.66 (0.23, 1.91) | 0.444 |
| 1.06–2.45 | 0.86 (0.34, 2.15) | 0.743 | 0.66 (0.23, 1.86) | 0.427 |
| >2.45 | 1.00 (0.41, 2.42) | 0.992 | 0.70 (0.25, 1.97) | 0.503 |
| Milk and Milk products (μg/day) | <148 pmol/L (n = 102) | p | <148 pmol/L (n = 102) | p |
| <0.27 | 1.00 (ref.) | - | 1.00 (ref.) | - |
| 0.27–0.53 | 0.84 (0.47, 1.52) | 0.562 | 0.88 (0.46, 1.71) | 0.711 |
| 0.53–0.88 | 1.12 (0.64, 1.96) | 0.698 | 1.28 (0.70, 2.37) | 0.425 |
| >0.88 | 0.58 (0.31, 1.08) | 0.086 | 0.49 (0.24, 1.01) | 0.054 |
| Treatment provider | No of consenting patients | Complications following tooth extractions | Complications following other treatment |
| Dental Hospital | 3 | 0 | 0 |
| Foundation Trust | 9 | 1 | 1 |
| District General | 69 | 2 | 1 |
| Primary Care Oral Surgery | 97 | 4 | 0 |
| Diabetes model | ||||||
| (High-fat feeding with low dose STZ) | ||||||
| Control | 0 mg/kg | 15 mg/kg | 20 mg/kg | 25 mg/kg | 30 mg/kg | |
| Glucose (mmol/l) | 12.7 ± 0.3 | 14.6 ± 1.8 | 14.7 ± 0.6 | 17.2 ± 1.2 * | 16.9 ± 1.5 * | 25.1 ± 1.1 *† |
| Insulin (ug/l) | 3.03 ± 0.51 | 2.68 ± 0.57 | 2.00 ± 0.31 | 1.59 ± 0.36 | 1.93 ± 0.26 | 1.04 ± 0.22 * |
| NEFA (mmol/l) | 0.28 ± 0.06 | 0.29 ± 0.05 | 0.29 ± 0.02 | 0.29 ± 0.01 | 0.14 ± 0.04 | 0.59 ± 0.07 *# |
| Triglycerides (mmol/l) | 1.79 ± 0.20 | 1.13 ± 0.22 | 0.87 ± 0.06 | 1.41 ± 0.15 | 1.79 ± 0.35 | 7.25 ± 1.33 *† |
| β-OHB (mmol/l) | 0.26 ± 0.04 | 0.33 ± 0.04 | 0.45 ± 0.07 | 0.77 ± 0.06 | 0.98 ± 0.21 | 5.39 ± 0.59 *† |
| Cholesterol (mmol/l) | 2.46 ± 0.13 | 2.07 ± 0.21 | 1.68 ± 0.15 | 2.11 ± 0.27 | 3.87 ± 0.58 *$ | 3.02 ± 0.44 € |
| Recognition of | Responses | Total number of participants that responded | ||
| Yes, n (%) | No, n (%) | Don't know, n (%) | ||
| 1. Cervical cancer risk factors | ||||
| Early onset of sexual activity | 320 (78.2) | 71 (17.4) | 18 (4.4) | 409 |
| Infection with a sexually transmitted germ/virus (HPV) | 342 (82.0) | 51 (12.2) | 24 (5.8) | 417 |
| Multiple male sexual partners | 378 (88.3) | 45 (10.5) | 5 (1.2) | 428 |
| Smoking cigarettes/tobacco | 203 (48.6) | 182 (43.5) | 33 (7.9) | 418 |
| Grand multiparity | 195 (48.6) | 181 (45.2) | 25 (6.2) | 401 |
| 2. Cervical cancer symptoms | ||||
| Intermenstrual vaginal bleeding | 344 (84.5) | 48 (11.8) | 15 (3.7) | 407 |
| Post‐menopausal vaginal bleeding | 354 (84.1) | 48 (11.4) | 19 (4.5) | 421 |
| Post‐coital vaginal bleeding | 324 (76.1) | 76 (17.8) | 26 (6.1) | 426 |
| Excessive vaginal discharge, often with offensive smell | 347 (83.0) | 53 (12.7) | 18 (4.3) | 418 |
| Lower abdominal pain | 368 (87.6) | 45 (10.7) | 7 (1.7) | 420 |
| Pain in the genital during sexual intercourse (dyspareunia) | 300 (71.1) | 95 (22.5) | 27 (6.6) | 422 |
| Sample | Plaque samples | Saliva samples | ||
| Day 1 | Day 22 | Day 1 | Day 22 | |
| Dexolac 2 | 45,167 ± 8,156 | 66,500 ± 7,914 | 21,167 ± 4,019 | 31,667 ± 3,601 |
| Lactodex 2 | 50,727 ± 9,931 | 65,273 ± 5,605 | 23,909 ± 4,549 | 31,000 ± 2,793 |
| Lactogen 3 | 48,615 ± 6,449 | 69,231 ± 6,906 | 23,154 ± 3,105 | 33,154 ± 3,716 |
| Variants | Clinical significance | Number of samples |
| BRCA1 c.5266dupC | Pathogenic | 2 |
| BRAC1 c.5095C>T | Pathogenic | 1 |
| BRCA1 c.3916_3917del | Pathogenic | 1 |
| BRCA2 c.6988A>G | VUS | 1 |
| BRCA2 c.8482A>G | VUS | 1 |
| BRCA2 c.8518A>G | VUS | 1 |
| Antibacterial Result | Gram-negative | Gram-positive | ||
| E. coliATCC 25922 | P. aeruginosaATCC 27853 | S. aureusATCC 25923 | B. subtilisATCC 6633 | |
| MIC (μg/mL) | 64 | 500 | 32 | 16 |
| Heating current of the emitter I (mA) | 0.8 | 0.9 | 1.0 | 1.1 |
| Steady temperature T (K) | 316.3087 | 323.0872 | 330.387 | 339.1644 |
| Gcon (W·K−1) | 1.34 × 10−6 | 1.33 × 10−6 | 1.32 × 10−6 | 1.31 × 10−6 |
| Gfr (W·K−1) | 1.49 × 10−8 | 1.59 × 10−8 | 1.70 × 10−8 | 1.84 × 10−8 |
| Items of the scale | Domains |
| 1. I feel guilty because I have HIV. | Internalized stigma |
| 2. People’s attitudes about HIV make me feel worse about myself. | Internalized stigma |
| 3. People with HIV lose their jobs when their employers learn. | Perceived stigma |
| 4. I feel I am not as good a person as others because I have HIV. | Internalized stigma |
| 5. People with HIV are treated like outcasts. | Perceived stigma |
| 6. Most people think that a person who has HIV is dirty. | Perceived stigma |
| 7. It is easier to avoid new friendships than worry about telling someone that I have HIV. | Internalized stigma |
| 8. Having HIV makes me feel unclean. | Internalized stigma |
| 9. Since learning I have HIV, I feel set apart and isolated from the rest of the world. | Internalized stigma |
| 10. Most people think that a person with HIV is disgusting. | Perceived stigma |
| 11. Having HIV makes me feel that I am a bad person. | Internalized stigma |
| 12. Most people with HIV are rejected when others find out. | Perceived stigma |
| 13. Most people are uncomfortable around someone with HIV. | Perceived stigma |
| 14. Having HIV in my body is disgusting to me. | Internalized stigma |
| Name | Sequence 53 |
| rmhS100 — F | ATgTCTTCCATCAgTATTCAggg |
| rmhS100 — R | TCTCCATCACTTTgTCCACC |
| rmhS100 — pr | [FAM] TCTTCAgCTTgTgCTTgTCACCCT [BH1] |
| Pmp22 — TM — S | gTgCTAgTgTTgCTCTTC |
| Pmp22 — TM — A | ggATgTggTACAgTTCTg |
| Pmp22 — TMpr | [FAM] CTCCACCATCgTCAgCCAAT [BH1] |
| rPmp2 — TM — S | ggAgACTATATCACCATTAgA |
| rPmp2 — TM — A | TCCAgCAACTTTCTCTTTA |
| Pmp2 — TMpr | [FAM] CCACTTCTgCACTTgCTTCA [BH1] |
| rmh18S — TMF | gCCgCTAgAggTgAAATTCTTg |
| rmh18S — TMR | CATTCTTggCAAATgCTTTCg |
| rmh18S TMpr | [HEX] ACCggCgCAAgACggACCAg [BH2] |
| Follow up | ||||
| Type of intervention | 3 months | 6 months | 1 year | 5 years |
| 2 | 6 [−9.8; 21.8] | 6.2 [−9.1; 21.4] | 6.6 [−7.7; 20.8] | 9.7 [−2.1; 21.5] |
| 3 | −11.8 [−19.6; −3.9] | −11.3 [−19; −3.6] | −10.4 [−17.7; −3.1] | −3.4 [−9.6; 2.9] |
| 4 | −11.9 [−23.5; −0.2] | −11.1 [−22.3; 0.2] | −9.5 [−20; 1] | 3.3 [−5.2; 11.8] |
| 6 | 1.2 [−6.1; 8.4] | 1.5 [−5.7; 8.6] | 2.1 [−4.8; 9] | 7 [0.6; 13.4] |
| 7 | 0.6 [−5.2; 6.5] | 0.6 [−5.2; 6.4] | 0.4 [−5.3; 6.2] | −0.5 [−6.1; 5.2] |
| GroupsParameters | Vitamin D ≤ 12.5 (nmol/l) | 12.5<vitamin D ≤ 25 | 25<vitamin D ≤ 35 | 35.1<vitamin D ≤ 150 |
| BMI (kg/m2) | 27.32 ± 5.02 | 26.44 ± 4.52 | 27.66 ± 5.16 | 26.99 ± 4.93 |
| Calcium intake (mg/day) | 503.39 ± 303.1* | 577.93 ± 304.9* | 595.84 ± 313.6* | 714.67 ± 330.8 |
| Characteristic | Cases (n = 300) | Controls (n = 299) | P |
| Age (years) | 57.9 (5.2) | 57.8 (5.2) | 0.82 |
| Body mass index (kg/m2) | 26.0 (3.3) | 26.5 (3.6) | 0.10 |
| Cigarettes per day | 19.2 (8.9) | 19.5 (7.9) | 0.63 |
| Years of smoking | 35.3 (8.9) | 36.7 (8.0) | 0.04 |
| History of BPH (% yes) | 4.7 | 3.0 | 0.29 |
| History of diabetes (% yes) | 4.0 | 3.0 | 0.51 |
| Family history of prostate cancer (% yes) | 7.6 | 4.9 | 0.21 |
| Physical activity (% active)1 | 62.0 | 57.2 | 0.23 |
| Education > primary school (% yes) | 41.0 | 30.4 | 0.007 |
| Serum cholesterol (mmol/L) | 6.27 (1.09) | 6.24 (1.30) | 0.74 |
| Serum β-carotene (μg/L) | 242 (197) | 214 (130) | 0.04 |
| Serum α-tocopherol (mg/L) | 11.8 (2.4) | 11.9 (2.4) | 0.87 |
| Alcohol consumption (g/d) | 16.3 (20.4) | 16.7 (19.2) | 0.80 |
| Energy intake (kcal/d) | 2675 (757) | 2696 (819) | 0.74 |
| Fat intake (g/d)2 | 117 (15) | 117 (15) | 0.64 |
| Saturated fat intake (g/d)2 | 49.7 (12.1) | 50.4 (12.3) | 0.50 |
| Fruit and vegetable intake (g/d)2 | 242 (132) | 241 (128) | 0.94 |
| β-Carotene intake (μg/d)2 | 2097 (1382) | 2044 (1333) | 0.62 |
| Total dairy product intake (g/d)2,3 | 780 | 771 | 0.74 |
| Red meat intake (g/d)2,4 | 32.0 | 31.5 | 0.79 |
| Estimated phytanic acid intake (mg/d)2,5 | 129 (54) | 133 (56) | 0.45 |
| Serum phytanic acid (% total fatty acids)6 | 0.08 (0.04) | 0.08 (0.04) | 0.83 |
| Serum phytanic acid (μg/mL) | 3.02 (1.57) | 3.09 (1.77) | 0.97 |
| Serum pristanic acid (% total fatty acids)6 | 0.01 (0.007) | 0.01 (0.008) | 0.45 |
| Serum pristanic acid (μg/mL) | 0.50 (0.32) | 0.51 (0.28) | 0.59 |
| Identifiable (n = 296)† n (%) | Anonymous (n = 315) †† n (%) | Chi2statistic (degrees of freedom), P value | Odds ratio (95% confidence interval) | Adjusted* odds ratio (95% confidence interval) | |
| Barriers to Care | |||||
| It is difficult to schedule an appointment | 66 (23.9) | 63 (22.0) | 0.31 (1), P = 0.580 | 0.89 (0.60-1.33) | 0.95 (0.64-1.41) |
| It is difficult to get time off | 86 (31.1) | 108 (36.9) | 2.14 (1), P = 0.143 | 1.30 (0.92-1.84) | 1.34 (0.94-1.91) |
| I don’t trust mental health professionals | 36 (12.7) | 42 (14.3) | 0.34 (1), P = 0.560 | 1.15 (0.71-1.86) | 1.17 (0.73-1.93) |
| My visit would not remain confidential | 69 (24.7) | 76 (26.0) | 0.13 (1), P = 0.722 | 1.07 (0.73-1.56) | 1.11 (0.76-1.63) |
| Leaders discourage the use of mental health services | 13 (4.6) | 27 (9.3) | 4.76 (1), P = 0.029 | 2.11 (1.06-4.18) | 2.23 (1.12-4.43) |
| Perceived social stigma | |||||
| It would be too embarrassing | 93 (32.5) | 122 (41.6) | 5.16 (1), P = 0.023 | 1.48 (1.05-2.08) | 1.55 (1.10-2.18) |
| It would affect my career | 116 (41.1) | 123 (41.8) | 0.03 (1), P = 0.864 | 1.03 (0.74-1.43) | 1.08 (0.77-1.51) |
| Others would have less confidence in me | 151 (53.0) | 171 (58.0) | 1.46 (1), P = 0.227 | 1.22 (0.88-1.70) | 1.29 (0.93-1.80) |
| My leaders would treat me differently | 152 (53.7) | 169 (57.3) | 0.75 (1), P = 0.387 | 1.16 (0.83-1.61) | 1.21 (0.87-1.69) |
| My leaders would blame me | 67 (23.5) | 74 (25.3) | 0.26 (1), P = 0.608 | 1.10 (0.76-1.62) | 1.18 (0.81-1.74) |
| I would be seen as weak | 95 (34.2) | 136 (46.6) | 9.09 (1), P = 0.003 | 1.68 (1.20-2.35) | 1.78 (1.26-2.50) |
| Biomarkera | Mean ± SD | Median (min/max) |
| IL-6 (pg/mL) | 2.42 ± 1.85 | 1.92 (0.25/10.0) |
| TNF-α (pg/mL)b | 1.92 ± 1.64 | 1.41 (0.5/14.3) |
| sTNF-RII (pg/mL) | 3,610 ± 1,489 | 3,235 (657/11,584) |
| sP-selectin (ng/mL) | 45.0 ± 16.6 | 42.5 (6.0/119.9) |
| CRP (ng/mL)c | 2,434 ± 3,181 | 1,403 (250/26,799) |
| Cu, Zn-SOD (U/g Hb) | 4,459 ± 1,688 | 4,288 (669/13,138) |
| GPx-1 (U/g Hb) | 19.2 ± 7.6 | 17.8 (5.5/50.7) |
| permanent transect ID | latitude of origin (° N) | longitude of origin (° W) | elevation (m) | burn severity class | burn severity score | soil pH (± s.e.) |
| 101 | 69.995 | 150.283 | 359 | severe | 1.8 | 4.6 (0.18) |
| 114 | 69.997 | 150.307 | 325 | severe | 1.5 | 4.5 (0.08) |
| 103 | 68.954 | 150.207 | 403 | moderate | 3.1 | 4.7 (0.05) |
| 104 | 68.951 | 150.210 | 412 | moderate | 2.5 | 4.9 (0.12) |
| 108 | 68.952 | 150.208 | 414 | unburned | 4.8 | 4.4 (0.15) |
| 109 | 68.933 | 150.273 | 435 | unburned | 5 | 4.5 (0.10) |
| Enzyme | Recognition site | Sensitivity to methylation |
| Aci I | 5'-CCGC-3' | CpG |
| Bfa I | 5'-CTAG-3' | none |
| BstU I | 5'-CGCG-3' | CpG |
| Cfo I | 5'-GCGC-3' | CpG |
| Hae III | 5'-GGCC-3' | none |
| MspI | 5'-CCGG-3' | CpNpG |
| Sau3A I | 5'-GATC-3' | none |
| Number of cases | Median (IQR) ng/mL | |
| sAxl | 1067 | |
| Healthy controls | 75 | 40.15 (35.22 - 46.85) |
| Tumors patients: | 402 | |
| All HCC | 347* | 78.69 (55.09 - 101.5) |
| HCC with cirrhosis | 272 | 83.37 (62.13 - 107.1) |
| HCC w/o cirrhosis | 35 | 61.92 (43.13 - 81.09) |
| BCLC A | 45 | 82.57 (52.13 - 110.2) |
| BCLC B | 45 | 73.46 (50.59 - 87.24) |
| BCLC C | 67 | 77.08 (55.09 - 96.33) |
| BCLC D | 12 | 114.50 (89.69 - 134.6) |
| CCA | 44 | 41.02 (33.89 - 48.11) |
| Adenoma | 11 | 31.41 (25.95 - 36.57) |
| Chronic liver diseases | 400 | |
| Fibrosis stages: | ||
| F0 | 54 | 40.70 (35.56 - 51.98) |
| F1 | 75 | 46.20 (38.64 - 55.07) |
| F2 | 80 | 46.76 (40.37 - 60.06) |
| F3 | 36 | 54.67 (43.45 - 74.92) |
| F4 (cirrhosis w/o HCC) | 155 | 94.74 (66.38 - 132.5) |
| Liver disease etiology: | 190 | |
| Viral hepatitis | 26 | 47.87 (42.30 - 61.75) |
| AIH | 18 | 48.40 (36.16 - 84.20) |
| Cholestatic liver disease | 30 | 40.97 (36.01 - 51.06) |
| NAFLD | 116 | 43.15 (37.72 - 53.85) |
| AFP | 326 | |
| Healthy controls | 28 | 2.60 (1.500 - 3.475) |
| All HCC | 274 | 12.90 (5.275 - 173.3) |
| HCC with cirrhosis | 194 | 11.50 (0 - 49.33) |
| HCC w/o cirrhosis | 28 | 23.60 (3.900 - 4743) |
| F4 (cirrhosis w/o HCC) | 24 | 4.65 (3.025 - 6.650) |
| Preoperative | 6 months | 12 months | 18 months | |
| Upper limb (n) | 15 | 12 | 7 | 1 |
| L-Dex [mean (range)] | 41.2 (18–75) | 35.3 (14–49) | 25.1 (13–45) | 27 |
| Significance | – | p = 0.068 | p = 0.018 | – |
| Mean excess volume [ml (range)] | 1139.5 (645–1755) | 67.9 (−697 to 422) | 18.7 (−244 to 218) | −339a |
| Mean excess volume [% (range)] | 44.2 (27–67) | 3.6 (−21 to 21) | 1.3 (−5 to 8) | −11a |
| Significance | – | p < 0.001 | p = 0.001 | – |
| Lower limb (n) | 6 | 5 | 1 | 0 |
| L-Dex [mean (range)] | 46.9 (12–97) | 49.3 (33–71) | 39.0 | – |
| Significance | – | p = 0.746 | – | – |
| Mean excess volume [ml (range)] | 4058 (2068–8294) | 400 (−112 to 867) | −103 | – |
| Mean excess volume [% (range)] | 47.3 (23–83) | 4.3 (−1 to 11) | −1.0 | – |
| Significance | – | p = 0.018 | – | – |
| Samples | Vitamin A | Vitamin B2 | Vitamin B3 | Vitamin C |
| Control | 0.01 | 0.01 | 0.05 | 62.54 |
| A | 1.98 | 30.25 | 0.18 | 40.72 |
| B | 2.00 | 25.42 | 0.15 | 34.12 |
| C | 2.20 | 22.12 | 0.15 | 30.56 |
| D | 3.15 | 12.25 | 0.20 | 22.14 |
| Sex | Woman |
| Age | 33 years |
| EPILEPSY | |
| Brain insult | TBI when she was 1 year old |
| Febrile seizure | No |
| First epileptic seizure | 9 years old |
| Age of onset Auras | 6 years old |
| Duration of seizures | 24 years |
| Frecuency | On cluster/4–5 month |
| Complex partial seizures | Yes |
| Antiepileptic treatment | Trileptal, Keppra, Noiafren and Stilnox |
| Neurological examination | Normal |
| Ictal EEG | Video EEG predominance interictal activity in left temporal lobe |
| Interictal EEG | Video EEG ictal activity in left temporal lobe |
| MRI | Reduction of left hippocampal size, with hypointensity and loss of internal differentiation |
| Interictal SPECT HMpao | Left anterior temporal lobe hypoperfusion |
| SURGERY | |
| Surgery procedure | Selective amigdalohippocampectomy transilvian (Yasargil technique) |
| Size of resection | Resection of the hippocampal gyrus, the subiculum and the parahippocampal gyrus. Resection of the anterior portion of the left hippocampus with preservation of the dorsal portion and tail |
| Histology | Hippocampal sclerosis. Massive pyramidal cells loss in Ammon's sectors (CA1 to CA4), astrocytosis and neuronal dispersion of dentate gyrus |
| Variables | Screening phase (n = 30) | Training cohort (n = 84) | Testing cohort (n = 214) | Additional validation cohort (n = 99) | ||||
| Cases (%) | Controls (%) | Cases (%) | Controls (%) | Cases (%) | Controls (%) | Cases (%) | Controls (%) | |
| Number | 20 | 10 | 36 | 42 | 101 | 113 | 41 | 50 |
| Gender | ||||||||
| Male | 14 (70) | 6 (60) | 25 (69) | 27 (64.3) | 77 (76.2) | 75 (66.4) | 24 (58.5) | 26 (52) |
| Female | 6 (30) | 4 (40) | 11 (31) | 15 (35.7) | 24 (23.8) | 38 (33.6) | 17 (41.5) | 24 (48) |
| Age | ||||||||
| < 65 | 13 (65) | 5 (50) | 20 (55.6) | 31 (73.8) | 65 (64.4) | 81 (71.2) | 25 (61) | 34 (68) |
| ≥ 65 | 7 (35) | 5 (50) | 16 (44.4) | 11 (26.2) | 36 (35.6) | 32 (28.8) | 16 (39) | 16 (32) |
| Smoking | ||||||||
| Smoker | 9 (45) | 14 (38.9) | 39 (38.6) | 17 (41.5) | ||||
| Non-smoker | 8 (40) | 15 (41.7) | 47 (46.5) | 22 (53.7) | ||||
| NA | 3 (15) | 7 (19.4) | 15 (14.9) | 2 (4.8) | ||||
| Drinking | ||||||||
| Drinker | 3 (15) | 7 (19.4) | 23 (22.7) | 7 (17.1) | ||||
| Non-drinker | 11 (55) | 23 (63.9) | 71 (70.3) | 26 (63.4) | ||||
| NA | 6 (30) | 6 (16.7) | 7 (7) | 8 (19.5) | ||||
| Differential | ||||||||
| well | 10 (50) | 19 (52.8) | 48 (47.5) | 19 (46.3) | ||||
| poor | 7 (35) | 14 (38.9) | 42 (41.6) | 14 (34.2) | ||||
| NA | 3 (15) | 3 (8.3) | 11 (10.9) | 8 (19.5) | ||||
| Location | ||||||||
| Up | 2 (10) | 3 (8.3) | 6 (5.9) | 4 (9.8) | ||||
| Middle | 9 (45) | 15 (41.7) | 31 (30.7) | 16 (39) | ||||
| Down | 7 (35) | 14 (38.9) | 49 (48.5) | 15 (36.6) | ||||
| NA | 2 (10) | 4 (11.1) | 15 (14.9) | 6 (14.6) | ||||
| TNM stage | ||||||||
| I | 8 (40) | 15 (41.7) | 46 (45.5) | 18 (43.9) | ||||
| II | 7 (35) | 14 (38.9) | 32 (31.7) | 18 (43.9) | ||||
| III | 5 (25) | 7 (19.4) | 23 (22.8) | 5 (12.2) |
| Lane | 1 | 2 | 3 |
| 1 | 1.00 | 0.72 | 0.37 |
| 2 | 0.72 | 1.00 | 0.45 |
| 3 | 0.37 | 0.45 | 1.00 |
| Arthritic patient volunteers (n = 13) | Healthy volunteers (n = 18) | |
| Age (y)* | 64.8 (6.4) | 33.8 (7.9) |
| Body mass index*, kg/m2 | 36.1 (5.4) | 23.3 (3.0) |
| Male, n | 7 | 6 |
| Category | P value | Total occurrence |
| Multicellular organismal process | 7.36E−09 | 1048 |
| Biological adhesion | 7.78E−07 | 409 |
| Cell adhesion | 7.78E−07 | 409 |
| Oxidation reduction | 9.32E−06 | 339 |
| Regulation of multicellular organismal process | 2.94E−05 | 358 |
| Developmental process | 3.21E−05 | 1756 |
| Cellular ion homeostasis | 4.49E−05 | 117 |
| Branching morphogenesis of a tube | 5.10E−05 | 40 |
| Morphogenesis of a branching structure | 5.84E−05 | 41 |
| Cellular chemical homeostasis | 9.57E−05 | 119 |
| Clinical parameters | Case(n =124 ) |
| Incidence rate , per 100 person-years | 5.4 |
| Median (IQR), duration from starting ARV to hepatitis, years | 1.3(0.5–3.5) |
| Mean ALT level at time of ALT elevation, IU/L (±SD) | 73 ± 107 |
| Mean AST level at time of ALT elevation, IU/L (±SD) | 58 ± 49 |
| Mean alkaline phosphatase level at time of ALT elevation, IU/L (±SD) | 97 ± 54 |
| Severity grading of chronic hepatitis **, n (%) | |
| o Mild (grade 1 or 2) | 122 (98.4) |
| o Severe, at least grade 3 | 2 (1.6) |
| Symptoms at time of ALT elevation, n (%) | |
| o Any | 64(51.6) |
| o Nausea/ vomiting | 30(24.2) |
| o Fatigue | 14(11.3) |
| o Anorexia | 9(7.3) |
| o Flatulence | 5(4.0) |
| o Weight loss | 4(3.2) |
| o Jaundice | 1(0.8) |
| o Liver tenderness | 1(0.8) |
| Characteristics | Physicians (N = 55) | Nurses (N = 78) | p | Total (N = 133) | |||
| n | % | n | % | n | % | ||
| Gender | |||||||
| - Male | 35 | 63.6 | 2 | 2.6 | <0.001 | 37 | 27.8 |
| - Female | 20 | 36.4 | 76 | 97.4 | 96 | 72.2 | |
| Age (mean / SD) | 39.8 (10.6) | 42.7 (8.6) | 0.090 | 41.5 (9.6) | |||
| - 25 – 44 | 37 | 67.3 | 41 | 52.6 | 78 | 58.6 | |
| - 45 – 60 | 18 | 32.7 | 37 | 47.4 | 55 | 41.4 | |
| Marital status | |||||||
| - Married or Cohabiting | 34 | 61.8 | 54 | 69.2 | 0.094 | 88 | 66.2 |
| - Single | 21 | 38.2 | 20 | 25.6 | 41 | 30.8 | |
| - Widow/divorced/separated | 0 | 0.0 | 4 | 5.1 | 4 | 3.0 | |
| Length of employment (years) | 13.9 (10.5) | 19.4 (9.4) | 0.232 | 17.1 (10.2) | |||
| - More than 20 | 18 | 32.7 | 36 | 46.2 | 54 | 40.6 | |
| - 20 or less | 37 | 67.3 | 42 | 53.8 | 79 | 59.4 | |
| Ever perform or assist in MC | 37 | 67.3 | 33 | 42.3 | 0.005 | 70 | 52.6 |
| Ever perform or assist in NMC | 8 | 14.5 | 5 | 6.4 | 0.120 | 13 | 9.8 |
| ypT0 | ypT1 | ypT2 | ypT3–4 | |||||
| Variable | n | % | n | % | n | % | n | % |
| Sex | ||||||||
| Male | 74 | 64.9 | 692 | 63.4 | 1297 | 65.2 | 5919 | 62.4 |
| Female | 40 | 35.1 | 399 | 36.6 | 692 | 34.8 | 3569 | 37.6 |
| Age | ||||||||
| <50 | 20 | 17.5 | 195 | 17.9 | 377 | 19 | 1933 | 20.4 |
| ≥50 | 94 | 82.5 | 896 | 82.1 | 1612 | 81 | 7555 | 79.6 |
| Race | ||||||||
| White | 99 | 86.8 | 910 | 83.4 | 1604 | 80.6 | 7764 | 81.8 |
| Black | 8 | 7 | 97 | 8.9 | 188 | 9.5 | 729 | 7.7 |
| Other | 7 | 6.2 | 84 | 7.7 | 197 | 9.9 | 995 | 10.5 |
| Pathological grading | ||||||||
| Grade I | 12 | 10.5 | 89 | 8.2 | 127 | 6.4 | 581 | 6.1 |
| Grade II | 63 | 55.3 | 707 | 64.8 | 1459 | 73.4 | 6474 | 68.2 |
| Grade III | 11 | 9.6 | 95 | 8.7 | 190 | 9.6 | 1273 | 13.4 |
| Grade IV | 2 | 1.8 | 5 | 0.5 | 8 | 0.4 | 111 | 1.2 |
| Unknown | 26 | 22.8 | 195 | 17.8 | 205 | 10.2 | 1049 | 11.1 |
| Histotype | ||||||||
| Adenocarcinoma | 109 | 95.6 | 1058 | 97 | 1911 | 96.1 | 8685 | 91.5 |
| Mucinous/Signet ring cell | 5 | 44 | 33 | 3 | 78 | 3.9 | 803 | 8.5 |
| LNs examined | ||||||||
| Median | 6 | 8 | 11 | 12 | ||||
| Rang | 1–21 | 1–25 | 1–28 | 1–35 |
| Unit | ||
| Male:female | n (%) | 11 (26.2):31 (73.8) |
| Age | years | 37 ± 12 (24–63) |
| Weight | kg | 70.3 ± 11.5 |
| BMI | kg/m2 | 23.9 ± 3.1 (19.0–30.4) |
| Current smoker | n (%) | 2 (4.8) |
| Nutrition | n (%) | |
| Meat-based | 37 (88.1) | |
| Flexitariana | 5 (11.9) | |
| Medication | n (%) | |
| Thyroid hormone (L-thyroxine) | 5 (11.9) | |
| Hormone replacement therapy | 2 (4.8) | |
| Antidepressant (NDRI or SSRI) | 2 (4.8) | |
| Proton pump inhibitor | 1 (2.4) | |
| Oral anticoagulant and statins | 1 (2.4) | |
| Methylphenidate and antidepressant (NDRI) | 1 (2.4) | |
| Glucocorticoidb | 1 (2.4) |
| Follow up | 1wk | 2 m | 6 m | ||
| CCC size | CCC size | Change from 1 week(percentage) | CCC size | Change from 2 months(percentage) | |
| Precizon (IOL A) | 20.69 ± 1.50 | 17.17 ± 3.23 | −3.53 ± 3.31 (17.06 ± 15.99%) | 17.01 ± 3.11 | − 0.16 ± 1.31 (0.64 ± 6.21%) |
| Microflex (IOL B) | 21.70 ± 0.86 | 21.07 ± 1.50 | − 0.62 ± 1.32 (2.87 ± 6.03%) | 20.48 ± 1.09 | − 0.60 ± 1.51 (2.47 ± 6.91%) |
| Asphina (IOL C) | 21.43 ± 1.09 | 20.34 ± 1.60 | −1.09 ± 1.53 (4.72 ± 6.10%) | 19.86 ± 1.58 | −0.48 ± 1.19 (2.12 ± 5.25%) |
| P-value† | 0.068 | < 0.001 | < 0.001 | < 0.001 | 0.170 |
| Drug(concentration) | Skin prick test(dilution factor) | Intradermal test(dilution factor) |
| Midazolam (5 mg/ml) | 5 mg/ml (pure) | 0.5 mg/ml (1:10) |
| Propofol (10 mg/ml) | 10 mg/ml (pure) | 1 mg/ml (1:10) |
| Ketamine (10 mg/ml) | 10 mg/ml (pure) | 1 mg/ml (1:10) |
| Thiopental (25 mg/ml) | 25 mg/ml (pure) | 2.5 mg/ml (1:10) |
| Etomidate (2 mg/ml) | 2 mg/ml (pure) | 0.2 mg/ml (1:10) |
| Morphine (10 mg/ml) | 1 mg/ml (1:10) | 0.01 mg/ml (1:1000) |
| Fentanyl (0.05 mg/ml) | 0.05 mg/ml (pure) | 0.005 mg/ml (1:10) |
| Remifentanil (0.05 mg/ml) | 0.05 mg/ml (pure) | 0.005 mg/ml (1:10) |
| Sufentanil (0.005 mg/ml) | 0.005 mg/ml (pure) | 0.0005 mg/ml (1:10) |
| Alfentanil (0.5 mg/ml) | 0.5 mg/ml (pure) | 0.05 mg/ml (1:10) |
| Atracurium (10 mg/ml) | 1 mg/ml (1:10) | 0.01 mg/ml (1:1000) |
| Cisatracurium (2 mg/ml) | 2 mg/ml (pure) | 0.02 mg/ml (1:100) |
| Rocuronium (10 mg/ml) | 10 mg/ml (pure) | 0.05 mg/ml (1:200) |
| Mivacurium (2 mg/ml) | 0.2 mg/ml (1:10) | 0.002 mg/ml (1:1000) |
| Pancuronium (2 mg/ml) | 2 mg/ml (pure) | 0.2 mg/ml (1:10) |
| Vecuronium (4 mg/ml) | 4 mg/ml (pure) | 0.4 mg/ml (1:10) |
| Suxamethonium (50 mg/ml) | 10 mg/ml (1:5) | 0.1 mg/ml (1:500) |
| Child | Deficiency of the limb | Associated anomaly | Relation of the relative | Limb anomaly of the relative |
| 1 | split hand of right upper limb | none | sibling | (not reported) |
| 2 | split hand of right upper limb | none | sibling | (not reported) |
| 3 | split hand of right upper limb | none | sibling | (not reported) |
| 4 | split hand of right upper limb | none | sibling | (not reported) |
| 5 | split hand of both upper limbs and split foot of both lower limbs | none | sibling | (not reported) |
| 6 | radial deficiency of left upper limb | Fanconi’s anemia | sibling | (not reported) |
| 7 | ulnar deficiency of right upper limb | none | sibling | (not reported) |
| 8 | transverse deficiency at the level of hand of right upper limb | none | sibling | (not reported) |
| 9 | split hand of right upper limb | none | mother | anomalies of radius and ulna |
| 10 | split hand of right upper limb | none | father | split hand |
| 11 | split hand of both upper limbs | none | father | split hand |
| 12 | split hand of left upper limb and tibial deficiency of both lower limbs | none | granduncle | split hand |
| 13 | split foot of right lower limb | none | someone other than sibling | (not reported) |
| 14 | ulnar deficiency of both upper limbs and split foot of both lower limbs | Leri-Weill syndrome | mother | Madelung deformity, and Leri-Weill syndrome |
| 15 | ulnar deficiency of both upper limbs and tibial deficiency of both lower limbs | none | mother and grandmother | upper limb anomaly |
| 16 | transverse deficiency at the level of hand of right upper limb | none | relative on the mother’s side | toe defect |
| 17 | transverse deficiency at the level of foot of both lower limbs | none | father and grandfather on the father’s side | anomaly of fifth finger |
| Genus (family) | Order/suborder | Organelle genome | Inheritance | Reference |
| Equisetum (Equisetaceae) | Equisetales | Plastome | Maternal | Guillon and Raquin, 2000 |
| Ceratopteris (Pteridaceae) | Polypodiales/Pteridineae | Plastome | Maternal | Adjie et al., 2007 |
| Pellaea (Pteridaceae) | Polypodiales/Pteridineae | Plastome and mitogenome | Maternal | Gastony and Yatskievych, 1992 |
| Asplenium (Aspleniaceae) | Polypodiales/Aspleniineae | Plastome | Maternal | Vogel et al., 1997 |
| Deparia (Athyriaceae) | Polypodiales/Aspleniineae | Plastome and mitogenome | Maternal | This study |
| Date | Event |
| 28 to 31 Oct 2008 | Fifteenth Session of the IBC (2 days); Joint Session of the IBC and IGBC (2 days) (Paris) |
| 9 to 10 Jul 2009 | Sixth Session of the IGBC (Paris) |
| 23 to 25 Nov 2009 | Sixteenth Session of the IBC (Mexico City) |
| 26 to 29 Oct 2010 | Seventeenth Session of the IBC (2 days)*,; Joint Session of the IBC and IGBC (2 days)* (Paris) |
| 31 May to 2 Jun 2011 | Eighteenth Session of the IBC* (Baku) |
| 5 to 6 Sep 2011 | Seventh Session of the IGBC* (Paris) |
| PredictiveVariables | HR | CI | P |
| Cyclin D1 | 10.864 | 1.055 – 86.250 | 0.03* |
| (baseline < 6.1) | - | - | - |
| Cyclin A | 13.886 | 1.012 – 190.579 | 0.0490* |
| (baseline < 10.5) | - | - | - |
| Positive Lymph node metastasis | 3.921 | 1.057 – 14.472 | 0.0410* |
| Stage IV | 3.411 | 1.048 – 12.083 | 0.03* |
| Depth of invasion | |||
| T3, T4 | 5.408 | 0.449 – 65.080 | 0.1836 |
| Age (years) | |||
| ≥50 | 1.996 | 0.678 – 5.878 | 0.2310 |
| Sex | 0.910 | 0.315 – 2.358 | 0.8453 |
| Whole group, n = 92 | ||||
| Age (median) 59.5 years | ||||
| Gender: | Male | 32 (35 %) | ||
| Female | 60 (65 %) | |||
| Treatment intent: | Palliative | 7 | Radical | 85 |
| N-stage | T-stage | No. of patients | % of total | |
| N0 | T1 | 19 | 20.7 | |
| N0 | T2 | 37 | 40.2 | |
| N0 | T3 | 20 | 21.7 | |
| N0 | T4 | 6 | 6.5 | |
| N1 | T3 | 1 | 1.1 | |
| N1 | T4 | 4 | 4.4 | |
| N2 | T3 | 3 | 3.3 | |
| N3 | T3 | 1 | 1.1 | |
| N3 | T4 | 1 | 1.1 | |
| Radical treatment | ||||
| Chemoradiotherapy plus boost, n = 52 | ||||
| Anal canal | Anal margin | |||
| Iridium boost, n = 36 | Electron boost, n = 16 | |||
| Age (median) 61 years | Age (median) 63 years | |||
| Stage | No. of patients (%) | Stage | No. of patients (%) | |
| T1 N0 | 3 (8.3) | T1 N0 | 4 (25) | |
| T2 N0 | 17 (47.2) | T2 N0 | 7 (43.8) | |
| T3 N0 | 14 (38.9) | T3 N0 | 2 (12.5) | |
| T2 N2 | 1 (2.8) | – | – | |
| T3 N2 | 1 (2.8) | – | – | |
| – | – | T4 N0 | 2 (12.5) | |
| – | – | T4 N1 | 1 (6.2) | |
| Radical treatment (other) | ||||
| External beam radiotherapy alone | 8 | |||
| Chemoradiotherapy without boost | 25 |
| Cell line | EC50 of MTX | |
| MCF-7 | human breast adenocarcinoma | 2.58 × 10−8M |
| MDA-MB 231 | human breast adenocarcinoma | 5.06 × 10−7M |
| T-24 | human bladder carcinoma | 8.07 × 10−8M |
| PANC-1 | human pancreatic carcinoma | 2.34 × 10−8M |
| HT29 | human colon adenocarcinoma | 6.09 × 10−8M |
| A375 | human melanoma | 3.37 × 10−8M |
| HT-1376 | human bladder carcinoma | 1.71 × 10−7M |
| OVCAR-3 | human ovarian carcinoma | 8.95 × 10−8M |
| Estimators | WF population | BF population | ||||
| BREAST CANCER | Scenario 1 | Scenario 2 | Scenario 3 | Scenario 1 | Scenario 2 | Scenario 3 |
| Observed rates | 0.973 | 0.974 | 0.975 | 0.956 | 0.964 | 0.965 |
| Population-weighted average | 0.967 | 0.943 | 0.968 | 0.887 | 0.761 | 0.910 |
| Global Empirical Bayes | 0.847 | 0.843 | 0.974 | 0.908 | 0.787 | 0.804 |
| Local Empirical Bayes | 0.964 | 0.952 | 0.971 | 0.899 | 0.782 | 0.921 |
| Poisson kriging (true γR(h)) | 0.971 | 0.972 | 0.947 | 0.716 | 0.842 | 0.887 |
| Poisson kriging | 0.965 | 0.913 | 0.940 | 0.761 | 0.927 | 0.803 |
| CERVIX CANCER | ||||||
| Observed rates | 0.937 | 0.939 | 0.970 | 0.935 | 0.935 | 0.922 |
| Population-weighted average | 0.933 | 0.901 | 0.933 | 0.852 | 0.743 | 0.888 |
| Global Empirical Bayes | 0.875 | 0.870 | 0.973 | 0.833 | 0.785 | 0.787 |
| Local Empirical Bayes | 0.960 | 0.920 | 0.962 | 0.875 | 0.771 | 0.901 |
| Poisson kriging (true γR(h)) | 0.963 | 0.947 | 0.973 | 0.931 | 0.935 | 0.966 |
| Poisson kriging | 0.968 | 0.924 | 0.934 | 0.940 | 0.893 | 0.935 |
| MCC 24 | CCC 46 | ACC 21 | MCC 46 | CCC 37 | MCC 35 | |||||||||||||
| E | S | N | E | S | N | E | S | N | E | S | N | E | S | N | E | S | N | |
| O/IR + FLL | 40 | 35 | 15 | 59 | 21 | 4 | 43 | 34 | 7 | 48 | 29 | 6 | 41 | 37 | 4 | 25 | 42 | 15 |
| Comparison% | 39 | 36 | 15 | 62 | 18 | 4 | 47 | 30 | 7 | 53 | 24 | 6 | 46 | 32 | 4 | 30 | 39 | 13 |
| Strain name | Genotype | Reference |
| yMD7 | MATaade2-1 ura3-1 his3-11,15 trp1-1 leu2-3,112 can1-100 bar1::Hyg | This study |
| pep4::KanMX | ||
| MCM6::MCM6-3 × FLAG (Nat-NT2) | ||
| yMD8 | MATaade2-1 ura3-1 his3-11,15 trp1-1 leu2-3,112 can1-100 bar1::Hyg | This study |
| pep4::KanMX | ||
| MCM6::MCM6-3 × FLAG (Nat-NT2) | ||
| his3::HIS3pRS303/CDT1,GAL4 | ||
| trp1::TRP1pRS304/MCM4, MCM5 leu2::LEU2pRS305/MCM6TC, MCM7 ura3::URA3pRS306/MCM2, CBP-MCM3 | ||
| yMD9 | MATaade2-1 ura3-1 his3-11,15 trp1-1 leu2-3,112 can1-100, | This study |
| cdc7-4, pep4:: Hyg, | ||
| MCM10::MCM10-3 × FLAG (Nat-NT2) | ||
| his3::HIS3pRS303/SLD3-13MYC, | ||
| trp1::TRP1pRS304/SLD2, leu2::LEU2pRS305/SLD7, CDC45, | ||
| ura3::URA3pRS306/DPB11 | ||
| yMD16 | MATa/α ade2-1/ade2-1 ura3-1/ura3-1 his3-11,15/his3-11,15 trp1-1/trp1-1 leu2-3,112/leu2-3,112 can1-100/can1-100 MCM10+/mcm10Δ472-571 (Nat-NT2) | This study |
| yMD17 | MATa/α ade2-1/ade2-1 ura3-1/ura3-1 his3-11,15/his3-11,15 trp1-1/trp1-1 leu2-3,112/leu2-3,112 can1-100/can1-100 MCM10+/mcm10Δ472-571 (Nat-NT2) RAD9/rad9Δ::KanMX | This study |
| CMP Solutions | cKDP/mM | MRR/(nm/min) | RMS/nm |
| 1 | 0 | 605 | 3.1 |
| 2 | 10 | 476 | 2.3 |
| 3 | 20 | 334 | 1.7 |
| 4 | 30 | 251 | 1.5 |
| 5 | 40 | 187 | 1.8 |
| 6 | 50 | 156 | 2.3 |
| 7 | 80 | 142 | 2.7 |
| 8 | 100 | 138 | 2.8 |
| Derivation n = 1420 | Validation n = 3949 | p-value | |
| Agea | 73.4 (10.0) | 72.7 (10.7) | 0.07 |
| Sex (% male) | 1275 (89.8) | 3375 (85.5) | < 0.0001 |
| FEV1% | 45.2 (16.2) | 45.3 (16.6) | 0.76 |
| FEV1%/FVC | 52.5 (13.4) | 52.5 (12.9) | 0.79 |
| FEV1% categories | < 0.0001 | ||
| ≥ 80% | 33 (3.8) | 62 (2.5) | |
| < 80 - > 50 | 272 (31.2) | 778 (31.0) | |
| < 50 - > 30 | 217 (24.3) | 1187 (47.3) | |
| ≤ 30 | 351 (40.2) | 482 (19.2) | |
| Body Mass Indexa | 27.9 (5.3) | 27.8 (5.7) | 0.35 |
| Smoking habit | 0.34 | ||
| - Ever smoker | 52 (4.3) | 182 (4.9) | |
| - Current smoker | 343 (28.2) | 977 (26.3) | |
| - Ex-smoker | 822 (67.5) | 2554 (68.8) | |
| Cigarette pack-yearsa | 55,82 (29.0) | 51,99 (30.3) | 0.003 |
| Charlson Comorbidity Indexa | 2,70 (1.8) | 1,79 (1.7) | < 0.0001 |
| 1–2 | 795 (56.0) | 2865 (72.5) | |
| ≥ 3 | 625 (44.0) | 1084 (27.4) | |
| Ischaemic heart disease | 205 (15.7) | 505 (12.8) | 0.008 |
| Cardiac failure | 299 (23.0) | 810 (20.5) | 0.07 |
| Peripheral vascular disease | 221 (17.2) | 494 (12.5) | < 0.0001 |
| Cerebrovascular disease | 146 (11.3) | 380 (9.6) | 0.09 |
| Cardiac-Cerebro-Peripheral vascular disease | 608 (46.2) | 2217 (44.9) | 0.41 |
| Dementia | 138 (3,49) | 52 (4,04) | 0.36 |
| Diabetes mellitus | 359 (26.2) | 1032 (26.1) | 0.95 |
| Previous COPD hospitalization | 1065 (76.7) | 1881 (51.3) | < 0.0001 |
| Mean of COPD-related admissions in the previous year | 1.92 (2.0) | 1.17 (1.8) | < 0.0001 |
| pH at arrival | 7.40 (0.1) | 7.40 (0.1) | 0.12 |
| Acidaemia during admission | 258 (19.3) | NA | |
| PaO2 at arrivala | 59.1 (15.6) | 60.4 (21.3) | 0.79 |
| PaCO2 at arrivala | 47.2 (14.4) | 48.4 (15.7) | 0.074 |
| Length of staya | 10.1 (6.9) | 9.3 (7.0) | < 0.0001 |
| Men (n = 29) | Women (n = 31) | |
| Age (years) | 40 (21–64, sd = 11.48) | 37 (23–57, sd = 9.77) |
| Body mass (kg) | 80.1 (53.9–130.6, sd = 13.25) | 61.7 (47.8–89.2, sd = 12.91) |
| Height (cm) | 179.0 (159.1–190.0, sd = 7.81) | 165.9 (154.4–184.2, sd = 7.90) |
| Body mass index (kg/m2) | 24.9 (20.7–39.3, sd = 3.46) | 22.4 (17.2–28.8, sd = 3.31) |
| Skin tone (scale 1–6) | 3.7 (1–5, sd = 1.39) | 3.7 (1–6, sd = 1.25) |
| Wrist circumference (cm) | 17.3 (16.0–21.0, sd = 1.11) | 15.4 (13.5–17.5, sd = 1.30) |
| VO2max (ml/kg/min) | 52.8 (38.2–66.6, sd = 8.48) | 45.3 (31.7–56.5, sd = 7.62) |
| KEGG ID | KEGG term | HypergeometricP-value | CorrectedP-value (BF) | |
| hsa05200 | Pathways in cancer | 6.16E−08 | 1.23E−05 | |
| hsa04110 | Cell cycle | 7.96E−08 | 1.58E−05 | |
| hsa04144 | Endocytosis | 1.34E−07 | 2.67E−05 | |
| Down | hsa04520 | Adherens junction | 2.55E−07 | 5.08E−05 |
| hsa04310 | Wnt signaling pathway | 1.16E−06 | 2.31E−04 | |
| hsa05220 | Chronic myeloid leukemia | 4.39E−06 | 8.73E−04 | |
| hsa04114 | Oocyte meiosis | 4.90E−06 | 9.75E−04 | |
| hsa05200 | Pathways in cancer | 2.47E−09 | 5.14E−07 | |
| hsa05220 | Chronic myeloid leukemia | 4.54E−08 | 9.45E−06 | |
| hsa04144 | Endocytosis | 3.80E−07 | 7.91E−05 | |
| hsa05215 | Prostate cancer | 7.45E−07 | 1.55E−04 | |
| Up | hsa04110 | Cell cycle | 7.71E−07 | 1.60E−04 |
| hsa04115 | p53 signaling pathway | 2.31E−06 | 4.80E−04 | |
| hsa04120 | Ubiquitin mediated proteolysis | 2.33E−06 | 4.84E−04 | |
| hsa05210 | Colorectal cancer | 2.51E−06 | 5.22E−04 | |
| hsa04520 | Adherens junction | 2.82E−06 | 5.87E−04 |
| plasma DBP (μg/mL) | GAgP group (n = 59) | Control group (n = 58) | ||
| r | P value | r | P value | |
| Mean BI | 0.1588 | 0.251 | 0.048 | 0.768 |
| Mean PD | −0.1347 | 0.327 | −0.190 | 0.216 |
| Mean AL | −0.164 | 0.230 | None | — |
| Severe sites % | −0.167 | 0.233 | None | — |
| NCC material | After 48 h | After 336 h | After 336 h + freezing and thawing |
| Untreated | − | − | + |
| 10 kGy | + | + | + |
| 20 kGy | +/− 1 | + | + |
| 30 kGy | − | +/− 1 | + |
| 40 kGy | − | +/− 1 | + |
| 50 kGy | − | − | + |
| 60 kGy | − | − | − |
| Group | Mean calluses width, mm ± SD | Mean calluses length, mm ± SD | Regeneration zones ± SD | Embryogenesis appearance, % |
| Control | 4.18 ± 1.36 | 6.22 ± 0.67 | 1.24 ± 0.48 | 20 |
| AgNPs | 5.37 ± 3.47 | 7.00 ± 2.54 | 2.01 ± 0.98 | 34 |
| AuNPs | 6.39 ± 2.82 | 6.55 ± 2.36 | 3.29 ± 1.07 | 49 |
| Surgery | Ratio between post-discharge SSIs and in-hospital SSIs |
| Vascular surgery | 0 |
| Breast surgery | 3,4 |
| Cesarean section | 2,5 |
| Cholecistectomy | 1,2 |
| Gastric surgery | 0,4 |
| Appendectomy | 0,2 |
| Colon surgery | 0,1 |
| Hernia repair | 1,4 |
| Abdominal hysterectomy | 0,6 |
| Vaginal hysterectomy | 1 |
| Outcome Measures | Importance | Validity | Scientific soundness | Usability | Feasibility | Ranking |
| CGI-SCH | HIGH | HIGH | MED | MED | HIGH | 1 |
| Degree of involvement in vocational rehabilitation | HIGH | HIGH | MED | MED | HIGH | |
| Brief Psychiatric Rating Scale | MED | HIGH | MED | MED | MED | |
| Degree of Independent Living | HIGH | HIGH | MED | LOW | MED | |
| PANSS | MED | MED | MED | MED | LOW | |
| Service user Satisfaction Survey Responses | HIGH | LOW | LOW | MED | MED | |
| Development of Metabolic Syndrome/Diabetes | HIGH | HIGH | MED | MED | MED | |
| GAF Score | MED | MED | MED | MED | MED | |
| Process Adherence Measures | ||||||
| Percentage of Service users on Multiple Antipsychotics (excluding clozapine) | MED | HIGH | MED | HIGH | MED | 1 |
| Percentage of service users who have metabolic monitoring at recommended intervals | HIGH | HIGH | HIGH | HIGH | LOW | 2 |
| Percentage of service users referred for supported employment/vocational services | HIGH | MED | HIGH | HIGH | HIGH | 3 |
| Percentage of service users referred to CBT for psychosis | HIGH | MED | HIGH | HIGH | HIGH | 4 |
| Percentage of service users on recommended dosages (within therapeutic range) of antipsychotic medication | MED | MED | MED | HIGH | LOW | |
| Percentage of service users with a summary of previous medication trials | MED | MED | MED | HIGH | MED | |
| Percentage of first-episode service users who have had a MRI brain | MED | LOW | LOW | HIGH | HIGH | |
| Percentage of service users that have an annual physical exam | MED | LOW | LOW | HIGH | HIGH |
| Ingenuity Canonical Pathwaya | C2b | C3 | C4 |
| Differential Regulation of Cytokine Production in Intestinal Epithelial Cells by IL-17A and IL-17F | 3.47E-08 | ||
| Communication between Innate and Adaptive Immune Cells | 6.17E-08 | ||
| TREM1 Signaling | 1.1E-07 | ||
| Differential Regulation of Cytokine Production in Macrophages and T Helper Cells by IL-17A and IL-17F | 2.09E-07 | ||
| Role of Cytokines in Mediating Communication between Immune Cells | 0.000331 | ||
| MSP-RON Signaling Pathway | 0.000331 | ||
| Dendritic Cell Maturation | 0.000427 | ||
| Acute Phase Response Signaling | 0.002399 | ||
| Crosstalk between Dendritic Cells and Natural Killer Cells | 0.002455 | ||
| IL-17A Signaling in Fibroblasts | 0.002754 | ||
| Chemokine Signaling | 0.012303 | ||
| Glucocorticoid Receptor Signaling | 0.016218 | ||
| NF-kB Signaling | 0.016982 | ||
| LXR/RXR Activation | 0.032359 | ||
| p38 MAPK Signaling | 0.033884 | ||
| IL-6 Signaling | 0.038019 | ||
| IL-12 Signaling and Production in Macrophages | 0.038905 | ||
| G-Protein Coupled Receptor Signaling | 0.006166 | ||
| Role of PI3K/AKT Signaling in the Pathogenesis of Influenza | 0.019055 | ||
| Crosstalk between Dendritic Cells and Natural Killer Cells | 0.039811 | ||
| Activation of IRF by Cytosolic Pattern Recognition Receptors | 1.58E-11 | ||
| Interferon Signaling | 1.23E-10 | ||
| Role of RIG1-like Receptors in Antiviral Innate Immunity | 2.24E-05 | ||
| Retinoic acid Mediated Apoptosis Signaling | 0.000148 | ||
| Role of PKR in Interferon Induction and Antiviral Response | 0.000832 | ||
| Role of JAK1, JAK2 and TYK2 in Interferon Signaling | 0.002884 | ||
| Role of MAPK Signaling in the Pathogenesis of Influenza | 0.032359 | ||
| IL-10 Signaling | 0.012303 | 0.00537 | |
| Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses | 3.31E-05 | 3.24E-08 | |
| Role of IL-17F in Allergic Inflammatory Airway Diseases | 0.000257 | 0.010965 | |
| Role of Hypercytokinemia/hyperchemokinemia in the Pathogenesis of Influenza | 0.000132 | 0.000891 | 0.006918 |
| Characteristic | Burkina Faso* | Senegal* | Niger* | Ghana* |
| Surveillance design | Prospective | Retrospective | Retrospective | Prospective |
| Geographic extent | Three districts | Dakar | Niamey | Northern area |
| Surveillance population | 880,000 | 950,000 | 550,000 | 140,000 |
| Rural/Urban | Both | Urban | Urban | Rural |
| Study years | 2002-2005 | 1970-1979 | 1981-1996 | 1998-2003 |
| Microbiological methods | Culture, antigen detection, PCR | Culture | Culture, antigen detection | Culture, antigen detection |
| Number of confirmed pneumococcal meningitis cases | 249 | 983 | 934 | 76 |
| Percent of cases occurring during dry/epidemic season months of Dec-Apr† | 75% | 49% | 63% | 69% |
| Two months with peak number of cases (percent of total)† | Jan-Feb (38%) | Feb-Mar (21%) | Feb-Mar (31%) | Dec-Jan (35%) |
| Relation of pneumococcal to meningococcal seasonal peak | Similar | 2 months in advance | 1 month in advance | 1 to 2 months in advance |
| 13-valent conjugate vaccine coverage of isolated serotypes | ||||
| Age <5 years | 67% | 78% (age<2 yrs) | No serotype data | 100% |
| Age 5+ years | 77% | 94% (age 2+ yrs) | No serotype data | 98% |
| Reference | 4,5 | 9 | 8 | 7 |
| Algal species | Protein | Carbohydrates | Lipids |
| Anabaena cylindrica[96] | 43–56 | 25–30 | 4–7 |
| Aphanizomenon flos-aquae[96] | 62 | 23 | 3 |
| Chlamydomonas reinhardtii[96] | 48 | 17 | 21 |
| Chlorella minutissima[21] | 9–24 | 14–42 | 31–57 |
| Auxenochlorella protothecoides[97] | 11–26 | 17–24 | 25–54 |
| Auxenochlorella protothecoides[21] | 36–38 | 41–52 | 11–23 |
| Chlorella pyrenoidosa[96] | 57 | 26 | 2 |
| Chlorella emersonii[21] | 28–32 | 11–41 | 29–63 |
| Chlorella sorokiniana[21] | 42–45 | 32–38 | 20–22 |
| Chlorella vulgaris[96] | 51–58 | 12–17 | 14–22 |
| Chlorella vulgaris[21] | 7–29 | 51–55 | 18–40 |
| Dunaliella salina[96] | 57 | 32 | 6 |
| Euglena gracilis[96] | 39–61 | 14–18 | 14–20 |
| Nannochloropsis sp.[98] | 23–59 | 5–17 | 9–62 |
| Porphyridium cruentum[96] | 28–39 | 40–57 | 9–14 |
| Scenedesmus obliquus[96] | 50–56 | 10–17 | 12–14 |
| Spirogyra sp.[96] | 6–20 | 33–64 | 11–21 |
| Arthrospira maxima[96] | 60–71 | 13–16 | 6–7 |
| Spirulina platensis[96] | 46–63 | 8–14 | 4–9 |
| Synechococcus sp.[96] | 63 | 15 | 11 |
| Factors | Post-progression survival | ||
| Hazard ratio | 95% CI | p-value | |
| Age (years) at the beginning of first-line treatment | 0.98 | 0.94–1.02 | 0.47 |
| Chemoradiotherapy (sequential/concurrent) | 2.25 | 0.66–7.04 | 0.18 |
| Best response at second-line treatment (NonPD/PD) | 0.22 | 0.10–0.47 | < 0.01 |
| Distant metastases at recurrence (yes/no) | 2.42 | 1.18–5.22 | 0.01 |
| Administration of platinum-based agents after first-line treatment (yes/no) | 0.92 | 0.41–1.98 | 0.83 |
| Number of regimens after first-line treatment | 0.75 | 0.56–0.98 | 0.04 |
| Route | N | (%) |
| Internet | 2511 | (42.0) |
| TV or Movie | 3185 | (53.2) |
| Retail Store | 2138 | (35.7) |
| Billboard | 810 | (13.6) |
| Vehicle | 483 | (8.1) |
| Event | 686 | (11.5) |
| Magazine or newspaper | 2062 | (34.9) |
| SLE patients | No lupus nephritis(α) | Lupus nephritis(β) | p-value |
| Gender (female: male) | 53:3 | 17:5 | 0.03* |
| mean± standard deviation (n = 56) | mean± standard deviation (n = 22) | ||
| Age (year) | 28.72±14.87 | 28.3±14.79 | 0.91 |
| Leukocytes (×1000/ml) | 5.73±2.92 | 7.53±3.57 | 0.03* |
| Hemoglobulin (mg/dL) | 12.04±1.56 | 11.60±2.46 | 0.45 |
| Neutrophil (%) | 62.49±11.95 | 73.07±12.68 | 0.002* |
| Lymphocyte (%) | 29.36±11.00 | 19.77±10.67 | 0.002* |
| Platelets (1000/μL) | 254.47±124.81 | 226.24±70.82 | 0.34 |
| Alanine aminotransferase (U/dL) | 16.88±12.84 | 25±0.21 | 0.21 |
| Erythrocyte Sediment Rate (mm/hr) | 28.84±29.15 | 27.07±23.66 | 0.84 |
| Albumin (mg/dL) | 4.25±0.42 | 3.27±0.89 | 0.01* |
| anti-dsDNA (U/dL) | 255.58±195.41 | 307.99±156.27 | 0.40 |
| C3 (mg/dL) | 85.69±25.70 | 75.95±23.61 | 0.16 |
| C4 (mg/dL) | 18.62±18.28 | 13.44±6.05 | 0.24 |
| Creatinine (mg/dL) | 0.63±0.12 | 1.35±1.26 | 0.03* |
| Urine protein/Creatinine | 168.58±149.48 | 1568.89±1468.85 | 0.003* |
| Species | Exon A | Exon B | Exon C | Exon D | Exon E | Exon F | Identity |
| Horse | 1480 | 86 | 206 | 133 | 134 | 130 | 100.0 |
| Cat | 1477 | 86 | 206 | 133 | 134 | 139 | 83.0 |
| Dog | 1477 | 86 | 206 | 133 | 134 | 139 | 81.1 |
| Cattle | 1474 | 86 | 206 | 130 | 131 | 145 | 79.2 |
| Elephant | 1510 | 86 | 206 | 133 | 137 | 187 | 75.1 |
| Human | 1480 | 86 | 206 | 133 | 134 | 187 | 81.9 |
| Chimpanzee | 1480 | 86 | 206 | 133 | 134 | 187 | 79.7 |
| Orangutan | 1480 | 86 | 206 | 133 | 134 | 187 | 81.2 |
| Rhesus | 1480 | 86 | 206 | 133 | 134 | 187 | 79.7 |
| Mouse | 1474 | 86 | 206 | 133 | 137 | 172 | 66.3 |
| Rat | 1489 | 86 | 206 | 133 | 131 | 172 | 65.5 |
| Guinea Pig | 1462 | 86 | 206 | 133 | 134 | 187 | 69.7 |
| Opossum | 1453 | 86 | 206 | 129 | 131 | 139 | 56.5 |
| Chicken | 1402 | 89 | 191 | 124 | 122 | 136 | 37.3 |
| Autism Spectrum Disorder M (SD) | Down Syndrome M (SD) | Typical development M (SD) | |
| Exploratory play | 0.29 (1.49) | -0.11 (0.66) | 0.17 (0.83) |
| (1) Unitary functional activity | 1.67 (2.09) | 0.49 (0.78) | 0.73 (0.86) |
| (2) Inappropriate combinatorial activity | -0.44 (0.30) | -0.38 (0.36) | -0.20 (0.62) |
| (3) Appropriate combinatorial activity | 0.25 (1.3) | -0.15 (0.68) | 0.36 (0.82) |
| (4) Transitional play | -0.31 (0.39) | -0.42 (0.28) | -0.19 (0.61) |
| Symbolic play | -0.18 (0.79) | -0.12 (0.68) | -0.05 (0.69) |
| (5) Self-directed pretense | 0.07 (0.85) | 0.02 (0.69) | 0.23 (0.80) |
| (6) Other-directed pretense | -0.12 (0.92) | -0.29 (0.34) | -0.12 (0.42) |
| (7) Sequential pretense | -0.11 (0.74) | 0.28 (0.96) | 0.22 (0.86) |
| (8) Substitution pretense | -0.55 (0.00) | -0.52 (0.11) | -0.54 (0.09) |
| Cohort 3 | Patients with ∆ reticulin and/or collagena (N = 7) | Patients with no ∆ collagen or reticulin (N = 51) | |
| Age, median (Q1, Q3), years | 47 (30, 60) | 44 (33, 61) | |
| ITP duration, median (Q1, Q3), years | 4.1 (1.2, 9.1) | 2.2 (1.2, 7.1) | |
| Prior splenectomy rate, n (%) | 2 (29) | 17 (33) | |
| Platelet responseb, median (Q1, Q3) | Time to first platelet response, weeks | 15 (7, 21)c | 3 (2, 8)d |
| Weeks with platelet response, % | 5 (0, 28) | 38 (28, 76) | |
| Exposuree, median (Q1, Q3) | Average weekly dose, μg/kg | 9 (7, 9) | 2 (1, 5) |
| Maximum weekly dose, μg/kg | 10 (9, 10) | 4 (3, 10) | |
| Cumulative dose, μg/kg | 1207 (204, 1358) | 345 (136, 610) |
| Pollen recipient (♀) | Pollen donor (♂) | Number of flowers | Number of fruits | Fruit set (%) | Mean number of seeds per fruit | Seed viability (%) | Mean number of viable seeds per fruita |
| B. crispa | B. crispa | 20 | 11 | 55 | 65.50 | 34 | 22.27 |
| B. officinalis | 24 | 14 | 58 | 8.00 | 68 | 5.44 | |
| Putative hybrid | 27 | 15 | 55 | 2.20 | 70 | 1.54 | |
| B. officinalis | B. crispa | 32 | 2 | 6 | 1.00 | 0 | 0.00 |
| B. officinalis | 23 | 10 | 43 | 65.00 | 91 | 59.15 | |
| Putative hybrid | 37 | 18 | 48 | 1.94 | 57 | 1.11 | |
| Putative hybrid | B. crispa | 31 | 19 | 61 | 2.79 | 0 | 0.00 |
| B. officinalis | 38 | 32 | 84 | 4.63 | 53 | 2.45 | |
| Putative hybrid | 45 | 7 | 15 | 0.43 | 0 | 0.00 |
| control | LBBB | |
| n | 100 | 33 |
| males, n (%) | 64 (64.0%) | 23 (69.7%) |
| age, years | 52.5 ± 16.9 | 69.7 ± 9.1 |
| QRS, ms | 82.4 ± 4.2 | 149.7 ± 15.5 |
| LVEF, % | 59.7 ± 2.1 | 34.6 ± 12.3 |
| heart rate, min-1 | 72.0 ± 10.8 | 69.3 ± 11.3 |
| cardiomyopathy | ||
| ischemic, n (%) | - | 17 (51.5%) |
| dilated, n (%) | - | 10 (30.3%) |
| hypertensive, n (%) | - | 2 (6.1%) |
| valvular, n (%) | - | 1 (3.0%) |
| Stroke/TIA Patients | Control Subjects | Significance | |
| Age, yr | 53.9±9.3 | 53.8±9.0 | ns. |
| Males, n (%) | 21 (52.5) | 21 (52.5) | ns. |
| Body mass index, kg/m2 | 28.7±4.8 | 25.3±4.1 | 0.002 |
| Body surface area, m2 | 2.0±0.2 | 1.8±0.2 | 0.033 |
| Caucasian race, n (%) | 40 (100.0) | 40 (100.0) | ns. |
| Hypertension, n (%) | 16 (40.0) | 0 (0.0) | <0.001 |
| Hyperlipidemia, n (%) | 14 (35.0) | 16 (40.0) | ns. |
| Diabetes, n (%) | 0 (0.0) | 0 (0.0) | ns. |
| Left ventricle ejection fraction, % | 66.0±10.2 | 63.7±7.7 | ns. |
| Left ventricle dysfunction, n (%) | 0 (0.0) | 0 (0.0) | ns. |
| Smokers, n (%) | 0 (0.0) | 1 (2.5) | ns. |
| Characteristics | n = 10 |
| Age | 63.8±12.0 |
| Body Mass Index | 27.1±3.7 |
| Parity | 2 (1-3) |
| Health problems | 6 |
| SUI | 2 |
| Previous hysterectomy | 5 |
| Previous POP surgery | 10 |
| POP | 10 |
| Point C/D POPQ median (range) | 3 (2-4) |
| Central compartment prolapse stage ≥ 3 | 10 |
| Cystocele stage ≥ 2 | 9 |
| Rectocele stage ≥ 2 | 7 |
| Enterocele stage ≥ 2 | 0 |
| Concomitant procedure | 6 |
| Anterior colporrhaphy | 4 |
| Posterior colporrhaphy | 2 |
| MUS | 0 |
| Solvents | Time | Means | ||
| 30 min | 60 min | 90 min | ||
| FRAP (theaflavin)μmol Fe2+/g | ||||
| Ethanol | 811.67 ± 10.21 | 958.33 ± 8.48 | 799.33 ± 12.31 | 856.44 ± 9.06a |
| Methanol | 698.67 ± 10.36 | 704.00 ± 8.65 | 658.67 ± 11.32 | 687.11 ± 12.03b |
| Water | 489.67 ± 10.56 | 612.25 ± 8.23 | 586.67 ± 13.01 | 562.86 ± 11.01c |
| 666.67 ± 10.54c | 758.19 ± 8.21a | 681.55 ± 9.06b | ||
| FRAP (thearubigins)μmol Fe2+/g | ||||
| Ethanol | 690.02 ± 1.23 | 845.01 ± 7.45 | 701.33 ± 12.23 | 745.44 ± 8.21a |
| Methanol | 538.67 ± 1.56 | 665.00 ± 7.49 | 591.67 ± 11.32 | 598.44 ± 11.20b |
| Water | 429.67 ± 10.23 | 537.33 ± 7.52 | 503.67 ± 10.25 | 490.22 ± 12.20c |
| 552.70 ± 10.21c | 682.40 ± 12.23a | 598.89 ± 9.12b | ||
| Glucose diffusion (theaflavin)% | ||||
| Ethanol | 90.37 ± 3.60 | 95.99 ± 6.34 | 90.88 ± 4.13 | 91.74 ± 4.16 |
| Methanol | 89.87 ± 4.21 | 93.69 ± 4.21 | 89.22 ± 6.12 | 89.96 ± 2.31 |
| Water | 87.30 ± 2.62 | 90.36 ± 5.32 | 88.40 ± 3.21 | 87.02 ± 3.12 |
| 89.18 ± 5.20 | 93.34 ± 3.12 | 89.50 ± 4.13 | ||
| Glucose diffusion (thearubigins)% | ||||
| Ethanol | 85.27 ± 2.3 | 89.99 ± 2.9 | 87.88 ± 4.2 | 87.71 ± 6.12 |
| Methanol | 83.87 ± 1.3 | 87.69 ± 3.2 | 83.22 ± 3.6 | 84.92 ± 6.42 |
| Water | 81.30 ± 3.6 | 85.36 ± 2.9 | 82.40 ± 4.2 | 83.02 ± 7.12 |
| 83.48 ± 4.32 | 87.68 ± 4.13 | 84.50 ± 6.34 |
| Infection-associated EHPM (+) | Infection-associated EHPM (−) | Odds ratio (95% CI) | P value | |
| HCV Ab (+) | 27 | 240 | 3.15 (1.19–8.37) | 0.0194 |
| HCV Ab (−) | 5 | 140 | ||
| HBs Ag (+) | 4 | 61 | 11.31 (2.03–63.11) | 0.0067 |
| HBs Ag (−) | 2 | 345 | ||
| No viral infection | 4 | 67 | 20.30 (2.23–184.46) | 0.0036 |
| Any viral infection | 1 | 340 |
| miRNAs | Known functional effect | Targets | References |
| mir-15a, miR-15b, miR-16, and miR-195 | Pancreas development, beta-cells fate and regeneration | Neurog3 | [33] |
| miR-375 | Beta- and alpha-cells expansion | [42] | |
| miR-7a | Beta-cell proliferation | mTOR pathway components | [44, 45, 48] |
| miR-124a | Pancreas development | Foxa2 | [33] |
| Patient/source | Our patient | Patients TB/LB from Joyce et al. [13] | Patient DP from Monk et al. [17] | Patients HC/AC from Monk et al. [16] | Patient from Eggermann et al. [6] (decipher 285981) | Decipher 289205 | Decipher 276327 | ISCA nssv579045 |
| Genomic location (hg19) | chr7:50654827-5122921 | chr7:42029531–51138357(D7S691-D7S242) | chr7:40742989–50861159 (D7S1769-GRB10) | chr7:41392336–54000000 (RP5-953B5-7p11.2) | chr7:47034222–52175639 | chr7:50713413-50982532 | chr7:43566637-51282735 | chr7:33367924-61831899 |
| Duplication size | 574Kb | ~10 cM | ~10 cM | >10 cM | 5.1 Mb | 270Kb | 7.72 Mb | 28.5 Mb |
| Inheritance/orign | de novo/maternal | LB: maternal | de novo/maternal | AC: maternal | de novo/paternal | inherited/paternal | de novo/unknown | unknown |
| TB: paternal | HC: unknown | |||||||
| Phenotype | SRS | SRS | SRS | SRS-like | overgrowth, DD, microcephaly, seizure | hypotonia, GDD | muscular hypotonia | FTT, GDD, large eyes, microcephaly, short stature, triangular face |
| Detection method | array | karyotype/FISH | karyotype/FISH | karyotype/FISH | array | array | array | array |
| Genes involved (Refseq) | GRB10 and part of COBL | >50 genes | >50 genes | >50 genes | >20 genes | Part of GRB10 | >40 genes | >180 genes |
| Characteristics | Total | Men | Women | P |
| Cases, n (%) | 1587 | 1272 (29.5) | 315 (15.1) | – |
| Age, year, mean (SD) | 64.41 (11.40) | 64.17 (11.42) | 65.40 (11.28) | 0.087 |
| OCSP, n (%) | ||||
| PACI | 895 (56.4) | 728 (57.2) | 167 (53.0) | 0.177 |
| TACI | 83 (5.2) | 62 (4.9) | 21 (6.7) | 0.201 |
| LACI | 104 (6.6) | 81 (6.4) | 23 (7.3) | 0.549 |
| POCI | 505 (31.8) | 401 (31.5) | 104 (33.0) | 0.006 |
| Stroke severity | ||||
| Mild | 1093 (68.9) | 889 (69.9) | 204 (64.8) | <0.001 |
| Moderate | 367 (23.1) | 289 (22.7) | 78 (24.8) | 0.442 |
| Severe | 127 (8.0) | 94 (7.4) | 33 (10.5) | 0.071 |
| Neurological functiona | ||||
| NIHSS | 5 (7) | 5 (7) | 6 (7) | 0.006 |
| BI | 60 (50) | 65 (50) | 55 (50) | 0.004 |
| mRS | 3 (2) | 3 (2) | 3 (2) | 0.007 |
| Risk factors, n (%) | ||||
| Hypertension | 1162 (73.2) | 908 (71.4) | 254 (80.6) | 0.001 |
| Diabetes | 472 (29.7) | 366 (28.8) | 106 (33.7) | 0.090 |
| Atrial fibrillation | 71 (4.5) | 52 (4.1) | 19 (6.0) | 0.135 |
| Artery stenosis | 416 (26.2) | 341 (26.8) | 75 (23.8) | 0.279 |
| Obesity | 157 (9.9) | 100 (7.9) | 57 (18.1) | <0.001 |
| Current smoking | 669 (42.2) | 628 (49.4) | 41 (13.0) | <0.001 |
| Alcohol drinking | 339 (21.4) | 335 (26.3) | 4 (1.3) | <0.001 |
| Group | Treatment (mg/kg) once daily orally | Study 1 | Study 2 | |
| A | None (placebo, control) | Cohort 1 | 4 f | 2 m & 2 f |
| Cohort 2 | 4 m | 2 m & 2 f | ||
| B | Benazepril (0.5–1.0) | Cohort 1 | 4 f | 2 m & 2 f |
| Cohort 2 | 4 m | 2 m & 2 f | ||
| C | Robenacoxib (1.0–2.4) | Cohort 1 | 4 f | 2 m & 2 f |
| Cohort 2 | 4 m | 2 m & 2 f | ||
| D | Benazepril (0.5–1.0) + Robenacoxib (1.0–2.4) | Cohort 1 | 4 f | 2 m & 2 f |
| Cohort 2 | 4 m | 2 m & 2 f |
| Variables | Weekly work hours | Total | p-value | ||
| Short* | Reference† | Long‡ | |||
| Total | 100(4.9) | 1209(59.2) | 735(36.0) | 2044 | |
| Age (years) | |||||
| 25-34 | 7(7.0) | 353(29.2) | 220(29.9) | 580 | <.0001 |
| 35-44 | 24(24.0) | 414(34.2) | 259(35.2) | 697 | |
| 45-54 | 39(39.0) | 305(25.2) | 173(23.5) | 517 | |
| 55-64 | 30(30.0) | 137(11.3) | 83(11.3) | 250 | |
| Marital status | |||||
| Married | 68(68.0) | 934(77.3) | 545(74.2) | 1547 | 0.056 |
| Unmarried | 32(32.0) | 275(22.8) | 190(25.9) | 497 | |
| Education | |||||
| ≤Junior high school | 46(46.0) | 122(10.2) | 110(15.0) | 278 | <.0001 |
| High school | 27(27.0) | 372(30.8) | 305(41.5) | 704 | |
| ≥College | 27(27.0) | 715(59.1) | 320(43.5) | 1062 | |
| Occupation | |||||
| Non-manual | 22(22.0) | 666(55.1) | 248(33.7) | 936 | <.0001 |
| Manual | 78(78.0) | 543(44.9) | 487(66.3) | 1108 | |
| Employment type | |||||
| Precarious | 84(84.0) | 254(21.0) | 130(17.7) | 468 | <.0001 |
| Non-precarious | 16(16.0) | 955(79.0) | 605(82.3) | 1576 | |
| Tenure (years) (Mean±S.D) | 7.1±8.6 | 8.7±8.1 | 6.4±6.4 | <.0001 | |
| Shift work | |||||
| Yes | 1(1.0) | 108(8.9) | 151(20.5) | 260 | <.0001 |
| No | 99(99.0) | 1101(91.1) | 584(79.5) | 1784 | |
| Job satisfaction | |||||
| Low | 35(35.0) | 102(8.4) | 102(13.9) | 239 | <.0001 |
| Average | 44(44.0) | 550(45.5) | 376(51.2) | 970 | |
| High | 21(21.0) | 557(46.1) | 257(35.0) | 835 | |
| Smoking in 2007 | |||||
| Yes | 65(65.0) | 629(52.0) | 441(60.0) | 1135 | 0.001 |
| No | 35(35.0) | 580(48.0) | 294(40.0) | 909 | |
| Smoking in 2008 | |||||
| Yes | 66(66.0) | 670(55.4) | 451(61.4) | 1187 | 0.019 |
| No | 34(34.0) | 539(44.6) | 284(38.6) | 857 | |
| Alcohol drinking | |||||
| Yes | 87(87.0) | 1023(84.6) | 627(85.3) | 1737 | 0.776 |
| No | 13(13.0) | 186(15.4) | 108(14.7) | 307 |
| %T0 | %24-hour | Fold change | P value | |
| a.) The most abundant members at time zero | ||||
| Oxalobacteraceae | 38.63 | 0.96 | −40.21 | 0.0002 |
| Pseudomonadaceae | 10.62 | 1.36 | −7.79 | 0.0158 |
| Flavobacteriaceae | 7.33 | 0.22 | −33.12 | 0.0002 |
| Comamonadaceae | 5.03 | 2.43 | −2.07 | 0.1982 |
| Xanthomonadaceae | 4.11 | 0.87 | −4.72 | 0.0154 |
| Rhizobiaceae | 3.57 | 0.13 | −27.76 | 0.0002 |
| Methylobacteriaceae | 3.50 | 0.03 | −140.14 | 0.0002 |
| Micrococcaceae | 2.52 | 0.01 | −176.45 | 0.0002 |
| Sphingomonadaceae | 2.28 | 0.03 | −79.78 | 0.0002 |
| Weeksellaceae | 2.20 | 0.07 | −33.30 | 0.0002 |
| Rhodobacteraceae | 2.11 | 0.03 | −73.74 | 0.0002 |
| Microbacteriaceae | 2.06 | 0.02 | −104.63 | 0.0002 |
| [Exiguobacteraceae] | 1.84 | 6.20 | 3.37 | 0.0002 |
| Caulobacteraceae | 1.58 | 0.03 | −55.16 | 0.0002 |
| Rickettsiales | 1.32 | 0.01 | −92.45 | 0.0002 |
| Sphingobacteriaceae | 1.29 | 0.08 | −17.20 | 0.0002 |
| Enterobacteriaceae | 1.14 | 3.59 | 3.13 | 0.0288 |
| Aurantimonadaceae | 1.01 | 0.01 | −93.98 | 0.0002 |
| Paenibacillaceae | 0.99 | 1.51 | 1.52 | 0.1238 |
| Rhizobiales;Other | 0.62 | 0.04 | −14.56 | 0.0002 |
| Bacillaceae | 0.61 | 3.08 | 5.01 | 0.0002 |
| Cytophagaceae | 0.60 | 0.01 | −111.36 | 0.0002 |
| b.) The most abundant members after a 24-hour mBPW enrichment | ||||
| Peptostreptococcaceae | 0.01 | 40.79 | 2957.09 | 0.0002 |
| Planococcaceae | 0.31 | 19.49 | 62.11 | 0.0002 |
| Clostridiaceae | 0.03 | 13.54 | 490.93 | 0.0002 |
| [Exiguobacteraceae] | 1.84 | 6.20 | 3.37 | 0.0002 |
| Enterobacteriaceae | 1.14 | 3.59 | 3.13 | 0.0288 |
| Bacillaceae | 0.61 | 3.08 | 5.01 | 0.0002 |
| Comamonadaceae | 5.03 | 2.43 | −2.07 | 0.1982 |
| Lachnospiraceae | 0.00 | 1.82 | 527.18 | 0.0002 |
| Paenibacillaceae | 0.99 | 1.51 | 1.52 | 0.1238 |
| Clostridiales;Other | 0.00 | 1.50 | ∞ | 0.0002 |
| Pseudomonadaceae | 10.62 | 1.36 | −7.79 | 0.0158 |
| Oxalobacteraceae | 38.63 | 0.96 | −40.21 | 0.0002 |
| Xanthomonadaceae | 4.11 | 0.87 | −4.72 | 0.0154 |
| Aeromonadaceae | 0.00 | 0.57 | 164.68 | 0.0002 |
| Extract of questionnaire | |||||
| Frequency of muscle pain that was reported in clinical trials on statins: | |||||
| Statins | Placebo | p-value | |||
| Cochrane 2013 N = 37,938, primary prevention | 9.5 % | 9.2 % | 0.40 | ||
| Finegold 2014 N = 46,262, primary prevention | 7.9 % | 7.6 % | 0.407 | ||
| Finegold 2014 N = 37,618, secondary prevention | 4.8 % | 4.6 % | 0.558 | ||
| Question: If 100 patients take this statin – in how many of them does the intake of this statin cause muscle pain?a | |||||
| Responses (No) | 0 | 1 | >1 | >10 | No response |
| Format multiple choice | |||||
| Group 6 (n = 87) Pharmacy group | 10 (12 %) | 12 (14 %) | 48 (55 %) | 14 (16 %) | 3 (3 %) |
| Themes | Subthemes | Representative statements |
| Cultural and linguistic barriers | Major barriers in terms of language and culture result in older adults' dependency on others when it comes to medical visits | “The biggest problem is the language barrier. We feel helpless since we do not speak English, and we cannot resolve matters without English. Even if you understand English you would not comprehend their technical terms.” “The people I contact are few. I don't want to bother my children.” |
| Immediate family support may not always be available to assist older adults with medical visits | “If you need your son to bring you to the doctor's clinic, he would have no time because he has to work. If you cannot find someone else, then you just have to wait until he comes home.” “To ride the bus you need to know how to get there... you need to draw it on a piece of paper with the directions. I was to take bus no. 4, and it would transfer three times. But still I did not make it (to the hospital). I was lucky to return home from the final bus stop.” | |
| Affordability of services | The health care system is poorly understood. The utilization and degree of satisfaction differ depending on older adults' insurance coverage and length of residence | “As new comers, we have nothing. My mother-in-law is old, and, moreover, I am old too, I am sixty eight years old. As we age, the most critical thing is medical treatment and benefits. Getting your white card, it would not be a big deal even if you are sick. We depend on the medical supply by mail. It is tough to see a doctor. Besides it is far away. And not knowing English, it is difficult to visit a doctor. The medical expenses are high.” “It's like we have to pay for everything. We have nothing and yet we need to pay for the medication expenses.” |
| For those who are fully insured, they feel fortunate compared to that of their counterparts in China | “Buying insurance is now only getting started in China. Previously, I bought insurance. Now I apply for low-income status. So I do not have to buy insurance and it is so much better. America is definitely taking that route. You have no money. The government helps out with a low income status. If you apply, it will not cost you any money.” “I think the most pleasant thing for me in the US is what happened to my two legs. My legs were broken twice in the US if that happened in China, my children and I would not be able to afford the surgeries. Here in the US, I do not have to pay a single cent. They even provided me the walking equipment and the toilet pans. I think this is the best thing happened to me. I feel very happy and thankful for that.” | |
| Availability of services | The long wait and inflexibility of health care services often frustrated participants | “I think the waiting period to see a doctor is too long. It takes several hours and you are not seeing your doctor right away. Definitely it is too long.” “I think there is something that America is not comparable to China. That is the appointment system. They are not letting you see the doctor today, unless you are going to the emergency room! They will not let you see the doctor right away; it would take a week. Then you need to go to the emergency room. I think that situation is not good.” |
| The expectation toward medical visits is often compared to older participants' experience in China where quick improvement is anticipated | “In Shanghai, if I do not feel good, I can go to see the doctor right away. Over here, this appointment thing, you would need two weeks to see your family physician. He has his vacations and you need to wait two weeks. But hey, I am sick... I have this illness and I need to see the doc right away. I think over here, you need to go to the hospital, the UIC Hospital. It is because of the insurance that requires you to visit the hospital. Today you can visit this hospital and tomorrow you can visit that hospital. And that is OK.” “Like suffering from nerve pain... if you are in China, you just visit the clinic to get a pain killer shot. Over here the waiting period is not fast. I went there and took several hours. Going to the hospital for minor ailments is not convenient.”. |
| Performance parameter | Melody type | |
| Simple | Complex | |
| 8th note onset | 0.57 | 0.49 |
| 16th note onset | 0.38 | 0.54 |
| Micro-timing onset | 0.14 | −0.12 |
| 8th note offset | 0.48 | 0.09 |
| 16th note offset | 0.23 | 0.26 |
| Micro-timing offset | −0.09 | −0.02 |
| 8th note duration | −0.37 | −0.35 |
| 16th note duration | −0.17 | −0.23 |
| Micro-timing duration | −0.05 | −0.08 |
| Density | 0.51 | 0.38 |
| R2 (variance explained) | 0.562 | 0.532 |
| Construct name | Primer combination |
| NbPDS (2046 bp) | NbPDSfor1 × NbPDSrev1 |
| NbPDS (1661 bp) | NbPDSfor2 × NbPDSrev1 |
| NbPDS (1304 bp) | NbPDSfor3 × NbPDSrev1 |
| NbPDS (959 bp) | NbPDSfor4 × NbPDSrev1 |
| NbPDS (610 bp) | NbPDSfor5 × NbPDSrev1 |
| NbPDS (257 bp) | NbPDSfor6 × NbPDSrev1 |
| NbPDS (345 bp) | NbPDSfor3 × NbPDSrev2 |
| NbPDS (192 bp) | NbPDSfor7 × NbPDSrev3 |
| NbPDS (103 bp) | NbPDSfor7 × NbPDSrev4 |
| NbPDS (54 bp) | NbPDSfor8 × NbPDSrev5 |
| NbPDS (385 bp) | NbPDSfor1 × NbPDSrev6 |
| NbPDS (357 bp) | NbPDSfor2 × NbPDSrev7 |
| NbPDS (349 bp) | NbPDSfor4 × NbPDSrev8 |
| NbPDS (353 bp) | NbPDSfor5 × NbPDSrev9 |
| NbPDS (2046 bp + polyA) | NbPDSfor1 × NbPDSrev6 |
| NbPDS (1661 bp + polyA) | NbPDSfor2 × NbPDSrev6 |
| NbPDS (1304 bp + polyA) | NbPDSfor3 × NbPDSrev6 |
| NbPDS (959 bp + polyA) | NbPDSfor4 × NbPDSrev6 |
| NbPDS (610 bp + polyA) | NbPDSfor5 × NbPDSrev6 |
| NbPDS (257 bp + polyA) | NbPDSfor6 × NbPDSrev6 |
| NbPDS (345 bp + polyA) | NbPDSfor7 × NbPDSrev7 |
| NbPDS (345 bp + polyG) | NbPDSfor7 × NbPDSrev8 |
| Set1 | Set2 | All ARs | |
| Set1 | 1 | 0.80 ± 0.35* | 0.89 ± 0.26 |
| Set2 | 0.83 ± 0.31 | 1 | 0.92 ± 0.19 |
| All ARs | 0.81 ± 0.35 | 0.80 ± 0.37 | 1 |
| CAT item | Comorbidity | p value | Cumulative R2 |
| Cough | |||
| None | |||
| Phlegm | |||
| None | |||
| Chest tightness | |||
| GERD (FSSG ≥ 8) | <0.001 | 0.0901 | |
| Depression (HAD-D ≥ 11) | 0.0033 | 0.123 | |
| Breathlessness | |||
| GERD (FSSG ≥ 8) | <0.001 | 0.0705 | |
| Osteoporosis | 0.0355 | 0.0876 | |
| Activity limitation | |||
| GERD (FSSG ≥ 8) | <0.001 | 0.0926 | |
| Depression (HAD-D ≥ 11) | <0.001 | 0.1452 | |
| Arrhythmia | 0.0026 | 0.1773 | |
| Osteoporosis | 0.0222 | 0.1954 | |
| Confidence to leave home | |||
| GERD (FSSG ≥ 8) | <0.001 | 0.0631 | |
| Depression (HAD-D ≥ 11) | <0.001 | 0.107 | |
| Osteoporosis | <0.001 | 0.1337 | |
| Hypertension | 0.0109 | 0.1571 | |
| Arrhythmia | 0.0445 | 0.1714 | |
| Sleep | |||
| Depression (HAD-D ≥ 11) | <0.001 | 0.0807 | |
| GERD (FSSG ≥ 8) | 0.0033 | 0.1134 | |
| Anxiety (HAD-A ≥ 11) | 0.01 | 0.1378 | |
| Arrhythmia | 0.0404 | 0.153 | |
| Energy | |||
| GERD (FSSG ≥ 8) | <0.001 | 0.1191 | |
| Depression (HAD-D ≥ 11) | <0.001 | 0.1972 | |
| Arrhythmia | <0.001 | 0.2487 | |
| Anxiety (HAD-A ≥ 11) | 0.0333 | 0.263 |
| Estimated value of K | ||||||
| ParameterV | True value ofK | σ2= 0 | σ2 = 0.1 | σ2= 0.5 | σ2 = 1 | σ2 = 10 |
| V = 1 | K = 1 | 0.895860924 | 1.198924271 | 2.060871616 | 2.392641064 | 2.2417669 |
| V = 1 | K = 10 | 9.942624719 | 9.417099524 | 5.18899955 | 3.041348517 | 2.3984733 |
| V = 1 | K = 50 | 49.84538377 | 50.3653591 | 49.79822957 | 48.21724047 | 17.612567 |
| V = 1 | K = 100 | 99.57735594 | 100.5475019 | 98.86122817 | 95.19722428 | 35.651171 |
| V = 1 | K = 500 | 499.7813772 | 498.9833568 | 495.3510638 | 501.8771493 | 450.50892 |
| V = 1 | K = 1000 | 999.2728579 | 997.8776983 | 995.7044492 | 988.870943 | 891.65597 |
| V = 10 | K = 1 | 0.970450637 | 1.006078611 | 1.094535769 | 1.282321201 | 2.1026316 |
| V = 10 | K = 10 | 9.975237184 | 9.997279446 | 9.847326837 | 9.531280999 | 5.3013845 |
| V = 10 | K = 50 | 50.05571987 | 49.87267536 | 49.91859144 | 50.0966008 | 49.055078 |
| V = 10 | K = 100 | 99.87386748 | 99.92057687 | 100.6109818 | 99.56079265 | 97.374093 |
| V = 10 | K = 500 | 500.0809047 | 499.7714225 | 499.802065 | 500.2063382 | 497.87452 |
| V = 10 | K = 1000 | 999.5597507 | 999.5670495 | 1000.211577 | 1001.028307 | 996.15873 |
| ELBW | NBW | |
| Sex | 54 males; 67 females | 56 males; 72 females |
| Birth weight in grams | 841.91 (123.91)* | 3380.10 (492.63)* |
| Mother's highest level of education | 5.61 (1.91) | 6.02 (1.98) |
| Young adult's highest level of education | 4.42 (1.33) | 4.70 (1.37) |
| Full scale WISC-R | 92.41 (14.66)* | 103.78 (12.44)* |
| Verbal IQ WISC-R | 91.74 (14.23)* | 101.30 (12.85)* |
| Performance IQ WISC-R | 94.83 (16.05)* | 106.02 (12.90)* |
| General information WISC-R | 9.16 (3.07)* | 10.11 (2.80)* |
| Similarities WISC-R | 9.16 (3.38)* | 10.66 (3.13)* |
| Arithmetic WISC-R | 8.12 (2.68)* | 10.53 (2.66)* |
| Vocabulary WISC-R | 8.45 (3.08)* | 10.01 (2.94)* |
| Comprehension WISC-R | 8.63 (2.68)* | 10.08 (2.42)* |
| Picture completion WISC-R | 9.12 (2.68)* | 11.40 (2.26)* |
| Picture arrangement WISC-R | 9.74 (4.12)* | 11.28 (3.00)* |
| Block design WISC-R | 9.21 (3.11)* | 11.13 (2.96)* |
| Object assembly WISC-R | 9.41 (3.06)* | 10.90 (2.76)* |
| Coding WISC-R | 8.71 (3.38)* | 9.83 (2.65)* |
| RCPM | 40.05 (26.53)* | 55.11 (29.12)* |
| ADHD rating scale inattentive score | 3.70 (2.97) | 3.06 (2.88) |
| ADHD rating scale hyperactivity/impulsivity score | 4.34 (2.97) | 4.38 (2.91) |
| ADHD rating scale total score | 8.04 (5.41) | 7.45 (5.10) |
| YASR attention problems | 2.83 (2.35) | 2.45 (2.05) |
| Variables | N (%) |
| Experienced an occupational injury | 13 (32.5) |
| Knows other workers who have been injured | 21 (52.5) |
| Major types of injury (N = 13) | |
| Broken bone | 3 (23.1) |
| Inhalation | 3 (23.1) |
| Accidental injection/needle stab | 3 (23.1) |
| Muscle sprain or strain | 3 (23.1) |
| Part of body injured | |
| Leg, knee, or hip | 4 (30.8) |
| Hand or wrist | 3 (23.1) |
| Eyes | 2 (15.4) |
| Head or neck | 1 (7.7) |
| Back | 1 (7.7) |
| Arms or shoulders | 1 (7.7) |
| Fingers | 1 (7.7) |
| Cause of injury | |
| Animal | 10 (76.9) |
| Machine | 2 (15.4) |
| Other | 1 (7.7) |
| Lost time due to injury | |
| No time lost | 8 (61.5) |
| 2-6 days lost | 1 (7.7) |
| More than 30 days lost | 4 (30.8) |
| Have health problems due to working with hogs | 11 (28.2) |
| Type of occupational health problems | |
| Allergies | 3 (7.5) |
| Asthma | 2 (5.0) |
| Bronchitis | 2 (5.0) |
| Coughing | 7 (17.5) |
| Eyes burning | 10 (25.0) |
| Headaches | 7 (17.5) |
| Hearing problems | 2 (5.0) |
| Infections | 1 (2.5) |
| Muscular pain | 9 (22.5) |
| Nausea | 4 (10.0) |
| Nasal congestion | 4 (10.0) |
| Sneezing | 6 (15.0) |
| Skin disorders | 1 (2.5) |
| Pain in throat | 3 (7.5) |
| Disease | Trimester | Aminotransferases | Bilirubin | INR | Treatment | Prognosis* |
| Hyperemesis gravidarum | First | Up to 2-3 times upper limit of normal | <4 | Always normal | Supportive | Excellent |
| Intrahepatic cholestasis of pregnancy | Second/third | Elevated sometimes rarely >1000 | Elevated but <6 | Typically normal | Ursodeoxycholic acid | Good |
| AFLP | Third | Elevated usually <1000 | Elevated | Usually elevated | Delivery | Guarded |
| HELLP | Third | Elevated, variable, 5-20 times upper limit of normal | >1.2 | Sometimes elevated | IV magnesium, BP control, delivery | Guarded |
| Acetaminophen | Any | >50 times upper limit of normal | Elevated usually <10 | Usually elevated | NAC | Good if NAC administered promptly |
| Ischemia | Any | >50 times upper limit of normal | Elevated usually <4 | Usually elevated (<3) | Supportive | Variable, depends on underlying disease |
| Viral | Any | >25 times upper limit of normal | Elevated | Variable | Supportive | Variable |
| Drug-induced | Any | >25 times upper limit of normal | Elevated | Variable | Supportive | Variable |
| Autoimmune | Any | 5-10 times upper limit of normal | Normal | Variable | Corticosteroids, azathioprine | Variable |
| Scenario | Skin Area | Months | Time |
| S1 | 35% (face, hands, forearms, lower legs) | March–September | Constant |
| S2 | 35% (face, hands, forearms, lower legs) | June–August | Constant |
| 10% (face and hands) | March–May, September | ||
| S3 | 10% (face and hands) | March–September | Constant |
| S4 | 35% (face, hands, forearms, lower legs) | June–August | Varies with latitude (equivalent to 1 SED) * |
| Affective words | Answer | Categories of associated words | ||||
| Synonyms | Antonym | Life event | Relative behavior | Others | ||
| Happiness | Number | 36 | 2 | 42 | 7 | 3 |
| Frequency (%) | 40.45 | 2.24 | 47.19 | 7.87 | 3.37 | |
| Sadness | Number | 21 | 0 | 47 | 17 | 4 |
| Frequency (%) | 23.60 | 0 | 52.81 | 19.10 | 4.49 | |
| Anger | Number | 25 | 1 | 45 | 10 | 8 |
| Frequency (%) | 28.09 | 1.12 | 50.56 | 11.24 | 8.99 | |
| Fear | Number | 29 | 0 | 52 | 6 | 1 |
| Frequency (%) | 32.58 | 0 | 58.43 | 6.74 | 1.12 |
| country | summarized area characteristics | number of species | references |
| Africa | continent-wide estimate (insects only) | 600 | DeFoliart (1992) |
| Africa | sub-Saharan Africa (insects only) | 250 | van Huis (2003) |
| Africa | Central and West Africa (plants only) | 1500 | Chege (1994) |
| Botswana | Tyua grow crops and use wild plants, animals, birds, fish and insects | 171 | Hitchcock (1999) |
| Congo | Mbuti Pygmies of forest: cultivators of cassava and plantain plus users of 230 animal and 100 plant species | 330 | Ishikawa (1999) |
| Ethiopia | subsistence agriculture, animal husbandry, semi-arid to humid | 44 | Fentahun & Hager (2009) |
| Ethiopia | country-wide estimate | 203 | Asfaw & Tadesse (2001) |
| Ethiopia | country-wide estimate | 300 | Asfaw (2009) |
| Ethiopia | agricultural, arid, open woodland (50% of plants in region edible) | 25 | Becker (1983) |
| Ethiopia | humid to semi-arid; forest to savannah, three ethnic groups in south Ethiopia | 66 | Balemie & Kebebew (2006) |
| Kenya | country-wide estimate for agricultural communities (plants only) | 800 | Maundu (1996) |
| Kenya | Turkana agro-pastoralists and rural fishing communities, arid and semi-arid | 14 | Levine & Crosskey (2006) |
| Madagascar | forest-dwelling, swidden cultivation in tropical forest | 150 | Styger et al. (1999) |
| Namibia | agriculture and livestock; tropical wetland, swamp and woodland in Caprivi | 21 | Mulonga (2003) |
| Nigeria | agricultural, savanna, semi-arid | 121 | Harris & Mohammed (2003) |
| Tanzania | agricultural, tropical forest, East Usambara mountains | 28 | Kessey (1998) |
| Tanzania | agricultural, tropical forest, East Usambara mountains | 46 | Hårkönen & Vainio-Mattila (1998) |
| Tanzania | Batemi agropastoralists, semi-arid (with 35 wild species cultivated) | 44 | Johns et al. (1996) |
| Uganda | agricultural households in southwest Uganda (some wild species cultivated and gathered from the wild) | 94 | Musinguzi et al. (2006) |
| Zambia | country-wide estimate | 15–25 | Pegler & Piearce (1980) |
| Summary of clinical data of the study group consisting of colon cancer patients, pre-malignant adenoma patients and healthy control patients | |||||
| Parameter | Value | Colon cancer (CC) patients | Healthy control (H) patients | Adenoma (A) patients | P-value |
| (n = 164) | (n = 119)* | (n = 34) | |||
| Sex | Female | 68 (41.5%) | 67 (56.3%) | 16 (47.1%) | 0.738 |
| Male | 96 (58.5%) | 52 (43.7%) | 18 (52.9%) | ||
| Age | Range | 40.5 – 99.1 | 19.5 – 90.8 | 28.1 – 86.1 | 0.144 (A vs H) |
| (years) | Mean | 69.59 | 62.41 | 63.65 | 0.004 (CC vs H) |
| Gene | Primer | Sequence | Annealing temperature/elongation time | Literature |
| 16S, rrnA | pF1 | AGAGTTTGATCCTGGCTCAG | 55°C/60 sec | [32] |
| pR4 | CCAGCAGCCGCGGTAATAC | [33] | ||
| sodA | sodA-F | TRCAYCATGAYAARCACCAT | 50°C/60 sec | [34] |
| sodA-R | ARRTARTAMGCRTGYTCCCARACRTC | [34] | ||
| groEL | StreptogroELd | GAHGTNGTIGAAGGIATGCA | 52°C/60 sec | [35] |
| StreptogroELr | ATTTGRCGIAYWGGYTCTTC | [35] | ||
| gdh | GDHsoralisF | ATGGACAAACCAGCTAGCTT | 55°C/60 sec | [6] |
| GDHsoralisR | GCTTGTGGTCCCATGCTTCC | [6] | ||
| gtfR | gtfRSoralisF | TCCCGGTCAGCAAACTCCAGCC | 52°C/60 sec | [36] |
| gtfRSoralisR | GCAACCTTTGGATTTGCAAC | [36] | ||
| cshA-like | CshA-F | AAGTACAAGGTGCAGATG | 46°C/40 sec | This study |
| CshA-R | CATTTGCAGTAGCTATCG | This study | ||
| rib-like | RibF | GTGACYTACCCAGATGG | 47°C/30 sec | This study |
| RibR1 | CAATWGAATCTTCWGCC | This study | ||
| pitA-like | pitAF | ATTWSTCCAATTCAGGGGC | 55°C/45 sec | This study |
| pitAR | AATGCCCGCGTCCATACC | This study | ||
| integrase | InGraF | CTCATGATGTCAAAGAG | 46°C/40 sec | This study |
| InGraR | GATTTGGAAYCGTGTGG | This study | ||
| hylA-like | hylAF | CAGCAAAGGGATGCCAAG | 60°C /60 sec | This study |
| hylAR | CCTTCCAGTTCCTGGTTTAAC | This study | ||
| Tigurinus 16S, rRNA | TIGFCTT | AGAACGCTGAAGCTTGGT | 55°C /30 sec | This study |
| TIGFAGA | GTAGAACGCTGAAGAGAGG | This study | ||
| TIGR | ATTATCATGCGATAATCAATT | This study | ||
| Mitis-group sodA | sodA-MSF | GCMAAYGCAGCTCTTGAA | 58°C /35 sec | This study |
| sodA-MSR | ACCAACCAHGCCCATCCA | This study |
| GR Operation | Operation Zone | Total Population | Total Populated Households | Total Households | Total Structures |
| GR1:Outer Islands, Temotu Province | Duff Islands | 556 | 118 | 158 | 399 |
| Reef Islands | 5958 | 1179 | 1468 | 3746 | |
| Utupua | 1300 | 259 | 330 | 770 | |
| Vanikolo | 1602 | 308 | 399 | 938 | |
| GR1: Total | 9416 | 1864 | 2355 | 5853 | |
| GR2: Santa Cruz, Temotu Province | Santa Cruz East | 3950 | 717 | 881 | 1873 |
| Santa Cruz West | 8162 | 1563 | 1970 | 4046 | |
| GR2: Total | 12112 | 2280 | 2851 | 5919 | |
| GR3: Tanna IRS Zone, Tafea Province | Health Zone 1 | 5363 | 1064 | 1283 | 5214 |
| Health Zone 2 | 9395 | 1863 | 2196 | 7299 | |
| Health Zone 3 | 3096 | 653 | 773 | 2923 | |
| Health Zone 4 | 4115 | 866 | 1001 | 3455 | |
| GR3: Total | 21969 | 4446 | 5253 | 18891 |
| ENINBSC study | CRONICAS study | |
| (n = 2,472) | (n = 2,945) | |
| Demographic variables | ||
| Sex (% females) | 1,209 (48.9%) | 1,500 (50.9%) |
| Age (mean (SD)) | 50.5 (12.1) | 55.3 (12.7) |
| Education in years (mean (SD)) | 7.8 (4.9) | 8.0 (4.9) |
| Behavioural variables | ||
| Current smoking (%) | 391 (15.9%) | 369 (11.5%) |
| Alcohol use (%) | 2,323 (94.1%) | 1,600 (54.3%) |
| Family history of diabetes (%) | 268 (11.2%) | 351 (11.9%) |
| Physical activity (% low level) | 606 (24.5%) | 938 (31.9%) |
| Anthropometric measures | ||
| Body mass index (mean (SD)) | 25.7 (4.5) | 27.6 (4.6) |
| Waist circumference (mean (SD)) | 91.0 (11.4) | 91.5 (11.0) |
| Waist-to-height ratio (mean (SD)) | 0.58 (0.08) | 0.59 (0.07) |
| Systolic blood pressure (mean (SD)) | 114.5 (18.5) | 117.2 (18.9) |
| Diastolic blood pressure (mean (SD)) | 71.1 (11.9) | 73.4 (11.1) |
| Hypertension (%) | 579 (23.8%) | 705 (24.0%) |
| Total cholesterol (mean (SD)) | 174.2 (36.9) | 199.7 (39.6) |
| HDL-cholesterol (mean (SD)) | 43.5 (5.3) | 41.7 (11.5) |
| Chromosome number | Number of SNPs | Number of significant SNPs | Markers with largest risk and protective effects | |||
| Largest risk effect | Largest protective effect | |||||
| Marker | Effect size | Marker | Effect size | |||
| 1 | 40929 | 142 | rs7519615 | 1.73638 | rs2275864 | -1.41482 |
| 2 | 44090 | 140 | rs655783 | 0.91779 | rs938869 | -2.3145 |
| 3 | 36690 | 138 | rs7616866 | 202.447 | rs9288967 | -4.23478 |
| 4 | 32628 | 133 | rs768063 | 155.04 | rs6816684 | -2.31044 |
| 5 | 33612 | 90 | rs344156 | 1.46745 | rs6899062 | -1.68164 |
| 6 | 35574 | 82 | rs6935937 | 3.06767 | rs1856363 | -2.18496 |
| 7 | 29244 | 130 | rs9632680 | 96.105 | rs4732523 | -2.41344 |
| 8 | 30990 | 130 | rs7006628 | 0.577914 | rs2853259 | -1.50527 |
| 9 | 26128 | 125 | rs6478815 | 154.845 | rs1387292 | -3.12822 |
| 10 | 28331 | 131 | rs2388121 | 0.777184 | rs1909668 | -1.36459 |
| 11 | 26477 | 119 | rs1879445 | 123.081 | rs7932437 | -6.04313 |
| 12 | 26365 | 129 | rs1146114 | 1.43868 | rs7300982 | -1.59685 |
| 13 | 20242 | 129 | rs2323883 | 4.76091 | rs9740397 | -3.53682 |
| 14 | 17951 | 124 | rs4296166 | 1.53678 | rs4983565 | -2.02512 |
| 15 | 16166 | 121 | rs7183817 | 0.814795 | rs3743372 | -2.60765 |
| 16 | 16460 | 111 | rs4238802 | 0.66247 | rs4783187 | -1.98159 |
| 17 | 14027 | 123 | rs2880328 | 92.8919 | rs9747823 | -1.31507 |
| 18 | 16450 | 123 | rs2303508 | 78.2526 | rs1982040 | -2.32656 |
| 19 | 9236 | 101 | rs3810256 | 1.11899 | rs10404348 | -3.04764 |
| 20 | 13843 | 114 | rs6513195 | 3.13637 | rs6138601 | -4.63256 |
| 21 | 8051 | 102 | rs2823819 | 0.971309 | rs1539902 | -1.08918 |
| 22 | 8205 | 90 | rs761917 | 1.46745 | rs17406434 | -1.68164 |
| Total | 531689 | 2627 |
| Gene | Sequence | Product size | Annealling temperature | |
| MMP-2 | Sense | 5'-GGATGATGCCTTTGCTCG-3' | 487 bp | 55°C |
| Anti-sense | 5'-ATAGGATGTGCCCTGGAA-3' | |||
| MMP-7 | Sense | 5'-CTTCAGGCAGAACATCCA-3' | 220 bp | 49°C |
| Anti-sense | 5'-ATTTATTGACATCTACCCAC-3' | |||
| MMP-9 | Sense | 5'-AGGACGGCAATGCTGATC-3' | 127 bp | 58°C |
| Anti-sense | 5'-TCGTAGTTGGCGGTGGTG-3' | |||
| MT1-MMP | Sense | 5'-CCTGCGTCCATCAACACT-3' | 481 bp | 57°C |
| Anti-sense | 5'-TCACCTCCGTCTCCTCCTC-3' | |||
| SFRP5 | Sense | 5'-AGGGTAAGGGAAAGGTGGAG-3' | 379 bp | 60°C |
| Anti-sense | 5'-GAGAAGCAGAGGCTGAGGAA-3' | |||
| GAPDH | Sense | 5'-GGGAAACTGTGGCGTGAT-3' | 309 bp | 56°C |
| Anti-sense | 5'-AAAGGTGGAGGAGTGGGT-3' |
| Variables | No. of cases | NQO1 strongly positive cases (%) | χ2 | Pvalue |
| Age | 0.161 | 0.689 | ||
| ≥48 | 97 | 57 (58.8%) | ||
| <48 | 63 | 35 (55.6%) | ||
| Menopausal status | 0.050 | 0.823 | ||
| Premenopausal | 76 | 43 (56.6%) | ||
| Postmenopausal | 84 | 49 (58.3%) | ||
| Histological grade | 19.056 | 0.000** | ||
| Grade-1 | 37 | 10 (27.0%) | ||
| Grade-2 | 47 | 29 (61.7%) | ||
| Grade-3 | 76 | 53 (69.7%) | ||
| FIGO stage | 26.458 | 0.000** | ||
| I-II | 92 | 37 (40.2%) | ||
| III-IV | 68 | 55 (80.9%) |
| Node | 2 | 3 | 5 | 6 |
| 2 | – | 0.001∗ | 0.506 | 0.928 |
| 3 | 0.001∗ | – | 0.075 | 0.004∗ |
| 5 | 0.506 | 0.075 | – | 0.563 |
| 6 | 0.928 | 0.004∗ | 0.563 | – |
| Effect | SS | df | MS | F | p value |
| Intercept | 23,302.85 | 1 | 23,302.85 | 89.56418 | 0.000000 |
| Species | 1446.16 | 2 | 723.08 | 2.77915 | 0.080571 |
| Treatment | 10,626.36 | 1 | 10,626.36 | 40.84227 | 0.000001 |
| Error | 6764.69 | 26 | 260.18 |
| Community | Type | MBR Culex spp. | MBR A. gambiae s.l. | EIR A. gambiae s.l. |
| Dzorwulu | UA | 234.4 (180.0–305.2) | 11.7 (7.9–17.3) | 27.82 |
| Korle Bu | UA | 141.4 (99.2–201.8) | 2.6 (1.5–4.4) | 6.07 |
| Kotobabi | UA | 127.8 (94.4–173.1) | 18.8 (9.4–37.7) | 44.72 |
| Kaneshie | U | 48.5 (26.9–87.3) | 10.6 (6.0–18.9) | 25.15 |
| La | U | 38.4 (19.2–76.8) | 2.1 (1.4–3.1) | 4.94 |
| Ushertown | U | 36.9 (16.6–81.9) | 1.1 (1.0–1.2) | 2.57 |
| Year | First author | Type of study | Number and type of patients considered | Patients with solitary splenic metastases from NPC | Patient’s age, sex (M, F) | Comorbidity | Primary treatment for NPC | Disease-free survival after primary treatment | Methods of detection of splenic metastasis | Treatment for solitary splenic metastasis | Confirmatory histology of NPC splenic metastases | Overall survival (status at last follow-up) | Relapse after splenic surgery |
| 2000 | Lam & Tang [3] | CS | 92 patients with splenic metastases | 1 (1.1 %) | M | NS | NS | NS | NS | - Splenectomy | UCNT | NS | NS |
| 2013 | Suh et al. [38] | CR | 1 non-keratinizing NPC | 1 | 35 years old, M | EBV | - Neoadjuvant chemotherapy (cysplatin and 5-fluorouracil)- Left medial maxillectomy with left modified radical neck dissection- Adjuvant radiochemotherapy (cysplatin and 63 Gy) | 7 months | FDG-PET/CT FNA biopsy | - Systemic chemotherapy (docetaxel and cysplatin)- Laparoscopic splenectomy | UCNT | 5 months (alive) | Nil |
| 2015 | Abu-Zaid et al. [27] | CR | 1 NPC | 1 | 26 years old, M | NS | - Surgical resection- Adjuvant radiochemotherpay | 6 years | CTFNA biopsy | - Splenectomy | UCNT | 12 months (alive) | Nil |
| 2015 | Present study | CR | 1 NPC | 1 | 56 years old, M | Smoker, EBV | - Neoadjuvant chemotherapy (docetaxel, carboplatin, and 5-Fluorouracil)- Radiotherapy (70 Gy) | 3 months | PET/CT | - Laparoscopic splenectomy | UCNT | 4 months (alive) | Nil |
| Health Effects | US | EU | Canada | Australia | New Zealand |
| Mortality: | 1,042 | 1,296,552 (premature death) [198] | |||
| VSL: Adults | 6,300,000 | 2,247,191 | 3,480,000 | 1,439,394 | 1,717,241 (1,724,138) [198] |
| VSL: Children | 2 × adult | 4088764 (infant) | |||
| VSLY | 134,831 | 70,455 | 118,621 | ||
| Morbidity: | 1929.55 (average cost/separation) [199] | ||||
| Morbidity: children | 2 × adults | ||||
| Chronic bronchitis | 340,000 | 213,483 | |||
| Chronic asthma | 39,000 | ||||
| Respiratory hospital admission | 14,000 | 2,247 | 1,032 | 2,069 | |
| CVD hospital admission | 21,000 | 2,247 | 1,052 | 2,759 | |
| Emergency room visit | 300 (asthma) | 541 (respiratory) 562 (CVD) | |||
| Doctor's visit | 60 | ||||
| RAD | 106 | 92 (working age) 78 (young, elderly) | 22 | 53 | |
| MRAD | 50 | 43 | |||
| Acute respiratory symptom | 3–24 | ||||
| Use of respiratory medication | 1.12 | ||||
| Asthma day | 32–74 | 43 | 15 | ||
| References: | [54] | [127] | [200] | [128]* | [129] |
| Non-Misusers | Misusers | p-value | RR (95% CI) | |
| Age | 54 | 48 | < 0.001 | |
| % Male | 38 | 59.7 | 0.005 | 1.56 (1.16 – 2.11) |
| CES-D | 22.5 | 26.0 | 0.080 | |
| PDI | 45.1 | 45.6 | 0.838 | |
| REALM | 50.7 | 53.5 | 0.492 | |
| % Current Smoker | 50 | 71 | 0.007 | 1.41 (1.12 – 1.79) |
| % History of Ethanol Abuse | 23 | 44 | 0.004 | 1.95 (1.25 – 3.03) |
| % History of Cocaine Abuse | 21 | 68 | < 0.001 | 3.30 (2.17 – 4.99) |
| % Positive Urine Cannabinoids | 12 | 33 | 0.001 | 2.70 (1.5 – 4.85) |
| % Multiple Drug Convictions | 1 | 11 | 0.001 | 15.13 (1.90 – 120) |
| % Drug or DUI Convictions | 11 | 40 | 0.001 | 3.60 (2.05 – 6.34) |
| Register | Data available | Register holder | Ref. |
| Medical Birth Register | Mother’s health data (incl. Smoking habits prior to and during pregnancy, other risk factors, interventions), pregnancy, delivery, live and stillbirths, GD, BMI, infant health data by age of 7 days | THL | [30] |
| Register of Induced Abortions | Data on mother, indication for induced abortion, diagnoses | THL | [38] |
| Register of Congenital Malformations | Mother’s health data, pregnancy, foetus/child, congenital anomalies and birth defects, diagnoses (ICD codes) | THL | [31] |
| Care Register for Health Care | Data from hospitals and special health care, diagnoses | THL | [33] |
| Register of Primary Health Care Visits | Data outpatient health care visits, diagnoses (available since 2011) | THL | [34] |
| Cancer Register | Persons with cancer, data on cancer type and death certificate | THL | [32] |
| Cause-of-Death Register | Causes of death, death certificates | Statistics Finland | [36] |
| Register of reimbursements for Prescription Medicines | Purchases of prescription medication eligible for reimbursement | KELAa | [35] |
| Finnish Maternity Cohort | Serum bank, data on mother, sampling date, expected due date, previous pregnancies | THLb | [42] |
| Population Register | Address history | Population Register Center | [37] |
| Serogroup | Serotype | Serosubtype | Number | Percentage |
| B | 1 | P1.4 | 4 | 1.8 |
| P1.16 | 4 | 1.8 | ||
| NT | 3 | 1.4 | ||
| Other | 1 | 0.5 | ||
| 2A | 3 | 1.4 | ||
| 4 | P1.4 | 57 | 26 | |
| P1.6 | 3 | 1.4 | ||
| P1.7 | 3 | 1.4 | ||
| P1.9 | 4 | 1.8 | ||
| P1.10 | 4 | 1.8 | ||
| P1.15 | 5 | 2.3 | ||
| NT | 28 | 12.8 | ||
| Other | 13 | 5.9 | ||
| NT | P1.1 | 6 | 2.7 | |
| P1.4 | 8 | 3.7 | ||
| NT | 8 | 3.7 | ||
| Other | 4 | 1.8 | ||
| Other | 17 | 7.8 | ||
| C | 2A | P1.2 | 12 | 5.5 |
| P1.5 | 9 | 4.1 | ||
| P1.7 | 1 | 0.5 | ||
| NT | 7 | 3.2 | ||
| 2B | P1.1 | 1 | 0.5 | |
| P1.2 | 7 | 3.2 | ||
| 4 | P1.4 | 3 | 1.4 | |
| NT | 2 | 0.9 | ||
| Other | 2 | 0.9 |
| Number (%) | Number (%) with smear completion rate <90% | Bivariable Odds Ratioa | 95%CI | Pb | Multi-variable Odds Ratioa | 95%CI | Pb | |
| Overall | 88 (100%) | 43 (48.9%) | ||||||
| Category of health facility | 0.025 | |||||||
| Health centre | 69 (78.4%) | 30 (43.5%) | 1 | |||||
| Hospital | 19 (21.6%) | 13 (68.4%) | 2.0 | 1.1-3.7 | ||||
| Location of health facility | 0.008 | |||||||
| Rural | 60 (68.2%) | 25 (41.7%) | 1 | |||||
| Urban | 28 (31.8%) | 18 (64.3%) | 2.1 | 1.2-3.8 | ||||
| Health facility status | 0.311 | |||||||
| Mission/private | 40 (45.5%) | 19 (47.5%) | 1 | |||||
| Public | 48 (54.5%) | 24 (50.0%) | 1.3 | 0.8-2.3 | ||||
| Most recent on-the-job training for TB staff | ||||||||
| Before 2006 or none at all | 47 (53.4%) | 22 (46.8%) | 1 | 0.643 | ||||
| 2006 | 41 (46.6%) | 21 (51.2%) | 1.1 | 0.7-2.0 | ||||
| Location of facilities (Province) | 0.045 | |||||||
| East | 13 (14.8%) | 8 (61.5%) | 1 | |||||
| Kigali | 17 (19.3%) | 11 (64.7%) | 1.4 | 0.6-3.6 | ||||
| North | 18 (20.5%) | 4 (22.2%) | 0.4 | 0.1-1.0 | ||||
| West | 22 (25.0%) | 11 (50.0%) | 0.9 | 0.3-2.2 | ||||
| South | 18 (20.5%) | 9 (50.0%) | 1.0 | 0.4-2.5 | ||||
| Number of new PTB cases in 6-month period | 0.001 | 0.001 | ||||||
| 1-5 | 32 (36.4%) | 9 (28.1%) | 1 | 1 | ||||
| 6-14 | 27 (30.7%) | 14 (51.9%) | 2.0 | 0.9-4.4 | 2.0 | 0.9-4.4 | ||
| ≥15 | 29 (33.0%) | 20 (69.0%) | 4.1 | 1.9-8.8 | 4.1 | 1.9-8.8 |
| Muscle | Mean polarization | Skewness | Kurtosis* |
| WT-RLC (standard) | 0.321 ± 0.033 | 2.886 ± 0.574 | 7.749 ± 3.734 |
| A13T-non-mutated (standard) | 0.314 ± 0.028 | 2.383 ± 0.260 | 4.610 ± 1.259 |
| A13T-mutated (non-standard) | 0.250 ± 0.037 | 1.623 ± 0.262 | 1.450 ± 1.021 |
| Frequency in patients: Percent (%)in four categories of severity | |||
| Severity of complaints | Population % Standard | ||
| Total score | |||
| No or little (-4) | 48 | 26.4 | 86.8 |
| Mild (5–8) | 25 | 18.2 | 8.4 |
| Moderate (9–15) | 20 | 27.8 | 4.0 |
| Severe (16+) | 8 | 27.6 | 0.8 |
| Psychological score | |||
| No or little (-1) | 48 | 30.7 | 82.5 |
| Mild (2–3) | 23 | 17.0 | 10.4 |
| Moderate (4–6) | 20 | 22.2 | 5.5 |
| Severe (7+) | 9 | 30.1 | 1.6 |
| Somatic score | |||
| No or little (-2) | 53 | 35.7 | 93.0 |
| Mild (3–4) | 24 | 22.7 | 5.1 |
| Moderate (5–7) | 15 | 25.5 | 1.6 |
| Severe (8+) | 8 | 16.1 | 0.3 |
| Sexual score | |||
| No or little (0) | 64 | 37.3 | 76.8 |
| Mild (1) | 13 | 13.3 | 11.6 |
| Moderate (2–3) | 16 | 22.2 | 8.7 |
| Severe (4+) | 7 | 27.3 | 2.9 |
| Attributes | SED Group | SEA Group | Unadjusted | ||
| Na | % | Na | % | OR (95% CI) | |
| SOCIODEMOGRAPHIC | |||||
| Marital Status | 213 | 424 | |||
| Has partner | 79 | 99 | 0.05 (0.02–0.13) | ||
| Education | 212 | 432 | |||
| Less than high school | 25 | 5 | 2.25 (1.93–2.63) | ||
| Cultural Identity | 211 | 428 | |||
| Canadian | 50 | 61 | 0.61 (0.44–0.85) | ||
| Language Spoken at Home | 217 | 431 | |||
| English | 63 | 82 | 0.37 (0.26–0.49) | ||
| Country of Birth | 215 | 421 | |||
| Canada | 45 | 70 | 0.35 (0.25–0.49) | ||
| WOMAN'S HEALTH | |||||
| Overall Health | 215 | 431 | |||
| Very good/Excellent | 41 | 59 | 0.48 (0.35–0.67) | ||
| Symptoms of Postpartum Depression | 211 | 426 | |||
| EPDS ≥ 12 | 19 | 8 | 2.7 (1.64–4.4) | ||
| Hospital Readmission | 216 | 431 | |||
| YES | 3 | 2 | 1.57 (0.57–4.28) | ||
| PHYSICIAN | |||||
| Has Family Doctor | 215 | 430 | |||
| YES | 96 | 97 | 0.74 (0.3–1.84) |
| Compounds | Range (ng/mL) | Linear regression equation | Correlation coefficient | LOD (ng mL−1) | LOQ (ng mL−1) |
| Nootkatone | 2.00-1000.00 | Y = 5910X + 2790 | 0.9979 | 0.60 | 2.00 |
| Yakuchinone A | 2.00-1000.00 | Y = 7090X + 12100 | 0.9997 | 0.60 | 2.00 |
| Yakuchinone B | 2.00-1000.00 | Y = 8100X + 6050 | 0.9901 | 0.60 | 2.00 |
| Oxyphyllacinol | 5.83-1165.00 | Y = 763X + 1130 | 0.9903 | 1.75 | 5.83 |
| Tectochrysin | 2.07-1135.00 | Y = 16300X + 8780 | 0.9973 | 0.62 | 2.07 |
| Izalpinin | 5.00-1000.00 | Y = 2160X + 2190 | 0.9908 | 1.50 | 5.00 |
| Chrysin | 2.00-1000.00 | Y = 5010X + 3010 | 0.9919 | 0.60 | 2.00 |
| Kaempferide | 2.16-1080.00 | Y = 1040X + 1470 | 0.9885 | 0.65 | 2.16 |
| Apigenin-7,4′-dimethylether | 5.00-1000.00 | Y = 165X + 375 | 0.9861 | 1.50 | 5.00 |
| Image | Diameter Measurement Method | Error (%) Relative to MD in Image LS | ||
| Min | Average | Max | ||
| LS | MAL-F2 | 0.1 | 1.2 | 3.8 |
| MD | 0.5 | 5.8 | 16 | |
| IS | MAL-F1 | 0.8 | 5.6 | 12.2 |
| MAL-F2 | 0.2 | 15.0 | 60.5 |
| Predictive factor | Vaccination document | At least one vaccine dose | Minimum vaccination | Basic vaccination | Extended vaccination | MMR1 |
| Weighted percent (%)a (95% CI) b | Weighted percent (%)a (95% CI)b | Weighted percent (%)a (95% CI)b | Weighted percent (%)a (95% CI)b | Weighted percent (%)a (95% CI)b | Weighted percent (%)a (95% CI)b | |
| Gender | n = 250 | n = 239 | n = 239 | n = 239 | n = 239 | n = 239 |
| Male | 89 (81–94) | 79 (70–86) | 31 (20–44) | 26 (17–37) | 17 (10–29) | 38 (27–51) |
| Female | 83 (67–92) | 83 (67–92) | 39 (27–52) | 30 (18–44) | 11 (4–23) | 48 (37–58) |
| P value | 0.3143 | 0.5779 | 0.2558 | 0.5160 | 0.0587 | 0.1706 |
| Type of settlement | n = 251 | n = 240 | n = 240 | n = 240 | n = 240 | n = 240 |
| Mainly houses (Type 1) | 97 (91–99) | 92 (82–97) | 44 (26–63) | 39 (22–58) | 17 (5–44) | 45 (28–64) |
| Houses and shacks/tents (Type 2) | 77 (59–88) | 74 (56–86) | 28 (15–46) | 22 (13–34) | 7 (3–16) | 35 (24–49) |
| Mainly shacks/tents (Type 3) | 85 (68–94) | 77 (61–88) | 34 (20–51) | 23 (10–45) | 17 (6–38) | 48 (33–63) |
| P value | 0.0304 | 0.0742 | 0.3984 | 0.2513 | 0.4500 | 0.4666 |
| Region (NUTS-1) | n = 251 | n = 240 | n = 240 | n = 240 | n = 240 | n = 240 |
| North Greece | 93 (75–98) | 87 (71–95) | 37 (22–54) | 31 (19–47) | 14 (5–33) | 44 (31–59) |
| Central Greece | 78 (59–89) | 76 (60–86) | 36 (20–55) | 25 (10–49) | 15 (5–38) | 44 (29–61) |
| Attica | 84 (76–89) | 73 (48–89) | 29 (18–44) | 22 (12–37) | 10 (3–24) | 37 (23–54) |
| Crete and Aegean islands | 73 (41–91) | 59 (32–81) | 25 (12–46) | 24 (12–42) | 21 (12–35) | 25 (12–46) |
| P value | 0.1420 | 0.2914 | 0.7835 | 0.6330 | 0.8377 | 0.7886 |
| Size of settlement | n = 251 | n = 240 | n = 240 | n = 240 | n = 240 | n = 240 |
| <100 families | 88 (75–95) | 79 (67–87) | 32 (20–48) | 21 (11–37) | 10 (4–26) | 41 (28–56) |
| ≥100 families | 84 (67–93) | 83 (65–93) | 38 (25–54) | 35 (23–50) | 18 (8–36) | 45 (33–57) |
| P value | 0.6467 | 0.6104 | 0.5612 | 0.1532 | 0.3936 | 0.7295 |
| Electricity available to ≥ 50% of houses in the settlement | n = 251 | n = 240 | n = 240 | n = 240 | n = 240 | n = 240 |
| Yes | 89 (78–95) | 84 (75–91) | 37 (26–49) | 29 (19–42) | 15 (8–28) | 45 (34–55) |
| No | 73 (52–87) | 62 (39–81) | 27 (14–45) | 19 (9–35) | 6 (2–21) | 34 (18–55) |
| P value | 0,0615 | 0,0312 | 0,3369 | 0.2660 | 0,2001 | 0,3313 |
| Usual service of vaccination | n = 215 | n = 207 | n = 207 | n = 207 | n = 207 | n = 207 |
| Hospital | 74 (57–86) | 69 (54–81) | 31 (18–48) | 27 (15–45) | 17 (7–37) | 38 (25–53) |
| Primary Health Centre | 93 (80–98) | 86 (53–97) | 56 (39–72) | 40 (13–74) | 27 (9–60) | 59 (42–73) |
| Medical-Social Centre | 95 (85–98) | 89 (75–96) | 37 (19–58) | 26 (13–45) | 2 (0–10) | 52 (40–63) |
| P value | 0,0027 | 0,1282 | 0,1665 | 0.6313 | 0,0751 | 0,1032 |
| Distance to usual vaccination service | n = 251 | n = 240 | n = 240 | n = 240 | n = 240 | n = 240 |
| ≤2Km | 93 (87–97) | 92 (84–96) | 46 (34–59) | 34 (20–51) | 15 (5–36) | 51 (42–61) |
| >2Km | 80 (64–90) | 71 (57–82) | 25 (15–39) | 22 (13–36) | 13 (6–27) | 36 (24–50) |
| P value | 0,0159 | 0,0015 | 0,0226 | 0.2321 | 0,8590 | 0,0676 |
| Self-reported vaccination barrier | n = 240 | n = 229 | n = 229 | n = 229 | n = 229 | n = 229 |
| No | 86 (77–92) | 88 (78–94) | 45 (32–59) | 32 (19–48) | 16 (8–30) | 54 (42–65) |
| Yes | 83 (69–92) | 72 (57–83) | 23 (11–40) | 19 (9–34) | 6 (2–19) | 31 (19–46) |
| P value | 0.5628 | 0.0098 | 0.0343 | 0.1467 | 0.0666 | 0.0163 |
| Characteristic | Entire cohort | By distance (m) to nearest A1–A3 roadway (m)b | ||
| ≥ 200 | 51–199 | 0–50 | ||
| Age (years)c | 42.0 ± 5.1 | 42.1 ± 5.1 | 41.9 ± 5.2 | 42.0 ± 5.3 |
| BMI (kg/m2) | 25.9 ± 6.0 | 25.8 ± 5.9 | 26.0 ± 6.1 | 26.4 ± 6.4 |
| Census tract median income ($10,000) | 6.68 ± 2.38 | 6.75 ± 2.29 | 6.66 ± 2.47 | 6.33 ± 2.56 |
| Census tract median home value ($100,000) | 1.72 ± 1.24 | 1.67 ± 1.08 | 1.84 ± 1.41 | 1.76 ± 1.57 |
| Caucasian race | 94 | 94 | 93 | 93 |
| Age at menarche (years) | ||||
| < 12 | 23 | 23 | 23 | 23 |
| 12 | 30 | 30 | 30 | 31 |
| > 12 | 46 | 47 | 46 | 46 |
| Parity | ||||
| Nulliparous | 18 | 16 | 21 | 25 |
| Parous | 82 | 84 | 79 | 75 |
| Oral contraception use | ||||
| Never | 14 | 13 | 16 | 15 |
| Past | 75 | 75 | 73 | 74 |
| Current | 10 | 10 | 10 | 10 |
| Cigarette smoking | ||||
| Never | 67 | 68 | 66 | 65 |
| Current | 9 | 8 | 10 | 10 |
| Former | 24 | 24 | 24 | 24 |
| Infertility | ||||
| Yes | 4 | 4 | 4 | 4 |
| No | 94 | 94 | 94 | 94 |
| Ever performed rotating shift work | ||||
| Yes | 69 | 69 | 69 | 70 |
| No | 31 | 31 | 31 | 30 |
| Region | ||||
| Northeast | 34 | 32 | 37 | 42 |
| Midwest | 34 | 35 | 31 | 30 |
| West | 15 | 14 | 20 | 15 |
| South | 17 | 19 | 13 | 13 |
| Values are mean ± SD or percent. aValues are standardized to the age distribution of the study population. bEach cohort member may be in multiple distance categories over follow-up. cValues are not age-adjusted |
| Team response1 | Individual response | |||
| Number of teams analysed | Number of questionnaires send | Number of questionnaires returned | Number of questionnaires analysed | |
| Internal medicine | 11 | 142 | 127 | 115 |
| Surgery | 10 | 83 | 77 | 69 |
| Radiology | 7 | 45 | 42 | 42 |
| Total | 28 | 270 | 246 | 226 |
| Query | SQL | SQL | SPARQL | SPARQL |
| count | time | count | time | |
| result | result | |||
| Recovery all Patients | 207.190 | 0,060s | 207.190 | 0,189s |
| Recovery all Therapies | 400.290 | 0,132s | 400.290 | 0,317s |
| Recovery all Diagnosis | 240.088 | 0,070s | 240.088 | 0,220s |
| Recovery all Courses | 108.297 | 0,030s | 108.297 | 0,155s |
| Recovery patients with diagnosis, therapies and courses | 207.190 | 1,048s | 207.190 | 0,204s |
| Recovery all female Patients | 105.714 | 0,231s | 105.714 | 0,189s |
| Recovery all female Patients with more of 60 years old | 62.603 | 0,245s | 62.603 | 0,192s |
| Error rate | |||||
| Individuals | Missing | Running time (sec) | Genotype inference | Heterozygous switch | Point-wise |
| 100 | 0.00 | 1437 | ------a | 0.4835 | 0.1569 |
| 100 | 0.05 | 1563 | 0.1106 | 0.4926 | 0.1618 |
| 100 | 0.10 | 1380 | 0.1202 | 0.4967 | 0.1639 |
| 100 | 0.15 | 1671 | 0.1267 | 0.4829 | 0.1614 |
| 200 | 0.00 | 4679 | ------ | 0.4964 | 0.1609 |
| 200 | 0.05 | 4620 | 0.0922 | 0.4960 | 0.1620 |
| 200 | 0.10 | 4673 | 0.0979 | 0.4966 | 0.1635 |
| 200 | 0.15 | 4382 | 0.1064 | 0.4961 | 0.1631 |
| 400 | 0.00 | 9417 | ------ | 0.5035 | 0.1634 |
| 400 | 0.05 | 9411 | 0.0904 | 0.5093 | 0.1666 |
| 400 | 0.10 | 9360 | 0.0966 | 0.4880 | 0.1609 |
| 400 | 0.15 | 8524 | 0.1024 | 0.4959 | 0.1652 |
| Jeddah A | Val68Met+Asn126Asp+Ser188Phe |
| Jeddah B | Val68Met+Ser188Phe |
| Jeddah C | Asn126Asp+Ser188Phe |
| Jeddah D | Ile48Thr+Val68Met |
| Jeddah E | Ile48Thr+Ser188Phe |
| Variables | Soft palate | Depth of the upper airway | Position of the hyoid bone | |||||||||||||||
| PM-U | SPT | NL/PM-U | PM-UPW | U-MPW | V-LPW | PASmin | AH-FH | AH-CV | ||||||||||
| SNA (°) | Coefficient | -0.010 | 0.111 | 0.001 | 0.178 | -0.088 | 0.040 | -0.075 | -0.068 | 0.033 | ||||||||
| P value | 0.919 | 0.252 | 0.991 | 0.066 | 0.365 | 0.684 | 0.439 | 0.484 | 0.738 | |||||||||
| SNB (°) | Coefficient | -0.064 | 0.223 | * | -0.106 | 0.119 | -0.098 | -0.009 | -0.099 | -0.032 | 0.081 | |||||||
| P value | 0.508 | 0.021 | 0.276 | 0.221 | 0.311 | 0.925 | 0.308 | 0.742 | 0.404 | |||||||||
| ANB (°) | Coefficient | 0.135 | -0.134 | 0.252 | ** | 0.200 | * | -0.069 | 0.064 | -0.005 | -0.093 | -0.029 | ||||||
| P value | 0.162 | 0.166 | 0.008 | 0.038 | 0.476 | 0.510 | 0.958 | 0.337 | 0.769 | |||||||||
| MnPl/SN (°) | Coefficient | 0.026 | -0.057 | 0.103 | -0.137 | 0.145 | -0.027 | 0.065 | 0.117 | -0.043 | ||||||||
| P value | 0.788 | 0.557 | 0.291 | 0.157 | 0.133 | 0.781 | 0.506 | 0.229 | 0.657 | |||||||||
| MxPl/MnPl (°) | Coefficient | -0.022 | -0.105 | 0.236 | * | 0.019 | 0.104 | -0.055 | -0.064 | 0.204 | * | -0.100 | ||||||
| P value | 0.824 | 0.281 | 0.014 | 0.842 | 0.285 | 0.573 | 0.510 | 0.034 | 0.302 | |||||||||
| MxMn-DF (mm) | Coefficient | 0.050 | 0.274 | ** | -0.079 | -0.065 | 0.094 | -0.052 | 0.023 | 0.423 | ** | 0.153 | ||||||
| P value | 0.609 | 0.004 | 0.417 | 0.502 | 0.332 | 0.592 | 0.813 | 0.000 | 0.113 | |||||||||
| TAFH (mm) | Coefficient | 0.240 | * | 0.180 | 0.120 | 0.041 | 0.086 | 0.217 | * | 0.188 | 0.444 | ** | 0.302 | ** | ||||
| P value | 0.012 | 0.063 | 0.215 | 0.673 | 0.373 | 0.024 | 0.051 | 0.000 | 0.001 | |||||||||
| TPFH (mm) | Coefficient | 0.257 | ** | 0.269 | ** | -0.082 | 0.062 | -0.081 | 0.271 | ** | 0.152 | 0.348 | ** | 0.291 | ** | |||
| P value | 0.007 | 0.005 | 0.397 | 0.521 | 0.402 | 0.005 | 0.117 | 0.000 | 0.002 | |||||||||
| Y axis/FH (°) | Coefficient | 0.188 | -0.139 | 0.003 | -0.141 | -0.115 | 0.083 | -0.030 | 0.178 | -0.079 | ||||||||
| P value | 0.051 | 0.153 | 0.978 | 0.147 | 0.236 | 0.395 | 0.757 | 0.065 | 0.415 | |||||||||
| Overjet (mm) | Coefficient | -0.053 | -0.199 | * | 0.140 | 0.037 | -0.057 | -0.050 | -0.165 | 0.096 | 0.033 | |||||||
| P value | 0.583 | 0.039 | 0.150 | 0.701 | 0.560 | 0.608 | 0.087 | 0.322 | 0.736 | |||||||||
| Overbite (mm) | Coefficient | 0.063 | -0.034 | 0.117 | 0.120 | -0.154 | -0.076 | -0.206 | -0.064 | -0.150 | ||||||||
| P value | 0.519 | 0.729 | 0.229 | 0.215 | 0.112 | 0.436 | 0.033 | 0.510 | 0.120 | |||||||||
| OPT-SN (°) | Coefficient | 0.199 | * | -0.239 | * | 0.417 | ** | 0.038 | 0.302 | ** | 0.353 | ** | 0.404 | 0.201 | * | 0.326 | ** | |
| P value | 0.039 | 0.013 | 0.000 | 0.693 | 0.001 | 0.000 | 0.000 | 0.037 | 0.001 | |||||||||
| c2sp-c4ip-SN (°) | Coefficient | 0.213 | * | -0.209 | * | 0.376 | ** | 0.013 | 0.253 | ** | 0.336 | ** | 0.360 | 0.202 | * | 0.278 | ** | |
| P value | 0.027 | 0.030 | 0.000 | 0.892 | 0.008 | 0.000 | 0.000 | 0.036 | 0.004 | |||||||||
| Body length (mm) | Coefficient | -0.079 | 0.073 | 0.206 | * | 0.318 | ** | 0.280 | ** | 0.136 | 0.212 | 0.210 | * | 0.235 | * | |||
| P value | 0.414 | 0.451 | 0.033 | 0.001 | 0.003 | 0.159 | 0.028 | 0.029 | 0.014 |
| Days with Instrument | Clear Nights (N = 2,379) | MEA < 0° (N = 7,952) | All Nights (N = 13,790) |
| SQM1 | 1.005 ± 0.012 | 1.02 ± 0.04 | 1.01 ± 0.05 |
| SQM2 | 1.168 ± 0.017 | 1.14 ± 0.06 | 1.14 ± 0.07 |
| SQM3 | 1.000 ± 0.010 | 1.02 ± 0.04 | 1.01 ± 0.05 |
| SQM4 | 1.079 ± 0.010 | 1.07 ± 0.04 | 1.09 ± 0.06 |
| SQM5 | 1.027 ± 0.008 | 1.04 ± 0.02 | 1.05 ± 0.02 |
| SQM6 | 1.014 ± 0.006 | 1.03 ± 0.03 | 1.03 ± 0.03 |
| SQM7 | 0.880 ± 0.004 | 0.89 ± 0.01 | 0.91 ± 0.04 |
| SQM8 | 0.835 ± 0.006 | 0.86 ± 0.03 | 0.87 ± 0.04 |
| SQM9 | 0.908 ± 0.007 | 0.92 ± 0.02 | 0.92 ± 0.03 |
| NHANES, FPED Dataset 1 | USDA-ERS Dataset 2 |
| Total meat | Total meat, fish, eggs and nuts |
| Meat Cured Meat Poultry Organ meat Seafood from high omega-3 sources Seafood from low omega-3 sources | Total red meat Total Poultry Total fresh and frozen, canned, and cured fish and shellfish Eggs Peanuts Total tree nuts Coconut |
| Meat | Total red meat |
| Beef Veal Pork Lamb Game meat | Beef Veal Pork Lamb |
| Cured Meat | Category not included in dataset |
| Cured or luncheon meat made from beef, pork or poultry | |
| Poultry | Total poultry |
| Chicken Turkey Cornish hens Game birds | Chicken Turkey |
| * Two categories of Seafood | Total fresh and frozen, canned, and cured fish and Shellfish |
| Seafood from high omega-3 sourcesFinfishShellfishOther seafood Seafood from low omega-3 sourcesFinfishShellfishOther seafood | Total fresh and frozen fish and shellfishFresh and frozen fishFresh and frozen shellfish Total canned fish and shellfishCanned salmonCanned sardinesCanned tunaCanned shellfishOther canned fish Cured Fish |
| Other Categories in the dataset | Other Categories in the dataset |
| Organ Meat | Eggs |
| Organ meat from beef, veal, pork, lamb, game or poultry | Peanuts |
| Total Tree nutsAlmondsHazelnutsPecansWalnutsMacadamia nutsPistachio nutsOther tree nuts | |
| Coconut |
| Controls | Snorers | OSAH, mild | OSAH, severe | |
| Subjects (n) | 7 | 14 | 15 | 19 |
| Age (yrs) | 40 ± 8 | 49 ± 13 | 49 ± 10 | 53 ± 8 * |
| BMI (kg/m2) | 24 ± 3 | 27 ± 4 | 26 ± 3 | 29 ± 3 * |
| FEV1(% pred) | 98 ± 10 | 96 ± 31 | 103 ± 25 | 95 ± 26 |
| FVC (% pred) | 97 ± 15 | 96 ± 24 | 100 ± 24 | 93 ± 20 |
| FEV1/FVC (%) | 88 ± 12 | 79 ± 11 | 81 ± 11 | 86 ± 1 |
| AHI | 2 ± 0.4 | 4 ± 2 | 18 ± 10 | 59 ± 16 |
| Departments | Internal Medicine (n = 19) | Urology (n = 19) | Total (n = 38) |
| Number of beds, mean (SD) | 67 (22) | 18 (9) | 43 (30) |
| % Female physicians, mean (SD) | 33 (13) | 17 (15) | 25 (16) |
| Teaching hospital department* | 17 (89) | 12 (63) | 29 (76) |
| Residents working at the department | 19 (100) | 16 (84) | 35 (92) |
| Microbiological laboratory in the same building as the department | 12 (63) | 8 (42) | 20 (53) |
| Reporting of a positive urine culture by phone (incidentally or structurally) | 0 | 2 (11) | 2 (5) |
| Structurala education on antibiotics for residents | 14 (74) | 4 (21) | 18 (47) |
| Structural education on antibiotics for senior staff members | 4 (21) | 0 | 4 (11) |
| Audit and feedback (incidentallyb or structurally) | |||
| On antibiotic prescriptionsc, at the department level | 2 (11) | 8 (42) | 10 (26) |
| On antibiotic prescriptionsc, at the individual level | 0 | 2 (11) | 2 (5) |
| On antibiotic resistance rates of the hospital | 9 (47) | 12 (63) | 21 (55) |
| Individual advice (of microbiologist/ pharmacist/ infectious diseases (ID) physician), incidentally or structurally, regarding streamlining therapy on the basis of blood or urine culture result | 16 (84) | 16 (84) | 32 (84) |
| Microbiologist and/or ID physician structurally present at ward rounds discussing antibiotic therapy | 6 (32) | 0 | 6 (16) |
| Quality improvement project concerning antibiotic prescribing in past 3 years | 8 (42) | 7 (37) | 15 (40) |
| Changes in antibiotic procedures or policies in past 3 yearsd | 13 (68) | 14 (74) | 27 (71) |
| Library ID | No. of Reads after Trimming | No. of Exogenous Reads | 3 No. of Putative Viral Contigs Detected in an Overall Screening | 4 No. of Viral Contigs Detected in an Individual Screening | ||
| ≤200 nt | Between 201 to 999 nt | ≥1000 nt | ||||
| 1 C1-960 | 37,811,400 | 3,826,317 | 40,187 | 76 | 41 | 7 |
| 1 C1-961 | 37,380,448 | 3,613,441 | 29,483 | 74 | 37 | 9 |
| 1 C1-962 | 36,452,005 | 3,528,784 | 30,834 | 72 | 32 | 6 |
| 1 C1-963 | 29,942,484 | 3,027,793 | 38,028 | 54 | 25 | 2 |
| 1 C4-964 | 35,511,705 | 3,741,954 | 33,719 | 10 | 4 | 4 |
| 1 C4-965 | 35,386,080 | 3,617,222 | 39,012 | 24 | 13 | 0 |
| 2 SN453 | 8,091,654 | 756,302 | 776 | 323 | 19 | 0 |
| 2 SN456 | 8,949,837 | 1,117,451 | 395 | 263 | 5 | 0 |
| 2 SN459 | 9,899,316 | 1,065,849 | 571 | 334 | 6 | 0 |
| 2 SN462 | 6,233,982 | 836,217 | 267 | 198 | 5 | 0 |
| 2 SN464 | 9,042,291 | 782,698 | 821 | 178 | 29 | 0 |
| 2 SN468 | 8,843,660 | 897,286 | 626 | 384 | 11 | 0 |
| 2 SN470 | 6,866,756 | 1,041,001 | 410 | 329 | 4 | 0 |
| 2 SN473 | 11,892,105 | 1,597,924 | 533 | 311 | 41 | 0 |
| 2 SN476 | 9,076,165 | 917,605 | 631 | 408 | 14 | 0 |
| 2 SN479 | 11,649,840 | 1,232,264 | 733 | 163 | 24 | 0 |
| 2 SN483 | 8,765,391 | 949,445 | 471 | 326 | 13 | 0 |
| 2 SN486 | 11,001,152 | 1,127,439 | 555 | 242 | 13 | 0 |
| 2 SN488 | 14,231,970 | 1,446,481 | 783 | 507 | 20 | 0 |
| Total | 337,028,241 | 35,123,473 | 218,835 | 4276 | 356 | 28 |
| miRNA Name | Consensus Sequence | Fold Change | |
| Up Regulated miRNAs | 3 h | 24 h | |
| miR-129-5p | CUUUUUGCGGUCUGGGCUUGC | 19.8 | 9.5 |
| miR-200a-3p | UAACACUGUCUGGUAACGAUGU | 15.9 | 8.8 |
| miR-297 | AUGUAUGUGUGCAUGUGCAUG | 15.6 | 18.6 |
| miR-200b-3p | UAAUACUGCCUGGUAAUGAUGA | 14.7 | 10.2 |
| miR-595 | GAAGUGUGCCGUGGUGUGUCU | 10.4 | 9.3 |
| miR-574-5p | UGAGUGUGUGUGUGUGAGUGUGU | 7.2 | 8.6 |
| miR-647 | GUGGCUGCACUCACUUCCUUC | 4.1 | 5.0 |
| miR-615-3p | UCCGAGCCUGGGUCUCCCUCUU | 3.9 | 4.3 |
| miR-1224-5p | GUGAGGACUCGGGAGGUGG | 3.5 | 4.2 |
| miR-1238-3p | CUUCCUCGUCUGUCUGCCCC | 2.2 | 2.2 |
| miR-196a-5p | UAGGUAGUUUCAUGUUGUUGGG | 3.1 | - |
| miR-616-3p | AGUCAUUGGAGGGUUUGAGCAG | 3.9 | - |
| miR-760 | CGGCUCUGGGUCUGUGGGGA | 3.7 | - |
| miR-1275 | GUGGGGGAGAGGCUGUC | 2.1 | - |
| miR-146a-5p | UGAGAACUGAAUUCCAUGGGUU | - | 13.7 |
| miR-631 | AGACCUGGCCCAGACCUCAGC | - | 12.6 |
| miR-661 | UGCCUGGGUCUCUGGCCUGCGCGU | - | 7.7 |
| miR-766-3p | ACUCCAGCCCCACAGCCUCAGC | - | 4.6 |
| miR-1273a | GGGCGACAAAGCAAGACUCUUUCUU | - | 2.8 |
| miR-1202 | GUGCCAGCUGCAGUGGGGGAG | - | 2.7 |
| miR-943 | CUGACUGUUGCCGUCCUCCAG | - | 2.7 |
| miR-1250-5p | ACGGUGCUGGAUGUGGCCUUU | - | 2.6 |
| miR-1229-3p | CUCUCACCACUGCCCUCCCACAG | - | 2.5 |
| Down Regulated miRNAs | |||
| miR-301b-3p | CAGUGCAAUGAUAUUGUCAAAGC | −3.3 | −2.8 |
| miR-548a-3p | CAAAACUGGCAAUUACUUUUGC | −3.1 | −3.1 |
| miR-377-3p | AUCACACAAAGGCAACUUUUGU | −2.1 | −3.2 |
| miR-602 | GACACGGGCGACAGCUGCGGCCC | −2.1 | - |
| miR-802 | CAGUAACAAAGAUUCAUCCUUGU | −2.2 | - |
| miR-376b-3p | AUCAUAGAGGAAAAUCCAUGUU | - | −2.9 |
| miR-216b-5p | AAAUCUCUGCAGGCAAAUGUGA | - | −2.4 |
| miR-216a-5p | UAAUCUCAGCUGGCAACUGUGA | - | −2.4 |
| miR-410-3p | AAUAUAACACAGAUGGCCUGU | - | −2.3 |
| miR-29b-3p | UAGCACCAUUUGAAAUCAGUGUU | - | −2.1 |
| Cohort and animal identifier | No. of SIV DNA copies per 106 cells | No. of SIV RNA copies per μg RNA | Brain MΦ-QVOA IUPM | |||
| Basal ganglia | Parietal cortex | Basal ganglia | Parietal cortex | Without wells (<50 copies/ml) | With wells (<50 copies/ml) | |
| A1 | ||||||
| PmA11 | <10 | <10 | <10 | <10 | 0.147 | 0.917 |
| PmA12 | <10 | <10 | <10 | <10 | 0.036 | 0.230 |
| PmA13 | <10 | 64 | <10 | <10 | 0.036 | 0.110 |
| A2 | ||||||
| PmA21 | <10 | <10 | <10 | <10 | 1.445 | 1.445 |
| PmA22 | <10 | <10 | <10 | <10 | 0.177 | 1.309 |
| PmA23 | <10 | <10 | <10 | <10 | 7.362 | 7.362 |
| PmA24 | <10 | <10 | <10 | <10 | <0.021 | <0.021 |
| PmA25 | <10 | <10 | <10 | <10 | 0.613 | 0.613 |
| Sample | Number of seeds per score category (n) | ||||
| No germination and seed coat infection (Score = n × 0) | Seed coat and radical tip infection (Score = n × 1) | Either seed coat or radical tip infection (Score = n × 2) | Healthy seed germination (Score = n × 3) | Total score | |
| Control (+) | None | None | None | 6 | 18 |
| Control (-) | 5 | 1 | None | None | 1 |
| 10 mg l-1 | 2 | 3 | 1 | None | 5 |
| 25 mg l-1 | 1 | 2 | 2 | 1 | 9 |
| 50 mg l-1 | None | None | 2 | 4 | 16 |
| 100 mg l-1 | None | None | 1 | 5 | 17 |
| 200 mg l-1 | None | None | None | 6 | 18 |
| Learner | General practice | Hospital | Other | All |
| Doctors | 43 (49%) | 3 (3%) | - | 46 (52%) |
| Nurses | 16 (18%) | 20 (23%) | 4 (5%) | 40 (45%) |
| Students | - | - | 2 (2%) | 2 (2%) |
| AMP family | D. melanogaster gene | HMM state | Induction | Average Coverage (Naïve) | Average Coverage (Infected) |
| Attacins | AttA | strongly induced | 21.59 | 1.33 | 38.37 |
| AttB | strongly induced | 23.23 | 2.26 | 70.20 | |
| AttC | strongly induced | 35.90 | 0.96 | 46.29 | |
| AttD | ND1 | ||||
| Cecropins | CecA1 | strongly induced | 27.33 | 1.18 | 43.20 |
| CecA2 | strongly induced | 43.80 | 0.68 | 39.59 | |
| CecB | ND | ||||
| CecC | ND | ||||
| Defensins | Def | moderately induced | 3.35 | 7.68 | 34.40 |
| Diptericins | Dpt | strongly induced | 80.26 | 2.99 | 320.51 |
| DptB | strongly induced | Inf | 0.00 | 30.37 | |
| Metchnikowin | Mtk | strongly induced | 23.47 | 7.94 | 249.23 |
| Drosocin | Dro | strongly induced | 17.07 | 28.03 | 640.13 |
| Drosomycins | Drs | strongly induced | 6.99 | 19.28 | 180.39 |
| Dro2 | ND | ||||
| Dro3 | ND | ||||
| Dro4 | not regulated | 0.95 | 12.74 | 10.00 | |
| Dro5 | ND | ||||
| Dro6 | ND | ||||
| Drs-l | ND |
| Home safety only (n = 15) | Home safety + Home exercise (n = 15) | |||
| OT | OT | Peer mentor | ||
| Mean (SD) | Mean (SD) | Mean (SD) | ||
| Telephone calls | Number | 3.7 (1.5) | 4.7 (2.2) | 3.1 (3.3) |
| Min | 13.9 (6.7) | 21.5 (11.6) | 29.5 (25.4) | |
| Cost (£) | 19.1 (9.2) | 29.5 (16.0) | 13.3 (11.4) | |
| Home visits | Number | 2.3 (0.5) | 3.1 (0.6) | 2.5 (0.5) |
| Min | 110.0 (38.5) | 210.7 (82.3) | 175.9 (55.6) | |
| Cost (£) | 150.7 (52.7) | 288.6 (112.7) | 135.4 (42.9) | |
| Patient-related non-face-to-face | Travel (min) | 21.7 (7.8) | 23.9 (7.3) | 144.1 (52.9) |
| Notes etc. (min) | 71.3 (34.9) | 115.6 (29.2) | Not applicable | |
| Cost (£) | 65.1 (23.5) | 97.7 (21.5) | 64.8 (23.8) | |
| Travel costs | Cost (£) | 13.82 (6.7) | 23.5 (13.4) | 20.9 (10.8) |
| Total average costs (£) | Mean £248.71 | Mean £674.32 |
| Variable | Age group | |||||||
| Birth cohort | 16-23 | 24-31 | 32-39 | 40-47 | 48-55 | 56-63 | 64-71 | ΔBMI cohort |
| 1910-17 | - | - | - | - | - | - | 25.2 | - |
| 1918-25 | - | - | - | - | - | 25.4 | 25.6 | ns |
| 1926-33 | - | - | - | - | 25.1 | 25.9 | 26.0 | 0.042* |
| 1934-41 | - | - | - | 24.7 | 25.4 | 25.9 | 26.3 | 0.067* |
| 1942-49 | - | - | 24.0 | 25.1 | 25.9 | 26.3 | - | 0.095* |
| 1950-57 | - | 23.2 | 24.5 | 25.6 | 26.4 | - | - | 0.13* |
| 1958-65 | 22.0 | 23.6 | 25.1 | 26.4 | - | - | - | 0.17* |
| 1966-73 | 22.2 | 24.0 | 25.6 | - | - | - | - | 0.21* |
| 1974-81 | 22.6 | 24.4 | - | - | - | - | - | 0.21* |
| 1982-89 | 22.7 | - | - | - | - | - | - | - |
| ΔBMI age group | 0.032* | 0.049* | 0.068* | 0.071* | 0.056* | 0.033* | 0.046* | |
| 1980/81 | 1988/89 | 1996/97 | 2004/05 |
| Artificial data | Biological data | |||
| Scenario characteristics | 1st design | 2nd design | 1st design | 2nd design |
| Total cost / expectation | 97443.4 | 151629.7 | 210917.0 | 535524.0 |
| Total cost / expectation of gains | 60.0 | 358.4 | 53448.0 | 77040.5 |
| Total cost / expectation of losses | 38024.0 | 56660.0 | 98376.0 | 187600.5 |
| Total cost / expectation of duplications | 26796.0 | 34324.6 | 38286.0 | 44639.6 |
| Total cost / expectation of transfers | 32563.4 | 60168.3 | 17887.0 | 223854.8 |
| Total cost / expectation of the gain_big events | 0.0 | 118.4 | 2920.0 | 2388.6 |
| Running time | <1m | 2m | 15m | 41m |
| Characteristics | Number | Percent |
| Age group (years) | ||
| 14–24 | 44 | 18.0 |
| 25–34 | 54 | 22.1 |
| 35–44 | 124 | 50.8 |
| 45 and above | 22 | 9.0 |
| Total | 244 | 100 |
| Highest educational level | ||
| Primary | 14 | 5.7 |
| Junior High School | 64 | 26.2 |
| Senior High School | 54 | 22.1 |
| Tertiary | 96 | 39.3 |
| Post-Graduate | 14 | 5.7 |
| Uneducated | 2 | 0.8 |
| Total | 244 | 100 |
| Tribe | ||
| Akan | 112 | 45.9 |
| Ewe | 58 | 23.8 |
| Ga | 44 | 18.0 |
| Northern | 30 | 12.3 |
| Total | 244 | 100 |
| Parity | ||
| Zero | 156 | 63.9 |
| 1 and above | 88 | 36.1 |
| Total | 244 | 100 |
| Body Mass Index | ||
| <25 | 76 | 31.1 |
| 25–29.9 | 78 | 32.0 |
| 30 and above | 90 | 36.9 |
| Total | 244 | 100 |
| Menstrual flow pattern (heavy flow) | ||
| Yes | 102 | 41.8 |
| No | 142 | 58.2 |
| Total | 244 | 100 |
| Type of menstrual cycle (irregular) | ||
| Yes | 164 | 67.2 |
| No | 80 | 32.8 |
| Total | 244 | 100 |
| Maturation - CD27/CD45RA | Differentiation - CD27/CD28 | |||||||
| % KLRG1+ TNa | % KLRG1+ Memorya | % KLRG1+CD28+a | % KLRG1+CD28− | |||||
| Estimate | 95 % CI | Estimate | 95 % CI | Estimate | 95 % CI | Estimate | 95 % CI | |
| Age (per year extra) | −0.84 | −4.32 – 2.77 | 1.12 | −2.19 – 4.53 | 1.54 | −1.73 – 4.93 | 0.05 | −0.81 – 0.92 |
| −0.16 | −4.22 – 4.07 | 0.32 | −3.53 – 4.32 | 0.49 | −3.16 – 4.28 | −0.24 | −1.24 – 0.76 | |
| IL-6 (per extra pg/mL) | −0.24 | −17.69 – 20.92 | −8.07 | −22.94 – 9.68 | 3.27 | −13.80 – 23.71 | −0.84 | −5.53 – 3.85 |
| −2.98 | −21.71 – 20.23 | −7.08 | −23.90 – 13.47 | 9.10 | −9.84 – 32.03 | 0.11 | −5.16 – 5.38 | |
| suPAR (per extra ng/mL) | −13.66 | −40.90 – 26.14 | −21.72 | −44.54 – 10.50 | −18.83 | −42.12 – 13.82 | −5.62 | −14.38 – 3.14 |
| −15.63 | −43.65 – 26.30 | −20.25 | −45.09 – 15.84 | −17.17 | −41.55 – 17.38 | −4.90 | −14.36 – 4.56 | |
| HOMA-IR (per extra 1-unit) | 16.39 | −17.36 – 63.93 | 18.91 | −13.42 – 63.30 | 27.27 | −6.34 – 72.93 | 6.02 | −1.96 – 14.01 |
| 35.74 | −9.23 – 103.01 | 22.91 | −16.71 – 81.38 | 27.45 | −10.90 – 82.29 | 6.98 | −2.65 – 16.16 | |
| Metabolic syndrome (vs. no metabolic syndrome) | 23.25 | −34.76 – 132.83 | 46.43 | −17.97 – 161.42 | 70.88 | −1.41 – 196.17 | 14.31* | 0.10 – 28.53 |
| 48.94 | −29.02 – 212.55 | 41.31 | −29.88 – 184.78 | 61.77 | −15.73 – 210.55 | 17.59* | 0.73 – 34.45 | |
| VAT (per extra cm2) | −0.10 | −0.55 – 0.35 | 0.28 | −0.12 – 0.70 | 0.45* | 0.06 – 0.84 | 0.10 | −0.00 – 0.20 |
| 0.14 | −0.54 – 0.82 | 0.28 | −0.34 – 0.90 | 0.62* | 0.07 – 1.16 | 0.16* | 0.01 – 0.31 | |
| lLMI (per extra kg/m2) | 66.47* | 10.22 – 151.43 | 36.88 | −5.52 – 98.30 | 22.54 | −20.06 – 87.86 | 7.92 | −2.88 – 18.71 |
| 59.19 | −0.55 – 154.80 | 45.52 | −1.35 – 114.65 | 33.83 | −13.85 – 107.92 | 10.09 | −1.22 – 21.39 |
| Included patients | Time ABI measurement1(min) Mean (SD) | |||
| Experienced | Non-experienced | |||
| GP2 | PA3 | GP2 | PA3 | |
| Patient 1 | 13.5 (5.9) (n = 47) | 19.7 (9.5) (n = 78) | 18.0 (8.1) (n = 73) | 19.1 (8.1) (n = 206) |
| Patient 2 | 14.2 (5.9) (n = 47) | 18.8 (8.7) (n = 76) | 16.7 (6.9) (n = 71) | 19.0 (7.3) (n = 201) |
| Patient 3 | 13.1 (5.4) (n = 43) | 19.6 (10.4) (n = 78) | 17.1 (7.5) (n = 71) | 18.8 (7.3) (n = 205) |
| Patient 4 | 12.4 (4.7) (n = 45) | 18.4 (7.8) (n = 77) | 16.6 (7.5) (n = 70) | 18.1 (7.1) (n = 205) |
| Patient 5 | 12.6 (5.8) (n = 47) | 18.4 (6.9) (n = 76) | 16.4 (9.6) (n = 71) | 18.1 (6.9) (n = 202) |
| Patient 6 – 10 | 12.8 (5.7) (n = 228) | 17.8 (7.4) (n = 367) | 16.0 (7.8) (n = 354) | 18.0 (7.5) (n = 993) |
| Patient 11 – 15 | 12.2 (5.2) (n = 211) | 17.7 (7.3) (n = 355) | 15.3 (7.5) (n = 341) | 17.5 (7.2) (n = 947) |
| Patient ≥ 16 | 12.5 (5.4) (n = 200) | 18.0 (7.5) (n = 347) | 15.5 (7.2) (n = 335) | 17.4 (6.9) (n = 936) |
| Instruments | Domains | Mean ± Standard Deviation |
| JSS | Payment–promotion | 3.38 ± 0.65 |
| Management–interpersonal relationship | 4.33 ± 0.66 | |
| Organization–communication | 4.41 ± 0.70 | |
| Total score | 3.92 ± 0.55 | |
| TAS-20 | Difficulty describing feelings | 12.97 ± 5.48 |
| Difficulty identifying feelings | 13.90 ± 5.18 | |
| Externally oriented thinking | 18.01 ± 4.27 | |
| Total score | 44.89 ± 11.56 |
| Variable | Odds ratio | 95 % confidence interval | p value |
| Moderate to high side effects (ref: no/low side effects) | 4.84 | 1.07–1.85 | 0.04 |
| Six County Study Area | Entire State of Michigan | |
| Current smoking | 25.1% | 25.1% |
| Heavy drinking (60+ drinks/mo) | 2.6% | 3.7% |
| Binge drinking (5+ drinks on 1+ occasions in past month) | 7.6% | 11.7% |
| Cholesterol never checked | 16.1% | 19.3% |
| Ever told cholesterol high (among tested) | 37.4% | 33.0% |
| Ever told high blood pressure | 33.6% | 31.4% |
| Overweight (BMI >= 27.8 for men, >= 27.3 for women) | 34.6% | 33.4% |
| Never had mammogram (among women 40+) | 19.0% | 22.2% |
| Stratification criteria | |
| Variable | Criteria |
| Student mobility | |
| IHE-Yes | Any respondent declaring at least one study-related trans-border movement |
| IHE-No | Any respondent declaring no study-related trans-border movement |
| IHE-North | Destination countries of international health electives (IHE) are pre-dominantly industrialised countries.(Eligible combinations: n, nn, snn, nns, nsn, nnn)* |
| IHE-South | Destination countries of international health electives (IHE) are pre-dominantly developing countries.(Eligible combinations: s, ss, sn, ns, ssn, sns, nss, sss)* |
| Exposure to educational interventions | |
| GH-yes | Any respondent declaring a participation in global health courses. |
| GH-no | Any respondent declaring no participation in global health courses. |
| TM-yes | Any respondent declaring a participation in courses of tropical medicine. |
| TM-no | Any respondent declaring no participation in courses of tropical medicine. |
| NP | Gestational day 20 | Gestational day 50 | |||||||
| Endometrium | Chorioallantoic membrane | Endometrium | Chorioallantoic membrane | ||||||
| H | A | H | A | H | A | H | A | ||
| PCR samples (No.) | 5 | 30 | 19 | 26 | 20 | 29 | 6 | 27 | 4 |
| WB samples (No.) | - | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| IF samples (No. of sections from different animals) | - | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Antigens | Patient (n) | Control (n) | Adjusted r2 | pa |
| IL1α | ||||
| Male | 1.15±0.42 (124) | 1.21±0.39 (131) | -0.002 | 0.228 |
| Female | 1.20±0.43 (76) | 1.32±0.39 (89) | 0.009 | 0.083 |
| Combined | 1.17±0.42 (200) | 1.26±0.39 (220) | 0.012 | 0.04 |
| IL1β | ||||
| Male | 0.70±0.28 (124) | 0.77±0.30 (131) | 0.019 | 0.04 |
| Female | 0.78±0.31 (76) | 0.80±0.33 (89) | -0.01 | 0.788 |
| Combined | 0.73±0.29 (200) | 0.78±0.31 (220) | 0.011 | 0.07 |
| IL6 | ||||
| Male | 1.13±0.21 (124) | 1.18±0.19 (131) | 0.01 | 0.038 |
| Female | 1.11±0.23 (76) | 1.24±0.22 (89) | 0.065 | 0.0008 |
| Combined | 1.12±0.22 (200) | 1.20±0.21 (220) | 0.034 | 0.0001 |
| IL8 | ||||
| Male | 0.97±0.35 (124) | 1.02±0.29 (131) | 0.003 | 0.134 |
| Female | 0.94±0.33 (76) | 1.12±0.35 (89) | 0.056 | 0.003 |
| Combined | 0.96±0.34 (200) | 1.06±0.32 (220) | 0.021 | 0.002 |
| TNF-α | ||||
| Male | 0.77±0.40 (124) | 0.95±0.60 (131) | 0.024 | 0.005 |
| Female | 0.85±0.48 (76) | 0.95±0.45 (89) | -0.002 | 0.226 |
| Combined | 0.80±0.43 (200) | 0.95±0.54 (220) | 0.017 | 0.003 |
| SOA | Compatibility group | Incompatibility group | ||
| d'id | d'loc | d'id | d'loc | |
| EXP. 1 | ||||
| 2.27* | 0.12* | 1.73* | −0.25* | |
| EXP. 2 | ||||
| 60 | 1.74* | 0.21* | 1.81* | −0.04 |
| 120 | 1.97* | 0.11 | 1.93* | 0.00 |
| 240 | 2.12* | 0.83 | 2.06* | −0.07 |
| 360 | 2.20* | 0.13* | 2.24* | −0.04 |
| 480 | 2.36* | 0.06* | 2.30* | 0.04 |
| 960 | 2.26* | 0.03 | 2.27* | 0.00 |
| 1440 | 2.20* | 0.11* | 2.27* | −0.03 |
| EXP. 3 (SAT) | ||||
| 60 | 0.21* | 1.04* | 0.13 | 0.15 |
| 120 | 0.19 | 0.72* | 0.50* | −0.18 |
| 240 | 0.86* | 0.39* | 0.96* | −0.16 |
| 360 | 1.71* | 0.06 | 1.82* | −0.19 |
| 480 | 2.33* | 0.10 | 2.29* | −0.04 |
| 960 | 2.88* | −0.01 | 2.72* | −0.02 |
| 1440 | 2.90* | 0.03 | 2.88* | 0.00 |
| EXP. 4 (SAT) | ||||
| 60 | 0.02 | 1.14* | 0.06 | 0.22* |
| 120 | 0.02 | 1.21* | 0.26* | −0.03 |
| 240 | 0.63* | 0.62* | 0.65* | −0.04 |
| 360 | 1.60* | 0.41* | 1.61* | −0.14 |
| 480 | 2.17* | 0.16* | 1.84* | −0.06 |
| 960 | 2.22* | 0.26* | 2.67* | −0.05 |
| 1440 | 2.43* | 0.14* | 2.57* | −0.07* |
| Scenario | Parameter | Settings |
| A1–A5 | Signal to noise (s2n) | 0.01, 0.05, 0.1, 0.15, and 0.20 |
| B1–B5 | Mean of significant variables in the case | 10, 15, 20, 25, and 30 |
| C1–C5 | Dispersion parameter of significant variables in the case | 0.125, 0.5, 1, 2, and 8 |
| Sample size (+/−) | 40 (20/20) | |
| Number of variables | 500 | |
| Mean of significant variables in the control | 5 | |
| Mean of insignificant variables | 5 | |
| Dispersion parameter of significant variables in the control | 1 | |
| Dispersion parameter of insignificant variables | 1 |
| Variables | p value | OR | 95% CI for OR | |
| Lower | Upper | |||
| Variables associated with diarrhea in children aged more than 6 months | ||||
| Starting of breastfeeding | ||||
| After an hour of birth | 0.045 | 1.479 | 1.009 | 2.166 |
| Within hour (reference category) | ||||
| Nutritional status of children | 0.029 | |||
| Moderate malnutrition | 0.758 | 0.909 | 0.497 | 1.666 |
| Overweight | 0.209 | 0.695 | 0.394 | 1.227 |
| Severe malnutrition | 0.018 | 1.853 | 1.111 | 3.089 |
| Normal (reference category) | ||||
| Duration of breastfeeding | ||||
| Up to 2 years | 0.026 | 2.506 | 1.114 | 5.638 |
| 2 years or more (reference category) | ||||
| Variables associated with cough and cold in children aged more than 6 months | ||||
| Hand washing before each feed | ||||
| Always (reference category) | ||||
| Sometimes | 0.039 | 0.620 | 0.394 | 0.977 |
| Nutritional status of child | 0.115 | |||
| Moderate malnutrition | 0.590 | 1.221 | 0.590 | 2.527 |
| Overweight | 0.636 | 1.182 | 0.591 | 2.363 |
| Severe malnutrition | 0.015 | 2.135 | 1.159 | 3.933 |
| Normal (reference category) | ||||
| Washing utensils after each feed | ||||
| After each feed (reference category) | ||||
| Sometimes | 0.001 | 0.457 | 0.282 | 0.740 |
| Occupation | ||||
| Employed | 0.022 | 0.546 | 0.325 | 0.916 |
| Housewife (reference category) |
| Culture medium/additives | Manufacturer | Order no. | Concentration |
| Dulbecco’s modified Eagle medium (DMEM) with l-glutamine, plus 4.5 g glucose, without NaHCO3, without Natriumpyruvate | Life Technology, Carlsbad, USA | 11966-025 | |
| Penicillin/streptomycin | Life Technology, Carlsbad, USA | 15640-055 | 100 IU penicillin/100 μg streptomycin/ml |
| Ca2+/Mg2+ free Hanks’ balanced salt solution (HBSS)–buffer | Life Technology, Carlsbad, USA | 14170-070 | |
| Fetal calf serum (FCS) | Life Technology, Carlsbad, USA | 10270-098 | 10% |
| l-Glutamate | Life Technology, Carlsbad, USA | 25030-024 | 1% |
| Ethylenediaminetetraacetic acid (EDTA) solution | Sigma Aldrich, St. Louis, USA | E7889 | 0.5 M |
| l-Ascorbic acid 2-phosphate | Sigma Aldrich, St. Louis, USA | A-8960 | 1 mmol/l ASC (affinity isolated antibody) |
| Dexamethasone | Serva Bioproducts, Heidelberg, Germany | 18660 | 100 nmol/l |
| Variable (units) | Low-salt sweat | Typical Sweat | Salty sweat | P value |
| <30 mmol·L−1 [sweat Na+] | 30–60 mmol·L−1 [sweat Na+] | >60 mmol·L−1 [sweat Na+] | ||
| Number/Frequency | 42/27 % | 84/54 % | 31/20 % | - |
| Men/women | 37/5 | 73/11 | 31/0 | 0.11 |
| Sweat Na+ concentration (mmol·l−1) | 21.4 ± 6.4* | 43.2 ± 8.8 | 71.0 ± 9.0*† | <0.01 |
| Sweat Cl− concentration (mmol·l−1) | 16.4 ± 4.3* | 31.9 ± 9.9 | 54.4 ± 10.7*† | <0.01 |
| Sweat K+ concentration (mmol·l−1) | 5.9 ± 0.9 | 5.9 ± 0.9 | 6.2 ± 0.6 | 0.26 |
| Sweat osmolality (mOsm·kg H2O−1) | 100.8 ± 38.9* | 150.4 ± 42.1 | 206.3 ± 40.3*† | <0.01 |
| Sweat rate (L·h−1) | 0.9 ± 0.2 | 0.9 ± 0.3 | 1.0 ± 0.2 | 0.76 |
| Sweat NaCl loss (g L−1) | 1.1 ± 0.3* | 2.1 ± 0.5 | 3.5 ± 0.6*† | <0.01 |
| Fluid intake (L·h−1) | 0.32 ± 0.18 | 0.31 ± 0.17 | 0.33 ± 0.15 | 0.85 |
| Na+ intake (mmol) | 12.3 ± 8.1 | 11.9 ± 9.9 | 14.6 ± 16.6 | 0.81 |
| Cl− intake (mmol) | 21.3 ± 13.0 | 20.8 ± 15.0 | 24.0 ± 25.0 | 0.72 |
| K+ intake (mmol) | 5.1 ± 6.0 | 4.7 ± 7.9 | 6.0 ± 5.6 | 0.85 |
| Running pace (m·s−1) | 3.0 ± 0.4 | 3.1 ± 0.5 | 3.2 ± 0.5 | 0.18 |
| Average training distance·week−1 (km) | 65.1 ± 32.0 | 60.5 ± 26.7 | 64.2 ± 24.1 | 0.65 |
| Explanatory variable | Unadjusted OR (95% CI) | Adjusted OR (95% CI) | p-value |
| Age | |||
| 18-24 | 1.0 | 1.00 | |
| 25-30 | 0.50 (0.30 - 0.84)* | 0.89 (0.54 - 1.27) | 0.45 |
| 31-40 | 0.80 (0.39 - 1.62) | 1.02 (0.72 - 1.43) | 0.87 |
| > 40 | 1.05 (0.30 - 3.71) | 0.56 (0.30 - 1.03) | 0.07 |
| Sex | |||
| Male | 1 | 1.00 | |
| Female | 0.75 (0.46 - 1.23) | 0.71 (0.42 - 1.23) | 0.23 |
| Married | |||
| No | 1 | 1.00 | |
| Yes | 9.15 (4.82 - 17.38)* | 2.15 (1.44 - 3.06) | 0.04* |
| Education | |||
| Certificate | 8.47 (3.57 - 20.11)* | 1.45 (1.04 - 1.99) | 0.04* |
| Diploma | 4.99 (1.94 - 12.84)* | 2.06 (1.20 - 3.56) | 0.01* |
| Degree | 1 | 1 | |
| Religion | |||
| Muslim | 1 | 1.00 | |
| Christian | 0.65 (0.41 - 1.03) | 0.86 (0.54 - 1.37) | 0.54 |
| Others | 0.76 (0.34 - 1.66) | 0.84 (0.59 - 1.23) | 0.37 |
| Profession | |||
| Health extension workers | 2.67 (1.57 - 4.55)* | 2.49 (1.43 - 4.35) | 0.01* |
| Health assistants | 2.20 (0.80 - 6.10) | 0.86 (0.61 - 1.23) | 0.37 |
| Health Officers | 0.88 (0.23 - 3.31) | 1.68 (1.04 - 2.67) | 0.04* |
| Nurses | 1 | 1 | |
| Specific training on RH services | |||
| Yes | 1.00 | 1.00 | |
| No | 4.17 (2.60 - 6.71)* | 5.27 (1.51 - 5. 89) | 0.01* |
| Service time in years | |||
| < 10 | 1.00 | 1.00 | |
| 10-20 | 2.49 (1.38 - 4.47)* | 1.07 (1.10- 1.45) | 0.08 |
| > 20 | 3.35 (0.88 - 12.74) | 0.77 (0.50 - 1.10) | 0.28 |
| Involvement in RH provision | |||
| Yes | 1.00 | 1.00 | |
| No | 1.03 (0.72 - 2.36) | 1.09 (0.79 - 1.47) | 0.67 |
| Family planning utilization status | |||
| Yes | 1.00 | 1.00 | |
| No | 2.18 (1.38 - 3.44)* | 1.77 (1.05 - 2.77) | 0.03* |
| Fold enrichment (P value) | ↑ in Dupl5q cortex | ↓ in Dupl5q cortex | ↑ In idiopathic ASD cortex | ↓ In idiopathic ASD cortex | |
| All genes | ↑ 1500 in DPSC neurons | 1.41(le-6) | 1.06(0.5) | 1.25(0.05) | 1.14(0.3) |
| ↓ 1500 in DPSC neurons | 0.87(0.1) | 0.95(0.6) | 0.97(0.8) | 1.07(0–6) | |
| All genes except 15qll-13 genes | ↑ 1500 in DPSC neurons | 1.37(le-5) | 1.07(0.4) | 1.26(0.04) | 1.09(0.5) |
| ↓ 1500 in DPSC neurons | 0.88(0.1) | 0.95(0.6) | 0.96(0.8) | 1.08(0.5) |
| Cytological findings | Final histological diagnosis | ||||||||
| SQC | SCLC | ADC | ADC/SQC | LC/LNC | Carcinoid | Other | Benign | Total | |
| SQC | 47 | 0 | 9 | 1 | 6 | 0 | 0 | 0 | 63 |
| SCLC | 0 | 3 | 1 | 0 | 3 | 0 | 0 | 0 | 7 |
| ADC | 1 | 0 | 107 | 1 | 3 | 0 | 0 | 0 | 112 |
| LC/LNC | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 2 |
| Carcinoid | 0 | 0 | 3 | 0 | 1 | 13 | 0 | 0 | 17 |
| Other | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Susp. | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Benign | 6 | 0 | 14 | 1 | 5 | 2 | 0 | 84 | 112 |
| Total | 54 | 3 | 136 | 3 | 20 | 15 | 0 | 84 | 315 |
| Characteristic | CTRL | MUSIC | P |
| No. of subjects | 11 (4 Lethbridge) | 11 (3 Lethbridge) | |
| Sex (M/F) | 5/6 | 6/5 | .67 |
| Age (yrs) | 67.0 (8.1) | 64.1 (4.2) | .33 |
| Disease duration (yrs) | 4.5 (3.3) | 6.4 (4.2) | .23 |
| MMSE | 28.4 (1.8) | 29.3 (1.3) | .20 |
| Hoehn and Yahr | 2.1 (0.4) | 2.3 (0.4) | .43 |
| Baecke score | 10.2 (4.8) | 8.9 (3.8) | .48 |
| UPDRS (III) score | 20.4 (5.0) | 25.5 (9.3) | .13 |
| Males | Females | |
| Age (years) | 55 ± 10 | 55 ± 11 |
| Stature (cm) | 177.6 ± 5.5 | 167.4 ± 5.8 |
| Body mass (kg) | 85.92 ± 12.50 | 71.43 ± 13.56 |
| BMI | 27.54 ± 4.11 | 25.63 ± 5.50 |
| Parameter | n* (%) |
| Gender | 86 |
| Male | 42 (48.8) |
| Female | 44 (51.2) |
| Age | 86 |
| Range, 13.5–85.4 years | — |
| Mean, 55.0 years | — |
| Median, 57.2 years | — |
| Tumor size | 78 |
| Range, 2.0–8.5 cm | — |
| Mean, 4.9 cm | — |
| Median, 5.0 cm | — |
| Tumor location | 86 |
| Parasagittal-falcine | 26 (30.2) |
| Convexity | 35 (40.7) |
| Base | 24 (27.9) |
| Frontal/frontobasal | 16 (18.6) |
| Tumor site | 86 |
| Left | 37 |
| Right | 31 |
| Bilateral | 18 |
| Duration of signs/symptoms | 80 |
| Range, 0–36 months | — |
| Mean, 7.5 months | — |
| Median, 4.0 months | — |
| Presenting signs/symptoms | 83 |
| Headache | 23 (25.9) |
| Hemiparesis | 22 (36.6) |
| Seizures | 20 (24.7) |
| Behavior changes | 12 (14) |
| Cranial nerve palsy | 6 (11.1) |
| Behavior changes | 83 |
| Present | 30 (36.1) |
| Absent | 53 (73.9) |
| Edema | 58 |
| Absent | 10 (17.2) |
| Mild | 31 (53.4) |
| Severe | 17 (29.3) |
| Cleavability | 42 |
| Cleavable | 18 (42.9) |
| Noncleavable | 24 (57.1) |
| SNP | Chr | Position | Related gene | Minor allele | MAF in telomere GWAS [13] | MAF in our data | Average imputation R-square1 | Melanoma beta2 | Melanoma P value2 | Nevus count beta | Nevus count P value |
| rs10936599 | 3 | 169492101 | TERC | T | 0.252 | 0.241 | 0.993 | −0.079 | 0.0003 | −0.020 | 0.48 |
| rs2736100 | 5 | 1286516 | TERT | C | 0.486 | 0.506 | 0.988 | 0.078 | 0.02 | −0.043 | 0.08 |
| rs7675998 | 4 | 164007820 | NAF1 | A | 0.217 | 0.222 | 0.988 | −0.063 | 0.03 | −0.036 | 0.22 |
| rs9420907 | 10 | 105676465 | OBFC1 | C | 0.135 | 0.142 | 1.000 | 0.083 | 0.001 | 0.051 | 0.14 |
| rs8105767 | 19 | 22215441 | ZNF208 | G | 0.291 | 0.290 | 0.996 | 0.028 | 0.16 | 0.025 | 0.34 |
| rs755017 | 20 | 62421622 | RTEL1 | G | 0.131 | 0.123 | 0.952 | 0.026 | 0.35 | 0.004 | 0.92 |
| rs11125529 | 2 | 54475866 | ACYP2 | A | 0.142 | 0.134 | 0.999 | −0.004 | 0.86 | 0.020 | 0.56 |
| Antibody | Staining pattern | Clone | Antigen retrieval | Dilution | Source | Interobserver variability (kappa) |
| ER | Nuclear | SP1 | EDTA pH 9 | 1:80 | Immunologic | 0.959 |
| PR | Nuclear | PgR636 | EDTA pH 9 | 1:500 | Dako | 0.961 |
| MLH1 | Nuclear | G168-15 | EDTA pH 9 | 1:40 | BD | 0.894 |
| PMS2 | Nuclear | A16-4 | EDTA pH 9 | 1:100 | BD | 0.800 |
| MSH2 | Nuclear | GB12 | EDTA pH 9 | 1:20 | Calbiochem | 0.848 |
| MSH6 | Nuclear | EPR3945 | EDTA pH 9 | 1:1000 | Abcam | 0.763 |
| PTEN | Nuclear and cytoplasmic | 6H2.1 | EDTA pH 9 | 1:100 | Dako | 0.724 |
| IMP3 | Cytoplasmic | 69.1 | EDTA pH 9 | 1:50 | Dako | 0.912 |
| β-Catenin | Membranous and cytoplasmic | 14/β-catenin | EDTA pH 9 | 1:200 | BD | 0.911 |
| L1CAM | Membranous | 14.10 | EDTA pH 9 | 1:100 | BioLegend | 0.921 |
| Ki-67 | Nuclear | MIB-1 | Citrate pH 6.0 | 1:40 | Dako | 0.998 |
| ARID1A | Nuclear | HPA005456 | Citrate pH 6.0 | 1:100 | Sigma | 0.796 |
| Stathmin | Cytoplasmic | 3351 | Citrate pH 6.0 | 1:50 | Cell Signaling | 0.824 |
| P53 | Nuclear | DO-7 | Citrate pH 6.7 | 1:200 | Immunologic | 0.901 |
| P16 | Nuclear and cytoplasmic | MX007 | HIER pH 8.0 | 1:60 | Immunologic | 0.779 |
| Source | Average degree | Average distance | Clustering coefficient | Diameter |
| Figure 4 (NESG IDs) | 19 | 2.7 | 0.43 | 6 |
| Figure 4 (JCSG IDs) | 45 | 1.5 | 0.46 | 3 |
| Figure 4 (TB IDs) | 6.7 | 2.0 | 0.46 | 4 |
| Figure 5a (DNA pol IDs) | 15 | 3.1 | 0.44 | 7 |
| Figure 5b (RNA pol IDs) | 13 | 3.1 | 0.44 | 7 |
| Figure 6a (PSI IDs) | 24 | 2.6 | 0.37 | 7 |
| Figure 6b (PDB IDs 1) | 6.1 | 3.9 | 0.31 | 9 |
| Figure 6b (PDB IDs 2) | 6.7 | 3.8 | 0.33 | 10 |
| Path coefficient | |||||||||
| To HOMA-IR | To leptin | To BMI | |||||||
| b | SE | β | b | SE | β | b | SE | β | |
| Left VS | 4.54 | 1.38 | 0.62** | 0.50 | 9.63 | 0.01 | 14.28 | 9.97 | 0.31 |
| HOMA-IR | 3.67 | 1.35 | 0.67* | −1.42 | 1.7 | −0.23 | |||
| Leptin | 0.82 | 0.27 | 0.72** | ||||||
| Total | 21.96 | 9.58 | 0.48* |
| Meters above sea level (masl)c | Mean annual temperature(matp)d | Mean annualrainfall (mar)e | Buffaloes tested | Seropositivity toT. gondii | ||||
| Regiona | Municipalityb | Climate | No. | No. | % | |||
| Olmeca | Las Choapas | 10 | Warm | 27.0°C | 2900 mm | 58 | 21 | 36.2 |
| Sayula de Alemán | 80 | Warm | 27.0°C | 1650 mm | 156 | 93 | 59.6 | |
| All | 214 | 114 | 53.3 | |||||
| Papaloapan | Isla | 60 | Warm-humid | 24.9°C | 2316 mm | 59 | 23 | 39.0 |
| J. Rodriguez Clara | 95 | Warm | 25.0°C | 1266 mm | 66 | 28 | 42.4 | |
| All | 125 | 51 | 40.8 | |||||
| All | 339 | 165 | 48.7 |
| Cell line | |||
| In vitro | Single BR (μg/ml) | Single NAC (mM) | Combination (BR + NAC) |
| LS174T | 20, 50 | 5, 10 | 20 + 5, 20 + 10, 50 + 5, 50 + 10 |
| MKN45 | 100, 200 | 5, 10 | 100 + 5, 100 + 10, 200 + 5, 200 + 10 |
| KATOIII | 50, 100 | 50, 100 | 50 + 50, 50 + 100, 100 + 50, 100 + 100 |
| In Vivo | Single BR (mg/kg) | Single NAC (mg/kg) | Combination (BR+NAC) |
| LS174T | 3, 6 | 300, 500 | 3 + 300, 3 + 500, 6 + 300, 6 + 500 |
| MKN45 | 3, 6 | 300, 500 | 3 + 300, 3 + 500, 6 + 300, 6 + 500 |
| Young-old | Old-old | |||
| Incidence rate | 95% CI | Incidence rate | 95% CI | |
| Sex | ||||
| Male | 9.3 | 8.3–10.4 | 36.2 | 32.8–39.9 |
| Female | 9.3 | 8.4–10.5 | 43.9 | 40.7–47.4 |
| Age | ||||
| 65–69 | 5.5 | 4.8–6.4 | – | – |
| 70–74 | 14.3 | 13.0–15.8 | – | – |
| 75–79 | – | – | 31.3 | 28.8–34.1 |
| 80–84 | – | – | 51.5 | 46.3–57.3 |
| ≥ 85 | – | – | 83.3 | 71.8–96.8 |
| Educational attainment | ||||
| < 10 yrs | 10.2 | 9.2–11.3 | 42.6 | 39.4–45.9 |
| ≥ 10 yrs | 8.9 | 7.8–10.1 | 36.2 | 32.6–40.1 |
| Lattice IV: Orthorhombic P | Lattice V: Hexagonal P | |
| Cell 4 | Cell 5 | |
| a(Å) | 5.0 | 10.0 |
| b(Å) | 6.123724 | 10.0 |
| c(Å) | 8.660254 | 6.123724 |
| α (°) | 90.0 | 90.0 |
| β (°) | 90.0 | 90.0 |
| γ (°) | 90.0 | 120.0 |
| V(Å3) | 265.17 | 530.33 |
| c/a | 1.7320 | 0.6124 |
| c/b | 1.4142 |
| Vegetarian (n = 44) % (n) | Omnivorous (n = 44) % (n) | p | |
| MSyn | 15.9 (7) | 52.3 (23) | < 0.001 |
| WC (≥ 90 cm) | 20.5 (9) | 63.6 (28) | < 0.001 |
| SBP (≥ 130 mm Hg) | 22.7 (10) | 45.5 (20) | 0.025 |
| DBP (≥ 85 mm Hg) | 13.6 (6) | 40.9 (18) | 0.004 |
| TG (≥ 150 mg/dL) | 25.0 (11) | 45.5 (20) | 0.045 |
| HDL-c (< 40 mg/dL) | 22.7 (10) | 36.4 (16) | 0.16 |
| FSG (≥ 100 mg/dL) | 27.3 (12) | 63.6 (28) | 0.001 |
| Total (n = 355) | Odds ratio (95% confidential interval) | P-Value | |
| Age (years) | |||
| <=20 | 83 | 1.00 | |
| 21-40 | 142 | 6.226 (0.88, 44.14) | 0.067 |
| 41-60 | 99 | 6.960 (1.39, 34.79) | 0.018 |
| 60+ | 31 | 4.505 (0.91, 22.30) | 0.065 |
| Gender | |||
| Male | 192 | 1.00 | |
| Female | 163 | 1.09 (0.45, 2.66) | 0.835 |
| Education | |||
| Higher secondary | 164 | 1.00 | |
| Degree-PG | 191 | 0.846 (0.34, 2.12) | 0.721 |
| Geographic location | |||
| Rural | 249 | 1.00 | |
| Urban | 106 | 1.399 (0.68, 2.87) | 0.36 |
| Stakeholders | |||
| Students | 124 | 1.00 | |
| Teachers | 105 | 0.577 (0.11, 3.07) | 0.519 |
| Persons engaged in social service | 76 | 0.160 (0.05, 0.53) | 0.003 |
| Kin of the family members | 50 | 1.301 (0.26, 6.48) | 0.748 |
| Experiment a | Coded Values b | Planned Values c | ||||
| t | V | H | Agitation Time (min) | ACN (mL) | Homogenization Time (s) | |
| 1 | 1 | 0 | 0 | 30 | 10.5 | 10.0 |
| 2 | 0.5 | 0.866 | 0 | 25 | 13.5 | 10.0 |
| 3 | 0.5 | 0.289 | 0.817 | 25 | 11.5 | 14.4 |
| 4 | −1 | 0 | 0 | 10 | 10.5 | 10.0 |
| 5 | −0.5 | −0.866 | 0 | 15 | 7.5 | 10.0 |
| 6 | −0.5 | −0.289 | −0.817 | 15 | 9.5 | 5.6 |
| 7 | 0.5 | −0.866 | 0 | 25 | 7.5 | 10.0 |
| 8 | 0.5 | −0.289 | −0.817 | 25 | 9.5 | 5.6 |
| 9 | −0,5 | 0.866 | 0 | 15 | 13.5 | 10.0 |
| 10 | 0 | 0.577 | −0.817 | 20 | 12.5 | 5.6 |
| 11 | −0.5 | 0.289 | 0.817 | 15 | 11.5 | 14.4 |
| 12 | 0 | −0.577 | 0.817 | 20 | 8.5 | 14.4 |
| 13 | 0 | 0 | 0 | 20 | 10.5 | 10.0 |
| 14 | 0 | 0 | 0 | 20 | 10.5 | 10.0 |
| 15 | 0 | 0 | 0 | 20 | 10.5 | 10.0 |
| Nondiabetics | Diabetics | Univariate (P) | |
| Median age (Years) | 48.0 | 52.5 | 0.207 |
| T | |||
| 1 | 27 (12%) | 4 (9%) | 0.684 |
| 2 | 77 (34%) | 12 (29%) | |
| 3 | 54 (24%) | 14 (35%) | |
| 4 | 67 (30%) | 10 (27%) | |
| N | |||
| 0 | 41 (18%) | 9 (23%) | 0.695 |
| 1 | 95 (42%) | 14 (34%) | |
| 2 | 56 (25%) | 8 (20%) | |
| 3 | 33 (15%) | 9 (23%) | |
| Grade | |||
| 1 | 29 (13%) | 7 (18%) | 0.087 |
| 2 | 81 (36%) | 20 (49%) | |
| 3 | 115 (51%) | 13 (33%) | |
| Hormone receptor | |||
| Positive | 112 (49%) | 28 (70%) | 0.018 |
| Negative | 113 (51%) | 12 (30%) | |
| HER2 | |||
| Positive | 60 (27%) | 5 (13%) | 0.079 |
| Negative | 165 (73%) | 35 (87%) | |
| Triple-negative | |||
| Positive | 59 (26%) | 7 (18%) | 0.262 |
| Negative | 166 (74%) | 33 (82%) | |
| Metastatic site | |||
| Single | 122 (54%) | 18 (45%) | 0.306 |
| Multiple | 103 (46%) | 22 (55%) | |
| Type of metastases | |||
| Nonvisceral | 86 (38%) | 16 (40%) | 0.790 |
| Visceral | 139 (62%) | 24 (60%) | |
| Median BMI at recurrence | 26.8 | 27.5 | 0.359 |
| RATER 1 | RATER 2 | RATER 3 | |||||||
| BIAS | SD | 95% LA | BIAS | SD | 95% LA | BIAS | SD | 95% LA | |
| Weight Bearing Arch Height | -0.09 | 0.24 | -0.57 – 0.39 | 0.02 | 0.17 | -0.31 – 0.35 | -0.08 | 0.13 | -0.33 – 0.18 |
| Weight Bearing Foot Length | 0.03 | 0.76 | -1.46 – 1.52 | -0.01 | 0.25 | -0.51 – 0.48 | -0.00 | 0.08 | -0.16 – 0.16 |
| Non-Weight Bearing Arch Height | 0.07 | 0.20 | -0.32 – 0.46 | 0.03 | 0.30 | -0.56 – 0.62 | 0.21 | 0.33 | -0.44 – 0.86 |
| Non-WeightBearing FootLength | -0.03 | 0.19 | -0.40 – 0.34 | -0.05 | 0.20 | -0.43 – 0.33 | 0.11 | 0.20 | -0.29 – 0.51 |
| AH Difference | 0.16 | 0.28 | -0.38 – 0.70 | 0.01 | 0.37 | -0.71 – 0.73 | 0.29 | 0.40 | -0.49 – 1.07 |
| Criterion | Duration of symptoms | Significance (P) | |
| ≤48 months | >48 months | ||
| Age | 39.22 ± 12.39 | 27.78 ± 6.732 | 0.0638* |
| Gender (f/m) | 3/8 | 3/1 | 0.7552# |
| ICRS score | 3.43 ± 0.53 | 3.62 ± 0.52 | 0.4623* |
| Defect size | 3.68 ± 1.34 | 3.97 ± 1.67 | 0.4437* |
| KOSS (MRI) | 5.86 ± 1.57 | 8.25 ± 1.98 | 0.0202* |
| Henderson score | 2.00 ± 0.82 | 2.87 ± 1.36 | 0.1697* |
| Kellgren-Lawrence score | 1.00 ± 0.58 | 0.87 ± 0.83 | 0.7023* |
| Duration of symptoms (months) | 23.43 ± 16.36 | 76.50 ± 23.95 | 0.0010* |
| Krenn score | 2.00 ± 1.41 | 2.25 ± 1.03 | 0.5048* |
| BMP-2-Syn | 2.28 ± 1.89 | 2.37 ± 2.06 | 1.0000* |
| BMP-2-C | 2.43 ± 1.90 | 2.25 ± 1.58 | 0.9500* |
| BMPR-1A-Syn | 5.00 ± 1.00 | 4.75 ± 0.89 | 0.6171* |
| BMPR-1A-C | 2.57 ± 1.62 | 2.62 ± 2.37 | 0.9000* |
| Mankin score | 8.00 ± 2.00 | 7.375 ± 3.02 | 0.8590* |
| Pritzker score | 3.43 ± 0.79 | 3.62 ± 1.51 | 0.9497* |
| Sensitivity | Specificity | Accuracy1 | Kappa | |
| P(CH = 1|SR = 1) | P(CH = 0|SR = 0) | (overall agreement) | ||
| Full sample | 0.90 | 0.80 | 0.83 | 0.66 |
| Age | ||||
| 25-34 | 0.71 | 0.88 | 0.85 | 0.64 |
| 35-49 | 0.86 | 0.81 | 0.82 | 0.57 |
| 50+ | 0.95 | 0.69 | 0.83 | 0.83 |
| Gender | ||||
| Females | 0.88 | 0.83 | 0.85 | 0.66 |
| Males | 0.9 | 0.8 | 0.8 | 0.59 |
| Marital Status | ||||
| Currently Married | 0.90 | 0.82 | 0.84 | 0.65 |
| Not Married | 0.89 | 0.80 | 0.83 | 0.65 |
| Race/ethnicity | ||||
| Latino | 0.89 | 0.85 | 0.86 | 0.65 |
| non-Hispanic White | 0.90 | 0.77 | 0.81 | 0.65 |
| non-Hispanic Black | 0.90 | 0.79 | 0.83 | 0.66 |
| Education | ||||
| <12 | 0.92 | 0.79 | 0.83 | 0.65 |
| 12 | 0.79 | 0.82 | 0.81 | 0.65 |
| 12+ | 0.86 | 0.82 | 0.83 | 0.66 |
| Annual Household Income | ||||
| <$10,000 | 0.77 | 0.83 | 0.81 | 0.66 |
| $10,000-19,999 | 0.92 | 0.83 | 0.86 | 0.65 |
| $20,000-34,999 | 0.89 | 0.79 | 0.81 | 0.65 |
| $35,000+ | 0.97 | 0.77 | 0.83 | 0.66 |
| In silico SNP performance assessment | F0 | F1 | F2 | F3 | F4 |
| # of SNPs | 66,254 | 21,944 | 10,032 | 3,187 | 1,329 |
| # of contigs with SNPs | 9,579 | 5,058 | 2,057 | 1,651 | 998 |
| # of SNPs submitted to the ADT | 621 | 605 | 583 | 367 | 547 |
| # of SNPs with ADT Score ≥ 0.6 | 598 | 572 | 557 | 353 | 525 |
| % of SNPs with ADT Score ≥ 0.6 | 96.3 | 94.5 | 95.5 | 96.2 | 96.0 |
| # of SNPs with ADT Score ≥ 0.9 | 314 | 316 | 297 | 177 | 291 |
| % of SNPs with ADT Score ≥ 0.9 | 50.6 | 52.2 | 50.9 | 48.2 | 53.2 |
| # of SNPs tested by the GGGT | 96 | 96 | 108 | 108 | 288 |
| Variables | Case (n = 97) #(%) | Control (n = 194) #(%) | Crude OR (95 % CI) |
| Ever heard of PITC | |||
| Yes | 54 (55.7) | 170 (87.6) | 1 |
| No | 43 (44.3) | 24 (12.4) | 5.64 (3.14,10.13)a |
| Know PITC is given to all OPD patients | |||
| Yes | 57 (58.8) | 146 (75.3) | 1 |
| No | 40 (41.2) | 48 (24.7) | 2.14 (1.27,3.59)a |
| Patient has right to refuse PITC | |||
| Yes | 93 (95.9) | 188 (96.9) | 1 |
| No | 4 (4.1) | 6 (3.1) | 1.35 (0.37,4.89) |
| Patients are benefited from PITC service | |||
| Yes | 89 (91.8) | 187 (96.4) | 1 |
| No | 8 (8.2) | 7 (3.6) | 2.4 (0.84,6.83) |
| Support provision of PITC service to all OPD patients | |||
| Yes | 57 (58.8) | 182 (93.8) | 1 |
| No | 40 (41.2) | 12 (6.2) | 10.64 (5.23,21.66)a |
| Perceive the benefits of PITC | |||
| Yes | 58 (59.8) | 185 (95.4) | 1 |
| No | 39 (40.2) | 9 (4.6) | 13.82 (6.32,30.23)a |
| PITC can affect health service utilization by patients | |||
| No | 81 (83.5) | 181 (93.3) | 1 |
| Yes | 16 (16.5) | 13 (6.7) | 2.75 (1.26,5.98)a |
| Name | 2010 | 2013 | Difference | ||||||
| h-core citations | h-index | Bh-index | h-core citations | h-Index | Bh-Index | h-core citations | h-Index | Bh-Index | |
| Boyer PD | 3103 | 29 | 48 | 3484 | 30 | 50 | 381 | 1 | 2 |
| Kohn W | 3215 | 20 | 53 | 4050 | 21 | 58 | 835 | 1 | 5 |
| Hershko A | 10410 | 39 | 97 | 12273 | 42 | 99 | 1863 | 3 | 2 |
| Shimomura O | 962 | 19 | 30 | 1246 | 22 | 37 | 284 | 3 | 7 |
| Chalfie M | 7301 | 35 | 78 | 8702 | 40 | 85 | 1401 | 5 | 7 |
| Curl RF | 4183 | 35 | 59 | 5027 | 40 | 68 | 844 | 5 | 9 |
| Molina MJ | 5399 | 44 | 80 | 6695 | 52 | 83 | 1296 | 8 | 3 |
| Ertl G | 13932 | 79 | 111 | 17198 | 87 | 128 | 3266 | 8 | 17 |
| abbreviation | muscle name | maximum isometric force (Fiso, N) | optimal fibre length (Lfopt, m) | tendon slack length (Ltsl, m) | pennation angle (°) |
| IC | M. iliotibialis cranialis | 889 | 0.174 | 0.0451 | 0 |
| ILa | M. iliotibialis lateralis (cranial part) | 1265 | 0.174 | 0.2432 | 0 |
| ILp | M. iliotibialis lateralis (caudal part) | 1265 | 0.174 | 0.3099 | 0 |
| AMB1 | M. ambiens, ventral (pubic) head | 971 | 0.039 | 0.1648 | 10 |
| AMB2 | M. ambiens, dorsal (iliac) head | 1793 | 0.044 | 0.3941 | 15 |
| FMTL | M. femorotibialis lateralis | 1434 | 0.088 | 0.1746 | 15 |
| FMTIM | M. femorotibialis intermedius | 1706 | 0.084 | 0.1863 | 25 |
| FMTM | M. femorotibialis medialis | 1089 | 0.089 | 0.0603 | 30 |
| ILFBa | M. iliofibularis (cranial part) | 1254 | 0.176 | 0.2134 | 0 |
| ILFBp | M. iliofibularis (caudal part) | 1254 | 0.176 | 0.2733 | 0 |
| ITCa | M. iliotrochantericus caudalis (cranial part) | 897 | 0.064 | 0.0469 | 25 |
| ITCp | M. iliotrochantericus caudalis (caudal part) | 897 | 0.064 | 0.038 | 25 |
| IFE | M. iliofemoralis externus | 479 | 0.025 | 0.0667 | 25 |
| ITM | M. iliotrochantericus medius | 181 | 0.058 | 0.0241 | 0 |
| ITCR | M. iliotrochantericus cranialis | 330 | 0.053 | 0.0488 | 10 |
| IFI | M. iliofemoralis internus | 410 | 0.041 | 0.0533 | 0 |
| FCM | M. flexor cruris medialis | 1109 | 0.036 | 0.435 | 35 |
| FCLP | M. flexor cruris lateralis pars pelvica | 544 | 0.24 | 0.2449 | 0 |
| ISF | M. ischiofemoralis | 419 | 0.033 | 0.0816 | 15 |
| PIFML | M. puboischiofemorales medialis + lateralis | 816 | 0.089 | 0.1669 | 15 |
| OM | M. obturatorius medialis | 3124 | 0.055 | 0.1651 | 25 |
| CFP | M. caudofemoralis pars pelvica (et caudalis) | 1125 | 0.108 | 0.215 | 15 |
| GL | M. gastrocnemius pars lateralis | 1836 | 0.12 | 0.5818 | 20 |
| GIM | M. gastrocnemius pars intermedius | 798 | 0.125 | 0.507 | 15 |
| GM | M. gastrocnemius pars medialis | 3124 | 0.094 | 0.5957 | 20 |
| FL | M. fibularis longus | 2270 | 0.081 | 0.9633 | 20 |
| FDL | M. flexor digitorum longus | 1130 | 0.048 | 1.0366 | 20 |
| FPPD3 | M. flexor perforans et perforatus digitorum 3 | 1154 | 0.025 | 1.0737 | 30 |
| FPD3 | M. flexor perforans digitorum 3 | 3210 | 0.017 | 1.02 | 35 |
| FPD4 | M. flexor perforans digitorum 4 | 1434 | 0.026 | 1.004 | 20 |
| FHL | M. flexor hallucis longus | 469 | 0.04 | 1.0939 | 25 |
| EDL | M. extensor digitorum longus | 833 | 0.049 | 0.8512 | 30 |
| TCf | M. tibialis cranialis (femoral head) | 686 | 0.045 | 0.4791 | 25 |
| TCt | M. tibialis cranialis (tibial head) | 686 | 0.045 | 0.4215 | 25 |
| Group ofCOPD+PAH (n = 12) | Group of COPD (n = 36) | Group of HS (n = 15) | |
| Sex, M/F | 11/1 | 32/4 | 9/6 |
| Age, Years | 70.8 (6.7) | 67.6 (9.2) | 58 (9.2) |
| Smoking, pack-years | 27 (7) | 25 (6) | 0 |
| FEV1% | 39.35 (11.45) | 48.13 (18.04) | 98.05 (11.65) |
| FVC% | 64.89 (14.90) | 69.39 (19.1) | 95.07 (13.34) |
| FEV1/FVC % | 46.95 (6.81) | 54.27 (12.46) | 101.37 (8.5) |
| RV% | 151 (38) | 143 (32) | 108 (11) |
| PaO2 (mmHg) | 60.83 (4.76) | 64.58 (6.16) | 97.2 (0.7) |
| PaCO2 (mmHg) | 39.4 (4.27) | 41.78 (5.01) | 38.4 (1.5) |
| PaPs (mmHg) | 51.08 (12.2)* | 26.05 (3.39) | NA |
| ET-1 EBC (pg/ml) | 22.36 (4) | 7.25 (0.23) | 5.24 (0.47) |
| ET-1 art (pg/ml) | 12.41 (2.13) | 7.22 (0.21) | 0.84 (0.37) |
| ET-1 ven (pg/ml) | 14.53 (2.76) | 7.29 (0.16) | 1 (0.42) |
| FENO (ppb) | 22.92 (11.38) | 35.07 (17.53) | 20.56 (3.67) |
| 6MWD | 383 (34)§ | NA | NA |
| Predictors (all T1 variables) | Odds Ratio | 95% CI |
| Independent | ||
| Neighborhood crime | 0.91 | 0.75–1.10 |
| Neighborhood drug selling/use | 1.39 | 1.16–1.66 |
| Noxious neighborhood | 1.03 | 0.90–1.19 |
| Controls | ||
| Age | 1.51 | 1.22–1.85 |
| Sex (Ref = Male) | 0.64 | 0.43–0.95 |
| SES | 1.08 | 0.88–1.30 |
| Occasions of marijuana use | 1.78 | 1.31–2.42 |
| Sense primer (5′ to 3′) | Anti-sense primer (5′ to 3′) | |
| Human CCL19 | CCAACTCTGAGTGGCACCAA | TGAACACTACAGCAGGCACC |
| Human CCL21 | TGGCCTCTTACTCACCCTCT | GCCTCTTGATCCCCTTAGCC |
| Human CCR7 | GCCTACGACGTCACCTACAG | GGCAGAAGAGTCGCCTATGG |
| Beta-actin | CCATCGTCCACCGCAAAT | TGTCACCTTCACCGTTCC |
| ALP | ATCTTTGGTCTGGCTCCCATG | TTTCCCGTTCACCGTCCAC |
| Human OCN | GGCAGCGAGGTAGTGAAGAG | CTGGAGAGGAGCAGAACTGG |
| Human COL1 | GAG AGC ATG ACC GAT GG | GTG ACG CTG TAG GTG AA |
| IBSP | CGCCAATGAATACGACAATG | GATGCAAAGCCAGAATGGAT |
| Human VEGF-A | GAGCCTTGCCTTGCTGCTCTA | CACCAGGGTCTCGATTGGAT |
| Runx-2 | GCAGCAACCCAGAAACACTT | AACACATGACCCAGTGCAAA |
| Osterix | AGAGGAGAGACTCGGGACAG | GAGTTGTTGAGTCCCGCAGA |
| ASD (n = 9) | Neurotypical (n = 9) | Group difference | ||||
| Mean | SD | Mean | SD | t(16) | p | |
| Chronological age (years) | 13.67 | 1.94 | 14.44 | 1.13 | -1.04 | 0.31 |
| WASI vocabulary | 52 | 10.99 | 63.78 | 6.72 | -2.74 | 0.01 |
| WASI matrix | 49.78 | 7.12 | 55.44 | 8.75 | -1.51 | 0.15 |
| WASI IQ | 101.78 | 13.84 | 117.22 | 13.15 | -2.43 | 0.03 |
| ADOS | ||||||
| Communication | 3.11 | 0.93 | 0.22 | 0.44 | 8.44 | <0.001 |
| Social interaction | 5.44 | 2.19 | 0.11 | 0.33 | 7.24 | <0.001 |
| Communication and social interaction total | 8.56 | 2.92 | 0.33 | 0.5 | 8.33 | <0.001 |
| Stereotyped behaviors and restricted interests | 2.0 | 1.41 | 0 | 0 | 4.26 | 0.001 |
| Characteristics | ORT corner users, n(%) | ORT corner non-users, n(%) | p value |
| Age: | 0.4905 | ||
| 18-19 years | 9(8) | 11(9) | |
| 20-29 years | 48(44) | 63(53) | |
| 30-39 years | 33(39) | 35(30) | |
| 40 and over | 10(9) | 9(8) | |
| Education: | 0.1048 | ||
| No formal education | 59(54) | 61(52) | |
| Primary or secondary education | 33(30) | 34(29) | |
| Tertiary education | 10(9) | 4(3) | |
| Other | 8(7) | 18(15) | |
| Occupation: | 0.0016* | ||
| Housewives | 35(32) | 58(48) | |
| Petty traders | 58(53) | 55(46) | |
| Government employee | 15(13) | 2(2) | |
| Students | 0(0) | 2(2) | |
| Other | 2(2) | 2(2) | |
| Religion: Muslim | 106(96) | 112(94) | 0.4271 |
| Marital Status: Married | 101(92) | 113(95) | 0.3373 |
| Number of children, Mean | 4.2 | 3.3 | 0.0027* |
| Schizophrenia | Controls | |||||
| Amplitudes (μV) | Latency (ms) | Amplitudes (μV) | Latency (ms) | |||
| Emotional syllables | Angry | F3 | -1.77 ± 1.20 | 245.27 ± 57.25 | -2.55 ± 1.12 | 251.00 ± 51.81 |
| Fz | -1.94 ± 1.23 | 239.33 ± 54.31 | -2.69 ± 1.19 | 247.93 ± 55.60 | ||
| F4 | -1.85 ± 1.30 | 244.87 ± 52.14 | -2.58 ± 1.02 | 256.27 ± 55.67 | ||
| Happy | F3 | -1.04 ± 0.94 | 245.33 ± 49.34 | -1.33 ± 0.68 | 259.33 ± 51.61 | |
| Fz | -1.17 ± 1.18 | 248.93 ± 51.43 | -1.51 ± 0.76 | 255.47 ± 51.24 | ||
| F4 | -1.01 ± 1.10 | 244.21 ± 40.41 | -1.45 ± 0.75 | 258.33 ± 47.54 | ||
| Non-vocal sounds | Angry-derived | F3 | -1.87 ± 1.15 | 245.13 ± 47.81 | -2.65 ± 1.16 | 251.13 ± 36.40 |
| Fz | -2.06 ± 1.14 | 245.00 ± 47.28 | -2.89 ± 1.18 | 249.00 ± 37.76 | ||
| F4 | -2.00 ± 1.00 | 237.93 ± 47.46 | -2.73 ± 1.20 | 248.07 ± 37.65 | ||
| Happy-derived | F3 | -0.75 ± 0.76 | 233.67 ± 54.83 | -0.76 ± 0.53 | 262.13 ± 56.30 | |
| Fz | -0.64 ± 0.85 | 241.87 ± 50.72 | -0.89 ± 0.57 | 261.60 ± 54.61 | ||
| F4 | 0.67 ± 0.91 | 251.47 ± 56.04 | -0.79 ± 0.55 | 253.07 ± 55.45 |
| N = 137 patients (23 residents) | |
| Physician's Use of Obesity Counseling | |
| % Counseled about Obesity (n) | 85.4 (117) |
| Mean Number of Counseling Practices1 (SD) (18 Items total) | 5.3 (4.6) |
| 5As | |
| Mean Number of Assess2 Practices (SD) (6 items) | 2.2 (2.0) |
| Mean Number of Advise3 Practices (SD) (4 items) | 1.3 (1.3) |
| Mean Number of Agree4 Practices (SD) (3 items) | 0.7 (1.2) |
| % Use Assist5 Practice (n) (1 item) | 25.6 (35) |
| Mean Number of Arrange6 Practices (SD) (4 items) | 0.8 (0.4) |
| Characteristics | No. of patients (%) |
| Age (years) | |
| Median (range) | 71.0 (65.0-81.0) |
| ECOG performance status | |
| 0-1 | 108 (81.2) |
| ≥ 2 | 25 (18.8) |
| BMI (kg/m2) | |
| < 30 | 96 (72.2) |
| ≥ 30 | 37 (27.8) |
| WIC | |
| ≥ 1 | 52 (39.1) |
| < 1 | 81 (60.9) |
| Baseline LVEF | |
| Median (range) | 61% (47.0–69.0) |
| TNM stage | |
| I-II | 39 (29.3) |
| III | 61 (45.9) |
| IV | 33 (24.8) |
| Anthracycline exposure | |
| Previous | 49 (36.8) |
| Concomitant | 22 (16.5) |
| None | 62 (46.6) |
| Anthracycline cumulative dose (mg/m2) | 116 (0-540) |
| Previous radiotherapy (thoracic wall) | |
| Yes | 19 (14.3) |
| No | 124 (93.2) |
| Number of Procedures | < 200h | > 200h | p value |
| History Takings in Initial Patient Care | 136.905 | 363.800 | 0.001075 |
| Non-cast immobilizations | 19.360 | 63.577 | 0.005303793 |
| Cast immobilizations | 32.811 | 102.160 | 0.000295235 |
| Simple sutures | 33.980 | 96.200 | 0.000032826369841 |
| Donatti sutures | 5.283 | 12.214 | 0.019836 |
| Trauma Resuscitation Room visits | 2.804 | 21.036 | 0.000045965 |
| Adolescent population* | Adolescents with emergency admission(s) for injury between 10 and 19 years of age, n (row %) | ||||
| Characteristics | Total | Total | Adversity | Accidents only | Other causes |
| All | 3 254 046 | 402 916 (100.0) | 141 248 (35.1) | 233 907 (58.1) | 27 761 (6.9) |
| Age† | |||||
| Girls (years) | 1 588 942 | 144 158 (100.0) | 72 805 (50.5) | 59 528 (41.3) | 11 888 (8.2) |
| 10–14 | 65 208 (100.0) | 23 178 (35.5) | 37 388 (57.3) | 4642 (7.1) | |
| 15–17 | 48 286 (100.0) | 31 573 (65.4) | 12 922 (26.8) | 3791 (7.9) | |
| 18–19 | 30 664 (100.0) | 18 054 (58.9) | 9155 (29.9) | 3455 (11.3) | |
| Boys (years) | 1 665 104 | 258 503 (100.0) | 68 403 (26.5) | 174 267 (67.4) | 15 833 (6.1) |
| 10–14 | 121 821 (100.0) | 17 667 (14.5) | 97 478 (80.0) | 6676 (5.5) | |
| 15–17 | 79 223 (100.0) | 25 014 (31.6) | 49 345 (62.3) | 4864 (6.1) | |
| 18–19 | 57 459 (100.0) | 25 722 (44.8) | 27 444 (47.8) | 4293 (7.5) | |
| Missing (sex) | 255 (100.0) | 40 (15.7) | 175 (68.6) | 40 (15.7) |
| Index | Weekdays | Weekend | p |
| Bedtime (HH:MM) | 11:46 p.m. ± 87.2 | 00:12 a.m. ± 102.0 | <0.001 |
| Wake-up Time (HH:MM) | 06:32 a.m. ± 80.6 | 07:26 a.m. ± 105.0 | <0.001 |
| Sleep Midpoint (HH:MM) | 03:09 a.m. ± 77.2 | 03:49 a.m. ± 96.4 | <0.001 |
| Time in Bed (min) | 406 ± 65.9 | 434 ± 75.4 | <0.001 |
| Total Sleep Time (min) | 354 ± 60.1 | 376 ± 70.2 | <0.001 |
| Sleep Efficiency (%) | 87.4 ± 8.2 | 87.1 ± 8.8 | 0.089 |
| Initial Sleep Index (min) | 38.8 ± 29.5 | 38.4 ± 33.7 | 0.613 |
| Month | Cross-validation (%) | Allometry (%) | Influential landmark | ||
| ♂ | ♀ | ||||
| JAN/2009 | Hilltop | 81 | 93 | 10.470* | #10 and #17 |
| Lowland | 100 | 100 | 15.968* | #2 and #9 | |
| JAN/2012 | Hilltop | 87 | 96 | 5.853* | #2 and #9 |
| Lowland | 76 | 77 | 2.141 | #10 and #17 | |
| JUL/2012 | Hilltop | 83 | 90 | 6.909* | #2 and #9 |
| Lowland | 92 | 95 | 5.924* | #9 and #10 | |
| JAN/2013 | Hilltop | 96 | 100 | 8.433* | #9 and #10 |
| Lowland | 100 | 100 | 3.962* | #9 and #10 |
| Country | Sample name | Latitude | Longitude |
| Poland | A | 53° 50′02.83′′N | 21° 03′30.36′′E |
| Poland | H | 54° 23′21.42′′N | 18° 28′42.18′′E |
| Germany | B | 52° 13′09.87′′N | 11° 42′25.14′′E |
| Germany | D | 53° 25′51.60′′N | 09° 46′39.78′′E |
| Denmark | I | 56° 12′13.48′′N | 08° 09′39.07′′E |
| Denmark | E | 55° 56′16.98′′N | 12° 28′35.70′′E |
| Sweden | F | 58° 52′20.04′′N | 14° 53′56.79′′E |
| Sweden | K | 64° 36′27.31′′N | 20° 57′04.32′′E |
| Ireland | G | 53° 35′24.27′′N | 08° 03′33.69′′W |
| UK | C | 52° 29′17.12′′N | 00° 55′59.12′′W |
| UK | J | 52° 44′34.76′′N | 01° 08′09.87′′W |
| ExpressHMM | ANTM | |
| Probe sensitivity | 65% | 44% |
| Novel probes predicted | 65% | 49% |
| Overlap exon Sensitivity | 58% | 58% |
| Novel transfrags predicted | 27% | 58% |
| 5' Splice site sensitivity | 16% | 9% |
| 3' Splice site sensitivity | 16% | 13% |
| N | % of sample (N = 201) | 95% C.I. | |
| < 2 weeks | 57 | 28.4 | 22.3 – 35.1 |
| 2 weeks | 42 | 20.9 | 15.5 – 27.2 |
| 1 month | 31 | 15.4 | 10.7 – 21.2 |
| 2 months | 15 | 7.5 | 4.2 – 12.0 |
| 3 months | 16 | 7.9 | 4.6 – 12.5 |
| 4 months | 40 | 19.9 | 14.6 – 26.1 |
| Total | 201 | 100.0 |
| Diagnosis | Parasite | Early [n (%)] | Peak [n (%)] | Late [n (%)] | Total [n (%)] | P value1 |
| Microscopy | P. vivax | 9 (1.7) | 13 (2.3) | 3 (0.5) | 25 (1.5) | 0.066 |
| P. falciparum | 0 | 0 | 0 | 0 | – | |
| Mixed infection | 0 | 0 | 0 | 0 | – | |
| Total | 9 (1.7) | 13 (2.3) | 3 (0.5) | 25 (1.5) | 0.066 | |
| nRT-PCR | P. vivax | 95 (18.4) | 152 (26.3) | 105 (17.9) | 352 (21.0) | 0.001 |
| P. falciparum | 0 | 14 (2.4) | 18 (3.1) | 32 (1.9) | < 0.001 | |
| Mixed infection | 0 | 8 (1.4) | 1 (0.2) | 9 (0.5) | 0.002 | |
| Total | 95 (18.4) | 174 (30.1) | 124 (21.2) | 393 (23.4) | 0.001 |
| Tandem repeat Family | Repeat Length | GC Content (%) | Genome Coverage (%)a | Consensus Sequenceb | Distribution |
| pBuM189 | 189 | 29 | 0.039 | GCAAAAGACTCCGTCAATTA GAAAACAAAAAATGTTATAGTTTTGAGGATTAACC GGCAAAAACCGTATTATTTGTTATAT GATTTCTGTATGGAATACCGTTTTAGAA GCGTCTTTTATCGTATTACTCAGATATATCT TAAGATTTAGCATAATCTAAGAACTTTT TGAAATATTCACATTTGTCCA | D. buzzatii cluster species D. mojavensis |
| DbuTR198 | 198 | 34 | 0.027 | AAGGTAGAAAGGTAGTTGGTGAGATAAACCAGAAAAA GAGCTAAAAACGGCTAAAAACGGCTAGAAAATAGCCA GAAAGGTAGATTGAACATTAATGGGCAAATGG ATGGATAAATAAGACTGGTCATCATCCAA TGAACAGAATCATGATTAAGAGATAGAAATA TGATTAGAAAGTAGGATAGAAAGGTTAGAAAG | D. buzzatii |
| Policosanol (Chemical formula) | Percent |
| Docosan-1-ol (C22-OH) | 1.52 ± 0.24 |
| Tricosan-1-ol (C23-OH) | 2.12 ± 0.39 |
| Tetracosan-1-ol (C24-OH) | 2.02 ± 0.50 |
| Hexacosan-1-ol (C26 -OH) | 2.50 ± 0.16 |
| Heptacosan-1-ol (C27−OH) | 1.90 ± 0.25 |
| Octacosan-1-ol (C28-OH) | 75.44 ± 2.41 |
| Nonacosan-1-ol (C29-OH) | 2.55 ± 0.62 |
| Triacontan-1-ol (C30-OH) | 8.61 ± 1.20 |
| Dotriacontan-1-ol (C32-OH) | 3.34 ± 0.56 |
| Experimental groups | Lipid parameters (mg/dL) | |||||||
| TC | TG | VLDL-c | HDL-c | LDL-c | LDL/HDL | CT/HDL | ||
| HC rats + dH2O | 156.09 ± 0.92 | 141.01 ± 0.63 | 28.21 ± 0.73 | 31.05 ± 0.48* | 109.28 ± 0.49 | 5.87 ± 0.05 | 8.44 ± 0.82 | |
| HC +4 weeks treatment | 240 mg/kg | 135.51 ± 0.51* | 101.62 ± 0.98* | 20.33 ± 0.79* | 26.73 ± 0.47 | 81.53 ± 0.5* | 3.05 ± 0.07* | 6.25 ± 0.34* |
| 320 mg/kg | 116.63 ± 0,54* | 95.06 ± 0.57* | 19.02 ± 0.66* | 28.35 ± 0.58* | 53.02 ± 0.83* | 1.87 ± 0.06* | 4.59 ± 0.16* | |
| 400 mg/kg | 106.07 ± 0.69* | 85.15 ± 0.64* | 16.65 ± 0.38* | 34.77 ± 0.6* | 36.17 ± 0.34* | 0.96 ± 0.04* | 3.96 ± 0.15* | |
| HC 4 weeks after treatment | 240 mg/kg | 130.12 ± 0.11* | 98.13 ± 0.30* | 18.30 ± 0.70* | 27.12 ± 0.17 | 80.31 ± 0.15* | 2.96 ± 0.02* | 4.79 ± 0.13* |
| 320 mg/kg | 110.22 ± 0,34* | 89.16 ± 0.33* | 16.12 ± 0.25* | 30.22 ± 0.32* | 48.22 ± 0.23* | 1.59 ± 0.03* | 3.64 ± 0.11* | |
| 400 mg/kg | 99.14 ± 0.44* | 79.17 ± 0.24* | 14.25 ± 0.31* | 36.43 ± 0.21* | 33.27 ± 0.14* | 0.91 ± 0.02* | 2.72 ± 0.12* | |
| HC + Atorvastatin | 1 mg/kg | 95.23 ± 0.57* | 86.84 ± 0.84* | 17.27 ± 0.63* | 31.05 ± 0.48* | 39.06 ± 0.97* | 1.26 ± 0.04* | 3.29 ± 0.42* |
| NC rats | 69.61 ± 0.92 | 69.46 ± 0.58 | 14.39 ± 0.57 | 30.83 ± 0.39 | 25.38 ± 0.66 | 0.83 ± 0.07 | 2.28 ± 0.07 |
| Anatomical region | Healthy | CS1 LWP LI | CS2 RWP LI | CS3 RWP LI | |||
| LWP LI (n = 12) | RWP LI (n = 6) | ||||||
| Mean | SD | Mean | SD | ||||
| SMG | 0.41 | 0.22 | 0.29 | 0.21 | −0.18 | −0.19 | −0.05 |
| PMd | 0.34 | 0.17 | −0.13 | 0.25 | −0.06 | 0.02 | 0.18 |
| SI | 0.56 | 0.32 | −0.34 | 0.30 | −0.56 | 0.42 | 0.19 |
| MI | 0.64 | 0.24 | −0.62 | 0.30 | −0.77 | 0.66 | 0.59 |
| Based on parent ATS report | Based on child ATS report | |
| MVPA of trips during the times reported by the parent | U = 390.5, p = 0.02* | U = 596.5, p = 0.02* |
| ATS trips (n = 99) 2.46 min (2.83) | ATS trips (n = 128) 2.40 min (2.68) | |
| Non-ATS trips (n = 13) 0.76 min (0.95) | Non-ATS trips (n = 15) 0.81 min (0.87) | |
| Missing trips = 170 (60.3%) | Missing trips = 139 (49.3%) | |
| MVPA of trips during the hour before the classes (7:56–8:55) | U = 665.5, p = 0.02* | U = 955.0, p = 0.01* |
| ATS trips (n = 104) 4.99 min (4.11) | ATS trips (n = 146) 4.99 min (3.91) | |
| Non-ATS trips (n = 19) 2.55 min (1.69) | Non-ATS trips (n = 20) 2.59 min (1.60) | |
| Missing trips = 159 (56.4%) | Missing trips = 116 (41.1%) |
| Case | Sex, Age (years) | Previous operations | Fusion length | ASF | Cause and further treatment |
| 1 | M, 62 | Yes | 2 | Yes | Patient had persitant back pain postoperatively and paresthesia in the lower extremity. MRI showed an adjacent vertebral fracture leading to an elongation of the initial fusion of up to 4 segments and second explorative operation due to persistant paresthesia. No specific cause was identifed for this. Sensation returned to normal in the further course. |
| 2 | F, 67 | No | 6 | Yes | Early adjacent failure was caused by an osteoporotic cut out of the upper uncemented pedicle screws. This led to an elongation of the fusion by two segements with cement-augmentation. |
| 3 | F, 74 | No | 5 | Yes | After the inital dorsoventral fusion, an osteoporotic adjacent segment failure in the upper instrumented vertebra caused the need of a fusion extension of one more segment with pedicle screw cement augmention. Thereafter, the patient developed a wound dehiscence. This led to a further operation for wound debridement and closure. |
| 4 | M, 65 | No | 6 | Yes | This adjacent segment failure included a pedicle fracture causing a transient paresis of the hip flexion requiring immediate screw removal and nerve exploration. There was no nerve root damage. The fusion was elongated by 2 levels. The muscle regained full function in the follow-ups. |
| 5 | F, 72 | No | 4 | Yes | This patient had a screw misplacement as idenfied by the CT-scan. The screw was causing irritation of the nerve root and had a cut out through upper vertebral plate. This complex cause of adjacent segment failure and spinal nerve compression lead to an early revision and elongation by one segment. |
| 6 | M, 85 | No | 5 | Yes | This patient showed during the primary operation a poor bone quality (osteoporosis) with the need to use cement augmentation of the upper instrumented vertebra. During the early mobilisation process, the patient suffered an adjacent vertebral fracture with progression needing a revision with elongation of 2 more segments with careful cement augmentation. |
| 7 | F, 67 | No | 6 | Yes | Due to osteoporotic bone, the upper pedicle screws were cement augmented. However, the poor bone quality caused an osteoporotic fracture with nerve irritation needing a revision surgery with elongation of the fusion by 2 segments. Unfortunately thereafter, a wound healing defect caused a further superfical wound revision. |
| 8 | F, 83 | No | 3 | Yes | Due to a collapse of the upper vertebral plate during the mobilisation process, a surgical revision with elongation of 1 segment with cement augmentation was necessary. |
| Leisure-time physical activity | p | |||
| Total N (%) | Yes (%) | No (%) | ||
| Feel too tired | 62 (63.3) | 59.3 | 64.8 | 0.612 |
| Chronic kidney disease | 50 (51.0) | 51.9 | 50.7 | 0.919 |
| Hemodialysis treatment | 47 (48.0) | 44.4 | 49.3 | 0.821 |
| Lack of time | 39 (39.8) | 33.3 | 42.3 | 0.493 |
| Lack of company | 37 (37.8) | 29.6 | 40.8 | 0.357 |
| Lack of money | 36 (36.7) | 44.4 | 33.8 | 0.329 |
| Fear of injury | 35 (35.7) | 40.7 | 33.8 | 0.522 |
| Disliking exercise | 25 (25.5) | 12.0 | 88.0 | 0.068* |
| Feel too old | 18 (18.4) | 14.8 | 19.7 | 0.772 |
| Having an injury/disease | 14 (14.3) | 11.1 | 15.5 | 0.752 |
| Active ingredient | Abbreviation/Pharmaceutical preparation | Trade name (US) | Manufacturer | Approval status (US) | Notes |
| Methylphenidate hydrochloride | MPH-MR08 (modified-release preparation) | RitalinR LA (using SODAS delivery system developed by Elan) | Novartis | available in US and Switzerland | |
| Methylphenidate hydrochloride | MPH-TDS Patch for transdermal drug delivery (o.a.d); 12 h duration of action | DaytranaR DOT matrix transdermal technology | Shire (in license from Noven) | US approval (children age 6–12 years) April 2006; 2nd line to oral drugs | Skin sensitization reported in 13–22% of subjects wearing the patch; product had been deemed non-approvable by FDA before (April 2003) |
| Dexmethylphenidate, a non-racemic form of methylphenidate: | d-MPH (the active isomer of methylphenidate) | FocalinR | Novartis (in license from Celgene) | Approved in US | |
| Dexmethylphenidate, a non-racemic form of methylphenidate: | d-MPH-ER (extended release formulation) | FocalinR XR | Novartis (in license from Celgene) | US approval (for \"children, adolescents, and adults\") May 2005 | |
| Lisdexamphetamine dimesylate | LisDEX; (pharmaceutical preparation with a o.a.d. dosing schedule) | NRP104 | Shire (in license from New River Pharmaceuticals) | US approval (for children age 6–12 years) granted in 2007 | Reduced abuse potential expected because amphetamine is linked to L-lysine and does no become active until metabolized in the gastrointestinal tract |
| Mixed amphetamine salts | MAS (immediate and extended release formulations | AdderallR, AdderallR XR | Shire | Available in US | Unlikely to be approved in Europe |
| ModafinilSuccessor compound: Armodafinil | MOD; dopamine reuptake inhibitor; effects on neuropetides possibleARM | SparlonR (licensed in US and UK as ProvigilR for narcolepsy)NuvigilR | Cephalon(SparlonR was planned to be co-promoted in the US by McNeil, a sister company of Janssen-Cilag) | After receiving a non-approvable letter for modafinil in ADHD from the FDA in August 2006, Cephalon refocused its R&D on armodafinil [61] | Suspected serious adverse events (skin rash/Stevens-Johnson syndrome) in association with modafinil |
| Current UK Vaccination Against Invasive Meningococcal Disease | ||
| Vaccine (Serogroups) | Year Introduced into schedule | Age given |
| B | 2015 | 8 weeks, 16 weeks, 1 year |
| C | 1999 | 1 yeara |
| ACWY | 2015 | 14 years, University students 19–25 years |
| Cell type | AR expression (method) | Reference |
| Stem cells and progenitor cells | ||
| Hematopoietic stem cell | Yes (RT-PCR, IF) | (33, 34) |
| Common myeloid progenitor | Yes (RT-PCR) | (33) |
| Common lymphoid progenitor | Yes (RT-PCR) | (33) |
| Granulocyte-macrophage progenitor | ND | |
| Common dendritic cell (DC) progenitor | ND | |
| Megakaryocyte-erythroid progenitor | ND | |
| Erythroblast | Yes (binding assay) | (32) |
| Early T cell progenitor | ND | |
| Myeloid-derived cells | ||
| Megakaryocyte | Yes (IHC, RT-PCR, IF) | (37, 38) |
| Platelet | Yes (IF) | (38) |
| Erythroid cell (nucleated and enucleated) | Not expressed (IHC) | (37) |
| Monocyte | Yes (RT-PCR) | (37) |
| Macrophage | Yes (C+NC) (flow, IF, IHC, RT-PCR) | (16, 36, 37, 39) |
| Myeloid-derived DC | Not expressed (WB) | (40) |
| Myelocyte | Yes (IHC) | (37) |
| Metamyelocyte | Yes (IHC) | (37) |
| Neutrophil (band cell) | Yes (IHC) | (37) |
| Neutrophil (segmented) | Yes (IHC) | (37) |
| Mature eosinophil | Not expressed (IHC) | (37) |
| Basophil | ND | |
| Mature mast cell | Yes (ImmGold) | (35, 41) |
| Lymphoid-derived cells | ||
| DN T cell | Yes (binding assay) | (42) |
| DP T cell | Yes (binding assay) | (42) |
| CD4+ T cell | Yes (C+NC) (flow, IF, binding assay) | (17, 28, 42) |
| CD8+ T cell | Yes (C+NC) (binding assay) | (17, 42) |
| Plasmacytoid DC | ND | |
| Pro-B cell | Yes (WB) | (43) |
| Pre-B cell | Yes (WB) | (43) |
| Immature B cell | ND | |
| Mature B cell | Not expressed (IHC, WB) | (37, 43) |
| Other | ||
| Thymic epithelial cells | Yes (IF) | (44) |
| Bone marrow stromal cells | Yes (IHC, WB) | (37, 43) |
| Name | Dock score | -PLP1 | -PLP2 | -PMF |
| Tryptophan | 171.283 | 27.71 | 27.51 | 23.06 |
| Diiodotyrosine | 171.000 | 20.22 | 20.27 | 23.51 |
| Saussureamine C | 170.814 | 27.27 | 24.71 | 42.2 |
| Eupachinilide J | 170.774 | 32.62 | 27.11 | 25.13 |
| Tryptophan | 169.656 | 36.05 | 32.98 | 21.91 |
| Diiodotyrosine | 168.307 | 33.24 | 27.04 | 16.58 |
| 5-Hydroxy-L-tryptophan | 166.948 | 30.73 | 32.06 | 27.43 |
| L-Tyrosine | 165.590 | 33.52 | 33.82 | 20.64 |
| S-Allylmercaptocysteine | 165.014 | 17.05 | 18.65 | 16.6 |
| Emetine | 162.586 | 29.04 | 27.44 | 8.71 |
| Query | Parameters inquired | Fluorescent wavelengths |
| 1 | FS, SS | 2, 3 or 4 |
| 2 | FS, SS, CD5 | 2, 3 or 4 |
| 3 | FS, SS, CD5, CD20 | 2, 3 or 4 |
| 4 | FS, SS, CD5, CD20, CD19, CD34 | 4 |
| LOS (days) | Av. daily weight gain (gr) | |||||
| β | 95% C.I. | Pr(>|t|) | β | 95% C.I. | Pr(>|t|) | |
| Male | -1.899 | -3.930 , 0.127 | 0.07 | 0.708 | -3.067 , 4.483 | 0.71 |
| Gestational Age | -3.373 | -3.916 , 2.830 | <0.001 | -0.338 | -1.344 , 0.668 | 0.51 |
| Birth Weight (gr) | -0.014 | -0.016 , -0.009 | <0.001 | -0.018 | -0.022 , -0.014 | <0.001 |
| Milk Volume at Study Enrollment (mL) | 0.002 | -0.004 , 0.009 | 0.44 | 0.059 | 0.045 , 0.072 | <0.001 |
| OMT | -5.906 | -7.944 , -3.869 | <0.001 | 3.707 | -0.065 , 7.479 | 0.06 |
| Housing arrangements | No. of chickens (score a, liver/body weight ratio b) | ||||||||
| Cage-free (Inoculated) | 1(1, 23.16) | 2(4, 40.92) | 3(2, 23.44) | 4(2, 32.19) | 5(4, 37.98) | 6(3, 33.25) | 7(2, 24.01) | 8(4, 36.78) | 9(2, 23.48) |
| Caged (Inoculated) | 10(0, 24.84) | 11(4, 36.47) | 12(1, 23.39) | 13(0, 22.08) | 14(4, 35.88) | 15(0, 24.12) | 16(2, 23.98) | 17 (1, 22.68) | 18(4, 38.11) |
| Cage-free (Negative) | 19(0, 23.98) | 20(0, 24.12) | 21(1, 22.65) | 22(0, 23.65) | 23(1, 24.09) | 24(0, 23.51) | 25(0, 22.98) | 26(1, 23.65) | 27(0, 24.01) |
| Caged (Negative) | 28(1, 22.99) | 29(0, 25.01) | 30(0, 23.98) | 31(0, 24.19) | 32(1, 24.67) | 33(2, 24.88) | 34(0, 22.87) | 35(1, 23.13) | 36(0, 24..35) |
| AKI progression | Number of patients | ICU mortality | p |
| AKI I (n = 4259) | |||
| with rising creatinine values | 1995 (46.8%) | 522 (26.2%) | < 0.0001 |
| with falling creatinine values | 2264 (53.2%) | 334 (14.8%) | |
| AKI II (n = 857) | |||
| with rising creatinine values | 439 (51.2%) | 157 (35.8%) | < 0.0001 |
| with falling creatinine values | 418 (48.8%) | 65 (15.6%) | |
| AKI III (n = 2782) | |||
| with rising creatinine values | 639 (23%) | 318 (49.8%) | < 0.0001 |
| with falling creatinine values | 296 (10.6%) | 62 (20.9%) | |
| AKI III based on RRT criteria | 1847 (66.4%) | 999 (54.1%) | |
| AKI I/AKI II progressing to AKI III | 1664 (59.8%) | 796 (47.8%) | p = 0.029 |
| AKI III without prior AKI I/AKI II | 1118 (40.2%) | 583 (46.2%) |
| d [g cm−3] | Porosity [φ] | ρ323 K [mΩ cm] | S323 K [μV K−1] | κL,773 K [W m−1 K−1] | |
| OM | 7.1 | 14.1% | 1.12 | −100 | 0.6 |
| RM | 7.9 | 4.5% | 0.63 | −88 | 0.7 |
| PMO (n = 149) | CON (n = 172) | p-Value | |
| Age, years | 61.4 (6.5)a | 57.5 (7.3)a | >0.05 |
| Height, cm | 159.2 (8.3)a | 165.1 (5.8)a | >0.05 |
| Weight, kg | 64.5 (7.2)a | 73.3 (5.1)a | >0.05 |
| Body mass index, kg/m2 | 26.7 (3.2)a | 27.3 (4.7)a | >0.05 |
| Years after menopause | 11.3 (4.5)a | 8.2 (2.7)a | >0.05 |
| Spine bone mineral density (BMD), g/cm2 | 0.944 (0.831; 1.090)b | 1.152 (1.024; 1.240)b | <0.01 |
| Femoral neck BMD, g/cm2 | 0.803 (0.707; 0.914)b | 0.983 (0.913; 1.13)b | <0.01 |
| Comm | Accom | Isol | NWI-NPRS | TeamVal | TeamEff | SharedLdr | |
| Comm | |||||||
| Accom | 0.81 | ||||||
| Isol | 0.84 | 0.75 | |||||
| NWI-NPRS | 0.38 | 0.36 | 0.25 | ||||
| TeamVal | 0.27 | 0.24 | 0.19 | 0.17 | |||
| TeamEff | 0.51 | 0.38 | 0.39 | 0.12^ | 0.75 | ||
| SharedLdr | -0.05^ | -0.07^ | 0.01^ | -0.25 | 0.02^ | 0.39 |
| Yes (+) | LBP+ | LBP+ | LBP− | LBP− | Missing answers on pain | LBP | SP | LBP | SP |
| No (−) | SP+ | SP− | SP+ | SP− | PIW+ | PIW+ | PINT+ | PINT+ | |
| Number of workers n (%) | 238 (45) | 101 (19) | 47 (9) | 79 (15) | 60 (12) | 156 (30) | 96 (18) | 180 (34) | 147 (28) |
| Lactate | <2 mmol/L (n = 138) | ≥6 mmol/L (n = 29) | P value |
| Major resection (%) | 26 (18.8) | 26 (89.7) | <0.001* |
| Pre-operative chemotherapy (%) | 38 (27.5) | 5 (17.2) | 0.351 |
| Pre-operative diabetes (%) | 6 (4.3) | 8 (27.6) | <0.001* |
| Post-operative renal dysfunction (%) | 3 (2.2) | 8 (27.6) | <0.001* |
| 90-day mortality (%) | 1 (0.7) | 8 (27.6) | <0.001* |
| Profile Width | Neff | |||
| Superfamily | Full | Trimmed | Full | Trimmed |
| (Trans)glycosidases | 410.4 | 23.93 | 13.11 | 3.21 |
| 4-helical cytokines | 85.71 | 43.57 | 4.3 | 2.86 |
| alpha/beta-Hydrolases | 509.43 | 22.32 | 16.32 | 3.65 |
| Cytochrome c | 413.62 | 18.86 | 12.64 | 3.7 |
| E Set domains | 182.73 | 33.27 | 7.99 | 3.16 |
| FAD/NAD(P)-binding | 616.52 | 20.57 | 15.33 | 3.68 |
| Fibronectin type | 1661.67 | 24.83 | 11.44 | 3.55 |
| Homeodomain-like | 255.21 | 39.33 | 7 | 3.34 |
| Immunoglobulin | 1614.7 | 69.04 | 11.33 | 3.65 |
| NAD(P)-binding | 463.14 | 29.55 | 12.32 | 3.27 |
| Nucleic acid-binding | 224.09 | 23.57 | 8.21 | 3.11 |
| P-loop | 483.03 | 26.44 | 11.64 | 2.92 |
| S-adenosyl | 472.42 | 22.08 | 14.88 | 3.22 |
| Thioredoxin-like | 471.72 | 25.28 | 12.61 | 3.58 |
| Viral coat | 265.28 | 35.93 | 6.11 | 2.96 |
| Winged helix | 206.94 | 24.81 | 8.11 | 3.13 |
| Zones | Most Used Pesticides (Top 5) in % | Cumulative % | ||||
| 1 | 2 | 3 | 4 | 5 | ||
| Obala | Ridomil (8%) | Onex (6.3%) | Actara (5.7%) | Callomil (5%) | Lamida Gold, Parastar and Plantomil (4.7% each) | 39.4 |
| Foumbot | Gramoxone (12.6%) | Timide (7.4%) | K-optimal (7.1%) | Roundup (6.7%) | Cigogne and Pencozeb (4.1% each) | 42 |
| Santa | Gramoxone (12.7%) | Banko (12%) | Pencozeb (8%) | Roundup and Mancozan (6.7% each) | Parastar (4.7%) | 50.8 |
| Njombe–Penja | Gramoxone (12.8%) | Pyriforce (9.4%) | Glyphader (7.2%) | Ridomil and Supraxone (4.7% each) | Roundup and Capsidor (4.3% each) | 47.4 |
| Ngong–Garoua | Roundup (23.7%) | Atrazine (20.1%) | Gramoxone (15.9%) | Diuron (14.8%) | Biosec Roundup 720 (3.2%) | 80.9 |
| F0 | F1 | F2 | F3 |
| Hip center speed (m/s) | Shoulder center speed (m/s) | Right hip speed (θ/s) Frontal plane | Right hip angle (θ) Frontal plane |
| Item | Item clearly stated | Agreement with item | ||||||
| Total n | Strongly agree | Somewhat agree | Combined agreement | Total n | Strongly agree | Somewhat agree | Combined agreement | |
| Figure | 85 | 45 (53%) | 37 (44%) | 82 (96%) | 85 | 41 (48%) | 33 (39%) | 74 (87%) |
| Stationary Behavior | ||||||||
| Definition | 86 | 62 (72%) | 17 (20%) | 79 (92%) | 84 | 56 (67%) | 20 (24%) | 65 (76%) |
| Caveats | 85 | 49 (58%) | 25 (29%) | 74 (87%) | 86 | 51 (59%) | 23 (27%) | 74 (86%) |
| Examples | 83 | 52 (63%) | 20 (24%) | 72 (87%) | 84 | 51 (61%) | 29 (35%) | 80 (95%) |
| Sedentary Behavior | ||||||||
| Definition | 86 | 74 (86%) | 12 (14%) | 86 (100%) | 86 | 74 (86%) | 10 (12%) | 84 (98%) |
| Caveats | 86 | 63 (73%) | 21 (24%) | 84 (98%) | 86 | 68 (79%) | 14 (16%) | 82 (95%) |
| Examples | 86 | 72 (84%) | 12 (14%) | 84 (98%) | 86 | 69 (80%) | 15 (17%) | 84 (98%) |
| Standing Still | ||||||||
| Definition | 85 | 64 (75%) | 17 (20%) | 81 (95%) | 86 | 65 (76%) | 19 (22%) | 84 (98%) |
| Caveats | 86 | 69 (80%) | 12 (14%) | 81 (94%) | 86 | 69 (80%) | 12 (14%) | 81 (94%) |
| Examples | 85 | 65 (76%) | 18 (21%) | 83 (98%) | 86 | 66 (77%) | 19 (22%) | 85 (99%) |
| Screen Time | ||||||||
| Definition | 85 | 70 (82%) | 12 (14%) | 82 (96%) | 84 | 71 (85%) | 10 (12%) | 81 (96%) |
| Caveats | 84 | 60 (71%) | 17 (20%) | 77 (92%) | 82 | 60 (73%) | 15 (18%) | 75 (91%) |
| Examples | 84 | 65 (77%) | 14 (20%) | 79 (94%) | 83 | 62 (75%) | 15 (18%) | 77 (93%) |
| Non-Screen-Based Sedentary Time | ||||||||
| Definition | 85 | 73 (86%) | 9 (11%) | 82 (96%) | 85 | 71 (84%) | 8 (9%) | 79 (93%) |
| Caveats | 85 | 66 (78%) | 11 (13%) | 77 (91%) | 86 | 64 (74%) | 15 (17%) | 79 (92%) |
| Examples | 85 | 66 (78%) | 13 (15%) | 79 (93%) | 86 | 63 (73%) | 14 (16%) | 77 (90%) |
| Sitting | ||||||||
| Definition | 85 | 72 (85%) | 9 (11%) | 81 (95%) | 86 | 70 (81%) | 11 (13%) | 81 (94%) |
| Caveats | 85 | 14 (16%) | 11 (13%) | 75 (88%) | 84 | 59 (70%) | 15 (18%) | 74 (88%) |
| Examples | 85 | 61 (72%) | 14 (16%) | 75 (88%) | 85 | 55 (65%) | 21 (25%) | 76 (89%) |
| Reclining | ||||||||
| Definition | 84 | 68 (81%) | 10 (12%) | 78 (93%) | 83 | 68 (82%) | 8 (10%) | 76 (92%) |
| Caveats | 84 | 70 (83%) | 8 (10%) | 78 (93%) | 83 | 69 (83%) | 7 (8%) | 76 (92%) |
| Examples | 84 | 70 (83%) | 9 (11%) | 79 (94%) | 83 | 67 (81%) | 10 (12%) | 77 (93%) |
| Lying | ||||||||
| Definition | 85 | 75 (88%) | 6 (7%) | 81 (95%) | 85 | 75 (88%) | 6 (7%) | 81 (95%) |
| Caveats | 84 | 76 (90%) | 3 (4%) | 79 (94%) | 85 | 76 (89%) | 4 (5%) | 80 (94%) |
| Examples | 85 | 75 (88%) | 6 (7%) | 81 (95%) | 85 | 75 (88%) | 6 (7%) | 81 (95%) |
| Sedentary Behavior Pattern | ||||||||
| Definition | 86 | 78 (91%) | 6 (7%) | 84 (98%) | 86 | 76 (88%) | 9 (10%) | 85 (99%) |
| Caveats | 86 | 72 (84%) | 9 (10%) | 81 (94%) | 85 | 71 (84%) | 9 (11%) | 80 (94%) |
| Examples | 86 | 60 (70%) | 19 (22%) | 79 (92%) | 85 | 58 (68%) | 19 (22%) | 77 (91%) |
| Average | ||||||||
| Definition | 71 (83%) | 11 (13%) | 82 (96%) | 70 (82%) | 11 (13%) | 81 (95%) | ||
| Caveats | 65 (77%) | 13 (15%) | 78 (92%) | 65 (77%) | 13 (15%) | 78 (92%) | ||
| Examples | 65 (77%) | 14 (16%) | 79 (93%) | 63 (74%) | 16 (19%) | 79 (94%) |
| Variables | GLM resultsinteraction effecta | Statistical changes over time(p value) | Adjusted mean differences between groups over timeb(Clinical changes) |
| Group * Time | T1 → T2 | T1 → T2 | |
| EORTCQLQ-C30: | |||
| Global quality of life | 12.5 | .000 | +8.2 |
| Functional scales: | |||
| Physical | 118.5 | .000 | - 16.2 |
| Role | 30.1 | .000 | - 11.0 |
| Emotional | 9.8 | .002 | +8.5 |
| Cognitive | 7.9 | .005 | - 6.0 |
| Social | 8.4 | .004 | - 7.0 |
| Symptom scales: | |||
| Fatigue | 22.7 | .000 | +12.0 |
| Nausea/vomiting | 4.7 | .030 | +3.4 |
| Pain | 13.3 | .000 | +8.6 |
| Dyspnea | 0.6 | .419 | +1.7 |
| Insomnia | 1.7 | .184 | +4.0 |
| Appetite loss | 0.1 | .707 | - 1.0 |
| Constipation | 8.6 | .004 | +7.5 |
| Diarrhea | 0.4 | .545 | - 1.1 |
| Financial difficulties | 51.7 | .000 | +21.7 |
| Sense of Coherence | 17.3 | .000 | - 6.5 |
| Spiritual Perspective Scale | 31.0 | .000 | - 6.6 |
| Religious Coping (+) | 9.8 | .002 | - 6.5 |
| Religious Coping (−) | 3.5 | .060 | +4.3 |
| Days in EB formation | Post EB differentiation | Differentiation conditions | Chondrogenic markers studied | Cells line(s) | Reference |
| 5 | Encapsulation of EBs in PEG hydrogel for 17 days | The EBs in hydrogel were differentiated in presence of chondrogenic medium (CM) treated with BMP-2 and TGF-β1 | Type I, II, X collagen, and osteocalcin. Proteoglycans content measurement | Mouse-D3 and human-BG03 | [12–15] |
| N/R | EB cells were seeded on ceramic particles | Cells on the ceramic scaffold was differentiated in vitro for 21 days in CM supplemented with TGF-β3 and 21 days of in vivo maturation | Morphology was studied and proteoglycans content was analyzed | Mouse-IB10, human MSC, and Goat MSCs | [4] |
| 7 RA from day 2 | EBs were plated | RA-treated EB outgrowth culture was treated with TGF-β3 | D15: proteoglycans, Col2a1, Sox9, Col10a1 and MMP13 | Mouse-CGR8, E14Tg2a, EFC1 | [16] |
| 28 | After 4 weeks the EBs were dissociated and self-assembled for additional 4 weeks | EBs were differentiated in chondrogenic medium supplemented with combinations of TGF-β1, TGF-β3, BMP-2, and IGF-1 (100 ng/mL) | Sox9, Col1a1, Col2a1 | Human-BG01V | [17] |
| Anteparturm hemorrhage | Transverse lie | Placenta previa | Breech presentation | Ectopic pregnancy | Twins | Poly /oligo hydromnious | |
| Very confident | 23.3 | 13.3 | 10 | 13.3 | 3.3 | 13.3 | 0 |
| Confident | 50 | 60 | 23.3 | 56.7 | 16.7 | 60 | 33.3 |
| Not confident | 10 | 13.3 | 46.7 | 23.3 | 40 | 27.3 | 43.3 |
| Cannot measure/diagnose | 16.7 | 13.3 | 20 | 6.7 | 40 | 0 | 23.3 |
| EEG indices | Site | Before inhalation (μV2) | During inhalation (μV2) | t-test | Pvalue∗ |
| Both nostrils | |||||
| RA | T3: left temporal | 0.4271 ± 0.066 | 0.5103 ± 0.070 | −2.593 | 0.029 |
| T4: right temporal | 0.4273 ± 0.073 | 0.5066 ± 0.080 | −2.459 | 0.036 | |
| RG | P3: left parietal | 0.0998 ± 0.033 | 0.0805 ± 0.032 | −2.400 | 0.040 |
| Left nostril | |||||
| ALB | P3: left parietal | 4.8147 ± 0.648 | 4.0104 ± 0.542 | 3.295 | 0.009 |
| RLB | Fp1: left prefrontal | 0.0326 ± 0.007 | 0.0437 ± 0.009 | −3.819 | 0.004 |
| Fp2: right prefrontal | 0.0334 ± 0.008 | 0.0438 ± 0.010 | −2.824 | 0.020 | |
| F3: left frontal | 0.0370 ± 0.010 | 0.0433 ± 0.011 | −2.394 | 0.40 | |
| Right nostril | |||||
| AT | F3: left frontal | 22.2562 ± 5.108 | 18.1241 ± 3.968 | 2.330 | 0.045 |
| P4: right parietal | 17.9657 ± 7.698 | 14.1190 ± 3.306 | 2.532 | 0.032 |
| Bacterial strain | Source | Reference |
| L. sakei 23K | Sausage | [66,67] |
| L. sakei MF1053 | Fermented fish (Norwegian \"Rakfisk\") | [30] |
| L. sakei LS 25 | Commercial starter culture for salami sausage | [68] |
| L. sakei Lb790x | Meat | [69] |
| L. sakei LTH673 | Fermented sausage | [70,71] |
| L. sakei MF1328 | Fermented sausage | [30] |
| L. sakei MF1058 (TH1) | Vakuum-packed cooked meat, protective culture | [9,10] |
| L. sakei CCUG 31331a (DSM 15831b, R 14 b/a) | Fermented sausage, type strain for L. sakei subsp. carnosus | [27,72] |
| L. sakei DSM 20017b (ATCC 15521c) | Sake, alcoholic beverage made by fermenting rice, type strain for L. sakei subsp. Sakei | [27] |
| L. sakei Lb16 (Lb1048d, CCUG 42687a) | Minced meat | [31,73] |
| Sex | |||||||||
| T | M | F | |||||||
| N | Mean difference ± SD(mm) | P | N | Mean ± SD | P | N | Mean ± SD | P | |
| UCPM | 359 | −0.41 ± 0.88 | *** | 169 | −0.21 ± 0.88 | ** | 190 | −0.59 ± 0.85 | *** |
| LCPM | −0.42 ± 0.91 | *** | −0.20 ± 0.91 | ** | −0.61 ± 0.86 | *** |
| Ligands | XPGScore | Winning score | CDM | |
| 2XYT-based α7 nAChR-LBD | 3SQ6-based α7 nAChR-LBD | |||
| Acetylcholine | −4.68 | −4.812 | −4.812 | 0.132 |
| epibatidine | −5.2 | −8.725 | −8.725 | 1.000 |
| nicotine | −3.1 | −7.512 | −7.512 | 0.731 |
| cytisine | −3.65 | −6.362 | −6.362 | 0.476 |
| PNU282987 | −4.518 | −5.878 | −5.878 | 0.368 |
| mecamylamine | −3.564 | −4.873 | −4.873 | 0.145 |
| MG624 | −4.954 | failed to dock | −4.954 | 0.163 |
| methyllycaconitine | −5.829 | failed to dock | −5.829 | 0.357 |
| Hexamethonium | −2.786 | −1.001 | −2.786 | −0.318 |
| NS1738 | −7.108 | −8.513 | −8.513 | 0.953 |
| PNU120596 | −4.992 | −6.188 | −6.188 | 0.437 |
| SB206553 | −4.373 | −6.671 | −6.671 | 0.544 |
| Predictors | B | SE B | β | t | p |
| Preference | 0.21 | 0.05 | 0.13 | 3.79 | <.0001 |
| Originality | 0.58 | 0.08 | 0.47 | 7.17 | <.0001 |
| Ambiguity | 0.32 | 0.06 | 0.29 | 5.05 | <.0001 |
| Understanding | − 0.39 | 0.02 | − 0.34 | − 14.05 | <.0001 |
| Methylated bases in 100 bp | SCREAM2 | FAMAa | FAMAb | SPCHa | SPCHb |
| LRH (Parent) | 0 | 17 | 14 | 0 | 30.2 |
| LRH-control | 0.1 | 13.5 | 12.9 | 0 | 29.2 |
| Entropy (Hχ) | 0.004 | 0.08 | 0.17 | 0.001 | 0.02 |
| LRH-LRH | 0.13 | 16.6 | 13.5 | 0.03 | 11.4 |
| Entropy (Hχ) | 0.003 | 0.05 | 0.05 | 0.001 | 0.02 |
| Control-control | 0 | 11.5 | 7.2 | 0 | 11.3 |
| Entropy (Hχ) | 0.000 | 0.08 | 0.07 | 0.015 | 0.000 |
| χ2 treatment | ns | <0.001 | <0.001 | ns | <0.001 |
| χ2 inheritance | ns | ns | ns | ns | <0.001 |
| ESTs per unigene | H. erato | H. melpomene |
| 1 (singletons) | 319 | 256 |
| 2 | 13 | 31 |
| 3 | 5 | 12 |
| 4 | 9 | 10 |
| 5–10 | 14 | 17 |
| 11–20 | 7 | 9 |
| 21–50 | 3 | 3 |
| >51 | 1 | 2 |
| Total: | 371 | 340 |
| Gene | Sequence | bp |
| Beclin-1 | Sense 5′ CCAGATGCGTTATGCCCAGAC 3′ Anti-sense 5′ CATTCCATTCCACGGGAACAC 3′ | 149 |
| mTOR | Sense 5′ AAACTGCACGTCAGCACCATC 3′ Anti-sense 5′ AGCCGTCTCAGCCATTCCA 3′ | 192 |
| ATG5 | Sense 5′CCATCAATCGGAAACTCATGGA 3′ Anti-sense 5′ATCTGCAGCCACAGGACGAA 3′ | 128 |
| ATG7 | Sense 5′ CTGTAACTTAGCCCAGTACCCTGGA 3′ Anti-sense 5′TACGGTCACGGAAGCAAACAAC 3′ | 113 |
| Actin | Sense 5′TGGCACCCAGCACAATGAA 3′ Anti-sense 5′CTAAGTCATAGTCCGCCTAGAAGCA 3′ | 128 |
| TIV | GM volume | WM volume | CSF volume | |
| FIS total | − 0.3540.023 | − 0.5870.011 | 0.3490.138 | − 0.4200.015 |
| FIS cognitive | − 0.3360.032 | − 0.6630.004 | 0.3990.089 | − 0.3710.030 |
| FIS physical | − 0.1740.276 | − 0.3040.206 | 0.3040.226 | − 0.3950.031 |
| FIS social | − 0.4000.010 | − 0.5980.009 | 0.3010.139 | − 0.4110.016 |
| COMPASS-31 | − 0.2610.099 | − 0.3330.163 | 0.2300.352 | − 0.3950.030 |
| CFQ | − 0.4830.001 | − 0.6890.002 | 0.3400.114 | − 0.5000.002 |
| Duration of symptoms | − 0.0200.901 | − 0.3840.096 | 0.1320.579 | 0.2420.159 |
| Age at onset | 0.2660.089 | − 0.1390.545 | 0.2130.377 | 0.3010.087 |
| Educationa | Household income (LICO)b | Neihgbourhood SEPc | Combined SEPd | |
| A- Maternal and infant health status indicators | ||||
| 1. Preterm Birth | + | NS | NS | + (*) (low-high) |
| 2. Small for gestational Age | NS | + | + | + (low-low) |
| 3. Self rated health | + | + | + | + (low-low) |
| 4. Postpartum Depression | + | + | + | + (low-low) |
| 5. Pre-pregnancy BMI (<18.5) | + | + | + | + (low-low) |
| 6. Pre-pregnancy BMI (>24.5) | + | + | NS | + (low-high) |
| B- Prenatal care | ||||
| 7. First prenatal care visit | + | + | + | + (low-low) |
| 8. Timing of ultrasound | - | NS | NS | NS |
| 9. HIV testing (no) | NS | - | NS | + (low-low) |
| 10. Received enough information during pregnancy | + | + | + | + (low-low) |
| 11. Weight gained during pregnancy (kg) - (Below recommended range) | + | + (*) | NS | + (*) (low-high) |
| 12. Weight gained during pregnancy (kg)-more (Above recommended range) | + | + | NS | + (low-high) |
| C- Labor and deliveryexpereinces | ||||
| 13. Type of birth (caesarean) | NS | - | NS | + (low-high) |
| 14. Epidural for a vaginal birth | - | - | NS | + (low-high) |
| 15. Shaving for a vaginal birth | + | + | + | + (low-high) |
| 16. Position for vaginal birth (not laying flat) | NS | + | + | + (low-low) |
| D- Medical care during the neonatal period | ||||
| 17. Infant hospital readmission | NS | NS | NS | NS |
| 18. Infant needing non-routine neonatal care after discharge? | - | - | - | - (low-low) |
| 19. Baby admitted to NICU after birth | NS | NS | NS | NS |
| 20. Length of hospital stay after caesarean birth (More than average) | NS | NS | + | + (high-low) |
| 21. Length of hospital stay after vaginal birth (More than average) | + (*) | NS | NS | NS |
| E- Postpartum infant care & maternal reflections on the overall experience of health care | ||||
| 22. Any breastfeeding at 3 months | + | + | - | + (low-high) |
| 23. Any breastfeeding at 6 months | + | + | - | + (low-high) |
| 24. Overall experience of labor and birth | NS | + | NS | + (low-high) |
| 25. Satisfaction with previous aspects of maternity care | + | +(*) | NS | NS |
| Demographic Variables | Number |
| Ages | |
| 15-19 | 2 |
| 20-24 | 2 |
| 25-29 | 2 |
| 30-34 | 1 |
| 35-39 | 2 |
| 40-44 | 1 |
| 45-49 | 0 |
| Total | 10 |
| Educational Attainment | |
| None | 1 |
| Grades 1-4 | 1 |
| Grades 5-8 | 3 |
| Grades 9-12 | 5 |
| Tertiary education | 0 |
| Total | 10 |
| Age at first birth | |
| 15-19 | 6 |
| 20-24 | 3 |
| 25-29 | 1 |
| 30-34 | 0 |
| 35-39 | 0 |
| 40-44 | 0 |
| 45-49 | 0 |
| Total | 10 |
| Marital Status | |
| Single | 8 |
| Customary marriage | 0 |
| Civil Marriage | 0 |
| Cohabiting | 2 |
| Total | 10 |
| Number of live births | |
| 0-2 | 2 |
| 04-Mar | 6 |
| 5+ | 2 |
| Total | 10 |
| Employment Status | |
| Unemployed | 7 |
| Employed | 2 |
| Other: e.g. self-employed as petty trader | 1 |
| Total | 10 |
| Ci(phenol), mg·L−1 | 15 | 40 | 100 | 150 | 200 | 250 | 300 |
| MIP 3 (EGDMA) | |||||||
| Q(MIP), mg·g−1 | 2.60 | 6.30 | 13.0 | 17.0 | 21.7 | 23.7 | 26.2 |
| Q(NIP), mg·g−1 | 2.60 | 6.51 | 13.7 | 17.3 | 22.4 | 24.6 | 27.2 |
| IF | 1.00 | 1.03 | 1.05 | 1.02 | 1.03 | 1.04 | 1.04 |
| MIP 4 (TEGDMA) | |||||||
| Q(MIP), mg·g−1 | 1.79 | 4.91 | 10.1 | 14.9 | 18.4 | 22.3 | 27.1 |
| Q(NIP), mg·g−1 | 1.72 | 4.76 | 9.7 | 14.2 | 17.4 | 21.2 | 25.6 |
| IF | 1.04 | 1.03 | 1.04 | 1.05 | 1.06 | 1.05 | 1.06 |
| MIP 5 (PETA) | |||||||
| Q(MIP), mg·g−1 | 2.52 | 5.41 | 11.5 | 15.4 | 18.2 | 21.9 | 24.6 |
| Q(NIP), mg·g−1 | 2.31 | 5.20 | 10.7 | 14.2 | 16.9 | 19.8 | 22.1 |
| IF | 1.09 | 1.04 | 1.07 | 1.09 | 1.08 | 1.11 | 1.12 |
| Group | Base | 2 h | 8 h | 24 h | 48 h |
| Ctrl | 0 (0–0) | 3 (3–4) | 3 (3–4) | 3 (2–4) | 3 (2–3) |
| Z-VEID | 0 (0–0) | 3 (2–4) | 3 (2–3) | 2 (1–3) | 2 (1–2)a |
| Z-IETD | 0 (0–0) | 3 (3–4) | 3 (2–3) | 2 (2–3) | 2 (1–2)a |
| Ingredient | Fish oil-based diet1 | Saturated fat-based diet2 | ||
| g (%) | Kcal | g (%) | Kcal (%) | |
| Protein | 23.7 | 20 | 23.7 | 20 |
| Carbohydrate | 41.4 | 35 | 41.4 | 35 |
| Fat1 | 23.6 | 45 | 23.6 | 45 |
| Casein | 200 (23.3) | 800 | 200 (23.3) | 800 |
| L-Cystine | 3 (0.35) | 12 | 3 (0.35) | 12 |
| Corn starch | 72.8 (9.88) | 291 | 72.8 (9.88) | 291 |
| Maltodextrin | 100 (11.65) | 400 | 100 (11.65) | 400 |
| Sucrose | 172.8 (20.14) | 691 | 172.8 (20.14) | 691 |
| Cellulose | 50 (5.83) | 0 | 50 (5.83) | 0 |
| Soybean Oil | 25 (2.91) | 225 | 25 (2.91) | 225 |
| Lard | 0 | 0 | 177.5 (20.68) | 1598 |
| Menhaden oil | 177.5 (20.68) | 1598 | 0 | 0 |
| Mineral mix | 10 (1.17) | 0 | 10 (1.17) | 0 |
| Vitamin mix | 10 (1.17) | 40 | 10 (1.17) | 40 |
| Choline bitartrate | 2 (0.23) | 0 | 2 (0.23) | 0 |
| Cholesterol | 0.17 (0.02) | 0 | 0.71 (0.08) | 0 |
| Total | 858.2 | 4057 | 858.2 | 4057 |
| Agent* | Time (s) | Capping efficiency |
| Acetic anhydride | 15 | 60 ± 4% |
| Acetic anhydride | 30 | 81 ± 2% |
| Acetic anhydride | 60 | 92 ± 2% |
| Acetic anhydride | 120 | 95 ± 2% |
| DMT-dT | 15 | 91 ± 2% |
| DMT-dT | 30 | 94 ± 1% |
| DMT-dT | 60 | 97 ± 1% |
| Abnormalcardiometabolic profile | Normalcardiometabolic profile | TOTAL | ||
| Untreated | \"Normal\" weight(BMI = 18.5 - 24.9) | 23.5%(16.3 million people)b | 76.5%(53.0 million people) | 100%(69.3 million people) |
| Treated | \"Overweight\"(BMI = 25.0 - 29.9) | 48.7%(34.1 million people) | 51.3%(35.9 million people)c | 100%(70.0 million people) |
| \"Obese\"(BMI ≥ 30.0) | 68.3%(42.0 million people) | 31.7%(19.5 million people)c | 100%(61.5 million people) | |
| TOTAL | 46%92.4 million people | 54%108.4 million people | 100%200.8 million people |
| Number of controls | |||||
| 10 | 60 | 110 | 160 | 210 | |
| Percentage of results that included the mutation (%) | 100 | 100 | 100 | 100 | 100 |
| Percentage of mutation loci in the top hit (%) | 46 | 43 | 37 | 38 | 37 |
| Mean length of haplotypes (number of SNPs) | 629 | 546 | 441 | 410 | 383 |
| Cantilever ID | L μm | -Sphere -material | Sphere number | Sphere diameter, μm | Resonance Frequency -kHz | ΔLm μm |
| DNP 6A | 108 | Gold | – | 0 | 62.8 | – |
| 19300 | 1 | 3.8 | 56.0 | +1.9 | ||
| kg·m−3 | 2 | 5.7 | 46.8 | −1.4 | ||
| 3 | 9.5 | 31.2 | −1.1 | |||
| – | 0 | 62.8 | – |
| Variable | Before matching | After matching | ||||||
| Atypical cohort N = 648 | Typical cohort N = 483 | p-value | Standardized difference | Atypical cohort N = 400 | Typical cohort N = 400 | p-value | Standardized difference | |
| Demographic characteristics | ||||||||
| Mean age (in years) [Mean(SD)] | 51.3 (13.0) | 52.6 (11.9) | 0.081 | −0.106 | 52.1 (11.8) | 51.7 (11.7) | 0.144 | 0.035 |
| Female [n(%)] | 357 (55.1%) | 267 (55.3%) | 0.950 | −0.004 | 226 (56.5%) | 224 (56.0%) | 0.715 | 0.010 |
| Retired [n(%)] | 338 (52.2%) | 282 (58.4%) | 0.037 | −0.125 | 222 (55.5%) | 228 (57.0%) | 0.109 | −0.030 |
| Concomitant medications [n(%)] | ||||||||
| Anxiolytics | 74 (11.4%) | 57 (11.8%) | 0.843 | −0.012 | 18 (4.5%) | 22 (5.5%) | 0.541 | −0.046 |
| Anticholinergics | 28 (4.3%) | 15 (3.1%) | 0.290 | 0.064 | 1 (0.3%) | 1 (0.3%) | 1.000 | <0.001 |
| Antidepressants | 24 (3.7%) | 22 (4.6%) | 0.473 | −0.043 | 1 (0.3%) | 4 (1.0%) | 0.375 | −0.095 |
| Sedative-hypnotics | 9 (1.4%) | 17 (3.5%) | 0.018 | −0.138 | 1 (0.3%) | 3 (0.8%) | 0.625 | −0.071 |
| Mood stabilizers | 7 (1.1%) | 6 (1.2%) | 0.787 | −0.015 | 2 (0.5%) | 1 (0.3%) | 1.000 | 0.041 |
| Mental comorbidities [n(%)] | ||||||||
| Sleep disorder | 38 (5.9%) | 29 (6.0%) | 0.921 | −0.006 | 14 (3.5%) | 10 (2.5%) | 0.481 | 0.059 |
| Depression | 15 (2.3%) | 16 (3.3%) | 0.309 | −0.060 | 1 (0.3%) | 4 (1.0%) | 0.375 | −0.095 |
| Anxiety disorder | 8 (1.2%) | 9 (1.9%) | 0.462 | −0.051 | 3 (0.8%) | 2 (0.5%) | 1.000 | 0.032 |
| Other psychotic disorder# | 6 (0.9%) | 3 (0.6%) | 0.740 | 0.035 | 1 (0.3%) | 0 (0.0%) | 1.000 | 0.071 |
| Resource utilization and cost (prior 3 months) | ||||||||
| Mean number of hospitalizations | 0.02 (0.15) | 0.05 (0.25) | 0.028 | −0.128 | 0.01 (0.07) | 0.01 (0.07) | 1.000 | <0.001 |
| Mean number of outpatient visits | 0.17 (0.58) | 0.22 (0.83) | 0.332 | −0.069 | 0.08 (0.34) | 0.05 (0.36) | 0.298 | 0.071 |
| Direct medical cost ($) [Mean(SD)] | 20 (124) | 42 (200) | 0.027 | −0.129 | 4 (45) | 3 (46) | 0.287 | 0.021 |
| All Sounds > Baseline | |
| Region | Number of Voxels |
| Right Frontal Cortex | 14335 |
| Frontal pole | |
| Frontal orbital cortex | |
| Middle frontal gyrus | |
| Pars opercularis | |
| Pars triangularis | |
| Right Temporal Cortex | 2243 |
| Middle temporal gyrus, posterior division and temporoccipital part | |
| Superior temporal gyrus, posterior division | |
| Heschl’s gyrus | |
| Left Temporal Cortex | 874 |
| Middle temporal gyrus, posterior division | |
| Superior temporal gyrus, posterior division | |
| Heschl’s gyrus | |
| Left Frontal Pole | 48 |
| Total | Recognise pregnancy warning signsb | Recognise pregnancy hypertension warning signs | Recognise convulsions | ||||
| N (%) | N (%) | OR (95 % CI)a | N (%) | OR (95 % CI)a | N (%) | OR (95 % CI)a | |
| Total | 81 (100.0) | 75 (92.6) | 33 (40.7) | 57 (70.4) | |||
| Sex | |||||||
| Male | 20 (24.7) | 19 (95.0) | 1.00 | 13 (65.0) | 1.00 | 18 (90.0) | 1.00 |
| Female | 53 (65.4) | 50 (94.3) | 0.88 (0.02 - 11.74) | 18 (34.0) | 0.28 (0.08 - 0.92)* | 34 (64.2) | 0.20 (0.02 - 1.00) |
| Missing | 8 (9.9) | 6 (75.0) | 0.17 (0.00 - 3.82) | 2 (25.0) | 0.19 (0.02 - 1.44) | 5 (62.5) | 0.20 (0.01 - 2.24) |
| Age | |||||||
| Median (IQR) | 46.0 (35.5 - 50.0) | - | 1.14 (1.02 - 1.34)* | - | 0.99 (0.95 - 1.03) | - | 0.99 (0.95 - 1.03) |
| Education | |||||||
| Primary | 54 (66.7) | 52 (96.3) | 1.00 | 22 (40.7) | 1.00 | 38 (70.4) | 1.00 |
| Secondary | 15 (18.5) | 14 (93.3) | 0.54 (0.03 - 34.01) | 7 (46.7) | 1.27 (0.34 - 4.68) | 11 (73.3) | 1.16 (0.28 - 5.73) |
| Missing | 12 (14.8) | 9 (75.0) | 0.12 (0.01 - 1.21) | 4 (33.3) | 0.73 (0.14 - 3.15) | 8 (66.7) | 0.84 (0.19 - 4.39) |
| Years working as community health worker | |||||||
| Median (IQR) | 2 (1–8) | - | 1.19 (0.93 - 1.94) | - | 1.04 (0.97 - 1.12) | - | 1.09 (0.99 - 1.24) |
| Any GI problem | Constipation | Reflux | Air swallowing | |||||||||
| (n = 94) | (n = 73) | (n = 51) | (n = 25) | |||||||||
| n (%) | OR (95 % CI) | p value | n (%) | OR (95 % CI) | p value | n (%) | OR (95 % CI) | p value | n (%) | OR (95 % CI) | p value | |
| N = 125 | N = 129 | N = 116 | N = 110 | |||||||||
| Age group | ||||||||||||
| 0 to <5 years | 50 (40.0) | baseline | – | 52 (40.3) | baseline | – | 48 (41.4) | baseline | – | 44 (40.0) | baseline | – |
| 5 to < 10 years | 42 (33.6) | 2.03 (0.83,4.94) | 0.12 | 42 (32.6) | 2.12 (0.90,5.00) | 0.08 | 36 (31.0) | 1.07 (0.42,2.72) | 0.88 | 37 (33.6) | 1.35 (0.37,4.86) | 0.65 |
| 10 years or older | 33 (26.4) | 3.5 (1.22,10.08) | 0.02 | 35 (27.1) | 2.78 (1.14,6.74) | 0.02 | 32 (27.6) | 2.24 (0.88,5.71) | 0.09 | 29 (26.4) | 7.48 (1.96,28.53) | 0.003 |
| Gender | ||||||||||||
| Female | 112 (89.6) | baseline | – | 115 (89.2) | baseline | – | 102 (87.9) | baseline | – | 110 (100) | baseline | – |
| Male | 13 (10.4) | 0.92 (0.25,3.44) | 0.90 | 14 (10.9) | 0.90 (0.28,2.90) | 0.85 | 14 (12.1) | 1.01 (0.31,3.34) | 0.99 | 0 | – | – |
| Mutation group | ||||||||||||
| No functional protein | 43 (34.4) | baseline | – | 43 (33.3) | baseline | – | 40 (34.5) | baseline | – | 34 (30.9) | baseline | – |
| Missense/in-frame mutation within catalytic domain | 38 (30.4) | 1.27 (0.46,3.50) | 0.64 | 40 (31.0) | 1.62 (0.65,4.03) | 0.30 | 34 (29.3) | 1.73 (0.66,4.51) | 0.27 | 34 (30.9) | 12.14 (2.08,70.68) | 0.01 |
| Truncation between aa172 and aa781 | 30 (24.0) | 0.67 (0.24,1.89) | 0.45 | 31 (24.0) | 2.17 (0.80,5.91) | 0.13 | 29 (25.0) | 1.01 (0.36,2.82) | 0.98 | 29 (26.4) | 8.03 (1.35,48.00) | 0.02 |
| Truncation after aa781 | 14 (11.2) | 0.81 (0.21,3.07) | 0.76 | 15 (11.6) | 0.74 (0.21,2.58) | 0.64 | 13 (11.2) | 0.49 (0.11,2.13) | 0.34 | 13 (11.8) | 14.21 (1.83,110.22) | 0.01 |
| 9-y-olds | 15-y-olds | ||||||
| MVPA (b (95% CI)) | p | n | MVPA (b (95% CI)) | p | n | ||
| Sleep | 0.3 (−1.5, 2.2) | 0.740 | 2053 | 1.3 (− 1.0, 3.6) | 0.274 | 1120 | |
| Screen time | −2.2 (−3.1, −1.3) | < 0.001 | 2033 | −1.7 (−2.7, −0.8) | < 0.001 | 1162 | |
| Active transport | |||||||
| ≤ 5 min/d | ref. | 900 | ref. | 619 | |||
| 6–15 min/d | 3.6 (0.9, 6.3) | 0.009 | 742 | 3.3 (0.4, 6.2) | 0.027 | 440 | |
| ≥ 16 min/d | 7.2 (4.0, 10.4) ♀♂ | < 0.001 | 424 | 9.0 (3.8, 14.1) | 0.001 | 137 | |
| Girls | ≤5 min/d | ref. | |||||
| 6–15 min/d | 4.6 (1.5, 7.8) | 0.004 | |||||
| ≥ 16 min/d | 10.5 (6.8, 14.3) | < 0.001 | |||||
| Boys | ≤5 min/d | ref. | |||||
| 6–15 min/d | 2.4 (−1.7, 6.6) | 0.253 | |||||
| ≥ 16 min/d | 5.0 (0.4, 9.7) | 0.033 | |||||
| Sports/exercise | |||||||
| ≤ 2 h/week | ref. | 736 | ref. | 350 | |||
| 3–7 h/week | 2.2 (−0.1, 4.5) | 0.062 | 1098 | 7.6 (4.3, 10.8) | < 0.001 | 555 | |
| ≥ 8 h/week | 9.2 (4.7, 13.7) ♀♂ | < 0.001 | 225 | 17.9 (14.0, 21.8) | < 0.001 | 279 | |
| Girls | ≤2 h/week | ref. | |||||
| 3–7 h/week | 1.1 (−2.2, 4.4) | 0.508 | |||||
| ≥ 8 h/week | 1.3 (−3.9, 6.5) | 0.635 | |||||
| Boys | ≤2 h/week | ref. | |||||
| 3–7 h/week | 4.5 (0.9, 8.2) | 0.014 | |||||
| ≥ 8 h/week | 14.7 (8.2, 21.3) | < 0.001 |
| Cytology | Mean Age | No. of SpecimensN,(%) | Overall HPV (+)% |
| Normal | 38.1 ± 9.4 (20-67) | 310 (77%) | 20% |
| Abnormal Cytology | 35.6 ± 8.7(19-58) | 93 (23%) | 36% |
| ASCUS | 37.0 ± 8.8 | 39 (42%) | 22% |
| LSIL | 33.6 ± 8.9 | 43 (46%) | 51% |
| HSIL | 38.0 ± 6.9 | 10 (11%) | 60% |
| General evidence | Managerial Accounting tools | HRM tools | ICT tools | Outcomes | Open issues | |
| Progressive patient care model | In some contexts implementation by law (e.g. Tuscany)Great autonomy of organizations on how to implement modelForms of implementation:poles; separation elective/unscheduled/emergency patients; distinct inpatient/outpatient pathways; emphasis on ED; pool beds; centralization of functions | Integrated Planning, Budgeting and Control systems (e.g. BSC)In concrete, however, MA tools not aligned to model (e.g. budgets still assigned to clinical wards) | New professional roles and a general reassignment of responsibilities (nurses and physicians)Need for:Competency based model;Separate professional/managerial career paths;Multi-source and 360° feedback system | Integrated electronic health records, to be jointly used and updated by physicians and nurses | Improved efficiency indicatorsIncreased patient satisfaction (medical and/or nursing tutor)More coordination between medical and surgical staffBetter implementation of clinical pathwaysLack of evidence in terms of improved clinical outcomes | Effective allocation of nurses to different settingsCorrect triage activity in ED and efficient allocations of patientsDesirability of medical day- or week- hospitalsInvolving professionals and of overcoming cultural barriersDefinition of clear repartition of responsibilities among professionals |
| Patient centered approach | The most analyzed aspect of PC is related to continuity of care among different settings (poorly explored within hospitals)An exception: analysis of general process improvements within EDs | New professional roles in hospitals (e.g. liason nurse) | ICT tools should ideally:prioritize information and detect individuals’ contextual situations,promote stronger inter-professional relationships with adequate exchange of information,enable interoperability and scalability between and within institutions,function across different platforms.Few pioneer experiences (e.g. Shared care platform)ICT tools still rudimental if compared to their potential | Significant relationships between specific elements of PC and outcomes, or between PC approach in general and a reduced ED utilization.Liason activities are associated with slightly higher (not significant), quality care transitions.Greater patient satisfactionImproved communication among professionalsGeneral evidence about the effects of PCC on clinical outcomes very limited | Poor attention of literature to PC within hospitalsNecessary switch from hospital information systems to health care information systemsNon exhaustive informationIndividuals involved are not tracedLack of tools to clearly assess PC | |
| Lean approach | Application of various features of lean such as new employee roles, staffing and scheduling, communication and coordination, workspace layout, process design etc.Application of lean tools within settings (EDs, ORs, outpatient settings)Only few examples of lean applied to pathways | Staff empowerment and “bottom-up approach”, by allowing the frontline staff to identify problems and come up with appropriate solutions | Many examples of improvement in efficiency indicatorsFewer examples of improvement in clinical outcomesA number of studies find inconsistent the evidence about lean’s contribution to higher organizational performance | Lean is often felt to be “a constellation of disjointed and poorly connected activities”Lack of “system-wide” improvement philosophyThe “bottom-up approach” is not fully implemented in concrete and barriers to implementation persistNeed of more formation for inter-professional collaboration |
| Chroma C* at 8 °C | ||||||
| Days | Without HPP Treatment | With HPP Treatment | ||||
| Control | PF Film | PS Film | Control | PF Film | PS Film | |
| 0 | 26.99 A,a ± 2.48 | 26.99 A,a ± 2.48 | 26.99 A,a ± 2.48 | 25.05 A,a ± 0.87 | 25.05 A,a ± 0.87 | 25.05 A,a ± 0.87 |
| 4 | 25.42 A,a ± 0.06 | 26.04 A,a ± 0.55 | 27.81 A,a ± 1.93 | 25.06 A,a ± 0.09 | 28.38 A,a ± 3.25 | 28.17 A,a ± 2.42 |
| 8 | 26.34 A,a ± 1.00 | 25.95 A,a ± 0.81 | 28.38 A,a ± 2.22 | 25.68 A,a ± 0.22 | 26.46 A,a ± 0.46 | 28.62 A,a ± 1.78 |
| 12 | 24.95 A,a ± 0.15 | 26.19 A,a ± 0.31 | 28.25 A,a ± 2.41 | 25.24 A,a ± 0.02 | 25.99 A,a ± 0.77 | 28.05 A,a ± 3.70 |
| 17 | 25.42 A,a ± 0.77 | 26.18 A,a ± 0.31 | 27.17 A,a ± 2.98 | 25.35 A,a ± 0.90 | 26.42 A,a ± 1.11 | 27.26 A,a ± 3.31 |
| 21 | 25.19 A,a ± 0.85 | 25.96 A,a ± 0.34 | 27.59 A,a ± 2.92 | 26.02 A,a ± 1.05 | 28.27 A,a ± 3.10 | 24.63 A,a ± 0.14 |
| 25 | 24.91 A,a ± 0.17 | 25.92 A,a ± 0.32 | 26.53 A,a ± 4.29 | 25.42 A,a ± 1.00 | 25.94 A,a ± 0.61 | 28.11 A,a ± 2.62 |
| 29 | 25.86 A,a ± 1.01 | 25.84 A,a ± 0.31 | 27.05 A,a ± 3.47 | 25.09 A,a ± 0.71 | 27.65 A,a ± 2.65 | 24.57 A,a ± 0.47 |
| 35 | 24.88 A,a ± 1.57 | 25.52 A,a ± 0.24 | 27.46 A,a ± 2.14 | 24.88 A,a ± 0.08 | 25.90 A,a ± 0.10 | 24.43 A,a ± 0.24 |
| 41 | 24.85 A,a ± 1.60 | 24.86 A,a ± 1.46 | 27.48 A,a ± 2.72 | 25.31 A,a ± 0.59 | 25.76 A,a ± 0.64 | 24.75 A,a ± 1.29 |
| 47 | 25.67 A,a ± 1.50 | 25.31 A,a ± 0.05 | 27.83 A,a ± 1.13 | 25.87 A,a ± 0.38 | 25.22 A,a ± 0.58 | 23.66 A,a ± 0.15 |
| Unigene No. | Gene name | Copies | %* |
| Fetal pituitary | |||
| Hs.1905 | prolactin+# | 312 | 9.46 |
| Hs.119689 | glycoprotein hormones, alpha +# | 146 | 4.43 |
| Hs.115352 | growth hormone 1+# | 48 | 1.46 |
| Hs.274460 | olfactory receptor 5V1# | 48 | 1.46 |
| Hs.195453 | ribosomal protein S27+# | 24 | 0.73 |
| Hs.75415 | beta-2-microglobulin+# | 22 | 0.67 |
| Hs.70312 | cytochrome c oxidase 7A2+# | 15 | 0.46 |
| Hs.315164 | hypothetical protein# | 14 | 0.42 |
| Hs.83484 | sex determining region Y-box 4# | 8 | 0.24 |
| Hs.7917 | DKFZP564K247 protein# | 7 | 0.21 |
| Hs.273385 | guanine nucleotide binding protein alpha+# | 7 | 0.21 |
| Hs.165590 | ribosomal protein S13# | 7 | 0.21 |
| Hs.131814 | tankyrase# | 7 | 0.21 |
| Hs.173912 | eukaryotic translation initiation factor+ | 6 | 0.18 |
| Hs.119222 | suppression of tumorigenicity 13+# | 6 | 0.18 |
| Hs.177530 | ATP synthase+ | 5 | 0.15 |
| Hs.177656 | calmodulin 1+ | 5 | 0.15 |
| Hs.241429 | cDNA DKFZp586C1923# | 5 | 0.12 |
| Hs.330994 | RAB9# | 4 | 0.12 |
| Hs.46328 | fucosyltransferase 2# | 4 | 0.12 |
| Adult pituitary | |||
| Hs.115352 | growth hormone 1+# | 358 | 6.09 |
| Hs.1905 | prolactin+# | 288 | 4.9 |
| Hs.1897 | proopiomelanocortin# | 46 | 0.78 |
| Hs.181165 | eukaryotic translation elongation factor1# | 45 | 0.77 |
| Hs.273385 | guanine nucleotide binding protein AS1+# | 44 | 0.75 |
| Hs.65149 | growth hormone 2# | 42 | 0.71 |
| Hs.279789 | glucose phosphate isomerase# | 41 | 0.7 |
| Hs.119689 | glycoprotein hormones, alpha+# | 37 | 0.63 |
| Hs.77385 | myosin, light polypeptide 6+# | 30 | 0.51 |
| Hs.278959 | galanin-related peptide LOC51083# | 25 | 0.43 |
| Hs.247474 | hypothetical protein FLJ21032# | 21 | 0.36 |
| Hs.180450 | ribosomal protein S24# | 20 | 0.34 |
| Hs.155482 | hydroxyacyl glutathione hydrolase# | 19 | 0.32 |
| Hs.76053 | DEAD/H box polypeptide 5# | 19 | 0.32 |
| Hs.75360 | carboxypeptidase E+# | 18 | 0.31 |
| Hs.112844 | maternally expressed 3# | 16 | 0.27 |
| Hs.117950 | phosphoribosylaminoimidazole carboxylase# | 16 | 0.27 |
| Hs.119598 | ribosomal protein L3# | 16 | 0.27 |
| Hs.5464 | skeletal muscle abundant protein# | 16 | 0.27 |
| Hs.179526 | thioredoxin interacting protein # | 15 | 0.26 |
| Variable | PFNA (n = 72) | DHS (n = 70) | P value |
| Total complications | 15 | 31 | 0.003 |
| Patients affected | 15 (20.8%) | 31 (42.9%) | 0.003 |
| Medical complications | 3 | 5 | 0.442 |
| Patients affected | 3 (4.2%) | 5 (7.1%) | 0.442 |
| Urinary tract infection | 1 | 1 | 1.000 |
| Pulmonary embolism | 0 | 2 | 0.241 |
| Atrial fibrillation | 2 | 0 | 0.497 |
| Acute renal failure | 0 | 2 | 0.241 |
| Orthopaedic complications | 12 | 26 | 0.011 |
| Patients affected | 12 (16.7%) | 26 (37.1%) | 0.011 |
| Periprosthetic fracture | 3 (4.2%) | 11 (15.7%) | 0.021 |
| Prosthetic instability | 1 | 2 | 0.617 |
| Dislocation | 1 | 3 | 0.363 |
| Limb length discrepancy (>2.5 cm) | 1 | 2 | 0.617 |
| Abductor tendon deficiency | 2 | 2 | 1.000 |
| Heterotopic ossification | 1 | 1 | 1.000 |
| Intraoperative nerve injury | 1 | 1 | 1.000 |
| Aseptic loosening | 0 | 1 | 0.241 |
| Periprosthetic infection | 2 | 2 | 1.000 |
| WHO AFRO SLIPTA Checklist Audit Score Sheet (Section) | Total Points |
| Section 1: Documents & Records | 25 |
| Section 2: Management Reviews | 17 |
| Section 3: Organization & Personnel | 20 |
| Section 4: Client Management & Customer Service | 8 |
| Section 5: Equipment | 30 |
| Section 6: Internal Audit | 10 |
| Section 7: Purchasing and Inventory | 30 |
| Section 8: Process Control and Internal & External Quality Audit | 33 |
| Section 9: Information Management | 18 |
| Section 10: Corrective Action | 12 |
| Section 11: Occurrence/Incident Management & Process Improvement | 12 |
| Section 12: Facilities and Safety | 43 |
| Total Score | 258 |
| Correlate | OR | 95 % CI | p-value |
| Socio-demographic factors | |||
| Age | |||
| (base) 18–29 | 1.00 | ||
| 30–39 | 0.95 | 0.77,1.17 | 0.613 |
| 40–49 | 1.12 | 0.92,1.38 | 0.263 |
| 50–55 | 1.11 | 0.88,1.40 | 0.370 |
| Married/de facto | 0.69 | 0.58, 0.81 | 0.000 |
| Socioeconomic disadvantagea | |||
| (base) 1st quintile | 1.00 | ||
| 2nd quintile | 1.09 | 0.87,1.35 | 0.456 |
| 3rd quintile | 0.90 | 0.73,1.11 | 0.330 |
| 4th quintile | 0.97 | 0.78,1.21 | 0.819 |
| 5th quintile | 0.73 | 0.58,0.93 | 0.010 |
| Clinical factors | |||
| Depression (12 month) | 4.49 | 3.74,5.40 | 0.000 |
| Anxiety (12 month) | 1.27 | 1.02,1.57 | 0.025 |
| Alcohol Harmful/Hazardous Use | 1.38 | 1.20,1.59 | 0.000 |
| Life Events (12 month) | |||
| Serious personal injury | 1.27 | 1.07,1.51 | 0.006 |
| Relationship end | 1.46 | 1.18,1.80 | 0.001 |
| Family conflict | 1.95 | 1.64,2.32 | 0.000 |
| Difficulty finding work | 1.95 | 1.65,2.39 | 0.000 |
| Legal troubles | 1.27 | 1.00,1.60 | 0.046 |
| Loss of personal property | 1.66 | 1.23,2.23 | 0.001 |
| Left hemisphere | Right hemisphere | |
| V1 | ||
| Smooth objects | 0.92 ± 0.09 | 0.82 ± 0.09 |
| Textured objects | 1.63 ± 0.11 | 1.50 ± 0.13 |
| V2 | ||
| Smooth objects | 0.92 ± 0.06 | 0.88 ± 0.06 |
| Textured objects | 1.33 ± 0.07 | 1.28 ± 0.09 |
| V3 | ||
| Smooth objects | 0.98 ± 0.09 | 0.92 ± 0.06 |
| Textured objects | 1.26 ± 0.11 | 1.18 ± 0.09 |
| LOC | ||
| Smooth objects | 0.99 ± 0.09 | 1.00 ± 0.08 |
| Textured objects | 0.81 ± 0.09 | 0.82 ± 0.06 |
| FFA | ||
| Smooth objects | 0.96 ± 0.17 | 1.10 ± 0.10 |
| Textured objects | 0.79 ± 0.19 | 1.05 ± 0.15 |
| Parameter | UM | SM | Total | RR (95% CI) | p-value | χ2 | p-value | |
| Age | <60 | 64 (61.5) | 40 (38.5) | 104 (42.7) | 2.2 (1.3–3.7) | 0.003 | 9.326 | 0.009 |
| 60–119 | 65 (82.3) | 14 (17.7) | 79 (33.1) | 1.00 | ||||
| 120+ | 42 (71.2) | 17 (28.8) | 59 (24.2) | 1.6 (0.8–3.0) | 0.150 | |||
| Total | 171 (70.7) | 71 (29.3) | 242 | |||||
| Gender | Male | 85 (68.6) | 39 (31.5) | 124 (51.5) | 1.2 (0.8–1.7) | 0.483 | 0.548 | 0.459 |
| Female | 86 (72.9) | 32 (27.1) | 118 (48.5) | |||||
| Total | 171 (70.7) | 71 (29.3) | 242 | |||||
| Study sites | Bamenda | 33 (71.7) | 13 (28.3) | 46 (19.0) | 1.3 (0.7–2.4) | 0.523 | 5.540 | 0.236 |
| Limbe | 67 (77.9) | 19 (22.1) | 86 (36.0) | 1.00 | ||||
| Yaounde | 39 (62.9) | 23 (37.1) | 62 (25.6) | 1.7 (1.0–2.8) | 0.064 | |||
| Maroua | 11 (57.9) | 8 (42.1) | 19 (7.9) | 1.9 (1.0–3.7) | 0.086 | |||
| Ngaoundere | 21 (72.4) | 8 (27.6) | 29 (12.4) | 1.3 (0.6–2.5) | 0.614 | |||
| Total | 171 (70.7) | 71 (29.3) | 242 |
| Study | Main perspective | Subject | Method |
| Hansen, Hegrenes, Larsen, Sehested, & Stokstad, 2005 | Biological Economic | Financial impact of technical herd performance indicators | Mathematical and statistical modelling |
| Kristensen, Østergaard, Krogh, & Enevoldsen, 2007 | Biological Economic | Financial impact of technical herd performance indicators | Mathematical modelling |
| Kristensen & Enevoldsen, 2008 | Managerial | Farmers’ goals, beliefs attitudes and behaviour | Interviews and survey |
| Kristensen, Nielsen, Jensen, Vaarst, & Enevoldsen, 2008 | Biological Managerial | Risk for metritis. Veterinarians perceptions and decision making | Interviews combined with quantitative analysis of herd data |
| Jansen, van den Borne, Renes, van Schaik, Lam, & Leeuwis, 2009 | Biological Managerial | Farmers’ attitudes and behaviour | Survey |
| Lastein, Vaarst, & Enevoldsen, 2009 | Managerial | Veterinarians’ perceptions and decision making | Field observations and interviews |
| Vaarst & Tind Sørensen, 2009 | Biological Managerial | Dairy farmers’ perceptions and attitudes related to calf management | Semi-structured interviews |
| Van Asseldonk, Renes, Lam, & Hogeveen, 2010 | Managerial | Farmers’ perceptions, intentions, actions and decision makings | Interviews |
| Illumina cg ID | Chromosome | Genomic location | Genea | Gene region | HR (95 % CI)b | P value |
| cg15786837 | 17 | 46806935 | HOXB13 | TSS1500 | 1.86 (1.37–2.53) | 6.97E-05 |
| cg22030072 | 2 | 119603673 | EN1 | Body | 3.61 (1.90–6.88) | 9.54E-05 |
| cg13604794 | 17 | 48050338 | DLX4 | Body | 1.92 (1.37–2.69) | 1.47E-04 |
| cg18944010 | 1 | 119522855 | TBX15 | 5′UTR | 2.12 (1.43–3.15) | 1.88E-04 |
| cg01002529 | 3 | 69591807 | 2.35 (1.50–3.70) | 2.23E-04 | ||
| cg08261841 | 7 | 142982463 | TMEM139 | 5′UTR | 0.56 (0.41–0.77) | 2.82E-04 |
| cg02926307 | 12 | 106520198 | NUAK1 | Body | 0.40 (0.25–0.67) | 3.60E-04 |
| cg05075579 | 11 | 121421206 | SORL1 | Body | 3.60 (1.77–7.30) | 3.99E-04 |
| cg15350661 | 12 | 322641 | SLC6A12 | 5′UTR | 2.31 (1.45–3.70) | 4.10E-04 |
| cg02770983 | 11 | 31822341 | PAX6 | Body | 2.11 (1.39–3.19) | 4.66E-04 |
| cg00232535 | 7 | 5593287 | 0.47 (0.30–0.72) | 4.79E-04 | ||
| cg18343474 | 1 | 229566908 | 1.93 (1.33–2.80) | 4.87E-04 | ||
| cg00725138 | 22 | 19716556 | 0.50 (0.34–0.74) | 5.34E-04 | ||
| cg03695909 | X | 47346601 | 0.30 (0.15–0.59) | 5.49E-04 | ||
| cg26236177 | 14 | 61110649 | 1.77 (1.28–2.44) | 5.60E-04 | ||
| cg13434989 | 13 | 78493305 | EDNRB | TSS1500 | 1.83 (1.30–2.58) | 5.67E-04 |
| cg24006505 | 6 | 41337238 | 1.95 (1.33–2.58) | 6.04E-04 | ||
| cg04636194 | X | 49594154 | PAGE4 | 5′UTR | 0.43 (0.27–0.70) | 6.07E-04 |
| cg23429749 | 14 | 102050815 | 0.47 (0.31–0.73) | 6.12E-04 | ||
| cg05231018 | 17 | 46806763 | HOXB13 | TSS1500 | 1.70 (1.25–2.29) | 6.18E-04 |
| cg02492708 | 16 | 2005062 | RPL3L | TSS1500 | 0.50 (0.34–0.75) | 6.24E-04 |
| cg21211271 | 1 | 6265071 | RNF207 | TSS1500 | 2.37 (1.44–3.90) | 6.48E-04 |
| cg16009714 | 17 | 70241415 | 3.48 (1.70–7.12) | 6.60E-04 | ||
| cg00321709 | 10 | 135341933 | CYP2E1 | Body | 2.04 (1.35–3.08) | 6.69E-04 |
| cg20401252 | 2 | 5834062 | SOX11 | 1stExon | 1.90 (1.31–2.73) | 6.70E-04 |
| cg19827511 | 14 | 93580644 | ITPK1 | Body | 0.56 (0.39–0.78) | 6.86E-04 |
| cg10827488 | 11 | 113953838 | ZBTB16 | Body | 3.42 (1.68–6.96) | 6.97E-04 |
| cg04327247 | 9 | 100564659 | 0.50 (0.34–0.75) | 7.84E-04 | ||
| cg26511386 | 7 | 142982262 | TMEM139 | 5′UTR | 0.52 (0.36–0.76) | 8.02E-04 |
| cg00332067 | 12 | 55004429 | GLYCAM1 | TSS200 | 2.10 (1.36–3.24) | 8.30E-04 |
| Parameter | Value | Parameter | Value |
| Radio chip | CC 2420 | TsRxWait | 2.2 ms |
| Transmit power (0 dBm) | 57.42 mW | TsAck (26 bytes) | 0.832 ms |
| Receive power | 62.04 mW | TsCCA | 0.128 ms |
| Listen power | 62.04 mW | TsRxTx (TxRx turnaround) | 0.192 ms |
| TsMaxPacket (133 bytes) | 4.256 ms |
| RD CsA (n = 99) | ST CsA (n = 100) | |
| Everolimus dose (mg/day) | ||
| Month 1 | 1.3 ± 0.5 | 1.4 ± 0.6 |
| Month 6 | 1.4 ± 0.6 | 1.3 ± 0.5 |
| Everolimus trough concentration (ng/mL) | ||
| Month 1 | 5.8 ± 3.6 | 5.8 ± 2.5 |
| Month 6 | 4.8 ± 1.7 | 5.3 ± 2.3 |
| Cyclosporine dose (mg/kg/day) | ||
| Month 1 | 3.8 ± 1.3 | 4.0 ± 1.4 |
| Month 6 | 2.5 ± 1.0 | 2.8 ± 0.8 |
| Cyclosporine trough concentration (ng/mL) | ||
| Months 1-2 | 195 ± 78 | 209 ± 87 |
| Month 6 | 120 ± 63 | 154 ± 68 |
| Cyclosporine C2 concentration (ng/mL) | ||
| Months 1-2 | 742 ± 272 | 693 ± 244 |
| Month 6 | 566 ± 278 | 707 ± 284 |
| Steroid dosea | 0.50 ± 1.40 | 0.32 ± 0.25 |
| Induction therapy | ||
| Antithymocyte globulin | 60 (60.6%) | 61 (61.0%) |
| Interleukin-2 receptor antagonist | 21 (21.2%) | 20 (20.0%) |
| Overall, n (%) n = 1096 | Male n (%) n = 460 (42.0) | Female n (%) n = 636 (58.0) | p-Value | |
| Age in years | ||||
| 10–12 | 635 (57.9) | 259 (56.3) | 376 (59.1) | |
| 13–14 | 461 (42.1) | 201 (43.7) | 260 (40.9) | 0.351 |
| Pubertal age (Tanner 1–5) | ||||
| Tanner 1 or 2 | 509 (46.4) | 217 (47.2) | 292 (45.9) | 1 |
| Tanner stage >2 | 584 (53.6) | 243 (52.8) | 344 (54.1) | |
| Education level | ||||
| Primary 5 | 563 (51.4) | 240 (52.2) | 323 (50.8) | |
| Primary 6 | 533 (48.6) | 220 (47.8) | 313 (49.2) | 0.650 |
| Socio-economic status | ||||
| Low | 315 (29.0) | 128 (28.2) | 187 (29.6) | |
| Medium | 511 (47.1) | 215 (47.4) | 296 (46.8) | |
| High | 260 (23.9) | 111 (24.4) | 149 (23.6) | 0.871 |
| Religion | ||||
| Moslem | 101 (9.2) | 48 (10.5) | 53 (8.3) | |
| Anglican/Pentecostal | 587 (53.7) | 245 (53.5) | 342 (53.9) | |
| Catholic | 405 (37.1) | 165 (36.0) | 240 (37.8) | 0.462 |
| Family and school factors | ||||
| Location of school | ||||
| Rural | 896 (81.8) | 368 (80) | 529 (83.2) | |
| Urban | 199 (18.2) | 92 (20) | 107 (16.8) | 0.178 |
| School absenteeism (truancy) | 249 (22.7) | 100 (21.7) | 149 (23.4) | 0.510 |
| Ever experienced bullying at school | 79 (17.3) | 119 (18.7) | 198 (18.1) | 0.528 |
| Number of parents alive | ||||
| Both alive | 905 (82.5) | 378 (82.2) | 527 (82.8) | |
| None/Single parent | 124 (11.3) | 48 (10.4) | 76 (12.0) | 0.350 |
| Access to media (TV, Social media or Tabloids) | ||||
| Television | 458 (41.8) | 217(47.3) | 241 (37.9) | 0.002 |
| Tabloid newspapers | 222 (20.3) | 125 (27.2) | 97 (15.3) | <0.0001 |
| Social media | 70 (6.4) | 27 (5.9) | 43 (6.8) | 0.558 |
| Ever watched pornographic content | 389 (35.5) | 191 (41.5) | 198 (31.2) | <0.0001 |
| Sexual behavior | ||||
| Ever had sex | 83 (7.6) | 67 (14.6) | 16 (2.5) | <0.0001 |
| Features | Missense mutations identified as divergent variants based on the analysis of whole-genome sequence datasets from Churra and Australian Merino samples | |||
| SNP position (Oar_v3.1) | 52,429,848 | 37,308,727 | 37,3557,21 | 37,356,400 |
| Chromosome | 2 | 6 | 6 | 6 |
| dbSNP_ID | rs160159505 | rs159958168 | rs419074913 | rs159958380 |
| Gene | NPR2 | NCAPG | LCORLa | LCORLa |
| Ref. (Texel Oar_v3.1) → Altb | T → C | C → T | T → A | A → T |
| Position in CDS | c.2540 | c.1754 | c.4321c | c.3642c |
| Base pair substitution in CDS | T → C | C → T | A → T | T → A |
| Breed (mutant allele)d | Merino | Merino | Churra | Merino |
| Codon change | cAc → cGc | TCC → TTC | ATA → TTA | GAT → GAA |
| Amino acid change | Histitine (H) → Arginine (R) | Serine (S)→ Phenilalanine (F) | Isoleucine (I)→ Leucine (L) | Aspartate (D) → Glutamate (E) |
| Protein change | NPR2_His847Arg | NCAPG_Ser585Phe | LCORL_Ile1441Leu | LCORL_Asp1214Glu |
| Functional impact (ensemblVEP_Oarv3.1) | Moderate | Moderate | Moderate | Moderate |
| Functional impact (Polyphen-2) | Benign | Benign (score = 0.252; sensitivity: 0.91; specificity: 0.88) | Benign | Benign |
| Functional impact (SIFT_Oarv3.1) | Tolerated | Deleterious | Tolerated (low confidence) | Tolerated |
| Properties of wild aminoacid | Moderate hydropathy, charge “+” | Hydrophilic, polar, no charge | Hydrophobic, no charge | Hydrophilic, charge “−” |
| Properties of mutant aminoacid | Hydrophilic, charge “+” | Hydrophobic, apolar, no charge | Hydrophobic, no charge | Hydrophilic,, charge “−” |
| Churra genotypes | TT (15) | CC (14), CT (1) | AT (1), TT (14) | AA (14), AT (1) |
| Australian Merino genotypes | CC (9), TC (4) | TT (9), TC (3), CC (1) | AA (9), AT (3), TT (1) | TT (9), TA (3), AA (1) |
| SNPs | Alleles | CAD | Control | OR | 95% CI | p |
| n (%) | n (%) | |||||
| rs6510599 | C | 324 (59.3) | 157 (56.5) | 1.125 | 0.840–1.507 | 0.455 |
| T | 222 (40.7) | 121 (43.5) | ||||
| rs35369365 | G | 182 (35.5) | 96 (32.8) | 1.172 | 0.866–1.586 | 0.320 |
| A | 330 (64.5) | 204 (67.2) | ||||
| rs9282860 | T | 76 (13.7) | 40 (13.9) | 1.014 | 0.672–1.532 | 1.000 |
| C | 478 (86.3) | 248 (86.1) | ||||
| rs3764640 | G | 176 (35.9) | 104 (38.2) | 1.104 | 0.813–1.500 | 0.531 |
| T | 314 (64.1) | 168 (61.8) | ||||
| rs12977689 | C | 341 (65.1) | 199 (70.6) | 1.287 | 0.941–1.759 | 0.117 |
| A | 183 (34.9) | 83 (29.4) |
| Predictors of analgesia/sedation | Univariate | Multivariate | ||
| p-value | OR (95% CI) | p-value | OR (95% CI) | |
| Gestational age (weeks) ≤32 | <.0001 | 3.54 (2.15–5.83) | ||
| CRIB score | <.0001 | 2.03 (1.66–2.48) | 0.0002 | 1.46 (1.20–1.77) |
| Asphyxia, APGAR <5 at 5’ | <.0001 | 33.17 (6.17–178.29) | ||
| Sex, female | 0.2999 | 0.78 (0.49–1.25) | ||
| Born in same hospital as NICU | 0.0307 | 0.497 (0.26–0.96) | ||
| Type of ventilation | ||||
| Invasive vs Spontaneous | <.0001 | 117.16 (43.88–312.82) | <.0001 | 62.59 (22.01–177.97) |
| Noninvasive vs Spontaneous | 2.61 (1.14–5.98) | 2.60 (1.02–6.61) | ||
| Use of pain scales | <.0001 | 19.04 (5.92–61.19) | 0.0046 | 5.38 (1.69–17.16) |
| Pain specialist physician | 0.2891 | 0.50 (0.14 – 1.81) | ||
| Pain specialist nurse | 0.1111 | 0.41 (0.14–1.23) | ||
| Pain management team | 0.4972 | 1.42 (0.52–3.91) | ||
| Local guidelines for pain assessment | 0.8953 | 1.10 (0.27–4.55) | ||
| NICU beds (≤ 15 beds vs >15 beds) | 0.0089 | 3.68 (1.39–9.77) | 0.0372 | 3.55 (1.08–11.69) |
| Number of NICU admission | 0.0677 | 0.99 (0.98–1.00) |
| Control (n = 10) | TP4 (n = 10) | |||||
| Time (Day) | 1 | 3 | 6 | 1 | 3 | 6 |
| GOT (U/L) | 42.1 ± 1.3 A | 44.2 ± 2.1 A | 41.6 ± 1.5 A | 102.1 ± 32.1 C | 43.2 ± 1.5 A | 45 ± 6.1 A |
| GPT (U/L) | 45.2 ± 1.1 A | 43.4 ± 4.3 A | 46.1 ± 3.3 A | 81.2 ± 5.2 C | 41.2 ± 4.7 A | 48 ± 3.7 A |
| CRE (mg/dL) | 0.2 ± 0.1 A | 0.6 ± 0.3 A | 0.4 ± 0.2 A | 0.3 ± 0.1 A | 0.5 ± 0.1 A | 0.5 ± 0.1 A |
| BUN (mg/dL) | 13.1 ± 2.1 A | 14 ± 0.3 AB | 16.1 ± 1 A | 14.2 ± 1.4 A | 15.4 ± 1.3 A | 16.2 ± 1 A |
| GLU (mg/dL) | 206.0 ± 11.1 A | 213.1 ± 11.3 A | 208 ± 13.1 A | 238.6 ± 32.1 AB | 209.1 ± 7.2 A | 220.1 ± 23.5 A |
| CPK (U/L) | 101.3 ± 1.7 A | 110.1 ±6.3 A | 104.9 ± 4.2 A | 109 ± 11.1 A | 108.1 ± 3.2 A | 109 ± 25.3 AB |
| Condition | Number (%) of cases | Mean number of coded diagnoses by coding volume | Mean number of coded diagnoses by employment status | Hospital level | |||
| Low | High | Part time | Full time | Non tertiary | Tertiary | ||
| Most complexDiabetes with complications | 2007(0.5%) | 7.9 | 7.9 | 7.7 | 7.9 | 7.0 | 9.5 |
| Alcohol abuse | 2511(0.6%) | 5.3 | 5.4 | 5.6 | 5.3 | 5.1 | 5.9 |
| Diabetes uncomplicated | 1802(0.4%) | 5.0 | 4.9 | 4.4 | 5.2 | 4.4 | 6.8 |
| Depression | 5860(1.4%) | 4.4 | 4.3 | 4.7 | 4.2 | 4.2 | 4.7 |
| Calculus of ureter | 3616(0.9%) | 1.5 | 1.7 | 1.5 | 1.7 | 1.6 | 1.4 |
| Singleton born in hospitalLeast Complex | 38,307(9.1) | 1.3 | 1.6 | 1.5 | 1.2 | 1.6 | 1.1 |
| Campylobacter phage | CP68 | CP75 | CP84 | CP7 | CP83 | CP21 | IBB_35 a |
| Infected strains | 31 (255) | 30 (255) | 34 (255) | 19 (255) | 15 (255) | 17 (255) | 12 (90)a |
| % positive | 12.2 | 11.8 | 13.3 | 7.5 | 5.9 | 6.7 | 13.3 |
| C. jejuni strains | 21 (227) | 20 (227) | 24 (227) | 14 (227) | 13 (227) | 13 (227) | 5 (76)a |
| % positive | 9.3 | 8.8 | 10.6 | 6.2 | 5.7 | 5.7 | 6.6 |
| C. coli strains | 10 (18) | 10 (18) | 10 (18) | 5 (18) | 2 (18) | 4 (18) | 7 (14)a |
| % positive | 55.6 | 55.6 | 55.6 | 27.8 | 11.1 | 22.2 | 50.0 |
| C. lari strains | 0 (5) | 0 (5) | 0 (5) | 0 (5) | 0 (5) | 0 (5) | 0 (5) |
| % positive | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| C. fetus strains | 0 (2) | 0 (2) | 0 (2) | 0 (2) | 0 (2) | 0 (2) | 0 (2) |
| % positive | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| C. sputorum strains | 0 (2) | 0 (2) | 0 (2) | 0 (2) | 0 (2) | 0 (2) | 0 (2) |
| % positive | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| C. hyointestinalis strains | 0 (1) | 0 (1) | 0 (1) | 0 (1) | 0 (1) | 0 (1) | 0 (1) |
| % positive | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Phage subgroup | A | A | A | B | B | B | (A) |
| Sample | Accession no. | ciHHV-6 | Integration sitea | Population or country |
| LEI-1501b | KT355575 | A | 19q | Leicester area (England) |
| HAPMAP NA18999 | KY316047 | A | Japan | |
| 3A-10q26.3c | KY316049 | A | 10q26.3 and junction isolated by PCR | Southeast England |
| GLA_4298d | KY316056 | A | Newcastle (England) | |
| GLA_15137e | KY316055 | A | Scotland | |
| GLA_ 25506e | KY316054 | A | Scotland | |
| 7A-17p13.3c | KY316048 | A | 17p13.3 | Southeast England |
| HGDP00092 | KY316037 | B | Balochi (Pakistan) | |
| HGDP00813 | KY316036 | B | Han (China) | |
| HGDP01065 | KY316035 | B | Junction isolated by PCR | Sardinia (Italy) |
| HGDP01077 | KY316034 | B | Junction isolated by PCR | Sardinia (Italy) |
| HAPMAP NA07022 (CEPH 1340.11) | KY316039 | B | Utah Mormon (north European) | |
| HAPMAP NA10863 (CEPH-1375.02) | KY316038 | B | Utah Mormon (north European) | |
| 4B-11p15.5c | KY316044 | B | 11p15.5 | Southeast England |
| BAN519f | KY316043 | B | Banff (Scotland) | |
| COR264f | KY316042 | B | Cornwall (England) | |
| CUM082f | KY316041 | B | Cumbria (England) | |
| DER512f | KY316040 | B | Junction isolated by PCR | Derbyshire (England) |
| 2B-9q34.3c | KY316045 | B | 9q34.3 | Southeast England |
| 1-ciHHV-6Bc | KY316046 | B | Junction isolated by PCR | Southeast England |
| LEI-ALD | KY316033 | B | Leicester area (England) | |
| ORCA1622 | KY316031 | B | Orkney | |
| ORCA1340 | KY316032 | B | Orkney | |
| ORCA3835 | KY316030 | B | Orkney | |
| GLA_3986d | KY316053 | B | Newcastle (England) | |
| GLA_29221e | KY316052 | B | Scotland | |
| GLA_34108e | KY316051 | B | Scotland | |
| GLA_35629e | KY316050 | B | Scotland |
| Variable | Adjusted odds ratio | 95% confidence interval | |
| Age (years) | 65-74 vs <65 | 1.82 | 1.49, 2.23 |
| 75-84 vs <65 | 2.52 | 2.11, 3.02 | |
| 85+ vs < 65 | 3.31 | 2.76, 3.95 | |
| Female | 1.14 | 1.04, 1.24 | |
| MAPLe score‡ | 2 vs 1 | 1.45 | 1.16, 1.81 |
| 3 vs 1 | 2.82 | 2.38, 3.33 | |
| 4 vs 1 | 3.42 | 2.88, 4.06 | |
| 5 vs 1 | 4.86 | 4.02, 5.88 | |
| Dementia | 1.79 | 1.63, 1.98 | |
| Injurious fall | 1.31 | 1.15, 1.49 | |
| Sepsis | 0.43 | 0.26, 0.72 | |
| Pneumonia | 0.70 | 0.65, 0.97 |
| Items | Low-Fps:Cps | High-Fps:Cps | P-value | |||||
| FA, g/d | 0 | 24 | 0 | 24 | SEM | Fps:Cps | FA | (Fps:Cps) × FA |
| CH4, L/d | 23.14 | 15.80 | 22.84 | 18.75 | 1.245 | 0.552 | 0.021 | 0.466 |
| CH4/DMI, L/kg | 21.03 | 14.54 | 20.94 | 17.95 | 1.044 | 0.365 | 0.020 | 0.341 |
| pH | 6.38 | 6.52 | 6.40 | 6.51 | 0.027 | 0.887 | 0.020 | 0.817 |
| Total VFA, mmol/L | 89.19 | 85.89 | 87.01 | 80.53 | 1.326 | 0.633 | < 0.001 | 0.187 |
| Individual VFA molar proportion, % | ||||||||
| Acetate | 70.24 | 65.50 | 66.93 | 63.50 | 0.526 | 0.009 | < 0.001 | 0.518 |
| Propionate | 14.80 | 20.58 | 19.07 | 21.98 | 0.437 | 0.001 | < 0.001 | 0.074 |
| Butyrate | 11.93a | 10.79b | 10.82b | 11.20ab | 0.170 | 0.303 | 0.259 | 0.026 |
| A:P | 4.89a | 3.62b | 3.74b | 3.15c | 0.095 | < 0.001 | < 0.001 | 0.048 |
| Case vignette | Respondents, n | Rank sum |
| 1 | 19 | 460.50 |
| 2 | 16 | 564.50 |
| 3 | 19 | 860.50 |
| 4 | 19 | 815.50 |
| Collaborative Problem Solving Skills | N | Mean | Standard Deviation | |
| Social Skills | Participation | 210 | 3.07 | 1.316 |
| Perspective Taking | 210 | 3.09 | 1.347 | |
| Social Regulation | 210 | 3.10 | 1.364 | |
| Cognitive skills | Task Regulation | 210 | 3.00 | 1.334 |
| Knowledge Building | 210 | 2.92 | 1.326 |
| Recall | |||
| 25 % | 50 % | 75 % | |
| Precision to benign | 82 % | 66 % | 52 % |
| Precision to malignant | 86 % | 74 % | 62 % |
| Precision (n=30) | |||
| Benign | 85 % | ||
| Malignant | 87 % |
| Variable | Whole sampleN = 3033n (%) | Public facilitiesn = 2751n (%) | Private facilitiesn = 282n (%) | P-Value |
| Age in years | < 0.001 | |||
| 15-24 | 1444(48.4) | 1378(50.9) | 66(23.8) | |
| > 25 | 1541(51.6) | 1330(49.1) | 211(76.2) | |
| Education/grades completed | < 0.001 | |||
| 0 - 4 | 1061(35.1) | 1060(38.7) | 1(0.4) | |
| 5 - 8 | 857(28.4) | 846(30.9) | 11(3.9) | |
| > 9 | 1103(36.5) | 834(30.4) | 269(95.7) | |
| Number of pregnancies | < 0.01 | |||
| 1 | 1524(50.3) | 1357(49.3) | 167(59.2) | |
| > 2 | 1508(49.7) | 1393(50.7) | 115(40.8) | |
| PMTCT knowledge | < 0.001 | |||
| Knowledgeable | 2240(76.5) | 1987(75.0) | 253(91.0) | |
| Not knowledgeable | 687(23.5) | 662(25.0) | 25(9.0) | |
| Previous HIV testing experience | < 0.001 | |||
| Yes | 2450(81.0) | 2185(79.7) | 265(94.0) | |
| No | 575(19.0) | 558(20.3) | 17(6.0) | |
| Previous HIV testing experiencewith partner | < 0.001 | |||
| Yes | 1673(57.2) | 1465(55.3) | 208(75.6) | |
| No | 1250(42.8) | 1183(44.7) | 67(24.4) | |
| Type of pre-test counselling | < 0.001 | |||
| Group pre-test information | 2130(73.8) | 2098(77.1) | 32(19.4) | |
| Individual counselling | 757(26.2) | 624(22.9) | 133(80.6) |
| Items | Benefits | Barriers | Unique Variance | |
| Osteoporosis drug treatment benefits† | ||||
| 1 | Drug treatments can help to build strong bones | 0.80 | 0.07 | 0.36 |
| 2 | You would feel good about taking drug treatments to prevent osteoporosis | 0.94 | -0.06 | 0.11 |
| 3 | Drug treatments can cut down the chances of broken bones | 0.87 | 0.10 | 0.25 |
| 6 | You would consider taking drug treatments to prevent broken bones | 0.90 | -0.06 | 0.17 |
| 11 | If your doctor advised you to, you would take drug treatments to prevent broken bones | 0.78 | -0.12 | 0.36 |
| Drug treatment barriers† | ||||
| 8‡ | You are taking too many medications | -0.12 | 0.85 | 0.25 |
| 9‡ | You have stomach problems that limit your ability to take drug treatment | 0.14 | 0.56 | 0.69 |
| β | S.E. | OR | CI 95% | p-value | |
| Pulse oximetry (SpO2 < 95%) | 1.39 | 0.63 | 4.02 | 1.16–13.85 | 0.022 |
| Clinical stage (III vs. IV) | 0.78 | 0.43 | 2.18 | 0.93–5.06 | 0.070 |
| Appetite (10 mm) | 0.13 | 0.06 | 1.14 | 1.01–1.30 | 0.041 |
| Fatigue (10 mm) | 0.21 | 0.09 | 1.23 | 1.03–1.47 | 0.019 |
| Responders | Biofeedback group | Control group |
| T2 | ||
| n (%) | 10 (67 %) | 2 (17 %) |
| T3 | ||
| n (%) | 12 (80 %) | 3 (25 %) |
| T4 | ||
| n (%) | 7 (47 %) | 2 (17 %) |
| Category | |||||
| Occupation | Documentation (N = 38) fraction % | Interactions (N = 36) fraction % | Adverse effects (N = 16) fraction % | Pregnancy and breastfeeding (N = 9) fraction % | Contraindications (N = 1) fraction % |
| Physicians (N = 54) | 23/54 42.6 | 15/54 27.8 | 12/54 22.2* | 3/54 5.6 | 1/54 1.9 |
| Pharmacists (N = 33) | 10/33 30.3 | 20/33 60.6** | 1/33 3.0 | 2/33 6.1 | |
| Midwifes (N = 3) | 3/3 100.0 | ||||
| Nurses (N = 2) | 1/2 50.0 | 1/2 50.0 | |||
| Other (N = 8)a | 4/8 50.0 | 1/8 12.5 | 3/8 37.5 |
| Genotype | Case | Control | Dominant | Recessive | Additive | |||
| n (%) | n (%) | OR (95%CI) | p | OR (95%CI) | p | OR (95%CI) | p | |
| GG | 89 (18.39) | 46 (21.90) | 0.96 (0.65,1.42) | 0.83 | 0.68 (0.44,1.06) | 0.09 | 0.87 (0.67,1.12) | 0.27 |
| GA | 243 (50.21) | 101 (48.10) | ||||||
| AA | 152 (31.40) | 63 (30.00) |
| Overall frequency | Uptake of facility-based delivery | ||||||
| N | % | % | PRu | 95 % CI | PRa | 95 % CIa | |
| Self-reported HIV status | (p < 0.001) | (p < 0.001) | |||||
| Not tested / unknown status before delivery | 686 | (7.8) | 44.4 | 0.56 | (0.49–0.64) | 0.60 | (0.54–0.68) |
| Self-reported HIV-negative before delivery | 7067 | (80.3) | 79.3 | 1.00 | 1.00 | ||
| Self-reportedHIV-positive before pregnancy | 584 | (6.6) | 82.2 | 1.04 | (0.99–1.09) | 1.04 | (1.00–1.09) |
| Self-reported HIV-positive during pregnancy | 459 | (5.2) | 80.4 | 1.01 | (0.97–1.06) | 1.05 | (1.01–1.09) |
| Aneurysms | Pseudo-aneurysms | |
| Location | 3% posterior | Posterior or inferior |
| Echocardiography | ||
| Anatomy | Thinned myocardium | Ruptures |
| Contractility | Non contractile | Dyskinesia |
| Consequences/Complications | Congestive heart failureEmbolic eventsVentricular arrhythmias | |
| Therapy | Medical or Surgical therapy | Surgery |
| Surgical risk | Dubious | Lower than medical therapy |
| Impression technique | n | Internal discrepancy to master model (μm) | |||||
| Premolar 34 | Molar 36 | FDP 34–36 | |||||
| Mean | (SD) | Mean | (SD) | Mean | (SD) | ||
| Conventional | 10 | 100 | 6.7 | 127 | 15.7 | 117 | 11.6 |
| Digital | 10 | 91 | 8.8 | 95 | 8.5 | 93 | 8.2 |
| Significance (2-tailed) (P < 0.01) | 0.016 | <0.001 | <0.001 |
| Numb PTB/Pon A2B2 complex | Numb PTB/Pon B1A2 complex | |
| Data collection | ||
| Space group | P3221 | P3112 |
| Cell dimensions | ||
| a, b, c (Å) | 43.392, 43.392, 181.304 | 65.593, 65.593, 143.879 |
| α, β, γ (°) | 90, 90, 120 | 90, 90,120 |
| Resolution (Å) | 50.00–2.00 (2.03–2.00)a | 50.00–1.70 (1.73–1.70)a |
| Rmerge (%) | 5.2 (76.2) | 5.6 (79.5) |
| I/σI | 24.6 (2.0) | 52.1 (3.1) |
| Completeness (%) | 98.6 (96.7) | 99.3 (97.7) |
| Redundancy | 4.8 (4.3) | 9.8 (9.4) |
| Refinement | ||
| Resolution (Å) | 36.80–2.00 | 30.39–1.70 |
| No. of reflections | 13,901 | 39,079 |
| Rwork/Rfree | 19.1/22.7 | 19.4/21.8 |
| No. of atoms | ||
| Protein | 1222 | 2164 |
| FMT | 3 | |
| Glycerol | 12 | |
| Water | 53 | 155 |
| B-factors | ||
| Protein | 30.84 | 29.00 |
| FMT | 41.56 | |
| Glycerol | 38.18 | |
| Water | 31.58 | 32.91 |
| R.m.s. deviations | ||
| Bond lengths (Å) | 0.010 | 0.011 |
| Bond angles (°) | 0.951 | 1.138 |
| Variable | Min | Max | Mean | SD | CV |
| RVd (cm) | 4.3 | 8.0 | 5.3 | 1.2 | 22% |
| RVs (cm) | 4.2 | 4.6 | 4.1 | 0.4 | 10% |
| LVd (cm) | 9.9 | 15.5 | 11.8 | 1.6 | 14% |
| LVs (cm) | 7.8 | 9.4 | 8.2 | 0.6 | 10% |
| RAd (cm) | 5.0 | 6.5 | 5.9 | 0.5 | 10% |
| RAs (cm) | 3.0 | 4.5 | 3.9 | 0.4 | 10% |
| LAd (cm) | 6.8 | 8.8 | 7.6 | 0.6 | 10% |
| LAs (cm) | 4.7 | 6.4 | 5.6 | 0.5 | 10% |
| RVWd (cm) | 1.5 | 2.4 | 1.8 | 0.2 | 10% |
| RVWs (cm) | 1.2 | 2.0 | 1.5 | 0.2 | 13% |
| IVSd (cm) | 1.7 | 3.0 | 2.1 | 0.3 | 14% |
| IVSs (cm) | 1.2 | 3.9 | 2.8 | 0.7 | 30% |
| LVWd (cm) | 1.8 | 3.4 | 2.8 | 0.4 | 14% |
| LVWs (cm) | 1.1 | 2.4 | 1.9 | 0.4 | 21% |
| AOd(cm) | 6.0 | 8.2 | 7.0 | 0.8 | 11% |
| PAd (cm) | 6.0 | 9.7 | 8.1 | 1.2 | 15% |
| TVDs (cm) | 2.6 | 6.8 | 4.1 | 1.1 | 27% |
| MVDs (cm) | 4.3 | 7.8 | 6.2 | 1.0 | 16% |
| District | No. of IDUs | Male | Female | Married | Education | Economic status |
| Peshawar | 100 | 98 | 2 | 62 | ||
| Kohat | 60 | 60 | - | 30 | Basic: 98% | < 1$/day: 95% |
| Mardan | 40 | 40 | - | 28 | High: 2% | Well off: 5% |
| Total | 200 | 198 | 2 | 120 |
| Tb (°C) | Season | |||||||
| Dec–Feb “Summer” | Mar–May “Autumn” | Jun–Aug “Winter” | Sep–Nov “Spring” | |||||
| M (n = 12) | F (n = 6) | M (n = 12) | F (n = 6) | M (n = 10) | F (n = 5) | M (n = 8) | F (n = 5) | |
| Mean | 37.7 ± 0.1 | 37.8 ± 0.1 | 37.5 ± 0.2 | 37.7 ± 0.1 | 37.3 ± 0.3 | 37.5 ± 0.5 | 37.5 ± 0.2 | 37.7 ± 0.1 |
| Minimum | 36.7 ± 0.2 | 36.7 ± 0.3 | 36.3 ± 0.2 | 36.8 ± 0.2 | 35.9 ± 0.4 | 36.3 ± 0.5 | 36.0 ± 0.3 | 36.4 ± 0.3 |
| Maximum | 38.8 ± 0.1 | 39.0 ± 0.1 | 38.7 ± 0.2 | 38.8 ± 0.1 | 38.6 ± 0.4 | 38.6 ± 0.6 | 38.8 ± 0.2 | 39.0 ± 0.1 |
| Amplitude | 2.1 ± 0.2 | 2.3 ± 0.3 | 2.5 ± 0.3 | 2.1 ± 0.2 | 2.7 ± 0.6 | 2.3 ± 0.3 | 2.8 ± 0.5 | 2.6 ± 0.3 |
| Gene | Primer | Annealing Temp (° C) |
| Fshr | F: TGGAGGCGGCAAACCTCTGAAC | 65 |
| R: TCTGGCTTTGGCGAGCAGGTC | ||
| Oct-4A | F: CCATGTCCGCCCGCATACGA | 61 |
| R: GGGCTTTCATGTCCTGGGACTCCT | ||
| Total | F: CCTGGGCGTTCTCTTTGGAAAGGTG | 68 |
| Oct-4 | R: GCCTGCACCAGGGTCTCCGA | |
| Nanog[34] | F: CAGGAGTTTGAGGGTAGCTC | 61 |
| R: CGGTTCATCATGGTACAGTC | ||
| Stella | F: ACGCTTTGGATGATACAGACGTCC | 67 |
| R: GCGCTTTGAACTTCCCTCCGGA | ||
| Fragilis | F: GGGGTGACTGAGCTGGGGGAA | 65 |
| R: TGTCCCTAGACTTCACAGAGTAGGC | ||
| Nobox | F: AGGGTGCTGAGAGGGTGGCAG | 66 |
| R: GGCGATACTAGTGCCCCAGGAC | ||
| HoxA10 | F:CACTTGTCCGGCACCCCTTCG | 65 |
| R: TTCGCCTTTGGAACTGCCTTGAC | ||
| Mvh | F: AGTGGAAGTGGTCGAGGTGGT | 61 |
| R: TGCCGGTGGTGCATCATGTCC | ||
| Scp3 | F: TGTTGCAGCAGTGGGAACTGGAT | 68 |
| R: CCATCTCTTGCTGCTGAGTTTCCA | ||
| Dmc-1 | F: TGGGGAATTGGCTGAACGCC | 68 |
| R: CAGGCATCTCGGGGCTGTCATAA | ||
| Stra8 | F: GTTTCCTGCGTGTTCCACAAG | 61 |
| R: CACCCGAGGCTCAAGCTTC | ||
| 18s | F:GGAGAGGGAGCCTGAGAAAC | 61 |
| R: CCTCCAATGGATCCTCGTTA | ||
| Gapdh[34] | F: GTCCCGTAGACAAAATGGTGA | 58 |
| R: TGCATTGCTGACAATCTTGAG |
| Cohorta | Age (years) | Effect | Measurement | Reference | |
| Verbal functions | |||||
| Vocabulary | Oswego | 3 | ↓ | MSCA Word Knowledge | Stewart et al. 2003b |
| 4.5 | – | MSCA Word Knowledge | Stewart et al. 2003b | ||
| Michigan | 4 | – | PPVT | Jacobson et al. 1990 | |
| 11 | ↓ | WISC-R Vocabulary | Jacobson and Jacobson 1996 | ||
| 11 | ↓ | WRMT Word Comprehension | Jacobson and Jacobson 1996 | ||
| Faroe Islands | 7 | –b | BNT | Grandjean et al. 2001 | |
| Verbal comprehension | Netherlands | 3.5 | ↓c | RLDS | Patandin et al. 1999b |
| Reading comprehension | Michigan | 11 | ↓ | WRMT Reading Comprehension | Jacobson and Jacobson 1996 |
| Verbal abstraction | Michigan | 11 | ↓ | WISC-R Similitudes | Jacobson and Jacobson 1996 |
| Faroe Islands | 7 | – | WISC-R Similitudes | Grandjean et al. 2001 | |
| Visual–spatial functions | |||||
| Visuo-motor integration | Oswego | 3 | ↓ | MSCA Block Building | Stewart et al. 2003b |
| 4.5 | – | MSCA Block Building | Stewart et al. 2003b | ||
| Michigan | 4 | – | BTVMI | Jacobson et al. 1990 | |
| Netherlands | 9 | – | Rey Complex Figure Test copy | Vreugdenhil et al. 2004a | |
| Faroe Islands | 7 | – | WISC Block Design | Grandjean et al. 2001 | |
| Mental rotation | Michigan | 11 | – | Mental Rotation | Jacobson and Jacobson 2003 |
| Visual discrimination | Michigan | 4 | – | KMFF | Jacobson et al. 1992 |
| Period | Experimental Station | Control Station | ||||||
| Male | Female | Total | Number of trains | Male | Female | Total | Number of trains | |
| Pre | 666 | 575 | 1,241 | 257 | 290 | 216 | 506 | 239 |
| Intervention | 1,115 | 1,164 | 2,279 | 247 | 243 | 216 | 459 | 246 |
| Post | 585 | 555 | 1,140 | 254 | 254 | 199 | 453 | 253 |
| Characteristics | Values |
| Sex | |
| Male | 41 (41.4%) |
| Female | 58 (58.6%) |
| Profession | |
| Medical Staff | 31 (31.3%) |
| Nursing Staff | 68 68.7%) |
| Age | |
| Years 20 – 29 | 59 (59.6%) |
| Years 30 – 39 | 37 (37.4%) |
| Years 40 – 49 | 2 (2.0%) |
| Drug | Theoretical Plates (n=6) | Tailing Factor (n=6) | Capacity Factor (n=6) | ||||||
| SD | Mean | R.S.D | SD | Mean | R.S.D | SD | Mean | R.S.D | |
| TRZ | 7.11 | 7029.16 | 0.101 | 0.00548 | 1.055 | 0.519 | 0.0131 | 2.3575 | 0.558 |
| PRZ | 12.72 | 6034.16 | 0.210 | 0.00837 | 1.105 | 0.757 | 0.0336 | 5.569 | 0.604 |
| DXZ | 24.77 | 5930.16 | 0.417 | 0.00837 | 1.085 | 0.771 | 0.0843 | 9.535 | 0.884 |
| Technique | Detection capability (mutant DNA/total DNA) (%) |
| Sanger sequencing | >10 |
| Pyrosequencing | 10 |
| Next-generation sequencing | >1 |
| Real-time | 1 |
| ARMS | 0.1 |
| Digital droplet PCR, BEAMing, PAP, TAM-seq, Safe-SeqS, CAPP-seq, PARE | <0.01 |
| dry season | wet season | |||||
| n | g kg−1 DM | n | g kg−1 DM | |||
| greater kudu (Tragelaphus scriptus) | 14 | 22 | ±6 | 20 | 26 | ±16 |
| giraffe (Giraffa camelopardalis) | 13 | 20 | ±6 | 18 | 24 | ±11 |
| nyala (Tragelaphus angasi) | 9 | 46 | ±12 | 6 | 30 | ±14 |
| impala (Aepyceros melampus) | 15 | 99 | ±28 | 20 | 147 | ±70 |
| waterbuck (Kobus ellipsiprymnus) | 5 | 117 | ±31 | 19 | 117 | ±32 |
| sable antelope (Hippotragus niger) | 8 | 59 | ±6 | 9 | 52 | ±10 |
| roan antelope (Hippotragus equinus) | 5 | 128 | ±10 | 7 | 95 | ±29 |
| blue wildebeest (Connochaetes taurinus) | 15 | 138 | ±11 | 19 | 132 | ±18 |
| tsessebe (Damaliscus lunatus) | 3 | 140 | ±28 | 16 | 131 | ±23 |
| African buffalo (Synceros caffer) | 15 | 146 | ±24 | 20 | 121 | ±20 |
| black rhino (Diceros bicornis) | 10 | 17 | ±6 | — | — | |
| African elephant (Loxodonta africana) | 20 | 47 | ±7 | 20 | 59 | ±14 |
| warthog (Phacochoerus aethiopicus) | 6 | 100 | ±12 | 6 | 163 | ±57 |
| plains zebra (Equus burchelli) | 6 | 126 | ±19 | 6 | 126 | ±16 |
| white rhino (Ceratotherium simum) | 10 | 75 | ±13 | — | — |
| Data set (training number, category) | MHW-KELM | Gauss-KELM | Poly-KELM | Original ELM | SCG-BP | |
| Wine Quality (2000, 7) | Mean | 54.59 | 49.69 | 52.14 | 45.79 | <10 |
| Std. | ±0.35 | ±0.52 | ±0.28 | ±0.85 | ||
| p value | 1.00 | 1.04e − 06 | 7.82e − 03 | 3.27e − 09 | 0 | |
| Time | 1.159 | 1.133 | 1.372 | 3.520 | 7.159 |
| Author, Year | Country | Study Design | Sample Size | Exposure Assessment | Outcome | Confounding Factors | Potential for Bias | Effect Size | Quality Score |
| Preterm birth and Birth weight | |||||||||
| Ando and Hattori, 1973 [10] | Japan | Case-control study | 713 | Objective assessment, aircraft noise, ECPNL (dB) | LBW (<2500 g) | Gender, maternal age, occupation, parity | High | Higher rate of LBW in noisy area above 75 dBA | 8 |
| Knipschild et al., 1981 [11] | Netherlands | Case-control study | 1840 | Objective assessment, aircraft noise, 3 subgroups Ldn < 65 dBA, Ldn 65–70 dBA, Ldn > 70 dBA | LBW | Gender, parental income | High | 18% LBW in low noise exposed group, 24% LBW in high noise exposed group, 29% in noise exposed above 70 dBA Dose response relationship between aircraft noise and LBW | 8 |
| Schell, 1981 [12] | USA | Cross-sectional study | 115 | Objective assessment, aircraft noise, SEL = 75–100 dBA | Birth weight Gestational length | Maternal age, obstetric history, parental weight and height, education, smoking, family income | High | r = −0.04, p = 0.76 males r = −0.22, p = 0.014 females r = −0.18, p = 0.16 males r = −0.38, p = 0.008 females | 11 |
| Matsui et al., 2003 [13] | Japan | Survey | 160,460 births | Objective assessment, aircraft noise, WECPNL (dB) Control group <75 dBA Exposed subgroups 75–80 dBA, 81–85 dBA, >85 dBA | LBW (<2500 g) Preterm birth (<37 weeks) | Gender, maternal age, socio-economic status, live birth order No adjustment for smoking | High | OR = 1.32 (95% CI 1.18–1.48), p = 0.0001 in the highest level of exposure compared to control group OR = 1.25 (95% CI 1.1–1.4), p = 0.0018 in the highest level of exposure compared to control group | 10 |
| Congenital malformations | |||||||||
| Jones and Tauscher, 1978 [14] | USA | Ecological study | 225146 births 2105 defects | Above vs. below >90 dBA | Birth defects | Information not provided | High | 1185 vs. 737 per 100,000 births p < 0.02 | 8 |
| Edmonds et al., 1979 [15] | USA | Survey | 1745 birth defects | Objective assessment, aircraft noise, high noise level exposure above 65 dBA Ldn | 17 categories of birth defects | Socioeconomic status, race | High | Non significant differences in rates of birth defects in exposed and non-exposed groups | 10 |
| Milk Fat | Fish Oil | Nanno | Schyzo | |
| Ingredients (%) | ||||
| Casein | 14.0 | 14.0 | 10.8 | 12.5 |
| Corn starch | 37.8 | 37.8 | 39.2 | 38.4 |
| Maltodextrin | 7.0 | 7.0 | 7.3 | 7.1 |
| Sucrose | 10.0 | 10.0 | 10.4 | 10.1 |
| Cellulose | 5.0 | 5.0 | 5.2 | 5.1 |
| Soybean oil | 8.0 | 4.0 | 5.9 | 6.5 |
| Milk fat | 12.0 | 12.0 | 12.5 | 12.2 |
| Fish oil | 0 | 4.0 | 0 | 0 |
| Nanno oil | 0 | 0 | 2.4 | 0 |
| Schyzo oil | 0 | 0 | 0 | 1.8 |
| Cholesterol | 1.25 | 1.25 | 1.30 | 1.27 |
| L-cysteine | 0.20 | 0.20 | 0.20 | 0.20 |
| Mineral AIN-93 M Mix | 3.50 | 3.50 | 3.60 | 3.60 |
| Vitamin AIN-93 M Mix | 1.00 | 1.00 | 1.00 | 1.00 |
| Choline bitartarate | 0.20 | 0.20 | 0.30 | 0.30 |
| TBHQ (antioxidant) | 0.001 | 0.001 | 0.001 | 0.001 |
| Chemical composition (g/100 g) | ||||
| Crude protein | 12.3 | 12.1 | 14.7 | 12.6 |
| Crude fat | 19.2 | 20.2 | 17.0 | 21.6 |
| Crude fibre | 3.80 | 3.80 | 3.80 | 3.80 |
| Moisture | 5.60 | 5.60 | 5.60 | 5.60 |
| Crude ash | 3.57 | 3.50 | 3.82 | 3.60 |
| Carbohydrates | 55.6 | 54.8 | 55.0 | 52.9 |
| Total FAME (mg/g) | 220 | 202 | 236 | 185 |
| Energy (kcal/100 g) | 444 | 449 | 432 | 456 |
| Fatty acid profile (%) | ||||
| 14:0 | 9.81 | 11.1 | 10.0 | 9.32 |
| 16:0 | 28.5 | 28.8 | 28.9 | 29.0 |
| 18:0 | 6.95 | 6.87 | 6.32 | 6.67 |
| 18:1n-9 | 20.3 | 19.1 | 18.0 | 17.0 |
| 18:2n-6 | 21.2 | 12.3 | 15.7 | 16.3 |
| 18:3n-3 | 2.56 | 1.59 | 1.88 | 2.04 |
| 18:4n-3 | 0.190 | 0.410 | 0.189 | 0.187 |
| 20:4n-6 | 0.086 | 0.138 | 0.587 | 0.110 |
| 20:5n-3 | ND | 1.15 | 3.16 | 0.10 |
| 22:6n-3 | ND | 1.19 | ND | 3.30 |
| Partial sums and ratios | ||||
| Total SFA | 51.1 | 52.9 | 51.2 | 52.1 |
| Total MUFA | 22.0 | 26.6 | 23.8 | 20.4 |
| Total PUFA | 24.3 | 17.8 | 21.9 | 23.7 |
| Total n-3 | 2.75 | 4.64 | 5.23 | 5.72 |
| Total n-6 | 21.4 | 12.7 | 16.4 | 17.8 |
| n-3/n-6 | 0.129 | 0.366 | 0.320 | 0.321 |
| Research site identifier | Site A | Site B | Site C | Site D |
| Telehealth deployment | ||||
| Year of introduction | 2007 | 2009 | 2006 | 2010 |
| Equipment purchased (P) or leased (L) | P | P | L | P |
| No. of telehealth units available for usea | 165 | 79 | n/a | 40 |
| No. of telehealth units in useb | 104 | 39 | 200 | 34 |
| Referral routes into telehealth | ||||
| Community matrons | ✓ | ✓ | ✓ | ✓ |
| Case managers | ✓ | ✓ | ||
| Specialist respiratory nurses | ✓ | ✓ | ✓ | |
| Specialist heart failure nurses | ✓ | ✓ | ✓ | |
| GPs | ✓ | |||
| Telehealth stakeholders | ||||
| NHS community healthcare provider | ✓ | ✓ | ✓ | |
| NHS hospital trust | ✓ | ✓ | ||
| Clinical commissioning group | ✓ | ✓ | ||
| Equipment manufacturer | ✓ | ✓ | ✓ | ✓ |
| Local authority | ✓ | ✓ | ✓ | |
| Community interest company | ✓ | ✓ | ||
| Private company | ✓ | ✓ |
| Populations | ACH | SRL | MON | TUR | NUQ | BUE | STU | MTU |
| ACH | __ | 59 | 31 | 13 | 6 | 9 | 4 | 7 |
| SRL | 0.00834 | __ | 56 | 38 | 8 | 11 | 5 | 10 |
| MON | 0.01602* | 0.00889 | __ | 26 | 10 | 15 | 5 | 11 |
| TUR | 0.03596*** | 0.01286* | 0.01880** | __ | 47 | 22 | 12 | 24 |
| NUQ | 0.08121*** | 0.05584*** | 0.04891*** | 0.01046 | __ | 18 | 41 | 35 |
| BUE | 0.05404*** | 0.04186*** | 0.03227*** | 0.02211** | 0.02697** | __ | 10 | 35 |
| STU | 0.11405*** | 0.09112*** | 0.09023*** | 0.04015*** | 0.01188 | 0.04721*** | __ | 15 |
| MTU | 0.06623*** | 0.04589** | 0.04233*** | 0.02050* | 0.01439 | 0.01421 | 0.03274* | __ |
| Category | n (%) | Total | Asthma | Medication for Asthma | p | ||||
| Mean | SD | Mean | SD | Mean | SD | ||||
| Age (years) | < 20 | 21 (19.4) | 744.60 | 175.82 | 601.58 | 158.36 | 234.55 | 109.62 | 0.000a |
| 20–59 | 61 (56.5) | 1,584.39 | 966.73 | 1,461.20 | 964.47 | 692.66 | 366.14 | 0.000b | |
| ≥ 60 | 26 (24.1) | 984.67 | 287.72 | 483.58 | 258.54 | 601.50 | 179.45 | ||
| Sex | Male | 29 (26.8) | 1,522.99 | 1,030.99 | 832.08 | 1,032.46 | 553.95 | 332.62 | 0.52a |
| Female | 79 (73.2) | 1,186.32 | 637.22 | 608.07 | 629.19 | 591.80 | 295.19 | 0.40b | |
| Family income | ≤ 1 minimum wage | 25 (23.1) | 1,315.72 | 553.62 | 709.37 | 560.46 | 731.36 | 388.32 | 0.58a |
| > 1 to 3 minimum wages | 53 (49.1) | 1,239.81 | 754.53 | 637.39 | 750.85 | 524.78 | 268.44 | 0.38a | |
| > 3 minimum wages | 30 (27.8) | 1,318.38 | 919.68 | 696.35 | 911.32 | 576.24 | 294.78 | ||
| Education level | Elementary school | 76 (70.4) | 1,164.34 | 592.57 | 611.44 | 591.90 | 556.90 | 263.78 | 0.92a |
| High School | 25 (23.1) | 1,614.84 | 1,131.14 | 827.46 | 1,126.16 | 583.42 | 358.14 | 0.55b | |
| Higher education | 7 (6.5) | 1,289.27 | 780.29 | 715.99 | 790.14 | 843.79 | 476.14 | ||
| Asthma duration | ≤ 10 | 36 (33.4) | 647.43 | 872.90 | 345.53 | 875.32 | 256.91 | 321.30 | 0.30a |
| > 10–20 | 26 (24.1) | 602.62 | 614.11 | 294.57 | 598.50 | 268.31 | 305.28 | 0.008b | |
| > 20 | 46 (42.5) | 651.47 | 756.80 | 348.69 | 752.14 | 330.08 | 290.30 | ||
| Asthma severity c | Intermittent | 42 (38.9) | 432.12 | 487.14 | 224.10 | 472.31 | 161.61 | 130.37 | |
| Mild | 24 (22.2) | 448.34 | 267.24 | 220.73 | 237.82 | 217.85 | 163.01 | 0.000a | |
| Moderate | 31 (28.7) | 656.08 | 888.60 | 345.91 | 886.33 | 283.11 | 171.84 | 0.000b | |
| Severe | 11 (10.2) | 1,403.84 | 1,180.52 | 790.73 | 1,184.74 | 750.39 | 570.27 | ||
| Asthma control c | Controlled | 53 (49.1) | 419.48 | 175.56 | 212.12 | 171.66 | 193.14 | 118.63 | 0.000a |
| Partially controlled | 42 (38.9) | 637.54 | 743.01 | 326.06 | 738.18 | 280.76 | 212.00 | 0.000b | |
| Uncontrolled | 13 (12.0) | 1,283.75 | 1,225.45 | 713.82 | 1,234.49 | 611.06 | 554.65 | ||
| Nutritional status | Normal weight | 44 (40.7) | 1,027.68 | 626.53 | 510.74 | 609.78 | 398.82 | 160.62 | 0.001a |
| Overweight | 35 (32.4) | 1,259.93 | 575.37 | 675.81 | 566.16 | 626.19 | 322.12 | 0.000b | |
| Obese | 29 (26.9) | 1,674.86 | 1,066.88 | 897.98 | 1,077.41 | 805.24 | 399.63 | ||
| Rhinitis | Yes | 90 (83.3) | 636.06 | 749.83 | 325.99 | 746.12 | 261.23 | 279.86 | 0.03a |
| No | 18 (16.7) | 649.85 | 843.33 | 377.69 | 838.13 | 438.75 | 379.39 | 0.0001b |
| Mutation | Gene | Mutation type | AA | References |
| m.3730T>Y | ND1 | Point mutation | Y142H | [39,48] |
| m.3425T>Y | ND1 | Point mutation | V40A | [39,48] |
| m.5212T>C | ND2 | Point mutation | L248P | [39] |
| m.10844A>C | ND4 | Point mutation | T29P | [39] |
| m.14510delA | ND6 | Point mutation | - | [39] |
| A | B | |||||||
| ARACNE | BANJO | ARACNE | BANJO | |||||
| PPV | Se | PPV | Se | PPV | Se | PPV | Se | |
| Keloid RMA | 0.238 | 0.556 | 0.3 | 0.667 | 0.6 | 1 | 0.4 | 0.667 |
| Normal RMA | 0.1875 | 0.333 | 0.3125 | 0.556 | 0.5 | 0.667 | 0.4 | 0.667 |
| Keloid MAS5 | 0.214 | 0.333 | 0.286 | 0.667 | 0.5 | 0.667 | 0.75 | 1 |
| Normal MAS5 | 0.25 | 0.667 | 0.304 | 0.778 | 0.75 | 1 | 0.6 | 1 |
| Random | 0.389 | 0.5 | ||||||
| C | D | |||||||
| ARACNE | BANJO | ARACNE | BANJO | |||||
| PPV | Se | PPV | Se | PPV | Se | PPV | Se | |
| Keloid RMA | 0.8 | 1 | 0.75 | 0.75 | 0.5 | 0.6 | 0.5 | 0.8 |
| Normal RMA | 1 | 0.75 | 0.8 | 1 | 0.5 | 0.6 | 0.2 | 0.2 |
| Keloid MAS5 | 0.5 | 0.25 | 0.6 | 0.75 | 0.5 | 0.6 | 0.625 | 1 |
| Normal MAS5 | 0.667 | 0.5 | 0.5 | 0.5 | 0.333 | 0.4 | 0.5 | 0.8 |
| Random | 0.667 | 0.5 | ||||||
| E | F | |||||||
| ARACNE | BANJO | ARACNE | BANJO | |||||
| PPV | Se | PPV | Se | PPV | Se | PPV | Se | |
| Keloid RMA | 0.375 | 0.6 | 0.364 | 0.8 | 0.375 | 0.75 | 0.5 | 1 |
| Normal RMA | 0.444 | 0.8 | 0.444 | 0.8 | 0.5 | 0.75 | 0.5 | 1 |
| Keloid MAS5 | 0.286 | 0.4 | 0.273 | 0.6 | 0.286 | 0.5 | 0.429 | 0.75 |
| Normal MAS5 | 0.333 | 0.6 | 0.364 | 0.8 | 0.2 | 0.25 | 0.429 | 0.75 |
| Random | 0.333 | 0.4 | ||||||
| G | ||||||||
| ARACNE | BANJO | |||||||
| PPV | Se | PPV | Se | |||||
| Keloid RMA | 0.5 | 0.5 | 0.714 | 0.833 | ||||
| Normal RMA | 0.667 | 0.667 | 0.625 | 0.833 | ||||
| Keloid MAS5 | 0.4 | 0.333 | 0.429 | 0.5 | ||||
| Normal MAS5 | 0.833 | 0.833 | 0.5 | 0.5 | ||||
| Random | 0.6 |
| Gene | No. positive (%) |
| msp-1 | 43 (86) |
| K1 | 40 (80) |
| MAD20 | 24 (48) |
| RO33 | 26 (52) |
| msp-2 | 47 (94) |
| FC27 | 44 (88) |
| IC/3D7 | 38 (76) |
| glurp | 24 (48) |
| Region ITS1 | Region ITS2 | ||
| Species | Controls | Species | Controls |
| Candida albicans | C7 | Candida albicans | C7 |
| Candida glabrata | C11SC | Cladosporium sp. | C11LF, C11SC |
| Cladosporium sp. | C12ERH, | Fusarium oxysporum | C3, C8, C10MD |
| Fungal sp. | C6 | Malassezia restricta | C8, C12ERH |
| Fusarium oxysporum | C3, C4, C5, C8, C10MD | Penicillium crustosum | C11ERH |
| Malassezia globosa | C13MD | Phoma sp. | C13ERH |
| Malassezia restricta | C11SD, C12SC | Saccharomyces cerevisiae | C2 |
| Penicillium crustosum | C11ERH | Uncultured eukaryote | C7 |
| Phoma sp. | C13ERH | Uncultured fungus | C11SC |
| Rhodotorula mucilaginosa | C12SC | Uncultured malassezia | C11MD, C11SC, C12SC, C13LF |
| Uncultured fungus | C1, C10ERH, C11SC, C13LFC, C13MD | Pichia membranifaciens | C11MD |
| Uncultured malassezia | C11MD, C13SC | ||
| Uncultured rhodotorula | C11LF |
| Dummy variable of Hospital C | Educational background | Research experience | Knowledge on EBN | |
| Setting | B=1.331 t=2.807 P= 0.005 | B=-1.151 t=2.807 P=0.005 | ||
| Nurse | B=-0.995 t=-2.048 P= 0.041 | |||
| Presentation | B=0.951 t=2.318 P= 0.021 | B=-2.398 t=-4.716 P= 0.000 | ||
| Barriers scale | B=3.396 t=2.415 P= 0.016 | B=-4.234 t=-2.429 P= 0.015 | ||
| Facilitators scale | B=0.925 t=2.417 P=0.016 |
| DRC* | Zambia | Kenya | Guatemala | Pakistan | Nagpur, India | Belgaum, India | |
| Number births | 14,306 | 16,352 | 18,319 | 10,590 | 34,379 | 15,022 | 34,509 |
| Home (%) | 74.4 | 52.7 | 64.7 | 71.0 | 56.6 | 14.0 | 16.3 |
| Health ctr(%) | 23.6 | 41.7 | 9.4 | 3.1 | 21.9 | 25.7 | 23.2 |
| Hospital(%) | 1.0 | 5.6 | 25.9 | 25.9 | 21.1 | 53.5 | 60.3 |
| Family/home (%) | 3.0 | 20.1 | 12.8 | 0.2 | 2.0 | 3.9 | 7.1 |
| HBA** (%) | 75.3 | 34.2 | 51.4 | 70.6 | 54.1 | 9.6 | 8.2 |
| Nurse/midwife (%) | 21.6 | 43.1 | 34.1 | 1.4 | 23.8 | 33.1 | 29.9 |
| Physician (%) | 0.1 | 2.6 | 1.7 | 27.8 | 20.0 | 53.5 | 37.9 |
| Pseudomonas aeruginosa strains | Bacteriocidal (+) | Bacteriostatic (−) |
| PAO1 | + | |
| PA103 | + | |
| PA14 | − | |
| Clinical strain | − |
| Accession | Transcription factor family | Log2 fold |
| Up-regulated genes | ||
| AK322452 | DREB3 | 2.5 |
| BP893968 | AP2d | 2.7 |
| AK320001 | RAV2 | 2.7 |
| AK319979 | Pti4 | 3.4 |
| AW034241 | ERF2 | 4.3 |
| AW651406 | bZIP | 2.6 |
| AK224603 | bZIP | 2.8 |
| AK326827 | bZIP | 3.1 |
| EU636698 | CONSTANS-like Zinc Finger | 3.5 |
| AJ784616 | Stress-associated protein 6 (Zinc finger) | 6.7 |
| BG627283 | BTF3-like (NAC) | 2.9 |
| AK324393 | NAM-like | 5 |
| BM412776 | WRKY | 5.8 |
| AK322575 | WRKY3 | 14.5 |
| TC239950 | TCP | 2.5 |
| AK319300 | TCP transcription factor 14 | 3 |
| TA41176_4081 | GRAS 6 | 3.3 |
| AK325371 | Putative transcription factor | 3.4 |
| BP879218 | Putative Squamosa promoter-binding protein | 3.5 |
| Down-regulated genes | ||
| DB690655 | CONSTANS-LIKE 16 Zinc Finger | 3.9 |
| DB697244 | CONSTANS-LIKE 9 Zinc Finger | 5.5 |
| AW624869 | CONSTANS-LIKE 10 Zinc Finger | 6.8 |
| AW622759 | WRKY | 3.9 |
| AK247980 | WRKY | 5.2 |
| AK247135 | PIF1 (bHLH) | 2.5 |
| BI935893 | putative bHLH | 2.4 |
| AK327992 | MADS box | 4 |
| AK327530 | PHD finger | 2.2 |
| BI925618 | Bell-like homeodomain protein 2 (POX domain) | 2.2 |
| BI921917 | Tubby-like F-box protein | 2.6 |
| REACH category and action | Identified priority programmes |
| Livestock and fisheries | |
| Animal husbandry, fisheries, and insect farming | • Backyard poultry production in Nepal |
| • Household animal and horticulture production in Ghana | |
| • Aquaculture development in Uganda | |
| • Aquaculture development and nutrition education in Uganda | |
| • School livestock programme in Ethiopia | |
| • Conditional livestock transfer in Ethiopia | |
| • Targeted cash and chicken transfer in Uganda | |
| Crops/horticulture | |
| Diversification and locally adapted varieties | • Home gardens in India |
| • Kitchen gardens in Bangladesh | |
| • School‐based fruit production in Tanzania | |
| • Home gardens and small livestock production in Uganda | |
| • Home gardens and small livestock production in Bangladesh | |
| Food processing, fortification, and storage | |
| Food processing (excl. fortification) | • Complementary food processing programme in Ghana |
| Fortification (including salt iodization and fortification of complementary foods) | • Point of consumption fortification in Nepal |
| • Micronutrient sachets for home fortification in India | |
| • Home‐based fortified flour production in Nepal | |
| • Complementary food production in Ethiopia | |
| • Mass media campaign on fortification with dried fish in Nigeria | |
| Food consumption practices for healthy diets | |
| Food‐based nutrition education | • School‐based feeding and nutrition education in Ethiopia |
| • Adolescent health and nutrition education in South Asia | |
| • School‐based nutrition education in Ghana | |
| • School‐based nutrition education in Uganda | |
| • School‐based agriculture education in Ghana | |
| Creating supportive environments to promote healthy diets in different settings | • School snack programme in Nepal |
| • Preschool feeding in Bangladesh | |
| Enabling environment | |
| Fiscal policy | • Milk transport subsidy in Nepal (livestock and fisheries) |
| • Decreasing transport costs in Tanzania (food consumption) | |
| • Rice subsidy in Nigeria (food processing, fortification, and storage) | |
| • Food tax and subsidy in Ghana (food consumption) | |
| • Solar drier subsidy in Nepal (food processing, fortification, and storage) | |
| Legislation, regulations/standards, protocols, and guidelines | • Food marketing association in Ghana (food consumption) |
| • Improved traditional wet markets in Tanzania (food consumption) | |
| • Local market development in Nepal (food consumption) | |
| • Quality assurance for infant complementary food (food consumption) | |
| • Government quality certification seal (food consumption) | |
| • Integrating nutrition into agriculture and health services in Tanzania (crops/horticulture) | |
| Social norms: Education/sensitization, behaviour change communication, and social marketing | • Technology‐enabled behaviour change communication in Nigeria (food consumption) |
| • Nutrition education and media campaign in India (food consumption) | |
| • Diet diversity media campaign in India (food consumption) | |
| • Maternal nutrition media campaign in India (food consumption) | |
| • Media and education campaign in Ethiopia (food consumption) | |
| • Edutainment in Ethiopia (food consumption) | |
| Vouchers or transfers (not defined by REACH) | |
| • Targeted and conditional cash transfer in India | |
| • Conditional cash transfer in Nigeria | |
| • Conditional cash and food transfers in Bangladesh | |
| • Food vouchers in India | |
| • Food vouchers in Tanzania | |
| • Conditional food transfer in Ethiopia |
| Study wave | Study region (canton) | |||||
| MONICA I | MONICA II | MONICA III | Vaud* | Fribourg* | Ticino | |
| Participants (n) | 3,442 | 3,466 | 3,252 | 4,263 | 1,378 | 4,519 |
| Age of inclusion (years) | 25-74 | 25-74 | 25-74 | 25-74 | 25-74 | 35-64 |
| Women (%) | 49.1 | 48.6 | 51.4 | 49.9 | 48.8 | 49.8 |
| Foreign nationals (%) | 14.7 | 18.6 | 21.2 | 17.7 | 7.4 | 21.8 |
| Age (in years, mean) | 47.6 | 47.8 | 47.8 | 47.0 | 45.7 | 49.0 |
| University education (%) | 6.5 | 7.7 | 8.5 | 9.0 | 6.5 | 6.5 |
| Tertiary education (%) | 14.0 | 10.2 | 11.6 | 16.5 | 12.8 | 7.4 |
| Upper secondary education (%) | 44.7 | 50.4 | 50.6 | 48.3 | 45.1 | 49.8 |
| Mandatory education (%) | 34.8 | 31.8 | 29.3 | 26.1 | 35.6 | 36.4 |
| Never married (%) | 13.4 | 12.0 | 12.1 | 13.6 | 15.8 | 10.5 |
| Married (%) | 76.8 | 76.9 | 76.0 | 73.7 | 77.4 | 79.0 |
| Widowed (%) | 4.2 | 4.1 | 3.7 | 4.2 | 3.6 | 4.0 |
| Divorced (%) | 5.6 | 6.9 | 8.2 | 8.5 | 3.3 | 6.5 |
| Start of examination VD/FR** | 29.10.1984 | 02.11.1988 | 23.11.1992 | |||
| Duration VD/FR (days) | 222 | 240 | 215 | |||
| Start of examination TI** | 11.11.1985 | 24.10.1988 | 28.10.1992 | |||
| Duration TI (days) | 198 | 185 | 210 |
| Source of variance | SS | df | Means square | F | P value | Partial eta squared (n) | Power |
| Within subjects | |||||||
| Time | 38.50 | 2 | 19.25 | 0.32 | 0.73 | 0.005 | 0.10 |
| Time × age | 31.06 | 2 | 15.53 | 0.26 | 0.77 | 0.004 | 0.90 |
| Time × group | 272.87 | 2 | 136.43 | 2.25 | 0.11 | 0.036 | 0.45 |
| Error | 7387.84 | 122 | 60.56 | ||||
| Between subjects | |||||||
| Intercept | 4134.92 | 1 | 4134.92 | 14.55 | 0.00 | 0.19 | 0.96 |
| Age | 266.00 | 1 | 266.00 | 0.94 | 0.34 | 0.02 | 0.16 |
| Group | 472.18 | 1 | 472.18 | 1.66 | 0.20 | 0.03 | 0.25 |
| Error | 17337.94 | 61 | 264.23 |
| Candida albicans | Non-Candida albicans | |||||||||||
| Antifungals | Sa | DDSb | Rc | S | DDS | R | ||||||
| n | % | n | % | n | % | n | % | n | % | n | % | |
| FLU | 55 | 94.8 | 3 | 5.2 | — | — | 26 | 83.9 | 5 | 16.1 | — | — |
| ITRA | 48 | 82.8 | 4 | 6.9 | 6 | 10.3 | 18 | 58.1 | 4 | 12.9 | 9 | 29.0 |
| KETO | 20 | 34.5 | 23 | 9.7 | 15 | 25.8 | 9 | 29.0 | 7 | 22.6 | 15 | 48.4 |
| MICO | 42 | 72.4 | 14 | 24.1 | 2 | 3.5 | 6 | 19.4 | 20 | 64.5 | 5 | 16.1 |
| VORI | 57 | 98.3 | 1 | 1.7 | — | — | 30 | 96.8 | 1 | 3.2 | — | — |
| AMB | 57 | 98.3 | — | — | 1 | 1.7 | 31 | 100.0 | — | — | — | — |
| Family history of AA | Coronary heart disease | Hypertension | Cerebrovascular disease | Diabetes | |
| AA (n = 169) | 2 | 68 | 103 | 22 | 17 |
| Non-AA (n = 156) | 0 | 27 | 38 | 2 | 10 |
| p value | 0.000* | 0.000* | 0.000* | 0.234 |
| Gene | Main associated phenotype | Gene product | Inheritance | Age of onset | Diagnostic clues |
| ADCY5 | ADCY5-related chorea | Adenylate cyclase 5 | AD/de novo | Infancy to childhood | Axial hypotonia and delayed milestonesDiurnal and sleep-related MD exacerbationsDystonia and myoclonus prominent in some cases |
| PDE10A | PDE10A-related chorea | Phosphodiesterase 10A | De novo/AD/AR | Infancy to childhood | Delayed motor-language milestones and dysarthria in recessive casesMRI: symmetrical T2-hyperintense bilateral striatal lesions in cases with heterozygous de novo mutations |
| FOXG1 | Congenital Rett disease | Forkhead Box G1 | De novo | Infancy to early childhood | Severe ID, absent language, acquired microcephalyMRI: corpus callosum aplasia/hypoplasia, delayed myelination, simplified gyration |
| ARX | Early infantile epileptic encephalopathy-type 1;X-linked mental retardation | Aristaless-related homeobox protein | XL | Infancy | Ohtahara/West syndrome, severe mental retardation, generalized dystonia/dyskinesias with recurrent status dystonicus |
| STXBP1 | Early infantile epileptic encephalopathy-type 4 | Syntaxin-binding protein 1 | De novo | Early infancy to childhood | Onset of seizures within one year of age. Developmental delay, ID, autistic-like features, ataxia with or without dyskinesias/dystonia |
| SYT1 | Severe motor delay and intellectual disability | Synaptotagmin-1 | De novo | Infancy | Severely delayed motor development without seizures |
| UNC13A | Congenital encephalopathy with dyskinesias | Unc-13 homolog A | De novo | Congenital | Developmental and speech delay; ID, congenital dyskinesias with intention tremor, rare febrile seizures |
| GNAO1 | Early infantile epileptic encephalopathy type 17/Ohtahara syndrome | Gαo subunit of GPCR | De novo | Infancy to childhood | Developmental delay and IDLong-lasting MD exacerbations not related to sleepEpilepsy can be absent or well controlled |
| GRIN1 | Mental retardation, autosomal dominant 8 | GluN1 subunit of NMDAR | De novo/AR | Infancy | Severe developmental delay and IDEarly-onset epileptic seizuresOculogyric crisesCortical blindness, dysmorphic traits, microcephaly |
| FRRS1L | Early infantile epileptic encephalopathy-type 37 | Ferric Chelate Reductase 1-like | AR | Infancy | Psychomotor regression after normal developmentSevere encephalopathic epilepsyChoreo-athetosis in infancy/childhood, parkinsonism in adolescence |
| TBC1D24 | Early infantile epileptic encephalopathy type 16 | TBC1 domain family, member 24 | AR | Infancy | Early-onset myoclonic seizuresVariable degrees of IDDystonia |
| GPR88 | GPR88-related chorea | G protein-coupled receptor 88 | AR | Infancy to childhood | Developmental and language delaySevere mental retardationScarcely progressive chorea |
| KMT2B | DYT28 dystonia | lysine-specific histone methyltransferase 2B | De novo/AD | Childhood-adolescence | Onset in lower limbs and prominent oro-mandibular/laryngeal involvementMild dysmorphic traits; mild IDGood and sustained response to pallidal DBS |
| ATP1A3 | AHCRDPCAPOS syndrome | Na+/K+ ATPase, α3 subunit | De novo/AD | Infancy to fifth decade | Abrupt onset of neurological signs (dystonia, muscular weakness, ataxia)Initial hemisomatic distributionIdentifiable triggering factors |
| Number of events | Event rate per 100 person years (95% CI) | |
| Any Stroke | 22 | 4.0 (2.3–5.6) |
| Posterior circulation stroke | 12 | 2.1 (0.9–3.3) |
| Any stroke or TIA | 41 | 7.9 (5.5–10.4) |
| Posterior circulation stroke or TIA | 26 | 4.8 (3.0–6.7) |
| Parasite density based on assumed WBC count | Parasite density based on measured WBC count | P value* | |
| P. falciparum (n = 143) | 15,208 (9,320-19,470) | 13,213 (7,680-16,273) | 0.49 |
| P. vivax (n = 33) | 5,364 (644-10,109) | 3,538 (595-12,698) | 0.96 |
| AUCg1 | AUCg2 | AvgAUCg | Height cm | Weight kg | WC cm | BMI kg/m2 | vWSR | TR years | Age years | LI | |
| AUCg1 | 1 | 0.571** | 0.861*** | .182 | −0.018 | −0.167 | −0.109 | −0.237 | 0.237 | −0.440* | 0.063 |
| AUCg2 | 1 | 0.909*** | −0.033 | −0.195 | −0.134 | −0.237 | −0.145 | −0.018 | −0.343 | −0.272 | |
| AvgAUCg | 1 | 0.071 | −0.130 | −0.168 | −0.202 | −0.210 | 0.110 | −0.436* | −0.139 | ||
| Height (cm) | 1 | 0.559** | 0.431* | 0.1270 | 0.145 | −0.323 | −0.329 | 0.062 | |||
| Weight (kg) | 1 | 0.870*** | 0.888*** | 0.767*** | 0.073 | 0.121 | −0.012 | ||||
| WC (cm) | 1 | 0.813*** | 0.954*** | 0.246 | 0.147 | −0.047 | |||||
| BMI (kg/m2) | 1 | 0.849*** | 0.350 | 0.283 | −0.061 | ||||||
| WSR | 1 | 0.279 | 0.387 | −0.078 | |||||||
| TR (years) | 1 | 0.394 | 0.321 | ||||||||
| Age (years) | 1 | 0.521* | |||||||||
| LI | 1 |
| Premature Ejaculation Profile Questions | Tramadol | Paroxetine | Placebo |
| Satisfaction with sexual intercourse (Z) | −5.31 | −3.55 | −1.10 |
| p-value | 0.0001 | 0.0001 | 0.270 |
| Control over ejaculation (Z) | −5.39 | −2.22 | −0.09 |
| p-value | 0.0001 | 0.026 | 0.923 |
| Ejaculation-related interpersonal difficulty (Z) | −4.001 | −2.34 | −1.90 |
| p-value | 0.0001 | 0.019 | 0.057 |
| Ejaculation-related distress (Z) | −3.97 | −2.29 | −0.81 |
| p-value | 0.0001 | 0.022 | 0.417 |
| Age1 | Sex F vs. M2 | Current Smoker vs. Not2 | FEV1 (% predicted)1 | Exacerbation Frequency (previous yr)3 | |
| Mean Heart Rate (min-1) | r = -0.28 | 80 vs. 77 | 77 vs. 78 | r = -0.26 | rho = 0.23 |
| p = 0.134 | p = 0.525 | p = 0.862 | p = 0.164 | p = 0.207 | |
| SD Heart Rate (min-1) | r = -0.39 | 4.7 vs. 5.0 | 4.5 vs. 4.9 | r = -0.35 | rho = -0.05 |
| p = 0.030* | p = 0.724 | p = 0.713 | p = 0.054 | p = 0.797 | |
| Mean Oxygen Saturation (%) | r = 0.08 | 94 vs. 95 | 95 vs. 95 | r = 0.14 | rho = 0.21 |
| p = 0.688 | p = 0.358 | p = 0.644 | p = 0.470 | p = 0.266 | |
| SD Oxygen Saturation (%) | r = 0.17 | 1.2 vs. 0.9 | 1.0 vs. 1.0 | r = -0.21 | rho = -0.03 |
| p = 0.350 | p = 0.027* | p = 0.769 | p = 0.267 | p = 0.862 | |
| Mean PEF (lmin-1) | r = -0.03 | 198 vs. 248 | 258 vs. 225 | r = 0.25 | rho = 0.09 |
| p = 0.858 | p = 0.085 | p = 0.378 | p = 0.172 | p = 0.647 | |
| SD PEF (lmin-1) | r = -0.02 | 12 vs. 11 | 10 vs. 12 | r = 0.10 | rho = 0.00 |
| p = 0.921 | p = 0.834 | p = 0.446 | p = 0.608 | p = 0.982 |
| Patient Characteristics | Univariate Analysis HR (95% CI) | p-Value | Multivariate Analysis HR (95% CI) | p-Value |
| Sex | 0.853 (0.549–1.326) | 0.481 | - | - |
| Age (years) | 1.326 (0.872–2.018) | 0.187 | - | - |
| Smoking Behaviour | 0.777 (0.476–1.268) | 0.313 | - | - |
| Family History | 0.808 (0.391–1.672) | 0.566 | - | - |
| Pathological Stage | 3.666 (2.694–4.988) | <0.001 | 3.118 (2.044–4.756) | <0.001 |
| Lymph Node Metastasis (N) | 1.988 (1.375–2.874) | <0.001 | 0.831 (0.554–1.247) | 0.371 |
| Distant Metastases | 5.286 (3.360–8.316) | <0.001 | 1.957 (1.119–3.422) | 0.019 |
| Tumor Location | 0.746 (0.581–0.957) | 0.021 | 0.852 (0.646–1.123) | 0.255 |
| Maximun Tumor Diameter (cm) | 2.528 (1.660–3.848) | <0.001 | 1.180 (0.752–1.852) | 0.472 |
| Serous Infiltration | 2.038 (1.587–2.618) | <0.001 | 0.972 (0.708–1.334) | 0.860 |
| ALB (g/L) | 0.485 (0.264–0.892) | 0.020 | 0.776 (0.247–2.438) | 0.664 |
| ALT (U/L) | 0.814 (0.535–1.239) | 0.337 | - | - |
| AST (U/L) | 0.965 (0.636–1.466) | 0.869 | - | - |
| LSR (ALT/AST) | 0.565 (0.368–0.868) | 0.009 | 0.610 (0.388–0.958) | 0.032 |
| CRP (mg/L) | 1.351 (0.888–2.057) | 0.160 | - | - |
| CA19-9 (U/mL) | 1.454 (0.950–2.224) | 0.085 | 0.710 (0.442–1.139) | 0.155 |
| CA72-4 (U/mL) | 2.035 (1.318–3.144) | 0.001 | 1.479 (0.941–2.325) | 0.090 |
| CEA (ng/mL) | 1.501 (0.983–2.293) | 0.060 | 1.331 (0.811–2.184) | 0.258 |
| Fbg (g/L) | 1.530 (1.002–2.338) | 0.049 | 1.070 (0.669–1.713) | 0.778 |
| GPS | 1.565 (1.033–2.373) | 0.035 | 0.929 (0.431–2.004) | 0.851 |
| p53 | 1.212 (1.005–1.462) | 0.045 | 1.128 (0.917–1.387) | 0.255 |
| Blood Type | 0.875 (0.741–1.033) | 0.115 | - | - |
| Algorithms | Sensitivity %, (95% CI) | Specificity %, (95% CI) | PPV %, (95% CI) | LR+ (95% CI) |
| A: ≥1 ICD-9 code for AVN | 81.9 (72.0–89.5) | 99.6 (99.4–99.7) | 66.0 (56.0–75.1) | 190.0 (134.5–268.5) |
| B: ≥2 ICD-9 codes for AVN at least 7 days apart | 57.8 (46.5–68.6) | 99.9 (99.8–99.9) | 81.4 (69.1–90.3) | 426.7 (229.9–792.1) |
| C: ≥2 ICD-9 codes for AVN at least 30 days apart | 44.6 (33.7–55.9) | 99.9 (99.8–99.9) | 78.7 (64.3–89.3) | 361.8 (186.2–703.1) |
| D: ≥3 ICD-9 codes for AVN at least 30 days apart | 44.6 (33.7–55.9) | 99.9 (99.8–100.0) | 82.2 (67.9–92.0) | 452.3 (217.3–941.4) |
| Age Group | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 |
| 20 to 30 years old | 334 | 278 | 242 | 329 | 271 | 297 | 301 | 286 |
| 31 to 40 years old | 600 | 614 | 549 | 623 | 659 | 673 | 728 | 729 |
| 41 to 50 years old | 714 | 644 | 598 | 681 | 748 | 843 | 844 | 898 |
| 51 to 60 years old | 872 | 817 | 783 | 857 | 858 | 930 | 942 | 964 |
| 61 to 70 years old | 979 | 963 | 968 | 940 | 1.007 | 1.074 | 1.197 | 1.209 |
| 71 to 80 years old | 954 | 847 | 865 | 844 | 895 | 1.030 | 1.024 | 1.141 |
| ≥81 years old | 393 | 418 | 416 | 433 | 473 | 477 | 581 | 596 |
| TOTAL | 4.846 | 4.581 | 4.421 | 4.707 | 4.911 | 5.324 | 5.617 | 5.823 |
| Variables | Patients with RVSD (N = 32) | Patients without RVSD (N = 13) | p-value |
| Right atrial end-systolic area, cm2 | 19.7 ± 7.6 | 15.8 ± 8.1 | 0.149 |
| Right atrial length, mm | 42.9 ± 10.2 | 42.5 ± 11.1 | 0.916 |
| Right ventricular basal diameter, mm | 49.6 ± 9.3 | 47.7 ± 10.7 | 0.583 |
| TAPSE, mm | 13.1 ± 2.6 | 20.3 ± 2.2 | <0.001* |
| Right ventricular S’, cm/s | 10.6 ± 3.2 | 15.3 ± 3.9 | <0.001* |
| RIMP | 1.09 ± 0.60 | 1.76 ± 1.30 | 0.032* |
| RV wall thickness, mm | 3.6 ± 1.2 | 3.5 ± 0.8 | 0.952 |
| Tricuspid Valve E:A ratio | 1.21 ± 0.44 | 0.90 ± 0.35 | 0.019* |
| Tricuspid Valve E/e’ | 5.08 ± 2.73 | 3.46 ± 1.45 | 0.023* |
| Left atrial diameter, mm | 43.2 ± 6.4 | 41.9 ± 6.2 | 0.548 |
| LV end-diastolic diameter, mm | 62.0 ± 7.5 | 62.4 ± 11.7 | 0.910 |
| LV ejection fraction, % | 32.4 ± 9.3 | 36.6 ± 7.7 | 0.127 |
| LV stroke volume index, L/m2 | 39.9 ± 12.3 | 51.4 ± 17.9 | 0.017 |
| Anti-log10 mitral valve E:A | 1.50 ± 0.62 | 1.31 ± 0.25 | 0.154 |
| Mitral valve E/e’ | 15.96 ± 7.13 | 15.61 ± 7.06 | 0.882 |
| PA acceleration time, ms | 61.8 ± 22.4 | 78.9 ± 28.0 | 0.037* |
| PA systolic pressure, mmHg | 47.4 ± 19.4 | 39.2 ± 21.5 | 0.246 |
| Mean PAP, mmHg | 30.6 ± 11.6 | 25.9 ± 13.1 | 0.273 |
| Pulmonary hypertension | 23 (71.9 %) | 7 (53.9 %) | 0.304 |
| Segments | Primers | Position | Length, bp |
| Internal standard | |||
| P1 | 5′-aacatacccatggccaacct-3′ | 3304–3836 | 533 |
| P2 | 5′-ggcaggagtaatcagaggtg-3′ | ||
| First cycle | |||
| P3 | 5′-tgaacctacgagtacaccga-3′ | 7901–14220 | 1342 |
| P4 | 5′-ttagtagtagttactggttg-3′ | ||
| Second cycle | |||
| P5 | 5′-ttcatgcccatcgtcctaga-3′ | 8201–13851 | 673 |
| P6 | 5′-gttgaggtctagggctgtta-3′ | ||
| Third cycle | |||
| P7 | 5′-cccctctagagcccactgtaaagc-3′ | 8282–13650 | 391 |
| P8 | 5′-ggggaagcgaggttgacctg-3′ |
| Canonical Pathways | Number of differentially expressed molecules (P-value) | ||||
| SPF | C | EF | CIF | EF·CIF | |
| Ranked according to ratio (differentially expressed genes/total number of genes) | |||||
| Antigen Presentation Pathway | 5/39 (< 0.0001) | 5/39 (< 0.0001) | 10/39 (< 0.0001) | 10/39 (< 0.0001) | 10/39 (< 0.0001) |
| Interferon Signaling | 1/29 (0.1) | 1/29 (0.1) | 9/29 (< 0.0001) | 6/29 (< 0.005) | 6/29 (< 0.01) |
| IL-10 Signaling | 1/70 (0.2) | 2/70 (< 0.05) | 12/70 (< 0.0001) | 12/70 (< 0.001) | 13/70 (< 0.0005) |
| p38 MAPK Signaling | 1/95 (0.3) | 2/95 (0.1) | 13/95 (< 0.001) | 15/95 (< 0.0005) | 17/95 (< 0.0001) |
| Cell Cycle: G2/M DNA Damage Checkpoint Regulation | N/A | N/A | 7/42 (< 0.01) | 5/42 (0.06) | 7/42 (< 0.01) |
| Inositol Metabolism | N/A | N/A | 4/24 (< 0.005) | 3/24 (0.13) | 4/24 (< 0.05) |
| Keratan Sulfate Biosynthesis | N/A | N/A | 5/31 (< 0.05) | 3/31 (026) | 5/31 (< 0.05) |
| IL-6 Signaling | N/A | 1/93 (0.41) | 13/93 (< 0.0005) | 13/93 (< 0.005) | 15/93 (< 0.0005) |
| Fatty Acid Metabolism | 1/187 (0.5) | 4/187 (< 0.05) | 28/187 (< 0.0001) | 26/187 (< 0.0001) | 28/187 (< 0.0001) |
| Ranked according to P-value (as determined by IPA) | |||||
| Total number of significant pathways | 2 | 6 | 15 | 44 | 40 |
| Fatty Acid Metabolism | 1/187 (0.3) | 2/187 (0.1) | 28/187 (< 0.0001) | 25/187 (< 0.0001) | 28/187 (< 0.0001) |
| LPS/IL-1 Mediated Inhibition of RXR Function | 1/170 (0.4) | 2/170 (0.2) | 33/170 (< 0.0001) | 26/170 (< 0.0001) | 31/170 (< 0.0001) |
| Tryptophan Metabolism | 2/237 (0.05) | 1/237 (0.4) | 26/237 (< 0.0001) | 22/237 (< 0.0001) | 24/237 (< 0.0001) |
| β-alanine Metabolism | N/A | N/A | 10/99 (< 0.0001) | 15/99 (< 0.0001) | 14/99 (< 0.0001) |
| Valine, Leucine and Isoleucine Degradation | N/A | N/A | 12/107 (< 0.0001) | 14/107 (< 0.0005) | 16/107 (< 0.0001) |
| Variables | aAdjusted HR | 95% CI | P value |
| Age (years) | 1.033 | 1.027–1.039 | < 0.001 |
| Female sex | 0.700 | 0.593–0.827 | < 0.001 |
| Hypertension | 1.025 | 0.897–1.172 | 0.713 |
| Diabetes mellitus | 1.427 | 1.216–1.675 | < 0.001 |
| Preoperative severe anemia(Hb < 8.0 g/dL) | 1.282 | 1.036–1.586 | 0.022 |
| Preoperative creatinine (mg/dL) | 2.022 | 1.711–2.389 | < 0.001 |
| Postoperative creatinine (mg/dL) | 1.010 | 1.004–1.017 | 0.003 |
| Intraoperative use of normal saline | 1.030 | 0.905–1.172 | 0.656 |
| Postoperative hyponatremia | 1.331 | 1.148–1.542 | < 0.001 |
| Equation | Correlation coefficient | LOD (ng g−1) | LOQ (ng g−1) | |
| α-HCH | y = 0.168−0.7642 | 0.9906 | 1.00 ± 0.33 | 3.35 ± 0.33 |
| HCB | y = 0.0866 + 0.3576 | 0.9985 | 1.44 ± 0.48 | 4.80 ± 0.48 |
| β-HCH | y = 0.0111−0.0155 | 0.9933 | 1.50 ± 0.50 | 4.99 ± 0.50 |
| Aldrin | y = 0.1025−0.1005 | 0.9971 | 0.49 ± 0.16 | 1.62 ± 0.16 |
| Heptachlor epoxide | y = 0.06−0.1873 | 0.9970 | 0.73 ± 0.24 | 2.43 ± 0.24 |
| o,p-DDE | y = 0.0147−0.0314 | 0.9978 | 0.76 ± 0.25 | 2.53 ± 0.25 |
| α-Endosulfan | y = 0.0289−0.053 | 0.9967 | 0.99 ± 0.32 | 3.30 ± 0.32 |
| p,p-DDE | y = 0.0197−0.0206 | 0.9978 | 1.34 ± 0.45 | 4.46 ± 0.45 |
| Dieldrin | y = 0.0234−0.0452 | 0.9963 | 1.20 ± 0.40 | 4.01 ± 0.40 |
| Endrin | y = 0.0364−0.1672 | 0.9900 | 0.60 ± 0.20 | 2.00 ± 0.20 |
| β-Endosulfan | y = 0.0087 + 0.011 | 0.9983 | 1.32 ± 0.44 | 4.41 ± 0.44 |
| p,p-DDD | y = 0.0105−0.0202 | 0.9971 | 0.78 ± 0.25 | 2.59 ± 0.25 |
| o,p-DDT | y = 0.0298−0.1573 | 0.9919 | 0.48 ± 0.16 | 1.61 ± 0.16 |
| p,p-DDT | y = 0.0101−0.0232 | 0.9975 | 1.19 ± 0.40 | 3.98 ± 0.40 |
| Mixture | Compressive Strength (MPa) * | ||||
| 3 Days | 7 Days | 14 Days | 28 Days | 90 Days | |
| C-0.50-N | 18.27 0.73 | 25.18 0.25 | 30.47 1.33 | 38.47 0.14 | 51.02 1.07 |
| C-0.50-H | 20.41 0.58 | 28.23 0.92 | 35.73 0.29 | 42.87 1.41 | 54.63 1.12 |
| C-0.50-SCM | 23.92 0.29 | 34.21 0.72 | 41.90 1.41 | 50.19 0.09 | 58.24 1.05 |
| 10FA-0.50-N | 16.87 0.61 | 23.62 0.39 | 28.47 1.33 | 36.71 0.77 | 46.76 1.07 |
| 10FA-0.50-H | 18.29 0.68 | 26.73 0.54 | 31.86 0.93 | 41.25 1.03 | 51.30 1.57 |
| 10FA-0.50-SCM | 21.14 0.09 | 29.84 0.16 | 35.24 0.19 | 45.78 0.15 | 55.83 1.14 |
| 20FA-0.50-N | 15.23 0.67 | 23.02 0.13 | 27.96 0.75 | 35.14 1.12 | 45.39 1.09 |
| 20FA-0.50-H | 18.02 0.32 | 25.72 0.65 | 31.43 0.42 | 39.21 0.67 | 49.59 0.35 |
| 20FA-0.50-SCM | 20.81 0.89 | 28.42 0.43 | 34.89 1.98 | 43.27 0.86 | 53.87 0.64 |
| 40FA-0.50-N | 14.97 0.22 | 22.86 0.56 | 26.74 0.21 | 34.95 0.45 | 44.23 1.69 |
| 40FA-0.50-H | 17.57 0.98 | 25.39 1.78 | 30.33 0.67 | 38.57 1.02 | 47.96 0.93 |
| 40FA-0.50-SCM | 20.17 0.34 | 27.92 1.67 | 33.91 0.39 | 42.18 0.82 | 51.68 0.74 |
| 60FA-0.50-N | 14.12 0.92 | 20.72 0.41 | 26.07 1.21 | 33.87 1.08 | 43.14 0.71 |
| 60FA-0.50-H | 17.03 0.86 | 23.11 0.79 | 29.44 0.29 | 37.05 0.69 | 46.55 1.49 |
| 60FA-0.50-SCM | 19.94 0.26 | 25.49 0.64 | 32.81 0.94 | 40.23 1.09 | 49.95 0.78 |
| Variables | Explanation |
| Measures of needs | |
| Age-adjusted mortality | |
| Physician density | The number of physicians who work for any medical facilities per 1,000 population |
| Hospital physician density | The number of physicians who work for hospitals per 1,000 population |
| Clinic physician density | The number of physicians who work for clinics per 1,000 population |
| Measures of residential quality | |
| Urban/rural status | The metropolitan area code defined by the Ministry of Internal Affairs and Communications |
| 1) urban centres, 2) suburban areas, | |
| 3) rural areas | |
| Per capita income | |
| Percent of the population | As a proxy for educational level in the community |
| with a university-level education | |
| Unemployment rate | The number of unemployed individuals per the number of all individuals currently in the labour force (workforce) |
| Percent of white-collar workers | The number of professionals, technical workers, managers, and administrators per number of workforce |
| Primary school students per number | As a proxy for children’s educational opportunities |
| of primary schools | |
| Crime rate | The number of crimes per total population as a proxy for neighbourhood safety |
| Temperature | As a proxy for climate discomfort. The discomfort index was calculated by using temperature and humidity and used in the model. |
| Humidity | |
| Other factors | |
| Total population | |
| Hospital beds per 1,000 population | |
| The presence or absence of | As a proxy for continuing education |
| medical schools |
| Number of episodes | ||||||||
| None | Single | Multiple | ||||||
| Variable | No. | % | No | % | No | % | χ2 | p |
| Age group | ||||||||
| <1 year | 24 | 57.1% | 9 | 21.4% | 9 | 21.4% | 180.20 | <0.001 |
| 1 to 4 years | 182 | 62.5% | 86 | 29.6% | 23 | 7.9% | ||
| 5 to 14 years | 517 | 82.9% | 90 | 14.4% | 17 | 2.7% | ||
| 15 to 64 years | 3,357 | 84.5% | 518 | 13.0% | 99 | 2.5% | ||
| 65+ years | 1,666 | 87.5% | 198 | 10.4% | 41 | 2.2% | ||
| Sex | ||||||||
| Male | 2,307 | 86.2% | 300 | 11.2% | 69 | 2.6% | 15.92 | <0.001 |
| Female | 3,439 | 82.7% | 601 | 14.4% | 120 | 2.9% | ||
| NS-SEC1 | ||||||||
| Managerial and professional occupations | 2,938 | 82.6% | 514 | 14.5% | 105 | 3.0% | 30.32 | 0.001 |
| Intermediate occupations | 256 | 83.1% | 47 | 15.3% | 5 | 1.6% | ||
| Small employers and own account workers | 574 | 82.7% | 96 | 13.8% | 24 | 3.5% | ||
| Lower supervisory and technical occupations | 620 | 89.5% | 63 | 9.1% | 10 | 1.4% | ||
| Semi-routine and routine occupations | 408 | 86.4% | 53 | 11.2% | 11 | 2.3% | ||
| Not classifiable | 950 | 85.4% | 128 | 11.5% | 34 | 3.1% | ||
| Quintile of deprivation2 | ||||||||
| 1 (most deprived) | 420 | 87.1% | 49 | 10.2% | 13 | 2.7% | 12.48 | 0.131 |
| 2 | 644 | 86.2% | 80 | 10.7% | 23 | 3.1% | ||
| 3 | 1,515 | 83.3% | 247 | 13.6% | 56 | 3.1% | ||
| 4 | 1,798 | 83.9% | 286 | 13.4% | 58 | 2.7% | ||
| 5 (least deprived) | 1,366 | 83.1% | 239 | 14.5% | 39 | 2.4% | ||
| Urban/rural indicator2 | ||||||||
| Urban | 3,445 | 84.5% | 514 | 12.6% | 116 | 2.8% | 15.06 | 0.005 |
| Town | 766 | 86.3% | 96 | 10.8% | 26 | 2.9% | ||
| Rural | 1,532 | 81.9% | 291 | 15.6% | 47 | 2.5% |
| Var | Cyt | Frequency (%) of callus induction | Frequency (%) of bud induction | Average number of buds per explant | |||
| Photoperiod | Dark | Photoperiod | Dark | Photoperiod | Dark | ||
| SK | BAP | 91.00 ± 3.71 a | 90.00 ± 3.33 a | 69.00 ± 6.74 a | 56.00 ± 7.18 a | 13.48 ± 0.43 abcd | 07.97 ± 1.20 cdef |
| TDZ | 0.00 ± 0.00 b | 0.00 ± .00 b | 12.00 ± 3.26 de | 16.00 ± 5.81 cde | 02.40 ± 0.70 e | 0.90 ± 0.3 1 f | |
| NM | BAP | 81.00 ± 6.04 a | 92.00 ± 4.42 a | 53.00 ± 5.17 ab | 66.00 ± 4.26 a | 08.30 ± 0.72 ce | 06.90 ± 0.30 def |
| TDZ | 0.00 ± 0.00 b | 0.00 ± 0.00 b | 0.00 ± .00 e | 06.40 ± 2.97 e | 0.00 ± .00 f | 0.80 ± 0.29 ef | |
| EW | BAP | 81.77 ± 6.30 a | 86.00 ± 3.05 a | 71.55 ± 9.59 a | 54.30 ± 7.38 ab | 11.30 ± 0.74 bcde | 06.48 ± 0.86 def |
| TDZ | 0.00 ± 0.00 b | 0.00 ± 0.00 b | 20.00 ± 0.00 cde | 28.00 ± 7.42 cd | 5.00 ± 0.00 ef | 0.90 ± 0.23 ef | |
| RL | BAP | 100.00 ± 0.00 | 100.00 ± 0.00 | 56.00 ± 6.53 a | 54.00 ± 5.81 ab | 18.82 ± 1.52 ab | 06.30 ± 0.65 def |
| TDZ | 0.00 ± 0.00 b | 06.00 ± 3.05 b | 10.00 ± 3.33 de | 34.00 ± 7.91 bc | 0.50 ± 0.16 f | 02.45 ± 0.72 ef | |
| ER | BAP | 100.00 ± 0.00 | 100.00 ± 0.00 | 62.00 ± 5.53 a | 62.70 ± 5.20 a | 19.67 ± 2.70 a | 15.26 ± 2.22 abc |
| TDZ | 0.00 ± 0.00 b | 0.00 ± 0.00 b | 0.00 ± .00 e | 06.40 ± 2.97 e | 0.00 ± .00 f | 0.80 ± 0.29 ef |
| M3 | M6 | ||||||||
| N | CD3+ | CD4+ | CD8+ | N | CD3+ | CD4+ | CD8+ | ||
| All patients | Haplo | 33 | 264 (0–2666) | 68 (0–1767) | 80 (0–1666) | 30 | 610 (140–2992) | 242 (88–760) | 270 (14–2596) |
| UCBT | 23 | 540 (180–4661) | 190 (72–885) | 280 (18–4092) | 21 | 852 (352–6440) | 336 (105–1288) | 456 (80–5152) | |
| p | 0.003 | 0.005 | 0.010 | 0.058 | 0.022 | 0.151 | |||
| Malignant Haplo-HSCT | Relapse | 8 | 279 (4–572) | 29 (0–264) | 84 (0–308) | 7 | 867 (154–2460) | 234 (98–369) | 480 (14–2132) |
| CR | 19 | 252 (0–2666) | 138 (0–1767) | 63 (0–1666) | 17 | 560 (140–2992) | 273 (88–546) | 248 (14–2596) | |
| p | 0.894 | 0.300 | 0.831 | 0.193 | 0.975 | 0.075 | |||
| Malignant UCBT | Relapse | 3 | 1040 (266–4661) | 234 (91–885) | 819 (154–3540) | 3 | 1250 (852–1288) | 324 (250–529) | 759 (516–1000) |
| CR | 15 | 715 (180–4465) | 153 (72–616) | 476 (18–4092) | 14 | 811 (352–6440) | 322 (105–1288) | 442 (80–5152) | |
| p | 0.441 | 0.594 | 0.441 | 0.314 | 0.801 | 0.313 |
| Cut off point | Sensitivity | Specificity | PPV | NPV | |
| Morphology(%) | 5.5 | 66% | 94% | 96% | 31% |
| Motility(%) | 72.5 | 29% | 94% | 94% | 26% |
| Concentration(million/ml) | 35.5 | 46% | 94% | 96% | 32% |
| Penciclovir cream (P) | Acyclovir cream (A) | Ratio (P/A) | Statistics | |||
| μg/cm2 | Mean | s.e.m | Mean | s.e.m | P value | |
| Strip 1 | 0.55 | 0.16 | 0.88 | 0.3 | 0.6 | 0.42 |
| Strip 2 | 0.29 | 0.06 | 0.06 | 0.03 | 4.9 | 0.002 |
| Pooled Strips | 0.32 | 0.12 | 0.07 | 0.04 | 4.5 | 0.07 |
| Epidermis | 1.15 | 0.35 | 1.01 | 0.04 | 1.1 | 0.32 |
| Dermis (residual stripped skin) | 0.10 | 0.04 | 0.07 | 0.04 | 1.4 | 0.63 |
| Permeation through the skin (receptor phase) | 0.41 | 0.19 | 0.12 | 0.10 | 3.4 | 0.18 |
| Penciclovir cream (P) | Acyclovir cream (A) | Ratio(P/A) | Statistics | |||
| % applied dose | Mean | s.e.m | Mean | s.e.m | P value | |
| Strip 1 | 1.15 | 0.41 | 0.30 | 0.11 | 3.8 | 0.06 |
| Strip 2 | 0.61 | 0.16 | 0.02 | 0.01 | 29.1 | 0.002 |
| Pooled Strips | 0.67 | 0.31 | 0.02 | 0.01 | 32.3 | 0.04 |
| Epidermis | 2.4 | 0.9 | 0.3 | 0.1 | 7.0 | 0.3 |
| Dermis (residual stripped skin) | 0.17 | 0.07 | 0.02 | 0.01 | 9.1 | 0.06 |
| Permeation through the skin (receptor phase) | 0.68 | 0.33 | 0.04 | 0.03 | 16.7 | 0.06 |
| Hospital | Percentage (fraction) | Adjusted Odds Ratio | 99% confidence interval | |
| 2000 | 2003 | |||
| Getting admission without help of any external agent | ||||
| Medical College | 73% (75/103) | 88% (87/99) | 2.49 | 0.91 – 6.85 |
| Sylhet DH | 60% (29/48) | 95% (36/38) | 12.14 | 2.09 – 70.63 |
| Sonamganj DH | 84% (45/53) | 94% (48/51) | 2.84* | 0.48 – 16.73* |
| Moulvibazaar DH | 87% (45/52) | 100% (56/56) | - | - |
| Hobiganj DH | 40% (18/45) | 92% (45/49) | 33.86 | 6.59 – 173.98 |
| Attended by a doctor within one hour of admission | ||||
| Medical College | 55% (56/101) | 72% (69/96) | 2.05* | 0.94 – 4.46* |
| Sylhet DH | 52% (25/48) | 63% (24/38) | 1.58* | 0.50 – 4.96* |
| Sonamganj DH | 43% (23/53) | 67% (34/51) | 2.61* | 0.92 – 7.39* |
| Moulvibazaar DH | 36% (18/50) | 55% (31/56) | 2.20* | 0.79 – 6.15* |
| Hobiganj DH | 45% (23/51) | 29% (14/48) | 0.50* | 0.17 – 1.49* |
| No more than one attendant with the patient | ||||
| Medical College | 54% (56/104) | 52% (51/99) | 0.91* | 0.44 – 1.88* |
| Sylhet DH | 64% (30/47) | 82% (31/38) | 2.51* | 0.67 – 9.39* |
| Sonamganj DH | 43% (23/53) | 47% (24/51) | 1.16* | 0.42 – 3.22* |
| Moulvibazaar DH | 46% (24/52) | 49% (27/55) | 1.13* | 0.41 – 3.07* |
| Hobiganj DH | 48% (25/52) | 60% (30/50) | 1.62* | 0.58 – 4.56* |
| Satisfaction with doctor | ||||
| Medical College | 63% (64/102) | 83% (82/99) | 3.29 | 1.33 – 8.14 |
| Sylhet DH | 92% (43/47) | 90% (34/38) | 0.79* | 0.12 – 5.41* |
| Sonamganj DH | 56% (27/48) | 77% (39/51) | 2.53* | 0.82 – 7.79* |
| Moulvibazaar DH | 56% (29/52) | 68% (38/56) | 1.67* | 0.60 – 4.70* |
| Hobiganj DH | 65% (34/52) | 76% (38/50) | 1.68* | 0.54 – 5.23* |
| Satisfaction with nurse | ||||
| Medical College | 64% (66/104) | 74% (73/99) | 1.62* | 0.74 – 3.55* |
| Sylhet DH | 87% (41/47) | 97% (37/38) | 5.41* | 0.41 – 72.19* |
| Sonamganj DH | 76% (40/53) | 80% (41/51) | 1.33* | 0.39 – 4.56* |
| Moulvibazaar DH | 62% (32/52) | 70% (39/56) | 1.43* | 0.50 – 4.10* |
| Hobiganj DH | 77% (40/52) | 92% (46/50) | 3.45* | 0.75 – 15.96* |
| Satisfaction with cleanliness | ||||
| Medical College | 38% (39/104) | 59% (58/99) | 2.46 | 1.17 – 2.15 |
| Sylhet DH | 92% (43/47) | 100% (38/38) | - | - |
| Sonamganj DH | 43% (23/53) | 61% (31/51) | 2.02* | 0.72 – 5.65* |
| Moulvibazaar DH | 25% (13/52) | 45% (25/56) | 2.42* | 0.83 – 7.06* |
| Hobiganj DH | 77% (39/51) | 56% (28/50) | 0.39* | 0.13 – 1.19* |
| Satisfaction with privacy | ||||
| Medical College | 39% (40/103) | 47% (46/98) | 1.39* | 0.67 – 2.91* |
| Sylhet DH | 69% (31/45) | 58% (22/38) | 0.62* | 0.19 – 2.04* |
| Sonamganj DH | 36% (19/53) | 39% (20/51) | 1.15* | 0.40 – 3.30* |
| Moulvibazaar DH | 44% (23/52) | 23% (13/56) | 0.38* | 0.13 – 1.12* |
| Hobiganj DH | 42% (22/52) | 58% (29/50) | 1.88* | 0.67 – 5.30* |
| Satisfaction with overall service | ||||
| Medical College | 40% (41/103) | 63% (62/98) | 2.54 | 1.20 – 5.36 |
| Sylhet DH | 81% (35/43) | 89% (34/38) | 1.94* | 0.36 – 10.48* |
| Sonamganj DH | 42% (22/52) | 51% (26/51) | 1.42* | 0.51 – 3.95* |
| Moulvibazaar DH | 26% (12/47) | 36% (20/56) | 1.62* | 0.53 – 4.98* |
| Hobiganj DH | 49% (25/51) | 62% (31/50) | 1.70* | 0.60 – 4.82* |
| Most frequent diagnostic categories * | |||
| Neoplasm and chemotherapy | 15 | 9 – 24 | |
| Respiratory infections | 9 | 4 – 16 | |
| Asthma | 5 | 2 – 11 | |
| Gastroenteritis | 5 | 2 – 11 | |
| Appendicitis | 4 | 1 – 10 | |
| Epilepsy or seizure | 3 | 0.6 – 9 | |
| Malfunctioning device or graft | 3 | 0.6 – 9 | |
| Length of stay | |||
| 1 day | 10 | 5 – 18 | |
| 2 days | 25 | 17 – 35 | |
| 3 days | 24 | 16 – 34 | |
| 4–7 days | 27 | 17 – 37 | |
| 8 to 103 days | 14 | 8 – 22 | |
| Devices * | |||
| Gastrostomy or jejuenostomy tubes | 10 | 5 – 18 | |
| Central venous line | 7 | 3 – 14 | |
| Medication nebulizer | 7 | 3 – 14 | |
| Ventriculoperitoneal shunt | 2 | 0.2 – 7 | |
| Tracheotomy | 1 | 0.03 – 5 | |
| Number of medications § | |||
| 0 | 18 | 11 – 27 | |
| 1 | 20 | 13 – 29 | |
| 2 | 26 | 18 – 36 | |
| 3 | 16 | 10 – 26 | |
| 4 | 7 | 3 – 14 | |
| 5 or more | 12 | 6 – 20 | |
| Number of daily medication administrations noted ‡ | |||
| 0 or PRN | 33 | 24 – 44 | |
| 1–4 | 30 | 21 – 40 | |
| 5–9 | 24 | 16 – 34 | |
| 10–22 | 12 | 6 – 20 | |
| Home nursing care | 8 | 4 – 15 | |
| Other forms of home care | 7 | 3 – 14 | |
| Disposition | |||
| Home | 91 | 84 – 96 | |
| Transfer | 3 | 0.6 – 9 | |
| Death | 1 | 0.03 – 6 | |
| Unknown | 5 | 2 – 11 |
| Income group | Mean reduction in daily calorie intake (kcal/person/day) | ||
| Female | Male | Overall | |
| Income group 1 (lowest) | 2.2 | 1.6 | 1.9 |
| Income group 2 | 1.9 | 1.9 | 1.9 |
| Income group 3 (highest) | 1.9 | 2.6 | 2.3 |
| Morning surge | Pulse wave velocity | Urinary albumin excretion | White matter lesions |
| m/s / mmHg | Ln (mg/mmol) / mmHg | OR/mmHg | |
| Mean ± SE | Mean ± SE | Mean ± SE | |
| All | |||
| MS1 | |||
| Unadjusted | 0.016 ± 0.010; p = 0.10 | 0.018 ± 0.007; p = 0.011 | 0.007 ± 0.014; p = 0.62 |
| Adjusted | −0.002 ± 0.010; p = 0.81 | 0.014 ± 0.007; p = 0.053 | −0.002 ± 0.015; p = 0.90 |
| MS2 | |||
| Unadjusted | 0.006 ± 0.016; p = 0.70 | 0.006 ± 0.009; p = 0.51 | 0.005 ± 0.013; p = 0.69 |
| Adjusted | −0.006 ± 0.011: p = 0.63 | 0.005 ± 0.008; p = 0.56 | −0.001 ± 0.016; p = 0.93 |
| Patients | |||
| MS1 | |||
| Unadjusted | −0.017 ± 0.025; p = 0.51 | 0.019 ± 0.012; p = 0.11 | −0.013 ± 0.022; p = 0.56 |
| Adjusted | −0.027 ± 0.020; p = 0.18 | 0.021 ± 0.012; p = 0.08 | −0.033 ± 0.024; p = 0.18 |
| MS2 | |||
| Unadjusted | −0.011 ± 0.027; p = 0.68 | −0.002 ± 0.013; p = 0.86 | 0.003 ± 0.023; p = 0.91 |
| Adjusted | −0.020 ± 0.022; p = 0.38 | 0.002 ± 0.014; p = 0.89 | −0.013 ± 0.027; p = 0.64 |
| Controls | |||
| MS1 | |||
| Unadjusted | 0.028 ± 0.016; p = 0.08 | 0.012 ± 0.007; p = 0.08 | 0.022 ± 0.019; p = 0.26 |
| Adjusted | 0.018 ± 0.014; p = 0.20 | 0.009 ± 0.007; p = 0.17 | 0.018 ± 0.020; p = 0.36 |
| MS2 | |||
| Unadjusted | 0.007 ± 0.019; p = 0.71 | 0.007 ± 0.008; p = 0.41 | 0.008 ± 0.021; p = 0.72 |
| Adjusted | 0.006 ± 0.016; p = 0.72 | 0.008 ± 0.008; p = 0.32 | 0.004 ± 0.022; p = 0.86 |
| Variable | Category | Total (N = 265) | BCP (N = 49) | MCP(N = 216) | p valuea |
| Demographics | |||||
| Age | |||||
| <50 | 145 (54.7) | 34 (69.4) | 111 (51.4) | 0.0057 | |
| ≥50 | 120 (45.3) | 15 (30.6) | 105 (48.6) | ||
| Ethnicity | |||||
| Chinese | 188 (70.9) | 23 (46.9) | 165 (76.4) | 0.0003 | |
| Malay | 24 (9.1) | 6 (12.2) | 18 (8.3) | ||
| Indian | 13 (4.9) | 3 (6.1) | 10 (4.6) | ||
| Others | 40 (15.1) | 17 (34.7) | 23 (10.6) | ||
| Parous | |||||
| Yes | 189 (71.3) | 37 (75.5) | 152 (70.4) | 0.4726 | |
| No | 76 (28.7) | 12 (24.5) | 64 (29.6) | ||
| Personal history of cancer | |||||
| Breast cancer | |||||
| Yes | 193 (72.8) | 47 (95.9) | 146 (67.6) | 0.0009 | |
| No | 72 (27.2) | 2 (4.1) | 70 (32.4) | ||
| Ovarian cancer | |||||
| Yes | 92 (34.7) | 4 (8.2) | 88 (40.7) | 0.0002 | |
| No | 173 (65.3) | 45 (91.8) | 128 (59.3) | ||
| Family history of cancer in relativesb | |||||
| Any cancer type | |||||
| Present | 203 (76.6) | 36 (73.5) | 167 (77.3) | 0.8350 | |
| Absent | 62 (23.4) | 13 (26.5) | 49 (22.7) | ||
| Breast cancer only | |||||
| Present | 33 (12.5) | 6 (12.2) | 27 (12.5) | 0.9508 | |
| Absent | 232 (87.5) | 43 (87.8) | 189 (87.5) | ||
| Ovarian cancer only | |||||
| Present | 7 (2.6) | 1 (2.0) | 6 (2.8) | 0.9985 | |
| Absent | 258 (97.4) | 48 (98.0) | 210 (97.2) | ||
| Breast and/or ovarian cancer only | |||||
| Present | 46 (17.4) | 8 (16.3) | 38 (17.6) | 0.9013 | |
| Absent | 219 (82.6) | 41 (83.7) | 178 (82.4) | ||
| Colorectal and/or endometrial cancer | |||||
| Present | 54 (20.4) | 8 (16.3) | 46 (21.3) | 0.8903 | |
| Absent | 211 (79.6) | 41 (83.7) | 170 (78.7) |
| Trial | Number | Setting | Trial duration | ICU | Population | Intervention | Comparator | Outcomes | |
| Inclusion criteria | Exclusion criteria | ||||||||
| Youness et al. [20] | 33 | Single-centre US | 24 months | Mixed | Intubated mechanically ventilated patients with new-onset (<48 h) atelectasis | CF, uncontrolled asthma, COPD, pneumothorax, pleura effusion, tumor-associated atelectasis, severe hypoxemia, hemodynamic instability, allergy to dornase alfa, use of nebulized acetylcysteine and pregnancy | Nebulized dornase alfa 2.5 mg twice daily in 7 days or until resolution of atelectasis | (1) Placebo (isotonic saline) same volume, dosage, and duration of treatment | Mortality |
| (2) Hypertonic saline (same volume, dosage, and duration of treatment) | |||||||||
| Zitter et al. [19] | 30 | Single-centre US | 12 months | Mixed | Mechanically ventilated patients aged >18 years with new-onset (<24 h) atelectasis | Quadriplegia, chronic ventilator dependence, pneumothorax, frank hemoptysis, elevated intracranial pressure, pregnancy or active nursing, concurrent use of other investigational drugs, and allergy to dornase alfa, Chinese hamster ovary-derived biologics or other components of the active component | Nebulized dornase alfa 2.5 mg twice daily until extubation, death or transfer (maximum 30 days) | Placebo (isotonic saline) same volume, dosage, and duration of treatment | Mortality |
| Cell Type | Number of Genes | % of Genes |
| adipocyte | 188 | 21.23 |
| alveolar macrophage | 127 | 14.11 |
| B-lymphoblast | 106 | 12.58 |
| B-lymphocyte | 628 | 70.79 |
| brown adipose | 1 | 0.11 |
| cardiac muscle cell | 33 | 3.72 |
| chondrocyte | 33 | 3.72 |
| dendritic cell | 56 | 6.35 |
| endothelium | 194 | 21.88 |
| eosinophil | 1 | 0.11 |
| epithelium | 604 | 68.49 |
| fibroblast | 485 | 54.92 |
| foam cell | 25 | 2.74 |
| germ cell | 435 | 49.02 |
| glial cell | 432 | 48.69 |
| glioblast | 42 | 4.7 |
| granulosa cell | 63 | 7.22 |
| hepatocyte | 3 | 0.33 |
| keratinocyte | 287 | 32.17 |
| leukocyte | 295 | 33.26 |
| lymphocyte | 86 | 9.63 |
| macrophage | 194 | 21.88 |
| mast cell | 2 | 0.22 |
| melanocyte | 283 | 31.84 |
| monocyte | 13 | 1.42 |
| muscle cell | 233 | 26.37 |
| myeloid cell | 149 | 17.4 |
| natural killer cell | 339 | 38.84 |
| neuroblast | 396 | 44.86 |
| neuroepithelium | 143 | 16.19 |
| neuron | 124 | 14 |
| pericyte | 128 | 14.66 |
| platelet | 1 | 0.11 |
| proerythroblast | 65 | 7.77 |
| promyeloblast | 14 | 1.86 |
| promyelocyte | 44 | 5.03 |
| retinal pigment epithelium | 514 | 57.55 |
| skeletal muscle cell | 499 | 56.56 |
| smooth muscle cell | 128 | 14.77 |
| squamous cell | 376 | 42.67 |
| stem cell | 626 | 70.79 |
| T-lymphocyte | 359 | 40.92 |
| transitional | 194 | 22.21 |
| white adipose | 41 | 4.81 |
| Demographic data | Control group N = 30 | Endometriosis group N = 30 | Ectopic group N = 22 | P value (control v endometriosis) |
| Age, median (range) | 40 (25–47) | 36 (18–45) | 40 (24–51) | P = 0.056 |
| BMI, median (range) | 27 (20–42) | 26 (20–38) | 27.1 (18–32) | P = 0.37 |
| Parity, median (range) | 2 (1–4) | 1 (0–3) | 1 (0–2) | P < 0.0001 |
| Smoker | 9/30 (30%) | 5/30 (17%) | 1/22 (5%) | P = 0.36 |
| Endometriosis stage, median (range) | – | 2 (1–4) | 4 (1–4) | N/A |
| Pt# | R Lung | L Lung | Spinal Cord | Heart | Spine Bone | |||||
| synCT | CT | synCT | CT | synCT | CT | synCT | CT | synCT | CT | |
| Pt1 | −747 | −637 | −740 | −616 | 72 | 33 | 68 | 120 | 268 | 244 |
| Pt2 | −752 | −701 | −737 | −693 | 72 | 69 | 70 | 38 | 252 | 349 |
| Pt3 | −747 | −774 | −738 | −766 | 72 | 55 | 68 | 130 | 260 | 422 |
| Pt4 | −730 | −745 | −701 | −702 | 62 | 64 | 70 | 45 | 260 | 299 |
| Pt5 | −692 | −714 | −698 | −721 | 67 | 49 | 70 | 49 | 260 | 365 |
| Pt6 | −714 | −739 | −690 | −726 | 74 | 78 | 69 | 44 | 266 | 505 |
| Pt7 | −730 | −650 | −685 | −674 | 109 | 52 | 66 | 41 | 269 | 300 |
| Pt8 | −740 | −741 | −727 | −706 | 72 | 70 | 70 | 42 | 260 | 405 |
| Pt9 | −734 | −812 | −734 | −793 | 65 | 42 | 68 | 31 | 256 | 249 |
| Pt10 | −759 | −775 | −758 | −775 | 74 | 46 | 65 | 40 | 266 | 292 |
| Pt11 | −760 | −838 | −760 | −822 | 86 | 57 | 63 | 146 | 268 | 268 |
| Mean ± SE | −737 ± 6 | −739 ± 19 | −724 ± 8 | −727 ± 18 | 75 ± 4 | 56 ± 4 | 68 ± 1 | 66 ± 13 | 262 ± 2 | 336 ± 25 |
| P-value | 0.90 | 0.88 | 0.007 | 0.90 | 0.014 |
| Challenge | CE | Matched compound | MF | RMF | Prob |
| 1 | 10 eV | Kanamycin A | 645 | 879 | 98.88 |
| 20 eV | Kanamycin A | 501 | 833 | 98.81 | |
| 30 eV | Kanamycin A | 531 | 776 | 98.66 |
| Motif | Count | Average length (bp) | Count/Mbp |
| Mononucleotide | 19 | 15.89 | 9.35 |
| Dinucleotide | 30 | 29.60 | 14.76 |
| Trinucleotide | 92 | 19.99 | 45.26 |
| Tetranucleotide | 39 | 15.87 | 19.19 |
| Pentanucleotide | 27 | 16.96 | 13.28 |
| Hexanucleotide | 9 | 20.22 | 4.43 |
| Total | 216 | 19.85 | 106.27 |
| Characteristic | ||
| n = 1,729 | ||
| Age (y) | Median (IQR) | 69 (62-74) |
| Range | 22-93 | |
| Male sex, n (%) | 1,156 (66.9) | |
| Absence of previous iodinated contrast media injections, n (%) | 973 (56.3) | |
| History of adverse reaction to iodinated contrast media, n (%) | 45 (2.6) | |
| History of allergy, n (%) | 164 (9.5) | |
| History of asthma, n (%) | 23 (1.3) | |
| Use of corticosteroid at entry, n (%) | 28 (1.6) | |
| Child–Pugh classification, n (%) | ||
| A | 1427 (82.5) | |
| B or C | 302 (17.5) | |
| Renal function at entry | ||
| eGFR (ml/min), Median (IQR) | 73.6 (61.7-87.3) | |
| Presence of renal impairment, n (%) | 383 (22.2) |
| Compounds | Content (Mean ± SD, n = 3) |
| mg/g | |
| Paeoniflorin | 59.55 ± 0.39 |
| Glycyrrhizin | 12.13 ± 0.01 |
| Guarantee the follow-up and referral to medical services of individuals with a positive diagnosis | |||
| PROCESS MEASURE | Indicator description | Method of Data collection | Data Collection Frequency |
| Monitoring of the number of individuals infected with HIV that have received medical care | Number of individuals infected with HIV that have received medical care/Number of individuals infected with HIV attended and that have received health care by the NGO in the evaluation year | NGO | 12 months |
| Monitoring of the number of individuals infected with HIV that are referred to other health services | Number of individuals infected with HIV that are referred to other health services/Number of individuals infected with HIV attended and that have received health care by the NGO in the evaluation year | NGO | 12 months |
| Monitoring of the number of individuals referred to each service | Numbers of individuals referred to each service | NGO | 12 months |
| Monitoring of the number of people working in a service | Number of people working in a service | NGO | 12 months |
| Monitoring of the hours dedicated to each activity | Hours dedicated to each activity | NGO | 12 months |
| OUTCOME MEASURE | Indicator description | Method of Data collection | Data Collection Frequency |
| Level of satisfaction with the service | Number of individuals infected with HIV that have received care, have responded to the satisfaction questionnaire, and have a high level of satisfaction/Number of infected individuals that have received care and have responded to the questionnaire | NGOAnswers to the satisfaction questionnaire | 12 months |
| Monitoring of the questionnaire of quality of life answers of individuals attended by the NGO | Descriptive analysis and monitoring of the global score and score by dimensions of the questionnaire of quality of life answers of individuals infected with HIV and attended by the NGO | NGOAnswers to the QQV | 12 months |
| Heparin | Citrate | |
| Renal days | 357 | 199 |
| Median renal days per patient episode | 3 | 3 |
| Number of filters used | 408 | 128 |
| Total filter cost (•) | 32807.28 | 10292.48 |
| Renal days per filter | 0.86 | 1.55 |
| Filter cost per renal day (•) | 91.89 | 51.72 |
| Blood transfusions per day | 0.33 | 0.25 |
| Control | Dextrose 24 scFOS 11 | Maltitol 35 | Maltitol 30 scFOS 5 | Maltitol 24 scFOS 11 | Maltitol 17.5 scFOS 17.5 | Dessert effect (P-value) | ||
| 0–24 h | Total score | 3.15±4.26a | 6.46±5.85b | 8.86±6.49b,c | 8.53±7.10b,c | 9.41±6.99b,c | 10.80±7.98b,c | <0.0001 |
| Flatulence | 1.21±1.49 | 2.11±2.26 | 3.37±2.56* | 2.74±2.50* | 3.68±2.46* | 4.11±2.34* | <0.0001 | |
| Borborygmi | 0.70±1.31 | 1.49±2.01 | 2.11±2.40* | 2.41±2.43* | 1.85±2.30* | 2.43±2.40* | <0.0001 | |
| Bloating | 0.70±1.69 | 1.40±2.20 | 1.60±2.24 | 1.74±2.15 | 1.82±2.41 | 2.17±2.72* | 0.0312 | |
| Discomfort | 0.55±1.68 | 1.46±2.41 | 1.77±2.44* | 1.65±2.98 | 2.06±2.95* | 2.09±2.70* | 0.0135 | |
| 24–48 h | Total score | 0.88±1.71a | 2.34±3.55a,b | 3.60±5.39b | 2.62±3.57b | 2.24±3.37a,b | 2.71±4.26b | 0.0063 |
| Flatulence | 0.27±0.80 | 0.83±1.50 | 1.37±1.99* | 1.12±1.61* | 1.06±1.54* | 1.20±1.78* | 0.0037 | |
| Borborygmi | 0.30±0.81 | 0.31±0.93 | 0.74±1.60 | 0.79±1.49 | 0.44±1.13 | 0.57±1.29 | 0.0823 | |
| Bloating | 0.12±0.55 | 0.49±1.17 | 0.69±1.64 | 0.35±0.92 | 0.47±1.02 | 0.57±1.36 | 0.2084 | |
| Discomfort | 0.18±0.58 | 0.71±1.54 | 0.80±1.64* | 0.35±1.01 | 0.26±0.79 | 0.37±1.19 | 0.0448 |
| Run | Controllable parameter | |||
| Table separation distance | Squeegee speed | Squeegee pressure | Table speed of solder printer | |
| 1 | 1 | 1 | 1 | 1 |
| 2 | 1 | 2 | 2 | 2 |
| 3 | 1 | 3 | 3 | 3 |
| 4 | 2 | 1 | 2 | 3 |
| 5 | 2 | 2 | 3 | 1 |
| 6 | 2 | 3 | 1 | 2 |
| 7 | 3 | 1 | 3 | 2 |
| 8 | 3 | 2 | 1 | 3 |
| 9 | 3 | 3 | 2 | 1 |
| Men | Women | All | ||||
| Study Population | 46 388 | 46% | 55 417 | 54% | 101 805 | 100% |
| Random sample | 2 300 | 46% | 2 730 | 54% | 5 030 | 100% |
| Study respondents | 1 132 | 36% | 2 021 | 64% | 3 153 | 100% |
| Students who responded to the question concerning use of the web-based health advice service | 1 113 | 36% | 2 001 | 64% | 3 114 | 100% |
| Users of the web-based health advice service | 92 | 25% | 278 | 75% | 370 | 100% |
| Cells | Assays | BCR-ABL-GFP* | BCR-ABL-GFP + N17 H-Ras* | GFP vector* |
| NIH 3T3 | # of foci | 117 +/- 16† | 11 +/- 2 | - |
| Bone marrow | # of colonies | 16 +/- 0.6 | 0.33 +/- 0.33 | - |
| β | p-value | |
| Total effect | 0.31 | <0.001 |
| Direct effect | 0.25 | <0.001 |
| Total indirect | 0.06 | <0.001 |
| Indirect effects | ||
| via cravings, urges to buy, unplanned purchases | 0.01 | 0.001 |
| via cravings, unplanned purchases | 0.04 | <0.001 |
| via urges to buy, unplanned purchases | 0.01 | 0.03 |
| Univariate Cox Model | Mutivariate Cox Model | |||||
| Hazard ratio | 95%CI | p value | Hazard ratio | 95%CI | p value | |
| Age ≤ 45 vs. > 45 | 0.703 | 0.523–0.946 | 0.02 | 0.89 | 0.509–1.03 | 0.474 |
| Male vs. Female | 0.906 | 0.686–1.197 | 0.488 | |||
| Astrocytic vs. oligodendroglial | 1.123 | 0.849–1.486 | 0.417 | |||
| IDH1-R132H positive vs. negative | 0.437 | 0.326–0.586 | 3.15E–08 | 0.517 | 0.369–0.723 | 1.19E–04 |
| ATRX loss vs. expression | 0.645 | 0.486–0.856 | 0.002 | 0.913 | 0.659–1.264 | 0.584 |
| WHO grade II/III vs. IV | 0.529 | 0.388–0.772 | 5.79E–05 | 0.724 | 0.509–1.030 | 0.072 |
| Bacterial strains | G. tenax extracts dose (mg) | MIC (mg/mL) | ||||
| 0.3 | 0.6 | 1.2 | 2.5 | 5.0 | ||
| Staphyloccocus aureus | 24.3 | 25.1 | 26.4 | 27.7 | 28.9 | 3.9 |
| Enterococcus faecalis | 11.2 | 15.6 | 20.3 | 24.5 | 29.3 | 7.8 |
| Pseudomonas aeruginosa | 10.2 | 15.5 | 23.1 | 24.2 | 26.6 | 15.6 |
| Escherichia coli | 15.4 | 18.9 | 20.3 | 21.6 | 23.2 | 3.9 |
| Form of regression model | AICc | ∆AICc | wi |
| Time + Vegetation density + Time: vegetation density | 404.97 | 0.00 | 0.99 |
| Time + Ruggedness + Time: ruggedness | 415.40 | 10.43 | 0.01 |
| Time + Kill probability + Time: kill probability | 425.81 | 20.84 | 0.00 |
| Time + Encounter risk + Time: encounter risk | 429.08 | 24.11 | 0.00 |
| Time | 436.25 | 31.28 | 0.00 |
| Vegetation density + Ruggedness + Vegetation: ruggedness | 901.25 | 496.28 | 0.00 |
| Vegetation | 904.90 | 499.93 | 0.00 |
| Vegetation density + Encounter risk + Vegetation: encounter risk | 907.93 | 502.97 | 0.00 |
| Vegetation density + Kill probability + Vegetation: kill probability | 908.53 | 503.56 | 0.00 |
| Ruggedness | 914.86 | 509.89 | 0.00 |
| Ruggedness + Kill probability + Ruggedness: kill probability | 917.95 | 510.93 | 0.00 |
| Ruggedness + Encounter risk + Ruggedness: encounter risk | 915.90 | 512.98 | 0.00 |
| Kill probability | 932.48 | 527.51 | 0.00 |
| Encounter risk | 933.88 | 528.91 | 0.00 |
| n | Baseline | 15 min ischemia | 2 hr reperfusion | |||||||
| HR | MAP | RPP | HR | MAP | RPP | HR | MAP | RPP | ||
| Vehicle | 7 | 375 ± 20 | 121 ± 5 | 51 ± 2 | 367 ± 20 | 106 ± 9 | 41 ± 2 | 366 ± 18 | 78 ± 8 | 36 ± 2 |
| MOR | 7 | 382 ± 23 | 121 ± 6 | 47 ± 3 | 378 ± 23 | 111 ± 7 | 42 ± 5 | 338 ± 35 | 65 ± 4 | 27 ± 2∗ |
| RAD + MOR | 7 | 343 ± 9 | 111 ± 5 | 45 ± 2 | 304 ± 13 | 74 ± 5 | 27 ± 2 | 311 ± 11 | 66 ± 4 | 28 ± 2 |
| DSG + MOR | 7 | 346 ± 9 | 127 ± 3 | 50 ± 3 | 347 ± 7 | 117 ± 6 | 45 ± 2 | 296 ± 9 | 82 ± 7 | 30 ± 2 |
| SB21 | 7 | 401 ± 8 | 108 ± 7 | 46 ± 4 | 395 ± 11 | 106 ± 10 | 44 ± 5 | 360 ± 12 | 81 ± 4 | 32 ± 2 |
| RAD + SB | 7 | 376 ± 11 | 107 ± 7 | 45 ± 3 | 363 ± 12 | 69 ± 5∗ | 28 ± 2 | 371 ± 13 | 72 ± 4 | 33 ± 2 |
| DSG + SB | 5 | 384 ± 8 | 124 ± 4 | 56 ± 2 | 384 ± 6 | 107 ± 7 | 45 ± 3 | 380 ± 8 | 79 ± 3 | 37 ± 1 |
| RAD | 7 | 361 ± 12 | 125 ± 5 | 52 ± 2 | 355 ± 10 | 129 ± 5 | 50 ± 2 | 333 ± 10 | 77 ± 4 | 33 ± 2 |
| DSG | 6 | 392 ± 7 | 110 ± 4 | 50 ± 1 | 388 ± 5 | 94 ± 10 | 42 ± 3 | 375 ± 7 | 78 ± 6 | 36 ± 3 |
| Age (years of growth) | Number of specimen | TRR | TRM |
| 1 | 5 | 0 | 1 |
| 2 | 8 | 1 | 2 |
| 3 | 8 | 2 | 3 |
| 4 | 8 | 3 | 4 |
| 5 | 5 | 4 | 5 |
| 8 | 3 | a | 8 |
| 10 | 1 | a | 10 |
| Total | Fixed-dose group | Adjusted-dose group | |
| January** | 22.7 ± 2.3 | 24.4 ± 0.5 | 21.5 ± 2.3 |
| February | 22.9 ± 3.0 | 24.4 ± 0.5 | 22.0 ± 3.5 |
| March | 22.4 ± 2.8 | 22.2 ± 2.9 | 22.6 ± 2.9 |
| April | 22.4 ± 2.9 | 21.5 ± 2.6 | 22.9 ± 3.1 |
| May | 21.8 ± 2.9 | 23.1 ± 1.2 | 20.9 ± 3.4 |
| June | 23.0 ± 1.9 | 23.4 ± 1.6 | 22.9 ± 2.1 |
| July | 23.3 ± 2.5 | 23.2 ± 2.5 | 23.3 ± 2.5 |
| August | 23.6 ± 2.6 | 24.2 ± 1.0 | 23.2 ± 3.2 |
| September* | 23.3 ± 1.8 | 24.2 ± 1.0 | 22.7 ± 2.0 |
| October* | 23.1 ± 2.8 | 24.3 ± 0.8 | 22.2 ± 3.4 |
| November* | 23.6 ± 1.4 | 24.3 ± 0.8 | 23.1 ± 1.5 |
| December** | 22.9 ± 2.8 | 24.4 ± 1.0 | 21.9 ± 3.2 |
| Tumor margin | HD group (n=23) | LD group (n=24) | χ2 | P | |
| Lobulated | Yes | 7 (30.4) | 17 (70.8) | 7.671 | <0.05 |
| No | 16 (69.6) | 7 (29.2) | |||
| Spiculated | Yes | 22 (95.7) | 21 (87.5) | 1.002 | >0.05 |
| No | 1 (4.3) | 3 (12.5) |
| CTAS visits | Trial 1 patients | Trial 2 patients | Trial 1% in level | Trial 2% In Level |
| CTAS 1 | 4 | 7 | 0.14% | 0.23% |
| CTAS 2 | 149 | 136 | 5.25% | 4.40% |
| CTAS 3 | 1010 | 1216 | 35.59% | 39.34% |
| CTAS 4 | 1412 | 1514 | 49.75% | 48.98% |
| CTAS 5 | 219 | 170 | 7.72% | 5.50% |
| Unknown | 44 | 48 | 1.55% | 1.55% |
| Total patients | 2838 | 3091 |
| Predictor | Estimate | Standard error | Degrees of freedom | t-value | p-value |
| Intercept | 0.107 | 0.028 | 12.5 | 3.862 | .002 |
| Task | 0.020 | 0.026 | 12.2 | 0.784 | .448 |
| Gold-MSI Musical Training | -0.003 | 0.001 | 11.1 | -0.327 | .750 |
| Task * Gold-MSI Musical Training | -0.001 | 0.001 | 8.8 | -0.816 | .436 |
| Device | Frequency (GHz) | Gain (dB) | Output Power (W) | PAE (%) |
| HPA 1 | 4.5–18 | 19 | 2 (CW and pulsed) | 25–30% |
| HPA 2 | 5–12 | 20 | 4 (pulsed) | 25–30% |
| Assembly | |
| Total number of reads | 1,104,651 |
| Number of reads after pre-processing | 990,945 |
| Average read length after pre-processing | 362 bp |
| Total number of contigs | 54,748 |
| Average contig length | 965 bp |
| Sequencing length | 52,832,938 bp |
| Contigs with ORF ≥200 bp (average length) | 30,552 (540 bp) |
| Average read coverage per contig | 4.34x |
| Average GC % content of contigs | 37.77% |
| Annotation | |
| % contigs with at least 1 GO term | 30.01% |
| % contigs with an EC number | 6.10% |
| % contigs with at least 1 IPR | 33.27% |
| Contigs with at least 1 blast hit against nr | |
| Total number | 20,333 |
| Average length | 1,394 bp |
| % of those contigs with at least 1 IPR | 42.61% |
| % of those contigs with at least 1 GO term | 78.43% |
| Contigs with ORF ≥200 bp (average length) | 18,080 (704 bp) |
| Contigs with no blast hits | |
| Total number | 34,416 |
| Average length | 712 bp |
| % of those contigs with at least 1 GO term | 1.41% |
| % of those contigs with at least 1 IPR | 28.01% |
| Contigs with ORF ≥200 bp (average length) | 12,472 (301 bp) |
| Database | Without Transfer Learning | With Transfer Learning | ||||||
| SVM Kernel (No. PC) | APCER | BPCER | ACER | SVM Kernel (No. PC) | APCER | BPCER | ACER | |
| ISPR-DB | RBF Kernel (No. PC = 200) | 2.8438 | 2.8550 | 2.8494 | Linear Kernel (No. PC = 70) | 0.0313 | 0.0310 | 0.0311 |
| Idiap (Full-DB) | RBF Kernel (No. PC = 70) | 0.0000 | 0.0000 | 0.0000 | Linear Kernel (No. PC = 60) | 0.0000 | 0.0000 | 0.0000 |
| Idiap (Cropped-DB) | RBF Kernel (No. PC = 105) | 1.0000 | 1.0000 | 1.0000 | RBF Kernel (No. PC = 95) | 0.0000 | 0.0000 | 0.0000 |
| Description of vision | Visual acuity |
| Good reading vision | 20/20 – 20/25 |
| Legal driving vision | 20/30 – 20/40 |
| Moderate visual loss | 20/50 – 20/100 |
| Legal blindness | ≤ 20/200 |
| Learning memory | Delayed recall memory | Recognition memory | Semantic verbal fluency test | Phonemic verbal fluency test | Trail test | |||||||
| β | p-value | Β | p-value | Β | p-value | Β | p-value | β | p-value | Β | p-value | |
| Age | − 0.105 | 0.001 | − 0.142 | < 0.001 | 0.004 | 0.896 | − 0.081 | 0.013 | − 0.041 | 0.208 | 0.259 | < 0.001 |
| Body mass index | − 0.105 | 0.001 | − 0.089 | 0.006 | − 0.038 | 0.253 | − 0.062 | 0.057 | − 0.046 | 0.162 | 0.092 | 0.005 |
| Systolic BP | − 0.124 | < 0.001 | − 0.154 | < 0.001 | − 0.082 | 0.012 | − 0.111 | 0.001 | − 0.119 | < 0.001 | 0.117 | < 0.001 |
| Diastolic BP | − 0.082 | 0.013 | − 0.119 | < 0.001 | − 0.073 | 0.026 | − 0.109 | 0.001 | − 0.125 | < 0.001 | 0.101 | 0.002 |
| Plasma glucose | − 0.108 | <0.001 | − 0.127 | < 0.001 | − 0.035 | 0.287 | − 0.016 | 0.634 | − 0.058 | 0.079 | 0.095 | 0.004 |
| Triglycerides | − 0.138 | < 0.001 | − 0.173 | < 0.001 | − 0.068 | 0.040 | − 0.065 | 0.050 | − 0.044 | 0.183 | 0.075 | 0.024 |
| HDL-cholesterol | 0.135 | < 0.001 | 0.187 | < 0.001 | 0.070 | 0.034 | 0.092 | 0.005 | 0.093 | 0.005 | − 0.093 | 0.005 |
| LDL-cholesterol | 0.037 | 0.261 | 0.030 | 0.359 | − 0.002 | 0.947 | 0.025 | 0.450 | 0.023 | 0.484 | − 0.039 | 0.242 |
| HOMA-IRa | − 0.087 | 0.008 | − 0.089 | 0.007 | − 0.012 | 0.722 | − 0.015 | 0.653 | − 0.043 | 0.192 | 0.004 | 0.911 |
| CRPa | − 0.032 | 0.329 | − 0.056 | 0.085 | − 0.019 | 0.554 | − 0.105 | 0.001 | − 0.046 | 0.161 | 0.084 | 0.011 |
| Patient | Age (y) | Menopause status | Histologic type | Histological grading | B classification | MIB-1 (%) | Receptor status | Molecular subtype | ||
| ER | PR | HER2 | ||||||||
| 1 | 75 | Post | IDC | 2 | 5b | 10 | + | + | − | Luminal A |
| 2 | 65 | Post | IDC | 2 | 5b | 10 | + | + | − | Luminal A |
| 3 | 54 | n.s. | IDC | 3 | 5b | n.s. | n.s. | n.s. | n.s. | n.s. |
| 4 | 39 | Pre | IDC | 2 | 5b | 40 | + | + | + | Luminal B |
| 5 | 66 | Post | IDC | 2 | 5b | 60 | + | + | − | Luminal A |
| 6 | 50 | Pre | IDC | 3 | 5b | 50 | + | + | + | Luminal B |
| 7 | 73 | Post | IDC | 3 | 5b | 20 | + | + | − | Luminal A |
| 8 | 76 | Post | IDC | 2 | 5b | 20 | + | + | − | Luminal A |
| 9 | 63 | Post | IDC | 3 | 5 | 30 | + | + | − | Luminal A |
| 10 | 48 | Post | IDC | 3 | 5b | 20 | + | + | + | Luminal B |
| 11 | 58 | Post | IDC | n.s. | 5c | 20 | + | + | + | Luminal B |
| 12 | 61 | Post | IDC | 3 | 5b | 70 | − | − | − | Triple negative |
| 13 | 52 | Pre | ILC | n.s. | 5b | 50 | + | + | − | Luminal A |
| 14 | 42 | Pre | IDC | 3 | 5b | 80 | + | − | − | Luminal A |
| 15 | 67 | Post | IDC | 3 | 5b | 40 | + | + | − | Luminal A |
| 16 | 61 | Post | ILC | 2 | 5b | 30 | + | + | − | Luminal A |
| 17 | 41 | Pre | Mucinous | 2 | 5b | 50 | + | + | + | Luminal B |
| Location | unadjusted | |||
| SNP ID | CHR | bp | Gene | p value |
| rs29013431 | 2 | 15,312,400 | 5.99E-03 | |
| rs29012194 | 2 | 26,095,592 | 6.28E-03 | |
| rs29016537 | 2 | 29,654,789 | 1.30E-03 | |
| rs29020907 | 4 | 59,252,723 | IMP2 | 4.97E-04 |
| rs29024570 | 10 | 4,359,586 | 4.30E-04 | |
| AAFC02107025 | 10 | 21,153,203 | DHRS1 | 4.73E-03 |
| rs29024728 | 13 | 28,618,368 | 3.34E-03 | |
| PRNP08 | 13 | 47,214,453 | PRNP | 4.38E-03 |
| rs29021171 | 14 | 10,106,755 | 3.84E-03 | |
| SCAFFOLD51887 | 14 | 43,984,153 | 7.25E-05* | |
| rs29014819 | 15 | 35,713,980 | 7.17E-04 | |
| rs29014820 | 15 | 35,714,095 | 6.05E-04 | |
| rs29014821 | 15 | 35,714,113 | 4.66E-04 | |
| AAFC02014662 | 16 | 65,943,749 | 7.95E-03 | |
| AAFC02012500_1 | 21 | 11,820,092 | MCTP2 | 1.82E-03 |
| AAFC02012500_2 | 21 | 11,820,201 | MCTP2 | 3.93E-03 |
| rs29026011 | 21 | 13,254,954 | LOC618464 | 3.00E-03 |
| rs29019629 | 21 | 33,209,686 | CSPG4 | 2.01E-03 |
| rs29011202 | 24 | 18,493,192 | 9.08E-03 | |
| AJ496776 | 28 | 31,495,721 | 5.74E-03 |
| Frequency | Percent | |
| Had been asked about desire to be pregnant | 95 | 76.8 (95%CI 68–83) |
| Not at risk for pregnancy | 59 | 47.2 |
| At risk for pregnancy (either planned or unplanned) | 36 | 28.8 |
| Using effective contraception | 13 | 10.4 |
| Using ineffective contraception** | 11 | 8.8 |
| Have knowledge* | 10 | 8.0 |
| Do not have knowledge | 1 | 0.8 |
| Non-contraceptive use | 12 | 9.6 |
| Have knowledge* | 8 | 6.4 |
| Do not have knowledge | 4 | 3.2 |
| Had never been asked about desire to get pregnant | 30 | 24.0 |
| Not at risk for pregnancy | 23 | 18.4 |
| At risk for pregnancy | 7 | 1.56 |
| Using effective contraception | 3 | 2.4 |
| Using ineffective contraception | 0 | 0 |
| No contraception | 4 | 3.2 |
| Have knowledge | 2 | 1.6 |
| Do not have knowledge | 2 | 1.6 |
| Disabling pain, no. (%) | No disabling pain, no. (%) | Unadjusted OR (95% CI) | Adjusted OR (95% CI)b | |
| Sex | ||||
| Men | 171 (43.0) | 54 (50.9) | 1.0 | 1.0 |
| Women | 227 (57.0) | 52 (49.1) | 1.38 (0.90–2.12) | 1.14 (0.89–1.47) |
| Age, years | ||||
| 50–64 | 197 (49.5) | 74 (69.8) | 1.0 | 1.0 |
| 65–74 | 111 (27.9) | 28 (26.4) | 1.49 (0.91–2.44) | 1.08 (0.81–1.44) |
| ≥75 | 90 (22.6) | 4 (3.8) | 8.45 (2.30–23.83) | 1.41 (1.01–1.96) |
| Body mass index, kg/m2 | ||||
| <25.0 | 81 (21.1) | 26 (25.2) | 1.0 | 1.0 |
| 25.0–29.9 | 129 (33.7) | 47 (45.6) | 0.88 (0.51–1.53) | 1.44 (1.02–2.02) |
| 30.0–34.9 | 89 (23.2) | 19 (18.4) | 1.50 (0.77–2.92) | 2.50 (1.73–3.59) |
| ≥35.0 | 84 (21.9) | 11 (10.7) | 2.45 (1.14–5.28) | 4.69 (3.12–7.08) |
| Neighborhood deprivation (quartiles) | ||||
| Least deprived | 65 (16.3) | 29 (27.4) | 1.0 | 1.0 |
| Upper mid‐deprived | 101 (25.4) | 25 (23.6) | 1.80 (0.97–3.35) | 1.22 (0.82–1.80) |
| Lower mid‐deprived | 106 (26.6) | 31 (29.2) | 1.53 (0.84–2.76) | 1.11 (0.75–1.65) |
| Most deprived | 126 (31.7) | 21 (19.8) | 2.68 (1.42–5.06) | 1.14 (0.78–1.67) |
| Individual occupational class | ||||
| Higher managerial/administrative/professional | 45 (12.7) | 19 (18.4) | 1.0 | 1.0 |
| Intermediate | 72 (20.4) | 9 (8.7) | 3.38 (1.41–8.11) | 1.86 (1.21–2.85) |
| Routine and manual | 236 (66.9) | 75 (72.8) | 1.33 (0.73–2.41) | 1.97 (1.35–2.88) |
| Physical activity level | ||||
| Low | 158 (46.2) | 961 (24.1) | 1.0 | 1.0 |
| Medium | 126 (36.8) | 1,694 (42.5) | 0.45 (0.35–0.58) | 0.53 (0.40–0.69) |
| High | 58 (17.0) | 1,335 (33.5) | 0.26 (0.19–0.36) | 0.33 (0.23–0.46) |
| Diabetes mellitus | ||||
| Absent | 310 (77.9) | 268 (96.8) | 1.0 | 1.0 |
| Present | 88 (22.1) | 9 (3.2) | 3.06 (1.49–6.30) | 1.5643 (1.04–1.95) |
| Explanatory variable | Transmission % for group | Univariate logistic regression | Multivariate logistic regression | |||
| OR (95% CI) | p | OR (95% CI) | P | |||
| Virus Group (cf none detected) | None | 20 of 95 (21.1%) | 1.00 (def) | - | 1.00 (def) | - |
| Picornavirus | 10 of 40 (25.0%) | 1.25 (0.524, 2.98) | 0.615 | 0.996 (0.398, 2.49) | 0.994 | |
| Influenza | 5 of 17 (29.4%) | 1.56 (0.493, 4.95) | 0.448 | 1.87 (0.552, 6.36) | 0.314 | |
| Coronavirus | 3 of 6 (50.0%) | 3.75 (0.703, 20.0) | 0.122 | 2.43 (0.409, 14.4) | 0.330 | |
| Other | 0 of 8 (0.00%) | - | - | - | - | |
| Sex (cf male) | Male | 9 of 69 (13.0%) | 1.00 (def) | - | 1.00 (def) | - |
| Female | 30 of 108 (27.8%) | 2.56 (1.13, 5.81) | 0.024 | 2.45 (1.01, 5.93) | 0.047 | |
| Smoking (cf not current smoker) | Not current smoker | 36 of 161 (22.4%) | 1.00 (def) | - | 1.00 (def) | - |
| Current smoker | 3 of 12 (25.0%) | 1.16 (0.298, 4.50) | 0.833 | 1.40 (0.319, 6.12) | 0.658 | |
| Age (cf 18–24 years) | 18-24 years | 9 of 47 (19.2%) | 1.00 (def) | - | Not included | - |
| 25-34 years | 5 of 28 (17.9%) | 0.918 (0.274, 3.08) | 0.890 | Not included | - | |
| 35-44 years | 15 of 37 (40.5%) | 2.88 (1.08, 7.66) | 0.034 | Not included | - | |
| 45-54 years | 6 of 36 (16.7%) | 0.844 (0.270, 2.64) | 0.771 | Not included | - | |
| 55-64 years | 4 of 29 (13.8%) | 0.676 (0.188, 2.43) | 0.549 | Not included | - | |
| Household size (cf size 2) | 2 | 14 of 64 (21.9%) | 1.00 (def) | - | Not included | - |
| 3 | 4 of 44 (9.09%) | 0.357 (0.109, 1.17) | 0.089 | Not included | - | |
| 4 | 11 of 46 (23.9%) | 1.22 (0.456, 2.76) | 0.801 | Not included | - | |
| 5 | 8 of 17 (47.1%) | 3.17 (1.03, 9.75) | 0.044 | Not included | - | |
| 6 | 2 of 3 (66.7%) | 7.14 (0.602, 84.7) | 0.119 | Not included | - | |
| 7 | 0 of 3 (0.00%) | - | - | Not included | - | |
| Presence of child (cf no children in house) | No child in house | 22 of 123 (17.9%) | 1.00 (def) | - | 1.00 (def) | - |
| At least one child in house | 17 of 54 (31.5%) | 2.11 (1.01, 4.41) | 0.047 | 2.63 (1.18, 5.88) | 0.018 |
| Response | Predictor | OR (95% CI) | P-value |
| Knowledge on malaria in pregnancy | Age category (years) | ||
| 20-24 | 2.3 (0.8, 6.6) | 0.124 | |
| 25-29 | 3.3 (1.2, 8.9) | 0.02* | |
| 30+ | 4.3 (1.6, 11.7) | 0.004* | |
| Education | |||
| Educated (>Primary School) | 1.7 (1.1, 2.8) | 0.046* | |
| Status in the household | |||
| Spouse | 2 (1.0, 4.2) | 0.06 | |
| Daughter | 1.8 (0.6, 5) | 0.263 | |
| Receiving two doses of SP | Age category (years) | ||
| 20-24 | 2.0 (0.5, 7.5) | 0.302 | |
| 25-29 | 3.0 (0.9, 10.5) | 0.077 | |
| 30+ | 3.3 (1.0, 10.8) | 0.05* | |
| Time spent at ANC clinic | |||
| 1-2 hr | 0.7 (0.4, 1.4) | 0.349 | |
| 3-4 hours | 0.7 (0.3, 1.5) | 0.38 | |
| 5-6 hours | 0.2 (0.1, 0.8) | 0.016* |
| Methodological quality featuresassessed in the included studies | Score | |
| A | Description of study objectives | 1 |
| B | Study design (retrospective = 0 point;prospective = 1 point; randomized prospective = 2 points) | 2 |
| C | Description of sample inclusion/exclusioncriteria | 1 |
| D | Intervention clearly described (reason forchoosing the extracted tooth/performing the wear) | 1 |
| E | Measures for evaluating the resultsdescribed | 1 |
| F | Determining the sample size (sample sizecalculation) | 1 |
| G | Description of statistical analysismethods | 1 |
| H | Sample description (demographic - age, sex andethnicity) | 1 |
| I | Sample description (overjet, overbite,perimeter discrepancy, Bolton, tooth form, oral health, profile) (0.5point/item. More than 6 items = 3 points) | 3 |
| J | Description of treatment duration and follow-up(1 point each) | 2 |
| K | Description of limitations, biases andinaccuracies of the study | 1 |
| L | Operator calibration | 1 |
| Strain/Population | Wing length in mm (standard error) | Fecundity* (standard error) | Blood-meal size (μl) (standard error) |
| Mbita | 2.86 (0.03) | 35.97 (2.56) | 3.15 (0.14) |
| Ifakara | 2.89 (0.03) | 49.27 (2.67) | 2.54 (0.08) |
| F1 from Mbita female × Ifakara male | 3.13 (0.03) | 74.87 (2.63) | 4.04 (0.16) |
| F1 from Ifakara female × Mbita male | 3.03 (0.02) | 83.20 (5.36) | 4.51 (0.21) |
| F5 from Mbita female × Ifakara male | 2.94 (0.02) | 68.93 (2.61) | 4.02 (0.16) |
| F5 from Ifakara female × Mbita male | 3.14 (0.02) | 68.77 2.69) | 3.38 (0.18) |
| Sponge isolate | Inhibition zone diameter (mm) | ||
| S. aureus 8325 | E. faecalis JH212 | C. albicans S314 | |
| Actinokineospora sp. EG49* | 0 | 0 | 12 |
| Dietzia sp. EG67 | 13 | 0 | 0 |
| Microbacterium sp. EG69* | 10 | 9 | 0 |
| Micromonospora sp. RV115 | 12 | 10 | 0 |
| Rhodococcus sp. EG33* | 12 | 8 | 0 |
| Rubrobacter sp. RV113** | 9 | 0 | 0 |
| Streptomyces sp. RV15* | 17 | 11 | 13 |
| Meaning units | Condensed text | Themes |
| Has gained greater insight from the patients’ perspective to better understand and involve the patients Has developed and increased an awareness of nurturing the whole patient | An increased understanding of the patients’ perspective makes it easier to involve patients. The awareness of caring for the whole patient has increased | Focus on the patient perspective and paying more attention to others |
| Working in study groups motivates one to engage more in studies and provides greater learning | It is motivational and educational to work in study groups | Learning from discussions and reflections on one’s own learning |
| Nulliparae | Multiparae | |||
| 1998-2002 | 2003-2007 | 1998-2002 | 2003-2007 | |
| Characteristics | OR* multivariable | OR* multivariable | ||
| (95% CI#) | (95% CI#) | |||
| referral | ||||
| - before the onset of labour (reference) | 1.00 | 1.00 | 1.00 | 1.00 |
| - during labour | 1.23 (1.18-1.28) | 1.02 (0.99-1.05) | 1.54 (1.48-1.60) | 1.12 (1.08-1.16) |
| process of birth | ||||
| - spontaneous, no induction, no augmentation (reference) | 1.00 | 1.00 | 1.00 | 1.00 |
| - induction | 0.74 (0.70-0.77) | 0.78 (0.75-0.81) | 0.78 (0.75-0.81) | 0.83 (0.80-0.86) |
| - augmentation | 0.81 (0.77-0.84) | 0.80 (0.77-0.82) | 0.79 (0.76-0.83) | 0.79 (0.76-0.82) |
| - vacuum/forceps/CS | 0.01 (0.01-0.02) | 0.03 (0.03-0.03) | 0.01 (0.01-0.01) | 0.01 (0.01-0.01) |
| time of birth | ||||
| - weekday 8.00-20.00 (reference) | 1.00 | 1.00 | 1.00 | 1.00 |
| - evening, night of weekend | 0.83 (0.80-0.86) | 0.71 (0.70-0.73) | 0.82 (0.80-0.85) | 0.75 (0.73-0.77) |
| Maternal age | ||||
| - < 25 | 1.03 (0.98-1.07) | 1.05 (1.02-1.08) | 0.97 (0.91-1.03) | 1.02 (0.97-1.08) |
| - 25-< 35 (reference) | 1.00 | 1.00 | 1.00 | 1.00 |
| - ≥ 35 | 0.96 (0.91-1.03) | 0.93 (0.89-0.97) | 0.99 (0.95-1.02) | 0.95 (0.92-0.98) |
| Ethnicity | ||||
| - western (reference) | 1.00 | 1.00 | 1.00 | 1.00 |
| - non-Western | 1.16 (1.10-1.22) | 1.07 (1.03-1.11) | 1.23 (1.19-1.28) | 1.04 (1.01-1.08) |
| Gestational age | ||||
| - < 32 weeks | 0.24 (0.21-0.28) | 0.20 (0.18-0.22) | 0.24 (0.21-0.28) | 0.24 (0.21-0.27) |
| - 32-< 37 weeks | 0.59 (0.55-0.62) | 0.63 (0.61-0.66) | 0.57 (0.54-0.61) | 0.61 (0.58-0.64) |
| - 37-< 42 weeks (reference) | 1.00 | 1.00 | 1.00 | 1.00 |
| - ≥ 42 weeks | 1.12 (1.04-1.19) | 1.19 (1.13-1.25) | 1.12 (1.06-1.19) | 1.21 (1.15-1.27) |
| Type of hospital | ||||
| - academic | 8.62 (8.01-9.28) | 2,12 (2,02-2,21) | 8,80 (8.46-9.52) | 3.29 (3.16-3.43) |
| - teaching (reference) | 1.00 | 1.00 | 1.00 | 1.00 |
| - non-teaching | 8.21 (8.02-9.28) | 3.50 (3.41-3.60) | 7.55 (7.18-7.94) | 4.09 (3.97-4.21) |
| Properties | Year | Crop | Stages | pH | Organic C | K2O | S | Zn | Fe | Mn | Mineral- N | Actinomycetes population |
| Year | 1 | |||||||||||
| Crop | 0.00 | 1 | ||||||||||
| Stages | 0.00 | 0.00 | 1 | |||||||||
| pH | -0.01 | 0.25 | 0.64** | 1 | ||||||||
| Organic C | 0.58 | 0.24 | 0.52** | 0.71** | 1 | |||||||
| K2O | -0.21 | 0.21 | 0.02 | 0.62** | 0.32 | 1 | ||||||
| S | -0.09 | 0.13 | 0.09 | 0.11 | 0.30 | 0.09 | 1 | |||||
| Zn | -0.02 | 0.34 | 0.37 | 0.66** | 0.93** | 0.45** | 0.40 | 1 | ||||
| Fe | -0.98 | 0.24 | 0.35 | 0.52* | 0.73** | 0.11 | 0.25 | 0.67 | 1 | |||
| Mn | -0.00 | 0.14 | 0.54* | 0.79** | 0.71** | 0.15 | 0.37 | 0.63** | 0.81** | 1 | ||
| Mineral-N | -0.00 | -0.03 | 0.30 | 0.81** | 0.92** | 0.27 | 0.24 | 0.85** | 0.74** | 0.81** | 1 | |
| Actinomycetes population | -0.06 | 0.11 | 0.82 | 0.54** | 0.82** | 0.45** | 0.04 | 0.84** | 0.64** | 0.56** | 0.85** | 1 |
| Citation | Type of study | Sample | Gene | Clinical assessments | Main findings |
| Tsao et al. 2006 [22] | Case-control and follow-up | 20 MDD22 Controls | 5-HTTIL-1βIL-6TNF-αIFN-α | Diagnosis based on DSM-IV criteriaHDRS | Higher expression of 5-HTT, IL-1β, IL-6, TNF-α and IFN-α in patients with MDD compared with controls. Significant decreased in expression of 5-HTT and IFN-α after 3 months of fluoxetine treatment. |
| Cattaneo et al. 2012 [23] | Case-control and follow-up | 74 MDD34 Controls | IL-1αIL-1βIL-4IL-6IL-7IL-8IL-10MIFTNF-α | Diagnosis based on DSM-IV or ICD-10 criteriaSCAN | Higher expression of IL-1β, IL-6, MIF and TNF-α and lower expression of IL-4 in patients with MDD compared with controls.IL-β, TNF-α and MIF expression predicted antidepressant response.Significant decrease in IL-6 expression after 8 weeks of antidepressant treatment (escitalopram or nortriptyline) in responders only. |
| Suzuki et al. 2010 [25] | Case-control | 43 MDD43 Controls | ApoER2VLDLR | Diagnosis based on DSM-IV criteriaHAM-DBPRS | Lower expression of ApoER2 in patients with MDD compared with controls.No significant difference in expression of VLDLR. |
| Galecki et al. 2012 [29] | Case-control | 181 rDD149 Controls | COX-2MPONOS2APLA2G2A | Diagnosis based on DSM-IV criteriaor ICD-10 criteriaCIDI | Higher expression of COX-2, MPO,NOS2A and PLA2G2A in patients with rDD compared with controls. |
| Weigelt et al. 2011 [33] | Case-control | 24 MDD22 BPD45 Controls | TREM-1DAP12PU.1ATF3EGR3MXD1MAFFNAB2 | Diagnosis based on DSM-IV criteriaSCID-I | Higher expression of TREM-1 and NAB2 in patients with BPD only.Higher expression of PU.1 in patients with MDD and a trend for higher expression of TREM-1.Higher expression of ATF3, EGR3, MAFF and MXD1 in patients with both MDD and BPD.No significant difference in expression of DAP12 in either patient group. |
| Symptoms | Mild | Moderate | Severe | Total |
| Age groups (year) | frequency (%) | frequency (%) | frequency (%) | frequency (%) |
| <10 | 89 (8.3) | 2 (9.5) | 3 (4.9) | 94 (8.2) |
| 10–19 | 168 (15.7) | 3 (14.3) | 9 (14.8) | 180 (15.6) |
| 20–29 | 355 (33.2) | 5 (23.8) | 22 (36.1) | 382 (33.2) |
| 30–39 | 165 (15.4) | 6 (28.6) | 8 (13.1) | 179 (15.6) |
| 40–49 | 116 (10.9) | 2 (9.5) | 10 (16.4) | 128 (11.1) |
| 50–50 | 92 (8.6) | 2 (9.5) | 2 (3.3) | 96 (8.3) |
| >60 | 84 (7.9) | 1 (4.8) | 7 (11.5) | 92 (7.9) |
| Total | 1069 (100) | 21 (100) | 61 (100) | 1151 (100) |
| Statistical test | χ2 = 11.11 p = 0.677 |
| Number of patients | Number of procedures | Efficiency | ||||||
| 2010 | 2011 | Total | 2010 | 2011 | Total | 2010 | 2011 | |
| EPS 1 | 242 | 350 | 592 | 7425 | 9253 | 16678 | 0,863 | 0,822 |
| EPS 2 | 102 | 84 | 186 | 1566 | 1185 | 2751 | 0,651 | 0,562 |
| Signaling questions | Answer | Risk of bias/applicability | Planned adjustment |
| Domain 1: Patient selection | |||
| Risk of bias | Low risk | ||
| Is a consecutive sample of patients enrolled? | Yes | ||
| Is a case-control design avoided? | Yes | ||
| Does the study avoid inappropriate exclusions? | Yes | ||
| Applicability | High concern | - Magnitude will be evaluated | |
| Are there concerns that the included patients and setting do not match the topic of our study (patients had symptoms suggestive of inflammatory bowel disease in primary care)? | |||
| Domain 2: Index test | |||
| Risk of bias | Low Risk | ||
| Are the index test results interpreted without knowledge of the results of the reference standard? | Yes | ||
| If a threshold was used, is it pre-specified? | Yes | ||
| Applicability | Low Concern | ||
| Are there concerns that the index test, its conduct, or interpretation differ from the topic of our study (fecal calprotectin was measured with ELISA)? | |||
| Domain 3: Reference standard | |||
| Risk of bias | High risk | ||
| Is the reference standard likely to correctly classify the target condition? | No | - Probably not clinically relevant | |
| - Adjustment in analysis[30,31] | |||
| Are the reference standard results interpreted without knowledge of the results of the index test? | Yes | ||
| Domain 4: Flow and timing | |||
| Risk of bias | High risk | ||
| Is there an appropriate interval between index test and reference standard? | No | - Represents care as usual | |
| - Repeated measurement index test before endoscopy | |||
| Do all patients receive a reference standard? | Yes | ||
| Do all patients receive the same reference standard? | No | - Adjustment in analysis[30,31] |
| Variable | Magnesium (% (n)) | Control (% (n)) | x2 value | P value | Total prevalence (% (n)) |
| Diabetes mellitus [11,24-26] | 22.4 (68/304) | 21.9 (70/319) | 0.016 | 0.9 | 22.2 (138/623) |
| Hypertension [24-26] | 31.2 (43/138) | 27.1 (38/140) | 0.543 | 0.5 | 29.1 (81/278) |
| β-blocker [21-25] | 45.6 (146/320) | 48.6 (152/313) | 0.548 | 0.5 | 47.1 (298/633) |
| Number (%) of mice with viable GAS in tissues | ||||||
| Blood | Spleen | Liver | ||||
| Time (h) from defined injury to infection | Trauma | Control | Trauma | Control | Trauma | Control |
| 0* | 4/5(80%) | 4/4(100%) | 4/5(80%) | (3/4)(75%) | 3/5(60%) | 2/4(50%) |
| 24 | 3/6(50%) | 4/6(67%) | 5/6(83%) | 5/6(83%) | 4/6(67%) | 4/6(67%) |
| 48** | 4/4(100%) | 5/5(100%) | 4/4(100%) | 5/5(100%) | 2/4(50%) | 5/5(100%) |
| Strategy | Clusters of terms | ||
| #clusters | Interval | Mean | |
| Semantic distance | 7,564 | [2; 1,354] | 132.67 |
| Terminology structuring | 748 | [1; 119] | 3.82 |
| (hierarchical+synonymy) | |||
| Merging (semantic distance + | 7,684 | [1; 1,354] | 130.75 |
| hierarchical + synonymy) |
| Original Network | Simplified Network | |||||||
| Se | Sp | Pr | F | Se | Sp | Pr | F | |
| Proposed Method | 0.63 | 1.0 | 1.0 | 0.77 | 0.67 | 1.0 | 1.0 | 0.80 |
| TDARACNE | 0.63 | 0.88 | 0.71 | 0.67 | 0.67 | 0.90 | 0.80 | 0.73 |
| BNFinder+BDe | 0.13 | 0.82 | 0.25 | 0.17 | 0.17 | 0.80 | 0.33 | 0.22 |
| BNFinder+MDL | 0.13 | 0.82 | 0.25 | 0.17 | 0.17 | 0.80 | 0.33 | 0.22 |
| BANJO | 0.25 | 0.76 | 0.33 | 0.27 | 0.50 | 0.70 | 0.50 | 0.50 |
| Males (n = 518) | Females (n = 626) | |||
| BP < 140/90 n = 195 | SBP ≥ 140 or DBP ≥ 90 n = 323 | BP=<140/90 n = 183 | SBP ≥ 140 or DBP ≥ 90 n = 443 | |
| Cardiovascular disease | 130 (66.7) | 131 (40.6)** | 73 (39.9) | 118 (26.6)** |
| Diabetes mellitus | 23 (12.3) | 33 (10.4) | 15 (8.5) | 50 (11.5) |
| Family history of early CVD | 50 (25.6) | 99 (30.7) | 62 (33.9) | 150 (33.9) |
| Daily smoking | 23 (11.9) | 34 (10.8) | 16 (9.1) | 41 (10.0) |
| Quit smoking | 133 (67.5) | 218 (68.2) | 50 (27.3) | 120 (27.1) |
| Alcohol > 14 times/month | 16 (9.4) | 32 (11.5) | 2 (1.4) | 11 (3.2) |
| No physical exercise | 29 (15.7) | 43 (13.9) | 39 (23.9) | 86 (21.4) |
| Hard physical exercise | 44 (25.0) | 90 (30.6) | 24 (15.4) | 64 (17.3) |
| BMI => 27 kg/m2 | 63 (32.3) | 147 (45.5)** | 80 (43.7) | 234 (52.8)* |
| Education < 12 years | 68 (65.4) | 113 (64.9) | 81 (86.2) | 223 (86.4) |
| Depressed mood | 5 (3.1) | 6 (2.1) | 11 (8.1) | 21 (6.3) |
| Less than good general health | 76 (40.2) | 104 (33.0) | 94 (53.1) | 191 (43.8)* |
| Statin treatment | 60 (30.8) | 68 (21.1)* | 58 (31.7) | 96 (21.7)* |
| Land cover class | Description |
| Crops, agricultural and open savannah | Agricultural land or grassland with occasional trees/bushes (not seasonally flooding) |
| Woodland and dense savannah | Grassland with dense trees/bushes (not seasonally flooding) and patches of woodland |
| Built up and bare ground | Towns or villages with high building density or bare murrum or mud |
| Open water | Areas of open water |
| Lake fringe swamps | Lake edges with a high density of papyrus, water hyacinth and water lilies |
| Seasonally flooded grassland | Savannah which floods during the wet season, with occasional trees/bushes |
| No. of suicide attempts by self-poisoning per case (i) | 0 | 1 | 2 | 3 | 4 | 5 | 6 | ≥7 |
| No. of cases (ni) | --- | 1,069 | 334 | 156 | 78 | 32 | 15 | 30 |
| Trait | Montbéliarde | Normande | Holstein |
| [HPD95%] | [HPD95%] | [HPD95%] | |
| Milk | 0.33 / 0.30* | 0.33/ 0.30* | 0.37 / 0.30* |
| [0.29 ; 0.38] | [0.29 ; 0.38] | [0.33 ; 0.41] | |
| Fat content | 0.42/ 0.50* | 0.44 / 0.50* | 0.48 / 0.50* |
| [0.36 ; 0.46] | [0.39 ; 0.49] | [0.45 ; 0.51] | |
| Fertility | 0.05 / 0.02* | 0.06 / 0.02* | 0.08 / 0.02* |
| [0.04 ; 0.06] | [0.04 ; 0.07] | [0.06 ; 0.09] |
| Variable | Study group | P value | |
| Hyal-Joint® (n = 11) | Placebo (n = 9) | ||
| Men/women | 4/7 | 5/4 | 0.653 |
| Age, years, mean (SD) | 57.7 (10.1) | 54.6 (7.7) | 0.448 |
| Ethnicity | 0.361 | ||
| Black | 0 | 1 | |
| Caucasian | 1 | 1 | |
| Hispanic | 10 | 6 | |
| Height, cm, mean (SD) | 164.7 (6.1) | 164.1 (10.8) | 0.889 |
| Weight, kg, mean (SD | 79.1 (26.3) | 80.9 (20.7) | 0.867 |
| Heart rate, beats/min, mean (SD) | 75.5 (12.3) | 75.7 (12.4) | 0.970 |
| Systolic BP, mm Hg, mean (SD) | 122.8 (16.4) | 135.6 (21.7) | 0.152 |
| Diastolic BP, mm Hg, mean (SD) | 77.8 (8.9) | 84.3 (10.4) | 0.148 |
| Rescue medication use (paracetamol 500 mg)* | |||
| No. capsules (range) | 4 (0–19) | 9 (0–29) | 0.425 |
| Mean (SD) | 6.8 (7.3) | 9.9 (9.6) | |
| WOMAC scores, mean (SD) | |||
| Pain | 10.4 (3.0) | 10.1 (2.7) | 0.848 |
| Stiffness | 4.4 (1.0) | 4.4 (1.0) | 0.862 |
| Physical function | 37.7 (7.4) | 35.4 (11.5) | 0.597 |
| Aggregated total symptoms | 52.5 (10.8) | 50.0 (14.4) | 0.667 |
| SF-36v2 scores, mean (SD) | |||
| Physical functioning | 30.8 (8.5) | 27.1 (8.5) | 0.342 |
| Role-physical | 35.3 (8.3) | 41.9 (7.8) | 0.084 |
| Bodily pain | 33.2 (4.8) | 36.9 (4.8) | 0.100 |
| General health | 44.1 (12.3) | 45.4 (10.3) | 0.814 |
| Vitality | 49.0 (11.3) | 50.4 (11.7) | 0.791 |
| Social functioning | 37.5 (12.0) | 43.5 (11.3) | 0.268 |
| Role-emotional | 36.1 (12.6) | 40.3 (12.9) | 0.467 |
| Mental health | 40.3 (19.7) | 47.5 (9.5) | 0.326 |
| Physical component summary (PCS-36) | 34.8 (6.3) | 34.6 (6.4) | 0.947 |
| Mental component summary (MCS-36) | 43.6 (17.5) | 50.6 (11.2) | 0.317 |
| Min | Q1 | Median | Q3 | Max | |
| Village prevalence (%) | |||||
| Situation 1 a | 0.32 | 2.39 | 3.72 | 5.23 | 12.1 |
| Situation 2 b | 0.95 | 2.07 | 4.5 | 5.79 | 12.3 |
| City prevalence (%) | |||||
| Situation 1 a | 2.39 | 2.51 | 3.54 | 4.17 | 6.72 |
| Situation 2 b | 1.52 | 2.41 | 4.06 | 4.72 | 7.26 |
| Baseline | Endline | |||
| Messages | Nutrition-focused MNCH2 (n = 747) | Standard MNCH (n = 767) | Nutrition-focused MNCH2 (n = 622) | Standard MNCH (n = 685) |
| Proper diet every day during pregnancy ensures weight gain of pregnant woman | 77.5 | 78.5 | 97.1* | 87.7 |
| Proper diet every day during pregnancy ensures adequate growth of baby inside the womb | 83.7 | 82.0 | 97.3* | 90.4 |
| Proper diet every day can ensure quick recovery of mothers after delivery | 75.5 | 72.1 | 95.3* | 86.0 |
| Proper diet every day during pregnancy can save costs on doctor and medicine for both mother and child | 46.3 | 49.3 | 84.7** | 58.1 |
| Proper diet during pregnancy will ensure that the child will be brainy | 49.7 | 53.7 | 86.0** | 61.9 |
| Pregnant women should consume ≥5 different food groups daily | 20.6 | 24.0 | 83.6*** | 16.4 |
| Nutritious food is not always expensive | 46.9 | 46.9 | 75.2*** | 46.1 |
| During pregnancy, take 1 IFA tablet every day | 83.7 | 78.6 | 95.8*** | 84.1 |
| During pregnancy, take 1 calcium tablet every day | 84.5* | 79.4 | 96.6*** | 84.7 |
| During pregnancy, take ≥2 h of rest every afternoon | 75.2 | 70.9 | 91.6*** | 72.1 |
| Avoid tea/coffee | 14.1 | 13.0 | 50.3*** | 14.9 |
| During pregnancy, a woman should gain 10–12 kg | 17.1 | 26.0 | 83.6*** | 21.8 |
| A pregnant woman should be weighed each month | 30.5 | 36.4 | 84.9*** | 32.7 |
| Total awareness score (range: 1–10)3 | 5.42 ± 2.12 | 5.47 ± 2.45 | 8.63 ± 1.89*** | 5.82 ± 2.12 |
| Case | Age (years) | Sex | Physical activity | Level affected |
| 1 | 9 | Girl | Jumping rope | T5 |
| 2 | 9 | Boy | Jumping rope | T6 |
| 3 | 10 | Boy | Handstand | T11 |
| 4 | 11 | Boy | Jumping rope | T7 |
| 5 | 12 | Boy | Physical education | T4 |
| 6 | 13 | Boy | Japanese box vaulting | T6 |
| Characteristics | Mean | Standard deviation |
| Age (years) | 25 | 1,0 |
| Body mass index (kg/m2) | 23,9 | 1,9 |
| Waist size (cm) | ||
| Male | 79 | 5,0 |
| Female | 76 | 2,0 |
| Systolic blood pressure (mmHg) | 114 | 10,0 |
| Diastolic blood pressure (mmHg) | 69 | 10,0 |
| Estimated GFR (ml/min) | 97,3 | 5,8 |
| Alanine amino-transférase (UI) | 28,1 | 1,7 |
| Macaque (sequence) | Tissuea | No. of sequences | Genetic diversity (DNAsp) | Population recombination rate (LDhat), rho | Molecular adaptation (HyPhy), ω/sites | Stop codons, N/h | |
| Pi | Theta | ||||||
| H1 (2,694 bp) | T | 21 | 0.002 | 0.005 | 0 | 0.648/0 | 1 |
| EPh | 18 | 0.011 | 0.011 | 9 | 0.484/1 | 0 | |
| EPb | 17 | 0.003 | 0.005 | 5 | 0.927/0 | 0 | |
| EPt | 18 | 0.014 | 0.014 | 42 | 0.38/2 | 0 | |
| VD | 25 | 0.008 | 0.011 | 26 | 0.498/3 | 0 | |
| SV | 20 | 0.01 | 0.013 | 25 | 0.519/3 | 1 | |
| PR | 21 | 0.013 | 0.014 | 26 | 0.588/4 | 0 | |
| UR | 22 | 0.005 | 0.006 | 0 | 0.499/1 | 3 (1) | |
| LN | 7 | 0.014 | 0.014 | 100 | 0.530/2 | 1 | |
| H2 (2,658 bp) | T | 1 | NA | NA | NA | NA | NA |
| EPh | 17 | 0.005 | 0.004 | 0 | 0.571/0 | 1 | |
| EPb | 20 | 0.01 | 0.013 | 100 | 0.466/7 | 0 | |
| EPt | 27 | 0.005 | 0.006 | 2 | 0.417/0 | 0 | |
| VD | 17 | 0.006 | 0.008 | 3 | 0.613/0 | 4 (2) | |
| SV | 19 | 0.01 | 0.009 | 17 | 0.487/2 | 1 | |
| PR | 19 | 0.01 | 0.014 | 100 | 0.534/3 | 0 | |
| UR | 22 | 0.007 | 0.007 | 5 | 0.522/1 | 0 | |
| LN | 18 | 0.011 | 0.012 | 98 | 0.479/4 | 0 | |
| M1 (2,688 bp) | T | 1 | NA | NA | NA | NA | NA |
| EPh | 8 | 0.012 | 0.013 | 21 | 0.354/2 | 0 | |
| EPb | 12 | 0.012 | 0.013 | 24 | 0.336/1 | 0 | |
| EPt | 10 | 0.011 | 0.013 | 53 | 0.324/2 | 0 | |
| VD | 16 | 0.012 | 0.015 | 100 | 0.35/3 | 0 | |
| SV | 16 | 0.013 | 0.014 | 100 | 0.310/3 | 0 | |
| PR | 12 | 0.012 | 0.014 | 11 | 0.392/0 | 0 | |
| UR | 10 | 0.01 | 0.011 | 4 | 0.375/2 | 0 | |
| LN | 15 | 0.012 | 0.015 | 100 | 0.331/3 | 0 |
| Clone name | Comment |
| Rp11-91k4 | Segmental duplication identified by BLASTN |
| Rp11-208g16 | Segmental duplication identified by BLASTN |
| Rp11-119l2 | Segmental duplication identified by BLASTN |
| RP11-168f7 | Localization on other chromosome (chr19) |
| CDT-2278f18 | Segmental duplication identified by BLASTN |
| RP11-129g16 | Misplacement in database; real localization on 3q |
| RP11-79o5 | Segmental duplication identified by BLASTN |
| RP11-666d14 | Not functioning probe in any experiment |
| Rp11-153k19 | Probe localized on other chromosome |
| Rp11-994b16 | Segmental duplication identified by BLASTN |
| Rp11-732m7 | Misplacement in database; real localization on 3p |
| Rp11-80p4 | Localization on other chromosome (chr4) |
| Rp11-125e8 | Segmental duplication identified by BLASTN |
| Unadjusted models | Adjusted model | |||||
| OR | 95 % CI | p value | OR | 95 % CI | p value | |
| Age (years) | 1.07 | 1.02 to 1.11 | 0.004 | |||
| IQCODE | 4.56 | 2.43 to 8.52 | <0.001 | 5.81 | 2.77 to 12.21 | 0.001 |
| APACHE II score | 1.11 | 0.96 to 1.27 | 0.15 | |||
| Independent in ADL | 0.24 | 0.12 to 0.49 | <0.001 | |||
| Time from admission to surgery, hours | 1.02 | 1.00 to 1.05 | 0.046 | 1.04 | 1.01 to 1.07 | 0.017 |
| Living in an institution | 4.61 | 1.80 to 11.76 | 0.001 | |||
| CSF Neopterin, nmol/La | 3.67 | 1.58 to 8.47 | 0.002 | 3.31 | 1.24 to 8.86 | 0.017 |
| Centre (reference: Oslo) | 0.59 | 0.30 to 1.19 | 0.14 | 0.58 | 0.22 to 1.52 | 0.27 |
| Period | O3 | NO | NO2 | NOX | OX | ||
| O3_mean | O3_1-h max | O3_8-h max | |||||
| 2008: 06/01–09/30 | 75 ± 25 | 157 ± 55 | 129 ± 46 | 5 ± 4 | 41 ± 10 | 46 ± 13 | 116 ± 27 |
| 2009: 07/13–09/30 | 69 ± 29 | 161 ± 54 | 126 ± 52 | 7 ± 5 | 43 ± 10 | 50 ± 13 | 113 ± 28 |
| 2010: 06/01–09/30 | 53 ± 22 | 120 ± 50 | 97 ± 42 | 6 ± 5 | 47 ± 13 | 54 ± 14 | 100 ± 32 |
| 2011: 06/01–08/10 | 79 ± 35 | 178 ± 75 | 143 ± 64 | 4 ± 4 | 39 ± 10 | 44 ± 12 | 118 ± 36 |
| Mean | 69 ± 28 | 154 ± 61 | 124 ± 51 | 5 ± 5 | 43 ± 11 | 49 ± 13 | 112 ± 31 |
| Sum of squares | df | Mean square | F | P | |
| Between group | 2984.547 | 5 | 596.909 | 1.115 | .359 |
| Within group | 45,518.750 | 85 | 535.515 | ||
| Total | 48,503.297 | 90 |
| Field hunting | Platform | Open room | Mantis | Net hole | |
| Clutter | <10−10 | <0.00005 | 0.58 | 0.07 | <0.001 |
| Net hole | <10−10 | <0.00005 | <0.001 | 0.33 | |
| Mantis | <10−10 | <0.00005 | 0.2 | ||
| Open room | <10−10 | <0.00005 | |||
| Platform | <10−10 | ||||
| Field hunting |
| Allicor | Placebo | |||||
| Time | All | Men | Women | All | Men | Women |
| (n = 26) | (n = 14) | (n = 12) | (n = 25) | (n = 14) | (n = 11) | |
| Absolute risk, % | ||||||
| At the baseline | 13.1 ± 3.8 | 22.3 ± 6.0 | 2.3 ± 0.6$ | 8.9 ± 2.4 | 14.3 ± 3.7 | 2.0 ± 0.7$ |
| After 12 months | 8.9 ± 2.3* | 15.1 ± 3.5* | 1.8 ± 0.6$ | 7.8 ± 2.4* | 12.4 ± 3.9* | 1.9 ± 0.6$ |
| Relative risk | ||||||
| At the baseline | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| After 12 months | 0.81 ± 0.08* | 0.76 ± 0.08* | 0.88 ± 0.15 | 1.05 ± 0.13 | 0.81 ± 0.10 | 1.36 ± 0.23$ |
| Images | Training samples | Testing samples | Total |
| Liver cancer | 40 | 40 | 80 |
| Normal cancer | 60 | 60 | 120 |
| Liver cirrhosis | 60 | 60 | 120 |
| Liver cyst | 60 | 60 | 120 |
| Atrial Fibrillation (AF)* | Supraventricular tachycardia (SVT)** | Atrial Flutter*** | Ventricular Ectopics | |
| Female, n (%) | 7 (28 %) | 5 (20 %) | 2 (8 %) | 1 (4 %) |
| Male, n (%) | 7 (28 %) | 0 | 3 (12 %) | 0 |
| No. | Factor (g/L) | Low level (-) | High level (+) |
| 1 | Isoeugenol | 1 | 5 |
| 2 | Dry Biomass | 2.5 | 5 |
| 3 | Tween 20 | 0 | 0.5 |
| 4 | Tween 80 | 0 | 0.5 |
| 5 | Glycerol | 0 | 0.1 |
| 6 | Yeast extract | 0 | 0.1 |
| 7 | Trypton | 0 | 0.1 |
| 8 | Cu+2 | 0 | 0.05 |
| 9 | Zn+2 | 0 | 0.05 |
| 10 | NaCl | 0 | 50 |
| Applications | Examples | References |
| Oil recovery | Microbial enhanced oil recovery (MEOR)Increase amount of recoverable oil aided by rhamnolipid-producing microorganisms | [73][2, 74] |
| Bioremediation | Bioremediation of petroleum at contaminated sitesAddition of rhamnolipids improves solubility of hydrocarbons to facilitate degradation | [46, 75–78] |
| Bioremediation of heavy metal at contaminated lands or in water treatment plant; rhamnolipids can be applied in foaming-surfactant technology to remove heavy metal contaminants | [2, 11, 79] | |
| Bioremediation of pesticides at agricultural fields; addition of rhamnolipids can enhance degradation of chemical pesticides | [11, 79] | |
| Pest control | As emulsifier, spreaders and dispersing agent in pesticide formulations | [2, 79] |
| As bio-pesticide against agricultural pests; rhamnolipids have insecticidal activity against green peach aphids and Aedes aegypti larvae | [43, 80] | |
| Crop protection | As biocontrol agent against several phytopathogenic fungi; addition of rhamnolipids or rhamnolipid-containing cell-free broth are effective in inhibiting growth of phytopathogens, e.g. F. oxysporum, B. cinerea, Mucor spp. and many more | [1, 7, 81–84] |
| As stimulant for plant immunity; induced genes involved in plant’s defense system in tobacco, wheat and Arabidopsis thaliana; induced biosynthesis of plant hormones important for signaling pathways involved in plant immunity | [43] | |
| Food processing | As food ingredients or additives functioning as emulsifier, solubilizer, foaming and wetting agent | [7] |
| As antimicrobial agent preventing food spoilage and for sanitization; rhamnolipids inhibit growth of foodborne pathogenic bacteria, e.g. L. monocytogenes, B. subtilis; rhamnolipids also prevent formation of biofilms due to their anti-adhesive nature | [1, 85, 86] | |
| As a source of (l)-rhamnose; enzymatic hydrolysis of rhamnolipids to obtain (l)-rhamnose, a raw material for production of flavor compounds | [42, 87] | |
| Medical use | As biofilm control agent to prevent medical device-related infections; inhibit biofilm formation; synergistic effect with caprylic acid to inhibit biofilms of more resistant pathogens, e.g. P. aeruginosa and S. aureus | [2, 88, 89] |
| As anticancer agent; rhamnolipids inhibit growth of many human cancer cell lines, e.g. HI-60, BV-173, SKW-3, JMSU-1 and Hela cells | [2, 19] | |
| Protein folding | Aid in folding of outer membrane protein A | [90] |
| Microbial fuel cells | Improve power density output of microbial fuel cells | [91] |
| Synthesis of nanoparticles | As structure-directing agent in nanoparticle synthesis | [92] |
| Parameters | Anemic patients | Non-anemic patients | ||
| N | Number (%) or mean ± SD | N | Number (%) or mean ± SD | |
| Demographics | ||||
| Age, years | 162 | 68.8 ± 13.2 | 295 | 66 ± 13.8 |
| Gender | ||||
| (Female/Male) | 162 | 91 (56.2) / 71 (43.8) | 295 | 124 (42.0) / 171 (58.0) |
| Race | ||||
| Chinese/Malay/Indian/Others | 162 | 99 (61.1) / 34 (21.0) / 16 (9.9) / 13 (8.0) | 295 | 202 (68.5) / 56 (19.0) / 18 (6.1) / 19 (6.4) |
| Clinical data | ||||
| Weight, kg | 67 | 61.8 ± 13.1 | 137 | 68.1 ± 15 |
| Height, m | 65 | 1.6 ± 0.1 | 135 | 1.6 ± 0.1 |
| Body mass index, kg/m2 | 65 | 25.4 ± 4.8 | 133 | 27 ± 5.3 |
| CKD stage | ||||
| Stage 1/2/3/4/5 | 162 | 3 (1.9) / 8 (4.9) / 29 (17.9) / 52 (32.1) / 70 (43.2) | 295 | 45 (15.3) / 0 (0.0) / 127 (43.1) / 104 (35.3) / 19 (6.4) |
| Laboratory data (serum levels), units | ||||
| Current Hb, g/dL | 162 | 9.2 ± 0.7 | 295 | 12.6 ± 1.7 |
| Previous Hb, g/dL | 162 | 9.9 ± 1.3 | 295 | 12.6 ± 1.7 |
| Sodium, mmol/L | 161 | 137.7 ± 3.8 | 292 | 138.1 ± 3.1 |
| Potassium, mmol/L | 161 | 4.5 ± 2.6 | 292 | 4.3 ± 0.5 |
| Chloride, mmol/L | 136 | 107 ± 5.8 | 257 | 106.1 ± 4 |
| Bicarbonate, mmol/L | 150 | 22.9 ± 3.9 | 270 | 24.7 ± 3.1 |
| Urea, mmol/L | 161 | 15.1 ± 8 | 292 | 10.5 ± 5.5 |
| Creatinine, μmol/L | 161 | 257 ± 188.7 | 293 | 174.3 ± 87.9 |
| Calcium, mmol/L | 150 | 2.2 ± 0.2 | 269 | 2.2 ± 0.1 |
| Corrected calcium, mmol/L | 99 | 2.3 ± 0.1 | 206 | 2.3 ± 0.1 |
| Phosphate, mmol/L | 148 | 1.3 ± 0.3 | 262 | 1.2 ± 0.2 |
| Alkaline phosphatase, U/L | 149 | 86.1 ± 58.5 | 262 | 73.4 ± 42.6 |
| Albumin, g/L | 145 | 34 ± 5.5 | 239 | 37.7 ± 4.2 |
| Total cholesterol, mmol/L | 128 | 4.6 ± 1.5 | 258 | 4.7 ± 1.3 |
| Triglycerides, mmol/L | 128 | 1.6 ± 0.8 | 258 | 1.8 ± 1.7 |
| High-density lipoprotein, mmol/L | 128 | 1.2 ± 0.4 | 257 | 1.2 ± 0.4 |
| Low-density lipoprotein, mmol/L | 128 | 2.7 ± 1.3 | 254 | 2.7 ± 1.1 |
| White blood cells, x109/L | 162 | 8.1 ± 4 | 295 | 7.8 ± 2.9 |
| HbA1c, % | 127 | 7 ± 1.5 | 193 | 7.4 ± 1.6 |
| Iron, μmol/L | 94 | 10.3 ± 5.7 | 80 | 11.4 ± 5.6 |
| Ferritin, μg/L | 97 | 397.9 ± 490.8 | 85 | 275.5 ± 520.0 |
| Transferrin, mg/dL | 94 | 186 ± 50.5 | 80 | 205.1 ± 53.6 |
| Total iron binding capacity, μmol/L | 94 | 48.4 ± 13.1 | 79 | 54.1 ± 12.7 |
| Transferrin saturation, % | 93 | 22.6 ± 11.9 | 79 | 22.2 ± 12.0 |
| Intact parathyroid hormone, pmol/L | 81 | 16.3 ± 15.4 | 129 | 11.9 ± 13.7 |
| 25-hydroxyvitamin D, μg/L | 34 | 17.1 ± 11 | 60 | 22.4 ± 11.8 |
| Folate, nmol/L | 39 | 52.7 ± 71.2 | 44 | 27.8 ± 33.4 |
| Vitamin B12, pmol/L | 42 | 488.7 ± 260.4 | 50 | 450.6 ± 292.9 |
| Variables | N (%) | |
| Sex | Female | 16 (34.8%) |
| Male | 30 (65.2%) | |
| Age 30.5 ± 6.9 (mean ± SD) | 23–28 year | 26 (56.5%) |
| 29–51 year | 20 (43.5%) | |
| Educational level | Diploma | 20 (43.5%) |
| BPharm degree | 25(54.3%) | |
| MSc degree | 1 (2.2%) | |
| Work experience in community pharmacy (years) 5.6 ± 3.9 (mean ± SD) | 1–4 year | 22 (47.8%) |
| 5–16 year | 24 (52.2%) | |
| Additional work experience | Yes | 18 (39.1%) |
| No | 28 (60.9%) | |
| Employment status | Owner | 18 (39.1%) |
| Employee | 28 (60.9%) | |
| Membership to any professional organization | Yes | 15 (32.6%) |
| No | 31 (67.4%) | |
| Awareness of CPD concept | Yes | 20 (43.5%) |
| No | 26 (56.5%) |
| Treatment | COC | GV | GVBD | MI | MII |
| (n) | (%) | (%) | (%) | (%) | |
| SOF | 75 | 11/78 (14.6) | 9/75 (12.0) | 14/75 (18.7) | 41/75 (54.7) |
| SOF + GM-CSF (1 ng/ml) | 71 | 11/71 (15.5) | 5/71 (7.0) | 13/71 (18.3) | 42/71 (59.2) |
| SOF + GM-CSF (10 ng/ml) | 59 | 8/59 (13.6) | 4/59 (6.8) | 15/59 (25.4) | 32/59 (54.2) |
| SOF + GM-CSF (100 ng/ml) | 89 | 14/89 (15.7) | 4/89 (4.5) | 18/89 (20.2) | 53/89 (59.6) |
| TCM | 95 | 1/95 (1.0) | 4/95 (4.2) | 11/95 (11.6) | 79/95 (83.2*) |
| Sl. No: | Factors | Level description | Level | Contribution |
| 1 | Temperature (°C) | 28 | 2 | 0.025 |
| 2 | pH | 5 | 2 | 0.081 |
| 3 | Galactose (%) | 0.8 | 1 | 0.223 |
| 4 | Cupric sulphate (mM) | 3 | 2 | 1.023 |
| 5 | Inoculum concentration | 6 | 2 | 0.117 |
| 6 | Substrate length (m) | 0.05 | 2 | 0.558 |
| Total contribution from all factors | 2.025 | |||
| Current grand average of performance | 54.743 | |||
| Expected result at optimum condition | 56.769 |
| Variable (number of patients evaluated) | PD-L1 expression | p-value | ||
| Positive | Negative | |||
| Tumor stage (99) | High | 2 | 14 | 0.66 |
| Low | 8 | 75 | ||
| NA | 0 | 4 | ||
| Depth of stromal invasion (87) | > 1mm | 4 | 32 | 0.16 |
| ≤ 1mm | 1 | 50 | ||
| NA | 5 | 11 | ||
| Lymph node involvement (71) | Present | 4 | 27 | 0.69 |
| Absent | 3 | 37 | ||
| NA | 3 | 29 | ||
| Metastasis (99) | Present | 1 | 4 | 0.42 |
| Absent | 9 | 85 | ||
| NA | 0 | 4 | ||
| Tumor grade (102) | High | 9 | 81 | 1.00 |
| Low | 1 | 11 | ||
| NA | 0 | 1 | ||
| Lymphovascular space invasion (88) | Present | 0 | 8 | 0.59 |
| Absent | 10 | 70 | ||
| NA | 0 | 15 | ||
| Haemangioinvasion (88) | Present | 0 | 6 | 1.00 |
| Absent | 10 | 72 | ||
| NA | 0 | 15 |
| EW | DW | p | |
| n (%) | 80 (79.2%) | 21 (20.8%) | |
| GA, mean ± SD (range), wk | 30.3 ± 2.5 | 27.5 ± 2.1 | < 0.0001 |
| (24 – 35) | (23 – 31) | ||
| BW, mean ± SD (range), g | 1198 ± 270 | 894 ± 251 | < 0.0001 |
| (450 – 1590) | (475 – 1520) | ||
| Male, n (%) | 39 (48.7%) | 9 (42.9%) | 0.81 |
| SGA, n (%) | 19 (23.7%) | 5 (23.8%) | 1 |
| Necrotizing enterocolitis, n (%) | 0 | 3 (14.3%) | < 0.0001 |
| Sepsis, n (%) | 5 (6.3%) | 11 (52.4%) | < 0.0001 |
| Intraventricular hemorrhage, n (%) | 4 (5%) | 4 (19.0%) | < 0.05 |
| Chronic lung disease, n (%) | 0 | 7 (33.3%) | < 0.0001 |
| Study | Asthma therapy | Number of subjects | Results |
| Farah et al., 2011 [36] | Fluticasone/salmeterol | 49 | Similar improvements in asthma control, spirometry, airway inflammation, and airway hyperresponsiveness across BMI groups |
| Sutherland et al., 2010 [46] | Fluticasone, montelukast | 1052 | Fluticasone greater improvement across all BMI categories when compared to montelukast |
| Sutherland et al., 2008 [37] | Glucocorticoids | 45 | Decreased in vitro response to glucocorticoids in obese asthmatics |
| Boulet and Franssen 2007 [35] | Fluticasone with or without salmeterol | 1242 | Fluticasone with salmeterol resulted in improved asthma control in both groups compared to fluticasone alone but overall decreased effectiveness with both regimens in obese patients |
| Dixon et al., 2006 [38] | Theophylline, montelukast, placebo | 488 | Increased risk of exacerbations in obese subjects treated with theophylline but no difference in montelukast treatment groups |
| Peters-Golden et al., 2006 [34] | Beclomethasone, montelukast, placebo | 3073 | Less improvement in asthma control days with inhaled corticosteroid with increasing BMI, no difference with montelukast |
| Quantity | Value | Description |
| z1 | 8 mm | Distance between the stem and the point light source [12] |
| z2 | 297 mm | Distance between the stem and the screen [12] |
| Δx | 229 mm (for the stem width = 6 mm) | Width of the geometrical shadow [12] |
| Δp | 5.2 μm | Camera pixel size |
| N | 7 pixels | Response of a fringe position to the stem margin shift by 1 μm |
| C | 38.125 | Sensitivity of the optical set-up |
| Age | women with breast cancer | |
| n | % | |
| ≤30 | 4 | 4.0 |
| 31-49 | 43 | 43.0 |
| 50-59 | 32 | 32.0 |
| 60-69 | 13 | 13.0 |
| ≥70 | 8 | 8.0 |
| Total | 100 | 100.0 |
| Mean=51.8 (±11.23)*Min 28; Max 77 |
| ID | Farm | Age (months) | Sex | Weight (kg) | Previous episodes of BRD | Spontaneous cough | Nasal discharge | Abnormal lung sounds | Read number NS sample | Read number TTA sample |
| 1a | TO1 | 14 | M | 400 | 3 months before sampling | Repeated | Cloudy and bilateral | Wheezes and crackles on the left side of the thorax | NP | 53,494 |
| 2b | CN1 | 6 | M | 180 | No | Absent | Absent | Absent | NP | 7902 |
| 3a | CN1 | 6 | M | 180 | 1 month before sampling | Occasional | Absent | Wheezes and crackles on both sides of the thorax | NP | 47,115 |
| 4b | CN1 | 6 | M | 180 | No | Absent | Absent | Absent | NP | 18,855 |
| 5b | CN1 | 6 | M | 180 | No | Absent | Absent | Absent | NP | 81,564 |
| 6a | CN2 | 6 | M | 180 | No | Absent | Cloudy and unilateral | Absent | 36,160 | 129,750 |
| 7b | CN2 | 6 | M | 180 | No | Absent | Absent | Absent | 28,543 | 118,454 |
| 8b | CN2 | 6 | M | 180 | No | Absent | Absent | Absent | 31,232 | 61,778 |
| 9a | CN2 | 6 | M | 180 | No | Absent | Cloudy and bilateral | Wheezes and crackles on both sides of the thorax | DNA < 5 ng/μl | DNA < 5 ng/μl |
| 10a | VC1 | 5 | F | 150 | No | Repeated | Absent | Wheezes and crackles on both sides of the thorax | 40,694 | 142,459 |
| 11a | VC1 | 5 | F | 150 | 2 months before sampling | Absent | Absent | Wheezes and crackles on both sides of the thorax | 12,952 | DNA < 5 ng/μl |
| 12b | VC1 | 5 | F | 150 | No | Absent | Absent | Absent | 5988 | DNA < 5 ng/μl |
| 13a | VC1 | 5 | M | 150 | No | Absent | Absent | Wheezes and crackles on both sides of the thorax | 24,070 | 26,910 |
| 14b | TO2 | 6 | M | 200 | No | Absent | Absent | Absent | DNA < 5 ng/μl | 68,954 |
| 15b | TO2 | 6 | F | 200 | No | Absent | Absent | Absent | 20,464 | 40,790 |
| 16a | TO2 | 6 | F | 200 | No | Absent | Absent | Wheezes and crackles on the right side of the thorax | 167,198 | 107,679 |
| 17a | TO2 | 6 | F | 200 | No | Absent | Cloudy and bilateral | Absent | DNA < 5 ng/μl | 143,886 |
| 18b | TO2 | 6 | M | 200 | No | Absent | Absent | Absent | 3932 | 55,630 |
| 19b | TO2 | 6 | M | 200 | No | Absent | Absent | Absent | DNA < 5 ng/μl | 1,825c |
| 20b | TO2 | 6 | M | 200 | No | Absent | Absent | Absent | 154,004 | 4585 |
| 21b | TO3 | 5 | M | 170 | No | Absent | Absent | Absent | 1,536c | 6833 |
| 22b | TO3 | 5 | M | 170 | No | Absent | Absent | Absent | 159c | 189c |
| CombinedPrograms | Single Program | t-value | Single Program | t-value |
| USR + GZD | USR | GZD | 0.150 | |
| USR + PS | USR | PS | ||
| USR + ROCS | USR | 2.489 | ROCS | |
| GZD + PS | GZD | PS | 2.014 | |
| GZD + ROCS | GZD | 2.402 | ROCS | 0.137 |
| PS + ROCS | PS | 3.547 | ROCS | 0.452 |
| S.No. | Angiogenesis analyzer parameter | FRG1 overexpression vector | Control vector | P-value |
| 1 | Number of extremities | 132 ± 25 | 107 ± 14 | 0.026 |
| 2 | Number of nodes | 263 ± 98 | 371 ± 96 | 0.039 |
| 3 | Number of junctions | 79 ± 28 | 110 ± 28 | 0.041 |
| 4 | Number of master junctions | 32 ± 16 | 46 ± 15 | 0.073 |
| 5 | Number of master segments | 51 ± 29 | 80 ± 28 | 0.057 |
| 6 | Total master segment length | 6288 ± 2837 | 9571 ± 2576 | 0.028 |
| 7 | Number of meshes | 16 ± 12 | 27 ± 12 | 0.057 |
| 8 | Total mesh area | 127029 ± 120136 | 306016 ± 163722 | 0.022 |
| 9 | Number of pieces | 183 ± 33 | 218 ± 36 | 0.052 |
| 10 | Number of segments | 83 ± 41 | 130 ± 43 | 0.039 |
| 11 | Number of branches | 69 ± 7 | 70 ± 8 | 0.41 |
| 12 | Number of isolated segments | 30 ± 11 | 17 ± 8 | 0.025 |
| 13 | Total length | 13624 ± 1677 | 15602 ± 1613 | 0.029 |
| 14 | Total branching length | 11200 ± 2393 | 14257 ± 2200 | 0.029 |
| 15 | Total segment length | 5964 ± 2756 | 9165 ± 2562 | 0.029 |
| 16 | Total branch length | 5236 ± 683 | 5091 ± 777 | 0.36 |
| 17 | Total isolated branches length | 2424 ± 867 | 1345 ± 620 | 0.014 |
| 18 | Branching interval | 87 ± 43 | 132 ± 41 | 0.046 |
| 19 | Mesh index | 200 ± 26 | 212 ± 28 | 0.22 |
| 20 | Mean mesh size | 6830 ± 1740 | 10358 ± 3523 | 0.024 |
| cis-element | Position (From ATG) | Sequence (5′-3′) |
| Light regulation elements | ||
| 3-AF1 binding site | −1444(+) | ATGAGATATTT |
| ACE | −1387(−) | CAAACGTATT |
| AT1-motif | −511(+) | AATTATTATTTATT |
| Box 4 | −126(+),−560(+),−615(+),−752(+),−1183(+) | ATTAAT |
| Box I | −390(+),−1363(+) | TTTCAAA |
| G-Box | −156(+) | TACGTG |
| I-box | −841(−) | GTAAAAGGCC |
| LAMP-element | −63(+) | CTTTATCA |
| chs-CMA1a | −1452(−) | TTACTTAA |
| Tissue-specific and development-related elements | ||
| GCN4_motif | −1023(+) | TGAGTCA |
| Skn-1_motif | −230(+),-1020(+),−1111(+) | GTCAT |
| Circadian | −1220(+) | AAAAGATATC |
| GARE-motif | −880(−) | AAACAGA |
| TCA | −199(−) | GAGAATAATA |
| ABRE | −156(+) | TACGTG |
| Abiotic stress response elements | ||
| MBS | −1081(−),−649(+) | (C/T)AACTG |
| HSE | −1307(−),−628(+) | A(A/G)AAAATTT(A/G) |
| DRE | −170(+) | TACCGACAT |
| TC-rich repeats | −1230(+) | ATTTTCTTAA |
| Dentistry (N = 31) | Health Sciences (N = 22) | Pharmacy (N = 28) | ||||
| Items | Mean | Agreement (%) | Mean | Agreement (%) | Mean | Agreement (%) |
| Q3_well_organized | 3.14 | 100 | 3.38 | 100 | 3.23 | 92.4 |
| Q4_safe_environment* | 3.34 | 100 | 3.68 | 100 | 3.62 | 100 |
| Q5_sufficient_information* | 3.03 | 86.2 | 3.45 | 95.5 | 3.40 | 100 |
| Q6_helpful_information** | 3.11 | 96.4 | 3.68 | 100 | 3.58 | 100 |
| Q7_engagement | 3.89 | 88.9 | 3.9 | 90.5 | 4.00 | 100 |
| Focus of Review | Methodological Rating | |||
| Strong | Moderate | Weak | Total | |
| Chronic Diseases (All) | 329 | 144 | 141 | 614 |
| Adult Health (All) | 244 | 117 | 98 | 459 |
| Child Health | 208 | 86 | 75 | 369 |
| Nutrition (All) | 187 | 96 | 83 | 366 |
| Addiction/Substance Use (All) | 152 | 79 | 81 | 312 |
| Physical Activity (All) | 148 | 79 | 78 | 305 |
| Adolescent Health | 139 | 71 | 80 | 290 |
| Mental Health (All) | 156 | 75 | 53 | 284 |
| Parenting, Infants and Children (All) | 152 | 67 | 52 | 271 |
| Injury Prevention/Safety (All) | 166 | 57 | 43 | 266 |
| Communicable Disease/Infection (All) | 134 | 56 | 51 | 241 |
| Reproductive Health (All) | 131 | 43 | 40 | 214 |
| Sexually Transmitted Infections (All) | 81 | 48 | 58 | 187 |
| Sexual Health (All) | 87 | 46 | 38 | 171 |
| Infant Health | 81 | 32 | 23 | 136 |
| Senior Health (All) | 84 | 27 | 22 | 133 |
| Healthy Communities (All) | 43 | 26 | 29 | 98 |
| Environmental Health (All) | 39 | 10 | 14 | 63 |
| Social Determinants of Health (All) | 30 | 13 | 8 | 51 |
| Dental Health (All) | 28 | 9 | 10 | 47 |
| Food Safety & Inspection (All) | 8 | 2 | 2 | 12 |
| Concentrations of Paclitaxel (nM) | BIM/GAPDH | PTEN/GAPDH | ||
| m-PTIP-GFP | m-PTIP-Sponge all | m-PTIP-GFP | m-PTIP-Sponge all | |
| 0 | 70.59 ± 3.4215 | 107.70 ± 2.3265 * | 122.77 ± 2.3265 | 137.67 ± 1.2452 |
| 20 | 94.13 ± 5.3265 | 154.08 ± 2.2641 * | 98.15 ± 5.8736 | 121.96 ± 1.4737 |
| 100 | 123.72 ± 3.1749 | 136.83 ± 1.5821 * | 122.59 ± 3.5521 | 130.93 ± 1.2481 |
| 200 | 109.54 ± 1.1399 | 164.46 ± 3.7326 * | 116.54 ± 1.3357 | 125.28 ± 3.2158 |
| Outcome measures | Operationalisation | Measurement | ||
| SCR | Qt | TIp | ||
| Usefulness | ||||
| Population reached | General characteristics of the participants and trainers | + | ||
| Target population and proportion of the intended target population | + | + | ||
| Number of participants that refused, dropped out or completed training and reasons for withdrawal | + | |||
| Self-reported benefit or achievement | Benefit regarding the training according to trainers | + | ||
| Benefit regarding the training according to participants | + | |||
| Use of identification cane in daily life | + | + | ||
| Achievement regarding to training goals | + | |||
| Experienced barriers and potential solutions | Deviations of each session element* | + | ||
| Main goal, strong and weak aspects of the training | + | + | ||
| Hampering and encouraging factors of the standardised training* | + | |||
| Matters for improvement – materials and standardised training* | + | |||
| Acceptability | ||||
| Extent to which intervention was performed according to protocol | Format, preparation time and duration of the session | + | ||
| Per session element: performance, duration and participation by participant* | + | |||
| Extent to which participant achieved training goals* | + | |||
| Participants’ exposure to and engagement in the training | Total number of sessions | + | ||
| Use of materials* | + | |||
| Opinion of trainer/participants regarding participant’s engagement | + | + | ||
| Extent to which participants complied with contracts* | + | |||
| Quality of action plans formulated by participant* | + | |||
| Opinion about the training | Overall opinion about the training by trainer and participant | + | + | |
| Opinion regarding number, duration and progress of the sessions by trainer and participant | + | + | ||
| Opinion regarding comprehensibility of the training | + | |||
| Opinion regarding number of extra sessions needed and whether the participant’s need for mobility support was met | + | + | ||
| Burden experienced by participant | + | |||
| Recommendation of the training to others | + | |||
| Overall opinion about the trainer | + | + |
| HCV-1 | HCV-2 | ||||||||
| SNP ID | SVR (+) | SVR (−) | P | OR (95% CI) | SNP ID | SVR (+) | SVR (−) | P | OR (95% CI) |
| N (%) | N (%) | N (%) | N (%) | ||||||
| rs1059513 | rs1059513 | ||||||||
| A allele | 294 (90.2) | 195 (95.6) | 0.42 (0.20, 0.91) | A allele | 333 (93.5) | 32 (94.1) | 0.90 (0.20, 4.01) | ||
| G allele | 32 (9.8) | 9 (4.4) | 0.0235* | 1 | G allele | 23 (6.5) | 2 (5.9) | 0.8954 | 1 |
| rs703817a | rs703817 | ||||||||
| A allele | 80 (24.5) | 63 (31.2) | 0.72 (0.49, 1.06) | A allele | 93 (26.1) | 5 (14.7) | 2.05 (0.77, 5.45) | ||
| G allele | 246 (75.5) | 139 (68.8) | 0.0948 | 1 | G allele | 263 (73.9) | 29 (85.3) | 0.1425 | 1 |
| rs324015a | rs324015 | ||||||||
| A allele | 145 (44.5) | 89 (44.1) | 1.02 (0.71, 1.45) | A allele | 172 (48.3) | 20 (58.8) | 0.65 (0.32, 1.34) | ||
| G allele | 181 (55.5) | 113 (55.9) | 0.9249 | 1 | G allele | 184 (51.7) | 14 (41.2) | 0.2416 | 1 |
| rs3024974 | rs3024974b | ||||||||
| C allele | 258 (79.1) | 161 (78.9) | 1.01 (0.66, 1.56) | C allele | 285 (80.5) | 27 (79.4) | 1.07 (0.45, 2.56) | ||
| T allele | 68 (20.9) | 43 (21.1) | 0.9518 | 1 | T allele | 69 (19.5) | 7 (20.6) | 0.8777 | 1 |
| Heart Health Program | Traditional Hospital Cardiac Programs | |
| Referral | No formal process, mostly word of mouth or opportunistic due to location. | Formal referral from doctor or cardiac nurse post cardiac event. |
| Attendance | As often as wanted, program runs weekly. No specific attendance required. | Set period, usually 4–6 weeks long. Attendance at every session usually required. |
| Health prerequisites | Nil, program provides information on any health issues requested by participants with primary focus on cardiac issues and diabetes. Do not need to have any chronic diseases or cardiac issues to attend. | Post cardiac event. |
| Transport | Provided to anyone who requires it at no cost. | Make own arrangements. |
| Food | Morning tea and lunch provided. | Not provided. |
| Exercise | Group walk and exercise-physiologist led rehabilitation exercises (walk pending weather). | Dependent on program. |
| Structure | Diabetes round-table discussion, followed by a group walk and morning tea. Group yarning on weekly health topic (session can be facilitator led, participant led, or a more formal presentation style talk depending on topic and presenter); lunch is provided during this session. Followed by weight exercises. Finished with a cardiac-specific discussion; sharing of personal experiences and asking questions is encouraged. Participants are free to leave at any point. Blood pressure and insulin measured throughout the day. | Typically PowerPoint presentation while seated at desks. |
| Lost to Follow-up N (%) | Completed Follow-up N (%) | RR (95% CI) | |
| Lost to Follow-up Status After Delivery, N | 1,385 | 277,733 | |
| Delivery location | |||
| Hospital | 451 (33.3) | 126,606 (45.6) | 1.0 |
| Clinic | 394 (29.1) | 68,689 (24.7) | 1.1 (1.0, 1.3) |
| Home/Other | 508 (37.5) | 82,303 (29.6) | 1.0 (0.8, 1.1) |
| Delivery mode | |||
| Vaginal | 1,110 (82.1) | 231,099 (83.2) | 1.0 |
| Vaginal assisted | 40 (3.0) | 4,161 (1.5) | 1.1 (0.6, 1.8) |
| C-section | 154 (11.4) | 33,052 (11.9) | 1.0 (0.9, 1.2) |
| Birth attendant | |||
| Physician | 384 (28.4) | 106,834 (38.5) | 1.0 |
| Nurse/Midwife/Health worker | 437 (32.3) | 88,316 (31.8) | 1.1 (1.0, 1.2) |
| Traditional birth attendant | 450 (33.3) | 63,892 (23.0) | 1.0 (0.8, 1.2) |
| Family/Other | 80 (5.9) | 18,593 (6.7) | 0.9 (0.8, 1.1) |
| Participated in FW (n = 2835) | |
| (Reference category: Did not participate in FW) | |
| OR (95% CI) | |
| Demographics | |
| Sex | |
| Man | 1.00 |
| Woman | 0.92 (0.76–1.13) |
| Age | 0.80 (0.78–.0.83)*** |
| Total years spent studying | 0.70 (0.67–0.74)*** |
| Place of birth | |
| Born outside of Norway | 1.00 |
| Born in Norway | 0.79 (0.57–1.09) |
| Religious identification | |
| Nonreligious | 1.00 |
| Religious | 1.01 (0.84–1.21) |
| Relationship status | |
| In a relationship | 1.00 |
| Single | 1.29 (1.08–1.53)** |
| Parental status | |
| Did not have child/children | 1.00 |
| Had child/children | 0.36 (0.23–0.56)*** |
| Educational institution | |
| Not business school | 1.00 |
| Business school | 1.60 (1.23–2.08)*** |
| Personality | |
| ExtroversionZ | 1.18 (1.07–1.29)** |
| AgreeablenessZ | 1.08 (0.99–1.19) |
| ConscientiousnessZ | 1.01 (0.92–1.10) |
| NeuroticismZ | 1.01 (0.90–1.13) |
| Intellect/imaginationZ | 0.96 (0.88–1.05) |
| Concurrent alcohol use (AUDIT-scoreZ) | 1.28 (1.16–1.41)*** |
| Psychological health | |
| Depression symptomsZ | 1.08 (0.94–1.23) |
| Anxiety symptomsZ | 0.93 (0.83–1.05) |
| Model, df = 16 and p < .001 | Cox & Snell R2 = .390; Nagelkerke R2 = .536 |
| Antibody | Identification | Dilution | Source |
| p16INK4a | E6H4 | undiluted | mtm laboratories AG, Heidelberg, Germany |
| MMP-7 | Clone ID2 | 1:30 | Calbiochem, Merck Chemicals Ltd., Nottingham, UK |
| MMP-12 | rabbit polyclonal | 1:50 | Sigma-Aldrich Inc., Saint Louis, MO |
| MMP-16 | rabbit polyclonal | 1:50 | Sigma-Aldrich Inc., Saint Louis, MO |
| CK8/18 | Clone 5D3 | 1:50 | Novocastra Lab’s Ltd., Vision Biosystems, Newcastle, UK |
| Laminin | rabbit polyclonal | 1:350 | DakoCytomation, Glostrup, Denmark |
| EDA-Fibronectin | Clone 52DH1 | 1:30 | Dr Ismo Virtanen [15] |
| E-cadherin | Clone 36 | 1:200 | BD Transduction Laboratories, Franklin Lakes, NJ |
| N-cadherin | Clone GC-4 | 1:30 | Sigma-Aldrich Inc., Saint Louis, MO |
| Beta-catenin | Clone 14 | 1:30 | BD Transduction Laboratories, Franklin Lakes, NJ |
| Dopant | SnO2–d (110) in Å | |||||
| Urea | Ammonia | Chemically Doped | Impregnated Powders | |||
| Urea | Ammonia | Urea | Ammonia | |||
| Undoped | 3.35853 | 3.35492 | - | - | - | - |
| Cu | - | - | 3.3732 | 3.36927 | 3.3682 | 3.3927 |
| Pt | - | - | 3.39422 | 3.38839 | 3.3801 | 3.35427 |
| Pd | - | - | 3.41855 | 3.40501 | 3.40697 | 3.35706 |
| Reference, Study Location and data collection period | Study Design Subject Characteristics and sample size | Exposure air pollutants | Health outcomes | Results | Adjustment for confounding factors | Limitations |
| Cross sectional studies | ||||||
| Karunasekara KAW et al.[40],Gampaha district.1998 | Children, 5-11 years,asthmatics (n = 441);non asthmatics (n = 1510) | No specific types are measured | Asthma | Prevalence of asthma was significantly higher in the presence of firewood smoke | Yes | No measurement of exposure |
| Lankatilake KN et al.[20],Kotte Medical Officer of Health area.1999 | Households = 397children = 604women = 130 | Respirable dust | Respiratory symptoms | Respiratory symptoms were significantly higher in houses using firewood | Yes | Only respirable dust levels were measured |
| Pathirane S M et al.[43]Kegalle and Kalutara districts.2004 | New borns (n = 369) | No specific types | Low birth weight | Low birth weight was associated with fuel type and kitchen characteristics | No | No measurement of exposure |
| Case-control Studies | ||||||
| Karunasekara KAW et al.[39],Colombo North Teaching Hospital1996-1997 | Children 1-10 years,age matched cases and controls (n = 300) | No specific type | Asthma | Dust at home was a significant risk factor for asthma | Yes | No measurement of exposure |
| Perera MAKK P et al.[42],National Cancer Hospital2004 | Lung cancer patients (n = 128) and controls (n = 128) | No specific type | Lung cancer | No significant association with biomass exposure | No | No measurement of exposure |
| Ranasinghe MH et al.[41], National Eye Hospital, Colombo2004 | Patients with cataracts (n = 197) and controls (n = 190) | No specific type | Cataract | Cataracts significantly associated with biomass exposure | No | No measurement of exposure |
| Cropping system cultivar | Organic | Conventional | Average | Difference in organic |
| Mg ha−1 | Mg ha−1 | Mg ha−1 | % | |
| Matt | 2.13 | 2.85 | 2.48 b | −25.0 |
| Saragolla | 3.62 | 4.09 | 3.85 a | −11.4 |
| Karalis | 2.33 | 3.22 | 2.78 b | −27.6 |
| Pablo | 2.57 | 2.99 | 2.78 b | −14.2 |
| San Carlo | 2.46 | 3.45 | 2.94 b | −28.8 |
| Average | 2.52 b | 3.23 a | 2.87 | −21.0 |
| Demographics | ||
| Age (yrs) (mean ± SD) | 65.8 ± 8.7 | |
| Male/Female | 46%/54% | |
| Wealth (%) | ||
| Poorest tertile | 34% | |
| Tertile 2 | 20% | |
| Richest tertile | 45% | |
| BMI (kg/m2) (mean ± SD) | 28.1 ± 4.9 | |
| Smoking status (%) | current smoker | 11% |
| Chronic illness (%) | 16% | |
| Physical exercise | ||
| Sedentary | 2% | |
| Low | 10% | |
| Moderate | 52% | |
| vigorous | 36% | |
| Alcohol consumption | ||
| Never | 35% | |
| Occasionally | 48% | |
| Daily | 17% | |
| Depression at baseline | 11% | |
| Depression at 4-year follow-up | 10% | |
| DHEA(S) (μmol/L) (mean ± SD) | 2.41 ± 1.80 |
| Vascular plants | Bryophytes | ||||||
| F-value | P-value | r | F-value | P-value | r | ||
| MAT | Plant community | 1.3 | 0.26 | −0.07 | 1.5 | 0.23 | −0.09 |
| Cluster I | 19.3 | ≤0.001 | −0.51 | 10.9 | ≤0.01 | −0.41 | |
| Cluster II | 11.4 | ≤0.001 | 0.41 | 3.7 | 0.06 | 0.22 | |
| TS | Plant community | 0.0 | 0.83 | 0.13 | 6.2 | ≤0.01 | 0.29 |
| Cluster I | 29.0 | ≤0.001 | 0.59 | 34.6 | ≤0.001 | 0.63 | |
| Cluster II | 39.6 | ≤0.001 | −0.66 | 4.1 | 0.04 | −0.24 | |
| MAP | Plant community | 0.2 | 0.68 | 0.12 | 1.8 | 0.18 | −0.12 |
| Cluster I | 5.1 | ≤0.05 | −0.27 | 11.0 | ≤0.001 | −0.40 | |
| Cluster II | 7.2 | ≤0.01 | 0.33 | 0.1 | 0.74 | 0.14 | |
| SOx | Plant community | 0.7 | 0.39 | −0.06 | 0.2 | 0.64 | −0.12 |
| Cluster I | 2.2 | 0.14 | −0.15 | 0.8 | 0.86 | −0.13 | |
| Cluster II | 0.2 | 0.63 | −0.12 | 0.2 | 0.68 | −0.13 | |
| NHx | Plant community | 0.3 | 0.59 | −0.11 | 1.9 | 0.18 | −0.13 |
| Cluster I | 2.6 | 0.11 | −0.17 | 1.7 | 0.19 | −0.12 | |
| Cluster II | 0.7 | 0.39 | −0.07 | 1.9 | 0.17 | 0.13 |
| Treatment Effect | Control Exacerbation Rate (per‐person year) | AAR | ERT |
| 0.5 | 1.3 | 0.82 | 0.83 |
| 1.8 | 0.87 | 0.88 | |
| 2.3 | 0.89 | 0.91 | |
| 0.7 | 1.3 | 0.34 | 0.35 |
| 1.8 | 0.38 | 0.39 | |
| 2.3 | 0.39 | 0.42 | |
| 1.0 (null case) | 1.3 | 0.05 | 0.05 |
| 1.8 | 0.05 | 0.06 | |
| 2.3 | 0.05 | 0.06 | |
| 1.5 | 1.3 | 0.47 | 0.49 |
| 1.8 | 0.51 | 0.54 | |
| 2.3 | 0.52 | 0.56 |
| Medium | Carbon source | Rationale |
| DSMZ 65 | Glucose Switchgrass MCC | DSMZ recommended T. bispora growth medium prepared with glucose |
| I/S | Glucose Switchgrass MCC | Previously reported actinobacteria isolation/screening medium prepared with MCC (Waldron and Eveleigh, 1986) |
| M9TE | MCC | Minimal medium + cellulose (Gladden et al., 2011) |
| DSMZ 84 | Rolled oats | Previous DSMZ recommended T. bispora growth medium prepared with soluble polysaccharides from rolled oats |
| Inclusion criteria | Exclusion criteria |
| 1. Written informed consent | 1. Unstable asthma |
| 2. Age 16 years or older | 2. Presence of active lung disease other than asthma |
| 3. Diagnosis of asthma by a health professional and duration of asthma symptoms ≥ 1 year. | 3. Mental impairment or language difficulties that make informed consent impossible. |
| 4. Asthma Control Questionnaire score (6 questions version) greater than or equal to 1 (suggesting poorly controlled asthma) | 4. Terminal illness |
| 5. Ability to access the internet (excluding via smart phone or tablet). | 5. Cognitive impairment. |
| Confounder | Slope | 95 % CI | P value |
| Age (years) | 0.009 | −0.020, 0.039 | 0.537 |
| % Males | −0.011 | −0.024, 0.002 | 0.106 |
| % Diabetics | 0.003 | −0.002, 0.008 | 0.255 |
| % Smokers | −0.004 | −0.009, 0.0004 | 0.075 |
| Dose (mg/day)a | −0.007 | −0.015, 0.001 | 0.091 |
| Baseline LDL-C (mg/dL) | 0.004 | −0.007, 0.016 | 0.435 |
| Unstable housing | |||||
| Characteristic | Total n (%) | Yes 1713 (69.8) | No2722 (29.4) | Odds ratio (95% CI) | p-value |
| Gender | |||||
| Male | 1620 (66.0) | 1147 (67.0) | 462 (64.0) | 1.14 (0.95-1.37) | 0.158 |
| Female | 833 (34.0) | 566 (33.0) | 260 (36.0) | ||
| Age, in years (median IQR) | 37.7 (29.7 – 44.1) | 37.8 (30.0 – 44.1) | 37.6 (29.6 – 44.0) | 1.00 (0.99-1.01) | 0.399 |
| Ancestry | |||||
| Caucasian | 1496 (61.0) | 1058 (61.8) | 430 (59.6) | 1.10 (0.92-1.31) | 0.308 |
| Other | 957 (39.0) | 655 (38.2) | 292 (40.4) | ||
| HIV serostatus | |||||
| Positive | 758 (30.9) | 551 (32.2) | 200 (27.7) | 1.23 (1.02-1.50) | 0.032 |
| Negative | 1692 (69.0) | 1161 (67.8) | 520 (72.0) | ||
| Sex work involvement3 | |||||
| Yes | 560 (22.8) | 410 (23.9) | 143 (19.8) | 1.27 (1.03-1.58) | 0.026 |
| No | 1883 (76.8) | 1296 (75.7) | 576 (79.8) | ||
| Daily heroin injection3 | |||||
| Yes | 909 (37.1) | 660 (38.5) | 242 (33.5) | 1.24 (1.04-1.49) | 0.020 |
| No | 1538 (62.7) | 1049 (61.2) | 478 (66.2) | ||
| Daily cocaine injection3 | |||||
| Yes | 733 (29.9) | 560 (32.7) | 164 (22.7) | 1.65 (1.35-2.02) | < 0.001 |
| No | 1704 (69.5) | 1143 (66.7) | 552 (76.5) | ||
| Daily non-injection cocaine use3 | |||||
| Yes | 590 (24.1) | 496 (29.0) | 90 (12.5) | 2.87 (2.25-3.66) | < 0.001 |
| No | 1860 (75.8) | 1214 (70.9) | 632 (87.5) | ||
| Enrolment in a methadone program3 | |||||
| Yes | 559 (22.8) | 373 (21.8) | 184 (25.5) | 0.82 (0.67-1.00) | 0.051 |
| No | 1885 (76.8) | 1332 (77.8) | 537 (74.4) | ||
| Incarceration3 | |||||
| Yes | 326 (13.3) | 255 (14.9) | 67 (9.3) | 1.71 (1.29-2.28) | <0.001 |
| No | 2122 (86.5) | 1454 (84.9) | 654 (90.6) | ||
| HCV serostatus | |||||
| Positive | 2025 (82.6) | 1450 (84.7) | 562 (77.8) | 1.59 (1.27-1.98) | <0.001 |
| Negative | 411 (16.8) | 252 (14.7) | 155 (21.5) |
| OR (95% CI) | P | ||
| Tvitals | Red | 6.57 (2.25-19.17) | < 0.001 |
| Orange | 6.69 (3.29-13.58) | < 0.0001 | |
| Yellow | 2.98 (1.31-5.45) | < 0.001 | |
| Green | 1.0 | ||
| Tfinal | Red | 5.43 (1.68-17.52) | < 0.005 |
| Orange | 1.49 (0.62-3.56) | ns | |
| Yellow | 1.34 (0.86-3.08) | ns | |
| Green | 1.0 |
| Study groups and time points | SF-36v2 scores, mean (SD) | |||
| Vitality | Social functioning | Role-emotional | Mental health | |
| Hyal-Joint® (n = 8) | ||||
| Baseline | 49.4 (9.9) | 38.4 (10.1) | 36.9 (10.9) | 42.3 (18.8) |
| Week 4 | 50.9 (4.4) | 46.6 (8.5) | 44.2 (5.5) | 49.7 (13.3) |
| Week 8 | 52.1 (4.7) | 43.2 (12.4) | 42.3 (10.2) | 44.4 (16.3) |
| Change baseline vs week 4 | 1.6 (9.9) | 8.2 (8.8) | 7.3 (7.3) | 7.4 (12.2) |
| P value | 0.669 | 0.033 | 0.026 | 0.131 |
| Change baseline vs week 8 | 2.7 (11.9) | 4.8 (12.5) | 5.4 (8.8) | 2.1 (15.2) |
| P value | 0.537 | 0.318 | 0.129 | 0.707 |
| Placebo (n = 8) | ||||
| Baseline | 49.8 (12.3) | 44.6 (11.6) | 39.4 (13.4) | 48.3 (9.9) |
| Week 4 | 49.4 (9.1) | 49.3 (8.2) | 38.9 (11.6) | 49.7 (10.9) |
| Week 8 | 53.3 (6.5) | 46.6 (8.9) | 44.7 (9.6) | 52.5 (8.4) |
| Change baseline vs week 4 | -0.4 (8.4) | 4.8 (4.5) | -0.5 (7.0) | 1.4 (9.4) |
| P value | 0.897 | 0.021 | 0.843 | 0.684 |
| Change baseline vs week 8 | 3.5 (9.3) | 2.0 (7.7 | 5.3 (6.2) | 4.2 (9.7) |
| P value | 0.323 | 0.477 | 0.045 | 0.258 |
| Species | Group | RG | RT | Skew1 |
| Chromosomes with strongest overall skew | ||||
| Candidatus Blochmannia floridanus | Gammaproteobacteria | 0.433 | 0.107 | 0.446 |
| Clostridium acetobutylicum ATCC 824 | Firmicutes | 0.426 | -0.087 | 0.435 |
| Ehrlichia canis str. Jake | Alphaproteobacteria. | 0.346 | 0.226 | 0.413 |
| Ehrlichia ruminantium str. Welgevonden | Alphaproteobacteria | 0.360 | 0.191 | 0.408 |
| Ehrlichia chaffeensis str. Arkansas | Alphaproteobacteria | 0.360 | 0.191 | 0.407 |
| Ehrlichia ruminantium str. Gardel | Alphaproteobacteria | 0.353 | 0.190 | 0.401 |
| Ehrlichia ruminantium str. Welgevonden | Alphaproteobacteria | 0.349 | 0.188 | 0.397 |
| Lactobacillus salivarius subsp. salivarius UCC118 | Firmicutes | 0.362 | -0.121 | 0.382 |
| Borrelia burgdorferi B31 | Spirochaetes | 0.229 | 0.300 | 0.378 |
| Clostridium perfringens str. 13 | Firmicutes | 0.350 | -0.086 | 0.360 |
| Borrelia garinii PBi | Spirochaetes | 0.207 | 0.287 | 0.354 |
| Xylella fastidiosa Temecula1 | Gammaproteobacteria | 0.254 | 0.228 | 0.341 |
| Bartonella quintana str. Toulouse | Alphaproteobacteria | 0.300 | 0.080 | 0.311 |
| Clostridium tetani E88 | Firmicutes | 0.273 | -0.137 | 0.305 |
| Bartonella henselae str. Houston-1 | Alphaproteobacteria | 0.284 | 0.080 | 0.295 |
| Xylella fastidiosa 9a5c | Gammaproteobacteria | 0.197 | 0.218 | 0.294 |
| Lactobacillus acidophilus NCFM | Firmicutes | 0.286 | -0.024 | 0.287 |
| Buchnera aphidicola str. Bp | Gammaproteobacteria | 0.254 | 0.124 | 0.282 |
| Lactobacillus johnsonii NCC 533 | Firmicutes | 0.260 | -0.042 | 0.263 |
| Carboxydothermus hydrogenoformans Z-2901 | Firmicutes | 0.260 | 0.000 | 0.260 |
| Chromosomes with weakest overall skew | ||||
| Corynebacterium efficiens YS-314 | Actinobacteria | 0.023 | 0.019 | 0.030 |
| Nostoc sp. PCC 7120 | Cyanobacteria | 0.028 | 0.005 | 0.028 |
| Sinorhizobium meliloti 1021 plasmid pSymA | Alphaproteobacteria | 0.022 | 0.014 | 0.026 |
| Mycobacterium avium subsp. paratuberculosis K-10 | Actinobacteria | 0.002 | 0.025 | 0.025 |
| Anaeromyxobacter dehalogenans 2CP-C | Deltaproteobacteria | 0.022 | -0.009 | 0.024 |
| Mycoplasma hyopneumoniae 232 | Firmicutes | 0.017 | 0.016 | 0.023 |
| Mycoplasma synoviae 53 | Firmicutes | -0.012 | 0.016 | 0.020 |
| Wigglesworthia glossinidia | Gammaproteobacteria | 0.016 | 0.011 | 0.020 |
| Mycoplasma mycoides subsp. mycoides SC str. PG1 | Firmicutes | 0.017 | 0.009 | 0.019 |
| Mycoplasma gallisepticum R | Firmicutes | -0.014 | 0.009 | 0.016 |
| Aquifex aeolicus VF5 | Aquificae | -0.006 | -0.014 | 0.015 |
| Mycoplasma hyopneumoniae 7448 | Firmicutes | -0.012 | -0.002 | 0.013 |
| Thermosynechococcus elongatus BP-1 | Cyanobacteria | -0.005 | -0.010 | 0.012 |
| Synechocystis sp. PCC 6803 | Cyanobacteria | 0.010 | -0.002 | 0.010 |
| Synechococcus sp. JA-2-3B'a(2–13) | Cyanobacteria | 0.009 | -0.001 | 0.009 |
| Baumannia cicadellinicola str. Hc | Gammaproteobacteria | -0.003 | -0.005 | 0.006 |
| Anabaena variabilis ATCC 29413 | Cyanobacteria | -0.005 | 0.003 | 0.006 |
| Mycoplasma pneumoniae M129 | Firmicutes | 0.003 | 0.003 | 0.004 |
| Synechococcus sp. JA-3-3Ab | Cyanobacteria | 0.001 | 0.004 | 0.004 |
| Gloeobacter violaceus PCC 7421 | Cyanobacteria | 0.003 | -0.002 | 0.004 |
| Measured parameters | Group | Pre-dose | 1 month | 2 month |
| Placebo | 24.53 + 2.55 | 24.33 + 2.28 | 24.33 + 2.46 | |
| Grip strength (Rt) (kg) | KP25 | 25.06 + 3.01 | 25 + 2.97 | 24.86 + 3.18 |
| KP90 | 23.93 + 3.30 | 24.6 + 3.13 | 24.8 + 3.14 | |
| Placebo | 21.06 + 1.83 | 21.33 + 1.58 | 21.2 + 1.56 | |
| Grip strength (Lt) (kg) | KP25 | 22.06 + 1.86 | 21.66 + 1.5 | 21.26 + 1.48 |
| KP90 | 20.86 + 2.72 | 21.6 + 2.02 | 21.6 + 1.84 | |
| Placebo | 19.13 + 2.79 | 19.26 + 1.43 | 18.93 + 1.70 | |
| 30-second chair stand test. (sec) | KP25 | 18.33 + 2.58 | 19 + 2.77 | 20 + 3.11 |
| KP90 | 18.6 + 2.52 | 19.6 + 2.13 | 20.66 + 2.28# | |
| Placebo | 567.33 + 33.52 | 598.73 + 31.57 | 571.26 + 32.05 | |
| 6 min. walk test (m.) | KP25 | 571.26 + 33.68 | 570.33 + 38.32 | 575.53 + 36.04 |
| KP90 | 572.8 + 32.65 | 575.46 + 34.29 | 601.26 + 33.70∗# | |
| Placebo | 164.8 ± 12.34 | 163.06 ± 10.35 | 165.06 ± 9.80 | |
| Tandem test (Opened Eye, Right leg is in front) (sec) | KP25 | 161.8 ± 11.16 | 164.06 ± 9.63 | 162.26 ± 8.93 |
| KP90 | 164 ± 10.50 | 166.6 ± 6.81 | 168.46 + 6.90 | |
| Placebo | 112.33 ± 11.00 | 110.66 ± 10.01 | 109 + 10.20 | |
| Tandem test (Opened Eye, Left leg is in front) (sec) | KP25 | 111.93 ± 7.77 | 112.33 ± 11.39 | 111.8 + 10.16 |
| KP90 | 108.2 ± 11.32 | 109.33 ± 13.62 | 110.46 + 13.31 | |
| Placebo | 33.8 ± 9.22 | 30.8 ± 10.74 | 31.66 + 10.41 | |
| Tandem test (Closed Eye, Right leg is in front) (sec) | KP25 | 31.86 ± 10.12 | 32.6 ± 7.44 | 32.73 + 7.67 |
| KP90 | 31.26 ± 11.09 | 31.86 ± 9.33 | 33.4 + 8.94 | |
| Placebo | 18.8 + 3.60 | 19.86 + 5.01 | 21.2 + 4.57 | |
| Tandem test (Closed Eye, Left leg is in front) (sec) | KP25 | 20.93 + 3.41 | 21.33 + 3.79 | 21.26 + 3.19 |
| KP90 | 20.46 + 4.24 | 21.26 + 4.58 | 22.06 + 3.93 |
| Adhesive systems | ||
| Name of the adhesive | Type of adhesives | Components |
| SBMP | ER, 3 steps | Phosphoric acid (35%) |
| Primer = HEMA, polyalkenoic acid copolymer, water | ||
| Bonding = HEMA, Bis-GMA, amines, photoinitiator | ||
| SB1 | ER, 2 steps | Phosphoric acid (35%) |
| Adhesive (primer + bonding) = dimethacrylates, HEMA, polyalkenoic acid copolymer, silanized silicium, alcohol, water, photo-initiator | ||
| ADSE | SE, 2 steps | Primer = dimethacrylate, phosphonic acid acrylate, initiators, stabilizers |
| Bonding = HEMA, dimethacrylate, silicon dioxide, Initiators, stabilizers | ||
| ADSE-1 | SE, 1 step | Derivates of bis-acrylamide, water, alcohol, bis-methacrylamide dihydrogen phosphate, amino acid acrylamide, hydroxyl alkyl methacrylamide, alkyl sulfonic acid acrylamide, highly dispersed silicon dioxide, initiators, stabilizers, and potassium fluoride |
| 2012 Logistic Regression Deviance | 2012 Logistic Regression Deviance Rank | 2013 Logistic Regression Deviance | 2013 Logistic Regression Deviance Rank | 2014 Logistic Regression Deviance | 2014 Logistic Regression Deviance Rank | 2012–2014 Logistic Regression Mean Deviance Rank | |
| Age | 17,739.3 | 1 | 16,378.7 | 1 | 15,230.7 | 1 | 1.0 |
| Pneumococcal Vaccination | 13,599.2 | 2 | 10,199.2 | 2 | 10,833.8 | 2 | 2.0 |
| Time Since Last Checkup | 8280.7 | 3 | 7738.6 | 3 | 7577.9 | 3 | 3.0 |
| Number of Personal Doctors | 1659.5 | 5 | 2014.3 | 4 | 1910.7 | 4 | 4.3 |
| Employment | 2244.6 | 4 | 1577.3 | 6 | 1749.8 | 5 | 5.0 |
| Annual Household Income | 1543.9 | 6 | 2013.3 | 5 | 1681.4 | 6 | 5.7 |
| Smoking Status | 680.7 | 8 | 785.3 | 7 | 772.3 | 8 | 7.7 |
| Health Care Coverage | 837.1 | 7 | 709.8 | 8 | 701 | 9 | 8.0 |
| Highest Education Level Attained | 616.5 | 9 | 707.6 | 9 | 773.2 | 7 | 8.3 |
| Characteristics | Total164 (%) | DiedN = 32(%) | Survived132(%) | p-Value |
| Maternal age | ||||
| < 20 years | 23 (14.0) | 4 (17.4) | 19 (82.6) | |
| ≥ 20 years | 141 (86.0) | 28 (20.0) | 113 (80.0) | 0.78 |
| Maternal education | ||||
| None | 7 (4.3) | 2 (28.6) | 5 (71.4) | 0.54 |
| Primary | 49 (29.9) | 6 (12.2) | 43 (87.2) | |
| Secondary | 81 (49.4) | 20 (24.7) | 61 (75.3) | 0.10 |
| Tertiary | 27 (16.5) | 4 (14.8) | 23 (85.2) | |
| Maternal income/month | ||||
| Unemployed/nil | 77 (47.0) | 14 (18.2) | 63 (81.8) | |
| 30-100 K | 84 (51.2) | 3 (10.0) | 27 (90.0) | |
| > 100 k | 3 (1.8) | 15 (26.3) | 42 (73.7) | 0.11 |
| Maternal parity | ||||
| Primiparous | 52 (31.7) | 10 (19.2) | 42 (80.8) | |
| 2–4 | 89 (54.3) | 17 (19.1) | 72 (80.9) | |
| > 4 | 23 (14.0) | 5 (21.7) | 18 (78.3) | 0.77 |
| Sex | ||||
| Male | 71 (43.3) | 18 (25.3) | 53 (74.7) | 0.10 |
| Female | 93 (56.7) | 14 (15.0) | 79 (85.0) | |
| Discharge weight | ||||
| < 1000 g | 37 (22.6) | 13 (34.1) | 24 (64.9) | 0.008 |
| 1000-1199 g | 73 (44.5) | 13 (17.8) | 60 (82.2) | |
| ≥ 1200 g | 54 (32.9) | 6 (11.1) | 48 (88.9) | |
| Postmenstrual age at discharge | ||||
| < 35 weeks | 95 (57.9) | 25 (26.3) | 70 (73.7) | 0.012 |
| ≥ 35 weeks | 69 (42.1) | 7 (10.1) | 62 (89.9) | |
| Period in KMC | ||||
| < 1 Week | 130 (79.3) | 20 (15.4) | 110 (84.6) | |
| 1-2 weeks | 29 (17.7) | 9 (31.0) | 20 (69.0) | 0.09 |
| > 2 weeks | 5 (3.0) | 3 (60.0) | 2 (40.0) | 0.04 |
| KMC support | ||||
| Supported | 34 (79.3) | 5 (15.6) | 29 (84.4) | |
| Not supported | 130 (20.7) | 27 (20.7) | 103 (79.3) | 0.43 |
| HIV exposure | ||||
| Yes | 30 (18.3) | 7 (23.3) | 23 (76.6) | 0.56 |
| No | 134 (81.7) | 25 (18.6) | 109 (81.3) | |
| Parents living together | ||||
| Yes | 139 (84.8) | 24 (17.3) | 115 (82.7) | |
| No | 25 (15.2) | 8 (32.0) | 17 (68.0) | 0.09 |
| SGA | ||||
| Yes | 98 (59.8) | 11 (11.2) | 87 (88.8) | |
| No | 66 (40.2) | 21 (31.8) | 45 (68.2) | 0.001 |
| PID with chlamydia (N = 175) | PID without chlamydia (N = 322) | P | |
| Mean age (years) | 27.9 ± 8.2 | 32.4 ± 8.3 | <0.0001 |
| Married (%) | 71 (40.6) | 223 (69.3) | <0.0001 |
| Parity | 0.7 ± 0.9 | 1.2 ± 1.0 | <0.0001 |
| Abortion | 1.0 ± 1.2 | 1.2 ± 1.5 | 0.36 |
| Cesarean sections (%) | 19 (10.9) | 89 (27.6) | <0.0001 |
| Previous pelvic surgery (%) | 35 (20.0) | 65 (20.2) | 0.530 |
| History of PID | 26 (14.9) | 61 (18.9) | 0.269 |
| Use of IUD (%) | 18 (10.3) | 38 (11.8) | 0.658 |
| Barrier contraceptive use (%) | 22 (12.6) | 46 (14.3) | 0.682 |
| Main symptoms (%) | |||
| Low abdominal pain | 110 (62.9) | 276 (85.7) | 0.001 |
| Acute abdomen | 19 (10.9) | 19 (5.9) | 0.321 |
| Vaginal discharge | 5 (2.9) | 6 (1.9) | 0.320 |
| Right upper quadrant pain | 34 (19.4) | 5 (1.6) | <0.0001 |
| Febril sensation | 7 (4.0) | 16 (5.0) | 0.628 |
| Menstrual problem | |||
| Menorrhagia (%) | 20 (14.0) | 15 (9.2) | 0.215 |
| Dysmenorrhea (%) | 20 (14.0) | 15 (9.2) | 0.215 |
| Alcohol (%) | 72 (41.1) | 107 (33.2) | 0.096 |
| Smoking (%) | 45 (25.7) | 74 (22.3) | 0.510 |
| Non-op | Plate | TEN | |
| Number | 37 | 41 | 24 |
| Age in years (stand. dev.) | 41 (18) | 38 (15) | 34 (14.5) |
| Robinson classification 2B1/B2 | 24/13 | 14/27 | 17/7 |
| Non-union (%) | 2 (5.4) | 0 | 1 (4.2) |
| Open reduction (%) | 41 (100) | 11 (46) | |
| Other complications | 1 lateral plate tear out after 4 weeks because of non-compliance | 1 delayed union (healed with ultrasound), 2 lateral dislocations of the TEN, 1 prominent nail medially: required shortening in local anesthesia | |
| Revision rate in % (major) | 2.4 | 8.4 (4.2) |
| Variables | Number (%) | ||
| Male | Female | Total | |
| Presence of diabetes related complications | 48 (70.6) | 141 (84.9) | 189 (80.8) |
| Presence of two or more concurrent diabetes complications | 18 (26.5) | 115 (69.3) | 133 (70.37) |
| Time of the diabetes related complication(s) diagnosis | |||
| Before being diagnosed with diabetes | 19 (27.9) | 43 (25.9) | 62 (32.8) |
| After being diagnosed with diabetes | 29 (42.6) | 98 (59.0) | 127 (67.2) |
| Type of diabetes related complication(s) | |||
| Neuropathy | 45 (66.2) | 97 (58.4) | 142 (75.0) |
| Retinopathy | 21 (30.9) | 57 (34.3) | 78 (41.4) |
| Cardiovascular complications | 30 (44.1) | 10 (6.0) | 40 (21.1) |
| Foot ulcers | 7 (10.3) | 3 (1.8) | 10 (5.1) |
| Medicine | Saving/unit (€) | Annual consumption | Annual saving (€) |
| IVIG | 9.5/g | 650 kg | 6,175,000 |
| Albumin | 0.4/g | 8,500 kg | 1,360,000 (based on 40% market share) |
| FIX | 0.04/IU | 15 MIU | 600,000 |
| FVIII | 0.02/IU | 120 MIU | 420,000 (based on 15% market share) |
| Mortality | |||
| 30-day | 90-day | Overall | |
| ICU cohort | |||
| Non-carrier | 55/209 (26.3) | 72/209 (34.4) | 115/209 (55) |
| Carrier | 11/28 (39.3) | 14/28 (50) | 23/28 (82.1)* |
| G1 cohort | |||
| Non-carrier | 40/292 (13.7) | 70/294 (24) | 90/292 (30.8) |
| Carrier | 5/23 (21.7) | 8/23 (34.8) | 8/23 (34.8) |
| G2 cohort | |||
| Non-carrier | 80/494 (16.2) | 113/494 (22.9) | 275/494 (56.0) |
| Carrier | 10/40 (25.0) | 11/40 (27.5) | 21/40 (52.5) |
| IPD cohort | |||
| Non-carrier | 24/155 (15.5) | NA | NA |
| Carrier | 1/8 (12.5) |
| Grade | Patients | |||
| 35 | ||||
| 1 | 2 | 3 | 4 | |
| Neutropenia (n, %) | 8 (22.8) | 5 (14.2) | 4 (11.4) | – |
| Anemia (n, %) | 3 (8.5) | – | – | – |
| Hypertension (n. %) | – | 14 (40) | 2 (5.7) | – |
| Epistaxis (n, %) | 27 (77.1) | 2 (5.7) | – | – |
| Proteinuria (n, %) | – | 1 (2.8) | – | – |
| Stomatitis (n, %) | 15 (42.8) | 2 (5.7) | 1 (2.8) | – |
| Gingivitis (n, %) | 1 (2.8) | 1 (2.8) | – | – |
| Rhinitis (n, %) | 3 (8.5) | 1 (2.8) | – | – |
| Conjunctivitis (n, %) | 3 (8.5) | – | – | – |
| Fatigue (n, %) | 26 (74.2) | 2 (5.7) | 1 (2.8) | – |
| Constipation (n, %) | 6 (17) | – | – | – |
| Diarrhea (n, %) | 8 (22.8) | 3 (8.5) | 1 (2.8) | – |
| Nausea (n, %) | 4 (11.4) | – | – | – |
| Vomiting (n, %) | – | – | 1 (2.8) | – |
| Neuropathy (n, %) | 14 (40) | 4 (11.4) | – | – |
| Headache (n, %) | 5 (14.2) | – | – | – |
| Myalgia (n, %) | 18 (51.4) | 1 (2.8) | – | – |
| Allergic reactions (n, %) | 1 (2.8) | – | – | – |
| Onychodystrophy (n, %) | 3 (8.5) | 1 (2.8) | – | – |
| ↑ Transaminase (n, %) | 5 (14.2) | 1 (2.8) | – | |
| Alopecia (n, %) | – | – | – | 35 (100) |
| C+1354T single nucleotide polymorphism | Systemic sclerosis patients (n = 115) | Control individuals (n = 140) |
| Genotype* | ||
| CC | 103 (89.6) | 108 (77.1) |
| CT | 12 (10.4) | 30 (21.4) |
| TT | 0 (0) | 2 (1.4) |
| Allele** | ||
| C | 218 (94.8) | 246 (87.6) |
| T | 12 (5.2) | 34 (12.4) |
| Metric | Observed | Predicted | |
| Braiding intensity | 6.8 | 6.4 | |
| Confluence node density, nodes km−2 | 91 | 83 | |
| Least squares regression coefficient of determination, R2, for relationship between: | Bar perimeter and bar area | 0.986 | 0.985 |
| Bar length and bar width | 0.903 | 0.881 | |
| Bar convex perimeter | 0.999 | 0.999 |
| β-catenin expression | |||
| Low (0–1) | High (2–3) | ||
| n(%) | 53 (34.6) | 100 (65.4) | p-value |
| Age, years | |||
| < 65 | 28 (52.8) | 48 (48.0) | 0.613 |
| ≥ 65 | 25 (47.2) | 52 (52.0) | |
| Gender | |||
| Male | 32 (60.4) | 52 (52.0) | 0.394 |
| Female | 21 (39.6) | 48 (48.0) | |
| T | |||
| 1 | 3 (5.7) | 8 (8.0) | 0.602 |
| 2 | 14 (26.4) | 26 (26.0) | |
| 3 | 34 (64.2) | 65 (65.0) | |
| 4 | 2 (3.8) | 1 (1.0) | |
| N | |||
| 0 | 15 (28.3) | 32 (32.0) | 0.714 |
| 1 | 38 (71.7) | 68 (68.0) | |
| Stage (WHO) | |||
| IA | 3 (5.7) | 6 (6.0) | 0.590 |
| IB | 6 (11.3) | 12 (12.0) | |
| IIA | 5 (9.4) | 14 (14.0) | |
| IIB | 37 (69.8) | 67 (67.0) | |
| III | 2 (3.8) | 1 (1.0) | |
| Lymph node ratio | |||
| < 20 % | 40 (75.5) | 77 (78.6) | 0.687 |
| ≥ 20 % | 13 (24.5) | 21 (21.4) | |
| Missing | 2 | ||
| Grade | |||
| 1 | 5 (10.9) | 17 (19.8) | 0.025 |
| 2 | 29 (63.0) | 60 (69.8) | |
| 3 | 12 (26.1) | 9 (10.5) | |
| Missing | 7 | 14 | |
| Perineural invasion | |||
| Yes | 34 (77.3) | 66 (77.6) | 1.000 |
| No | 10 (22.7) | 19 (22.4) | |
| Missing | 9 | 15 | |
| Perivascular invasion | |||
| Yes | 19 (43.2) | 24 (30.0) | 0.169 |
| No | 25 (56.8) | 56 (70.0) | |
| Missing | 9 | 20 |
| No. | ORF No. | Protein Name | MS/MASCOT Score | Mowse Score | % Coverage | Annotation | Putative kDa/pI | Calculated kDa/pI |
| 1 | 2338 | polA2* | 15 | 39 | 13 | DNA polymerase | 150/4.38 | 148.9/4.39 |
| 2 | 2096 | cctB | 668 | 33 | Thermosome β | 70/4.12 | 69/4.1 | |
| 3 | 2381 | uvrC* | 40 | 51 | 18 | Excision nuclease chain C | 63.7/4.8 | 63/4.89 |
| 4 | 6363 | Orc4/CDC6 | 82 | 30 | Orc4/CDC6 | 58/4.51 | 58/4.52 | |
| 5 | 715 | thiC | 57 | 28 | Thiamine biosynthesis protein | 51/4.15 | 51.5/4.15 | |
| 6 | 1601 | gcvP2* | 20 | 47 | 20 | Glycine Dehydrogenase II | 50/4.43 | 51/4.4 |
| 7 | 1356 | fumC | 378 | 27 | Fumarate hydratase | 50/4.4 | 50/4.38 | |
| 8 | 2649 | eef1A | 158 | 18 | Translation elongation factor α subunit | 46/4.32 | 46.2/4.3 | |
| 9 | 2606 | thiD | 83 | 21 | Thiamine biosynthesis protein | 45/4.2 | 47/4.17 | |
| 10 | 95 | gapB | 220 | 13 | Glyceraldehyde 3-PDH | 35/4.26 | 35.5/4.2 | |
| 11 | 903 | yufN* | 20 | 47 | 8 | ABC transporter | 33/4.02 | 33.2/4.02 |
| 12 | 683 | vng0683C* | 73 | 63 | 14 | Hypothetical | 28/4.69 | 28.9/4.6 |
| 13 | 2331 | vng0309C* | 56 | 46 | 12 | Hypothetical | 25/4.48 | 26.9/4.31 |
| 14 | 1027 | tpiA | 50 | 13 | Triosephosphate isomerase | 21/3.97 | 21.3/4.01 | |
| 15 | 2443 | dpsA | 60 | 19 | Stress induced DNA binding protein | 20/4.14 | 20.4/4.16 | |
| 16 | 890 | imD2 | 196 | 25 | Inosine-5'-monophosphate dehydrogenase | 20/4.76 | 20.1/4.8 | |
| 17 | 1914 | ppiA* | 20 | 45 | 11 | 20/4.02 | 21/4.1 | |
| 18 | 633 | purE | 72 | 20 | Phosphoribosylamino subunit | 21/4 | 21.7/4.07 | |
| 19 | 1180 | msrA | 71 | 38 | Peptide methionine sulfoxide red. | 19.4/4.2 | 21.1/4.18 | |
| 20 | 1607 | cheC2 | 76 | 12 | Chemotaxis protein | 21/4.23 | 21.7/4.2 | |
| 21 | 2118 | pyrE2* | 25 | 51 | 22 | Orotatephosphoribosyl transferase | 18/4.11 | 19.2/4.13 |
| 22 | 626 | maoC2* | 27 | 52 | 22 | Acyl Dehydratase | 16.8/4.15 | 16.9/4.2 |
| 23 | 1807 | vng1807H | 55 | 38 | Hypothetical | 15/4.29 | 16/4.32 | |
| 24 | 6254 | vng6254* | 21 | 42 | 12 | Conserved Hypothetical | 11.4/3.85 | 12.2/3.9 |
| 25 | 1137 | rpl18E* | 22 | 44 | 17 | Ribosome assembly | 12.5/5.6 | 12.1/5.62 |
| 26 | 1157 | rphs6* | 30 | 47 | 12 | Ribosome assembly | 12.7/3.79 | 12.5/3.81 |
| 27 | 2467 | rpl31E | 110 | 71 | Ribosome assembly | 10/4.52 | 10.2/4.4 | |
| 28 | 1922 | trh5* | 32 | 54 | 26 | Lrp like regulator | 8.0/4.24 | 8.4/4.11 |
| 29 | 1300 | vng1300H* | 49 | 71 | 91 | Hypothetical | 6.5/3.91 | 8.0/4.0 |
| 30 | 2047 | rps27aE* | 30 | 49 | 10 | Ribosome assembly | 6/3.87 | 8.2/3.86 |
| Treatment groups (mg/kg) | % MNPCE (mean ± SD) | % PCE (mean ± SD) |
| Nondiabetic control | 0.32 ± 0.08 | 48.4 ± 1.81 |
| Nondiabetic + naringin (25) | 0.30 ± 0.07 | 48.2 ± 2.16 |
| Nondiabetic + naringin (50) | 0.28 ± 0.08 | 49.0 ± 1.41 |
| Diabetes | 0.92 ± 0.13** | 45.6 ± 3.97 |
| Diabetes + naringin (25) | 0.60 ± 0.12a | 47.0 ± 2.54 |
| Diabetes + naringin (50) | 0.44 ± 0.11b | 47.4 ± 2.40 |
| Organism | r | P-value |
| C185 | Constant | |
| C212 | 0.791 | 0.034 * |
| C148 | 0.932 | 0.002 ** |
| C119 | 0.791 | 0.034 * |
| C280 | 0.487 | 0.268 |
| C238 | -0.791 | 0.034 * |
| C216 | Constant | |
| C149 | 0.277 | 0.547 |
| C202 | 0.866 | 0.012* |
| C295 | 0.552 | 0.199 |
| C274 | Not applicable | |
| C222 | Constant |
| F0 male diet | CD | CD | HFD | HFD |
| F1 male diet | CD | HFD | CD | HFD |
| F1 Male offspring | n = 14 | n = 14 | n = 20 | n = 19 |
| Total body weight (g)1 | 36.4 ± 0.8 a | 39.8 ± 0.9 bc | 37.7 ± 0.8 ab | 42.1 ± 0.8 c |
| Reproductive organs | ||||
| Testes (g; L + R) | 0.21 ± 0.01 | 0.20 ± 0.01 | 0.22 ± 0.01 | 0.22 ± 0.01 |
| Seminal Vesicles (g; L + R) | 0.36 ± 0.03 a | 0.38 ± 0.04 ab | 0.41 ± 0.03 ab | 0.46 ± 0.03 b2 |
| Gonadal fat depot (% TBW) | 1.45 ± 0.21 a | 2.68 ± 0.23 b | 2.04 ± 0.21 a | 3.91 ± 0.20 c |
| Sex Hormone | ||||
| Testosterone (ng ml−1) | 2.51 ± 0.53 | 2.58 ± 0.41 | 2.41 ± 0.29 | 3.18 ± 0.28 |
| Groups | Mean ± standard deviation (h) | p-value | |
| Misoprostol | Foley catheter | ||
| Latent phase | 8.5 ± 5.1 | 10 ± 6.8 | > 0.1 |
| Time to delivery | 11.08 ± 5.6 | 13.6 ± 16.9 | < 0.05 |
| Group | Severity Scale | Weekly occurrence | ||
| < 21 | ≥ 21 | < 4 day | ≥ 4 day | |
| Day workers (Group A), n (%) | 11 (50) | 11 (50) | 13 (59.1) | 9 (40.9) |
| Rotational shift workers, n (%) | ||||
| - Group B | 14 (36.8) | 24 (63.2) | 16 (42.1) | 22 (57.9) |
| - Group C | 11 (28.9) | 27 (71.1) | 18 (47.4) | 20 (52.6) |
| - Groups B and C | 25 (32.9) | 51 (67.1) | 34 (44.7) | 42 (55.3) |
| Microbial agent | Relative rate of incidence, n (%) | |
| Early infections (39 episodes) | Late infections (187 episodes) | |
| Coagulase-negative Staphylococci | 20 (51.3) | 56 (29.9) |
| Pseudomonas species | 10 (25.6) | 47 (25.2) |
| Sternotrophomonas maltophylia | 6 (15.4) | 30 (16.1) |
| Escherichia coli | / | 15 (8.0) |
| Staphylococcus aureus | 3 (7.7) | 14 (7.5) |
| Enterococcus faecalis | / | 9 (4.8) |
| Candida species | / | 8 (4.3) |
| Enterococcus | / | 4 (2.1) |
| Klebsiella pneumoniae | / | 4 (2.1) |
| Drug [brand or alternative name(s)] | Common clinical formulation(s) (USA unless stated otherwise) | Classification; origin | Clinical use | Cellular target |
| Buprenorphine (e.g., Suboxone, Subutex, Buprenex) | Buprenorphine hydrochloride, buprenorphine naloxone (4:1) | Semisynthetic opiate; thebaine of the opium poppy (104) | Analgesia and maintenance therapy or opiate addiction treatment (Step 3 pain medication) (104) | Partial MOR agonist, KOR antagonist, nociceptin receptor agonist and antagonist (105, 106) |
| Fentanyl (e.g., Actiq, Duragesic, Fentora) | Fentanyl citrate | Synthetic opioid; N-phenethyl-piperidone (95) | Chronic and acute pain; administered orally, IV, transdermal patches (Step 3 pain medication) (107, 108) | Full MOR agonist, weak KOR agonist (109) |
| Heroin (i.e., diamorphine) | Diamorphine (UK) (110), diacetylmorphine (Canada/Switzerland) (111) | Opiate; morphine, and opium poppy (112) | Strong analgesic (Step 3 pain medication) (113, 114), opiate addiction treatment (Switzerland, Netherlands, Germany, England, Denmark) (115) | Partial MOR agonist (116) acts as prodrug (see active metabolites). |
| Hydrocodone (i.e., dihydrocodeinone) (e.g., Zohydro ER, Vicodin) | Hydrocodone bitartrate, hydrocodone bitartrate, and acetaminophen (117) | Semisynthetic opioid (118, 119); codeine (from opium poppy) | Chronic pain and opioid maintenance therapy (117) | Full MOR agonist (118) |
| Hydromorphone (e.g., Dilaudid) | Hydromorphone hydrochloride (120) | A semisynthetic opioid; the hydrogenated ketone of morphine (121) | Acute and chronic analgesia (Step 3 pain medication) (122), 5–8× more potent than morphine (123) | Full MOR agonist, partial DOR agonist, and weak KOR agonist (124, 125) |
| Methadone (e.g., Dolophine) | Methadone hydrochloride [(R) or racemic mixture] (126, 127) | Synthetic opioid (128); diphenylacetonitrile (129); and 1-dimethylamino-2-chloropropane (130) | Opioid dependence treatment (detoxification), chronic pain (131, 132) | Levo: full MOR agonist (109); dextro (d) NMDA antagonist (127). |
| Morphine (e.g., morphine sulfate ER, Roxanol, MsContin) | Morphine sulfate | Opiate; opium poppy (133) | Acute and chronic pain (Step 3 pain medication) (134) | Partial MOR agonist, weak DOR agonist (109, 135) |
| Oxycodone (e.g., Oxycontin, Norco, etc.) | Oxycodone hydrochloride, oxycodone acetaminophen, and oxycodone aspirin | Semisynthetic opiate; thebaine of the (136) opium poppy (137, 138) | Acute and chronic pain; may be superior than morphine for some types of pain (Step 3 pain medication) (139, 140) | Medium MOR agonist, partial KOR agonist (141), and partial DOR agonist (137, 142) |
| Remifentanil (e.g., Ultiva) | Remifentanil hydrochloride (always administered IV) | Synthetic opioid (143); derivative of fentanyl (144) | Acute pain or sedation (50–100× more potent than morphine) often used for surgical procedures (145–148) | Full MOR agonist (143) |
| Tramadol (e.g., Ultram) | Tramadol hydrochloride [racemic (+/−)], Tramadol hydrochloride, and acetaminophen | Synthetic opioid; salicylic acid with addition of 3-methoxyphenyl magnesium halide (149) | Moderate pain (Step 2 pain medication) (149, 150). Analgesic potency is 10% that of morphine (149) | (+/−) MOR agonist (151), (−) monoamine reuptake inhibitor (152) |
| Difficulties | Frequency (n = 59)** | Percentage |
| Institutional related | ||
| Few staff & heavy workload | 20 | 33.9 |
| Lack of testing kits and other logistical support | 12 | 20.3 |
| Occupational hazards (pricking self and infections) | 7 | 11.9 |
| Lack of prior sensitization before referral for testing | 6 | 10.2 |
| Poor motivation of staff | 3 | 5.1 |
| Lack of ARVs | 2 | 3.4 |
| Lack of child-friendly environment | 2 | 3.4 |
| Caretaker related | ||
| Unwillingness of caretakers to disclose to child | 15 | 25.4 |
| Caretakers refusing children to be tested | 7 | 11.9 |
| Caretakers look at HIV-infected children as a burden | 3 | 5.1 |
| Sick and weak parents | 3 | 5.1 |
| Clients not sympathetic to health workers due to desperation | 2 | 3.4 |
| Some parents deny parenthood (stigma) | 2 | 3.4 |
| Lack of consistency by caregivers | 2 | 3.4 |
| Child related | ||
| Children cannot express themselves easily | 8 | 13.6 |
| Dependency nature of children | 6 | 10.2 |
| Children require more time for counselling | 5 | 8.9 |
| Most children are needy & orphans | 4 | 6.8 |
| Need a lot of support to adhere to treatment | 3 | 5.1 |
| Children have many fears - death and abandonment | 2 | 3.4 |
| Health worker related | ||
| Failure to cope with knowledge demand for HIV care | 14 | 23.7 |
| Lack of specialized skills in paediatric counselling & management | 10 | 16.9 |
| Difficult of dealing with non-parents | 7 | 11.9 |
| Difficult to draw blood from children | 4 | 6.8 |
| Difficult to disclose to children | 3 | 5.1 |
| Caretakers refuse other monitoring tests for ART | 2 | 3.4 |
| Median pericardial volume | Univariate analysis | ||||
| Parameters | Grade 2, 3 | Grade 0 | Odds ratioa | 95% CI | P value |
| V5 Gy (%) | 79.7 (51.8–100.0) | 66.5 (45.7–88.5) | 1.08 | 1.03–1.13 | 0.0004 |
| V10 Gy (%) | 74.2 (46.5–97.6) | 61.1 (40.8–84.7) | 1.08 | 1.03–1.13 | 0.0003 |
| V20 Gy (%) | 68.2 (38.8–88.2) | 53.4 (33–80.2) | 1.08 | 1.03–1.13 | 0.0003 |
| V30 Gy (%) | 55.9 (32.1–83.3) | 44.5 (19.5–74.3) | 1.08 | 1.03–1.13 | 0.0005 |
| V40 Gy (%) | 43.8 (19.2–78.8) | 34.2 (8.9–57.1) | 1.06 | 1.02–1.11 | 0.0024 |
| V50 Gy (%) | 24.5 (10.9–47.3) | 16.5 (6.7–35.8) | 1.13 | 1.05–1.23 | 0.0009 |
| V60 Gy (%) | 8.0 (0.3–21.6) | 4.5 (0.4–14.8) | 1.19 | 1.04–1.39 | 0.0228 |
| Mean dose (Gy) | 31.7 (16.7–44.1) | 25.6 (14.3–37.9) | 1.16 | 1.06–1.28 | 0.0005 |
| Parameter | Value |
| Frequency | 2.41 GHz |
| Transmitted Power Level | 0 dBm |
| Antenna gain | 5 dBi |
| Vertical plane angle resolution Δθ | 1° |
| Horizontal plane angle resolution Δφ | 1° |
| Reflections | 5 |
| Parameter, n (%) | Treatment-naïve patients |
| (N = 39) | |
| At any time during study | |
| Increase from baseline ≥10 mm Hg | 12 (30.8) |
| Post-baseline IOP ≥25 mm Hg | 15 (38.5) |
| Post-baseline IOP ≥35 mm Hg | 5 (12.8) |
| At final visit | |
| Increase from baseline ≥10 mm Hg | 4 (10.3) |
| IOP ≥25 mm Hg | 4 (10.3) |
| IOP ≥35 mm Hg | 0 (0) |
| Glaucoma surgery (laser/incisional) | 0 (0) |
| IOP-lowering medication used secondary to retina treatment | 12 (30.8) |
| Consequence of muscle paralysis | Options for intervention |
| Motor weakness | Tendon transfer if muscle of adequate power (Grade V on the MRC scale) is available |
| Bracing if muscle of adequate power is not available | |
| Muscle imbalance | Tendon transfer from stronger side of the joint to the weaker side of the joint if muscle of adequate power is available |
| Weaken muscles on stronger side of the joint if muscle of adequate power is not available for transfer | |
| Instability of joint | Tendon transfer if:(a) Muscle of adequate muscle power available for transfer, (b) Instability is unidirectional (possibly bi-directional around ankle and foot) |
| Osteotomy to alter the biomechanics and restore stability (e.g., shifting the axis of movement of the joint) | |
| Bracing if tendon transfer or osteotomy is not feasible | |
| Arthrodesis (appropriate only for spine, shoulder, wrist and foot) | |
| Deformity | Soft tissue contracture release (release of tendons, fascia, joint capsule) |
| Osteotomy for residual deformity after soft tissue release | |
| Ignore if deformity contributes to stability (e.g., mild genu recurvatum or mild equinus in child with quadriceps paralysis) | |
| Shortening of lower limb | Lengthening of short lower limb |
| Growth arrest of long lower limb | |
| Compensate with shoe lift (especially if orthosis is required for shorter limb) | |
| Ignore shortening in the upper limb and if <2 cm in the lower limb |
| Effect of Dex | ||
| Fold change of AQP5 mRNA | Fold change of AQP5 protein | |
| Dividing cells | ||
| <70% confluent | ↓ 0–2x | ↓ 0–2x |
| Nondividing cells | ||
| 90–100% confluent | ↓ 4–6x | ↓ 4–6x |
| Matrigel treated cells | ↓ 4–6x; after 2 h | ↓ 4–6x; after 6 h |
| Characteristic | Value |
| Age, years | 71 (51; 78) |
| Height, cm | 169 ± 7 |
| Weight, kg | 74 (72; 85) |
| Body mass index, kg/cm2 | 26.4 (23.9; 30.1) |
| Sex | |
| Male | 21 (84%) |
| Female | 4 (16%) |
| Simplified acute physiology score 2 | 29.2 ± 7.6 |
| Type of surgery | |
| Abdominal | 10 (40%) |
| Vascular | 5 (20%) |
| Endocrine | 4 (16%) |
| Urologic | 3 (12%) |
| Others | 3 (12%) |
| Richmond agitation-sedation scale score | |
| −1 | 9 (36%) |
| 0 | 16 (64%) |
| Length of stay, days | 2.6 ± 2.2 |
| Length of mechanical ventilation, days | 1.4 ± 0.9 |
| PDB Entry | 5WZE | |
| Data collection | Space group | P 21 21 21 |
| Cell dimension | ||
| a, b, c (Å) | 111.197,123.432,149.485 | |
| α, β, γ (°) | 90, 90, 90 | |
| Wavelength | 0.97776 | |
| Resolution (Å) | 48.01–1.783 (1.847–1.783) | |
| I/I | 19.714 (2.167) | |
| Completeness (%) | 0.99 | |
| Rmerge | 0.099 (0.709) | |
| Redundancy | 8.9 (6.4) | |
| Refinement | Resolution (Å) | 48.01–1.783 (1.847–1.783) |
| No. of reflections | 194404 (18600) | |
| Rwork/Rfree | 0.2105/0.2206 | |
| No. of atoms | ||
| Protein | 1783 | |
| Ligand/ion | 90 | |
| Water | 1153 | |
| B-factor | ||
| Protein | 27.37 | |
| Ligand/ion | 38.94 | |
| Water | 30.89 | |
| R.m.s. deviations | ||
| Bond lengths (Å) | 0.011 | |
| Bond angles (°) | 1.00 | |
| Ramachandran plot | 98/1.5/0 |
| Test database MegaBLAST score | |||||||
| FAexpTRL | Annotation | Lp_MF | Zm_MF | Zm_TA | Hv_TA | Gm_TA | At_TA |
| LOC_Os04g16450 | aquaporin PIP2.8, putative, expressed | 470 | 357 | 351 | 838 | 121 | 121 |
| LOC_Os04g16680 | Sedoheptulose-1,7-bisphosphatase, chloroplast precursor, putative, expressed | 289 | 995 | 1112 | 1112 | 184 | 129 |
| LOC_Os04g16740 | ATP synthase alpha chain, putative, expressed | 1037 | 644 | 743 | 1126 | 856 | 815 |
| LOC_Os04g16750 | Photosystem I P700 chlorophyll a apoprotein A2, putative, expressed | 613 | 868 | 644 | 628 | 470 | 462 |
| LOC_Os04g16760 | Photosystem I P700 chlorophyll a apoprotein A1, putative, expressed | 503 | 1465 | 1100 | 323 | 357 | 252 |
| LOC_Os04g16770 | Photosystem Q, putative, expressed | 936 | 190 | 539 | 1891 | 848 | 987 |
| LOC_Os04g16780 | Chloroplast 30S ribosomal protein S3, putative, expressed | 129 | 287 | 474 | 498 | 97.6 | 141 |
| LOC_Os04g16790 | DNA-directed RNA polymerase alpha chain, putative, expressed | 525 | - | 1086 | 1219 | 216 | 206 |
| LOC_Os04g16819 | DNA-directed RNA polymerase beta chain, putative, expressed | 264 | 1265 | 410 | 394 | 105 | 188 |
| LOC_Os04g16820 | DNA-directed RNA polymerase beta chain, putative, expressed | 1072 | - | 1096 | 460 | 266 | - |
| LOC_Os10g21200 | Photosystem Q, putative, expressed | 936 | 1037 | 539 | 1883 | 840 | 979 |
| LOC_Os10g21270 | ATP synthase beta chain, putative, expressed | 991 | 1524 | 1376 | 527 | 573 | 793 |
| LOC_Os10g21280 | Ribulose bisphosphate carboxylase large chain precursor, putative, expressed | 936 | 591 | 1766 | 1701 | 531 | 981 |
| LOC_Os10g21310 | Photosystem II P680 chlorophyll A apoprotein, putative, expressed | 561 | 287 | 551 | 170 | 206 | - |
| LOC_Os10g21330 | DNA-directed RNA polymerase alpha chain, putative, expressed | 525 | 184 | 1070 | 1203 | 216 | 206 |
| LOC_Os10g38229 | Photosystem I P700 chlorophyll a apoprotein A1, putative, expressed | 496 | 914 | 1092 | 323 | 357 | 252 |
| LOC_Os10g38248 | Photosystem I P700 chlorophyll a apoprotein A2, putative, expressed | 1033 | 949 | 936 | 906 | 716 | 1076 |
| LOC_Os10g38270 | ATP synthase alpha chain, putative, expressed | 1029 | - | 698 | 1098 | 848 | 815 |
| LOC_Os10g38292 | Chloroplast ATP synthase a chain precursor, putative, expressed | 109 | 258 | - | 1096 | 545 | 614 |
| Mean MegaBLAST score | 214 | 260 | 504 | 473 | 155 | 151 |
| B | SE a | Sig | 95% CI for B | ||
| Lifetime anxiety | 0.151 | 0.216 | 0.487 | 0.590 | 0.287 |
| Lifetime depression | 0.006 | 0.136 | 0.964 | 0.271 | 0.283 |
| Age | 0.004 | 0.003 | 0.142 | 0.001 | 0.009 |
| Employmentb | |||||
| Unemployed | 0.080 | 0.142 | 0.574 | 0.368 | 0.207 |
| Not in labor force | 0.213 | 0.103 | 0.047 | 0.423 | 0.003 |
| Educationc | |||||
| 12 years | 0.068 | 0.080 | 0.396 | 0.230 | 0.093 |
| 13 15 years | 0.038 | 0.075 | 0.617 | 0.114 | 0.189 |
| 16 years or more | 0.123 | 0.113 | 0.283 | 0.106 | 0.353 |
| Marital statusd | |||||
| Divorced / Separated / Widowed | 0.265 | 0.088 | 0.005 | 0.443 | 0.086 |
| Never married | 0.316 | 0.079 | < 0.001 | 0.477 | 0.156 |
| Regione | |||||
| Midwest | 0.200 | 0.181 | 0.278 | 0.169 | 0.569 |
| South | 0.010 | 0.142 | 0.944 | 0.278 | 0.298 |
| West | 0.079 | 0.169 | 0.644 | 0.423 | 0.265 |
| Intercept | 3.138 | 0.197 | < 0.001 | 2.737 | 3.539 |
| Subgroup 1 (n = 11) VPIT test performance without support | |||||||||
| VPIT parameters | Test Mean ± SD | Retest Mean ± SD | Test-Retest Mean difference ± SD | Kendall’s tau correlation | Kendall’s tau correlation with transformed data | ICC (95 % CI) | SEM agreement | SDD | SDD% |
| Tex [s] | 113.14 ± 64.54 | 83.56 ± 27.26 | 29.57 ± 61.17 | .19a | 0.31c | 0.35 (−0.90–0.81) | 37.01 | 102.50 | 682.87 |
| Ndp | 0.12 ± 0.23 | 0.12 ± 0.23 | 0.0 ± 0.34 | 0.0 | - | 0.25 (−6.04–0.69) | 0.20 | 0.55 | 3.66 |
| Fg go [N] | 10.49 ± 4.84 | 10.13 ± 4.09 | 0.36 ± 3.4 | 0.20a | 0.24c | 0.84 (0.40–0.96) | 1.79 | 4.95 | 32.97 |
| Fg return [N] | 1.74 ± 0.92 | 1.55 ± 1.22 | 0.19 ± 0.93 | 0.13a | 0.13d | 0.78 (0.18–0.94) | 0.50 | 1.39 | 9.26 |
| Nzc [1/s] go | 11.18 ± 1.79 | 10.79 ± 1.97 | 0.39 ± 1.21 | 0.06 | - | 0.89 (0.60–0.97) | 0.62 | 1.73 | 11.53 |
| Nzc [1/s] return | 11.72 ± 1.91 | 10.80 ± 1.83 | 0.92 ± 1.29 | 0.09 | - | 0.82 (0.28–0.95) | 0.79 | 2.20 | 14.66 |
| Etraj go [cm] | 0.56 ± 0.27 | 0.47 ± 0.15 | 0.09 ± 0.20 | 0.16a | 0.10b,c | 0.70 (0.00–0.92) | 0.12 | 0.32 | 2.13 |
| 0.29 ± 0.18c | 0.35 ± 0.15c | 0.06 ± 0.11c | 0.83 (0.38–0.95)c | 0.07c | 0.19c | 1.27c | |||
| Etraj return [cm] | 0.79 ± 0.28 | 0.75 ± 0.35 | 0.04 ± 0.42 | 0.06 | - | 0.18 (−2.80–0.80) | 0.29 | 0.79 | 5.26 |
| Fcmean [N] | 1.08 ± 0.72 | 1.18 ± 0.66 | −0.10 ± 0.52 | 0.02 | - | 0.84 (0.41–0.96) | 0.28 | 0.77 | 5.13 |
| SUL | PAF | PTV | PAD | PBT | BAU | BOB | BPN | BFL | |
| Gene number | 6 | 13 | 13 | 13 | 5 | 26 | 18 | 18 | 18 |
| dS/t | 1.5 × 10-10 | 2.9 × 10-09 | 3.6 × 10-09 | 4.8 × 10-09 | 1.3 × 10-08 | 1.1 × 10-08 | 7.9 × 10-08 | 6.4 × 10-08 | 8.9 × 10-08 |
| dN/t | 5.8 × 10-11 | 2.0 × 10-10 | 2.4 × 10-10 | 3.1 × 10-10 | 9.5 × 10-10 | 1.0 × 10-09 | 5.2 × 10-09 | 5.6 × 10-09 | 7.9 × 10-09 |
| Rank | Microbe | Evidence |
| 1 | Helicobacter pylori | PMID:24782613 |
| 2 | Clostridium difficile | PMID:23734349 |
| 3 | Prevotella | PMID:23613868 |
| 4 | Actinobacteria | PMID:23613868 |
| 5 | Staphylococcus aureus | PMID:16495627 |
| 6 | Lachnospiraceae | unconfirmed |
| 7 | Staphylococcus | PMID:24385898 |
| 8 | Haemophilus | unconfirmed |
| 9 | Bacteroides | PMID:20140211 |
| 10 | Enterobacteriaceae | PMID:25759592 |
| Pre (N=174) | During (N=116) | Post (N=174) | Overall (N=464) | |
| Median age years (IQR) | 76 (65–82) | 74.5 (61–84) | 75 (62–83) | 75 (62–83) |
| Female (%) | 81/174 (46.6) | 63/116 (54.3) | 97/174 (55.7) | 241/464 (51.9) |
| Dispatched as stroke (%) (all diagnoses) | 134/168 (79.8) | 105/111 (94.6) | 159/171 (93.0) | 398/450 (88.4) |
| Final Diagnosis of stroke (%) | 98/162 (60.5) | 53/106 (50.0) | 62/159 (39.0) | 213/427 (49.9) |
| Variable | No.# N = 346 | 3-year OS (%) | p-value | 3-year LRFS (%) | p-value | 3-year DFS (%) | p-value |
| Age | 0.002 | 0.001 | 0.008 | ||||
| <50 y | 225 | 87 | 97 | 80 | |||
| ≥50 y | 121 | 75 | 87 | 69 | |||
| N-stage | 0.003 | 0.685 | 0.024 | ||||
| N0 | 63 | 92 | 94 | 84 | |||
| N1 | 110 | 87 | 92 | 77 | |||
| N2 | 113 | 84 | 94 | 77 | |||
| N3 | 60 | 67 | 96 | 65 | |||
| T-stage | 0.105 | 0.838 | 0.050 | ||||
| T3 | 59 | 90 | 95 | 88 | |||
| T4 | 287 | 82 | 93 | 74 | |||
| Overall stage | 0.038 | 0.684 | 0.024 | ||||
| III | 53 | 92 | 94 | 91 | |||
| IV | 293 | 82 | 94 | 74 | |||
| Chemotherapy | 0.386 | 0.059 | 0.427 | ||||
| Yes | 327 | 84 | 94 | 77 | |||
| No | 19 | 72 | 83 | 68 | |||
| Prescribed dose | 0.926 | 0.985 | 0.793 | ||||
| ≤73.92 Gy | 311 | 83 | 93 | 76 | |||
| >73.92 Gy | 35 | 85 | 94 | 75 | |||
| Residual tumor* | 0.007 | 0.002 | <0.001 | ||||
| No | 205 | 90 | 97 | 82 | |||
| Yes | 141 | 73 | 89 | 67 |
| GO.ID | Term1 | Corrected p-value2 |
| GO:0050825 | ice binding | < 1E-26 |
| GO:0003677 | DNA binding | 4.01E-15 |
| GO:0003700 | transcription factor activity | 1.26E-13 |
| GO:0043565 | sequence-specific DNA binding | 5.79E-13 |
| GO:0005199 | structural constituent of cell wall | 1.00E-08 |
| GO:0004879 | ligand-dependent nuclear receptor activity | 3.15E-07 |
| GO:0003682 | chromatin binding | 2.54E-06 |
| GO:0003723 | RNA binding | 7.63E-05 |
| GO:0008270 | zinc ion binding | 0.000303826 |
| GO:0004969 | histamine receptor activity | 0.0008013 |
| GO:0045735 | nutrient reservoir activity | 0.0008013 |
| GO:0003702 | RNA polymerase II transcription factor activity | 0.001116964 |
| GO:0003676 | nucleic acid binding | 0.001580342 |
| GO:0003705 | RNA polymerase II transcription factor activity, enhancer binding | 0.009862154 |
| GO:0003735 | structural constituent of ribosome | 0.02671 |
| GO:0005249 | voltage-gated potassium channel activity | 0.049858667 |
| GO:0004386 | helicase activity | 0.065105625 |
| GO:0016563 | transcription activator activity | 0.13355 |
| GO:0003714 | transcription corepressor activity | 0.13355 |
| GO:0005179 | hormone activity | 0.199622105 |
| Experiment | Mean POG | RSOG | RSOG Distribution | PRSOG | Experiment | Mean POG | RSOG | RSOG Distribution | PRSOG | ||
| Mean | SD | Mean | SD | ||||||||
| 1.1 | 0.34 | 0.26 | 0.21 | 0.0070 | 1.11 × 10−16 | 2.1 | 0.38 | 0.23 | 0.24 | 0.0067 | 0.88 |
| 1.2 | 0.085 | 0.047 | 0.046 | 0.0009 | 0.19 | 2.2 | 0.060 | 0.030 | 0.033 | 0.0022 | 0.84 |
| 1.3 | 0.085 | 0.045 | 0.046 | 0.0005 | 0.94 | 2.3 | 0.065 | 0.031 | 0.034 | 0.0024 | 0.83 |
| 1.4 | 0.100 | 0.051 | 0.053 | 0.0004 | 0.99 | 2.4 | 0.040 | 0.019 | 0.019 | 0.0020 | 0.58 |
| 1.5 | 0.055 | 0.030 | 0.029 | 0.0027 | 0.47 | 2.5 | 0.120 | 0.053 | 0.063 | 0.0035 | 0.99 |
| 1.6 | 0.060 | 0.027 | 0.030 | 0.0031 | 0.81 | 2.6 | 0.040 | 0.015 | 0.019 | 0.0020 | 0.95 |
| Items | Sampling time, h | |||||||||
| Criterion | 0 | 8 | 16 | 24 | 32 | 40 | 48 | 56 | 64 | 72 |
| Anisidine value | 0.24 | 0.34 | 0.50 | 1.09 | 1.26 | 1.83 | 2.44 | 3.48 | 4.29 | 5.40 |
| Crude fat, % | >99.75 | >99.75 | >99.75 | >99.75 | >99.75 | >99.75 | >99.75 | >99.75 | >99.75 | >99.75 |
| DDE1, mg/mL | 56.6 | 52.8 | 21.5 | 24.2 | 30.5 | 65.7 | 343.9 | 716.8 | 948.7 | 1276.4 |
| Free fatty acids, % | 1.12 | 1.12 | 0.83 | 1.83 | 0.70 | 0.98 | 1.27 | 1.41 | 1.40 | 1.84 |
| Hexanal, μg/g | 1.70 | 1.90 | 2.24 | 3.27 | 3.90 | 4.61 | 5.22 | 5.79 | 6.08 | 6.60 |
| HNE2, μg/g | 2.0 | 2.2 | 1.4 | 1.8 | 3.2 | 6.6 | 8.7 | 10.5 | 24.1 | 27.0 |
| Insoluble, % | <0.15 | <0.15 | <0.15 | <0.15 | <0.15 | <0.15 | <0.15 | <0.15 | <0.15 | <0.15 |
| Moisture, % | <0.1 | <0.1 | <0.1 | <0.1 | <0.1 | <0.1 | <0.1 | <0.1 | <0.1 | <0.1 |
| Peroxide value, mEq/kg | 2.11 | 2.87 | 6.17 | 7.06 | 8.12 | 13.10 | 13.75 | 13.94 | 13.85 | 13.57 |
| TBARS3, mg MDA4 eq/g oil | 0.018 | 0.023 | 0.023 | 0.027 | 0.020 | 0.034 | 0.032 | 0.027 | 0.029 | 0.032 |
| Unsaponafiable, % | 0.78 | 0.73 | 0.76 | 0.82 | 0.78 | 0.70 | 0.68 | 0.67 | 0.77 | 0.83 |
| Viscosity, cP @ 20C | 56.6 | 56.3 | 56.6 | 58.5 | 60.4 | 62.8 | 65.7 | 70.9 | 74.9 | 78.8 |
| OSI5, h | 10.33 | 8.91 | 6.58 | 3.97 | 2.59 | 1.14 | <1.00 | <1.00 | <1.00 | <1.00 |
| Fatty acids, % of total fat6 | ||||||||||
| Pentadecanoic acid (C15:0) | 0.00 | 0.00 | 0.00 | 0.00 | 0.09 | 0.13 | 0.14 | 0.16 | 0.18 | 0.15 |
| Palmitic (16:0) | 14.36 | 12.26 | 11.50 | 11.63 | 11.88 | 11.81 | 12.20 | 12.26 | 12.55 | 13.02 |
| Palmitoleic (9c-16:1) | 0.14 | 0.11 | 0.10 | 0.11 | 0.11 | 0.11 | 0.11 | 0.12 | 0.12 | 0.11 |
| Margaric (17:0) | 0.00 | 0.08 | 0.00 | 0.09 | 0.09 | 0.09 | 0.09 | 0.10 | 0.10 | 0.00 |
| Stearic (18:0) | 1.75 | 1.87 | 1.89 | 1.93 | 2.00 | 1.99 | 2.02 | 2.04 | 2.13 | 2.07 |
| Oleic (9c-18:1) | 28.93 | 29.79 | 29.97 | 30.16 | 30.51 | 30.56 | 30.79 | 31.04 | 31.49 | 31.60 |
| Linoleic (18:2n6) | 53.06 | 53.66 | 54.21 | 53.69 | 52.63 | 52.67 | 51.91 | 51.40 | 50.40 | 50.32 |
| Linolenic (18:3n3) | 0.89 | 0.90 | 0.92 | 0.91 | 0.85 | 0.87 | 0.82 | 0.81 | 0.77 | 0.75 |
| Arachidic (20:0) | 0.28 | 0.37 | 0.40 | 0.41 | 0.43 | 0.44 | 0.41 | 0.42 | 0.46 | 0.40 |
| Gonodic (20:1n9) | 0.26 | 0.33 | 0.35 | 0.34 | 0.36 | 0.36 | 0.34 | 0.36 | 0.00 | 0.35 |
| Behenoic (22:0) | 0.12 | 0.17 | 0.16 | 0.21 | 0.20 | 0.21 | 0.20 | 0.20 | 0.22 | 0.19 |
| Lignoceric (24:0) | 0.00 | 0.15 | 0.19 | 0.19 | 0.21 | 0.26 | 0.22 | 0.25 | 0.24 | 0.27 |
| Flexion PPIVMs | ||||
| LSI | Sensitivity (CI) | Specificity (CI) | LR+ (CI) | LR- (CI) |
| Rotation LSI | .05 (.01, .36) | .99 (.96, .1.00) | 4.12 (.21, 80.3) | .96 (.83, 1.11) |
| Translation LSI | .05 (.01, .22) | .995 (.97, 1.00) | 8.73 (.57, 134.7) | .96 (.88, 1.05) |
| Extension PPIVMs | ||||
| LSI | Sensitivity (CI) | Specificity (CI) | LR+ (CI) | LR- (CI) |
| Rotation LSI | .22 (.06, .55) | .97 (.94, .99) | 8.40 (1.88, 37.55) | .80 (.56, 1.13) |
| Translation LSI | .16 (.06, .38) | .98 (.94, .99) | 7.07 (1.71, 29.2) | .86 (.71, 1.05) |
| Pre | Post | Fu3 | Change Pre-Post | Change Pre-Fu3 | |||
| Mean (SD) | Mean (SD) | Mean (SD) | Mean (95% CI) | Effect size (d)a | Mean (95% CI) | Effect size (d) a | |
| Positive Day Time Ratings | |||||||
| Bibliotherapy with support (n = 44) | 2.5 (0.79) | 3.2 (0.70) | 3.1 (0.74) | 0.69 (0.46 to 0.92) | 0.94 | 0.58 (0.34 to 0.82) | 0.78 |
| Bibliotherapy (n = 45) | 2.6 (0.65) | 3.0 (0.72) | 3.0 (0.84) | 0.38 (0.19 to 0.58) | 0.58 | 0.44 (0.21 to 0.67) | 0.58 |
| Waiting list control (n = 43) | 2.6 (0.73) | 2.8 (0.75) | 2.7 (0.76) | 0.17 (-0.02 to 0.36) | 0.27 | 0.13 (-0.07 to 0.32) | 0.13 |
| Day Time Fatigue (DTF) | |||||||
| Bibliotherapy with support (n = 44) | 2.8 (0.98) | 1.5 (1.0) | 1.8 (1.1) | -1.23 (-1.54 to -0.91) | -1.31 | -0.98 (-1.3 to -0.66) | -0.96 |
| Bibliotherapy (n = 45) | 2.7 (0.82) | 2.2 (0.99) | 2.1 (0.94) | -0.49 (-0.81 to -0.17) | -0.55 | -0.61 (-0.92 to -0.31) | -0.68 |
| Waiting list control (n = 43) | 2.7 (0.82) | 2.4 (0.89) | 2.6 (1.0) | -0.28 (-0.50 to -0.05) | -0.35 | -0.14 (-0.42 to 0.13) | -0.11 |
| Perceived Stress Scale (PSS) | |||||||
| Bibliotherapy with support (n = 44) | 17.4 (7.4) | 13.1 (5.7) | 13.2 (5.9) | -4.3 (-6.0 to -2.6) | -0.65 | -4.2 (-6.1 to -2.3) | -0.63 |
| Bibliotherapy (n = 45) | 18.8 (6.2) | 16.1 (7.1) | 15.1 (7.4) | -2.7 (-4.2 to -1.1) | -0.41 | -3.6 (-5.2 to -2.0) | -0.54 |
| Waiting list control (n = 44) | 19.0 (6.8) | 17.2 (6.3) | 17.3 (7.2) | -1.8 (-3.0 to -0.6) | -0.27 | -1.7 (-3.3 to -0.2) | -0.24 |
| CORE-OM | |||||||
| Bibliotherapy with support (n = 44) | 37.0 (17.7) | 24.4 (14.0) | 27.2 (17.0) | -12.5 (-17.0 to -8.0) | -0.79 | -9.7 (-14.7 to -4.7) | -0.56 |
| Bibliotherapy (n = 45) | 36.7 (15.8) | 32.5 (16.1) | 29.6 (15.4) | -4.2 (-8.5 to 0.1) | -0.26 | -7.1 (-11.6 to -2.7) | -0.46 |
| Waiting list control (n = 44) | 41.7 (15.6) | 36.2 (15.3) | 36.0 (18.4) | -5.5 (-8.9 to-2.0) | -0.36 | -5.7 (-9.6 to -1.7) | -0.33 |
| Factor 1 (Cardiopulmonary) | Factor 2 (Pain-fatigue) | Factor 3 (Gastrointestinal) | Factor 4 (Dysmenorrhea) | |
| PHQ11: Shortness of breath | 0.799 | |||
| PHQ10: Palpitation | 0.738 | |||
| PHQ07: Chest pain | 0.709 | |||
| PHQ09: Fainting spells | 0.661 | |||
| PHQ03: Pain in extremities | 0.689 | |||
| PHQ02: Back pain | 0.662 | |||
| PHQ06: Headache | 0.638 | |||
| PHQ08: Dizziness | 0.603 | |||
| PHQ14: Sleep disturbance | 0.594 | |||
| PHQ15: Fatigue | 0.524 | 0.520 | ||
| PHQ13: Nausea or indigestion | 0.715 | |||
| PHQ01: Stomach pain | 0.651 | |||
| PHQ12: Constipation or diarrhea | 0.612 | |||
| PHQ05: Sexual problems | 0.428 | |||
| PHQ04: Menstrual cramps | 0.822 |
| Organ ischaemia and I/R injury | Expression of TLRs | Upregulation of TLRs in ischaemia | Evidence for role of TLR in pathophysiology | Potential endogenous ligand implicated in pathogenesis |
| Cerebral | Glial cells: TLR 1–9 [32, 33]Neurons: TLR 2 and 4 [34] | TLR 2, 4 and 9 [34, 35] | TLR 2 and 4 knockout mice have reduced infarct size following ischaemia [34, 36–38] | HSP 70 [34] |
| Liver | Hepatocytes: TLR 2, 3, 4 and 5 [39]Non-parenchymal cells: TLR 2, 3, 4, 5, 7 and 9 [39] | TLR 2 [40] | TLR 4 and 9 knockout mice are protected against ischaemia-induced liver injury [41–43] | HSP 72 [44] and HMGB-1 [42, 45] |
| Renal | Parenchyma: TLRs 1–10 at varying detection levels [46–48] | TLR 2 and 4 [47, 49] | TLR 2 and 4 knockout mice are protected against renal I/R injury, and this is associated with a reduction in inflammatory cytokine levels [49–52] | HMGB-1, hyaluronan and biglycan [49, 51, 53] |
| Myocardial | Myocytes: TLR 2, 3, 4 and 6 [54] | TLR 4 [55] | TLR 2- and 4-deficient mice show reduced myocardial infarct size [56–59]. TLR 4 antagonist eritoran leads to reduced infarct size, NF-κB nuclear translocation, and proinflammatory cytokine expression [60] | HMGB-1 [61] |
| Skeletal muscle | TLR 1–9 [62–64] | TLR 2, 4, 6 [65] | TLR 2 antagonsim reduces pro-inflammatory cytokine expression in an in vitro model of skeletal muscle ischaemia [65] | Under investigation |
| Populationa | Relatively benign (n = 30 SNPs) | Relatively deleterious (n = 29 SNPs) | ||
| Mean (s.d.) | Mean difference compared to EUR (95% CI); P value | Mean (s.d.) | Mean difference compared to EUR (95% CI); P value | |
| AFR | 29.85 (2.846) | 1.98 (0.38, 3.58); 0.016 | 34.68 (3.109) | 1.18 (−0.51, 2.87); 0.167 |
| AMR | 28.28 (3.449) | −0.41 (−1.35,2.17); 0.642 | 36.12 (3.768) | 2.62 (0.76,4.48); 0.007 |
| EAS | 28.56 (3.127) | 0.69 (−0.98,2.36); 0.412 | 35.66 (2.881) | 2.16 (0.53, 3.79); 0.010 |
| SAS | 28.35 (3.332) | 0.48 (−1.25,2.21); 0.579 | 34.10 (3.243) | 0.60 (−1.12, 2.32); 0.488 |
| EUR | 27.87 (3.283) | ref | 33.50 (3.360) | ref |
| Clinical characterization | SOX2/TERC amplifications/polyploidy | Odds ratio (95% confidence interval), p (two-tailed Fisher exact test) | |||||
| Normal | Polyploidy only | Amplification and poliploidy | Total abnormal FISH results | Normal vs. total abnormal FISH results | Normal vs. Polyploidy only | Normal vs. amplification with poliploidy | |
| Controls | 21 | 0 | 1 | 1 | 46.77 (5.91-370) 0.00 | N/D2 (N/D2) 0.00 | 21.00 (2.56-455) 0.00 |
| OSCC | 22 | 27 | 22 | 49 | |||
| Stage: I, II, III | 8 | 7 | 8 | 15 | 1.29 (0.39 – 4.23), 0.78 | 1.25 (0.41-6.03) 0.76 | 1.00 (0.25-4.07) 1.00 |
| Stage: IV | 14 | 20 | 14 | 34 | |||
| Stage: I, II | 4 | 5 | 7 | 12 | 0.69 (0.17-2.77), 0.76 | 0.98 (0.18-5,13) 1.00 | 0.48 (0.09-2.34) 0.49 |
| Stage: III, IV | 18 | 22 | 15 | 37 | |||
| Oropharynx | 6 | 11 | 10 | 21 | 2.00 (0.59-6.93), 0.29 | 1.83 (0.47-7.46) 0.38 | 2.22 (0.53-9.52) 0.34 |
| Outside oropharynx1 | 16 | 16 | 12 | 28 |
| Total DW | Shoot DW | Root DW | Shoot Zn cont. | Shoot Zn conc. | Root number | RSA | % fine roots | Root: shoot ratio | |
| Total DW | – | 0.99 | 0.97 | 0.89 | –0.01 | 0.72 | 0.81 | –0.38 | –0.17 |
| Shoot DW | 0.99 | – | 0.94 | 0.87 | –0.06 | 0.70 | 0.80 | –0.37 | –0.24 |
| Root DW | 0.95 | 0.90 | – | 0.91 | 0.14 | 0.75 | 0.78 | –0.41 | 0.08 |
| Shoot Zn cont. | 0.91 | 0.94 | 0.77 | – | 0.43 | 0.72 | 0.69 | –0.29 | 0.01 |
| Shoot Zn conc. | –0.47 | –0.42 | –0.55 | –0.14 | – | 0.20 | –0.07 | 0.1 | 0.50 |
| Root number | 0.90 | 0.89 | 0.85 | 0.82 | –0.40 | – | 0.75 | –0.34 | 0.05 |
| RSA | 0.92 | 0.89 | 0.93 | 0.72 | –0.58 | 0.84 | – | –0.45 | –0.16 |
| % fine roots | –0.63 | –0.63 | –0.59 | –0.59 | 0.27 | –0.37 | –0.58 | – | –0.06 |
| Root:shoot ratio | 0.27 | 0.16 | 0.52 | 0.01 | –0.42 | 0.22 | 0.38 | –0.24 | – |
| Total population (N = 16) | ||
| Age [years] | N | 16 |
| Mean (SD) | 62.5 (13.4) | |
| Median (min, max) | 67.0 (31, 76) | |
| Gender [n (%)]∗ | Male | 7 (43.7%) |
| Female | 9 (56.3%) | |
| Duration of diabetes [years] | Mean (SD) | 20.1 (7.6) |
| Median (min, max) | 21.5 (2, 30) | |
| Type of diabetes mellitus [n (%)]∗ | Type 1 | 1 (6.3%) |
| Type 2 | 15 (93.7%) | |
| Treatment of diabetes [n (%)]∗ | Insulin | 16 (100.0%) |
| Hba1c [%] | Mean (SD) | 7.76 (0.7) |
| Median (min, max) | 7.70 (6.3, 9) | |
| Classification of diabetic retinopathy [n (%)]∗ | Nonproliferative | 14 (87.5%) |
| Proliferative | 2 (12.5%) |
| % | Sun exposure | Localization | Clinical aspects | Colors | Histology | |
| Superficial spreading melanoma | 70 | Intermittent | Back—Man Legs—Woman | Flat Papule Nodule | Tan, Brown, Gray, Black, Violaceous, Pink | Radial growth phase characterized by the proliferation within the epidermis of single atypical melanocytes in a pagetoid pattern |
| Nodular melanoma | 5 | Intermittent | Trunk Limb | Nodule Ulcerated polyp Elevated plaque | Brown Black Achromic | Radial growth phase absent |
| Lentigo maligna melanoma | 4–15 | Long term | Head Neck | Flat Papula | Brown Black | Radial growth phase composed of a lentiginous proliferation atypical melanocytes at the dermo-epidermal junction |
| Acral lentiginoso melanoma | 5 | N/A | Glabrous skin (palmoplantar, subungueal) | Flat Nodule Plaque | Irregular, poorly circumscribed pigmentation | Radial growth phase characterized by lentiginous proliferation of atypical melanocytes, marked acanthosis and elongation of the rete ridges of the epidermis |
| Desmoplastic melanoma | 2 | Long term | Head Neck | Papule Nodule | Erythemato us Flash colored Achromic | Vertical growth phase composed of atypical spindle cells embedded in a fibrous stroma |
| Melanoma arising from blu nevus | Rare | N/A | Head | Recent history of enlargement or change in pre-existing nevus | Blu-Black | Malignant dermal, deep seated component juxtaposed to a benign blue nevus |
| Melanoma arising in a giant | Rare | N/A | Trunk | Nodule growing in | Dark, brown | Dermal sharply delineated nodule |
| Congenital nevus | A nevus | Black | Composed of atypical ephitelioid, spindle or small cells, arising in a preexisting giant congenital nevus | |||
| Melanoma of childhood | 0,4 | N/A | Trunk | SSM or NM | SSM: Tan, Brown, Gray, Black, Violaceous, Pink | Conventional epithelioid melanoma or small cells or melanoma simulating Spitz nevus |
| Nevoid melanoma | 1-2 | N/A | Leg, trunk | Small papule | Tan to dark, brown | Nevus-like silhouette, limited intraepidermal component, loss/lack of maturation, cytological atypia, mitoses in the dermal component |
| PFS-rates | |||
| 3 years | 5 years | 10 years | |
| Entire cohort | 92.30% | 87.00% | 84.10% |
| Group 1 (unknown/Grade I) | 96.80% | 92.70% | 89.60% |
| Group 2 (Grade II/III) | 52.60% | 19.70% | n/a |
| Unknown histology | 97.40% | 94.20% | 90.40% |
| Grade I | 93.90% | 85.80% | 85.80% |
| Grade II | 62.70% | 41.80% | n/a |
| Grade II | 29.30% | n/a | n/a |
| Volume < 60 ccm | 95.80% | 91.20% | 89.30% |
| Volume > 60 ccm | 100% | 85.70% | n/a |
| Primary RT | 98.10% | 98.10% | 96.80% |
| Postoperative RT | 87.60% | 78.10% | 73.40% |
| nFSRT | 92.70% | 88.90% | 86.90% |
| hFSRT | 92.40% | 80.90% | n/a |
| SRS | 95.80% | 87.80% | n/a |
| Variables | Measures used/source | |
| Outcomes or responses | Musculoskeletal symptoms by body region | Modified from NIOSH symptom report items (NIOSH 2000)Hand diagram (Katz et al. 1990) |
| Signs from physical exam | Modified from SHARP physical exam protocol (Viikari-Juntura 2000) | |
| MSDs | Combinations of signs and symptoms used to define working case definitions (Sluiter et al. 2001; Palmer et al. 2000 and Walker-Bone et al. 2002; Gerr et al. 2002) | |
| Acute work-related injury | Self-report | |
| Health-related quality of lifea | SF-12 (Ware et al. 1996) | |
| Upper extremity functiona | Upper extremity function scale (Pransky et al. 1997) | |
| Depressive symptomsa | CES-D (Radloff 1977) | |
| Exposures | Work requirements Repetition, posture, force, temperature, tool use | Key informant interviews, project-specific self-report exposure tool |
| Modifiers | Work organization (decision latitude, control, demand, social support, job satisfaction) | Job Content Questionnaire (Karasek et al. 1998) |
| Discrimination and response | Self-reported by race or gender and usual response (Krieger and Sidney 1996) | |
| Assertiveness at work | Scale measure from self-reported items; developed from key. informant interviews | |
| Coping style | John Henryism Active Coping Scale (James et al. 1987) | |
| Socioeconomic strain | Self-report of “Weeks you could be out of work without pay before loss of income would be a major problem.” | |
| Other health conditions | Medical history (select items based on possible relationship to MSDs—pregnancy, hormonal therapies, diabetes, etc.) |
| GM allotypes | Proportions (number of individuals) |
| 5 | 100% (216) |
| 17 | 100% (216) |
| 1 | 99.5% (215) |
| 14 | 98.6% (213) |
| 13 | 82.4% (178) |
| 6 | 49.5% (107) |
| 3 | 1.9% (4) |
| 21 | 1.4% (3) |
| 23 | 0.5% (1) |
| Evaluation criteria | ML-kNN | kNN | RankSVM | BPMLL |
| Average_Precision(%) | 77.4 ± 3.3 | 73.6 ± 3.1 | 71.0 ± 2.1 | 75.4 ± 2.7 |
| Coverage | 3.31 ± 0.31 | 3.44 ± 0.30 | 3.69 ± 0.28 | 3.36 ± 0.33 |
| Ranking_Loss | 0.283 ± 0.035 | 0.386 ± 0.037 | 0.419 ± 0.041 | 0.311 ± 0.039 |
| Type of intervention | Specific intervention | Votes | % of total votes |
| Other vaccines | None specified by any group | 0 | 0 |
| Information & skills | Lifestyle education | 20 | 10 |
| Oral health education (with or without provision of toothbrush and paste) | 18 | 9 | |
| Diet & exercise education | 17 | 8 | |
| Sexual & reproductive health and rights | 12 | 6 | |
| Hygiene education (with or without provision of soap) | 12 | 6 | |
| Health promotion through the school health programme | 12 | 6 | |
| Road safety education | 10 | 5 | |
| Education on mental health | 8 | 4 | |
| Screening | Visual acuity | 31 | 15 |
| General health checks | 15 | 7 | |
| Commodities & treatment | Deworming, including schistosomiasis and/or soil-transmitted helminth treatment | 38 | 18 |
| Youth-friendly services provision | 12 | 6 | |
| Provision of school meals | 3 | 1 | |
| Total | 208 | 100 |
| Spring Tides | Neap Tides | |||
| PC1 (75.0%) | PC2 (17%) | PC1 (84.0%) | PC2 (8%) | |
| AChla | 0.40 | 0.88 | 0.24 | −0.94 |
| DTB | 0.80 | −0.35 | 0.83 | 0.24 |
| DNB | −0.27 | <0.01 | −0.37 | −0.18 |
| GZB | −0.32 | 0.29 | −0.32 | 0.11 |
| FChla | <0.01 | <0.01 | <0.01 | <0.01 |
| Protein | Sequence | NetCTLpansupertype prediction | Antigen specific T-cell response |
| HLA alleles assessed | |||
| NP | IPVYQVNNL | B7 | B7: HLA-B*07:02 |
| RLEELLPAV | A2 | A2: HLA-A*02:01 | |
| FLSFASLFL | A2 | A2: HLA-A*02:01 | |
| HPLARTAKV | B7 | B7: HLA-B*07:02, HLA-B*35:01, HLA-B*51:01 | |
| GLFPQLSAI | A2 | A2: HLA-A*02:01 | |
| FPQLSAIAL | B7 | A2: HLA-A*02:01B7: HLA-B*07:02 | |
| QTNAMVTLR | A3 | A3: HLA-A*03:01, HLA-A*11:01 | |
| KLTEAITAA | A2 | A2: HLA-A*02:01 | |
| VP40 | LPQYFTFDL | B7 | B7: HLA-B*07:02, HLA-B*35:01 |
| FTFDLTALK | A3 | A3: HLA-A*03:01, HLA-A*11:01 | |
| “Pre-295 All GP” | ILFQRTFSI | A2 | A2: HLA-A*02:01A3: HLA-A*03:01, HLA-A*11:01 |
| FLLQLNETI | A2 | A2: HLA-A*02:01 | |
| “Post-295 GP” | MASENSSAM | B7 | A2: HLA-A*02:01B7: HLA-B*07:02 |
| LITNTIAGV | A2 | A2: HLA-A*02:01 | |
| LANETTQAL | B7 | B7: HLA-B*07:02, HLA-B*35:01 | |
| RTFSILNRK | A3 | A2: HLA-A*02:01A3: HLA-A*03:01, HLA-A*11:01 | |
| KAIDFLLQR | A3 | A2: HLA-A*02:01A3: HLA-A*03:01, HLA-A*11:01 | |
| VP24 | VLSDLCNFL | A2 | A2: HLA-A*02:01 |
| L | IISDLSIFI | A2 | A2: HLA-A*02:01, HLA-A*69:01 |
| LLADGLAKA | A2 | A2: HLA-A*02:01, HLA-A*69:01 | |
| HSGFIYFGK | A3 | A3: HLA-A*11:01, HLA-A*31:01 | |
| KLINTLFHA | A2 | A2: HLA-A*02:01 | |
| TPVMSRFAA | B7 | B7: HLA-B*07:02, HLA-B*35:01 | |
| KPTFKHASV | B7 | B7: HLA-B*07:02 |
| Steel | YS (MPa) | TS (MPa) | % Elongation | σppt (MPa) |
| CMn | 267 | 401 | 33 | – |
| 1.7 Cu | 452 | 567 | 15.2 | 158 |
| TiMo | 642 | 770 | 16.6 | 347 |
| 1.7 CuTiMo | 695 | 840 | 11.6 | 380 |
| Complete blood count | Coagulation | ||
| Erythrocytes | 3.52 × 1012 cells/L | PT-INR | 1 |
| Hemoglobin | 6.5 g/dL | aPTT | 35 seconds |
| Hematocrit | 27.7% | Fib | 4.41 g/L |
| White blood cells | 9.94 × 109/L | Other tests | |
| Platelets | 11 × 109/L | AST | 35 U/L |
| Reticulocyte count | 1.92% | ALT | 19 U/L |
| Cr | 1.1 mg/dL | ||
| Urea | 40 mg/dL | ||
| Na | 140 mEq/L | ||
| K | 3.9 mEq/L | ||
| Total bilirubin | 1.0 mg/dL | ||
| Uric acid | 7.3 mg/dL | ||
| Lactate dehydrogenase | 183 U/L | ||
| Ferritin blood test | 148 ng/Ml | ||
| Transferrin saturation | 11.8% | ||
| Serum iron | 38 μg/dL | ||
| B12 vitamin | 668.4 pg/mL |
| Variables | Best Cutoff Values | AUC (95% CI) | Sensitivity (%) | Specificity (%) | Accuracy (%) |
| AF duration | 66.5 mhs | 0.653(0.593 ~ 0.712) | 39.7 | 89.0 | 55.3 |
| Pre-op BNP | 251 pg/ml | 0.691(0.636 ~ 0.746) | 60.3 | 71.4 | 67.2 |
| Pre-op heart rate | 82 bpm | 0.842(0.802 ~ 0.882) | 75.1 | 81.5 | 75.8 |
| Pre-op LAD | 67.9 mm | 0.600(0.540 ~ 0.660) | 31.8 | 91.4 | 68.7 |
| Demographic characteristics | Cases | 2008 population | Attack rate per 1000 | |
| Age | 0–4 | 12 | 524 | 23 |
| 5–8 | 13 | 510 | 26 | |
| 9–13 | 11 | 675 | 16 | |
| 14+ | 29 | 3554 | 8 | |
| Sex | Male | 42 | 2650 | 16 |
| Female | 23 | 2613 | 9 | |
| Total | 65 | 5263 | 12 |
| Demographic characteristics | N | % | |||
| Female gender | 243 | 64.5 | |||
| M | SD | Range | |||
| Age at study (years) | 25.0 | 2.1 | 22.5 - 30.9 | ||
| Disease characteristics | N | % | N | % | |
| Congenital disorder | 200 | 53.1 | Daily medicine use | 196 | 52.0 |
| Perceptible disability | 159 | 42.2 | Medical aids/devices | 184 | 48.8 |
| Course of illness | Limitations in fingers/hand | 148 | 39.3 | ||
| Worse/variable | 156 | 41.4 | Limitation of sight | 90 | 23.9 |
| Stable/positive | 221 | 58.6 | Limitations of hearing | 31 | 8.2 |
| Able to sit half an hour | 350 | 92.8 | |||
| Able to stand half an hour | 220 | 58.4 | |||
| Chronic conditions | N | ||||
| Visually impaired/blind | 51 | ||||
| Spasm | 45 | ||||
| Rheumatoid arthritis | 45 | ||||
| Epilepsy | 31 | ||||
| Back complaints | 28 | ||||
| Hearing impaired/deaf | 27 | ||||
| Intestinal complaints | 21 | ||||
| CFS | 20 | ||||
| Lung complaints | 20 | ||||
| Accident damage | 19 | ||||
| Paralysis | 19 | ||||
| Cancer | 18 | ||||
| Muscular dystrophy | 17 | ||||
| Arthritis | 16 | ||||
| Kidney diseases | 13 | ||||
| Skin disease | 9 | ||||
| Migraine | 9 | ||||
| Heart disease | 7 | ||||
| Other | 119 |
| HCH- isomers | Incubation period (days) | Degradation by isolate DAB-1Y (5 μg/mL) in % | Degradation by isolate. DAB-1W(5 μg/mL) in % |
| α | 8 | 86 | 93 |
| 28 | 18 | 10 | |
| β | 8 | 12 | 14 |
| 28 | 35 | 32 | |
| γ | 8 | 94 | 98 |
| 28 | 30 | 28 | |
| δ | 8 | 80 | 76 |
| 28 | 32 | 28 |
| Variablea | Odds ratio | P-value |
| (95% CI) | ||
| Basal-like n = 205 (pr = 72, nr = 133) | ||
| B/P | 1.26 (0.95-1.68) | 0.12 |
| T/NK | 1.53 (0.93-2.51) | 0.09 |
| M/D | 1.66 (1.15-2.39) | 0.007 |
| Claudin-low n = 47 (pr = 17, nr = 30) | ||
| B/P | 1.92 (1.10-3.34) | 0.02 |
| T/NK | 2.08 (0.80-5.47) | 0.14 |
| M/D | 1.11 (0.43-2.86) | 0.82 |
| HER2-E n = 72 (pr = 26, nr = 46) | ||
| B/P | 1.31 (0.84-2.04) | 0.23 |
| T/NK | 0.83 ( 0.36-1.92) | 0.67 |
| M/D | 1.19 (0.54-2.59) | 0.67 |
| LumB n = 133 (pr = 23, nr = 110) | ||
| B/P | 1.33 (0.93-1.89) | 0.11 |
| T/NK | 1.44 ( 0.86-2.42) | 0.16 |
| M/D | 1.71(1.01-2.91) | 0.05 |
| LumA n = 207 (pr = 7, nr = 200) | ||
| B/P | 1.52 (0.82-2.83) | 0.19 |
| T/NK | 1.16 (0.52-2.60) | 0.72 |
| M/D | 0.93 (0.43-2.02) | 0.85 |
| Genes | Frequency of mRNA level changes, % | Median of mRNA level changes, n-fold* | ||||
| ccRCC | pRCC | ccRCC | pRCC | |||
| ↓ | ↑ | ↓ | ↑ | |||
| LRRN1 | 53 (9/17) | 0 (0/17) | 11 (1/9) | 33 (3/9) | 3↓(1–15↓) | 3↑(2.1 × 103↑–10↓) |
| GORASP1 | 42 (5/12) | 0 (0/12) | 36 (4/11) | 0 (0/12) | 1 (1–3↓) | 1 (1–7↓) |
| IQSEC1 | 0 (0/12) | 8 (1/12) | 58 (7/12) | 0 (0/12) | 1 (3↑–1) | 2↓ (1–53↓) |
| FOXP1 | 20 (2/10) | 0 (0/10) | 17 (2/12) | 25 (3/12) | 1 (1–2↓) | 1 (19↑–14↓) |
| GNAI2 | 8 (1/12) | 33 (4/12) | 17 (2/12) | 25 (3/12) | 1 (4↑–2↓) | 1 (3↑–4↓) |
| FGD5 | 25 (3/12) | 8 (1/12) | 83 (10/12) | 0 (0/12) | 1 (3↑–7↓) | 3↓(1–59↓) |
| PLCL2 | 50 (6/12) | 0 (0/12) | 83 (10/12) | 8 (1/12) | 1 (1–5↓) | 3↓(2↑–8↓) |
| ALDH1L1 | 92 (11/12) | 0 (0/12) | 92 (11/12) | 0 (0/12) | 4↓(1–1.1 × 102↓) | 6↓(1–1.6 × 102↓) |
| Odd ratio (95% CI) | |
| Crude: Age < 50 years | 1 |
| < 50 years | 8.14 (3.49~18.98) |
| Gender - Male | 1 |
| - Female | 2.36 (1.12~5.11) |
| p-CagA - Sparse | 1 |
| - Weak | 4.38 (1.15~16.72) |
| - Strong | 8.34 (2.21~31.55) |
| Age and gender adjusted | |
| Sparse p-CagA | 1 |
| Weak p-CagA | 3.67 (0.93~14.37) |
| Strong p-CagA | 8.44 (2.08~34.12) |
| Age, gender and disease adjusted | |
| Sparse p-CagA | 1 |
| Weak p-CagA | 3.93 (0.92~16.94) |
| Strong p-CagA | 10.45 (2.25~48.48) |
| Surgery | Pre-surgery | Post-surgery | Median change |
| Control | 0—11.0 ng/mL | NA | NA |
| Lumpectomy | 0.1—15.8 ng/mL | 1.0—53.8 ng/mL | 4.8 |
| Mastectomy | 0.4—7.6 ng/mL | 6.4—53.8 ng/mL | 14.7 |
| Liver | Estimated ELOVL6 activity | Estimated SCD1 activity | C16:0/C18:2n-6 | C16:0 | ||||||||
| C18:0/C16:0 | C18:1/C16:1 | C16:1/C16:0 | C18:1/C18:0 | |||||||||
| Adult | Old | Adult | Old | Adult | Old | Adult | Old | Adult | Old | Adult | Old | |
| C16:1n-7 | −0.797** | −0.718** | −0.865** | −0.658** | 0.970** | 0.946** | 0.887** | 0.517** | 0.466* | −0.602** | 0.514* | −0.485** |
| C18:1n-9 | −0.735** | −0.096 | −0.508* | 0.589** | 0.734** | 0.294 | 0.954** | 0.843** | 0.494* | −0.355 | 0.662** | −0.707** |
| C20:4n-6 | 0.727** | −0.016 | 0.618** | −0.643** | −0.475* | −0.152 | −0.552* | −0.722** | −0.291 | 0.245 | −0.735** | 0.560** |
| RNAi | Strain | ||
| rrf-1 %Mog (n) | rrf-1; fbf-1 %Mog (n) | rrf-1; fbf-2 %Mog (n) | |
| Control day 1 | 0 | 0 | 0 |
| day 3 | 0 | 0 | 0 |
| mtr-4 day 1 | 43% (23) | 97% (33) | 80% (45) |
| day 3 | 37% (27) | 89% (35) | 48% (31) |
| prp-17 day 1 | 62% (42) | 100% (33) | 98% (64) |
| day 3 | 47% (15) | 87% (46) | 93% (29) |
| F43G9.12 day 1 | 4% (23) | 41% (34) | 52% (46) |
| day 3 | 0% (26) | 56% (34) | 25% (56) |
| Variable | non-Xp11.2 translocation group (n = 82) | Xp11.2 translocation group (n = 16) | P value |
| Age(y) | 0.296 | ||
| Media(Range) | 40 (18–45) | 27 (21–40) | |
| Gender(n) | 0.086 | ||
| Male | 56 (68.3 %) | 7 (43.8 %) | |
| Female | 25 (31.7 %) | 9 (56.3 %) | |
| Size(cm) | 0.588 | ||
| Media(Range) | 4.6 (1.8–17.0) | 4.5 (3.0–11.5) | |
| Laterality(n) | 1.000 | ||
| Left | 39 (47.6 %) | 7 (43.8 %) | |
| Right | 43 (52.4 %) | 9 (56.3 %) | |
| Symptoms(n) | |||
| Asymptomatic | 57 (69.5 %) | 11 (68.8 %) | |
| Symptomatic | 25 (30.5 %) | 5 (31.3 %) | 1.000 |
| Nephrectomy (n) | 0.156 | ||
| Radical | 49 (59.8 %) | 13 (81.3 %) | |
| Partial | 33 (40.2 %) | 3 (18.8 %) | |
| Overall stage(n) | 0.026 | ||
| I | 57 (69.5 %) | 10 (62.5 %) | |
| II | 22 (26.8 %) | 2 (12.5 %) | |
| III | 2 (2.4 %) | 3 (18.8 %) | |
| IV | 1 (1.2 %) | 1 (6.3 %) | |
| TNM(2010AJCC) | |||
| T(n) | 0.026 | ||
| T1 | 57 (69.5 %) | 10 (62.5 %) | |
| T2 | 22 (26.8 %) | 2 (12.5 %) | |
| T3 | 2 (2.4 %) | 3 (18.8 %) | |
| T4 | 1 (1.2 %) | 1 (6.3 %) | |
| N(n) | 0.013 | ||
| N0 | 81 (98.8 %) | 13 (81.3 %) | |
| N1 | 1 (1.2 %) | 3 (18.8 %) | |
| M(n) | |||
| M0 | 82 (100 %) | 16 (100 %) | |
| M1 | 0 (0) | 0 (0) | |
| Tumor grade (n) | 0.011 | ||
| Low | 25 (30.5 %) | 0 (0 %) | |
| Medium | 38 (46.3 %) | 9 (56.3 %) | |
| High | 19 (23.2 %) | 7 (43.8 %) | |
| Follow-up (mo) | 0.464 | ||
| Media(Range) | 33.5 (7–71) | 29 (3–70) |
| Total Score | Vegetables | Fruit | Meat * | Meat Alt. * | Grains | Dairy | |
| Age Groups | |||||||
| Total (n = 93,252) | 34.1 ± 9.7 | 11.5 ± 4.3 | 5.5 ± 2.9 | 3.0 ± 1.6 | 2.6 ± 1.3 | 5.7 ± 2.3 | 4.0 ± 2.1 |
| 16–24 years (n = 37,229) | 32.6 ± 9.7 | 10.6 ± 4.3 | 5.4 ± 2.8 | 2.7 ± 1.6 | 2.5 ± 1.4 | 5.6 ± 2.3 | 3.9 ± 2.1 |
| 25–34 years (n = 26,068) | 33.1 ± 8.9 | 11.5 ± 4.0 | 4.8 ± 2.6 | 2.9 ± 1.6 | 2.6 ± 1.3 | 5.5 ± 2.3 | 3.8 ± 2.0 |
| 35–44 years (n = 12,322) | 34.5 ± 9.1 | 12.3 ± 4.0 | 5.1 ± 2.8 | 3.2 ± 1.6 | 2.7 ± 1.3 | 5.6 ± 2.4 | 3.8 ± 2.0 |
| 45–54 years (n = 9214) | 35.3 ± 8.9 | 12.9 ± 3.8 | 5.4 ± 2.8 | 3.4 ± 1.6 | 2.6 ± 1.3 | 5.4 ± 2.3 | 3.8 ± 2.0 |
| 55–64 years (n = 5840) | 36.5 ± 8.7 | 13.5 ± 3.6 | 5.8 ± 2.7 | 3.5 ± 1.6 | 2.7 ± 1.2 | 5.4 ± 2.2 | 4.0 ± 1.9 |
| 65–74 years (n = 2111) | 37.2 ± 8.5 | 13.7 ± 3.6 | 6.1 ± 2.6 | 3.6 ± 1.6 | 2.7 ± 1.2 | 5.3 ± 2.1 | 4.2 ± 1.9 |
| 75+ years (n = 468) | 35.8 ± 15.3 | 12.1 ± 6.0 | 6.2 ± 3.7 | 3.2 ± 1.8 | 2.9 ± 1.8 | 5.7 ± 3.2 | 4.0 ± 2.3 |
| 16–44 years (n = 75,619) | 33.1 ± 9.4 | 11.2 ± 4.2 | 5.1 ± 2.8 | 2.9 ± 1.6 | 2.6 ± 1.3 | 5.6 ± 2.3 | 3.8 ± 2.1 |
| 45–75 years+ (n = 17,633) | 35.9 ± 9.0 | 13.2 ± 3.8 | 5.6 ± 2.8 | 3.5 ± 1.6 | 2.7 ± 1.3 | 5.4 ± 2.3 | 3.9 ± 2.0 |
| p-value | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
| 16–44 years vs. 45–75+ years | |||||||
| Sex | |||||||
| Females (n = 71,290) | 34.5 ± 9.3 | 11.8 ± 4.2 | 5.7 ± 2.8 | 3.0 ± 1.6 | 2.6 ± 1.3 | 5.7 ± 2.3 | 3.9 ± 2.1 |
| 16–24 years (n = 27,977) | 33.0 ± 9.4 | 10.9 ± 4.2 | 5.5 ± 2.8 | 2.6 ± 1.6 | 2.5 ± 1.4 | 5.6 ± 2.2 | 3.8 ± 2.1 |
| 25–34 years (n = 20,033) | 33.8 ± 8.6 | 11.8 ± 3.9 | 5.0 ± 2.6 | 2.9 ± 1.6 | 2.7 ± 1.3 | 5.6 ± 2.2 | 3.8 ± 2.0 |
| 35–44 years (n = 9516) | 35.1 ± 8.9 | 12.6 ± 3.9 | 5.3 ± 2.7 | 3.2 ± 1.6 | 2.7 ± 1.3 | 5.6 ± 2.3 | 3.9 ± 2.0 |
| 45–54 years (n = 7393) | 35.8 ± 8.9 | 13.2 ± 3.7 | 5.5 ± 2.8 | 3.4 ± 1.6 | 2.7 ± 1.3 | 5.4 ± 2.3 | 3.9 ± 2.0 |
| 55–64 years (n = 4544) | 37.0 ± 8.6 | 13.8 ± 3.5 | 5.8 ± 2.7 | 3.5 ± 1.6 | 2.7 ± 1.2 | 5.4 ± 2.2 | 4.1 ± 2.0 |
| 65–74 years (n = 1556) | 37.9 ± 8.4 | 14.1 ± 3.5 | 6.3 ± 2.5 | 3.7 ± 1.6 | 2.7 ± 1.2 | 5.3 ± 2.1 | 4.3 ± 1.9 |
| 75+ years (n = 271) | 35.1 ± 14.2 | 11.8 ± 5.8 | 6.1 ± 3.5 | 3.1 ± 1.8 | 2.8 ± 1.6 | 5.4 ± 3.2 | 4.1 ± 2.3 |
| Males (n = 21,962) | 33.1 ± 10.6 | 10.7 ± 4.5 | 5.2 ± 3.1 | 3.2 ± 1.6 | 2.5 ± 1.4 | 5.7 ± 2.5 | 4.0 ± 2.1 |
| 16–24 years (n = 9252) | 31.5 ± 10.5 | 9.7 ± 4.5 | 5.0 ± 3.0 | 3.0 ± 1.6 | 2.4 ± 1.4 | 5.6 ± 2.3 | 4.0 ± 2.1 |
| 25–34 years (n = 6035) | 30.7 ± 9.3 | 10.4 ± 4.3 | 4.2 ± 2.7 | 3.0 ± 1.6 | 2.5 ± 1.3 | 5.3 ± 2.3 | 3.5 ± 2.0 |
| 35–44 years (n = 2806) | 32.6 ± 9.4 | 11.4 ± 4.2 | 4.5 ± 2.8 | 3.3 ± 1.6 | 2.6 ± 1.3 | 5.4 ± 2.4 | 3.6 ± 1.9 |
| 45–54 years (n = 1821) | 33.4 ± 9.0 | 11.9 ± 4.1 | 4.9 ± 2.8 | 3.4 ± 1.6 | 2.6 ± 1.3 | 5.4 ± 2.3 | 3.6 ± 2.0 |
| 55–64 years (n = 1296) | 34.7 ± 8.7 | 12.6 ± 4.0 | 5.2 ± 2.7 | 3.5 ± 1.6 | 2.7 ± 1.2 | 5.4 ± 2.2 | 3.7 ± 1.9 |
| 65–74 years (n = 555) | 35.1 ± 8.2 | 12.6 ± 3.6 | 5.7 ± 2.6 | 3.6 ± 1.6 | 2.6 ± 1.2 | 5.3 ± 2.1 | 4.0 ± 2.0 |
| 75+ years (n = 197) | 36.8 ± 16.6 | 12.5 ± 6.2 | 6.3 ± 3.9 | 3.3 ± 1.8 | 3.0 ± 1.9 | 6.0 ± 3.5 | 4.0 ± 2.2 |
| p-value | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
| females vs. males |
| Physician | Chiropractor | Physiotherapist | Total N | |||||||
| Gender | Prevalence (%) | S.E. | Freq. | Prevalence (%) | S.E. | Freq. | Prevalence (%) | S.E. | Freq. | |
| Men | 25.596 | 0.028 | 639613 | 5.86 | 0.02 | 146321 | 5.09 | 0.01 | 127058 | 2498871 |
| Women | 32.260 | 0.030 | 802309 | 6.36 | 0.02 | 158221 | 8.81 | 0.02 | 219067 | 2486999 |
| EAST | CENTRAL1 | CENTRAL 2 | WEST | SOUTH | BGD | MYA | |
| CENTRAL 1 | -0.009 | ||||||
| CENTRAL 2 | 0.071* | 0.175** | |||||
| WEST | -0.004 | 0.013 | 0.074 | ||||
| SOUTH | -0.007 | -0.010 | 0.065* | -0.002 | |||
| BGD | 0.032 | 0.146** | 0.180* | 0.026 | 0.060 | ||
| MYA | 0.024 | 0.063* | 0.267*** | 0.031 | 0.050** | 0.014 | |
| THAI | 0.055*** | 0.043 | 0.351*** | 0.069*** | 0.078*** | 0.071 | 0.002 |
| Characteristic | All patients no. (%) | Marital status | ||||
| Married no. (%) | Widowed no. (%) | Never married no. (%) | Divorced no. (%) | P‐value | ||
| No. of patients | 61077 (100.0) | 40527 (66.4) | 2768 (4.5) | 12889 (21.1) | 4893 (8.0) | |
| Sex | ||||||
| Male | 13388 (21.9) | 9798 (24.1) | 256 (9.2) | 2547 (19.8) | 787 (16.1) | 0.001 |
| Female | 47689 (78.1) | 30729 (75.8) | 2512 (90.8) | 10342 (80.2) | 4106 (83.9) | |
| Age (mean ± SD) | 47.7 ± 14.8 | 48.9 ± 12.9 | 68.3 ± 11.9 | 38.0 ± 15.2 | 51.5 ± 12.1 | |
| <45 | 25975 (42.5) | 15937 (39.3) | 108 (3.9) | 8523 (66.1) | 1407 (28.8) | 0.001b |
| Mean ± SD | 33.8 ± 7.6 | 36.1 ± 5.7 | 38.0 ± 5.4 | 29.0 ± 8.6 | 37.0 ± 5.9 | |
| ≥45 | 35102 (57.5) | 24590 (60.7) | 2660 (96.1) | 4366 (33.9) | 3486 (71.2) | |
| Mean ± SD | 57.9 ± 9.6 | 57.1 ± 9.0 | 69.6 ± 10.4 | 55.5 ± 8.5 | 57.4 ± 8.6 | |
| Race | ||||||
| Black | 3869 (6.3) | 1763 (4.4) | 238 (8.6) | 1383 (10.7) | 485 (9.9) | 0.001 |
| White | 56566 (92.6) | 38351 (94.6) | 2515 (90.9) | 11329 (87.9) | 4371 (89.3) | |
| Othera | 642 (1.0) | 413 (1.0) | 15 (0.5) | 177 (1.4) | 37 (0.8) | |
| Histology type | ||||||
| Papillary | 57427 (94.0) | 38273 (94.4) | 2535 (91.6) | 12042 (93.4) | 4577 (93.5) | 0.001 |
| Follicular | 3650 (6.0) | 2254 (5.6) | 233 (8.4) | 847 (6.6) | 316 (6.5) | |
| T stage | ||||||
| T1/T2 | 47104 (77.1) | 31658 (78.1) | 1969 (71.1) | 9649 (74.9) | 3828 (78.2) | 0.001 |
| T3/T4 | 13973 (22.9) | 8869 (21.9) | 799 (28.9) | 3240 (25.1) | 1065 (21.8) | |
| N stage | ||||||
| N0 | 46913 (76.8) | 31637 (78.1) | 2274 (82.2) | 9021 (70.0) | 3981 (81.4) | 0.001 |
| N1a | 7098 (11.6) | 4536 (11.2) | 223 (8.1) | 1905 (14.8) | 434 (8.9) | |
| N1b | 7066 (11.6) | 4354 (10.7) | 271 (9.8) | 1963 (15.2) | 478 (9.8) | |
| Distant Metastasis | 1602 (2.6) | 937 (2.3) | 122 (4.4) | 428 (3.3) | 115 (2.4) | 0.001 |
| TNM Stage | ||||||
| I | 44537 (72.9) | 29209 (72.1) | 1469 (53.1) | 10540 (81.8) | 3319 (67.8) | 0.001 |
| II | 5088 (8.3) | 3380 (8.3) | 337 (12.2) | 880 (6.8) | 491 (10.0) | |
| III | 6991 (11.4) | 4871 (12.0) | 543 (19.6) | 915 (7.1) | 662 (13.5) | |
| IV | 4461 (7.3) | 3.67 (7.6) | 419 (15.1) | 554 (4.3) | 421 (8.6) | |
| Surgery procedures | ||||||
| Lobe.±Isth. | 8769 (14.4) | 5840 (14.4) | 504 (18.2) | 1698 (13.2) | 727 (14.9) | >0.05 |
| Lobe.±Partial Contra‐lobe. | 457 (0.7) | 305 (0.8) | 29 (1.9) | 79 (0.6) | 44 (0.9) | |
| TT or near TT | 51851 (84.9) | 34382 (84.8) | 2235 (80.7) | 11112 (86.2) | 4122 (82.4) | |
| Adjuvant therapy | ||||||
| None | 28158 (46.1) | 18651 (46.0) | 1468 (53.0) | 5717 (44.4) | 2322 (47.5) | >0.05 |
| Radioisotopes | 30512 (50.0) | 20322 (50.1) | 1167 (42.2) | 6656 (51.6) | 2367 (48.4) | |
| Beam radiation | 2407 (3.9) | 1554 (3.9) | 133 (2.8) | 516 (2.0) | 204 (2.1) |
| Possibilities causing anxiety | Frequency | Percentages | Mean state anxiety score |
| Fear of death | 91 | 82.7 | 56.3 ± 8.2 |
| Fear of unknown | 58 | 52.7 | 57.8 ± 8.9 |
| Financial loss due to hospitalization | 47 | 42.7 | 54.7 ± 8.6 |
| Results of operation | 46 | 41.8 | 55.7 ± 7.9 |
| Needing blood transfusion | 43 | 39.1 | 57.4 ± 9.2 |
| Concern about family | 43 | 39.1 | 56.9 ± 6.9 |
| Postoperative pain | 43 | 39.1 | 55.7 ± 9.2 |
| Change of environment | 41 | 37.3 | 55.2 ± 7.7 |
| Long waiting time for operation | 40 | 36.4 | 54.9 ± 9.0 |
| Unexpected events | 39 | 35.5 | 55.2 ± 9.2 |
| Being patient and coming to hospital | 35 | 31.8 | 51.8 ± 8.9 |
| Dependency | 34 | 30.9 | 55.1 ± 8.7 |
| Fear of physical disability | 33 | 30 | 53.9 ± 8.7 |
| Fear of complications | 31 | 28.2 | 53.3. ± 7.3 |
| Cancellations | 31 | 28.2 | 54.6 ± 9.0 |
| Alteration in body image | 26 | 23.6 | 56.7 ± 7.5 |
| Possible unknown diagnostic results | 24 | 21.8 | 53.2 ± 6.6 |
| Lack of information | 18 | 16.4 | 51.3 ± 8.1 |
| Nil per mouth | 16 | 14.5 | 55.6 ± 1.0 |
| Harm from doctor or nurse mistake | 16 | 14.5 | 57.7 ± 8.8 |
| Terminology and language used | 16 | 14.5 | 53.8 ± 1.2 |
| Sickness and vomiting | 15 | 13.6 | 53.7 ± 8.3 |
| Fear of not knowing what occurs while unconscious during anesthesia | 14 | 12.7 | 52.8 ± 9.2 |
| Concern about fellow patient | 13 | 11.8 | 55.6 ± 9.2 |
| Absence from work | 13 | 11.8 | 55.7 ± 9.8 |
| Inaccurate information | 12 | 10.9 | 55.5 ± 8.9 |
| Short waiting time for operation | 10 | 9.1 | 56.1 ± 7.4 |
| Getting stuck of needle | 9 | 8.2 | 54.3 ± 1.2 |
| Lack of knowledge of ward | 9 | 8.2 | 51.3 ± 8.1 |
| Not awakening from anesthesia | 8 | 7.3 | 55 ± 1.2 |
| Information from previous negative hospital experiences | 8 | 7.3 | 55 ± 1.2 |
| Familiarity with facilities | 7 | 6.4 | 58 ± 7.1 |
| Lack of recognition of staff | 5 | 4.5 | 55.6 ± 6.7 |
| Awareness during surgery | 4 | 3.6 | 63.3 ± 2.5 |
| Autism (20) | Control (20) | P-values | |||
| Age (years) | Mean±s.d. | 11.25±1.58 | 11.26±1.64 | t (38)=−0.02 | 0.97 |
| IQ | Mean±s.d. | 108.25±14.31 | 115.95±10.97 | t (38)=−1.9 | 0.06 |
| Sex | Male:female | 16:4 | 13:7 | χ2(1)=1.12 | 0.28 |
| Handedness | Right:left | 18:2 | 17:3 | χ2(1)=0.22 | 0.63 |
| Genipin concentration (% w/v) | Surface density (mg/mm3) | Degree of cross-link (%) | Contact angle (°) |
| 0 | 1.28 ± 0.04 | — | 54.91 ± 4.29 |
| 0.010 | 1.33 ± 0.06* | 13.84 ± 2.59 | 54.71 ± 9.74 |
| 0.025 | 1.33 ± 0.03* | 18.82 ± 4.00 | 52.06 ± 7.66 |
| 0.050 | 1.36 ± 0.09* | 22.64 ± 1.89† | 53.85 ± 3.29 |
| 0.075 | 1.35 ± 0.07* | 29.75 ± 6.46† | 52.63 ± 3.57 |
| 0.100 | 1.35 ± 0.10* | 38.97 ± 4.51† | 54.04 ± 10.10 |
| Histone H3 Acetyl K9 1 | Histone H3 Tri Methyl K4 2 |
| Blocking solution 3: 5 min | Blocking solution 3: 5 min |
| primary antibody 1: 1:200 in PBS 5, incubation: 16 h, 4 °C | primary antibody 2: 1:500 in PBS 5, incubation: 16 h, 4 °C |
| PostBlock 3: 20 min | PostBlock 3: 20 min |
| HRP Polymer 3: 30 min | HRP Polymer 3: 30 min |
| Chromogen: DAB 4 (0.5 min) | Chromogen: DAB 4 (1 min) |
| Target concentration | Mean measured concentration | |||||
| Net type | Chemical | Units | Mean | Range | Roof | Sides |
| PermaNet 3.0 | Deltamethrin | g/kg | 2.8 (sides) | 2.1 - 3.5 | - | 3.1 |
| g/kg | 4 (roof) | 3.0 - 5.0 | 3.9 | - | ||
| Piperonyl butoxide | g/kg | 25 (roof) | 18.8 - 31.3 | 18.7 | - | |
| PermaNet 2.0 | Deltamethrin | mg/m2 | 55 | 41.3 - 68.8 | 69.4 | 65.6 |
| NetProtect | Deltamethrin | g/kg | 1.8 | 1.4 - 2.3 | 1.6 | 1.6 |
| Interceptor | Alpha-cypermethrin | mg/m2 | 200 | 150.0 - 250.0 | 171.0 | 251.0 |
| Olyset | Permethrin | g/kg | 20 | 17.0 - 23.0 | 21.0 | 21.6 |
| Female | Normal weight (BMI 5th to 85th) | P value | Overweight (BMI over 85th) | P value | P value | ||
| NW | CONW | OW | COOW | ||||
| 604 (72.7%) | 83 (9.6%) | NW versus CONW | 20 (2.5%) | 125 (15.1%) | OW versus COOW | Among groups | |
| Age (years) | 15.4 ± 0.1 | 15.4 ± 0.2 | 0.879 | 15.6 ± 0.4 | 15.3 ± 0.2 | 0.579 | 0.945 |
| Height (cm) | 160.5 ± 0.3 | 158.7 ± 1 | 0.074 | 161.9 ± 0.8 | 160.8 ± 0.5 | 0.227 | 0.082 |
| Weight (kg) | 50.8 ± 0.2 | 54.9 ± 1.0 | <0.0001 | 65.1 ± 1.2 | 68.6 ± 1 | <0.022 | <0.0001 |
| BMI (kg/m2) | 19.7 ± 0.1 | 21.7 ± 0.2 | <0.0001 | 24.8 ± 0.3 | 26.5 ± 0.3 | <0.0001 | <0.0001 |
| WC (cm) | 65.8 ± 0.2 | 75.1 ± 0.6 | <0.0001 | 71.3 ± 0.6 | 81 ± 0.7 | <0.0001 | <0.0001 |
| WHR | 41 ± 0.1 | 47.3 ± 0.2 | <0.0001 | 44.0 ± 3.0 | 50.4 ± 0.4 | <0.0001 | <0.0001 |
| SBP (mmHg) | 101.8 ± 0.5 | 102.1 ± 1.4 | 0.813 | 102.2 ± 2.8 | 105.7 ± 1 | 0.242 | <0.006 |
| DBP (mmHg) | 65.7 ± 0.4 | 64.7 ± 1.2 | 0.374 | 66.6 ± 2 | 66.7 ± 1 | 0.953 | 0.568 |
| Glucose (mg/dL) | 87.5 ± 0.3 | 88 ± 0.7 | 0.401 | 87.5 ± 1.2 | 89.9 ± 0.8 | 0.081 | <0.028 |
| Insulin (μU/mL) | 11.4 (11–11.8) | 12.9 (11.9–13.9) | <0.006 | 14.3 (12.0–17.1) | 16 (14.5–17.7) | 0.272 | <0.0001 |
| HOMA-IR | 2.5 (2.4–2.5) | 2.8 (2.6–3) | <0.006 | 3.1 (2.6–3.7) | 3.5 (3.2–3.9) | 0.201 | <0.0001 |
| TG (mg/dL) | 71.6 (68.7–74.7) | 77.5 (69.5–86.6) | 0.186 | 77.3 (59.2–100.9) | 89 (80.0–99.1) | 0.344 | <0.002 |
| HDL (mg/dL) | 56.4 ± 0.5 | 54.6 ± 1.5 | 0.284 | 50.8 ± 2.1 | 49.4 ± 1.2 | 0.563 | <0.0001 |
| TG/HDL | 1.3 (1.2–1.4) | 1.5 (1.3–1.7) | 0.121 | 1.5 (1.2–2.1) | 1.8 (1.6–2.1) | 0.285 | <0.0001 |
| ALT (U/L) | 10 (9.7–10.3) | 11.5 (10.8–12.3) | <0.001 | 11.8 (9.9–14.1) | 12.9 (11.6–14.3) | 0.392 | <0.0001 |
| AST (U/L) | 16 (15.7–16.3) | 15.6 (14.8–16.5) | 0.458 | 15.6 (13.9–17.5) | 15.8 (15.3–16.4) | 0.839 | 0.861 |
| WBC (109/L) | 5.9 (5.8–6) | 6.1 (5.7–6.6) | 0.260 | 6.3 (5.7–7.0) | 6.7 (6.4–7.0) | 0.351 | <0.0001 |
| EE Estimation Models | Static Activities | Dynamic Activities | Average | ||||
| SI | ST | REST | WK | AS | RU | ||
| (1) Single (IMU) | 1.11 (0.54) | 0.94 (0.37) | 1.74 (0.33) | 1.48 (0.72) | 2.37 (0.81) | 2.63 (0.91) | 1.71 (0.68) |
| (2) Single (IMU + ECG) | 0.98 (0.55) | 0.90 (0.52) | 1.18 (0.56) | 0.98 (0.39) | 1.22 (0.70) | 1.74 (1.22) | 1.17 (0.31) |
| (3) Activity-specific (IMU) | 0.62 (0.40) | 0.48 (0.29) | 1.75 (0.44) | 1.78 (0.41) | 1.92 (0.63) | 2.22 (0.93) | 1.46 (0.73) |
| (4) Activity-specific (IMU + ECG) | 0.44 (0.18) | 0.46 (0.19) | 0.76 (0.26) | 1.05 (0.29) | 1.10 (0.54) | 1.54 (1.16) | 0.89 (0.42) |
| Items | Control (n = 11) | DOX (n = 6)a | PDOX (n = 12) | P value |
| Peripheral blood routine | ||||
| RBC (T/L) | 9.39 (9.17–9.84) | 9.60 (8.73–12.31) | 9.23 (6.65–9.75) | >0.05 |
| WBC (×109/L) | 5.8 (4.6–7.9) | 5.9 (4.2–20) | 6.4 (4.7–7.6) | >0.05 |
| HGB (g/L) | 144 (140–153) | 151.5 (145–189) | 150.5 (121–157) | >0.05 |
| PLT (×109/L) | 1171 (892–1666) | 1291.5 (1197–1492) | 1602.5 (1350–1772)b | <0.05 |
| NEUT (×109/L) | 1.8 (1.1–1.3) | 1.75 (0.7–4.2) | 2.7 (1.6–3.5) | >0.05 |
| LYM (×109/L) | 1.9 (1.1–3.5)c | 1.55 (0.8–6.1) | 1.25 (0.6–1.8) | =0.03 |
| Liver functions | ||||
| AST (U/L) | 148.1 (116.9–237.8) | 136.6 (120.8–241.0) | 123.4 (108.1–182.2) | >0.05 |
| ALT (U/L) | 49.8 (40.3–159.9) | 47.1 (41.0–123.0) | 42.9 (30.4–115.0 | >0.05 |
| Renal functions | ||||
| BUM (mmol/L) | 6.0 (3.6–9.0) | 6.2 (5.4–10.7) | 5.6 (3.3–8.3) | >0.05 |
| CR (mmol/L) | 36.0 (30.0–45.0) | 36.0 (33.0–39.0) | 37.0(31.0–39.0) | >0.05 |
| Cardiac functions | ||||
| CK (U/L) | 1022.1 (592.1–2078.4) | 954.05 (183.7–2485.0) | 1396.9 (593.7–1804.1) | >0.05 |
| CK-MB (U/L) | 530.4 (184.8–912.7) | 579.9 (375.9–868.9) | 708.7 (1475.2–1016.4)c | =0.01 |
| LDH (U/L) | 1600 (914.6–2323.8) | 1659.7 (1031.4–2027.2) | 1835.3 (1448.3–2250.1) | >0.05 |
| Blood products within the first 24 h | Median [IQR] |
| Red Blood Cells (Unit) | 14 [11–19] |
| Fresh Frozen Plasma (Unit) | 12 [8–16] |
| Platelet (Unit) | 2 [1–3] |
| Fibrinogen concentrate (gr) | 4.5 [3–7.5] |
| Emergency procedures | N (%) |
| Surgery for bleeding | 206 (64) |
| Embolization | 83 (26) |
| Assaulted | Not assaulted | P | |
| STAI | 101 (89-109) | 77 (69-98) | < 0,001 |
| Anxiety trait | 48 (41-55) | 40 (38-43) | 0,01 |
| Anxiety state | 51 (46-59) | 39 (34-46) | < 0,001 |
| n = 105 | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) |
| MMSE ≤ 26 | 64.10 | 79.59 | 71.42 | 73.58 |
| CVLT-LDTR ≤ 4 | 72.91 | 70.31 | 64.81 | 77.58 |
| MMSE ≤ 26 and/or CVLT-LDTR ≤ 4 | 94.80 | 63.26 | 67.27 | 93.93 |
| MMSE ≤ 26 and CVLT-LDTR ≤ 4 | 43.58 | 91.83 | 80.95 | 67.16 |
| Parity | Pigs | Rabbits | ||
| Litter size | Average BW | Litter size | Average BW | |
| 1 | 0.21 | 0.29 | 0.09 | 0.23 |
| 2 | 0.25 | 0.33 | 0.19 | 0.26 |
| 3 | 0.24 | 0.35 | 0.27 | 0.32 |
| 4 | 0.22 | 0.33 | 0.29 | 0.37 |
| 5 | 0.19 | 0.30 | 0.24 | 0.39 |
| Characteristic | Case 1 | Case 2 | Case 3 | Case 4 | Case 5 | Case 6 | Case 7 | Case 8 | Case 9 |
| Sex | Male | Female | Female | Female | Female | Female | Female | Male | Female |
| Age (years) | 41 | 44 | 36 | 45 | 43 | 51 | 49 | 31 | 37 |
| Medical history | |||||||||
| Palpitations/headaches/sweating/hypertension | Yes | Yes | Yes | Yes | |||||
| Other | Type 1 neurofibromatosis | Takotsubo | |||||||
| Blood pressure at admission (mmHg) | 160/120 | 180/108 | 157/107 | 130/110 | 140/100 | 130/85 | 141/107 | 160/100 | 129/99 |
| Pre-ECMO LVEF (%) | 5 | 20 | 15 | 20 | 30 | 20 | 20 | 30 | 20 |
| Maximum troponin I (ng/L) | 2200 | 34,000 | 43,000 | 15,000 | 2000 | 18,000 | 237 | 4994 | 2083 |
| NT pro-BNP at admission (ng/L) | 18,363 | 25,282 | 6363 | 18,471 | 9264 | ||||
| ECMO duration (days) | 4 | 1 | 6 | 7 | 3 | 3 | 2 | 7 | 4 |
| Urinary metanephrine (N < 340 μg/24 h) | ND | ND | ND | ND | 1894 | 7192 | 8738 | 2862 | 2582 |
| Urinary normetanephrine (N < 440 μg/24 h) | ND | ND | ND | ND | 4973 | 3650 | 11,910 | 11,268 | 9254 |
| Pheochromocytoma size (mm), side | 78 × 75 × 70, right | 60 mm, left | ND, autopsy | 29, left | 70, left | 103 × 95 × 75, right | 57 × 47, right | 59 × 38, left | 88 × 74×91, left |
| n | Days with absence from worka | Days with partial absence from workb | Total days affectedc | Percent absence from workd | Excess percent absence from work | FTE* | |
| Mild/No Psychological Distress | 2,463 | 0.6 (0.05) | 1.6 (0.14) | 1.4 (0.11) | 5.0% | Reference | -- |
| Moderate Psychological Distress | 414 | 1.1 (0.10) | 2.4 (0.32) | 2.2 (0.25) | 7.9% | 2.9% | 18 |
| Severe Psychological Distress | 226 | 2.1 (0.26) | 3.1 (0.43) | 3.6 (0.36) | 12.8% | 7.8% | 23 |
| Total Excess Absence from Work (FTE) | 41 |
| MIGS ID | Property | Term | Evidence codea |
| Domain Bacteria | TAS [5] | ||
| Phylum Cyanobacteria | TAS [6-8] | ||
| Class Cyanobacteria | TAS [8,9] | ||
| Current classification | Order Unknown | ||
| Family 1.1 | TAS [7] | ||
| Genus Rubidibacter | TAS [1] | ||
| Species Rubidibacter lacunae | TAS [1] | ||
| Type strain KORDI 51-2 | TAS [1] | ||
| Gram stain | Not reported | ||
| Cell shape | Rods | TAS [1] | |
| Motility | None | TAS [1] | |
| Sporulation | None | IDA | |
| Temperature range | 25-35oC | TAS [1] | |
| Optimum temperature | 30oC | TAS [1] | |
| MIGS-6 | Habitat | Seawater | TAS [1] |
| MIGS-6.3 | Salinity | 2-7% (optimum: 5) | TAS [1] |
| MIGS-22 | OxygenCarbon sourceEnergy source | AerobicAutotrophPhototroph | TAS [1]TAS [1]TAS [1] |
| MIGS-15 | Biotic relationship | Free living | TAS [1] |
| MIGS-14 | Pathogenicity | None | NAS |
| MIGS-4 | Geographic location | Chuuk state, Micronesia | TAS [1] |
| MIGS-5 | Sample collection time | July, 2004 | IDA |
| MIGS-4.1 | Latitude | 7o 13’ N | IDA |
| MIGS-4.2 | Longitude | 151o 58’ E | IDA |
| MIGS-4.3 | Depth | 40 m | IDA |
| MIGS-4.4 | Altitude | Not applicable | NAS |
| Model 1:Demographics | Model 2:ACGs & Demographics | Model 3:ADGs, Sel. EDCs & Demographics | Model 4:2002 Expenditures & Demographics | Model 5:ADGs, Sel. EDCs, 2002 Expenditures & Demographics | |
| 2003 Top 0.5% Predicted User | |||||
| Demographics | 0.49%* | 0.10% | 0.03% | 0.03% | 0.02% |
| ACGs & Demographics | 0.50% | 0.07% | 0.08% | 0.06% | |
| ADGs, 19 EDCs & Demographics | 0.50% | 0.19% | 0.29% | ||
| 2002 Expenditures & Demographics | 0.50% | 0.36% | |||
| ADGs, 19 EDCs, 2002 Expenditures & Demographics | 0.50% | ||||
| 2003 Top 1% Predicted User | |||||
| Demographics | 1.00% | 0.21% | 0.11% | 0.15% | 0.11% |
| ACGs & Demographics | 1.00% | 0.30% | 0.30% | 0.32% | |
| ADGs, 19 EDCs & Demographics | 1.00% | 0.40% | 0.65% | ||
| 2002 Expenditures & Demographics | 1.00% | 0.69% | |||
| ADGs, 19 EDCs, 2002 Expenditures & Demographics | 1.00% | ||||
| 2003 Top 5% Predicted User | |||||
| Demographics | 4.96%* | 2.43% | 2.09% | 2.46% | 2.01% |
| ACGs & Demographics | 5.00% | 3.43% | 3.02% | 3.21% | |
| ADGs, 19 EDCs & Demographics | 5.00% | 3.09% | 4.06% | ||
| 2002 Expenditures & Demographics | 5.00% | 3.73% | |||
| ADGs, 19 EDCs, 2002 Expenditures & Demographics | 5.00% |
| Patient’s results | Reference range | |
| Immunoglobulin levels | ||
| IgM, serum (mg/dL) | 30 | 41–164 |
| IgA, serum (mg/dL) | 68 | 14–122 |
| IgE, total (IU/mL) | 10 | < 60 |
| IgG, serum (mg/dL) | 868 | 331–1164 |
| Lymphocyte subset panel | ||
| CD4+ lymphocyte (%) | 43.3 | 23–48 |
| CD4+ lymphocyte count (/μL) | 1115.74 | 500–2400 |
| CD8+ lymphocyte (%) | 30.06 | 14–33 |
| CD8+ lymphocyte count (/μL) | 788.49 | 300–1600 |
| CD 56+ cell (%) | 12 | 4–23 |
| Characteristics | Study patients | P-value | |
| Case (preterm labour) | Control (term labour) | ||
| N (%) | N (%) | ||
| Age | |||
| 16–20 | 7 (7.0) | 13 (13.0) | 0.098 |
| 21–25 | 15 (15.0) | 17 (17.0) | |
| 26–30 | 33 (33.0) | 30 (30.0) | |
| 31–35 | 27 (27.0) | 25 (25.0) | |
| 36–40 | 18 (18.0) | 15 (15.0) | |
| Mean ± SD (years) | 29.75 ± 5.24 | 28.63 ± 5.92 | |
| Age range = 16–39 years | |||
| Parity | |||
| Primigravidae | 17 (17.0) | 22 (22.0) | 0.534 |
| Multigravidae | 83 (83.0) | 78 (78.0) | |
| Marital status | |||
| Single | 20 (20.0) | 19 (19.0) | 0.064 |
| Married | 80 (80.0) | 81 (81.0) | |
| Tribe | |||
| Hausa | 13 (13.0) | 10 (10.0) | 0.830 |
| Ibo | 25 (25.0) | 23 (23.0) | |
| Yoruba | 47 (47.0) | 51 (51.0) | |
| Others | 15 (15.0) | 16 (16.0) | |
| Religion | |||
| Christianity | 62 (62.0) | 53 (53.0) | 0.106 |
| Islam | 33 (33.0) | 46 (46.0) | |
| Others | 5 (5.0) | 1 (1.0) | |
| Social class | |||
| Upper | 17 (17.0) | 14 (14.0) | 0.139 |
| Middle | 50 (50.0) | 57 (57.0) | |
| Lower | 33 (33.0) | 29 (29.0) | |
| Total | 100 (100.0) | 100 (100.0) |
| Times until treatment | With complications | Without complications | Total |
| <24 hours | 6 | 9 | 15 |
| 1-2 days | 5 | 3 | 8 |
| 3–7 days | 3 | 5 | 8 |
| 8–14 days | 2 | 0 | 2 |
| >15 days | 5 | 2 | 7 |
| Total | 21 | 19 | 40 |
| Technical Characteristic | Value |
| Measurement range | 30 m (indoors)/15 m (outdoors) |
| Measurement speed | 43,200 points/second |
| Accuracy in the 3D representation | ±0.1% |
| Field of view | 270° (H) × 360° (V-in rotation) |
| Weight of head scanner | 1.0 kg |
| Estimated vs actual Y | |||||||
| Missing | 15 % | 30 % | |||||
| Framework | Method | Bias | Var | MSE | Bias | Var | MSE |
| Plain | 1NN | 0.16957 | 0.00072 | 0.02947 | 0.30959 | 0.00114 | 0.09698 |
| kNN | 0.10961 | 0.00035 | 0.01236 | 0.21987 | 0.00068 | 0.04902 | |
| wkNN | 0.10947 | 0.00035 | 0.01233 | 0.21958 | 0.00068 | 0.04890 | |
| RReliefF10 | 1NN | 0.15170 | 0.00075 | 0.02377 | 0.29608 | 0.00163 | 0.08928 |
| kNN | 0.10036 | 0.00042 | 0.01049 | 0.20963 | 0.00104 | 0.04498 | |
| wkNN | 0.10023 | 0.00041 | 0.01046 | 0.20947 | 0.00104 | 0.04492 | |
| RReliefF20 | 1NN | 0.15246 | 0.00063 | 0.02387 | 0.29331 | 0.00136 | 0.08738 |
| kNN | 0.09850 | 0.00035 | 0.01005 | 0.20607 | 0.00087 | 0.04333 | |
| wkNN | 0.09839 | 0.00035 | 0.01002 | 0.20580 | 0.00087 | 0.04322 | |
| RReliefF30 | 1NN | 0.15202 | 0.00068 | 0.02379 | 0.29081 | 0.00122 | 0.08579 |
| kNN | 0.09893 | 0.00033 | 0.01012 | 0.20508 | 0.00079 | 0.04285 | |
| wkNN | 0.09877 | 0.00033 | 0.01008 | 0.20474 | 0.00079 | 0.04271 | |
| Bagging | 1NN | 0.10287 | 0.00030 | 0.01088 | 0.20756 | 0.00063 | 0.04370 |
| kNN | 0.10608 | 0.00030 | 0.01156 | 0.21240 | 0.00061 | 0.04572 | |
| wkNN | 0.10544 | 0.00030 | 0.01142 | 0.21078 | 0.00061 | 0.04503 | |
| Random | 1NN | 0.10629 | 0.00030 | 0.01160 | 0.20738 | 0.00059 | 0.04359 |
| kNN | 0.10626 | 0.00030 | 0.01159 | 0.20638 | 0.00058 | 0.04317 | |
| wkNN | 0.10622 | 0.00030 | 0.01158 | 0.20631 | 0.00058 | 0.04314 | |
| Bagging + Random | 1NN | 0.11010 | 0.00031 | 0.01243 | 0.21258 | 0.00060 | 0.04579 |
| kNN | 0.11101 | 0.00032 | 0.01264 | 0.21422 | 0.00060 | 0.04649 | |
| wkNN | 0.11083 | 0.00032 | 0.01260 | 0.21386 | 0.00060 | 0.04633 | |
| Mean Imputation | 0.11857 | 0.00035 | 0.01441 | 0.22512 | 0.00063 | 0.05130 |
| Experimental group | Control group | Risk Ratio | p-value | |
| (95% CI) | ||||
| n = 500 | n = 502 | |||
| n (%) | n (%) | |||
| Episiotomies 95/950 (10.0%)* | 43 (9.0) | 52 (11.0) | 0.89 (0.71-1.13) | 0. 301 |
| Perineal lacerations (caesarean sections excluded) | ||||
| 1 degree 643/950 | 347 (69.4) | 339 (67.5) | 1.17 (0.85-1.62) | 0. 304 |
| 2 degree 160/950 | 85 (17.0) | 75 (14.9) | 1.23 (0.87-1.74) | 0. 214 |
| 3 degree 53/950 | 23 (4.6) | 30 (6.0) | 1.00 (0.65-1.56) | 0. 978 |
| No laceration 56/950 | 22 (4.6) | 29 (6.1) | 1.0 Ref. | |
| Oedema (caesarean sections excluded) | ||||
| VAS 0-3 | 300 (82.1) | 303 (85.8) | 1.0 Ref. | |
| VAS 4-7 | 56 (15.4) | 44 (12.5) | 1.13 (0.93-1.36) | 0. 247 |
| VAS 8-10 | 9 (2.5) | 6 (1.7) | 1.21 (0.79-1.83) | 0. 433 |
| mAb | Specificity/Reference | WT | vti13 | prp3 | prp3/vti13 | csld2 | csld3-2 | xxt1 | xxt2 | xxt5 |
| PECTINS | ||||||||||
| JIM7 | High DE HG[31] | - | - | - | - | - | NA | - | - | - |
| LM19 | Low DE HG[23] | ++ | ++ | + | ++ | - | NA | + | + | + |
| LM5 | (1–4)-galactan[32] | - | - | - | - | - | NA | - | - | - |
| LM6 | (1–5)-arabinan[33] | - | - | - | - | - | NA | - | - | - |
| INRA-RU1 | Rhamnogalacturonan-I[34] | - | - | - | - | - | NA | - | - | - |
| XYLOGLUCAN | ||||||||||
| LM15 | xylosylated XyG[29] | ++ | - | ++ | ++ | + | NA | - | - | - |
| LM25 | galactosylated XyG epitope[20] | ++ | - | + | ++ | + | NA | - | - | - |
| MANNAN | ||||||||||
| BS-400-4 | ß(1–4)-mannan/galacto-ß(1–4)-mannan[35] | - | - | - | - | - | NA | - | - | - |
| XYLAN | ||||||||||
| LM10 | (1–4)-xylan[36] | ++ | - | ++ | ++ | ++ | NA | - | ++ | ++ |
| LM11 | ß(1–4)-xylan/arabinoxylan[36] | + | - | + | + | - | NA | - | - | - |
| AGP | ||||||||||
| LM2 | AGP[37] | - | - | - | - | - | NA | - | - | - |
| JIM13 | AGP[38] | + | + | + | + | + | NA | + | + | + |
| JIM8 | AGP[39] | + | + | + | + | + | NA | + | + | - |
| EXTENSIN | ||||||||||
| LM1 | Extensin[40] | ++ | ++ | + | ++ | + | NA | + | + | + |
| JIM20 | Extensin[41] | + | + | + | + | + | NA | + | + | + |
| Ratio | Pb | Cd | Cu | Fe | Mn | Cr | Ni | Zn | Hg |
| hair/vegetables | 104.2 | 2.3 | 13.7 | 2.6 | 0.7 | 1.9 | 1.7 | 47.3 | 201.3 |
| hair/rice | 229.7 | 1.1 | 1.9 | 2.3 | 0.3 | 1.4 | 1.2 | 17.9 | 138.6 |
| hair/soil | 0.148 | 0.533 | 0.217 | 0.001 | 0.004 | 0.001 | 0.006 | 1.865 | 4.033 |
| hair/irrigation | 3636 | 1655 | 1856 | 114 | 23 | 66 | 60 | 5203 | 5717 |
| Migraine | Tension-type headache | pMOH | ||||
| OR | P | OR | P | OR | P | |
| Habitation | ||||||
| Rural | reference | reference | reference | |||
| Urban | 1.1 [0.77-1.6] | 1.1 [0.77-1.6] | 8.6 [3.2-23.6] | 0.0001 | ||
| Education | ||||||
| None/primary | reference | reference | reference | |||
| Secondary | 1.4 [0.95-2.0] | 0.46 [0.34-0.64] | <0.0001 | 0.59 [0.38-0.90] | 0.0147 | |
| College or university | 2.1 [1.4-3.2] | 0.0004 | 0.22 [0.14-0.37] | <0.0001 | 1.1 [0.71-1.8] | |
| Employment | ||||||
| None | reference | reference | reference | |||
| Unskilled | 1.2 [0.84-1.7] | 1.5 [1.1-2.1] | 0.0149 | 1.6 [1.1-2.6] | 0.0232 | |
| Skilled | 1.1 [0.83-1.6] | 1.6 [1.2-2.2] | 0.0010 | 1.5 [1.03-2.3] | 0.0343 | |
| Professional | 2.1 [1.4-3.2] | 0.0005 | 0.46 [0.26-0.82] | 0.0080 | 1.5 [0.91-2.7] | |
| Income per month (USD) | ||||||
| ≤40 | reference | reference | reference | |||
| >40 | 1.3 [0.88-1.8] | 1.3 [0.93-1.9] | 6.0 [2.8-13.1] | <0.0001 |
| Variable | Students (n = 22) | Academics (n = 10) | Alumni (n = 74) | |||
| M | SD | M | SD | M | SD | |
| MAKSS Awareness | 2.53 | 4.39 | 2.58 | 3.27 | 2.62 | 4.06 |
| MAKSS Knowledge | 2.44 | 5.11 | 2.36 | 6.23 | 2.57 | 5.54 |
| MAKSS Skills | 2.58 | 6.82 | 2.40 | 6.06 | 2.70 | 7.20 |
| MCSDS Social Desirability | 0.46 | 2.62 | 0.56 | 3.23 | 0.52 | 3.10 |
| 30-day Mortality | 30-day to 5year Mortality | |||||
| HR | 95% CI | p Value | HR | 95% CI | p Value | |
| Model 1 | ||||||
| Aging | 1.069 | 1.018–1.123 | .007 | 1.058 | 1.036–1.080 | <.001 |
| Women | 1.082 | 0.456–2.571 | .858 | 0.831 | 0.542–1.275 | .396 |
| LVEF <40% | 1.301 | 0.351–4.823 | .694 | 1.007 | 0.509–1.994 | .984 |
| Stroke history | 3.868 | 1.411–10.597 | .009 | 1.601 | 1.049–2.445 | .029 |
| Malignant arrhythmias/cardiac syncope/cardiogenic shock attack | 26.110 | 4.477–91.187 | <.001 | 1.548 | 0.533–4.498 | .422 |
| STEMI | 1.209 | 0.457–3.202 | .702 | 1.328 | 0.893–1.975 | .162 |
| Hyperuricemia | 5.849 | 2.171–15.761 | <.001 | 1.372 | 0.856–2.199 | .188 |
| Albumin level | 0.913 | 0.834–0.999 | .048 | 0.923 | 0.877–0.973 | .003 |
| FBG at admission | 0.983 | 0.894–1.081 | .720 | 1.003 | 0.948–1.062 | .906 |
| SBP at admission | 1.008 | 0.989–1.026 | .410 | 1.004 | 0.997–1.011 | .278 |
| Admission eGFR <60 mL/min/1.73 m2 | 0.633 | 0.242–1.657 | .352 | 1.087 | 0.684–1.726 | .724 |
| KDIGO classification | ||||||
| Absence of AKI | 1.000 | – | – | 1.000 | – | – |
| Stage 1 | 3.344 | 1.186–9.433 | .023 | 1.076 | 0.680 –1.701 | .755 |
| Stage 2 | 6.320 | 2.206–23.305 | <.001 | 1.705 | 0.798–3.643 | .168 |
| Stage 3 | 7.922 | 2.321–35.252 | <.001 | 3.593 | 1.305–9.892 | .013 |
| Aspirin therapy | 0.300 | 0.100–0.897 | .031 | 0.472 | 0.185–1.203 | .116 |
| β-Blocker therapy | 0.133 | 0.047–0.375 | <.001 | 0.644 | 0.434–0.955 | .028 |
| ACEI/ARB therapy | – | – | – | 0.855 | 0.525–1.392 | .530 |
| PCI | 1.714 | 0.474–6.203 | .412 | 0.282 | 0.144–0.555 | <.001 |
| CABG | 10.010 | 0.996–42.021 | .052 | 0.773 | 0.182–3.290 | .728 |
| Model 2 | ||||||
| Aging | 1.067 | 1.018–1.118 | .007 | 1.055 | 1.034–1.078 | <.001 |
| Women | 1.020 | 0.436–2.398 | .965 | 0.857 | 0.560–1.131 | .477 |
| LVEF <40% | 1.083 | 0.325–3.611 | .897 | 1.029 | 0.527–2.011 | .933 |
| Stroke history | 4.157 | 1.538–11.238 | .005 | 1.610 | 1.054–2.460 | .028 |
| Malignant arrhythmias/cardiac syncope/cardiogenic shock attack | 23.478 | 7.259–75.937 | <.001 | 1.527 | 0.523–4.456 | .438 |
| STEMI | 1.067 | 0.415–2.744 | .893 | 1.356 | 0.910–2.021 | .135 |
| Hyperuricemia | 5.301 | 2.059–13.647 | <.001 | 1.541 | 0.980–2.421 | .061 |
| Albumin level | 0.909 | 0.828–0.998 | .045 | 0.929 | 0882 –0.978 | .005 |
| FBG at admission | 0.974 | 0.888–1.068 | .570 | 1.015 | 0.963–1.070 | .577 |
| SBP at admission | 1.010 | 0.992–1.028 | .268 | 1.003 | 0.995–1.010 | .495 |
| Admission eGFR ≥60 mL/min/1.73 m2 without AKI | 1.000 | – | – | 1.000 | – | – |
| Admission eGFR <60 mL/min/1.73 m2 without AKI | 0.519 | 0.102–3.022 | .721 | 1.505 | 0.910–2.421 | .113 |
| Admission eGFR ≥60 mL/min/1.73 m2 with AKI | 4.352 | 1.521–15.302 | .035 | 1.682 | 1.123–2.657 | .018 |
| Admission eGFR <60 mL/min/1.73 m2 with AKI | 6.353 | 1.699–26.102 | .001 | 1.870 | 1.144–3.113 | .040 |
| Aspirin therapy | 0.323 | 0.113–0.922 | .035 | 0.485 | 0.191–1.231 | .128 |
| β-Blocker therapy | 0.137 | 0.048–0.387 | <.001 | 0.648 | 0.439–0.958 | .030 |
| ACEI/ARB therapy | – | – | – | 0.825 | 0.508–1.340 | .435 |
| PCI | 1.636 | 0.455–5.890 | .451 | 0.282 | 0.143–0.554 | <.001 |
| CABG | 11.878 | 0.533–43.569 | .058 | 0.902 | 0.216 –3.772 | .888 |
| NS-TOPSAR | Sentinel-1 | Airborne | ||
| IW Mode | EW Mode | TOPSAR in [24] | ||
| Carrier frequency (GHz) | 9 | 5.405 | 5.405 | 9.65 |
| Altitude (km) | 25 | 693 | 693 | 5 |
| Resolution | 4.5 × 4.5 | 5 × 20 | 20 × 40 | 2 × 1 |
| (range × azimuth, m) | ||||
| Swathwidth (km) | 100 | 250 | 400 | 20 |
| Revisit time | several hours | 6 days | 6 days | within one hour |
| Endurance | up to a few years | tens of years | tens of years | up to a few days |
| Variable | Univariate analysis | Multivariate analysis | ||
| OR (95% CI) | P value | OR (95% CI) | P value | |
| Age | – | 0.0875 | – | 0.809 |
| Gender (Female sex) | 1.11 (0.33–3.74) | 0.869 | – | – |
| Hypertension | 1.34 (0.38–4.67) | 0.647 | – | – |
| BAV | 0.84 (0.18–3.87) | 0.882 | – | – |
| PDA | 0.93 (0.26–3.32) | 0.912 | – | – |
| VSD | 0.36 (0.10–1.25) | 0.107 | – | – |
| AR | 2.90 (0.32–26.33) | 0.343 | – | – |
| AS | – | 0.990 | – | – |
| Collateral circulation | 4.11 (1.00–16.84) | 0.050 | 8.35 (0.85–82.11) | 0.069 |
| Severity of CoA(severe) | 4.93 (1.33–18.31) | 0.017 | 7.46 (1.19–46.76) | 0.032 |
| Variable | No. of patients (%) |
| Age, years (mean ± SD) | 64.7 ± 13.7 |
| Gender, male | 24 (77.4) |
| Current/ex-smoker | 15 (48.4) |
| Underlying disease | 30 (96.8) |
| DM | 18 (58.1) |
| Chronic lung disease | 12 (38.7) |
| COPD/asthma | 8 (25.8) |
| Old TB | 2 (6.5) |
| Bronchiectasis | 2 (6.5) |
| Solid organ cancer | 4 (12.9) |
| Hematologic disease | 4 (12.9) |
| Liver cirrhosis | 3 (9.7) |
| Systemic steroids before diagnosis | 17 (54.8) |
| Duration of steroids before ICU admission, day, median (IQR) | 49 (14–90) |
| Daily dosage of steroids, mg, median (IQR) | 50 (29–71) |
| Inhaled corticosteroids before diagnosis | 3 (9.7) |
| H1N1 infection before diagnosis | 3 (9.7) |
| Male ID | Approximate time between death and necropsy (hours) | Whole RNA concentration (ng/μl) | |||||
| Testis | Heart | Spleen | Intestine | Kidney | Lung | ||
| Agaz0820 | 1 | 900 | 160 | 1467 | 105 | 550 | 500 |
| Agaz0821 | 13 | 1888 | 180 | 1100 | 650 | 667 | 160 |
| Agaz1001 | 18 | 578 | 90 | 200 | 34 | 4 | 180 |
| Agaz1006 | 7 | 432 | 160 | 200 | 115 | 175 | 381 |
| Agaz1007 | 8 | 500 | 135 | 389 | 160 | 514 | 160 |
| Agaz1008 | 8 | 1000 | 75 | 375 | 165 | 446 | 85 |
| Agaz1009 | 20 | 938 | 115 | 160 | 200 | 408 | 338 |
| Agaz1010 | 20 | 737 | 120 | 563 | 596 | 534 | 89 |
| Agaz1011 | 30 | – | 64 | 737 | 333 | 175 | 115 |
| Predictor | ANCS <42 points | ANCS ≥42 points | Crude RR (95% CI) | Adjusted RR (95% CI)a |
| Group - ITT | ||||
| Control PCHUs | 75 (17.0%) | 365 (83.0%) | 1 | 1 |
| Intervention PCHUs | 91 (11.8%) | 679 (88.2%) | 1.05 (1.01–1.10) | 1.05 (1.00–1.09) |
| Socioeconomic class | ||||
| Upper/Upper Middle | 13 (11.3%) | 102 (88.7%) | 1 | 1 |
| Middle | 58 (10.0%) | 523 (90.0%) | 0.95 (0.89–1.02) | 1.10 (0.97–1.25) |
| Lower | 46 (16.3%) | 236 (83.7%) | 1.01 (0.95–1.08) | 0.95 (0.88–1.01) |
| Illicit Drug use | ||||
| Yes | 8 (25.8%) | 23 (74.2%) | 1 | 1 |
| No | 133 (12.4%) | 935 (87.6%) | 1.14 (1.01–1.29) | 1.01 (0.95–1.08) |
| Codon position (HXB2 gp41) | Selection analysis method | Detected elsewherea | ||
| SLAC | FEL | IFEL | ||
| 24 | B, D | B, D | T, C | |
| 54 | B, F, CRF 02_AG | CRF 01_AE | ||
| 96 | C, D | C, A, D | C, B, D, CRF 01_AE | T |
| 101 | B, G | B, G | B, G | |
| 130 | B | C, A, B | C, B | T |
| 137 | A, B | A, B, G | B | T |
| 163 | C, D, CRF 02_AG | C | C, D, CRF 02_AG | C |
| 165 | D, G | C, A, G | ||
| 172 | C, B, G, CRF 02 _AG | |||
| 210 | C, A, CRF 01_AE | C, A, B, D, F, G | C, D, CRF 01_AE | |
| 214b | A | A, B | A, B | |
| 221 | G, CRF 01_AE | C, A, G, CRF 01_AE, CRF 02_AG | C, D, G, CRF 01_AE | |
| 230 | A, D | A, G, CRF 01_AE | ||
| 271 | C, CRF 01_AE | C, B, D | ||
| 328 | C, B, G | C, B, G | C, B, G | |
| 332 | A, B, G | A, B, G | B, D, G, CRF 01_AE | C |
| 349 | C, F, CRF 01_AE, CRF 02_AG | CRF 02_AG | C |
| Study population | Time (number) of survey | Survey population | No. examined (%) | Mean age years | No. positive (%) | GMI* for all examined | |
| Community surveys | Kirare | Nov-11 (8) | 178 | 120 (67.4) | 10.1 | 33 (27.5) | 0.3384 |
| Kiomoni | Nov-11 (8) | 145 | 107 (73.8) | 9.9 | 24 (22.4) | 0.2776 | |
| Kisimatui | Nov-11 (8) | 180 | 129 (71.7) | 9.4 | 25 (19.4) | 0.2468 | |
| All 3 communities combined | Nov-11 (8) | 503 | 356 (70.8) | 9.8 | 82 (23.0) | 0.2865 | |
| School surveys | All 4 schools combined | Nov-10 (7) | 453 | 362 (79.9) | 7.4 | 61 (16.9)# | 0.2776§ |
| Dec-11 (8) | 382 | 334 (87.3) | 7.2 | 38 (11.4)# | 0.2153§ |
| Strain | Selected on: | Resistant to: |
| KWAG-base | No selection | - |
| KWAG-perm | Permethrin (0.75%) | Permethrin |
| MBN-base | No selection | DDT (low-level) |
| MBN-DDT | DDT (4%) | DDT, deltamethrin and permethrin (cross-resistance) |
| Adult patients | Elderly patients | P-value | |
| Healthy donors, number | 14 | 16 | |
| Age, y, mean ± SD | 24.0 ± 8.1 | 78.4 ± 8.2 | <0.001 |
| Male, n (%) | 11 (79) | 11 (69) | 0.45 |
| Comorbidity, n (%) | 0 (0) | 5 (31) | 0.30 |
| Severe sepsis, number of patients | 15 | 40 | |
| Age, y, mean ± SD | 34.8 ± 11.9 | 77.6 ± 7.1 | <0.001 |
| Male, n (%) | 12 (80) | 28 (70) | 0.45 |
| Septic shock, n (%) | 5 (33) | 18 (45) | 0.43 |
| Ventilator rate, n (%) | 11 (73) | 31 (78) | 0.75 |
| APACHE II score, mean ± SD | 19.2 ± 6.9 | 22.5 ± 6.9 | 0.14 |
| APACHE II-age score, mean ± SD | 19.0 ± 5.0 | 15.8 ± 7.6 | 0.08 |
| SAPS II score, mean ± SD | 46.6 ± 17.5 | 58.6 ± 16.1 | 0.10 |
| SAPS II-age score, mean ± SD | 43.3 ± 9.6 | 42.7 ± 11.6 | 0.17 |
| SOFA score, mean ± SD | 7.4 ± 4.6 | 7.3 ± 4.1 | 0.87 |
| Comorbidity, n (%) | 4 (27) | 31 (78) | 0.01 |
| Types of bacteria detected in first 72 h, n (%) | |||
| Gram-positive bacteria | 8 (53) | 22 (55) | 0.91 |
| Gram-negative bacteria | 15 (100) | 40 (100) | 1.00 |
| Fungi | 6 (40) | 17 (43) | 0.87 |
| Treatment, n (%) | |||
| Adjunctive hydrocortisone, n (%) | 1 (7) | 2 (5) | 0.81 |
| Organ support types | |||
| Ventilator, n (%) | 12 (80) | 35 (86) | 0.48 |
| Hemofiltration, n (%) | 3 (20) | 10 (25) | 0.70 |
| Organ support duration | |||
| Ventilator, d, mean ± SD | 11.6 ± 12.3 | 9.3 ± 16.1 | 0.68 |
| Hemofiltration, d, mean ± SD | 7.3 ± 6.6 | 9.9 ± 12.8 | 0.26 |
| ICU stay, d, mean ± SD | 21.9 ± 22.6 | 16.6 ± 16.1 | 0.57 |
| ICU-free days in 28 days, d, mean ± SD | 11.6 ± 9.6 | 10.9 ± 11.6 | 0.64 |
| Hospital stay, d, mean ± SD | 36.3 ± 35.9 | 39.6 ± 41.9 | 0.41 |
| Haematological parameter | Control (n=10) | Buffaloes suffering from FUO (n=30) |
| Hb (g/dL) | 12.64±0.40 | 10.25±0.64* |
| TLC (103/μL) | 8.33±0.34 | 10.57±0.94 |
| Neutrophils (%) | 39.50±1.31 | 54.63±5.48* |
| Lymphocytes (%) | 57.00±0.95 | 40.33±5.60* |
| Monocytes (%) | 2.30±0.45 | 3.53±0.93 |
| Eosinophils (%) | 1.20±0.35 | 1.5±0.61 |
| Basophils (%) | - | - |
| PCV (%) | 36.90±1.21 | 30.08±1.31* |
| TEC (106/μL) | 5.84±0.13 | 5.15±0.26 |
| MCV (fL) | 63.18±1.44 | 58.83±2.83 |
| MCH (pg) | 21.64±0.37 | 20.11±1.22 |
| MCHC (%) | 34.25±0.78 | 34.09±2.11 |
| In vitroresponse to: | ControlsN (%) | TST+, suspected LTBIN (%) | Cured TBN (%) | |
| 13 (100) | 106 (100) | 29 (100) | ||
| QFT-IT | ||||
| Positive N.(%) | 0 | 70 (66.03) | 19 (63.3) | |
| IFN-γ (IU/ml) median (IQR)Among all | 0 (0-0.1) | 2.3 (0-15.1) | 1.1 (0.1-4.2) | |
| IFN-γ (IU/ml) median (IQR)Among the positive responders | NA | 8.1 (2.4-22.6) | 3.8 (1.5-5.0) | |
| RD1 proteins | ||||
| Positive N.(%) | 0 | 64 (60.3) | 19 (65.5) | |
| IFN-γ (IU/ml) median (IQR)Among all | 0 (0-0.2) | 1.4 (0.2-8.9) | 1.6 (0.4-2.9) | |
| IFN-γ (IU/ml) median (IQR)Among the positive responders | NA | 7.6 (2.3-20.3) | 2.6 (1.6-6.2) |
| Unit* | Color¶ | Day† | Positive culture‡ | Leakage§ |
| 1 | Red | None | No | No |
| 2 | Yellow/orange | 30 | Yes | Yes§ |
| 3 | Yellow | 9 | Yes | Yes§ |
| 4 | Red | None | No | No |
| 5 | Yellow/orange | 19 | Yes | Yes§ |
| 6 | Orange | 15 | Yes | Yes§ |
| 7 | Red | None | No | No |
| 8 | Orange | 25 | No | No |
| 9 | Red | None | No | No |
| 10 | Yellow | 4 | Yes | Yes§ |
| 11 | Red | None | No | No |
| 12 | Red | None | No | No |
| 13 | Yellow | 4 | Yes | Yes§ |
| 14 | Red | None | No | No |
| 15 | Yellow | 13 | No | Yes§ |
| 16 | Orange | 26 | No | No |
| 17 | Orange | 15 | No | No |
| 18 | Red | None | No | No |
| 19 | Orange | 30 | No | No |
| 20 | Yellow | 18 | No | Yes§ |
| Study population characteristics | mean (SD) |
| Gestational age (weeks) | 32.5 (2.1) |
| Weight (g) | 1700 (401) |
| Length (cm) | 41.1 (3.3) |
| Head circumference (cm) | 29.9 (1.6) |
| Apgar score at 1 minute | 8 (1) |
| Apgar score at 5 minutes | 9 (1) |
| Structure identifier | Description | No. of models | Reference(s) |
| U_1D3Z | Solution NMR ensemble | 10 | [35] |
| U_COCO | Solution NMR ensemble (1D3Z.pdb) plus COCO-derived conformers | 20 | this study |
| U_1XQQ | DER ensemble | 128 | [14] |
| U_2NR2 | MUMO ensemble | 144 | [15] |
| U_2K39 | EROS ensemble | 116 | [10] |
| U_ISD | ISD ensemble(ensemble provided as an example with the ISD 1.1 package) | 25 | [26] |
| U_NNR | NOE(2)+S2(8)+RDC(8) restrained ensemble | 32 | this study |
| U_CNS | RECOORD ensemble calculated with CNS | 25 | [34] |
| U_CNW | RECOORD ensemble calculated with CNS in water | 25 | [34] |
| U_CYA | RECOORD ensemble calculated with CYANA | 25 | [34] |
| U_CYW | RECOORD ensemble calculated with CYANA in water | 25 | [34] |
| U_1UBQMD | 5ns MD simulation started from the X-ray structure 1UBQ | 32 | this study |
| U_1G6J | Ubiquitin in reverse micelles | 32 | [36] |
| U_1V80 | Ubiquitin at 30 bar | 10 | [37] |
| U_1V81 | Ubiquitin at 3000 bar | 10 | [37] |
| U_2JZZ | Solid-state NMR structure | 20 | [38] |
| Variables | Fragmented QRS(n = 79) | Non-fragmented QRS(n = 257) | p value |
| Age,years | 51.4 ± 4.6 | 50.8 ± 3.1 | 0.408 |
| Gender, Male,% | 59.5 | 62.6 | 0.614 |
| Hypertension,% | 30.4 | 25.3 | 0.970 |
| Smoking,% | 38 | 27.6 | 0.079 |
| CAD,% | 41.8 | 30.4 | 0.059 |
| MVD,% | 25.3 | 5.1 | < 0.001 |
| Stenotic CAD,% | 40.5 | 10.5 | < 0.001 |
| LDL,mg/dl | 125 ± 34 | 118 ± 26 | 0.089 |
| TG,mg/dl | 161 ± 43 | 156 ± 46 | 0.124 |
| HDL,mg/dl | 39.1 ± 8.2 | 39.2 ± 8 | 0.979 |
| Glucose | 91 ± 14 | 89 ± 11 | 0.195 |
| Creatinin | 0.95 ± 0.25 | 0.9 ± 0.18 | 0.127 |
| WBC | 6.9 ± 2.3 | 6.7 ± 2.2 | 0.474 |
| Hemoglobin | 13 ± 2.3 | 13.1 ± 2.4 | 0.635 |
| LVEF | 59.3 ± 6 | 60.7 ± 5.1 | 0.070 |
| Patient no. | Underlying disease | CSF WBC (cells/mm3) | Imaging pattern (MRI) | CSF HSV viral load (copies/ml) | Outcome |
| 1 | Normal | 230 | Fronto-temporal lesions | 16,975 | Complete recovery |
| 2 | Normal | 350 | Fronto-temporal lesions | 2214 | Complete recovery |
| 3 | Normal | 70 | Fronto-temporal lesions | Qualitative PCR | Complete recovery |
| 4 | Normal | 730 | Temporal lobe lesions | 11,755,813 | Partial recovery |
| 5 | Normal | 22 | Fronto-temporal and thalamic lesions | 500,000 | Partial recovery |
| 6 | Normal | 90 | Temporal lobe lesions | 71,875 | Complete recovery |
| 7 | Hematologic malignancy | 147 | Temporal lobe lesions | 30,750 | Complete recovery |
| 8 | Normal | 75 | Fronto-temporal and thalamic lesions | 12,200 | Partial recovery |
| 9 | DM | 510 | Other cortical and subcortical lesions | 3325 | Dead |
| 10 | Normal | 40 | Normal CT | 1491 | Partial recovery |
| 11 | Hematologic Malignancy | 40 | Other cortical and subcortical lesions | 740 | Dead |
| 12 | Normal | 60 | Fronto-temporal and thalamic lesions | 39 | Partial recovery |
| 13 | DM | 15 | N/A | Qualitative PCR | Partial recovery |
| 14 | Normal | 600 | Temporal lobe lesions | Qualitative PCR | Partial recovery |
| 15 | Old ischemic stroke | 22 | Fronto-temporal lesions | Qualitative PCR | Partial recovery |
| 16 | Normal | 30 | Temporal lobe lesions | Qualitative PCR | Partial recovery |
| 17 | Normal | 20 | Other cortical and subcortical lesions | Qualitative PCR | Partial recovery |
| Variable | Range (Q4–Q1) | Slope of index inequality (95 % CI) | Relative index of inequality (95 % CI) | Concentration Index | ||||||
| 2008 | 2012 | 2008 | 2012 | Change in equity (P-value) | 2008 | 2012 | Change in equity (P-value) | 2008 | 2012 | |
| Received any ANC | –4.3 | 2.6 | −0.047**(−0.094 - -0.001) | 0.051(−0.027 - 0.130) | 0.030 | 0.951**(0.904 - 1.000) | 1.056(0.971 - 1.149) | 0.037 | −0.005 | 0.015 |
| Attended ≥4 ANC visits | 5.7 | 16.0 | 0.024(−0.084 - 0.132) | 0.209***(0.129 - 0.288) | 0.005 | 1.027(0.909 - 1.160) | 1.271***(1.139 - 1.417) | 0.008 | 0.011 | 0.033 |
| ANC visit <20 weeks gestation | 23.5 | 30.1 | 0.274***(0.106 - 0.442) | 0.312***(0.165 - 0.460) | 0.741 | 1.831***(1.268 - 2.644) | 1.593***(1.278 - 1.984) | 0.525 | 0.116 | 0.077 |
| Skilled birth attendant | 8.5 | 8.4 | 0.121***(0.066 - 0.176) | 0.113**(0.020 - 0.207) | 0.888 | 1.135***(1.071 - 1.202) | 1.124**(1.021 - 1.238) | 0.869 | 0.017 | 0.018 |
| Doctor attended childbirth | 44 | 53.7 | 0.401***(0.270 - 0.531) | 0.587***(0.449 - 0.724) | 0.063 | 5.285***(2.971 - 9.398) | 5.802***(3.856 - 8.728) | 0.797 | 0.300 | 0.268 |
| Offered HIV testing in pregnancy | −8.4 | −7.0 | −0.042(−0.106 - 0.021) | −0.042(−0.093 - 0.009) | 0.999 | 0.951(0.880 - 1.028) | 0.940(0.862 - 1.024) | 0.833 | −0.007 | −0.004 |
| HIV test in past 2 years | –2.8 | 1.3 | −0.050(−0.152 - 0.051) | −0.004(−0.049 - 0.041) | 0.419 | 0.943(0.838 - 1.061) | 0.996(0.951 - 1.042) | 0.405 | 0.000 | −0.006 |
| Never had HIV Test | –1.4 | 5.0 | −0.028(−0.120 - 0.065) | 0.030(−0.031 - 0.091) | 0.297 | 0.739(0.264 - 2.068) | 2.631(0.395 - 17.518) | 0.236 | −0.001 | 0.450 |
| Planned pregnancy | 22.5 | 30.6 | 0.134(−0.032 - 0.301) | 0.391***(0.258 - 0.524) | 0.009 | 1.391(0.929 - 2.084) | 2.999***(2.096 - 4.292) | 0.004 | 0.078 | 0.161 |
| Five or more children | –8.2 | −11.5 | −0.099***(−0.139 - -0.060) | −0.117***(−0.162 - -0.073) | 0.548 | 0.129***(0.033 - 0.497) | 0.045***(0.014 - 0.144) | 0.255 | −0.326 | −0.324 |
| Poor-fair health status | –10.5 | −1.0 | −0.150***(−0.234 - -0.066) | 0.022(−0.068 - 0.112) | 0.004 | 0.331***(0.167 - 0.654) | 1.165(0.631 - 2.151) | 0.004 | −0.043 | −0.040 |
| HIV infection | –20.6 | −21.7 | −0.281***(−0.427 - -0.136) | −0.251***(−0.372 - -0.129) | 0.38 | 0.340***(0.178 - 0.649) | 0.372***(0.224 - 0.620) | 0.821 | −0.193 | −0.213 |
| CR & TT at T0 | CR at T1 | TT at T1 | CR at T2 | TT at T2 | CR at T3 | TT at T3 | CR at T4 | TT at T4 | CR at T5 | TT at T5 | |
| n=121 | n=62 | n=59 | n=62 | n=59 | n=50 | n=51 | n=30 | n=36 | n=16 | n=18 | |
| arm symptoms | 24,33 | 21,00 (2,50) | 18,07 (2,32) | 21,24 (2,82) | 18,01 (2,08) | 22,02 (3,73) | 26,33 (4,27) | 19,89 (5,10) | 19,96 (4,40) | 11,14 (5,76) | 18,78 (6,49) |
| breast symptoms | 20,94 | 33,30 a (2,78) | 29,57 (2,74) | 23,67 (2,58) | 24,10 (2,35) | 17,99 (3,17) | 15,94 (2,52) | 14,55 (4,24) | 12,60 (3,30) | 6,87 (5,63) | 16,77 (4,99) |
| body image | 73,35 | 69,60 (2,14) | 70,62 (2,49) | 73,21 (2,48) | 77,80 (2,55) | 74,74 (3,67) | 77,51 (2,87) | 73,62 (5,76) | 78,40 (4,93) | 74,91 (7,02) | 79,08 (7,36) |
| future perspective | 53,44 | 57,33 (3,64) | 51,02 (3,44) | 58,36 (3,38) | 58,62 (3,26) | 61,78 (4,03) | 65,44 (3,53) | 64,55 (5,84) | 64,55 (6,27) | 59,69 (7,59) | 68,03 (10,08) |
| systemic treatment side effects | 14,64 | 22,50 (1,87) | 25,81a (2,83) | 22,52 (2,06) | 21,21 (2,88) | 18,01 (2,20) | 17,88 (2,57) | 19,40 (3,19) | 13,20 (2,95) | 17,62 (4,80) | 15,24 (4,28) |
| n=21 | n=22 | n=26 | n=16 | n=20 | n=8 | n=10 | n=8 | n=6 | n=3 | n=3 | |
| upset by hair loss | 34,92 | 48,25 a (8,16) | 27,51 (9,26) | 23,81 a (11,11) | 40,48 a (5,56) | 46,02 a (11,10) | 28,25 a (16,33) | 1,62 a (0,00) | 23,81 (29,40) | 34,92 a (0,00) | 34,92 a (0,00) |
| n=104 | n=53 | n=50 | n=53 | n=53 | n=42 | n=45 | n=26 | n=30 | n=13 | n=15 | |
| sexual functioning | 23,85 | 21,02 (2,68) | 23,52 (3,45) | 24,48 (3,04) | 22,60 (3,36) | 24,65 (3,50) | 24,59 (2,90) | 21,85 (4,44) | 27,19 (3,61) | 25,14 (6,92) | 21,63 (5,36) |
| n=61 | n=23 | n=23 | n=29 | n=32 | n=24 | n=29 | n=15 | n=19 | n=8 | n=9 | |
| sexual enjoyment | 55,74 | 53,98 (5,39) | 47,40 (3,31) | 48,16 (5,77) | 50,61 (5,45) | 61,29 a (4,86) | 49,94 (4,98) | 64,07 (5,98) | 48,59 (5,16) | 62,40 a (6,67) | 46,21 (9,52) |
| Variable | Non-smoker (n = 22) | Smoker (n = 22) | t-test | |||
| Mean | SD | Mean | SD | t-value | P-value | |
| Age (years) | 41.5 | 15.8 | 46.0 | 11.4 | 1.1 | .290 |
| Duration of smoking (years) | NA | NA | 24.3 | 9.7 | NA | NA |
| Number of cigarettes smoked daily | NA | NA | 17.4 | 7.0 | NA | NA |
| Brinkman index | NA | NA | 430 | 246.7 | NA | NA |
| Pathogenic step | Candidate biomarkers | Potential approaches and targets of disease-specific therapy |
| Elevated production of Gd-IgA1 | Serum level of Gd-IgA1 (lectin or antibody ELISA)IgA1 hinge-region O-glycopeptide profiles (mass spectrometric analysis) | Reduce production of Gd-IgA1Manipulate enzyme expression in IgA1-producing cellsReduce number of cells secreting Gd-IgA1 |
| Production of autoantibodies specific for Gd-IgA1 | Serum levels of autoantibodies (IgG and IgA) specific for Gd-IgA1 | Reduce production of autoantibodies specific for Gd-IgA1Deplete cells producing the autoantibodyManipulate affinity maturation of autoantibodies to reduce affinity for the autoantigenRemove the autoantibodies from circulation |
| Formation of pathogenic IgA1-containing immune complexes | Circulating IgA-containing immune complexesSpecific components of circulating immune complexes | Block immune complex formation and enhance their removal from circulation and catabolismBlock epitopes of autoantigen (Gd-IgA1) by non-crosslinking antibodiesBlock autoantibodies by an epitope-containing glycopeptide or glycomimeticBlock activation of complement |
| Glomerular deposition and injury | Complement components and their degradation productsNovel markers of glomerular injuryUrinary immune complexesUrinary peptidomic profiles | Block activation of mesangial cellsReduce complement activation in situBlock binding of IgA1-containing immune complexes to mesangial cellsBlock mesangial-cell signaling induced by IgA1-containing immune complexes |
| Brain region intensity | MNI peak coordinates (X, Y, Z) | Volume | Peak activity | ||
| Precuneus | 3 | −69 | 57 | 120 | 9.2972 |
| Posterior cingulate gyrus | 0 | −66 | 12 | 63 | 6.3883 |
| Right medial superior frontal gyrus | 3 | 63 | 9 | 67 | 6.6306 |
| Left middle frontal gyrus | −12 | 33 | 51 | 30 | 6.0696 |
| Left medial superior frontal gyrus | −3 | 30 | 57 | 74 | 6.6797 |
| Left supplementary motor area | −3 | 15 | 69 | 52 | 5.598 |
| Variable | HR (95% CI) | P value |
| MACE | ||
| CTO-PCI successful | 0.58 (0.32–0.94) | <0.01 |
| Prior MI | 3.89 (1.95–7.84) | <0.05 |
| CKD | 3.51 (1.52–7.87) | <0.01 |
| LVEF (per-10% increment) | 0.94 (0.88–0.99) | <0.05 |
| Mortality | ||
| CTO-PCI successful | 0.35 (0.19–0.68) | <0.01 |
| Age | 1.08 (1.02–1.11) | <0.01 |
| Prior MI | 2.31 (0.73–7.35) | 0.16 |
| CKD | 7.18 (2.95–17.40) | <0.01 |
| LVEF (per-10% increment) | 0.87 (0.77–0.93) | <0.01 |
| Serum (ng/ml) | Urine (μg/mmol creatinine) | |||||
| Odds ratio | 95% confidence interval | P value | Odds ratio | 95% confidence interval | P value | |
| Full study | (219 cases/891 controls) | (198 cases/797 controls) | ||||
| Total isoflavones | 1.03 | 0.95 to 1.11 | 0.479 | 1.08 | 1.00 to 1.16 | 0.055 |
| Total lignans | 0.99 | 0.90 to 1.08 | 0.728 | 1.01 | 0.94 to 1.09 | 0.758 |
| Daidzein | 1.04 | 0.98 to 1.10 | 0.225 | 1.05 | 0.99 to 1.10 | 0.096 |
| Equol | 1.04 | 0.98 to 1.10 | 0.167 | 1.03 | 0.99 to 1.06 | 0.131 |
| o-Desmethylangolensin | 1.03 | 0.97 to 1.09 | 0.390 | 1.02 | 0.98 to 1.06 | 0.250 |
| Genistein | 1.00 | 0.94 to 1.05 | 0.911 | 1.01 | 0.97 to 1.05 | 0.706 |
| Glycitein | 1.03 | 0.97 to 1.10 | 0.345 | 1.03 | 0.98 to 1.07 | 0.248 |
| Enterodiol | 1.02 | 0.96 to 1.09 | 0.461 | 1.01 | 0.96 to 1.05 | 0.772 |
| Enterolactone | 0.98 | 0.91 to 1.05 | 0.564 | 0.99 | 0.94 to 1.04 | 0.718 |
| Oestrogen receptor-positive subgroup | (105 cases/365 controls) | (95 cases/329 controls) | ||||
| Total isoflavones | 1.01 | 0.91 to 1.12 | 0.818 | 1.09 | 0.97 to 1.22 | 0.154 |
| Total lignans | 1.02 | 0.89 to 1.17 | 0.774 | 1.12 | 0.99 to 1.28 | 0.083 |
| Daidzein | 1.05 | 0.97 to 1.13 | 0.260 | 1.03 | 0.96 to 1.10 | 0.468 |
| Equol | 1.01 | 0.93 to 1.09 | 0.887 | 1.07 | 1.01 to 1.12 | 0.013 |
| o-Desmethylangolensin | 1.05 | 0.96 to 1.14 | 0.314 | 1.04 | 0.98 to 1.10 | 0.192 |
| Genistein | 0.99 | 0.92 to 1.06 | 0.775 | 1.00 | 0.94 to 1.05 | 0.882 |
| Glycitein | 1.03 | 0.93 to 1.13 | 0.614 | 1.04 | 0.98 to 1.10 | 0.186 |
| Enterodiol | 1.00 | 0.92 to 1.09 | 0.990 | 1.04 | 0.98 to 1.11 | 0.235 |
| Enterolactone | 1.01 | 0.91 to 1.14 | 0.806 | 1.08 | 0.98 to 1.19 | 0.115 |
| Demographic data | Households | |
| Number of household members | N | % |
| 1–4 members | 29 | 26.9% |
| 5–8 members | 32 | 29.6% |
| 9–12 members | 34 | 31.5% |
| >13 members | 13 | 12.0% |
| Total | 108 | 100.0% |
| Mean household size (members) | 8.6 | |
| Median household size (members) | 8 | |
| Number of children <5 in households | N | % |
| 0 children | 9 | 8.3% |
| 1 children | 16 | 14.8% |
| 2 children | 34 | 31.5% |
| 3 children | 29 | 26.9% |
| 4 children | 10 | 9.3% |
| 5 children | 3 | 2.8% |
| 6 children | 5 | 4.6% |
| ≥10 children | 2 | 1.8 |
| Total | 97 | 100.0 |
| Mean number of children <5 per household | 2.6 | |
| Median number of children <5 per household | 2 | |
| Profession of head of household | N | % |
| Subsistence farmer | 46 | 42.6% |
| Subsistence farmer + Daily worker | 8 | 7.4% |
| Subsistence farmer + Other profession* | 6 | 5.6% |
| Subsistence farmer + Farmer for trading | 5 | 4.6% |
| Health worker | 5 | 4.6% |
| No work | 5 | 4.6% |
| Workman | 4 | 3.7% |
| Subsistence farmer + Hunter | 4 | 3.7% |
| Subsistence farmer + Teacher | 3 | 2.8% |
| Subsistence farmers + Other professions† | 14 | 13.0% |
| Other professions‡ | 7 | 6.5% |
| Missing | 1 | 0.9% |
| Total | 108 | 100.0% |
| HIV-infected | Healthy controls | ||
| LTNP | Normal progressors | ||
| Number | 5 | 13 | 7 |
| Median age, years | 49 | 39 | 41 |
| Median CD4 cells, cells/μl | 1240 | 565 | n.a. |
| Median Log (viral load) | 1.7 | 4.3 | n.a. |
| Year of birth | Number of ONS Birth records | Number of ONS birth records linked to HES birth records | Percentage linked |
| 2005 | 617 613 | 609 778 | 98.73 |
| 2006 | 640 271 | 633 183 | 98.89 |
| 2007 | 659 061 | 651 551 | 98.86 |
| 2008 | 676 999 | 668 967 | 98.81 |
| 2009 | 675 330 | 669 926 | 99.20 |
| 2010 | 687 100 | 682 261 | 99.30 |
| 2011 | 688 681 | 683 768 | 99.29 |
| 2012 | 698 457 | 693 221 | 99.25 |
| 2013 | 668 433 | 662 963 | 99.18 |
| 2014 | 664 967 | 659 192 | 99.13 |
| Model | Covariates included | OR (95% CI)* | Pvalue |
| 1 | Long PPI exposure (2 or more days) | 2.19 (1.27 – 3.78) | .005 |
| H2RA use | 1.12 (0.70 – 1.79) | .628 | |
| Antibiotic use | 2.53 (1.23 – 5.23) | .012 | |
| Immunosuppression | 0.79 (0.51 – 1.23) | .297 | |
| 2 | Long PPI exposure (2 or more days) | 2.08 (1.26 – 3.43) | .004 |
| Antibiotic use | 2.53 (1.25 – 5.29) | .010 | |
| Immunosuppression | 0.79 (0.51 – 1.22) | .282 | |
| 3 | Long PPI exposure (2 or more days) | 2.03 (1.23 – 3.36) | .006 |
| Antibiotic use | 2.52 (1.23 – 5.18) | .012 |
| MBA failures | MBA controls | p-Value | |
| Transportal ACLR (n = 26) | 25.0 | 20.7 | <0.001 |
| Transtibial ACLR (n = 28) | 24.0 | 20.3 | 0.003 |
| Variable | SHAM | STZ |
| Aortic flow rate (mL g-1 min-1) | 24.4 ± 1.5 | 14.2 ± 2.9* |
| Coronary flow rate (mL g-1 min-1) | 6.05 ± 0.39 | 7.16 ± 0.65 |
| Work (J kg-1) | 1.48 ± 0.09 | 1.06 ± 0.11* |
| Total Vo2 (J kg-1) | 10.4 ± 0.51 | 10.0 ± 0.66 |
| Total efficiency (%) | 14.5 ± 0.49 | 10.4 ± 0.88* |
| Factor | Respondents(n = 56) |
| Comorbidities of parturient | 31 (55) |
| BMI | 39 (70) |
| Quality of SAD seal | 42 (75) |
| Fasting status | 24 (43) |
| Other | |
| Team skill | 2 (4) |
| Clinical situation | 2 (4) |
| Speed of surgeon | 2 (4) |
| Health behaviour | Amount or frequency | Girls | Boys | ||||
| Latent class I n = 1256 | Latent class II n = 1071 | Latent class III n = 1098 | Latent class I n = 862 | Latent class II n = 628 | Latent class III n = 1583 | ||
| Stress-related eating | At least to some extent | 732 (58.3%) | 527 (49.2%) | 218 (19.9%) | 188 (21.8%) | 142 (22.6%) | 136 (8.6%) |
| Physical activity | <2 hours a week | 310 (24.7%) | 694 (64.8%) | 384 (35.0%) | 126 (14.6%) | 361 (57.5%) | 471 (29.8%) |
| 2–3 hours a week | 407 (32.4%) | 252 (23.5%) | 369 (33.6%) | 229 (26.6%) | 124 (19.7%) | 361 (22.8%) | |
| >3 hours a week | 539 (42.9%) | 125 (11.7%) | 345 (31.4%) | 507 (58.8%) | 143 (22.8%) | 751 (47.4%) | |
| Tobacco use | Never smoked or taken snuff | 304 (24.2%) | 97 (9.1%) | 735 (66.9%) | 291 (33.8%) | 70 (11.1%) | 765 (48.3%) |
| Experimental or occasional use of cigarettes or snuff | 557 (44.3%) | 455 (42.5%) | 363 (33.1%) | 351 (40.7%) | 146 (23.2%) | 704 (44.5%) | |
| Smoking or taking snuff regularly | 395 (31.4%) | 519 (48.5%) | 0 (0%) | 220 (25.5%) | 412 (65.6%) | 114 (7.2%) | |
| Sleeping | <8 hours per night | 388 (30.9%) | 378 (35.3%) | 72 (6.6%) | 167 (19.4%) | 252 (40.1%) | 100 (6.3%) |
| 8–9 hours per night | 735 (58.5%) | 549 (51.3%) | 951 (86.6%) | 564 (65.4%) | 253 (40.3%) | 1224 (77.3%) | |
| ≥9 hours per night | 133 (10.6%) | 144 (13.4%) | 75 (6.8%) | 131 (15.2%) | 123 (19.6%) | 259 (16.4%) | |
| Binge eating | Once a month - daily | 167 (13.3%) | 139 (13.0%) | 2 (0.2%) | 111 (12.9%) | 145 (23.1%) | 64 (4.0%) |
| Strict diet to control weight | Occasionally or often | 792 (63.1%) | 213 (19.9%) | 17 (1.5%) | 241 (28.0%) | 35 (5.6%) | 27 (1.7%) |
| Heavy exercise to control weight | Occasionally or often | 1256 (100.0%) | 0 (0%) | 207 (18.9%) | 862 (100.0%) | 0 (0%) | 46 (2.9%) |
| Eating meals with one’s family | A few times a week or less often | 574 (45.7%) | 572 (53.4%) | 103 (9.4%) | 250 (29.0%) | 300 (47.8%) | 220 (13.9%) |
| Genes | Forward primer(5′‐ 3′) | Reverse primer(5′‐ 3′) |
| GAPDH | CGCTAACATCAAATGGGGTG | TTGCTGACAATCTTGAGGGAG |
| HIF‐1α | AAGCCCAGAGTCACTGGGACT | GTACTCACTGGGACTGTTAGGCTC |
| BMP‐2 | GAAGCCATCGAGGAACTTTCAG | GGAAATTTTGAGCTGGCTGTG |
| Runx2 | ACTCTGCCGAGCTACGAAATG | GGGACCGTCCACTGTCACT |
| COL‐I | CCGTGACCTCAAGATGTGCC | GAACCTTCGCTTCCATACTCG |
| OST | GATGCGGTCCCTAGTTCTACC | CCTCCAGTGAGTGGGATGTTT |
| OPN | AGCACACAAGCAGACGTTTTG | GCAACTGGGATGACCTTGATAG |
| ERK1 | CTGGCTTTCTGACCGAGTATGT | AATTTAGGTCCTCTTGGGATGG |
| ERK2 | GCACCAACCATTGAGCAGAT | TCACGGTGCAGAACATTAGCT |
| p38 | AGATGCCGAAGATGAACTTCG | GGTCAGGCTCTTCCATTCGT |
| JNK | TCCAGCACCCGTACATCAAC | TCTTAGTTCGCTCCTCCAAATC |
| Participant (diagnosis) | Trauma type | Psychotic symptoms | Target hotspot and associated memory | Key tf-CBTp; phase 4 intervention |
| P1Primary: unspecified non-organic psychosisSecondary: PTSD | Childhood; multipleSought asylum in the UK | Auditory command hallucinationsVisual hallucinationsParanoia | Witnessing murder of childhood friend; childhood physical abuse; held captive and tortured | Cognitive restructuringReliving with CRImagery rescripting (for nightmares and visions) |
| P2Primary: schizophreniaSecondary: severe depressive episode with psychotic symptoms | Adult; single event | Auditory command hallucinationsPersecutory beliefs | Living in conflict zone and held at gunpoint by terrorists | Cognitive restructuringReliving with CR |
| P3Primary: other non-organic psychotic disorderSecondary: PTSD | Childhood; multipleSought asylum in the UK | Auditory hallucinationsVisual, tactile, and olfactory hallucinationsPersecutory beliefs | Living in conflict zone (civil war/genocide); parents killed. Held captive and gang raped; witnessed murder of grandfather | Cognitive restructuringImagery rescripting |
| P4Primary: unspecified non-organic psychosisSecondary: none | Childhood; single event | Auditory command hallucinationsVisual and tactile hallucinationsPersecutory beliefs | Rape in childhood | Cognitive restructuringImagery rescripting for trauma event and visual hallucinationsSchema work |
| P5Primary: PTSDSecondary: emotionally unstable personality disorder | Adult; multiple | Auditory command hallucinationsVisual, olfactory, and tactile hallucinationsPersecutory beliefs | Several rapes and extreme physical assaults (long-term domestic violence); stillbirth of child | Cognitive restructuringReliving with CR for trauma eventsImagery rescripting for visual, olfactory tactile, and hallucinations |
| P6Primary: severe depressive episode with psychotic symptomsSecondary: none | Childhood; single event | Auditory hallucinationsPersecutory beliefs | Physical and emotional abuse | Imagery rescriptingSchema work |
| P7Primary: schizophreniaSecondary: severe depressive episode with psychotic symptoms | Adult; single event | Auditory hallucinationsVisual, tactile, and olfactory hallucinationsPersecutory beliefs | Being threatened with a knife | Cognitive restructuring reliving with CR |
| P8Primary:PTSDSecondary: severe depressive episode with psychotic symptoms | Adult; multipleSought asylum in the UK | Commanding voicesVisual and tactile hallucinationsPersecutory beliefs | Long-term imprisonment with physical and sexual torture. Witnessing murder in prison | Cognitive restructuring reliving with CRImagery rescripting |
| P9Primary: severe depressive episode with psychotic symptomsSecondary: none | Childhood; multiple | Auditory command hallucinationsVisual and tactile hallucinationsPersecutory beliefs | Repeated childhood physical abuse | Cognitive restructuringImagery rescripting for trauma events, visual and tactile hallucinations, and nightmares |
| Complain | n of cases | n of positive cases |
| Discharge | 750 | 20 (2.7%) |
| Discharge and itching | 120 | 10 (8.3%) |
| Discharge, itching and burning sensation | 130 | 20 (15.4%) |
| Total | 1000 | 50 |
| P value | 0.129 |
| Pancreatitis | Neoplastic conditions | Other | |||
| Acute | 34.4 % | pancreatic ACC | 19.8 % | fistula | 2.3 % |
| Chronic | 15.3 % | n. r. | 9.9 % | transplant rejection | 1.5 % |
| NEC | 4.6 % | ||||
| adeno-carcinoma | 3.8 % | anastomotic leakage | 0.8 % | ||
| IPMN | 3.1 % | ||||
| other | 4.6 % | ||||
| Total | 49.6 % | total | 45.8 % | total | 4.6 % |
| Test variable | Schizophrenia patients (24) | Healthy adults (24) | ||
| M | SD | M | SD | |
| Age | 42.43 | 6.85 | 40.63 | 6.66 |
| Education (in years) | 10.5 | 3.41 | 11.08 | 2.78 |
| Digit span forward | 4.58 | 1.31 | 5.00 | 1.59 |
| Digit span backward | 4.08 | 1.38 | 4.88 | 1.73 |
| PANAS pos | 29.05 | 4.90 | 31.25 | 3.23 |
| PANAS neg | 18.95 | 4.25 | 22.29 | 6.67 |
| BPRS | ||||
| Total | 22.56 | 3.14 | ||
| Positive symptoms | 7.31 | 1.67 | ||
| Negative symptoms | 3.56 | 1.80 |
| Gene | Forward | Reverse |
| 18s rRNA | CCCAGTGAGAATGCCCTCTA | TGGCTGAGCAAGGTGTTATG |
| Scleraxis | CCCAAACAGATCTGCACCTT | ATCCGCCTCTAACTCCGAAT |
| Tenascin-C | AACCCGTCCAAAGAGACCTT | GCGTGGGATGGAAGTATCAT |
| Tenomodulin | GTCCCTCAAGTGAAGGTGGA | CCTCGACGGCAGTAAATACAA |
| Collagen type-1 alpha 1 | TGCGAAGACACCAAGAACTG | GACTCCTGTGGTTTGGTCGT |
| Cartilage oligomeric matrix protein | AGAACATCATCTGGGCCAAC | CGCTGGATCTCGTAGTCCTC |
| Thrombos pondin-4 | GGGAAATGGGGTTACCTGTT | CGGGTAGCAGGGATGATATT |
| Level of guidance | Nature of guidance | Health Technology | |
| Meta regression findings | Number of sessions not related to outcome | Better outcomes where guidance provided, and where based on CBT | No differences between technologies (email, telephone, face to face) |
| Meta synthesis findings | No relevant findings | No relevant findings | No relevant findings |
| Consensus exercise | Agreement on timing, duration, and number of sessions | Agreement that patient preference should determine the nature of guidance | Agreement that health technology should be accessible, and help with literacy problems. |
| Incorporated into the intervention | 3–10 sessions, 15–30 minutes duration over 5–12 weeks | CBT based. Patient preference delivery of guidance | Devised a self-help manual and also a CD |
| Who should deliver guided self-help | Personal experience of depression | Ambivalent help seeking and covert presentation of problems | |
| Meta regression findings | No differences in outcome between professional and paraprofessionals | No relevant findings | No relevant findings |
| Meta synthesis findings | No relevant findings | Personal experience characterised by feeling of inability to cope, and disturbances to functioning. Use of lay language/metaphors important | Point in illness trajectory where people make service contact, and their prior contact with other help may determine acceptability |
| Consensus exercise | Most frequent were nurses and primary care graduate workers. Specific training needed | Mixed response to inclusion of lay language and metaphors. Agreement on importance of social functioning, and relapse prevention | None relevant |
| Incorporated into the intervention | Primary care graduate workers or other mental health professionals | Emphasised return of social functioning. Lay language, metaphors and causal explanations included. Relapse prevention incorporated | Expectations and prior contact emphasised and included in the intervention. Choices and patient preference for interventions included |
| Control and helplessness in engaging with treatment | Stigma associated with treatment | Patients' understanding of self-help | |
| Meta regression findings | No relevant findings | No relevant findings | No relevant findings |
| Meta synthesis findings | Patients reported coping strategies such as distraction, or the use of locations associated with feelings of safety and control | Extent to which guided self-help acknowledges issues of stigma likely to determine acceptability | Seeing the self as the agent of change may be very important |
| Consensus exercise | Mixed response but emphasis on collaborative working, patient centred goals, and roles i.e. patient as change agent | None relevant | Agreement of collaborative working, explicitly detail roles of both patient and MHW i.e. patient as change agent, coach as facilitator |
| Incorporated into the intervention | Highlighting intervention as a method of regaining control and incorporating use of coping strategies termed 'respite' in the intervention | Discussed guided self-help as requiring a sense of acting on the world and enhancing self-worth | Explicit team rationale, with the patient as 'team captain', facilitator renamed as 'self-help coach' |
| Strain | Acetate | Formate | Succinate | Ethanol | Carbon Recovery (%) |
| E. coli C | 0.95 ± 0.08 | 1.21 ± 0.03 | 0.29 ± 0.03 | 0.58 ± 0.05 | 100.9 ± 0.41 |
| CCE14 | 0.39 ± 0.04 | 0.67 ± 0.04 | 0.28 ± 0.04 | 2.08 ± 0.01 | 104.5 ± 0.22 |
| KO11 | 0.79 ± 0.04 | 1.59 ± 0.06 | ND | 1.63 ± 0.01 | 98.7 ± 0.32 |
| Variable | Range | |
| Sex, M/F | 33/41 | |
| Age, years | 63.5 ± 1.1 | 38–78 |
| BMI, kg/m2 | 23.0 ± 4.0 | 13.7–35.3 |
| Smoking status, ever/never | 31/43 | |
| CTD | ||
| RA/SSc/PMDM/SjS/MCTD/ | 24/14/14/11/5 | |
| SLE/overlap syndrome | 1/5 | |
| Surgical lung biopsy, yes/no | 33/41 | |
| Corticosteroids/immunosuppressant | 23/10 | |
| FVC, % predicted | 81.0 ± 19.1 | 38.3–127.0 |
| DLco, % predicted | 57.1 ± 19.2 | 22.6–113.6 |
| RV, % predicted | 81.2 ± 31.5 | 17.9–181.9 |
| TLC, % predicted | 80.3 ± 18.3 | 47.9–138.6 |
| PaO2, mmHg | 80.8 ± 9.9 | 60.2–103.2 |
| A-a gradient, mmHg | 20.2 ± 11.5 | −3.8–38.1 |
| MPAP, mmHg | 17.2 ± 5.5 | 8–36 |
| CI, l/min/m2 | 3.59 ± 0.77 | 1.89–5.18 |
| PVR, Wood units | 127.3 ± 59.9 | 34.0–406.0 |
| PVRI, Wood units/m2 | 223.5 ± 102.1 | 52.0–606.0 |
| Characteristic | Non-pregnant women (n = 12) | Pregnant women (n = 12) | P |
| Age, years | 24.5 (5.6) | 26.2 (8.7) | 0.56 |
| Weight, kg | 59.9 (1.2) | 61.3 (10.1) | 0.77 |
| Height, cm | 164.5 (7.6) | 166 (7.2) | 0.93 |
| Gestational age, weeks | – | 32.0 (15.0–40.0) | – |
| Hemoglobin, g/dL | 10.0 (1.4) | 9.0 (1.0) | 0.05 |
| Parasite count, rings/μL† | 14,288 (1,170–65,000) | 12,642 (1,716–89,700) | 0.78 |
| Urea, mg/dL | 25.3 (1.2) | 26.1 (1.5) | 0.16 |
| Asparate aminotransferase, IU | 4.5 (1.8) | 5.4 (2.4) | 0.31 |
| Alanine aminotransferase, IU | 12.5 (6.0) | 13.5 (4.7) | 0.65 |
| Gene | LTA from strain | Concentration (μg/mL) | Time | ||
| 1 h | 3 h | 24 h | |||
| TNF | 233 | 1 | 4.6 ± 0.3 | 68 ± 1.8 | 3.2 ± 0.2 |
| 10 | 5.7 ± 0.0 | 110 ± 2.9 | 14.1 ± 0.2 | ||
| T1–18 | 1 | 3.6 ± 0.3 | 44 ± 10.0 | 2.8 ± 0.1 | |
| 10 | 6.1 ± 0.3 | 114 ± 2.2 | 13.4 ± 0.3 | ||
| IL6 | 233 | 1 | 1.2 ± 0.0 | 10.2 ± 0.8 | 1.9 ± 0.1 |
| 10 | 1.3 ± 0.1 | 18.5 ± 0.2 | 4.3 ± 0.04 | ||
| T1–18 | 1 | 1.2 ± 0.1 | 7.1 ± 1.7 | 1.7 ± 0.1 | |
| 10 | 1.2 ± 0.1 | 18.5 ± 0.6 | 4.1 ± 0.1 | ||
| CXCL8 | 233 | 1 | 2.9 ± 0.05 | 38 ± 2.7 | 3.2 ± 0.0 |
| 10 | 3.2 ± 0.1 | 69 ± 1.1 | 10.2 ± 0.2 | ||
| T1–18 | 1 | 2.1 ± 0.1 | 25 ± 4.3 | 2.5 ± 0.3 | |
| 10 | 3.2 ± 0.2 | 74 ± 1.7 | 9.3 ± 0.1 | ||
| CCL5 | 233 | 1 | 0.9 ± 0.01 | 6.6 ± 0.3 | 6.0 ± 0.1 |
| 10 | 1.1 ± 0.1 | 14.7 ± 0.6 | 28 ± 1.1 | ||
| T1–18 | 1 | 1.0 ± 0.01 | 3.7 ± 1.2 | 4.9 ± 0.4 | |
| 10 | 1.0 ± 0.1 | 13.4 ± 1.2 | 33 ± 2.8 | ||
| NOS2A | 233 | 1 | 1.0 ± 0.04 | 55 ± 3.2 | 2.0 ± 0.1 |
| 10 | 1.0 ± 0.02 | 119 ± 5.4 | 7.3 ± 0.1 | ||
| T1–18 | 1 | 0.9 ± 0.13 | 31 ± 12.8 | 1.7 ± 0.1 | |
| 10 | 1.0 ± 0.05 | 112 ± 9.7 | 6.1 ± 0.3 | ||
| LAP | 233 | 1 | 1.0 ± 0.08 | 2.9 ± 0.08 | 17 ± 3.5 |
| 10 | 1.0 ± 0.04 | 4.6 ± 0.48 | 47 ± 1.0 | ||
| T1–18 | 1 | 0.9 ± 0.05 | 2.2 ± 0.22 | 11 ± 1.4 | |
| 10 | 1.0 ± 0.04 | 4.2 ± 0.03 | 39 ± 0.7 | ||
| SAA3 | 233 | 1 | 1.1 ± 0.02 | 34 ± 4.6 | 31 ± 2.2 |
| 10 | 1.1 ± 0.00 | 50 ± 0.6 | 124 ± 30 | ||
| T1–18 | 1 | 1.1 ± 0.02 | 23 ± 6.9 | 45 ± 8.0 | |
| 10 | 1.2 ± 0.01 | 50 ± 1.6 | 119 ± 18 | ||
| CYP1A1 | 233 | 1 | 1.0 ± 0.02 | 1.7 ± 0.1 | 1.0 ± 0.04 |
| 10 | 2.1 ± 0.03 | 25 ± 1.5 | 1.5 ± 0.1 | ||
| T1–18 | 1 | 1.0 ± 0.03 | 1.4 ± 0.2 | 1.3 ± 0.2 | |
| 10 | 1.8 ± 0.11 | 20 ± 0.6 | 1.8 ± 0.1 |
| Environmental variables | Childhood diarrhea | COR with 95% CI | AOR with 95% CI | |
| Yes | No | |||
| Drinking water source | ||||
| Protected | 16 | 235 | 1 | |
| Unprotected | 168 | 285 | 8.658(5.040, 14.873) | 2.449(1.264, 4.744)a |
| Volume of water collected | ||||
| ≤ 15 L/C/d | 127 | 246 | 2.482(1.737, 3.546) | 1.535(1.004, 2.346)a |
| > 15 L/C/d | 57 | 274 | 1 | |
| Water is shared with livestock at the source | ||||
| Yes | 163 | 211 | 11.367(6.985, 18.498) | 4.403(2.424, 7.999)a |
| No | 21 | 309 | 1 | |
| The water storage container is covered at the time of the survey | ||||
| Yes | 2 | 24 | 1 | |
| No | 182 | 496 | 4.403(1.030, 18.818) | 15.681(0.191, 1287.490) |
| How to withdraw water from the storage | ||||
| Pouring | 182 | 502 | 1 | |
| Dipping | 2 | 18 | 0.306(0.070, 1.334) | 16.464(0.191, 1421.947) |
| Availability of any type of latrine | ||||
| Yes | 21 | 120 | 1 | |
| No | 163 | 400 | 2.329(1.415, 3.832) | 2.278(1.045, 4.965)a |
| Faeces observed in the compound | ||||
| Yes | 179 | 457 | 4.935(1.953, 12.470) | 11.391(2.100, 61.787)a |
| No | 5 | 63 | 1 | |
| Hand washing after visiting the toilet | ||||
| Yes | 173 | 464 | 1 | |
| No | 11 | 56 | 0.527(0.270, 1.029) | 16.511(3.304, 82.509)a |
| Number of rooms | ||||
| Only one room | 167 | 231 | 12.290(7.248, 20.840) | 5.827 (3.208, 10.581)a |
| Two rooms | 17 | 289 | 1 | |
| Floor type | ||||
| Earth floor | 168 | 426 | 2.317(1.324, 4.053) | 2.039 (0.938, 4.434) |
| Cemented floor | 16 | 94 | 1 |
| Survival | Body Weight | Ascites Fluid (mL) on the 10th Day | Tumour Cells b | Neutrophil c | ||
| Day 1 | Day 11 | |||||
| Control EAC | 3/10 | 23.1 ± 0.6 | 29.2 ± 0.5 | 6.0 ± 0.3 | ++ | +++ |
| EAC-5-FU | 8/10 | 21.8 ± 0.7 | 26.3 ± 1.1 | 4.0 ± 0.5 | + | ++ |
| EAC-HS | 6/10 | 22.3 ± 0.6 | 27.1 ± 0.9 | 4.5 ± 0.4 | + | ++ |
| EAC-(BDP+5-FU) | 10/10 | 22.5 ± 0.5 | 25.3 ± 0.5 | 2.3 ± 0.6 | - | + |
| EAC-(BDP+HS) | 10/10 | 23.0 ± 0.5 | 26.2 ± 0.7 | 2.6 ± 0.4 | - | + |
| Control | 10/10 | 24.5 ± 0.4 | 25.1 ± 0.3 | 0 | - | + |
| Locus | Alleles | Parasitaemia | χ2 significance | |
| Low (< 1,000/μl) | Moderate to high (≥1,000/μl) | |||
| Pfcrt 76 | Mutant | 8 | 31 | <0.001 |
| Wild | 23 | 13 | ||
| Pfcrt 271 | Mutant | 0 | 4 | 0.138* |
| Wild | 31 | 40 | ||
| Pfcrt 326 | Mutant | 0 | 9 | 0.009* |
| Wild | 31 | 35 | ||
| Pfcrt 356 | Mutant | 1 | 17 | <0.001* |
| Wild | 30 | 27 | ||
| Pfcrt 371 | Mutant | 22 | 36 | 0.409 |
| Wild | 9 | 8 | ||
| Pfmdr1 -86 | Mutant | 0 | 4 | 0.138* |
| Wild | 31 | 40 | ||
| Pfmdr1 -1246 | Mutant | 0 | 3 | 0.263* |
| Wild | 31 | 41 |
| Data subset | Accuracy | Accuracy (%) | False positives | False negatives | MCC score |
| All samples | 2290 of 2315 | 98.92 | 2 of 2159 | 23 of 156 | 0.91 |
| EC origin cells | 558 of 564 | 98.94 | 0 of 535 | 6 of 29 | 0.89 |
| EN origin cells | 849 of 857 | 99.07 | 1 of 790 | 7 of 67 | 0.93 |
| M origin cells | 1015 of 1030 | 98.54 | 3 of 944 | 12 of 86 | 0.9 |
| Random non-channel subset | 2221 of 2315 | 95.94 | 13 of 2006 | 81 of 309 | 0.81 |
| Primary antibody | Host | Manufacturer; catalog no.; dilution | Secondary antibody |
| Enhanced chemiluminescent (ECL) detection | |||
| Anti-phospho-S6 (P-S6) Ser235/236 | Rabbit | Cell Signaling Technology, Beverly, MA; #4858; 1:500 in 5 % BSA in TBS-Ta | Anti-rabbit IgG, HRP-conjugated; Cell Signaling Technology, Beverly, MA; #7074; 1:10000 in 5 % nonfat milk in TBS-T |
| Anti-S6 (S6) | Rabbit | Cell Signaling Technology, Beverly, MA; #2217; 1:1000 in 5 % BSA in TBS-T | |
| Anti-mTOR | Rabbit | Cell Signaling Technology, Beverly, MA; #2983; 1:1000 in 5 % BSA in TBS-T | |
| Anti-caspase-3 | Rabbit | Cell Signaling Technology, Beverly, MA; #9662; 1:1000 in 5 % BSA in TBS-T | |
| Anti-GFP | Rabbit | MBL International Corporation, Geel, Belgium; #598; 1:2000 in 5 % nonfat dry milk in TBS-T | |
| Anti-Elmo1 | Rabbit | Eurogentec, Liege, Belgium; custom orderb; 1:500 in 5 % nonfat dry milk in TBS-T | |
| Anti-α-tubulin | Mouse | Sigma-Aldrich, St. Louis, MO; #T5168; 1:20,000 in 5 % nonfat dry milk in TBS-T | Anti-mouse IgG, HRP-conjugated; Cell Signaling Technology, Beverly, MA; #7076; 1:10000 in 5 % nonfat milk in TBS-T |
| Anti-β-actin-HRP | Mouse | Sigma-Aldrich, St. Louis, MO; A3854; 1:15,000 in 5 % nonfat dry milk in TBS-T | N/A |
| Immunofluorescence | |||
| Anti-phospho-S6 (P-S6) Ser235/236 | Rabbit | Cell Signaling Technology, Beverly, MA; #4858; 1:200 in 1 % donkey serum in PBS-Tc | Anti-rabbit IgG Alexa Fluor 488; Life Technologies, Carlsbad, CA; A-21206; 1:500 in 1 % donkey serum in PBS-T |
| Anti-c-Fos | Rabbit | Santa Cruz Biotechnology, Santa Cruz, CA; #7202; 1:200 in 1 % donkey serum in PBS-T | |
| Anti-GFAP | Mouse | Millipore, Darmstadt, Germany; #04-1031; 1:500 in 1 % donkey serum in PBS-T | |
| Anti-GFP | Mouse | MBL International Corporation, Geel, Belgium; #598; 1:1000 in GDB bufferd |
| Type of study | Complete articles | Abstracts | Total | No. of Patients |
| All studies | 8 | 2 | 10 | 249 |
| Prospective | 5 | 1 | 6 | 106 |
| Retrospective | 3 | 1 | 4 | 143 |
| De novo use of RTX | 6 | 1 | 7 | 179 |
| RTX used for refractory AMR | 2 | 1 | 3 | 70 |
| Pediatric | 1 | 0 | 1 | 20 |
| Adult | 7 | 2 | 9 | 229 |
| Strain | Maximum specific growth rate (h-1) |
| HZ848 | 0.15 ± 0.01 |
| HZ848-siz1Δ | 0.19 ± 0.00 |
| W303a | 0.19 ± 0.01 |
| W303a-siz1Δ | 0.30 ± 0.01 |
| Sample | Size (nm) | Zeta Potential (mV) | PdI | Encapsulation Efficiency (%) |
| CNPs | 159.6 ± 2.2 | 24.50 ± 3.64 | 0.272 ± 0.01 | - |
| CNPs/BJ 5 | 179.3 ± 9.4 ** | 23.03 ± 3.09 | 0.188 ± 0.08 | 76.7 |
| CNPs/BJ 10 | 174.7 ± 5.0 ** | 24.91 ± 2.91 | 0.203 ± 0.07 | 67.7 |
| CNPs/BJ 15 | 187.3 ± 7.5 *** | 31.40 ± 3.86 | 0.185 ± 0.07 | 74.0 |
| CNPs/BE 5 | 189.4 ± 1.0 *** | 20.71 ± 2.93 | 0.305 ± 0.05 | 97.2 |
| CNPs/BE 10 | 160.0 ± 2.3 | 19.00 ± 2.76 | 0.302 ± 0.01 | 87.6 |
| CNPs/BE 15 | 200.3 ± 5.6 *** | 27.21 ± 1.50 | 0.328 ± 0.05 | 88.1 |
| Initial polysomnography | Titration studya | At therapeutic pressureb | |
| Time in Bed (min) | 355 | 360 | 84.5 |
| Total Sleep Time (min) | 277.5 | 253 | 83 |
| Stage N1 (%/min) | 3.6/10 | 4/10 | 35/29 |
| Stage N2 (%/minutes) | 29.2/81 | 25.1/64 | 15/12 |
| Stage N3 (%/minutes) | 49.5/137 | 43.3/110 | ~1/<1 |
| REM (%/minutes) | 17.7/49 | 27.7/70 | 50/42 |
| Obstructive Apneas | 23 | 1 | 0 |
| Hypopneas | 96 | 30 | 4 |
| Central apneas | 39 | 14 | 1c |
| REM central apneas | 39 | 14 | 1c |
| Mixed apneas | 7 | 0 | 0 |
| Time below 90% O2 saturation (%) | 22.9 | 4.7 | 0 |
| Function | cis element | Sequence | Position | TF family | |
| 1 | Defense against insect herbivory | AtMYC2 BS in RD22 | CACATG | (1578-1583) | BHLH |
| 2 | Development | Bellringer/Replumless /Pennywise | AAATTAAA | (2593-2600) | Homeobox |
| 3 | Development | Bellringer/Replumless /Pennywise | AAATTAGT | (1368-1375) | Homeobox |
| 4 | Development | Bellringer/Replumless /Pennywise | ACTAATTT | (293-300) | Homeobox |
| 5 | Response to hiperosmolarity | ATB2/AtbZIP53/AtbZlP44/GBF5 BS in ProDH | ACTCAT | (2537-2542) | bZIP |
| 6 | Auxins response | ARFI binding site motif | TGTCTC | (177-182) (1820-1825) | ARF |
| 7 | ABA response | DPBF1&2 binding site motif | ACACTAG | (897-904) | bZIP |
| 8 | MYB binding site promoter | AACCAAAC | (2359–2366) | MYB | |
| 9 | Defense and stress | MYB4 binding site motif | AACAAAC | (825-831) (775-781) (2446-2452) | MYB4 |
| 10 | Leaf maturation and senescence | RAVI-A binding site motif | CAACA | (1-5) (2138-2142) (1508-1512) (583-587) (360-367) | ABI3VPl |
| 11 | Development | LFY consensus binding site motif | CCAATG | (1413-1418) | LFY |
| 12 | Boxll promoter motif | GGTTAA | (2810-2815) | ||
| 13 | Drought response | DRE-like promoter motif | TACCGACCA | (533-541) | |
| 14 | Light response | GATA promoter motif [LRE] | TGATAG | (2957-2962) | |
| 15 | Light response | GATA promoter motif [LRE] | AGATAA | (287-292) (96-101) | |
| 16 | Light response | GATA promoter motif [LRE] | TGATAA | (2308-2313) | |
| 17 | Hexamer promoter motif | CCGTCG | (649-654) | ||
| 18 | T-box promoter motif | ACTTIG | (1529-1534) |
| Variable | No. of subjectsa | HEV antibody prevalence (%) | Odds ratio (95% CI) | P |
| Age (years) | <0.008b | |||
| 5-10 | 66 | 9.1 | 1.00 | |
| 11-20 | 107 | 4.7 | 0.49 (0.11-2.03) | |
| 21-30 | 67 | 19.4 | 2.41 (0.78-8.23) | |
| 31-50 | 101 | 17.8 | 2.17 (0.76-7.05) | |
| >50 | 47 | 17.0 | 2.05 (0.57-7.72) | |
| Sex | ||||
| Female | 184 | 14.1 | 1.23 (0.65-2.34) | 0.290 |
| Male | 204 | 11.8 | 1.00 | |
| Past history of hepatitis | ||||
| No | 337 | 13.3 | 1.00 | 0.631 |
| Yes | 52 | 9.8 | 0.71 (0.21-1.91) | |
| Education of household head (years of schooling) | 0.046b | |||
| 0 | 81 | 18.5 | 2.73 (0.80-11.92) | |
| 1-4 | 174 | 13.2 | 1.83 (0.58-7.61) | |
| 5-8 | 81 | 9.9 | 1.32 (0.33-6.29) | |
| >8 | 52 | 7.7 | 1.00 | |
| Wealth index (quartiles)c | ||||
| 1 (poorest) | 109 | 12.8 | 1.60 (0.57-4.92) | 0.497b |
| 2 | 98 | 14.3 | 1.81 (0.64-5.57) | |
| 3 | 98 | 15.3 | 1.96 (0.70-5.99) | |
| 4 (least poor) | 83 | 8.4 | 1.00 | |
| Water source | ||||
| Well | 366 | 13.4 | 1.00 | 0.382 |
| River/stream | 22 | 4.5 | 0.31 (0.01-2.01) | |
| Drinking water filtrated or chlorinated | ||||
| Yes | 302 | 13.2 | 1.00 | 0.961 |
| No | 72 | 13.9 | 1.06 (0.45-2.30) | |
| Crowding (number of inhabitants/room) | ||||
| <1 | 161 | 13.7 | 1.00 | 0.673b |
| 1-1.9 | 181 | 12.1 | 0.87 (0.44-1.73) | |
| 2-3 | 22 | 18.2 | 1.40 (0.32-4.83) | |
| >3 | 24 | 8.3 | 0.57 (0.06-2.63) |
| Region | States in region | Selected states, medical colleges, and cities |
| North | Delhi, Rajasthan, Jammu and Kashmir, Himachal Pradesh, Punjab, Haryana, Uttarakhand and Chandigarh | NCT of Delhi (Lady Harding Medical College, Delhi), Rajasthan (NIMS Medical College and Hospital, Jaipur) |
| South | Tamil Nadu, Karnataka, Kerala, Andhra Pradesh, Puducherry, Lakshadweep, Andaman and Nicobar | Karnataka (Kasturba Medical College, Manipal), Tamil Nadu (Madras Medical College, Chennai) |
| East | Sikkim, Assam, Tripura, Manipur, Nagaland, Arunachal Pradesh, Mizoram, Meghalaya, Bihar, Jharkhand, West-Bengal and Orissa | Manipur (Regional Institute Medical Sciences, Imphal), Orissa (Kalinga Institute of Medical Sciences, Odisha) |
| West | Dadar and Nagar Haveli, Daman and Diu, Goa, Maharashtra and Gujarat | Gujarat (M.P. Shah Medical College, Jamnagar), Maharashtra (L.T.M. Medical College and General Hospital, Mumbai) |
| Central | Uttar Pradesh, Chhattisgarh, and Madhya Pradesh | Uttar Pradesh (Integral Institute of Medical Sciences and Research, Lucknow), Madhya Pradesh (G.R. Medical College, Gwalior) |
| Risk Factor Goals | |
| Blood Pressure | BP 130/80 mmHg |
| Diabetes Mellitus | Fasting or pre-prandial glucose of 4-6, or a HbA1C < 6.5% |
| Lipids | Total cholesterol less than 4 mmol/l or an LDL < 2.0 mmol/l |
| Smoking | Smoking cessation |
| Weight | BMI < 25 |
| Strain | SC 5314 | opt1Δ | opt2Δ opt3Δ | opt4Δ | opt5Δ | opt1–opt5Δ | ptr2Δ ptr22Δ | opt1–opt5Δ ptr2Δ ptr22Δ |
| Peptide | MIC (μg mL-1) | |||||||
| F2 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.5 | >128 | >128 |
| F3 | 0.25 | 0.5 | 0.5 | 0.5 | 0.5 | 1 | >128 | >128 |
| F6 | 4 | 8 | 32 | 8 | 8 | >128 | 4 | >128 |
| F7 | 16 | 32 | >>128 | 32 | 32 | >128 | 16 | >128 |
| P10 | 64 | 64 | 64 | 64 | 64 | 64 | 64 | 64 |
| F11 | 16 | 32 | 128 | 32 | 16 | >128 | 16 | >128 |
| Regimens | n (n = 612) | CINV [n (%)] | |
| Grade 0-II (n = 339) | Grade III-IV (n = 273) | ||
| CAF | 59 | 36 (61.0) | 23 (39.0) |
| CEF | 107 | 59 (55.1) | 48 (44.9) |
| TEC | 57 | 29 (50.9) | 28 (49.1) |
| TE | 122 | 74 (60.7) | 48 (39.3) |
| TAC | 61 | 40 (65.6) | 21 (34.4) |
| TA | 51 | 24 (47.1) | 27 (52.9) |
| AC | 40 | 21 (52.5) | 19 (47.5) |
| EC | 115 | 56 (48.7) | 59 (51.3) |
| Compositional Category | Features in Chloroplast |
| CP genome length (nt) | 155,989 |
| LSC length (nt) | 85,912 |
| SSC length (nt) | 17,517 |
| IR length (Ira/b) (nt) | 52,560 |
| AT/GC contents (%) | 62.34/37.66 |
| No. of total/unique genes | 129/111 |
| Genic occupancy (nt) | 88,065 |
| Intergenic occupancy (nt) | 67,924 |
| Protein-coding genes | 78 |
| Transfer RNAs (tRNAs) | 29 |
| Ribosomal RNAs (rRNAs) | 4 |
| No. of genes duplicated in IR regions | 16 |
| Total number of genes with intron(s) | 17 |
| Gene(s) with single intron | 14 |
| Gene(s) with multiple introns | 3 |
| tRNAs with intron(s) | 5 |
| Data Set | Score Used | Positive | Negative | Close to Zero | Total Tested |
| Ma–Mu | Sum of signs of translation shift scores | 597 | 569 | 58 | 16,942 |
| Fa–Fu | Sum of signs of translation shift scores | 48 | 60 | 5 | 15,045 |
| Fa–Fu | Count of CpG | 84 | 85 | 15 | 12,491 |
| no DM | DM | P | |
| XMP | 13 585 (8 386, 29 579) | 62 101 (14 261, 158 938) | 5.0E-7* |
| VMA | 173 153 (107 165, 279 690) | 104 186 (67 902, 164 683) | 1.5E-6* |
| Glucose | 2 935 (1 046, 5 294) | 6 245 (2 777, 9 807) | 3.1E-6* |
| 3-PG | 2 475 150 (1 882 036, 333 2264) | 3 767 372 (2 250 378, 5 598 373) | 4.9E-5* |
| Methionine | 195 026 (152 633, 239 841) | 243 230 (195 219, 283 910) | 4.5E-5* |
| Adenosine | 1 942 (1 463, 3 457) | 3 078 (1 706, 5 137) | 8.6E-4 |
| mevalonate-5P | 192 139 (136 927, 291 930) | 292 904 (165 128, 433 871) | 2.8E-4* |
| ornithine | 1 385 224 (1 083 311, 1 721 772) | 1 657 626 (1 351 270, 1 913 549) | 3.2E-4* |
| uracil | 6 888 567 (4 490 348, 9 622 913) | 4 784 283 (3 740 917, 6 592 407) | 5.7E-4 |
| lactose | 3 140 699 (2 178 153, 4 835 219) | 4 519 336 (2 900 447, 6 650 384) | 3.8E-4 |
| xanthosine | 10 839 (7 518, 22 311) | 22 007 (8 845, 36 474) | 1.0E-3 |
| tyrosine | 222 479 (174 354, 277 562) | 247 875 (210 621, 309 004) | 2.2E-3 |
| serine | 352 671 (280 146, 415 607) | 381 134 (319 491, 476 035) | 4.6E-3 |
| PEP | 312 003 (189 719, 522 172) | 462 016 (257 705, 925 860) | 1.3E-3 |
| ribose-5-P-rib | 144 443 (104 797, 208 719) | 180 078 (116 088, 322 799) | 8.7E-3 |
| Participant | Outcome measure | Instrument | baseline | 3 months | 6 months |
| Patient | Self-perceived performance in daily activitiesa | Canadian Occupational Performance Measure (COPM; performance rating) [25] | √ | √ | √ |
| Self-perceived satisfaction with performance in daily activities | Canadian Occupational Performance Measure (COPM; satisfaction rating) [25] | √ | √ | √ | |
| Objective performance in daily activities | Perceive Recall Plan Perform system (PRPP) [26] | √ | √ | - | |
| Participation | Activity Card Sort (ACS) [27,28] | √ | √ | - | |
| Utrecht Scale for Evaluation of Rehabilitation Participation (USER-P; satisfaction part) [29,30] | √ | √ | √ | ||
| Health-related quality of life | Parkinson’s Disease Questionnaire (PDQ-39) [31-33] | √ | √ | √ | |
| Impact of fatigue | Fatigue Severity Scale (FSS) [34,35] | √ | √ | √ | |
| Mood | Becks Depression Inventory (BDI) [36] | √ | √ | √ | |
| Caregiver | Perceived caregiver burden | Zarit Burden Interview (ZBI) [37] | √ | √ | √ |
| Objective caregiver burden | Objective care burden questionnaire; hours of care | √ | √ | √ | |
| Mood | Hospital Anxiety and Depression Scale (HADS) [38] | √ | √ | √ | |
| Both | Quality of life | Euroqol EQ-5 D [39] | √ | - | √ |
| Quality of life overall | Visual Analogue Scale for Quality of life; VAS QoL | √ | √ | √ | |
| Proactive coping | Utrecht Proactive Coping Competence scale (UPCC) [40] | √ | √ | √ | |
| Resource utilization | Resource utilization questionnaire: patient and caregiver version | √ | √ | √ |
| Birth defects | Number of cases | Birth prevalence/10,000 and 95%CI |
| Anencephaly | 0 | 0 (0–6.3) |
| Spin bifida | 1 | 1.7 (0–9.5) |
| Encephalocele | 0 | 0 (0–6.3) |
| Microcephaly | 1 | 1.7 (0–9.5) |
| Arhinencephaly/holoprosencephaly | 4 | 6.8 (1.9–17.4) |
| Hydrocephaly | 4 | 6.8 (1.9–17.4) |
| Buphtalmos | 1 | 1.7 (0–9.5) |
| Congenital cataract | 2 | 3.4 (0.4–12.3) |
| Anotia/microtia | 1 | 1.7 (0–9.5) |
| Transposition of great vessels | 4 | 6.8 (1.9–17.4) |
| Tetralogy of Fallot | 2 | 3.4 (0.4–12.3) |
| Ventricular septal defect | 42 | 71.3 (51.4–96.4) |
| Atrial septal defect | 4 | 6.8 (1.9–17.4) |
| Endocardial cushion defects | 3 | 5.1 (1.1–14.9) |
| Ebstein's anomaly | 1 | 1.7 (0–9.5) |
| Hypoplastic left heart syndrome | 0 | 0 (0–6.3) |
| Coarctation of aorta | 3 | 5.1 (1.1–14.9) |
| Choanal atresia, bilateral | 0 | 0 (0–6.3) |
| Cleft palate without cleft lip | 1 | 1.7 (0–9.5) |
| Cleft lip with or without cleft palate | 2 | 3.4 (0.4–12.3) |
| Oesophageal atresia/stenosis | 4 | 6.8 (1.9–17.4) |
| Congenital hypertrophic pyloric stenosis | 1 | 1.7 (0–9.5) |
| Small intestine atresia/stenosis | 0 | 0 (0–6.3) |
| Anorectal atresia/stenosis | 1 | 1.7 (0–9.5) |
| Hirschsprung's disease | 1 | 1.7 (0–9.5) |
| Anomalies of intestinal fixation | 0 | 0 (0–6.3) |
| Hypospadias | ||
| Indeterminate sex | 0 | 0 (0–6.3) |
| Renal agenesis | 1 | 1.7 (0–9.5) |
| Cystic kidney | 3 | 5.1 (1.1–14.9) |
| Bladder exstrophy | 0 | 0 (0–6.3) |
| Polydactyly and syndactyly | 4 | 6.8 (1.9–17.4) |
| Total limb reduction defects | Not analysed | Not analysed |
| Diaphragmatic hernia | 1 | 1.7 (0–9.5) |
| Omphalocele | 0 | 0 (0–6.3) |
| Gastroschisis | 0 | 0 (0–6.3) |
| Trisomy 13 | 0 | 0 (0–6.3) |
| Trisomy 18 | 0 | 0 (0–6.3) |
| Down syndrome | 6 | 10.2 (3.7–22.2) |
| Prader Willi syndrome | 0 | 0 (0–6.3) |
| Total | 98 | 166.4 |
| T2DM | T2DM + MC | Control | |
| Gender (M/F) | 73/39 | 77/41 | 37/23 |
| Age (years) | 75.1 ± 2.1 | 76.1 ± 3.1 | 73.3 ± 6.2 |
| Duration (years) | 15.2 ± 4.3 | 16.8 ± 3.4 | NA |
| BMI (kg/m2) | 26.17 ± 3.83★ | 27.10 ± 4.01★ | 23.13 ± 3.83 |
| WHR | 0.94 ± 0.63★ | 0.98 ± 0.31★ | 0.85 ± 0.07 |
| SBP (mmHg) | 137 ± 9★ | 143 ± 13★ | 123 ± 16 |
| DBP (mmHg) | 69 ± 6 | 67 ± 6 | 65 ± 7 |
| AF, n | 34 | 45 | 12 |
| CKD, n | 33★ | 45★ | 10 |
| CHD, n | 37★ | 55★● | 16 |
| 1 | 64 | 45 | None |
| 2 | 33 | 47 | None |
| 3 | 13 | 28● | None |
| User | Dice | ASSD(mm) | κ |
| 1 | 0.81±0.02 | 2.73±0.62 | 0.931 |
| 2 | 0.82±0.03 | 2.57±0.60 | 0.936 |
| 3 | 0.81±0.03 | 2.75±0.61 | 0.949 |
| 4 | 0.80±0.03 | 2.81±0.73 | 0.941 |
| 5 | 0.82±0.02 | 2.58±0.61 | 0.948 |
| 6 | 0.82±0.02 | 2.63±0.61 | 0.945 |
| 7 | 0.82±0.02 | 2.61±0.74 | 0.941 |
| 8 | 0.81±0.03 | 2.76±0.67 | 0.936 |
| All | 0.82±0.02 | 2.67±0.63 | 0.932 |
| Service area | Number of MNH providers observed | Number of provider-client interactions observed | Intraclass Correlation Coefficient (ICC) | ||||||
| Total | Inter-vention group | Com-parison group | Total | Inter-vention group | Com-parison group | Cluster level | Inter-vention group | Com-parison group | |
| ANC | 63 | 29 | 34 | 232 | 118 | 114 | Facility | 0.551 | 0.458 |
| Provider | 0.763 | 0.667 | |||||||
| Labor & delivery | 117 | 57 | 60 | 226 | 123 | 123 | Facility | 0.632 | 0.474 |
| Provider | 0.775 | 0.454 | |||||||
| PNC | 109 | 57 | 52 | 229 | 119 | 110 | Facility | 0.530 | 0.573 |
| Provider | 0.658 | 0.574 |
| Females | Males | |||||
| Gene | Coefficient estimate | Standard error | P-value | Coefficient estimate | Standard error | P-value |
| AQP9 | 0.411 | 0.133 | 0.003** | 0.028 | 0.156 | 0.857 |
| AS3MT | −0.115 | 0.074 | 0.126 | 0.058 | 0.082 | 0.483 |
| GSTM1 | 0.107 | 0.435 | 0.806 | −0.279 | 0.506 | 0.584 |
| SLC39A2 | −0.105 | 0.101 | 0.300 | −0.015 | 0.089 | 0.870 |
| Anti-VLY scFv | Expression level, % of total cell protein | Oligomeric state | Activity (%) after 12 months storage at 4°C |
| scFv 9B4 (VL-VH) | 20-30 | monomeric | 100 |
| scFv 9B4 (VH-VL) | 20-30 | monomeric | 100 |
| scFv 23A2 (VL-VH) | 20-30 | monomeric | 75 |
| scFv 23A2 (VH-VL) | 20-30 | monomeric | 75 |
| Plasma membrane number / % | Intracellular number / % | Total immunogold number / % | |
| P7 | |||
| Dendritic spines | 88/7,6 | 107/9,2 | 195/16,9 |
| Dendritic shafts | 415/35,9 | 521/45 | 936/80,9 |
| Axon terminals | 19/1,6 | 7/0,6 | 26/2.2 |
| P12 | |||
| Dendritic spines | 191/10,8 | 237/13,4 | 428/24,1 |
| Dendritic shafts | 698/39,2 | 581/32,7 | 1279/72,1 |
| Axon terminals | 55/3,1 | 13/0,7 | 68/3,8 |
| P15 | |||
| Dendritic spines | 588/30,2 | 157/8,1 | 745/38,3 |
| Dendritic shafts | 541/27,9 | 434/22,3 | 975/50,1 |
| Axon terminals | 176/9 | 51/2,6 | 227/11,7 |
| P21 | |||
| Dendritic spines | 697/32,3 | 213/9,9 | 910/42,1 |
| Dendritic shafts | 602/27,9 | 422/19,6 | 1024/47,4 |
| Axon terminals | 172/8 | 55/2,5 | 227/10,5 |
| P60 | |||
| Dendritic spines | 798/33,4 | 241/10,1 | 1039/43,4 |
| Dendritic shafts | 639/26,7 | 415/17,3 | 1054/44,1 |
| Axon terminals | 232/9,7 | 67/2,8 | 299/12,5 |
| Characteristics | % (SE) |
| Age, yb | 45.2 ± 0.2 |
| < 65 | 86.2 (0.6) |
| ≥ 65 | 13.8 (0.6) |
| Sex | |
| Male | 49.5 (0.5) |
| Female | 50.5 (0.5) |
| BMI, kg/m2 | |
| < 25 | 68.9 (0.9) |
| ≥ 25 | 31.1 (0.9) |
| Smoking exposure | |
| Never | 74.3 (0.7) |
| Former or current | 25.7 (0.7) |
| Alcohol drinking, g/day | |
| < 30 | 90.1 (0.6) |
| ≥ 30 | 9.9 (0.6) |
| Residence area | |
| Rural | 20.2 (1.8) |
| Urban | 79.8 (1.8) |
| Education | |
| ≤ High school | 70.4 (1.0) |
| ≥ College | 29.6 (1.0) |
| Occupation | |
| Agriculture & fishery | 5.6 (0.6) |
| Industry | 9.2 (0.5) |
| Services | 85.3 (0.8) |
| GFR, ml/min/1.73 m2b | 95.1 ± 0.5 |
| Blood pressureb | |
| SBP, mmHg | 116.9 ± 0.4 |
| DBP, mmHg | 76.7 ± 0.3 |
| MAP, mmHg | 88.7 ± 0.2 |
| Comparison | Keyword | Gene Set | Gene Set Description | Size | p-valueExp. 2 | Significant Genes | p-valueExp. 1 |
| Control vs ALC-NTO/ALC-NTC (see legends) | Growth,Growth Regulation* | GO:0016049GO:0040007 | ^Cell growth^Growth | 4775 | 0.0020.005 | (Ctgf, Igfbp2, Emp1, Osm, Cyr61, Gap43, Crim1, Tgfb3, Igfbp7, Nov, Emp3), Gpc3, Csf1, Socs2, Bmp6, Bmp4, Inhbb, Lepre1, Wrn, Wig1, Cish | 0.0100.010 |
| GO:0001558GO:0040008 | Regulation of cell growthRegulation of growth | 3956 | 0.0020.016 | (Ctgf, Igfbp2, Osm, Cyr61, Gap43, Crim1, Igfbp7, Nov), Gpc3, Csf1, Socs2, | 0.0060.017 | ||
| GO:0005520 | Insulin-like growth factor binding | 14 | 0.000 | Ctgf, Igfbp2, Cyr61, Crim1, Igfbp7, Nov | 0.012 | ||
| Heart* | GO:0001525 | Angiogenesis | 53 | 0.022 | Ctgf, Anxa2, Cyr61, Thbs1, Vegfa, Tie1, Elk3, Flt1, Crhr2, Vegfc, Kdr, Bmp4, Adra2b, Tnfrsf12a | 0.022 | |
| Eye# | GO:0001654 | Eye Development | 26 | 0.040 | Mab21l1, Neurod1, Neurod4, Ntrk2, Fkbp8, Bmpr1b, Crb1, Stat3, Tspan5, Pax6, Bmp4, Map3k1 | 0.004 | |
| Epigenetic factor~,^ | GO:0006334 | Nucleosome modeling | 30 | 0.021 | Hist3h2b, a; Hist1h3f; Hist1h1c; Hist1h2b, c; Hist1h3a; H1f0; Smarca2; Nap1l3 | 0.033 | |
| ALC-NTO vs ALC-NTC | Growth, Growth retardation | GO:0007173 | Epidermal growth factor receptor (EGFR) signaling pathway | 5 | 0.019 | Pde6g, Egfr, Hbegf(Enriched in ALC-NTC) | 0.023 |
| Criterion | Response | No. | Mean ± SD | p-Value |
| Occupational exposure (mean ± SD) | ||||
| Yes | Bone Pb | 108 | 14.4 ± 0.50a | < 0.001 |
| No | 99 | 3.22 ± 0.50a | ||
| Yes | Blood Pb | 107 | 2.73 ± 2.39 | < 0.001 |
| No | 98 | 1.25 ± 2.10 | ||
| Smoked ever/never | ||||
| Yes | Bone Pb: exposed | 65 | 18.1 ± 0.61a | 0.002 |
| No | 43 | 6.87 ± 0.86a | ||
| Yes | Blood Pb: exposed | 64 | 3.67 ± 12.0 | < 0.001 |
| No | 43 | 1.76 ± 2.49 | ||
| Ever used estrogen | ||||
| Yes | Bone Pb: referent | 29 | 7.73 ± 0.94a | 0.003 |
| No | 70 | 1.41 ± 0.60a | ||
| Yes | Blood Pb: referent | 28 | 1.56 ± 2.21 | 0.038 |
| No | 70 | 1.15 ± 2.03 | ||
| Still have menstrual periods | ||||
| Yes | Blood Pb: referent | 59 | 1.04 ± 1.97 | 0.002 |
| No | 39 | 1.65 ± 2.14 | ||
| Yes | Blood Pb: exposed | 46 | 2.09 ± 2.49 | 0.012 |
| No | 61 | 3.33 ± 2.19 | ||
| Surgical menopause | ||||
| Yes | Blood Pb: exposed | 47 | 2.87 ± 2.12 | 0.008 |
| No | 14 | 5.46 ± 2.02 | ||
| Postmenopausal women who have used estrogen | ||||
| Yes | Bone Pb: referent | 24 | 9.18 ± 1.08a | 0.007 |
| No | 16 | 1.83 ± 1.32a | ||
| Ever used oral contraceptives | ||||
| Yes | Bone Pb: referent | 73 | 1.39 ± 0.61a | 0.036 |
| No | 26 | 7.22 ± 0.90a | ||
| Yes | Blood Pb: referent | 72 | 1.13 ± 2.00 | 0.006 |
| No | 26 | 1.66 ± 2.66 |
| Parameter | (n = 504) |
| Age (Years) | |
| <50 Years | 422 (84) |
| >50 Years | 82(16) |
| Sex | |
| Male | 423(84) |
| Female | 82(16) |
| Pre existing comorbid conditions | |
| Respiratory disease | 51 (10) |
| Renal Disease | 27 (50) |
| Malignancy | 25 (5) |
| Hypertension | 11 92) |
| Diabetes mellitus | 5 (1) |
| Signs and symptoms | |
| Pain | 495 (98) |
| Vomiting | 296 (59) |
| Abdominal distention | 221 (44) |
| Constipation | 193 (38) |
| Fever | 124 (25) |
| Diarrhoea | 35 (7) |
| Tachycardia (pulse >/110/minute) | 115 (23) |
| Hypotention (Systolic blood pressure <100 mm Hg) | 44 (9) |
| Urine output (<30 ml/hr) | 80 (16) |
| Tacchypnea (respiratory rate >20/minute) | 334 (66) |
| Investigations | |
| Pneumoperitoneum on Chest X-Ray | 340(67) |
| Air fluid levels on abdominal X-Ray | 108(21) |
| Hyponatraemia(Na<130 mEq/L) | 148(29) |
| Hypokalemia(K<2.7 mEq/L) | 44(09) |
| Blood Urea Nitrogen(>167 mg/dl) | 76(15) |
| Serum Creatinine(<1.7 mg/dl) | 65(13) |
| Group | n | Before therapy | After therapy |
| Met + Acu Group | 49 | 5.57 ± 0.257 | 3.23 ± 0.170***△△ |
| Control Group | 49 | 5.50 ± 0.244 | 4.25 ± 0.197*** |
| Practice related variables | Percentage (%) |
| Monitor blood glucose | |
| Daily | 10 (8) |
| Weekly | 18 (15) |
| Monthly | 45 (37) |
| Never | 49 (40) |
| Blood pressure monitor | |
| Daily | 12 (10) |
| Weekly | 4 (3) |
| Monthly | 49 (40) |
| Never | 57 (47) |
| Adherence to medication | |
| Regular | 53 (43) |
| Irregular | 69 (57) |
| Visiting an eye specialist | |
| Every 6–12 months | 13 (11) |
| Every year | 45 (37) |
| Felt problem with vision | 64 (52) |
| Species | Population | Hostplant | Coordinates | |
| T. bartmani | JL | Abies concolor | 34.170000 | -117.002017 |
| T. bartmani | RS | Abies concolor | 34.210000 | -117.098333 |
| T. boharti | ML | Adenostoma | 32.881200 | -116.445917 |
| T. californicum | Fremont | Adenostoma | 36.763517 | -121.502533 |
| T. californicum | HW1 | Quercus | 36.286933 | -121.841883 |
| T. chumash | HW2 | Adenostoma | 34.269700 | -118.168483 |
| T. chumash | ED | Ceanothus | 33.885183 | -116.859783 |
| T. cristinae | WTA | Adenostoma | 34.515833 | -120.073150 |
| T. cristinae | OJ | Ceanothus | 34.485300 | -119.298117 |
| T. knulli | Trail | Sequoia | 35.836200 | -121.391483 |
| T. knulli | BC | Ceanothus | 36.071017 | -121.595567 |
| T. petita | Ma | Ceanothus | 36.358900 | -121.900350 |
| T. petita | Mo | Ceanothus | 36.476533 | -121.936133 |
| T. podura | HW243 | Adenostoma | 33.815117 | -116.791033 |
| T. podura | Seq | Ceanothus | 35.583333 | -118.533333 |
| T. poppensis | Fish | Pseudotsuga | 38.885283 | -123.517150 |
| T. poppensis | Mado | Sequoia | 36.996433 | -121.717783 |
| T. cristinae | OGA | Adenostoma | 33.990567 | -116.061417 |
| T. cristinae | R23A | Adenostoma | 34.519067 | -120.077500 |
| T. cristinae | SC | Ceanothus | 34.522300 | -119.831283 |
| T. cristinae | PEC | Ceanothus | 34.491333 | -119.795017 |
| Phenotype | Life-history Classification | ||||
| Resident Rainbow (RR) | Steelhead Smolt (SS) | P | |||
| Mean | SE | Mean | SE | H0: μRR = μSS | |
| Length605 | 94.90909 | 1.59297 | 95.25000 | 0.81523 | 0.849 |
| Length905 | 193.47727 | 2.48981 | 191.07143 | 1.27420 | 0.391 |
| Lenght606 | 218.77273 | 3.08109 | 232.58333 | 1.57680 | <0.0001 |
| Weight605 | 9.72290 | 0.55520 | 10.04140 | 0.26860 | 0.618 |
| Weight905 | 106.12000 | 4.26820 | 92.40100 | 2.06510 | 0.006 |
| Weight606 | 137.09091 | 6.11324 | 139.24941 | 3.12855 | 0.754 |
| Kfact605 | 1.14757 | 0.01643 | 1.11501 | 0.00841 | 0.079 |
| Kfact905 | 1.44220 | 0.01103 | 1.29540 | 0.00534 | <0.0001 |
| Kfact606 | 1.25300 | 0.01039 | 1.08040 | 0.00503 | <0.0001 |
| IGRL1 | 0.67905 | 0.00876 | 0.66566 | 0.00448 | 0.175 |
| IGRW1 | 2.26189 | 0.02634 | 2.14185 | 0.01348 | <0.0001 |
| IGRL2 | 0.04539 | 0.00189 | 0.07573 | 0.00092 | <0.0001 |
| IGRW2 | 0.08184 | 0.00594 | 0.15670 | 0.00288 | <0.0001 |
| AvgPix | 25.27810 | 2.91850 | 72.17890 | 0.70010 | <0.0001 |
| PWL | 10.85140 | 0.34410 | 3.79260 | 0.21880 | <0.0001 |
| BPNa | 213.32000 | 3.15090 | 187.58000 | 2.00820 | <0.0001 |
| Centroid_Size | 2111.85000 | 49.41540 | 2191.30000 | 25.94380 | 0.156 |
| RelW2 | 0.01278 | 0.00104 | -0.01308 | 0.00052 | <0.0001 |
| RelW3 | 0.01461 | 0.00095 | 0.00911 | 0.00047 | <0.0001 |
| RelW4 | 0.00502 | 0.00117 | 0.00420 | 0.00061 | 0.540 |
| RelW5 | −0.00131 | 0.00124 | 0.00054 | 0.00065 | 0.188 |
| RelW6 | 0.00225 | 0.00091 | 0.00353 | 0.00045 | 0.226 |
| RelW7 | 0.00239 | 0.00079 | 0.00279 | 0.00041 | 0.656 |
| RelW8 | 0.00081 | 0.00069 | 0.00253 | 0.00036 | 0.029 |
| RelW9 | 0.00142 | 0.00071 | -0.00007 | 0.00037 | 0.089 |
| RelW10 | −0.00063 | 0.00083 | −0.00146 | 0.00043 | 0.374 |
| Sample | h-IgA Addition (ng/mL) | Detection (ng/mL) | Recovery |
| 1 | 0 | 190.83 | --- |
| 25 | 214.25 | 93.7% | |
| 50 | 242.25 | 102.8% | |
| 2 | 0 | 218.83 | --- |
| 25 | 242.65 | 95.28% | |
| 50 | 274.93 | 112.2% |
| PHASE | ACTIVITY | PURPOSE | LOGISTICS | PARTICIPANTS | OUTPUTS |
| 1.Max.5 × 8hourshifts | Initial unstructuredobservations | • Familiarisation with space and use of space• Familiarisation with rhythm of setting• Starting to build relationships and trust• Determine who is amenable to shadowing• Identify key locations for stationaryobservations• Identify key policy/guideline documents | • Background observation ofactivity (potentiallyaccompanying key initialcontact in the setting)• Introductions with staffmembers• 5 shifts on different days ofthe week (over 2 weeks)(= max 40 hours) | All staff | • Map of settings• Timetable of key regular events• List of 6-8 key informants• Collected documents for lateranalysis (e.g. policies, guidelines)• Fieldnotes |
| 2.Max.8 × 8hourshifts | Shadowing staffmembers | • Observe mechanics of interactionalconstruction of safe practice• Observe interactions newcomers/old-timers• Observe use of tools/artefacts/environment• Identifying key practices to follow in laterstage | • Shadow each staff memberfor 1 shift/part shift• Audio recording of keymeetings attended by staffmember• Field notes of informal talk• Field interviews | 2 doctors2 nurses2 allied health2 managers | • Map of practices of each keyinformant - how they construepatient safety and how they goabout trying to maintain it• Fieldnotes• Transcriptions of meetings |
| 3.Max.2 × 8hourshifts | Stationaryobservations in keylocations | • Observe role of key artefacts in constitution ofsafety (e.g. phone in nurse's station; filingcabinet etc).• Observe patterns of movement of staff | • 2 locations, 1 shift each(max. 16 hours) | All staff | • Fieldnote account of how artefactsand space play a role in theconstitution of safety• Actor-artefact network map |
| 4.Max.4 × 8hourshifts | Tracing keypractices | • Observe the unfolding of specific practicespreviously identified as key to preservation ofsafety• Observe differences in activity when practice isin the course of the everyday (e.g. admission/discharge) and, if appropriate, when it followsbreakdown in order (e.g. incident review) | • 1 'everyday' practice overthe course of 2 shifts• 1 practice dealing withdeviation from the normal (i.e.when safe practice hasbroken down in some way) | Staff involved inpractices chosen | • Map of 'practice nets' involved inpractices key to preservation ofsafety• How practice nets change whensafety breaks down |
| 5.Approx.1 hr perinterview | Interviews | • Elicit narrative accounts of safety preservation• Observe how the meaning of safety isconstructed by different professionals - what'rules and resources' do they draw on?• Test emerging findings/maps of practices | • 6-8 interviews - audiorecordings | 6-8 key informantsfrom phase 2 | • Transcripts for analysis |
| 6.Approx.30 minspersurvey | •Social networksurvey | • Provide triangulation of observation andinterview data• Map overall patterns of communication aboutsafety issues within and between the twosettings under study | • Administer a social networkquestionnaire to all staff in theinpatient team andcommunity team under study. | All staff | • Social network diagrams providingvisual representation of patterns ofsafety communication |
| Variables | CUc (N = 35) | nCUd (N = 48) | t | p | ||
| Mean | SD | Mean | SD | |||
| Age | 22.51 | 5.63 | 21.67 | 3.56 | 0.84 | 0.40 |
| UnExa | 7.63 | 6.04 | 5.44 | 3.71 | 1.90 | 0.06 |
| CogDisb | 10.46 | 5.75 | 10.73 | 4.97 | −0.23 | 0.82 |
| Cigarettes/week | 24.66 | 28.67 | n/a | n/a | n/a | n/a |
| Joints/week | 11.14 | 12.16 | n/a | n/a | n/a | n/a |
| Nicotine use severity | 1.94 | 1.86 | 0.08 | 0.45 | 5.78 | 0.00 |
| Cannabis use severity | 2.97 | 1.95 | 0.00 | 0.00 | 9.03 | 0.00 |
| Alcohol use severity | 2.29 | 1.84 | 1.31 | 1.42 | 2.72 | 0.01 |
| ERAP2 genotype | Fetal | Maternal | Total | |||||||
| rs2248374 | rs2549782 | Observed | Expected | P-value | Observed | Expected | P-value | Observed | Expected | P-value |
| AA | TT | 0 | 57 | 5.66 e-14 | 0 | 52 | 8.20 e-13 | 0 | 114 | <2.2 e-16 |
| AA | TG | 90 | 28 | 7.79 e-09 | 81 | 27 | 1.69 e-07 | 130 | 56 | 4.50 e-08 |
| AA | GG | 43 | 14 | 1.71 e-04 | 44 | 14 | 1.14 e-04 | 59 | 28 | 1.16 e-03 |
| AG | TT | 151 | 111 | 0.01 | 138 | 106 | 0.04 | 289 | 221 | 1.60 e-03 |
| GG | TT | 346 | 215 | 1.99 e-10 | 350 | 214 | 4.22 e-11 | 696 | 429 | <2.2 e-16 |
| Mycotoxin Content (μg/kg) a | ||||||
| % >LOD | Mean | SEM b | Median | 90th Percentile | Maximum | |
| DON | 66 | 473 | 99 | 100 | 2510 | 9880 |
| ZEA | 22 | 18 | 7 | 5 | 47 | 1000 |
| NIV | 25 | 16 | 3 | 3 | 75 | 290 |
| Country | Discount | Annual cash flow (profit/loss) | Present value of annual cash flow | Present value of all annual cash flows | Present value of terminal valuea | Total present valueb |
| Singapore | 50% annually | 3.13 | 0.41 | 1.51 | 4.13 | 5.64 |
| 25% annually | 3.13 | 1.03 | 3.15 | 10.27 | 13.41 | |
| 15% annually | 3.13 | 1.56 | 4.42 | 15.58 | 20.00 | |
| Netherlands | 50% annually | 10.76 | 1.42 | 6.06 | 14.17 | 20.23 |
| 25% annually | 10.76 | 3.53 | 12.12 | 35.27 | 47.39 | |
| 15% annually | 10.76 | 5.35 | 16.80 | 53.51 | 70.31 | |
| USA | 50% annually | −94.76 | 0 | 0 | 0 | 0 |
| 25% annually | −94.76 | 0 | 0 | 0 | 0 | |
| 15% annually | −94.76 | 0 | 0 | 0 | 0 |
| Order | Symbol | Name | Similarity | Parameter | Remark |
| 1 | CENP-E | kinesin | 0. 8169 | 3 | |
| 2 | GCN4 | 0.7611 | 3 | monomer yeast transcriptional activator | |
| 3 | ROCK1 | Serine kinase | 0.7394 | 3 | Rho-associated,coiled-coil containing protein kinase 1 |
| 6 | CENP-B | 0.7297 | 3 | ||
| 4 | PAK1 | 0.6481 | 3 | P21 activated kinase | |
| 7 | GP41-HIV | 0. 6010 | 3 | ||
| 8 | ATG12 | 0.4749 | 3 | ||
| 5 | ROCK2 | 0.4478 | 3 | ||
| 9 | CENP-A | 0 | 0 |
| high secure-intensive care | Male admission/high secure | Male medium secure-1 | Male medium secure-2 | Long term low security | Male low secure rehab | Male pre-discharge/community h1gh support | ANOVADf = 6 | ||
| N | 7 | 10 | 14 | 16 | 10 | 15 | 15 | F/p | |
| GAF | mean | 34.6 | 45.8 | 47.4 | 54.4 | 47.8 | 60.5 | 73 | 13.8/0.001 |
| 95% CI | 20.3-48.8 | 35.3-56.3 | 39.8-55.1 | 49.2-59.5 | 40.3-55.3 | 56.7-64.4 | 67.6-78.4 | ||
| PANSS positive | mean | 21.4 | 13.6 | 17.9 | 13.3 | 14.6 | 11.3 | 8.9 | 5.4/0.001 |
| 95% CI | 13.4-29.5 | 11.1-16.1 | 13.7-22.1 | 10.5-16.2 | 8.7-20.5 | 8.6-13.9 | 7.1-10.6 | ||
| PANSS negative | mean | 23.6 | 22.3 | 21.9 | 15.6 | 21.1 | 17.0 | 10.9 | 5.9/0.001 |
| 95% CI | 16.3-30.8 | 16.1-28.5 | 17.4-26.4 | 12.6-18.5 | 16.1-26.2 | 13.4-20.6 | 8.7-12.9 | ||
| PANSS general | mean | 37.6 | 31.5 | 32.4 | 28.8 | 29.1 | 25.9 | 21.9 | 3.5/0.008 |
| 95% CI | 27.0-48.1 | 24.7-38.3 | 27.4-37.5 | 23.6-34.0 | 21.8-36.4 | 21.5-30.4 | 18.8-36.4 | ||
| PANSS total | mean | 82.6 | 67.4 | 72.3 | 57.7 | 64.8 | 54.2 | 41.6 | 5.6/0.001 |
| 95% CI | 57.9-107.2 | 54.8-79.9 | 60.2-84.4 | 47.9-67.5 | 48.4-81.2 | 44.1-64.3 | 35.7-47.5 | ||
| CANFOR staff met needs | mean | 7.0 | 6.1 | 6.1 | 8.1 | 6.9 | 6.5 | 7.0 | 0.9/0.5 (NS) |
| 95% CI | 4.2-9.8 | 4.6-7.6 | 4.1-7.9 | 6.6-9.5 | 4.8-8.9 | 5.4-7.5 | 5.7-8.3 | ||
| CANFOR staff unmet needs | mean | 5.7 | 3.1 | 4.4 | 2.9 | 2.7 | 1.4 | 1.0 | 5.9/0.001 |
| 95% CI | 3.5-7.9 | 1.5-4.7 | 2.2-6.7 | 2.0-3.9 | 1.2-4.2 | 0.8-2.0 | 0.4-1.6 | ||
| CANFOR staff total needs | mean | 12.7 | 9.2 | 10.5 | 11.0 | 9.6 | 7.9 | 8.0 | 2.2/0.052 (NS) |
| 95% CI | 8.7-16.7 | 6.3-12.1 | 7.3-13.7 | 9.1-12.9 | 6.2-12.9 | 6.8-8.9 | 6.6-9.4 |
| Measurementa | No. (%) |
| Range of motion (knee) | 34 (57) |
| X-ray (knee) | 19 (32) |
| Pain score (knee) | 10 (17) |
| Subjects were asked to first stand and then walk along a 10 m walkway | 5 (8) |
| Range of motion (shoulder) | 5 (8) |
| Pain score (shoulder) | 5 (8) |
| Stability of joint function (stabilometry) | 4 (7) |
| Pain score (upper limb) | 4 (7) |
| Hand grip strength | 3 (5) |
| Range of motion (hip) | 3 (5) |
| Strength of the knee extensors | 3 (5) |
| Chair rise test | 2 (3) |
| Muscle power (shoulder) | 2 (3) |
| Range of motion (ankle) | 2 (3) |
| Range of motion (finger/wrist) | 2 (3) |
| Range of motion (lower limb, matching task) | 2 (3) |
| X-ray (elbow) | 2 (3) |
| X-ray (hip) | 2 (3) |
| X-ray (shoulder) | 2 (3) |
| Compound | Adsorption capacity, μmol g−1 | Distribution coefficient (k), g L−1 |
| 1-Naphthol | 62 | 200 |
| 2-Naphthol | 60 | 170 |
| Resorcinol | 59 | 190 |
| Phenol | 0 ± 2 | – |
| Characteristic | Value | ICUSteps | UCCDIP | Verbal | Total | p Value |
| Age (years) | Mean±SD | 59±15.26 | 60±15.19 | 61±17.48 | 60±16.04 | 0.72 |
| Ethnicity (white British) | n (%) | 34 (71) | 40 (78) | 41 (69) | 115 (73) | 0.54 |
| Gender (male) | n (%) | 25 (52) | 26 (51) | 31 (53) | 82 (52) | 0.99 |
| Medical/Surgical ICU | Medical, n (%) | 28 (58) | 28 (55) | 26 (44) | 82 (52) | 0.30 |
| Admission type (emergency) | n (%) | 38 (79) | 40 (78) | 44 (75) | 122 (77) | 0.83 |
| APACHE II score | ICU admissionMedian (range) | 17 (24) | 18.0 (30) | 16.0 (29) | 17.0 (30) | 0.41 |
| ICU discharge Median (range) | 8.0 (20) | 9.5 (20) | 9.0 (21) | 9.0 (21) | 0.66 | |
| Length of stay | ICU daysMedian (range) | 6.0 (62) | 7.0 (104) | 6.0 (371) | 6.0 (371) | 0.24 |
| Hospital daysMedian (range) | 16.0 (132) | 21.5 (220) | 22.0 (166) | 21.0 (221) | 0.25 | |
| Level 3 critical illness | n (%) | 29 (60) | 35 (69) | 34 (58) | 98 (62) | 0.58 |
| Total number of participants | n (%) | 48 (100) | 51 (100) | 59 (100) | 158 (100) | NA |
| Group 1 | Group 2 | Chi-square | Significance (p value) | |
| A | 123/339 (36.3 %) | 84/370 (22.7 %) | 15.784 | <0.001 |
| B | 146/339 (43.1 %) | 99/370 (26.8 %) | 20.813 | <0.001 |
| C | 14/339 (4.1 %) | 19/370 (5.1 %) | 0.403 | 0.594 |
| D | 144/339 (42.5 %) | 143/370 (38.6 %) | 1.077 | 0.320 |
| E | 68/339 (20.1 %) | 93/370 (25.1 %) | 2.597 | 0.127 |
| F | 79/339 (23.3 %) | 132/370 (35.7 %) | 12.954 | <0.001 |
| G | 162/339 (47.8 %) | 200/370 (54.1 %) | 2.780 | 0.099 |
| Seroprotection status | ||||||
| Vaccine strain | Young cohort (n = 58) | Older cohort (n = 54) | p | |||
| Placebo | B. longum + Gl-OS | Placebo | B. longum + Gl-OS | |||
| n/N (%) | n/N (%) | n/N (%) | n/N (%) | |||
| A/California/7/2009 (H1N1) | Before | 20/29 (69)a | 13/29 (45)a | 5/28 (18) | 1/26 (4) | < 0.001 |
| After | 29/29 (100) | 27/29 (93)a | 22/27 (81) | 16/26 (62) | < 0.001 | |
| A/Perth/16/2009 (H3N2) | Before | 10/29 (34) | 13/29 (45) | 8/28 (29) | 12/26 (46) | NS |
| After | 26/29 (90) | 27/29 (93) | 25/27 (93) | 22/26 (85) | NS | |
| B/Brisbane/60/2008 | Before | 4/29 (14) | 0/29 (0) | 4/24 (17) | 5/26 (19) | NS |
| After | 28/29 (97) | 20/29 (76) | 14/27 (52) | 11/26 (42) | < 0.001 |
| Sampling date | ACE | Chao1 | Shannon diversity (H') | Simpson diversity (1/D) |
| Jul. 13 | 383(363,415) | 386(361,433) | 3.58(3.55,3.62) | 11(11,11) |
| Jul. 31 | 409(386,445) | 405(380,451) | 4.19(4.16,4.22) | 25(25,25) |
| Aug. 16 | 463(443,495) | 458(436,498) | 3.99(3.96,4.03) | 16(16,16) |
| Sep. 1 | 507(493,531) | 514(494,552) | 4.33(4.31,4.35) | 33(33,33) |
| Sep. 15 | 459(436,493) | 454(429,497) | 4.18(4.15,4.21) | 25(25,25) |
| Sep. 30 | 401(381,435) | 399(375,442) | 4.43(4.39,4.46) | 33(33,33) |
| Creatinine-Cystatin C-based eGFR, ml/min/1.73 m2 | C-reactive protein levels, mg/L | |||||
| ≥60(n = 1750) | <60(n = 605) | P-value | <3(n = 1564) | ≥3(n = 791) | P-value | |
| Age, years | 71.2 ± 5.04 | 75.4 ± 5.3 | <0.001 | 72.0 ± 5.3 | 72.7 ± 5.6 | 0.004 |
| Men, No. (%) | 1465 (83.7%) | 422 (69.8%) | <0.001 | 1291 (82.5%) | 596 (75.3%) | <0.001 |
| Higher education a, n (%) | 767 (44.0%) | 238 (39.7%) | 0.064 | 715 (45.9%) | 290 (36.9%) | <0.001 |
| Body mass indexb, kg/m2 | 27.6 ± 3.6 | 28.1 ± 4.1 | 0.003 | 27.3 ± 3.4 | 28.6 ± 4.15 | <0.001 |
| Physically activec, n (%) | 389 (22.3%) | 87 (14.5%) | <0.001 | 340 (21.8%) | 136 (17.3%) | 0.010 |
| Current smoker, n (%) | 267 (15.3%) | 83 (13.8%) | 0.363 | 184 (11.8%) | 166 (21.0%) | <0.001 |
| Alcohol use ≥1 glass/week, n (%) | 1286 (73.6%) | 360 (59.9%) | <0.001 | 1135 (72.8%) | 510 (64.8%) | <0.001 |
| Antidepressant use, n (%) | 78 (4.5%) | 40 (6.6%) | 0.036 | 67 (4.3%) | 51 (6.4%) | 0.023 |
| Time since myocardial infarction, years | 4.5 ± 3.1 | 4.7 ± 3.4 | 0.110 | 4.5 ± 3.2 | 4.7 ± 3.2 | 0.117 |
| Self-reported history of stroke, n (%) | 94 (5.4%) | 58 (9.7%) | <0.001 | 84 (5.4%) | 68 (8.7%) | 0.003 |
| Diabetesd, n (%) | 93.1 (22.3%) | 188 (31.1%) | <0.001 | 375 (24.0%) | 204 (25.8%) | 0.334 |
| Systolic blood pressure, mmHg | 142.9 ± 20.5 | 141.6 ± 23.7 | 0.188 | 143.4 ± 20.9 | 140.9 ± 22.1 | 0.006 |
| Use of cardiovascular medicatione, n (%) | ||||||
| Antithrombotic agents | 1713 (97.9%) | 584 (96.5%) | 0.063 | 1529 (97.8%) | 768 (97.1%) | 0.322 |
| Blood pressure lowering drugs | 1729 (98.8%) | 591 (97.7%) | 0.051 | 1537 (98.3%) | 783 (99.0%) | 0.176 |
| Statins | 1553 (88.7%) | 513 (84.8%) | 0.011 | 1399 (89.5%) | 667 (84.3%) | <0.001 |
| High-sensitivity C-reactive protein, mg/L | 1.42 (0.71-3.15) | 3.33 (1.27-6.91) | <0.001 | 1.01 (0.61-1.72) | 5.66 (4.04-8.83) | <0.001 |
| Serum creatininef, mg/dl | 0.96 ± 0.18 | 1.54 ± 0.61 | <0.001 | 1.05 ± 0.33 | 1.22 ± 0.56 | <0.001 |
| Serum cystatin C, mg/L | 0.89 ± 0.13 | 1.41 ± 0.42 | <0.001 | 0.96 ± 0.24 | 1.15 ± 0.42 | <0.001 |
| Analyte | Plasma | CSF | ||
| Sensitivity (pg/mL) | Inter-assay CV range (QC concentration range) | Sensitivity (pg/mL) | Inter-assay CV range (QC concentration range) | |
| IL-1Ra | 16 | 8.2 to 3.2 (360 to 10,009 pg/mL) | Same assay as for plasma | |
| IL-1α | 6.1 | 9.0 to 4.2 (25 to 366 pg/mL) | 4.75 | 6.6 to 9.2 (20 to 800 pg/mL) |
| IL-1β | 1.3 | 10.3 to 6.3 (17.5 to 146 pg/mL) | 0.48 | 30.3 to 10.9 (1.3 to 10.9 pg/mL) |
| IL-6 | 1.7 | 5.9 to 2 (41 to 322 pg/mL) | 17 | 7.1 to 2.6 (213 to 1,229 pg/mL) |
| IL-8 | 4.7 | 7.9 to 16 (109 to 975 pg/mL) | 17 | 8.9 to 15.8 (185 to 9,152 pg/mL) |
| IL-10 | 1.3 | 10.3 to 6.26 (7.5 to 146 pg/mL) | 0.82 | 10.6 to 5.5 (5.16 to 232 pg/mL) |
| MCP-1 | 45 | 19.5 to 11.3 (207 to 1,759 pg/mL) | 147 | (19 to 6.5 (9,303 to 11,275 pg/mL) |
| TNF-α | 0.35 | 6.7 to 7.0 (16.8 to 159 pg/mL) | 2.5 | 25 to 15.8 (4.3 to 28.1 pg/mL) |
| CRP | 350 | 14.8 to 1 (9.2 to 97 mg/L) | ND |
| Age (years) | MDI/FSIQ < 85 | Externalizing Problems ≥ 60 | Hyperactivity subscale ≥ 60 | Behavioral Symptoms Index ≥ 60 | ||||
| n (%) | OR (95% CI) | n (%) | OR (95% CI) | n (%) | OR (95% CI) | n (%) | OR (95% CI) | |
| 1 | 52 (18.25) | 1.22 (0.51, 2.91) | — | — | — | — | — | — |
| 2 | 78 (32.64) | 0.83 (0.39, 1.78) | 12 (5.00) | 5.86 (2.21, 15.55) | 28 (11.67) | 3.06 (1.17, 7.98) | 14 (5.83) | 1.30 (0.44, 3.84) |
| 3 | 51 (23.18) | 1.76 (0.78, 3.99) | 37 (16.30) | 2.13 (0.99, 4.56) | 33 (14.54) | 2.68 (1.17, 6.16) | 32 (14.10) | 2.54 (1.08, 5.98) |
| 4 | — | — | 17 (10.30) | 1.51 (0.44, 5.21) | 17 (10.30) | 2.22 (0.55, 9.01) | 13 (7.88) | 2.02 (0.49, 8.39) |
| 5 | 25 (13.97) | 1.70 (0.36, 7.94) | 17 (9.29) | 2.66 (0.47, 15.06) | 19 (10.38) | 4.45 (1.31, 15.14) | 16 (8.74) | 4.80 (1.19, 19.26) |
| Adjusted for maternal age at enrollment, race, education, marital status, maternal serum cotinine concentrations at enrollment, maternal IQ, child sex, maternal depression, household income, and HOME Inventory score. |
| Variables | Prevalence (95% CI) | Crude OR (95% CI) | Wald | Adjusted ORa (95%CI) | p value | |
| Locality | Urban | 38.44 (35.60, 41.37) | R | |||
| Rural | 44.04 (40.55, 47.60) | 1.14 (1.00, 1.30) | ||||
| Sex | Male | 36.53 (33.23, 39.96) | R | |||
| Female | 43.35 (40.31, 46.45) | 1.17 (1.03, 1.34) | ||||
| Ethnicity | Malay | 39.76 (36.76, 42.84) | R | |||
| Chinese | 36.09 (31.88, 40.51) | 1.01 (0.85, 1.19) | ||||
| Indian | 40.74 (32.82, 49.16) | 1.05 (0.80, 1.39) | ||||
| Other Bumiputera | 56.46 (49.04, 63.61) | 2.05 (1.59, 2.66) | ||||
| Others | 39.89 (24.11, 58.09) | 0.76 (0.42, 1.35) | ||||
| Marital status | Single | 46.13 (31.71, 61.24) | R | |||
| Married | 35.25 (32.51, 38.09) | 0.75 (0.49, 1.17) | ||||
| Widow/Widower | 50.59 (46.61, 54.56) | 1.33 (0.85, 2.08) | ||||
| Household income | Poorest 20% | 43.57 (39.48, 47.74) | 1.44 (1.16, 1.78) | |||
| Poor 20% | 40.88 (36.41, 45.50) | 1.18 (0.94, 1.48) | ||||
| Middle income | 37.63 (32.29, 43.29) | 1.14 (0.89, 1.45) | ||||
| Rich 20% | 36.86 (30.96, 43.18) | 1.10 (0.85, 1.42) | ||||
| Richest 20% | 37.50 (32.15, 43.18) | R | ||||
| Education level | No formal education | 56.68 (51.89, 61.15) | 3.90 (2.71, 5.61) | 12.83 | 2.81 (1.60, 4.96) | <0.001 |
| Completed Primary Education | 40.87 (37.83, 43.99) | 2.06 (1.45, 2.92) | 4.25 | 1.62 (1.02, 2.55) | 0.28 | |
| Completed Secondary Education | 29.41 (25.35, 33.82) | 1.28 (0.89, 1.85) | 0.00 | 0.99 (0.62, 1.61) | 0.99 | |
| Completed Tertiary Education | 18.73 (12.96, 26.30) | R | R | |||
| Diabetes mellitus | Yes | 43.33 (39.81, 46.82) | 1.24 (1.08, 1.42) | |||
| No | 38.02 (35.14, 40.99) | R | ||||
| Hypertension | Yes | 42.34 (39.60,45.13) | 1.21 (1.05, 1.40) | |||
| No | 34.86 (31.13, 38.58) | R | ||||
| Hypercholesterolemia | Yes | 39.87 (37.19,42.61) | 1.20 (1.05, 1.38) | |||
| No | R | |||||
| Body mass index | Normal | 36.48 (33.11, 40.00) | R | |||
| Underweight | 55.00 (44.52, 65.07) | 1.98 (1.46, 2.69) | ||||
| Overweight | 35.15 (31.15, 39.47) | 0.90 (0.76, 1.05) | ||||
| Obese | 32.58 (27.78, 37.79) | 0.92 (0.75, 1.13) | ||||
| Mental health problems | Yes | 34.38 (27.91,4.48) | 1.69 (1.32, 2.15) | 14.01 | 1.68 (1.28, 2.20) | <0.001 |
| No | 28.42 (24.74, 32.42) | R | R | |||
| Physical inactivity | Yes | 53.07 (49.71,56.40) | 2.98 (2.60, 3.42) | 28.98 | 1.94 (1.52, 2.47) | <0.001 |
| No | 27.54 (24.77, 30.49) | R | R | |||
| Current smoker | Yes | 33.47 (28.07,39.35) | 0.72 (0.59, 0.87) | 4.65 | 0.68 (0.48, 0.97) | 0.03 |
| No | 40.98 (38.48, 43.52) | R | R | |||
| Current drinker | Yes | 23.00 (15.02,33.54) | 0.39 (0.24, 0.64) | |||
| No | 40.67 (38.35, 43.04) | R |
| SSRMarker | Motif | SSR Location | LG | nB | nF | nH | nN | nL | hB | hF | hH | hN | hL |
| IM27 | (AAG)12 | 5' UTR | 18 | 2 | 1 | 1 | 1 | 4 | 0.24 | 0.00 | 0.00 | 0.00 | 0.64 |
| IM55 | (GAA)9 | CDS | 1 | 6 | 7 | 4 | 1 | 10 | 0.76 | 0.83 | 0.68 | 0.00 | 0.82 |
| IM61 | (AGC)7 | CDS | 4 | 5 | 3 | 2 | 3 | 8 | 0.71 | 0.40 | 0.49 | 0.36 | 0.69 |
| IM93 | (ACC)8 | CDS | 9 | 6 | 2 | 2 | 2 | 6 | 0.76 | 0.38 | 0.28 | 0.13 | 0.72 |
| IM95 | (AAG)8 | 5' UTR | 17 | 6 | 1 | 3 | 3 | 11 | 0.80 | 0.00 | 0.50 | 0.65 | 0.82 |
| IM123 | (TCT)10 | CDS | 3 | 7 | 4 | 2 | 5 | 8 | 0.83 | 0.65 | 0.50 | 0.61 | 0.81 |
| IM144 | (CAG)6 | CDS | 3 | 5 | 1 | 2 | 2 | 5 | 0.67 | 0.00 | 0.49 | 0.41 | 0.64 |
| IM146 | (ACG)6 | CDS | 5 | 4 | 2 | 2 | 4 | 6 | 0.72 | 0.15 | 0.38 | 0.53 | 0.77 |
| IM152 | (CTA)6 | CDS | 6 | 4 | 3 | 2 | 2 | 5 | 0.37 | 0.57 | 0.28 | 0.34 | 0.64 |
| IM156 | (GAG)7 | CDS | 4 | 4 | 3 | 2 | 1 | 6 | 0.62 | 0.29 | 0.15 | 0.00 | 0.36 |
| IM164 | (AGC)6 | CDS | 12 | 2 | 2 | 3 | 4 | 7 | 0.46 | 0.44 | 0.57 | 0.66 | 0.82 |
| IM165 | (CAG)6 | 3' UTR | 5 | 3 | 1 | 3 | 2 | 5 | 0.64 | 0.00 | 0.57 | 0.24 | 0.72 |
| IM196 | (AAG)7 | CDS | 10 | 6 | 5 | 3 | 7 | 16 | 0.68 | 0.72 | 0.54 | 0.83 | 0.90 |
| IM200 | (GAA)23 | CDS | 1 | 9 | 4 | 2 | 3 | 10 | 0.87 | 0.51 | 0.28 | 0.44 | 0.77 |
| IM203 | (CTT)7 | 5' UTR | 13 | 7 | 2 | 3 | 3 | 9 | 0.80 | 0.50 | 0.40 | 0.60 | 0.75 |
| IM234 | (GCA)7 | CDS | 2 | 3 | 1 | 4 | 5 | 8 | 0.50 | 0.00 | 0.71 | 0.67 | 0.70 |
| IM235 | (TGC)6 | 3' UTR | 12 | 4 | 2 | 4 | 3 | 10 | 0.66 | 0.44 | 0.58 | 0.62 | 0.83 |
| IM283 | (CCT)8 | CDS | 21 | 2 | 2 | 2 | 1 | 4 | 0.13 | 0.15 | 0.15 | 0.00 | 0.55 |
| IM299 | (TA)6 | 3' UTR | 19 | 4 | 4 | 3 | 4 | 7 | 0.66 | 0.51 | 0.57 | 0.73 | 0.80 |
| IM303 | (TCC)6 | 5' UTR | 16 | 6 | 5 | 2 | 1 | 10 | 0.80 | 0.69 | 0.15 | 0.00 | 0.77 |
| IM319 | (GAG)7 | 5' UTR | 5 | 9 | 1 | 3 | 3 | 11 | 0.87 | 0.00 | 0.29 | 0.52 | 0.82 |
| IM327 | (GA)12 | 5' UTR | 20 | 6 | 7 | 4 | 4 | 13 | 0.78 | 0.79 | 0.60 | 0.70 | 0.88 |
| IM341 | (GAG)6 | 5' UTR | 12 | 3 | 1 | 3 | 1 | 7 | 0.50 | 0.00 | 0.65 | 0.00 | 0.69 |
| IM348 | (AGG)7 | CDS | 2 | 7 | 3 | 8 | 4 | 11 | 0.70 | 0.49 | 0.85 | 0.46 | 0.77 |
| IM364 | (CTT)6 | CDS | 9 | 9 | 4 | 2 | 2 | 10 | 0.87 | 0.65 | 0.15 | 0.24 | 0.73 |
| IM377 | (ATT)6 | 5' UTR | 7 | 3 | 2 | 1 | 2 | 7 | 0.26 | 0.44 | 0.00 | 0.41 | 0.78 |
| IM378 | (TTC)9 | 5' UTR | 6 | 3 | 3 | 2 | 2 | 6 | 0.50 | 0.57 | 0.15 | 0.50 | 0.78 |
| IM389 | (CTT)8 | CDS | 14 | 8 | 3 | 1 | 4 | 9 | 0.84 | 0.29 | 0.00 | 0.66 | 0.70 |
| IM391 | (TTC)12 | 5' UTR | 15 | 6 | 7 | 2 | 5 | 12 | 0.69 | 0.83 | 0.15 | 0.73 | 0.87 |
| IM395 | (TC)8 | 3' UTR | 15 | 3 | 3 | 3 | 4 | 7 | 0.57 | 0.61 | 0.57 | 0.53 | 0.80 |
| IM402 | (CTT)10 | 5' UTR | 13 | 7 | 2 | 2 | 3 | 9 | 0.82 | 0.49 | 0.15 | 0.60 | 0.78 |
| IM426 | (TCT)7 | 5' UTR | 4 | 6 | 4 | 2 | 4 | 11 | 0.76 | 0.71 | 0.38 | 0.62 | 0.85 |
| IM429 | (AGA)8 | 5' UTR | 14 | 3 | 3 | 3 | 2 | 8 | 0.44 | 0.40 | 0.40 | 0.34 | 0.75 |
| IM442 | (GA)7 | 5' UTR | 16 | 2 | 1 | 1 | 2 | 2 | 0.34 | 0.00 | 0.00 | 0.46 | 0.47 |
| IM450 | (CAG)7 | CDS | 2 | 7 | 2 | 5 | 4 | 10 | 0.74 | 0.28 | 0.53 | 0.64 | 0.70 |
| IM460 | (GA)7 | 5' UTR | 8 | 7 | 2 | 3 | 4 | 13 | 0.83 | 0.28 | 0.54 | 0.66 | 0.85 |
| IM486 | (AGC)7 | CDS | 11 | 3 | 5 | 4 | 7 | 12 | 0.57 | 0.72 | 0.68 | 0.80 | 0.89 |
| IM501 | (AG)13 | 5' UTR | 7 | 6 | 3 | 5 | 4 | 14 | 0.76 | 0.40 | 0.72 | 0.61 | 0.88 |
| IM503 | (CT)12 | 5' UTR | 10 | 7 | 6 | 5 | 7 | 18 | 0.82 | 0.82 | 0.68 | 0.76 | 0.89 |
| IM526 | (CAC)6 | CDS | 11 | 6 | 3 | 5 | 3 | 9 | 0.73 | 0.40 | 0.76 | 0.52 | 0.83 |
| Mean | 5.2 | 3.0 | 2.9 | 3.2 | 8.9 | 0.65 | 0.41 | 0.41 | 0.47 | 0.76 |
| Serum samples against: | Clade | HI titer (log2) against | HA identity* | |
| TK16 | Homologous antigen | |||
| A/chicken/Egypt/AR234-FAOF8NLQP/2014 (H5N1) | 2.2.1.2 | 7 | 9 | 99.4/100 |
| A/chicken/Egypt/0879-NLQP/2008 (H5N1) | 2.2.1.1 | 5 | 10 | 94.7/94.2 |
| A/teal/Germany/WV632/2005 (H5N1) | 2.2 | 6 | 9 | 88.7/90.6 |
| A/turkey/Germany-MV/R2472/2014 (H5N8) | 2.3.4.4 | 2 | 7 | 88.7/90.6 |
| A/Vietnam/1194/2004 (H5N1) | 1 | 6 | 8 | 93.2/95.1 |
| BMI | Age | 12-month | |||
| DSM-5 diagnosis | N | % | M (SD) | M (SD) | N |
| RAN | 364 | 16.3 | 16.1 (1.6) | 23.2 (6.6) | 102 |
| ANB/P | 295 | 13.2 | 16.8 (1.4) | 24.3 (7.1) | 67 |
| BN | 874 | 39.1 | 23.6 (4.3) | 26.4 (8.0) | 219 |
| BED | 124 | 5.6 | 31.4 (7.7) | 30.2 (10.2) | 22 |
| AAN | 310 | 13.9 | 22.7 (4.5) | 26.0 (7.0) | 69 |
| Sub BED | 11 | 0.5 | 30.2 (7.6) | 34.4 (13.2) | - |
| PD | 184 | 8.2 | 21.9 (3.5) | 25.4 (7.9) | 39 |
| UFED | 71 | 3.2 | 19.9 (6.7) | 26.1 (9.1) | 12 |
| Pseudo-chromosome | No. of SNPs | No. of InDels | No. of SSRs | Physical size (Mb) |
| Pseudo-chromosome 1 | 25,395 (941) | 596 (22) | 798 (30) | 26.8 |
| Pseudo-chromosome 2 | 40,350 (961) | 895 (21) | 1,376 (33) | 42.1 |
| Pseudo-chromosome 3 | 27,111 (1,084) | 548 (22) | 764 (31) | 24.6 |
| Pseudo-chromosome 4 | 20,975 (874) | 552 (23) | 789 (33) | 24.0 |
| Pseudo-chromosome 5 | 20,446 (786) | 545 (21) | 760 (29) | 25.8 |
| Pseudo-chromosome 6 | 19,016 (906) | 516 (25) | 584 (27) | 21.3 |
| Pseudo-chromosome 7 | 14,219 (836) | 344 (20) | 562 (33) | 17.1 |
| Pseudo-chromosome 8 | 11,360 (668) | 452 (27) | 502 (29) | 17.3 |
| Total | 178,872 (899) | 4,448 (22) | 6,135 (31) | 199.0 |
| Parameters | Pre-treatment | First weekpost-treatment | Second weekpost-treatment |
| Volume of ejaculate (ml) | 0.30 ± 0.02 * | 0.23 ± 0.02 | 0.15 ± 0.02* |
| Color of ejaculate | Milky to creamy white | Milky to creamy white | Milky to creamy white |
| Sperm motility | 85% * | 80% | 70% * |
| Spermatozoa viability | 96% * | 90% | 83% * |
| Sperm concentration (x 109/ml) | 428 ± 4.26 * | 341 ± 6.63 * | 289 ± 4.81* |
| Variable | Analysis with CCP score | Analysis with mPS | ||
| Hazard ratio (95% CI) | P value | Hazard ratio (95% CI) | P value | |
| CCP score | 1.60 (1.14, 2.24) | 0.006 | ||
| mPS | 1.77 (1.18, 2.66) | 0.006 | ||
| Age at diagnosis | 1.03 (1.01, 1.05) | 0.016 | 1.03 (1.01, 1.05) | 0.016 |
| Sex | 0.343 | 0.342 | ||
| Male | 1 | 1 | ||
| Female | 0.82 (0.54, 1.25) | 0.82 (0.54, 1.24) | ||
| Smoking status | 0.676 | 0.675 | ||
| Never | 1 | 1 | ||
| Former | 1.35 (0.69, 2.95) | 1.35 (0.69, 2.95) | ||
| Current | 1.41 (0.60, 3.51) | 1.41 (0.60, 3.51) | ||
| Surgical procedure | <0.001 | <0.001 | ||
| Pneumonectomy/Bilobectomy/Lobectomy | 1 | 1 | ||
| Segmentectomy | 3.31 (1.62, 6.30) | 3.31 (1.62, 6.30) | ||
| Wedge resection | 4.65 (2.71, 7.91) | 4.65 (2.71, 7.90) | ||
| Tumor size | 1.64 (1.24, 2.14) | <0.001 | 1.64 (1.24, 2.15) | <0.001 |
| Pathological stage | 0.720 | 0.158 | ||
| IA | 1 | 1 | ||
| IB | 0.87 (0.39, 1.90) | 0.53 (0.22, 1.28) | ||
| Pleural invasion | 0.056 | 0.057 | ||
| PLX/PL0 | 1 | 1 | ||
| PL1 | 1.94 (0.91, 4.12) | 1.94 (0.91, 4.12) | ||
| PL2 | 3.39 (1.15, 8.79) | 3.38 (1.15, 8.76) | ||
| Lymphatic invasion | 0.020 | 0.019 | ||
| Absent | 1 | 1 | ||
| Present | 1.73 (1.09, 2.77) | 1.74 (1.10, 2.78) | ||
| Vascular invasion | 0.089 | 0.091 | ||
| Absent | 1 | 1 | ||
| Present | 1.52 (0.94, 2.44) | 1.51 (0.94, 2.44) | ||
| Morphological grade | 0.012 | 0.011 | ||
| Low | 1 | 1 | ||
| Intermediate | 3.08 (0.92, 19.13) | 3.08 (0.92, 19.13) | ||
| High | 5.09 (1.46, 32.18) | 5.10 (1.46, 32.22) |
| Variable | N° total dogs | N° positiveT. annaedog (%) | |
| Age (years) | ≤3 | 65 | 53 (81.54)** |
| >3 | 47 | 22 (46.81) | |
| unknown | 8 | 0 | |
| Sex | Male | 58 | 38 (65.5) |
| Female | 55 | 37 (67.2) | |
| unknown | 7 | 0 | |
| Size (kg) | ≤22 | 77 | 59 (76.6)* |
| >22 | 35 | 16 (45.71) | |
| unknown | 8 | 0 | |
| Breed | Pure breed | 86 | 53 (61.6) |
| Crossbreed | 33 | 22 (66.6) | |
| unknown | 1 | 0 | |
| Lifestyle | Hunting | 75 | 56 (74.6)* |
| Companion | 28 | 13 (46.4) | |
| Guard | 12 | 6 (50) | |
| unknown | 5 | 0 | |
| Habitat | Rural | 96 | 64 (66.6) |
| Urban | 24 | 11 (45.8) | |
| Tick infestation | Yes | 50 | 35 (70) |
| No | 49 | 27 (55.1) | |
| unknown | 21 | 13 (10.8) | |
| Seasonality | spring | 20 | 14 (70) |
| summer | 20 | 10 (50) | |
| autumn | 60 | 38 (63.3) | |
| winter | 20 | 13 (65) |
| Parameter | Correlation coefficient (r) | p value |
| CD11avs.sICAM-1 | 0.317 | >0.01 |
| CD11avs.sVCAM-1 | 0.366 | > 0.01 |
| CD11bvs.sICAM-1 | 0.251 | > 0.05 |
| CD11bvs. sVCAM-1 | 0.258 | > 0.05 |
| CD49dvs.sICAM-1 | 0.315 | >0.01 |
| CD49dvs.sVCAM-1 | 0.419 | > 0.01 |
| sICAM-1vs.TNF-α | 0.355 | >0.01 |
| sVCAM-1vs.TNF-α | 0.419 | > 0.01 |
| Male | 60 (67%) |
| Age | |
| 20–40 years of age | 52 (58%) |
| 41–50 years of age | 21 (23%) |
| >50 years of age | 17 (19%) |
| Practitioner type | |
| Attending physician | 56 (62%) |
| Resident | 13 (14%) |
| Extender | 21 (23%) |
| Experience | |
| 1–5 years | 38 (42%) |
| >5–10 years | 15 (17%) |
| >10 years | 37 (41%) |
| Practice facility | |
| Academic | 54 (60%) |
| Private or community | 32 (36%) |
| Urgent care | 4 (4%) |
| Average annual census | |
| <30 k | 5 (6%) |
| 30–75 k | 33 (37%) |
| >75 k | 52 (57%) |
| Parameter | South Asian | Western European | p-value |
| WB SAS | 0.7 ± 0.8 | 1.8 ± 2.3 | 0.10 |
| Head/neck SAS | 0.5 ± 1.1 | 1.9 ± 4.0 | 0.21 |
| Aorta SAS | 0.9 ± 2.6 | 1.3 ± 3.1 | 0.59 |
| Abdomen SAS | 1.8 ± 3.8 | 3.2 ± 4.4 | 0.26 |
| Iliofemoral SAS | 0.0 ± 0.0 | 1.9 ± 6.9 | 0.048 |
| Run-off SAS | 0.7 ± 2.2 | 0.9 ± 2.9 | 0.77 |
| Normal vessels | 501 (97%) | 1117 (95%) | 0.2 |
| Vessels with 1–50% stenosis | 14 (3%) | 46 (4%) | 0.1 |
| Vessels with 51–70% stenosis | 1 (0.2%) | 9 (0.8%) | 0.08 |
| Vessels with 71–99% stenosis | 0 | 3 (0.2%) | 0.3 |
| Occluded vessels | 0 | 1 (0.01%) | 0.3 |
| Occupational exposure | Never smokers | Former smokers | Current smokers | P valueb | |||
| No. | % | No. | % | No. | % | ||
| Never exposed | 52 | 70.3 | 38 | 48.7 | 32 | 69.6 | Reference |
| Ever exposed (any agent) | 22 | 29.7 | 40 | 51.3 | 14 | 30.4 | 0.01 |
| Wood dust | 12 | 16.2 | 21 | 26.9 | 10 | 21.7 | 0.10 |
| Leather dust | 10 | 13.5 | 17 | 21.8 | 2 | 4.3 | 0.01 |
| Nickel compounds | 0 | 0.0 | 2 | 2.6 | 2 | 4.3 | 0.23 |
| Chromium compounds | 1 | 1.4 | 3 | 3.8 | 0 | 0.0 | 0.16 |
| PAH | 0 | 0.0 | 1 | 1.3 | 1 | 2.2 | 0.47 |
| Cork dust | 1 | 1.4 | 0 | 0.0 | 0 | 0.0 | 0.51 |
| Product | Batch | Nonfucosylated (%) | Hybrid (%) | Sialylated (%) | Galactosylated (%) | High mannose (%) |
| MabThera | H0605 | 1.81 ± 0.04 | 5.00 ± 0.32 | 0.72 ± 0.08 | 43.34 ± 1.42 | 4.37 ± 0.42 |
| N3518 | 1.69 ± 0.11 | 3.48 ± 0.24 | 0.98 ± 0.22 | 46.21 ± 1.54 | 3.19 ± 0.54 | |
| B62222 | 1.89 ± 0.11 | 2.91 ± 0.18 | 0.82 ± 0.12 | 45.58 ± 0.47 | 3.03 ± 0.17 | |
| Kikuzubam | 5445130608 | 0.65 ± 0.21 | 2.72 ± 0.39 | 0.80 ± 0.21 | 57.08 ± 8.52 | 3.25 ± 0.43 |
| 5445131216 | 0.65 ± 0.21 | 2.80 ± 0.08 | 0.71 ± 0.13 | 56.35 ± 0.64 | 3.31 ± 0.16 | |
| 5445131015 | 0.67 ± 0.05 | 3.19 ± 0.25 | 0.77 ± 0.13 | 54.26 ± 3.02 | 3.51 ± 0.23 |
| RIO—Psychosocial Measure | Coefficient of Correlation | |
| Temp. Fingers—Temp. Nose | 0.450 | ** |
| —Interference General (BPI) | −0.390 | * |
| —Interference Affective (BPI) | −0.517 | * |
| —Interference Relationship (BPI) | −0.437 | * |
| —Interference Sleep (BPI) | −0.600 | *** |
| —Interference Enjoy (BPI) | −0.665 | *** |
| —Pain (NAS of SF-MPQ) | −0.584 | ** |
| —Loneliness (L-UCLA) | −0.487 | ** |
| Temp. Chin—Temp. Maxillofacial | 0.483 | ** |
| —Temp. Nose | 0.459 | ** |
| —Internal Control of Anger (STAXI-2) | 0.383 | * |
| —Alexithymia (TAS) | −0.446 | * |
| —Supression (EQR) | −0.481 | * |
| Temp. Maxillary—Temp. Nose | 0.821 | *** |
| —Interference Sleep (BPI) | −0.520 | ** |
| —Interference Enjoy (BPI) | −0.461 | ** |
| —Pain (NAS of SF-MPQ) | −0.504 | ** |
| Temp. Nose—Interference Sleep (BPI) | −0.443 | * |
| —Pain (NAS of SF-MPQ) | −0.413 | * |
| Temp. Periorbital—Temp. Forehead | 0.469 | ** |
| —Reappraisal (EQR) | −0.485 | * |
| Experiment | Total reads | Aligned reads | Mean PCR duplicates (%) | Aligned reads on target | On-target rate (%) | Uniquely aligned readsa | Uniquely aligned reads on targeta | On-target rate (%)a | Mean coverage on target |
| dCATCH-SeqCATCH-Seq | 853,358841,154 | 414,965802,931 | 47.42.8 | 382,625291,808 | 92.2136.34 | 406,331762,445 | 379,084289,558 | 93.2937.98 | 145.98110.18 |
| Treatment | Dose (μg/plate) | Number of His+ revertants colonies/plate | |||
| TA97a | TA98 | TA100 | TA102 | ||
| Spontaneous | 140.0 ± 4.0 | 31.0 ± 3.6 | 128.7 ± 9.8 | 245.7 ± 23.3 | |
| Positive control (NaN3) | 1.5 | 246.3 ± 16.0 | 52.7 ± 2.1 | 352.0 ± 33.0 | 343.3 ± 33.3 |
| aMurraya koenigii | 12.5 | 164.3 ± 12.3 | 46.0 ± 4.0 | 191.7 ± 13.3 | 286.7 ± 26.3 |
| 25 | 145.0 ± 15.5 | 37.3 ± 7.0 | 172.3 ± 18.9 | 260.0 ± 24.1 | |
| 50 | 124.7 ± 9.1 | 30.7 ± 8.5 | 153.0 ± 19.7 | 245.3 ± 24.4 | |
| 100 | 118.0 ± 10.5 | 24.0 ± 4.6 | 127.0 ± 15.5 | 228.3 ± 19.6 | |
| bMurraya koenigii + NaN3 | 12.5 | 225.3 ± 33.6 (25.6) | 51.3 ± 6.0 (20.0) | 316.3 ± 32.0 (22.3) | 332.3 ± 34.9 (19.4) |
| 25 | 200.7 ± 22.7* (45.1) | 45.3 ± 4.2 (47.8) | 258.0 ± 29.6* (52.3) | 313.0 ± 32.1 (36.4) | |
| 50 | 168.0 ± 22.3** (64.4) | 39.0 ± 8.2* (62.1) | 212.7 ± 26.6** (70.0) | 292.7 ± 18.6 (51.7) | |
| 100 | 137.3 ± 12.7*** (84.9) | 31.7 ± 6.5** (73.2) | 162.0 ± 21.0** (84.4) | 260.3 ± 14.0* (72.2) | |
| Fvalue | 18.069 | 8.288 | 33.690 | 6.917 | |
| R2value | 0.999 | 0.953 | 0.969 | 0.996 |
| Regression indices and explanatory variable | Dependent variable‡ | |
| Eggs | Excreta | |
| Intercept | -1.33** (0.45) | 2.97** (0.23) |
| Regression coefficients | ||
| Area (Reference: Faridpur) | ||
| Madaripur | 0.46** (0.15) | 0.09 (0.08) |
| Chandpur | -0.29* (0.15) | 0.01 (0.08) |
| Satkhira | -0.28 (0.15) | 0.02 (0.08) |
| Jessore | -0.22 (0.15) | 0.03 (0.08) |
| Age (weeks) | 0.01** (0.00) | -0.00 (0.00) |
| Feed type (Reference: Commercial feed) | 0.00 (0.13) | 0.06 (0.07) |
| Arsenic in drinking-water (ppb) | 0.41** (0.03) | 0.44** (0.02) |
| Arsenic in feed (ppb) | 0.40** (0.09) | 0.52** (0.04) |
| R2 | 0.55 | 0.82 |
| F value | 36.83** | 133.42** |
| Species | Accession used for sequencing | Raw paired-end reads (DNA-, RNA-seq) (M) | Trimmed paired-end reads (DNA-, RNA-seq) (M) | Repetitive fraction (%) (SE) |
| H. agrestis | 673199 | 38.3–40.4,40.0–44.0 | 28.6–29.5,36.3–39.9 | 83.33 (0.02) |
| H. carnosus | 649956 | 34.0–38.6,48.5–56.9 | 24.6–28.3,44.0–51.7 | 74.48 (0.04) |
| H. porteri | 649918 | 42.4–63.5,35.8–49.7 | 31.1–48.0,32.6–45.2 | 74.78 (0.20) |
| Predictor | β coefficient | 95% CI | Unadjusted p valuea |
| Age | 0.08 | 0.02–0.15 | 0.009 |
| Female | −0.22 | −1.17 to 0.74 | 0.655 |
| Marital status | 0.02 | −0.34 to 0.38 | 0.920 |
| Burn | 1.17 | 0.27–2.07 | 0.012 |
| Total body surface area % | −0.01 | −0.04 to 0.02 | 0.577 |
| Graft | −1.67 | −2.84 to −0.49 | 0.006 |
| BDI | 0.09 | 0.06–0.13 | <0.001 |
| IES-R | 0.04 | 0.02–0.05 | <0.001 |
| Pre-morbid employment | 0.54 | −0.16 to 1.24 | 0.131 |
| Return to same employment | 2.08 | 1.06–3.10 | <0.001 |
| Time off from work | 0.51 | 0.20–0.82 | 0.001 |
| Women who selected specified method | Women who did not select specified method | |||||||||
| Perception statement | Method | Strongly agree/agree n (%) | Strongly disagree/disagree n (%) | No opinion/do not know n (%) | Missing (n) | Method (%) | Strongly agree/agree (%) | Strongly disagree/disagree (%) | No opinion/do not know (%) | Missing (n) |
| Prevents pregnancy effectively | Pill | 8969 (95.7) | 92 (1.0) | 309 (3.3) | 74 | Pill | 8263 (90.2) | 222 (2.4) | 680 (7.4) | 178 |
| Patch | 1284 (84.7) | 11 (0.7) | 221(14.6) | 33 | Patch | 10525(63.6) | 469 (2.8) | 5546(33.5) | 698 | |
| Ring | 4837 (89.1) | 13 (0.2) | 580 (10.7) | 110 | Ring | 8348 (66.2) | 270 (2.1) | 3986(31.6) | 643 | |
| Many side effects | Pill | 2351 (25.2) | 3941 (42.3) | 3029 (32.5) | 123 | Pill | 4258 (46.5) | 2344 (25.6) | 2564 (28.0) | 177 |
| Patch | 151 (10.1) | 649 (43.4) | 696 (46.5) | 53 | Patch | 2429 (14.7) | 3435 (20.9) | 10610 (64.4) | 764 | |
| Ring | 361 (6.7) | 2861 (52.9) | 2182 (40.4) | 136 | Ring | 1335 (10.6) | 3200 (25.5) | 8038 (63.9) | 674 | |
| Can be dangerous for your health | Pill | 1704 (18.3) | 4528 (48.7) | 3073 (33.0) | 139 | Pill | 3000 (32.8) | 3092 (33.8) | 3045 (33.3) | 206 |
| Patch | 119 (7.9) | 804 (53.7) | 574 (38.3) | 52 | Patch | 1575 (9.6) | 6082 (37.0) | 8760 (53.4) | 821 | |
| Ring | 339 (6.3) | 3276 (60.7) | 1785 (33.1) | 140 | Ring | 956 (7.6) | 4824 (38.4) | 6774 (54.0) | 693 | |
| Easy to use | Pill | 8627 (92.5) | 214 (2.3) | 489 (5.2) | 114 | Pill | 6293 (69.2) | 1473 (16.2) | 1334 (14.7) | 243 |
| Patch | 1318 (87.7) | 34 (2.3) | 151 (10.1) | 46 | Patch | 9248 (56.4) | 1779 (10.8) | 5382 (32.8) | 829 | |
| Ring | 4188 (77.5) | 149 (2.8) | 1067 (19.7) | 136 | Ring | 4257 (33.9) | 2568 (20.5) | 5716 (45.6) | 706 | |
| Easy to forget | Pill | 4894 (52.7) | 2457 (26.5) | 1931 (20.8) | 162 | Pill | 7140 (78.3) | 983 (10.8) | 998 (10.9) | 222 |
| Patch | 229 (15.3) | 860 (57.6) | 405 (27.1) | 55 | Patch | 4716 (28.7) | 4635 (28.2) | 7073 (43.1) | 814 | |
| Ring | 713 (13.3) | 3179 (59.2) | 1475 (27.5) | 173 | Ring | 2532 (20.2) | 4072 (32.6) | 5902 (47.2) | 741 | |
| Regular menstrual bleeding | Pill | 8274 (88.8) | 221 (2.4) | 825 (8.9) | 124 | Pill | 7571 (82.9) | 405 (4.4) | 1155 (12.7) | 212 |
| Patch | 1063 (70.7) | 31 (2.1) | 410 (27.3) | 45 | Patch | 8177 (49.9) | 431 (2.6) | 7789 (47.5) | 841 | |
| Ring | 4064 (75.5) | 86 (1.6) | 1233 (22.9) | 157 | Ring | 6003 (47.9) | 346 (2.8) | 6180 (49.3) | 718 | |
| Protects against cancer | Pill | 2686 (28.9) | 1542 (16.6) | 5076 (54.6) | 140 | Pill | 2687 (29.5) | 1495 (16.4) | 4941 (54.2) | 220 |
| Patch | 358 (23.9) | 204 (13.6) | 938 (62.5) | 49 | Patch | 2735 (16.7) | 2458 (15.0) | 11231 (68.4) | 814 | |
| Ring | 1457 (27.0) | 645 (11.9) | 3299 (61.1) | 139 | Ring | 1920 (15.3) | 1896 (15.1) | 8725 (69.6) | 706 | |
| Many women use it | Pill | 8361 (89.3) | 82 (0.9) | 920 (9.8) | 81 | Pill | 7455 (81.3) | 256 (2.8) | 1454 (15.8) | 178 |
| Patch | 413 (27.4) | 185 (12.3) | 910 (60.3) | 41 | Patch | 1744 (10.6) | 4154 (25.2) | 10584 (64.2) | 756 | |
| Ring | 1316 (24.4) | 706 (13.1) | 3379 (62.6) | 139 | Ring | 1310 (10.4) | 2756 (21.9) | 8514 (67.7) | 667 |
| Secure environment (SE) employment type | Less than 10 years | 11 – 20 years | 21 – 30 years | Over 30 years | TOTAL |
| GPs predominantly employed in SE | 3 | 8 | 8 | 4 | 23 |
| GP principals | 1 | 2 | 4 | 2 | 9 |
| TOTAL | 4 | 10 | 12 | 6 | 32 |
| National sponsors | International sponsors | |
| When to report adverse events | Frequency | Frequency |
| Serious adverse events | ||
| No later than 1 hour | 0 | 0 |
| No later than 24 hours | 0 | 31 |
| No later than 7 days | 1 | 2 |
| No later than 15 days | 0 | 1 |
| Others | 0 | 5 |
| Did not specify | 30 | 32 |
| Total | 31 | 71 |
| Unexpected adverse events | ||
| No later than 1 hour | 0 | 1 |
| No later than 24 hours | 0 | 12 |
| No later than 7 days | 1 | 1 |
| No later than 15 days | 0 | 3 |
| Others | 0 | 6 |
| Did not specify | 30 | 48 |
| Total | 31 | 71 |
| PCS-36 | MCS-36 | DHI | HADS | |
| PCS-36 | 1 | |||
| MCS-36 | 0.22** | 1 | ||
| DHI | −0.64*** | −0.57*** | 1 | |
| HADS | −0.32*** | −0.82*** | 0.58*** | 1 |
| DoD | 0.13 | −0.09 | −0.01 | 0.004 |
| FoD | −0.20* | −0.03 | 0.24** | 0.04 |
| AvP | 0.24** | 0.10 | −0.25** | −0.07 |
| VNVa | F = 7.94*** | 4.64* | 5.65** | 5.18** |
| Age | −0.03 | 0.01 | 0.004 | −0.02 |
| Gender | 0.03 | 0.13 | −0.12 | −0.03 |
| Mean (SD) or % | |
| Age, mean (SD) | 63.5 (13.8) |
| 18–45, % | 11.5% |
| 46–70, % | 51.5% |
| ≥ 71, % | 37.0% |
| Male, % | 35.3% |
| Marital status, % | |
| Married | 70.7% |
| Single | 3.7% |
| Widowed/Separated/divorced | 25.6% |
| Living alone, % | 15.2% |
| Level of education, % | |
| ≤ Elementary | 47.9% |
| Middle School | 16.7% |
| High School | 23.8% |
| ≥ University | 11.7% |
| Employment status, % | |
| Regular/long-term | 25.0% |
| Non-regular/temporary | 23.5% |
| Unemployed | 2.5% |
| Economically inactive/students | 50.0% |
| Medical aid, % | 8.3% |
| Perceived social status | 3.6 (1.5) |
| Group | HC (n = 21) | Mild AD (n = 17) | AD-MCI (n = 23) | p |
| Female | 13 | 7 | 11 | 0.42 |
| Male | 8 | 10 | 12 | |
| Age | 66.4 ± 7.5 | 68.9 ± 8.1 | 67.6 ± 5.4 | 0.53 |
| MMSE score | 29.4 ± 0.8 | 22.1 ± 4.3 | 26.8 ± 2.0 | <0.01 |
| Delayed recall (CERAD) | 6.5 ± 2.1 | 0.9 ± 1.8 | 3.1 ± 2.0 | <0.01 |
| Clinical features | Pathoanatomy | Treatment based approach | Screening/Prediction tool | Pain mechanisms | |||||
| Barker 1990 [79] | 2 | Bernard and Kirkaldy Willis 1987 [41] | 2 | Albert et al. 2012 [61] | 4 | Fritz et al. 2007 [64] | 3 | Schafer et al. 2009 [65] | 5 |
| Ben Debba et al. 2000 [36] | 3.5 | Cassisi et al. 1993 [38] | 3 | Hall et al. 1994 [49] | 5 | Roach et al. 1997 [63] | 3 | Smart et al. 2011 [66] | 5 |
| Glassman et al. 2011 [37] | 2.5 | Hahne et al. 2011 [38] | 3 | Mckenzie 1981 [49] | 5.5 | Scholz et al. 2009 [62] | 4 | Nijs et al. 2015 [75] | 2.5 |
| Nachemson and Andersson 1982 [80] | 3.5 | Paatelma et al. 2009 [44] | 3.5 | Delitto et al. 2012 [48] | 3.5 | ||||
| Spitzer et al. 1987 [25] | 4 | Petersen et al. 2003 [39] | 4 | ||||||
| Sweetman et al. 1992 [26] | 2.5 | Vining et al. 2013 [46] | 3.5 |
| Gene | Primer | Sequence | Amplicon | Tm (°C) |
| GK | Forward | 5′-CATATGTGCTCCGCAGGACTA-3′ | 105 bp | 61.7 |
| Reverse | 5′-CTTGTACACGGAGCCATCCA-3′ | |||
| HK | Forward | 5′-ACCCACGAAACAACACCATCA-3′ | 69 bp | 79 |
| Reverse | 5′-GACGTACAACAATGGCTCACTAAAG-3′ | |||
| PFK-1 (L) | Forward | 5′-TTACCGATCACCCTCGTTCCT-3′ | 80 bp | 84 |
| Reverse | 5′-TTCCCCTTAGTGCTGGGATCT-3′ | |||
| PFK-1 (M) | Forward | 5′-GTGGACACTGATATGACCATTGG-3′ | 67 bp | 82 |
| Reverse | 5′-ATGGCGTCCACGATCTCTACA-3′ | |||
| G6Pase | Forward | 5′-GGATCTACCTTGCGGCTCACT-3′ | 132 bp | 62.7 |
| Reverse | 5′-TGTAGATGCCCCGGATGTG-3′ | |||
| F16BP | Forward | 5′-CGTCCTATGCTACCTGTGTCCTT-3′ | 73 bp | 81 |
| Reverse | 5′-CCCCTCTTCTCGGGCTCTATTAT-3′ | |||
| PEPCK | Forward | 5′-GCAACTTCTCTCGGCTCGTT-3′ | 99 bp | 62.7 |
| Reverse | 5′-TGGCAGTTCTACTGGGCTACAC-3′ | |||
| G6PDH | Forward | 5′-GATGGCCTTCTACCCGAAGAC-3′ | 72 bp | 82 |
| Reverse | 5′-GCGGATGTCATCCACTGTGA-3′ | |||
| P13K | Forward | 5′-CCTGAAAGAGCTGGTGCTACATT-3′ | 71 bp | 81 |
| Reverse | 5′-GTGTGACATTGAGGGAGTCATTG-3′ |
| Sampling time (expression change) | Ischemia-related | PACAP-related | PACAP in ischemia-related | Common: ischemia-related and PACAP in ischemia-related | Common: PACAP-related and PACAP in ischemia-related |
| 6 h (upregulated) | 1,237 | 435 | 839 | 171 | 43 |
| 6 h (downregulated) | 622 | 743 | 498 | 31 | 24 |
| 24 h (upregulated) | 2,759 | 263 | 831 | 49 | 30 |
| 24 h (downregulated) | 2,104 | 271 | 1468 | 28 | 75 |
| JIA-associated NIU (n = 14) | Pure NIU (n = 11) | Total | |
| Bilateral (pts) | 12/14 | 11/11 | 23/25 |
| Total eyes with NIU | 24 | 22 | 46 |
| Location: | |||
| Anterior/Posterior/Panuveitis | 12/6/2 | 2/4/2 | 16/7/2 |
| Nutrients | Number of Foods | Energy | Saturated Fatty Acids | Cholesterol | Na | Total Sugar | Added Sugars | Ca | Vitamin D | K | Fiber | |
| Units of Nutrient Intake | Kcal | g | Mg | mg | g | g | mg | μg | mg | g | ||
| All foods | Mean intake | 15.1 (0.2) | 2064 (23) | 27.4 (0.4) | 221.4 (4.8) | 3176 (55) | 142.5 (1.9) | 92.7 (1.9) | 1059 (17) | 5.9 (0.2) | 12.8 (0.2) | 12.8 (0.2) |
| % contribution b,c | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |
| IFIC category foods d | Mean intake | 11.7 (0.2) | 1457 (22) | 18.6 (0.4) | 152.3 (3.8) | 2133 (45) | 111.0 (2.0) | 69.3 (1.7) | 795 (19) | 4.9 (0.2) | 9.3 (0.2) | 9.3 (0.2) |
| % contribution b,c | 77.8 (0.8) | 70.6 (0.9) | 67.8 (1.1) | 68.8 (1.2) | 67.2 (1.1) | 77.9 (0.8) | 74.8 (0.9) | 75.1 (1.2) | 84.1 (1.4) | 72.2 (1.0) | 72.2 (1.0) | |
| 1. Minimally processed foods | Mean intake | 3.4 (0.1) | 252 (9) | 4.3 (0.2) | 64.6 (3.0) | 250 (10) | 20.4 (0.7) | 1.3 (0.3) | 333 (12) | 3.2 (0.1) | 1.9 (0.1) | 1.9 (0.1) |
| % contribution b,c | 22.8 (0.5) | 12.2 (0.4) | 15.5 (0.6) | 29.2 (1.2) | 7.9 (0.3) | 14.3 (0.5) | 1.4 (0.3) | 31.4 (0.9) | 54.1 (1.4) | 14.8 (0.6) | 14.8 (0.6) | |
| 2. Foods processed for preservation | Mean intake | 0.6 (0.0) | 59 (2) | 0.1 (0.0) | 0.4 (0.1) | 36 (3) | 11.1 (0.5) | 0.6 (0.1) | 34 (3) | 0.1 (0.0) | 0.6 (0.0) | 0.6 (0.0) |
| % contribution b,c | 3.9 (0.1) | 2.8 (0.1) | 0.3 (0.1) | 0.2 (0.0) | 1.1 (0.1) | 7.8 (0.4) | 0.6 (0.1) | 3.2 (0.2) | 1.0 (0.2) | 5.0 (0.3) | 5.0 (0.3) | |
| 3. Mixtures of combined ingredients | Mean intake | 2.5 (0.1) | 298 (9) | 3.9 (0.2) | 27.5 (1.5) | 604 (18) | 11.8 (0.5) | 8.9 (0.5) | 154 (5) | 0.3 (0.0) | 2.0 (0.1) | 2.0 (0.1) |
| % contribution b,c | 16.4 (0.3) | 14.4 (0.4) | 14.2 (0.5) | 12.4 (0.6) | 19.0 (0.6) | 8.3 (0.4) | 9.6 (0.5) | 14.5 (0.5) | 5.0 (0.3) | 15.9 (0.7) | 15.9 (0.7) | |
| 4. Ready-to-eat processed foods | Mean intake | 5.0 (0.1) | 751 (16) | 8.8 (0.3) | 45.8 (1.7) | 1007 (25) | 66.6 (2.0) | 58.1 (1.8) | 236 (9) | 1.3 (0.1) | 4.1 (0.1) | 4.1 (0.1) |
| % contribution b,c | 32.9 (0.6) | 36.4 (0.8) | 32.1 (0.9) | 20.7 (0.8) | 31.7 (0.8) | 46.7 (1.1) | 62.7 (1.2) | 22.2 (0.7) | 22.7 (1.0) | 31.9 (0.9) | 31.9 (0.9) | |
| 5. Prepared foods/meals | Mean intake | 0.3 (0.0) | 98 (7) | 1.6 (0.1) | 14.0 (1.2) | 236 (19) | 1.1 (0.1) | 0.5 (0.1) | 39 (4) | 0.1 (0.0) | 0.6 (0.1) | 0.6 (0.1) |
| % contribution b,c | 1.7 (0.1) | 4.7 (0.3) | 5.7 (0.4) | 6.3 (0.5) | 7.4 (0.5) | 0.8 (0.1) | 0.5 (0.1) | 3.7 (0.4) | 1.3 (0.2) | 4.6 (0.4) | 4.6 (0.4) | |
| Foods from restaurants/Cafeterias | Mean intake | 3.4 (0.1) | 608 (22) | 8.8 (0.3) | 69.2 (3.4) | 1042 (44) | 31.5 (1.2) | 23.4 (0.9) | 263 (13) | 0.9 (0.1) | 3.6 (0.1) | 3.6 (0.1) |
| % contribution b,c | 22.2 (0.8) | 29.4 (0.9) | 32.2 (1.1) | 31.2 (1.2) | 32.8 (1.1) | 22.1 (0.8) | 25.2 (0.9) | 24.9 (1.2) | 15.9 (1.4) | 27.8 (1.0) | 27.8 (1.0) |
| Reference | Strains | Plasmids | Time (h) | IPTG-conc. (mM) | RPM (1/min) | Temperature (°C) | δ-ALA-conc. (mM) | Thiamin-conc. (mM) |
| [46] | BL21(DE3) | pET28a | 2 | 0.2 | 25 | |||
| 4 | 0.5 | 30 | ||||||
| 6 | 0.8 | 34 | ||||||
| 8 | 1 | 37 | ||||||
| 10 | ||||||||
| [49] | JM109 | pCWori | 12 | 0.2 | 150 | 18 | 0.2 | 0.5 |
| DH5α | pET28a | 20 | 0.4 | 170 | 25 | 0.4 | 1 | |
| C100 | pTreHis | 24 | 0.6 | 200 | 30 | 0.6 | 1.5 | |
| DE3 | 30 | 0.8 | 250 | 37 | 0.8 | |||
| CodonPlus | ||||||||
| Pril |
| Current | Projected | ||
| Only MVA3 | MVA/Misoprostol4 | ||
| Procedure type distribution for first trimester, legal, induced abortion | |||
| MVA ($17) | 100 % | 70 % | |
| Misoprostol-alone ($10) | - | 30 % | |
| Total annual cost | $314,008[$287,406 - $502,522] | $250,332 | $219,408 |
| Percent decrease from current costs | - | 20 % | 30 % |
| Clinical parameter | SLE patients | Healthy Controls | P value |
| Patients (number) | 52 | 52 | – |
| Age (years) | 31 (12–52) | 32 (20–56) | 0.438 |
| Female:Male ratio | 46:6 | 45:7 | 0.767 |
| Laboratory data | |||
| TG (mmol/L) | 1.62 (0.50–8.93) | 0.80 (0.35–2.52) | <0.001 |
| TC (mmol/L) | 4.18 (1.92–9.28) | 4.28 (3.25–5.52) | 0.207 |
| HDL (mmol/L) | 1.06 (0.35–2.01) | 1.44 (1.05–2.15) | <0.001 |
| LDL (mmol/L) | 2.50 (0.89–7.06) | 2.53 (1.44–3.78) | 0.062 |
| APOA1 (g/L) | 1.14 (0.57–2.01) | 1.45 (1.08–1.89) | <0.001 |
| APOB (g/L) | 0.93 (0.38–2.06) | 0.89 (0.57–1.25) | 0.002 |
| APOM (mg/L) | 2.92 (1.54-17.75) | 14.80 (3.53–56.07) | <0.001 |
| Lpa (mg/L) | 154.15 (9.70–1517.40) | 78.80 (3.40–1043.50) | 0.041 |
| hs-CRP (mg/L) | 2.26 (0.12–125.44) | 0.37 (0.04–5.68) | 0.008 |
| 25-OHD3 (ng/ml) | 9.72 (3.00-19.26) | 16.16 (6.98-34.22) | <0.001 |
| Anti-dsDNA antibodies (%) | 19 (36.5%) | – | – |
| Anti-SM antibodies (%) | 21 (40.4%) | – | – |
| SLEDAI | 15 (5-29) | – | – |
| Model | Test set | SN(%) | PE(%) | ACC(%) | MCC(%) | AUC(%) |
| Ourmethod | 1 | 91.66 | 92.40 | 92.00 | 85.28 | 97.15 |
| 2 | 90.49 | 92.01 | 91.11 | 83.79 | 96.91 | |
| 3 | 91.13 | 91.05 | 91.19 | 83.94 | 96.97 | |
| 4 | 90.41 | 91.48 | 91.01 | 83.64 | 97.07 | |
| 5 | 89.64 | 92.76 | 91.47 | 84.38 | 97.23 | |
| Average | 90.67 ± 0.69 | 91.94 ± 0.62 | 91.36 ± 0.36 | 84.21 ± 0.59 | 97.07 ± 0.12 | |
| Guos' work | ACC | 89.93 ± 3.68 | 88.87 ± 6.16 | 89.33 ± 2.67 | N/A | N/A |
| AC | 87.30 ± 4.68 | 87.82 ± 4.33 | 87.36 ± 1.38 | N/A | N/A | |
| Zhous'work | SVM+LD | 87.37 ± 0.22 | 89.50 ± 0.60 | 88.56 ± 0.33 | 77.15 ± 0.68 | 95.07 ± 0.39 |
| Yangs'work | Cod1 | 75.81 ± 1.20 | 74.75 ± 1.23 | 75.08 ± 1.13 | N/A | N/A |
| Cod2 | 76.77 ± 0.69 | 82.17 ± 1.35 | 80.04 ± 1.06 | N/A | N/A | |
| Cod3 | 78.14 ± 0.90 | 81.86 ± 0.99 | 80.41 ± 0.47 | N/A | N/A | |
| Cod4 | 81.03 ± 1.74 | 90.24 ± 1.34 | 86.15 ± 1.17 | N/A | N/A |
| Compound | Inhibitor concentration (mg/L) |
| Furfural | 19.65 ± 0.81 |
| Hydroxymethylfurfural (HMF) | 3.89 ± 0.25 |
| Glucuronic acid | ND |
| p-coumaric acid | ND |
| Syringic acid | ND |
| Ferulic acid | ND |
| Targeted neurotransmitter | Agents under investigation | Status | Ref. | |
| Acetylcholine | LatrepirdineHuperzine A | (III) | 76 | |
| GABA | SGS742 | (II)* | ||
| ADS‐8704 (NMDA antagonist) | (III) | |||
| Serotonin | 5HT1A | Lecozotan | (II) | |
| 5‐HT4 | PRX‐03140TD‐8954 | – | ||
| 5‐HT6 | SB‐742457 | (II) | ||
| Histamine | PF03654746AB288 | (I)(II) | ||
| Adenosine | SCH58261 | – |
| Factors | Outcome (n = 10) | |
| Boiling/treatment of drinking water: | Yes | 0 |
| No | 10 (100%) | |
| Regular hand washing after toilet use: | Yes | 3 (30%) |
| No | 7 (70%) | |
| Regular hand washing after handling pork with: | Soap | 9 (90%) |
| Sanitizer | 0 | |
| Water only | 1 (10%) | |
| Wearing of hand gloves and aprons at work: | Yes | 0 |
| No | 10 (100%) | |
| Consumption of pork: | Yes | 10 (100%) |
| No | 0 | |
| Roasting and eating pork while handling raw pork: | Yes | 4 (40%) |
| No | 6 (60%) | |
| Method of pork processing for consumption: | Cooked | 4 (40%) |
| Cooked and fried | 2 (20%) | |
| Roasted | 4 (40%) | |
| Knowledge on public health significance of Taenia solium: | Yes | 0 |
| No | 10 (100%) |
| Abiotic stress | Reference | |
| Drought | CZP 9802; 863B, PRLT 2/89-33ICMP 83720, ICMV 9413, and ICMV 94472 | Yadav, 2004; Dwivedi et al., 2010 |
| Heat | H77/833-2, H77/29-2, CVJ 2-5-3-1-3, 77/371XBSECT CP1, 96AC-93, 1305, 77/371, Togo II, 99HS-18, G73107, 77/371 | Yadav et al., 2014 |
| Salinity | ICMB 02111, ICMB 94555, ICMB 95333, ICMB 00888, ICMB 01222, ICMP 451, IP 3732, IP 3757, IP8210, and PRLT 2/89-33, 10876 and 10878 (Sudan), 18406 and 18570 (Namibia), and ICMV93753 and ICMV 94474 (India); 863-B, CZI 98-11, CZI 9621, HTP 94/54 | Ali et al., 2004; Dwivedi et al., 2010 |
| Biotic stress | IP #16438 and 16762; P 310-17 and P 1449-3; IP18292; IP18293;700651; ICML #12, 13, 14, 15, 16, and 22; ICMP #312, 423, and 85410; 7042S; 841A; IP #9, 55, 104, 253, 262, 336, 346, 498, 545, and 558; landrace such as Ardi-Beniya Ka Bas, Dhodsar local and Desi Bajri-Chomu | Singh et al., 1997; Khairwal and Yadav, 2005; Thakur et al., 2006; Sharma et al., 2007 |
| Downy mildew (Sclerospora graminicola) | ICMPE #13-6-30, 134-6-9, 134-6-34, 13-6-27, 37, and 71;ICML #1, 2, 3, 4, 5, 6, 7, 8, 9, 10; ICMA #91333, 91444, and 91555; ICMA 92666 and ICMB 92666 (resistant to ergot, smut, and downy mildew) | Thakur et al., 1982; Willingale et al., 1986; Thakur and King, 1988a,b; Thakur et al., 1992; Rai et al., 1998b; Khairwal and Yadav, 2005 |
| Ergot (Claviceps fusiformis) | ExB 46-1-2-S-2, ExB 112-1-S-1-1, ICMV 8282, ICMV8283; ICMA 88006A and ICMA 88006B (resistant to smut and downy mildew);ICMA#91333, 91444 and 91555; 44 accessions selected from the screening of 1747 germplasm; ICML #5–10; ICMPS #100-5-1, 700-1-5-4, 900-1-4-1, 900-3-1, 900-9-3, 1300-2-1-2, 1400-1-6-2, 1600-2-4, 1500-7-3-2, 1800-3-1-2, and 2000-5-2; SSC FS 252-S-4, ICI 7517-S-1, ExB 132-2-S-5-2-DM-1, and P-489-S-3; SSC 46-2-2-1, SC 77-7-2-3-1, SSC 18-7-3-1 | Thakur et al., 1983; Thakur and King, 1988c; Yadav and Duhan, 1996; Rai et al., 1998a; Khairwal and Yadav, 2005 |
| Smut (Moesziomyces penicillariae) | ICML #5, 6, 7, 8, 9, and 10; ICML #17, 18, 19, 20 and 21; Tif leaf 3; Tift 3 (PI 547035) and Tift 4 (PI 547036); Tift 65 (resistant to rust and leaf spot) | Bourland, 1987; Thakur and King, 1988a; Wilson and Burton, 1991; Burton and Wilson, 1995; Hanna et al., 1997 |
| Rust (Puccinia sp.) | IP #16438 and 16762; P 310-17 and P 1449-3; IP18292; IP18293;700651; ICML #12, 13, 14, 15, 16, and 22; ICMP #312, 423, and 85410; 7042S; 841A; IP #9, 55, 104, 253, 262, 336, 346, 498, 545, and 558; landrace such as Ardi-Beniya Ka Bas, Dhodsar local and Desi Bajri-Chomu | Singh et al., 1997; Khairwal and Yadav, 2005; Thakur et al., 2006; Sharma et al., 2007 |
| Variables | Attempted suicide | Completed suicide | p-value | |||
| No. (%) | Annual incidence rate | No. (%) | Annual incidence rate | |||
| Gender | Male | 2939(96.9) | 74.98 | 94(3.1) | 2.40 | 0.004 |
| Female | 3649(98) | 94.51 | 75(2) | 1.94 | ||
| Age | 10–14years | 143(98.6) | 20.21 | 2(1.4) | 0.28 | 0.0001 |
| 15–24year | 4001(97.7) | 172.42 | 96(2.3) | 4.14 | ||
| 25–34years | 1788(98) | 82.87 | 36(2) | 1.67 | ||
| 35–44years | 411(96) | 29 | 17(4) | 1.2 | ||
| 45–54years | 152(96.2) | 17.88 | 6(3.8) | 0.71 | ||
| 55–64years | 51(92.7) | 9 | 4(7.3) | 0.71 | ||
| ≥65 years | 37(82.2) | 7.83 | 8(17.8) | 1.69 | ||
| Marital status | Single | 4008(97.5) | 137.51 | 101(2.5) | 3.47 | 0.001 |
| Married | 2532(97.5) | 56.15 | 64(2.5) | 1.42 | ||
| Divorced and Widow | 24(85.7) | 6.73 | 4(14.3) | 1.12 | ||
| level of education | Illiterate | 435(94.8) | 29.46 | 24(5.2) | 1.63 | 0.0001 |
| Elementary | 551(96.2) | 49.33 | 22(3.8) | 1.97 | ||
| Secondary | 1240(96.6) | 140.47 | 43(3.4) | 4.87 | ||
| High school and Diploma | 3278(98.3) | 137.46 | 56(1.7) | 2.35 | ||
| University educated | 759(98.4) | 42.88 | 12(1.6) | 0.68 | ||
| Occupation status | Housewife | 1581(98.1) | 71.17 | 30(1.9) | 1.35 | 0.0001 |
| Unemployed | 2291(97.9) | 295.54 | 48(2.1) | 6.19 | ||
| Self-employed | 526(97.2) | 117.87 | 15(2.8) | 3.36 | ||
| Office worker | 173(97.2) | 23.4 | 5(2.8) | 0.68 | ||
| Farmer | 109(86.5) | 13.03 | 17(13.5) | 2.03 | ||
| Student | 1308(97.6) | 70.66 | 32(2.4) | 1.73 | ||
| Worker | 128(96.2) | 45.54 | 5(3.8) | 1.78 | ||
| place of life | Urban | 3544(98.3) | 71.05 | 61(1.7) | 1.22 | 0.005 |
| Rural | 2001(97.2) | 72.03 | 57(2.8) | 2.05 | ||
| City of Residence | Abdanan | 531(98.3) | 81.62 | 9(1.7) | 1.38 | 0.087 |
| Ilam | 2615(97.9) | 87.38 | 57(2.1) | 1.9 | ||
| Ayvan | 942(98) | 134.46 | 19(2) | 2.71 | ||
| Dareh-shahr | 1289(96.6) | 154.56 | 45(3.4) | 5.4 | ||
| Dehloran | 349(98.9) | 38.31 | 4(1.1) | 0.44 | ||
| Shirvan-Chardavol | 585(97.2) | 57.84 | 17(2.8) | 1.68 | ||
| Malekshahi | 89(96.7) | 28.91 | 3(3.3) | 0.97 | ||
| Mehran | 130(96.3) | 34.55 | 5(3.7) | 1.33 |
| Unexposed | Exposed* | Surgery targeted by study | |||
| Time window | Tissue/structure group | Subject | No. (%) | No. (%) | OR (95% CI) |
| Time window 4 | Lymph nodes | Case | 165 (98.8) | 2 (1.2) | |
| MC | 831 (99.5) | 4 (0.5) | 2.50 (0.46–13.72) | ||
| UMC | 2,216 (99.6) | 8 (0.4) | 3.13 (0.72–13.69) | ||
| Blood vessels | Case | 165 (98.8) | 2 (1.2) | ||
| MC | 828 (99.2) | 7 (0.8) | 1.46 (0.33–6.48) | ||
| UMC | 2,217 (99.7) | 7 (0.3) | 3.88 (0.82–18.34) | ||
| Anterior ophthalmic | Case | 166 (99.4) | 1 (0.6) | ||
| structures | MC | 833 (99.8) | 2 (0.6) | 2.50 (0.23–27.77) | |
| UMC | 2,217 (99.7) | 7 (0.3) | 1.77 (0.24–13.29) | ||
| Skeletal muscle | Case | 164 (98.2) | 3 (1.8) | ||
| MC | 813 (97.4) | 22 (2.6) | 0.68 (0.20–2.29) | ||
| UMC | 2,169 (97.5) | 55 (2.5) | 0.57 (0.17–1.89) | ||
| Peritoneum | Case | 162 (97.0) | 5 (3.0) | ||
| MC | 826 (98.9) | 9 (1.1) | 2.78 (0.93–8.32) | ||
| UMC | 2,194 (98.7) | 30 (1.3) | 2.13 (0.80–5.66) | ||
| Other tissues | Case | 161 (96.4) | 6 (3.6) | ||
| MC | 826 (98.9) | 9 (1.1) | 3.51 (1.24–9.96) | ||
| UMC | 2,190 (98.5) | 34 (1.5) | 2.02 (0.83–4.93) | ||
| Time window 5 | Brain | Case | 165 (98.8) | 2 (1.2) | |
| MC | 835 (100.0) | 0 (0.0) | |||
| UMC | 2,223 (100.0) | 1 (0.0) | 36.35 (1.86–711.57) | ||
| Dura mater | Case | 165 (98.8) | 2 (1.2) | ||
| MC | 835 (100.0) | 0 (0.0) | |||
| UMC | 2,223 (100.0) | 1 (0.0) | 36.35 (1.86–711.57) | ||
| Lymph nodes | Case | 166 (99.4) | 1 (0.6) | ||
| MC | 831 (99.5) | 4 (0.5) | 1.25 (0.14–11.26) | ||
| UMC | 2,218 (99.7) | 6 (0.3) | 2.07 (0.28–15.05) | ||
| Skeletal muscle | Case | 161 (96.4) | 6 (3.6) | ||
| MC | 825 (98.8) | 10 (1.2) | 3.13 (1.13–8.65) | ||
| UMC | 2,196 (98.7) | 28 (1.3) | 2.76 (1.11–6.89) | ||
| Peritoneum | Case | 161 (96.4) | 6 (3.6) | ||
| MC | 832 (99.6) | 3 (0.4) | 10.00 (2.49–40.15) | ||
| UMC | 2,210 (99.4) | 14 (0.6) | 5.50 (2.07–14.66) | ||
| Other tissues | Case | 166 (99.4) | 1 (0.6) | ||
| MC | 826 (98.9) | 9 (1.1) | 0.56 (0.07–4.41) | ||
| UMC | 2,214 (99.6) | 10 (0.4) | 1.66 (0.19–14.86) |
| Tract | Wave-1 | Wave-2 | P-value | N | % ΔFA/year | M |
| ACF | 0.437 ± 0.033 | 0.420 ± 0.028 | <0.001 | 74 | −1.50 | 1 |
| LH CST | 0.434 ± 0.025 | 0.439 ± 0.023 | 0.014 | 76 | 0.49 | 0 |
| RH CST | 0.424 ± 0.027 | 0.427 ± 0.028 | 0.058 | 74 | 0.36 | 2 |
| Variable | Hazard ratio | 95% CI | Pvalue |
| Age | 0.987 | 0.938-1.039 | 0.611 |
| Interval time (mos.) from AP | 0.564 | 0.147-2.158 | 0.403 |
| Multi-agent failure therapy | 3.177 | 1.277-7.908 | 0.013 |
| Liver metastasis | 1.897 | 0.787-4.573 | 0.154 |
| Kidney metastasis | 2.654 | 1.125-6.261 | 0.026 |
| Craniotomy | 1.835 | 0.565-5.962 | 0.312 |
| FIGO score | 1.279 | 1.061-1.541 | 0.010 |
| Sorghum containing diets | Dose | TVFA(mM) | Acetate(mM) | Propionate(mM) | Butyrate(mM) |
| HFD (80R : 20C) | 0 | 51.5 | 34.2 | 11.1 | 6.3 |
| 5 | 62.7 | 39.8 | 16.2 | 6.7 | |
| 10 | 63.0 | 38.7 | 18.1 | 6.3 | |
| 15 | 66.2 | 40.0 | 19.9 | 6.3 | |
| MFD (50R : 50C) | 0 | 61.8 | 40.4 | 14.5 | 7.0 |
| 5 | 58.8 | 38.5 | 15.3 | 5.0 | |
| 10 | 68.2 | 43.4 | 19.4 | 5.4 | |
| 15 | 71.5 | 42.2 | 22.1 | 7.2 | |
| LFD (20R : 80C) | 0 | 64.5 | 43.8 | 12.7 | 7.9 |
| 5 | 70.3 | 43.2 | 19.5 | 7.6 | |
| 10 | 71.0 | 42.4 | 21.5 | 7.1 | |
| 15 | 72.7 | 41.9 | 23.0 | 7.7 | |
| SEM | Diet (D) | 1.04 | 0.69 | 0.45 | 0.19 |
| Treatment (T) | 1.20 | NS | 0.52 | 0.22 | |
| D × T | NS | 1.38 | NS | 0.04 |
| N | (%) | |
| Uterine atony | 179 | (55) |
| Placenta abnormalities; | 173 | (53) |
| Retained | 54 | (17) |
| Previa | 37 | (11) |
| Abnormally invasive placenta | 32 | (10) |
| Remnant | 30 | (9) |
| Abruption | 20 | (6) |
| Laceration; | 40 | (12) |
| Vagina | 23 | (7) |
| Cervix | 17 | (5) |
| Uterine rupture | 20 | (6) |
| Iatrogenic during/after cesarean | 11 | (3) |
| Other | 22 | (7) |
| Unknown | 9 | (3) |
| Apical segment | Middle segment | Basal segment | |
| Wild-type | 207 ± 50 | 253 ± 23 | 247 ± 27 |
| ugt78d2 | 194 ± 17 | 118 ± 14* | 142 ± 18* |
| Feasibility (% of n = 50 valid) | Number (test-retest) | Visit 1, mean (SD) | Visit 2, mean (SD) | t | p | Cohen’s d | ICC | |
| DCCS | 84 | 17 | 3.32 (2.35) | 3.89 (2.27) | −1.51 | .15 | .13 | .88 |
| Flanker | 82 | 17 | 4.44 (1.98) | 4.33 (2.33) | 0.23 | .82 | .23 | .75 |
| List sorting | 66 | 14 | 9.36 (4.31) | 8.00 (4.47) | −1.56 | .14 | .31 | .84 |
| Oral reading | 90 | 17 | −3.94 (3.18) | −3.88 (3.31) | 0.71 | .49 | .03 | .99 |
| Pattern comparison | 90 | 16 | 29.53 (13.47) | 35.35 (12.86) | 2.08 | .01 | .44 | .90 |
| Picture sequence memory | 78 | 17 | −1.39 (0.72) | −1.12 (1.05) | 1.45 | .18 | .46 | .76 |
| Picture vocabulary | 92 | 17 | −2.50 (2.13) | −3.05 (1.94) | −1.27 | .22 | .27 | .77 |
| Standard binary method | Augmented binary method | |||||
| End point | Fostamatinib 100 mg response rate | Placebo response rate | Difference (95% CI) | Fostamatinib 100 mg response rate | Placebo response rate | Difference (95%CI) |
| ACR20 | 0.47 (0.42, 0.53) | 0.34 (0.29, 0.39) | 0.13 (0.05,0.21) | 0.53 (0.49, 0.58) | 0.34 (0.29, 0.39) | 0.19 (0.13, 0.26) |
| ACR50 | 0.23 (0.18, 0.27) | 0.08 (0.05, 0.11) | 0.15 (0.09,0.20) | 0.26 (0.22, 0.30) | 0.13 (0.10, 0.16) | 0.13 (0.08, 0.18) |
| ACR70 | 0.10 (0.06, 0.13) | 0.02 (0.00, 0.04) | 0.08 (0.04,0.11) | 0.10 (0.09, 0.12) | 0.04 (0.03, 0.05) | 0.06 (0.04, 0.08) |
| DAS28 <3.2 | 0.26 (0.21, 0.30) | 0.11 (0.07, 0.14) | 0.15 (0.09,0.21) | 0.25 (0.21, 0.28) | 0.12 (0.09, 0.14) | 0.13 (0.08, 0.17) |
| DAS28 <2.6 | 0.13 (0.09, 0.16) | 0.05 (0.02, 0.07) | 0.08 (0.04,0.12) | 0.12 (0.10, 0.15) | 0.05 (0.04, 0.06) | 0.07 (0.05, 0.10) |
| Outcome: any type ofTP53-mutationsin a tumor | HR | 95% CI | p-value |
| Having both disruptiveTP53-mutationsandUGT2B17-deletions | 2.22 | 1.30 to 3.80 | 0.004 |
| p16-positive tumor | 0.53 | 0.29 to 0.99 | 0.047 |
| Stage IV | 2.32 | 1.44 to 3.74 | 0.001 |
| Poorly differentiated tumor grade | 1.66 | 1.01 to 2.74 | 0.047 |
| Accuracy | Mean Absolute Error | Area under the ROC Curve | |
| Logistic Regression | 80.0% | 0.201 | 0.854 |
| Bayesian Network | 96.4% | 0.129 | 0.931 |
| Artificial Neural Network | 96.4% | 0.045 | 0.941 |
| Silica Gels | Zeolites | ALPOS/SAPOS | Composites | MOFs | Activated Carbons | |
| Adsorption heat (kJ/kg) | 160 ÷ 180 * | 50 ÷ 300* | 250 ÷ 300 * | 50 ÷ 250* | 20 ÷ 200 ** | 45 ÷ 900 *** |
| Typical desorption temperatures [°C] | 50 ÷ 80 | 70 ÷ 350 | 60 ÷ 90 | 60 ÷ 90 | 60 ÷ 150 | 80 ÷ 200 |
| Density (kg/m3) | 650 ÷ 700 | 650 ÷ 900 | 800 ÷ 900 | 300 ÷ 600 | 1000 ÷ 2000 | 700 ÷ 750 |
| Specific heat (kJ/kgK) | 0.8 ÷ 0.9 | 0.85 ÷ 0.95 | 0.85 ÷ 0.95 | 0.95 ÷ 1.05 | 0.8 ÷ 1.2 | 0.8 ÷ 1.5 |
| Thermal conductivity (W/mK) | 0.15 ÷ 0.20 | 0.15 ÷ 0.25 | 0.15 ÷ 0.25 | 0.15 ÷ 0.30 | 0.10 ÷ 015 | 0.15 ÷ 0.75 |
| Possible refrigerants | water | water | water | water, methanol, ethanol | water, methanol, ethanol | methanol, ethanol, ammonia |
| Amount of uptake exchanged in a typical cyle [g/g] | 0.03 ÷ 0.10 | up to 0.2 | up to 0.25 | up to 0.8 | 0.16 ÷ 0.40 | 015 ÷ 0.60 |
| Study 1 | Study 2 | |
| Location | Newcastle, Australia | Bad Nauheim, Germany |
| Aim | Develop model, Determine spontaneous recanalization rate | Determine recanalization rates with microbubble + sonothrombolysis enhancement of tPA |
| Primary Outcome [method] | Recanalization [Laser Doppler] | Recanalization [Laser Doppler] |
| Secondary Outcome(s) [method] | Infarct Volumes [TTC], Mortality, Neurological Deficit scores | Clot lysis [Inspection of the major branches of the cerebral arterial circulation] |
| Survival post-embolism | 24 h | 2 h |
| Treatment groups (n) | No treatment (n = 7) | Saline (n = 10), tPA (n = 10), tPA + Ultrasound + BR38 microbubbles (n = 10) |
| Laser Doppler Monitoring | Continuous | Discontinuous |
| To 4 h post-embolism | Pre-embolism, Post-embolism, Pre-treatment, Post-treatment |
| RASgrf1 | primers | Length (bp) |
| Segment 1 | Forward TTTGTGAGGAAAGATGGTGTTGReverse AAACCATAAAAACCTTCACATAACTAC | 349 |
| Segment 2 | Forward GTAGAGAAGAGGAAAATAAGGAGGReverse CGAAAACCCCTAAAAATATTACAC | 347 |
| # | Code | Site Name | Country | N | Latitude | Longitude |
| 1 | GRO | Grosbeak Lake | Canada | 11 | 59.792 | -111.996 |
| 2 | FOR | Forgotten Pass Lake | Canada | 2 | 59.58 | -111.451 |
| 3 | HAY | Hay Camp Lake | Canada | 3 | 59.541 | -111.465 |
| 4 | TUR | Estany d'en Turies | Spain | 7 | 42.243 | 3.103 |
| 5 | CHI | Salada de Chiprana | Spain | 8 | 41.239 | -0.182 |
| 6 | ERA | Laguna de las Eras | Spain | 10 | 41.202 | -4.582 |
| 7 | SA2 | Balsa de Santed II | Spain | 10 | 41.016 | -1.542 |
| 8 | GAL | Laguna de Gallocanta | Spain | 5 | 40.974 | -1.508 |
| 9 | TON | Torreblanca Marsh, Poza Norte | Spain | 4 | 40.148 | 0.17 |
| 10 | TOS | Torreblanca Marsh, Poza Sur | Spain | 12 | 40.146 | 0.168 |
| 11 | MAN | Laguna de Manjavacas | Spain | 9 | 39.416 | -2.866 |
| 12 | TIA | Tianjin | China | 3 | 39.158 | 117.176 |
| 13 | SAL | Laguna del Salobrejo | Spain | 5 | 38.914 | -1.469 |
| 14 | PET | Laguna de Pétrola | Spain | 9 | 38.84 | -1.566 |
| 15 | MOJ | Laguna de Mojón Blanco | Spain | 2 | 38.798 | -1.432 |
| 16 | SLD | Laguna del Saladar | Spain | 4 | 38.789 | -1.419 |
| 17 | HOY | Laguna de Hoya Rasa | Spain | 2 | 38.785 | -1.428 |
| 18 | CAS | Laguna de Casa Nueva | Spain | 2 | 38.776 | -1.433 |
| 19 | ATA | Laguna de Atalaya de los Ojicos | Spain | 3 | 38.773 | -1.43 |
| 20 | CLO | Clot de Galvany | Spain | 2 | 38.246 | -0.546 |
| 21 | FUE | Laguna de Fuente de Piedra | Spain | 2 | 37.109 | -4.767 |
| 22 | CAP | Laguna de Capacete | Spain | 5 | 37.016 | -4.842 |
| 23 | EEL† | Eel Pond | Japan | 4 | 34.717 | 136.533 |
| 24 | ATL | Atlit coast | Israel | 1 | 32.703 | 34.94 |
| 25 | SAP | Sapelo | USA | 1 | 31.5 | -81.219 |
| 26 | EIL | Eilat | Israel | 1 | 29.56 | 34.967 |
| 27 | MEA | Meagher Pond | USA (Caribbean) | 1 | 19.295 | -81.232 |
| 28 | WAN | Lake Wannamal | Australia | 2 | -31.109 | 116.049 |
| 29 | PEA | Pearse's Lake | Australia | 3 | -31.629 | 116.914 |
| 30 | YEN | Yenyenning Lakes | Australia | 1 | -32.235 | 117.233 |
| 31 | HOT | Hotham River | Australia | 1 | -32.64 | 116.977 |
| 32 | BUS | Bushy Swamp | Australia | 2 | -33.541 | 117.27 |
| 33 | DUN | Dunn's Swamp | Australia | 1 | -33.924 | 120.155 |
| 34 | BUL | Lake Bulla | Australia | 1 | -34.755 | 142.361 |
| 35 | COL | Lake Colongulac | Australia | 2 | -38.173 | 143.163 |
| 36 | TOH | Tower Hill Lake | Australia | 5 | -38.325 | 142.368 |
| Protein | Construct OPPF_ | Yield/(mg/l) | Number of 96 well plates | Structure |
| ZHX1 | 1612 | 4.5 | 16 | |
| 1613 | 2.1 | 10 | ||
| 1615 | 2.3 | 14 | ||
| 1632 | 1.8 | 12 | ||
| 1633 | 2.3 | 6 | ||
| 1635 | 3.5 | 17 | ||
| 1636 | 5.9 | 11 | ||
| 2264 | 4.1 | 12 | ||
| 2265 | 3.9 | 32 | Yes | |
| ZHX2 | 2268 | 11.5 | 25 | |
| 2273 | 5.0 | 14 | Yes | |
| ZHX3 | 2274 | 2.5 | 8 | |
| 2279 | 6.3 | 8 |
| Number of | BMI | Time of smoking | Average number of smoked cigarettes | Passive smoking at work | Passive smoking at home | ||||
| Subjects | Women | Men | Women | Men | |||||
| Urine | |||||||||
| Smokers | 26 | 16 | 10 | 22.2 | 24.9 | In the evening | 6–10 | Yes | Yes |
| Passive smokers | 25 | 13 | 12 | 23.01 | 22.32 | n/a | n/a | Yes | Yes |
| Control group | 16 | 10 | 6 | 20.7 | 22.2 | n/a | n/a | No | No |
| Saliva | |||||||||
| Smokers | 11 | 8 | 3 | 22.7 | 24.2 | In the evening | 1–5 | No | Yes |
| Passive smokers | 16 | 11 | 5 | 22.4 | 23.1 | n/a | n/a | No | Yes |
| Control group | 10 | 7 | 3 | 21.8 | 23.4 | n/a | n/a | No | No |
| Delirium (n = 35) | No delirium (n = 15) | Differences (p value) | |
| Age in years, mean (SD) | 73 (9.9) | 67 (10) | 0.03 |
| Male, n (%) | 23 (66) | 13 (87) | 0.12 |
| Admission type: | |||
| Surgical (%) | 8 (23) | 3 (20) | |
| Medical (%) | 26 (74) | 10 (67) | 0.35 |
| Neurotrauma (%) | 1 (3) | 2 (13) | |
| APACHE-II score (SD) | 26 (7) | 28 (9) | 0.42 |
| Sepsis (patients), n (%) | 16 (46) | 3 (20) | 0.08 |
| PRE-DELIRIC score (mean, SD) | 78 (18) | 74 (19) | 0.45 |
| History of cognitive disorder, n (%) | 4 (11) | 1 (7) | 0.52 |
| Diabetes mellitus, n (%) | 5 (14) | 1 (7) | 0.41 |
| COPD, n (%) | 1 (3) | 2 (13) | 0.21 |
| Acute kidney injury, n (%) | 12 (34) | 3 (20) | 0.25 |
| Cardiovascular disease, n (%) | 1 (3) | 1 (7) | 0.51 |
| Use of steroids, n (%) | 18 (51) | 8 (53) | 0.57 |
| Study arm (DLA), n (%) | 19 (54) | 8 (53) | 0.6 |
| Intubation, n (%) | 31(89) | 14(93) | 0.52 |
| Hours of mechanical ventilation, median (IQR) | 158 (96–281) | 194 (116–383) | 0.58 |
| LOS-ICU in days, median (IQR) | 12 (10–19) | 15 (9–24) | 0.45 |
| LOS-hospital in days, median (IQR) | 30 (17–42) | 35 (19–50) | 0.79 |
| Hospital mortality, n (%) | 12 (34) | 3 (20) | 0.25 |
| Clinicopathologic parameter | Total case (n = 134) | High level of HSF-1 in tumor (%) | P | High level of HSF-1 in stromal (%) | P |
| Age (years) | |||||
| ≤61 | 67 | 37 (55.2) | 0.727 | 36 (53.7) | 0.486 |
| >61 | 67 | 39 (58.2) | 40 (59.7) | ||
| Gender | |||||
| Female | 26 | 11 (42.3) | 0.099 | 10 (38.5) | 0.036* |
| Male | 108 | 65 (60.2) | 66 (61.1) | ||
| Degree of differentiation | |||||
| G1 | 42 | 18 (42.9) | 0.082 | 17 (40.5) | 0.021* |
| G2 | 57 | 37 (64.9) | 39 (68.4) | ||
| G3 | 35 | 21 (60.0) | 20 (57.1) | ||
| T status | |||||
| T1–2 | 48 | 15 (31.2) | <0.001* | 15 (31.2) | <0.001* |
| T3–4 | 86 | 61 (70.9) | 61 (70.9) | ||
| N status | |||||
| N0 | 65 | 29 (44.6) | 0.006* | 28 (43.1) | 0.002* |
| N1 | 69 | 47 (68.1) | 48 (69.6) | ||
| M status | |||||
| M0 | 128 | 73 (57.0) | 1.000 | 72 (56.2) | 0.935 |
| M1 | 6 | 3 (50.0) | 4 (66.7) | ||
| Clinical stage | |||||
| I–II | 72 | 32 (44.4) | 0.002* | 33 (45.8) | 0.006* |
| III–IV | 62 | 44 (71.0) | 43 (69.4) |
| Sr. No. | Formulation | Droplet size (nm) | Zeta potential (mv) |
| 1 | AILP – A | 246 | -0.232 |
| 2 | AILP – B | 213 | -0.114 |
| 3 | AILP – C | 200 | -0.535 |
| 4 | AILP – D | 144 | -0.596 |
| 5 | AILP – E | 136 | -0.185 |
| Combination Label | Transfer Function (Hidden Neuron) | Transfer Function (Output Neuron) | No. of Output Neurons |
| CA | logsig | logsig | 4 |
| CB | tansig | logsig | 4 |
| CC | logsig | logsig | 2 |
| CD | tansig | logsig | 2 |
| CE | logsig | purelin | 1 |
| CF | tansig | purelin | 1 |
| Tracking method – mechanism | Disadvantages | Advantages |
| GFP, luciferase – DNA transfer can be mediated virally (transduction), via liposomes (lipofection), or by electrical parameters (electroporation/transfection) | - Genetic manipulation of cells may alter their function | - Human ASCs with GFP or luciferase resume proliferation normally |
| - Since they are cytosolic in location; the vector (mRNA/DNA) and/or the protein (GFP) could be transmitted to host cells via fusion elements and/or microvesicle secretion, resulting in contamination. Hence, there is concern for false positivity and their detection may not equate to viability of donor cells | - Detection is sensitive to in vivo non-invasive bioluminescence imaging | |
| - Technique requires serial passages, not suitable for use with fresh uncultured cells | ||
| - Many mammalian tissues have endogenous fluorescence | ||
| BrdU – this nuclear marker is a thymidine analog that replaces (3H) thymidine and can penetrate cell membranes to incorporate into newly synthesized DNA strands of actively proliferating cells | - Optimal labeling requires longer incubation time | - BrdU labeling has no effects on the ASC differentiation/proliferation and is not cytotoxic |
| - Not suitable for non-invasive methods of detection | ||
| - Does not indicate viability | ||
| - Cells lose BrdU rapidly with serial passages | ||
| Lipophilic dyes (DiI, DiR) –long-chain carbocyanine dyes with long aliphatic tails that incorporate into the lipid regions of the cell membranes | - Rapidly contaminates neighboring cells by macrophage-mediated phagocytosis, exchange of membrane microdomains, microvesicle and/or exosome transfer | - Easy technique for labeling and identification of cells |
| - May be cytotoxic to cells | ||
| - The dye fades with serial passages | ||
| Amine reactive probes (CFSE) – these diffuse into cells and react with cytosolic amine-containing residues to form dye–protein adducts that are retained | - The dye is toxic to ASCs | - Good staining efficiency |
| - Not suitable for in vivo non-invasive imaging | ||
| - Does not correlate with viability | ||
| - Contamination of neighboring cells can occur via macrophage-mediated phagocytosis, microvesicle and/or exosome transfer | ||
| Nanoparticles – small crystals made up of inorganic molecules; for example, iron oxide, cadmium | - Can be toxic to cells in high concentration and detection is difficult with low concentrations | - Photostable, remain resistant for long periods of time |
| - Contamination of neighboring cells can occur via phagocytosis, microvesicles and/or exosome transfer | - Can be used for in vivo non-invasive imaging | |
| - Does not correlate with viability | ||
| Real-time PCR for endogenous retroviral sequence (ERV-3) – the gene is present as a single copy in the human genome and so can be used to detect the presence of transplanted human cells in animal models | - Not suitable for non-invasive methods of detection | - Gives a quantitative estimate of number of cells |
| - False positives can occur by macrophage-mediated phagocytosis but this is very low | - Very sensitive and specific | |
| - The gene is already present in the human cells, so there is no need to stain the cells | ||
| FISH detection of human-specific cell surface markers or Alu sequences | - Alu sequences occur in large numbers in the primate genome, which makes higher likelihood of a false positive detection by transmission to host cells/macrophages via microvesicles/exosomes | - The gene is already present in the human cells, so there is no need to stain the cells |
| - Not suitable for non-invasive methods of detection | ||
| - Does not correlate with viability |
| Features | Bt X022 | Bt 4.0718 |
| Chromosome size | 5,460,989 bp | 5,641,982 bp |
| Number of plasmids | 7 | 6 |
| Predicted CDSs | 5888 | 6797 |
| Hypothetical genes | 1592 | 1826 |
| ncRNAs | 148 | 94 |
| Predicted insecticidal genes | 4 | 6 |
| Signal + harmonic | Frequency estimation (Hz) | Error (Hz) | ||
| Mean (μ) | Standard deviation (σ) | Mean (μ) | Standard deviation (σ) | |
| 2nd | 60.0000 | 0.0000 | 0.0000 | 0.0000 |
| 3rd | 60.0000 | 0.0000 | 0.0000 | 0.0000 |
| 3rd + 5th | 60.0000 | 0.0000 | 0.0000 | 0.0000 |
| Clinical observations and epidemiological arguments | |
| (I) | The prevalence rates of OCS in schizophrenia increased after market approval of SGAs such as clozapine. |
| (II) | The comorbidity rates in later stages of schizophrenia are higher than during the ARMS or at first manifestation of psychosis. |
| (III) | In parallel to antipsychotic treatment OCS manifest de novo or show a marked aggravation. |
| (IV) | High prevalence rates of OCS are observed during CLZ treatment. |
| (V) | Schizophrenia patients with SGA-induced OCS markedly contribute to the entire sample of comorbid patients. |
| Evidence derived from pharmacological considerations | |
| (I) | Pharmacodynamic properties modulate the risk for OCS: marked difference between samples treated with first generation antipsychotics or mainly dopaminergic SGAs (such as aripiprazole or amisulpride) compared to CLZ. |
| (II) | OCS manifest as an unfavourable drug effect de novo during treatment with potent antiserotonergic SGAs such as CLZ. |
| (III) | Indicators of a dose-effect relation: the severity of OCS is positively correlated with duration, dosage, and serum levels of CLZ treatment. |
| (IV) | OCS severity persists over time in patients under stable CLZ treatment. |
| (V) | The severity of OCS improves after reduction of CLZ dosage to minimally sufficient levels (due to augmentation or combination). |
| Classification of Theileria gene pairsa | Theileria consecutive gene pairs with orthologs in P. falciparumc | Pairs in Theileria with conserved synteny in Plasmodiumb | Percent conserved pairsd |
| Opposite strand | 940 | 64 | 22.66 |
| Opposite strand Overlap | 182 | 64 | 35.16 |
| Same-strand | 805 | 125 | 15.53 |
| Focus groups | Age category | Gender | Relationship | |||
| More homogeneous groups | ||||||
| < 50 yrs | 50 + yrs | Female | Male | Spouse | Other | |
| Group A | 2 | 5 | 5 | 2 | 6 | 1 |
| Asian Indian = 5 | ||||||
| Asian Pakistani = 2 | ||||||
| Group B | 1 | 6 | 4 | 3 | 2 | 5 |
| Asian Indian = 7 | ||||||
| Group C | 0 | 5 | 2 | 3 | 4 | 1 |
| White British = 5 | ||||||
| Group D | 0 | 3 | 3 | 0 | 3 | 0 |
| White British = 3 | ||||||
| Group E | 3 | 4 | 5 | 2 | 2 | 5 |
| Black Caribbean = 3 | ||||||
| Black African = 4 | ||||||
| More heterogeneous groups | ||||||
| Group F | 0 | 5 | 3 | 2 | 4 | 1 |
| Asian Indian = 1 | ||||||
| Asian Pakistani = 2 | ||||||
| Black Caribbean = 1 | ||||||
| White British = 1 | ||||||
| Group G | 2 | 5 | 7 | 0 | 7 | 0 |
| Asian Indian = 4 | ||||||
| Black African = 1 | ||||||
| White British = 1 | ||||||
| Black Caribbean = 1 | ||||||
| Total = 41 | 8 | 33 | 29 | 12 | 28 | 13 |
| Pregnant | Not pregnant | |
| Percent of total cycles | 36.7 | 63.3 |
| Age (years) | 36.5 ± 5.3 | 37.0 ± 4.6 |
| Embryos biopsied (n) | 7.7 ± 3.7 | 7.0 ± 3.8 |
| ≤ 6 n (%) | 20 (50.0) | 35 (50.7) |
| ≥ 7 n (%) | 20 (50.0) | 34 (49.3) |
| Euploid embryos (n)1 | 4.5 ± 2.4 | 3.3 ± 2.2 |
| ≤ 3 n (%) | 16 (40.0) | 42 (60.9) |
| % pregnant | 27.6 | |
| ≥ 4 n (%) | 24 (60.0) | 27 (39.1) |
| % pregnant | 47.1 | |
| Embryos transferred (n) | 2.1 ± 0.7 | 1.6 ± 0.8 |
| ≥ 2 euploid embryos available2 | ||
| n (%) pregnant ET x 1 | 4/35 (11.4) | |
| n (%) pregnant ET x 2 | 36/74 (48.6) |
| Factor | Numerator df | Denominator df | F | P |
| Support level | 4 | 528 | 5.36 | 0.0003 |
| Stimulus intensity | 9 | 528 | 211.62 | <0.0001 |
| Background EMG | 1 | 528 | 0.88 | 0.3497 |
| Support × Stimulus | 36 | 528 | 0.83 | 0.7505 |
| Support × Background | 4 | 528 | 2.34 | 0.0542 |
| Stimulus × Background | 9 | 528 | 1.41 | 0.1805 |
| Support × Stimulus × Background | 36 | 528 | 1.10 | 0.3248 |
| Distances | ||||||||
| Classifiers | 1 | 2 | 3 | 4 | 5 | 6 | 7 | Avg. |
| NB | 68.57 | 69.52 | 72.38 | 75.24 | 75.24 | 72.38 | 70.48 | 71.97 |
| 75.24 | 83.81 | 81.90 | 83.81 | 85.71 | 86.67 | 86.67 | 83.40 | |
| 67.62 | 73.33 | 72.38 | 73.33 | 74.29 | 74.29 | 75.24 | 72.93 | |
| LMT | 75.24 | 78.10 | 76.19 | 77.14 | 77.14 | 80.00 | 82.86 | 78.09 |
| 80.00 | 82.86 | 80.00 | 83.81 | 86.67 | 86.67 | 82.86 | 83.27 | |
| 70.48 | 80.95 | 78.10 | 81.90 | 76.19 | 79.05 | 80.95 | 78.23 | |
| RT | 74.29 | 63.81 | 75.24 | 74.29 | 78.10 | 71.43 | 71.43 | 72.66 |
| 68.57 | 76.19 | 76.19 | 80.95 | 71.43 | 71.43 | 76.19 | 74.42 | |
| 63.81 | 65.71 | 74.29 | 64.76 | 71.43 | 77.14 | 62.86 | 68.57 | |
| RF | 71.43 | 74.29 | 83.81 | 84.76 | 82.86 | 80.00 | 76.19 | 79.05 |
| 83.81 | 87.62 | 81.90 | 88.57 | 86.67 | 90.48 | 83.81 | 86.12 | |
| 77.14 | 81.90 | 73.33 | 82.86 | 78.10 | 82.86 | 82.86 | 79.86 | |
| SVM | 80.00 | 84.76 | 87.62 | 89.52 | 91.43 | 90.48 | 92.38 | 88.03 |
| 89.52 | 90.48 | 94.29 | 94.29 | 95.24 | 96.19 | 95.24 | 93.60 | |
| 85.71 | 89.52 | 90.48 | 89.52 | 90.48 | 90.48 | 91.43 | 89.66 |
| TIMP-1 (ng/mL) | |||||||
| MMP-13 (ng/mL) | 12.18 | 20.09 | 33.12 | 54.60 | 90.02 | 148.41 | |
| 33.12 | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 | Referencepoint | |
| 54.60 | 4.96 [0.27; 9.64] p = 0.038 | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 | |
| 90.02 | 4.30 [0.021; 8.59] p = 0.049 | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 | |
| 148.41 | N/A | N/A | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 | |
| 244.69 | N/A | N/A | p > 0.05 | 3.93 [0.084; 7.79] p = 0.045 | 4.60 [0.69; 8.51] p = 0.022 | 4.43 [0.29; 8.58] p = 0.037 |
| Rank | Name and cell line | Mean | N | Enrichment | P | Specificity |
| 12 | Estradiol-ssMCF7 | 0.700 | 2 | 0.989 | 0.00016 | 0.0000 |
| 31 | Estradiol-HL60 | 0.303 | 8 | 0.590 | 0.00335 | 0.1585 |
| 3091 | Estradiol-MCF7 | 0.222 | 19 | 0.485 | Null | Null |
| 3580 | Estradiol-PC3 | -0.040 | 8 | 0.223 | Null | Null |
| Walls | Moduli identified (MPa) | Measurements | Model | ||
| f1 (Hz) | f2 (Hz) | f1 (Hz) | f2 (Hz) | ||
| Wall A | 104 | 12.25 ± 0.05 | 16.25 ± 0.12 | 12.25 | 16.48 |
| Wall B | 98 | 11.87 ± 0.08 | 16.20 ± 0.09 | 11.87 | 15.97 |
| Wall C | 90 | 11.38 ± 0.10 | 15.38 ± 0.22 | 11.38 | 15.31 |
| CBT | MRT |
| Treatment focus on perpetuating factors | Treatment focus depending on the relation between the(precipitating, predisposing and perpetuating) factorsand the presented complaints. |
| Afterwards feedback at next therapy session | Immediately feedback during therapy |
| Pays no attention to physical sensations | Stimulating awareness of healthy bodily symptoms |
| CBT | CBT incorporated with principles of mindfulness |
| Tender point count (outcome) | |||
| Model 1β coefficient (95% confidence intervals) | Model 2β coefficient (95% confidence intervals) | Model 3β coefficient (95% confidence intervals) | |
| Psychological distress (HAD) (0–42) | 0.28 (0.20, 0.36) | 0.19 (0.08, 0.30) | 0.19 (0.09, 0.30) |
| Age | |||
| Youngest (34–57)Middle (58–69)Oldest (70–97) | (referent)0.50 (−0.9, 1.87)1.30 (−0.09, 2.5) | (referent)0.45 (−0.88, 1.78)1.46 (0.22, 2.70) | (referent)0.24 (−1.10, 1.59)0.86 (−0.53, 2.25) |
| Sex | |||
| MaleFemale | (referent)1.99 (0.98, 3.35) | (referent)1.71 (0.61, 2.80) | (referent)1.86 (0.77, 2.94) |
| Catastrophising (PCS) (0–50) | −0.03 (−0.13, 0.07) | −0.03 (−0.13, 0.07) | |
| Sleep quality (PSQI) (0–21) | 0.29 (0.07, 0.52) | 0.28 (0.05, 0.50) | |
| Pain beliefs (Brief IPQ) | |||
| Consequences (0–10)Concern (0–10)Coherence (0–10)Timeline (0–10)Treatment control (0–10)Personal control (0–10)Identity (0–10)Emotion (0–10) | 0.06 (−0.28, 0.39)−0.01 (−0.30, 0.33)0.03 (−0.15, 0.21)0.14 (−0.02, 0.30)0.001 (−0.17, 0.16)0.01 (−0.19, 0.21)0.16 (−0.14, 0.47)−0.09 (−0.43, 0.24) | −0.001 (−0.32, 0.32)−0.04 (−0.26, 0.34)−0.05 (−0.13, 0.23)0.12 (−0.04, 0.28)0.01 (−0.15, 0.18)0.01 (−0.19, 0.21)0.13 (−0.18, 0.44)−0.12 (−0.45, 0.20) | |
| Smoking | |||
| Never-smokerEx-smokerCurrent smoker | (referent)0.25 (−0.80, 1.31)0.69 (−1.37, 2.75) | (referent)0.19 (−0.86, 1.23)0.40 (−1.80, 2.61) | |
| Alcohol consumption (units) | |||
| (0–60) | −0.04 (−0.09, 0.01) | −0.03 (−0.08, 0.02) | |
| Osteoarthritis count | |||
| 0 sites1 site2 sites3 sites | (referent)−0.50 (−1.33, 2.33)0.78 (−1.47, 3.03)5.00 (0.46, 9.54) | ||
| Medication count (0–17) | 0.10 (−0.09, 0.28) | ||
| Adjusted R squared | 0.23 | 0.29 | 0.30 |
| # Significant Loci | ||||||||
| Species Flock | GR | LM PC 1 | LM PC 2 | LM PC 3 | GM PC 2 | Date | Depth | Total |
| Neuchâtel | 0/ 0/ 0 | 0/ 0/ 0 | 0/ 0/ 0 | 0/ 0/ 0 | 0/ 0/ 0 | 0/ 0/ 0 | 0/ 0/ 0 | 0 |
| Biel | 0/ 0/ 0 | n/a | n/a | n/a | 0/ 0/ 0 | 0/ 0/ 0 | 0/ 0/ 0 | 0 |
| Thun | 2/ 4/ 4 | 3/ 5/ 6 | 0/ 0/ 0 | 1/ 2/ 2 | 0/ 0/ 1 | 0/ 0/3 | 0/ 0/ 1 | 17 |
| Brienz | 0/ 2/ 4 | 0/ 0/ 0 | 0/ 0/ 0 | 0/ 0/ 0 | 0/ 0/ 0 | 0/ 0/ 1 | 0/ 0/ 0 | 5 |
| Lucerne | 1/ 2/ 5 | 0/ 0/ 0 | 0/ 0/ 1 | 0/ 0/ 0 | 0/ 0/ 0 | 0/ 0/ 0 | 2/ 3/ 3 | 9 |
| Constance | 0/ 0/ 1 | 0/ 0/ 1 | 0/ 0/ 0 | 0/ 0/ 0 | 0/ 0/ 0 | 0/ 0/ 0 | 0/ 0/ 0 | 2 |
| Walen | 0/ 1/ 1 | 0/ 1/ 1 | 0/ 0/ 1 | 0/ 0/ 0 | 0/ 0/ 1 | 0/ 0/ 0 | 0/ 0/ 2 | 6 |
| Zuerich | 0/ 4/ 4 | 0/ 0/ 0 | 0/ 0/ 0 | 0/ 0/ 0 | 0/ 0/ 0 | 0/ 0/ 0 | 0/ 0/ 0 | 4 |
| Maggiore | 0/ 0/ 0 | 0/ 0/ 0 | 0/ 0/ 0 | 0/ 0/ 0 | 0/ 0/ 0 | 0/ 0/ 0 | 0/ 0/ 0 | 0 |
| Total | 19 | 8 | 2 | 2 | 2 | 4 | 6 | 43 |
| Variable | Control group n = 16 | RA nonbiological DMARDs n = 16 | RA biological DMARDs n = 18 |
| Age (years) | 51.81 ± 9.75 | 51.31 ± 6.70 | 52.05 ± 8.26 |
| Weight (Kg) | 75.46 ± 22.85 | 69.86 ± 14.18 | 70.82 ± 19.96 |
| Height (m) | 1.59 ± 0.05 | 1.56 ± 0.07 | 1.58 ± 0.05 |
| BMI (Kg/m2) | 29.48 ± 7.35 | 28.65 ± 7.09 | 28.20 ± 8.19 |
| WC (cm) | 89.84 ± 17.74 | 91.31 ± 15.89 | 88.41 ± 27.20 |
| SBP (mmHg) | 117.50 ± 11.25 | 121.00 ± 7.10 | 122.11 ± 8.82 |
| DBP (mmHg) | 75.93 ± 9.86 | 79.18 ± 5.23 | 78.72 ± 4.72 |
| Type of nerves | Outcome variables | |||
| Peripheral nerve function (N = 50) | Number of nerves involved (N = 50) | |||
| Normal, n (%) | Abnormal, n (%) | <2, n (%) | ≥2, n (%) | |
| Motor nerve | 23 (46) | 27 (54) | 36 (72) | 14 (28) |
| Sensory nerve | 14 (28) | 36 (72) | 23 (46) | 27 (54) |
| Mixed nerve | 10 (20) | 40 (80) | 15 (30) | 35 (70) |
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | |
| 1. Communication (FI) | |||||||||||||||||||||
| 2. Demanding (FI) | 0.34 | ||||||||||||||||||||
| 3. Colleagues (FI) | 0.21 | 0.24 | |||||||||||||||||||
| 4. Supervisor (FI) | 0.35 | 0.31 | 0.44 | ||||||||||||||||||
| 5. Organization (FI) | 0.49 | 0.39 | 0.40 | 0.70 | |||||||||||||||||
| 6. Career (FI) | 0.44 | 0.44 | 0.26 | 0.38 | 0.51 | ||||||||||||||||
| 7. Conditions (FI) | 0.32 | 0.34 | 0.20 | 0.20 | 0.32 | 0.38 | |||||||||||||||
| 8. Decision range (FI) | 0.43 | 0.47 | 0.32 | 0.40 | 0.53 | 0.46 | 0.39 | ||||||||||||||
| 9. Time aspects (FI) | 0.27 | 0.37 | 0.25 | 0.22 | 0.24 | 0.34 | 0.41 | 0.36 | |||||||||||||
| 10. Compensations (FI) | 0.32 | 0.33 | 0.20 | 0.27 | 0.37 | 0.49 | 0.30 | 0.38 | 0.32 | ||||||||||||
| 11. Framework (FI) | 0.34 | 0.36 | 0.25 | 0.29 | 0.37 | 0.37 | 0.44 | 0.45 | 0.50 | 0.36 | |||||||||||
| 12. Communication (FS) | 0.73 | 0.36 | 0.26 | 0.39 | 0.53 | 0.50 | 0.37 | 0.49 | 0.31 | 0.41 | 0.40 | ||||||||||
| 13. Demanding (FS) | 0.34 | 0.76 | 0.28 | 0.30 | 0.37 | 0.47 | 0.34 | 0.49 | 0.39 | 0.41 | 0.40 | 0.40 | |||||||||
| 14. Colleagues (FS) | 0.25 | 0.25 | 0.80 | 0.43 | 0.43 | 0.33 | 0.23 | 0.35 | 0.28 | 0.28 | 0.27 | 0.31 | 0.31 | ||||||||
| 15. Supervisor (FS) | 0.36 | 0.33 | 0.36 | 0.82 | 0.67 | 0.39 | 0.23 | 0.43 | 0.26 | 0.30 | 0.29 | 0.43 | 0.37 | 0.41 | |||||||
| 16. Organization (FS) | 0.52 | 0.40 | 0.28 | 0.37 | 0.54 | 0.54 | 0.39 | 0.47 | 0.33 | 0.55 | 0.41 | 0.64 | 0.47 | 0.37 | 0.43 | ||||||
| 17. Career (FS) | 0.41 | 0.45 | 0.28 | 0.35 | 0.49 | 0.76 | 0.37 | 0.47 | 0.33 | 0.47 | 0.38 | 0.52 | 0.53 | 0.36 | 0.41 | 0.58 | |||||
| 18. Conditions (FS) | 0.29 | 0.35 | 0.27 | 0.20 | 0.28 | 0.35 | 0.68 | 0.33 | 0.35 | 0.29 | 0.40 | 0.36 | 0.37 | 0.32 | 0.24 | 0.41 | 0.40 | ||||
| 19. Decision range (FS) | 0.42 | 0.56 | 0.32 | 0.38 | 0.48 | 0.44 | 0.40 | 0.64 | 0.44 | 0.39 | 0.48 | 0.51 | 0.64 | 0.38 | 0.43 | 0.50 | 0.48 | 0.37 | |||
| 20. Time aspects (FS) | 0.29 | 0.40 | 0.31 | 0.33 | 0.38 | 0.38 | 0.40 | 0.45 | 0.66 | 0.38 | 0.52 | 0.36 | 0.46 | 0.37 | 0.38 | 0.41 | 0.42 | 0.40 | 0.57 | ||
| 21. Compensations (FS) | 0.31 | 0.31 | 0.18 | 0.23 | 0.32 | 0.48 | 0.25 | 0.31 | 0.27 | 0.74 | 0.29 | 0.37 | 0.37 | 0.26 | 0.28 | 0.48 | 0.46 | 0.31 | 0.31 | 0.35 | |
| 22. Framework (FS) | 0.34 | 0.38 | 0.30 | 0.27 | 0.40 | 0.44 | 0.50 | 0.43 | 0.46 | 0.49 | 0.50 | 0.43 | 0.47 | 0.38 | 0.34 | 0.56 | 0.51 | 0.54 | 0.53 | 0.57 | 0.46 |
| Standard | Mean ± SD of Score | Standard Achieved*(% of notes) |
| Contents | 14.4 ± 2.1 | 16 (6.8) |
| Legibility | 3.9 ± 0.2 | 232 (99.1) |
| ANKLe | 18.4 ± 2.1 | 61 (26.1) |
| Variables | Group A | Group B | Difference | **P-value | |||||
| Baseline | 3rdmonth | *P-value | Baseline | 3rdmonth | *P-value | Group A | Group B | ||
| Pyridinoline | 51.17 ± 87.90 | 13.06 ± 5.81 | 0.766 | 41.01 ± 38.94 | 15.67 ± 11.05 | 0.268 | −40.8 ± 96.5 | −28.2 ± 42.6 | 0.656 |
| Osteocalcin | 2.20 ± 0.47 | 2.5 ± 0.58 | 0.564 | 2.22 ± 0.60 | 2.24 ± 0.82 | 0.230 | 0.37 ± 0.80 | 0.23 ± 0.96 | 0.390 |
| Urine Calcium | 9.09 ± 9.08 | 8.10 ± 6.98 | 0.045 | 6.95 ± 5.03 | 5.77 ± 6.31 | 0.044 | −1 ± 9.1 | 0.21 ± 5.9 | 0.683 |
| Urine Creatinine | 120.55 ± 58.59 | 108.23 ± 48.99 | 0.273 | 111.68 ± 72.39 | 130.39 ± 68.47 | 0.003 | −11.2 ± 64 | 34.6 ± 49.2 | 0.029 |
| Bone Alkaline phosphatase | 24.9 ± 7 | 20.8 ± 19.7 | 0.014 | 23.8 ± 10.4 | 20.6 ± 7.5 | 0.048 | −4.5 ± 7 | −3 ± 10.8 | 0.364 |
| TNF-α | 91.68 ± 52.92 | 88.84 ± 55.75 | 0.006 | 90.85 ± 27.21 | 80.94 ± 28.73 | 0.026 | −4.2 ± 26.1 | −12.4 ± 28.2 | 0.267 |
| Normal alleles | Norwegian (present study) | Finnish [43] | Cuban [65] | Indian [66] | Caucasian [67] | French [26] | ||
| North | South | |||||||
| GAA repeat sizes | 5-12 | 83.5 % | 83 % | 79.5 % | 89.1 % | 94.1 % | 80 % | 83 % |
| 13-34 | 16.5 % | 17 % | 20.5 % | 10.9 % | 5.9 % | 20 % | 17 % | |
| Alleles range | 6-34 | 6-27 | 7-27 | 5-31 | 7-16 | 5-23 | 7-34 |
| Haplotype | Frequencya | Chi-square | Pb | |||||
| rs929763 | rs732157 | rs2303134 | rs1063310 | rs3805455 | Control | SLE | ||
| T | C | A | C | C | 0.406 | 0.345 | 3.580 | 0.03 |
| A | C | A | C | C | 0.228 | 0.220 | 0.091 | 0.803 |
| A | T | A | A | T | 0.223 | 0.185 | 1.942 | 0.166 |
| A | C | A | A | T | 0.037 | 0.057 | 2.516 | 0.334 |
| T | C | A | A | T | 0.044 | 0.026 | 1.893 | 0.431 |
| A | C | A | C | T | 6.4E − 4 | 0.105 | 102.6 | 4.2E − 24 |
| Other | 0.062 | 0.062 | — | — |
| Criteria | Exclusion | Method |
| Significant co-morbid disease that would threaten safety or impair ability to participate in interventions or testing, previous acute knee injury, bilateral severe tibiofemoral OA, severe patellofemoral OA (JSN = 3 using OARSI atlas), no definite medial tibiofemoral OA, severe obesity, low weight. | Symptomatic or severe coronary artery disease; severe HTN; active cancer other than skin cancer; anemia; dementia; liver disease; COPD; peripheral vascular disease; inability to walk without an assistive device; blindness; type 1 diabetes; type 2 diabetes on thiazolidinedione agents; bilateral severe medial tibiofemoral OA (KL = 4), no definite medial tibiofemoral OA (KL = 0, 1), BMI < 20 or > 45 kg.m-2 | Medical history; physical exam; PA and skyline knee x-ray; height and weight. |
| OA disease location and alignment restrictions: predominant knee OA other than medial tibiofemoral OA; valgus, or extreme varus alignment. | Lateral tibiofemoral OA > medial tibiofemoral OA, severe patellofemoral OA; valgus knee alignment > 2°, or varus alignment > 10° | Knee PA and skyline view x-rays, lower extremity long x-ray. |
| Excess alcohol use | ≥ 21 drinks per week | Questionnaire |
| Inability to finish 18-month study or unlikely to be compliant | Lives > 50 miles from site or planning to leave area ≥ 3 months during the next 18 months | Questionnaire, interview |
| Conditions that prohibit CT | BMI > 45 kg.m-2 | height and weight |
| Significant cognitive impairment | diagnosis of dementia or a MoCA score <20 | Medical history, MoCA |
| Low Pain | Pain ≤ 3 on a scale from 0-20 | WOMAC |
| BASELINE | TIME OF SACRIFICE | |||||
| TC(mM/L) | HDL-C(mM/L) | Non HDL-C(mM/L) | TC(mM/L) | HDL-C(mM/L) | Non HDL-C(mM/L) | |
| SALINE | 0.86 ± 0.07 | 0.77 ± 0.09 | 0.09 ± 0.07 | 2.64 ± 0.29* | 0.65 ± 0.03 | 1.99 ± 0.28* |
| rHDL | 0.84 ± 0.06 | 0.63 ± 0.06 | 0.21 ± 0.06 | 2.53 ± 0.49* | 0.66 ± 0.06 | 1.87 ± 0.46* |
| ETC-642 | 0.99 ± 0.05 | 0.73 ± 0.04 | 0.26 ± 0.06 | 2.87 ± 0.27* | 0.61 ± 0.05 | 2.25 ± 0.26* |
| Percentile | Chlorpyrifos viaIndoor Dust | Chlorpyrifos viaOutdoor Soils | Cypermethrin viaIndoor Dust | Cypermethrin viaOutdoor Soils |
| P50 | <0.001% (<0.001%, <0.001%) | <0.001% (<0.001%, <0.001%) | <0.001% (<0.001%, <0.001%) | <0.001% (<0.001%, <0.001%) |
| P75 | 0.002% (0.002%, 0.002%) | 0.001% (0.001%, 0.001%) | 0.004% (0.004%, 0.004%) | <0.001% (<0.001%, <0.001%) |
| P90 | 0.019% (0.019%, 0.019%) | 0.007% (0.007%, 0.007%) | 0.052% (0.052%, 0.053%) | 0.005% (0.005%, 0.005%) |
| P95 | 0.079% (0.079%, 0.079%) | 0.029% (0.029%, 0.029%) | 0.208% (0.207%, 0.209%) | 0.023% (0.023%, 0.023%) |
| P97.5 | 0.254% (0.253%, 0.255%) | 0.102% (0.101%, 0.102%) | 0.629% (0.627%, 0.631%) | 0.080% (0.079%, 0.080%) |
| P99 | 0.884% (0.880%, 0.887%) | 0.412% (0.410%, 0.414%) | 2.042% (2.035%, 2.049%) | 0.310% (0.308%, 0.311%) |
| P99.9 | 8.313% (8.234%, 8.392%) | 4.819% (4.782%, 4.856%) | 16.89% (16.75%, 17.04%) | 3.155% (3.124%, 3.186%) |
| Cancer | Mean age ± SD at diagnosis of CD |
| Non Hodgkin's lymphoma | 46.1 ± 13.8 |
| Small bowel | 59 ± 10 |
| Colon | 51.3 ± 9.4 |
| Stomach | 53.5 ± 15.4 |
| Hodgkin's lymphoma | 54.3 ± 6 |
| Breast | 41.2 ± 12.8 |
| All neoplasms | 47.6 ± 10.2 |
| Compound Described | Mechanism of Action | Targeting | References |
| PRIMA-1Met (APR-246) | Converted to MQ; MQ binds to thiol groups in the core domain of mutp53 to restore wtp53 function | Restoration | Bykov 2002 [66], 2005 [67]Lambert 2009 [68], 2010 [69] |
| PhiKan083 or PhiKan7088 | Binding to p53-Y220C specific core cavity and restore wtp53-like folding | Restoration of p53 Y220C | Boeckler 2008 [70]Liu 2013 [71] |
| PEITC | Unknown; p53-R172H specific; restores wtp53-like function | Restoration of p53 R172H | Aggarwal 2016 [72] |
| ReACp53 | Small peptide; blocks amyloid-like aggregation of mutp53 to shift to wtp53-like folding state | Deaggregation, Restoration | Soragni 2016 [73] |
| pCAP | Small peptide; binds preferentially to mutp53 when it transiently exhibits wtp53-like conformation to shift the equilibrium towards the wtp53 | Stabilize wtp53 structure | Tal 2016 [74] |
| ZMC-1 | Metallochaperone; increases intracellular zinc level to restore zinc-deficient p53 mutants such as p53-R175H which allows proper wtp53-like folding | Restoration and activation | Yu 2012 [75]Blanden 2015 [76] |
| RETRA | Not well known; disrupts mutp53/p73 complexes | Activation of p73 | Kravchenko 2008 [77] |
| Prodigiosin | Not well known; induces TAp73 expression and disrupts its interaction with mutp53 | Activation of p73 | Hong 2014 [78] |
| Chetomin (CTM) | Binds to Hsp40 and increases the binding of Hsp40 to p53 R175H which leads to restoration of wtp53 conformation | Restoration of p53 R175H | Hiraki 2015 [79] |
| Hsp90 inhibitors | e.g., 17AAG and Ganetespib; disrupt chaperone complexes to release and activate MDM2 and/or CHIP which degrade mutp53 | Mutp53 degradation | Esser 2005 [35]Li 2011 [37]Alexandrova 2015 [15] |
| Statin | e.g., Lovastatin inhibits Hsp40 (by decreasing mevalonate-5-phosphate) or Cerivastatin (more potent) inhibits Hsp90 (by inhibiting HDAC6) to release and reactivate CHIP and MDM2 leading to mutp53 degradation | Mutp53 degradation | Parrales 2016 [60]Ingallina 2018 [59] |
| Attribute and level | Available coloura | |||
| Treated (T) or untreated (U) | Shape | Size (feet) | Price (000 TSH) | |
| T (Olyset brand) | Rectangular | 4 × 6 | 2, 4, 6, 8 | Aqua blue |
| T (Olyset brand) | Rectangular | 6 × 6 | 2, 4, 6, 8 | Navy blue and whiteb |
| U (Safinet brand) | Rectangular | 4 × 6; 6 × 6 | 2, 4, 6, 8 | White |
| U (Safinet brand) | Conical | 3.5 × 6c; 6 × 6 | 2, 4, 6, 8 | White |
| Mean | SD | Range | n (%) high scores | n (%) low scores | |
| PDQ-Carer: Personal and Social Activities | 44.15 | 28.82 | 0-95.83 | 4 (5.5) | 1 (1.4) |
| PDQ-Carer: Anxiety and Depression | 46.86 | 22.97 | 0-100 | 2 (2.7) | 1 (1.4) |
| PDQ-Carer: Self Care | 32.53 | 26.10 | 0-90.0 | 12 (16.4) | 2 (2.7) |
| PDQ-Carer: Strain | 48.17 | 22.31 | 0-91.67 | 3 (4.1) | 1 (1.4) |
| SF-36: Physical Functioning | 71.51 | 27.81 | 5.00-100 | 1 (1.4) | 12 (16.4) |
| SF-36: Role Physical | 71.92 | 39.07 | 0-100 | 11 (15.1) | 43 (58.9) |
| SF-36: Role Emotional | 64.84 | 44.41 | 0-100 | 20 (27.4) | 42 (57.5) |
| SF-36: Social Functioning | 67.12 | 27.68 | 0-100 | 1 (1.4) | 18 (24.7) |
| SF-36: Mental Health | 62.63 | 23.93 | 0-100 | 1 (1.4) | 3 (4.1) |
| SF-36: Energy/Vitality | 54.18 | 23.50 | 0-100 | 1 (1.4) | 2 (2.7) |
| SF-36: Pain | 60.22 | 28.44 | 0-100 | 1 (1.4) | 14 (19.2) |
| SF-36: General Health Perception | 56.34 | 20.84 | 5.00-97.00 | 1 (1.4) | 1 (1.4) |
| Diskus | Turbuhaler | Difference | |
| PIFR (L/min) | 77.6, 89.3, 72.2 | 55.3, 64.5, 47.8 | significant |
| VI (L) | 1.63, 2.19, 1.40 | 1.11, 1.66, 0.95 | significant |
| F0.3 (L/min) | 64.9, 71.6, 58.3 | 47.2, 52.1, 39.1 | significant |
| TPF (s) | 0.69, 0.89, 0.57 | 0.74, 0.93, 0.61 | ns |
| Source of variation | df | SS | MS | Est. variance | Variation (%) | P |
| Among individuals | 83 | 2276.02 | 27.42 | 8.36 | 70.7 | < 0.001 |
| Within individuals | 157 | 543.45 | 3.46 | 3.46 | 29.3 | |
| Total | 240 | 2819.47 | 11.83 | 100 |
| Cancer. related Function | PLS predicted Target genes in the respective functions | The nos. of cancer related miRNAs associated with the mRNA targets |
| Cancer | ANXA2, BHLHE40, CANX, CAPG, COTL1, CYBA, DDIT4, FTL, GPX1, GSTP1, IFITM1, MIF, MMP11, OAZ1, ODC1, S100A11, SLC12A8, SLC7A11, SOX4 and UBE2I (20) | 15 |
| Tumorigenesis | ANXA2, BHLHE40, CANX, CAPG, COTL1, CYBA, DDIT4, FTL, GPX1, GSTP1, IFITM1, MIF, MMP11, NUDT1, OAZ1, ODC1, PRDX2, S100A11, SLC12A8, SLC7A11, SOX4 and UBE2I (22) | 15 |
| Carcinoma | ANXA2, BHLHE40, CANX, COTL1, CYBA, FTL, GSTP1, IFITM1, MMP11, OAZ1, ODC1, S100A11 and SLC7A11 (13) | 12 |
| Malignant tumor | ANXA2, BHLHE40, CANX, COTL1, CYBA, FTL, GPX1, GSTP1, IFITM1, MIF, MMP11, OAZ1, ODC1, S100A11, SLC7A11 and SOX4 (16) | 12 |
| Primary tumor | ANXA2, BHLHE40, CANX, COTL1, CYBA, FTL, GPX1, GSTP1, IFITM1, MIF, MMP11, OAZ1, ODC1, PRDX2, S100A11, SLC7A11 and SOX4 (17) | 12 |
| Angiogenesis | ANXA2, CANX and GPX1 (3) | 8 |
| Severity of inflammatory cell infiltration | Score 1 (n=7) | Score 2 (n=10) | Score 3 (n=17) | Score 4 (n=12) |
| Patients without TBM-IgG3 | 4 | 3 | 2 | 6 |
| Patients with mild deposited TBM-IgG3 | 3 | 7 | 9 | 4 |
| Patients with strong deposited TBM-IgG3 | 0 | 0 | 6 | 2 |
| WC | WHR | BMI | LDL | Triglycerides | HDL | BOP | IL-1β | MMP-8 | |
| WHR | 0.640** | ||||||||
| BMI | 0.664** | 0.924** | |||||||
| LDL | 0.217 | 0.264* | 0.214 | ||||||
| Triglycerides | 0.006 | 0.064 | 0.059 | −0.147 | |||||
| HDL | −0.173 | −0.263* | −0.240* | 0.078 | −0.179 | ||||
| BOP | −0.103 | −0.173 | −0.114 | 0.233* | −0.020 | 0.119 | |||
| IL-1β | 0.200 | 0.270* | 0.340** | 0.342** | −0.274* | 0.073 | 0.220* | ||
| MMP-8 | 0.254* | 0.242* | 0.234* | 0.332** | −0.061 | 0.114 | 0.293** | 0.596** | |
| MMP-9 | 0.159 | 0.144 | 0.137 | 0.206 | −0.118 | 0.013 | 0.181 | 0.568** | 0.772** |
| Target | Primer | Sequence (5′ → 3′) | Ta (°C) | Reference |
| Total bacteria | UniF | GTGSTGCAYGGYYGTCGTCA | 60 | [23] |
| UniR | ACGTCRTCCMCNCCTTCCTC | |||
| Bifidobacterium | BIF-F | TCG CGTC(C/T)GGTGTGAAAG | 58 | [24] |
| BIF-R | CCACATCCAGC(A/G)TCCAC | |||
| Clostridium leptum group | sg-Clept-F | GCACAAGCAGTGGAGT | 53 | [25] |
| sg-Clept-R3 | CTTCCTCCGTTTTGTCAA | |||
| Bacteroides-Prevotella-Porphyromonas | BPP-F | GGTGTCGGCTTAAGTGCCAT | 56 | [24] |
| BPP-R | CGGA(C/T)GTAAGGGCCGTGC | |||
| Clostridium coccoides group | g-ccoc-F | AAATGACGGTACCTGACTAA | 58 | [26] |
| g-ccoc-R | CTTTGAGTTTCATTCTTGCGAA | |||
| Lactobacillus | Lac1F | AGCAGTAGGGAATCTTCCA | 58 | [27] |
| Lab667 | CACCGCTACACATGGAG |
| Prognostic factors | n | Median survival | Hazard Ratio | 95% Confidence Interval | P |
| Age, yrs | |||||
| < 70 | 24 | 17.4 | |||
| ≥ 70 | 9 | 5.1 | 1.81 | 1.165–2.813 | 0.008 |
| Gender | |||||
| Male | 12 | 13.0 | |||
| Female | 21 | 20.0 | 0.346 | 0.142–0.844 | 0.020 |
| Smoking history | |||||
| No smoking | 21 | 20.0 | |||
| Smoking | 12 | 5.4 | 6.752 | 2.418–18.855 | <0.001 |
| Thoracoscopic findings | |||||
| Pleural nodules | |||||
| Yes | 24 | 15.6 | |||
| No | 6 | 17.4 | 1.009 | 0.399–2.554 | 0.985 |
| Pleural hyperemia | |||||
| Yes | 21 | 18.9 | |||
| No | 9 | 15.3 | 0.573 | 0.223–1.468 | 0.246 |
| Pleural adhesion | |||||
| Yes | 6 | 5.4 | |||
| No | 24 | 19.1 | 0.277 | 0.097–0.788 | 0.016 |
| Pleural edema | |||||
| Yes | 9 | 18.9 | |||
| No | 21 | 17.1 | 0.908 | 0.404–2.038 | 0.814 |
| Pleural plaques | |||||
| Yes | 12 | 13.0 | |||
| No | 18 | 19.1 | 0.387 | 0.170–0.879 | 0.023 |
| Histological type | |||||
| Epithelioid | 12 | 12.8 | |||
| Non-epithelioid | 21 | 20.4 | 0.095 | 0.031–0.293 | <0.001 |
| Staging | |||||
| I | 0 | ||||
| II | 9 | 28.4 | |||
| III | 15 | 17.1 | |||
| IV | 9 | 3.0 | 21.042 | 6.156–71.923 | <0.001 |
| Therapeutic regimen | |||||
| Chemotherapy | 21 | 20.0 | |||
| Chemotherapy and radiotherapy | 3 | 15.3 | |||
| No therapy | 9 | 3.0 | 0.087 | 0.021–0.359 | 0.001 |
| Mean 24-week change from baseline | |||
| 9.5 mg/24 h patch | Capsule (3–12 mg/day) | Placebo | |
| Primary outcomes | |||
| ADAS-cog | −0.6** | −0.6** | 1.0 |
| ADCS-CGIC | 3.9** | 3.9** | 4.2 |
| Secondary outcomes | |||
| MMSE | 1.1** | 0.8** | 0.0 |
| ADCS-ADL | −0.1** | −0.5* | −2.3 |
| Trail making test part A | −12.3*** | −9.8*** | 7.7 |
| Adverse events, % | |||
| Nausea | 7.2 | 23.1*** | 5.0 |
| Vomiting | 6.2 | 17.0*** | 3.3 |
| n | % | Mean | LCI | UCI | |
| Maternal outcomes from most recent pregnancy | |||||
| Unplanned pregnancy (n = 2039) | 657 | 32.2 | |||
| Early booking (n = 2038) | 886 | 43.5 | |||
| Late booking (n = 2038) | 1037 | 50.9 | |||
| Unbooked (n = 2042) | 114 | 5.6 | |||
| Low birth weight (n = 2007) | 173 | 8.6 | |||
| Mean birth weight in grammes (n = 2007) | 3036 | 3016.66 | 3055.85 | ||
| Premature (n = 2009) | 31 | 1.54 | |||
| Caesarian Section (n = 2002) | 65 | 3.25 | |||
| Extended hospital Stay (4+ days during delivery) | 149 | 7.6 | |||
| Maternal outcomes from previous pregnancies | |||||
| Age at first pregnancy (mean) n = 2042 | 20.22 | 20.09 | 20.35 | ||
| Gravidity (mean no. of lifetime pregnancies) (n = 2042) | 2.22 | 2.17 | 2.27 | ||
| History of miscarriage (n = 2039) | 234 | 11.5 | |||
| History of a stilbirth (n = 2038) | 30 | 1.37 | |||
| History of a premature baby (n = 2037) | 35 | 1.72 | |||
| History of a neonatal death (n = 2007) | 188 | 9.37 |
| Variable | L2–4 BMD | Femoral neck BMD | ||
| r | p | r | p | |
| Trunk rotation ROM | 0.38 | 0.02* | 0.36 | (0.03)* |
| Hip adduction moment (N.m/Kg) | 0.47 | 0.005** | 0.43 | (0.011)* |
| Hip extension moment (N.m/Kg) | 0.44 | 0.009 ** | 0.46 | (0.006)** |
| H1S (W/Kg) | 0.55 | 0.001*** | 0.64 | (0.0003)*** |
| H2S (W/Kg) | 0.41 | 0.017 * | 0.52 | (0.004)** |
| H3S (W/Kg) | 0.50 | 0.003 ** | 0.40 | (0.018)* |
| K4S (W/Kg) | 0.51 | 0.003 ** | 0.47 | (0.004)** |
| A2S (W/Kg) | 0.66 | 0.0001 *** | 0.65 | (0.003)** |
| Main effect | Escape latency | Path length |
| Day 1 | F < 1, p = n.s. | F < 1, p = n.s. |
| Day 2 | F(5, 66) = 26.29, p < 0.001 | F(5, 66) = 33.94, p < 0.001 |
| Day 3 | F(5, 66) = 27.73, p < 0.001 | F(5, 66) = 29.83, p < 0.001 |
| Day 4 | F(5, 66) = 29.86, p < 0.001 | F(5, 66) = 35.68, p < 0.001 |
| Day 5 | F(5, 66) = 3.78, p = 0.005 | F(5, 66) = 3.73, p = 0.005 |
| Characteristic | Slept under ITN last night | Significance (p-value) using chi square test | ||
| Yes n(%) | No n(%) | |||
| Sex | Male | 928(39.8) | 1 404(60.2) | 0.001 |
| Female | 1 095(44.2) | 1 383(55.8) | ||
| Residence | Rural | 552(36.1) | 978(63.9) | 0.005 |
| Urban | 1 471(44.8) | 1 809(55.2) | ||
| Region | Luapula | 91(28.0) | 234(72.0) | 0.000 |
| Central | 236(44.9) | 289(55.1) | ||
| Copperbelt | 336(37.1) | 570(62.9) | ||
| Eastern | 429(54.1) | 364(45.9) | ||
| Lusaka | 151(30.9) | 338(69.1) | ||
| North Western | 136(51.7) | 127(48.3) | ||
| Northern | 252(48.3) | 270(51.7) | ||
| Southern | 207(34.7) | 390(65.3) | ||
| Western | 185(47.4) | 205(52.6) | ||
| Age group (yrs) | 5-9 | 932(46.3) | 1 080(53.7) | 0.000 |
| 10-14 | 647(38.8) | 1 022(61.2) | ||
| 15-19 | 444(39.3) | 685(60.7) | ||
| Number of 5–19 headed by Male or Female | Male | 1 618(42.2) | 2 213(57.8) | 0.934 |
| Female | 405(41.4) | 574(58.6) | ||
| Wealth quintile | Lowest | 391(40.4) | 576(59.6) | 0.465 |
| Second | 293(48.8) | 307(51.2) | ||
| Middle | 407(43.4) | 531(56.6) | ||
| Fourth | 450(40.4) | 663(59.6) | ||
| Highest | 482(40.4) | 710(59.6) | ||
| Ratio of nets to sleeping spaces | Inadequate nets | 653(24.9) | 1 969(75.1) | 0.000 |
| Adequate nets | 1 370(62.6) | 818(37.4) | ||
| Education level of head of household | Never attended school | 150(41.8) | 209(58.2) | 0.013 |
| Primary | 819(41.2) | 1 168(58.8) | ||
| Secondary | 764(40.3) | 1 130(59.7) | ||
| Tertiary | 290(50.9) | 280(49.1) | ||
| Age group household head (years) | <25 | 95(57.6) | 70(42.4) | 0.001 |
| 25-34 | 508(48.0) | 551(52.0) | ||
| 35-44 | 734(41.8) | 1 020(58.2) | ||
| 45-59 | 514(35.8) | 922(64.2) | ||
| 60+ | 172(43.4) | 224(56.6) | ||
| Number of ITNs | 1 | 268(16.4) | 1 366(83.6) | 0.000 |
| 2 | 773(50.0) | 774(50.0) | ||
| 3 or more | 982(60.3) | 647(39.7) |
| Item | Wanted to know the sex of the baby | Did not want to know the sex of the baby | p value |
| Mean age, years | 29.4 | 29.4 | 0.80 |
| n (%) | n (%) | ||
| Age groups | 0.99 | ||
| 17–24 years | 214 (16.1) | 160 (15.9) | |
| 25–34 years | 923 (69.4) | 697 (69.4) | |
| 35–47 years | 193 (14.5) | 148 (14.6) | |
| Origin | 0.45 | ||
| Nordic | 1245 (92.1) | 950 (92.3) | |
| Non-Nordic | 107 (7.9) | 79 (7.7) | |
| Education | 0.32 | ||
| Low | 584 (43.3) | 465 (45.5) | |
| High | 764 (56.7) | 558 (54.5) | |
| Previous children | 0.43 | ||
| No previous childen | 624 (46.0) | 456 (44.3) | |
| Has previous children | 732 (54.0) | 573 (55.7) | |
| Income | 0.53 | ||
| Low | 620 (46.9) | 485 (48.2) | |
| High | 703 (53.1) | 521 (51.8) | |
| Pregnancy planning | 0.34 | ||
| Very/fairly planned | 1004 (74.7) | 781 (76.4) | |
| Neither planned nor unplanned | 180 (13.4) | 139 (13.6) | |
| Very/fairly unplanned | 160 (11.9) | 102 (10.0) | |
| Gone through another method of fetal diagnostics | 594 (43.8) | 388 (37.7) | <0.001 |
| Importance of religion | 0.44 | ||
| Great importance | 146 (10.9) | 127 (12.4) | |
| Neither important nor unimportant | 296 (22.0) | 231 (22.5) | |
| Little importance | 903 (67.1) | 667 (65.1) |
| Cluster | Cluster | Voxel | Voxel | |||||
| P | Size | P | T | x | y | z | Side | Location |
| 0.008 | 22 | 0.004 | 5.15 | −56 | −18 | 40 | L | IPL |
| 0.011 | 16 | 0.008 | 5.16 | −38 | −42 | 60 | L | aIPS |
| Demographic group | % of survey respondents who travelled to the mainland in previous 8 weeks in 2013 (N) | % of survey respondents who travelled to the mainland in previous 8 weeks in 2014 (N) |
| Overall | 8.1% (20,536) | 8.7% (20,880) |
| Children aged 2-14 | 6.2% (7,555) | 6.1% (8,039) |
| Aged 15 or over | 9.6% (11,498) | 10.9% (11,436) |
| Living in urban sites | 10.9% (12,080) | 11.9% (12,309) |
| Living in rural sites | 4.0% (8,456) | 4.1% (8,571) |
| Highest SES quintile | 9.8% (4,686) | 14.3% (5,496) |
| Lowest SES quintile | 3.9% (2,499) | 4.6% (2,974) |
| S.N. | Name of genotype | Pedigree/source |
| I. Elite coffee genotypes used for genetic diversity in the cultivated genepool | ||
| 1 | Taferikela | C. arabica; Pureline from Ethiopian collections |
| 2 | HdeT | C. arabica; Amphidiploid coffee, a natural hybrid from C. arabica and C. canephora |
| 3 | S2790 | C. arabica; HdeT × Tafarikela, selection |
| 4 | S2792 | C. arabica; Tafarikela × HdeT, selection |
| 5 | S10 | C. arabica; Double Cross Hybrid; Caturra with Cioccie and S.795 (both arabica) |
| 6 | S11 | C. arabica; Amphidiploid, C. liberica × C. eugenioides |
| 7 | BM | C. arabica; Blue Mountain Pure line |
| 8 | Agaro-Sln4 | C. arabica; Pureline from Ethiopian collections |
| 9 | Kagganahalla | C. canephora; Selection |
| 10 | BR9 | C. canephora; Selection |
| 11 | BR11 | C. canephora; Selection |
| 12 | CXR | C. canephora; Hybrid of C. congenis × C. canephora |
| 13 | L1Valley | C. canephora; Selection |
| 14 | S3329 | C. canephora; Selection |
| 15 | S3334 | C. canephora; Selection |
| 16 | Sln27 | C. canephora; Pure line |
| II. Parents and mapping population used for testing utility in mapping analysis | ||
| Parents: CXR (12) and Kagganahalla (9); Mapping population: 175 segregating progenies | ||
| III. Species of Coffea and Psilanthus (related taxa of cultivated coffee) used for transferability studies | ||
| a | C. congensis | Erythrocoffea (W. & C. Africa) |
| b | C. excelsa | Pachycoffea (Srilanka) |
| c | C. liberica | Pachycoffea (W. & C. Africa) |
| d | C. abeokuteae | Pachycoffea (Srilanka) |
| e | C. dewevrei | Pachycoffea (USDA) |
| f | C. arnoldiana | Pachycoffea (SanMarino) |
| g | C. aruwemiensis | Pachycoffea (SanMarino) |
| h | C. eugenioides | Mozambicoffea (C. Africa) |
| i | C. racemosa | Mozambicoffea (E. Africa) |
| j | C. salvatrix | Mozambicoffea (E. Africa) |
| k | C. kapakata | Mozambicoffea (C. Africa) |
| l | C. stenophylla | Melanocoffea (W. Africa) |
| m | P. wightiana | Paracoffea (India) |
| n | P. bengalenis | Paracoffea (India) |
| Description | Answers | p-value model | ORb | 95 % CIc |
| Work sequence depending on healthy before sick pigs (Ref.a Yes) | No | <0.01 | 16.68 | 3.4-81.8 |
| Working on other farms (Ref. No) | Yes | <0.01 | 0.05 | 0.006-0.4 |
| Distance to the next pig farm (Ref. ≥ 500 metres) | <500 metres | 0.01 | 9.88 | 1.7-57.1 |
| Visitor boots available (Ref. No boots available) | Yes, clean | 0.97 | 1.03 | 0.2-4.7 |
| Yes, dirty | 0.01 | 0.06 | 0.006-0.5 | |
| Analysis of production parameters (Ref. by others (external)) | By farmer (program, computer, written, none) | 0.01 | 0.12 | 0.02-0.6 |
| Application of homoeopathic agents (Ref. Yes) | No | 0.02 | 10.49 | 1.4-78.8 |
| Mixing pigs of different suppliers within the same pen (Ref. No mixing) | Yes | 0.05 | 4.16 | 1.0-17.4 |
| Categories | Sepsis/SS group(n = 50) | Non-sepsis group(n = 20) | p value |
| WBC (×109/L) | 11.9 (7.9-15.3) | 9.7 (7.3-13.4) | 0.170 |
| hs-CRP (mg/L) | 143.4 (82.6-212.4) | 50.9 (32.3-74.1) | 0.000 |
| PCT (ng/ml) | 0.84 (0.36-5.8) | 0.08 (0.05-0.54) | 0.000 |
| Alive | Dead | p-Value | ||
| n = 41,516 | n = 1346 | |||
| Mobility (%) | No problems | 3210 (7.7) | 52 (3.9) | <0.001 |
| Moderate problems | 38,190 (92.0) | 1279 (95.0) | ||
| Severe problems | 116 (0.3) | 15 (1.1) | ||
| Self-care (%) | No problems | 32,066 (77.2) | 910 (67.6) | <0.001 |
| Moderate problems | 9102 (21.9) | 403 (29.9) | ||
| Severe problems | 348 (0.8) | 33 (2.5) | ||
| Usual activities (%) | No problems | 16,086 (38.7) | 460 (34.2) | <0.001 |
| Moderate problems | 21,125 (50.9) | 684 (50.8) | ||
| Severe problems | 4305 (10.4) | 202 (15.0) | ||
| Pain/discomfort (%) | No problems | 631 (1.5) | 16 (1.2) | <0.001 |
| Moderate problems | 23,822 (57.4) | 706 (52.5) | ||
| Severe problems | 17,063 (41.1) | 624 (46.4) | ||
| Anxiety/depression (%) | No problems | 23,963 (57.7) | 711 (52.8) | <0.001 |
| Moderate problems | 16,079 (38.7) | 568 (42.2) | ||
| Severe problems | 1474 (3.6) | 67 (5.0) | ||
| EQ VAS score (SD) | 54.77 (22.17) | 50.61 (21.76) | <0.001 | |
| Pain VAS score (SD) | 62.39 (15.91) | 62.67 (17.34) | 0.53 | |
| Females (%) | 23,358 (56.3) | 633 (47.0) | <0.001 | |
| Age (SD) | 67.70 (10.09) | 75.76 (8.83) | <0.001 | |
| Educational level (%) | low | 14,018 (33.8) | 658 (48.9) | <0.001 |
| middle | 17,038 (41.0) | 466 (34.6) | ||
| high | 10,460 (25.2) | 222 (16.5) | ||
| Hospital (%) | University | 3018 (7.3) | 117 (8.7) | <0.001 |
| County | 13,026 (31.4) | 464 (34.5) | ||
| Rural | 17,490 (42.1) | 603 (44.8) | ||
| Private | 7982 (19.2) | 162 (12.0) | ||
| Fixation (%) | Cemented | 28,237 (68.4) | 1168 (87.0) | <0.001 |
| Uncemented | 6363 (15.4) | 58 (4.3) | ||
| Hybrid | 536 (1.3) | 12 (0.9) | ||
| Reverse hybrid | 5503 (13.3) | 102 (7.6) | ||
| Resurfacing | 639 (1.5) | 2 (0.1) |
| Age group (years) | Sex | Number of AWE (%) | |
| M (%) | F (%) | ||
| 11–13 | 4 (26.7) | 0 | 4 (22.2) |
| 14–16 | 2 (13.3) | 0 | 2 (11.1) |
| 17–19 | 9 (60) | 3 (100) | 12 (66.7) |
| Total | 15 (100) | 3 (100) | 18 (100) |
| Zebrafishglucose-related immune protein | p-value | GO annotation |
| gpia | 0.004833 | humoral immune response |
| hif1ab | 0.0065 | inflammatory response |
| ins | 0.006833 | glucose transport/T cell activation |
| Genus | Species | Name | Feeding Strategy | Genome Size (Mb) | Proteome size | CWDE’s Identified |
| Bursaphelenchus | B. xylophilus | Pine wood nematode | Stem/Bulb Nematodes | 73.09 | 18,074 | 119 |
| Globodera | G. pallida | Potato cyst nematode | Sedentary Endo-parasites | 123.63 | 16,417 | 100 |
| Meloidogyne | M. floridensis | Peach root-knot nematode | Sedentary Endo-parasites | 96.67 | 21,038 | 102 |
| M. hapla | Northern root-knot nematode | Sedentary Endo-parasites | 53.01 | 14,420 | 78 | |
| M. incognita | Southern root-knot nematode | Sedentary Endo-parasites | 82.1 | 20,365 | 131 |
| Overall (%) | |
| Returned home with the presence of adults | 42.3 |
| Returned home without the presence of adults | 12.5 |
| Returned home with the presence of siblings | 10.9 |
| Participated in extracurricular activity | 23.5 |
| Socializing with friends without the presence of adults | 9.9 |
| Wandering the streets alone | 0.9 |
| Type of Tool | Respondents | Number of Interviews (Key Informat Interviews) | Number of participants per interview | Total number of participants |
| Key Informat Interviews | Medical Officers, Clinical Care Experts and Maternal and Child Health Cordinator | 12 (3 in each of the 4 districts) | 1 | 12 |
| Health Facility in-charge | 4 (1 in each of the 4 districts) | 1 | 4 | |
| Focus Group Discussions | Mothers of children below one year | 4 (1 in each of the health facilities from each district) | 8–10 | 38 |
| Community Health Volunteers (CHWs, NHC, TBAs)a | 4 (1 in each of the health facilities from each district) | 6–8 | 30 | |
| Total | 24 | 84 |
| Type of organization | Organization/department | Position | No. of interviewees |
| National Ministry of Health | Monitoring and Evaluation | Head, M&E | 1 |
| Health information system | Head, HIS | 1 | |
| Health Financing | Head, Health financing division | 2 | |
| National Treasury | IFMIS | 2 | |
| e-PROMIS | Director | 1 | |
| Social Insurance Agency | National Hospital Insurance Fund | 1 | |
| University of Nairobi | School of Economics | Senior Lecturer | 1 |
| School of Public Health | Head, Health system and policy department | 1 | |
| Tertiary Hospital | Kenyatta hospital | 1 | |
| Multilateral organizations | WHO | Health System Advisor | 1 |
| World Bank | Regional Health Specialist | 1 | |
| DFID | Secretary, Health & Education departments | 1 | |
| USAID or PEPFAR funded | Abt Associates | 1 | |
| implementers | i-TECH | 1 | |
| Futures group | 3 | ||
| Nairobi County | Mbagathi District Hospital | 4 | |
| Kajiado County | County administration | 2 | |
| Hospital | Health administration officer | 1 | |
| Muranga County | County administration | 2 | |
| Muranga County Hospital | Medical Superintendent | 1 | |
| Nakuru County | County administration | 1 | |
| Nakuru Regional Hospital | 2 | ||
| TOTAL | 32 |
| Coverage | 35× | 70× | 140× | ||||
| Error rate | 1% | 3% | 1% | 3% | 1% | 3% | |
| α for Lighter | 0.2 | 0.2 | 0.1 | 0.1 | 0.05 | 0.05 | |
| Quake | 89.68 | 48.77 | 89.64 | 48.82 | 89.59 | 48.78 | |
| SOAPec | 57.71 | 38.00 | 57.57 | 37.71 | 57.09 | 36.76 | |
| Recall | Musket | 93.75 | 92.62 | 93.73 | 92.64 | 93.73 | 92.63 |
| Bless | 99.81 | 99.33 | 99.82 | 99.58 | 99.82 | 99.58 | |
| Lighter | 99.87 | 98.53 | 99.84 | 98.72 | 99.86 | 98.78 | |
| Quake | 99.99 | 99.99 | 99.99 | 99.99 | 99.99 | 99.99 | |
| SOAPec | 99.99 | 100.00 | 99.99 | 99.99 | 99.99 | 99.99 | |
| Precision | Musket | 99.99 | 99.93 | 99.99 | 99.93 | 99.99 | 99.93 |
| Bless | 99.73 | 98.86 | 99.73 | 99.35 | 99.72 | 99.36 | |
| Lighter | 99.98 | 99.96 | 99.98 | 99.96 | 99.98 | 99.96 | |
| Quake | 94.55 | 65.56 | 94.54 | 65.61 | 94.51 | 65.57 | |
| SOAPec | 73.18 | 55.07 | 73.07 | 54.77 | 72.68 | 53.75 | |
| F score | Musket | 96.77 | 96.14 | 96.76 | 96.15 | 96.76 | 96.15 |
| Bless | 99.77 | 99.09 | 99.77 | 99.47 | 99.77 | 99.47 | |
| Lighter | 99.93 | 99.24 | 99.91 | 99.33 | 99.92 | 99.36 | |
| Quake | 89.67 | 48.76 | 89.64 | 48.82 | 89.59 | 48.78 | |
| SOAPec | 57.70 | 38.00 | 57.57 | 37.71 | 57.09 | 36.75 | |
| Gain | Musket | 93.74 | 92.56 | 93.72 | 92.58 | 93.72 | 92.57 |
| Bless | 99.54 | 98.19 | 99.54 | 98.93 | 99.54 | 98.94 | |
| Lighter | 99.85 | 98.49 | 99.81 | 98.68 | 99.84 | 98.73 | |
| Quake | 17 | 17 | 17 | 17 | 17 | 17 | |
| SOAPec | 17 | 17 | 17 | 17 | 17 | 17 | |
| k | Musket | 23 | 19 | 23 | 19 | 23 | 19 |
| Bless | 31 | 23 | 31 | 23 | 31 | 23 | |
| Lighter | 23 | 19 | 23 | 19 | 23 | 19 |
| CT score | CT status | Morphology features on CT | EMVI status |
| 0 | Definite No | Absence of tumor extension beyond the colon wall/ Tumor extension through the colon wall but no adjacent vessels (Mesenteric contralateral side) | Negative |
| 1 | Suspicious No | Stranding in proximity of vessels but no tumor density in vessels (Mesenteric side) | Negative |
| 2 | Suspicious Yes | Similar tumor density in adjacent vessels; vessel expansion by tumor (Mesenteric side) | Positive |
| 3 | Definite Yes | Similar tumor density in adjacent vessels; Irregular vessel contour by tumor (Mesenteric side) | Positive |
| Characteristics | Total | HOXA1 expression | P value | Cyclin D1 expression | P value | ||
| Negative (120) | Positive (144) | Negative (127) | Positive (137) | ||||
| Age(years) | 0.457 | 0.845 | |||||
| <65 | 121 | 58 | 63 | 59 | 62 | ||
| ≥65 | 143 | 62 | 81 | 68 | 75 | ||
| Gender | 0.095 | 0.712 | |||||
| Male | 157 | 78 | 79 | 77 | 80 | ||
| Female | 107 | 42 | 65 | 50 | 57 | ||
| T stage | 0.040* | 0.816 | |||||
| T1 | 76 | 44 | 32 | 38 | 38 | ||
| T2 | 42 | 20 | 22 | 22 | 20 | ||
| T3 | 118 | 47 | 71 | 53 | 65 | ||
| T4 | 28 | 9 | 19 | 14 | 14 | ||
| N stage | 0.004* | 0.179 | |||||
| N0 | 116 | 67 | 49 | 56 | 60 | ||
| N1 | 91 | 35 | 56 | 48 | 43 | ||
| N2 | 40 | 13 | 27 | 19 | 21 | ||
| N3 | 17 | 5 | 12 | 4 | 13 | ||
| M stage | 0.355 | 0.751 | |||||
| M0 | 254 | 117 | 137 | 123 | 131 | ||
| M1 | 10 | 3 | 7 | 4 | 6 | ||
| UICC stage | <0.001* | 0.400 | |||||
| I | 95 | 54 | 41 | 49 | 46 | ||
| II | 48 | 28 | 20 | 24 | 24 | ||
| III | 89 | 28 | 61 | 43 | 46 | ||
| IV | 32 | 10 | 22 | 11 | 21 | ||
| Differentiation | <0.001* | 0.044* | |||||
| High | 47 | 33 | 14 | 30 | 17 | ||
| Moderate | 42 | 20 | 22 | 21 | 21 | ||
| Low | 175 | 67 | 108 | 76 | 99 |
| United States | United Kingdom | Canada | International | ||
| Source | U.S. government | The Medical Letter | U.K. government | Canadian government | World Health Organization |
| Primaquine as Primary Prophylaxis | As an alternative to suppressive options or:With travel where malaria is primarily P. vivaxShort-term travelShort-notice travel | Only as an alternative to suppressive options | Not recommended | Only as an alternative to suppressive options | None specified except for special risk groups (infants, pregnant women, vulnerable children in seasonal high transmission) |
| Primaquine following a diagnosis of P. vivax | Recommended | Recommended | Recommended | Recommended | Strongly recommended |
| Primaquine following suppressive prophylaxis | Recommended | No recommendation | Not recommended | Recommended for high risk groups | No recommendation |
| References | [21] | [22, 23] | [24, 25] | [26] | [27] |
| Number | Act | PLS | EN-PLS | ||||
| Pred. | REP | PRESS | Pred. | REP | PRESS | ||
| 1 | 108.33 | 100.04 | −8.29 | 68.72 | 95.66 | −12.67 | 160.53 |
| 2 | 105.95 | 109.26 | 3.31 | 10.96 | 101.16 | −4.79 | 22.94 |
| 3 | 107.54 | 121.08 | 13.54 | 183.33 | 150.84 | 43.30 | 1874.89 |
| 4 | 100.00 | 95.54 | −4.46 | 19.89 | 110.57 | 10.57 | 111.72 |
| 5 | 100.79 | 94.68 | −6.11 | 37.33 | 97.03 | −3.76 | 14.14 |
| 6 | 89.68 | 103.86 | 14.18 | 201.07 | 101.68 | 12.00 | 144.00 |
| 7 | 91.27 | 105.41 | 14.14 | 199.94 | 87.64 | −3.63 | 13.18 |
| 8 | 85.32 | 121.30 | 35.98 | 1294.56 | 103.43 | 18.11 | 327.97 |
| 9 | 101.87 | 85.91 | −15.96 | 254.72 | 104.86 | 2.99 | 8.94 |
| 10 | 102.25 | 111.26 | 9.01 | 81.18 | 104.34 | 2.09 | 4.37 |
| 11 | 108.61 | 96.89 | −11.72 | 137.36 | 112.05 | 3.44 | 11.83 |
| 12 | 116.10 | 102.6 | −13.50 | 182.25 | 107.22 | −8.88 | 78.85 |
| 13 | 91.76 | 96.31 | 4.55 | 20.70 | 90.37 | −1.39 | 1.93 |
| 14 | 92.13 | 99.56 | 7.43 | 55.20 | 100.61 | 8.48 | 71.91 |
| 15 | 82.83 | 82.06 | −0.77 | 0.59 | 86.56 | 3.73 | 13.91 |
| 16 | 82.53 | 85.69 | 3.16 | 9.99 | 82.04 | −0.49 | 0.24 |
| 17 | 115.58 | 120.84 | 5.26 | 27.67 | 122.50 | 6.92 | 47.89 |
| 18 | 120.29 | 115.73 | −4.56 | 20.79 | 125.46 | 5.17 | 26.73 |
| 19 | 135.14 | 126.63 | −8.51 | 72.42 | 136.89 | 1.75 | 3.06 |
| 20 | 126.45 | 110.55 | −15.90 | 252.81 | 121.62 | −4.83 | 23.33 |
| 21 | 122.46 | 104.37 | −18.09 | 327.25 | 116.8 | −5.66 | 32.04 |
| 22 | 121.38 | 129.29 | 7.91 | 62.57 | 113.11 | −8.27 | 68.39 |
| 23 | 119.20 | 122.39 | 3.19 | 10.18 | 133.17 | 13.97 | 195.16 |
| 24 | 102.41 | 120.91 | 18.50 | 342.25 | 99.67 | −2.74 | 7.51 |
| Three primary batches | |||||||||
| Time interval | Day 0 | The 15th day | The 30th day | ||||||
| Evaluation parameters | B-1 | B-2 | B-3 | B-1 | B-2 | B-3 | B-1 | B-2 | B-3 |
| ∗Hardness (Kg/cm2) ± SD | 1.3 ± 0.58 | 1.2 ± 0.29 | 1.8 ± 0.29 | 1.4 ± 0.50 | 1.5 ± 0.00 | 1.7 ± 0.29 | 1.3 ± 0.5 | 1.5 ± 0.29 | 1.5 ± 0.29 |
| Friability (%) | 0.1 | 0.4 | 0.6 | 0.3 | 0.2 | 0.2 | 0.4 | 0.2 | 0.3 |
| ∗Drug content ± SD | 100.8 ± 3.36 | 95.6 ± 2.34 | 93.8 ± 1.24 | 99.5 ± 2.14 | 94.5 ± 2.67 | 94.8 ± 1.23 | 98.3 ± 1.98 | 95.4 ± 1.65 | 95.7 ± 3.63 |
| ∗∗Disintegration time (sec) ± SD | 37 ± 4.79 | 40 ± 3.64 | 35 ± 2.27 | 35 ± 3.60 | 42 ± 4.44 | 38 ± 2.18 | 40 ± 3.64 | 38 ± 1.05 | 41 ± 1.31 |
| Number (%) of facilities assessed in evaluation | ||
| 2010 | 2012 | |
| Total | 52 | 50 |
| Region: | ||
| Tanga | 6 (12) | 6 (12) |
| Arusha | 5 (10) | 5 (10) |
| Lindi | 3 (6) | 3 (6) |
| Morogoro | 5 (10) | 5 (10) |
| Manyara | 5 (10) | 4 (8) |
| Iringa | 4 (8) | 4 (8) |
| Tabora | 6 (12) | 6 (12) |
| Kilimanjaro | 5 (10) | 5 (10) |
| Kigoma | 3 (6) | 3 (6) |
| Pwani | 3 (6) | 3 (6) |
| Mtwara | 3 (6) | 3 (6) |
| Ruvuma | 4 (8) | 4 (8) |
| Facility type: | ||
| Regional hospital | 12 (23) | 12 (24) |
| Health centre/Dispensary | 40 (77) | 38 (76) |
| Characteristics | Number | Percentage (95% confidence interval [CI]) |
| Total n | 138 | |
| Median age (y) | 30 (16–41) | |
| Median gravidity | 2 (1–9) | |
| Median parity | 1 (0–5) | |
| Race/ethnicity | ||
| Non-Hispanic White | 114 | 82.6 (75.4–88.1) |
| Non-Hispanic African-American | 23 | 16.7 (11.3–13.8) |
| Other | 1 | 0.7 (0–4.4) |
| Type of insurance | ||
| Private | 97 | 70.3 (62.2–77.3) |
| Medical assistance | 41 | 29.7 (22.7–37.8) |
| Obstetrical provider Type | ||
| Private physician | 100 | 72.5 (64.5–79.3) |
| Maternal fetal medicine | 3 | 2.2 (0.5–6.5) |
| OB/GYN residents | 25 | 18.1 (12.5–25.4) |
| Midwife | 8 | 5.8 (2.8–11.2) |
| Family practitioner | 2 | 1.4 (0.07–5.5) |
| Type of delivery | ||
| Vaginal | 116 | 84.1 (77.0–89.3) |
| Cesarean after labor | 22 | 15.9 (10.7–23.0) |
| Patient documentation of nature of the penicillin allergy | 78 | 56.5 (48.2–64.5) |
| Patients with documentation that they received antibiotic prophylaxis | 135 | 97.8 (93.5–99.5) |
| Type of antibiotics received | ||
| Cephalosporin | 41 | 30.4 (23.2–38.6) |
| Clindamycin | 54 | 40 (32.1–48.4) |
| Erythromycin | 2 | 1.5 (0.07–5.6) |
| Vancomycin | 36 | 26.7 (19.9–34.7) |
| Penicillin | 2 | 1.5 (0.07–5.6) |
| Characteristic | N | % |
| VTE event type | ||
| Lower extremity DVT | 37 | 37.4 |
| Pulmonary embolism | 26 | 26.3 |
| Portal vein thrombosis | 2 | 2 |
| Upper extremity DVT | 26 | 26.3 |
| Other venous thrombotic episode | 8 | 8.1 |
| Median time to thrombocytopenia (days) | 89.5 | NA |
| Karnataka state | Uttar Pradesh state | |||||||
| Bagalkot | Hassan | Agra | Gorakhpur | |||||
| % API | OXYTOCIN (%) | METHYL-ERGOMETRINE (%) | OXYTOCIN (%) | METHYL-ERGOMETRINE (%) | OXYTOCIN (%) | METHYL- ERGOMETRINE (%) | OXYTOCIN (%) | METHYL- ERGOMETRINE (%) |
| 0%-25% | 0.0 | 0.0 | 8.9 | 0.0 | 2.0 | 2.0 | 0.0 | 2.0 |
| 26-50% | 0.0 | 9.5 | 2.2 | 0.0 | 6.0 | 2.0 | 0.0 | 0.0 |
| 51%-75% | 4.2 | 7.1 | 4.4 | 13.0 | 14.0 | 8.0 | 2.0 | 6.0 |
| 76%-89% | 27.1 | 83.3 | 22.2 | 82.6 | 16.0 | 42.0 | 10.0 | 36.0 |
| WITHIN MANU-FACTURER SPECIFICA-TION (90%-110%) | 66.7 | 0.0 | 60.0 | 4.3 | 50.0 | 46.0 | 78.0 | 56.0 |
| 111%-120% | 2.1 | 0.0 | 2.2 | 0.0 | 12.0 | 0.0 | 8.0 | 0.0 |
| Missing data | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 2.0 | 0.0 |
| TOTAL | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 |
| % Out of specification | 33.0 | 100.0 | 40.0 | 95.7 | 50.0 | 54.0 | 22.0 | 44.0 |
| Median API | 98.5 | 84.4 | 98.7 | 85.8 | 99.0 | 89.2 | 102.9 | 90.4 |
| N of ampoules of analysis | 48 | 42 | 45 | 46 | 50 | 50 | 50 | 50 |
| Variable | Frequency | Percentage |
| Recording condition of the baby after birth | ||
| Yes | 203 | 84.9 |
| No | 36 | 15.1 |
| Mode of delivery | ||
| SVD | 181 | 75.7 |
| C/S | 23 | 9.6 |
| Note recorded | 35 | 14.6 |
| Fetal outcome | ||
| Alive | 192 | 80.3 |
| Dead | 3 | 1.3 |
| Not recorded | 44 | 18.4 |
| Active management of third stage of labour | ||
| Yes | 133 | 55.6 |
| No | 106 | 44.4 |
| Sex of the new born | ||
| Recorded | 189 | 79.1 |
| Not recorded | 50 | 20.9 |
| Weight of the new born | ||
| Recorded | 192 | 80.3 |
| Not recorded | 47 | 19.7 |
| Time of delivery | ||
| Recorded | 202 | 84.5 |
| Not recorded | 37 | 15.5 |
| APGAR score | ||
| Good (7–10) | 195 | 81.6 |
| Not good (1–6) | 3 | 1.3 |
| Not recorded | 41 | 17.2 |
| Family worries or complains about alcohol use | Alcohol use causing problems with others | Alcohol interfered with responsibilities | Drinking ever interfered with work/school/job/home | Drinking problem causing family/friend argues/problems | |
| OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | |
| Sex | |||||
| Male | 2.70 (2.47–2.96) | 3.24 (2.35–4.47) | 2.56 (1.86–3.53) | 0.98 (0.82–1.17) | 1.08 (0.90–1.30) |
| Female | 1 | 1 | 1 | ||
| Age (group) | |||||
| ≤34 years | 2.05 (1.71–2.46) | 2.57 (1.36–4.85) | 5.63 (2.46–12.91) | 2.03 (1.36–3.03) | 1.23 (0.85–1.79) |
| 35–49 years | 2.75 (2.30–3.29) | 2.33 (1.22–4.45) | 4.15 (1.78–9.65) | 2.07 (1.39–3.09) | 1.75 (1.21–2.54) |
| 50–64 years | 2.19 (1.18–2.66) | 2.12 (1.07–4.20) | 1.77 (0.68–4.56) | 1.91 (1.25–2.91) | 1.84 (1.23–2.75) |
| ≥65 years | 1 | 1 | 1 | 1 | 1 |
| Education (years) | |||||
| 0–11 | 2.24 (1.96–2.58) | 1.82 (1.15–2.87) | 0.72 (0.44–1.17) | 1.06 (0.81–1.39) | 1.38 (1.05–1.81) |
| 12 | 1.71 (1.50–1.96) | 1.30 (0.83–2.03) | 0.73 (0.48–1.13) | 1.06 (0.82–1.39) | 1.29 (0.99–1.68) |
| 13–15 | 1.66 (1.45–1.91) | 1.36 (0.86–2.14) | 1.07 (0.72–1.60) | 1.05 (0.80–1.37) | 1.34 (1.02–1.76) |
| ≥16 | 1 | 1 | 1 | 1 | 1 |
| Income | |||||
| <$20,000 | 1.37 (1.22–1.53) | 1.12 (0.75–1.68) | 1.05 (0.70–1.55) | 0.86 (0.70–1.07) | 0.95 (0.77–1.18) |
| $20,000–29,999 | 1.17 (1.01–1.35) | 1.39 (0.86–2.24) | 0.77 (0.44–1.37) | 1.05 (0.80–1.39) | 0.85 (0.64–1.13) |
| $30,000–49,999 | 1.19 (1.04–1.35) | 1.16 (0.75–1.80) | 1.12 (0.73–1.71) | 1.06 (0.84–1.34) | 0.85 (0.67–1.08) |
| ≥$50,000 | 1 | ||||
| Ethnicity | |||||
| Non-Hispanic black | 0.81 (0.73–090) | 0.52 (0.35–0.78) | 0.49 (0.32–0.73) | 0.77 (0.63–0.95) | 0.75 (0.61–0.92) |
| Hispanic/others | 0.65 (0.58–0.72) | 0.80 (0.57–1.13) | 0.72 (0.50–1.03) | 1.06 (0.86–1.31) | 0.91 (0.73–1.12) |
| Non-Hispanic white | 1 | 1 | 1 | 1 | 1 |
| Physical health rating | |||||
| Good | 1.34 (1.16–1.54) | 1.02 (0.62–1.67) | 1.45 (0.92–2.29) | 1.24 (0.94–1.64) | 1.22 (0.92–1.61) |
| Fair/poor | 2.02 (1.75–2.33) | 1.60 (0.98–2.62) | 0.97 (0.53–1.76) | 1.05 (0.79–1.39) | 1.06 (0.80–1.40) |
| Very good/excellent | 1 | 1 | 1 | 1 | 1 |
| Mental health rating | |||||
| Good | 1.59 (1.39–1.82) | 1.26 (0.77–2.06) | 1.01 (0.61–1.67) | 1.01 (0.77–1.32) | 1.08 (0.82–1.41) |
| Fair/poor | 2.63 (2.24–3.08) | 2.56 (1.51–4.36) | 1.60 (0.87–2.94) | 0.97 (0.72–1.32) | 1.25 (0.92–1.70) |
| Very good/excellent | 1 | 1 | 1 | 1 | 1 |
| Smoke | |||||
| Yes | 1.51 (1.19–1.92) | 1.70 (0.66–4.37) | 1.39 (0.52–3.68) | 0.77 (0.50–1.17) | 0.77 (0.50–1.18) |
| No | 1 | 1 | 1 | 1 | 1 |
| Variables | n with information | % |
| Place of residence | ||
| Plak-Ô | 33 | 66.0 |
| Terra Nova | 64 | 34.0 |
| Gender | ||
| Male | 44 | 45.4 |
| Female | 53 | 54.6 |
| Age | ||
| <2 years | 32 | 33.0 |
| ≥2 years | 65 | 67.0 |
| Garbage collection | ||
| Adequate | - | - |
| Inadequate | 97 | 100.0 |
| Birthplacea | ||
| Maternity/hospital | 94 | 97.9 |
| Home | 2 | 2.1 |
| Vitamin A supplementationa | ||
| Yes | 67 | 77.0 |
| No | 20 | 23.0 |
| Iron deficiency anemia | ||
| No | 41 | 42.3 |
| Yes | 56 | 57.7 |
| Presence of parasitic infestationa | ||
| No | 24 | 32.9 |
| Yes | 49 | 67.1 |
| MCT4 | PDK1 | CAIX | MCT1/MCT4* | ||||||
| Variable | n | % | p | % | p | % | p | % | p |
| PSA (ng/ml) | 0.296 | 0.451 | 0.250 | 0.525 | |||||
| ≤ 5.0 | 245 | 47.9 | 16.2 | 85.9 | 27.1 | ||||
| >5.0 | 123 | 44.0 | 17.5 | 82.2 | 27.5 | ||||
| pT | 0.445 | 0.258 | 0.522 | 0.009 | |||||
| 2 | 359 | 40.2 | 18.7 | 86.4 | 20.8 | ||||
| 3 | 99 | 41.7 | 15.2 | 86.9 | 33.3 | ||||
| Perineural | |||||||||
| Invasion | 0.155 | 0.069 | 0.399 | 0.255 | |||||
| Absent | 119 | 45.4 | 13.4 | 85.8 | 26.9 | ||||
| Present | 327 | 39.4 | 19.8 | 87.2 | 23.3 | ||||
| Biochemical | |||||||||
| Recurrence | 0.104 | 0.176 | 0.003 | 0.052 | |||||
| Absent | 410 | 40.2 | 18.5 | 75.4 | 22.6 | ||||
| Present | 69 | 49.3 | 13.0 | 89.0 | 32.8 |
| Single mothers (n = 442) | Partnered mothers (n = 2218) | All mothers (n = 2660) | ||||||||||
| Moderate (n = 115) vs. non-smoking (n = 236) | Heavy (n = 91) vs. non-smoking (n = 236) | Moderate (n = 413) vs. non-smoking (n = 1607) | Heavy (n = 198) vs. non-smoking (n = 1607) | Moderate (n = 528) vs. non-smoking (n = 1843) | Heavy (n = 289) vs. non-smoking (n = 1843) | |||||||
| Coping styles | OR | CI 95% | OR | CI 95% | OR | CI 95% | OR | CI 95% | OR | CI 95% | OR | CI 95% |
| Substance consumption | 1.54 | 1.38-1.72 | 1.80 | 1.58-2.04 | 1.51 | 1.44-1.58 | 1.66 | 1.55-1.78 | 1.51 | 1.45-1.58 | 1.72 | 1.62-1.82 |
| Self-blame/rumination | 1.04 | 0.93-1.16 | 1.24 | 1.10-1.40 | 0.98 | 0.93-1.04 | 1.00 | 0.94-1.07 | 0.99 | 0.95-1.04 | 1.06 | 1.00-1.12 |
| Blaming others | 1.07 | 0.95-1.20 | 0.94 | 0.84-1.06 | 0.96 | 0.90-1.02 | 0.99 | 0.91-1.07 | 0.99 | 0.94-1.04 | 0.97 | 0.91-1.03 |
| Positive self-verbalisation | 1.07 | 0.96-1.19 | 1.11 | 0.98-1.25 | 1.02 | 0.97-1.07 | 0.97 | 0.91-1.04 | 1.03 | 0.99-1.08 | 1.03 | 0.98-1.09 |
| Active influence | 1.19 | 1.04-1.37 | 1.08 | 0.94-1.25 | 1.03 | 0.97-1.10 | 1.03 | 0.94-1.13 | 1.05 | 0.99-1.11 | 1.02 | 0.95-1.09 |
| Genetic model | Pooled OR (95% CI) | P-value | Study number | T2DM size | Control size | Pheterogeneity(I2%) |
| Allelic genetic model | 1.350 (1.270–1.420) | <0.00001* | 10 | 7607 | 8129 | 0.07 (42.9%) |
| Chinese subgroup | 1.350 (1.270–1.430) | <0.00001* | 6 | 5079 | 5880 | 0.01 (66.7%) |
| Korean subgroup | 1.300 (1.100–1.520) | 0.002* | 1 | 865 | 496 | NA |
| Indian subgroup | 1.510 (1.000–2.300) | 0.05 | 2 | 1429 | 1576 | 1.0 (0%) |
| Malaysian subgroup | 1.450 (1.070–1.960) | 0.02* | 1 | 234 | 177 | NA |
| Recessive genetic model | 0.650 (0.570–0.730) | <0.00001* | 10 | 7607 | 8129 | 0.79 (0%) |
| Chinese subgroup | 0.640 (0.560–0.730) | <0.00001* | 6 | 5079 | 5880 | 0.38 (5.6%) |
| Korean subgroup | 0.680 (0.490–0.950) | 0.02* | 1 | 865 | 496 | NA |
| Indian subgroup | 0.790 (0.100–6.160) | 0.82 | 2 | 1429 | 1576 | 1.0 (0%) |
| Malaysian subgroup | 0.660 (0.350–1.270) | 0.22 | 1 | 234 | 177 | NA |
| Dominant genetic model | 1.450 (1.286–1.634) | <0.00001* | 10 | 7607 | 8129 | <0.044* (48.1%) |
| Chinese subgroup | 1.424 (1.198–1.692) | <0.00001* | 6 | 5079 | 5880 | 0.005 (70.5%) |
| Korean subgroup | 1.410 (1.124–1.768) | 0.003* | 1 | 865 | 496 | NA |
| Indian subgroup | 1.509 (0.986–2.309) | 0.058 | 2 | 1429 | 1576 | 0.907 (0%) |
| Malaysian subgroup | 1.616 (1.091–2.395) | 0.017* | 1 | 234 | 177 | NA |
| Additive genetic model | 1.346 (1.275–1.422) | <0.00001* | 10 | 7607 | 8129 | <0.072 (42.9%) |
| Chinese subgroup | 1.344 (1.187–1.522) | <0.00001* | 6 | 5079 | 5880 | 0.01 (66.7%) |
| Korean subgroup | 1.296 (1.102–1.524) | 0.002* | 1 | 865 | 496 | NA |
| Indian subgroup | 1.513 (0.998–2.295) | 0.051 | 2 | 1429 | 1576 | 0.999 (0%) |
| Malaysian subgroup | 1.448 (1.068–1.962) | 0.017* | 1 | 234 | 177 | NA |
| Habituation | Extinction | |||
| CS+ | CS− | CS+ | CS− | |
| SC measurement first | 0.020 (0.019) | 0.006 (0.019) | 0.025 (0.030) | −0.064 (0.026) |
| SC measurement second | 0.021 (0.017) | 0.023 (0.019) | 0.014 (0.018) | −0.029 (0.006) |
| SC measurement third | −0.008 (0.015) | 0.027 (0.020) | 0.013 (0.012) | 0.007 (0.011) |
| SC measurement fourth | −0.002 (0.005) | −0.005 (0.005) | 0.004 (0.008) | −0.025 (0.024) |
| Gene | Forward Primer | Reverse Primer |
| Slc22a1 | TCTGGCTACAGGAGAACGACGGCCA | TGCTCCATTATCCTGACAGCTCGCGT |
| Slc22a2 | TCGAAACAGAGGAGGATTGTGGGAATA | GAGAGGTGTTTCCCATTGCACTTAGCCAC |
| Slc22a6 | TATGTGGGCACCTTGATTGGC | AGGGTGAGGTCCAGCCTTCCT |
| Slc22a8 | ATCTCATCAACATCTATTGGG | AGGGCCTTTGAGTATTTTCCA |
| Slco1a1 | TATGGAGGACAAGCCAGAGAG | AGAGGTGGTTAATCCAGCAAC |
| Slco1a2 | CACAGAAAAAAGGCCAAGGAA | TAAGGAAAGACAGAAGGTACT |
| Slco1a5 | CACAGAGAAAAAGCCAAAGAG | AGAGGCAGTTAAGCCGGCAAC |
| Score cutpoint | Sensitivity (%) | Specificity (%) | LR+ | AUC (95% CI) | |
| Total delay | 40 | 74.68 | 48.81 | 1.46 | 0.62 (0.57-0.69) |
| Patient delay | 55 | 66.67 | 77.80 | 3.00 | 0.72 (0.61-0.84) |
| Provider delay | 40 | 81.17 | 20.24 | 1.02 | 0.51 (0.46-0.55) |
| Mycotoxigenic Fungi | Corn Silage | Barley Silage | Hay |
| Fusarium culmorum | 100 | 0 | 0 |
| F. poae | 0 | 100 | 100 |
| F. verticillioides | 0 | 100 | 0 |
| F. sporotrichioides | 0 | 100 | 0 |
| Aspergillusflavus | 100 | 20 | 0 |
| Penicillium roqueforti | 100 | 100 | 100 |
| P. crustosum | 20 | 0 | 20 |
| P. paneum | 20 | 0 | 20 |
| P. citrinum | 50 | 25 | 0 |
| Author | N | Year | ICU | Language | DeliriumN (%) | Sensitivity | Specificity | APACHE II | QUADAS |
| Ely [19] | 38 | 2001 | MedicalCoronary | English | 33 (87)1 | 100 (95.2 to 100) | 100 (79.4 to 100) | 17.1 ± 8.7# | 13 |
| Ely [18] | 96 | 2001 | Medical Coronary | English | (25.2)2 | 100 (95.4 to 100) | 88.8 (83.8 to 92.7) | 23 (18 to 29)* | 13 |
| Lin [7] | 102 | 2004 | Medical | Chinese | 22 (22.4) | 95.5 (77.2 to 99.9) | 97.5 (91.3 to 99.7) | NR | 13 |
| van Eijk [17] | 126 | 2009 | General | English Dutch | 43 (34) | 64.3 (48.0 to 78.4) | 88.8 (79.0 to 94.1) | 20. 9 ± 7.5# | 14 |
| Luetz [4] | 156 | 2010 | Surgical | German | 63 (40) | 78.8 (72.0 to 84.5) | 97.1 (94.9 to 98.5) | 16 (13 to 19)* | 14 |
| Heo [11] | 22 | 2011 | Medical | Korean | 16 (72.7) | 89.5 (78.5 to 98.0) | 71.4 (47.8 to 88.7) | 25.5 (9 to 39)* | 13 |
| van Eijk [14] | 181 | 2011 | MedicalSurgical | English Dutch | 80 (28.3) | 46.7 (35.1 to 58.6) | 98.1 (93.4 to 99.8) | 18.6 ± 7.5# | 13 |
| Gusmao-Flores [9] | 119 | 2011 | MedicalSurgical | Portuguese | 46 (38.6) | 72.5 (56.1 to 85.4) | 96.2 (89.3 to 99.2) | 15 ± 6# | 14 |
| Mitasova [10] | 129 | 2012 | Stroke Unit | Czech | 55 (42.6)1 | 78.9 (73.7 to 83.5) | 98.3 (97.1 to 99.1) | NR | 14 |
| Total PSA | Prostate cancer | |
| No | Yes | |
| 2-2.9 | 4 (6.2%) | 5 (7.7%) |
| 3-3.9 | 6 (9.4%) | 8 (12.3%) |
| 4+ | 54 (84.4%) | 52 (80.0%) |
| ICD-9 procedure code | N = 50,225^ n (%) | Description |
| 41.31 | 5,185 (10.3%) | Biopsy of bone marrow |
| 38.93 | 4,066 (8.1%) | Venous catheterization, not elsewhere classified |
| 01.59 | 3,160 (6.3%) | Other excision or destruction of lesion or tissue of brain |
| 03.31 | 2,705 (5.4%) | Spinal tap |
| 86.07 | 2,264 (4.5%) | Insertion of totally implantable vascular access device [VAD] |
| 85.05 | 1,147 (2.3%) | Incision with removal of foreign body or device from skin and subcutaneous tissue |
| 02.2 | 1,076 (2.1%) | Ventriculostomy |
| 40.11 | 1,038 (2.1%) | Biopsy of lymphatic structure |
| 40.3 | 827 (1.7%) | Regional lymph node excision |
| 54.4 | 819 (1.6%) | Excision or destruction of peritoneal tissue |
| Recommended timeline | Building the infrastructure | Educational development | Program accreditation | Marketing and recruitment |
| 6–12 months | Institutional affiliation and training site | |||
| Budget/funding Timeline | ||||
| 3–4 months | Review and apply ACGME requirements | |||
| Develop your educational vision | ||||
| 4–6 months | Curriculum and program design | Complete the application | ||
| 2–3 months | Faculty development | Prepare for site visit | ||
| 3–6 months | Await accreditation decision | Strategic marketing | ||
| 8 months (July–February) | Active recruitment | |||
| 4 Months (March–June) | The beginning: match and orientation |
| RCC subtype | % | Number of samples |
| Clearcell RCC | 48% | (17/35) |
| Papillary RCC | 32% | (11/35) |
| Chromophobe RCC | 20% | (7/35) |
| TNM | ||
| T1a | 31% | (11/35) |
| T1b | 23% | (8/35) |
| T2 | 8% | (3/35) |
| T3a | 26% | (9/35) |
| T3b | 12% | (4/35) |
| N0 | 65% | (23/35) |
| N1 | 23% | (8/35) |
| N2 | 12% | (4/35) |
| Fuhrman’s Classification | ||
| Grade 1 | 8% | (3/35) |
| Grade 2 | 43% | (15/35) |
| Grade 3 | 49% | (17/35) |
| Harvestable amount | pH | OM | TN | P2O5 |
| Root length | 0.452 | 0.888∗∗ | 0.921∗∗ | 0.630 |
| Case | Fracture type | Time to fracture (mo) | Treatment | Plates | Bone graft | Time to union (mo) | Duration of follow-up (mo) | Outcome | JOA score |
| 1 | Oblique | 104 | ORIF | DFLCP | - | 4 | 22 | Union | 63 |
| 2 | Transverse | 100 | ORIF | Reverse DFLCP | Auto, fibula | 6 | 28 | Union | 77 |
| 3 | Transverse | 75 | Revision (IBG) +ORIF | LCP | Allo, auto, iliac | 3 | 119 | Union | 68 |
| 4 | Transverse (with stem fracture) | 88 | Revision (IBG) | - | Allo | 4 | 45 | Union | 77 |
| 5 | Transverse | 78 | ORIF | Dall-Miles plate | Auto, fibula | 7 | 115 | Nonunion* | 53 |
| 6 | Oblique | 99 | ORIF | LCF | Auto, iliac | 4 | 74 | Union | 60 |
| 7 | Transverse | 12 | ORIF | Dall-Miles plate | Auto, fibula | 8 | 180 | Union | 67 |
| 8 | Oblique | 120 | ORIF | DFLCP | Allo | 4 | 35 | Union | 60 |
| 9 | Oblique | 142 | ORIF | DFLCP | - | 4 | 10 | Union | 62 |
| 10 | Transverse | 114 | ORIF | Reverse DFLCP | Auto, iliac | 6 | 12 | Union | 72 |
| 11 | Oblique | 240 | ORIF | DFLCP | - | 2 | 8 | Union | 81 |
| Total | ||||
| Characteristic | n | IR | IRR | 95% CI |
| Total | 338 | 0.92 | NA | |
| Race | ||||
| Whites | 295 | 0.97 | 1.00 | Reference |
| Blacks | 20 | 0.59 | 0.61 | 0.37 to 0.96 |
| Other/unspecified | 23 | ~ | ~ | ~ |
| Calendar period | ||||
| 1977 to 1986 | 79 | 0.78 | 1.00 | Reference |
| 1987 to 1996 | 121 | 1.02 | 1.30 | 0.97 to 1.76 |
| 1997 to 2006 | 138 | 0.96 | 1.23 | 0.93 to 1.65 |
| Age | ||||
| <50 years | 59 | 0.25 | 1.00 | Reference |
| ≥50 years | 279 | 2.70 | 11.02 | 8.31 to 14.87 |
| Laterality | ||||
| Right | 164 | 0.45 | 1.00 | Reference |
| Left | 173 | 0.47 | 1.06 | 0.85 to 1.32 |
| Not specified | 1 | ~ | ~ | ~ |
| Site | ||||
| Upper outer quadrant | 105 | 0.29 | 1.00 | Reference |
| Upper inner quadrant | 29 | 0.08 | 0.28 | 0.18 to 0.43 |
| Lower outer quadrant | 23 | 0.06 | 0.22 | 0.13 to 0.35 |
| Lower inner quadrant | 14 | ~ | ~ | ~ |
| Nipple/central | 28 | 0.08 | 0.27 | 0.17 to 0.41 |
| Overlapping | 89 | 0.24 | 0.83 | 0.62 to 1.11 |
| Not specified | 50 | 0.14 | 0.47 | 0.33 to 0.67 |
| Stage | ||||
| Localized | 320 | 0.87 | 1.00 | Reference |
| Regional | 14 | ~ | ~ | ~ |
| Distant | 1 | ~ | ~ | ~ |
| Unstaged | 3 | ~ | ~ | ~ |
| LN and sizea | ||||
| LN negative, ≤2 cm | 126 | 0.50 | 1.00 | Reference |
| LN negative, >2 cm | 67 | 0.26 | 0.52 | 0.38 to 0.71 |
| LN positive, ≤2 cm | 2 | ~ | ~ | ~ |
| LN positive, >2 cm | 3 | ~ | ~ | ~ |
| Other/not specified | 46 | 0.18 | 0.36 | 0.25 to 0.51 |
| Hormone receptorsb | ||||
| ER-negative/PR-negative | 128 | 0.56 | 1.00 | Reference |
| ER-negative/PR-positive | 6 | ~ | ~ | ~ |
| ER-positive/PR-positive | 21 | 0.09 | 0.16 | 0.10 to 0.25 |
| ER-positive/PR-negative | 12 | ~ | ~ | ~ |
| Other/not specified | 55 | 0.24 | 0.42 | 0.30 to 0.59 |
| Journal Name | ||||||||
| BMJ | Lancet | NEJM | JAMA | BJS | BJC | BJOG | Total | |
| 2007-8 | ||||||||
| Original articles | 6 | 5 | 5 | 1 | 10 | 16 | 10 | 541 (1.6%) |
| Pilot or feasibility study in preparation for a trial | 0 | 3 | 3 | 0 | 2 | 1 | 3 | 12 |
| Piloting new technique, combination of treatments | 1 | 0 | 0 | 0 | 4 | 2 | 6 | 13 |
| Phase I, II trials | 0 | 1 | 1 | 0 | 0 | 7 | 0 | 9 |
| Piloting screening program | 2 | 0 | 0 | 1 | 1 | 1 | 0 | 5 |
| Piloting guidelines, educational package, patient care strategy | 3 | 1 | 0 | 0 | 2 | 3 | 1 | 10 |
| Laboratory testing of activity of compounds | 0 | 0 | 1 | 0 | 1 | 2 | 0 | 4 |
| Total research papers | 292 | 379 | 444 | 383 | 338 | 1084 | 398 | 3318 |
| 2000-12 | ||||||||
| Original articles | 11 | 17 | 3 | 7 | 9 | 33 | 10 | 90 (2.0%) |
| Total research papers | 372 | 1115 | 434 | 619 | 396 | 1132 | 381 | 4449 |
| Variable | Number (percent) |
| Gender | Male: 7 (28%) |
| Female: 18 (72%) | |
| Racial/ethnic background | White: 19 (76%) |
| African-American: 2 (8%) | |
| Hispanic: 1 (4%) | |
| Asian: 3 (12%) | |
| Highest Education level | High School or less: 3 (12%) |
| Some college, no degree: 3 (12%) | |
| Associate’s degree: 11 (44%) | |
| Bachelor’s degree: 4 (16%) | |
| Post-graduate training: 4 (16%) | |
| Recruitment source | Office staff: 7 (28%) |
| Website volunteer: 8 (32%) | |
| Practice volunteer: 6 (24%) | |
| Department staff volunteer: 4 (16%) | |
| Newest Vital Sign Health Literacy category | Adequate literacy: 18 (72%) |
| Possible limited literacy: 5 (20%) | |
| High likelihood limited literacy: 2 (8%) | |
| REALM grade level | High School: 21 (84%) |
| 7th – 8th grade: 3 (12%) | |
| 4th to 6th grade: 1 (4%) | |
| Mean (sd, range) | |
| Age, years | 51.4, (13.8, 22 to 71) |
| Subjective numeracy scale | 4 (0.75, 2.25 to 5.38) |
| Steatosis grade | Fibrosis stage | Lobular inflammation | Ballooning | |
| Serum (n=138) | ||||
| Campesterol | −0.025 | −0.002 | −0.025 | 0.092 |
| Sitosterol | −0.027 | 0.029 | −0.028 | 0.159 |
| Avenasterol | 0.092 | 0.099 | 0.086 | 0.128 |
| Sitostanol | 0.100 | 0.026 | 0.098 | 0.024 |
| Liver (n=38) | ||||
| Campesterol | 0.013 | 0.137 | −0.052 | 0.119 |
| Sitosterol | −0.392* | −0.097 | −0.395* | 0.054 |
| Avenasterol | 0.041 | 0.086 | −0.025 | −0.107 |
| Sitostanol | 0.650† | 0.215 | 0.407* | 0.059 |
| Characteristic | N = 110 | |
| Sex | Male | 60 (54.5%) |
| Female | 50 (45.5%) | |
| Age | Mean | 60.97 ± 2.34 |
| BMI | Mean | 27.06 ± 0.98 |
| Ethnicity (skin color) | Yellow | 6 (6.8%%) |
| White | 55 (62.5%) | |
| Brown | 21 (23.9%) | |
| Black | 6 (6.8%) | |
| AKA | YesNo | 67 (60.9%)43 (39.1%) |
| Smoker | YesNoEx-smoker | 61 (55.5%)32 (29.1%)17 (15.5%) |
| Diabetes | YesNo | 15 (13.6%)95 (86.4%) |
| SAH | YesNo | 72 (65.5%)38 (34.5%) |
| Dyslipidemia | YesNo | 46 (58.2%)64 (41.8%) |
| Metabolic syndrome | YesNo | 25 (22.7%)85 (77.3%) |
| Aortic aneurysm | YesNo | 42 (38.2%)68 (61.8%) |
| Dissection of the aorta | YesNo | 14 (12.7%)96 (87.3%) |
| Mural thrombus | YesNo | 27 (24.5%)83 (75.5%) |
| Number of | Lower 95% of risk | |||
| Outcome | Events | Patients | rule of 3 | Exact CI |
| Epidural haematoma | ||||
| Cardiac | 0 | 4971 | 1 in 1,700 | 1 in 1,350 |
| Thoracic | 0 | 4108 | 1 in 1,400 | 1 in 1,100 |
| Vacular | 0 | 5026 | 1 in 1,700 | 1 in 1,350 |
| Combined | 0 | 14105 | 1 in 4,700 | 1 in 3,800 |
| Permanent neurological injury | ||||
| Combined | 0 | 13827 | 1 in 4,600 | 1 in 3,750 |
| Species | Group | NSkull | NMandible |
| C. australis (aus) | mendocinus | 31 | 27 |
| C. azarae (aza) | mendocinus | 29 | 26 |
| C. flamarioni (fla) | mendocinus | 32 | 22 |
| C. porteousi (por) | mendocinus | 30 | 28 |
| C. mendocinus (men) | mendocinus | 24 | 14 |
| C. ibicuiensis (ibi) | torquatus | 16 | 10 |
| C. lami (lam) | torquatus | 89 | 66 |
| C. minutus (min) | torquatus | 197 | 122 |
| C. pearsoni (pea) | torquatus | 77 | 60 |
| C. perrensi (per) | torquatus | 9 | 9 |
| C. roigi (roi) | torquatus | 7 | 7 |
| C. torquatus (tor) | torquatus | 222 | 124 |
| Total | 763 | 515 |
| Percentile | |||||||
| Sample | No. > LOD/total (%)a | 10th | 25th | 50th | 75th | 90th | 95th |
| Maternal blood (pg/g)a | 13/92 (14) | < LOD | < LOD | < LOD | < LOD | 1.5 | 2.5 |
| Umbilical cord blood (pg/g)a | 8/65 (12) | < LOD | < LOD | < LOD | < LOD | 2.3 | 2.5 |
| Postpartum meconium (ng/g)b | 23/83 (28) | < LOD | < LOD | < LOD | 0.44 | 0.62 | 0.77 |
| Sub-county | Year | Monthly targeta | Yearly targetb | No. of dose 1c | % coverage for dose 1 | No. of dose 2d | % coverage for dose 2 | Dropout (%) |
| Kiambu | 2014 | 285 | 1425 | 1530 | 107.4 | 1174 | 82.4 | 23.3 |
| 2015 | 285 | 3420 | 4351 | 127.2 | 3977 | 116.3 | 8.6 | |
| 2016 | 295 | 1180 | 1613 | 136.7 | 1467 | 124.3 | 9.1 | |
| Total | 6025 | 7494 | 124.4 | 6618 | 109.8 | 11.7 | ||
| Mbita | 2014 | 402 | 2010 | 1096 | 54.5 | 667 | 33.2 | 39.1 |
| 2015 | 414 | 4968 | 3821 | 76.9 | 3348 | 67.4 | 12.4 | |
| 2016 | 426 | 1704 | 1327 | 77.9 | 1156 | 67.8 | 12.9 | |
| Total | 8682 | 6244 | 71.9 | 5171 | 59.6 | 17.1 |
| Case | MP Pulse Therapy | Prednisone | Others | Proteinuria (month) | Outcome |
| 1 | + | MMF | 7 | RBC, 14/HP after 15 months | |
| 2 | Tripterygium | 2 | Normal urine test after 13 months | ||
| 3 | + | MMF | 4 | RBC, 14/HP after 20 months | |
| 4 | + | + | CTX | 5 | Normal urine test after 17 months |
| 5 | + | Tripterygium | 1 | Normal urine test after 7 months | |
| 6 | + | + | CTX | 5 | RBC, 10/HP after 15 months |
| 7 | + | 4 | RBC, 8/HP after 19 months | ||
| 8 | + | Tripterygium | 2 | RBC, 6/HP after 17 months | |
| 9 | Tripterygium | 4 | Normal urine test after 13 months | ||
| 10 | + | + | CTX | 4 | Normal urine test after 15 months |
| 11 | + | MMF | 4 | RBC, 15/HP after 13 months |
| Hyperhomocysteinemiaa | Hypercysteinemiaa | |||||||
| Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | |
| n | 253 | 254 | 254 | 254 | 253 | 254 | 254 | 254 |
| Total protein intake | ||||||||
| Crude OR (95% CI)b | 1 | 1.20(0.84-1.71) | 1.30(0.91-1.85) | 1.94(1.36-2.77)** | 1 | 1.20(0.70-2.06) | 1.60(0.96-2.68) | 1.78(1.07-2.96)* |
| Adjusted OR (95% CI)c | 1 | 1.30(0.89-1.91) | 1.37(0.94-1.99) | 2.13(1.45-3.12)** | 1 | 1.16(0.66-2.04) | 1.67(0.97-2.86) | 1.73(1.03-2.92)* |
| Adjusted OR (95% CI)d | 1 | 1.48(0.98-2.25) | 1.57(1.02-2.41)* | 2.63(1.70-4.07)** | 1 | 1.14(0.64-2.03) | 1.56(0.89-2.75) | 1.69(1.02-2.87)* |
| Animal protein intake | ||||||||
| Crude OR (95% CI)b | 1 | 1.46(1.01-2.10)* | 1.79(1.25-2.58)* | 3.32(2.30-4.79)** | 1 | 1.27(0.76-2.13) | 1.34(0.80-2.24) | 1.50(0.91-2.49) |
| Adjusted OR (95% CI)c | 1 | 1.51(1.03-2.22)* | 1.87(1.27-2.75)* | 3.73(2.52-5.54)** | 1 | 1.28(0.74-2.21) | 1.45(0.84-2.51) | 1.59(0.93-2.70) |
| Adjusted OR (95% CI)d | 1 | 1.56(1.03-2.38)* | 2.01(1.31-3.08)* | 4.14(2.67-6.43)** | 1 | 1.34(0.77-2.36) | 1.51(0.85-2.68) | 1.60(0.91-2.80) |
| Plant protein intake | ||||||||
| Crude OR (95% CI)b | 1 | 0.77(0.54-1.10) | 0.51(0.35-0.72)** | 0.46(0.32-0.66) ** | 1 | 1.01(0.62-1.62) | 0.91(0.55-1.48) | 0.88(0.53-1.44) |
| Adjusted OR (95% CI)c | 1 | 0.77(0.53-1.10) | 0.54(0.37-0.79)* | 0.47(0.32-0.68)** | 1 | 1.11(0.66-1.86) | 1.02(0.61-1.70) | 0.90(0.53-1.51) |
| Adjusted OR (95% CI)d | 1 | 0.76(0.51-1.13) | 0.63(0.41-0.96)* | 0.59(0.38-0.91)* | 1 | 1.28(0.73-2.26) | 1.12(0.64-1.93) | 0.96(0.56-1.64) |
| Variable | No. | IRa (95% CI) | Unadjusted IRR (95% CI) | Adjusted IRRb (95% CI)b | Pc |
| Total | |||||
| Controls | 798 | 40.8 (38.1-43.7) | 1(reference) | 1 (reference) | - |
| ESRD | 62 | 102 (79.5-131) | 2.50 (1.93-3.24) | 2.41 (1.83-3.16) | <0.001 |
| Sex Controls | |||||
| Men | 404 | 33.9 (30.8-37.4) | 1 (reference) | 1 (reference) | - |
| Women | 394 | 51.5 (46.7-56.9) | 1.52 (1.32-1.75) | 1.54 (1.34-1.77) | <0.001 |
| ESRD | |||||
| Men | 27 | 71.3 (48.9-104) | 1 | 1 | - |
| Women | 35 | 153 (110–213) | 2.14 (1.30-3.54) | 2.11 (1.27-3.48) | 0.004 |
| Age (years) Controls | |||||
| 14-49 | 83 | 18.8 (15.2-23.3) | 1 (reference) | 1 (reference) | - |
| 50-64 | 242 | 40.2 (35.5-45.7) | 2.14 (1.67-2.75) | 2.11 (1.64-2.71) | <0.001 |
| ≥ 65 | 473 | 51.8 (47.3-56.7) | 2.75 (2.18-3.48) | 2.51 (1.98-3.18) | <0.001 |
| ESRD | |||||
| 14-49 | 15 | 73.0 (44.0-121) | 1 (reference) | 1 (reference) | - |
| 50-64 | 34 | 165 (118–231) | 2.26 (1.23-4.15) | 2.39 (1.30-4.39) | 0.005 |
| ≥ 65 | 13 | 66.0 (38.3-114) | 0.90 (0.43-1.90) | 1.03 (0.48-2.19) | 0.9 |
| Comorbidity level d Controls | |||||
| Low | 591 | 36.8 (34.0-39.9) | 1 (reference) | 1 (reference) | - |
| Medium | 152 | 52.1 (44.4-61.1) | 1.41 (1.18-1.69) | 1.23 (1.02-1.47) | 0.03 |
| High | 55 | 91.7 (70.4-119) | 2.49 (1.89-3.28) | 2.12 (1.60-2.81) | <0.001 |
| ESRD | |||||
| Low | 40 | 130 (95.1-177) | 1 (reference) | 1 (reference) | - |
| Medium | 15 | 98.4 (59.3-163) | 0.76 (0.42-1.37) | 0.77 (0.42-1.41) | 0.4 |
| High | 7 | 47.5 (22.6-99.6) | 0.37 (0.16-0.82) | 0.39 (0.17-0.87) | 0.02 |
| Approaches | # of selected nodes | # of Sampled records | Recall (%) | Precision (%) |
| hLDA | 20 | 200 | 48.2 | 76.5 |
| Ours without domain knowledge | 20 | 200 | 61.7 | 82.56 |
| Ours with domain knowledge | 20 | 200 | 65.86 | 82.33 |
| Male/female | 21/4 |
| Injured side | |
| Right/left | 18/7 |
| Dominance | |
| Right/left | 21/4 |
| Mechanism of primary injury | |
| Bicycling | 9 |
| Simple fall | 7 |
| Sport | 7 |
| Traffic accident | 2 |
| Rockwood type in primary radiographs | |
| II | 3 |
| III | 6 |
| IV | 1 |
| V | 15 |
| Mean age at time of injury, y (range) | 44 (22–59) |
| Mean age at time of examination, y (range) | 48 (24–63) |
| Variables | Sample Number (Persons) | Weighted Number (Million Persons) | Proportion (%) |
| Total | 1,909,199 | 985 | 100 |
| Age group (years) | |||
| 18–39 | 822,041 | 423 | 42.95 |
| 40–64 | 836,406 | 432 | 43.84 |
| 65+ | 250,752 | 130 | 13.21 |
| Gender | |||
| Male | 949,955 | 490 | 49.74 |
| Female | 959,244 | 495 | 50.26 |
| Illiterate | |||
| Yes | 302,635 | 160 | 16.25 |
| No | 1,606,564 | 825 | 83.75 |
| Residence | |||
| Rural | 1,229,862 | 665 | 67.57 |
| Urban | 679,337 | 319 | 32.43 |
| Region | |||
| East | 769,169 | 401 | 40.73 |
| Central | 558,169 | 317 | 32.2 |
| West | 581,861 | 267 | 27.07 |
| Marital status | |||
| Unmarried | 227,393 | 115 | 11.66 |
| Married | 1,523,107 | 788 | 80.03 |
| Divorced or widowed | 158,699 | 82 | 8.31 |
| Employment | |||
| Yes | 1,367,709 | 719 | 72.99 |
| No | 541,490 | 266 | 27.01 |
| Annual family income per capita by residential area * | |||
| >national average | 462,517 | 233 | 23.69 |
| ≤national average | 1,446,682 | 751 | 76.31 |
| Predictive variables | Dependent variable LDL score* | ||
| p | OR | 95.0% CI for OR | |
| lower–upper | |||
| WC (1) | 0.029 | 1.80 | 1.06–3.05 |
| Age (2) | 0.935 | 0.93 | 0.97–1.03 |
| WC (1) | 0.091 | 1.60 | 0.92–2.76 |
| Age (2) | 0.853 | 0.99 | 0.96–1.03 |
| Apo B (2) | 0.001 | 9.90 | 2.64–37.10 |
| WC (1) | 0.525 | 1.21 | 0.67–2.18 |
| Age (2) | 0.352 | 0.98 | 0.94–1.01 |
| Apo B (2) | 0.124 | 3.20 | 0.72–14.12 |
| Triglycerides (2) | <0.001 | 1.01 | 1.00–1.02 |
| Level of consciousness | Example of positive collective values |
| 7. Service: Self-less service to the world | Social responsibility, future generations, long-term perspective, ethics, compassion, humility |
| 6. Making a difference: to the local community or health district | Collaboration, community involvement, strategic partnerships.Staff fulfilment, coaching/mentoring, leadership development |
| 5. Internal cohesion: Building internal organisational community | Shared values, vision, commitment, integrity, trust, passion, creativity, openness, transparency |
| 4. Transformation: Continuous renewal and learning | Accountability, adaptability, empowerment, teamwork, goals orientation, personal growth |
| 3. Self-esteem: High performance and quality of care | Systems, processes, quality, best practices, pride in performance.Bureaucracy, arrogance, image, hoarding information |
| 2. Relationships: With colleagues and patients | Loyalty, open communication, patient experience, friendship.Blame, internal competition, rivalry, manipulation |
| 1. Survival: Resources and safety | Sufficient budget, equipment, employee health, safety.Control, chaos, caution, job security |
| Number | Response rate | |
| Invitational e-mails sent | 1345 | 17% (227/1345) |
| Valid emails addresses | 1131 | 20% (227/1131) |
| Emails opened | 693 | 33% (227/693) |
| Links to survey opened | 293 | 77% (227/293) |
| Participants that completed survey | 227 |
| ρ | Method | Auc | Sensitivity | nIMS | nTMS |
| 0.3 | AucEN | 0.81 | 0.45 | 3 | 12 |
| AucL | 0.81 | 0.45 | 3 | 6 | |
| LogEN | 0.85 | 0.50 | 3 | 3 | |
| LogL | 0.85 | 0.50 | 2 | 2 | |
| MSauc | 0.82 | 0.45 | 2 | 6 | |
| 0.9 | AucEN | 0.81 | 0.45 | 3 | 4 |
| AucL | 0.81 | 0.45 | 2 | 2 | |
| LogEN | 0.80 | 0.40 | 2 | 2 | |
| LogL | 0.80 | 0.40 | 1 | 1 | |
| MSauc | 0.79 | 0.40 | 1 | 3 |
| III.2 | III.3 | III.6 | III.7 | III.8 (Proband) | III.9 | |
| Lab ID | PI-2568 | PI-2569 | PI-2570 | PI-1202 | PI-1124 | PI-2571 |
| Gender | F | F | F | M | M | F |
| ATXN10 repeat (SMRT/Cas9 capture)* | 1315 | 1363 | 1076 | 1363 | 1304 | 1080 |
| Age at onset (years) | 35 | 48 | unaffected | 48 | 38 | 37 |
| Onset of seizures (years) | 60 | 57 | – | 53 | – | – |
| Current age (years) | 71 | 68 | 61 | 65 | 57 | 53 |
| Duration of disease (years) | 36 | 20 | – | 17 | 19 | 16 |
| Seizures | + | + | – | + | – | – |
| Gait ataxia | + | + | – | + | – | + |
| Intention tremor | + | + | – | – | + | – |
| Dysarthria | + | + | – | + | – | + |
| Dysmetria | + | + | – | + | – | + |
| Dysdiadochokinesia | + | + | – | – | + | + |
| Nystagmus | + | + | – | + | – | + |
| Ocular dyskinesia | + | + | – | + | – | – |
| Hypotonia | – | – | – | – | – | – |
| Hyperreflexia | – | – | – | + | – | – |
| Babinski’s sign | – | – | – | – | – | – |
| Leg spasticity | – | – | – | – | – | – |
| Aggressiveness | + | + | – | – | – | + |
| Depression | + | + | – | + | + | + |
| MoCA | 9/30 | 2/30 | 29/30 | U | U | 25/30 |
| SARA | 23.5/40 | 24.5/40 | 0/40 | U | 6/40 | 16/40 |
| B-SIT (% tile) | NP | NP | 27% | U | 29% | 20% |
| B-SIT (category) | NP | NP | Normal | U | Normal | Normal |
| Controls | Carcinomas | Adenomas, all | High-risk adenomas | Low-risk adenomas | |
| No (%) | No (%) | No (%) | No (%) | No (%) | |
| No. of subjects | 399 | 157 | 983 | 227 | 756 |
| Gendera | |||||
| Male | 157 (39.3) | 87 (55.4) | 603 (61.3) | 150 (66.1) | 453 (59.9) |
| Female | 242 (60.7) | 70 (44.6) | 380 (38.7) | 77 (33.9) | 303 (40.1) |
| Ageb | |||||
| Mean (SD) | 54.2 (3.3) | 67.9 (11.2) | 57.3 (3.7) | 57.3 (3.5) | 57.3 (3.8) |
| Smoking status * | |||||
| Never smoked | 155 (46.7) | 33(31.1) | 253 (30.6) | 51 (27.0) | 202 (31.7) |
| Ever smoked | 177 (53.3) | 73 (68.9) | 574 (69.4) | 138 (73.0) | 436 (68.3) |
| Mean no. of cigarette years (SD) | 249(229) | 383(339) | 360(263) | 389(244) | 351(269) |
| Alcohol consumption * | |||||
| < 1 unit/month | 72 (21.7) | 36 (34.0) | 180 (21.8) | 43 (22.8) | 137 (21.5) |
| ≥ 1 unit/month | 260 (78.3) | 70 (66.0) | 647 (78.2) | 146 (77.2) | 501 (78.5) |
| Mean units of alcohol per month (SD) | 11.1 (12.2) | 15.5 (22.3) | 16.4 (22.9) | 18.4 (29.8) | 15.8 (20.4) |
| Species and tissue or cell type | Relevant properties of tissue or cells | Name of library in NCBI and contributor(s) | Total number of ESTs per library (March 2006) | Number of ESTs matching genes in Arabidopsis (e < 10-7) | Number of contigs identified using CAP3 | Number of singletons identified using CAP3 | Unigenes (contigs plus singletons) |
| Zea mays | |||||||
| Sperm | Male | Zea mays sperm cell cDNA library (S. McCormick) Engel et al.[64] | 5174 | 2457 | 384 | 781 | 1165 |
| Egg | Female | Zea mays egg cell cDNA library (H. Yang and S. McCormick) Yang et al. [65] | 4085 | 1957 | 264 | 863 | 1127 |
| Triticum aestivum | |||||||
| Anther-meiotic | Male | Wheat meiotic anther cDNA library (O. Anderson) | 9139 | 6118 | 860 | 3058 | 3918 |
| Ovary | Female | Ov (Genoplante) | 5311 | 3699 | 813 | 1295 | 2108 |
| Brassica napus | |||||||
| Microspores (from 3 to 4 mm buds) | Male | 65JKBNM0 (M. Malik and J. Krochko) | 6539 | 5325 | 781 | 1620 | 2401 |
| Buds and young flowers | Heterogeneous (male, female and somatic) | ADIS-MPIZ 021 (B. Weisshaar) | 8747 | 6164 | 995 | 2665 | 3660 |
| Region no. | ORFa | Region size (nt) | Size of sequenced region (nt) | Left coordinatea | Right coordinatea | Newly found changes in the regions suggested by CGS | Newly found changes not suggested by mapping phase of CGS | Confirmation of SNPs identified by CGS in this regionb |
| 1 | TP0012 | 37 | 390 | 12322 | 12711 | 3 nt deletion | - | - |
| 2 | TP0076 | 29 | 529 | 83788 | 84316 | - | 1 solitary SNP | - |
| 3 | TP0117 | 86 | 699 | 134808 | 135506 | 7 clustered SNPs | - | - |
| 4 | TP0117 | 86 | 3 clustered SNPs | - | - | |||
| 5 | TP0126 | 29 | 393 | 147948 | 148340 | 1 solitary SNP | - | - |
| 6 | upstream | 29 | 460 | 149103 | 149562 | 2 clustered SNPs | - | - |
| of TP0128 | 1 nt + 5 nt insertions | |||||||
| 7 | TP0131 | 421 | 723 | 150925 | 151647 | 3 clustered SNPs, 1 solitary SNP | 2 clustered SNPs | - |
| 8 | upstream of TP0136 | 29 | 404 | 156348 | 156751 | 64 nt deletion | - | - |
| 9 | TP0136 | 1087 | 1609 | 156752 | 158360 | 19 clustered SNPs | 8 clustered SNPs | 21 SNPs |
| 1 nt + 1 nt + 1 nt + 6 nt deletions | 2 solitary SNPs | |||||||
| 10 | TP0272 | 29 | 480 | 288647 | 289126 | - | - | - |
| 11 | TP0304 | 37 | 466 | 318761 | 319226 | 3 nt deletion | - | - |
| 12 | TP0326 | 79 | 452 | 345605 | 346056 | 8 clustered SNPs | - | 1 SNP |
| 13 | TP0352 | 29 | 465 | 376926 | 377390 | - | - | - |
| 14 | TP0394 | 29 | 505 | 420353 | 420857 | - | - | 1 SNP |
| 15 | TP0431 | 29 | 465 | 458973 | 459437 | - | - | 1 SNP |
| 16 | TP0457 | 29 | 465 | 487935 | 488399 | - | - | - |
| 17 | TP0484 | 29 | 468 | 514441 | 514908 | - | - | - |
| 18 | TP0486 | 29 | 494 | 517297 | 517790 | - | 1 nt insertion, 1 nt deletion | - |
| 19 | TP0493 | 29 | 478 | 529146 | 529623 | - | - | - |
| 20 | TP0515 | 44 | 506 | 555754 | 556259 | 3 clustered SNPs | - | 4 SNPs |
| 21 | TP0544 | 29 | 611 | 585940 | 586550 | 6 nt insertion | - | - |
| 22 | TP0548 | 835 | 1189 | 591557 | 592745 | 22 clustered SNPs | 2 clustered SNPs | 5 SNPs |
| 3 nt + 4 nt + 5 nt insertions | 1 solitary SNP | |||||||
| 23 | TP0577 | 37 | 405 | 628247 | 628651 | 1 solitary SNP | - | - |
| 24 | TP0598 | 29 | 550 | 648851 | 649400 | - | 4 1 nt insertions | - |
| 25 | TP0620–TP0621 | 51 | 3469 | 670958 | 674426 | - | 4 clustered SNPs | - |
| 26 | TP0668 | 37 | 462 | 730080 | 730541 | 6 nt deletion | - | - |
| 27 | TP0699 | 51 | 469 | 766143 | 766611 | 1 solitary SNP | - | - |
| 28 | TP0785 | 29 | 438 | 851631 | 852068 | - | - | - |
| 29 | TP0814 | 29 | 476 | 882990 | 883465 | - | - | - |
| 30 | TP0865 | 29 | 480 | 943847 | 944326 | 3 nt insertion | - | 1 SNP |
| 31 | TP0866 | 29 | 543 | 944677 | 945219 | - | 1 nt insertion | - |
| 32 | TP0868 | 29 | 454 | 947257 | 947710 | 7 nt deletion | - | - |
| 33 | TP0896–TP0898 | 667 | 3038 | 974053 | 977090 | 4 SNPsc and 7 variable regionsd | 1 SNP | |
| 34 | TP0898 | 27 | 416 | 978349 | 978764 | - | - | - |
| 35 | TP0933 | 29 | 164 | 1014034 | 1014197 | - | - | - |
| 36 | TP0973 | 44 | 396 | 1057660 | 1058055 | 1 solitary SNP | - | 1 SNP (igr) |
| 37 | TP1030–TP1031 | 1507 | 402 | 1123660 | 1124061 | 18 clustered SNPs | 1 nt insertion, | 16 SNPs |
| 1775 | 1124256 | 1126030 | 1 solitary SNP | |||||
| 38 | TP1036 | 29 | 550 | 1132558 | 1133107 | - | - | - |
| Independent variable | Odds ratio | Std. Err. | z | p | 95% conf. interval |
| Basal circumference | 1.21 | 0.08 | 2.79 | 0.005 | [1.06; 1.39] |
| PwarmQ | 3.90 | 0.70 | 7.63 | <0.001 | [2.75; 5.53] |
| Ave. of the 5 windiest days | 2.59 | 0.50 | 4.92 | <0.001 | [1.77; 3.79] |
| Pwarmq*Ave. of the 5 windiest days | 3.85 | 0.90 | 5.73 | <0.001 | [2.43; 6.10] |
| Leptosols | 4.86 | 1.54 | 4.99 | <0.001 | [2.61; 9.04] |
| Regosols | 0.67 | 0.13 | −2.06 | 0.039 | [0.46; 0.98] |
| Constant | 0.21 | 0.05 | −6.39 | <0.001 | [0.13; 0.34] |
| Body weight (g) | GHb (%) | Urine volume (ml/24 hours) | |
| Normal | 618 ± 71 | 5.7 ± 0.6 | 9 ± 8 |
| Diabetes | 369 ± 65 | 11.1 ± 2.1* | 106 ± 20* |
| Diab + Nutr | 354 ± 63 | 9.8 ± 2.4* | 92 ± 42* |
| Average gold-standard | Average real-time | Wilcoxon p-value | |
| For all subjects (63/63) | |||
| Endocardial border | 3.9 | 3.9 | 0.23 |
| Papillary muscle | 4.0 | 3.9 | 0.03* |
| Blood pool | 4.0 | 3.6 | <0.001* |
| Mitral valve | 3.9 | 3.4 | <0.001* |
| Myocardium | 3.9 | 3.9 | 0.45 |
| Cardiac motion | 3.9 | 3.9 | 1.00 |
| Radial GRAPPA with 26 calibration frames (23/63) | |||
| Endocardial border | 3.9 | 3.9 | 0.73 |
| Papillary muscle | 4.0 | 4.0 | 0.71 |
| Blood pool | 4.0 | 3.7 | <0.01* |
| Mitral valve | 3.8 | 3.2 | <0.001* |
| Myocardium | 3.9 | 4.0 | 0.17 |
| Cardiac motion | 3.9 | 4.0 | 0.14 |
| Radial GRAPPA with 6 calibration frames (40/63) | |||
| Endocardial border | 4.0 | 3.9 | 0.05 |
| Papillary muscle | 4.0 | 3.9 | 0.02* |
| Blood pool | 4.0 | 3.6 | <0.001* |
| Mitral valve | 3.9 | 3.5 | <0.001* |
| Myocardium | 4.0 | 3.9 | 0.07 |
| Cardiac motion | 4.0 | 3.9 | 0.23 |
| Stepwise multiple regression | Predictor variables | ||||||
| Model | Variable | Beta | P | ||||
| F | df | P | R2 | ||||
| B cells all | 21.650 | 3 | 0.000 | 0.391 | CXCL13 | 0.745 | 0.000 |
| CXCL12 | −0.490 | 0.001 | |||||
| BAFF | 0.320 | 0.012 | |||||
| B cells | 18.098 | 2 | 0.000 | 0.262 | CXCL13 | 0.616 | 0.000 |
| CXCL12 | −0.271 | 0.010 | |||||
| Plasmablasts | 20.265 | 2 | 0.000 | 0.287 | CXCL13 | 0.413 | 0.000 |
| BAFF | 0.234 | 0.009 | |||||
| T cells | 6.001 | 2 | 0.003 | 0.110 | BAFF | −0.498 | 0.001 |
| APRIL | 0.296 | 0.05 | |||||
| Monocytes | No variables included |
| Country | Years |
| Bangladesh | 1999 |
| Benin | 2006, 2001, 1996 |
| Bolivia | 2003, 1998 |
| Cameroon | 2004, 1998, 1991 |
| Colombia | 2010, 2005, 2000, 1995 |
| Dominican republic | 2007, 1999, 1996 |
| Egypt | 2008, 2005, 2000, 1996 |
| Ghana | 2008, 2003, 1993 |
| India | 2005, 1992 |
| Indonesia | 2007 |
| Kenya | 2008, 2003, 1998, 1993 |
| Madagascar | 2008, 2003, 1997, 1992 |
| Mali | 2001, 1995 |
| Nepal | 2006, 1996 |
| Philippines | 2008, 1998, 1993 |
| Senegal | 2005 |
| Tanzania | 2004, 1999, 1996 |
| Turkey | 1998, 1993 |
| Uganda | 2006, 2000, 1995 |
| Zambia | 2007, 2001, 1996, 1992 |
| Cancer type | #Patient | #Gene | MMF | AMN | AMF | NG |
| HNSCC [6] | 74 | 4920 | 46 | 94.5 | 1.42 | 2 |
| GBM1 [6] | 84 | 178 | 43 | 9.6 | 4.5 | 8 |
| GBM2 [2] | 90 | 1126 | 48 | 21.8 | 1.74 | 5 |
| LC [1] | 163 | 356 | 64 | 6.0 | 2.75 | 4 |
| OC [2] | 313 | 5385 | 251 | 49.0 | 2.85 | 101 |
| Endpoint | Exposure conditions | Results of exposure | Comments | Reference |
| Weight gain, survival, in SD rats, urinalysis, hematology, blood biochemistry after exposure | 849 MHz CDMA and 1.95 GHz WCDMA, 45 min/day, 5 days/week for 1 year, at 2 W/kg per signal, animals freely moving, am or pm alternately | No significant effects except significant increase in mean corpuscular hemoglobin level and alkaline phosphatase in males, and significant decrease in total bilirubin and lactate dehydrogenase in females | (48) | |
| Weight gain, survival, lymphoma incidence in AKR/J mice, blood biochemistry after 26 weeks of exposure, metastatic infiltration by IHC | 849 MHz CDMA and 1.95 GHz WCDMA, 45 min/day, 5 days/week for 42 weeks, at 2 W/kg per signal, animals freely moving, am or pm alternately | No significant effects. Significant decrease in metastatic infiltration in brain of males, increase in females, not due to exposure | (49) |
| RF | GBM | KNN | SVM | |||||
| mean | sd | mean | sd | mean | sd | mean | sd | |
| ACC | 97,98 | 0,12 | 97,85 | 0,20 | 97,43 | 0,61 | 97,98 | 0,12 |
| Spe | 95,67 | 0,84 | 95,39 | 1,02 | 94,63 | 2,04 | 95,94 | 0,65 |
| Sen | 98,71 | 0,11 | 98,77 | 0,13 | 98,33 | 0,23 | 98,63 | 0,25 |
| Kappa | 94,46 | 0,34 | 94,09 | 0,66 | 92,92 | 1,72 | 94,45 | 0,50 |
| AUC | 97,01 | 0,48 | 96,65 | 0,23 | 96,47 | 1,10 | 97,29 | 0,30 |
| TJ-54 (n = 48) | Placebo (n = 50) | Test statics | |
| Age (years) | 46.4 ± 9.7 | 5.4 ± 9.6 | ns |
| Gender (males/females) | 28/20 | 32/18 | ns |
| Duration of disease (years) | 23.7 ± 10.4 | 22.5 ± 9.6 | ns |
| Duration of treatment (years) | 3.2 ± 10.5 | 21.0 ± 10.3 | ns |
| CPZ equivalents (mg) | 1905.8 ± 1541.5 | 1941.8 ± 1948.1 | ns |
| Type | |||
| Paranoid | 39 | 35 | |
| Catatonic | 6 | 5 | |
| Undifferentiated | 3 | 10 | ns |
| PANSS (total) | 113.0 ± 23.0 | 111.1 ± 21.1 | ns |
| PANSS (positive) | 28.6 ± 5.4 | 28.7 ± 6.0 | ns |
| PANSS (negative) | 27.9 ± 7.1 | 27.8 ± 7.3 | ns |
| PANSS (general) | 56.6 ± 13.3 | 54.6 ± 11.9 | ns |
| CGI-S | 5.4 ± 0.8 | 5.5 ± 0.8 | ns |
| GAF | 27.4 ± 7.5 | 27.2 ± 6.4 | ns |
| DIEPSS | 4.3 ± 4.0 | 4.8 ± 4.5 | ns |
| No. | Strain | Species | Culture conditions | Active acidity | Bacteriocin production | |
| S1 | CCDM 731 | Lactococcus lactis subsp. Lactis | 37°C 18 h | M17 broth | 4.65 | Nisin |
| S2 | CCDM 857 | Enterococcus faecalis | M17 broth | 4.51 | Enterocin | |
| S3 | CCDM 108 | Lactobacillus helveticus | MRS broth | 4.14 | Enterocin | |
| S4 | RL 26-P | Lactobacillus plantarum | MRS broth | 3.67 | Plantaricin | |
| S5 | CCM 7165 | Enterococcus faecium | M17 broth | 4.68 | Enterocin | |
| S6 | RL 23-P | Lactobacillus sp. | MRS broth | 4.11 | Plantaricin | |
| S7 | CCDM 768 | Lactobacillus helveticus | MRS broth | 4.07 | Enterocin | |
| S8 | CCDM 182 | Lactobacillus plantarum | MRS broth | 3.81 | Plantaricin | |
| S9 | RL 22-P | Lactobacillus gasseri | MRS broth | 4.51 | Plantaricin |
| Cross | Generation | No. of total plants | No. of dwarf plants (< 60 cm) | No. of high plants (≥60 cm) | χ2 (1:1) |
| (Huaai11/Monker)/Huaai 11 | BC1 | 135 | 62 | 73 | 0.90 |
| (Huaai11/Monker)/Aiganqi | TC1 | 119 | 0 | 119 | 0 |
| (Huaai 11/Monker)/Himalaya | TC1 | 157 | 0 | 157 | 0 |
| (Huaai 11/Monker)/Indian dwarf | TC1 | 117 | 0 | 117 | 0 |
| (Huaai 11/Monker)/Maris Mink | TC1 | 143 | 0 | 143 | 0 |
| Rat Number | Treatment | Hemisphere | Frequency (kHz) | Voltage (V) |
| 1 | IRE | Left | - | 100 |
| H-FIRE | Right | 250 | 100 | |
| 2 | IRE | Left | - | 200 |
| H-FIRE | Right | 250 | 200 | |
| 3 | H-FIRE | Left | 250 | 300 |
| H-FIRE | Right | 250 | 400 | |
| 4 | IRE | Left | - | 50 |
| H-FIRE | Right | 500 | 400 |
| Standard of care (SOC) | Community-based intervention (CBI) | |
| Adult patients asked to bring child contacts to TB clinic for screening | X | X |
| Child contacts screened with symptom questionnaire | X | X |
| IPT offered to eligible child contacts | X | X |
| Monthly IPT visits | X | X |
| HIV testing encouraged for eligible child contacts | X | X |
| Active community contact tracing | X | |
| Community-based health education using study brochure | X | |
| Child screening and IPT provision according to clinical algorithm | X | |
| Nurse training and ongoing mentorship | X | |
| Health education for caregivers using treatment literacy curriculum | X | |
| Active tracking of IPT provision | X | |
| Consistent community support via VHW | X | |
| Social support and navigation by VHW | X | |
| SMS medication and appointment reminder messages | X | |
| Review of IPT monitoring data at quarterly multidisciplinary team meetings | X |
| Socio-Demographic Characteristics | Total n = 60 |
| Age Range (Min, max) | 70–97 |
| Mean (SD) | 77 (6.27) |
| Sex, n (%) | |
| Female | 40 (66.7) |
| Male | 20 (33.3) |
| Educational Level, n (%) | |
| High school or less | 48 (80) |
| Some college education | 12 (20) |
| Monthly Income, n (%) | |
| Low(<$1000) | 50 (83) |
| Medium ($1000–$2000) | 8 (13) |
| High (>$2000) | 2 (3) |
| Health Conditions, n (%) | |
| Hypertension | 35 (58) |
| Musculoskeletal | 33 (55) |
| Diabetes | 32 (53) |
| Visual | 15 (25) |
| Respiratory | 13 (23) |
| Cardiac | 12 (20) |
| Overweight | 12 (20) |
| 3-month mRS 0–2 in all patients (n = 646) | 3-month mRS 0–2 in rtPA patients (n = 376) | |
| R2 (coefficient, p) | R2 (coefficient, p) | |
| Time to CT (h) | 0.058 (0.081, p = 0.009) | 0.099 (0.131, p = 0.002) |
| Time to treatment | 0.096 (0.137, p = 0.01) | |
| Acute NIHSS | 0.203 (0.119, p < 0.001) | 0.116 (0.161, p < 0.001) |
| Diabetes | 0.001 (0.011, p = 0.904) | 0.009 (0.027, p < 0.001) |
| Age | 0.027 (0.079, p = 0.013) | 0.019 (0.154, p < 0.001) |
| Hypertension | 0.002 (0.021, p = 0.238) | 0.018 (0.018, p = 0.181) |
| Smoker | 0.001 (0.019, p = 0.446) | 0.001 (0.007, p = 0.417) |
| AF | 0.001 (0.091, p = 0.451) | 0.001 (0.108, p = 0.538) |
| Lipids | 0.001 (0.014, p = 0.741) | 0.001 (0.027, p = 0.461) |
| Gene Contributes to Core Enrichment | Gene Does Not Contribute to Core Enrichment | |||
| BMP4 | SP1 | ACTB | GJA1 | PDPK1 |
| BMP6 | TBXAS1 | AKAP1 | GNAS | PECAM1 |
| CCL2 | TGFB1 | ANXA2 | GNB2 | PFDN5 |
| CD34 | THBD | ANXA5 | GNG5 | PTGS2 |
| CENPF | THBS1 | APOE | GRN | RGS5 |
| CTGF | TRA1 | APS | HADHSC | RPL30 |
| CXCL12 | TUBG1 | ARF4L | HMOX1 | RPL34 |
| CYP1B1 | VCAM1 | ASS | ICAM1 | RPS11 |
| CYR61 | VIPR1 | CAV1 | IFITM3 | RPS7 |
| DPYSL3 | XPO1 | CCL15 | IL13RA1 | SAT |
| EDN1 | CCL25 | IL15 | SCGF | |
| EEF1A2 | CD164 | IL16 | SELE | |
| ELN | CD1D | IL1R1 | SERPINE1 | |
| F3 | CD58 | IL1RL1 | SERPINE2 | |
| FGF2 | CD68 | ITGB3 | SLC35F2 | |
| FN1 | CDKN1A | JARID1A | SMARCD1 | |
| GAPD | CEACAM1 | JUN | SOD2 | |
| GBP1 | CYP1A1 | KLF2 | SPARC | |
| GJA5 | DKK2 | LAMB1 | SPTA1 | |
| GSTP1 | E2F5 | LIMS1 | SPTAN1 | |
| IL8 | EDN3 | LRP2 | STAM | |
| ILK | EFEMP1 | METAP2 | TEK | |
| JAG2 | EGR1 | MGP | TFPI | |
| JUNB | EIF4EBP2 | MMP1 | TGFB1I4 | |
| KIF20A | EIF4G3 | MMP14 | THBS4 | |
| KLF4 | ESM1 | MMRN1 | TNFRSF1A | |
| LIG3 | F2 | MYD88 | TNFRSF5 | |
| MAPRE1 | F2R | NFKB1 | TNFSF8 | |
| MATN2 | FGF6 | NOTCH4 | TUBA3 | |
| MYC | FGFR3 | NQO1 | TXNRD1 | |
| NOS3 | FLT1 | NUMA1 | UNG | |
| PFDN2 | FOS | OGT | VCL | |
| PLAT | FOSL1 | OLR1 | VEGFC | |
| RGS3 | FTH1 | PBP | VWF | |
| RHOA | FTL | PCQAP | WNT2B | |
| RHOB | GARS | PDGFRA | ||
| S100A10 | GAS | PDGFRB |
| VSSinitial | VSSmax | |||||||
| Chi-square | OR | 95% CI | P | Chi-square | OR | 95% CI | P | |
| VSS 0/1 | 94.31 | 4.10 | 3.03 to 5.54 | <0.0001 | 65.7 | 3.45 | 2.54 to 4.77 | <0.0001 |
| VSS 1/2 | 11.32 | 2.11 | 1.38 to 3.23 | 0.0008 | 0.89 | 1.22 | 0.84 to 1.76 | 0.35 |
| VSS 2/3 | 13.04 | 3.21 | 1.73 to 5.97 | 0.0003 | 23.23 | 3.63 | 2.14 to 6.17 | <0.0001 |
| VSS 3/4 | 0.01 | 1.029 | 0.48 to 2.22 | 0.94 | 8.90 | 2.95 | 1.50 to 5.81 | 0.0029 |
| Study | Adequate sequence generated? | Allocation concealment? | Blinding of participants and personnel? | Blinding of viral load assessment? | Incomplete outcome data addressed? (Missing at follow up = treatment failure) | Free of other bias? |
| Jaffar et al. [37] | Yes. | Yes. | No. | Yes. | No. | Yes. |
| Cards were sealed in advance and labelled with stratum numbers and placed into a box | Sealed cards were drawn from a concealed box. | The study was cluster randomized trial; researchers and participants knew which clusters were receiving the interventions. | Probably done, because Blood taken for viral load testing was for research purposes; the testing was done in batches rather than in real-time. | “Those who withdrew or were lost to follow-up before 12 months were excluded from the primary endpoint analysis...” | The two groups were well balanced according to baseline characteristics apart from CD4-cell count, which was lower in the home-based than in the facility-based group [39]. There were no losses of clusters. The analysis adjusted for the effect clustering | |
| Nachega et al. [35] | Yes. | Yes. | No. | Unclear. | Yes. | No. |
| Probably done, because there was sequential allocation concealment | “[T]reatment assignments were placed in opaque envelopes, which were sequentially opened by the study coordinator at enrolment.” | The study was an open-label, randomized controlled trial; both the researchers and the participants knew which intervention was being administered. | Measurement of viral loads performed was every 6 months as part of routine monitoring | Missing viral load values were considered detectable. | Trial terminated early for futility by an independent Data and Safety Monitoring Board | |
| Chang et al. [38] | Yes. | Yes. | No. | Unclear. | No. | No. |
| An allocation sequence was generated | Random allocation was by drawing of lots. | The study was cluster randomized trial; researchers and participants knew which clusters were receiving the interventions. | \"Viral loads ... were performed every 24 weeks on all patients as part of routine patient monitoring procedures.\" | Those who died or were lost to follow-up were excluded from the analysis of shorter-term virologic outcomes | Contamination in the control arm was reported in subsequent evaluation study [40]. | |
| Taiwo et al. [36] | Yes. | Yes. | Yes. | No. | Yes. | Yes. |
| “Using a computer-generated allocation sequence, randomization was performed ...” | Probably done, because there was computer-generated allocation sequence. | “The study pharmacist, who was blinded to treatment arm, provided one-on-one reinforcement of the education provided by the adherence counsellor plus information specific to each participant’s regimen.” | Probably not done because patients who had detectable viral loads at week 24 underwent intensive adherence retraining with the adherence counsellor. | “[P]articipants who were missing virologic indicators and were reported to have died were counted as failures.” | There were no significant differences between treatment groups at baseline. | |
| Matovu et al. [17] | Yes. | Unclear. | No. | Unclear. | No. | No. |
| Probably done, because patients were randomly allocated. | Insufficient information to permit judgement of “Yes” or “No”. | The study was an open randomized non-inferiority intervention trial. | Insufficient information to permit judgement of “Yes” or “No”. | Patients lost to follow-up were excluded from the analysis. | Baseline viral load was adjusted for. This means there were significant differences in viral loads between intervention groups at baseline. |
| Variable | Male (n=12) | Female (n=8) |
| Age (years) | ||
| Mean | 63.50 | 73.38 |
| Range | 21–80 | 63–87 |
| Minimum (%) | 21 (12.5) | 63 (25.0) |
| Maximum (%) | 80 (12.5) | 87 (37.5) |
| Grade of differentiation (n) | ||
| IIB (%) | 1 (8.3) | 0 (0) |
| IIC (%) | 1 (8.3) | 0 (0) |
| IIIB (%) | 1 (8.3) | 2 (25.0) |
| IIIA (%) | 1 (8.3) | 1 (12.5) |
| Colon (%) | 9 (75.0) | 4 (50.0) |
| Sigmoid (%) | 3 (25.0) | 4 (50.0) |
| pI | |||
| Spot | Relative zymolytic level | Without phosphatase | After phosphatase treatment |
| 1 | 18 | 5.005 | 5.129 |
| 2 | 13 | 5.048 | 5.175 |
| 3 | 52 | 5.110 | 5.228 |
| 4 | 13 | 5.169 | 5.276 |
| 5 | 5 | 5.226 | 5.330 |
| Cases | Sex/Age | Site | Depth | Largest diameter (cm) | Immunohistochemistry | Karyotype |
| 1 | M/59 | Paratesticular | Subcutaneous | 5.5 | CD34 Positive | 45,XY,add(5)(p13~15),-7,der(13)t(1;13)(q12~21;q14~21),-14,der(16)t(7;16)(q11;q22),del(18)(q21),+mar[9]/46,XY[2] |
| S100 Negative | ||||||
| ER Negative | ||||||
| PGR Negative | ||||||
| 2 | M/79 | Scrotum | Subcutaneous | 7 | CD34 Positive | 46,XY,t(10;15)(p13;q22),del(13)(q12q22)[15] |
| S100 Negative | ||||||
| ER Focal positive (20%) | ||||||
| PGR Focal positive (10%) |
| HA concentration, % | HA/DVS weight ratio | ξ (nm) |
| 5 | 10 : 1 | 223 ± 5 |
| 5 | 5 : 1 | 94 ± 6 |
| Small ponds | Large ponds | |||
| Taxonomic groups | Periphyton | Phytoplankton | Periphyton | Phytoplankton |
| Chlorophytes | p > 0.05 | p = 0.045 | p = 0.013 | p = 0.004 |
| Euglenophytes | p > 0.05 | p > 0.05 | p = 0.021 | p > 0.05 |
| Diatoms | p = 0.013 | p > 0.05 | p > 0.05 | p > 0.05 |
| Dinophytes | p = 0.001 | p = 0.038 | p > 0.05 | p > 0.05 |
| Cyanoprocaryotes | p > 0.05 | p > 0.05 | p = 0.023 | p = 0.020 |
| Control | Concussion | |
| n | 7 | 10 |
| Age (year) | 20.0 ± 1.4 | 19.4 ± 1.1 |
| Height (m) | 1.80 ± 0.11 | 1.79 ± 0.11 |
| Weight (m) | 81.2 ± 13.8 | 78.4 ± 12.2 |
| BMI (kg/m2) | 24.8 ± 1.7 | 24.7 ± 4.0 |
| Gender (M/F) | 6/1 | 8/2 |
| Pairs | Trios | |
| HGDP reference | 0.0009 | 0.0026 |
| Reich2012 reference | 0.0013 | 0.0034 |
| Measurement | Single measure ICC (2,1) | 95% CI | SEM cm (mm) |
| Right shoulder (1st measurement) | .92 | .86 to .96 | 0.40 (4 mm) |
| Left shoulder (1st measurement) | .93 | .88 to .96 | 0.37 (4 mm) |
| Dominant shoulder (1st measurement) | .93 | .86 to .96 | 0.38 (4 mm) |
| Non dominant shoulder (1st measurement) | .92 | .87 to .96 | 0.39 (4 mm) |
| Average measure ICC (2,3) | 95% CI | SEM cm (mm) | |
| Right shoulder (mean of 3) | .96 | .93 to .98 | 0.29 (3 mm) |
| Left shoulder (mean of 3) | .92 | .94 to .98 | 0.28 (3 mm) |
| Dominant shoulder (mean of 3) | .96 | .94 to .98 | 0.29 (3 mm) |
| Non dominant shoulder (mean of 3) | .96 | .93 to .98 | 0.28 (3 mm) |
| variables | Category | Latrine utilization | COR (95% CI) | AOR (95% CI) | |
| Yes (%) | No (%) | ||||
| Age | < 35 | 45 (51.7) | 41 (48.3) | 2.820 (1.435, 5.539) | 3.112 (1.539, 6.294)** |
| 36–50 | 80 (50.6) | 78 (49.4) | 2.699 (1.462, 4.984) | 2.776 (1.464, 5.266)** | |
| > 50 | 19 (27.5) | 50 (72.5) | 1.00 | 1.00 | |
| Education | Illiterate | 77 (41.0) | 110 (59.0) | 1.00 | 1.00 |
| Primary and above | 67 (46.8) | 59 (53.2) | 1.637 (1.039, 2.58) | 2.03 (1.427, 4.638) | |
| Occupation | Other | 20 (69.0) | 8 (31.0) | 1.00 | 1.00 |
| Farmer | 124 (43.5) | 161 (56.5) | 0.347 (0.153, 0.788) | 0.351 (0.150, 0.826)* | |
| Type of latrine | Open pit | 8 (23.5) | 25 (76.5) | 1.00 | |
| Pit without slab | 99 (45.2) | 120 (54.8) | 2.681 (1.162, 6.185) | ||
| Pit with slab | 35 (60.3) | 23 (39.7) | 4.946 (1.910, 12.803) | ||
| Ventilated latrine | 2 (66.7) | 1 (33.3) | 6.500 (0.519, 81.424) | ||
| Maintenance requirement | Need maintenance | 118 (43.2) | 154 (56.8) | 1.00 | |
| Maintained | 26 (63.4) | 15 (36.6) | 2.277 (1.155, 4.490) | ||
| Privacy | No privacy | 89 (42.0) | 122 (58.0) | 1.00 | 1.00 |
| Poor privacy | 25 (39.7) | 38 (60.3) | 0.909 (0.512, 1.614) | 0.822 (0.448, 1.508) | |
| Adequate privacy | 30 (76.9) | 9 (23.1) | 4.607 (2.084, 10.184) | 2.942 (1.251, 6.919)* | |
| Latrine cleanness | No | 101 (39.6) | 153 (60.4) | 1.00 | 1.00 |
| Yes | 43 (72.9) | 16 (27.1) | 4.098 (2.190, 7.667) | 4.098 (2.190, 7.667)*** |
| Clinical signs and symptoms (%) | Percentage positivity (%) | |
| DF (n = 145) | DHF (n = 74) | |
| Headache | 89.5 | 95.4 |
| Retroorbital pain | 58.3 | 69.3 |
| Nausea/vomiting | 72.7 | 75.5 |
| Rash | 6.6 | 13.1 |
| Abdominal pain∗ | 29.3 | 48.0 |
| Sore throat | 18.2 | 28.5 |
| Lethargy | 82.5 | 89.4 |
| Myalgia | 84.6 | 91.8 |
| Arthralgia | 85 | 88.1 |
| Red eyes | 25.8 | 20.9 |
| Ecchymosis/bruising | 2.3 | 1.6 |
| Bleeding | 8.7 | 15.9 |
| ε-recommended | ε-optimized | C-recommended | C-optimized | γ-optimized | |
| Model for H2-Db | 0.0475 | 0.0150 | 10.34 | 18.39 | 0.0316 |
| Model for H2-Kb | 0.0513 | 0.5134 | 10.88 | 34.41 | 0.0316 |
| Model for H2-Kk | 0.0152 | 0.0152 | 10.00 | 10.00 | 0.3162 |
| Cell line | STL/cell | Significance |
| AG11395 EV1 | 11.4 | |
| AG11395 EV2 | 9.2 | |
| AG11395 EV3 | 10.6 | |
| AG11395 WRN1 | 7.1 | P < 0.0005 |
| AG11395 WRN2 | 6.9 | P < 0.01 |
| AG11395 WRN3 | 4.4 | P < 0.0001 |
| AG11395 hTERT | 2.8 | P < 0.00001 |
| Diagnostic group | Comparison | |||||||
| 22q11.2DS | Controls | t test | Pearson’s chi-square | ANOVA | p value | |||
| N | 95 | 100 | ||||||
| Gender (male (%)) | 45 (47.36 %) | 48 (48 %) | 0.008 | 0.930 | ||||
| Age at first time point (mean (SD)) | 12.80 (4.23) | 13.17 (4.43) | 0.596 | 0.552 | ||||
| Full-scale IQ at first time point (mean (SD)) | 70.71 (12.27) | 110.37 (13.62) | 454.57 | <0.001 | ||||
| VABS outcome measure at last time point (mean (SD)) | ABC score | 66.73 (12.53) | ||||||
| Communication score | 71.17 (17.00) | |||||||
| Daily living skills score | 71.06 (15.22) | |||||||
| Socialization score | 73.83 (14.51) | |||||||
| Psychiatric diagnosis (N (%)) | Simple phobia | 42 (44.21 %) | ||||||
| Attention deficit disorder | 36 (37.89 %) | |||||||
| Generalized anxiety | 16 (16.84 %) | |||||||
| Major depressive episode | 13 (13.68 %) | |||||||
| Psychosis | 8 (8.42 %) | |||||||
| Obsessive-compulsive disorder | 7 (7.37 %) | |||||||
| Psychotropic medication | Total | 39 (41.05 %) | ||||||
| Categories | Methylphenidate | 26 (66.66 %) | ||||||
| Antidepressants | 12 (30.77 %) | |||||||
| Antipsychotics | 7 (17.95 %) | |||||||
| Antiepileptic | 7 (17.95 %) | |||||||
| Anxiolytic | 3 (7.69 %) |
| Virus | gorillas | orangutans | chimpanzees |
| n = 77 | n = 179 | n = 305 | |
| RSV | 79.3 # (61) | 72.1 (129) | 96.4 (294) |
| hMPV | 46.8 (36) | 10.1 (18) | 42.6 (130) |
| inf A H3N2 | 3.9 (3) | 5.6 (10) | 11.2 (34) |
| inf A H1N1 | 3.9 (3) | 19.0 (34) | 71.5 (218) |
| infl B | 58.4 (45) | 75.4 (135) | 26.2 (80) |
| Variable | RMP | CI 95% | P |
| Gender | |||
| Male | 1 | ||
| Female | 23.6 | 6.9–81.1 | <0.05 |
| Occupacion | |||
| Other | 1 | ||
| Housewife | 22.8 | 4.9–106.1 | <0.05 |
| Contact with Stagnant Water | |||
| No | 1 | ||
| Yes | 5.2 | 1.7–15.9 | <0.05 |
| Contact with Urine or Excrement | |||
| No | 1 | ||
| Yes | 5.1 | 1.9–13.1 | <0.05 |
| Variables | Unadjusted | Adjusted | |||
| N | OR (95% CI) | P value | OR (95% CI) | P value | |
| Age group (months) | 1.0 (0.9;1.050) | 0.6 | |||
| 06-11 | 144 | 1 | 1 | 0.4 | |
| 12-23 | 273 | 0.6 (0.3;1.2) | 0.1 | 0.7 (0.3;1.2) | 0.2 |
| 24-35 | 284 | 0.7 (0.3;1.6) | 0.3 | 0.7 (0.3;1.7) | 0.5 |
| 36-47 | 301 | 0.9 (0.4;1.9) | 0.7 | 1.0 (0.5;2.2) | 0.9 |
| 48-59 | 246 | 0.6 (0.2;1.3) | 0.1 | 0.6 (0.2;1.4) | 0.2 |
| Health regions | |||||
| Western Region | 56 | 1 | 1 | 0.1 | |
| North Bank West Region | 104 | 0.8 (0.2;4.1) | 0.8 | 0.5 (0.1;2.4) | 0.4 |
| Central River Region | 714 | 1.5 (0.6;4.0) | 0.4 | 0.6 (0.3;1.4) | 0.3 |
| Upper River Region | 359 | 0.6 (0.2;1.9) | 0.3 | 0.4 (0.1;1.0) | 0.06 |
| Sex | |||||
| Male | 681 | 1 | 1 | 0.6 | |
| Female | 567 | 0.9 (0.6;1.4) | 0.8 | 0.9 (0.6;1.3) | |
| Wealth quintiles | |||||
| Poorest | 500 | 1 | 1 | ||
| Second | 224 | 0.4 (0.2;0.8) | 0.009 | 0.4 (0.2;0.7) | 0.002 |
| Third | 260 | 0.5 (0.2;0.9) | 0.03 | 0.5 (0.3;0.9) | 0.03 |
| Fourth | 146 | 0.2 (0.1;0.5) | 0.001 | 0.3 (0.1;0.6) | 0.002 |
| Richest | 103 | 0.1 (0.04;0.3) | <0.001 | 0.1 (0.04;0.3) | <0.001 |
| Wall type | |||||
| Good | 451 | 1 | 1 | ||
| Poor | 797 | 2.3 (1.3;4.1) | 0.005 | 1.8 (1.1;3.1) | 0.01 |
| Floor type | |||||
| Good | 644 | 1 | 1 | ||
| Poor | 604 | 2.5 (1.5;3.9) | <0.001 | 2.0 (1.4;3.0) | 0.001 |
| Roof type | |||||
| Good | 799 | 1 | 1 | ||
| Poor | 449 | 2.4 (1.6;3.7) | <0.001 | 2.2 (1.4;3.3) | <0.001 |
| Window type | |||||
| Good | 730 | 1 | 1 | ||
| Poor | 513 | 2.0 (1.3;3.0) | 0.001 | 1.8 (1.1;3.0) | 0.01 |
| 1ARU | 1BGP | 1H58 | |
| 1CXP | 9% | 7% | 6% |
| 1ARU | - | 14% | 7% |
| 1BGP | - | - | 40% |
| Theme | Sub-theme |
| 1. Views on smoking | 1.1 Hostility towards smoking |
| 3. Reasons to quit smoking | 3.1 To improve health |
| 3.2 Social stigma | |
| 3.3 Saving money | |
| 3.4 Personal | |
| 4. Emotions connected with smoking initiation | 4.1 Regret starting |
| 6. Beliefs that influence quit attempts | 6.1 Control of nicotine dependence |
| 6.2 Motivation and willpower | |
| 6.3 Confidence | |
| 7. Difficulties quitting/cutting down | 7.4 Lack of motivation |
| 8. Goals | 8.1 Smoking cessation |
| 9. Methods used to quit smoking | 9.1 Abrupt |
| 9.2 Cut down first | |
| 10. Methods of cutting down | 10.1 Not smoking as many cigarettes |
| 10.2 Not smoking in the morning | |
| 10.3 Smoking only part of the cigarette | |
| 11. Non-medical aids to quit smoking | 11.1 Distraction |
| 11.2 Motivation | |
| 11.3 Exercising | |
| 12. Reasons for using NRT | 12.1 To aid quit attempt |
| 12.4 To help with cravings | |
| 12.5 Rid of habit | |
| 15. Factors to encourage use of NRT | 15.1 Free samples |
| 15.2 Aid quit attempt | |
| 16. Use of NRT | 16.2 Incorrect use/underuse |
| 17. Length of NRT use | 17.1 Short-term |
| 17.2 Long-term | |
| 18. Knowledge about NRT | 18.1 Current regulations |
| 19. Concerns about NRT | 19.1 Addiction |
| 19.2 Harmful when used long-term | |
| 19.3 Effective | |
| 19.4 Health consequences | |
| 19.5 Delays quitting process | |
| 22. Helpfulness of NRT | 22.1 Recommend |
| 23. Recommendation of cessation aids | 23.2 Other forms of therapy |
| 24. Stop smoking services | 24.1 Advantages |
| 24.2 Disadvantages |
| 2q23.1 deletion syndrome | SMS431* |
| Developmental delay | + |
| Motor delay | + |
| Language impairment | + |
| Behavioral problems | + |
| Autistic-like symptoms | + |
| Sleep disturbances | + |
| Repetitive behaviors (stereotypies) | + |
| Self-injurious behaviors | + |
| Short attention span | + |
| Aggression | + |
| Seizures | + |
| Infantile hypotonia | + |
| Infantile feeding difficulties | + |
| Eye abnormalities | + |
| Heavy arched eyebrows | - |
| Prominent nose | - |
| Thin upper lip | + |
| Widely spaced teeth | - |
| Differences | SD | Significance | |||
| Maxillomandibular relationship | Saggital | ANB(dg) | −0.113 | 0.146 | 0.065 NS |
| Wits(mm) | 0.112 | 0.216 | 0.185 NS | ||
| overjet(mm) | −0.107 | 0.189 | 0.152 NS | ||
| Vertical | FMA(dg) | 0.062 | 0.417 | 0.684 NS | |
| Y-axis(dg) | 0.100 | 0.141 | 0.085 NS | ||
| ANS-Me(mm) | 0.200 | 0.634 | 0.402 NS | ||
| S-Go(mm) | 0.200 | 0.160 | 0.010* | ||
| S-Go/N-Me | −0.001 | 0.002 | 0.906 NS | ||
| ANS-Me/N-Me | 0.000 | 0.002 | 0.906 NS | ||
| overbite(mm) | −0.037 | 0.199 | 0.611 NS | ||
| Maxillary skeletal changes | Saggital | SNA(dg) | 0.400 | 0.523 | 0.067 NS |
| ptm-A(mm) | 0.312 | 0.083 | 0.036* | ||
| ptm-S(mm) | 0.225 | 0.128 | 0.002** | ||
| Vertical | N-ANS(mm) | 0.337 | 0.856 | 0.302 NS | |
| PP-FH(dg) | 0.087 | 0.339 | 0.490 NS | ||
| OP-SN(dg) | 0.100 | 0.277 | 0.342 NS | ||
| Changes in maxillary dentition | Saggital | UI-NA(dg) | 0.137 | 0.388 | 0.350 NS |
| UI-NA(mm) | 0.037 | 0.272 | 0.708 NS | ||
| UI-AP(mm) | −0.142 | 0.440 | 0.700 NS | ||
| U6-PTM(mm) | 0.312 | 0.318 | 0.027* | ||
| UI-SN(dg) | 0.200 | 0.325 | 0.125 NS | ||
| Vertical | UI-PP(mm) | 0.025 | 0.401 | 0.143 NS | |
| U6-PP(mm) | 0.137 | 0.184 | 0.073 NS | ||
| Changes in mandibular dentition | Saggital | LI-NB(dg) | −0.087 | 0.294 | 0.429 NS |
| LI-NB(mm) | −0.213 | 0.314 | 0.096 NS | ||
| LI-AP(mm) | −0.163 | 0.272 | 0.135 NS | ||
| FMIA(dg) | −0.25 | 0.239 | 0.021* | ||
| Vertical | LI-MP(mm) | 0.187 | 0.325 | 0.064 NS | |
| L6-MP(mm) | 0.175 | 0.211 | 0.310 NS | ||
| Mandibular skeletal changes | Saggital | SNB(dg) | 0.363 | 0.082 | 0.003** |
| Go-Pg(mm) | 0.462 | 0.106 | 0.001** | ||
| Pcd-S(mm) | 0.212 | 0.124 | 0.002** | ||
| Vertical | Go-Co(mm) | 0.400 | 0.220 | 0.001*** | |
| MP-SN(dg) | 0.237 | 0.106 | 0.000*** | ||
| Y-axis(dg) | 0.150 | 0.277 | 0.170 NS | ||
| Soft tissue changes | UL-EP(mm) | −0.225 | 0.116 | 0.001*** | |
| LL-EP(mm) | 0.250 | 0.141 | 0.002** | ||
| Z-angel(dg) | −0.225 | 0.128 | 0.002** | ||
| UL-A′-FH(dg) | 0.025 | 0.362 | 0.850 NS | ||
| N′-Pg′-FH(dg) | 0.375 | 0.183 | 0.001*** | ||
| N′-SN-Pg′(dg) | 0.375 | 0.070 | 0.000*** |
| Parameter | Measured and calculated values |
| Ash weight (g) | 376.33 |
| Char weight (g) | 752.67 |
| Tar weight (g) | 73.58 |
| Syngas flow rate (Nm3/hr) | 16.02 |
| Fuel consumption rate (kg/hr) | 6.37 |
| Gas yield (Nm3/kg) | 2.51 |
| Cold gas efficiency (%) | 60.37 |
| Mass conversion efficiency (%) | 89.98 |
| Carbon conversion efficiency (%) | 91.18 |
| Age (years) | Day of cycle before GnRHa therapy | Stage of endometriosis |
| (a) Tissue for DIGE assay (n = 4) | ||
| 33 | 15 | IV |
| 27 | 16 | IV |
| 27 | 18 | IV |
| 37 | 27 | III |
| (b) Tissue for WB assay (n = 10) | ||
| 33 | 10 | IV |
| 25 | 14 | IV |
| 32 | 17 | IV |
| 29 | 13 | III |
| 27 | 15 | IV |
| 26 | 13 | III |
| 29 | 15 | IV |
| 23 | 11 | IV |
| 39 | 9 | IV |
| 36 | 12 | III |
| System | α-Helix | Short segment | β-Turn | |
| BSA | Frequency (cm−1) | 1655 | 1642 | 1682 |
| Content (%) | 55.71 | 34.51 | 9.78 | |
| BSA-DIO | Frequency (cm−1) | 1654 | 1639 | 1682 |
| Content (%) | 47.58 | 27.70 | 24.72 | |
| BSA-DIO-Co2+ | Frequency (cm−1) | 1657 | 1639 | 1689 |
| Content (%) | 45.55 | 38.52 | 15.93 | |
| BSA-DIO-Zn2+ | Frequency (cm−1) | 1657 | 1639 | 1685 |
| Content (%) | 51.48 | 38.30 | 10.22 |
| Age and gender | Population-at-risk | Annual incidence (per 100,000 person-years) 2002–2014 | |||
| Odontoid fractures | Hangman's fractures | Atypical fractures | Total | ||
| Men <70 | 201,402 | 1.0 | 0.4 | 0.5 | 1.9 |
| Women <70 | 201,444 | 0.5 | 0.2 | 0.03 | 0.8 |
| Men ≥70 | 28,713 | 15.8 | 0.8 | 1.3 | 17.9 |
| Women ≥70 | 41,382 | 16.0 | 1.1 | 0.7 | 17.8 |
| Total | 472,941 | 3.0 | 0.4 | 0.4 | 3.8 |
| Parameter | Supplement group | Placebo group | P-value supplement vs placebo (ANCOVA) |
| CD4+: % | |||
| 0 days | 17.69 ± 15.37 | 13.94 ± 11.62 | – |
| 60 days | 19.45 ± 15.14 | 14.69 ± 12.40 | 0.752 |
| 180 days | 23.57 ± 12.45 | 19.89 ± 11.12 | 0.861 |
| 365 days | 26.33 ± 9.95 | 24.07 ± 9.53 | 0.643 |
| CD8+: % | |||
| 0 days | 12.60 ± 13.48 | 7.65 ± 8.63 | – |
| 60 days | 11.65 ± 10.40 | 8.16 ± 9.04 | 0.981 |
| 180 days | 13.72 ± 12.39 | 7.76 ± 5.38 | 0.578 |
| 365 days | 12.44 ± 6.76 | 10.76 ± 6.33 | 0.546 |
| CD4+/CD8+ ratio | |||
| 0 days | 2.01 ± 1.39 | 2.80 ± 1.90 | – |
| 60 days | 2.41 ± 2.12 | 2.31 ± 1.33 | 0.394 |
| 180 days | 3.10 ± 3.15 | 2.92 ± 1.50 | 0.238 |
| 365 days | 3.21 ± 3.43 | 2.75 ± 1.11 | 0.721 |
| IL-6: pg/ml | |||
| 0 days | 382.91 ± 940.53 | 269.95 ± 1054.1 | – |
| 60 days | 138.65 ± 371.02 | 393.12 ± 1424.6 | 0.165 |
| 180 days | 192.38 ± 456.17 | 118.67 ± 184.77 | 0.728 |
| 365 days | 314.92 ± 1024.5 | 34.63 ± 55.48 | 0.612 |
| IL-10: pg/ml | |||
| 0 days | 22.69 ± 76.01 | 17.92 ± 63.47 | – |
| 60 days | 7.52 ± 12.67 | 38.51 ± 147.25 | 0.208 |
| 180 days | 4.33 ± 4.34 | 69.35 ± 231.80 | 0.172 |
| 365 days | 6.53 ± 10.01 | 2.68 ± 0.74 | 0.282 |
| TNF-α: pg/ml | |||
| 0 days | 123.14 ± 292.94 | 81.58 ± 308.77 | – |
| 60 days | 40.47 ± 95.60 | 112.17 ± 397.27 | 0.150 |
| 180 days | 59.21 ± 144.19 | 44.82 ± 72.46 | 0.811 |
| 365 days | 73.11 ± 233.46 | 13.23 ± 19.81 | 0.597 |
| IFN-γ: pg/ml | |||
| 0 days | 15.97 ± 35.87 | 3.49 ± 8.12 | – |
| 60 days | 7.04 ± 13.64 | 1.39 ± 2.33 | 0.264 |
| 180 days | 0.81 ± 0.84 | 0.84 ± 0.42 | 0.980 |
| 365 days | 4.58 ± 13.43 | 1.30 ± 0.97 | 0.544 |
| Multivariate odds ratio3 | 95% Confidence interval for OR | P-value | |
| Postmenopausal (1 = yes, 0 = no) | 0.120 | 0.069 – 0.207 | <0.001 |
| % Body fat > cut-off(1 = yes, 0 = no) | 0.414 | 0.297 – 0.578 | <0.001 |
| hs-CRP2 (1 = 3-10 mg/L, 0 = <3 mg/L) | 0.571 | 0.369 – 0.884 | 0.012 |
| RBC LC-PUFA,% of total fatty acids | 0.896 | 0.793 – 1.012 | 0.068 |
| Oral contraceptive use (1 = yes, 0 = no) | 0.426 | 0.262 – 0.693 | 0.078 |
| Food insecure (1 = yes, 0 = no) | 1.37 | 0.98 – 1.92 | 0.001 |
| Food insecure* RBC LC-PUFA | 0.842 | 0.721 – 0.984 | 0.030 |
| 40-49 | 50-69 | Total (40-69) | |
| Women invited | 56,888 | 63,552 | 120,440 |
| Observed one-year participation rate | 32.6% | 30.6% | 31.6% |
| Estimated one-year participation rate | 37.1% | 35.1% | 36.1% |
| Observed two-year participation rate | 55.1% | 50.3% | 52.5% |
| Estimated two-year participation rate | 59.6% | 54.8% | 57.0% |
| Inhibitors | Target | Anti‐CSC activity |
| Tenovin‐6 | SIRT1/2 | CML, AML |
| BDF4‐1, ‐2a, ‐2b, ‐2d | SIRT1/2 | Colon, glioblastoma |
| AGK2 | SIRT2 | Glioblastoma |
| Salermide | SIRT1/2 | Colorectal |
| Inhibitors | Target | Anticancer activity |
| Nicotinamide | SIRT1/2/3/5/6 | Leukemia, oral, prostate |
| Sirtinol | SIRT2 | Breast, lung, prostate, oral |
| Salermide | SIRT1/2 | Lung, breast, colon |
| JGB‐1741 | SIRT1 | Breast |
| Cambinol | SIRT1/2/5 | Burkitt lymphoma |
| EX527 | SIRT1 | Leukemia |
| AC‐93253 | SIRT1/2/3 | Prostate, pancreas, lung |
| Inauhzin | SIRT1 | Lung, colon |
| Tenovin‐1 | Unknown | Burkitt lymphoma, melanoma |
| H5N1 | H1N1 | H7N9 | |||||
| Residues | Avian | Human | Avian | Human | Avian | Human | |
| Then-2009/03 | 2009/04-Now | ||||||
| 470K | 2712 | 227 | 493 | 113 | 8127 | 98 | 494 |
| 470R | 0 | 0 | 1 | 1421 | 87 | 0 | 0 |
| Characteristics | Partial colectomy (N=9352) | Hemicolectomy (N=18758) | P | ||
| Gender | <0.001 | ||||
| Male | 3663 | 39.2% | 6749 | 36.0% | |
| Female | 5689 | 60.8% | 12009 | 64.0% | |
| Race | <0.001 | ||||
| Black | 544 | 5.8% | 1229 | 6.6% | |
| White | 7971 | 85.3% | 16458 | 87.7% | |
| Others | 837 | 8.9% | 1071 | 5.7% | |
| AJCC Stage | 0.002 | ||||
| Stage I | 2338 | 25.0% | 4327 | 23.1% | |
| Stage II | 4021 | 43.0% | 8275 | 44.1% | |
| Stage III | 2993 | 32.0% | 6156 | 32.8% | |
| AJCC T stage | <0.001 | ||||
| T1/T2 | 2641 | 28.2% | 4905 | 26.1% | |
| T3/T4 | 6711 | 71.8% | 13853 | 73.9% | |
| AJCC N stage | <0.001 | ||||
| N0 | 6359 | 68.0% | 12602 | 67.2% | |
| N1 | 2042 | 21.8% | 3902 | 20.8% | |
| N2 | 951 | 10.2% | 2254 | 12.0% | |
| Grade | <0.001 | ||||
| Grade I/II | 7514 | 80.3% | 13595 | 72.4% | |
| Grade III/IV | 1623 | 17.4% | 4739 | 25.3% | |
| Unknown | 215 | 2.3% | 424 | 2.3% | |
| Tumor location | <0.001 | ||||
| Right sided colon cancer | 4035 | 43.1% | 16619 | 88.6% | |
| Left sided colon cancer | 5317 | 56.9% | 2139 | 11.4% | |
| Histology | <0.001 | ||||
| Adenocarcinoma | 8386 | 89.7% | 15995 | 85.3% | |
| Mucous Tumor | 900 | 9.6% | 2571 | 13.7% | |
| Others | 66 | 0.7% | 192 | 1.0% | |
| Tumor size (cm) | <0.001 | ||||
| 0-5 | 5511 | 58.9% | 9850 | 52.5% | |
| ≥5 | 3841 | 41.1% | 8908 | 47.5% |
| Female: egg or central cell | Male: pollen or sperm | F1progeny | F1progeny | ||||||||
| CHX | CHX | CHX | Expect | Obs | |||||||
| 17 | 18 | 19 | 17 | 18 | 19 | 17 | 18 | 19 | (%) | (%) | |
| a | – | + | – | – | + | – | –/– | +/+ | –/– | 50 | 62 (95) |
| – | + | – | – | – | – | –/– | +/– | –/– | 50 | 3 (5) | |
| b | – | + | – | – | + | – | –/– | +/+ | –/– | 50 | 98 (70) |
| – | – | – | – | + | – | –/– | +/– | –/– | 50 | 41 (30) | |
| c | – | – | + | – | – | + | –/– | –/– | +/+ | 50 | 92 (97) |
| – | – | + | – | – | – | –/– | –/– | +/– | 50 | 3 (3) | |
| d | – | – | + | – | – | + | –/– | –/– | +/+ | 50 | 69 (75) |
| – | – | – | – | – | + | –/– | –/– | +/– | 50 | 23 (25) |
| Factor | MPT ≥9 s n (%) | MPT <9 s n (%) | Significance |
| Method of RLN reconstruction | |||
| Direct anastomosis | 33 (94.3) | 2 (5.7) | N.S. |
| Ansa cervicalis-RLN anastomosis | 152 (86.9) | 23 (13.1) | |
| Free nerve grafting | 12 (80.0) | 3 (20.0) | |
| VCP preoperatively | |||
| Yes | 92 (88.5) | 12 (11.5) | N.S. |
| No | 108 (87.5) | 16 (12.9) | |
| Site of distal anastomosis | |||
| Outside | 146 (87.4) | 21 (12.6) | N.S. |
| Inside | 54 (88.5) | 7 (11.5) |
| Groups | MAP (mmHg) | Herat rate (bpm) | LVSP (mmHg) | LVEDP (mmHg) | LV dP/dt/P (1/sec) |
| N = 6 | |||||
| Control | 107±6 | 255±5 | 125±7 | 6.3±1.1 | 64±2.3 |
| Sham | 106±6 | 249±10 | 117±4 | 5.6±0.9 | 60±1.4 |
| Isoproterenol (Iso) | 66±6b | 323±15a | 72±9c | 21±1.2c | 38±9.1b |
| O. basilicum (10 mg/kg) + Iso | 78±6 | 285±19 | 95±4 | 5.8±1.1*** | 69±4.5** |
| O. basilicum (20 mg/kg) + Iso | 90±11 | 294±21 | 109±10** | 9.0±3.4*** | 73±4.6*** |
| O. basilicum (40 mg/kg) + Iso | 113±4*** | 312±16 | 127±3*** | 6.6±1.5*** | 95±2.8*** |
| Movements from | Movements to | ||||||
| Na | Total | With haulier | %b | Total | With haulier | % | |
| Premises type | |||||||
| Small-pig producer | 1755 | 3888 | 108 | 3% | 1927 | 211 | 11% |
| Non-assured commercial producers | 285 | 6277 | 3550 | 57% | 1232 | 798 | 65% |
| QHA producers | 290 | 12237 | 9973 | 81% | 4019 | 3601 | 90% |
| Slaughterhouse | 29 | 2 | 0 | 0% | 14105 | 8448 | 60% |
| Market | 13 | 682 | 259 | 38% | 1858 | 892 | 48% |
| Showground | 8 | 20 | 0 | 0% | 22 | 0 | 0% |
| Ferry collection centres | 2 | 63 | 62 | 98% | 6 | 2 | 33% |
| Scottish Regions | |||||||
| Highlands and Islands | 677 | 2690 | 821 | 31% | 2058 | 274 | 13% |
| Mid Scotland and Fife | 185 | 1464 | 562 | 38% | 1311 | 166 | 13% |
| Scotland Central Belt | 229 | 1994 | 901 | 45% | 5134 | 3904 | 76% |
| South Scotland | 428 | 3538 | 1810 | 51% | 2337 | 841 | 36% |
| East Scotland | 514 | 12872 | 9618 | 75% | 8471 | 5639 | 67% |
| English Regions | |||||||
| Yorkshire and The Humber | 70 | 30 | 21 | 70% | 371 | 351 | 95% |
| North East England | 105 | 175 | 32 | 18% | 1501 | 1362 | 91% |
| North West England | 83 | 256 | 84 | 33% | 660 | 470 | 71% |
| West Midlands | 13 | 5 | 0 | 0% | 31 | 22 | 71% |
| East Midlands | 21 | 46 | 27 | 59% | 685 | 458 | 67% |
| East of England | 29 | 12 | 3 | 25% | 585 | 460 | 79% |
| South East England | 5 | 0 | 0 | 0% | 7 | 1 | 0% |
| South West England | 10 | 6 | 4 | 67% | 7 | 2 | 29% |
| Northern Ireland | - | 63 | 62 | 98% | 6 | 2 | 33% |
| Wales | 8 | 8 | 3 | 38% | 4 | 0 | 0% |
| Other countries | - | 10 | 4 | 40% | 1 | 0 | 0% |
| Strains | No. of plants inoculated | Infection rate (%) | Wilt indexa |
| Fusarium solani CFD-1 | 160 | 96.3 | 3.6 |
| Fusarium oxysporum CFD-1 | 144 | 97.9 | 3.7 |
| Covariate | Multivariate analysis hazard ratio | p value |
| Sex, male versus female | 0.87 (0.23–3.29) | 0.837 |
| Age at revision | 1.02 (0.96–1.08) | 0.497 |
| Body mass index | 1.05 (0.93–1.18) | 0.461 |
| Revision indication | ||
| Pseudotumor versus | 1.00 | Baseline |
| Fracture | 0.21 (0.31-1.40) | 0.106 |
| Other | 0.31 (0.49–1.90) | 0.203 |
| Type of revision | ||
| Femoral only with metal-on-metal bearing versus all component revision with nonmetal-on-metal bearing | 5.65 (1.08–29.4) | 0.040 |
| Variable | Sulpiride | Placebo | p-value |
| Mean (SD) | Mean (SD) | ||
| Participant characteristics | |||
| Age (years) | 24.58 (4.19) | 23.92 (4.70) | 0.717 |
| Body mass index (kg/m2) | 24.56 (1.45) | 24.32 (3.57) | 0.832 |
| Education (years) | 15.92 (1.45) | 14.92 (2.78) | 0.289 |
| Raven’s matrices (percentile) | 88.00 (16.69) | 86.08 (15.68) | 0.774 |
| Total (N = 2,716) | CDSMP non-completion (N = 557) | CDSMP completion (N = 2,159) | ||
| N (%) | N (%) | N (%) | P-value* | |
| Female | 1,985 (73.1) | 397 (71.3) | 1, 588 (73.6) | 0.280 |
| Living alone | 68 (2.5) | 19 (3.4) | 49 (2.3) | 0.124 |
| Rural–urban commuting area codes | 0.009 | |||
| Metro | 2,479 (91.3) | 524 (94.1) | 1, 955 (90.6) | |
| Non-metro | 237 (8.7) | 33 (5.9) | 204 (9.5) | |
| Workshop delivery site | 0.010 | |||
| Other | 341 (12.6) | 77 (13.8) | 264 (12.2) | |
| Area agency on aging/senior centers | 741 (27.3) | 123 (22.1) | 618 (28.6) | |
| Health care organization | 379 (14.0) | 77 (13.8) | 302 (14.0) | |
| Residential facilities | 431 (15.9) | 111 (19.9) | 320 (14.8) | |
| Community/multi-purpose | 720 (26.5) | 148 (26.6) | 572 (26.5) | |
| Faith-based organization | 104 (3.8) | 21 (3.8) | 83 (3.8) | |
| Mean (±SD) | Mean (±SD) | Mean (±SD) | P-valuea | |
| Age in years (from 50 to 101) | 71.3 (±9.2) | 71.2 (±9.5) | 71.4 (± 9.2) | 0.670 |
| Neighborhood median income in $10,000 unit (from 2.2 to 11.6) | 6.2 (±1.4) | 6.2 (±1.5) | 6.2 (± 1.3) | 0.466 |
| Number of chronic conditions (from 0 to 10) | 2.0 (±1.5) | 1.9 (±1.4) | 2.1 (± 1.5) | 0.009 |
| % Of Asian-Americans in the workshop | 57.5 (±36.8) | 53.2 (±36.7) | 58.6 (± 36.7) | 0.002 |
| Workshop completion rate (%) | 74.9 (±18.7) | 66.4 (±18.7) | 77.1 (± 18.0) | <0.001 |
| Renal failure (n = 30) | Matched controls (n = 30) | p-Value | |
| Liver SUVmax | 2.90 (1.60–3.90) | 2.60 (1.80–3.90) | 0.62 |
| Psoas muscle SUVmax | 1.30 (1.10–2.50) | 1.35 (0.90–2.80) | 0.57 |
| Control Group Individuals (n = 32) | Intervention Group Individuals (n = 37) | Unadjustedsignificance | Adjusted for highest qualification at baseline | |||||
| Individual Domain | Mean baseline | Mean follow-up | Mean baseline | Meanfollow-up | Coefficient | P value | Coefficient | P value |
| i) Finding relevant literature | 6.42 | 6.89 | 6.00 | 7.59 | 0.72 | 0.16 | 0.87 | 0.10 |
| ii) Critically reviewing the literature | 6.03 | 6.72 | 5.78 | 6.69 | -0.33 | 0.95 | 0.25 | 0.61 |
| iii) Using a computer referencing system (eg Endnote) | 4.52 | 5.22 | 3.47 | 4.71 | 0.59 | 0.38 | 0.54 | 0.43 |
| iv) Writing a research protocol | 4.06 | 4.39 | 3.67 | 5.69 | 1.42 | < 0.05* | 1.76 | < 0.05* |
| v) Securing research funding | 2.90 | 3.29 | 2.75 | 4.70 | 1.53 | < 0.05* | 1.46 | < 0.05* |
| vi) Submitting an ethics application | 3.48 | 3.47 | 3.58 | 6.10 | 2.38 | < 0.001** | 2.37 | < 0.001** |
| vii) Designing questionnaires | 5.00 | 5.67 | 4.39 | 5.96 | 0.61 | 0.38 | 0.86 | 0.23 |
| viii) Collecting data e.g. surveys, interviews | 5.58 | 6.72 | 5.53 | 7.00 | 0.22 | 0.76 | 0.42 | 0.57 |
| ix) Using computer data management systems | 4.16 | 5.22 | 3.71 | 4.68 | -0.39 | 0.93 | 0.11 | 0.81 |
| x) Analysing qualitative research data | 4.39 | 5.47 | 2.97 | 5.10 | 1.14 | < 0.1† | 1.27 | < 0.05* |
| xi) Analysing quantitative research data | 3.94 | 5.17 | 3.67 | 4.39 | -0.54 | 0.38 | -0.40 | 0.53 |
| xii) Writing a research report | 4.45 | 4.39 | 4.00 | 5.18 | 0.96 | < 0.1† | 1.28 | < 0.05* |
| xiii) Writing for publication in peer-reviewed journals | 3.81 | 4.00 | 3.14 | 4.80 | 1.15 | < .0.05* | 1.04 | < 0.1† |
| xiv) Integrating research findings into practice | 6.34 | 7.11 | 6.28 | 6.76 | -0.27 | 0.67 | -0.18 | 0.79 |
| xv) Providing advice to less experienced researchers | 6.67 | 3.76 | 3.00 | 4.93 | 1.22 | < 0.05* | 1.23 | < 0.05* |
| Total score | 4.65 | 5.19 | 4.13 | 5.63 | 0.98 | < 0.05* | 1.11 | < 0.05* |
| Frequency | Detected rate (n (%)) | Amplitude (dB SPL) | S/N (dB) | ||||||
| TTH | Control | P-value | TTH | Control | P-value | TTH | Control | P-value | |
| Overall echo level | 45 (97.8) | 51 (98.1) | 0.930 | 12.7 ± 4.1 | 12.5 ± 3.5 | 0.796 | 16.6 ± 4.6 | 14.9 ± 4.9 | 0.059 |
| 0.5-1 kHz | 45 (97.8) | 51 (98.1) | 0.930 | 11.2 ± 4.3 | 10.4 ± 3.7 | 0.339 | 17.2 ± 5.8 | 14.5 ± 5.1 | 0.015 |
| 1-2 kHz | 46 (100) | 52 (100) | - | 5.3 ± 5.9 | 7.0 ± 4.8 | 0.135 | 16.9 ± 5.7 | 17.2 ± 5.3 | 0.792 |
| 2-4 kHz | 17 (37.0) | 15 (28.8) | 0.393 | −9.5 ± 4.6 | −10.1 ± 3.3 | 0.437 | 3.1 ± 5.0 | 2.7 ± 3.7 | 0.621 |
| Non-diabetes HbA1c <5.7%n = 380 | Pre-diabetes HbA1c ≥5.7%n = 259 | Diabetesan = 84 | Pb | |
| Total FAs (mg/L) | 3,790 (3,680 to 3,900)c | 3,680 (3,560 to 3,810) | 4,050 (3,820 to 4,300) | 0.02 |
| Saturated FAs | 33.2 (32.9 to 33.4) | 33.2 (32.9 to 33.5) | 34.0 (33.5 to 34.5) | 0.01 |
| Monounsaturated FAs | 22.9 (22.5 to 23.2) | 23.2 (22.7 to 23.6) | 24.0 (23.2 to 24.8) | 0.03 |
| n-6 PUFAs | 35.0 (34.4 to 35.5) | 34.5 (33.9 to 35.2) | 32.8 (31.8 to 33.9) | 0.002 |
| n-3 PUFAs | 7.2 (7.0 to 7.5) | 7.4 (7.1 to 7.8) | 7.2 (6.6 to 7.8) | 0.61 |
| α-Linolenic acid | 0.71 (0.69 to 0.73) | 0.73 (0.70 to 0.75) | 0.72 (0.68 to 0.77) | 0.38 |
| Eicosapentaenoic acid | 1.80 (1.68 to 1.92) | 1.91 (1.76 to 2.07) | 1.78 (1.54 to 2.05) | 0.49 |
| Docosapentaenoic acid (n-3) | 0.62 (0.60 to 0.63) | 0.63 (0.61 to 0.65) | 0.62 (0.58 to 0.65) | 0.55 |
| Docosahexaenoic acid | 3.69 (3.56 to 3.82) | 3.73 (3.58 to 3.90) | 3.63 (3.37 to 3.91) | 0.79 |
| n-3 PUFA / n-6 PUFA ratio | 0.21 (0.20 to 0.22) | 0.22 (0.20 to 0.23) | 0.22 (0.20 to 0.24) | 0.41 |
| Characteristics | Number (n) | *Percent (%) |
| Age group of women (years) | ||
| 15-19 | 1933 | 17.5 |
| 20-29 | 6770 | 61.3 |
| 30-49 | 2336 | 21.2 |
| Missing | [141] | |
| Parity | ||
| 0 | 3811 | 35.7 |
| 1 | 2155 | 20.2 |
| 2-4 | 3210 | 30.1 |
| ≥5 | 1492 | 14.0 |
| Missing | [512] | |
| Singleton/Multiple | ||
| Singleton | 9696 | 95.6 |
| Multiple | 451 | 4.4 |
| Missing | [1033] | |
| Occupation of mother | ||
| Salaried employee/business | 1062 | 20.6 |
| Subsistence farmer | 1215 | 23.5 |
| Housewife | 2886 | 55.9 |
| Missing | [6017] | |
| Mbarara | 3916 | 35.0 |
| Bushenyi | 3510 | 31.4 |
| Ibanda | 1045 | 9.3 |
| Isingiro | 936 | 8.4 |
| Kiruhura | 905 | 8.1 |
| Other districts | 868 | 7.8 |
| Name of health facility attended | ||
| Comboni hospital | 636 | 5.7 |
| Ibanda hospital | 1803 | 16.1 |
| Ishaka Adventist hospital | 1435 | 12.8 |
| Kitagata hospital | 1098 | 9.8 |
| Mbarara regional referral hospital | 5731 | 51.3 |
| Rushere Community hospital | 477 | 4.3 |
| Structured Care (31) | Care-As-Usual (11) | P -value | |
| Yearly check performed by (%) | |||
| General practitioner | 29.0 | 36.4 | 0.65 |
| Practice nurse | 51.6 | 63.6 | 0.49 |
| Practice assistant | 6.5 | 0 | 0.39 |
| Diabetes specialist nurse | 3.2 | 0 | 0.55 |
| GP with PN/PA | 9.7 | 0 | 0.28 |
| Tri-monthly checks performed by (%) | |||
| General practitioner | 16.1 | 9.1 | 0.57 |
| Practice nurse | 61.6 | 63.6 | 0.89 |
| Practice assistant | 22.6 | 27.3 | 0.75 |
| Insulin treatments provided by (%) | |||
| Internist | 6.5** | 63.6** | <0.001 |
| General practitioner | 61.3 | 36.4 | 0.15 |
| Practice nurse | 16.1 | 18.2 | 0.88 |
| Diabetes specialist nurse | 67.7** | 18.2** | 0.005 |
| Consultation between healthcare professionals (%) | |||
| General practitioner | 100* | 80.0* | 0.02 |
| Practice nurse | 71.4 | 70.0 | 0.93 |
| Practice assistant | 46.4 | 40.0 | 0.73 |
| Diabetes specialist nurse | 78.6** | 30.0** | 0.005 |
| Dietician | 50.0* | 10.0* | 0.03 |
| Estimated percentage of patients that received education | |||
| Diet % (sd) | 86.7 (17.9) | 83.5 (28.7) | 0.91 |
| Exercise % (sd) | 89.6 (16.0) | 76.0 (29.5) | 0.17 |
| Smoking behavior % (sd) | 90.0 (11.4) | 73.3 (44.2) | 0.17 |
| Foot examination % (sd) | 89.3 (17.0) | 69.5 (38.3) | 0.14 |
| Education on diet, exercise, foot examination or smoking behavior. | |||
| by DSN (%) | 35.0* | 0.0* | 0.04 |
| by GP (%) | 61.3 | 81.8 | 0.24 |
| by PN/PA (%) | 87.1 | 90.0 | 0.74 |
| Diabetes passport, often or always used in practice (%) | 78.6* | 40.0* | 0.05 |
| Plant part | Use | Use form | Percentage of users | Management |
| Stem | Mescal production | Whole stems are backed inside an earthen pit, grounded, fermented and distilled | 100 | Extraction of whole individuals from wild populations |
| Flower buds | Food | Flowering buds are boiled or roasted, coocked with eggs or hot chilli sauce | 66 | People extract the whole scape, to get the flowering buds |
| Floral scape | Roasted over the fire while working in the field | 33 | Extract the young whole floral scape | |
| Leaf bases | Food | People ask for the backed leave bases to the mescal producer and eat them as candy | 30 | Leave bases remaining from mescal production |
| Medicine | An infusion of cooked agave leaf for lung affections | 10 | ||
| Applying a piece of fresh leaf (or roasted) directly to wounded area | 33 | Eventually cutting up one leaf | ||
| Floral escape | Fodder | Cattle eat the growing scape | 40 | Cattle eat the early floral scape while it is starting to grow |
| Construction | Used in small fences | 16 | Extract the whole floral scape | |
| Whole plant | Religious | Agaves are transplanted from the wild to “little mountains” (montecitos) dedicated to the GuadalupeVirgin | 10 | Each year in December small agave individuals are transplanted from wild populations to home gardens |
| Uses of Mescal | As medicine | A small glass of mezcal aliviate the stomach-ache, flu symptoms, fever and cold- weat | 30 | (produced from agave stems) |
| Ritual | A small glass of mezcal is offered to the death in the “ofrendas de muertos” | 80 |
| Items | Growth rate | ERR % | Weight of single cocoon, g | Weight of single shell, g | Shell ratio, % |
| DPPH | −0.366 | −0.494 | −0.737 | −0.830* | −0.798 |
| ABTS | −0.271 | −0.057 | −0.138 | −0.719 | −0.786 |
| Nitric oxide | −0.358 | −0.717 | −0.864* | −0.322 | −0.158 |
| Superoxide | −0.847* | −0.975** | −0.794 | −0.704 | −0.613 |
| Reducing Power | 0.927** | 0.817* | 0.679 | 0.899* | 0.835* |
| Author | Mean (m) or median (M) follow-up (mo) | PSM | Local or distant recurrence |
| Rogers [9] | 15.7 (m) | 0 | No |
| Dogra [10] | 29.4 (m) | 0 | No |
| Nazemi [15] | 4 (M) | 0 | No |
| Hemal [17] | 8.3 (m) | NR | No |
| Abaza [12] | 15.4 (m) | 0 | No |
| Klingler [3] | NR | 0 | NR |
| Lorenzo [13] | 12 (M) | 0 | No |
| White [14] | 10.5 (m) | NR | NR |
| Boger [16] | NR | NR | NR |
| Rogers [11] | NR | NR | NR |
| Localisation | Gland | Type |
| Lips | Upper lip | Serous |
| Lower lip | Serous | |
| Cheek | Buccal mucosa | Mixed (predominantly mucous) |
| Parotid | Serous | |
| Hard palate | Postero-lateral hard palate | Mucous |
| Tongue | Von Ebner (dorsal) | Serous |
| Weber Blandin Nuhn (marginal) | Mixed (predominantly mucous) | |
| Floor of mouth | Submandibular | Mixed (predominantly serous) |
| Sublingual | Mixed (predominantly mucous) |
| Cell source | No. of slices | Total number of counted cells | Regional distribution of counted cells | |||||||
| U | M | L | CP | IZ | Medial | Middle | Lateral | |||
| GE | 11 | 23556 | 8632 | 7219 | 4804 | 20655 | 2901 | 6522 | 8475 | 8559 |
| cortical | 11 | 21657 | 4911 | 5342 | 5555 | 15808 | 5849 | 5863 | 7546 | 8248 |
| Mixed | 10 | 20386 | 7430 | 6055 | 4344 | 17829 | 2557 | 5261 | 6814 | 8311 |
| MRI finding | PCNSL | GBM | p-value | |
| Localization | only supratentorial | 66.7% | 98.1% | <0.001 |
| only infratentorial | 5.5% | 1.9% | 0.308 | |
| supra- and infratentorial | 27.7% | 0% | <0.001 | |
| Type of lesions | solitary demarcated lesion | 3.7% | 13% | 0.046 |
| solitary infiltrative type | 20.4% | 51.9% | 0.121 | |
| multiple infiltrative lesions | 51.9% | 35.2% | 0.081 | |
| diffuse infiltrative type | 24.1% | 0% | <0.001 | |
| Type of enhancement | homogeneous | 64.8% | 0% | <0.001 |
| nonhomogeneous | 14.8% | 98.1% | <0.001 | |
| diffuse infiltrative – worm-like, patchy, stripy... | 20.4% | 0% | <0.001 | |
| presence of necrosis | 5.6% | 88.9% | <0.001 | |
| Involvement of brain surface | without reaching brain surface | 12.9% | 11.1% | 0.567 |
| reaching brain surface | 87% | 88.9% | 0.846 | |
| meningeal infiltration | 35.2% | 46.3% | 0.240 | |
| ependymal infiltration | 53.7% | 37% | 0.054 | |
| Optic nerves, chiasma or tracts involvement | 42.6% | 5.6% | <0.001 | |
| Cranial nerves involvement (optical nerves and tracts excluded) | 5.6% | 0% | 0.079 | |
| Corpus callosum infiltration | 42.6% | 44.4% | 0.846 | |
| Butterfly pattern | 24.1% | 14.8% | 0.224 | |
| Basal ganglia involvement | 55.6% | 18.5% | <0.001 | |
| Cerebral cortex involvement | 83.3% | 51.9% | <0.001 | |
| aDWI | free diffusion | 1.9% | 10.4% | 0.189 |
| restricted diffusion in some part of the solid | 97% | 89.6% | 0.189 | |
| Signs of bleeding | 5.6% | 44.4% | <0.001 | |
| Presence of vasogenic edema | 92.6% | 83.3% | 0.139 |
| Sequencing results | Number of total raw reads | 60,866,926 |
| Number of total clean reads | 51,606,364 | |
| Number of total clean nucleotides (nt) | 4,644,572,760 | |
| Q20 percentage of total clean reads | 95.92% | |
| GC percentage of total clean nucleotides | 51.26% | |
| N percentage of total clean nucleotides | 0.00% | |
| Assembling results | Number of unigenes | 38,504 (5,372 into distinct clusters; 33,132 singletons) |
| Total length (nt) of total unigenes | 21,977,286 | |
| Mean length (nt) of total unigenes | 571 | |
| N50 (nt) of total unigenes | 711 | |
| Annotation | Unigenes with Nr database | 25,456 (66% of 38,504 unigenes) |
| (E-value < =1e-5) | Unigenes with Nt database | 20,554 (53%) |
| Unigenes with Swiss-Prot database | 17,651 (46%) | |
| Unigenes with KEGG database | 16,622 (43%), 257 pathways | |
| Unigenes with COG database | 7,204 (19%), 25 functional categories | |
| Unigenes with GO database | 16,588 (43%), 62 subcategories grouped to 3 main categories | |
| Biological process | 27 sub-categories | |
| Cellular component | 17 sub-categories | |
| Molecular function | 18 sub-categories | |
| Total unigenes annotated | 26,650 (69% of 38,504 unigenes) |
| \"gold standard\" = result of sentinel node biopsy | ||||
| occult metastatic disease: Yes | occult metastatic disease: No | |||
| new predictive marker for occult metastatic disease (ECAD) | Low ECAD | true positive | false positive | all test positives |
| expression | a | b | a + b | |
| High ECAD | c | d | all test | |
| expression | false negative | true negative | negatives | |
| c + d | ||||
| a + c | b + d | |||
| all with occult | all without occult | |||
| disease | disease |
| Variable | CH group | CR group | |
| (N = 313) | (N = 313) | ||
| Gender, n (%) | Male | 167 (53.4) | 170 (54.3) |
| Female | 146 (46.6) | 143 (45.7) | |
| Age [years], mean (SD) | 50.8 (14.6) | 48.8 (14.0) | |
| Weight [kg], mean (SD) | 81.8 (16.4) | 83.4 (17.4) | |
| BMI [kg/m2], mean (SD) | 28.0 (5.1) | 28.6 (5.7) | |
| Race, n (%) | Asian | 14 (4.5) | 7 (2.2) |
| Black | 13 (4.2) | 17 (5.4) | |
| White | 246 (78.6) | 253 (80.8) | |
| Other | 40 (12.8) | 36 (11.5) | |
| GI comorbidities, n (%) | Dyspepsia-like | 204 (65.2) | 201 (64.2) |
| IBS-like | 44 (14.1) | 41 (13.1) | |
| Current smoker, n (%) | 79 (25.2) | 83 (26.5) | |
| ReQuestTM total score | 10.23 | 11.37 | |
| GERDyzerTM sum score | 46.12 | 49.45 |
| Gases | Training Set | Unlabeled Set | Test Set |
| Carbon monoxide | 116 | 116 | 116 |
| Toluene | 132 | 132 | 132 |
| Formaldehyde | 253 | 253 | 253 |
| All-3 | 501 | 501 | 501 |
| Boys | |||||
| Overall | Children | Adolescents | Normalweight | Overweight | |
| Chocolate and snacks | 23.2 | 20.5 | 25.3 | 22.5 | 25.1 |
| Biscuits and ice creams | 18.5 | 19.2 | 18.0 | 18.4 | 18.8 |
| Fat Meat | 10.9 | 13.3 | 9.1 | 11.5 | 9.3 |
| Filled cakes and sweets | 8.0 | 6.7 | 8.9 | 8.3 | 6.9 |
| Fried potatoes | 7.5 | 6.6 | 8.2 | 8.1 | 5.4 |
| Oils and condiments | 5.6 | 3.7 | 7.1 | 5.1 | 7.2 |
| Lean meet | 5.1 | 7.1 | 3.6 | 5.4 | 4.2 |
| Cold cuts | 4.9 | 4.9 | 4.9 | 5.4 | 3.3 |
| Bread and pasta | 4.4 | 4.4 | 4.5 | 3.8 | 6.3 |
| Pizza | 4.1 | 4.9 | 3.4 | 4.0 | 4.2 |
| Juices and drinks | 2.4 | 2.4 | 2.4 | 2.3 | 2.7 |
| Dairy products | 1.5 | 0.8 | 2.0 | 1.4 | 1.8 |
| Vegetables | 1.3 | 2.4 | 0.5 | 1.3 | 1.5 |
| Non-sweet fruits and cereals | 1.0 | 1.8 | 0.3 | 0.7 | 1.8 |
| Eggs | 0.7 | 0.5 | 0.9 | 0.7 | 0.9 |
| Fried fish | 0.6 | 0.5 | 0.7 | 0.6 | 0.6 |
| Fish | 0.3 | 0.5 | 0.1 | 0.4 | 0.0 |
| Sweet fruit | 0.1 | 0.0 | 0.3 | 0.1 | 0.3 |
| Girls | |||||
| Overall | Children | Adolescents | Normalweight | Overweight | |
| Chocolate and snacks | 26.5 | 25.6 | 27.2 | 27.2 | 22.4 |
| Biscuits and ice creams | 16.3 | 17.0 | 15.7 | 15.7 | 19.5 |
| Bread and pasta | 9.2 | 9.8 | 8.8 | 8.2 | 15.1 |
| Oils and condiments | 8.0 | 4.5 | 10.8 | 7.9 | 8.3 |
| Fried potatoes | 7.6 | 6.9 | 8.1 | 7.9 | 5.4 |
| Filled cakes and sweets | 7.0 | 6.7 | 7.2 | 7.4 | 4.4 |
| Fat Meat | 5.4 | 4.8 | 5.9 | 5.6 | 4.4 |
| Cold cuts | 5.3 | 5.3 | 5.4 | 5.2 | 5.9 |
| Lean meet | 4.2 | 6.1 | 2.7 | 4.3 | 3.9 |
| Juices and drinks | 2.5 | 3.0 | 2.1 | 2.3 | 3.9 |
| Pizza | 2.5 | 3.5 | 1.7 | 2.4 | 2.9 |
| Dairy products | 1.8 | 1.6 | 2.0 | 1.9 | 1.5 |
| Non-sweet fruits and cereals | 1.0 | 1.4 | 0.7 | 1.1 | 0.5 |
| Vegetables | 0.9 | 1.6 | 0.4 | 1.0 | 0.5 |
| Sweet fruit | 0.6 | 1.1 | 0.3 | 0.7 | 0.5 |
| Eggs | 0.5 | 0.6 | 0.4 | 0.4 | 1.0 |
| Fish | 0.4 | 0.3 | 0.4 | 0.4 | 0.0 |
| Fried fish | 0.3 | 0.2 | 0.4 | 0.3 | 0.0 |
| Characteristics | Patients (n=62) | EGFR overexpression (n=51) | EGFR FISH (n=22) | ||
| No. (%) | No./Subgroup (%) | P value | No./Subgroup (%) | P value | |
| Age (year) | |||||
| <=65 | 47 (75.8) | 36/47 (76.6) | 0.052b | 17/47 (36.2) | 0.842 |
| >65 | 15 (24.2) | 15/15 (100.0) | 5/15 (33.3) | ||
| Gender | |||||
| Male | 50 (80.6) | 39/50 (78.0) | 0.102b | 18/50 (36.0) | 1.000b |
| Female | 12 (19.4) | 12/12 (100.0) | 4/12 (33.3) | ||
| Performance status | |||||
| 0-1 | 59 (95.2) | 48/59 (81.4) | 1.000b | 22/59 (37.3) | 0.546b |
| 2 | 3 (4.8) | 3/3 (100.0) | 0/3 (0.0) | ||
| Smoking | |||||
| Never | 23 (37.1) | 22/23 (95.7) | 0.042b | 8/23 (34.8) | 0.929 |
| Ever | 39 (62.9) | 29/39 (74.4) | 14/39 (35.9) | ||
| Histologic grade | |||||
| G1 | 6 (9.7) | 5/6 (83.3) | 0.305b | 3/6 (50.0) | 0.004b |
| G2 | 17 (27.4) | 12/17 (70.6) | 11/17 (64.7) | ||
| G3 | 39 (62.9) | 34/39 (87.2) | 8/39 (20.5) | ||
| No. of previous chemotherapy | |||||
| None or 1 | 43 (69.4) | 41/43 (95.3) | <0.001b | 15/43 (34.9) | 0.882 |
| 2 or more | 19 (30.6) | 10/19 (52.6) | 7/19 (36.8) | ||
| Disease extent | |||||
| Locally advanced | 6 (9.7) | 3/6 (50.0) | 0.063b | 2/6 (33.3) | 1.000b |
| Metastatic | 56 (90.3) | 48/56(85.7) | 20/56 (35.7) |
| Clinical features | Mean ± SD, n (%) |
| Age | 66.5 ± 8.0 |
| Weight | 73.2 ± 8.5 |
| Body mass index | 27.8 ± 2.6 |
| Gender | |
| Male | 12 (60) |
| Female | 8 (40) |
| Smoking | 9 (45) |
| Diseases | |
| Hypertension | 17 (85) |
| Heart failure | 3 (15) |
| Diabetes | 10 (50) |
| Medication | |
| Organic nitrates | 0 (0) |
| Aspirin | 20 (100) |
| Beta-blockers | 14 (70) |
| Angiotensin inhibitors | 9 (45) |
| Calcium channel blockers | 5 (25) |
| Hypolipidaemics | 13 (65) |
| Cell type | Action | References |
| Langerhans cells | Activate and proliferate Treg cells in resting state; limit activation of Treg cells in presence of pathogen | [116] |
| Induce Treg cells favoring flora tolerance with limited antigens presentation | [117] | |
| Induce Treg cells by secretion of IL-10 and TGF-β | [118] | |
| Memory Treg cells | Localize to hair folliclesNon-migratory and non-responsive in normal skinProliferate and produce IL-17 in inflamed skin | [119] |
| Are activated, proliferated and differentiated into potent suppressorAttenuate autoimmune reactions in tissues upon repeated responses to antigens | [120] | |
| Macrophages | Promote expression of the chemokine CCL22Induce migration and activation of Treg cells | [121] |
| Express M2-like TIM-4hiCD169+Act immunoregulatory function and promote engraftment of cardiac allografts | [122] | |
| Mast cells | Act as intermediate at Treg cells dependent allograft tolerance via IL-9 | [123] |
| Counteract Treg cell function through IL-6 and OX40/OX40L axis toward Th17 cell differentiation | [124] | |
| Dermal dendritic cells | Are capable of antigen capture and presentation to CD4+ T cells and Treg cells generation | [125] |
| Dermal regulatory cells | Induce Treg cells through PD-1 engagement with expression of ABCB5+ molecules | [126] |
| Dermal fibroblasts | Induce proliferation of natural Treg cells with IL-15 | [127] |
| Dermal stromal cells | Express CD90+ and induce Tregs cells | [128] |
| Variable | Training group (n = 77) | Validation group (n = 119) | ||||||||||||||
| Low Risk | High Risk | Unadjusted | Adjusted# | Low Risk | High Risk | Unadjusted | Adjusted# | |||||||||
| R | N | R | N | HR (95% CI) | P | HR (95% CI) | P | R | N | R | N | HR (95% CI) | P | HR (95% CI) | P | |
| ACSL1 | 10 | 51 | 12 | 26 | 2.93 (1.26–6.81) | 0.013 | 2.34 (0.91–6.02) | 0.082 | 5 | 61 | 13 | 58 | 3.12 (1.11–8.76) | 0.021 | 3.86 (1.16–12.79) | 0.017 |
| ACSL4 | 9 | 54 | 13 | 23 | 4.92 (2.09–11.62) | 0 | 5.6 (2.19–14.32) | 0 | 8 | 78 | 10 | 41 | 2.59 (1.02–6.57) | 0.045 | 2.31 (0.85–6.27) | 0.1 |
| SCD | 3 | 26 | 19 | 51 | 3.57 (1.06–12.08) | 0.018 | 3.13 (0.9–10.93) | 0.046 | 3 | 57 | 15 | 62 | 5.32 (1.54–18.38) | 0.002 | 4.08 (1.12–14.9) | 0.017 |
| x3 | 6 | 46 | 16 | 31 | 5.36 (2.09–13.74) | 0.000 | 4.99 (1.81–13.77) | 0.001 | 2 | 58 | 16 | 61 | 9 (2.07–39.21) | 0.0002 | 8.68 (1.9–39.66) | 6E-04 |
| t-statistic and p-values for correlation significance | ||
| t-statistics | ||
| Sig | NN | |
| Sig | ||
| NN | 2.917 | |
| NNSig | 2.969 | 0.052 |
| p-values | ||
| Sig | NN | |
| Sig | ||
| NN | 0.998 | |
| NNSig | 0.998 | 0.521 |
| WTP | (% N) |
| 0 | 40.5% |
| < € 15,000 | 9.7% |
| = € 15,000 | 18.8% |
| > € 15,000 | 16.9% |
| > € 30,000 | 14.1% |
| Mean | € 13,764 |
| Standard deviation | € 21,719 |
| 95% CI | €11,863 – €15,665 |
| Minimum | 0 |
| Maximum | € 100,000 |
| Percentiles | |
| 25 | 0 |
| 50 | € 10,000 |
| 75 | € 20,000 |
| Age, sex, and education | Dhaka (urban) | Matlab (rural) | ||||
| COPD | Hypertension | Comorbidity | COPD | Hypertension | Comorbidity | |
| Age | 54.4 ± 15.1 | 55.5 ± 13.7 | 63.2 ± 10.2 | 63.6 ± 13.5 | 62.3 ± 11.9 | 68.9 ± 10.8 |
| Mean ± std | ||||||
| Median | 54.6 | 56.3 | 62.5 | 64.4 | 62.8 | 69.6 |
| % of female patients | 25.0 | 53.3 | 32.1 | 24.7 | 57.9 | 32.4 |
| Level of education | ||||||
| % of none | 46.2 | 22.0 | 35.8 | 43.5 | 29.3 | 41.9 |
| % of primary (class I-V) | 25.5 | 26.0 | 34.0 | 37.3 | 40.7 | 32.4 |
| % of secondary + (class VI+) | 28.2 | 52.0 | 30.2 | 19.2 | 30.0 | 25.7 |
| No. of patients (N) | 184 | 246 | 53 | 292 | 140 | 74 |
| Generated Commands | Description |
| Start | SLAM and control algorithms begin |
| Stop | Stops robot's movements but the SLAM algorithm continues |
| Turn to the left | Sustained command to make the robot turning to user's left |
| Turn to the right | Sustained command to make the robot turning to user's right |
| Exit | SLAM stops and a map is visualized |
| Variable | Odds ratio (95% CI), P Value | |
| Before accounting for confounding by indicationa | After accounting for confounding by indication | |
| Methicillin-sensitive S. aureus carrier | 0.5 (0.3, 1.0), 0.03 | 0.4 (0.2, 0.8), 0.01 |
| Intubation | 4.7 (1.8, 12.3), 0.002 | 5.3 (2.0, 14.4), 0.001 |
| Fluoroquinolone | 1.9 (1.2, 3.0), 0.01 | - |
| Aminoglycoside | - | 0.3 (0.1, 0.7), 0.003 |
| Days from ICU admission to negative swab | < .0001 | < .0001 |
| 1 | 1.0, reference | 1.0, reference |
| 2 | 2.0 (1.2, 3.3) | 2.2 (1.3, 3.7) |
| ≥ 3 | 15.6 (8.4, 29.0) | 19.6 (10.4, 37.1) |
| Chronic liver disease | - | 4.1 (1.2, 13.6), 0.02 |
| Everolimus 1.5 mg (n = 61) | MMF 2 g (n = 61) | |
| Recipient characteristics | ||
| Age (years) | ||
| Mean ± standard deviation | 42.5 ± 14.13 | 38.6 ± 11.36 |
| Median (range) | 42.0 (18 to 65) | 36.0 (20 to 64) |
| Gender, n (%) | ||
| Male | 46 (75.4) | 37 (60.7) |
| Female | 15 (24.6) | 24 (39.3) |
| Body mass index (kg/m2) | ||
| Mean ± standard deviation | 22.46 ± 4.03 | 21.79 ± 2.78 |
| Median (range) | 21.97 (15.5 to 37.5) | 21.09 (16.0 to 27.6) |
| Primary disease leading to transplantation, n (%) | ||
| Glomerulonephritis/glomerular disease | 16 (26.2) | 9 (14.8) |
| Polycystic disease | 3 (4.9) | 3 (4.9) |
| Hypertension/nephrosclerosis | 5 (8.2) | 2 (3.3) |
| Diabetes mellitus | 3 (4.9) | 5 (8.2) |
| Interstitial nephritis | 2 (3.3) | 0 (0.0) |
| Obstructive disorder/reflux | 6 (9.8) | 3 (4.9) |
| IgA nephropathy | 11 (18.0) | 16 (26.2) |
| Unknown | 8 (13.1) | 16 (26.2) |
| Other | 7 (11.5) | 7 (11.5) |
| Current dialysis | ||
| None | 12 (19.7) | 8 (13.1) |
| Hemodialysis | 42 (68.9) | 48 (78.7) |
| Peritoneal dialysis | 7 (11.5) | 5 (8.2) |
| HLA mismatches | ||
| 1 | 7 (11.5) | 2 (3.3) |
| 2 | 9 (14.8) | 16 (26.2) |
| 3 | 25 (41.0) | 24 (39.3) |
| <3 | 16 (26.2) | 18 (29.5) |
| ≥3 | 45 (73.8) | 43 (70.5) |
| Donor characteristics | ||
| Mean ± standard deviation age (years) | 52.3 ± 8.99 | 55.2 ± 8.23 |
| Deceased heart beating, n (%) | 1 (1.6) | 0 (0.0) |
| Deceased nonheart beating, n (%) | 0 (0.0) | 1 (1.6) |
| Living related, n (%) | 36 (59.0) | 43 (70.5) |
| Living unrelated, n (%) | 24 (39.3) | 17 (27.9) |
| Shape | S-12 | S-11 | S-10 | S-9 | S-8 | S-7 | S-6 | S-5 | S-4 | S-3 | S-2 | S-1 | S-0 |
| Asymmetry_NEF Value | 0.002 | 0.304 | 1.544 | 2.900 | 3.328 | 3.545 | 5.149 | 3.830 | 4.944 | 5.665 | 2.469 | 0.615 | 0.0002 |
| Core/HP | Sample Depth | PCR-Product cp77444 | PCR-Product cp103595 | Cloning Success cp77444 | Cloning Success cp103595 | No. of Retrieved Sequences cp77444 | Detected Variants cp77444 | No. of Retrieved Sequences cp103595 | Detected Variants cp103595 |
| L14-02 | 7.53 m | + | + | + | - | 0 | - | - | - |
| - | EN2 | - | - | n. c. | n.c. | - | - | - | - |
| L14-03 | 6.72 m | + | + | + | + | 0 | - | 13 | T |
| - | EN3 | - | - | n.c. | n.c. | - | - | - | - |
| L14-03 | 7.59 m | + | - | + | n.c. | 11 | A | - | - |
| L14-03 | 8.56 m | + | + | + | + | 8 | A | 7 | 3× C, 4× T |
| L14-03 | 9.61 m | - | - | n.c. | n.c. | - | - | - | - |
| L14-03 | 10.11 m | - | - | n.c. | n.c. | - | - | - | - |
| L14-03 | 11.77 m | + | + | + | + | 9 | A | 3 | T |
| - | EN5 | - | - | n.c. | n.c. | - | - | - | - |
| L14-05 | 3.3 m | - | + | + | + | 1 | A | 1 | T |
| L14-05 | 3.7 m | - | - | n.c. | n.c. | - | - | - | - |
| - | EN6 | - | - | n.c. | n.c. | - | - | - | - |
| L14-04 | 6.15 m | - | + | n.c. | + | - | - | 2 | C |
| L14-04 | 7.27 m | + | + | + | + | 7 | A | 13 | T |
| - | EN7 | - | - | n.c. | n.c. | - | - | - | - |
| L14-04 | 8.03 m | + | + | + | + | 7 | 3× C, 4× A | 7 | 1× C, 6× T |
| L14-04C | 2.05 m | + | + | + | + | 9 | A | 11 | C |
| L14-04C | 3.15 m | + | + | + | + | 10 | A | 15 | 8× C, 7× T |
| L14-04C | 3.55 m | + | + | + | + | 6 | A | 13 | 2× C, 11× T |
| - | EN8 | - | - | n.c. | n.c. | - | - | - | - |
| - | NTCs | - | - | n.c. | n.c. | - | - | - | - |
| Metabolite | Number of neighbors | P value |
| Reporter metabolites (up) | ||
| Glutathione [c] | 10 | 6.0E-05 |
| UDP-glucose [c] | 11 | 3.1E-04 |
| D-galactose [e] | 6 | 2.5E-03 |
| Alpha,alpha-trehalose 6-phosphate [c] | 4 | 3.7E-03 |
| Alpha,alpha-trehalose [c] | 4 | 6.0E-03 |
| Alpha-D-glucose 6-phosphate [c] | 8 | 8.2E-03 |
| Oxidized glutathione [c] | 4 | 6.6E-03 |
| CDP-diacylglycerol [m] | 4 | 8.6E-03 |
| Alpha-D-glucose [c] | 23 | 2.2E-02 |
| D-glucose 1-phosphate [c] | 6 | 1.2E-02 |
| Reporter metabolites (down) | ||
| AMP [c] | 42 | 5.4E-09 |
| ATP [c] | 83 | 1.1E-08 |
| 5-phospho-alpha-D-ribose 1-diphosphate [c] | 15 | 2.5E-06 |
| L-glutamine [c] | 17 | 6.6E-06 |
| L-histidine [c] | 7 | 8.2E-05 |
| L-aspartate [c] | 12 | 8.7E-05 |
| CO2 [m] | 10 | 1.3E-04 |
| Isocitrate[m] | 5 | 2.5E-04 |
| Phosphate [c] | 49 | 8.5E-05 |
| Glycine [m] | 4 | 9.6E-04 |
| No nGER (n = 42) | nGER (n = 48) | p-value | |
| Exhaled air: | |||
| FeNO (ppb) | 15 (13–20) | 17 (11–25) | 0.48 |
| EBC: | |||
| Substance P (pg/ml) | 623 (562–676) | 741 (626–821) | <0.001 |
| Neurokinin A (% detected) | 17 % | 30 % | 0.13 |
| Pepsin (ng/ml) | 0.8 (0.8–3.6) | 2.5 (0.8–5.8) | 0.03 |
| IL-8 EBC (% detected) | 12 % | 19 % | 0.37 |
| 8-isoprostane (pg/ml) | 2.6 (2.2–2.9) | 3.0 (2.7–3.9) | 0.002 |
| PEx: | |||
| Albumin (mg/ga) | 73 (57–91) | 48 (31–69) | <0.001 |
| SP-A (mg/ga) | 38 (31–43) | 25 (20–35) | <0.001 |
| Albumin/SP-A (ratio) | 1.92 (1.50–2.64) | 1.74 (1.26–2.95) | 0.79 |
| Plasma: | |||
| hs-CRP (mg/l) | 1.05 (0.68–2.26) | 1.08 (0.62–1.94) | 0.96 |
| IL-8 plasma (% detected) | 57 % | 52 % | 0.63 |
| SP-A (ng/ml) | 34.7 (29.8–48.6) | 35.6 (27.6–47.0) | 0.81 |
| Treatment | Belief | N | Recommendations | N | Adherence | N | Challenges to Adherence |
| Blood pressure | Believes blood pressure affects PKD | 16 | Prescribed blood pressure medication | 16 | Number of days per week when remember to take medication: | • Believes diet and exercise are better than drugs• Forgets when feeling well• Forgets when rushed, busy, or tired | |
| <7 days/week | 4 | ||||||
| 7 days/week | 12 | ||||||
| Exercise | Believes exercise or physical activity affects PKD | 14 | Told to avoid certain types of exercise or physical activity | 11 | Does not adhere to recommendations to avoid certain exercises of physical activity | 2 | • Activity helps mentally• Disagrees with recommendations (that exercise is harmful) |
| Diet | Believes diet affects PKD | 16 | Told to follow certain diets | 15 | Adherence to low-salt diet: | • Absence of or conflicting recommendations• Affects social aspects of eating• Difficult to measure | |
| • By non-physician sources | 10 | Does not add salt to food | 12 | ||||
| Avoids salty food | 4 | ||||||
| Does not eat out/Cooks own meals | 4 | ||||||
| Water Intake | Believes drinking a lot of water affects PKD | 10 | Told to drink “a lot of water” | 12 | Adheres to recommendations | 10 | • Frequent urination• Experiences symptoms• Difficult to develop habit |
| • By non-physician sources | 3 | Does not adhere to recommendations | 1 | ||||
| Uncertain | 5 | Uncertain but tries to adhere to recommendations | 5 |
| Maternal age (years) | ||||
| ≤15 | 16–19 | |||
| Adjusted OR (95% CI) | p-value | Adjusted OR (95% CI) | p-value | |
| Antenatal medical issuea | ||||
| Previous cesarean history | 0.09 (0.04–0.20) | <0.001 | 0.43 (0.41–0.46) | <0.001 |
| Prolonged pregnancy | 0.54 (0.39–0.77) | <0.001 | 0.84 (0.79–0.90) | <0.001 |
| Preeclampsia | 0.69 (0.47–1.02) | 0.063 | 0.98 (0.91–1.05) | 0.501 |
| PIH | 0.52 (0.31–0.88) | 0.014 | 0.93 (0.86–1.02) | 0.11 |
| Anemia | 1.00 (0.73–1.38) | 0.991 | 1.32 (1.24–1.40) | <0.001 |
| IUGR | 1.37 (1.00–1.89) | 0.042 | 1.30 (1.21–1.40) | <0.001 |
| Oligohydramnios | 0.82 (0.54–1.25) | 0.349 | 1.21 (1.12–1.32) | <0.001 |
| Antepartum hemorrhage, abruptio/previa placenta | 0.77 (0.53–1.12) | 0.175 | 0.76 (0.70–0.82) | <0.001 |
| Perinatal medical issueb | ||||
| Premature ROM | 0.80 (0.60–1.07) | 0.131 | 0.97 (0.92–1.03) | 0.294 |
| Failed labor induction | 1.33 (0.97–1.83) | 0.075 | 1.33 (1.24–1.43) | <0.001 |
| Dystocia | 0.82 (0.67–1.01) | 0.066 | 0.86 (0.83–0.90) | <0.001 |
| Malpresentation | 0.94 (0.75–1.17) | 0.57 | 0.92 (0.88–0.97) | <0.001 |
| Fetal distress | 0.78 (0.58–1.05) | 0.102 | 1.20 (1.14–1.26) | <0.001 |
| Preterm delivery | 2.98 (2.48–3.58) | <0.001 | 1.58 (1.51–1.66) | <0.001 |
| Postpartum hemorrhage | 1.03 (0.74–1.43) | 0.856 | 1.00 (0.94–1.08) | 0.917 |
| Metric | Questions | Average | Standard |
| response | deviation | ||
| Overall usability | 1–19 | 6.02 | 1.04 |
| System usefulness | 1–8 | 6.13 | 0.93 |
| Information quality | 9–15 | 5.66 | 1.20 |
| Interface quality | 16–18 | 6.24 | 0.99 |
| Functional traits | Interpretation |
| Calvin–Benson cycle | CO2 fixation |
| Utilization of various carbon sources | Adaptation to the diverse organic matter in sponge mesohyl |
| Anaerobic respiration | Energy supply in anoxic environment |
| Denitrification | Energy supply in anoxic environment |
| Sulfate reduction | Energy supply in anoxic environment |
| Peptidase | Compensation for the reduced amino acid synthesis capacity |
| Endospore formation | Resistance to environmental threats; widespread distribution |
| Metal resistance | Resistance to environmental threats |
| Antibiotic resistance | Competition in symbiotic communities; resistance to environmental threats |
| Eukaryotic-like proteins | Host–microbe recognition |
| Type II secretion system | Interaction with host environment |
| Widespread Colonization Island | Tight adhesion |
| Type VI secretion system | Host–microbe interaction, microbe–microbe competition |
| Controls | COPD | P value | |
| Gender M:F | 2:6 | 9:7 | |
| Age - median (range) | 63.5 (56-78) | 65.5 (49-78) | 0.779 |
| Smoking history (pack years) | |||
| Median (range) | 50.0 (2-110) | 51.5 (5-180) | 0.625 |
| FEV1 (% predicted) | |||
| Median (range) | 88.0 (78-107) | 43.5 (27-75) | <0.001 |
| FEV1/FVC - Median | 101.5 | 59.7 | <0.001 |
| DLCO (% predicted) | |||
| Median (range) | 62.0 (34-122) | 54.0 (27-99) | 0.416 |
| Procedures | References | Detergents | Detergent concentrations (C) | Ultrasound treatment (S)1) | Homogenization (H)2) | Filtration (F) |
| 1 | S.B. Singh-Verma (1968), LR. Bakken (1985) | Sodium hexametaphosphate | C1) 0,2% (w/v) | S1) 40 W, 60 sec, 5 impulses/sec (different repetitions) | H1) none | F1 none |
| C2) 0,5% (w/v) | S2) 65 W, 60 sec, 5 impulses/sec (different repetitions) | H2) 60 sec, speed 5 (different repetitions) | F2) 12–15 μm filter | |||
| 2 | S.B. Singh-Verma (1968), LR. Bakken (1985) | Bromhexine hydrochloride | C1) 0,2% (w/v) | S1) 40 W, 60 sec + 65 W, 60 sec, 5 impulses/sec | H1) none | n.a. |
| H2) 2× 60 sec, speed 5 | ||||||
| 3 | W.B. Yoon and R.A. Rosson (1990) | Tween | C1) 5 μg/ml | S1) 15 W, 30 sec, 5 impulses/sec | H1) none | n.a. |
| C2) 10 μg/ml | S2) 35 W, 30 sec, 5 impulses/sec | H2) 5 min, speed 5 | ||||
| C3) 25 μg/ml | ||||||
| 4 | E.L Schmidt (1974) | Tween 80 + 0.007 g ml-1 flocculation reagent (Ca (OH)2: MgCO3 (2:5)) | C1) 25 μl/ml | n.a. | n.a. | n.a. |
| 5 | O. Resina-Pelfort et al. (2003) | Triton X-100 | C1) 10 μg/ml | S1) 35 W, 30 sec, 5 impulses/sec | H1) none | n.a. |
| C2) 20 μg/ml | S2) 45 W, 30 sec, 5 impulses/sec | H2) 5 min, speed 5 | ||||
| 6 | L R. Bakken (1985) | Sodium pyrophosphate | C1) 0,2% (w/v) | S1 3× 40 W, 60 sec, 5 impulses/sec | H1) 3× 60 sec, speed 5 | n.a. |
| Programme, Country | Water Frequency 1 | Fruit Juices Frequency 2 | Soft Drinks Frequency 2 |
| VIASANO, Belgium | 4 (4–5) | 6 (4–6) | 4 (2–5) |
| Healthy kids in Bulgaria, Bulgaria | 6 (5–6) | 4 (3–5) | 2 (1–4) |
| EPODE Flandre Lys, France | 4 (4–5) | 6 (4–6) | 3 (2–5) |
| Paideiatrofi, Greece | 5 (5–6) | 4 (4–5) | 1 (1–2) |
| MAIA, Portugal | 5 (4–6) | 4 (2–4) | 2 (1–3) |
| SETS, Romania | 5 (5–6) | 4 (3–5) | 2 (2–4) |
| JOGG Zwolle, The Netherlands | 4 (3–4) | 3 (2–5) | 3 (2–6) |
| Total | 5 (4–6) | 4 (3–6) | 2 (1–4) |
| Authors | Results |
| Gavini et al. [25] | Ion-implanted instruments reached significantly higher cycle numbers before fracture compared to annealed and non-implanted files. |
| Wolle et al. [26] | Argon II improved the performance of S1 files moderately, whereas nitrogen ion-implanted files performed worse in the fatigue test. |
| Cause of corneal opacification | Eyes |
| Posttrauma | 25 |
| Postcorneal ulcer | 20 |
| Glaucoma | 4 |
| Unknown | 4 |
| Age group (years) | Total | RVID (cm) | PADP (mm Hg) | TRVel (m/s) | PASP (mm Hg) | TVIRVOT (cm) | PVCSA (cm2) | PBF (L/min) | PVRECHO (Woods Unit) |
| Study group | |||||||||
| A (18 - 25) | 30 | 2.93 | 10.4 | 2.23 | 19.3 | 25.7 | 3.48 | 7.54 | 1.103 |
| B (26 - 32) | 15 | 2.92 | 10.4 | 2.26 | 20.2 | 25.4 | 3.57 | 7.58 | 1.04 |
| C (33 - 40) | 11 | 3.13 | 10.9 | 2.27 | 20.1 | 25.36 | 3.52 | 7.53 | 1.07 |
| Total | 56 | 2.94 | 10.5 | 2.24 | 19.8 | 25.45 | 3.52 | 7.5 | 1.04 |
| Control group | |||||||||
| A (18 - 25) | 8 | 2.59 | 10 | 2.30 | 20.5 | 20.5 | 3.5 | 5.3 | 1.27 |
| B (26 - 32) | 4 | 2.71 | 10.2 | 2.33 | 22.4 | 20.7 | 3.51 | 5.1 | 1.28 |
| C (33 - 40) | 3 | 2.78 | 9.8 | 2.32 | 22 | 20.6 | 3.5 | 5.4 | 1.32 |
| Total | 15 | 2.67 | 10.1 | 2.3 | 21.2 | 20.5 | 3.5 | 5.3 | 1.28 |
| Domains | mean (SD) | Difference | P | ||
| 1. | Activities | before | 3.52 (1.41) | 2.84 | < 0,001 |
| after | 0.68 (0.93) | ||||
| 2. | Sleep | before | 2.48 (1.8) | 2.17 | < 0,001 |
| after | 0.31 (0.58) | ||||
| 3. | General problems | before | 1.79 (1.55) | 1.3 | < 0.001 |
| after | 0.49 (0.77) | ||||
| 4. | Practical problems | before | 3.57 (1.68) | 2.89 | < 0.001 |
| after | 0.68 (1.01) | ||||
| 5. | Nasal symptoms | before | 3.91 (1.66) | 3.17 | < 0.001 |
| after | 0.74 (0.99) | ||||
| 6. | Eye symptoms | before | 2.92 (2.01) | 2.53 | < 0.001 |
| after | 0.39 (0.74) | ||||
| 7. | Emotions | before | 3.03 (1.43) | 2.65 | < 0.001 |
| after | 0.38 (0.69) | ||||
| Overall QoL | before | 2.95 (1.32) | 2.19 | <0.001 | |
| after | 0.76 (0.55) |
| GenBank accession no. | Original name | Country |
| HQ591366 | PCV2 , isolate 90-08-21 | Croatia, 2008 |
| HQ591367 | PCV2, isolate 110-08-2 | Croatia, 2008 |
| AY256460 | PCV2, strain 375 | Hungary, 2003 |
| AY424405 | PCV2, isolate AUT5 | Austria, 2003 |
| HQ591368 | PCV2, isolate 126-07-5 | Croatia, 2007 |
| HQ591369 | PCV2, isolate 147-07-7 | Croatia, 2007 |
| HQ591370 | PCV2, isolate 161-08-2 | Croatia, 2008 |
| HQ591365 | PCV2, isolate 70-08-2 | Croatia, 2008 |
| AY180397 | PCV2, strain Pingtung-5 | Taiwan, 2002 |
| AY484410 | PCV2, isolate NL-control-4 | Netherlands, 2003 |
| AF311296 | BFDV | Australia, 2000 |
| AF071879 | PCV1 | SAD, 1998 |
| GU930366 | PRRSV, isolate Hun06 | Hungary, 2009 |
| AY035960 | PRRSV, isolate 361-4 | Denmark, 1994 |
| JQ043210 | PRRSV, 174-07-1 | Croatia, 2007 |
| DQ324711 | PRRSV, isolate Prz-87 | Poland, 2005 |
| JQ043212 | PRRSV, isolate 660-07-2 | Croatia, 2007 |
| JQ043213 | PRRSV, isolate 1152-08-10 | Croatia, 2008 |
| AY035976 | PRRSV, strain 2567/96 | Italy, 1996 |
| AY035961 | PRRSV, isolate 48/92-1 | Denmark, 2001 |
| AY035975 | PRRSV, isolate 2481/97 | Denmark, 2001 |
| M96262 | Lelystad virus | Netherlands, 1991 |
| JQ043211 | PRRSV, 177-07-2-1 | Croatia, 2007 |
| GU930368 | PRRSV, isolate Hun08 | Hungary, 2009 |
| DQ324708 | PRRSV, strain Okt-46 | Belarus, 2004 |
| DQ324719 | PRRSV, strain Soz-6 | Belarus, 2004 |
| DQ324727 | PRRSV, strain Yuz-34 | Belarus, 2004 |
| EU071271 | PRRSV, strain KR | Russia, 2007 |
| AF438362 | PRRSV, strain Aus | Lithuania, 2000 |
| DQ324701 | PRRSV, strain Bor-41 | Belarus, 2004 |
| DQ324702 | PRRSV, strain Bor-54 | Belarus, 2004 |
| L39363 | PRRSV, isolate IL1 | United States, 1996 |
| L39362 | PRRSV, isolate IA6 | United States, 1996 |
| U18750 | PRRSV, isolate ISU-3927 | United States, 1996 |
| Total | Men | Women | ||||
| Descriptor | Cases/total study group, n | ID (95% CI)c | Cases/total study group, n | ID (95% CI)c | Cases/total study group, n | ID (95% CI)c |
| DM without OAAs | 42/5619 | 74.7 (52.2 to 97.3) | 11/2599 | 42.3 (17.4 to 67.3) | 31/3019 | 102 (66.7 to 138) |
| Met only | 43/5627 | 76.4 (53.7 to 99.2) | 18/2637 | 68.2 (36.8 to 99.7) | 25/2989 | 83.6 (51.0 to 116) |
| DM without OAAs | 140/14503 | 96.5 (80.6 to 112) | 52/7101 | 73.2 (53.4 to 93.1) | 88/7402 | 118 (94.2 to 143) |
| SUs only | 145/13370 | 108 (90.9 to 126) | 59/6581 | 89.6 (66.9 to 112) | 86/6788 | 126 (100 to 153) |
| DM without OAAs | 282/30957 | 91.1 (80.5 to 101)d | 100/14064 | 71.1 (57.2 to 85.0)e | 182/16893 | 107 (92.2 to 123)f |
| SUs + Met | 127/32236 | 39.4 (32.6 to 46.2)d | 45/14791 | 30.4 (21.5 to 39.3)e | 82/17444 | 47.0 (36.9 to 57.2)f |
| Variable | No. patients (n = 41)* | Median expression Survivin DeltaEx3 | AD | p |
| FIGO stage | ||||
| IB | 0 (8) | 0 | 0 | 0.59 |
| IIB | 2 (16) | 0.09 | 24.51 | |
| IIIB | 2 (17) | 0.11 | 35.68 | |
| Histology of tumors | ||||
| Squamous cell | 2 (34) | 0.01 | 16.99 | 0.04 |
| Adenocarcinoma | 2 (5) | 0.22 | 60.12 | |
| Adenosquamous | 0 (2) | 0 | 0 | |
| Menopause | ||||
| Pre-Menopause | 2 (10) | 0.14 | 48.94 | 0.33 |
| Menopause | 1 (8) | 0.02 | 10.65 | |
| Post-Menopause | 1 (23) | 0.01 | 14.99 |
| Independent association with increasing RANKL expression (Pvalue) | Independent association with increasing RANK expression (Pvalue) | |
| Diagnosis during pregnancy (yes vs. no) | <0.001 | 0.67 |
| Tumor size (≤2 cm vs. >2 cm) | 0.23 | 0.87 |
| Nodal involvement (negative vs. positive) | 0.15 | 0.19 |
| Histological grade (I vs. II vs. III) | 0.09 | 0.7 |
| Breast cancer subtypes (luminal A vs. luminal B vs. HER2 vs. triple negative) | 0.75 | <0.001 |
| Increasing progesterone receptor expression by IHC (continuous variable) | <0.001 | 0.17 |
| Neoadjuvant chemotherapy (yes vs. no) | 0.69 | <0.001 |
| Variable | PHDs cohortN = 1,346 (%) | Comparison cohortN = 5,384 (%) | p-value |
| Age, years (SD)a | 47.38 (14.56) | 46.74 (15.77) | 0.183 |
| <45 | 820 (60.92) | 3,280 (60.92) | |
| 45–64 | 404 (30.01) | 1,616 (30.01) | |
| ≥65 | 122 (9.07) | 488 (9.07) | |
| Sex | 0.999 | ||
| Female | 959 (71.25) | 3,836 (71.25) | |
| Male | 387 (28.75) | 1,548 (28.75) | |
| Co-morbidities | |||
| Hypertension | 72 (5.35) | 305 (5.66) | 0.342 |
| DM | 25 (1.86) | 101 (1.88) | 0.732 |
| IHD | 14 (1.04) | 53 (0.98) | 0.476 |
| Hyperlipidaemia | 22 (1.63) | 99 (1.84) | 0.142 |
| AF | 1 (0.07) | 7 (0.13) | 0.503 |
| Event (strokes) in the endpoint | 100 (7.43) | 287 (5.33) | 0.002 |
| Years of follow-up (SD)a | 4.57 (1.22) | 4.60 (1.20) | 0.465 |
| Variable | Admission Serum Chloride (Cl0)≥110 mEq/L(n = 303) | Admission Serum Chloride (Cl0)101–109 mEq/L(n = 561) | Admission Serum Chloride (Cl0)≤100 mEq/L(n = 181) | P-value |
| Demographics | ||||
| Age, years, mean ± SD | 67.9 ± 15.6 | 64.8 ± 16.7 | 67.0 ± 14.6 | 0.0146* |
| Male, % | 44.9% | 53.7% | 55.8% | 0.0214* |
| African-American, % | 42.6% | 33.2% | 24.9% | 0.0002* |
| Chronic conditions | ||||
| Baseline SCr, mg/dl, median (IQR) | 1.2 (0.9–1.7) | 1.2 (0.9–1.6) | 1.2 (0.9–1.6) | 0.0794 |
| Baseline eGFR, mL/min/1.73m2, median (IQR) | 57.0 (40.4–76.8) | 63.1 (44.2–87.9) | 61.2 (42.1–88.0) | 0.1032 |
| Diabetes, % | 23.8% | 20.1% | 21.6% | 0.4648 |
| Hypertension, % | 46.5% | 46.5% | 43.7% | 0.8050 |
| Heart failure, % | 3.3% | 2.1% | 4.4% | 0.2423 |
| Anemia, % | 88.6% | 85.1% | 74.4% | 0.0001* |
| Drug Exposure | ||||
| Diuretic, % | 44.2% | 44.0% | 55.8% | 0.0161* |
| Statin, % | 28.7% | 30.8% | 30.4% | 0.8073 |
| Iodine contrast, % | 27.7% | 33.9% | 29.3% | 0.1446 |
| Aminoglycoside, % | 8.3% | 6.1% | 1.7% | 0.0119* |
| Critical indicators | ||||
| Oliguria, % | 9.0% | 6.2% | 5.3% | 0.2467 |
| CFB 72 h, liters, median (IQR) | 3.1 (−0.1–8.0) | 2.0 (−0.5–5.4) | 0.75 (−2.1–3.8) | 0.0005* |
| Pressor or inotrope, % | 37.3% | 30.1% | 27.6% | 0.0408* |
| Mechanical ventilation, % | 51.2% | 39.4% | 33.2% | <0.0001* |
| Red blood cell transfusion, % | 6.6% | 2.0% | 0.6% | <0.0001* |
| Base Deficit, mmol/L Median (IQR) | 3.6 (1.7–6.4) | 1.1 (−1.7–4.0) | −2.6 (−7.4–2.4) | <0.0001 |
| APACHE II score, mean ± SD | 14.9 ± 7.0 | 12.1 ± 5.9 | 11.80 ± 5.06* | <0.0001 |
| SOFA score, mean ± SD | 5.8 ± 3.8 | 4.5 ± 3.4 | 4.4 ± 3.4* | <0.0001 |
| Overall ranking scale (on a scale from 1–10) | |
| Question: In the last two days of care, how well did the doctors, nurses and other professional staff... | Average |
| Provide medical care that respected his/her wishes? | 8.2 |
| Make sure that [patient] died with dignity – that is died on her/his own terms? | 8.2 |
| Make sure [patient’s] symptoms were controlled to a degree acceptable to her/him? | 8 |
| Communicate with patient and family about the illness and likely outcomes of care? | 7.3 |
| Provide emotional support for you and [patient’s] family and friends? | 6.8 |
| What number would you give the overall care that [patient] received in the last two days of life? | 7.7 |
| Scale score | 7.7 |
| Comparison of Domain Scores (range: 0 to 1) | |
| Advance care planning | 0.10 |
| Coordination | 0.16 |
| Focus on individual | 0.271 |
| Informing & decision making | 0.301 |
| Attend to family | 0.511 |
| General CVRM networks | Specific CVRM networks | |||||||
| Mean | SD | Min | Max | Mean | SD | Min | Max | |
| Density | 0.38 | 0.17 | 0.08 | 0.83 | 0.37 | 0.22 | 0 | 0.83 |
| Number of high frequency contacts | 8.87 | 5.64 | 0 | 20 | 10.65 | 8.24 | 0 | 33 |
| Centrality of CVRM coordinator | 6.61 | 3.38 | 2.00 | 16 | 7.07 | 4.97 | 0 | 24 |
| Homophily on SBP targets | 0.60 | 0.43 | −0.42 | 1.00 | 0.55 | 0.46 | −0.46 | 1.00 |
| Homophily on LDL targets | 0.53 | 0.49 | −0.87 | 1.00 | 0.52 | 0.52 | −0.87 | 1.00 |
| Healthy population | Clinic populationa | Pairwise comparisons | ||||
| BV = 0 | BV = 0 | BV = 1 | HP vs. CPBVneg | HP vs. CPBVpos | CPBVneg vs. CPBVpos | |
| N = 30 | N = 29 | N = 12 | ||||
| N (%) | N (%) | N (%) | p-value | p-value | p-value | |
| L. crispatus | 23 (77) | 23 (79) | 5 (42) | 1.000 | 0.067 | 0.029 |
| L. iners | 20 (67) | 25 (86) | 10 (83) | 0.125 | 0.453 | 1.000 |
| L. jensenii | 17 (57) | 15 (52) | 3 (25) | 0.796 | 0.091 | 0.171 |
| L. gasseri | 19 (63) | 7 (24) | 1 (8) | 0.004 | 0.002 | 0.214 |
| L. vaginalis | 22 (73) | 18 (62) | 1 (8) | 0.421 | <0.001 | 0.002 |
| G. vaginalis | 10 (33) | 20 (69) | 12 (100) | 0.009 | <0.001 | 0.039 |
| A. vaginae | 4 (13) | 8 (28) | 11 (92) | 0.209 | <0.001 | <0.001 |
| P-3075 | Placebo | |
| Gender, N (%) | ||
| Males | 8 (28.6) | 3 (21.4) |
| Females | 20 (71.4) | 11 (78.6) |
| Age, years | ||
| Mean ± SD | 40.3 ± 11.3 | 39.3 ± 11.3 |
| Median | 40 | 34 |
| Range | 20–60 | 26–60 |
| Partner Medicines | Below 85 % | Within 85–115 % | Above 115 % | Total N = 254 |
| Amodiaquinean (%) | 28 (25.2) | 64 (57.7) | 19 (17.1) | 111 (100.0) |
| Median (IQR) | 80.6 (72.6–82.9) | 92.7 (88.3–97.2) | 118.8 (117.2–121.4) | 92.0 (84.9–101.7) |
| Lumefantrinebn (%) | 4 (3.0) | 120 (89.6) | 10 (7.5) | 134 (100.0) |
| Median (IQR) | 83.3 (77.4–84.4) | 99.4 (93.2–105.0) | 117.6 (116.2–118.5) | 100.3 (93.1–107.1) |
| Piperaquinecn (%) | 0 (0.0) | 3 (33.3) | 6 (66.7) | 9 (100.0) |
| Median (IQR) | 0 | 112.1 (111.5–114.7) | 121.1 (117.5–123.8) | 117.5 (114.7–121.7) |
| Combinedn (%) | 32 (12.6) | 187 (73.6) | 35 (13.8) | 254 (100.0) |
| Median (IQR) | 81.4 (72.8–83.0) | 96.6 (91.6–103.4) | 118.7 (117.2–120.7) | 96.8 (88.9–108.4) |
| Code | Alkali Treatment | Silane Coupling Agent | Volume Fraction of Fiber Vf (vol %) |
| PA1010 | - | - | - |
| HF | - | - | 20 |
| HF-S1 | NaOH | S1 (Aminosilane) | 20 |
| HF-S2 | NaOH | S2 (Epoxysilane) | 20 |
| HF-S3 | NaOH | S3 (Ureidosilane) | 10, 20, 30 |
| Purification step | Total fused peptide (mg) | Total p53pAnt (mg) | Purity (%) | Yield (%) |
| Total protein extract | n.d | n.d | 43* | 100 |
| Inclusion bodies | n.d | n.d | 79* | - |
| First affinity chromatography | 184** | 43 | 90* | - |
| Precipitation recovery | 184 | 43 | - | 100* |
| Thrombin cleavage | - | - | - | 95* |
| Second affinity chromatography | - | 34** | 95 | 85* |
| Variables | Chlorhexidine | Placebo | Dry cord |
| Hospital data | (n = 86) | (n = 86) | (n = 75) |
| Age of mother (years, mean ± SD) | 23.87 ± 2.54 | 23.77 ± 2.86 | 25.12 ± 3.24 |
| Vaginal delivery | 100.0 | 100.0 | 100.0 |
| Male births | 48.8 | 64.0 | 58.7 |
| Birth weight (grams, mean ± SD) | 2728.3 ± 479.5 | 2684.3 ± 453.6 | 2794.8 ± 437.6 |
| No. of pelvic examinations (mean ± SD) | 2.37 ± 1.25 | 2.07 ± 1.00 | 2.00 ± 0.97 |
| Problems during delivery | |||
| Meconium staining | 2.3 | 2.3 | 5.3 |
| Prolonged labor | 2.3 | 1.2 | 1.3 |
| Maternal risk factors for infection | |||
| LPVb > 24 h | 4.7 | 2.3 | 2.7 |
| Chorioamnionitis | 0.0 | 0.0 | 0.0 |
| Fever in mother | 1.2 | 0 | 1.3 |
| Maternal UTI | 0.0 | 0.0 | 1.3 |
| Time since birth (hrs:min, mean ± SD) | 4:39 ± 2.31 | 4:35 ± 2:49 | 4:12 ± 2:37 |
| Community data | (n = 36) | (n = 24) | (n = 19) |
| Age of mother (years, mean ± SD) | 24.42 ± 3.95 | 24.62 ± 4.13 | 25.79 ± 3.91 |
| Male births | 38.9 | 50.0 | 52.6 |
| Did the person clean hands before conducting delivery | 97.2 | 100.0 | 100.0 |
| New razor blade for cutting the cord | 100.0 | 95.8 | 100.0 |
| Baby given bath immediately after delivery | 94.4 | 100.0 | 100.0 |
| # of Subband | Freq. (Hz) | # of Subband | Freq. (Hz) | # of Subband | Freq. (Hz) | # of Subband | Freq. (Hz) |
| 1 | 86.7 | 13 | 886.7 | 25 | 2484.6 | 37 | 7231.5 |
| 2 | 153.3 | 14 | 953.3 | 26 | 2715.9 | 38 | 7904.8 |
| 3 | 220 | 15 | 1020 | 27 | 2968.8 | 39 | 8640.9 |
| 4 | 286.7 | 16 | 1115 | 28 | 3242.2 | 40 | 9445.4 |
| 5 | 353.3 | 17 | 1218.8 | 29 | 3547.4 | 41 | 10,324.9 |
| 6 | 420 | 18 | 1332.3 | 30 | 3877.7 | 42 | 11,286.3 |
| 7 | 486.7 | 19 | 1456.3 | 31 | 4238.7 | 43 | 12,337.2 |
| 8 | 553.3 | 20 | 1591.9 | 32 | 4633.4 | 44 | 13,485.9 |
| 9 | 620 | 21 | 1740.2 | 33 | 5064.9 | 45 | 14,741.6 |
| 10 | 686.7 | 22 | 1902.2 | 34 | 5536.5 | 46 | 16,114.3 |
| 11 | 753.3 | 23 | 2079.3 | 35 | 6052 | 47 | 17,614.7 |
| 12 | 820 | 24 | 2272.9 | 36 | 6615.5 | 48 | 19,254.8 |
| Characteristics | Frequency n = 82 | Percent (%) |
| Mean Age =27.6, SD =4.5 | ||
| 16–20 | 6 | 7.3 |
| 21–25 | 22 | 26.8 |
| 26–30 | 37 | 45.1 |
| 31–35 | 12 | 14.6 |
| 36-40 | 5 | 6.1 |
| Married | 76 | 92.7 |
| Single | 1 | 1.2 |
| Cohabiting | 2 | 2.4 |
| No response | 3 | 3.7 |
| Employed | 16 | 19.5 |
| Student | 8 | 9.8 |
| Civil servant | 2 | 2.4 |
| Unemployed | 8 | 9.8 |
| Artisan | 14 | 17.1 |
| Trading | 32 | 39 |
| No response | 2 | 2.4 |
| Primary | 9 | 10.9 |
| JSS | 21 | 25.6 |
| SSS | 11 | 13.4 |
| Poly technique | 21 | 25.6 |
| University | 15 | 18.3 |
| No response | 5 | 6.1 |
| Christianity | ||
| Islam | 34 | |
| 48 | 41.5 | |
| 58.5 | ||
| Yoruba | 72 | 87.8 |
| Igbo | 6 | 7.3 |
| No response | 4 | 4.8 |
| miR ID | Present result | Previous report | Type of sample | Reference |
| hsa-miR-106b-5p | ↑ | ↓ | Brain | [13] |
| hsa-miR-181b-5p | ↓ | ↓ | Brain, lymphoblastoid cell line | [13,16] |
| hsa-miR-195-5p | ↑ | ↑ | Lymphoblastoid cell line | [15] |
| hsa-miR-19b-3p | ↑ | ↓ | Lymphoblastoid cell line | [14] |
| hsa-miR-320a | ↓ | ↓ | Lymphoblastoid cell line | [14] |
| hsa-miR-328 | ↓ | ↓ | Brain | [13] |
| hsa-miR-663a | ↓ | ↑ | Lymphoblastoid cell line | [14] |
| Accuracy (%) | Sensitivity (%) | Specificity (%) | Auc (%) | |
| FEATURE 1 | 95.00 | 87.50 | 96.87 | — |
| FEATURE 2 | 87.80 | 100.00 | 84.84 | — |
| FEATURE 1&2 | 95.00 | 87.50 | 96.87 | 92.00 |
| FEATURE 1&2 (SVM)* | 97.50 | 100.00 | 96.97 | 93.75 |
| Cell Line | Tumor Type | NOTCH1 Mutation | Effect on NOTCH1 Signaling | Reference |
| KOPT-K1 | T-LL | L1600P/del(P)* | Gain | [3] |
| REC-1 | MCL | del(ECN1)/del(P)* | Gain | this paper/ [7] |
| MAVER-1 | MCL | None | N.A. | [7] |
| HCC1599 | Breast Carcinoma | del(ECN1) | Gain | [10] |
| MB-157 | Breast Carcinoma | del(ECN1) | Gain | Unpublished data |
| HCC1587 | Breast Carcinoma | None | N.A. | [10] |
| Assessment1 | Telehone interview | Baseline visit | 3 month visit | 6 month visit | 12 month visit | 24 month visit |
| AD patient | ||||||
| Inclusion criteria | X | |||||
| Demographics, diagnoses, drugs | X | |||||
| CDR | X | X | ||||
| MMSE | X | X | X | |||
| Verbal flow, clock drawing test | X | X | X | X | X | |
| MNA | X | |||||
| Weight, BMI | X | X | X | X | X | |
| Mobility and balance tests by Guralnik | X | X | X | X | X | |
| FIM | X | X | X | X | X | |
| NPI | X | X | ||||
| Grip strength, blood pressure, heart rate | X | X | X | X | X | |
| Cornell depression scale | X | X | ||||
| Falls and fractures | X | X | X | X | ||
| Use of health and social services, admission to permanent institutional care, mortality | X | X | X | X | ||
| Spousal caregiver | ||||||
| Demographics, diagnoses, drugs | X | |||||
| Zarit burden scale | X | X | X | |||
| GDS | X | X | ||||
| RAND-36 QOL | X | X | X | |||
| Mobility and balance tests by Guralnik | X | X | ||||
| Use of health and social services, mortality | X | X | X | X |
| Gender | Age | Age at onset | Evidence for a diagnosis of epilepsy | MRI | ||
| EEG | Other features | Treatment response | ||||
| M | 70 | 66 | Non-specific bilateral temporal lobe slowing | Oroalimentary automatisms, gustatory hallucinations | Complete | Normal |
| M | 62 | 54 | L temporal epileptiform | Oroalimentary automatisms | Complete | Normal |
| M | 68 | 65 | Non-specific L temporal slowing | No | Complete | Normal |
| M | 72 | 71 | Non-specific R temporal slowing | Déjà vu | Complete | Bilateral high T2 signal in hippocampus |
| M | 68 | 62 | Bilateral (L more marked) mid-anterior temporal sharp and slow-wave epileptiform | Oroalimentary automatisms; brief unresponsiveness | Complete | Normal |
| M | 76 | 65 | Non-specific bilateral temporal slowing | Olfactory hallucinations | Complete | Normal |
| M | 66 | 56 | Normal | Olfactory hallucinations; brief unresponsiveness | Complete | Normal |
| M | 64 | 61 | Bilateral temporal epileptiform | Olfactory hallucinations; oroalimentary automatisms | Complete | Normal |
| M | 63 | 59 | Normal | No | Complete | Normal |
| M | 76 | 73 | Normal | Oroalimentary automatisms; brief unresponsiveness | Complete | Normal |
| F | 60 | 55 | Non-specific bilateral temporal slowing | Brief unresponsiveness | Complete | Normal |
| level of convergence | phenotype | organism | references |
| nucleotide | |||
| coding mutations in several genes | rate of proliferation in a novel host and at higher temperature | X174 virus | [21] |
| Gly119Ser in ace-1 | organophosphate resistance | seven insect species | [22,23] |
| gene | |||
| pykF and nadR | rate of proliferation in a glucose-limited medium | Escherichia coli | [24] |
| yellow | wing spot | Drosophila tristis and Drosophila biarmipes | [25] |
| protein accumulation profile | |||
| proteins regulated by guanosine tetraphosphate | rate of proliferation in a glucose-limited medium | E. coli | [26] |
| molecular pathway | |||
| RNA polymerase complex | rate of proliferation at high temperature | E. coli | [14] |
| organ | |||
| compound eye | sensitivity to light | certain annelids, arrow worms, insects | [7] |
| behaviour and organs | |||
| no sound production and flat wings | no sound production, protection against parasitoids | criquets | [27] |
| feeding behaviour and habitat adaptations | ecology and body morphology | lizards | [28] |
| Maize gene | Intron TE insertion(s) | Maize gene length (Kb) | Sorghum ortholog gene length (Kb) |
| ZmTti1 | 2 Kb hobo DNA transposon | 20.87 | 12.1 |
| ZmTti2 | 6 Kb Gypsy LTR retrotransposon | 9.1 | 4.2 |
| ZmATM | 2.2 Kb L1/CIN4 retrotransposon | 131 | 71 |
| 2.1 Kb L1/CIN4 retrotransposon | |||
| 1.7 Kb L1/CIN4 retrotransposon | |||
| 3.1 Kb Ty1/Copia retrotransposon | |||
| 1.2 Kb Ty1/Copia retrotransposon | |||
| ZmATR | 2.4 Kb Gypsy LTR retrotransposon | 45 | 31 |
| 10.2 Kb Gypsy LTR retrotransposon | |||
| 3 Kb Ty1/Copia retrotransposon | |||
| 4.7 Kb Ty1/Copia retrotransposon | |||
| ZmSMG1 | 1.4 Kb Ty1/Copia retrotransposon | 30 | 22.6 |
| 2.1 Kb L1/CIN4 retrotransposon | |||
| ZmTOR | 2 Kb L1/CIN4 retrotransposon | 51 | 31.8 |
| 5 Kb Ty1/Copia retrotransposon |
| Paternal MHC class I Haplotypea | Non-BNP calves (n = 21) | BNP calves (n = 9) | P-valueb | FDR-derived significance thresholdsc |
| A11 | 3 | 6 | 0.008 | 0.004 |
| A14 | 0 | 1 | 0.300 | 0.007 |
| UU3 | 0 | 1 | 0.300 | 0.011 |
| UU9 | 3 | 0 | 0.535 | 0.014 |
| UU8 | 2 | 1 | 1.000 | 0.018 |
| A13 | 1 | 0 | 1.000 | 0.021 |
| UU1 | 2 | 0 | 1.000 | 0.025 |
| A18v2 (UU) | 1 | 0 | 1.000 | 0.029 |
| A12 (UU) | 2 | 0 | 1.000 | 0.032 |
| A15v1 | 1 | 0 | 1.000 | 0.036 |
| A19variants | 2 | 0 | 1.000 | 0.039 |
| A20variant | 1 | 0 | 1.000 | 0.043 |
| H2 | 1 | 0 | 1.000 | 0.046 |
| H5v2(UU) | 2 | 0 | 1.000 | 0.050 |
| ICD-10 Code | # of patients | Prescribed Antibiotic | Cases that needed antibiotic | Cases that needed + received antibiotics | Appropriate prescription rate (%) | Adequate prescription rate (%) |
| J00 | 581 | 17 | 14 | 1 | 82.36 | 7.14 |
| J01 | 93 | 70 | 4 | 4 | 5.71 | 100 |
| J02 | 306 | 157 | 9 | 5 | 3.18 | 2.94 |
| J03 | 166 | 138 | 16 | 15 | 11.59 | 93.75 |
| J04 | 34 | 12 | 0 | 0 | – | – |
| J05 | 8 | 0 | 0 | 0 | – | – |
| J06 | 191 | 117 | 0 | 0 | 0 | 0 |
| J10 | 0 | 0 | 0 | 0 | – | – |
| J11 | 0 | 0 | 0 | 0 | – | – |
| H65 | 8 | 6 | 2 | 2 | 33.33 | 100 |
| H66 | 6 | 6 | 6 | 6 | 100 | 100 |
| Total | 1393 | 523 | 51 | 33 | 9.75 | 64.70 |
| G grade | Number of tumor samples | ||
| CD146 expression | |||
| Low/absent | incomplete high | complete high | |
| 1 | 3 | ||
| 2 | 4 | 3 | 12 |
| 3 | 2 | 9 | 7 |
| 4 | 1 | ||
| total | 6 | 15 | 20 |
| Base model | Effect modification model | |||
| OR | 95%CI | OR | 95%CI | |
| SNAP participation (ref = eligible non-participants) | 2.02 | 1.44-2.83 | 2.09 | 1.48-2.95 |
| Age (years) | 1.02 | 1.01-1.03 | 1.02 | 1.01-1.03 |
| Gender (ref = female) | 0.45 | 0.30-0.67 | 0.45 | 0.30-0.67 |
| Race/ethnicity (ref = Non-Hispanic white) | ||||
| Non-Hispanic black | 2.79 | 1.45-5.38 | 2.76 | 1.43-5.32 |
| Hispanic | 2.15 | 1.30-3.56 | 2.12 | 1.28-3.51 |
| Other | 1.46 | 0.64-3.35 | 1.42 | 0.62-3.26 |
| Marital status (ref = married) | ||||
| Cohabitating, not married | 1.12 | 0.70-1.81 | 1.11 | 0.69-1.79 |
| Single | 0.94 | 0.67-1.32 | 0.93 | 0.66-1.31 |
| Working status (ref = yes) | 0.96 | 0.70-1.32 | 0.95 | 0.69-1.32 |
| Mental health (ref = not having a mental health problem) | 1.53 | 0.93-2.50 | 1.54 | 0.94-2.52 |
| Neighborhood poverty category (ref = not poor) | ||||
| Poor | 1.18 | 0.78-1.80 | 1.16 | 0.76-1.77 |
| Very poor | 1.02 | 0.67-1.57 | 1.01 | 0.66-1.55 |
| Density unhealthy food outlets | 1.01 | 0.98-1.03 | 1.00 | 0.97-1.03 |
| SNAP participation* Density unhealthy food outlets | 1.02 | 0.99-1.05 |
| RADIODENCITY OF BONE GRAFTS | At 7th day follow-up | At 1st month follow-up | At 6 months follow-up | At 1 year follow-up | ||||
| No. of pts. | % | No. of pts. | % | No. of pts. | % | No. of pts. | % | |
| GOOD | 178 | 100 | 171 | 96.1 | 162 | 91.0 | 147 | 82.6 |
| PARTIAL | 00 | 00 | 03 | 1.7 | 09 | 5.1 | 17 | 9.5 |
| LUCENT | 00 | 00 | 04 | 2.2 | 07 | 3.9 | 14 | 7.9 |
| Total | 178 | 100.0 | 178 | 100.0 | 178 | 100.0 | 178 | 100 |
| 1st visitFebruary 2012 | 2nd visitApril 2012 | Last visit before starting dialysis June 2014 | |
| Weight (kg) | 84,3 | 82,9 | 76 |
| BMI (kg/m2) | 29 | 28 | 25 |
| eGFR (mL/min/1,73 m2) | 19 | 16 | 12 |
| P-Urea (mmol/L) | 28,8 | 18,3 | 24,4 |
| P-Creatinine (μmol/L) | 389 | 401 | 777 |
| P-Phosphate (mmol/L) | 1,3 | 1,3 | 1,4 |
| P-Potassium (mmol/L) | 3,6 | 3,8 | 4,0 |
| P-Albumin (g/L) | 38 | 39 | 38 |
| Pt(U)-Urea (mmol/d) | 205 = 47 g protein | 162 = 40 g protein |
| Subject number | Region of interest | H&E staining | APP staining |
| Sheep 01 | AL | Normal | 0 |
| AR | Normal | 1 | |
| BL | Normal | 0 | |
| BR | Microglial activation | 2 | |
| C | Focal hemorrhagic necrosis | 2 | |
| D | Normal | 0 | |
| Sheep 03 | AL | Normal | 0 |
| AR | Normal | 0 | |
| BL | Normal | 0 | |
| BR | Normal | 0 | |
| C | Normal | 0 | |
| D | Small perivascular petechial hemorrhage | 1 | |
| Sheep 04 | AL | Normal | 0 |
| AR | Normal | 0 | |
| BL | Normal | 0 | |
| BR | Small perivascular petechial hemorrhage at edge, artifact? | 0 | |
| C | Small perivascular petechial hemorrhage at edge, artifact? | 0 | |
| D | Normal | 0 | |
| Sheep 05 | AL | Normal | 0 |
| AR | Normal | 0 | |
| BL | Normal | 0 | |
| BR | Normal | 0.5 | |
| C | Normal | 0 | |
| D | Normal | 0 | |
| Sheep 06 | AL | Localized focus of acute meningitis and SAH in depth of sulcus | 0 |
| AR | Normal | 0 | |
| BL | Normal | 0 | |
| BR | Normal | 0 | |
| C | Focal hemorrhage near deep gray nuclei | 2 | |
| D | Normal | 0 | |
| Sheep 07 | AL | Normal | 0 |
| AR | Normal | 0 | |
| BL | Normal | 0 | |
| BR | Normal | 0 | |
| C | Normal | 0 | |
| D | Normal | 0 |
| Recipient | No. of embryos transferred | No. offetuses | Days of gestation | Fetal fibroblast cell lines | Mono-allelic cell lines (%) | Bi-allelic cell lines (%) |
| R725 | 205 | 6 | 26 | F1, F2, F3, F4, F5, F6 | F3, F4, F5(50.0) | F1, F2(33.3) |
| R801 | 181 | 2 | 29 | F7, F8 | -(0%) | -(0%) |
| Groups | Days | HOMA-IR | HOMA-β |
| NCD | 0 | 4.18(3.66—5.16)bc | 200.98(143.36–346-67)bc |
| 28 | 4.23(3.71–4.77)bc | 192.12(186.6–265.41)bc | |
| T28-T0 | −0.10(−0.57–0.83) | 22.96(−157.98–63.57) | |
| HCHFD | 0 | 12.31(10.78–14.96)abc | 243.13(207.99–299.08)bc |
| 28 | 14.41(12.59–15.86)abc | 274.65(230.55–355.33)Sbc | |
| T28-T0 | 1.8(0.9–2.9) | 28.87(9.44–59.39) | |
| HCHFD200 | 0 | 11.58(11–14.86)abc | 238.48(222.92–284.91)bc |
| 28 | 5.31(4.85–6.41)Sbc | 240.23(153.31–417.24)bc | |
| T28-T0 | −6.36(−9.37_−5.38) | −5.57(−82.47–189.53) | |
| DBC | 0 | 28.24(21.39–29.41)a | 53.34(44.03–89.46)a |
| 28 | 26.86(21.11–28.75)a | 56.04(44.24–89.15)a | |
| T28-T0 | −0.64(−3.01–0.13) | 0.86(−0.31–3.52) | |
| DB200 | 0 | 27.10(20.58–29.96)a | 56.68 (49.59–83.27) a |
| 28 | 8.74(6.82–10.73)Sabc | 110.96(85.22–132.01) Sacb | |
| T28-T0 | −17.99(−19.22_−13.76) | 49.23 (31.78–68.42) | |
| DB400 | 0 | 26.63(21.14–32.28)a | 54.44 (49.38–74.84) |
| 28 | 5.32(4.26–5.44)Sbc | 142.75 (97.52–157.70) Sbc | |
| T28-T0 | −21.23(−28.01_−15.89) | 79.00 (48.14–107.25) | |
| DBMET | 0 | 27.40(23.41–29.12)a | 59.08 (49.53–66.67) a |
| 28 | 6.48(5.4–7.28)Sabc | 122.11 (93.53–185.55) Sbc | |
| T28-T0 | −21.22(−23.11_16.91) | 70.99 (26.86–127.90) |
| SVMs Models With Different Input Variable | Mean Absolute Percentage Error (MAPE) (%) |
| (a) Rebound Hammer (RH) Test | 8.92% |
| (b) Ultrasonic Pulse Velocity (UPV) Test | 9.25% |
| (c) SonReb (RH+UPV) Test | 6.77% |
| Province | Area (Hectares) | National Percentage | Province | Area (Hectares) | National Percentage |
| Agusan del Norte | 244.98 | 0.1 | Leyte | 5,807.07 | 2.26 |
| Aklan | 1,144.44 | 0.45 | Maguindanao | 907.92 | 0.35 |
| Albay | 1,081.17 | 0.42 | Marinduque | 2,732.22 | 1.06 |
| Antique | 945.9 | 0.37 | Masbate | 5,302.08 | 2.06 |
| Aurora | 497.07 | 0.19 | Metropolitan Manila | 39.69 | 0.02 |
| Basilan | 7,641.18 | 2.97 | Misamis Occidental | 2,066.49 | 0.8 |
| Bataan | 238.59 | 0.09 | Misamis Oriental | 341.19 | 0.13 |
| Batangas | 508.95 | 0.2 | Negros Occidental | 4,393.26 | 1.71 |
| Biliran | 231.39 | 0.09 | Negros Oriental | 2,004.93 | 0.78 |
| Bohol | 9490.5 | 3.69 | Northern Samar | 4,286.52 | 1.67 |
| Bulacan | 391.14 | 0.15 | Occidental Mindoro | 1,842.93 | 0.72 |
| Cagayan | 5,175.27 | 2.01 | Oriental Mindoro | 2,975.31 | 1.16 |
| Camarines Norte | 3,628.17 | 1.41 | Palawan | 5,6261.3 | 22.23 |
| Camarines Sur | 5,315.31 | 2.07 | Pampanga | 251.73 | 0.1 |
| Camiguin | 4.95 | 0 | Pangasinan | 1,206.63 | 0.47 |
| Capiz | 1,999.8 | 0.78 | Quezon | 14,170 | 5.51 |
| Catanduanes | 1,671.3 | 0.65 | Romblon | 792.45 | 0.31 |
| Cavite | 35.73 | 0.01 | Samar | 10,140.6 | 3.94 |
| Cebu | 2,893.77 | 1.13 | Sarangani | 92.61 | 0.04 |
| Compostela Valley | 130.14 | 0.05 | Shariff Kabunsuan | 1,018.89 | 0.4 |
| Davao del Norte | 195.57 | 0.08 | Siquijor | 70.2 | 0.03 |
| Davao del Sur | 361.53 | 0.14 | Sorsogon | 3,895.74 | 1.52 |
| Davao Oriental | 1975.5 | 0.77 | South Cotabato | 13.86 | 0.01 |
| Dinagat Islands | 1654.56 | 0.64 | Southern Leyte | 643.68 | 0.25 |
| Eastern Samar | 5,595.93 | 2.18 | Sultan Kudarat | 949.95 | 0.37 |
| Guimaras | 577.08 | 0.22 | Sulu | 2,0564.8 | 8 |
| Ilocos Norte | 127.53 | 0.05 | Surigao del Norte | 11867 | 4.62 |
| Ilocos Sur | 228.87 | 0.09 | Surigao del Sur | 5,642.55 | 2.19 |
| Iloilo | 1,322.91 | 0.51 | Tawi-Tawi | 11,322.2 | 4.4 |
| Isabela | 592.29 | 0.23 | Zambales | 981.54 | 0.38 |
| La Union | 144.18 | 0.06 | Zamboanga del Norte | 1,961.82 | 0.76 |
| Lanao del Norte | 1,580.94 | 0.61 | Zamboanga del Sur | 9,501.66 | 3.7 |
| Lanao del Sur | 620.37 | 0.24 | Zamboanga Sibugay | 13,889.2 | 5.4 |
| Symptom | Appetite | Tired-ness | Depression | Well-being | Pain | Anxiety | Nausea | Short of Breath | Drowsiness |
| One Month Before Death (n = 82) | |||||||||
| Appetite | 895.3 | ||||||||
| Tiredness | 242.4 | 399.6 | |||||||
| Depress. | 296.1 | 188.5 | 513.6 | ||||||
| Well-being | 427.5 | 218.8 | 320.6 | 550.1 | |||||
| Pain | 370.8 | 221.8 | 231.3 | 255.7 | 514.4 | 0.47 | 0.41 | 0.40 | 0.48 |
| Anxiety | 336.0 | 110.6 | 388.1 | 390.7 | 236.9 | 577.2 | 0.50 | 0.14 | 0.57 |
| Nausea | 172.4 | 97.6 | 177.7 | 144.6 | 153.3 | 190.3 | 297.2 | 0.16 | 0.40 |
| Short of Breath | 8.5 | 87.5 | 43.0 | 70.3 | 181.2 | 66.3 | 54.6 | 443.5 | 0.19 |
| Drowsy | 353.4 | 332.4 | 301.2 | 321.4 | 227.3 | 275.9 | 143.0 | 85.0 | 505.8 |
| One Week Before Death (n = 82) | |||||||||
| Appetite | 1029.2 | ||||||||
| Tiredness | 318.4 | 623.3 | |||||||
| Depress. | 250.5 | 261.9 | 848.6 | ||||||
| Well-being | 426.3 | 262.9 | 446.2 | 549.8 | |||||
| Pain | 166.4 | 310.1 | 276.5 | 226.1 | 715.9 | 0.40 | 0.37 | 0.42 | 0.43 |
| Anxiety | 205.2 | 241.8 | 661.9 | 372.4 | 280.1 | 811.5 | 0.65 | 0.33 | 0.49 |
| Nausea | 150.7 | 177.6 | 423.6 | 300.1 | 234.4 | 423.5 | 620.8 | 0.39 | 0.39 |
| Short of Breath | 204.4 | 164.4 | 347.7 | 227.4 | 288.5 | 243.8 | 252.2 | 739.6 | 0.32 |
| Drowsy | 406.6 | 522.2 | 359.0 | 376.6 | 295.1 | 345.6 | 250.5 | 226.7 | 765.1 |
| Category | Category | ||||||||
| Patient | 1 | 2 | 3 | 4 | Patient | 1 | 2 | 3 | 4 |
| 1 | 1 | 0 | 0 | 0 | 24 | 0.14 | 0.86 | 0 | 0 |
| 2 | 0 | 0 | 0.95 | 0.05 | 25 | 1 | 0 | 0 | 0 |
| 3 | 0.5 | 0.5 | 0 | 0 | 26 | 1 | 0 | 0 | 0 |
| 4 | 0.24 | 0.76 | 0 | 0 | 27 | 0 | 0.93 | 0.07 | 0 |
| 5 | 0 | 1 | 0 | 0 | 28 | 1 | 0 | 0 | 0 |
| 6 | 0 | 1 | 0 | 0 | 29 | 1 | 0 | 0 | 0 |
| 7 | 0.68 | 0.32 | 0 | 0 | 30 | 0.82 | 0.18 | 0 | 0 |
| 8 | 0 | 0 | 1 | 0 | 31 | 1 | 0 | 0 | 0 |
| 9 | 0 | 1 | 0 | 0 | 32 | 0 | 0 | 1 | 0 |
| 10 | 0 | 0.85 | 0.15 | 0 | 33 | 1 | 0 | 0 | 0 |
| 11 | 0 | 0 | 0 | 1 | 34 | 0 | 1 | 0 | 0 |
| 12 | 0 | 0.65 | 0.35 | 0 | 35 | 0 | 0.93 | 0.07 | 0 |
| 13 | 1 | 0 | 0 | 0 | 36 | 0 | 0 | 0.73 | 0.27 |
| 14 | 0.11 | 0.89 | 0 | 0 | 37 | 0.14 | 0.85 | 0.02 | 0 |
| 15 | 0.99 | 0.01 | 0 | 0 | 38 | 0 | 0.51 | 0.49 | 0 |
| 16 | 1 | 0 | 0 | 0 | 39 | 0 | 0 | 1 | 0 |
| 17 | 1 | 0 | 0 | 0 | 40 | 1 | 0 | 0 | 0 |
| 18 | 1 | 0 | 0 | 0 | 41 | 1 | 0 | 0 | 0 |
| 19 | 0 | 1 | 0 | 0 | 42 | 0.89 | 0.11 | 0 | 0 |
| 20 | 0.1 | 0.9 | 0 | 0 | 43 | 0 | 0.93 | 0.07 | 0 |
| 21 | 0 | 1 | 0 | 0 | 44 | 0.99 | 0.01 | 0 | 0 |
| 22 | 0 | 1 | 0 | 0 | 45 | 0 | 1 | 0 | 0 |
| 23 | 0 | 1 | 0 | 0 |
| Cause of death | Men | Women | ||
| 1997 (95% CI) | 2014 (95% CI) | 1997 (95% CI) | 2014 (95% CI) | |
| I00–I99 Diseases of the circulatory system | 709.3 (699.9–718.6) | 401.5 (395.2–407.8) | 449.8 (444.0–455.6) | 283.2 (278.9–287.5) |
| I20–I25 Ischemic heart diseases | 378.6 (371.9–385.3) | 174.4 (170.3–178.5) | 194.7 (190.9–198.6) | 95.3 (92.8–97.7) |
| I60–I69 Cerebrovascular diseases | 142.6 (138.4–146.8) | 73.4 (70.7–76.1) | 117.6 (114.6–120.6) | 62.8 (60.8–64.8) |
| I30–I52 Other forms of heart disease | 99.9 (96.3–103.5) | 100.9 (97.6–104.1) | 75.5 (73.1–77.) | 78.5 (76.3–80.7) |
| C00–D48 Neoplasms | 341.2 (334.9–347.4) | 289 (283.9–294.1) | 225.5 (221.2–229.8) | 208.2 (204.3–212.1) |
| C15–C26 Malignant neoplasms of digestive organs | 99.8 (96.5–103.2) | 86 (83.2–88.7) | 69.6 (67.2–72.0) | 61.6 (59.5–63.7) |
| C61 Malignant neoplasm prostate | 76.7 (73.6–79.7) | 61.1 (58.6–63.5) | ** | ** |
| C50–C50 Malignant neoplasm of breast | 0.3 (0.1–0.5) | 0.1 (0.0–0.2) | 32.5 (30.9–34.1) | 26.5 (25.1–27.8) |
| C51–C58 Malignant neoplasms of female genital organs | ** | ** | 27.5 (26.0–29.0) | 22.6 (21.3–23.9) |
| C30–C39 Malignant neoplasms of respiratory and intrathoracic organs | 54.6 (52.2–57.1) | 43.1 (41.1–45.0) | 26.6 (25.0–28.1) | 36.1 (34.4–37.7) |
| C34 Malignant neoplasm of bronchus and lung | 51.7 (49.3–54.0) | 40.9 (39.0–42.8) | 25.5 (24.0–27.0) | 35.5 (33.9–37.1) |
| J00–J99 Diseases of the respiratory system | 117.2 (113.3–121.1) | 71.1 (68.4–73.7) | 70.1 (67.8–72.5) | 48.7 (46.8–50.5) |
| J09–J18 Influenza and pneumonia | 62.2 (59.3–65.1) | 25.6 (23.9–27.2) | 41.8 (40.1–43.6) | 14.2 (13.3–15.2) |
| J40–J47 Chronic lower respiratory diseases | 42.5 (40.2–44.8) | 31.9 (30.1–33.6) | 21.2 (19.9–22.5) | 28.5 (27.1–29.9) |
| V01–Y98 External causes of morbidity and mortality | 74.7 (71.9–77.4) | 69.4 (66.9–71.9) | 33.2 (31.6–34.8) | 33 (31.5–34.5) |
| X60–X84 Intentional self-harm | 20.8 (19.4–22.2) | 16.6 (15.4–17.8) | 7.7 (6.9–8.5) | 7.4 (6.6–8.5) |
| W00–W19 Falls | 10.1 (9.0–11.1) | 14.2 (13.0–15.4) | 5.2 (4.5–5.8) | 7.5 (6.8–8.2) |
| F00–F99 Mental and behavioral disorders | 37.5 (35.4–39.7) | 55.3 (52.9–57.7) | 34 (32.4–35.6) | 64.3 (62.3–66.3) |
| F03 Unspecified dementia | 18 (16.4–19.6) | 37.3 (35.3–39.3) | 25.3 (23.9–26.6) | 49.5 (47.8–51.3) |
| G00–G99 Diseases of the nervous system | 22 (20.5–23.6) | 41.9 (39.9–43.9) | 19.9 (18.6–21.1) | 41.8 (40.1–43.5) |
| G30 Alzheimer’s disease | 6 (5.2–6.9) | 20.1 (18.7–21.6) | 7 (6.3–7.8) | 26.2 (24.9–27.4) |
| A00–B99 Certain infectious and parasitic diseases | 12.9 (11.7–14.2) | 27.1 (25.5–28.8) | 9 (8.1–9.8) | 18.2 (17.1–19.3) |
| R00–R99 Symptoms, signs, abnormal clinical and laboratory findings, not elsewhere classified | 26.7 (24.8–28.6) | 30.1 (28.4–31.8) | 25.9 (24.5–27.3) | 29.3 (27.9–30.7) |
| Total | 1451.1 (1438–1464) | 1078.6 (1068–1089) | 944.3 (936–953) | 793.9 (787–801) |
| Marker | D number | Primer sequences (5’>3’) | Annealing temperature (°C) | Product size (bp) |
| ATA29H01 | D12S1048 | GGTCTGCTTAGGTCCCTTTT | 55 | 209-229 |
| AAGGAACCAAGGAGTGGAAG | ||||
| Mfd75A | D12S59 | CTCACTCATGCTTGTTTTGA | 60.3 | 164-179 |
| GATCACGTCAGACTGGGCT | ||||
| AFM092wd11 | D12S331 | TAACATTTATTCATCTCCATACTGA | 57.8 | 175-181 |
| ACATGTAAGAGAGNAAGTTTACAAA | ||||
| AFM296yg5 | D12S345 | CAGCCTGGGTAACAAA | 57.8 | 209-238 |
| AGCAATGTGTGCATTC | ||||
| UT8102 | D16S689 | GCCTGGGCGATAAGTGAGA | 56 | 209 |
| TCACCACAACCCAAACATTC | ||||
| AFM156xb8 | D16S3026 | CTCCCTGAGCAACAAACACC | 55 | 178-210 |
| GGTCATTTATATGCGCCTGA | ||||
| AFMa306yf1 | D16S3063 | AGCTTGTTTTAGCAANAATTTC | 59 | 218-260 |
| TGCCTGATTCCACCAA | ||||
| AFM342xd9 | D16S3121 | CATGTTGTACATCGTGATGC | 58 | 79-85 |
| AGCTTTTATTTCCCAGGGGT |
| Gene | Forward | Reverse |
| EP1 | 5′-ATGGTGGGCCAGCTTGTC-3′ | 5′-GCCACCAACACCAGCATTG-3′ |
| EP2 | 5′-TCCTTGCCTTTCACGATTT-3′ | 5′-AGAGCTTGGAGGTCCCATT-3′ |
| EP3 | 5′-TGGTCTCCGCTCCTGATAA-3′ | 5′-TGCATTCTTTCTGCTTCTCC-3′ |
| EP4 | 5′-TGCTCTTCTTCAGCCTGTCC-3′ | 5′-GAGCTACCGAGACCCATGTT-3′ |
| FP | 5′-TCTGGTCTGTGCCCACTTC-3′ | 5′-GACTCCAATACACCGCTCAAT-3′ |
| PGT | 5′-CTGGTGGATTTCATTAAACGG-3′ | 5′-GGCTGCTGAGGTGCCATAC-3′ |
| MRP4 total | 5′-AAAGTGCCAAAGTAATCCAGC-3′ | 5′-GTTCAAAGCCACAGAATCCA-3′ |
| MRP4 variant 1 | 5′-CGGGCATACAAAGCAGAA-3′ | 5′-GGACCCAAAGGCAACG-3′ |
| HIV-uninfecteda | HIV-infectedb | ||||||
| All | Benin | Gabon | Mozambique | All | Kenya | Mozambique | |
| n = 946 | n = 349 | n = 257 | n = 340 | n = 768 | n = 351 | n = 417 | |
| Age (years), mean (SD) | |||||||
| 24.3 (6.3) | 25.4 (5.2) | 24.4 (6.7) | 23.1 (6.8) | 26.7 (5.7) | 26.9 (5.4) | 26.5 (5.9) | |
| Parity, n (%) | |||||||
| Primigravidae | 265 (28) | 69 (20) | 66 (26) | 130 (38) | 81 (11) | 30 (9) | 51 (12) |
| Multigravidae | 681 (72) | 280 (80) | 191 (74) | 210 (62) | 687 (89) | 321 (91) | 366 (88) |
| Gestational age at baseline (weeks), mean (SD) | |||||||
| 21.0 (4.9) | 22.0 (4.1) | 19.5 (5.4) | 21.3 (5.2) | 20.3 (5.5) | 19.9 (5.9) | 20.6 (5.2) | |
| MUAC at baseline (cm), mean (SD) | |||||||
| 25.9 (3.0) | 25.3 (2.3) | 25.7 (3.6) | 26.8 (3.0) | 26.8 (2.7) | 27.0 (2.7) | 26.7 (2.7) | |
| RPR at baseline, n (%) | |||||||
| Positive | 9 (1) | 2 (1) | 1 (0) | 6 (2) | 39 (5) | 12 (3) | 27 (7) |
| Negative | 928 (99) | 347 (99) | 247 (100) | 334 (98) | 726 (95) | 338 (97) | 388 (93) |
| Literate, n (%) | |||||||
| No | 371 (39) | 280 (80) | 34 (13) | 57 (17) | 142 (18) | 16 (5) | 126 (30) |
| Yes | 575 (61) | 69 (20) | 223 (87) | 283 (83) | 626 (82) | 335 (95) | 291 (70) |
| HIV viral load (copies/mL) at baseline, n (%)c | |||||||
| < 399 | 181 (24) | 125 (36) | 56 (13) | ||||
| 400/999 | 183 (24) | 76 (22) | 107 (26) | ||||
| 1000/9999 | 243 (32) | 97 (28 | 146 (35) | ||||
| 10,000/max | 123 (16) | 49 (14) | 74 (18) | ||||
| UNK | 38 (5) | 4 (1) | 34 (8) | ||||
| CD4 (cells/μL) at baseline, n (%)d | |||||||
| < 350 | 279 (36) | 137 (39) | 142 (34) | ||||
| 350/max | 460 (60) | 212 (60) | 248 (59) | ||||
| UNK | 29 (4) | 2 (1) | 27 (6) | ||||
| Maternal haemoglobin at baseline (g/dL), mean (SD) | |||||||
| 10.4 (1.5) | 10.3 (1.2) | 10.3 (1.4) | 10.7 (1.8) | 10.1 (1.7) | 10.2 (1.9) | 10.0 (1.6) | |
| IPTp, n (%) | |||||||
| Antimalarial 1e | 629 (66) | 230 (66) | 172 (67) | 227 (67) | 390 (51) | 174 (50) | 216 (52) |
| Antimalarial 2e | 317 (34) | 119 (34) | 85 (33) | 113 (33) | 378 (49) | 177 (50) | 201 (48)) |
| Gestational age at delivery (weeks),f mean (SD) | |||||||
| 39.6 (1.7) | 39.2 (1.2) | 41.1 (1.8) | 38.9 (1.2) | 38.8 (1.2) | ND | 38.8 (1.2) | |
| Preterm birth,g n (%) | |||||||
| No | 867 (95) | 328 (95) | 238 (95) | 301 (95) | 374 (96) | ND | 374 (96) |
| Yes | 44 (5) | 16 (5) | 13 (5) | 15 (5) | 17 (4) | ND | 17 (4) |
| Body Areas | Severity of Hirsutism | p | |||||
| Mild | Moderate | Severe | |||||
| Mean | SE * | Mean | SE | Mean | SE | ||
| Upper lip | 1.99 | 0.07 | 2.60 | 0.07 | 3.10 | 0.22 | <0.001 |
| Chin | 2.07 | 0.11 | 3.16 | 0.10 | 3.95 | 0.05 | <0.001 |
| Upper back | 0.53 | 0.05 | 1.30 | 0.09 | 2.55 | 0.23 | <0.001 |
| Lower back | 0.64 | 0.06 | 2.08 | 0.11 | 3.40 | 0.17 | <0.001 |
| Upper arm | 0.25 | 0.04 | 1.01 | 0.10 | 2.75 | 0.26 | <0.001 |
| Thighs | 2.07 | 0.07 | 3.13 | 0.07 | 3.70 | 0.11 | <0.001 |
| Chest | 0.30 | 0.05 | 0.96 | 0.09 | 2.60 | 0.21 | <0.001 |
| Upper abdomen | 1.01 | 0.07 | 2.22 | 0.08 | 3.25 | 0.16 | <0.001 |
| Lower abdomen | 3.48 | 0.08 | 3.88 | 0.04 | 4.00 | 0.00 | <0.001 |
| Sideburn | 1.33 | 0.07 | 2.91 | 0.10 | 3.90 | 0.07 | <0.001 |
| Lower jaw/neck | 0.66 | 0.08 | 1.34 | 0.11 | 3.00 | 0.23 | <0.001 |
| Buttock/perineum | 0.67 | 0.08 | 1.92 | 0.12 | 2.90 | 0.27 | <0.001 |
| Total m-FG score 9 areas | 12.33 | 0.20 | 20.34 | 0.22 | 28.10 | 0.47 | <0.001 |
| Total score for 3 new areas | 3.33 | 0.21 | 6.17 | 0.23 | 9.40 | 1.00 | <0.001 |
| Total score for all 12 areas | 15.67 | 0.33 | 26.51 | 0.40 | 37.85 | 1.07 | <0.001 |
| Technique | Comments | |
| PRECONTRAST | ||
| Dark blood stacks typically in axial, coronal and sagittal planes e.g. HASTE | Provides vessel wall imaging as well as complementary information to CE-MRA regarding lumen | |
| Noncontrast bright blood stack(s) e.g. SSFP | ||
| CONTRAST | ||
| 3D contrast-enhanced magnetic resonance angiography e.g. spoiled gradient echo | Appropriate vasculature should be covered depending on clinical questions and known or suspected diagnosis (see Table 2) | |
| POSTCONTRAST | ||
| T1-weighted vessel wall imaging e.g. VIBE or FAME | Additional vessel wall imaging, particularly useful to delineate thickening and thrombus | |
| CARDIAC ACQUISITIONS | ||
| Multiplane cine imaging e.g. SSFP Aortic valve velocity-encoded cine Myocardial imaging: T2 precontrast, T1W early post contrast, late post-gadolinium imaging | May be appropriate when aortic root disease involves the aortic valve or when myocardial inflammation is suspected, particularly in small-vessel vasculitides |
| Gene symbol | Gene name | Log2FC (P/M) | FDR |
| Igj | Immunoglobulin joining chain | 8.6779562 | 2.29E-11 |
| Ly6c2 | Lymphocyte antigen 6 complex, locus C2 | 12.30121239 | 2.92E-09 |
| Slfn4 | Schlafen 4 | 15.5668286 | 1.75E-06 |
| Lcn2 | Lipocalin 2 | 7.312076677 | 3.37E-05 |
| Slpi | Secretory leukocyte peptidase inhibitor | 12.73813718 | 5.33E-05 |
| Ccdc126 | Coiled-coil domain containing 126 | −8.341365207 | 0.000225043 |
| Atp5g3 | ATP synthase, H+ transporting, mitochondrial F0 complex, subunit C3 (subunit 9) | −11.69540624 | 0.000280756 |
| Fsd1l | Fibronectin type III and SPRY domain containing 1-like | −6.703008314 | 0.000462131 |
| Dnajc12 | DnaJ heat shock protein family | −14.11777559 | 0.000618267 |
| Rbm8a | RNA binding motif protein 8a | −11.28615955 | 0.001526552 |
| Fat3 | FAT atypical cadherin 3 | −14.08641235 | 0.003575335 |
| Col3a1 | Collagen, type III, alpha 1 | 14.61654737 | 0.003584831 |
| Akap17b | A kinase (PRKA) anchor protein 17B | −10.53057236 | 0.009607167 |
| Cysltr1 | Cysteinyl leukotriene receptor 1 | −14.65367542 | 0.009752316 |
| Sgip1 | SH3-domain GRB2-like (endophilin) interacting protein 1 | −6.380242524 | 0.011651515 |
| Pou2af1 | POU domain, class 2, associating factor 1 | 9.055182034 | 0.019402858 |
| Dnm1 | Dynamin 1 | −12.9307709 | 0.050431759 |
| Variable | Baseline | 6 months |
| Energy (Kcal) | 2225 ± 1109 | 1589 ± 384 ** |
| Carbohydrate (g) | 273 ± 194 | 199 ± 74 * |
| Protein (g) | 98 ± 36 | 78 ± 23 * |
| Fat (g) | 84 ± 39 | 55 ± 18 ** |
| Starch (g) | 148 ± 48 | 114 ± 36 * |
| Sugar (g) | 121 ± 171 | 74 ± 64 |
| Non-starch polysaccharide (g) | 18 ± 5 | 14 ± 3 ** |
| Saturated fatty acids (g) | 30 ± 16 | 20 ± 6 ** |
| Monounsaturated fatty acids (g) | 29 ± 12 | 19 ± 7 ** |
| Polyunsaturated fatty acids (g) | 16 ± 8 | 10 ± 4 ** |
| Knee painn = 404 | Symptomaticknee OAn = 109 | OR (95% CI) | |
| Pain unbearable at times | 36% | 59% | 2.0 (1.3 to 3.3) |
| Limited activity | 39% | 64% | 2.4 (1.5 to 4.0) |
| Herbal medicine | 25% | 60% | 4.4 (2.7 to 7.5) |
| Acupuncture | 20% | 40% | 2.2 (1.3 to 3.8) |
| Massage | 4% | 6% | 1.2 (0.4 to 3.3) |
| Other TCM | 26% | 35% | 1.6 (0.9 to 2.6) |
| NSAIDs | 78% | 88% | 2.1 (1.1 to 4.4) |
| Paracetamol | 2% | 6% | 3.4 (1.0 to 11.2) |
| Other Western medicine | 13% | 21% | 2.0 (1.0 to 4.0) |
| Physiotherapy | 10% | 17% | 1.1 (0.5 to 2.2) |
| Doctor past year? | 33% | 59% | 2.9 (1.8 to 4.8) |
| S-RNase Region (codon positions) | ||||||
| Test | HVa (1-38) | HVb (44-62) | C3 (63-68) | V1 (69-84) | C4 (85-93) | V2 (94-131) |
| ωp/ωsαPhysalis codons | 7,8, 10,11, 13,14,15, 26, 33 | 44, 46, 4952, 53,56 (0.97), 5962 | ---- | 69, 71, 84 | 87 (0.98) | 9, 101, 104, 110, 111,112, 119 (0.96), 120 (0.96),123, 124 (0.97), 125127 (0.95), 129, 131 |
| FEL CSPbPhysalis codons | 8, 9,13, 24,26 (0.08), 31 | 46, 53 | - | 84 | 87 | 96, 99, 116, 125127, 129, 131 |
| FEL Clade APhysalis codons | 3, 6, 9,10, 13 | 46, 56 | - | 87, 89, 90 | 96, 99, 110, 121 | |
| FEL Clade CPhysalis codons | 9, 14, 24 | 44, 57 | - | 92 | 97, 127, 129 | |
| FEL Clade ScSolanum codons | 21, 22, 23, 2930, 32, 34, 35, 38 | 60 | Clade A as forground- | 77 | 103, 106, 109 | |
| FEL Clade ScSolanum codons | 23, 31 | 47, 48, 50 | Clade C as forground- | 80 | 124 |
| Species | Volume (μL) | Mycotoxin | Extraction Procedure | Detection Technique | LOD (μg/L) | LOQ (μg/L) | Reference |
| Single mycotoxin | |||||||
| Human | 50 | OTA | LLE: CH2Cl2 | ELISA vs. CE-LIF (CE/laser-induced FD) | 0.5 | - | [39] |
| Human | - | OTA | IAC | HPLC-FD | - | - | [42] |
| Human | - | OTA | SPE: Sep-Pak RP-18. IAC: Ochraprep | HPLC-FD | 0.1 | 0.4 | [44] |
| Human | - | OTA | LLE: CHCl3/HCl | HPLC-FD | 0.05 | - | [35] |
| Human | 2000 | OTA | LLE: CHCl3 | HPLC-FD LC-ESI-MS/MS | 0.01 | 0.07 | [36] |
| Human | 6000 | OTA | SPE: C18 | HPLC-FD | 0.1 | 0.2 | [41] |
| Human | 1000 | OTA | LLE: CHCl3, SPE | HPLC-FD | 0.05 | - | [37] |
| Human | 2000–3000 | OTA | LLE: CHCl3, IAC: Ochraprep | ELISA and HPLC-FD | - | 0.050 | [38] |
| Human | - | OTA | IAC: Ochraprep | HPLC-FD | - | 0.1 | [43] |
| Human | - | AFB1 | IAC: Easi-Extract Aflatoxin | ELISA | - | - | [50] |
| Rat | 100 | ZON | LLE: TBME | LC-MS/MS | - | 0.5 | [48] |
| Rat | 100 | ZON | LLE: TBME | HPLC-FD | - | 10 | [49] |
| Swine | 800 | OTA | LLE: CH2Cl2 | HPLC | 0.1 | - | [40] |
| Chicken | 250 | DON | LLE: ACN | LC-MS/MS | 0.1–0.2 | 1 | [46,47] |
| Horse | 2000 | OTA | LLE: CH2Cl2, IAC: Ochratest | ELISA, HPLC-FD | 0.015 | - | [21] |
| Multi-mycotoxin | |||||||
| Human | 500 | OTA, OTα | LLE: CHCl3/isopropanol | HPLC-FD | 0.05 | 0.1 | [58] |
| Chicken | 20–250 | EN B, EN B1 | LLE: ACN | LC/MS/MS, UHPLC-HRMS | 0.000091–0.00017 | 0.025 | [45] |
| Pig | 250 | EN A, A1, B, B1 | LLE: ACN | LC-MS/MS | 0.01–0.001 | 0.1–0.2 | [52,53] |
| Pig | 250 | DON, T-2, HT-2, OTA, FB1, AFB1, ZON, ZAN, α-ZOL, β-ZOL, α-ZAL, β-ZAL, DOM-1 | LLE: ACN | LC-MS/MS | 0.01–0.52 | 0.5–10 | [51,54] |
| Chicken, pig, laying hens, turkey poults | 250 | ZON, α-ZOL, β-ZOL, ZAN, α-ZAL, β-ZAL | LLE: ACN | LC–MS/MS (U)HPLC–HR-MS | 0.004–0.07 | 0.2–5 | [55,57] |
| Chicken, Pig | 250 | DON, 3-ADON, 15-ADON, DOM-1 | LLE: ACN | LC–MS/MS | 0.01–0.7 | 0.1–2 | [56] |
| Fish | 250 | AFB1, AFB2, AFG1, AFG2, OTA, FUS-X, STG, FB1, FB2, FB3, BEA, EN A, EN A1, EN B, EN B1 | DLLME: ACN/EtOAc | LC/MS/MS | 0.1–12.0 | 1.5–17.0 | [59] |
| Product/active ingredient(s) | Formulation | Country of origin* | 2005 availability (n = 29) | Named in the top 3 sellers in 2005 (n = 28) | Mean selling price 2005† |
| 1. artemether/lumefantrine | 20/120 mg tablets, co-formulated | Switzerland | 21 (72.4%) | 5 (17.9%) | $ 7.59 |
| 2. artesunate and mefloquine | 200 mg and 250 mg tablets, co-packaged | Switzerland | 17 (58.6%) | 0 | $ 7.05 |
| 3. artesunate | 50 mg tablets | China | 6 (20.7%) | 0 | $ 4.62 |
| 4. artesunate | 50 mg tablets | France | 24 (82.8%) | 7 (25.0%) | $ 5.48 |
| 5. artesunate | 50 mg tablets | Switzerland | 8 (27.6%) | 0 | $ 5.26 |
| 6. artesunate | 50 mg tablets | Belgium | 28 (96.6%) | 3 (10.7%) | $ 3.53 |
| 7. artesunate | 50 mg tablets | India | 17 (58.6%) | 0 | $ 2.51 |
| 8. artesunate | 100 mg tablets | Belgium | 28 (96.6%) | 28 (100%) | $ 4.99 |
| 9. artesunate | 100 mg tablets | Tanzania | 7 (24.1%) | 1 (3.6%) | $ 2.19 |
| 10. artesunate | 100 mg tablets | Tanzania | 20 (69.0%) | 6 (21.4%) | $ 1.92 |
| 11. artesunate | 100 mg tablets | Kenya | 2 (6.9%) | 0 | $ 2.31 |
| 12. artesunate | 200 mg tablets | Switzerland | 19 (65.5%) | 1 (3.6%) | $ 6.72 |
| 13. artemether | 40 mg tablets | India | 8 (27.6% 0 | 0 | $ 2.24 |
| 14. artemether | 50 mg tablets | China | 24 (82.8%) | 15 (53.6%) | $ 4.74 |
| 15. artemether | 180 mg/60 ml suspension | Belgium | 18 (62.1%) | 0 | $ 4.65 |
| 16. artemether | 300 mg/100 ml suspension | Belgium | 3 (10.3%) | 0 | $ 5.75 |
| 17. dihydroartemisinin | 60 mg tablets | Korea | 18 (62.1%) | 0 | $ 4.36 |
| 18. dihydroartemisinin | 60 mg tablets | China | 25 (86.2%) | 9 (35.7%) | $ 4.55 |
| 19. dihydroartemisinin | 160 mg/80 ml suspension | China | 20 (69.0%) | 0 | $ 4.18 |
| Overall survival | Distant disease-free survival | |||||
| HR | 95% CI | P | HR | 95% CI | P | |
| pT2 + pT3 | 1.75 | 0.99 to 3.10 | 0.06 | 1.33 | 0.83 to 2.15 | 0.24 |
| Molecular subtype | 0.02 | 0.08 | ||||
| Basal | 1 | 1 | ||||
| Luminal A | 0.22 | 0.08 to 0.60 | 0.46 | 0.25 to 0.85 | ||
| HER2 | 0.25 | 0.03 to 1.85 | 0.53 | 0.16 to 1.73 | ||
| Luminal B | 0.87 | 0.48 to 1.59 | 0.82 | 0.49 to 1.38 | ||
| Adjuvant chemotherapy | 0.96 | 0.38 to 2.45 | 0.94 |
| Reference strains | International code1 | Source |
| L.(L.)mexicana | MHOM/BZ/62/BEL21 | 1 |
| L.(L.)mexicana | MHOM/BZ/62/M379 | 1 |
| L.(L.)amazonensis | IFLA/BR/67/PH8 | 1 |
| L.(L.)amazonensis | MHOM/BR/73/M2269 | 1 |
| L.(L.)garnhami | MHOM/VE/75/HM76 | 1 |
| L.(L.)garnhami | MHOM/VE/76/JAP78 | 1 |
| L.(L.)pifanoi | MHOM/VE/57/LL1 | 1 |
| IHC | FISH | |
| Positive | Negative | |
| Positive | 9 | 5 |
| Negative | 2 | 6 |
| P value | 0.183 |
| Amplicon | Test of equality* | Test of variance** |
| Cav | p = 0.24 | p < 0.001 |
| CTGF | p < 0.001 | p < 0.001 |
| Eln | p = 1 | p < 0.001 |
| FN | p = 0.65 | p < 0.001 |
| L27 | p = 0.8 | p < 0.001 |
| Perl | p = 1 | p < 0.001 |
| PAI-1 | p = 0.93 | p < 0.001 |
| Scenarios (Detailed description in Method section)and total number of respondents | Expected responses (Detailed description in Method section) | Most often selected strategy by French respondents(N = 99) | Agreement in French study with expected choice(Yes/No/Partial) | Most often selected strategy by Swedish respondents[[2]] (N = 59) | Agreement in previous Swedish study with expected choice(Yes/No/Partial) | Agreement between French and previous Swedish study(Yes/No/Partial) |
| 1 N = 96 | Quick fix | Quick fix (41%) | Yes | Quick fix (54%) | Yes | Yes |
| 2 N = 97 | Quick fix or Symptom- guided MC | Clinical findings-guided MC (53%) (moderate consensus) | No | Symptom-guided MC (44%) | Yes | No |
| 3 N = 91 | Try again | 2nd opinion (21%) or try again (20%) | Partial | Try again (42%) | Yes | Partial |
| 4 N = 95 | Symptom-guided MC or (possibly) Clinical findings-guidedMC | Symptom-guided MC (39%) or Clinical findings- guided MC(39%) | Yes | Symptom-guided MC (46%) | Yes | Yes |
| 5 N = 95 | Try again or External help-keep in touch | 2nd opinion (27%) | No | Try again (25%) or Clinical findings- guided MC(24%) | Yes | No |
| 6 N = 92 | Try again or External help-keep in touch | External help- keep in touch (27%) or try again (26%) | Yes | Try again (37%) | Yes | Yes |
| 7 N = 92 | Try again or external help-keep in touch | 2nd opinion (48%) | No | Try again (32%) | Yes | No |
| 8 N = 92 | 2ndopinion | 2nd opinion (71%) (excellent consensus) | Yes | 2ndopinion (59%) | Yes | Yes |
| 9 N = 91 | 2ndopinion | 2nd opinion (61%) (moderate consensus) | Yes | 2ndopinion (59%) | Yes | Yes |
| Genotype | Number of subjects | Overall effect | Heterogeneity | |||||
| COPD | Total | OR (95%CI) | Z | p | Chi2 | p | I2 (%) | |
| GA/GG | 1432/1201 | 6227/6188 | 1.27 (1.15- 1.40) | 4.81 | <10-5 | 7.71 | 0.17 | 35 |
| AA/GG | 438/1201 | 1621/6188 | 1.50 (1.30- 1.73) | 5.51 | <10-5 | 2.02 | 0.85 | 0 |
| Sample name | Total reads | Total mapped | Multiple mapped | Uniquely mapped |
| L1 | 51313614 | 37633474 (73.34 %) | 1891840 (3.69 %) | 35741634 (69.65 %) |
| L2 | 38408586 | 28132542 (73.25 %) | 1626290 (4.24 %) | 26506252 69.01 %) |
| L3 | 38156116 | 23779230 (62.32 %) | 1254082 (3.29 %) | 22525148 (59.03 %) |
| L4 | 28642682 | 18996768 (66.32 %) | 873594 (3.05 %) | 18123174 (63.27 %) |
| L5 | 29417132 | 18996768 (64.58 %) | 2319892 (7.89 %) | 16676876 (56.69 %) |
| L6 | 34296982 | 24799284 (72.31 %) | 1048878 3.06%) | 23750406 (69.25 %) |
| L7 | 28755318 | 16604970 (57.75 %) | 896548 (3.12 %) | 15708422 (54.63 %) |
| L8 | 31712370 | 21846718 (68.89 %) | 980318 (3.09 %) | 20866400 (65.80 %) |
| L9 | 28387782 | 17806510 (62.73 %) | 917208 (3.24 %) | 16889302 (59.49 %) |
| L10 | 32217694 | 20532020 (63.73 %) | 896152 (2.78 %) | 19635868 (60.95 %) |
| H1 | 27038432 | 19212408 (71.06 %) | 944260 (3.50 %) | 18268148 (67.56 %) |
| H2 | 32458530 | 23913728 (73.67 %) | 999786 (3.08 %) | 22913942 (70.59 %) |
| H3 | 31355676 | 23459842 (74.82 %) | 933980 (2.98 %) | 22525862 (71.84 %) |
| H4 | 32236792 | 22698066 (70.41 %) | 949798 (2.95 %) | 21748268 (67.46 %) |
| H5 | 31144146 | 20791688 (66.76 %) | 1004534 (3.23 %) | 19787154 63.53 %) |
| H6 | 32072196 | 22910946 (71.44 %) | 1293062 (4.04 %) | 21617884 (67.40 %) |
| H7 | 38188984 | 25973682 (68.01 %) | 1154850 (3.02 %) | 24818832 64.99 %) |
| H8 | 32100360 | 23224306 (72.35 %) | 945914 (2.95 %) | 22278392 (69.40 %) |
| H9 | 30227962 | 20288464 (67.12 %) | 997090 (3.30 %) | 19291374 (63.82 %) |
| H10 | 29321524 | 19085218 (65.09 %) | 1073550 (3.66 %) | 18011668 (61.43 %) |
| H11 | 32631714 | 21820588 (66.87 %) | 1021428 (3.13 %) | 20799160 (63.74 %) |
| H12 | 26763546 | 14871754 (55.57 %) | 748546 (2.80 %) | 14123208 (52.77 %) |
| H13 | 28755192 | 16809674 (58.46 %) | 870238 (3.03 %) | 15939436 (55.43 %) |
| Personality Disorder | Healthy control | |||
| Passednumber, rate | Failednumber, rate | Passednumber, rate | Failednumber, rate | |
| Hand lowering | 55, 71.4% | 22, 28.6% | 106, 68.8% | 48, 31.2% |
| Moving hands apart | 52, 67.5% | 25, 32.5% | 108, 70.1% | 46, 29.9% |
| Mosquito hallucination | 44, 57.1% | 33, 42.9% | 89, 57.8% | 65, 42.2% |
| Taste hallucination | 55, 71.4% | 22, 33.8% | 98, 63.6% | 56, 36.4% |
| Arm rigidity | 52, 67.5% | 25, 32.5% | 99, 64.3% | 55, 35.7% |
| Dream | 38, 49.4%* | 39, 50.6% | 55, 35.7% | 99, 64.3% |
| Age regression | 65, 84.4% | 12, 15.6% | 127, 82.5% | 27, 17.5% |
| Arm immobilization | 42, 54.5% | 35, 45.5% | 76, 49.4% | 78, 50.6% |
| Anosmia to ammonia | 16, 20.8% | 61, 79.2% | 39, 25.3% | 115, 74.7% |
| Hallucinated voice | 7, 9.1% | 70, 90.9% | 10, 6.5% | 144, 93.5% |
| Negative visual hallucination | 23, 29.9% | 54, 70.1% | 52, 33.8% | 102, 66.2% |
| Posthypnotic amnesia | 22, 28.6%* | 55, 71.4% | 23, 14.9% | 131, 85.1% |
| Gene name | Description | Adjusted P value (DB/WT) | Adjusted P value (GGQL/DB) |
| Pgam1 | Phosphoglycerate mutase 1 | <0.0001 | 0.0038 |
| Igf1 | Insulin-like growth factor 1 | 0.0060 | 0.0029 |
| Cpeb4 | Cytoplasmic polyadenylation element binding protein 4 | 0.0141 | 0.0283 |
| Slc38a2 | Solute carrier family 38, member 2 | 0.0000 | <0.0001 |
| Vegfa | Vascular endothelial growth factor A | 0.0001 | 0.0005 |
| Banp | BTG3-associated nuclear protein | <0.0001 | 0.0100 |
| Rbm38 | RNA-binding motif protein 38 | 0.0078 | 0.0380 |
| Rasgef1b | RasGEF domain family, member 1B | 0.0003 | 0.0037 |
| Anxa3 | Annexin A3 | <0.0001 | 0.0309 |
| Cyp1a1 | Cytochrome P450, family 1, subfamily a, polypeptide 1 | <0.0001 | 0.0016 |
| Trib1 | Tribbles homolog 1 (Drosophila) | 0.0004 | 0.0118 |
| Nphp3 | Nephronophthisis 3 (adolescent) | <0.0001 | 0.0275 |
| Fhl3 | Four and a half LIM domains 3 | 0.0036 | 0.0045 |
| Serpine1 | Serine (or cysteine) peptidase inhibitor, clade E, member 1 | <0.0001 | 0.0016 |
| Acer2 | Alkaline ceramidase 2 | <0.0001 | 0.0016 |
| Arhgap32 | Rho GTPase activating protein 32 | <0.0001 | <0.0001 |
| Atf4 | Activating transcription factor 4 | 0.0044 | 0.0016 |
| Zc3h6 | Zinc finger CCCH type containing 6 | <0.0001 | 0.0136 |
| Tet1 | Tet methylcytosine dioxygenase 1 | 0.0006 | 0.0016 |
| Klk1b26 | Kallikrein 1-related petidase b26 | 0.0146 | 0.0189 |
| Ppp1r3c | Protein phosphatase 1, regulatory (inhibitor) subunit 3C | 0.0000 | 0.0029 |
| Ttc30b | Tetratricopeptide repeat domain 30B | <0.0001 | 0.0054 |
| Fign | Fidgetin | <0.0001 | 0.0195 |
| AI593442 | Expressed sequence AI593442 | <0.0001 | 0.0350 |
| 5730480H06Rik | RIKEN cDNA 5730480H06 gene | 0.0019 | 0.0029 |
| Gm26703 | Predicted gene, 26703 | <0.0001 | <0.0001 |
| Risk Factor Increase | Risk Factor | Mean % Change in Daily Visits per Risk Factor Increase | T-test p-value |
| 0.01 ppm | Ozone | 3.2 (1.4, 5) | 0.000 |
| 1 μg m-3 | PM2.5 | -0.2 (-0.6, 0.2) | 0.331 |
| 1000 spores m-3 | Mold Count | -0.2 (-1.1, 0.7) | 0.707 |
| 10 grains m-3 | Weed Pollen | -2.9 (-6.8, 1.1) | 0.148 |
| 100 grains m-3 | Tree Pollen | 1.8 (0.9, 2.6) | 0.000 |
| 10 grains m-3 | Grass Pollen | 1.6 (-2, 5.4) | 0.378 |
| 1°F | Temperature | 0.2 (0.1, 0.4) | 0.007 |
| Knockout mouse | Phenotype | Reference |
| TRPC1 | No effect on Ang II-induced cardiac hypertrophy | (39) |
| Reduced pathological cardiac hypertrophy by double knockout with TRPC4 | ||
| TRPC3 | Resistant to pressure-overload-induced cardiac remodeling | (4, 5, 18) |
| Reduced ischemia–reperfusion (I/R) injury by triple knockout with TRPC6 and TRPC7 | (59) | |
| TRPC4 | No effect on Ang II-induced cardiac hypertrophy | (39) |
| Reduced pathological cardiac hypertrophy by double knockout with TRPC4 | ||
| TRPC5 | No further reduction of pathological cardiac hypertrophy to that of double knockout of TRPC1/C4 | (39) |
| TRPC6 | Resistant to pressure-overload induced cardiac remodeling | (18) |
| Reduced I/R injury by triple knockout with TRPC3 and TRPC7 | (59) | |
| TRPC7 | Reduced I/R injury by triple knockout with TRPC3 and TRPC6 | (59) |
| Category | Variables | Key references |
| Personal social learning indicators | Willingness to share ideas with other stakeholders | Pelling and High (2005); Collins and Ison (2009); Nilsson and Swartling (2009); Cundill (2010); Roux et al. (2011); Murray, Roux, and Hill (2010); Muro and Jeffrey (2012); Bos, Brown, and Farrelly (2013); Cundill et al. (2013). |
| Development of trust among stakeholders | Pelling and High (2005); Pelling et al. (2008); Collins and Ison (2009); Nilsson and Swartling (2009); Cundill (2010); Roux et al. (2011); Murray et al. (2010); Muro and Jeffrey (2012); Cundill et al. (2013) | |
| Participation by all stakeholders | Pelling et al. (2008); Cundill and Fabricius (2009); Collins and Ison (2009); Nilsson and Swartling (2009); Cundill (2010); Roux et al. (2011); Murray et al. (2010); Muro and Jeffrey (2012) | |
| Capacity for conflict resolution | Nilsson and Swartling (2009); Cundill (2010); Roux et al. (2011); Muro and Jeffrey (2012) | |
| Collective action towards project goals | Pelling and High (2005); Pelling et al. (2008); Collins and Ison (2009); Cundill (2010); Roux et al. (2011); Muro and Jeffrey (2012); Bos et al. (2013) | |
| Continuous interaction and feedback | Cundill and Fabricius (2009); Collins and Ison (2009); Nilsson and Swartling (2009); Cundill (2010); Roux et al. (2011); Murray et al. (2010) | |
| Flexibility in planning and implementation | Pelling and High (2005); Pelling et al. (2008); Cundill (2010); Roux et al. (2011); Muro and Jeffrey (2012) | |
| Willingness to share information | Collins and Ison (2009); Nilsson and Swartling (2009); Cundill (2010); Roux et al. (2011); Muro and Jeffrey (2012); Bos et al. (2013) | |
| Organisational variables | Empowerment of junior employees to experiment | Pelling and High (2005); Pelling et al. (2008); Nilsson and Swartling (2009); Cundill (2010); Bos et al. (2013) |
| Existence of processes to translate feedback into changed practices | Pelling et al. (2008); Cundill (2010); Roux et al. (2011); Murray et al. (2010); Muro and Jeffrey (2012); Bos et al. (2013); Tàbara et al. (2010) | |
| Sufficient budget to regularly engage with stakeholders | Cundill (2010); Roux et al. (2011); Murray et al. (2010); Cundill et al. (2013) | |
| Continuous updating of project or planning processes | Nilsson and Swartling (2009); Muro and Jeffrey (2012); Tàbara et al. (2010). | |
| Support for locally initiated projects | Bos et al. (2013); Cundill et al. (2013) | |
| Development of local stakeholders’ capacity to engage with projects or interventions | Cundill and Fabricius (2009); Collins and Ison (2009); Nilsson and Swartling (2009); Cundill (2010); Roux et al. (2011); Muro and Jeffrey (2012) |
| Tissue | miRNA | Molecular targets | Functions | Reference |
| Aging heart | miR-21 ↑ | ERK–MAP kinase signaling | Profibrotic [role on cardiac fibroblast (CFs)] | (51) |
| Aging heart | miR-22 ↑ | Mimecan/Osteoglycin | Accelerate CF senescence and migration | (52) |
| Aging heart | miR-18 and miR-19 ↓ | Thrombospondin-1 and connective tissue growth factor | Anti-heart failure-related fibrosis during aging | (58) |
| Aging heart | miR-17-3p ↓ | PAR-4 | Reduce CF cellular senescence | (61) |
| Aging heart | miR-34a ↑ | Phosphatase 1 nuclear targeting subunit | Increase age-related cardiomyocyte apoptosis and cardiac dysfunction | (62) |
| Vascular aging | miR-34a ↑ | SIRT1 | Stimulates senescence in endothelial cell and vascular smooth muscle cells | (68, 71) |
| Vascular aging | miR-217 ↑ | SIRT1 | Stimulates endothelial senescence decreasing nitric oxide | (73) |
| Vascular aging | miR-29 ↑ | Collagen and elastin | Extracellular matrix impairment (risk of age-related aortic aneurism) | (74–77) |
| Vascular aging | miR-146 ↑ or ↓ | IRAK and NOX4 | Pro-inflammation or anti-oxidative stress | (78, 79) |
| Vascular aging | miR-92 ↓ | Tumor necrosis factor α receptor 1 and collagen type 1 | miR-92 reduction mimic arterial aging | (80) |
| Cisplatin excretion | ||||||
| 0–12 h | 12–24 h | 24–48 h | ||||
| SCT (R/p value) | ULiR (p value) | SCT (R/p value) | ULiR (p value) | SCT (R/p value) | ULiR (p value) | |
| Number variation (range) | ||||||
| Haemoglobin | 0.000/1.000 | 0.7375 | 0.047/0.737 | 0.7835 | 0.024/0.867 | 0.0609 |
| Leukocytes | 0.101/0.471 | 0.4833 | 0.256/0.064 | 0.1695 | 0.162/0.247 | 0.1122 |
| Neutrophils | 0.125/0.372 | 0.4689 | 0.237/0.088 | 0.0969 | 0.183/0.190 | 0.0740 |
| Lymphocytes | 0.071/0.613 | 0.2391 | 0.118/0.401 | 0.9156 | 0.073/0.605 | 0.1955 |
| Platelets | −0.170/0.223 | 0.3899 | 0.063/0.653 | 0.6527 | −0.350/0.806 | 0.9802 |
| Creatinine | −0.055/0.698 | 0.7700 | 0.105/0.459 | 0.5176 | 0.290/0.037 | 0.3827 |
| Creatinine clearance | 0.009/0.951 | 0.9380 | 0.096/0.496 | 0.7957 | 0.259/0.063 | 0.3884 |
| SCT (R/p value) | ULoR (p value) | SCT (R/p value) | ULoR (p value) | SCT (R/p value) | ULoR (p value) | |
| Severity by grade | ||||||
| Anaemia | 0.073/0.601 | 0.3811 | 0.141/0.315 | 0.4889 | 0.025/0.858 | 0.3717 |
| Leukopenia | 0.041/0.771 | 0.8971 | −0.039/0.784 | 0.5143 | 0.061/0.663 | 0.7397 |
| Neutropenia | −0.007/0.960 | 0.9863 | −0.067/0.632 | 0.3471 | 0.047/0.741 | 0.7066 |
| Lymphopenia | 0.071/0.613 | 0.4500 | 0.118/0.401 | 0.2684 | 0.073/0.605 | 0.7810 |
| Thrombocytopenia | 0.038/0.786 | 0.3511 | −0.067/0.631 | 0.2847 | −0.020/0.889 | 0.4774 |
| Increase in serum creatinine | −0.069/0.627 | 0.6263 | 0.200/0.155 | 0.9527 | 0.325/0.019 | 0.1462 |
| Reduction in creatinine clearance | −0.100/0.483 | 0.4715 | 0.249/0.078 | 0.9217 | 0.276/0.050 | 0.7730 |
| Nausea | −0.065/0.642 | 0.6791 | −0.124/0.377 | 0.5203 | 0.009/0.949 | 0.7742 |
| Vomiting | −0.101/0.471 | 0.4140 | −0.154/0.270 | 0.7819 | −0.024/0.866 | 0.9087 |
| Diarrhoea | −0.195/0.161 | 0.1685 | −0.103/0.463 | 0.3765 | −0.044/0.754 | 0.6894 |
| Type of TEAE observed | No. (%) of subjects | |||
| ESRD subjects (n = 8) | Healthy subjects (n = 8) | Total (N = 16) | ||
| Dosing after hemodialysis | Dosing before hemodialysis | |||
| Any TEAE | 3 (37.5) | 2 (25.0) | 1 (12.5) | 5 (31.3) |
| Upper RTI | 2 (25.0) | 0 | 0 | 2 (12.5) |
| Viral upper RTI | 1 (12.5) | 0 | 0 | 1 (6.3) |
| Dizziness | 1 (12.5) | 0 | 0 | 1 (6.3) |
| Headache | 0 | 1 (12.5) | 0 | 1 (6.3) |
| Infusion site erythema | 0 | 0 | 1 (12.5) | 1 (6.3) |
| Bronchospasm | 0 | 1 (12.5) | 0 | 1 (6.3) |
| Papular rash | 1 (12.5) | 0 | 0 | 1 (6.3) |
| Clinical N staging | |
| cN0 | 3 (11.5%) |
| cN1 | 6 (23.1%) |
| cN2 | 14 (53.8%) |
| cN3 | 3 (11.5%) |
| Species (tax id, short name) | Number of proteins | Number of PPI | Source |
| E. coli K12 (83333, eco) | 4121 | 216426 | SNDB [22] |
| S. typhimurium (99287, stm) | 4239 | 94609 | SNDB [22] |
| C. crescentus (190650, ccr) | 3365 | 40524 | SNDB [22] |
| Yeast (4932, sce) | 4738 | 15417 | DIP [13] |
| Fly (7227, dme) | 7165 | 23484 | DIP [13] |
| Worm (6239, cel) | 3029 | 3393 | DIP [13] |
| Noise | Cluster Number | GO MF (-log P-value) | GO BP (-log P-value) | GO CC (-log P-value) |
| 0% | 50 | 5.18 | 7.44 | 6.38 |
| 5% | 44.15 ± 2.28 | 5.19 ± 0.19 | 7.34 ± 0.31 | 6.52 ± 0.35 |
| 10% | 42.49 ± 2.50 | 5.13 ± 0.28 | 7.26 ± 0.33 | 6.50 ± 0.35 |
| 15% | 39.94 ± 2.69 | 5.20 ± 0.28 | 7.31 ± 0.44 | 6.51 ± 0.49 |
| 20% | 37.43 ± 3.40 | 5.28 ± 0.48 | 7.54 ± 0.62 | 6.66 ± 0.53 |
| 25% | 35.13 ± 2.98 | 5.29 ± 0.42 | 7.47 ± 0.54 | 6.59 ± 0.54 |
| Variables | Total (n = 223) | U (n = 99) | B (n = 37) | V (n = 30) | B + V (n = 57) |
| Anxious/depressed n (%) | 16.0 (7.2) | 4.0 (4.0) | 3.0 (8.1) | 4.0 (13.3) | 5.0 (8.8) |
| Withdrawn/depressed n (%) | 15.0 (6.7) | 3.0 (3.0) | 5.0 (13.5) | 3.0 (10.0) | 4.0 (7.0) |
| Somatic complaints n (%) | 28.0 (12.6) | 11.0 (11.1) | 7.0 (18.9) | 3.0 (10.0) | 7.0 (12.3) |
| Social problems n (%) | 13.0 (5.8) | 2.0 (2.0) | 2.0 (5.4) | 5.0 (16.7) | 4.0 (7.0) |
| Thought problems n (%) | 19.0 (8.5) | 6.0 (6.1) | 6.0 (16.2) | 4.0 (13.3) | 3.0 (5.3) |
| Attention problems n (%) | 19.0 (8.5) | 4.0 (4.0) | 2.0 (5.4) | 5.0 (16.7) | 8.0 (14.0) |
| Rule-breaking n (%) | 12.0 (5.4) | 1.0 (1.0) | 2.0 (5.4) | 3.0 (10.0) | 6.0 (10.5) |
| Aggressive behavior n (%) | 20.0 (9.0) | 3.0 (3.0) | 1.0 (2.7) | 7.0 (23.3) | 9.0 (15.8) |
| Internalizing n (%) | 34.0 (15.3) | 10.0 (10.1) | 8.0 (21.6) | 7.0 (23.3) | 9.0 (15.8) |
| Externalizing n (%) | 30.0 (13.5) | 7.0 (7.1) | 3.0 (8.1) | 8.0 (26.7) | 12.0 (21.1) |
| Total n (%) | 36.0 (16.1) | 10.0 (10.1) | 6.0 (16.2) | 8.0 (26.7) | 12.0 (21.1) |
| Age (yr)* | 37.14 ± 7.58 | |
| Employment record (yr)* | 11.48±4.47 | |
| Educational level** | Two trained courses after diploma | 8(2.23) |
| Baccalaureate | 311(86.11) | |
| Masters/doctorate | 42(11.66) | |
| Marital status ** | Married | 72(19.91) |
| Single | 279(77.21) | |
| Divorced/Widow | 10(2.88) | |
| Gender | Female | 339(93.94) |
| Male | 22(6.06) | |
| Current work setting ** | General hospital | 232(64.35) |
| Primary health care center | 109(30.21) | |
| Private hospital | 20(5.54) |
| Land | SE index* a | NO2 | Education* b | NO2 | ||||
| n | Mean | S. D. | n | Mean | S. D. | |||
| Urban <50% | 1.04-1.24 | 11 | 18.71 | 4.31 | 2.72-3.03 | 11 | 17.14 | 6.11 |
| 1.25-1.34 | 16 | 13.29 | 3.55 | 3.04-3.24 | 13 | 13.40 | 4.62 | |
| 1.35-1.46 | 10 | 11.69 | 4.81 | 3.25-3.49 | 25 | 10.01 | 3.97 | |
| 1.47-1.65 | 24 | 12.43 | 5.65 | 3.50-3.82 | 12 | 13.30 | 6.04 | |
| 1.66-2.05 | 5 | 5.39 | 1.94 | 3.83-4.26 | 8 | 15.27 | 6.14 | |
| Urban ≥50% | 1.04-1.24 | 14 | 22.15 | 5.85 | 2.72-3.03 | 3 | 14.91 | 6.01 |
| 1.25-1.34 | 23 | 21.95 | 4.87 | 3.04-3.24 | 10 | 23.89 | 5.62 | |
| 1.35-1.46 | 14 | 23.99 | 1.60 | 3.25-3.49 | 26 | 23.06 | 3.68 | |
| 1.47-1.65 | 10 | 25.35 | 1.58 | 3.50-3.82 | 15 | 23.23 | 3.89 | |
| 1.66-2.05 | 2 | 24.29 | 0.81 | 3.83-4.26 | 10 | 25.41 | 1.51 | |
| All | 1.04-1.24 | 25 | 20.64 | 5.42 | 2.72-3.03 | 14 | 16.66 | 5.93 |
| 1.25-1.34 | 39 | 18.40 | 6.11 | 3.04-3.24 | 23 | 17.96 | 7.27 | |
| 1.35-1.46 | 24 | 18.87 | 6.99 | 3.25-3.49 | 51 | 16.66 | 7.60 | |
| 1.47-1.65 | 34 | 16.23 | 7.66 | 3.50-3.82 | 27 | 18.82 | 6.99 | |
| 1.66-2.05 | 7 | 10.79 | 9.36 | 3.83-4.26 | 18 | 20.90 | 6.60 |
| Meta-Method | Mean Error |
| Fisher | 0.276 |
| POE with Bss/Wss | 0.375 |
| POE with IC | 0.301 |
| GeneMeta | 0.525 |
| RankProd | 0.475 |
| Simple | 0.617 |
| Cross-Validation | 0.329 |
| mDEDS | 0.277 |
| Question | Level of ecological framework targeted |
| Introduction | |
| 1. How long have you worked/lived in [name of agency or community]? | N/A |
| Meaning of Good Health | |
| First, I want you to think about your own health and life. | Intra-Personal |
| 2. What do you consider “good health”? | |
| 3. What do you think it means to live a healthy lifestyle? | |
| Now I want you think about [insert name of community]. I’d like for you to think about the community residents that you see every day and interact with either personally or for your job. I also want you to think about the community’s physical environment, stores, restaurants, health and human services, community programs, and so on. | Community/Institutional |
| 4. What does it mean for a community to be “healthy”? | |
| 5. Do you consider your community to be healthy? | |
| 6. How would you rate the health of this community as a whole on a scale of 1 to 5, with 1 being poor and 5 being excellent? | |
| Probe: What factors did you take into account with your rating? | |
| Enabling and Inhibiting Factors of Good Health | |
| 7. What are the values around being healthy in this community? | Inter-Personal |
| 8. What are the unique characteristics (strengths) in [insert name of community] that help residents in being healthy? | |
| Probe: What other characteristics within this community support being healthy? | |
| 9. What are the unique characteristics (weaknesses) in [insert name of community] that prevent residents from being healthy? | |
| Probe: What other characteristics within your community discourage residents from being healthy? | |
| 10. Which of these characteristics, good and not good, are specific to the [insert Native/MSFW/Latino] culture in this community? | |
| 11. What are the biggest (or most important/pressing) health-related concerns in this community? | Community/Institutional |
| Probe: In your point of view, what are the factors that contribute to these health problems? | |
| 12. What resources are available or in place in [insert name of community] to support healthy living among the residents? | Macro Level/Public Policy |
| Probe: How much are these resources used by community residents? | |
| Probe: How widely known are these resources by community residents? | |
| Wrap Up | |
| 13. What are other important health issues in this community that we have not discussed so far? | All |
| Drug | Cases (n=32) | Controls (n=64) | p |
| Zidovudine | |||
| Yes | 11 | 12 | 0.15 |
| No | 21 | 52 | |
| Lamivudine | |||
| Yes | 17 | 28 | 0.5 |
| No | 15 | 36 | |
| Tenofovir | |||
| Yes | 15 | 35 | 0.6 |
| No | 17 | 29 | |
| Emtricitabine | |||
| Yes | 4 | 20 | 0.08 |
| No | 28 | 44 | |
| Emtricitabine+tenofovir | |||
| Yes | 4 | 20 | 0.08 |
| No | 28 | 44 | |
| Zidovudine+lamivudine | |||
| Yes | 7 | 11 | 0.8 |
| No | 25 | 53 | |
| Didanosine | |||
| Yes | 4 | 4 | 0.4 |
| No | 28 | 60 | |
| Abacavir | |||
| Yes | 3 | 4 | 0.6 |
| No | 29 | 60 | |
| Efavirenz | |||
| Yes | 11 | 20 | 0.9 |
| No | 21 | 44 | |
| Nevirapine | |||
| Yes | 3 | 6 | 1 |
| No | 29 | 58 | |
| Atazanavir | |||
| Yes | 6 | 16 | 0.6 |
| No | 26 | 48 | |
| Fosamprenavir | |||
| Yes | 2 | 2 | 0.6 |
| No | 30 | 62 | |
| Lopinavir/ritonavir | |||
| Yes | 2 | 5 | 1 |
| No | 30 | 59 |
| Characteristics | Frequency (%) | OR (95% CI) | p-value |
| Gender | <0.001 | ||
| Male | 335 (65.4) | Reference | |
| Female | 503 (76.1) | 1.90 (1.44-2.51) | |
| Age (years) | 0.347 | ||
| 20–39 | 369 (69.5) | Reference | |
| 40–59 | 312 (71.6) | 1.14 (0.84-1.54) | |
| ≥ 60 | 157 (76.2) | 1.39 (0.88-2.19) | |
| Educational level | 0.620 | ||
| Low-intermediate education | 107 (67.3) | Reference | |
| High education | 728 (72.1) | 1.10 (0.75-1.62) | |
| Monthly income | 0.202 | ||
| < 500 Kuwaiti Dinars (KD) | 176 (68.2) | Reference | |
| 500–1000 Kuwaiti Dinars (KD) | 334 (74.1) | 1.29 (0.91-1.83) | |
| > 1000 Kuwaiti Dinars (KD) | 329 (72.6) | 1.37 (0.96-1.97) | |
| Personal health | 0.258 | ||
| Excellent | 320 (69.1) | Reference | |
| Very good | 348 (71.5) | 1.11 (0.83-1.49) | |
| Good/Fair | 170 (76.2) | 1.41 (0.94-2.13) | |
| Chronic disease | 0.798 | ||
| Yes | 297 (74.1) | Reference | |
| No | 541 (70.1) | 0.96 (0.69-1.3) |
| Variable | Univariate | Multivariate | ||||
| P | HR | 95% CI | P | HR | 95% CI | |
| Sex | 0.880 | 1.021 | 0.778-1.339 | 0.266 | 1.176 | 0.883-1.566 |
| Age | 0.059 | 1.011 | 1.000-1.022 | 0.466 | 1.004 | 0.993-1.016 |
| Tumor size | 0.474 | 1.002 | 0.997-1.007 | 0.381 | 1.002 | 0.997-1.008 |
| KPS | <0.001 | 0.964 | 0.954-0.974 | <0.001 | 0.974 | 0.963-0.986 |
| Resection | 0.014 | 0.731 | 0.568-0.940 | 0.091 | 0.800 | 0.618-1.036 |
| Adjuvant treatment | <0.001 | 0.577 | 0.487-0.684 | 0.001 | 0.726 | 0.597-0.884 |
| MGMT promoter | 0.162 | 0.823 | 0.626-1.081 | 0.925 | 1.015 | 0.749-1.375 |
| IDH1-R132H mutation | 0.006 | 0.450 | 0.255-0.794 | 0.018 | 0.489 | 0.270-0.885 |
| Serum albumin level | <0.001 | 0.938 | 0.912-0.964 | 0.023 | 0.966 | 0.938-0.995 |
| Exposure to iAs in Water | Na | Range | AM | GM | GSD | |
| iAs, current concentration (ppb) | 258 | 3.1 | 215.2 | 42.9 | 24.4 | 2.9 |
| iAs, cumulative exposure 1993-2008 (ppm.years) | 255 | 0.0 | 6.73 | 1.8 | 1.3 | 2.3 |
| iAs, cumulative exposure 1993-1997 (ppm.years) | 255 | 0.0 | 5.8 | 0.7 | 0.5 | 2.8 |
| iAs, cumulative exposure 1998-2002 (ppm.years) | 255 | 0.0 | 4.5 | 0.6 | 0.5 | 2.3 |
| iAs, cumulative exposure 2002-2007 (ppm.years) | 255 | 0.0 | 1.2 | 0.5 | 0.4 | 2.1 |
| Metabolites of iAs in Urine (ng/mL) | ||||||
| tAs | 256 | 2.3 | 233.7 | 41.2 | 24.7 | 2.8 |
| iAsIII | 257 | 0.1 | 37.2 | 4.2 | 2.1 | 3.4 |
| MAsIII | 257 | ND | 2.4 | 0.4 | 0.1 | 2.3 |
| DMAsIII | 257 | ND | 64.8 | 4.7 | 0.9 | 3.2 |
| iAsV | 257 | ND | 32.9 | 1.4 | 1.5 | 4.7 |
| MAsV | 257 | 0.1 | 36.2 | 5.0 | 1.1 | 1.1 |
| DMAsV | 257 | 0.1 | 162.6 | 22.5 | 2.4 | 1.3 |
| DMAs/MAs ratio | 257 | 0.4 | 26.4 | 5.6 | 4.8 | 1.7 |
| MAs/iAs ratio | 257 | 0.0 | 5.1 | 1.3 | 1.1 | 2.0 |
| Variable | Survivors (n = 36) | Nonsurvivors (n = 25) | P value |
| cTnT (pg/mL), median (IQL) | 20 (18–24) | 34.5 (27.5–41.5) | <0.05* |
| Gene | Positions and nt sequence sizes (bp) | Start and stop codons | tRNA Anti-codons | Intergenic nt (bp) | ||||
| PL (5’-3’) | PC (5’-3’) | PL | PC | PL | PC | PL | PC | |
| cox3 | 1-645 (645) | 1-645 (645) | ATG/TAG | ATG/TAG | 0 | 0 | ||
| tRNA-His (H) | 647-714 (68) | 647-715 (69) | GTG | GTG | 1 | 3 | ||
| cytb | 717-1829 (1113) | 720-1832 (1113) | ATG/TAG | ATG/TAG | 2 | 4 | ||
| SNCR | 1830-1894 (64) | 1833-1890 (58) | 0 | 0 | ||||
| nad4L | 1895-2158 (264) | 1891-2154 (264) | ATG/TAG | ATG/TAG | 0 | 0 | ||
| nad4 | 2119-3399 (1281) | 2115-3395 (1281) | GTG/TAG | GTG/TAG | −40 | −40 | ||
| tRNA-Gln (Q) | 3404-3469 (66) | 3398-3462 (65) | TTG | TTG | 4 | 2 | ||
| tRNA-Phe (F) | 3501-3567 (67) | 3489-3553 (65) | GAA | GAA | 31 | 26 | ||
| tRNA-Met (M) | 3565-3629 (65) | 3553-3615 (63) | CAT | CAT | −3 | −1 | ||
| atp6 | 3630-4145 (516) | 3616-4131 (516) | ATG/TAG | ATG/TAG | 0 | 0 | ||
| nad2 | 4153-5025 (873) | 4139-5011 (870) | ATA/TAG | GTG/TAG | 7 | 7 | ||
| tRNA-Val (V) | 5049-5112 (64) | 5014-5077 (64) | TAC | TAC | 23 | 2 | ||
| tRNA-Ala (A) | 5122-5187 (66) | 5085-5154 (70) | TGC | TGC | 9 | 7 | ||
| tRNA-Asp (D) | 5197-5266 (70) | 5165-5229 (65) | GTC | GTC | 9 | 10 | ||
| nad1 | 5269-6165 (897) | 5233-6129 (897) | ATG/TAG | ATG/TAG | 2 | 3 | ||
| tRNA-Asn (N) | 6170-6235 (66) | 6142-6207 (66) | GTT | GTT | 4 | 12 | ||
| tRNA-Pro (P) | 6235-6300 (66) | 6208-6270 (63) | TGG | TGG | −1 | 0 | ||
| tRNA-Ile (I) | 6302-6363 (62) | 6272-6334 (63) | GAT | GAT | 1 | 1 | ||
| tRNA-Lys (K) | 6370-6435 (66) | 6344-6409 (66) | CTT | CTT | 6 | 9 | ||
| nad3 | 6436-6792 (357) | 6410-6766 (357) | ATG/TAG | ATG/TAG | 0 | 0 | ||
| tRNA-Ser (S1) | 6810-6868 (59) | 6785-6843 (59) | GCT | GCT | 17 | 18 | ||
| tRNA-Trp (W) | 6878-6941 (64) | 6853-6915 (63) | TCA | TCA | 9 | 9 | ||
| cox1 | 6942-8486 (1545) | 6916-8460 (1545) | ATA/TAG | GTG/TAG | 0 | 0 | ||
| tRNA-Thr (T) | 8500-8561 (62) | 8470-8534 (65) | TGT | TGT | 13 | 9 | ||
| rrnL | 8562-9556 (995) | 8535-9520 (986) | 0 | 0 | ||||
| tRNA-Cys (C) | 9557-9623 (67) | 9527-9586 (60) | GCA | GCA | 0 | 6 | ||
| rrnS | 9624-10372 (749) | 9592-10340 (749) | 0 | 5 | ||||
| cox2 | 10373-10954 (582) | 10341-10919 (579) | ATG/TAG | ATG/TAG | 0 | 0 | ||
| nad6 | 10948-11400 (453) | 10920-11372 (453) | GTG/TAG | GTG/TAG | −7 | 0 | ||
| tRNA-Tyr (Y) | 11420-11485 (66) | 11389-11455 (67) | GTA | GTA | 19 | 16 | ||
| tRNA-Leu (L1) | 11496-11557 (62) | 11470-11536 (67) | TAG | TAG | 10 | 14 | ||
| tRNA-Ser (S2) | 11558-11624 (67) | 11538-11609 (72) | TGA | TGA | 0 | 1 | ||
| tRNA-Leu (L2) | 11644-11708 (65) | 11646-11710 (65) | TAA | TAA | 19 | 36 | ||
| tRNA-Arg (R) | 11709-11775 (67) | 11713-11779 (67) | TCG | TCG | 0 | 2 | ||
| nad5 | 11775-13358 (1584) | 11780-13360 (1581) | GTG/TAA | ATG/TAG | −1 | 0 | ||
| tRNA-Gly (G) | 13359-13431 (73) | 13365-13433 (69) | TCC | TCC | 0 | 4 | ||
| tRNA-Glu (E) | 13440-13507 (68) | 13451-13515 (65) | TTC | TTC | 8 | 17 | ||
| LNCR | 13508-14050 (543) | 13516-14014 (499) | 0 | 0 |
| Materials employed | Composition | Manufacturer |
| GC Fuji II Universal Restorative | Powder: 95% fluoroaluminosilicate glass (amorphous)5% polyacrylic acid | G.C. Corporation, Tokyo, Japan |
| Liquid: 50% distilled water40% polyacrylic acid | ||
| GC Fuji II Capsule | Powder/liquid ratio (g/g) 0.30/0.11 | G.C. Corporation, Tokyo, Japan |
| GC Fuji II Universal Restorative Liquid | 50% distilled water40% polyacrylic acid | G.C. Corporation, Tokyo, Japan |
| GC Dentin Conditioner | 10% polyacrylic acid | G.C. Corporation, Tokyo, Japan |
| Data set | Number of instances | Number of attributes |
| Sonar | 208 | 60 |
| Live disorder | 345 | 6 |
| Breast cancer | 680 | 10 |
| Cystic fibrosis | 177 | Depends on q |
| Leukemia | 355 | Depends on q |
| Lung cancer | 91 | 54675 |
| Group O (n = 40) | Group L (n = 39) | p valuesa | |
| Surgical indication | 0.968b | ||
| Inflammation | 3 (7.50) | 3 (7.69) | |
| Stricture | 24 (60.00) | 23 (58.97) | |
| Internal fistula/mass | 11 (27.50) | 10 (25.64) | |
| Hemorrhage | 2 (5.00) | 3 (7.69) | |
| Type of surgery | 0.629b | ||
| Small bowel resection | 11 (27.50) | 10 (25.64) | |
| Ileocolic resection | 21 (52.50) | 24 (61.54) | |
| Colonic resection | 8 (20.00) | 5 (12.82) | |
| Hand-assisted anastomosis | 11 (28.21) | ||
| Length of incision (cm) | 10.30 ± 1.79 | 5.00 ± 1.23 | <0.001 |
| Operation duration (min) | 86.85 ± 24.31 | 121.53 ± 33.62 | <0.001 |
| Blood loss (mL) | 122.25 ± 53.61 | 54.10 ± 21.97 | <0.001 |
| No history of MTSS | History of MTSS | P-value | Effect size (r) | |
| Navicular Drop (mm) | 7.1 ± 2.0 | 7.1 ± 1.9 | 0.98 | 0.01 |
| Leg Heel Alignment (°) | 5.0 ± 1.4 | 5.1 ± 2.0 | 0.72 | 0.08 |
| Age (mean, SD) | 32.6, 13.0 |
| Minority/racial group member | 50.2 |
| Not married | 45.0 |
| No. children in household | 49.6 |
| No education beyond high school | 37.4 |
| Not employed | 45.4 |
| Income below federal poverty line | 17.9 |
| Not pregnant | 94.7 |
| Smokes | 13.6 |
| Fair/poor health | 17.3 |
| PTSD symptoms | 6.3 |
| Anxiety symptoms | 21.8 |
| Depression symptoms | 13.7 |
| Overwhelmed by stress | 12.5 |
| Poor mental health | 14.2 |
| Perceived need for mental health help | 23.2 |
| Utilized mental health help | 9.8 |
| Intimate partner violence | 9.9 |
| Physically assaulted | 19.7 |
| Sexually assaulted | 10.6 |
| Death of someone close | 29.7 |
| Lived in foster care | 3.4 |
| Lived with someone abusing substances | 22.3 |
| Lived with someone mentally ill | 16.8 |
| Lived with mother victimized by violence | 18.4 |
| Lived with someone incarcerated | 7.6 |
| Emotionally abused by adult in home | 18. 4 |
| Physically assaulted | 19.1 |
| Sexually assaulted | 11.2 |
| GUH (N = 34) | WHC (N = 21) | Total (N = 55) | |
| Age (N = 55) | M = 55.4 SD = 8.2 | M = 53.7 SD = 6.7 | M = 54.7 SD = 7.6 |
| Race/Ethnicity # | |||
| White (N = 19) | 50% | 10.5% | 35.8% |
| African American (N = 30) | 38.2% | 89.5% | 56.6% |
| Other (N = 4) | 11.8% | 0 | 7.5% |
| Education | |||
| < HS grad (N = 14) | 20.6% | 33.3% | 25.5% |
| Voc/trade or some college (N = 12) | 14.7% | 33.3% | 21.8% |
| College Graduate (N = 7) | 20.6% | 0 | 12.7% |
| Graduate work/degree (N = 22) | 44.1% | 33.3% | 40.0% |
| Marital Status | |||
| Married (N = 37) | 70.6% | 61.9% | 67.3% |
| Other (N = 18) | 29.4% | 38.1% | 32.7% |
| Internet access at home/work | |||
| Yes (N = 41) | 82.4% | 61.9% | 74.5% |
| No (N = 14) | 17.6% | 38.1% | 25.5% |
| Home/Work Computer Internet Usage (among those with access at home/work) | |||
| Few times yr/few times month (N = 7) | 7.1% | 38.5% | 17.1% |
| Once/twice a wk (N = 5) | 14.3% | 7.7% | 12.2% |
| Daily (N = 29) | 78.6% | 53.8% | 70.7% |
| Receiving Health Related Information # | |||
| Prefers Internet (N = 23) | 47.1% | 36.8% | 43.4% |
| Prefers Booklet (N = 30) | 52.9% | 63.2% | 56.6% |
| Willingness to Read Prostate Cancer Info on the Internet # | |||
| Definitely/Probably would (N = 42) | 76.5% | 84.2% | 79.3% |
| Definitely/Probably would not (N = 11) | 23.5% | 15.8% | 20.7% |
| Awareness of Disagreement in Medical Community Regarding Whether to Screen for PrCa | |||
| Unaware of disagreement (N = 45) | 82.4% | 81.0% | 81.8% |
| Aware of disagreement (N = 4) | 2.9% | 14.3% | 7.3% |
| Not Sure (N = 6) | 14.7% | 4.8% | 10.9% |
| Drug | n | Median Dosage (mg/kg/day) | Median Length of Treatment (Days) | Side Effects (n) |
| Rifampicin | 415 | 17.5 | 240 | Itch, vomit and headache (1); rash (1); hypertransaminasemia (4) |
| Pyrazinamide | 411 | 27 | 95 | Hypertransaminasemia (7); vomit and malaise (1); epigastric pain (1); hyperuricemia (5); drug induced hepatitis (1) |
| Isoniazid | 396 | 10 | 242 | Drug induced hepatitis (1); hypertransaminasemia (4) |
| Ethambutol | 245 | 17 | 86 | Vomit and malaise (1); neutropenia (1); drug induced hepatitis (1); epigastric pain (1) |
| Streptomycin | 35 | 19 | 31 | |
| Moxifloxacin | 31 | 10.3 | 161 | Tendinopathy (1); long QT syndrome (1) |
| Linezolid | 17 | 19.1 | 108 | |
| Amikacin | 12 | 16.8 | 24,5 | |
| Cycloserine | 11 | 14.1 | 220 | |
| Levofloxacin | 7 | 11.6 | 202 | |
| PAS 1 | 6 | 118 | 172.5 | |
| Ethionamide | 6 | 15.4 | 91.6 | |
| Clarithromycin | 5 | 15.6 | 39.6 | |
| Kanamicina | 1 | 10 | 142 | |
| Ciprofloxacin | 4 | 17 | 238 | Vomit and weight loss (1) |
| Genes groupa | Number of genesb |
| Glucose-dependent | 667 (18%) |
| Upregulated genes | 349 |
| Downregulated genes | 318 |
| CcpA-dependent | 407 (11%) |
| Upregulated by CcpA | 197 |
| Downregulated by CcpA | 210 |
| Regulated by glucose in a CcpA-dependent manner | 361 (10%) |
| Upregulated genes | 170 |
| Downregulated genes | 191 |
| Regulated by glucose in a CcpA-independent manner | 303 (8%) |
| Upregulated genes | 177 |
| Downregulated genes | 126 |
| Regulated by CcpA in absence of glucose | 43 (1%) |
| Upregulated by CcpA | 8 |
| Downregulated by CcpA | 35 |
| Regulated by CcpA independent of glucose | 3 (0.08%) |
| Upregulated by CcpA | 2 |
| Downregulated by CcpA | 1 |
| Atypical regulation | 112 (0.3%) |
| Upregulated genes | 39 |
| Downregulated genes | 73 |
| No. | Disease | Medicine | Formulation | Strength | Target size pack |
| 1 | Intestinal parasite | Albendazole | tablet | 200 mg | 2 |
| 2 | Infectious disease | Amoxicillin | capsule | 250 mg | 10 |
| Infectious disease | Amoxicillin | suspension | 125 mg | 100 ml | |
| 3 | Aminophyllin | injection | 25 mg/ml | 1 vial | |
| 4 | Infectious disease | Amoxicillin_Clavulanic acid | tablet | 125 mg + 125 mg, tab | 10 |
| Infectious disease | Amoxicillin_Clavulanic acid | suspension | 125 mg + 31.25 mg | 100 ml | |
| Infectious disease | Amoxicillin_Clavulanic acid | suspension | 250 mg + 62.50 mg | 100 ml | |
| 5 | Infectious disease | Azithromycin | capsule | 250 mg | 6 |
| Infectious disease | Azithromycin | suspension | 200 mg/5 ml | 100 ml | |
| 6 | Asthma | Beclomethason | inhaler | 50 mg/day | 1 inhaler (200 doses) |
| 7 | Infectious disease | Benzylpenicillin | injection | 600 mg = 1 million IU | 1 vial |
| 8 | Seizure Disorder | Carbamazepine | tablet | 100 mg | 20 |
| Seizure Disorder | Carbamazepine | suspension | 100 mg/5 ml | 100 ml | |
| 9 | Infectious disease | Cefazolin | injection | 1 g, vial | 1 vial |
| 10 | Infectious disease | Ceftriaxone | injection | 500 mg vial | 1 vial |
| 11 | Infectious disease | Chloramphenicol | tablet | 250 mg | 10 |
| Infectious disease | Chloramphenicol | injection | 1 g, vial | 1 vial | |
| 12 | Infectious disease | Chlorpheniramine | tablet | 4 mg | 24 |
| 13 | Infectious disease | Clarithromycin | suspension | 125 mg/ 5 ml | 100 ml |
| Infectious disease | Clarithromycin | tablet | 125 mg | 10 | |
| 14 | Infectious disease | Cotrimoxazole | tablet | 100 mg + 20 mg (also expressed as 400 mg + 80 mg) | 10 |
| Infectious disease | Cotrimoxazole | suspension | 100 ml | ||
| 15 | Seizure Disorder | Diazepam | tablet | 5 mg | 10 |
| 16 | Anemia | Ferrous salt | suspension | 30 mg/5 ml | 100 ml |
| 17 | Fungal infection | Fluconazole | capsule | 150 mg | 6 |
| 18 | Infectious disease | Gentamycin | injection | 10 mg/ml | 1 vial |
| 19 | Pain/inflammation | Ibuprofen | tablet | 2 mg | 24 |
| Pain/inflammation | Ibuprofen | suspension | 100 ml | ||
| 20 | Tuberculosis | Isoniazide | tablet | 100 mg | 56 |
| 21 | Pain | Morphine | tablet | 10 mg | 56 |
| Pain | Morphine | oral solution | 10 mg/5 ml | 100 ml | |
| 22 | Dehydration | ORS | sachet | 500 ml | 1 sachet |
| 23 | Pain/inflammation | Paracetamol | tablet | 250 mg | 10 |
| Pain/inflammation | Paracetamol | suppository | 125 mg | 10 | |
| Pain/inflammation | Paracetamol | suppository | 250 mg | 10 | |
| Pain/inflammation | Paracetamol | suspension | 125 mg | 100 ml | |
| 24 | Seizure Disorder | Phenobarbital | tablet | 30 mg | 10 |
| Seizure Disorder | Phenobarbital | injection | 100 mg/ml | 1 vial | |
| 25 | Seizure Disorder | Phenytoin | tablet | 50 mg, | 90 |
| Seizure Disorder | Phenytoin | suspension | 25 mg, 30 mg/5 ml | 500 ml | |
| 26 | Infectious disease | Procain penicillin | injection | 1 g, vial | 1 vial |
| 27 | Asthma | Salbutamol | inhaler | 100mcg | 1 inhaler (200 doses) |
| 28 | Xerophthalmia | Vitamin A | capsule | 100.000 IU | 50 |
| 29 | Anemia | Vitamin B6 | injection | 50 mg/ml | 1 vial |
| 30 | Dehydration | Zinc | tablet | 20 mg | 14 |
| 31 | Spacer | Device |
| Gene Name | Forward primer sequence (5′-3′) | Reverse primer sequence (5′-3′) |
| β-actin | ACTGGGACGACATGGAGAAGATC | AAACCTTACCACTCCCGCC |
| ADRA1B | TCTGGTCGCTGTGCGTGAT | ATCAAGACCACCAAGACATCCG |
| ARL3 | CATCCCTTGCTCTACATTACTTCC | AAACGACGGGTGCCACAG |
| BAP1 | ACCCGCACTCCTCCCTTAT | GAGAACCAAGTGGAGCAGACA |
| TRPA1 | AGTAGCGGCAACATGTCCACC | CCAAACTAACCCTGAAAGACCG |
| PPAR | Human | Mouse | Zebrafish |
| PPARA | |||
| Genes | 1 | 1 | 2 |
| Splice variants | 1 | 1 | 1 per gene |
| Isoforms | 1 | 1 | 1 per gene |
| Size (cds, bp) | 1,407 | 1,407 | pparaa: 1,413pparab: 1,380 |
| Protein similarity to zebrafish | 67% for pparaa 74% for pparab | 65% for pparaa 71% for pparab | |
| PPARD | |||
| Genes | 1 | 1 | 2 |
| Splice variants | 1 | 1 | 1 per gene |
| Isoforms | 1 | 1 | 1 per gene |
| Size (cds, bp) | 1,326 | 1,323 | pparda: 1,491ppardb: 1,554 |
| Protein similarity to zebrafish | 71% for pparda 73% for ppardb | 70% for pparda 73% for ppardb | |
| PPARG | |||
| Genes | 1 | 1 | 1 |
| Splice variants | 4 | 1 | 1 |
| Isoforms | 2 | 2 | 1 |
| Size (cds, bp) | PPARG1 = 1,434PPARG2 = 1,518 | PPARG1 = 1,428PPARG2 = 1,518 | pparg: 1,584 |
| Protein similarity to zebrafish | 67% | 67% |
| SZ (n = 22) | HC (n = 20) | t/x2 | p-Value | |||
| Age, years | 33 (9.78) | 33.05 (9.31) | −0.002 | 0.99 | ||
| Sex, M/F | 17/5 | 14/6 | 0.63 | 0.54 | ||
| Parent SESa | 7.89 (5.85) | 5.68 (3.92) | 1.34 | 0.19 | ||
| Smoking status (smoker/non-smoker) | 19/3 | 10/10 | ||||
| Smoking, packs per day | 0.73 (0.54) | 0.39 (0.57) | 1.97 | 0.06 | ||
| Medication naive | n = 9 | |||||
| Months off medication | 27.75 (49.99) | |||||
| Diagnosis (schizophrenia/schizoaffective) | (19/3) | |||||
| Age of onset, years | 21.857 (3.38) | |||||
| RBANS totalb | 70.55 (12.67) | 93.5 (14.81) | −2.89 | 0.006 | ||
| SZ 0 | SZ 6c | HC 0 | HC 6 | |||
| BPRSd | ||||||
| Total | 48.59 (10.32) | 29.52 (8.14) | 8.88 | < 0.001 | ||
| Positive | 8.86 (2.48) | 4.52 (2.58) | 7.82 | < 0.001 | ||
| Negative | 7.05 (2.38) | 5.14 (2.31) | 3.01 | 0.007 | ||
| Task reaction time, s | ||||||
| Congruent | 0.91 (0.18) | 0.90 (0.19) | 0.80 (0.10) | 0.79 (0.13) | ||
| Incongruent | 1.04 (0.18) | 1.03 (0.23) | 1.00 (0.14) | 0.91 (0.10) | ||
| Stroop | 0.13 (0.07) | 0.13 (0.07) | 0.19 (0.09) | 0.14 (0.08) | ||
| Missing trials | ||||||
| Congruent | 8.45 (11.86) | 6.80 (13.76) | 2.85 (8.38) | 2.75 (5.30) | ||
| Incongruent | 4.32 (7.08) | 4.20 (7.85) | 1.05 (2.63) | 1.25 (2.61) | ||
| Task errors | ||||||
| Congruent | 10.71 (15.83) | 8.06 (12.49) | 2.75 (4.28) | 4.30 (7.14) | ||
| Incongruent | 4.52 (5.23) | 3.28 (3.75) | 4.25 (5.46) | 3.90 (5.09) |
| Grade 2 (n = 20) | Grade 5 (n = 20) | |
| Null-Prime | 0.51 (0.50) | 0.62 (0.49) |
| Prime | 0.52 (0.50) | 0.72 (0.45) |
| Pre-intervention | Post-intervention | ||||
| Intervention(n = 43) | Control(n = 30) | Intervention(n = 37) | Control(n = 28) | P-value | |
| Attitudes (agreement with statement) | |||||
| Teachers do not need to act as role models for being active | 5.0 | 11.5 | 0.0 | 7.5 | 0.09 |
| It is not the role of the teacher to teach movement skills | 14.3 | 10.0 | 5.7 | 19.2 | 0.10 |
| It is not important that children participate in structured active play | 9.8 | 13.3 | 0.0 | 0.0 | - |
| Safety concerns limit active play opportunities in the preschool setting | 60.0 | 70.0 | 38.9 | 58.3 | 0.14 |
| It is not the role of the teacher to teach about healthy eating | 14.5 | 3.5 | 2.8 | 15.5 | 0.07 |
| Parents should be able to send any type of food to school with their child. | 7.3 | 3.3 | 0.0 | 3.7 | 0.25 |
| It is alright to sell chocolates and sweets for fundraising | 56.1 | 56.5 | 59.0 | 48.0 | 0.39 |
| Confidence | |||||
| I am confident that I can teach movement skills to children. | 97.6 | 90.0 | 97.3 | 95.7 | 0.73 |
| I am confident in talking to parents about their child's movement skills. | 80.5 | 96.7 | 97.0 | 90.9 | 0.33 |
| I am confident in talking to parents about their child's lunchbox contents | 76.9 | 89.7 | 89.7 | 95.8 | 0.40 |
| Confident talking to parents about their child's television viewing | 47.5 | 78.6 | 68.8 | 75.0 | 0.68 |
| Knowledge of recommended guidelines | |||||
| Daily serves of fruit | 100.0 | 93.0 | 94.5 | 96.0 | 0.79 |
| Daily serves of vegetables | 89.7 | 96.6 | 94.3 | 87.5 | 0.36 |
| Recreational screen time (TV/DVDs) (hrs/day) | 84.2 | 62.1 | 73.5 | 87.0 | 0.22 |
| Probe Set | z-score | DMFS | Gene Symbol | Gene Title |
| 209648_x_at | 4.01 | - | SOCS5 | suppressor of cytokine signaling 5 |
| 208127_s_at | 3.75 | - | SOCS5 | suppressor of cytokine signaling 5 |
| 209550_at | 3.18 | - | NDN | necdin homolog (mouse) |
| 201162_at | 3.14 | - | IGFBP7 | insulin-like growth factor binding protein 7 |
| 213910_at | 2.87 | - | IGFBP7 | insulin-like growth factor binding protein 7 |
| 212279_at | 2.91 | + | MAC30 | hypothetical protein MAC30 |
| 213337_s_at | 2.88 | + | SOCS1 | suppressor of cytokine signaling 1 |
| Blood culture/IFAT | Total | |||
| Positive | Negative | |||
| PCR | Positive | 25/29 | 11/7 | 36/36 |
| Negative | 4/3 | 10/11 | 14/14 | |
| Total | 29/32 | 21/18 | 50/50 |
| Control group | Study group | Total analysed | |
| Toes | 156 (50 %) | 156 (50 %) | 312 |
| Males | 37 | 26 | 63 |
| Females | 44 | 58 | 102 |
| Average age | 27.19 | 25.35 | 26.27 |
| Standard deviation | 9.48 | 9.04 | 9.26 |
| Median (range) | 23 (12–50) | 23 (10–50) | 23 (10–50) |
| Variable | Description and unit | Mean | Std. Dev. |
| Hypertension | 1if has hypertension; 0 otherwise | 0.43 | 0.49 |
| Obesity | 1 if obese; 0 otherwise | 0.31 | 0.46 |
| Age | In years | 55.46 | 16.06 |
| Marital status | 1 if married; 0 otherwise | 0.56 | 0.49 |
| Education | 1 if some college or higher; 0 otherwise | 0.51 | 0.49 |
| Employment | 1 if employed; 0 otherwise | 0.40 | 0. 49 |
| Income | Annual income in dollars | $40,774 | $24,815 |
| Gender | 1 if male; 0 if female | 0.38 | 0.48 |
| Race | 1 if white; 0 if race other than white | 0.90 | 0.29 |
| Sleep | Number of sleepless days in previous month | 8.50 | 10.56 |
| Drinks | 1 if drinks alcohol; 0 otherwise | 0.34 | 0.47 |
| Smokes | 1 if smokes; 0 otherwise | 0.21 | 0.41 |
| Exercise | Number of minutes engaged in exercise for the previous week | 403.57 | 674.95 |
| References | Primary outcomes | Secondary outcomes |
| Fiske (strong)1[17] | There was no difference in sales of healthier food options between intervention and control groups. | |
| Kocken (strong) [20] | Higher sales of healthier food options were observed in intervention groups compared to control groups. |
| Section of economizer | Condition design |
| Length was 250 mm | |
| Evaporator section | Hot water flow was 80°C |
| Volumetric flow rate was 5 l/min | |
| Adiabatic section | Length was 250 mm |
| Length was 250 mm | |
| Condenser section | Cool water flow was 25°C |
| Volumetric flow rate was 1 l/min |
| Item | Dimension | Missing values (%) |
| 1. I work hard to keep my HIV a secreta | Disclosure concerns | 0.0 |
| 2. Most people believe a person who has HIV is dirtya | Public attitudes | 3.4 |
| 3. Having HIV makes me feel uncleana | Negative self-image | 8.6 |
| 4. Most people think a person with HIV is disgustinga | Public attitudes | 1.7 |
| 5. Having HIV makes me feel I'm a bad persona | Negative self-image | 0.0 |
| 6. Most with HIV are rejected when others learna | Public attitudes | 5.2 |
| 7. I am very careful whom I tell that I have HIVa | Disclosure concerns | 3.4 |
| 8. Having HIV in my body feels disgustinga | Negative self-image | 0.0 |
| 9. I have been hurt by how people reacted to learning I have HIV | Personalized stigma | 19.0 |
| 10. I worry that people who know I have HIV will tell others | Disclosure concerns | 13.8 |
| 11. I have stopped socializing with some due to their reactions to my HIV | Personalized stigma | 19.0 |
| 12. I have lost friends by telling them I have HIV | Personalized stigma | 24.1 |
| Healthy normal control | Obese control | OHS | OSAS | P | |||||
| Med. | Perc.25/75 | Med. | Perc.25/75 | Med. | Perc.25/75 | Med. | Perc.25/75 | ||
| Trials administered | 103.5 | 81128 | 117 | 10728 | 128 | 128128 | 128 | 102.5128 | 0.04 |
| Total number of correct answers | 76 | 6388.25 | 78 | 62.584.5 | 56 | 43.578.5 | 66 | 52.572.5 | 0.12 |
| Total number of incorrect answers | 23.5 | 12.7537.25 | 32 | 24.564 | 72 | 49.584.5 | 62 | 2875.5 | 0.01 |
| Total number of persistent errors | 13,5 | 4.7519.25 | 16 | 928.5 | 53 | 18.565.5 | 24 | 9.540 | 0.03 |
| Number of completed categories | 6a,b | 5.56 | 6 | 26 | 1a | 13 | 2b | 14.5 | 0.01 |
| Percentage of persistent errors | 9.5 | 7.7516 | 12 | 1123 | 14 | 12.520 | 20 | 1229 | 0.15 |
| The percentage of conceptual level responses | 73 | 65.2580.75 | 64 | 35.571.5 | 27 | 1850.5 | 28 | 21.568.5 | 0.01 |
| Learning to learn scores | 0.26 | -1.622.12 | 1.97 | -2.062 | -10.5 | 11.5 | -6.85 | -28.30.2 | 0.24 |
| Variable | <35 | p-value | ≥35 | p-value |
| Adjusted odds ratio (95% CI) | Adjusted odds ratio (95% CI) | |||
| a. Adjusted Confounder Model for not having tested for HIV in the past 2 years, stratified by age | ||||
| Asian ethnicity | 2.04 (1.08-3.86) | 0.028 | 0.65 (0.28-1.51) | 0.32 |
| English or French as first language | 1.29 (0.69-2.43) | 0.426 | 1.28 (0.62-2.66) | 0.51 |
| Age (in years) of participate at study enrolment. | 0.97 (0.92-1.02) | 0.245 | 1.01 (0.98-1.03) | 0.58 |
| IDU ever | 0.81 (0.41-1.56) | 0.522 | 0.42 (0.20-0.86) | 0.017 |
| At the present time, do you smoke cigarettes? | 1.31 (0.84-2.03) | 0.234 | 1.15 (0.68-1.95) | 0.60 |
| Not told doctor of male sex partners | 5.83 (3.67-9.24) | <0.001 | 3.47 (1.90-6.35) | <0.001 |
| b. Adjusted Confounder Model for not having tested for Hepatitis C Virus in the past 2 years, stratified by age | ||||
| Asian ethnicity | 2.30 (1.27-4.19) | 0.006 | 1.05 (0.51-2.15) | 0.90 |
| English or French as first language | 1.25 (0.71-2.22) | 0.435 | 1.14 (0.61-2.13) | 0.68 |
| Age (in years) of participate at study enrolment. | 0.99 (0.95-1.04) | 0.664 | 1.02 (1.00-1.04) | 0.063 |
| Not told doctor of male sex partners | 7.06 (4.30-11.60) | <0.001 | 2.43 (1.41-4.18) | 0.001 |
| c. Adjusted Confounder Model for not having tested for syphilis in the past 2 years, stratified by age | ||||
| Asian ethnicity | 0.85 (0.45-1.61) | 0.625 | 0.67 (0.32-1.40) | 0.29 |
| English or French as first language | 1.19 (0.66-2.15) | 0.563 | 0.81 (0.43-1.52) | 0.51 |
| Age (in years) of participate at study enrolment. | 0.96 (0.92-1.01) | 0.124 | 0.99 (0.97-1.01) | 0.48 |
| IDU ever | 1.59 (0.86-2.93) | 0.137 | 1.77 (1.08-2.90) | 0.023 |
| At the present time, do you smoke cigarettes? | 0.66 (0.44-1.00) | 0.048 | 0.65 (0.43-0.98) | 0.038 |
| Not told doctor of male sex partners | 0.11 (0.07-0.18) | <0.001 | 0.24 (0.14-0.42) | <0.001 |
| Variables | Category | (1) | (2) | (3) | (4) | (5) |
| rifEI | rifWI | rifARCI | rifSRCI | rifAC | ||
| Demographic characteristics | ||||||
| Gender | Female (Reference) | |||||
| Male | −0.019*** | −0.019*** | −0.011*** | −0.008** | −0.005*** | |
| Age group | Quartile 4 (56+) (Reference) | Reference | ||||
| Quartile 1 (18–33) | −0.079*** | −0.073*** | −0.049*** | −0.024*** | −0.020*** | |
| Quartile 2 (33–43) | −0.022*** | −0.018** | −0.020*** | 0.002 | −0.006*** | |
| Quartile 3 (43–56) | −0.014** | −0.011 | −0.012*** | 0.001 | −0.003** | |
| Ethnicity | Ethnic Minority (Reference) | |||||
| Han | −0.016** | −0.016** | −0.007** | −0.010*** | −0.004** | |
| Marital status | Divorced, separated, or widowed (Reference) | |||||
| Married | −0.083*** | −0.084*** | −0.039*** | −0.045*** | −0.021*** | |
| Single | −0.075*** | −0.075*** | −0.036*** | −0.039*** | −0.019*** | |
| Household size | −0.002 | −0.001 | −0.001 | −0.000 | −0.000 | |
| Health insurance | Yes = 1; No = 0 | 0.024*** | 0.024*** | 0.012*** | 0.012*** | 0.006*** |
| Socioeconomic status | ||||||
| Per capita household income | −0.054*** | −0.054*** | −0.026*** | −0.029*** | −0.014*** | |
| Work status | Work = 1; Not working = 0 | 0.045*** | 0.047*** | 0.018*** | 0.028*** | 0.011*** |
| Education degree | Primary education (Reference) | |||||
| Secondary education | −0.025*** | −0.027*** | −0.009*** | −0.018*** | −0.006*** | |
| Tertiary education | 0.228*** | 0.231*** | 0.102*** | 0.129*** | 0.057*** | |
| Lifestyle factors | ||||||
| Smoking history | Yes = 1; No = 0 | −0.004 | −0.004 | −0.001 | −0.003 | −0.001 |
| Drinking alcohol | Yes = 1; No = 0 | 0.014** | 0.015** | 0.005* | 0.010*** | 0.003** |
| BMI | Normal weight (Reference) | |||||
| Underweight | 0.095*** | 0.095*** | 0.046*** | 0.049*** | 0.024*** | |
| Overweight | −0.011 | −0.01 | −0.007 | −0.003 | −0.003 | |
| Obese | 0.002 | 0.003 | 0.000 | 0.003 | 0.001 | |
| Home environment | ||||||
| Tap water | Yes = 1; No = 0 | −0.035*** | −0.036*** | −0.016*** | −0.020*** | −0.009*** |
| Flush toilet | Yes = 1; No = 0 | −0.023*** | −0.025*** | −0.009*** | −0.016*** | −0.006*** |
| Region | Eastern (Reference) | |||||
| Middle | −0.017*** | −0.020*** | −0.004 | −0.016*** | −0.004*** | |
| Western | −0.027*** | −0.031*** | −0.005* | −0.026*** | −0.007*** | |
| Year | 1991 (Reference) | |||||
| 1993 | 0.022*** | 0.022*** | 0.010*** | 0.012*** | 0.006*** | |
| 1997 | 0.064*** | 0.065*** | 0.029*** | 0.036*** | 0.016*** | |
| 2000 | 0.080*** | 0.080*** | 0.039*** | 0.041*** | 0.020*** | |
| 2004 | 0.065*** | 0.064*** | 0.033*** | 0.031*** | 0.016*** | |
| 2006 | 0.044*** | 0.043*** | 0.024*** | 0.020*** | 0.011*** | |
| Constant | 0.505*** | 0.501*** | 0.246*** | 0.255*** | 0.126*** | |
| Observations | 31,958 | 31,958 | 31,958 | 31,958 | 31,958 |
| Variable | Cross River | Bauchi | |||
| n/N | OR (95% CIca) | n/N | OR (95% CIca) | ||
| Sex of child | Male | 767/2,206 | 1.04 | 1,191/2,590 | 1.02 |
| Female | 769/2,276 | (0.92–1.18) | 1,112/2,448 | (0.92–1.14) | |
| Duration of fever | ≤ 5 days | 866/2,800 | 0.68 | 1,537/3,587 | 0.67 |
| >5 days | 662/1,662 | (0.59–0.78) | 704/1,334 | (0.57–0.79) | |
| Number of children in household | 0–2 children | 639/1,887 | 0.96 | 775/1,701 | 1.00 |
| +3 children | 796/2,292 | (0.83–1.12) | 1,490/3,277 | (0.89–1.13) | |
| Sex of household head | Male | 1,280/3,673 | 1.15 | 2,286/4,993 | 1.27 |
| Female | 254/800 | (0.93–1.42) | 10/25 | (0.53–3.01) | |
| Household food in last week | Enough | 1,260/3,539 | 1.39 | 2,108/4,551 | 1.28 |
| Not enough | 261/915 | (1.15–1.67) | 183/455 | (1.00–1.64) | |
| Safety of water source | Safe | 681/1,720 | 1.46 | 918/1,830 | 1.32 |
| Unsafe | 850/2,744 | (1.13–1.89) | 1,377/3,186 | (1.04–1.68) | |
| Mother has own income | Yes | 891/2,436 | 1.29 | 1,476/3,192 | 1.09 |
| No | 550/1,777 | (1.10–1.50) | 788/1,786 | (0.92–1.29) | |
| Perceived relative financial status | Average or above | 1,026/2,884 | 1.18 | 1,896/4,159 | 0.96 |
| Below average | 504/1,579 | (1.00–1.38) | 395/848 | (0.78–1.19) | |
| Education of household head | Junior secondary + | 975/2,588 | 1.41 | 744/1,234 | 2.20 |
| < junior secondary | 541/1,807 | (1.17–1.70) | 1,533/3,751 | (1.78–2.71) | |
| Education of the mother | Junior secondary + | 989/2,623 | 1.45 | 280/423 | – |
| < junior secondary | 535/1,816 | (1.21–1.74) | 2,019/4,610 | ||
| Education of the mother | Formal education | 1,426/4,132 | - | 606/979 | 2.27 |
| No formal education | 98/307 | 1,693/4,054 | (1.84–2.78) | ||
| Education of the father | Junior secondary + | 1,086/2,932 | 1.37 | 729/1,215 | 2.16 |
| < junior secondary | 401/1,332 | (1.13–1.65) | 1,543/3,764 | (1.75–2.66) | |
| Urban/rural community | Urban | 407/1,259 | 0.89 | 419/724 | 1.77 |
| Rural | 1,129/3,224 | (0.63–1.25) | 1,884/4,314 | (1.37–2.29) | |
| Type of road to community | Paved/stoned | 1,051/3,085 | 0.92 | 859/1,780 | 1.16 |
| Dirt | 447/1,242 | (0.63–1.35) | 1,425/3,193 | (0.86–1.55) | |
| Health facility in settlement | Yes | 1,269/3,273 | 2.31 | 1,533/3,171 | 1.33 |
| No | 239/1,109 | (1.57–3.39) | 763/1,847 | (1.01–1.7) |
| Anatomic site | Time period | Incidence rate (95% CI) by race/ethnicity | Rate ratios (95% CI) | |||
| Non-Hispanic white | Hispanic | American Indian | H versus NHW | AI versus NHW | ||
| Men | ||||||
| Right side | 1995–1999 | 19.2 (17.4–21.2) | 17.5 (14.9–20.4) | 10.0 (5.9–15.6) | 0.92 (0.75–1.10) | 0.52 (0.31–0.82) |
| 2000–2004 | 20.4 (18.7–22.3) | 17.7 (15.4–20.3) | 9.4 (5.9–14.2) | 0.87 (0.73–1.02) | 0.46 (0.29–0.70) | |
| 2005–2009 | 17.0 (15.5–18.7) | 14.1 (12.3–16.2)a | 8.7 (5.6–12.7) | 0.83 (0.70–0.98) | 0.51 (0.33–0.75) | |
| Left side | 1995–1999 | 14.5 (13.0–16.2) | 13.9 (11.6–16.4) | 10.6 (6.3–16.4) | 0.96 (0.78–1.17) | 0.73 (0.43–1.15) |
| 2000–2004 | 12.8 (11.5–14.3) | 15.8 (13.6–18.2) | 9.4 (5.9–14.0) | 1.23 (1.02–1.48) | 0.73 (0.45–1.11) | |
| 2005–2009 | 10.8 (9.6–12.1)a | 12.3 (10.6–14.2) | 9.4 (6.2–13.6) | 1.13 (0.94–1.37) | 0.87 (0.56–1.28) | |
| Rectum and rectosigmoid junction | 1995–1999 | 15.7 (14.1–17.4) | 18.6 (16.0–21.5) | 9.4 (5.8–14.4) | 1.19 (0.98–1.42) | 0.60 (0.36–0.93) |
| 2000–2004 | 15.1 (13.6–16.7) | 20.2 (17.7–22.8) | 14.5 (9.9–20.3) | 1.33 (1.13–1.57) | 0.96 (0.65–1.37) | |
| 2005–2009 | 14.5 (13.1–16.1) | 17.8 (15.7–20.0) | 11.9 (8.4–16.4) | 1.22 (1.04–1.43) | 0.82 (0.57–1.14) | |
| Women | ||||||
| Right side | 1995–1999 | 15.2 (13.8–16.7) | 13.0 (11.1–15.2) | 10.1 (6.5–14.8) | 0.86 (0.71–1.03) | 0.66 (0.42–0.99) |
| 2000–2004 | 16.6 (15.2–18.1) | 13.7 (11.8–15.7) | 9.7 (6.5–13.7) | 0.82 (0.70–0.97) | 0.58 (0.39–0.84) | |
| 2005–2009 | 14.4 (13.1–15.8) | 14.6 (12.9–16.5) | 12.7 (9.3–16.9) | 1.02 (0.86–1.18) | 0.88 (0.63–1.19) | |
| Left side | 1995–1999 | 10.8 (9.6–12.2) | 9.2 (7.6–11.0) | 6.9 (4.0–11.0) | 0.85 (0.68–1.05) | 0.64 (0.37–1.03) |
| 2000–2004 | 8.6 (7.6–9.8)a | 9.5 (8.0–11.2) | 7.1 (4.4–10.7) | 1.11 (0.89–1.36) | 0.83 (0.51–1.27) | |
| 2005–2009 | 7.4 (6.4–8.4)a | 8.0 (6.7–9.4) | 5.1 (3.0–8.0) | 1.08 (0.87–1.34) | 0.69 (0.40–1.10) | |
| Rectum and rectosigmoid junction | 1995–1999 | 8.7 (7.6–9.9) | 9.9 (8.2–11.8) | 7.2 (4.1–11.6) | 1.14 (0.91–1.42) | 0.83 (0.47–1.36) |
| 2000–2004 | 9.1 (8.0–10.3) | 9.2 (7.8–10.9) | 5.5 (3.3–8.7) | 1.01 (0.82–1.25) | 0.61 (0.35–0.97) | |
| 2005–2009 | 9.5 (8.4–10.7) | 9.6 (8.2–11.1) | 5.2 (3.2–7.9) | 1.00 (0.82–1.21) | 0.54 (0.33–0.84) |
| Characteristics | Lipoatrophy | Fat abnormality | ||||
| OR | 95% CI | P value | OR | 95% CI | P value | |
| Boys | 4.3 | 1.6–11.6 | 0.004 | 2.7 | 1.2–6.3 | 0.02 |
| Age ≥ 10 years | 1.3 | 0.6–2.9 | 0.54 | 1.4 | 0.6–3.0 | 0.42 |
| Puberty onset: Yes | 1.2 | 0.5–2.7 | 0.64 | 1.3 | 0.6–2.7 | 0.52 |
| Moderate wastingb: Yes | 1.7 | 0.7–3.9 | 0.20 | 1.4 | 0.6–3.1 | 0.43 |
| WHO classification Stagec 3/4 vs 1/2 | 1.7 | 0.5–5.0 | 0.37 | 2.0 | 0.7–5.8 | 0.23 |
| Viral load > 40 copies/mL: Yes | 1.1 | 0.5–2.6 | 0.76 | 0.9 | 0.4–2.0 | 0.82 |
| CD4 < 500 cells/mm3: Yes | 0.5 | 0.1–1.7 | 0.26 | 0.6 | 0.2–1.8 | 0.34 |
| Stavudine ever used: Yes | 2.1 | 0.9–5.2 | 0.09 | 2.1 | 0.9–5.0 | 0.08 |
| Stavudine exposure 1 year vs No | 1.5 | 0.5–4.8 | 0.48 | 1.7 | 0.6–4.9 | 0.32 |
| ≥1 year vs No | 3.6 | 1.0–12.6 | 0.04 | 3.1 | 0.9–10.8 | 0.07 |
| Zidovudine recent: Yes | 1.0 | 0.4–2.4 | 0.94 | 1.0 | 0.4–2.3 | 0.93 |
| Zidovudine exposure < 3 years vs No | 0.5 | 0.2–1.8 | 0.30 | 0.6 | 0.2–1.7 | 0.30 |
| ≥3 years vs No | 1.3 | 0.5–3.3 | 0.61 | 1.2 | 0.5–3.0 | 0.63 |
| Lopinavir/r recent: Yes | 1.3 | 0.6–3.1 | 0.51 | 1.1 | 0.5–2.5 | 0.86 |
| Lopinavir/r exposure < 3 years vs No | 0.3 | 0.0–2.5 | 0.28 | 0.3 | 0.0–2.0 | 0.20 |
| ≥3 years vs No | 2.2 | 0.9–5.4 | 0.09 | 1.8 | 0.7–4.3 | 0.21 |
| Aboriginal | Non-Aboriginal | ||
| Had surgery n/N (%) | Had surgery n/N (%) | p-valueb | |
| All people | 37/120 (30) | 2666/6757 (39) | - |
| Sex | 0.972 | ||
| Male | 21/72 (29) | 1637/4335 (38) | |
| Female | 16/48 (33) | 1029/2422 (42) | |
| Age at diagnosis (years) | 0.367 | ||
| 18–59 | 13/40 (33) | 613/1210 (51) | |
| 60+ | 24/80 (30) | 2053/5547 (37) | |
| Spread of disease | 0.831 | ||
| Localised | 20/64 (31) | 1584/3928 (40) | |
| Regional | 17/56 (30) | 1082/2829 (38) | |
| Place of residence | 0.641 | ||
| Major cities | 13/39 (33) | 2044/4760 (43) | |
| Inner regional | 13/44 (30) | 480/1498 (32) | |
| Ruralc | 11/37 (30) | 142/499 (28) | |
| Comorbiditiesd | 0.018 | ||
| No comorbidities | 9/41 (22) | 1390/3196 (43) | |
| At least one comorbidity | 28/79 (35) | 1276/3561 (36) | |
| Socioeconomic disadvantage | 0.245 | ||
| Least and second least disadvantaged | 5/15 (33) | 1095/2477 (44) | |
| Third least disadvantaged | 3/16 (19) | 464/1168 (40) | |
| Second most and most disadvantaged | 29/89 (33) | 1107/3112 (36) |
| Variable | Training groups | P value‡ | ||
| Control groupn = 60Mean (SD) | Endurance n = 59Mean (SD) | Strength n = 60Mean (SD) | ||
| Demographic | ||||
| Age, years | 46 (5) | 46 (6) | 45 (6) | 0.73 |
| Height, cm | 164 (5) | 165 (6) | 165 (5) | 0.74 |
| Weight, kg | 69 (12) | 68 (10) | 67 (11) | 0.64 |
| Body mass index | 26 (4) | 25 (3) | 25 (3) | 0.40 |
| Clinical characteristic | ||||
| Duration of neck pain, years | 8 (5) | 9 (6) | 8 (6) | 0.30 |
| Neck pain, mm (VAS†, scale 0-100) | 58 (20) | 56 (22) | 57 (20) | 0.89 |
| Detection range | Passerinesa | Wadersb | Hooded crow (Corvus cornix) | Gulls | Mallard (Anas platyrhynchos) | Raven (Corvus corax) | Greylag goose (Anser anser) | White‐tailed eagle (Haliaeetus albicilla) |
| RCS (dBm2) | −32.0 | −28.5 | −24.9 | −23.5 | −22.7 | −22.4 | −19.5 | −18.3 |
| Modeled | 707 | 859 | 1,051 | 1,140 | 1,193 | 1,214 | 1,435 | 1,537 |
| Lower range | 578 | 703 | 859 | 932 | 975 | 992 | 1,173 | 1,257 |
| Upper range | 870 | 1,057 | 1,293 | 1,402 | 1,468 | 1,494 | 1,765 | 1,891 |
| Mean | 959 | 2,058 | 1,013 | 1,653 | 1,434 | 1,043 | 1,932 | 1,497 |
| SE | 53 | 179 | 49 | 48 | 202 | 63 | 114 | 22 |
| Minimum | 135 | 371 | 214 | 346 | 418 | 292 | 504 | 249 |
| Maximum | 2,866 | 4,377 | 2,869 | 3,564 | 3,103 | 3,446 | 3,722 | 3,643 |
| N | 76 | 33 | 74 | 220 | 11 | 58 | 38 | 725 |
| mean (SD) | |
| Age, y | 31.6 (4.3) |
| Age at menarche, y | 13.2 (1.5) |
| Pre-pregnancy BMI, kg/m2 | 24.3 (3.7) |
| % (n) | |
| Pre-pregnancy BMI group | |
| Underweight (BMI < 18.5) | 11 (8) |
| Normal weight (BMI 18.5 - 24.9) | 52 (61) |
| Overweight (BMI 25 - 29.9) | 30 (36) |
| Obese (BMI ≥ 30) | 7 (8) |
| Educational level | |
| Not completed post high school education | 32 (38) |
| Completed post high school education | 68 (80) |
| Shot ID | Dimensions | Treatment | No. of samples analysed | ||
| d [mm] | Weight [g] | C | S | ||
| 81A1527 | 85.0 | 2410.8 | SS | 2 | 0 |
| 81A2310 | 82.6 | 2199.9 | SS | 2 | 0 |
| 81A3470 | 84.8 | 2107.0 | SS | 2 | 0 |
| 81A3550 | 84.1 | 2361.0 | SS | 1 | 0 |
| 81A3839 | 86.0 | 2014.8 | SS | 3 | 1 |
| 82A2618 | 85.3 | 2012.5 | SS | 4 | 1 |
| 82A4365[a] | 99.0 | 3500.0 | SS | 1 | 0 |
| 82A4233[a] | 86.0 | 2802.6 | SS | 2 | 0 |
| 81A3461[a] | 84.0 | 568.3 | SS | 2 | 0 |
| 81A6218[a] | 193.0 | 26 000 | SS | 1 | 0 |
| 81A6219[a] | 192.0 | 25 750 | SS | 1 | 0 |
| 81A6143 | 79.9 | 1818.1 | HWAS | 1 | 1 |
| 83A0161 | 83.6 | 1743.2 | HW | 1 | 1 |
| 83A0189 | 70.6 | 1263.7 | HWAS | 1 | 1 |
| 83A0446 | [b] | 1052.0 | HW | 1 | 0 |
| 81A0177 | [b] | [b] | HWAS | 1 | 0 |
| 81A6102 | 83.7 | 2045.1 | HW | 0 | 1 |
| A | B | C | D | E | F | |||||||
| Subject J \\Cells | WT | MT | WT | MT | WT | MT | WT | MT | WT | MT | WT | MT |
| 1-1 | 3 | 6 | 3 | 3 | 3 | 3 | 6 | 9 | 11 | 7 | 1 | 4 |
| 1-2 | 2 | 3 | 0 | 9 | 1 | 5 | 1 | 8 | 4 | 7 | 2 | 6 |
| 1-3 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 2 | 1 | 1 |
| 1-4 | 0 | 0 | 0 | 0 | 1 | 6 | 2 | 1 | 4 | 1 | 1 | 0 |
| 1-5 | 0 | 3 | 0 | 1 | 0 | 2 | 2 | 0 | 3 | 6 | 4 | 1 |
| 1-6 | 1 | 1 | 1 | 3 | 0 | 3 | 1 | 4 | 1 | 7 | 2 | 3 |
| 2-1 | 3 | 12 | 1 | 2 | 3 | 4 | 2 | 7 | 5 | 5 | 4 | 18 |
| 2-2 | 1 | 6 | 0 | 13 | 5 | 4 | 1 | 1 | 4 | 2 | 4 | 11 |
| 2-3 | 2 | 3 | 2 | 2 | 3 | 8 | 1 | 6 | 4 | 9 | 3 | 13 |
| 2-4 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 |
| 2-5 | 3 | 5 | 2 | 1 | 3 | 10 | 1 | 4 | 2 | 7 | 3 | 7 |
| 2-6 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 2 | 0 |
| 2-7 | 5 | 5 | 2 | 5 | 0 | 10 | 0 | 19 | 10 | 10 | 4 | 5 |
| Totals | 23 | 46 | 11 | 39 | 19 | 55 | 17 | 63 | 49 | 65 | 32 | 69 |
| Status at consent | ||||
| High non-tryer | High tryer | Pregnant | ||
| % | % | % | ||
| Age, years | <18 | 0 | 0 | 1.4 |
| 18–19 | * | 0 | 3.3 | |
| 20–34 | 90.9 | 83.7 | 76.5 | |
| 35+ | * | 16.3 | 18.7 | |
| Mean (standard deviation) | 27.7 (4.0) | 30.7 (4.1) | 29.2 (5.7) | |
| Race/ethnicity | Asian, non-Hispanic | * | * | 4.2 |
| Black, non-Hispanic | * | * | 6.4 | |
| Hispanic | 22.7 | 10.2 | 20.0 | |
| Other^ | 20.5 | 20.4 | 8.0 | |
| White, non-Hispanic | 50.0 | 67.3 | 61.5 |
| Organism | Degradosome-dependence | PNPase role | References |
| Yersinia pestis | ? | Catalytic activity plays an essential role in cold growth | Rosenzweig et al., 2005 |
| ? | Required for virulence in a catalytic-activity-independent manner | Rosenzweig et al., 2005 | |
| ? | S1 domain sufficient for mediating virulence | Rosenzweig et al., 2005 | |
| ? | The first 15 aa residues of the S1 domain are dispensable for virulence; however, the first 30 aa residues are required for virulence | Rosenzweig et al., 2007 | |
| ? | Amino acid residue F638 within the PNPase S1 domain is required for virulence and cold growth | Rosenzweig et al., 2007 | |
| Yersinia pseudotuberculosis | No | S1 and KH domains also contribute to cold growth. | Rosenzweig et al., 2005 |
| No | Degradosome-independent role in cold growth | Henry et al., 2012 | |
| Yes | Degradosome assembly required for virulence | Yang et al., 2008 | |
| Yes | Degradosome-dependent role in oxidative stress response | Henry et al., 2012 | |
| No | PNPase is dispensable for antibiotic/chemical stress responses | Henry et al., 2012 |
| Number | Outcomes |
| 1 | Patient-provider communication |
| 2 | Monitor treatment response |
| 3 | Detect unrecognised problems |
| 4 | Changes to patient health behaviour |
| 5 | Changes to patient management |
| 6 | Improved patient satisfaction |
| 7 | Improved health outcomes |
| 8 | Strong & effective quality improvement |
| 9 | Increased transparency, accountability, public reporting |
| 10 | Better system performance (monitoring, planning, financing; evaluating, responding) |
| 11 | Mediating variables on the effect (both at individual and organisation level) |
| 12 | Possible subgroup effects |
| Stratification criteria | Description |
| Physician Integrated Network (PIN) [30] | A Manitoba Health primary care renewal initiative that focuses on fee-for-service (FFS) physician groups. |
| Its goal is to facilitate systemic improvements in the delivery of primary care. | |
| Objectives: | |
| ● To improve access to primary care | |
| ● To improve Primary Care Providers’ access to and use of information | |
| ● To improve the work life for all primary care providers | |
| ● To demonstrate high quality primary care with a specific focus on Chronic Disease Management | |
| Uniting Primary Care and Oncology Network (UPCON)[31] | A collaborative partnership between Winnipeg family practice clinics/primary health care centres and CancerCare Manitoba (CCMB) that is dedicated to promoting and supporting the shared care of the cancer patient. |
| Tissue sample | Type of core | No. of cores in TMA blocks |
| Control Normal Samples | Normal | 119 |
| DCIS | Normal in DCIS | 12 |
| DCIS pure lesion | 54 | |
| IDC | Normal in IDC | 61 |
| DCIS in IDC | 39 | |
| IDC pure lesion | 120 |
| Cancer | Accession number | Array | Sample size | Log-2 mRNA signal intensity (mean ± SD*) | P | ||
| Control | Case | Control | Case | ||||
| Breast cancer | GSE42568 | HG-U133_Plus_2 | 17 | 104 | 6.36 ± 0.54 | 7.57 ± 0.78 | <0.001 |
| GSE15852 | HG-U133A | 43 | 43 | 9.49 ± 0.18 | 9.74 ± 0.21 | <0.001 | |
| Lung cancer | E-MEXP-231 | HG-U133A | 9 | 49 | 7.83 ± 0.40 | 8.62 ± 0.65 | 0.001 |
| GSE19804 | HG-U133_Plus_2 | 60 | 60 | 8.13 ± 0.73 | 8.41 ± 0.78 | 0.046 | |
| Prostate cancer | GSE6956 | HG-U133A_2 | 20 | 69 | 9.44 ± 1.11 | 10.46 ± 0.36 | <0.001 |
| GSE6919 | HG_U95Av2 | 81 | 65 | 4.62 ± 0.24 | 4.67 ± 0.23 | 0.040 | |
| Hepatocellular carcinoma | GSE14323 | HG-U133A_2 | 19 | 38 | 6.95 ± 0.46 | 7.82 ± 0.53 | <0.001 |
| GSE6764 | HG-U133_Plus_2 | 10 | 62 | 7.57 ± 0.81 | 8.45 ± 0.54 | <0.001 |
| Dry mucus membranes (eyes/mouth) | Lighter/uneasy sleep | Heavier sleep | Sleepiness at daytime | Increased fatigue | Dizziness | |
| Patient #1 | x | x | x | |||
| Patient #2 | x | x | ||||
| Patient #3 | x | x | ||||
| Patient #4 | x | x | ||||
| Patient #5 | x | x |
| Surgery group | Packing group | P | |
| Re-bleeding | 0 | 4 | 0.001 |
| Discomfort after the treatment | 2.4±1.4 | 7.6±1.0 | 0.001 |
| Adhesion of nasal cavity | 2 | 7 | 0.007 |
| Gene | Primer sequences | |
| hsa-miR-155 | RT | 5′-GCGCGTGAGCAGGCTGGAGAAATTAACCACGCGCACCCCT-3′ |
| Forward | 5′- CTTAATGCTAATCGTGAT -3′ | |
| Reverse | 5′- GAG CAG GCT GGA GAA -3′ | |
| hsa-miR-146a | RT | 5′-GCGCGTGAGCAGGCTGGAGAAATTAACCACGCGCAACCCA -3′ |
| Forward | 5′- CTGAGAACTGAATTCCA -3′ | |
| Reverse | 5′- GAG CAG GCT GGA GAA -3′ | |
| U6 | RT | 5′-CGCTTCACGAATTTGCGTGTCAT -3′ |
| Forward | 5′- CTCGCTTCGGCAGCACATA -3′ | |
| Reverse | 5′- CGCTTCACGAATTTGCGTG -3′ | |
| TGF-β1 | Forward | 5′- CCAACTATTGCTTCAGCTCCA -3′ |
| Reverse | 5′- GTGTCCAGGCTCCAAATGT -3′ | |
| TNF-α | Forward | 5′- CCCAGGGACCTCTCTCTAATCA -3′ |
| Reverse | 5′- AGCTGCCCCTCAGCTTGAG -3′ | |
| GAPDH | Forward | 5′-CCCCTTCATTGACCTCAACTAC-3′ |
| Reverse | 5′-GATGACAAGCTTCCCGTTCTC-3′ |
| Division | Asembo | Uyoma | Maranda | Nyang’oma | Usigu | Overall |
| Mean [F]±SD | 0.92±0.46 | 1.39±0.84 | 0.69±0.42 | 1.00±0.59 | 0.78±0.66 | 0.85±0.67 |
| Highest | 2.27 | 5.44 | 1.7 | 2.23 | 2.34 | 5.44 |
| >3.0 ppm | - | 01(9.1%) | - | - | - | 1(0.8%) |
| 1.5-2.9 ppm | 3(8.6%) | 2(18.2%) | 2(4.5%) | 2(33.3%) | 5(16.7) | 14(10.9%) |
| 1.0-1.4 ppm | 9(24.3%) | 2(18.2%) | 6(13.6%) | 0(0.0%) | 4(13.3%) | 216(16.4%) |
| 0.5-0.9 ppm | 20(57.1%) | 3(27.5%) | 21(47.7%) | 3(50.0%) | 9(30.0%) | 56(43.8%) |
| 0-0.4 ppm | 5(14.3%) | 3(27.5%) | 15(34.1%) | 1(16.7%) | 12(40.0%) | 36(28.1%) |
| Lowest | 0.17 | 0.01 | 0.02 | 0.2 | 0.11 | 0.01 |
| % [F] > 1 ppm | 28.6 | 45.5 | 18.2 | 33.3 | 30 | 28.1 |
| Sample size (n) | 37 | 11 | 44 | 6 | 30 | 128 |
| O2− (nmol/mL) | H2O2 (nmol/mL) | NO2− (nmol/mL) | TBARS (μmol/mL) | |
| Control (X ± SE) | 19.97 ± 0.45 | 20.28 ± 0.04 | 23.14 ± 1.17 | 26.20 ± 0.38 |
| DL-Hcy TLHC (X ± SE) | 20.19 ± 0.47 | 20.23 ± 0.03 | 23.52 ± 1.13 | 25.88 ± 0.91 |
| No. | Ab. 1 | Ag.2 | Frequency | Redundancy |
| 1 | D | K | 22.0% (13/59) | 1.92 (25/13) |
| 2 | Y | E | 18.6% (11/59) | 2.45 (27/11) |
| 3 | Y | N | 16.9% (10/59) | 1.80 (18/10) |
| 4 | S | E | 16.9% (10/59) | 1.70 (17/10) |
| 5 | Y | K | 15.3% ( 9/59) | 1.78 (16/9) |
| 6 | N | R | 15.3% ( 9/59) | 1.44 (13/9) |
| 7 | Y | R | 15.3% ( 9/59) | 3.56 (32/9) |
| 8 | D,Y | K | 15.3% ( 9/59) | 1.78 (16/9) |
| 9 | S,Y | Q | 13.6% ( 8/59) | 1.75 (14/8) |
| 10 | G | R | 13.6% ( 8/59) | 4.38 (35/8) |
| Gene_symbol | Description | Log2 Ratio (A253-5/A253-0) | P value |
| MAPK10 | mitogen-activated protein kinase 10 | −1.1440 | 0.000264947 |
| AKT1 | v-akt murine thymoma viral oncogene homolog 1 | 1.1076 | 0.014492851 |
| PDGFB | platelet-derived growth factor beta polypeptide | 1.0834 | 6.23066E-05 |
| BIRC3 | baculoviral IAP repeat containing 3 | 1.0176 | 0.001517394 |
| PGF | placental growth factor | −1.0496 | 0.025969431 |
| COL4A1 | collagen, type IV, alpha 1 | 2.1236 | 1.58011E-20 |
| FN1 | fibronectin 1 | 3.6490 | 3.35978E-24 |
| THBS1 | thrombospondin 1 | 1.0290 | 0.000135356 |
| FLT1 | fms-related tyrosine kinase 1 | 1.2325 | 0.025381832 |
| RASGRF1 | Ras protein-specific guanine nucleotide-releasing factor 1 | 1.7221 | 1.11117E-05 |
| CCND2 | cyclin D2 | 2.3619 | 8.02038E-19 |
| COL5A2 | collagen, type V, alpha 2 | 1.2806 | 0.030736616 |
| TNC | tenascin C | 1.6496 | 9.83873E-07 |
| PARVA | parvin, alpha | 1.2195 | 9.20291E-07 |
| Item | Mean | SD | Range | 95% CI |
| 1. I have a desire to succeed | 4.6 | 0.62 | 1–5 | 4.56; 4.72 |
| 2. I have my own plan for how to stay or become well | 3.9 | 0.92 | 1–5 | 3.80; 4.05 |
| 3. I have goals in life that I want to reach | 4.2 | 0.90 | 1–5 | 4.08; 4.32 |
| 4. I believe that I can meet my current personal goals | 3.7 | 0.98 | 1–5 | 3.59; 3.85 |
| 5. I have a purpose in life | 3.8 | 0.94 | 1–5 | 3.72; 3.97 |
| 6. Even when I don’t care about myself, other people do | 4.1 | 0.83 | 1–5 | 4.0; 4.21 |
| 7. Fear doesn’t stop me from living the way I want to | 3.1 | 1.30 | 1–5 | 2.90; 3.25 |
| 8. I can handle what happens in my life | 3.3 | 1.02 | 1–5 | 3.20; 3.47 |
| 9. I like myself | 3.2 | 1.20 | 1–5 | 2.99; 3.31 |
| 10. If people really knew me, they would like me | 3.7 | 0.84 | 1–5 | 3.60; 3.82 |
| 11. I have an idea of who I want to become | 3.5 | 1.05 | 1–5 | 3.40; 3.67 |
| 12. Something good will eventually happen | 4.0 | 0.81 | 1–5 | 3.93; 4.14 |
| 13. I’m hopeful about my future | 3.9 | 0.99 | 1–5 | 3.72; 3.97 |
| 14. I continue to have new interests | 3.7 | 1.09 | 1–5 | 3.57; 3.86 |
| 15. Coping with my mental illness is no longer the main focus of my life | 3.1 | 1.23 | 1–5 | 2.98; 3.30 |
| 16. My symptoms interfere less and less with my life | 3.4 | 1.20 | 1–5 | 3,25; 3.54 |
| 17. My symptoms seem to be a problem for shorter periods of time each time they occur | 3.5 | 1.13 | 1–5 | 3.32; 3.61 |
| 18. I know when to ask for help | 3.9 | 1.06 | 1–5 | 3.78; 4.05 |
| 19. I am willing to ask for help | 4.1 | 0.92 | 1–5 | 4.01; 4.25 |
| 20. I ask for help when I need it | 3.8 | 1.08 | 1–5 | 3.68; 3.96 |
| 21. I can handle stress | 3.0 | 1.14 | 1–5 | 2.88; 3.18 |
| 22. I have people I can count on | 4.3 | 0.78 | 1–5 | 4.18; 4.38 |
| 23. Even when I don’t believe in myself, other people do | 4.0 | 0.87 | 1–5 | 3.88; 4.10 |
| 24. It is important to have a variety of friends | 3.5 | 1.40 | 1–5 | 3.31; 3.67 |
| Summary scales | ||||
| Personal confidence and hope (mean of items 7, 8, 9, 10, 11, 12, 13, 14 & 21) | 3.5 | 0.68 | 1.67–5 | 3.40; 3.58 |
| Willingness to ask for help (mean of items 18, 19 & 20) | 4.0 | 0.89 | 1–5 | 3.84; 4.07 |
| Goal and success orientation (mean of items 1, 2, 3, 4 & 5) | 4.1 | 0.63 | 1.4–5 | 3.99; 4.15 |
| Reliance on others (mean of items 6, 22, 23 & 24) | 4.0 | 0.68 | 2–5 | 3.88; 4.06 |
| Not dominated by symptoms (mean of items 15, 16 & 17) | 3.3 | 0.95 | 1–5 | 3.21; 3.45 |
| Total scale (mean of items) | 3.7 | 0.56 | 1.92–5 | 3.66; 3.80 |
| Total scale (sum of items) | 89.5 | 13.39 | 46–120 | 87.75; 91.24 |
| Study design | Methods & numbers | Research instruments | Respondents |
| Qualitative study | *GDs: 14 (One group from each hospital) | GD guideline: semi-structured open-ended questions with probes | From district hospitals: civil surgeon, obstetrics and pediatrics consultants, anesthesiologist, nursing superintendent, and two senior staff nurses |
| From MCWCs: deputy director of family planning, anesthesiologist, medical officer, one nurse, and one family welfare visitor | |||
| From UHCs: upazila health and family planning officer, obstetrics and gynecology specialists, pediatrician, anesthesiologist, resident medical officer, and one nurse | |||
| **IDIs:56 (four interviews from each hospital) | IDI guideline: semi-structured open-ended questions with probes | From district hospitals, MCWCs, and UHCs: One laboratory technician/pharmacist, one ward master/nursing supervisor, one ancillary staff from the maternal or neonatal wards, and one cleaner | |
| Quantitative study | Exit interviews: 112 (eight exit interviews from each hospital) | Structured questionnaire | Patients or their attendants from maternal, labor, and neonatal wards at district hospitals, MCWCs, and UHCs |
| Colorectal cancer characteristic | Black Mississippians | White Mississippians | Difference (Black–White) | P value |
| Statistically-significant health disparities | ||||
| % (Age 50+) reporting NEVER had a sigmoidoscopy or colonoscopy (average: 2006, 2008 and 2010 BRFSS) | 53.2 % | 41.9 % | 11.3 % | <.0001 |
| Age-adjusted colorectal cancer incidence rate (per 100,000; 2006–2010 MCR data) | 64.9 | 50.5 | 14.4 | <.0001 |
| Age-adjusted colorectal cancer mortality rate (per 100,000; 2006–2010 MCR data) | 26.2 | 17.5 | 8.8 | 0.0001 |
| CRC mortality-to-incidence rate | 0.40 | 0.35 | 0.05 | 0.0035 |
| No discernible differences between groups | ||||
| % Advanced stage (regional + distant disease) at initial diagnosis | 52.9 % | 52.3 % | 0.6 % | 0.7926 |
| Database | Crops | Web link | Reference |
| Gramene | Grasses | http://www.gramene.org | Tello-Ruiz et al., 2016 |
| International Rice Informatics Consortium | Rice (Oryza sativa) | http://iric.irri.org | n/a |
| Maize Genetics and Genomics Database | Maize (Zea mays) | http://www.maizegdb.org | Lawrence et al., 2004 |
| SoyKB | Soybean (Glycine max) | http://soykb.org | Joshi et al., 2014 |
| T3 Triticaceae toolbox | Wheat (Triticum aestivum), barley (Hordeum vulgare) and oat (Avena sativa) | https://triticeaetoolbox.org/ | Blake et al., 2016 |
| Wheat Information System | Wheat (Triticum aestivum) | http://wheatis.org | n/a |
| One missing | Two missing | Three missing | Four missing | No missing | Total | |
| Sex | ||||||
| Female | 277 (18.3%) | 131 (8.6%) | 89 (5.9%) | 77 (5.1%) | 933 (61.9%) | 1507 (100%) |
| Male | 109 (15.5%) | 97 (13.8%) | 70 (10%) | 34 (4.8%) | 389 (55.6%) | 699 (100%) |
| Total | 386 (17.4%) | 228 (10.3%) | 159 (7.1%) | 111 (4.9%) | 1322 (59.9%) | 2206 (100%) |
| Age | ||||||
| 7–15 | 29 (23.9%) | 38 (31.4%) | 18 (14.8%) | 1 (0.8%) | 35 (28.9%) | 121 (100%) |
| 16–30 | 108 (20.8%) | 13 (2.5%) | 0 (0%) | 0 (0%) | 398 (76.6%) | 519 (100%) |
| 31–45 | 115 (19.1%) | 84 (13.9%) | 29 (4.8%) | 2 (0.3%) | 371 (61.7%) | 601 (100%) |
| 46–60 | 102 (13.8%) | 50 (6.7%) | 72 (9.7%) | 34 (4.6%) | 479 (64.9%) | 737 (100%) |
| >60 | 8 (3.4%) | 32 (14%) | 74 (32.4%) | 74 (32.4%) | 40 (17.5%) | 228 (100%) |
| Age mean | Visits before | Visits after | Visitors before | Visitors after | Change visits | Change visitors | ||
| (2 years) | (2 years) | n (%) | n (%) | |||||
| Men 25-44 | 34.7 | n | ||||||
| Visits to GP-all | 166365 | 237432 | 261847 | 91484 | 95276 | 24415 (10.3) | 3792 (4.1) | |
| Income below median | 85643 | 113878 | 126929 | 43402 | 45621 | 13051 (11.5) | 2219 (5.1) | |
| Income above median | 80722 | 123554 | 134918 | 48082 | 49655 | 11364 (9.2) | 1573 (3.3) | |
| Men 45-64 | 54.4 | |||||||
| Visits to GP-all | 154444 | 336028 | 378838 | 100717 | 108068 | 42810 (12.7) | 7351 (7.3) | |
| Income below median | 75384 | 177655 | 195310 | 49224 | 52150 | 17655 (9.9) | 2926 (5.9) | |
| Income above median | 79060 | 158373 | 183528 | 51493 | 55918 | 25155 (15.9) | 4425 (8.6) | |
| Men 65-84 | 72.6 | |||||||
| Visits to GP-all | 90190 | 309857 | 340047 | 73379 | 82331 | 30190 (9.7) | 8952 (12.2) | |
| Income below median | 45090 | 160781 | 171075 | 36641 | 36802 | 10294 (6.4) | 161 (0.4) | |
| Income above median | 45100 | 149076 | 168972 | 36738 | 38450 | 19896 (13.3) | 1712 (4.7) | |
| Women 25-44 | 34.7 | |||||||
| Visits to GP-all | 160983 | 376175 | 419338 | 110827 | 114475 | 43163 (11.5) | 3648 (3.3) | |
| Income below median | 78160 | 175822 | 197920 | 51151 | 53139 | 22098 (12.6) | 1988 (3.9) | |
| Income above median | 82823 | 200353 | 221418 | 59676 | 61336 | 21065 (10.5) | 1660 (2.8) | |
| Women 45-64 | 54.5 | |||||||
| Visits to GP-all | 153401 | 470358 | 517804 | 115657 | 121277 | 47446 (10.1) | 5602 (4.9) | |
| Income below median | 78558 | 265618 | 288359 | 60308 | 62654 | 22741 (8.6) | 2346 (3.9) | |
| Income above median | 74843 | 204740 | 229445 | 55367 | 58623 | 24705 (12.1) | 3256 (5.9) | |
| Women 65-84 | 73.3 | |||||||
| Visits to GP-all | 103605 | 432104 | 468395 | 88908 | 90010 | 36291 (8.4) | 1102 (1.2) | |
| Income below median | 51788 | 225746 | 238731 | 44685 | 44567 | 12985 (5.8) | −118 (−0.3) | |
| Income above median | 51817 | 206358 | 229664 | 44223 | 45443 | 23306 (11.3) | 1220 (2.8) |
| Family | Name | Local RDB | National RL rank | Main habitat | Life forms |
| Azollaceae | Azolla japonica | 35 | VU | Paddy, Ditch | perennial fern |
| Hydrocharitaceae | Blyxa echinosperma | 42 | VU | Paddy, Ditch | annual |
| Alismataceae | Caldesia parnassifolia | 37 | VU | Pond, Lake, Paddy | perennial |
| Compositae | Gnaphalium hypoleucum | 40 | VU | Forest edge | annual |
| Isoetaceae | Isoetes japonica | 36 | NT | Pond, Paddy, Ditch | perennial fern |
| Compositae | Ixeris chinensis subsp. strigosa | 40 | VU | Grassland, Roadside | perennial |
| Labiatae | Leonurus macranthus | 39 | VU | Grassland | perennial |
| Marsileaceae | Marsilea quadrifolia | 46 | VU | Paddy, Ditch | perennial fern |
| Pontederiaceae | Monochoria korsakowii | 39 | NT | Lake, River, Ditch, Paddy(fallow) | annual |
| Labiatae | Mosla japonica | 36 | NT | Roadside | annual |
| Najadaceae | Najas gracillima | 40 | NT | Pond, Paddy | annual |
| Menyanthaceae | Nymphoides peltata | 40 | NT | Lake, Pond, Paddy | perennial |
| Saxifragaceae | Penthorum chinense | 41 | NT | Swamp | perennial |
| Polygonaceae | Persicaria foliosa var. paludicola | 36 | VU | Swamp, Paddy(fallow), Pond | annual |
| Polygonaceae | Persicaria taquetii | 36 | VU | Swamp, Paddy | annual |
| Potamogetonaceae | Potamogeton berchtoldii | 44 | NT | Lake, Pond, River, Ditch | perennial |
| Salviniaceae | Salvinia natans | 40 | NT | Paddy, Ditch | annual fern |
| Compositae | Saussurea pulchella | 39 | VU | Grassland, Forest edge | annual |
| Sparganiaceae | Sparganium fallax | 41 | NT | Lake, Pond, River | perennial |
| Sparganiaceae | Sparganium stenophyllum | 41 | VU | Lake, Pond | perennial |
| Trapaceae | Trapa incisa | 37 | VU | Lake, Pond, Ditch, Paddy | annual |
| Lentibulariaceae | Utricularia uliginosa | 43 | NT | Swamp | perennial |
| Asclepiadaceae | Vincetoxicum pycnostelma | 44 | NT | Grassland | perennial |
| Rat number | Control group | Cyanoacrylate group | ||
| Researcher 1 | Researcher 2 | Researcher 1 | Researcher 2 | |
| 1 | 0 | 0 | 1 | 1 |
| 2 | 0 | 0 | 0 | 0 |
| 3 | 2 | 2 | 1 | 2 |
| 4 | 2 | 2 | 2 | 2 |
| 5 | 1 | 1 | 2 | 2 |
| 6 | 2 | 2 | 1 | 1 |
| 7 | 0 | 0 | 1 | 2 |
| 8 | 2 | 2 | 2 | 1 |
| SSP no. | Accession no. | Protein Description | Mass in kDa (experiment/predicted) | pI (experiment/predicted) | Sequence coverage (%) | Number of peptides matched | Mowse score | Error (ppm) |
| pH 4–7 | ||||||||
| 2120 | 6065880 | Heterogeneous nuclear ribonucleoprotein H2 | 38.43/49.52 | 3.96/5.89 | 46 | 15 | 171 | 14 |
| 3609 | 515634 | Ubiquinol-cytochrome-c reductase complex core protein I, mitochondrial precursor | 54.55/52.75 | 5.30/5.94 | 46 | 15 | 170 | 17 |
| 3617 | 4826760 | Heterogeneous nuclear ribonucleoprotein F | 57.18/45.87 | 5.25/5.38 | 31 | 8 | 88 | 9 |
| 4422 | 57093855 | Similar to heterogeneous nuclear ribonucleoprotein H (hnRNP H) | 38.53/46.38 | 4.46/6.61 | 43 | 12 | 131 | 6 |
| pH 6–11 | ||||||||
| 7818 | 8574295 | Voltage-dependent anion channel 2 | 20.00/31.65 | 9.43/7.49 | 41 | 8 | 88 | 18 |
| 7821 | 21619296 | Guanine nucleotide binding protein (G protein), beta polypeptide 2-like 1 | 20.00/34.95 | 9.40/8.37 | 23 | 7 | 72 | 9 |
| Control (n = 20) | Imagery (n = 20) | |
| mean ± SD | mean ± SD | |
| Did you .... | ||
| ... feel your imagery improved? (1: not at all, 7: considerably) | 5.45 ± 1.10 | 5.80 ± 0.77 |
| ... image as instructed and practiced? **(1: not at all, 7: exactly) | 5.65 ± 0.67 | 6.20 ± 0.70 |
| ... notice any movement in the non-dominant hand? (1:not at all, 7: full grasping) | 3.70 ± 1.08 | 3.32 ± 1.25 |
| How ... | ||
| ... easy to image the feelings? (1: very hard, 7: very easy) | 5.00 ± 1.41 | 5.20 ± 1.01 |
| ... clear and vivid was the imagery? (1: no image at all, 7: perfectly clear/vivid) | 5.40 ± 0.94 | 5.45 ± 0.76 |
| Parameter | Activity rate | Time (%) in novel | Crossing/min |
| VEH controls | 3.79 ± 0.21 | 79.7 ± 1.09 | 2.55 ± 0.26 |
| DAT-i mice | 4.10 ± 0.22 | 78.6 ± 1.75 | 2.98 ± 0.33 |
| GO ID1 | p-values | GO group description | ||||||
| [1, 10-2) | [10-2, 10-5) | [10-5, 10-10) | [10-10, 10-20) | [10-20, 10-50) | [10-50, 10-100) | [10-100, 0] | ||
| * GO0005215(392) | 94.13 | 3.68 | 0.66 | 0.42 | 0.52 | 0.26 | 0.33 | transporter activity |
| ** GO0042626(43) | 85.6 | 2.1 | 2.21 | 4.1 | 2.21 | 1.99 | 1.77 | ATPase activity, coupled to transmembrane movement of substances |
| *** GO0042625(30) | 85.75 | 1.84 | 1.61 | 3.68 | 3.91 | 2.07 | 1.15 | ATPase activity, coupled to transmembrane movement of ions |
| **** GO0019829(19) | 92.4 | 2.92 | 0 | 1.75 | 1.75 | 0 | 1.17 | cation-transporting ATPase activity |
| ***** GO0046961(18) | 92.16 | 2.61 | 0 | 1.96 | 1.96 | 0 | 1.31 | hydrogen-transporting ATPase activity, rotational mechanism |
| **** GO0015662(12) | 30.3 | 0 | 10.61 | 19.7 | 21.21 | 13.64 | 4.55 | ATPase activity, coupled to transmembrane movement of ions, phosphorylative mechanism |
| **GO0015267(11) | 87.27 | 3.64 | 1.82 | 0 | 0 | 1.82 | 5.45 | channel or pore class transporter activity |
| *** GO0015268(9) | 88.89 | 5.56 | 2.78 | 0 | 0 | 2.78 | 0 | alpha-type channel activity |
| **** GO0005216(7) | 85.71 | 4.76 | 4.76 | 0 | 0 | 4.76 | 0 | ion channel activity |
| ** GO0015238(14) | 41.76 | 10.99 | 15.38 | 12.09 | 10.99 | 1.1 | 7.69 | drug transporter activity |
| *** GO0015239(11) | 47.27 | 9.09 | 14.55 | 9.09 | 12.73 | 0 | 7.27 | multidrug transporter activity |
| ** GO0015144(27) | 21.08 | 1.71 | 3.13 | 8.55 | 23.65 | 5.7 | 36.18 | carbohydrate transporter activity |
| *** GO0051119(24) | 0.36 | 1.81 | 3.62 | 10.87 | 30.07 | 7.25 | 46.01 | sugar transporter activity |
| **** GO0015145(17) | 0 | 0 | 0 | 0 | 0 | 11.03 | 88.97 | monosaccharide transporter activity |
| ***** GO0015149(17) | 0 | 0 | 0 | 0 | 0 | 11.03 | 88.97 | hexose transporter activity |
| ****** GO0005354(6) | 0 | 0 | 0 | 0 | 0 | 33.33 | 66.67 | galactose transporter activity |
| ****** GO0015578(15) | 0 | 0 | 0 | 0 | 0 | 0 | 100 | mannose transporter activity |
| ****** GO0005353(15) | 0 | 0 | 0 | 0 | 0 | 0 | 100 | fructose transporter activity |
| ****** GO0005355(16) | 0 | 0 | 0 | 0 | 0 | 0 | 100 | glucose transporter activity |
| ** GO0015075(140) | 95.6 | 3.02 | 0.16 | 0.29 | 0.37 | 0.2 | 0.36 | ion transporter activity |
| *** GO0046873(38) | 91.18 | 4.98 | 0.14 | 0.28 | 0.71 | 1.28 | 1.42 | metal ion transporter activity |
| **** GO0046915(29) | 88.67 | 6.9 | 0.25 | 0.25 | 0.49 | 1.48 | 1.97 | transition metal ion transporter activity |
| ***** GO0005375(8) | 82.14 | 10.71 | 0 | 3.57 | 0 | 3.57 | 0 | copper ion transporter activity |
| ***** GO0005381(10) | 75.56 | 6.67 | 0 | 0 | 0 | 8.89 | 8.89 | iron ion transporter activity |
| *** GO0042625(30) | 85.75 | 1.84 | 1.61 | 3.68 | 3.91 | 2.07 | 1.15 | ATPase activity, coupled to transmembrane movement of ions |
| **** GO0019829(19) | 92.4 | 2.92 | 0 | 1.75 | 1.75 | 0 | 1.17 | cation-transporting ATPase activity |
| ***** GO0046961(18) | 92.16 | 2.61 | 0 | 1.96 | 1.96 | 0 | 1.31 | hydrogen-transporting ATPase activity, rotational mechanism |
| **** GO0015662(12) | 30.3 | 0 | 10.61 | 19.7 | 21.21 | 13.64 | 4.55 | ATPase activity, coupled to transmembrane movement of ions, phosphorylative mechanism |
| Primers | Sequence (5′-3′) |
| Primers for gene disruption and complementation | |
| LwblA-F | AAGCTTTCGGGTACGCCATCTCGTA |
| LwblA-R | TCTAGAGCTGCTCCCTGAACGAACA |
| RwblA-F | GGATCCACGACGAGGTGTACGAGAAC |
| RwblA-R | GATATCTGACGCTGCTGGAGGAGAT |
| Kan-F | TCTAGAGATCCCCTGGATACCGCTCG |
| Kan-R | GGATCCGTACCCGAACCCCAGAGTC |
| wblAJ-F | AACTGGCGGCGGTGAATA |
| wblAJ-R | ACGGACGGAGCACATATAGG |
| CwblA-F | GGATCCGCCTGAACGGACGGAGCACATA |
| CwblA-R | TCTAGAAGCACACTGACACCGAGGAACTTGGC |
| Primers for qRT-PCR | |
| RTsanG-F | GGCGTACACAGCTCAAGAGC |
| RTsanG-R | AATTCGTCGATGAGCTGATC |
| RTsanN-F | AGATCATGCGCTCGGACTGT |
| RTsanN-R | TGGCGTGCAGGATCGGTA |
| RTsanO-F | ACTGCGATCCGTGGTCAA |
| RTsanO-R | TGTACTCCAGGCACTCCC |
| RTsanF-F | CGGCGCTGGAGGAACGTAC |
| RTsanF-R | GGGTGTAGAGGCCGATGCT |
| RThrdB-F | GCTGGCCAAGGAACTCGACAT |
| RThrdB-R | CGAAGCGCATGGAGACGACG |
| Time (weeks) | Chemical composition | ||||
| Ash | Crude protein | Cellulose | Hemicellulose | Lignin | |
| 0 | 54.0 d | 32.8 d | 470.6 c | 299.4 a | 79.1 ab |
| 1 | 56.1 cd | 34.3 cd | 470.7 c | 293.9 ab | 82.4 a |
| 2 | 58.4 c | 36.0 bc | 485.7 ab | 279.7 bc | 83.6 a |
| 3 | 61.2 b | 36.0 bc | 489.8 ab | 268.3 cd | 81.1 ab |
| 4 | 61.7 ab | 36.1 bc | 484.9 b | 262.2 d | 74.1 b |
| 5 | 62.3 ab | 38.4 ab | 494.5 ab | 240.7 e | 59.3 c |
| 6 | 63.8 a | 39.1 a | 488.9 ab | 235.2 ef | 57.1 cd |
| 7 | 63.7 a | 37.9 ab | 498.3 a | 220.2 fg | 49.2 de |
| 8 | 64.1 a | 38.9 a | 496.6 ab | 215.5 g | 48.6 e |
| RMSE | 0.89 | 0.95 | 4.40 | 5.71 | 2.79 |
| P | < 0.0001 | < 0.0001 | < 0.0001 | < 0.0001 | < 0.0001 |
| Gene Locus ID | Gene description | Normalized Fold (Log2) | ||
| P | HC | PHC | ||
| GSVIVT00016386001 | Vitis vinifera respiratory burst oxidase homolog protein E (VvRBOHE) | 0.30 ± 0.21 | 1.11 ± 0.18 | −1.22 ± 0.06 |
| GSVIVT00002525001 | Vitis vinifera respiratory burst oxidase homolog protein A (VvRBOHA) | −0.64 ± 0.06 | −1.53 ± 0.29 | −1.96 ± 0.16 |
| GSVIVT00031598001 | Vitis vinifera peroxidase 72 (VvPOD72) | 1.59 ± 0.77 | 2.09 ± 1.18 | 4.19 ± 0.18 |
| GSVIVT00031723001 | Vitis vinifera peroxidase 12 (VvPOD12) | −0.79 ± 0.05 | −0.74 ± 0.25 | −1.71 ± 0.13 |
| GSVIVT00020782001 | Vitis vinifera alpha-dioxygenase 1 (VvDOX1) | 1.83 ± 1.16 | 2.82 ± 0.55 | 0.13 ± 0.25 |
| GSVIVT00001920001 | Vitis vinifera glutathione peroxidase 2 (VvGPX2) | 0.34 ± 0.39 | 0.28 ± 0.45 | 1.10 ± 0.54 |
| GSVIVT00004080001 | Vitis vinifera catalase isozyme 1-like (VvCAT1) | −0.35 ± 0.17 | −1.52 ± 0.02 | −1.57 ± 0.15 |
| GSVIVT00036747001 | Vitis vinifera cytosolic ascorbate peroxidase (VvAPX3) | −0.47 ± 0.24 | −1.05 ± 0.09 | −1.75 ± 0.04 |
| GSVIVT00007083001 | Vitis vinifera superoxide dismutase [Fe] 3, chloroplastic (VvFSD3) | 0.40 ± 0.17 | 0.17 ± 0.10 | 1.82 ± 0.11 |
| GSVIVT00014163001 | Vitis vinifera superoxide dismutase [Fe], chloroplastic (VvFSD) | 0.50 ± 0.13 | 0.33 ± 0.22 | −1.60 ± 0.17 |
| GSVIVT00003173001 | Vitis vinifera alternative oxidase 2, mitochondrial (VvAOX2) | 0.44 ± 0.16 | 2.43 ± 0.37 | 1.07 ± 0.18 |
| GSVIVT00036443001 | Vitis vinifera hemoglobin-2 (VvHB2) | −0.52 ± 0.43 | 4.41 ± 0.34 | 3.08 ± 0.43 |
| Short Name | Designation after VDA 239-100 | Thickness in mm |
| DP600 | CR330Y590T-DP-GI50/50-U | 1.00 |
| DH600 | CR330Y590T-DH-GI50/50-U | 1.00 |
| DP800 | CR440Y780T-DP-GI50/50-U | 1.00 |
| DH800 | CR440Y780T-DH-GI50/50-U | 1.00 |
| CP800 | CR570Y780T-CP-GI50/50-U | 1.00 |
| DP1000 | CR660Y980T-DP-GI50/50-U1 | 1.00 |
| DH1000 | CR700Y980T-DH-GI50/50-U | 1.00 |
| CP1000 | CR780Y980T-CP-GI70/70-U | 1.00 |
| CH1000 | CR780Y980T-CH-EG53/53-U1 | 1.20 |
| DH1200 | CR850Y1180T-DH-EG53/53-U1 | 1.00 |
| CP1200 | CR900Y1180T-CP-EG53/53-U | 1.20 |
| CH1200 | CR900Y1180T-CH-UC-U1 | 1.00 |
| Background characteristics | Infants starting the intervention (N = 86) | Infants completing 3 weeks (N = 81) | ||
| Acupuncture group (n = 46) | Control group (n = 40) | Acupuncture group (n = 43) | Control group (n = 38) | |
| Firstborn, n (%) | 22 (48) | 22 (55) | 21 (48) | 21 (55) |
| Gender, female, n (%) | 22 (48) | 19 (48) | 21 (50) | 19 (50) |
| Gestational age, weeks. Mean (SD) | 39.2 (1.5) | 39.5 (1.3) | 39.3 (1.4) | 39.5 (1.3) |
| Age when colic started, weeks. Mean (SD) | 1.9 (1.3) | 1.5 (1.0) | 2 (1.3) | 1.5 (1) |
| Age at inclusion, weeks. Mean (SD) | 5.0 (1.9) | 5.3 (1.7) | 5.1 (1.9) | 5.2 (1.6) |
| Solely breastfed, n (%) | 35 (76) | 26 (65) | 32 (74) | 25 (66) |
| Having a parent and/or sibling with food intolerance/allergy, n (%) | 17 (37) | 18 (45) | 15 (35) | 17 (45) |
| Having a parent and/or sibling who had had infantile colic, n (%) | 29 (63) | 23 (58) | 25 (58) | 20 (53) |
| Have tried simeticone, n (%) | 43 (93) | 37 (92) | 40 (93) | 35 (92) |
| With no effect, n (%) | 28 (61) | 25 (63) | 26 (60) | 23 (61) |
| With uncertain effect, n (%) | 15 (33) | 12 (30) | 14 (33) | 12 (32) |
| Have tried lactobacillus reuteri, Semper Magdroppar ®, n (%) | 6 (13) | 7 (18) | 6 (14) | 6 (16) |
| With no effect, n (%) | 4 (9) | 7 (18) | 4 (9) | 6 (16) |
| With uncertain effect, n (%) | 2 (4) | 0 (0) | 2 (5) | 0 (0) |
| Have tried a diet free from cow'rotein without effect, n (%) | 33 (72) | 32 (80) | 31 (72) | 30 (79) |
| Changed to this diet during the intervention weeks, n (%) | 1 (2) | 1 (3) | 1 (2) | 1 (3) |
| Not ensured if this diet is tried, n (%) | 12 (26) | 7 (18) | 11 (26) | 7 (18) |
| Received antibiotics, either through mother's medication or by own intake, n (%) | 14 (30) | 10 (25) | 12 (28) | 9 (24) |
| 1995 | 2001 | Change % | |
| Admitted patients/doctor/year | 101 | 87 | -13.9 |
| Admitted patients/nurse/year | 24 | 22 | -8.3 |
| Admitted patients/office staff/year | 106 | 83 | -21.7 |
| In-hospital patients at all hours | 813 | 793 | -2.5 |
| In-hospital patients at all hours/doctor | 2,2 | 1,6 | -28.3 |
| In-hospital patients at all hours/nurse | 0.5 | 0,39 | -20.0 |
| In-hospital patients at all hours/office staff | 2,3 | 1.5 | -34.8 |
| Deliveries/midwife/year | 57 | 44 | -22.8 |
| Out-patients consultations/doctor/year | 629 | 530 | -15.7 |
| Out-patients consultations/nurse/year | 147 | 134 | -8.8 |
| Out-patients consultations/office staff/year | 656 | 503 | -23.3 |
| Surgical procedures/doctor/year – total* | 160 | 128 | -20.0 |
| General surgery | 151 | 134 | -11.4 |
| Orthopedic surgery | 189 | 155 | -18.0 |
| Neurosurgery | 98 | 100 | +2.0 |
| Otorhinolaryngology | 177 | 125 | -29.4 |
| Ophthalmology | 135 | 152 | +12.6 |
| Gynecology | 109 | 71 | -34.9 |
| Anesthetized patients/anesthesiologist/year§ | 661 | 534 | -19.2 |
| Hours with anesthesia/anesthesiologist/year | 1 322 | 1 148 | -13.2 |
| Imaging procedures/radiologist/year | 7 003 | 5 198 | -25.8 |
| Imaging procedures/radiology technician/year | 2 436 | 2 077 | -14.7 |
| Lab test and procedures/technologist/year# | 15 981 | 15 256 | -4.5 |
| Drug | UDS proportion (95% CI)* | CASI | ||
| Past 7 days | Past 6 months | Lifetime | ||
| Any drugs | 53.5 (47.0-60.0) | 42.0‡ | 59.3 | 92.4 |
| Marijuana | 36.0 (29.7-42.3) | 28.6‡ | 44.1 | 85.0 |
| Cocaine | 25.8 (20.1-31.5) | 18.9‡ | 29.5 | 66.8 |
| Opiates | 7.6 (4.1-10.1) | 7.5 | 18.5 | 43.8 |
| Meth/amphetamine | 2.2 (0.3-4.1) | 1.8 | 6.2 | 25.2 |
| Injection | N/A | 0.4 | 1.8 | 23.7 |
| Outcome | P value |
| Arthralgia | 0.390 |
| Bone pain | 0.608 |
| Back pain | 0.744 |
| Pain in extremity | 0.056 |
| Myalgia | 0.794 |
| LS BMD 12 months (normal at baseline-ZOL trials) | 0.0003 |
| LS BMD 12 months (osteopenic at baseline-ZOL trials) | 0.296 |
| LS BMD 12 months (residronate and ibandronate trials) | 0.345 |
| Categories | First-line treatment (XELOX plus bevacizumab) | Second-line treatment (FOLFIRI) | Clinical Support | Death | ||||
| R$ | % | R$ | % | R$ | % | R$ | % | |
| Medications | 27,592.00 | 89.57 | 4327.80 | 33.33 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preparation (Pharmacy) | 120.08 | 0.39 | 270.18 | 2.08 | 0.00 | 0.00 | 0.00 | 0.00 |
| Administration (Nursing) | 1006.40 | 3.27 | 6700.74 | 51.61 | 0.00 | 0.00 | 0.00 | 0.00 |
| Laboratory tests | 367.00 | 1.19 | 409.08 | 3.15 | 265.48 | 5.28 | 0.00 | 0.00 |
| Imaging tests | 1720.00 | 5.58 | 1276.20 | 9.83 | 0.00 | 0.00 | 0.00 | 0.00 |
| Hospitalization | 0.00 | 0.00 | 0.00 | 0.00 | 4767.03 | 94.72 | 0.00 | 0.00 |
| Total | 30,805.48 | 100.00 | 12,984.00 | 100.00 | 5032.51 | 100.00 | 0.00 | 0.00 |
| Genotypes | Normotensives | Hypertensive free from current antihypertensive medication | Current use of antihypertensive medication | ||||||
| N | SBP(mm Hg) | DBP(mm Hg) | N | SBP(mm Hg) | DBP(mm Hg) | N | SBP(mm Hg) | DBP(mm Hg) | |
| G482S genotypes | |||||||||
| G482G | 250 | 119.7(0.6) | 77.7(0.4) | 86 | 150.7(1.4) | 90.2(0.9) | 155 | 151.2(1.9) | 89.0(1.0) |
| G482S | 428 | 120.1(0.5) | 77.2(0.3) | 155 | 149.6(1.1) | 90.8(0.7) | 209 | 152.6(1.6) | 88.4(0.8) |
| S482S | 169 | 121.3(0.7) | 78.2(0.5) | 61 | 148.6(1.8) | 90.6(1.2) | 86 | 144.8(2.5) | 87.0(1.3) |
| p values | 0.207 | 0.286 | 0.647 | 0.897 | 0.023 | 0.426 | |||
| +2962A/G genotypes | |||||||||
| +2962A/A | 429 | 120.5(0.5) | 77.6(0.3) | 179 | 149.6(1.1) | 90.9(0.7) | 232 | 149.2(1.5) | 87.4(0.8) |
| +2962A/G | 336 | 120.1(0.5) | 77.6(0.4) | 127 | 150.2(1.3) | 90.0(0.8) | 178 | 151.0(1.8) | 89.4(0.9) |
| +2962G/G | 82 | 119.4(1.1) | 77.2(0.7) | 39 | 149.6(2.3) | 91.0(1.5) | 40 | 159.9(3.6) | 89.4(1.9) |
| p values | 0.580 | 0.899 | 0.930 | 0.667 | 0.020 | 0.181 |
| Gene | SNPa | AA changeb | Protein domainc | dbSNP ID |
| TLR2 | 42 C > T | Silent 14 | -d | rs1388116474:C > T |
| 53 C > T | M18T | - | rs1388116475:C > T | |
| 108 C > T | Silent 36 | LRR 8 | rs1388116476:C > T | |
| 153 G > A | Silent 51 | LRR_RI | rs1388116477:G > A | |
| 156 C > T | Silent 52 | LRR_RI | rs1388116478:C > T | |
| 374 T > C | A125V | LRR 8 | rs1388116479:T > C | |
| 381 A > G | Silent 127 | LRR 8 | rs1388116480:A > G | |
| 482/483 GC > CT | S161T | LRR 8 | rs1388116481:GC > CT | |
| 519 G > C | Silent 173 | LRR_RI | rs1388116482:G > C | |
| 1034 A > G | S345N | - | rs1388116483:A > G | |
| 1375 T > C | Silent 459 | LRR4 | rs1388116484:T > C | |
| 1407 C > T | Silent 469 | LRR4 | rs1388116485:C > T | |
| 1650 G > A | Silent 550 | LRR_CT | rs1388116486:G > A | |
| 1678 A > G | A560T | LRR_CT | rs1388116487:A > G | |
| 1707 C > Te | Silent 569 | LRR_CT | rs1388116488:C > T | |
| 1731 C > T | Silent 577 | LRR_CT | rs1388116489:C > T | |
| 1740 C > T | Silent 580 | LRR_CT | rs1388116490:C > T | |
| 2064 T > C | Silent 688 | TIR | rs1388116491:T > C | |
| TLR4 | 572 A > Cf | Y191S | LRR8 | rs1388116492:A > CG |
| 572 A > Gf | silent | LRR8 | rs1388116492:A > CG | |
| 574 C > T | Q192W | LRR8 | rs1388116493:C > T | |
| 575 A > G | Q192W | LRR8 | rs1388116494:A > G | |
| 576 T > G | Silent192 | LRR8 | rs1388116495:T > G | |
| 577 G > A | E193K | LRR8 | rs1388116496:G > A | |
| 579 A > G | Silent193 | LRR8 | rs1388116497:A > G | |
| 647 G > A | Silent216 | LRR_RI | rs1388116498:G > A | |
| 662 G > A | Silent221 | - | rs1388116499:G > A | |
| 672 A > C | Silent224 | - | rs1388116500:A > C | |
| TLR9 | 2340 C > T | Silent780 | - | rs1388116501:C > T |
| 2475 A > G | Silent825 | - | rs1388116502:A > G |
| Age group | HIV-positive children n = 123 | HIV-uninfected children n = 192 | Total | ||
| Months | Male | Female | Male | Female | |
| 0–5.9 | 1 | 2 | 4 | 4 | 11 |
| 6–11.9 | 15 | 8 | 21 | 14 | 58 |
| 12–23.9 | 36 | 21 | 66 | 37 | 160 |
| 24–35.9 | 17 | 8 | 19 | 6 | 50 |
| 36–47.9 | 4 | 4 | 6 | 6 | 20 |
| 48–59.9 | 2 | 5 | 5 | 4 | 16 |
| Total | 75 | 48 | 121 | 71 | 315 |
| Factor | Cronbach's alpha | Number of items |
| Privacy | .756 | 3 |
| Culture | .926 | 3 |
| Attitude toward telemedicine | .755 | 3 |
| Benefit | .729 | 5 |
| Connectivity | .794 | 3 |
| IT capability | .706 | 3 |
| Compatibility | .763 | 3 |
| Data warehouse | .749 | 3 |
| Technical support | .787 | 3 |
| Top management support | .706 | 3 |
| Cost | .728 | 4 |
| Policy | .815 | 3 |
| Upper-level leadership | .818 | 3 |
| Variables/Group | Control (n = 15) | TKD (n = 15) | Time × Group Interaction | |||
| Baseline | 16-Week | Baseline | 16-Week | F | p | |
| Word test (score) | 44.67 ± 10.89 | 45.33 ± 9.06 | 45.87 ± 8.62 | 47.60 ± 7.73 | 1.029 | 0.319 |
| CV | 0.24 | 0.20 | 0.19 | 0.16 | ||
| Color test (score) | 44.73 ± 8.73 | 45.27 ± 8.18 | 46.20 ± 7.40 | 47.87 ± 6.44 | 2.429 | 0.130 |
| CV | 0.20 | 0.18 | 0.16 | 0.13 | ||
| Color-Word test (score) | 49.07 ± 7.84 | 48.87 ± 8.07 | 50.33 ± 6.63 | 52.40 ± 6.23 # | 13.952 | 0.001 ** |
| CV | 0.16 | 0.17 | 0.13 | 0.12 |
| Patients (n = 38) | Controls (n = 23) | |
| Median age (range) years | 37 (18 to 50) | 36 (24 to 49) |
| Sex distribution | 26 F/12 M | 15 F/7 M |
| CIS/MS at 12 months | 19/19 | — |
| Median lesion volume (range) mL | 0.54 (0 to 38.1) | — |
| Median number of new lesions | 1 (0 to 4) | — |
| Median OR lesion volume (range) mL | 0.06 (0 to 21.3) | — |
| Construct | Measure | Administration |
| Primary Outcome measure | ||
| Symptom Severity | Irritable Bowel Symptom Severity Scale | Pre, 2 wk, 3 mo, 6 mo, 12 mo post |
| Secondary Outcome measures | ||
| Symptom frequency | Daily Symptom Diary | Daily during the intervention and for 2 weeks post |
| IBS-related anxiety | Visceral Sensitivity Index | Pre, 2 wk, 3 mo, 6 mo, 12 mo post |
| Economic impact of IBS | The Work Productivity and Activity Impairment for IBS (WPAI: IBS) | Pre, 2 wk, 3 mo, 6 mo, 12 mo post |
| Co-Morbid Symptoms | Recent Physical Symptoms Questionnaire (RPSQ) | Pre, 2 wk, 3 mo, 6 mo, 12 mo post |
| General psychological distress | Brief Symptom Inventory (BSI) | Pre, 2 wk, 3 mo, 6 mo, 12 mo post |
| Anger and its expression | The State-trait Anger Expression Inventory (STAXI) | Pre, 2 wk, 3 mo, 6 mo, 12 mo post |
| Maladaptive coping methods | Coping Strategies Questionnaire (CSQ) | Pre, 2 wk, 3 mo, 6 mo, 12 mo post |
| Quality of life specific to IBS | IBS-QOL | Pre, 2 wk, 3 mo, 6 mo, 12 mo post |
| Effect modification measures | ||
| Expectancy of success of intervention | Borkovec and Nau credibility scales | Prior to second session |
| Catalogue of distressing prior events | Family Inventory of Life Events (FILE) | Pre intervention only |
| Demographics | Age, race, education, marital status, income | Pre intervention only |
| Process measures | ||
| Measure of mindfulness: Multiple constructs | Five Facet Mindfulness Questionnaire (FFMQ) | Pre, 2 wk, 6 mo, 12 mo post |
| Measure of mindfulness: Acceptance construct | Toronto Mindfulness Scale | Pre, 2 wk, 6 mo, 12 mo post |
| Organizations | Carbohydrates | Fiber | Protein | Fat |
| American Diabetes Association (ADA) | 50–60% | Not specified | 10–15% | 30–35% |
| The British Diabetic Association/Diabetes UK | 45–60% | <30 g/day | 30–35% | <35% |
| European Association for the Study of Diabetes (EASD) | 45–60% | Increase fiber with low-GI food | 10–20% | 35% |
| The Canadian Diabetes Association (CDA) | 50–60% | 25–35 g/day | 11% | 30% |
| Japan | 60% | 1 fruit + 400 g vegetables | 15–20% | 20–25% |
| South Africa | 50–60% | 40 g/day | 12–30% | ≤30% |
| India | >65% | 40 g/day | 12–20% | <21% |
| Mediterranean diet | 40–42% | ~23 g/day | ~16% | 40–42% |
| Gene | Reagent Sequences |
| MIP-1α | F; AGCTGACACCCCGACTGC |
| R; GTCAACGATGAATTGGCGTG | |
| P; TGCTGCTTCTCCTACAGCCGGAAGAT | |
| MIP-1β | F; AGCTCTGCGTGTCTGCCC T |
| R; GCTGAGAACCCTAGAGCACA | |
| P; TCTCCT CTTGCTCGTGGCTGCCTT | |
| TNFα | F; TCCAGGCGGTGCCTATGT |
| R; GAGCGTGGTGGCCCC | |
| P; TCAGCCTCTTCTCATTCCTGCTTGTGG | |
| iNOS | F; TGATGTCCGAAGCAAACATCA |
| R; TGTGGCTCCCATGTTGCAT | |
| P; TTCAGATCCCGAAACGCTTCACTTCC | |
| IL-1β | F; TTGGGCCTCAAAGGAAAGAAT |
| R; TCTCCAGCTGCAGGGTGG | |
| P; TATACCTGTCCTGTGTAATGAAAGACGGCA CA | |
| IκBα | F; CGGAGGACGGAGGACTCGTT |
| R; ACTTCCATGGTCAGCGGCT | |
| P; TGCACTTGGCAATCATCCACGAAGA | |
| FasL | F; TACCACCGCCATCACAACC |
| R; TTTGTGTTGTGGTCCTTCTTCTTTAG | |
| P; CTCCCACTGCCGCCACTGACC | |
| GFAP | F; GGAGCTCAATGACCGCTTTG |
| R; AGCGCCTTGTTTTGCTGCTC | |
| P; CAGCTACATCGAGAAGGTTCG | |
| RANTES | F; TCTTGCAGTCGTGTTTGTCAC |
| R; TCTTGAACCCACTTCTTCTCT | |
| P; AGGAACCGCCAAGTGTGTGC | |
| CCR5 | F; GGAATGACACACTGCTGCCTAA |
| R; GAACACTGAGAGATAACTCCGGAAC | |
| P; CCCTGTCATCTATGCCTTTGTTGGAGAGA |
| Sexual behaviors | Number (%) |
| Diagnosed with an STI in the past 6 months | 16 (10.8) |
| Sought treatment for most recent STI symptom (n = 16) | 2 (11.1) |
| Facility where the most recent STI was treated | |
| Public health center/hospital (n = 2) | 1 (50.0) |
| Non-governmental clinic/hospital (n = 2) | 1 (50.0) |
| Had sexual intercourse in the past 3 months | 59 (41.3) |
| Used condom in last sexual intercourse (n = 59) | 21 (35.6) |
| Had sexual intercourse when intoxicated (n = 59) | 22 (37.3) |
| up to 30 | from 31 to 60 | over 61 | Male | Female | |||||||||||
| % | 95% C.I. | % | 95% C.I. | % | 95% C.I. | % | 95% C.I. | % | 95% C.I. | ||||||
| Inadequate directions | 0.51 | 0.00 | 1.21 | 4.09 | 3.62 | 4.55 | 3.18 | 2.57 | 3.79 | 1.98 | 0.61 | 0.94 | 4.36 | 3.96 | 4.75 |
| Inadequate cooperation of personnel working in the Institute | 2.79 | 1.14 | 4.44 | 0.73 | 0.53 | 0.93 | 2.45 | 1.91 | 2.98 | 1.01 | 0.82 | 1.19 | 1.46 | 1.23 | 1.69 |
| Inadequate treatment received by Doctors of the Institute | 0.76 | 0.00 | 1.62 | 0.55 | 0.38 | 0.72 | 2.90 | 2.32 | 3.49 | 0.78 | 0.61 | 0.94 | 1.31 | 1.10 | 1.53 |
| Short waiting time for the medical consultation after scheduling an appointment | 1.78 | 0.46 | 3.09 | 2.04 | 1.71 | 2.37 | 2.17 | 1.67 | 2.68 | 1.38 | 1.16 | 1.60 | 2.44 | 2.15 | 2.74 |
| Inadequate general service provided by this Institute | 3.05 | 1.32 | 4.77 | 0.72 | 0.52 | 0.91 | 5.75 | 4.93 | 6.57 | 0.78 | 0.61 | 0.94 | 3.02 | 2.69 | 3.34 |
| Variable | Preview | No-Preview | ||
| IB | No-IB | IB | No-IB | |
| Fixation distance (in pixels) from moving coin on experimental trial | 334 (122) | 296 (123) | 398 (122) | 390 (125) |
| Fixation distance (in pixels) from moving coin on free-viewing trial | 339 (224) | 202 (137) | 380 (156) | 307 (143) |
| PROBABILITY OF FIXATION DURING CRITICAL PERIOD | ||||
| Starting napkin | 0.06 (0.14) | 0.03 (0.11) | 0.03 (0.12) | 0.00 (0.00) |
| End napkin | 0.00 (0.00) | 0.07 (0.17) | 0.00 (0.00) | 0.02 (0.06) |
| Space between napkins | 0.06 (0.14) | 0.22 (0.35) | 0.00 (0.00) | 0.13 (0.23) |
| Cup | 0.64 (0.73) | 0.36 (0.38) | 0.62 (0.32) | 0.35 (0.33) |
| Face | 0.00 (0.00) | 0.11 (0.26) | 0.19 (0.27) | 0.19 (0.29) |
| PROBABILITY OF FIXATION DURING FREE-VIEWING TRIAL | ||||
| Starting napkin | 0.33 (0.29) | 0.06 (0.17) | 0.04 (0.10) | 0.04 (0.13) |
| End napkin | 0.17 (0.29) | 0.16 (0.23) | 0.00 (0.00) | 0.06 (0.16) |
| Space between napkins | 0.17 (0.29) | 0.37 (0.37) | 0.08 (0.13) | 0.18 (0.28) |
| Cup | 0.17 (0.29) | 0.16 (0.29) | 0.28 (0.31) | 0.35 (0.42) |
| Face | 0.17 (0.29) | 0.05 (0.13) | 0.26 (0.25) | 0.07 (0.18) |
| TIME TO FIXATE AFTER CRITICAL PERIOD (msec) | ||||
| Starting napkin | 1210 (1783) | 2046 (1904) | 1186 (1782) | 1595 (1978) |
| End napkin | 4539 (1182) | 2591 (2807) | 3426 (1445) | 996 (1532) |
| Space between napkins | 317 (242) | 1180 (1405) | 7687 (7148) | 773 (765) |
| Face | 2382 (3363) | 3454 (2000) | 892 (1509) | 3004 (3083) |
| Condition | Stimulus type | n | Before RF (ms) | After RF (ms) | t | P |
| Genuine EMF | Rarefaction | 13 | 1.67 ± 0.14 | 1.66 ± 0.15 | 0.34 | 0.737 |
| Condensation | 13 | 1.69 ± 0.18 | 1.65 ± 0.19 | 1.18 | 0.260 | |
| Alternating | 13 | 1.79 ± 0.09 | 1.78 ± 0.12 | 1.06 | 0.310 | |
| Sham EMF | Rarefaction | 15 | 1.61 ± 0.21 | 1.63 ± 0.19 | -0.50 | 0.624 |
| Condensation | 14 | 1.66 ± 0.09 | 1.68 ± 0.14 | -0.24 | 0.807 | |
| Alternating | 14 | 1.74 ± 0.10 | 1.76 ± 0.11 | -1.23 | 0.239 |
| Size Factor | Iterations | Nodes | Elements | Max. Elem. Vol. (mm3) |
| Initial | -- | 2396 | 7574 | 0.08 |
| 1.15 | 17 | 1332 | 3904 | 0.51 |
| 1.25 | 21 | 777 | 2200 | 1.49 |
| 1.35 | 20 | 612 | 1615 | 2.97 |
| Characteristics | Number (%) |
| Age range (year) | 6–88 |
| Mean age (year) (SD) | 42.5 ± 17.53 |
| Length of stay (day) range | 0–15 |
| Mean length of stay (day) (SD) | 8.3 ± 5.3 |
| Length of stay (day) | |
| ≤1 week | 67 (57.7) |
| More than one week | 21 (18.1) |
| Sex | |
| Male | 63 (54.4) |
| Female | 53 (45.6) |
| Hospitalization | |
| Yes | 87 (75) |
| No | 29 (25) |
| Nosocomial infection | |
| Yes | 22 (18.9) |
| No | 94 (81.1) |
| MRSA | 49 (42.2) |
| MSSA | 67 (57.7) |
| PVL gene positive | 25 (18.3) |
| MRSA carry PVL gene | 14 (28.5) |
| MSSA carry PVL gene | 11 (16.4) |
| Parameter | Unit | Soil sample | |||||
| WD1 | WD2 | WD3 | ZR1 | ZR2 | ZR3 | ||
| Particle size | SL | SL | SL | SL | SL | SL | |
| pH | 8.4 | 8.3 | 8.4 | 8.3 | 8.6 | 8.2 | |
| EC | dS m−1 | 2.1 | 3.2 | 2.2 | 3.7 | 3.0 | 2.2 |
| CEC | cmol kg−1 | 19.4 | 20.7 | 21.1 | 22.3 | 17.2 | 20.3 |
| ESP | % | 8.9 | 9.2 | 2.6 | 9.9 | 1.8 | 3.9 |
| OM | % | 2.0 | 1.1 | 2.1 | 1.6 | 1.0 | 2.1 |
| CaCO3 | % | 33.1 | 32.5 | 36.1 | 40.6 | 61.6 | 22.3 |
| Fe | % | 0.56 | 0.63 | 0.58 | 0.51 | 0.51 | 0.53 |
| Ca | mg kg−1 | 2759.1 | 2891.1 | 5508.8 | 3549.0 | 2421.3 | 5051.4 |
| Mg | mg kg−1 | 552.6 | 594.3 | 178.8 | 737.1 | 175.5 | 475.2 |
| Na | mg kg−1 | 398.0 | 439.7 | 125.6 | 509.2 | 70.0 | 181.2 |
| K | mg kg−1 | 42.3 | 49.9 | 29.4 | 26.9 | 36.8 | 31.9 |
| Fe | mg kg−1 | 3.6 | 3.6 | 3.5 | 3.7 | 3.9 | 3.5 |
| NH4+ | mg kg−1 | 18.7 | 37.0 | 18.6 | 14.8 | 31.6 | 43.0 |
| NO3− | mg kg−1 | 35.0 | 37.0 | 43.5 | 87.2 | 39.6 | 94.8 |
| HIV Knowledge and Prevention Practices | Men | Women | Test for difference by sexc | ||||
| n = 755 | n = 1369 | ||||||
| Yes | No | Don’t know/not sure | Yes | No | Don’t know/not sure | ||
| Have you heard of HIV or AIDS? | 739 (97.9) | 16 (2.1) | 1361 (99.4) | 8 (0.6) | 0.003 | ||
| Ways of transmitting HIV/AIDSa | |||||||
| Can be transmitted by sex with someone who looks healthy | 628 (83.3) | 63 (8.4) | 63 (8.4) | 1084 (79.2) | 122 (8.9) | 162 (11.8) | 0.03 |
| Can’t be transmitted by mosquito or other insect bites | 480 (63.8) | 173 (23.0) | 100 (13.3) | 638 (46.6) | 435 (31.8) | 295 (21.6) | <0.001 |
| Can’t be transmitted by bewitchment/curses or supernatural means | 652 (86.6) | 34 (4.5) | 67 (8.9) | 1159 (84.9) | 56 (4.1) | 151 (11.1) | 0.28 |
| Can’t be transmitted by sharing food with HIV infected person | 656 (87.1) | 36 (4.8) | 61 (8.1) | 1141 (83.4) | 82 (6.0) | 145 (10.6) | 0.03 |
| Can be transmitted by having sex without condom | 726 (96.6) | 4 (0.5) | 21 (2.8) | 1338 (98.0) | 11 (0.8) | 17 (1.2) | 0.08 |
| Knowledge about PMTCTa | |||||||
| HIV can be transmitted to child during pregnancy | 330 (43.7) | 298 (39.5) | 127 (16.8) | 544 (39.7) | 537 (39.2) | 288 (21.0) | 0.08 |
| HIV can be transmitted to child during delivery | 670 (88.7) | 22 (2.9) | 63 (8.3) | 1265 (92.4) | 34 (2.5) | 70 (5.1) | 0.005 |
| HIV can be transmitted to child during breastfeeding | 653 (86.5) | 23 (3.1) | 79 (10.5) | 1248 (91.2) | 30 (2.2) | 91 (6.7) | 0.001 |
| Do you practise any HIV prevention methods?b | 723 (97.8) | 16 (2.1) | 1347 (99.0) | 14 (1.0) | 0.04 | ||
| HIV prevention practices usedb | |||||||
| Abstinence | 260 (35.2) | 477 (64.6) | 1 (0.1) | 478 (35.2) | 880 (64.7) | 2 (0.2) | 0.99 |
| Faithfulness | 510 (69.0) | 226 (30.6) | 3 (0.4) | 1044 (76.7) | 316 (23.2) | 1 (0.1) | <0.001 |
| Condom use | 368 (49.8) | 371 (50.2) | 0 (0.0) | 262 (19.3) | 1097 (80.7) | 1 (0.1) | <0.001 |
| Circumcision | 21 (2.9) | 685 (92.8) | 32 (4.3) | 5 (0.4) | 1073 (78.8) | 283 (20.8) | <0.001 |
| Others | 123 (18.5) | 451 (67.9) | 90 (13.6) | 180 (14.3) | 828 (66.8) | 231 (18.6) | 0.02 |
| Doctors | Organisations/ Designated body | GMC |
| Licensed doctors who are not trainees must:- Have a connection to one organisation (known as a designated body).- Take part in regular appraisal- Collect supporting information for appraisal: 6 types • CPD (annually) • significant events (annually) • review of complaints and complements (as occur) • quality improvement activity • feedback from colleagues • feedback from patients- Reflect on supporting informationAll trainees must:- Have a connection to either a Local Education Training Board or Deanery- Supporting information and discussion of progress and learning needs as generated for curriculum and training programme. | Organisations are required by the GMC to provide:- a RO new role, responsible for the revalidation recommendation)- an up to date appraisal system and ensure every licensed doctor has a regular appraisal- a sufficient number of trained appraisers- clinical governance systems that can provide supporting information- policies and systems for identifying and responding to concerns about doctors- link with other organisations where doctors work, so information about their practice can be sharedRO makes one of three possible revalidation recommendation to the GMC:- Revalidation- Deferral (request for GMC to provide more time for revalidation decision). Does not affect licence to practise.- Non-engagement (can lose licence) | As the regulator the GMC is responsible for:- setting guidelines- Making the final revalidation decision based on RO’s recommendation (to revalidate; how much time to provide for deferral and whether to refer to a Fitness to Practise Panel)- Provide an Employer Liaison Service to help responsible officers with revalidation and the management of concerns about doctors |
| Small-for-gestational age group (n = 10) | Appropriate-for-gestational age group (n = 7) | |
| Age at delivery (years) | 27.3 ± 5.2 | 26.4 ± 6.5 |
| Gestational age at delivery (weeks) | 38.4 ± 1.0 | 39.7 ± 0.7 |
| Birth weight (grams) | 2159 ± 506 | 3156 ± 301* |
| TGF-β1 levels at 34 weeks (ng/mL) | 32.5 ± 3.2 | 39.2 ± 9.8* |
| TGF-β1 levels at 38 weeks (ng/mL) | 36.04 ± 4.3 | 36.7 ± 7.0 |
| Indicators | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 |
| Interviewed | 54,369 | 54,251 | 54,353 | 54,367 | 54,339 | 54,144 | 45,448 |
| Females (%) | 53.9 | 53.9 | 53.9 | 53.9 | 53.9 | 53.9 | 53.9 |
| Mean age (SD) | 40.1 (16.2) | 40.3 (16.2) | 40.5 (16.2) | 40.8 (16.1) | 40.9 (16.3) | 41.1 (16.3) | 41.3 (16.4) |
| 0-4 years of schooling (%) | 21.6 | 20.4 | 19.4 | 18.0 | 16.8 | 17.2 | 16.1 |
| Response rate (%) | 90.9 | 92.3 | 94.2 | 97.0 | 97.7 | 97.8 | 94.1 |
| Output variable | Predictive variables | R2 | B(Coef) | p | 95%CI | HL* |
| Cardiovascular risk (PDAY) | Sex | 0.271 | 0.090 | < 0.01 | 0.044-0.183 | 0,939 |
| Waist circumference | 0.043 | < 0.01 | 0.014-0.136 |
| NH4NO3 (g/L) | Residual sugar (g/L) | Cell biomass (g/L) | PMA (g/L) | Productivity (g/L h) | Yield (YP/X, g/g) | Yield (YP/S, g/g) |
| 0.1 | 56.67 ± 0.50 | 6.23 ± 0.71 | 6.17 ± 0.29 | 0.06 ± 0.003 | 1.00 ± 0.137 | 0.18 ± 0.011 |
| 0.5 | 40.77 ± 0.12 | 13.09 ± 1.09 | 10.86 ± 1.91 | 0.09 ± 0.042 | 0.85 ± 0.246 | 0.25 ± 0.081 |
| 1.0 | 24.57 ± 0.31 | 17.17 ± 0.77 | 14.01 ± 0.04 | 0.15 ± 0.000 | 0.82 ± 0.037 | 0.21 ± 0.000 |
| 2.0 | 16.95 ± 1.91 | 21.31 ± 3.81 | 20.02 ± 2.81 | 0.21 ± 0.029 | 0.96 ± 0.242 | 0.24 ± 0.032 |
| 4.0 | 16.70 ± 0.35 | 23.55 ± 0.85 | 17.31 ± 0.24 | 0.18 ± 0.003 | 0.74 ± 0.024 | 0.24 ± 0.002 |
| 10.0 | 14.52 ± 0.58 | 24.20 ± 1.96 | 16.57 ± 0.90 | 0.17 ± 0.009 | 0.69 ± 0.081 | 0.22 ± 0.013 |
| Score cutoff | Sensitivity | Specificity | PPV b | NPV b | LR+ | LR- |
| ≧1 | 0.96 | 0.13 | 0.37 | 0.86 | 1.10 | 0.31 |
| ≧2 | 0.96 | 0.18 | 0.38 | 0.89 | 1.16 | 0.23 |
| ≧3 | 0.75 | 0.69 | 0.56 | 0.84 | 2.41 | 0.36 |
| ≧4 | 0.63 | 0.78 | 0.60 | 0.80 | 2.81 | 0.48 |
| 5 | 0.21 | 1.00 | 1.00 | 0.70 | a | 0.79 |
| Before 14 days | At/later 14 days | p-value | |
| N | 150 | 26 | |
| Mean age, years (SD) | 51.8 (12.7) | 52.6 (15.5) | NS |
| First transplantation | 138/150 (92.0%) | 24/26 (92.3%) | NS |
| Mode of dialysis, hemodialysis | 95 (22.9%) | 19 (73.1%) | NS |
| Mean time on dialysis, days (SD) | 842 (614.1) | 899 (410.2) | NS |
| Donor age, years (SD) | 51.0 (14.3) | 56.3 (SD 10.9) | NS |
| CIT, hours (SD) | 21.7 (3.7) | 23.2 (3.4) | NS |
| ECD donor status | 53 (35.3%) | 16 (61.5%) | 0.008 |
| Day 1 creatinine, μmol/L (SD) | 508 (219.4) | 676 (224.6) | 0.002 |
| Day 1 urine output, mL (SD) | 1983 (1594.0) | 392 (446.6) | <0.0001 |
| 1-year graft survival | 148 (98.7%) | 19/26 (73.1%) | <0.0001 |
| 1-year patient survival | 149 (99.3%) | 25 (96.2%) | NS |
| Without CKDa | With CKD | |||||
| Variables | BMI 18.5-24.9 (N = 1398) | BMI 25–29.9 (N = 2314) | BMI ≥ 30 (N = 1548) | BMI 18.5-24.9 (N = 379) | BMI 25–29.9 (N = 418) | BMI ≥ 30 (N = 152) |
| No. of person-years | 12329 | 17274 | 9936 | 2094 | 4748 | 3834 |
| No. of incidence CVD | 64 | 135 | 82 | 30 | 78 | 50 |
| Incidence rate | 52 | 78 | 82 | 143 | 164 | 130 |
| (per 10,000 person-years) | ||||||
| Unadjusted HRs | 1 | 1.52 (1.13-2.06)* | 1.60 (1.15-2.23)* | 2.94 (1.90-4.55)* | 3.36 (2.41-4.67)* | 2.64 (1.82-3.83)* |
| Adjusted HRs | ||||||
| Model 1† | 1 | 1.65 (1.22-2.22)* | 2.03 (1.45-2.83)* | 1.45(0.92-2.27) | 2.02 (1.42-2.85)* | 2.11 (1.42-3.12)* |
| Model 2‡ | 1 | 1.24 (0.86-1.79) | 1.12 (0.62-1.99) | 1.41(0.90-2.22) | 1.43 (0.95-2.15) | 1.08 (0.59-1.99) |
| Skin Prick | sIgE | APT | History | |||||
| A | B | A | B | A | B | A | B | |
| D. pteronyssinus | 59 | 56 | 56 | 56 | 34 | 39 | 52 | 34 |
| Cat dander | 54 | 44 | 49 | 46 | 12 | 10 | 23 | 30 |
| Grass pollen | 65 | 57 | 75 | 59 | 18 | 15 | 33 | 31 |
| Birch pollen | 65 | 49 | 65 | 53 | 11 | 17 | 13 | 20 |
| ZA group (n = 27) | Control group (n = 27) | |
| Age (years), mean (SD) | 60.1 (11.7) | 59.4 (13.3) |
| Sex, female:male | 15:12 | 14:13 |
| BMI (kg/m2), mean (SD) | 26 (4) | 25 (5) |
| Operation time (minutes), mean (SD)a | 118 (27) | 103 (17) |
| Blood loss (mL), mean (SD) | 502 (312) | 387 (162) |
| Diagnosis (OA/AVN) | 16/11 | 17/10 |
| S. No | Water soluble | Exchangeable | Carbonate & sulfide | Reducible fraction | Oxidisable fraction | Residual fraction | Total Cr |
| 1a | 51.85 ± 0.34 | 29.62 ± 0.20 | 17.28 ± 0.30 | 98.76 ± 0.92 | 55.55 ± 0.32 | 64.81 ± 0.67 | 317.9 ± 2.1 |
| 1b | 83.29 ± 0.61 | 36.74 ± 0.60 | 14.69 ± 0.40 | 102.8 ± 1.20 | 52.05 ± 0.43 | 42.87 ± 0.41 | 332.5 ± 2.8 |
| 1c | 44.48 ± 0.21 | 23.47 ± 0.05 | 13.59 ± 0.06 | 98.86 ± 0.58 | 49.43 ± 0.17 | 24.70 ± 0.04 | 254.6 ± 1.9 |
| 2a | 80.29 ± 0.42 | 29.29 ± 0.15 | 13.38 ± 0.22 | 105.8 ± 0.73 | 42.57 ± 0.21 | 36.49 ± 0.35 | 307.8 ± 2.7 |
| 2b | 49.11 ± 0.33 | 36.83 ± 0.30 | 19.64 ± 0.33 | 115.4 ± 0.72 | 30.69 ± 0.41 | 39.90 ± 0.06 | 291.6 ± 0.9 |
| 2c | 81.04 ± 0.61 | 12.27 ± 0.60 | 18.41 ± 0.16 | 103.1 ± 0.80 | 36.83 ± 0.33 | 61.39 ± 0.61 | 313.1 ± 2.1 |
| 3a | 57.09 ± 0.23 | 35.98 ± 0.45 | 17.36 ± 0.23 | 107.9 ± 0.90 | 34.11 ± 0.31 | 68.23 ± 0.63 | 327.7 ± 1.7 |
| 3b | 34.58 ± 0.21 | 44.33 ± 0.21 | 16.00 ± 0.31 | 108.3 ± 0.32 | 36.94 ± 0.42 | 36.94 ± 0.32 | 277.1 ± 1.1 |
| 3c | 22.55 ± 0.09 | 45.11 ± 0.38 | 42.60 ± 0.62 | 112.7 ± 0.56 | 43.85 ± 0.26 | 25.06 ± 0.12 | 291.9 ± 0.7 |
| 4a | 38.58 ± 0.08 | 13.78 ± 0.30 | 16.50 ± 0.24 | 26.18 ± 0.32 | 44.78 ± 0.51 | 31.00 ± 0.05 | 170.9 ± 0.8 |
| 4b | 47.52 ± 0.11 | 32.51 ± 0.80 | 27.59 ± 0.14 | 12.50 ± 0.04 | 28.13 ± 0.44 | 56.29 ± 0.22 | 204.5 ± 1.3 |
| 4c | 33.46 ± 0.05 | 11.15 ± 0.10 | 26.77 ± 0.72 | 94.82 ± 0.71 | 25.93 ± 0.07 | 25.10 ± 0.80 | 217.3 ± 1.4 |
| 5a | 44.24 ± 0.53 | 34.41 ± 0.70 | 57.76 ± 0.43 | 110.7 ± 0.48 | 30.72 ± 0.62 | 18.43 ± 0.22 | 296.2 ± 1.5 |
| 5b | 32.08 ± 0.33 | 34.55 ± 0.32 | 25.91 ± 0.41 | 103.7 ± 0.83 | 49.35 ± 0.70 | 2.77 ± 0.01 | 240.3 ± 2.0 |
| 5c | 44.05 ± 0.42 | 31.81 ± 0.27 | 14.68 ± 0.32 | 99.11 ± 0.37 | 30.59 ± 0.17 | 48.94 ± 0.42 | 269.2 ± 0.7 |
| 6a | 37.34 ± 0.06 | 9.03 ± 0.20 | 25.20 ± 0.13 | 17.01 ± 0.03 | 42.00 ± 0.51 | 35.00 ± 0.04 | 218.9 ± 1.4 |
| 6b | 76.20 ± 0.23 | 29.49 ± 0.61 | 40.56 ± 0.73 | 307.2 ± 1.31 | 67.60 ± 0.48 | 30.70 ± 0.18 | 551.9 ± 2.3 |
| 6c | 116.7 ± 0.92 | 26.20 ± 0.39 | 17.86 ± 0.44 | 78.60 ± 0.43 | 29.71 ± 0.32 | 29.77 ± 0.27 | 298.9 ± 1.7 |
| 7a | 36.63 ± 0.07 | 29.37 ± 0.26 | 40.30 ± 0.72 | 102.5 ± 0.72 | 30.53 ± 0.05 | 39.69 ± 0.62 | 279.1 ± 1.5 |
| 7b | 32.40 ± 0.05 | 44.86 ± 0.32 | 29.91 ± 0.51 | 112.1 ± 0.61 | 37.38 ± 0.44 | 24.90 ± 0.20 | 281.6 ± 1.2 |
| 7c | 50.69 ± 0.61 | 34.61 ± 0.27 | 17.30 ± 0.04 | 92.72 ± 0.47 | 28.43 ± 0.37 | 40.18 ± 0.51 | 264.0 ± 1.7 |
| 8a | 62.98 ± 0.45 | 53.29 ± 0.42 | 25.43 ± 0.64 | 17.25 ± 0.04 | 33.30 ± 0.41 | 27.25 ± 0.31 | 272.3 ± 1.1 |
| 8b | 36.37 ± 0.34 | 12.12 ± 0.33 | 13.33 ± 0.06 | 12.12 ± 0.03 | 48.49 ± 0.60 | 16.62 ± 0.05 | 183.1 ± 0.6 |
| 8c | 29.62 ± 0.21 | 24.69 ± 0.50 | 59.25 ± 0.76 | 29.62 ± 0.12 | 37.03 ± 0.42 | 21.60 ± 0.03 | 201.8 ± 0.9 |
| 9a | 27.03 ± 0.13 | 49.23 ± 0.52 | 35.15 ± 0.04 | 81.24 ± 0.64 | 55.39 ± 0.42 | 52.31 ± 0.71 | 303.4 ± 1.0 |
| 9b | 42.22 ± 0.37 | 37.25 ± 0.24 | 24.83 ± 0.11 | 99.35 ± 0.83 | 31.04 ± 0.53 | 27.94 ± 0.50 | 262.7 ± 0.5 |
| 9c | 287.2 ± 2.10 | 12.04 ± 0.10 | 66.26 ± 0.63 | 93.97 ± 0.53 | 33.13 ± 0.04 | 21.08 ± 0.07 | 515.7 ± 1.7 |
| 10a | 46.29 ± 0.70 | 37.03 ± 0.70 | 27.77 ± 0.32 | 115.7 ± 0.74 | 57.89 ± 0.08 | 57.87 ± 0.53 | 342.6 ± 1.4 |
| 10b | 33.80 ± 0.40 | 31.38 ± 0.30 | 26.55 ± 0.06 | 96.75 ± 0.44 | 36.21 ± 0.33 | 51.30 ± 0.42 | 275.8 ± 1.3 |
| 10c | 27.39 ± 0.53 | 48.99 ± 0.44 | 34.29 ± 0.16 | 17.54 ± 0.34 | 42.87 ± 0.51 | 51.31 ± 0.87 | 180.0 ± 0.7 |
| Genus | Individuals | Assemblages | Mean vector (μ) | Length of mean vector (r) | Concentration | Circular variance | Circular standard deviation | Rayleigh's Z (P) | Rao's spacing test (P) |
| Astroblepidae | |||||||||
| Astroblepus* | 6 | 3 | 52° | 0.74 | 1.27 | 0.26 | 45° | 0.031 | < 0.05 |
| Loricariidae | |||||||||
| Hypoptopomatinae | |||||||||
| Hypoptopoma | 7 | 2 | 274° | 0.22 | 0.00 | 0.78 | 99° | 0.722 | 0.90 > P > 0.50 |
| Hypostominae | |||||||||
| Ancistrini | |||||||||
| Ancistrus* | 44 | 9 | 192° | 0.45 | 0.99 | 0.56 | 73° | 0.000 | < 0.01 |
| Baryancistrus† | 23 | 4 | 14° | 0.32 | 0.67 | 0.68 | 87° | 0.098 | < 0.01 |
| Chaetostoma* | 44 | 5 | 179° | 0.68 | 1.88 | 0.32 | 51° | 0.000 | < 0.01 |
| Dekeyseria | 2 | 1 | 271° | 1.00 | 20.46 | 0.00 | 4° | 0.139 | – |
| Etsaputu* | 12 | 2 | 120° | 0.59 | 1.36 | 0.41 | 59° | 0.012 | < 0.01 |
| Hemiancistrus* | 51 | 5 | 60° | 0.46 | 1.03 | 0.54 | 72° | 0.000 | < 0.01 |
| Hopliancistrus | 5 | 1 | 86° | 0.31 | 0.02 | 0.69 | 88° | 0.650 | 0.50 > P > 0.10 |
| Hypancistrus* | 25 | 4 | 157° | 0.88 | 4.62 | 0.12 | 28° | 0.000 | < 0.01 |
| Lasiancistrus* | 17 | 4 | 174° | 0.57 | 1.38 | 0.43 | 61° | 0.003 | < 0.05 |
| Leporacanthicus* | 12 | 2 | 136° | 0.68 | 1.82 | 0.32 | 50° | 0.002 | < 0.01 |
| Lithoxus | 2 | 1 | 69° | 0.97 | 1.90 | 0.03 | 13° | 0.158 | – |
| Panaque* | 41 | 5 | 343° | 0.34 | 0.72 | 0.66 | 84° | 0.008 | < 0.01 |
| Peckoltia* | 15 | 5 | 113° | 0.64 | 1.59 | 0.36 | 55° | 0.001 | < 0.01 |
| Pseudacanthicus | 1 | 1 | 110° | 1.00 | – | – | – | 0.512 | – |
| Pseudancistrus* | 32 | 4 | 53° | 0.75 | 2.34 | 0.25 | 44° | 0.000 | < 0.01 |
| Pseudolithoxus* | 24 | 3 | 108° | 0.50 | 1.16 | 0.50 | 67° | 0.002 | 0.10 > P > 0.05 |
| Scobinancistrus | 2 | 1 | 149° | 0.99 | 6.29 | 0.01 | 7° | 0.143 | – |
| Spectracanthicus | 4 | 1 | 86° | 0.69 | 1.72 | 0.31 | 49° | 0.148 | 0.50 > P > 0.10 |
| Hypostomini | |||||||||
| H. cochliodon grp.† | 30 | 7 | 329° | 0.30 | 0.63 | 0.70 | 89° | 0.063 | < 0.05 |
| H. plecostomus grp.* | 97 | 14 | 302° | 0.19 | 0.39 | 0.81 | 104° | 0.028 | < 0.05 |
| Pterygoplichthyini | |||||||||
| Pterygoplichthys | 2 | 2 | 254° | 0.73 | 0.22 | 0.27 | 45° | 0.396 | – |
| Loricariinae | |||||||||
| Farlowellini | |||||||||
| Farlowella | 4 | 3 | 251° | 0.51 | 0.77 | 0.49 | 66° | 0.376 | 0.50 > P > 0.10 |
| Harttiini | |||||||||
| Harttia* | 14 | 2 | 1° | 0.98 | 18.40 | 0.02 | 12° | 0.000 | < 0.01 |
| Lamontichthys* | 10 | 1 | 174° | 0.97 | 12.64 | 0.03 | 14° | 0.000 | < 0.01 |
| Sturisoma* | 16 | 2 | 187° | 0.65 | 1.74 | 0.35 | 53° | 0.001 | < 0.01 |
| Loricariini | |||||||||
| Limatulichthys | 20 | 3 | 304° | 0.25 | 0.51 | 0.75 | 96° | 0.299 | < 0.01 |
| Loricaria | 10 | 5 | 339° | 0.36 | 0.50 | 0.64 | 82° | 0.289 | 0.90 > P > 0.50 |
| Loricariichthys | 5 | 2 | 6° | 0.55 | 1.01 | 0.45 | 63° | 0.231 | 0.50 > P > 0.10 |
| Pseudoloricaria† | 3 | 1 | 331° | 0.93 | 2.01 | 0.07 | 22° | 0.062 | – |
| Rineloricaria* | 52 | 5 | 313° | 0.26 | 0.54 | 0.74 | 94° | 0.030 | < 0.01 |
| Spatuloricaria | 17 | 6 | 90° | 0.21 | 0.42 | 0.80 | 102° | 0.497 | < 0.01 |
| Sodium ibuprofen(geometric means) | Ibuprofen/ poloxamer(geometric means) | Standard ibuprofen(geometric means) | Ratio (%)sodium ibuprofen/ standard ibuprofen | 90% confidence interval | Ratio (%)ibuprofen/ poloxamer/ standard ibuprofen | 90% confidence interval | |
| AUC 0-0.08 (μg/h/mL) | Not estimated | Not estimated | Not estimated | Not estimated | Not estimated | Not estimated | Not estimated |
| AUC 0-0.17 (μg/h/mL) | 0.06 | 0.03 | 0.03 | 217.32 | 95.29-495.60 | 118.65 | 49.21-286.08 |
| AUC 0-0.25 (μg/h/mL) | 0.49 | 0.13 | 0.09 | 529.77 | 262.01-1071.16 | 138.56 | 68.53-280.17 |
| AUC 0-0.33 (μg/h/mL) | 1.61 | 0.50 | 0.18 | 905.93 | 462.33-1775.19 | 278.80 | 142.28-546.31 |
| AUC 0-0.42 (μg/h/mL) | 3.57 | 1.24 | 0.55 | 644.02 | 362.66-1143.69 | 224.33 | 126.32-398.37 |
| AUC 0-0.50 (μg/h/mL) | 6.09 | 2.34 | 1.31 | 466.40 | 287.78-755.90 | 179.01 | 110.45-290.13 |
| AUC 0-0.58 (μg/h/mL) | 8.99 | 3.72 | 2.30 | 390.44 | 251.21-606.85 | 161.71 | 104.04-251.34 |
| AUC 0-0.67 (μg/h/mL) | 12.08 | 5.39 | 3.52 | 343.55 | 227.18-519.53 | 153.34 | 101.40-231.89 |
| AUC 0-0.83 (μg/h/mL) | 18.03 | 9.24 | 6.36 | 283.49 | 195.09-411.95 | 145.21 | 99.93-211.00 |
| AUC 0-1.00 (μg/h/mL) | 23.71 | 13.65 | 9.54 | 248.48 | 176.57-349.68 | 143.08 | 101.67-201.35 |
| Activity | A1 | A2 | A3 | A4 | A5 | A6 | A7 |
| A1 | 30 | 0 | 0 | 0 | 0 | 0 | 0 |
| A2 | 1 | 29 | 0 | 0 | 0 | 0 | 0 |
| A3 | 0 | 0 | 30 | 0 | 0 | 0 | 0 |
| A4 | 0 | 0 | 0 | 30 | 0 | 0 | 0 |
| A5 | 0 | 0 | 0 | 0 | 19 | 7 | 4 |
| A6 | 0 | 0 | 0 | 0 | 7 | 15 | 8 |
| A7 | 0 | 0 | 0 | 0 | 4 | 6 | 20 |
| Diagnosis | anti-MAP1Abs+ | anti-MAP1Abs− | anti-MAP2Abs+ | anti-MAP2Abs− | IS900+ | IS900− |
| CD | 13 (46%) | 15 (54%) | 11 (39%) | 17 (61%) | 18 (64%) | 10 (36%) |
| UC | 1 (3%) | 29 (97%) | 5 (16.7%) | 25 (83.3%) | 10 (33%) | 20 (67%) |
| nIBD | 3 (5%) | 59 (95%) | 4 (6%) | 58 (94%) | 7 (9.7%) | 55 (90.3%) |
| RBM, umb | RBM, umc | ASM% large AW | ASM% small AW | T-cella | B- cell | MF | Mast | Eos | CD15 | PDC | Mucus large AW (0–3) | Mucus small AW (0–3) |
| Cases | ||||||||||||
| 2,8 | 4,4 | 13 | 11 | 121 | 118 | 431 | 129 | 27 | 23 | 0 | 2,5 | 1 |
| 5,6 | 5,6 | 29 | 17 | 309 | 30 | 345 | 353 | 65 | 140 | 4 | 2 | 1 |
| 2,3 | 3,4 | 7 | 9 | 1097 | 560 | 875 | 154 | 1240 | 659 | 100 | 3 | 1 |
| 4,0 | 3,9 | 9 | 17 | 297 | 64 | 342 | 149 | 77 | 80 | 4 | 2 | 1 |
| 6,9 | 6,3 | 15 | 20 | 191 | 49 | 455 | 92 | 240 | 140 | 20 | 3 | 2 |
| 5,8 | 6,2 | 20 | 14 | 393 | 87 | 300 | 113 | 653 | 73 | 80 | 2 | 1 |
| 6,4 | 5,7 | 28 | 14 | 521 | 19 | 239 | 106 | 360 | 87 | 20 | 3 | 0 |
| 3,4 | 4,6 | 12 | 8 | 508 | 225 | 500 | 149 | 20 | 813 | 24 | 2 | 1 |
| 6,4 | 4,7 | 14 | 18 | 421 | 443 | 1133 | 153 | 320 | 107 | 20 | 3 | 1 |
| 4,8 | 5 | 10 | NA | 166 | 51 | 320 | 151 | 700 | 140 | 14 | 3 | 1 |
| 6,6 | 6,4 | 17 | 13 | 150 | 35 | 161 | 79 | 1 | 9 | 20 | 3 | 2,5 |
| 6,2 | 5,6 | 35 | 19 | 427 | 194 | 520 | 146 | 467 | 447 | 40 | 2 | 1 |
| Controls | ||||||||||||
| 2,3 | 3,8 | 6 | 6 | NA | 22 | 158 | 140 | 0 | 640 | 0 | 0 | 0 |
| 3,1 | 4,9 | 16 | 14 | 454 | 29 | 184 | 248 | 0 | 147 | 0 | 1 | 0 |
| 1,7 | 3,3 | 16 | 22 | 257 | 25 | 219 | 169 | 0 | 73 | 12 | 0 | 0 |
| 3,2 | 3,6 | 18 | 17 | 487 | 51 | 204 | 95 | 6 | 47 | 4 | 1 | 0 |
| 1,7 | 2,6 | 14 | 9 | 400 | 81 | 167 | 131 | 12 | 320 | 8 | 1 | 0 |
| 2,8 | 3,4 | 14 | 11 | 450 | 48 | 188 | 187 | 0 | 347 | 4 | 0 | 0 |
| 1,8 | 2,4 | 11 | 14 | 68 | 12 | 157 | 65 | 0 | 113 | 12 | 1 | 0 |
| 2,4 | 3,3 | NA | NA | 325 | NA | 144 | NA | 0 | 120 | 4 | 0 | 0 |
| Mouse | Number | Rate | Theoretical rate | Theoretical value | χ2 test |
| Total | 657 | — | — | — | — |
| WT | 153 | 1 | 1 | 164.25 | |
| Heterozygous | 330 | 2.06 | 2 | 328.5 | |
| KO | 174 | 0.98 | 1 | 164.25 | 0.50759 |
| Density Measure | Confirmed Spn Casesa | RSV+ Casesb | Controls Targeted for CRP Testingc | Confirmed Non- Spn Bacterial Casesd |
| NP/OP PCR Spn density | (n = 36) | (n = 858) | (n = 597) | (n = 79) |
| NP/OP PCR density > 106.9 copies/mLe alone | 21 (58.3) | 109 (12.7) | 73 (12.2) | 20 (25.3) |
| + CRP ≥40 mg/L | 17 (47.2) | 33 (3.9) | 3 (0.5) | 17 (21.5) |
| + CRP ≥100 mg/L | 15 (41.7) | 8 (0.9) | 0 (0.0) | 14 (17.7) |
| Whole-blood PCR Spn density | (n = 35) | (n = 847) | (n = 597) | (n = 78) |
| Density >102.2 copies/mLe alone | 18 (51.4) | 19 (2.2) | 119 (19.9) | 4 (5.1) |
| + CRP ≥40 mg/L | 17 (48.6) | 3 (0.4) | 5 (0.8) | 3 (3.9) |
| + CRP ≥100 mg/L | 16 (45.7) | 1 (0.1) | 1 (0.2) | 1 (1.3) |
| NP/OP PCR Spn density or whole-blood PCR Spn density | (n = 34) | (n = 835) | (n = 593) | (n = 77) |
| (NP/OP density >106.9 copies/mL or whole-blood density >102.2 copies/mL)e alone | 27 (79.4) | 126 (15.1) | 179 (30.2) | 23 (29.9) |
| + CRP ≥40 mg/L | 23 (67.7) | 35 (4.2) | 8 (1.4) | 19 (24.7) |
| + CRP ≥100 mg/L | 21 (61.8) | 9 (1.1) | 1 (0.2) | 15 (19.5) |
| NP/OP PCR Spn density and whole-blood PCR Spn density | (n = 37) | (n = 870) | (n = 601) | (n = 80) |
| (NP/OP density >106.9 copies/mL and whole-blood density >102.2 copies/mL)e alone | 12 (32.4) | 2 (0.2) | 13 (2.2) | 1 (1.3) |
| + CRP ≥40 mg/L | 11 (29.7) | 1 (0.1) | 0 (0.0) | 1 (1.3) |
| + CRP ≥100 mg/L | 10 (27.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Number of patients with positive test result(n = 30) | |
| Spices | 27 |
| Seeds and nuts | 24 |
| Seafood | 24 |
| Starch | 22 |
| Food additives | 21 |
| Vegetables | 21 |
| Cheese | 20 |
| Fruits | 20 |
| Sugar products | 20 |
| Other additives | 14 |
| Eggs | 14 |
| Milk and milk products | 14 |
| Infusions | 13 |
| Salads | 10 |
| Mushrooms | 9 |
| Yeast | 5 |
| Meat | 5 |
| n = 88 | |
| Patient age (years)Mean ± SD | 36 ± 9.3 |
| Sex (female/male)n (%) | 60/28 (68.19/31.81 %) |
| BMI (kg/m2)Mean ± SD | 48.65 ± 7.71 |
| Non-interacting | Interacting | |
| unconstrained | Z-score = 8.17, AUC = 93.48% | Z-score = 7.09, AUC = 91.06% |
| constrained | Z-score = 4.32, AUC = 87.01% | Z-score = 6.94, AUC = 90.07% |
| Endocan (pg/ml) | Osteoprotegerin (pmol/l) | |
| Baseline | 146 ± 110 | 4,4 ± 2,4 |
| 2 months | 168 ± 133 | 4,5 ± 2,7 |
| 4 months | 168 ± 134 | 4,6 ± 2,3 |
| 6 months | 179 ± 224 | 4,4 ± 2,0 |
| 8 months | 196 ± 238 | 4,3 ± 2,1 |
| Paired sample t-test | p-value = 0,036 | p-value = 0,668 |
| Friedman test | Chi-Square: 12,696Asymp. Significance: 0,013 | Chi-Square: 8,309Asymp. Significance: 0,081 |
| International source | Range of time requirement in minutes | Average time requirement in minutes |
| ECDC Round Table Report | < 15–60 | 40 |
| ProMED-mail | < 15–45 | 35 |
| WHO Event Information Site (EIS) | < 15–30 | 25 |
| EPIS for Food- and Waterborne Diseases and Zoonoses (EPIS-FWD) | < 15–30 | 15 |
| WHO Disease Outbreak News (DON) | < 15–30 | 20 |
| European Early Warning and Response System (EWRS) | < 15–40 | 30 |
| Eurosurveillance | < 15–30 | 25 |
| Emerging Infections (EI) Summary | < 15–45 | 20 |
| Morbidity and Mortality Weekly Report (MMWR) | < 15 | 10 |
| WHO Weekly Epidemiological Records (WER) | < 15 | 10 |
| TOTAL | 150–330 | 230 |
| Agent | Specific mechanism | Highest level of studies | Result |
| Tauroursodeoxycholic acid | Chemical chaperone | Randomized controlled trials | Improved insulin sensitivity in muscle and liver in obese individuals [86] |
| Phenylbutyrate | Chemical chaperone | Randomized controlled trials | Improved insulin sensitivity and beta-cell function in lipid-infused individuals [87] |
| Azoramide | ATF6 activators | Rodents | Improves insulin sensitivity and beta-cell function in obese mice [89] |
| Valproate | Increasing GRPP78 | Rodents | Ameliorates atherosclerosis and hepatic steatosis in Apoe−/−mice [90] |
| L-Carnitine or carnitine-orotate | Fatty acid transfer for beta-oxidation | Randomized controlled trials | Twelve of 17 studies showing improved insulin sensitivity or glycemic control in type 2 diabetic patients or alleviation of hepatic steatosis [98, 99] |
| Co-enzyme Q10 | Electron carrier from complex I and II to complex III | Randomized controlled trials | No net effect on glycemic control in type 2 diabetic patients [100] |
| α-lipoic acid | Antioxidant | Randomized controlled trials; rodent | Weight-reducing, glucose-lowering, and insulin-sensitizing effect; prevention of hepatic steatosis [101–110] |
| Vitamin E | Antioxidant | Randomized controlled trials | Inconsistent results on glycemic control [111–115]; reduced hepatic steatosis [122] |
| N-acetylcysteine | Antioxidant | Rodents | Prevents diet-induced obesity [116–118] |
| Peptide SS31 | Mitochondria-targeted antioxidant peptide | Rodent | Improved glucose tolerance in diet-induced obese mice [38] |
| Resveratrol | SIRT1 agonist | Randomized controlled trials | Improved insulin sensitivity and glycemic control in diabetic patients; no effect in nondiabetic patients [120]; |
| GSK5182 | Estrogen-related receptor gamma inverse agonist | Rodents | Reduces hyperglycemia due to inhibition of hepatic gluconeogenesis [121] |
| Trehalose, imanitib | Enhance autophagy | Rodents | Improved glucose tolerance and insulin sensitivity in obese mice [84] |
| Dh404 | Nrf2 activator | Rodents | Increased viability of islet by enhancing autophagy [123] |
| Factor | Parameter Estimate (95% CI) | P |
| Mean arterial blood pressure | ||
| Smoker | 3.49 (−2.67, 9.64) | .257 |
| Male sex | −38.45 (−91.78 to 14.88) | .151 |
| Age | 0.25 (−.14 to .64) | .202 |
| Body mass index | 0.19 (−.61 to .99) | .625 |
| Antihypertensive | 1.44 (5.19–8.06) | .662 |
| CD4+ iTreg count,a per 10-fold increase | 20.72 (7.03–34.41) | .004 |
| Sex-associated CD4+ iTreg frequencyb | −18.40 (−41.80 to 4.99) | .119 |
| Diastolic blood pressure | ||
| Smoker | 3.09 (−3.54 to 9.72) | .349 |
| Male sex | −62.14 (−119.59 to −4.70) | .035 |
| Age | −0.04 (−.45 to .38) | .858 |
| Body mass index | 0.44 (−.42 to 1.30) | .301 |
| Antihypertensive | 1.86 (−5.28 to 8.99) | .600 |
| CD4+ iTreg count, per 10-fold increase | 21.50 (6.75–36.25) | .006 |
| Sex-associated CD4+ iTreg frequencya,b | −28.07 (−53.27 to −2.87) | .030 |
| Parameter | Univariate analysis | Multivariate analysis | ||
| HR(95% CI) | P-value | HR (95% CI) | P-value | |
| Gender | ||||
| Female | 1(Referent) | |||
| Male | 3.272 (1.781-6.01) | 0.091 | ||
| Histology | ||||
| WHO Type 2 | 1(Referent) | |||
| WHO Type 3 | 0.813(0.539-1.227) | 0.324 | ||
| Age at diagnosis (years) | ||||
| <50 | 1(Referent) | |||
| ≥50 | 1.154(0.751-1.773) | 0.513 | ||
| Tumor classification | ||||
| T1+2 | 1(Referent) | |||
| T3+4 | 2.876(1.814-4.558) | <0.001 | 1.847 (1.106-3.084) | 0.019 |
| Lymph node classification | ||||
| N0+1 | 1(Referent) | |||
| N2+3 | 2.550(1.644-3.953) | <0.001 | 1.827 (1.126-2.966) | 0.015 |
| TNM stage(AJCC) | ||||
| I+II | 1(Referent) | |||
| III+IV | 11.791(3.728-37.225) | <0.001 | 4.757(1.316-17.201) | 0.017 |
| GGT | ||||
| <23 | 1(Referent) | |||
| ≥23 | 3.465 (2.174-5.523) | <0.001 | 3.119 (1.955-4.976) | 0.031 |
| Cat no. | Category | No. of questions |
| Questionnaire 1 (QS1) | 24 | |
| n/a | Have you ever heard of masesea? | 1 |
| 1 | Acquisition & transmission of T. solium infections | 3 |
| 2 | Acquisition of NCC | 2 |
| 3 | TS in general | 3 |
| 4 | NCC in general | 3 |
| 5 | PCC diagnosis | 4 |
| 6 | PCC treatment | 2 |
| 7 | Relationship between PCC/TS/NCC | 3 |
| 8 | Prevention of PCC/TS/NCC | 3 |
| Questionnaire 2 (QS2) | 15 | |
| 1 | General knowledge | 5 |
| 2 | Transmission | 5 |
| 3 | Prevention | 5 |
| CD274/PD-L1 FISH | Cases | PD-L1 IHC | |||
| n = 80 | Score3+ | Score2+ | Score1+ | Score0 | |
| High Level Amplification | 12 (15%) | 7/12 | 1/12 | 2/12 | 2/12 |
| Low Level Amplification | 3 (4%) | 1/3 | 0/3 | 0/3 | 2/3 |
| Polysomy | 16 (20%) | 3/16 | 3/16 | 3/16 | 7/16 |
| Disomy | 49 (61%) | 3/49 | 8/49 | 5/49 | 33/49 |
| Total (N=60) | Group 1 (N=39, 65%) | Group 2 (N=21, 35%) | P value | |
| HPV-HR | ||||
| Positive | 23 (56) | 14 (61) | 9 (50) | 0.54 |
| Negative | 18 (44) | 9 (39) | 9 (50) | |
| HPV-16/18 | ||||
| Positive | 15 (37) | 8 (35) | 7 (39) | 1 |
| Negative | 26 (63) | 15 (65) | 11 (61) | |
| p16 | ||||
| Positive | 27 (66) | 16 (70) | 11 (61) | 0.74 |
| Negative | 14 (34) | 7 (30) | 7 (39) | |
| Cyclin D1 | ||||
| Positive | 12 (29) | 4 (17) | 8 (44) | |
| Negative | 29 (71) | 19 (83) | 10 (56) | 0.09 |
| Statement | Agree (%) | Disagree (%) | ? (%) |
| 1. A man doesn't reach a orgasm during sexual intercourse. Still, the woman can become pregnant. | 50 | 34 | 16 |
| 2. It is unhealthy to use the oral contraceptive pill for a period longer than 10 years. | 44 | 14 | 42 |
| 3. If a woman uses the oral contraceptive pill, she can become infertile. | 22 | 60 | 18 |
| 4. If a woman uses the oral contraceptive pill, her desire for sex becomes less. | 7 | 73 | 20 |
| 5. The oral contraceptive pill is the most reliable contraceptive method. | 49 | 43 | 8 |
| 6. The injectable contraceptive contains hormones, just as the oral contraceptive pill. | 63 | 6 | 31 |
| 7. An intrauterine device can reside in the uterus without problems for 5 years. | 42 | 20 | 38 |
| 8. A condom is not reliable because it ruptures rapidly. | 39 | 53 | 8 |
| Without vaccination | With vaccinationa | Difference | |
| Casesb | 59,495 | 25,281 | 34,214 |
| Treated at home | 47,622 | 22,389 | 25,232 |
| GP visits | 11,453 | 2,786 | 8,667 |
| Hospitalised (community acquired) | 2,817 | 353 | 2,464 |
| Hospitalised (nosocomial) | 421 | 106 | 315 |
| Deaths | 0.65 | 0.16 | 0.48 |
| Total QALYs lostc | 173 | 64 | 109 |
| Total direct costsa (x1000)c | € 7,470 | € 1,185 | € 6,282 |
| Total indirect costs (x1000) c | € 2,193 | € 888 | € 1,305 |
| Characteristics | HCC n(%) | CHB n(%) | HEAL n(%) | P value | |
| n = 392 | n = 344 | n = 372 | |||
| Age | <55 | 252(64.3) | 223(64.8) | 245(65.9) | 0.90 |
| ≥55 | 140(35.7) | 121(35.2) | 127(34.1) | ||
| Gender | Male | 345(88.0) | 267(77.6) | 306(82.3) | 0.001 |
| Female | 47(12.0) | 77(22.4) | 66(17.7) | ||
| Alcohol abuse | Absent | 75(19.1) | 44(12.8) | 31(8.3) | <0.001 |
| Present | 317(80.9) | 300(87.2) | 341(91.7) | ||
| Cirrhosis | Absent | 50(12.8) | 331(96.2) | 372 | |
| Present | 342(87.2) | 13(3.8) | 0 | ||
| Anti-HCV positive | 0 | 0 | 0 | ||
| HBsAg positive | 364(92.9) | 344(100.0) | 0 | ||
| AFP(ng/ml) | 923.3 ± 597.1 | 7.6 ± 6.9 | <0.001 | ||
| ALT(IU/L) | 51.0 ± 24.0 | 54.0 ± 41.0 | 21.0 ± 8.1 | 0.30 | |
| AST(IU/L) | 36.3 ± 29.4 | 45.3 ± 34.3 | 26.1 ± 6.9 | 0.67 | |
| GGT(IU/L) | 27.7 ± 23.5 | 39.4 ± 35.7 | 19.5 ± 17.1 | 0.56 | |
| TBIL(μmol/L) | 16.4 ± 12.6 | 19.0 ± 7.3 | 12.1 ± 4.2 | 0.56 |
| Data set | Variance component (%) | ||
| Among groups | Among populations within group | Within populations | |
| All six cattle breeds | 7.80 | 0.70 | 91.45 |
| Indigenous and local developed breeds | 7.80 | 1.40 | 90.80 |
| Individual/Demographic | Total Leisure Time Physical Activity (LTPA) | ||||
| (ALL) n = 428 | T1 n = 143 | T2 n = 142 | T3 n = 143 | p Trend | |
| Sex | <0.001 | ||||
| Men | 182 (42.5%) | 49 (34.3%) | 51 (35.9%) | 82 (57.3%) | |
| Women | 246 (57.5%) | 94 (65.7%) | 91 (64.1%) | 61 (42.7%) | |
| Age (years) | 68.0 (63.0;72.0) | 67.0 (62.0;71.0) | 68.0 (63.0;72.0) | 69.0 (65.0;73.0) | 0.016 |
| BMI (kg/m2) | 30.0 (27.5;32.1) | 30.9 (28.3;33.0) | 29.7 (27.4;31.8) | 29.9 (27.2;31.6) | 0.012 |
| Educational Level | 0.159 | ||||
| Primary school or lesser | 365 (85.9%) | 125 (87.4%) | 125 (88.7%) | 115 (81.6%) | |
| Secondary School or greater | 60 (14.1%) | 18 (12.6%) | 16 (11.3%) | 26 (18.4%) | |
| Smoking status | 0.008 | ||||
| Former | 118 (27.6%) | 31 (21.7%) | 28 (19.7%) | 59 (41.3%) | |
| Current | 70 (16.4%) | 31 (21.7%) | 25 (17.6%) | 14 (9.79%) | |
| Never | 240 (56.1%) | 81 (56.6%) | 89 (62.7%) | 70 (49.0%) | |
| Total LTPA (METs min/day) | 198 (93.8;330) | 50.1 (14.6;93.7) | 198 (160;226) | 432 (330;573) | <0.001 |
| Light LTPA (METs min/day) | 87.9 (14.0;176) | 28.0 (0.00;70.0) | 140 (76.0;173) | 177 (44.4;298) | <0.001 |
| Moderate-vigorous LTPA (METs min/day) | 49.5 (6.03;179) | 8.00 (0.00;24.0) | 57.6 (8.01;132) | 277 (123;455) | <0.001 |
| Model 1 | Model 2 | Model 3 | ||||
| Characteristics | Coeff | (95% CI) | Coeff | 95% CI | Coeff | 95% CI |
| Sociodemographic | ||||||
| Wealth quintile | ||||||
| First Quintile (REF) | ||||||
| Second Quintile | 0.074 | 0.034, 0.115 | 0.056 | 0.017, 0.096 | 0.063 | 0.020, 0.107 |
| Third Quintile | 0.090 | 0.050, 0.130 | 0.068 | 0.030, 0.107 | 0.063 | 0.021, 0.104 |
| Fourth Quintile | 0.109 | 0.068, 0.150 | 0.089 | 0.049, 0.129 | 0.083 | 0.039, 0.126 |
| Fifth Quintile | 0.138 | 0.098, 0.177 | 0.100 | 0.061, 0.139 | 0.092 | 0.050, 0.133 |
| Behavioural | ||||||
| Tobacco consumption | ||||||
| Never smoked (REF) | ||||||
| Current smoker | −0.084 | −0.113,-0.055 | −0.087 | −0.120, −0.054 | ||
| Former smoker | 0.003 | −0.025, 0.030 | 0.021 | −0.010, 0.052 | ||
| Snuff use | −0.038 | −0.096, 0.020 | −0.036 | −0.098, 0.026 | ||
| Chewing tobacco use | −0.104 | −0.258, 0.050 | −0.05 | −0.200, 0.100 | ||
| Diet | ||||||
| Vegetable servings/week | 0.001 | −0.000, 0.001 | ||||
| Bread slices/week | 0.001 | 0.000, 0.002 | 0.001 | 0.001, 0.003 | ||
| Sugary drinks/week | 0.003 | −0.001, 0.007 | ||||
| Biological | ||||||
| Self-reported Diabetes | 0.099 | 0.023, 0.175 | ||||
| Tested HIV positive | −0.066 | −0.113, −0.019 | ||||
| Reported tuberculosis | −0.082 | −0.118, −0.045 | ||||
| R2 | 0.075 | 0.16 | 0.196 | |||
| ∆R2 | 0.074 | 0.036 | ||||
| F (p-value) | <0.001 | <0.001 | <0.001 | |||
| BIC | −702.152 | −719.666 | −561.063 |
| Unadjusted model (OR; CI95%) | Model 1 (OR; CI95%) | Model 2 (OR; CI95%) | Model 3 (OR; CI95%) | |
| Glomerular filtration rate (eGFR) | ||||
| eGFR ≥ 60 mL/min/1.73 m2 | 1 | 1 | 1 | 1 |
| eGFR 45–59 mL/min/1.73 m2 | 2.07 (1.5-2.8) | 1.2 (0.9-1.7) | 1.2 (0.9-1.8) | 1.2 (0.9-1.8) |
| eGFR 30–44 mL/min/1.73 m2 | 4.6 (2.9-7.3) | 2.5 (1.5-4.1) | 2.3 (1.4-3.8) | 2.3 (1.4-3.9) |
| eGFR < 30 mL/min/1.73 m2 | 8.4 (3.6-19.9) | 4.3 (1.7-10.7) | 4.1 (1.6-10.2) | 4.1 (1.6-10.2) |
| For each unit below 60 mL/min/1.73 m2 | 1.072 (1.06-1.09) | 1.045 (1.03-1.06) | 1.042 (1.02-1.06) | 1.043 (1.02-1.06) |
| UACR | ||||
| Normoalbuminuria | 1 | 1 | 1 | 1 |
| Microlbuminuria (30–299 mg/gr) | 1.9 (1.4-2.7) | 1.8 (1.2-2.6) | 1.8 (1.3-2.7) | 1.6 (1.1-2.4) |
| Macroalbuminuria (≥300 mg/gr) | 5.0 (2.3-11.1) | 4.6 (1.9-10.9) | 4.2 (1.8-10.2) | 3.9 (1.6 -9.5) |
| For each unit above 29 mg/gr | 1.001 (0.99-1.01) | 1.001 (0.99-1.01) | 1.001 (0.99-1.01) | 1.001 (0.99-1.01) |
| UACR (normal) + GFR (normal) | 1 | 1 | 1 | 1 |
| UACR ↑ and eGFR ↓ | 3.3 (1.5-7.3) | 2.3 (1.0-5.3) | 2.4 (1.0-5.4) | 2.2 (0.9-5.2) |
| Bayes Factor 10 | Bayes Factor 30 | Bayes Factor 50 | ||||
| Blood | Brush | Blood | Brush | Blood | Brush | |
| Mean # CNVS per subject | 314.0 | 385.7 | 151.5 | 183.0 | 103.1 | 109.1 |
| Size of CNVs (kb) | ||||||
| Mean | 15.9 | 16.2 | 19.9 | 19.0 | 19.4 | 19.0 |
| 25th percentile | 1.0 | 1.1 | 1.0 | 1.1 | 1.1 | 1.2 |
| Median | 2.1 | 2.1 | 1.9 | 2.1 | 1.9 | 2.0 |
| 75th percentile | 6.0 | 5.8 | 4.4 | 4.8 | 3.9 | 4.2 |
| Size of CNVs (probes) | ||||||
| Mean | 15.9 | 16.6 | 17.2 | 18.4 | 17.9 | 17.0 |
| 25th percentile | 12.0 | 12.0 | 13.0 | 14.0 | 14.0 | 14.0 |
| Median | 16.0 | 16.0 | 17.0 | 17.0 | 17.0 | 17.0 |
| 75th percentile | 18.0 | 18.0 | 18.0 | 18.0 | 18.0 | 18.0 |
| Practices in first cohort | Practices in second cohort | |||||
| Practice characteristic | 2006-2008 | 2009-2011 | 2009-2011 | |||
| N | % | N | % | N | % | |
| Practice type | ||||||
| Single handed | 17 | 25% | 18 | 26% | 19 | 27% |
| Health center | 10 | 14% | 11 | 16% | 8 | 12% |
| Other | 42 | 61% | 40 | 58% | 42 | 61% |
| Practice location1 | ||||||
| Urban | 23 | 33% | 23 | 33% | 25 | 36% |
| Semi-urban | 34 | 49% | 34 | 49% | 33 | 48% |
| Rural | 12 | 18% | 12 | 18% | 11 | 16% |
| Average number of patients per practice | 4629 | 4808 | 4830 |
| Females | Males | |||
| Control | Prenatal stress | Control | Prenatal stress | |
| P1 | 6.4 ± 1.1 | 5.9 ± 1.5aa | 6.7 ± 1.3 | 6.2 ± 1.6 |
| P21 | 40.8 ± 2.4 | 39.8 ± 2.1 | 39.5 ± 2.2 | 43.2 ± 2.7 |
| P28 | 57.8 ± 2.9 | 64.8 ± 2.7a | 68.2 ± 2.5 | 66.2 ± 2.8 |
| Storage time | Test organism exposed to (name of the test) | Staphylococcus aureus | Staphylococcus epidermidis | Micrococcus luteus | Corynebacterium jeikeium | Candida albicans |
| < 1 min | neutralizer in saline peptone water (neutralizer toxicity test) | 1.86 ± 0.05 | 1.81 ± 0.03 | 1.77 ± 0.01 | 1.82 ± 0.02 | 2.05 ± 0.01 |
| antiseptic solution (material control test) | 0* | 0* | 0* | 0* | 0* | |
| saline peptone water (organism viability test) | 1.90 ± 0.05 | 1.84 ± 0.07 | 1.74 ± 0.03 | 1.79 ± 0.02 | 2.02 ± 0.03 | |
| 3 h | neutralizer in saline peptone water (neutralizer toxicity test) | 1.83 ± 0.02 | 1.81 ± 0.02 | 1.72 ± 0.03 | 1.89 ± 0.08 | 2.05 ± 0.06 |
| antiseptic solution (material control test) | 0* | 0* | 0* | 0* | 0* | |
| saline peptone water (organism viability test) | 1.88 ± 0.06 | 1.81 ± 0.02 | 1.73 ± 0.05 | 1.77 ± 0.08 | 2.03 ± 0.02 |
| Samples | Number | Gender | Age | Mean age |
| Controls (n = 15) | 7 | Male | 32–77 | 51.1 ± 15.3 |
| 8 | Female | 46–61 | 52.6 ± 4.9 | |
| Symptomatic HD (n = 16) | 8 | Male | 48–65 | 60.6 ± 5.6 |
| 8 | Female | 46–67 | 55.2 ± 7.3 |
| Haplotype | case(frequency) | control(frequency) | P-value | OR(95% CI) |
| C G G | 323.66 (0.680) | 852.26 (0.670) | 0.745 | 1.039 [0.826~ 1.306] |
| G A A | 103.66 (0.218) | 324.60 (0.255) | 0.099 | 0.809 [0.629~ 1.041] |
| G GG | 42.34 (0.089) | 74.71 (0.059) | 0.025* | 1.561 [1.054~ 2.312] |
| Global result | 0.034 |
| Age group | Number of patients with condylar changes |
| 20–40 (Group A) | 16 (64%) |
| 41–60 (Group B) | 22 (88%) |
| 61 and above (Group C) | 23 (92%) |
| MiRNA | Control | p16 Carriers | p Value |
| hsa-let-7b | 0.118 ± 0.001 | 0.104 ± 0.012 | 0.217 |
| hsa-let-7g | 0.056 ± 0.007 | 0.051 ± 0.011 | 0.350 |
| hsa-miR-125b | 1.319 ± 0.125 | 1.251 ± 0.150 | 0.368 |
| hsa-miR-126 | 0.113 ± 0.019 | 0.127 ± 0.018 | 0.425 |
| hsa-miR-128 | 2.034 ± 0.210 | 1.826 ± 0.206 | 0.242 |
| hsa-miR-137 | 0.052 ± 0.005 | 0.045 ± 0.006 | 0.252 |
| hsa-miR-148a | 0.094 ± 0.011 | 0.083 ± 0.008 | 0.224 |
| hsa-miR-149 | 0.024 ± 0.004 | 0.028 ± 0.006 | 0.310 |
| hsa-miR-17 | 0.101 ± 0.17 | 0.097 ± 0.013 | 0.418 |
| hsa-miR-199a | 0.017 ± 0.004 | 0.016 ± 0.010 | 0.451 |
| hsa-miR-19a | 0.421 ± 0.067 | 0.409 ± 0.053 | 0.446 |
| hsa-miR-19b | 0.558 ± 0.090 | 0.543 ± 0.077 | 0.450 |
| hsa-miR-20b | 0.123 ± 0.020 | 0.107 ± 0.012 | 0.273 |
| hsa-miR-21 | 0.775 ± 0.074 | 0.789 ± 0.054 | 0.441 |
| hsa-miR-221 | 0.335 ± 0.030 | 0.311 ± 0.023 | 0.273 |
| hsa-miR-222 | 0.589 ± 0.062 | 0.519 ± 0.062 | 0.182 |
| hsa-miR-23a | 0.520 ± 0.095 | 0.473 ± 0.072 | 0.350 |
| hsa-miR-29a | 0.625 ± 0.054 | 0.593 ± 0.044 | 0.323 |
| hsa-miR-423-3p | 0.088 ± 0.014 | 0.078 ± 0.006 | 0.264 |
| hsa-miR-92a | 0.341 ± 0.053 | 0.306 ± 0.034 | 0.292 |
| Type of Intervention | Overall mean blood : sweat ratio | ||||
| BDE 28 | BDE 47 | BDE 99 | BDE 100 | BDE 153 | |
| Exercise (n = 3) | 137.2 | 25.5 | 4.8 | 16.9 | 26.9 |
| Infrared sauna (n = 8) | 17.9 | 32.1 | 3.25 | 94.6 | 71.8 |
| Steam sauna (n = 6) | 69.5 | 26.3 | 5.6 | 2.4 | 121.2 |
| Key barriers | Key facilitators |
| Capabilities: Stress associated with being an asylum seeker | Stress drove activity |
| Decision process: Living in limbo | Feeling settled and secure |
| Resources and environment Lack of money for food and equipment Lack of knowledge of facilities in local area The weather Time Lack of childcare | |
| Social | |
| Exercising With friends/ family Alone in the UK Cultural influences | Exercising With friends/ family |
| Knowledge and skills | |
| The phrase ‘physical activity’ and recommended levels | Levels of exercise and physical activity back home |
| Understanding consequences Impact on physical health Weight gain Impact on mental health |
| Disease | miRNA | Expression level | Contributors |
| Breast cancer | miR-29a | Up-regulation | Wu et al., J Biomed Biotechnol. (2010) [76] |
| miR-21 | Asaga et al., Clin Chem. (2011) [77] | ||
| Lung cancer | miR-21,1254,574-5p | Up-regulation | Wei et al., Chin J Cancer. (2011) [79] |
| Foss et al., J Thorac Oncol. (2011) [78] | |||
| Hepatocellular carcinoma | miR-16,miR-199a | Down-regulation | Qu et al., J Clin Gastroenterol. (2011) [80] |
| miR-21,miR-122,miR-223 | Up-regulation | Xu et al., Mol Carcinog. (2010) [81] | |
| Malignant melanoma | miR-221 | Up-regulation | Kanemaru et al., J Dermatol Sci. (2011) [82] |
| Gastric cancer | miR-1,20a,27a,34,423-5p | Up-regulation | Liu et al., Eur J Cancer. (2011) [83] |
| Categories | Cohorts (n) | HR (95%CI) | P value | I2 (%) | Model types |
| OS | 8 (4448) | 0.99 (0.77–1.27) | 0.96 | 82 | Random-effects |
| PFS | 3 (2861) | 1.26 (1.15–1.39) | <0.00001 | 32 | Fixed-effects |
| Ethnicity | Random-effects | ||||
| Asian | 4 (1879) | 0.97 (0.72–1.32) | 0.85 | 76 | |
| Caucasian | 4 (2569) | 1.03 (0.65–1.63) | 0.90 | 86 | |
| Median follow-up time (months) | Random-effects | ||||
| >60 | 4 (2540) | 1.12 (0.89–1.42) | 0.11 | 51 | |
| <60 | 4 (1908) | 0.98 (0.64–1.48) | 0.91 | 87 | |
| Mean age (years) | Random-effects | ||||
| >50 | 5 (2497) | 0.92 (0.62–1.37) | 0.69 | 84 | |
| <50 | 3 (1951) | 1.18 (0.96–1.44) | 0.11 | 47 | |
| Publication year | Fixed-effects | ||||
| Before 2010 | 4 (2780) | 0.70 (0.60–0.83) | <0.0001 | 0 | |
| After 2010 | 4 (1668) | 1.26 (1.13–1.41) | <0.00001 | 0 | |
| Specimen sources | Fixed-effects | ||||
| Serum | 5 (2875) | 1.24 (1.11–1.38) | <0.0001 | 42 | |
| Tissue | 3 (1573) | 0.71 (0.60–0.84) | <0.00001 | 0 | |
| Testing methods | Fixed-effects | ||||
| ELISA | 4 (2575) | 1.21 (1.08–1.35) | 0.0001 | 21 | |
| IHC | 4 (1873) | 0.83 (0.71–0.96) | <0.0001 | 84 | |
| Chemotherapy | Random-effects | ||||
| With | 4 (1172) | 0.93 (0.65–1.33) | 0.70 | 75 | |
| Without | 4 (3276) | 1.05 (0.69–1.59) | 0.84 | 88 | |
| Segment type | Random-effects | ||||
| M30 | 5 (2902) | 1.17 (0.95–1.45) | 0.13 | 69 | |
| M65 | 3 (1546) | 0.72 (0.61–0.86) | 0.0003 | 0 |
| Total (n) | Always % (standard error) | Not in international competition | Not >10 fights | Other | Never | |
| Total | 431 | 71.5 (5.6) | 7.2 (3.2) | 10.7 (3.8) | 4.9 (2.7) | 5.8 (3.0) |
| Sex | ||||||
| Male | 310 | 64.2 (6.9) | 8.7 (4.2) | 13.9 (5.1) | 5.8 (3.5) | 7.4 (3.9) |
| Female** | 116 | 90.5 (7.2) | 2.6 (4.5) | 2.6 (4.5) | 2.6 (4.5) | 1.7 (4.0) |
| Unlisted | 5 | 80 (34.7) | 20 (34.7) | 0 (28.5) | 0 (28.5) | 0 (28.5) |
| Age | ||||||
| ≤18 | 32 | 53.1 (20.7) | 15.6 (16.2) | 12.5 (15.1) | 9.4 (13.9) | 9.4 (13.9) |
| 19–40 | 236 | 68.6 (7.7) | 5.5 (4) | 14 (5.8) | 5.1 (3.8) | 6.8 (4.3) |
| >40 | 160 | 78.8 (8.2) | 8.1 (5.7) | 5.6 (4.9) | 3.8 (4.2) | 3.8 (4.2) |
| Unlisted | 3 | 100 (34.4) | 0 (34.4) | 0 (34.4) | 0 (34.4) | 0 (34.4) |
| Role | ||||||
| Active boxer* | 154 | 58.4 (10.0) | 9.7 (6.3) | 18.8 (8) | 7.1 (5.5) | 5.8 (5.1) |
| Retired boxer | 113 | 77.9 (9.9) | 6.2 (6.2) | 7.1 (6.5) | 4.4 (5.5) | 4.4 (5.5) |
| Parent of boxer | 53 | 86.8 (12.0) | 5.7 (9.2) | 3.8 (8.2) | 1.9 (7.0) | 1.9 (7.0) |
| Coach | 169 | 74.6 (8.5) | 5.9 (4.9) | 7.7 (5.4) | 5.3 (4.7) | 6.5 (5.1) |
| Official | 44 | 77.3 (15.6) | 4.5 (9.6) | 9.1 (11.7) | 0 (6.6) | 9.1 (11.7) |
| Administrator | 41 | 82.9 (14.8) | 7.3 (11.4) | 4.9 (10.2) | 4.9 (10.2) | 0 (7.0) |
| Fan | 20 | 75 (22.5) | 5 (15.6) | 10 (18.0) | 5 (15.6) | 5 (15.6) |
| Other | 9 | 88.9 (26.3) | 0 (21.2) | 11.1 (26.3) | 0 (21.2) | 0 (21.2) |
| Southern zone | Middle zone | Northern zone | |||||
| Indication | Medicine name | Before | After | Before | After | Before | After |
| Malaria | ACTs | 53.80 | 7.70 | 33.30 | 0 | 40.00 | 0 |
| Asthma | Salbutamol | 25.00 | 7.70 | 26.70 | 6.20 | 0 | 20.00 |
| Diabetes | Gilbendamide | 38.50 | 30.80 | 20.00 | 18.80 | 60.00 | 60.00 |
| Cardiovascular disease | Atenolol | 58.30 | 23.10 | 20.00 | 25.00 | 40.00 | 40.00 |
| Depression | Amitriptyline | 58.30 | 38.50 | 33.30 | 50.00 | 60.00 | 60.00 |
| Infectious disease | Ciprofloxacin | 8.30 | 0 | 13.30 | 6.20 | 20.00 | 0 |
| Infectious disease | Co-trimoxazole | 25.00 | 7.70 | 6.00 | 6.20 | 0 | 0 |
| Infectious disease | Amoxiillin | 15.40 | 7.70 | 13.30 | 6.20 | 20.00 | 0 |
| Central nervous system disease | Diazepam | 15.40 | 7.70 | 13.30 | 6.20 | 20.00 | 50.00 |
| Ulcer | Omeprazole | 30.80 | 15.40 | 26.50 | 18.80 | 25.00 | 50.00 |
| Paper | # of patients | Types of mutations |
| Bartsch et al 1997 [7] | 1 | Translocation |
| Matsumoto et al 1997 [6] | 1 | Deletion |
| Møller et al 2008 [8] | 2 | 2 translocations |
| Fujita et al 2010 [9] | 1 | Deletion |
| Oegema et al 2010 [10] | 2 | 2 deletions |
| Yamamoto et al 2011 [11] | 3 | 3 deletions |
| van Bon et al 2011 [12] | 1 | Deletion |
| Valetto et al 2012 [13] | 1 | Deletion |
| Courcet et al 2012 [14] | 2 | 1 deletion, 1 frameshift |
| O’Roak et al 2012 [15] | 3 | 2 frameshifts, 1 splice site |
| Okamoto et al 2015 [27] | 1 | Nonsense |
| Redin et al 2014 [16] | 2 | 1 nonsense, 1 frameshift |
| Iglesias et al 2014 [17] | 1 | Nonsense |
| Ruaud et al 2015 [19] | 2 | 1 nonsense, 1 missense |
| van Bon et al 2015 [18] | 5 | 2 nonsense, 3 splice site |
| Bronicki et al 2015 [20] | 10 | 3 nonsense, 2 missense, 4 frameshift, 1 deletion |
| Ji et al 2015 [21] | 14 | 3 nonsense, 3 missense, 3 frameshift, 5 deletions |
| Name | Origin | Sex | C14 Date (calibrated) | Endogenous (%) | Unique (%) | MT and Y haplogroup | Mean autosomal coverage |
| L | Linton | Female | 360–50 BCE | 72 | 54 | H1e | 1.4 |
| HI1 | Hinxton | Male | 160 BCE–26 CE | 16 | 63 | K1a1b1b, R1b1a2a1a2c | 1.3 |
| HI2 | Hinxton | Male | 170 BCE–80 CE | 83 | 65 | H1ag1, R1b1a2a1a2c1 | 11.8 |
| O1 | Oakington | Female | 420–570 CE | 81 | 50 | U5a2a1 | 3.8 |
| O2 | Oakington | Female | 385–535 CE | 92 | 68 | H1g1 | 2.7 |
| O3 | Oakington | Female | 395–540 CE | 95 | 64 | T2a1a | 8.2 |
| O4 | Oakington | Female | 400–545 CE | 67 | 77 | H1at1 | 6.3 |
| HS1 | Hinxton | Female | 666–770 CE | 36 | 91 | H2a2b1 | 4.4 |
| HS2 | Hinxton | Female | 631–776 CE | 42 | 74 | K1a4a1a2b | 3.8 |
| HS3 | Hinxton | Female | 690–881 CE | 16 | 71 | H2a2a1 | 0.9 |
| Evaluation criteria | Medium range contacts | Long range contacts |
| Top L/5 | .34 (.18) | .30 (.05) |
| Top L/5, δ = 1 | .55 (.27) | .48 (.07) |
| Top L/5, δ = 2 | .64 (.29) | .56 (.08) |
| MRSA outbreaks | Number of days | Validity | |||||||||||
| TP | FP | FN | TN | Se | (95% CI) | Sp | (95% CI) | PPV | (95% CI) | NPV | (95% CI) | ||
| All | 10 | 27 | 39 | 722 | 20 | (10–34) | 96 | (95–98) | 27 | (16–42) | 95 | (92–96) | |
| Any hospital | 5 | 13 | 25 | 755 | 17 | (6–35) | 98 | (97–99) | 28 | (13–50) | 97 | (96–97) | |
| University hospital | 0 | 1 | 8 | 791 | 0 | 100 | (99–100) | 0 | 99 | (99–99) | |||
| General hospital | 5 | 12 | 17 | 764 | 23 | (8–45) | 98 | (97–99) | 29 | (14–52) | 98 | (97–98) | |
| Any hospital and unknown location | 6 | 12 | 33 | 747 | 15 | (6–31) | 98 | (97–99) | 33 | (17–56) | 96 | (95–96) | |
| University hospital and unknown location | 0 | 1 | 17 | 783 | 0 | 100 | (99–100) | 0 | 98 | (98–98) | |||
| General hospital and unknown location | 6 | 11 | 25 | 756 | 19 | (7–37) | 99 | (97–99) | 35 | (18–58) | 97 | (96–97) | |
| Nursing home | 1 | 15 | 6 | 778 | 13 | (0–53) | 98 | (97–99) | 6 | (1–31) | 99 | (99–99) | |
| Nursing home and unknown location | 2 | 14 | 14 | 770 | 13 | (2–38) | 98 | (97–99) | 13 | (3–37) | 98 | (98–99) | |
| Other location | 0 | 3 | 3 | 795 | 0 | 100 | (99–100) | 0 | 100 | (100–100) | |||
| Other location and unknown location | 0 | 3 | 12 | 786 | 0 | 100 | (99–100) | 0 | 99 | (98–99) |
| Mean fold change | Upper limit C.I | Lower limit C.I | ||
| AHPC | Overexpressed in virulent strains compared to the avirulent ATCC 33658 T | |||
| Transcription Ratio of AHPC in the virulent strains compared to ATCC 33658 T: | 5.80E + 01 | 1.38E + 02 | 2.17E + 01 | |
| ATP-F | Overexpressed under iron-deprived conditions | |||
| Transcription Ratio of the iron-poor cultures compared to the iron-rich ones: | 2.50E + 01 | 4.73E + 01 | 1.32E + 01 | |
| Enolase | Overexpressed under iron-deprived conditions | |||
| Transcription Ratio of the iron-poor cultures compared to the iron-rich ones: | 6.10E + 02 | 2.23E + 03 | 1.68E + 02 | |
| H-NS | Under-expressed under iron-deprived conditions | |||
| Transcription Ratio of the iron-rich cultures compared to the iron-poor ones: | 1.89E + 03 | 3.29E + 03 | 1.09E + 03 | |
| VapA | Overexpressed under iron-deprived conditions | |||
| Transcription Ratio of the iron-poor cultures compared to the iron-rich ones: | 3.65E + 01 | 5.14E + 01 | 2.64E + 01 |
| Years of formal education | Frequency (% out of n=43) | Frequency of Cognitive Dysfunction (%) | Frequency of normal Cognition (%) | Chi-square (x2) test | p-value |
| More than 12 years | 16 (37.2) | 8 (50.0) | 8 (50.0) | 2.563 | 0.11 (>0.05) |
| Less than 12 years | 27 (62.8) | 20 (74.1) | 7 (25.9) |
| Type/site of TB | HIV-TB group |
| PTB [n(%)] | 25 (20)* |
| EPTB [n(%)] | 98 (80) |
| DTB [n(%)] | 39 (32) |
| Lung + Pleura + mediastinal LN [n(%)] | 11 (9)* |
| Pleura + RP/mesenteric LN [n(%)] | 6 (5) |
| Lung + pleura [n(%)] | 4 (3) |
| Ascites + RP/mesenteric LN + mediastinal LN [n(%)] | 4 (3) |
| Ascites + hepatosplenomegaly + RP/mesenteric LN + mediastinal LN [n(%)] | 3 (2) |
| Lung + pleura + Ascites + RP/mesenteric LN [n(%)] | 3 (2) |
| Ascites + hepatosplenomegaly + mediastinal LN [n(%)] | 2 (2) |
| Lung + pleura + Ascites + hepatosplenomegaly + RP/mesenteric LN [n(%)] | 2 (2) |
| Lung + pleura + Ileocaecal + RP/mesenteric LN [n(%)] | 2 (2) |
| Cervical LN + mediastinal LN + RP/mesenteric LN [n(%)] | 2 (2) |
| Abdomen [n(%)] | 23 (19) |
| Ascites + RP/mesenteric LN [n(%)] | 8 (7) |
| Ascites + hepatosplenomegaly + RP/mesenteric LN [n(%)] | 7 (6) |
| Ascites + hepatosplenomegaly [n(%)] | 4 (3) |
| Ileocaecal + RP/mesenteric LN [n(%)] | 4 (3) |
| Lymph node [n(%)] | 16 (13) |
| Cervical [n(%)] | 10 (8)† |
| Abdominal [n(%)] | 4 (3) |
| RP + mesenteric LN | 2 (2) |
| RP LN | 1 (1) |
| Periportal + mesenteric LN | 1 (1) |
| Mediastinal [n(%)] | 2 (2) |
| Pleural effusion [n(%)] | 11 (9) |
| CNS [n(%)] | 6 (5) |
| Meningitis [n(%)] | 3 (2) |
| Tuberculoma [n(%)] | 2 (2) |
| Meningitis + Tuberculoma [n(%)] | 1 (1) |
| MTB [n(%)] | 2 (2) |
| Pott's spine [n(%)] | 1 (1) |
| Dataset type | Control dataset | Real sample dataset | ||||
| Dataset Name | D1 | D2 | D3 | D4 | D5 | D6 |
| Instrument | LCQ | LTQ | LTQ/FT | LCQ | LTQ | LTQ/FT |
| Reference or notes | [46] | [55] | unpublished | [44] | [56] | unpublished |
| Sample | 12 purified proteins + 23 peptides | 49 purified human proteins | 8 purified proteins | Human K562 cell line | Human liver | Human Liver |
| Data source | the BIATECH Institute (Bothell, WA 98011, USA) | Proteomics Standards Research Group (sPRG) [55] | Beijing proteome Research Center (Beijing 102206, China) | Open Proteomics Database (OPD)[57] | Beijing proteome Research Center (Beijing 102206, China) | Beijing proteome Research Center (Beijing 102206, China) |
| Group | N (Male/Female) | Maternal Age (Years) | Maternal BMI before Pregnancy | Gestational Age (Weeks) | Birth Weight (g) | Body Length (cm) | Ponderal Index (kg/m3) | Head Circumference (cm) | Placenta Weight (g) |
| NBW | 12 (6/6) | 31 ± 3 | 21.3 ± 2.2 | 39.1 ± 0.8 | 3452 ± 96 | 50.8 ± 1.1 | 26.2 ± 1.4 | 34.6 ± 0.8 | 701.2 ± 106.7 |
| LBW | 12 (6/6) | 31 ± 4 | 21.1 ± 2.9 | 38.9 ± 0.9 | 2623 ± 207 | 49.2 ± 4.6 | 23.2 ± 5.2 | 31.9 ± 1.6 | 492.8 ± 38.5 |
| p value | - | 0.76 | 0.82 | 0.58 | <0.01 ** | 0.34 | 0.02 * | 0.013 * | <0.01 ** |
| Result/PCR target positivity | Interpretation/meaning | Action |
| G3PD 567 bp (+) | Valid results for parasite diagnosis | Conclude diagnostic test observation |
| pUC 316 bp (+) | ||
| L. braziliensis 138 bp (+) | ||
| G3PD 567 bp (+) | Valid results for parasite diagnosis despite small loss of DNA in extraction | Conclude diagnostic test observation |
| pUC 316 bp (-) | ||
| L. braziliensis 138 bp (+) | ||
| G3PD 567 bp (-) | Valid results for parasite diagnosis despite small degradation of sample | Conclude diagnostic test observation |
| pUC 316 bp (+) | ||
| L. braziliensis 138 bp (+) | ||
| G3PD 567 bp (-) | Degradation of DNA sample/presence of PCR inhibitors and/or whole DNA loss during extraction | Repeat diagnostic procedure since the blood sample collection |
| pUC 316 bp (-) | ||
| L. braziliensis 138 bp (-) | ||
| G3PD 567 bp (-) | Degradation of DNA sample before extraction | Repeat diagnostic procedure since the blood sample collection |
| pUC 316 bp (+) | ||
| L. braziliensis 138 bp (-) | ||
| G3PD 567 bp (+) | Significant DNA loss (affecting mainly parasite genome) during extraction process | Repeat the DNA extraction procedure |
| pUC 316 bp (-) | ||
| L. braziliensis 138 bp (-) | ||
| G3PD 567 bp (+) | True negative result for Leishmania detection assured by the positivity of quality controls | Conclude diagnostic test observation |
| pUC 316 bp (+) | ||
| L. braziliensis 138 bp (-) |
| Microtiter plate [28] | Microtiter plate [29] | RISE [30] | |||
| Round 1 (h) | Round 1 (h) | Round 1 (h) | |||
| Target incubation | 18 | Target incubation | 2 | Target incubation | 18 |
| Wash-postcoat | 2.25 | Wash-postcoat | 1.5 | Wash-postcoat | 4 |
| Phage incubation | 1 | Phage incubation | 1 | Cell growth tubes | 3 |
| Wash-elution | 0.5 | Wash-elution | 2.25 | Infection | 3 |
| Infection | Infection | Wash | 0.5 | ||
| - amplification | 4.5 | - amplification | 5 | Cell/phage/target incubation | 16 |
| Phage recovery | 0.5 | Phage recovery | 18 | Phage recovery | 0.5 |
| Time | ~27 h | ~30 h | ~45 h | ||
| 2 additional panning rounds | 2 additional panning rounds | 3 additional panning rounds | |||
| TOTAL TIME | ~81 h | ~90 h | ~180 h |
| Group | ||||||||||
| Variables | G1: Nordic walking (N=8) | pa | G2: Water aerobics (N=8) | pa | G3: Non-exercising (N=8) | pa | pb | |||
| Baseline | Eight weeks | Baseline | Eight weeks | Baseline | Eight weeks | |||||
| RT right (s) | 39.1 ± 10.83 | 31.0 ± 10.45 | 0.04* | 32.3 ± 16.82 | 33.6 ± 15.10 | 0.11 | 25.3 ± 9.30 | 24.9 ± 9.03 | 0.40 | 0.08 |
| RT left (s) | 40.8 ± 5.68 | 32.1 ± 9.75 | 0.02* | 29.0 ± 11.01 | 31.5 ± 10.93 | 0.08 | 37.4 ± 7.93 | 37.0 ± 5.50 | 0.48 | 0.07 |
| VP right | 29.4 ± 6.44 | 36.1 ± 10.27 | 0.04* | 25.6 ± 10.34 | 31.1 ± 8.41 | 0.09 | 37.3 ± 12.06 | 38.9 ± 12.37 | 0.89 | 0.24 |
| VP left | 34.6 ± 9.10 | 39.0 ± 6.85 | 0.12 | 38.1 ± 15.13 | 35.0 ± 11.50 | 0.09 | 34.5 ± 8.96 | 33.3 ± 9.10 | 0.48 | 0.83 |
| Time Series | Germ layer | TP# | Switching# | Gene# | % | Non-Xover | % | Xover | % |
| Cerebellar development | Ectoderm | 12 | 48,489 | 5433 | 21.6 | 38,722 | 79.9 | 9767 | 20.1 |
| Human iPS to neuron (wt) 1 | Ectoderm | 4 | 45,069 | 6692 | 26.5 | 41,302 | 91.6 | 3767 | 8.4 |
| Trachea epithelia differentiation | Endoderm | 19 | 8389 | 2458 | 9.8 | 6112 | 72.9 | 2277 | 27.1 |
| Adipocyte differentiation | Mesoderm | 16 | 66,087 | 5996 | 23.8 | 57,857 | 87.5 | 8230 | 12.5 |
| Epithelial to mesenchymal | Mesoderm | 21 | 132,661 | 7004 | 27.8 | 109,252 | 82.4 | 23,409 | 17.6 |
| BMM TB activation IL13 | Mesoderm | 11 | 825 | 527 | 2.1 | 564 | 68.4 | 261 | 31.6 |
| AoSMC response to IL1b | Mesoderm | 10 | 192 | 159 | 0.6 | 129 | 67.2 | 63 | 32.8 |
| Macrophage response to LPS | Mesoderm | 23 | 32,234 | 4557 | 18.1 | 22,239 | 69.0 | 9995 | 31.0 |
| ES to cardiomyocyte | Mesoderm | 13 | 189 | 163 | 0.6 | 100 | 52.9 | 89 | 47.1 |
| Myoblast to myotube | Mesoderm | 9 | 21,912 | 4249 | 16.9 | 18,735 | 85.5 | 3177 | 14.5 |
| Variable | Univariate analysis | Multivariate analysis | ||||
| Hazard ratio | Confidence interval | p-value | Hazard ratio | Confidence interval | p-value | |
| NKp30, C1D1, LFS | 0.24 | 0.099–0.61 | 0.002 | 0.14 | 0.043–0.43 | 0.001 |
| NKp30, C1D1, OS | 0.28 | 0.088–0.91 | 0.034 | 0.17 | 0.037–0.78 | 0.022 |
| NKp46, C1D21, LFS | 0.25 | 0.10–0.59 | 0.001 | 0.28 | 0.093–0.82 | 0.020 |
| NKp46, C1D21, OS | 0.21 | 0.067–0.66 | 0.007 | 0.22 | 0.047–1.05 | 0.058 |
| Number | Data Source | Age/years | Professional background |
| 1 | Focus group | 53 | Bereavement counselor |
| 2 | Focus group | 39 | Communication consultant |
| 3 | Focus group | 46 | Director & Trainer PR Company |
| 4 | Focus group | 50 | Dietician |
| 5 | Focus group | 47 | Fitness trainer |
| 6 | Focus group | 36 | General practitioner |
| 7 | Focus group | 45 | Social worker |
| 8 | Assignment | 55 | Facilitator in development sector |
| 9 | Assignment | 55 | Physiotherapist |
| 10 | Assignment | 69 | Counselor |
| 11 | Assignment | 39 | Communication consultant |
| 12 | Assignment | 61 | Nurse practitioner/Health coach |
| 13 | Assignment | 55 | Executive coach |
| 14 | Assignment | 44 | Clinical psychologist |
| 15 | Assignment | 36 | General practitioner |
| 16 | Assignment | 54 | General practitioner |
| 17 | Assignment | 42 | Social Worker |
| Characteristic | Training set | Testing set | Total |
| Age | |||
| Median | 59 | 58 | 59 |
| Range | 38∼85 | 30∼87 | 30∼87 |
| Clinical stage | |||
| Stage I | 0 | 0 | 0 |
| Stage II | 8 | 13 | 21 |
| Stage III | 163 | 158 | 321 |
| Stage IV | 31 | 31 | 62 |
| Vital status | |||
| Living | 91 | 88 | 179 |
| Dead | 112 | 116 | 228 |
| All cases (n) | Fatality (n) | CFR(95%CI) (%) | RSE (%) | |
| Pre-intervention period | ||||
| (Eclampsia patients) | 1233 | 258 | 20.9(18.7, 23.2) | 5.5 |
| Intervention period | ||||
| (Eclampsia patients) | 996 | 23 | 2.3(1.4, 3.2) | 20.9 |
| Certified Reference Materials | DON Immunosensor (ppm) | ELISA (ppm) | Vendor (ppm) |
| Wheat | 0.3 | 0.2 | 0.71 |
| Corn | 0.92 | 1.1 | 1.88 |
| Roasted coffee | 0.19 | 0.24 | 0.77 |
| Genetic comparison | Overall and subgroup analysis | No. of studies | Heterogeneity | Model | Meta-analysis | ||
| p | I2(%) | OR(95%CI) | p | ||||
| T vs. C | Overall | 8 | 0.78 | 0.00 | Fixed | 0.92(0.81-1.12) | 0.57 |
| AgP | 3 | 0.52 | 0.00 | Fixed | 0.92(0.71-1.20) | 0.55 | |
| CP | 5 | 0.63 | 0.00 | Fixed | 0.97(0.80-1.19) | 0.79 | |
| Asian | 5 | 0.68 | 0.00 | Fixed | 0.97(0.80-1.16) | 0.71 | |
| Jordanian | 2 | 0.31 | 3.82 | Fixed | 0.85(0.59-1.23) | 0.40 | |
| Italian | 1 | 1.00 | 0.00 | Fixed | 1.11(0.64-1.92) | 0.70 | |
| Mixed | 3 | 0.34 | 8.52 | Fixed | 0.98(0.76-1.28) | 0.90 | |
| None | 4 | 0.72 | 0.00 | Fixed | 0.91(0.74-1.13) | 0.42 | |
| TT vs. CC | Overall | 6 | 0.33 | 13.32 | Fixed | 1.22(0.80-1.87) | 0.36 |
| AgP | 2 | 0.50 | 0.00 | Fixed | 1.74(0.88-3.45) | 0.11 | |
| CP | 4 | 0.31 | 17.10 | Fixed | 0.98(0.57-1.68) | 0.93 | |
| Asian | 4 | 0.72 | 0.00 | Fixed | 0.84(0.48-1.45) | 0.52 | |
| Jordanian | 2 | 0.95 | 0.00 | Fixed | 2.10(1.09-4.07) | 0.03 | |
| Mixed | 3 | 0.15 | 47.51 | Fixed | 1.39(0.83-2.31) | 0.21 | |
| None | 3 | 0.55 | 0.00 | Fixed | 0.92(0.43-1.97) | 0.84 | |
| CT vs. CC | Overall | 6 | 0.80 | 0.00 | Fixed | 0.92(0.69-1.23) | 0.58 |
| AgP | 2 | 0.33 | 0.00 | Fixed | 0.74(0.46-1.20) | 0.22 | |
| CP | 4 | 0.98 | 0.00 | Fixed | 1.05(0.72-1.52) | 0.80 | |
| Asian | 4 | 0.56 | 0.00 | Fixed | 0.87(0.60-1.28) | 0.49 | |
| Jordanian | 2 | 0.72 | 0.00 | Fixed | 0.99(0.63-1.55) | 0.96 | |
| Mixed | 3 | 0.93 | 0.00 | Fixed | 1.00(0.69-1.45) | 1.00 | |
| None | 3 | 0.43 | 0.00 | Fixed | 0.81(0.50-1.29) | 0.37 | |
| TT vs. (CC+CT) | Overall | 6 | 0.15 | 38.91 | Fixed | 1.19(0.81-1.74) | 0.37 |
| AgP | 2 | 0.67 | 0.00 | Fixed | 1.98(1.04-3.80) | 0.04 | |
| CP | 4 | 0.22 | 32.14 | Fixed | 0.92(0.57-1.46) | 0.71 | |
| Asian | 4 | 0.41 | 0.00 | Fixed | 0.84(0.52-1.36) | 0.49 | |
| Jordanian | 2 | 0.84 | 0.00 | Fixed | 2.11(1.14-3.91) | 0.02 | |
| Mixed | 3 | 0.06 | 63.53 | Random | 1.40(0.66-2.99) | 0.38 | |
| None | 3 | 0.29 | 18.41 | Fixed | 1.02(0.49-2.10) | 0.96 | |
| (TT+CT) vs. CC | Overall | 6 | 0.04 | 57.80 | Random | 0.66(0.44-1.01) | 0.06 |
| AgP | 2 | 0.27 | 18.76 | Fixed | 0.45(0.30-0.68) | <0.01 | |
| CP | 4 | 0.16 | 41.19 | Fixed | 0.86(0.60-1.22) | 0.39 | |
| Asian | 4 | 0.09 | 54.35 | Random | 0.59(0.34-1.01) | 0.05 | |
| Jordanian | 2 | 0.05 | 72.43 | Random | 0.82(0.37-1.81) | 0.62 | |
| Mixed | 3 | 0.14 | 49.45 | Fixed | 0.83(0.59-1.18) | 0.30 | |
| None | 3 | 0.21 | 35.43 | Fixed | 0.45(0.29-0.69) | <0.01 |
| Confidence ratings at end of module (N≥294) | Confidence ratings 3–6 Months after completion (N≥106) | |||
| Mean1 | %2 | Mean1 | %2 | |
| Respondent’s Confidence in his or her ability to: | ||||
| (a) diagnose depression | 1.23 | 99.7 | 1.19 | 100 |
| (b) screen for addictions | 1.74 | 92.4 | 1.67 | 94.5 |
| (c) screen for other mental health conditions | 1.83 | 91.8 | 1.73 | 96.3 |
| (d) treat depression | 1.43 | 99.0 | 1.28 | 100 |
| (e) treat other mental health disorders | 1.99 | 85.2 | 1.93 | 87.2 |
| (f) prescribe medications for mental health conditions | 1.67 | 95.0 | 1.61 | 95.5 |
| (g) assess patients’ problems and strengths | 1.79 | 91.0 | 1.66 | 92.7 |
| (h) develop systematized care plans for patients where a mental health care plan is not appropriate | 2.07 | 77.5 | 1.86 | 84.0 |
| (i) create a mental health care plan fitting Medical Service Plan [provincial program] guidelines | 1.87 | 83.4 | 1.69 | 89.8 |
| (j) engage mental health patients in a range of interventions (e.g., cognitive behavioural and interpersonal skills training) | 1.97 | 81.4 | 1.90 | 82.6 |
| (k) offer and coach the Antidepressant Skills Workbook | 1.95 | 80.2 | 1.83 | 85.0 |
| (l) offer and support the Bounce Back program | 1.54 | 92.1 | 1.56 | 91.7 |
| (m) In general, how confident are you in the quality of mental health care you provide to your patients? | 1.71 | 96.3 | 1.46 | 99.1 |
| Respondent’s confidence in her or his knowledge/awareness of: | ||||
| (a) non-pharmacological interventions (cognitive behavioral skills such as activation, relaxation, negative thinking) | 1.90 | 86.8 | 1.76 | 91.7 |
| (b) regional mental health resources for mental health patients | 2.05 | 82.8 | 1.87 | 88.1 |
| Reaction | Genes | Primer names | Forward primer sequence | Reverse primer sequence | Size (bp) |
| hsp60 (groEL_1) | hsp3/hsp4 | GACCGCCAGTTAAGATAGCG | TCTCTAGCTACTTCGCAACAAATCC | 297 | |
| 1 | CTL0626 | CTL06265'F/CTL06265'R | GCACACCATCACTATCAC | GCGCTTGCTTGAGATTTC | 226 |
| 2 | CTL0627 | CTL06275'F/CTL06275'R | GTTGGCGAGTCCGATGATG | GACTTCTAATACAGCACCATGTTTG | 195 |
| 3 | CTL0628 | CTL06285'F/CTL06285'R | GAAACGGTCTCCTACTAGC | GGTGGGAAGAAATAGTTAAGG | 357 |
| Impact factors | P-value | Impact factors | P-value |
| Epidemiologic information | Chemotherapy detail | ||
| Age at diagnosis | 0.335 | PEB/PVB | 0.043 |
| Ethnic group | 0.856 | Bleomycin/pingyangmycin | 0.755 |
| Individual history | Weekly/monthly | 0.031 | |
| Prior lung disease | 1.000 | Route of administration | 0.041 |
| Allergic history | 0.603 | Cumulative dose | 0.000 |
| Disease state | Average course interval | 0.256 | |
| Stage of disease | 0.081 | Combined treatment | |
| Histological subtype | 0.741 | G-CSF | 0.331 |
| Side effects of treatment | Antibiotics | 0.904 | |
| Renal dysfunction | 0.001 | Blood transfusion | - |
| Drug allergy | 0.332 | Erythrocyte | 0.116 |
| Granulopenia | 0.176 | Thrombocyte | 0.035 |
| Anemia | 0.041 | Chalybeate | 0.067 |
| Thrombocytopenia | 0.000 | Post-chemotherapy surgery | 0.072 |
| >Stage of development | >WT versus AS | >WT versus OE |
| Immature green | 234 | 333 |
| Mature green | 68 | 112 |
| Red ripe | 105 | 332 |
| Total | 407 | 777 |
| All digital ulcers | Fingertip digital ulcers | Extensor digital ulcers | |||||||
| GTN | PBO | Comparison | GTN | PBO | Comparison | GTN | PBO | Comparison | |
| DUCore | |||||||||
| AUC (arbitrary perfusion units) | 26,245.42 (19,829.5) | 23,973.97 (18,607.44) | 1.2 (1.0 to 1.6) | 18,453.6 (10,721.8) | 16,506.8 (12,498.3) | 1.3 (0.7 to 2.2) | 32,924.1 (24,038.9) | 29,574.3 (21,161.2) | 1.2 (1.0 to 1.6) |
| Peak perfusion/baseline perfusion (ratio) | 2.5 (1.4) | 1.9 (0.9) | 1.2 (1.0 to 1.5) | 2.7 (1.7) | 2.1 (0.8) | 1.2 (0.8 to 1.9) | 2.3 (1.2) | 1.8 (1.0) | 1.2 (1.0 to 1.6) |
| DUPeriphery | |||||||||
| AUC (arbitrary perfusion units) | 62,025.2 (41,910.7) | 52,185.4 (33,734.3) | 1.1 (0.8 to 1.6) | 51,939.1 (42,923.2) | 49,019.0 (32,584.1) | 0.9 (0.4 to 2.0) | 70,670.4 (42,293.6) | 54,560.3 (36,606.2) | 1.4 (1.1 to 1.7) |
| Peak perfusion/baseline perfusion (ratio) | 2.2 (1.5) | 2.1 (1.4) | 1.0 (0.9 to 1.2) | 2.4 (2.2) | 2.5 (2.1) | 0.9 (0.7 to 1.2) | 2.0 (0.7) | 1.8 (0.8) | 1.1 (1.0 to 1.4) |
| No. | shRNA Targets of RB1 |
| siRNA-RB1-2 | GGGUUGUGUCGAAAUUGGATT |
| siRNA-RB1-4 | GGAGUAUGAUUCUAUUAUATT |
| Negative control siRNA (NC siRNA) | UUCUCCGAACGUGUCACGUTT |
| Module I: Basic concepts in global health | |
| 01. | Defining and measuring global health |
| 02. | Global health definitions, case studies |
| 03. | Historical origin and evolution |
| 04. | Health systems and global health |
| Module II: Understanding the key global health challenges | |
| 01. | Current global health status |
| 02. | Global burden of disease |
| 03. | Global health priorities for twenty-first century |
| 04. | Global health at the human–animal–ecosystem interface |
| Module III: Cross-cutting themes in global health and emerging trends | |
| 01. | Environment, climate, and migration |
| 02. | Food, water, and sanitation |
| 03. | Health disparities |
| 04. | Women’s health |
| 05. | Emerging, remerging infectious diseases |
| 06. | NCD and injuries |
| 07. | Maternal and child health |
| 08. | Childhood immunization |
| 09. | Adolescent health |
| 10. | Neglected tropical diseases |
| 11. | Antimicrobial resistance |
| Module IV: Global health diplomacy | |
| 01. | Overview of global health diplomacy |
| 02. | Global health actors and activities |
| 03. | Global health financing |
| 04. | Global health policy and governance |
| 05. | Drivers of policy for global health diplomacy |
| 06. | Globalization, trade, work, and health |
| 07. | Foreign policy and health |
| Module V: Global health security | |
| 01. | Global health security |
| 02. | Pandemics and health security responses |
| 03. | Health in complex humanitarian emergencies |
| 04. | Humanitarian response and humanitarian dilemmas |
| 05. | Global health equity |
| 06. | Values in global health |
| 07. | Toward a social justice approach to global health |
| Module VI: Research, development, innovation, and technology for global health | |
| 01. | The environment, sustainable development, and health |
| 02. | Universal health coverage in the context of aging |
| 03. | Sustaining good health with equity at low cost |
| 04. | Science and technology for global health |
| 05. | Scaling up effective models in global health delivery |
| Questions | Partners | Regenstrief | Intermountain Health Care | Veterans' Health Administration |
| CIS modules offered (products that have capability to provide decision support)? | Yes, CPOE, results review, laboratory, outpatient clinical documentation, eMAR, Drug-Drug/Allergy/Lab Interaction checking. BCMA | Yes, CPOE, consults from specialists. Documentation: patient visit notes, ADT summaries, problem lists. Links to test results, notes | Yes, Antibiotic, TPN; Results review; RN, RT, Pharmacist charting; Infection & Disease monitoring, ADR triggers, VTE high risk alerts | Yes, Order menus, sets, quick orders. documentation. Templates. Drug-Drug/Allergy/Lab Interaction checking. BCMA |
| EHR delivery model? | Onsite | Onsite | Onsite (Server and web based) | Onsite (move to regional server) |
| CDS content implemented/configured/maintained by customer or vendor? | maintained by informaticians. Most content separate from code viewed thru repository | Clinician/Informaticians update terminology and decision support rules as needed | Users responsible for content. Programmers logic. Updated weekly, larger updates quarterly | CDS maintained, implemented locally. National releases with local configuration. |
| Collect structured data and which controlled vocabularies? | LOINC, RxNorm, SNOMED, ICD-9, CPT, FDB | ICD-9 & CPT codes avail. Most entered via Regenstrief Dict. mapped to standard vocabs. | Mostly coded data, some dictated notes as free text. LOINC, SNOMED, ICD-9 | Not from clinician notes, but reminder templates do. ICD-9 for problem list |
| Support ad-hoc queries? Live replicating database? | Yes. Yes, weekly to monthly depending on data element | Queries done by data analysts on real database, in response to requests from end users. | Yes, but most reports run on EDW from programmers. Have some canned reports monthly | Yes, use replicated DB, varied update frequency; ProClarity data cubes |
| HL7 InfoButton? | Yes | No | Yes | No, but something similar |
| Arden Syntax for MLM? | No | No. Gopher Care Rules corresponds to Arden Syntax. | No (some graduate projects) | No |
| Clinical knowledge editor for user to create CDS? | Yes | Editor used by infomaticians to create CDS | Ability for knowledgeable users to create CDS | Not by end user. Some local configuration by support staff |
| Content mgmt system separate from EHR? | Yes | No | Online K repository, most review/updates programmers | No. Pilots are ongoing. |
| Reporting capability to track effect/usage of CDS content? | Yes | User responses prospectively, not retrospective | Yes, from reports in the EDW | Yes, focused on performance measures not CDS usage |
| Drug database supplier? | FDB | In-house drug terms | FDB | Internal Drug/Allergy files |
| 3rd party CDS content vendors? | Thompson Micromedex, UpToDate | No | MicroMedex through Info-buttons | MicroMedex, UpToDate, etc. at point of care |
| Provide clinical content (starter sets). What content is included, how and how often and is it updated? | CDS content provided and maintained by the Informatics groups. Updates distributed on an as needed basis. | Alerts, drug-drug. Formulary, price. Order sets. Default drug strengths, frequencies, or instructions. updates mult/yr. | All alert logic is provided, developed, and maintained by institution. weekly and quarterly updates | Local development of reminders, order menus, document templates. |
| On-line collaborative knowledge development environment web 2.0? | Yes | No | No | Yes, starting SharePoint sites for national groups |
| Internet repository for clients to share locally generated CDS? | No | No | No | Some networks have web sites to share CDS |
| NZ | BL | SY | BK | WL† | EB† | |
| NZ | - | 0.030 | 0.074 | 0.096 | ||
| BL | 0.014 | - | 0.038 | 0.030 | 0.061 | 0.104 |
| SY | 0.042 | 0.053 | - | 0.099 | 0.105 | |
| BK | 0.038 | 0.070 | 0.033 | - | 0.096 | 0.111 |
| WL† | 0.048 | 0.047 | 0.079 | 0.080 | - | 0.033 |
| EB† | 0.078 | 0.105 | 0.067 | 0.057 | 0.054 | - |
| H3K27me3 | P value | |||
| Low | High | Total | ||
| pS9-GSK3β | ||||
| Low | 13 | 10 | 23 | |
| High | 23 | 64 | 87 | |
| Total | 36 | 74 | 110 | |
| 0.006 |
| AS Genome | AM Genome | ||||
| Chromosome | Length, bp | Change (SNPs) | Change Rate | Change (SNPs) | Change Rate |
| 1 | 66,776,104 | 391 | 170,783 | 404 | 165,287 |
| 2 | 44,510,304 | 258 | 172,521 | 250 | 178,041 |
| 3 | 48,258,781 | 208 | 232,013 | 204 | 236,563 |
| 4 | 43,347,107 | 176 | 246,290 | 195 | 222,293 |
| 5 | 37,320,184 | 190 | 196,422 | 200 | 186,601 |
| 6 | 28,216,978 | 76 | 371,276 | 86 | 328,104 |
| Unmapped | 32,912,371 | 148 | 222,381 | 151 | 217,963 |
| Total | 301,341,829 | 1447 | 208,253 | 1490 | 202,243 |
| Model 1 | Model 2 | Model 3 | |
| Waist Circumference (abnormal versus normal) | 1.697 (1.305–2.207) | 1.712 (1.308–2.242) | 1.40 (1.02–1.91) |
| Body Mass Index (abnormal versus normal) | 1.901 (1.347–2.680) | 1.941 (1.367–2.754) | — |
| % Body Fat (abnormal versus normal) | 1.398 (1.044–1.872) | 1.436 (1.068–1.930) | 1.24 (0.90–1.71) |
| Muscle Mass Index (abnormal versus normal) | 1.113 (0.788–1.572) | 1.190 (0.836–1.692) | 1.42 (0.90–2.07) |
| Humans and Great Apes | All other mammals e.g. mouse | Peptide abbreviation | Gene name |
| Relaxin-1 | Relaxin# | RLX1 | RLN1 |
| Relaxin-2# | RLX2 | RLN2 | |
| Relaxin-3 | Relaxin-3 | RLX3 | RLN3 |
| Identifier | Best Arabidopsis match | Possible function | Position (kb) | Gene ID |
| C2H2 TF | AT3G18290 | RING finger and CHY zinc finger encoding BRUTUS (BTS), E3 ligase protein with metal ion binding and DNA binding domains, which negatively regulates the response to iron deficiency | 1,000 | MDP0000283750 |
| C2H2 TF | AT1G68360 | C2H2 and C2HC zinc finger family | 1,020 | MPD0000183099 |
| MdMYB7 | AT1G68320 | MYB involved in regulation of phosphate starvation responses and gibberellic acid biosynthesis. | 1,070 | MDP0000659260 |
| bHLH | AT1G25330 | bHLH75, BR enhanced | 1,080 | MDP0000725991 |
| COL | AT1G68520 | Contans-like light regulation of secondary metabolites | 1,220 | MDP0000185616 |
| bZIP | AT1G68640 | HBP-1b(c1), BZIP - PAN is essential for AG activation in early flowering | 1,380 | MDP0000250967 |
| MdG2L6 | AT1G25550 | Golden-like ARR18 MYB-related | 1,440 | MDP0000202657 |
| MdAP2D36 TF | AT1G68840 | Regulator of vac ATPase Rav2 is part of a complex that has been named 'regulator of the (H+)-ATPase of the vacuolar and endosomal membranes' (RAVE) | 1,480 | MDP0000939633 |
| LAR1 | MdLAR1 | 1,540 | MDP0000376284 | |
| bHLH | AT1G68810 | Known bHLH, no other function | 1,550 | MDP0000319726 |
| bHLH | AT1G68920 | bHLH49 Known bHLH, no other function | 1,890 | MDP0000154272 |
| MdbHLH21 | AT1G69010 | BES1-INTERACTING MYC-LIKE PROTEIN 2 | 1,970 | MDP0000149222 |
| PCI | No PCI | ||||||
| Study | Events | Total | Incidence (%) | Events | Total | Incidence (%) | Weight (%) |
| VALG | 7 | 136 | 5.1 | 16 | 145 | 11.0 | 10.5 |
| MDACC | 2 | 46 | 4.3 | 14 | 51 | 27.5 | 9.0 |
| RTOG 8403 | 8 | 93 | 8.6 | 18 | 94 | 19.1 | 12.2 |
| SWOG | 1 | 111 | 0.9 | 13 | 115 | 11.3 | 8.7 |
| RTOG 0214 | 13 | 163 | 8.0 | 32 | 177 | 18.1 | 20.9 |
| Li | 10 | 81 | 12.3 | 29 | 75 | 38.7 | 20.5 |
| NVALT-11 | 7 | 87 | 8.0 | 27 | 88 | 30.7 | 18.3 |
| Total | 48 | 717 | 149 | 745 |
| Placebo(n = 62) | 30 mg/d LDX(n = 119) | 50 mg/d LDX(n = 116) | 70 mg/d LDX(n = 121) | All LDX Doses(n = 356) | |
| Baseline[Mean (SD)] | 6.9(1.34) | 7.4(1.69) | 7.4(1.51) | 7.2(1.42) | 7.3(1.54) |
| Endpoint[Mean (SD)] | 7.0(1.33) | 7.2(1.21) | 7.0(1.44) | 7.0(1.61) | 7.1(1.43) |
| Change[LS Mean (SE)] | -0.1(0.15) | -0.1(0.11) | -0.3(0.11) | -0.2(0.11) | -0.2(0.07) |
| Week | Weekly theme |
| 1 | Introduction and briefing on the aims of the rehabilitation program• Introduction to group• Introduction of the concept of self-efficacy• Information on post-stroke balance self-efficacy and rehabilitation |
| 2 | Understanding the relationships between thoughts, emotions, and behavior• Introduction to the CBT model• Understanding fear, fear of falling, fall risks, and actual falls• Understanding the automatic thoughts and emotional and behavioral reflection associated with fear of falling |
| 3 | Exploring thoughts and maladaptive responses• Identifying maladaptive thoughts leading to physical inactivity• Adapting realistic views of fall risk and the consequences of falls• Recognizing risky behavior• Overcoming barriers to physical activity |
| 4 | Exploring adaptive thoughts and behavioral responses• Fall prevention strategies and safety issues• Recognizing and minimizing fall risk |
| 5 | Implementing and reviewing behavioral changes related to ADL• Setting personal goals for ADL• Planning to achieve personal goals in small stages• Recognizing potential hazards and planning for safety |
| 6 | Implementing and reviewing behavioral changes related to social activities• Setting personal goals for social activities• Planning to achieve personal goals in small stages• Recognizing potential hazards and planning for safety |
| 7 | Reviewing and advancing individual therapeutic goals• Reviewing personal goals for ADL and social activities• Establishing a regular exercise plan |
| 8 | Consolidating the experiences of the rehabilitation program• Sharing attitudes and experiences of fear of falling before and after the group• Sharing experiences of applying cognitive-restructuring skills• Establishing the long-term personal goals of regular exercise, ADL independence, and social engagement |
| Athletes | Controls | P‐values | |
| Baseline characteristics | |||
| n | 19 | 8 | |
| Age (year) | 26 ± 5 | 31 ± 4 | 0.07 |
| Height (m) | 1.77 ± 0.08 | 1.80 ± 0.10 | 0.47 |
| Body mass (kg) | 72.6 ± 9.5 | 84.1 ± 12.2 | 0.02 |
| Body mass index (kg/m2) | 23 ± 2 | 26 ± 3 | 0.01 |
| Maximal oxygen uptake (mL/kg·min−1) | 55.9 ± 4.9 | 39.2 ± 5.0 | <0.001 |
| Resting values | |||
| n | 19 | 8 | |
| Heart rate (bpm) | 54 ± 8 | 58 ± 5 | 0.20 |
| Mean arterial pressure (mmHg) | 73 ± 10 | 74 ± 10 | 0.92 |
| Middle cerebral artery mean blood velocity (cm/sec) | 63.9 ± 11.7 | 65.5 ± 14.8 | 0.75 |
| Cerebrovascular conductance index (cm sec−1 mmHg−1) | 0.88 ± 0.14 | 0.91 ± 0.23 | 0.72 |
| Healthy (n = 18) | Post-OP (n = 28) | Sepsis (n = 15) | |
| IL-6 (pg/ml) | 0.0; 0.0–0.8 | 216.7; 48.8–360.5 | 577.7; 521.9–583.2 |
| P-value | Healthy versus Post-OP: P < .001*** | ||
| Healthy versus Sepsis: P < .001*** | |||
| Post-OP versus Sepsis: P <.001*** | |||
| TRX1 (ng/ml) | 11.0; 10.0–12.1 | 11.3; 9.6–15.6 | 34.0; 19.7–57.7 |
| P-value | Healthy versus Post-OP: P = .458 | ||
| Healthy versus Sepsis: P < .001*** | |||
| Post-OP versus Sepsis: P <.001*** | |||
| MIF (pg/ml) | 161.6; 148.5–214.0 | 156.4; 115.1–398.7 | 1821.1; 412.2–3708 |
| P-value | Healthy versus Post-OP: P = .954 | ||
| Healthy versus Sepsis: P = .005** | |||
| Post-OP versus Sepsis: P < .001*** |
| No. | Age | Sex | AQP1/4 tissue | Brief history | Probable cause/ |
| (years) | immunoreactivity* | underlying cause of | |||
| CPM | |||||
| 1 | 56 | M | 0 | Alcoholism; nausea and vomiting 1 week; hyponatremia, abnormal liver function tests; presented to Emergency Room in cardiorespiratory arrest. | Rapid correction of hyponatremia |
| 2 | 53 | M | 0 | Depression and chronic obstructive pulmonary disease. Not seen for 4 days; found dehydrated and malnourished; drug and alcohol screen negative. | Dehydration, malnutrition and hypernatremia |
| 3 | 33 | M | 0 | Cryptogenic cirrhosis with antitrypsin heterozygosity; orthotopic liver transplant and hyponatremia followed by progressive obtundation and seizures. | Orthotopic liver transplant |
| 4 | 45 | M | 0 | Small-cell lung carcinoma, metastatic to liver; abnormal liver function tests; possible malnutrition; hyperkalemia; several syncopal episodes in preceding hours; presented with respiratory failure. | SIAD secondary to small-cell lung carcinoma |
| 5 | 24 | F | ↑ | Hepatic failure and autoimmune thrombocytopenic purpura, 6 months; altered consciousness level and nonconvulsive status epilepticus 5 weeks before death; hypocalcemia, hyperammonemia and elevated liver enzymes. | Hepatic failure and hypocalcemia |
| 6 | 68 | F | ↑ | Hypertension, obesity, diabetes mellitus, hyperuricemia and remote endometrial carcinoma (treated by resection, chemotherapy, and radiotherapy); presented with gangrene of the right fifth toe; generalized seizure followed by unresponsiveness. | Diabetes mellitus type II |
| Health risk behavior | Men | Women | ||
| N | (%) | N | (%) | |
| Current smoking | 10784 | (57.3) | 3099 | (15.6) |
| Excess alcohol consumption | 5177 | (27.4) | 1155 | (5.8) |
| Physical inactivity | 13989 | (71.2) | 14926 | (72.0) |
| Poor dietary habits | 7974 | (40.6) | 5671 | (27.4) |
| Stress | 9639 | (51.9) | 12151 | (61.3) |
| Non-attendance of health check-ups | 5243 | (27.5) | 8532 | (42.3) |
| Time-dependent Burden | Emotional Burden | Exisitential Burden | Physical Burden | Service-related Burden | Total Care Burden | BIC Total | |
| SF-8 | |||||||
| PF (Physical Functioning) | -0.36 | -0.35 | -0.40 | -0.52 | -0.26 | -0.44 | -0.52 |
| p-value | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 0.0001 |
| RP (Role functioning Physical) | -0.47 | -0.48 | -0.49 | -0.57 | -0.28 | -0.56 | -0.65 |
| p-value | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 0.0001 |
| BP (Bodily Pain) | -0.41 | -0.38 | -0.40 | -0.64 | -0.26 | -0.44 | -0.56 |
| p-value | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 0.0001 |
| GH (General Health perceptions) | -0.39 | -0.40 | -0.40 | -0.56 | -0.27 | -0.46 | -0.59 |
| p-value | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 0.0001 |
| VT (Vitality) | -0.35 | -0.41 | -0.41 | -0.50 | -0.26 | -0.41 | -0.47 |
| p-value | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 0.0001 |
| SF (Social Functioning) | -0.59 | -0.48 | -0.49 | -0.54 | -0.31 | -0.57 | -0.62 |
| p-value | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 0.0001 |
| RE (Role functional Emotional) | -0.52 | -0.50 | -0.51 | -0.55 | -0.25 | -0.58 | -0.60 |
| p-value | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 0.0001 |
| MH (Mental Health) | -0.55 | -0.58 | -0.55 | -0.55 | -0.29 | -0.59 | -0.64 |
| p-value | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 0.0001 |
| CES-D | 0.49 | 0.54 | 0.53 | 0.48 | 0.32 | 0.51 | 0.62 |
| p-value | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 0.0001 |
| ZBI | 0.76 | 0.72 | 0.70 | 0.68 | 0.38 | 0.80 | 0.84 |
| p-value | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 0.0001 |
| Controls (n = 1846) | Cases (n = 695) | p-Value 2 | |
| Age (years), mean (SD) | 56.1 (9.1) | 56.4 (9.6) | 0.44 |
| Female, n (%) | 596 (32.3) | 222(31.9) | 0.87 |
| Family history of colorectal cancer (yes) 1, n (%) | 99 (5.4) | 58 (8.4) | 0.006 |
| BMI, n (%) | |||
| <25 kg/m2 | 1225 (66.4) | 476 (68.5) | 0.31 |
| ≥25 kg/m2 | 621 (33.6) | 219 (31.5) | |
| Educational level, n (%) | |||
| <12 years | 282 (15.6) | 252 (36.3) | <0.001 |
| ≥12 years | 1521 (84.4) | 443 (63.7) | |
| Smoking status, n (%) | |||
| Never | 818 (44.3) | 315 (45.3) | 0.65 |
| Ever | 1028 (55.7) | 380 (54.7)) | |
| Alcohol consumption, n (%) | |||
| Never | 560 (30.3) | 210 (30.2) | 0.95 |
| Ever | 1286 (69.7) | 485 (69.8) | |
| Regular exercise (yes), n (%) | 1048 (58.2) | 226 (32.5) | <0.001 |
| Total caloric intake (kcal/day), mean (SD) | 1689.9 (560.4) | 2018.7 (529.7) | <0.001 |
| CRP (ng/mL), median (IQR) | 101.5 (48.3, 217.3) | 212.6 (88.4, 614.7) | <0.001 |
| Microaerobic culture | |||||
| + | - | Total | |||
| 4.1 Campylobacter coli detection in faecal samples | + | 125 | 1 | 126 | |
| Real-time PCR | - | 3 | 17 | 20 | |
| Total | 128 | 18 | 146 | ||
| 4.2 Campylobacter coli detection in feed samples | + | 21 | 1 | 22 | |
| Real-time PCR | - | 2 | 26 | 28 | |
| Total | 23 | 27 | 50 | ||
| 4.3 Campylobacter coli detection in environmental samples | + | 34 | 2 | 36 | |
| Real-time PCR | - | 3 | 47 | 50 | |
| Total | 37 | 49 | 86 |
| Sequences | Descent | Ascent | Stop (Life Bases) | P | |||
| n | % | n | % | n | % | ||
| Feeling pain (FP) | 10 | 31.2 | 14 | 43.8 | 8 | 25 | 0.4633 |
| Putting meaning to those feelings (PM) | 5 | 17.8 | 16 | 57.2 | 7 | 25 | 0.0269 * |
| Adjusting running style (AR) | 6 | 40 | 7 | 46.6 | 2 | 13.4 | 0.3593 |
| Attempting to overcome the problem (OP) | 0 | 0 | 0 | 0 | 7 | 100 | 0.0009 * |
| Influence of other runners (IR) | 0 | 0 | 5 | 23.8 | 16 | 76.2 | 0.0005 * |
| Assessing the overall situation (AS) | 3 | 10.3 | 5 | 17.3 | 21 | 74.4 | 0.0005 * |
| Total | 24 | 18.2 | 47 | 35.6 | 61 | 46.2 | 0.0003 * |
| Characteristics | Parameter estimate | Standard error | Odds ratio (95 % CI) | P-value |
| Univariate analysis | ||||
| Age | 0.006 | 0.010 | 1.01 (0.99,1.03) | 0.563 |
| BMI | 0.027 | 0.026 | 1.03 (0.98,1.08) | 0.311 |
| FEV1, predicted % | −0.003 | 0.004 | 1.00 (0.99,1.01) | 0.555 |
| Wheezing* | 0.509 | 0.228 | 1.66 (1.06,2.60) | 0.026 |
| Theophylline | 0.134 | 0.515 | 1.14 (0.42,3.14) | 0.794 |
| Oral steroids | −0.281 | 0.218 | 0.76 (0.49,1.16) | 0.197 |
| Inhaled LABA | −0.363 | 0.486 | 0.70 (0.27,1.80) | 0.455 |
| Inhaled LAMA | −0.369 | 0.245 | 0.69 (0.43,1.12) | 0.133 |
| Inhaled ICS* | 0.412 | 0.210 | 1.51 (1.00,2.28) | 0.049 |
| Ischemic heart disease | 0.312 | 0.362 | 1.37 (0.67,2.77) | 0.389 |
| Heart failure | −0.549 | 0.537 | 0.58 (0.20,1.66) | 0.307 |
| Hypertension | 0.409 | 0.220 | 1.50 (0.98,2.32) | 0.063 |
| Arrhythmia | 0.438 | 0.487 | 1.55 (0.60,4.03) | 0.368 |
| Depression | 1.294 | 0.797 | 3.65 (0.76,17.4) | 0.105 |
| Anxiety | −0.124 | 0.823 | 0.88 (0.18,4.43) | 0.880 |
| CAT score* | 0.085 | 0.017 | 1.09 (1.05,1.13) | <0.001 |
| mMRC score* | 0.264 | 0.125 | 1.30 (1.02,1.66) | 0.035 |
| Variable | Numberb | Percent | |
| Pregnancy | 1st trimester | 710 | 18.40 |
| 2nd trimester | 1344 | 34.83 | |
| 3rd trimester | 1557 | 40.35 | |
| Postpartum 1 m | 248 | 6.43 | |
| Age (years) | ≤25 | 173 | 4.47 |
| 26 ~ 35 | 2859 | 73.93 | |
| ≥36 | 835 | 21.59 | |
| Employment status | No | 886 | 23.08 |
| Yes | 2952 | 76.92 | |
| Marital status | Married | 3747 | 97.07 |
| Single and others | 113 | 2.93 | |
| Monthly income (NT$)a | <30,000 | 151 | 3.94 |
| 30,000 ~ 100,000 | 2437 | 63.61 | |
| >100,000 | 1243 | 32.45 | |
| Educational level | <9 years | 886 | 1.19 |
| 9 ~ 12 years | 2952 | 12.78 | |
| >12 years | 886 | 86.03 | |
| Parity | 1 | 2194 | 59.51 |
| 2+ | 1493 | 40.49 |
| Parameters | Early RRT(n = 58) | Standard RRT(n = 60) | P value |
| Age (years), mean (SD) | 67.5 (15.0) | 66.7 (16.7) | 0.80 |
| Male, n (%) | 29 (50) | 29 (48.3) | 0.86 |
| ICU, n (%) | 0.79 | ||
| Medical | 40 (69) | 40 (66.7) | |
| Surgical | 18 (31) | 20 (33.3) | |
| Mechanical ventilation, n (%) | 48 (82.8) | 50 (83.3) | 0.93 |
| Vasopressors, n (%) | 45 (77.6) | 47 (78.3) | 0.92 |
| Sepsis, n (%) | 37 (63.8) | 32 (53.3) | 0.25 |
| APACHE II score, mean (SD) | 24.5 (6.4) | 21.8 (6.9) | 0.027 |
| SOFA score, mean (SD) | 12.7 (3.3) | 11.4 (4.0) | 0.058 |
| Nonrenal SOFA score, mean (SD) | 9.9 (3.3) | 9.1 (4.1) | 0.21 |
| Baseline serum creatinine (mg/dL), mean (SD) | 1.14 (0.44) | 1.03 (0.37) | 0.16 |
| Estimated GFR (mL/min/1.73m2), mean (SD)a | 70.31 (28.1) | 69.98 (22.8) | 0.95 |
| AKI staging, n (%) | 0.06 | ||
| 1 | 11 (19) | 12 (20) | |
| 2 | 27 (46.6) | 16 (26.7) | |
| 3 | 20 (34.5) | 32 (53.3) | |
| Blood urea nitrogen at enrollment (mg/dL), median (IQR) | 42 (37–78) | 51 (37.5–61.25) | 0.52 |
| Serum creatinine at enrollment (mg/dL), median (IQR) | 2 (2–3) | 2.5 (2–3) | 0.88 |
| Co-morbidities, n (%) | |||
| Hypertension | 29 (50) | 24 (56.7) | 0.47 |
| Diabetes | 14 (24.1) | 15 (25) | 0.91 |
| Dyslipidemia | 16 (27.6) | 16 (26.7) | 0.91 |
| Ischemic heart disease | 12 (20.7) | 10 (16.7) | 0.58 |
| Malignancy | 12 (20.7) | 8 (13.3) | 0.29 |
| Cerebrovascular disease | 5 (8.6) | 7 (11.7) | 0.58 |
| Chronic liver disease | 10 (17.2) | 11 (18.3) | 0.88 |
| Nephrotoxic drugs, n (%) | |||
| Colistin | 5 (8.6) | 10 (16.7) | 0.19 |
| Vancomycin | 1 (1.7) | 1 (1.7) | 0.98 |
| Contrast | 8 (13.8) | 11 (18.3) | 0.50 |
| Aminoglycosides | 2 (3.4) | 2 (3.3) | 0.97 |
| Amphotericin | 2 (3.4) | 0 (0) | 0.15 |
| NSAIDs | 2 (3.4) | 1 (1.7) | 0.54 |
| Cardiac surgery, n (%) | 13 (22.4) | 8 (13.3) | 0.20 |
| Treatment limitation, n (%)b | 12 (20.7) | 10 (16.7) | 0.58 |
| Fluid accumulation at randomization (mL), median (IQR) | 4763 (2837–8515) | 5114 (2050–8803) | 0.84 |
| Percentage of fluid overload, median (IQR)c | 9.53 (3.43–19.68) | 7.63 (2.10–12.02) | 0.87 |
| Baseline NGAL (ng/mL), median (IQR) | 625 (376–1362) | 860 (447–1204) | 0.63 |
| Baseline NT-proBNP (pg/mL), median (IQR) | 4301 (515–35,000) | 5844 (869–10,007) | 0.71 |
| Baseline angiopoietin-2 (ng/mL), median (IQR) | 16,784 (8649–35,545) | 22,294 (12539–33,186) | 0.95 |
| Kinesthetic variables | Test session 1 Mean (SD) | Test session 2 Mean (SD) | Mean difference (SDdiff), 95% CI | ICC2,1(95% CI) | 95% LOAratio |
| TE20 | 0.98 (0.37) | 1.03 (0.51) | 0.05 (0.35), -0.10 – 0.19 | 0.70 (0.42 – 0.86) | 0.57 – 1.78 |
| TE40 | 1.20 (0.52) | 1.26 (0.75) | -0.06 (0.84), -0.41 – 0.30 | 0.16 (-0.27 – 0.53) | 0.31 – 3.09 |
| TF20 | 1.55 (0.66) | 1.29 (0.70) | -0.26 (0.55), -0.49 – -0.03 | 0.63 (0.31 – 0.83) | 0.42 – 1.57 |
| TF40 | 0.79 (0.28) | 0.81 (0.34) | 0.02 (0.28), -0.10 – 0.14 | 0.59 (0.25 – 0.80) | 0.51 – 2.01 |
| Parameter | Exposed | Controls |
| CC16 [pg/mL] | 6.7 (3.7 - 9.0) | 7.2 (5.0 - 8.7) |
| IL-6 [pg/mL] | <4.7 (<4.7 - 7.4) | <4.7 (<4.7 - 23.9) |
| IL-8 [pg/mL] | 21.7 (11.0 - 38.9) | 16.5 (11.4 - 34.4) |
| BPI [pg/mL] | 3201 (<408 - 4741) | 2310 (<408- 4102) |
| LBP [μg/mL] | 19.9 (15.8 - 25.2) | 22.0 (15.8 - 29.2) |
| sCD14 [μg/mL] | 1.3 (1.0 - 1.8) | 1.2 (1.1 - 2.1) |
| Precursor | Bond length in precursor (Å) | Bond length in transition state structures (Å) | ||||
| M-S bond a | C-S bond | M-S bond a | C-S bond | C-N bond | N-H bond b | |
| Ag(SCOPh) | 2.540 | 1.820 | 2.398 | 2.660 | 1.603 | 1.061 |
| Cu(SCOPh) | 2.348 | 1.812 | 2.173 | 2.669 | 1.601 | 1.060 |
| Cd(SCOPh)2 | 2.632 | 1.803 | 2.454 | 2.801 | 1.564 | 1.102 |
| In(SCOPh)3 | 2.725 | 1.777 | 2.373 | 2.608 | 1.628 | 1.035 |
| Number | Incidence (%) | Anomalies (%) | |
| Benign anomalies | |||
| CA from RCS | 8 | 1.07 | 24.24 |
| Absence of LMA | 7 | 0.93 | 21.21 |
| Posterior RCA | 1 | 0.13 | 3.03 |
| Potentially clinically significant anomalies | |||
| Superior RCA | 7 | 0.93 | 21.21 |
| CFX from RCS | 4 | 0.53 | 12.12 |
| CFX from RCA | 2 | 0.26 | 6.06 |
| Coronary fistula | 1 | 0.13 | 3.03 |
| Coronary aneurysm | 1 | 0.13 | 3.03 |
| Metric | Value |
| Families making <Q 2000a per month | 66 % |
| Families making Q 2000–4000a per month | 34 % |
| Average persons per household | 6.4 |
| Average children per household | 3.3 |
| # Samples | # Pairs | # IBD Segments | Mean/Median/SD # IBD Segments/Pair | Mean/Median/SD Size (Mb)/Segment | Mean/Median/SD Size (Mb)/Pair | |
| NLD | 92 | 4186 | 4548 | 1.09/1/1.05 | 3.99/3.57/1.36 | 4.34/3.5/4.57 |
| TWN | 58 | 1653 | 15444 | 9.34/8/6.45 | 9.34/7.22/8.20 | 87.25/71.99/73.88 |
| p-value | <0.0001 | <0.0001 | <0.0001 |
| Baseline | Normal protein | High protein | Reference range | |
| Glucose mg/dL | 83 ± 12 | 85 ± 14 | 84 ± 19 | 65–99 |
| BUN mg/dL | 22 ± 5 | 23 ± 5 | 23 ± 6 | 7–25 |
| Creatinine mg/dL | 1.1 ± 0.2 | 1.1 ± 0.1 | 1.1 ± 0.2 | 0.60–1.35 |
| eGFR ml/min/1.73 m2 | 96 ± 20 | 102 ± 18 | 101 ± 18 | § |
| BUN/Creatinine ratio | 19.4 ± 5.4 | 21.2 ± 4.5 | 20.5 ± 2.8 | 6–22 |
| Sodium mmol/L | 139 ± 2 | 138 ± 2 | 138 ± 1 | 135–146 |
| Potassium mmol/L | 4.3 ± 0.4 | 4.2 ± 0.3 | 4.3 ± 0.2 | 3.5–5.3 |
| Chloride mmol/L | 103 ± 2 | 102 ± 1 | 102 ± 3 | 98–110 |
| Carbon Dioxide mmol/L | 27 ± 2 | 27 ± 4 | 27 ± 2 | 19–30 |
| Calcium mg/dl | 9.7 ± 0.2 | 9.6 ± 0.3 | 9.6 ± 0.3 | 8.6–10.3 |
| Total Protein g/dL | 7.2 ± 0.4 | 7.2 ± 0.3 | 7.1 ± 0.4 | 6.1–8.1 |
| Albumin g/dL | 4.7 ± 0.2 | 4.6 ± 0.2 | 4.6 ± 0.3 | 3.6–5.1 |
| Globulin g/dL | 2.5 ± 0.3 | 2.6 ± 0.3 | 2.6 ± 0.3 | 1.9–3.7 |
| Albumin/Globulin ratio | 1.9 ± 0.2 | 1.8 ± 0.2 | 1.8 ± 0.2 | 1.0–2.5 |
| Total Bilirubin mg/dL | 0.7 ± 0.3 | 0.7 ± 0.2 | 0.7 ± 0.3 | 0.2–1.2 |
| Alkaline Phosphatase U/L | 65 ± 17 | 66 ± 20 | 65 ± 16 | 40–115 |
| AST U/L | 28 ± 9 | 27 ± 6 | 27 ± 6 | 10–40 |
| ALT U/L | 29 ± 19 | 27 ± 9 | 28 ± 10 | 9–46 |
| Study 1 | Study 2 | |
| Age, y | 24 ± 4 | 26 ± 3 |
| Body mass, kg | 72.9 ± 3.9 | 65.8 ± 9.0 |
| Height, m | 1.70 ± 0.09 | 1.70 ± 0.10 |
| BMI, kg/m2 | 25.0 ± 1.1 | 22.8 ± 0.9 |
| Body fat, kg | 24.2 ± 11.4 | 19.3 ± 3.7 |
| Body fat, % | 32.4 ± 2.0 | 29.8 ± 6.5 |
| Lean mass, kg | 45.3 ± 8.1 | 43.6 ± 8.7 |
| Peak bike power, watts | n/a | 145 ± 43 |
| Peak VO2, mL/kg/min | n/a | 26.4 ± 5.9 |
| Peak heart rate, beats/min | n/a | 179 ± 15 |
| Total cholesterol, mmol/L | 3.98 ± 0.99 | 4.03 ± 0.90 |
| HDL cholesterol, mmol/L | 1.21 ± 0.37 | 1.11 ± 0.33 |
| Triglycerides, mmol/L | 0.74 ± 0.39 | 0.89 ± 0.31 |
| C-reactive protein, nmol/L | 18.4 ± 19.9 | 11.0 ± 5.2 |
| Glucose, mmol/L | 4.7 ± 0.2 | 4.8 ± 0.5 |
| Insulin, pmol/L | 41 ± 28 | 41 ± 27 |
| Systolic blood pressure, mmHg | 109 ± 9 | 112 ± 10 |
| Diastolic blood pressure, mmHg | 68 ± 8 | 62 ± 7 |
| Compound | LOD (μg/L) | LOQ (μg/L) | RSD (%) | Recovery (%) | Method | References |
| Caffeine | 3610 | 10,940 | 1.7 | 95 ± 7 | HPLC–DAD–MS | [4] |
| Theobromine | 30 | 100 | 6.5 | 97 ± 3 | ||
| Trigonelline | 3770 | 11,420 | 1.0 | 102 ± 2 | ||
| Caffeine | 80 | – | 0.20–6.2 | 99 ± 3 | HPLC–UV | [9] |
| Theobromine | 140 | 2.8–9.1 | 103 ± 6 | |||
| Trigonelline | 260 | 1.1–5.0 | 99 ± 5 | |||
| Caffeine | 11.9 | 39.6 | 2.1–4.7 | 97 ± 4 | LC–MS | [12] |
| Theobromine | – | – | – | – | ||
| Trigonelline | 36.4 | 121.5 | 3.2–3.5 | 140 ± 16 | ||
| Caffeine | 2 | 40 | 3 | 99 ± 2 | Fluorescence | This study |
| Theobromine | 6 | 20 | 3 | – | ||
| Trigonelline | 7 | 20 | 4 | 99 ± 2 |
| Inclusion Criteria | Exclusion Criteria |
| ◆ Student at Haskell Indian Nations University◆ Age at least 18 years or older◆ Have a valid college/university email address, telephone number, and home address◆ Willing to participate in all study components◆ Willing to be followed-up over several years (1-4 years, depending on freshman cohort year) | ◆ Planning to leave or graduate from the University before the end of the current academic year◆ Unable to participate in all components of the study |
| Mean radio-density | Technique | p-values* | ||||
| At depth of | 1 (Syringe Spreader) | 2 (Syringe Lentulo Spiral) | 3 (Specially Designed Paste Carrier) | 1 cf 2 | 1 cf 3 | 2 cf 3 |
| 1 mm | 6.9 (3.2-10.5) | 13.9 (6.6-21.1) | 28.8 (22.6-35.0) | 0.236 | 0.001 | 0.001 |
| 3 mm | 14.1 (7.1-21.2) | 23.9 (17.6-30.2) | 35.2 (28.9-41.6) | 0.086 | 0.001 | 0.037 |
| 5 mm | 13.5 (7.1-19.8) | 21.9 (12.7-31.1) | 36.8 (31.3-42.2) | 0.250 | 0.001 | 0.009 |
| 7 mm | 22.4 (16.7-30.2) | 23.5 (15.5-31.4) | 34.5 (28.5-40.6) | 1.000 | 0.047 | 0.079 |
| Overall density | 14.2 (9.9-18.6) | 20.8 (16.0-25.6) | 33.83 (30.2-37.5) | 0.077 | 0.001 | 0.001 |
| Vasectomy technique | Early recanalization | Vasectomy outcome | Total | ||
| Failurea n (%) | Successb n (%) | Indeterminatec n (%) | |||
| FI trial | |||||
| LE | |||||
| Yes | 46 (87) | 49 (15) | 10 (31) | 105 (25) | |
| No | 7 (13) | 282 (85) | 22 (69) | 311 (75) | |
| Total | 53 (100) | 331 (100) | 32 (100) | 416 (100) | |
| LE and FI | |||||
| Yes | 20 (83) | 20 (6) | 1 (2) | 41 (10) | |
| No | 4 (17) | 323 (94) | 42 (98) | 369 (90) | |
| Total | 24 (100) | 343 (100) | 43 (100) | 410 (100) | |
| Cautery study | |||||
| EC | |||||
| Yes | 2 (100) | 13 (7) | 2 (40) | 17 (9) | |
| No | 0 (0) | 177 (93) | 3 (60) | 180 (91) | |
| Total | 2 (100) | 190 (100) | 5 (100) | 197 (100) | |
| TC and FI | |||||
| Yes | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |
| No | 1 (100) | 188 (100) | 3 (100) | 192 (100) | |
| Total | 1 (100) | 188 (100) | 3 (100) | 192 (100) |
| Time interval(months) | Primary endpoint* | ARR(%) | RRR[95% CIs] (%) | NNT(per month) | |
| Clopidogrel(%) | Placebo(%) | ||||
| CURE trial | |||||
| 0–1 | 4.3 | 5.5 | 1.2 | 22 [9, 32] | 84 |
| 1–3 | 1.8 | 2.5 | 0.8 | 32 [13, 46] | 240 |
| 3–6 | 1.8 | 1.8 | 0.0 | 4 [−27, 27] | 5174 |
| 6–9 | 1.3 | 1.4 | 0.1 | 6 [–34, 34] | 3171 |
| 9–12 | 1.1 | 1.3 | 0.2 | 14 [−32, 44] | 1600 |
| 0–12 | 10.3 | 12.6 | 2.4 | 19 | 507 |
| CHARISMA trial | |||||
| 0–28 | 6.8 | 7.3 | 0.5 | 7* | 5591 |
| Subgroup of patients with clinically evident atherosclerotic disease | |||||
| 0–28‡ | 6.9 | 7.9 | 1.0 | 12 | 2800 |
| Nutrient | Unfortified cereal (n = 37) | Fortified cereal (n = 34) | P valueb | ||
| Pre-intervention | Post-intervention | Pre-intervention | Post-intervention | ||
| Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | ||
| Vitamin B1 (mg) | 1.1 (0.40) | 1.3 (0.35)** | 1.2 (0.50) | 2.2 (0.36)** | <0.001 |
| Vitamin B2 (mg) | 1.0 (0.41) | 1.4 (0.35)** | 1.2 (0.43) | 2.7 (0.50)** | <0.001 |
| Niacin (mg) | 25 (8.1) | 27 (9.0) | 27 (11.1) | 41 (10.3)** | <0.001 |
| Vitamin B6 (mg) | 1.2 (0.45) | 1.8 (0.40)** | 1.3 (0.53) | 3.0 (0.64)** | <0.001 |
| Vitamin B12 (μg) | 3.1 (1.81) | 2.8 (1.09) | 2.8 (1.44) | 4.1 (1.78)** | <0.001 |
| Folate (μg) | 148 (55) | 151 (61) | 171 (69) | 314 (54)** | <0.001 |
| Vitamin D (μg) | 1.5 (1.35) | 1.6 (0.91) | 1.8 (1.28) | 5.5 (1.32)** | 0.007 |
| Calcium (mg) | 677 (282) | 822 (248)** | 713 (282) | 775 (177) | <0.001 |
| Sodium (mg) | 2419 (7367) | 2528 (631) | 2335 (863) | 2576 (637) | 0.628 |
| Iron (mg) | 8.3 (2.47) | 7.7 (2.37) | 8.9 (2.86) | 13.1 (2.31)** | <0.001 |
| Group | |||
| Variable | Dry | 10 kg milk | 20 kg milk |
| Diameter of vein (cm) | 0.69 ± 0.13 (0.28 - 1.10) | 0.63 ± 0.09 (0.38 - 0.87) | 0.87 ± 0.15 (0.54 - 1.32) |
| Maximum blood flow velocity (cm/s) | 61.78 ± 12.8 (30.0 - 94.9) | 118.08 ± 19.9 (77.6 - 189.5) | 119.13 ± 16.0 (78.8 - 159.8) |
| Minimum blood flow velocity (cm/s) | 1.96 ± 0.40 (0.8 - 3.1) | 8.80 ± 2.80 (2.9 - 18.4) | 7.87 ± 1.40 (3.4 - 11.0) |
| Mean maximum blood flow velocity (cm/s) | 30.59 ± 5.6 (15.1 - 43.5) | 81.90 ± 16.3* (45.2 - 136.3) | 85.15 ± 12.3*(59.6 - 116.5) |
| Blood flow volume (l/min) | 0.52 ± 0.20 (0.0 - 1.5) | 0.70 ± 0.10 (0.5 - 0.9) | 1.57 ± 0.40 (0.8 - 3.1) |
| Food-specific decentering | Awareness of food thoughts | Meditation experience | |
| Food cravings | −0.62a | 0.27 | −0.47 a |
| Food-specific decentering | −0.29 | 0.25 | |
| Awareness of food thoughts | −0.20 |
| Value | Uniforma | Uniform | Uniform |
| Placentalb | Peripheralc | ||
| Sensitivity Histology (Median, CI) | 0.497 (0.414, 0.588) | 0.498 (0.410, 0.589) | 0.504 (0.397, 0.646) |
| Sensitivity PCR (Median, CI) | 0.960 (0.862, 0.998) | 0.961 (0.859, 0.998) | 0.953 (0.841, 0.998) |
| Specificity Histology (Median, CI) | 0.976 (0.963, 0.987) | 0.972 (0.955, 0.985) | 0.971 (0.951, 0.986) |
| Specificity PCR (Median, CI) | 0.991 (0.969, 0.9996) | 0.994 (0.974, 0.9997) | 0.964 (0.906, 0.998) |
| Prevalence Mozambique (Median, CI) | 0.368 (0.305, 0.436) | 0.370 (0.301, 0.437) | 0.334 (0.252, 0.412) |
| Prevalence Malawi (Median, CI) | 0.0813 (0.056, 0.110) | 0.063 (0.039, 0.094) | 0.094 (0.049, 0.150) |
| Group | Frequency (kHz) | ||||||||
| 0.5 | 0.7 | 1.0 | 1.4 | 2.0 | 3.0 | 4.0 | 5.0 | 6.0 | |
| With stimuli | 9.2±4.5 | 12.5±5.1 | 12.1±5.3 | 13.4±6.1 | 7.9±6.4 | 5.5±5.3 | 4.9±4.6 | 2.9±7.4 | -0.4±7.4 |
| Without stimuli | 9.7±5.0 | 12.0±5.9 | 12.4±5.6 | 13.6±5.9 | 7.7±6.2 | 5.6±6.0 | 4.4±5.0 | 2.9±77 | -0.4±7.8 |
| P value | 0.452 | 0.357 | 0.433 | 0.627 | 0.716 | 0.863 | 0.310 | 0.966 | 0.937 |
| Logistic portion of the ZIP model | |||
| Model 4 | Model 5 | Model 6 | |
| Lifetime Earnings§ | .55*(.28, .91) | 1.08(.81, 1.42) | 1.10(.80, 1.51) |
| Gender | 1.15(.50, 2.64) | 1.16(.50, 2.71) | |
| Age | .77***(.67, .83) | .76***(.66, .82) | |
| Race(white is reference) | .35(.08, 1.45) | .32(.08, 1.37) | |
| Educational Attainment(less than high school is reference) | |||
| High School/GED | 2.03(.73, 5.69) | ||
| Some College or more | .84(.27, 2.55) | ||
| Poisson Portion of the ZIP model | |||
| Model 4 | Model 5 | Model 6 | |
| lifetime earnings§ | .93***(.91, .95) | .93***(.91, .95) | .95***(.93, .98) |
| Gender | 1.14***(1.08, 1.20) | 1.11***(1.05, 1.17) | |
| Age | 1.02***(1.02, 1.03) | 1.02***(1.02, 1.03) | |
| Race(white is reference) | 1.22(.54, 2.78) | 1.23(.53, 2.83) | |
| Educational Attainment(less than high school is reference) | |||
| High School/GED | .26(.06, 1.06) | ||
| Some College or more | 1.76(.63, 4.89) |
| MolNo. | R1 | R2 | Predicted activity | Lipinski’s scoreandScreen |
| R-1 | 4-nitrophenyl | 4-methoxyphenyl | 0.8564 | ADRXWS (6) |
| R-2 | 4-nitrophenyl | 4-nitrophenyl | -0.3876 | ADRXWS (6) |
| R-3 | Benzyl | 4-hydroxyphenyl | 0.9765 | ADRXWS (6) |
| R-4 | 3-aminophenyl | 4-nitrophenyl | 0.8450 | ADRXWS (6) |
| Percent of invaded area | Himalayan blackberry | English ivy |
| In clusters | 98.5 | 99.3 |
| In outliers | 1.5 | 0.7 |
| MB | no-MB | ||||
| Pre- training | Post-training | Pre- training | Post-training | ||
| LBD | Subacute | 63.4 ± 3.1 | 61.8 ± 3.1 | 63.9 ± 3.1 | 64.7 ± 3.1 |
| Chronic | 69.2 ± 2.6 | 65.5 ± 2.6 | 67.4 ± 2.6 | 67.8 ± 2.6 | |
| RBD | Subacute | 70.2 ± 2.4 | 68.7 ± 2.4 | 67.1 ± 2.4 | 68.1 ± 2.4 |
| Chronic | 66.4 ± 3.3 | 65.4 ± 3.3 | 66.8 ± 3.3 | 65.1 ± 3.3 |
| KDQOL-36TM Subscales | Mean | SD | Minimal (Floor%) | Maximal (Ceiling%) |
| Symptoms/problems list | 74.22 | 15.24 | 37.50 (1) | 100 (2.9) |
| Effects of kidney disease | 54.78 | 20.10 | 00.00 (1) | 96.88 (1) |
| Burden of kidney disease | 33.07 | 23.31 | 00.00 (13.6) | 100 (1) |
| Physical Composite Sore | 36.60 | 7.83 | 17.05 (1) | 54.92 (1) |
| Mental Composite Score | 46.82 | 9.81 | 22.17 (1) | 65.09 (1) |
| VARIABLE/CLUSTER | CLUSTER 1: \"Highest Risk\" | CLUSTER 2: \"At Risk\" | CLUSTER 3: \"Right Behavior/Wrong Results\" | CLUSTER 4: \"Getting Best Results\" | CLUSTER 5: \"Doing OK\" | P valuea |
| Gender (% female) | 53.0 | 45.6 | 59.8 | 72.2 | 62.1 | 0.008 ** |
| Education (%) | 0.000 *** | |||||
| Less than high school | 0.0 | 3.7 | 0.0 | 0.0 | 0.0 | |
| High school grad | 2.4 | 11.0 | 3.6 | 11.1 | 5.3 | |
| Some college | 54.8 | 58.1 | 56.5 | 31.5 | 49.1 | |
| Bachelors or more | 42.9 | 27.2 | 39.9 | 57.4 | 45.6 | |
| Income (%) | 0.000 *** | |||||
| Less than $20,000 | 17.3 | 20.2 | 5.6 | 7.1 | 14.5 | |
| $20,001 to $35,000 | 10.7 | 21.1 | 16.0 | 11.9 | 32.7 | |
| $35,001 to $50,000 | 16.0 | 18.4 | 9.0 | 14.3 | 16.4 | |
| $50,001 to $65,000 | 16.0 | 18.4 | 17.4 | 9.5 | 9.1 | |
| $65,001 or greater | 40.0 | 21.9 | 52.1 | 57.1 | 27.3 | |
| Children (% has children) | 37.3 | 45.3 | 48.2 | 45.5 | 32.8 | 0.216 |
| Employment (%) | ||||||
| Employed | 53.0 | 46.0 | 43.5 | 58.2 | 79.3 | 0.000 *** |
| Unemployed | 2.4 | 3.7 | 0.6 | 3.6 | 3.4 | 0.417 |
| Retired | 27.7 | 13.2 | 13.6 | 23.6 | 19.0 | 0.027 * |
| Age range (%) | 0.000 *** | |||||
| 16–24 | 0.0 | 19.0 | 9.5 | 12.7 | 10.2 | |
| 25–34 | 15.7 | 23.4 | 17.9 | 16.4 | 30.5 | |
| 35–44 | 19.3 | 23.4 | 27.4 | 16.4 | 10.2 | |
| 45–54 | 26.5 | 12.4 | 21.4 | 16.4 | 18.6 | |
| 55–64 | 12.0 | 8.8 | 11.9 | 12.7 | 11.9 | |
| 65 or more | 26.5 | 13.1 | 11.9 | 25.5 | 18.6 | |
| Region (%) | 0.001 *** | |||||
| Northern | 27.7 | 28.7 | 30.2 | 31.5 | 19 | |
| South | 19.3 | 27.2 | 23.1 | 29.6 | 46.6 | |
| Middle America | 16.9 | 27.9 | 30.2 | 20.4 | 22.4 | |
| West | 36.1 | 16.2 | 16.6 | 18.5 | 12.1 | |
| Urban characteristic (%) | 0.163 | |||||
| Rural | 30.1 | 26.3 | 33.9 | 23.6 | 38.6 | |
| Suburban | 43.4 | 41.4 | 45.8 | 54.5 | 45.6 | |
| Urban | 26.5 | 32.3 | 20.2 | 21.8 | 15.8 |
| Measure | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| 1. PCL-F | -- | |||||||
| 2. PCL-F symptom group B | 0.73 *** | -- | ||||||
| 3. PCL-F symptom group C | 0.90 *** | 0.45 *** | -- | |||||
| 4. PCL-F symptom group D | 0.86 *** | 0.53 *** | 0.65 *** | -- | ||||
| 5. CAPS frequency score | 0.72 *** | 0.52 *** | 0.61 *** | 0.65 *** | -- | |||
| 6. CAPS frequency symptom group B | 0.33 ** | 0.58 *** | 0.11 | 0.26 * | 0.62 *** | -- | ||
| 7. CAPS frequency symptom group C | 0.62 *** | 0.25 * | 0.68 *** | 0.53 *** | 0.86 *** | 0.24 * | -- | |
| 8. CAPS frequency symptom group D | 0.66 *** | 0.50 *** | 0.49 *** | 0.70 *** | 0.82 *** | 0.40 *** | 0.60 *** | -- |
| Comparison (5-Aza) | Methods | Cuffdiff | SAMSeq | baySeq | DESeq | Noiseq |
| 5 μM vs 0 μM | T-test | 25.8% | 22.5% | 24.5% | 25.8% | 29.7% |
| SAM | 39.9% | 39.9% | 42.7% | 44.5% | 33.5% | |
| Ebayes | 39.5% | 39.5% | 42.2% | 44.0% | 33.3% | |
| 10 μM vs 5 μM | T-test | 0.5% | 0.5% | 0.6% | 0.6% | 0.0% |
| SAM | 31.1% | 30.2% | 32.6% | 34.2% | 19.4% | |
| Ebayes | 30.3% | 28.3% | 31.9% | 33.5% | 19.1% |
| Local density | Coeff. variation nearest distances | Area | |
| Local density | 1.00 | --- | --- |
| Coeff. Variation nearest distances | 0.22* | 1.00 | --- |
| Area | -0.10 | 0.11 | 1.00 |
| Variable | Factor | P value | HR | 95.0% CI |
| Age | Continuous | 0.367 | 1.02 | 0.98–1.05 |
| Sex | Male | 0.001 | 0.36 | 0.20–0.66 |
| ECOG-PS | >1 | 0.034 | 2.13 | 1.06–3.39 |
| Comorbidities (CVD or DM) | Positive | 0.084 | 0.53 | 0.25–1.07 |
| Metastatic disease | Positive | <0.001 | 9.34 | 5.12–17.1 |
| Frailty discriminant score | >2.30 | 0.005 | 3.03 | 1.41–5.51 |
| miRNA | Target | Effector cell | Affected chemokine | Role in atherosclerosis | References |
| miR-181b | Importin-α3 | ECs | CXCL1 | Protective | [58] |
| miR-103 | KLF4 | ECs | CXCL1CCL2 | Damaging | Unpublished |
| miR-126-3p | RGS16 | ECs | CXCL12 | Protective | [64] |
| miR-10a | TAK1, β‐TRC | ECs | CCL2 | Protective | [87] |
| miR-92a | KLF2, KLF4, SOCS5 | ECs | CCL2CXCL1? | Damaging | [88] |
| miR-21 | PPARα | ECs | CCL2 | Damaging | [79] |
| let-7g | THBS1, TGFBR1, SMAD2 | ECs | CCL2 | Protective | [97] |
| miR-155 | BCL6 | Macrophages | CCL2 | Damaging | [43] |
| miR-342-5p | AKT1 | Macrophages | CCL2 (via miR-155) | Damaging | [102] |
| miR-467b | LPL | Macrophages | CCL2 | Protective | [105] |
| miR-24 | CHI3L1 | Macrophages | CCL2 | Protective | [108] |
| STIB900-M vs. STIB900 | STIB900-P vs. STIB900 | |||||
| Overall | CDS | NS | Overall | CDS | NS | |
| Chr1 | 0 | 0 | 0 | 2 | 0 | 0 |
| Chr2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Chr3 | 0 | 0 | 0 | 1 | 0 | 0 |
| Chr4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Chr5 | 2 | 0 | 0 | 1 | Tb927.5.286b | G430R |
| Chr6 | 1 | 0 | 0 | 0 | 0 | 0 |
| Chr7 | 0 | 0 | 0 | 1 | 0 | 0 |
| Chr8 | 1 | 0 | 0 | 0 | 0 | 0 |
| Chr9 | 6 | 0 | 0 | 5 | Tb927.9.8310* | D31G |
| Chr10 | 0 | 0 | 0 | 0 | 0 | 0 |
| Chr11 | 2 | Tb927.11.500 | R131L | 4 | Tb927.11.500 | R131L |
| Total | 12 | 1 | 1 | 14 | 3 | 3 |
| Groups | ||||||
| NH | CI | |||||
| Long, complex sentences | Highly meaningful sentences | Nonsense sentences | Long, complex sentences | Highly meaningful sentences | Nonsense sentences | |
| Verbal Working Memory | ||||||
| LSpan (total letters correctly recalled) | .10 | .05 | .07 | .64** | .57** | .68** |
| Rspan (total letters correctly recalled) | ‐.01 | .06 | .13 | ‐.03 | .01 | ‐.02 |
| Modality‐General Neurocognitive Scores | ||||||
| Attention Sustained (scaled score) | .14 | .07 | ‐.08 | .14 | .19 | .29 |
| Forward Memory (scaled score) | ‐.10 | ‐.35 | .17 | .23 | .23 | .14 |
| Reverse Memory (scaled score) | .06 | ‐.11 | .08 | .20 | .20 | .04 |
| Verbal Stroop–Congruent (response time) | ‐.04 | .20 | .07 | ‐.28 | ‐.29 | ‐.36 |
| Verbal Stroop–Incongruent (response time) | ‐.14 | ‐.05 | ‐.03 | ‐.41* | ‐.43* | ‐.43* |
| * p‐value < 0.05 | ||||||
| ** p‐value < 0.01CI = cochlear impant; LSpan = Listening Span; NH = normal hearing; RSpan = Reading Span |
| Parameters | No of patients with ≥ G2 RP (%) | No of patients with G0-1 RP (%) | p value |
| Age | 0.074 | ||
| < 75 years old | 1 (11) | 25 (45) | |
| ≥ 75 | 8 (89) | 31 (55) | |
| Sex | 0.392 | ||
| Man | 6 (67) | 45 (80) | |
| Female | 3 (33) | 11 (20) | |
| PS | 0.458 | ||
| 0 or 1 | 8 (89) | 53 (95) | |
| 2 | 1 (11) | 3 (5) | |
| Location of primary tumor | 0.706 | ||
| Upper or Middle lobe | 7 (78) | 36 (64) | |
| Lower lobe | 2 (22) | 20 (36) | |
| Clinical Stage | 1.000 | ||
| II | 5 (56) | 32 (57) | |
| III | 4 (44) | 24 (43) | |
| Total dose | 1.000 | ||
| ≤ 72 Gy RBE | 8 (89) | 46 (82) | |
| > 72 Gy RBE | 1 (11) | 10 (18) | |
| Chemotherapy | 0.187 | ||
| Yes | 0 | 14 (25) | |
| No | 9 (100) | 42 (75) | |
| Brinkman Index | 1.000 | ||
| < 600 | 3 (33) | 19 (34) | |
| ≥ 600 | 6 (67) | 37 (66) | |
| Pulmonary emphysema | 0.191 | ||
| Yes | 0 | 12 (21) | |
| No | 9 (100) | 44 (79) |
| Dose (mg/cm2) | # | Mortality record for applied pests | |||
| Record after 24 hours | Average ± SD record after 24 hours | Record after 48 hours | Average ± SD record after 48 hours | ||
| 1.77 | 10 | 10 | 9.66 ± 0.57 | 10 | 9.66 ± 0.57 |
| 1.77 | 10 | 10 | 10 | ||
| 1.77 | 10 | 9 | 9 | ||
| 0.88 | 10 | 10 | 9.00 ± 1.00 | 10 | 9.00 ± 1.00 |
| 0.88 | 10 | 9 | 9 | ||
| 0.88 | 10 | 8 | 8 | ||
| 0.44 | 10 | 5 | 5.33 ± 0.57 | 6 | 5.66 ± 0.57 |
| 0.44 | 10 | 6 | 6 | ||
| 0.44 | 10 | 5 | 5 | ||
| 0.22 | 10 | 2 | 2.00 ± 1.00 | 2 | 2.33 ± 0.57 |
| 0.22 | 10 | 1 | 2 | ||
| 0.22 | 10 | 3 | 3 | ||
| Control | 10 | 0 | 0.00 | 0 | 0.00 |
| Variables | Unstandardised coefficients (B) | S.E | Standardised coefficients (Beta) | P value |
| Age | − 0.020 | 0.017 | − 0.066 | 0.241 |
| Marital status | 0.052 | 0.041 | 0.077 | 0.205 |
| Income level | 0.064 | 0.023 | 0.163 | 0.006 |
| The current condition | − 0.023 | 0.019 | − 0.074 | 0.222 |
| Pain severity score | − 0.011 | 0.002 | − 0.353 | < 0.001 |
| Pain interference score | − 0.007 | 0.001 | − 0.350 | < 0.001 |
| Post-treatment pain | − 0.010 | 0.051 | − 0.012 | 0.842 |
| Selection | Comparability | Outcome assessment | |||||||
| Author | Year | 1 | 2 | 3 | 4 | 5 | 6 | 7 | Score |
| Kon | 2007 | * | * | * | * | ** | * | - | ******* |
| Zhao | 2008 | - | * | * | ** | * | * | - | ****** |
| Reicher | 2007 | * | * | * | ** | ** | * | - | ******** |
| Vassiliades | 2009 | * | * | * | ** | * | * | * | ******** |
| Delhaye | 2010 | * | * | * | ** | * | * | - | ******* |
| Hu | 2010 | * | * | * | ** | ** | * | * | ********* |
| Halkos | 2011 | * | * | * | * | * | * | - | ****** |
| Bachinsky | 2012 | - | * | * | ** | ** | * | - | ******* |
| Leacche | 2012 | - | * | * | ** | * | * | - | ****** |
| Items | Normal controls | IPF | NSIP | HP | Sarcoidosis |
| No. | 41 | 86 | 22 | 20 | 19 |
| Age (year) | 55(35–72) | 67(59–75)* | 60.1(39–70) | 51.3(28–70)† | 43.3 (28–69)† |
| Sex (male/female) | 24/17 | 51/ 35 | 9/13 | 10/10 | 10/9 |
| Smoke (CS/ES/NS) | 9/11/14 | 19/25/36 | 2/5/12 | 3/3/12 | 5/2/9 |
| Survival/Death | ND | 57/21 | ND | ND | ND |
| Follow up duration (years) | ND | 3.6(1.6–6.5) | ND | ND | ND |
| FVC (% pred.) | 106.1(87.0–119.0) | 67.0(52.0–80.0)* | 78.0(66.0–91.8)* | 64.5(57.0–82.5)* | 77.0(65.0–86.0)* |
| FEV1 (% pred.) | 102.1(88.2–117.0) | 83.0(59.0–93.0)* | 85.0(73.8–101.3)* | 74.5(64.3–92.0)* | 85.0(64.0–101.0)* |
| DLCO (% pred.) | 85.6(77.5–108.0) | 57.0(46.0–71.0)* | 76.0(59.0–92.0)* | 67.0(55.0–90.0)* | 75.5(57.8–84.5)* |
| dFVC (%/year) | NA | –7.1(–15.8–2.8) | NA | NA | NA |
| BAL total cell count (×104/mL) | 3.46 ± 0.82 | 7.58 ± 2.24* | 17.64 ± 3.86* | 13.03 ± 3.78* | 8.45 ± 3.78* |
| Macrophages (×104/mL) | 3.02 ± 0.41 | 5.12 ± 1.71* | 11.51 ± 3.07* | 8.25 ± 2.38* | 6.76 ± 3.79* |
| Neutrophils (×104/mL) | 0.21 ± 0.047 | 1.45 ± 0.38* | 2.31 ± 1.01* | 3.14 ± 2.36* | 0.45 ± 0.16* |
| Eosinophils (×104/mL) | 0.02 ± 0.01 | 0.29 ± 0.07* | 0.45 ± 0.14* | 0.41 ± 0.19* | 0.11 ± 0.07 |
| Lymphocytes (×104/mL) | 0.04 ± 0.01 | 0.14 ± 0.05 | 2.68 ± 0.18*† | 2.20 ± 0.19*† | 2.17 ± 0.24*† |
| Kinases | Phosphatases | Growth factors | Cytokines | Transcription factors |
| Fgfr1 | Acpp | Clec11a | Il10 | Gata6 |
| Pdk4 | Dusp23 | Gas6 | Pf4 | Lass4 |
| Srms | Nt5e | Gdf6 | Thpo | Lhx4 |
| Srk3 | Pon1 | Igf1 | Wnt5a | Nfatc2 |
| Ppap2b | Igf2 | Per2 | ||
| Inhbe | Tal1 | |||
| Mst1 | Tcf7l2 | |||
| Sox9 |
| Variablesa | Preoperative | Discharge | 6 months | 1 year |
| Size 19 mm (n) | 31 | 29 | 29 | 25 |
| Peak gr, (mmHg)b | 76.1 ± 28.7 | 25.3 ± 9.5 | 24.1 ± 8.2 | 29.5 ± 11.0 |
| Mean gr (mmHg)b | 45.7 ± 18.3 | 13.5 ± 5.7 | 13.2 ± 4.4 | 16.6 ± 5.8 |
| EOA (cm2)b | 1.0 ± 0.5 | 1.6 ± 0.4 | 1.4 ± 0.4 | 1.4 ± 0.1 |
| EOAI (cm2/m2)b | 0.2 ± 0.4 | 1.1 ± 0.7 | 1.0 ± 0.1 | 1.0 ± 0.1 |
| LVMI (g/m2)b | 136.2 ± 8.2 | 124.2 ± 23.3 | 118.1 ± 44.6 | 123.4 ± 40.4 |
| EF (%) | 58.7 ± 9.4 | 55.5 ± 8.2 | 57.3 ± 5.9 | 58.4 ± 6.1 |
| Size 21 mm (n) | 58 | 57 | 56 | 51 |
| Peak gr (mmHg)b | 87.7 ± 25.6 | 18.2 ± 5.2 | 17.9 ± 5.2 | 18.3 ± 5.2 |
| Mean gr (mmHg)b | 54.7 ± 17.3 | 9.8 ± 2.9 | 9.4 ± 2.7 | 9.9 ± 3.0 |
| EOA (cm2)b | 0.7 ± 0.2 | 1.9 ± 0.9 | 2.0 ± 0.3 | 2.1 ± 0.5 |
| EOAI (cm2/m2)b | 0.5 ± 0.1 | 1.1 ± 0.3 | 1.2 ± 0.3 | 1.4 ± 0.4 |
| LVMI (g/m2)b | 146.1 ± 22.8 | 142.2 ± 52.3 | 120.5 ± 48.7 | 127.7 ± 57.1 |
| EF (%) | 58.4 ± 7.9 | 56.4 ± 8.4 | 56.8 ± 8.2 | 55.9 ± 8.4 |
| Size 23 mm (n) | 58 | 56 | 56 | 53 |
| Peak gr (mmHg)b | 77.6 ± 29.9 | 14.4 ± 5.0 | 15.1 ± 4.8 | 16.6 ± 5.4 |
| Mean gr (mmHg)b | 47.8 ± 20.3 | 7.6 ± 2.3 | 8.2 ± 3.1 | 9.1 ± 3.2 |
| EOA (cm2)b | 1.1 ± 0.6 | 2.1 ± 0.3 | 1.9 ± 0.3 | 1.8 ± 0.2 |
| EOAI (cm2/m2)b | 0.6 ± 0.8 | 1.1 ± 0.3 | 1.0 ± 0.1 | 1.2 ± 0.1 |
| LVMI (g/m2)b | 140.8 ± 25.8 | 135.2 ± 37.3 | 123.4 ± 33.2 | 125.9 ± 30.8 |
| EF (%) | 55.7 ± 8.9 | 52.4 ± 8.9 | 54.5 ± 9.5 | 53.4 ± 8.6 |
| Size 25/27 mm (n) | 31 | 31 | 31 | 27 |
| Peak gr (mmHg)b | 62.7 ± 28.9 | 13.6 ± 5.2 | 14.4 ± 4.6 | 14.1 ± 4.7 |
| Mean gr (mmHg)b | 36.7 ± 18.0 | 7.4 ± 2.8 | 8.2 ± 2.5 | 7.7 ± 2.4 |
| EOA (cm2)b | 1.2 ± 0.5 | 2.2 ± 0.8 | 2.0 ± 0.8 | 2.5 ± 1.3 |
| EOAI (cm2/m2)b | 0.9 ± 0.4 | 1.2 ± 0.4 | 1.2 ± 0.5 | 1.5 ± 0.5 |
| LVMI (g/m2)b | 157.0 ± 53.1 | 126.2 ± 42.9 | 118.4 ± 24.3 | 100.9 ± 41.0 |
| EF (%) | 54.5 ± 11.1 | 50.8 ± 9.7 | 55.5 ± 8.9 | 56.2 ± 9.5 |
| Gene ID | I_CN | I_0 | Annotation |
| Kinase | |||
| Unigene43155_xckb | D_U | F_F | Proline-rich receptor-like protein kinase PERK2 |
| Unigene66089_xckb | U_D | F_F | G-type lectin S-receptor-like serine/threonine-protein kinase SD1-13 |
| Unigene13595_xckb | U_D | F_F | Protein kinase domain containing protein |
| CL3347.Contig1_xckb | U_D | F_F | Cysteine-rich receptor-like protein kinase 8 |
| Unigene60834_xckb | U_D | F_F | Probable LRR receptor-like serine/threonine-protein kinase At4g29180 |
| Unigene68690_xckb | U_D | F_F | Proline-rich receptor-like protein kinase PERK10 |
| Unigene35121_xckb | U_D | F_F | Proline-rich receptor-like protein kinase PERK2 |
| TF | |||
| Unigene65053_xckb | U_D | F_F | MADS-box transcription factor 15 |
| Unigene34602_xckb | U_F | F_F | Ethylene-responsive transcription factor ABI4 |
| Unigene69673_xckb | U_F | F_F | Ethylene-responsive transcription factor ERF109 |
| Resistance | |||
| Unigene68271_xckb | U_D | F_F | Leucine-rich repeat extensin-like protein 3 |
| CL2708.Contig2_xckb | U_D | F_F | Pollen-specific leucine-rich repeat extensin-like protein 1 |
| Unigene72805_xckb | U_D | F_F | Resistance protein RGA2 |
| CL6805.Contig1_xckb | F_U | F_F | Hydroxyproline-rich glycoprotein gp1 |
| Unigene48841_xckb | F_U | F_F | Hydroxyproline-rich glycoprotein gp1 |
| Unigene46836_xckb | U_D | F_F | Hydroxyproline-rich glycoprotein gp1 |
| Unigene72060_xckb | U_D | F_F | Hydroxyproline-rich glycoprotein gp1 |
| Diagnosis | Cases |
| Head injury | 7 |
| Skin lesions | 5 |
| Poisoning | 4 |
| Polytrauma | 3 |
| Others | 2 |
| Measure | Early | Late | ||||
| Negative | Neutral | Positive | Negative | Neutral | Positive | |
| BEHAVIORAL | ||||||
| RT (ms) | 666.06 (139.98) | 668.84 (138.55) | 667.24 (150.35) | 631.73 (128.06) | 647.42 (131.51) | 641.09 (120.62) |
| ACC | 0.94 (0.04) | 0.96 (0.03) | 0.95 (0.04) | 0.96 (0.04) | 0.95 (0.05) | 0.95 (0.05) |
| FACE-LOCKED ERPs | ||||||
| N170 (μV) | −8.36 (5.21) | −9.35 (5.24) | −8.74 (5.45) | −11.10 (5.81) | -12.03 (5.97) | −11.44 (5.70) |
| P3 (μV) | 19.26 (5.55) | 17.46 (5.64) | 18.99 (6.49) | 15.99 (6.98) | 14.89 (7.31) | 16.07 (8.00) |
| IAPS-LOCKED ERPs | ||||||
| LPP (μV * ms) | 2843.84 (4114.14) | 1611.45 (3200.67) | 535.69 (2636.49) | 3259.33 (3327.15) | 1808.66 (3186.92) | 1248.49 (3779.14) |
| Plasmid | Transfer frequency (transconjugant/recipient) (%)* | ||||
| 1 | 2 | 3 | 4 | Mean ± SD | |
| pIJ303 | 93.83 | 103.18 | 101.03 | 95.90 | 95.83 ± 1.57 |
| pIJ303ΔspdA2 | 97.49 | 96.48 | 95.77 | 92.92 | 100.20 ± 4.04 |
| pIJ303-sps | 95.43 | 96.95 | 92.74 | 98.16 | 96.35 ± 3.44 |
| pIJ303spdA2c | 96.55 | 104.19 | 95.87 | 106.21 | 98.30 ± 5.69 |
| Kind of complications | n = 20 (23.2 %) | Need for reoperation n = 19 (22.0 %) | Way the complication was handled |
| - Femoral shaft fracture | 4 (4.6 %) | 4 (4.6 %) | cerclage, cemented stem |
| - Calcar fracture | 1 (1.2 %) | 1 (1.2 %) | change of approach |
| - Dislocation | 2 (2.3 %) | 2 (2.3 %) | closed reduction |
| - Sintering | 1 (1.2 %) | 1 (1.2 %) | larger neck size |
| - Periprosthetic fracture | 6 (6.9 %) | 6 (6.9 %) | plate osteosynthesis, cerclage, cemented stem, augmentation, total exchange |
| - Cup displacement | 1 (1.2 %) | 1 (1.2 %) | cemented cup |
| - Infection | 2 (2.3 %) | 2 (2.3 %) | exchange of head & inlay |
| - Hematoma | 3 (3.5 %) | 2 (2.3 %) | lavage, punction |
| - Thrombosis (%) | 0 (0.0 %) | 0 (0.0 %) | - |
| - Pulmonary embolism (%) | 0 (0.0 %) | 0 (0.0 %) | - |
| Cortisol | DHEA | ||||||||
| IBS | Control | IBS | Control | ||||||
| Day 1 | Time 1 | 2.93 | (0.29) | 2.68 | (0.24) | 1.09 | (0.08) | 1.04 | (0.06) |
| Time 2 | 3.82 | (0.30) | 3.87 | (0.24) | 1.08 | (0.08) | 1.14 | (0.06) | |
| Time 3 | 1.44 | (0.29) | 1.08 | (0.25) | 0.74 | (0.08) | 0.81 | (0.06) | |
| Day 2 | Time 1 | 3.24 | (0.30) | 3.50 | (0.24) | 1.19 | (0.08) | 1.09 | (0.07) |
| Time 2 | 4.64 | (0.30) | 3.65 | (0.24) | 1.10 | (0.08) | 1.12 | (0.06) | |
| Time 3 | 1.85 | (0.30) | 2.06 | (0.25) | 0.80 | (0.08) | 0.77 | (0.06) | |
| Day 3 | Time 1 | 3.19 | (0.32) | 3.33 | (0.23) | 1.16 | (0.08) | 1.25 | (0.06) |
| Time 2 | 4.52 | (0.32) | 4.22 | (0.23) | 1.11 | (0.08) | 1.26 | (0.06) | |
| Time 3 | 1.66 | (0.33) | 1.94 | (0.26) | 0.73 | (0.08) | 0.80 | (0.06) | |
| Day 4 | Time 1 | 2.56 | (0.31) | 3.13 | (0.25) | 0.94 | (0.09) | 1.00 | (0.07) |
| Time 2 | 3.28 | (0.31) | 3.19 | (0.25) | 0.95 | (0.08) | 1.04 | (0.06) | |
| Time 3 | 1.15 | (0.33) | 1.64 | (0.25) | 0.65 | (0.08) | 0.70 | (0.06) | |
| DHEA-S | DHEA-S/DHEA | ||||||||
| IBS | Control | IBS | Control | ||||||
| Day 1 | Time 1 | 3.85 | (0.44) | 3.48 | (0.36) | 3.85 | (0.53) | 3.38 | (0.44) |
| Time 2 | 2.23 | (0.45) | 2.93 | (0.36) | 2.23 | (0.55) | 2.55 | (0.44) | |
| Time 3 | 2.80 | (0.45) | 2.43 | (0.36) | 4.07 | (0.55) | 3.07 | (0.44) | |
| Day 2 | Time 1 | 3.13 | (0.45) | 3.52 | (0.36) | 2.58 | (0.55) | 3.10 | (0.49) |
| Time 2 | 2.26 | (0.45) | 2.56 | (0.36) | 2.04 | (0.55) | 2.44 | (0.44) | |
| Time 3 | 1.76 | (0.45) | 2.26 | (0.36) | 2.32 | (0.55) | 3.16 | (0.44) | |
| Day 3 | Time 1 | 3.77 | (0.47) | 3.86 | (0.36) | 3.52 | (0.58) | 3.25 | (0.44) |
| Time 2 | 1.70 | (0.47) | 2.23 | (0.36) | 1.52 | (0.58) | 1.84 | (0.43) | |
| Time 3 | 2.01 | (0.45) | 2.59 | (0.36) | 3.00 | (0.55) | 3.42 | (0.44) | |
| Day 4 | Time 1 | 2.62 | (0.48) | 3.29 | (0.37) | 2.61 | (0.62) | 3.50 | (0.46) |
| Time 2 | 1.95 | (0.46) | 3.20 | (0.37) | 2.22 | (0.57) | 3.20 | (0.45) | |
| Time 3 | 2.14 | (0.45) | 2.47 | (0.37) | 3.51 | (0.55) | 3.67 | (0.45) |
| Demographic Data | Diabetes Medication | Frequency | |
| Male (%) | 44 (61) | OHA | 39 |
| Female (%) | 28 (39) | Insulin | 7 |
| Mean age | 56 | OHA + Insulin | 18 |
| Median age | 59 | Nil | 8 |
| Mean BMI | 39 | HbA1c | (mmol/mol) |
| Median BMI | 39 | Mean HbA1c | 67 |
| Median Hb A1c | 57 |
| National average | Less than $25,000 | $25,000 to $34,999 | $35,000 to $49,999 | $50,000 to $74,999 | $75,000 to $99,999 | $100,000 or more | |
| They are being harmed now | 38 | 46 | 45 | 34 | 38 | 32 | 33 |
| In 10 years | 13 | 10 | 13 | 12 | 13 | 13 | 16 |
| In 25 years | 12 | 12 | 12 | 10 | 16 | 12 | 10 |
| In 50 years | 12 | 10 | 11 | 14 | 12 | 12 | 12 |
| In 100 years | 11 | 9 | 7 | 14 | 9 | 14 | 12 |
| Never | 14 | 12 | 11 | 16 | 11 | 17 | 17 |
| χ2, p < 0.01; n = 2,073 |
| Natural populations | Year (number of accessions) | TaFlo2-A1aMean ± SEa (number of accessions) | TaFlo2-A1bMean ± SE (number of accessions) | Mean difference ± SE | PVE (%)b TGW | |||
| TGW | GpS | TGW | GpS | TGW | GpS | |||
| Chinese Micro Core Collection | 2002 (137) | 33.6 ± 0.54(98) | 50.8 ± 1.2(98) | 40.6 ± 1.2(39) | 49.7 ± 1.5(39) | 7.0 ± 1.1** | 1.06 ± 2.1ns | 6.19 |
| 2005 (169) | 30.7 ± 0.52(128) | 43.1 ± 0.8(128) | 38.5 ± 1.1(41) | 40.5 ± 1.1(41) | 7.8 ± 1.1** | 2.6 ± 1.5 ns | 7.76 | |
| 2006 (185) | 32.8 ± 0.43(141) | 51.4 ± 0.7(141) | 41.2 ± 0.9(44) | 48.6 ± 1.2(43) | 8.4 ± 0.9** | 2.7 ± 1.5 ns | 8.37 | |
| Pakistani collection | 2009 (130) | 40.6 ± 0.43(85) | 46.6 ± 1.1(85) | 45.1 ± 0.55(45) | 44.4–1.8(45) | 4.5 + 0.71** | 2.2 ± 1.9 ns | 4.42 |
| 2010 (130) | 40.5 ± 0.47(85) | 47.8 ± 1.2(85) | 45.7 ± 0.46(45) | 44.9 + 1.6(45) | 5.2 ± 0.72** | 2.9 ± 2.0 ns | 5.11 |
| Test | Occlusive patch (means) | Scotogenic lens (means) | Significance (K–S test), p value |
| Symptom control | 9.73 | 9.27 | 0.985 |
| Comfort | 4.36 | 7.45 | 0.047 |
| Aesthetics | 2.00 | 9.45 | <0.001 |
| Overall assessment | 4.18 | 8.54 | <0.001 |
| % of |P| | |||||
| # of ops as% of n | Method | 0 | ≤ 15% | ≤ 20% | ≤ 50% |
| 1 | 97 | 97 | 97 | 100 | |
| 10 | 2 | 97 | 97 | 97 | 100 |
| 3 | 96 | 96 | 96 | 99 | |
| 1 | 93 | 93 | 93 | 100 | |
| 15 | 2 | 93 | 93 | 93 | 100 |
| 3 | 89 | 89 | 89 | 100 | |
| 1 | 84 | 84 | 93 | 100 | |
| 20 | 2 | 83 | 83 | 92 | 100 |
| 3 | 76 | 76 | 85 | 100 | |
| 1 | 78 | 88 | 88 | 100 | |
| 25 | 2 | 76 | 86 | 86 | 100 |
| 3 | 67 | 77 | 77 | 100 | |
| 1 | 68 | 83 | 93 | 100 | |
| 29 | 2 | 66 | 81 | 89 | 100 |
| 3 | 57 | 69 | 76 | 100 |
| Assays | Treatment Group | MeanCFU Counts | Treatment Effect Group | |||
| CFU-GM | N | 79.3 | A | |||
| APS | 52.3 | B | ||||
| TPO | 50.0 | B | ||||
| C | 34.5 | C | ||||
| BFU-E | N | 55.3 | A | |||
| TPO | 31.2 | B | ||||
| APS | 22.3 | C | ||||
| C | 8.3 | D | ||||
| CFU-GEMM | N | 27.7 | A | |||
| APS | 19.7 | B | ||||
| TPO | 18.0 | B | ||||
| C | 8.3 | C | ||||
| CFU-MK | N | 51.8 | A | |||
| APS | 32.5 | B | ||||
| TPO | 37.5 | B | ||||
| C | 15.3 | C | ||||
| CFU-F | N | 29.8 | A | |||
| APS | 27.6 | A | ||||
| TPO | 19.3 | B | ||||
| C | 8.8 | C |
| Diets1 | Normal (%) | Degree of Steatosis2 | |||
| < 5% | 5-33% | 33-6% | > 66% | ||
| CNC | 100 | - | - | - | - |
| CC | 40 | - | 20 | 40 | |
| LWS50 | 100 | - | - | - | - |
| CS50 | 20 | - | - | - | 80 |
| OS50 | 60 | 20 | - | - | 20 |
| Case | Age | Disease recurrence | Presence of metastasis* | Follow-up (months) | Life status |
| 1 | 41 | No | No | 64 | Alive |
| 2 | 37 | No | Yes | 22 | Alive |
| 3 | 55 | NI | NI | NI | NI |
| 4 | 59 | No | Yes | 16 | Dead |
| 5 | 46 | No | No | 107 | Alive |
| 6 | 27 | No | No | 28 | Alive |
| 7 | 33 | Yes | No | 36 | Alive |
| 8 | 67 | No | No | 34 | Alive |
| 9 | 40 | No | No | 35 | Alive |
| 10 | 54 | No | Yes | 48 | Dead |
| 11 | 57 | Yes | No | 30 | Alive |
| 12 | 61 | No | No | 9 | Alive |
| 13 | 67 | No | No | 32 | Alive |
| 14 | 38 | No | No | 17 | Alive |
| 15 | 71 | No | No | 5 | Alive |
| 16 | 40 | No | No | 87 | Alive |
| 17 | 40 | No | No | 10 | Alive |
| 18 | 58 | No | Yes | 47 | Dead |
| 19 | 47 | No | No | 22 | Alive |
| 20 | 41 | No | No | 14 | Alive |
| 21 | 39 | No | Yes | 9 | Dead |
| 22 | 40 | No | Yes | 48 | Alive |
| 23 | 45 | No | No | 35 | Alive |
| 24 | 53 | No | Yes | 13 | Alive |
| 25 | 29 | No | Yes | 14 | Dead |
| 26 | 36 | No | Yes | 19 | Dead |
| 27 | 24 | No | Yes | 6 | Alive |
| 28 | 48 | No | Yes | NI | Dead |
| 29 | 56 | No | No | 22 | Alive |
| 30 | 77 | No | Yes | 17 | Alive |
| Prior to replacement (RR*, 95% CI) | Subsequent to replacement(RR, 95% CI) | |
| All Outdoor Injuries | 1.65 (1.50-1.82) | 2.07 (1.91-2.24) |
| Non-equipment injuries | 1.68 (1.50-1.89) | 2.41 (2.20-2.64) |
| Equipment-related injuries | 1.52 (1.24-1.86) | 1.13 (0.95-1.32) |
| KwaZulu-Natal (KZN) | Other South Africa (Other SA) | |||||
| Initial, 2002 | Annual growth (%) | Initial, 2002 | Annual growth (%) | |||
| AIDS | No AIDS | AIDS | No AIDS | |||
| Employment (1000s) | 1,902 | 0.63 | 1.75 | 7,988 | 0.81 | 1.64 |
| African | 1,436 | 0.90 | 2.24 | 5,677 | 1.05 | 2.11 |
| Skilled | 184 | 0.87 | 1.73 | 679 | 1.01 | 1.67 |
| Semi-skilled | 718 | 0.99 | 2.23 | 2,844 | 1.06 | 2.04 |
| Low skilled | 534 | 0.78 | 2.43 | 2,154 | 1.05 | 2.33 |
| Other | 466 | -0.31 | -0.24 | 2,311 | 0.15 | 0.24 |
| Labour productivity | - | 1.80 | 1.92 | - | 1.80 | 1.88 |
| African | - | 1.80 | 2.02 | - | 1.80 | 1.95 |
| Skilled | - | 1.80 | 1.93 | - | 1.80 | 1.89 |
| Semi-skilled | - | 1.80 | 2.02 | - | 1.80 | 1.96 |
| Low skilled | - | 1.80 | 2.10 | - | 1.80 | 2.00 |
| Other | - | 1.80 | 1.82 | - | 1.80 | 1.82 |
| Wages (Rands) | 75,511 | 3.09 | 4.05 | 96,054 | 2.94 | 3.93 |
| African | 59,219 | 2.48 | 2.88 | 91,944 | 2.67 | 3.33 |
| Skilled | 64,824 | 2.53 | 3.24 | 120,083 | 2.76 | 3.63 |
| Semi-skilled | 33,516 | 2.30 | 2.69 | 41,826 | 2.33 | 2.89 |
| Low skilled | 20,098 | 2.63 | 1.86 | 21,979 | 2.74 | 2.33 |
| Other | 91,803 | 3.44 | 4.68 | 100,163 | 3.19 | 4.41 |
| Polar Bear Scaffolds | 5′ LTR Location | 3′ LTR Location | Overall Mean K2P Distance | Age Estimation Mya |
| Scaffold 1 | 66,674,296–66,674,797 | 66,681,308–66,681,790 | 0.002 | 0.625 |
| Scaffold 7 | 30,626,500–30,627,187 | 30,633,692–30,634,278 | 0.007 | 2.1875 |
| Scaffold 162 | 7152–7643 | 13,824–14,441 | ND | ND |
| Scaffold 200 | 145,219–145,715 | 152,850–153,350 | 0 | 0 |
| Cardiac infarction | Crude estimate | Age-adjusted estimate | |||||
| Age (years) | Gender | Total | Yes | No | OR (95% CI), p-value | OR (95% CI), p-value | |
| iNPH | ≥ 35 - 70 | Female | 95 | 2 (2.1%) | 93 (97.9%) | 2.8 (0.7 – 11.6), NS | 1.5 (0.4 – 6.4), NS |
| HUNT3 | ≥ 35 - 70 | Female | 18,988 | 143 (0.8%) | 18,845 (99.2%) | ||
| iNPH | ≥ 35 - 70 | Male | 81 | 13 (16.0%) | 68 (84.0%) | 5.0 (2.8 – 9.1), <0.001 | 2.6 (1.4 – 4.7), 0.002 |
| HUNT3 | ≥ 35 - 70 | Male | 16,425 | 604 (3.7%) | 15,821 (96.3%) | ||
| iNPH | ≥70 - 90 | Female | 125 | 7 (5.6%) | 118 (94.4%) | 0.8 (0.64 – 1.8), .NS | 0.8 (0.4 – 1.8), NS |
| HUNT3 | ≥70 - 90 | Female | 4,384 | 298 (6.8%) | 4,086 (93.2%) | ||
| iNPH | ≥70 - 90 | Male | 139 | 19 (13.7%) | 120 (86.3%) | 0.8 (0.5 – 1.3), NS | 0.8 (0.5 – 1.3), NS |
| HUNT3 | ≥70 - 90 | Male | 3,590 | 580 (16.2%) | 3,010 (83.8%) |
| S-RAMM items | AUC | 95% confidence interval of AUC | p | Odds ratio | 95% confidence interval of OR | p | ||
| Lower | Upper | Lower | Upper | |||||
| B1 History of deliberate self harm | 0.474 | 0.275 | 0.672 | 0.783 | 1.186 | 0.582 | 2.416 | 0.639 |
| B2 Seriousness of previous suicidality | 0.411 | 0.215 | 0.607 | 0.349 | 1.513 | 0.724 | 3.159 | 0.271 |
| B3 Previous hospitalisation | 0.630 | 0.463 | 0.796 | 0.172 | 0.540 | 0.225 | 1.298 | 0.168 |
| B4 Mental disorder | 0.488 | 0.304 | 0.672 | 0.903 | 1.286 | 1.115 | 1.483 | 1.000 |
| B5 Substance abuse disorder | 0.554 | 0.372 | 0.737 | 0.568 | 0.792 | 0.368 | 1.703 | 0.550 |
| B6 Personality | 0.512 | 0.328 | 0.696 | 0.903 | 0.862 | 0.243 | 3.055 | 0.819 |
| B7 Childhood adversity | 0.529 | 0.370 | 0.688 | 0.760 | 0.906 | 0.423 | 1.939 | 0.799 |
| B8 Suicide in the family | 0.437 | 0.245 | 0.629 | 0.508 | 1.504 | 0.546 | 4.143 | 0.430 |
| B9 Age, Gender and marital status | 0.628 | 0.430 | 0.826 | 0.179 | 0.220 | 0.059 | 0.820 | 0.024 |
| C1 Suicidal ideation, communication and intent | 0.512 | 0.328 | 0.696 | 0.903 | 0.778 | 0.674 | 0.897 | 0.036 |
| C2 Hopelessness | 0.581 | 0.412 | 0.750 | 0.392 | ||||
| C3 Psychological symptoms | 0.650 | 0.486 | 0.815 | 0.114 | 0.452 | 0.178 | 1.149 | 0.095 |
| C4 Treatment adherence | 0.686 | 0.541 | 0.831 | 0.050 | ||||
| C5 Substance use | 0.500 | 0.314 | 0.686 | 1.000 | ||||
| C6 Psychiatric admission and discharge | 0.489 | 0.289 | 0.960 | 0.911 | 1.561 | ′0.089 | 27.253 | 0.760 |
| C7 Psychosocial stress | 0.709 | 0.534 | 0.884 | 0.028 | 0.254 | 0.073 | 0.882 | 0.031 |
| C8 Problem solving deficits | 0.682 | 0.513 | 0.852 | 0.055 | 0.349 | 0.125 | 0.974 | 0.045 |
| F1 Access to preferred method of suicide | 0.418 | 0.231 | 0.604 | 0.386 | 1.556 | 0.512 | 4.728 | 0.436 |
| F2 Future service contact | 0.686 | 0.513 | 0.859 | 0.050 | 0.407 | 0.167 | 0.990 | 0.047 |
| F3 Future response to drug treatment | 0.686 | 0.513 | 0.859 | 0.050 | 0.407 | 0.167 | 0.990 | 0.047 |
| F4 Future response to psychological intervention | 0.729 | 0.579 | 0.879 | 0.016 | 0.323 | 0.129 | 0.809 | 0.016 |
| F5 Future Stress | 0.520 | 0.328 | 0.712 | 0.831 | 0.803 | 0.264 | 2.444 | 0.699 |
| 50–64 yrs.(N = 1,021,648)n (%) | ≥ 65 yrs.(N = 1,011,817)N (%) | ODDS RATIO(OR)OR 95%CI | |
| Immunocompromising conditions | |||
| Primary immunodeficiency | 295 (<0.1) | 294 (<0.1) | 1.01 (0.85–1.19) |
| HIV infection | 2825 (0.3) | 449 (<0.1) | 0.16 (0.14–0.18) |
| Nephrotic syndrome | 577 (0.1) | 903 (0.1) | 1.58 (1.42–1.76) |
| Severe renal failure (GFR < 30) | 1058 (0.1) | 14,410 (1.4) | 13.94 (13.04–14.84) |
| Bone marrow trasplantation | 2415 (0.2) | 2619 (0.3) | 1.10 (1.04–1.16) |
| Recent cancer | 30,339 (3.0) | 73,609 (7.3) | 2.56 (2.53–2.68) |
| Immunosuppressive medication/Radiotherapy | 22,319 (2.2) | 49,721 (4.9) | 2.31 (2.28–2.35) |
| Other high risk condition | |||
| Asplenia | 186 (<0.1) | 108 (<0.1) | 0.59 (0.46–0.75) |
| Cochlear implant | 23 (<0.1) | 53 (<0.1) | 2.33 (1.39–3.91) |
| CSF leaks | 11 (<0.1) | 30 (<0.1) | 2.75 (1.33–5.83) |
| Chronic respiratory disease | 67,987 (6.7) | 144,268 (14.3) | 2.33 (2.31–2.36) |
| Chronic heart disease | 49,362 (4.8) | 199,015 (19.7) | 4.82 (4.77–4.87) |
| Liver disease | 20,567 (2.0) | 21,167 (2.1) | 1.04 (1.02–1.06) |
| Diabetes mellitus | 100,855 (9.9) | 240,680 (23.8) | 2.85 (2.83–2.87) |
| Alcoholism | 36,808 (3.6) | 21,973 (2.2) | 0.59 (0.58–0.60) |
| Smoking | 242,626 (23.7) | 74,932 (7.4) | 0.26 (0.25–0.27) |
| Recurrence | |
| Intrahepatic recurrence | 222 (76.6%) |
| Extrahepatic recurrence | 68 (23.4%) |
| Main treatment for recurrence | |
| Transplantation | 10 (3.4%) |
| Repeat resection | 29 (9.8%) |
| Local ablation therapy | 29 (9.8%) |
| TACE | 172 (58.1%) |
| Chemotherapy | 26 (4.3%) |
| Radiation therapy | 16 (5.4%) |
| Cause of death | |
| Recurrent HCC | 182 (80.9%) |
| Complication of liver cirrhosis without recurrence | 25 (11.1%) |
| Unrelated (including perioperative death) | 18 (8.0%) |
| Normoxic | Hypoxic | Hypoxic + CPP | |
| Alkaline Phosphatase | 179 | 195 | 176 |
| ALT | 25 | 30 | 33 |
| AST | 48 | 73 | 81 |
| Creatine Kinase | 163 | 236 | 225 |
| GGT | 2.0 | 3.0 | 2.4 |
| Albumin | 2.9 | 2.9 | 2.8 |
| Total Protein | 5.6 | 5.2 | 5.0 |
| Total Bilirubin | 0.1 | 0.1 | 0.1 |
| Blood Urea Nitrogen | 18.8 | 26.3 | 20.0 |
| Transient neurological symptoms | Age (years) | |||||||
| All | 65–74 (N=3657) | 75–84 (N=2618) | 85+ (N=473) | |||||
| N | Per cent* | N | Per cent* | N | Per cent* | N | Per cent* | |
| Loss of speech | 149 | 2.1 | 55 | 1.5 | 84 | 3.3 | 10 | 2.0 |
| Weakness | 239 | 3.7 | 117 | 3.4 | 106 | 4.1 | 16 | 3.4 |
| Loss of sight | 410 | 6.3 | 214 | 6.3 | 170 | 6.6 | 26 | 4.5 |
| At least one symptom | 675 | 9.8 | 327 | 9.3 | 304 | 11.6 | 44 | 7.8 |
| Subjects with DLCO | Subjects without DLCO | p-value | |
| Sample size | 53 | 20 | - |
| Age, years* | 64 (1) | 61 (2) | 0.16 |
| Sex, M/F | 32/21 | 10/10 | 0.43 |
| Pack years* | 54 (3) | 49 (5) | 0.49 |
| Current smokers (%) | 15 (28) | 4 (20) | 0.48 |
| ICS use (%) | 24 (45) | 12 (60) | 0.27 |
| SCS use (%) | 3 (6) | 2 (10) | 0.52 |
| % FEV1 * | 51 (4) | 51 (6) | 0.97 |
| FEV1/FVC* | 45 (2) | 46 (4) | 0.89 |
| Targets | <|P|> | <|N|> | dDFIRE | OPUS_PSP | RWplus | GOAP | ROTAS | |
| 4state_reduced | 7 | 195 | 468 | 0.86 | 0.80 | 0.81 | 0.91 | 0.92 |
| fisa | 2 | 47 | 453 | 0.79 | 0.60 | 0.79 | 0.79 | 0.77 |
| lmds | 2 | 60 | 439 | 0.74 | 0.64 | 0.66 | 0.61 | 0.56 |
| fisa_casp3 | 2 | 20 | 1672 | 0.74 | 0.58 | 0.72 | 0.68 | 0.70 |
| moulder | 19 | 151 | 169 | 0.95 | 0.93 | 0.95 | 0.95 | 0.96 |
| rosetta | 27 | 50 | 50 | 0.71 | 0.66 | 0.74 | 0.75 | 0.77 |
| I-TASSER | 31 | 229 | 217 | 0.79 | 0.71 | 0.77 | 0.80 | 0.80 |
| Amber99 | 41 | 219 | 821 | 0.87 | 0.79 | 0.83 | 0.93 | 0.93 |
| CASP5-8 | 89 | 14 | 7 | 0.82 | 0.75 | 0.84 | 0.83 | 0.84 |
| Total | 220 | 105 | 245 | 0.82 | 0.75 | 0.82 | 0.84 | 0.85 |
| p-value | 1.02E-04 | 7.70E-27 | 1.30E-03 | 2.03E-06 |
| # | Size | GO-ID | GO-Term | p-value | N% |
| 1 | 17 | GO:0030880 | RNA polymerase complex | 3.30986E-39 | 100.0 % |
| 2 | 8 | GO:0044428 | Nuclear part | 3.70274E-05 | 100.0 % |
| 3 | 7 | GO:0030126 | COPI vesicle coat | 1.37069E-21 | 100.0 % |
| 4 | 14 | GO:0044428 | Nuclear part | 7.23152E-10 | 100.0 % |
| 5 | 27 | GO:0005739 | Mitochondrion | 9.82318E-22 | 100.0 % |
| 7 | 18 | GO:0000502 | Proteasome complex | 1.76807E-40 | 100.0 % |
| 8 | 12 | GO:0005634 | Nucleus | 3.90352E-06 | 100.0 % |
| 9 | 7 | GO:0030008 | TRAPP complex | 1.02802E-20 | 100.0 % |
| 11 | 21 | GO:0005634 | Nucleus | 2.04087E-10 | 100.0 % |
| 12 | 10 | GO:0044425 | Membrane part | 4.18992E-10 | 100.0 % |
| 13 | 5 | GO:0035097 | Histone methyl–transferase complex | 1.31389E-11 | 100.0 % |
| 14 | 5 | GO:0030126 | COPI vesicle coat | 1.18247E-14 | 100.0 % |
| 15 | 9 | GO:0016585 | Chromatin remodeling complex | 2.37606E-17 | 100.0 % |
| 16 | 15 | GO:0000502 | Proteasome complex | 2.20275E-33 | 100.0 % |
| 17 | 13 | GO:0043189 | Histone acetyl–transferase complex | 1.21627E-39 | 100.0 % |
| 20 | 12 | GO:0016514 | SWI/SNF complex | 4.98150E-37 | 100.0 % |
| 21 | 60 | GO:0005634 | Nucleus | 2.15384E-32 | 100.0 % |
| 22 | 81 | GO:0043227 | Membrane-bound organelle | 4.87516E-23 | 100.0 % |
| 24 | 63 | GO:0044464 | Cell part | 3.42642E-05 | 98.4 % |
| 23 | 4 | GO:0031011 | INO80 complex | 4.13601E-07 | 75.0 % |
| ER-β | PR | |||||
| (+) | (-) | P | (+) | (-) | P | |
| Age (years) | ||||||
| ≥50 | 16 | 22 | 0.706 | 16 | 22 | 0.107 |
| <50 | 52 | 62 | 32 | 82 | ||
| Tumor size (cm) | ||||||
| ≥5 | 48 | 58 | 0.837 | 38 | 68 | 0.086 |
| <5 | 20 | 26 | 10 | 36 | ||
| Laterality | ||||||
| Bilateral | 50 | 57 | 0.446 | 41 | 67 | 0.008 |
| UnilateraI | 18 | 27 | 7 | 37 | ||
| Peritoneal metastasis | ||||||
| No | 57 | 44 | <0.001 | 40 | 61 | 0.003 |
| Yes | 11 | 40 | 8 | 43 | ||
| Signet-ring cells | ||||||
| Positive | 26 | 46 | 0.042 | 21 | 51 | 0.544 |
| Negative | 42 | 38 | 27 | 53 | ||
| Ascites | ||||||
| No | 30 | 23 | 0.031 | 19 | 34 | 0.407 |
| Yes | 38 | 61 | 29 | 70 | ||
| Ovarian metastases | ||||||
| Synchronous | 41 | 52 | 0.839 | 28 | 65 | 0.624 |
| Metachronous | 27 | 32 | 20 | 39 | ||
| Serum CEA (ng/mL) | ||||||
| Normal | 58 | 61 | 0.059 | 38 | 81 | 0.859 |
| >5 | 10 | 23 | 10 | 23 | ||
| Serum CA19-9 (U/mL) | ||||||
| Normal | 43 | 53 | 0.986 | 31 | 65 | 0.805 |
| >39 | 25 | 31 | 17 | 39 | ||
| Serum CA125 (U/mL) | ||||||
| Normal | 27 | 25 | 0.199 | 14 | 38 | 0.373 |
| >35 | 41 | 59 | 34 | 66 |
| Parameters | Present study | Verkerk et al. [16] | Tüysüz et al. [15] | |
| Ind IV:3 | Ind IV:4 | |||
| Gender | M | M | 3F/2M | 3F/1M |
| Age at last examination (y.) | 14 | 12 | 1.5/21/22/23/24 | 2.5/10.5/11/17 |
| Head circumference | −2SD | −2SD | −1 to −2.5 SD | −2 to −4 SD |
| Height (cm) | 157 | 137 | NA | NA |
| Intellectual disability | Severe | Severe | Severe in 5/5 | Severe in 3/4 |
| Seizures | + | - | - | + |
| Shy character | - | - | + | + |
| Aggressive behavior | + | + | - | - |
| Stereotype laughter | - | - | + | + |
| Severe speech disorder | + | + | + | + |
| Infantile hypotonia | + | + | + | + |
| Hypertonia | + | + | + | + |
| Hyperreflexia | + | + | NA | NA |
| Babinski sign | + | + | + | NA |
| Spasticity | + | + | + | + |
| Club feet | - | - | + | + |
| Independent walking (y.) | 2 | 4 | - | +/− |
| Ambulation | - | - | - | - |
| Craniofacial features | ||||
| Facial hypotonia | - | - | NA | + |
| Bitemporal narrowing | - | - | NA | + |
| Broad nasal bridge | - | - | NA | + |
| Bulbous nose | - | + | NA | + |
| Short philtrum | + | + | NA | + |
| Brain MR imaging | Yes | No | 3/5 | 4/4 |
| Widened lateral ventricles | + | + | + | |
| Thin splenium of the CC | + | + | + | |
| Cerebellar hypoplasia/atrophy | + | 2/3 | - |
| Characteristic | Value | % |
| Age (years) | ||
| Range | 30–87 | |
| Mean ± SD (range) | 60.3±15.9 | |
| Gender, n | ||
| Male | 62 | 51.2 |
| Female | 59 | 48.8 |
| Diagnosis method, n | ||
| Histological diagnosis | 78 | 64.5 |
| Imaging and medical history diagnosis | 43 | 35.5 |
| Tumor type, n | ||
| Colorectal cancer | 52 | 43.0 |
| Lung cancer | 19 | 15.7 |
| Breast cancer | 14 | 11.6 |
| Renal cancer | 7 | 5.8 |
| Gastric cancer | 5 | 4.1 |
| Other | 24 | 19.8 |
| Tumor loading, n | ||
| With | 72 | 59.5 |
| Without | 49 | 40.5 |
| Adjuvant radiotherapy and/or chemotherapy, n | ||
| With | 71 | 58.7 |
| Without | 50 | 41.3 |
| Investigator | Patient | Total fibres | % COX positive | % Intermediate positive | % Intermediate negative | % COX negative |
| 1 | DYSF 1 | 1491 | 98.2% | 1.8% | 0.0% | 0.0% |
| DYSF 2 | 577 | 75.4% | 18.4% | 6.1% | 0.1% | |
| DYSF 3 | 963 | 65.5% | 21.9% | 11.9% | 0.6% | |
| DYSF 4 | 1774 | 97.7% | 5.0% | 0.1% | 0.0% | |
| DYSF 5 | 397 | 86.9% | 12.8% | 0.3% | 0.0% | |
| DYSF 6 | 563 | 80.8% | 17.9% | 0.9% | 0.4% | |
| DYSF 7 | 132 | 69.7% | 30.3% | 0.0% | 0.0% | |
| DYSF 8 | 453 | 92.5% | 4.9% | 2.0% | 0.7% | |
| 2 | DYSF 1 | 1357 | 83.6% | 16.3% | 0.07% | 0.0% |
| DYSF 2 | 382 | 71.7% | 26.9% | 1.5% | 0.0% | |
| DYSF 3 | 328 | 65.9% | 30.4% | 3.7% | 0.0% | |
| DYSF 4 | 1131 | 97.1% | 2.6% | 0.2% | 0.1% | |
| DYSF 5 | 395 | 77.7% | 22.0% | 0.3% | 0.0% | |
| DYSF 6 | 726 | 70.4% | 27.1% | 1.9% | 0.6% | |
| DYSF 7 | 135 | 58.5% | 31.1% | 10.4% | 0.0% | |
| DYSF 8 | 463 | 78.2% | 20.3% | 1.2% | 0.4% |
| Metagenome source | Sample | Metagenome type | Categories observedN | Shannon diversity Index (H’) | Evenness (E) |
| This study | Cow 2202C | Virome | 20 | 2.192 | 0.732 |
| Cow 657 | Virome | 21 | 2.162 | 0.710 | |
| Cow 1995 | Virome | 22 | 2.299 | 0.744 | |
| Cow 2028 | Virome | 20 | 2.052 | 0.685 | |
| Cow 2042 | Virome | 17 | 2.011 | 0.710 | |
| Cow 2165 | Virome | 16 | 1.911 | 0.689 | |
| Cow 3060 | Virome | 16 | 2.150 | 0.775 | |
| Cow 4570 | Virome | 15 | 2.023 | 0.747 | |
| Cow 5679 | Virome | 18 | 2.184 | 0.756 | |
| Cow 6833 | Virome | 19 | 2.125 | 0.722 | |
| Cow 6857 | Virome | 18 | 2.142 | 0.741 | |
| Cow 6870 | Virome | 16 | 1.756 | 0.633 | |
| Cow 7939 | Virome | 21 | 2.200 | 0.722 | |
| Average* | Virome | 18.4 | 2.093 | 0.720 | |
| Other Studies | Cow 6993 [8] | Virome | 36 | 2.425 | 0.677 |
| Cow 766 [8] | Virome | 34 | 2.553 | 0.724 | |
| Cow 7887 [8] | Virome | 35 | 2.580 | 0.726 | |
| Swine Faeces [18]+ | Virome | 33 | 2.398 | 0.686 | |
| Human Saliva [19]+ | Virome | 36 | 2.221 | 0.620 | |
| Pond [20]+ | Virome | 31 | 2.537 | 0.739 | |
| Cow 2202C[6] | Microbial | 27 | 2.731 | 0.829 | |
| Cow 3063C[6] | Microbial | 30 | 2.794 | 0.822 | |
| Cow 6803C[6] | Microbial | 30 | 2.778 | 0.817 | |
| Cow 6852C[6] | Microbial | 29 | 2.809 | 0.834 | |
| Cow 6859C[6] | Microbial | 29 | 2.860 | 0.849 | |
| Cow 6882C[6] | Microbial | 24 | 2.752 | 0.866 | |
| Cow 7920C[6] | Microbial | 28 | 2.762 | 0.829 |
| Group 1 | Group 2 | Group 3 | ||||||
| Relapsing- remitting MS | Primary progressive MS | Secondary progressive MS | Healthy controls | Pediatric onset MS | Pediatric healthy controls | Pre- relapse patients | Relapse patients | |
| N | 20 | 13 | 12 | 48 | 12 | 10 | 18 | 11 |
| Males N (%) | 3 (15.0) | 6 (46.2) | 1 (8.3) | 14 (29.2) | 4 (33.3) | 3 (30.0) | 3 (16.7) | 2 (18.2) |
| Age Mean (SD) | 43.0 (8.9) | 56.9 (7.7) | 53.6 (12.5) | 45.1 (13.1) | 13.9 (2.3) | 11.4 (3.3) | 40.7 (11.3) | 36.4 (10.9) |
| Hispanic N (%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (8.3) | 1 (10.0) | 1 (5.6) | 0 (0) |
| White N (%) | 18 (90.0) | 13 (100) | 12 (100) | 44 (91.7) | 10 (83.3) | 8 (80.0) | 17 (94.4) | 9 (81.8) |
| BMI Mean (SD) | 27.7 (5.0) | 30.1 (5.4) | 30.7 (7.9) | 26.0 (6.2) | 26.9 (9.2) | 21.4 (3.7) | 26.2 (4.4) | 29.5 (6.3) |
| EDSS Median (Range) | 2 (0–4.5) | 6 (1.5-7) | 5.0 (2.5-8.0) | 1.75 (0–2) | 1.75 (0–6) | 2 (0–3.5) | ||
| Disease Duration Mean (SD) | 11.3 (9.3) | 14.5 (7.6) | 19.9 (9.6) | 1.75 (2.1) | 8.1 (6.6) | 8.2 (5.5) | ||
| Leptin (pg/ml) Mean (SD) | 23,462.3 (27,708.9) | 17,924.6 (14,009.8) | 40,412.6 (27,951.8) | 13,840.5 (18,447.6) | 27,357.3 (20,207.4) | 11,177.0 (11,484.7) | 24,381.6 (20,350.1) | 37,587.1 (26,465.4) |
| A-FABP (ng/ml) Mean (SD) | 21.2 (14.6) | 34.9 (18.9) | 38.8 (15.5) | 18.4 (18.8) | 26.7 (18.0) | 14.7 (7.6) | 17.5 (10.5) | 27.7 (13.1) |
| Code | Test | Supported draft |
| INV_1_24 | FISH/int | UMD (85%) |
| INV_1_53.3 | FISH/int | UMD (94%) |
| INV_4_7.2 | FISH/int | UMD (90%) |
| INV_7_103.2 | FISH/int | UMD (96%) |
| INV_10_59.3 | FISH/int | UMD (95%) |
| INV_14_32 | FISH/int | UMD (73%) |
| INV_20_0 | FISH/int | UMD (98%) |
| INV_23_0 | FISH/met. | UMD |
| INV_26_18.8 | FISH/int | UMD (75%) |
| INV_27_42.3 | FISH/int | UMD (90%) |
| MDP_4_16.2 | FISH/int | Btau (98%) |
| MDP_5_9.6 | FISH/met. | UMD |
| MDP_7_7.6 | PCR | UMD |
| MDP_7_43.1 | PCR | - |
| MDP_28_0.7 | PCR | UMD |
| DCM_2-11 | FISH/met | UMD |
| DCM_3-13 | FISH/met | Btau |
| DCM_3-2 | FISH/met | UMD |
| DCM_3-22 | FISH/met | UMD |
| DCM_7-X | FISH/met | UMD |
| DCM_10-1 | FISH/met | UMD |
| DCM_10-4 | FISH/met | UMD |
| DCM_15-X | FISH/met | UMD |
| DCM_27-21 | FISH/met | Btau |
| Allpaths-LG/ | Allpaths-LG/ | ||
| Scaffold sequences | Allpaths-LG | Sspace/GapClose | Sspace/GapClose/Reapr |
| Number | 57 815 | 16 090 | 13 206 |
| Total size, without gaps, bp | 469 049 393 | 565 959 143 | 476 867 120 |
| Total size, with gaps, bp | 614 626 609 | 586 542 612 | 503 314 177 |
| Number > 10 Kbp | 10 029 | 8602 | 8348 |
| Number > 20 Kbp | 6920 | 6791 | 6647 |
| Number > 100 Kbp | 1100 | 1709 | 1304 |
| Number > 1 Mbp | 2 | 0 | 0 |
| Longest sequence, bp | 1 844 569 | 979 053 | 558 523 |
| Average size, bp | 10 631 | 36 454 | 38 112 |
| N50 length, bp | 57 726 | 97 266 | 80 946 |
| L50 count | 2595 | 1792 | 1906 |
| GC % | 33.63 | 33.57 | 33.62 |
| Process Type | processes | instances | Time | Total ($) |
| Blast | 21945 | 100 | 40 hours 0 mins | $ 3,680 |
| Ortholog Estimation | 281160 | 100 | 28 hours 21 mins | $ 2,622 |
| Odds ratio | 95% Confidence interval | P value | |
| Predictors of AKI | |||
| Log angiopoietin-2 | 4.41 | 2.02–9.63 | <0.0001 |
| Log osteoprotegerin | 1.98 | 1.02–3.82 | 0.043 |
| Agea | 1.07 | 1.04–1.10 | <0.0001 |
| Predictor of severe malaria | |||
| Log angiopoietin-2 | 5.35 | 2.01–14.25 | 0.001 |
| Log osteoprotegerin | 2.66 | 1.15–6.14 | 0.022 |
| Log parasite count | 1.47 | 1.15–1.89 | 0.002 |
| Treatment | N | Median | IQR | RR | 95% CI | z value | p value |
| No insecticide | 1054 | 47.0 | 22.0 – 110.3 | 45.0 | [23.1, 87.8] | 11.168 | NA |
| Transfluthrin coils | 737 | 71.0 | 28.0 – 92.5 | 41.1 | [33.6, 50.2] | -0.897 | 0.369 |
| Metofluthrin coils | 877 | 67.0 | 39.8 – 103.0 | 51.1 | [42.0, 62.3] | 1.273 | 0.203 |
| DDT 2gm2 | 821 | 42.5 | 37.5 – 72.3 | 44.9 | [36.8, 54.8] | -0.014 | 0.989 |
| Any enteric pathogen | Campylobacter spp. | Giardia spp. | Pathogenic Escherichia coli† | |||||
| PR (95% CI) | P value | PR (95% CI) | P value | PR (95% CI) | P value | PR (95% CI) | P value | |
| Neighborhood: Old Town | 1.32 (0.50, 3.49) | 0.57 | 1.91 (0.71, 5.14) | 0.18 | 1.56 (0.48, 6.46) | 0.45 | 0.73 (0.14, 3.78) | 0.64 |
| Poor hygiene | 1.97 (0.75, 5.62) | 0.17 | 3.42 (1.30, 12.3) | 0.02 | 1.69, (0.53, 7.27) | 0.39 | 0.55 (0.07, 3.37) | 0.34 |
| Neighborhood: Old Town | 1.37 (0.51, 3.72) | 0.53 | 2.15 (0.80, 5.97) | 0.13 | 1.60 (0.49, 6.78) | 0.47 | 0.70 (0.11, 5.02) | 0.56 |
| Poor hygiene | 2.01 (0.76, 5.77) | 0.16 | 3.61 (1.37, 11.4)† | 0.01 | 1.72 (0.54, 7.57) | 0.54 | 0.53 (0.09, 4.10) | 0.31 |
| Pathway | TF | miRNA |
| Activin | TP53 | miR-143 |
| AKT | MYC | miR-145 |
| ALK | GATA4 | miR-187 |
| ATM | SMAD1 | miR-296 |
| BMI1 | ESRRB | miR-301 |
| BMP | SOX2 | miR-21 |
| Cell cycle | NANOG | let-7a |
| EGF/EGFR | KLF4 | miR-371 |
| ERBB2 | MYB | miR-372 |
| ERK | MYCN | miR-373 |
| FGF | ZFX | miR-367 |
| Glycolysis | STAT3 | miR-302a |
| Hippo | ZIC3 | miR-302a* |
| IGF | ZFP42 | miR-302b |
| JAK/STAT | SALL4 | miR-302b* |
| c-KIT | REST | miR-302c |
| Lefty | TCF3 | miR-302c* |
| LIF | HOXB1 | miR-302d |
| MAPK | HAND1 | miR-200c |
| MEK/ERK | POU5F1 | miR-222 |
| NF-κB | SRY | |
| NHEJ/HR a | TBX5 | |
| Nodal | E2F4 | |
| Notch | GATA6 | |
| p53 | PAX6 | |
| PRC2 | TCF4 | |
| PDGF | FOXD3 | |
| PI3K | CNOT3 | |
| PTEN | ZEB2 | |
| RAS | ESX1L | |
| RTK | ||
| Hedgehog (SHH) | ||
| Smad | ||
| Stat3 | ||
| Telomerase | ||
| TGFβ | ||
| VEGF | ||
| WNT |
| Variable | Dextrose75 g | Dextrose150 g | Lipid33 g | Lipid66 g |
| Kilocalories | 2023 ± 237 | 2354 ± 242 | 1983 ± 206 | 1789 ± 181 |
| Protein (g) | 92 ± 11 | 102 ± 9 | 95 ± 13 | 88 ± 16 |
| Carbohydrate (g) | 261 ± 39 | 315 ± 41 | 248 ± 31 | 247 ± 33 |
| Fat (g) | 72 ± 11 | 81 ± 12 | 72 ± 13 | 57 ± 9 |
| Vitamin C (mg) | 64 ± 26 | 47 ± 11 | 40 ± 7 | 51 ± 13 |
| Vitamin E (mg) | 4 ± 2 | 4 ± 1 | 3 ± 1 | 3 ± 1 |
| Vitamin A (RE) | 267 ± 82 | 374 ± 110 | 228 ± 113 | 236 ± 102 |
| Parameter | Shams | Exposure to AO nanowhiskers for: | |
| 2 wks | 4 wks | ||
| Total cells/mouse, n x 103 | 74.0 ± 7.9 | 171.6 ± 19.7 ** | 440.3 ± 33.6 *** |
| Total protein, μg/mL | 107.7 ± 4.7 | 108.0 ± 1.5 | 101.2 ± 2.7 |
| LDH activity, U/L | 180 ± 18 | 146 ± 17 | 191 ± 10 |
| Variables | Cases | Controls | P value | ||
| N = 357 | % | N = 1,428 | % | ||
| Age at DM | 0.483 | ||||
| 30-60 | 69 | 15.90 | 300 | 17.28 | |
| ≥60 | 288 | 66.36 | 1,128 | 64.98 | |
| Sex | 1.000 | ||||
| Male | 215 | 49.54 | 568 | 32.72 | |
| Female | 142 | 32.72 | 860 | 49.54 | |
| Peptic ulcer history | 172 | 39.63 | 334 | 19.24 | <0.001 |
| Ulcer bleeding history | 61 | 14.06 | 156 | 8.99 | <0.001 |
| HP eradication rate | 33 | 7.60 | 139 | 8.01 | 0.779 |
| Comorbidities | |||||
| CAD | 120 | 27.65 | 603 | 34.74 | 0.003 |
| CVD | 84 | 19.35 | 466 | 26.84 | <0.001 |
| CLD | 78 | 17.97 | 337 | 19.41 | 0.484 |
| COPD | 98 | 22.58 | 465 | 26.79 | 0.063 |
| CKD | 77 | 17.74 | 431 | 24.83 | 0.001 |
| GERD or EE | 21 | 4.84 | 91 | 5.24 | 0.733 |
| Medications | |||||
| Pioglitazone | 25 | 5.76 | 154 | 8.87 | 0.033 |
| Rosiglitazone | 34 | 7.83 | 211 | 12.15 | 0.010 |
| Metformin | 236 | 54.38 | 990 | 57.03 | 0.241 |
| Sulfonylurea | 256 | 58.99 | 1,022 | 58.87 | 0.958 |
| Glucosidase inhibitors | 36 | 8.29 | 293 | 16.88 | <0.001 |
| Meglitinides (Glinides) | 35 | 8.06 | 241 | 13.88 | <0.001 |
| DPP-4 inhibitors | 1 | 0.23 | 85 | 4.90 | <0.001 |
| Insulin | 37 | 8.53 | 265 | 15.26 | <0.001 |
| Statins | 86 | 19.82 | 531 | 30.59 | <0.001 |
| ARBs | 88 | 20.28 | 534 | 30.76 | <0.001 |
| ACE inhibitors | 126 | 29.03 | 560 | 32.26 | 0.173 |
| Aspirin | 118 | 27.19 | 610 | 35.14 | <0.001 |
| COX-2 inhibitors | 27 | 6.22 | 189 | 10.89 | 0.003 |
| NSAIDs | 74 | 17.05 | 432 | 24.88 | <0.001 |
| Gram | Bacterial strain | Concentration of SS-capped AgNPs (mM) | MIC (mM) | ||||
| 0.001 | 0.004 | 0.008 | 0.017 | 0.034 | |||
| + | MRSA | T | T/C | C | C | C | 0.008 |
| + | S. aureus | T | T/C | C | C | C | 0.008 |
| + | B. subtilis | T | T/C | C | C | C | 0.008 |
| − | P. aeruginosa | T | C | C | C | C | 0.004 |
| − | A. baumannii | C | C | C | C | C | 0.001 |
| − | E. coli | T | C | C | C | C | 0.004 |
| ACE genotype | II | D carriers | ||
| Percent body fat category | Normal fat(n = 30) | Overfat(n = 15) | Normal fat(n = 62) | Overfat(n = 45) |
| SBP (mmHg) | 103.2 (1.3)* | 105.7 (1.9) | 102.6 (0.9)# | 108.1 (1.1)*# |
| DBP (mmHg) | 68.6 (1.1) | 70.2 (1.6) | 69.5 (0.8) | 71.4 (1.0) |
| TCPC (n = 6) | TCPC + AVR (n = 4) | |
| Morphology of AV valve | ||
| SAVV (morphologically tricuspid valve) | 5 (83 %) | 0 |
| CAAV | 1 (17 %) early death | 4 (100 %) |
| Degree of AV valve regurgitation | ||
| Slight | 3 (50 %) | 0 |
| Mild | 3 (50 %) | 0 |
| Moderate | 0 | 2 (50 %) |
| Severe | 0 | 2 (50 %) |
| Early mortality | 1 | 0 |
| Patient | 1 | 2 | 3 | 4 |
| Age at onset (y) | 6 | 1 | 0.8 | 2 |
| Age at diagnosis* (y) | 10 | 6 | 11 | 5 |
| Present age (y) | 13 | 8 | 15 | Died at 8 Y |
| Family history | + | + | - | - |
| First symptom | Septicemia | Otitis media | Otitis media | Otitis media |
| Otitis media | + | + | + | + |
| Sinusitis | + | - | + | - |
| Pneumonia | + | + | + | + |
| Bronchiectasis | + | - | + | - |
| Arthritis | + | - | - | + |
| Skin infection | + | + | - | - |
| Septicemia | + | + | + | + |
| Meningitis/encephalitis | + | - | + | - |
| Recurrent diarrhea | - | - | - | + |
| Tonsils | Absent | Hypoplastic | Absent | Hypoplastic |
| Duration of IVIG treatment (m) | 25 | 17 | 33 | 12 |
| Gene Set | Number of Genes | Categorized Genes | p-Value |
| Galactose metabolism | 16 | Gck | <0.0001 |
| Cysteine metabolism | 16 | Sult1c2 | 0.003 |
| Aminoacyl-tRNA biosynthesis | 16 | Vars2 | 0.009 |
| Wnt signaling pathway | 112 | Sox17Dkk2 * | 0.014 |
| Taste transduction | 29 | Gnat3 *Tas2r114 | 0.046 |
| C21-Steroid hormone metabolism | 10 | Cyp21a1 | 0.1250 |
| Chondroitin sulfate biosynthesis | 14 | B3gat2Chst12 | 0.1260 |
| Antigen processing and presentation | 58 | RT1-Aw2 | 0.163 |
| Primer | Forward | Reverse |
| IFN-γ | GGTCAACAACCCACAGGTCC | CGACTCCTTTTCCGCTTCC |
| IL-4 | TCTCGAATGTACCAGGAGCCATATC | AGCACCTTGGAAGCCCTACAGA |
| IL-10 | GCTCCTAGAGCTGCGGACT | TGTTGTCCAGCTGGTCCTTT |
| IL-17A | AGGACGCGCAAACATGAGTC | TTGGACACGCTGAGCTTTGAG |
| TGF-β | CTGGATACCAACTACTGCTTCAG | TTGGTTGTAGAGGGCAAGGACCT |
| Foxp3 | ACACCCAGGAAAGACAGCAAC | CTCGAAGACCTTCTCACAACCAG |
| GAPDH | CAACTTTGGCATTGTGGAAGG | ACACATTGGGGGTAGGAACAC |
| Aspects | Score/question |
| 1. Risk factors associated with obstetric fistula | 1 |
| - Early pregnancy | 0.125 |
| - Home delivery | 0.125 |
| - Female Genital Mutilation | 0.125 |
| - Evil spirits | 0.125 |
| - Breach of a prohibited act | 0.125 |
| - Prolonged labour | 0.125 |
| - Bad luck | 0.125 |
| - Malnutrition of the mother | 0.125 |
| 2. Symptoms of obstetric fistula | 1 |
| - Urinary incontinence | 0.2 |
| - Faecal incontinence | 0.2 |
| - Continuous sleeping | 0.2 |
| - Stomach ache | 0.2 |
| - Vulva irritation | 0.2 |
| 3. Duration of normal labour | 1 |
| 4. Source of emergency obstetric care | 1 |
| Total | 4 |
| Standard Deviation (change) | Treatment Change | N per group | N total |
| 18 | 20 | 14 | 28 |
| 28 | 8 | 16 | |
| 30 | 7 | 14 | |
| 20 | 20 | 17 | 34 |
| 28 | 9 | 18 | |
| 30 | 8 | 16 | |
| 22 | 20 | 20 | 40 |
| 28 | 11 | 22 | |
| 30 | 10 | 20 | |
| 25 | 20 | 26 | 52 |
| 28 | 14 | 28 | |
| 30 | 12 | 24 |
| Patients’ characteristics | ADC | NAET | Whole sample | Chi square (p-value) | |
| Number (%) | Number (%) | Number (%) | |||
| Industrial sector | Wood | 16 (50) | 5 (24) | 21 (40) | 14.60 (0.001) |
| Leather | 11 (34) | 2 (10) | 13 (25) | ||
| Other | 5 (16) | 14 (67) | 19 (36) | ||
| Age (years) | ≤59 | 8 (25) | 10 (48) | 18 (34) | 4.17 (0.125) |
| 60–74 | 8 (25) | 6 (29) | 14 (26) | ||
| >74 | 16 (50) | 5 (23) | 21 (40) | ||
| Smoking (pack-years) | 0 | 17 (53) | 14 (67) | 31 (58) | 2.67 (0.263) |
| ≤18 | 6 (19) | 5 (24) | 11 (21) | ||
| >18 | 9 (29) | 2 (9) | 11 (21) | ||
| Sex | M | 26 (81) | 14 (67) | 40 (75) | 1.46 (0.227) |
| W | 6 (19) | 7 (33) | 13 (25) | ||
| Chronic Sinusitis | Yes | 6 (19) | 4 (19) | 10 (19) | 0.001 (0.978) |
| No | 26 (81) | 17 (81) | 43 (81) | ||
| Allergies | Yes | 4 (13) | 2 (10) | 6 (11) | 0.11 (0.738) |
| No | 28 (87) | 19 (90) | 47 (89) | ||
| Site of onset | Ethmoid | 32 (100) | 6 (29) | 38 (72) | |
| Maxillary | 0 | 8 (38) | 8 (15) | ||
| Septum | 0 | 7 (33) | 7 (13) | ||
| ADC subtype | ITACa | 30 (94) | - | - | |
| Non-ITAC | 2 (6) | - | - |
| sense | antisense | |
| #1 | GTATCTGCACTCTCAATCAGGAGC | AAACTGTAACCCCTATCTCTACTCAC |
| #2 | CCTGGGTTTCCACCATATGCTTTC | AGTTCCTTGCACTCCTGTTAACAA |
| #3 | CCTGGGTTTCCACCATATGCTTTC | GGTCGCCTAGTGTCATGACCA |
| #4 | GACCACATCCCAACCGAATC | CACAGGCCAGACTGACACCC |
| #5 | GACCACATCCCAACCGAATC | CTGACACCCAGTAGTGAAGG |
| #6 | GATAGCAGCCGCAGAAGAGC | CCACCTGGGTTTCCACCATA |
| Commercial laboratory variable | Mean change younger cohort | Mean change older cohort | p-value |
| CD3% | −2.75 | 2.33 | 0.036 |
| CD4% | −2.50 | 1.67 | 0.028 |
| WBC | 2.13 | −0.70 | 0.031 |
| IgA | 4.25 | −13.17 | 0.059 |
| Zinc/Copper Ratio | −0.08 | 0.13 | 0.061 |
| Strain | Source | Accession no. | Genome size (bp) | N50 (bp) | No. of scaffolds (>300 bp) | G+C content (%) |
| Arcobacter sp. AF1028 | Human feces | JART00000000 | 2,414,790 | 148,259 | 46 | 27.24 |
| Arcobacter sp. AF1078 | Human feces | JARS00000000 | 2,496,885 | 127,252 | 53 | 27.18 |
| All articles (n=168) | Including NEJM protocols (n=61) | |
| Characteristics | n (%) | n (%) |
| Journal | ||
| NEJM | 61 (36) | 61 |
| Lancet | 64 (38) | |
| JAMA | 19 (11) | |
| BMJ | 8 (5) | |
| Annals of Internal Medicine | 5 (2) | |
| PLoS Medicine | 7 (4) | |
| Archives of Internal Medicine | 2 (1) | |
| JAMA of Internal Medicine | 2 (1) | |
| Year of publication | ||
| 2010 | 26 (15) | 9 (15) |
| 2011 | 27 (16) | 9 (15) |
| 2012 | 29 (17) | 8 (13) |
| 2013 | 39 (23) | 19 (31) |
| 2014 | 27 (16) | 10 (16) |
| 2015 | 20 (12) | 6 (10) |
| Type of intervention | ||
| Drug | 112 (67) | 44 (72) |
| Surgery | 22 (13) | 7 (11) |
| Other | 34 (20) | 10 (16) |
| Randomisation | ||
| Patient | 163 (97) | 59 (97) |
| Cluster | 5 (3) | 2 (3) |
| Power | ||
| 80% | 6 (36) | 19 (31) |
| 85% | 11 (7) | 5 (8) |
| 90% | 65 (39) | 26 (43) |
| 71–99% (excluding the above) | 21 (12) | 11 (18) |
| Not reported/unclear | 10 (6) | 0 |
| Composite outcome | ||
| Yes | 78 (46) | 37 (61) |
| No | 90 (54) | 24 (39) |
| Disease | ||
| Heart disease | 30 (18) | 13 (21) |
| Blood disorder | 19 (11) | 6 (10) |
| Cancer | 16 (10) | 8 (13) |
| Diabetes | 11 (7) | 2 (3) |
| Thromboembolism | 6 (4) | 6 (10) |
| Skin infection (non-contagious) | 3 (2) | 2 (3) |
| Urinary tract infection | 3 (2) | 0 |
| Arthritis | 3 (2) | 1 (2) |
| Opthomology | 3 (2) | 1 (2) |
| Pneumonia | 3 (2) | 1 (2) |
| Complications in pregnancy | 3 (2) | 0 |
| Stroke | 3 (2) | 2 (3) |
| Testing method | 3 (2) | 1 (2) |
| Appendicitis | 2 (1) | 1 (2) |
| Depression | 2 (1) | 0 |
| Other non-infectious disease | 18 (11) | 7 (11) |
| HIV | 18 (11) | 2 (3) |
| Tuberculosis | 6 (4) | 4 (7) |
| Malaria | 4 (2) | 1 (2) |
| Skin infection (contagious) | 2 (1) | 0 |
| Hepatitis C | 2 (1) | 2 (3) |
| Other infectious disease | 8 (5) | 1 (2) |
| Author | Study design | Oral health criteria | Study population | Results |
| Bundgaard et al. (85) | Case-control | Missing teeth | 161 patients and 400 controls (Denmark) | Significantly increased risk of developing oral SCCA for patients with fewer than 15 teeth |
| Rezende et al. (86) | Case-control | CPITNa and DMFTb | 50 patients and 50 controls (Cuba) | 76% of subjects in cancer group showed greater than 6 mm pockets compared to 10% of control group |
| Garrote et al. (87) | Case-control | Missing teeth | 200 patients and controls (Cuba) | Significantly increased risk of oral cancer for patients missing 16 or more teeth |
| Hiraki et al. (88) | Case-control | Missing teeth | 429 patients and 10,480 controls (Japan) | Significantly increased risk of head and neck cancer with decreased number remaining teeth |
| Marshall et al. (89) | Case-control | Missing teeth | 290 patients and controls (United States) | Significantly increased risk of oral cancer with loss of 11 or more teeth |
| Michaud et al. (90) | Cohort | Self-reported history of periodontal disease (confirmed by radiographs and missing teeth) | 118 patients (United States) | No significant increase in risk for oropharyngeal cancer with history of periodontal disease or increased number of tooth loss |
| Rosenquist et al. (91) | Case-control | Missing teeth | 132 patients and 320 controls (Sweden) | Significantly increased risk of oral and oropharyngeal cancer for missing over 20 teeth |
| Tezal et al. (92) | Cohort | Clinical attachment loss (CAL) | 131 oral tumors and 323 oral pre-cancerous lesions (United States) | Significantly increased risk of oral tumor and pre-cancerous lesion with >1.5 mm clinical attachment loss |
| Tezal et al. (81) | Case-control | Alveolar bone loss | 51 cases and 54 controls (United States) | Significantly increased risk of tongue cancer with increased alveolar bone loss |
| Tezal et al. (82) | Case-control | Alveolar bone loss | 266 patients and 207 controls (United States) | Significantly increased risk of oral cavity SCC with periodontitis |
| Tezal et al. (93) | Case-control | Alveolar bone loss | 124 head and neck SCC patients (United States) | Periodontitis is associated with tumor HPV status |
| Wen et al. (94) | Cohort | Medical records from insurance claims | 96,375 gingivitis and 51,791 periodontitis cases (Taiwan) | Significantly increased risk of oral cancer with the history of periodontitis |
| Zheng et al. (95) | Case-control | Missing teeth | 404 subjects and controls (United States) | Significantly increased risk of oral cancer with increased missing teeth |
| Injure | 1-4 y | 5-9 y | 10-14 y |
| Transport accidents | 21(47.7) | 23(39.7) | 45(51.7) |
| Accidental drowning and submersion | 2(4.5) | 17(29.3) | 28(32.2) |
| Falls | 7(15.9) | 5(8.6) | 5(5.7) |
| Suicide | 0(0) | 1(1.7) | 4(4.6) |
| Suffocation | 4(9.0) | 3(5.2) | 2(2.3) |
| Other | 14(31.8) | 11(19) | 3(3.4) |
| Characteristic | Patients (n= 19)(%) |
| Sex (males/females) | 12/7 |
| Age, years, median (range) | 54 (30–75) |
| Underlying liver disease | |
| Hepatitis B virus | 11 (57.89) |
| Alcoholic | 3 (15.79) |
| Autoimmune hepatitis | 1 (5.26) |
| Hybrid cause | 4 (21.05) |
| Basic underlying disease | |
| Cardiovascular disease | 4 (21.05) |
| Diabetes mellitus type 2 | 2 (10.53) |
| Chronic lung diseases | 2 (10.53) |
| Complications | |
| Hepatic encephalopathy | 8 (42.10) |
| Hepatic renal syndrome | 4 (21.05) |
| Upper gastric bleeding | 4 (21.05) |
| Ascites | 16 (84.21) |
| Hydrothorax | 10 (52.63) |
| Hepatic carcinoma | 2 (10.53) |
| CTP scores (mean ± SD) | 11 ± 2 |
| Child B | 6 (31.58) |
| Child C | 13 (68.42) |
| MELD (mean ± SD) | 22 ± 7 |
| Neutropenia | 2 (10.53) |
| Broad-spectrum antibiotics usage | 18 (94.74) |
| One antibiotic | 9 (47.37) |
| Two antibiotics | 4 (21.05) |
| Three antibiotics | 5 (26.32) |
| Steroids exposure(longer than 1 week) | 11 (57.89) |
| Survival rate | |
| 1 month | 5/19 |
| 3 month | 4/19 |
| Mean | Median | Min | Max | |
| % of Patients Who Should Receive DES, 1st Year Following Approval | ||||
| Bare metal stent patients | 42.8% | 30.0% | 5.1% | 100.0% |
| CABG patients | 16.8% | 10.0% | 5.0% | 50.0% |
| % of Patients Who Should Receive DES, 2nd Year Following Approval | ||||
| Bare metal stent patients | 56.0% | 50.0% | 10.2% | 100.0% |
| CABG patients | 25.5% | 20.0% | 5.0% | 80.0% |
| % of Patients Who Should Receive DES, 3rd Year Following Approval | ||||
| Bare metal stent patients | 70.1% | 90.0% | 30.0% | 100.0% |
| CABG patients | 31.4% | 30.0% | 5.0% | 90.0% |
| % of Patients Who Should Receive DES, 4th Year Following Approval | ||||
| Bare metal stent patients | 79.7% | 90.0% | 40.6% | 100.0% |
| CABG patients | 37.8% | 35.0% | 5.0% | 90.0% |
| % of Patients Who Should Receive DES, 5th Year Following Approval | ||||
| Bare metal stent patients | 86.8% | 90.0% | 60.8% | 100.0% |
| CABG patients | 43.7% | 40.0% | 5.0% | 90.0% |
| Job satisfaction domains | Level of satisfaction | |
| Satisfied | Dissatisfied | |
| N (%) | N (%) | |
| Leadership and planning | 175 (43.2) | 230 (56.8) |
| Culture and communications | 180 (44.6) | 225 (55.4) |
| Employee’s role | 211 (52.1) | 194 (47.9) |
| Work environment | 178 (43.9) | 227 (56.1) |
| Relationship with supervisor | 163 (40.2) | 242 (59.8) |
| Training and development | 165 (41.4) | 237 (58.6) |
| Pay and benefits | 148 (36.5) | 257 (63.5) |
| Coworker relation ship | 209 (51.6) | 196 (48.4) |
| Overall satisfaction | 179 (44.2) | 226 (55.8) |
| Overweight* | Body fat (%)+ | Lean body mass (kg)+ | |
| Birth weight (z) | 1.18 (1.02 to 1.35) | 0.02 (−0.39 to 0.43) | 1.54 (1.15 to 1.93) |
| P for trend | 0.02 | 0.9 | <0.001 |
| Ponderal index (z) | 1.15 (1.00 to 1.32) | 0.28 (−0.14 to 0.69) | 0.41 (0.01 to 0.82) |
| P for trend | 0.05 | 0.2 | 0.04 |
| Placental weight (z) | 1.06 (0.93 to 1.22) | 0.15 (−0.26 to 0.56) | 0.90 (0.51 to 1.29) |
| P for trend | 0.4 | 0.5 | <0.001 |
| Max placental diam (z) | 1.02 (0.89 to 1.16) | −0.02 (−0.43 to 0.38) | 0.45 (0.06 to 0.84) |
| P for trend | 0.8 | 0.9 | 0.02 |
| Lesser placental diam (z) | 0.99 (0.86 to 1.13) | −0.21 (−0.61 to 0.20) | 0.48 (0.09 to 0.88) |
| P for trend | 0.9 | 0.3 | 0.02 |
| Placental area (z) | 0.98 (0.86 to 1.13) | −0.14 (−0.55 to 0.27) | 0.47 (0.08 to 0.87) |
| P for trend | 0.8 | 0.5 | 0.02 |
| Tall mothers(HEIGHT > 160 cm) | |||
| Birth weight (z) | 1.11 (0.94 to 1.31) | 0.21 (−0.29 to 0.71) | 1.46 (0.95 to 1.97) |
| P for trend | 0.2 | 0.4 | <0.001 |
| Ponderal index (z) | 1.12 (0.96 to 1.32) | 0.44 (−0.01 to 0.90) | 0.47 (0.00 to 0.95) |
| P for trend | 0.2 | 0.06 | 0.05 |
| Placental weight (z) | 1.06 (0.90 to 1.24) | 0.01 (−0.47 to 0.49) | 0.83 (0.33 to 1.32) |
| P for trend | 0.5 | 1.0 | 0.001 |
| Max placental diam (z) | 1.06 (0.89 to 1.25) | 0.12 (−0.39 to 0.62) | 0.75 (0.23 to 1.28) |
| P for trend | 0.5 | 0.6 | 0.005 |
| Lesser placental diam (z) | 1.18 (1.00 to 1.38) | 0.58 (0.10 to 1.07) | 0.65 (0.14 to 1.15) |
| P for trend | 0.05 | 0.02 | 0.01 |
| Placental area (z) | 1.12 (0.95 to 1.32) | 0.40 (−0.10 to 0.89) | 0.71 (0.21 to 1.23) |
| P for trend | 0.2 | 0.1 | 0.006 |
| Surgical Margins | Pathological Stage | P | ||
| (Group 1) | pT2 | pT3 | Total | |
| Negative | 44 (95.7%) | 02 (4.3%) | 46 (100%) | 0.027F |
| Positive | 06 (66.7%) | 03 (33.3%) | 09 (100%) | |
| Total | 50 (90.9%) | 05 (9.1%) | 55 (100%) | |
| (Group 2) | pT2 | pT3 | Total | |
| Negative | 44 (95.7%) | 02 (4.3%) | 46 (100%) | <0.001F |
| Positive | 02 (20.0%) | 08 (80.0%) | 10 (100%) | |
| Total | 46 (82.1%) | 10 (17.9%) | 56 (100%) |
| Activity and Level | No. | Model 1a | Model 2b | Model 3c | |||
| B | 95% CI | B | 95% CI | B | 95% CI | ||
| Attendance at sports/PA clubs | |||||||
| Low | 2,333 | 0 | Referent | 0 | Referent | 0 | Referent |
| Medium | 2,299 | 2.0 | 1.5, 2.6 | 0.6 | 0.1, 1.1 | 0.3 | −0.2, 0.8 |
| High | 3,830 | 3.4 | 2.9, 3.9 | 1.2 | 0.7, 1.6 | 0.6 | 0.2, 1.1 |
| Sports/PA with siblings | |||||||
| Low | 945 | 0 | Referent | 0 | Referent | 0 | Referent |
| Medium | 1,887 | 0.8 | 0.1, 1.6 | −0.1 | 0.6, 0.8 | −0.1 | −0.8, 0.6 |
| High | 5,630 | −0.4 | −1.0, 0.3 | −0.7 | −1.3, −0.1 | −0.6 | −1.2, 0.0 |
| Sports/PA with parents | |||||||
| Low | 1,824 | ||||||
| Medium | 3,090 | 1.1 | 0.6, 1.7 | 0.5 | 0.0, 1.0 | 0.4 | −0.2, 0.9 |
| High | 3,548 | 0.4 | −0.1, 1.0 | 0.1 | −0.4, 0.6 | 0.2 | −0.3, 0.6 |
| Park/playground visits | |||||||
| Low | 1,513 | 0 | Referent | 0 | Referent | 0 | Referent |
| Medium | 2,690 | 0.7 | 0.1, 1.3 | 0.2 | −0.4, 0.7 | 0.2 | −0.4, 0.7 |
| High | 4,259 | −0.5 | 0.1, 1.0 | 0.3 | −0.2, 0.8 | 0.3 | −0.2, 0.8 |
| Cy-3-G (μmol/L) | Papp (×10−7 cm/s) | Efflux Ratio | Transport Efficiency (%) | |
| B → A | A → B | |||
| 10 | 10.57 ± 1.12 | 14.96 ± 1.88 | 0.71 | 2.41 |
| 20 | 6.45 ± 0.46 | 8.98 ± 1.12 | 0.72 | 1.45 |
| 40 | 3.58 ± 0.37 | 4.75 ± 0.51 | 0.75 | 0.76 |
| Variable | Neonatal mortality rate (NMR) | Infant mortality rate (IMR) | Under-5 mortality rate (U5MR) |
| Behvarz density | -0.108 (-2.09 – 1.87) | -0.021 (-0.13 – 0.08) | -0.012 (-0.11 – 0.09) |
| Effect of rural family physician program and social protection scheme | -0.906 (-1.94 – 0.13) | 0.002 (-0.05 – 0.06) | 0.006 (-0.04 – 0.06) |
| Annual incremental effect of rural family physician program and social protection scheme | -0.341* (-0.57 – -0.11) | -0.016* (-0.03 – -0.01) | -0.003 (-0.01 – 0.01) |
| Time effect | -0.231* (-0.39 – -0.07) | -0.034** (-0.04 – -0.03) | -0.040** (-0.05 – -0.03) |
| Years of schooling | 0.237 (0.35 – 0.82) | 0.024 (-0.01 – 0.06) | 0.020 (-0.01 – 0.05) |
| Wealth index | -0.889* (-1.43 – -0.35) | -0.052** (-0.08 – -0.02) | -0.055** (-0.08 – -0.03) |
| Sex ratio | 2.051 (-33.44 – 37.54) | 0.904 (-0.99 – 2.80) | 1.312 (-0.49 – 3.11) |
| Logarithmic scale of rural population size | -0.918 (-4.05 – 2.21) | -0.223* (-0.39 – 0.06) | -0.219* (-0.38 – -0.06) |
| Outcomes | Support (N = 105) | Control (N = 107) | RR (95%CI) | p value |
| Apgar score at 1 minute < 7 | 20 | 21 | 0.97 (0.56–1.68) | 0.915 |
| Apgar score at 5 minutes < 7 | 3 | 2 | 1.53 (0.26–8.96) | 0.681* |
| Birthweight (g) (mean ± SD 95%) | 3.197 (2.360–4.245) | 3.246 (2.410–4.145) | - | 0.370¶ |
| Admission to NICU | 5 | 6 | 0.91 (0.47–1.77) | 0.781 |
| Immediate contact mother/newborn | 52 | 41 | 1.29 (0.95–1.76) | 0.100 |
| Time of contact mother/newborn (min) (mean ± 95% SD) | 25.1 (10–55) | 22.7 (10–40) | - | 0.360† |
| Takes breast/suckles in delivery room | 12 | 7 | 1.75 (0.72–4.26) | 0.213 |
| Takes breast/suckles (12 h following birth) | 99 | 100 | 1.08 (0.59–1.97) | 0.801 |
| Breast fissure | 7 | 6 | 1.19 (0.41–3.42) | 0.747 |
| Number of breast-feeds 12 hours following birth (mean) | 4.3 (0–12) | 4.4 (0–10) | - | 0.589† |
| Method | Precision (%) | Recall (%) | F-score (%) |
| hHMM | 98.5 ± 0.4 | 93.5 ± 1.9 | 95.9 ± 0.9 |
| eDTW | 94 ± 1.2 | 93.5 ± 0.8 | 93.8 ± 0.5 |
| Peak detection | 87.4 ± 1.2 | 95.9 ± 1.8 | 91.5 ± 0.4 |
| pDTW | 91.8 ± 2.1 | 90.1 ± 2.2 | 90.9 ± 1.4 |
| UNIPROT KEY | DESCRIPTION | MW (kDa) | Mascot score | A/C ratio | A/C std. dev. | A/C p value | At/C ratio | At/C std. dev. | At/C p value |
| Q9JI91 | Alpha-actinin-2 | 103.8 | 353.78 | 2.875 | 0.825 | 1.84E-03 | 3.030 | 0.865 | 1.72E-03 |
| P26231 | Catenin alpha-1 | 100.1 | 100 | 2.212 | 0.193 | 5.04E-04 | 2.230 | 0.226 | 5.03E-04 |
| P63260 | Actin, cytoplasmic 2 | 41.8 | 5740.2 | 1.422 | 0.265 | 1.49E-02 | 2.386 | 0.305 | 1.10E-04 |
| P60710 | Actin, cytoplasmic 1 | 41.7 | 5483.9 | 1.483 | 0.163 | 4.84E-05 | 1.785 | 0.184 | 1.80E-06 |
| Q68FF6 | ARF GTPase-activating protein GIT1 | 85.2 | 62.49 | 1.590 | 0.610 | 6.57E-02 | 1.308 | 0.369 | 8.19E-02 |
| Q60737 | Casein kinase II subunit alpha | 36.5 | 45.1 | 1.532 | 0.485 | 8.67E-02 | 1.267 | 0.274 | 5.76E-02 |
| Q61739 | Integrin alpha-6 | 97.3 | 122.1 | 1.499 | 0.175 | 1.12E-03 | 1.022 | 0.066 | 2.41E-01 |
| Q3V3R4 | Integrin alpha-1 | 130.7 | 236.53 | 1.325 | 0.065 | 3.38E-09 | 0.598 | 0.0308 | 3.26E-08 |
| P62835 | Ras-related protein Rap-1A | 21.0 | 444.1 | 1.063 | 0.235 | 4.03E-01 | 0.747 | 0.156 | 8.04E-02 |
| Q04736 | Tyrosine-protein kinase Yes | 92.38 | 60.6 | 1.008 | 0.090 | 5.49E-01 | 0.706 | 0.066 | 8.97E-05 |
| Q9QUI0 | Transforming protein RhoA | 21.8 | 242.8 | 1.018 | 0.114 | 7.23E-01 | 0.741 | 0.083 | 1.42E-02 |
| Q9QZQ1 | Afadin | 202.0 | 206.4 | 0.996 | 0.129 | 1.84E-03 | 0.559 | 0.051 | 2.40E-06 |
| P09055 | Integrin beta-1 | 88.2 | 333.2 | 0.989 | 0.048 | 5.76E-01 | 0.575 | 0.021 | 5.21E-11 |
| Q02248 | Catenin beta-1 | 85.4 | 2060.4 | 0.973 | 0.514 | 9.08E-01 | 0.740 | 0.255 | 1.97E-01 |
| P27601 | Guanine nucleotide-binding protein subunit alpha-13 | 44.0 | 108.65 | 0.938 | 0.252 | 6.44E-01 | 0.550 | 0.230 | 3.39E-02 |
| Q7TPR4 | Alpha-actinin-1 | 103.0 | 1300.8 | 0.940 | 0.229 | 3.63E-02 | 1.029 | 0.190 | 3.50E-02 |
| P63001 | Ras-related C3 botulinum toxin substrate 1 | 21.4 | 111.49 | 0.932 | 0.057 | 2.94E-01 | 0.611 | 0.052 | 2.37E-06 |
| P26041 | Moesin | 67.7 | 1657.9 | 0.913 | 0.024 | 2.01E-02 | 0.605 | 0.017 | 9.9E-20 |
| P26040 | Ezrin | 69.4 | 594.85 | 0.904 | 0.068 | 3.22E-03 | 0.732 | 0.062 | 4.39E-04 |
| P26043 | Radixin | 68.5 | 691.5 | 0.871 | 0.106 | 3.00E-01 | 0.694 | 0.053 | 3.37E-05 |
| Q62470 | Integrin alpha-3 | 116.7 | 178.09 | 0.846 | 0.049 | 2.24E-02 | 0.543 | 0.0373 | 5.97E-09 |
| Q61879 | Myosin-10 | 228.9 | 3486.6 | 0.843 | 0.028 | 2.04E-08 | 0.778 | 0.019 | 9.9E-20 |
| A2ARA8 | Integrin alpha-8 | 117.5 | 69.83 | 0.803 | 0.232 | 2.51E-01 | 0.537 | 0.108 | 1.11E-02 |
| P62141 | Serine/threonine-protein phosphatase PP1-beta catalytic subunit | 37.2 | 61.83 | 0.779 | 0.124 | 5.84E-02 | 0.598 | 0.103 | 1.50E-02 |
| Q8VDD5 | Myosin-9 | 226.2 | 7387 | 0.741 | 0.089 | 4.55E-03 | 0.742 | 0.056 | 2.71E-03 |
| Q64727 | Vinculin | 16.6 | 2596.1 | 0.755 | 0.315 | 2.53E-01 | 0.685 | 0.301 | 1.69E-01 |
| P26039 | Talin-1 | 269.7 | 3143 | 0.728 | 0.022 | 5.00E-10 | 0.684 | 0.020 | 2.19E-12 |
| Q9JKF1 | RasGTPase-activating-like protein IQGAP1 | 188.7 | 188.6 | 0.696 | 0.186 | 6.47E-02 | 0.699 | 0.193 | 6.48E-02 |
| O55222 | Integrin-linked protein kinase | 51.3 | 330.25 | 0.668 | 0.060 | 9.41E-05 | 0.704 | 0.045 | 1.05E-03 |
| Variables | Persistently Active (n=45) | Persistently Sedentary (n=10) | p-value |
| Median (IR) | Median (IR) | ||
| M/F | 29 / 16 | 4 / 6 | |
| Age (years) | 38.3 (6.9) | 43.8 (13) | 0.121 |
| Body weight (Kg) | 77.3 (17) | 74.8 (17.5) | 0.639 |
| Height (cm) | 174.1 (12.8) | 166.3 (18.5) | 0.015 |
| BMI (Kg/m2) | 24.3 (4.8) | 26.1 (9.4) | 0.190 |
| WC (cm) | 80.5 (13.2) | 88.5 (21.5) | 0.210 |
| Body fat (%) | 24.1 (10.5) | 40.2 (17.6) | 0.001 |
| Trunk fat (%) | 31.3 (8.2) | 47.9 (14.6) | 0.001 |
| Glucose (mg/dL) | 89.3 (9.1) | 91.1 (11.5) | 0.413 |
| Triglycerides (mg/dL) | 76.2 (46.9) | 127.7 (36.8) | 0.002 |
| Total cholesterol (mg/dL) | 190.1 (47.8) | 225.4 (54.2) | 0.036 |
| HDL-C (mg/dL) | 52.5 (12.3) | 50.1 (19.9) | 0.793 |
| LDL-C (mg/dL) | 123.2 (40.2) | 132.3 (38.2) | 0.385 |
| LDL-C/HDL-C (mg/dL) | 2.3 (1.2) | 2.7 (1.3) | 0.789 |
| VLDL-C (mg/dL) | 15.2 (9.3) | 25.5 (7.4) | 0.001 |
| HbA1c (mmol/mol) | 5.3 (0.5) | 5.3 (0.8) | 0.637 |
| CIT (mm) | 0.60 (0.11) | 0.78 (0.11) | 0.001 |
| FIT (mm) | 0.49 (0.08) | 0.53 (0.12) | 0.287 |
| Steps/day | 9,476.1 (3148) | 6,848.8 (4474) | 0.001 |
| SBP (mmHg) | 110 (20) | 105 (30) | 0.920 |
| DBP (mmHg) | 80 (10) | 75 (20) | 0.885 |
| Risk factor | Intervention options if risk factor identified |
| History of falls/falls injuries | Referral to GPAppropriate acute management if injury recent |
| Medications (number) | Refer to GP for medication review |
| Medications (associated with increased falls risk) | Refer to GP/specialist for medication review |
| Medical conditions (associated with increased falls risk) | Refer to GP/specialist for review |
| Sensory loss: vision | Brochure on lighting and home safetyRefer to optometristRefer to Ophthalmologist via GPRefer to Vision Australia (includes mobility training and aids for visually impaired)Refer to OT for home assessmentRefer to GP |
| Sensory loss: hearing | Refer to audiologist |
| Sensory loss: somatosensory | Refer to podiatristRefer to GP |
| Feet and footwear | Refer to podiatristProvide information about good footwear and falls prevention |
| Cognitive status | Refer to GPMemory Clinic referral in consultation with GP if memory problems have not been investigatedReferral to OT for strategies to facilitate memory and/or home assessment |
| Continence | Refer to GPContinence clinic referralRefer to physiotherapistRefer for OT home assessment/functional assessment, including need for commode |
| Nutritional status | Provide brochure on nutritionRefer to dieticianGP referral |
| Environment | Provide with information pamphlet on safety in the homeRefer for OT home assessment/functional assessment and training |
| Function | Refer to OT for home assessment/functional assessment and trainingRefer to Physiotherapist for assessment and exercise to improve functionReferral for support services |
| Functional behaviour | Refer to physiotherapist, OT, GP |
| Balance | Home exercise programReferral to PhysiotherapistReferral for OT for a home assessmentReferral to GP for further investigation |
| Gait and physical activity | Home exercise programReferral to PhysiotherapistReferral for OT home assessment/functional assessment and trainingBrochure on tips for walking |
| Osteoporosis risk | Refer to GP for consideration of calcium and/or vitamin D supplementsRefer to dieticianHip protectors |
| Additional options for preventing falls injury | Hip protectorsPersonal alarm |
| Patient # | Sex | Age(year) | Injected activity (MBq) | Diagnosis |
| 1 | M | 2 | 320 | Mediastinum 7-cm diameter NET |
| 2 | F | 7 | 450 | |
| 3 | M | 11 | 490 | Right adrenal pheochromocytoma (only shown in SPECT/CT image) |
| 4-Aa | F | 12 | 500 | |
| 5 | F | 12 | 600 | |
| 4-Ba | F | 13 | 450 | |
| 6 | F | 13 | 480 | Appendix NET, area of accumulation above the uterus |
| 7 | F | 14 | 600 | MEN-1, head of the pancreas NET and lymph node accumulation on the left side |
| 8 | M | 14 | 940 | |
| 9 | F | 16 | 500 | |
| 10 | F | 16 | 600 | |
| 11 | M | 17 | 720 | MEN-1, head of the pancreas insulinoma |
| Positive-to-Negative Ratio | Accuracy | F-Measure | MCC | Recall | Precision |
| 1:1 | 0.6800 | 0.6667 | 0.3612 | 0.6400 | 0.6957 |
| 1:2 | 0.6667 | 0.5098 | 0.2638 | 0.5652 | 0.4643 |
| 1:3 | 0.6832 | 0.3043 | 0.0992 | 0.3043 | 0.3043 |
| Cell line | Media | Comment |
| 1. 293 | DMEM | Embryonic kidney |
| 2. A549 | DMEM | Adenocarcinomic alveolar basal epithelial |
| 3. C33a | DMEM | Cervical carcinoma |
| 4. DUT145 | DMEM | Prostate cancer |
| 5. H1229 | RPMI | Lung carcinoma |
| 6. HaCAT | RPMI | Immortalized, non-tumorigenic keratinocyte |
| 7. HCT116 | McCoy 5A | Colorectal carcinoma |
| 8. HeLa | Joklik | Cervical carcinoma |
| 9. hESC2 | DMEM | Human embryonic stem cells |
| 10. HFF | DMEM | Human foreskin fibroblasts |
| 11. HL60 | IMM | Promyelocytic leukemia cells |
| 13. Huh7.0 | DMEM | Hepatocarcinoma |
| 14. Huh7.5 | DMEM | Hepatocarcinoma (RIG-I-deficient) |
| 14. MCF7 | DMEM | Breast carcinoma |
| 15. MDaMB231 | L15 | Breast carcinoma |
| 16. Mdm13 | DMEM | Monocyte-derived macrophages |
| 17. NB4 | RPMI | Acute promyelocytic cell line |
| 18. PANC1 | DMEM | Pancreatic carcinoma, epithelial-like |
| 19. PC3 | DMEM | Prostate cancer |
| 20. SAOS | McCoy 5A | Epithelial-like osteosarcoma cell line |
| 21. SW480 | L15 | Colon adenocarcinoma |
| 22. U2OS | DMEM | Osteosarcoma |
| 23. U251 | DMEM | Glioblastoma |
| 24. U937 | RPMI | Leukemic monocyte lymphoma |
| Gene abbreviationa | Gene symbola | Accession no.b | Gene description | Gene group | Z-Testc | Ratiod | 95% CIe |
| Up-regulated gene expression | |||||||
| TECK/CCL25 | Scya25 | NM_009138 | small inducible cytokine A25 | Chemokine | 1.5 × 10–14 | 4.2 | 6.2–2.9 |
| Mdk | Mdk | NM_010784 | midkine | Neurotrophic group | 2.9 × 10–7 | 3.0 | 4.7–1.9 |
| IL-5 | Il5 | NM_010558 | interleukin 5 | Interleukin | 9.5 × 10–4 | 1.9 | 2.9–1.3 |
| VEGF-A | Vegf | NM_009505 | vascular endothelial growth factor | Angiogenic factor | 2.5 × 10–5 | 1.8 | 2.2–1.4 |
| Down-regulated gene expression | |||||||
| EphA3 | Epha3 | M68513 | eph-related receptor tyrosine kinase (Mek4) | Eph family | 4.0 × 10–8 | 0.5 | 0.6–0.4 |
| CCR-4 | Cmkbr4 | NM_009916 | chemokine (C-C) receptor 4 | Chemokine receptor | 1.8 × 10–5 | 0.6 | 0.8–0.5 |
| LIF | Lif | NM_008501 | leukemia inhibitory factor | Cytokine and receptors | 3.0 × 10–5 | 0.6 | 0.8–0.4 |
| GDF-7 | Gdf7 | U08339 | BALB/c putative growth factor GDF7 (Gdf7) gene | TGF-beta superfamily | 2.4 × 10–4 | 0.5 | 0.7–0.3 |
| EBF | Ebf | NM_007897 | early B-cell factor | Signal transduction | 3.7 × 10–4 | 0.5 | 0.7–0.4 |
| CD27/TNFRSF7 | Tnfrsf7 | L24495 | CD27 antigen | TNF superfamily | 6.4 × 10–4 | 0.6 | 0.8–0.4 |
| SLIT-3 | Slit3 | AF088902 | SLIT1 protein | Developmental factor | 9.2 × 10–4 | 0.7 | 0.8–0.5 |
| CX3CL1 | Scyd1 | NM_009142 | small inducible cytokine subfamily D, 1 | Chemokine | 1.2 × 10–3 | 0.4 | 0.7–0.2 |
| SMAD1 | Madh1 | NM_008539 | MAD homolog 1 (Drosophila) | Signal transduction | 1.3 × 10–3 | 0.6 | 0.8–0.5 |
| A1 | Bcl2a1a | L16462 | hemopoietic-specific early response protein | Apoptosis related | 1.5 × 10–3 | 0.6 | 0.8–0.4 |
| Variables | Single-Pollutant Model | Model Adjusting PM2.5 | Z Value * | p Value * |
| NO2 | ||||
| Lag0 | 0.40 (0.02 to 0.78) | 0.72 (0.12 to 1.31) | −0.870 | 0.385 |
| Lag1 | −0.13 (−0.46 to 0.20) | −0.23 (−0.60 to 0.14) | 0.407 | 0.684 |
| Lag2 | −0.08 (−0.38 to 0.23) | −0.38 (−0.69 to −0.06) | 0.232 | 0.816 |
| 3 days average | −0.37 (−0.84 to 0.10) | −0.65 (−1.23 to −0.07) | 0.738 | 0.460 |
| SO2 | ||||
| Lag0 | 0.67 (0.35 to 1.00) | 0.76 (0.39 to 1.12) | −0.336 | 0.737 |
| Lag1 | 0.34 (0.04 to 0.64) | 0.39 (0.05 to 0.74) | −0.224 | 0.823 |
| Lag2 | 0.22 (−0.05 to 0.49) | 0.03 (−0.26 to 0.33) | 0.913 | 0.361 |
| 3 days average | 0.36 (−0.10 to 0.82) | 0.38 (−0.12 to 0.89) | −0.072 | 0.943 |
| CO | ||||
| Lag0 | 2.07 (1.20 to 2.95) | 4.13 (2.79 to 5.49) | −2.520 | 0.012 |
| Lag1 | 0.78 (0.04 to 1.52) | 0.69 (−0.11 to 1.51) | 0.146 | 0.884 |
| Lag2 | −0.25 (−0.94 to 0.45) | −0.62 (−1.33 to 0.10) | 0.736 | 0.461 |
| 3 days average | 0.56 (−0.50 to 1.64) | 0.77 (−0.50 to 2.05) | −0.242 | 0.809 |
| Ozone | ||||
| Lag0 | −2.06 (−2.39 to −1.73) | −2.23 (−2.57 to −1.90) | 0.732 | 0.464 |
| Lag1 | −1.48 (−1.78 to −1.18) | −1.54 (−1.85 to −1.22) | 0.265 | 0.791 |
| Lag2 | −1.44 (−1.73 to −1.15) | −1.32 (−1.63 to −1.02) | −0.547 | 0.584 |
| 3 days average | −1.90 (−2.35 to −1.45) | −2.12 (−2.58 to −1.65) | 0.652 | 0.514 |
| Features$ | Starter Group | Experimental Group | P Value |
| P1 max | 0.080 ± 0.080 | 0.044 ± 0.044 | 0.011 * |
| P1 mean | 0.050 ± 0.049 | 0.030 ± 0.030 | 0.017 * |
| P2 max | 0.114 ± 0.118 | 0.068 ± 0.072 | 0.024 * |
| P2 mean | 0.082 ± 0.082 | 0.051 ± 0.055 | 0.029 * |
| P3 max | 0.136 ± 0.129 | 0.070 ± 0.055 | 0.003 ** |
| P3 mean | 0.088 ± 0.083 | 0.058 ± 0.061 | 0.029 * |
| Total max | 0.138 ± 0.128 | 0.075 ± 0.061 | 0.003 ** |
| Total mean | 0.075 ± 0.068 | 0.048 ± 0.050 | 0.015 * |
| L_level % | 53 ± 27 | 80 ± 30 | 0.025 * |
| M_level % | 32 ± 21 | 15 ± 23 | 0.055 * |
| H_level % | 15 ± 19 | 5 ± 10 | 0.077 |
| Organization | Country | Title | Year |
| National Institute of Health Care and Excellence | United Kingdom | Recognition, referral, diagnosis, and management of adults with autism | 2012 |
| Australian Psychological Association | Australia | Clinical Assessment Resource: An overview of best practice tools and approaches to conducting biopsychosocial and developmental assessment of child, young people, and adults with a disability who display behaviors of concern | 2011 |
| Canadian Association of Occupational Therapists (CAOT) | Canada | Position Statement on Autism Spectrum Disorders and Occupational Therapy | 2015 |
| American Occupational Therapy Association (AOTA) | United States | Scope of Occupational Therapy Services for Individuals with ASD across the Life Course | 2015 |
| College of Occupational Therapy | United Kingdom | Occupational Therapy and Learning Disabilities | 2012 |
| Coefficients of variation (CVs) | Children groups | ANOVA | |||
| Spastic CP (n =10) | TD (n =10) | F1,18 | p value | Effect size d | |
| Utterance duration | |||||
| Mono-syllable task | 17.87 ± 11.87 | 5.23 ± 2.33 | 10.923 | 0.004* | 0.615 |
| Poly-syllable task | 24.30 ± 17.90 | 7.57 ± 4.11 | 8.299 | 0.010 | 0.562 |
| Peak vertical oral opening displacement | |||||
| Mono-syllable task | 24.34 ± 13.53 | 34.14 ± 26.16 | 1.108 | 0.307 | 0.241 |
| Poly-syllable task | 18.30 ± 15.82 | 29.42 ± 20.20 | 1.880 | 0.187 | 0.308 |
| Peak vertical oral opening velocity | |||||
| Mono-syllable task | 17.21 ± 14.97 | 24.69 ± 13.50 | 1.376 | 0.256 | 0.266 |
| Poly-syllable task | 15.63 ± 17.09 | 15.16 ± 18.78 | 0.003 | 0.954 | 0.014 |
| Blastn (WGS An. gambiae) | Blastx (Nr) | Blastn (Nr) | Blastn (dbEST) | Unannotated | Total | |
| 3 Positive Controls | No Significant Hit | 3 | 3 | |||
| 403 Unique Transcripts | 403 | 240 | 8 | 112 | 43 | 403 |
| Early Genes | 144 | 77 | 2 | 45 | 20 | 144 |
| Middle Genes | 130 | 78 | 6 | 36 | 10 | 130 |
| Late Genes | 139 | 93 | 2 | 31 | 13 | 139 |
| Total | 413 | 248 | 10 | 112 | 43 | 413 |
| Study | Bacterial strain | Preparation | Patient population | Intervention | Results |
| Cell or animal type | |||||
| In vitro experiments | |||||
| Strunk et al.,78 2012 | SE 1457 | Heat-killed | GA<30wk, 31-33 wk, 37-41 wk | 6 h | IL-1β, IL-6, IL-8, TNF-α↑with GA |
| 108cfu/ml | Cord & adult peripheral MNCs | Adult level TLR2 expression & phagocytosis | |||
| Mohamed et al.,79 2007 | SE PT 9657 | Heat-killed | Healthy term infants | 4 h | IL-1β, IL-6, IL-8, TNF-α↑with time |
| 103cfu/ml | Cord & adult peripheral WBC | Pro-inflammatory effect: SE <E.coli & GBS | |||
| Tatad et al.,80 2008 | Clinical isolate | Heat-killed | Healthy term & preterm infants | 18 h | IL-6, IL-8, IL-10, IL-12↑ similar to adult |
| 104cfu/ml | Cord & adult peripheral WBC | Inflammatory response: preterm > term | |||
| Härtel et al.,81 2007 | ATCC 12228 | Live bacteria | Term & preterm infants | 24 h | IL-6, TNF-α↑with GA |
| Strain 94B080 | 1cfu:1 WBC & | Neonatal peripheral WBC | Pro-inflammatory effect: BF+ strain<BF- strain | ||
| Strain 94B575 | 10 cfu:1 WBC | IL-10, TGF-β expression independent of GA | |||
| Peoples et al.,82 2009 | Clinical isolate | Heat-killed | Healthy term & preterm infants | 18 h | IL-6, IL-10↑> adult |
| 104 cfu/ml | Cord & adult peripheral WBC | IL-8, IL-12, INF-NK, INF-T↑ similar to adult | |||
| Inflammatory response: preterm=term | |||||
| Haase et al.,83 2011 | ATCC 12228 | Live bacteria | Healthy term & preterm infants | 1 h | TNF-α, IL-6, IL-8↑ |
| Strain 94B080 | 1cfu:1 WBC | Cord WBC | Pro-inflammatory effect: BF+ strain>BF- strain | ||
| Strain 94B575 | |||||
| Björkqvist et al.,77 2004 | Clinical isolate | Live bacteria | Healthy term & preterm infants | 30 min | Oxidative burst intensity: preterm < term |
| 10 cfu:1 PMNL | Neonatal peripheral PMNLs | SE similar to GBS | |||
| Ivarsson et al.,104 2013 | Clinical isolate | Live bacteria | Vascular endothelial cells | 18 h | IL-8, ICAM-1 ↑ |
| 104cfu/ml | Small airway epithelial cells | Pro-inflammatory effect: SE > SA | |||
| Hussain et al.,105 2013 | Strain 94B080 | Live bacteria | Bronchial epithelial cells | 36 h | TNF-α, IL-6, IL-8 and iNOS↑ with time |
| 104cfu/ml | Expression of ENaC and CFTR↑ | ||||
| In vivo experiments | |||||
| Kronforst et al.,87 2012 | SE 1457 | Live bacteria | C57BL/6 WT mice | 48 h | At 2 h: |
| up to 2×109 cfu/ml | < 24 h old | IL-1β, IL-6, TNF-α, TLR2↑ with inoculum | |||
| At 24 h & 48 h: | |||||
| Inoculum-dependent neonatal weight loss | |||||
| Bi et al.,86 2015 | SE 1457 | Live bacteria | C57BL/6J WT mice | 72 h | At 6 h: |
| 1×108cfu/ml | < 24 h old | IL-6, CCL2, CXCL1, IL-12↑ in blood & brain | |||
| Caspase-3 & TLR2 mRNA ↑ in the brain | |||||
| At 24 h: | |||||
| PMNLs↑ in blood & cerebral spinal fluid | |||||
| White and grey matter impairment |
| Characteristic | S‐HFpEF (n=83) | AD‐HFpEF (n=78) | Overall (n=161) | P Value |
| Demographics | ||||
| Age, years: n, median (25th–75th) | 83, 72 (65–79) | 78, 73 (65–79) | 161, 72 (65–79) | 0.970 |
| Male sex | 43/83 (51.8%) | 39/78 (50.0%) | 82/161 (50.9%) | 0.819 |
| Race (% white) | 74/83 (89.2%) | 62/78 (79.5%) | 136/161 (84.5%) | 0.091 |
| Weight, kg (median, 25th–75th) | 93.2 (80.5–103.6) | 95.0 (79.1–112.3) | 93.2 (80.5–108.2) | 0.535 |
| Body mass index, (median, 25th–75th) | 32.3 (27.4–37.1) | 33.6 (28.5–37.9) | 32.9 (27.9–37.5) | 0.163 |
| Ejection fraction: n, median (25th–75th) | 83, 62.0 (58.0–66.0) | 78, 55.0 (55.0–61.0) | 161, 60.0 (55.0–65.0) | <0.001 |
| Systolic blood pressure, mm Hg: n, median (25th–75th) | 83, 122 (113–137) | 78, 119 (107–131) | 161, 122 (112–135) | 0.029 |
| Heart rate, beats/min: n, median (25th–75th) | 83, 69 (62–80) | 78, 72 (65–84) | 161, 72 (62–80) | 0.073 |
| JVP≥8 cm | 36/80 (45.0%) | 68/72 (94.4%) | 104/152 (68.4%) | <0.001 |
| Edema≥2 | 12/83 (14.5%) | 53/76 (69.7%) | 65/159 (40.9%) | <0.001 |
| Comorbidities | ||||
| Hospitalization for heart failure in past year | 29/83 (34.9%) | 47/76 (61.8%) | 76/159 (47.8%) | <0.001 |
| Hypertension | 65/83 (78.3%) | 69/78 (88.5%) | 134/161 (83.2%) | 0.085 |
| Ischemia as cause of HF | 33/83 (39.8%) | 37/78 (47.4%) | 70/161 (43.5%) | 0.326 |
| Atrial fibrillation/flutter | 42/83 (50.6%) | 55/78 (70.5%) | 97/161 (60.2%) | 0.010 |
| Diabetes mellitus | 29/83 (34.9%) | 48/78 (61.5%) | 77/161 (47.8%) | <0.001 |
| Orthopnea | 45/78 (57.7%) | 63/74 (85.1%) | 108/152 (71.1%) | <0.001 |
| COPD | 16/83 (19.3%) | 27/78 (34.6%) | 43/161 (26.7%) | 0.028 |
| NYHA class | <0.001 | |||
| II | 40/83 (48.2%) | 4/69 (5.8%) | 44/152 (28.9%) | |
| III | 43/83 (51.8%) | 50/69 (72.5%) | 93/152 (61.2%) | |
| IV | 0/83 (0.0%) | 15/69 (21.7%) | 15/152 (9.9%) | |
| Baseline anemia | 25/83 (30.1%) | 56/78 (71.8%) | 81/161 (50.3%) | <0.001 |
| Medications at enrollment | ||||
| ACE inhibitor or ARB | 53/83 (63.9%) | 30/78 (38.5%) | 83/161 (51.6%) | 0.001 |
| Beta blockers | 61/83 (73.5%) | 64/78 (82.1%) | 125/161 (77.6%) | 0.193 |
| Aldosterone antagonist | 5/83 (6.0%) | 20/78 (25.6%) | 25/161 (15.5%) | <0.001 |
| Any diuretic | 70/83 (84.3%) | 76/78 (97.4%) | 146/161 (90.7%) | 0.004 |
| Loop diuretic | 64/83 (77.1%) | 76/78 (97.4%) | 140/161 (87.0%) | <0.001 |
| Calcium channel blocker | 26/83 (31.3%) | 25/78 (32.1%) | 51/161 (31.7%) | 0.921 |
| Statin | 54/83 (65.1%) | 49/78 (62.8%) | 103/161 (64.0%) | 0.767 |
| Laboratory values | ||||
| Sodium, mg/L: n, median (25th–75th) | 75, 140 (138–142) | 78, 139 (137–142) | 153, 140 (137–142) | 0.127 |
| Blood urea nitrogen, mg/dL: n, median (25th–75th) | 68, 25.1 (18.7–35.0) | 78, 33.5 (26.0–49.0) | 146, 30.0 (22.0–44.0) | <0.001 |
| Creatinine, mg/dL: n, median (25th–75th) | 83, 1.2 (0.9–1.5) | 78, 1.6 (1.3–1.9) | 161, 1.4 (1.1–1.8) | <0.001 |
| NT‐pro BNP, pg/mL: n, Median (25th–75th) | 83, 648.1 (352.9–1334) | 78, 3146 (1583–5747) | 161, 1482 (596.0–3172) | <0.001 |
| eGFR, mL/min; n, median (25th–75th) | 83, 53.5 (39.0–71.4) | 78, 40.0 (30.0–48.9) | 161, 45.6 (34.5–57.7) | <0.001 |
| Baseline core lab cystatin C value (mg/L): n, median (25th–75th) | 83, 1.4 (1.0–1.8) | 78, 1.7 (1.4–2.1) | 161, 1.6 (1.2–2.0) | <0.001 |
| 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | TOTAL | |
| Horses | 783 | 822 | 1,506 | 2,002 | 3,220 | 7,296 | 15,629 |
| LNR group | Ratio/Node quota | N | Differentiation grade (well/med./poor) | N-status (N1/N2) | Lymph nodes (median) | Chemotherapy eligibility (yes/no) | |
| Assessed | Positive | ||||||
| 1 | 0–0.15 | 46 | 4/36/6 | 46/0 | 10 (1–19) | 1 (0–3) | 27/19 |
| 2 | 0.16–0.65 | 45 | 3/30/12 | 15/30 | 10 (4–21) | 4 (1–11) | 23/22 |
| 3 | 0.66–1 | 45 | 0/14/31 | 6/39 | 9 (2–32) | 8 (2–26) | 27/18 |
| Total | 0–1 | 136 | 7/80/49 | 67/69 | 10 (1–32) | 4 (0–26) | 77/59 |
| Drug’s name | Dose | Comments |
| Vasodilator drugs (hypotensives) | ||
| Propofol | 2 - 2.5 mg/kg load, 25 - 75 μg/kg/min maintain | Local irritation, propofol infusion syndrome |
| Remifentanil | 1 μg/kg load, 0.05 μg/kg/min maintain | Respiratory depression, hyperalgesia, vomiting |
| Dexmetedomidine | 1 mg/kg load, 0.7 mg/kg/h maintain | Sedative effects |
| Nitroprusside | 1 - 2 μg/kg/min | Severe hypotension, cyanide toxicity |
| Nitroglycerine | 25 - 250 μg/min | Reflex tachycardia, methemoglobinemia |
| Nicardipine | 5 mg/h | Braycardia, severe hypotension, cardiac blocks |
| Esmolol | 5 - 10 mg/3 - 5 min bolus | AV block, bronchial hyperactivity |
| Labetalol | 5 - 10 mg bolus | |
| Urapidil | 10 - 15 mg/h | Severe hypotension |
| Clonidine | 0.1 - 1.2 mg | Rebound hypertension, dry mouth |
| Magnesium sulfate | 1 - 8 mg load, 1 - 4 mg/h maintain | Potentiates muscle relaxants |
| Vasoconstrictor drugs (hypertensives) | ||
| Epinephrine | 1 - 20 μg/min | Tachycardia |
| Norepinephrine | 1 - 30 μg/min | Reflective bradycardia |
| Dopamine | 5 - 10 μg/min | Tachycardia, arrhythmias |
| Phenilephrine | 10 - 100 μg/min | Reflective bradycardia |
| Vasopressin | 0.1 - 0.4 units/min | Myocardial infarction |
| Ephedrine | 5 - 10 mg | None |
| Mean (SD) | Non-atopic asthma n = 37 | Atopic asthma n = 137 | p value |
| HAD-Anxiety | 8.43 (4.35) | 7.98 (4.45) | 0.607 |
| HAD-Depression | 7.57 (4.52) | 6.85 (4.43) | 0.277 |
| HAD- Total | 16.00 (7.51) | 14.82 (8.10) | 0.302 |
| ACT | 17.97 (4.89) | 18.42 (5.18) | 0.486 |
| AQLQ-Total | 4.45 (1.24) | 4.29 (1.24) | 0.683 |
| AQLQ-Symptom | 4.90 (1.34) | 4.72 (1.39) | 0.550 |
| AQLQ-Activity | 4.10 (1.35) | 4.02 (1.25) | 0.855 |
| AQLQ-Emotional | 4.63 (1.49) | 4.47 (1.59) | 0.771 |
| Intervention | At Risk Target Population | Numbers at Risk Reached | % of Identified at Risk Reached by the RED Strategy | General Target Population in RED Catchment Areas | % of Additional Population Reached through the RED Strategy |
| Additional immunized children | 489 | 477 | 97.55 | 3126 (children 1-15) | 15% of the target children for immunization |
| Additional registered populations at Family Group Practices clinics | 2598 | 2485 | 95.65 | 8708(Total Population in RED Area) | 28.5% of total registered population at the family clinics |
| Additional ANC care contacts | 515 | 508 | 98.64 | 5616(Total ANC Contacts in RED Area) | 9% of all ANC Contacts |
| Additional family planning contacts | 1047 | 1047 | 100.00 | 96560(Total Family Planning Contacts in RED Area) | 1.08% of all family planning contacts |
| Additional emergency food provision | Not yet fully assessed | 515 | Not yet fully assessed | 8708(Total Population in RED Area) | 5.9% of Target population |
| Total | Previously incarcerated N(%) | First incarceration N(%) | Crude odds ratio (95% CI) | Adjusted odds ratio (95% CI), P | |
| Age in years Mean [SD] | 707 | 32 [10.5] | 28.1 [10.3] | 1 (0.99–1.02) | 1.04(1.02–1.06), P < 0.001 |
| Sex | |||||
| Male Female | 64760 | 333(96.8)11(3.2) | 314 86.5)49(13.5) | 4.7(2.4–9.2) | 4.3 (2–9.1), P < 0.001 |
| Antisocial disorder | |||||
| Yes No | 245462 | 162(47.1)182 (52.8) | 83 (22.9)280(77.1) | 3 (2.2–4.1) | 2.6 (1.8–3.7), P < 0.001 |
| Generalized anxiety disorder | |||||
| Yes No | 182525 | 92(26.7)252(73.3) | 90(24.8)273(75.2) | 1.1 (0.8–1.5) | 0.8 (0.5–1.3), P = 0.4 |
| Psychosis | |||||
| Yes No | 51656 | 37(10.7)307(89.3) | 14(3.9)349(96.1) | 3 (1.6–5.7) | 1.4 (0.7–2.9), P = 0.01 |
| Substance addiction | |||||
| Yes No | 235472 | 153(44.5)191 (55.52) | 82(22.6)281(77.4) | 2.7(2–3.8) | 1.9 (1.3–2.7), P = 0.001 |
| Alcohol addiction | |||||
| Yes No | 124583 | 88(25.6)256(74.4) | 36(9.9)327(90.1) | 3.1 (2–4.7) | 1.7 (1.1–2.8), P = 0.02 |
| PTSD | |||||
| Yes No | 107600 | 64(18.6)280(81.4) | 43(11.9)320(88.1) | 1.7(1.1–2.6) | 1.3 (0.8–2.2), P = 0.3 |
| Social phobia | |||||
| Yes No | 63644 | 34(9.9)310(90.1) | 29(8)334(92) | 1.2 (0.74–2.1) | 1.2 (0.6–2.3), P = 0.6 |
| Agoraphobia | |||||
| Yes No | 76631 | 46(13.4)298(86.4) | 30(8.2)333(91.8) | 1.7 (1.05–2.8) | 1.1 (0.6–2.1), P = 0.6 |
| Panic attacks | |||||
| Yes No | 48659 | 27(7.9)317(92.1) | 21(5.8)342(94.2) | 1.4 (0.7–2.5) | 0.8 (0.4–1.6), P = 0.5 |
| Manic | |||||
| Yes No | 26681 | 18(5.2)326(94.8) | 8(2.2)355(97.8) | 2.56 (1.05–5.7) | 1.3 (0.5–3.6), P = 0.5 |
| Mood disorders | |||||
| Yes No | 38669 | 19(5.5)325(94.5) | 19(5.2)344(94.8) | 1.1 (0.5–2) | 0.5 (0.2–1.2), P = 0.13 |
| Suicidality | |||||
| Yes No | 93614 | 54(15.7)290(84.3) | 39(10.7)324(89.3) | 1.5 (0.99–2.4) | 1.2 (0.7–2), P = 0.6 |
| Depression | |||||
| Yes No | 101606 | 63 (18.3)281(81.7) | 38 (10.53)325(89.5) | 1.9 (1.2–3) | 1.7 (0.96–3), P = 0.06 |
| All | Girls | Boys | ||||||
| OW | NW | All | OW | NW | All | OW | NW | |
| n | 94 | 51 | 78 | 54 | 24 | 67 | 40 | 27 |
| Age (years) | 7.6 ± 1.1 | 7.3 ± 1.1 | 7.5 ± 1.1 | 7.5 ± 1.1 | 7.5 ± 1.2 | 7.5 ± 1.0 | 7.7 ± 1.0 | 7.2 ± 0.9c |
| Ethnicity (%) | ||||||||
| caucasian | 70 | 73 | 68 | 69 | 67 | 75 | 73 | 77.8 |
| asiatic | 30 | 25 | 31 | 31 | 29 | 25 | 27 | 22.2 |
| black | - | 2 | 1 | - | 4 | - | - | - |
| Graduation mothers (%) | ||||||||
| < 10 years | 28 | 20 | 24 | 26 | 21 | 25 | 30 | 18 |
| = 10 years | 23 | 35 | 33 | 30 | 42 | 21 | 15 | 30 |
| > 10 years | 49 | 45 | 42 | 44 | 37 | 54 | 55 | 52 |
| Graduation fathers (%) | ||||||||
| < 10 years | 31 | 31 | 29 | 26 | 38 | 33 | 38 | 26 |
| = 10 years | 25 | 22 | 21 | 26 | 8 | 28 | 25 | 33 |
| > 10 years | 44 | 47 | 50 | 48 | 54 | 39 | 37 | 41 |
| Primary attachment figure (%) | ||||||||
| Mother | 76 | 75 | 77 | 74 | 83.3 | 74 | 79 | 67 |
| Father | 2 | 6 | 4 | 4 | 4.2 | 3 | 0 | 8 |
| Others | 22 | 19 | 19 | 22 | 12.5 | 23 | 21 | 25 |
| Mothers’ BMI (kg/m2) | 27.6 ± 6.5 | 23.6 ± 4.0a | 26.6 ± 6.1 | 27.3 ± 6.6 | 24.9 ± 4.7 | 25.7 ± 6.0 | 27.9 ± 6.6 | 22.5 ± 2.8c |
| Fathers’ BMI (kg/m2) | 28.8 ± 4.9 | 27.3 ± 3.8 | 28.3 ± 4.8 | 29.0 ± 5.0 | 26.9 ± 3.9 | 28.2 ± 4.4 | 28.5 ± 4.8 | 27.7 ± 3.8 |
| Weight (kg) | 36.1 ± 7.2 | 26.7 ± 3.9a | 33.0 ± 7.2 | 35.3 ± 7.1 | 27.9 ± 4.2b | 32.5 ± 8.3 | 37.1 ± 7.4 | 25.5 ± 3.4c,d |
| Height (m) | 1.30 ± 0.1 | 1.26 ± 0.07a | 1.29 ± 0.09 | 1.29 ± 0.1 | 1.28 ± 0.07 | 1.28 ± 0.09 | 1.31 ± 0.09 | 1.24 ± 0.07c,d |
| BMI (kg/m2) | 21.2 ± 2.1 | 16.8 ± 1.2a | 19.8 ± 2.6 | 21.0 ± 2.1 | 17.0 ± 1.4b | 19.4 ± 3.0 | 21.4 ± 2.1 | 16.5 ± 1.0c |
| BMI-SDS | 1.89 ± 0.47 | 0.44 ± 0.58a | 1.41 ± 0.81 | 1.81 ± 0.47 | 0.50 ± 0.67b | 1.35 ± 0.93 | 2.00 ± 0.46b | 0.38 ± 0.48c |
| High level FK778 | Mid level FK778 | Low level FK77 | MMF | |
| N = 87 | N = 92 | N = 92 | N = 93 | |
| Anemia | 37 (42.5) | 42 (45.7) | 36 (39.1) | 35 (37.6) |
| Leukopenia | 7 (8) | 11 (12) | 6 (6.5) | 13 (14) |
| Thrombocytopeniaa | 9 (10.3) | 4 (4.3) | 11 (12) | 2 (2.2) |
| Diarrhea | 14 (16.1) | 20 (21.7) | 16 (17.4) | 23 (24.7) |
| Constipation | 15 (17.2) | 8 (8.7) | 7 (7.6) | 17 (18.3) |
| Nausea | 9 (10.3) | 5 (5.4) | 6 (6.5) | 9 (9.7) |
| Vomiting | 11 (12.6) | 12 (13) | 7 (7.6) | 11 (11.8) |
| Peripheral edema | 13 (14.9) | 17 (18.5) | 15 (16.3) | 12 (12.9) |
| Chest painb | 9 (10.3) | 2 (2.2) | 2 (2.2) | 2 (2.2) |
| Bacterial urinary tract infection | 19 (21.8) | 29 (31.5) | 28 (30.4) | 27 (29) |
| Cytomegalovirus infection | 4 (4.6) | 5 (5.4) | 9 (9.8) | 10 (10.8) |
| Hypocalcaemia | 13 (14.9) | 13 (14.1) | 12 (13) | 9 (9.7) |
| Hyperglycemia | 11 (12.6) | 15 (16.3) | 10 (10.9) | 10 (10.8) |
| Hyperlipidemia | 5 (5.7) | 4 (4.3) | 2 (2.2) | 11 (11.8) |
| Hypokalemia | 15 (17.2) | 10 (10.9) | 12 (13) | 7 (7.5) |
| Hypoalbuminemiac | 5 (5.7) | 0 | 1 (1.1) | 0 |
| Hyperuricemia | 9 (10.3) | 21 (22.8) | 20 (21.7) | 12 (12.9) |
| Headache | 11 (12.6) | 11 (12) | 9 (9.8) | 4 (4.3) |
| Tremor | 9 (10.3) | 12 (13) | 9 (9.8) | 14 (15.1) |
| Insomnia | 4 (4.6) | 3 (3.3) | 4 (4.3) | 10 (10.8) |
| Hypertension | 20 (23) | 16 (17.4) | 20 (21.7) | 25 (26.9) |
| Characteristic | Training set (n = 142) | Validation set (n = 112) | ||||||||
| Patients | B4GALT1 expression | Patients | B4GALT1 expression | |||||||
| NO. | % | Low | High | P | NO. | % | Low | High | P | |
| Age, years | 0.614 | 0.763 | ||||||||
| Mean ± SD | 62.4 ± 10.8 | 61.8 ± 10.9 | 62.7 ± 10.8 | 61.5 ± 8.7 | 61.8 ± 9.7 | 61.3 ± 7.6 | ||||
| Range, median | 30–82,62 | 34–82,62 | 30–82,62 | 35–81,62 | 35–81,62 | 46–75,61 | ||||
| Gender | 0.925 | 0.581 | ||||||||
| Male | 118 | 83.1 | 45 | 73 | 97 | 86.6 | 48 | 49 | ||
| Female | 24 | 16.9 | 10 | 14 | 15 | 13.4 | 9 | 6 | ||
| Tumor size, cm | 0.053 | 0.411 | ||||||||
| Mean ± SD | 3.8 ± 1.9 | 4.2 ± 2.1 | 3.6 ± 1.7 | 3.8 ± 1.8 | 3.9 ± 2.0 | 3.7 ± 1.6 | ||||
| Range | 0.5–10.0 | 1.0–10.0 | 0.5–8.0 | 0.8–9.5 | 0.8–9.5 | 1.3–9.0 | ||||
| pT stage | 0.971 | 0.720 | ||||||||
| T2 | 68 | 47.9 | 27 | 41 | 49 | 43.8 | 27 | 22 | ||
| T3 | 48 | 33.8 | 18 | 30 | 49 | 43.8 | 23 | 26 | ||
| T4 | 26 | 18.3 | 10 | 16 | 14 | 12.4 | 7 | 7 | ||
| Grade | 0.017 | 0.950 | ||||||||
| low | 24 | 16.9 | 15 | 9 | 11 | 9.8 | 6 | 5 | ||
| high | 118 | 83.1 | 40 | 78 | 101 | 90.2 | 51 | 50 | ||
| LVI | 0.157 | 0.741 | ||||||||
| absent | 53 | 37.3 | 25 | 28 | 78 | 69.6 | 41 | 37 | ||
| present | 89 | 62.7 | 30 | 59 | 34 | 30.4 | 16 | 18 | ||
| CCI | 0.116 | 0.263 | ||||||||
| ≤ 1 | 47 | 33.1 | 23 | 24 | 44 | 39.3 | 19 | 25 | ||
| ≥ 2 | 95 | 66.9 | 32 | 63 | 68 | 60.7 | 38 | 30 |
| Composition | CAS | RP-A | RP-E |
| Moisture | 9.7 | 9.8 | 10.9 |
| Protein | 87.3 | 86.4 | 79.6 |
| Carbohydrate | 0.2 | 0.9 | 2.5 |
| Lipids | 0.5 | 0.8 | 0.8 |
| Ash | 1.7 | 1.0 | 1.5 |
| Dietary fiber | 0.6 | 1.1 | 4.7 |
| Design | Intervention | Country | Focus | Sample | Sample size(n) | Duration | Reference |
| Cluster blind RCT | Electronic decision support system | USA | GP | T1D, T2D | 639 | 21 months | [15] |
| Cluster RCT | Diabetes register | UK | GP | T2D | 3, 608 | 15 months | [16] |
| Cluster RCT | Diabetes register | USA | GP | T2D | 7, 101 | 12 months | [17] |
| Cluster RCT | Electronic telemedicine | USA | Patient | T2D | 1, 665 | 12 months | [18] |
| Cluster RCT | Electronic telemedicine | USA | GP | T2D | 1, 665 | 12 months | [19] |
| Cluster RCT | Electronic self-management system | USA | Patient | T2D | 886 | 12 months | [20] |
| RCT | Electronic self-management system | USA | Patient | T1D, T2D | 122 | 6 months | [21] |
| RCT | Electronic self-management system | USA | Patient | T1D, T2D | 104 | 12 months | [22] |
| RCT | Electronic self-management system | USA | Patient | T1D, T2D | 62 | 6 months | [23] |
| Nonrandomised cluster control trial | Electronic management system | USA | GP | T1D, T2D | 6, 646 | 24 months | [24] |
| Nonrandomised control trial | Diabetes register | USA | GP | T1D, T2D | 898 | 20 months | [25] |
| Nonrandomised control trial | Personal Digital Assistant (PDA) based electronic management system | USA | GP | T2D | 173 | 16 months | [26] |
| Nonrandomised control trial | Diabetes register | USA | GP | T1D, T2D | 661 | 2 years | [27] |
| Nonrandomised control trial | Electronic decision support system | USA | GP | T1D, T2D | 16 | 6 months | [28] |
| Single sample before and after design | Diabetes register | USA | GP | T1D, T2D | 62 | 3 years | [29] |
| Single sample before and after design | Diabetes register | Korea | GP | T1D, T2D | 185 | 3 months | [30] |
| Amplitude of extension reflex score < 2.5 | Rotarod time on rod < 90 s | Symmetry of extension reflex score < 1 | Stride length < 5 cm | |
| hA30Pα-syn+/+ | 18.1 ± 0.2 months | 19.3 ± 0.2 months | 20.0 ± 0.2 months | 20.7 ± 0.2 months |
| parkin+/-; hA30Pα-syn+/+ | 18.4 ± 0.2 months | 20.2 ± 0.2 months | 22.3 ± 0.2 months | 23.0 ± 0.2 months |
| parkin-/-; hA30Pα-syn+/+ | 21.0 ± 0.2 months | 23.2 ± 0.2 months | 23.4 ± 0.2 months | > 24 months |
| % | ||||||||
| Arthritis | Stroke | Angina | Diabetes | Lung disease | Asthma | Depression | Cataracts | |
| No hypertension | 18.30 | 1.13 | 5.85 | 4.55 | 3.33 | 3.16 | 3.76 | 2.78 |
| Hypertension diagnosed and measured | 35.61 | 8.91 | 6.25 | 21.44 | 4.02 | 7.35 | 3.63 | 8.92 |
| Hypertension measured but not diagnosed | 18.83 | 2.24 | 3.43 | 4.32 | 1.54 | 3.05 | 1.40 | 1.18 |
| Normal blood pressure but diagnosed with hypertension | 38.90 | 3.91 | 12.32 | 15.65 | 7.72 | 14.43 | 7.55 | 12.56 |
| Outcome | Impact of Statins on rate of events modeled using Cox Proportional Hazards (HR, 95% CI) (Statin versus No Statin) | Impact of Statins on number of events, modeled using Generalized Linear Models (RR, 95% CI) (Statin versus No Statin) |
| All-cause re-hospitalizations | ||
| Modeled without propensity score | 0.84 (0.78-0.90) | 0.97 (0.90-1.04) |
| Modeled with propensity score | 0.98 (0.91-1.06) | 1.04 (0.97-1.12) |
| CVD re-hospitalizations | ||
| Modeled without propensity score | 0.98 (0.90-1.07) | 0.90 (0.86-1.12) |
| Modeled with propensity score | 1.11 (1.02-1.22) | 1.03 (0.92-1.16) |
| All physician visits | N/A | |
| Modeled without propensity score | 0.84 (0.79-0.88) | |
| Modeled with propensity score | 0.97 (0.92-1.02) | |
| CVD-related physician visits | N/A | |
| Modeled without propensity score | 1.18 (1.09-1.29) | |
| Modeled with propensity score | 1.34 (1.23-1.46) | |
| Coronary Revascularizations | N/A | |
| Modeled without propensity score | 1.55 (1.30-1.84) | |
| Modeled with propensity score | 1.15 (0.97-1.36) | |
| Mortality | N/A | |
| Modeled without propensity score | 0.41 (0.35-0.49) | |
| Modeled with propensity score | 0.74 (0.63-0.88) |
| Variables | Category | TB status | p value | |
| No (N = 520) | Yes (N = 130) | |||
| Age in year, mean ± std. error of mean | 33.6 ± 0.4 | 33.4 ± 0.8 | 0.850 | |
| Gender | Male, N (%) | 165 (31.7) | 56 (43.1) | 0.017 |
| Female, N (%) | 355 (68.3) | 74 (56.9) | ||
| Residence | Rural, N (%) | 125 (24) | 35 (26.9) | 0.569 |
| Urban, N (%) | 395 (76) | 95 (73.1) | ||
| Marital status | Never married N (%) | 102 (19.6) | 26 (20.0) | 0.160 |
| Ever married, N (%) | 418 (80.4) | 104 (80.0) | ||
| Educational level | Illiterate, N (%) | 102 (19.6) | 37 (28.5) | 0.168 |
| Primary, N (%) | 183 (35.2) | 39 (30) | ||
| Secondary, N (%) | 175 (33.7) | 39 (30) | ||
| Tertiary, N (%) | 60 (11.5) | 15 (11.5) | ||
| Employment status | Unemployed, N (%) | 350 (67.3) | 91 (70.0) | 0.257 |
| Employed, N (%) | 170 (33.7) | 39 (30.0) | ||
| Drug addiction behavior | No, N (%) | 246 (47.3) | 57 (43.8) | 0.479 |
| Yes, N (%) | 274 (52.7) | 73 (56.2) | ||
| Weight in kg, mean ± std. error of mean | 52.0 ± 0.4 | 49.1 ± 0.8 | 0.003 | |
| CD4 in cells/mm3, mean ± std. error of mean | 153.8 ± 3.8 | 128.7 ± 9.7 | 0.006 | |
| BMI in kg/m2, mean ± std. error of mean | 19.4 ± 0.1 | 18.2 ± 0.3 | <0.001 | |
| Hgb mg/dl, mean ± std. error of mean | 12.3 ± 0.1 | 11.03 ± 0.2 | <0.001 | |
| WHO clinical stage | Stage I/II, N (%) | 334 (64.2) | 0 (0) | <0.001 |
| Stage III, N (%) | 157 (30.2) | 85 (65.4) | ||
| Stage IV, N (%) | 29 (5.6) | 45 (34.6) | ||
| ART regimen | Non TDF based, N (%) | 325 (63.3) | 76 (59.2) | <0.001 |
| TDF-based, N (%) | 196 (37.7) | 53 (40.8) | ||
| Functional status | Working, N (%) | 378 (72.7) | 51 (38.7) | <0.001 |
| Ambulatory, N (%) | 127 (24.4) | 66 (50.8) | ||
| Bed ridden, N (%) | 15 (2.9) | 13 (10) |
| Locus | Sample localities | |||||||||
| 11°N | 9°N | GARa | 7°S | 11°S | 17°S | 23°S | 32°S | 38°S | ||
| 16S rRNA encoding gene(300 bp) | Nb | - | 13,310 | - | 2008 | 7531 | 6688 | 1899 | 6400 | 3046 |
| hc | - | 7 | - | 3 | 6 | 6 | 3 | 4 | 5 | |
| Hd | - | 0.030 | - | 0.157 | 0.020 | 0.029 | 0.026 | 0.009 | 0.029 | |
| πe | - | 1.0E-04 | - | 5.3E-04 | 6.6E-05 | 9.5E-05 | 8.7E-05 | 3.0E-05 | 9.8E-05 | |
| COI Cytochrome C oxidase subunit I(443 bp) | N | 3294 | 3692 | 1583 | 2246 | 2157 | 2545 | 1029 | 2332 | 737 |
| h | 36 | 24 | 40 | 8 | 11 | 59 | 17 | 33 | 19 | |
| H | 0.80 | 0.70 | 0.72 | 0.77 | 0.68 | 0.86 | 0.84 | 0.67 | 0.73 | |
| π | 0.003 | 0.002 | 0.003 | 0.003 | 0.002 | 0.003 | 0.004 | 0.002 | 0.003 | |
| dnaK Chaperone protein(469 bp) | N | 2465 | 3100 | 2995 | 2362 | 2671 | 1876 | 1967 | 2367 | 2300 |
| h | 5 | 39 | 23 | 22 | 19 | 45 | 4 | 33 | 43 | |
| H | 0.42 | 0.78 | 0.62 | 0.80 | 0.67 | 0.65 | 0.45 | 0.82 | 0.83 | |
| π | 0.001 | 0.003 | 0.002 | 0.003 | 0.002 | 0.002 | 0.001 | 0.003 | 0.003 | |
| pgi Glucose-6-phosphate isomerase(441 bp) | N | 1966 | 2986 | 2466 | 1972 | 1918 | 2668 | 1339 | 3747 | 1528 |
| h | 35 | 30 | 57 | 16 | 16 | 70 | 11 | 151 | 103 | |
| H | 0.82 | 0.85 | 0.85 | 0.67 | 0.70 | 0.87 | 0.46 | 0.91 | 0.91 | |
| π | 0.004 | 0.004 | 0.004 | 0.003 | 0.003 | 0.004 | 0.002 | 0.008 | 0.006 | |
| pykF Pyruvate kinase(404 bp) | N | 2234 | 3051 | 3475 | 2770 | 3020 | 2629 | 1602 | 3150 | 1934 |
| h | 39 | 37 | 57 | 32 | 65 | 43 | 21 | 87 | 39 | |
| H | 0.75 | 0.81 | 0.77 | 0.74 | 0.90 | 0.79 | 0.79 | 0.88 | 0.78 | |
| π | 0.003 | 0.006 | 0.005 | 0.006 | 0.006 | 0.003 | 0.004 | 0.006 | 0.003 | |
| rpoD RNA polymerase, sigma D factor(388 bp) | N | 3326 | 4328 | 3901 | 3650 | 4090 | 3717 | 2403 | 4797 | 2199 |
| h | 30 | 26 | 25 | 26 | 22 | 42 | 27 | 18 | 42 | |
| H | 0.84 | 0.76 | 0.81 | 0.80 | 0.80 | 0.64 | 0.70 | 0.65 | 0.68 | |
| π | 0.004 | 0.003 | 0.004 | 0.004 | 0.004 | 0.002 | 0.004 | 0.002 | 0.003 | |
| soxA Sulfur oxidation protein A(361 bp) | N | 4196 | 5036 | 4085 | 3763 | 4652 | 3370 | 2715 | 3879 | 4105 |
| h | 6 | 9 | 12 | 7 | 3 | 5 | 8 | 4 | 6 | |
| H | 0.45 | 0.70 | 0.70 | 0.47 | <0.01 | 0.34 | 0.03 | 0.03 | 0.17 | |
| π | 0.001 | 0.001 | 0.002 | 0.001 | <0.001 | 0.001 | <0.001 | <0.001 | <0.001 |
| Age <75 years | Age ≥75 years | p | |
| Histological grade (well/mod/poor) | 54 (35.8 %)/83 (55.0 %)/14 (9.2 %) | 19 (35.8 %)/28 (52.8 %)/6 (11.4 %) | 0.99 |
| Lymphatic invasion (no/yes) | 6 (4.0 %)/145 (96.0 %) | 6 (11.3 %)/47 (88.7 %) | 0.02 |
| Vessel invasion (no/yes) | 20 (13.2 %)/131 (86.8 %) | 7 (13.2 %)/46 (86.8 %) | 0.99 |
| Operation time (min) | 480 (80–713) | 241 (74–645) | 0.35 |
| Blood loss (g) | 185 (10–1400) | 129 (20–510) | 0.07 |
| Laparoscopic surgery (no/yes) | 83 (55.0 %)/69 (45.0 %) | 31 (58.5 %)/22 (41.5 %) | 0.62 |
| Composite resection (no/yes) | 143 (94.7 %)/8 (5.3 %) | 48 (90.6 %)/5 (9.4 %) | 0.38 |
| Postoperative chemotherapy (no/yes) | 36 (23.8 %)/115 (76.2 %) | 32 (60.4 %)/21 (39.6 %) | <0.01 |
| Postoperative complication (no/yes) | 95 (62.9 %)/56 (37.1 %) | 32 (60.4 %)/21 (39.6 %) | 0.74 |
| Hospital stay (days) | 25.7 (14–31) | 25.5 (16–40) | 0.93 |
| Variable | Mean (SD) | P-value | |
| Material | CEM cement | 68* (28) | 0.92 |
| MTA | 67 (39) | ||
| Subgroups | AP+GP | 55 (28) | 0.005 |
| AP+TO | 67 (14) | ||
| Obturation with AP material | 56 (29) | ||
| Unfilled | 96 (37) |
| Komfo-Anokye (disclosure intervention) | Korle-Bu (usual care) | Total | ||
| N = 131(%) | N = 167(%) | P value | N = 298(%) | |
| Agee | 43.2 ± 10.8 | 42.1 ± 10.0 | 0.34a | 42.6 ± 10.4 |
| Marital statusc | 0.09b | |||
| Single | 17 (13.0) | 22 (13.2) | 39 (13.1) | |
| Married | 63 (48.1) | 98 (58.7) | 161 (54.0) | |
| Divorce/separated | 17 (13.0) | 23 (13.8) | 40 (13.4) | |
| Widowed | 34 (26.0) | 24 (14.4) | 58 (19.5) | |
| Gender | 0.38b | |||
| Male | 22 (16.8) | 36 (21.6) | 58 (19.5) | |
| Female | 109 (83.2) | 131 (78.4) | 240 (80.5) | |
| HIV status | 0.9b | |||
| No or not sure | 53 (40.8) | 65 (39.6) | 118 (40.1) | |
| Yes | 77 (59.2) | 99 (60.4) | 176 (59.9) | |
| Education | <0.0001b | |||
| No school | 17 (13.0) | 30 (18.0) | 47 (15.8) | |
| Elementary education | 96 (73.3) | 71 (42.5) | 167 (56.0) | |
| Secondary and post-secondary education | 18 (13.7) | 66 (39.5) | 84 (28.2) | |
| Employment status | 0.62b | |||
| Unemployed | 18 (13.8) | 22 (13.3) | 40 (13.5) | |
| Self-employed | 103 (79.2) | 127 (76.5) | 230 (77.7) | |
| Private or government sector employment | 9 (6.9) | 17 (10.2) | 26 (8.8) | |
| Monthly household income (GHS)d | <0.0001b | |||
| >50 per month | 26 (20.2) | 2 (1.2) | 28 (9.6) | |
| 50–300 per month | 84 (65.1) | 99 (60.7) | 183 (62.7) | |
| >300 per month | 19 (14.7) | 62 (38.0) | 81 (27.7) | |
| Distance from clinic/hospital | 0.0001b | |||
| 0–20 kilometers | 98 (75.4) | 90 (53.9) | 188 (63.3) | |
| More than 20 kilometers | 32 (24.6) | 77 (46.1) | 109 (36.7) | |
| Receiving own care at | 0.56b | |||
| Clinic/hospital | 126 (96.9) | 165 (98.8) | 291 (98.0) | |
| Clinic/hospital and Traditional/homeopathic healer | 2 (1.5) | 1 (0.6) | 3 (1.0) | |
| Other | 2 (1.5) | 1 (0.6) | 3 (1.0) |
| Author | GA at diagnosis (weeks) | Treatment | Complications | Follow-up (months) | Outcome |
| Benedetto et al. | 9 | Endoscopy with HCPs | no | 1 | Normal |
| Chen et al. | 31 | Endoscopy with HCPs | HELLP syndrome | 2 | Normal |
| GBR | Auto only | Auto + xeno | Xeno only | Syn only | Total |
| No | 40 | 44 | 79 | 17 | 180 |
| % | 22.2 | 24.4 | 43.9 | 9.4 | 100.0 |
| Variable | Biliary acute Pancreatitis (n = 425) | Hypertriglyceridemia acute Pancreatitis (n = 305) | P value |
| Hospital mortality, no. | 36(8.5%) | 24(7.9%) | 0.787 |
| Need of surgery, no. | 39(9.2%) | 33(10.8%) | 0.529 |
| ICU admission | 260(61.2%) | 186(61.0%) | 1 |
| Length of ICU stay, days | 4(2,12) | 4(2,10.5) | 0.975 |
| Length of hospital stay, days | 9(4,22.5) | 9(5,23) | 0.58 |
| Cost, Thousand CHY | 48.7(22.8157.8) | 51.0(27.9134.6) | 0.623 |
| Drug | Disease/disturbance | Side effect |
| Cefradine | Urinary tract infection | Hypersensitivity, elevated liver enzyme, diarrhea |
| Nitroxoline | Urinary tract infection | Gastrointestinal intolerance, urine coloration |
| Sulfonamide | Urinary tract infection | Hypersensitivity, folic acid deficiency, hematological abnormality |
| Levofloxacin | Urinary tract infection | Diarrhea, tendinitis, seizure neuropathy, elevated liver enzyme |
| Atenolol | Hypertension | Bradycardia, cough, Raynaud's syndrome |
| Amlodipine | Hypertension | Flush, tachycardia, edema |
| Solantin | Thromboembolism | Dizziness, abdomen distress, angina, headache |
| Ursodeoxycholic acid | Liver cirrhosis | Gastrointestinal disturbance |
| Atorvastatin | Hyperlipidemia | Gastrointestinal disturbance, elevated liver enzyme, myopathy, neuropathy |
| Chinese herb drugs | Multiple somatic complaints | Unknown |
| males | females | ||||||
| DEPCAT | Region | 1980–82 | 1990–92 | 2000–02 | 1980–82 | 1990–92 | 2000–02 |
| H&I | 342 | 315 | 244 | 114 | 172 | 132 | |
| NE | 290 | 217 | 170 | 170 | 177 | 135 | |
| Clyde | 330 | 221 | 161 | 201 | 135 | 119 | |
| 1 | Central | 304 | 309 | 125 | 150 | 111 | 90 |
| East | 318 | 238 | 199 | 162 | 146 | 140 | |
| SW | 349 | 198 | 140 | 210 | 76 | 111 | |
| SE | 296 | 225 | 132 | 187 | 145 | 119 | |
| H&I | 425 | 276 | 221 | 249 | 171 | 145 | |
| NE | 367 | 247 | 218 | 217 | 160 | 132 | |
| Clyde | 386 | 287 | 215 | 229 | 204 | 140 | |
| 2 | Central | 377 | 288 | 202 | 226 | 220 | 138 |
| East | 366 | 289 | 204 | 202 | 195 | 135 | |
| SW | 420 | 257 | 240 | 221 | 194 | 139 | |
| SE | 365 | 282 | 190 | 239 | 155 | 116 | |
| H&I | 445 | 334 | 290 | 265 | 190 | 169 | |
| NE | 406 | 299 | 272 | 254 | 171 | 154 | |
| Clyde | 454 | 374 | 281 | 277 | 196 | 168 | |
| 3 | Central | 439 | 436 | 265 | 295 | 196 | 168 |
| East | 422 | 326 | 259 | 257 | 197 | 150 | |
| SW | 479 | 327 | 254 | 265 | 197 | 155 | |
| SE | 426 | 288 | 289 | 232 | 171 | 161 | |
| H&I | 564 | 403 | 334 | 281 | 199 | 200 | |
| NE | 446 | 370 | 371 | 248 | 223 | 179 | |
| Clyde | 534 | 449 | 352 | 297 | 222 | 196 | |
| 4 | Central | 491 | 329 | 341 | 321 | 215 | 202 |
| East | 462 | 361 | 304 | 272 | 232 | 176 | |
| SW | 472 | 344 | 302 | 297 | 251 | 190 | |
| SE | 447 | 407 | 329 | 267 | 222 | 197 | |
| H&I | 661 | 521 | 390 | 192 | 312 | 186 | |
| NE | 592 | 416 | 497 | 324 | 262 | 242 | |
| Clyde | 565 | 446 | 445 | 315 | 252 | 230 | |
| 5 | Central | 511 | 416 | 412 | 298 | 228 | 226 |
| East | 489 | 430 | 386 | 338 | 238 | 206 | |
| SW | 554 | 428 | 375 | 323 | 272 | 234 | |
| SE | 513 | 462 | 410 | 287 | 258 | 224 | |
| H&I | 913 | 452 | 846 | 350 | 100 | 88 | |
| NE | 392 | 435 | 583 | 277 | 249 | 260 | |
| Clyde | 646 | 518 | 515 | 368 | 293 | 255 | |
| 6 | Central | 628 | 782 | 388 | 318 | 338 | 261 |
| East | 506 | 466 | 445 | 369 | 291 | 249 | |
| SW | 591 | 488 | 425 | 351 | 276 | 262 | |
| SE | 561 | 411 | 403 | 300 | 302 | 220 | |
| H&I | 607 | 0 | 0 | 0 | |||
| NE | |||||||
| Clyde | 735 | 635 | 717 | 403 | 382 | 340 | |
| 7 | Central | ||||||
| East | 557 | 2547 | 623 | 303 | 0 | 307 | |
| SW | 794 | 544 | 206 | 268 | |||
| SE | 697 | 666 | 675 | 380 | 397 | 455 |
| Gene | Exon/intron | Nucleotide change | Aminoacid change | LCn = 175OR (95% CI) | MPT-LCn = 115OR (95% CI) | MPTn = 68OR (95% CI) | Controlsn = 506 |
| RAD50 | Ex. 4 | c.379G>A | p.V127I | 2 | - | - | 2 |
| 2.91 (0.41-20.85) | |||||||
| Ex. 7 | c.943G>T | p.V315L | - | 2 | - | 1 | |
| 8.96 (0.81-99.68) | |||||||
| Ex. 25 | c.3876C>T | - | 1 | - | - | 0/180 | |
| 8.71 (0.35-215) | |||||||
| MRE11 | Int. 16 | c.1783-86delAG | - | 39 | 18 | 20 | 61/279 |
| 1.03 (0.65-1.62) | 0.66 (0.37-1.18) | 1.49 (0.82-2.69) |
| Patient study code | Pre-study dopamine agonist | Trial arm | First IMP | Daily dose (mg) | Number of days on IMP | Second IMP | Daily dose (mg) | Number of days on IMP |
| PD1 | RPR | 1 | PPX | 2.1 | 3 | RPRa, b | 8 | 134 |
| PD2 | RPR | 1 | PPX | 2.62 | 58 | RPR | 10 | 48 |
| PD3 | RPR | 2 | RPR | 6 | 51 | PPX | 1.57 | 58 |
| PD4 | RPR | 2 | RPR | 4 | 40 | PPX | 1.05 | 55 |
| PD5 | Consented but then withdrew before taking first IMP | |||||||
| PD6 | PPX | 1 | PPX | 2.1 | 64 | RPR | 8 | 52 |
| PD7 | PPX | 2 | RPR | 10 | 13 | PPXa, b | 2.62 | 97 |
| PD8 | RPR | 2 | RPR | 12 | 54 | PPX | 3.15 | 62 |
| PD9 | PPX | 1 | PPX | 1.57 | 62 | RPR | 6 | 56 |
| PD10 | RPR | 1 | PPX | 2.1 | 53 | RPR | 8 | 68 |
| PD11 | PPX | 1 | PPX | 1.05 | 48 | RPRb | 4 | 30 |
| PD12 | PPX | 2 | RPR | 10 | 52 | PPX | 2.62 | 56 |
| PD13 | Consented but then withdrew before taking first IMP | |||||||
| PD14 | PPX | 1 | PPX | 0.52 | 52 | RPR | 2 | 37 |
| PD15 | Consented but then withdrew before taking first IMP | |||||||
| PD16 | PPX | 1 | PPX | 1.57 | 63 | RPR | 6 | 55 |
| PD17 | PPX | 2 | RPR | 6 | 60 | PPX | 1.57 | 37 |
| PD18 | PPX | 2 | RPR | 6 | 3 | Withdrew from IMP and study | ||
| PD19 | RPR | 1 | PPX | 2.1 | 55 | RPR | 8 | 84 |
| PD20 | PPX | 2 | RPR | 8 | 66 | PPX | 2.1 | 41 |
| PD21 | PPX | 1 | PPX | 3.15 | 100 | RPRb | 12 | 7 |
| PD22 | RPR | 2 | RPR | 6 | 55 | PPX | 1.57 | 48 |
| PD23 | PPX | 2 | RPR | 8 | 5 | Withdrew from IMP and study | ||
| PD24 | RPR | 2 | RPR | 6 | 58 | PPX | 1.57 | 37 |
| PD25 | RPR | 2 | RPR | 2 | 68 | PPX | 0.52 | 62 |
| Parental feeding practices | Family breakfast frequency | Family dinner frequency | Family supper frequency |
| Monitoring | .11* | .04 | .02 |
| Child control | -.09** | -.11* | -.03 |
| Encourage balance and variety | .06 | .08** | .04 |
| Environment | .13* | .09** | .12* |
| Involvement | .01 | -.00 | .02 |
| Pressure to eat | .08** | .00 | .01 |
| Restriction for weight | -.01 | -.04 | -.02 |
| Food as reward | -.02 | -.09** | -.00 |
| Restriction for health | -.05 | -.06 | -.05 |
| Teaching nutrition | .10* | .06 | .09** |
| Modeling | .11* | .06 | .08** |
| Emotion regulation | -.02 | -.08** | .01 |
| Variables | T1D (n = 19) | T2D (n = 21) | P value |
| Female/male (n/n) | 13/6 | 9/12 | 0.105 |
| Age (years) | 35 ± 19 | 52 ± 10 | 0.001 |
| Duration of diabetes (years) | 7.00 (0.00–26.00) | 5.00 (0.00–15.00) | 0.455 |
| Plasma glucose (mmol/L) | 31.82 ± 8.53 | 26.37 ± 6.81 | 0.035 |
| HbA1c (%) | 12.97 ± 2.25 | 12.07 ± 1.73 | 0.214 |
| Arterial pH | 7.01 ± 0.16 | 7.04 ± 0.14 | 0.486 |
| HCO3 (mmol/L) | 4.71 ± 3.50 | 5.54 ± 3.48 | 0.420 |
| Alanine aminotransferase (U/L) | 15.57 ± 5.79 | 15.92 ± 6.22 | 0.880 |
| Aspartate aminotransferase (U/L) | 19.21 ± 13.46 | 18.08 ± 5.98 | 0.782 |
| γ-glutamyl transpeptidase (U/L) | 17.31 ± 7.20 | 18.62 ± 6.99 | 0.643 |
| Total bilirubin (μmol/L) | 11.42 ± 4.38 | 11.06 ± 4.71 | 0.843 |
| Direct bilirubin (μmol/L) | 4.42 ± 1.27 | 4.78 ± 1.97 | 0.597 |
| Total protein (g/L) | 58.48 ± 11.60 | 60.32 ± 7.10 | 0.632 |
| Albumin (g/L) | 36.66 ± 4.76 | 35.42 ± 5.55 | 0.463 |
| Globulin (g/L) | 21.85 ± 6.94 | 26.48 ± 4.90 | 0.061 |
| Prealbumin (mg/dL) | 135.40 ± 52.78 | 130.53 ± 53.91 | 0.775 |
| Serum creatinine (μmol/L) | 99.06 ± 53.62 | 119.32 ± 90.06 | 0.399 |
| eGFR (mL/min per 1.73 m2) | 62.90 ± 25.03 | 57.19 ± 26.58 | 0.490 |
| Uric acid (μmol/L) | 458.53 ± 128.66 | 476.58 ± 157.40 | 0.746 |
| Target gene symbol | miRNAs | Non-tumor | Tumor | Adjusted P value * | Regulation in HCC tumor |
| Mean (Log2), SD | Mean (Log2), SD | ||||
| GRASP | hsa-miR-320b | −8.97, 0.75 | −10.10, 0.96 | 8.95E-03 | Down |
| TSPYL5 | hsa-miR-193a-3p | −8.21, 1.06 | −9.53, 0.88 | 7.58E-03 | Down |
| hsa-let-7g | −3.43, 0.67 | −4.11, 0.55 | 2.32E-02 | Down | |
| hsa-let-7a | −6.43, 0.64 | −7.35, 0.86 | 1.42E-02 | Down | |
| hsa-let-7e | −4.05, 0.82 | −4.78, 0.63 | 3.86E-02 | Down | |
| hsa-let-7c | −6.88, 0.50 | −8.62, 1.08 | 2.24E-04 | Down | |
| hsa-let-7b | −4.53, 0.86 | −5.89, 1.18 | 8.94E-03 | Down | |
| hsa-miR-320b | −8.97, 0.75 | −10.10, 0.96 | 8.95E-03 | Down | |
| hsa-miR-27b | −5.69, 0.79 | −6.48, 0.70 | 2.84E-02 | Down |
| Diagnoses | Patient count | % of Total |
| Pre-Index Period | ||
| Total Unique Patients in the Population | 5,490 | |
| Patients with ≥ 1 Pertussis-like event | 3,140 | 57 |
| Acute Respiratory: | 2,857 | 52 |
| COUGH | 1,350 | 25 |
| UPPER RESPIRATORY TRACT INFECTION | 1,004 | 18 |
| ACUTE BRONCHITIS | 938 | 17 |
| ASTHMA | 449 | 8 |
| ALLERGY | 413 | 8 |
| LOWER RESPIRATORY TRACT INFECTION | 387 | 7 |
| OTHER PNEUMONIA | 313 | 6 |
| Other : | 1,798 | 33 |
| HYPERTENSION | 579 | 11 |
| SHORTNESS OF BREATH | 368 | 7 |
| HIGH CHOLESTEROL | 316 | 6 |
| GERD | 290 | 5 |
| CHEST PAIN | 266 | 5 |
| COPD AND OTHER ALLIED CONDITIONS | 229 | 4 |
| DIABETES | 224 | 4 |
| LUMBAR STRAIN OR BACK PAIN | 171 | 3 |
| Post-Index Period | ||
| Total Unique Patients in the Population | 5,490 | 100 |
| Acute Respiratory: | 5,053 | 92 |
| WHOOPING COUGH-UNSPECIFIED ORGANISM | 2,224 | 41 |
| COUGH | 2,222 | 40 |
| UPPER RESPIRATORY TRACT INFECTION | 770 | 14 |
| ACUTE BRONCHITIS | 694 | 13 |
| WHOOPING COUGH-BORDETELLA PERTUSSIS | 605 | 11 |
| ASTHMA | 551 | 10 |
| OTHER PNEUMONIA | 468 | 9 |
| ALLERGY | 404 | 7 |
| LOWER RESPIRATORY TRACT INFECTION | 359 | 7 |
| PNEUMONIA IN WHOOPING COUGH | 237 | 4 |
| Other: | 2,309 | 42 |
| HYPERTENSION | 851 | 16 |
| HIGH CHOLESTEROL | 495 | 9 |
| SHORTNESS OF BREATH | 445 | 8 |
| DIABETES | 421 | 8 |
| GERD | 421 | 8 |
| COPD AND OTHER ALLIED CONDITIONS | 388 | 7 |
| CHEST PAIN | 300 | 5 |
| Item | Experiment A [8] | Experiment B |
| Study design | Design: parallel crossover Diets: control (CON) and treatment (TRMT)Duration: 22 d with glucose kinetics assessed on day 19 of study | Design: parallel crossoverDiets: control (CON) and treatment (TRMT)Duration: 63 d with glucose kinetics assessed on day 35 of study |
| Study population | A total of 6 neutered male Labrador Retrievers, 3-black-coated (3.9 yr; 27.3 kg) and 3-chocolate-coated (6.8 yr; 35.0 kg) | A total of 12 black Labrador Retrievers, 5 spayed females and 7 neutered males (27.0 ± 0.6 kg; 4.9 ± 0.2 yr of age) |
| Key details of glucose kinetics experiment | Isotope: U-13C-glucosePrime: 77.8 μmol/kgConstant: 0.136 μmol/min·kgFasting collections (18 h since last meal): 6 blood samples were taken at 60, 85, 110, 135, 160, and 185 min followed by 4 breath samples taken at 220, 245, 270, and 295 min after isotope infusion (start of isotope infused considered time 0) Postprandial collections: total food ration of 14 g/kg divided into 15 equal sized meals fed in 25 min intervals; 6 blood samples were taken at 60, 85, 110, 135, 160, and 185 min followed by 4 breath samples taken at 220, 245, 270, 295, 320, and 345 min after initial meal | Isotope: U-13C-glucosePrime: 8.1 μmol/kgConstant: 0.136 μmol/min·kgFasting collections (18 h since last meal): 6 fasting blood samples were taken at 90, 105, 120, 135, 150, and 165 min followed by 6 breath samples taken at 180, 205, 230, 255, 280, and 305 min after isotope infusion (start of isotope infused considered time 0)Postprandial collections: total food ration of 23 g/kg divided into 14 equal sized meals fed in 25 min intervals; 6 fasting blood samples were taken at 90, 105, 120, 135, 150, and 165 min followed by 6 breath samples taken at 180, 205, 230, 255, 280, and 305 min after initial meal. |
| Cutoff OD | Model usinga: | Overall accuracy (%)b | |||
| On-admission sample alone | Paired samples | ||||
| Sensitivity | Specificity | Sensitivity | Specificity | ||
| 1.010 | 78.6 (68.8–85.2) | 100 (98.2–100) | 85.2 (77.4–87.1) | 93.5 (92.5–96.2) | 93.3 |
| 1.023 | 73.3 (64.7–81.5) | 100 (98.2–100) | 85.2 (77.4–87.1) | 93.5 (92.5–96.2) | 93.0 |
| 1.080 | 73.3 (64.7–81.5) | 100 (98.2–100) | 85.2 (77.4–87.1) | 94.4 (93.5–97.1) | 93.3 |
| 1.093 | 70.0 (61.3–77.8) | 100 (98.2–100) | 85.2 (77.4–87.1) | 94.4 (93.5–97.1) | 93.0 |
| 1.165 | 70.0 (61.3–77.8) | 100 (98.2–100) | 85.2 (77.4–87.1) | 95.3 (94.4–98.1) | 93.3 |
| 1.214 | 70.0 (61.3–77.8) | 100 (98.2–100) | 85.2 (77.4–87.1) | 95.3 (94.4–98.1) | 93.3 |
| 1.273 | 70.0 (61.3–77.8) | 100 (98.2–100) | 85.2 (77.4–87.1) | 96.3 (95.3–99.0) | 93.7 |
| 1.275 | 70.0 (61.3–77.8) | 100 (98.2–100) | 85.2 (77.4–87.1) | 96.3 (95.3–99.0) | 93.7 |
| 1.307 | 69.0 (60.6–76.9) | 100 (99.1–100) | 85.2 (77.4–87.1) | 97.2 (96.3–100) | 94.1 |
| 1.474 | 69.0 (60.6–76.9) | 100 (99.1–100) | 85.7 (77.4–86.7) | 98.1 (97.2–100) | 94.4 |
| PCC | Total | TR | TS | ||||
| S | NS | S | NS | S | NS | ||
| MACCS | 154 | 1050 | 126 | 838 | 28 | 212 | |
| 0.25 | Descriptors | 154 | 1050 | 123 | 841 | 31 | 209 |
| Random | 154 | 1050 | 123 | 840 | 31 | 210 | |
| MACCS | 98 | 1106 | 85 | 879 | 13 | 227 | |
| 0.30 | Descriptors | 98 | 1106 | 80 | 884 | 18 | 222 |
| Random | 98 | 1106 | 78 | 962 | 20 | 222 |
| BMI <25 kg/m2 (n=1296) | BMI ≥25 kg/m2 (n=3382) | P-value | |
| Use of allopirunol, n | 379(29.2) | 2031(60.1) | <0.05 |
| Use of febuxostat, n | 82(6.3) | 189(5.6) | >0.05 |
| Use of benzbromarone, n | 367(28.3) | 228(6.7) | <0.05 |
| Use of combination urate-lowering therapies, n | 35(2.7) | 577(17.1) | <0.05 |
| Lifestyle intervention only, n | 433(33.4) | 357(10.6) | <0.05 |
| Parameters | N = 506 |
| Age in years, mean (SD) | 23.8 (3.4) |
| Age categories | |
| <20 yr, n (%) | 10 (1.9) |
| 20-29 yr, n (%) | 454 (89.9) |
| ≥30 yr, n (%) | 41 (8.1) |
| Residence | |
| Urban, n (%) | 148 (29.2) |
| Rural, n (%) | 359 (70.8) |
| Education | |
| No schooling, n (%) | 161 (31.8) |
| Primary, n (%) | 136 (26.8) |
| Secondary, n (%) | 173 (34.2) |
| Higher, n (%) | 36 (7.1) |
| SES1 rank (quintiles) n (%) | |
| 1 – Poorest | 117 (23.1) |
| 2 | 107 (21.2) |
| 3 | 112 (22.1) |
| 4 | 85 (16.8) |
| 5 | 85 (16.8) |
| Gravidity | |
| Primigravidae, n (%) | 216 (42.7) |
| Secundigravidae, n (%) | 162 (32.0) |
| Gravidae-3, n (%) | 73 (14.4) |
| Gravidae-4, n (%) | 34 (6.7) |
| Multigravidae (≥5)2 n (%) | 21 (4.2) |
| Used bednet previous night, n (%) | 89 (17.8) |
| ITN (any), n (%) | 1 (0.2) |
| Used any drug to prevent malaria, n (%) | 4 (0.8) |
| Reported using haematinics, n (%) | 427 (84.7) |
| Morbidity and Outcomes | |
| Reported fever previous week, n (%) | 82 (16.2) |
| Used antimalarial for fever, n (%) | 10 (1.9) |
| Maternal fever at delivery3, n (%) | 35 (6.9) |
| Birth weight± (g), mean (SD) | 2621 (450) |
| Birth weight <2500 g, n (%) | 176 (37.1) |
| Baby’s gestational age in weeks4, mean, (SD) | 37.2 (1.3) |
| Preterm babies <37 weeks), n (%) | 95 (20.0) |
| Stillbirths≠, n (%) | 22 (4.4) |
| Stillbirths in uninfected women, n (%) | 18 (3.6) |
| Maternal Hb (g/dL), mean (SD) | 10.5 (2.2) |
| Toxicity | Overall incidence, no. (%) | Grade 1 and 2, no. (%) | Grade 3 and 4, no. (%) |
| Hyperglycemia | 19 (79) | 19 (79) | |
| Fatigue | 19 (79) | 18 (75) | 1 (4) |
| Thrombocytopenia | 12 (50) | 12 (50) | |
| Headache | 11 (46) | 10 (43) | 1 (4) |
| Nausea | 10 (42) | 9 (38) | 1 (4) |
| Leukopenia | 9 (38) | 9 (38) | |
| ALT elevations | 8 (33) | 8 (33) | |
| AST elevations | 7 (29) | 7 (29) | |
| Bilirubin elevations | 5 (21) | 5 (21) | |
| Neutropenia | 5 (21) | 5 (21) | |
| Anemia | 5 (21) | 4 (17) | 1 (4) |
| Seizures | 5 (21) | 4 (17) | 1 (4) |
| Vomiting | 5 (21) | 4 (17) | 1 (4) |
| Thyroid toxicity | 4 (17) | 4 (17) | |
| Diarrhea | 4 (17) | 4 (17) | |
| Myalgias/Arthralgias | 3 (13) | 3 (13) | |
| Rash | 2 (8) | 2 (8) | |
| Pyrexia | 2 (8) | 2 (8) | |
| Lipase | 1 (4) | 1 (4) | |
| Amylase | 1 (4) | 1 (4) | |
| Mucositis | 1 (4) | 1 (4) |
| Characteristics | Category | Male N (%) | Female N (%) | Total N (%) |
| Age (years) | <10 | 12 (46.2) | 56 (14.0) | 68 (16.0) |
| 11–14 | 10 (38.5) | 178 (44.5) | 188 (44.1) | |
| >14 | 4 (15.4) | 166 (41.5) | 170 (39.9) | |
| Education | Preschool | 4 (15.4) | 22 (5.5) | 26 (6.1) |
| Pupil | 19 (73.1) | 224 (56.0) | 243 (57.0) | |
| Other | 3 (11.5) | 154 (38.5) | 157 (36.9) | |
| Perpetrator | Father | 1 (3.8) | 12 (3.0) | 13 (3.1) |
| Stepfather | 0 | 24 (6.0) | 24 (5.6) | |
| Stepbrother | 3 (11.5) | 2 (0.5) | 5 (1.2) | |
| Cousin | 3 (11.5) | 2 (0.5) | 5 (1.2) | |
| Grandfather | 1 (3.8) | 0 | 1 (0.2) | |
| Other relative | 0 | 31 (7.8) | 31 (7.3) | |
| Familiar | 10 (38.5) | 189 (47.3) | 199 (46.7) | |
| Stranger | 8 (30.8) | 140 (35.0) | 148 (34.7) | |
| Escorter | Alone | 0 | 43 (10.8) | 43 (10.1) |
| Mother | 9 (34.6) | 96 (24.0) | 105 (24.6) | |
| Parents | 6 (23.1) | 21 (5.3) | 27 (6.3) | |
| Other relative | 2 (7.7) | 9 (2.3) | 11 (2.6) | |
| Familiar | 4 (15.4) | 18 (4.5) | 22 (5.2) | |
| Paramedical officer | 0 | 13 (3.3) | 13 (3.1) | |
| Police | 5 (19.2) | 200 (50.0) | 205 (48.1) |
| Age | 87 years |
| Symptoms | Nocturnal leg cramps of moderate intensity since years. Since three weeks intensity of symptoms increased despite the use of quinine for symptomatic relief |
| Medical history | myocardial infarction in 2002 with consecutive coronary artery bypass graft (CABG)arterial hypertensionchronic kidney disease IIIknee replacement left + right. |
| Medication | aspirin 100 mg 1-0-0bisoprolol 2,5 mg 1-0-0ramipril 5 mg 1-0-0simvastatin 40 mg 0-0-1vitamin D3 1000 IU 1-0-0torasemide 5 mg 1-0-0fentanyl patch 12,5 μg once every 3 days.Self-medication: quinine200 mg once daily |
| Possible outcome in eradication studies | How does the outcome affect reservoir measures? |
| 1. Preferential reduction in intact proviruses | Integrated HV DNA is likely to be unchanged. Proviral sequencing would likely detect a reduction in the fraction of replication-competent proviruses which could be combined with integration measures to determine the absolute reduction in intact proviruses |
| 2. Preferential reduction in defective proviruses | Integrated HIV DNA would decrease, without reflecting a contraction in the size of the “true” reservoir. Proviral sequencing would likely capture the change in the fraction of defective proviruses |
| 3. Decrease in both intact and defective proviruses | If intact and defective proviruses are targeted differently, a decrease in integrated HIV DNA would occur, but would not likely be proportional to the decrease in the number of intact proviruses. Proviral sequencing combined with integration measures would likely capture the changes in the reservoir size and character |
| Time point | N | PD | F | P value |
| Mean ± SD | ||||
| Baseline | 25 | 61.04 ± 10.45 | 5.399 | 0.00* |
| Second week | 25 | 66.60 ± 10.74 | ||
| Fourth week | 25 | 69.64 ± 9.45 | ||
| Sixth week | 25 | 71.40 ± 8.23 |
| Paper | Country | Time period of breast cancer deaths | Cases (n) | Screening exposure | Crude Ors (95% CI) | ORs adjusted for self-selection bias |
| Allgood et al. [15] | UK | 1995-2004 | 284 | Ever/Never attendance before (pseudo) diagnosis | 0.35 (0.24-0.51) | 0.52 (0.32-0.84) |
| Fielder et al. [16] | Wales | 1998-2001 | 419 | Ever/Never attendance before (pseudo) diagnosis | 0.62 (0.47-0.82) | 0.75 (0.49-1.14) |
| Gabe et al. [17] | Iceland | 1990-2002 | 226 | Ever/Never attendance before (pseudo) diagnosis | 0.59 (0.41-0.84) | 0.65 (0.39-1.09) |
| Paap et al. [18] | Netherlands | 2004-2005 | 118 | Screened at index invitation | 0.30 (0.14-0.63) | 0.24 (0.10-0.58) |
| Puliti et al. [19] | Italy | 1988-2002 | 1750 | Ever/Never attendance before (pseudo) diagnosis | 0.46 (0.38-0.56) | 0.55 (0.36-0.85) |
| Roder et al. [20] | Australia | 2002-2005 | 491 | Ever/Never attendance before (pseudo) diagnosis | 0.59 (0.47-0.74) | 0.70a |
| n (%) | L1CAM expression n (%) | n (%) | |||
| Negative | ≤ 20% of tumor cells | >20% of tumor cells | P value | ||
| Recurrence | 9 (16) | 14 (24) | 34 (60) | 57 | |
| No recurrence | 24 (43) | 19 (34) | 13 (23) | 56 | < 0.0001 |
| Class I (Positive) | Class II (Positive) |
| Cw10, B27, B57, B51, B61, B13, B44 | |
| B75, B55, Cw4, Cw12, B49, B38, Cw1 | |
| B76, B54, Cw16, B8, B48, B35, Cw15 | |
| B42, Cw7, Cw9, B41, B7, B62, Cw6 | |
| B82, B37, Cw17, B60, B56, B65, B45, B81 | Negative |
| B59, B52, B39, Cw2, Cw14, B78, B46 | |
| Cw5, Cw8, B72, B58, B63, B77, B73 | |
| B71, B64, B53, B67, B47, B18, Cw18 | |
| B50, A11 |
| Strains | Genes | Average Ct | Average ΔCt± SE | ΔΔCt | RQ |
| WT | SPS18 | 28.701 | 6.369 ± 0.415 | 0 | 1 |
| SPS19 | 22.432 | 0.101 ± 0.425 | 0 | 1 | |
| SMK1 | 30.164 | 7.832 ± 0.39 | 0 | 1 | |
| ACT1 | 22.331 | ||||
| oaf1Δ | SPS18 | 31.573 | 9.419 ± 0.383 | 3.049 | 0.121 |
| SPS19 | 27.651 | 5.497 ± 0.121 | 5.396 | 0.024 | |
| SMK1 | 30.1 | 7.946 ± 0.293 | 0.114 | 0.924 | |
| ACT1 | 22.154 | ||||
| sum1Δ | SPS18 | 28.908 | 4.118 ± 0.916 | −2.251 | 4.762 |
| SPS19 | 24.793 | 0.003 ± 0.976 | −0.098 | 1.07 | |
| SMK1 | 31.873 | 7.083 ± 0.985 | −0.749 | 1.681 | |
| ACT1 | 24.79 | ||||
| sum1Δoaf1Δ | SPS18 | 29.109 | 6.552 ± 0.499 | 0.183 | 0.881 |
| SPS19 | 25.45 | 2.893 ± 0.655 | 2.793 | 0.144 | |
| SMK1 | 29.943 | 7.386 ± 0.408 | −0.446 | 1.362 | |
| ACT1 | 22.556 |
| Fully vaccinated, positive responsesan = 75n (%) | Non-vaccinated positive responsesan = 119n (%) | Fisher’s exact testp-value | |
| Knowledge items | |||
| HPV is a sexually transmitted infection | 73 (97.3) | 106 (89.8) | 0.08 |
| Men and women can be carriers of HPV | 74 (98.7) | 108 (91.5) | 0.05 |
| HPV vaccine protects against genital warts | 58 (77.3) | 86 (72.3) | 0.50 |
| HPV vaccine protects against cervical cancer | 72 (96.0) | 104 (87.4) | 0.07 |
| HPV vaccine protects against other cancers | 36 (48.0) | 56 (47.9) | 1.00 |
| HPV vaccine is safe | 71 (95.9) | 102 (85.7) | 0.03* |
| HPV vaccine is effective | 71 (95.9) | 104 (87.4) | 0.07 |
| HPV vaccine has few side effects | 64 (85.3) | 83 (70.3) | 0.02* |
| HPV vaccination leads to lasting immunity | 49 (65.3) | 58 (49.2) | 0.04* |
| HPV vaccine is recommended for girls and boys | 68 (90.7) | 83 (70.3) | <0.001* |
| Attitude items | |||
| HPV vaccination may lead to risky sexual behavior | 4 (5.3) | 10 (8.4) | 0.57 |
| I have enough information to be able to counsel about HPV vaccine | 35 (46.7) | 45 (38.1) | 0.29 |
| I feel comfortable counseling about HPV vaccination | 34 (45.3) | 44 (37.3) | 0.29 |
| I would recommend the HPV vaccine to friends and family | 73 (97.3) | 81 (69.2) | <0.001* |
| HPV vaccine should be mandatory | 53 (72.6) | 44 (38.3) | <0.001* |
| Gene | Sequence (5' to 3') |
| Abcc4 | |
| - forward | TGCTTCCCAGACTCTGCACAAC |
| - reverse | AAGCAAGTCGTCCATGTGTCCG |
| Akr1c9 | |
| - forward | CAAGTGCCTTTGAATGCTGAGCC |
| - reverse | ACACCCACTTCATGCCCAAGAC |
| AR | |
| - forward | AGAAAAAATCCCACATCCTGC |
| - reverse | CATCATTTCAGGAAAGTCCACG |
| Dhcr24 | |
| - forward | TGCTGAACTCCATTGGCTGGAC |
| - reverse | TTGTGGGACGATGACTCGATGC |
| Facl3 | |
| - forward | TCAGGCCAAGGCAAACTCCATTC |
| - reverse | TGCCAAAGCAAACTGGAGGAGG |
| Gucy1a3 | |
| - forward | AAGCTGAAGGCAACCTTGGAGC |
| - reverse | TTTGTCCTTGCCAGAGCTGCTG |
| Proteins with high IS | P-value | |
| 100 most abundant proteins with IS in L. interrogans | 7 | .0067 |
| 100 most abundant non-ribosomal proteins with IS in L. interrogans | 9 | .033 |
| 100 most abundant non-ribosomal proteins with IS in E. coli | 6 | .0013 |
| 100 most abundant non-ribosomal proteins with IS in E. coli | 9 | .033 |
| Variables | Specificity (%) | Sensitivity (%) | PPV (%) | NPV (%) | AUC | YI | Best Cut-off | p |
| miR-3960 | 93.33 | 64.71 | 84.62 | 82.35 | 0.8333 | 0.624 | 18.96 | – |
| miR-126-3p | 86.67 | 35.29 | 60.00 | 70.27 | 0.7510 | 0.557 | 8.64 | – |
| miR-335-5p | 90.00 | 41.18 | 70.00 | 72.97 | 0.7294 | 0.388 | 15.67 | – |
| miR-23a-3p | 83.33 | 11.76 | 28.57 | 62.50 | 0.6275 | 0.331 | 14.24 | – |
| miR-3960 + miR-126-3p | 96.67 | 70.59 | 92.31 | 85.29 | 0.8529 | 0.673 | – | 0.567a |
| Emergency | Elective | p-value | |
| Recurrent PAD | 2.61 (1.66, 4.10) | 1.36 (0.99, 1.86) | 0.0192 |
| Incident PAD | 2.29 (1.63, 3.22) | 1.09 (0.81, 1.46) | 0.0011 |
| Recurrent CeVD | 0.56 (0.40, 0.78) | 0.62 (0.30, 1.26) | 0.7973 |
| Incident CeVD | 0.42 (0.34, 0.51) | 0.51 (0.29, 0.90) | 0.4981 |
| Recurrent CHD | 1.29 (1.14, 1.46) | 0.92 (0.77, 1.10) | 0.0020 |
| Incident CHD | 1.00 | 1.00 | - |
| Children with ESRD | |
| (n=92) | |
| Age (years) | 13.1 (0.7-19.1) |
| Male* | 51 (55%) |
| Weight (kilograms) | 37.8 (4.3-96.0) |
| BSA (m2) | 1.2 (0.4-2.2) |
| Height (cm) | 138 (61–184) |
| Duration of RRT (years) | 1.8 (0.0-6.8) |
| Modality at time of Echocardiography* | |
| -Hemodialysis | 26 (28%) |
| -Peritoneal dialysis | 24 (26%) |
| -Transplantation | 42 (46%) |
| Totle SNP | Non coding SNP | Coding SNP | Synonymous | Nonsynonymous |
| 12,518 | 8863(70.80 %) | 3655(29.20 %) | 3632 | 23 |
| Incidence before varicella vaccination (per 1000 population) | Reduction since varicella vaccination* (%) | |||
| USA | Uruguay | USA | Uruguay | |
| <1 year | 19.7 | 14.3 | 68–81 | 63–80 |
| 1–4 years | 48.8 | 56.7 | 83–90 | 94–97 |
| 5–9 years | 34.5 | 41.6 | 63–77 | 73–81 |
| 10–14 years | 9.5 | 13.2 | 65–80 | 62–65 |
| First author | Year | Country | Racial/descent | Source of controls | Case | Control | Genotype distribution | Pfor HWEa | Genotying type | |||||
| Case | Control | |||||||||||||
| GG | GA | AA | GG | GA | AA | |||||||||
| Catarino | 2005 | Portugal | Caucasian | Healthy base | 143 | 103 | 35 | 64 | 44 | 9 | 55 | 39 | 0.091 | PCR-RFLP |
| Jeon | 2005 | Korean | Asian | Hospital base | 222 | 314 | 49 | 112 | 61 | 80 | 160 | 74 | 0.730 | PCR-RFLP |
| Catarino | 2008 | Portugal | Caucasian | Hospital base | 226 | 247 | 60 | 103 | 63 | 40 | 138 | 69 | 0.037 | PCR-RFLP |
| Satinder | 2008 | India | Asian | Healthy base | 150 | 150 | 33 | 64 | 53 | 30 | 65 | 55 | 0.184 | PCR-RFLP |
| Thakur | 2009 | India | Asian | Hospital base | 200 | 200 | 39 | 94 | 67 | 47 | 119 | 34 | 0.006 | PCR-RFLP |
| Castro | 2009 | Sweden | Caucasian | Population base | 952 | 1713 | 229 | 463 | 260 | 465 | 837 | 411 | 0.367 | Multiplex PCR and hybridization |
| Ni | 2011 | China | Asian | Hospital base | 300 | 312 | 48 | 160 | 92 | 70 | 137 | 105 | 0.051 | PCR-RFLP |
| Warchoł | 2011 | Poland | Caucasian | Healthy base | 129 | 288 | 35 | 65 | 29 | 116 | 123 | 49 | 0.100 | PCR-RFLP |
| Wang | 2012 | China | Asian | Population base | 327 | 411 | 86 | 180 | 61 | 92 | 203 | 116 | 0.859 | PCR-RFLP |
| Djansugurova | 2013 | Kazakhstan | Caucasian | Healthy base | 215 | 160 | 54 | 103 | 58 | 41 | 78 | 41 | 0.752 | Direct sequencing |
| ASD | TD | |
| Head ROI | ||
| Implicit mentalizing-action | 4.64 (9.68) | 2.32 (12.01) |
| Implicit either-action | 4.32 (8.00) | 0.37 (11.08) |
| Explicit mentalizing-non-mentalizinga | 0.06 (18.05) | 1.91 (13.13) |
| Poker chip ROI | ||
| Implicit mentalizing-action | 1.16 (6.15) | − 1.83 (8.76) |
| Implicit either-action | 2.36 (5.58) | 2.12 (11.96) |
| Explicit mentalizing-non-mentalizinga | 4.12 (15.89) | 0.75 (6.21) |
| Release point ROI | ||
| Implicit mentalizing-action | − 5.34 (3.98) | − 1.99 (5.52) |
| Implicit either-action | − 6.04 (4.24) | − 3.67 (4.76) |
| Explicit mentalizing-non-mentalizinga | − 3.53 (6.81) | − 3.82 (2.70) |
| Name | Genome size (Mbp) | GC Content (%) | Coverage (X) | Scaffolds | N50 | Protein coding genes | Reference |
| AMDSBA1 | 4.56 | 52.19 | 258 | 155 | 65,127 | 4629 | This study |
| AMDSBA2 | 3.07 | 52.37 | 10 | 409 | 10,877 | 3312 | This study |
| AMDSBA3 | 3.68 | 55.54 | 113 | 129 | 49,240 | 3785 | This study |
| AMDSBA4 | 4.11 | 51.67 | 25 | 179 | 63,277 | 4254 | This study |
| AMDSBA5 | 3.65 | 49.15 | 92 | 161 | 65,096 | 3870 | This study |
| S. thermosulfidooxidans AT-1 (DSM 9293) | 3.86 | 49.64 | N/D | 2 | - | 3875 | IMG JGI |
| S. thermosulfidooxidans ‘Cutipay’ | 3.86 | 49.30 | 116 | 35 | 509,367 | 3600 | Travisany [16] |
| S. acidophilus NALT (DSM 10332) | 3.56 | 56.75 | 168 | 1 | - | 3626 | Anderson [17] |
| S. acidophilus ‘TPY’ | 3.55 | 56.70 | 26 | 1 | - | 3770 | Li [2] |
| Isolate No. | sex | Specimen | Date Of detection | STs | Carbapenemase | ESBL |
| TJ1 | F | Sp | 23/1/2015 | ST11 | KPC-2 | CTX-14,TEM-1 |
| TJ2 | M | Bl | 1/2/2015 | ST888 | NDM-1 | CTX-15,TEM-1 |
| TJ3 | M | Ca | 6/3/2015 | ST11 | KPC-2 | CTX-14,TEM-1 |
| TJ4 | M | Bl | 7/3/2015 | ST11 | KPC-2 | CTX-15 |
| TJ5 | M | Sp | 15/7/2015 | ST11 | KPC-2 | CTX-14,TEM-1 |
| TJ6 | M | Sp | 16/7/2015 | ST11 | KPC-2 | CTX-14 |
| TJ7 | F | Ur | 18/7/2015 | ST20 | NDM-1 | TEM-1 |
| TJ8 | M | Ca | 4/8/2015 | ST11 | KPC-2 | CTX-14 |
| TJ9 | M | Ca | 8/8/2015 | ST11 | KPC-2 | CTX-14,TEM-1 |
| TJ10 | F | Bl | 11/8/2015 | ST11 | KPC-2 | CTX-14,TEM-1 |
| TJ11 | M | Ur | 26/8/2015 | ST11 | KPC-2 | CTX-14,TEM-1 |
| TJ12 | M | Bl | 31/8/2015 | ST11 | KPC-2 | CTX-15 |
| TJ13 | M | Bl | 4/9/2015 | ST11 | KPC-2 | CTX-14,TEM-1 |
| TJ14 | F | Ca | 13/9/2015 | ST20 | NDM-1 | CTX-14,TEM-1 |
| TJ15 | M | Sp | 13/9/2015 | ST11 | KPC-2 | CTX-14,TEM-1 |
| TJ16 | M | Ca | 22/9/2015 | ST20 | NDM-1 | CTX-14 |
| TJ17 | F | Sp | 25/9/2015 | ST11 | KPC-2 | CTX-14,TEM-1 |
| TJ18 | F | Ur | 30/9/2015 | ST11 | KPC-2 | CTX-14,TEM-1 |
| TJ19 | M | Bl | 2/10/2015 | ST11 | KPC-2 | CTX-14,TEM-1 |
| TJ20 | F | Ur | 6/10/2015 | ST11 | KPC-2 | CTX-14,TEM-1 |
| TJ21 | M | Ur | 8/10/2015 | ST11 | KPC-2 | CTX-14,TEM-1 |
| TJ22 | F | Ur | 12/10/2015 | ST11 | KPC-2 | CTX-14,TEM-1 |
| TJ23 | M | Bl | 25/10/2015 | ST11 | KPC-2 | – |
| TJ24 | M | Bl | 28/10/2015 | ST20 | NDM-1 | CTX-14 |
| TJ25 | F | Ur | 20/11/2015 | ST11 | KPC-2 | CTX-14,TEM-1 |
| TJ26 | F | Bl | 20/11/2015 | ST11 | KPC-2 | CTX-14 |
| TJ27 | M | Ur | 21/11/2015 | ST11 | KPC-2 | CTX-14,TEM-1 |
| TJ28a | – | Radiant warmer | 8/9/2015 | ST11 | KPC-2 | CTX-14,TEM-1 |
| TJ29a | – | Radiant warmer | 8/9/2015 | ST20 | NDM-1 | CTX-14 |
| TJ30b | – | Nurses hand | 8/9/2015 | ST11 | KPC-2 | CTX-14,TEM-1 |
| TJ31c | – | Radiant warmer | 8/9/2015 | ST11 | KPC-2 | CTX-14,TEM-1 |
| TJ32b | – | Nurses hand | 8/9/2015 | ST20 | NDM-1 | CTX-14 |
| Frequency of complication | In-hospital deaths | Relative risk of in-hospital death | ||||
| N | % | N | % | Adj. RR | 95% CI | |
| No complication | 18,415 | 77.5 | 108 | 0.6 | ||
| Complication | ||||||
| Gastrointestinal | 263 | 1.1 | 18 | 6.8 | 3.61 | 2.32-5.63 |
| Respiratory | 636 | 2.7 | 44 | 6.9 | 2.05 | 1.30-3.03 |
| Urologic | 546 | 2.3 | 102 | 18.7 | 3.62 | 2.62-5.00 |
| Infection | 449 | 1.9 | 18 | 4.0 | 2.45 | 1.47-4.07 |
| Bleeding or acute posthaemorrhage anemia | 4,371 | 18.4 | 188 | 4.3 | 2.11 | 1.73-2.57 |
| Bleeding or acute posthaemorrhage anemia requiring blood transfusion | 3,086 | 13.0 | 157 | 5.1 | 1.96 | 1.57-2.44 |
| Transformable isolateb | Phylogenetic position | Plasmids tested | 16S-rRNA gene identityc |
| Marinobacter sp. | Gammaproteobacteria; | pM1, pM2, | 77 |
| Alteromonadales | pM3 | ||
| Kocuria rosea | Actinobacteria; | pM2 | 79 |
| Photobacterium | Gammaproteobacteria; | pM1, pM2, | 86 |
| phosphoreum | Vibrionales | pM3 | |
| Psychrobacter | Gammaproteobacteria; | pM1, pM2, | 96 |
| marincola | Pseudomonadales | pM3 |
| Cardinal clinical feature | ||||
| Ataxia(n = 54) | Tremor(n = 4) | Cognitive deficits(n = 28) | Total(N = 86) | |
| Age (mean ± SD) | 67.7 ± 9.1 | 59.0 ± 8.6 | 70.0 ± 9.2 | 68.0 ± 9.3 |
| Age-of-onset (mean ± SD) | 59.0 ± 6.8 | 54.0 ± 1.4 | 60.5 ± 6.7 | 59.2 ± 6.7 |
| With additional cardinal features (n) | 13 | 1 | 4 | 18 |
| Family history (n) | ||||
| None | 33 | 3 | 14 | 50 |
| Unknown | 21 | 1 | 14 | 36 |
| Variable | Mothers | Fathers |
| Mean (sd) | Mean (sd) | |
| Age (when index child born) | 33.2 (4.7) | 34.7 (5.7) |
| Parental education: | ||
| No qualifications | – | 1 (0.7%) |
| GCSE | 8 (5.5%) | 13 (8.9%) |
| A levels or equivalent | 14 (9.6%) | 13 (8.9%) |
| Diploma or equivalent degree | 27 (18.5%) | 25 (17.1%) |
| Degree | 46 (31.5%) | 51 (34.9%) |
| Postgraduate | 46 (31.5%) | 40 (27.4%) |
| Missing | 5 (3.4%) | 3 (2.0%) |
| Parental occupation: | ||
| Managerial/professional | 81 (55.5%) | |
| Intermediate occupations | 39 (26.7%) | |
| Routine/manual | 25 (17.1%) | |
| Unemployed | 1 (0.7%) |
| Cox proportional hazard ratios | Sites discovered before E.O. [Exp(B)] | Chance of listing (%)a | Sites discovered after E.O. Exp(B) | Chance of listing (%)a |
| Marginalized populations | ||||
| Hispanic (%) | 1.002 | 2 | 1.005 | 5 |
| American Indian (%) | 1.003 | 3 | 0.923 | −77 |
| Minority (%) | 0.998 | −2 | 0.993 | −7 |
| Institutionalized population (%) | 1.002 | 2 | 0.998 | −2 |
| Elder population (%) | 0.999 | −1 | 1.042 | 42 |
| Wealth and power indicators | ||||
| Mean family income ($1,000s) | 1.004 | 4 | 1.004 | 4 |
| Mean value of housing ($1,000s) | 0.999 | −1 | 1.006 | 6 |
| Owned housing (%) | 1.001 | 1 | 1.019 | 19 |
| Professional careers (%) | 1.007 | 7 | 0.934 | −66 |
| College degree or higher (%) | 1.001 | 1 | 0.975 | −25 |
| No high school diploma (%) | 1.000 | 0 | 1.010 | 10 |
| Below the poverty line (%) | 0.984 | −16 | 0.969 | −31 |
| Gender and family | ||||
| Female headed households (%) | 1.005 | 5 | 1.048 | 48 |
| Children < 18 (%) | 1.000 | 0 | 0.991 | −9 |
| Urbanization | ||||
| Population density | 1.000 | 0 | 1.000 | 0 |
| Urban | 0.998 | −2 | 1.002 | 2 |
| Site-specific characteristics | ||||
| PRPs identified | 1.344 | 134 | 0.617 | 62 |
| Hazardous ranking score | 0.977 | −23 | 0.987 | −13 |
| Cases | ||||
| Listed | 1,410 | 53 | ||
| Censored | 48 | 8 | ||
| Total | 1,458 | 61 | ||
| Missing | 21 | 0 |
| Plant family/Plant sample - Herbarium voucher number | Traditional use | Part used in this study | Potential active compounds characterized | Previously screened activity |
| APOCYNACEAE/Alstonia boonei De Wild – 43368/HNC | Fever, painful micturition, insomnia, chronic diarrhea, rheumatic pains, anti-venom (snake bites), malaria, diabetes, helminths, arthritis [28, 29]. | Leaves, bark | Echitamine, echitamidine, Voacangine, akuammidine, N- α-formylechitamidine, N- α-formyl-12-methoxyechitamidine [29]. | Antimalarial, antioxidant, analgesic, anti-inflammatory, antipyretic [30–32]. |
| APOCYNACEAE/Catharanthus roseus L. – 5689/HNC. | Bleeding arresting, diabetes, fever, rheumatism, cancer [20, 33]. | Leaves, stem | Vincristine, vinblastine, benzoic acid, p-hydroxybenzoic acid, salicylic acid, 2,3-dihydroxybenzoic acid, 2,5-dihydroxybenzoic acid, 3,4-dihydroxybenzoic acid, 3,5-dihydroxybenzoic acid, gallic acid, vanillic acid, chlorogenic acid, kaemferol trisaccharides, Quercetin trisaccharides, Syringetin glycosides [20, 34]. | Wound-healing, antimicrobial, hypoglycemic, antioxidant [18, 20, 33]. |
| ASTERACEAE/Ageratum conyzoïdes Linn. – 19050/SFR-Cam | Purgative, fever, ulcers, wound, mental, infectious diseases, headaches, anti-inflammatory, diarrhea [35, 36]. | Whole plant | β-caryophyllene, precocene I, friedelin, Lycopsamine, echinatine,β-sitosterol, stigmasterol, 5-methoxynobiletin, linderoflavone B, eupalestin, sabinene, α and β pinene, β-phellandrene, 1,8-cineole and limonene, ocimene, eugenol [35]. | Antimicrobial, anticonvulsant, analgesic, anti-inflammatory, antipyretic, insecticidal, antioxidant, antiplasmodial, cytotoxic [35, 37, 38]. |
| EUPHORBIACEAE/Croton macrostachys Hochst. – 40501/HNC | Malaria, antidiabetic, purgative mastitis, wounds, gastrointestinal Complications [39–41]. | Leaves | Neoclerodan-5,10-en-19,6β;20,12-diolide; 3α,19-Dihydroxytrachylobane; 3α,18,19-Trihydroxytrachylobane, lupeol, lupenone, betulinic acid, 28-O-acetylbetulin, betulin, lupeol acetate, zeorin, benzoic acid, methyl gallate, methyl 2,4-dihydroxy-3,6-dimethylbenzoate, lichexanthone, β-sitosterol, and β-sitosterol palmitate, stigmasterol, botulin, crotepoxide [42, 43]. | Antimicrobial, antimalarial, cytotoxic [38, 39, 41]. |
| FABACEAE/Cassia obtusifolia L. – 39847/HNC | Laxative, eye infections, diarrhea, urinary tract infections, gingivitis, fever, cough [25]. | Whole plant | aloe-emodin, 1-methylaurantio-obtusin-2-O-β-D-glucopyranoside, emodin, 1,2- dihydroxyanthraquinone, obtusin, chrysoobtusin, aurantioobtusin, gluco-obtusifolin, glucoaurantioobtusin, gluco-chryso-obtusin, 1-desmethylaurantio-obtusin, 1-desmethylaurantio-obtusin-2-O-β- D-glucopyranoside, 1-desmethylchryso-obtusin, 1-desmethyl-obtusin, aurantio-obtusin-6-O-β-D-glucopyranoside, alaternin-1-O-β-D-glucopyranoside, chrysoobtusin-2-O-β-D-glucopyranoside physicon-8-O-β-D-glucoside, obtusifolin, O-methyl-chrysophanol, emodin-1-O-β-gentio-bioside, chrysophanol-1-O-β-gentiobioside, physcion-8-O-β-gentiobioside, physcion-8-O-β-glucoside, chrysophanol-1-O-β-D-glucopyranosyl-(13)-β-D-glucopyranosyl-(1 → 6)-β-D-glucopyranoside, chrysophanic acid, physcion, questin, 1,3-dihydroxy-8-methylanthraquinone, chrysophanol- 10,10′-bianthrone, torosachrysone [44]. | Antibacterial, antifungal, mosquito larvicidal activity, platelet antiaggregatory, neuroprotective [25, 45–47]. |
| SAPINDACEAE/Paullinia pinnata L. – 10702/SRF-Cam | Malaria, erectile dysfunction [24]. | Leaves, stem | Paullinoside A, paullinomides A and B, β-amyrin, 13β,17β-dihydroxy-28-norolean-12-ene, β-sitosterol glucopyranoside, 2-O-methyl-L-chiro-inositol, L-quebrachitol, β-sitosterol, friedelin, daucosterol, aridanin, lotoidoside [24, 48]. | Antiparasitic, antimicrobial, cytotoxic [24, 38, 49]. |
| Age (Year) | Calibration Model | Total Body Burden (Bq) | Estimated Total Uptake (Bq) | 24-h Thyroid Uptake (%) |
| 53 | Homogenous | 3927 ± 135 | 4243 ± 146 | - |
| Thyroid and others | 3716 ± 128 | 4015 ± 138 | <7.2 ± 1.1 | |
| 49 | Homogenous | 2321 ± 165 | 2508 ± 178 | - |
| Thyroid and others | 2320 ± 165 | 2507 ± 178 | <10.7 ± 3.8 | |
| 35 | Homogenous | 3918 ± 127 | 4233 ± 137 | - |
| Thyroid and others | 4050 ± 131 | 4376 ± 142 | <16.7 ± 2.7 | |
| 34 | Homogenous | 1284 ± 182 | 1387 ± 197 | - |
| Thyroid and others | 1140 ± 162 | 1232 ± 175 | <49.9 ± 11.0 | |
| 27 | Homogenous | 2623 ± 195 | 2834 ± 211 | - |
| Thyroid and others | 2454 ± 182 | 2652 ± 197 | <44.1 ± 5.8 |
| t3 | |||||
| No/little burden | Moderate burden | (Very) severe burden | |||
| t1 | No/little burden | 22 | 3 | 0 | 25 (48.1 %) |
| Moderate burden | 7 | 8 | 3 | 18 (34.6 %) | |
| (Very) severe burden | 0 | 4 | 5 | 9 (17.3 %) | |
| 29 (55.8 %) | 15 (28.8 %) | 8 (15.4 %) | 52 (100 %) |
| Genotypes | SCA-HU+ patientsN (%) | SCA-HU− patientsN (%) | OR(95% CI) | p value |
| MPO −463G>A | N = 35 (100%) | N = 66 (100%) | ||
| GG | 10 (28.57%) | 34 (51.52%) | 2.66 | 0.045∗ |
| GA + AA | 25 (71.43%) | 32 (48.48%) | (1.10–6.39) | |
| NQO1 609C>T | N = 35 (100%) | N = 67 (100%) | ||
| CC | 24 (68.57%) | 41 (61.19%) | 0.72 | 0.604∗ |
| CT + TT | 11 (31.43%) | 26 (38.81%) | (0.30–1.72) | |
| CYP2E1 −1293G>C/−1053C>T | N = 35 (100%) | N = 67 (100%) | ||
| c1c1 | 26 (74.29%) | 63 (94.03%) | 5.45 | 0.009∗∗ |
| c1c2 + c2c2 | 9 (25.71%) | 4 (5.97%) | (1.54–19.28) | |
| GSTT1 | N = 35 (100%) | N = 67 (100%) | ||
| GSTT1+ | 26 (74.29%) | 49 (73.13%) | 0.94 | 0.911∗ |
| GSTT1− | 9 (25.71%) | 18 (26.87%) | (0.37–2.39) | |
| GSTM1 | N = 35 (100%) | N = 67 (100%) | ||
| GSTM1+ | 21 (60%) | 45 (67.16%) | 1.36 | 0.616∗ |
| GSTM1− | 14 (40%) | 22 (32.84%) | (0.58–3.18) |
| Baseline (Awake) | Baseline (Urethane) 10-20 min | Formalin 1st phase (0-10 min) | Formalin 2nd phase (10-60 min) | |||||
| FR(d/s) | Ratio(%) | FR(d/s) | Ratio(%) | FR(d/s) | Ratio(%) | FR(d/s) | Ratio(%) | |
| Overall | 5.25 ± 0.80 | 0.64 ± 0.24 | 1.14 ± 0.57 | 1.22 ± 0.14 | ||||
| Tonic | 5.08 ± 0.80 | 96.65 | 0.64 ± 0.24 | 100.00 | 1.09 ± 0.57 | 95.73 | 1.12 ± 0.14 | 91.99 |
| Burst Spike | 0.17 ± 0.03 | 3.35 | 0.00 ± 0.00 | 0.0 | 0.05 ± 0.52 | 4.27 | 0.10 ± 0.01 | 8.01 |
| Outcome measures | B | 3 m | 6 m | 9 m | 12 m | R |
| Questionnaires | ||||||
| Patient | ||||||
| CCQ | X | |||||
| MRC dyspnea | X | |||||
| SGRQ | X | X | X | X | X | |
| McGill QOL | X | X | X | X | X | |
| HADS | X | X | X | X | X | |
| Illness understanding | X | X | X | X | X | |
| Demographic questionnaire | X | |||||
| Informal caregiver | ||||||
| SPPIC | X | X | X | X | X | |
| HADS | X | X | X | X | X | |
| Illness understanding | X | X | X | X | X | |
| Demographic questionnaire | X | |||||
| Lung specialist | ||||||
| CRF | X | |||||
| Medical files | ||||||
| Number of hospitalisations of unexpected hospital admissions for AECOPD | X | |||||
| Number of days of unexpected hospital admissions for AECOPD | X | |||||
| Number of hospitalisations of unexpected ICU admissions for AECOPD | X | |||||
| Number of days of unexpected ICU admissions for AECOPD | X | |||||
| Are the choices of ACP documented in the medical file at baseline? (when yes/when no) | X | |||||
| Are the choices of ACP documented in the medical file after one year or at time of death? (when yes/when no) | X | |||||
| Did the patient die within one year after inclusion? (when yes/when no) | X | |||||
| Date of death | X | |||||
| Place of death (ICU/hospital/hospice/nursing home/at home) | X | |||||
| Is preferred place of death known? (when yes/when no) | X | |||||
| Has this wish come true? (when yes/when no) | X | |||||
| Primary cause of death (pulmonary insufficiency/other cause) | X | |||||
| Secondary cause of death (pulmonary insufficiency/other cause) | X | |||||
| Did the patient have an unexpected hospital readmission for AECOPD within 8 weeks? (when yes/when no) | X | |||||
| Date of first unexpected hospital readmission for AECOPD. | X |
| Botanical name | Family | Common name | Density (ind/hectare) mean ± stdv | Uses | |
| 1 | Virola surinamensis (Rol.) Warb. | Myristicaceae | Urucurana | 97.3 ± 97.1 | M, T, O |
| 2 | Xylopia brasiliensis Sprengel | Annonaceae | Pindaíba | 63.3 ± 60.3 | - |
| 3 | Carapa guianesenis Aubl. | Meliaceae | Andiroba | 46.7 ± 50.3 | M, T, O |
| 4 | Symphonia globulifera Linn. f. | Clusiaceae | Guanandi/Guananim | 43.4 ± 40.4 | M, T |
| 5 | Mauritia flexuosa L.F. | Arecaceae | Buriti | 33.3 ± 32.1 | F, S |
| 6 | Euterpe oleraceae Mart. | Arecaceae | Juçara/Açai | 33.3 ± 43.6 | F, H |
| 7 | Richeria dressleri G.L. Webster | Phyllanthaceae | Jaca-da-baixa | 30.0 ± 43.6 | - |
| 8 | Anacardium sp. | Anacardiaceae | Caju-da-baixa | 26.7 ± 46.2 | F |
| 9 | n.i. | n.i. | Casca-grossa | 20.0 ± 34.6 | - |
| 10 | Attalea maripa (Aubl.) Mart | Arecaceae | Inajá | 16.7 ± 15.3 | F, H, O |
| 11 | Tapirira guianensis Aubl. | Anacardiaceae | Pau-pombo | 16.7 ± 15.3 | - |
| 12 | Annona sp | Annonaceae | Araticum-da-baixa | 13.3 ± 5.8 | F |
| Polymorphism | Strand | Primer sequence |
| rs429358 (APOE) | Sense | 5′-GAACTGGAGGAACAACTGAC |
| Antisense | 5′-CGCTCGCGGATGGCGCTGA | |
| rs7412 (APOE) | Sense | 5′-GAACTGGAGGAACAACTGAC |
| Antisense | 5′-CGCTCGCGGATGGCGCTGA | |
| rs4680 (COMT) | Sense | 5′-GCTACTCAGCTGTGCGCATG |
| Antisense | 5′-ACGTGGTGTGAACACCTGGT | |
| SL6A3 repeat (DAT1) | Sense | 5′-TGTGTGCGTGCATGTGG |
| Antisense | 5′-GCTTGGGGAAGGAAGGG | |
| rs1108580 (DBH) | Sense | 5′-ACGCCTGGAGTGACCAGAAG |
| Antisense | 5′-CCATCCTCCTTGGCTTTCTC | |
| rs747302 (DRD4) | Sense | 5′-CGGAGGGAATGGAGGAGGGA |
| Antisense | 5′-AGACCTGAGCTCAGGCTCTG |
| Variable | OR | 95% CI |
| Age | ||
| 17–24 | 1.2 | 0.49, 3.1 |
| 25–34 | 1.0 | |
| 35 and over | 0.84 | 0.29, 2.4 |
| First Pregnancy | ||
| No | 1.0 | |
| Yes | 0.75 | 0.29, 1.9 |
| Highest Level of Education Completed | ||
| Less than Secondary School | 1.0 | |
| Secondary School or Beyond | 3.4* | 1.6, 7.3 |
| Number of Durable Goods Owned | ||
| 0 | 1.0 | |
| 1–2 | 2.2 | 0.60, 7.8 |
| 3–4 | 3.1 | 0.80, 11 |
| Employment Status | ||
| Never had a job | 1.0 | |
| Currently unemployed | 1.1 | 0.41, 2.8 |
| Currently employed | 0.62 | 0.28, 1.4 |
| Living with Partner | ||
| No | 1.0 | |
| Yes | 0.70 | 0.26, 1.9 |
| Marital Status | ||
| Single | 1.0 | |
| Married | 2.5 | 0.74, 8.8 |
| Believe mosquito nets that you have to buy are better quality (more effective in preventing malaria) than nets that are given out for free | ||
| No | 1.0 | |
| Yes | 0.36* | 0.15, 0.88 |
| Believe children suffer from malaria more than adults | ||
| No | 1.0 | |
| Yes | 0.49 | 0.22, 1.1 |
| Think mosquito nets are difficult to use | ||
| No | 1.0 | |
| Yes | 0.19 | 0.034, 1.0 |
| Characteristics | KRAS WTN (%) | KRAS MUTN (%) | P‐valueKRAS status | PTEN negativeN (%) | PTEN positiveN (%) | P‐valuePTEN status |
| All | 48 (64) | 27 (36) | 56 (75) | 19 (25) | ||
| Sex | ||||||
| Female | 17 (63) | 10 (37) | 1.000 | 17 (63) | 10 (37) | 0.141 |
| Male | 31 (65) | 17 (35) | 39 (81) | 9 (19) | ||
| Primary tumor | ||||||
| Colon | 32 (71) | 13 (29) | 0.185 | 34 (76) | 11 (24) | 1.000 |
| Rectum | 16 (53) | 14 (47) | 22 (73) | 8 (27) | ||
| Lung metastases | ||||||
| Synchronous | 12 (67) | 6 (33) | 1.000 | 15 (83) | 3 (17) | 0.368 |
| Metachronous | 35 (64) | 20 (36) | 39 (71) | 16 (29) | ||
| Localization | ||||||
| Unilateral | 39 (65) | 21 (35) | 0.718 | 45 (75) | 15 (25) | 1.000 |
| Bilateral | 9 (60) | 6 (40) | 11 (73) | 4 (27) | ||
| Chemotherapy prior to lung surgery | ||||||
| Yes | 22 (55) | 18 (45) | 0.135 | 34 (85) | 6 (15) | 0.053 |
| No | 26 (74) | 9 (26) | 22 (63) | 13 (37) | ||
| Adjuvant chemotherapy | ||||||
| No | 41 (66) | 21 (34) | 1.000 | 45 (73) | 17 (27) | 1.000 |
| Yes | 5 (62) | 3 (38) | 6 (75) | 2 (25) | ||
| Extrapulmonary metastases | ||||||
| Yes | 41 (68) | 19 (32) | 0.207 | 44 (73) | 16 (27) | 0.745 |
| No | 7 (47) | 8 (53) | 12 (80) | 3 (20) | ||
| Nodal involvement | ||||||
| Yes | 27 (60) | 18 (40) | 0.308 | 33 (73) | 12 (27) | 0.550 |
| No | 16 (72) | 6 (28%) | 18 (82) | 4 (18) |
| Baseline | 6 months after RDN | p value | |
| Office systolic blood pressure (mmHg) | 180.4 ± 6.79 | 164.8 ± 8.06 | 0.01 |
| Office diastolic blood pressure (mmHg) | 94.88 ± 4.72 | 87.88 ± 3.63 | 0.04 |
| Daytime ABPM systolic (mmHg) | 158.3 ± 4.72 | 154.4 ± 5.53 | 0.49 |
| Daytime ABPM diastolic (mmHg) | 89.43 ± 2.84 | 88.29 ± 4.32 | 0.74 |
| Nighttime ABPM systolic (mmHg) | 151.3 ± 5.78 | 138.1 ± 8.00 | 0.06 |
| Nighttime ABPM diastolic (mmHg) | 83.71 ± 2.80 | 75.57 ± 4.64 | 0.03 |
| Primer | Sequence (5′-3′) |
| F3 | CTCGTGTCGTGAGATGTTG |
| B3 | GAACGTATTCACCGTGGC |
| FIP | CCCACTCCATAAGGGCCATGAGGGACTTTAAGGAAACTGCC |
| BIP | CAATGGTGGCTACAATGGGCTGGCAGAGTACAATCCGAACTG |
| LoopF | CCACCTTCCTCCAGTTTATCAC |
| LoopB | CGCGAGGCTAAGCTAATCC |
| History of visit n (%) | ||
| Sex | Male | 11,028 (60) |
| Female | 7,515 (40) | |
| Age | 18-30 | 5,181 (27.9) |
| 31-45 | 6,752 (36.3) | |
| 46-60 | 4,949 (26.6) | |
| 61-75 | 1,336 (7.2) | |
| 75-90 | 360 (1.9) | |
| Mode of arrival at EDs | Ambulance | 585 (2.9) |
| Non-ambulance | 18,150 (91.9) | |
| Hospital | Public | 19,164 (97.0) |
| Private | 588 (3.0) | |
| Treated for chest pain in last 72 hours | Male | 1,888 (54.4) |
| Female | 1,546 (44.5) | |
| Episode of care | First visit | 16,532 (83.7) |
| Follow-up visit | 643 (3.2) | |
| Don't know | 85 (0.4) | |
| Number of ED visits within last 12 months | 0 | 6,072 (30.7) |
| 1 | 3,750 (18.9) | |
| 2 | 1,198 (6) | |
| 3 | 540 (2.7) | |
| 4-10 | 518 (2.6) | |
| Don't know | 173 (0.9) |
| Original CE scale | New CE scale | New CE scale—social cohesion subscale | New CE scale— informal social control subscale | |
| Disorder | −0.39 | −0.33 | −0.28 | −0.33 |
| Exchange | 0.43 | 0.53 | 0.52 | 0.41 |
| Research question | Outcome | Method of analysis | Results from the model data set | |
| All respondents, n = 244 | Highly compliant respondents, answering 80% (≥15/18 weeks), n = 161 | |||
| 4A: Association of baseline variables with outcome | Weekly recorded pain days, count variable, assuming a binominal distribution | Multilevel mixed-effects logistic regression or generalized estimating equation assuming a logit link function (Long previous duration reference category) | Subject specific OR = 3.31 (95% CI: 2.1-5.1) Population average OR = 1.96 (95% CI 1.4-2.6) (Note: Interaction duration*week significant) | Subject specific OR = 2.67 (95% CI: 1.6-4.5) Population average OR =1.52 (95% CI 1.1- 2.2) (Note: Interaction duration*week significant) |
| 4B: Association of baseline variables with outcome | Weekly recorded pain days, count variable, assuming a Poisson distribution | Multilevel mixed-effects Poisson regression assuming a log link function (Long previous duration reference category) | Subject specific IRR = 1.92 (95% CI: 1.5 – 2.4) (Note: Interaction duration*week significant) | Subject specific IRR = 1.82 (95% CI: 1.4 – 2.4) (Note: Interaction duration*week significant) |
| 4 C: Association of baseline variables with outcome | Weekly recorded pain days, considered a count variable and assuming a normal distribution | Generalized linear regression or mixed linear model assuming an identity link function | Average difference in pain days for Long duration – Short duration 1.20 (95% CI: 0.8 – 1.5) (Note: Interaction duration*week significant) | Average difference in pain days for Long duration –Short duration 0.95 (95% CI: 0.6-1.4) Note: Interaction duration*week significant) |
| Antibody | Species | Epitope | Dilution |
| Santa Cruz #sc-1751 | Goat polyclonal (clone C-20) | near C-terminus | 1:300 |
| Santa Cruz #sc-48371 | Mouse monoclonal (clone D-9) | aa 21-140 (near N-terminus) | 1:200 |
| Santa Cruz #sc-28237 | Rabbit polyclonal (clone H-120) | aa 21-140 (near N-terminus) | 1:300 |
| Abcam #ab140595 | Rabbit monoclonal | aa 350 to the C-terminus | 1:100 |
| Abcam #ab40693 | Rabbit polyclonal | aa 350 to the C-terminus | 1:500 |
| ProteinTech #12133-2-AP | Rabbit polyclonal | human TIA1-GST fusion protein | 1:100 |
| Response* | Percent (n = 83) |
| I managed the patient myself | 34 |
| The patient improved while waiting to be seen | 29 |
| I referred to a pediatric infectious disease specialist instead | 28 |
| I referred to adult rheumatologist instead | 20 |
| I referred to a pediatric orthopedist instead | 12 |
| I referred to a pediatric hematology/oncology specialist instead | 9 |
| Other | 9 |
| The distance or time to travel was too long | 8 |
| I referred to a pediatric sports medicine specialist instead | 4 |
| I referred to a general orthopedist instead | 4 |
| The patient’s insurance would not cover a PR referral | 1 |
| HC 1 (%) | HC 2 (%) | |
| Frequency of product consumption | ||
| More than once per day | 42 | 46 |
| Once per day | 58 | 54 |
| Amount of product given per day | ||
| <1 sachet | 18 | 4 |
| 1 sachet | 80 | 96 |
| >1 sachet | 2 | 0 |
| Child took product as instructed | ||
| Yes, always or most of time | 83 | 85 |
| Yes, about half the time | 7 | 0 |
| No, usually not | 11 | 8 |
| No response | 1 | 2 |
| Variables | Subgroup | N | Mean rank | Sum rank | U | p |
| Lymphovascular invasion | No | 85 | 69.88 | 5939.50 | 1285.500 | 0.010 |
| Yes | 42 | 52.11 | 2188.50 | |||
| PIK3CA gene mutation | Wild type | 120 | 62.23 | 7467.00 | 207.000 | 0.024 |
| Mutation | 7 | 94.43 | 661.00 |
| All States | NH | ME | VT | |
| Total Population | 3,119,527 | 1,235,791 | 1,274,915 | 608,821 |
| Psychiatric Admissions | 22,503 | 6,842 | 12,319 | 3,342 |
| Percent Female | 53% | 56% | 51% | 57% |
| Length of Stay (days) | ||||
| Mean (SD) | 8.97 (11.83) | 8.22 (10.12) | 9.6 (13.81) | 8.17 (9.42) |
| Median | 6 | 6 | 7 | 6 |
| Range | 1-297 | 1-297 | 1-252 | 1-128 |
| Diagnosis | ||||
| Psychosis | 47% | 47% | 45% | 55% |
| Substance Use Disorder | 23% | 22% | 28% | 11% |
| Neurosis | 12% | 11% | 10% | 16% |
| Detoxification | 5% | 4% | 5% | 2% |
| Organic Disorder | 5% | 7% | 4% | 5% |
| Adjustment Disorder | 4% | 3% | 3% | 6% |
| Personality Disorder | 2% | 3% | 1% | 4% |
| Other | 3% | 1% | 4% | 1% |
| Age | ||||
| 18-24 | 14% | 12% | 15% | 13% |
| 25-44 | 48% | 47% | 48% | 49% |
| 45-64 | 22% | 22% | 20% | 22% |
| 65-74 | 7% | 7% | 7% | 6% |
| > 75 | 11% | 12% | 10% | 10% |
| Diagnosis | No. | M:F ratio | Median age (Range) | Diagnostic category | Blind in at least one eye (%) | Previously diagnosed (%) | ||
| 1 | 2 | 3 | ||||||
| POAG with normal IOP | 50 | 26:24 | 63 (53–99) | 36 | 14 | 0 | 4 (8) | 2 (4) |
| POAG with high IOP | 22 | 11:11 | 66 (51–86) | 13 | 5 | 4 | 5 (22.73) | 6 (27.27) |
| Total POAG | 72 | 37:35 | 65 (51–99) | 49 | 19 | 4 | 9 (12.5) | 8 (11.11) |
| Group | Thickness | Buckling value, μm | ||
| ds, μm | db, μm | Experiment | Model | |
| 2 | 42 | 83 | 1.55 | 1.59 |
| 3 | 42 | 97 | 1.31 | 1.42 |
| 4 | 31 | 83 | 0.90 | 1.03 |
| Cells | Stimulus | Effect | Reference |
| Alveolar macrophages | LPS | ↓ inflammatory cytokines | Baldwin et al. [16] |
| Pacifici et al. [17] | |||
| Monocytes | LPS | ↓ inflammatory cytokines | Zurier et al. [95] |
| Impairs differentiation to dendritic cells | Roth et al. [122] | ||
| Thioglycollate-elicited macrophages | LPS | ↓ tumor necrosis factor-α protein processing | Zheng and Specter [99] |
| ↑ interleukin-1β | Zhu et al. [94] | ||
| LPS/interferon-γ | ↓ nitric oxide synthase-2 | Coffey et al. [102] | |
| ↓ nitric oxide | Mestre et al. [92] | ||
| ↑ interleukin-10 | Correa et al. [109] | ||
| Blood mononuclear cells | LPS | ↓ interleukin-1α | Watzl et al. [96] |
| Biphasic dose-response | Berdyshev et al. [97] | ||
| Microglial cells | LPS | ↓ cytokine mRNA | Puffenbarger et al. [103] |
| ↑ IL-1 receptor antagonist | Molina-Holgado et al. [111] | ||
| ↓ nitric oxide | Merighi et al. [123] | ||
| LPS/interferon-γ | ↑ interleukin-10 | Correa et al. [110] | |
| ↓ nitric oxide | Waksman et al. [124] | ||
| Dendritic cells | LPS | ↓ TLR4 expression | Xu et al. [106] |
| BV-2 cells | LPS | ↓ NF-κB activity | More et al. [101] |
| ↓ cytokine mRNA | |||
| ↓ interferon-β mRNA | Kozela et al. [125] | ||
| J774 cells | LPS | ↓ nitric oxide | Chang et al. [93] |
| ↓ interleukin-6 | |||
| ↓ cyclooxygenase-2 | |||
| RAW 264.7 cells | LPS | ↓ tumor necrosis factor-α protein processing | Fischer-Stenger et al. [100] |
| ↓ nitric oxide synthase-2 | Jeon et al. [104] | ||
| ↓ nitric oxide | |||
| ↓ NF-κB activity | |||
| TLR4-transfected HEK293 cells | LPS | ↓ interferon-β mRNA | Downer et al. [126] |
| ↓ IRF3 activity | |||
| Glioma U87MG cells | Peptidoglycan | ↓ NF-κB activity | Echigo et al. [105] |
| TLR3-transfected HEK293 cells | Polyinosinic:polycytidylic acid | ↑ interferon-β mRNA | Downer et al. [127] |
| ↑ IRF3 activity | Downer et al. [126] | ||
| ↓ tumor necrosis factor-α | |||
| ↓ NF-κB activity | |||
| Blood mononuclear cells | Polyinosinic:polycytidylic acid | ↑ interferon-β mRNA | Downer et al. [126] |
| ↓ tumor necrosis factor-α |
| DATASET | ALL | GA-FS | H-MTL | GA-MTL | GA-MTL-IR | e-GA-MTL |
| M = 2 for ANN | ||||||
| Breast | 53.0(9.9) | 58.8(8.6) | 52.9(9.0) | 70.7(8.7) | 64.7(9.2) | 64.8(9.2) |
| Colon | 71.3(10.2) | 64.7(9.5) | 73.4(8.4) | 85.7(9.8) | 85.7(9.1) | 85.7(8.4) |
| Leukemia | 55.6(7.5) | 44.4(8.3) | 55.4(8.1) | 71.7(7.8) | 77.8(7.5) | 83.3(7.4) |
| Ovarian | 55.6(6.1) | 64.9(6.2) | 74.4(6.1) | 77.7(7.6) | 79.7(7.3) | 81.5(7.0) |
| Average | 58.5(8.4) | 58.6(8.1) | 64.3(8.0) | 76.1(8.4) | 76.3(8.2) | 78.8(8.0) |
| M = 10 for ANN | ||||||
| Breast | 48.1(8.8) | 55.4(8.4) | 65.1(8.0) | 69.2(8.1) | 63.9(9.6) | 66.8(8.4) |
| Colon | 71.3(10.0) | 85.3(9.7) | 83.5(10.5) | 92.2(9.7) | 93.1(10.0) | 92.6(10.8) |
| Leukemia | 65.4(8.5) | 77.4(7.8) | 75.6(8.1) | 64.8(6.8) | 78.4(6.2) | 91.5(6.0) |
| Ovarian | 61.3(5.1) | 65.6(5.9) | 77.0(4.3) | 79.4(5.0) | 87.0(5.4) | 80.4(5.5) |
| Average | 61.0(8.1) | 71.8(8.1) | 75.8(7.6) | 78.1(7.9) | 82.2(7.8) | 82.6(7.6) |
| N, n | Mean performance score | SD | F-test, p-value | |
| Location | 67 | - | - | 0.028* |
| National government hospital 1 | 16 | 32.6 | 11.0 | |
| Regional government hospital 2 | 17 | 22.5 | 8.1 | |
| Regional government hospital 3 | 15 | 27.4 | 10.6 | |
| District government hospital 4 | 12 | 26.8 | 9.6 | |
| District private non-profit hospital 5 | 7 | 21.3 | 6.1 | |
| Type of near-miss complication | 67 | - | - | 0.7* |
| NM haemorrhage | 28 | 27.0 | 11.8 | |
| NM hypertensive disorder | 17 | 25.9 | 9.9 | |
| NM obstructed labour | 13 | 28.1 | 9.2 | |
| NM infection/sepsis | 6 | 27.7 | 5.6 | |
| NM anaemia | 3 | 18.8 | 4.4 | |
| Project maturity | 67 | - | - | 0.5* |
| First half of audits | 33 | 27.5 | 10.2 | |
| Second half of audits | 34 | 25.9 | 10.1 | |
| Moderation of audit team | 50# | - | - | 0.030* |
| by a midwife | 24 | 23.4 | 9.1 | |
| by a physician | 26 | 29.7 | 10.7 |
| Use categories | No. of taxa | No. of use reports | Consensus factor |
| Stomach disorder (diarrhoea/dysentry) | 8 | 178 | 0.96 |
| Cuts and wounds | 4 | 160 | 0.98 |
| Fever and headache | 6 | 125 | 0.96 |
| Skin diseases/skin irritation | 2 | 4 | 0.67 |
| Worms in stomach | 2 | 120 | 0.99 |
| Nausea and vomiting | 2 | 73 | 0.98 |
| Snake and scorpion bites | 2 | 8 | 0.85 |
| Cough and cold | 4 | 186 | 0.98 |
| Category | Males | Females | Total |
| People living with HIV | 9 | 14 | 23 |
| Intervention | 5 | 10 | 15 |
| Control | 4 | 4 | 8 |
| Peer Supporters | 3 | 6 | 9 |
| Program staff | 3 | 4 | 7 |
| Total | 15 | 24 | 39 |
| Study population characteristic | HCV Prevalence (%) | Unadjusted OR (95 % CI) | Adjusted OR (95 % CI)a |
| Overall | 29.8 | NA | NA |
| Gender | |||
| Male | 32.2 | Ref | Ref |
| Female | 25.3 | 0.71 (0.56, 0.91) | 0.65 (0.48, 0.86) |
| Age group | |||
| 1913–1939 | 40.5 | Ref. | Ref |
| 1940–1949 | 45.0 | 1.20 (0.79, 1.82) | 1.32 (0.85, 2.04) |
| 1950–1959 | 42.1 | 1.07 (0.73, 1.57) | 1.17 (0.78, 1.76) |
| 1960–1969 | 27.2 | 0.55 (0.36, 0.83) | 0.59 (0.38, 0.91) |
| 1970–1979 | 15.0 | 0.26 (0.16, 0.43) | 0.27 (0.16, 0.45) |
| 1980+ | 6.8 | 0.11 (0.06, 0.19) | 0.10 (0.06, 0.20) |
| Education | |||
| No schooling, literacy only, or religious school | 35.5 | Ref. | Ref. |
| Primary through secondary | 27.6 | 0.69 (0.54, 0.88) | 1.21 (0.91, 1.61) |
| Higher education | 21.8 | 0.55 (0.46, 0.66) | 0.90 (0.51, 1.59) |
| Migration pattern | |||
| Current same as birth – rural | 35.1 | Ref. | Ref. |
| Current same as birth - urban | 15.7 | 0.34 (0.18, 0.66) | 0.41 (0.20, 0.84) |
| Urban to urban migration | 17.7 | 0.40 (0.27, 0.58) | 0.32 (0.21, 0.50) |
| Rural to rural migration | 41.2 | 1.30 (0.92, 1.82) | 1.03 (0.70, 1.51) |
| Rural to urban migration | 32.2 | 0.88 (0.59, 1.3) | 0.64 (0.41, 0.99) |
| Urban to rural migration | 12.3 | 0.26 (0.12, 0.57) | 0.21 (0.09, 0.48) |
| Birthplace | |||
| Urban | 16.7 | Ref. | Ref. |
| Rural | 37.5 | 3.00 (2.30, 3.91) | 2.36 (1.68, 3.31)b |
| Residence at time of interview | |||
| Urban | 22.2 | Ref. | Ref. |
| Rural | 36.9 | 2.04 (1.62, 2.57) | 1.35 (1.01, 1.83)b |
| Attribute | Total Assessment Score for Pâté Made From | p Value | SEM a | |
| Fresh Livers | Frozen Livers | |||
| Color on surface | 70.5 | 67.1 | 0.29 | 3.25 |
| Color inside | 28.7 | 47.6 | <0.001 | 3.20 |
| Color likeability | 38.6 | 40.4 | 0.63 | 3.62 |
| Texture on cutting | 29.9 | 30.9 | 0.8 | 3.63 |
| On-eating firmness | 41.3 | 22.1 | <0.001 | 4.43 |
| On-eating dissolvability | 73.9 | 75.1 | 0.72 | 3.31 |
| Flavor strength | 52.7 | 61.9 | <0.001 | 2.21 |
| Fatty | 39.0 | 37.6 | 0.62 | 2.65 |
| Livery | 40.4 | 41.0 | 0.84 | 2.68 |
| Acidic | 8.4 | 12.8 | <0.05 | 1.93 |
| Rancid | 3.6 | 4.2 | 0.45 | 0.69 |
| Sweet | 30.6 | 30.7 | 0.94 | 2.33 |
| Peppery | 21.3 | 22.3 | 0.7 | 2.63 |
| Herby | 29.9 | 33.1 | 0.2 | 2.55 |
| Salty | 22.2 | 22.8 | 0.71 | 1.49 |
| Residue after eating | 20.1 | 7.8 | <0.001 | 2.84 |
| Flavor likeability | 44.8 | 51.0 | <0.05 | 2.65 |
| Overall likeability | 36.0 | 48.6 | <0.001 | 3.05 |
| Vertical Anomalies | Age 3 (Year) | Age 4 (Year) | Age 5 (Year) | Total | ||||
| n | % | n | % | n | % | n | % | |
| Deep overbite | 532 | 62.9 | 499 | 68.5 | 457 | 60.1 | 1488 | 63.7 |
| Mild (>1/2, ≤3/4) | 204 | 24.1 | 172 | 23.6 | 144 | 18.9 | 520 | 22.3 |
| Moderate (>3/4, <1) | 202 | 23.9 | 224 | 30.8 | 185 | 24.3 | 611 | 26.2 |
| Severe (all cover) | 126 | 14.9 | 103 | 14.1 | 128 | 16.8 | 357 | 15.3 |
| Open bite | 5 | 0.6 | 3 | 0.4 | 2 | 0.3 | 10 | 0.4 |
| Moderate (>3 mm, ≤5 mm) | 4 | 0.5 | 3 | 0.4 | 1 | 0.1 | 8 | 0.3 |
| Severe (>5 mm) | 1 | 0.1 | 0 | 0.0 | 1 | 0.1 | 2 | 0.1 |
| Overall (%) | Non-Hispanic White (%) | Non-Hispanic Black (%) | Hispanic (%) | Other (%) | |
| N | 1005 | 649 | 118 | 157 | 81 |
| During past 12 months, have you received a flu shot or vaccine? | |||||
| Yes | 42.3 | 45.4 a | 50.9 a | 20.8 b | 44.4 a |
| No | 57.7 | 54.6 a | 49.1 a | 79.2 b | 55.6 a |
| If yes, in which month did you receive your most recent flu vaccine? | |||||
| September | 27.7 | 27.6 | 33.3 | 27.6 | 20.0 |
| October | 40.8 | 43.8 | 33.3 | 27.6 | 40.0 |
| November | 18.2 | 16.9 | 14.8 | 27.6 | 28.6 |
| December | 2.6 | 3.4 | 1.9 | 0.0 | 0.0 |
| January/February | 4.3 | 3.1 a | 5.6 a | 13.8 b | 5.8 a |
| How likely are you to get a flu Vaccination this season (2016–2017)—that is, this Fall or Winter? | |||||
| Already received | 13.5 | 14.7 a,b | 19.3 b | 6.5 c | 8.8 a,c |
| Will definitely get one | 26.7 | 27.6 a | 31.1 a | 18.2 b | 27.5 a,b |
| Will probably get one | 13.8 | 12.0 a | 10.1 a | 18.8 b | 25.0 b |
| Will probably not get one | 18.9 | 20.8 a | 15.1 a,b | 19.5 a | 8.8 b |
| Will definitely not get one | 27.0 | 24.8 a | 24.4 a | 37.0 b | 30.0 a,b |
| Thinking about 2013, 2014, and 2015, in how many of those years did you get a flu vaccination? | |||||
| Received in all three years | 35.7 | 39.7 a | 37.9 a | 16.4 b | 33.8 a |
| Received in two years | 10.7 | 9.5 | 13.8 | 12.9 | 12.5 |
| Received one year | 12.5 | 11.0 a | 12.1 a,b | 19.3 b | 15.0 a,b |
| None | 41.1 | 39.7 a | 36.2 a | 51.4 b | 38.8 a,b |
| Have you ever delayed getting a recommended flu vaccination for reasons other than illness or allergy? | |||||
| Yes | 19.2 | 19.8 | 19.5 | 17.2 | 17.3 |
| Have you ever declined getting a recommended flu vaccination for reasons other than illness or allergy? | |||||
| Yes | 29.5 | 31.9 a | 18.6 b | 27.8 a,b | 29.6 a,b |
| Sample name | Raw reads | Clean reads | Q20 (%) | Q30 (%) | Total mapped (%) | Uniquely mapped (%) |
| V10_1 | 53,944,714 | 52,820,194 | 97.37 | 93.68 | 75.82 | 74.70 |
| V10_2 | 59,160,706 | 57,378,292 | 97.39 | 93.81 | 76.44 | 75.46 |
| V10_3 | 53,875,186 | 51,827,434 | 97.17 | 93.2 | 77.45 | 76.26 |
| NC10_1 | 57,025,992 | 54,713,970 | 96.84 | 92.51 | 77.09 | 75.89 |
| NC10_2 | 60,174,142 | 58,164,444 | 95.01 | 88.06 | 71.81 | 70.75 |
| V18_1 | 58,591,660 | 56,688,518 | 95.1 | 88.24 | 72.40 | 71.34 |
| V18_2 | 63,030,008 | 60,813,608 | 95.05 | 88.16 | 71.95 | 70.89 |
| V18_3 | 44,002,734 | 42,770,420 | 96.75 | 92.22 | 73.96 | 72.89 |
| NC18_1 | 51,089,720 | 48,895,588 | 96.24 | 91.26 | 74.02 | 72.96 |
| NC18_2 | 61,366,046 | 59,972,578 | 97.11 | 93.2 | 75.05 | 73.90 |
| NC18_3 | 68,023,822 | 65,597,914 | 97.36 | 93.79 | 76.15 | 75 |
| Name | Amount [mg/100g Star-fruit weight]* |
| Carotene | 0.003 - 0.55 |
| Tartaric acid | 4.37 |
| Oxalic acid | 9.6 |
| Ketoglutaric acid | 2.2 |
| Citric acid | 1.32 |
| Vitamin B1 & B2 | 0.12 |
| Vitamin C | 25.8 |
| *on a dry weight basis |
| Serial no. | Class of Motifs | No. of exclusive IFN-γ peptide | No. of exclusive rest of cytokine inducing peptide |
| 1 | None | 696 | 384 |
| 2 | Koolman-Rohm | 1481 | 219 |
| 3 | Betts-Russell (Hydorphobic) | 1731 | 187 |
| 4 | Betts-Russell (Polar) | 1318 | 234 |
| 5 | Betts-Russell (Small) | 1668 | 186 |
| 6 | ALL class | 3058 | 679 |
| 22q11DSMean (SD) | Median | HCMean (SD) | Median | Statistic (p), effect size (r) | |
| BORB | |||||
| Field dependence/independence | |||||
| Figure-ground segmentation | |||||
| Single letters | 0.90 (0.1) | 0.92 | 0.84 (0.1) | 0.84 | 0.04 (0.23) NS |
| Paired drawings | 0.97 (0.2) | 0.97 | 0.88 (0.1) | 0.89 | 0.40 (0.08) NS |
| Triplet letters | 0.96 (0.1) | 0.95 | 0.95 (0.2) | 0.88 | 0.03 (0.23) NS |
| Form perception | |||||
| Form perception easy sub-tests (easy foreshortened + easy minimal features) | 47.20 (2.78) | 48.0 | 49.13 (1.38) | 50.0 | 0.001 (0.43) |
| Form perception hard sub-tests (hard foreshortened + hard minimal features) | 38.91 (4.1) | 40.0 | 41.76 (1.8) | 43.0 | 0.001 (0.43) |
| Visual object recognition | |||||
| Picture naming | 12.56 (1.87) | 13.0 | 13.70 (1.66) | 14.0 | 0.001 (0.37) |
| Implicit memory | |||||
| Object decision (easy) | 28.04 (3.94) | 29.83 (1.49) | |||
| Object decision (hard) | 24.7 0(3.48) | 26.53 (3.03) | |||
| Implicit memory sub-total | 53.04 (5.88) | 54.0 | 56.37 (3.36) | 57.0 | 0.003 (0.33) |
| Semantic memory | |||||
| Associative matching | 27.29 (3.07) | 28.0 | 29.27 (1.08) | 30.0 | 0.001 (0.44) |
| Embedded figures test | |||||
| Total score | 21.10 (4.0) | 22.0 | 22.22 (1.85) | 23.0 | 0.5 (0.09) NS |
| Reaction time (s) | 33.89 (17.1) | 30.3 | 26.76 (12.06) | 24.3 | 0.07 (0.22) NS |
| Receptor | t1/2 |
| LRP | 0.5 min |
| LDLR | 4.8 min |
| ApoER2 | 8.1 min |
| VLDLR | 8.2 min |
| SNPs | Chr | Gene | A1 | MAF | Identification LifeLines I | Replication | Meta-analysis Replication | |||||
| LifeLines II | Vlagtwedde-Vlaardingen | |||||||||||
| OR | P | OR | P | OR | P | OR | P | |||||
| rs11813494 | 10 | 638 kb 3′ of SFTA1P | G | 0.24 | 1.279 | 1.12E-06 | 1.110 | 0.114 | 0.776 | 0.096 | 1.049 | 0.427 |
| rs840952 | 2 | 60 kb 5′ of SPRED2 | G | 0.10 | 1.212 | 1.09E-05 | 1.168 | 0.006 | 0.814 | 0.169 | 1.035 | 0.401 |
| rs7633390 | 3 | 27 kb 5′ of ZNF717 | T | 0.18 | 1.237 | 2.24E-05 | 1.037 | 0.581 | 0.865 | 0.305 | 1.005 | 0.938 |
| rs4977230 | 9 | SLC24A2 | T | 0.71 | 0.817 | 3.35E-05 | 1.020 | 0.744 | 0.986 | 0.910 | 1.013 | 0.806 |
| rs4780334 | 16 | CIITA | G | 0.69 | 1.209 | 3.78E-05 | 0.985 | 0.802 | 0.875 | 0.295 | 0.964 | 0.500 |
| rs844033 | 15 | 126 kb 5′ of NDN | C | 0.91 | 0.702 | 3.84E-05 | 1.163 | 0.115 | 1.213 | 0.342 | 1.172 | 0.068 |
| rs422564 | 5 | 3.9 kb 3′ of TBCA | T | 0.21 | 1.201 | 3.97E-05 | 1.035 | 0.549 | 1.196 | 0.123 | 1.065 | 0.222 |
| rs12153520 | 5 | 77 kb 3′ of HINT1 | A | 0.16 | 1.259 | 4.48E-05 | 1.012 | 0.875 | 1.020 | 0.904 | 1.013 | 0.844 |
| rs893966 | 1 | EPHB2 | T | 0.50 | 1.248 | 4.72E-05 | 0.992 | 0.909 | 0.909 | 0.532 | 0.975 | 0.707 |
| rs6775462 | 3 | ROBO2 | C | 0.50 | 0.739 | 4.81E-05 | 0.952 | 0.588 | 1.124 | 0.497 | 0.987 | 0.869 |
| rs4766584 | 12 | ACACB | G | 0.45 | 0.821 | 5.15E-05 | 0.929 | 0.234 | 0.994 | 0.964 | 0.941 | 0.274 |
| rs16918212 | 12 | A2MP1 | A | 0.20 | 0.717 | 5.41E-05 | 0.882 | 0.196 | 0.613 | 0.021 | 0.828 | 0.033 |
| rs2623166 | 8 | GEM | T | 0.13 | 1.293 | 7.68E-05 | 0.994 | 0.948 | 0.635 | 0.029 | 0.928 | 0.360 |
| rs17729233 | 18 | DSG4 | G | 0.44 | 1.257 | 7.89E-05 | 1.034 | 0.668 | 0.997 | 0.982 | 1.026 | 0.714 |
| rs2850106 | 21 | HLCS | G | 0.12 | 0.839 | 8.29E-05 | 1.050 | 0.384 | 0.998 | 0.989 | 1.040 | 0.434 |
| rs10758982 | 9 | PTPRD | G | 0.34 | 1.211 | 8.36E-05 | 0.967 | 0.602 | 0.827 | 0.163 | 0.939 | 0.284 |
| rs2845804 | 21 | HLCS | C | 0.18 | 0.841 | 9.93E-05 | 0.976 | 0.663 | 1.090 | 0.461 | 0.996 | 0.941 |
| Index/subtests/development scales | WPPSI-III | ||||
| N | IQ/DQ/scores | Subtest mean | Std. deviation | Range | |
| WPPSI verbal IQ (VIQ) | 113 | 84,8 | 16,1 | 53–133 | |
| Information | 112 | 7,4 | 3,3 | 1–16 | |
| Vocabulary | 110 | 7,4 | 2,9 | 2–16 | |
| Word Reasoning | 111 | 7,2 | 3,1 | 1–15 | |
| Comprehension | 63 | 9,0 | 2,9 | 3–15 | |
| Similarities | 67 | 7,9 | 2,6 | 3–15 | |
| WPPSI performance IQ (PIQ) | 113 | 93,6 | 16,7 | 53–135 | |
| Block Design | 112 | 10,3 | 3,6 | 1–18 | |
| Matrix Reasoning | 111 | 8,8 | 3,5 | 1–16 | |
| Picture Concepts | 111 | 8,2 | 3,4 | 1–17 | |
| Picture Completion | 67 | 9,6 | 3,5 | 2–19 | |
| WPPSI Processing speed (PSQ) | 85 | 76,7 | 12,2 | 49–107 | |
| Coding | 110 | 5,1 | 2,9 | 1–12 | |
| Symbol Search | 95 | 5,9 | 2,6 | 2–14 | |
| WPPSI General Language (GLC) | 99 | 89,9 | 17,1 | 45–128 | |
| Receptive Vocabulary | 96 | 8,2 | 3,1 | 1–15 | |
| Picture Naming | 95 | 8,5 | 3,2 | 2–16 | |
| WPPSI full scale IQ (FSIQ) | 113 | 84,5 | 14,7 | 51–121 | |
| Griffiths' verbal functioning | 77 | 33,5 | 15,9 | 8–72 | |
| Griffiths' performance functioning | 77 | 46,7 | 16,3 | 15–79 | |
| Griffiths' global functioning | 77 | 41,6 | 14,5 | 13–73 | |
| VABS Communication | 187 | 71,9 | 18,9 | 34–120 | |
| VABS DLS | 187 | 73,8 | 16,4 | 38–117 | |
| VABS Socialization | 187 | 70,6 | 14,7 | 46–112 | |
| VABS Motor | 187 | 76,4 | 14,5 | 43–117 | |
| VABS total | 187 | 70,5 | 15,0 | 42–114 |
| Variable | |
| Stroke severity on admission, n (%) | |
| NIHSS 0–5 | 36 (27.5) |
| NIHSS 6–10 | 46 (35.1) |
| NIHSS 11–16 | 29 (22.1) |
| NIHSS >16 | 17 (13.0) |
| Undetermined | 3 (2.3) |
| Stroke etiology (TOAST), n (%) | |
| Large artery atherosclerosis | 49 (37.4) |
| Small vessel occlusion | 13 (9.9) |
| Cardioembolic | 27 (20.6) |
| Other/undetermined | 42 (32.1) |
| Imaging data | |
| ASPECTS, median (IQR) | |
| On admission | 10 (9–10) |
| 24 h after thrombolysis | 9 (5–10) |
| Affected vessel territory, n (%) | |
| MCA | 82 (62.6) |
| ICA | 11 (8.4) |
| MCA + ICA | 10 (7.6) |
| VB | 28 (21.4) |
| Level of occlusion, n (%) | |
| No stenosis/occlusion | 34 (26.0) |
| Stenosis | 27 (20.6) |
| Occlusion | 70 (53.4) |
| Outcomes, n (%) | |
| Functional outcome at 7 days | |
| Favorable outcome | 49 (37.4) |
| No change | 42 (32.1) |
| Unfavorable outcome | 20 (15.3) |
| Functional outcome at 90 days | |
| mRS 0–2 | 57 (43.5) |
| mRS 3–6 | 51 (38.9) |
| Undetermined | 23 (17.6) |
| Intracranial hemorrhage (ECASS II) | |
| aSICH | 7 (5.3) |
| SICH | 6 (4.6) |
| Group | Body weight in grams (SEM) | ||
| Baseline | Post-test | ||
| Male | Ctrl | 297.2 (3.4) | 350.0* (7.1) |
| SPS | 297.5 (4.9) | 341.9* (7.9) | |
| Female | Ctrl | 191.5 (3.0) | 213.9* (5.4) |
| SPS | 194.5 (3.0) | 214.8* (3.2) |
| Variables | Instruments | Time of Measurement | ||
| Baseline/1 week after discharge ICU | 6 months | 12 months | ||
| Pain (intensity, frequency) | NRS | Q | Q | Q |
| Anxiety (intensity, frequency) | NRS, HADS-D | Q | Q | Q |
| Agitation (intensity, frequency) | CAM | Q | Q | Q |
| Mortality | Survival: Yes/No | Q | Q | Q |
| Morbidity | International classification of diseases, version 10 | MR/Q | MR/Q | MR/Q |
| Quality of life (HR-QOL)1 | SF-36 | Q | Q | Q |
| Baseline | Intervention | Difference | p-value a | |
| Simple reactiontime test | ||||
| Mean Tput b score (SE) | 209 (6) | 220 (6) | 11 (4) | 0.01 |
| Mean reaction time in msec (SE) | 293 (9) | 279 (9) | -15 (7) | 0.03 |
| Complex reactiontime test | ||||
| Mean Tput b score (SE) | 85 (3) | 92 (4) | 7 (2) | < 0.001 |
| Mean reaction time in msec (SE) | 629 (18) | 606 (21) | -23 (8) | 0.002 |
| Mean % correct (SE) | 97.5 (0.4) | 98.2 (0.3) | 0.7 (0.3) | 0.01 |
| Mean lapses c (SE) | 5.5 (0.9) | 4.3 (1.0) | -1.2 (0.6) | 0.05 |
| Mean impulses d (SE) | 6.1 (0.8) | 4.5 (0.9) | -1.6 (0.4) | < 0.001 |
| Platform | Cost (US$) |
| Vinoculer | 5 K |
| UAV | 16–80 K |
| Unsuccessful Breastfeeding | Successful Breastfeeding | P-value, Wilcox rank sum test | |
| VAS 6 Hours | n = 10 | n = 73 | |
| Median (Q1/Q3) | 1.5 (0/4) | 3 (0/4) | 0.56 |
| Mean (Upper/Lower 95%) | 2.0 (0.7-3.4) | 2.73 (2.1-3.3) | |
| VAS 12 Hours | n = 9 | n = 75 | |
| Median (Q1/Q3) | 1 (0/1) | 2 (0/5) | 0.39 |
| Mean (Upper/Lower 95%) | 1.6 (0-3.3) | 2.6 (1.9-3.2) | |
| VAS 24 h | n = 10 | n = 80 | |
| Mean (Upper/Lower 95%) | 4.5 (2/6) | 3 (1/5) | 0.31 |
| Median (Q1/Q3) | 4.1 (2.2-6.1) | 3.2 (2.6-3.8) |
| Author | Sample size | Prevalence (%) | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) |
| Gaspari et al. [39] | 104 | 51 | 87 | 82 | 84 | 86 |
| Watkins et al. [40] | 57 | 68 | 80 | 83 | 91 | 65 |
| Moak et al. [41] | 107 | 36 | 76 | 78 | 66 | 86 |
| Herbst et al. [42] | 670 | 47 | 73 | 73 | 71 | 75 |
| Regression parameter | Slope (a) | Intercept (b) | Data point count | R2 |
| value | 1.09 | 0.03 | 679 | 0.98 |
| CA125 (U/ml) | HE4 (pmol/l) | ROMA (%) | ROMA P (%) | p (ROMA vs. ROMA P) | |||||
| Median | Range | Median | Range | Median | Range | Median | Range | ||
| Ovarian cancer (all) | 397.5 | 9–7459.1 | 340.7 | 12–9264 | 90.3 | 0.5–100 | 91.46 | 1.33–99.9 | 0.8641 |
| Serous | 421.1 | 9–7459.1 | 390.7 | 15–9264 | 91.9 | 0.5–100 | 92.5 | 1.3–99.9 | 0.7963 |
| Mucinous | 58.8 | 11.3–600 | 69.2 | 15–538 | 30.1 | 6.2–95.8 | 27.2 | 1.9–96.1 | 0.9699 |
| Clear cell | 389.9 | 95.8–1725.5 | 184.8 | 49.5–849.9 | 81.5 | 8.1–98.2 | 73.7 | 15.6–98.3 | 0.9581 |
| Endometrioid | 00 | 41.5–2996.8 | 340.7 | 46.1–1235 | 94.6 | 21–99.3 | 93.2 | 2.5–99.4 | 0.9591 |
| FIGO stages I and II | 130.3 | 9–2347 | 79 | 15–1235 | 35.3 | 0.5–99.3 | 33.6 | 1.3–99.3 | 0.8610 |
| FIGO stages III and IV | 591 | 18–7459.1 | 593.75 | 20.7–9264 | 96.8 | 9–100 | 97.1 | 10.1–99.9 | 0.6691 |
| Grade 1 | 68.2 | 9–459.7 | 70.8 | 15–414.3 | 20.5 | 0.5–93.9 | 23.1 | 1.3–93.8 | 0.9087 |
| Grade 2 | 420.1 | 14–7459.1 | 289.3 | 20.7–9264 | 88.5 | 8.4–100 | 88.9 | 10.1–99.9 | 0.0114 |
| Grade 3 | 535.1 | 11.2–5109.8 | 569.8 | 20.4–8160 | 96.7 | 1–100 | 96.4 | 2.98–99.9 | 0.8963 |
| Benign diseases (all) | 22.5 | 3.2–502.7 | 46.7 | 17.8–206.5 | 6.7 | 0.7–87 | 8.29 | 1.15–85.2 | 0.0001 |
| Endometriosis | 45.5 | 6.7–377 | 45.2 | 17.8–86.7 | 6.6 | 0.7–35.34 | 9.1 | 1.2–26.16 | 0.2295 |
| Teratoma tumors | 15.5 | 6.3–51.9 | 46.6 | 26.3–724 | 6.48 | 1.65–17.9 | 6.76 | 1.87–17.6 | 0.2835 |
| Follicular cysts | 14.5 | 3.2–88 | 55.3 | 24.2–206.5 | 8.76 | 1.6–65.7 | 9.9 | 1.6–67.8 | 0.4886 |
| Paraovarian cysts | 13.7 | 4.1–52.7 | 48.6 | 36.4–186.8 | 7.5 | 3.7–87 | 7.9 | 3.8–85.2 | 0.7075 |
| Hemorrhagic cysts | 15.4 | 5.5–274.8 | 44.3 | 24.8–95.7 | 5.7 | 1.7–31.6 | 6.5 | 3.2–30.9 | 0.6522 |
| AGE interval | |||||||||
| W1 ovarian cancer group | – | – | – | – | – | – | – | – | – |
| W2 ovarian cancer group | 55.2 | 27–135.1 | 45.4 | 44.1–103.9 | 6.2 | 6–35 | 7.5 | 7.1–37.7 | 0.3827 |
| W3 ovarian cancer group | 403.6 | 98.1–1252 | 95.4 | 15–464.8 | 31.5 | 0.5–95.5 | 43.6 | 1.3–95.6 | 0.3619 |
| W4 ovarian cancer group | 265.4 | 14–4638.8 | 92.9 | 15–1500 | 34.7 | 0.5–99.7 | 44.7 | 1.3–99.4 | 0.7743 |
| W5 ovarian cancer group | 500 | 9–5887 | 439.3 | 12–1655 | 96.4 | 4.5–99.7 | 96.3 | 1.9–99.8 | 0.7883 |
| W6 ovarian cancer group | 233.3 | 9.8–7459.1 | 334.5 | 22–9264 | 90.9 | 6–100 | 91.6 | 5.2–99.9 | 0.9786 |
| W7 ovarian cancer group | 839 | 21–5659 | 658.4 | 37–8160 | 97 | 25–100 | 97.2 | 23.8–99.9 | 0.7710 |
| W8 ovarian cancer group | 777.5 | 66.9–3724 | 871.2 | 85.8–4940 | 97.7 | 55.1–100 | 97.9 | 55.1–99.9 | 1.0000 |
| W1 benign group | 16 | 4.1–274.8 | 41.5 | 24.2–84.7 | 6.2 | 1.56–22.1 | 6.4 | 1.56–22.1 | 0.9420 |
| W2 benign group | 28.1 | 7.7–377 | 45.5 | 26.3–80.4 | 5.4 | 1.65–20.3 | 6.2 | 1.87–22.7 | 0.0913 |
| W3 benign group | 32.3 | 7.1–191.5 | 47.3 | 31.7–86.7 | 7 | 2.6–24.1 | 9.2 | 3.2–26.2 | 0.9529 |
| W4 benign group | 21.6 | 5.5–168.8 | 44.5 | 17.8–74.2 | 6 | 0.7–17.6 | 8.9 | 1.15–21.3 | 0.0079 |
| W5 benign group | 12.4 | 3.2–82.1 | 48.5 | 27.5–85.1 | 6.9 | 1.8–35.3 | 8.4 | 4.4–23.4 | 0.6641 |
| W6 benign group | 15.9 | 6.7–79.8 | 63.8 | 47.1–206.5 | 14.3 | 6.7–65.7 | 14.1 | 6.6–67.8 | 0.6232 |
| W7 benign group | 9.55 | 6.3–52.7 | 69.5 | 52–186 | 9.7 | 7.3–87 | 9.7 | 7.6–85.2 | 1.0000 |
| Genogroup rate used | Segregation | Time (yr) since divergencea | 95% CIb | |
| Lower | Upper | |||
| 5B and 5A | 5A and 5B | 7.14 | 1.71 | 28.36 |
| 5B and Bandim 6 | 3.47 | 0.86 | 13.70 | |
| 5B and Bandim 13/14 | 2.00 | 0.53 | 7.91 | |
| 5B only | 5A and 5B | 2.29 | 1.68 | 2.95 |
| 5B and Bandim 6 | 1.16 | 0.79 | 1.61 | |
| 5B and Bandim 13/14 | 0.81 | 0.56 | 1.12 | |
| Firth et al. (26) | 5A and 5B | 30.37 | 20.85 | 41.05 |
| 5B and Bandim 6 | 14.21 | 8.26 | 21.24 | |
| 5B and Bandim 13/14 | 8.03 | 3.87 | 12.93 |
| Month | 2008 | 2009 | 2010 | 2011 | 2012 | ||||||||||
| Total | Positive | Total | Positive | Total | Positive | Total | Positive | Total | Positive | ||||||
| n | % | n | % | n | % | n | % | n | % | ||||||
| January | 10 | 6 | 60 | 8 | 1 | 13 | 16 | 5 | 31 | 14 | 3 | 21 | 6 | 1 | 17 |
| February | 16 | 3 | 19 | 13 | 4 | 31 | 13 | 3 | 23 | 15 | 7 | 47 | 12 | 5 | 42 |
| March | 18 | 5 | 28 | 16 | 5 | 31 | 16 | 2 | 13 | 26 | 15 | 58 | 18 | 9 | 50 |
| April | 3 | 1 | 33 | 21 | 8 | 38 | 21 | 7 | 33 | 26 | 15 | 58 | 35 | 24 | 69 |
| May | 15 | 2 | 13 | 22 | 9 | 41 | 23 | 6 | 26 | 24 | 12 | 50 | 23 | 11 | 48 |
| June | 15 | 3 | 20 | 24 | 7 | 29 | 26 | 3 | 12 | 15 | 10 | 67 | 22 | 6 | 27 |
| July | 5 | 1 | 20 | 24 | 7 | 29 | 29 | 8 | 28 | 18 | 4 | 22 | - | - | - |
| August | 8 | 2 | 25 | 17 | 3 | 18 | 18 | 6 | 33 | 16 | 4 | 25 | - | - | - |
| September | 5 | 1 | 20 | 10 | 4 | 40 | 22 | 9 | 41 | 15 | 7 | 47 | - | - | - |
| October | 10 | 5 | 50 | 27 | 5 | 19 | 25 | 11 | 44 | 26 | 15 | 58 | - | - | - |
| November | 25 | 11 | 44 | 21 | 6 | 29 | 27 | 5 | 19 | 17 | 7 | 41 | - | - | - |
| December | 13 | 6 | 46 | 39 | 13 | 33 | 24 | 6 | 25 | 30 | 13 | 43 | - | - | - |
| Total | 143 | 46 | 32 | 242 | 72 | 30 | 260 | 71 | 27 | 242 | 112 | 46 | 116 | 56 | 48 |
| Baseline | Postexposure | |||||
| Outcome | na | Mean ± SD | Range | Mean ± SD | Range | p-Value |
| White blood cells (103/mm3) | 62 | 7.31 ± 1.6 | 3.6–10.4 | 7.3 ± 1.7 | 4.0–13.0 | 0.91 |
| Granulocytes (%) | 62 | 58.9 ± 7.2 | 43.5–76.0 | 58.2 ± 7.6 | 44.6–80.6 | 0.23 |
| Lymphocytes (%) | 62 | 30.7 ± 6.7 | 15.4–44.1 | 32.0 ± 7.3 | 15.7–47.0 | 0.069 |
| Monocytes (%) | 62 | 10.4 ± 3.5 | 4.5–19.4 | 9.8 ± 3.5 | 3.7–17.5 | 0.22 |
| LTL (T/S ratio) | 57 | 1.23 ± 0.28 | 0.68–1.86 | 1.43 ± 0.51 | 0.72–3.34 | < 0.001 |
| hTERT expression (2−ΔΔCT) | 58 | 1.68 ± 0.86 | 0.72–4.86 | 1.31 ± 0.75 | 0.52–5.55 | < 0.001 |
| hTERT methylation (% 5mC) | ||||||
| Position 1 | 59 | 93.9 ± 1.0 | 90.5–96.8 | 93.9 ± 1.1 | 89.9–96.8 | 0.84 |
| Position 2 | 59 | 93.8 ± 2.8 | 80.4–100.0 | 93.6 ± 3.1 | 79.2–97.1 | 0.67 |
| Position 3 | 59 | 90.0 ± 1.9 | 86.3–95.5 | 90.2 ± 1.5 | 85.9–93.2 | 0.36 |
| Matrix | Filler | Code name |
| PP-SL262MW | – | PP |
| PP-SL262MW | Sol-gel (catalyst: acetic acid) | PP-Acetic |
| PP-SL262MW | Sol-gel (catalyst: formic acid) | PP-Formic |
| PP-SL262MW | Sol-gel (catalyst: ammonium hydroxide) | PP-Base |
| PP-SL262MW | Natural HNT | PP-HNT |
| PP-SL262MW | Functionalized HNT | PP-PolyHNT |
| PP-SL262MW | Untreated CNT | PP-CNT |
| PP-SL262MW | Functionalized CNT | PP-CNTF |
| Factors | Domain | Data collected | Sources of information |
| Technical factors | Reporting system | Type of new tools introduced by the NTCP and their use | Interviews |
| Availability of tuberculosis and routine information tools | Observation | ||
| Designer of reporting forms | Designer of the routine information system | Interviews | |
| Changes in the design of routine information after TDTC creation | |||
| Complexity of the reporting forms | Complexity of the tuberculosis and routine information tools | Interviews | |
| Procedures | Rules for tuberculosis and routine data collection,analysis and transmission | Document review | |
| Changes in routine HIS procedures following the creation of the TDTC | Interviews | ||
| Organisational factors | Information distribution | Type of reports sent by the hospital before and after the creation of the TDTC | Interviews |
| Services receiving hospital reports | |||
| Interest devoted to reporting | Motivation of the TDTC staff for reporting | Interviews | |
| Motivation of the ward staff members for reporting | |||
| Quarterly HIS supervision | Staff members supervised in the use of thetuberculosis HIS (frequency) | Interviews Observation | |
| Staff members supervised in the use of the routine HIS (frequency) | |||
| Training | Training received on HIS management: trainees and date | Interviews | |
| Behavioural factors | Level of knowledge of content of HIS forms | Staff members involved in monthly routine reporting | Interviews |
| Knowledge of the content of HIS tools by hospital staff | |||
| Skills | Skills in data collection, processing and analysis | Interviews | |
| Motivation | Level of motivation | Interviews | |
| Processes | Data collection | Data completeness in registers (tuberculosis and routine care data) | Observation |
| Data processing | Availability of tuberculosis and routine reports(period) at the hospital level | Observation | |
| Data analysis | Type of analysis conducted on tuberculosis data and on routine data | Interviews Document review | |
| Data transmission | Availability of tuberculosis and routine reports (period)at the district and regional levels | Interviews Observation | |
| Data display andfeedback to nurses | Type of data displayed (for tuberculosis and routine care data) | Observation | |
| Data quality checking | Procedures of data checking and actors involved | Interviews |
| Variables | Average | Minimum | Maximum |
| Herd size | 100 | 40 | 220 |
| Milk production (kg/herd/year) | 815,429 | 340,000 | 1,850,000 |
| Milk production (kg/cow/year) | 8,174 | 5,333 | 10,434 |
| Number of present young stock per year | 69 | 19 | 152 |
| Parameter | % found | ||
| Tb+3 | La+3 | Ce+3 | |
| Alkaline degradation FMT added = 20ng/ml | |||
| 100.68 ± 0.87 | 100.18 ± 0.59 | 100.10 ± 0.58 | |
| Student’s t test | 0.17 (2.78) | 0.53 (2.78) | 0.72 (2.78) |
| Variance ratio F test | 1.97 (6.94) | 1.10 (6.94) | 1.14 (6.94) |
| Alkaline degradation FMT added= 40ng/ml | |||
| 100.08 ± 0.84 | 99.99 ± 0.50 | 100.15 ± 0.46 | |
| Student’s t test | 0.84 (2.78) | 0.98 (2.78) | 0.50 (2.78) |
| Variance ratio F test | 1.84 (6.94) | 1.54 (6.94) | 1.82 (6.94) |
| Oxidative degradation FMT added = 20ng/ml | |||
| 99.87 ± 0.71 | 100.88 ± 0.80 | 99.90 ± 0.67 | |
| Student’s t test | 0.70 (2.78) | 0.07 (2.78) | 0.76 (2.78) |
| Variance ratio F test | 1.31 (6.94) | 1.66 (6.94) | 1.17 (6.94) |
| Oxidative degradation FMT added = 40ng/ml | |||
| 99.82 ± 0.48 | 99.89 ± 0.52 | 100.08 ± 0.73 | |
| Student’s t test | 0.45 (2.78) | 0.66 (2.78) | 0.82 (2.78) |
| Variance ratio F test | 1.67 (6.94) | 1.42 (6.94) | 1.39 (6.94) |
| Intra-day precision (spiked plasma) | |||
| 100.28 ± 2.09 | 99.67 ±1.28 | 101.24 ± 1.50 | |
| Inter-day precision (spiked plasma) | |||
| 100.39 ± 1.59 | 99.44 ± 1.73 | 100.30 ± 0.87 | |
| Intra-day precision (real plasma) | |||
| 97.01 ± 0.75 | 103.21 ± 0.65 | 102.13 ± 0.74 |
| J Inertia (Kg/m2) | R Resister (Ohm) | Kt Torque constant (Nm/A) | Km Restoring constant (Nm/rad) | |||
| Simulation | Experiment | Simulation | Experiment | |||
| X-axis | 3.58e-9 | 42 | 4.84e-4 | 6.25e-4 | 4.34e-4 | 4.62e-4 |
| Y-axis | 55.65e-9 | 145 | 2.14e-2 | 2.17e-2 | 7.07e-3 | 6.28e-3 |
| Variable | HBV status | P-value | |
| Positive | Negative | ||
| (N = 29) | (N = 171) | ||
| Age group | 0.211 | ||
| <20 | 1 (3.4) | 10 (5.8) | |
| 20-29 | 17 (58.6) | 98 (57.3) | |
| 30-39 | 11 (37.9) | 45 (26.3) | |
| 40-49 | 0 (0.0) | 18 (10.5) | |
| Marital status | 0.518 | ||
| Single | 23 (79.3) | 119 (69.6) | |
| Married | 6 (20.7) | 50 (29.2) | |
| Divorced | 0 (0.0) | 2 (1.2) | |
| Educational level | 0.977 | ||
| None | 1 (3.4) | 6 (3.5) | |
| Basic | 10 (34.5) | 66 (38.6) | |
| Secondary | 16 (55.2) | 89 (52.0) | |
| Tertiary | 2 (6.9) | 10 (5.8) | |
| Working Experience (years) | 0.423 | ||
| <1 | 2 (6.9) | 5 (2.9) | |
| 1-5 | 15 (51.7) | 83 (48.5) | |
| 6-10 | 9 (31.0) | 45 (26.3) | |
| 11-15 | 3 (10.3) | 17 (9.9) | |
| 16-20 | 0 (0.0) | 15 (8.8) | |
| >20 | 0 (0.0) | 6 (3.5) | |
| Ever had Blood transfusion? | 0.472 | ||
| Yes | 0 (0.0) | 3 (1.8) | |
| No | 29 (100) | 168 (98.2) | |
| Ever undergone dental procedure? | 0.259 | ||
| Yes | 1 (3.4) | 17 (9.9) | |
| No | 28 (96.6) | 154 (90.1) | |
| Tattoo/Body piercing | 0.448 | ||
| Yes | 3 (10.3) | 27 (15.8) | |
| No | 26 (89.7) | 144 (84.2) | |
| Use of IV drugs | 0.214 | ||
| Yes | 4 (13.8) | 12 (7.0) | |
| No | 25 (86.2) | 159 (93.0) | |
| Ever had unprotected sex before? | 0.779 | ||
| Yes | 24 (82.8) | 145 (84.8) | |
| No | 5 (17.2) | 26 (15.2) | |
| Vaccinated for Hepatitis B | 0.182 | ||
| Yes | 0 (0.0) | 10 (5.8) | |
| No | 29 (100) | 161 (94.2) |
| All | SUDOSCAN Risk Score | p | |||||||
| No Risk | Moderate Risk | Elevated Risk | |||||||
| Mean | SD | Mean | SD | Mean | SD | Mean | SD | ||
| Women | n=537 | n=162 | n=188 | n=187 | |||||
| Age (years) | 49.7 | 8.3 | 42.8 | 7.8 | 51.3 | 6.3 | 54.0 | 6.7 | <0.0001 |
| BMI (kg/m2) | 25.9 | 4.5 | 23.2 | 2.8 | 25.0 | 3.2 | 29.1 | 4.9 | <0.0001 |
| Weight (kg) | 69.7 | 12.9 | 63.5 | 8.7 | 66.9 | 9.5 | 77.9 | 14.7 | <0.0001 |
| Waist (cm) | 88.6 | 12.2 | 81.3 | 8.5 | 86.6 | 9.1 | 96.7 | 12.9 | <0.0001 |
| Body fat (%) | 33.9 | 6.9 | 29.5a | 5.7 | 33.0 | 5.7 | 38.7b | 5.9 | <0.0001* |
| SBP (mm Hg) | 138 | 19 | 132 | 17 | 139 | 19 | 142 | 20 | <0.0001 |
| DBP (mm Hg) | 89 | 11 | 86 | 10 | 89 | 11 | 92 | 10 | <0.0001 |
| HbA1C (%)& | 5.7 | 0.4 | 5.5a | 0.4 | 5.7 | 0.3 | 6.9 | 0.4 | <0.0001* |
| Estimated VO2max (METs)&& | 9.1 | 1.8 | 10.3 | 1.7 | 9.0 | 1.5 | 7.9b | 1.2 | <0.0001* |
| Hand ESC (μS) | 70.0 | 10.0 | 74.0 | 9.0 | 71.0 | 10.0 | 66.0 | 11.0 | <0.0001* |
| Foot ESC (μS) | 81.0 | 8.0 | 86.0 | 4.0 | 82.0 | 6.0 | 76.0 | 9.0 | <0.0001* |
| Men | n=113 | n=31 | n=48 | n=34 | |||||
| Age (years) | 51.2 | 8.2 | 44.4 | 9.4 | 51.9 | 5.8 | 56.5 | 5.1 | <0.0001 |
| BMI (kg/m2) | 25.9 | 3.5 | 23.3 | 2.5 | 25.9 | 2.7 | 28.3 | 3.7 | <0.0001 |
| Weight (kg) | 81.8 | 12.8 | 74.9 | 11.9 | 81.2 | 10.1 | 88.9 | 13.4 | <0.0001 |
| Waist (cm) | 95.3 | 11.0 | 86.8 | 8.2 | 95.5 | 8.7 | 102.9 | 10.6 | <0.0001 |
| Body fat (%) | 21.3 | 5.9 | 16.7 | 4.7 | 21.4 | 4.8 | 25.2 | 5.6 | <0.0001 |
| SBP | 149 | 19 | 148 | 15 | 146 | 16 | 155 | 25 | NS |
| DBP | 92 | 11 | 91 | 9 | 93 | 11 | 93 | 14 | NS |
| HbA1C (%) | 6.2 | 1.0 | 5.7 | 0.2 | 6.4 | 1.5 | 6.3 | 0.8 | - |
| Estimated VO2max (METs)&& | 12.2 | 2.5 | 13.9 | 2.4 | 12.1 | 2.3 | 10.4 | 1.9 | <0.0001 |
| Hand ESC (μS) | 69.0 | 11.0 | 75.0 | 6.0 | 69.0 | 11.0 | 65.0b | 12.0 | 0.0003* |
| Foot ESC (μS) | 83.0 | 5.0 | 86.0 | 4.0 | 84.0 | 4.0 | 80.0 | 6.0 | <0.0001* |
| Characteristics | Feminized Male CRC (Total = 26) No. (%) | Non-Feminized Male CRC (Total = 31) No. (%) | Total Males (Total = 57) No. (%) | p-Value |
| MSS—wild type BRAF | 24 (92.3) | 17 (56.7) | 41 (72.0) | 0.0026 * |
| Wild-type BRAF | 26 (100) | 23 (74.2) | 49 (86.0) | 0.0088 * |
| MMR proficient | 24 (92.3) | 19 (61.2) | 43 (75.4) | 0.0107 * |
| Prior Probability of Mutation in a BRCA gene | |||||||
| Case # | Cancer diagnosis (index-case) | Age at diagnosis (ys) | Cancer family history* | ASCO criteria | Limited Family Structure | Myriad Prevalence Tables (%) | Couch Prediction Model (%) |
| 1-RJ | Breast | 33 | MAT Br (F-45) | Yes | No | 16.3 | 20.0 |
| 2-RJ | Ovarian | 47 | PAT Ov (60), Br (F-30), End (64) | Yes | No | 46.8 | 44.0 |
| 3-RS | Ovarian | 52 | MAT Br (F-44), Ov (F-76), Ov (F-66), Ut (F-78), Ut (N/A), Ga (M-68),CRC (M-69), HeN (M-N/A), HeN (M-75) | No | No | 46.8 | 43.0 |
| PAT Lu (M-N/A), CRC (M-N/A), CRC (F-N/A), Ut (35), Br (M-62), Ga (M-N/A), Br (F-36), Bilat Br (F-45), Br (F-44), Br (F-45) | Yes | No | 40.8 | 33.0 | |||
| 4-RJ | Bilateral Breast | 45 and 50 | MAT BilatBr (F-45,50), Ov (39) Br (F-49), Bilat Br (F-47,50) | Yes | No | 40.7 | 31.0 |
| 5-RJ | Bilateral Breast | 46 and 47 | PAT Lu (M-N/A), Ga (M-N/A) CRC (M-N/A) | No | Yes | 6.9 | 9.0 |
| 6-RJ | Bilateral Breast | 33 and 38 | - | No | Yes | 6.9 | 15.0 |
| 7-RS | Bilateral Breast | 35 and 45 | MAT Ov (F-58), Ov (F-49), Br (F-90) Br (F-49), Ga (M-70), Liv (M-70) | Yes | No | 40.7 | 47.0 |
| Oligo ID | Gene | Purpose | Sequences (5' to 3') |
| swcM1 | M | capture | CTGACTAAGGGAATTTTAGGATTTGTGTTCACGCTCACCG |
| swcM2 | M | capture | TGATTCACAGCATCGGTCTCACAGACAGATGGCTACTACC |
| swcM3 | M | capture | AAGGCTATGGAACAGATGGCTGGATCGAGTGAACAGGCAG |
| swcH1 | HA | capture | GAAGGCAATACTAGTAGTTCTGCTATATACATTTGCAACC |
| swcH2 | HA | capture | CCTGGGAAATCCAGAGTGTGAATCACTCTCCACAGCAAGC |
| swcH3 | HA | capture | GTTTTTGTGGGGTCATCAAGATACAGCAAGAAGTTCAAGC |
| swcH4 | HA | capture | GAAGCAAAATTAAACAGAGAAGAAATAGATGGGGTAAAGC |
| swcN1 | NA | capture | TTCGGTCTGTATGACAATTGGAATGGCTAACTTAATATTA |
| swcN2 | NA | capture | GTGGTTTCCGTGAAATTAGCGGGCAATTCCTCTCTCTGCC |
| swcN3 | NA | capture | CAATGGAACCATTAAAGACAGGAGCCCATATCGAACCCTA |
| swcN4 | NA | capture | ACGCCCTAATGATAAGACAGGCAGTTGTGGTCCAGTATCG |
| swiM1 | M | intermediate | AAAGCCGAGATCGCGCAGAGACTGGAAAGTGTCTTTGCAG * |
| swiM2 | M | intermediate | CCACTAATCAGGCATGAAAACAGAATGGTGCTGGCTAGCA * |
| swiM3 | M | intermediate | GCCTGAGTCCATGAGGGAAGAATATCAACAGGAACAGCAG * |
| swiM4 | M | intermediate | AATGGGAGTGCAGATGCAGCGATTCAAGTGATCCTCTCGT * |
| swiH1 | HA | intermediate | AAGACAAGCATAACGGGAAACTATGCAAACTAAGAGGGGT * |
| swiH2 | HA | intermediate | GTGGAAACACCTAGTTCAGACAATGGAACGTGTTACCCAG * |
| swiH3 | HA | intermediate | AAACGGCTGCTTTGAATTTTACCACAAATGCGATAACACG * |
| swiN1 | NA | intermediate | CTTGGGAATCAAAATCAGATTGAAACATGCAATCAAAGCG * |
| swiN2 | NA | intermediate | GTAAAGACAACAGTGTAAGAATCGGTTCCAAGGGGGATGT* |
| swiN3 | NA | intermediate | CAGTCGCTTGGTCAGCAAGTGCTTGTCATGATGGCATCAA * |
| swiN4 | NA | intermediate | TACGGCAATGGTGTTTGGATAGGGAGAACTAAAAGCATTA * |
| ABI04mF | M | PCR | TAACCGAGGTCGAAACGTA |
| ABI04mR | M | PCR | TTACTCTAGCTCTATGTTGACAAA |
| ABI05hF | HA | PCR | ATGAAGGCAATACTAGTAGTTCTGCT |
| ABI05hR | HA | PCR | TTCTACACTGTAGAGACCCATTAG |
| ABI06nF | NA | PCR | ATGAATCCAAACCAAAAGATAATAA |
| ABI06nR | NA | PCR | TTACTTGTCAATGGTAAATGGCAACT |
| Clinical guidelines directly related to the practice of dentistry | No. |
| American Dental Association | 2 |
| American Academy of Pediatric Dentistry | 22 |
| American Cleft Palate Craniofacial Association | 1 |
| American Academy of Pediatrics | 1 |
| American Academy of Sleep Apnea | 1 |
| Center for Disease Control | 1 |
| US Preventive Services Task Force | 2 |
| New York State Department of Health | 2 |
| Health Partners | 4 |
| University of Texas at Austin | 1 |
| Non US Government Agencies | 8 |
| Areas covered by other stomatognathic clinical guidelines | |
| Preventive Services | 12 |
| Cancer | 3 |
| Infectious Diseases | 7 |
| TOTAL | 67 |
| Age group | Outcome | Indicator | Measurement tool |
| Adults | Healthy eating* | Binary: consumption of five or more portions of fruit and vegetables per day (‘five-a-day’) | Food frequency questionnaire |
| Adults | Healthy physical activity* | Binary: doing five or more sessions of moderate intensity physical activity per week lasting at least 30 min (‘five-a-week’) | International Physical Activity Questionnaire |
| Adults | Mental wellbeing - positive | Continuous: Hope Scale score | Hope Scale |
| Adults | Mental wellbeing - negative | Binary: reports feeling anxious or depressed | EQ5D (1 item) |
| Adults | Mental wellbeing - negative | Binary: reports visiting GP for anxiety or depression or other emotional problem | Individual questionnaire item |
| Adolescents | Healthy eating - positive | Binary: frequent consumption of fruit | Individual questionnaire item |
| Adolescents | Healthy eating negative | Continuous: score summarizing frequency of consumption of chips, sweets or chocolate, and s ugar sweetened soft drinksb | Individual questionnaire items |
| Adolescents | Healthy physical activity* | Continuous: IPAQ score | Physical Activity Questionnaire for Adolescents |
| Adolescents | Mental health - negative* | Binary: score above threshold for normal mental health | Strengths and Difficulties Questionnaire |
| Adolescents | Mental health - positive wellbeing* | Continuous: positive affect score and negative affect score | Positive and negative affect scale |
| Pre Meeting | Meeting | Test | ||
| Gender | Males | 27 | 24 | NS |
| Females | 7 | 9 | ||
| Age | (av +/- sd) | 46.6 +/- 8.6 | 44.5 +/- 9.3 | NS |
| Experience | (av +/- sd) | 18.3 +/- 10.6 | 18.3 +/- 10.3 | NS |
| Braces/y | (med – 95% IC) | 150 (30–965) | 200 (28–1725) | NS |
| Less than 100 | 8 | 5 | ||
| 100–300 | 15 | 12 | ||
| Over 300 | 5 | 9 | ||
| Profession | MD-OS | 12 | 9 | NS |
| MD-PRM | 6 | 9 | ||
| CPO | 5 | 8 | ||
| PT | 9 | 7 | ||
| Oth | 2 | 2 |
| PR n=15 | GR n=15 | p Value | |
| Age: mean (SD) | 59.1 (7.2) | 51.7 (10.8) | 0.04* |
| Gender, number of patients: M (F) | 10 (5) | 8 (7) | 0.46** |
| Time since stroke: mean (SD) and range (months) | 40.7 (42.6) 6–165 | 31.3 (28.2) 6–116 | 0.74* |
| Ratio of ischaemic to primary intracerebral haemorrhagic stroke | 12:3 | 13:2 | – |
| ARAT: mean (SD) (max 57) | 32.9 (8.5) | 52.7 (5.49) | <0.01* |
| Grip mean: (SD) (% unaffected side) | 41.4 (14.3) | 74.6 (18.57) | <0.01* |
| Motricity index: mean (SD) (% unaffected side) | 65.2 (11.4) | 91.9 (4.2) | <0.01* |
| NHPT: mean (SD) (% unaffected side) | 5.8 (5.9) | 53.1 (23.7) | <0.01* |
| PFOS | PFOA | PFAA sumb | |
| Testosterone | −0.087 (−0.32 to 0.15) | −0.98 (−2.33 to 0.37) | −0.093 (−0.303 to 0.116) |
| lnEstradiol | −0.001 (−0.008 to 0.005) | −0.012 (−0.051 to 0.027) | −0.001 (−0.007 to 0.005) |
| lnSHBG | 0.002 (−0.007 to 0.012) | −0.009 (−0.067 to 0.048) | 0.002 (−0.007 to 0.011) |
| lnLH | 0.000 (−0.014 to 0.012) | −0.010 (−0.084 to 0.064) | 0.000 (−0.012 to 0.010) |
| lnFSH | 0.004 (−0.13 to 0.22) | −0.037 (−0.14 to 0.064) | 0.003 (−0.013 to 0.018) |
| lnInhibin B | −0.004 (−0.21 to 0.12) | 0.012 (−0.084 to 0.11) | −0.003 (−0.018 to 0.012) |
| lnFAI | −0.006 (−0.015 to 0.002) | −0.038 (−0.087 to 0.011) | −0.006 (−0.014 to 0.001) |
| lnTestosterone/LH | −0.003 (−0.017 to 0.011) | −0.037 (−0.12 to 0.045) | −0.003 (−0.016 to 0.009) |
| lnFAI/LH | −0.006 (−0.020 to 0.009) | −0.028 (−0.114 to 0.058) | −0.005 (−0.018 to 0.008) |
| lnEstradiol/testosterone | 0.003 (−0.005 to 0.010) | 0.035 (−0.010 to 0.081) | 0.003 (−0.004 to 0.010) |
| lnInhibin/FSH | −0.009 (−0.039 to 0.022) | 0.049 (−0.13 to 0.23) | −0.006 (−0.034 to 0.022) |
| Characteristics | Patient 1 | Patient 2 |
| Age at first visit to fertility clinic | 28 years | 31 years |
| Pubarche (spontaneous) | at 14 years | at 15 years |
| Heights | 170 cm | 156 cm |
| Weight | 65 kg | 53 kg |
| Breast development by Tanner scale | Stage V | Stage IV |
| Sense of odors | Normal | Normal |
| Karyotype | 46, XX | 46, XX |
| MRI of the pituitary | Size: 10 mm x 6 mm x16 mm. Signs of signal reduction in the right half of the posterior pituitary (4 mm x 3 mm x 2 mm), depicting a cyst. | Size: 3.5 mm x 5 mm x 9 mm showing signs of moderate pituitary hypoplasia |
| Vaginal ultrasound | Uterus: 27 mm x 43 mm x 30 mmEndometrium: 2.3 mmRight ovary: 18 mm x 16 mm with 4 follicles (6 to 8 mm).Left ovary: 17 mm x 18 mm with 5 follicles (6 to 7 mm).Moderate hypoplasia of the uterus and ovaries. | Uterus: 35 mm x 22 mm x30 mmEndometrium: 1.8 mmRight ovary: 21 mm x 18 mm with 3 follicles (3 to 5 mm)Left ovary: 17 mm x 18 mm with 5 follicles (6 to 7 mm). Moderate hypoplasia of the ovaries. |
| Partner characteristics for IVF with ICSI | Ejaculate volume: 2 mlSperm concentration: 39x106/ml,Motile sperms: 3 %Normal forms by Kruger strict criteria: 2 %. | Ejaculate volume: 5 mlSperm concentration: 31x106/mlMotile sperms: NoneNormal forms by Kruger strict criteria: 1 %. |
| Parameter | PA (n = 30) | EH (n = 31) | p |
| Age (years) | 55 ± 11 | 54 ± 10 | NS |
| Gender (male/female) | 8/22 | 16/14 | NS |
| Body mass index (kg/m2) | 26.9 ± 4 | 25.1 ± 3 | NS |
| SBP/DBP | 135 ± 17/82 ± 10 | 129 ± 11/79 ± 6 | NS/NS |
| Heart rate (bpm) | 70 ± 10 | 70 ± 8 | NS |
| Glycemia (mg/dL) | 92 ± 13 | 94 ± 18 | NS |
| Metabolic syndrome | 11/30 | 8/31 | NS |
| Serum K+ (mEq/dL) | 3.99 ± 0.68 | 4.27 ± 0.37 | <0.05 |
| Creatinine (mg/dL) | 1 ± 0.19 | 0.86 ± 0.15 | <0.001 |
| PAC (ng/dl) | 426 ± 422 | 104 ± 60 | <0.0001 |
| PAC/PRA (ng/dl:ng/ml/h) | 84.3 ± 79 | 17.6 ± 15 | <0.00002 |
| 2nd AI | Number of records | Embryonic mortality rate (%) |
| 18–29 D | 769,103 | 23.00 |
| 30–60 D | 592,243 | 21.97 |
| 61–90 D | 462,098 | 16.91 |
| 91–140 D | 383,979 | 8.47 |
| 141 D–parturition | 351,455 | 3.30 |
| Age | Gender | Handedness | Brain areas with Foci |
| 38 | Male | Right | Right temporal lobe |
| 54 | Female | Right | Left amygdala, left hippocampus, right hippocampus |
| 42 | Male | Right | Left amygdala, left hippocampus |
| 35 | Male | Left | Right amygdala, right hippocampus |
| 41 | Male | Right | Left hippocampus, left frontal lobe |
| 21 | Female | Right | Left amygdala, left hippocampus |
| 24 | Female | Right | Right amygdala, right hippocampus, right frontal lobe |
| 23 | Male | Right | Right amygdala, right hippocampus |
| 54 | Female | Right | Left hippocampus |
| 56 | Female | Right | Right occipetal lobe |
| 40 | Female | Right | Right amygdala, right hippocampus |
| 54 | Female | Right | Right hippocampus |
| 20 | Male | Right | Right temporal lobe |
| 53 | Female | Right | Right amygdala, right hippocampus, left amygdala, left hippocampus |
| Sampling subjects | Source of sample | Number of sample screened | Positive samples on microbiological analysis | Positive samples on biochemical analysis | Genus specific PCR positive | Serotype identified by multiplex PCR |
| Human infants (<5 years) | Male | 200 | 23 | 2 | 2 | Salmonella Enteritidis (n=1), other Salmonella serotypes (n=1) |
| Female | 200 | 30 | 3 | 3 | Salmonella Enteritidis (n=1), Salmonella Typhimurium (n=2) | |
| Young animals (<6 months) | Canine | 25 | 8 | 2 | 2 | Other Salmonella serotypes (n=2) |
| Bovine | 15 | 3 | 0 | 0 | ND | |
| Equine | 10 | 0 | 0 | 0 | ND | |
| Fresh vegetables | Cilantro leaves | 10 | 5 | 1 | 1 | Salmonella Typhimurium (n=1) |
| Tomato | 20 | 3 | 1 | 1 | Other Salmonella serotypes (n=1) | |
| Mint leaves | 20 | 0 | 0 | 0 | ND | |
| Sewage waste | 50 | 20 | 5 | 5 | Other Salmonella serotypes (n=5) |
| Waca Playa (Bolivia) | Pitumarca (Peru) | |
| Human Development Index | 0.36 a | 0.51 b |
| Life expectancy (years) | 52.4 a | 70.0 b |
| National social health security | SUMI: coverage for pregnant women and children under age 5 | SIS: coverage for all adult population living in poverty or extreme poverty |
| Community biomedical facilities | Rudimentary medical post with one auxiliary nurse provides ambulatory health care to 20 villages. Approximately one visit by auxiliary nurse every two months to each village.c | Health center with 11 health professionals, including one medical doctor. One visit by a nurse per month to each village. 4 to 6 health workers trained in each village. c |
| Distance from community to villages where households were interviewed (km) | 5 to 9 c | 4 to 5 c |
| Distance from community to nearest hospital (km) | approximately 40 (dirt road) c | 35 (paved road) c |
| Beds per inhabitant (number) | 0.66 d | 0.84 e |
| Subpopulation | ko (h−1) | kd (h−1) | ko/kd |
| Virgin females | 0.063 ± 0.003 | 0.055 ± 0.003 | 1.16 |
| Virgin males | 0.065 ± 0.005 | 0.055 ± 0.004 | 1.18 |
| Once-mated females | 0.067 ± 0.004 | 0.058 ± 0.004 | 1.18 |
| Once-mated males | 0.062 ± 0.004 | 0.053 ± 0.003 | 1.18 |
| Mixed-sex group: females | 0.095 ± 0.007 | 0.084 ± 0.006 | 1.12 |
| Mixed-sex group: males | 0.099 ± 0.011 | 0.087 ± 0.008 | 1.14 |
| Mean | 0.072 ± 0.003 | 0.062 ± 0.003 |
| Step 1 | Step 2 | Step 3 | Step 4 | Step 5 | Step 6 | Step 7 | |
| # Minigaps | 27 | 27 | 15 | 13 | 1 | 0 | 0 |
| Assembled nt in the big gap | 0 | 0 | 12,511 | 12,511 | 12,511 | 35,746 | 35,746 |
| Total nt assembled* | 1,808,353 | 1,808,353 | 1,828,147 | 1,828,363 | 1,832,588 | 1,851,716 | 1,851,618 |
| Subjects | Mild | Moderate | Severe | Not related | Possibly related | Probably related | Definitely related | |
| Overall | 120 (71.9) | 61 (36.5) | 50 (29.9) | 9 (5.4) | 32 (19.2) | 9 (5.4) | 19 (11.4) | 60 (35.9) |
| Application site pain | 51 (30.5) | 38 (22.8) | 12 (7.2) | 1 (0.6) | 0 | 2 (1.2) | 9 (5.4) | 40 (24.0) |
| Dysgeusia | 35 (21.0) | 30 (18.0) | 5 (3.0) | 0 | 0 | 4 (2.4) | 7 (4.2) | 24 (14.4) |
| Application site reaction | 9 (5.4) | 7 (4.2) | 2 (1.2) | 0 | 0 | 1 (0.6) | 2 (1.2) | 6 (3.6) |
| Application site irritation | 7 (4.2) | 7 (4.2) | 0 | 0 | 0 | 1 (0.6) | 0 | 6 (3.6) |
| Throat irritation | 8 (4.8) | 6 (3.6) | 2 (1.2) | 0 | 0 | 1 (0.6) | 2 (1.2) | 5 (3.0) |
| Chest discomfort | 4 (2.4) | 4 (2.4) | 0 | 0 | 1 (0.6) | 0 | 0 | 3 (1.8) |
| Nausea | 7 (4.2) | 2 (1.2) | 5 (3.0) | 0 | 1 (0.6) | 1 (0.6) | 2 (1.2) | 3 (1.8) |
| Dizziness | 6 (3.6) | 4 (2.4) | 2 (1.2) | 0 | 0 | 3 (1.8) | 1 (0.6) | 2 (1.2) |
| Paresthesia | 4 (2.4) | 3 (1.8) | 1 (0.6) | 0 | 1 (0.6) | 1 (0.6) | 1 (0.6) | 1 (0.6) |
| Vomiting | 4 (2.4) | 2 (1.2) | 2 (1.2) | 0 | 2 (1.2) | 0 | 2 (1.2) | 0 |
| Diarrhea | 4 (2.4) | 3 (1.8) | 1 (0.6) | 0 | 3 (1.8) | 0 | 1 (0.6) | 0 |
| Gastroenteritis viral | 6 (3.6) | 3 (1.8) | 3 (1.8) | 0 | 6 (3.6) | 0 | 0 | 0 |
| Influenza | 4 (2.4) | 1 (0.6) | 3 (1.8) | 0 | 4 (2.4) | 0 | 0 | 0 |
| Nasopharyngitis | 12 (7.2) | 10 (6.0) | 2 (1.2) | 0 | 12 (7.2) | 0 | 0 | 0 |
| Sinusitis | 11 (6.6) | 4 (2.4) | 6 (3.6) | 1 (0.6) | 10 (6.0) | 1 (0.6) | 0 | 0 |
| Upper respiratory tract infection | 18 (10.8) | 15 (9.0) | 3 (1.8) | 0 | 18 (10.8) | 0 | 0 | 0 |
| Urinary tract infection | 5 (3.0) | 3 (1.8) | 2 (1.2) | 0 | 5 (3.0) | 0 | 0 | 0 |
| Clinical characteristic | CCR7+ MUC1+ | CCR7+ MUC1- | CCR7- MUC1+ | CCR7- MUC1- | P value |
| Gender | 0.46 | ||||
| Male | 57/116 | 12/116 | 17/116 | 30/116 | |
| Female | 14/37 | 5/37 | 9/37 | 9/37 | |
| Age(year) | 0.61 | ||||
| ≥50 | 52/108 | 11/108 | 20/108 | 25/108 | |
| <50 | 19/45 | 6/45 | 6/45 | 14/45 | |
| Length of tumor(cm) | 0.65 | ||||
| <3 cm | 16/35 | 4/35 | 4/35 | 11/35 | |
| 3 ~ 5 cm | 34/72 | 8/72 | 16/72 | 14/72 | |
| >5 cm | 21/46 | 5/46 | 6/46 | 14/46 | |
| Invasion depth | 0.170 | ||||
| T1 | 9/25 | 2/25 | 2/25 | 12/25 | |
| T2 | 35/76 | 9/76 | 14/76 | 18/76 | |
| T3 + T4a | 27/52 | 6/52 | 10/52 | 9/52 | |
| Lymphatic metastasis | <0.001 | ||||
| Yes | 53/89 | 7/89 | 18/89 | 11/89 | |
| No | 18/64 | 10/64 | 8/64 | 28/64 | |
| Differentiation | 0.06 | ||||
| Well/moderate | 26/67 | 8/67 | 9/67 | 24/67 | |
| Low | 45/86 | 9/86 | 17/86 | 15/86 | |
| Weight loss | 0.2 | ||||
| Yes | 12/23 | 3/23 | 6/23 | 2/23 | |
| No | 59/130 | 14/130 | 20/130 | 37/130 | |
| Regional lymphatic recurrence | <0.001 | ||||
| Yes | 46/78 | 8/78 | 15/78 | 9/78 | |
| No | 25/75 | 9/75 | 11/75 | 30/75 |
| Panel | Criteria |
| Professional | • Be 18 years or older, AND• Live in Australia, Canada, Ireland, New Zealand, United Kingdom or the United States, AND• Have a minimum of 2 years’ experience specialising in research on or treatment of problem gambling. |
| Lived experience | • Be 18 years or older, AND• Live in Australia, Canada, Ireland, New Zealand, United Kingdom or the United States, AND• Have a lived experience of gambling problems, but are currently recovered and have experience in an advocacy or peer support role, OR• Are a family member or friend who has assisted a person with a gambling problem and have experience in an advocacy or peer support role. |
| Case study | ||||
| DHp: 9 contacts out of 46 | RR: 24 contacts out of 68 | |||
| Contacts among top 9 | p-value | Contacts among top 24 | p-value | |
| MI | 3 | 0.2503 | 9 | 0.4864929 |
| MIc | 4 | 0.0800 | 9 | 0.4864929 |
| Control | E. coli | p value | Control | S. Typhimurium | p value | |
| Apical IL-8 concentration | 101.92 ± 4.54 | 425.60 ± 20.12 | 0.0015 | 143.72 ± 16.98 | 1129.74 ± 50.37 | <0.001 |
| Basolateral IL-8 concentration | 16.68 ± 2.78 | 1188.47 ± 45.02 | <0.001 | 48.14 ± 14.43 | 2516.64 ± 66.17 | <0.001 |
| Evaluation | Days after Enrolment | ||||
| 0 | 3–4 | 13–15 | 24–32 | 84–92 | |
| Notification to study center | X | ||||
| Entry criteria | X | ||||
| Written Informed Consent | X* | X* | |||
| Demography | X | ||||
| Clinical data | X | X | X | X | X |
| (Serious) Adverse events | X | X | X | X | X |
| Mortality | X | X | X | X | |
| Blood culture | X | ||||
| Urine culture | X | X | |||
| Randomization and allocation to study treatment | X | ||||
| End of treatment assessment | X | ||||
| Contact – in person | X | X | X | ||
| Contact – by phone | X | X |
| Patient number | Sex | Age at diagnosis (years) | Follow up (years) | Surfactant disorder | Mutation |
| 1* | M | 0.3 | 2.9 | SP-C | c.424delC |
| 2* | M | 0.4 | 3.6 | SP-C | c.566 G > A (C189Y) |
| 3* | F | 0.3 | 3.8 | SP-C | c.566 G > A (C189Y) |
| 4* | M | 0.2 | 1.4 | SP-C | c.325-1 G > A |
| 5* | M | 2.4 | 0.4 | SP-C | c.218 T > C (I73T) |
| 6* | F | 5.8 | 0 | SP-C | c.218 T > C (I73T) |
| 7* | F | 1.6 | 2.4 | SP-C | c.218 T > C (I73T) |
| 8* | F | 0.4 | 1.4 | SP-C | c.218 T > C (I73T) |
| 9* | F | 1.2 | 1.2 | SP-C | c.218 T > C (I73T) |
| 10* | M | 0.8 | 2.5 | SP-C | c.218 T > C (I73T) |
| 11* | F | 0.3 | 4.2 | SP-C | c.218 T > C (I73T) |
| 12* | F | 0 | 1.8 | SP-C | c.218 T > C (I73T) |
| 13* | M | 1.6 | md | SP-C | c.218 T > C (I73T) |
| 14* | M | 0.7 | 4.2 | SP-C | c.218 T > C (I73T) |
| 15* | M | 2.2 | 3.1 | SP-C | c.218 T > C (I73T) |
| 16* | F | 0.2 | 6.2 | SP-C | c.218 T > C (I73T) |
| 17* | F | 2.7 | 11.7 | SP-C | c.218 T > C (I73T) |
| 18* | F | 0.5 | 12.4 | SP-C | c.218 T > C (I73T) |
| 19* | M | 0.4 | 6.6 | SP-C | c.218 T > C (I73T) |
| 20* | M | 0.3 | 2.4 | SP-C | c.581 T > C (L194P) |
| 21* | M | 8.5 | 0 | SP-C | c.563 T > C (L188P) |
| 22* | F | 0.4 | 17.2 | SP-C | c.116 T > C (V39A) |
| 23 | M | 0 | 0.1 | SP-B | g.1549 C > GAA (121ins2) −/− |
| 24 | M | 0 | 0.1 | SP-B | g.1549 C > GAA (121ins2) −/− |
| 25 | M | 0.2 | 0 | SP-B | g.1549 C > GAA (121ins2) −/− |
| 26 | F | 0 | 0.2 | SP-B | g.1549 C > GAA (121ins2) −/− |
| 27 | M | 0.1 | 0 | SP-B | c.496delG −/− |
| 28 | M | 0 | 0.1 | SP-B | Y253X −/− |
| 29 | F | 0 | 0.2 | SP-B | 672 + 2del5 −/− |
| 30* | F | 0 | 9.2 | ABCA3 | c.3518 C > G (T1173R) −/− |
| 31* | M | 0.3 | 10.9 | ABCA3 | c.757 G > C (D253H) −/− |
| 32* | F | 2.3 | MD | ABCA3 | c.3518 C > G (T1173R) −/− |
| 33* | M | 0.3 | 3.4 | ABCA3 | P585 −/− |
| 34* | F | 12.3 | 3 | ABCA3 | c.3518 C > G (T1173R) −/− |
| 35* | F | 0.1 | 4.8 | TTF1 | c.786_787del2 (p.L263fs) |
| 36* | F | 0.1 | 1.5 | TTF1 | c.493 C > T(R165W) |
| Sex ratio 1 | Median 0.3 | Median 2.4 |
| Molecular function | GO Name | Count | % | P value | FDR |
| GO:0004984 | olfactory receptor activity | 178 | 32.07207 | 5.862E-158 | 8.27E-155 |
| GO:0034212 | peptide N-acetyltransferase activity | 3 | 0.540541 | 0.006224705 | 8.432901467 |
| GO:0004596 | peptide alpha-N-acetyltransferase activity | 3 | 0.540541 | 0.006224705 | 8.432901467 |
| GO:0005344 | oxygen transporter activity | 4 | 0.720721 | 0.007951513 | 10.65236765 |
| GO:0005218 | intracellular ligand-gated calcium channel activity | 3 | 0.540541 | 0.01014878 | 13.40426119 |
| GO:0005219 | ryanodine-sensitive calcium-release channel activity | 3 | 0.540541 | 0.01014878 | 13.40426119 |
| GO:0042043 | neurexin binding | 3 | 0.540541 | 0.020398884 | 25.23210706 |
| GO:0004683 | calmodulin-dependent protein kinase activity | 4 | 0.720721 | 0.026734392 | 31.7727638 |
| Biological Process | GO Name | Count | % | P value | FDR |
| GO:0007608 | sensory perception of smell | 179 | 32.25225 | 1.284E-157 | 2.15E-154 |
| GO:0007606 | sensory perception of chemical stimulus | 179 | 32.25225 | 6.6567E-148 | 1.11E-144 |
| GO:0007600 | sensory perception | 181 | 32.61261 | 4.4745E-105 | 7.48E-102 |
| GO:0050890 | cognition | 185 | 33.33333 | 3.8912E-100 | 6.51E-97 |
| GO:0007186 | G-protein coupled receptor protein signaling pathway | 189 | 34.05405 | 2.47502E-87 | 4.14E-84 |
| GO:0050877 | neurological system process | 193 | 34.77477 | 3.0364E-85 | 5.08E-82 |
| GO:0007166 | cell surface receptor linked signal transduction | 201 | 36.21622 | 5.69264E-59 | 9.52E-56 |
| GO:0051258 | protein polymerization | 9 | 1.621622 | 0.000194423 | 0.324648125 |
| GO:0007018 | microtubule-based movement | 11 | 1.981982 | 0.00446377 | 7.208705512 |
| GO:0015671 | oxygen transport | 4 | 0.720721 | 0.008202995 | 12.8682872 |
| GO:0051225 | spindle assembly | 4 | 0.720721 | 0.017671563 | 25.78281061 |
| GO:0015669 | gas transport | 4 | 0.720721 | 0.020691633 | 29.50783311 |
| GO:0007158 | neuron adhesion | 3 | 0.540541 | 0.020837821 | 29.68360693 |
| GO:0035176 | social behavior | 4 | 0.720721 | 0.023976546 | 33.35959701 |
| GO:0044065 | regulation of respiratory system process | 3 | 0.540541 | 0.034182249 | 44.10238982 |
| GO:0002087 | regulation of respiratory gaseous exchange by neurological system process | 3 | 0.540541 | 0.034182249 | 44.10238982 |
| GO:0007625 | grooming behavior | 3 | 0.540541 | 0.049984805 | 57.57958749 |
| Cellular Component | GO Name | Count | % | P value | FDR |
| GO:0005886 | plasma membrane | 241 | 43.42342 | 5.86933E-35 | 7.69E-32 |
| GO:0016021 | integral to membrane | 289 | 52.07207 | 1.23979E-32 | 1.62E-29 |
| GO:0031224 | intrinsic to membrane | 293 | 52.79279 | 1.36024E-31 | 1.78E-28 |
| GO:0005833 | hemoglobin complex | 4 | 0.720721 | 0.005887046 | 7.444488585 |
| Pathway | Pathway name | Count | % | P value | FDR |
| hsa04740 | Olfactory transduction | 170 | 30.63063 | 2.80E-137 | 3.05E-134 |
| hsa05130 | Pathogenic Escherichia coli infection | 8 | 1.441441 | 0.027376 | 25.8675045 |
| OMIM_DISEASE | Count | % | P value | FDR | |
| Genetic correlates of brain aging on MRI and cognitive test measures: a genome-wide association and linkage analysis in the Framingham Study | 3 | 0.540541 | 0.011938 | 12.52341992 | |
| Genome-wide association and linkage analyses of hemostatic factors and hematological phenotypes in the Framingham Heart Study | 3 | 0.540541 | 0.026364 | 25.7439374 | |
| C1r/C1s deficiency, combined | 2 | 0.36036 | 0.034033 | 32.00636058 |
| Mean+/-SD(nmol/L) | Pvalue | < 25 nmol/L,% (95%CI) | < 50 nmol/L,% (95%CI) | < 75 nmol/L,% (95%CI) | |
| 0-1y stage (infancy) | |||||
| Total (n = 2116) | 98.7 ± 47.1 | 0.4 (NC) | 5.4 (4.4-6.4) | 33.6 (31.6-35.6) | |
| Gender | 0.763 | ||||
| Male (n = 1221) | 98.5 ± 47.0 | 0.4 (NC) | 5.3 (4.0-6.6) | 34.3 (31.6-37.0) | |
| Female (n = 895) | 99.1 ± 47.2 | 0.3 (NC) | 5.5 (4.0-7.0) | 32.7 (29.6-35.8) | |
| 2-5y stage (preschool) | |||||
| Total (n = 2269) | 69.6 ± 30.4 | 1.1 (NC) | 21.9 (20.2-23.6) | 68.6 (66.7-70.5) | |
| Gender | 0.108 | ||||
| Male (n = 1454) | 70.4 ± 31.4 | 1.2 (NC) | 20.8 (18.7-22.9) | 67.7 (65.3-70.1) | |
| Female (n = 815) | 68.2 ± 28.6 | 1.1 (NC) | 24.0 (21-27) | 70.1 (67.0-73.2) | |
| 6-11y stage (school age) | |||||
| Total (n = 1440) | 56.1 ± 19.9 | 2.0 (NC) | 40.4 (37.9-42.9) | 88.3 (86.6-90.0) | |
| Gender | 0.969 | ||||
| Male (n = 1019) | 56.1 ± 18.7 | 1.6 (NC) | 39.1 (36.1-42.1) | 88.8 (86.9-90.7) | |
| Female (n = 421) | 56.1 ± 22.6 | 3.1 (NC) | 43.7 (39.0-48.4) | 86.9 (83.7-90.1) | |
| 12-16y stage(adolescence) | |||||
| Total (n = 183) | 52.1 ± 17.0 | 3.3 (NC) | 46.4 (39.2-53.6) | 89.6 (85.2-94.0) | |
| Gender | 0.051 | ||||
| Male (n = 135) | 53.5 ± 17.0 | 2.2 (NC) | 44.4 (36-52.8) | 88.1 (82.6-93.6) | |
| Female (n = 48) | 48.0 ± 16.6 | 6.3 (NC) | 52.1 (38-66.2) | 93.8 (87.6-100) |
| Follow up point | Variables in the equation | OR (95% CI) | Nagelkerke* | sn/sp |
| 14 days (n = 235) | Pain for >30 days in year | 3.2 (1.9 to 5.6) | 0.26 | 90/25 |
| Pain (for every 1 point increase) | 0.8 (0.8 to 0.9) | |||
| 30 days (n = 131) | Duration | 0.32 | 92/29 | |
| < 1 month | 1.0 | |||
| 1–3 months | 5.6 (1.8 to 17.0) | |||
| >3 months | 2.4(1.1 to 5.5) | |||
| 90 days (n = 150) | 0.45 | 94/23 | ||
| Duration | ||||
| < 1 month | 1.0 | |||
| 1–3 months | 9.3 (3.0 to 29.0) | |||
| >3 months | 3.0(1.3 to 7.0) |
| Chemistry | Selection | Counter-selection | Targeted or identified targets | Number of cycles | Reference |
| Mammalian Cells | |||||
| DNA | YPEN-1 | N9 | Pigpen | 8 | [58] |
| DNA | B lymphoma cells | No | ND | 10 | [71] |
| DNA | Differenciated PC12 | PC12 | ND | 6 | [60] |
| DNA | U251 | No | Tenascin-C | 21 | [67] |
| 2′F-Py RNA | CHO-kinin B1 receptor | No | Kinin B1 receptor | 8 | [72] |
| 2′F-Py RNA | PC12-MEN2A | PC12/PC12-MEN2A | RET | 15 | [16] |
| 2′F-Py RNA | CHO-TbRIII | CHO | TbRIII | 11 | [73] |
| DNA | aMSCs | No | ND | 11 | [74] |
| DNA | CCRF-CEM | Ramos | PTK7 | 20 | [65,70] |
| DNA | Ramos | No | mmunoglobin heavy mu chain | 23 | [69,75] |
| DNA | SAOS-2 osteoblasts | No | ND | 10 | [68] |
| DNA | MEAR | BNL | Non-muscle myosin | 16 | [62] |
| DNA | NCI-H69 | NCI-H661 | ND | 25 | [76] |
| DNA | EPCs | No | ND | 10 | [77] |
| DNA | iDC (mDC) | mDC (iDC) | Several (see reference) | 10 | [66] |
| DNA | Burkitt lymphoma cells | No | ND | 10 | [59] |
| DNA | A549 | HLAMP | ND | 25 | [78] |
| DNA | HL60 | NB4 | ND | 16 | [64] |
| 2′F-Py RNA | U87MG | T98G | ND | 14 | [79] |
| DNA | CT26-E2 | CT26 | Virus Glycoprotein E2 | 13 | [80] |
| DNA | Infected A549 | Non-infected A549 | ND | 13 | [63] |
| RNA | SKBR3 | SKBR3/siHER-2/MDAMB231 | HER-2 | 20 | [81] |
| DNA | HEK293T-TLR2-Fc | No | TLR2 | 7 | [82] |
| DNA | Vaccinia virus-infected HeLa | Non-infected HeLa | Hemagglutinin | 20 | [61] |
| 2′F-Py RNA | HET-SR-1 | HET-SR | ND | 10 | [83] |
| DNA | Tov-21G/CAOV-3 | HeLa | ND | 22 | [84] |
| DNA | DLD-1/HCT 116 | HCT 116/HT-29 | ND | 16 | [85] |
| DNA | NIH3T3 | IL-17RA-deficient NIH3T3 | IL-17RA | 12 | [86] |
| Viruses | |||||
| 2′NH2-Py RNA | Human cytomegalovirus | No | Glycoprotein B and H | 16 | [57] |
| RNA | Influenza A panama virus | Influenza A Aichi Virus | Haemagglutinin | 10 | [87] |
| Bacteria | |||||
| DNA | B. anthracis spores | No | ND | 4 | [55] |
| DNA | M. Tuberculosis H37Rv | M. Tuberculosis BCG | ND | 10 | [88] |
| DNA | L. Acidophilus | No | S-layer protein | 8 | [89] |
| DNA | S. aureus | Streptococcus/S. epidermidis | ND | 5 | [90] |
| DNA | C. Jejuni | Non relevant mix | ND | 10 | [91] |
| DNA | P. aeruginosa | S. Maltophilia/A. Baumannii | ND | 16 | [92] |
| Parasites | |||||
| RNA | T. brucei | No | ND | 12 | [56] |
| 2′F-Py RNA | T. cruzi trypomastigote | Epimastigote | Several (see reference) | 8 | [93] |
| 2′NH2-Py RNA | T. brucei | No | ND | 13 | [94] |
| PRN | PM | MPDR | ||
| Mean (mm) | Standard Deviation (mm) | Mean (mm) | Standard Deviation (mm) | |
| PRN 3 | 10.9 | 0.4 | 0.01 | 0.4 |
| PRN 6 | 3.4 | 0.3 | −0.01 | 0.4 |
| PRN 10 | 29.6 | 1.5 | 0.07 | 0.7 |
| PRN 16 | 4.8 | 0.4 | 0.05 | 0.6 |
| PRN 18 | 7.5 | 0.3 | −0.01 | 0.5 |
| PRN 21 | 1.5 | 0.2 | −0.05 | 0.5 |
| PRN 24 | −16.0 | 0.3 | 0.01 | 0.5 |
| PRN 25 | 23.1 | 0.5 | −0.03 | 0.5 |
| PRN 29 | −6.7 | 0.4 | 0.03 | 0.5 |
| Venue | Cluster 1 (N = 2715) low-use mean | Cluster 2 (N = 1236) high-use mean | Importance (%) |
| Sports centre | 1.20 | 2.69 | 1.00 |
| Cinema or theatre | 1.35 | 2.73 | 1.00 |
| Vending machine | 1.19 | 2.62 | 1.00 |
| Street stall or small shop | 1.70 | 2.9 | 1.00 |
| Newsagent | 1.13 | 2.68 | 1.00 |
| Petrol station | 1.23 | 2.64 | 1.00 |
| Cafe | 1.81 | 2.94 | 1.00 |
| A fast food restaurant (KFC, McDonalds) | 1.76 | 2.83 | 0.99 |
| A convenience store (7-eleven) | 1.84 | 2.99 | 0.94 |
| Group A (n = 31) (Peg-IFNα + RBV + placebo) | Group B (n = 31) (Peg-IFNα + RBV + Silybin, Vit E, phospholipids) | P Value | |
| Psychological disorders | 14% | 12% | NS |
| Hypercholesterolemia | 16% | 32% | P < 0.01 |
| Fatigue | 48% | 44% | NS |
| Headache | 41% | 42% | NS |
| Musculoskeletal pain | 54% | 35% | P < 0.01 |
| Myalgia | 58% | 32% | P < 0.01 |
| Hypertriglyceridemia | 44% | 30% | P < 0.01 |
| Nausea | 31% | 24% | P < 0.05 |
| Anorexia | 6% | 8% | NS |
| Irritability | 30% | 22% | P < 0.05 |
| Hyperglycemia | 13% | 8% | P < 0.05 |
| Weight loss | 12% | 7% | P < 0.05 |
| Decrease of hemoglobin values at the end of treatment | from 13.6 g/dL (range 11.4–14.4) to 11.6 g/dL (range 10.4–14.2 g/dL) | from 13.6 g/dL (range 11.6–15.9 g/dL) to 10.6 (range 10.4–12.8 g/dL) | NS |
| MIGS ID | Property | Term | Evidence code |
| Current classification | Domain Bacteria | TAS [15] | |
| Phylum Proteobacteria | TAS [16] | ||
| Class Betaproteobacteria | TAS [17,18] | ||
| Order Burkholderiales | TAS [18,19] | ||
| Family Burkholderiaceae | TAS [18,20] | ||
| Genus Burkholderia | TAS [21-23] | ||
| Species Burkholderia sp. | IDA | ||
| Strain WSM2230 | IDA | ||
| Gram stain | Negative | IDA | |
| Cell shape | Rod | IDA | |
| Motility | Motile | IDA | |
| Sporulation | Non-sporulating | NAS | |
| Temperature range | Mesophile | IDA | |
| Optimum temperature | 30°C | IDA | |
| Salinity | Non-halophile | IDA | |
| MIGS-22 | Oxygen requirement | Aerobic | IDA |
| Carbon source | Varied | IDA | |
| Energy source | Chemoorganotroph | NAS | |
| MIGS-6 | Habitat | Soil, root nodule, on host | IDA |
| MIGS-15 | Biotic relationship | Free living, symbiotic | IDA |
| MIGS-14 | Pathogenicity | Non-pathogenic | IDA |
| Biosafety level | 1 | IDA | |
| Isolation | Root nodule of Kennedia coccinea | IDA | |
| MIGS-4 | Geographic location | Karijini National Park, Australia | IDA |
| MIGS-5 | Soil collection date | September 2001 | IDA |
| MIGS-4.1MIGS-4.2 | LatitudeLongitude | 117.99-22.5 | IDAIDA |
| MIGS-4.3 | Depth | 0-10 cm | IDA |
| MIGS-4.4 | Altitude | Not reported |
| HIV+ group only | ||
| Median Nadir CD4-T+ cells/μL | 198 | IQR: 31-279 |
| Median current CD4-T+ cells/μL | 597 | IQR: 342-748 |
| % Plasma undetectable HIV RNA (<50 cp/mL)1 | 95.5% | - |
| % CSF Undetectable HIV RNA (<50 cp/mL)2 | 97.6% | - |
| Median HIV duration (years) | 20.5 | IQR: 14-25 |
| % AIDS status (CDC 1993) | 70.5% | - |
| % With past AIDS defining illness | 53% | - |
| Median current cART duration (months) | 30 | IQR: 12-54 |
| % MSM as HIV risk factor | 89% | - |
| Average educational level (years) | 13.82 | SD: 2.95 |
| % Current hAND | 61.3% | - |
| % Past hAND | 31.8% | - |
| % APOE any ε4 allele carriers | 30.9% (N = 13) | - |
| % APOE ε4/ε4 allele carriers | 7.1% (N = 3) | - |
| % APOE ε2/ε3 allele carriers | 7.1% (N = 3) | - |
| % APOE ε3/ε3 allele carriers | 61.9% (N = 26) | - |
| Switching | Combination | Augmentation | Total | |
| (N = 133) | (N = 80) | (N = 60) | (N = 273) | |
| Age (years), mean (95%CI) | 46.5 (44.5-48.4) | 45.9 (43.4-48.1) | 49.0 (46.5-51.4) | 46.8 (45.5-48.1) |
| Sex (female), n (%) | 92 (69.2) | 53 (66.3) | 40 (66.7) | 185 (67.8) |
| Marital status, n (%) | ||||
| Single | 16 (12.0) | 11 (13.8) | 14 (23.3) | 41 (15.0) |
| Married | 80 (60.2) | 48 (60.0) | 35 (58.3) | 163 (59.7) |
| Divorced or separated | 37 (27.8) | 21 (26.3) | 11 (18.3) | 69 (25.3) |
| Education level, n (%) | ||||
| No education/ Primary education | 78 (58.7) | 46 (57.5) | 41 (68.3) | 165 (60.4) |
| Secondary/ University education | 55 (41.4) | 34 (42.5) | 19 (31.7) | 108 (39.6) |
| Family structure, n (%) | ||||
| Living alone | 17 (12.8) | 8 (10.0) | 11 (18.3) | 36 (13.2) |
| Couple family | 17 (12.8) | 18 (22.5) | 8 (13.3) | 43 (15.8) |
| Parental family | 13 (9.8) | 9 (11.3) | 11 (18.3) | 33 (12.1) |
| Own family | 86 (64.7) | 45 (56.3) | 30 (50.0) | 161 (59.0) |
| Socioeconomic status, n (%) | ||||
| Low/Low-Middle | 55 (41.4) | 30 (37.5) | 23 (38.3) | 108 (39.6) |
| Middle | 62 (46.6) | 40 (50.0) | 31 (51.7) | 133 (48.7) |
| Middle-High | 16 (12.0) | 10 (12.5) | 6 (10.0) | 32 (11.7) |
| Work status, n (%) | ||||
| Active | 79 (59.4) | 50 (62.5) | 20 (33.3) | 149 (54.6) |
| Unemployed | 39 (29.3) | 19 (23.8) | 20 (33.3) | 78 (28.6) |
| Retired/Pensioner | 15 (11.3) | 11 (13.8) | 20 (33.3) | 46 (16.9) |
| Important or very important to plan for care | Have discussed wishes for treatment | Have discussed unacceptable states of health | Prepared written advance care plan or living will | |
| Overall | 76.3% | 51.4% | 46.6% | 16.6% |
| Sex | ||||
| Male | 69.0%¶ | 47.1%† | 46.3% | 15.3% |
| Female | 82.8%¶ | 55.3%† | 46.8% | 17.7% |
| Age | ||||
| 18–34 | 75.9% | 43.5% | 40.9% | 8.9%† |
| 35–54 | 74.6% | 49.5% | 47.2% | 14.3%† |
| 55–64 | 76.6% | 53.8% | 46.8% | 20.5%† |
| ≥65 | 81.3% | 69.6% | 56.3% | 33.0%† |
| Education | ||||
| < or completedHigh school | 69.2% | 48.9% | 41.4%† | 17.3% |
| Some postsecondary | 77.1% | 53.0% | 50.1%† | 17.3% |
| CompletedPostsecondary | 79.2% | 49.2% | 42.5%† | 15.4% |
| Income | ||||
| <$30,000 | 75.3% | 53.1% | 44.4% | 18.5% |
| $30,000 to $59,999 | 74.6% | 54.2% | 47.5% | 16.4% |
| $60,000–89,999 | 78.0% | 46.0% | 44.7% | 12.5% |
| <$90,000 | 75.7% | 51.0% | 47.3% | 17.6% |
| Refused | 77.8% | 52.9% | 47.2% | 17.8% |
| Residence | ||||
| Large urban | 74.9% | 52.3% | 47.7% | 19.0% |
| Other | 77.3% | 50.7% | 45.8% | 14.8% |
| Health conditions | ||||
| None | 73.3% | 43.2%† | 39.2%¶ | 12.2% |
| One | 75.3% | 50.2%† | 44.9%¶ | 18.1% |
| Two or more | 80.8% | 62.4%† | 56.8%¶ | 20.7% |
| Involved in funeral planning | ||||
| Never | 70.2%* | 36.5%¶ | 34.3%¶ | 7.9%¶ |
| Once | 80.0%* | 52.5%¶ | 44.0%¶ | 13.5%¶ |
| Twice or more | 80.2%* | 67.1%¶ | 61.7%¶ | 28.8%¶ |
| ALL | ||
| (n = 504) | ||
| Age(years) | Median(IQR) | 71 (59–80) |
| <40 yr | 47 (9.3) | |
| ≧40 yr. <60 yr | 88 (17.5) | |
| ≧60 yr. <80 yr | 236 (46.8) | |
| ≧80 yr | 133 (26.4) | |
| Male | 255 (50.6) | |
| Disease | Adrenocortical insufficiency | 264 (52.4) |
| Adrenal crisis | 194 (38.5) | |
| Secondary adrenocortical insufficiency | 28 (5.6) | |
| Post-procedural adrenocortical hypofunction | 10 (2.0) | |
| Steroid withdrawal syndrome | 5 (1.0) | |
| Iatrogenic adrenocortical insufficiency | 3 (0.6) | |
| Department | Internal medicine | 255 (50.6) |
| Neurosurgery | 94 (18.7) | |
| Urology | 18 (3.6) | |
| Others | 137 (27.2) | |
| Season | Jan - March | 149 (29.6) |
| April–June | 112 (22.2) | |
| July - Sept | 112 (22.2) | |
| Oct - Dec | 131 (26.0) |
| Taxon | Species | Isoenzyme | Sequence identity, % |
| Mammals | Homo sapiens - Microcebus murinus | GAPD-1 | 91 |
| Homo sapiens - Callitrix jacchus | GAPD-2 | 94 | |
| Teleosts | Tetraodon nigroviridis - Takifugu rubripes | GAPD-1 | 94 |
| Tetraodon nigroviridis - Takifugu rubripes | GAPD-2 | 92 | |
| Insects | Drosophila ananassae - Drosophila virilis | GAPD | 87 |
| Predictor variable | Odds Ratio | p-value | 95% Confidence Interval |
| Health declaration (N = 1459) | |||
| IVQ33/ITQ50: confidence | 0.69 | 0.017 | (0.51, 0.94) |
| Depression coding: IVQ33ITQ50 model (N = 1459) | |||
| Non-professional background | 4.39 | 0.010 | (1.44, 13.40) |
| IVQ33/ITQ50: confidence | 0.52 | 0.013 | (0.31, 0.87) |
| Depression coding: ITQ100 model (N = 1619) | |||
| Non-professional background | 4.78 | 0.001 | (1.97, 11.60) |
| Algorithm | Results | Training | Testing | ||||||||
| Gmean (%) | TN | FP | TP | FN | Gmean (%) | TN | FP | TP | FN | ||
| RA-PSO | AVG | 99.90 | 5110 | 30 | 20 | 0 | 98.59 | 5106 | 34 | 19 | 1 |
| MAX | 99.91 | 5111 | 29 | 20 | 0 | 99.86 | 5107 | 33 | 20 | 0 | |
| MIN | 99.87 | 5107 | 33 | 20 | 0 | 97.33 | 5103 | 37 | 19 | 1 | |
| STDEV | 1.15 | 1.33 |
| Client Mode | Indicates | Server Mode | Indicates |
| INIT | Initialization. | INIT | Initialization. |
| SPEAKER | Client is speaker. | SPEAKERS_TURN | Signal creation |
| HEARER | Client is hearer. | HEARERS_TURN | Signal recognition |
| FEEDBACK | Client is receiving feedback. | FEEDBACK | Clients are receiving feedback. |
| Before treatment | After treatment | n | P | |
| Epidermal thickness average (μm) | ||||
| LN | 39.34 (SD 7.83) | 43.37 (SD 9.40) | 16 | 0.09 |
| PS | 38.26 (SD 6.52) | 42.28 (SD 8.24) | 15 | 0.13 |
| Grenz zone thickness average (μm) | ||||
| LN | 61.41 (SD 29.50) | 64.37 (SD 18.07) | 16 | 0.71 |
| PS | 71.08 (SD 25.98) | 80.58 (SD 37.04) | 15 | 0.36 |
| Pigment intensity score | ||||
| LN | 75.42 (DP 13.27) | 71.88 (DP 17.68) | 16 | 0.54 |
| PS | 69.55 (DP 11.04) | 58.89 (DP 12.39) | 15 | 0.025 |
| Specimen Source Treatment | n | MIC Range | MIC50 (μg/mL) | MIC90 (μg/mL) | |
| Minimum (μg/mL) | Maximum (μg/mL) | ||||
| Urogenital | |||||
| Gepotidacin 1500 mg | 30 | ≤0.06 | 1 | 0.12 | 0.5 |
| Gepotidacin 3000 mg | 39 | ≤0.06 | 1 | 0.25 | 0.5 |
| Gepotidacin total | 69 | ≤0.06 | 1 | 0.12 | 0.5 |
| Pharyngeal | |||||
| Gepotidacin 1500 mg | ... | ... | ... | ... | ... |
| Gepotidacin 3000 mg | 2a | ≤0.06 | 0.12 | ... | ... |
| Gepotidacin total | 2a | ≤0.06 | 0.12 | ... | ... |
| Rectal | |||||
| Gepotidacin 1500 mg | 1 | 0.12 | 0.12 | ... | ... |
| Gepotidacin 3000 mg | 2 | 0.12 | 0.25 | ... | ... |
| Gepotidacin total | 3 | 0.12 | 0.25 | ... | ... |
| Korean sample | STAR*D | ||||||||
| Gene | Gene full name | SNPs with p < 0.05 | SNPs (tot N) | Permuted p | SNPs with p < 0.05 | SNPs (tot N) | Permuted p | ||
| N true | N false | / | N true | N false | / | ||||
| A | |||||||||
| AGBL1 | ATP/GTP Binding Protein-Like 1 | 268 (7 %) | 3454 (92 %) | 3722 | <0.00001 | 65 (9 %) | 601 (90 %) | 656 | 8.9e-5 |
| CYB5A | Cytochrome B5 Type A (Microsomal) | 216 (58 %) | 152 (41 %) | 368 | <0.00001 | 25 (37 %) | 41 (62 %) | 66 | 3.9e-5 |
| MTRF1L | Mitochondrial Translational Release Factor 1-Like | 85 (47 %) | 95 (52 %) | 180 | <0.00001 | 10 (38 %) | 16 (61 %) | 26 | 0.0003 |
| RGS22 | Regulator Of G-Protein Signaling 22 | 129 (29 % | 311 (70 %) | 440 | <0.00001 | 25 (46 %) | 29 (53 %) | 104 | 0.0001 |
| B | |||||||||
| CTNNA3 | Catenin (Cadherin-Associated Protein), Alpha 3 | 446 (6 %) | 6628 (93 %) | 7074 | <0.00001 | 118 (11 %) | 952 (88 %) | 1070 | <0.00001 |
| HS6ST3 | Heparan Sulfate 6-O-Sulfotransferase 3 | 305 (15 %) | 1626 (84 %) | 1931 | <0.00001 | 50 (14 %) | 298 (85 %) | 348 | 8.9e-5 |
| Pre-dictive ethics | Iterative ethics | |
| 1 | Ethical risks are generally predictable | Ethical risks may NOT be predictable |
| 2 | Ethical procedures should be pre-specified - Ethics as ‘requirement’ | Ethical procedures should be emergent to take into account the unfolding context - Ethics as ‘process’ |
| 3 | Treats participants as being ‘subject to’ research | Treats participants as being ‘subjective participants within’ research |
| 4 | Ethics reviews aim to protect participants | Ethics reviews aim to help researchers to think sensitively about how to maintain an ethical stance towards and with research participants |
| 5 | Ethics reviews aim to evaluate researchers | Ethics reviews aim to work with researchers to explore ethical concerns |
| 6 | Ethics reviews ‘apply’ codes of conduct and treat ethics as a set of ‘accountable standards’ | Ethics reviews analyse ethical concerns with researchers in relation to the specific research context |
| 7 | Researchers treated as independent from practices of data collection and regarded as implementing a research protocol | Researchers seen as reflexive participants within research |
| 8 | Work with a binary of ‘ethical’/‘non-ethical’ | Treat ethical problems as multidimensional and contextually framed |
| Items | Criteria of remission | Remitted | Non-remitted | Statistics (df)/Cohen’s d |
| MMSE Total score | SWGC* | 26.80 (2.71) | 25.02 (4.42) | t(110) = 2.576,p = .011/0.485 |
| PANSS PNS** | 27.33 (2.61) | 25.15 (4.06) | t(110) = 3.033,p = .003/0.638 | |
| PANSS TS*** | 27.62 (2.47) | 25.40 (3.93) | t(110) = 2.713,p = .008/0.676 | |
| BACS list learning | SWGC* | 9.31 (4.77) | 9.92 (4.59) | t(99) = −.652,p = 0.516/NA° |
| PANSS PNS** | 9.10 (5.24) | 9.89 (4.35) | t(99) = −.806,p = 0.422/NA° | |
| PANSS TS*** | 8.62 (5.42) | 9.94 (4.38) | t(99) = 1.236,p = 0.219/NA° | |
| BACS Digit sequencing task | SWGC* | 14.75 (6.06) | 11.26 (6.19) | t(99) = 2.86,p = .005/0.571 |
| PANSS PNS** | 16.30 (5.65) | 11.23 (6.01) | t(99) = 4.112p < .0001/0.969 | |
| PANSS TS*** | 17.31 (5.47) | 11.56 (5.98) | t(99) = 4.247p < .0001/1.00 | |
| BACS Verbal Fluency/category istances | SWGC* | 9.89 (4.98) | 8.10 (4.96) | t(99) = 1.801,p = .075/0.360 |
| PANSS PNS** | 10.66 (4.27) | 8.10 (5.20) | t(99) = 2.479,p = .014/0.538 | |
| PANSS TS*** | 10.75 (4.21) | 8.40 (5.16) | t(99) = 2.056,p = .042/0.499 | |
| BACS Verbal FluencyControlled Oral Words ass.test | SWGC* | 15.05 (3.89) | 14.50 (5.49) | t(99) = 0.569 p = .571/NA° |
| PANSS PNS** | 15.46 (4.31) | 14.41 (4.96) | t(99) = 1.061 p = .27/NA° | |
| PANSS TS*** | 15.21 (4.89) | 14.63 (4.73) | t(99) = 0.536 p = .593/NA° | |
| BACS Symbol coding | SWGC* | 32.60 (13.64) | 28.60 (12.29) | t(99) = 1.549,p = 0.125/NA° |
| PANSS PNS** | 36.10 (12.87) | 27.67 (12.29) | t(99) = 3.228,p = .002/0.669 | |
| PANSS TS*** | 37.85 (12.48) | 28.20 (12.43) | t(99) = 3.263,p = .001/0.774 | |
| BACS Tower of London | SWGC* | 11.38 (5.98) | 9.5 (6.53) | t(99) = 1.445,p = 0.152/NA° |
| PANSS PNS** | 12.80 (5.44) | 9.25 (6.33) | t(99) = 2.815,p = .006/0.601 | |
| PANSS TS*** | 13.16 (5.65) | 9.60 (6.21) | t (99) = 2.536,p = .013/0.599 |
| Patient | Angiographic findings* | gradient reduction** | Number of additional Revisions | Follow up |
| 1 | HV, PV, SMV occluded | 17 → 8 | 2 | 2 years |
| 2 | HV occluded | 30 → 7 | 1 | 4 years |
| 3 | HV occluded | 23 → 10 | 3 | 2 years |
| 4 | HV occluded | 29 → 12 | 2 | 12 years |
| 5 | HV occluded | 46 → 6 | 1 | 5 years |
| 6 | HV, PV, IVC occluded | 35 → 6 | 8 | 7 years |
| 7 | HV occluded | 32 → 6 | 4 | 11 years |
| 8 | HV occluded | 25 → 10 | 1 | 3 years |
| 9 | HV occluded | 20 → 8 | 2 | 6 years |
| 10 | HV occluded | 32 → 3 | 0 | 3 years |
| 11 | HV occluded | 31 → 9 | 3 | 3 years |
| 12 | HV occluded | 10 → 4 | 6 | 10 years |
| 13 | HV occluded | 38 → 6 | 0 | 1/2 year |
| Current | Desired | Gap | Academic Gap | Community Gap | |
| Estimating incremental risk incurred by conditional risk factors | 3.84 | 4.59 | 0.75 | 0.83 | 0.67 |
| Estimating cardiovascular risk in primary prevention | 4.14 | 4.75 | 0.61 | 0.73 | 0.48 |
| Estimating incremental risk incurred by predisposing risk factors | 4.07 | 4.67 | 0.60 | 0.68 | 0.52 |
| Identifying | 4.07 | 4.65 | 0.59 | 0.67 | 0.51 |
| Estimating cardiovascular risk in secondary prevention | 4.29 | 4.75 | 0.46 | 0.56 | 0.36 |
| Identifying predisposing cardiovascular risk factors | 4.41 | 4.78 | 0.37 | 0.45 | 0.29 |
| Identifying | 4.49 | 4.79 | 0.30 | 0.37 | 0.23 |
| Z | J | Milk | Where | Store | Pig | Past | Green | Finish | Bathroom | Hungry | Blue | |
| Z | 100% | - | - | - | - | - | - | - | - | - | - | - |
| J | - | 95% | - | - | - | - | - | - | - | - | - | 5% |
| Milk | - | - | 100% | - | - | - | - | - | - | - | - | - |
| Where | - | 2% | - | 94% | - | - | 4% | - | - | - | - | - |
| Store | - | 5% | - | - | 95% | - | - | - | - | - | - | - |
| Pig | - | - | - | - | - | 100% | - | - | - | - | - | - |
| Past | - | - | - | - | 3% | - | 92% | - | 4% | - | 1% | - |
| Green | - | - | - | - | 7% | - | - | 93% | - | - | - | - |
| Finish | - | - | - | - | - | - | - | - | 100% | - | - | - |
| Bathroom | - | - | - | - | - | - | - | - | - | 100% | - | - |
| Hungry | - | - | - | - | - | - | - | - | - | - | 100% | - |
| Blue | - | - | - | 2% | - | - | - | - | - | - | - | 98% |
| Substances | Retention time | OLALPZER | OLALPVIT |
| (min) | Area (%) | Area (%) | |
| α-Thujene | 12.6 | 3.7 | - |
| α-Pinene | 12.9 | 1.7 | 10.1 |
| Camphene | 13.6 | 0.2 | - |
| Sabinene | 14.7 | 13.8 | 1.2 |
| β-Pinene | 14.8 | 3.0 | 35.3 |
| β-Myrcene | 15.4 | 1.1 | - |
| Phellandrene | 16.1 | 0.3 | - |
| α-Terpinene | 16.6 | 4.0 | - |
| ρ-Cymene | 16.9 | 4.8 | - |
| Limonene | 17.1 | 1.8 | 1.5 |
| 1,8-Cineol | 17.2 | 15.3 | - |
| α-Terpinolene | - | 2.0 | - |
| cis-Sabinene | 20 | 2.2 | - |
| Terpinen-4-ol | 23.2 | 19.7 | - |
| α-Cubebene | 29.0 | - | 2.1 |
| Copaene | 30 | - | 2.4 |
| β-Cubebene | 30.4 | - | 2.4 |
| β-Caryophyllene | 31.5 | 3.2 | 1.0 |
| β-Gurjunene | 32.4 | - | 1.7 |
| Aromadendrene | 32.8 | - | 0.7 |
| cis-Muurola-4(14),5-diene | 33.1 | - | 0.6 |
| Germacrene-D | 33.4 | - | 0.6 |
| epi-Bicyclosesquiphellandrene | 33.8 | - | 1.0 |
| epi-Cubebol | 33.9 | - | 5.0 |
| Calamenene | 34.7 | - | 2.0 |
| Cadina-1(2),4-diene | 35.0 | 0.8 | |
| Viridiflorol | 37.2 | 1.75 | |
| 1-epi-Cubenol | 37.8 | 1.43 | |
| 1,10-di-epi-Cubenol | 38.2 | 1.24 | |
| Caryophyllene oxide | 36.5 | 1.9 | - |
| Others | - | 21.2 | 27.2 |
| Patient | Age | First presentation | Patient interval | Residential areaa | Full-time job | Cohabitant children |
| Pre-disaster | ||||||
| 1 | (50–65] | Apr.-Jun. 2007 | 120 months | Voluntary evacuation zone | Yes | No |
| 2 | (65- | Apr.-Jun. 2008 | 48 months | Voluntary evacuation zone | No | No |
| 3 | (50–65] | Sep.-Nov. 2008 | 18 months | Voluntary evacuation zone | No | No |
| 4 | (65- | Dec. 2008-Feb. 2009 | 120 months | Non-evacuation zone | No | Yes |
| 5 | −50] | Sep.-Nov. 2009 | 36 months | Mandatory evacuation zone | Yes | Yes |
| Post-disaster | ||||||
| 1 | (50–65] | Dec. 2011-Feb. 2012 | 24 months | Non-evacuation zone | No | Yes |
| 2 | (65- | Jun.-Aug. 2012 | 18 months | Non-evacuation zone | No | No |
| 3 | (50–65] | Sep.-Nov. 2012 | 17 months | Voluntary evacuation zone | Yes | No |
| 4 | (65- | Sep.-Nov. 2012 | 12 months | Voluntary evacuation zone | No | No |
| 5 | −50] | Dec. 2012-Feb. 2013 | 12 months | Voluntary evacuation zone | No | No |
| 6 | (65- | Dec. 2012-Feb. 2013 | 25 months | Voluntary evacuation zone | Yes | No |
| 7 | (65- | Mar.-May 2013 | 24 months | Voluntary evacuation zone | No | No |
| 8 | (65- | Mar.-May 2014 | 12 months | Non-evacuation zone | No | No |
| 9 | −50] | Jun.-Aug. 2014 | 13 months | Non-evacuation zone | Yes | Yes |
| 10 | (65- | Sep.-Nov. 2014 | 24 months | Voluntary evacuation zone | No | No |
| 11 | (65- | Sep.-Nov. 2014 | 84 months | Voluntary evacuation zone | No | Yes |
| 12 | −50] | Sep.-Nov. 2014 | 24 months | Voluntary evacuation zone | No | No |
| 13 | (65- | Dec. 2014-Feb. 2015 | 24 months | Voluntary evacuation zone | No | No |
| 14 | (50–65] | Jun.-Aug. 2015 | 24 months | Mandatory evacuation zone | No | No |
| 15 | (65- | Sep.-Nov. 2015 | 24 months | Voluntary evacuation zone | No | No |
| 16 | (65- | Sep.-Nov. 2015 | 120 months | Voluntary evacuation zone | No | No |
| 17 | (50–65] | Sep.-Nov. 2015 | 13 months | Mandatory evacuation zone | No | Yes |
| 18 | (50–65] | Dec. 2015-Feb. 2016 | 12 months | Voluntary evacuation zone | Yes | No |
| Treatment group | Control group | p-value | |
| Stage Ib | 15 (1) | 16 (2) | - |
| Stage II | 1 | 0 | - |
| Total gastrectomy | 4 | 3 | - |
| Distal gastrectomy | 12 (1) | 13 (2) | - |
| Sex (M:F) | 13 (2):3 | 13 (1):3 | - |
| Age (year, mean ± SD, median) | 53.75±10.25, 54 | 54.87±11.51, 52.5 | 0.77 |
| BMI (mean ± SD) | 23.21±2.09 | 23.57±1.93 | 0.63 |
| Systolic BP (mmHg, mean ± SD) | 112.88±9.23 | 108.88±9.84 | 0.24 |
| Diastolic BP (mmHg, mean ± SD) | 70.75±7.69 | 72.38±8.16 | 0.57 |
| Pulse rates (mean ± SD) | 73.06±12.89 | 74.94±10.88 | 0.65 |
| Top | Regulator | Out- degree | Supported bya |
| 1 | hsa-miR-590-3p | 320 | - |
| 2 | hsa-miR-548c-3p | 302 | - |
| 3 | hsa-miR-570 | 243 | - |
| 4 | hsa-miR-340 | 242 | - |
| 5 | hsa-miR-495 | 218 | - |
| 6 | hsa-miR-106ab | 207 | PMID: 19209007 |
| 7 | hsa-miR-106bb | 202 | - |
| 8 | hsa-miR-20ab | 201 | PMID: 16266980 |
| 9 | hsa-miR-20bb | 200 | - |
| 10 | hsa-miR-944 | 200 | - |
| 1 | MYC | 116 | PMID: 11720740 |
| 2 | TP53 | 95 | PMID: 12619108 |
| 3 | E2F1 | 73 | PMID: 22803943 |
| 4 | TFAP2A | 64 | PMID: 22143938 |
| 5 | SP1 | 61 | PMID: 22158040 |
| 6 | JUN | 59 | - |
| 7 | E2F4 | 50 | PMID: 19473719 |
| 8 | HIF1A | 48 | PMID: 22115707 |
| 9 | NFKB1 | 48 | - |
| 10 | STAT1 | 44 | PMID: 17348819 |
| Sample | Extent of ageing (weeks) | Difference in colour (aged versus unaged) | Mean tensile properties | ||||
| ΔE00* | ΔL* | Δa* | Δb* | Breaking load (N) | Extension (%) | ||
| WU | 0 | 0.00 | 0.00 | 0.00 | 0.00 | NDa | ND |
| 1 | 1.14 | 0.05 | −0.40 | 1.38 | ND | ND | |
| 2 | 1.33 | 0.32 | −0.48 | 1.58 | ND | ND | |
| 3 | 1.75 | 0.17 | −0.61 | 2.16 | ND | ND | |
| 4 | 2.44 | −0.22 | −0.72 | 3.17 | ND | ND | |
| SU | 0 | 0.00 | 0.00 | 0.00 | 0.00 | 70.2 (4.9)b | 28.2 (1.7)b |
| 1 | 1.04 | −0.06 | −0.32 | 1.00 | 64.2 (4.4) | 25.2 (0.8) | |
| 2 | 1.57 | 0.00 | −0.44 | 1.54 | 65.5 (4.8) | 24.9 (2.5) | |
| 3 | 2.16 | −0.48 | −0.54 | 2.17 | 62.3 (4.7) | 24.8 (2.7) | |
| 4 | 2.59 | −0.40 | −0.57 | 2.70 | 61.6 (4.3) | 21.7 (2.1) | |
| AU | 0 | 0.00 | 0.00 | 0.00 | 0.00 | 239.9 (43.1) | 3.9 (0.5) |
| 1 | 2.39 | −2.17 | 0.67 | 2.78 | 255.5 (38.1) | 3.7 (0.5) | |
| 2 | 3.08 | −2.82 | 1.05 | 3.43 | 262.8 (47.3) | 3.8 (0.5) | |
| 3 | 3.03 | −1.63 | 1.39 | 4.22 | 250.0 (40.3) | 3.9 (0.6) | |
| 4 | 3.95 | −2.64 | 1.76 | 5.29 | 248.8 (28.9) | 3.5 (0.5) | |
| CU | 0 | 0.00 | 0.00 | 0.00 | 0.00 | 117.1 (9.2) | 9.1 (0.8) |
| 1 | 0.62 | −0.15 | −0.10 | 0.61 | 101.9 (15.7) | 8.2 (1.0) | |
| 2 | 1.20 | 0.06 | −0.06 | 1.26 | 107.2 (11.6) | 8.2 (0.7) | |
| 3 | 1.52 | −0.84 | −0.07 | 1.48 | 107.1 (8.3) | 8.6 (0.5) | |
| 4 | 1.82 | −0.28 | −0.06 | 1.92 | 108.2 (11.0) | 8.1 (0.5) | |
| Wp1 | 0 | 0.00 | 0.00 | 0.00 | 0.00 | ND | ND |
| 1 | ND | ND | ND | ND | ND | ND | |
| 2 | 2.74 | −0.50 | −0.39 | 2.73 | ND | ND | |
| 3 | 3.64 | 0.42 | −0.46 | 3.70 | ND | ND | |
| 4 | 5.70 | 3.33 | −0.62 | 5.21 | ND | ND | |
| Sp1 | 0 | 0.00 | 0.00 | 0.00 | 0.00 | 62.9 (4.9) | 25.0 (2.6) |
| 1 | 1.07 | −0.61 | −0.17 | 1.13 | 55.6 (6.1) | 19.7 (1.4) | |
| 2 | 1.78 | −0.31 | −0.30 | 1.98 | 46.0 (3.7) | 14.5 (0.7) | |
| 3 | 2.15 | 0.25 | −0.41 | 2.37 | 34.2 (9.4) | 13.2 (1.5) | |
| 4 | 3.27 | 2.02 | −0.39 | 3.24 | 33.2 (6.1) | 10.1 (1.8) | |
| Ac1 | 0 | 0.00 | 0.00 | 0.00 | 0.00 | 105.9 (18.3) | 2.1 (0.3) |
| 1 | 3.04 | 0.24 | 0.11 | 3.17 | 14.6 (4.9) | 1.8 (0.4) | |
| 2 | 4.54 | −0.37 | 0.63 | 4.64 | 6.5 (1.9) | 1.0 (0.3) | |
| 3 | 5.33 | −0.68 | 1.20 | 5.34 | NDc | NDc | |
| 4 | 4.96 | −2.00 | 1.08 | 4.75 | NDc | NDc | |
| Cc1 | 0 | 0.00 | 0.00 | 0.00 | 0.00 | 68.3 (5.3) | 6.9 (0.7) |
| 1 | 7.35 | −4.23 | 0.30 | 6.92 | 29.5 (3.9) | 4.9 (0.6) | |
| 2 | 10.49 | −4.68 | 1.29 | 10.55 | 13.0 (0.4) | 3.7 (0.6) | |
| 3 | 12.15 | −5.71 | 2.29 | 12.24 | 7.7 (1.1) | 3.5 (0.2) | |
| 4 | 13.24 | −6.72 | 3.02 | 13.22 | 6.2 (0.7) | 3.5 (0.2) |
| Symptom | n | % |
| Bloated stomach | 56 | 61.5 |
| Anemia | 48 | 52.7 |
| Weight loss | 44 | 48.3 |
| Diarrhea | 36 | 39.6 |
| Vomiting | 18 | 19.8 |
| Other symptoms/signs | 31 | 34.1 |
| Studies | Number of studies | Heterogeneity test | Analysis model | OR (95% CI) | Hypothesis test | Begg's test | Egger's test | ||||
| Q | P | Z | P | Z | P | t | P | ||||
| Overall | |||||||||||
| 3-year OS | 11 | 40.12 | 0.000 | Random-effects model | 1.33 (0.97–1.84) | 1.74 | 0.081 | 0.31 | 0.755 | 0.59 | 0.572 |
| 5-year OS | 10 | 41.72 | 0.000 | Random-effects model | 1.38 (1.04–1.82) | 2.26 | 0.024 | 1.25 | 0.210 | 0.96 | 0.364 |
| Gastric cancer | |||||||||||
| 3-year OS | 6 | 11.40 | 0.044 | Random-effects model | 1.69 (1.28–2.25) | 3.66 | 0.000 | 0.38 | 0.707 | 1.18 | 0.302 |
| 5-year OS | 5 | 15.67 | 0.003 | Random-effects model | 1.74 (1.26–2.41) | 3.32 | 0.001 | 2.20 | 0.027 | 7.28 | 0.005 |
| Colorectal cancer | |||||||||||
| 3-year OS | 5 | 12.34 | 0.015 | Random-effects model | 0.84 (0.48–1.47) | 0.62 | 0.536 | 0.73 | 0.462 | 0.46 | 0.679 |
| 5-year OS | 5 | 17.38 | 0.002 | Random-effects model | 1.05 (0.67–1.65) | 0.20 | 0.840 | 0.73 | 0.462 | 0.57 | 0.608 |
| Variable | Non malignant N (%) | Malignant N (%) | COR (95% CI) | AOR (95% CI) | |
| Sex | Male | 171(92.4) | 14(7.6) | 1.05(0.56-1.94) | |
| Female | 613(92.7) | 48(7.3) | 1 | ||
| Age in years | 0-10 | 22(95.7) | 1(4.3) | 1.5(0.18-12.76) | 1.31(.156-11.78) |
| 11-20 | 231(97.1) | 7(2.9) | 1 | ||
| 21-30 | 236(91.8) | 21(8.2) | 2.94(1.23-7.04) | 2.94(1.19-7.2) | |
| 31-40 | 133(91.7) | 12(8.3) | 2.98(1.14-7.75) | 2.68(0.99-7.22) | |
| 41-50 | 91(91) | 9(9) | 3.26(1.18-9.03) | 3.26(1.14-9.33) | |
| 51-60 | 48(88.9) | 6(11.1) | 4.13(1.33-12.82) | 4.97(1.51-16.33) | |
| >60 | 23(79.3) | 6(20.7) | 8.61(2.67-27.78) | 10.96(3.15-38.1) | |
| Size in cm | 0-1.49 | 6(100) | 0 | ||
| 1.5-1.99 | 3(100) | 0 | |||
| 2-2.49 | 9(90.0) | 1(10) | 1.41(0.18-11.3) | 02.87(0.22-15.98) | |
| 3-3.5 | 6(85.7) | 1(14.3) | 2.11(0.25-17.83) | 2.36(0.236-23.70) | |
| >3.5 | 760(92.7) | 60(7.3) | 1 | 1 | |
| Duration of enlargement in year | <0.6 years | 58(93.5) | 4(6.5) | 2.48(0.27-23.1) | |
| 0.6-1 year | 115(85.8) | 19(14.2) | 5.95(0.77-46.0) | ||
| 2-5 years | 365(93.1) | 27(6.9) | 2.66(0.35-2018) | ||
| 6-10 years | 160(94.7) | 9 (5.3) | 2.03(0.25-16.50) | ||
| 11-15 years | 36(97.3) | 1(2.7) | 1 | ||
| >15 years | 50(96.2) | 2(3.8) | 1.44(0.13-16.50) | ||
| Type of enlargement | Solitary | 78(78.8) | 21(21.2) | 9.154(3.75-22.35) | 8.82(3.49-22.32) |
| MNG | 468(93.2) | 34(6.8) | 2.47(1.08-5.66) | 2.52(1.07-5.93) | |
| Diffuse | 238(97.1) | 7(2.9) | 1 | 1 |
| P value | OR | 95% CI | |
| Clavicle tunnel position (x-axis) | .454 | 1.19 | 0.77–2.00 |
| Duration (within 5 days) | .002 | 1.82 | 1.32–2.87 |
| Initial reduction (Good) | .003 | 59.71 | 6.71–1855.80 |
| Gene1 | Gene product2 | Reference |
| SCO4262 | Hypothetical protein | [55] |
| SCO6638 | Hypothetical protein | [55] |
| SCO0762 | Protease inhibitor | [55] |
| SCO4246 | Hypothetical protein | [55] |
| SCO4251 | Putative secreted protein | This study |
| SCO4252 | Hypothetical protein | This study |
| SCO4253 | Conserved hypothetical protein | This study |
| SCO5071 | Hydroxylacyl-CoA dehydrogenase, ActVI-ORFA | [14] |
| SCO5073 | Putative oxidoreductase, ActVI-ORF2 | [14] |
| SCO5074 | Putative dehydratase, ActVI-ORF3 | [14] |
| SCO5075 | Putative oxidoreductase, ActVI-ORF4 | [14] |
| SCO5078 | Hypothetical protein | [14] |
| SCO5079 | Conserved hypothetical protein | [14] |
| SCO5086 | Ketoacyl reductase, ActIII | [14] |
| SCO5088 | Polyketide beta-ketoacyl synthase, ActI-ORF2 | [14] |
| SCO5090 | Actinorhodin polyketide cyclase/dehdratase, ActVII | [14] |
| SCO5895 | Putative methyltransferase, RedI | [20] |
| SCO0392 | Putative methyltransferase | [31] |
| SCO0395 | Putative epimerase/dehydratase | [31] |
| SCO0400 | Putative epimerase | [31] |
| SCO0401 | Putative aminotransferase | [31] |
| SCO0991 | Conserved hypothetical protein | [31] |
| SCO0994 | Integral membrane protein | [31] |
| SCO0995 | Probable methyltransferase | [31] |
| SCO6637 | Hypothetical protein | [31] |
| Domain | Question | Key process probed | Significance |
| Background | Previous occupation? | Previous cognitive/auditory function, noise exposure | Correct interpretation of hearing tests |
| Previous level of musical training and interest, early language development and education? | Prior auditory expertise | Correct interpretation of hearing tests | |
| Course | When was hearing impairment first noticed? | Duration of impairment (relative to cognitive decline) | Nature of underlying disease process |
| Has this deteriorated, fluctuated or improved since onset? | Tempo of impairment | Nature of underlying disease process | |
| Symptoms | |||
| Sound detection | Is there a lack of reaction to sounds? | Impaired sound detection | May signify deafness (any cause) |
| Is there a tendency to turn up the volume of radio or TV or to ask people to speak louder? | Impaired sound detection | May signify deafness (any cause) | |
| Is there a complaint that increasing volume makes sounds suddenly seem too loud? | Impaired sound detection | May signify cochlear pathology (‘loudness recruitment’) | |
| Abnormal auditory perception: deficient | Is there particular difficulty following conversations in background noise or over a noisy telephone line? | Auditory scene analysis | May signify a cerebral disorder (e.g., Alzheimer’s disease) in absence of significant hearing loss |
| Is there difficulty locating sounds (e.g., an alarm or mobile, a person speaking in same the room)? | Auditory scene analysis | May signify a cerebral disorder in absence of significant hearing loss | |
| Is there particular difficulty understanding speech versus other sounds? | Feature analysis | May signify word deafness | |
| Is there more difficulty understanding less familiar accents? | Apperceptive processing | May signify a cerebral disorder in absence of significant hearing loss | |
| Is there more difficulty understanding a person’s tone of voice (e.g., angry or upset)? | Apperceptive and emotional processing | May signify a frontotemporal dementia in appropriate context | |
| Has there been any problem recognising familiar voices, music or other sounds? | Semantic processing | May signify auditory agnosia or semantic dementia, in appropriate context | |
| Abnormal auditory perception: excessive | Is there a persistent complaint of buzzing or ringing in the ears? | Tinnitus | May be peripheral or central in origin |
| Are other sounds ever heard when no sounds are present? | Formed hallucinations | May signify Lewy body disease, in appropriate context | |
| Abnormal auditory behaviour | Is there intolerance to moderately loud sounds or particular sounds? | Hyperacusis | May signify a frontotemporal dementia in appropriate context |
| Has there been any change in liking for or interest in music or other sounds? | Auditory hedonic processing | May signify a frontotemporal dementia in appropriate context |
| Level of education | Specialization/means of accessing information | n | Heard about aflatoxins |
| Frequency (% of n) | |||
| Specialization | |||
| Low | Life/social sciences | 0 | 0 (0) |
| None/other fields | 110 | 12 (11) | |
| High | Life/social sciences | 132 | 55 (42) |
| None/other fields | 16 | 4 (25) | |
| Total | 258 | 71 (28) | |
| Means of accessing information | |||
| Low | Reading | 3 | 1 (33) |
| Mass media (radio/TV) | 69 | 6 (9) | |
| Seminars/experts | 11 | 1 (9) | |
| Friends/neighbours | 8 | 3 (37) | |
| High | Reading | 3 | 2 (67) |
| Mass media (radio/TV) | 69 | 43 (91) | |
| Seminars/experts | 11 | 10 (91) | |
| Friends/neighbours | 8 | 5 (63) |
| Biological process | Number of genes affected by FOS* | |
| Mitochondria | Complex I | 27 |
| Complex II | 5 | |
| Complex III | 2 | |
| Complex IV | 13 | |
| Complex V | 21 | |
| Metabolism and TCA cycle | 53 | |
| Mitochondrial ribosomes | 33 | |
| Protein transport | 11 | |
| Miscellaneous | 12 | |
| Protein turnover | Protein degradation | 31 |
| Translation | 44 | |
| Protein maturation | 32 | |
| Miscellaneous | 6 | |
| Transcription | Chromatin related | 22 |
| mRNA metabolism | 7 | |
| Transcription | 26 | |
| Miscellaneous | 6 | |
| Cell turnover | Apoptosis | 19 |
| Growth/Differentiation | 16 | |
| Mucosal barrier | 30 | |
| Cytoskeleton | 26 | |
| Transport | 20 | |
| Oxidative stress | 16 | |
| Vesicle related | 10 | |
| Peptide hormones | 6 | |
| Other† | 503 | |
| 997 |
| Beat type | Number of beats in Test data set | Number of beats in Training data set | Possession rate (%) |
| Normal | 54516 | 5000 | 70.2573 |
| LBBB | 6036 | 1000 | 7.7746 |
| RBBB | 5410 | 1000 | 6.9889 |
| PVC | 5293 | 1000 | 6.8166 |
| APB | 1896 | 1000 | 2.4407 |
| PB | 2702 | 1000 | 3.4853 |
| Total | 75853 | 10000 | 97.76 |
| Input Text Symbol | |||||||||
| Current State | A | B | C | D | E | F | ... | Z | Match |
| 0 | 1 | 0 | 7 | 0 | 0 | 0 | 0,0,...,0 | 0 | Ø |
| 1 | 1 | 0 | 2 | 0 | 0 | 0 | 0,0,...,0 | 0 | Ø |
| 2 | 3 | 0 | 7 | 0 | 6 | 0 | 0,0,...,0 | 0 | Ø |
| 3 | 1 | 0 | 4 | 0 | 0 | 0 | 0,0,...,0 | 0 | Ø |
| 4 | 3 | 0 | 7 | 5 | 6 | 0 | 0,0,...,0 | 0 | Pep2 |
| 5 | 1 | 0 | 7 | 0 | 0 | 0 | 0,0,...,0 | 0 | Pep1 |
| 6 | 1 | 0 | 7 | 0 | 0 | 0 | 0,0,...,0 | 0 | Pep3 |
| 7 | 8 | 0 | 7 | 0 | 0 | 0 | 0,0,...,0 | 0 | Ø |
| 8 | 1 | 0 | 9 | 0 | 0 | 0 | 0,0,...,0 | 0 | Ø |
| 9 | 3 | 0 | 7 | 0 | 6 | 0 | 0,0,...,0 | 0 | Pep2 |
| Patient characteristics | NNStotal | NNS carb.beverages | NNS non-carb.beverages | NNSsweeteners | ||||
| B | p-value | B | p-value | B | p-value | B | p-value | |
| Gender (female/male) | −0.10 | 0.838 | 0.519 | 0.285 | −0.049 | 0.924 | −2.896 | 0.005 |
| Age (years) | −0.04 | 0.073 | −0.014 | 0.544 | −0.045 | 0.063 | 0.002 | 0.951 |
| BMI (kg/m2) | −0.025 | 0.640 | −0.007 | 0.902 | −0.032 | 0.582 | 0.040 | 0.510 |
| Living with someone | −0.728 | 0.151 | −0.030 | 0.953 | −0.981 | 0.060 | −0.011 | 0.985 |
| Working | −0.124 | 0.594 | 0.383 | 0.114 | −0.379 | 0.126 | −0.047 | 0.858 |
| Smoking | 0.194 | 0.485 | 0.196 | 0.492 | −0.043 | 0.884 | −0.110 | 0.715 |
| Perceived general health | 0.011 | 0.965 | 0.070 | 0.793 | 0.098 | 0.722 | 0.083 | 0.771 |
| Total physical activity | −0.184 | 0.029 | −0.086 | 0.308 | −0.030 | 0.732 | 0.014 | 0.883 |
| Heavy physical activity | −0.477 | 0.011 | −0.368 | 0.052 | −0.212 | 0.278 | 0.116 | 0.576 |
| Hypertension | 0.201 | 0.607 | 0.261 | 0.518 | −0.128 | 0.759 | −0.340 | 0.442 |
| Diabetes | 0.971 | 0.039 | 0.639 | 0.174 | 1.227 | 0.012 | 0.171 | 0.748 |
| Fibromyalgia | 0.696 | 0.131 | 0.202 | 0.664 | 0.718 | 0.132 | 0.568 | 0.249 |
| Muscle-skeletal pain score (range 0-12) | −0.004 | 0.952 | 0.001 | 0.987 | −0.097 | 0.149 | 0.058 | 0.397 |
| HSCL10 > 1.85 | 0.073 | 0.855 | −0.194 | 0.639 | −0.664 | 0.137 | −0.028 | 0.951 |
| WHO-5 (poor wellbeing) | 0.452 | 0.249 | 0.805 | 0.046 | −0.135 | 0.746 | −0.297 | 0.509 |
| Fatigue | 1.232 | 0.001 | 0.490 | 0.184 | 0.316 | 0.408 | 0.575 | 0.159 |
| IBS | 0.317 | 0.444 | −0.193 | 0.651 | 0.207 | 0.633 | −0.047 | 0.915 |
| Functional bloating | −0.379 | 0.486 | 0.600 | 0.280 | −0.714 | 0.258 | −1.365 | 0.067 |
| Functional diarrhea | NA | NA | NA | NA | NA | NA | NA | NA |
| GSRS-diarrhea (score) | 0.625 | 0.009 | 0.178 | 0.447 | 0.176 | 0.467 | 0.626 | 0.012 |
| GSRS-bloating (score) | −0.112 | 0.509 | −0.033 | 0.849 | −0.324 | 0.084 | −0.184 | 0.320 |
| Blood tests | ||||||||
| Haemoglobin (g/dl) | −0.299 | 0.149 | −0.063 | 0.765 | −0.625 | 0.007 | −0.534 | 0.022 |
| Serum iron (μmol/L | −0.015 | 0.648 | −0.042 | 0.237 | −0.011 | 0.768 | −0.049 | 0.205 |
| Transferrin saturation | −0.875 | 0.673 | −0.025 | 0.255 | −0.011 | 0.631 | −0.033 | 0.167 |
| Ferritin (μg/dL) | 0.002 | 0.311 | −0.001 | 0.450 | 0.000 | 0.909 | −0.001 | 0.615 |
| CRP (mg/L) | 0.040 | 0.226 | 0.029 | 0.393 | 0.081 | 0.020 | 0.042 | 0.228 |
| s-Glucose (mmol/L) | 0.110 | 0.082 | 0.122 | 0.055 | 0.044 | 0.492 | 0.005 | 0.944 |
| HbA1C (%) | 0.294 | 0.052 | 0.235 | 0.117 | 0.367 | 0.018 | 0.076 | 0.644 |
| c-peptide (nmol/L) | 0.662 | 0.005 | 0.410 | 0.077 | 0.279 | 0.244 | 0.509 | 0.052 |
| Cholesterol (mmol/L) | 0.116 | 0.542 | 0.188 | 0.339 | −0.043 | 0.830 | −0.096 | 0.661 |
| HDL (mmol/L) | −0.612 | 0.291 | −0.164 | 0.782 | −1.017 | 0.115 | 0.541 | 0.394 |
| LDL (mmol/L) | 0.164 | 0.427 | 0.164 | 0.438 | −0.026 | 0.907 | −0.179 | 0.457 |
| Vitamin A (μmol/L) | 0.291 | 0.536 | −0.725 | 0.136 | −0.232 | 0.644 | 0.050 | 0.921 |
| Vitamin B1 (nmol/L) | 0.008 | 0.243 | 0.006 | 0.356 | 0.001 | 0.876 | 0.007 | 0.363 |
| Vitamin B6 (nmol/L) | 0.004 | 0.479 | 0.005 | 0.407 | −0.011 | 0.178 | −0.002 | 0.759 |
| Vitamin B12 (pmol/L) | −0.001 | 0.384 | 0.000 | 0.727 | 0.000 | 0.940 | −0.001 | 0.503 |
| Vitamin D (nmol/L) | 0.006 | 0.458 | 0.012 | 0.166 | 0.001 | 0.952 | 0.000 | 0.966 |
| Folic acid (nmol/L) | −0.024 | 0.269 | −0.007 | 0.759 | −0.021 | 0.362 | −0.018 | 0.433 |
| Attentional bias index to fearful expression | |||||
| 12 months | 18 months | 24 months | 36 months | ||
| Fear scale (IBQ-R or ECBQ) | 12 months | −.020 | - | - | - |
| 18 months | .240 | −.231 | - | - | |
| 24 months | −.100 | −.335 | −.262 | - | |
| 36 months | .174 | −.463 | .105 | .017 | |
| Average score of scales loading on Negative Affect | 12 months | .527** | - | - | - |
| 18 months | .403 | −.083 | - | - | |
| 24 months | .222 | −.286 | −.023 | - | |
| 36 months | .309 | −.276 | −.125 | .146 |
| Pearls | Cheese matrix | |
| Total solids (%) | 79.09 | 70.37 |
| Fat (%) | 28 | 32 |
| FDM (%) | 35.4 | 45.5 |
| Free leucine (%) | 1.0 | – |
| Gait speed change DT | P | Stand. β | R2 | 95% CI |
| SAI mean | <0.001 | −0.46 | 0.22 | [−39.0, −13.7] |
| Adjusted for age | <0.001 | −0.47 | 0.23 | [−39.6, −14.3] |
| Adjusted for age, MoCA | 0.015 | −0.34 | 0.27 | [−34.8, −3.9] |
| Stud # | Institution | Parents | Habitat | |||
| Stud # | Sex | XXL | MIN | QIO | ||
| 358 | WOLONG | Wild | - | 0 | 0 | 1.0 |
| 425 | CHENGDU | 298 | M | 0 | 1.0 | 0 |
| 314 | F | 0.5 | 0 | 0.5 | ||
| 557 | WOLONG | 399 | M | 0 | 0 | 1.0 |
| 446 | F | 0 | 1.0 | 0 |
| Variables | Number of participants | Candidiasis | Bacterial vaginosis | Trichomoniasis |
| N (%) | N (%) | N (%) | N (%) | |
| Age of participants | ||||
| <20 | 31 (7.6) | 1 (3.2) | 1 (3.2) | 0 |
| 20–29 | 218 (53.3) | 16 (7.3) | 5 (2.3) | 5 (2.3) |
| 30–39 | 107 (26.2) | 14 (13.1) | 1 (0.9) | 2 (1.9) |
| 40–49 | 53 (12.9) | 3 (5.6) | 5 (9.4)*** | 1(1.9) |
| Marital status | ||||
| Single | 54 (13.2) | 2 (3.7) | 2 (3.7) | 0 |
| Married | 312 (76.3) | 30 (9.6) | 9 (2.9) | 8 (25) |
| Divorced | 43 (10.5) | 2 (4.7) | 1 (2.3) | 0 |
| Residence | ||||
| Rural | 116 (28.4) | 8 (6.9) | 7 (10.3)*** | 4 (3.4) |
| Urban | 293 (71.6) | 26 (8.9)* | 5 (1.7) | 4 (1.4) |
| Religion | ||||
| Orthodox | 368 (90) | 27 (7.3) | 12 (2.7) | 6 (1.6) |
| Other | 41 (10) | 7 (17.1)*** | 0 | 2 (0.5) |
| Educational status | ||||
| College and above | 121 (29.6) | 13 (10.7) | 1 (0.8) | 0 |
| Highs school | 70 (17.1) | 9 (12.9) | 1 (1.4) | 3 (4.3) |
| Elementary | 41 (10) | 1 (2.4) | 2 (4.9) | 0 |
| Read and write | 39 (9.5) | 4 (10.3) | 2 (5.1) | 0 |
| Illiterate | 138 (33.7) | 7 (5.1) | 6 (4.3) | 5 (3.6) |
| Occupational status | ||||
| Employed | 131 (32) | 15 (11.5) | 1 (0.8)*** | 1 (0.8) |
| Farmer | 104 (25.4) | 9 (8.7) | 8 (7.7) | 3 (2.9) |
| Merchant | 28 (6.9) | 5 (17.9)*** | 0 | 1 (3.6) |
| Students | 44 (10.8) | 3 (6.8) | 2 (4.5) | 1 (2.3) |
| Unemployed | 101 (24.8) | 2 (2) | 1 (1) | 2 (2) |
| Total | 409 (100) | 34 (8.2) | 12 (2.9) | 8 (2) |
| Name | Sequences (5'-3') | Description |
| OP-F | TCTGGAATGGCTGAAGAAGACG | Forward primer for the actin gene of T. vaginalis in the first stage |
| OP-R | CAGGGTACATCGTATTGGTC | Reverse primer for the actin gene of T. vaginalis in the first stage |
| IP-F | CAGACACTCGTTATCG | Forward primer for the actin gene of T. vaginalis in the second stage |
| IP-R | CGGTGAACGATGGATG | Reverse primer for the actin gene of T. vaginalis in the second stage |
| Drugs | Direct Inhibition of HERG K+ Channel | Inhibition of HERG K+ Channel Trafficking |
| Phenothiazines | + | ? |
| Pentamidine | - | + |
| Geldalamicin | - | + |
| Arsenic Trioxide | - | + |
| Fluoxetine, Norfluoxetine | + | + |
| Ketoconazole | + | + |
| Digitoxin, Ouabain, Digoxin | - | + |
| Sparfluoxacin, Ciprofloxacin, Ofloxacin | + | - |
| Amsacrin | + | - |
| Probucol | - | + |
| Cisapride | + |
| Characteristic | Total nut intake (g/day) | Peanut butter intake (g/day) | |||||
| 0 g/day | 0.1–< 5 | 5–< 10 | 10 +g/day | 0 g/day | 0.1–< 5 | 5 + g/day | |
| (n = 821) | (n = 735) | (n = 225) | (n = 246) | (n = 1493) | (n = 351) | (n = 183) | |
| Age (years) | 62.2 (4.4) | 61.1 (4.2) | 60.1 (4.0) | 60.6 (3.9) | 61.6 (4.3) | 60.9 (4.0) | 60.7 (4.0) |
| Height (cm) | 164.9 (6.5) | 165.5 (5.8) | 165.6 (6.0) | 165.8 (6.2) | 165.4 (6.1) | 165.1 (6.0) | 165.2 (6.6) |
| BMI (kg/m2) | 25.3 (3.8) | 25.1 (3.4) | 24.4 (3.1) | 24.5 (3.3) | 25.0 (3.6) | 25.2 (3.4) | 24.4 (3.2) |
| Physical activity (min/day) | 62.9 (55.2) | 65.8 (48.1) | 71.7 (55.1) | 60.8 (37.4) | 62.3 (48.4) | 72.8 (60.0) | 68.3 (49.2) |
| Age at menarche (years) | 13.7 (1.8) | 13.6 (1.7) | 13.7 (1.8) | 13.6 (1.7) | 13.6 (1.7) | 13.7 (1.9) | 13.8 (1.9) |
| Age at menopause (years) | 48.7 (4.4) | 48.7 (4.6) | 49 (4.4) | 48.9 (4.3) | 48.7 (4.5) | 48.6 (4.4) | 49.6 (4.2) |
| Alcohol intake (g/day) | 4.9 (9.5) | 5.8 (8.8) | 7.2 (9.3) | 8.6 (10.9) | 6.1 (9.7) | 5.5 (9.1) | 4.9 (7.9) |
| Peanut butter intake (g/day) | 1.0 (3.5) | 1.2 (3.7) | 1.3 (3.5) | 1.3 (3.3) | |||
| Total nut intake (g/day) | 4.1 (8.3) | 5.2 (8.7) | 4.9 (8.5) | ||||
| Never smoker (%) | 60.7 | 59.3 | 49.8 | 50.4 | 57.9 | 54.7 | 62.3 |
| University or higher vocational education (%) | 6.2 | 10.7 | 14.3 | 12.6 | 8.4 | 11.5 | 14.8 |
| Nulliparous (%) | 17.7 | 20.5 | 16.9 | 17.6 | 18.1 | 19.0 | 22.0 |
| Age at first birth ≥ 30 years (% of parous) | 22.8 | 19.5 | 26.6 | 26.7 | 22.4 | 21.3 | 25.9 |
| Ever used oral contraceptives (%) | 20.6 | 24.9 | 35.6 | 33.2 | 24.3 | 27.8 | 29.5 |
| Ever used hormone replacement therapy (%) | 12.2 | 13.8 | 13.3 | 16.4 | 13.8 | 13.5 | 9.7 |
| Family history breast cancer (%) | 8.4 | 10.2 | 6.7 | 7.7 | 9.1 | 9.1 | 5.5 |
| History benign breast disease (%) | 6.8 | 9.4 | 8.4 | 6.5 | 8.5 | 6.3 | 6.0 |
| aMEDra score (excluding nuts) 5–7 pts (%) | 20.5 | 27.3 | 26.7 | 32.1 | 23.4 | 27.9 | 33.3 |
| Variant | p-valuea | Annotation |
| rs1800361 | 3.01E-04 | nonsynonymous |
| rs145497019 | 1.20E-05 | nonsynonymous |
| rs1800362 | 9.71E-06 | nonsynonymous |
| rs1800368 | 9.71E-06 | nonsynonymous |
| rs138629441 | 5.79E-06 | nonsynonymous |
| rs143152201 | 3.19E-06 | nonsynonymous |
| 9:97869388 | 2.33E-06 | nonsynonymous |
| FANCC | 2.27E-06b | |
| 9:97887391 | 2.27E-06 | nonsynonymous |
| rs1800367 | 2.27E-06 | nonsynonymous |
| 9:97876956 | 2.20E-06 | nonsynonymous |
| rs140687953 | 1.87E-06 | nonsynonymous |
| rs140781259 | 1.70E-06 | nonsynonymous |
| 9:97934335 | 1.66E-06 | nonsynonymous |
| rs1800366 | 1.65E-06 | nonsynonymous |
| rs121917783 | 1.59E-06 | stop-gain |
| rs1800365 | 1.48E-06 | nonsynonymous |
| Total | Blood | Urine | Abscess drainage | Other | |
| Gram-positivea | 90 | 44 | 27 | 25 | 18 |
| Streptococcus pneumonia | 29 | 14 | 20b | 0 | 5 |
| Alpha hemolytic streptococci | 18 | 7 | 0 | 6 | 7 |
| Group A/C/G streptococci | 13 | 6 | 0 | 9 | 1 |
| Group B streptococci | 2 | 1 | 0 | 1 | 0 |
| Enterococci | 6 | 3 | 2 | 0 | 2 |
| Staphylococcus aureus | 20 | 11 | 4 | 9 | 3 |
| Staphylococcus caprae | 1 | 1 | 0 | 0 | 0 |
| Aerococcus viridans | 1 | 1 | 1 | 0 | 0 |
| Gram-negativea | 55 | 32 | 21 | 8 | 9 |
| Escherichia coli | 27 | 19 | 13 | 3 | 3 |
| Klebsiella | 10 | 6 | 5 | 0 | 1 |
| Enterobacter | 1 | 1 | 0 | 0 | 0 |
| Proteus | 2 | 0 | 0 | 1 | 1 |
| Other Enterobacteriaceae | 5 | 2 | 3 | 1 | 0 |
| Pseudomonas aeruginosa | 2 | 1 | 0 | 1 | 1 |
| Stenotrophomonas maltophilia | 1 | 0 | 0 | 1 | 0 |
| Neisseriae meningitides | 2 | 2 | 0 | 0 | 0 |
| Haemophilus influenzae | 2 | 1 | 0 | 0 | 1 |
| Haemophilus parainfluenzae | 2 | 0 | 0 | 0 | 2 |
| Unspecified gram negative rods | 1 | 0 | 0 | 1 | 0 |
| Anaerobic bacteria | 17 | 6 | 0 | 3 | 9 |
| Clostridium species | 5 | 2 | 0 | 0 | 3c |
| Bacteroides species | 5 | 3 | 0 | 1 | 2 |
| Prevotella | 4 | 0 | 0 | 2 | 2 |
| Slackia exigua | 1 | 1 | 0 | 0 | 0 |
| Fusobacterium | 1 | 0 | 0 | 0 | 1 |
| Unspecified gram positive rods | 1 | 0 | 0 | 0 | 1 |
| Other | 9 | 0 | 0 | 3 | 6 |
| Candida species | 7 | 0 | 0 | 3 | 4 |
| Aspergillus species | 1 | 0 | 0 | 0 | 1 |
| Influenzavirus A | 1 | 0 | 0 | 0 | 1 |
| Patients with ≥1 positive test | 129 | 74 | 40 | 23 | 29 |
| Grade of fibrosis | Histological changes |
| 0 | Normal lung |
| 1 | Minimal fibrous thickening of alveolar/bronchial walls |
| 2 | Intermediary stage between 1 and 3 |
| 3 | Moderate thickening of walls without obvious damage to the lung architecture |
| 4 | Intermediary stage between 3 and 5 |
| 5 | Increased fibrosis with definite damage to lung structure and formation of fibrous bands or small fibrous masses |
| 6 | Intermediary stage between 5 and 7 |
| 7 | Severe distortion of structure and large fibrous areas; honeycombing lung is placed in this category |
| 8 | Total fibrous obliteration of the field |
| Cell lines | Tissue | Bozepinib | |
| IC50 (μM) | TI | ||
| MCF-7a | Breast cancer | 0,355 ± 0,011 | 5,14 |
| MDA-MB 231a | Breast cancer | 0,166 ± 0,063 | 11 |
| MDA-MB 468 | Breast cancer | 0,850 ± 0,003 | 2,14 |
| SKBR-3 | Breast cancer | 0,330 ± 0,003 | 5,53 |
| MCF-10Aa | Normal breast | 1,825 ± 0,003 | NDb |
| Caco-2 | Colon cancer | 0,631 ± 0,008 | 3,18 |
| T-84 | Colon cancer | 1,019 ± 0,281 | 1,97 |
| HT-29 | Colon cancer | 1,352 ± 0,281 | 1,48 |
| SW-480 | Colon cancer | 0,235 ± 0,011 | 8,56 |
| HCT-116 | Colon cancer | 0,570 ± 0,020 | 3,52 |
| CCD-18Co | Normal colon | 2,012 ± 0,012 | NDb |
| Dutch intervention group | Dutch control group | Suriname | Indonesia | |||||||||
| Time point | T = 0 | T = 1 | p (χ2) | T = 0 | T = 1 | p (χ2) | T = 0 | T = 1 | p (χ2) | T = 0 | T = 1 | p (χ2) |
| Gender (%) | 193 (100) | 144 (100) | 0.535 | 182 (100) | 133 (100) | 0.955 | 142 (100) | 153 (100) | 0.718 | 308 (100) | 317 (100) | 0.825 |
| Boy | 140 (72.5) | 100 (69.4) | 95 (52.2) | 69 (51.9) | 62 (43.7) | 70 (45.8) | 129 (41.9) | 130 (41.0) | ||||
| Girl | 53 (27.5) | 44 (30.6) | 87 (47.8) | 64 (48.1) | 80 (56.3) | 83 (54.2) | 179 (58.1) | 187 (59.0) | ||||
| Age (%) | 193 (100) | 145 (100) | 0.040 | 183 (100) | 132 (100) | < 0.001 | 143 (100) | 153 (100) | 0.693 | 311 (100) | 316 (100) | < 0.001 |
| < 14 | – | – | 2 (0.0) | 3 (0.0) | – | – | – | – | ||||
| 14 | 100 (51.8) | 55 (37.9) | 78 (42.6) | 27 (20.5) | 1 (0.0) | 0 (0.0) | 4 (0.0) | 2 (0.0) | ||||
| 15 | 92 (47.7) | 89 (61.4) | 97 (53.0) | 89 (67.4) | 22 (15.4) | 20 (13.1) | 129 (41.5) | 64 (20.3) | ||||
| 16 | 1 (0.0) | 1 (0.0) | 6 (0.1) | 13 (9.9) | 52 (36.4) | 59 (38.6) | 175 (56.3) | 233 (73.7) | ||||
| > 16 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 68 (47.6) | 74 (48.4) | 3 (0.0) | 17 (0.1) | ||||
| Education (%) | 193 (100) | 144 (100) | 0.559 | 184 (100) | 128 (100) | 0.099 | 143 (100) | 153 (100) | – | 311 (100) | 317 (100) | – |
| HAVO | 73 (37.8) | 50 (34.7) | 50 (27.2) | 46 (35.9) | 0 (0) | 0 (0) | 311 (100) | 317 (100) | ||||
| VWO | 120 (62.2) | 94 (65.3) | 134 (72.8) | 82 (64.1) | 143 (100) | 153 (100) | 0 (0) | 0 (0) | ||||
| Science | 190 (100) | 146 (100) | 0.719 | 184 (100) | 133 (100) | 0.215 | 142 (100) | 150 (100) | 0.959 | 310 (100) | 316 (100) | 0.024 |
| Nonscience | 44 (23.2) | 39 (26.7) | 107 (58.2) | 73 (54.9) | 29 (20.4) | 31 (20.7) | 55 (17.7) | 36 (11.4) | ||||
| Science | 144 (75.8) | 105 (71.9) | 77 (41.8) | 60 (45.1) | 113 (79.6) | 119 (79.3) | 255 (82.3) | 280 (88.6) | ||||
| Don't know | 2 (0.0) | 2 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Absolute change in | One-way travel time by automobile to SPH, min | |||
| <45 (n = 69) | 45–150 (n = 25) | 150–360 (n = 39) | >360 (n = 11) | |
| FEV1 % predicted/year | −0.9 [−1.6, 0.1] | −0.5 [−1.8, 0.8] | 0.1 [−1.0, 1.2] | −3.1∗ [−5.1, −1.1] |
| BMI (kg/m2)/year | 0.0 [−0.1, 0.1] | 0.1 [−0.2, 0.3] | 0.3£ [0.1, 0.5] | −0.3 [−0.6, 0.1] |
| Chrom-dataset | cM | Nearest Marker | lodscore | Chrom-dataset | cM | Nearest Marker | lodscore |
| 1-1 | 102.0 | D1S1665 | 1.29 | 8-1 | 26.0 | D8S1106 | 1.59 |
| 1–3 | 114.0 | D1S551 | 1.10 | 8-3 | 39.8 | D8S1145 | 1.78 |
| 1-1 | 140.0 | D1S3723 | 1.11 | 8-2 | 41.2 | D8S136 | 2.20 |
| 1–5 | 202.0 | D1S518 | 1.15 | 8-4 | 50.4 | D8S136 | 1.95 |
| 1–3 | 233.0 | D1S2141 | 1.13 | 9-5 | 85.4 | D9S1120 | 1.29 |
| 1–4 | 233.0 | D1S2141 | 1.87 | 9-6 | 85.4 | D9S1120 | 1.78 |
| 1–5 | 234.4 | D1S2141 | 1.22 | 9-1 | 114.6 | D9S938 | 1.42 |
| 1–6 | 235.8 | D1S2141 | 1.37 | 10-6 | 35.6 | D10S1430 | 1.81 |
| 2–3 | 99.0 | D2S1777 | 1.58 | 10-4 | 38.2 | D10S1430 | 1.71 |
| 2–6 | 99.0 | D2S1777 | 1.81 | 10-3 | 51.2 | D10S1423 | 1.52 |
| 2-2 | 145.0 | D2S1334 | 1.27 | 10-1 | 63.0 | D10S1208 | 4.23 |
| 2–5 | 145.0 | D2S1334 | 1.66 | 11-1 | 106.0 | D11S1986 | 1.60 |
| 2-1 | 157.2 | D2S1399 | 1.46 | 11-3 | 119.0 | D11S4464 | 2.43 |
| 3–5 | 22.0 | D3S1304 | 1.00 | 11-4 | 119.0 | D11S4464 | 1.71 |
| 3-3 | 74.2 | D3S2409 | 1.34 | 11-5 | 119.0 | D11S4464 | 2.29 |
| 3-2 | 77.4 | D3S1766 | 1.17 | 11-2 | 124.6 | D11S4464 | 3.51 |
| 3-2 | 170.6 | D3S1763 | 1.02 | 11-6 | 124.6 | D11S4464 | 2.70 |
| 4-3 | 93.0 | D4S2361 | 2.03 | 14-3 | 70.6 | D14S592 | 1.38 |
| 4-3 | 146.0 | D4S1625 | 1.62 | 14-2 | 86.0 | D14S53 | 1.60 |
| 4-5 | 146.0 | D4S1625 | 1.25 | 16-2 | 24.4 | D16S748 | 1.30 |
| 4-6 | 146.0 | D4S1625 | 1.41 | 16-3 | 24.4 | D16S748 | 1.20 |
| 5-3 | 0.0 | D5S392 | 2.37 | 16-5 | 27.2 | D16S764 | 1.65 |
| 5-4 | 0.0 | D5S392 | 1.25 | 16-4 | 28.6 | D16S764 | 1.62 |
| 5-5 | 0.8 | D5S2488 | 1.52 | 16-1 | 41.2 | D16S403 | 2.33 |
| 5-2 | 1.0 | D5S2488 | 1.66 | 16-2 | 61.6 | D16S3396 | 1.67 |
| 6-2 | 130.8 | D6S1040 | 1.53 | 18-1 | 7.0 | D18S481 | 1.72 |
| 6-1 | 149.6 | GATA184A08 | 4.53 | 18-1 | 28.0 | D18S843 | 1.18 |
| 6-3 | 166.0 | D6S305 | 1.55 | 18-1 | 85.4 | D18S1357 | 1.06 |
| 6-4 | 166.0 | D6S305 | 1.62 | ||||
| 6-5 | 166.0 | D6S305 | 1.15 | ||||
| 6-6 | 166.0 | D6S305 | 3.09 |
| Respondents agreeing to each statement | |||
| Women% | Men% | p-value* | |
| There is often violence at parties | 25 | 14 | < 0.001 |
| Property is often destroyed at parties | 43 | 39 | 0.08 |
| There are often accidents with physical injury at parties | 54 | 46 | 0.008 |
| I often baby-sit drunk friends | 80 | 83 | 0.09 |
| I feel I can talk to a friend about his/her alcohol habits | 89 | 90 | 0.26 |
| My sleep is often disturbed due to others partying | 29 | 21 | 0.001 |
| My study habits are often disturbed due to others partying | 17 | 15 | 0.15 |
| Complications and outcomes | Conventional (n = 40) | Restrictive (n = 41) |
| Total complications | 43 | 45 |
| Cardiovascular complications | ||
| Atrial fibrillation | 2 (4.6) | 1 (2.2) |
| Hypertensive crisis | 4 (9.3) | 0 (0) |
| Pulmonary thromboembolism | 0 (0) | 1 (2.2) |
| Total | 6 (13.9) | 2 (4.4) |
| Tissue-healing complications | ||
| Evisceration | 2 (4.6) | 0 (0) |
| Anastomotic leak | 2 (4.6) | 1 (2.4) |
| Total | 4 (9.3) | 1 (2.4) |
| Infectious complications | ||
| Nosocomial pneumonia | 4 (9.3) | 6 (13.3) |
| Occult septic shock | 1 (2.3) | 0 (0) |
| Peritonitis | 2 (4.6) | 0 (0) |
| Blood stream infection | 0 (0) | 1 (2.2) |
| Wound abscess | 2 (4.6) | 0 (0) |
| Total | 9 | 7 |
| Other complications | ||
| Extubation failure | 1 (2.3) | 0 (0) |
| Renal dysfunction | 1 (2.3) | 0 (0) |
| Gastrointestinal dysfunction | 3 (6.9) | 1 (2.2) |
| Total | 5 | 1 |
| Total number of major complications | 24 | 11 |
| Number of patients with complications | 18 (41.8) | 9 (20.0)* |
| Number of complications per patient | 0.55 | 0.24 |
| Outcomes | ||
| LOS in the ICU | 2.0 [1.0 to 4.0] | 2.0 [2.0 to 5.0] |
| LOS in the hospital | 6.0 [4.0 to 9.0] | 6.0 [4 to 10] |
| 30-day mortality rate | 2 (4.6) | 0 (0) |
| 60-day mortality rate | 3 (6.9) | 1 (2.2) |
| Type of cost | Identification | Measurement | Valuation | ||
| Categories | Costing method | Sources of data | Valuation method | Sources of data | |
| Recurrent | |||||
| Personnel | Administration and management, clinical staff (doctors, nurses, lay workers*), and support staff (cleaning) | Percentage of time spent on different activities | Observation** and semi-structured interviews with providers | Total remuneration package costs | Provider expenditure reports |
| Supplies | Sputum and culture tests, x-rays and drugs | Quantity consumed | Patient records | Market prices | Provincial and private laboratories and pharmacy price lists |
| Vehicle operating and maintenance | Vehicle running costs | Number of kilometres travelled | Vehicle logbook, interview with clinic manager | Actual expenditure on fuel, oil and maintenance | Automobile Association rates |
| Building operating and maintenance | Overheads (water, electricity, telephone, fax, stationeries etc) | Proportion of total visits for which TB patients accounted | Actual costs from facility records, interview with clinic manager | Actual expenditure | Provider expenditure reports |
| Capital† | |||||
| Buildings | Offices, clinics and hospitals | Proportion of total visits for which TB patients accounted | Interview with clinic manager | Replacement prices | CSIR Building and Construction Technology |
| Equipment | Furniture, medical and non-medical equipment | Proportion of total visits for which TB patients accounted) | Interview with clinic manager | Replacement prices | Local manufacturers |
| Vehicles | Vehicles used for TB patients | Vehicle utilisation (km travelled) | Vehicle log book, interview with clinic manager | Replacement prices | Local car dealers |
| Training | Community \"treatment supporters\" training | Number of treatment supporters trained | Actual costs from NGO records | Actual expenditure | Provider expenditure reports |
| No hypotension | iNIBP | dNIBP | p value | |
| The number of cases in which hypotension was detected faster (n (%)) | 24 | 47 (61.8) | 29 (38.2) | 0.03 |
| Activity (U/ml)1 | ||||||
| Enzymes | Soluble fraction | Insoluble fraction | Percent of activity found in insoluble fraction2 | Enzyme amount (mg/ml)3 | Specific activity (U/mg enzyme)3 | Specific activity relative to the native enzyme3 |
| AMA | ||||||
| AMA-native | 734.4 ± 37.5 | 9.63 ± 2.29 | 1.3% | 0.47 | 1563 | 100% |
| AMA-ELK16 | 66.7 ± 5.1 | 468.7 ± 12.9 | 87.5% | 0.25 | 1875 | 120% |
| XynB | ||||||
| XynB-native | 398.8 ± 9.7 | 136.2 ± 17.0 | 25.4% | 0.31 | 1290 | 100% |
| XynB-ELK16 | 13.6 ± 0.6 | 230.0 ± 9.8 | 94.4% | 0.23 | 991 | 77% |
| Multivariable logistic regression analysis (n = 362) | |
| Sociodemographic factors | aOR (95%-CI)a |
| Age (continuous) | 1.03 (1.00-1.05) |
| Health-related factors | |
| Current smoker | |
| Yes | 2.31 (1.27-4.23) |
| Not anymore | 1.13 (0.66-1.95) |
| Never smoked | (Reference) |
| Ever had a diagnosed depression/depressive mood | |
| Yes | 1.85 (1.12-3.06) |
| No | (Reference) |
| Work-related exposures | |
| Carrying and lifting heavy loads (> 20 kg) | |
| Frequently | 2.69 (1.53-4.75) |
| Sometimes | 1.26 (0.68-2.34) |
| Rarely/Never | (Reference) |
| Exposure to environmental impacts | |
| Frequently | 2.18 (1.26-3.76) |
| Sometimes | 1.76 (0.98-3.13) |
| Rarely/Never | (Reference) |
| Variable | OR (95 % CI) | ||
| Binary | Multinomial | ||
| Overweight | Obesity | ||
| Age | 1.09 (1.08, 1.11) | 1.08 (1.07, 1.10) | 1.12 (1.10, 1.15) |
| Marital statusa | |||
| With partner | 1.32 (1.07, 1.63) | 1.23 (0.98, 1.53) | 1.64 (1.22, 2.21) |
| Race/colourb | |||
| Brown | 0.56 (0.39, 0.82) | 0.60 (0.41, 0.88) | 0.47 (0.29, 0.76) |
| White | 0.41 (0.28, 0.58) | 0.43 (0.30, 0.62) | 0.36 (0.23, 0.56) |
| Mother’s schoolingc | |||
| 9–11 years | 1.09 (0.86, 1.38) | 1.00 (0.78, 1.28) | 1.37 (0.98, 1.91) |
| 12 or more years | 1.40 (1.04, 1.89) | 1.16 (0.84, 1.59) | 2.22 (1.50, 3.30) |
| Domestic overloadd | |||
| High | 1.60 (1.28, 1.99) | 1.52 (1.21, 1.92) | 1.80 (1.34, 2.42) |
| Years worked at night | 1.00 (0.98, 1.02) | 0.99 (0.97, 1.01) | 1.02 (0.99, 1.04) |
| Self-rated healthe | |||
| Poor | 2.17 (1.74, 2.70) | 1.83 (1.45, 2.31) | 3.31 (2.47, 4.44) |
| Consumption of fried foodf | |||
| 1–3×/month | 1.96 (1.30, 2.95) | 1.81 (1.18, 2.77) | 2.44 (1.34, 4.43) |
| 1–3×/week | 1.69 (1.13, 2.54) | 1.44 (0.94, 2.20) | 2.62 (1.45, 4.73) |
| 4–6×/week | 2.44 (1.05, 3.96) | 2.21 (1.33, 3.66) | 3.23 (1.61, 6.45) |
| Daily | 2.05 (1.16, 3.63) | 1.90 (1.05, 3.43) | 2.49 (1.11, 5.58) |
| Physical inactivityg | |||
| Yes | 1.58 (1.26, 1.99) | 1.44 (1.13, 1.83) | 2.07 (1.49, 2.87) |
| BMI at age 20 years | 1.63 (1.55, 1.71) | 1.52 (1.44, 1.60) | 1.95 (1.83, 2.07) |
| UniProt ID | Species Name | Protein Name | e-value | Similarity |
| Q9XKY50 | Phytomonas serpens | MURF1 | 5.3e-148 | 100.0% |
| Q33559 | Leishmania tarentolae | MURF1 | 2.7e-109 | 90.9% |
| Q8HE85 | Trypanosoma sp. | MURF1 | 3.1e-17 | 87.6% |
| Q33547 | Blastocrithidia culicis | MURF1 | 1.2e-16 | 86.5% |
| Q33552 | Crithidia fasciculata | MURF1 | 6e-16 | 88.4% |
| Q33556 | Herpetomonas muscarum | MURF1 | 5.1e-13 | 85.0% |
| Q34937 | Leishmania. tarentolae | MURF2 | 2e-09 | 60.4% |
| Q34096 | Crithidia fasciculata | MURF2 | 3.2e-09 | 56.3% |
| Q34192 | Crithidia oncopelti | NAD5 | 3.8e-09 | 54.5% |
| P48903 | Chondrus crispus | NAD2 | 5.4e-07 | 57.9% |
| Q5LRX2 | Silicibacter pomeroyi | Putative membrane protein | 1.2e-06 | 58.0% |
| Q6E773 | Saprolegnia ferax | NAD2 | 1.5e-06 | 53.8% |
| Q6SKY5 | Speleonectes tulumensis | NAD5 | 2.3e-06 | 55.2% |
| Q5AG49 | Candida albicans | Hypothetical protein | 3.3e-06 | 67.7% |
| Q5AGI5 | Candida albicans | Hypothetical protein | 7.1e-06 | 67.9% |
| Q8SKS6 | Ancylostoma duodenale | NAD4 | 7.4e-06 | 57.3% |
| Q85TH7 | Melipona bicolor | NAD4 | 7.7e-06 | 58.1% |
| Q33575 | Trypanosoma brucei | NAD4 | 8.7e-06 | 57.3% |
| P24499 | Trypanosoma brucei brucei | ATP6 | 1.1e-05 | 55.4% |
| Q70NW4 | Strongyloides stercoralis | NAD4 | 1.2e-05 | 56.7% |
| Q33570 | Trypanosoma cruzi | ATP6 | 1.5e-05 | 56.9% |
| Q5CV17 | Cryptosporidium parvum | Hypothetical protein | 1.5e-05 | 61.5% |
| Q057W5 | Buchnera aphidicola | NADH dehydrogenase I chain L | 1.9e-05 | 54.9% |
| Q8IBJ6 | Plasmodium falciparum | Hypothetical protein | 2.9e-05 | 58.4% |
| Algal species | Molecular technique | Bacterial phyla | Country origin | Reference |
| CHLOROPHYTA | ||||
| Bryopsis hypnoides | CLO, FISH | BA, FI, PR (al, ep, ga) | Mexico | Hollants et al. (2011a,b) |
| Bryopsis pennata | CLO, FISH | BA, FI, PR (al, ep, ga) | Mexico | Hollants et al. (2011a,b) |
| Caulerpa taxifolia | CLO, RFLP | BA, PR (al, be, de, ga) | 4 Countries | Meusnier et al. (2001) |
| Chara aspera | FISH | AC, BA, PL, PR (al, be, ga) | Germany | Hempel et al. (2008) |
| Desmidium grevillii | CLO | BA, PR (al, be, ga) | USA | Fisher et al. (1998) |
| Halimeda opuntia | CLO | AC, BA, CH, CL, CY, FI, PL, PR | N. Antilles | Barott et al. (2011) |
| Hyalotheca dissiliens | CLO | BA, PR (al, be, ga) | USA | Fisher et al. (1998) |
| Spondylosium pulchrum | CLO | BA, PR (al, be, ga) | USA | Fisher et al. (1998) |
| Ulva australis | CLO, DGGE | AC, BA, PL, PR (al, de, ga) | Australia | Longford et al. (2007) |
| Ulva australis | CLO | AC, BA, CY, PL, PR (al, de, ga), VE | Australia | Burke et al. (2011b) |
| Ulva australis | CFISH, DGGE | BA, PR (al, ga) | Australia | Tujula et al. (2010) |
| Ulva intestinalis | CLO, DGGE | AC, BA, PR (al, de, ep, ga), VE | Germany | Lachnit et al. (2011) |
| Ulva prolifera | CLO, DGGE | AC, BA, CY, FI, FU, PL, PR (al, be, de, ep, ga), SP, VE | China | Liu et al. (2011) |
| HETEROKONTOPHYTA | ||||
| Dictyota bartayresiana | CLO | AC, BA, CH, CL, CY, FI, PL, PR | N. Antilles | Barott et al. (2011) |
| Fucus vesiculosus | CLO, DGGE | BA, CY, PL, PR (al, be, de, ep, ga), VE | Germany | Lachnit et al. (2011) |
| Laminaria hyperborea | DGGE, FISH | AC, BA, CY, PL, PR (al, be, ga), VE | Norway | Bengtsson et al. (2010) |
| Laminaria rodriguezii | CLO | AR*, PR (be) | Spain | Trias et al. (2012) |
| Saccharina latissima | CLO, DGGE | BA, PR (al, ga) | Germany | Staufenberger et al. (2008) |
| RHODOPHYTA | ||||
| Coralline crustose | CLO | AC, BA, CH, CL, CY, FI, PL, PR | N. Antilles | Barott et al. (2011) |
| Delisea pulchra | CLO, DGGE | AC, BA, CH, CY, PL, PR (al, de, ga), VE | Australia | Longford et al. (2007) |
| Delisea pulchra | CLO, DGGE | BA, PL, PR (al, ga) | Australia | Fernandes (2011) |
| Gracilaria vermiculophylla | CLO, DGGE | AC, CY, DT, PL, PR (al, be, de) | Germany | Lachnit et al. (2011) |
| Osmundaria volubilis | CLO | AR*, PR (be) | Spain | Trias et al. (2012) |
| Phyllophora crispa | CLO | AR*, PR (be) | Spain | Trias et al. (2012) |
| Porphyra yezoensis | CLO | BA, LE, PR (al, be, ga) | Japan | Namba et al. (2010) |
| 3 spp. macroalgae | CLO, TRFLP | BA, CY, PL, PR (al, ga), VE | Chile | Hengst et al. (2010) |
| 12 spp. macroalgae | CLO | PL | Portugal | Lage and Bondoso (2011) |
| Unidentified turf algae | CLO | AC, BA, CH, CL, CY, FI, PL, PR | N. Antilles | Barott et al. (2011) |
| Type 2 diabetes phenotype A (n = 77) | Type 2 diabetes phenotype B (n = 45) | Control group | ANOVA | |
| (n = 54) | p-value | |||
| Age (years) | 60 ± 11 | 56 ± 11 a | 56 ± 14 a | 0.108 |
| Male (%) | 65.9 | 64.6 | 57.4 a, b | <0.001 |
| BMI (kg/m2) | 29.6 ± 6.2 | 31.1 ± 4 a | 25.9 ± 3.6 a, b | <0.001 |
| Waist (cm) | 104 ± 15 | 108 ± 13 a | 92 ± 11 a, b | <0.001 |
| Diabetes duration (years) | 12 ± 11 | 9 ± 8 a | - | |
| Insulin use (%) | 58 | 52 a | - | |
| Lipid lowering drugs (%) | 30 | 28 | - | |
| HbA1c (%) | 9.1 ± 2.1 | 9.6 ± 2.3 a | 5.3 ± 0.6 a, b | <0.001 |
| Hypertension (%) 1 | 69.4 | 68.2 | - | |
| Retinopathy (%) | 29.6 | 29.5 | - | |
| Albuminuria (%) | 24 | 29.6 a | - | |
| Coronary heart disease (%) 2 | 5.6 | 15.9 a | - | |
| Total cholesterol (mmol/L) | 4.78 ± 1.09 | 5.64 ± 1.53 a | 5.00 ± 0.79 b | 0.004 |
| Triglycerides (mmol/L) | 1.46 ± 0.79 | 3.89 ± 3.30 a | 0.87 ± 0.37 a,b | <0.001 |
| VLDLc (mmol/L) | 0.65 ± 0.30 | 1.43 ± 1.12 a | 0.40 ± 0.17 a,b | <0.001 |
| LDLc (mmol/L) | 2.86 ± 0.95 | 3.10 ± 0.96 a | 2.94 ± 0.66 b | 0.281 |
| HDLc (mmol/L) | 1.28 ± 0.33 | 1.02 ± 0.27 a | 1.64 ± 0.37 a,b | <0.001 |
| NEFA (mmol/L) | 0.64 ± 0.29 | 0.90 ± 0.48 | 0.41 ± 0.19 a,b | <0.001 |
| apoB (g/L) | 0.93 ± 0.32 | 1.09 ± 0.28 a | 0.80 ± 0.19 a,b | <0.001 |
| apoA-I (g/L) | 1.46 ± 0.24 | 1.37 ± 0.25 a | 1.57 ± 0.31 a,b | 0.001 |
| apoA-II (g/L) | 0.33 ± 0.07 | 0.34 ± 0.06 | 0.35 ± 0.05 | 0.081 |
| LDL size (nm) | 26.0 ± 0.4 | 25.0 ± 0.4 a | 26.3 ± 0.1 b | <0.001 |
| Particle | Loading capacity (%) | Loading efficiency (%) | Size (nm) | Administration route | In vitro/in vivo results | Ref. |
| NLCs (glyceryl tridecanoate, glyceryl tripalmitate, soy lecithin and Kolliphor HS15, and chitosan) | 3 | 99 | 50 | Oral | High stability in both acidic and neutral environments.In vitro studies performed in THP-1-derived macrophages showed a decrease in inflammation and accumulation of cholesterol. | [27] |
| NLCs (phosphatidylcholine, Kolliphor HS15, and alpha-tocopherol acetate) | 10 | 96 | 108 | N/A | Increased EGCG stability. Enhanced accumulation inside macrophages and decrease in the production of MCP-1. | [28] |
| Phosphatidylcholine, phosphatidylethanolamine, phosphatidic acid, and phosphatidylinositol | N/A | N/A | 30–80 | Oral | Enhanced EGCG oral bioavailability in vivo and induction of α-secretase activity in neuronal cells in vitro. | [29] |
| NLCs (cetyl palmitate/Phospholipon 80, sesame oil, and Tween-80) | 2.7–3.6 | 99 | 126–167 | Topical | Photodegradation of EGCG under UVA radiation. | [30] |
| SLN (glycerol monostearate, stearic acid, soya lecithin, and Pluronic F68) | N/A | 67 | 157 | N/A | Enhanced stability in physiological fluids. Increased induction of cell death in breast cancer cells MDA-MB-231 and prostate cancer cells DU-145. | [31] |
| Cationic lipid nanocarriers (Softisan® 100, Poloxamer 188, glycerol, Lipoid® S75, and CTAB/DDAB) | N/A | N/A | ~150 | Ocular | Prolonged release of EGCG in biological medium. Permeation of rabbit cornea and sclera. | [32] |
| Variable | Adherence | OR (95% CI) | p-value | |
| Yes [n,(%)] | No [n,(%)] | |||
| Perceived benefits of DM drugs | ||||
| A lot of benefits | 251 (85.9) | 41 (14.1) | 1.00 | |
| Some benefits | 182 (75.2) | 42 (24.8) | 0.64 (0.40 – 1.02) | 0.063 |
| Duration on DM drugs | ||||
| Less or equal to 3years | 198 (77.6) | 57 (22.4) | 1.00 | |
| More than 3 years | 235 (88.7) | 30 (11.3) | 2.25 (1.38 – 3.66) | <0.001 |
| Type of DM drugs taken | ||||
| Orals only | 241 (80.3) | 50 (19.3) | 1.00 | |
| Injections only | 182 (87.9) | 25 (12.1) | 1.78 (1.07 – 2.96) | 0.024 |
| Both oral and injections | 10 (81.8) | 3 (18.2) | 1.10 (0.23 – 5.24) | 0.903 |
| Do you get all the prescribed drugs | ||||
| Sometimes | 133(74.2) | 43 (25.8) | 1.00 | |
| Always | 297 (87.9.) | 41 (12.1) | 2.56 (1.56 – 4.16) | 0.001 |
| Ever experienced side effects | ||||
| Yes | 56 (76.7) | 17 (23.3) | 1.00 | |
| No | 365 (84.9) | 65 (15.1) | 1.70 (0.93 – 3.12) | 0.080 |
| Time when last seen by the health worker | ||||
| Less or equal to one month | 211 (82.4) | 45 (17.6) | 1.00 | |
| More than one month | 214 (84.6) | 39 (15.6) | 1.17 (0.73 – 1.87) | 0.430 |
| Use of alternative medicine | ||||
| Yes | 53 (69.7) | 23 (30.3) | 1.00 | |
| No | 367 (85.9) | 60 (14.1) | 2.65 (1.50 – 4.68) | <0.001 |
| Ever had diabetic education | ||||
| No | 8 (61.5) | 5 (38.5) | 1.00 | |
| Yes | 421 (84.2) | 79 (15.8) | 3.33 (1.06 – 11.10) | 0.029 |
| Understanding the drug regimen | ||||
| Yes | 415 (83.5) | 82 (16.5) | 1.00 | |
| No | 16 (73.7) | 7 (26.3) | 0.55 (0.19 – 1.58) | 0.262 |
| Reminders to take drugs | ||||
| Radio/TV | 87 (86.1) | 14 (13.9) | 1.00 | |
| Watch/clock | 126 (84.0) | 24 (26.0) | 0.84 (0.41- 1.72) | 0.643 |
| Phones | 73 (84.9) | 13 (15.1) | 0.90 (0.39 - 2.04) | 0.808 |
| Shadows | 8 (88.9) | 1 (11.1) | 1.28 (0.14 – 11.2) | 0.818 |
| Others | 108 987.1) | 16 (12.9) | 1.08 (0.50 – 2.35) | 0.833 |
| None | 30 (61.2) | 19 (38.8) | 0.25 (0.10 – 0.56) | 0.006 |
| Model | Unstandardized Coefficients B | Unstandardized Coefficients SE | Standardized Coefficient ß | t | p |
| A. Results of the linear Regression for Variables Predicting PTSD Symptoms | |||||
| Constant | −3.28 | 1.75 | −1.88 | p = .063 | |
| MACE SUM | 0.21 | 0.06 | .29 | 3.42 | p = .001 |
| Physical Neglect at age 5 | 2.28 | 0.80 | .24 | 3.86 | p = .005 |
| Emotional Neglect at age 6 | 0.60 | 0.43 | .12 | 1.41 | p = .161 |
| Sexual Abuse at age 12 | 6.73 | 1.89 | .25 | 3.56 | p = .001 |
| B. Results of the linear Regression for Variables Predicting Symptoms of Shutdown Dissociation | |||||
| Constant | 3.47 | 0.73 | −1.88 | p < .001 | |
| Physical Neglect at age 5 | 0.70 | 0.48 | .14 | 1.46 | p = .147 |
| Emotional Neglect at age 4 | 0.57 | 0.26 | .21 | 2.17 | p = .032 |
| Parental Non-verbal Emotional Abuse at age 14 | 0.44 | 0.26 | .16 | 1.73 | p = .086 |
| Sexual Abuse at age 12 | 3.02 | 1.12 | .22 | 2.69 | p = .008 |
| C. Results of the linear Regression for Variables Predicting Symptoms of Depression | |||||
| Constant | 14.82 | 1.29 | 11.48 | p < .001 | |
| F2 diagnosis | −5.12 | 0.14 | −.34 | −4.49 | p < .001 |
| MACE duration | 0.01 | 0.01 | .15 | 1.39 | p = .166 |
| Emotional Neglect at age 9 | 0.51 | 0.30 | .17 | 1.67 | p = .097 |
| Sexual Abuse at age 12 | 2.69 | 1.37 | .16 | 1.97 | p = .051 |
| Phenotype | SNP | Chromosome | Position (bp)a | Alleleb | MAFc (%) in cases | MAFc (%) in controls | RRd (95% CI) | P value | Nearby genee |
| BE | rs3072 | 2p24 | 20,741,887 | G/A | 38.1 | 37.0 | 1.05 (0.91–1.21) | 5.32 × 10−01 | GDF7 |
| BE | rs2701108 | 12q24 | 113,158,644 | G/A | 35.5 | 38.6 | 0.87 (0.75–1.01) | 6.38 × 10−02 | TBX5 |
| BE | rs3784262 | 15q22 | 56,040,398 | G/A | 40.7 | 46.4 | 0.79 (0.68–0.91) | 9.70 × 10−04 | ALDH1A2 |
| EAC | rs3072 | 2p24 | 20,741,887 | G/A | 41.3 | 37.0 | 1.20 (1.07–1.34) | 1.48 × 10−03 | GDF7 |
| EAC | rs2701108 | 12q24 | 113,158,644 | G/A | 35.6 | 38.6 | 0.88 (0.78–0.98) | 2.47 × 10−02 | TBX5 |
| EAC | rs3784262 | 15q22 | 56,040,398 | G/A | 44.3 | 46.4 | 0.92 (0.82–1.03) | 1.30 × 10−01 | ALDH1A2 |
| BE/EAC | rs3072 | 2p24 | 20,741,887 | G/A | 40.3 | 37.0 | 1.15 (1.04–1.27) | 7.53 × 10−03 | GDF7 |
| BE/EAC | rs2701108 | 12q24 | 113,158,644 | G/A | 35.6 | 38.6 | 0.88 (0.79–0.97) | 1.12 × 10−02 | TBX5 |
| BE/EAC | rs3784262 | 15q22 | 56,040,398 | G/A | 43.1 | 46.4 | 0.88 (0.79–0.97) | 8.06 × 10−03 | ALDH1A2 |
| Characteristic | Rotavirus Diarrhea (n = 71) | Nonrotavirus Diarrhea (n = 149) | P Value |
| Age, moa | 9 (3–27) | 10 (2–30) | .335 |
| Male sex | 42 (59.2) | 78 (52.3) | .422 |
| Prior hospital admission for diarrhea | 22 (31.0) | 37 (24.8) | .423 |
| Home has a separate room for kitchen | 40 (56.3) | 88 (59.1) | .813 |
| No. of bedrooms in homea | 2 (1–4) | 2 (1–4) | .278 |
| No. of people sleeping in homea | 7 (1–20) | 6 (4–21) | .368 |
| No. of children sleeping in homea | 4 (1–8) | 3 (1–13) | .459 |
| Family owns a mattress | 51 (71.8) | 98 (65.8) | .457 |
| Family owns a mobile phone | 70 (98.6) | 130 (87.2) | .013 |
| Family owns a radio | 38 (53.5) | 79 (53.0) | 1.000 |
| From the Iraqw tribe | 37 (52.1) | 95 (63.8) | .133 |
| Maternal agea | 27 (16–47) | 26 (17–41) | .919 |
| Mother completed secondary school | 50 (70.4) | 87 (58.4) | .116 |
| Protected drinking water source | 27 (38.0) | 70 (47.0) | .269 |
| Child still breastfeeding | 63 (88.7) | 119 (79.9) | .151 |
| Author | Age | Symptoms | Site of tumor | Histology | Treatment | Relapse(months) | Treatment of relapse |
| Our case | 56 | Urinary symptomsLower abdominal distention | Corpus | IT | Hysterectomy | Yes (3) | BEP × 1 |
| Newsom-Davis et al., 2009 [5] | 82 | Vaginal bleeding | Corpus | IT | Hysterectomy and bilateral salpingooophorectomy | Yes (6) | EP × 1, ET × 1, TP × 1 + surgery |
| Gomez-Lobo et al., 2007 [6] | 15 | Vaginal bleedingPelvic pain | ns | IT, high grade | Lesion excision + chemotherapy | ns | — |
| Iwanaga et al., 1993 [7] | 36 | Pelvic painLower abdominal distention | Fundus | IT, grade 3 | Hysterectomy + chemotherapy (VAC × 2) | No | — |
| Ansah-Boateng et al., 1985 [8] | 37 | Vaginal bleeding | ns | IT, grade 2 | Hysterectomy + radiotherapy | No | — |
| n | 1108 | |
| Age (yrs) | Median | 61.5 |
| Range | 40.2-79 | |
| PSA (ng/ml) | Median | 6.99 |
| Range | 0.3-20 | |
| Pathological Stage | pT2 | 770 (69.6%) |
| pT3 | 335 (30.4%) | |
| Tumour Grade | Low (GS 6) | 153 (13.8%) |
| Intermediate (GS 7) | 848 (76.5%) | |
| GS 3+4 | 583 (68.8%) | |
| GS 4+3 | 265 (31.3%) | |
| High (GS 8-10) | 107 (9.7%) | |
| Extraprostatic Extension | Absent | 782 (70.6%) |
| Present | 326 (29.4%) | |
| Seminal Vesicle Invasion | Absent | 1042 (94.1%) |
| Present | 66 (6%) | |
| Recurrence | No | 812 (76.8%) |
| (n=1057) | Yes | 245 (23.2%) |
| Total Tumour Volume (cc) | Median | 2.6 |
| IQR | 1.3-4.8 | |
| Prostate Volume (cc) | Median | 32.2 |
| IQR | 24.2-43.5 |
| Expected | Jinan | Xuzhou | Hefei | Shanghai 2000 | Shanghai 1986 | ||||||
| Centile | (%) | Boys | Girls | Boys | Girls | Boys | Girls | Boys | Girls | Boys | Girls |
| 3 | 3 | 2.6 | 2.8 | 2.7 | 3.1 | 2.8 | 3.1 | 2.6 | 2.8 | 2.7 | 2.8 |
| 5 | 2 | 1.8 | 2.0 | 1.6 | 1.7 | 1.7 | 1.8 | 1.8 | 1.8 | 0.5 | 1.7 |
| 10 | 5 | 4.6 | 4.4 | 4.9 | 4.7 | 4.7 | 4.7 | 5.0 | 4.7 | 5.1 | 3.4 |
| 25 | 15 | 16.5 | 14.8 | 15.9 | 14.8 | 15.8 | 14.6 | 16.1 | 15.4 | 15.5 | 15.7 |
| 50 | 25 | 26.0 | 27.2 | 26.0 | 26.3 | 25.8 | 25.6 | 25.7 | 25.8 | 27.1 | 26.8 |
| 75 | 25 | 23.1 | 24.4 | 23.6 | 25.1 | 24.4 | 25.8 | 23.5 | 24.8 | 25.9 | 26.5 |
| 90 | 15 | 14.0 | 13.9 | 14.3 | 14.2 | 14.1 | 14.8 | 14.7 | 14.6 | 15.0 | 13.3 |
| 95 | 5 | 5.7 | 4.9 | 5.3 | 5.0 | 5.4 | 4.3 | 5.5 | 4.8 | 3.8 | 5.2 |
| 97 | 2 | 2.6 | 2.3 | 2.6 | 1.7 | 2.1 | 1.9 | 2.3 | 2.0 | 1.2 | 1.9 |
| 100 | 3 | 3.1 | 3.5 | 3.1 | 3.4 | 3.2 | 3.3 | 3.0 | 3.3 | 3.2 | 2.8 |
| Non smokersn = 19 | Ex-smokersn = 6 | Current smokersn = 14 | ||||
| Males (n, %) | 7 | 36,8 | 6 | 100 | 11 | 78,6 |
| Age, years; mean+SD | 46,6 | 4 | 46 | 4,5 | 45,6 | 4,6 |
| Years of employment; mean ± SD | 24,1 | 4,2 | 22,8 | 3,3 | 23,4 | 4,5 |
| Respiratory PPE use (n, %) | 3 | 15,8 | 0 | 3 | 21,4 | |
| Spirometry | ||||||
| FVC; mean+SD | 86,4 | 7,1 | 84 | 3,4 | 80,4 | 11,3 |
| < 80% of pred. FVC (n, %) | 1 | 5,3 | 0 | 4 | 28,6 | |
| FEV1; mean+SD | 87,8 | 10,3 | 87,9 | 4,9 | 82 | 11,5 |
| < 80% of pred. FEV1 (n, %) | 1 | 5,3 | 0 | 4 | 28,6 | |
| FEV1/FVC, < 70% (n, %) | 1 | 5,3 | 0 | 0 | ||
| Asbestos bodies | ||||||
| in BALF | 9 | 47,4 | 2 | 33,3 | 3 | 21,4 |
| in IS | 6 | 31,6 | 0 | 2 | 14,3 |
| Parameter | Unit | Tier within the breeding program | ||
| Nucleus | Multiplier | Commercial | ||
| Flock breeding ewes | Head | 826 | 7000 | 180,000 |
| Flock breeding rams | Head | 10 | 70 | 1800 |
| Ewes mated to terminal sires | % | 0 | 0 | 20 |
| Ewes/ram | Head | 80 | 100 | 100 |
| Ewe replacement rate | % | 35 | 35 | 30 |
| Mixed age ewe lambing ratea | % | 210 | 190 | 165 |
| Ewe lamb lambing rate | % | 100 | 90 | 80 |
| Lamb survival | % | 79 | 79 | 82 |
| Weaning rate | % | 166 | 150 | 135 |
| Lambs sold as storesb | % | – | – | 20 |
| Direct | Indirect | ||||||
| IC1 | n | 2.5 | 50 | 97.5 | 2.5 | 50 | 97.5 |
| Eire | 1949 | 0.1 | 0.2 | 0.2 | 0.0 | 0.0 | 0.1 |
| Great Britain | 1416 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 |
| Eastern Europe | 61 | 0.2 | 0.5 | 1.0 | 0.1 | 0.3 | 0.7 |
| Northern Europe | 45 | 0.0 | 0.3 | 0.8 | 0.0 | 0.2 | 0.5 |
| Southern Europe | 60 | 0.0 | 0.2 | 0.5 | 0.0 | 0.1 | 0.3 |
| Western Europe | 13 | 0.1 | 0.7 | 2.1 | 0.0 | 0.5 | 1.8 |
| Anglo New World | 13 | 0.1 | 0.5 | 1.7 | 0.0 | 0.3 | 1.4 |
| Latin America | 25 | 0.5 | 1.3 | 2.4 | 0.6 | 1.3 | 2.4 |
| Cluster | ||||||
| Professional | Consumer | Organizational | Financial | Regulatory | ||
| Breast | 4 | 9 | 4 | 0 | 0 | |
| Gastrointestinal | 2 | 2 | 2 | 0 | 0 | |
| Genitourinary | 2 | 4 | 2 | 0 | 0 | |
| Gynecological | 1 | 1 | 1 | 0 | 0 | |
| Head and neck | 0 | 2 | 0 | 0 | 0 | |
| Diagnosis | Hematologic | 1 | 2 | 1 | 0 | 0 |
| Lung | 0 | 3 | 0 | 0 | 0 | |
| Melanoma | 1 | 1 | 1 | 0 | 0 | |
| Neuro-oncology | 0 | 0 | 0 | 0 | 0 | |
| Sarcoma | 1 | 0 | 1 | 0 | 0 | |
| Not specified | 5 | 6 | 5 | 0 | 0 |
| Laparoscopic cholecystectomy(n = 120) | Small-incision cholecystectomy(n = 137) | Statistical analysis | |
| Mortality | 0 | 0 | |
| Complications | 21 | 16 | p = 0.119 |
| intra-operative | 5 | 3 | p = 0.363 |
| postoperative | 16 | 13 | p = 0.331 |
| Failed symptom relief | 11 (9.2%) | 14 (10.2%) | p = 0.777 |
| Operative time (min): | |||
| mean (SD) | 71.9 (25.8) | 60.4 (18.3) | p < 0.001 |
| median (range) | 68.5 (26-215) | 60.0 (29-105) | |
| Conversion rate | 14 (11.7%) | 22 (16.1%) | p = 0.312 |
| Operative team: | |||
| surgeon-resident | 15 (12.5%) | 21 (15.3%) | p = 0.515 |
| resident-surgeon | 84 (70.0%) | 100 (73.0%) | p = 0.596 |
| resident-resident | 21 (17.5%) | 18 (13.1%) | p = 0.331 |
| Hospital stay* | |||
| mean (SD) | 2.4 (4.6) | 3.1 (12.4) | p = 0.560 |
| median (range) | 1 (1 - 36) | 2 (1 - 144) | |
| Hospital stay* (without 1 extreme value)mean (SD) | 2.1 (3.4) | 2.0 (2.4) | p = 0.877 |
| Number of patients with: | |||
| 1 night stay postoperative | 67 (55.8%) | 62 (45.3%) | p = 0.091 |
| 2 nights stay postoperative | 38 (31.7% | 56 (40.9%) | p = 0.127 |
| Category from the VIM tool | Phase 1 | Phase 3 |
| 112 patients | 16 patients | |
| Management—investigations, e.g. fields test | 88% (99) | 100% (16) |
| Self-management—importance of taking eyedrops | 83% (93) | 100% (16) |
| Management—regular monitoring | 63% (70) | 81% (13) |
| Management—appointment issues | 63% (70) | 94% (15) |
| Treatment—options for eyedrops | 60% (67) | 100% (16) |
| Risk—family | 55% (62) | 100% (16) |
| Diagnosis | 54% (60) | 100% (16) |
| Treatment—side effects | 43% (48) | 100% (16) |
| Prognosis—loss of sight | 24% (27) | 100% (16) |
| Driving | 16% (18) | 94% (15) |
| Support—help with eyedrops | 13% (15) | 100% (16) |
| Prognosis—symptomless | 11% (12) | 100% (16) |
| Prognosis—sight can’t be recovered | 10% (11) | 100% (16) |
| Support—support groups | 10% (11) | 94% (15) |
| Prognosis—when treated most don’t go blind | 3% (3) | 100% (16) |
| Registration of loss of sight | 2% (2) | 6% (1) |
| Variables | Coefficient | Standard error | p-value |
| Course year | - 0.542 | 0.215 | 0.015 |
| Participation in emergency course | - 0.903 | 0.437 | 0.044 |
| Complication | Frequencyn | Percent% |
| Present | 73 | 44.8 |
| Absent | 90 | 55.2 |
| Total | 163 | 100.0 |
| Warm-up 1.47 min | Front leaning stance | L stance |
| Begin with Postural alignment.Shoulders relaxed and in alignment with hips and feet and all facing forward. When standing, feet start shoulder width apart. Repeat each 4 times. | Step forward one stride length, toes first and facing forward as knee bends. Maintain feet shoulders width apart. Opposite foot, toes slightly turned out (30°) and leg straight. Shift weight to back foot. Bend back knee and straighten front knee when shifting weight to back foot. Both feet remain flat on floor at all times. Connect breath and arms with leg movements (as weight shifts forward, raise arms and take in a deep breath, as shifting back, exhale). | Step back with one foot, making an L with feet (creating a 90° angle). Feet should be a comfortable distance apart and the heel of the back foot should land in line with front foot. Shift weight to back foot and front foot should be settled on heel with toes pointing up in the air. Most of weight on the back foot with knee bent and front knee is straight. Shift weight from back to front foot and bend front knee as back knee straightens. Connect breath and arms with leg movements (as weight shifts forward, raise arms and take in a deep breath, as shifting back, exhale). |
| Sign Gestures 8.13 min | Description | Integration of Breath |
| Healthy, Happy, Holy Practiced from standing position, incorporating the front leaning stance | Healthy: Bring hands to chest with palms open. Extend arms forward in a powerful manner with hands clenched into fist as muscles in forearm and upper arm tighten, assuming the boxers posture. Follow timing of music. | Breath:Breathe in as hands placed on chest. Breathe out as arms extended. |
| Happy: Rolling your hands upward and outward, starting low in your abdomen. This rolling motion is continuous. | Breath: Breathe in as hands move in a continuous motion rolling outward. Breathe out with continuous motion. | |
| Holy: The right index and middle finger (the H sign) glide across the palm of your left hand extending upward and out on an angle. | Breath: Breathe in as the right fingers are placed on the palm of left hand. Breathe out as fingers brush across palm and extend upward and outward. | |
| Check blood pressure and heart rate at 0, 5, and 10 min. (Record heart rate every minute, and up to 10 min following cessation of movement.) |
| miRNA gene | upstream TATA-box | ISRE-IRF1 M00972 | IRF1 M00747 | PU.1 | GAS | IRF3 M00772 | IRF8 M01665 | NF-kappaB M00051 | ETS2 M00340 | Genbank Accesion # |
| miR462a/731 cluster | 1 | 2 | 1 | 1 | 2 | 1 | 1 | - | - | gi|925216714:63629639-63631038 (NC_027314.1) |
| ssa-mir-462b | 1 | 2 | 1 | 1 | 1 | 2 | 1 | - | - | gi|925216718:28307432-28308831 (NC_027312.1) |
| ssa-mir-146a-1 | - | - | - | - | 3 | - | 1 | - | - | gi|925216706:4556929-4558189 (NC_027317.1) |
| ssa-mir-146a-2 | - | - | - | - | 2 | - | - | - | - | gi|925216783:47301787-47303047 (NC_027300.1) |
| ssa-mir-146b | - | 1 | 1 | - | 5 | - | 1 | - | - | gi|925216704:2641623-2642883 (NC_027318.1) |
| ssa-mir-146a-3 | - | - | 3 | - | 3 | - | - | - | - | gi|925216704:51691919-51693179 (NC_027318.1) |
| ssa-mir-21a-1 | 2 | - | - | - | 1 | - | 1 | - | - | gi|925216727:116610294-116611574 (NC_027308.1) |
| ssa-mir-21a-2 | 1 | - | - | - | 1 | - | 2 | - | - | gi|925216702:60966622-60967902 (NC_027319.1) |
| ssa-mir-21b-1 | 1 | - | - | - | 1 | - | 1 | - | - | gi|925216769:50774080-50775360 (NC_027303.1) |
| ssa-mir-21b-2 | - | - | 1 | - | 1 | 1 | 1 | - | - | gi|925216718:73813159-73814439 (NC_027312.1) |
| ssa-mir-1338 | - | - | 2 | - | 1 | - | 2 | - | - | gi|925216772:45802741-45804012 (NC_027302.1) |
| ssa-mir-155-1 | - | 1 | - | - | 6 | - | - | 1 | 1 | gi|925146043:6698-7958 (NW_012350889.1) |
| ssa-mir-92a-3 | - | - | - | - | 1 | - | - | - | - | gi|925125935:50220-51479 (NW_012343521.1) |
| ssa-mir-7132b-1 | 2 | - | - | 1 | 4 | - | - | - | - | gi|925216780:44866633-44867894 (NC_027301.1) |
| ssa-mir-7132b-2 | 3 | - | - | 1 | 1 | - | - | - | - | gi|925216720:24179665-24180926 (NC_027311.1) |
| ssa-mir-7132a-1 | - | - | 1 | 1 | 1 | - | 1 | - | - | gi|925216772:70457167-70458424 (NC_027302.1) |
| ssa-mir-7132a-2 | - | - | 1 | 1 | 1 | - | - | - | - | gi|925216757:28942285-28943542 (NC_027305.1) |
| ssa-mir-734 | - | - | - | - | - | - | - | - | - | gi|925216691:29709642-29710902 (NC_027324.1) |
| ssa-mir-181b | 1 | - | - | - | - | 1 | - | - | - | gi|925216772:43728947-43730207 (NC_027302.1) |
| ssa-mir-181c | 1 | - | - | - | 2 | - | - | - | - | gi|925216723:49524703-49525962 (NC_027310.1) |
| ssa-mir-2188-1 | - | - | - | - | - | - | - | - | - | gi|925216702:26812353-26813612 (NC_027319.1) |
| ssa-mir-2188-2 | - | - | - | - | - | - | - | - | - | gi|925216694:16936155-16937414 (NC_027323.1) |
| miR-223-1 | 1 | - | 1 | - | 4 | - | 1 | - | - | gi|925216769:43698893-43700211 (NC_027303) |
| miR-223-2 | - | - | 1 | - | 2 | 1 | 1 | - | - | gi|925216718:81008935-81010247 (NC_027312.1) |
| Groups | Treatment groups | Description |
| Group I | Normal control | Received only diet and water |
| Group II | Vehicle control | Received water and treated with SRBC |
| Group III | Positive control | Received Ginseng extract 200 mg/kg |
| Group IV | Low dosage treatment | Received 125 mg/kg of D. morbifera |
| Group V | Intermediate dosage treatment | Received 250 mg/kg of D. morbifera |
| Group VI | High dosage treatment | Received 500 mg/kg of D. morbifera |
| Branch | Leading toa | #Sets | #Genes in Sets | # Significant Sets | |||
| Before Pruning | Without Top Scoring Gene | After Pruning | |||||
| 1 | Homininae | African Apes(Hu, Ch, Go) | 1,415 | 7,600 | 8 | 6 | 2 |
| 2 | Hominidae | Great Apes(Hu, Ch, Go, Or) | 1,424 | 7,849 | 34 | 32 | 7 |
| 3 | Hominoidae | Apes(Hu, Ch, Go, Gi) | 1,441 | 8,016 | 43 | 42 | 6 |
| 4 | Catarrhini | Apes & Old World Monkeys (Hu, Ch, Go, Gi, Ma) | 1,441 | 8,058 | 95 | 93 | 9 |
| Gene ID | Annotation | FPKM Ctrl | FPKM -N | Log2 FC |
| GRMZM2G326707 | Inorganic phosphate transmembrane transporter, PHT1;4 | 73.0 | 305.5 | 2.07 |
| GRMZM2G154090 | Inorganic phosphate transmembrane transporter, PHT1;4 | 6.7 | 695.6 | 6.69 |
| GRMZM2G112377 | Inorganic phosphate transmembrane transporter, PHT1;4 | 1.4 | 271.3 | 7.64 |
| GRMZM2G069542 | Phosphoenolpyruvate carboxylase | 92.7 | 154.5 | 0.74 |
| GRMZM2G074122 | Phosphoenolpyruvate carboxylase | 42.7 | 73.6 | 0.79 |
| GRMZM2G110714 | Phosphoenolpyruvate carboxylase | 3.2 | 22.9 | 2.83 |
| GRMZM2G008507 | Sucrose-phosphate synthase | 1.2 | 77.9 | 6.02 |
| GRMZM2G047995 | Lipase class 3 family protein | 4.0 | 87.0 | 4.45 |
| GRMZM2G169562 | Lipase class 3 family protein | 2.9 | 27.3 | 3.23 |
| GRMZM5G829946 | Senescence-related gene 3, glycerophosphodiester phosphodiesterase | 0.3 | 159.3 | 8.92 |
| GRMZM2G064962 | Glycerophosphoryl diester phosphodiester family protein | 19.2 | 108.0 | 2.49 |
| GRMZM2G315848 | Protein nucleotide pyrophosphatase/phosphodiesterase | 6.7 | 65.8 | 3.29 |
| GRMZM2G477503 | Sulfoquinovosyldiacylglycerol 2 | 6.5 | 348.0 | 5.75 |
| GRMZM2G141320 | 1,2-diacylglycerol 3-beta-galactosyltransferase/UDP-galactosyltransferase | 0 | 159.8 | – |
| GRMZM2G152447 | Acid phosphatase/protein serine/threonine phosphatase | 1.0 | 318.8 | 8.34 |
| GRMZM2G138756 | Acid phosphatase/protein serine/threonine phosphatase | 0.1 | 17.7 | 8.00 |
| GRMZM5G836174 | Phosphatase | 0.5 | 1991.8 | 11.83 |
| GRMZM2G015908 | Phosphatase | 3.9 | 309.9 | 6.30 |
| GRMZM2G021106 | Phosphatase | 0.4 | 48.1 | 6.81 |
| GRMZM2G171423 | SPX domain gene 2 | 1.0 | 84.6 | 6.46 |
| GRMZM5G805389 | SPX domain gene 3 | 3.3 | 1246.0 | 8.57 |
| GRMZM2G065989 | SPX domain gene 3 | 2.5 | 1008.0 | 8.65 |
| GRMZM5G828488 | SPX domain gene 3 | 0.5 | 399.5 | 9.65 |
| Metformin | Pioglitazone | Empagliflozin | Anticipated effect? | |
| Cardiovascular death | ↓ | ↔ | ↓↓ | ↓↓↓ |
| All-cause death | ↓ | ↔ | ↓↓ | ↓↓↓ |
| Myocardial infarction | ↓ | ↓ | ↔ | ↓↓ |
| Stroke | ↓ | ↓ | ↔ | ↓↓ |
| Peripheral arterial disease | ↓ | ↔ | ↔ | ↓ |
| Fluid retention | ↔ | ↑ | ↓ | ↔ |
| Heart failure | ↔ | ↑ | ↓ | ↔ |
| Weight | ↓ | ↑ | ↓ | ↓ |
| Blood pressure | ↔ | ↓ | ↓ | ↓↓ |
| HbA1c | ↓ | ↓ | ↓ | ↓↓↓ |
| LDL-cholesterol | ↓ | ↔ | ↑ | ↔ |
| HDL-cholesterol | ↔ | ↑ | ↑ | ↑↑ |
| Albuminuria | ↔ | ↓ | ↓ | ↓↓ |
| Insulin sensitivity | ↑ | ↑↑ | ↑ | ↑↑↑↑ |
| Year | Confirmed positive | Donor population | Prevalence by gender | Total prevalence | |
| 1st year | Male | 124 | 80253 | 0.15% | 0.18% |
| Female | 36 | 6524 | 0.55% | ||
| 2nd year | Male | 133 | 81841 | 0.16% | 0.19% |
| Female | 34 | 6044 | 0.56% | ||
| Total | 327 | 174662 | 0.18% |
| Variable | Subgroups | Number of respondents | Percentages |
| Age (years) | <20 | 33 | 11.3 |
| 20–25 | 221 | 75.4 | |
| >25 | 39 | 13.3 | |
| Age of menarche | <13 | 83 | 28.3 |
| 13–15 | 161 | 54.0 | |
| > 15 | 49 | 16.7 | |
| Gynecological age (years) | < 5 | 14 | 4.8 |
| 5–10 | 214 | 73.0 | |
| > 10 | 65 | 22.2 | |
| Religious affiliationa | Christianity | 208 | 71.0 |
| Islam | 79 | 27.0 | |
| Type of accommodation at menarchea | Single room | 46 | 15.7 |
| Chamber and hall | 55 | 18.8 | |
| Several rooms in a compound house | 52 | 17.7 | |
| Self-contained apartment | 126 | 43.0 | |
| Mansion | 10 | 3.4 | |
| Area of residence during vacationa | Urban area | 181 | 61.8 |
| Sub-urban | 88 | 30.0 | |
| Rural | 21 | 7.2 |
| Dyad 1 | Dyad 2 | Dyad 3 | Dyad 4 | Dyad 5 | |
| Mother age | 43 | 31 | 52 | 45 | 48 |
| Youth age | 13 | 13 | 13 | 13 | 13 |
| Youth grade | 8 | 8 | 8 | 8 | 8 |
| Youth gender | Girl | Girl | Girl | Boy | Boy |
| Mother income | $40–49K | $10–19K | $50–74K | $75–99K | $50–74K |
| Mother education level | Some college | Some college | College graduate | College graduate | College graduate |
| Race | White | African American | White | White | White |
| Number of responses | % | Overall(N Trusts with at least one response/Total N Trusts in regionb) | Diabetes(N Trusts with at least one response) | Cardiac(N Trusts at least one response) | |
| ENGLAND | |||||
| London | 27 | 15.2 | 15/22 | 13 | 13 |
| South West | 23 | 12.9 | 12/16 | 10 | 8 |
| South Central | 10 | 5.6 | 5/9 | 5 | 4 |
| South East Coast | 8 | 4.5 | 6/11 | 6 | 2 |
| East England | 16 | 9.0 | 11/17 | 9 | 5 |
| Yorkshire & Humber | 15 | 8.4 | 9/13 | 8 | 8 |
| West Midlands | 21 | 11.8 | 13/15 | 10 | 13 |
| East Midlands | 8 | 4.5 | 5/8 | 3 | 5 |
| North East | 16 | 9.0 | 6/8 | 4 | 6 |
| North West | 17 | 9.6 | 10/20 | 8 | 8 |
| Total number in England | 161 | 90.5 | 92/139 | 76 | 72 |
| SCOTLAND | 12 | 6.7 | 12 responses covering ≥7/14 health boards (2 responses only identified as “Scotland”) | 6 | 6 |
| WALES | 3 | 1.7 | 3 responses covering 3 of the 7 local health boards. | 2 | 3 |
| NORTHERN IRELAND | 2 | 1.1 | 2 responses covering 2 of the 5 health and social care Trusts | 2 | 2 |
| Total | 178a | 100.0 |
| Primer name | Sequence |
| Notch-1 | |
| Forward | CACTGTGGGCGGGTCC |
| Reverse | GTTGTATTGGTTCGGCACCAT |
| Hes1 | |
| Forward | AGCCAACTGAAAACACCTGATT |
| Reverse | GGAGTTTATGATTAGCAGTGG |
| Dll4 | |
| Forward | GGTGACCTGGCGAACAGACGAGCAAAAT |
| Reverse | GGTGACCTGGCGAACAGACGAGCAAAAT |
| GAPDH | |
| Forward | GGCATCCTGGGCTACACT |
| Reverse | CCACCACCCTGTTGCTGT |
| Features used | Attribute type |
| Gene Neighborhood score, obtained from STRING | Real valued, ranges from 0-999 |
| Gene Fusion score, obtained from STRING | Real valued, ranges from 0-999 |
| Gene Co-occurrence score, obtained from STRING | Real valued, ranges from 0-999 |
| Gene Co-expression score, obtained from STRING | Real valued, ranges from 0-999 |
| GO Cellular component based feature | Real valued, ranges from 0-0.5 |
| GO: Molecular function | Real valued, ranges from 0-0.5 |
| GO: Biological process | Real valued, ranges from 0-0.5 |
| Number of cases | Gender (%) | Age median (Range) | PDAC stage (%) | |
| Cohort 1 (Exploratory phase) | ||||
| Healthy | n = 16 | M (62.5)F (37.5) | 59 (54–65) | Stage IA (16)Stage IIA (24)Stage IIB (56)ND (4) |
| PDAC | n = 25 | M (40)F (60) | 50 (47–82) | |
| Cohort 2 (Confirmatory phase) | ||||
| Healthy | n = 131 | M (49.6)F (50.4) | 55 (44–66) | Stage IA (1.5)Stage IB (0.8)Stage IIA (16.8)Stage IIB (66.4)Stage III (0.8)Stage IV (2.3)ND (11.4) |
| Chronic pancreatitis | n = 30 | M (73.3)F (26.7) | 53 (34–79) | |
| PDAC | n = 131 | M (49.6)F (50.4) | 70 (38–88) |
| Excipient | Recovery (% ± SD)(a) |
| Starch (50)(b) | 99.46 ± 0.46 |
| Glucose (10) | 99.58 ± 1.23 |
| Lactose (10) | 100.37 ± 0.87 |
| Acacia (10) | 98.84 ± 0.39 |
| Talc (5) | 101.53 ± 1.02 |
| MS(c)(10) | 97.97 ± 1.26 |
| Average ± SD | 99.63 ± 1.23 |
| Haplotypes | n (%) | Number of mutated positions | 95% CI |
| Single-type(n = 27) | |||
| YEYSNVD | 17 (60.7) | 1 | 42.62 - 78.8 |
| NEFSNVD | 3 (10.7) | 1 | 0 - 22.16 |
| YEFSNVD | 1 (3.6) | 2 | 0 - 10.44 |
| NEYSNVD | 6 (21.4) | 0 | 6.23 - 36.63 |
| Mixed-type (n = 1) | |||
| N/Y EFSNVD | 1 (3.6) | 2 | 0 - 10.44 |
| Characteristics | Cases (n = 394) | Controls (n = 794) | p valuea |
| Marital status (%) | |||
| Unitedb | 304 (77.2%) | 636 (80.1%) | 0.24 |
| Not united | 90 (22.8%) | 158 (19.9%) | |
| Educational level (%) | |||
| Elementary school or less | 177 (44.9%) | 358 (45.1%) | < 0.001 |
| Junior high school | 66 (16.7%) | 199 (25.1%) | |
| High school | 70 (17.8%) | 144 (18.1%) | |
| University or more | 81 (20.6%) | 93 (11.7%) | |
| History of chronic diseasesc (%) | |||
| Yes | 229 (58.1%) | 327 (41.2%) | < 0.001 |
| No | 165 (41.9%) | 467 (58.8%) | |
| History of STDd (%) | |||
| Yes | 105 (26.7%) | 87 (11.0%) | < 0.001 |
| No | 288 (73.1%) | 706 (88.9%) | |
| Missing | 1 (0.2%) | 1 (0.1%) | |
| Family history of PCe (%) | |||
| Yes | 41 (10.2%) | 20 (2.6%) | < 0.001 |
| No | 353 (89.6%) | 774 (97.5%) | |
| Dairy consumption (portion/d) (%) | |||
| Low | 124 (32.1%) | 286 (36.7%) | 0.004 |
| Middle | 104 (26.1%) | 251 (31.1%) | |
| High | 166 (41.8%) | 257 (32.2%) | |
| Energy | |||
| Mean ± SD | 2172.13 ± 717.81 | 1959.28 ± 681.88 | < 0.001 |
| Life course PA patternsf (%) | |||
| None | 58 (14.7%) | 74 (9.3%) | < 0.001 |
| A | 98 (24.9%) | 135 (17.0%) | |
| B | 218 (55.3%) | 532 (67.0%) | |
| C | 20 (5.1%) | 53(6.7%) |
| Type of vaginal infections | Asymptomatic women (N = 261) | Symptomatic women (N = 148) | P-value | Pregnant women (N = 214) | Non-pregnant women (N = 195) | P-value | Total |
| Candidiasis | 24 (9.2) | 10 (6.8) | 0.08 | 20 (9.3) | 14 (7.2) | 0.48 | 34 (8.2) |
| Bacterial vaginosis | 6 (2.3) | 6(4.1) | 0.73 | 1 (0.5) | 11 (5.6) | 0.002 | 12 (2.9) |
| Trichomoniasis | 6 (2.3) | 2 (1.4) | 1.00 | 3 (1.4) | 5 (2.6) | 0.49 | 8 (2) |
| Gonococcus | 4 (1.6) | 0.0 % | 0.58 | 2 (1) | 2 (0.93) | 1.00 | 4 (1) |
| Group B Streptococcus | 4(1.5) | 1 (0.7) | 1.00 | 0 | 5 (2.6) | 0.02 | 5 (1.2) |
| Total | 44 (16.9) | 19 (12.8) | 0.82 | 26 (13.3) | 37 (17.3) | 0.03 | 63 (15.4) |
| Variables | KPNA2 expression | P | |
| Low (N = 23) | High (N = 80) | ||
| Mean age, y ± SD | 66.9 ± 9.0 | 68.5 ± 8.9 | 0.513 |
| Sex, n (%) | 0.414 | ||
| Male | 14 (61) | 56 (70) | |
| Female | 9 (39) | 24 (30) | |
| Histological type, n (%) | 0.215 | ||
| Well, moderately | 19 (83) | 56 (70) | |
| Poor | 4 (17) | 24 (30) | |
| T factor (UICC), n (%) | 0.160 | ||
| T1, 2 | 15 (65) | 39 (49) | |
| T3, 4 | 8 (35) | 41 (51) | |
| Tumor size, n (%) | 0.978 | ||
| <30 mm | 11 (48) | 38 (48) | |
| ≥30 mm | 12 (52) | 42 (52) | |
| Lymph node metastasis, n (%) | 0.062 | ||
| Absent | 18 (78) | 46 (58) | |
| Present | 5 (22) | 34 (42) | |
| Vascular invasion, n (%) | 0.098 | ||
| Absent | 18 (78) | 48 (60) | |
| Present | 5 (22) | 32 (40) | |
| Perineural invasion, n (%) | 0.938 | ||
| Absent | 11 (48) | 39 (49) | |
| Present | 12 (52) | 41 (51) | |
| TNM stage (UICC), n (%) | 0.897 | ||
| I-II | 19 (83) | 67 (84) | |
| III-IV | 4 (17) | 13 (16) | |
| Recurrence, n (%) | 0.024* | ||
| Absent | 15 (65) | 31 (39) | |
| Present | 8 (35) | 49 (61) |
| Run no. | Pretreatment conditions | H2O addition method | Solid residue (wt%) | Glucose yield (%) | Xylose yield (%) |
| 1 | 105°C 6 h | Aliquot | 34.9 | 20.7 ± 0.4 | 99.8 ± 2.6 |
| 2b | 105°C 6 h | Aliquot | 34.8 | 24.2 ± 0.3 | 98.6 ± 1.8 |
| 3c | 105°C 6 h | Aliquot | 34.8 | 27.4 ± 0.7 | 95.1 ± 2.0 |
| 4 | 160°C 1 h | Aliquot | 13.7 | 37.1 ± 1.2 | 83.4 ± 3.8 |
| 5 | 160°C 1.5 h | Aliquot | 6.7 | 69.4 ± 2.5 | 81. 9 ± 2.8 |
| 6 | 160°C 1.5 h | Pumped @ 10 min | 13.8 | 38.6 ± 2.7 | 92.6 ± 5.5 |
| 7 | 160°C 1.5 h | Pumped @ 15 min | 10.2 | 83.3 ± 1.9 | 52.1 ± 1.2 |
| Variables | Evaluation instruments | Quality of instruments | Time application instruments |
| Demographic & obstetric data | Included in antenatal interview | Antenatal | |
| Antenatal risk of PPD | Interview (Riguetti-Veltema & et. al, [14]) | Sensitivity = 84,5%, Specificity = 73% | Antenatal |
| Symptoms of depression | EPDS*Edinburgh Postnatal Depression Scale (Cox & et. al, [51]) | Sensitivity = 86%, Specificity = 78% | Antenatal and postnatal |
| Relationship with partner | DASS*Dyadic Adjustement Scale (Spanier, [52]) | Fidelity: Cronbach Alpha = 0.96 | Antenatal and postnatal |
| Social support | FSSQ*Functional Social Support Questionnaire (Broadhead, [53]) | Fidelity: Cronbach Alpha = 0.90 | Antenatal and postnatal |
| Stress | Stress events* (Holmes & Rahe, [54]) | Antenatal and postnatal | |
| Birth outcomes | Hospital clinical data and post-partum questionnaire* | Postnatal |
| Characteristic | Frequency | Percentage |
| Sex | ||
| Male | 372 | 62.0 |
| Female | 228 | 38.0 |
| Age category | ||
| 1 (15–35) | 287 | 47.8 |
| 2 (36–55) | 202 | 33.7 |
| 3 (≥56) | 111 | 18.5 |
| HIV status | ||
| Positive | 162 | 27.0 |
| Negative | 438 | 73.0 |
| Mycobacterial testing results | ||
| ZN smear positive | 34 | 12.1 |
| LED-FM smear positive | 16 | 5.0 |
| Xpert positive | 82 | 13.7 |
| Culture (MGIT and/or LJ) positive | 96 | 16.0 |
| BSI scale | UK outpatient mean/SD | Pretreatment score | Posttreatment score |
| PAR | M = 1.54/SD = 1.08∗ | 2.20 | 1.50 |
| ANX | M = 1.87/SD = 1.03∗ | 2.50 | 1.60 |
| Title | No of species | Authors | Reference |
| Sporadic study in India | 20 | Gosh A K, Maiti P K | [44] |
| Bhil of Rajasthan | 17 | Sharma S K | [43] |
| Bhil, Gamit, Kokna etc. of Maharastra | 15 | Patil S H | [42] |
| Chhattisgarh | 10 | Oudhia P | [41] |
| Chhattisgarh | 7 | Oudhia P | [40] |
| Kachch (Gujrat) | 34 | Gupta Leena et al. | [39] |
| Irular, Kurimba of Tamilnadu | 26 | Solvan A et al. | [38] |
| Kanikar, Paliyar of Taminadu | 11 | Ranjit Singh ASA | [37] |
| Mogya, Meena, Bawaria of Rajasthan | 15 | Mahawar, Jaroli | [33] |
| Saharia of Rajasthan | 15 | Mahawar, Jaroli | [36] |
| Monpas | 11 | Solanki GS and Chutia P | [11] |
| Mizoram | 56 | Lalramnghinglova | [12] |
| Chakhesang of Nagaland | 23 | Kakati and Doulo | [16] |
| Naga tribe of Nagaland | 26 | Jamir N S et al. | [14] |
| Dibrugarh (Assam) | 4 | Dilip Kalita | [15] |
| Ao tribe of Nagaland | 25 | Kakati L N et al. | [17] |
| Nyishi & Galo Tribe of Arunachal Pradesh | 36 | Chakravorty et al. | [13] |
| Biate Tribe, Dima Hasao, Assam | 34 | Present Study |
| Material | Total thermal conductivity (W/m-K) | LA (%) | TA (%) | ZA (%) | Optical (%) |
| Black phosphorene (zigzag) | 110 | 32 | 22 | 31 | 15 |
| Black phosphorene (armchair) | 36 | 28 | 33 | 12 | 27 |
| Blue phosphorene | 78 | 26 | 27 | 44 | 3 |
| MoS229 | 108 | 28 | 24 | 39 | 9 |
| Graphene30 | 3600 | 8 | 15 | 76 | 1 |
| Parameters | NGT | Pre-diabetes | p value |
| (n = 24) | (n = 26) | ||
| Anthropometric measures | |||
| Age (years) | 36 ± 2 | 39 ± 2 | 0.232 |
| Weight (Kg) | 69 ± 2 | 77 ± 3* | 0.026 |
| Body Mass Index (kg/m2) | 24.0 ± 0.6 | 26.5 ± 0.6* | 0.005 |
| Waist Circumference (cm) | 90.3 ± 1.7 | 98.3 ± 3.1* | 0.032 |
| Waist - Hip Ratio | 0.96 ± 0.01 | 0.98 ± 0.01 | 0.070 |
| Systolic Blood Pressure (mmHg) | 119.0 ± 1.8 | 122.8 ± 2.6 | 0.240 |
| Diastolic Blood Pressure (mmHg) | 76.3 ± 1.6 | 76.6 ± 1.9 | 0.992 |
| Biochemical parameters | |||
| OGTT | |||
| Fasting plasma glucose (mmol/l) | 5.0 ± 0.1 | 5.7 ± 0.1** | 0.0001 |
| 2Hr Post plasma glucose (mmol/l) | 5.6 ± 0.2 | 8.1 ± 0.3** | 0.0001 |
| Glycated Hemoglobin [HbA1c] (%) | 5.4 ± 0.1 | 5.8 ± 0.1* | 0.0013 |
| Fasting Insulin (pmol/l) | 49.8 ± 5 | 95.1 ± 10** | 0.0002 |
| 2Hr post Insulin (pmol/l) | 325.8 ± 49 | 780.0 ± 75** | 0.0001 |
| HOMA-IR | 1.9 ± 0.2 | 4.0 ± 0.4** | 0.0001 |
| Lipid profile | |||
| Total Cholesterol (mmol/l) | 4.6 ± 0.2 | 4.9 ± 0.2 | 0.376 |
| Serum Triglycerides (mmol/l) | 1.51 ± 0.2 | 1.9 ± 0.2 | 0.166 |
| HDL Cholesterol (mmol/l) | 1.0 ± 0.04 | 0.9 ± 0.04 | 0.459 |
| LDL Cholesterol (mmol/l) | 2.9 ± 0.1 | 3.0 ± 0.2 | 0.632 |
| VLDL Cholesterol (mmol/l) | 0.7 ± 0.1 | 0.9 ± 0.1 | 0.163 |
| Others | |||
| Serum Creatinine (μmol/l) | 79.6 ± 1.8 | 106.9 ± 27.1 | 0.364 |
| Hs-CRP (mg/l) | 2.5 ± 0.5 | 3.1 ± 0.5 | 0.341 |
| Microalbuminuria (μg/mg) | 5.2 ± 0.8 | 7.6 ± 1.5 | 0.344 |
| Strain | Fold-change (light:dark) |
| A0047 | 1.01 ± 0.38 |
| A0255 | 1.01 ± 0.25 |
| A0304 | 1.29 ± 0.089 |
| A0318 | 1.39 ± 0.34 |
| A0670 | 1.31 ± 0.20 |
| A0740 | 1.44 ± 0.54 |
| A1173 | 1.41 ± 0.34 |
| A1181 | 1.79 ± 0.39 |
| A1731 | 1.85 ± 0.79* |
| A1798 (rbc) | 1.16 ± 0.13 |
| A1929 | −1.09 ± 0.30 |
| A1930 | 1.11 ± 0.017 |
| A1961 | −1.33 ± 0.30 |
| A1962 | 1.03 ± 0.39 |
| A2062 | 1.46 ± 0.23 |
| A2127 | 1.21 ± 0.40 |
| A2165 | 1.45 ± 0.015* |
| A2210 | −1.34 ± 0.44 |
| A2520 | 2.02 ± 0.90 |
| A2531 | 1.35 ± 0.031 |
| A2579 | 1.14 ± 0.45 |
| A2595 | 1.45 ± 0.42 |
| A2596 | −1.05 ± 0.10 |
| A2663 | 1.13 ± 0.31 |
| A2813 | 2.28 ± 0.73 |
| Groups | Compared with groups | Mean difference (I-J) | Std. Error | Sig. | Lower bound | Upper bound |
| 1 | 2 | -.80000 | 2.49933 | .999 | −8.5278 | 6.9278 |
| 3 | 4.00000 | 2.49933 | .606 | −3.7278 | 11.7278 | |
| 4 | −7.40000 | 2.49933 | .066 | −15.1278 | .3278 | |
| 2 | 1 | 6.60000 | 2.49933 | .126 | −1.1278 | 14.3278 |
| 3 | 11.40000 | 2.49933 | .002 | 3.6722 | 19.1278 | |
| 4 | 7.40000 | 2.49933 | .066 | -.3278 | 15.1278 | |
| 3 | 1 | 2.60000 | 2.49933 | .899 | −5.1278 | 10.3278 |
| 2 | 3.40000 | 2.49933 | .749 | −4.3278 | 11.1278 | |
| 4 | −4.00000 | 2.49933 | .606 | −11.7278 | 3.7278 | |
| 4 | 1 | −6.60000 | 2.49933 | .126 | −14.3278 | 1.1278 |
| 2 | .80000 | 2.49933 | .999 | −6.9278 | 8.5278 | |
| 3 | 4.80000a | 2.49933 | .415 | −2.9278 | 12.5278 |
| Case 1 | Case 2 | Case 3 | |
| Age, years | 59 | 41 | 46 |
| Sex | Female | Female | Female |
| Initial stage | 1A | ND | 2A |
| Histology | IDC | IDC | ILC |
| Histological grade | 2 | 2 | 1 |
| Nuclear grade | 1 | 2 | 1 |
| Estrogen receptor (AS) | Negative (0) | Positive (8) | Positive (8) |
| Progesterone receptor (AS) | Negative (0) | Positive (8) | Positive (8) |
| HER2 status (IHC score) | Negative (0) | Negative (0) | Negative (1+) |
| PIK3CA hotspot mutation | H1047R | Negative | H1047R |
| TERT hotspot mutation | C250T | C228T | C228T |
| Relapse-free survival, months | 83 | 226 | 270 |
| Overall survival, months | 100 | 446 | 300 |
| Status | Alive | Alive | Alive |
| Women | Men | ||||
| Months from diagnosis | Services | IRR | 95% CI | IRR | 95% CI |
| −12 to −10 | GP | 1.07 | 1.06-1.09 | 1.13 | 1.12-1.15 |
| Diagnostics | 1.24 | 1.20-1.28 | 1.37 | 1.32-1.42 | |
| Hospital | 1.21 | 1.18-1.25 | 1.31 | 1.28-1.35 | |
| −9 to −7 | GP | 1.10 | 1.09-1.11 | 1.17 | 1.16-1.19 |
| Diagnostics | 1.32 | 1.28-1.36 | 1.51 | 1.46-1.56 | |
| Hospital | 1.24 | 1.21-1.28 | 1.38 | 1.35-1.42 | |
| −6 to −4 | GP | 1.20 | 1.19-1.21 | 1.34 | 1.33-1.36 |
| Diagnostics | 1.66 | 1.61-1.71 | 2.08 | 2.02-2.15 | |
| Hospital | 1.39 | 1.35-1.43 | 1.64 | 1.60-1.68 | |
| −3 to −1 | GP | 1.97 | 1.96-1.99 | 2.38 | 2.36-2.39 |
| Diagnostics | 9.61 | 9.47-9.76 | 10.86 | 10.69-11.03 | |
| Hospital | 5.27 | 5.20-5.34 | 5.16 | 5.09-5.23 | |
| 1 to 3 | GP | 2.12 | 2.10-2.14 | 2.54 | 2.51-2.56 |
| Diagnostics | 24.49 | 24.11-24.87 | 29.20 | 28.73-29.67 | |
| Hospital | 19.91 | 19.68-20.14 | 14.91 | 14.73-15.10 | |
| 4 to 6 | GP | 1.67 | 1.65-1.69 | 2.05 | 2.02-2.07 |
| Diagnostics | 6.25 | 6.12-6.38 | 8.46 | 8.29-8.64 | |
| Hospital | 15.11 | 14.89-15.34 | 12.08 | 11.90-12.27 | |
| 7 to 9 | GP | 1.50 | 1.48-1.52 | 1.84 | 1.81-1.86 |
| Diagnostics | 4.88 | 4.77-4.99 | 6.42 | 6.27-6.57 | |
| Hospital | 9.98 | 9.80-10.16 | 7.86 | 7.72-8.00 | |
| 10 to 12 | GP | 1.43 | 1.41-1.45 | 1.73 | 1.70-1.75 |
| Diagnostics | 4.37 | 4.27-4.48 | 5.49 | 5.35-5.63 | |
| Hospital | 5.29 | 5.19-5.40 | 5.82 | 5.71-5.94 |
| (A) | Healthy controls (n = 19) | ARMS (n = 19) | First-episode schizophrenia (n = 19) | Chronic schizophrenia (n = 19) | Group comparison | |
| Male/female | 9/10 | 9/10 | 9/10 | 9/10 | n.s. | |
| Age (years) | 19.4 (2.5) | 19.4 (3.6) | 22.8 (5.2) | 22.9 (3.6) | F(3,74) = 4.94, p = 0.004 | |
| Age of onset (years) | – | – | 22.2 (5.2) | 17.9 (3.9) | p = 0.007 | |
| Duration of illness (years) | – | – | 0.7 (0.6) | 5.0 (2.3) | – | |
| Drug dosea | – | 0.1 (0.4) | 1.7 (2.0) | 3.7 (4.2) | F(2,56) = 8.54, p = 0.001 | |
| SAPS | – | 17.3 (7.4) | 27.0 (16.9) | 19.2 (18.0) | F(2,56) = 2.29, p = 0.11 | |
| SANS | – | 60.8 (24.3) | 60.6 (27.2) | 53.3 (22.9) | F(2,56) = 0.52, p = 0.59 | |
| (B) | Healthy controls (n = 19) | ARMS (n = 19) | First-episode schizophrenia (n = 19) | Chronic schizophrenia (n = 19) | Analyze of variance (df = 3,75), group effect | |
| F | p | |||||
| dMMN amplitude (μV) | ||||||
| F3 | −6.9 (1.7) | −6.2 (2.0) | −5.0 (1.8) | −4.6 (1.0) | 7.505 | <0.001** |
| F4 | −7.5 (1.4) | −6.5 (2.2) | −5.2 (2.1) | −4.6 (2.0) | 7.767 | <0.001** |
| Fz | −7.4 (1.4) | −6.5 (2.0) | −5.4 (1.9) | −4.8 (1.5) | 8.322 | <0.001** |
| Cz | −6.0 (1.4) | −5.6 (2.1) | −4.8 (1.9) | −3.7 (0.9) | 6.831 | <0.001** |
| Pz | −4.2 (1.4) | −4.5 (4.0) | −3.3 (1.4) | −2.2 (0.9) | 6.240 | 0.001** |
| dMMN latency (ms) | ||||||
| F3 | 167.3 (15.1) | 172.1 (17.5) | 173.0 (23.0) | 177.8 (30.7) | 0.702 | 0.55 |
| F4 | 169.1 (15.4) | 175.8 (18.3) | 172.5 (19.7) | 176.6 (24.0) | 0.404 | 0.75 |
| Fz | 172.2 (15.6) | 177.3 (12.6) | 173.0 (19.1) | 176.8 (25.6) | 0.364 | 0.77 |
| Cz | 168.4 (14.8) | 182.3 (18.7) | 174.6 (16.7) | 177.6 (26.2) | 1.675 | 0.18 |
| Pz | 173.0 (15.8) | 188.6 (24.4) | 178.3 (17.4) | 174.8 (30.7) | 1.753 | 0.16 |
| P3a amplitude (μV) | ||||||
| F3 | 1.6 (1.8) | 1.1 (1.4) | 1.3 (2.2) | 1.5 (1.3) | 0.277 | 0.84 |
| F4 | 1.4 (2.3) | 1.2 (1.8) | 1.6 (2.1) | 1.4 (1.4) | 0.110 | 0.95 |
| Fz | 2.0 (2.3) | 1.7 (1.5) | 1.7 (2.2) | 1.7 (1.1) | 0.179 | 0.91 |
| Cz | 2.4 (2.4) | 2.1 (1.6) | 2.5 (2.1) | 2.1 (1.4) | 0.209 | 0.89 |
| Pz | 2.0 (2.2) | 1.8 (1.4) | 2.3 (1.8) | 1.8 (1.3) | 0.408 | 0.74 |
| P3a latency (ms) | ||||||
| F3 | 255.6 (23.5) | 265.2 (25.0) | 264.2 (28.3) | 262.8 (23.0) | 0.395 | 0.75 |
| F4 | 256.9 (20.2) | 269.7 (28.0) | 262.9 (31.1) | 255.2 (30.8) | 0.755 | 0.52 |
| Fz | 254.6 (21.5) | 268.7 (28.8) | 261.8 (30.9) | 262.3 (22.3) | 0.314 | 0.81 |
| Cz | 255.1 (21.7) | 266.0 (25.9) | 254.8 (28.7) | 262.2 (22.9) | 0.509 | 0.67 |
| Pz | 255.7 (19.8) | 272.2 (27.2) | 254.7 (27.6) | 261.4 (19.7) | 0.359 | 0.78 |
| RON amplitude (μV) | ||||||
| F3 | −4.4 (1.7) | −4.1 (1.7) | −3.5 (1.3) | −3.3 (1.3) | 2.320 | 0.08 |
| F4 | −5.2 (1.8) | −4.2 (1.5) | −3.6 (1.7) | −3.4 (1.6) | 4.191 | 0.009** |
| Fz | −5.1 (1.6) | −4.2 (1.8) | −3.9 (1.4) | −3.4 (1.7) | 3.143 | 0.03* |
| Cz | −4.3 (1.9) | −3.8 (2.1) | −3.6 (1.6) | −3.2 (1.6) | 1.143 | 0.33 |
| Pz | −3.1 (1.8) | −2.7 (1.7) | −2.5 (1.5) | −2.6 (1.6) | 0.391 | 0.76 |
| RON latency (ms) | ||||||
| F3 | 396.3 (51.8) | 380.7 (49.4) | 395.0 (42.7) | 389.0 (52.6) | 0.395 | 0.75 |
| F4 | 392.7 (53.9) | 404.0 (54.1) | 409.1 (53.1) | 385.4 (53.8) | 0.755 | 0.52 |
| Fz | 396.2 (50.2) | 397.2 (46.8) | 409.3 (40.9) | 397.7 (53.3) | 0.314 | 0.81 |
| Cz | 401.2 (39.0) | 398.3 (44.4) | 412.5 (40.9) | 397.0 (47.4) | 0.509 | 0.67 |
| Pz | 409.5 (48.2) | 401.7 (45.7) | 411.7 (40.7) | 397.4 (58.2) | 0.359 | 0.78 |
| Code | Value | % Age | Description |
| J | 165 | 2.51 | Translation, ribosomal structure and biogenesis |
| A | 0 | 0.00 | RNA processing and modification |
| K | 131 | 1.99 | Transcription |
| L | 620 | 9.44 | Replication, recombination and repair |
| B | 1 | 0.02 | Chromatin structure and dynamics |
| D | 47 | 0.72 | Cell cycle control, Cell division, chromosome partitioning |
| V | 67 | 1.02 | Defense mechanisms |
| T | 138 | 2.10 | Signal transduction mechanisms |
| M | 203 | 3.09 | Cell wall/membrane biogenesis |
| N | 30 | 0.46 | Cell motility |
| U | 52 | 0.79 | Intracellular trafficking and secretion |
| O | 152 | 2.31 | Posttranslational modification, protein turnover, chaperones |
| C | 185 | 2.82 | Energy production and conversion |
| G | 131 | 1.99 | Carbohydrate transport and metabolism |
| E | 215 | 3.27 | Amino acid transport and metabolism |
| F | 62 | 0.94 | Nucleotide transport and metabolism |
| H | 146 | 2.22 | Coenzyme transport and metabolism |
| I | 65 | 0.99 | Lipid transport and metabolism |
| P | 188 | 2.86 | Inorganic ion transport and metabolism |
| Q | 126 | 1.92 | Secondary metabolites biosynthesis, transport and catabolism |
| R | 535 | 8.14 | General function prediction only |
| S | 483 | 7.35 | Function unknown |
| - | 2,826 | 43.02 | Not in COGs |
| Characteristic | rs3736228 | p-value | rs41494349 | p-value | rs2306862 | p-value | |||
| CC | CT | AA | AG+GG | CC | CT+TT | ||||
| Age (years) | 58 (45–73) | 55 (45–75) | 0.002 | 58 (45–75) | 57 (45–72) | 0.989 | 58 (45–73) | 56 (45–75) | 0.224 |
| N | 210 | 67 | 245 | 30 | 193 | 68 | |||
| BMI (kg/m2) | 22.77 (15.46–39.54) | 22.88 (18.75–33.91) | 0.804 | 22.77 (15.46–39.54) | 23.14 (19.34–30.47) | 0.878 | 22.55 (15.46–39.54) | 23.06 (18.44–33.91) | 0.350 |
| N | 210 | 67 | 245 | 30 | 193 | 68 | |||
| Lumbar spine BMD (g/cm2) | 1.018 (0.700–1.564) | 0.983 (0.778–1.555) | 0.584 | 1.013 (0.700–1.564) | 1.003 (0.778–1.353) | 0.388 | 1.013 (0.700–1.564) | 0.993 (0.778–1.555) | 0.787 |
| N | 160 | 45 | 183 | 22 | 147 | 46 | |||
| Femoral neck BMD (g/cm2) | 0.787 (0.434–1.204) | 0.789 (0.612–1.224) | 0.728 | 0.785 (0.434–1.204) | 0.831 (0.562–1.224) | 0.154 | 0.785 (0.434–1.141) | 0.788 (0.548–1.224) | 0.905 |
| N | 178 | 55 | 210 | 23 | 165 | 56 | |||
| Total radial BMD (g/cm2) | 0.469 (0.265–0.961) | 0.500 (0.262–0.623) | 0.011 | 0.475 (0.262–0.961) | 0.475 (0.353–0.584) | 0.702 | 0.471 (0.265–0.961) | 0.485 (0.262–0.623) | 0.191 |
| N | 210 | 67 | 245 | 30 | 193 | 68 | |||
| Radial 33 BMD (g/cm2) | 0.614 (0.315–0.785) | 0.657 (0.350–0.818) | 0.001 | 0.623 (0.315–0.818) | 0.634 (0.447–0.722) | 0.769 | 0.613 (0.315–0.785) | 0.649 (0.350–0.818) | 0.015 |
| N | 210 | 67 | 245 | 30 | 193 | 68 | |||
| Total hip BMD (g/cm2) | 0.870 (0.229–1.281) | 0.875 (0.636–1.322) | 0.565 | 0.870 (0.229–1.322) | 0.909 (0.600–1.252) | 0.625 | 0.869 (0.229–1.281) | 0.876 (0.636–1.322) | 0.636 |
| N | 178 | 55 | 210 | 23 | 165 | 56 |
| Period | Before education | First period of education | Second period of education | Total | p-value |
| Patients | 276,541 | 78,052 | 56,950 | 411,543 | |
| Age (years) | 67.6 ± 17.3 | 68.5 ± 17.3 | 68.5 ± 17.3 | 67.9 ± 17.3 | < 0.0001 |
| Gender male (%) | 139,350 (50.3) | 39,063 (50.0) | 28,376 (49.8) | 206,789 (50.2) | 0.0229 |
| Charlson index | 4.7 ± 1.8 | 4.8 ± 1.9 | 4.9 ± 1.9 | 4.7 ± 1.8 | < 0.0001 |
| Urgent admission (%) | 208,660 (75.4) | 59,088 (75.7) | 43,241 (75.9) | 310,989 (75.5) | 0.0345 |
| LOS (days) | 11.0 ± 14.2 | 11.2 ± 13.8 | 10.6 ± 12.0 | 11.0 ± 13.8 | < 0.0001 |
| Hospital deaths (%) | 17,270 (6.2) | 5,237 (6.7) | 3,732 (6.6) | 26,239 (6.4) | < 0.0001 |
| AA | Codon | N | RSCU | AA | Codon | N | RSCU |
| Ala | GCU | 10137 | 0.61 | Ile | AUU | 4320 | 0.60 |
| GCC | 24014 | 1.45 | AUC | 15296 | 2.15 | ||
| GCA | 12455 | 0.75 | AUA | 1764 | 0.25 | ||
| GCG | 19668 | 1.19 | Thr | ACU | 3820 | 0.55 | |
| Gly | GGU | 6589 | 0.52 | ACC | 9325 | 1.35 | |
| GGC | 28815 | 2.28 | ACA | 4071 | 0.59 | ||
| GGA | 5724 | 0.45 | ACG | 10460 | 1.51 | ||
| GGG | 9391 | 0.75 | Asn | AAU | 3336 | 0.44 | |
| Val | GUU | 4886 | 0.47 | AAC | 11992 | 1.56 | |
| GUC | 15337 | 1.46 | Lys | AAA | 3143 | 0.20 | |
| GUA | 1760 | 0.17 | AAG | 28292 | 1.80 | ||
| GUG | 19933 | 1.90 | Tyr | UAU | 2544 | 0.38 | |
| Phe | UUU | 4949 | 0.46 | UAC | 10814 | 1.62 | |
| UUC | 16637 | 1.54 | Cys | UGU | 1939 | 0.32 | |
| Leu | UUA | 607 | 0.06 | UGC | 10191 | 1.68 | |
| UUG | 9058 | 0.95 | Asp | GAU | 8318 | 0.50 | |
| CUU | 6427 | 0.67 | GAC | 24990 | 1.50 | ||
| CUC | 17960 | 1.88 | Glu | GAA | 5918 | 0.27 | |
| CUA | 1143 | 0.12 | GAG | 37809 | 1.73 | ||
| CUG | 22200 | 2.32 | His | CAU | 3460 | 0.49 | |
| Pro | CCU | 5738 | 0.70 | CAC | 10620 | 1.51 | |
| CCC | 10406 | 1.26 | Gln | CAA | 3321 | 0.27 | |
| CCA | 6064 | 0.74 | CAG | 21528 | 1.73 | ||
| CCG | 10677 | 1.30 | Arg | CGU | 3247 | 0.48 | |
| Ser | UCU | 3832 | 0.59 | CGC | 13515 | 1.98 | |
| UCC | 9749 | 1.49 | CGA | 3447 | 0.51 | ||
| UCA | 3167 | 0.49 | CGG | 9678 | 1.42 | ||
| UCG | 7423 | 1.14 | AGA | 2479 | 0.36 | ||
| AGU | 2706 | 0.42 | AGG | 8501 | 1.25 | ||
| AGC | 12156 | 1.87 |
| Variable | EVAM (n = 85) | OVAM (n = 439) | P value |
| Demographics | |||
| Age (years, mean ± SD) | 5.6 ± 3.0 | 5.3 ± 3.1 | NS |
| Sex [no. (%)] | |||
| Male | 50 (58.8) | 250 (56.9) | NS |
| Female | 35 (41.2) | 189 (43.1) | |
| Clinical symptoms [no. (%)] | |||
| Fever | 67 (78.8.) | 388 (88.4) | 0.017 |
| Headache | 60 (70.6) | 241 (54.9) | 0.007 |
| Neck stiffness | 46 (54.1) | 254 (57.9) | NS |
| Vomitting | 62 (72.9) | 284 (64.7) | NS |
| Convulsion | 5 (5.8) | 73 (16.6) | 0.011 |
| Lethargy | 9 (10.6) | 73 (16.6) | NS |
| Diarrhea | 3 (3.5) | 9 (2.0) | NS |
| Laboratory findings [no. (%)] | |||
| EEG abnormal | 50 (58.8) | 261 (59.5) | NS |
| Skull CT abnormal | 24 (28.2) | 102 (23.2) | NS |
| CSF pleocytosis | 36 (42.4) | 199 (45.3) | NS |
| Elevated CSF protein | 25 (29.4) | 140 (31.9) | NS |
| outcome | PHFWs | CHWs | Total | P-value |
| Number (%) | Number (%) | Number (%) | ||
| Child recovered | <0.001* | |||
| Yes | 254 (71.7) | 346 (85.2) | 600 (78.9) | |
| No | 100 (28.2) | 60 (14.8) | 160 (21.0) | |
| Total | 354 | 406 | 760 | |
| Required extra treatment | 0.362 | |||
| Yes | 25 (7.2) | 32 (9.1) | 57 (8.1) | |
| No | 322 (92.8) | 320 (90.9) | 642 (91.8) | |
| Total | 347 | 352 | 699 | |
| Child died | 0 (0) | 0 (0) | 0 | N/A |
| Had complications | 0.302 | |||
| Yes | 6 (1.7) | 3 (0.9) | 9 (1.3) | |
| No | 338 (98.3) | 347 (99.1) | 685 (98.7) | |
| Total | 344 | 350 | 694 | |
| Still on treatment | 0.184 | |||
| Yes | 30 (7.5) | 22 (5.2) | 52 (6.4) | |
| No | 369 (92.5) | 397 (94.7) | 766 (93.6) | |
| Total | 399 | 419 | 818 | |
| Behavioural change following treatment | ||||
| Sleeping under a net | ||||
| Yes | 265 (66.7) | 330 (79.3) | 595 (73.2) | <0.001* |
| No | 132 (33.2) | 86 (20.6) | 218 (26.8) | |
| Total | 397 | 416 | 813 | |
| Drinking clean water | ||||
| Yes | 242 (60.8) | 310 (74.7) | 552 (67.9) | <0.001* |
| No | 156 (39.2) | 105 (25.3) | 261 (32.1) | |
| Total | 398 | 415 | 813 | |
| Feeding the sick child | ||||
| Yes | 266 (67.0) | 330 (79.1) | 596 (73.2) | <0.001* |
| No | 131 (33.0) | 87 (20.9) | 218 ( 26.8) | |
| Total | 397 | 417 | 814 |
| Mailed questionnaire | Telephone interview | |||
| % | N | % | N | |
| Gender | ||||
| Men | 50.5 | 1319 | 49.0 | 681 |
| Women | 49.5 | 1292 | 51.0 | 708 |
| Age | ||||
| 20 – 30 | 26.7 | 698 | 25.3 | 352 |
| 31 – 40 | 25.0 | 653 | 25.0 | 347 |
| 41 – 50 | 24.9 | 649 | 25.3 | 351 |
| 51 – 60 | 23.4 | 611 | 24.4 | 339 |
| Total | 100 | 2611 | 100 | 1389 |
| Type of ringworm | ||||
| Dermatophytes | Tinea capitisn (%) | Tinea pedisn (%) | Tinea corporisn (%) | Totaln (%) |
| E. floccosum | 0 (0.0) | 1 (9.1) | 0 (0.0) | 1 (2.4) |
| M. audouinii | 2 (6.7) | 0 (0.0) | 0 (0.0) | 2 (4.8) |
| M. canis | 14 (46.7) | 0 (0.0) | 1 (100.0) | 15 (35.7) |
| T. mentagrophytes | 4 (13.3) | 4 (36.4) | 0 (0.0) | 8 (19.0) |
| T. rubrum | 3 (10.0) | 5 (45.5) | 0 (0.0) | 8 (19.0) |
| T. schoenleinii | 1 (3.3) | 1 (9.1) | 0 (0.0) | 2 (4.8) |
| T. violaceum | 6 (20.0) | 0 (0.0) | 0 (0.0) | 6 (14.3) |
| Total | 30 (100.0) | 11 (100.0) | 1 (100.0) | 42 |
| SSRs | Probes used in study | References | |
| Mitotic chromosomes | Polytene chromosomes | ||
| A | A20 | (21, 40) | |
| C | C20 | (40) | |
| AC; AG | (AC)10; (AG)10 | (27) | (27, 40) |
| AAC; AAG; AAT, AAC; AGC; ACT; AGC; AGG; ATC; CCG | (AAC)5; (AAG)5; (AAT)5; (ACC)5; (ACG)5; (ACT)5; (AGC)5; (AGG)5; (ATC)5; (CCG)5 | ||
| GACA | (GACA)5 | (21) | |
| GATA | (GATA)5 | (31) | (21) |
| AAGAC; AAGAG; AATAC; AATAT | (AAGAC)3; (AAGAG)3; (AATAC)3; (AATAT)3 | (10) | |
| AACAC | (AACAC)3; | (11) | (11) |
| N = 14 (%) | ||
| Clinical characteristics | ||
| Age (SAH), years (mean, SD) | 46.1 ± 12Range: 20–63 | |
| Age (healthy controls), years (mean, SD) | 47.1 ± 12Range: 20–64 | |
| Gender (SAH), female | 8 (57) | |
| Gender (healthy controls), female | 8 (57) | |
| Admission H&H grade | 1 | 9 (64) |
| 2 | 4 (29) | |
| 3 | 1 (7) | |
| Loss of consciousness | 0 (0) | |
| Admission APACHE II score | 4 (2–5) | |
| Admission radiological characteristics | ||
| mFisher scale | 0 | 1 (7) |
| 1 | 1 (7) | |
| 2 | 1 (7) | |
| 3 | 6 (43) | |
| 4 | 5 (36) | |
| SAH sum score | 13Range: 10–15 | |
| IVH sum score | 0 (0–2) | |
| Aneurysm location AcomA = anterior communicating artery | 5 (36) | |
| No aneurysm detected | 9 (64) | |
| Aneurysm size above 10 mm | 0 (0) | |
| Generalized cerebral edema | 0 (0) | |
| Intracerebral hematoma | 0 (0) | |
| Surgical procedures | ||
| Hydrocephalus requiring EVD/Shunt | 0 (0) | |
| Coiling | 5 (36) | |
| Clipping | 0 (0) | |
| No aneurysm | 9 (64) | |
| Hemicraniectomy | 0 (0) | |
| Complications | ||
| Pneumonia | 0 (0) | |
| Delayed cerebral infarction | 0 (0) | |
| Anemia requiring transfusion | 0 (0) | |
| Aneurysm rebleeding | 0 (0) | |
| Hyperosmolar therapy | 0 (0) | |
| Outcome characteristics | ||
| Length of hospital stay, days | 19.5Range: 17–21 | |
| Discharge mRS | 0 | 9 (64) |
| 1 | 5 (36) | |
| 3‐month mRS | 0 | 9 (64) |
| 1 | 5 (36) | |
| 12‐months mRS | 0 | 11 (79) |
| 1 | 3 (21) |
| Model 1 | Model 2 | |||||||
| Variable | B | SE | β | t | B | SE | β | t |
| Gender | –0.408 | 0.419 | –0.084 | –0.974 | ||||
| Age | 0.090 | 0.075 | 0.106 | 1.204 | ||||
| Self-esteem | –0.611 | 0.195 | –0.257 | –3.14∗∗ | –0.680 | 0.215 | –0.283 | –3.16∗∗ |
| Condition (1 = materialism, –1 = control) | 0.498 | 0.159 | 0.257 | 3.14∗∗ | 0.509 | 0.160 | 0.261 | 3.19∗∗ |
| Self-esteem × Condition | 0.487 | 0.195 | 1.265 | 2.497∗ | 0.412 | 0.202 | 1.070 | 2.043∗ |
| R2 = 0.176 F(3,123) = 8.780∗∗ | R2 = 0.196 F(5,120) = 5.862∗∗ |
| Location | Tissue | Date of collection | Time period reflected | N | N males | N females |
| Newfoundland | Claws | April 2016 | Winter | 24 | 8 | 16 |
| Whole blood | December 2013 to January 2014 | Winter | 35 | 30 | 5 | |
| Nuuk, Greenland | Claws | April 2014 | Winter | 33 | 6 | 29 |
| Whole blood | April 2014 | Late winter | 34 | 6 | 29 | |
| East Bay Island | Claws | June to July 2014 | Winter | 109 | 0 | 109 |
| Red blood cells | June to July 2014 | Spring migration | 108 | 0 | 108 | |
| Claws | June to July 2015 | Winter | 115 | 43 | 72 | |
| Red blood cells | June to July 2015 | Spring migration | 125 | 51 | 74 |
| Suggestions from COECSA partners | Suggestions from United Kingdom partners |
| Program planning and design• There is need for continuous dialog and joint planning• COECSA to drive the process by demonstrating both demand and ownership• More opportunities for visits to the United Kingdom to “see how things are done”• LINK to facilitate setting up of more VISION 2020 twinning links in the region• LINK to provide more scope for interaction between the institutions in the ECSA region• Expand the scope of collaboration to include research, subspecialty programs, mentoring and instrumentsProgram implementation• Build capacity of editors of the scientific journal• Involve middle-level eye care cadres in the LINK• Training of examiners should be more intensive than just 1 day before the exams, “perhaps even organized in modules”• Make the partnership equal and mutual• Strengthen leadership of the COECSA and the LINKEvaluation• Gather evidence to demonstrate impact of the LINK• Strengthen monitoring and evaluation, and source funding for it | Program planning and design• Build on the successes of the partnership in future planningProgram implementation• COECSA needs to build develop staff to take lead in all the activities• Ensure the right people are on board for LINK activities• Encourage continuity for lead roles or smooth handover/transition when new persons take up roles• Aim to make each activity effective and evaluate effectiveness• Ensure United Kingdom facilitators have clarity on their roles• Improve frequency and regularity of communicationEvaluation• COECSA to strengthen reporting on LINK activities• Constantly evaluate if expectations of COECSA are being met |
| BMI (kg/m2) | ||||||
| Overall | Underweight | Normal | Overweight | Obese I | Obese II/III | |
| Males (n = 55,303) | ||||||
| Diabetes mellitus | 4.27 | 1.74 (106) | 2.93 (100) | 4.85 (144) | 9.33 (168) | 14.01 (155) |
| Hypertension | 12.44 | 5.06 (107) | 7.82 (100) | 15.90 (141) | 23.57 (159) | 29.66 (141) |
| Varices | 4.15 | 2.27 (89) | 3.41 (100) | 4.67 (128) | 6.05 (129) | 8.40 (109) |
| Respiratory diseases | 5.75 | 8.45 (103) | 4.66 (100) | 6.32 (135) | 8.84 (153) | 11.75 (137) |
| Bronchial asthma | 3.25 | 4.89 (123) | 2.92 (100) | 3.26 (115) | 4.65 (138) | 7.68 (122) |
| Thyroid diseases | 1.01 | 0.83 (87) | 0.74 (100) | 1.18 (128) | 1.76 (132) | 1.46 (132) |
| Osteoarthritis | 16.41 | 14.83 (112) | 12.10 (100) | 19.83 (140) | 25.64 (156) | 27.25 (124) |
| Lower back pain and sciatica | 8.20 | 5.66 (114) | 6.53 (100) | 9.71 (124) | 11.06 (133) | 12.09 (157) |
| Osteoporosis | 1.22 | 2.39 (141) | 1.09 (100) | 1.26 (145) | 1.55 (130) | 2.31 (198) |
| Cancer | 0.97 | 3.29 (92) | 0.85 (100) | 0.98 (145) | 1.36 (177) | 1.44 (119) |
| Myocardial infarction | 1.87 | 1.82 (99) | 1.17 (100) | 2.30 (148) | 3.57 (172) | 7.30 (191) |
| Angina pectoris | 1.05 | 0.52 (52) | 0.71 (100) | 1.37 (146) | 1.47 (169) | 2.18 (169) |
| Thrombosis | 1.05 | 1.69 (165) | 0.79 (100) | 1.14 (142) | 1.93 (165) | 3.19 (127) |
| MI – Angina pectoris – Thrombosis1 | 3.41 | 3.56 (112) | 2.27 (100) | 4.16 (146) | 6.05 (170) | 10.62 (163) |
| Females (n = 59,716) | ||||||
| Diabetes mellitus | 4.76 | 0.92 (73) | 2.78 (100) | 7.57 (173) | 13.05 (171) | 19.06 (171) |
| Hypertension | 16.32 | 6.68 (73) | 10.60 (100) | 26.27 (161) | 36.39 (169) | 37.98 (151) |
| Varices | 12.32 | 5.19 (72) | 9.37 (100) | 17.68 (135) | 23.21 (149) | 26.68 (141) |
| Respiratory diseases | 4.60 | 3.12 (86) | 3.40 (100) | 6.33 (153) | 9.35 (142) | 10.39 (144) |
| Bronchial asthma | 3.31 | 2.64 (93) | 2.69 (100) | 4.23 (129) | 5.60 (119) | 6.10 (124) |
| Thyroid diseases | 5.47 | 3.27 (72) | 4.76 (100) | 6.77 (117) | 8.40 (115) | 8.91 (105) |
| Osteoarthritis | 27.91 | 13.40 (70) | 21.77 (100) | 40.24 (153) | 47.59 (160) | 50.06 (162) |
| Lower back pain and sciatica | 10.71 | 4.51 (77) | 8.88 (100) | 14.60 (127) | 16.86 (131) | 20.25 (127) |
| Osteoporosis | 9.93 | 5.81 (69) | 7.90 (100) | 14.10 (172) | 15.82 (187) | 15.64 (173) |
| Cancer | 1.29 | 0.82 (63) | 1.06 (100) | 1.72 (156) | 1.90 (170) | 2.62 (177) |
| Myocardial infarction | 0.91 | 0.63 (77) | 0.67 (100) | 1.32 (175) | 1.79 (181) | 1.62 (162) |
| Angina pectoris | 1.12 | 0.79 (79) | 0.79 (100) | 1.63 (173) | 2.19 (184) | 2.76 (166) |
| Thrombosis | 1.06 | 0.72 (97) | 0.76 (100) | 1.50 (168) | 1.93 (188) | 3.83 (129) |
| MI – Angina pectoris – Thrombosis1 | 2.73 | 1.87 (82) | 1.98 (100) | 3.90 (171) | 5.12 (186) | 7.40 (145) |
| STAV-AB xenograft | STAV-FCS xenograft | Localization | |
| MESOTHELIAL AND EPITHELIAL MARKERS | |||
| Calretinin | ++ | ++ | Cytoplasm and nucleus |
| EMA | + | +(+) | Cell membrane |
| E-cadherin | + (Focal) | + | Cell membrane |
| CK-HMW | ++ | ++ | Cytoplasm |
| Cytokeratin 7 | + | ++ | Cytoplasm |
| Cytokeratin 8 | − | − | Cytoplasm |
| Cam 5.2 | +++ | ++ | Cell membrane and cytoplasm |
| Syndecan-1 | + | + | Cell membrane |
| MNF-116 | +++ | +++ | Cell membrane and cytoplasm |
| DIFFERENTIATION-RELATED MARKERS | |||
| TrxR1 | ++ | +++ | Cytoplasm and nucleus |
| Integrin α5 | + | + | Cytoplasm |
| HSP-47 | +++ | +++ | Cell membrane and cytoplasm |
| Annexin-II | ++ | ++ | Cell membrane |
| MESENCHYMAL MARKERS | |||
| Vimentin | ++ | ++ | Cytoplasm |
| SM actin | +(+) | + | Cytoplasm |
| Syndecan-2 | ++ | ++ | Cytoplasm |
| PROLIFERATION MARKER | |||
| Mib-1 | >80% | 40% | Nucleus |
| Poorest | Poorer | Middle | Richer | Richest | All | ||
| OOP | Non-chronic | 2287.30 | 2550.10 | 2854.72 | 3057.06 | 4013.26 | 2952 |
| Hypertension | 2378.66 | 3352.36 | 2980.83 | 3096.64 | 4856.84 | 3330 | |
| Hypertension and else | 3019.58 | 3420.42 | 4664.66 | 5920.34 | 6547.86 | 4709 | |
| p-value | 0.031 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | |
| CTP | Non-chronic | 5471.32 | 9215.98 | 13688.45 | 20350.67 | 38227.57 | 17380 |
| Hypertension | 4635.55 | 8450.70 | 11313.45 | 17624.12 | 37316.36 | 15835 | |
| Hypertension and else | 4915.02 | 8260.34 | 13035.33 | 19446.03 | 36329.90 | 16361 | |
| p-value | 0.905 | 0.187 | 0.004 | 0.006 | 0.548 | 0.004 | |
| CHE (%) | Non-chronic | 35.37 | 15.75 | 8.30 | 4.39 | 2.76 | 13.33 |
| Hypertension | 57.14 | 32.41 | 16.59 | 7.37 | 3.72 | 23.48 | |
| Hypertension and else | 71.19 | 38.66 | 30.17 | 18.64 | 11.11 | 34.01 | |
| p-value | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
| Antibody | Supplier | Western dilution |
| β-Actin | Sigma Aldrich | 1 in 3000 |
| CDK6 | Santa Cruz | 1 in 200 |
| γH2AX (Ser139) | Cell Signaling | 1 in 1000 |
| Lamin a/c | Santa Cruz | 1 in 500 |
| MEK2 | BD Biosciences | 1 in 3000 |
| PP1α | Bethyl Laboratory | 1 in 1000 |
| PP1β | Bethyl Laboratory | 1 in 1000 |
| PP1γ | Santa Cruz | 1 in 200 |
| p53 | Oncogene | 1 in 500 |
| pATM (Ser1981) | Epitomics | 1 in 500 |
| p-p53 (Ser15) | Cell Signaling | 1 in 500 |
| Rad21 (SCC1) | abcam | 1 in 1000 |
| Rb | Santa Cruz | 1 in 200 |
| p73 | Santa Cruz | 1 in 100 |
| p63 | abcam | 1 in 1000 |
| p63(TA) | bioLegend | 1 in 1000 |
| three to five days | 17-19 days | |||||||
| Net | Family No. | Species* | N | No. Dead | % Mortality | N | No. Dead | % Mortality |
| LLIN#1 | 1 | S | 10 | 0 | 0.0 | 10 | 0 | 0.0 |
| 7 | S | 10 | 0 | 0.0 | 11 | 4 | 36.4 | |
| 15 | An. arabiensis | 9 | 0 | 0.0 | 9 | 3 | 33.3 | |
| 39 | M | 11 | 0 | 0.0 | 10 | 0 | 0.0 | |
| 44 | M | 10 | 0 | 0.0 | 11 | 1 | 9.1 | |
| 104 | S | 10 | 0 | 0.0 | 10 | 0 | 0.0 | |
| 149 | An. arabiensis | 10 | 0 | 0.0 | 9 | 5 | 55.6 | |
| 208 | M | 10 | 0 | 0.0 | 10 | 0 | 0.0 | |
| 225 | M | 10 | 0 | 0.0 | 10 | 3 | 30.0 | |
| 250 | M | 10 | 0 | 0.0 | 9 | 4 | 44.4 | |
| 263 | M | 10 | 0 | 0.0 | 10 | 5 | 50.0 | |
| 279 | M | 10 | 0 | 0.0 | 13 | 5 | 38.5 | |
| LLIN#2 | 803 | M | 11 | 0 | 0.0 | 11 | 4 | 36.4 |
| 815 | An. arabiensis | 11 | 4 | 36.4 | 11 | 11 | 100.0 | |
| 843 | M | 9 | 5 | 55.6 | 10 | 5 | 50.0 | |
| 858 | M | 10 | 3 | 30.0 | 10 | 1 | 10.0 | |
| 875 | An. arabiensis | 10 | 8 | 80.0 | 13 | 13 | 100.0 | |
| 883 | An. arabiensis | 8 | 7 | 87.5 | 15 | 13 | 86.7 | |
| 1062 | S | 9 | 1 | 11.1 | 15 | 0 | 0.0 | |
| LLIN#3 | 1156 | S | 11 | 2 | 18.2 | 7 | 0 | 0.0 |
| 1157 | S | 9 | 0 | 0.0 | 7 | 0 | 0.0 | |
| 1165 | S | 9 | 1 | 11.1 | 7 | 1 | 14.3 | |
| 1196 | S | 11 | 0 | 0.0 | 5 | 0 | 0.0 | |
| 1131 | S | 10 | 0 | 0.0 | 10 | 1 | 10.0 | |
| 1135 | S | 9 | 0 | 0.0 | 8 | 0 | 0.0 | |
| 1188 | S | 11 | 0 | 0.0 | 10 | 0 | 0.0 | |
| 1198 | M | 10 | 0 | 0.0 | 9 | 1 | 11.1 | |
| 1203 | S | 9 | 0 | 0.0 | 10 | 1 | 10.0 |
| Characteristic | Boys 8 years of age (n = 304) | Boys 9 years of age (n = 185) | Total boys (n = 489) |
| Growth and sexual maturation parameters | |||
| Age [years (mean ± SD)] | 8.04 ± 0.10 | 9.02 ± 0.08 | 8.41 ± 0.49 |
| Height [cm (mean ± SD)] | 128.42 ± 5.91 | 133.00 ± 5.96 | 130.16 ± 6.32 |
| Weight [kg (mean ± SD)] | 26.49 ± 5.47 | 28.37 ± 5.65 | 27.20 ± 5.61 |
| BMI (mean ± SD) | 15.94 ± 2.30 | 15.94 ± 2.34 | 15.94 ± 2.31 |
| Penile length [cm (mean ±SD)]a | 5.49 ± 0.78 | 5.37 ± 0.67 | 5.45 ± 0.74 |
| TV (mL) [no. (%)]b | |||
| 1 | 8 (3) | 4 (2) | 12 (2) |
| 2 | 151 (50) | 80 (44) | 231 (48) |
| 3 | 108 (36) | 66 (36) | 174 (36) |
| 4 | 28 (9) | 22 (12) | 50 (10) |
| 5 | 5 (2) | 8 (4) | 13 (3) |
| 6 | 3 (1) | 2 (1) | 5 (1) |
| TV > 3 mL [no. (%)]b | 36 (12) | 32 (18) | 68 (14) |
| Tanner staging [no. (%)] | |||
| Genitalia | |||
| G1 | 237 (78) | 107 (58) | 344 (70) |
| G2 | 67 (22) | 78 (42) | 145 (30) |
| Pubarche | |||
| P1 | 293 (96) | 154 (83) | 447 (91) |
| P2 | 11 (4) | 31 (17) | 42 (9) |
| Birth history | |||
| Birth weight [kg (mean ± SD)]c | 3.34 ± 0.54 | 3.33 ± 0.52 | 3.34 ± 0.53 |
| Gestational age [weeks (mean ± SD)]d | 38.96 ± 1.88 | 39.15 ± 1.54 | 39.03 ± 1.76 |
| Household characteristics | |||
| Family income (rubles/month) [no. (%)]e | |||
| < 2,200 | 16 (5) | 15 (8) | 31 (6) |
| 2,200–3,599 | 33 (11) | 33 (18) | 66 (14) |
| 3,500–4,999 | 41 (13) | 35 (19) | 76 (16) |
| 5,000–7,200 | 71 (24) | 56 (30) | 127 (26) |
| > 7,200 | 142 (47) | 46 (25) | 188 (38) |
| Mother’s age at son’s birth (mean ± SD)f | 24.2 ± 5.3 | 23.6 ± 4.8 | 24.0 ± 5.1 |
| Blood lead levels (μg/dL) | |||
| Median (25th–75th percentile) | 3 (2–4) | 4 (3–5) | 3 (2–5) |
| 0–2 [no. (%)] | 103 (34) | 39 (21) | 142 (29) |
| 3–4 [no. (%)] | 129 (43) | 81 (44) | 210 (43) |
| ≥ 5 [no. (%)] | 72 (24) | 65 (35) | 137 (28) |
| Tocopherol | Cell type/Cancer model | Result | References |
| α-Tocopherol | Human retinal pigment epithelial cells (ARPE-19) | ↑ Nrf2 protein levels, ↑ glutamate cysteine ligase, NQO1, HO-1, GST, SOD | [90] |
| γ-TmT | Prostate carcinogenesis in TRAMP male mice | ↑ Nrf2 protein levels, ↑ GSTm1, UGT1A1, HO-1, catalase, SOD, glutathione peroxidase, | [43] |
| γ-TmT | Estrogen-induced mammary hyperplasia in female ACI rats | ↑ Nrf2 protein levels | [92] |
| Sample | Mean ± SD |
| Blank | 1.247 ± 0.004 |
| VC, 0.01 mM (1.7 mg/mL) | 0.045 ± 0.003 * |
| BCE, 2.5 μL (875 μg/μL) | 0.668 ± 0.016 * |
| BCE, 5 μL (875 μg/μL) | 0.368 ± 0.018 * |
| BCE, 10 μL (875 μg/μL) | 0.171 ± 0.008 * |
| BCE, 20 μL (875 μg/μL) | 0.102 ± 0.007 * |
| BCE, 40 μL (875 μg/μL) | 0.085 ± 0.004 * |
| BCE, 80 μL (875 μg/μL) | 0.074 ± 0.003 * |
| CBHI (26) | Non-CBHI (114) | t-test | |
| Population density (per km2) | 184.62 | 46.42 | -2.571* |
| Poverty rate (%) | 29.6 | 40.1 | 3.386** |
| Literacy rate (%) | 79.00 | 64.2 | -4.061** |
| % of labor non-agriculture | 33.38 | 12.09 | -5.868** |
| % HHs with electricity | 73.7 | 41.87 | -5.948** |
| Avg time to nearest health center (mins) | 57.65 | 161 | 4.5322** |
| % pop Lao-tai (vs. ethnic minority) | 56.09 | 26.93 | -3.741** |
| % pop Buddhist | 79.48 | 53.29 | -3.71** |
| Characteristic | Amiodarone n=20 | Metaprolol n=30 | P value |
| AF%age | 20% | 26.7% | NS |
| Time of Development of AF | 62.15+ 18 | 48.4+ 10.2 | NS |
| Duration of AF | 12.04+ 10.2 | 18.8+ 10.4 | NS |
| Maximum Ventricular rate during AF | 118.+ 30.4 | 148+ 22.2 | NS |
| AF on discharge | 1 | 3 | NS |
| Length of hospital stay | 12.7+ 4.5 | 13.2+ 5.2 | NS |
| Cost of Care | 1.17+ 0.12 | 1.18+0.10 | NS |
| Characteristics | Number of patients (%) |
| Sex | |
| Male | 42 (98) |
| Female | 1 (2) |
| Age (years) | |
| Range | 39–80 |
| Median | 66 |
| Stage | |
| T1 | 1 (2) |
| T2 | 16 (37) |
| T3 | 9 (21) |
| T4 | 17 (40) |
| N | |
| Yes | 3 (7) |
| No | 39 (91) |
| NA | 1 (2) |
| M | |
| Yes | 6 (14) |
| No | 36 (84) |
| NA | 1 (2) |
| Histological type | |
| Papillary | 3 (7) |
| Colonic | 25 (58.1) |
| Solid | 5 (11.6) |
| Mucinous | 10 (23.3) |
| Wood dust exposure | |
| Yes | 26 (60) |
| No | 9 (21) |
| NA | 8 (19) |
| Recurrence | |
| Yes | 24 (56) |
| No | 17 (40) |
| NA | 2 (4) |
| Outcome | |
| Alive | 16 (37) |
| Died of disease | 16 (37) |
| Died of other causes | 9 (21) |
| NA | 2 (5) |
| Before the phlebotomy training May 2014 | After the phlebotomy training July 2014 | ||||
| CHC/CDC | Blood registrations | Blood rejections n (%) | Blood registrations | Blood rejections n (%) | p |
| A | 7557 | 60 (0.79) | 10 218 | 79 (0.77) | 0.876 |
| B | 3973 | 45 (1.13) | 4114 | 48 (1.17) | 0.886 |
| C | 2321 | 38 (1.64) | 2279 | 37 (1.62) | 0.971 |
| D | 589 | 8 (1.36) | 630 | 7 (1.11) | 0.696 |
| Subgroup | No. of datasets | RR (95% CI) | I2 | Pheterogeneity |
| Total | 7 | 1.06 (0.89, 1.26) | 25% | 0.24 |
| Geographical area | ||||
| North America | 4 | 1.11 (0.79, 1.56) | 62% | 0.05 |
| Europe | 3 | 1.05 (0.85, 1.32) | 0% | 0.98 |
| Menopausal status | ||||
| Postmenopausal | 3 | 1.15 (0.92, 1.45) | 0% | 0.87 |
| Premenopausal | 0 | NA | NA | NA |
| Coffee type | ||||
| Caffeinated | 3 | 1.09 (0.70, 1.68) | 78% | 0.01 |
| Decaffeinated | 3 | 0.89 (0.66, 1.20) | 0% | 0.99 |
| Adjusted for smoking | ||||
| No | 1 | 1.02 (0.62, 1.69) | NA | NA |
| Yes | 6 | 1.07 (0.88, 1.31) | 37% | 0.16 |
| Adjusted for BMI | ||||
| No | 2 | 1.13 (0.87, 1.45) | 0% | 0.76 |
| Yes | 5 | 1.05 (0.81, 1.36) | 46% | 0.12 |
| Adjusted for education | ||||
| No | 2 | 0.89 (0.62, 1.27) | 55% | 0.14 |
| Yes | 5 | 1.17 (0.97, 1.41) | 0% | 0.69 |
| Adjusted for alcohol intake | ||||
| No | 4 | 0.96 (0.76, 1.22) | 26% | 0.26 |
| Yes | 3 | 1.18 (0.95, 1.47) | 0% | 0.40 |
| K | AIC | ΔAICc | wi | |
| All species | ||||
| Distance to road | 2 | 2401.35 | 0 | 0.78 |
| Constant survival | 1 | 2405.17 | 3.82 | 0.11 |
| Distance to edge | 2 | 2406.59 | 5.24 | 0.06 |
| Distance to power lines | 2 | 2407.04 | 5.69 | 0.05 |
| Macrohabitat type | 5 | 2411.51 | 10.16 | 0.00 |
| Species | 16 | 2424.29 | 25.86 | 0.00 |
| BLGR | ||||
| Distance to edge | 2 | 201.684 | 0 | 0.48 |
| Constant survival | 1 | 207.16 | 1.19 | 0.26 |
| Distance to power lines | 2 | 208.28 | 2.59 | 0.13 |
| Distance to road | 2 | 209.26 | 3.15 | 0.10 |
| Macrohabitat type | 5 | 212.60 | 6.48 | 0.02 |
| BRTH | ||||
| Constant survival | 1 | 273.10 | 0 | 0.37 |
| Distance to edge | 2 | 274.11 | 1.01 | 0.22 |
| Distance to road | 2 | 274.90 | 1.80 | 0.15 |
| Macrohabitat type | 4 | 175.12 | 2.02 | 0.13 |
| Distance to power lines | 2 | 275.229 | 2.13 | 0.13 |
| INBU | ||||
| Distance to power lines | 2 | 188.55 | 0 | 0.83 |
| Constant survival | 1 | 193.48 | 4.93 | 0.07 |
| Macrohabitat type | 5 | 194.29 | 5.74 | 0.05 |
| Distance to edge | 2 | 195.51 | 6.96 | 0.03 |
| Distance to road | 2 | 195.71 | 7.16 | 0.02 |
| NOCA | ||||
| Constant survival | 1 | 1225.21 | 0 | 0.44 |
| Distance to power lines | 2 | 1226.68 | 1.47 | 0.21 |
| Distance to road | 2 | 1227.02 | 1.81 | 0.18 |
| Distance to edge | 2 | 1227.24 | 2.03 | 0.16 |
| Macrohabitat type | 5 | 1232.03 | 6.81 | 0.01 |
| WEVI | ||||
| Constant survival | 1 | 76.03 | 0 | 0.59 |
| Distance to power lines | 2 | 78.33 | 2.30 | 0.19 |
| Distance to edge | 2 | 79.38 | 3.34 | 0.11 |
| Distance to road | 2 | 79.39 | 3.36 | 0.11 |
| Macrohabitat type | 4 | 89.69 | 13.65 | 0.00 |
| Characteristics | CMV infection | No CMV infection | p |
| N = 21 | N = 65 | ||
| Age, mean ± SD, y | 51.4 ± 13.8 | 46.8 ± 15.6 | 0.244 |
| Gender, male (%) | 57.1 | 69.2 | 0.308 |
| Type of transplant, Kidney /Kidney + pancreas (%) | 24.4/25.0 | 75.6/75.0 | 0.977 |
| Allograft function, (eGFR), mean ± SD | |||
| Day 30 | 44.0 ± 15.4 | 50.2 ± 23.3 | 0.347 |
| Day 90 | 43.7 ± 17.4 | 52.6 ± 21.8 | 0.136 |
| Blood transfusion, N Yes/No | 12 /9 | 24 /38 | 0.140 |
| Donor, D+/D- (%) | 23.4/33.3 | 76.6/66.7 | 0.682 |
| Pretransplant recipient CMV serostatus R+/R- (%) | 22.4/33.1 | 77.6/66.9 | 0.410 |
| The time of VGCV initiation after KTx (days); mean ± SD | 9 ± 5 | 9 ± 5 | 0.905 |
| The time of VGCV discontinuation after KTx (days); mean ± SD | 94 ± 9 | 92 ± 14 | 0.458 |
| Duration of antiviral prophylaxis (days); mean ± SD | 85 ± 9 | 82 ± 15 | 0.382 |
| total IgG concentration (g/L) < 7 / ≥7% | |||
| Day 0 | 0.0/26.3 | 100.0/73.7 | 0.571 |
| Day 90 | 41.1/18.0 | 58.9/82.0 | 0.057 |
| anti-CMV IgG titer (AU/ml) mean ± SD | |||
| Day 0 | 138 ± 113 | 168 ± 109 | 0.803 |
| Day 90 | 113 ± 85 | 159 ± 109 | 0.087 |
| leukocyte blood count (G/L) mean ± SD | |||
| Day 0 | 7.8 ± 2.4 | 7.9 ± 2.3 | 1.000 |
| Day 30 | 8.5 ± 2.7 | 9.2 ± 4.0 | 0.800 |
| Day 90 | 6.6 ± 4.9 | 6.5 ± 3.2 | 0.080 |
| Induction therapy (%) | 0.026 | ||
| Yes basiliximab | 25.8 | 74.2 | |
| Yes thymoglobulin | 57.1 | 42.9 | |
| None | 5.9 | 94.1 | |
| QuantiFERON-CMV assay (IU/mL) < 0.2/≥0.2 (%) | |||
| All time points used | 42.9/15.6 | 57.1/84.4 | 0.005 |
| Day 7 | 39.0/14.6 | 61.0/85.4 | 0.015 |
| Day 30 | 40.7/9.1 | 59.3/90.9 | 0.003 |
| Day 90 | 42.8/16.4 | 57.2/83.6 | 0.008 |
| lymphocyte blood count (G/L) < 0.8/≥0.8 (%) | |||
| Day 0 | 0.0/25.3 | 100.0/74.7 | 1.000 |
| Day 30 | 42.9/21.0 | 57.1/79.0 | 0.090 |
| Day 90 | 53.8/20.0 | 46.2/80.0 | 0.015 |
| gammaglobulin blood concentration (g/dL) < 0.8/≥0.8 (%) | |||
| Day 0 | 18.2/24.8 | 81.8/75.2 | 0.623 |
| Day 90 | 41.7/5.9 | 58.3/94.1 | 0.0004 |
| Characteristic | Total Group (n = 270) | IR (n = 183) | ID/IDA (n = 87) | p-Value 1 |
| Age (years) | 25.9 ± 5.0 | 26.3 ± 4.9 | 25.3 ± 5.2 | 0.131 |
| Highest Educational Attainment 2 (n, %) | ||||
| Secondary | 75 (27.8) | 41 (22.4) | 34 (39.1) | 0.014 |
| Certificate/Diploma | 43 (15.9) | 33 (18.0) | 10 (11.5) | |
| Higher education | 152 (56.3) | 109 (59.6) | 43 (49.4) | |
| Location (n, %) | ||||
| Rural | 89 (33.0) | 66 (36.1) | 23 (26.4) | 0.116 |
| Urban | 181 (67.0) | 117 (63.9) | 64 (73.6) | |
| Ethnicity (n, %) | ||||
| Asia | 44 (16.3) | 29 (15.8) | 15 (17.2) | 0.362 |
| Europe | 186 (68.9) | 123 (67.2) | 63 (72.4) | |
| Other * | 40 (14.8) | 31 (16.9) | 9 (10.3) | |
| Weight Status (n, %) | ||||
| Obese weight | 126 (46.7) | 89 (48.6) | 37 (42.5) | 0.347 |
| Normal weight | 144 (53.3) | 94 (51.4) | 50 (57.5) | |
| Weight (kg) | 77.9 ± 23.8 | 79.0 ± 23.4 | 75.7 ± 24.5 | 0.285 |
| BMI (kg/m2) | 28.5 ± 8.6 | 28.8 ± 8.3 | 27.9 ± 9.4 | 0.453 |
| Waist circumference (cm) | 84.4 ± 18.6 | 85.3 ± 18.7 | 82.5 ± 19.1 | 0.252 |
| Activity (MET-min/week) | ||||
| Total | 2573 ± 2137 | 2533 ± 2079 | 2658 ± 2263 | 0.654 |
| Dietary Restraint (n, %) | ||||
| Low | 81 (30.0) | 57 (31.1) | 24 (27.6) | 0.368 |
| Medium | 117 (43.3) | 82 (44.8) | 35 (40.2) | |
| High | 72 (26.7) | 44 (24.0) | 28 (32.2) | |
| Energy Reporting (n, %) | ||||
| Low energy reporting | 156 (57.8) | 95 (51.9) | 61 (70.1) | 0.005 |
| Plausible energy reporting | 114 (42.2) | 88 (48.1) | 26 (29.9) | |
| Oral Contraceptive Pill (n, %) ^ | ||||
| Yes | 76 (32.3) | 52 (32.7) | 24 (31.6) | 0.863 |
| No | 159 (67.7) | 107 (67.3) | 52 (68.4) |
| Gene name | Gene Accession number | Score (d) | Log2 expression ratio | |
| Genes mainly expressed in skeletal muscle | Nebulette (Actin-binding Z-disk protein) | NM_006393 | 42.93 | 3.81 |
| Troponin I, fast skeletal muscle (Troponin I, fast-twitch isoform) | NM_003282 | 34.39 | 2.60 | |
| Huntingtin interacting protein 1 (HIP-I) | NM_005338 | 33.55 | 2.59 | |
| Myosin light chain 2a | NM_021223 | 32.80 | 3.26 | |
| Troponin C, skeletal muscle | NM_003279 | 32.21 | 2.45 | |
| Myosin light chain 2 | NM_013292 | 29.25 | 3.06 | |
| Myosin heavy chain, skeletal muscle, perinatal | NM_002472 | 28.14 | 2.80 | |
| Troponin T, fast skeletal muscle isoforms | NM_006757 | 26.04 | 2.71 | |
| Myosin heavy chain, cardiac muscle beta isoform | NM_000257 | 24.94 | 3.12 | |
| Actin, alpha skeletal muscle (Alpha-actin 1) | NM_001100 | 24.21 | 3.50 | |
| Troponin C, slow | NM_003280 | 21.31 | 2.54 | |
| Nebulin | NM_004543 | 20.17 | 2.78 | |
| Smoothelin | NM_134269 | 19.50 | 1.32 | |
| Tropomyosin 1 alpha chain (Alpha-tropomyosin) | NM_000366 | 18.92 | 1.99 | |
| Myotilin | NM_006790 | 18.07 | 1.56 | |
| Genes mainly expressed in MCF-7 cells | Actin, cytoplasmic 2 (Gamma-actin) | NM_001614 | -30.24 | -2.58 |
| Elongation factor 1-beta (EF-1-beta) | NM_001959 | -22.14 | -1.26 | |
| Actin binding protein anillin, | NM_018685 | -20.12 | -1.13 | |
| Keratin, type I cytoskeletal 18 | NM_000224 | -18.78 | -2.83 | |
| Ankyrin 3 (ANK-3) (Ankyrin G) | NM_020987 | -16.43 | -2.17 | |
| Gamma-parvin | NM_022141 | -16.30 | -1.03 | |
| Spectrin beta chain, brain 2 (Spectrin, non-erythroid beta chain 2) (Beta-III spectrin) | NM_006946 | -16.28 | -0.84 | |
| Coronin 1B (Coronin 2) | NM_020441 | -15.97 | -0.84 | |
| Beta-centractin (Actin-related protein 1B) (ARP1B) | NM_005735 | -15.79 | -1.40 | |
| NB thymosin beta | NM_021992 | -14.92 | -1.42 | |
| Coronin 2A (WD-repeat protein 2) (IR10) | NM_052820 | -14.39 | -1.24 | |
| ARP2/3 complex 16 kDa subunit (P16-ARC) (Actin-related protein 2/3 complex subunit 5) | NM_005717 | -13.74 | -1.06 | |
| Tight junction protein ZO-1 (Zonula occludens 1 protein) (Zona occludens 1 protein) (Tight junction protein 1) | NM_003257 | -13.70 | -1.28 | |
| Transcription factor 7 (T-cell-specific transcription factor 1) (TCF- 1) (T-cell factor 1) | NM_003202 | -13.60 | -0.67 | |
| Catenin delta-1 (p120 catenin) (p120(ctn)) (Cadherin-associated Src substrate) (CAS) (p120(cas)) | NM_001331 | -13.60 | -0.77 |
| Gene IDa | Primers (5′-3′) | Accession No. | Amplicon length |
| Act- β | Forward: CGGCATCGAGGACAGGATReverse: CATCGTACTCCTGCTTGCTGAT | NM_173979.3 | 169 |
| GAPDH | Forward: CCTGCCCGTTCGACAGATAReverse: GGCGACGATGTCCACTTTG | NM_001034034.1 | 150 |
| FAU | Forward: CCGCATGCTTGGAGGTAAAGReverse: CACAACATTGACAAAGCGCC | NM_174731.3 | 154 |
| RPS9 | Forward: CCGCATGCTTGGAGGTAAAGReverse: CACAACATTGACAAAGCGCC | NM_001101152.2 | 188 |
| HPRT1 | Forward:GGATTACATCAAAGCACTGAACAReverse: CATTGTCTTCCCAGTGTCAATT | NM_001034035 | 194 |
| Characteristic/subcategory | Discomfort of acupuncture: No. (%) | No discomforta | Slight discomforta | ||||
| No | Slight | Moderate to severe | OR (95% CI) | P value | OR (95% CI) | P value | |
| Age | |||||||
| ≥70 | 20 (18.1) | 51 (46.4) | 39 (35.5) | 1.00 | 1.00 | ||
| ≤19 | 7 (12.3) | 35 (61.4) | 15 (26.3) | 1.12 (0.37–3.41) | 0.841 | 2.02 (0.94–4.32) | 0.070 |
| 20–29 | 8 (5.7) | 76 (54.3) | 56 (40.0) | 0.35 (0.13–0.90) | 0.030 | 1.16 (0.66–2.03) | 0.605 |
| 30–39 | 11 (9.8) | 66 (58.9) | 35 (31.3) | 0.78 (0.32–1.94) | 0.596 | 1.57 (0.86–2.85) | 0.142 |
| 40–49 | 22 (15.0) | 88 (59.9) | 37 (25.1) | 1.37 (0.62–3.02) | 0.443 | 1.85 (1.04–3.30) | 0.037 |
| 50–59 | 52 (22.7) | 114 (49.8) | 63 (27.5) | 1.69 (0.84–3.39) | 0.138 | 1.39 (0.82–2.37) | 0.226 |
| 60–69 | 26 (20.0) | 69 (53.1) | 35 (26.9) | 1.21 (0.55–2.65) | 0.638 | 1.31 (0.71–2.39) | 0.379 |
| Fear of needles: Are you afraid of acupuncture needles? | |||||||
| No | 132 (18.1) | 407 (55.8) | 190 (26.1) | 1.00 | 1.00 | ||
| Yes | 14 (7.2) | 92 (46.9) | 90 (45.9) | 0.25 (0.14–0.48) | <0.001 | 0.50 (0.36–0.72) | <0.001 |
| Fear of pain: How much are you afraid of pain? | |||||||
| Not at all | 79 (26.0) | 171 (56.3) | 54 (17.8) | 1.00 | 1.00 | ||
| A little | 36 (10.7) | 176 (52.5) | 123 (36.7) | 0.22 (0.13–0.37) | <0.001 | 0.47 (0.32–0.69) | <0.001 |
| Very much | 31 (10.8) | 152 (53.1) | 103 (36.0) | 0.24 (0.14–0.41) | <0.001 | 0.50 (0.33–0.75) | 0.001 |
| Knowledge of acupuncture: How much do you know about acupuncture? | |||||||
| Not at all | 51 (23.5) | 110 (50.7) | 56 (25.8) | 1.00 | 1.00 | ||
| A little | 72 (13.6) | 291 (54.9) | 167 (31.5) | 0.43 (0.26–0.71) | 0.001 | 0.85 (0.58–1.24) | 0.394 |
| Very well | 23 (12.9) | 98 (55.1) | 57 (32.0) | 0.40 (0.21–0.77) | 0.006 | 0.82 (0.51–1.32) | 0.423 |
| Characteristics | Category | NSSIs | p-value | |
| Present | Absent | |||
| Faculty | MBBS | 18 (64.3) | 10 (35.7) | |
| BDS | 9 (56.3) | 7 (43.8) | 0.042 | |
| B.Sc. Nursing | 29 (39.7) | 44 (60.3) | ||
| C. Nursing | 34 (36.6) | 59 (63.4) | ||
| Age Group (years) | ≤22 | 51 (34.0) | 99 (66.0) | <0.001 |
| >22 | 39 (65.0) | 21 (35.) | ||
| Sex | Male | 24 (61.5) | 15 (38.5) | |
| Female | 66 (38.6) | 105 (61.4) | <0.001 | |
| Nationality | Nepalese | 87 (42.4) | 118 (57.6) | 0.653 |
| Indian | 3 (60.0) | 2 (40.0) |
| Item | Descriptions |
| Number of stations | 12 |
| Date span | 1–30 May 2015; 1–30 July 2016 |
| Signal selection | GPS: L1/L2/L5; GLONASS: L1/L2; BeiDou: B1/B2/B3; Galileo: E1/E5a/E5b |
| Sampling interval | 30 s |
| Elevation cut off | 10° |
| Time system | GPS time |
| Tropospheric delay | Dry component: corrected with GPT model [26], wet component: estimated as random-walk process, GMF mapping function applied. |
| First order ionospheric delay | Single-frequency SPP: |
| GPS/GLONASS: Klobuchar model | |
| BDS: Klobuchar model [27] | |
| Galileo: The NeQuick model [28] | |
| Dual-frequency: First order eliminated by ionosphere-free combination | |
| Relativistic effect | IERS2010 [29] |
| Sagnac effect | IERS2010 [29] |
| Phase wind-up effect | Corrected [30] |
| Satellite PCO and PCV | GPS and GLONASS: Fixed to igs08_1861.atx values; |
| Tide displacement | IERS2010 [29] |
| Station reference coordinates | IGS SINEX solutions or daily GPS-only PPP solutions |
| Ethnic group | α-globin genotypes | Total | ||
| - -α3.7/αα | - -α4.2/αα | - -SEA/αα | ||
| Malay (n = 315) | 32 | 0 | 1 | 33 |
| Chinese (n = 73) | 2 | 1 | 1 | 4 |
| Indian (n = 12) | 0 | 0 | 0 | 0 |
| Total (n = 400) | 34 | 1 | 2 | 37 |
| Strain | D | Yxs | rs | rCO2 | rO2 | retoh | racet | RQ | Cs | Cbalance | Totsant |
| (h-1) | (g g-1) | (mmol g biomass-1h-1) | (rCO2/rO2) | (mM) | (%) | (mg 24 h-1l-1) | |||||
| SCIGS28 | 0.051 ±0.002 | 0.50 ±0.01 | 0.57 ±0.01 | 1.12 ±0.08 | 1.12 ±0.06 | 0 | 0 | 1.00 ±0.02 | 0.18 ±0.02 | 100.3 ±2.1 | 11.8 ±0.3 |
| 0.10 ±0.01 | 0.50 ±0.01 | 1.11 ±0.03 | 2.67 ±0.15 | 2.49 ±0.07 | 0 | 0 | 1.07 ±0.05 | 0.16 ±0.01 | 101.9 ±1.1 | 5.2 ±0.2 | |
| SCIGS29 | 0.050 ±0.003 | 0.29 ±0.01 | 0.97 ± 0.04 | 3.17 ±0.04 | 2.95 ±0.15 | 0.082 ±0.001 | 0.024 ±0.001 | 1.07 ±0.07 | 1.16 ±0.04 | 96.9 ±3.2 | 37.6 ±0.2 |
| 0.10 ±0.01 | 0.28 ±0.01 | 1.95 ±0.05 | 6.40 ±0.18 | 5.51 ±0.20 | 0.128 ±0.004 | 0.039 ±0.008 | 1.16 ±0.22 | 0.39 ±0.01 | 95.0 ±0.9 | 20.4 ±0.1 | |
| SCIGS30 | 0.051 ±0.001 | 0.28 ±0.02 | 1.09 ±0.05 | 3.60 ±0.09 | 3.41 ±0.22 | 0.099 ±0.015 | 0.024 ±0.003 | 1.05 ±0.09 | 1.15 ±0.04 | 94.7 ±0.4 | 39.4 ±0.4 |
| 0.10 ±0.02 | 0.25 ±0.01 | 2.26 ±0.09 | 7.70 ±0.19 | 6.37 ±0.29 | 0.161 ±0.007 | 0.032 ±0.005 | 1.21 ±0.14 | 0.40 ±0.01 | 93.5 ±1.2 | 20.1 ±0.1 | |
| SCIGS31 | 0.051 ±0.001 | 0.33 ±0.01 | 0.86 ±0.01 | 2.31 ±0.08 | 1.42 ±0.23 | 0.501 ±0.077 | 0.047 ±0.007 | 1.62 ±0.11 | 30.67 ±0.78 | 105.4 ±4.9 | 6.1 ±0.1 |
| SCIGS24 | 0.051 ±0.001 | 0.24 ±0.01 | 1.16 ± 0.03 | 3.85 ±0.05 | 3.21 ±0.07 | 0.185 ±0.003 | 0.020 ±0.008 | 1.20 ±0.02 | 2.53 ±0.09 | 93.7 ±5.3 | 26.9 ±0.2 |
| SCIGS25 | 0.048 ±0.003 | 0.21 ±0.01 | 1.26 ±0.02 | 4.41 ±0.04 | 3.82 ±0.04 | 0.195 ±0.005 | 0.027 ±0.007 | 1.16 ±0.03 | 2.91 ±0.14 | 93.8 ±2.9 | 24.9 ±0.3 |
| PPI Dataset | Methods | Precision | Recall | F-score | Sn | PPV | Accuracy |
| DIP | CDUN | 0.6 | 0.551 | 0.575 | 0.431 | 0.641 | 0.526 |
| CSO | 0.497 | 0.623 | 0.553 | 0.538 | 0.631 | 0.582 | |
| Cluster ONE | 0.337 | 0.441 | 0.382 | 0.378 | 0.696 | 0.513 | |
| COAN | 0.41 | 0.597 | 0.486 | 0.445 | 0.529 | 0.483 | |
| COACH | 0.307 | 0.602 | 0.406 | 0.544 | 0.456 | 0.498 | |
| CMC | 0.485 | 0.428 | 0.455 | 0.306 | 0.643 | 0.443 | |
| HUNTER | 0.852 | 0.119 | 0.208 | 0.164 | 0.644 | 0.325 | |
| MCODE | 0.423 | 0.14 | 0.21 | 0.282 | 0.362 | 0.32 | |
| TransClust | 0.13 | 0.674 | 0.218 | 0.622 | 0.725 | 0.672 | |
| SpecClust | 0.122 | 0.331 | 0.179 | 0.548 | 0.529 | 0.538 | |
| MIPS | CDUN | 0.438 | 0.331 | 0.377 | 0.244 | 0.612 | 0.387 |
| CSO | 0.391 | 0.344 | 0.365 | 0.283 | 0.641 | 0.426 | |
| Cluster ONE | 0.273 | 0.267 | 0.27 | 0.235 | 0.725 | 0.412 | |
| COAN | 0.356 | 0.352 | 0.354 | 0.261 | 0.636 | 0.407 | |
| COACH | 0.239 | 0.347 | 0.283 | 0.317 | 0.385 | 0.35 | |
| CMC | 0.335 | 0.322 | 0.328 | 0.361 | 0.468 | 0.411 | |
| HUNTER | 0.538 | 0.14 | 0.222 | 0.289 | 0.333 | 0.31 | |
| MCODE | 0.365 | 0.153 | 0.215 | 0.189 | 0.572 | 0.329 | |
| TransClust | 0.145 | 0.623 | 0.236 | 0.544 | 0.71 | 0.621 | |
| SpecClust | 0.095 | 0.182 | 0.125 | 0.41 | 0.37 | 0.389 | |
| STRING | CDUN | 0.446 | 0.674 | 0.537 | 0.715 | 0.518 | 0.609 |
| Cluster ONE | 0.13 | 0.343 | 0.188 | 0.671 | 0.494 | 0.569 | |
| COACH | 0.181 | 0.458 | 0.26 | 0.963 | 0.154 | 0.385 | |
| HUNTER | 0.5 | 0.017 | 0.033 | 0.107 | 0.353 | 0.194 | |
| MCODE | 0.079 | 0.131 | 0.099 | 0.681 | 0.257 | 0.418 | |
| TransClust | 0.11 | 0.517 | 0.181 | 0.842 | 0.528 | 0.667 | |
| SpecClust | 0.066 | 0.347 | 0.111 | 0.652 | 0.519 | 0.582 |
| M | SD | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | |
| Threat appraisal | 54.34 | 14.84 | 0.00 | 0.27* | 0.14 | 0.05 | −0.32* | −0.27* | −0.08 | −0.12 | |
| Internality | 27.72 | 6.04 | 0.28* | 0.23 | 0.12 | 0.02 | 0.10 | 0.38** | 0.00 | ||
| Social externality | 25.45 | 5.23 | 0.17 | 0.26 | 0.01 | −0.20 | 0.09 | 0.14 | |||
| Fatalistic externality | 22.06 | 7.15 | 0.18 | 0.07 | −0.15 | 0.02 | 0.24 | ||||
| Rumination | 28.53 | 7.43 | 0.46*** | 0.30* | 0.69*** | 0.49*** | |||||
| Search for affiliation | 32.58 | 9.23 | 0.57*** | 0.40** | 0.60*** | ||||||
| Threat minimization | 39.57 | 4.90 | 0.39** | 0.39** | |||||||
| Search for information | 28.11 | 7.36 | 0.26 | ||||||||
| Search for meaning in religion | 8.46 | 4.25 |
| Species Name | LC50/EC50 (95% Confidence Interval Limit) | Study |
| Oreochromis niloticus | 3760 mg∙L−1 (2990–4010) | Omoregie et al. (2009) [39] |
| Chironomus yoshimatsui | 1520 mg∙L−1 | Kegley et al. (2014) [40] |
| Viviparus bengalensis | 2280 mg∙L−1 | Kegley et al. (2014) [40] |
| Radix luteola | 3000 mg∙L−1 | USEPA, (2015) [41] |
| 0.033 mg/kg/day | 0.067 mg/kg/day | |||||||||
| Total | Glucose intolerant type | Time point evaluated as the glucose intolerant type | Total | Glucose intolerant type | Time point evaluated as the glucose intolerant type | |||||
| Before | 60 mina | 120 min | Before | 60 min* | 120 min | |||||
| Baseline | 31 (100 %) | 3 (9.7 %) | 1 (3.2 %) | 0 (0.0 %) | 2 (6.5 %) | 34 (100 %) | 1 (2.9 %) | 0 (0.0 %) | 0 (0.0 %) | 1 (2.9 %) |
| 52 weeks | 29 (100 %) | 3 (10.3 %) | 0 (0.0 %) | 2 (6.9 %) | 1 (3.4 %) | 34 (100 %) | 3 (8.8 %) | 0 (0.0 %) | 3 (8.8 %) | 0 (0.0 %) |
| 104 weeks | 29 (100 %) | 2 (6.9 %) | 0 (0.0 %) | 0 (0.0 %) | 2 (6.9 %) | 32 (100 %) | 2 (6.3 %) | 0 (0.0 %) | 0 (0.0 %) | 2 (6.3 %) |
| 156 weeks | 25 (100 %) | 1 (4.0 %) | 0 (0.0 %) | 0 (0.0 %) | 1 (4.0 %) | 29 (100 %) | 2 (6.9 %) | 0 (0.0 %) | 0 (0.0 %) | 2 (6.9 %) |
| 208 weeks | 25 (100 %) | 0 (0.0 %) | 0 (0.0 %) | 0 (0.0 %) | 0 (0.0 %) | 28 (100 %) | 3 (10.7 %) | 0 (0.0 %) | 2 (7.1 %) | 1 (3.6 %) |
| 260 weeks | 23 (100 %) | 1 (4.3 %) | 1 (4.3 %) | 0 (0.0 %) | 0 (0.0 %) | 27 (100 %) | 4 (14.8 %) | 0 (0.0 %) | 1 (3.7 %) | 3 (11.1 %) |
| 2010 auditn = 82 | 2011 re-auditn = 140 | |
| Patients who had at least one neuroimaging procedure (through MAS or previous), n (%) | 56 (68) | 106 (76) |
| Neuroimaging requested through MAS, n (%) | 48 (59) | 88 (63) |
| Previous neuroimaging, n (%) | 8 (9) | 18 (13) |
| Patients who declined assessment/scan, n (%) | 13 (16) | 29 (21) |
| Patients with documented reasons for not having neuroimaging (unable to tolerate scan, moved out of area, died), n (%) | 0 (0) | 4 (3) |
| Patients with no reason documented for not having neuroimaging, n (%) | 13 (16) | 1 (1) |
| Of the patients who did not have any neuroimaging, proportion with no reason documented, n/N (%) | 13/26 (50) | 1/34 (3) |
| Type of neuroimaging performed (through MAS and previous), n/N (%) | ||
| CT scan | 49/56 (88) | 92/106 (87) |
| MRI scan | 5/56 (9) | 14/106 (13) |
| Other (FDG-PET/CT, HMPAO-SPECT) | 2/56 (4) | 0/106 (0) |
| Coronal imaging on CT scans requested through MAS, n/N (%) | Data not available | 45/78 (58) |
| Length of time between scan requests and scan appointments, days | ||
| Range | 6-42 | 11-71 |
| Mean | 22 | 30 |
| Range across different sectors of patients who had a neuroimaging procedure, % | 33-100 | 58-84 |
| VA outcome | Fox (n = 19) | Clark (n = 36) | Al-Mezaine (n = 17) | Shirodkar (n = 26) | Overall (n = 98) |
| ≥20/40 | 9 (47.3%) | 18 (50%) | 5 (29.4%) | 13 (50%) | 45 (45.9%) |
| 20/50 ≥ 20/400 | 6 (31.5%) | 10 (28%) | 4 (23.5%) | 6 (23%) | 26 (26.5%) |
| <20/400 ≥ 5/200 | 1 (5.2%) | 2 (5%) | 2 (11.7%) | 2 (7.7%) | 7 (7.1%) |
| <5/200-NLP | 3 (15.8%) | 6 (17%) | 6 (35%) | 5 (19.2%) | 20 (20.4%) |
| Parameter | Definition |
| N | Number of individuals in the population |
| Z | Probability to reproduce by self-fertilization |
| w | Fitness of an individual |
| n | Number of TE copies in the genome |
| si | Effect of insertion i on fitness |
| μs | Average effect of TE insertions on fitness |
| σs | Standard deviation of the effect on fitness |
| Ps > 0 | Proportion of TE insertions that improve the fitness |
| u | Replicative transposition rate |
| v | Deletion rate |
| ai | Activity of a copy i (ability to produce the transposition machinery) |
| m | Mutation rate (toward a less active copy) |
| σm | Standard deviation of the effect of a mutation on activity |
| Gene list | N genes | Proportion of genome | SNP heritability (P value) | ||
| SNPs | Mb | All samples | Infliximab+Adalimumab | ||
| Whole genome | — | 1 | 1 | 0.18 (0.02) | 0.36 (0.005) |
| Drug metabolism* | 215 | 0.07 | 0.10 | 0.05 (0.3) | 0.04 (0.09) |
| Immune-related† | 6,001 | 0.65 | 0.58 | 0.07 (0.2) | 0.21 (0.01) |
| TNF/TNFR pathway‡ | 333 | 0.11 | 0.14 | 0.05 (0.04) | 0.02 (0.3) |
| CD84 coexpression (ImmGen) | 200 | 0.08 | 0.11 | 0 (0.5) | 0 (0.5) |
| Sample | [M]/[I] | mM, g | mC, mg |
| MWS-1 MWS-2 MWS-3 | 1/1,000 | 5 | 14.05 |
| MWS-4 MWS-5 MWS-6 | 1/5,000 | 5 | 2.81 |
| MWS-7 MWS-8 MWS-9 | 1/10,000 | 5 | 1.41 |
| Human protein | Targeting DNA virus families | Targeting RNA virus families |
| HNRPK – heterogeneous nuclear ribonucleoprotein K | Asfarviridae, Herpesviridae, Papillomaviridae, Poxviridae | Arteriviridae, Filoviridae, Flaviviridae, Orthomyxoviridae, Paramyxoviridae, Togaviridae |
| YBOX1 – nuclease‐sensitive element‐binding protein 1 | Herpesviridae, Papillomaviridae, Polyomaviridae, Poxviridae | Arteriviridae, Flaviviridae, Orthomyxoviridae, Paramyxoviridae, Reoviridae, Togaviridae |
| EF1A1 – elongation factor 1‐alpha 1 | Herpesviridae, Papillomaviridae, Poxviridae | Bunyaviridae, Filoviridae, Flaviviridae, Orthomyxoviridae, Paramyxoviridae, Reoviridae, Togaviridae |
| IMA1 – Importin subunit alpha‐1 | Adenoviridae, Herpesviridae, Papillomaviridae, Parvoviridae, Polyomaviridae, Poxviridae | Coronaviridae, Orthomyxoviridae, Paramyxoviridae |
| ADT2 – ADP/ATP translocase 2 | Herpesviridae, Papillomaviridae, Poxviridae | Filoviridae, Flaviviridae, Orthomyxoviridae, Paramyxoviridae, Reoviridae,Togaviridae |
| TBA1C – Tubulin alpha‐1C chain | Herpesviridae, Papillomaviridae, Poxviridae | Arenaviridae, Bunyaviridae, Filoviridae, Orthomyxoviridae, Paramyxoviridae, Reoviridae |
| ROA1 – heterogeneous nuclear ribonucleoprotein A1 | Herpesviridae, Papillomaviridae, Poxviridae | Arteriviridae, Coronaviridae, Filoviridae, Flaviviridae, Orthomyxoviridae, Togaviridae |
| GRP78 – 78 kDa glucose‐regulated protein | Herpesviridae, Papillomaviridae, Poxviridae | Bunyaviridae, Flaviviridae, Orthomyxoviridae, Paramyxoviridae, Rhabdoviridae, Togaviridae |
| TBB5 – Tubulin beta chain | Herpesviridae, Poxviridae | Bunyaviridae, Filoviridae, Flaviviridae, Orthomyxoviridae, Paramyxoviridae, Reoviridae, Togaviridae |
| P53 – cellular tumor antigen p53 | Adenoviridae, Herpesviridae, Papillomaviridae, Parvoviridae, Polyomaviridae | Flaviviridae, Orthomyxoviridae, Paramyxoviridae, Togaviridae |
| NPM – nucleophosmin | Adenoviridae, Herpesviridae, Papillomaviridae, Poxviridae | Flaviviridae, Orthomyxoviridae, Paramyxoviridae, Togaviridae |
| GBLP – guanine nucleotide‐binding protein subunit beta‐2‐like 1 | Adenoviridae, Herpesviridae, Papillomaviridae, Poxviridae | Arteriviridae, Orthomyxoviridae, Paramyxoviridae, Togaviridae |
| TCPG – T‐complex protein 1 subunit gamma | Adenoviridae, Herpesviridae, Papillomaviridae | Arenaviridae, Bunyaviridae, Orthomyxoviridae, Paramyxoviridae, Reoviridae |
| EF1A3 – putative elongation factor 1‐alpha‐like 3 | Herpesviridae, Papillomaviridae, Poxviridae | Bunyaviridae, Filoviridae, Orthomyxoviridae, Paramyxoviridae, Reoviridae |
| HNRPC – heterogeneous nuclear ribonucleoproteins C1/C2 | Herpesviridae, Papillomaviridae, Poxviridae | Arteriviridae, Orthomyxoviridae, Paramyxoviridae, Rhabdoviridae, Togaviridae |
| TCPE – T‐complex protein 1 subunit epsilon | Adenoviridae, Herpesviridae | Arenaviridae, Bunyaviridae, Filoviridae, Orthomyxoviridae, Paramyxoviridae, Reoviridae |
| HS90B – heat shock protein HSP 90‐beta | Herpesviridae, Poxviridae | Bunyaviridae, Filoviridae, Flaviviridae, Orthomyxoviridae, Paramyxoviridae, Togaviridae |
| HNRH1 – heterogeneous nuclear ribonucleoprotein H | Herpesviridae, Papillomaviridae | Arteriviridae, Bunyaviridae, Filoviridae, Flaviviridae, Orthomyxoviridae, Paramyxoviridae |
| TBA1A – Tubulin alpha‐1A chain | Herpesviridae, Poxviridae | Arenaviridae, Bunyaviridae, Filoviridae, Orthomyxoviridae, Paramyxoviridae, Reoviridae |
| HNRPF – heterogeneous nuclear ribonucleoprotein F | Herpesviridae, Papillomaviridae | Arteriviridae, Bunyaviridae, Filoviridae, Flaviviridae, Orthomyxoviridae, Paramyxoviridae |
| ROA2 – heterogeneous nuclear ribonucleoproteins A2/B1 | Herpesviridae, Poxviridae | Arteriviridae, Filoviridae, Flaviviridae, Orthomyxoviridae, Paramyxoviridae, Togaviridae |
| Stage of Lactation (Month) | 2 | 5 | 9 | 12 |
| Maternal age (years) | 32.9 ± 4.21 (28–40) | 33.4 ± 4.27 (24–40) | 34.0 ± 4.57 (25–43) | 34.1 ± 4.35 (26–44) |
| Maternal BMI | 27.1 ± 7.15 (20.1–38.5) | 23.5 ± 4.46 (18.0–35.2) | 24.0 ± 5.15 (18.7–37.2) | 24.8 ± 5.6 (18.2–34.6) |
| Parity | 2.10 ± 0.75 (1–4) | 2.13 ± 0.85 (1–4) | 1.96 ± 0.94 (1–4) | 2.05 ± 0.98 (1–4) |
| Infant sex (Male/Female) | 12/9 | 16/16 | 17/13 | 12/12 |
| Infant birth weight (kg) | 3.58 ± 0.64 (2.66–4.23) | 3.49 ± 0.45 (2.66–4.46) | 3.49 ± 0.46 (2.82–4.46) | 3.59 ± 0.46 (2.80–4.46) |
| Infant body length (cm) | 57.6 ± 2.17 (54.2–61.3) | 64.5 ± 2.09 (61.5–69.5) | 70.9 ± 2.11 (68.0–74.5) | 73.9 ± 2.38 (71.5–78.5) |
| Group | E1′ (MPa) | E2′ (MPa) | ts (min) | G∞ | R2 |
| L65 | 10.1408 ± 5.8173 | 16.4475 ± 5.8594 | 0.6501 ± 0.1888 | 0.4174 ± 0.0479 | 0.7877 ± 0.0257 |
| L60 | 5.9513 ± 3.0988 | 9.1808 ± 2.9271 | 0.7275 ± 0.0806 | 0.3785 ± 0.0676 | 0.8254 ± 0.0134 |
| R | 1.2904 ± 0.6890 | 2.6453 ± 1.0379 | 0.8094 ± 0.2709 | 0.3273 ± 0.0706 | 0.8495 ± 0.0416 |
| Characteristics | Yes n (%) | Non-compliance to HPV vaccination | |||
| Prevalence | p value | Odds Ratio (CI 95 %) | |||
| Parent’s religion | Protestant | 262 (44,1 %) | 17,9 % | ns | 1,03 (0,576–1,45) |
| Non protestant | 332 (55,9 %) | 17,5 % | 1 | ||
| Parent’s schooling | Elementary school | 203 (26,8 %) | 16,7 % | ns | 0,98 (0,71–1,73) |
| High school / higher | 554 (73,2 %) | 16,9 % | 1 | ||
| Monthly household income | Up to I$ 400 | 353 (49,5 %) | 16,1 % | ns | 1,02 (0,61–1,41) |
| More than I$ 400 | 360 (50,5 %) | 18,6 % | 1 | ||
| Type of school | Private school | 99 (12,5 %) | 43,7 % | 0,003 | 4,51 (1,63–12,46) |
| Public school | 698 (87,5 %) | 15,9 % | 1 | ||
| Correct answers in 10 knowledge questions | Less than 50 % | 287 (38,8 %) | 20,2 % | 0,02 | 1,60 (1,05–2,42) |
| More than 50 % | 453 (61,2 %) | 13,6 % | 1 | ||
| Knowing that HPV infections is not rare | Wrong | 400 (50,2 %) | 21,5 % | 0,001 | 1,81 (1,24–2,64) |
| Right | 397 (49,8 %) | 13,1 % | 1 | ||
| Knowing the recommended age group for vaccination | Wrong | 700 (87,8 %) | 18,3 % | 0,04 | 1,94 (1,02–3,86) |
| Right | 97 (12,2 %) | 10,3 % | 1 | ||
| Knowing that the vaccine is effective in preventing HPV | Wrong | 301 (37,7 %) | 20,6 % | 0,01 | 1,62 (1,08–2,41) |
| Right | 496 (62,3 %) | 14,0 % | 1 | ||
| Knowing that the vaccine prevents cervical cancer | Wrong | 152 (19,1 %) | 24,4 % | 0,01 | 1,73 (1,14–2,84) |
| Right | 645 (80,9 %) | 15,6 % | 1 | ||
| Knowing that HPV is a STD | Wrong | 248 (31,1 %) | 17,7 % | ns | 1,04 (0,73–1,66) |
| Right | 549 (68,9 %) | 17,1 % | 1 | ||
| Knowing that men are affected by HPV | Wrong | 449 (56,3 %) | 18,0 % | ns | 1,12 (0,71–1,60) |
| Right | 348 (43,7 %) | 16,3 % | 1 | ||
| Knowing that HPV causes genital warts | Wrong | 484 (60,7 %) | 18,8 % | ns | 1,41 (0,92–2,17) |
| Right | 313 (39,3 %) | 15,0 % | 1 | ||
| Knowing that HPV causes CC | Wrong | 152 (19,1 %) | 19,7 % | ns | 1,35 (0,85–2,16) |
| Right | 645 (80,9 %) | 16,7 % | 1 | ||
| Knowing that the HPV infection is usually asymptomatic | Wrong | 610 (76,5 %) | 16,1 % | ns | 0,71 (0,43–1,06) |
| Right | 187 (23,5 %) | 21,4 % | 1 | ||
| Knowing that there is no curative treatment for HPV | Wrong | 731 (91,7 %) | 17,6 % | ns | 1,53 (0,63–3,67) |
| Right | 66 (8,3 %) | 13,6 % | 1 |
| Population | IDF guideline recommendation | Assessment in study |
| All acne patients | Assign treatment according to acne severity | Not assessed in study: could not be evaluated by computerized query (Disease severity not stated within diagnosis field) |
| All acne patients | Progress gradually between treatment lines | Correctness of treatment progression assessed for treatment courses of distinct acne medications (see Table 4) |
| Patients treated with oral retinoids | Rule out psychiatric diagnoses prior to treatment initiation, and refer to psychiatrist if necessary | Not assessed in study: information not available in computerized patient records |
| Patients treated with oral retinoids | Monitor laboratory test values (liver enzymes, plasma lipid profile) before and during treatment. | Not assessed in study: computerized laboratory test records were not available for cross analysis between databases. |
| Patients treated with oral retinoids | Prescribe supportive care if necessary. | Concomitant prescribing or dispensing of supportive care medications was assessed (see Table 5). |
| Patients treated with oral retinoids | Restrict patient participation in strenuous physical activity by temporarily adjusting medical profile. | Not assessed in study: documentation of temporary change in medical profile was not available after reinstatement of permanent profile. |
| Female patients treated with oral retinoids (teratogenic) | - Rule out pregnancy (laboratory test). | Documented concomitant prescribing or dispensing of oral contraceptives to female patients receiving OI’s. |
| - Inform the patient of potential hazards and explain about required birth control measures. | ||
| - Have the patient sign a statement and file in their medical record (see background). |
| Characteristic | No. of patients | % |
| Patients evaluable | 70 | 100 |
| Age, years | ||
| Median (range) | 65 (32–75) | |
| Sex | ||
| Male | 41 | 58.5 |
| Female | 29 | 41.5 |
| Response to prior chemotherapy | ||
| Yes | 44 | 63 |
| No | 26 | 37 |
| Status of primary tumor | ||
| Resected | 25 | 36 |
| Unresected | 45 | 64 |
| Tumor histology | ||
| Diffuse | 33 | 47.2 |
| Intestinal | 29 | 41.4 |
| Unknown | 8 | 11.4 |
| ECOG PS | ||
| 0 | 10 | 14.5 |
| 1 | 40 | 57 |
| 2 | 20 | 28.5 |
| Number of metastatic sites | ||
| 1 | 17 | 24 |
| 2 | 32 | 46 |
| 3 | 21 | 30 |
| Site of metastases | ||
| Liver | 48 | 68.5 |
| Nodes | 41 | 58.5 |
| Peritoneum | 41 | 58.5 |
| Lung | 13 | 18.5 |
| Bone | 6 | 8.5 |
| PFS under first-line chemotherapy | ||
| ≥ 6 months | 42 | 60 |
| < 6 months | 28 | 40 |
| Chemotherapy-free interval | ||
| > 3 months | 38 | 54 |
| < 3 months | 32 | 46 |
| 1995 | 1996 | 1997 | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | Sum | % | |
| jan | 5 | 5 | 0,31 | ||||||||||||||||
| fev | 2 | 9 | 7 | 32 | 1 | 3 | 1 | 55 | 3,38 | ||||||||||
| mar | 2 | 3 | 8 | 2 | 1 | 3 | 13 | 8 | 2 | 42 | 2,58 | ||||||||
| avr | 23 | 128 | 20 | 105 | 45 | 3 | 50 | 20 | 10 | 41 | 8 | 5 | 16 | 7 | 2 | 482 | 29,59 | ||
| may | 8 | 1 | 12 | 2 | 6 | 11 | 10 | 2 | 53 | 3,25 | |||||||||
| jun | 3 | 129 | 1 | 14 | 69 | 21 | 1 | 33 | 2 | 19 | 29 | 9 | 46 | 6 | 25 | 407 | 24,98 | ||
| jul | 28 | 5 | 90 | 1 | 53 | 5 | 21 | 12 | 37 | 1 | 11 | 264 | 16,21 | ||||||
| aug | 25 | 1 | 3 | 2 | 54 | 18 | 103 | 6,32 | |||||||||||
| sep | 49 | 12 | 61 | 3,74 | |||||||||||||||
| oct | 15 | 3 | 10 | 9 | 3 | 36 | 76 | 4,67 | |||||||||||
| nov | 5 | 8 | 1 | 8 | 9 | 4 | 35 | 2,15 | |||||||||||
| dec | 7 | 7 | 26 | 2 | 4 | 46 | 2,82 | ||||||||||||
| Sum | 54 | 262 | 1 | 34 | 353 | 70 | 33 | 154 | 56 | 57 | 105 | 58 | 215 | 107 | 24 | 5 | 41 | 1629 | 100 |
| % | 3,31 | 16,08 | 0,06 | 2,09 | 21,67 | 4,30 | 2,03 | 9,45 | 3,44 | 3,50 | 6,45 | 3,56 | 13,20 | 6,57 | 1,47 | 0,31 | 2,52 | 100 |
| Lipid emulsion (n = 16) | Control (n = 11) | |
| Initiation of enteral nutrition (h) | 10.63 ± 5.49 | 9.27 ± 6.69 |
| Age at feeds >100 mL/kg per day (days) | 11.69 ± 4.75 | 7.55 ± 3.77* |
| Period of parenteral nutrition (days) | 12.75 ± 5.84 | 8.91 ± 3.70* |
| Human milk/enteral nutrition at 2 weeks (%) | 91.29 ± 21.55 | 73.84 ± 39.72 |
| Lipid emulsion | ||
| Initiation (day) | 5.13 ± 2.31 | – |
| Amount of initiation (g/kg per day) | 0.60 ± 0.17 | – |
| Period (days) | 6.88 ± 3.61 | – |
| Total amount of infusion (g/kg) | 3.89 ± 3.22 | – |
| Indicator | Participantsa | P | |
| With probable depression at baseline(n = 309) | Without probable depression at baseline(n = 266) | ||
| Treatment outcome, no. (%) | |||
| Treatment success | 269 (87.1) | 257 (96.6) | < 0.001 |
| Treatment failure | 4 (1.3) | 2 (0.8) | ND |
| Treatment default | 12 (3.9) | 2 (0.8) | < 0.05 |
| Death | 24 (7.8) | 5 (1.9) | < 0.01 |
| Quality-of-life score, mean(SD)b,c | |||
| At baseline before tuberculosis treatment | 4.7 (2.7) | 5.7 (2.4) | < 0.001 |
| After 6 months of treatment | 5.0 (2.4) | 6.0 (2.2) | < 0.001 |
| Disability score, median(IQR)c,d | |||
| At baseline before tuberculosis treatment | 30 (16) | 18 (8) | < 0.001 |
| After 6 months of treatment | 22 (19) | 14 (4) | < 0.001 |
| Age group, years | ||
| Demographics | < 65 | ≥65 |
| Participants, n | 9,883 | 3,566 |
| Person-years, | 124,466 | 50,269 |
| Deaths (all causes), n | 460 | 1,379 |
| Deaths (CVD), n (% of all deaths) | 119 (26) | 592 (43) |
| Mean age at baseline, years (± SD) | 45.8 (11.3) | 73.1 (6.1) |
| Mean body mass index, kg/m2 (± SD) | 29.5 (4.0) | 29.0 (3.9) |
| Mean waist circumference, cm (± SD) | 95.3 (10.0) | 95.1 (10.3) |
| Mean SBP, mmHg (± SD) | 142.5 (17.3) | 160.9 (22.3) |
| Mean DBP, mmHg (± SD) | 85.1 (11.0) | 87.7 (12.9) |
| Mean serum triglycerides, mmol/L (± SD) | 2.8 (1.4) | 2.6 (1.1) |
| Mean serum glucose, mmol/L (± SD) | 5.6 (1.7) | 6.3 (2.4) |
| Mean serum HDL, mmol/L (± SD) | 1.1 (0.3) | 1.2 (0.3) |
| Mean percentage of people taking diabetes medication (± SD) | 3.8 (0.04) | 12.6 (0.1) |
| Mean percentage of people taking BP medication (± SD) | 11.5 (0.1) | 33 (0.3) |
| Mean percentage of current smokers (± SD) | 32.2 (0.3) | 15.9 (0.1) |
| Mean percentage of sedentary occupational work (± SD) | 28 (0.2) | 45 (0.3) |
| Mean percentage of college or university education (± SD) | 18 (0.2) | 5 (0.05) |
| Participants' PA levelsb, % | ||
| Inactive | 9 | 19 |
| Low | 38 | 39 |
| Moderate | 27 | 29 |
| High | 26 | 12 |
| History of diagnosed diabetes | P-value* | |||
| Overall | No | Yes | ||
| N | 1873 | 1587 | 286 | |
| Age (years; mean ± SE) | 73.0 ± 0.14 | 73.0 ± 0.15 | 73.1 ± 0.36 | 0.943 |
| Sex (% female) | 48.7 | 48.7 | 48.6 | 0.973 |
| Education (years; mean ± SE) | 4.9 ± 0.11 | 4.9 ± 0.12 | 5.1 ± 0.30 | 0.535 |
| Marital status (%married or living with partner) | 66.8 | 67.2 | 64.3 | 0.338 |
| Smoking status (%current) | 19.4 | 19.7 | 17.8 | 0.454 |
| Functional status (%) | ||||
| High | 47.7 | 50.5 | 32.5 | < 0.001 |
| Middle | 44.6 | 43.0 | 53.8 | |
| Low | 7.6 | 6.6 | 13.6 | |
| Heart disease (% yes) | 23.4 | 21.6 | 32.9 | < 0.001 |
| Hypertension (% yes) | 39.6 | 37.3 | 52.3 | < 0.001 |
| Stroke (% yes) | 7.6 | 6.4 | 14.4 | < 0.001 |
| Number of other conditions† (%) | ||||
| 0 | 49.6 | 52.1 | 35.3 | < 0.001 |
| 1 | 32.8 | 32.4 | 34.5 | |
| ≥ 2 | 17.7 | 15.4 | 30.2 | |
| Duration of diabetes (years; mean ± SE) | 10.0 ± 0.55 | - | ||
| Use Insulin (% yes) | 19.7 | - |
| Masamoto et al. [5] | Lee et al. [6] | Matsuda et al. [7] | Oswal and Agarwal [8] | Ville et al. [11] | Ville et al. [11] | Present case | |
| Warfarin dose (mg/day) | 3.5 | 6–7 | NA | NA | 3–6 | 5–6 | 3–4.5 |
| Start of warfarin (weeks) | 20 | 14 | 14 | 24 | 26 | 15 | 12 |
| PT (INR) | 2.7–2.9 | 2.2–3.0 | NA | NA | 1.7–2.5 | 0.7–1.9 | 1.5–2.0 |
| GA at diagnosis (weeks) | 23 | 23 | 31 | 24 | 32 | 29 | 31 |
| Hemorrhage site | Subdural | Subdural | Subdural | Subdural | Intraventricular | Intraventricular | Subdural |
| Delivery (weeks) | 23 | 25 | 31 | 24 | 36 | 29 | 36 |
| Fetal outcome | Stillbirth | Neonatal death | Alive | Termination | Stillbirth | Stillbirth | Alive |
| Crude immediate brush material [21] | 2-step ALI [5, 8, 22, 23] | 2-step suspension [2, 3, 24, 25] | 3D-E spheroids [9, 13] | |
| Characteristics | ||||
| Sampling of cells | Nasal brush biopsy | Nasal brush biopsy | Removal of nasal polyp or nasal forceps biopsy | Removal of nasal polyp/nasal brush biopsy |
| Anesthesia required | No | No | Yes | Yes (polyp removal)No (nasal brush) |
| Preparation steps | Cell collectionCell dispersion | Cell collectionCell dispersionCell proliferation Ciliary regeneration | Tissue washingEnzymatic tissue digestionCell dispersionCell proliferationCiliary regeneration | Cell collectionCell dispersionSpheroid formation |
| Longevity of cells/culture | 1–3 days | >1 month | >1 month | At least 16 days |
| Time from sampling to analysis | Immediately | 4 weeks | 4–6 weeks | 24 h |
| Materials and reagents | Falcon tubeNaClGlass slide | Falcon tubeCulture mediumT25/75 flask24-well plateTranswell insert filtersD-PBSTrypsin–EDTATrypsin-inhibitorCentrifugeCO2 incubator | Falcon tubePronaseCulture mediumPlastic plateCollagen gelCollagenaseT25/75 flaskGyrotori shakerCO2 incubator | Falcon tubeCulture medium24-well plateCO2 incubator |
| Complexity | Simple | Complex | Complex | Simple |
| Terminally differentiated cells | Yes | No | No | Yes |
| Cell divisions | No | Yes | Yes | No |
| Ciliogenesis | No | Yes | Yes | No |
| Known applications | ||||
| Diagnostics | Yes | Yes | Yes | Yes |
| Study of transport mechanisms | No | Yes | No | Yes |
| Study of ciliary physiology | Yes | Yes | Yes | Yes |
| Potential applications | ||||
| Study of drug effects | No | Yes | Yes | Yes |
| Analysis | Description of measurement of benefits/effects | Hypothetical example applied to simulation |
| Cost minimisation analysis (CMA) | A comparison of costs when the effects are considered equal in all respects | Measurement of the simulation education method versus an alternative education method produced equivalent learning outcomes within a meaningful threshold; however, the simulation method is less costly. |
| Cost-effectiveness analysis (CEA) | Benefits/effects are measured in natural units (e.g. students educated) | Measurement of the simulation education method resulted in less clinical errors by the learner than the alternative education method. |
| Cost utility analysis (CUA) | Benefits/effects measured in ‘utility’ units—e.g. a measure of satisfaction derived from consumption/attainment of benefit | Measurement of the simulation education method resulted in higher levels of patient satisfaction with their care compared to the alternative education method. |
| Cost benefit analysis (CBA) | Benefits monetized | The simulation education method was measured to be of higher value (willingness to pay) by the learners when compared to the alternative education method. |
| nFiles | Total | gql = 0 | gql = 3 |
| 2 | 706 | 378 | 92 |
| 4 | 1076 | 666 | 105 |
| 8 | 1708 | 1179 | 124 |
| 12 | 2270 | 1659 | 137 |
| Variable | Solutions for the fixed effects using the mixed effect model | p-value | |||||
| Intercept | cos FA | cos2FA | cos3FA | Flexion/ extension | Natural/ TKA | Natural/ TKA | |
| Quadriceps load | 52.88 | −7.51 | +0.23 | −0.0011 | +118.91 | +3.79 | 0.28 |
| Tibial rotation | −1.00 | +0.067 | −0.0011 | +4.75e-6 | −0.38 | +2.66 | 0.001 |
| Peak pressure | 0.89 | −0.058 | 0.0018 | −8.83e-6 | +0.45 | +2.66 | 0.004 |
| Peak pressure (ridge) | 0.99 | +0.063 | 0.0021 | −0.00001 | +0.48 | −0.61 | 0.0001 |
| Peak pressure (medial) | −0.10 | −0.015 | +0.00089 | −4.00e-6 | +0.27 | −1.24 | 0.064 |
| Peak pressure (lateral) | 0.42 | −0.032 | +0.0011 | −5.09e-6 | +0.30 | −0.16 | 0.011 |
| Contact area | 285.99 | −0.30 | +0.0097 | -0.00014 | +7.36 | −0.14 | <0.0001 |
| Proximalization | 8.55 | +0.31 | −0.0058 | + 0.000019 | +2.51 | +3.58 | <0.0001 |
| Preferred strategy | Patient characteristics |
| Invasive | Recurrent angina or ischaemia at rest or with low-level activities despite intensive medical therapy |
| Elevated cardiac biomarkers (troponin I or T) | |
| New or presumably new ST-segment depression | |
| Signs or symptoms of heart failure or new or worsening mitral regurgitation | |
| High-risk findings from non-invasive testing | |
| Haemodynamic instability | |
| Sustained ventricular tachycardia | |
| PCI within 6 months | |
| Prior CABG | |
| High-risk score (e.g. TIMI, GRACE) | |
| Reduced left-ventricular function (LVEF < 40%) | |
| Conservative | Low-risk score (e.g. TIMI, GRACE) |
| Patient or physician preference in the absence of high-risk features |
| DemographicCharacteristics | Insured (n = 2080) | Uninsured (n = 2554) | Total (n = 4634) | |||
| n | % | n | % | n | % | |
| Sex | ||||||
| Male | 883 | 42.45 | 1005 | 39.35 | 1888 | 40.74 |
| Female | 1197 | 57.55 | 1549 | 60.65 | 2746 | 59.26 |
| p = 0.033 χ2 = 4.569 | ||||||
| Age | ||||||
| 18--24 | 889 | 42.74 | 1487 | 58.22 | 2376 | 51.27 |
| 25--34 | 872 | 41.92 | 784 | 30.70 | 1656 | 35.74 |
| 35+ | 319 | 15.34 | 283 | 11.08 | 598 | 12.99 |
| p = 0.000 χ2 = 110.003 | ||||||
| Education | ||||||
| Illiterate | 8 | 0.38 | 25 | 0.98 | 33 | 0.71 |
| Primary | 66 | 3.17 | 94 | 3.68 | 160 | 3.43 |
| Junior high school | 1056 | 50.77 | 1568 | 61.39 | 2624 | 56.63 |
| Senior high school | 705 | 33.89 | 722 | 28.27 | 1427 | 30.79 |
| College | 192 | 9.23 | 116 | 4.54 | 276 | 6.65 |
| University or above | 53 | 2.55 | 29 | 1.14 | 82 | 1.77 |
| p = 0.000 χ2 = 92.019 | ||||||
| Marital status | ||||||
| Single | 708 | 34.03 | 1349 | 52.81 | 1847 | 39.86 |
| Married | 1364 | 65.60 | 1081 | 42.33 | 2772 | 59.82 |
| Others | 19 | 0.91 | 124 | 4.86 | 15 | 0.32 |
| p = 0.000 χ2 = 266.095 | ||||||
| Occupation | ||||||
| Administrative | 341 | 16.39 | 327 | 12.80 | 668 | 14.42 |
| Clerk/technician | 591 | 28.41 | 638 | 24.98 | 1229 | 26.52 |
| General worker | 1051 | 50.53 | 1390 | 54.42 | 2441 | 52.68 |
| Others | 97 | 4.66 | 199 | 7.79 | 296 | 6.39 |
| p = 0.000 χ2 = 36.214 | ||||||
| Monthly Income (CNY) | ||||||
| < 500 | 26 | 1.25 | 108 | 4.23 | 134 | 2.89 |
| 500--999 | 965 | 46.39 | 1433 | 56.11 | 2398 | 51.75 |
| 1000-1499 | 684 | 32.88 | 611 | 23.92 | 1295 | 27.95 |
| 1500-1999 | 206 | 9.90 | 202 | 7.91 | 408 | 8.80 |
| 2000+ | 199 | 9.57 | 200 | 7.83 | 399 | 8.61 |
| p = 0.000 χ2 = 98.215 |
| Nurses | Midwives | |||||||
| Baseline inputs | Doctors | Clinical officers | registered | enrolled | registered | enrolled | direct entry | Total |
| Number of staff | ||||||||
| At baseline (2008)1 | 806 | 1236 | 1453 | 5134 | 339 | 1711 | 0 | 10 679 |
| Minimum level required to meet need (same for all years)2 | 1778 | 3737 | 14 053 | 4751 | 24 319 | |||
| Inflow from training | ||||||||
| Annual training enrolment (# of new students)3 | 74 | 155 | 660 | 423 | 136 | 173 | 174 | 1795 |
| Total years of training required3 | 7 | 3 | 3 | 2 | 1 | 1 | 2 | n/a |
| Graduation rate (% of students)3 | 90.0% | 90.0% | 96.7% | 94.3% | 97.1% | 90.7% | 90.0% | n/a |
| Public sector entry rate from training schools (% of graduates)3,4 | 85.3% | 91.4% | 75.5% | 81.4% | 81.4% | 81.4% | 81.4% | n/a |
| Inflow from immigration (# per year)4 | 20 | 0 | 0 | 0 | 0 | 0 | 0 | 20 |
| Outflow from attrition | ||||||||
| Training program requires other professional diploma/degree and work experience before enrolling; or enrols students who leave the public sector workforce before enrolling | No | No | Yes | No | Yes | Yes | no | n/a |
| If yes, which specific cadre is the feeder cadre for training programs | n/a | n/a | enrolled nurses | n/a | registered nurses | enrolled nurses | n/a | n/a |
| Percent of enrolling students to which entry barrier applies (% per year) | n/a | n/a | 14.89% | n/a | 100% | 100% | n/a | n/a |
| Total attrition from cadre (% per year) | 9.80% | 4.48% | 5.30% | 4.48% | 4.48% | 4.48% | 4.48% | n/a |
| Involuntary attrition (% per year) [24,26] | 6.66% | 3.05% | 3.60% | 3.05% | 3.05% | 3.05% | 3.05% | n/a |
| Voluntary attrition (% per year) [25,26] | 3.14% | 1.43% | 1.70% | 1.43% | 1.43% | 1.43% | 1.43% | n/a |
| Neural-Network Parameters | Levenberg-Marquardt |
| Number of input parameters | 3 |
| Number of hidden neurons | 9 |
| Number of output parameters | 1 |
| Hidden transfer function | Sigmoidal |
| Output transfer function | linear |
| Maximum number of epochs | 1000 |
| Learning rate | 0.01 |
| Momentum rate | 0.9 |
| Stopping gradient | 5.5292 × 10−8 |
| MU (momentum ) | 1 × 10−8 |
| OR (95% CI) | p | |
| Age, y | 1 (0.96,1.05) | .926 |
| Gender | ||
| Female | 1 | |
| Male | 0.3 (0.08,1.15) | .079 |
| BMI, kg/m2 | 1.22 (0.99,1.49) | .056 |
| Smoking | ||
| Never smoked | 1 | |
| Light smokers | 0.63 (0.12,3.3) | .589 |
| Severe smokers | 0.29 (0.05,1.57) | .150 |
| Osteoporosis | NA | |
| Lumbar lordosis, | ||
| <50 | 1 | |
| ≥50 | 0.14(0.03,0.57) | .006* |
| L4-5 spinous height | ||
| ≤20 | 1 | |
| 20-30 | 2.57 (0.25,26.24) | .426 |
| 30-40 | 0.36 (0.08,1.64) | .186 |
| ≥40 | 0.86 (0.12,6.01) | .877 |
| L4-5 interspinous height | ||
| ≤25 | 1 | |
| 25-30 | 0.38 (0.06,2.53) | .318 |
| 30-35 | 0.52 (0.08,3.36) | .496 |
| ≥35 | 0.86 (0.05,13.48) | .913 |
| Operating time, h | 1.46 (0.37,5.82) | .589 |
| Blood loss, mL | 1 (1,1.01) | .261 |
| Hospital stay, d | 1.25 (0.98,1.6) | .067 |
| Time wearing brace, mo | ||
| ≤3 | 1 | |
| 4-5 | 2.18 (0.19,25.01) | .531 |
| ≥6 | 1.82 (0.49,6.76) | .372 |
| Time performing low back muscle exercises, mo | ||
| 0 | 1 | |
| ≤3 | NA | |
| 3-6 | 0.77 (0.16,3.74) | .745 |
| ≥7 | 1.03 (0.19,5.51) | .976 |
| Variables | Cases/Controls | Genotypes (Cases/Controls) | pa | OR (95% CI) a | |||
| AA/AG | GG | ||||||
| n | % | n | % | ||||
| Total age | 690/675 | 610/572 | 88.4/84.7 | 80/103 | 11.6/15.3 | 0.041 | 0.72 (0.52–0.99) |
| <68 | 275/397 | 246/335 | 89.4/84.4 | 29/62 | 10.6/15.6 | 0.199 | 0.72 (0.43–1.19) |
| ≥68 | 415/278 | 364/237 | 87.7/85.2 | 51/41 | 12.3/14.8 | 0.379 | 0.82 (0.52–1.28) |
| Exposure years | |||||||
| <27 | 268/261 | 236/216 | 88.1/82.8 | 32/45 | 11.9/17.2 | 0.060 | 0.62 (0.38–1.02) |
| ≥27 | 422/414 | 374/356 | 88.6/86.0 | 48/58 | 11.4/14.0 | 0.268 | 0.79 (0.52–1.20) |
| Smoking status | |||||||
| Never | 339/351 | 302/295 | 89.1/84.0 | 37/56 | 10.9/16.0 | 0.049 | 0.64 (0.41–1.00) |
| Ever | 351/324 | 308/277 | 87.8/85.5 | 43/47 | 12.2/14.5 | 0.344 | 0.81(0.52–1.26) |
| Stage | |||||||
| I | 413/675 | 368/572 | 89.1/84.7 | 45/103 | 10.9/15.3 | 0.032 | 0.66 (0.45–0.96) |
| II | 216/675 | 193/572 | 89.4/84.7 | 23/103 | 10.6/15.3 | 0.213 | 0.73 (0.44–1.20) |
| III | 61/675 | 49/572 | 80.3/84.7 | 12/103 | 19.7/15.3 | 0.188 | 1.59 (0.80–3.18) |
| Intervention | Control | ||
| (n, first year) | (n = 343) | (n = 350) | |
| (n, second year) | (n = 330) | (n = 241) | P (2) |
| (n, both years) | (n = 673) | (n = 591) | |
| Received the study leaflet | |||
| First year | 37.0 | 20.0 | 0.005 |
| Second year | 48.2 | 44.4 | 0.748 |
| Both years | 42.5 | 29.9 | 0.090 |
| Seen the study poster | |||
| First year | 27.7 | 12.6 | 0.016 |
| Second year | 50.6 | 34.4 | 0.142 |
| Both years | 38.9 | 21.5 | 0.014 |
| Received the advice on maternal care from township midwives | |||
| First year | 70.0 | 49.1 | 0.031 |
| Second year | 63.9 | 64.7 | 0.942 |
| Both years | 67.0 | 55.5 | 0.196 |
| Received the advices on maternal care from FP worker | |||
| First year | 16.0 | 17.4 | 0.797 |
| Second year | 33.3 | 37.8 | 0.698 |
| Both years | 24.5 | 25.7 | 0.858 |
| Strain | Carbon source (50 g/L) | Consumed carbon source (g/L) | 2,3-Butanediol (g/L) | Lactate (g/L) | Acetate (g/L) | Acetoin (g/L) | Ethanol (g/L) | Biomass (g/L) | 2,3-Butanediol yield (g/g) |
| KG1 | Glucose | 49.29 ± 0.65 | 16.76 ± 0.22 | 3.62 ± 0.21 | 4.52 ± 0.45 | 1.73 ± 0.09 | 2.67 ± 0.16 | 4.80 ± 0.32 | 0.34 |
| Lactose | 49.39 ± 0.59 | 16.28 ± 0.13 | 2.95 ± 0.15 | 2.98 ± 0.28 | 3.26 ± 0.11 | 4.16 ± 0.32 | 2.80 ± 0.43 | 0.33 | |
| Fructose | 44.84 ± 0.61 | 14.41 ± 0.16 | 2.27 ± 0.12 | 2.85 ± 0.33 | 2.46 ± 0.13 | 3.22 ± 0.25 | 4.06 ± 0.52 | 0.32 | |
| Galactose | 34.89 ± 0.48 | 10.27 ± 0.11 | 3.33 ± 0.15 | 2.83 ± 0.32 | 1.80 ± 0.10 | 2.64 ± 0.28 | 3.89 ± 0.18 | 0.29 | |
| Maltose | 49.20 ± 0.51 | 17.30 ± 0.21 | 2.03 ± 0.14 | 2.79 ± 0.16 | 3.56 ± 0.12 | 4.45 ± 0.45 | 3.87 ± 0.21 | 0.35 | |
| ΔadhE | Glucose | 49.27 ± 0.42 | 23.65 ± 0.25 | 1.35 ± 0.09 | 2.05 ± 0.12 | 0.60 ± 0.04 | 0.52 ± 0.04 | 3.95 ± 0.52 | 0.48 |
| Lactose | 17.76 ± 0.25 | 8.76 ± 0.12 | 1.61 ± 0.11 | 3.85 ± 0.42 | 2.01 ± 0.08 | 0.36 ± 0.06 | 1.76 ± 0.35 | 0.49 | |
| Fructose | 49.47 ± 0.52 | 21.40 ± 0.24 | 1.48 ± 0.13 | 1.58 ± 0.12 | 0.83 ± 0.06 | 0.94 ± 0.02 | 3.25 ± 0.28 | 0.43 | |
| Galactose | 36.35 ± 0.42 | 14.05 ± 0.42 | 0.73 ± 0.07 | 1.96 ± 0.09 | 3.70 ± 0.21 | 0.65 ± 0.03 | 2.99 ± 0.42 | 0.39 | |
| Maltose | 49.49 ± 0.47 | 18.18 ± 0.23 | 2.96 ± 0.10 | 1.27 ± 0.08 | 4.58 ± 0.24 | 0.91 ± 0.08 | 4.27 ± 0.25 | 0.36 | |
| Δpta | Glucose | 49.27 ± 0.54 | 20.20 ± 0.62 | 0.77 ± 0.09 | 3.15 ± 0.11 | 2.31 ± 0.15 | 1.69 ± 0.32 | 3.40 ± 0.52 | 0.41 |
| Lactose | 10.10 ± 0.25 | 2.98 ± 0.11 | 0.96 ± 0.07 | 2.01 ± 0.10 | _ | 0.30 ± 0.02 | 1.01 ± 0.46 | 0.30 | |
| Fructose | 49.51 ± 0.55 | 18.36 ± 0.32 | 1.01 ± 0.10 | 2.20 ± 0.09 | 2.81 ± 0.11 | 1.87 ± 0.14 | 2.96 ± 0.26 | 0.37 | |
| Galactose | 39.49 ± 0.23 | 11.88 ± 0.12 | 0.19 ± 0.06 | 1.98 ± 0.12 | 1.56 ± 0.14 | 1.29 ± 0.21 | 3.27 ± 0.43 | 0.30 | |
| Maltose | 40.28 ± 0.54 | 14.57 ± 0.24 | 4.68 ± 0.08 | 2.50 ± 0.14 | 1.91 ± 0.12 | 3.26 ± 0.33 | 3.74 ± 0.44 | 0.36 |
| Intake | All dysphagic patients (N = 120) | Spinal onset dysphagic patients (N = 64) | Bulbar onset dysphagic patients (N = 56) | p |
| Normal | 8 (7) | 7 (11) | 1 (2) | ns |
| Postural | 31 (26) | 20 (31) | 11 (20) | ns |
| Syrup/nectar | 13 (11) | 12 (19) | 1(2) | 0.007 |
| Cream | 43 (36) | 22 (34) | 21 (37) | ns |
| Percutaneous endoscopic gastrostomy | 25 (20) | 3 (5) | 22 (39) | 0.0001 |
| Frequency (%) questions | Most often | sometimes | Not often | never | No answer |
| How often are you giving oral health education to school (nurseries) children? | 48 (19.7) | 70 (44.6) | 19 (12.1) | 20 (12.7) | — |
| How do you supervise fluoride mouth wash programme in school? | 31 (19.7) | 54 (34.4) | 20 (12.7) | 52 (33.2) | 10 (6) |
| Are you examining mouth and teeth of pregnant women? | 59 (37.6) | 35 (22.3) | 17 (10.8) | 46 (29.3) | — |
| How do you refer the patients to dentist or oral hygienist? | 76 (48.4) | 37 (23.6) | 19 (12.1) | 25 (15.9) | — |
| yes | no | No answer | |||
| Have you had any partnership with parents regarding oral health? | 45 (28.7) | 112 (71.3) | — | ||
| Have you had any partnership with other health sector regarding oral health? | 24 (15.3) | 133 (84.7) | — | ||
| Do you know about the water fluoride content of your area? | 26 (16.6) | 107 (68.1) | 24 (15.3) | ||
| Do you have any information about oral health status (DMFT/CPITN) of the population under your care? | 55 (35) | 102 (65) | — | ||
| Do you complete the annual oral health report form? | 76 (30.2) | 81 (51.6) | — |
| Type of study | Scale of analysis | Data sources | Interviewee profiles | No. of interviewees |
| History of free care | National | Scientific literature, administrative archives and print media, in-depth semi-structured interviews | Health, agriculture and education (decision-makers, technicians, implementers) | n = 28 |
| Fee exemptions for malaria (prevention, treatment) | District (Hauts-Bassins region) | Scientific literature, routine data, in-depth semi-structured interviews, group discussions | Decision-makers, local actors (NGOs, associations) and healthcare providers | n = 63 |
| Antiretroviral drug exemptions for children and adults | Regional (Centre and Hauts-Bassins regions) | Scientific literature, routine data, semi-structured interviews | Institutional decision-makers, local actors (NGOs, associations), healthcare providers, service users | n = 30 |
| Raw data | Clean data | ||
| Number of reads | 300,582 | 23,498 | |
| Number of nucleotides (bp) | 673,594,247 | 20,685,462 | |
| Longest read length (bp) | 11,914 | 2,261 | |
| Mean read length (bp) | 2,241 | 880 | |
| Genome coverage % | 100% | ||
| Average depth of coverage | 132× | ||
| Number of contigs | 1 | ||
| Whole cp genome length (bp) | 156,749 | ||
| Run time | 45 min×2 | ||
| Total DNA requirements (ng) | 700 |
| Apicomplexan species | Positive training set | Negative training set |
| B. bovis | 18 | 30 |
| B. microti | 23 | 22 |
| C. hominis | 1 | 28 |
| C. muris | 0 | 34 |
| C. parvum | 2 | 33 |
| E. tenella | 30 | 143 |
| N. caninum | 21 | 77 |
| P. berghei | 49 | 94 |
| P. chabaudi | 51 | 98 |
| P. cynomolgi | 31 | 90 |
| P. falciparum | 51 | 132 |
| P. knowlesi | 48 | 90 |
| P. vivax | 51 | 101 |
| P. yoelii | 41 | 87 |
| T. annulata | 23 | 41 |
| T. parva | 25 | 61 |
| T. gondii | 42 | 86 |
| Variables | N | Pre-intervention | Post intervention | p-value |
| TUG (sec) | 37 | 9.35 (7.16;12.62) | 8.34 (6.27;11.12) | <0.01 |
| FTSST (sec) | 37 | 16.61 (12.50;20.18) | 12.94 (10.07;15.82) | <0.01 |
| Total CCQ score | 37 | 3.6 (3.2;4.3) | 3.3 (2.5;3.6) | 0.039 |
| Compound | Spiked concentration (μg/mL) | Intraday | Interday | ||
| Detected concentration (μg/mL) | RSDa (%) | Detected concentration (μg/mL) | RSD (%) | ||
| Gallic acid | 5 | 5.03 | 2.57 | 5.30 | 1.77 |
| 10 | 9.64 | 1.80 | 9.59 | 2.02 | |
| 20 | 20.17 | 0.42 | 20.13 | 0.58 | |
| Ellagic acid | 5 | 5.34 | 0.78 | 5.45 | 2.80 |
| 10 | 9.67 | 2.14 | 9.88 | 2.26 | |
| 15 | 15.11 | 0.95 | 14.93 | 1.27 | |
| Eugenol | 10 | 10.52 | 0.83 | 10.39 | 0.36 |
| 25 | 25.09 | 0.28 | 25.16 | 0.14 | |
| 40 | 39.81 | 0.12 | 39.81 | 0.08 |
| With hardiness n (%) | No hardiness n (%) | Total | p value | |
| With burnout, | 40 | 101 | 141 | |
| n (%) | (7.02%) | (17.72%) | (24.74%) | |
| No burnout, | 85 | 344 | 429 | |
| n (%) | (14.91%) | (60.35%) | (75.26%) | |
| Total, | 125 | 445 | 570 | 0.033 |
| n (%) | (21.93%) | (78.07%) | (100.00%) |
| Naïve | GBT | |||
| Train Acc | Test Acc | Train Acc | Test Acc | |
| AP | 97.56 (0.70) | 96.00 (5.62) | 97.56 (0.70) | 96.00 (5.62) |
| OVR | 97.85 (0.82) | 96.67 (5.67) | 97.85 (0.82) | 96.67 (5.67) |
| Dense | 67.56 (2.88) | 68.00 (16.27) | 97.70 (0.74) | 96.00 (6.44) |
| Sparse | 66.67 (1.16) | 66.67 (10.42) | 97.78 (0.92) | 95.33 (5.49) |
| Total | High-Blimp-1 | Low-Blimp-1 | P value |
| (n = 24) | (n = 13) | (n = 11) | |
| Age, years | |||
| Median | 61 | 59 | 0.797 |
| Range | 23–75 | 24–77 | |
| Gender | |||
| Male | 6 | 4 | 0.628 |
| Female | 7 | 7 | |
| WBC, × 109/l | |||
| Median | 82.9 | 24.9 | 0.033 |
| Range | 5.8–364.6 | 5.1–87 | |
| PB blast, % | |||
| Median | 68 | 73 | 0.721 |
| Range | 1.9–93.8 | 18–90.8 | |
| Absolute blast counts, × 109/l | |||
| Median | 41 | 16 | 0.026 |
| Range | 0.1–342 | 3–47 | |
| BM blast, % | |||
| Median | 60 | 64.5 | 0.626 |
| Range | 1.5–88 | 34.5–79 | |
| Cytogeneticsa | |||
| Adverse | 6 | 6 | 0.799 |
| Intermediate | 5 | 4 | |
| Favorable | 1 | 1 |
| MZ twins(n = 126; 63 twin pairs) | DZ twins(n = 76; 38 twin pairs) | |||
| r value | 95% CI | r value | 95% CI | |
| Weight | 0.881 | 0.800-0.931 | 0.437 | 0.077-0.737 |
| Waist circumference | 0.865 | 0.763-0.935 | 0.510 | 0.052-0.781 |
| Systolic blood pressure | 0.598 | 0.426-0.731 | 0.055 | -0.524-0.576 |
| Diastolic blood pressure | 0.608 | 0.444-0.728 | 0.147 | -0.321-0.648 |
| Serum total cholesterol | 0.445 | 0.259-0.633 | 0.640 | 0.363-0.845 |
| Serum HDL-cholesterol | 0.840 | 0.626-0.895 | 0.658 | -0.293-0.798 |
| Serum triglycerides | 0.527 | 0.281-0.707 | 0.349 | -0.023-0.625 |
| Fasting blood glucose | 0.523 | 0.453-0.804 | 0.545 | 0.068-0.744 |
| Fasting insulin | 0.513 | 0.292-0.725 | 0.492 | 0.209-0.716 |
| Serum creatinine | 0.639 | 0.479-0.784 | 0.159 | -0.065-0.434 |
| Serum uric acid | 0.691 | 0.542-0.799 | 0.629 | 0.453-0.772 |
| Fibrinogen | 0.663 | 0.499-0.791 | 0.322 | 0.024-0.639 |
| Serum homocysteine | 0.681 | 0.505-0.781 | 0.838 | 0.582-0.948 |
| Serum C-reactive protein | 0.683 | 0.460-0.851 | 0.138 | -0.199-0.555 |
| Variable | n or M | % or SD | |
| Time Since Loss (months) | 6.25 | 2.36 | |
| Severity of PGDa | 23.33 | 10.27 | |
| Age (years) | 44.30 | 16.07 | |
| Gender | Female | 123 | 71.9% |
| Male | 47 | 27.5% | |
| Education | Less than High School | 1 | 0.6% |
| High School | 35 | 20.5% | |
| College/Undergraduate Degree | 92 | 53.8% | |
| Graduate Degree | 31 | 18.1% | |
| Professional Degree | 9 | 5.3% | |
| Relationship to the Deceased | Grandparent | 22 | 12.9% |
| Spouse | 36 | 21.1% | |
| Child | 6 | 3.5% | |
| Sibling | 12 | 7% | |
| Parent | 59 | 34.5% | |
| Friend | 18 | 10.5% | |
| Ex-Spouse/Partner | 3 | 1.8% | |
| Other | 14 | 8.2% | |
| Cause of Death | Suicide | 12 | 7.0% |
| Accident | 7 | 4.1% | |
| Illness | 109 | 63.7% | |
| Natural Sudden | 35 | 20.5% | |
| Other | 7 | 4.1% |
| CEPS | CEPM | P value | CEPS | CEPM | P value | ||
| 19 | PPM (82) | PPM (19) | No PPM (19) | No PPM (11) | |||
| PG max (mmHg) | 36,97 ± 12,29 | 34,65 ± 7,45 | 0,45 | 38,05 ± 7,99 | 29,36 ± 7,31 | 0,006 | |
| PG mean (mmHg) | 20,65 ± 7,86 | 18,69 ± 4,54 | 0,34 | 21,47 ± 5,36 | 14,60 ± 2,84 | 0,0001 | |
| DVI | 0,39 ± 0,08 | 0,49 ± 0,13 | 0,007 | 0,53 ± 0,12 | 0,59 ± 0,08 | 0,17 | |
| EOAi (cm2/m2) | 0,58 ± 0,12 | 0,71 ± 0,39 | 0,17 | 1,13 ± 0,44 | 1,03 ± 0,40 | 0,55 | |
| 21 | PPM (49) | PPM (19) | No PPM (27) | No PPM (24) | |||
| PG max (mmHg) | 31,79 ± 8,72 | 31,15 ± 12,78 | 0,81 | 29,56 ± 9,20 | 28,42 ± 10,95 | 0,69 | |
| PG mean (mmHg) | 17,43 ± 5,09 | 17,36 ± 6,24 | 0,96 | 15,81 ± 5,64 | 15,95 ± 5,52 | 0,93 | |
| DVI | 0,42 ± 0,09 | 0,59 ± 0,47 | 0,017 | 0,59 ± 0,18 | 0,60 ± 0,26 | 0,89 | |
| EOAi (cm2/m2) | 0,65 ± 0,11 | 0,65 ± 0,18 | 0,99 | 1,04 ± 0,19 | 1,03 ± 0,28 | 0,85 | |
| 23 | PPM (32) | PPM (9) | No PPM (26) | No PPM (15) | |||
| PG max (mmHg) | 27,86 ± 12,86 | 22,11 ± 7,04 | 0,09 | 26,46 ± 11,22 | 24,28 ± 7,61 | 0,52 | |
| PG mean (mmHg) | 14,97 ± 6,99 | 12, 00 ± 4,80 | 0,24 | 12,92 ± 4,50 | 13,36 ± 4,53 | 0,77 | |
| DVI | 0,40 ± 0,07 | 0,63 ± 0,45 | 0,16 | 0,51 ± 0,9 | 0,52 ± 0,12 | 0,67 | |
| EOAi (cm2/m2) | 0,71 ± 0,11 | 0,85 ± 0,43 | 0,37 | 1,16 ± 0,20 | 1,03 ± 0,21 | 0,095 | |
| 25 | PPM (8) | PPM (2) | No PPM (11) | No PPM (11) | |||
| PG max (mmHg) | 28,25 ± 10,82 | 36,00 ± 9,89 | 0,39 | 23,90 ± 6,52 | 20, 55 ± 8,38 | 0,34 | |
| PG mean (mmHg) | 14,63 ± 5,55 | 18,00 ± 4,24 | 0,45 | 12,80 ± 4,10 | 10,90 ± 4,31 | 0,33 | |
| DVI | 0,32 ± 0,15 | 0,44 ± 0,11 | 0,31 | 0,49 ± 0,06 | 0,57 ± 0,13 | 0,15 | |
| EOAi (cm2/m2) | 0,63 ± 0,13 | 0,68 | 0,73 | 0,85 ± 0,41 | 1,29 ± 0,40 | 0,063 |
| Stage | Role names | Questionable |
| 1 | 17 (4.03%) | 0 |
| 2 | 230 (54.5%) | 84 |
| 3 | 30 (7.11%) | 1 |
| 4 | 2 (0.47%) | 1 |
| 5 | 11 (2.61%) | 0 |
| No data | 132 (31.28%) | NA |
| Characteristics | Total (n = 412) | Men (n = 198) | Women (n = 214) |
| Total steps per day | 8182.4 ± 3537.1 | 8448.4 ± 3379.5 | 7934.4 ± 3668.7 |
| Total energy expenditure (kcal/day) | 624.6 ± 275.1 | 722.7 ± 298.9* | 531.7 ± 212.9 |
| Actical total counts (per day) | 186699.7 ± 104354.9 | 203739.6 ± 110309.5ψ | 170724.9 ± 95992.9 |
| Time in sedentary activity (actical) (min/d) | 1098.1 ± 99.2 | 1092.8 ± 99.8 | 1103.0 ± 98.6 |
| Time in light activity (actical) (min/d) | 206.9 ± 59.8 | 204.1 ± 59.3 | 209.6 ± 60.3 |
| Time in moderate activity (actical) (min/d) | 131.2 ± 51.7 | 138.7 ± 53.3ψ | 124.1 ± 49.2 |
| Time in vigorous activity (actical) (min/d) | 3.8 ± 7.8 | 4.3 ± 8.6 | 3.3 ± 7.0 |
| Total self reported energy expenditure (MET*hr/wk) | 388.6 ± 74.8 | 381.9 ± 77.5 | 394.9 ± 71.9 |
| Paramètres | ε3 (E3/E3) | ε4 (E4/E3+ E4/E4) |
| Nombre de sujets | 31 | 9 |
| Age (années) | 58±7 | 59±7 |
| BMI (kg/m2) | 26±5 | 30±2* |
| TA (mm Hg) | 15±3 | 14±3 |
| Cholestérol total (mg/dl) | 278 | 300±15 |
| LDL cholestérol (mg/dl) | 219± 27 | 230±25 |
| Triglycérides (mg/dl) | 120±12* | 210±18* |
| Apo B (g/l) | 135±15* | 148±20* |
| t.Xt (%) | 17 | 20 |
| MCV (%) | 18 | 20 |
| No. | Hospital Level | Original Supply | Optimal Supply at Week 1 | Optimal Supply at Week 2 | Optimal Supply at Week 3 | Optimal Supply at Week 4 |
| 1 | 2 | 74 | 45.5 | 48.8 | 48.8 | 51.6 |
| 2 | 2 | 79 | 44.5 | 49.4 | 48.4 | 66.2 |
| 3 | 2 | 160 | 90.0 | 126.0 | 73.9 | 111.9 |
| 4 | 1 | 106 | 148.5 | 136.4 | 141.8 | 142.2 |
| 5 | 1 | 65 | 160.0 | 159.5 | 160.0 | 160.0 |
| 6 | 2 | 87 | 104.5 | 73.1 | 121.5 | 61.0 |
| 7 | 2 | 152 | 130.0 | 129.8 | 128.6 | 130.0 |
| Group | BWC (g) | TW (g) | Testosterone (nmol/L) | TSC (104) | MF (per 30 min) |
| Normal control | 49 ± 16.26 | 3.40 ± 0.48 | 6.99 ± 3.09∗ | 47 ± 05.81 | 19 ± 1.02∗ |
| Untreated | 39 ± 16.23 | 2.76 ± 0.08 | 3.01 ± 2.82 | 35 ± 07.94 | 09 ± 1.00 |
| Sildenafil (20 mg/kg) | 50 ± 15.44 | 3.55 ± 0.41 | 14.93 ± 8.34∗∗ | 37 ± 05.92 | 64 ± 1.01∗∗ |
| O.p (50 mg/kg) | 65 ± 17.47 | 3.33 ± 0.20 | 2.12 ± 1.54 | 53 ± 20.17 | 16 ± 3.09 |
| O.p (250 mg/kg) | 97 ± 12.26∗ | 3.62 ± 0.62 | 6.60 ± 3.51∗ | 74 ± 10.56∗ | 18 ± 3.54∗ |
| M.p (50 mg/kg) | 44 ± 11.60 | 4.21 ± 0.41 | 2.58 ± 0.71 | 46 ± 2.56 | 32 ± 3.11∗∗ |
| M.p (250 mg/kg) | 48 ± 13.23 | 4.29 ± 0.11 | 10.95 ± 3.42∗ | 49 ± 14.13 | 46 ± 1.20∗∗ |
| Outcome | Rank obtained | Percentage of responders | Priority | |||||||||
| Post | Pre | Chi | ||||||||||
| Post | Pre | Post | Pre | P1 | P2 | P3 | P1 | P2 | P3 | P | ||
| Aesthetics | Aes | 1 | 3 | 100% | 89% | 78% | 19% | 3% | 58% | 26% | 5% | <0.01 |
| Quality of life | QoL | 2 | 4 | 91% | 74% | 75% | 6% | 9% | 63% | 21% | 0% | <0.01 |
| Disability | Dis | 3 | 11 | 91% | 63% | 69% | 6% | 16% | 47% | 11% | 5% | <0.01 |
| Back Pain | BP | 4 | 7 | 87% | 68% | 63% | 13% | 13% | 58% | 16% | 11% | <0.01 |
| Psychological well-being | PWB | 5 | 84% | 66% | 13% | 6% | 79% | 5% | 0% | |||
| Progression in adulthood | PiA | 6 | 2 | 84% | 84% | 56% | 28% | 0% | 74% | 5% | 16% | <0.01 |
| Breathing function | BF | 7 | 1 | 84% | 95% | 44% | 25% | 16% | 63% | 16% | 5% | <0.01 |
| Scoliosis Cobb degrees | SCD | 8 | 5 | 84% | 84% | 44% | 34% | 6% | 58% | 11% | 21% | <0.01 |
| Needs of further treatments in adulthood | NTA | 9 | 6 | 81% | 89% | 53% | 22% | 6% | 53% | 21% | 0% | <0.01 |
| Rib hump | RH | 10 | 8 | 78% | 84% | 59% | 13% | 6% | 42% | 26% | 0% | <0.01 |
| Self control of posture | 11 | 75% | 41% | 25% | 9% | |||||||
| Perdriolle degrees | PD | 12 | 9 | 75% | 84% | 16% | 50% | 9% | 47% | 11% | 11% | <0.01 |
| Knowledge and understanding of scoliosis | 13 | 72% | 44% | 16% | 13% | |||||||
| Movement of the vertebral column | 14 | 72% | 38% | 25% | 9% | |||||||
| Kypho-lordosis Cobb degrees | KLD | 15 | 10 | 72% | 68% | 31% | 34% | 6% | 58% | 26% | 5% | <0.01 |
| Balance | 16 | 69% | 44% | 19% | 6% | |||||||
| Body motor awareness and learning skills | 17 | 69% | 9% | 34% | 25% | |||||||
| Sensory motor integration of the corrective pattern | 18 | 62% | 41% | 16% | 6% | |||||||
| Improved processing of vestibular input | 19 | 59% | 6% | 31% | 22% | |||||||
| Equality of weight bearing | 20 | 56% | 22% | 19% | 16% | |||||||
| Exercise efficiency | 21 | 56% | 22% | 28% | 6% |
| Normal controls | 2-kidneys-1-clip model of hypertension | 1-kidney-1-clip model of hypertension | P | |
| Heart rate (bpm) | 455.3 ± 60.8 | 472.5 ± 54.9 | 463.6 ± 55.4 | ns |
| Systolic blood pressure - baseline (mmHg) | 100.9 ± 5.5 | 144.8 ± 13.0 | 152.3 ± 16.6 | <0.0001 |
| Diastolic blood pressure - baseline (mmHg) | 76.7 ± 4.3 | 106.4 ± 12.7 | 109.2 ± 8.7 | 0.0001 |
| Heart rate – after atropine (bpm) | 559.8 ± 58.1 | 575.9 ± 82.5 | 604.4 ± 55.4 | ns |
| Systolic blood pressure - after atropine (mmHg) | 108.9 ± 6.6 | 152.7 ± 16.1 | 151.2 ± 15.3 | <0.0001 |
| Diastolic blood pressure - after atropine (mmHg) | 85.9 ± 6.0 | 116.0 ± 11.9 | 111.2 ± 8.4 | <0.0001 |
| Heart rate – after metoprolol (bpm) | 463.0 ± 74.0 | 513.8 ± 67.6 | 479.3 ± 49.4 | ns |
| Systolic blood pressure - after metoprolol (mmHg) | 100.2 ± 10.8 | 155.1 ± 14.9 | 151.1 ± 15.3 | <0.0001 |
| Diastolic blood pressure - after metoprolol (mmHg) | 77.3 ± 9.2 | 114.1 ± 13.4 | 111.4 ± 10.5 | <0.0001 |
| GEO | Tissue type | Test sample size (n vs. c) | Sig genes DN | Reference |
| GSE18520 | Ovary | 10 vs. 53 | 79 | [66] |
| GSE14407 | Ovary | 12 vs. 12 | 109 | [67] |
| GSE764 | Uterus | 4 vs. 7 benign | 0 | Unpublished |
| GSE764 | Uterus | 4 vs. 8 malignant | 2 | Unpublished |
| GSE15471 | Pancreas | 39 vs. 39 | 120 | [68] |
| GSE23878 | Colon | 24 vs. 35 | 74 | Unpublished |
| Animals | −7 | −4 | −1 | +1 | +2 | +3 | +4 | +7 | +8 | +10 | +11 | +14 | |
| d a.i. | d a.i. | h a.i. | dpi | dpi | dpi | dpi | dpi | dpi | dpi | dpi | dpi | ||
| PFT | C. psittaci | n = 18 | n = 18 | n = 18 | n = 15 | n = 12 | n = 9 | n = 9 | n = 6 | n = 6 | |||
| Controls | n = 18 | n = 18 | n = 18 | n = 15 | n = 12 | n = 9 | n = 9 | n = 6 | n = 6 | ||||
| Blood | C. psittaci | n = 21 | n = 21 | n = 21 | n = 18 | n = 15 | n = 12 | n = 9 | n = 6 | ||||
| Controls | n = 21 | n = 21 | n = 21 | n = 18 | n = 15 | n = 12 | n = 9 | n = 6 |
| Variable | Adopted children (N = 18) | Parents (N = 26) | Pa |
| Mean (SD) [range] | Mean (SD) [range] | ||
| Age (years) | 14.0 (4.1) [7.9 to 20.0] | 49.0 (5.7) [40.0 to 65.0] | <0.001 |
| Height (cm) | 157.7 (16.4) [130.0 to 180.0] | 167.2 (10.6) [150.0 to 183.0] | 0.021 |
| Weight (kg) | 50.4 (15.4) [28.0 to 81.0] | 80.5 (16.6) [48.0 to 120.0] | <0.001 |
| BMI (kg/m2) | 19.8 (3.1) [13.2 to 26.6] | 28.5 (4.1) [20.7 to 38.3] | <0.001 |
| PAI | 4.8 (1.4) [3.1 to 5.8] | 4.0 (1.2) [3.5 to 5.5] | n.s. |
| Smoking index | 50 (0.0) [50 to 50] (N 1) | 237.5 (152.3) [75 to 525] (N 8) | n.s. |
| Sleep duration (h) | 8.3 (1.9) [5 to 10] | 7.1 (1.3) [6 to 10] | 0.011 |
| Fractures (No.) | 2.0 (1.4) [1 to 3] | 1.2 (0.5) [1 to 2] | n.s. |
| Spine BMD Z score | 1.4 (1.1) [−1.4 to 2.8] | −0.1 (0.9) [−2.3 to 1.7] | <0.001 |
| Total femur BMD Z score | 0.9 (1.0) [−2.1 to 2.3] | 0.5 (0.8) [−1.1 to 2.4] | n.s. |
| Radius 1/3 BMD Z score | −0.8 (0.9) [−2.4 to 1.5] | −0.0 (0.9) [−1.6 to 2.3] | 0.015 |
| Energy (kcal) | 3177.1 (1070.0) [1369.1 to 5401.2] | 2170.5 (950.3) [833.5 to 4246.5] | 0.008 |
| Protein (g/1000 kcal) | 33.8 (5.5) [25.8 to 45.6] | 39.2 (5.8) [30.4 to 50.4] | 0.011 |
| Fat (g/1000 kcal) | 37.0 (6.9) [23.2 to 46.0] | 36.6 (3.8) [29.8 to 45.2] | n.s. |
| Carbohydrate (g/1000 kcal) | 136.7 (20.1) [106.9 to 174.2] | 129.0 (16.6) [81.1 to 156.8] | n.s. |
| Dietary fiber (g/1000 kcal) | 10.1 (3.5) [6.2 to 19.6] | 11.3 (2.3) [6.5 to 19.1] | n.s. |
| Calcium (mg/1000 kcal) | 395.3 (99.7) [276.4 to 593.9] | 356.8 (118.3) [201.9 to 599.3] | n.s. |
| Vitamin D (IU/1000 kcal) | 27.8 (10.2) [15.3 to 47.4] | 33.3 (15.0) [16.1 to 73.9] | n.s. |
| Study | Subject (number) | Design | Particles | Results |
| Gong et al [26] | Healthy volunteers (12)Patients with mild asthma (12) | Crossover | Filtered air, Fine CAPS (174 μg/m3) | CAPS induced modest and similar increases in parasympathetic stimulation of HRV in both groups |
| Gong et al [42] | Healthy elderly, age (6)Elderly patients with COPD (13) | Crossover | Filtered air, Fine CAPS (200 μg/m3) | Decrease in HRV in healthy elderly but not in COPD patients |
| Frampton et al [40] | Healthy volunteers (40), Patients with asthma (16) | Crossover | Filtered airUltrafine carbon particles (10, 25 and 50 μg/m3) | In healthy subjects, reduced CD54 and CD18 on monocytes; decreased CD18 and CD49d on granulocytes; decreased CD25 in blood monocytes, basophils, and eosinophils; increased lymphocyte expression of CD25.In asthma, reduced CD11b on monocytes and eosinophils, CD54 on granulocytes, the percentage of CD4+ T cells, basophils, and eosinophils |
| Piatropaoli et al [41] | Healthy volunteers (40), Patients with asthma (16) | Crossover | Filtered airUltrafine carbon particles (10, 25 and 50 μg/m3) | No changes in airway eNO and total cell count/differentials in induced sputum; Increased percentage macrophages in the sputum of asthmatics;No changes in IL-6 and IL-8 in the sputum |
| Gong et al [67] | Healthy volunteers (4)Patients with mild asthma (12) | Crossover | Filtered air Coarse CAPS (157 μg/m3) | Decrease HR and PNN50 4 hours post-exposure |
| Stenfors et al [43] | Healthy volunteers (25)Patients with mild asthma (15) | Single-blind randomized crossover | Filtered airDiesel exhaust (PM10, 108 μg/m3) | Increased neutrophils, IL-8 and IL-6 in BAL fluid and P-selectin and VCAM-1 in bronchial biopsy, no difference between normal and asthmatics |
| Gong et al [44] | Healthy volunteers (14)Patients with mild asthma (17) | Crossover | Filtered airUltrafine CAPS (100 μg/m3 or 145,000/cm3 particle counts | Decreased O2sat, FEV1 and low frequency power; no differences between normal and asthmatics |
| Specialty | No. of clinics | No. ofpatients | % of total costrepresented by pharmacy cost(mean ± sd) | Correlation between costs including and excluding pharmacy costs1) |
| General clinics | 4,695 | 3,807,917 | 32.04 ± 23.84 | 0.99 |
| Internal medicine | 3,611 | 4,852,887 | 38.23 ± 25.23 | 0.87 |
| Pediatrics | 2,128 | 2,333,778 | 26.18 ± 19.80 | 0.99 |
| Otorhinolaryngology | 1,737 | 2,561,254 | 24.10 ± 15.40 | 0.99 |
| Orthopedic surgery | 1,725 | 1,585,045 | 20.23 ± 21.56 | 0.99 |
| Obstetrics & gynecology | 1,604 | 873,524 | 21.09 ± 20.82 | 0.98 |
| Ophthalmology | 1,207 | 1,515,235 | 23.38 ± 17.31 | 0.97 |
| General surgery | 1,193 | 794,618 | 27.65 ± 23.32 | 0.97 |
| Family medicine | 1,055 | 1,009,541 | 34.11 ± 23.20 | 0.95 |
| Urology | 888 | 581,503 | 30.82 ± 23.46 | 0.90 |
| Dermatology | 803 | 779,600 | 29.02 ± 21.96 | 0.93 |
| Psychiatry | 708 | 308,835 | 19.00 ± 27.05 | 0.99 |
| Anesthesiology | 588 | 296,653 | 28.90 ± 25.95 | 0.99 |
| Neurosurgery | 362 | 298,801 | 27.49 ± 25.29 | 0.99 |
| Rehabilitation medicine | 276 | 158,182 | 27.17 ± 26.74 | 0.99 |
| Diagnostic radiology | 244 | 156,622 | 10.61 ± 21.37 | 0.96 |
| Neurology | 132 | 104,304 | 41.56 ± 28.60 | 0.92 |
| Thoracic surgery | 82 | 64,099 | 31.97 ± 23.83 | 0.97 |
| Plastic surgery | 74 | 6,251 | 13.22 ± 20.15 | 0.98 |
| Total | 23,112 | 22,088,649 | 29.76 ± 23.80 | 0.95 |
| EPDnew database | Source data: type, reference or source repository | # of libraries | total tags (millions) |
| H. sapiens | CAGE from ENCODE/RIKEN, downloaded from UCSC genome browser database (12) | 148 | 3841 |
| M. musculus | CAGE from FANTOM5 (http://fantom.gsc.riken.jp/5/)) | 339 | 6236 |
| D. melanogaster | CAGE from modENCODE (ftp://data.modencode.org/) TSS-seq from Machibase (13) | 57 | 646 |
| D. rerio | CAGE from Nepal et al. (14), downloaded from SRA (8), ID SRA055273 | 12 | 65 |
| C. elegans | GRO-cap from Kruesi et al. (15) | 8 | 236 |
| Socio-demographic factors | STHs infection status | Total | X2 | P-value | ||
| Negative | Positive | |||||
| Age | 6–10 | 156 (81.7%) | 35 (18.3%) | 191 (100.0%) | 0.49 | 0.12 |
| 11–15 | 102 (81.0%) | 24 (19.0%) | 126 (100.0%) | |||
| Gender | Girl | 145 (78.4%) | 40 (21.6%) | 185 (100.0%) | 0.068 | 0.031 |
| Boy | 113 (85.6%) | 19 (14.4%) | 132 (100.0%) | |||
| Family size | 1 parent and child | 4 (80.0%) | 1 (20.0%) | 5 (100.0%) | 0.03 | 0.0 |
| 1 parent and 2 children | 15 (88.2%) | 2 (11.8%) | 17 (100.0%) | |||
| 2 parents and 2 children | 40 (88.9%) | 5 (11.1%) | 45 (100.0%) | |||
| 2 parents & > 2 children | 193 (79.4%) | 50 (20.6%) | 243 (100.0%) | |||
| Latrine available | Yes | 216((83.7%) | 42 (16.3%) | 258 (100.0%) | 0.09 | 0.05 |
| No | 36 (67.9%) | 17 (32.1%) | 53 (100.0%) | |||
| Type of latrine | Ventilated improved | 50 (92.6%) | 4 (7.4%) | 54 (100.0%) | 0.036 | – |
| Traditional pit latrine | 152 (79.6%) | 39 (20.4%) | 191 (100.0%) | |||
| Water flash | 13 (100.0%) | 0(.0%) | 13 (100.0%) | |||
| Finger nail trimming | Yes | 115 (85.8%) | 19 (14.2%) | 134 (100.0%) | .039 | .024 |
| No | 31 (72.1%) | 12 (27.9%) | 43 (100.0%) |
| Putative virus integration-harboring regionsa | SNPs | Insertions | Deletions |
| Chr3:140,567,185-140,575,795 | 26 | 6 | 2 |
| Chr6:33,823,990-33,832,089 | 0 | 0 | 0 |
| Chr18:102,747-110,847 | 178 | 5 | 9 |
| Dependent variable | P | OR | 95% CI | |
| AIH-1 | ||||
| Model 1 | ||||
| HLA-DRB1∗ | Different from 03 and/or 13 | <0.001 | 8.28 | 3.46–19.82 |
| 03 and/or 13 | ||||
| IL13 rs20541 | AG plus GG | 0.002 | 9.45 | 2.28–39.18 |
| AA | ||||
| IL4RA rs1805011 | AG plus GG | 0.001 | 3.72 | 1.78–7.77 |
| AA | ||||
| IL5 rs2069812 | ||||
| Model 2 | ||||
| Treatment suspension | Yesa | 0.004 | 6.41 | 1.83–22.44 |
| No | ||||
| IgE levels | ||||
| Model 3 | ||||
| IL4 rs2227284 | TT and GT | 0.022 | 7.42 | 1.33–41.34 |
| GG |
| Model | Insight | Author, weblink |
| TECHNIQUES TO STUDY METABOLIC ADAPTATION IN SALMONELLA | ||
| S. Typhimurium metabolite profiling for different (nutrient poor, virulence induced) environments and genome-scale metabolite model | →Central carbon metabolism strongly altered (depletion in glycerol catabolism (glycerol, glycerol 3-phosphate, dihydroxyacetone phosphate, and pyruvate), increased glucose. Synthesis and uptake of polyamines (may protect Salmonella against osmotic stress inside host cells). | Kim et al., 2013 |
| doi: 10.1039/C3MB25598K | ||
| Metabolic model and microbiology, metabolite measurements; for survival (unrelated to growth): “maintenance requirements” and “costs” (to resist host) are calculated as ATP expenditure. | → Accumulation of metabolites in the infected gut (lactose, galactinol, melibiose, and raffinose) Salmonella and murine host lack necessary enzymes → used by Bacteroidetes and other commensals (glycosidases). | Deatherage Kaiser et al., 2013 |
| PMID: 22168414 | ||
| → Model predicted hundreds of virulence phenotypes with 90% accuracy. | ||
| → Costs become very high under excess nutrient availability | ||
| Model | Result | Author, weblink |
| METABOLIC MODELING TECHNIQUES | ||
| Hypothesis of nutrient-limitation during infection | → Inactivation of Salmonella enzyme → metabolic bottleneck → overexpression of another enzyme. | Steeb et al., 2013 |
| PMID: 23633950 | ||
| Deletion effects, e.g., calculations for Δppc | → No compensatory flux via the glyoxylate shunt. | Fong et al., 2013 |
| PMID: 23432746 | ||
| Model | Result | Author, weblink |
| MODELING REGULATION OF SALMONELLA METABOLISM | ||
| Boolean modeling of genes in SPI1, SPI2, and T6SS Integrated: osmolarity, glucose, iron, calcium and magnesium concentrations, growth phase-dependent stationary phase factors. | → Description of pathogenicity island cross-talk (e.g., SPI2-secreted proteins low → activation of T6SS). → Antagonistic cross-talk (e.g., SsrAB to SciS; MviA to RcsB). | Das et al. (2013) |
| doi: 10.1186/1757-4749-5-28 | ||
| Spatiotemporal distribution of ROS in neutrophils, macrophages carrying Salmonella and in vivo expression of ROS defense enzymes (KatG, SodAB, and host NADPH oxidase). | → (a) Neutrophils: lethal concentrations of hydrogen peroxide | Burton et al. (2014) |
| → (b) Macrophages: only sub-lethal ROS concentration during infection | PMID: 24439899 |
| Booklet themes | Principal professionala |
| Aging | PT |
| Physical activity helps keep you physically fit | PT |
| Food is a prerequisite for health | PT |
| You can take care of problems with your health | RN |
| How to use medicine | RN |
| Coping with everyday life | OT |
| You do not need to feel insecure | OT |
| Technology in everyday life | OT |
| Will I lose my memory? | OT |
| Life events and quality of life during aging | SW |
| Anyone who needs help can get help | SW |
| Subgroup | Group | No. of AS | Person-years | IR | IRR (95% CI) | P value |
| By age | ||||||
| < 40 years | Control subjects | 11 | 86,359 | 12.7 | 1 (reference) | |
| All uveitis | 32 | 15,430 | 207.4 | 17.64 (8.87–35.09) | < 0.001 | |
| Recurrent uveitis | 12 | 2461 | 487.5 | 46.78 (19.61–111.61) | < 0.001 | |
| 40–59 years | Control subjects | 16 | 87,723 | 18.2 | 1 (reference) | |
| All uveitis | 19 | 15,745 | 120.7 | 6.70 (3.44–13.06) | < 0.001 | |
| Recurrent uveitis | 8 | 2994 | 267.2 | 15.12 (6.41–35.65) | < 0.001 | |
| > 59 years | Control subjects | 17 | 85,785 | 19.8 | 1 (reference) | |
| All uveitis | 6 | 15,739 | 38.1 | 1.90 (0.75–4.81) | 0.178 | |
| Recurrent uveitis | 1 | 2119 | 47.2 | 2.46 (0.33–18.53) | 0.382 | |
| By sex | ||||||
| Male | Control subjects | 29 | 142,124 | 20.4 | 1 (reference) | |
| All uveitis | 33 | 25,678 | 128.5 | 6.34 (3.84–10.44) | < 0.001 | |
| Recurrent uveitis | 12 | 4224 | 284.1 | 14.38 (7.28–28.41) | < 0.001 | |
| Female | Control subjects | 15 | 117,744 | 12.7 | 1 (reference) | |
| All uveitis | 24 | 21,235 | 113.0 | 9.54 (4.99–18.24) | < 0.001 | |
| Recurrent uveitis | 9 | 3350 | 268.7 | 23.61 (10.05–55.47) | < 0.001 |
| Gene name | Cytoband | Probeset on U133A array | No. cases with LOH | No. cases without LOH | No. SNPs | Fold change with LOH | Fold change without LOH | T-test | P-value |
| ATXN7 | chr3p21.1-p12 | 204516_at | 4 | 2 | 10 | 0.574 | 0.258 | -8.233 | 1.333E-03 |
| CTDSPL | chr3p21.3 | 213597_s_at | 3 | 3 | 13 | 0.997 | 0.890 | -5.414 | 8.188E-03 |
| F2R | chr5q13 | 203989_x_at | 3 | 2 | 4 | 6.083 | 1.217 | -6.771 | 7.275E-03 |
| RAB5A | chr3p24-p22 | 209089_at | 5 | 2 | 6 | 0.419 | 0.240 | -9.065 | 5.698E-04 |
| RAF1 | chr3p25 | 201244_s_at | 3 | 2 | 9 | 0.555 | 0.389 | -24.008 | 5.074E-04 |
| SCN10A | chr3p22-p21 | 208578_at | 3 | 4 | 23 | 1.806 | 0.884 | -4.253 | 8.107E-03 |
| ARHGAP5 | chr14q12 | 217936_at | 2 | 5 | 1 | 1.731 | 0.769 | -4.809 | 8.159E-03 |
| CYP11B1 | chr8q21 | 214610_at | 2 | 6 | 3 | 0.915 | 1.114 | 4.728 | 3.469E-03 |
| NFATC4 | chr14q11.2 | 205897_at | 2 | 3 | 1 | 1.363 | 0.903 | -11.692 | 2.823E-03 |
| PAX9 | chr14q12-q13 | 207059_at | 2 | 5 | 1 | 0.898 | 0.319 | -5.395 | 5.706E-03 |
| PPFIA1 | chr11q13.3 | 202066_at | 7 | 2 | 12 | 7.524 | 2.448 | -3.918 | 6.425E-03 |
| TP63 | chr3q28 | 211834_s_at | 2 | 13 | 17 | 0.901 | 1.197 | 3.438 | 9.809E-03 |
| TP63 | chr3q28 | 211194_s_at | 2 | 13 | 18 | 0.987 | 2.649 | 4.008 | 3.640E-03 |
| Gene symbol/lncRNA | Degree | Style | Type |
| Shmt2 | 55 | Up | Coding |
| NONMMUT069313 | 54 | Up | Noncoding |
| Vimp | 54 | Down | Coding |
| NONMMUT068653 | 54 | Up | Noncoding |
| Asap3 | 53 | Up | Coding |
| NONMMUT001721 | 53 | Down | Noncoding |
| NONMMUT067923 | 53 | Up | Noncoding |
| Flna | 52 | Up | Coding |
| XR_141418 | 52 | Down | Noncoding |
| Ganab | 52 | Down | Coding |
| Variable | Cases | Controls | P value |
| Age, mean years | 64.21 ± 18.1 | 60.74 ± 21.7 | 0.198 |
| Sex | |||
| Male | 41 (47.1%) | 86 (46.7%) | 0.952 |
| Female | 46 (59.9%) | 98 (53.3%) |
| Phage | Farm | Genome Size (bp) | GC Content (%) | ORFs (n) | Terminal Repeat (bp) | Promoters (n) | Terminators (n) | Accession Number |
| fPS-7 | 3 | 38,966 | 45.6 | 51 | 200 | 12 | 4 | LT961840 |
| fPS-9 | 3 | 39,034 | 45.6 | 52 | 200 | 13 | 5 | LT960606 |
| fPS-10 | 3 | 39,179 | 45.5 | 51 | 202 | 12 | 4 | LT962907 |
| fPS-16 | 3 | 39,227 | 45.5 | 51 | 200 | 12 | 4 | LT962906 |
| fPS-19 | 3 | 38,938 | 45.6 | 51 | 200 | 12 | 4 | LT961838 |
| fPS-21 | 3 | 39,180 | 45.5 | 51 | 202 | 12 | 4 | LT961844 |
| fPS-26 | 5 | 38,792 | 45.7 | 51 | 205 | 12 | 4 | LT961836 |
| fPS-50 | 7 | 39,764 | 45.5 | 50 | 224 | 12 | 4 | LT961843 |
| fPS-52 | 7 | 39,888 | 45.4 | 50 | 224 | 12 | 4 | LT961837 |
| fPS-53 | 7 | 40,451 | 45.4 | 50 | 196 | 11 | 3 | LT962379 |
| fPS-54-ocr | 7 | 40,074 | 45.5 | 49 | 200 | 11 | 4 | LT962475 |
| fPS-59 | 21 | 38,391 | 45.7 | 47 | 190 | 11 | 4 | LT961845 |
| fPS-64 | 5 | 39,326 | 45.5 | 50 | 204 | 12 | 4 | LT961846 |
| fPS-85 | 26 | 40,429 | 45.4 | 50 | 196 | 11 | 3 | LT962380 |
| fPS-86 | 28 | 39,024 | 45.6 | 51 | 215 | 12 | 4 | LT961842 |
| fPS-89 | 25 | 40,405 | 45.4 | 50 | 195 | 11 | 3 | LT961841 |
| NC | HFD | |||
| Mig-6f/f | Mig-6d/d | Mig-6f/f | Mig-6d/d | |
| Total-cholesterol (mg/dL) | 120.0 ± 7.0 | 170.1 ± 18.4∗ | 107.2 ± 11.0 | 319.0 ± 25.7∗∗∗### |
| HDL-cholesterol (mg/dL) | 86.5 ± 3.1 | 133.8 ± 13.7∗∗ | 77.4 ± 6.9 | 244.6 ± 19.4∗∗∗### |
| LDL-cholesterol (mg/dL) | 11.1 ± 1.7 | 13.6 ± 2.0 | 10.9 ± 1.4 | 35.1 ± 3.5∗∗∗### |
| TG (mg/dL) | 54.7 ± 7.7 | 60.2 ± 9.0 | 57.6 ± 7.0 | 123.3 ± 17.3∗∗## |
| FFA (uEq/dL) | 34.2 ± 2.3 | 34.0 ± 2.3 | 21.1 ± 1.5### | 32.3 ± 2.5## |
| Dose scenario | Design | |
| 3 + 3 | CRM | |
| Scenario 1: (0.00, 0.30, 0.40, 0.60) | 10.1 (3.2) | 12.0 (1.7) |
| Scenario 2: (0.05, 0.05, 0.30, 0.30) | 13.3 (3.5) | 11.8 (2.0) |
| Scenario 3: (0.05, 0.10, 0.15, 0.30) | 14.4 (3.7) | 11.9 (2.2) |
| Scenario 4: (0.00, 0.25, 0.30, 0.45) | 11.3 (3.7) | 12.1 (1.7) |
| Most prevalent colonizing serotype(s) | Region | Reference |
| Ia, Ib, II, III, V | North America, United States, Europe | Johri et al., 2006; Ippolito et al., 2010; Lamagni et al., 2013; Melin and Efstratiou, 2013; Florindo et al., 2014; Fabbrini et al., 2016 |
| Ia | Mexico | Ippolito et al., 2010 |
| IV, Ia | United Arab Emirates | Amin et al., 2002 |
| V | Egypt | Shabayek et al., 2014 |
| Ia, VI | Malaysia | Karunakaran et al., 2009; Dhanoa et al., 2010 |
| VI, VIII | Japan | Lachenauer et al., 1999; Matsubara et al., 2002 |
| Variable | Dubti | Amibara | |||||
| Female (%) | Male (%) | Total (%) | Female (%) | male (%) | Total (%) | Total (%) | |
| TBL is a health problem: | |||||||
| Yes | 49 (35.8) | 66 (30.6) | 115 (32.6)* | 28 (16.2) | 38 (17.6) | 66 (17.0)* | 181 (24.4) |
| Rare | 84 (61.3) | 146 (67.6) | 230 (65.2)* | 133 (76.9) | 168 (77.8) | 301 (77.4)* | 531 (71.6) |
| No | 4 (2.9) | 4 (1.9) | 8 (2.3) | 12 (6.9) | 10 (4.6) | 22 (5.7) | 30 (4.0) |
| Do not know | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| TBL is a public health problem since when: | |||||||
| Since many years ago | 85 (64.4) | 129 (61.1) | 214 (62.4)* | 156 (96.9) | 196 (95.1) | 352 (95.9)* | 566 (79.7) |
| Since recent years | 46 (34.8) | 82 (38.9) | 128 (37.3)* | 3 (1.9) | 9 (4.4) | 12 (3.3)* | 140 (19.7) |
| Do not know | 1 (0.8) | 0 (0) | 1 (0.3) | 2 (1.2) | 1 (0.5) | 3 (0.8) | 4 (0.6) |
| TBL mostly attacks: | |||||||
| Male | 10 (7.4) | 31(14.5) | 41(11.7) | 12 (7.0) | 29 (13.4) | 41(10.6) | 82 (11.1) |
| Female | 7 (5.1) | 6 (2.8) | 13 (3.7) | 8 (4.7) | 7 (3.2) | 15 (3.9) | 28 (3.8) |
| Both | 100 (73.5) | 160 (74.8) | 260 (74.3) | 124 (72.1) | 145 (67.1) | 269 (69.3) | 529 (71.7) |
| Do not know | 19 (14.0) | 17 (7.9) | 36 (10.3) | 28 (16.3) | 35 (16.2) | 63 (16.2) | 99 (13.4) |
| TBL mostly attacks: | |||||||
| Under 5 years | 96 (70.1) | 147 (69.0) | 243 (69.4)* | 88 (51.5) | 130 (59.9) | 218 (56.2)* | 461 (62.5) |
| Children b/n 5 - 15 years | 119 (86.9)* | 200 (93.9)* | 319 (91.1)* | 104 (60.8) | 139 (64.1) | 243 (62.6)* | 562 (76.2) |
| Adult under 60 years | 103 (75.2) | 144 (67.6) | 247 (70.6)* | 146 (85.4) | 173 (79.7) | 319 (82.2)* | 566 (76.7) |
| Old person over 60 years | 97 (70.8) | 146 (68.5) | 243 (69.4)* | 141 (82.5) | 170 (78.3) | 311 (80.2)* | 554 (75.1) |
| Do not know | 6 (4.4) | 2 (0.9) | 8 (2.3) | 15 (8.8) | 16 (7.4) | 31 (8.0) | 39 (5.3) |
| H1 | Mesendoderm | Trophoblast-like cells | Mesenchymal stem cells | Neuronal progenitor cells | |
| 1 | H3K4me2,H3K4me1, H2aK5ac,H3K27ac, H2bK5ac,H3K23ac, H3K9me3,H3K79me1, H3K4ac,H3K9ac, H2bK120ac | H3K4me2,H3K4me1, H3K27ac,H3K23ac, H3K9ac,H3K18ac | H2aK5ac,H2bK5ac, H3K27me3,H3K23ac, H3K9me3,H3K79me1, H3K4ac,H3K9ac, H2bK120ac,H3K18ac | H3K4me2,H3K36me3, H3K27ac,H2bK5ac, H3K23ac,H3K9me3, H3K4ac,H3K9ac, H2bK120ac | H3K4me1,H3K36me3, H2aK5ac,H3K27ac, H2bK5ac,H3K27me3, H3K23ac,H3K79me1, H3K9ac,H2bK120ac |
| 2 | H2aK5ac,H2bK5ac, H3K23ac,H3K79me1, H3K4ac,H2bK120ac | H3K4me2,H3K4me1, H3K27ac,H3K23ac, H3K9ac,H2bK120ac | H3K4me1,H2bK5ac, H3K27me3,H3K23ac, H3K9me3,H3K79me1, H3K4ac,H3K9ac, H2bK120ac,H3K18ac | H3K4me2,H3K36me3, H2bK5ac,H3K23ac, H3K4ac,H2bK120ac | H3K4me1,H3K36me3, H3K27ac,H2bK5ac, H3K27me3,H3K9me3, H3K79me1,H3K9ac, H2bK120ac |
| 3 | H2bK5ac,H3K27me3, H3K23ac,H3K79me1, H3K4ac,H3K9ac | H2aK5ac,H2bK5ac, H3K79me1,H3K4ac, H2bK120ac,H3K18ac | H3K27ac,H2bK5ac, H3K27me3,H3K23ac, H3K9me3,H3K18ac | H3K36me3,H2aK5ac, H2bK5ac,H3K23ac, H3K9me3,H3K4ac H3K9ac | H3K4me2,H2aK5ac, H3K23ac,H3K9me3, H3K4ac,H2bK120ac |
| 4 | H3K4me2,H3K4me1, H2aK5ac,H3K27ac, H2bK5ac,H3K27me3, H3K23ac,H3K79me1, H3K4ac,H3K9ac,H3K18ac | H3K4me1,H3K36me3, H3K27ac,H3K23ac, H3K79me1,H3K4ac, H3K9ac,H2bK120ac, H3K18ac | H3K27ac,H2bK5ac, H3K27me3,H3K23ac, H3K9me3,H2bK120ac | H3K36me3,H2aK5ac, H2bK5ac,H3K23ac, H3K4ac,H3K9ac | H3K4me2,H2aK5ac, H3K23ac,H3K9me3, H3K9ac,H2bK120ac |
| 5 | H2bK5ac,H3K27me3, H3K23ac,H3K79me1, H3K4ac,H3K18ac | H3K27ac,H3K27me3, H3K9me3,H3K4ac, H2bK120ac,H3K18ac | H3K27ac,H2bK5ac, H3K27me3,H3K23ac, H3K9me3,H3K9ac | H3K4me2,H3K36me3, H2bK5ac,H3K23ac, H3K9me3,H3K9ac | H3K27ac,H2bK5ac, H3K27me3,H3K9me3, H3K9ac,H2bK120ac |
| 6 | H2aK5ac,H2bK5ac, H3K9me3,H3K79me1, H3K4ac,H2bK120ac | H3K4me2,H3K27ac, H3K9me3,H3K4ac, H2bK120ac,H3K18ac | H3K27ac,H2bK5ac, H3K27me3,H3K23ac, H3K9me3,H3K79me1 | H3K36me3,H2aK5ac, H2bK5ac,H3K9me3, H3K4ac,H2bK120ac | H3K27ac,H2bK5ac, H3K27me3,H3K9me3, H3K4ac,H2bK120ac |
| 7 | H2aK5ac,H2bK5ac, H3K23ac,H3K79me1, H3K4ac,H3K9ac | H3K4me2,H3K4me1, H3K27ac,H3K27me3, H3K9me3,H3K18ac | H3K27ac,H2bK5ac, H3K27me3,H3K23ac, H3K9me3,H3K4ac | H3K4me2,H3K36me3, H2bK5ac,H3K23ac, H3K9me3,H3K4ac | H3K4me2,H3K4me1, H3K23ac,H3K9me3, H3K9ac,H2bK120ac |
| 8 | H3K4me2,H2aK5ac, H3K27ac,H2bK5ac, H3K27me3,H3K23ac, H3K9me3,H3K79me1, H3K4ac,H3K9ac,H3K18ac | H3K4me2,H3K4me1, H3K27ac,H3K27me3, H3K4ac,H3K18ac | H3K4me2,H3K27ac, H3K27me3,H3K23ac, H3K9me3,H3K9ac | H3K4me2,H3K36me3, H2bK5ac,H3K23ac, H3K4ac,H3K9ac, H2bK120ac | H3K4me2,H3K4me1, H3K23ac,H3K9me3, H3K4ac,H2bK120ac |
| 9 | H3K4me2,H3K4me1, H2aK5ac,H3K27ac, H2bK5ac,H3K23ac, H3K9me3,H3K79me1, H3K4ac,H3K9ac H3K18ac | H3K4me2,H3K4me1, H3K27ac,H3K27me3, H3K4ac,H2bK120ac | H3K4me1,H3K27ac, H3K27me3,H3K23ac, H3K9me3,H3K79me1 | H3K4me2,H3K4me1, H3K9me3,H3K4ac, H3K9ac,H2bK120ac | H3K4me2,H3K4me1, H3K36me3,H2aK5ac, H3K27me3,H3K23ac, H3K79me1,H3K9ac, H2bK120ac |
| 10 | H2aK5ac,H2bK5ac, H3K9me3,H3K79me1, H3K4ac,H3K9ac | H3K4me2,H3K27ac, H3K27me3,H3K4ac, H2bK120ac,H3K18ac | H3K4me1,H3K27ac, H3K27me3,H3K23ac, H3K9me3,H3K79me1 | H3K4me2,H3K36me3, H2bK5ac,H3K23ac, H3K9me3,H2bK120ac | H3K4me2,H3K4me1, H2aK5ac,H3K27ac, H3K9me3,H3K9ac, H2bK120ac |
| Proteins | Pfam | SMART | GO | Taxonomy | Semantic similarity | Functional similarity | |
| GOTaxExplorer | b,f,c | b,f,c | b,f,c | b,f,c | b,f,c | b,f,- | b,f,- |
| UniProt | b,f,c | b,f,c | b,f,c | b,f,c | b,f,c | -,-,- | -,-,- |
| Pfam | b,f,- | b,f,- | -,f,- | -,f,- | b,f,- | -,-,- | -,-,- |
| SMART | b,f,- | -,f,- | b,f,- | b,f,- | b,f,- | -,-,- | -,-,- |
| PANTHER* | b,f,- | -,-,- | -,-,- | b,f,c | b,f,c | -,-,- | -,-,- |
| InterPro | b,f,c | b,f,c | b,f,c | b,f,c | b,f,c | -,-,- | -,-,- |
| BioDW | b,f,- | -,-,- | -,-,- | b,f,- | -,-,- | b,f,- | -,-,- |
| GOGraph | -,-,- | -,-,- | -,-,- | -,-,- | -,-,- | b,-,- | b,-,- |
| DynGO | b,f,- | -,-,- | -,-,- | b,f,- | -,-,- | -,-,- | b,-,- |
| GFSST† | b,f,- | -,-,- | -,-,- | b,f,- | -,-,- | -,-,- | b,-,- |
| First author | Year | Year of recruitment | Race | Stage | Pathological type | No. of Patients | HPV + veN (%) | Age, y | Genotype(s) | DNA method | Median follow-up period (months) | Hazardratio |
| Iwamasa | 2000 | 1993-1995 | Asian | I-II | LSCC | 41 | 25(61.0) | 69.8(+)/70.8(-) | 6,11,16,18 | PCR | NA | SC |
| Miyagi | 2001 | 1995-1997 | Asian | I-II | LA+LSCC | 120 | 41(34.2) | LA: 67.3(+)/66.9(-)LSCC: 66.3(+)/69.7(-) | 6,11,16,18 | PCR | NA | SC |
| Hsu | 2009 | 2000-2006 | Asian | I | NSCLC | 171 | 17(9.9) | 65.2 (37-83) | 16,18 | IMC | 56.4 | SC |
| Wu | 2012 | 1998-2014 | Asian | I-III | NSCLC | 165 | 74(44.8) | NA | 16,18 | PCR | 59.3 | SC |
| Chen | 2013 | 2002-2007 | Asian | I-III | LC | 319 | 91(28.5) | NA | 16,18 | PCR | 57.6 | SC |
| Anantharaman | 2014 | 2007-2010 | Caucasian | NA | LC | 62 | 15(24.2) | 62.1 | 21 types* | PCR | 43.44 | Report |
| Chen | 2014 | 1993-2014 | Asian | NA | NSCLC | 117 | 62(53.0) | NA | 16,18 | PCR | NA | Report |
| Wang | 2014 | 2003-2011 | Asian | I-IV | LA | 210 | 74(35.2) | 69.5 | 16,18 | PCR | 12.6 | Report |
| Type of Study/Description | Advantages | Limitations |
| Cell culture – in vitroFood item is placed in cells or other tissues in culture conditions. | Help determine mechanisms of action.Provide clues for further investigation to define mechanisms responsible for how food components interact with host cells. | What occurs in cells may be different from what occurs in human body.Not conclusive. |
| Animal – in vivoFood item is fed to laboratory animals (e.g. rat, mouse, guinea pig, rabbit). Tests the effects of food on certain diseases, physiological conditions, and behaviors | Can be tightly controlled for testing the metabolism, specificity, and reproducibility of the effect of a certain food component.Tests the toxicity and safety of food components added to the diet. | Humans differ from animals in many aspects of their physiology, such as food digestion, nutrient absorption, genetics, lifestyle, etc.Not conclusive. |
| Case studiesOne individual’s experience with food or a food component is documented. | Help determine how certain food/components may affect clinical conditions or disorders in humans.Focus on social, psychological, or medical conditions.Provide clues for further investigation. | Not scientifically rigorous – only one person’s experience.Not conclusive but is more evidence-building. |
| Epidemiological/observationalGroups of subjects, typically living in one geographical area, who have developed a disease or condition are compared with a similar sample of subjects who have not developed the disease. | Address whether a certain food/component could cause a disease but not whether it did cause a disease. | Memory recall is often used to assess how a food/component might have affected an individual – long-term memory recall may not be accurate.Regionally biased – differences observed between regions may be related to different dietary of cultural preferences or genetic differences.Not conclusive but is more evidence-building. |
| Prospective cohort studiesA large group of individuals with a similar background who are healthy when the study begins are followed over time. Diets are assessed at the beginning, during, and end of the study. Eating habits of those who get a disease are compared to those who do not acquire a disease. | Provide clues about the risk/benefits of a given diet, food component or lack of an important vitamin/mineral (e.g., development of iron deficiency and neurodevelopmental impairment) over time. | The controls may not be similar to those who acquire a disease with respect to demographic and health factors.Not conclusive but is more evidence-building. |
| Randomized, controlled clinical trial (RCT)Evaluates the efficacy of a specific nutritional intervention (e.g., food/component) within a population. Subjects with similar backgrounds are randomly allocated to receive either the test item or placebo. | Represents the “gold standard” for clinical trial methodology.Randomization minimizes allocation bias by balancing both known and unknown social and health factors.Sample sizes are often large to detect subtle differences in treatments, diet or food component when they exist.Provides most conclusive evidence. | Unethical to randomize breastfed infants into an infant formula feeding group. |
| Meta-analysisReview of the existing scientific literature. Pooled data from several studies are subjected to a statistical meta-analysis. | Meta-analysis of trials provides a more precise estimate of the treatment effect because of the increased sample size and statistical power.Results can be generalized to a larger population.Inconsistency of results across studies can be quantified and analyzed. | The validity of the meta-analysis depends on the quality of the systematic review and studies included in the analysis.If confounding variables are not controlled for in the primary studies, there will be potential bias in the meta-analysis (e.g., differing definitions of breastfeeding). |
| Reliability | |||||
| Study characteristics | # of data points K | Total sample size N | Sample-weighted mean reliability (SD) | 95nnnnn CI | PVASE |
| EDI total | 2 | 471 | .81 (.06) | .72 - .90 | 12.68% |
| EDI body dissatisfaction subscale | 3 | 256 | .77 (.14) | .62 - .92 | 10.66% |
| EDI drive for thinness subscale | 4 | 715 | .60 (.15) | .45 - .75 | 10.07% |
| EDI bulimia subscale | 4 | 715 | .64 (.12) | .53 - .76 | 14.12% |
| EAT-26 | 4 | 920 | .87 (.02) | .85 - .88 | 100.00% |
| p/qa | p/qb | ||||
| rs16861210 | GG (224) | GA (12) | AA (1) | ||
| All | 7.76 (7.32-8.22) | 10.27 (8.29-12.45) | 11.79 (5.33-20.77) | 0.029/0.032 | 0.143/0.495 |
| GG (224) | AA, AG (13) | ||||
| All | 7.76 (7.32-8.22) | 10.38 (8.47-12.48) | 0.008/0.032 | 0.201/0.495 | |
| rs17366568 | GG (169) | GA (59) | AA (9) | ||
| All | 8.40 (7.88-8.94) | 6.90 (6.16-7.69) | 6.44 (6.48-8.48) | 0.003/0.032 | 0.893/0.840 |
| GG (169) | AA, AG (68) | ||||
| All | 8.40 (7.88-8.49) | 6.84 (6.15-7.58) | 0.0007/0.032 | 0.850/0.840 | |
| rs2241766 | TT (224) | TG (13) | |||
| All | 7.82 (7.38-8.28) | 9.70 (7.83-11.76) | 0.056/0.032 | 0.020/0.279 | |
| Menc | 6.45 (5.85-7.08) | 12.54 (8.49-17.37) | 0.003/0.131 | ||
| Womend | 8.87 (8.32-9.44) | 9.38 (7.30-11.71) | 0.660/0.092 | ||
| rs6773957 | GG (104) | AG (110) | AA (23) | ||
| All | 7.36 (6.74-8.00) | 8.12 (7.51-8.75) | 9.45 (8.05-10.96) | 0.016/0.032 | 0.711/0.840 |
| GG (104) | AA, AG (133) | ||||
| All | 7.35 (6.73-8.00) | 8.34 (7.77-8.92) | 0.021/0.032 | 0.559/0.840 | |
| AG, GG (214) | AA (23) | ||||
| All | 7.76 (7.31-8.22) | 9.47 (8.06-10.99) | 0.022/0.032 | 0.772/0.840 | |
| rs2082940 | CC (224) | CT (13) | |||
| All | 7.82 (7.38-8.28) | 9.70 (7.83-11.76) | 0.056/0.032 | 0.020/0.279 | |
| Mene | 6.45 (5.85-7.08) | 12.54 (8.49-17.37) | 0.003/0.131 | ||
| Womenf | 8.87 (8.32-9.44) | 9.38 (7.30-11.71) | 0.660/0.092 |
| S. no. | Inflammatory response/pathologic condition | Reference | Treatment dose | Radiation dose | Period of course | Drug type |
| 1 | Pneumonitis | (107) | Adriamycin: 50 mg/m2 rechallenged for two further cycles with no symptoms with steroid cover | 15 Gy | 2 months | Steroid |
| 2 | (108) | Adriamycin: 30 mg/m2 | 36 Gy | 3 weeks | Steroids | |
| 3 | (108) | Adriamycin: 30 mg/m2 | 59.4 Gy | 6 weeks | Steroids | |
| 4 | (109) | Paclitaxel: 175 mg/m2 rechallenged for one further cycle with no recurrence after premedication with steroids | 43.2 Gy | 12 days | Not specified | |
| 5 | (110) | Intrapleural instillation of 30 mg of adriamycin | 36.5 Gy | 1 month | Steroids and diuretics | |
| 6 | (111) | Mn porphyrin, MnTE-2-PyP5+ (6 mg/kg/24 h) | 28 Gy | 2 weeks | Antioxidant and redox-modulating Mn porphyrin | |
| 7 | (112) | Genistein diet (10 mg/kg) (in combination with radiation) | 10 Gy | 9 fractions of 3.1 Gy over 30 days | Soy isoflavone | |
| 8 | (113) | Omeprazole, esomeprazole, and lansoprazole | Radiation regimen was reformulated after 50 Gy if the lesion was extended | 7 days | Proton pump inhibitors | |
| 9 | (114) | Pentoxifylline (400 mg orally) | 40–84 Gy | 8 weeks | Anticytokine | |
| 10 | Stages I–III NSCLC after radiation therapy | (80, 81) | Angiotensin-converting enzyme inhibitors (ACEIs) | 60 Gy | During the entire course of RT (not specified for individual patient) | ACEIs |
| 11 | Radiation pneumonitis/radiation-induced fibrosis | (115) | Cyclooxygenase-2 inhibitor twice daily | 13.5–14.75 Gy | 40 consecutive days from the day of local thoracic irradiation or 40 or 80 days later | Celecoxib (an inducible enzyme) |
| Factor | Items | Responses | values |
| Outcome variables | |||
| Latrine ownership | Ownership of latrine | No/Yes for ownership of latrine | 0/1 |
| Consistent latrine use | |||
| Predictor variables | |||
| Risk Perception | |||
| Vulnerability | How high or low are the chances that you contract diarrheal disease when defecating in the open field? | Five point scale, that ranges from almost Very low, to Very high | 1 to 5 |
| Severity | If you have diarrheal disease because of open defecation, how severely would that impact your life? | Five point scale, that ranges from almost Very low, to Very high | 1 to 5 |
| Attitude (affective) | |||
| How much beneficial/important it is building Five point scale, that ranges from almost Very low, to Very highyour own latrine in the one year | 1 to 5 | ||
| How much beneficial/important it is to defecate using latrine regularly | Five point scale, that ranges from almost Very low, to Very high | 1 to 5 | |
| How much do you like to use latrine? | Five point scale, that ranges from almost Very low, to Very high | 1 to 5 | |
| How much do you do you enjoy defecating in latrine? | Five point scale, that ranges from almost Very low, to Very high | 1 to 5 | |
| Self-efficacy (latrine ownership)Injective norm (latrine ownership) | How much ability you think you have building your own latrine in the next one year | Five point scale, that ranges from almost Very low, to Very high | 1 to 5 |
| Most of the people in my village think I should have my own latrine | Five point scale, that ranges from completely disagree to completely agree | 1 to 5 | |
| People in my village will judge me if I don’t have my own | Five point scale, that ranges from completely disagree to completely agree | 1 to 5 | |
| Descriptive norm (latrine use) | Most of the people I know in the community defecate using latrine regularly | Five point scale, that ranges from completely disagree to completely agree | 1 to 5 |
| How many of your neighbors use latrine for defecation? | Five point scale, that ranges from almost nobody to almost all | 1 to 5 | |
| Using latrine regularly is the right thing to do because everybody does so | Five point scale, that ranges from completely disagree to completely agree | 1 to 5 | |
| Injunctive norm (latrine use) | people who are important to me approve /disapprove that you use latrine | Five point scale, that ranges from completely disagree to completely agree | 1 to 5 |
| Defecating using latrine is regularly is something that most of the people in my village think | Five point scale, that ranges from completely disagree to completely agree | 1 to 5 | |
| People in my village will judge me if I defecate in the open field | Five point scale, that ranges from completely disagree to completely agree | 1 to 5 | |
| Cues to action | |||
| Exposure to Health education (HEW) | Yes/No | ||
| Exposure to CLTSH triggering | Yes/No |
| Cases | Controls | Total | |
| Number of admissions to rehab facility | n (%) | n (%) | n (%) |
| 0 | 27 (84) | 19 (79) | 46 (82) |
| 1 | 3 (9) | 5 (21) | 8 (14) |
| 2 | 1 (3) | 0 (0) | 1 (2) |
| 3 | 1 (3) | 0 (0) | 1 (2) |
| Total | 32 (100) | 24 (100) | 56 (100) |
| Variable | Mean | Median | Standard deviation | Relative standard deviation |
| Child survey | ||||
| Percentage of overweight and obese pre-school children (5–6 years) (dependent variable) | 9.31 | 8.60 | 4.19 | 45.02 |
| Social index (based on parents education and employment status) | 13.97 | 14.00 | 1.95 | 13.97 |
| Percentage of non-German children | 35.78 | 33.40 | 22.57 | 63.09 |
| Percentage of non German children with insufficient German language skills | 8.29 | 6.50 | 8.34 | 100.51 |
| Percentage of children with measles vaccination | 91.15 | 92.40 | 4.18 | 4.59 |
| Percentage of children with bad dental hygiene | 12.39 | 11.20 | 7.24 | 58.41 |
| Percentage of children participating in regular medical check-ups | 87.67 | 88.00 | 4.68 | 5.34 |
| Percentage of children living in household with at least one smoking parent | 36.03 | 37.20 | 10.72 | 29.75 |
| Percentage of children having their own TV in bedroom | 11.45 | 10.10 | 7.06 | 61.63 |
| Percentage of children with poor eye-hand coordination | 15.63 | 15.40 | 6.80 | 43.50 |
| Percentage of German children with poor language skills | 11.85 | 9.30 | 8.48 | 71.61 |
| Percentage of non-German children with poor language skills | 20.80 | 20.70 | 13.14 | 63.18 |
| Percentage of children attending Kindergarten | 89.82 | 90.20 | 5.21 | 5.80 |
| Environmental variables and urban characteristics | ||||
| Percentage of area with vegetation | 0.22 | 0.17 | 0.16 | 71.25 |
| Area of parks per km2 | 7.1 × 10−2 | 5.5 × 10−2 | 5.2 × 10−2 | 73.23 |
| Number of parks per km2 | 2.2 × 10−3 | 2.2 × 10−3 | 1.2 × 10−2 | 55.39 |
| Area of parks per 1000 inhabitants | 15.7 × 103 | 11.6 × 103 | 13.9 × 10−3 | 89.21 |
| Number of parks per 1000 inhabitants | 0.00 | 0.00 | 0.00 | 67.86 |
| Euclidean distance to parks | 429.16 | 330.27 | 326.13 | 75.99 |
| Area of playgrounds per km2 | 6.5 × 10−3 | 4.6 × 10−3 | 5.9 × 10−3 | 90.82 |
| Number of playgrounds per km2 | 3.7 × 10−3 | 2.2 × 10−3 | 3.5 × 10−3 | 95.53 |
| Area of playgrounds per 1000 inhabitants | 9.1 × 102 | 8.7 × 102 | 3.7 × 102 | 40.43 |
| Number of playgrounds per 1000 inhabitants | 5.1 × 10−1 | 4.9 × 10−1 | 1.8 × 10−1 | 34.60 |
| Euclidean distance to playgrounds | 488.96 | 359.74 | 403.17 | 82.45 |
| Number of fast food restaurants per km2 | 3.8 × 10−6 | 1.5 × 10−6 | 5.0 × 10−6 | 132.29 |
| Number of fast food restaurants per 1000 inhabitants | 4.3 × 10−1 | 3.6 × 10−1 | 2.8 × 10−1 | 65.05 |
| Availability of public transport | 1134.74 | 868.42 | 914.95 | 80.63 |
| Walkability | ||||
| Connectivity | −0.04 | −0.09 | 1.00 | −2377.29 |
| Entropy | −0.10 | 0.03 | 1.00 | −1012.31 |
| Population density | −0.03 | −0.34 | 1.00 | −3948.53 |
| Device | Number of Bits | Sampling Rate (GSPS) |
| Texas Instruments ADC12DJ3200 | 12 | 6.4 |
| Texas Instruments ADC32RF45 | 14 | 3.0 |
| Texas Instruments ADS54J60 | 16 | 1.0 |
| Texas Instruments ADS1675 | 24 | 0.004 |
| Value | |
| Number of patients | 71 |
| Pathologic lesion, n (%) | |
| Yes | 42 (59.2) |
| No | 29 (40.8) |
| Indication, n (%) | |
| Primary staging | 16 (22.5) |
| Follow-up/re-staging | 53 (74.6) |
| Non-oncological (FUO and aortic aneurysm graft) | 2 (2.8) |
| Tumour type, n | |
| Lymphoma (NHL/HD) | 18 (11/7) |
| Lung cancer (proved/suspicious/incidental) | 13 (10/2/1) |
| Breast cancer | 9 |
| Melanoma | 7 |
| Renal cell | 3 |
| Oesophagus, larynx, stomach | 2 |
| Adrenal, anal, colon, fibrosarcoma, follicular thyroid, hypopharynx, nasopharynx, oropharynx, ovarian, paraganglioma, myeloid sarcoma, mesothelioma, rectal, SCC right upper arm | 1 |
| Under therapy, n (%) | |
| Yes | 13 (18.3) |
| No | 56 (78.9) |
| N/A | 2 (2.8) |
| Lipase | Porcine pancreatic lipase (PPL) | Pseudomonas sp. (PSL) | Pseudomonas fluorescens lipase (Lipase AK, AKL) | Candida cylindracea A.Y. lipase (AYL) | Candida rugosa lipase (CRL) | Novozyme 435 |
| Activity (μmol/h/g) | 2.25 | 0.67 | 1.32 | 0.54 | 0.27 | 1.47 |
| S/L† group (n = 72) | R/H‡ group (n = 13) | Total (n = 85) | p | |
| number (%) * | number (%) * | number (%) * | ||
| EpidemiologicalData | ||||
| Sex | 0.758 | |||
| Male | 44 (61.1) | 9 (69.2) | 53 (62.4) | |
| Female | 28 (38.9) | 4 (30.8) | 32 (37.6) | |
| Age (mean years ± SEM§) | 33.7 ± 1.1 | 31.4 ± 1.5 | 33.4 ± 0.9 | 0.426 |
| Transmission route | 0.184 | |||
| Heterosexual: extramarital | 31 (43.1) | 6 (46.2) | 37 (43.5) | |
| Heterosexual: infected-partner | 31 (43.1) | 2 (15.4) | 33 (38.8) | |
| Others | 10 (13.9) | 5 (38.5) | 15 (17.6) | |
| Clinical Data | ||||
| Common clinical findings | ||||
| Fever of Unknown Origin (FUO) | 27 (37.5) | 6 (46.2) | 33 (38.8) | 0.554 |
| Acute febrile syndrome | 23 (31.9) | 8 (61.5) | 31 (36.5) | 0.060 |
| Asymptomatic | 17 (23.6) | 3 (23.1) | 20 (23.5) | 1.000 |
| Diarrea | 18 (25.0) | 2 (15.4) | 20 (23.5) | 0.724 |
| Pulmonary TBc | 17 (23.6) | 2 (15.4) | 19 (22.4) | 0.723 |
| Others | 24 (33.3) | 6 (46.2) | 30 (35.3) | 0.529 |
| CDC Clinical category1 | 0.342 | |||
| A | 27 (37.5) | 4 (30.8) | 31 (36.5) | |
| B | 19 (26.4) | 6 (46.2) | 25 (29.4) | |
| C | 26 (36.1) | 3 (23.1) | 29 (34.1) | |
| CDC CD4 category2 | 0.063 | |||
| 1 | 8(11.1) | 2 (15.4) | 10 (11.8) | |
| 2 | 30(41.7) | 1 (7.7) | 31 (36.5) | |
| 3 | 34(47.2) | 10(76.9) | 44 (51.8) | |
| Combined CDC AIDS Category3 | 41 (56.9) | 10(76.9) | 51 (60.0) | 0.227 |
| Virological Data | ||||
| Genotype | 1.000 | |||
| HIV-1C | 72(100) | 13(100) | 85(100) | |
| Phenotype | 1.000 | |||
| R5 | 68 (94.4) | 13(100) | 81 (95.3) | |
| ×4 | 4 (5.6) | 0 (0) | 4 (4.7) | |
| p24 Ag titer (pg/ml; mean ± SEM§) | 189.0 ± 5.8 | 1745.7 ± 64.9 | 427.1 ± 62.1 | <0.001¶ |
| Bias | Limits of agreement | 95%-CI | p-value | |||
| Lower | Upper | Lower | Upper | |||
| GAT2 (S) – GAT1 (S) | −0.06 | −1.74 | 1.63 | −0.235 | 0.347 | 0.701 |
| ICP2 (S) – ICP1 (S) | −0.2 | −3.3 | 2.8 | −0.312 | 0.745 | 0.411 |
| ICP2 (R) – ICP1 (R) | −0.2 | −4.4 | 4.1 | −0.584 | 0.890 | 0.676 |
| TPA2 (S) – TPA1 (S) | 0.1 | −3.3 | 3.5 | −0.699 | 0.477 | 0.703 |
| TPA2 (R) – TPA1 (R) | 0.0 | −2.7 | 2.7 | −0.465 | 0.465 | 1.000 |
| MICP (S) – MGAT (S) | 0.8 | −4.6 | 6.2 | −0.085 | 1.780 | 0.074 |
| MICP (R) – MGAT (S) | 1.7 | −2.9 | 6.2 | 0.864 | 2.439 | <0.001 |
| MTPA (S) – MGAT (S) | 0.5 | −4.1 | 5.1 | −0.266 | 1.321 | 0.1856 |
| MTPA (R) – MGAT (S) | 2.3 | −3.4 | 8.0 | 1.319 | 3.292 | < 0.001 |
| MICP (R) – MICP (S) | 0.8 | −4.0 | 5.6 | −0.032 | 1.640 | 0.059 |
| MTPA (R) – MTPA (S) | 1.8 | −2.8 | 6.3 | 0.995 | 2.560 | <0.001 |
| PercentageEBP-K | PercentageEBP-A | PercentageEBP-P | PercentageEBP-F | |
| Total | 19.21 ± 3.2% | 20.83 ± 2.1% | 48.97 ± 8.6% | 17.82 ± 5.7% |
| Gender | ||||
| Male | 19.23 ± 2.2% | 20.84 ± 2.8% | 48.96 ± 7.9% | 17.83 ± 1.7% |
| Female | 19.18 ± 1.8% | 20.82 ± 2.2% | 48.99 ± 8.4% | 17.88 ± 6.1% |
| P value | 0.920 | 0.200 | 0.414 | 0.925 |
| Program subtypes | ||||
| Five-year | 19.25 ± 2.8% | 20.82 ± 1.7% | 48.95 ± 7.6% | 17.80 ± 5.4% |
| Eight-year | 19.01 ± 3.4% | 20.86 ± 1.1% | 49.11 ± 9.5% | 17.85 ± 4.8% |
| P value | 0.508 | 0.094 | 0.528 | 0.283 |
| Confusion Matrix | Expert Classification | ||
| Positive | Negative | ||
| Classifier classification | Positive | TP = 19,050 | FP = 3772 |
| Negative | FN = 950 | TN = 76,228 |
| Associated risk factors | BAB | PAB | VAB |
| Age (years) 85 and over | + | ||
| Male gender | + | + | + |
| Functionally independent | + | ||
| Mild-moderate or severe cognitive impairment | + | + | + |
| Sleep disturbance | + | + | + |
| Psychologically distressed | + | + | |
| Use of benzodiazepine drugs | + | ||
| Use of neuroleptic drugs | + | + | + |
| Use of physical restraints | + |
| Increase | Decrease | No response | Total | |
| Normal | 11 (58%) | 5 (26%) | 3 (16%) | 19 (100%) |
| Lesioned | 19 (68%) | 4 (14%) | 5 (18%) | 28 (100%) |
| N | Yes (%) | |
| “Access to his/her diabetes EMR via a web portal ...” | 128 | |
| stimulates the self-management and self-correcting behaviour of the patient | 75.8 | |
| improves communication during consultation with a well prepared patient | 44.5 | |
| results in saving time | 21.9 | |
| results in deceased workload | 10.9 | |
| “I write the medical information...” | 128 | |
| as I always did | 63.3 | |
| in an easier language than before | 37.5 | |
| with less information than before | 7.8 | |
| “I think that patients who use the patient portal...” | 122 | |
| have an increased frequency of visits | 2.5 | |
| have an unchanged frequency of visits | 80.3 | |
| have a decreased frequency of visits | 17.2 | |
| “How do you feel about patients sending you an e-message?” | 128 | |
| (very) positive | 65.6 | |
| neutral | 28.1 | |
| (very) negative | 6.3 | |
| “How many e-messages do you receive per week?” | 124 | |
| 0 messages | 33.1 | |
| 1–10 messages | 59.7 | |
| ≥ 11messages | 7.3 | |
| “Who usually answers the e-message of patients?” | 80a | |
| the health care provider answers only the messages of his/her own patients | 31.3 | |
| the physician (GP or internist) answers all messages | 2.5 | |
| the nurse (nurse practitioner or diabetes nurse) answers all messages | 66.3 |
| Hazard ratio for in-hospital death | 95% CI | p value | Hazard ratio for death within 1 year | 95% CI | p value | |
| Age | 0.068 | 0.005 | ||||
| 18–64 years | 1 | 1 | ||||
| ≥65 years | 1.72 | 1.0–3.03 | 2.17 | 1.27–3.70 | ||
| Sex | 0.426 | 0.707 | ||||
| Female | 1 | 1 | ||||
| Male | 1.32 | 0.67–2.60 | 1.12 | 0.61–2.10 | ||
| Etiology | 0.060b | 0.066b | ||||
| Staphylococcus aureus | 1 | 1 | ||||
| CoNSc | 0.87 | 0.33–2.26 | 0.93 | 0.36–2.40 | ||
| Viridans streptococci | 0.90 | 0.40–2.03 | 0.85 | 0.40–1.81 | ||
| Enterococcus faecalis | 0.36 | 0.08–1.57 | 0.55 | 0.16–1.90 | ||
| Streptococcus pneumoniae | 2.37 | 0.85–6.59 | 2.58 | 0.94–7.09 | ||
| Other pathogens | 0.35 | 0.08–1.54 | 0.31 | 0.07–1.36 | ||
| Culture negative | 0.42 | 0.17–1.05 | 0.51 | 0.23–1.13 | ||
| Affected valves | <0.001b | <0.001b | ||||
| Prosthetic | 1 | 1 | ||||
| Aortic | 1.13 | 0.48–2.65 | 1.01 | 0.46–2.19 | ||
| Mitral | 0.45 | 0.16–1.31 | 0.60 | 0.24–1.47 | ||
| Tricuspid | 1.04 | 0.22–4.88 | 0.73 | 0.16–3.35 | ||
| Two native valves | 3.55 | 1.49–8.47 | 3.75 | 1 68–8.34 | ||
| Echocardiography | ||||||
| Major Criterion | 0.346 | 0.015 | ||||
| No | 1 | 1 | ||||
| Yes | 1.43 | 0. 68–3.00 | 2.44 | 0.19–5.0 | ||
| Vegetation | 0.102 | 0.005 | ||||
| No | 1. | 1 | ||||
| Yes | 1.81 | 0.90–3.68 | 2.62 | 1.35–5.09 | ||
| Neurological complicationsd | 0.009 | 0.003 | ||||
| No | 1 | 1 | ||||
| Yes | 2.17 | 1.21–3.90 | 2.30 | 1.34–3.96 | ||
| Peripheral embolid | 0.036 | 0.016 | ||||
| No | 1 | 1 | ||||
| Yes | 1.86 | 1.04–3.33 | 1.95 | 1.14–3.35 | ||
| Heart failured | <0.001 | <0.001 | ||||
| No | 1 | 1 | ||||
| Yes | 5.98 | 2.35–15.17 | 7.62 | 3.26–17.83 | ||
| Serum CRP on admission | 0.008 | <0.001 | ||||
| < 100 mg/l | 1 | 1 | ||||
| ≥100 mg/l | 2.92 | 1.33–6.40 | 3.90 | 1.81–8.43 |
| Socio-demographic characteristics | Frequency | Percentage |
| LGA | ||
| Idemili South | 70 | 46.4 |
| Onitsha South | 81 | 53.6 |
| Groups | ||
| Mothers of women who delivered 6 months before study | 79 | 52 |
| Husbands of women who delivered 6 months before study | 72 | 48 |
| Marital status | ||
| Married | 147 | 97.4 |
| Widowed | 4 | 2.6 |
| Educational level | ||
| No formal education | 6 | 4 |
| Primary | 55 | 36.4 |
| Secondary | 75 | 49.7 |
| Post-secondary | 15 | 9.9 |
| Occupation | ||
| Unemployed | 42 | 28 |
| Civil servant | 44 | 29 |
| Trader | 45 | 30 |
| Artisan | 20 | 13 |
| Age group | ||
| 35-39 | 24 | 15.9 |
| 40-44 | 29 | 19.2 |
| 45-49 | 36 | 23.8 |
| 50-54 | 26 | 17.2 |
| 55+ | 36 | 23.8 |
| Variables | LVEF ≤ 25% | LVEF > 25% | P values |
| 115 patients | 821 patients | ||
| Braden score | 14.4 ± 2.6 | 14.8 ± 2.6 | 0.121 |
| Total Glasgow coma score | 12.1 ± 3.9 | 12.5 ± 3.6 | 0.345 |
| Heart rate (beats/minute) | 88.6 ± 17.8 | 84.2 ± 19.2 | 0.021 |
| Diastolic NBP (mmHg) | 59.2 ± 12.0 | 60.8 ± 13.6 | 0.249 |
| Systolic NBP (mmHg) | 110.2 ± 16.9 | 120.1 ± 20.2 | <0.001 |
| Respiratory rate (breaths/minute) | 21.0 ± 4.8 | 19.2 ± 4.6 | <0.001 |
| Oxygen saturation (%) | 96.8 ± 3.9 | 97.2 ± 2.9 | 0.278 |
| Temperature (°C) | 36.6 ± 0.8 | 36.7 ± 0.8 | 0.474 |
| Blood urea nitrogen (mg/dL) | 37.6 ± 26.4 | 28.9 ± 22.3 | <0.001 |
| Carbon dioxide (mmol/L) | 22.9 ± 5.0 | 23.4 ± 5.0 | 0.266 |
| Glucose (mg/dL) | 172.2 ± 78.1 | 151.9 ± 65.7 | 0.003 |
| Hemoglobin (mmol/L) | 11.9 ± 2.4 | 11.4 ± 2.0 | 0.032 |
| Platelets (×103 cells/μL) | 244.2 ± 112.5 | 235.2 ± 108.3 | 0.408 |
| Potassium (mmol/L) | 4.3 ± 0.6 | 4.2 ± 0.7 | 0.050 |
| Sodium (mmol/L) | 137.8 ± 5.2 | 138.5 ± 4.7 | 0.139 |
| White blood cells (×103 cells/μL) | 12.7 ± 5.6 | 12.8 ± 8.3 | 0.971 |
| Age (years) | 70.6 ± 15.1 | 67.3 ± 16.4 | 0.045 |
| Weight on admission (kg) | 77.1 ± 18.6 | 83.0 ± 25.7 | 0.018 |
| SAPS I score on admission | 13.9 ± 5.9 | 13.4 ± 5.5 | 0.428 |
| SOFA score on admission | 6.3 ± 4.2 | 5.4 ± 4.3 | 0.036 |
| Males (%) | 74 (64.4) | 432 (52.6) | 0.018 |
| Compound | Catechol | Phenol | Total |
| Yield [% w/w] | 5.7 ± 0.1 | 3.9 ± 0.1 | 9.6 ± 0.3 |
| Content (mM) | 101 | 25 | 126 |
| SUV | Myocardium | Muscle |
| SUV 7.5 min p.i. | ||
| TGwt | 9.6 ± 2.2 | 0.5 ± 0.1 |
| TGwt insulin | 16.9 ± 2.8* | 0.8 ± 0.2* |
| TGmut | 5.8 ± 1.6** | 0.7 ± 0.1 |
| TGmut insulin | 6.4 ± 1.4 | 1.1 ± 0.5* |
| SUV 60 min p.i. | ||
| TGwt | 20.4 ± 3.3 | 0.7 ± 0.2 |
| TGwt insulin | 21.8 ± 4.3 | 1.1 ± 0.2* |
| TGmut | 12.6 ± 4.1 | 1.0 ± 0.2 |
| TGmut insulin | 7.2 ± 2.6* | 1.5 ± 0.6* |
| Gene | OMIM accession number | SNP | Ancestral alleles | Type | MAF | p-value | p-value adjusted | Beta | SE | Trait |
| AGTR 1 | *106165 | rs5186 | A | 3’UTR | 28.933 | 8.34×10-04 | 0.027 | −0.051 | 0.032 | SBP |
| 6.96×10-03 | 0.041 | −0.045 | 0.051 | DBP | ||||||
| CSF2 | *138960 | rs25882 | T | Exonic | 25.596 | 4.67×10-06 | 3.83×10-04 | 0.124 | 0.030 | SBP |
| 7.25×10-07 | 5.94×10-05 | 0.148 | 0.048 | DBP | ||||||
| F7 | 227500 | rs5742910 | NA | Upstream | 15.024 | 3.72×10-04 | 0.030 | −0.028 | 0.041 | SBP |
| 3.34×10-04 | 0.027 | −0.042 | 0.065 | DBP | ||||||
| rs6046 | C | Exonic | 12.874 | 5.33×10-04 | 0.044 | −0.028 | 0.044 | SBP | ||
| IL1B | *147720 | rs1143634 | C | Exonic | 19.397 | 4.21×10-04 | 0.035 | −0.044 | 0.035 | SBP |
| 5.92×10-04 | 0.049 | −0.052 | 0.056 | DBP | ||||||
| LDLR | 606945 | rs5742911 | A | 3’UTR | 32.308 | 4.31×10-04 | 0.035 | 0.06 | 0.029 | SBP |
| 1.17×10-04 | 0.010 | 0.071 | 0.047 | DBP | ||||||
| LPL | 609708 | rs1800590 | G | 5’UTR | 2.586 | 3.46×10-04 | 0.028 | 0.076 | 0.088 | SBP |
| TGFB1 | *190180 | rs1800469 | C | Upstream | 29.048 | 4.44×10-04 | 0.036 | −0.026 | 0.030 | SBP |
| 9.77×10-06 | 8.02×10-04 | −0.038 | 0.047 | DBP | ||||||
| VDR | *601769 | rs2228570 | T | Exonic | 40.139 | 1.16×10-05 | 9.48×10-04 | −0.012 | 0.028 | SBP |
| 6.02×10-06 | 4.93×10-04 | −0.009 | 0.045 | DBP |
| Baseline | 1 month | 3 months | 6 months | 12 months | |
| S100A12 | 0.78***/0.75*** | 0.68***/0.65*** | 0.35/0.27 | 0.55*/0.45* | 0.43/0.43 |
| ESR | 0.37/0.48* | 0.36/0.35 | 0.45*/0.42 | 0.32/0.33 | 0.35/0.40 |
| CRP | 0.33/0.34 | 0.04/0.11 | 0.49*/0.35 | 0.59**/0.43 | 0.57**/0.55* |
| CHILD | |||||
| Educational level | Underweight(%) | Normalweight(%) | Overweight(%) | Obese(%) | TotalNo. (%) |
| MOTHER | |||||
| Low | 0.8 | 69.1 | 20.8 | 9.3 | 534 (100) |
| Medium | 0.6 | 70.0 | 21.9 | 7.5 | 837 (100) |
| High | 0.5 | 69.8 | 23.9 | 5.8 | 298 (100) |
| Total No. | 11 | 1147 | 371 | 140 | 1669 (100) |
| Chi square for trend | p = 0.76 | p = 0.93 | p = 0.59 | p = 0.15 | |
| Kendall's τb | p = 0.19 |
| Patient no. | FOXP3 | OX40 | CD123 | DC-LAMP | ||||
| SLN | NSLN | SLN | NSLN | SLN | NSLN | SLN | NSLN | |
| 1 | 1958 | 957 | 193 | 65 | 232 | 280 | 818 | 660 |
| 2 | 1925 | 1477 | 119 | 192 | 1450 | 621 | 957 | 648 |
| 3 | 2205 | 1060 | 15 | 60 | 222 | 214 | 573 | 1038 |
| 4 | 1562 | 1450 | 117 | 29 | 938 | 242 | 592 | 657 |
| 5 | 2123 | 2086 | 245 | 192 | 1154 | 566 | 1059 | 384 |
| 6 | 2814 | 1747 | 61 | 33 | 244 | 225 | 925 | 744 |
| 7 | 1768 | 1633 | 54 | 60 | 395 | 1040 | 1171 | 989 |
| Sham (n = 6) | 2nd PO week (n = 3) | 4th PO week (n = 4) | 6th PO week (n = 5) | |
| Albumin (g/dL) | 2.5 ± 0 | BDL: 2.4 ± 0.37BDL + AM: 2.85 ± 0.07 | BDL: 1.88 ± 0.5∗BDL + AM: 2.9 ± 0† | BDL: 1.99 ± 0.17BDL + AM: 3.33 ± 0.36‡† |
| ALT (U/L) | 70 ± 7.07 | BDL: 79.75 ± 17.99BDL + AM: 106 ± 0 | BDL: 124.6 ± 58.8BDL + AM: 76 ± 7.07 | BDL: 79 ± 46.16BDL + AM: 56.71 ± 35.5 |
| Alkaline phosphatase (U/L) | 573 ± 99 | BDL: 420 ± 84BDL + AM: 324 ± 0 | BDL: 635.6 ± 197.53BDL + AM: 419 ± 56.57 | BDL: 421 ± 172.52BDL + AM: 278 ± 171 |
| GGT (U/L) | 0 ± 0 | BDL: 24.75 ± 28.93BDL + AM: 79 ± 0 | BDL: 35.8 ± 21.29BDL + AM: 13.5 ± 19.09 | BDL: 33 ± 27.4BDL + AM: 1.86 ± 3.49†† |
| Bilirubin (mg/dL) | 0.1 ± 0 | BDL: 2.73 ± 2.86BDL + AM: 10.7 ± 5.23 | BDL: 2.84 ± 1.68∗BDL + AM: 2.65 ± 3.61 | BDL: 4.23 ± 1.12BDL + AM: 2.39 ± 2.50 |
| Item | Points | Definition |
| Pain | 25 | No pain |
| 20 | Mild, occasional | |
| 15 | Moderate (tolerable) | |
| 0 | Severe, intolerable | |
| Return to sport (work) at 6 months | 25 | Return without protection |
| 20 | Return with protection | |
| 15 | Restricted return to sport, only exercises | |
| 0 | Unable to return to sport | |
| Range of motion | 25 | 90-100% (normal) |
| 20 | 80-89% | |
| 15 | 70-70% | |
| 0 | 50-69% | |
| Grip strength | 25 | 90-100% (normal) |
| 15 | 80-89% | |
| 10 | 70-70% | |
| 0 | 50-69% |
| Test | Channel | Average | |||||||||
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | ||
| A | 0.240 | 0.423 | 0.325 | 0.726 | 0.681 | 0.682 | 0.701 | 0.663 | 0.681 | 0.246 | 0.537 |
| B | 0.548 | 0.697 | 0.307 | 0.612 | 0.537 | 0.429 | 0.629 | 0.711 | 0.715 | 0.618 | 0.580 |
| C | 0.444 | 0.287 | 0.299 | 0.510 | 0.546 | 0.425 | 0.512 | 0.662 | 0.674 | 0.430 | 0.479 |
| Infants (younger than or equal to 1-year old) | Older patients (older than 1-year old) | P value | |
| Number of cases | 18 | 108 | |
| Gender (M/F) | 10/8 | 72/36 | |
| Age range (median) | 0.66 | 4.8 | |
| Histology (%) | 0.45 | ||
| Embryonal | 88.9 | 75.9 | |
| Alveolar | 11.1 | 24.1 | |
| Site of origin (%) | 0.28 | ||
| Head and neck (%) | |||
| Parameningeal | 11.1 | 30.6 | |
| Orbit | 11.1 | 7.4 | |
| Head and neck (nonpara nonorbit) | 5.6 | 13 | |
| GU | |||
| Bladder/prostate | 11.1 | 12 | |
| Nonbladder/nonprostate | 11.1 | 7.4 | |
| Extremities | 11.1 | 11.1 | |
| Others | 38.9 | 18.5 | |
| TNM stage (%) | |||
| N1 | 5.6 | 38.9 | |
| M1 | 11.1 | 19.4 | |
| Size (%) | 0.928 | ||
| >5 | 55.6 | 57.4 | |
| ≤5 | 38.9 | 33.3 | |
| Unknown | 5.5 | 9.3 | |
| IRS stage (%) | 0.34 | ||
| I | 27.8 | 24.6 | |
| II | 27.8 | 15.1 | |
| III | 33.3 | 42.1 | |
| IV | 11.1 | 18.3 | |
| Clinical group (%) | 0.74 | ||
| I | 11 | 9 | |
| II | 6 | 4 | |
| III | 72 | 68 | |
| IV | 11 | 19 | |
| Risk (%) | 0.64 | ||
| Low | 22.2 | 15.7 | |
| Intermediate | 66.7 | 65.7 | |
| High | 11.1 | 18.6 |
| Reexposure Test Result | Hepatocellular Injury | Cholestatic or Mixed Liver Injury | ||
| ALTb | ALTr | ALPb | ALPr | |
| ●Positive | <5N | ≥2ALTb | <2N | ≥2ALPb |
| ●Negative | <5N | <2ALTb | <2N | <2ALPb |
| ●Negative | ≥5N | ≥2ALTb | ≥2N | ≥2ALPb |
| ●Negative | ≥5N | <2ALTb | ≥2N | <2ALPb |
| ●Uninterpretable | <5N | n.a. | <2N | n.a. |
| ●Uninterpretable | n.a. | ≥2ALTb | n.a. | ≥2ALPb |
| ●Uninterpretable | n.a. | n.a. | n.a. | n.a. |
| Ancestry | Replicate | Descendants of Affected (DA) | Markov blanket of Affected (MBA) | Children of Affected (DA ∩ MBA) | |||
| Number of causal SNPs/number of SNPs | P(X ≥ k) | Number of causal SNPs/number of SNPs | P(X ≥ k) | Number of causal SNPs/number of SNPs | P(X ≥ k) | ||
| Asian | 1–10 | 12/25 | 0.0485 | 11/45 | 0.891 | 2/3 | 0.228 |
| 11–20 | 2/7 | 0.695 | 9/36 | 0.850 | 0/2 | 1 | |
| 1–20 | 69/182 | 0.000467 | 15/55 | 0.798 | 2/7 | 0.695 | |
| 21–40 | 15/69 | 0.983 | 24/63 | 0.113 | 2/4 | 0.367 | |
| 1 | 77/237 | 0.152 | 63/221 | 0.973 | 16/54 | 0.658 | |
| 2 | 75/235 | 0.305 | 55/221 | 0.999 | 17/64 | 0.851 | |
| 3 | 74/217 | 0.0278 | 66/190 | 0.0355 | 22/43 | 0.00227 | |
| 4 | 76/227 | 0.0479 | 55/190 | 0.894 | 11/42 | 0.821 | |
| 5 | 76/240 | 0.371 | 66/218 | 0.758 | 25/68 | 0.155 | |
| 6 | 74/224 | 0.102 | 55/191 | 0.909 | 13/45 | 0.694 | |
| 7 | 67/203 | 0.160 | 60/202 | 0.826 | 16/55 | 0.693 | |
| 8 | 65/212 | 0.663 | 66/226 | 0.937 | 14/61 | 0.958 | |
| 9 | 73/230 | 0.368 | 67/226 | 0.887 | 24/86 | 0.816 | |
| 10 | 65/204 | 0.376 | 59/220 | 0.998 | 15/57 | 0.848 | |
| European | 1–10 | 34/105 | 0.155 | 11/46 | 0.849 | 1/6 | 0.874 |
| 11–20 | 6/11 | 0.0604 | 6/22 | 0.655 | 2/2 | 0.0822 | |
| 1–20 | 0/1 | 1 | 2/16 | 0.972 | 0/1 | 0.711 | |
| 21–40 | 35/107 | 0.124 | 9/34 | 0.703 | 3/4 | 0.0732 | |
| African | 1–10 | 10/60 | 0.929 | 9/47 | 0.795 | 0/3 | 1 |
| 11–20 | 22/99 | 0.613 | 10/44 | 0.566 | 0/4 | 1 | |
| 1–20 | 7/34 | 0.695 | 11/53 | 0.707 | 0/4 | 1 | |
| 21–40 | 2/2 | 0.0508 | 3/17 | 0.786 | 1/1 | 0.226 |
| Decades | # cites | Paper | Domain | Institution | Country |
| 1945 to 1954 | - | All cited articles only cited once | - | - | - |
| 1955 to 1964 | 9 | Wilkening, E. A. (1952, May). 'Acceptance of improved farm practices in three coastal plains countries.' Technical Bulletin 98. North Carolina Agricultural Experiment Station. | Diffusion of innovation | University of Chicago | USA |
| 1965 to 1974 | 36 | Rogers, E.M. (1962). Diffusion of Innovations. First Edition. New York: The Free Press. | Diffusion of innovation | Ohio State University, United States | USA |
| 1975 to 1984 | 70 | Rogers, E.M. & Shoemaker, F.F. (1971). Communication of Innovations: A Cross Cultural Approach.* New York: The Free Press | Diffusion of innovation | Stanford University/University of Denver | USA |
| 1985 to 1994 | 89 | Rogers, E.M. (1983). Diffusion of Innovations. Third Edition. New York: The Free Press. | Diffusion of innovation | University of Southern California | USA |
| 1995 to 2004 | 229 | Evidence-based Medicine Working Group (1992). 'Evidence-based medicine. A new approach to teaching the practice of medicine.' JAMA, 268(17), 2420–2425. | EBM | McMaster University | Canada |
| Characteristics | Death during treatmentN (%) | Alive throughout treatmentN (%) | p value | |
| N | 37 | 528 | ||
| Mean age at diagnosis ± SD | 45.0 ± 16.2 | 40.7 ± 13.5 | 0.03 | |
| Median (Min-Max) | 41 (22-88) | 38 (18-94) | ||
| Male Gender | 29 (78.4) | 423 (80.1) | 0.95 | |
| Race | American Indian | 0 | 9 (1.7) | 0.99 |
| African American/Black | 13 (35.1) | 187 (35.4) | 0.97 | |
| Asian/Pacific Islander | 1 (2.7) | 10 (1.9) | 0.73 | |
| White | 23 (62.2) | 322 (61.0) | Ref | |
| Hispanic ethnicity | 7 (18.9) | 159 (30.1) | 0.16 | |
| US born | 31 (83.8) | 364 (68.9) | 0.03 | |
| HIV positive | 24 (64.9) | 180 (34.1) | 0.02 | |
| HAART during tuberculosis therapy | 1/24 (4.2) | 27/180 (15.0) | 0.10 | |
| History of opportunistic infection | 21/24 (87.5) | 101/180 (56.1) | 0.01 | |
| CD4 count | ||||
| ≤ 200 cells/μL1 | 17/19 (89.5) | 108/156 (69.2) | 0.14 | |
| Median CD4 count at diagnosis (IQR)1 | 68 (34-104) | 105 (47-269) | 0.06 | |
| Received directly observed therapy2 | Yes | 28 (75.7) | 251 (47.7) | 0.02 |
| Partial* | 4 (10.8) | 90 (17.1) | 0.67 | |
| No | 5 (13.5) | 185 (35.2) | Ref | |
| Episode of inadequate therapeutic regimen | 25 (67.6) | 161 (30.5) | 0.01 | |
| During intensive phase3 | 24 (64.9) | 129/525 (24.6) | 0.001 | |
| Median duration of inadequate treatment (days) (IQR) (n = 153) | 23 (6-35) | 18 (9-34) | 0.18 | |
| During continuation phase4 | 10/33 (30.3) | 116/523 (22.2) | 0.44 | |
| Median duration of inadequate treatment (days) (IQR) (n = 126) | 37 (24-50) | 29 (13-50) | 0.24 | |
| Due to non-adherence | 22 (59.5) | 142 (26.9) | 0.01 | |
| During intensive phase3 | 21 (56.8) | 109/525 (20.8) | 0.001 | |
| Median duration of inadequate treatment (days) (IQR) (n = 130) | 8 (5-28) | 15 (7-24) | 0.13 | |
| During continuation phase4 | 10/33 (30.3) | 108/523 (20.7) | 0.64 | |
| Median duration of inadequate treatment (days) (IQR) (n = 118) | 30 (16-50) | 29 (14-53) | 0.11 | |
| Due to adverse reaction5 | 10 (27.0) | 49/527 (9.3) | 0.10 | |
| During intensive phase5 | 7 (18.9) | 39/527 (7.4) | 0.21 | |
| Median duration of inadequate treatment (days) (IQR) (n = 46) | 29 (8-39) | 14 (6-38) | 0.75 | |
| During continuation phase5 | 3 (8.1) | 18/527 (3.4) | 0.98 | |
| Median duration of inadequate treatment (days) (IQR) (n = 21) | 25 (1-31) | 14 (7-20) | 0.40 | |
| Hospitalized for tuberculosis6 | 29 (78.4) | 253/526 (48.1) | 0.003 | |
| Homeless within 1 year of diagnosis7 | 16/27 (59.3) | 138/356 (38.8) | 0.04 | |
| Substance abuse at diagnosis | 23 (62.2) | 228 (43.2) | 0.13 | |
| Sputum smear positive | 27 (73.0) | 233 (44.1) | 0.004 | |
| Sputum culture positive | 34 (91.9) | 471 (89.2) | 0.62 | |
| Extrapulmonary disease in addition to pulmonary disease | 18 (48.7) | 143 (27.1) | 0.13 | |
| Cavitary disease | 4 (10.8) | 129 (24.4) | 0.12 | |
| Any prior medical condition | 25 (67.6) | 288 (54.6) | 0.13 |
| Variable | Alive | Dead of Disease | Dead other Causes | p-value | |
| Surgical Approach, n (%) | <0.0001 | ||||
| Adrenalectomy | 374 (88.6) | 437 (63.8) | 111 (67.7) | ||
| None | 36 (8.5) | 212 (30.9) | 41 (25.0) | ||
| Other | 11 (2.6) | 30 (4.4) | 9 (5.5) | ||
| Laterality, n (%) | 0.08 | ||||
| Left | 222 (52.6) | 347 (50.7) | 96 (58.5) | ||
| Right | 190 (45.0) | 300 (43.8) | 61 (37.2) | ||
| Bilateral | 1 (0.3) | 8 (1.1) | 1 (0.6) | ||
| T Classification, n (%) | <0.0001 | ||||
| TX | 39 (9.3) | 82 (12.0) | 30 (18.3) | ||
| T0 | 1 (0.2) | 0 | 0 | ||
| T1 | 32 (7.6) | 10 (1.5) | 14 (8.5) | ||
| T2 | 228 (54.0) | 192 (28.0) | 57 (34.8) | ||
| T3 | 68 (16.1) | 91 (13.3) | 18 (11.0) | ||
| T4 | 47 (11.1) | 136 (19.8) | 31 (18.9) | ||
| N Classification, n (%) | <0.0001 | ||||
| NX | 79 (18.7) | 244 (35.6) | 58 (35.4) | ||
| N0 | 332 (78.7) | 356 (52.0) | 89 (54.2) | ||
| N1 | 11 (2.6) | 85 (12.4) | 17 (10.4) | ||
| Metastasis, n (%) | 7 (1.7) | 174 (25.4) | 14 (8.5) | <0.0001 | |
| SEER Stage, n (%) | <0.0001 | ||||
| Localized | 274 (64.9) | 205 (29.9) | 77 (46.9) | ||
| Regional | 106 (25.1) | 206 (30.1) | 40 (24.4) | ||
| Distant | 20 (4.8) | 216 (31.5) | 28 (17.1) | ||
| Unstaged | 22 (5.2) | 58 (8.5) | 19 (11.6) | ||
| Median Survival, months (IQR) | 53 (17, 112) | 9 (3, 24) | 10 (1, 51) | <0.0001 |
| n (%) | Positive CAPs | Positive SPTs | n (%) | n (%) | |
| Distribution of food allergies | All patients (n = 496) | N (min‐max, median) (n = 496) | N (range wheal, median) (n = 496) | Mueller 0–2 (n = 238) | Mueller 3–4 (n = 258) |
| List of 10 out of 14 major food allergens1 | |||||
| Cow's milk | 34 (7%) | 31 (0.40–101, 2.02) | 11 (1–4, 2) | 12 (5%) | 22 (9%) |
| Hen's egg | 29 (6%) | 26 (0.40–101, 2.38) | 11 (1–4, 2) | 14 (6%) | 15 (5%) |
| Peanut | 191 (39%) | 114 (0.39–101, 4.32) | 136 (1–5, 2) | 75 (32%) | 116 (45%) |
| Tree nuts | 283 (57%) | ||||
| Hazelnut | 212 (43%) | 127 (0.36–100, 6.64) | 156 (1–4, 2) | 93 (39%) | 119 (46%) |
| Almond | 125 (25%) | 30 (0.4–5.70, 1.69) | 105 (1–4, 2) | 61 (26%) | 64 (25%) |
| Walnut | 115 (23%) | 48 (0.4–45.10, 1.95) | 84 (1–4, 2) | 48 (20%) | 67 (26%) |
| Brazil nut | 9 (2%) | 9 (0.73–42, 2.68) | Not determined | 0 | 9 (4%) |
| Pistachio | 24 (5%) | 24 (0.4–100, 1.44) | Not determined | 6 (3%) | 18 (7%) |
| Cashew nut | 41 (8%) | 28 (0.39–57, 3.55) | 23 (1–4, 2) | 11 (5%) | 30 (12%) |
| Fish2 | 4 (1%) | 3 (1%) | 1 (0.4%) | ||
| Cod | 3 (0.5–10.90, 6.30) | 2 (2–4, 3) | |||
| Crustaceans2 | 29 (6%) | 9 (4%) | 20 (8%) | ||
| Shrimp | 21 (0.4–61, 2.23) | 16 (1–4, 2) | |||
| Lobster | 14 (0.36–55, 2.12) | 5 (1–3, 2) | |||
| Crab | 13 (0.39–52, 1.70) | 6 (1–3, 1) | |||
| Sesame | 33 (7%) | 22 (0.5–82, 4.85) | 22 (1–4, 2) | 9 (4%) | 24 (9%) |
| Soy | 46 (9%) | 25 (0.4–12.7, 1.14) | 33 (1–4, 2) | 14 (6%) | 32 (12%) |
| Lupin | 2 (0.4%) | 2 (3.86–19.90, 11.88) | Not determined | 1 (0.4%) | 1 (0.4%) |
| Celery | 36 (7%) | 4 (0.5–4.87, 2.33) | 34 (1–4, 2) | 16 (7%) | 20 (8%) |
| Other allergens, not belonging to the major allergens | |||||
| Fruit (all)3 | 338 (68%) | 175 (74%) | 163 (63%) | ||
| Fruit (top 3) | |||||
| Apple | 270 (54%) | 154 (0.38–58.10, 3.73) | 215 (1–5, 3) | ||
| Kiwi | 171 (35%) | 45 (0.36–31.10, 1.20) | 147 (1–5, 3) | ||
| Peach | 124 (25%) | 40 (0.44–70.20, 2.60) | 110 (1–2, 2) | ||
| Vegetables (all)3, 4 | 154 (31%) | 72 (30%) | 82 (32%) | ||
| Vegetables (top 3) | |||||
| Tomato | 82 (17%) | 20 (0.4–26.10, 1.55) | 73 (1–4, 2) | ||
| Carrot | 73 (15%) | 17 (0.82–45,2.78) | 67 (1–4, 2) | ||
| Paprika | 44 (9%) | 5 (0.40–3.53, 0.71) | 41 (1–3, 2) | ||
| Other food allergies | 6 (1%) | 1 (0.4%) | 5 (2%) | ||
| Mean number of food allergies3 (SD, min‐max) | 2.9 (1.87, 1–9) | 2.6 (1.74, 1–9) | 3.1 (1.95, 1–9) |
| AQP4 Isoforms | Cell Type | Intracellular Localization | Reference |
| AQP4a (M1) | Astrocytes | PM | [85,90,95] |
| AQP4c (M23) | Astrocytes, skeletal muscle, kidney | PM | [85,90,95] |
| AQP4e (Mz) | Astrocytes (rat), organ of Corti (rat) | PM, intracellular vesicles, GA, EC | [72,89,96] |
| AQP4b | Astrocytes (rat) | GA | [89] |
| AQP4d | Astrocytes (rat) | GA, EC | [72,89] |
| AQP4f | Astrocytes (rat) | GA | [89] |
| AQP4-Δ | Skeletal muscle | ER, faintly in the PM | [91] |
| Site | Invoiced dollar (US$) | Matching dollar (US$) | Donated time dollar (US$) | Total additional investment (US$) | Rankinga | Degree of change |
| Site 1 | 1.00 | 2.91 | 2.33 | 5.24 | 2 | H |
| Site 2 | 1.00 | 3.05 | 0.52 | 3.57 | 5 | H |
| Site 3 | 1.00 | 1.81 | 1.10 | 2.91 | 7 | L |
| Site 4 | 1.00 | 0.84 | 0.04 | 0.88 | 10 | L |
| Site 5 | 1.00 | 1.95 | 1.05 | 3.00 | 6 | L |
| Site 6 | 1.00 | 1.18 | 0.05 | 1.23 | 9 | L |
| Site 7 | 1.00 | 4.25 | 0.46 | 4.72 | 4 | H |
| Site 8 | 1.00 | 6.06 | 1.41 | 7.47 | 1 | H |
| Site 9 | 1.00 | 4.67 | 0.42 | 5.09 | 3 | H |
| Site 10 | 1.00 | 2.35 | 0.12 | 2.46 | 8 | L |
| Average, all sites | 1.00 | 3.29 | 0.85 | 4.14 |
| Year and season | Mean | Lower limit (2.50%) | Median | Upper limit (97.50%) |
| 2001 - Rainy/Summer | 0.2286 | 0.009099 | 0.1516 | 0.6998 |
| 2001 - Dry/Winter | 0.7513 | 9.63E-04 | 0.2329 | 5.646 |
| 2002 - Rainy/Summer | 0.03168 | 6.83-E-04 | 0.0143 | 0.1307 |
| 2002 - Dry/Winter | 0.7903 | 0.08158 | 0.487 | 3.028 |
| Risk Factors | No. HHV8 Infection/No. Tested (%) | aORs (95%CI) * | p-values |
| Ever injected drugs | |||
| No | 21/145 (14.5) | 1.00 | |
| Yes | 56/296 (18.9) | 1.50 (0.83–2.69) | 0.181 |
| Ever sharing syringe | |||
| No | 75/430 (17.4) | 1.00 | |
| Yes | 2/11 (18.2) | 1.06 (0.20–5.46) | 0.949 |
| Steady partner | |||
| No | 41/232 (17.7) | 1.00 | |
| Yes | 36/209 (17.2) | 0.97 (0.55–1.72) | 0.922 |
| Ever had sex in the past month | |||
| No | 53/288 (18.4) | 1.00 | |
| Yes | 24/153 (15.7) | 0.85 (0.42–1.71) | 0.650 |
| Condom use in the last sex intercourse | |||
| Never or no sex | 69/380 (18.2) | 1.00 | |
| Yes | 8/61 (13.1) | 0.57 (0.21–1.56) | 0.273 |
| Ever had commercial sex | |||
| No | 69/409 (16.9) | 1.00 | |
| Yes | 8/32 (25.0) | 6.05 (0.80–45.67) | 0.081 |
| Frequency of condom use in commercial sex | |||
| Always or no sex | 71/414 (17.1) | 1.00 | |
| Sometimes | 3/8 (37.5) | 1.59 (0.16–6.12) | 0.120 |
| Never | 3/19 (15.8) | 0.72 (0.06–8.32) | 0.790 |
| HIV | |||
| No | 77/439 (17.5) | - | |
| Yes | 0/2 (0.0) | - | - |
| HCV | |||
| No | 32/170 (18.8) | 1.00 | |
| Yes | 45/271 (16.6) | 0.82 (0.48–1.41) | 0.476 |
| Syphilis | |||
| No | 76/429 (17.7) | 1.00 | |
| Yes | 1/12 (8.3) | 0.50 (0.06–4.09) | 0.519 |
| Prakasam district | Azamgarh district | |||||
| Sex worker | Casual unpaid partner | Any partner# | Sex worker | Casual unpaid partner | Any partner# | |
| % | % | % | % | % | % | |
| Total sample size | 633 | 633 | 633 | 639 | 639 | 639 |
| Migrants who never had sex | 75.0 | 44.9 | 42.0 | 75.9 | 54.1 | 48.8 |
| Migrants who initiated sex in place of origin | 9.8 | 42.5 | 43.4 | 7.5 | 42.7 | 43.7 |
| Migrants who initiated sex in place of destination | 15.2 | 12.6 | 14.5 | 16.6 | 3.1 | 7.5 |
| p-value | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
| Number who initiated sex in place of origin | 62 | 269 | 275 | 48 | 273 | 279 |
| Had sex in destination after initiating at place of origin [total] | 59.7 | 39.4 | 46.9 | 49.0 | 23.5 | 47.7 |
| Had sex in destination only | 19.4 | 6.7 | 6.9 | 29.2 | 2.6 | 9.0 |
| Had sex both in destination and in origin during their migration | 40.3 | 32.7 | 40.0 | 18.8 | 20.9 | 38.7 |
| Had sex in only origin areas during their migration | 16.1 | 39.4 | 32.7 | 43.8 | 53.1 | 35.5 |
| Did not have sex in any area during migration after they first had sex before migration | 24.2 | 21.2 | 20.4 | 8.3 | 23.4 | 16.9 |
| Number who initiated sex in place of destination | 96 | 80 | 92 | 106 | 20 | 48 |
| Had sex in destination areas only but not in origin | 45.8 | 56.3 | 54.4 | 85.9 | 75.0 | 79.2 |
| Had sex in both destination and origin areas | 54.2 | 43.8 | 45.7 | 14.2 | 25.0 | 20.8 |
| Calcination temperature (°C) | Time (min) | Sheet resistance (mΩ/□) |
| 400 | 30 | 7.4 |
| 350 | 30 | 27.2 |
| 300 | 30 | 41.3 |
| 300 | 60 | 40.6 |
| 250 | 30 | 47.6 |
| 250 | 60 | 45.4 |
| 200 | 30 | – |
| Non-calcination | 0 | – |
| NEO-PI-R scales | Never-smokers (n = 341) | Former-smokers (n = 429) | Current-smokers (n = 318) | F | Partial η2 |
| Neuroticism | 48.9 (.51)a | 50.7 (.46)b | 51.6 (.55)b | 6.9** | .013 |
| Extraversion | 48.8 (.44) | 49.3 (.40) | 48.4 (.48) | 1.0 | .002 |
| Openness | 45.6 (.44) | 46.4 (.39) | 46.5 (.47) | 1.2 | .002 |
| Agreeableness | 50.9 (.49) | 50.9 (.44) | 49.9 (.52) | 1.3 | .002 |
| Conscientiousness | 49.4 (.52)a | 49.0 (.46)a | 47.0 (.55)b | 5.5** | .010 |
| N1: Anxiety | 49.7 (.46)a | 51.0 (.41)b | 51.7 (.50)b | 4.7** | .009 |
| N2: Angry Hostility | 49.5 (.50)a | 50.7 (.45)a | 52.3 (.54)b | 6.9** | .013 |
| N3: Depression | 49.3 (.57)a | 50.8 (.51)a | 53.1 (.61)b | 10.0** | .019 |
| N4: Self-consciousness | 48.4 (.52)a | 50.1 (.46)b | 50.0 (.56)b | 3.6* | .007 |
| N5: Impulsiveness | 48.3 (.48)a | 49.8 (.43)b | 49.7 (.52)b | 3.4* | .007 |
| N6: Vulnerability | 49.3 (.58)a | 50.4 (.52)a | 52.7 (.63)b | 7.9** | .015 |
| E1: Warmth | 48.9 (.52) | 48.4 (.46) | 47.2 (.56) | 2.4 | .005 |
| E2: Gregariousness | 50.5 (.50) | 51.0 (.45) | 49.7 (.54) | 1.7 | .003 |
| E3: Assertiveness | 50.1 (.51) | 49.6 (.46) | 49.2 (.55) | 0.7 | .001 |
| E4: Activity | 48.1 (.49) | 47.3 (.43) | 46.9 (.52) | 1.5 | .003 |
| E5: Excitement-Seeking | 46.9 (.47)a | 47.7 (.42)a | 49.0 (.50)b | 4.4* | .008 |
| E6: Positive Emotions | 48.9 (.51)a | 48.9 (.46)a | 47.0 (.55)b | 3.9* | .007 |
| O1: Fantasy | 47.8 (.44) | 48.5 (.39) | 48.3 (.47) | 0.7 | .001 |
| O2: Aesthetics | 48.3 (.48) | 49.4 (.43) | 49.4 (.52) | 1.7 | .003 |
| O3: Feelings | 46.7 (.46) | 47.6 (.41) | 47.0 (.50) | 1.2 | .002 |
| O4: Actions | 45.2 (.50) | 46.1 (.45) | 46.0 (.54) | 1.0 | .002 |
| O5: Ideas | 46.5 (.48) | 46.9 (.43) | 48.1 (.52) | 2.7 | .005 |
| O6: Values | 45.0 (.45) | 45.6 (.40) | 44.6 (.48) | 1.4 | .003 |
| A1: Trust | 47.2 (.53) | 46.6 (.47) | 46.2 (.57) | 0.9 | .002 |
| A2: Straightforwardness | 50.7 (.50) | 51.0 (.44) | 50.2 (.53) | 0.7 | .001 |
| A3: Altruism | 50.2 (.52)a | 51.6 (.46)b | 49.9 (.55)a | 3.5* | .007 |
| A4: Compliance | 50.5 (.55)a | 48.8 (.49)b | 48.4 (.59)b | 3.8* | .007 |
| A5: Modesty | 50.9 (.50) | 51.5 (.45) | 51.1 (.54) | 0.3 | .001 |
| A6: Tender-mindedness | 52.0 (.50) | 52.4 (.44) | 52.2 (.53) | 0.2 | .000 |
| C1: Competence | 50.0 (.56)a | 49.9 (.50)a | 46.7 (.60)b | 10.2** | .019 |
| C2: Order | 47.5 (.47) | 47.0 (.42) | 46.8 (.51) | 0.5 | .001 |
| C3: Dutifulness | 49.0 (.51)a | 48.5 (.45)a | 45.9 (.55)b | 9.0** | .017 |
| C4: Achievement Striving | 49.0 (.55)a | 48.4 (.49)a | 46.4 (.58)b | 5.4** | .010 |
| C5: Self-Discipline | 48.6 (.55)a | 47.7 (.49)a | 46.3 (.59)b | 3.8* | .007 |
| C6: Deliberation | 53.5 (.53)a | 52.6 (.48)a | 50.0 (.57)b | 10.1** | .019 |
| 2D matrix | Navg | Nti | Nsi | Nring | Ny | SBW (Hz) | Tacq (min:s) | |
| EPSI | 32 × 32 | 4 | 1 | 1 | NA | 32 | 2380 | 8:32 |
| Re‐CRT | 32 × 32 | 4 | 2 | 1 | 16 | NA | 2500 | 8:32 |
| DW‐CRT with α = 1 | 32 × 32 | 1 | 2 | 4 | 16 | NA | 2500 | 8:32 |
| DW‐CRT with α = 1.71 | 32 × 32 | 1 | 2 | 4 | 16 | NA | 2500 | 8:32 |
| Re‐CRT | 48 × 48 | 4 | 2 | 1 | 24 | NA | 2500 | 12:48 |
| DW‐CRT with α = 1 | 48 × 48 | 1 | 2 | 4 | 24 | NA | 2500 | 12:48 |
| E.coli | S.typhimurium | Y.pestis | Y.enterocolitica | P.luminescens | |
| E.coli | *** | 66.7 | 28.6 | 33.3 | 52.4 |
| Age | Males | Females | ||||||||||
| % | ASR | Offered/Uptake | % Uptake Rate | CI | Sig | % | ASR | Offered/Uptake | % Uptake Rate | CI | Sig | |
| 40-44 | 25.6 | -5.1 | 684/1345 | 0.51 | (0.48–0.54) | *** | 24.0 | -7.4 | 729/1727 | 0.42 | (0.40–0.45) | *** |
| 45–49 | 20.8 | -2.3 | 555/1551 | 0.36 | (0.33–0.38) | * | 21.3 | 2.1 | 645/1232 | 0.52 | (0.50–0.55) | * |
| 50–54 | 20.3 | -1.0 | 543/1460 | 0.37 | (0.34–0.40) | NS | 17.5 | -.3 | 532/1078 | 0.49 | (0.46–0.52) | NS |
| 55–59 | 13.4 | -2.8 | 358/1040 | 0.34 | (0.32–0.37) | ** | 11.9 | -1.9 | 362/779 | 0.47 | (0.43–0.50) | NS |
| 60–64 | 10.1 | 7.0 | 270/512 | 0.53 | (0.48–0.57) | *** | 11.6 | 2.0 | 351/658 | 0.53 | (0.49–0.57) | * |
| 65–69 | 6.7 | 10.9 | 178/250 | 0.71 | (0.65–0.77) | *** | 9.4 | 5.3 | 285/463 | 0.62 | (0.57–0.66) | *** |
| 70–74 | 3.1 | 6.1 | 81/120 | 0.68 | (0.57–0.75) | *** | 4.0 | 7.8 | 130/162 | 0.80 | (0.74–0.87) | *** |
| Total | 100 % | 2669/6962 | 100 % | 3034/6101 |
| AE | Lacidipine (n = 162) | Amlodipine (n = 153) |
| Nervous system | ||
| Headache | 3 (1.9) | 6 (3.9) |
| Dizziness | 2 (1.2) | 1 (0.7) |
| Drowsiness | 0 | 1 (0.7) |
| Hoarseness | 0 | 0 |
| Tremor | 0 | 0 |
| Cardiovascular system | ||
| Chest discomfort | 0 | 0 |
| Dyspnea | 1 (0.6) | 0 |
| Palpitation | 1 (0.6) | 1 (0.7) |
| Syncope | 0 | 0 |
| General | ||
| Fatigue | 0 | 1 (0.7) |
| Facial flushing | 2 (1.2) | 5 (3.3) |
| Edema, low extremity | 1 (0.6) | 5 (3.3) |
| Dry mouth | 0 | 0 |
| Skin | ||
| Rash | 1 (0.6) | 0 |
| Laboratory | ||
| AST/ALT elevation | 0 | 1 (0.7) |
| Dyslipidemia | 1 (0.6) | 2 (1.3) |
| Anemia | 0 | 0 |
| Total patients | ||
| With at least 1 AE | 12 (7.4) | 17 (11.1) |
| With no AEs | 150 (92.6) | 136 (88.9) |
| Withdrawn due to AEs | 3 (1.9) | 3 (2.0) |
| Species | Number of Retrocopies | Number of Parental Genes |
| Human | 7,831 | 2,570 |
| Chimpanzee | 7,478 | 2,560 |
| Gorilla | 7,706 | 2,669 |
| Orangutan | 6,873 | 2,439 |
| Rhesus | 7,502 | 2,453 |
| Marmoset | 10,465 | 3,067 |
| Squirrel monkey | 9,320 | 2,864 |
| Mouse | 7,109 | 2,205 |
| Rat | 7,364 | 2,114 |
| HVLP groupN = 20 | Taper groupN = 20 | |
| Age (years) | 61.8 ± 12.9 | 64.9 ± 12.7 |
| Gender (male/female) | 10/10 | 10/10 |
| Body weight (kg) | 59.4 ± 13.7 | 57.3 ± 7.9 |
| Height (cm) | 161.6 ± 7.5 | 159.5 ± 9.9 |
| BMI (kg/m2) | 22.6 ± 4.6 | 22.5 ± 2.5 |
| Mallampati score (1/2/3/4) | 8/11/1/0 | 7/12/1/0 |
| Cormack-Lehane grade (1/2/3/4) | 11/8/1/0 | 9/11/0/0 |
| Tracheal tube size (7.0/7.5/8.0/8.5) | 2/11/6/1 | 3/7/8/2 |
| Composition | Concentration |
| Sodium chloride (NaCl) | 140 mM |
| HEPES | 10 mM |
| Glucose | 10 mM |
| Potassium chloride (KCl) | 5 mM |
| Magnesium chloride (MgCl2) | 1 mM |
| Calcium chloride (CaCl2) | 1 mM |
| pH 7.4 | |
| 300 mOsm (310 for SMG) |
| Child normal weight | Child overweight*† | Child obese† | |
| (n = 7349; 85%) | (n = 1272; 15%) | (n = 264; 3%) | |
| Sociodemographic factors | |||
| Male sex (%) | 51.2 | 44.8‡ | 46.2‡ |
| Both parents born outside Sweden (%) | 28.7 | 28.8 | 34.2‡ |
| Mother low education (%) | 13.2 | 13.8 | 19.9‡ |
| Father low education (%) | 14.3 | 15.6 | 22.1‡ |
| Firstborn (%) | 46.1 | 44.8 | 41.9 |
| No day care (%) | 4.6 | 4.1 | 7.5 |
| Crowded living (%) | 10.8 | 11.1 | 15.5‡ |
| Not taken part of parental education (%) | 47.4 | 49.7 | 54.4‡ |
| Parental overweight | |||
| Mother overweight (%) | 27.3 | 37.6‡ | 49.3‡ |
| Father overweight (%) | 52.1 | 69.3‡ | 73.7‡ |
| Both parents overweight (%) | 17.0 | 29.1‡ | 40.0‡ |
| Life style factors | |||
| Child's intake of sweetened beverages (%) | 10.5 | 12.0 | 12.7 |
| Secondhand tobacco smoke at 4 years of age (%) | 22.6 | 26.4‡ | 32.6‡ |
| Early life factors | |||
| Mother smoking during pregnancy (%) | 9.6 | 13.6‡ | 20.0‡ |
| Secondhand tobacco smoke at 0-4 weeks (%) | 22.3 | 26.1‡ | 33.6‡ |
| Secondhand tobacco smoke at 8 months (%) | 24.8 | 28.2‡ | 37.0‡ |
| High birth weight (>4000 g) (%) | 15.8 | 24.0‡ | 25.6‡ |
| Not breastfed (%) | 3.9 | 5.0 | 6.5‡ |
| Economic and psychosocial factors (%) | |||
| Parental low emotional support (%) | 21.1 | 22.3 | 26.3 |
| Parental low practical support (%) | 29.8 | 29.5 | 28.9 |
| Parental economic stress (%) | 6.1 | 8.0‡ | 9.6‡ |
| Season | Similarity (%) | Nseqs | Sobs |
| amoA D∗ | 90 | 87 | 7 |
| amoA T∗∗ | 90 | 82 | 3 |
| Artery size measurement method | Tortuosity < 0.1 | All subjects |
| A | 1.23 (1.09-1.34) | 1.32 (1.24-1.40) |
| B | 1.35 (1.20-1.46) | 1.30 (1.13-1.42) |
| Pathway name | # input genes in the pathway | P value |
| Long adhesion | 13 | 1.02E − 06 |
| Long-term depression | 6 | 3.85E − 04 |
| ECM-receptor interaction | 6 | 6.59E − 04 |
| Small cell lung cancer | 5 | 0.004769 |
| Regulation of actin cytoskeleton | 8 | 0.005003 |
| Prostate cancer | 5 | 0.005006 |
| Tight junction | 6 | 0.007175 |
| Melanoma | 4 | 0.012134 |
| Bladder cancer | 3 | 0.015551 |
| MAPK signaling pathway | 8 | 0.016136 |
| Axon guidance | 5 | 0.022646 |
| Endometrial cancer | 3 | 0.027335 |
| mTOR signaling pathway | 3 | 0.027335 |
| Gap junction | 4 | 0.02851 |
| Insulin signaling pathway | 5 | 0.029243 |
| Non-small cell lung cancer | 3 | 0.030129 |
| GnRH signaling pathway | 4 | 0.031564 |
| Alzheimer's disease | 2 | 0.033214 |
| Wnt signaling pathway | 5 | 0.03603 |
| p53 signaling pathway | 3 | 0.048047 |
| Glioma | 3 | 0.048047 |
| Cell cycle | 4 | 0.048272 |
| B cell receptor signaling pathway | 3 | 0.049885 |
| Long-term potentiation | 2 | 0.049885 |
| Neurodegenerative diseases | 2 | 0.050764 |
| Wnt signaling pathway | 7 | 0.001962 |
| B cell receptor signaling pathway | 4 | 0.00836 |
| VEGF signaling pathway | 4 | 0.011283 |
| Natural killer cell mediated cytotoxicity | 5 | 0.01976 |
| Hedgehog signaling pathway | 3 | 0.026203 |
| Neuroactive ligand-receptor interaction | 7 | 0.036606 |
| T cell receptor signaling pathway | 4 | 0.037492 |
| Dorsoventral axis formation | 2 | 0.039028 |
| Experimental Model/Method | Exposure | Mechanism of Resveratrol | Dosage of Resveratrol | Duration of Resveratrol Treatment | Reference |
| PC12 cells | Aβ25–35 induced | attenuated Aβ-induced cytotoxicity, apoptotic features, and intracellular ROI accumulation. | 25 μM | 24 h | [13] |
| PC12 cells | Aβ25–35 induced | inhibited the cell apoptosis | 12.5–100 μM | 24–48 h | [14] |
| prevented the LDH leakage | |||||
| maintained the intracellular Ca2+ homeostasis | |||||
| Purified baculovirus-expressed BACE-1 | - | inhibition of BACE-1 | 11.9 μM (IC50) | - | [30] |
| TRF assay | - | inhibition of BACE-1 | 28 μM (IC50) | 30 min | [31] |
| Neuro2a cells HEK293 | transfected with a plasmid containing APPsw | reduced γ-secretase activity | 2.5–20 μM | 24 h | [32] |
| induced MMP-9 activation | |||||
| autophagy-related 5 knockdown HEK293 | - | induced conversion of LC3-I to LC3-II | 60 μM | 24 h | [33] |
| suppression of Presenilin-1 induction | |||||
| suppressed Aβ production | |||||
| SK-N-SH cells | - | induction of NEP and ACE activity | 10 μM | 4 days | [34] |
| Hippocampal samples from AD patients | AD | binds to both fibril and monomer Aβ | 1.56–100 μM | - | [35] |
| Variable | Significance (p) | Relative risk | 95% CI |
| Diabetes mellitus | 0.009 | 4.0232 | 1.417–11.424 |
| Duration of dialysis (years) | 0.008 | 1.2499 | 1.059–1.475 |
| Treatment assignment | Follow-up status | |||
| Calcium | Placebo | Includeda | Not included | |
| (N = 334) | (N = 336) | (N = 563) | (N = 107) | |
| Variable | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) |
| Age (years) | 26.9 (5.6) | 25.9 (5.3)b | 26.5 (5.5) | 26.2 (5.3) |
| Education (years) | 10.8 (2.9) | 11.0 (3.2) | 10.9 (3.1) | 10.6 (2.9) |
| Number of pregnancies | 2.0 (1.0) | 2.1 (1.1) | 2.1 (1.0) | 2.0 (0.9) |
| Number of children | 0.8 (0.8) | 0.8 (0.9) | 0.8 (0.9) | 0.7 (0.7) |
| Number of months previous breastfeeding (cumulative lifetime) | 5.6 (8.9) | 6.8 (9.0) | 6.4 (9.2) | 5.1 (7.2) |
| BMI (kg/m2) | 25.9 (4.1) | 25.8 (3.7) | 25.9 (3.9) | 25.9 (3.9) |
| Energy intake (kcal/day) | 1888 (592) | 1862 (637) | 1860 (613) | 1951 (619) |
| Calcium intake (mg/day) | 1108 (492) | 1083 (532) | 1096 (515) | 1091 (497) |
| Hematocrit (%) | 39.1 (3.3) | 39.1 (3.0) | 39.1 (3.2) | 39.1 (2.7) |
| NTx (nM BCE/mM creatinine)c | 62.3 (1.7) | 62.9 (1.7) | 62.9 (1.7) | 52.2 (1.7) |
| \"Successful\" States | \"Unsuccessful\" States | |
| Political arrangement | Varied: democracy (Senegal, multiparty), authoritarian (Uganda) | Varied: democracy (multiparty, Zambia), others including authoritarian (Namibia, Ethiopia) |
| Institutional structures | Centralised (now decentralising) | Varied (decentralised and centralised) |
| Technology achieved | STIs, some ARV through centralised institution | Some behaviour/education, centralised STIs, sparse centralised ARVs |
| Method | Bias | MSE | ||
| LA | 0.42 | (0.14) | 2.06 | (0.21) |
| LDLA | 0.31 | (0.14) | 2.15 | (0.23) |
| LD decay | 0.31 | (0.14) | 2.02 | (0.21) |
| Two-marker | 0.16 | (0.13) | 1.82 | (0.18) |
| IBD | 0.23 | (0.13) | 1.69 | (0.20) |
| Autoimmune disease | Autoimmune target | Mean age of onset (range) years | Female:male ratio | Reference |
| Mid-adult onset | ||||
| Multiple sclerosis | Myelin sheath | 37 (25–45) | 1.8:1 | (205) |
| Myasthenia gravis | Neuromuscular junction | 40 | 2.7:1 | (205) |
| Systemic lupus erythematosus | Nuclear contents (systemic) | 40 (30–50) | 9:1 | (205, 206) |
| Neuromyelitis optica | Optic nerve/spinal cord | 32.6–45.7 | 2.4:1ratio highest after age 65 | (207, 208) |
| Graves’ disease | Thyroid | 48 | 7.3:1 | (205) |
| Systemic sclerosis | Connective tissue (systemic) | 50 (35–65) | 11.5:1 | (209) |
| Late-adult onset | ||||
| Granulomatosis with polyangiitis (GPA) (formerly Wegener’s granulomatosis) | Cytoplasmic contents of neutrophils (systemic, vascular) | 55 (40–70) | 1:1M > F after age 70 | (205) |
| Rheumatoid arthritis | Joints | 58 (42–74) | 3:1 | (210) |
| Polymyalgia rheumatica | Selected muscle groups | 70–80 | 2.3:1 | (211) |
| Giant cell arteritis | Vascular system | 70–80 | 2.3:1 | (211) |
| COOH-MWCNTs | Criterion | E (GPa) | σu (MPa) | T-3% (MPa.mm/mm) |
| 0 wt% (neat) | Mean | 21.70 | 320 | 6.70 |
| STD | 0.7 | 11.93 | 0.25 | |
| 0.5 wt% | Mean (% increase) | 20.40 (−6%) | 348 (8%) | 6.96 (3.9%) |
| STD | 0.61 | 6.24 | 0.52 | |
| 1.0 wt% | Mean (% increase) | 19.33 (−10%) | 340 (6%) | 6.77 (1.04%) |
| STD | 0.85 | 23.90 | 0.45 | |
| 1.5 wt% | Mean (% increase) | 20.40 (−6%) | 344 (7%) | 6.94 (3.48%) |
| STD | 0.82 | 29.28 | 0.36 |
| ARC | WHOQOL-BREF | Social Network | ||||||||
| Variable | Personal | Social | Physical | Psych | Social | Enviro | Group substance use | Non-using groups identification | Heavy using groups identification | Non-using groups importance |
| ARC | ||||||||||
| Personal | – | |||||||||
| Social | .87*** | – | ||||||||
| WHOQOL-BREF | ||||||||||
| Physical | .74*** | .54** | – | |||||||
| Psychological | .62** | .52* | .61** | – | ||||||
| Social | .39† | .52* | .24 | .68*** | – | |||||
| Environmental | .58** | .72*** | .49* | .46* | .41† | – | ||||
| Social Network | ||||||||||
| Groups substance use status | -.50* | -.47* | -.39 | -.10 | .02 | -.44† | – | |||
| Non-using groups identification | .37 | .44† | .24 | .03 | .05 | .53* | -.81*** | – | ||
| Heavy-using groups identification | -.32 | -.29 | -.25 | -.08 | -.14 | -.38 | .66** | -.41 | – | |
| Non-using groups importance | .33 | .38† | .26 | -.07 | -.08 | .48* | -.88*** | .94*** | -.44† | – |
| Heavy-using groups importance | -.43† | -.39† | -.38† | -.10 | -.08 | -.47* | .67** | -.42† | .90*** | -.47* |
| Study | Number | Metabolic syndrome | Htn | High TG | Impaired FBS | Low HDL | High WC | |
| Iran | Gorgan | 100 | 31% | 16% | 16% | 17% | 30% | 29% |
| North East | 160 | 20.62% | 3.12% | 20% | 14.30% | 29.37% | 34.37% | |
| Babol | 984 | 31% | 12.1% | 41.5% | 12.1% | 48.6% | 76.6% | |
| Tehran | 940 | 53.5% | 16.5% | 104.4% | 66.2% | 12.5% | 9.8% | |
| Brazil | 323 | 44.4% | 65% | 12.4% | 11.8% | 79.6% | 50.9% | |
| Argentina | 124 | 22% | 8% | 8% | 2% | 10% | 13% | |
| Ecuador | 325 | 41.5% | 65.9% | 83% | 29.6% | 80% | 83.7% | |
| Korea | 778 | 54.6% | 63.6% | 39.3% | 26% | 69.8% | 67.1% |
| Genome Effect |
| Changes in ploidy (mostly WGD) |
| Alteration of epigenetic modifications to the genome |
| Alterations in expression patterns across the genome |
| Activation and spread of mobile DNA elements |
| Genome restructuring involving mobile DNA elements |
| Changes in chromosome structure and karyotype |
| Alteration of tandem repetitive DNA arrays and centromeres |
| Insomnia | With (N = 159,989) | Without (N = 319,979) | P-value |
| X-year(s) of suicide attempts | Numbers of suicide attempts | ||
| 1 | 285 | 101 | < 0.001 |
| 2 | 525 | 157 | < 0.001 |
| 3 | 700 | 195 | < 0.001 |
| 4 | 808 | 222 | < 0.001 |
| 5 | 890 | 248 | < 0.001 |
| 6 | 965 | 265 | < 0.001 |
| 7 | 1020 | 276 | < 0.001 |
| 8 | 1052 | 286 | 0.001 |
| 9 | 1070 | 295 | < 0.001 |
| 10 | 1084 | 296 | < 0.001 |
| 11 | 1198 | 297 | < 0.001 |
| 12 | 1198 | 297 | < 0.001 |
| 13 | 1198 | 297 | < 0.001 |
| Determinant | Ready to enroll/re-enroll, n (%) | P-Value | COR | AOR |
| Region CHF enrolment rate | ||||
| Low | 186(81.6) | 0.513 | 1 | |
| High | 190(81.9) | 1.0(0.6-1.6) | ||
| Locality | ||||
| Rural | 185(78.7) | 0.056 | 1 | 1 |
| Urban | 191(84.9) | 1.5(0.9-2.5)a | 1.5(0.9-2.4) | |
| Sex | ||||
| Male | 157(78.5) | 0.073 | 1 | 1 |
| Female | 219(58.2) | 1.5(0.9-2.4)a | 1.4(0.8-2.2) | |
| Age group | ||||
| < 35 years | 218(83.5) | 0.155 | 1 | |
| 35+ years | 158(79.4) | 0.8(0.5-1.2) | ||
| Marital status | ||||
| Single | 40(72.7) | 0.056 | 1 | 1 |
| Married, divorced, widow etc | 336(83.0) | 1.8(1.0-3.5)a | 2.0(1.1-3.8) | |
| Education | ||||
| None/primary | 310(82.2) | 0.330 | 1 | 1 |
| Secondary/above | 66(79.5) | 0.84(0.5-1.5) | ||
| Family monthly average income | ||||
| Low (< median) | 170(82.5) | 0.507 | 1 | |
| High (≥median) | 193(82.1) | 1.0(0.6-1.6) | ||
| Family size (number of members) | ||||
| Small (<median 6) | 174(78.7) | 0.061 | 1 | 1 |
| Larger(≥median 6) | 200(84.7) | 1.5(0.9-2.4)a | 1.5(1.0-2.5) | |
| Number of marketing strategies ever exposed | ||||
| Never/one strategy | 113(83.1) | 0.366 | 1 | |
| Two & more strategies | 263(81.2) | 0.9(0.5-1.5) | ||
| Influence of leaders ever heard CHF message community leaders | ||||
| No | 175(79.5) | 0.126 | 1 | |
| Yes | 167(84.3) | 1.4(0.8-2.4) |
| All subjects (N=30) | 6.25-12.5 Hz | 12.5-25 Hz | 25-50 Hz |
| Global Efficiency | -0.13 | -0.25 | 0.15 |
| Local Efficiency | -0.21 | -0.33 | 0.08 |
| Interdensity | -0.15 | -0.13 | 0.02 |
| Intradensity Unaffected Hemi | -0.26 | * -0.46 | -0.07 |
| Intradensity Affected Hemi | -0.07 | -0.14 | 0.23 |
| Cortex Subjects (N=17) | |||
| Global Efficiency | -0.05 | * -0.60 | 0.08 |
| Local Efficiency | -0.26 | * -0.66 | -0.20 |
| Interdensity | 0.08 | -0.21 | 0.01 |
| Intradensity Unaffected Hemi | -0.24 | * -0.75 | -0.40 |
| Intradensity Affected Hemi | 0.04 | -0.39 | 0.49 |
| Significant consensus genes from continuous and extreme data, excluding children data | No. of overlap | No. not overlapping | % Overlap |
| Single-probe analysis | 232 | 9085 | 2.49 |
| Region analysis | 39 | 364 | 9.70 |
| P-values for small group | ||||
| Genes in small group | Known genes | Known genes in data set | Genes in data set | P-value |
| 6 | 2 | 7 | 129 | 0.0342 |
| 50 | 6 | 7 | 129 | 0.0136 |
| Region | PS-DHA | Placebo | p Value |
| Left Frontal Cortex | 52.23 ± 1.31 | 42.89 ± 0.94 | 0.054 |
| Right Frontal Cortex | 51.67 ± 1.22 | 37.69 ± 0.76 | 0.011 |
| Left Hippocampus | 59.50 ± 2.93 | 39.74 ± 2.53 | 0.016 |
| Right Hippocampus | 55.91 ± 2.81 | 38.37 ± 2.22 | 0.008 |
| Globus Pallidus | 46.44 ± 0.35 | 34.13 ± 0.26 | 0.001 |
| Hypothalamus | 66.27 ± 3.26 | 52.09 ± 0.43 | 0.013 |
| Thalamus | 47.24 ± 0.58 | 36.25 ± 0.07 | 0.004 |
| Corpus Callosum | 49.34 ± 0.79 | 31.23 ± 0.27 | 0.059 |
| Left Internal Capsule | 43.77 ± 0.64 | 30.60 ± 0.38 | 0.052 |
| Right Internal Capsule | 42.70 ± 0.34 | 30.46 ± 0.29 | 0.032 |
| B | SE B | OR | [95% CI] | p-value | |
| Child’s BMI, kg/ m2 | .63 | .06 | 1.88 | [1.66, 2.13] | .000 |
| Migration background(child), yes | .47 | .20 | 1.60 | [1.07, 2.37] | .020 |
| Self-efficacy to influencechild’s physical activity,high | -.54 | .19 | 0.58 | [0.40, 0.85] | .005 |
| Univariate analysis | Multivariate | |||||||
| Gametocytes | No gametocytes | OR | 95% CI | P value | OR | 95% CI | P value | |
| Placental malaria (haemozoin or qPCR) | 14/15 (93.3%) | 89/295 (30.2%) | 32.4 | 4.2 - 250.2 | <0.01 | -- | -- | -- |
| Haemozoin | 12/15 (80.0%) | 58/295 (19.7%) | 16.3 | 4.5-59.8 | <0.01 | 10.3 | 1.9 – 55.1 | <0.01 |
| qPCR | 9/15 (60.0%) | 62/304 (20.4%) | 5.9 | 2.0-17.1 | <0.01 | 2.8 | 0.8 – 9.3 | 0.09 |
| Mean maternal haemoglobin (g/dL) at enrolment (standard deviation) | 10.9 (1.5) | 11.8 (1.6) | 0.7 | 0.6 – 1.0 | 0.02 | 1.1 | 0.7 – 1.5 | 0.76 |
| Asexual stage parasitaemia at enrolment | 12/22 (54.5%) | 48/424 (11.3%) | 9.4 | 3.9 – 22.9 | <0.01 | 1.4 | 0.4 – 5.8 | 0.62 |
| Malaria treatment prior to enrolment | 6/22 (27.3%) | 56/422 (13.2%) | 2.5 | 0.9 – 6.5 | 0.09 | 2.8 | 0.8 – 10.1 | 0.11 |
| Mean maternal age in years (standard deviation) | 20.3 (3.1) | 20.1 (3.2) | 1.0 | 0.9 – 1.2 | 0.77 | -- | -- | -- |
| Primigravid | 13/22 (59.1%) | 268/424 (63.2%) | 1.2 | 0.5 – 2.8 | 0.70 | -- | -- | -- |
| Mean gestational age in weeks at the time of enrolment (standard deviation) | 20.1 (4.0) | 20.1 (4.4) | 1.0 | 0.9 – 1.1 | 0.97 | -- | -- | -- |
| Mother slept under a bed net the previous night | 9/22 (40.9%) | 211/422 (50.0%) | 1.4 | 0.6 – 3.5 | 0.40 | -- | -- | -- |
| Maternal axillary temperature (°C) at enrolment (standard deviation) | 36.5 (0.4) | 36.6 (0.4) | 0.8 | 0.3 – 2.2 | 0.72 | -- | -- | -- |
| Comparison and protein | Entrez gene name | P value | Fold change |
| LMP1 vs pBabe: no inhibitors (P = 1.92E−05) | |||
| DNAJC7 | DnaJ (Hsp40) homologue, subfamily C, member 7 | 3.90E−02 | −1.852 |
| HSPA14 | Heat shock 70-kDa protein 14 | 1.98E−02 | −1.667 |
| HSPB1 | Heat shock 27-kDa protein 1 | 1.20E−02 | 3.427 |
| PSMD2 | Proteasome (prosome, macropain) 26S subunit, non-ATPase, 2 | 5.38E−03 | 1.171 |
| PSMD8 | Proteasome (prosome, macropain) 26S subunit, non-ATPase, 8 | 1.92E−02 | −1.728 |
| THOP1 | Thimet oligopeptidase 1 | 3.73E−02 | −1.982 |
| UBE2V1 | Ubiquitin-conjugating enzyme E2 variant 1 | 1.10E−03 | 1.739 |
| USP5 | Ubiquitin-specific peptidase 5 | 2.61E−02 | −1.490 |
| USP14 | Ubiquitin-specific peptidase 14 | 2.57E−02 | −2.353 |
| LMP2 vs pBabe: no inhibitors (P = 1) | |||
| None | |||
| LMP1 vs pBabe: with inhibitors (P = 2.35E−06) | |||
| BAG1 | BCL2-associated athanogene | 2.96E−03 | 2.613 |
| BIRC3 | Baculoviral IAP repeat-containing 3 | 1.58E−02 | −1.760 |
| CUL1 | Cullin-1 | 3.57E−03 | −1.414 |
| DNAJC5 | DnaJ (Hsp40) homologue, subfamily C, member 5 | 2.41E−02 | −2.692 |
| HLA-B | Major histocompatibility complex, class I, B | 2.06E−02 | 4.993 |
| HSP90AA1 | Heat shock protein 90-kDa alpha (cytosolic), class A member 1 | 3.43E−02 | −1.335 |
| HSPA6 | Heat shock 70-kDa protein 6 (HSP70B′) | 5.54E−03 | −1.492 |
| HSPA8 | Heat shock 70-kDa protein 8 | 4.62E−02 | −2.934 |
| HSPA1A | Heat shock 70-kDa protein 1A | 2.34E−03 | −1.242 |
| PSMB1 | Proteasome (prosome, macropain) subunit, beta type, 1 | 1.08E−03 | 2.223 |
| PSMB8 | Proteasome (prosome, macropain) subunit, beta type, 8 | 9.89E−03 | 2.207 |
| PSMB10 | Proteasome (prosome, macropain) subunit, beta type, 10 | 1.03E−02 | 2.319 |
| PSMC2 | Proteasome (prosome, macropain) 26S subunit, ATPase, 2 | 1.89E−02 | 1.127 |
| PSMD14 | Proteasome (prosome, macropain) 26S subunit, non-ATPase, 14 | 4.95E−02 | −1.390 |
| RBX1 | Ring box 1, E3 ubiquitin protein ligase | 2.30E−02 | −1.494 |
| TCEB1 | Transcription elongation factor B (SIII), polypeptide 1 | 4.49E−02 | −1.414 |
| TCEB2 | Transcription elongation factor B (SIII), polypeptide 2 | 1.33E−03 | −1.690 |
| UBE2I | Ubiquitin-conjugating enzyme E2I | 1.19E−02 | −1.485 |
| UBE2L3 | Ubiquitin-conjugating enzyme E2L 3 | 1.42E−02 | 4.031 |
| UBE3B | Ubiquitin protein ligase E3B | 6.61E−03 | 1.659 |
| UBE4A | Ubiquitination factor E4A | 1.94E−02 | −2.941 |
| USP38 | Ubiquitin-specific peptidase 38 | 3.60E−02 | −3.717 |
| LMP2 vs pBabe: with inhibitors (P = 4.26E−05) | |||
| CDC34 | Cell division cycle 34 | 3.99E−02 | −2.274 |
| DNAJA1 | DnaJ (Hsp40) homologue, subfamily A, member 1 | 5.00E−02 | −1.763 |
| HSCB | HscB mitochondrial iron-sulfur cluster cochaperone | 4.67E−02 | −2.333 |
| PSMB1 | Proteasome (prosome, macropain) subunit, beta type, 1 | 1.73E−02 | 1.456 |
| PSMC2 | Proteasome (prosome, macropain) 26S subunit, ATPase, 2 | 2.62E−03 | 1.287 |
| PSMD2 | Proteasome (prosome, macropain) 26S subunit, non-ATPase, 2 | 2.70E−02 | −1.227 |
| TAP2 | Transporter 2, ATP-binding cassette, subfamily B | 3.16E−02 | −2.098 |
| TCEB2 | Transcription elongation factor B (SIII), polypeptide 2 | 1.27E−02 | −1.275 |
| TRAF6 | TNF receptor-associated factor 6, E3 ubiquitin protein ligase | 5.71E−03 | −1.943 |
| UBA1 | Ubiquitin-like modifier activating enzyme 1 | 2.85E−03 | −1.117 |
| UBE2C | Ubiquitin-conjugating enzyme E2C | 1.21E−02 | −5.242 |
| UBE2L6 | Ubiquitin-conjugating enzyme E2L 6 | 2.87E−02 | −2.430 |
| UBE3B | Ubiquitin protein ligase E3B | 4.58E−02 | 1.134 |
| UBE4A | Ubiquitination factor E4A | 9.86E−03 | −7.551 |
| USP38 | Ubiquitin-specific peptidase 38 | 2.81E−02 | −5.336 |
| USP48 | Ubiquitin-specific peptidase 48 | 8.21E−03 | −1.919 |
| CRHR1 antagonist | Studies | Dosage | Outcome | Comments |
| Antalarmin | Rissman et al. (2012) [59], Dong et al. (2014) [43], Park et al. (2015) [44], | 20 mg/kg | Rissman (2012) - Able to block acute stress induced tau phosphorylation but not that induced by chronic stress [59]. Dong (2014) - Able to decrease Aβ levels and plaque load in a chronic stress paradigm [43]. Park (2015) - Unable to block rises in Aβ in response to acute stress [44]. | Dong (2014) measured PBS soluble Aβ, which represents roughly 5% of total Aβ. |
| A-helical CRH | Park et al. (2015) [44] | 5 & 10 μM | Unable to block CRH induced Aβ increases in vitro. | |
| Astressin | Park et al. (2015) [44] | 5 & 10 μM | Unable to block CRH induced Aβ increases in vitro. | |
| NBI 30775/R121919 | Rissman et al. (2012) [59], Campbell et al. (2015) [51], Dong et al. (2014) [43], Zhang et al. (2016) [64] | 20 mg/kg. Zhang (2016) utilized osmotic mini pump | Campbell (2015) [51] – able to decrease AT8 and PHF-1 phosphorylation in CRH overexpressing mice but not at S262 and S422. Rissman (2012) [59] – Able to decrease stress induced AT8 and PHF-1 increases in phosphorylation | |
| NBI27914 | Park et al. (2015) [44], Lee et al. (2009) [83], Carroll et al. (2011) [54] | 10 mg/kg | Carroll (2011) [54] - NBI27914 rescued freezing and decreased AT8 phosphorylation and decreased neurodegeneration in PS1 tau transgenic mice.Lee (2009) [83] – NBI27914 reduced stress induced increases in Aβ levels and plaque load.Park (2015) [44] – NBI27914 increased secreted Aβ42/ Aβ40 ratio in vitro |
| d— difference between G values | Selection rate2.5 % | 5.0 % | 10.0 % | Effect of divergent selection (χ2 test) |
| 3 % | 1.8-2.0 | 1.6-1.9 | 1.6-2.0 | Not significant at any of the tested selection rates |
| 5 % | 2.7-4.2* | 2.1-3.2 | 1.9-2.2 | Significant at 2.5 % selection rate |
| 7.5 % | 3.5-5.5* | 2.5-3.1 | 2.3-2.5 | Significant at 2.5 % selection rate |
| 10 % | 7.6-10.5* | 4.7-5.7* | 3.5-4.0* | Significant at each assessed selection rate |
| Population size | 1200 | 600 | 300 | 30 extreme RILs from each tail |
| Variable | Descriptive statistic |
| Age | 27.1 ± 5.8 years |
| Age group | |
| 15–24 | 37.8% |
| 25–34 | 48.3% |
| 35–44 | 13.5% |
| < 15 and > 44 | 0.4% |
| Marital status | |
| Married | 86.9% |
| Single | 12.0% |
| Widow or separated or divorced | 1.2% |
| Years of formal education | 10.3 ± 3.3 years |
| None | 0.4% |
| Primary (1–8) | 35.9% |
| Secondary (9–12) | 42.9% |
| Tertiary (> 12) | 20.8% |
| Total number of pregnancies | 2.6 ± 1.7 pregnancies |
| 1–4 | 86.1% |
| > 4 | 13.9% |
| Living children | 2.5 ± 1.6 children |
| Male | 1.2 ± 1.1 |
| Female | 1.3 ± 1.2 |
| Gene Name | Primer Sequence | Length of Product (bp) |
| Reverse Transcription Quantitative PCR (RT-qPCR) | ||
| CmCHS1 | F: CTGGAACAGCAACGGAAACT | 190 |
| R: TCCGTTGTTGATGAGCCAGA | ||
| CmCHT1 | F: TGCTGGCAACAACAACTACAATC | 231 |
| R: ATCTCCACGCTCTTAGGGTCTT | ||
| CmCDA1 | F: AAGAAATGGCGGGTATGAGGGTG | 142 |
| R: AGTGGTGGATTAGACAAAGGTGCG | ||
| CmActin | F: GAGCGTGGTTACTCATTCA | 283 |
| R: TGTCAACATCGCACTTCA | ||
| CmCYPA792 | F: TTGATGCGGATGTTGACG | 164 |
| R: ATGCCCTTTGGAGTTGGA | ||
| CmGST | F: AACTGTATTCGGCTTTATCC | 234 |
| R: ACACACTTGCTGCCTTTTCC | ||
| PCR for cDNA Sequencing | ||
| CmCDA1 | F1: GTCTACGGTTGCGTTGCTCC | 911 |
| R1: GAGCAACGCAACCGTAGACGACTGG | ||
| F2: CATCATCGTTGTGCGTGACAGAGTG | 970 | |
| R2: ACGACAGCACAATCACCGCACCTT | ||
| F3: GCCGTCCTCGGAGCAGAAACAGTCA | 830 | |
| R3: CCAACAACGA CGAATATCTTCCAGG | ||
| CmCHT1 | F1: TGTCCTCGATGCCGTACCTGCCCAC | 1300 |
| R1: AAGGGGTGCTGACCGCTGCTGTGCCGCT | ||
| F2: CACGCCGGGGCGGTACACCGCC | 300 | |
| R2: TGGGAAGACAAGGGCTGTCCAACCAACA | ||
| CmCHSA | F1: ACTATGTGGCACGAAACGAA | 354 |
| R1: TAGTACATGTACAT | ||
| F2: CATTTGAAAGATAAGGC | 580 | |
| R2: ACCAACATRAGRAADAT | ||
| F3: CGCCTTACATCGCTTACC | 1258 | |
| R3: ACBARACCRATNGGYTCC |
| Oligonucleotide designation | Oligonucleotide (5′→3′) | Genome position |
| p1167 | ACCCTACTGACTGACGAACAGATTGCTTC | 6816−6847 |
| p1168 | TGTTGTTGAGCGTAATGAGTCCGTCCT | 6230–6256 |
| p1303 | GTCTTGTCAAACGTTTATAATCTATGGCAAATACGTGA | 6549–6586 |
| p1305 | TCAGCTCCACAAACATGTCATGAAAATTCGCATAGG | 6503–6538 |
| p1321 | GTTATAAACAGTTTCCATGGTGCATCACACTTATC | 3466–3500 |
| p1322 | ACGGGACTTGACAAATATTCCATAATTAACTGCCT | 4502–4536 |
| p1338 | ATTGCTCACCCTTGTTGGGAACGTTACCCTT | 1303–1333 |
| p1343 | AACTTAAACCTTTCGACACTTGGGAAGAAGTA | 7001–7032 |
| p1362 | AACGGCACAATAGTCATCGTCCCG | 6469–6492 |
| p1363T | TGGCCGTCATGGTGGCGAATAATGTCAACCTAATCT-ACGGTAAGATGAGTCT | 6051–6080 |
| p1438 | AGATGCAAAGGAACTGACAATGACGAACTT | 1011–1040 |
| p1439 | TTCATTTGAGCAAGATATAATGAGCGTCTATAGTGGGT | 1150–1187 |
| Condition | Brain region | MNI coordinate | BA | T-value | ||
| x | y | z | ||||
| Resting-state | PCC | −6 | −60 | 28 | 31 | 18.17 |
| Left IPC (lIPC) | −42 | −66 | 44 | 40 | 15.45 | |
| MPFC | 1 | 50 | 24 | 9, 10 | 10.97 | |
| Right IPC (rIPC) | 48 | −57 | 36 | 39, 40 | 9.25 | |
| Right ITC (rITC) | 63 | −27 | −20 | 20 | 7.43 | |
| Left ITC (lITC) | −59 | −21 | −20 | 20, 21 | 6.43 | |
| Left HC (lHC) | −24 | −12 | −28 | 35 | 5.82 | |
| Right HC (rHC) | 24 | −30 | −16 | 36 | 6.77 | |
| Task-state | PCC | −1 | −63 | 24 | 7, 31 | 15.81 |
| Left IPC (lIPC) | −45 | −69 | 39 | 39, 40 | 9.38 | |
| MPFC | −6 | 54 | 28 | 9 | 15.18 | |
| Right IPC (rIPC) | 52 | −66 | 28 | 39 | 5.12 | |
| Right ITC (rITC) | 54 | 6 | −36 | 21 | 9.43 | |
| Left ITC (lITC) | −51 | −9 | −28 | 20, 21 | 10.39 | |
| Left HC (lHC)* | −24 | −12 | −28 | 35 | 5.82 | |
| Right HC (rHC)* | 24 | −30 | −16 | 36 | 6.77 |
| SSR Pattern | SSR Numbers in Non-redundant White Clover ESTs | Frequency (%) | Designed EST-SSR Primers | |||
| Mismatch 0 | Mismatch 1 | Mismatch 2 | Total | |||
| AG | 211 | 16.67 | 30 | 19 | 44 | 93 |
| AT | 22 | 1.74 | 7 | 3 | 15 | 25 |
| AC | 8 | 0.63 | 4 | 6 | 11 | 21 |
| GC | 0 | 0.00 | 0 | 0 | 0 | 0 |
| AAC | 182 | 14.38 | 49 | 64 | 139 | 252 |
| AAG | 179 | 14.14 | 35 | 90 | 246 | 371 |
| GGT | 170 | 13.43 | 27 | 63 | 157 | 247 |
| ATC | 113 | 8.93 | 30 | 49 | 151 | 230 |
| AAT | 86 | 6.79 | 17 | 21 | 66 | 104 |
| AGC | 79 | 6.24 | 8 | 33 | 90 | 131 |
| GGA | 36 | 2.84 | 10 | 34 | 89 | 133 |
| GGC | 19 | 1.50 | 2 | 8 | 47 | 57 |
| ACT | 16 | 1.26 | 5 | 12 | 21 | 38 |
| ACG | 4 | 0.32 | 0 | 5 | 21 | 26 |
| AATG | 26 | 2.05 | 3 | 12 | 19 | 34 |
| AAAT | 23 | 1.82 | 4 | 13 | 30 | 47 |
| AAAG | 20 | 1.58 | 3 | 5 | 44 | 52 |
| AGTG | 8 | 0.63 | 0 | 0 | 0 | 0 |
| ATAG | 8 | 0.63 | 0 | 0 | 0 | 0 |
| AATT | 8 | 0.63 | 3 | 2 | 17 | 22 |
| ATAC | 5 | 0.39 | 0 | 0 | 0 | 0 |
| AACC | 4 | 0.32 | 0 | 0 | 0 | 0 |
| AAAC | 4 | 0.32 | 0 | 9 | 34 | 43 |
| AACT | 3 | 0.24 | 0 | 0 | 0 | 0 |
| Other tetra-nucleotide repeats | 32 | 2.53 | 4 | 8 | 35 | 47 |
| Total | 1266 | 100 | 241 | 456 | 1276 | 1973 |
| Informant | Area of expertise | Recruitment | Interview setting | Informant characteristics | |
| STEP 1 EXPERTS (N = 4) (key informant interviews) | Professor Peter Krustrup (PK) | Extensive knowledge and experience in human physiology and soccer research | Personal contact at a meeting | The informant’s office | Professor of Team Sport and Health; main research areas include muscle physiology, prevention and treatment of lifestyle diseases through physical activity, and training and testing in elite sport. |
| Professor Klaus Brasso (KB) | Extensive experience with clinical research and medical treatment of prostate cancer patients | Personal email | Meeting room, Department of Urology, Copenhagen University Hospital, Rigshospitalet | Professor, senior consultant/resident, M.D., Ph.D.; previously involved in research on the efficacy of recreational soccer in men with prostate cancer undergoing androgen deprivation therapy and a member of the FCPC Steering Committee | |
| Dr. Svend Aage Madsen (SM) | Extensive knowledge and clinical experience in male psychology and gender-sensitive health promotion | Personal email | Telephone interview | Licensed specialist in psychotherapy, Ph.D.; co-founder and board member of the Danish Network on Research in Men and Masculinities and co-founder and president of the Danish Men’s Health Society | |
| Professor Michael Borre (MB) | Extensive experience with clinical research and medical treatment of prostate cancer patients | Personal email | Office, Health Research Department, Copenhagen University Hospital, Rigshospitalet | Professor, senior consultant/resident, D.M.Sc., M.D., Ph.D.; chair of the executive board of the Danish Multidisciplinary Cancer Group (DMCG) and the Danish Prostate Cancer Group (DaProCa) |
| Est | SE | β | p | Lower CI | Upper CI | FMI | Δ R2 | |
| MVPA: (F(9,171) = 1.97, R2=.09) | ||||||||
| (Intercept) | 19.22 | 18.56 | 0.00 | 0.30 | −17.16 | 55.60 | 0.06 | Covariates = .07 |
| Female | −9.04 | 3.22 | −0.21 | <0.01 | −15.34 | −2.74 | 0.03 | |
| Age | −0.76 | 0.80 | −0.08 | 0.34 | −2.33 | 0.80 | 0.06 | |
| Self-efficacy | 1.44 | 3.25 | 0.04 | 0.66 | −4.93 | 7.80 | 0.05 | Individual = .004 |
| Parent support | 0.82 | 1.85 | 0.04 | 0.66 | −2.81 | 4.46 | 0.06 | Social = .012 |
| Nurturance | 0.44 | 1.85 | 0.02 | 0.81 | −3.19 | 4.07 | 0.08 | |
| Limit-setting | 0.99 | 2.00 | 0.05 | 0.62 | −2.93 | 4.91 | 0.06 | |
| Monitoring | 0.90 | 2.33 | 0.04 | 0.70 | −3.67 | 5.47 | 0.10 | |
| Home resources | 0.13 | 0.67 | 0.01 | 0.85 | −1.19 | 1.45 | 0.05 | Environmental = .008 |
| Neighborhood support | 3.47 | 3.16 | 0.09 | 0.27 | −2.71 | 9.66 | 0.04 | |
| Light PA: (F(9,171) = 5.23, R2=.22) | ||||||||
| (Intercept) | 350.23 | 58.42 | 0.00 | <0.01 | 235.71 | 464.75 | 0.04 | Covariates = .143 |
| Female | −17.39 | 10.48 | −0.12 | 0.10 | −37.95 | 3.16 | 0.07 | |
| Age | −11.33 | 2.51 | −0.33 | <0.01 | −16.25 | −6.40 | 0.03 | |
| Self-efficacy | −9.47 | 10.31 | −0.07 | 0.36 | −29.69 | 10.74 | 0.04 | Individual = .001 |
| Parent support | 15.67 | 5.88 | 0.21 | 0.01 | 4.14 | 27.21 | 0.05 | Social = .045 |
| Nurturance | −8.66 | 5.85 | −0.11 | 0.14 | −20.13 | 2.81 | 0.06 | |
| Limit-setting | 2.30 | 6.36 | 0.03 | 0.72 | −10.17 | 14.77 | 0.06 | |
| Monitoring | 7.24 | 7.36 | 0.09 | 0.33 | −7.19 | 21.66 | 0.08 | |
| Home resources | −3.47 | 2.14 | −0.12 | 0.10 | −7.66 | 0.71 | 0.04 | Environmental = .027 |
| Neighborhood support | 19.97 | 10.15 | 0.14 | 0.049 | 0.08 | 39.87 | 0.06 |
| Foot pain in last month n (%) | No foot pain in last month n (%) | Unadjusted OR (95 % CI) | Adjusteda OR (95 % CI) | |
| N | 248 | 875 | - | - |
| Age, mean (SD) | 66.6 (11.7) | 65.0 (12.7) | 1.11b (0.99, 1.24) | 1.14b (0.94, 1.38) |
| Gender: | ||||
| Male | 190 (76.6) | 752 (85.9) | 1.0 | 1.0 |
| Female | 58 (23.4) | 123 (14.1) | 1.87 (1.31, 2.65) | 1.33 (0.77, 2.30) |
| Neighbourhood deprivation tertiles: | ||||
| Most deprived | 93 (37.5) | 258 (29.5) | 1.0 | 1.0 |
| Mid-deprived | 78 (31.5) | 304 (34.7) | 0.71 (0.50, 1.00) | 0.81 (0.50, 1.31) |
| Least deprived | 77 (31.1) | 313 (35.8) | 0.68 (0.48, 0.96) | 1.14 (0.71, 1.82) |
| BMI (kg/m2): | ||||
| <25.0 | 34 (15.2) | 177 (21.1) | 1.0 | 1.0 |
| 25.0–29.9 | 90 (40.2) | 397 (47.2) | 1.18 (0.77, 1.82) | 1.64 (0.89, 2.99) |
| 30.0–34.9 | 62 (27.7) | 182 (21.6) | 1.77 (1.11, 2.83) | 2.23 (1.16, 4.27) |
| ≥35.0 | 38 (17.0) | 85 (10.1) | 2.33 (1.37, 3.95) | 2.61 (1.25, 5.45) |
| Anxiety: | ||||
| None | 133 (60.7) | 677 (81.8) | 1.0 | 1.0 |
| Mild | 41 (18.7) | 96 (11.6) | 2.17 (1.44, 3.28) | 1.05 (0.57, 1.95) |
| Moderate | 25 (11.4) | 34 (4.1) | 3.74 (2.16, 6.48) | 1.38 (0.56, 3.39) |
| Severe | 20 (9.1) | 21 (2.5) | 4.85 (2.56, 9.19) | 1.21 (0.41, 3.51) |
| Depression: | ||||
| None | 93 (47.0) | 644 (80.2) | 1.0 | 1.0 |
| Mild | 52 (26.3) | 90 (11.2) | 4.00 (2.67, 6.00) | 3.02 (1.78, 5.11) |
| Moderate | 20 (10.1) | 43 (5.4) | 3.22 (1.82, 5.71) | 1.42 (0.58, 3.46) |
| Moderately severe | 20 (10.1) | 18 (2.2) | 7.69 (3.93, 15.08) | 3.41 (1.22, 9.57) |
| Severe | 13 (6.6) | 8 (1.0) | 11.25 (4.54, 27.88) | 4.55 (1.20, 17.18) |
| Comorbidity: | ||||
| Diabetes mellitus | 59 (23.8) | 134 (15.3) | 1.73 (1.22, 2.44) | 1.00 (0.60, 1.66) |
| Hypertension | 166 (66.9) | 529 (60.5) | 1.32 (0.98, 1.78) | 0.98 (0.62, 1.57) |
| Hyperlipidaemia | 117 (47.2) | 374 (42.7) | 1.20 (0.90, 1.59) | 1.12 (0.74, 1.71) |
| Ischaemic heart disease | 56 (22.6) | 140 (16.0) | 1.53 (1.08, 2.17) | 1.43 (0.87, 2.35) |
| Cerebrovascular disease | 18 (7.3) | 62 (7.1) | 1.03 (0.60, 1.77) | 0.83 (0.40, 1.69) |
| Gout characteristics: | ||||
| Duration, mean (SD) | 12.7 (13.4) | 11.8 (11.8) | 1.06c (0.94, 1.20) | 1.05c (0.88, 1.25) |
| Current attack | 62 (26.1) | 65 (7.7) | 4.21 (2.87, 6.19) | 2.38 (1.35, 4.20) |
| Number of attacks in last 12 months: | ||||
| 0 | 63 (27.2) | 313 (37.5) | 1.0 | 1.0 |
| 1–2 | 77 (33.2) | 323 (38.7) | 1.18 (0.82, 1.71) | 0.96 (0.58, 1.59) |
| ≥3 | 92 (39.7) | 199 (23.8) | 2.30 (1.59, 3.31) | 1.17 (0.66, 2.05) |
| Oligo/polyarticular attacks | 132 (56.4) | 289 (34.4) | 2.47 (1.84, 3.32) | 1.67 (1.11, 2.51) |
| Current allopurinol use | 144 (62.1) | 463 (55.6) | 1.31 (0.97, 1.76) | 1.11 (0.72, 1.72) |
| 2008 Criteria for PMF | 2016 Criteria for pre-PMF | 2016 Criteria for overt PMF |
| Major criteria | ||
| MK proliferiferation and atypia with fibrosis (reticulin and/or collagen) or increased marrow cellularity, granulocytic proliferation and decreased erythropoesis in the absence of fibrosis | MK proliferation and atypia without reticulin fibrosis with increased marrow cellularity, granulocytic proliferation and often decreased erythropoesis | MK proliferiferation and atypia with fibrosis (reticulin and/or collagen) |
| Does not meet WHO criteria for other myeloid neoplasms | Does not meet WHO criteria for other myeloid neoplasms | Does not meet WHO criteria for other myeloid neoplasms |
| Presence of JAK2V617F or other clonal marker or no evidence of reactive fibrosis. | Presence of JAK2, CALR or MPL mutation or other clonal marker with no evidence of reactive fibrosis | Presence of JAK2, CALR or MPL mutation or other clonal marker with no evidence of reactive fibrosis |
| Minor criteria | ||
| Leukoerythroblastosis | Leukocytosis (⩾11 × 109/L) | Leukoerythroblastosis |
| Increased serum lactate dehydrogenase | Increased serum lactate dehydrogenase | Increased serum lactate dehydrogenase |
| Anemia | Anemia (not due to comorbidities) | Anemia (not due to comorbidities) |
| Palpable splenomegaly | Palpable splenomegaly | Palpable splenomegaly |
| Leukocytosis (⩾11 × 109/L) |
| Test Method | ASTM Standard | Dimension (L × W × T, mm3) | Calibrating Length (mm) |
| 90°/0° tensile | D3039/D3039M-08 | 220 × 20 × 2.5 | 140 |
| ±45° tensile | D3518/D3518M-13 | 180 × 20 × 2.5 | 100 |
| ±45°/90°/0° compression | D3410/D3410M-95 | 160 × 20 × 2.5 | 80 |
| DCB | D5528-13 | 220 × 25 × 2.5 | 25 (precrack) |
| 3ENF | D7905/D7905M-14 | 100 × 25 × 2.5 | 80 |
| Mode III | E1922-04 | 100 × 25 × 2.5 | 25 (precrack) |
| Question | Responses | Frequency | % | Total/350 | Recoding/Routing |
| A1. In which of the following is the property situated? | Centre of a large city | 0 | 0.0 | 336 | |
| Suburbs/Outskirts of a large city | 257 | 73.4 | |||
| Large town or small city | 76 | 21.7 | |||
| Small town | 3 | 0.9 | |||
| Village | 0 | 0.0 | |||
| Countryside | 0 | 0.0 | |||
| Other | 0 | 0.0 | |||
| Missing | 14 | 4.0 | |||
| B4. Looking at this card [show card 1], overall, how satisfied or dissatisfied are you personally with living in this neighbourhood? Would you say that you are very satisfied, satisfied, neither satisfied nor dissatisfied, dissatisfied or very dissatisfied? | Very satisfied | 112 | 32.0 | 350 | |
| Satisfied | 160 | 45.7 | |||
| Neither satisfied nor dissatisfied | 25 | 7.1 | |||
| Dissatisfied | 27 | 7.7 | |||
| Very dissatisfied | 26 | 7.4 | |||
| Missing | 0 | 0.0 | |||
| C2. Looking at this card [show card 1], overall, how satisfied or dissatisfied are you personally with living in this home? Would you say that you are very satisfied, satisfied, neither satisfied nor dissatisfied, dissatisfied or very dissatisfied? | Very satisfied | 138 | 39.4 | 350 | |
| Satisfied | 163 | 46.6 | |||
| Neither satisfied nor dissatisfied | 21 | 6.0 | |||
| Dissatisfied | 16 | 4.6 | |||
| Very dissatisfied | 12 | 3.4 | |||
| Missing | 0 | 0.0 | |||
| C9. Looking at this list [show card 3], which best describes your current situation with this home? Do you or your family: | Own outright or with a mortgage | 228 | 65.1 | 348 | Responses to this questions were recoded as to whether they had some stake in the property or not, i.e., A: (Own/Mortgage/Part mortgage), B: (Private Rent/Association Rent). |
| Part-rent and part-own with a mortgage | 9 | 2.6 | |||
| Rent from a private landlord/letting agency | 53 | 15.1 | |||
| Rent from a Housing Association or Council | 53 | 15.1 | |||
| Other | 5 | 1.4 | |||
| Missing | 2 | 0.6 | |||
| C12. From any room in this home, can you see:Construction Activity | No | 202 | 57.7 | 345 | |
| Yes | 143 | 40.9 | |||
| Missing | 5 | 1.4 |
| Variables | Total | Progastrin staining in HP epithelial cells | |||
| N = 48 | No/Low expression | Moderate expression | High expression | p-value | |
| N = 21 | N = 12 | N = 15 | |||
| Percentage of p-ERK1/2 stained cells, N mean (SD) | N = 43 33% (30) | N = 18 27% (29) | N = 12 23% (22) | N = 13 53% (29) | 0.015a |
| Expression of p-ERK1/2 | 0.008b | ||||
| No/low expression | 35% [21%-51%] | 50% [26%-74%] | 42% [15%-72%] | 8% [0%-36%] | |
| Moderate expression | 37% [23%-53%] | 33% [13%-59%] | 42% [15%-72%] | 38% [14%-68%] | |
| High expression | 28% [15%-44%] | 17% [4%-41%] | 16% [2%-48%] | 54% [25%-81%] | |
| Percentage of pY-STAT3 stained cells, N mean (SD) | N = 35 10% (23) | N = 15 11% (29) | N = 7 3% (7) | N = 13 12% (23) | 0.297 |
| Expression of pY-STAT3 | 0.3116 | ||||
| No/low expression | 77% [60%-90%] | 80% [52%-96%] | 86% [42%-100%] | 69% [39%-91%] | |
| Moderate expression | 14% [5%-30%] | 7% [0%-32%] | 14% [0%-58%] | 23% [5%-54%] | |
| High expression | 9% [2%-23%] | 13% [2%-40%] | 0% [0%-41%] | 8% [0%-36%] |
| From | To | Rate (95% HPD)* | No. of Jumps (95% HPD)† | Jump proportion‡ | BF§ |
| Elk | Bison | 0.59 (0.02–1.42) | 5.24 (2.05–7.71) | 0.021 | 110 |
| Livestock | 1.68 (0.25–3.46) | 16.36 (14.23–19.16) | 0.070 | 44,206 | |
| Bison | Elk | 1.85 (0.27–3.79) | 12.24 (7.26–18.50) | 0.053 | 44,206 |
| Livestock | 0.33 (0.00–2.32) | 0.00 (0.00–1.56) | 0.002 | <3 | |
| Livestock | Bison | 0.31 (0.00–2.30) | 0.00 (0.00–0.29) | 0.000 | <3 |
| Elk | 0.36 (0.00–1.96) | 0.06 (0.00–2.41) | 0.002 | <3 |
| Adverse event | Estimated incidence |
| a) death | 20%* |
| b) necrotising enterocolitis or focal intestinal perforation diagnosed on clinical grounds, or at surgery | 15%* |
| c) intracranial abnormality (parenchymal haemorrhage or focal white matter damage) on cranial ultrasound | 15%* |
| d) requirement for supplementary oxygen 28 days after birth | 55%* |
| e) patent ductus arteriosus requiring medical or surgical management | 25%* |
| f) retinal surgery for retinopathy of prematurity | 5%* |
| g) sustained tachycardia (greater than 220 beats per minute for more than 30 minutes in a 60 minute period) | 20%** |
| h) pulmonary haemorrhage | 5%** |
| i) persistent weight loss after 14 days after birth in the absence of infection. | 10%** |
| PCr/ATP | |||
| Subject | MaxV | MaxV‐50V | Mean |
| 1 | 1.96 ± 0.29 | 1.94 ± 0.43 | 1.95 ± 0.35 |
| 2 | 2.01 ± 0.37 | 1.85 ± 0.47 | 1.93 ± 0.38 |
| 3 | 1.93 ± 0.37 | 2.08 ± 0.38 | 2.00 ± 0.30 |
| 4 | 2.27 ± 0.28 | 2.23 ± 0.58 | 2.25 ± 0.39 |
| 5 | 2.14 ± 0.52 | 2.13 ± 0.64 | 2.13 ± 0.55 |
| 6 | 2.02 ± 0.45 | 2.20 ± 0.55 | 2.11 ± 0.47 |
| 7 | 2.19 ± 0.27 | 2.11 ± 0.35 | 2.15 ± 0.27 |
| 8 | 2.47 ± 0.59 | 2.38 ± 0.66 | 2.42 ± 0.61 |
| 9 | 2.22 ± 0.29 | 2.33 ± 0.31 | 2.28 ± 0.29 |
| Mean | 2.13 ± 0.17 | 2.14 ± 0.17 | 2.14 ± 0.16 |
| Strain | Growth rate | masses | terminal phenotype |
| w1118 | +++ | - | viable |
| da-Gal4 | +++ | - | viable |
| tub-Gal4 | +++ | - | homozygous lethal |
| act5c-Gal4 | +++ | - | homozygous lethal |
| UAS-Dis3 (35090) | +++ | - | viable |
| UAS-Dis3 (35091) | +++ | - | homozygous lethal |
| da-Gal4/UAS-Dis3 (35090) | + | + | 2nd instar larva lethal |
| da-Gal4/UAS-Dis3 (35091) | + | + | 2nd instar larva lethal |
| tub-Gal4/UAS-Dis3 (35090) | + | + | 2nd instar larva lethal |
| act5c-Gal4/UAS-Dis3 (35090) | + | + | 2nd instar larva lethal |
| Number | Mixtures Composition (wt %) | ||
| Stellite 6 | WS2 | NbC | |
| Coating 1 | 100 | - | - |
| Coating 2 | 85 | 15 | - |
| Coating 3 | 70 | - | 30 |
| Coating 4 | 60 | 10 | 30 |
| Coating 5 | 55 | 15 | 30 |
| Coating 6 | 50 | 20 | 30 |
| Region | R/L/M | BA | MNI coordinate | Stats | |||
| x | y | z | T | Sizea | |||
| Group difference | |||||||
| IGO < Control | |||||||
| rACC/vmPFC | L | 32 | −6 | 50 | 12 | 18.8 | 29 |
| IGO > Control | |||||||
| NS | |||||||
| Group × reward-type interaction | |||||||
| IP region | L | 39 | −46 | −56 | 20 | 20.5 | 26 |
| mOFC/vmPFC | M | 11 | −2 | 44 | −10 | 19.8 | 24 |
| Characteristics | Group-1 (n = 53) No SG | Group-2 (n = 27) Mild SG | Group-3 (n = 65) Severe SG | p-value |
| Age (years) | 31 (27-34) | 27 (25-29) | 28 (24-30) | 0.001 |
| Gravidity (2 / 3 / 4 / >4) | 40/10/3/0 | 20/6/1/0 | 53/11/1/0 | 0.826 |
| Abortus (0 / 1 / 2) | 39/11/3 | 20/6/1/0 | 51/13/1/0 | 0.952 |
| Education (≤ 5 years / middle / high / university) | 14/15/11/13 | 6/6/9/6 | 17/20/12/6 | 0.433 |
| Level of income(low / middle / high) | 17/21/15 | 4/17/6 | 18/33/14 | 0.322 |
| Smoking habit (-/+) | 49/4 | 25/2 | 54/11 | 0.215 |
| SG in first pregnancy (-/+) | 52/1 | 6/21 | 3/62 | <0.001 |
| Family history of SG (-/+) | 27/26 | 16/11 | 21/44 | 0.027 |
| Striae on buttocks (-/+) | 3/50 | 4/23 | 18/47 | 0.007 |
| Striae on leg (-/+) | 8/45 | 8/19 | 31/34 | 0.001 |
| Striae on breasts (-/+) | 0/53 | 0/27 | 6/59 | 0.021 |
| Period between two C/S (years) | 4.99±2.87 | 4.09±1.91 | 4.82±2.90 | 0.516 |
| GW at first C/S | 39 (38-40) | 40 (38-40) | 40 (39-41) | 0.039 |
| Birth weight of first baby (gram) | 3309±581 | 3281±587 | 3327±586 | 0.884 |
| BMI at previous C/S (kg/m2) | 27 (25-29) | 29 (24-31) | 30 (26-33) | 0.003 |
| BMI at present C/S (kg/m2) | 27 (26-30) | 29 (27-31) | 32 (30-35) | <0.001 |
| GW at present C/S | 38.42±1.08 | 38.63±0.88 | 38.74±0.67 | 0.335 |
| Birth weight of second baby (gram) | 3315±297 | 3270±458 | 3351±381 | 0.658 |
| Pregnancy and Neonatal Outcomes | Cobalt (μg/L) | Copper (μg/dL) | Zinc (μg/dL) | Selenium (μg/L) | ||||||||||||
| High (n = 9) | Not High (n = 236) | pa | pb | High (n = 172) | Not High (n = 73) | pa | pb | Low (n = 187) | Not Low (n = 58) | pa | pb | Low (n = 5) | Not Low (n = 240) | pa | pb | |
| Gestational diabetes, n (%) | 0 (0) | 18 (7.6) | 0.76 | 0.80 | 15 (8.7) | 3 (4.1) | 0.22 | 0.45 | 15 (8.0) | 3 (5.2) | 0.47 | 0.58 | 0 (0) | 18 (7.5) | 0.96 | 0.79 |
| Preeclampsia, n (%) | 0 (0) | 5 (2.1) | 0.62 | 0.43 | 2 (1.2) | 3 (4.1) | 0.16 | 0.03 | 5 (2.7) | 0 (0) | 0.40 | 0.54 | 0 (0) | 5 (2.1) | 0.42 | 0.44 |
| Gestational age at delivery, weeks, median | 39.6 | 39.5 | 0.43 | 0.27 | 39.4 | 39.6 | 0.37 | 0.99 | 39.6 | 39.5 | 0.88 | 0.44 | 39.6 | 39.4 | 0.39 | 0.64 |
| Baby weight, g, median | 3540 | 3180 | 0.08 | 0.03 | 3180 | 3190 | 0.76 | 0.47 | 3180 | 3175 | 0.59 | 0.30 | 3440 | 3180 | 0.04 | 0.03 |
| Preterm, n (%) | 0 (0) | 11 (4.7) | 0.98 | 0.65 | 10 (5.8) | 1 (1.4) | 0.16 | 0.18 | 7 (3.7) | 4 (6.9) | 0.32 | 0.66 | 0 (0) | 11 (4.6) | 0.72 | 0.64 |
| Low birth weight, n (%) | 0 (0) | 9 (3.8) | 0.88 | 0.94 | 6 (3.5) | 3 (4.1) | 0.81 | 0.72 | 8 (4.3) | 1 (1.7) | 0.38 | 0.56 | 0 (0) | 9 (3.8) | 0.63 | 0.97 |
| Small for gestational age, n (%) | 1 (11.1) | 35 (14.8) | 0.76 | 0.40 | 27 (15.7) | 9 (12.3) | 0.50 | 0.80 | 31 (16.6) | 5 (8.6) | 0.14 | 0.19 | 0 (0) | 36 (15.0) | 0.68 | 0.50 |
| Congenital abnormality, n (%) | 0 (0) | 14 (5.9) | 0.89 | 0.83 | 10 (5.8) | 4 (5.5) | 0.92 | 0.84 | 11 (5.9) | 3 (5.2) | 0.84 | 0.94 | 0 (0) | 14 (5.8) | 0.83 | 0.95 |
| All synolog pairs | ≥90% protein sequence identity between synolog pairs | |||||
| Median ± MAD | Min | Max | Median ± MAD | Min | Max | |
| Number of carbohydrate metabolism synologs | 49.0 ± 35.0 | 0 | 394 | 0.0 ± 0.0 | 0 | 47 |
| Number of carbohydrate metabolism synolog groups | 20.0 ± 13.0 | 0 | 128 | 0.0 ± 0.0 | 0 | 16 |
| Average protein sequence identity between synolog pairs2 [%] | 36.8 ± 4.2 | 13.4 | 100.0 | 97.3 ± 1.8 | 90.0 | 100.0 |
| Synolog fraction of carbohydrate metabolism genes [%] | 30.0 ± 9.7 | 0.0 | 85.7 | 0.0 ± 0.0 | 0.0 | 34.6 |
| Source | Variable | # Items | Response options | Cronbach’s α | Pearson’s r | Potential Range | Actual Range | Mean (SD) |
| Social Support for Healthy Eating | ||||||||
| Child | Family Food Culture | 4 | 0 (Never or almost never) to 2 (almost always or always) | .64 | NA | 0–8 | 0–8 | 5.36 (1.80) |
| Parent | Instrumental support for healthy eating | 7 | 0 (No) to 1 (Yes) | .76 | NA | 0–7 | 0–7 | 4.38 (2.04) |
| Parent | Home availability and accessibility of FV | 6 | 0 (Never) to 3 (All of the time) | .72 | NA | 0–18 | 1–18 | 10.75 (3.57) |
| Parent | Home availability of SSB | 1 | 0 (Never) to 3 (All of the time) | NA | NA | 0–3 | 0–3 | 1.59 (.87) |
| Parent | Emotional support for healthy eating | 6 | 0 (Strongly disagree) to 4 (Strongly agree) | .71 | NA | 0–24 | 0–24 | 17.66 (3.82) |
| Parent | Rules for healthy eating | 3 | 0 (Strongly disagree) to 4 (Strongly agree) | .77 | NA | 0–12 | 0–12 | 8.96 (2.46) |
| Parent | Modeling vegetable intake | 1 | 0 (Never) to 4 (About once a day) | NA | NA | 0–4 | 0–4 | 3.48 (.84) |
| Parent | Modeling SSB | 1 | 0 (Never) to 4 (About once a day) | NA | NA | 0–4 | 0–4 | 2.79 (1.18) |
| Social Support for Physical Activity | ||||||||
| Parent | Instrumental support for PA | 2 | 0 (Never) to 7 (7 days) | NA | .46 | 0–14 | 0–14 | 3.96 (3.38) |
| Parent | Emotional support for PA | 4 | 0 (Strongly disagree) to 4 (Strongly agree) | .74 | NA | 0–16 | 0–16 | 12.73 (2.52) |
| Parent | Modeling PA | 1 | 0 (Never) to 4 (About once a day) | NA | NA | 0–4 | 0–4 | 3.55 (.82) |
| FACTOR1 | ||||
| GO ID | GO Term | Size | Count | Pvalue |
| GO.0007051 | spindle organization | 6 | 2 | 8.20E-03 |
| GO.0050931 | pigment cell differentiation | 7 | 2 | 0.011 |
| GO.0000279 | M phase of meiotic cell cycle | 79 | 6 | 0.012 |
| GO.0000079 | regulation of cyclin dependent protein kinase activity | 9 | 2 | 0.019 |
| GO.0016570 | histone modification | 13 | 2 | 0.038 |
| GO.0015698 | inorganic anion transport | 53 | 4 | 0.039 |
| GO.0007156 | homophilic cell adhesion | 32 | 3 | 0.041 |
| Kegg ID | Kegg pathway | Size | Count | Pvalue |
| map05216 | Thyroid cancer | 11 | 2 | 0.020 |
| map05130 | Pathogenic Escherichia coli infection | 12 | 2 | 0.024 |
| map04520 | Adherens junction | 31 | 3 | 0.024 |
| FACTOR2 | ||||
| GO ID | GO Term | Size | Count | Pvalue |
| GO.0006195 | purine nucleotide catabolic process | 5 | 3 | 2.23E-05 |
| GO.0030168 | platelet activation | 7 | 3 | 7.65E-05 |
| GO.0007051 | spindle organization | 6 | 2 | 2.55E-03 |
| GO.0007596 | blood coagulation | 24 | 3 | 3.76E-03 |
| GO.0030336 | negative regulation of cell migration | 12 | 2 | 0.011 |
| GO.0032879 | regulation of localization | 103 | 5 | 0.012 |
| GO.0001775 | cell activation | 74 | 4 | 0.016 |
| GO.0001890 | placenta development | 18 | 2 | 0.023 |
| GO.0017038 | protein import | 49 | 3 | 0.027 |
| GO.0006403 | RNA localization | 22 | 2 | 0.034 |
| GO.0006816 | calcium ion transport | 56 | 3 | 0.038 |
| Kegg ID | Kegg pathway | Size | Count | Pvalue |
| map00230 | Purine metabolism | 64 | 4 | 0.013 |
| Complication | Incidence [25] | Cost for treatment |
| Re-operation (any reason) (including infection) | 0.30% (3 out of 1,000) | - CPT 29871 (surgical, for infection, lavage and drainage); $521.91 |
| - APC 0041(knee arthroscopy/drainage); $2,111.62 | ||
| Venous thromboembolism (VTE) | 0.19% (1.9 out of 1,000) | Costs over a 12 month timeframe for treating VTE; $14,865 |
| Deep vein thrombosis (DVT) | 0.12% (1.2 out of 1,000) | Costs over a 12 month timeframe for treating DVT [43]; $14,865 |
| Pulmonary embolism (PE) | 0.08% (0.8 out of 1,000) | Costs over a 12 month timeframe for treating PE [43]; $22,900 |
| Markers | Chromosome | Position (bp) | Number of individuals | |||
| a | h | b | Total | |||
| mSI_26 | CH1 | 3 377 732 | 5 | 228 | 118 | 351 |
| mSI_88 | CH1 | 3 499 444 | 5 | 224 | 111 | 340 |
| mSI_89 | CH1 | 3 525 756 | 5 | 233 | 114 | 352 |
| mSI_32 | CH1 | 3 649 333 | 4 | 236 | 120 | 361 |
| mTcCIR15 | CH1 | 3 711 664 | 4 | 227 | 117 | 348 |
| mSI_73 | CH1 | 3 790 637 | 4 | 291 | 138 | 429 |
| mSI_101 | CH1 | 3 935 902 | 3 | 243 | 119 | 365 |
| mSI_102 | CH1 | 3 966 163 | 2 | 249 | 119 | 370 |
| mSI_140 | CH1 | 3 988 656 | 2 | 217 | 125 | 344 |
| mSI_141 | CH1 | 4 010 921 | 2 | 308 | 138 | 448 |
| mSI_103 | CH1 | 4 021 267 | 3 | 387 | 228 | 618 |
| mSI_366 | CH1 | 4 053 385 | 0 | 508 | 253 | 761 |
| mSI_367 | CH1 | 4 054 418 | 0 | 366 | 216 | 582 |
| mSI_369 | CH1 | 4 057 532 | 0 | 419 | 221 | 640 |
| mSI_440 | CH1 | 4 066 036 | 0 | 476 | 253 | 729 |
| mSI_370 | CH1 | 4 070 474 | 0 | 466 | 266 | 732 |
| mSI_372 | CH1 | 4 073 585 | 0 | 297 | 170 | 467 |
| mSI_375 | CH1 | 4 091 577 | 2 | 429 | 228 | 659 |
| mSI_107 | CH1 | 4 130 575 | 4 | 374 | 212 | 590 |
| mTcCIR356 | CH1 | 4 149 062 | 6 | 232 | 118 | 354 |
| mSI_112 | CH1 | 4 233 257 | 6 | 339 | 163 | 502 |
| mSI_113 | CH1 | 4 252 975 | 6 | 284 | 172 | 456 |
| mSI_462 | CH4 | 1414 | 222 | 425 | 2 | 649 |
| mSI_466 | CH4 | 4737 | 191 | 385 | 0 | 576 |
| mSI_474 | CH4 | 10 127 | 198 | 380 | 0 | 578 |
| mSI_7 | CH4 | 20 673 | 259 | 488 | 0 | 747 |
| mSI_34 | CH4 | 28 166 | 238 | 487 | 0 | 725 |
| mSI_8 | CH4 | 28 166 | 142 | 270 | 0 | 412 |
| mTcCir312 | CH4 | 32 259 | 277 | 516 | 0 | 793 |
| mSI_35 | CH4 | 33 618 | 183 | 348 | 0 | 531 |
| mSI_2 | CH4 | 43 494 | 191 | 335 | 0 | 526 |
| mSI_542 | CH4 | 63 388 | 33 | 68 | 0 | 101 |
| mSI_303 | CH4 | 119 995 | 299 | 578 | 0 | 877 |
| mSI_458 | CH4 | 136 890 | 208 | 399 | 0 | 607 |
| mSI_460 | CH4 | 139 590 | 198 | 406 | 0 | 604 |
| mSI_308 | CH4 | 139 780 | 211 | 408 | 0 | 619 |
| mSI_309 | CH4 | 141 679 | 205 | 411 | 0 | 616 |
| mSI_310 | CH4 | 142 517 | 193 | 383 | 0 | 576 |
| mSI_315 | CH4 | 233 706 | 301 | 563 | 0 | 864 |
| mSI_402 | CH4 | 246 098 | 259 | 506 | 0 | 765 |
| mSI_535 | CH4 | 252 815 | 110 | 232 | 0 | 342 |
| mSI_411 | CH4 | 258 684 | 125 | 242 | 1 | 368 |
| mS_413 | CH4 | 270 916 | 118 | 253 | 1 | 372 |
| mSI_39 | CH4 | 278 179 | 277 | 421 | 1 | 699 |
| mSI_42 | CH4 | 343 424 | 109 | 233 | 2 | 345 |
| mSI_46 | CH4 | 428 250 | 119 | 230 | 2 | 352 |
| mSI_54 | CH4 | 751 986 | 55 | 127 | 4 | 521 |
| mSI_294 | CH4 | 1 686 245 | 109 | 248 | 16 | 373 |
| Location | PT-INR tests | Range stated | Cause stated |
| PHCC Östergötland | 499 | 480 | 495 |
| PHCC Eksjö | 65 | 65 | 65 |
| PHCC total (men/women) | 564 (289/275) | 545 (282/263) | 560 (289/271) |
| ACC Östergötland | 470 | 470 | 464 |
| ACC Eksjö | 58 | 58 | 58 |
| ACC Värnamo | 399 | 399 | 393 |
| ACC Total (men/women) | 927 (540/387) | 927 (540/387) | 915 (531/384) |
| Parameters | Cases ± SD | Controls ± SD | p value |
| Total SOD Activity (U/ml) | 285.44 ± 114.36 | 319.79 ± 126.12 | 0.144 |
| SOD Activity (U/ml) of cases on Metformin onlya | 274.81 ± 122.73 | - | a*b*c =0.771 |
| SOD Activity (U/ml) of cases on Metformin and other drugsb | 281.75 ± 111.91 | - | Post hoc: |
| SOD Activity (U/ml) of cases on other drugs aside Metforminc | 307.98 ± 133.40 | a*b =0.824 ; | |
| a*c =0.499; | |||
| b*c =0.5265 |
| Group | A | B | C | D |
| Parameters | Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD |
| Normal Morphology | 97.44 ± 0.94 | 91.09 ± 2.91*** | 91.60 ± 3.37*** | 94.56 ± 1.12*** |
| Abnormal Head | 1.74 ± 0.69 | 3.87 ± 1.64** | 3.73 ± 2.49* | 1.84 ± 0.61 |
| Abnormal Tail | 0.82 ± 0.39 | 5.04 ± 2.65*** | 4.67 ± 2.06*** | 3.6 ± 1.04*** |
| Derivation set (N = 38) | P-value (Wilcoxon) | ||
| No response (N = 21) | Response (N = 16) | ||
| miR375 | |||
| Mean ± STD | 5.2 ± 2.2 | 7.1 ± 1.8 | 0.01 |
| Median (min–max) | 5.8 (−0.5–7.9) | 7.3 (4.2–9.8) | |
| miR149 | |||
| Mean ± STD | 7.2 ± 1.4 | 4.8 ± 1.8 | <0.001 |
| Median (min–max) | 6.5 (5.0–9.5) | 4.8 (1.8–7.8) | |
| Validation set (N = 22) | P-value (Wilcoxon) | ||
| No response (N = 13) | Response (N = 9) | ||
| miR375 | |||
| Mean ± STD | 3.8 ± 1.7 | 2.3 ± 2.3 | 0.07 |
| Median (min–max) | 2.8 (2.0–6.6) | 1.7 (−0.2–7.6) | |
| miR149 | |||
| Mean ± STD | 5.4 ± 1.7 | 4.2 ± 1.2 | 0.11 |
| Median (min–max) | 5.3 (1.8–7.2) | 4.3 (2.4–5.8) |
| Variant | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| Length (bp) | 1536 | 1425 | 1419 | 1425 | 1230 | 1326 | 1188 | 1425 |
| M (%) | 94 | 99 | 96 | 99 | 98 | 99 | 98 | 100 |
| m (%) | 54 | 51 | 64 | 76 | 54 | 51 | 61 | 76 |
| Type of analysis | HR | SE | 95% CI | P-value |
| VTE risk | ||||
| Crude analysis | 0.66 | 0.29 | (0.28-1.54) | 0.33 |
| PS stratified analysis* | 0.63 | 0.29 | (0.25-1.57) | 0.33 |
| Hospital Mortality | ||||
| Crude analysis | 1.26 | 0.18 | (0.95-1.68) | 0.10 |
| PS stratified analysis* | 0.98 | 0.16 | (0.72-1.36) | 0.94 |
| Mating systems | Promiscuity | ||
| Humans included in the model | |||
| Relative brain size | F = 6.59 | p = 0.002 | p = 0.570 |
| Relative testis size | F = 26.93 | p<0.0001 | p<0.0001 |
| Sexual dimorphism | F = 3.83 | p = 0.021 | p = 0.721 |
| Humans excluded from the model | |||
| Relative brain size | F = 3.93 | p = 0.019 | p = 0.341 |
| Relative testis size | F = 26.52 | p<0.0001 | p<0.0001 |
| Sexual dimorphism | F = 3.83 | p = 0.023 | p = 0.818 |
| First-born children born in 2008 | The 2008 birth cohort | The 2006 birth cohort* | ||||
| Total n | % | Total n | % | Total n | % | |
| MS score negative (=0) | 617 | 91 | 1525 | 89** | 955 | 85** |
| F group (oral hygiene and fluoride) | 242 | 91 | 686 | 87 | 419 | 83 |
| X group (diet and xylitol) | 176 | 89 | 390 | 88 | 231 | 89 |
| Control group | 199 | 92 | 449 | 93 | 305 | 86 |
| P | 0.658 | 0.011 | 0.129 |
| Transcript support | 5' end | 3' end |
| FANTOM3 | 3,211 | 3,211 |
| PUBLIC | 2,666 | 2,666 |
| 5' ESTs | 20,866 | - |
| 3' ESTs | - | 32,166 |
| Public ESTs | 41,543 | 15,989 |
| GIS | 1,279 | 1,279 |
| GSC | 27,616 | 27,616 |
| CAGE | 162,707 | - |
| Total count | 259,888 | 82,927 |
| Type of drug related questions | Response N (%) | ||
| Never | Sometimes | Always | |
| Price | 5 (10.4) | 14 (29.2) | 29 (60.4) |
| Dosage | 0 | 27 (56.2) | 21 (43.8) |
| Drug identification | 2 (4.2) | 32 (66.7) | 14 (29.1) |
| Efficacy of drugs | 8 (16.6) | 27 (56.3) | 13 (27.1) |
| Adverse drug reactions | 4 (8.3) | 33 (68.8) | 11 (22.9) |
| Contraindications | 4 (8.4) | 34 (70.8) | 10 (20.8) |
| Drug interactions | 7 (14.6) | 34 (70.8) | 7 (14.6) |
| Pharmaceutical compatibility and stability | 32 (66.7) | 11 (22.9) | 5 (10.4) |
| Poisoning | 21 (43.8) | 26 (54.1) | 1 (2.1) |
| Herbal drugs | 25 (52.1) | 22 (45.8) | 1 (2.1) |
| Non-injection drug users | Injection drug users | |||||||
| Total | Current IM use | No current IM use | Total | Current IM use | No current IM use | |||
| n = 955 | n = 113 | n = 842 | n = 460 | n = 157 | n = 303 | |||
| n(%)d | n(%) | n(%) | p-valuea | n(%)d | n(%) | n(%) | p-valuea | |
| Sex | ||||||||
| Male | 664 (69.5) | 76 (67.3) | 588 (69.8) | 0.576 | 370 (80.4) | 125 (79.6) | 245 (80.9) | 0.751 |
| Female | 289 (30.3) | 37 (32.7) | 252 (29.9) | 0.541 | 88 (19.1) | 30 (19.1) | 58 (19.1) | 0.993 |
| Transgender | 2 (0.2) | 0 (0) | 2 (0.2) | 1.000b | 2 (0.4) | 2 (1.3) | 0 (0) | 0.120b |
| Race | ||||||||
| Hispanic | 430 (45.0) | 67 (59.3) | 363 (43.1) | 0.001 | 373 (81.1) | 133 (84.7) | 240 (79.2) | 0.172 |
| Black | 436 (45.7) | 36 (31.9) | 400 (47.5) | 0.002 | 21 (4.6) | 5 (3.2) | 16 (5.3) | 0.304 |
| White | 25 (2.6) | 1 (0.9) | 24 (2.9) | 0.960b | 51 (11.1) | 16 (10.2) | 35 (11.6) | 0.651 |
| Other | 64 (6.7) | 9 (8.0) | 55 (6.5) | 0.567 | 14 (3.0) | 3 (1.9) | 11 (3.6) | 0.398b |
| Mean age (SD)c | 30.1 (6.5) | 31.8 (6.2) | 29.8 (6.5) | 0.002 | 26.4 (5.3) | 26.1 (4.9) | 26.6 (5.5) | 0.388 |
| Sexual orientation | ||||||||
| Heterosexual | 786 (82.3) | 100 (88.5) | 686 (81.5) | 0.033 | 395 (85.9) | 133 (84.7) | 262 (86.5) | 0.961 |
| MSMe | 90 (9.4) | 5 (4.4) | 85 (10.1) | 0.051 | 13 (8.3) | 32 (10.6) | 13 (8.3) | 0.447 |
| WSWf | 102 (10.7) | 9 (8.0) | 93 (11.0) | 0.327 | 11 (7.0) | 21 (6.9) | 11 (7.0) | 0.955 |
| < High school education | 526 (55.1) | 68 (60.2) | 458 (54.4) | 0.246 | 190 (41.3) | 67 (42.7) | 123 (40.6) | 0.709 |
| Homeless in last 6 months | 549 (57.5) | 60 (53.1) | 489 (58.1) | 0.315 | 332 (72.2) | 117 (74.5) | 215 (71.0) | 0.419 |
| Main source of income | ||||||||
| Employed | 180 (18.8) | 18 (15.9) | 162 (19.2) | 0.334 | 59 (12.8) | 20 (12.7) | 39 (12.9) | 0.925 |
| Illegal | 386 (40.4) | 53 (46.9) | 333 (39.5) | 0.203 | 254 (55.2) | 99 (63.1) | 155 (51.2) | 0.021 |
| Public Assistance | 221 (23.1) | 27 (23.9) | 194 (23.0) | 0.956 | 65 (14.1) | 16 (10.2) | 49 (16.2) | 0.071 |
| Other | 146 (15.3) | 15 (13.3) | 131 (15.6) | 0.459 | 72 (15.7) | 20 (12.7) | 52 (17.2) | 0.194 |
| Have children | 547 (57.3) | 77 (68.1) | 470 (55.8) | 0.013 | 216 (47.0) | 70 (44.6) | 146 (48.2) | 0.463 |
| Ever been incarcerated | 661 (69.2) | 88 (77.9) | 573 (68.1) | 0.044 | 323 (70.2) | 112 (71.3) | 211 (69.6) | 0.632 |
| Site | ||||||||
| Bronx | 348 (36.4) | 43 (38.1) | 305 (36.2) | 0.704 | 232 (50.4) | 83 (52.9) | 149 (49.2) | 0.453 |
| Harlem | 449 (47.0) | 53 (46.9) | 396 (47.0) | 0.980 | 171 (37.2) | 59 (37.6) | 112 (37.0) | 0.907 |
| Brooklyn | 67 (7.0) | 11 (9.7) | 56 (6.7) | 0.228 | 22 (4.8) | 6 (3.8) | 16 (5.3) | 0.487 |
| Queens | 47 (4.9) | 5 (4.4) | 42 (5.0) | 0.880 | 6 (1.3) | 3 (1.9) | 3 (1.0) | 0.415 |
| Lower East Side | 40 (4.2) | 0 (0) | 40 (4.8) | 1.000b | 27 (5.9) | 6 (3.8) | 21 (6.9) | 0.178 |
| HIV+ | 101 (10.6) | 6 (5.3) | 95 (11.3) | 0.056 | 22 (4.8) | 6 (3.8) | 16 (5.3) | 0.457 |
| HBV+ | 211 (22.1) | 24 (21.2) | 187 (22.2) | 0.832 | 141 (30.7) | 47 (29.9) | 94 (31.0) | 0.763 |
| HCV+ | 36 (3.8) | 6 (5.3) | 30 (3.6) | 0.247b | 255 (55.4) | 86 (54.8) | 169 (55.8) | 0.596 |
| Variables | Stroke n = 358 | Non-stroke n = 58 | P |
| Age | 69.2 ± 13.8 | 70.6 ± 11.4 | 0.397 |
| Male, n (%) | 210 (58.7) | 37 (63.8) | 0.460 |
| SBP, mmHg | 168.8 ± 31.9 | 147.8 ± 27.6 | <0.001* |
| DBP, mmHg | 91.8 ± 20.7 | 80.8 ± 14.3 | <0.001* |
| bpm | 80.9 ± 18.1 | 80.0 ± 13.3 | 0.742 |
| Medical history, n (%) | |||
| Smoker | 146 (40.8) | 20 (34.5) | 0.339 |
| Hypertension | 202 (56.4) | 34 (58.6) | 0.992 |
| Diabetes | 58 (16.2) | 14 (24.1) | 0.157 |
| Hyperlipidemia | 40 (11.2) | 9 (15.5) | 0.407 |
| Ischemic heart disease | 36 (10.1) | 8 (13.8) | 0.434 |
| Atrial fibrillation | 28 (7.8) | 1 (1.7) | 0.148 |
| Symptoms & signs, n (%) | |||
| Asymmetric facial weakness | 181 (50.6) | 8 (13.8) | <0.001* |
| Asymmetric arm weakness | 217 (60.6) | 7 (12.1) | <0.001* |
| Asymmetric leg weakness | 228 (63.7) | 9 (15.5) | <0.001* |
| Speech disturbance | 195 (54.5) | 17 (29.3) | <0.001* |
| Visual field defect | 68 (19.0) | 1 (1.7) | 0.001* |
| gaze palsy | 115 (32.1) | 5 (8.6) | <0.001* |
| Sensory deficits | 78 (21.8) | 8 (13.8) | 0.163 |
| Loss of consciousness or syncope | 119 (33.2) | 10 (17.2) | 0.015* |
| Seizure activity | 21 (5.9) | 6 (10.3) | 0.319 |
| Pathologic reflex | 102 (28.5) | 8 (13.8) | 0.019* |
| Meningeal irritation | 22 (6.1) | 0 (0) | 0.102 |
| Vertigo | 26 (7.3) | 19 (32.8) | <0.001* |
| Headache | 25 (7.0) | 3 (5.2) | 0.816 |
| Nausea | 59 (16.5) | 26 (44.8) | <0.001* |
| Vomiting | 51 (14.2) | 23 (39.7) | <0.001* |
| Score | |||
| GCS > 8, n (%) | 297 (83) | 56 (96.6) | 0.007* |
| GCS ≤ 8, n (%) | 61 (17) | 2 (3.4) | 0.007* |
| GCS, median (IQR) | 15 (12–15) | 15 (15–15) | <0.001* |
| Primer | Sequence |
| miR-182 | F: 5′-GGCAATGGTAGAACTCACACT-3′ |
| R: 5′-AACATGTACAGTCCATGGATG-3′ | |
| HOXA9 | F: 5′-TGCCCTCCAGCCGGCCTTAT-3′ |
| R: 5′-CCGCTTTGTGCGGGGATGGT-3 | |
| Wnt | F: 5′-GCTAGCGAAAGTCATTGGC -3′ |
| R: 5′-CATTGCATCGAAGTCGTG-3′ | |
| CTNNB1 | F: 5′-ACAAACTGTTTTGAAAATCCA-3′ |
| R: 5′-CGAGTCATTGCATACTGTCC-3′ | |
| WIF-1 | F: 5′-CCGAAATGGAGGCTTTTGTA-3′ |
| R: 5′-TGGTTGAGCAGTTTGCTTTG-3′ | |
| Survivin | F: 5′-CCGAGGGACTGTGTGGGGGTC-3′ |
| R: 5′-CCAGGCACAGACCAAGGACGC-3′ | |
| CCND1 | F: 5′-AATGGGCCTTAGAATGACTGC-3′ |
| R: 5′-ATGCCAACACAGATGGCTTT-3′ | |
| C-myc | F: 5′-CTACCAGCAGCAGCAGCAGAGC-3′ |
| R: 5′-CGTCCGGGTCGCACATGAA-3′ | |
| BIM | F: 5′-CGTAGCGCATGCGATA-3′ |
| R: 5′-CATGCCGTATAAGCTAGTT-3′ | |
| Bax | F: 5′-GGCCCACCAGCTCTGAGCAGA-3′ |
| R: 5′-GCCACGTGGGGGTCCCAAAGT-3′ | |
| Mcl-1 | F: 5′-AGAAAGCTGCATCGAACCATTA-3′ |
| R: 5′-GGAAGAACAACTCCACAAACCCATC-3′ | |
| Bcl-xl | F: 5′-TTGGACAATGGACTGGTTGA-3′ |
| R: 5′-GTAGAGTGGATGGTCAGTG-3′ | |
| Snail | F: 5′-CTCCTCTACTTCAGCCTCTT-3′ |
| R: 5′-CTTCATCAACGTCCTGTGGG-3′ | |
| GAPDH | F: 5′-CCACCCATGGCAAATTCCATGGCA-3′ |
| R: 5′-TCTAGACGGCAGGTCAGGTCCAC-3′ | |
| U6 | F: 5′-CTCGGCTTCGGCAGCACA-3′ |
| R: 5′-AACGCTTCACGAATTTGCGT-3′ |
| Subgroup (Number of studies) | Summary DOR (95% CI) | |
| Study design | Case-control (24) | 134.4 (65.2 – 213.1) |
| Cross-sectional (60) | 171.1 (106.7 – 274.2) | |
| Blinding | Single or double blinded (29) | 90.2 (46.2 – 176.2) |
| Unblinded or NR (55) | 221.2 (137.7 – 355.2) | |
| DNA extraction method | Chemical (55) | 153.7 (90.1 – 262.4) |
| Physical (29) | 171.7 (96.2 – 306.6) | |
| Amplification method | PCR/multiplex (68) | 139.3 (89.2 – 217.7) |
| Nested PCR (16) | 266.6 (140.8 – 504.6) | |
| Target sequence | IS6110 (54) | 236.1 (152.9 – 364.6) |
| Other target (30) | 77.4 (38.2 – 156.9) | |
| Detection method | Probe (49) | 130.6 (78.4 – 217.6) |
| Gel-UV (35) | 215.4 (115.1 – 403.2) | |
| Sputum smear status | Pos/Both/NR (78) | 161.5 (107.5 – 242.6) |
| Negative (6) | 128.6 (33.4 – 495.1) |
| Region | Value added of export spillover (100 million yuan)a | Proportion of export spilloverb (%) | ||||
| 1997 | 2002 | 2007 | 1997 | 2002 | 2007 | |
| Eastern provinces | ||||||
| Beijing | 127 | 237 | 1211 | 27 | 34 | 38 |
| Tianjin | 136 | 306 | 858 | 39 | 40 | 48 |
| Hebei | 77 | 115 | 562 | 33 | 34 | 45 |
| Shanghai | 334 | 518 | 2234 | 31 | 24 | 34 |
| Jiangsu | 340 | 495 | 2563 | 31 | 19 | 26 |
| Zhejiang | 173 | 784 | 3148 | 20 | 36 | 39 |
| Fujian | 174 | 185 | 868 | 22 | 16 | 26 |
| Shandong | 172 | 269 | 1019 | 18 | 18 | 17 |
| Guangdong | 1457 | 1430 | 6078 | 33 | 24 | 34 |
| Hainan | 21 | 11 | 18 | 28 | 28 | 13 |
| Central provinces | ||||||
| Shanxi | 45 | 25 | 76 | 27 | 13 | 15 |
| Anhui | 53 | 69 | 240 | 34 | 38 | 41 |
| Jiangxi | 21 | 21 | 90 | 22 | 27 | 24 |
| Henan | 32 | 34 | 145 | 20 | 18 | 23 |
| Hubei | 36 | 27 | 103 | 19 | 18 | 19 |
| Hunan | 38 | 26 | 117 | 25 | 19 | 28 |
| Western provinces | ||||||
| Inner Mongolia | 18 | 14 | 49 | 28 | 20 | 20 |
| Guangxi | 42 | 46 | 102 | 25 | 33 | 26 |
| Chongqing | 18 | 35 | 96 | 32 | 42 | 35 |
| Sichuan | 27 | 35 | 79 | 16 | 17 | 17 |
| Guizhou | 15 | 10 | 47 | 34 | 22 | 36 |
| Yunnan | 30 | 17 | 35 | 24 | 20 | 23 |
| Shaanxi | 37 | 2 | 128 | 32 | 32 | 36 |
| Gansu | 10 | 38 | 101 | 33 | 33 | 25 |
| Qinghai | 5 | 12 | 10 | 39 | 41 | 17 |
| Ningxia | 6 | 4 | 37 | 34 | 37 | 32 |
| Xinjiang | 12 | 19 | 46 | 28 | 22 | 17 |
| Northeastern provinces | ||||||
| Liaoning | 122 | 175 | 596 | 19 | 20 | 28 |
| Jilin | 36 | 55 | 98 | 27 | 38 | 39 |
| Heilongjiang | 69 | 33 | 76 | 23 | 18 | 21 |
| Nanoparticle (NP) | Size of NP (nm) | Ligand/receptor | Drug/agent | Method to trace NP/drug/agent | Ref. |
| Polymer | 70 | Protein/TfR | siRNA | PCR | [236] |
| Liposome | ns | Ab/TfR | p53 | p53 via PCR | [271] |
| No of patients | 61 |
| No of CTCs | 1262 |
| Age | |
| Median (range) | 62 (23–82) |
| N (%) | |
| Menopausal status | |
| Pre | 17 (27.9) |
| Post | 41 (67.2) |
| UN | 3 (4.9) |
| ER | |
| Positive | 38 (62.3) |
| Negative | 20 (32.8) |
| UN | 3 (4.9) |
| PR | |
| Positive | 30 (49.2) |
| Negative | 28 (45.9) |
| UN | 3 (4.9) |
| HER 2 | |
| Positive | 14 (22.9) |
| Negative | 44 (72.1) |
| UN | 3 (4.9) |
| Triple negative | 11 (18.0) |
| Histology grade | |
| 1 | 1 (1.6) |
| 2 | 16 (26.2) |
| 3 | 26 (42.6) |
| UN | 18 (29.5) |
| No of CTCs/patients | |
| Median (range) | 2- 162 |
| 2-4 | 21 (34.4) |
| ≥5 | 40 (65.6) |
| V. albo-atrum | V. longisporum | V. dahliae | V. tricorpus |
| 234 | Bob-7 | 2341 | 2933 |
| CBS-8 | Vd-1 | 330 | 2901 A |
| CBS-7 | 43-3 | G12-1 | CBS-12 |
| 2934 | Vd-11 | Vd-7 | 1901 |
| G12-2 |
| Factor | Category | Attendees | Non-attendees | OR (95 % CI) | OR (95 % CI) | OR (95 % CI) |
| N (%) | N (%) | Crude | Age-adjusted | Adjusteda | ||
| Cancer in family | No | 647 (48.7) | 57 (46.0) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| Yes | 681 (51.3) | 67 (54.0) | 1.12 (0.77–1.61) | 1.12 (0.77–1.62) | 1.10 (0.76–1.60) | |
| Missing | 0 | 0 | – | – | – | |
| Cancer in close relations | No | 656 (49.4) | 62 (50.0) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| Yes | 672 (50.6) | 62 (50.0) | 0.98 (0.68–1.41) | 1.04 (0.72–1.51) | 1.07 (0.74–1.56) | |
| Missing | 0 | 0 | – | – | – | |
| Breast cancer in family | No | 1144 (86.1) | 104 (83.9) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| Yes | 184 (13.9) | 20 (16.1) | 1.20 (0.72–1.98) | 1.17 (0.71–1.94) | 1.18 (0.72–1.97) | |
| Missing | 0 | 0 | – | – | – | |
| Breast cancer in close relations | No | 761 (57.3) | 74 (59.7) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| Yes | 567 (43.1) | 50 (40.3) | 0.91 (0.62–1.32) | 0.98 (0.67–1.43) | 1.04 (0.71–1.53) | |
| Missing | 0 | 0 | – | – | – | |
| Have had cancer | No | 994 (74.8) | 89 (71.8) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| Yes | 334 (25.2) | 35(28.2) | 1.17 (0.78–1.76) | 1.16 (0.77–1.75) | 1.16 (0.77–1.75) | |
| Missing | 0 | 0 | – | – | – | |
| Have had breast cancer | No | 1224 (92.2) | 120 (96.8) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| Yes | 104 (7.8) | 4 (3.2) | 0.39 (0.14–1.08) | 0.40 (0.14–1.10) | 0.41 (0.15–1.15) | |
| Missing | 0 | 0 | – | – | – |
| Percentage of cell positive for MHC class II | |||||||
| MSCs: horse (ELA haplotype; age) | P2 | P3 | P4 | P5 | P6 | P7 | P8 |
| 1 (A3; 20 years) | 58.36 | 54.67 | 63.07 | 53.54 | 46.22 | 51.72 | 38.44 |
| 2 (A2; 12 years) | 59.95 | 78.58 | 98.14 | 97.25 | 91.45 | 94.47 | 97.62 |
| 3 (A3; 3 years) | 70.31 | 1.53 | 1.35 | 1.75 | 0.86 | 0.85 | 0.68 |
| 3 (A3; 3 years) 2nd harvest | 76.09 | 65.22 | 59.74 | 64.83 | 50.49 | 48.56 | 45.14 |
| 4 (A2; 3 years) | 32.42 | 8.19 | 4.03 | 4.52 | 2.56 | 0.49 | 0.50 |
| 4 (A2; 3 years) 2nd harvest | 82.60 | 59.25 | 56.05 | 65.31 | 64.85 | 67.08 | 68.96 |
| 5 (A3; 6 years) | 0.18 | 0.57 | 0.29 | 0.77 | 0.44 | 0.08 | 1.38 |
| 5 (A3; 6 years) 2nd harvest | 10.05 | 1.05 | 0.90 | 1.59 | 0.47 | 0.51 | 0.45 |
| 6 (A2; 5 years) | 70.68 | 72.32 | 64.62 | 22.10 | 2.32 | 1.93 | 1.29 |
| 7 (A3; 19 years) | 74.67 | 66.49 | 93.13 | 94.54 | 93.68 | 93.33 | 95.43 |
| 8 (A9; 11 years) | 74.36 | 71.32 | 67.04 | 41.82 | 25.97 | 8.16 | 0.90 |
| 9 (A2; 6 years) | 58.75 | 41.79 | 4.92 | 0.78 | 0.76 | 0.48 | 0.46 |
| 10 (A2; 5 years) | 98.35 | 91.92 | 95.69 | 96.15 | 94.89 | 91.39 | 85.01 |
| Essential public health operation | Climate change and foodborne pathogens example |
| 1: Food and foodborne disease surveillance | Enhanced cross country surveillance through the establishment of the European Centre for Disease Prevention and Control. This is tasked with collecting, examining and disseminating surveillance data on over 50 infectious diseases from EU and European Economic Area |
| 2: Monitoring and response to food and health hazards and emergencies | Bodies such as INFOSAN, through which the WHO, enable countries to rapidly share information during food safety emergencies to limit the spread of food hazards |
| 3: Health protection including food safety and others | Regulations including EU General Food Law which specifies the general principles that food producers and retailers should adhere to in order to provide safe food. It also ensures the traceability of food and outlines measures detailing how unsafe food should be withdrawn or recalled |
| 4: Health promotion including action to address social determinants and health inequity | Health promotion campaigns to inform, educate and empower people about health issues that may be associated with climate change |
| 5: Food and foodborne disease prevention, including early detection of illness | Enhance use of rapid diagnostic techniques, such as real-time PCR for rapid and hence early detection of foodborne pathogens |
| 6: Assuring governance for health and wellbeing | Organisations such as the Med-Vet-Net Association for Zoonoses Research which promote cross national and multidisciplinary approaches bringing together veterinary, medical and food scientists |
| 7: Assuring a sufficient and competent public health workforce | Support by organisations such as the WHO and ECDC for materials and activities which increase awareness and build capacity within countries to understand and prevent the negative impacts of climate change on health |
| 8: Assuring sustainable organisational structures and financing | Long-term and sustainable funding for measures to prevent climate-sensitive foodborne diseases |
| 9: Advocacy communication and social mobilisation for health | The European Strategy for the control of non-communicable diseases which highlights the importance of patient empowerment and patient’s rights |
| 10: Advancing public health research to inform policy and practice | UK funding for a series of Health Protection Research Units (HPRUs); partnerships between academics and public health practitioners. The Environmental Change and Health HPRU is tasked with the joint development of knowledge, foresight and tools to mitigate against and adapt to environmental change |
| Parental Dietary Pattern | Children’s Dietary Pattern | ||||||||
| Sweet & Fat | Ref. Cereals | Animal Products | |||||||
| N | OR | 95%CI | N | OR | 95%CI | N | OR | 95%CI | |
| Maternal dietary pattern (N = 1607) | |||||||||
| Different & soft drink not available (reference) | 742 | 1.00 | 1017 | 1.00 | 767 | 1.00 | |||
| Different & soft drink is available | 138 | 1.97 | 1.20; 3.25 | 294 | 0.46 | 0.25; 0.84 | 256 | 0.95 | 0.65; 1.38 |
| Identical & soft drink not available | 521 | 2.04 | 1.49; 2.80 | 246 | 2.48 | 1.43; 4.27 | 496 | 2.16 | 1.59; 2.92 |
| Identical & soft drink is available | 206 | 2.78 | 1.80; 4.28 | 50 | 1.67 | 0.66; 4.22 | 88 | 1.42 | 0.82; 2.47 |
| Paternal dietary pattern (N = 763) | |||||||||
| Different & soft drink not available (reference) | 465 | 1.00 | 407 | 1.00 | 360 | 1.00 | |||
| Different & soft drink is available | 92 | 1.55 | 0.90; 2.68 | 122 | 0.43 | 0.18; 1.04 | 80 | 0.83 | 0.45; 1.52 |
| Identical & soft drink not available | 151 | 2.48 | 1.58; 3.87 | 209 | 2.05 | 1.22; 3.45 | 256 | 2.48 | 1.62; 3.79 |
| Identical & soft drink is available | 55 | 4.26 | 2.16; 8.41 | 25 | 1.97 | 0.61; 6.39 | 67 | 1.80 | 0.96; 3.36 |
| Variables | Quintiles of household income per capita (mean values) | Brazil | ||||
| 1st | 2nd | 3rd | 4th | 5th | ||
| Area (%) | ||||||
| Rural | 31.1 | 18.5 | 14.6 | 9.0 | 4.7 | 15.6 |
| Urban | 68.9 | 81.5 | 85.4 | 91.0 | 95.3 | 84.4 |
| Region (%) | ||||||
| North and Northeast | 61.4 | 40.2 | 28.3 | 19.0 | 15.8 | 33.0 |
| Mid-South | 38.6 | 59.8 | 71.7 | 81.0 | 84.2 | 67.1 |
| Number of dwellers in households | 4.5 | 3.7 | 3.0 | 2.8 | 2.5 | 3.3 |
| Proportion of children under 2 years of age in family unit (%) | 6.4 | 4.0 | 2.5 | 1.9 | 1.4 | 3.2 |
| Proportion of children 2–9 years of age in family unit (%) | 17.2 | 11.2 | 6.9 | 5.6 | 3.7 | 8.9 |
| Proportion of adolescents (10–19 years) in family unit (%) | 23.0 | 18.1 | 12.3 | 9.7 | 7.5 | 14.1 |
| Proportion of elderly (65 years or older) in family unit (%) | 2.6 | 7.1 | 16.8 | 15.9 | 15.7 | 11.6 |
| Proportion of women in family unit (%) | 50.7 | 51.3 | 51.6 | 52.7 | 52.6 | 51.8 |
| Monthly household income per capita (US$) | 97.22 | 213.22 | 353.00 | 591.38 | 1968.82 | 644.70 |
| Proportion of monthly household income per capita dedicated to monthly medicine expenses per capita (out-of-pocket expenditure) (%) | 5.1 | 3.6 | 3.3 | 2.9 | 2.0 | 3.4 |
| Threshold | False positives | True positives |
| 0 | 21.2% | 89.5% |
| 5 | 16.9% | 86.3% |
| 10 | 13.5% | 85.1% |
| 15 | 10.7% | 82.8% |
| 20 | 8.5% | 81.1% |
| Additional inclusion criteria | |
| Pain intensity of 20 mm or more by VAS in the previous 48 hours when walking on a flat surface;At least grade II to III on the Kellgren-Lawrence scale by an X-ray taken within 6 months; | And reluctant to continue on previous drug but willing to change drug treatment. |
| Exclusion criteria | |
| Patients presenting with any of the following will be excluded from the study. | |
| Grade I or Grade IV severity of the index knee based on the Kellgren and Lawrence radiographic criteria as applicable;Use of intra-articular injections or arthroscopy of the index knee within 3 months prior to screening;Evidence of crystalline-induced synovitis in the index knee;History, physical examination, or radiographic results suggestive of acute inflammatory arthritis, rheumatoid arthritis, psoriatic arthritis, septic arthritis, gout, pseudogout, fibromyalgia, systemic lupus erythematosus, or other types of inflammatory arthritis of the index knee;Pain in either knee of neurologic origin; | Signs of clinically important active inflammation in the index knee joint including redness, warmth, and/or a large, bulging effusion with the loss of normal contour at the screening and/or baseline visits;History of acute inflammatory arthritis or pseudogout of the study joint;Cancer/metastatic disease;Systemic or intra-articular corticosteroid use within 60 days of the Screening visit;Known sensitivity to any of the ingredients listed in the treatments under investigation;Significant medical and skin conditions which, in the opinion of the investigator, will interfere with study participation and patch adherence;Replacement of the knee joint. |
| Pathway name | No. genes* | ES | NES | FDRq value |
| PHONG_TNF_RESPONSE_VIA_P38_COMPLETE | 13 | 0.583 | 1.743 | 0.580 |
| DELYS_THYROID_CANCER_DN | 11 | 0.612 | 1.748 | 0.599 |
| CORRE_MULTIPLE_MYELOMA_DN | 3 | 0.897 | 1.733 | 0.603 |
| SHEPARD_BMYB_MORPHOLINO_UP | 10 | 0.609 | 1.712 | 0.617 |
| LI_INDUCED_T_TO_NATURAL_KILLER_UP | 17 | 0.537 | 1.724 | 0.617 |
| WILCOX_PRESPONSE_TO_ROGESTERONE_UP | 6 | 0.705 | 1.700 | 0.621 |
| WAMUNYOKOLI_OVARIAN_CANCER_LMP_DN | 13 | 0.562 | 1.674 | 0.632 |
| KEGG_RENIN_ANGIOTENSIN_SYSTEM | 3 | 0.932 | 1.761 | 0.632 |
| OSWALD_HEMATOPOIETIC_STEM_CELL_IN_COLLAGEN_GEL_DN | 11 | 0.605 | 1.751 | 0.633 |
| REACTOME_POST_TRANSLATIONAL_PROTEIN_MODIFICATION | 16 | 0.535 | 1.685 | 0.644 |
| N = 7 | Mean | SD | Range |
| Age [yrs] | 71.3 | 8.3 | 59-85 |
| Height [cm] | 171 | 5.6 | 163.0-177.0 |
| Weight [kg] | 70.85 | 10.1 | 58.0-90.0 |
| BMI [kg/m2] | 25.1 | 4.5 | 21.7-33.9 |
| MOCA [0-30] | 21.4 | 1.4 | 20-24 |
| Age of disease onset [yrs] | 61.0 | 2.6 | 47-70 |
| Duration of disease [yrs] | 10.3 | 5.7 | 4-19 |
| Hoehn and Yahr | 2.5 | 0.5 | 2-3 |
| Harar HDSS | Kersa HDSS | Oromia* | Ethiopia* | |
| TFR | 1.9 | 5.3 | 4.85 | 4.8 |
| GFR | 64 | 166.8 | 153.30 | 128.80 |
| CBR | 20.3 | 37.2 | 33.90 | 30.10 |
| AMSA NaCl | AMSA EPI All | P-value | AMSA EPI 0.02 mg/kg/dose | P-value | AMSA EPI 0.03 mg/kg/dose | P-value | |||||
| MCC 20 s | 12.1 | (9.6-14.0)b | 13.0 | (10.9-16.0)d | 0.4099 | 13.0 | (11.8-13.0)c | 0.3913 | 13.1 | (10.6-15.0)a | 0.5752 |
| MCC 60 s | 12.4 | (10.8-15.3)b | 14.4 | (11.4-16.8)d | 0.4990 | 13.7 | (10.8-17.6)c | 0.7751 | 14.6 | (13.0-15.8)a | 0.4288 |
| MCC 120 s | 13.8 | (12.1-16.3)b | 16.0 | (14.2-18.7)d | 0.1974 | 16.0 | (14.2-19.8)c | 0.1779 | 15.5 | (13.8-17.6)a | 0.3734 |
| MCC 180 s | 14.7 | (13.3-17.9)b | 17.0 | (12.8-19.0)d | 0.3749 | 17.0 | (12.8-19.3)c | 0.4877 | 17.0 | (15.3-18.3)a | 0.4288 |
| Inj #1 | 14.3 | (12.7-16.8)b | 15.9 | (13.9-16.7)d | 0.4725 | 15.4 | (9.7-16.7)c | 0.4142 | 16.1 | (13.3-16.7)a | 0.6682 |
| Peak #1 | 14.7 | (11.5-15.9)b | 14.6 | (13.0-16.2)d | 0.6121 | 14.6 | (13.8-15.9)c | 0.7133 | 14.7 | (12.7-16.2)a | 0.6444 |
| Inj #2 | 13.9 | (11.0-15.4)b | 14.0 | (11.6-14.5)d | 0.8824 | 14.3 | (13.0-14.9)c | 0.7751 | 13.8 | (11.6-14.3)a | 0.6209 |
| Peak #2 | 13.5 | (10.4-14.7)b | 12.5 | (11.0-14.6)d | 1.0000 | 13.1 | (11.9-17.5)c | 0.5956 | 12.2 | (10.4-13.9)a | 0.6682 |
| Inj #3 | 13.7 | (11.4-14.8)b | 11.5 | (9.7-13.8)d | 0.2285 | 11.5 | (10.2-20.9)c | 0.5676 | 11.2 | (9.5-11.7)a | 0.1616 |
| Peak #3 | 12.7 | (10.6-15.5)b | 12.5 | (11.1-14.5)d | 0.9831 | 13.1 | (10.2-20.9)c | 0.5954 | 12.2 | (11.3-14.3)a | 0.7169 |
| Inj # 4 | 13.9 | (11.3-15.3)b | 11.0 | (9.7-13.5)d | 0.1696 | 11.8 | (10.5-14.3)c | 0.6534 | 10.6 | (8.8-12.2)a | 0.0806 |
| Peak #4 | 14.0 | (11.4-15.3)e | 11.0 | (8.9-15.9)d | 0.8841 | 16.8 | (9.9-11.1)c | 0.3165 | 9.9 | (8.8-14.3)a | 0.2814 |
| Reference value | day 1 | day 2 | day 5 | day 8 | day 11 | day 15 | day 21 | day 28 |
| PLT:100–400 *109/L | 48 | 37 | 12 | 106 | 173 | 177 | 212 | 268 |
| HB:110–155 g/L | 79 | 75 | 85 | 86 | 87 | 91 | 105 | 119 |
| ESR:0–20 mm/h | 56 | 122 | 124 | 111 | 119 | 78 | 64 | |
| CRP: < 1 mg/L | > 160 | 44 | 14 | < 1 | < 1 | < 1 | ||
| GPT:5–50 U/L | 64 | 1645 | 642 | 183 | 90 | 109 | ||
| GOT:5–55 U/L | 35 | 866 | 142 | 48 | 93 | 79 | ||
| GGT:5–50 U/L | 15 | 182 | 107 | 57 | 38 | 29 |
| Model description | Category | Numberof deaths | Person-years | SPM (μg/m3) | PM2.5 (μg/m3)b | SO2 (ppb) | NO2 (ppb) | ||||
| HR | 95% CI | HR | 95% CI | HR | 95% CI | HR | 95% CI | ||||
| Sex- and age-adjusted | (All) | 518 | 550 339 | 1.18 | (1.13–1.24) | 1.27 | (1.19–1.36) | 1.36 | (1.20–1.54) | 1.20 | (1.17–1.24) |
| Base modelc | (All) | 518 | 550 339 | 1.16 | (1.08–1.25) | 1.24 | (1.12–1.37) | 1.26 | (1.07–1.48) | 1.17 | (1.10–1.26) |
| Full modeld | (All) | 421 | 472 762 | 1.16 | (1.06–1.25) | 1.23 | (1.09–1.38) | 1.19 | (0.97–1.45) | 1.15 | (1.06–1.24) |
| By sexe | Male | 407 | 257 120 | 1.17 | (1.09–1.26) | 1.26 | (1.14–1.39) | 1.30 | (1.12–1.52) | 1.18 | (1.11–1.26) |
| Female | 111 | 293 219 | 1.12 | (0.99–1.26) | 1.17 | (0.98–1.39) | 1.11 | (0.88–1.40) | 1.13 | (1.01–1.27) | |
| By sex and smoking statusf | Male current smokers | 292 | 146 031 | 1.23 | (1.14–1.34) | 1.35 | (1.20–1.52) | 1.36 | (1.06–1.75) | 1.23 | (1.12–1.35) |
| Male former smokers | 90 | 63 092 | 1.08 | (0.83–1.39) | 1.11 | (0.77–1.60) | 1.25 | (0.75–2.10) | 1.13 | (0.88–1.44) | |
| Female never smokers | 73 | 254 145 | 1.11 | (1.01–1.22) | 1.16 | (1.02–1.33) | 1.09 | (0.92–1.29) | 1.11 | (1.02–1.20) | |
| Base model, excluding participants with a history of respiratory diseasesc,g | (No history of respiratory disease) | 438 | 509 369 | 1.15 | (1.06–1.26) | 1.23 | (1.08–1.39) | 1.22 | (1.02–1.45) | 1.16 | (1.07–1.25) |
| Base model, using average concentrations during the follow-up periodc,h | (All) | 518 | 550 339 | 1.27 | (1.14–1.41) | 1.41 | (1.21–1.64) | 1.97 | (1.41–2.75) | 1.21 | (1.10–1.33) |
| IMRT | 3DRT | |||
| Mean maximum | Mean average | Mean maximum | Mean average | |
| Tongue cancer | ||||
| Lower teeth | ||||
| Anterior | 56.9 | 42.8 | 36.4 | 32.5 |
| Pre-molars | 51.5 | 43.6 | 56.9 | 49.5 |
| Molars | 50.8 | 42.3 | 64.7 | 59.1 |
| Upper teeth | ||||
| Anterior | 41.0 | 26.4 | 23.7 | 19.0 |
| Pre-molars | 42.7 | 36.1 | 20.9 | 16.8 |
| Molars | 47.5 | 36.7 | 43.7 | 37.7 |
| Oral cavity cancer | ||||
| Lower teeth | ||||
| Anterior | 47.0 | 34.6 | 48.9 | 43.7 |
| Pre-molars | 43.5 | 37.2 | 46.1 | 39.9 |
| Molars | 46.3 | 39.2 | 66.8 | 51.6 |
| Upper teeth | ||||
| Anterior | 38.4 | 24.0 | 37.2 | 34.3 |
| Pre-molars | 34.7 | 26.1 | 47.7 | 42.6 |
| Molars | 44.7 | 35.5 | 56.7 | 52.2 |
| Oropharynx cancer | ||||
| Lower teeth | ||||
| Anterior | 32.3 | 25.0 | 24.9 | 18.3 |
| Pre-molars | 36.5 | 31.3 | 40.6 | 34.5 |
| Molars | 50.5 | 41.0 | 57.0 | 52.1 |
| Upper teeth | ||||
| Anterior | 28.0 | 19.6 | 20.6 | 13.2 |
| Pre-molars | 34.1 | 28.4 | 47.5 | 39.9 |
| Molars | 46.8 | 36.6 | 55.7 | 49.2 |
| Nasopharynx cancer | ||||
| Lower teeth | ||||
| Anterior | 30.2 | 22.3 | 32.2 | 21.5 |
| Pre-molars | 37.1 | 28.0 | 44.9 | 37.5 |
| Molars | 54.6 | 39.9 | 65.6 | 57.2 |
| Upper teeth | ||||
| Anterior | 31.7 | 23.6 | 28.6 | 18.2 |
| Pre-molars | 35.1 | 28.7 | 40.7 | 30.3 |
| Molars | 52.5 | 38.8 | 60.8 | 50.3 |
| Number of subjects | Mean | Standard deviation | Median | Minimum | Maximum | |
| Age (years) | 98 | 36.00 | 8.44 | 37.00 | 18.00 | 50.00 |
| Height (cm) | 98 | 158.67 | 5.19 | 158.35 | 146.00 | 169.60 |
| Weight (kg) | 98 | 81.84 | 19.32 | 80.45 | 47.00 | 127.40 |
| Body mass index (kg/m2) | 98 | 32.6 | 7.69 | 31.12 | 17.84 | 49.30 |
| Waist circumference (cm) | 91 | 96.68 | 14.67 | 94.00 | 64.00 | 135.00 |
| VO2 max (Bruce test) | 74 | 23.67 | 6.12 | 24.46 | 9.24 | 41.07 |
| Body fat (%) | 96 | 46.16 | 6.56 | 46.80 | 29.00 | 56.90 |
| Scoring used in the study | |
| The patient has resumed work-related and other activities with slight or no symptoms. | 3: Excellent |
| The patient has resumed work-related and other activities but occasionally feels pain in the back or lower limbs after strenuous work. | 2: Good |
| The patient has reduced work-related and other activities because of residual pain in the back or lower limbs. | 1: Fair |
| The patient cannot work or carry out activities of daily living and is considered to be disabled. | 0: Poor |
| Exocyclic M1dG and 8-oxodG Adducts | |||||
| N | M1dG ± SE | p-Value | 8-oxodG ± SE | p-Value | |
| Adduct background in presence or absence of AMF exposures | |||||
| Control cells | |||||
| Nonexposed to AMF | |||||
| Incubation times | |||||
| 24 h a | 10 | 0.4 ± 0.1 | 3.2 ± 0.2 | ||
| 48 a | 10 | 0.4 ± 0.1 | 3.1 ± 0.2 | ||
| Exposed to AMF (20 min) | |||||
| Incubation times | |||||
| 24 h a | 10 | 0.5 ± 0.1 | 3.2 ± 0.2 | ||
| 48 a | 10 | 0.5 ± 0.1 | 3.3 ± 0.3 | ||
| Exposed to AMF (40 min) | |||||
| Incubation times | |||||
| 24 h a | 10 | 0.5 ± 0.1 | 3.4 ± 0.2 | ||
| 48 a | 10 | 0.5 ± 0.1 | 3.9 ± 0.3 | ||
| Adduct levels of treated cells in presence or absence of AMF exposures | |||||
| NP treated cells | |||||
| Nonexposed to AMF | |||||
| Incubation times | |||||
| 24 h a | 10 | 0.7 ± 0.1 | <0.05 b | 16.7 ± 1.7 | <0.05 b |
| 48 a | 10 | 0.8 ± 0.1 | <0.05 b | 21.2 ± 1.9 | <0.05 b |
| Exposed to AMF (20 min) | |||||
| Incubation times | |||||
| 24 h a | 10 | 4.6 ± 0.5 | <0.05 b | 40.3 ± 3.3 | <0.05 b |
| 48 a | 10 | 6.9 ± 0.6 | <0.05 b | 69.3 ± 1.4 | <0.05 b |
| Exposed to AMF (40 min) | |||||
| Incubation times | |||||
| 24 h a | 10 | 6.4 ± 1.4 | <0.05 b | 36.5 ± 4.0 | <0.05 b |
| 48 a | 10 | 15.9 ± 6.7 | <0.05 b | 79.3 ± 1.1 | <0.05 b |
| StandardOrder | Isoeugenol | Tween 80 | NaCl | Dry Biomass | Vanillin yield (g/L) | |
| Observed | Predicted | |||||
| 1 | -1 | -1 | 0 | 0 | 1.53 | 1.48 |
| 2 | +1 | -1 | 0 | 0 | 1.79 | 1.78 |
| 3 | -1 | +1 | 0 | 0 | 1.07 | 1.11 |
| 4 | +1 | +1 | 0 | 0 | 1.87 | 1.96 |
| 5 | 0 | 0 | -1 | -1 | 1.79 | 1.73 |
| 6 | 0 | 0 | +1 | -1 | 1.34 | 1.37 |
| 7 | 0 | 0 | -1 | +1 | 1.29 | 1.25 |
| 8 | 0 | 0 | +1 | +1 | 2.11 | 2.16 |
| 9 | -1 | 0 | 0 | -1 | 1.56 | 1.63 |
| 10 | +1 | 0 | 0 | -1 | 1.89 | 1.89 |
| 11 | -1 | 0 | 0 | +1 | 1.46 | 1.47 |
| 12 | +1 | 0 | 0 | +1 | 2.43 | 2.37 |
| 13 | 0 | -1 | -1 | 0 | 1.32 | 1.40 |
| 14 | 0 | +1 | -1 | 0 | 1.12 | 1.07 |
| 15 | 0 | -1 | +1 | 0 | 1.43 | 1.44 |
| 16 | 0 | +1 | +1 | 0 | 1.69 | 1.58 |
| 17 | -1 | 0 | -1 | 0 | 1.73 | 1.75 |
| 18 | +1 | 0 | -1 | 0 | 1.78 | 1.83 |
| 19 | -1 | 0 | +1 | 0 | 1.53 | 1.53 |
| 20 | +1 | 0 | +1 | 0 | 2.58 | 2.61 |
| 21 | 0 | -1 | 0 | -1 | 1.40 | 1.37 |
| 22 | 0 | +1 | 0 | -1 | 1.04 | 1.04 |
| 23 | 0 | -1 | 0 | +1 | 1.28 | 1.29 |
| 24 | 0 | +1 | 0 | +1 | 1.39 | 1.43 |
| 25 | 0 | 0 | 0 | 0 | 2.15 | 2.14 |
| 26 | 0 | 0 | 0 | 0 | 2.19 | 2.14 |
| 27 | 0 | 0 | 0 | 0 | 2.18 | 2.14 |
| Time (days) | Treatment | Calcium (mg/dl) |
| 21 | Control | 9.468 ± 0.275 |
| Osteoinduced | 13.496 ± 0.892** |
| Pre-injury | 5-months post-injury | 12-months post-injury | NZ general population survey | |
| Total | 2842 | 1470 | 2262 | 1250 |
| Age: | ||||
| 18-24 | 14.4% | 13.1% | 12.1% | 7.0% |
| 25-34 | 20.8% | 19.5% | 19.5% | 13.3% |
| 35-44 | 22.5% | 23.5% | 22.5% | 20.4% |
| 45-54 | 24.5% | 26.5% | 26.3% | 20.2% |
| 55-64 | 17.8% | 17.4% | 19.6% | 16.4% |
| 65+ | – | – | – | 21.0% |
| Not reported | – | – | – | 1.8% |
| Sex: | ||||
| Male | 61.4% | 60.8% | 58.9% | 42.7% |
| Female | 38.6% | 39.2% | 41.1% | 56.0% |
| Not reported | – | – | – | 1.3% |
| Recovery Status: | n = 1248 | n = 1937 | ||
| Recovered | 23.0% | 36.4% | ||
| Not recovered | 77.0% | 63.6% | ||
| Injury Type: | ||||
| Intracranial | 3.7% | 3.7% | 3.8% | |
| Head/neck superficial | 3.6% | 3.2% | 3.6% | |
| Spine dislocation, sprain, or strain | 16.1% | 15.3% | 15.9% | |
| Upper extremity fracture | 17.7% | 20.5% | 17.6% | |
| Upper extremity dislocation, sprain, or strain | 14.3% | 15.1% | 13.7% | |
| Upper extremity open wound | 6.0% | 6.1% | 5.8% | |
| Upper extremity superficial | 5.0% | 4.8% | 4.9% | |
| Lower extremity fracture | 17.2% | 18.0% | 18.1% | |
| Lower extremity dislocation, sprain, or strain | 24.6% | 21.9% | 25.2% | |
| Lower extremity open wound | 4.0% | 3.9% | 3.9% | |
| Lower extremity superficial | 6.6% | 6.3% | 6.5% | |
| Other injury region/nature | 17.1% | 19.3% | 17.4% | |
| UnadjustedEQ-5D social tariff | 0.94 | 0.75 | 0.78 | 0.82 |
| Classifier | Accuracy (%) | Sensitivity (%) | Specificity (%) | Strength (%) | ROCAUC |
| BindN-RF | 80.00 | 73.08 | 80.63 | 76.86 | 0.8495 |
| BindN | 70.81 | 68.70 | 71.01 | 69.85 | 0.7648 |
| DP-Bind | 78.89 | 65.89 | 80.76 | 73.32 | 0.8149 |
| DBS-PSSM | 67.91 | 37.48 | 70.72 | 54.10 | 0.5528 |
| The Tested Compounds | Side Effects of Rats Treated with Artesunate and Artemisinin, Respectively | ||
| The Loss of Body Weight | Vomiting | Diarrhea | |
| Artesunate | − | − | − |
| Artemisinin | − | − | − |
| Characteristics | Frequencies (n=271) | Percentage (%) |
| Household Members Ever Suffer Jigger Infestation: | ||
| Yes | 239 | 88.2 |
| Households reported with jiggers infested persons: | ||
| Yes | 64 | 23.6 |
| Number of household members infested | ||
| 1 Member | 40 | 14.8 |
| 2 Members | 19 | 7.0 |
| 3 Members | 4 | 1.5 |
| 5 Members | 1 | 0.3 |
| Number of households with jiggers infested persons seen during the study: | ||
| Yes | 51 | 18.8 |
| Number of infested household members | ||
| 1Person | 32 | 11.8 |
| 2 Persons | 15 | 5.5 |
| 3 Persons | 4 | 1.5 |
| Severity of retinopathy | Retinal findings in severe malaria (indirect ophthalmoscopy; n = 139) | ||||||
| Any retinopathy | Hemorrhages | Papilloedema* | Whitening | ||||
| White-centered | Any | Macular | Peripheral | Any | |||
| Fatal (n = 21) | |||||||
| Mild | 6 (29%) | 15 (71%) | 8 (38%) | 0 (0%) | 0 (0%) | 0 (0%) | |
| Moderate to severe | 12 (57%) | 0 (0%) | 8 (38%) | 9 (43%) | 2 (10%) | 1 (5%) | 2 (10%) |
| Total | 18 (86%) | 15 (71%) | 16 (76%) | 9 (43%) | 2 (10%) | 1 (5%) | 2 (10%) |
| Non-fatal (n = 118) | |||||||
| Mild | 23 (19%) | 29 (25%) | 25 (21%) | 0 (0%) | 1 (1%) | 0 (0%) | |
| Moderate to severe | 6 (5%) | 0 (0%) | 4 (3%) | 0 (0%) | 2 (2%) | 0 (0%) | 2 (2%) |
| Total | 29 (25%) | 29 (25%) | 29 (25%) | 0 (0%) | 2 (2%) | 1 (1%) | 2 (2%) |
| Outcome | Unadjusted Estimate (95% CI) | Unadjusted p Value | Adjusted Estimate (95% CI) | Adjusted p Value |
| BPD | 0.507 † | 0.546 † | ||
| - 28 Weeks | 0.01 (−0.10, 0.11) | 0.921 | −0.01 (−0.11, 0.10) | 0.914 |
| - 36 Weeks | −0.03 (−0.12, 0.11) | 0.466 | −0.04 (−0.13, 0.05) | 0.361 |
| BPD z-score | 0.153 † | 0.210 † | ||
| - 28 Weeks | 0.13 (−0.18, 0.44) | 0.414 | 0.10 (−0.21, 0.42) | 0.522 |
| - 36 Weeks | −0.10 (−0.35, 0.44) | 0.400 | −0.11 (−0.35, 0.14) | 0.399 |
| HC | 0.991 † | 0.802 † | ||
| - 28 Weeks | −0.05 (−0.38, 0.27) | 0.755 | −0.12 (−0.45, 0.22) | 0.489 |
| - 36 Weeks | −0.05 (−0.33, 0.27) | 0.723 | −0.07 (−0.34, 0.20) | 0.618 |
| HC z-score | 0.983 † | 0.806 † | ||
| - 28 Weeks | −0.05 (−0.26, 0.16) | 0.621 | −0.08 (−0.30, 0.13) | 0.440 |
| - 36 Weeks | −0.05 (−0.23, 0.16) | 0.588 | −0.05 (−0.24, 0.13) | 0.567 |
| FL | 0.212 † | 0.269 † | ||
| - 28 Weeks | −0.06 (−0.14, 0.02) | 0.143 | −0.06 (−0.14, 0.01) | 0.110 |
| - 36 Weeks | 0.00 (−0.07, 0.02) | 0.994 | −0.01 (−0.08, 0.05) | 0.692 |
| FL z-score | 0.499 † | 0.633 † | ||
| - 28 Weeks | −0.14 (−0.37, 0.09) | 0.224 | −0.14 (−0.36, 0.09) | 0.235 |
| - 36 Weeks | −0.04 (−0.26, 0.09) | 0.719 | −0.07 (−0.29, 0.15) | 0.547 |
| AC | 0.264 † | 0.187 † | ||
| - 28 Weeks | −0.16 (−0.60, 0.29) | 0.490 | −0.29 (−0.74, 0.16) | 0.208 |
| - 36 Weeks | 0.13 (−0.28, 0.29) | 0.531 | 0.06 (−0.35, 0.47) | 0.785 |
| AC z-score | 0.501 † | 0.281 † | ||
| - 28 Weeks | −0.06 (−0.27, 0.15) | 0.584 | −0.13 (−0.34, 0.08) | 0.211 |
| - 36 Weeks | 0.02 (−0.18, 0.15) | 0.839 | −0.00 (−0.21, 0.21) | 0.992 |
| EFW | 0.175 † | 0.173 † | ||
| - 28 Weeks | −40.93 (−105.51, 23.64) | 0.214 | −56.34 (−123.01, 10.33) | 0.098 |
| - 36 Weeks | 22.54 (−62.18, 23.64) | 0.602 | 7.75 (−76.06, 91.57) | 0.856 |
| EFW z-score | 0.478 † | 0.351 † | ||
| - 28 Weeks | −0.09 (−0.28, 0.10) | 0.350 | −0.14 (−0.33, 0.05) | 0.155 |
| - 36 Weeks | −0.01 (−0.20, 0.10) | 0.915 | −0.03 (−0.22, 0.16) | 0.753 |
| MTLM | 0.433 † | 0.395 † | ||
| - 28 Weeks | 0.09 (−0.26, 0.44) | 0.617 | 0.05 (−0.31, 0.41) | 0.800 |
| - 36 Weeks | 0.33 (−0.18, 0.44) | 0.201 | 0.31 (−0.19, 0.81) | 0.227 |
| MTFM | 0.833 † | 0.823 † | ||
| - 28 Weeks | 0.08 (−0.35, 0.51) | 0.711 | 0.07 (−0.37, 0.51) | 0.765 |
| - 36 Weeks | −0.02 (−0.91, 0.51) | 0.968 | −0.04 (−0.93, 0.85) | 0.932 |
| AFM | 0.467 † | 0.661 † | ||
| - 28 Weeks | −0.10 (−0.41, 0.22) | 0.548 | −0.17 (−0.49, 0.14) | 0.288 |
| - 36 Weeks | −0.26 (−0.68, 0.22) | 0.216 | −0.27 (−0.68, 0.14) | 0.194 |
| SSFM | 0.872 † | 0.736 † | ||
| - 28 Weeks | −0.18 (−0.44, 0.09) | 0.189 | −0.21 (−0.48, 0.05) | 0.119 |
| - 36 Weeks | −0.14 (−0.57, 0.09) | 0.524 | −0.13 (−0.55, 0.29) | 0.550 |
| Cooking fuel | Numbers of patients | Cases vs non-eye-disease controls | Case vs non-cataract eye-disease patients | Case vs combined controls | |||||
| CS | NE | NC | a-OR (95% CI) | p- value* | a-OR (95% CI) | p- value* | a-OR (95% CI) | p- value* | |
| Family h/o cataract | |||||||||
| No | 53 | 66 | 67 | 1 (ref) | 0.03 | 1 (ref) | 0.02 | 1 (ref) | 0.007 |
| Yes | 27 | 14 | 13 | 2.14 (1.03, 4.43) | 2.66 (1.15, 6.15) | 2.31 (1.25, 4.26) | |||
| Formal education | |||||||||
| At least secondary | 6 | 17 | 13 | 1 (ref) | 0.02 | 1 (ref) | 0.35 | 1 (ref) | 0.02 |
| Primary | 39 | 28 | 23 | 4.21 (1.40, 12.6) | 2.19 (0.62, 5.65) | 3.66 (1.35, 9.95) | |||
| None | 35 | 35 | 34 | 3.07 (1.05, 8.93) | 1.87 (0.62, 5.65) | 3.00 (1.12, 8.04) | |||
| Rice straw | |||||||||
| Never used | 54 | 64 | 59 | 1 (ref) | 0.02 | 1 (ref) | 0.29 | 1 (ref) | 0.04 |
| Used | 26 | 16 | 21 | 2.86 (1.10, 7.45) | 1.47 (0.71, 3.01) | 1.95 (1.03, 3.69) | |||
| Cow dung | |||||||||
| Never used | 55 | 47 | 43 | 1 (ref) | 0.04 | 1 (ref) | 0.03 | 1 (ref) | 0.009 |
| Used | 25 | 33 | 37 | 0.46 (0.21, 1.00) | 0.45 (0.21, 0.93) | 0.45 (0.24, 0.84) | |||
| Family h/o cataract | |||||||||
| No | 44 | 59 | 56 | 1 (ref) | 0.009 | 1 (ref) | 0.08 | 1 (ref) | 0.01 |
| Yes | 26 | 12 | 16 | 3.59 (1.27, 10.2) | 2.41 (0.86, 6.74) | 2.68 (1.22, 5.87) | |||
| Smoking status | |||||||||
| Never smoked | 18 | 28 | 37 | 1(ref) | 0.12 | 1(ref) | 0.003 | 1(ref) | 0.009 |
| Current or past | 52 | 43 | 35 | 2.05 (0.82, 5.11) | 3.40 (1.42, 8.14) | 2.43 (1.21, 4.88) | |||
| Formal education | |||||||||
| At least secondary | 12 | 27 | 20 | 1 (ref) | 0.007 | 1 (ref) | 0.39 | 1 (ref) | 0.05 |
| Primary | 34 | 25 | 31 | 5.65 (1.67, 19.1) | 1.97 (0.62, 6.30) | 3.08 (1.18, 8.00) | |||
| None | 24 | 19 | 21 | 4.90 (1.23, 19.5) | 2.27 (0.67, 7.66) | 2.73 (1.00, 7.42) | |||
| Wood or dry leaves | |||||||||
| Never used | 47 | 58 | 51 | 1 (ref) | 0.01 | 1 (ref) | 0.42 | 1 (ref) | 0.10 |
| Used | 23 | 13 | 21 | 3.51 (1.24, 9.95) | 1.46 (0.57, 3.74) | 1.84 (0.89, 3.83) |
| Monkey Species and ID | Protein(ng/ml) | Levels of p27 (ng/ml) | TCID50I.U./ml | Viral copy #x 107 per ml |
| SM-FYy | 784.8 | 119.41 | 2.2355 | 3.13 |
| SM-FMy | 474.6 | 63.03 | 1.1771 | 2.76 |
| SM-FJt | 384.8 | 48.7 | 4.1347 | 3.83 |
| RM-RDd3 | 1786.9 | 351.18 | 4.9960 | 2.75 |
| RM-RVe7 | 1059.4 | 151.30 | 2.5674 | 2.79 |
| RM-RLg10 | 557.6 | 69.30 | 1.2364 | 2.55 |
| Cut-off | Maxillary | Anterior ethmoid | Posterior ethmoid | Frontal | Sphenoid |
| >3 mm* | 26 | 4 | 4 | 2 | 3.5 |
| >4 mm* | 25 | 3 | 2.8 | 1.4 | 3.2 |
| Molecular function | Biological process | Cellular function | |||
| GO term | GO score | GO term | GO score | GO term | GO score |
| GO:0043169 | 0.96 | GO:0006689 | 0.80 | GO:0016020 | 0.80 |
| GO:0046982 | 0.80 | GO:0030203 | 0.80 | GO:0005764 | 0.80 |
| GO:0005529 | 0.56 | GO:0042552 | 0.80 | GO:0005625 | 0.56 |
| GO:0016231 | 0.56 | GO:0050885 | 0.80 | GO:0001669 | 0.56 |
| GO:0042803 | 0.56 | GO:0019915 | 0.80 | ||
| GO:0007605 | 0.80 | ||||
| GO:0007040 | 0.80 | ||||
| GO:0001501 | 0.80 | ||||
| GO:0008219 | 0.80 | ||||
| GO:0031323 | 0.56 |
| RMAP | Posterior PMR | Anterior PMR | P-value | |
| (n = 23) | (n = 10) | (n = 6) | ||
| Age, years | 70 ± 6 | 65 ± 7 | 68 ± 8 | 0.16 |
| Male | 17 (73.9) | 9 (90.0) | 3 (50.0) | 0.21 |
| NYHA functional class | ||||
| 1 | 2 (8.7) | 0 | 0 | 0.48 |
| 2 | 12 (52.2) | 3 (30.0) | 1 (16.7) | 0.21 |
| 3 | 8 (34.8) | 4 (40.0) | 3 (50.0) | 0.79 |
| 4 | 1 (4.3) | 3 (30.0) | 2 (33.3) | 0.071 |
| Preoperative inotropic support | 2 (8.7) | 3 (30.0) | 2 (33.3) | 0.19 |
| Etiology | ||||
| Ischemic | 23 (100) | 8 (80.0) | 1 (16.7) | <0.001 |
| Non-ischemic | 0 | 2 (20.0) | 5 (83.3) | <0.001 |
| Echocardiographic data | ||||
| MR grade | 2.6 ± 0.6 | 3.8 ± 0.4a | 3.7 ± 0.5a | <0.01 |
| LVEDD (mm) | 66.3 ± 6.4 | 70.4 ± 7.4 | 66.2 ± 3.6 | 0.24 |
| LVESD (mm) | 48.7 ± 12.0 | 61.2 ± 9.7a | 57.3 ± 4.2 | <0.01 |
| LVEF (%) | 40.4 ± 11.7 | 31.9 ± 5.4a | 29.7 ± 7.4a | 0.026 |
| Center | |||
| Parameter | R2* | P* | Correlation |
| p120-catenin membrane vs. β-catenin membrane | 0.15 | <0.01 | positive |
| vs. β-catenin cytoplasm | 0.07 | 0.03 | inverse |
| p120-catenin cytoplasm vs. β-catenin membrane | 0.13 | <0.01 | inverse |
| vs. β-catenin cytoplasm | 0.15 | <0.01 | positive |
| Invasive front | |||
| Parameter | R2* | P* | Correlation |
| p120-catenin membrane vs. β-catenin membrane | 0.33 | <0.01 | positive |
| vs. E-cadherin membrane | 0.60 | <0.01 | positive |
| β-catenin membrane vs. E-cadherin membrane | 0.29 | <0.01 | positive |
| Age and sex-adjusted | ||||
| Beta | 95% CI | p | R2 | |
| Vascular risk factors (VRFs) | ||||
| Hypertension | −0.049 | (−0.617, 0.519) | 0.87 | 0.04 |
| Hypercholesterolemia | 0.262 | (−0.153, 0.676) | 0.22 | 0.05 |
| Diabetes mellitus | 0.128 | (−0.592, 0.848) | 0.73 | 0.04 |
| Overweight (BMI ≥25) | − 0.391 | (− 0.840, 0.059) | 0.09 | 0.04 |
| Smoking (current) | 0.050 | (−0.677, 0.778) | 0.89 | 0.04 |
| ≥ 2 VRFs | 0.121 | (−0.370, 0.612) | 0.63 | 0.03 |
| ≥ 3 VRFs | −0.371 | (−0.889, 0.147) | 0.16 | 0.04 |
| Framingham Stroke Risk Profile, women* | −0.297 | (−2.769, 2.175) | 0.81 | 0.00 |
| Framingham Stroke Risk Profile, men* | 0.930 | (−1.638, 3498) | 0.47 | 0.01 |
| ApoE ε4 carrier | 0.384 | (−0.069, 0.836) | 0.10 | 0.06 |
| Vascular diseases | ||||
| Heart disease | 0.196 | (−0.380, 0.771) | 0.50 | 0.04 |
| Atrial fibrillation | −0.159 | (0.902, 0.583) | 0.67 | 0.04 |
| Peripheral vascular disease | 0.512 | (−0.834, 1.858) | 0.46 | 0.04 |
| Cerebrovascular event (stroke and/or TIA) | −0.315 | (−0.896, 0.265) | 0.29 | 0.04 |
| MRI findings | ||||
| Cortical infarcts (1 = cortical infarcts, 0 = no cortical infarcts) | 0.707 | (−0.518, 1.932) | 0.26 | 0.04 |
| Lacunes (1 = ≥1 lacune on MRI, 0 = no lacunes) | −0.177 | (−0.867, 0.514) | 0.61 | 0.04 |
| Infarcts (cortical and/or lacunes) | 0.038 | (−0.611, 0.687) | 0.91 | 0.03 |
| White matter hyperintensities Fazekas 3 | −0.291 | (−0.872, 0.290) | 0.32 | 0.04 |
| White matter hyperintensities Fazekas 2 or 3 | −0.207 | (−0.776, 0.362) | 0.47 | 0.04 |
| Infarcts and/or WMH Fazekas 3 | −0.079 | (−0.625, 0.468) | 0.78 | 0.03 |
| Infarcts and/or WMH Fazekas 2 or 3 | −0.298 | (−0.872, 0.277) | 0.31 | 0.04 |
| MTA (mean of right and left side) | 0.036 | (−0.262, 0.334) | 0.81 | 0.04 |
| Placebo | Coffee | |||||
| base | 30 min | 60 min | base | 30 min | 60 min | |
| HR (bpm) | 68.1 ± 13.3 | 64.4 ± 13.4 | 66.3 ± 15.3 | 73.6 ± 10.1 | 68.7 ± 12.4 | 69.4 ± 14.4 |
| SBP (mmHg) | 114.3 ± 5.2 | 117.9 ± 7.3 | 119.6 ± 7.5a | 117.2 ± 6.7 | 130.6 ± 8.5a,b | 134.7 ± 8.9a,b |
| DBP (mmHg) | 69.1 ± 6.0 | 72.0 ± 7.0 | 76.7 ± 9.5a | 66.8 ± 4.9 | 78.3 ± 6.7a,b | 80.4 ± 6.1a |
| MAP (mmHg) | 84.2 ± 5.1 | 87.2 ± 6.1 | 91.0 ± 7.9a | 83.6 ± 4.8 | 96.7 ± 6.8a,b | 98.5 ± 5.8a,b |
| Pulse pressure (mmHg) | 45.2 ± 3.9 | 45.8 ± 6.1 | 42.9 ± 6.5 | 50.4 ± 4.8 | 52.3 ± 3.4 | 54.3 ± 7.9 |
| Systolic MCAv (cm/s) | 88.8 ± 10.9 | 86.7 ± 14.4 | 83.6 ± 12.9 | 88.9 ± 13.2 | 78.6 ± 14.0 | 77.2 ± 11.7 |
| Diastolic MCAv (cm/s) | 36.4 ± 5.2 | 36.8 ± 6.1 | 36.2 ± 6.1 | 37.0 ± 4.5 | 32.7 ± 5.2a | 32.1 ± 3.7a |
| Mean MCAv (cm/s) | 53.8 ± 6.2 | 53.5 ± 7.5 | 52.1 ± 7.4 | 54.3 ± 6.6 | 48.0 ± 7.6a | 47.1 ± 5.8a |
| Pulse MCAv (cm/s) | 52.4 ± 7.9 | 49.9 ± 11.7 | 47.3 ± 8.9 | 51.9 ± 10.3 | 45.9 ± 9.4 | 45.1 ± 8.7 |
| MCA PI | 0.99 ± 0.10 | 0.95 ± 0.15 | 0.94 ± 0.11 | 0.96 ± 0.10 | 0.98 ± 0.07 | 0.99 ± 0.07 |
| MCA CVCi (cm/s/mmHg) | 0.65 ± 0.07 | 0.61 ± 0.10 | 0.57 ± 0.10a | 0.66 ± 0.09 | 0.50 ± 0.06a,b | 0.48 ± 0.06a,b |
| baPWV (cm/s) | 1056 ± 87 | 1067 ± 121 | 1064 ± 134 | 1030 ± 82 | 1117 ± 143a | 1131 ± 126a,b |
| petCoz (mmHg) | 38.6 ± 2.2 | 38.7 ± 1.8 | 38.3 ± 1.6 | 38.3 ± 2.3 | 37.0 ± 1.9a,b | 36.1 ± 2.7a,b |
| Type of test | G1 | G2 | G3 | G4 | |
| LR_tests of fixed effects | Spatial fixed effects | 6732.35** | 2607.12** | 2021.77** | 415.62** |
| Temporal fixed effects | 7461.23** | 2729.13** | 753.29** | 309.58** | |
| LM_Tests | LM Lag test | 1506.82** | 2939.76** | 47.13** | 6.42* |
| Robust LM Lag test | 6.84** | 186.74** | 20.45** | 7.11** | |
| LM Error test | 1500.82** | 2773.34** | 39.29** | 4.62* | |
| Robust LM Error test | 0.84 | 20.32** | 12.61** | 5.30* |
| Br | Au | In | Vi | |
| Br | - | 0.146 | 0.108 | 0.177 |
| Au | 0.216 | - | 0.037 | 0.092 |
| In | 0.211 | 0.168 | - | 0.052 |
| Vi | 0.196 | 0.155 | 0.103 | - |
| Operation Mode | Operation Current | Power Consumption |
| Idle | 2 mA | 2 mAh |
| Data sampling | 80 mA | 0.178 mAh |
| Data transmitting | 60 mA | 0.067 mAh |
| Categories emerged | Positive valued | Negative valued |
| The degree of difficulty/demand of the studies | The degree of difficulty/demand was experienced as stimulating | The degree of difficulty/demand was experienced as too heavy |
| The teachers engagement | Very engaged teachers | Not engaged teachers |
| The organisation of the program | A stimulating organisation of the program was noticed | No stimulating organisation of the program was noticed |
| Contents in the studies associated to the profession | The certificate to be a nurse is attractive – long for working as a nurse | The certificate and the profession frightened the student |
| The attitude towards the studies | Having a positive attitude towards the studies | Having a negative attitude towards the studies |
| The study result achieved | Achieving a good study result | Not achieving a good study results |
| The life situation surrounding the studies | Having a good life situation | Having a bad life situation |
| Friendship during the studies | A good friendship is experienced | A bad or no friendship is experienced |
| Population | Intervention | Assessment tool(s)a | Analysis | ||||||
| Papers | Randomization | Justification of sample size | Control group | Allocation concealment | Underlying theory | Validity | Reliability | Intention-to-treat | Attrition rate |
| Alonso, Fernandez, Mataix et al. (1999) | No | Not mentioned | No | N/A | None | N/A | N/A | N/A | N/A |
| Beasley, Capossela, Brigham, Gunderson and Gortmaker (1997) | No | No | No | N/A | None | N/A | N/A | N/A | N/A |
| Bleakley (2010) | No | No | No | N/A | None | N/A | N/A | N/A | N/A |
| Dettle, Sagel and Chrysler (1994) | No | No | Yes (but no statistical comparison between groups) | Not mentioned | None | Not mentioned | Not mentioned | no | 40% attrition; |
| No analysis of dropouts | |||||||||
| Kittur, McMenamin and Knott (1990) | No | No | Yes | Not randomly assigned | None | N/A | N/A | N/A | N/A |
| Light (1987) | No | No | Yes (but no statistical comparison between groups) | Not randomly assigned | None | N/A | N/A | N/A | N/A |
| Milanés, Gonzalez, Hernandez, Arminio, Clesca and Rivas-Vetencourt (2003) | No | No | No | N/A | None | N/A | N/A | N/A | N/A |
| Nelson, Marymont, Durand, Reyes and Davis (1992) | Random cluster probability method | No | Yes | Not randomly assigned | None | Field testing of the questionnaire (but validity/reliability assessment not detailed) | N/A | N/A | |
| Niday, Painter, Peak et al. (2007) | No | No | No | N/A | None | N/A | N/A | N/A | N/A |
| Riker and White (1995) | No | No | Yes | Not randomly assigned | None | N/A | N/A | N/A | N/A |
| Shafer, Durand, Hueneke, et al. (1998) | No | No | No | N/A | None | N/A | N/A | N/A | N/A |
| Stark, Wikoren and Martone (1994) | No | No | No | N/A | None | N/A | N/A | N/A | N/A |
| Taylor, Young and Kneteman (1997) | No | No | No | N/A | ‘Change theory’ (not referenced) | N/A | N/A | N/A | N/A |
| Van Gelder, Van Hees, de Roey, Monbaliu, Aerts, Coosemans et al. (2006) | No | No | No | N/A | None | N/A | N/A | N/A | N/A |
| Wight, Cohen, Roels and Miranda (2000) | No | No | No | N/A | None | N/A | N/A | N/A | N/A |
| Parameter | Youth (n = 618) | Middle age (n = 613) | Senior (n = 279) | ||||||
| Total sample | Men | Women | Total sample | Men | Women | Total sample | Men | Women | |
| Age (yr) | 30.8 ± 5.7 | 30.4 ± 5.5 | 31.1 ± 5.8 | 49.2 ± 5.5 | 49.2 ± 5.8 | 49.2 ± 5.8 | 68.1 ± 4.5 | 68.9 ± 4.2 | 67.5 ± 4.6 |
| BMI (kg/m2) | 22.5 ± 3.6 | 23.5 ± 3.6 | 21.7 ± 3.4 | 24.3 ± 3.3 | 24.5 ± 3.1 | 24.2 ± 3.4 | 25.0 ± 3.4 | 24.6 ± 2.9 | 25.4 ± 3.6 |
| 25(OH)D (ng/mL) | 18.2 ± 9.2a | 17.6 ± 9.5a | 18.7 ± 9.0 | 22.8 ± 8.7 | 23.4 ± 8.5 | 22.4 ± 8.1 | 19.9 ± 7.8a | 22.2 ± 8.4 | 18.2 ± 6.9b |
| iPTH (pg/mL) | 33.0 ± 13.2a | 32.3 ± 12.3 | 33.5 ± 13.8 | 30.8 ± 13.3 | 35.0 ± 13.9 | 27.9 ± 12.1b | 32.8 ± 15.2a | 35.6 ± 14.1 | 30.8 ± 15.7b |
| Total calcium (mmol/mL) | 2.4 ± 0.1 | 2.4 ± 0.1 | 2.4 ± 0.1 | 2.4 ± 0.2 | 2.4 ± 0.1 | 2.4 ± 0.2 | 2.4 ± 0.2 | 2.4 ± 0.2 | 2.4 ± 0.2 |
| Phosphate (mmol/mL) | 1.1 ± 0.2 | 1.1 ± 0.2 | 1.1 ± 0.1 | 1.1 ± 0.2 | 1.0 ± 0.2 | 1.1 ± 0.1b | 1.0 ± 0.2 | 1.0 ± 0.1 | 1.1 ± 0.1b |
| Creatinine (umol/L) | 67.1 ± 14.1 | 69.3 ± 11.5 | 66.5 ± 14.7 | 73.8 ± 10.4 | 74.2 ± 12.3 | 71.9 ± 11.1 | 76.6 ± 13.1c | 78.4 ± 11.5 | 74.7 ± 10.6 |
| Mediator | Control | S | S+D | S+C1 | S+C2 | S+C3 |
| Total protein | 5.35±0.25 | 9.1±0.32 | 7.36±1.81 | 14.80±2.66 | 4.90±1.18 | 3.94±0.51 |
| PLA2 | 7.49±0.54 | 12.12±1.34 | 7.68±0.75 | 22.05±3.07 | 7.48±0.09 | 7.39±0.04 |
| Histamine | 7.73±1.15 | 32.92±1.62 | 28.45±2.01 | 27.05±1.81 | 17.34±2.3 | 1.84±0.25*** |
| Mean | SD | Cronbach's α | RA | PC | EU | IUMHS | |
| RA | 2.37 | 0.92 | 0.90 | CR = 0.93 | |||
| AVE = 0.72 | |||||||
| PC | 2.51 | 0.96 | 0.78 | 0.31∗∗ | CR = 0.90 | ||
| AVE = 0.82 | |||||||
| EU | 2.45 | 1.13 | 0.81 | 0.13 | 0.09 | CR = 0.89 | |
| AVE = 0.74 | |||||||
| IUMHS | 2.70 | 0.83 | 0.93 | 0.57∗∗ | 0.39∗∗ | 0.38∗∗ | CR = 0.95 |
| AVE = 0.83 |
| Disease | Regimen | No. pts. | PFS | Efficacy | Ref. |
| Metastatic head and neck cancer | Vorinostat: 400 mg orally daily | 13 | SD 2 pts. OR 0% | [51] | |
| Metastatic breast cancer | Vorinostat: 400 mg orally daily | 14 | SD 4 pts | [52] | |
| Relapsed NSCLC | Vorinostat: 400 mg or 300 mg once daily on days 1–14 of the 21 day cycle | 16 | Median: 2.3 m. | SD 57% | [53] |
| Metastatic prostate cancer | Vorinostat: 400 mg orally daily | 27 | Median: 2.8 m. | SD 2 pts. | [54] |
| Ovarian or primary peritoneal carcinoma | Vorinostat: 400 mg orally daily | 27 | PR 1 pt. | [55] | |
| Recurrent GBM | Vorinostat: 200 mg p.o.twice a day for 14 days, followed by a 7-day rest period | 66 | 6-m.-PFS: 9 of the first 52 patients | OR 2 pts. | [56] |
| Metastatic colorectal cancer | Vorinostat: 800 or 1,400 mg/day once a day × 3 days, every 2 weeks +5-FU: preceded by leucovorin, at 400 mg/m2 followed by a 46 h infusion at 2.400 mg/m2 on days 2–3 | 58 | PFS rate did not reach the threshold of 27 out of 43 patients | PR 1 pt. | [57] |
| Untreated stage IIIB or IV NSCLC | Vorinostat: 400 mg or Placebo on days 1 through 14 of each 3-week cycle +Carboplatin: AUC 6 +Paclitaxel: 200 mg/m2, both on day 3 of each 21-day cycle | 94 | Median: Vorinostat: 6.0 m. Placebo: 4.1 m. P = ns | RR Vorinostat: 34% Placebo: 12.5% P = 02 | [58] |
| Advanced thyroid cancer | Vorinostat: 400 mg orally daily | 19 | SD 56% OR 0 | [59] | |
| Recurrent GBM | Vorinostat: 400 mg daily for 14 days of a 21-day cycle + Bortezomib: 1.3 mg/m2 intravenously on days 1,4, 8, and 11 of a 21-day cycle | 37 | Median: 1.5 m. | PR 1 pt. | [60] |
| Bacteria, plasmid, or gene | Relevant features or sequence (5′–3′) | References or sources |
| Bacteria | ||
| E. coli DH5α | endA1 glnV44 thi-1 recA1 relA1 gyrA96 deoR F- Φ80dlacZΔM15 Δ(lacZYA-argF)U169, hsdR17(rK- mK +), λ– | Invitrogen |
| L. lactis NZ9000 | MG1363 nisRK ΔpepN | NIZO [35, 36] |
| Lb. plantarum ATCC 8014 | Wild type | ATCC |
| Plasmid | ||
| pNZ8148 | pSH71 derivative, PnisA, CmR, nisin-controlled expression | NIZO [35, 36] |
| pNZRK | pNZ8148 containing nisR and nisK genes | This work |
| pNZ-IRFP713 | pNZ8148 containing irfp713 gene | This work |
| pNZ-IRFP682 | pNZ8148 containing irfp682 gene | This work |
| pNZRK-IRFP713 | pNZ8148 containing irfp713, nisR and nisK genes | This work |
| pMA-T-IRFP713 | pMA-T containing irfp713 gene | This work |
| pMSP3545 | Emr, PnisA, nisRK, NcoI for translational fusion, ColE1 and pAMβ1 replicons | [37] |
| pMSP3545-IRFP713 | pMSP3545 containing irfp713 gene | This work |
| pGEM::CP25-IRFP | pGEM-T Easy containing irfp713 gene under the control of CP25 promoter | [27] |
| Gene | ||
| irfp713 | This work | |
| Primers | ||
| nisR-F | GATGATAAGCTGTCCAAAC | This work |
| nisK-R | TTTAGGATAACTTCTGCCC | This work |
| 682-1F | CTCAGACTTTTCTGGTGTAGTAATCGCAGAGGATAG | This work |
| 682-2F | GCATTATCCTGCCAGTGCTGTTCCAGCCCAAGC | This work |
| 682-3F | CCATCTTACGATCTGTTTCACCTTGTCATTTAGAGTTTATGCG | This work |
| 682-1R | CTATCCTCTGCGATTACTACACCAGAAAAGTCTGAG | This work |
| 682-2R | GCTTGGGCTGGAACAGCACTGGCAGGATAATGC | This work |
| 682-3R | CGCATAAACTCTAAATGACAAGGTGAAACAGATCGTAAGATGG | This work |
| Predictors | Model 8 | 95% CI | ||
| Fixed effects | ||||
| Intercept | −0.81 * | (0.35) | −1.55 | −0.09 |
| Ego gender | 0.25 | (0.51) | −0.80 | 1.30 |
| Change in activity scorea | 0.38 ** | (0.11) | 0.16 | 0.59 |
| Change in contact frequencya | −0.71 *** | (0.17) | −1.03 | −0.38 |
| Participant mean change in activity score | 0.18 | (0.24) | −0.31 | 0.68 |
| Participant mean change in contact frequency | −0.20 | (0.27) | −0.76 | 0.35 |
| Gender × change in activity score | 0.35 * | (0.15) | 0.06 | 0.64 |
| Gender × change in contact frequency | 0.51 * | (0.25) | 0.03 | 1.00 |
| Covariance parameters | ||||
| Random intercept (participants) | 1.12 ** | (0.38) | 0.58 | 2.20 |
| miRNA | RT (Primer) | PCR (Forward primer) | PCR (Reverse primer) |
| mir-144 | GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCAGTACA | CGGCCGGTACAGTATAGATGA | GTGCAGGGTCCGAGGT |
| mir-106b* | GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCGCAGCA | AATGCCGCACTGTGGGTACT | GTGCAGGGTCCGAGGT |
| mir-669k* | GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCGCACAC | GCCCGGTGTGCATGTGTGTATAGTT | GTGCAGGGTCCGAGGT |
| mir-142-3p | GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCTCCATA | GCGCTGTAGTGTTTCCTACTT | GTGCAGGGTCCGAGGT |
| mir-223 | GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCTGGGGT | CCGCCCGTGTCAGTTTGTCAAAT | GTGCAGGGTCCGAGGT |
| mir-210 | GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCTCAGCC | AATCCTGTGCGTGTGACAGC | GTGCAGGGTCCGAGGT |
| mir-32* | GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCAATATC | CGCGCGGCCAATTTAGTGTGTGT | GTGCAGGGTCCGAGGT |
| mir-669C | GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCACACAC | CGCGCCATAGTTGTGTGTGGAT | GTGCAGGGTCCGAGGT |
| mir-466i-5p | GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCCACACA | CGCCCTGTGTGTGTGTGTG | GTGCAGGGTCCGAGGT |
| mir-122* | GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCTTAGTG | CGCCCAAACGCCATTATCA | GTGCAGGGTCCGAGGT |
| mir-34C* | GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCCCTGGC | GCCCAATCACTAACCACACA | GTGCAGGGTCCGAGGT |
| mir-541* | GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCAGTATG | ACACCCTGGCGAACACAGAATC | GTGCAGGGTCCGAGGT |
| U6 | CTCGCTTCGGCAGCACA | AACGCTTCACGAATTTGCGT |
| Quality Index items | Imamura et al. (1998) | Tillu and Gupta (1998) | Perez Millan and Foster (2001) |
| Reporting | |||
| 1. Study hypothesis/aim/objective | 1 | 1 | 1 |
| 2. Main outcomes | 1 | 1 | 1 |
| 3. Characteristics of the participants | 0 | 0 | 0 |
| 4. Interventions of interest | 0 | 1 | 0 |
| 5. Distributions of principal confounders in each group | 0 | 0 | 0 |
| 6. Main findings | 0 | 1 | 1 |
| 7. Estimates of random variability for main outcomes | 1 | 0 | 1 |
| 8. All the important adverse events that may be a consequence of intervention | 0 | 0 | 0 |
| 9. Characteristics of patients lost to follow-up | 0 | 1 | 1 |
| 10. Actual probability values for main outcomes | 0 | 1 | 0 |
| External validity | |||
| 11. Were subjects who were asked to participate representative of the entire population from which they were recruited? | 1 | 1 | 0 |
| 12. Were subjects who were prepared to participate representative of the entire population from which they were recruited? | 0 | 0 | 0 |
| 13. Were the staff, places, and facilities representative of the treatment the majority of subjects received? | 1 | 0 | 1 |
| Internal validity (bias) | |||
| 14. Was an attempt made to blind subjects to the intervention they received? | 0 | 0 | 0 |
| 15. Was an attempt made to blind those measuring main outcomes of the intervention? | 0 | 0 | 0 |
| 16. If any of the results of the study were based on\"data dredging\", was this made clear? | 0 | 1 | 1 |
| 17. Do analyses adjust for different lengths of follow-up? | 0 | 1 | 1 |
| 18. Were appropriate statistical tests used to assess the main outcomes? | 1 | 1 | 1 |
| 19. Was compliance with the intervention reliable? | 1 | 1 | 1 |
| 20. Were main outcome measures reliable and valid? | 0 | 0 | 0 |
| Internal validity (selection bias) | |||
| 21. Were patients in different intervention groups recruited from the same population? | 0 | 0 | 0 |
| 22. Were subjects in different intervention groups recruited over the same period of time? | 0 | 0 | 0 |
| 23. Were subjects randomized to intervention groups? | 0 | 0 | 0 |
| 24. Was the randomized intervention assignment concealed from both patients and staff until recruitment was complete and irrevocable? | 0 | 0 | 0 |
| * 25. Was there adequate adjustment for confounding in the analyses from which main findings were drawn? | x | x | x |
| 26. Were losses of subjects to follow-up taken into account? | 0 | 1 | 1 |
| Power | |||
| * 27. Did the study have sufficient power to detect a clinically important effect where the probability for a difference due to chance was less than 5%? | x | x | x |
| Total score (/27) | 7 | 12 | 11 |
| Paraclinical findings | Number a(%) | Number b (%) |
| Chest X ray | ||
| Normal | 98 (94,2) | 57 (96,6) |
| Abnormal | 6 (5,8) | 3 (5,1) |
| Cardiomegaly | 2 (1,9) | 1 (1,7) |
| Enlargement of the superior mediastinum | 3 (2,9) | 1 (1,7) |
| Interstitial Syndrome | 1 (1) | 0 |
| Spirometry | ||
| Normal | 94 (90,4) | 56 |
| Restrictive profile | 7 (6,7) | 1 (1,7) |
| Obstructive ventilatory defect | 3 (2,9) | 2 (3,4) |
| Electrocardiogram | ||
| Normal | 92 (88,5) | 54 |
| Abnormal | 12 (11,5) | 5 (8,5) |
| Right atrial hypertrophy | 10 (9,6) | 4 (6,8) |
| Arrhythmia | 2 (1,9) | 1 (1,7) |
| PANTHER Pathways | Annotated | Dapulian (DT_DC) | Landrace (LT_LC) | ||||||
| Significant | Expected | Fold Enrichment | p-Value | Significant | Expected | Fold Enrichment | p-Value | ||
| Angiogenesis (P00005) | 147 | 27 | 13.37 | 2.02 | 6.50 × 10−4 | 27 | 14.56 | 1.85 | 2.16 × 10−3 |
| Cholecystokinin receptor(CCKR) signaling map (P06959) | 155 | 30 | 14.1 | 2.13 | 1.43 × 10−4 | 23 | 15.35 | 1.5 | 4.00 × 10−2 |
| Epidermal growth factor (EGF) receptor signaling pathway (P00018) | 134 | 24 | 12.19 | 1.97 | 1.73 × 10−3 | 23 | 13.27 | 1.73 | 9.35 × 10−3 |
| Fibroblast growth factor (FGF) signaling pathway (P00021) | 124 | 21 | 11.28 | 1.86 | 5.97 × 10−3 | 19 | 12.28 | 1.55 | 4.47 × 10−2 |
| Parkinson disease (P00049) | 104 | 20 | 9.46 | 2.11 | 1.82 × 10−3 | 23 | 10.3 | 2.23 | 4.26 × 10−4 |
| PI3 kinase pathway (P00048) | 45 | 10 | 4.09 | 2.44 | 9.36 × 10−3 | 11 | 4.46 | 2.47 | 6.18 × 10−3 |
| Ras Pathway (P04393) | 80 | 22 | 7.28 | 3.02 | 7.76 × 10−6 | 14 | 7.92 | 1.77 | 3.17 × 10−2 |
| T cell activation (P00053) | 83 | 16 | 7.55 | 2.12 | 4.81 × 10−3 | 15 | 8.22 | 1.82 | 2.11 × 10−2 |
| Toll receptor signaling pathway (P00054) | 59 | 10 | 5.37 | 1.86 | 4.69 × 10−2 | 11 | 5.84 | 1.88 | 3.63 × 10−2 |
| Ubiquitin proteasome pathway (P00060) | 65 | 11 | 5.91 | 1.86 | 3.89 × 10−2 | 13 | 6.44 | 2.02 | 1.48 × 10−2 |
| Gonadotropin releasing hormone receptor pathway (P06664) | 223 | 41 | 20.28 | 2.02 | 3.09 × 10−5 | – | – | – | – |
| Apoptosis signaling pathway (P00006) | 129 | 24 | 11.73 | 2.05 | 1.06 × 10−3 | – | – | – | – |
| Fas signaling pathway (P00020) | 41 | 11 | 3.73 | 2.95 | 1.65 × 10−3 | – | – | – | – |
| Vascaular endothelial growth factor (VEGF) signaling pathway (P00056) | 61 | 13 | 5.55 | 2.34 | 4.71 × 10−3 | – | – | – | – |
| Integrin signaling pathway (P00034) | 153 | 24 | 13.92 | 1.72 | 8.50 × 10−3 | – | – | – | – |
| p53 pathway feedback loops 2 (P04398) | 53 | 11 | 4.82 | 2.28 | 1.06 × 10−2 | – | – | – | – |
| De novo purine biosynthesis (P02738) | 46 | 10 | 4.18 | 2.39 | 1.08 × 10−2 | – | – | – | – |
| Oxidative stress response (P00046) | 29 | 7 | 2.64 | 2.65 | 1.83 × 10−2 | – | – | – | – |
| Transforming growth factor beta(TGF-β) signaling pathway (P00052) | 90 | 15 | 8.19 | 1.83 | 2.04 × 10−2 | – | – | – | – |
| Hypoxia response via HIF activation (P00030) | 30 | 7 | 2.73 | 2.57 | 2.15 × 10−2 | – | – | – | – |
| Platelet derived growth factor (PDGF) signaling pathway (P00047) | 141 | 21 | 12.82 | 1.64 | 2.17 × 10−2 | – | – | – | – |
| Interleukin signaling pathway (P00036) | 101 | 16 | 9.19 | 1.74 | 2.56 × 10−2 | – | – | – | – |
| Inflammation mediated by chemokine and cytokine signaling pathway (P00031) | 228 | 30 | 20.74 | 1.45 | 3.19 × 10−2 | – | – | – | – |
| Heme biosynthesis (P02746) | 14 | 4 | 1.27 | 3.14 | 4.04 × 10−2 | – | – | – | – |
| Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade (P00032) | 35 | 7 | 3.18 | 2.2 | 4.35 × 10−2 | – | – | – | – |
| p53 pathway (P00059) | 92 | 14 | 8.37 | 1.67 | 4.60 × 10−2 | – | – | – | – |
| Coenzyme A biosynthesis (P02736) | 11 | – | – | – | – | 5 | 1.09 | 4.59 | 5.21 × 10−3 |
| Salvage pyrimidine ribonucleotides (P02775) | 13 | – | – | – | – | 5 | 1.29 | 3.88 | 1.02 × 10−2 |
| B cell activation (P00010) | 68 | – | – | – | – | 13 | 6.74 | 1.93 | 2.05 × 10−2 |
| General transcription regulation (P00023) | 34 | – | – | – | – | 8 | 3.37 | 2.38 | 2.19 × 10−2 |
| Lysine biosynthesis (P02751) | 6 | – | – | – | – | 3 | 0.59 | >5 | 2.25 × 10−2 |
| Insulin/insulin-like growth factor (IGF) pathway-protein kinase B signaling cascade (P00033) | 49 | – | – | – | – | 10 | 4.85 | 2.06 | 2.67 × 10−2 |
| Angiotensin II-stimulated signaling through G proteins and β-arrestin (P05911) | 30 | – | – | – | – | 7 | 2.97 | 2.36 | 3.20 × 10−2 |
| Notch signaling pathway (P00045) | 40 | – | – | – | – | 8 | 3.96 | 2.02 | 4.88 × 10−2 |
| Diagnosis | |
| Guillain-Barré syndrome, n (%) | 26 (63.4) |
| Autoimmune encephalitis, n (%) | 6 (14.6) |
| Miller-Fisher syndrome, n (%) | 2 (4.9) |
| Chronic relapsing inflammatory optic neuropathy (CRION), n (%) | 1 (2.4) |
| Multiple sclerosis, n (%) | 1 (2.4) |
| Parainfectious myelitis, n (%) | 1 (2.4) |
| Myasthenia gravis, n (%) | 1 (2.4) |
| Anti-Yo-associated paraneoplastic cerebellar degeneration, n (%) | 1 (2.4) |
| Anti-Hu-associated polyneuropathy, n (%) | 1 (2.4) |
| Neuromyelitis optica, n (%) | 1 (2.4) |
| Variables | Algorithm |
| P(X) = base rate of event for person X | Produce a time series for C and S events: |
| P(X|Y) = rate of event for X given Y did | |
| P(X|X) = probability of event repetition | Do 1000 timesIf rand < P(C)C outputs event (=1)Else if rand < P(C|C) and C = 1C outputs eventOtherwiseC outputs no event (=0)If rand < P(S|C) and C = 1S outputs event (=1)Else if rand < P(S)S outputs eventElse if rand < P(S|S) and S = 1S outputs eventOtherwiseS outputs no event (=0) |
| Disability screening but not in regression model | In regression model | p Value | Number of missing values/4219 (%) | |
| Allocation to intervention in original trial | 316/901 (35%) | 1786/3318 (54%) | <0.001 | |
| Household appliance score: none of assets on list | 475/901 (53%) | 1754/3318 (53%) | 0.801 | |
| Household appliance score: most expensive assets | 58/901 (6%) | 187/3318 (6%) | ||
| Positive disability screen | 73/901 (8%) | 241/3318 (7%) | 0.395 | |
| Included in initial regression model but dropped from final model | ||||
| Four skilled antenatal care visits | 87/901 (10%) | 296/3315 (9%) | 0.501 | 3 (<1%) |
| Possible symptoms of preeclampsia | 499/873 (57%) | 1697/3210 (53%) | 0.024 | 136 (3%) |
| Delivery room heated | 681/901 (76%) | 2651/3318 (80%) | 0.005 | 0 |
| Infant had fever in neonatal period | 156/901 (17%) | 489/3318 (15%) | 0.057 | 0 |
| Retained in final logistic regression model | ||||
| Maternal underweight (BMI<18∙5) | 89/675 (13%) | 382/3318 (12%) | 0.220 | 226 (5%) |
| Mother cohabited with husband when <16 years old | 178/716 (25%) | 812/3318 (24%) | 0.827 | 185 (4%) |
| Skilled birth attendant | 18/733 (3%) | 91/3318 (3%) | 0.664 | 168 (4%) |
| Infant size ‘very small’ | 12/901 (1%) | 108/3318 (3%) | 0.002 | 0 |
| Infant illness: diarrhoea and repeated vomiting | 46/901 (5%) | 159/3318 (5%) | 0.698 | 0 |
| Mean weight in grams at 1 month (SD) | 4395(963) n=335 | 4271(898) n=3318 | 0.017 | 566 (13%) |
| Target | Active compounds | Inactive compounds | Ratio (active/inactive compounds) | Sensitivity | Precision | Specificity | κ |
| PPARA | 1955 | 1465 | 1.33 | 0.96 | 0.94 | 0.92 | 0.89 |
| MMP2 | 2742 | 2363 | 1.16 | 0.96 | 0.96 | 0.96 | 0.92 |
| MAOA | 732 | 733 | 1.00 | 0.79 | 0.80 | 0.81 | 0.59 |
| NR1I2 | 249 | 1090 | 0.23 | 0.82 | 0.73 | 0.93 | 0.72 |
| TMPRSS15 | 139 | 724 | 0.19 | 0.43 | 0.54 | 0.93 | 0.39 |
| HSD17B10 | 3410 | 11,510 | 0.30 | 0.41 | 0.40 | 0.82 | 0.23 |
| KDM4E | 3938 | 35,059 | 0.11 | 0.22 | 0.29 | 0.94 | 0.18 |
| LMNA | 14,533 | 171,164 | 0.09 | 0.49 | 0.13 | 0.72 | 0.10 |
| TDP1 | 23,133 | 276,782 | 0.08 | 0.76 | 0.38 | 0.90 | 0.45 |
| TARDBP | 12,193 | 387,934 | 0.03 | 0.22 | 0.08 | 0.92 | 0.08 |
| ALOX15 | 1932 | 69,362 | 0.03 | 0.49 | 0.12 | 0.90 | 0.16 |
| BRCA1 | 8619 | 363,912 | 0.02 | 0.72 | 0.20 | 0.93 | 0.29 |
| DRD2 | 4613 | 343,076 | 0.01 | 0.96 | 0.93 | 1.00 | 0.94 |
| GSK3B | 3334 | 300,186 | 0.01 | 0.85 | 0.72 | 1.00 | 0.78 |
| JAK2 | 2158 | 213,915 | 0.01 | 0.85 | 0.81 | 1.00 | 0.83 |
| POLK | 773 | 389,418 | 0.002 | 0.55 | 0.17 | 0.99 | 0.26 |
| FEN1 | 1050 | 381,575 | 0.003 | 0.35 | 0.03 | 0.96 | 0.04 |
| HDAC3 | 369 | 311,425 | 0.001 | 0.98 | 0.76 | 1.00 | 0.86 |
| Prediction set | Published [14] | BRAKER1/soft-masked |
| Number of protein coding genes predicted | 20,964 | 15,747 |
| Mean protein length (amino acids) | 218.8 | 344.5 |
| Number of single exon genes | 1,728 | 2,326 |
| Mean number of exons per genea | 5.9 | 7.8 |
| Proportion of noncanonical (GC-AG) introns | 8.87% | 0.79% |
| Percentage mapping to publicly available transcriptome reads | ||
| Sanger ESTs | 80.45% | 84.26% |
| Roche 454 reads | 37.18% | 58.03% |
| BUSCO score for proteome | ||
| Complete | 47.8% | 94% |
| Fragmented | 34.7% | 4.3% |
| Number of proteins with no hits in Uniref90 | 8,962 | 2,889 |
| Protein singletons in clustering | 5,442 | 1,112 |
| Conserved, single-copy orthologuesb | ||
| Total | 2,089 | 2,330 |
| Missing | 377 | 141 |
| Expanded | 184 | 84 |
| Factors | B | SE | Df | Sig. | Exp ( B ) | 95% confidence interval lower/upper |
| Sex | −0.795 | 0.857 | 1 | 0.354 | 0.452 | 0.084/2.423 |
| Age | 0.135 | 0.061 | 1 | 0.026 | 1.145 | 1.016/1.291 |
| FEV1 (%) | 0.018 | 0.026 | 1 | 0.490 | 1.018 | 0.968/1.070 |
| Tumour side | 0.014 | 0.597 | 1 | 0.982 | 1.014 | 0.314/3.268 |
| pT* | 1.390 | 0.424 | 1 | 0.001 | 4.014 | 1.749/9.213 |
| pN** | 0.796 | 0.576 | 1 | 0.167 | 2.217 | 0.717/6.861 |
| Neoadjuvant | −0.579 | 0.800 | 1 | 0.469 | 0.561 | 0.117/2.687 |
| Organism | Group | tag | Lanes in Figure 2 |
| Gallus gallus | Animals | CACTCACAAGCTCGACGTACAC | 1 and 8 |
| Canis familiaris | Animals | CAGACAGCACTCGTTCGTACAC | 2 and 9 |
| Arabidopsis thaliana | Plants | GACTGAACGTGCTCTGCTACTG | 3 and 10 |
| Sulfolobus acidocaldarius str. DSM639 | Crenarchaeota | CAGTCACAGCACACGAGTACAC | 4 and 11 |
| Bartonella henselae str. Houston-1 | Alphaproteobacteria | CAGACACGAGCAACGACTACAC | 5 and 12 |
| Bartonella henselae str. UGA 8 | Alphaproteobacteria | CAGACACGAGCAACGACTACAC | 6 and 13 |
| Anabaena PCC7120 | Cyanobacteria | CACTCTGTGCTCGTTGCTACAC | (Figure 3) |
| Synechocystis PCC 6803 | Cyanobacteria | CAGACAGCAAGCAGCACTACAC | (Figure 3) |
| Odds Ratio (95% Confidence Interval) | ||
| Any pneumococcal serotype | ||
| Univariable | Multivariable | |
| Male | 1.56 (1.35–1.81) | 0.81 (0.67–0.99) |
| Age increase by 12 months | ||
| 0–11 months | 4.60 (2.83–7.50) | 4.19 (2.39–7.33) |
| 1 to 19 yr | 0.85 (0.84–0.87) | 0.85 (0.84–0.87) |
| 20 + years | 0.99 (0.98–1.01) | 1.00 (0.99–1.02) |
| Annual increase | ||
| Pre-PCV13 | 1.07 (0.98–1.18) | 0.86 (0.75–0.98) |
| Post-PCV13 | 0.88 (0.75–1.05) | 1.37 (1.08–1.74) |
| Respiratory symptoms | 1.48 (1.14–1.94) | 1.01 (0.72–1.43) |
| Nasal discharge | 4.84 (4.01–5.74) | 2.49 (2.00–3.09) |
| Recent antibiotic use | 0.73 (0.55–0.98) | 0.48 (0.33–0.69) |
| Remoteness | ||
| Metropolitan | Ref | Ref |
| Regional | 1.36 (0.97–1.89) | 1.31 (0.88–1.96) |
| Remote | 1.86 (1.47–2.35) | 2.21 (1.67–2.92) |
| ETS | 1.24 (1.06–1.46) | 1.06 (0.87–1.29) |
| ≥5 people sharing (crowding) | 1.35 (1.15–1.58) | 1.36 (1.11–1.67) |
| Sharing with ≥1 child <5 years | 1.15 (0.96–1.37) | 1.07 (0.85–1.34) |
| Season | ||
| Spring | Ref | Ref |
| Summer | 0.91 (0.66–1.27) | 0.95 (0.62–1.45) |
| Autumn | 0.86 (0.70–1.07) | 1.35 (0.91–2.00) |
| Winter | 1.29 (1.08–1.53) | 1.11 (0.73–1.69) |
| H. influenzae | 10.29 (8.60–12.30) | N/A |
| M. catarrhalis | 7.10 (6.01–8.39) | N/A |
| S. aureus | 0.56 (0.44–0.72) | N/A |
| Parameter | Responders (n = 15) | Nonresponders (n = 13) | ||||
| Baseline | Before INO | P value | Baseline | Before INO | P value | |
| Leucocytes (106/ml) | 10.4 ± 4.4 | 1.6 ± 1.0† | ≤ 0.01 | 8.8 ± 2.4 | 0.9 ± 0.3* † | ≤ 0.01 |
| Neutrophils (%) | 56 ± 12 | 65 ± 14 | 0.074 | 53 ± 10 | 48 ± 17* | 0.45 |
| Macrophage (%) | 44 ± 12 | 34 ± 15 | 0.064 | 47 ± 10 | 51 ± 17* | 0.45 |
| Thrombocytes (106/ml) | 408 ± 77 | 185 ± 54† | ≤ 0.01 | 355 ± 61 | 175 ± 68† | ≤ 0.01 |
| Proteins (mg/ml) | 47 ± 6.0 | 33 ± 5.4† | ≤ 0.01 | 46 ± 6 | 34 ± 5† | ≤ 0.01 |
| Endotoxin (pg/ml) | 0 | 45 (3.8 to 296)† | ≤ 0.01 | 0 (0 to 4.5) | 32 (0 to 392)† | 0.011 |
| Endothelin-1 (pg/ml) | 0 | 3.0 (1.8 to 8)† | ≤ 0.01 | 0 | 0.1 (0.1 to 8) | 0.31 |
| PGF2α (pg/ml) | 265 (236 to 327) | 759 (356 to 1498)† | ≤ 0.01 | 218 (171 to 512) | 380 (342 to 1632)† | ≤ 0.01 |
| TXB2 (pg/ml) | 692 (530 to 778) | 2881 (860 to 4504)† | ≤ 0.01 | 643 (574 to 821) | 3883 (2286 to 5051)† | ≤ 0.01 |
| 6-keto-PGF1α (pg/ml) | 291 (232 to 323) | 1023 (810 to 1560)† | ≤ 0.01 | 518 (274 to 899) | 603 (557 to 1099) | 0.33 |
| LTB4 (pg/ml) | 28 (16 to 41) | 372 (41 to 486)† | ≤ 0.01 | 38 (9 to 48) | 274 (46 to 414)† | ≤ 0.01 |
| TNFα (pg/ml) | 15 (11 to 22) | 18 (10 to 39) | 0.083 | 12 (8 to 21) | 10 (5 to 27) | 1.0 |
| IL-8 (ng/ml) | 0 | 24(7.2 to 32)† | ≤ 0.01 | 0 | 4 (1.5 to 47)† | 0.03 |
| Nitrates (nmol/ml) | 212 (173 to 352) | 183 (147 to 236)† | ≤ 0.01 | 183 (133 to 255) | 173 (150 to 212) | 0.58 |
| Breast Clinicopathological details | Cancer | Fibroadenoma | Normal |
| Number of patients | 103 | 35 | 30 |
| Median Patient Age yrs | 56 (35-90) | 44 (17-62) | 46.5 (24-58) |
| Menopausal Status | |||
| Post | 72 | ||
| Pre | 32 | ||
| Histological Subtype | |||
| Invasive Ductal | 78 | ||
| Invasive Lobular | 11 | ||
| Other | 14 | ||
| Intrinsic Subtype | |||
| Luminal A (ER/PR+, HER2/neu-) | 42 | ||
| Luminal B (ER/PR+, HER2/neu+) | 18 | ||
| HER2 Over expressing (ER-, PR-, HER2/neu+) | 16 | ||
| Triple-Negative (ER-, PR-, HER2/neu-) | 16 | ||
| Unknown | 11 | ||
| Tumour Grade | |||
| 1 | 5 | ||
| 2 | 32 | ||
| 3 | 55 | ||
| Tumour size | |||
| 1 | 19 | ||
| 2 | 39 | ||
| 3 | 10 | ||
| UICC Stage | |||
| Stage 1 | 23 | ||
| Stage 2 | 36 | ||
| Stage 3 | 21 | ||
| Stage 4 | 10 |
| Estrogen | Progesterone | Her-2 | |||||
| Polymorphisms | Negative | Positive | Negative | Positive | Negative | Positive | Inconclusive |
| rs3803662 - TT N (%) | 13 (16.5) | 20 (18.0) | 16 (18.0) | 17 (16.5) | 23 (16.9) | 7 (14.9) | 3 (100.0) |
| rs3803662 - TC N (%) | 33 (41.8) | 56 (50.5) | 51 (41.8) | 38 (42,7) | 66 (48.5) | 21 (44.7) | 0 (0.0) |
| rs3803662 – CC N (%) | 33 (41.8) | 35 (31.5) | 46 (37.7) | 35 (39.3) | 47 (34.6) | 19 (40.4) | 0 (0.0) |
| Total | 79 (100.0) | 111 (100.0) | 122 (100.0) | 89 (100.0) | 136 (100.0) | 47 (100.0) | 3 (100.0) |
| P valuea | 0.257 | 0.504 | 0.469 | ||||
| rs2981582 – TT N (%) | 15 (219.2) | 31 (27.2) | 16 (18.0) | 30 (28.6) | 33 (23.9) | 21 (25.5) | 1 (33.4) |
| rs2981582 – TC | 38 (48.7) | 60 (52.6) | 47 (52.8) | 52 (49.5) | 65 (47.1) | 28 (59.6) | 2 (66.6) |
| N (%) | |||||||
| rs2981582 – CC | 25 (32.1) | 23 (20.2) | 26 (29.2) | 23 (21.9) | 40 (29.0) | 7 (14.9) | 0 (0.0) |
| N (%) | |||||||
| Total | 78 (100.0) | 114 (100.0) | 89 (100.0) | 105 (100.0) | 138 (100.0) | 47 (100.0) | 3 (100.0) |
| P valuea | 0.054 | 0.076 | 0.120 | ||||
| rs13281615 - AA N (%) | 20 (25.3) | 30 (26.3) | 26 (28.9) | 25 (23.8) | 32 (23.2) | 14 (29.2) | 2 (66.6) |
| rs13281615 - AG N (%) | 35 (44.3) | 56 (49.1) | 40 (44.4) | 51 (48.6) | 68 (49.3) | 20 (41.7) | 1 (33.4) |
| rs13281615 - GG N (%) | 24 (30.4) | 28 (24.6) | 24 (26.7) | 29 (27.6) | 38 (27.5) | 14 (29.2) | 0 (0.0) |
| Total | 79 (100.0) | 114 (100.0) | 90 (100.0) | 105 (100.0) | 138 (100.0) | 48 (100.0) | 3 (100.0) |
| P valuea | 0.523 | 0.566 | 0.291 | ||||
| rs889312 - CC N (%) | 12 (15.2) | 15 (13.2) | 10 (11,1) | 17 (16.2) | 21 (15.2) | 5 (10.4) | 0 (0.0) |
| rs889312 - CA N (%) | 35 (44.3) | 54 (47.4) | 45 (50.0) | 45 (42.9) | 61 (44.2) | 25 (52.1) | 1 (33.3) |
| rs889312 - AA N (%) | 32 (40.5) | 45 (39.5) | 35 (38.9) | 43 (41.0) | 56 (40.6) | 18 (37.5) | 2 (66.7) |
| Total | 79 (100.0) | 114 (100.0) | 90 (100.0) | 105 (100.0) | 138 (100.0) | 48 (100.0) | 3 (100.0) |
| P valuea | 0.921 | 0.760 | 0.554 | ||||
| rs3817198 - TT N (%) | 42 (53.8) | 51 (44.7) | 49 (55.1) | 45 (42,9) | 68 (49.3) | 21 (44.7) | 0 (0.0) |
| rs3817198 - TC N (%) | 31 (39,7) | 54 (47.4) | 34 (38.2) | 52 (49,5) | 59 (42.8) | 23 (48.9) | 3 (100) |
| rs3817198 - CC N (%) | 5 (6.4) | 9 (7.9) | 6 (6.7) | 8 (7.6) | 11 (8.0) | 3 (6.4) | 0 (0.0) |
| Total | 78 (100.0) | 114 (100.0) | 89 (100.0) | 105 (100.0) | 138 (100.0) | 47 (100.0) | 3 (100.0) |
| P valuea | 0.248 | 0.145 | 0.449 |
| Participants from wards with high staff moralea (n = 12) | Participants from wards with low staff moralea (n = 9) | |
| Gender | 50 % (6/12) male; 50 % (6/12) female | 89 % (8/9) male; 11 % (1/9) female |
| Age | 25 % (3/12) 16–17 years | 22 % (2/9) 18–25 years |
| 8 % (1/12) 18–25 years | 33 % (3/9) 26–35 years | |
| 25 % (3/12) 26–35 years | 11 % (1/9) 36–45 years | |
| 16 % (2/12) 36–45 years | 33 % (3/9) 46–55 years | |
| 8 % (1/12) 46–55 years | ||
| 16 % (2/12) 56–65 years | ||
| Ethnicity | 50 % (6/12) British or White British | 33 % (3/9) British or White British |
| 17 % (2/12) White & Black Caribbean | 22 % (2/9) Black African | |
| 8 % (1/12) Indian | 11 % (1/9) Caribbean | |
| 8 % (1/12) White other | 11 % (1/9) Black other | |
| 8 % (1/12) Black other | 11 % (1/9) Asian | |
| 8 % (1/12) Mixed ethnicity | 11 % (1/9) Mixed ethnicity | |
| Ward type | 25 % (3/12) Female acute ward | 33 % (3/9) Male psychiatric intensive care unit |
| 25 % (3/12) Mixed gender recovery unit | 33 % (3/9) Male acute ward | |
| 25 % (3/12) Mixed gender child and adolescent unit | 33 % (3/9) Mixed gender acute ward | |
| 25 % (3/12) Male rehabilitation unit |
| Parameter | BSP | Control | P | |
| Gender | Male | 62 | 65 | >0.05 |
| Female | 38 | 35 | ||
| Age | ≤40 | 33 | 29 | >0.05 |
| >41 | 67 | 71 | ||
| Etiology | Trauma | 31 | 31 | >0.05 |
| Other | 69 | 69 |
| Group 1 (n = 33) admitted to HSS | Group 2 (n = 27) admitted to RS | P valuea) | |||||
| Total number | Mean per patient | SD | Total number | Mean per patient | SD | ||
| Specialist health care services | |||||||
| In-patient days (total number) | 245 | 7.4 | 12.1 | 300 | 11.1 | 22.1 | 0.872 |
| Number in-patient days at HSS | 118 | 3.6 | 7.0 | 156 | 5.8 | 11.7 | 0.621 |
| Number in-patient days at RS | 117 | 3.5 | 6.4 | 131 | 4.9 | 11.4 | 0.813 |
| Number in-patient days other hospitals | 10 | 0.3 | 1.0 | 13 | 0.5 | 1.5 | 0.952 |
| Out-patient/X-ray consult. (total number) | 70 | 2.1 | 3.0 | 37 | 1.4 | 2.3 | 0.201 |
| Out-patient/X-ray consultations at HSS | 26 | 0.8 | 1.4 | 6 | 0.2 | 0.5 | 0.044* |
| Out-patient/X-ray consultations at RS | 29 | 0.9 | 1.3 | 16 | 0.6 | 1.0 | 0.318 |
| Out-patient/X-ray consult. other hospitals | 15 | 0.5 | 0.9 | 15 | 0.6 | 1.4 | 0.752 |
| Municipal health care services | |||||||
| Nursing homes (days) | 355 | 10.8 | 30.0 | 524 | 19.4 | 50.0 | 0.078 |
| Home care total (hours) | 2415 | 73.2 | 136.2 | 3019 | 111.8 | 245.6 | 0.796 |
| Home nursing (hours) | 1983 | 60.1 | 117.6 | 2669 | 98.9 | 227.4 | 0.856 |
| Practical help (hours) | 432 | 13.1 | 26.4 | 350 | 13.0 | 24.0 | 0.970 |
| GP office consultations (number) | 470 | 14.2 | 11.8 | 352 | 13.0 | 13.3 | 0.562 |
| GP consultations (number) | 263 | 8.0 | 7.2 | 193 | 7.2 | 7.6 | 0.612 |
| Nurse consultations (number) | 207 | 6.3 | 7.4 | 159 | 5.9 | 7.4 | 0.976 |
| Cod | Whey | Gluten | Casein | |
| MCP-1 | ||||
| Fasting | 22 ± 11 | 21 ± 7 | 23 ± 12 | 21 ± 11 |
| iAUC 0-240 min (pg/ml·240 min) | - 826 ± 1255x | - 77 ± 1092y | -943 ± 925x | -469 ± 757xy |
| CCL5 | ||||
| Fasting | 340 ± 238 | 490 ± 396 | 490 ± 321 | 409 ± 297 |
| iAUC 0-240 min (pg/ml·240 min) | 50 764 ± 58 218x | - 18 510 ± 81 999y | 11 235 ± 55 558yz | 44 488 ± 37 862xz |
| IL-1ra | ||||
| Fasting | 68 ± 18 | 79 ± 39 | 76 ± 34 | 66 ± 24 |
| iAUC 0-240 min (pg/ml·240 min) | 743 ± 2 871 | -1 972 ± 4 005 | -1 454 ± 5 068 | 2 173 ± 4 320 |
| PDGF-bb1 | ||||
| Fasting | 40 ± 41 | 161 ± 260 | 65 ± 78 | 110 ± 232 |
| iAUC 0-240 min (pg/ml·240 min) | 11 837 (6 285 - 20 952) | 4 303 (2 102 - 6 995) | 6 660 (4851 - 10 742) | 8 604 (6348 - 10 435) |
| IFN-g | ||||
| Fasting | 25 ± 12 | 28 ± 25 | 30 ± 21 | 28 ± 24 |
| iAUC 0-240 min (pg/ml·240 min) | 865 ± 1 610 | -1 300 ± 3 747 | -791 ± 2 622 | 397 ± 2 614 |
| Adiponectin | ||||
| Fasting | 1.5 ± 0.5 | 1.5 ± 0.6 | 1.5 ± 0.6 | 1.5 ± 0.5 |
| iAUC 0-240 min (μg/ml·240 min) | -7.7 ± 48 | -8.5 ± 49 | 6.3 ± 38 | -6.9 ± 36 |
| Eotaxin | ||||
| Fasting | 52 ± 12 | 53 ± 14 | 51 ± 14 | 49 ± 16 |
| iAUC 0-240 min (pg/ml·240 min) | - 45 ± 819 | 601 ± 2237 | - 64 ± 686 | 983 ± 1039 |
| G-CSF | ||||
| Fasting | 11 ± 3 | 12 ± 6 | 11 ± 4 | 12 ± 7 |
| iAUC 0-240 min (pg/ml·240 min) | 23 ± 719 | -420 ± 1 242 | -114 ± 685 | -194 ± 955 |
| IP-10 | ||||
| Fasting | 579 ± 166 | 558 ± 109 | 588 ± 226 | 542 ± 142 |
| iAUC 0-240 min (pg/ml·240 min) | -2 343 ± 24 198 | -10 371 ± 19 737 | -3 403 ± 21 448 | -5 159 ± 10 121 |
| MIP-1b | ||||
| Fasting | 45 ± 16 | 46 ± 16 | 44 ± 14 | 43 ± 15 |
| iAUC 0-240 min (pg/ml·240 min) | -908 ± 1 248 | -331 ± 1 411 | -302 ± 534 | -219 ± 428 |
| VEGF | ||||
| Fasting | 7 ± 3 | 10 ± 6 | 7 ± 3 | 8 ± 4 |
| iAUC 0-240 min (pg/ml·240 min) | 693 ± 921 | 270 ± 1 058 | 233 ± 448 | 317 ± 419 |
| Insulin | ||||
| Fasting | 65 ± 28 | 63 ± 33 | 66 ± 31 | 62 ± 32 |
| iAUC 0-240 min (pmol/l·240 min) | 41 158 ± 11 003x | 73 693 ± 28 022y | 38 738 ± 10 691x | 50 978 ± 21 477x |
| Triglycerides | ||||
| Fasting | 2.0 ± 1.0 | 1.8 ± 0.8 | 1.9 ± 0.7 | 1.8 ± 0.9 |
| iAUC 0-240 min (mmol/l·240 min) | 138 ± 108 | 122 ± 95 | 132 ± 95 | 127 ± 94 |
| Stage | Serum creatinine criteria |
| 1 | 1.5-1.9 times baseline |
| OR | |
| ≥ 26.5 5 μmol/l (0.3 mg/dl) increase within 48 hoursa | |
| 2 | 2.0-2.9 times baseline |
| 3 | ≥ 3.0 times baseline |
| OR | |
| Increase in serum creatinine to ≥ 354 μmol/l (4.0 mg/dl)b | |
| OR | |
| Initiation of renal replacement therapy |
| DMFT component | Disabledmean ± SD | Normalmean ± SD | t-value | df | P value |
| Decayed (D) | 0.64 ± 1.32 | 1.06 ± 1.40 | 2.33 | 234 | 0.02 |
| Missing (M) | 0.68 ± 2.23 | 0.03 ± 0.21 | 3.2 | 234 | 0.002 |
| Filled (F) | 0.14 ± 0.72 | 0 | 2.1 | 234 | 0.037 |
| Decayed (d) | 0.08 ± 0.38 | 0 | 2.35 | 234 | 0.019 |
| Filled (f) | 0 | 0 | 0 | 0 | — |
| Characteristic | VA | FFS | ||
| OR (95% CI) | p-value | OR (95% CI) | p-value | |
| Comorbidity | ||||
| Unadjusted | 0.78 (0.61, 1.00) | 0.04 | 1.08 (0.82, 1.42) | 0.59 |
| Adjusted | 0.76 (0.58, 1.00) | 0.045 | 1.09 (0.82, 1.44) | 0.57 |
| Age (≥ 70 years) | ||||
| Unadjusted | 0.98 (0.79, 1.23) | 0.88 | 0.97 (0.80, 1.18) | 0.76 |
| Adjusted | 1.08 (0.85, 1.36) | 0.54 | 0.96 (0.78, 1.17) | 0.67 |
| Race (white) | ||||
| Unadjusted | 0.80 (0.49, 1.31) | 0.39 | 1.12 (0.61, 2.08) | 0.72 |
| Adjusted | 0.83 (0.51, 1.37) | 0.47 | 1.12 (0.60, 2.09) | 0.72 |
| Factors | Categories | No. of patients (%) | P value |
| Gender | Female | 465(27.1) | 0.301 |
| Male | 1250(72.9) | ||
| age | 57.5 ± 10.9 | <0.001 | |
| Past medical history | No | 1258(73.4) | 0.022 |
| Yes | 457(26.6) | ||
| Family history of gastric cancer | No | 1431(83.4) | 0.431 |
| Yes | 284(16.6) | ||
| Location of tumor | Lower third | 1086(63.3) | <0.001 |
| Middle third | 281(16.4) | ||
| Upper third | 193(11.3) | ||
| Whole stomach | 155(9.03) | ||
| Eradicative degree of surgery | Utterly | 809(47.8) | <0.001 |
| Relatively | 473(27.6) | ||
| Palliative | 433(25.2) | ||
| Tumor size(mm) | <40 | 364(21.2) | <0.001 |
| ≥40 | 1315(78.8) | ||
| Stage | I | 301(17.5) | <0.001 |
| II | 425(24.8) | ||
| III | 497(29.0) | ||
| IV | 492(28.7) | ||
| Combined evisceration | No | 1323(77.1) | <0.001 |
| Yes | 392(22.9) | ||
| Histologic grade | Well differentiated | 521(30.3) | <0.001 |
| Moderately differentiated | 253(14.8) | ||
| Poorly differentiated | 941(54.9) | ||
| Depth of invasion | T1 | 145(8.5) | <0.001 |
| T2 | 879(51.3) | ||
| T3 | 549(32.0) | ||
| T4 | 142(8.3) | ||
| Lymph node status | N0 | 629(36.7) | <0.001 |
| N1 | 717(41.8) | ||
| N2 | 272(15.9) | ||
| N3 | 97(5.7) |
| Method | Algorithm | False positive rate | False negative rate |
| MEMSAT-SVM | SVM | 0.00% | 0.44% |
| MEMSAT3 | NN | 0.50% | 0.50% |
| SOSUI | Hydrophobicity analysis | 0.33% | 1.10% |
| OCTOPUS | NN + HMM | 0.00% | 2.51% |
| PHOBIUS | HMM | 2.72% | 0.44% |
| Denmark | Norway | Sweden | |
| TKA | |||
| Mean | 146 | 70 | 143 |
| Median | 132 | 53 | 105 |
| Range | 1–345 | 1–275 | 1–527 |
| UKA | |||
| Mean | 35 | 19 | 30 |
| Median | 29 | 16 | 24 |
| Range | 1–85 | 1–57 | 1–104 |
| Genotypes | Azoospermic men (n=108) | Controls (n=119) | p-value | OR (CI; 95%) |
| AA | 19 (17.6) | 51 (42.8) | ||
| AG | 52 (48.2) | 22 (38.7) | 0.149 | 1.47 (0.869-2.498) |
| GG | 37 (34.3) | 46 (18.5) | 0.007 | 2.298 (1.248-4.229) |
| Variable | Univariate analysis | Multivariate analysis | ||
| HR (95% CI) | p-value | HR (95% CI) | p-value | |
| Age (Years) | 1.04 (0.98-1.11) | 0.23 | 1.02 (0.95-1.09) | 0.68 |
| PSA | 1.02 (1.01-1.03) | <0.0001 | 1.01 (1.00-1.03) | 0.10 |
| Gleason | ||||
| <7 | Reference | <0.0001 | Reference | 0.02 |
| 7 | 2.97(1.52-5.82) | 0.002 | 2.28 (1.12-4.65) | 0.02 |
| >7 | 6.27 (2.59-15.22) | <0.0001 | 3.78 (1.43-9.99) | 0.04 |
| pT stage | ||||
| T2 | Reference | <0.0001 | Reference | 0.42 |
| T3 | 2.01 (1.10-3.69) | 0.03 | 1.06 (0.54-2.10) | 0.86 |
| T4 | 4.63 (2.08-10.33) | <0.0001 | 1.77 (0.72-4.39) | 0.21 |
| Surgical margin | 2.97 (1.71-5.16) | <0.0001 | 2.03 (1.09-3.78) | 0.03 |
| ERG expression | 0.91 (0.51-1.61) | 0.74 | 0.88 (0.47-1.64) | 0.70 |
| p-mTOR | 0.36 (0.20-0.66) | 0.001 | 0.45 (0.24-0.84) | 0.01 |
| Parameter | HR | 95 % CI | P |
| Disease-free survival: Cox regression model | |||
| TNM stage | 0.06 | ||
| III-IV (vs. I-II) | 2.528 | 1.299–4.921 | |
| Tumor differentiation | 0.021 | ||
| Poor (vs. Well/moderate) | 1.785 | 1.089–2.925 | |
| AREG expression | 0.168 | ||
| Positive (vs. Negative) | 1.418 | 0.863–2.331 | |
| AREG/EGFR coexpression | 0.587 | ||
| Negative (vs. Positive) | 0.922 | 0.687–1.237 | |
| Overall survival: Cox regression model | |||
| Tumor size | 0.485 | ||
| T3-4 (vs. T1-2) | 1.24 | 0.677–2.271 | |
| TNM stage | 0.03 | ||
| III-IV (vs. I-II) | 2.25 | 1.081–4.684 | |
| Tumor differentiation | 0.004 | ||
| Poor (vs. Well/moderate) | 2.125 | 1.277–3.537 | |
| Resection margins | 0.045 | ||
| Positive (vs. Negative) | 1.84 | 1.277–3.537 | |
| Lymph node metastasis | 0.417 | ||
| Yes (vs. No) | 1.233 | 0.743–2.048 | |
| AREG expression | 0.03 | ||
| Positive (vs. Negative) | 1.822 | 1.058–3.137 |
| Comparison | CTCs | ctDNA | Exosomes |
| Origin | Includes apoptotic tumor and viable tumor cells from a primary or metastatic tumor [71, 73]. | Includes cfDNA, from the viable tumor cells or from CTCs [17, 219, 221, 224, 225]. | Includes DNA, proteins, lipids, RNAs and metabolites and are discharged by all cells including tumor cells [333, 336, 352, 355–357]. |
| Bio-banked samples used for study | Frozen plasma, urine and other biofluids cannot be used for study of CTCs [116]. | Frozen plasma, urine and other biofluids can be used for study of cfDNA [116, 260]. | Frozen plasma, urine and other biofluids can be used for study of exosomes [260]. |
| Stability | Unstable [114, 116, 117] | Stable [116] | Very stable [334] |
| Genetic materials | DNA and RNA [117, 122, 123] | DNA [17, 219, 221] | DNA and RNA [355, 357, 359–361] |
| Analytic Techniques | CellSearch [84, 148–150, 180, 182, 190], Microfluidic [187, 181], SE-iFISH [186], MetaCell [184], Immunofluorescence [181, 185, 188], ScreenCell [185], ISET Test [188, 190] etc. | dPCR [289], CAPP-Seq [293], TAM-Seq [276], ddPCR [290, 307, 308, 310], COLD-PCR [167], Safe-Seq [294], NGS [299, 308–310], BEAMing [291, 292], WGA [297, 298] etc. | Ultracentrifugation [387, 386, 389–391, 393], ExoChip [392], Precipitation [386], Size-based isolation [386], Immunoaffinity-based isolation [386], Microfluidics-based isolation etc [386]. |
| Morphological study and functional study of tumor cells ex vivo | Yes [128, 129, 188, 190, 206, 210, 213, 214] | No | No |
| Analysis of protein location on tumor cells | Yes [101, 102] | No | No |
| Identification of mutations | Yes [165, 185, 187] | Yes [306, 319] | Yes [387, 390, 393] |
| Identification of epigenetic changes | Yes [414, 415] | Yes [322–325] | Yes [357] |
| Analysis of RNA transcription profiles | Yes [157, 192] | No | Yes [359–361, 367] |
| Proteomics Analysis | Yes [157] | No | Yes [367, 387, 392] |
| Analysis tumor heterogeneity | Yes [206] | Yes [332] | No |
| Use as drug delivery vehicle | No | No | Yes [406, 410] |
| Label | Start | Name | Function | References | |
| ldRNA | BSU_misc_RNA_3 | 119855 | ldlJ | Ribosomal protein L10 leader mRNA sequence | 26101249 |
| suRNA | BSU_misc_RNA_7 | 486092 | swaO | ATP‐, cyclic di‐AMP‐sensing riboswitch | 25086507, 25086509 |
| CDS | BSU04785 | 528025 | cmpA | Factor allowing degradation of SpoIVA by ClpXP | 26387458 |
| suRNA | BSU_misc_RNA_65 | 532642 | sncO | ICEBs1 mobile element: conserved small untranslated RNA | 20525796, 22505685 |
| suRNA | BSU_misc_RNA_66 | 559610 | sncZ | No identified function: borders undefined | 20525796 |
| suRNA | BSU_misc_RNA_8 | 626446 | aswA | Adenine riboswitch | 25573585 |
| CDS | BSU09958 | 1071402 | sscA | Spore assembly and germination protein | 21670523 |
| CDS | BSU09959 | 1071613 | sscB | Spore assembly and germination protein | 21670523 |
| suRNA | BSU_misc_RNA_67 | 1233405 | roxS | Small regulatory RNA (NO regulated) | 28436820 |
| CDS | BSU12815 | 1348356 | spoIISC | Three component toxin/antitoxin/antitoxin SpoIISABC, antitoxin C | 25039482, 26300872, 27294956 |
| Riboswitch | BSU_misc_RNA_16 | 1376328 | guwA | Guanidinium riboswitch | 28212758 |
| Riboswitch | BSU_misc_RNA_68 | 1395622 | swmG | Magnesium riboswitch (modest affinity) | 28455443 |
| Riboswitch | BSU_misc_RNA_87 | 1410633 | mnrW | Manganese ion riboswitch | 25794618, 25794619 |
| Riboswitch | BSU_misc_RNA_88 | 1457005 | gswA | Riboswitch regulating ptsGHI expression via GlcT binding | 15155854, 22750856 |
| suRNA | BSU_misc_RNA_69 | 1483557 | fsrA | Regulatory RNA controlling iron‐dependent metabolism | 24576839 |
| suRNA | BSU_misc_RNA_70 | 1534070 | srrA | Small regulatory RNA and messenger RNA (arginine metabolism) | 27449348 |
| CDS | BSU14629 | 1534120 | rgpA | Regulator of GapA synthesis | 27449348 |
| CDS | BSU15140 | 1580622 | rsmH | 16S rRNA m4C1402 methyltransferase | 27711192 |
| suRNA | BSU_misc_RNA_89 | 1780554 | surX | sigW‐dependent | 23155385 |
| CDS | BSU17845 | 1916955 | yzzP | No identified function, present in some S. pneumoniae strains | 27144405 |
| CDS | BSU18978 | 2069883 | bsrE | Type I toxin (BsrE/AsrE) | 26940229 |
| suRNA | BSU_misc_RNA_74 | 2070115 | asrE | Small regulatory antitoxin RNA, toxin‐antitoxin type I system (BsrE/AsrE) | 26940229 |
| CDS | BSU19749 | 2146053 | yoyG | Putative toxin of a type I toxin family (sporulation operon) | 20156992, 21670523 |
| fCDS | BSU20049 | 2160397 | nrdFBc | Phage SP beta nucleoside diphosphate reductase minor subunit (C‐terminus) | 23391036 |
| fCDS | BSU20051 | 2161778 | nrdFBn | Phage SP beta nucleoside diphosphate reductase minor subunit (N‐terminus) | 23391036 |
| suRNA | BSU_ncRNA_1 | 2208880 | aimX | Small RNA controlling lysogeny of phage SPbeta | 28099413 |
| CDS | BSU20850 | 2208980 | aimP | Arbitrium lysis /lysogeny regulatory peptide (GMPRGA) | 28099413 |
| CDS | BSU20860 | 2210154 | aimR | Arbitrium peptide sensor regulator | 28099413 |
| asRNA | BSU_misc_RNA_90 | 2219849 | apbT | Antisense RNA of Toxin SpbT | 24576839 |
| CDS | BSU21000 | 2219960 | spbT | Toxin | 24576839 |
| suRNA | BSU_misc_RNA_91 | 2472880 | pswI | Proline T‐box riboswitch upstream of porI | 21233158 |
| suRNA | BSU_misc_RNA_82 | 2773783 | surF | Expressed under sporulation conditions | 25790031 |
| ldRNA | BSU_misc_RNA_43 | 2855915 | ldlU | Ribosomal protein L21 leader mRNA sequence | 27381917 |
| CDS | BSU28475 | 2910746 | lysCB | Beta subunit of aspartokinase II | 1980002 |
| ldRNA | BSU_misc_RNA_47 | 2953550 | ldlT | Ribosomal protein L20 leader mRNA sequence | 23611891 |
| ldRNA | BSU_misc_RNA_93 | 3035589 | ldsD | Ribosomal protein S4 leader mRNA sequence | 23611891 |
| asRNA | BSU_ncRNA_2 | 3335545 | auzJ | Putative antisense RNA for YuzJ putative toxin (toxin I signature) | 20156992, 21670523 |
| suRNA | BSU_misc_RNA_94 | 4169919 | mswM | Manganese riboswitch | 25794618, 25794619 |
| Characteristic | Beijing | Chongqing | Guangzhou | Total | ||||
| n | % | n | % | n | % | n | % | |
| Number of children | 10,372 | 42.70% | 9,846 | 40.53% | 4,072 | 16.77% | 24,290 | |
| Response rate | 98.60% | 97.21% | 90.90% | 96.62% | ||||
| Gender | ||||||||
| Male | 5,455 | 52.59% | 5,258 | 53.40% | 2,195 | 53.90% | 12,908 | 53.14% |
| Female | 4,917 | 47.41% | 4,588 | 46.60% | 1,877 | 46.10% | 11,382 | 46.86% |
| Age (mean ± SD) | 7.63 ± 4.04 | 8.74 ± 2.72 | 8.39 ± 3.53 | 8.20 ± 3.51 |
| Top 16 most significant in order | Chemical shift (ppm) | I/II stage of CRC vs healthy controls | Related metabolomic pathway | ||
| VIPa | p-valueb | Variations vs HC | |||
| Choline | 3.19(s) | 2.25 | 0.000 | ↓ | Choline metabolism, Lipid metabolism |
| Phenylalanine | 3.19(m)3.98(dd) | 2.251.43 | 0.0000.004 | ↓↓ | Amino acid metabolism, Phenylalanine metabolism |
| Asparagine | 2.80(dd) | 1.90 | 0.000 | ↓ | Urea metabolism, Amino acid metabolism |
| Isocitrate | 3.98(d) | 1.84 | 0.005 | ↓ | TCA cycle |
| Cysteine | 3.97(dd)3.06(m) | 1.841.70 | 0.0030.000 | ↓↓ | Amino acid metabolism, Glutamate Metabolism, Glutathione Metabolism |
| Hippurate | 3.96(d) | 1.84 | 0.005 | ↓ | Gut microflora metabolism |
| Dimethyl sulfone | 3.138(s) | 1.72 | 0.000 | ↓ | Gut microflora metabolism, Endogenous methanethiol metabolism |
| Creatinine | 3.03(s)4.05(s) | 1.701.43 | 0.0070.003 | ↓↓ | Urea metabolism, Creatinine metabolism |
| Alanine | 1.46(d) | 1.67 | 0.017 | ↓ | Amino acid metabolism, Gluconeogenesis |
| Methylamine | 2.59(s) | 1.12 | 0.018 | ↓ | Gut microflora metabolism, Disulfiram Pathway |
| Homocysteine | 2.14(m) | 1.76 | 0.014 | ↑ | Amino acid metabolism, Methionine metabolism |
| Glutamine | 2.12(m)3.76(t) | 1.761.53 | 0.0010.017 | ↑↑ | Glutaminolysis, TCA cycle |
| cis-Aconitate | 3.43(d) | 1.64 | 0.043 | ↑ | TCA cycle, Glyoxylate, Dicarboxylate metabolism |
| Acetoacetate | 2.27(s)3.43(s) | 1.591.64 | 0.0090.043 | ↑↑ | Fatty acid metabolism, TCA cycle |
| trans-Aconitate | 3.74(s) | 1.54 | 0.019 | ↑ | TCA cycle |
| Guanidoacetate | 3.78(s) | 1.53 | 0.017 | ↑ | Urea metabolism |
| Carbon | 1 | 2 | 3 | 8 | 9 | 10 |
| 1 | 158.0 (s) | 161.2 (s) | 160.0 (s) | 162.1 (s) | 160.0 (s) | 159.3(s) |
| 2 | 113.5 (d) | 94.3 (d) | 92.7 (d) | 118.2 (s) | 117.5 (s) | 160.2 (s) |
| 3 | 152.6 (s) | 162.4 (s) | 161.3 (s) | 166.5 (s) | 166.4 (s) | 166.5 (s) |
| 4 | 104.8 (d) | 90.7 (d) | 130.2 (s) | 123.0 (s) | 122.1 (s) | 131.2 (s) |
| 4a | 143.3 (s) | 140.7 (s) | 141.2 (s) | 139.3 (s) | 139.0 (s) | 124.8 (s) |
| 5a | 144.0 (s) | 140.7 (s) | 141.3 (s) | 139.3 (s) | 140.2 (s) | 133.2 (s) |
| 5 | 145.1 (s) | 104.4 (d) | 146.2 (s) | 115.0 (d) | 116.1 (d) | 114.5 (d) |
| 6 | 143.3 (s) | 144.0 (s) | 119.8 (d) | 131.2 (d) | 131.3 (d) | 131.4 (d) |
| 7 | 118.3 (d) | 117.2 (d) | 143.1 (s) | 123.0 (d) | 123.0 (d) | 123.6 (d) |
| 8 | 162.3 (d) | 126.9 (d) | 117.2 (d) | 124.0 (d) | 124.1 (d) | 126.8 (d) |
| 8a | 115.6 (s) | 120.4 (s) | 121.5 (s) | 121.5 (s) | 121.6 (s) | 122.1 (s) |
| 9 | 178.2 (s) | 180.8 (s) | 181.1 (s) | 177.2 (s) | 178.3 (s) | 181.6 (s) |
| 9a | 104.7 (s) | 108.2 (s) | 108.1 (s) | 114.9 (s) | 114.9 (s) | 116.2 (s) |
| OMe | 57.5 (q) | 56.4 (q) | 60.9 (q) | 62.8 (q) | - | - |
| 59.3 (q) | - | - | - | - | - | |
| 61.9 (q) | - | - | - | - | - | |
| N-Me | - | - | 34.3 (q) | 30.5 (q) | 31.5 (q) | 31.7 (q) |
| 2’ | - | - | - | 73.4 (s) | 73.4 (s) | 72.3 (s) |
| 2’Me | - | - | - | 24.4 (q) | 25.0 (q) | 24.7 (q) |
| 26.1 (q) | 26.2 (q) | 26.0 (q) | ||||
| 3’ | - | - | - | 28.1 (t) | 28.2 (t) | 28.1 (t) |
| 4’ | - | - | - | 79.6 (d) | 78.6 (d) | 92.3 (d) |
| Group | Mean ± SD | P value |
| A | 77.17±1.00 | <0.001 |
| B | 76.99±.65 | <0.001 |
| C | 78.31±1.22 | <0.001 |
| Characteristic | HIV infected patients | Normal controls |
| Subject no. | 32 | 35 |
| Age (years, mean ± SD) | 34 ± 6 | 36 ± 6 |
| Male (No, %) | 15 (46.9%) | 15 (42.9%) |
| Han Ethnic (No, %) | 32 (100%) | 35 (100%) |
| CD4 (cells/μL, mean ± SD) | 331 ± 235 | N/A |
| VL [log copies/mL (mean ± SD)] | 4.15 ± 1.09 | N/A |
| Time since diagnosis (weeks, mean, range) | 65 (1–336) | N/A |
| Model mechanism | Symbol | Mathematical expressions |
| First-order decay (n=1) | F1 | (1–α) |
| Second-order decay (n=2) | F2 | (1– α)2 |
| Third-order decay (n=3) | F3 | 0.5 · (1– α)3 |
| Avrami-Erofeev (n=2) | A2 | 2 · (1– α) · [–ln(1– α)]0.5 |
| Preamble | |
| These recommendations are relevant to all practitioners and organizations communicating the new Canadian Physical Activity Guidelines for Youth. These recommendations should be used to create a clear understanding of the new Canadian Physical Activity Guidelines for Youth and to construct and to deliver messages that promote achievement of the guidelines. | |
| Recommendations | |
| Target Audience | Messages should separately target younger youth (12-14 yrs) and their parents and older youth (15-17 yrs) and their parents. |
| Clarification Messages | Clarification messages should: a) provide concise and clear descriptions of the guidelines and physical activity, b) define different levels of physical activity intensity (e.g., vigorous, vs. moderate), c) identify physical activity opportunities, d) include information about where to access more information about physical activity, e) indicate that science has evolved since the release of the old guidelines and that the new guidelines reflect latest evidence about physical activity, f) address the semantic differences between the old and new guidelines (e.g., up to 90 minutes vs. at least 60 minutes), and g) provide a wide variety of examples of physical activity – from active living to sport. |
| Motivational Messages | Motivational messages should emphasize a) parents’ pivotal role in encouraging and supporting their youth’s physical activity, b) a variety of benefits that physical activity offers including emotional, developmental, physical and academic benefits, c) that physical activity can be a collective-social movement that promotes community, active living and the environment, d) the importance of planning physical activity by parents and youth, e) strategies for overcoming barriers to physical activity, and f) empowering youth to choose how they will meet the guidelines. |
| Examples | |
| 60 minutes every day! As a parent, you can help your teen get there. | |
| Move your teen to move more. | |
| Life looks better with physical activity. | |
| Pick a time. Pick a place. Move your teens to move more. | |
| Pick a time. Pick a place. How you want to get active is up to you! | |
| Plan ahead for roadblocks! | |
| Expand your horizons! How you want to get active is up to you! | |
| Channels of Delivery | Messages should be disseminated to parents through websites, mass media campaigns featuring celebrities, magazines and news articles, and smart phone applications. |
| Messages should be disseminated to youth through websites, promotional materials within their school, public service announcements featuring celebrities, social media, smart phone applications, and community organizations and events. |
| Univariable | Multivariable | |||
| Variable | OR [95 % CI] | p-value | OR [95 % CI] | p-value |
| Age (years) | ||||
| 15 | Ref | |||
| 16 | 1.1 (0.5-2.6) | 0.808 | 0.81 (0.29-2.24) | 0.685 |
| 17 | 1.5 (0.7-3.3) | 0.328 | 1.39 (0.57-3.43) | 0.469 |
| 18 | 1.5 (0.7-3.2) | 0.320 | 1.65 (0.71-3.85) | 0.243 |
| Sex | ||||
| Female | Ref | |||
| Male | 0.6 (0.3-1.0) | 0.044 | 0.35 (0.18-0.73) | 0.004 |
| Setting | ||||
| Rural | Ref | |||
| Urban | 1.7 (1.1-3.2) | 0.025 | 2.21 (1.21-4.05) | 0.010 |
| Education Level | ||||
| No schooling | Ref | |||
| Primary | 0.4 (0.1-1.9) | 0.264 | 0.28 (0.06-1.26) | 0.098 |
| Secondary | 0.4 (0.1-1.6) | 0.175 | 0.31 (0.07-1.32) | 0.113 |
| Tertiary | 1.9 (0.2-22.8) | 0.602 | 1.93 (0.16-22.83) | 0.603 |
| Marital status | ||||
| Never married | Ref | |||
| Currently or living as married | 1.4 (0.6-3.1) | 0.407 | 1.91 (0.84-4.32) | 0.121 |
| Divorced or separated | 4.4 (0.6-33.7) | 0.156 | 6.0 (0.77-46.21) | 0.087 |
| Employment status | ||||
| Unemployed | Ref | |||
| Employed | 1.5 (0.4-6.8) | 0.564 | 1.0 (0.13-7.56) | 0.989 |
| Pupil/Student | 0.4 (0.2-0.6) | 0.000 | 0.33 (0.17-0.63) | 0.001 |
| Wealth Quintile | ||||
| Lowest | Ref | |||
| Second lowest | 1.7 (0.6-5.0) | 0.334 | 1.8 (0.3-3.9) | 0.095 |
| Middle | 2.3 (0.8-6.5) | 0.100 | 2.3 (0.3-4.4) | 0.026 |
| Fourth | 2.0 (0.7-5.7) | 0.207 | 1.8 (0.3-3.9) | 0.085 |
| Highest | 1.5 (0.5-4.4) | 0.461 | 2.0 (0.0-4.1) | 0.055 |
| Gene | Variant | Position | OR | Common/Rare | Domain | Variant domain effect | Effect on AP | Ref |
| C3 | R102G | 19:6718387 | 1.7–2.6 | Common | Macroglobulin 1 | Decreased binding efficiency of C3b to its inhibitor CFH decreasing CFH’s cofactor activity | Increased AP | [20, 65] |
| C3 | P314L | 19:6713262 | 1.5 | Common | Macroglobulin 3 | Decreased binding efficiency of C3b to its inhibitor CFH decreasing CFH’s cofactor activity | Increased AP | [65] |
| C3 | K155Q | 19:6718146 | 2.8–3.8 | Rare | Macroglobulin 2 | Reduces binding to FH and C3b proteolytic cleavage by CFI | Increase C3 convertase production | [59, 65] |
| CFB | R32Q | 6:31914180 | 0.32 | Common | Ba | Reduced affinity for C3b and reduced hemolytic activity | Decrease formation of C3 convertase; reduced AP | [130] |
| CFB | L9H | 6:31914024 | 0.37 | Common | Signal peptide | Affects secretion of CFB | Decrease formation of C3 convertase; reduced AP | [12] |
| CFH | Y402H | 1:196659291 | 2.45–5.57 | Common | Complement control protein 7 | Affects binding to GAG heparin sulfate, sialic acid, and C-reactive protein | Reduces ability of CFH to degrade C3: increased AP | [131] |
| CFH | R1210C | 1:196716375 | 23.11 | Rare | Complement control protein 20 | Defective binding to C3b, C3d, and heparin | Impaired CFH attachment to host surfaces; reduces AP regulation | [58] |
| CFH | R53C | 1:196642206 | Rare | Complement control protein 1 | Reduced accelerating activity for AP C3 convertase | Altered CFH-mediated cofactor activity or decay-accelerating activity; increased AP | [63] | |
| CFH | D90G | 1:196643011 | Rare | Complement control protein 2 | Alters CFI cofactor activity | Decreased cofactor-mediated inactivation; increased AP | [63] | |
| CFH | I62V | 1:196642233 | 1.95–2.79 | Common | Complement control protein 2 | Binds more efficiently to C3b | Enhanced cofactor activity and increased formation of iC3b; reduced AP | [63] |
| CFH | N1050Y | 1:196712596 | 0.4 | Common | Complement control protein 18 | Possibly affects GAG and sialic acid binding | Increased AP | [62] |
| CFHR1/3 | CFHR1/3del | 0.29 | Common | n/a | n/a | Reduces cofactor activity for CFI and inhibits C5 convertase; reduced AP | [13] [132–135] | |
| CFI | G119R | 4:110685820 | 22.2 | Rare | Scavenger receptor cysteine-rich | Perturbs interdomain packing and stability of CFI | Diminished ability to degrade C3b; increased formation of C5 convertase; increased AP | [19] |
| CFI | G188A | 4:110682768 | Rare | Scavenger receptor cysteine-rich | Perturbs interdomain packing and stability of CFI | Diminished ability to degrade C3b; increased formation of C5 convertase; increased AP | [19] | |
| C9 | P167S | 5:39331894 | 2.2 | Rare | Membrane attack complex/perforin | Alters oligomerization and possibly inhibits C9's lytic activity | Affects binding with CD59; alters pore formation | [59] |
| Alcohol consumption | MTHFR genotype | Cases n (%) | Controls n (%) | Age-adjusted OR (95% CI) |
| Low | CC | 3 (8) | 29 (20) | 1.00 (ref) |
| Low | CT + TT | 5 (14) | 39 (27) | 1.25 (0.28–5.65) |
| High | CC | 14 (38) | 31 (21) | 4.43 (1.15–17.05) |
| High | CT + TT | 15 (41) | 47 (32) | 3.10 (0.83–11.65) |
| p-interaction (multiplicative) | 0.51 | |||
| p-interaction (additive) | 0.58 |
| Variable | Women alive (0) (n)% | Women dead (1) (n)% | P-value |
| Overall (n = 42,703) | (n = 39,605) 92.75 | (n = 3,098) 7.25 | |
| Age in years at entry | <0.001 | ||
| 15–19 | (18,220) 46.0 | (491) 15.85 | |
| 20–24 | (6,174) 15.59 | (615) 19.85 | |
| 25–29 | (4,722) 11.92 | (655) 21.14 | |
| 30–34 | (3,579) 9.04 | (534) 17.24 | |
| 35–39 | (2,895) 7.31 | (402) 12.98 | |
| 40–44 | (2,346) 5.92 | (293) 9.46 | |
| 45–49 | (1,669) 4.21 | (108) 3.49 | |
| Area of residence | <0.001 | ||
| Rural | (22,737) 57.4 | (1,802) 58.17 | |
| Urban | (4,023) 10.16 | (142) 4.58 | |
| Peri-urban | (12,753) 32.20 | (1,154) 37.25 | |
| Migration status | <0.001 | ||
| Never moved | (11,495) 29.02 | (1,314) 42.41 | |
| Internal only | (3,982) 10.05 | (273) 8.81 | |
| External only | (7,237) 18.27 | (606) 19.56 | |
| Internal and external | (16,891) 42.65 | (905) 29.21 | |
| Minimum HSE class index | <0.001 | ||
| Upper 20% | (4,568) 12.73 | (225) 7.59 | |
| Middle 40% | (12,064) 33.61 | (1,007) 33.96 | |
| Lower 40% | (19,263) 53.66 | (1,733) 58.45 | |
| Ever married | 0.015 | ||
| No | (32,752) 82.7 | (2,615) 84.41 | |
| Yes | (6,853) 17.3 | (483) 15.59 | |
| Ever employed | 0.353 | ||
| No | (29,701) 74.99 | (2,300) 74.24 | |
| Yes | (9,904) 25.01 | (798) 25.76 | |
| Highest level of education | <0.001 | ||
| More than 8 years | (24,647) 71.88 | (1,469) 62.25 | |
| Less than 8 years | (8,083) 23.57 | (742) 31.44 | |
| No school | (1,559) 4.55 | (149) 6.31 | |
| Self-reported minimum general health | <0.001 | ||
| Good | (17,095) 79.68 | (770) 69.43 | |
| Fair | (3,808) 17.75 | (253) 22.81 | |
| Poor | (5,51) 2.57 | (86) 7.75 | |
| Woman HIV status | <0.001 | ||
| HIV tested and negative | (9,532) 24.07 | (117) 3.78 | |
| HIV tested and positive | (4,645) 11.73 | (532) 17.17 | |
| Never tested | (25,428) 64.20 | (2,449) 79.05 | |
| Maximum parity (M, SD) | 1.79, 2.13 | 2.28, 2.06 | <0.001 |
| Pregnancy outcome summarized from maternity history | <0.001 | ||
| All live births | (22,005) 55.56 | (1,917) 61.88 | |
| ≥ 1 pregnancy was a still birth | (29,68) 7.49 | (317) 10.23 | |
| No outcome reported | (14,632) 36.94 | (864) 27.89 |
| Model | Fatal + non-fatal events | Fatal events | ||
| Women | Men | Women | Men | |
| Crude | 1.16 (1.04–1.29 | 1.05 (0.96–1.15) | 1.27(1.04–1.55) | 1.24 (1.02–1.50) |
| Adjusted* | 1.06 (0.95–1.17) | 0.96 (0.88–1.06) | 1.11 (0.91–1.35) | 1.09 (0.90–1.33) |
| Formulation | Hardness (kg/cm2) | Friability (%) | %Drug content | Disintegration time (sec.) |
| S1 | 3.6±0.17 | 0.61±0.10 | 98.99±0.3 | 67.4±1.2 |
| S2 | 3.7±0.11 | 0.67±0.11 | 99.29±0.7 | 38.5±1.8 |
| S3 | 3.3±0.15 | 0.65±0.11 | 99.45±0.11 | 42.1±1.3 |
| S4 | 3.8±0.11 | 0.63±0.15 | 99.75±0.15 | 30.2±1.5 |
| S5 | 3.5±0.12 | 0.62±0.09 | 99.89±0.12 | 14.4±1 |
| S6 | 3.2±0.10 | 0.60±0.16 | 99.25±0.13 | 71.2±1.5 |
| S7 | 3.9±0.08 | 0.62±0.13 | 99.76±0.11 | 69.3±1.7 |
| S8 | 3.5±0.16 | 0.62±0.16 | 99.69±0.10 | 52.8±1.2 |
| S9 | 3.6±0.15 | 0.63±0.11 | 99.88±0.09 | 48.6±1.4 |
| S10 | 3.8±0.14 | 0.62±0.12 | 99.92±0.11 | 38.7±1.3 |
| Peak torque (Nm) | Mean ± SD | Within | Between | All | P-value | 95% CI | SEM (%) ± | ||
| Session 1 | Session 2 | Session 3 | ICC (2–3) | ICC (1–2) | ICC | lower; upper | MDC (%) | ||
| Quadriceps right | |||||||||
| Concentric at 60os−1 | 229.4 ± 37.5 | 223.5 ± 33.9 | 224.5 ± 37.5 | .93 | .93 | .95 | 0.290 | 0.90; 0.98 | 3.6 ± 9.9 |
| Isometric | 257.8 ± 46.9 | 255.3 ± 55.7 | 245.9 ± 55.4 | .99 | .92 | .96 | 0.210 | 0.92; 0.98 | 4.2 ± 11.6 |
| Eccentric at 60os−1 | 303.0 ± 63.6 | 303.3 ± 66.7 | 298.4 ± 62.7 | .97 | .93 | .96 | 0.055 | 0.93; 0.98 | 4.1 ± 11.3 |
| Hamstrings right | |||||||||
| Concentric at 60os−1 | 125.0 ± 27.3 | 129.9 ± 29.6 | 129.7 ± 27.9 | .97 | .89 | .95 | 0.021 | 0.90; 0.98 | 4.9 ± 13.5 |
| Isometric | 138.1 ± 34.1 | 139.9 ± 33.8 | 131.1 ± 33.5 | .99 | .93 | .96 | 0.660 | 0.92; 0.98 | 4.8 ± 13.3 |
| Eccentric at 60os−1 | 171.5 ± 33.8 | 166.9 ± 40.9 | 162.4 ± 40.3 | .97 | .91 | .95 | 0.088 | 0.91; 0.98 | 5.1 ± 14.1 |
| Quadriceps left | |||||||||
| Concentric at 60os−1 | 219.4 ± 36.5 | 215.9 ± 38.0 | 213.8 ± 38.5 | .96 | .96 | .95 | 0.343 | 0.91; 0.98 | 3.8 ± 10.5 |
| Isometric | 236.0 ± 43.9 | 235.3 ± 46.5 | 235.3 ± 43.7 | .94 | .94 | .93 | 0.688 | 0.87; 0.97 | 4.8 ± 13.3 |
| Eccentric at 60os−1 | 267.8 ± 58.8 | 268.4 ± 59.9 | 271.8 ± 59.6 | .96 | .96 | .96 | 0.988 | 0.92; 0.98 | 4.4 ± 12.2 |
| Hamstrings left | |||||||||
| Concentric at 60os−1 | 129.3 ± 26.6 | 127.6 ± 25.9 | 130.0 ± 31.2 | .96 | .96 | .96 | 0.809 | 0.91; 0.98 | 4.8 ± 13.3 |
| Isometric | 129.8 ± 33.5 | 129.6 ± 31.2 | 127.7 ± 31.0 | .91 | .91 | .94 | 0.755 | 0.89; 0.97 | 5.7 ± 15.8 |
| Eccentric at 60os−1 | 162.2 ± 36.4 | 156.2 ± 33.7 | 161.8 ± 34.1 | .98 | .98 | .97 | 0.075 | 0.94; 0.99 | 3.5 ± 9.7 |
| Age < 65 (n = 43) | Age ≥ 65 (n = 23) | P Value | |||
| Mean | Std Dev | Mean | Std Dev | ||
| Volume | 1610.9 | 395.6 | 1677.6 | 434.6 | 0.61 |
| D98% | 48.9 | 1.8 | 48.8 | 1.6 | 0.50 |
| D2% | 53.9 | 1.5 | 53.9 | 1.3 | 0.61 |
| Median | 51.7 | 1.6 | 51.9 | 1.3 | 0.61 |
| Mean | 51.7 | 1.6 | 51.7 | 1.2 | 0.30 |
| Homogeneity index | 0.1 | 0.0 | 0.1 | 0.0 | 0.61 |
| Conformity index | 0.9 | 0.1 | 0.9 | 0.2 | 0.30 |
| Strain detected | |||
| Pathogen | Only by BC | Only by SeptiFast | Both methods |
| S.aureus (MSSA) | 0 | 3 | 3 |
| S.aureus (MRSA) | 2 | 0 | 4 |
| S.pneumoniae | 0 | 1 | 0 |
| Streptococcus spp. | 0 | 2 | 1 |
| Enterococcus faecalis | 0 | 1 | 0 |
| Enterococcus faecium | 2 | 0 | 0 |
| Enterobacter aerogenes/cloacae | 0 | 3 | 1 |
| Escherichia coli | 0 | 3 | 9 |
| Klebsiella pneumoniae/oxytoca | 1 | 5 | 1 |
| Pseudomonas aeruginosa | 1 | 4 | 1 |
| Candida albicans | 0 | 1 | 0 |
| Candida tropicalis | 0 | 1 | 1 |
| Sub-total | 6 | 24 | 21 |
| Not detectable by SeptiFast | 5 | 0 | 0 |
| Total | 11 | 24 | 21 |
| Negative binomial counts > 0 | Univariate | Multivariable | ||||
| Variable | IRR | 95 % CI | IRR | 95 % CI | ||
| No. of persons sleeping in house | 0.902 | 0.740 | 1.100 | – | – | – |
| No. of ITNs per house | 0.559* | 0.349* | 0.897* | – | – | – |
| IRS, ever | 0.902 | 0.440 | 1.851 | 1.039 | 0.444 | 2.433 |
| Closed eaves | 0.217 | 0.016 | 2.956 | 0.102* | 0.011* | 0.904* |
| Metal roof | 3.197 | 0.287 | 35.610 | – | – | – |
| Fire burned previous night | 0.810 | 0.252 | 2.608 | – | – | – |
| Open well | 2.229* | 1.078* | 4.608* | 2.257* | 1.068* | 4.766* |
| Rainy season | 1.420 | 0.714 | 2.824 | 1.000 | 0.360 | 2.776 |
| Within 3 km of Lake Mweru | 0.601 | 0.291 | 1.243 | 0.204* | 0.072* | 0.581* |
| Interaction: Season by inland/lakeside | 0.634 | 0.145 | 2.766 | 3.932* | 1.024a | 15.096* |
| Year | Authors | Age, gender | Concurrent malignancy (location) | Past history of recurrence | Diagnostic modality |
| 2015 | Jerraya H, et al. | 59, F | Insulinoma (pancreas) | NA | NA |
| 2015 | Jung SY, et al. | 11, F | Insulinoma (pancreas) | Non | US, CT, MRI |
| 2009 | Wheeler YY, et al. | 62, M | Renal cell carcinoma (right kidney) | Non | CECT |
| 2015 | Present case | 23, M | SCS (abdominal) | Abdominal | US, CECT, MRI |
| LOO AUC (SE) | Sensitivity | Specificity | Median number of peaks per LOO iteration | Mean number of peaks per LOO iteration (SD) | |
| Lymph node status | |||||
| Negative vs Positive | 0.95 (0.03) | 73.9 | 91.7 | 1 | 1 (0) |
| Histological subtype | |||||
| Squamous ca. vs adenoca. | 0.88 (0.05) | 88.2 | 59.0 | 1 | 1 (0) |
| Squamous ca. vs adsq ca. | 0.85 (0.06) | 84.6 | 100 | 4 | 3.8 (0.9) |
| Adenoca. vs adsq ca. | 0.94 (0.06) | 94.1 | 100 | 1 | 0.9 (0.3) |
| LVSI | |||||
| Negative vs Positive | 0.81 (0.06) | 78.1 | 73.1 | 1 | 1 (0) |
| Recurrence | |||||
| Negative vs Positive | 0.92 (0.04) | 79.2 | 90.0 | 3 | 3 (0) |
| Annual expenses ($) | |
| Annual cost of mobile health clinic | 565,700 |
| Total annual visits | 4,848 |
| Total visits discounted by 20% | 3,878 |
| Cost per visit | 117 |
| Cost of preventable emergency department visit [9] | 923 |
| Cost avoided per mobile clinic visit | 806 |
| Annual projected costs avoided | 3,125,668 |
| Cohorts | TCGA | TCGA-sub | RT-qPCR | Ivshina | Schmidt | Symmans | Wang |
| N | 520 | 59 | 71 | 249 | 200 | 298 | 286 |
| Histological type | |||||||
| Ductal | 442 (85.0) | 51 (86.4) | 56 (78.9) | – | – | – | – |
| Lobular | 41 (7.9) | 3 (5.1) | 5 (7.0) | – | – | – | – |
| Mixed and others | 36 (6.9) | 5 (8.5) | 9 (12.7) | – | – | – | – |
| Tumour diameter | |||||||
| ≤2.0 cm | 133 (25.6) | 20 (33.9) | 39 (54.9) | 126 (50.6) | 112 (56.0) | – | – |
| >2.0 cm | 364 (70.0) | 38 (64.4) | 32 (45.1) | 123 (49.4) | 88 (44.0) | – | – |
| Regional lymph nodes | |||||||
| Negative | 253 (48.7) | 25 (42.4) | 34 (47.9) | 159 (63.9) | 200 (100) | 175 (58.7) | 286 (100) |
| Positive | 256 (49.2) | 34 (57.6) | 36 (50.7) | 81 (32.5) | 0 (0) | 112 (37.6) | 0 (0) |
| Distant metastasis | |||||||
| Negative | 491 (94.4) | 57 (96.6) | – | – | – | – | – |
| Positive | 15 (2.9) | 1 (1.7) | – | – | – | – | – |
| TNM stage | |||||||
| I | 89 (17.1) | 13 (22.0) | – | – | – | – | – |
| II | 290 (55.8) | 34 (57.6) | – | – | – | – | – |
| III | 110 (21.2) | 11 (18.6) | – | – | – | – | – |
| IV | 14 (2.7) | 1 (1.7) | – | – | – | – | – |
| Tumour grade | |||||||
| Grade 1 | – | – | 7 (9.9) | 68 (27.3) | 29 (14.5) | – | – |
| Grade 2 | – | – | 25 (35.2) | 126 (50.6) | 136 (68.0) | – | – |
| Grade 3 | – | – | 36 (50.7) | 55 (22.1) | 35 (17.5) | – | – |
| ER status | |||||||
| Negative | 117 (22.5) | 9 (15.3) | 18 (25.4) | 34 (13.7) | – | 0 (0) | 77 (26.9) |
| Positive | 396 (76.2) | 48 (81.4) | 52 (73.2) | 211 (84.7) | – | 298 (100) | 209 (73.1) |
| PR status | |||||||
| Negative | 176 (33.8) | 16 (27.1) | 22 (31.0) | – | – | – | – |
| Positive | 336 (64.6) | 41 (69.5) | 48 (67.6) | – | – | – | – |
| HER2 status | |||||||
| Negative | 361 (69.4) | 48 (81.4) | 60 (84.5) | – | – | – | – |
| Positive | 101 (19.4) | 10 (16.9) | 10 (14.1) | – | – | – | – |
| Triple-negative | |||||||
| True | 72 (13.8) | 7 (11.9) | 11 (15.5) | – | – | – | – |
| False | 448 (86.2) | 52 (89.1) | 60 (84.5) | – | – | – | – |
| PAM50 subtype | |||||||
| Basal-like | 96 (18.5) | 11 (18.6) | – | – | – | – | – |
| HER2-enriched | 58 (11.2) | 4 (6.8) | – | – | – | – | – |
| Luminal A | 231 (44.4) | 32 (54.2) | – | – | – | – | – |
| Luminal B | 127 (24.4) | 12 (20.3) | – | – | – | – | – |
| Normal-like | 8 (1.5) | 0 (0) | – | – | – | – | – |
| Primer | Gene | Sequence | Fragment size (bp) |
| rpoB-FS | TGGTCCGCTTGCACGAGGGTCAGA | ||
| rpoB | 758 | ||
| rpoB-RS | CAGGAAGGGAATCATCGCGG | ||
| katG-FS | TGCAGATGGGGCTGATCTACG | ||
| katG | ACCCATGTCTCGGTGGATCAG | 596 | |
| katG-RS | |||
| inhA-FS | ACATACCTGCTGCGCAAT | ||
| inhA | TCACATTCGACGCCAAAC | 400 | |
| inhA-RS |
| Toxo DB typea | No. of isolates | Designation |
| 9, (Chinese1) | 1 | TgDgCo4 |
| 10 (Type I) | 2 | TgCtCo 2, 7 |
| 14 | 6 | TgDgCo9,12,15,18; TgCkCo2;TgCtco14 |
| 18 | 3 | TgCtCo 12, 13; TgDgCo3 |
| 23 | 1 | TgDgCo19 |
| 28 | 2 | TgCtCo 1; TgCkCo5 |
| 29 | 5 | TgDgCo1,2,10,20; TgCkCo20 |
| 38 | 13 | TgCkCo6,8,10,12,13,15,21,23,24; TgCtCo 4,10,11; TgDgCo17 |
| 40 | 1 | TgCtCo5x |
| 44 | 3 | TgDgCo5,6,11 |
| 46 | 3 | TgDgCo8,14,16 |
| 61 | 2 | TgCtCo 5,6 |
| 62 | 2 | TgCtCo3,9 |
| 79 | 1 | TgDgCo13 |
| 101 | 1 | TgCtCo15 |
| 122 | 1 | TgDgCo7 |
| 128 | 1 | TgCtCo8 |
| 178 | 1 | TgCkCo4 |
| 179 | 2 | TgCkCo17,22 |
| 188 | 1 | TgCkCo9 |
| Region-based test result | Truth | ||
| True HA | True H0 | Total | |
| p-value < Threshold: reject null hypothesis | A | C | A + C |
| p-value ≥ Threshold: do not reject null hypothesis | B | D | B + D |
| Total | A + B | C + D |
| Informatively cued letter-parity task | Non-informatively cued letter-parity task | Informatively cued color-shape task | ||||
| Young | Older | Young | Older | Young | Older | |
| Hits | ||||||
| TS | 89 ± 7 | 67 ± 15 | 87 ± 6 | 67 ± 15 | 93 ± 6 | 73 ± 16 |
| TR | 88 ± 6 | 70 ± 15 | 88 ± 7 | 71 ± 13 | 94 ± 5 | 77 ± 15 |
| Errors | ||||||
| TS | 10 ± 7 | 29 ± 14 | 13 ± 6 | 31 ± 15 | 7 ± 6 | 26 ± 15 |
| TR | 12 ± 5 | 27 ± 13 | 11 ± 6 | 28 ± 12 | 5 ± 4 | 21 ± 13 |
| RT | ||||||
| TS | 769 ± 145 | 1095 ± 171 | 1016 ± 156 | 1311 ± 148 | 611 ± 129 | 1038 ± 188 |
| TR | 762 ± 147 | 1063 ± 158 | 997 ± 160 | 1282 ± 143 | 575 ± 110 | 1005 ± 229 |
| SC | ||||||
| 7 ± 53 | 32 ± 61 | 19 ± 62 | 28 ± 78 | 36 ± 41 | 33 ± 103 | |
| MC | ||||||
| 164 ± 109 | 309 ± 132 | 402 ± 109 | 510 ± 109 | 89 ± 84 | 338 ± 192 |
| Items | Cu NPs | Cu MPs | |
| Shape | Spherical | Spherical | |
| Primary sizea | 32.7 ± 10.5 nm | 25.3 ± 6.6 μm | |
| Hydrodynamic size (nm)b | pH 1.5 | n.a | n.a |
| pH 6.5 | 516 ± 116.9 | n.a | |
| pH 7.8 | 334 ± 128.3 | n.a | |
| Surface area (m2/g)c | 14.7 | 0.16 | |
| Zeta potential (mV)d | pH 1.5 | 25.5 ± 0.8 | n.a |
| pH 6.5 | 1.32 ± 1.2 | n.a | |
| pH 7.8 | −6.2 ± 0.2 | n.a |
| Category label | Observed average | Infit MNSQ | Outfit MNSQ | Structure calibration |
| 1 | -23.71 | 1.10 | 41.06 | None |
| 2 | -14.67 | 1.01 | .99 | -21.95 |
| 3 | -5.31 | 0.98 | .94 | -9.63 |
| 4 | .54 | 1.10 | 1.06 | 3.82 |
| 5 | 9.94 | 0.81 | .80 | 7.69 |
| 6 | 16.12 | .93 | .94 | 20.07 |
| β intercept (standardised coefficient) | P value | |
| Height | 0.094 | 0.48 |
| Weight | 0.003 | 0.98 |
| Fat% | 0.058 | 0.53 |
| Physical activity | 0.215 | <0.01 |
| Age of onset of diabetes | 0.16 | 0.09 |
| Duration of diabetes | −0.046 | 0.56 |
| HbA1c | −0.451 | <0.01 |
| Insulin dose | 0.20 | 0.07 |
| Calcium intake | 0.05 | 0.53 |
| 25(OH) vitamin D3 | −0.003 | 0.964 |
| Alkaline phosphatase | −0.19 | 0.09 |
| PTH | −0.026 | 0.71 |
| IGF-1 | 0.31 | <0.01 |
| Testosterone | 0.14 | 0.12 |
| SHBG | 0.11 | 0.24 |
| Parameter | Meaning | Value |
| kphr | Phosphorylation of RsbR | 0.1 / 1 |
| kdpr | Dephosphorylation of RsbR-P | 0.06 |
| kphs | Phosphorylation of RsbS | 0.4 |
| kdps | Dephosphorylation of RsbS-P | 1 |
| Ethnic Genotype | N | TC (mmol/l) | TAG (mmol/l) | HDL-C (mmol/l) | LDL-C (mmol/) | Apo A1 (g/l) | ApoB (g/l) | ApoA1/ApoB |
| Han | ||||||||
| CC | 566 | 5.23±1.37 | 1.14(0.86) | 1.68±0.43 | 2.92±1.00 | 1.35±0.27 | 0.89±0.23 | 1.59±0.49 |
| CT | 197 | 5.02±0.86 | 1.12(0.78) | 1.73±0.41 | 2.91±0.76 | 1.36±0.26 | 0.87±0.19 | 1.63±0.51 |
| TT | 102 | 4.92±0.9 | 0.98(0.70) | 2.00±1.14 | 2.72±0.70 | 1.40±0.27 | 0.82±0.21 | 1.82±0.60 |
| F | 4.073 | −0.064 | 14.725 | 1.974 | 2.021 | 4.750 | 8.280 | |
| P | 0.017 | 0.949 | 0.000 | 0.140 | 0.133 | 0.009 | 0.000 | |
| Mulao | ||||||||
| CC | 555 | 5.06±1.22 | 2.88(2.39) | 1.74±0.43 | 2.97±0.89 | 1.35±0.39 | 1.00±0.58 | 1.66±1.29 |
| CT | 230 | 4.95±1.16 | 2.86(2.31) | 1.83±0.55 | 2.87±0.87 | 1.32±0.48 | 1.07±0.71 | 1.64±0.85 |
| TT | 117 | 4.88±1.69 | 2.68(2.15) | 1.86±0.65 | 2.72±1.09 | 1.26±0.58 | 1.02±0.67 | 1.56±0.98 |
| F | 1.386 | −6.446 | 4.582 | 3.810 | 7.813 | 1.127 | 3.028 | |
| P | 0.251 | 0.000 | 0.010 | 0.023 | 0.000 | 0.324 | 0.049 |
| Sex | Age | Pituitary MRI | Internal carotid RMI | Other characteristics | Molecular studies | References | |
| 1 | N | N | Not specified (except for normal posterior pituitary). | Absence of ICA and carotid canal. | Not specified. | NP | [14] |
| 2 | M | 18 m | Pituitary hypoplasia. | Anomaly of right ICA. | TSH, GH, ACTH deficiency. Central diabetes insipidus. Possible hypogonadism. | NP | [13] |
| 3 | F | 5 m | Absence of anterior pituitary and ectopic pituitary posterior lobe. | Absence of right common carotid artery, right ICA, right anterior cerebral artery. | TSH, ACTH and GH deficiency. No evidence of diabetes insipidus. Genitalia were normal. Single central maxillary incisor. | NP | [7] |
| 4 | M | 23 year | Absence of anterior pituitary and ectopic pituitary posterior lobe. | Absence of right ICA and carotid canal and A1 segment of the right anterior cerebral artery. | Congenital microphthalmia with cataract and coloboma of the right eye, encephalocele. Hormonal substitution treatments not specified. | NP | [5] |
| 5 | M | 37 year | Absence of anterior pituitary. | Hypoplasia of right ICA and carotid canal. | Amblyopia of the left eye caused by an optic nerve coloboma, encephalocele. Hormonal substitution treatments not specified. | NP | [5] |
| 6 | F | 29 year | Pituitary hypoplasia and ectopic pituitary posterior lobe. | Absence of right ICA, carotid canal, and A1 segment of the right anterior cerebral artery. | TSH, ACTH, and GH deficiency. No evidence of diabetes insipidus. Hypogonadism. Chiari I malformation with syringomyelia. | NP | [9] |
| 7 | M | 5 year | Absence of anterior pituitary and ectopic pituitary posterior lobe. | Absence of left ICA and carotid canal, A1 segment of the left anterior cerebral artery and the anterior communicating artery. | Retrognathia, microphallus, and cryptorchidism. TSH, ACTH, GH deficiency, but no evidence of diabetes insipidus. Possibile hypogonadism. | NP | [10] |
| 8 | M | 11 year | Pituitary hypoplasia | Absence of left ICA and carotid canal; hypoplasia of A1 segment of left anterior cerebral artery | TSH, ACTH, GH deficiency. Central diabetes insipidus. Microphallus with possible hypogonadism. | NP | [6] |
| 9 | F | 10 year | Hypoplastic anterior pituitary, flat sella turcica, absent pituitary stalk | Agenesis of the left ICA and the left carotid canal | GH, TSH, gonadotropin deficiency. No evidence of diabetes insipidus. Born out of a consanguineous marriage. | No HESX1, LHX4, OTX2 mutations | [8] |
| 10 | F | 7 month | Adenohypophyseal hypoplasia with a lack of posterior pituitary hyperintensity | Absence of the left ICA | Desaturation episodes, recurrent respiratory infections. Short hands and feet. GH, ACTH and TSH deficiency. | 17q24.2 deletion | [3] |
| 11 | F | 2 year | Adenohypophyseal hypoplasia with a lack of posterior pituitary hyperintensity | Absence of the right ICA | GH, TSH, and gonadotropin deficiency. No clinical evidence of diabetes insipidus. | NP | [11] |
| 12 | M | 3 week | Absence of anterior pituitary with ectopic posterior pituitary | Absence of the left ICA and carotid canal | GH, TSH, ACTH and gonadotropin deficiency. Microphallus. | NP | [12] |
| 13 | M | 17 year | Adenohypophyseal hypoplasia with a lack of posterior pituitary hyperintensity | Agenesis of the left ICA | GH deficiency. No other pituitary deficiencies. No clinical evidence of diabetes insipidus. | Normal array-CGH | Our case |
| # | SET I (8-week-old) | Summary |
| 1 | Control diet (CD) | Peliosis, nuclear dysplasia and nuclear retreat. |
| 2 | CD + Quercetin | Small & large lymphoplasmacytic clusters. |
| 3 | CD + δ-Tocotrienol | Large lymphoplasmacytic (LP) cluster, Councilman body. |
| 4 | CD + Dexamethasone | Councilman body, nuclear retreat and dysplasia, microvesicular steatosis, large lymphoplasmacytic (LP) cluster, closed sinusoids, cytoplasmic condensation. |
| SET II (46-week-old) | Summary | |
| 5 | Control diet (CD) | LP clusters, nuclear Retreat and dysplasia, microvesicular steatosis. |
| 6 | CD + Quercetin | Coucilman body, nuclear dysplasia and nuclear retreat. |
| 7 | CD + δ-Tocotrienol | Small & large Lymphoplasmacytic clusters. |
| 8 | CD + Dexamethasone | Small LP cluster, Councilman body, nuclear Retreat and dysplasia cytoplasmic condensation. |
| TLE (n = 20) | Controls (n = 12) | |
| Age | 33.60 (7.32) | 31.58 (3.03) |
| Years of education | 15.35 (1.98) | 16.75 (1.14) |
| Duration of epilepsy (years) | 20.40 (11.22) | |
| Age at epilepsy onset (years) | 13.65 (8.67) | |
| Seizure freq. (per month) | 3.50 (0.91) | |
| AEDs (number) | 1.85 (0.62) | |
| 1 | 30% | |
| 2 | 55% | |
| ≥ 3 | 15% |
| Acronym | Description | Source |
| GDP | Gross Domestic Product per capita (PPS$), i.e. a measure of the economic activity and of the wealth of a country. | (1) |
| Real GDP Growth rate | The growth rate of the GDP in terms of volume (%), values determined by the prices of the previous year, and thus computed volume changes are imposed on the level of a reference year so that price movements will not inflate the growth rate. | (2) |
| Government Debt | General government gross debt (% of GDP, million EUR). | (1) |
| U | Unemployment rate (%), i.e. the percentage of unemployed people in the active population. | (3) |
| Variable | Mean | 95% CI |
| Children seen per day | 1.8 | 1.8-1.9 |
| Time spent on seeing children (hrs)/day | 0.4 | 20.9-21.1 |
| No of Health education activities/day | 2.5 | 2.3-2.6 |
| Time spent on IEC (hrs) | 0.2 | 11.4-12.8 |
| Follow-ups/day | **2.6 | 2.4-2.8 |
| Hours on follow-up/child | 1.7 | 1.5-1.8 |
| Total hours spent on CCMm activities/day | *4.8 | 3.9-5.3 |
| Study | Cell type | Treatment | Time points | Array |
| Expression profiling studies on 3T3-L1 cell line | ||||
| Guo et al. 2000 [14] | 3T3-L1 | DMI | 0h, 6d | 18k mouse cDNA filter arrays |
| Soukas et al. 2000 [15] | 3T3-L1 | DMI | PC,0h,6h,12h,24h,2d,3d, 4d, 7d,28d | Affymetrix mouse Mu11k |
| Ross et al. 2002 [16] | 3T3-L1 | DMI|DMI+Wnt-1↑ | 0h, 16h, 32h, 2d, d14 | Affymetrix mouse U74A |
| Burton et al. 2002 [17] | 3T3-L1 | DMI | 0h,2h,8h,16h,24h | AffymetrixmouseMu11k |
| Burton et al. 2004 [18] | 3T3-L1 | DMI|DMI+TSA | 0h,2h,8h,16h,24h,d2,d4 | Affymetrix mouse U74A |
| Jessen at al. 2002 [19] | 3T3-L1 | DMI | 0h, 1d, 4d, 7d | Affymetrix Mu11kB| U74Av2 |
| Gerhold et al. 2002 [20] | 3T3-L1 | DMI+TZD|nTZD | 0h, PA 6hT, PA 48hT, AD 6hT, AD 48hT | 4k Affymetrix mouse mu6800 |
| Hsiao et al. 2004 [21] | 3T3-L1 | TZDs | AD 24hT | Affymetrix mouse U74Av2 |
| Hackl et al. 2005 [22] | 3T3-L1 | DMI | PC,0h,6h,12h,24h,2d,3d,4d,7d,14d | 27K mouse cDNA microarray |
| Liu et al. 2005 [23] | 3T3-L1 | DMI|DI | Affymetrix mouse MOE430A | |
| Pantoja et al. 2005 [24] | 3T3-L1 | D↔M I| M↔D I | 38 k MEEBO microarray oligo set | |
| Adipogenesis expression studies on other mouse cell models including over-expression and knock out strategies | ||||
| Huo et al. 2006 [25] | 3T3-F442A | GH | Affymetrix mouse U74Av2 | |
| Akerblad et al. 2005 [26] | NIH-3T3 | Ebf1↑|Pparg↑ | Affymetrix mouse U74Av2 | |
| Baudry et al. 2006 [27] | PKB-/-MEF | 22k Affy mouse MOE430A | ||
| Christian et al. 2005 [28] | RIPKO | Affymetrix mouse MOE430 2.0 | ||
| Otto TC et al. 2007 [29] | C3H10T1/2 | Bmp4↑ | Affymetrix mouse MOE430 2.0 | |
| Tseng et al. 2005 [30] | IRSKO PA | Affymetrix mouse U74Av2 | ||
| Timmons et al. 2007 [31] | wPA, bPA | 0d, 1d, 4d, 8d | Affymetrix mouse U74Av2 | |
| Adipogenesis of human cell models | ||||
| Hung et al. 2004 [32] | hMSC | DMI | 0h,3d | 8k human Universochip |
| Sekiya et al. 2004 [33] | hMSC | 0h,1d,7d,14d,21d | 12k Affymetrix human U95Av2 | |
| Nakamura et al. 2003 [34] | hMSC | 3.4k focused cDNA microarray | ||
| Scheideler et al. 2008 [35] | hMADS | DMI+ROS | PC,-2d, 0h, 8h, 1d, 2d, 5d, 10d, 15d | 30k human spotted oligo array |
| Urs et al. 2004 [36] | PA|AD | 19K human cDNA microarray |
| Indicator | r | p value |
| GDP | 0.812 | 0.000 |
| GERD | 0.758 | 0.000 |
| RDP | 0.533 | 0.000 |
| NP | 0.804 | 0.000 |
| NC | 0.837 | 0.000 |
| NTP | 0.822 | 0.000 |
| Characteristic | Crude odds ratios with 95% confidence interval | Adjusted odds ratios with 95% confidence interval |
| Age above 25 years | 1.65 (1.33-2.04)* | .74 (.54-1.02) |
| Age 24 years & below -Ref | ||
| Income 5001 NPR or above | .85 (.71-1.00) | 1.30 (1.04-1.62)** |
| 5000 NPR or less/month- Ref | ||
| Education secondary or higher | .35 (.27-.44)* | .41 (.31-.55)* |
| Uneducated or Primary level- Ref | ||
| Hindu religion | .15 (.09-.24)* | .09 (.05-.18)* |
| Non-Hindu - Ref | ||
| ≥ 3 Children | 2.48 (1.93-3.19)* | 2.05 (1.56-2.71)* |
| ≤ 2 Children - Ref | ||
| Desire more children | .78 (.62-.99)** | .72 (.55-.95)** |
| No more desire - Ref | ||
| Men attempt domestic violence | 1.87 (1.56-2.24)* | 1.29 (1.04-1.61)** |
| Not attempt - Ref | ||
| Associated factors for male decision making to contraceptive use (N = 2394) | ||
| Age above 25 years | 1.63 (1.30-2.05)* | 1.57 (1.15-2.14)** |
| Age 24 years & below -Ref | ||
| Income 5001 NPR or above | 1.09 (.92-1.30) | .67 (.54-.82)* |
| 5000 NPR or less/month- Ref | ||
| Education secondary or higher | 4.54 (3.53-5.84)* | 4.11 (3.12 - 5.42)* |
| Uneducated or Primary level- Ref | ||
| Hindu religion | 2.32 (1.70-3.16)* | 1.43 (.95-2.16) |
| Non-Hindu - Ref | ||
| Non-Indigenous ethnicity | 2.40 (1.85 -3.10)* | 1.49 (1.06-2.10)** |
| Indigenous ethnicity - Ref | ||
| ≥ 3 Children | .67 (.54-.82)* | .70 (.55-.88)** |
| ≤ 2 Children - Ref | ||
| Desire more children | .64 (.50-.82)* | .66 (.50-.87)** |
| No more desire - Ref | ||
| Men attempt domestic violence | .62 (.52-.73)* | .83 (.68-1.02) |
| Not attempt - Ref |
| Variable | HZ patients(n = 38 743) | Comparison patients(n = 116 229) | P value | ||
| n | % | n | % | ||
| Sex | |||||
| Male | 20 514 | 52.95 | 61 542 | 52.95 | |
| Female | 18 229 | 47.05 | 54 687 | 47.05 | |
| Age, years | |||||
| 50–59 | 12 174 | 31.42 | 36 679 | 31.56 | 0.8824 |
| 60–69 | 11 847 | 30.58 | 35 490 | 30.53 | |
| ≥70 | 14 722 | 38.00 | 44 060 | 37.91 | |
| Diabetes | |||||
| Yes | 4984 | 12.86 | 11 308 | 9.73 | <0.0001 |
| No | 33 759 | 87.14 | 104 921 | 90.27 | |
| Monthly income (NT$) | |||||
| Financially dependent | 11 942 | 30.82 | 33 855 | 29.13 | <0.0001 |
| 1–15 840 | 10 066 | 25.98 | 22 550 | 19.40 | |
| 15 841–25 200 | 9818 | 25.34 | 43 673 | 37.57 | |
| ≥25 201 | 6917 | 17.85 | 16 151 | 13.90 | |
| Urbanization | |||||
| Metropolitan | 24 068 | 62.12 | 48 105 | 41.39 | <0.0001 |
| City | 6509 | 16.80 | 28 048 | 24.13 | |
| Town | 5528 | 14.27 | 25 957 | 22.33 | |
| Rural | 2638 | 6.81 | 14 119 | 12.15 | |
| Charlson comorbidity index(means ± SD) | 0.41 ± 0.84 | 0.29 ± 0.67 | <0.0001 |
| cELISA | ||||
| Positive | Negative | Total | ||
| T. equi (A) | ||||
| IFAT | Positive | 48 | 7 | 55 |
| Negative | 10 | 43 | 53 | |
| Total | 58 | 50 | 108 | |
| B. caballi (B) | ||||
| IFAT | Positive | 4 | 16 | 20 |
| Negative | 3 | 85 | 88 | |
| Total | 7 | 101 | 108 |
| Quality of life measure | BaselineN = 159 | 1-monthN = 136 | 4-monthsN = 127 | p-value* |
| General health | 77.3 (20.5) | 72.2 (23.7) | 72.0 (21.5) | .008 |
| Spouse | 74.0 (19.8) | 70.5 (19.8) | 70.4 (22.0) | .237 |
| Adult child | 80.9 (19.9) | 69.5 (26.4) | 72.3 (22.3) | .008 |
| Other relative | 77.4 (22.4) | 79.7 (20.7) | 76.0 (18.7) | .940 |
| Mental health | 72.5 (20.3) | 74.7 (19.8) | 76.6 (18.7) | .009 |
| Spouse | 70.4 (21.5) | 70.6 (21.5) | 74.8 (17.9) | .029 |
| Adult child | 72.9 (19.2) | 75.6 (18.8) | 76.7 (20.1) | .308 |
| Other relative | 76.5 (19.8) | 80.5 (17.0) | 81.7 (17.6) | .144 |
| Physical functioning | 80.4 (24.4) | 78.2 (24.6) | 78.4 (22.4) | .263 |
| Spouse | 75.5 (25.8) | 72.9 (26.5) | 73.9 (23.1) | .439 |
| Adult child | 89.8 (16.9) | 80.8 (24.6) | 85.3 (19.1) | .261 |
| Other relative | 73.1 (28.3) | 83.1 (19.7) | 76.0 (24.0) | .659 |
| Aniso nucleosis (±) | Large cherry red nucleoli (±) | Small cherry red nucleoli (±) | Large cells (±) | Mesothelial like sheets (±) | 3 dimensional cluster (±) | |
| Malignant | 7/4 | 9/2 | 2/9 | 4/7 | 5/6 | 11/0 |
| Non-malignant | 17/26 | 1/42 | 20/23 | 39/4 | 21/22 | NA |
| p value | * | 0.0252 | * | * | * | <0.0001 |
| Variables | Disability Beta (SD) | T | Anxiety | t | Depression | t |
| Age | 0.011 (0.016) | 0.71 | −0.046 (0.014) | −3.24 ** | −0.014 (0.011) | −1.33 |
| Organic Beliefs | 0.222 (0.052) | 4.26 *** | 0.035 (0.046) | 0.76 | 0.071 (0.035) | 2.01 * |
| Psychological Beliefs | 0.229 (0.058) | 3.94 *** | 0.259 (0.052) | 5.02 *** | 0.086 (0.039) | 2.19 * |
| Self-efficacy | −0.225 (0.019) | −12.31 *** | −0.103 (0.017) | −6.24 *** | −0.163 (0.013) | −12.93 *** |
| LOC—Internal | −0.041 (0.044) | −0.93 | −0.003 (0.040) | −0.07 | 0.002 (0.030) | 0.07 |
| LOC—Chance | −0.015 (0.043) | −0.34 | 0.170 (0.038) | 4.47 *** | 0.074 (0.029) | 2.55 * |
| LOC—Other | −0.021 (0.036) | −0.57 | 0.048 (0.032) | 1.49 | −0.001 (0.024) | −0.06 |
| No DGE | DGE | P | ||||
| n = 70 | n = 98 | |||||
| Age, years | 62 (51–69) | 68 (60–74) | 0.003 | |||
| Gender | 0.39 | |||||
| female | 24 | (34%) | 40 | (41%) | ||
| male | 46 | (66%) | 58 | (59%) | ||
| BMI | 24,6 ± 3,8 | 24,4 ± 4 | 0.888 | |||
| Diagnosis | ||||||
| Malignant | 54 | (77%) | 76 | (78%) | 0.95 | |
| Ductal adenocarcinoma | 31 | (44%) | 40 | (41%) | ||
| Ampullary carcinoma | 10 | (14%) | 19 | (19%) | ||
| Distal bile duct carcinoma | 7 | (10%) | 9 | (9%) | ||
| Benign | 16 | (23%) | 22 | (22%) | ||
| Pancreatitis | 13 | (19%) | 15 | (15%) | ||
| DM | pre | 12 | (17%) | 19 | (19%) | 0.712 |
| post | 15 | (21%) | 20 | (20%) | 0.835 | |
| Alcohol | 19 | (27%) | 19 | (19%) | 0.236 | |
| Smoker | 31 | (44%) | 38 | (39%) | 0.474 | |
| Weight loss | 32 | (46%) | 32 | (33%) | 0.086 | |
| Preoperative biliary drainage | 43 | (61%) | 58 | (59%) | 0.831 | |
| Cholangitis | 20 | (29%) | 17 | (17%) | 0.083 |
| Review | Professional background (code used in the quotes) | Knowledge of the clinical area | DTA-related knowledge | Systematic review methods | Academic role within university | Policy- making experience |
| Galactomannan detection for invasive aspergillosis in immune-compromized patients | Hematologist (H1) | Yes | Good | Some | Yes | Yes |
| Hematologist (H2) | Yes | Good | Some | Yes | Yes | |
| Policy maker (PM1) | No | Some | Good | Yes | Yes | |
| Systematic reviewer (SR1) | No | Little | Good | Yes | No | |
| Health economist (HE1) | No | Little | Good | No | No | |
| Systematic reviewer (SR2) | No | Good | Good | Yes | Yes | |
| Physical examination for lumbar radiculopathy due to disc herniation in patients with low back pain | GP (GP1) | Yes | Little | Little | No | No |
| GP (GP2) | Yes | Little | Little | No | No | |
| Physiotherapist (PH1) | Yes | Little | Good | Yes | No | |
| GP (GP3) | Yes | Good | Good | No | Yes | |
| Physiotherapist (PH2) | Yes | Good | Good | Yes | Yes | |
| Policy maker (PM2) | Yes | Good | Good | Yes | Yes | |
| Policy maker (PM3) | No | Some | Good | Yes | Yes | |
| MRI versus CT for detection of acute vascular lesions in patients presenting with stroke symptoms | Radiologist (R1) | Yes | Little | Little | No | No |
| Systematic reviewer (SR3) | No | Little | Some | No | No | |
| Health economist (HE2) | No | Good | Good | No | Yes | |
| Health economist (HE3) | No | Little | Some | No | No | |
| Systematic reviewer (SR4) | No | Little | Good | Yes | No | |
| Systematic reviewer (SR5) | No | Good | Good | Yes | No | |
| Systematic reviewer (SR6) | Yes | Some | Good | Yes | No | |
| Policy maker (PM4) | Yes | Good | Good | Yes | Yes |
| Variable | Cases (n=454) | Controls (n=512) | P |
| Age (years) | 61.04 ± 10.81 | 61.05 ± 11.01 | 0.990 |
| Female/male | 167/287 | 180/332 | 0.599 |
| Smoking (No/Yes) | 184/270 | 358/154 | <0.001 |
| Drinking (No/Yes) | 329/125 | 436/76 | <0.001 |
| Diabetes (No/Yes) | 295/159 | 435/77 | <0.001 |
| FPG (mmol/l) | 6.40 ± 1.65 | 5.65 ± 1.46 | <0.001 |
| Hypertension (No/Yes) | 185/269 | 300/212 | <0.001 |
| BMI (kg/m2) | 27.77 ± 3.11 | 25.50 ± 3.13 | <0.001 |
| Total cholesterol (mmol/l) | 4.81 ± 1.05 | 4.52 ± 1.05 | <0.001 |
| HDL (mmol/l) | 1.13 ± 0.33 | 1.61 ± 0.39 | <0.001 |
| LDL (mmol/l) | 2.89 ± 0.88 | 2.69 ± 0.75 | <0.001 |
| $3000 single | 12 mo. spacing | 60 mo. spacing | $1000 single | |
| $3000 single | ||||
| 12 mo. spacing | t = −1.539, p = 0.14 | |||
| 60 mo. spacing | t = −1.31, p = 0.20 | t = 0.77, p = 0.45 | ||
| $1000 single | t = 0.87, p = 0.40 | t = 1.67, p = 0.11 | t = 1.09, p = 0.29 |
| Question | Session | n | ≥ 4 (%) |
| I believe the work in this session is relevant for professional nurses | 1 | 52 | 98 |
| 2 | 49 | 84 | |
| I believe the work in this session is relevant for me as an individual | 1 | 52 | 96 |
| 2 | 49 | 88 | |
| Overall I am satisfied with this session | 1 | 49 | 94 |
| 2 | 49 | 76 |
| Algorithms | MAPE (%) | RMSPE (%) | Error of RUL prediction |
| INW–ESN (dynamica) | 9.32 | 7.27 | 23 min |
| INW–ESN (static) | 17.14 | 14.64 | Failed |
| RNN (dynamica) | 16.38 | 13.44 | 138 min |
| ESN (dynamica) | 14.60 | 10.87 | 161 min |
| ELM (static) | 13.91 | 9.48 | 69 min |
| PCR | Forward (F) primer/reverse (R) primer (5′–3′) | PCR mixture | Cycling conditions |
| rDNA21 | Nest1 F: GCTGTAGGTGAACCTGCAGCAGCTGGATCATT | 50 μL reaction; 5 μL DNA from filter papers (or 5 μL N1), 25 μL QIAGEN HotStar Taq Master Mix (QIAGEN), 0.3 μM primers | 95°C, 15 minutes |
| Nest1 R: GCGGGTAGTCCTGCCAAACACTCAGGTCTG | 35–40 cycles | ||
| Nest2 F: GCAGCTGGATCATTTTCC | 94°C, 0.5 minutes | ||
| Nest2 R: AACACTCAGGTCTGTAAAC | 58°C, 0.5 minutes | ||
| 72°C, 1.5 minutes | |||
| 60°C, 1 minutes | |||
| 75°C, 10 minutes | |||
| ITS222 | F: GGGAGAAGCTCTATTGTG | 25 μL reaction; 1 μL N2 product from rDNA PCR, KCl buffer (15 mM MgCl2, Bioline, London, UK), 2 mM deoxynucleotide triphosphates, 0.4 μM primers, 1U Taq polymerase | 94°C, 2 minutes |
| R: ACACTCAGGTCTGTAAAC | 40 cycles | ||
| 94°C, 20 seconds | |||
| 53°C, 30 seconds | |||
| 72°C, 1 minutes | |||
| 72°C, 10 minutes | |||
| kDNA6 | Nest1 F: C/GA/GTA/GCAGAAAC/TCCCGTTCA | 50 μL reaction; 5 μL DNA from filter papers (OR 5 μL N1), 25 μL QIAGEN HotStar Taq Master Mix, 0.3 μM primers | 95°C, 15 minutes |
| Nest1 R: ATTTTTCG/CGA/TTTT/CGCAGAACG | 30 cycles at | ||
| Nest2 F: ACTGGGGGTTGGTGTAAAATAG | 94°C, 1 minutes | ||
| Nest2 R: TCGCAGAACGCCCCT | 55°C, 1 minutes | ||
| 72°C, 1.5 minutes | |||
| 60°C, 1 minutes | |||
| 75°C,10 minutes |
| Treatments | Reaction time in seconds (mean ± SEM) | ||||
| 0 min | 15 min | 30 min | 45 min | 60 min | |
| Control (normal saline) | 4.25 ± 0.57 | 4.50 ± 0.34 | 4.42 ± 0.45 | 4.58 ± 0.44 | 5.17 ± 0.80 |
| Morphine sulfate | 6.50 ± 1.22 | 11.04 ± 0.73∗ab | 11.92 ± 0.84∗ab | 12.83 ± 0.35∗ab | 13.33 ± 0.83∗ab |
| Sodium salicylate | 4.13 ± 0.54 | 5.29 ± 0.57 | 6.75 ± 0.62∗a | 5.75 ± 0.56 | 6.79 ± 1.24 |
| Quercus infectoria (galls) extract | 6.67 ± 0.85a | 7.04 ± 0.67a | 8.04 ± 0.73a | 7.00 ± 0.92a | 6.67 ± 0.86 |
| Items_Details | Number of genes | Adjusted p-Valuea | Genes |
| Signaling pathways | |||
| Focal adhesion | 27 | 1.8E-08 | ITGA1, MAPK1, comP, ITGA6, ERBB2, LAMA2, CCND2, BCAR1, DIAPH1, PTEN, ITGA2, SPP1, ACTB, LAMC1, CAPN2, COL4A1, EGFR, VAV2, THBS4, ITGA9, THBS2, PTK2, PIK3CG, VEGFA, fn1, PPP1CB, VAV3 |
| Regulation of actin cytoskeleton | 27 | 3.5E-08 | PIP4K2A, ITGA1, MAPK1, ARPC2, ITGA6, ITGB2, ARPC1B, F2R, BCAR1, DIAPH1, GNA12, ITGA2, NCKAP1L, GSN, ACTB, TMSB4X, EGFR, VAV2, ITGA9, CD14, PTK2, Kras, BAIAP2, PIK3CG, fn1, PPP1CB, VAV3 |
| ECM-receptor interaction | 14 | 5.8E-06 | ITGA1, comP, ITGA6, LAMA2, ITGA2, GP1BB, SPP1, LAMC1, COL4A1, THBS4, ITGA9, THBS2, AGRN, fn1 |
| Adherens junction | 12 | 2.7E-05 | MAPK1, PARD3, CTNNA3, ACP1, ERBB2, PTPRJ, ACTB, EGFR, BAIAP2, CREBBP, SORBS1, PVRL3 |
| Metabolic pathways | |||
| Valine, leucine and isoleucine degradation | 12 | 2.3E-07 | ALDH3A2, BCAT1, OXCT1, EHHADH, IVD, BCKDHB, ECHS1, ACADSB, HADHA, PCCB, AUH, ALDH2 |
| Lysine degradation | 9 | 0.0002 | MLL5, ALDH3A2, EHHADH, NSD1, WHSC1L1, ECHS1, HADHA, setmar, ALDH2 |
| Purine metabolism | 16 | 0.00033 | NUDT2, Pgm2, GMPR2, POLR2G, ENPP1, RRM2B, FHIT, GUCY1A3, ADA, NT5C2, NME6, PGM1, PRPS2, ATIC, NT5E, POLR3E |
| beta-Alanine metabolism | 6 | 0.00088 | ALDH3A2, EHHADH, ECHS1, CARNS1, HADHA, ALDH2 |
| Arginine and proline metabolism | 8 | 0.0014 | ALDH3A2, ACY1, P4HA1, GLUD1, CARNS1, AMD1, ALDH4A1, ALDH2 |
| Fatty acid metabolism | 7 | 0.0014 | ALDH3A2, EHHADH, ECHS1, ACADSB, ACSL4, HADHA, ALDH2 |
| Cellular processes | |||
| Phagosome | 21 | 9.2E-08 | comP, CTSS, ATP6V1C1, ITGB2, ITGA2, PIK3C3, ACTB, CYBB, CYBA, TFRC, THBS4, CD14, THBS2, NCF4, NCF2, DYNC1I2, EEA1, FCGR2B, MRC1, TUBA8, TUBA4A |
| Protein processing in endoplasmic reticulum | 21 | 7E-07 | nsfl1c, BAG2, UBE4B, PARK2, SAR1B, HSPH1, SEC24D, DNAJC1, CAPN2, DDOST, BCAP31, HSPA2, PDIA3, CUL1, UBE2D4, HERPUD1, EDEM2, DNAJA1, DERL1, CKAP4, TUSC3 |
| mRNA surveillance pathway | 13 | 0.000016 | SAP18, PPP2R5A, CPSF6, CLP1, PPP2R2A, PAPOLA, PAPOLB, PPP2CB, Fip1l1, ETF1, HBS1L, CPSF3, CSTF2T |
| Endocytosis | 20 | 3.61E-05 | RAB11FIP5, PARD3, KIT, F2R, DNM2, EHD1, RABEP1, ARRB2, GRK5, DNM1L, FOLR1, EGFR, TFRC, HSPA2, WWP1, ZFYVE16, SMAP2, EEA1, epn1, FAM125B |
| N | Zinc concentration | N | Height for age z score (mean ± sd) | ||
| Cuba | STH uninfected | 160 | 112.55 (88.3–136.0) a | 1251 | 0.11 ± 0.97 |
| STH infected | 70 | 113.35 (94.4–143.7) a | 117 | −0.31 ± 1.16 | |
| Cambodia | STH uninfected | 1239 | 7.74 ± 1.70 b | 1450 | −1.81 ± 1.05 |
| STH infected | 254 | 7.52 ± 1.70 b | 296 | −1.84 ± 1.09 |
| NPI domains | FxS ICC (95% CI) | Distress ICC (95% CI) |
| Delusions | 0.936 (0.860, 0.971) | 0.958 (0.908, 0.981) |
| Hallucinations | 0.897 (0.780, 0.953) | 0.882 (0.750, 0.946) |
| Agitation/aggression | 0.799 (0.596, 0.906) | 0.818 (0.630, 0.916) |
| Depression/dysphoria | 0.728 (0.473, 0.870) | 0.699 (0.427, 0.855) |
| Anxiety | 0.670 (0.381, 0.840) | 0.508 (0.149, 0.749) |
| Elation/euphoria | 0.600 (0.276, 0.802) | 0.923 (0.834, 0.965) |
| Apathy/indifference | 0.691 (0.415, 0.851) | 0.621 (0.307, 0.813) |
| Disinhibition | 0.296 (-0.104, 0.614) | 0.531 (0.179, 0.762) |
| Irritability/lability | 0.524 (0.170, 0.758) | 0.542 (0.195, 0.768) |
| Aberrant motor behavior | 0.976 (0.946, 0.989) | 1.000 (1.000, 1.000) |
| Total | 0.909 (0.804, 0.959) | 0.890 (0.766, 0.950) |
| Sleep/nighttime behavior disorders | 0.650 (0.350, 0.829) | 0.741 (0.496, 0.877) |
| Appetite and eating changes | 0.607 (0.286, 0.805) | 0.648 (0.347, 0.828) |
| Toxin | Mussels | Clams | Scallops | Oysters | ||||
| LOD | LOQ | LOD | LOQ | LOD | LOQ | LOD | LOQ | |
| GTX4 | 0.0183 | 0.0549 | 0.0201 | 0.0603 | 0.0221 | 0.0663 | 0.048 | 0.144 |
| GTX1 | 0.0642 | 0.1926 | 0.0320 | 0.0960 | 0.0488 | 0.1464 | 0.057 | 0.171 |
| dcGTX3 | 0.0071 | 0.0213 | 0.0096 | 0.0288 | 0.0097 | 0.0291 | 0.003 | 0.009 |
| GTX5 | 0.0011 | 0.0033 | 0.0088 | 0.0264 | 0.0298 | 0.0894 | 0.025 | 0.075 |
| dcGTX2 | 0.0210 | 0.0630 | 0.0181 | 0.0543 | 0.0244 | 0.0732 | 0.030 | 0.090 |
| GTX3 | 0.0055 | 0.0165 | 0.0072 | 0.0216 | 0.0073 | 0.0219 | 0.011 | 0.033 |
| GTX2 | 0.0099 | 0.0297 | 0.0306 | 0.0918 | 0.0199 | 0.0597 | 0.023 | 0.069 |
| NEO | 0.0239 | 0.0717 | 0.0329 | 0.0987 | 0.0375 | 0.1125 | 0.018 | 0.054 |
| dcSTX | 0.0047 | 0.0141 | 0.0172 | 0.0516 | 0.0074 | 0.0222 | 0.0005 | 0.001 |
| STX | 0.0100 | 0.0300 | 0.0394 | 0.1182 | 0.0111 | 0.0333 | 0.009 | 0.027 |
| C1 | 0.0001 | 0.0003 | ||||||
| C2 | 0.0011 | 0.0033 |
| Trait | Rep | Block(Rep) | Variety | h2 |
| LLGHT | <0.001 | < 0.001 | < 0.001 | 0.90 |
| TIL | < 0.001 | 0.0009 | < 0.001 | 0.80 |
| SDW | 0.0043 | < 0.0001 | < 0.0001 | 0.73 |
| DEPTH | 0.0254 | 0.0003 | 0.0002 | 0.35 |
| MRL | 0.1428 | 0.0277 | 0.0001 | 0.46 |
| NCR | 0.2270 | < 0.0001 | < 0.0001 | 0.84 |
| NR_T | <0.001 | 0.3450 | < 0.0001 | 0.72 |
| THK | 0.0071 | 0.0017 | < 0.0001 | 0.84 |
| DW0020 | 0.0546 | < 0.0001 | < 0.0001 | 0.74 |
| DW2040 | 0.1605 | < 0.0001 | < 0.0001 | 0.68 |
| DW4060 | 0.4307 | < 0.001 | < 0.0001 | 0.69 |
| DWB60 | 0.0260 | 0.0047 | < 0.0001 | 0.70 |
| DRW | 0.0863 | 0.0004 | < 0.0001 | 0.75 |
| RDW | 0.0650 | < 0.0001 | < 0.0001 | 0.75 |
| PDW | 0.0364 | < 0.0001 | < 0.0001 | 0.73 |
| SRP | 0.0207 | 0.0002 | < 0.0001 | 0.72 |
| DRP | 0.0179 | 0.0045 | < 0.0001 | 0.65 |
| R_S | < 0.0001 | < 0.0001 | < 0.0001 | 0.75 |
| Unit | LUTs | BRAM | SLICES | MULT18×18 |
| uF | 908 | 0 | 615 | 4 |
| uIS | 1,115 | 1 | 870 | 2 |
| PLC | 2,636 | 2 | 1,410 | 0 |
| ioP | 24 | 0 | 15 | 0 |
| System manager | 213 | 0 | 117 | 0 |
| CP | 1,105 | 0 | 788 | 0 |
| Total | 6,001 | 3 | 3,815 | 6 |
| Available | 14,752 | 36 | 29,504 | 36 |
| Covariate | Hazard ratio | 95% CI | P-value |
| LBC1936 (n = 920, nevents = 135) | |||
| Age (years) | 1.05 | [0.85, 1.30] | 0.65 |
| Sex (female) | 0.66 | [0.46, 0.95] | 0.025 |
| Telomere length | 0.95 | [0.80, 1.13] | 0.56 |
| Hannum age | 1.12 | [0.94, 1.33] | 0.21 |
| LBC1921 (n = 414, nevents = 280) | |||
| Age (years) | 0.98 | [0.79, 1.22] | 0.86 |
| Sex (female) | 0.89 | [0.69, 1.15] | 0.37 |
| Telomere length | 0.86 | [0.76, 0.97] | 0.012 |
| Hannum age | 1.24 | [1.11, 1.39] | 1.3×10-4 |
| LBC1921 + LBC1936 (n = 1344, nevents = 415) | |||
| Age (years) | 1.11 | [1.08, 1.14] | < 2 × 10−16 |
| Sex (female) | 0.82 | [0.67, 1.01] | 0.07 |
| Telomere length | 0.89 | [0.79, 1.00] | 0.047 |
| Hannum age | 1.25 | [1.11, 1.40] | 1.4×10-4 |
| Studies | Dystrophin IHC staining using FFPE muscle sections | ||
| Rod domain (DYS1) | C-terminus (DYS2) | N-terminus (DYS3) | |
| Present study | Successful | Successful | Unsuccessful |
| Hoshino et al. 2000 [17] | Successful | Successful | Unsuccessful |
| Sheriffs et al. 2001 [18] | Successful | Successful | Successful |
| Sajid et al. 2010 [19] | Not performed | Successful | Not performed |
| Cases | Controls | Total | ||||
| N | % | n | % | n | % | |
| All subjects | 603 | 33 | 1206 | 66 | 1809 | 100 |
| Gender | ||||||
| Male | 341 | 57 | 682 | 57 | 1023 | 57 |
| Female | 262 | 43 | 524 | 43 | 786 | 43 |
| Age strata | ||||||
| 0-4 years | 224 | 37 | 448 | 37 | 672 | 37 |
| 5-9 years | 176 | 29 | 352 | 29 | 528 | 29 |
| 10-14 years | 112 | 19 | 224 | 19 | 336 | 19 |
| 15-19 years | 91 | 15 | 182 | 15 | 273 | 15 |
| Season | ||||||
| Summer | 110 | 18 | 220 | 18 | 330 | 18 |
| Autumn | 172 | 29 | 344 | 29 | 516 | 29 |
| Winter | 192 | 32 | 384 | 32 | 576 | 32 |
| Spring | 129 | 21 | 258 | 21 | 387 | 21 |
| Block 1 | SNPs | Frequency of the haplotype | ||||||||||
| rs915941 | rs915942 | population | Group A | Group B | Males | Females | Males | Group B | ||||
| Group A | Group A | Group B | Females | |||||||||
| Haplotypes | A | G | 0.880 | 0.890 | 0.870 | - | 0.870 | 0.878 | 0.871 | |||
| C | A | 0.119 | 0.110 | 0.124 | - | 0.120 | 0.122 | 0.126 | ||||
| Block 2 | SNPs | Frequency of the haplotype | ||||||||||
| rs2071429 | rs2230037 | rs4898389 | rs5986877 | rs7879049 | Population (0.64) | Group A (0.73) | Group B (0.77) | Males Group A (N/R) | Females Group A (0.77) | Males Group B (0.76) | Females Group B (0.48) | |
| Haplotypes | A | G | A | C | A | 0.545 | 0.553 | 0.540 | 0.475 | 0.540 | 0.585 | 0.516 |
| G | A | G | G | G | 0.402 | 0.394 | 0.407 | 0.475 | 0.365 | 0.364 | 0.431 | |
| G | G | G | G | A | 0.034 | 0.033 | 0.034 | 0.013 | 0.041 | 0.028 | 0.038 |
| Fatigue | Abdominal complaints | Musculo- skeletal complaints | Weight changes | Itch | |
| Alkaline Phosphatase (AF) | x | x | x | ||
| Alanine aminotransferase (ALAT) | x | x | x | x | |
| Amylase | x | x | |||
| Anti-endomysium | x | x | |||
| Aspartate aminotransferase (ASAT) | x | x | x | ||
| Bilirubin | x | ||||
| Erythrocyte sedimentation rate (ESR) | x | x | x | x | x |
| Carbohydrate-deficient transferrin (CDT) | x | x | x | x | |
| Creatinin kinase (CK) | x | ||||
| Creatinin | x | x | x | x | x |
| C-reactive protein (CRP) | x | ||||
| Differentiated leukocyte count | x | x | x | x | |
| Eosinophils | x | ||||
| Ferritin | x | x | x | x | |
| Gamma glutamyl transferase (GGT) | x | x | x | x | |
| Glucose | x | x | x | x | x |
| Haemoglobin (Hb) | x | x | x | x | x |
| Potassium (K) | x | x | |||
| Latex fixation test | x | ||||
| Lactate dehydrogenase (LDH) | x | x | |||
| Leukocyte count | x | x | x | x | |
| Monosticon | x | ||||
| Total IgE | x | x | |||
| Thyroid stimulating hormone (TSH) | x | x | x | x | x |
| Transferrin saturation (TS) | x | x | x | x | |
| Urea | x | ||||
| Uric acid | x | ||||
| Total number of tests | 17 | 18 | 11 | 17 | 14 |
| SNPs | Position | Genotypes and alleles | No | Frequencies, % |
| rs4693084 | Intron 3 | GG | 91 | 61.5 |
| GT | 50 | 33.8 | ||
| TT | 7 | 4.7 | ||
| G | 232 | 78.4 | ||
| T | 64 | 21.6 | ||
| rs4693083 | Intron 3 | AA | 91 | 61.5 |
| AT | 50 | 33.8 | ||
| TT | 7 | 4.7 | ||
| A | 232 | 78.4 | ||
| T | 64 | 21.6 | ||
| rs4693609 | Intron 3 | TT | 88 | 59.5 |
| TC | 53 | 35.8 | ||
| CC | 7 | 4.7 | ||
| T | 229 | 77.4 | ||
| C | 67 | 22.6 | ||
| rs4693608 | Intron 3 | AA | 56 | 37.8 |
| AG | 62 | 41.9 | ||
| GG | 30 | 20.3 | ||
| A | 174 | 58.8 | ||
| G | 122 | 41.2 | ||
| rs11099592 | Exon 7 | GG | 91 | 61.5 |
| GA | 49 | 33.1 | ||
| AA | 8 | 5.4 | ||
| G | 231 | 78 | ||
| A | 65 | 22 |
| Variable | Single etiologic agent(n = 126) | Multiple etiologic agents(n = 153) | P-value |
| Gram-positive cocci | |||
| Aerobic | |||
| Staphylococcus aureus | |||
| Methicillin-susceptible S. aureus | 27 (21.4) | 15 (9.8) | 0.007* |
| Methicillin-resistant S. aureus | 20 (15.9) | 34 (22.2) | 0.182 |
| Coagulase-negative Staphylococcus | 2 (1.6) | 11 (7.2) | 0.042* |
| Streptococcus | |||
| Beta-hemolytic (Group A) | 13 (10.3) | 24 (15.7) | 0.188 |
| Beta-hemolytic (Group B) | 2 (1.6) | 4 (2.6) | 0.693 |
| Non-group A or B | - | 2 (0.7) | - |
| S. viridans | 2(1.6) | 36 (23.5) | <0.001* |
| Enterococcus faecalis | 1(0.8) | 45 (29.4) | <0.001* |
| Anaerobic | |||
| Peptostreptococcus | - | 38 (13.6) | - |
| Gram-positive rods | |||
| Aerobic | |||
| Corynebacterium | - | 8 (2.9) | - |
| Anaerobic | |||
| Clostridium spp. | - | 5 (1.8) | - |
| Gram negative rods | |||
| Aerobic | |||
| Acinetobacter baumannii | 3 (2.4) | 20 (13.1) | 0.001* |
| Aeromonas spp. | 11 (8.7) | 11 (7.2) | 0.635 |
| Citrobacter spp. | 2 (1.6) | 9 (5.9) | 0.119 |
| E.coli. | 2 (1.6) | 35 (22.9) | <0.001* |
| Enterobacter spp. | 1 (0.8) | 19 (12.4) | <0.001* |
| Klebsiella pneumoniae | 13 (10.3) | 28 (18.3) | 0.061 |
| Pseudomonas aeruginosa | 3 (2.4) | 16 (10.5) | 0.008* |
| Vibrio spp. | 21 (17.5) | - | - |
| Eikenella corrodens | - | 4 (2.6) | - |
| Klebsiella oxytoca | - | 3 (2.0) | - |
| Proteus mirabillis | - | 23 (15.0) | - |
| Serratia marcescens | - | 7 (4.6) | - |
| Other gram negative rods | 1 (0.8) | 15 (9.2) | 0.002* |
| Anaerobic | |||
| Prevotella spp. | 2 (1.6) | 10 (6.5) | 0.071 |
| Bacteroides fragilis | - | 15 (9.8) | - |
| Fusobacterium | - | 1 (0.7) | - |
| Veillonella | - | 3 (2.0) | - |
| Fungus | - | 6 (3.9) | - |
| Formulation | Aromatic Content in Polymer (%) | EE (%) | LC (%) |
| Cur-Nano1 | 0 | 61.3 ± 0.5 | 6.8 ± 0.1 |
| Cur-Nano2 | 25 | 61.3 ± 0.1 | 6.8 ± 0.0 |
| Cur-Nano3 | 100 | 113.8 ± 3.4 | 12.6 ± 0.4 |
| Outcome | Perceived labour ≥24 hours | Perceived labour <24 hours | RR (95% CI) |
| n = 434 | n = 813 | ||
| n (%) | n (%) | ||
| Mode of birth | |||
| Vaginal | 189 (43.5) | 412 (50.7) | 0.86 (0.76-0.98) |
| Forceps or vacuum | 122 (28.1) | 237 (29.2) | 0.96 (0.80–1.16) |
| Cesarean birth | 123 (28.3) | 164 (20.2) | 1.40 (1.15-1.72) |
| Primary indication for cesarean | |||
| Dystocia/CPD | 99 (80.5) | 122 (74.4) | 1.08 (0.95-1.23) |
| Fetal Distress | 24 (19.5) | 42 (25.6) | 0.76 (0.49–1.19) |
| Length of time from admission to birth (minutes, mean ± sd) | 714.6 ± 467.9 | 580.7 ± 441.6 | p < .001 |
| Length of first stage (minutes, mean ± sd) | 916.1 ± 501.0 | 775.5 ± 417.8 | p < .001 |
| Length of second stage (minutes, mean ± sd) | 125.3 ± 92.5 | 118.1 ± 97.8 | ns |
| Cervical dilation on admission ≤ 3 cm | 223 (52.0) | 347 (43.3) | 1.21 (1.07-1.36) |
| Continuous Electronic Fetal Monitoring | 316 (72.8) | 533 (65.6) | 1.11 (1.03-1.20) |
| IV fluids | 384 (88.5) | 629 (77.6) | 1.14 (1.08–1.20) |
| Augmentation of labour | 331 (76.3) | 65 (57.2) | 1.33 (1.23–1.44) |
| Analgesia | |||
| Narcotic (IM or IV) | 206 (47.5) | 320 (39.4) | 1.21 (1.06–1.37) |
| Nitrous Oxide | 294 (67.7) | 568 (69.9) | 0.97 (0.90–1.05) |
| Epidural analgesia | 327 (75.3) | 495 (60.9) | 1.18 (1.09–1.28) |
| Blood loss | |||
| After vaginal birth (>500 cc) | 65 (19.9) | 112 17.2) | 1.21 (0.92-1.59) |
| After cesarean birth (>1000 cc) | 5 (4.1) | 6 (3.7) | 1.11 (0.353.56) |
| Laboratory ID | Laboratory type | Correct diagnosis | ||
| All Specimens, n (%) | Smear-Positive Specimens, n (%) | Smear-Negative Specimens, n (%) | ||
| 1 | Network | 3 (42.9) | 2 (33.3) | 1 (100) |
| 2 | Network | 7 (100) | 6 (100) | 1 (100) |
| 3 | Standalone | 1 (14.3) | 0 (0) | 1 (100) |
| 4 | Standalone | 1 (14.3) | 0 (0) | 1 (100) |
| 5 | Network | 1 (14.3) | 0 (0) | 1 (100) |
| 6 | Standalone | 6 (85.7) | 6 (100) | 0 (0) |
| 7 | Network | 7 (100) | 6 (100) | 1 (100) |
| Indus Hospital | N/A | 7 (100) | 6 (100) | 1 (100) |
| Reference/reference number | Surrogate product | Countries | Study population | Method |
| Green [59] | Female condom, foaming tablets, contraceptive sponge, Delfen foam, film and gel | Uganda | 131 women; 21 men | Qual |
| Jones [33] | Astroglide Silken Secret (high-viscosity gel), KY Jelly (low-viscosity gel), Lubrin (suppository) | Zambia | 301 women | Quant |
| Martin [15] | Gel | Thailand | 23 women; 28 men | Qual |
| Montgomery [20] | Gel | South Africa, Tanzania, Uganda, Zambia | 45 couples | Qual |
| Pool [48] | Female condom, foaming tablets, contraceptive sponge, Delfen foam, film and gel | Uganda | 138 women; 42 men | Qual |
| Salter [43] | Gel | Malawi | 1686 women; 21 men | Mixed |
| Tanner [21] | Silken Secret vaginal moisturizer | USA | 40 women | Qual |
| van der Straten [61] | Ring | South Africa, Tanzania | 157 women; 19 men | Qual |
| Weeks [74] | Vaginal moisturizer | USA | 546 women interviewed/surveyed; 94 participating in surrogate trial | Mixed |
| Research Authors (Year) | Purpose | Characteristics | Outcomes |
| Alwan et al. [110] (2006) | Fall detection | The authors used dummies of humans to simulate original fall events. The experimental tests of falls were performed on concrete floors. A dummy was used to emulate the scenario of a person falling while attempting to get out of a chair. Another dummy was used to emulate the scenario of a person falling with upright position. The experiments were repeated three times with the same dummies. | 100% accuracy. |
| Lombardi et al. [111] (2015) | Movement detection | A data model was proposed for storing and processing floor data. The proposed approach focused on estimating the center of floor pressure based on the widely used biomechanical concept of ground reaction force. Some practical tests on a real sensing floor prototype were attempted. The novel approach outperformed the traditional background subtraction schemas for the correct detection and tracking of people. | 97% accuracy. |
| Serra et al. [112] (2014) | Footstep recognition | An easy-to-install and unobtrusive smart flooring system was proposed based on piezoelectric polymer floor sensors. The smart flooring system was utilized for efficient human footsteps recognition based on the Pearson product–moment correlation coefficient between the testing and reference signals for similarity calculation. | 99% accuracy. |
| LDA | SVM (Linear) | |||||
| Accuracy | Precision | Recall | Accuracy | Precision | Recall | |
| Forehead_axis + Mouth_axis | 77.8 | 76.9 | 66.7 | 77.8 | 76.9 | 66.7 |
| Forehead_axis + Mouth_region | 66.7 | 46.2 | 54.6 | 63.9 | 46.2 | 50.0 |
| Forehead_region + Mouth_axis | 88.9 | 92.3 | 80.0 | 88.9 | 92.3 | 80.0 |
| Forehead_region + Mouth_region | 75.0 | 85.7 | 63.2 | 77.8 | 84.6 | 64.7 |
| Time | 0 h | 2 h | 12 h | 24 h |
| Intensity of FSC | 320.3 ± 34.3 | 359.1 ± 34.4 | 382.0 ± 38.4 | 410.7 ± 51.1 |
| Species | No tested | No of positive humans, buffaloes and a lion (Prevalence) | |||||||
| RBPT | BAPA | Riv.T | 95 % CI | TITER | |||||
| No | % positive | No | %Positive | No | % positive | ||||
| Humans | 340 | 5 | 1.5 | 2 | 0.6 | 2 | 0.6 | 0.1, 2.1 | 1:200* |
| Buffaloes | 38 | 4 | 10.5 | 3 | 7.9 | 3 | 7.9 | 1.7, 21.4 | 1:200* |
| Lion | 2 | 1 | 1/2 | 1 | 1/2 | 1 | 1/2 | 1:200* | |
| Zebra | 2 | 0 | 0 | 0 | 0 | 0 |
| Characteristic | Value |
| Age, years | |
| Mean ± SD | 58.2 ± 13.6 |
| Range | 30–92 |
| Sex, % (n) | |
| Male | 78.1 (25) |
| Female | 21.9 (7) |
| Race/ethnicity % (n) | |
| Caucasian/white | 59.4 (19) |
| African-American/black | 31.3 (10) |
| Asian/Pacific Islander | 9.4 (3) |
| Marital status, % (n) | |
| Married | 28.1 (9) |
| Single | 40.6 (13) |
| Other (widowed/divorced) | 31.3 (10) |
| Smoking | |
| History of smoking, % (n) | 75.0 (24) |
| Pack years, mean ± SD | 21.0 ± 20.7 |
| History of hypertension, % (n) | 71.9 (23) |
| Creatinine on admission (g/dL), mean ± SD | 1.9 ± 1.7 |
| Etiology of heart failure, % (n) | |
| Ischemic | 28.1 (9) |
| Idiopathic | 65.6 (21) |
| Unknown/other | 6.3 (2) |
| Ejection fraction <40%, % (n) | 71.9 (23) |
| ACEi/ARB use—study end, % (n) | 62.5 (20) |
| Beta blocker use—study end, % (n) | 78.1 (25) |
| High-risk diagnoses for the elderly scale | |
| Low (0) = 9.5% chance dying in 1 year | 0 (0) |
| Intermediate (1-2) = 31% chance | 53.1 (17) |
| High risk (3–5) = 46% chance | 31.3 (10) |
| Very high risk (≥6) = 74% chance | 15.6 (5) |
| Length of hospital stay, days | |
| Mean ± SD | 9.5 ± 9.9 |
| Median | 6.5 |
| Range | 1–41 |
| Physical therapy—in hospital, % (n) | 34.4 (11) |
| LVAD received during study admission, % (n) | 6.3 (2) |
| Discharged with physical therapy, occupational therapy, or home health, % (n) | 40.6 (13) |
| Cardiac events—90 days after discharge, % (n) | |
| Cardiac readmission | 34.4 (11) |
| Heart transplant | 3.1 (1) |
| Mortality | 9.4 (3) |
| Before treatment | After 1 month | P value | After 6 months | P value | After 12 months | P value | Follow-up | P value | |
| Group A Peg-IFN α + RBV + placebo (n = 31) | |||||||||
| Work ability index | 36.9 ± 5.2 | 21.4 ± 5.3 | <0.01 | 37.8 ± 5.9 | NS | 38.7 ± 5.8 | NS | 39.8 ± 6.7 | <0.001 |
| STAI | 50.1 ± 7.6 | 59.2 ± 7.4 | <0.01 | 60.4 ± 7.7 | <0.001 | 58.2 ± 7.4 | <0.001 | 61.4 ± 7.2 | <0.001 |
| BDI | 30.8 ± 6.9 | 44.6 ± 6.7 | <0.01 | 46.7 ± 6.8 | <0.001 | 40.9 ± 6.9 | <0.001 | 40.4 ± 6.2 | <0.001 |
| Group B Peg IFN α + RBV + Silybin, Vit E, phospholipids (n = 31) | |||||||||
| Work ability index | 35.4 ± 5.9 | 30.2 ± 6.2 | <0.001 | 38.4 ± 6.8 | NS | 40.7 ± 6.1 | <0.05 | 39.8 ± 6.4 | <0.05 |
| STAI | 50.8 ± 7.9 | 59.8 ± 7.1 | <0.001 | 50.4 ± 7.2 | NS | 47.4 ± 7.8 | NS | 50.6 ± 7.0 | NS |
| BDI | 30.7 ± 7.1 | 48.7 ± 7.8 | <0.001 | 34.6 ± 7.1 | NS | 30.1 ± 7.2 | NS | 30.4 ± 6.8 | NS |
| MMQL-UK (PF) component | |||||
| MMQL-UK (CF) component | Physical Appearance | School | Social Functioning | Emotional Functioning | Physical Functioning |
| Physical Appearance | 0.51** | 0.05 | 0.20** | 0.25** | 0.12** |
| School | 0.13** | 0.56** | 0.22* | 0.14** | 0.21** |
| Social Functioning | 0.14** | 0.10* | 0.31** | 0.23** | 0.18** |
| Emotional Functioning | 0.35** | 0.20** | 0.26** | 0.38** | 0.25** |
| Physical Activities | 0.33** | 0.25** | 0.21** | 0.27** | 0.61** |
| Variable | Non-diabetic individuals | All IR individuals | ||||
| IS(n = 16 [6 M, 10 F]) | IR(n = 27 [(10 M, 17 F]) | IS vs IRp value | T2DM(n = 14 [(4 M, 10 F]) | IR + T2DM(n = 41, [14 M, 27 F]) | IS vs IR + T2Dp value | |
| Age (years) | 36.6 (11.8) | 33.9 (8.1) | 0.3 | 41.2 (10.8) | 36.4 (9.7) | 0.96 |
| BMI (kg/m2) | 42.9 (5.0) | 44.3 (7.1) | 0.57 | 43.5 (7.1) | 44.0 (7.0) | 0.55 |
| SBP (mmHg) | 127.1 (18.3) | 126.9 (23.2) | 0.69 | 128.2 (10.2) | 127.3 (19.6) | 0.98 |
| DBP (mmHg) | 71.29 (9.5) | 72.78 (14.6) | 0.98 | 73.86 (8.9) | 73.2 (12.8) | 0.62 |
| MAP (mmHg) | 89.90 (9.0) | 90.81 (14.6) | 0.85 | 92.4 (9.0) | 91.4 (12.9) | 0.70 |
| Cholesterol (mmol/l) | 4.48 (0.9) | 5.0 (0.9) | 0.53 | 5.10 (0.7) | 5.0 (0.8) | 0.04 |
| LDL-cholesterol (mmol/l) | 2.75 (0.6) | 3.21 (1.0) | 0.94 | 2.95 (0.8) | 3.1 (0.9) | 0.16 |
| Triacylglycerol (mmol/l) | 1.0 (0.8–1.4) | 1.3 (0.9–1.9) | 0.50 | 1.6 (1.3–2.8) | 1.4 (1.0–2.1) | 0.02 |
| HDL-cholesterol (mmol/l) | 1.25 (0.29) | 1.20 (0.22) | 0.15 | 1.24 (0.29) | 1.2 (0.24) | 0.67 |
| FPG (mmol/l) | 4.9 (0.5) | 5.8 (0.9) | 0.11 | 9.58 (5.81) | 7.3 (3.8) | <0.01 |
| Insulin (pmol/l) | 50.7 (34.0–59.03) | 99.3 (79.2–145.2) | <0.01 | 99.3 (71.5–138.2) | 99.3 (78.5–141.7) | <0.01 |
| HOMA-IR | 1.5 (1.1–1.9) | 3.9 (3.0–6.6) | <0.01 | 6.0 (3.4–9.0) | 4.3 (3.0–7.2) | <0.01 |
| Albumin (g/l) | 41.5 (36.3–44.0) | 42.0 (38.5–45.5) | 0.40 | 42.0 (39.8–44.3) | 42.0 (39.0–44.0) | 0.34 |
| ALP (U/l) | 67.0 (57.0–102.0) | 73.0 (58.5–82.3) | 0.48 | 83.5 (60.5–117.3) | 74.0 (59.8–85.8) | 0.85 |
| ALT (U/l) | 17.0 (11.0–21.0) | 23.0 (19.0–27.0) | 0.03 | 29.5 (13.8–39.8) | 24.0 (17.0–45.0) | <0.01 |
| AST (U/l) | 18.0 (16.0–19.0) | 23.5 (15.0–29.3) | 0.02 | 21.5 (14.0–32.5) | 23.0 (15.0–30.8) | 0.05 |
| Bilirubin (μmol/l) | 8.0 (6.5–13.0) | 8.0 (5.8–10.3) | 0.54 | 5.0 (4.0–7.3) | 6.5 (5.0–9.0) | 0.17 |
| Georgia | Cobb County, GA | Dekalb County, GA | Fulton County, GA | Gwinnett County, GA | |
| Total Asian | 320,905 | 31,164 | 37,095 | 52,213 | 86,957 |
| Chinese (except Taiwanese) | 44,604 | 4,961 | 5,767 | 10,025 | 10,624 |
| Taiwanese | 3,483 | 378 | 525 | 959 | 886 |
| Disinfectant | Concentrations tested (contact time in minutes used) | Effective | Level of Evidence | Comments | Reference |
| Chlorhexidine gluconate | <0.02% (1440), 0.5% (0.5), 2% (2), 4% (3, 180, 1800) | Yes | Good | Most studied antiseptic. Limited clinical evaluation. | Schelenz et al., 2016; Abdolrasouli et al., 2017; Moore et al., 2017; Sherry et al., 2017 |
| Chlorhexidine gluconate in isopropyl alcohol | 2%/70% (2) | Yes | Low | In vitro testing only. | Moore et al., 2017 |
| Povidone-iodine | 10% (2, 3, 180, 1800) | Yes | Moderate | In vitro testing only. | Abdolrasouli et al., 2017; Moore et al., 2017; |
| Alcohol | 70% | Yes | Low | Limited clinical evaluation. | Biswal et al., 2017 |
| Hyperkalaemia (≥6 mmol/L)* | Creatinine ≥220 μmol/L | ≥30% increase in creatinine | |
| Number with adverse biochemical values† | 128/6373 (2.0%) | 177/6520 (2.7%) | 877/6520 (13.5%) |
| Number discontinuing AA‡ | 68/128 (53.1%) | 76/177 (42.9%) | 251/877 (28.6%) |
| Clean-up method | According to reference | Total solvent (mL) | Time (h) | Swelling (%) | Release of oligomers (%) |
| Soxhlet extraction ethylacetate | Smedes and Booij (2012) | 400 | 100 | 92 | 2.5 |
| Extraction ethylacetate | Shahpoury and Hageman (2013) | 400 | 48 | 76 | 2.4 |
| Extraction n-hexane/acetone (3:1) | Schäfer et al.(2010) | 800 | 96 | 124 | 2.5 |
| ASE n-hexane/acetone (1:1) | This study | 169 | 1.2 | 42 | 2.2 |
| Recurrence | No recurrence | p value | |||
| n | 9 | 187 | |||
| Mean age (SD) | 55.3 | (13.9) | 55.9 | (12.1) | n.s. |
| Stagea | |||||
| I | 2 | 87 | |||
| IIA or B | 4 | 96 | <0.01 | ||
| IIIA or B | 3 | 4 | |||
| Histology | |||||
| Ductal | 7 | 161 | |||
| Lobular | 2 | 11 | n.s. | ||
| Others | 0 | 15 | |||
| High nuclear grade | 11% | (1/9) | 4% | (7/181) | n.s. |
| High histological grade | 22% | (2/9) | 4% | (6/141) | n.s. |
| ERb | 100% | (9/9) | 100% | (187/187) | n.s. |
| PRb | 67% | (6/9) | 78% | (145/187) | n.s. |
| Mean Ki67 (%) (SD) | 37.9 | (21.7) | 24.1 | (18.5) | <0.05 |
| (Neo-) adjuvant therapy | |||||
| Endocrine + chemotherapy | 9 | 52 | |||
| Endocrine therapy only | 0 | 127 | |||
| Chemotherapy only | 0 | 1 | |||
| None | 0 | 7 |
| Category | Value |
| Total patients enrolled | 80 |
| Number of groups | 15 |
| Number of geographic areas with groups | 9 |
| Average number of patients per group | 5.3 |
| Female, number (%) | 51 (63.8%) |
| Age at enrollment (years), median (IQR) | 44 (36–51) |
| CD4 count at enrollment (cells/mL), median (IQR) | 509 (382–670) |
| Months on ART prior to enrollment, median (IQR) | 45.2 (22.4–65.6) |
| Group 1 (dose escalation) | Group 2 (1.35 × 105 PfSPZ) | Group 3 (2.7 × 105 PfSPZ) | Group 4 (2.7 × 105 PfSPZ) | Total PfSPZ vaccine | NS controls | |
| Number of volunteers | 3 | 20 | 20 | 6 | 49 | 8 |
| Total number of injections | 9 | 99 | 100 | 29 | 237 | 40 |
| Number of local AEs | 0 | 0 | 0 | 0 | 0 | 0 |
| Numbers of systemic AEs (% of total immunizations) | ||||||
| All | 1 (11%) | 10 (10.1%) | 6 (6%) | 0 | 17 (7.2%) | 2 (5.0%) |
| Headache* | 1 (11%) | 7 (7%)† | 2 (2%) | 0 | 10 (4.2%) | 1 (2.5%) |
| Abdominal pain | 0 | 2 (2%) | 1 (1%) | 0 | 3 (1.3%) | 0 |
| Chills | 0 | 0 | 1 (1%) | 0 | 1 (0.4%) | 0 |
| Fever | 0 | 0 | 2 (2%) | 0 | 2 (0.8%) | 0 |
| Diarrhea | 0 | 0 | 0 | 0 | 0 | 1 (2.5%) |
| Chest pain | 0 | 1 (1%) | 0 | 0 | 1 (0.4%) | 0 |
| Other | 0 | 0 | 0 | 0 | 0 | 0 |
| Systemic AEs - no. volunteers with ≥ 1 event (% of volunteers) | ||||||
| Any | 1 (33%) | 7 (35%) | 2 (10%) | 0 | 10 (20.4%) | 1 (13%) |
| Headache | 1 (33%) | 6 (30%) | 2 (10%) | 0 | 9 (18.4%) | 1 (13%) |
| Abdominal pain | 0 | 2 (10%) | 1 (5%) | 0 | 3 (6.1%) | 0 |
| Chills | 0 | 0 | 1 (5%) | 0 | 1 (2.0%) | 0 |
| Fever | 0 | 0 | 2 (10%) | 0 | 2 (4.1%) | 0 |
| Diarrhea | 0 | 0 | 0 | 0 | 0 | 1 (13%) |
| Chest pain | 0 | 1 (5%) | 0 | 0 | 1 (2.0%) | 0 |
| All other | 0 | 0 | 0 | 0 | 0 | 0 |
| Clinicopathological features | n | China | n | Japan |
| Age(mean +SD, yr) | 9793 | 59.25+9.83* | 162 | 68.77+8.82 |
| Sex(male : female) | 9776 | 6151:3625* | 154 | 104:50 |
| Tumor size(<3cm:≥3cm) | 2132 | 1062:1070* | 99 | 72:27 |
| Lymph node metastasis(+) | 2324 | 1013(43.6) * | 153 | 54(35.3) |
| Histological type | 8948 | 156 | ||
| Adenocarcinoma | 4910(54.9) | 86(55.1) | ||
| Squamous cell carcinoma | 3270(36.5) * | 38(24.4) | ||
| Small cell carcinoma | 494(5.5) * | 18(9.0) | ||
| Large cell carcinoma | 274(3.1) * | 14(11.5) | ||
| TNM staging | 2608 | 101 | ||
| I | 1030(39.49) * | 61(60.4) | ||
| II | 533(20.4) | 13(12.9) | ||
| III | 846(32.4) | 26(25.7) | ||
| IV | 199(7.6) * | 1(1.0) |
| PhenX family history of MI? | PMRP family history of MI/Angina | ||||||
| Yes | No | Yes | No | ||||
| N | % | N | % | N | % | N | % |
| 1108 | 52.8 | 991 | 47.2 | 589 | 28.1 | 1510 | 71.9 |
| Kappa=0.352 (95% CL=0.317, 0.386) |
| Combined category | Includes | Constructed for wave |
| Any mood disorder | MDD, Dysthymia | 1 and 2 |
| Any anxiety disorder W1 | Panic disorder, Agoraphobia without a history of panic disorder, Specific phobias, Social phobia, GAD, OCD, PTSD. | 1 |
| Any Anxiety disorder W1–2 | Panic disorder, Agoraphobia without a history of panic disorder, Specific phobias, Social phobia, GAD. | 1 and 2 |
| Any anxiety disorder W1–2 excluding specific phobias | Panic disorder, Agoraphobia without a history of panic disorder, Social phobia, GAD. | 1 and 2 |
| AUD | Alcohol abuse, Alcohol dependence. | 1 and 2 |
| Any mental disorder W1 | Any mood disorder, Any anxiety disorder W1, AUD. | 1 |
| Any mental disorder W1–2 | Any mood disorder, Any anxiety disorder W1–2, AUD. | 1 and 2 |
| Any mental disorder W1–2 excluding specific phobias | Any mood disorder, Any anxiety disorder W1–2 excluding specific phobias, AUD. | 1 and 2 |
| Categories only presented in Supplementary table | ||
| Drug use disorder | Drug abuse, drug dependence. | 1 |
| Any substance use disorder | Drug use disorder, AUD. | 1 |
| Any disorder W1- supplement | Any mood disorder, Any anxiety disorder W1, Any substance use disorder | 1 |
| Parameters | Value |
| Number of unigenes | 68,961 |
| Number of transcripts | 134,793 |
| Average unigene length (bp) | 1322 |
| Average transcript length (bp) | 1600 |
| Unigene N50 (bp) | 1721 |
| transcript N50 (bp) | 2263 |
| Minimum unigene length (bp) | 201 |
| Minimum transcript length (bp) | 201 |
| Maximum unigene length (bp) | 15,890 |
| Maximum transcript length (bp) | 15,890 |
| Characteristic | Univariate analysis | Multivariate analysis | ||
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Age (≤ 40 vs. > 40 years) | 1.038 (0.614–1.752) | 0.890 | – | |
| T stage (pT0–T1 vs. pT2-T4) | 1.393 (0.897–2.164) | 0.140 | – | |
| Family history of breast cancer (yes vs. no) | 0.771 (0.386–1.543) | 0.463 | – | |
| Axillary lymph node status (negative vs. positive) | 2.507 (1.615–3.890) | < 0.001 | 2.055 (1.190–3.547) | 0.010 |
| TNM stage (0-I vs. II-III) | 2.063 (1.221–3.485) | 0.007 | 1.237 (0.653–2.346) | 0.514 |
| Pathological type (invasive ductal carcinoma vs. others) | 0.874 (0.450–1.695) | 0.689 | – | |
| Vascular invasion (yes vs. no) | 2.486 (1.497–4.126) | < 0.001 | 1.901 (1.124–3.216) | 0.017 |
| ATG5 rs473543 genotype (AA/GA vs. GG) | 1.717 (1.036–2.847) | 0.036 | 1.729 (1.041–2.870) | 0.034 |
| A | B | C | D | E | F | G | H | I | J | K |
| 1 | 24 | LD | Good | 86 | 48 + 8 | Screw track infection | 12 | 90/85 | Excellent | 10–40 |
| 2 | 24 | RS | Good | 36 | 13 + 7 | – | 12 | 89/78 | Excellent | 15–50 |
| 3 | 24 | Repair | Good | 27 | 9 + 5 | Superficial infection | 6 | 91/80 | Excellent | 10–30 |
| 4 | 12 | RS | Good | 60 | 13 + 6 | – | 6 | 91/81 | Good | 5–20 |
| 5 | 24 | RS | Good | 97 | 8 + 7 | – | 9 | 89/80 | Good | 15–60 |
| 6 | 12 | RS | Fair | 62 | 44 + 5 | Superficial infection | 6 | 90/78 | Good | 5–30 |
| 7 | 24 | Repair | Good | 26 | 8 + 6 | – | 6 | 88/75 | Excellent | 15–50 |
| 8 | 24 | RS | Good | 28 | 10 + 9 | – | 6 | 87/77 | Excellent | 10–40 |
| 9 | 36 | ALT | Good | 83 | 36 + 7 | – | 12 | 94/77 | Excellent | 5–30 |
| 10 | 24 | Repair | Good | 32 | 22 + 8 | – | 6 | 90/80 | Good | 10–40 |
| 11 | 24 | Repair | Good | 27 | 21 + 8 | Screw track infection | 6 | 91/79 | Good | 20–50 |
| 12 | 12 | Repair | Good | 47 | 9 + 6 | – | 12 | 95/81 | Good | 10–30 |
| 13 | 12 | Repair | Good | 31 | 13 + 9 | – | 6 | 90/80 | Good | 10–40 |
| 14 | 24 | LD | Good | 54 | 26 + 7 | – | 6 | 93/80 | Excellent | 10–50 |
| 15 | 24 | RS | Good | 97 | 11 + 9 | – | 6 | 87/84 | Good | 10–40 |
| 16 | 12 | Repair | Good | 51 | 27 + 11 | – | 12 | 90/75 | Good | 10–20 |
| Household assets | Yes | No |
| Electricity | 120 (32%) | 261 (69%) |
| Running water (tap) | 39 (10%) | 342 (90%) |
| Water closet toilet | 65 (17%) | 316 (83%) |
| Solar power | 57 (15%) | 324 (85%) |
| Television | 181 (48%) | 200 (53%) |
| Vehicle | 95 (25%) | 286 (75%) |
| Fridge | 81 (22%) | 300 (78%) |
| Indoor bathroom | 93 (24%) | 288 (76%) |
| Laundry machine | 12 (3%) | 369 (97%) |
| Computer | 142 (37%) | 239 (62%) |
| Micro wave oven | 6 (2%) | 375 (98%) |
| Fixed telephone | 6 (2%) | 375 (98%) |
| Mobile telephone | 341 (90%) | 40 (10%) |
| Patient characteristics | ||||
| Mean age | Years 40.3 | SD 16.4 | Min 27.0 | Max 55.0 |
| Median length of stay | Years 5.5 | SD 6.8 | Min 0.5 yrs | Max 33.5 yrs |
| Ward location | ||||
| Low secure hostel | 6 [12%] | |||
| Low secure rehabilitation ward | 11 [20%] | |||
| Medium security rehabilitation | 15 [29%] | |||
| Medium security sub-acute | 14 [27%] | |||
| High secure [long stay] | 6 [12%] | |||
| Community leave status | ||||
| Community leave | 36 [70%] | |||
| No community Leave | 16 [30%] | |||
| Primary Diagnosis | ||||
| Schizophrenia/ Schizoaffective disorder | 52 [100%] |
| 5 Fr Catheters (n = 49) | 7 Fr Catheters (n = 48) | P | |
| Total discomfort#1 | 3.2 ± 0.2 | 3.9 ± 0.2 | 0.018 |
| Difficulty with eating#1 | 2.2 ± 0.1 | 2.7 ± 0.2 | 0.079 |
| Nasal hemorrhage#2 | 1 (2) | 0 (0) | 0.320 |
| Sore throat#2 | 6 (12) | 9 (18) | 0.376 |
| Nausea#2 | 0 (0) | 1 (2) | 0.310 |
| Caught on a nearby object#2 | 1 (2) | 1 (2) | 0.988 |
| Other adverse events#2 | 10 (20) | 10 (20) | 0.481 |
| Error number:Check the appropriate boxes | Physician assessment number: 1 or 2 | |
| Potential severity according to the Medication Error Index (3) | ||
| No consequences for the patient | ||
| An error avoided that would not cause patient harm | ||
| An error avoided that would require monitoring to confirm that it did not result in patient harm | ||
| Temporary damage | Potential clinical consequences | Potential hospitalisation and treatment* |
| An error avoided that could have contributed to temporary harm to the patient, requiring intervention | Acute renal failure | Hospitalisation |
| Cardiac toxicity | Prolongation of the initial hospitalisation | |
| Skin toxicity | New hospitalisation | |
| An error avoided that could have contributed to temporary harm to the patient, requiring initial or prolonged hospitalisation | Neutropenia | Type of ward |
| Thrombopenia | Standard hospitalisation unit | |
| Anemia | Day-care unit | |
| Febrile neutropenia | Intensive care unit | |
| Neurotoxicity | Number of additional days of hospitalisation | |
| Permanent damage | Hepatic cytolysis | Treatments |
| An error avoided that could have contributed to permanent patient harm | Hepatic cholestasis | Platelet transfusions |
| Compromised vital prognosis | Diarrhea | Erythrocyte transfusions |
| An error avoided that could have required intervention necessary to sustain life | Vomiting | Granulocyte Colony Stimulating Factor |
| Patient death | Other: | Parenteral nutrition |
| Other: | ||
| An error avoided that could have contributed to the patient's death |
| Characteristics | Younger men without CAD (n = 25) | Older men without CAD (n = 25) | Younger men with CAD (n = 19) | Older men with CAD (n = 19) | P-value | Adjusted P-valuea |
| Age (years) | 53.6 ± 1.4 | 72.6 ± 1.5 | 54.3 ± 1.9 | 73.4 ± 1.9 | <0.001 | - |
| BMI (kg/m2) | 28.1 ± 1.1 | 27.0 ± 0.7 | 29.0 ± 1.2 | 26.3 ± 0.5 | 0.21 | 0.33 |
| Waist circumference (cm) | 100.4 ± 3.2 | 99.9 ± 1.7 | 102.2 ± 3.3 | 100.6 ± 1.7 | 0.94 | 0.81 |
| Glucose (mmol/L) | 5.12 ± 0.23 | 5.73 ± 0.20 | 6.00 ± 0.27 | 5.50 ± 0.20 | 0.06 | 0.06 |
| Total cholesterol (mmol/L) | 4.61 ± 0.20 | 3.78 ± 0.21 | 4.33 ± 0.30 | 3.91 ± 0.19 | 0.03 | 0.48 |
| LDL-C (mmol/L) | 2.58 ± 0.16 | 2.02 ± 0.17 | 2.67 ± 0.27 | 2.14 ± 0.16 | 0.04 | 0.63 |
| HDL-C (mmol/L) | 1.22 ± 0.08 | 1.16 ± 0.06 | 1.03 ± 0.05 | 1.12 ± 0.06 | 0.21 | 0.20 |
| Fasting triglyceridemia (mmol/L)b | 1.58 ± 0.37 | 1.22 ± 0.14 | 1.48 ± 0.12 | 1.33 ± 0.11 | 0.27 | 0.79 |
| Smoking (ever/never) | 15/10 | 14/11 | 14/5 | 9/9 | 0.50 | - |
| Medication (%) | ||||||
| ARB | 4 (16) | 5 (20) | 5 (26.3) | 4 (21.1) | 0.89 | - |
| ASA | 6 (24) | 9 (36) | 11 (57.9) | 16 (84.2) | <0.001 | - |
| β-Blocker | 8 (32) | 7 (28) | 9 (47.4) | 11 (57.9) | 0.16 | - |
| Diuretic | 8 (32) | 10 (40) | 3 (15.8) | 5 (26.3) | 0.36 | - |
| Calcium channel blocker | 2 (8) | 6 (24) | 9 (47.4) | 7 (36.8) | 0.02 | - |
| Lipid-lowering drugs | 8 (32) | 17 (68) | 12 (63.2) | 18 (94.7) | 0.003 | - |
| ACE inhibitors | 11 (44) | 8 (32) | 8 (42.1) | 6 (31.6) | 0.75 | - |
| Nitroglycerine | 1 (4) | 4 (16) | 5 (26.3) | 9 (47.4) | 0.005 | - |
| Mean ABCA1 DNA methylation (%) | 36.1 ± 1.5 | 35.9 ± 1.5 | 33.9 ± 1.3 | 40.7 ± 2.0c,d,e | 0.04 | <0.001 |
| Personal history of hiatal hernia | Family history of hiatal hernia | EA | GCA | DGA | |||||||
| Controls | Cases | OR (95% CI)a | Pa | Cases | OR (95% CI)a | Pa | Cases | OR (95% CI)a | Pa | ||
| No | No | 1117 | 93 | 1.00 (ref) | 129 | 1.00 (ref) | 249 | 1.00 (ref) | |||
| No | Yes | 68 | 6 | 1.26 (0.52-3.08) | 0.61 | 13 | 1.89 (0.99-3.61) | 0.056 | 8 | 0.89 (0.40-1.97) | 0.77 |
| Yes | No | 82 | 36 | 4.91 (3.04-7.93) | <0.001 | 23 | 2.36 (1.40-3.97) | 0.001 | 17 | 1.44 (0.80-2.60) | 0.22 |
| Yes | Yes | 12 | 10 | 10.75 (4.26-27.12) | <0.001 | 9 | 6.55 (2.60-16.50) | <0.001 | 2 | - | - |
| P for interaction= | 0.50 | 0.48 | 0.99 |
| GG n = 146 | GC/CC n = 64 | p value | |
| Infection type | |||
| Gram-negative | 62% | 81% | 0.0062 |
| Gram-positive | 83% | 83% | 1.0000 |
| Fungal | 52% | 58% | 0.4565 |
| Viral | 18% | 17% | 1.0000 |
| Parasitic | 0% | 0% | |
| Other | 1% | 3% |
| Stem cell source | Benefits | Drawbacks | ||
| Donor | Recipient | Donor | Recipient | |
| BM | Lower risk of GvHD | More invasive HSC collection | ||
| PBSC | No general anesthesia for collection; less discomfort and pain | Faster hematopoietic engraftment and immune reconstitution; enhanced GvL effect | Higher risk of GvHD | |
| CB | Non-invasive | Lower risks of GvHD and relapse; rapid availability; increased level of HLA-disparity tolerated | Lower number of HSCs; slower immune reconstitution |
| Characteristic | Unit | Recommended values (Santos and Borem, 2013) | CTC20 | CTC175-A |
| Fiber | % sugarcane | 10–13 | 10.72 | 10.41 |
| Starch | mg/kg | <1,000 | 875 | 948 |
| Brix | % juice | >14 | 21.02 | 20.84 |
| Dextran | mg/kg | <10 | <10 | <10 |
| RS | % juice | <0.8 | 0.47 | 0.47 |
| TRS | % juice | >15 | 20.54 | 20 |
| pH | – | 4.8–5.8 | 5.4 | 5.3 |
| Pol | % juice | >14 | 19.43 | 19.26 |
| Purity | % juice | >85 | 92.44 | 92.42 |
| CNE | Mt | Zt | Mg | Zg | Trans&Gene | NoTrans&Gene | |
| Hs259 | Limbs | + | - | + | - | Yes | |
| Spinal cord | - | + | + | + | |||
| Hs327 | Hindbrain | + | + | + | + | ||
| Forebrain | - | + | + | + | |||
| Spinal cord | + | + | + | - | Yes | ||
| Midbrain | - | + | + | + | |||
| Hs382 | Forebrain | + | + | + | + | ||
| Somites | + | + | + | + | |||
| Spinal cord | + | - | + | + | |||
| DRG | + | - | + | - | Yes | ||
| Eye | - | + | + | + | |||
| Notochord | - | + | + | + | |||
| Hindbrain | + | - | + | + | |||
| Midbrain | + | - | + | + | |||
| Hs422 | Forebrain | + | + | + | + | ||
| Spinal cord | - | + | - | - | |||
| Nose | + | - | + | - | Yes | ||
| Hindbrain | - | + | - | - | |||
| Hs595 | Forebrain | + | + | + | + | ||
| Midbrain | + | - | + | + | |||
| Nose | + | - | + | - | Yes | ||
| Hs609 | Forebrain | + | - | + | + | ||
| Limbs | + | - | + | - | Yes | ||
| Hs671 | Forebrain | + | + | + | + | ||
| Eye | - | + | + | + | |||
| Hindbrain | - | + | + | + | |||
| DRG | - | + | + | - | |||
| Hs672 | Forebrain | + | - | + | + | ||
| Midbrain | + | + | + | + | |||
| Spinal cord | + | - | + | - | Yes | ||
| Hs687 | Forebrain | + | + | + | + | ||
| Spinal cord | + | - | + | - | Yes | ||
| Hs774 | Hindbrain | + | + | + | + | ||
| Limbs | + | + | + | - | Yes | ||
| Forebrain | - | + | + | + | |||
| Eye | - | + | - | + | Yes | ||
| Hs1114 | Midbrain | + | + | + | + | ||
| Hindbrain | + | + | - | + | |||
| Spinal cord | + | + | + | + |
| ISAV Sample(s) | Sequence direction | No. of trimmed reads | Percent of reads identical to Sanger sequence |
| SCN1a | HE gene forward | 50552 | 82.4 |
| HE gene reverse | 69684 | 91.4 | |
| F gene forward | 44498 | 91.9 | |
| F gene reverse | 49118 | 89.2 | |
| SCN pool | HE gene forward | 25695 | 78.3 |
| (SCN2, SCN3, SCN4) | HE gene reverse | 68481 | 92.2 |
| F gene forward | 31230 | 92.1 | |
| F gene reverse | 35799 | 89.5 | |
| OBK1b | HE gene forward | 52038 | 92.4 |
| HE gene reverse | 88172 | 93.0 | |
| F gene forward | 31546 | 91.4 | |
| F gene reverse | 46835 | 89.7 | |
| OBK pool | HE gene forward | 40458 | 92.1 |
| (OBK2, OBK3, OBK4) | HE gene reverse | 51772 | 92.8 |
| F gene forward | 45909 | 91.9 | |
| F gene reverse | 44498 | 91.9 |
| Treatment | Total cells | Eosinophils | Monocytes | Lymphocytes | Neutrophils |
| PBS | 240 ± 38§ | 3 ± 1§ | 201 ± 18 | 8 ± 5§ | 10 ± 7 |
| Dpt+Vit A 50 | 612 ± 36 | 293 ± 28 | 198 ± 24 | 86 ± 15 | 34 ± 8 |
| Dpt+Vit A 500 | 624 ± 59 | 312 ± 29 | 199 ± 22 | 82 ± 12 | 29 ± 7 |
| Dpt+Vit A 2500 | 428 ± 46 | 46 ± 35* | 284 ± 34 | 79 ± 11 | 19 ± 7 |
| Duration (year) | n | % | Mean score | 95%CI | t | p |
| < 10 | 142 | 77 | 3.0 | 2.67–3.28 | 2.17 | 0.032 |
| 10–19 | 33 | 18 | 3.8 | 3.11–4.42 | ||
| ≥ 20 | 9 | 5 | 4.0 | 2.78–5.12 | 0.27 | 0.788 |
| Accurate Priced | Over Priced | Low Priced | ||
| Professional Year | N (%) | Median (Min-Max) | Median (Min-Max) | Median (Min-Max) |
| 0-5 | 53 (35.57) | 1 (0-6) | 19 (8-28) | 9 (1-20) |
| 6-10 | 45 (30.20) | 2 (0-5) | 19 (9-27) | 10 (2-20) |
| 11-15 | 24 (16.10) | 2 (0-6) | 18.5 (11-26) | 9.5 (3-14) |
| 16-20 | 13 (8.72) | 1 (0-3) | 13 (2-25) | 14 (5-27)* |
| >20 | 14 (9.39) | 1.5 (0-5) | 18.5 (2-18) | 9.5 (2-18) |
| P | 0.564 | 0.091 | 0.031 |
| Reporting criteria | CDE Programme |
| Where was the intervention delivered and why? | Primary care settings (GP surgeries) and community settings with a single lay educator (or with the use of interpreters when necessary |
| What behavioural change theory has intervention been based on (if any)? | Social learning theory |
| What behaviour change techniques were used by people delivering the intervention (if any)*? | 1, 2, 4, 6, 8, 10, 19, 22, 24 |
| A description of the activities and material provided in each workshop and their intended outcomes? | Material: information on weight management, choosing healthier foods, meal planning, physical exercise, checking and improving metabolic control and preventing complications. |
| Activities: participants taking each other’s blood pressure, BMI calculations, understanding sugar and salt content in foods, Eat-well plate, food maps, guided imagery, ‘freethink’. | |
| Intended outcomes: desirable body weight, learn to shop for food, increase physical activity, take medication properly and regularly, recognise early symptoms of condition, regularly attend clinics, improved symptom control, reduced BMI, improved quality of life and knowledge of condition, reduced level of prescribing, slower disease progression, management of condition, carry out normal roles and activities, and manage emotional impact of illness. | |
| What support (if any) was provided to individuals outside of workshops? | No contact outside of workshops. |
| Was a manual or protocol used to deliver the intervention and are there details on how it can be accessed? | Manual is available to lay educators, however, not used during intervention. Can be accessed via permission from Health Exchange. |
| How were individuals referred to the programme? | Patients suffering from diabetes mellitus, coronary heart disease and/or chronic kidney disease were invited to attend the programme. Patients referred to the programme by general practitioners, practice nurses or practice staff. Practices citing a lack of time asked CDEs to contact patients on chronic disease registers directly by phone or postal mail. |
| Were any cultural or structural adaptations used? | Delivery in various languages, cultural adaptation of educational material, application of visual aids and demonstrations, understandable terminology, emotional well-being, culturally sensitive approach to delivery, recruitment of lay personnel, delivery in community locations, and religious/cultural acknowledgement. |
| Trial I | Trial II | |||
| Filtered music | Headphones only condition | Filtered music | Unfiltered music | |
| Mean age (SD)b | Mean age (SD)b | Mean age (SD)b | Mean age (SD)b | |
| Met at least partial criteria on ADI-Ra | ||||
| Male | 58.24 (10.14), n = 25 | 49.46 (10.96), n = 23 | 54.89 (14.83), n = 44 | 56.20 (9.36), n = 27 |
| Femalec | 48.67 (11.99), n = 11 | 61.00 (7.91), n = 5 | 44 (20.66), n = 6 | 60.33 (9.29), n = 5 |
| Total | 55.37 (11.42), n = 36 | 52.67 (11.30), n = 28 | 53.33 (15.95), n = 50 | 56.74 (9.25), n = 32 |
| Fatty acids | 0.04 % CO2 | 2 % CO2 | 5 % CO2 | ||||||
| 4th day | 8th day | 12th day | 4th day | 8th day | 12th day | 4th day | 8th day | 12th day | |
| C16:0 | 23.92 | 24.69 | 24.00 | 20.94 | 16.63 | 14.54 | 19.28 | 16.63 | 12.54 |
| C16:1 | ND | ND | 1.65 | 1.26 | 0.42 | ND | 1.92 | 0.42 | ND |
| C16:2 | 6.10 | 7.33 | 7.50 | 4.41 | 1.44 | 0.71 | 4.09 | 2.04 | 0.91 |
| C16:3 | 8.82 | 7.02 | 6.59 | 8.38 | 3.90 | 3.13 | 7.78 | 3.30 | 4.13 |
| C18:0 | 3.21 | 2.47 | 2.11 | 1.00 | 2.22 | 2.16 | 1.42 | 2.02 | 2.16 |
| C18:1 | 8.61 | 8.52 | 8.00 | 15.57 | 47.69 | 55.41 | 16.24 | 49.69 | 59.41 |
| C18:2 | 23.29 | 24.73 | 26.89 | 21.18 | 13.00 | 11.00 | 21.85 | 11.00 | 10.23 |
| C18:3 | 25.84 | 23.85 | 22.41 | 25.60 | 12.27 | 10.62 | 24.00 | 10.27 | 8.62 |
| Others | 0.32 | 1.42 | 0.85 | 1.66 | 2.42 | 2.43 | 3.41 | 4.62 | 2.00 |
| Low utilization | Intermediate utilization | High utilization | ||||
| Median | IQR | Median | IQR | Median | IQR | |
| Volume measures (n) | ||||||
| Annual PICU admissions | 1582 | (977, 2602) | 2283 | (1678, 2657) | 1614 | (1475, 2241)NS |
| Annual cardiac surgical volume | 184 | (116, 340) | 233 | (145, 314) | 224 | (180, 249)NS |
| PICU severity of illness measures (%) | ||||||
| Mechanical ventilation admits | 36.8% | (26.9, 53.4) | 43.9% | (37.5, 46.9) | 36.9% | (31.3, 45.2)NS |
| APR DRG SOI category 3 | 32.4% | (28.7, 34.3) | 31.7% | (29.0, 33.7) | 30.5% | (29.7, 34.0)NS |
| APR DRG SOI category 4 | 20.3% | (15.2, 22.2) | 24.2% | (17.4, 27.2) | 20.7% | (19.1, 21.9)NS |
| Measured variables | Pretest(n = 17) | Posttest(n = 17) | Test power | Effect size |
| Mean ± SD | Mean ± SD | |||
| SMMI | 8.97 ± 1.69 | 10.52 ± 2.35 | 0.95 | 0.7529 |
| Physical fitness | ||||
| Standing on one foot (seconds) | 3.30 ± 7.19 | 7.36 ± 12.32 | 0.95 | 0.4023 |
| Shoulder–arm flexibility (centimeters) | −37.50 ± 16.33 | − 28.56 ± 13.94 | 0.95 | 0.5884 |
| 8-ft up and go test (seconds) | 36.2 ± 24.57 | 22.00 ± 17.25 | 0.95 | −0.7091 |
| Grip strength (kilograms) | 11.19 ± 7.36 | 14.45 ± 7.48 | 0.95 | 0.4399 |
| Five repeated sit-to-stand tests (seconds) | 42.42 ± 22.98 | 30.58 ± 15.31 | 0.95 | −0.6063 |
| AF (n = 13) | nAF (n = 21) | p-value | |
| Gender (M/F) | 9/4 | 15/6 | 0.716 |
| Age (yrs) | 64.6 ± 11.3 | 59.6 ± 12.1 | 0.237 |
| BMI (kg/m2) | 30.2 ± 6.14 | 27.5 ± 3.41 | 0.247 |
| Height (m) | 1.62 ± 0.19 | 1.67 ± 0.08 | 0.475 |
| Weight (kg) | 80.1 ± 3.86 | 77.7 ± 2.69 | 0.623 |
| MI | 33% | 24% | 0.555 |
| Stroke | 8.3% | 14% | 0.614 |
| PVD | 17% | 4.8% | 0.252 |
| PCI | 0.0% | 0.0% | 1.000 |
| Hypertension | 75% | 76% | 0.939 |
| Hypercholesterolaemia | 92% | 90% | 0.909 |
| Family History | 45% | 65% | 0.291 |
| Diabetes- On Insulin | 58%25% | 43%24% | 0.3920.939 |
| Smoking | 17% | 24% | 0.629 |
| Alcohol >10u per week | 25% | 25% | 1.000 |
| Score of the reader | Sensitivity | Specificity | PPV | NPV |
| CXR on all suspects (n = 998) | ||||
| a) Highly consistent for TB | 68 (64–72) | 90 (87–93) | 0.90 (0.87–0.93) | 0.69 (0.65–0.72) |
| b) Consistent for TB | 23 (19–26) | 77 (73–80) | 0.55 (0.49–0.62) | 0.44 (0.40–0.47) |
| c) Pathology, but no TB | 2 (0–3) | 96 (94–98) | 0.33 (0.16–0.51) | 0.43 (0.40–0.46) |
| 91 (88–93) | 67 (62–71) | 0.78 (0.74–0.81) | 0.84 (0.81–.088) | |
| 92 (90–94) | 63 (58–67) | 0.76 (0.73–0.79) | 0.86 (0.82–0.90) | |
| CXR on suspects excluding those who were ZN positive (n = 657) | ||||
| a) Highly consistent for TB | 48 (42–55) | 90 (87–93) | 0.72 (0.65–0.79) | 0.77 (0.73–0.81) |
| b) Consistent for TB | 31 (25–37) | 77 (73–81) | 0.42 (0.34–0.49) | 0.68 (0.83–0.90) |
| c) Pathology but no TB | 3 (1–5) | 96 (95–98) | 0.27 (0.9–0.46) | 0.65 (0.62–0.69) |
| 80 (74–85) | 67 (62–71) | 0.56 (0.50–0.61) | 0.86 (0.83–0.90) | |
| The entire diagnostic process (n = 998) | ||||
| ZN followed by CXR | 93 (91–95) | 62 (57–67) | 0.76 (0.72–0.79) | 0.87 (0.83–0.91) |
| CXR followed by ZN | 89 (86–91) | 97(84–90) | 0.90 (0.87–0.92) | 0.86 (0.83–0.89) |
| Non-survey days | Survey days | Adjusted comparisona | |||||
| Number of consultations per day | Difference | 95 % CI | p | ||||
| Mean (SD) | 11.9 | (7.3) | 14.1 | (10.3) | 2.03 | 1.20- 2.86 | <0.001 |
| Median (IQR) | 11 | (7–16) | 12 | (8–17) | |||
| Missing MTUHA information | n | % | n | % | OR | 95 % CI | p |
| Age | 133 | 1.4 % | 106 | 1.1 % | 0.65 | 0.46-0.91 | 0.011 |
| Gender | 36 | 0.4 % | 13 | 0.1 % | 0.20b | 0.05-0.86b | 0.031b |
| Village of origin | 5,937 | 60.4 % | 6,919 | 71.0 % | 1.65c | 1.13-2.40c | 0.010c |
| Previous attendance | 1,604 | 16.3 % | 2,127 | 21.8 % | 0.54 | 0.26-1.13 | 0.103 |
| Subscriber type | 4,152 | 42.2 % | 5,785 | 59.4 % | 1.92c | 1.38-2.67c | <0.001c |
| Malaria diagnostic and treatment (primary outcomes) | n/N | % | n/N | % | OR | 95 % CI | p |
| RDT result recorded | 1,811/9,834 | 18.4 % | 2,010/9,745 | 20.6 % | 1.11 | 0.98-1.26 | 0.097 |
| AM prescription with a negative RDT | 168/1,721 | 9.8 % | 160/1,901 | 8.4 % | 0.83 | 0.56-1.23 | 0.343 |
| AM prescription without a RDT result | 210/8,023 | 2.6 % | 182/7,735 | 2.4 % | 0.73 | 0.53-1.00 | 0.052 |
| Honey source | Samples | Parameters | |||||
| pH | Moisture (%) | EC (mS/cm) | TDS (ppm) | Colour (nm) | ABS450 (mAU,50w/v) | ||
| Apis mellifera | I | 4.46 ± 0.095 | 11.870 ± 0.703 | 0.163 ± 0.0153 | 264.1 ± 0.59 | 1.986 ± 0.001 | 961.33 ± 0.58 |
| II | 4.22 ± 0.077 | 11.537 ± 0.454 | 0.217 ± 0.1155 | 282.0 ± 0.25 | 2.102 ± 0.001 | 988.33 ± 1.15 | |
| III | 4.04 ± 0.124 | 11.817 ± 0.301 | 0.240 ± 0.0200 | 316.3 ± 0.06 | 2.108 ± 0.001 | 1006.33 ± 1.53 | |
| Mean | 4.24 ± 0.20b | 11.74 ± 0.47a | 0.207 ± 0.04a | 287.46 ± 22.95b | 2.065 ± 0.06b | 985.33 ± 19.64c | |
| Hypotrigona sp. | I | 3.85 ± 0.111 | 18.310 ± 0.900 | 0.317 ± 0.0058 | 399.1 ± 0.35 | 2.103 ± 0.001 | 724.33 ± 0.58 |
| II | 3.65 ± 0.036 | 17.053 ± 0.489 | 0.270 ± 0.0200 | 349.0 ± 0.36 | 1.861 ± 0.001 | 630.00 ± 1.73 | |
| III | 3.75 ± 0.042 | 17.127 ± 0.239 | 0.323 ± 0.0493 | 362.0 ± 0.15 | 1.886 ± 0.001 | 682.67 ± 0.58 | |
| Mean | 3.75 ± 0.11a | 17.50 ± 0.80c | 0.303 ± 0.04b | 370.01 ± 22.51c | 1.950 ± 0.12b | 679.00 ± 40.95a | |
| Melipona sp. | I | 3.80 ± 0.027 | 13.507 ± 0.047 | 0.217 ± 0.0152 | 209.0 ± 0.31 | 1.533 ± 0.000 | 762.33 ± 2.31 |
| II | 4.18 ± 0.066 | 15.203 ± 0.186 | 0.240 ± 0.0100 | 211.7 ± 0.15 | 2.012 ± 0.001 | 792.33 ± 1.15 | |
| III | 4.65 ± 0.053 | 12.863 ± 0.221 | 0.257 ± 0.0153 | 221.2 ± 0.15 | 1.632 ± 0.001 | 805.33 ± 0.58 | |
| Mean | 4.21 ± 0.37b | 13.86 ± 1.06b | 0.238 ± 0.02a | 214.00 ± 5.55a | 1.726 ± 0.22a | 786.67 ± 19.14b |
| Pathogen | Host | |||||
| Measure (n) | Among regions | Among populations | Within populations | Among regions | Among populations | Within populations |
| Infectivity (n > 840) | 0.000 | 0.026 | 0.450 | 0.000 | 0.032 | 0.492 |
| Time to sporulation (n > 532) | 0.000 | 0.000 | 0.255 | 0.000 | 0.002 | 0.052 |
| Aggressiveness (n > 527) | 0.000 | 0.000 | 0.202 | 0.000 | 0.000 | 0.065 |
| Colony size (n > 527) | 0.000 | 0.008 | 0.137 | 0.000 | 0.000 | 0.058 |
| Fitness 1 (n > 527) | 0.000 | 0.000 | 0.240 | 0.000 | 0.000 | 0.090 |
| Fitness 2 (n > 527) | 0.000 | 0.000 | 0.254 | 0.000 | 0.000 | 0.092 |
| Sexual spore production (n > 291) | 0.000 | 0.232 | 0.663 | 0.001 | 0.000 | 0.105 |
| Scenario | Deaths per 1,000 live births in 2010 (95% CI) | Annualized rate of decline, 1990–2010 (95% CI) |
| Currently estimated values | 111 (108, 115) | 2.2% (2.0–2.4%) |
| Counterfactual at 2005 coverage levels | 119 (114, 123) | 1.9% (1.7–2.1%) |
| Counterfactual at 2000 coverage levels | 124 (118, 129) | 1.7% (1.5–1.9%) |
| GO-ID | Term | Categorya | FDRb | P-Value | #Test | #Ref | #notAnnot Test | #notAnnot Ref |
| GO:0005506 | iron ion binding | F | 3.99E-07 | 9.40E-11 | 17 | 153 | 115 | 9554 |
| GO:0055114 | oxidation-reduction process | P | 1.09E-06 | 6.16E-10 | 31 | 636 | 101 | 9071 |
| GO:0016491 | oxidoreductase activity | F | 1.09E-06 | 7.68E-10 | 31 | 642 | 101 | 9065 |
| GO:0004497 | monooxygenase activity | F | 6.16E-06 | 5.87E-09 | 13 | 106 | 119 | 9601 |
| GO:0020037 | heme binding | F | 6.16E-06 | 8.61E-09 | 15 | 157 | 117 | 9550 |
| GO:0046906 | tetrapyrrole binding | F | 6.16E-06 | 9.33E-09 | 15 | 158 | 117 | 9549 |
| GO:0044710 | single-organism metabolic process | P | 6.16E-06 | 1.02E-08 | 52 | 1747 | 80 | 7960 |
| GO:0016705 | oxidoreductase activity, acting on paired donors, with incorporation | F | 117 | 9534 | ||||
| or reduction of molecular oxygen | 1.53E-05 | 2.88E-08 | 15 | 173 | ||||
| GO:0003824 | catalytic activity | F | 5.33E-03 | 1.13E-05 | 75 | 3644 | 57 | 6063 |
| Gingival index | Number of patients |
| 0 | 23 |
| 1 | 55 |
| 2 | 16 |
| 3 | 14 |
| Total | 108 |
| Peptide | Sequence | Portal vein (nM/h) | Jugular vein (nM/h) | CL Rat (mL/min/Kg) | Liver first pass effect (%) |
| (4) | [Abu-Leu-NMe-D-Leu-NMe-Leu-Leu-D-Pro] | 1839 | 1656 | 41 | 11 |
| (5) | [Ala-Leu-NMe-D-Leu-NMe-Leu-Leu-D-Pro] | 449 | 104 | 70 | 77 |
| Group | 0 month | 6 months | 12 months | 18 months | 24 months | 30 months | 36 months |
| O | 31.33 ± 4.62 | 31.61 ± 4.47 | 32.83 ± 4.69 | 34.11 ± 4.85 | 35.69 ± 5.01 | 37.92 ± 4.94 | 40.67 ± 5.08 |
| M | 32.4 ± 3.92 | 33.13 ± 4.49 | 34.53 ± 4.53 | 36.33 ± 4.7 | 38.4 ± 4.75 | 40.67 ± 4.37 | 43.33 ± 3.22 |
| O + B + C* | 30.38 ± 6.02 | 31.67 ± 6.12 | 33.46 ± 5.93 | 36.04 ± 5.76 | 38.96 ± 5.69 | 41.96 ± 4.65 | 44.83 ± 3.71 |
| O + B | 31.83 ± 5.84 | 33.58 ± 5.42 | 35.75 ± 4.59 | 38.83 ± 3.64 | 43.17 ± 2.08 | 46.58 ± 1.16 | 47.42 ± 0.79 |
| Postal | Electronic |
| Monetary or non-monetary incentives | Non-monetary incentives |
| Teaser on the envelope | Personalised questionnaires |
| Pre-notification | Include pictures |
| Follow-up with another copy included | Not including ‘survey’ in subject line |
| Handwritten addresses | Male signature |
| University sponsorship | White background |
| Use recorded delivery | Short questionnaire |
| Include return envelope | Offer of results |
| Avoid sensitive questions | Statement that others have responded |
| Control | iStroke | P | |
| Time, minutes, mean ± SD | 14.6 ± 7.4 | 7.3 ± 5.2 | 0.010 |
| Total missed contraindication counts, n (%a) | 23 (42.6) | 7 (13.0) | 0.001 |
| Missed contraindication counts per physician | |||
| Mean ± SD | 1.9 ± 0.7 | 0.6 ± 1.0 | 0.001 |
| Median | 2.0 | 0 | 0.002 |
| Missed contraindication counts per item | |||
| Mean ± SD | 3.8 ± 2.5 | 1.2 ± 1.5 | 0.047 |
| Median | 3.5 | 1.0 | 0.027 |
| Mutation | Score | Confidence | Domain | Prediction |
| R61W | 0.773 | Sensitivity: 0.76 | EGF-like 1 | Possibly damaging |
| Especificity: 0.86 | ||||
| R75P | 0.884 | Sensitivity: 0.71 | EGF-like 1 | Possibly damaging |
| Especificity: 0.89 | ||||
| D80G | 0.694 | Sensitivity: 0.78 | EGF-like 2 | Possibly damaging |
| Especificity: 0.85 | ||||
| R213K | 0.171 | Sensitivity: 0.89 | EGF-like 5 | Benign |
| Especificity: 0.72 |
| Source | Df | F |
| Species | 8 | 24.6*** |
| Water Level | 1 | 13.3*** |
| Species* Water | 8 | 1.2 |
| Age of spores | Mean spore diameter/radius (μm) | Spore volume (mm3) | Viability (%) | Germination (%) |
| 14 days | 30.4/15.2 | 0.000015 | 90 | 0 |
| 30 days | 64.2/32.1 | 0.000139 | 90 | 40 |
| 60 days | 96/48 | 0.00046 | 90 | 38 |
| 90 days | 105.7/52.8 | 0.00061 | 95 | 50 |
| Bacterial strains/Plasmids | Characteristic | Source/Reference |
| Brucella ovis | ||
| PA | virulent strain, natural NalR | CITA collection |
| BoΔwadA | PA in frame deletion mutant in wadA Δ58-679 | This work |
| BoΔwadB | PA in frame deletion mutant in wadB Δ49-195 | This work |
| BoΔwadC | PA in frame deletion mutant in wadC Δ17-306 | This work |
| BoPA-Gm | challenge strain, PA GmR | UN collection |
| Brucella melitensis | ||
| Rev 1 | reference vaccine | CITA collection |
| E. coli | ||
| S17-1 λpir | mating strain with plasmid RP4 inserted into the chromosome | Simon et al. [[19]] |
| TOP10 F’ | F−lacIq Tn 10 (TetR) mcrA Δ(mrr-hsdRMS-mcrBC) 80lacZ ΔM15 ΔlacX74 recA1alaD139 endA1 nupG | Invitrogen |
| Plasmids | ||
| pCR2.1 | cloning vector | Invitrogen |
| pJQK | derivated of pJQ200KS+; KmR, GmS | Scupham and Triplett [[20]] |
| pYRI-12 | 913-bp of B. abortus parental chromosomal DNA containing the wadA deletion allele, generated by PCR and cloned into pCR2.1 | This work |
| pYRI-13 | BamHI-XbaI fragment from pYRI-12 cloned into the corresponding sites of pJQK | This work |
| pYRI-1 | 570-bp of B. abortus parental chromosomal DNA containing the wadB deletion allele, generated by PCR and cloned into pCR2.1 | Gil-Ramírez et al. [[7]] |
| pYRI-2 | BamHI-XbaI fragment from pYRI-1 cloned into the corresponding sites of pJQK | Gil-Ramírez et al. [[7]] |
| pYRI-14 | 934-bp of B. ovis parental chromosomal DNA containing the wadC deletion allele, generated by PCR and cloned into pCR2.1 | This work |
| pYRI-15 | BamHI-XbaI fragment from pYRI-14 cloned into the corresponding sites of pJQK | This work |
| Age | P0–P1a | P10 | P21 | |||
| Dnaaf1m4Bei | Observedb | Expected | Observedc | Expected | Observedd | Expected |
| Wild-type | 29 | 20.5 | 21 | 17.5 | 12 | 8.25 |
| Heterozygote | 39 | 41 | 43 | 35 | 21 | 16.5 |
| Homozygote | 14 | 20.5 | 6 | 17.5 | 0 | 8.25 |
| Laterality defect | 8 (57.1%) | 2 (33.3%) | N/Ae | |||
| Situs inversus | 3 | 0 | ||||
| Heterotaxy | 5 | 2 | ||||
| Lrrc48m6Bei | Observed | Expected | Observed | Expected | Observed | Expected |
| Wild-type | 21 | 18 | 24 | 19.75 | 22 | 17.75 |
| Heterozygote | 33 | 36 | 36 | 39.5 | 31 | 35.5 |
| Homozygote | 18 | 18 | 19 | 19.75 | 18 | 17.75 |
| Laterality defect | 2 (11.1%) | 1 (5.3%) | N/Ae | |||
| Situs inversus | 2 | 0 | ||||
| Heterotaxy | 0 | 1 |
| Cell type | Stimulation | Type of HA binding | HA receptor | Reference |
| Monocyte (human) | TNFα, LPS, IL-1, IFN-γ | Inducible | CD44 | (59–61) |
| Alveolar macrophages (human, rodents) | None | Constitutive | CD44 | (17, 46 –48, 50) |
| Peritoneal macrophage (mouse) | LPS with IFNγ, or IL-4 | Inducible | CD44 | (62) |
| Bone marrow-derived macrophages (mouse) | LPS with IFNγ, TNFα, or IL-4 | Inducible | CD44 | (62) |
| Monocyte-derived DC (human) | CD40L expressing fibroblasts | Inducible | CD44 | (63) |
| B cells (human, mouse) | PMA, IL-5, LPS | Inducible, a subset binds | CD44 | (64 –67) |
| T cells (mouse) | PMA/ionomycin, CD3 antibodies, specific antigen, or superantigen | Inducible, often a subset binds | CD44 | (54, 55, 68) |
| CD4+ CD25+ T regulatory cells (human and mouse) | CD3 +/− CD28 activation | Inducible, a subset binds | CD44 | (69, 70) |
| Neutrophil (mouse) | LPS induced liver inflammation in vivo | Binding to SHAP modified HA | CD44, not RHAMM | (71) |
| NK cells (mouse) | IL-2, IL-15 | Inducible, a subset binds | CD44 | (72) |
| Platelets (mouse) | None | Constitutive | CD44 | (73) |
| Compound | Elution time (min) | Fraction theoretically contained in |
| Phenylalanine | 5.964 ± 0.003 | B |
| Caffeic acid | 13.471 ± 0.170 | C |
| Coumaric acid | 15.941 ± 0.208 | D |
| Vanillin | 16.187 ± 0.065 | D |
| Cinnamic acid | 23.595 ± 0.155 | E |
| Capsaicin | 32.801 ± 0.053 | G |
| Group Variables | With iron deficiency | Without iron deficiency | P-value | |
| Type of febrile seizure | Simple | 12(37.5%) | 20(62.5%) | 0.04 |
| Complex | 12(66.7%) | 6(33.3%) |
| Characteristics of the Patients at Baseline | Total population (n = 257) | SR-group (n = 148) | AF-group (n = 109) | p Value |
| Age — yr | 80.8 ± 6.0 | 80.6 ± 6.0 | 80.9 ± 6.0 | 0.736 |
| Male sex — no. (%) | 118 (45.9%) | 62 (41.9%) | 56 (51.4%) | 0.163 |
| Body-mass index (kg/m2) | 28.2 ± 5.5 | 28.3 ± 5.6 | 28.1 ± 5.3 | 0.724 |
| Diabetes mellitus (n. %) | 110 (42.8%) | 57 (38.5%) | 53 (48.6%) | 0.126 |
| Diabetes treated with insulin | 68 (26.5%) | 33 (22.3%) | 35 (32.1%) | 0.087 |
| Hypertension | 223 (86.8%) | 126 (85.1%) | 97 (89.0%) | 0.457 |
| Dyslipidemia (n. %) | 179 (69.6%) | 102 (68.9%) | 77 (70.6%) | 0.785 |
| PAD | 40 (15.6%) | 17 (11.5%) | 23 (21.1%) | 0.038 |
| Chronic obstructive pulmonary disease (n %) | 50 (19.5%) | 33 (22.3%) | 17 (15.6%) | 0.204 |
| Medical history — no. (%) | ||||
| Chronic kidney disease on dialysis | 8 (3.1%) | 7 (4.7%) | 1 (0.9%) | 0.143 |
| History of cancer | 64 (24.9%) | 40 (27.0%) | 24 (22.0%) | 0.384 |
| Active cancer | 20 (7.8%) | 10 (6.8%) | 10 (9.2%) | 0.489 |
| Coronary heart disease | 210 (81.7%) | 120 (81.1%) | 90 (82.6%) | 0.871 |
| Coronary-artery bypass surgery | 36 (14.0%) | 18 (12.2%) | 18 (16.5%) | 0.365 |
| Myocardial infarction | 30 (11.7%) | 15 (10.1%) | 15 (13.8%) | 0.433 |
| PCI | 67 (26.1%) | 42 (28.4%) | 25 (22.9%) | 0.389 |
| Pacemaker | 32 (12.5%) | 11 (7.4%) | 21 (19.3%) | 0.007 |
| Stroke | 40 (15.6%) | 22 (14.9%) | 18 (16.5%) | 0.731 |
| NYHA III | 164 (63.8%) | 96 (64.9%) | 68 (62.4%) | 0.695 |
| NYHA IV | 61 (23.7%) | 31 (20.9%) | 30 (27.5%) | 0.238 |
| Strain | Gene name | Protein name | Metabolic function | Fold change |
| P5 | TPI1 | Triosephosphateisomerase | Glycolisis | 27.28 |
| AHP1 | Peroxiredoxin type-2 | Oxidative stress | 20.07 | |
| PDC1 | Pyruvate DeCarboxylase | Glycolisis, Glucose fermentation | 13.95 | |
| TSA1 | Thioredoxin peroxidase | Oxidative stress | 5.28 | |
| CDC19 | Pyruvatekinase | Glycolisis, Glucose fermentation | 5.16 | |
| ENO2 | Enolase II, phosphopyruvatehydratase | Glycolisis | 3.28 | |
| FBA1 | Fructose 1,6-bisphosphate aldolase | Glycolisis | 2.15 | |
| P24 | RPL31A | Ribosomal Protein of the Large subunit | Structural constituent of ribosome | 17.65 |
| TDH1 | Glyceraldehyde-3-phosphate dehydrogenase | Glycolisis | 7.11 | |
| TEF1 | Translational elongation factor EF-1 alpha | Translation | 5.12 | |
| TDH3 | Glyceraldehyde-3-phosphate dehydrogenase | Glycolisis | 4.76 | |
| GPM1 | Glycerate phosphomutase | Glycolisis | 3.53 | |
| ENO2 | Enolase II, phosphopyruvatehydratase | Glycolisis | -4.09 |
| Protein | Species | Mitochondrial function | Stimulus driving mitochondrial localization | Reference |
| NF-κB | Rat, mouse | Suppression of mitochondrial genes | Steady-state conditions | Johnson et al., 2011; Johnson and Perkins, 2012 |
| CREB | Rat, mouse | Activation of mitochondrial genes | Steady-state conditions | Lee et al., 2005; Ryu et al., 2005 |
| MEF-2D | Mouse | Transcriptional Activation of ND6 | Steady-state conditions | She et al., 2011 |
| TERT | Human, mouse, Rat | Reverse Transcription of mitochondrial tRNAs,Protection from mtDNA damage | Oxidative stress, steady state conditions | Haendeler et al., 2009; Sharma et al., 2012; Saretzki, 2014 |
| RECQL4 | Human, mouse | Restores mtDNA replication, Ensures mtDNA integrity | Steady-state conditions | De et al., 2012; Gupta et al., 2014; Wang et al., 2014; Lu et al., 2016 |
| STAT3 | Mouse, human | Modulation ETC through direct binding to respiratory complexes | Steady-state conditionsActivated Ras | Gough et al., 2009; Wegrzyn et al., 2009 |
| P53 | Rat, mouse, human | Modulation of mitochondrial permeability, apoptosis and necrosis,Promotion of mtDNA accuracy and stability. | Pro-apoptotic signals, oxidative stress, hypoxia, ultraviolet irradiation | Jiang et al., 2006; Marchenko et al., 2007; Bakhanashvili et al., 2008; Vaseva et al., 2012 |
| IRF3 | Human | Apoptosis induction by mitochondrial recruitment of BAX | RNA virus infection | Chattopadhyay et al., 2010 |
| STAT1 | Mouse, Rat | ND | Steady-state conditions | Boengler et al., 2010 |
| HIF-1α | Human | ND | Hypoxia | Briston et al., 2011 |
| 30–59 yrs. old | ≥60 yrs. old | ||||||
| Causes | 2010–2012n (%) | 2013–2015n (%) | Totaln (%) | 2010–2012n(%) | 2013–2015n (%) | Totaln (%) | |
| Blindness | MMD | 9(34.6) | 7(25.9) | 16(30.2) | 14(19.2) | 18(22.8) | 32(21.1) |
| Glaucoma | 5(19.2) | 5(18.5) | 10(18.9) | 15(20.5) | 17(21.5) | 32(21.1) | |
| AMD | 0(0) | 0(0) | 0(0) | 20(27.4) | 17(21.5) | 37(24.3) | |
| DR | 3(11.5) | 7(25.9) | 10(18.9) | 3(4.1) | 5(6.3) | 8(5.3) | |
| ONA | 3(11.5) | 1(3.7) | 4(7.5) | 4(5.5) | 5(6.3) | 9(5.9) | |
| RP | 5(19.5) | 6(22.2) | 11(20.8) | 4(5.5) | 4(5.1) | 8(5.3) | |
| Others | 1(3.7) | 1(3.7) | 2(3.8) | 13(17.8) | 13(16.5) | 26(17.1) | |
| Total | 26 | 27 | 53 | 73 | 79 | 152 | |
| Low Vision | MMD | 55(78.6) | 57(70.4) | 112(74.2) | 53(42.7) | 95(57.9) | 148(51.4) |
| Glaucoma | 1(1.4) | 3(3.7) | 4(2.6) | 10(8.1) | 10(6.1) | 20(6.9) | |
| AMD | 3(4.3) | 3(3.7) | 6(3.9) | 35(28.2) | 31(18.9) | 66(22.9) | |
| DR | 1(1.4) | 13(16.0) | 14(9.3) | 8(6.5) | 10(6.1) | 18(6.3) | |
| Others | 10(14.2) | 5(6.2) | 15(9.9) | 18(14.5) | 18(11.0) | 36(12.5) | |
| Total | 70 | 81 | 151 | 124 | 164 | 288 |
| Growth and nutritional status of rats | |||||
| Body weight gain (g) | Liver weight (g) | Food intake (g/day) | Water intake (ml/day) | Feed efficiency (B.W gain/food intake) | |
| C | 16.4 ± 6.67a | 6.92 ± 1.42 a | 16.03 ± 2.47a | 9.33 ± 1.91 ab | 1.02 |
| FSO | 24.55 ± 9.7 a | 8.15 ± 0.83 b | 14.94 ± 1.82 ab | 10.04 ± 1.53 a | 1.64 |
| OSO | 20.33 ± 7.81 a | 7.54 ± 0.64 ab | 13.74 ± 2.41c | 9.82 ± 1.5 ab | 1.47 |
| MG | 25.83 ± 6.64 a | 7.27 ± 0.7 a | 14.24 ± 2.17 bc | 9.07 ± 1.22 b | 1.81 |
| Variable | StapleMean (SD) | SutureMean (SD) | t value | P value |
| Nurse VAS score on day 5 | 7.57 (1.30) | 7.00 (1.10) | 2.31 | 0.023 |
| Nurse VAS score at 6 weeks | 8.71 (1.45) | 8.55 (1.23) | 0.58 | 0.566 |
| Nurse observer scar width (OSAS) score | 1.94 (0.67) | 2.26 (1.01) | −1.80 | 0.075 |
| Nurse observer scar height (OSAS) score | 1.74 (0.74) | 2.09 (0.86) | −2.07 | 0.041 |
| Nurse observer scar pliability (OSAS) score | 2.06 (1.13) | 2.36 (1.11) | −1.288 | 0.201 |
| Total nurse OSAS score+ | 5.74 (1.87) | 6.70 (2.62) | −2.039 | 0.044 |
| Observer 1 VAS score at 6 weeks | 8.00 (0.91) | 8.32 (1.00) | −1.62 | 0.109 |
| Observer 2 VAS score at 6 weeks | 5.34 (1.81) | 5.91 (1.90) | −1.50 | 0.136 |
| Average VAS score | 6.67 (1.19) | 7.11 (1.33) | −1.71 | 0.091 |
| Observer 1 OSAS width | 2.49 (0.72) | 2.32 (0.78) | 1.10 | 0.275 |
| Observer 2 OSAS width | 4.55 (1.73) | 4.26 (1.71) | 0.84 | 0.404 |
| Observer 1 OSAS height | 2.26 (0.94) | 2.19 (1.10) | 0.30 | 0.763 |
| Observer 1 OSAS height | 3.51 (1.49) | 3.51 (1.53) | −0.14 | 0.892 |
| Average OSAS score | 6.40 (1.78) | 6.15 (1.92) | 0.64 | 0.524 |
| Size | 5 μm | 10 μm | 15 μm | 20 μm |
| Breakdown voltage | 21.25 V | 12 V | 11.8 V | 11.7 V |
| Dark current | 200 pA | 60 pA | 85 pA | 106 pA |
| Sample (μg/100 μL) | % Inhibition of DPPH | |||
| Crude extract a | Acidic fraction b | Neutral fraction c | Oil fraction d | |
| Ajwain | ||||
| 50 | 66.3 ± 1.5 | 60.4 ± 2.6 | 51.3 ± 2.4 | 60.3 ± 1.4 |
| 100 | 74.5 ± 1.0 | 69.5 ± 2.9 | 61.6 ± 3.0 | 67.6 ± 2.0 |
| 150 | 83.6 ± 2.3 | 76.5 ± 1.6 | 68.6 ± 2.1 | 77.5 ± 2.3 |
| 200 | 90.6 ± 2.8 | 85.4 ± 1.9 | 77.5 ± 2.4 | 83.0 ± 1.8 |
| 250 | 95.7 ± 3.0 | 91.6 ± 2.9 | 83.4 ± 1.8 | 88.0 ± 2.1 |
| Mustard seeds | ||||
| 50 | 57.0 ± 1.5 | 45.2 ± 1.2 | 37.1 ± 0.6 | 51.0 ± 1.5 |
| 100 | 59.2 ± 0.8 | 52.6 ± 1.7 | 44.2 ± 1.5 | 56.2 ± 0.9 |
| 150 | 66.5 ± 2.5 | 61.8 ± 2.1 | 54.4 ± 2.1 | 60.5 ± 2.6 |
| 200 | 73.5 ± 2.1 | 68.7 ± 1.5 | 59.6 ± 3.0 | 67.5 ± 2.1 |
| 250 | 79.4 ± 1.5 | 74.5 ± 0.9 | 65.8 ± 2.9 | 73.4 ± 1.6 |
| Fenugreek | ||||
| 50 | 50.4 ± 0.5 | 43.2 ± 2.3 | 35.1 ± 2.3 | 43.6 ± 1.5 |
| 100 | 55.3 ± 1.6 | 49.5 ± 2.5 | 40.6 ± 2.2 | 49.7 ± 2.6 |
| 150 | 62.0 ± 2.1 | 56.5 ± 1.8 | 47.7 ± 2.1 | 54.2 ± 1.1 |
| 200 | 67.0 ± 1.9 | 61.4 ± 1.9 | 55.8 ± 1.9 | 59.5 ± 1.8 |
| 250 | 73.0 ± 1.8 | 67.2 ± 2.1 | 60.7 ± 1.1 | 65.5 ± 2.8 |
| Poppy seeds | ||||
| 50 | 44.0 ± 1.0 | 38.5 ± 0.9 | 29.0 ± 1.5 | 37.2 ± 1.0 |
| 100 | 53.0 ± 1.5 | 43.5 ± 1.3 | 35.0 ± 3.0 | 44.7 ± 1.5 |
| 150 | 59.0 ± 2.3 | 49.5 ± 1.5 | 40.0 ± 2.8 | 49.5 ± 2.3 |
| 200 | 63.0 ± 1.8 | 55.0 ± 1.9 | 46.0 ± 2.7 | 54.0 ± 1.8 |
| 250 | 66.5 ± 0.6 | 62.0 ± 3.0 | 55.5 ± 1.6 | 60.5 ± 0.6 |
| Clinical parameters | KAP1 | TIMP1 | STC2 | |||||||||
| Low | High | χ2 | P | Low | High | χ2 | P | Low | High | χ2 | P | |
| N | 13 | 99 | 12 | 100 | 11 | 101 | ||||||
| Gender | 1.52 | 0.22 | 0.68 | 0.41 | 3.08 | 0.079 | ||||||
| Male | 7 | 70 | 7 | 70 | 5 | 72 | ||||||
| Female | 6 | 29 | 5 | 30 | 6 | 29 | ||||||
| Location | 0.184 | 0.91 | 1.82 | 0.40 | 1.99 | 0.369 | ||||||
| Proximal | 1 | 11 | 0 | 12 | 0 | 12 | ||||||
| Middle | 4 | 32 | 5 | 31 | 5 | 31 | ||||||
| Distal | 8 | 56 | 7 | 57 | 6 | 58 | ||||||
| Size | 0.227 | 0.633 | 0.156 | 0.693 | 0.484 | 0.487 | ||||||
| <5 cm | 5 | 45 | 6 | 44 | 6 | 44 | ||||||
| ≥5 cm | 8 | 54 | 6 | 56 | 5 | 57 | ||||||
| Lauren classification | 0.56 | 0.45 | 0.55 | 0.46 | 0.037 | 0.85 | ||||||
| Intestinal | 8 | 50 | 5 | 53 | 6 | 52 | ||||||
| Diffuse | 5 | 49 | 7 | 47 | 5 | 49 | ||||||
| Histology | 1.53 | 0.675 | 5.376 | 0.146 | 2.62 | 0.454 | ||||||
| Papillary adenocarcinoma | 0 | 5 | 0 | 5 | 0 | 5 | ||||||
| Tubular adenocarcinoma | 11 | 69 | 12 | 68 | 10 | 70 | ||||||
| Mucinous adenocarcinoma | 1 | 15 | 0 | 16 | 1 | 15 | ||||||
| Signet-ring cell carcinoma | 1 | 10 | 0 | 11 | 0 | 11 | ||||||
| Histologic differentiation | 0.013 | 0.91 | 1.97 | 0.16 | 0.10 | 0.75 | ||||||
| Well-moderately | 4 | 32 | 6 | 30 | 4 | 32 | ||||||
| Poorly-undifferentiated | 9 | 67 | 6 | 70 | 7 | 69 | ||||||
| TNM Stages | 24.31 | 0.001 | 36.46 | 0.001 | 20.26 | 0.001 | ||||||
| I | 7 | 7 | 8 | 6 | 6 | 8 | ||||||
| II | 4 | 36 | 2 | 38 | 3 | 37 | ||||||
| III | 2 | 37 | 2 | 37 | 1 | 38 | ||||||
| IV | 0 | 19 | 0 | 19 | 1 | 18 | ||||||
| Lymph node metastasis | 48.37 | 0.001 | 24.15 | 0.001 | 41.32 | 0.001 | ||||||
| No | 7 | 1 | 5 | 3 | 6 | 2 | ||||||
| Yes | 6 | 98 | 7 | 97 | 5 | 99 | ||||||
| Distant metastasis | 0.898 | 0.343 | 2.746 | 0.098 | 0.537 | 0.464 | ||||||
| No | 12 | 81 | 12 | 81 | 10 | 83 | ||||||
| Yes | 1 | 18 | 0 | 19 | 1 | 18 |
| Retention indices | Identification % | ||||
| van den Dool and Kratz | Kovats | ||||
| Calculated | Adams 2009 | Calculated | Adams 2009 | ||
| 1010 | 1008 | 1011 | 1011 | δ-3-carene | 55.36 |
| 933 | 932 | 938 | 939 | α-pinene | 15.62 |
| 1027 | 1025 | 1031 | 1030 | sylvestrene | 10.69 |
| 1479 | 1480 | 1481 | 1481 | germacrene D | 2.48 |
| 1377 | 1379 | 1379 | 1381 | β-patchoulene | 1.99 |
| 988 | 988 | 990 | 990 | mircene | 1.89 |
| 1355 | 1356 | 1357 | 1359 | eugenol | 1.71 |
| 1087 | 1086 | 1089 | 1088 | terpinolene | 1.52 |
| 1392 | 1390 | 1393 | 1391 | sativene | 0.93 |
| 1418 | 1419 | 1419 | 1420 | β-cedrene | 0.89 |
| 1675 | 1674 | 1676 | 1675 | cis-α-santalol | 0.77 |
| 1447 | 1448 | 1449 | 1450 | cis-muurola-3,5-diene | 0.76 |
| 1546 | 1546 | 1548 | 1548 | hedycaryol | 0.66 |
| 1336 | 1335 | 1339 | 1338 | δ-elemene | 0.44 |
| 1434 | 1434 | 1436 | 1436 | γ-elemene | 0.41 |
| Total | 96.11 |
| A | LAeq | LHC | ||||
| HR | CR | CR-HR | HR | CR | CR-HR | |
| 25 | 47.8 | 54.2 | 6.4 | 115.9 | 115.7 | -0.2 |
| 28 | 49.2 | 55.6 | 6.4 | 118.4 | 118.3 | -0.1 |
| 31 | 50.7 | 57.1 | 6.4 | 121.0 | 121.0 | 0.0 |
| 34 | 52.1 | 58.5 | 6.4 | 123.6 | 123.7 | 0.1 |
| 37 | 53.6 | 60.0 | 6.4 | 126.2 | 126.3 | 0.1 |
| 40 | 55.1 | 61.5 | 6.4 | 128.8 | 128.9 | 0.1 |
| 43 | 56.5 | 62.9 | 6.4 | 131.5 | 131.6 | 0.1 |
| 46 | 58.0 | 64.4 | 6.4 | 134.2 | 134.2 | 0.0 |
| 49 | 59.5 | 65.8 | 6.3 | 137.0 | 136.8 | -0.2 |
| 52 | 60.9 | 67.3 | 6.4 | 139.8 | 139.5 | -0.3 |
| 55 | 62.4 | 68.7 | 6.3 | 142.6 | 142.1 | -0.5 |
| 58 | 63.9 | 70.2 | 6.3 | 145.5 | 144.7 | -0.8 |
| Point | Details |
| 1 | Five sites per organ |
| 2 | Avoidance of pressure artefacts |
| 3 | Elimination of secretions |
| 4 | Adequate focus and contrast adjustment |
| 5 | High quality recording |
| LM35 | CHTM-02 | MC112 | MC115 | MQ2 | MQ8 | |
| μHS (V) | 0.2370 | 1.6930 | 0.3750 | 0.4620 | 2.8099 | 3.6299 |
| Δ | 0.01 °C | 0.01%RH | 1 ppm | 1 ppm | 1 ppm | 1 ppm |
| Normal | PanIN | PDAC | P-value* | |
| Average No. | Average No. | Average No. | ||
| CD8p | 107.6 | 90.3 | 58.1 | 0.0114 |
| CD8i | 13 | 4.2 | 0.6 | <0.0001 |
| CD4p | 14.2 | 57.8 | 22.5 | <0.0001 |
| CD4i | 0.09 | 2.03 | 0.3 | <0.0001 |
| FOXP3p | 3.6 | 7.1 | 10.9 | <0.0001 |
| FOXP3i | 0 | 0.12 | 0.5 | <0.0001 |
| CD163 (M2)p | 115.1 | 140 | 153.4 | 0.0016 |
| CD163 (M2)i | 1.1 | 3.16 | 3.6 | <0.0001 |
| iNOS (M1)p | 4.32 | 1 | 0.38 | <0.0001 |
| iNOS (M1)i | 0.17 | 0 | 0 | 0.006 |
| Parent Rating Score | |||
| Variable | β1 (95% CI) | β2 | p |
| Length-for age z-score | −0.416 (−0.928, 0.096) | −0.060 | 0.111 |
| Weight-for-length z-score | −0.747 (−1.483, −0.010) | −0.072 | 0.047 |
| Birth weight (kg) | −0.843 (−1.507, −0.180) | −0.094 | 0.013 |
| Not breastfeeding 3 | −0.284 (−0.785, 0.217) | −0.041 | 0.266 |
| Duration of exclusive breastfeeding (age) | |||
| 3–4 months 4 | −0.715 (−1.209, −0.221) | −0.110 | 0.005 |
| 5–6 months 4 | −0.975 (−1.637, −0.314) | −0.112 | 0.004 |
| Frequent intake of jarred infant food 5 | 0.419 (−0.122, 0.961) | 0.056 | 0.129 |
| Frequent intake of commercial infant cereal 5 | 1.376 (0.892, 1.860) | 0.206 | <0.001 |
| Caregiver passed at least grade 10 6 | 0.344 (−0.225, 0.913) | 0.043 | 0.236 |
| Male infant 7 | 0.683 (0.238, 1.127) | 0.109 | 0.003 |
| Adjusted R2 | 0.094 |
| Variables | Intervention Group (n = 22) | Comparison Group (n = 22) | p-Value |
| Sex, n (%) | Male, 13 (59.0) | Male, 11 (50.0) | 0.763 |
| GA at birth, week ± day | 29 ± 12 day | 30 ± 14 day | 0.501 |
| Twin, n (%) | 3 (13.6) | 6 (27.3) | 0.457 |
| Growth status at birth | |||
| Birth weight, g | 1192 ± 202 | 1151 ± 208 | 0.502 |
| Length, cm | 39.1 ± 2.6 | 38.4 ± 3.7 | 0.525 |
| Head circumference, cm | 26.1 ± 1.8 | 26.4 ± 1.9 | 0.626 |
| SGA at birth | |||
| Body weight, n (%) | 1 (4.5) | 2 (9.1) | 1.000 |
| Length, n (%) | 1 (4.5) | 1 (4.5) | 1.000 |
| Head circumference, n (%) | 2 (9.1) | 2 (9.1) | 1.000 |
| SGA at discharge | |||
| Body weight, n (%) | 19 (86.4) | 20 (90.9) | 1.000 |
| Length, n (%) | 10 (45.5) | 14 (63.6) | 0.364 |
| Head circumference, n (%) | 15 (68.2) | 12 (54.5) | 0.453 |
| PMA at discharge, week ± day | 37 ± 12 day | 38 ± 20 day | 0.199 |
| LOS, days | 52 ± 12 | 53 ± 17 | 0.895 |
| Feeding type at discharge, n (%) | |||
| Breast milk feeding | 18 (81.8) | 17 (77.3) | 1.000 |
| Mixed feeding | 3 (13.6) | 4 (18.2) | 1.000 |
| Standard formula | 1 (4.5) | 2 (9.1) | 1.000 |
| Growth status at term (40 weeks) | |||
| Body weight, g | 2631 ± 538 | 2426 ± 531 | 0.145 |
| Length, cm | 47.7 ± 2.7 | 46.9 ± 2.9 | 0.318 |
| Head circumference, cm | 33.1 ± 1.6 | 32.2 ± 2.3 | 0.470 |
| Maternal age (years) | 22.5 ± 4.8 | 25.3 ± 5.5 | 0.087 |
| Patient | Sex | Age (years) | Diagnosis | SAPS II score | Pao2/Fio2 ratio (mmHg) | Crs (ml/cmH2O) | LIP (cmH2O) | Pplat (cmH2O) | UIP (cmH2O) |
| 1 | F | 56 | Aspiration | 42 | 121 | 58 | 15 | 22 | - |
| 2 | M | 68 | CAP | 45 | 95 | 25 | 15 | 40 | - |
| 3 | M | 40 | Aspiration | 36 | 89 | 122 | 10 | 19 | - |
| 4 | M | 51 | CAP | 25 | 71 | 34 | 5 | 24 | 54 |
| 5 | M | 31 | Aspiration | 34 | 82 | 43 | - | 27 | - |
| 6 | M | 41 | Pneumocystis | 36 | 161 | 50 | 12 | 27 | 35 |
| 7 | M | 50 | CAP | 19 | 110 | 73 | 8 | 24 | - |
| 8 | M | 73 | Legionella | 32 | 72 | 75 | 13 | 31 | - |
| 9 | M | 31 | Pneumocystis | 9 | 112 | 78 | - | 24 | - |
| 10 | M | 31 | Aspiration | 74 | 104 | 55 | 7 | 26 | - |
| 11 | M | 66 | Peritonitis | 85 | 55 | 41 | - | 32 | 46 |
| 12 | F | 43 | CAP | 46 | 170 | 75 | 8 | 12 | 27 |
| 13 | F | 42 | CAP | 22 | 187 | 52 | - | 22 | - |
| 14 | M | 70 | Aspiration | 40 | 191 | 68 | - | 22 | 31 |
| 15 | F | 36 | CAP | 43 | 216 | 51 | 13 | 27 | 53 |
| 16 | F | 57 | Aspiration | 36 | 172 | 56 | 10 | 30 | - |
| 17 | F | 66 | CAP | 36 | 112 | 12 | - | 39 | 26 |
| 50 ± 15 | 39 ± 18 | 134 ± 60 | 56 ± 26 | 27 ± 7 |
| Unstandardized estimates | S.E. | C.R. | P | Standardized estimates | |||
| PRIVATE HEALTH INSURANCE COVERAGE | <--- | PERCEIVED HEALTH | -.038 | .014 | 2.825 | .005 | -.010 |
| PRIVATE HEALTH INSURANCE COVERAGE | <--- | PERCEIVED NEED | -.041 | .029 | -1.403 | .161 | -.08 |
| PRIVATE HEALTH INSURANCE COVERAGE | <--- | PERCEIVED VALUE | -.041 | .014 | -2.875 | .004 | -.07 |
| PRIVATE HEALTH INSURANCE COVERAGE | <--- | SES | .071 | .014 | 5.230 | *** | .24 |
| PRIVATE HEALTH INSURANCE COVERAGE | <--- | GENDER | .006 | .027 | .225 | .822 | -.06 |
| PRIVATE HEALTH INSURANCE COVERAGE | <--- | AFRICAN AMERICAN | -.175 | .037 | -4.742 | *** | -.226 |
| PRIVATE HEALTH INSURANCE COVERAGE | <--- | HISPANIC | -.252 | .034 | -7.332 | *** | -.18 |
| Inclusion criteria | Exclusion criteria |
| 1. Study design: interventional or observational | 1. Studies of exclusively pediatric population (age <18 years) |
| 2. Included population: hospitalized aSAH patients | 2. Non-human studies |
| 3. Included intervention: RBC transfusion | 3. Duplicates or ‘sub-cohorts’ of previously published cohorts |
| 4. Comparator: a different transfusion threshold or no transfusion | |
| 5. Study outcome: any |
| MIxS-BE term |
| Carbon dioxidea |
| Ventilation typea |
| Organism counta |
| BE core |
| Surface material |
| Surface-air contaminant |
| Relative air humidity |
| Absolute air humidity |
| Surface humidity |
| Air temperature |
| Surface temperature |
| Surface moisture pH |
| Surface moisture |
| Dew point |
| Building occupancy type |
| BE Building properties |
| Indoor space (room type) |
| Indoor surface |
| Filter type |
| Heating and cooling system type |
| Substructure type |
| Building setting |
| Light type |
| BE Sample properties |
| Sample size sorting method |
| Space typical state |
| Typical occupant density |
| Occupancy at sampling |
| Occupant density at sampling |
| Dose studied | 100 μg | 200 μg | 400 μg | 600 μg | 800 μg |
| 1 | √ | √ | |||
| 2 | √ | √ | |||
| 3 | √ | √ | |||
| 4 | √ | √ |
| Locality | Sample size | CHIKV titer Median copy number (IQR) | ||||
| w+ | w− | |||||
| w+ | w− | Midguts | Salivary glands | Midguts | Salivary glands | |
| Besar Island, Malacca | 55 | 59 | 6.07 (5.21, 6.93)a* | 2.38 (1.63, 4.63)a | 7.02 (4.01, 7.80)a | 2.16 (1.22, 3.45)a |
| Tenggol Island, Terengganu | 58 | 60 | 7.44 (5.20, 8.09)b | 2.70 (1.45, 6.36)a | 7.83 (6.10, 8.53)b | 2.25 (1.44, 4.34)a |
| Bandar Rinching, Selangor | 60 | 57 | 7.01 (6.04, 7.69)b | 2.93 (1.73, 5.39)a | 6.98 (6.02, 7.50)a | 2.81 (1.28, 5.50)a |
| Treatments | Species | Duration | Metabolic disorders | Potential mechanism | Reference |
| 0–250 μmol/l capsaicin | 3T3-L1 preadipocytes and adipocytes | 24–72 h | Decreased the amount of intracellular triglycerides, GPDH activity | Inhibited the expression of PPARγ, C/EBP-α, and leptin | Hsu et al. [52] |
| Induced apoptosis | Induced up-regulation of adiponectin at the protein level | ||||
| Inhibited adipogenesis | |||||
| 1 μmol/l capsaicin | 3T3-L1 preadipocytes | 3–8 days | Prevented the adipogenesis | Increased intracellular calcium | Zhang et al. [53] |
| 0.015% capsaicin | Male C57BL/6 mice | 10 weeks | Decreased triglyceride levels | Decreased TRPV-1 expression in adipose tissue | Kang et al. [54] |
| Lowered fasting glucose, insulin, and leptin levels | Increased mRNA/protein of adiponectin in the adipose tissue | ||||
| Increased PPARα/PGC-1α mRNA in the liver | |||||
| 10 mg/kg body weight capsaicin | Std ddY mice | 2 weeks | Lower body weight | Increased oxygen consumption | Ohnuki et al. [55] |
| Markedly suppressed body fat accumulation | Stimulated the secretion of adrenalin | ||||
| Decreased triglyceride levels | |||||
| 0.3% capsinoids | C57BL/6J mice | 8 weeks | Suppressed body weight gain under the HFD | Increased energy expenditure | Saito et al. [57], Ohyama et al. [58] |
| Decreased plasma cholesterol level | Activation of fat oxidation in skeletal muscle | ||||
| Prevented diet-induced liver steatosis | Activation lipolysis in BAT | ||||
| Increased cAMP levels and PKA activity in BAT | |||||
| 0.003%, 0.01%, and 0.03% capsaicin | wild-type and TRPV1−/− mice | 16 weeks | Promoted weight loss | Increased the expression of UCP-1, BMP8b, SIRT-1, PGC-1α, and PRDM-16 in BAT | Baskaran et al. [59] |
| Enhanced the respiratory exchange ratio | Increased the phosphorylation of SIRT-1 | ||||
| Countered hypercholesterolemia | |||||
| 0.01% capsaicin | wild-type and TRPV1−/− mice | 26 weeks | Countered obesity | Promoted SIRT-1 expression | Baskaran et al. [60] |
| Browning of WAT | Increased the expression of PGC-1α | ||||
| Facilitated PPARγ–PRDM-16 interaction | |||||
| 0.01% capsaicin | wild-type and TRPV1−/− mice | 24 weeks | Ameliorated abnormal glucose homeostasis | Activation of TRPV1-mediated GLP-1 secretion in the intestinal cells | Wang et al. [49] |
| Increased GLP-1 levels in the plasma and ileum | |||||
| 640 μmol/L, 2 ml/kg capsaicin | Sprague-Dawley rats | 15 min | Increased superior mesenteric artery blood flow | Induced a dichotomous pattern of blood flow changes | Leung et al. [68] |
| Reduction in hydrogen gas clearance | |||||
| 0.01% capsaicin | C57BL/6J male mice | 9 weeks | Reduced weight gain | Modest modulation of the gut microbiota | Shen et al. [69] |
| Improved glucose tolerance | Up-regulated the expression of Muc2 and antimicrobial protein gene Reg3g in the intestine |
| Themes | Subtheme | Item |
| LEADERSHIP/Governance | Systematic Approach | Giving no priority to the discharge planning in heath systemLack of comprehensive plan to develop discharge planning in the ministry of healthLack of patient-centered approach in the health systemLack of systematic and comprehensive approach to the planDisregarding the holistic care in training curriculum |
| Structure | Lack of referral system and rationing of health services systemLack of structured, systematic and coordinated systemLack of comprehensive benefit packageLack of specific standards, rules, regulations on discharge planning | |
| Management | Low willpower of senior managersPoor monitoring and evaluation systemPoor and inefficient management in heath systemManagers and policy makers’ inaccurate comprehension of discharge planning | |
| Communication | Poor inter and intra sectional contributionLack of defined interaction and communication among medical personnel to provide careWeakness in written supportive policies on discharge planning | |
| Advocacy | Lack of home care system in health systemLack of powerful supportive centers (such as community-based organizations) |
| Treatment | DF | F-value | P-value | R-square | |
| Emergence Holes | Depth (D) | 4 | 19.90 | <0.001 | 68.53 |
| Volume (V) | 2 | 83.25 | <0.001 | ||
| Error | 113 | ||||
| Air holes | Depth (D) | 4 | 22.51 | <0.001 | 71.60 |
| Volume (V) | 2 | 97.46 | <0.001 | ||
| Error | 113 | ||||
| Seed Weight | Depth (D) | 4 | 19.00 | <0.001 | 56.84 |
| Volume (V) | 2 | 36.41 | <0.001 | ||
| Error | 113 |
| Mcm2 immunoreactivity | |||||
| Variable | Categorisation | n analysable | negative (<40%) | positive (≥40%) | pa |
| Clinico-pathologic data: | |||||
| Age at diagnosis | |||||
| <65 years | 47 | 27 | 20 | 1.000 | |
| ≥65 years | 63 | 37 | 26 | ||
| Gender | |||||
| male | 72 | 39 | 33 | 0.593 | |
| female | 57 | 34 | 23 | ||
| Ann Arbor Stage | |||||
| 1 | 15 | 10 | 5 | 0.342 | |
| 2 | 34 | 15 | 19 | ||
| 3 | 23 | 14 | 9 | ||
| 4 | 35 | 22 | 13 | ||
| International prognostic index | |||||
| 0 | 2 | 2 | 0 | 0.122 | |
| 1 | 48 | 27 | 21 | ||
| 2 | 21 | 14 | 7 | ||
| 3 | 20 | 13 | 7 | ||
| 4 | 14 | 4 | 10 | ||
| Bone marrow involvement | |||||
| no | 72 | 39 | 33 | 0.414 | |
| yes | 35 | 22 | 13 | ||
| Extranodal involvement | |||||
| no | 40 | 27 | 13 | 0.103 | |
| yes | 62 | 31 | 31 | ||
| Bulky disease | |||||
| no | 62 | 44 | 20 | 0.003 | |
| yes | 35 | 13 | 22 | ||
| Serum levels of LDH at diagnosis | |||||
| <300 U/l | 42 | 23 | 19 | 0.505 | |
| ≥300 U/l | 41 | 26 | 15 |
| 4-week exposure | 13-week exposure | |||
| Control | BaSO4 | Control | BaSO4 | |
| BaSO4 lung burden (mg) | 0.84 ± 0.18 | 1.73 ± 0.85 | ||
| Total cells (million) | ||||
| 1 day | 0.649 ± 0.20 | 0.562 ± 0.12 | 0.610 ± 0.20 | 0.836 ± 0.15* |
| 35 days | 0.580 ± 0.11 | 0.454 ± 0.12 | ND | ND |
| Neutrophils (million) | ||||
| 1 day | 0.007 ± 0.003 | 0.021 ± 0.010* | 0.016 ± 0.006 | 0.204 ± 0.175* |
| 35 days | 0.019 ± 0.008 | 0.032 ± 0.024 | ND | ND |
| Total protein (mg/L) | ||||
| 1 day | 60 ± 4 | 77 ± 13* | 52 ± 10 | 64 ± 13 |
| 35 days | 81 ± 23 | 59 ± 13 | ND | ND |
| GGT (nkat/L) | ||||
| 1 day | 37 ± 17 | 40 ± 10 | 41 ± 7 | 64 ± 13* |
| 35 days | 42 ± 12 | 37 ± 12 | ND | ND |
| ALP (μkat/L) | ||||
| 1 day | 0.83 ± 0.16 | 0.83 ± 0.20 | 0.51 ± 0.10 | 0.87 ± 0.21* |
| 35 days | 0.70 ± 0.09 | 0.70 ± 0.12 | ND | ND |
| MCP-1 (pg/ml) | ||||
| 1 day | 14.0 ± 0.0 | 54.7 ± 14.3* | 24.2 ± 8.4 | 176.7 ± 126.1*# |
| 35 days | 17.3 ± 2.6 | 14.7 ± 1.7 | ND | ND |
| CINC-1/IL-8 (pg/ml) | ||||
| 1 day | 104.2 ± 26.7 | 158.7 ± 22.4* | 93.7 ± 18.7 | 223.8 ± 125.7* |
| 35 days | 158.8 ± 38.1 | 167.6 ± 41.1 | ND | ND |
| Fibroblast | PD+/− rotenone (R) | Number of DEGs |
| MRC-5 | PD38 − R to PD38 + R | 1 |
| PD42 − R to PD42 + R | 2086 | |
| PD48 − R to PD48 + R | 3527 | |
| PD52 − R to PD52 + R | 319 | |
| HFF | PD22 − R to PD22 + R | 1 |
| PD26 − R to PD26 + R | 4873 | |
| PD30 − R to PD30 + R | 8151 | |
| PD34 − R to PD34 + R | 6424 | |
| PD58 − R to PD58 + R | 5726 | |
| PD74 − R to PD74 + R | 60 |
| Groups | AUC | Sens. | Spec. | Acc. |
| 0 versus 123 | 0.945 | 0.750 | 0.959 | 0.930 |
| 01 versus 23 | 0.919 | 0.886 | 0.900 | 0.872 |
| 012 versus 3 | 0.970 | 0.986 | 0.818 | 0.965 |
| Common name | Species | LTA | LTB |
| Deer mouse | Peromyscus maniculatus | AY251294 | AY282503 |
| House mouse | Mus musculus | NM_010735 | MMU16984 |
| Rat | Rattus norvegicus | NM_080769 | BX883046 |
| Woodchuck | Marmota monax | AF095586 | AF095587 |
| Human | Homo sapiens | AY216498 | AY216497 |
| miRNA | Regulation [17] | Potential regulation mechanism [17, 18] | Class [17] |
| miR-9-5p | Up | Chromosomal gain (1q) | Late |
| miR-15b-5p | Up | Chromosomal gain (3q) | Late |
| miR-28-5p | Up | Chromosomal gain (3q) | Early continuous |
| miR-100-5p | Down | Chromosomal loss (11q) | Late |
| miR-125b-5p | Down | Chromosomal loss (11q) | Late |
| miR-149-5p | Down | DNA methylation | Early continuous |
| miR-203a-3p | Down | DNA methylation | Early continuous |
| miR-375 | Down | DNA methylation | Late |
| Period of time | Significant difference between quarters | ||||||||
| Quarter 1 | Quarter 2 | Quarter 3 | Quarter 4 | ||||||
| Cost category | Means | (SD) | Means | (SD) | Means | (SD) | Means | (SD) | |
| Direct healthcare costs | |||||||||
| Physicians | 115.00 | (94.54) | 139.14 | (145.99) | 133.33 | (119.93) | 135.91 | (108.93) | **1 vs. 2; *1 vs. 4 |
| Physiotherapist | 13.57 | (49.18) | 19.57 | (57.59) | 16.98 | (48.73) | 19.10 | (57.80) | |
| Ambulatory clinic in hospital | 5.17 | (20.14) | 7.92 | (37.99) | 14.99 | (84.45) | 7.75 | (32.38) | |
| Inpatient care | 1436.71 | (4175.58) | 1529.02 | (4774.59) | 723.35 | (2851.91) | 959.82 | (3070.25) | *2 vs. 3 |
| Inpatient/outpatient rehabilitation | 1238.61 | (1085.16) | 68.38 | (405.57) | 24.51 | (217.36) | 52.56 | (365.25) | **1 vs. 2, 1 vs. 3, 1 vs. 4 |
| Drugs | 325.58 | (178.80) | 339.94 | (203.90) | 337.11 | (200.37) | 312.89 | (204.51) | **4 vs. 2, 4 vs. 3 |
| Sum of direct healthcare costs | 3134.64 | (4271.98) | 2104.00 | (4898.88) | 1250.28 | (3010.82) | 1488.07 | (3270.83) | **1 vs. 2, 1 vs. 3, 1 vs. 4, 2 vs. 3 |
| Direct non-healthcare costs | |||||||||
| Outpatient nursing service | 34.67 | (162.79) | 43.50 | (237.95) | 38.70 | (181.42) | 28.56 | (151.73) | |
| Paid household help | 96.38 | (643.07) | 111.01 | (684.75) | 109.03 | (626.12) | 102.05 | (645.84) | |
| Informal care | 35.45 | (177.98) | 43.72 | (190.73) | 46.47 | (194.71) | 54.74 | (205.98) | **1 vs. 4 |
| Sum of direct non-healthcare costs | 166.49 | (710.79) | 198.21 | (811.39) | 194.20 | (729.73) | 185.35 | (743.39) | |
| Sum of costs | 3301.14 | (4353.64) | 2302.21 | (5068.35) | 1444.50 | (3197.00) | 1673.42 | (3402.68) | **1 vs.2, 1 vs. 3, 1 vs. 4, 2 vs. 3 |
| Animal | Skin non-midge fed** | Skin midge fed*** | Tonsil | Lips | Lung |
| Sheep VH56/ 3 dpi | Minor engorgement, with indistinct vacuolation of epidermal cells. | Mildly oedematous/focal epidermal crusts/mild dermal inflammation *(lymphocytes, plasma cells and eosinophils). | Epithelial cells markedly vacuolated. Low numbers of eosinophils in tonsil itself. | Oedematous (especially around capillaries) and inflamed* (lymphocytes, plasma cells and eosinophils). Indistinct vacuolation of lip epidermal cells. | Peribronchial connective tissue is markedly oedematous and moderately inflamed*(lymphocytes, plasma cells and eosinophils). |
| Sheep VH67/ 4 dpi | Moderate oedema around capillaries and mild engorgement, mild aggregation of plasma cells around capillaries. | Moderately oedematous, especially around capillaries, with mild engorgement. Mild aggregation of plasma cells around capillaries, low numbers of neutrophils and eosinophils. Focal collagen necrosis.Note: C. sonorensis were last fed on this sheep 48 h prior to collection of skin samples. | Epithelial cells markedly vacuolated. Moderate numbers of eosinophils in connective tissue just below epithelium. | Focally dense aggregates of lymphocytes and plasma cells especially around capillaries and adnexae in mid dermis, lighter inflammation in superficial dermis. | Moderate inflammation *(lymphocytes, plasma cells) of peribronchial connective tissue. |
| Sheep VH58/ 6 dpi | Mild oedema and moderate engorgement, sparse dermal inflammation *(neutrophils, lymphocytes, plasma cells) | Moderately oedematous and engorged, with focal degeneration of epidermis. Moderate to marked diffuse dermal inflammation (Figure 2a) *(lymphocytes, plasma cells, eosinophils), with scattered foci of, predominantly, eosinophils associated with collagen necrosis. | Epithelial cells vacuolated. Glassy appearance to nuclei of macrophages, lymphocytes, plasma cells in lymphoid parenchyma. | Oedematous (especially around capillaries) and inflamed *(lymphocytes, plasma cells, eosinophils) – focally markedly so. Indistinct vacuolation of epidermal cells, but also apoptosis, epidermal oedema and erosion. | Peribronchial connective tissue is moderately oedematous and moderately inflamed *(plasma cells, lymphocytes). |
| Sheep VH57/ 8 dpi | Moderate oedema with mild perivascular inflammation *(lymphocytes and plasma cells). | Markedly oedematous (dermis and epidermis). Moderate to marked diffuse dermal inflammation around capillaries *(plasma cells, lymphocytes, eosinophils, neutrophils). Some crusts of surface and dermal foci of macrophages, plasma cells, lymphocytes and eosinophils, including granulomas in superficial dermis (neutrophils and eosinophils centrally with encircling epithelioid macrophages (Figure 2b). | Epithelial cells moderately to markedly vacuolated, numerous lymphocytes and plasma cells in epidermis. Glassy appearance to nuclei of macrophages, lymphocytes and plasma cells in lymphoid parenchyma. | Moderately oedematous (especially around capillaries) and moderately inflamed *(plasma cells, lymphocytes, rarely eosinophils). | Peribronchial connective tissue moderately oedematous and moderately inflamed *(plasma cells, lymphocytes). Diffuse engorgement and congestion. |
| Sheep VH66/ 9 dpi | Minor vacuolation of deep sweat gland cells as well as mild oedema with mild perivascular inflammation *(lymphocytes and plasma cells). | Moderate perivascular oedema and engorgement with patchy haemorrhage. One capillary contained a fibrin thrombus. Moderate to marked inflammation (plasma cells, lymphocytes, eosinophils, and neutrophils). | Areas of markedly vacuolated epithelial cells. There are also areas containing large numbers of lymphocytes and plasma cells in the tonsillar epithelium. | Engorged, haemorrhagic and oedematous (especially around capillaries) with mild inflammation *(plasma cells, lymphocytes, eosinophils and macrophages). Endothelial cells in the walls of some capillaries are degenerate. | Modest peribronchial inflammation *(plasma cells lymphocytes). Mild oedema, moderate engorgement, small numbers of vessels contain fibrin thrombi. |
| Age category, y | BRCA1 carriers | BRCA2 carriers | ||||
| No. of events | HR per unit SD increase in the ER- PRS (95% CI) | P† | No. of events | HR per unit SD increase in the overall BC PRS (95% CI) | P† | |
| Outcome: breast cancer | ||||||
| 18–39 | 4125 | 1.63 (1.52 to 1.74) | – | 1731 | 1.65 (1.44 to 1.88) | – |
| 40–49 | 2557 | 1.18 (1.13 to 1.23) | 4.2 × 10−15 | 1587 | 1.22 (1.14 to 1.31) | 8.5 × 10−5 |
| 50–59 | 846 | 1.14 (1.09 to 1.21) | .40 | 718 | 1.10 (1.02 to 1.19) | .05 |
| ≥60 | 269 | 1.20 (1.11 to 1.29) | .33 | 294 | 1.12 (1.03 to 1.23) | .75 |
| Interaction HR | 0.993 (0.990 to 0.996) | 3.3 × 10−6 | 0.995 (0.991 to 0.999) | .01 | ||
| Main effect PRS | 1.69 (1.50 to 1.91) | 1.55 (1.29 to 1.87) | ||||
| Outcome: ovarian cancer | ||||||
| 18–49 | 1258 | 1.55 (1.42 to 1.69) | 172 | 3.05 (2.35 to 3.97) | ||
| 50–59 | 808 | 1.11 (1.05 to 1.18) | 1.1 × 10−9 | 227 | 1.52 (1.26 to 1.84) | 8.2 × 10−6 |
| ≥60 | 396 | 1.14 (1.06 to 1.21) | .67 | 232 | 1.21 (1.12 to 1.30) | .03 |
| Interaction HR | 0.992 (0.988 to 0.998) | .003 | 0.991 (0.979 to 1.00) | .11 | ||
| Main effect PRS | 1.83 (1.43 to 2.34) | 2.48 (1.34 to 4.58) |
| Controls | Pre-RA | Univariate | Multivariate | |||
| OR (95 % CI) | p-value | OR (95 % CI)a | p-value | |||
| Intensity, n (%) | ||||||
| Model 1 | ||||||
| Never | 133 (44) | 36 (36) | reference | - | reference | - |
| Former | 59 (19) | 28 (28) | 1.90 (1.01–3.59) | 0.047 | 2.48 (1.27–4.84) | 0.008 |
| Current | 80 (26) | 30 (30) | 1.45 (0.81–2.56) | 0.205 | 1.57 (0.85–2.93) | 0.151 |
| Model 2 | ||||||
| Never | 133 (43) | 36 (35) | reference | - | reference | - |
| Current, 1–15 cig/day | 39 (13) | 20 (20) | 1.88 (0.98–3.61) | 0.059 | 2.16 (1.06–4.39) | 0.034 |
| Current, >16 cig/day | 41 (10) | 10 (10) | 0.95 (0.42–2.13) | 0.905 | 0.97 (0.43–2.28) | 0.974 |
| Former, quit ≤10 years | 27 (9) | 16 (16) | 2.18 (1.04–4.55) | 0.039 | 2.79 (1.29–6.07) | 0.009 |
| Former, quit >11 years | 32 (11) | 12 (12) | 1.50 (0.66–3.41) | 0.328 | 2.02 (0.84–4.89) | 0.115 |
| Current pipe/cigar/occasional | 31 (10) | 7 (7) | 0.93 (0.36–2.41) | 0.888 | 1.24 (0.46–3.34) | 0.670 |
| Attribute | Number (%) |
| Age | |
| Mean Age | 40.6 years |
| Standard deviation | 9.1 years |
| Marital status (N = 220) | |
| Married | 229 (71.5) |
| Single | 45 (14.1) |
| Widowed | 49 (14.4) |
| Religion (N = 316) | |
| Islam | 182 (57.6) |
| Christian | 134 (42.4) |
| Education (N = 300) | |
| None | 8 (2.7) |
| Primary | 109 (36.3) |
| Secondary | 155 (51.7) |
| Post-secondary | 28 (9.3) |
| Ethnicity | |
| Yoruba | 284 (89.3) |
| Igbo | 26 (8.2) |
| Hausa | 8 (2.5) |
| Category | Frequency | % |
| Gender | ||
| Female | 91 | 49.2 |
| Male | 94 | 50.8 |
| Age | ||
| ≤6 months | 8 | 4.3 |
| >6 months | 176 | 95.7 |
| Gestational age | ||
| >38 weeks | 78 | 42.4 |
| 27-34 weeks | 34 | 18.5 |
| 34-38 weeks | 72 | 39.1 |
| Birth weight | ||
| <1500g | 20 | 10.9 |
| >2500g | 89 | 48.4 |
| 1500-2500g | 75 | 40.8 |
| gene | forward primer | reverse primer | probe |
| HPRT | 5′-tgaacgtcttgctcgagatgtg-3′ | 5′-ccagcaggtcagcaaagaattt-3′ | 5′-tgggaggccatcacattgtagcc-3′ |
| SNCA | 5′-ccaaagagcaagtgacaaatgttg-3′ | 5′-agccagtggctgctgcaat-3′ | 5′-tgacgggtgtgacagcagtagccca-3′ |
| 5HT3AR | 5-ggctggtgcacaagcaagac-3′ | 5-ggctggtgcacaagcaagac-3′ | 5-ctgcttggctgcgtcacctggttct-3′ |
| 5HT4R | 5′-attccgggttgaacccttttc-3′ | 5′-aggtcttcggtagcgctcatc-3′ | 5′-acgtgccttcctcatcatcctct-3′ |
| M3R | 5′-cagctgcatacccaaaaccttt-3′ | 5′-tgaatgttttgttgcacagagcata-3′ | 5′-caacagcaccgtgaaccccgtgtg-3′ |
| VIP | 5′-aataaggcccagctccttgtg-3′ | 5′-cccaacctgagagcagaaggt-3′ | 5′-cttctcacagacttcggcatggc-3′ |
| Property | Water | Blood | Units |
| Density ρ | 1000 | 1050 [25] | kg/m3 |
| Specific heat c | 4190 [26] | 3850 [25] | J/(kg · K) |
| Thermal conductivity k | 0.61 [27] | 0.53 [28] | W/(m · K) |
| Thermal diffusivity α = k/ρc | 1.4 × 10-7 | 1.3 × 10-7 | m2/s |
| Absolute viscosity μ | 7 × 10-4 [26] | 3.5 × 10-3 [29] | Pa · s |
| Kinematic viscosity ν = μ/ρ | 7 × 10-7 | 3.3 × 10-6 | m2/s |
| Coefficient of thermal expansion β | 2.1 × 10-4 [26] | 4.0 × 10-4 [30] | K-1 |
| Source | df | SS | MS | Est. Var. | % |
| Among Pops | 10 | 164.219 | 16.422 | 0.628 | 12% |
| Among Indiv | 66 | 528.158 | 8.002 | 3.443 | 66% |
| Within Indiv | 74 | 86.000 | 1.162 | 1.162 | 22% |
| Total | 150 | 778.377 | 5.188 | 100% |
| Un-adjusted HRs (95% C.I.) | Adjusteda HRs (95% C.I.) | |||
| LNs extracted | Stage II | Stage III | Stage II | Stage III |
| Current guideline | ||||
| < 12 | ref | ref | ref | ref |
| ≥ 12 | 0.65 (0.40, 1.07) | 1.13 (0.77, 1.64) | 0.61 (0.37, 1.00) | 0.97 (0.64, 1.46) |
| Quartiles | ||||
| 1-6 | ref | ref | ref | ref |
| 7-11 | 0.93 (0.60, 1.43) | 1.64 (0.91, 2.94) | 0.85 (0.43, 1.67) | 0.87 (0.41, 1.85) |
| 12-19 | 0.89 (0.58, 1.34) | 0.97 (0.55, 1.71) | 0.68 (0.35, 1.32) | 0.97 (0.55, 1.70) |
| ≥ 20 | 0.54 (0.35, 0.83) | 1.02 (0.57, 1.82) | 0.42 (0.20, 0.90) | 0.74 (0.39, 1.40) |
| Current guideline | ||||
| < 12 | ref | ref | ref | ref |
| ≥ 12 | 0.69 (0.44, 1.07) | 1.09 (0.76, 1.56) | 0.65 (0.42, 1.02) | 0.95 (0.64, 1.40) |
| Quartiles | ||||
| 1-6 | ref | ref | ref | ref |
| 7-11 | 0.69 (0.37, 1.28) | 0.84 (0.48, 1.48) | 0.75 (0.40, 1.40) | 0.83 (0.47, 1.47) |
| 12-19 | 0.68 (0.38, 1.24) | 1.01 (0.60, 1.70) | 0.67 (0.37, 1.22) | 0.94 (0.56, 1.59) |
| ≥ 20 | 0.45 (0.23, 0.87) | 0.94 (0.55, 1.61) | 0.45 (0.23, 0.87) | 0.69 (0.38, 1.26) |
| Total (n = 1,304) | NSV (n = 806) | Rape (n = 183) | NCS (n = 315) | OR RAPE/NSV | OR NCS/NSV | OR Rape/NCS | χ2/F† | |
| Have been separated from family | 284 (22.1%) | 137 (17.2%) | 50 (27.8%) | 97 (31.2%) | 1.85** | 2.18** | 0.85 | 29.38** |
| Have witnessed violent acts against family members or friends | 172 (13.4%) | 84 (10.5%) | 37 (20.3%) | 51 (16.9%) | 2.17** | 1.72** | 1.26 | 16.29** |
| Had family members or friends violently killed during the war | 515 (40.6%) | 292 (37.3%) | 96 (53.3%) | 127 (41.5%) | 1.92** | 1.19 | 1.61 | 15.76** |
| Experienced pillage or setting your house on fire | 592 (47.1%) | 335 (43.1%) | 116 (65.9%) | 141 (46.4%) | 2.56** | 1.14 | 2.23** | 30.15** |
| Experienced gunfire attacks | 525 (42.3%) | 276 (35.7%) | 106 (59.6%) | 143 (49.1%) | 2.65** | 1.74** | 1.52 | 41.06** |
| Have seen somebody being killed | 479 (38.1%) | 245 (31.0%) | 79 (51.3%) | 155 (49.7%) | 2.34** | 2.20** | 1.07 | 45.92** |
| Have seen dead or mutilated bodies | 491 (38.4%) | 250 (31.5%) | 108 (59.7%) | 133 (43.5%) | 3.21** | 1.67** | 1.92* | 53.79** |
| Have been injured during the war | 113 (8.9%) | 36 (4.5%) | 41 (26.3%) | 36 (11.5%) | 7.56** | 2.75** | 2.74** | 79.69** |
| Have been in prison | 74 (5.7%) | 6 (7.0%) | 48 (26.7%) | 20 (6.4%) | 48.18** | 9.11** | 5.29** | 183.22** |
| Have been enrolled in an armed group | 48 (3.8%) | 3 (.4%) | 25 (16.0%) | 20 (6.4%) | 50.76** | 18.22** | 2.79* | 95.73** |
| Have been kidnapped by an armed group | 85 (6.5%) | 16 (2.0%) | 51 (28.0%) | 18 (5.7%) | 19.17** | 2.99** | 6.40** | 165.01** |
| Have been forced to kill, injure or rape someone themselves | 75 (5.9%) | 25 (3.3%) | 35 (22.2%) | 14 (4.6%) | 8.45** | 1.42 | 5.96* | 85.67** |
| Have seen someone being raped | 180 (14.1%) | 67 (8.4%) | 56 (31.6%) | 57 (18.9%) | 5.08** | 2.56** | 1.98** | 72.79** |
| Total traumatic exposure (mean, SD) | 2.83 (2.43) | 2.19 (1.90) | 4.71 (3.05) | 3.16 (2.45) | 2.43** | 1.01** | 1.42** | 86.62** |
| Screening or Intervention (Dependent Variable) | |||||
| Asked about AOD use | Suggested cutting down or stopping AOD use | Referred for specialty care | Counseled for > = 5 min | Asked and provided any treatment | |
| Independent Variable | OR [95% CI] | OR [95% CI] | OR [95% CI] | OR [95% CI] | OR [95% CI] |
| MHI-5 Score (0–100) | 1.01 [1.00–1.01] | 1.01 [1.00–1.02] | 0.97 [0.96–0.98]*** | 0.97 [0.97–0.98]*** | 0.98 [0.97–0.99]*** |
| PESQ Risk Flags | |||||
| Red (vs. Green) | 1.69 [1.19–2.40]** | 8.89 [5.59–14.14]*** | 2.80 [1.73–4.54]*** | 3.48 [2.29–5.30]*** | 4.44 [3.11–6.36]*** |
| Yellow (vs. Green) | 1.36 [0.96–1.92] | 2.37 [1.37–4.09]** | 1.14 [0.61–2.14] | 2.15 [1.35–3.42]*** | 2.03 [1.37–3.01]*** |
| Age | 1.25 [1.17–1.34]*** | 0.98 [0.88–1.11] | 0.96 [0.85–1.08] | 0.88 [0.80–0.97]* | 0.93 [0.85–1.01] |
| Gender | |||||
| Female (vs. Male) | 1.19 [0.93–1.52] | 0.61 [0.41–0.91]* | 0.81 [0.53–1.25] | 0.93 [0.65–1.33] | 0.81 [0.60–1.08] |
| Race | |||||
| Black (vs. White) | 0.42 [0.27–0.66]*** | 1.03 [0.51–2.08] | 1.00 [0.50–1.99] | 0.91 [0.50–1.68] | 0.80 [0.48–1.33] |
| Hispanic (vs. White) | 0.40 [0.26–0.64]*** | 0.98 [0.49–1.97] | 1.17 [0.58–2.33] | 1.12 [0.62–2.01] | 0.93 [0.57–1.54] |
| Multi/Other (vs. White) | 0.56 [0.31–0.99]* | 1.05 [0.41–2.69] | 0.88 [0.32–2.38] | 1.46 [0.69–3.10] | 1.12 [0.58–2.13] |
| Mother’s Education | |||||
| At least some college (vs. less than college) | 1.07 [0.81–1.41] | 0.93 [0.59–1.45] | 1.10 [0.69–1.76] | 1.31 [0.89–1.93] | 1.22 [0.88–1.69] |
| Clinic | |||||
| Clinic A (vs. Clinic D) | 0.80 [0.52–1.26] | 1.53 [0.75–3.12] | 1.45 [0.68–3.10] | 1.25 [0.67–2.32] | 1.36 [0.81–2.30] |
| Clinic B (vs. Clinic D) | 0.66 [0.43–1.02] | 1.08 [0.53–2.20] | 1.86 [0.92–3.76] | 1.36 [0.76–2.44] | 1.26 [0.76–2.08] |
| Clinic C (vs. Clinic D) | 0.87 [0.54–1.40] | 0.98 [0.45–2.15] | 1.79 [0.87–3.69] | 0.79 [0.41–1.55] | 0.98 [0.56–1.70] |
| Rank | Feature description |
| 1 | Cumulative number of 30-day readmissions |
| 2 | Presence of acute respiratory failure ICD-9 code |
| 3 | Number of abnormal sodium level laboratory tests |
| 4 | Presence of pneumonia (organism unspecified) ICD-9 code |
| 5 | Number of abnormal chloride level laboratory tests |
| 6 | Presence of acute kidney failure (unspecified) ICD-9 code |
| 7 | Presence of diabetes (with other specified manifestations) ICD-9 code |
| 8 | Presence of acute kidney failure (any) ICD-9 code |
| 9 | Presence of respiratory failure, WKF |
| 10 | Presence of disorders of fluid electrolyte and acid-base balance (any) ICD-9 code |
| 11 | Presence of disorders of fluid/electrolyte/acid-base, WKF |
| 12 | Number of abnormal albumin level laboratory tests |
| 13 | Presence of asphyxia and hypoxemia ICD-9 code |
| 14 | Presence of anemia of chronic illness ICD-9 code |
| 15 | Presence of hypokalemia ICD-9 code |
| Location | Number |
| Spleen | 14 |
| Liver | 13 |
| Kidney | 2 |
| Diaphragm | 2 |
| Pancreas | 2 |
| Measure | Whole sample | Males | Females | Mean difference (male–female) | ||||||||||
| N | Range | Mean | SD | N | Range | Mean | SD | N | Range | Mean | SD | t | p | |
| Social isolation | 2061 | 0–24 | 3.29 | 4.35 | 976 | 0–24 | 3.74 | 4.51 | 1085 | 0–24 | 2.87 | 4.15 | 4.56 | <0.001 |
| Loneliness | 2051 | 0–8 | 1.57 | 1.94 | 973 | 0–8 | 1.51 | 1.93 | 1078 | 0–8 | 1.62 | 1.95 | −1.39 | 0.17 |
| Depression | 2063 | 0–9 | 1.81 | 2.97 | 979 | 0–9 | 1.44 | 2.70 | 1084 | 0–9 | 2.13 | 3.16 | −5.32 | <0.001 |
| Tap | Channel A | Channel B | Doppler | ||
| Relative Delay (ns) | Average Power (dB) | Relative Delay (ns) | Average Power (dB) | Spectrum | |
| 1 | 0 | 0.0 | 0 | –2.5 | Classic |
| 2 | 310 | –1.0 | 300 | 0 | Classic |
| 3 | 710 | –9.0 | 8900 | –12.8 | Classic |
| 4 | 1090 | –10.0 | 12,900 | –10.0 | Classic |
| 5 | 1730 | –15.0 | 17,100 | –25.2 | Classic |
| 6 | 2510 | –20.0 | 20,000 | –16.0 | Classic |
| Invasive fungal rhinosinusitis with orbital complications (n = 35) | Bacterial rhinosinusitis with orbital complications (n = 65) | Adjusted odds ratio (95% CI) | P value | |
| Nasal crust | 14 | 1 | 77.78 (1.95–3095.00) | <0.001 |
| Oculomotor nerve involvement | 34 | 45 | 15.11 (2.16–644.26) | 0.001 |
| Trochlear nerve involvement | 33 | 43 | 5.70 (0.52–62.57) | 0.10 |
| Optic nerve involvement | 22 | 17 | 3.77 (1.50–9.50) | 0.002 |
| Abducens nerve involvement | 33 | 45 | 3.70 (0.40–34.57) | 0.22 |
| Facial swelling | 10 | 8 | 2.37 (0.82–6.80) | 0.10 |
| Trigeminal nerve involvement | 16 | 13 | 1.62 (0.77–3.42) | 0.20 |
| Pus in middle meatus | 16 | 27 | 1.36 (0.57–3.25) | 0.49 |
| Swelling of middle meatus | 28 | 31 | 1.29 (0.55–3.04) | 0.56 |
| Secretion in nasopharynx | 4 | 10 | 0.56 (0.18–1.73) | 0.31 |
| Proptosis | 27 | 45 | 0.53 (0.16–1.79) | 0.30 |
| Periorbital swelling | 20 | 58 | 0.32 (0.12–0.83) | 0.01 |
| Chemosis | 27 | 53 | 0.26 (0.06–1.18) | 0.06 |
| Group | (1a) Ultramutated POLE mutant | (1b) Hypermutated dMMR/MSI | (2) CIN/SCNA-high, MSS |
| Mutation rate | ++++ | +++ | + |
| Somatic copy number alterations | +/− | + | +++ |
| Key molecular/genetic abnormality | POLE EDM proofreading mutation | Defective MMR/MLH1 promoter hypermethylation | Variety of mutated cancer genes; WNT pathway activation (mostly by APC mutation/inactivation) |
| Predominant histological type | Moderately differentiated adenocarcinoma | Mucinous, or signet ring, or poorly differentiated adenocarcinoma | Moderately differentiated adenocarcinoma |
| Proportion of all colorectal carcinomas | ∼3 % | ∼13 % | ∼84 % |
| Prognosis | Good (more data required) | Good/poor after relapse | Good-poor (depending on other characteristics) |
| N0S0 | N0Sπ | |||||||
| HH | LL | LH | HL | HH | LL | LH | HL | |
| Obs. 1 | Limited** | Limited** | Super* | Super | ||||
| Obs. 2 | Limited** | Limited** | Super | Limited** | Super | Limited** | ||
| Obs. 3 | Limited** | Limited** | Limited** | Limited* | Super** | Super | ||
| Obs. 4 | Limited** | Limited** | Limited** | Limited** | Super |
| Regimens of first-line chemotherapy | Overall | MTB or MK infection | |
| (+) | (–) | ||
| N = 30 | N = 7 | N = 23 | |
| Intensive regimens | 26 | 6 | 20 |
| FOLFOX | 8 | 2 | 6 |
| FOLFOX + Bmab | 6 | 1 | 5 |
| FOLFIRI | 6 | 1 | 5 |
| FOLFOX + Pmab/Cmab | 2 | 2 | 0 |
| FOLFIRI + Pmab/Cmab | 2 | 0 | 2 |
| FOLFIRI + Bmab | 1 | 0 | 1 |
| XELOX | 1 | 0 | 1 |
| Non-intensive regimens | 4 | 1 | 3 |
| UFT/LV | 1 | 1 | 0 |
| S-1 | 2 | 0 | 2 |
| Capecitabine | 1 | 0 | 1 |
| Response rate (%) | 40.0 | 28.6 | 43.5 |
| CR | 1 | 1 | 0 |
| PR | 11 | 1 | 10 |
| SD | 10 | 2 | 8 |
| PD | 7 | 3 | 4 |
| NE | 1 | 0 | 1 |
| Days | Body weight (g) | |||
| N30 (100 mg/kg) | N30 (50 mg/kg) | Solvent control | Control | |
| 0 | 17.0 ± 1.1 | 17.0 ± 1.3 | 16.0 ± 0.9 | 15.9 ± 0.7 |
| 5 | 23.7 ± 0.9 | 21.6 ± 1.0 | 22.0 ± 1.9 | 22.7 ± 1.3 |
| 10 | 28.5 ± 2.1 | 26.3 ± 0.9 | 26.2 ± 2.3 | 27.6 ± 1.0 |
| 14 | 30.1 ± 2.5 | 27.7 ± 1.5 | 27.9 ± 2.6 | 29.9 ± 1.6 |
| Activity against the Isolates | ||||
| Antibiotics | Resistance Prevalence (%) | MIC (mg L−1) | ||
| Range | 50% | 90% | ||
| Ampicillin (AMP) | 100.0 | 64 to ≥1024 | 1024 | 1024 |
| Amoxicillin (AMO) | 100.0 | 1 to ≥1024 | 1024 | 1024 |
| Streptomycin Sulfate (STR) | 92.3 | 1 to ≥1024 | 128 | 512 |
| Trimethoprim (TRI) | 98.0 | 8 to ≥1024 | 1024 | 1024 |
| Chloramphenicol (CHL) | 100.0 | 256 to ≥1024 | 1024 | 1024 |
| Sulfonamide (SUL) | 100.0 | 512 to ≥1024 | 1024 | 1024 |
| Tetracycline (TET) | 90.6 | 2 to ≥512 | 128 | 256 |
| Oxytetracycline (OXY) | 90.6 | 1 to ≥1024 | 256 | 512 |
| Nalidixic Acid (NAL) | 73.6 | 1 to ≥1024 | 512 | 1024 |
| Erythromycin (ERY) | 92.5 | 4 to ≥1024 | 128 | 512 |
| Spiramycin (SPIRA) | 90.6 | 2 to ≥1024 | 512 | 1024 |
| Kanamycin (KAN) | 54.7 | 1 to ≥1024 | 128 | 1024 |
| Cases (n = 830) | Controls (n = 907) | P | |
| Age* | 43 (39–47) | 41 (36–44) | <0.001 |
| Female | 354 (43%) | 407 (45%) | 0.421 |
| Black | 353 (43%) | 354 (39%) | 0.207 |
| HTN | 371 (45%) | 181 (20%) | <0.001 |
| MI | 62 (7.5%) | 14 (1.5%) | <0.001 |
| DM | 147 (18%) | 55 (6%) | <0.001 |
| Smoking | 348 (42%) | 257 (28%) | <0.001 |
| OC | 57 (16%) | 34 (8%) | <0.001 |
| Migraine | |||
| MWA | 226 (27%) | 193 (21%) | 0.005 |
| MWoA | 56 (7%) | 73 (8%) | 0.346 |
| Characteristics, n (%) | Participants completing the SF-6D | Participants completing the EQ-5D-3L |
| (N = 1021) | (N = 1015) | |
| Female | 521 (51.0) | 512 (50.4) |
| Age (years) | ||
| 21-29 | 190 (18.6) | 194 (19.1) |
| 30-39 | 222 (21.7) | 228 (22.5) |
| 40-49 | 272 (26.6) | 269 (26.5) |
| 50-59 | 206 (20.2) | 200 (19.7) |
| 60+ | 131 (12.8) | 124 (12.2) |
| Ethnicity | ||
| Chinese | 392 (38.4) | 387 (38.1) |
| Malay | 396 (38.8) | 399 (39.3) |
| Indian | 233 (22.8) | 229 (22.6) |
| Education level | ||
| Primary (6 years) or less | 177 (17.3) | 190 (18.7) |
| Secondary (11 years) | 562 (55.0) | 576 (56.8) |
| Diploma/degree or higher | 282 (27.6) | 249 (24.5) |
| Married/partner | 765 (74.9) | 761 (75.0) |
| Employed or self-employed | 659 (64.5) | 643 (63.4) |
| General health status | ||
| Poor | 4 (0.4) | 8 (0.8) |
| Fair | 70 (6.9) | 99 (9.8) |
| Good | 443 (43.4) | 424 (41.8) |
| Very good | 419 (41.0) | 383 (37.7) |
| Excellent | 85 (8.3) | 101 (10.0) |
| Self-reported health on EQ-5D-3L VAS, Mean (SD) | 84.5 (11.2) | 83.0 (12.1) |
| Study | Year | N | Criteria | Treatment | Findings |
| Hu et al. [6] | 2006 | 84 | Solitary brain metastasis | SRS or surgery | Stage I intrathoracic patients had better OS outcomes than stage III |
| Bonnette et al. [7] | 2001 | 108 | Brain metastasis (98 with solitary) | Surgery | Adenocarcinoma, T stage, complete resection with better outcomes |
| Rodrigues et al. [8] | 2011 | 66 | ≤6 intracranial lesions | Image-guided SIB RT | Presence of systemic disease, lower performance status correlated with decreased OS |
| Iwasaki et al. [9] | 2004 | 41 | Solitary brain metastasis | Resection of primary site and brain metastasis | Risk score criteria for improved OS:adenocarcinoma, node-negative, normal CEA level |
| Mussi et al. [10] | 1996 | 52 | Solitary brain metastasis | Resection of primary site and brain metastasis | No status, lobectomy associated with decreased OS. 5-year OS in patients with synchronous/metachronous lesions 6.6/19%, respectively |
| Machiarini et al.[11] | 1991 | 37 | Solitary brain metastasis. Synchronous (<1 month) and metachronous included. | Resection of primary site and brain metastasis | Most frequent site of first recurrence was ipsilateral thorax (n = 14) and brain (n = 6). The receipt of adjuvant chemotherapy was strongest predictor of disease-free interval |
| Wronski et al. [12] | 1995 | 231 | Single (87%) or multiple (13%) metastatic intracranial lesions | Resection | Female gender, complete location, infratentorial location, no systemic metastases, age < 60 years associated with improved OS |
| Average weekly doses (IU/kg) | ||||||
| Population by | Weeks 12–24 | Weeks 37–52 | ||||
| Frequency of administration | n (%) | Mean ± SD | Median (Range) | n (%) | Mean ± SD | Median (Range) |
| 3× per week | 158 (100.0) | 103.5 ± 88.0 | 77.9 (13.3–804.0) | 126 (79.8) | 114.4 ± 130.7 | 90.5 (0.0–1293.6) |
| 2× per week | 150 (100.0) | 76.9 ± 58.5 | 62.2 (11.5–417.5) | 131 (87.3) | 79.2 ± 68.6 | 62.01 (2.5–436.5) |
| 1× per week | 103 (100.0) | 65.9 ± 57.8 | 48.8 (2.3–335.0) | 88 (85.4) | 80.9 ± 96.8 | 47.5 (0.0–622.6) |
| Dialysis type | ||||||
| Predialysis | 32 (100.0) | 87.7 ± 73.5 | 56.0 (19.1–335.0) | 26 (81.2) | 122.6 ± 133.3 | 73.2 (14.9–622.6) |
| Haemodialysis | 288 (100.0) | 82.3 ± 57.9 | 66.5 (2.3–396.0) | 242 (84.0) | 90.5 ± 102.6 | 69.0 (0.0–1293.6) |
| Peritoneal dialysis | 91 (100.0) | 89.8 ± 107.3 | 60.4 (12.2–804.0) | 77 (84.6) | 88.8 ± 92.4 | 61.9 (4.4–436.5) |
| Total | 411 (100.0) | 84.4 ± 72.7 | 64.8 (2.3–804.0) | 345 (83.9) | 92.5 ± 103.1 | 66.0 (0.0–1293.6) |
| Spot no | Fold difference | Average normalized volumes | |
| HF | KF | ||
| 102 | 4.9 | 1.474 | 0.301 |
| 94 | 10.1 | 0.337 | 3.404 |
| 101 | 26.7 | 0.121 | 3.220 |
| 105 | 6.8 | 0.452 | 3.090 |
| 103 | 11.0 | 1.516 | 0.138 |
| 86 | 7.6 | 0.358 | 2.738 |
| 83 | 4.6 | 1.506 | 0.330 |
| 96 | 5.0 | 0.442 | 2.215 |
| 90 | 5.4 | 0.484 | 2.633 |
| 99 | 4.6 | 0.601 | 2.786 |
| 129 | 3.8 | 0.441 | 1.692 |
| 125 | 6.1 | 0.524 | 3.219 |
| 145 | 3.5 | 0.666 | 2.324 |
| 148 | 7.7 | 0.283 | 2.180 |
| 144 | 36.9 | 0.074 | 2.725 |
| 110 | 4.8 | 1.343 | 0.280 |
| 104 | 7.7 | 1.508 | 0.196 |
| 116 | 6.1 | 0.430 | 2.616 |
| 135 | 3.1 | 0.663 | 2.026 |
| 122 | 3.7 | 0.738 | 2.698 |
| 35 | 3.6 | 0.599 | 2.163 |
| 27 | 6.8 | 1.537 | 0.226 |
| 39 | 4.2 | 0.566 | 2.363 |
| 46 | 4.9 | 0.659 | 3.250 |
| 38 | 9.8 | 0.374 | 3.662 |
| 16 | 5.3 | 2.011 | 0.381 |
| 10 | 5.3 | 2.046 | 0.389 |
| 19 | 3.3 | 0.576 | 1.925 |
| 24 | 5.0 | 1.465 | 0.290 |
| 18 | 6.9 | 0.362 | 2.506 |
| 65 | 6.5 | 1.664 | 0.257 |
| 56 | 5.2 | 0.469 | 2.455 |
| 73 | 9.2 | 1.553 | 0.169 |
| 69 | 7.2 | 0.364 | 2.635 |
| 71 | 3.2 | 1.307 | 0.410 |
| 48 | 4.2 | 0.717 | 2.991 |
| 45 | 6.1 | 3.287 | 0.538 |
| 52 | 4.5 | 2.628 | 0.589 |
| 55 | 5.2 | 1.772 | 0.341 |
| 51 | 11.1 | 0.235 | 2.618 |
| Diabetic (N = 8) | Non-diabetic (N = 60) | p value | |
| Days till admission, median (range) | 4 (0–49) | 15 (0–49) | 0.367 |
| Referral, No (%) | 0.088 | ||
| Admission to hospital > 1 day | 7 (87.5) | 49 (81.7) | |
| Admission to hospital refused by patient | 1 (12.5) | 0 (0.0) | |
| Day treatment | 0 (0.0) | 11 (18.3) | |
| Additional hospitalization, No (%)a | 1 (12.5) | 8 (13.6) | 1.000 |
| Median length of stay, days (range) | 20 (4–41) | 5 (1–30) | 0.025 |
| Complications, No (%)b | 5 (62.5) | 10 (17.5) | 0.013 |
| Treatment, No (%)a | 0.549 | ||
| Graft | 7 (87.5) | 54 (91.5) | |
| Necrotectomy only | 0 (0.0) | 1 (1.7) | |
| Conservative | 1 (12.5) | 4 (6.8) | |
| Additional surgery, No (%)a | 2 (25.0) | 4 (6.8) | 0.147 |
| Complete epithelialization after first treatment, No (%)c | 6 (85.7) | 45 (83.3) | 1.000 |
| Days till complete epithelialization, median (range) | 44 (17–93) | 31 (10–192) | 0.660 |
| Take graft, No (%)d | |||
| 0.365 | |||
| Good | 6 (75.0) | 48 (85.7) | |
| Moderate | 1 (12.5) | 4 (7.1) | |
| Inapplicable | 1 (12.5) | 4 (7.1) |
| Univariate analysis | Multivariate analysis | |||
| p-value | OR (95% CI) | p-value | OR (95% CI) | |
| Age | 0.011* | 1.038 (1.008 ~ 1.068) | 0.004* | 1.048 (1.015 ~ 1.081) |
| Male sex | 0.197 | 1.631 (0.776 ~ 3.428) | 0.194 | 1.748 (0.753 ~ 4.060) |
| Hypertension | 0.182 | 1.689 (0.783 ~ 3.643) | ||
| Diabetes | 0.151 | 1.622 (0.838 ~ 3.140) | ||
| Cigarette smoking | 0.036* | 2.068 (1.048 ~ 4.081) | 0.015* | 2.764 (1.215 ~ 6.289) |
| Daily alcohol use | 0.068 | 2.566 (0.934 ~ 7.045) | 0.345 | 1.722 (0.558 ~ 5.317) |
| Right hemispheric involvement | 0.377 | 1.381 (0.674 ~ 2.830) | ||
| Stroke syndrome (ref. lacunar syndrome) | ||||
| Major hemispheric | 0.001* | 5.070 (1.864 ~ 13.791) | 0.003* | 4.781 (1.711 ~ 13.356) |
| Minor hemispheric | 0.698 | 1.334 (0.311 ~ 5.726) | 0.809 | 1.199 (0.275 ~ 5.221) |
| Brainstem-cerebellum | 0.227 | 1.988 (0.652 ~ 6.063) | 0.294 | 1.831 (0.592 ~ 5.664) |
| Angiographic result | Total (n = 108) (%) | Anterior circulation (n = 92) (%) | Posterior circulation (n = 16) (%) |
| mTICI 0 | 8 (7.4) | 4 (4.4) | 4 (25) |
| mTICI 1 | 8 (7.4) | 7 (7.6) | 1 (6.3) |
| mTICI 2a | 10 (9.3) | 9 (9.8) | 1 (6.3) |
| mTICI 2b | 39 (36.1) | 37 (40.2) | 2 (12.5) |
| mTICI 3 | 43 (39.8) | 35 (38.0) | 8 (50) |
| Method | Phen. allowed a | Input values b | Kc | Link |
| Ref-based | Any | Beta | N/A | http://people.oregonstate.edu/~housemae/software/TutorialLondon2014 |
| http://bioconductor.org/packages/release/bioc/html/minfi.html | ||||
| Ref-free | Any | Beta | Estimated | http://cran.r-project.org/web/packages/RefFreeEWAS/index.html |
| SVA | Any | Beta or logit(beta) | Estimated | http://bioconductor.org/packages/release/bioc/html/sva.html |
| ISVA | Continuous | Beta or logit(beta) | Estimated | http://cran.r-project.org/web/packages/isva/index.html |
| EWASher | Binary | Beta | Estimated | http://research.microsoft.com/en-us/downloads/472fe637-7cb9-47d4-a0df-37118760ccd1 |
| CellCDec | Not used | Beta | Input | https://github.com/jameswagner/CellCDec |
| Deconf | Not used | Beta or logit(beta) | Input | http://web.cbio.uct.ac.za/~renaud/CRAN |
| RUV | Any | Beta or logit(beta) | Estimated | https://cran.r-project.org/web/packages/ruv/index.html |
| Waiting List v Community | Comparison of Means | ROC | Absolute Performance Gain | ||||||||||||
| Instruments | Community (n = 111) | OWL(n = 45) | Effect size # | SD. | t | RE | Area Under Curve | Asymptotic 95% CI | Z | APG % | 95% CI | ||||
| M | SD. | M | SD | Lower | Upper | Lower | Upper | ||||||||
| AQOL | |||||||||||||||
| Utility Score | 0.50 | 0.19 | 0.37 | 0.25 | 0.66 | 0.21 | 3.7** | 1.00 | **0.67 | 0.57 | 0.77 | reference | |||
| Independent living | 0.80 | 0.18 | 0.69 | 0.22 | 0.58 | 0.19 | 3.3** | 0.79 | *0.66 | 0.57 | 0.75 | 0.10 | 1.9 | -16.6 | 20.5 |
| Social relationships | 0.84 | 0.15 | 0.76 | 0.26 | 0.24 | 0.19 | 2.4* | 0.41 | 0.56 | 0.45 | 0.67 | 1.08 | 21.5 | 1.9 | 41.1 |
| Physical senses | 0.90 | 0.09 | 0.92 | 0.07 | -0.26 | 0.08 | -1.4 | 0.16 | 0.43 | 0.33 | 0.53 | ^1.97 | 48.5 | 24.4 | 72.7 |
| Psychological wellbeing | 0.81 | 0.11 | 0.67 | 0.23 | 0.88 | 0.15 | 4.9** | 1.78 | *0.65 | 0.54 | 0.76 | 0.22 | 4.4 | -15.2 | 23.9 |
| SF-36 | |||||||||||||||
| Physical function | 40.8 | 21.0 | 29.8 | 24.9 | 0.50 | 22.2 | 2.8* | 0.57 | **0.67 | 0.57 | 0.77 | -0.02 | 0.5 | -22.7 | 23.8 |
| Role physical | 26.7 | 37.1 | 10.6 | 22.9 | 0.48 | 33.7 | 2.7* | 0.53 | *0.61 | 0.52 | 0.70 | 0.47 | 11.6 | -12.3 | 35.5 |
| Bodily pain | 42.7 | 18.8 | 33.9 | 17.2 | 0.48 | 18.3 | 2.7* | 0.53 | *0.63 | 0.53 | 0.72 | 0.43 | 8.8 | -11.1 | 28.7 |
| General health | 56.6 | 22.2 | 51.7 | 20.8 | 0.22 | 21.8 | 1.3 | 0.12 | 0.56 | 0.47 | 0.66 | 0.86 | 21.1 | -3.0 | 45.2 |
| Vitality | 44.7 | 19.5 | 43.3 | 22.0 | 0.07 | 20.2 | 0.4 | 0.01 | 0.52 | 0.42 | 0.63 | 1.22 | 29.4 | 5.8 | 53.1 |
| Social function | 68.4 | 24.8 | 56.4 | 28.7 | 0.46 | 26.0 | 2.6* | 0.49 | *0.62 | 0.52 | 0.72 | 0.46 | 9.8 | -11.2 | 30.9 |
| Role emotional | 55.1 | 44.6 | 43.0 | 45.9 | 0.27 | 45.0 | 1.5 | 0.17 | 0.57 | 0.47 | 0.67 | 0.81 | 19.9 | -4.2 | 44.0 |
| Mental health | 68.3 | 17.9 | 61.3 | 22.3 | 0.36 | 19.2 | 2.1* | 0.30 | 0.59 | 0.48 | 0.69 | 0.69 | 16.5 | -6.9 | 39.8 |
| PCS | 31.8 | 9.3 | 27.8 | 8.1 | 0.44 | 9.0 | 2.5* | 0.46 | *0.64 | 0.55 | 0.74 | 0.20 | 5.0 | -19.5 | 29.4 |
| MCS | 47.8 | 11.6 | 44.9 | 13.4 | 0.24 | 12.1 | 1.4 | 0.13 | 0.56 | 0.46 | 0.66 | 0.91 | 21.4 | -1.6 | 44.3 |
| WOMAC | |||||||||||||||
| Pain | 41.6 | 20.7 | 54.3 | 21.9 | -0.60 | 21.0 | -3.4** | 0.84 | *0.66 | 0.57 | 0.76 | 0.08 | 1.7 | -20.3 | 0.2 |
| Stiffness | 50.0 | 18.5 | 59.4 | 18.9 | -0.51 | 18.6 | -2.9* | 0.60 | *0.63 | 0.53 | 0.72 | 0.37 | 8.3 | -13.5 | 0.3 |
| Physical function | 42.5 | 19.4 | 58.5 | 19.3 | -0.82 | 19.4 | -4.7** | 1.57 | **0.71 | 0.62 | 0.80 | -0.38 | 8.1 | -12.8 | 0.3 |
| Total score | 42.9 | 18.4 | 57.7 | 19.0 | -0.79 | 18.6 | -4.5** | 1.46 | **0.70 | 0.61 | 0.79 | -0.28 | 6.0 | -14.7 | 0.3 |
| VAS (over past week) | |||||||||||||||
| Average pain | -43.7 | 23.8 | -60.7 | 21.6 | 0.74 | 23.2 | 4.2** | 1.26 | **0.70 | 0.61 | 0.79 | -0.28 | 6.0 | -0.2 | 0.3 |
| Pain at rest | -26.9 | 22.2 | -41.8 | 22.6 | 0.67 | 22.3 | 3.8** | 1.03 | **0.70 | 0.61 | 0.78 | -0.22 | 5.0 | -0.2 | 0.3 |
| ADL Restriction | -37.8 | 26.0 | -51.2 | 23.9 | 0.53 | 25.4 | 3.0* | 0.64 | *0.65 | 0.56 | 0.74 | 0.18 | 3.9 | -0.2 | 0.3 |
| Material | Fixation method | Approximate global size (mm) | Maximum deviation factor | Minimum size factor | Number of elements |
| Cement | — | 2.0 | 0.02 | 0.1 | 107556 |
| Femoral prosthesis | — | 1.5 | 0.05 | 0.1 | 631470 |
| Femur | Cemented | 2.0 | 0.05 | 0.1 | 761218 |
| Noncemented | 2.0 | 0.05 | 0.1 | 792849 | |
| Total number of elements | Cemented | — | — | — | 1500244 |
| Noncemented | — | — | — | 1424319 |
| Facies type | Model | Nugget | Partial sill | Range (m) |
| Sand flats | Exponential | 0.103 | 0.223 | 3015 |
| Mixed flats | Spherical | 0.186 | 0.065 | 1029 |
| Mud flats | Spherical | 0.099 | 0.295 | 7575 |
| Variable | ACS, | No ACS, |
| N = 128 (%) | N = 790 (%) | |
| Age (years) (mean; SD) | (56.2; 12.0) | (61.4; 12.2) |
| Male gender | 78 (60.9) | 362 (45.8) |
| Prior disease | 60 (46.8) | 119 (15.0) |
| Family history of CAD | 42 (32.8) | 232 (29.3) |
| Hypertension | 106 (82.8) | 525 (66.4) |
| Cholesterol | 98 (76.5) | 412 (52.1) |
| Diabetes mellitus | 43 (33.6) | 228 (28.8) |
| Tobacco | 53 (41.4) | 268 (33.9) |
| Cocaine | 4 (3.1) | 30 (3.8) |
| Amphetamine | 7 (5.4) | 21 (2.6) |
| Normal ECG | 52 (40.6) | 456 (57.7) |
| GCA Classification Criteria |
| (1) Age at onset ≥50 years |
| (2) A new headache |
| (3) Temporal artery abnormality such as tenderness to palpation or decreased pulsation |
| (4) Erythrocyte sedimentation rate ≥50 mm/h |
| (5) Abnormal artery biopsy showing vasculitis with mononuclear cell or granulomatous inflammation, usually with giant cells |
| Items | Issues |
| Model units | • Headcounts do not reflect variation in effective workforce.• FTE measured in working hours can translate into a variable effective workforce.• FTE defined in reference to the most active physician category makes the assumption that the activity level in that category is relevant. |
| Data quality | • Routine data are useful, but provide generally limited information.• Various data sources coexist, with inconsistencies between them.• Qualitative data for in-depth understanding of trends is often lacking. |
| Categories of resources | • Computation of human resources requirements by specialty obviates professional interactions and skill mix.• Assessing skill-mix requirements is a complex task and documentation is often lacking. |
| Supply parameters | • Information other than age, sex and services volume is often unavailable.• Productivity is sensitive to the working and societal environment and is rapidly evolving. |
| Demand parameters | • Assessing the impact of new technologies, emerging pathologies and demographic changes requires a large quantity of data and expertise that are often unavailable.• Level and mode of health care utilization are sensitive to the environment and are rapidly evolving. |
| Modeling | • Deterministic models are likely to generate inaccuracies without providing a means to evaluate them.• Regression modeling with stochastic simulation can be innovative in the HRH field but background is lacking• Regular updating of data is paramount but resource-consuming. |
| Control | Laser 0.5 | Laser 1.0 | p value* | |||
| Control versus 0.5 | Control versus 1.0 | 0.5 versus 1.0 | ||||
| T0 | 0.8±0.3 100% | 0.8±0.3 100% | 1.0±0.0 93.4% | 0.9266 | 0.0705 | 0.0705 |
| T24 | 1.8±0.3 100% | 2.8±0.3 94.9% | 3.8±0.3 96.8% | 0.0039** | 0.0039** | 0.0039** |
| T48 | 2.8±0.3 100% | 3.5±0.0 97.8% | 4.3±0.8 98.5% | 0.0024** | 0.0039** | 0.0705 |
| T72 | 3.0±0.0 98.6% | 3.8±0.3 100% | 4.0±0.0 100% | 0.0024** | 0.0013** | 0.0705 |
| Variable | N | % |
| Age in years (n = 1533) | ||
| 15–19 | 15 | 1 |
| 20–29 | 455 | 29.7 |
| 30–39 | 710 | 46.3 |
| 40–49 | 242 | 15.8 |
| 50 and above | 111 | 7.2 |
| Sex (n = 1549) | ||
| Female | 1333 | 86.1 |
| Caregiver relationship to a child (n = 1546) | ||
| Mother | 1257 | 81.3 |
| Father | 130 | 8.4 |
| Relative | 159 | 10.3 |
| Marital status (n = 1546) | ||
| Married | 1210 | 78.3 |
| Single, separated or divorced | 179 | 11.5 |
| Widow or widower | 157 | 10.2 |
| Education level (n = 1546) | ||
| None or informal | 170 | 11.0 |
| Primary | 285 | 18.4 |
| Secondary | 703 | 45.5 |
| Postsecondary Diploma and above | 388 | 25.1 |
| Employment status (n = 1532) | ||
| None | 326 | 21.3 |
| Employed in informal sector | 988 | 64.5 |
| Employed in formal sector | 218 | 14.2 |
| Income status (n = 1474) | ||
| <N18,000 | 914 | 62.0 |
| N18,000–50,000 | 427 | 29.0 |
| N51,000–100,000 | 105 | 7.1 |
| >N100,000 | 28 | 1.9 |
| Category | Subcategory | Cases | Monocytes(/mm3) | P value | |
| <545 | ≥545 | ||||
| Gender | Male | 310 | 115 | 195 | 0.102 |
| Female | 41 | 20 | 21 | ||
| Age | <50 years | 268 | 102 | 166 | 0.418 |
| ≥50 years | 83 | 33 | 50 | ||
| HBsAg | Negative | 49 | 14 | 35 | 0.083 |
| Positive | 302 | 121 | 181 | ||
| AFP(ng/ml) | <200 | 161 | 61 | 100 | 0.463 |
| ≥200 | 190 | 74 | 116 | ||
| Edmonson grading | I-II | 271 | 107 | 164 | 0.278 |
| III-IV | 80 | 28 | 52 | ||
| Tumor size | <5 cm | 70 | 35 | 35 | 0.019 |
| ≥5 cm | 281 | 100 | 181 | ||
| Surgical margin | <1 cm | 122 | 44 | 78 | 0.289 |
| ≥1 cm | 229 | 91 | 138 | ||
| Liver cirrhosis | Absent | 82 | 29 | 53 | 0.3 |
| Present | 269 | 106 | 163 | ||
| PVTT | Absent | 278 | 108 | 170 | 0.44 |
| Present | 73 | 27 | 46 | ||
| Capsulation | Capsulated | 224 | 92 | 132 | 0.111 |
| Non-caspulated | 127 | 43 | 84 | ||
| Tumor number | Single | 276 | 107 | 169 | 0.465 |
| Multiple | 75 | 28 | 47 | ||
| Macrovascular invasion | Absent | 261 | 102 | 159 | 0.391 |
| Present | 90 | 33 | 57 |
| Collection time | AKI (renal replacement) | Mean | Std | p-value |
| T1 preoperative | No | 1,0 | ,27 | 0,06 |
| Yes | 1,24 | ,43 | ||
| T2 start CBP | No | ,80 | ,21 | 0,07 |
| Yes | ,96 | ,31 | ||
| T3 20 minutes after CBP start | No | ,89 | ,21 | 0,06 |
| Yes | 1,05 | ,32 | ||
| T4 OP-end | No | 1,00 | ,26 | 0,03 |
| Yes | 1,22 | ,30 | ||
| T5 24 h postoperative | No | 1,26 | ,52 | 0,002 |
| Yes | 1,93 | ,47 | ||
| T6 discharge(max. day 6) | No | 1,28 | ,40 | 0,001 |
| Yes | 2,09 | ,57 |
| Model | Standardized coefficients | t | Sig. | 95.0 % confidence interval for B | |
| Beta | Lower bound | Upper bound | |||
| (Constant) | −12.353 | <0.001 | −1.67 | −1.21 | |
| Educational level of mothers | 0.08 | 3.273 | 0.001 | 0.06 | 0.23 |
| Appropriate complementary feeding score | 0.04 | 1.927 | 0.05 | −0.002 | 0.27 |
| Diarrhoeal infection | 0.10 | 4.499 | <0.001 | 0.14 | 0.35 |
| Gender of child | 0.05 | 2.209 | 0.03 | 0.012 | 0.209 |
| Phytochemical | Name of the tests | Observed changes | Result |
| Alkaloids | Mayer's test | Creamy white precipitate | − |
| Hager's test | Yellow crystalline precipitate | + | |
| Wagner's test | Brown or deep brown precipitate | − | |
| Dragendorff's test | Orange or orange-red precipitate | − | |
| Tannic acid test | Buff color precipitate | − | |
| Carbohydrates | Molisch's test | A red or reddish violet ring is formed at the junction of two layers and on shaking a dark purple solution is formed | + |
| Barfoed's test (general test for monosaccharides) | Red precipitate | − | |
| Fehling's test | A red or brick-red precipitate | − | |
| Benedict's test | + | ||
| Test for combined reducing sugar | A brick-red precipitate | − | |
| Glycosides | General test | Yellow color | − |
| Bromine water test | yellow precipitate | + | |
| Test for glucoside | Production of brick-red precipitation (carried out with the hydrolyzed extract) | − | |
| Flavonoids | Alkaline reagent test | Red color | +/− |
| Shinoda test (magnesium hydrochloride reduction test) | Green to blue color | + | |
| Zinc hydrochloride reduction test | Red color after few minutes | − | |
| Saponins | Frothing test | Formation of stable foam | + |
| Steroids | Libermann-Burchard's test | Greenish color | − |
| Tannins | Lead acetate test | A yellow or red precipitate | + |
| Ferric chloride test | Blue green color | − | |
| Alkaline reagent test | Yellow to red precipitate | + | |
| Terpenoids | Salkowski test | Yellow color appears at the lower layer | − |
| Dynesys group (n = 95) | PLIF group (n = 81) | p | |
| ODI (%)a | |||
| Pre op | 57.1 ± 7.7 | 56.1 ± 8.1 | 0.391 |
| Mid-term | 33.5 ± 6.6 | 33.9 ± 7.1 | 0.738 |
| Final | 25.9 ± 5.7 | 24.9 ± 5.9 | 0.271 |
| VASback (mm)a | |||
| Pre op | 43.7 ± 14.5 | 45.3 ± 13.9 | 0.451 |
| Mid-term | 19.5 ± 11.7 | 18.6 ± 11.3 | 0.633 |
| Final | 10.6 ± 9.1 | 11.4 ± 8.5 | 0.568 |
| VASleg (mm)a | |||
| Pre op | 51.6 ± 15.7 | 52.3 ± 16.3 | 0.752 |
| Mid-term | 13.2 ± 8.9 | 11.5 ± 8.2 | 0.199 |
| Final | 6.7 ± 8.3 | 7.1 ± 7.5 | 0.782 |
| Morning Snack | Lunch | Afternoon Snack | ||||||||||
| Na (mg) | Na density (mg/MJ) | Energy (kJ) | Na (mg) | Na Density (mg/MJ) | Energy (kJ) | Na (mg) | Na Density (mg/MJ) | Energy (kJ) | Total Sodium (mg) | Total Energy Density (mg/MJ) | Total Energy (kJ) | |
| Centre 1 a | 40 (0.5) | 94 (4) | 428 (17) | 135 (82) | 194 (126) | 719 (134) | 386 (335) | 660 (478) | 612 (206) | 561 | 943 | 1759 |
| Centre 2 | 50 (0.9) | 113 (7) | 437(25) | 220 (61) | 140 (52) | 1614 (208) | 331 (199) | 537 (302) | 578 (118) | 601 | 789 | 2629 |
| Centre 3 | 40 (0.7) | 97 (11) | 427 (66) | 419 (308) | 297 (164) | 1333 (249) | 389 (188) | 586 (182) | 642 (222) | 848 | 985 | 2402 |
| Centre 4 a | 166 (55) | 219 (29) | 936 (330) | 66 (68) | 151 (112) | 433 (145) | 154 (147) | 174 (123) | 824 (394) | 386 | 560 | 2193 |
| Centre 5 | 48 (1) | 89 (5) | 557 (32) | 164 (60) | 152 (24) | 1093 (396) | 357 (219) | 516 (180) | 652 (238) | 569 | 757 | 2302 |
| Centre 6 | 49 (0.7) | 100 (9) | 495 (53) | 220 (124) | 203 (154) | 1205 (410) | 220 (109) | 482 (356) | 900 (593) | 489 | 773 | 2600 |
| Centre 7 | 51 (0.8) | 105 (7) | 468 (34) | 429 (168) | 220 (110) | 1415 (650) | 199 (43) | 292 (77) | 697 (111) | 679 | 609 | 2580 |
| Average across centres | 63 (45) | 116 (46) | 535 (183) | 236 (139) | 194 (55) | 1116 (543) | 291 (97) | 464 (171) | 701(118) | 590 (146) | 774 (156) | 2352(453) |
| Analyte | RT (min) | [M − H]− (m/z) | MSn (m/z) |
| Paeoniflorin sulfonate (12) | 2.18 | 543.11 | 121.02 |
| Albiflorin (2) | 3.67 | 525.16 | 121.02 |
| Paeoniflorin (1) | 3.90 | 525.16 | 121.02 |
| Liquirtin apioside (5) | 4.04 | 549.16 | 255.06 |
| Liquiritin (3) | 4.07 | 417.12 | 255.06 |
| Isoliquiritin apioside (6) | 4.26 | 549.16 | 255.06 |
| Isoliquiritin (4) | 4.33 | 417.12 | 255.06 |
| Liquiritigenin (8) | 4.56 | 255.06 | 135.01 |
| Isoliquiritigenin (9) | 4.91 | 255.06 | 119.05 |
| Glycyrrhizic acid (10) | 5.02 | 821.39 | 351.05 |
| Glycyrrhetinic acid (11) | 6.22 | 469.33 | 425.34 |
| Ginsenoside Rb1 (IS1) | 4.50 | 1107.59 | 1107.59 |
| Swertiamarin (IS2) | 2.77 | 419.11 | 179.05 |
| Kaempferol-3-O-rutinoside (IS3) | 4.16 | 593.15 | 285.04 |
| Strength of interaction | Definition |
| Strong | A strong inhibitor for a specific CYP is defined as an inhibitor that increases the AUC of a substrate for that CYP by equal to or more than 5-fold (or >80% decrease in clearance) |
| Moderate | A moderate inhibitor for a specific CYP is defined as an inhibitor that increases the AUC of a sensitive substrate for that CYP by less than 5-fold but equal to or more than 2-fold (or 50%–80% decrease in clearance) |
| Weak | A weak inhibitor for a specific CYP is defined as an inhibitor that increases the AUC of a sensitive substrate for that CYP by less than 2-fold but equal to or more than 1.25-fold (or 20%–50% decrease in clearance) |
| Annotation category | Resource | Comments |
| Genomic | GENCODE | Variant classification and mapping to gene |
| Human DNA Repair Genes | Curated list from [40] | |
| Protein | UniProt | Protein-specific annotation |
| dbNSFP | Conservation and prediction scores | |
| Cancer variant | COSMIC | Catalogue of Somatic Mutations in Cancer |
| Non-cancer variant | 1000 Genomes Project | Germline SNVs |
| Country | Sample Size SpA | Sample Size (Control) | Prevalence in Population | Prevalence in SpA | Prevalence in AS | OR AS/GP [95% CI] | Reference |
| Algeria | 129 AS (ESSG and NY) | 76 healthy blood donors | 4% | 69% | 54.14 [16.09–182.18] | [17] | |
| Egypt | 380 normal individuals | 4.7% | [18] | ||||
| Egypt | 75 SpA (ESSG) including 34 AS | 58.7% | [19] | ||||
| Egypt | 100 healthy controls | 1% | [20] | ||||
| Iraq | 25 AS | 2.1% | 84% | [21] | |||
| Iran | 60 AS | 430 healthy blood donors | 3.95% | 66.67% | 48.59 [23.57–100.17] | [22] | |
| Iran | 119 AS | 68.91% | [23] | ||||
| Iran | 98 AS (NY) | 73.4% | [24] | ||||
| Israel | 38 AS | 456 normal individuals | 3% | 79% | [25] | ||
| Jordan | 22 AS (NY) | 75% | [26] | ||||
| Jordan / Qatar | 129 AS | 2579 healthy individuals | 2.4% | 72.22% | 104.87 [66.21–166.11] | [12] | |
| Kuwait | 58 SpA (27 AS) | 69.43% | 82.56% | [27] | |||
| Kuwait | 35 SpA + AS patients | 544 controls | 4% | 25.7% | 8.21 [3.44–19.60] | [28] | |
| Lebanon | 105 SpA (ESSG)24 AS (NY) | 841 Rheumatolgy patients | 1.44% | 13.85% | 26.32% | 24.46 [7.78–68.19] | [29] |
| Morocco | 46 AS + coxitis | 183 healthy controls | 6.16% | 58.70% | 22.09 [9.48–51.49] | [30] | |
| Morocco | 49 SpA (Amor and ESSG) | 67% | [31] | ||||
| Oman | 321 healthy | 0.3% | [32] | ||||
| Qatar | 119 AS (NY) | 74% | [33] | ||||
| Saudi Arabia | 12 AS | 66.67% | [34] | ||||
| Syria | 50 AS (NY) | 217 healthy controls | 1.4% | 60% | 105.64 [29.98–381.87] | [35] | |
| Tunisia | 365 AS and/or BD | 124 controls | 3.2% | 42.9% | [36] | ||
| Tunisia | 100 AS (NY) | 100 healthy controls | 3% | 62% | 52.75 [15.61–178.31] | [37] | |
| Tunisia | 50 AS (Amor / ESSG) | 69% | [38] | ||||
| Turkey | 112 AS (NY) | 55 controls | 2.8–6.8% | 70% | 29.82 [9.99–89.05] | [39] | |
| Turkey | 216 AS (67 analyzed) | 91% | [40] | ||||
| UAE | 760 healthy | 6.4% | [41] | ||||
| UAE | 17 AS | 56% | [42] |
| Covariate | Relative risk | 95 % CI | p value |
| p62 | 0.764 | NS | 0.619 |
| Histological grading | 1.239 | NS | 0.392 |
| Lymph node metastases | 0.794 | NS | 0.510 |
| Tumour stage | 1.647 | NS | 0.141 |
| Distant metastases | 3.176 | 1.453-6.940 | 0.004 |
| Variables | Syphilis | COR (95% CI) | AOR (95%CI) | P-value | ||
| NR(n = 469) | R(n = 25) | |||||
| Age(years) | < 25 | 155 (96.3) | 6 (3.7) | 1 | ||
| 25-29 | 202 (94.4) | 12 (5.6) | 1.5 (0.563-4.180) | |||
| ≥30 | 112 (94.1) | 7 (5.9) | 1.6 (0.528-4.935) | |||
| Residence | Urban | 312 (93.7) | 21 (6.3) | 2.6 (0.892-7.829)** | 2.6 (0.845-7.982) | 0.096 |
| Rural | 157 (97.5) | 4 (2.5) | 1 | |||
| Education | Illiterate | 57 (96.6) | 2 (3.4) | 1 | ||
| Elementary | 160 (95.2) | 8 (4.8) | 1.4 (0.294-6.909) | |||
| Secondary | 156 (94.0) | 10 (6.0) | 1.8 (0.388-8.592) | |||
| Tertiary | 96 (95.0) | 5 (5.0) | 1.5 (0.279-7.903) | |||
| Occupational | House wife | 231 (93.9) | 15 (6.1) | 2.8 (0.359-21.695) | ||
| Health worker | 17 (89.5) | 2 (10.5) | 5.0 (0.430-59.525) | |||
| Employed | 128 (96.2) | 5 (3.8) | 1.7 (0.191-14.780) | |||
| Merchant | 50 (96.2) | 2 (3.8) | 1.7 (0.151-19.632) | |||
| Student | 43 (97.7) | 1 (2.3) | 1 | |||
| Marital status | Married | 426 (95.3) | 21 (4.7) | 1 | ||
| Not cohabiting* | 43 (91.5) | 4 (8.5) | 1.9 (0.619-5.751) | |||
| Gestational age at screening | First trimester | 98 (98.0) | 2 (2.0) | 1 | ||
| Second trimester | 170 (94.4) | 10 (5.6) | 2.9 (0.619-13.423)** | 3.8 (0.778-18.847) | 0.099 | |
| Third trimester | 201 (93.9) | 13 (6.1) | 3.2 (0.701-14.319)** | 4.6 (0.959-22.340) | 0.056 | |
| Gravidity | Primigravidae | 153 (95.6) | 7 (4.4) | 1 | ||
| Multigravidae(≥2) | 316 (94.6) | 18 (5.4) | 1.2 (0.509-3.044) | |||
| Frequency of | 1 | 196 (96.1) | 8 (3.9) | 1 | ||
| ANC visit | ≥2 | 273 (94.1) | 17 (5.9) | 1.5 (0.646-3.606) | ||
| Multiple sexual | Yes | 41 (91.1) | 4 (8.9) | 2.0 (0.651-6.701) | ||
| Partner | No | 428 (95.3) | 21 (4.7) | 1 | ||
| Place of | Home | 89 (93.7) | 6 (6.3) | 1.3 (0.464-3.502) | ||
| previous birth | Health institution | 227 (95.0) | 12 (5.0) | 1 | ||
| HIV | Non-reactive | 429 (96.8) | 14 (3.2) | 1 | ||
| Reactive | 40 (79.4) | 11 (21.6) | 8.4 (3.859-19.786)** | 10.3 (4.213-25.185) | 0.001 |
| Food | GI |
| Gluten-free bread | 230 |
| Gluten-free pasta | 255 |
| Quinoa | 186 |
| Laccase Isoform | Experimental Affinity Rank 1 | HINT Score |
| Beta | 1 | 430 |
| Gamma | 2 | 206 |
| Delta | 3 | 104 |
| Variables | Number | All | Fish | Meat | Supplement | Pa |
| Characteristics | ||||||
| Gender n (%) | 415 | 0.546 | ||||
| Male | 195 (47.0) | 56 (43.8) | 73 (50.3) | 66 (46.5) | ||
| Female | 220 (53.0) | 72 (56.3) | 72 (49.7) | 76 (53.5) | ||
| Age (years) | 415 | 14.6 ± 0.3 | 14.6 ± 0.3 | 14.6 ± 0.3 | 14.6 ± 0.3 | 0.531 |
| BMI (kg/m2) | 385 | 19.8 ± 3.0 | 19.8 ± 3.4 | 19.7 ± 2.3 | 19.9 ± 3.1 | 0.940 |
| Parental education level n (%) | 341 | 0.793 | ||||
| Elementary/vocational school | 132 (38.7) | 41 (39.4) | 47 (40.5) | 44 (36.4) | ||
| College/university | 209 (61.3) | 63 (60.6) | 69 (59.5) | 77 (63.6) | ||
| Family income in NOKb n (%) | 338 | 0.201 | ||||
| < 200,000–749,999 | 70 (20.7) | 21 (20.4) | 17 (14.8) | 32 (26.7) | ||
| 750,000–1,249,999 | 171 (50.6) | 50 (48.5) | 66 (57.4) | 55 (45.8) | ||
| 1,250,000- > 2,000,000 | 97 (28.7) | 32 (31.1) | 32 (27.8) | 33 (27.5) | ||
| Immigrantc n (%) | 341 | 7 (2.1) | 2 (1.6) | 2 (1.7) | 3 (2.5) | 0.914 |
| Nutritional status | ||||||
| LA, 18:2n-6 (%) | 415 | 10.8 ± 1.3 | 10.8 ± 1.4 | 10.8 ± 1.2 | 10.9 ± 1.3 | 0.707 |
| AA, 20:4n-6 (%) | 415 | 15.6 ± 1.5 | 15.6 ± 1.4 | 15.6 ± 1.6 | 15.6 ± 1.5 | 0.958 |
| EPA, 20:5n-3 (%) | 415 | 0.9 ± 0.4 | 0.9 ± 0.3 | 0.9 ± 0.4 | 0.9 ± 0.4 | 0.960 |
| DPA, 22:5n-3 (%) | 415 | 2.4 ± 0.3 | 2.4 ± 0.3 | 2.4 ± 0.3 | 2.3 ± 0.3 | 0.110 |
| DHA, 22:6n-3 (%) | 415 | 4.9 ± 1.1 | 4.9 ± 1.0 | 5.0 ± 1.2 | 4.8 ± 1.0 | 0.171 |
| Omega-3 indexd | 415 | 5.8 ± 1.3 | 5.8 ± 1.2 | 5.9 ± 1.4 | 5.7 ± 1.3 | 0.304 |
| ≤ 8 n (%) | 395 (95.2) | 122 (95.3) | 135 (93.1) | 138 (97.2) | 0.271 | |
| s-25(OH)D (nmol/L) | 424 | 48.8 ± 17.4 | 49.1 ± 17.1 | 49.7 ± 17.8 | 48.3 ± 17.4 | 0.671 |
| < 50 nmol/L n (%)e | 229 (54.0) | 72 (54.5) | 76 (52.1) | 81 (55.5) | 0.832 | |
| s-Ferritin (μg/l) | 412 | 40.7 ± 23.1 | 40.9 ± 22.4 | 41.2 ± 24.5 | 40.4 ± 22.3 | 0.953 |
| <15 μg/l n (%)e | 40 (9.7) | 12 (9.4) | 13 (9.2) | 15 (10.6) | 0.912 | |
| UIC (μg/L) | 415 | 122.6 ± 63.7 | 122.6 ± 71.3 | 122.9 ± 59.3 | 125.0 ± 66.7 | 0.693 |
| < 100 μg/le | 164 (39.5) | 55 (42.6) | 49 (34.3) | 60 (42.0) | 0.282 | |
| Dietary intake | 414 | |||||
| Fish for dinnerf | 1.5 (0.9) | 1.5 (1.0) | 1.4 (0.9) | 1.5 (0.9) | 0.780 | |
| Herring/mackerel/salmon for dinnerf | 1.0 (0.9) | 1.0 (1.0) | 0.9 (0.9) | 1.0 (1.0) | 0.852 | |
| Fish as bread spreadf | 0.6 (1.0) | 0.7 (1.0) | 0.6 (1.0) | 0.6 (0.9) | 0.620 | |
| Fish oil supplements (n (%))g | 413 | 0.659 | ||||
| Never | 220 (53.3) | 60 (46.9) | 81 (56.3) | 79 (56.0) | ||
| 1–3 times/month | 53 (12.8) | 18 (14.1) | 18 (12.5) | 17 (12.1) | ||
| 1–3 times/week | 45 (10.9) | 19 (14.8) | 14 (9.7) | 12 (8.5) | ||
| 4–6 times/week | 20 (4.8) | 6 (4.7) | 5 (3.5) | 9 (6.4) | ||
| Every day | 75 (18.2) | 25 (19.5) | 26 (18.1) | 24 (17.0) |
| Screening set | Validation set | Merge set | |||||||
| SNP | Controls (n = 100) | LCs (n = 100) | OR (95% CI/Ptrend)a | Controls (n = 751) | LCs (n = 284) | OR (95% CI/Ptrend)a | Controls (n = 851) | LCs (n = 384) | OR (95% CI/Ptrend)a |
| rs8021276 | |||||||||
| AA | 72 | 43 | Reference | 543 | 120 | Reference | 615 | 163 | Reference |
| AG | 24 | 35 | 2.97 (1.43–6.16/3.52 × 10-3) | 178 | 100 | 2.45 (1.75–3.42/1.417 × 10-7) | 202 | 135 | 2.48 (1.84–3.33/2.00 × 10-9) |
| GG | 4 | 22 | 11.92 (3.42–41.55/9.97 × 10-5) | 30 | 64 | 6.54 (3.85–11.10/3.49 × 10-12) | 34 | 86 | 6.98 (4.35–11.22/9.27 × 10-16) |
| AG/GG | 28 | 57 | 4.16 (2.11–8.18/3.62 × 10-5) | 208 | 164 | 3.09 (2.27–4.19/5.33 × 10-13) | 236 | 221 | 3.17 (2.42–4.16/8.08 × 10-17) |
| rs7158733 | |||||||||
| GG | 57 | 32 | Reference | 345 | 112 | Reference | 402 | 144 | Reference |
| GT | 30 | 35 | 3.59 (1.62–7.99/1.72 × 10-3) | 242 | 97 | 1.25 (0.89–1.75/0.21) | 272 | 132 | 1.41 (1.014–1.91/0.03) |
| TT | 13 | 33 | 6.59 (2.57–16.88/8.57 × 10-5) | 164 | 75 | 1.38 (0.95–2.00/0.10) | 177 | 108 | 1.70 (1.22–2.37/1.78 × 10-3) |
| GT/TT | 43 | 68 | 4.50 (2.18–9.31/4.98 × 10-5) | 406 | 172 | 1.30 (0.96–1.75/0.09) | 449 | 240 | 1.52 (1.17–1.99/2.03 × 10-3) |
| rs10146249 | |||||||||
| CC | 46 | 20 | Reference | 292 | 93 | Reference | 338 | 113 | Reference |
| CA | 41 | 48 | 3.08 (1.47–6.43/2.76 × 10-3) | 288 | 141 | 1.72 (1.23–2.40/1.40 × 10-3) | 329 | 189 | 1.96 (1.45–2.64/1.26 × 10-4) |
| AA | 13 | 32 | 5.77 (2.31–14.37/1.59 × 10-4) | 171 | 50 | 1.20 (0.78–1.83/0.41) | 184 | 82 | 1.67 (1.16–2.41/5.80 × 10-3) |
| CA/AA | 54 | 80 | 3.74 (1.87–7.49/1.86 × 10-4) | 459 | 191 | 1.54 (1.13–2.09/6.24 × 10-3) | 513 | 271 | 1.86 (1.41–2.46/1.58 × 10-3) |
| Microorganisms | PN-EO | CHDa | 1b | 2b | 3b | 4b | 1 + 2 + 3 + 4c |
| E. faecalis | 250.0 | 14.8 | >4000 | >4000 | >4000 | >4000 | >4000 |
| S. salivarius | 250.0 | 7.4 | 4000 | 4000 | 4000 | 4000 | 4000 |
| S. mutans | 3.9 | 1.8 | >4000 | >4000 | >4000 | >4000 | 1000 |
| S. mitis | 31.3 | 14.8 | 4000 | 4000 | 4000 | 4000 | 4000 |
| S. sobrinus | 62.5 | 1.8 | >4000 | >4000 | >4000 | >4000 | 4000 |
| S. sanguinis | 62.5 | 7.4 | 4000 | >4000 | >4000 | >4000 | >4000 |
| L. casei | 31.3 | 3.7 | 4000 | 4000 | 4000 | 4000 | 500 |
| Isolates | Body site | spa type | SCCmec | STa | PFTb |
| 27 N | nasal | t002 | II | ST105 | A1 |
| 08 N | nasal | t311 | II | ST105 | B1 |
| P65N | nasal | t002 | II | ST105 | C |
| 98I | groin | t14789 | IVa | ST1176 | D1 |
| 62 N | nasal | t149 | I | ST5 | E1 |
| P32N | nasal | t37 | III | ST239 | F1 |
| 78 N | nasal | t110 | I | ST105 | G |
| 111 N | nasal | t002 | II | ST105 | H |
| 59 N | nasal | t149 | IVa | ST1510 | I |
| Year | Trade Specialization Index (TSI) |
| 2001 | -0.940 |
| 2006 | -0.898 |
| 2010 | -0.844 |
| Features | DNA configurations | ||
| A | B | Z | |
| Helix orientation | Right-handed | Right-handed | Left-handed |
| DNA diameter | 2.55 | 2.37 | 1.84 |
| bp diameter | 1.0 | 1.0 | 0.6 |
| bp axial step | 0.23 | 0.33 | 0.38 |
| Helix pitch | 2.46 | 3.2 | 3.0 |
| bp/helix turn | 10.7 | 10 | 12 |
| bp/nucleosome | 286 | 198 | 172 |
| Helix axial shift | 0.76 | 1.2 | 0.77 |
| Target angular aperture | 87° | 73° | 60° |
| Target height | 0.119 | 0.183 | 0.249 |
| Total number of bp | 7.72 × 108 | 5.35 × 108 | 4.64 × 108 |
| Target volume (nm3) | 0.12 | 0.13 | 0.10 |
| GOLD stage * | Number of patients (%) |
| Stage I | 18 (17.0%) |
| Stage II | 42 (39.6%) |
| Stage III | 28 (26.4%) |
| Stage IV | 18 (17.0%) |
| Total LAA score † | Patient number (%) |
| 7-12 | 46 (43.4%) |
| 13-18 | 24 (22.6%) |
| 19-24 | 36 (34.0%) |
| Kano Model | Refined Kano Model | |
| Quality Attribute | High Important Attributes | Low Important Attribute |
| Attractive quality | High attractive quality | Low attractive quality |
| One-dimensional quality | High value-added quality | Low value-added quality |
| Must-be quality | Critical quality | Necessary quality |
| Indifferent quality | Potential quality | Care-free quality |
| Molecule | Actions/effects | Reference |
| Sulfur dioxide | Possible long-term cardiac abnormality | Pishgoo et al. (15) |
| Cardiac and mitochondrial dysfunction (rats) | Qin et al. (1) | |
| Increase heart susceptibility to oxidative stress | Zaky et al. (16) | |
| Inhibits the proapoptotic effect of isopropylarterenol on myocardial tissue through a bcl-2/cytc/caspase-9/caspase-3 pathway | Jin et al. (11) | |
| Aggravates myocardial I/R injury | Zhang et al. (17) | |
| Sulfur dioxide | Ameliorated systemic hypertension and pulmonary hypertension prevented the development of atherosclerosis and protected against myocardial ischemia-reperfusion (I/R) injury and isoproterenol-induced myocardial injury | Huang et al. (18) |
| Sulfites | ||
| Sulfur mustard | Modification of the ratio prooxidant/antioxidant | Shohrati et al. (19) |
| Reduction of serum GSH, increase of serum malondialdehyde (MDA) | ||
| Sulfites | Deleterious effects through the mitochondrial Fe3+ cyt c-mediated ROS | Velayutham et al. (20) |
| Reduced the length and volume of the ventricular capillaries (rats) | Noorafshan et al. (21) | |
| With sulfite oxidase contributes in NO signaling | Wang et al. (22) | |
| They can affect voltage-gated sodium (Na+) channels (VGSC) in a concentration-dependent manner in isolated rat ventricular myocytes. Protective action of catechins | Wei and Meng (23) |
| ST use | RR/OR | |||||||
| Sourcea | Typeb | Exposurec | Smoking | Sex | Id. | Casesd | Estimate (95%CI) | Adjustment factorse |
| Case-control studies | ||||||||
| Wynder et al. 1957 [40] | ||||||||
| - larynx cancer | Chew | Ever | Any | M | 1 | NA | no associationf | none |
| Vincent and Marchetta 1963 [45] | ||||||||
| - larynx cancer | Snuff | Use | Any | M | 2 | 5 | 1.81 (0.33–9.97) | none |
| Williams and Horm 1977 [55] | ||||||||
| - larynx cancer | ST | Ever | Any | M | 3 | 16 | 2.01 (1.15–3.51)g | age, race, smok |
| Wynder and Stellman 1977 [56] | ||||||||
| - larynx cancer | Chew | Ever | Any | M | 4 | 46 | 1.35 (0.96–1.89)g | none |
| Snuff | 5 | 15 | 1.46 (0.82–2.57)g | none | ||||
| ST | 6 | 61 | 1.40 (1.04–1.89)h | none | ||||
| Engzell et al. 1978 [57] | ||||||||
| - nasal cancer | Snuff | Use | Any | M | 7 | NA | no association | none |
| Brinton et al. 1984 [64] | ||||||||
| - nasal cancer | Chew | Use | Any | M+F | 8 | 15 | 0.74 (0.40–1.50) | sex |
| Snuff | 9 | 23 | 1.47 (0.80–2.80) | |||||
| ST | 10 | 38 | 1.08 (0.68–1.70)h | none | ||||
| Stockwell and Lyman 1986 [70] | ||||||||
| - nasal cancer | ST | Ever | Any | M+F | 11 | 1 | 2.93 (0.40–21.66)g | none |
| - larynx cancer | ST | Ever | Any | M+F | 12 | 6 | 2.02 (0.84–4.86)g | none |
| Young et al. 1986 [71] | ||||||||
| - larynx cancer | ST | Ever | Any | M | 13 | NA | no association | none |
| Lewin et al. 1998 [102] | ||||||||
| - larynx cancer | Snuff | Current | Any | M | 14 | 15 | 1.00 (0.50–1.90) | age, alc, res, smok |
| Former | 15 | 9 | 0.80 (0.40–1.70) | |||||
| Ever | 16 | 24 | 0.90 (0.50–1.50) |
| Variable | Mean | ICC | 95% CI for ICC | Deff | na |
| Age (years) | 26.1 | 0.018 | 0.004-0.033 | 5.3 | 265 |
| Month stopped working | 6.9 | 0.015 | <0.001-0.032 | 2.6 | 99 |
| Workload (hours daily) | 8.0 | 0.040 | 0.007-0.072 | 6.9 | 98 |
| Pre-pregnancy weight (Kg) | 62.1 | 0.021 | 0.005-0.038 | 6.6 | 250 |
| Height (m) | 1.6 | 0.041 | 0.011-0.071 | 9.8 | 238 |
| Final weight (Kg) | 73.2 | 0.022 | 0.005-0.040 | 6.4 | 237 |
| Weight gain in pregnancy (Kg) | 10.9 | 0.012 | 0.001-0.023 | 4.5 | 229 |
| Initial Body Mass Index (Kg/m2) | 24.4 | 0.012 | 0.001-0.024 | 4.5 | 230 |
| Final Body Mass Index (Kg/m2) | 28.7 | 0.016 | 0.002-0.030 | 5.5 | 220 |
| Number of pregnancies | 2.4 | 0.006 | <0.001-0.013 | 2.8 | 265 |
| Number of vaginal deliveries | 0.8 | 0.005 | <0.001-0.011 | 2.5 | 265 |
| Number of cesarean sections | 0.3 | 0.014 | 0.002-0.025 | 4.7 | 265 |
| Number of abortions | 0.3 | 0.006 | <0.001-0.013 | 2.3 | 265 |
| Number of uterine curettage | 0.2 | 0.008 | <0.001-0.015 | 2.9 | 264 |
| GroupNo. | Description | Body site whereS. aureus detectedin Parsonnet 2005studya | Ab present inParsonnet 2005studyb | No. of subjectsenrolledc | No. of subjectscompleting allvisits |
| 1 | Carriers of SA TSST-1(+) | Vagina | Yes or No | 14 | 11 |
| 2 | Carriers of SA TSST-1(+) | Nose or anus | Yes | 78 | 64 |
| 3 | Carriers of SA TSST-1(-) | Any site | Yes | 69 | 49 |
| 4 | Non-carriers | None | Yes | 75 | 58 |
| 5 | Negative Ab control(Carriers or Non-carriers) | Any site | No | 75 | 61 |
| Gay/Lesbian | |||||||
| Model 1 (adjusted for socio-demographic characteristics)a | Model 2 (controlling for depressive symptoms)b | % reduction in association controlling for PHQ-9 | Sobel test for significance of mediator | ||||
| Outcome | OR* | (95% CI) | OR* | (95% CI) | Z Value | P-Value | |
| Current Smoker | 1.843 | (1.17, 2.92) | 1.812 | (1.14, 2.88) | 1.68 | 1.846 | 0.064 |
| BMI (Overweight/Obese) | 1.128 | (0.78, 1.64) | |||||
| Lifetime History of Drug Use (Excluding Marijuana) | 1.786 | (1.10, 2.91) | 1.766 | (1.09, 2.87) | 1.12 | 1.4863 | 0.137 |
| Lifetime History of Marijuana Use | 1.753 | (1.09, 2.82) | 1.746 | (1.09, 2.81) | 0.40 | 1.50534 | 0.132 |
| Risky Drinking (5 or more drinks) in Past 12 months | 1.01 | (0.61, 1.69) | |||||
| Lifetime Period of Risky Drinking | 1.271 | (0.76, 2.12) | |||||
| Bisexual | |||||||
| Model 1 (adjusted for socio-demographic characteristics)a | Model 2 (controlling for depressive symptoms)b | % reduction in association controlling for PHQ-9 | Sobel test for significance of mediator | ||||
| Outcome | OR* | (95% CI) | OR* | (95% CI) | Z Value | P-Value | |
| Current Smoker | 2.124 | (1.65, 2.73) | 2.044 | (1.59, 2.63) | 3.77 | 3.04054 | 0.0023 |
| BMI (Overweight/Obese) | 0.897 | (0.61, 1.31) | - | - | - | - | |
| Lifetime History of Drug Use (Excluding Marijuana) | 3.381 | (2.24, 5.10) | 3.301 | (2.20, 4.96) | 2.37 | 1.93298 | 0.0532 |
| Lifetime History of Marijuana Use | 2.928 | (2.05, 4.19) | 2.901 | (2.02, 4.16) | 0.92 | 3.44351 | <0.001 |
| Risky Drinking (5 or more drinks) in Past 12 months | 1.499 | (1.05, 2.15) | Cannot Estimate | ||||
| Lifetime Period of Risky Drinking | 2.901 | (1.67, 5.04) | Cannot Estimate |
| Scenario | MP Windows (s) | PRN |
| 1 | 8–16 | 27 |
| 21–25 | 11, 22 | |
| 30–35 | 16 | |
| 40–45 | 1, 4, 21, 27 | |
| 2 | 20–80 | 1, 4, 21, 27 |
| AUC | 95%CI | z statistic | P value (Area=0.5) | Associated criterion | Sensitivity | Specificity | |
| With or without WBRT(0:no/1:yes) | 0.650±0.0717 | 0.551-0.741 | 2.098 | 0.0359 | >0 | 33.33 | 96.74 |
| Fraction(f) | 0.712±0.0637 | 0.615-0.797 | 3.335 | 0.0009 | <=2 | 66.67 | 66.30 |
| BED(cGy) | 0.892±0.0335 | 0.816-0.945 | 11.710 | <0.0001 | >7410 | 91.67 | 84.78 |
| Diagnostic Stage | Diagnostic Modality | Sensitivity (%) | |
| Central | Peripheral | ||
| Initial Diagnosis | Sputum cytology | 71 | 49 |
| Bronchoscopy | 88 | 78 | |
| Washings | 47 | 43 | |
| Brushings | 56 | 54 | |
| Biopsy | 74 | 57 | |
| Radiologically guided transthoracic biopsy | - | 90 | |
| Radial probe EBUS | - | 73 | |
| Electromagnetic navigation | - | 68 | |
| Cryobiopsy | 95 | 74 | |
| Linear EBUS TBNA | 82 | - | |
| Mediastinal Staging | Bronchoscopic TBNA | 78 | |
| Linear EBUS TBNA | 89 | ||
| EUS | 89 | ||
| EUS + EBUS | 91 | ||
| Video assisted surgical mediastinoscopy | 89 |
| MMP | ANOVA | Post Test Results |
| pMMP-9 | p = 0.0817 | No significant differences. |
| aMMP-9 | p = 0.0944 | No significant differences. |
| pMMP-2 | p = 0.0010 | pH 5.6 (24 h) < Positive Control (24 h) (p < 0.05) |
| pH 9 (24 h) < Positive Control (24 h) (p < 0.01) | ||
| Negative Control (72 h) < Positive Control (24 h) (p < 0.001) | ||
| Positive Control (72 h) < Positive Control (24 h) (p < 0.05) | ||
| pH 4 (72 h) < Positive Control (24 h) (p < 0.05) | ||
| pH 5.6 (72 h) < Positive Control (24 h) (p < 0.05) | ||
| Negative Control (72 h) < pH 4 (24 h) (p < 0.05) | ||
| aMMP-2 | p = 0.0019 | pH 9 (24 h) < Positive Control (24 h) (p < 0.01) |
| pH 9 (24 h) < pH 4 (24 h) (p < 0.05) | ||
| Negative Control (72 h) < Positive Control (24 h) (p < 0.01) | ||
| Negative Control (72 h) < pH 4 (24 h) (p < 0.05) |
| Health consumer | ||||
| Health professional | Integration | Assimilation | Separation | Individualism (Marginalization) |
| Integration | Consensual | Problematic | Conflictual | Problematic |
| Assimilation | Problematic | Consensual | Conflictual | Problematic |
| Separation | Conflictual | Conflictual | Conflictual | Conflictual |
| Individualism | Conflictual | Conflictual | Conflictual | Conflictual |
| Immuno-staining | DLBCL component positive | LP cells positive | Reduced expression in DLBCL component | Enhanced expression in DLBCL component | Identical expression in DLBCL and NLPHL component | Identical expression in DLBCL and NLPHL in simultaneous cases |
| Bcl6 | 33/33 (100%) | 33/33 (100%) | 3% | 0% | 97% | 96% |
| CD79a | 33/33 (100%) | 33/33 (100%) | 0% | 33% | 67% | 62% |
| CD19 | 32/33 (97%) | 25/32 (78%) | 3% | 66% | 31% | 32% |
| CD75 | 31/33 (94%) | 32/33 (97%) | 12% | 9% | 79% | 81% |
| EMA | 24/33 (73%) | 27/33 (82%) | 18% | 6% | 76% | 85% |
| J-chain | 24/33 (73%) | 27/33 (82%) | 27% | 3% | 70% | 77% |
| Bcl2* | 20/32 (63%) | 27/33 (82%) | 0% | 38% | 63% | 69% |
| MUM1 | 21/33 (63%) | 24/32 (72%) | 13% | 13% | 75% | 77% |
| JAK2 | 12/30 (40%) | 4/27 (15%) | 0% | 23% | 77% | 82% |
| CD10 | 12/33 (36%) | 2/33 (6%) | 0% | 33% | 67% | 69% |
| p-STAT6 | 9/30 (30%) | 8/26 (31%) | 9% | 5% | 86% | 89% |
| CD30 | 7/33 (21%) | 7/33 (21%) | 6% | 6% | 88% | 92% |
| CD15 | 4/33 (12%) | 2/33 (6%) | 0% | 12% | 88% | 85% |
| IgD | 4/33 (12%) | 5/33 (15%) | 3% | 0% | 97% | 96% |
| PCO | |||
| X | Y | Z | |
| C31 | −5 | 0 | 100 |
| C32 | −4.5 | −30 | 250 |
| C33 | −20 | 0 | 150 |
| C34 | −20 | 0 | 150 |
| Name | Position | Length | Orientation | Distance | Located on | Accession |
| 001-G11-CCfw | 70,072 | 669 | fw | 37,428 | SSCR | FI107918 |
| 001-G11-CCrv | 107,500 | 778 | rv | LSCR | FI107577 | |
| 002-M15-CCfw | 115,079 | 852 | fw | 42,542 | SSCR | KG642400 |
| 002-M15-CCrv | 7899 | 780 | rv | LSCR | KG642401 | |
| 198-M21-ccrv | 111,193 | 579 | fw | 39,080 | SSCR | JY420463 |
| 198-M21-pIfw | 551 | 617 | rv | LSCR | JY420464 |
| Variable | Value |
| Age (years) | 63 (58–73) |
| Sex ratio (male/female) | 16/9 |
| Body mass index (kg/m2) | 26 (22–27) |
| Euroscore 2 (%) | 5 (3–8) |
| Left ventricular ejection fraction (%) | 60 (60–66) |
| Preoperative serum creatinine (μmol/l) | 76 (59–90) |
| Glomerular filtration rate (ml/min/1.73 m2) | 82 (75–91) |
| Comorbidities (n, %) | |
| Hypertension | 15 (60) |
| Chronic obstructive pulmonary disease | 2 (8) |
| Dyslipidemia | 11 (45) |
| Smokers | 6 (24) |
| Type of surgery (n, %) | |
| Coronary surgery | 8 (32) |
| Valve surgery | 12 (48) |
| Combined surgery | 2 (8) |
| Other cardiac surgery | 3 (12) |
| Thoracic surgery | 4 (16) |
| Chronic medications (n, %) | |
| Beta blockers | 10 (40) |
| Renin angiotensin system inhibitors | 12 (48) |
| Statins | 11 (44) |
| Antiplatelet agents | 9 (36) |
| Calcium channel blockers | 5 (20) |
| Nitrates | 2 (8) |
| Vasoactive support | |
| Norepinephrine at baseline (μg/kg/min) | 0.03 ± 0.10 |
| During POAF | |
| Kaliemia (mmol/l) | 4.1 ± 0.4 |
| Hemoglobin (g/dl) | 10.8 ± 1.6 |
| SpO2 (%) | 96.0 ± 1.8 |
| Prevention protocol | Treatment protocol | |||||
| DIO | L. laricina | L. laricina | DIO | L. laricina | L. laricina | |
| 125 mg/kg | 250 mg/kg | 125 mg/kg | 250 mg/kg | |||
| Retroperitoneal fat pad (g) | 1.34 ± 0.05 | 1.26 ± 0.04 | 1.14 ± 0.05* | 1.51 ± 0.08 | 1.35 ± 0.24 | 1.44 ± 0.04 |
| Epididymal fat pad (g) | 2.40 ± 1.00 | 2.56 ± 0.08 | 2.56 ± 0.07 | 1.21 ± 0.03 | 1.32 ± 0.18 | 1.85 ± 0.12* |
| Brown fat pad (g) | 0.30 ± 0.03 | 0.33 ± 0.01 | 0.28 ± 0.02 | 0.44 ± 0.01 | 0.37 ± 0.06 | 0.42 ± 0.02 |
| Liver weight (g) | 1.77 ± 0.09 | 1.85 ± 0.05 | 1.80 ± 0.07 | 2.62 ± 0.15 | 2.44 ± 0.38 | 2.57 ± 0.12 |
| Liver index | 410 ± 2 | 429 ± 1 | 437 ± 1 | 551 ± 3 | 539 ± 5 | 555 ± 2 |
| Classification accuracy(%) | |||||
| Participant | SELDA (M) | SELDA (C) | SEQDA(M) | SEQDA(C) | |
| P1 | AR | 96.98 | 96.39 | 95.52 | 96.26 |
| FC | 96.48 | 96.10 | 97.56 | 99.18 | |
| P2 | AR | 93.56 | 93.14 | 88.78 | 92.84 |
| FC | 96.28 | 95.19 | 95.69 | 97.45 | |
| P3 | AR | 97.32 | 96.20 | 98.59 | 99.44 |
| FC | 98.87 | 98.04 | 98.60 | 99.51 | |
| P4 | AR | 92.95 | 92.15 | 92.03 | 92.63 |
| FC | 92.18 | 92.31 | 93.87 | 94.27 | |
| P5 | AR | 92.37 | 89.78 | 91.25 | 93.58 |
| FC | 93.97 | 92.80 | 95.07 | 97.90 | |
| P6 | AR | 96.61 | 94.85 | 95.83 | 97.00 |
| FC | 96.10 | 95.46 | 97.06 | 97.91 | |
| P7 | AR | 93.72 | 91.64 | 85.45 | 88.76 |
| FC | 90.16 | 89.37 | 93.09 | 94.59 | |
| P8 | AR | 93.97 | 93.14 | 97.55 | 98.03 |
| FC | 95.87 | 95.49 | 98.11 | 97.70 | |
| P9 | AR | 97.58 | 97.48 | 96.78 | 97.14 |
| FC | 97.78 | 97.80 | 98.24 | 99.00 | |
| P10 | AR | 96.18 | 95.72 | 95.98 | 97.59 |
| FC | 95.33 | 94.93 | 96.53 | 97.13 | |
| Mean | AR | 95.12 | 94.05 | 93.87 | 95.33 |
| FC | 95.30 | 94.75 | 96.38 | 97.46 |
| F25 | F57 | Ethanol × Fish Oil | |||
| Final body weight (g) | C | 425.2 ± 4.4 c | 440.2 ± 4.7 a | 437.0 ± 10.7 b | 0.74 |
| E | 392.0 ± 11.9 * | 379.3 ± 12.9 | 398.7 ± 6.0 | ||
| Relative liver weight (%) 3 | C | 2.2 ± 0 b | 2.3 ± 0 b | 2.5 ± 0 a | 0.4533 |
| E | 2.9 ± 0 * | 3.1 ± 0.1 | 3.2 ± 0.2 | ||
| Plasma ALT activity (U/L) | C | 33.7 ± 1.9 b | 39.7 ± 6.9 a,b | 41.8 ± 6.7 a | 0.1781 |
| E | 78.0 ± 15.0 * | 81.2 ± 21.4 | 66.2 ± 13.4 | ||
| Plasma AST activity (U/L) | C | 75.8 ± 5.0 b | 77.2 ± 1.2 b | 91.5 ± 3.2 a | 0.0003 |
| E | 151.5 ± 10.0 *,e | 122.0 ± 9.8 f | 131.2 ± 16.8 f | ||
| Hepatic TGs (mg TGs/g liver) | C | 9.05 ± 0.64 | 10.00 ± 0.68 | 12.26 ± 1.25 | <0.0001 |
| E | 15.51 ± 0.42 *,e | 11.61 ± 1.06 f | 8.93 ± 0.52 g | ||
| Hepatic TC (mg TC/g liver) | C | 13.10 ± 0.70 b | 14.60 ± 1.00 a,b | 17.10 ± 1.10 a | 0.8515 |
| E | 17.90 ± 0.90 * | 19.00 ± 1.30 | 20.50 ± 1.40 | ||
| Plasma adiponectin (μg/mL) | C | 12.2 ± 1.0 a | 13.9 ± 0.9 a,b | 16.5 ± 2.0 b | 0.947 |
| E | 5.1 ± 1.3 *,f | 7.4 ± 1.3 e,f | 10.3 ± 1.5 e |
| Substance name | Mechanism of action | Clinical trial, design and results | Reference |
| TAK-242 (Resatorvid) | Binds covalently to Cys747 of TLR4-TIR domain and blocks TLR4/TIRAP and TLR4/TRAM interactions | Randomized, double-blind, placebo-controlled phase 2 trial (274 patients). Failed to suppress cytokine levels in patients with sepsis and shock or respiratory failure. | [124] |
| Eritoran (E5564) | Lipid A mimic, binds to MD-2 | Phase 2, double-blind, placebo-controlled, ascending-dose study (152 patients). Eritoran was well tolerated but did not attenuated systemic inflammation significantly. | [127] |
| Randomized, double-blind, placebo-controlled, multinational phase 3 trial (1961 patient). Treatment did not improve 28-day survival. | [131] | ||
| Prospective, randomized, double-blind, placebo-controlled, multicenter, ascending-dose phase II trial (293 patients). Eritoran was well tolerated but the mortality was not decreased significantly. | [132] |
| P-value | Lower 95% CI | Upper 95% CI | ||
| 2hPG | Crude | <.001 | 8.553 | 9.238 |
| Adjusted | <.001 | 8.546 | 9.241 | |
| FPG | Crude | <.001 | 6.164 | 6.473 |
| Adjusted | <.001 | 6.162 | 6.476 | |
| HbAlc | Crude | .001 | 6.123 | 6.346 |
| Adjusted | .002 | 6.124 | 6.342 |
| All patients | Patients with OS >50 months | Patients with OS <50 months | Pvalue | |
| ORR (%)* | 44.9 | 82.6 | 17.9 | <0.00001 |
| CBR (%)* | 63.3 | 100 | 35.7 | <0.00001 |
| TTF* | 10 | 26 | 5 | 0 |
| TTP* | 18 | 34 | 5 | 0 |
| OS* | 38 | 68 | 17 | <0.00001 |
| OS from diagnosis of MBC | 52 | 113 | 20 | <0.00001 |
| Number Of chemotherapy regimens* | 1 (0-3) | 1 (0-3) | 1 (0-3) | 0.66 |
| Number of chemotherapy regimens for BC | 3 (1-7) | 4 (1-7) | 4 (1-6) | 0.36 |
| Number of chemotherapy regimens for MBC | 3 (1-7) | 3 (1-7) | 3 (1-5) | 0.2 |
| PD (n = 14) | CON (n = 17) | P value | |
| Means ± SD | Means ± SD | ||
| Age (years) | 62.79 ± 4.59 | 61.35 ± 4.27 | 0.376 |
| Gender* | 11 M/3 F | 13 M/4 F | 0.889 |
| Disease duration (years) | 2.46 ± 1.43 | — | — |
| UPDRS score | |||
| Part I—mood/cognition | 2.93 ± 1.14 | — | — |
| Part II—activities of daily living | 9.93 ± 2.27 | — | — |
| Part III—motor examination | 21.79 ± 5.66 | — | — |
| Part IV—complications of therapy | 0 | — | — |
| MMSE score | 23.93 ± 2.13 | — | — |
| VAS | 4.77 ± 1.30 | 5.69 ± 1.25 | 0.064 |
| WST | 37.01 ± 1.44 | 35.74 ± 1.39 | 0.022 |
| HPT | 47.74 ± 2.09 | 45.33 ± 3.44 | 0.042 |
| Age group | Cyano. | N | Expo. to RBC (%) | RBC in CPB (%) | Expo. to FFP (%) | FFP in CPB (%) | Expo. to PLT (%) |
| < 1 mo. | 1 | 8 | 6 (75) | 4 (50) | 2 (25) | 8 (100) | 0 (0) |
| 0 | 21 | 19 (90) | 18 (86) | 12 (57) | 21 (100) | 5 (24) | |
| 1 to 6 mo. | 1 | 21 | 15 (71) | 8 (38) | 2 (9) | 2 (9) | 1 (5) |
| 0 | 24 | 19 (79) | 21 (87) | 1 (4) | 0 (0) | 1 (4) | |
| 6 to 12 mo. | 1 | 10 | 2 (20) | 1 (10) | 0 (0) | 0 (0) | 0 (0) |
| 0 | 15 | 11 (73) | 5 (33) | 0 (0) | 1 (7) | 0 (0) | |
| 1 to 3 yr. | 1 | 13 | 4 (31) | 2 (15) | 1 (8) | 1 (8) | 0 (0) |
| 0 | 25 | 13 (52) | 4 (16) | 0 (0) | 1 (4) | 0 (0) | |
| > 3 yr. | 1 | 12 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| 0 | 33 | 1 (3) | 1 (3) | 0 (0) | 0 (0) | 0 (0) |
| SERPINB9 | CD83 | CD9 | ||||
| Pool | Indiv | Pool | Indiv | Pool | Indiv | |
| Control | 1 | 1 | 1 | 1 | 1 | 1 |
| MS | 0.5 | 2.47 | 1.1 | 0.58 | 1.23 | 3.5 |
| QoL Domains | Mesor | Amplitude | Circadian Quotient | Rhythm Quotient | 24-hr Correlation | Night-day Sleep Balance |
| EORTC Symptom Items | ||||||
| Fatigue | -0.4 | -0.41 | -0.52 | |||
| Pain | -0.39 | |||||
| Loss of Appetite | -0.47 | |||||
| EORTC Functional Domains | ||||||
| Social | .34 | |||||
| Role | 0.56 | |||||
| Cognitive | 0.45 | |||||
| EORTC Global Health item | 0.53 | |||||
| Ferrans-Powers QLI Domains | ||||||
| Health/Function | 0.44 | 0.51 | 0.45 | 0.39 | ||
| Social/Economic | 0.38 | 0.39 | 0.40 | |||
| Psychological Spiritual | .45 | 0.4 | 0.45 | |||
| Family | 0.45 |
| Case | Signs/symptoms | Treatment | R |
| 1 | Anorexia, weight loss, fasting hypoglycemia, and mental aberrations | IVH, Di | [12] |
| 2 | Weakness, anorexia, orthostatic dizziness, failure to lactate, and weight loss | BB, C | [13] |
| 3 | Myalgia, anorexia, nausea, vomiting, weight loss, and failure to lactate | IVH, C | [14] |
| 4 | Lethargy, anorexia, vomiting, and weight loss | IVH, C, AT, RAI | [15] |
| 5 | Fatigue, weakness, nausea, vomiting, myalgia, arthralgia, and weight loss | C | [16] |
| 6 | Lethargy, myalgia, arthralgia, myopathy, nausea, vomiting, anorexia, weight loss, and failure to lactate | C, AT | [17] |
| 7 | Confusion, tachycardia, and dehydration | C, RAI | [17] |
| 8 | Disturbed mental state, severe nausea, vomiting, increased thirst, polyuria, and weight loss | AT, C, DDAVP | [4] |
| 9 | Anorexia, diarrhea, night sweats, myalgia, and weight loss | IVH, BP, AT, C | [18] |
| 10 | Headache, anorexia, weakness, fever, tachycardia, mental changes, and failure to lactate | C, IVH, KI, AT, BB | [19] |
| 11 | Nausea, vomiting, fever, and lethargy | C | [7] |
| 12 | Anorexia, nausea, vomiting, and severe dehydration | C, IVH | [20] |
| 13 | Vomiting and diarrhea | IVH, BB, C | [21] |
| PC | Vomiting, nausea, constipation, and weight loss | IVH, C, Di, BP, AT, BB |
| miR-96 (per million) | miR-182 (per million) | miR-183 (per million) | |
| HER2-enriched (n = 34) | 55.0 ± 46.9* | 49308.2 ± 31807.6 | 24494.0 ± 16871.2* |
| Basal (n = 105) | 42.3 ± 30.6 | 38971.0 ± 24170.6** | 21991.9 ± 16491.6* |
| Luminal A (n = 406) | 40.4 ± 35.5 | 50347.2 ± 34351.2 | 17668.1 ± 13604.2 |
| Luminal B (n = 109) | 38.0 ± 25.5 | 43312.6 ± 27928.1 | 17779.5 ± 13563.3 |
| Community-based organization Naloxone distribution | Traditional prescription | Pharmacy-based Naloxone models | ||||
| CPA | Standing medication order | Protocol order | Pharmacist prescribing | |||
| Who issues prescription? | Prescriber via standing order | Prescriber | Non-pharmacist prescriber | Non-pharmacist prescriber | Licensing board | Pharmacist |
| Medical professionals required | Varies by state: prescriber, state/local health department | Prescriber + pharmacist | Prescriber + pharmacist | Prescriber + pharmacist | Pharmacist | Pharmacist |
| Potential recipients | Individuals served by the community-based organization | Patients of the prescriber | Varies by state | Anyone meeting criteria specified by prescriber | Anyone meeting criteria specified by licensing board | Anyone for whom medication is indicated |
| Target overdose risk population served | People who use drugs (prescription opioids, heroin) who access the community-based organization* | People who use drugs who are in treatment/visit a prescriber* | People who use drugs (prescription opioids, heroin) who visit a pharmacy* | People who use drugs (prescription opioids, heroin) who visit a pharmacy* | People who use drugs (prescription opioids, heroin) who visit a pharmacy* | People who use drugs (prescription opioids, heroin) who visit a pharmacy* |
| Patients prescribed opioids who are at risk of overdose* | Patients filling a prescription for opioids at a pharmacy who are at risk of overdose* | Patients filling a prescription for opioids at a pharmacy who are at risk of overdose* | Patients filling a prescription for opioids at a pharmacy who are at risk of overdose* | Patients filling a prescription for opioids at a pharmacy who are at risk of overdose* | ||
| Geographic reach | Limited to where community-based organizations are located and operate | Limited to where the prescriber practices | Any participating pharmacy within the state | Any participating pharmacy within the state | Any participating pharmacy within the state | Limited to where the pharmacist practices |
| Group (n) | M/F,n(missing data) | Age at death, yr (mean ± SD) | Sections available,n | ||
| Frontal | Temporal | Hippocampal | |||
| Controls (32) | 14/18 | 72.0 ± 21.0 | 19 | 32 | 31 |
| AD (46) | 23/23 | 72.0 ± 6.0 | 46 | 41 | 41 |
| MND (25) | 20/5 | 64.3 ± 12.0 | 17 | 25 | 24 |
| FTLD (72) | 41/31 | 65.6 ± 9.1 | 71 | 66 | 60 |
| FTLD-tau (31) | 14/14 (3) | 67.2 ± 9.6 | 31 | 25 | 25 |
| MAPT (5) | 2/3 | 62.2 ± 5.4 | 5 | 4 | 4 |
| Pick (26) | 12/11 (3) | 68.3 ± 10.1 | 26 | 21 | 21 |
| FTLD-TDP (41) | 26/15 | 64.7 ± 8.7 | 40 | 41 | 35 |
| Type A (17) | 8/9 | 68.7 ± 4.2 | 17 | 17 | 14 |
| Type B (14) | 12/2 | 58.3 ± 9.0 | 13 | 14 | 12 |
| Type C (10) | 6/4 | 66.5 ± 9.4 | 10 | 10 | 9 |
| Patientsn | Tested forvitamin Dlevels (%) | Deficientor severelydeficienta (%) | Minimum level ofvitamin D for bonehealthb (%) | Vitamin D at> 75 nmol/L | |
| Male | 14 | 8 (57) | 6 (75) | 2 (25) | 0 (0) |
| Female | 42 | 19 (45.2) | 15 (79) | 4 (21) | 0 (0) |
| White | 39 | 18 (46.1) | 13 (72.2) | 5 (27.8) | 0 (0) |
| BME | 17 | 9 (52.9) | 9 (100) | 0 (0) | 0 (0) |
| Total | 56 | 27 (48) | 22 (81.5) | 5 (18.5) | 0 (0) |
| Term | Count | P-value | Genes |
| Regulation of transcription, DNA-dependent | 105 | 4.82E–06 | REST, RORA, ZNF254, HOXC6, TDGF3, GATA6, TDGF1, OLIG2, MLL3, PITX2, NODAL, EMX2, ZNF814, EOMES, SUZ12, HES5, SOX7, LIN28A, NR2C2, ARX, FOXH1, LHX9, DNMT3A, SALL4, FOXA2, NR6A1, PAX3, GLI2, POU5F1, HEY2, ZNF720, SOX10, NANOG, DMRT3, OTX2, RUNX1T1, SPEN, HAND1, ISL1, POU5F1B, ATRX, RBAK, THRAP3, PBX2 |
| Embryonic morphogenesis | 26 | 3.44E–04 | RBP4, FOXA2, PAX3, GLI2, TDGF3, SPRY2, HAND1, PRKRA, TDGF1, CEP290, NODAL, EOMES, PCDH8, CFC1, DKK1, SALL4, GNAQ, HOXB6, LRP6, PTCH1, MAB21L2, PBX2 |
| Lung development | 11 | 0.004697 | SPRY2, RBP4, FOXA2, PDGFA, GATA6, DHCR7, NODAL, VEGFA, GLI2, FOXP1, KDR |
| Regulation of neurogenesis | 13 | 0.026608 | PHOX2B, NBN, BMP2, FOXA2, REST, ISL1, GLI2, RUFY3, HES5, CCND2, NUMB, NEFM, ASPM |
| Forebrain development | 16 | 7.60E–04 | OTX2, EMX2, GLI2, ISL1, AHSG, ARX, SALL3, ATRX, FEZF2, DKK1, GNAQ, NUMB, PAFAH1B1, LRP8, RELN, ASPM |
| Neuron differentiation | 32 | 8.12E–04 | FGFR1, FOXA2, ONECUT2, GRIN3A, PAX3, RORA, GLI2, PTEN, CXCL12, KLHL1, ARX, KAL1, NUMB, CEP290, OLIG1, PAFAH1B1, OLIG2, RET, BHLHE22, OTX2, EMX2, LIFR, ISL1, CDKN1C, SALL3, FEZF2, EPHA4, ADM, GNAQ, HES5, VEGFA, RELN |
| Cerebral cortex development | 6 | 0.008017 | ARX, EMX2, LRP8, PAFAH1B1, RELN, AHSG |
| Telencephalon development | 7 | 0.038287 | ARX, SALL3, EMX2, LRP8, PAFAH1B1, RELN, AHSG |
| Type of complication | Prevalence N (%) |
| Retinopathy | 6 (0.9) |
| LVH | 12 (2) |
| IHD | 51 (8.3) |
| HF | 75 (12.2) |
| CKD | 20 (3.3) |
| Hypertensive urgency | 39 (6.4) |
| Sexual dysfunction | 4 (0.67) |
| Stroke | 34 (5.5) |
| AF | 6 (0.9) |
| Total TOD | 247 (100.0) |
| Parameters | Total (N = 268 ) | Test (N = 134) | Control (N = 134) | P value |
| Female | 110 | 57 | 53 | 0.619 |
| Age (months)* | 46.3 ± 30.3 | 44.5 ± 29.6 | 48.13 ± 31.1 | 0.331 |
| 12–17 | 35 (13%) | 21 (16%) | 14 (10%) | 0.282 |
| 18–59 | 160 (60%) | 81 (60%) | 79(59%) | 0.282 |
| 60 and over | 73 (27%) | 32 (24%) | 41(31%) | 0.282 |
| Weight (Kg)* | 14.1 ± 6.5 | 14.21 ± 7.75 | 14.1 ± 5.0 | 0.834 |
| Temperature (°C) | 36.7 | 36.7 | 36.7 | 0.519 |
| Pulse Rate (per minute)** | 85.7 ± 8.1 | 85.66 ± 8.12 | 85.7 ± 8.2 | 0.946 |
| Hemoglobin (g/dl)* | 11.2 ± 1.2 | 11.2 ± 1.1 | 11.2 ± 1.3 | 0.819 |
| TLC (mm3)* | 10,762.3 ± 3,466.5 | 11,062.0 ± 3,627.3 | 10,462.7 ± 3,284.0 | 0.157 |
| Neutrophils (%) * | 42.1 ± 13.0 | 42.6 ± 13.9 | 41.61 ± 12.0 | 0.554 |
| Lymphocytes (%) * | 45.1 ± 12.7 | 44.4 ± 13.1 | 45.8 ± 12.3 | 0.410 |
| Eosinophils (%) * | 5.4 ± 4.7 | 5.46 ± 5.1 | 5.39 ± 4.3 | 0.902 |
| Basophils (%) * | 0.4 ± 0.5 | 0.39 ± 0.3 | 0.44 ± 0.6 | 0.359 |
| Monocytes (%) * | 6.4 ± 3.1 | 6.44 ± 2.8 | 6.32 ± 3.3 | 0.760 |
| Platelet Count (lakhs/mm3) * | 3.2 ± 1 .2 | 3.3 ± 1 .0 | 3.2 ± 1.4 | 0.403 |
| Variable | Active group | Control group | df | x2/ T | P |
| N = 80 | N = 80 | ||||
| Age* (y) | 63.66 ± 6.37 | 63.1 ± 6.85 | 158 | −0.53 | 0.59 |
| Sex (n%) | |||||
| Female | 43(53.75) | 42(52.5) | 1 | 0.025 | 0.87 |
| Male | 37(46.25) | 38(47.5) | |||
| Diabetes duration* (y) | 9.56 ± 2.92 | 9.65 ± 2.93 | 158 | 0.18 | 0.85 |
| Education (n%) | |||||
| High school | 55(8.75) | 56(70) | 1 | 0.029 | 0.86 |
| Higher | 25 (31.25) | 24(30) | |||
| BMI* | 27.49 ± 0.88 | 27.32 ± 0.87 | 158 | −1.24 | 0.21 |
| HbA1C* (mmol/lit) | 7.13 ± 0.16 | 7.17 ± 0.23 | 158 | 1.50 | 0.13 |
| MMSE Score* | |||||
| MMSE total | 28.2 ± 2.18 | 25.23 ± 1.75 | 158 | −8.08 | 0.001 |
| MMSE in female | 28.2 ± 2.4 | 25.19 ± 1.77 | 83 | −6.94 | 0.001 |
| MMSE in male | 28.2 ± 1.98 | 25.28 ± 1.76 | 73 | −5.58 | 0.001 |
| Foot care practice* | 4.77 ± 0.77 | 4.45 ± 0.83 | 158 | −2.54 | 0.01 |
| (day/week) |
| Treatment | Conc. (μg/ml) | Mean absorbance ± SD | Percentage inhibition of haemolysis | |
| Heated solution | Unheated solution | |||
| Control | - | 0.67 ± 0.13 | 0.3 ± 0.01 | |
| Extract | 100 | 0.25 ± 0.04** | 0.4 ± 0.01 | 66.46 ± 2.89 |
| 200 | 0.28 ± 0.04** | 0.08 ± 0.03 | 65.14 ± 4.58 | |
| 400 | 0.42 ± 0. 07** | 0.12 ± 0.03 | 46.53 ± 2.52 | |
| 600 | 0.42 ± 0.06** | 0.25 ± 0.06 | 61.88 ± 4.51 | |
| 800 | 0.43 ± 0.09** | 0.38 ± 0.08 | 86.67 ± 3.06 | |
| Indomethacin | 200 | 0.05 ± 0.01*** | 0.02 ± 0.00 | 95.32 ± 3.51 |
| Malalignment parameter | Difference compared to pre-opMedian (IQR) | Significancea | |
| Cutting guide (n = 4) | Visualisation (n = 4) | ||
| Coronal shift in mm, ulnar (−), radial (+) | 3.1 (1.9 to 10.0) | −2.6 (−3.0 to 3.5) | 0.200 |
| Sagittal shift in mm, volar (−), dorsal (+) | 10.2 (−7.3 to 18.1) | −6.7 (−26.4 to −2.6) | 0.200 |
| Radial length in mm | 2.2 (−2.0 to 15.7) | 4.3 (0.3 to 5.4) | 0.686 |
| Palmar tilt in deg, dorsal (−), volar (−) | −6.8 (−24.5 to 4.4) | 8.5 (5.2 to 14.9) | 0.114 |
| Radial inclination in deg, ulnar (−), radial (+) | −3.2 (−9.3 to 5.7) | 0.3 (−11.4 to 5.3) | 1.000 |
| Axial rotation in deg, pronation (−), supination (+) | 23.0 (11.5 to 30.6) | 1.8 (−13.1 to 30.0) | 0.343 |
| Analyte | Concn (ng/ml) | |
| Low | High | |
| Amodiaquine | 4.0 | 4,192 |
| Desethylamodiaquine | 4.0 | 4,192 |
| Lumefantrine | 25 | 20,000 |
| Chloroquine | 4.0 | 4,192 |
| Desethylchloroquine | 4.0 | 4,192 |
| Dihydroartemisinin | 1.6 | 2,875 |
| Piperaquine | 1.2 | 575 |
| Mefloquine | 70 | 4,000 |
| Carboxymefloquine | 70 | 4,000 |
| Primaquine | 10 | 400 |
| Carboxyprimaquine | 50 | 4,000 |
| Panitumumab + mFOLFOX6 (n = 88) | Bevacizumab + mFOLFOX6 (n = 82)* | |
| Median DoR, months (95% CI) | 11.4 (10.0, 16.3) | 9.0 (7.6, 9.5) |
| HR† (95% CI) | 0.59 (0.39, 0.88) | |
| p value‡ | 0.011 | |
| Median TTR, months (95% CI) | 2.3 (1.9, 3.7) | 3.8 (2.1, 5.7) |
| HR† (95% CI) | 1.19 (0.81, 1.74) | |
| p value‡ | 0.37 | |
| Median DpR, % (Q1, Q3) | 65.0 (45.7, 89.5) | 46.3 (29.5, 63.3) |
| p value¶ | 0.0018 | |
| Any resection, n (%) | 12 (14) | 9 (11) |
| Liver only§ | 9 (75) | 6 (67) |
| Complete resection | 9 (10) | 7 (9) |
| Liver only^ | 7 (78) | 6 (86) |
| Time to resection, months – median (range) | 5.1 (3–19) | 4.4 (3–12) |
| Progression-free at 6 months, n (%) | ||
| Patients with resection | 8/12 (67) | 4/9 (44) |
| Patients without resection | 45/76 (59) | 48/73 (66) |
| Alive at 2 years, n (%) | ||
| Patients with resection | 8/12 (67) | 8/9 (89) |
| Patients without resection | 18/76 (24) | 12/73 (16) |
| High-risk subject | Low-risk subject | |||||||
| N | Meana | CI | N | Meana | CI | P | ||
| Women | .022 | |||||||
| Divorced | 118 | .51 | .36–.67 | 516 | .20 | .13–.26 | ||
| Not divorced | 1051 | .07 | .01–.12 | 11068 | -.03 | -.05– -.02 | ||
| Total | 1169 | .12 | 11584 | -.02 | ||||
| Men | .108 | |||||||
| Divorced | 122 | .67 | .49–.86 | 438 | .26 | .18–.34 | ||
| Not divorced | 1264 | .18 | .12–.23 | 8934 | -.06 | -.07– -.04 | ||
| Total | 1386 | .22 | 9372 | -.04 |
| Gene | Encoded protein | Fold change | Cell cycle |
| AURKA | Aurora kinase A | −2.712 | STOP |
| AURKB | Aurora kinase B | −4.146 | STOP |
| CCNA2 | Cyclin A2 | −4.652 | STOP |
| CCNB1 | Cyclin B1 | −5.752 −5.820 −5.857 | STOP |
| CCNB2 | Cyclin B2 | −3.392 | STOP |
| CCND1 | Cyclin D1 | −2.476 | STOP |
| CCND3 | Cyclin D3 | −1.539 | STOP |
| CCNE1 | Cyclin E1 | −1.777 | STOP |
| CCNE2 | Cyclin E2 | −2.847 | STOP |
| CCNF | Cyclin F | −3.211 | STOP |
| CDC6 | Cell division cycle 6 | −1.936 | STOP |
| CDC20 | Cell division cycle 20 | −3.113 | STOP |
| CDC25B | Cell division cycle 25B | −1.636 | STOP |
| CDC25C | Cell division cycle 25C | −2.414 | STOP |
| CDC45 | Cell division cycle 45 | −1.769 | STOP |
| CDCA2 | Cell division cycle associated 2 | −3.461 | STOP |
| CDCA3 | Cell division cycle associated 3 | −3.003 | STOP |
| CDCA5 | Cell division cycle associated 5 | −3.053 | STOP |
| CDCA7L | Cell division cycle associated 7-like | −4.123 | STOP |
| CDCA8 | Cell division cycle associated 8 | −3.467 | STOP |
| CDK1 | Cyclin-dependent kinase 1 | −3.227 | STOP |
| CDK15 | Cyclin-dependent kinase 15 | 1.618 | GO |
| CDK19 | Cyclin-dependent kinase 19 | 1.619 | GO |
| CDK5R1 | Cyclin-dependent kinase 5, regulatory subunit 1 (p35) | 1.597 | — |
| CENPA | Centromere protein A | −1.895 | STOP |
| CENPE | Centromere protein E, 312 kDa | −4.140 | STOP |
| CENPF | Centromere protein F, 350/400 kDa | −3.927 | STOP |
| CENPI | Centromere protein I | −2.899 | STOP |
| CENPK | Centromere protein K | −2.813 | STOP |
| CENPL | Centromere protein L | −1.864 | STOP |
| CENPM | Centromere protein M | −3.407 | STOP |
| CENPN | Centromere protein N | −2.465 | STOP |
| CENPU | Centromere protein U | −1.624 | STOP |
| SKA1 | Spindle and kinetochore associated complex subunit 1 | −1.532 | STOP |
| SKA2 | Spindle and kinetochore associated complex subunit 2 | −1.582 | STOP |
| SKA3 | Spindle and kinetochore associated complex subunit 3 | −3.490 | STOP |
| SKP2 | S-phase kinase-associated protein 2, E3 ubiquitin protein ligase | −1.845 | STOP |
| SPC25 | SPC25, NDC80 kinetochore complex component | −4.148 | STOP |
| Criteria | Assessment | |
| 1 | A diagnosis of PD | Queen's Square Brain Bank Criteria |
| 2 | PD developed prior to the onset of dementia | Patient/caregiver history or ancillary records |
| 3 | PD associated with a decreased global cognitive efficiency | MMSE < 26 |
| 4 | Cognitive deficiency severe enough to impair daily life | Caregiver interview or pill questionnaire |
| 5 | Impairment of more than one cognitive domain | Impairment of at least two of the following domains |
| Attention | ||
| Executive function | ||
| Visuo-constructive ability | ||
| Memory |
| Case/sex/age (years) | Initial treatment | Associated pseudocyst | Rebleeding | Secondary treatment | Length of follow-up (months) | Outcome |
| 1/M/59 | A | No | No | No | 57 | S |
| 2/M/33 | TG, L | No | No | No | 38 | S |
| 3/M/46 | E | Yes* | Yes | E‡, L, ED | 4 | D |
| 4/F/71 | E | No | Yes | E | 18 | S |
| 5/M/36 | Nearly TP, Sp | No | No | No | 50 | S |
| 6/M/33 | DP+ | Yes* | Yes | E‡, L, ED | 87 | S |
| 7/M/28 | DP, Sp | Yes+ | No | GC+ | 15 | S |
| 8/M/38 | A, ED | Yes+ | No | RD | 51 | S |
| 9/M/35 | DP, Sp | Yes | No | No | 10 | S |
| Materials | Size (L = Length; W = Width; H = Height) | ||
| Grinding media | Steel ball (∅15 mm) | Square (L: 12 × W: 12 × H: 12 mm) | Cylinder (∅12 × H: 16 mm) |
| Iron ore particle | 2–2.8 mm | ||
| Lifter | L: 40 × W: 20 × H: 10 mm | L: 40 × W: 20 × H: 15 mm | L: 40 × W: 20 × H: 20 mm |
| Variables | TSH 0.40–2.49 mIU/L | TSH 2.50–4.99 | p-value |
| (n = 26) | (n = 12) | ||
| Intrauterine fetal death | 2 (7.7%) | 0 | 1.00 |
| Preterm birth | 2 (7.7%) | 1 (8.3%) | 1.00 |
| Term birth | 22 (84.6%) | 11 (91.7%) | 0.55 |
| Duration of gestation (d) | 263.83 ± 15.8 | 266.6 ± 19.6 | 0.66 |
| C/S section | 15/24 (62.5%) | 6 /12 (50%) | 0.47 |
| NICU administration | 2 (7.7%) | 2 (16.6%) | 0.57 |
| Birth weight(g) | 2923 ± 728 | 3102 ± 628 | 0.47 |
| Newly referred patients | Long-term follow-up patients | |||||||
| Level 1 (n = 9) | Level 2 (n = 125) | Level 3 (n = 111) | All (n = 245) | Level 1 (n = 18) | Level 2 (n = 236) | Level 3 (n = 165) | All (n = 419) | |
| Age (years, range) | 55.3 (42–62) | 62.3 (23–89) | 65.8 (23–93) | 63.6 (23–93) | 55.3 (28–68) | 63.6 (19–89) | 68.6 (38–93) | 65.2 (19–93) |
| Male sex – no. (%) | 3 (33.3) | 82 (65.6) | 71 (64.0) | 156 (63.7) | 9 (50) | 160 (67.8) | 113 (68.5) | 282 (67.3) |
| BMI (kg/m2)a | 30.3 ± 8.2 | 30.5 ± 6.2 | 29.6 ± 5.3 | 30.1 ± 6.1 | 28.0 ± 5.3 | 30.1 ± 5.6 | 30.5 ± 5.9 | 30.2 ± 5.7 |
| Diabetes duration - years | 3.9 ± 5.1 | 5.4 ± 5.8 | 7.9 ± 8.0 | 6.5 ± 7.0 | 6.2 ± 5.3 | 8.5 ± 6.0 | 11.5 ± 7.1 | 9.6 ± 6.6 |
| SBP (mmHg) | 120.6 ± 7.0 | 140.6 ± 15.8 | 142.3 ± 24.4 | 140.7 ± 19.8 | 114.8 ± 9.1 | 134.0 ± 13.8 | 136.7 ± 17.4 | 134.3 ± 15.7 |
| DBP (mmHg) | 70.9 ± 5.2 | 81.1 ± 9.5 | 80.0 ± 12.7 | 80.3 ± 11.1 | 72.3 ± 5.3 | 78.2 ± 8.7 | 76.8 ± 10.1 | 77.4 ± 9.2 |
| HbA1c (%) (mmol/mol) | 6.3 ± 2.4 (45 ± 3) | 7.1 ± 3.1 (54 ± 10) | 8.5 ± 4.5 (69 ± 26) | 7.7 ± 4.1 (61 ± 21) | 6.1 ± 2.7 (43 ± 6) | 6.8 ± 3.1 (51 ± 10) | 7.6 ± 3.9 (60 ± 19) | 7.1 ± 3.5 (54 ± 15) |
| TC (mmol/l) | 4.8 ± 0.8 | 4.4 ± 1.0 | 4.3 ± 1.2 | 4.3 ± 1.1 | 4.2 ± 1.4 | 4.0 ± 0.8 | 4.1 ± 1.1 | 4.0 ± 0.9 |
| LDL-C (mmol/l) | 2.3 ± 0.7 | 2.2 ± 1.0 | 2.1 ± 0.9 | 2.2 ± 0.9 | 2.2 ± 1.1 | 1.8 ± 0.6 | 1.9 ± 1.0 | 1.8 ± 0.8 |
| HDL-C(mmol/l) | 1.7 ± 0.4 | 1.3 ± 0.5 | 1.2 ± 0.4 | 1.3 ± 0.5 | 1.4 ± 0.4 | 1.3 ± 0.4 | 1.3 ± 0.4 | 1.3 ± 0.4 |
| TG (mmol/l) | 1.9 ± 0.6 | 2.0 ± 1.2 | 2.3 ± 1.5 | 2.1 ± 1.3 | 1.2 ± 0.6 | 2.1 ± 1.2 | 2.2 ± 1.3 | 2.1 ± 1.2 |
| Retinopathy – no. (%) | ||||||||
| Any stage | 0 | 3 (2.4) | 6 (5.4) | 9 (3.7) | 0 | 20 (8.5) | 35 (21.2) | 55 (13.1) |
| Macular oedema or | ||||||||
| proliferative retinopathy | 0 | 0 | 3 (2.7) | 3 (1.2) | 0 | 0 | 4 (2.4) | 4 (1.0) |
| Neuropathy – no. (%) | ||||||||
| Peripheral neuropathy or insufficiency | 0 | 60 (48.0) | 58 (52.3) | 118 (48.2) | 0 | 128 (54.2) | 111 (67.3) | 139 (33.2) |
| Previous or existing ulcer or Charcot foot | 0 | 0 | 8 (7.2) | 8 (3.3) | 0 | 0 | 13 (7.9) | 13 (3.1) |
| Nephropathy – no. (%) | 0 | 0 | 36 (32.4) | 36 (14.7) | 0 | 0 | 89 (53.9) | 89 (21.2) |
| Former MACE – no. (%) | 0 | 25 (20.0) | 34 (30.6) | 59 (24.1) | 0 | 45 (19.1) | 51 (30.9) | 96 (22.9) |
| >1 MACE, symptomatic CVD or NYHA II-IV – no. (%) | 0 | 0 | 26 (23.4) | 26 (10.6) | 0 | 0 | 56 (33.9) | 56 (13.4) |
| Number of examined samples | n (%) | |
| Pure buffalo samples | Adulterated samples | |
| 50 | 5 (10) | 45 (90) |
| SI | Prediction method | |||||
| Feature selection method | # of SNP | LR | SVM | RF | EN | LDA |
| LR | 100 | 0.7597 | 0.7171 | 0.7067 | 0.7670 | 0.7605 |
| 500 | 0.9139 | |||||
| SVM | 100 | 0.6819 | 0.6421 | 0.6204 | 0.6794 | 0.6813 |
| 500 | 0.7953 | 0.8178 | 0.6930 | 0.7943 | 0.8075 | |
| RF | 100 | 0.5961 | 0.6101 | 0.5980 | 0.5848 | 0.5957 |
| 500 | 0.6185 | 0.6312 | 0.6138 | 0.6010 | 0.6210 | |
| EN | 100a | 0.7937 | ||||
| 163a | 0.8157 | 0.8084 | 0.7454 | 0.8188 | 0.8180 | |
| LDA | 100 | 0.6338 | 0.5925 | 0.5807 | 0.6273 | 0.6343 |
| 500 | 0.7387 | 0.7503 | 0.6212 | 0.7176 | 0.7464 |
| Menopausal symptoms | Number (%) | Severe | Very severe |
| Somatic | |||
| Sleeping problems | 574 (78.7) | 93 | 1 |
| Hot flushes, sweating | 508 (69.7) | 157 | 75 |
| Joint and muscular discomfort | 500 (68.6) | 86 | 0 |
| Heart discomfort | 360 (49.4) | 0 | 0 |
| Psychological | |||
| Physical and mental exhaustion | 536 (73.5) | 68 | 4 |
| Depressive mood | 402 (55.2) | 109 | 12 |
| Irritability | 339 (46.5) | 105 | 10 |
| Anxiety | 334 (45.8) | 114 | 7 |
| Urogenital | |||
| Dryness of vagina | 449 (61.6) | 102 | 4 |
| Bladder problems | 385 (52.8) | 38 | 2 |
| Sexual problems | 343 (47.1) | 56 | 6 |
| Variable | No post-pyloric tubeMedian (IQR) | Post-pyloric tubeMedian (IQR) |
| Age | 53 (42-64) | 56 (40-67) |
| Sex (M:F) | 35:29 | 19:25 |
| APACHE II score | 26 (21-31.5) | 28.5 (22.5-33.5) |
| Length of stay in days | 4.97 (2.0-10.0) | 5.57 (2.8-9.8) |
| Ventilator days | 3.43 (1.6-8.4) | 4.92 (2.3-8.2) |
| Number of interal feed days | 3.1 (1.3-6.6) | 4.02 (1.9-7.5) |
| Reading Task | Times New Roman | EasyReadingTM |
| Excerpt (t(531) = −32.12, p < 0.001) | 3.50 ± 0.94 | 4.16 ± 1.09 |
| Words (t(532) = −18.14, p < 0.001) | 3.03 ± 0.88 | 3.33 ± 0.93 |
| Non-words (t(532) = −10.37, p < 0.001) | 1.86 ± 0.60 | 2.04 ± 0.61 |
| Mechanism | Source | Description |
| Soluble CD25 | RS cells | Prevent interaction of IL-2 with IL-2Rs |
| IL-10 | RS cells, Tregs, cells of TME | Repress IL-2 and IFN-γ production |
| TGF-β | RS cells, Tregs, cells of TME | Repress IL-2 and IFN-γ productionDownregulate activating receptors (NKG2D, NKp30) and corresponding ligands (MICA, ULBP2, ULBP4) |
| IL-15 | RS cells | Competition of RS cells and NK cells |
| CXCL9, CXCL10 | RS cells (mainly EBV+) | Attract CD56bright–CD16dim NK cells |
| HLA-G and HLA-E | RS cells | Bind to inhibitory receptors on NK cells |
| Soluble MICA | RS cells | Endocytosis and degradation of NKG2D |
| BAG6/BAT3 | RS cells | Endocytosis and degradation of NKp30 |
| Rosetting | Macrophages, Tregs, Th2 T-helper cells | Physical shield of HRS cells from NK cells |
| c-FLIP | Overexpressed by RS cells | NK FasL-mediated apoptosis resistance |
| FasL | RS cells | Apoptosis of Fas-expressing NK cells |
| PD-L1 | RS cells | Suppression of NK cell activation |
| MHC-I | RS cells (EBV+) | Bind to KIRs, inhibit NK cell activation |
| PTSD Prevalence | War victims | Crime victims | Natural disaster | Road fatalities | |
| PTSD Prevalence | - | 0.87*** | 0.69* | 0.29 | -0.16 |
| War victims | - | 0.73* | 0.57* | 0.22 | |
| Crime victims | - | 0.48 | -0.08 | ||
| Natural disaster | - | 0.04 | |||
| Road fatalities | - | ||||
| Individual values | |||||
| Security | 0.35 | 0.57 | 0.46 | 0.19 | 0.50 |
| Conformity | -0.32 | -0.29 | -0.25 | -0.33 | -0.37 |
| Tradition | -0.09 | -0.17 | -0.24 | 0.16 | -0.16 |
| Benevolence | 0.002 | -0.08 | 0.20 | -0.54 | -0.33 |
| Universalism | -0.36 | -0.48 | -0.42 | 0.07 | -0.27 |
| Self-direction | -0.14 | -0.39 | -0.47 | -0.45 | -0.80** |
| Stimulation | 0.44 | 0.73* | 0.62† | 0.15 | 0.59† |
| Hedonism | -0.04 | 0.19 | 0.04 | 0.48 | 0.44 |
| Achievement | -0.31 | -0.37 | -0.35 | -0.01 | -0.17 |
| Power | -0.25 | -0.48 | -0.37 | 0.00 | -0.40 |
| Aggregated values | |||||
| Traditional | 0.13 | 0.36 | 0.25 | -0.00 | 0.24 |
| Modern | 0.28 | 0.56 | 0.36 | 0.23 | 0.44 |
| Controls | Cases | |||||
| All | Male | Female | All | Male | Female | |
| CAD | 2292 | 1245(0.54) | 1047(0.46) | 2323 | 1777(0.76) | 546(0.24) |
| MI | 853 | 558(0.65) | 295(0.35) | 2180 | 1682(0.77) | 498(0.23) |
| T2DM | 954 | 524(0.55) | 430(0.45) | 1589 | 1175(0.74) | 414(0.26) |
| HTN | 1559 | 828(0.53) | 731(0.47) | 1962 | 1474(0.75) | 488(0.25) |
| hChol | 593 | 312(0.53) | 281(0.47) | 1078 | 796(0.74) | 282(0.26) |
| lHDL | 729 | 487(0.67) | 242(0.33) | 1181 | 979(0.83) | 202(0.17) |
| hTG | 427 | 267(0.63) | 160(0.37) | 728 | 554(0.76) | 174(0.24) |
| hLDL | 886 | 456(0.51) | 430(0.49) | 965 | 717(0.74) | 248(0.26) |
| FH | 542 | 299(0.55) | 243(0.45) | 359 | 287(0.80) | 72(0.20) |
| OBS | 888 | 385((0.43) | 503(0.57) | 857 | 573(0.67) | 284(0.33) |
| Smokers | 685 | 639(0.93) | 46(0.07) | 1059 | 1031(0.97) | 28(0.03) |
| VD 1 | 0 | 0 | 0 | 885 | 642(0.73) | 243(0.27) |
| 2 | 0 | 0 | 0 | 456 | 356(0.78) | 100(0.22) |
| 3 | 0 | 0 | 0 | 965 | 717(0.74) | 248(0.26) |
| Clinical characteristics | ||||||
| Age | 50.6 ± 0.4 | 51.2 ± 0.5 | 49.8 ± 0.5 | 60.3 ±0.2 | 59.8 ± 0.3 | 61.8 ± 0.54 |
| BMI | 29.0 ±0.2 | 27.97 ± 0.2 | 30.3 ± 0.3 | 28.9 ± 0.1 | 28.3 ± 0.1 | 31.0 ± 0.3 |
| Total Chol | 4.51 ± 0.02 | 4.42 ± 0.03 | 4.62 ± 0.03 | 4.48 ± 0.02 | 4.43 ±0.03 | 4.66 ± 0.05 |
| HDL-Chol | 1.26 ±0.01 | 1.18 ±0.03 | 1.33 ±0.01 | 1.15 ±0.01 | 1.15 ± 0.01 | 1.25 ± 0.02 |
| LDL-Chol | 2.76 ± 0.02 | 2.73 ± 0.03 | 2.80 ±0.03 | 2.71 ±0.02 | 2.68 ± 0.02 | 2.84 ±0.06 |
| TG | 1.52 ± 0.02 | 1.60 ± 0.03 | 1.44 ± 0.03 | 1.78 ± 0.02 | 1.78 ± 0.03 | 1.78 ± 0.05 |
| Fasting glucose | 6.87 ± 0.16 | 6.80 ± 0.23 | 6.92 ± 0.22 | 9.45 ± 0.31 | 9.27 ± 0.37 | 9.88 ± 0.56 |
| BP | 120/83 | 119/81 | 121/82 | 128/84 | 130/85 | 127/83 |
| Range of ages (months) | Average age (SD) | Rang of intelligibility | Average intelligibility scores (SD) |
| 48–59 | CI: 51.66 (3.87)N: 54.15 (3.69) | CI: 56–100 | 68.52 (1.47)100 (0.00) |
| 60–71 | CI: 64.25 (4.19)N: 65.75 (3.27) | CI: 58.46–63.07 | 60.76 (1.97)100 (0.00) |
| 72–83 | CI: 76.57 (2.87)N: 75.55 (3.67) | CI: 55.38–66.15 | 60.87 (3.85)100 (0.00) |
| 84–95 | CI: 90.66 (3.77)N: 88.00 (3.79) | CI: 47.69–76.92 | 61.79 (1.14)100 (0.00) |
| Variables | Lower-Grade Glioma | Glioblastoma |
| Numbers | 170 | 133 |
| Median age (range) | 39 (10–75) | 49 (8–81) |
| Sex (male) | 103 | 86 |
| Pathology (Astrocytic) | 69 | - |
| IDH1 mutational status | - | - |
| IDH1 mutation | 100 | 18 |
| IDH1 wild-type | 34 | 78 |
| 1p/19q status | - | - |
| 1p/19q co-deletion | 34 | 2 |
| No 1p/19q co-deletion | 108 | 106 |
| Age at death (years) | |||||||||
| Never smoked | Light smoker | Medium smoker | Heavy smoker | ||||||
| Predicted survival percentile1 | Men | Women | Men | Women | Men | Women | Men | Women | |
| Age at 1st Jan 1965 | |||||||||
| 25 years | 5% | 54.92 | 59.50 | 52.33 | 53.33 | 49.08 | 51.67 | 47.08 | 51.42 |
| 50% | 82.83 | 85.83 | 80.75 | 81.33 | 77.17 | 80.17 | 75.50 | 80.00 | |
| 95% | 100.50 | 103.92 | 96.33 | 94.08 | 91.25 | 92.08 | 89.17 | 91.83 | |
| 45 years | 5% | 55.25 | 58.92 | 54.00 | 55.00 | 52.00 | 53.92 | 51.17 | 90.50 |
| 50% | 78.50 | 84.33 | 75.92 | 78.42 | 72.08 | 76.75 | 70.33 | 76.50 | |
| 95% | 98.00 | 102.58 | 93.75 | 92.75 | 88.67 | 90.83 | 86.58 | 53.75 | |
| 65 years | 5% | 66.75 | 68.42 | 66.62 | 67.00 | 66.00 | 66.75 | 65.83 | 66.75 |
| 50% | 78.58 | 83.33 | 76.75 | 79.08 | 74.58 | 77.75 | 73.33 | 77.58 | |
| 95% | 94.00 | 100.08 | 90.58 | 91.25 | 86.58 | 89.50 | 85.17 | 89.25 |
| Characteristic | N (%) or Mean ± SD |
| Sex | |
| Female | 183 (70.4 %) |
| Male | 77 (29.6 %) |
| Age (years) | 38.8 (13.7) |
| Referral source | |
| Primary Care | 231 (88.8 %) |
| Respirologist | 7 (2.7 %) |
| Allergist | 2 (0.8 %) |
| Other | 10 (3.8 %) |
| Unknown | 10 (3.8 %) |
| Diagnosis of atopy | |
| Allergic rhinitis | 120 (46.2 %) |
| Asthma | 90 (34.6 %) |
| Atopic dermatitis | 61 (23.5 %) |
| Venom allergy | 5 (1.9 %) |
| Drug allergy | 42 (16.2 %) |
| Urticaria | 60 (23.1 %) |
| Eczema | 61 (23.5 %) |
| Pollen food syndrome | 35 (13.5 %) |
| Absorbed dose to the thyroid (Gy) | Number of differentially expressed transcripts | Number of up- and down-regulated transcripts |
| 0.05 | 1,225 | ↑ 338 |
| ↓ 887 | ||
| 0.5 | 1,636 | ↑ 480 |
| ↓ 1,156 | ||
| 1.4 | 544 | ↑ 284 |
| ↓ 260 | ||
| 11 | 575 | ↑ 412 |
| ↓ 163 | ||
| 32 | 425 | ↑ 293 |
| ↓ 132 |
| Sample | shell | N | R(Å) | σ2(×10-3 Å2) | ΔE0(eV) |
| Standard ZnS | Zn-S | 4 | 2.35 ± 0.02 | 4.6 ± 0.3 | 4.6 |
| Zn-S-Zn | 12 | 3.85 ± 0.02 | 15.3 ± 0.9 | 5.1 | |
| Zn-S | 9 | 4.55 ± 0.02 | 12.5 ± 1.9 | 8.5 | |
| PCMS-0.5 | Zn-S | 2.3 | 2.32 ± 0.02 | 6.9 ± 2.2 | 3.0 |
| Zn-O | 1.7 | 1.99 ± 0.03 | 6.5 ± 4.0 | 3.0 | |
| PCMS-1 | Zn-S | 3.5 | 2.33 ± 0.02 | 5.2 ± 0.5 | 3.7 |
| Zn-O | 1 | 1.97 ± 0.02 | 6.9 ± 3.2 | 3.7 | |
| Zn-S-Zn | 4.5 | 3.84 ± 0.04 | 15.9 ± 3.3 | 5.1 | |
| Zn-S | 3 | 4.51 ± 0.10 | 15.5 ± 9.6 | 8.5 | |
| PCMS-2.5 | Zn-S | 4 | 2.34 ± 0.02 | 5.4 ± 0.6 | 4.6 |
| Zn-S-Zn | 5 | 3.83 ± 0.03 | 15.8 ± 4.1 | 5.1 | |
| Zn-S | 3 | 4.52 ± 0.07 | 14.8 ± 12.3 | 8.5 | |
| PCMS-5 | Zn-S | 4 | 2.33 ± 0.02 | 5.1 ± 0.5 | 3.7 |
| Zn-S-Zn | 6 | 3.82 ± 0.02 | 16.1 ± 2.8 | 5.1 | |
| Zn-S | 4 | 4.55 ± 0.05 | 15.1 ± 7.8 | 8.5 |
| N (%) | |
| Lesion location | |
| Right upper lobe | 40/68 (58.8) |
| Right middle lobe | 21/68 (30.9) |
| Right lower lobe | 22/68 (32.4) |
| Left upper lobe | 33/68 (48.5) |
| Left lower lobe | 21/68 (30.9) |
| Lesion distribution | |
| Bilateral | 30/68 (44.1) |
| Multilobar (≥3 lobes with abnormalities) | 21/68 (30.9) |
| Lesion characteristics | |
| Multiple nodules | 42/68 (61.8) |
| Bronchiectasis | 24/68 (35.3) |
| Cavity | 13/68 (19.1) |
| Unilateral | 9/68 (13.2) |
| Bilateral | 4/68 (5.9) |
| Radiographic classification | |
| Upper lobe cavitary pattern | 12/68 (17.6) |
| Nodular bronchiectatic pattern | 17/68 (25.0) |
| Unclassifiable | 39/68 (57.4) |
| Element | Al2O3 | CaO | Fe2O3 | K2O | MgO | SO3 | SiO2 | TiO2 | LOI |
| SO1 | 3,94 | 70,20 | 0,19 | 0,18 | 0,25 | 0,00 | 23,36 | 0,10 | 0,40 |
| SO2 | 3,66 | 70,22 | 0,14 | 0,18 | 0,25 | 0,00 | 24,28 | 0,11 | 0,60 |
| SO3 | 3,95 | 70,56 | 0,17 | 0,18 | 0,89 | 0,10 | 23,75 | 0,09 | 0,33 |
| SO4 | 3,83 | 69,85 | 0,25 | 0,16 | 0,25 | 0,04 | 24,39 | 0,13 | 0,41 |
| SO5 | 3,95 | 70,00 | 0,24 | 0,17 | 0,27 | 0,00 | 24,40 | 0,17 | 0,32 |
| SO6 | 4,08 | 70,04 | 0,31 | 0,18 | 0,27 | 0,00 | 24,46 | 0,15 | 0,53 |
| Frequency | Sensitivity | Specificity |
| ≥0.05 | 99.17% (SNV 99.30%; indel 96.60%) | >99.5% |
| ≥0.10 | 99.66% (SNV 99.76%; indel 97.67%) | >99.5% |
| >0.20 | 99.70% (SNV 99.80%; indel 96.40%) | >99.5% |
| Normal | Borderline | Case | |
| Anxiety | |||
| Baseline (n=37) | 28 | 6 | 3 |
| 3 months (n=37) | 30 | 5 | 2 |
| 6 months (n=28) | 20 | 6 | 1 |
| Depression | |||
| Baseline (n=37) | 31 | 4 | 2 |
| 3 months (n=37) | 31 | 4 | 2 |
| 6 months (n=28) | 23 | 4 | 1 |
| Variants | P-value |
| Age at diagnosis | 0.249 |
| Gender | 0.543 |
| WBC at diagnosis | 0.533 |
| Bone marrow blasts | 0.733 |
| Peripheral blasts | 0.406 |
| FLT3-ITD positive | 0.153 |
| NPM1 mutation | 0.031 |
| CEBPA mutation | 0.050 |
| Coefficients | Estimate | Std. Error | t Value |
| (Intercept) | −1.222e + 02 | 1.251e + 02 | −0.977 |
| SWB | −4.421e − 03 | 4.916e − 02 | −0.090 |
| SDI | 9.152e − 02 | 5.400e − 02 | 1.695 |
| Dallas Theological Seminary | −5.706e − 01 | 1.473e + 00 | −0.387 |
| Denver Seminary | 1.066e − 00 | 1.629e + 00 | 0.655 |
| Gordon-Conwell Seminary | 2.005e − 01 | 1.541e + 00 | 0.130 |
| Oral Roberts University | 2.190e − 02 | 2.209e + 00 | 0.010 |
| Male | −3.381e + 00 | 1.364e + 00 | −2.478 |
| Birth Year | 7.702e − 02 | 6.276e − 02 | 1.227 |
| Non-Hispanic White or Euro-American | 2.627e + 00 | 1.295e + 00 | 2.028 |
| Latino or Hispanic American | 8.577e + 00 | 2.872e + 00 | 2.987 |
| Other/Multi-Racial | −5.138e + 00 | 3.248e + 00 | −1.582 |
| Concentration μg/mL | Viability (%)/compound | ||||||
| 9 | 10 | 11a | 11b | 12 | 13 | 14 | |
| 500 | 8.43 | 8.32 | 23.84 | 10.32 | 4.29 | 4.83 | 3.74 |
| 250 | 15.82 | 16.01 | 48.67 | 19.47 | 11.82 | 12.56 | 8.91 |
| 125 | 24.67 | 23.65 | 72.89 | 27.93 | 20.49 | 19.74 | 14.82 |
| 62.5 | 30.93 | 29.86 | 90.31 | 38.76 | 26.54 | 28.63 | 20.94 |
| 31.25 | 41.28 | 37.40 | 98.16 | 50.37 | 32.75 | 35.16 | 25.86 |
| 15.6 | 48.71 | 46.89 | 100 | 68.24 | 41.87 | 46.29 | 31.43 |
| 7.8 | 62.39 | 58.62 | 100 | 81.49 | 55.46 | 57.18 | 37.82 |
| 3.9 | 78.24 | 73.94 | 100 | 90.65 | 73.82 | 70.42 | 45.27 |
| 2 | 88.65 | 81.47 | 100 | 97.34 | 81.46 | 83.29 | 50.94 |
| 1 | 94.27 | 89.53 | 100 | 100 | 88.73 | 89.64 | 62.35 |
| 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Organism | HIV seropositive cases(n = 144) | HIV seronegative subjects(n = 50) | P value (chi-square test) |
| C. parvum | 87 (60.42%) | 1 (2.00%) | 0.0001 |
| I. belli | 13 (9.03%) | 1 (2.00%) | 0.082 |
| Cyclospora spp. | 2 (1.39%) | 0 | — |
| Microsporidium spp. | 1 (0.69%) | 0 | — |
| E. histolytica | 7 (4.86%) | 1 (2.00%) | 0.343 |
| G. lamblia | 3 (2.08%) | 2 (4.00%) | 0.726 |
| A. lumbricoides | 5 (3.47%) | 1 (2.00%) | 0.514* |
| C. difficile | 26 (18.06%) | 3 (6.00%) | 0.040 |
| Diarrheagenic E. coli | 16 (11.11%) | 2 (4.00%) | 0.166* |
| Shigella spp. | 4 (2.78%) | 0 | — |
| C. albicans | 37 (25.69%) | 2 (4.00%) | 0.0001 |
| Univariate Analysis | Multivariate Analysis | |||||
| Variable | Hazard ratio | 95% C.I. | P | Hazard ratio | 95% C.I. | P |
| Age, years (continuous) | 1.01 | 0.96-1.06 | 0.78 | - | - | - |
| Gender (female [n = 12] vs male [n = 40]) | 0.48 | 0.11-2.10 | 0.33 | - | - | - |
| Stage (UICC II and higher [n = 32] vs. UICC I [n = 20]) | 3.72 | 1.07-12.98 | 0.04 | 2.00 | 0.42-9.09 | 0.39 |
| Grade (3+4 [n = 22] vs. 1+2 [n = 30]) | 1.43 | 0.55-3.71 | 0.46 | - | - | - |
| T category (T3/T4 [n = 8] vs. T1/T2 [n = 44]) | 2.48 | 0.80-7.68 | 0.11 | - | - | - |
| N category (. N+ [n = 28] vs N0 [n = 24]) | 3.27 | 1.06-10.02 | 0.04 | 2.04 | 0.51-8.33 | 0.32 |
| Number of metastatic lymph nodes (continuous) | 1.35 | 1.17-1.56 | <0.001 | - | - | - |
| TILs and macrophages in primary tumour site (high vs. low) | ||||||
| Hazard ratio | 95% C.I. | P | Hazard ratio | 95% C.I. | P | |
| Intraepithelial | ||||||
| CD3+ TIL | 0.76 | 0.29-1.98 | 0.58 | - | - | - |
| CD8+ TIL | 1.26 | 0.48-3.32 | 0.63 | - | - | - |
| CD20+ TIL | 2.05 | 0.79-5.32 | 0.14 | - | - | - |
| CD68+ TIM | 0.69 | 0.27-1.80 | 0.45 | - | - | - |
| FoxP3+ TIL | 0.78 | 0.30-2.03 | 0.61 | - | - | - |
| Granzyme B+ TIL | 0.72 | 0.21-2.53 | 0.61 | - | - | - |
| Stromal | - | - | - | |||
| CD3+ TIL | 0.86 | 0.33-2.23 | 0.76 | - | - | - |
| CD8+ TIL | 0.85 | 0.33-2.20 | 0.74 | - | - | - |
| CD20+ TIL | 0.80 | 0.31-2.08 | 0.65 | - | - | - |
| CD68+ TIM | 0.81 | 0.31-2.10 | 0.66 | - | - | - |
| FoxP3+ TIL | 0.23 | 0.08-0.72 | 0.01 | 0.25 | 0.08-0.78 | 0.016 |
| Granzyme B+ TIL | 0.87 | 0.33-2.29 | 0.78 | - | - | - |
| Ratio stromal CD68 (primary tumour)/stromal FoxP3 (primary tumour) | 4.02 | 1.31-12.36 | 0.02 | |||
| TIL and macrophages in metastatic tissue (high vs. low) | ||||||
| Intraepithelial | Hazard ratio | 95% C.I. | P | |||
| CD3+ TIL | 0.32 | 0.09-1.12 | 0.07 | |||
| CD8+ TIL | 1.14 | 0.35-3.76 | 0.83 | |||
| CD20+ TIL | 0.20 | 0.03-1.58 | 0.13 | |||
| CD68+ TIM | 0.96 | 0.29-3.16 | 0.95 | |||
| FoxP3+ TIL | 0.58 | 0.17-1.99 | 0.39 | |||
| Granzyme B+ TIL | 0.88 | 0.19-4.09 | 0.87 | |||
| Stromal | ||||||
| CD3+ TIL | 0.61 | 0.19-2.03 | 0.42 | |||
| CD8+ TIL | 1.16 | 0.35-3.81 | 0.81 | |||
| CD20+ TIL | 0.51 | 0.15-1.75 | 0.28 | |||
| CD68+ TIM | 1.30 | 0.40-4.28 | 0.66 | |||
| FoxP3+ TIL | 0.81 | 0.25-2.69 | 0.74 | |||
| Granzyme B+ TIL | 0.75 | 0.23-2.46 | 0.63 | |||
| Lymphocytes and macrophages in uninvolved regional lymph node (high vs. low) | ||||||
| Hazard ratio | 95% C.I. | P | ||||
| CD3+ | 0.47 | 0.17-1.26 | 0.13 | |||
| CD8+ | 0.84 | 0.32-2.19 | 0.72 | |||
| CD20+ | ||||||
| CD68+ | 0.56 | 0.21-1.47 | 0.24 | |||
| FoxP3+ | 1.03 | 0.40-2.68 | 0.95 | |||
| Granzyme B+ | 0.35 | 0.12-0.99 | 0.05 |
| Patient A | Patient B | Patient C | Patient D | Patient E | |||||||
| Parameters obtained from data | Hb (g dl−1) | 10.5 | 10.8 | 11.5 | 9.8 | 9 | |||||
| CO (l min−1) | 11.1 | 7.2 | 5.6 | 7.7 | 5.9 | ||||||
| FIO2 | 0.8 | 0.9 | 0.5 | 0.8 | 1 | ||||||
| Parameters obtained through optimization | VR (b min−1) | 12.25 | 12.14 | 16.04 | 17.68 | 17.0 | |||||
| IE | 0.28 | 0.25 | 0.38 | 0.38 | 0.43 | ||||||
| RQ | 0.6 | 0.6 | 0.9 | 0.7 | 0.61 | ||||||
| VO2 (ml min−1) | 294.3 | 300 | 200 | 257.2 | 246.8 | ||||||
| % of compartments collapsed | 26 | 29 | 12 | 20 | 21 | ||||||
| Parameters fixed for RM trials | Pv (cm H2O) | 15 | 15 | 15 | 15 | 15 | |||||
| PEEP (cm H2O) | 5 | 5 | 5 | 5 | 5 | ||||||
| Data | Model | Data | Model | Data | Model | Data | Model | Data | Model | ||
| Results of fitting the model to the data | PvO2 (mmHg) | 47.3 | 49.5 | 38.3 | 39.4 | 48 | 45.4 | 42.83 | 42.2 | 34.5 | 30.3 |
| PvCO2 (mmHg) | 44.4 | 46.2 | 55.5 | 54.4 | 47.6 | 49.9 | 51 | 48.8 | 33.82 | 36.07 | |
| Qs/Qt (%) | 28.6 | 31.8 | 31.7 | 33.9 | 22.6 | 19.4 | 32.3 | 31.4 | 43.1 | 39.14 | |
| PaO2 (mmHg) | 153.7 | 149.9 | 85.5 | 87.9 | 130.5 | 129.6 | 110.3 | 109.6 | 64.5 | 64.95 |
| Non-nosocomial (n = 352) | Nosocomial (n = 25) | P value | |
| Median week from admission | 3 (2–4) | ||
| Male (%) | 65·9 (230/349) | 60·0 (15/25) | 0·664 |
| Age (weeks, median) | 16·2 (8·8–43·5) | 9·0 (6·5–14·7) | 0·001 |
| Preterm birth (<37 weeks) | 26·8 (94/351) | 44 (11/25) | 0·103 |
| Birthweight (kg) | 2·7 (2·2–3·0) | 2·5 (2·2–3·1) | 0·113 |
| Previous hospitalization (%) | 40·2 (140/348) | 56 (14/25) | 0·143 |
| Within previous 14 days (%) | 28·1 (99/352) | 40 (10/25) | 0·370 |
| Transfer from other ward (%) | 46·9 (165/352) | 60·0 (15/25) | 0·220 |
| Pre-existing illness (%) | 34·8 (122/351) | 32 (8/25) | 0·832 |
| Duration of hospitalization (days) | 7·0 (5·0–13·0) | 21·0 (12·0–30·0) | 0·000 |
| Outcome other than full recovery (%) | 16·8 (59/352) | 52·0 (13/25) | 0·000 |
| Deaths | 2·6 (9/352) | 16·0 (4/25) | 0·007 |
| Laboratory tests | |||
| Hemoglobin (g/dl) | 10·7 (9·8–11·5) | 10·3 (9·2–11·5) | 0·318 |
| Hematocrit (%) | 32·3 (30·1–35·3) | 30·8 (27·4–33·5) | 0·071 |
| Leukocytes (×1000/μl) | 14·0 (10·7–17·1) | 13·0 (9·6–16·4) | 0·313 |
| Neutrophils (%) | 49·5 (31·9–61·2) | 32·0 (26·0–44·8) | 0·001 |
| Lymphocytes (%) | 39·7 (28·1–56·1) | 53·7 (45·7–65·2) | 0·002 |
| Platelets (×1000/μl) | 311·0 (210·0–425·0) | 268·0 (185·5–412·0) | 0·230 |
| Recall | Precision | F-score | |
| Any | 79.46 | 78.45 | 78.95 |
| Unrelated | 60.26 | 70.59 | 65.02 |
| Altered expression | 77.96 | 79.90 | 78.91 |
| Genetic variation | 77.76 | 82.45 | 80.04 |
| Regulatory modification | 69.17 | 73.28 | 71.16 |
| Overall | 76.61 | 79.46 | 78.00 |
| All patients | PiCCO | PAC | p value | |
| Mean daily FB (ml/day) | 490 (-216, 1,259) | 659 (-128, 1,403) | 350 (-573, 1,064) | 0.017 |
| MV days | 5 (2, 10) | 6 (2, 10) | 4 (2, 10) | 0.44 |
| MV-free days in 28 days | 15 (0, 24) | 12 (0, 23) | 21 (0, 25) | 0.045 |
| ICU days | 6 (3, 14) | 7 (3, 13) | 6 (3, 14) | 0.58 |
| ICU-free days in 28 days | 11 (0, 22) | 5 (0, 21) | 14 (0, 22) | 0.15 |
| Hospital days | 19 (9, 38) | 20 (9, 45) | 17 (8, 33) | 0.15 |
| ICU mortality | 34.7% | 38.5% | 30.0% | 0.11 |
| Hospital mortality | 42.0% | 45.8% | 36.9% | 0.12 |
| Elderly patients | Non-elderly patients | p value | |
| Patients (n) | 157 (32.6%) | 325 (67.4%) | |
| Age (years), mean (range) | 79.3 (75–90) | 63.9 (27–74) | |
| Sex, male/female | 92/65 | 197/128 | 0.67 |
| Lesion (n) | 164 (32.7%) | 337 (67.3%) | |
| Tumor location (n) | |||
| Cecum and colon | 112 (68.3%) | 227 (67.4%) | 0.83 |
| Rectum | 52 (31.7%) | 131 (32.6%) | |
| Tumor size | |||
| Long axis (mm), mean ± SD | 37.0 ± 16.5 | 35.2 ± 15.9 | 0.26 |
| Short axis (mm), mean ± SD | 29.7 ± 15.4 | 27.7 ± 13.6 | 0.23 |
| Morphology (n) | |||
| LST-G | 93 (56.7%) | 173 (51.3%) | 0.68 |
| LST-NG | 55 (33.5%) | 122 (36.2%) | |
| Protruded | 14 (8.5%) | 34 (10.1%) | |
| Depressed | 0 (0.0%) | 2 (0.6%) | |
| Residual/local recurrence | 2 (1.2%) | 6 (1.8%) | |
| Histological classification (n) | |||
| Adenoma | 52 (31.7%) | 131 (38.9%) | 0.47 |
| Intramucosal cancer | 89 (54.3%) | 164 (48.7%) | |
| SM superficial cancer | 11 (6.7%) | 20 (5.9%) | |
| SM deep cancer | 11 (6.7%) | 19 (5.6%) | |
| Others | 0 (0.0%) | 2 (0.6%) | |
| Failure of retrieval | 1 (0.6%) | 1 (0.3%) |
| Key words | Other variations of key words | |
| NCDs metabolic risk factors plus proximal determinants plus distal determinants plus geographic location | NCDs metabolic risk factors | High blood pressure, hypertension, high blood glucose, hyperglycemia, diabetes, high BMI, obesity, overweight, waist circumference, waist-hip ratio |
| Proximal determinants | Determinants, risk, diet, salt intake, tobacco, smoking, alcohol, physical inactivity, lifestyle | |
| Distal determinants | Social determinants, education, income, gender, race, caste, ethnicity, socio-economic status, wealth index, income | |
| South Asia | Nepal, India, Bangladesh, Pakistan, Sri Lanka, Bhutan, Maldives, Afghanistan |
| Characteristics | Prevalence (%) of PN (n = 300) | Univariate models | Multivariate models | |||
| Odds ratio (OR) (95% CI) | p-value | Adjusted odds ratio (aOR) (95% CI) | p-value | |||
| Age | 42 (±9.2) | 1.1 (1.0, 1.1) | <0.001 | 1.1 (1.0, 1.1) | <0.001* | |
| Gender | Female | 210 (57) | 1.0 (ref) | 0.25 | ||
| Male | 87 (63) | 1.3 (0.8, 1.9) | ||||
| Education | None | 73 (65) | 1.0 (ref) | 1.0 (ref) | ||
| Primary | 128 (51) | 0.6 (0.4, 0.9) | 0.01 | 0.6 (0.3, 1.0) | 0.04* | |
| > = Secondary | 99 (69) | 1.2 (0.7, 2.0) | 0.55 | 0.6 (0.3, 1.3) | 0.2 | |
| Occupation | Public employed | 29 (69) | 1.0 (ref) | 1.0 (ref) | ||
| Peasant/Farmer | 106 (47) | 0.4 (0.2, 0.8) | 0.01 | 0.9 (0.3, 2.2) | 0.76 | |
| Self employed | 56 (63) | 0.8 (0.3, 1.7) | 0.5 | 0.3 (0.1, 0.9) | 0.03 | |
| Unemployed | 109 (72) | 1.1 (0.5, 2.4) | 0.74 | 0.6 (0.2, 1.4) | 0.22 | |
| Marital status | Single | 18 (51) | 1.0 (ref) | |||
| Married | 112 (48) | 0.9 (0.4, 1.8) | 0.75 | |||
| Divorced/Separated | 63 (78) | 3.3 (1., 4) | <0.01 | |||
| Window/Widower | 107 (66) | 1. 9 (0.9, 4.) | 0.09 | |||
| Setting/Residence | Urban | 200 (78) | 1.0 (ref) | 1.0 (ref) | ||
| Rural | 99 (40) | 0.2 (0.1, 0.3) | <0.001 | 0.1 (0.06, 0.3) | <0.001* | |
| CD4 cell count | <=350 | 91 (49) | 1.0 (ref) | |||
| >350 | 209 (59) | 1.0 (0.7, 1.5) | 1.008 | |||
| Duration since HIV diagnosis | 0 – 3 years ago | 84 (54) | 1.0 (ref) | 1.0 (ref) | ||
| 4 – 6 years ago | 96 (51) | 0.9 (0.6, 1.4) | 0.60 | 0.6 (0.3,1.1) | 0.08 | |
| 7 and above yrs | 120 (73) | 2.3 (1.5, 3.7) | <0.001 | 1.4 (0.7, 3.0) | 0.33 | |
| Current ARV regimen | Non D4T containing | 247 (61) | 1.0 (ref) | |||
| D4T containing | 53 (51) | 1.0 (0.4, 1.0) | 0.06 | |||
| Duration on ARVs (in years) | 0 – 1 | 52 (42) | 1.0 (ref) | 1.0 (ref) | ||
| 1 – 3 | 101 (64) | 2.4 (1.5, 3.8) | <0.001 | 2.6 (1.4, 4.8) | 0.001 | |
| 4 – 6 | 108 (64) | 2.4 (1.5, 3.9) | <0.001 | 2.0 (10, 4.1) | 0.05 | |
| 7 and above | 39 (70) | 3.1 (1.6, 6.1) | 0.001 | 2.2 (0.8, 5.9) | 0.1 | |
| ARV regimen changes | None | 48 (57) | 1.0 (ref) | |||
| Once | 150 (56) | 0.9 (0.6, 1.5) | 0.80 | |||
| Two and more | 92 (68) | 1.6 (1.0, 2.8) | 0.08 | |||
| ARV started with | Non D4T containing | 104 (63) | 1.0 (ref) | |||
| D4T containing | 196 (57) | 0.8 (0.6, 1.2) | 0.27 |
| Training set | Development set | Test set | Entire corpus | |
| Abstracts | 3,500 | 3,500 | 3,000 | 10,000 |
| Nr. characters | 4,883,753 | 4,864,558 | 4,199,068 | 13,947,379 |
| Nr. tokens | 770,855 | 766,331 | 662,571 | 2,199,757 |
| Abstracts with SACEM | 2,916 | 2,907 | 2,478 | 8,301 |
| Nr. mentions | 29,478 | 29,526 | 25,351 | 84,355 |
| Nr. chemicals | 8,520 | 8,677 | 7,563 | 19,805 |
| Nr. journals | 193 | 188 | 188 | 203 |
| TRIVIAL | 8,832 | 8,970 | 7,808 | 25,610 |
| SYSTEMATIC | 6,656 | 6,816 | 5,666 | 19,138 |
| ABBREVIATION | 4,538 | 4,521 | 4059 | 13,118 |
| FORMULA | 4,448 | 4,137 | 3,443 | 12,028 |
| FAMILY | 4,090 | 4,223 | 3,622 | 11,935 |
| IDENTIFIER | 672 | 639 | 513 | 1,824 |
| MULTIPLE | 202 | 188 | 199 | 589 |
| NO CLASS | 40 | 32 | 41 | 113 |
| FeNO | CalvNO | nNO | |
| Asthma | Normal/increased | Normal/increased | Normal/increased |
| COPD | Normal/increased | Increased | NS |
| CF | Normal/decreased | Contradictory results | Decreased |
| PCD | Normal/decreased | Contradictory results | Decreased |
| Allergic rhinitis | Normal/increased | Normal | NS |
| BPD | Normal/decreased | Decreased | NS |
| HPS | Decreased | Increased | NS |
| PAH | Decreased | Increased | NS |
| SSc | Normal/decreased | Increased | NS |
| Rhinovirus infection | Increased | NS | NS |
| Allograft rejection | Increased | NS | NS |
| Allele | DYS635 | DYS456 | DYS458 | DYS391 | DYS392 | DYS390 | DYS393 | DYS438 | DYS385a,b | |||
| 8 | 0.0185 | 10,12 | 0.0093 | 13,17 | 0.0093 | |||||||
| 9 | 0.0185 | 10,17 | 0.0185 | 13,18 | 0.0926 | |||||||
| 10 | 0.7407 | 0.0093 | 0.7593 | 11,11 | 0.0370 | 13,19 | 0.0278 | |||||
| 11 | 0.2315 | 0.1481 | 0.2130 | 11,12 | 0.0278 | 13,20 | 0.0093 | |||||
| 12 | 0.0093 | 0.1481 | 0.5556 | 0.0093 | 11,13 | 0.0093 | 13,21 | 0.0278 | ||||
| 13 | 0.0093 | 0.0093 | 0.3519 | 0.2593 | 11,16 | 0.0185 | 13,26 | 0.0093 | ||||
| 14 | 0.2685 | 0.0185 | 0.2685 | 0.1111 | 11,17 | 0.0370 | 14,17 | 0.0185 | ||||
| 15 | 0.4815 | 0.1296 | 0.0741 | 0.0741 | 11,18 | 0.0093 | 14,18 | 0.0185 | ||||
| 15 | 0.0093 | 11,19 | 0.0370 | 14,19 | 0.0093 | |||||||
| 16 | 0.1574 | 0.1852 | 12,12 | 0.0370 | 14,21 | 0.0093 | ||||||
| 17 | 0.0741 | 0.2778 | 12,14 | 0.0093 | 14,22 | 0.0093 | ||||||
| 18 | 0.0093 | 0.2222 | 12,15 | 0.0093 | 15,17 | 0.0093 | ||||||
| 19 | 0.1389 | 0.1111 | 12,16 | 0.0741 | 15,19 | 0.0093 | ||||||
| 20 | 0.2778 | 0.0185 | 0.0093 | 12,17 | 0.0185 | 15,20 | 0.0093 | |||||
| 21 | 0.2778 | 0.0093 | 12,19 | 0.0926 | 15,22 | 0.0093 | ||||||
| 22 | 0.2037 | 0.0093 | 0.0093 | 12,20 | 0.0741 | 18,19 | 0.0093 | |||||
| 23 | 0.0556 | 0.5093 | 13,13 | 0.1204 | ||||||||
| 24 | 0.0370 | 0.2407 | 13,14 | 0.0370 | ||||||||
| 25 | 0.0093 | 0.2222 | 13,15 | 0.0093 | ||||||||
| 26 | 0.0093 | 13,16 | 0.0278 | |||||||||
| GD | 0.7876 | 0.6719 | 0.8165 | 0.4010 | 0.7617 | 0.6390 | 0.6120 | 0.3813 | 0.9983 |
| KEGGID | Pvalue | Count | Size | Term |
| 4530 | 0.011 | 3 | 11 | Tight junction |
| 533 | 0.046 | 1 | 1 | Keratan sulfate biosynthesis |
| 604 | 0.046 | 1 | 1 | Glycosphingolipid biosynthesis - ganglio series |
| 1031 | 0.047 | 2 | 8 | Glycan structures - biosynthesis 2 |
| 4620 | 0.047 | 2 | 8 | Toll-like receptor signaling pathway |
| 51 | 0.059 | 2 | 9 | Fructose and mannose metabolism |
| 4210 | 0.059 | 2 | 9 | Apoptosis |
| 3010 | 0.064 | 3 | 21 | Ribosome |
| 52 | 0.089 | 1 | 2 | Galactose metabolism |
| 512 | 0.089 | 1 | 2 | O-Glycan biosynthesis |
| 720 | 0.089 | 1 | 2 | Reductive carboxylate cycle (CO2 fixation) |
| 5213 | 0.089 | 1 | 2 | Endometrial cancer |
| 5218 | 0.089 | 1 | 2 | Melanoma |
| 5223 | 0.089 | 1 | 2 | Non-small cell lung cancer |
| Gene | Abbreviation | Teleost accession number | Transcript in the greater amberjack | In silico group | DE* male vs female gonads | Sex determining in |
| DM domain gene on the Y chromosome/ doublesex and mab-3-related transcription factor 1a | dmY/dmrt1a | Oryzias latipes NM_0 011 04680/ XM_004086451 unplaced scaffold | maker-jcf7180000931253-snap-gene-0.40-mRNA-1 | SD7 | Up in male gonads | Oryzias latipes [23, 65] |
| Gonadal soma-derived factor | gsdf | Oryzias latipes NM_0 011 77742 chr.12 | Augustus-masked-jcf7180000916295-processed-gene-0.7-mRNA-1 | SD17 | Up in male gonads | Oryzias luzonensis [66] |
| Y chromosome–specific antimuellerian hormone | amhY | Oryzias latipes NM_0 011 04728 chr. 4 | maker-jcf7180000931145-snap-gene-0.73-mRNA-2 | SD4 | Up in male gonads | Odontesthes hatcheri [67] HM153803.1 |
| Antimuellerian hormone receptor 2 | amhr2 | Lates calcarifer KR492510 Oryzias latipes DQ499644.1 chr. 5 or 7 | maker-jcf7180000889430-snap-gene-0.77-mRNA-5 | SD1 | No expression | Takifugu genus [68] |
| Sexually dimorphic o the Y chromosome | sdY | Salmonidae family | n/a | n/a | n/a | Salmonidae family [69] |
| SRY-box containing protein 3Y | sox3Y | Oryzias latipes AJ245396 chr.10 | augustus-masked-jcf7180000920392-processed-gene-0.31-mRNA-1 | SD18 | Up in female gonads | Oryzias dancena [65] |
| Number of women (percentage) | 357 | (92%) |
| Median years of age (IQR) | 52 | (8) |
| Median years of age diagnosed with a pain disorder (IQR)a | 30 | (18) |
| Median PPI (IQR) | 4 | (3) |
| Median number of comorbid pain conditions (IQR) | 3 | (2) |
| Median number of current pain medications (IQR) | 3 | (3) |
| Median number of past pain medications (IQR) | 6 | (7) |
| Nurses | Controls | ||
| N | 32 | 30 | |
| Age (in years) | 40.3 (11.3) | 40.0 (12.3) | |
| Sex (male/female) | 7/25 | 3/27 | |
| Education | lower secondary school (Hauptschule) | 7 | 4 |
| Intermediate secondary school (Realschule) | 18 | 22 | |
| Higher education entrance qualification (Abitur) (finished or enrolled) | 5 | 4 | |
| University degree | 2 | 0 |
| Dependent variable | Fivefolded cross-validated R2 (%) | Effect size, f2 |
| MUSICIANS ONLY | ||
| Judgment line orientation | 15 | 0.18 |
| Letter-number sequencing | 14 | 0.16 |
| Tower rule violations | 0 | 0.00 |
| Letter fluency | 0 | 0.00 |
| CVLT-II SDFR | 0 | 0.00 |
| Grooved pegboard – dominant hand | 29 | 0.21 |
| Grooved pegboard – non-dominant hand | 28 | 0.20 |
| PT number | Global | For strengthening exercises | For stretching exercises |
| 1 | 0.74 (0.58–0.84) | 0.68 (0.38–0.84) | 0.78 (0.57–0.91) |
| 2 | 0.72 (0.57–0.81) | 0.71 (0.43–0.84) | 0.68 (0.46–0.81) |
| 3 | 0.86 (0.76–0.92) | 0.79 (0.57–0.91) | 0.92 (0.86–0.95) |
| 4 | 0.82 (0.73–0.89) | 0.81 (0.71–0.87) | 0.84 (0.67–0.96) |
| 5 | 0.86 (0.73–0.93) | 0.82 (0.48–0.94) | 0.88 (0.73–0.94) |
| 6 | 0.88 (0.79–0.94) | 0.82 (0.56–0.92) | 0.96 (0.91–0.98) |
| Year | |||||
| Variable | 2010 | 2011 | 2012 | 2013 | Total |
| N (%) | N (%) | N (%) | N (%) | N (%) | |
| Sex | |||||
| Female | 41(45) | 26(50) | 83(36.4) | 131(41.8) | 281(41.1) |
| Male | 50(55) | 26(50) | 145 (63.6) | 182(58.2) | 403(58.9) |
| Total | 91(100) | 52(100) | 228 (100) | 313(100) | 684(100) |
| Age (Months) | |||||
| 0–5 | 20(22) | 13 (25) | 66(29) | 82(26) | 181(26) |
| 6–11 | 28(31) | 16(31) | 74(32) | 112(36) | 230(34) |
| 12–17 | 19(21) | 11(21) | 49(21) | 57(18) | 136(20) |
| 18–23 | 12(13) | 7(13) | 18(8) | 31(10) | 68(10) |
| > 24 | 12(13) | 5(10) | 21(10) | 31(10) | 69(10) |
| Total | 91(100) | 52(100) | 228(100) | 313(100) | 684(100) |
| EIA Result | |||||
| Positive | 15(16.4) | 18(34.6) | 59(25.9) | 94(30) | 186(27.1) |
| Negative | 76(83.6) | 34(65.4) | 169(74.1) | 219(70) | 498(72.9) |
| Total | 91(100) | 52(100) | 228(100) | 313(100) | 684(100) |
| Welding Positions | No. of Butt Welds | Laser Beam Power, W | Traveling Speed, m/min | Heat Input, kJ/m |
| Vertical up | U01 | 2200 | 0.5 | 275 |
| U02 | 2500 | 1.2 | 125 | |
| Vertical down | D01 | 2200 | 0.5 | 275 |
| D02 | 2500 | 1.2 | 125 |
| Organs | n | Elks up to 2 years | n | Elks older than 3 years | |||
| Mean ± SD | Median | Mean ± SD | Median | ||||
| Cu | Liver | 8 | 18.61 ± 18.63 | 7.02 | 27 | 24.45 ± 30.03 | 10.77 |
| Kidney | 8 | 4.51 ± 2.43 | 3.72 | 27 | 5.13 ± 5.73 | 4.01 | |
| Muscle | 8 | 2.68 ± 0.57 | 2.44 | 27 | 2.28 ± 0.49 | 2.31 | |
| Mo | Liver | 8 | 0.75 ± 0.42 | 0.79 | 27 | 0.97 ± 0.48 | 1.00 |
| Kidney | 8 | 0.25 ± 0.33 | 0.12 | 27 | 0.46 ± 0.67 | 0.35 | |
| Muscle | 8 | 0.07 ± 0.06 | 0.05 | 27 | 0.047 ± 0.02 | 0.05 |
| Voyage | ||||||
| 1 | 2 | 3 | ||||
| Measure | Mean | SD | Mean | SD | Mean | SD |
| Indoor cabin temp (°C) | 20.97 | 1.1 | 20.83 | 0.9 | 21.05 | 1.7 |
| Outdoor temp (°C) | 6.19 | 3.4 | 6.13 | 2.1 | 6.10 | 1.9 |
| Expedition length (h) | 3.29 | 0.7 | 3.12 | 0.8 | 3.08 | 0.7 |
| Wind velocity (km/h) | 26.36 | 13.3 | 12.73 | 7.9 | 18.52 | 13.0 |
| Wind chill (°C) | 1.92 | 5.55 | 3.50 | 3.08 | 2.63 | 0.94 |
| Category | Term | Count | P-value | Benjamini |
| KEGG_PATHWAY | Cytokine-cytokine receptor interaction | 24 | 9.00E-07 | 1.30E-04 |
| GOTERM_BP_FAT | Immune response | 18 | 1.90E-03 | 2.50E-01 |
| GOTERM_CC_FAT | Extracellular region part | 15 | 1.60E-02 | 6.30E-01 |
| GOTERM_MF_FAT | Cytokine activity | 14 | 1.80E-03 | 1.90E-01 |
| GOTERM_CC_FAT | Extracellular space | 14 | 2.10E-02 | 4.90E-01 |
| KEGG_PATHWAY | Natural killer cell mediated cytotoxicity | 13 | 8.10E-04 | 5.50E-02 |
| KEGG_PATHWAY | Chemokine signaling pathway | 13 | 3.20E-02 | 2.90E-01 |
| GOTERM_BP_FAT | Defense response | 12 | 1.40E-02 | 4.60E-01 |
| KEGG_PATHWAY | Jak-STAT signaling pathway | 12 | 1.80E-02 | 2.00E-01 |
| KEGG_PATHWAY | T cell receptor signaling pathway | 10 | 1.50E-02 | 2.10E-01 |
| KEGG_PATHWAY | Hematopoietic cell lineage | 9 | 1.10E-02 | 1.80E-01 |
| KEGG_PATHWAY | Toll-like receptor signaling pathway | 9 | 2.30E-02 | 2.40E-01 |
| KEGG_PATHWAY | NOD-like receptor signaling pathway | 8 | 5.50E-03 | 1.40E-01 |
| KEGG_PATHWAY | Allograft rejection | 8 | 7.40E-03 | 1.60E-01 |
| GOTERM_BP_FAT | Response to wounding | 8 | 1.30E-02 | 5.10E-01 |
| KEGG_PATHWAY | Fc epsilon RI signaling pathway | 8 | 1.70E-02 | 2.10E-01 |
| KEGG_PATHWAY | Asthma | 7 | 2.00E-03 | 6.80E-02 |
| GOTERM_BP_FAT | Inflammatory response | 7 | 7.90E-03 | 3.90E-01 |
| KEGG_PATHWAY | Cytosolic DNA-sensing pathway | 7 | 8.20E-03 | 1.50E-01 |
| KEGG_PATHWAY | Autoimmune thyroid disease | 7 | 5.70E-02 | 4.20E-01 |
| GOTERM_BP_FAT | Chemotaxis | 6 | 1.40E-02 | 4.20E-01 |
| GOTERM_MF_FAT | Cytokine binding | 6 | 3.40E-02 | 8.60E-01 |
| GOTERM_BP_FAT | Locomotors behavior | 6 | 3.40E-02 | 7.10E-01 |
| KEGG_PATHWAY | Graft-versus-host disease | 6 | 4.30E-02 | 3.60E-01 |
| INTERPRO | Immunoglobulin | 6 | 4.50E-02 | 9.00E-01 |
| KEGG_PATHWAY | Type I diabetes mellitus | 6 | 6.90E-02 | 4.70E-01 |
| GOTERM_BP_FAT | Behavior | 6 | 7.90E-02 | 9.20E-01 |
| GOTERM_BP_FAT | Cell migration | 5 | 1.80E-03 | 4.30E-01 |
| GOTERM_BP_FAT | Cell motility | 5 | 3.30E-03 | 2.90E-01 |
| INTERPRO | Small chemokine, C-C group, conserved site | 5 | 5.50E-02 | 8.80E-01 |
| GOTERM_BP_FAT | Leukocyte migration | 4 | 6.40E-03 | 4.00E-01 |
| INTERPRO | Chemokine receptor | 4 | 6.40E-02 | 8.70E-01 |
| GOTERM_MF_FAT | C-C chemokine receptor activity | 4 | 7.20E-02 | 9.40E-01 |
| GOTERM_MF_FAT | C-C chemokine binding | 4 | 7.20E-02 | 9.40E-01 |
| GOTERM_MF_FAT | Chemokine receptor activity | 4 | 9.50E-02 | 9.40E-01 |
| Time (min) | % Eluent A (0.1% TFA in dH2O) | % Eluent B (MeOH) | Flow Rate (mL/min) |
| 0 | 15 | 85 | 1.5 |
| 6 | 0 | 100 | 1.5 |
| 25 | 0 | 100 | 1.5 |
| 26 | 15 | 85 | 1.5 |
| 35 | 15 | 85 | 1.5 |
| Variable | PCS | MCS | KDCS | ||||
| Score | p-value | Score | p-value | Score | p-value | ||
| Age | <45 years (n = 11) | 49.8 | 0.89 | 58.3 | 0.55 | 62.9 | 0.08 |
| >45 years (n = 11) | 51.1 | 64.4 | 72.9 | ||||
| Sex | Male (n = 13) | 54.1 | 0.38 | 64.0 | 0.52 | 68.1 | 0.93 |
| Female (n = 9) | 45.2 | 57.4 | 67.6 | ||||
| Marital status | Married (n = 12) | 56.2 | 0.20 | 68.3 | 0.12 | 70.9 | 0.25 |
| Not married (n = 10) | 43.6 | 52.9 | 64.3 | ||||
| Education status | Secondary or below (n = 9) | 47.1 | 0.58 | 63.4 | 0.73 | 65.5 | 0.52 |
| Above secondary (n = 13) | 52.8 | 60.0 | 69.4 | ||||
| Employment status | Employed (n = 11) | 51.9 | 0.78 | 66.6 | 0.29 | 70.4 | 0.39 |
| Unemployed (n = 11) | 49.0 | 56.0 | 65.4 | ||||
| Dialysis vintage | <12 months (n = 10) | 49.1 | 0.81 | 62.6 | 0.82 | 70.2 | 0.39 |
| >12 months (n = 12) | 51.6 | 60.3 | 66.0 | ||||
| Yearly total household income | <$4000 (n = 16) | 43.3 | 0.30 | 51.2 | 0.04 | 67.8 | 0.99 |
| >$4000 (n = 6) | 56.1 | 75.2 | 67.9 |
| Characteristics | OCP-patch (N = 30) | LTS-2 patch (N = 30) | ||
| Definition of reaction | At 24 h | At 30 h | At 24 h | At 30 h |
| None | 3 (10.0) | 2 (6.7) | 5 (16.7) | 0 |
| Oedema under the patch (any score) | NA | NA | 25 (83.3) | 30 (100) |
| 100 % of area oedematous (score 3) | NA | NA | 17 (56.7) | 27 (90.0) |
| > 50 % of area oedematous (score 2) | NA | NA | 4 (13.3) | 3 (10.0) |
| < 50 % of area oedematous (score 1) | NA | NA | 4 (13.3) | 0 |
| 0 % of area oedematous (score 0) | NA | NA | 5 (15.7) | 0 |
| All reactions | 27 (90.0) | 28 (93.3) | 25 (83.3) | 30 (100) |
| Very easily visible reaction | 18 (60.0) | 24 (80.0) | 22 (73. | 19 (63.3) |
| Easily visible reaction | 2 (6.7) | 3 (10.0) | 0 | 1 (3.3) |
| Attentive visual inspection required | 7 (23.3) | 1 (3.3) | 3 (10.0) | 10 (33.3) |
| Character of papules | ||||
| None | 3 (10.0) | 2 (6.7) | 5 (16.7) | 0 |
| Vague | 4 (13.3) | 1 (3.3) | 3 (10.0) | 0 |
| Pinheads | 16 (53.3) | 16 (53.3) | 0 | 0 |
| Pinpoints | 7 (23.3) | 11 (36.7) | 19 (63.3) | 29 (96.7) |
| Urticariform | 0 | 0 | 3 (10.0) | 1 (3.3) |
| Extension beyond patch area | 2 (6.7) | 8 (26.7) | 0 | 0 |
| Studies | Reported outcomes | Follow up period | Bias grade |
| Brar2008 | Death, MI | 9.7 months | - |
| I-LOVE IT 2 | NACCE, death, MI, stroke, TVR, TLR, ST, all bleeding, major bleeding | 12 and 18 months | B |
| ISAR-SAFE | Primary endpoints, death, MI, ST, stroke, TIMI major and minor bleeding, BARC bleeding | 9 months | B |
| Tarantini2016 | Death, MI, composite endpoints, stent thrombosis, BARC type 3 or 5 bleeding, stroke, revascularization | 1 year | - |
| ARCTIC | Primary endpoints, Death, MI, ST, stroke, revascularization | 17 months | B |
| OPTIMIZE | NACCE, death, MI, stroke, ST, major bleeding, TLR, TVR, any bleeding | 1 year | B |
| RESET | Primary endpoints, death, MI, TVR, ST, major and minor bleeding, stroke | 1 year | B |
| EXCELLENT | Death, MI, stroke, TVR, TLR, ST, any bleeding, TIMI major bleeding | 1 year | B |
| PEGASUS | Death, MI, stroke, TIMI major and minor bleeding | 3 years | B |
| DAPT | ST, MACCEs, death, stroke, MI, BARC type 2,3 or 5 | 12 to 30 months | B |
| Sardella2011 | Death, MI, stroke, TIMI minor bleeding, revascularization | 2 years | - |
| PRODIGY | Death, MI, stroke, ST, TLR, TVR, TIMI major and minor bleeding, BARC bleeding | 2 years | B |
| Thukkani2015 | Death, MI, Stroke | 4 years | - |
| ENDEAVOR | Death, MI, ST (definite and probable), stroke, major bleeding | 2 years | B |
| ITALIC | Primary endpoints, minor bleeding, minimal bleeding, death, MI, stroke, TVR, ST, major bleeding | 1 year | B |
| Variable | Univariate | Multivariate | Covariate height | Covariate gender | ||||
| B (95% CI) | P value | B (95% CI) | P value | B (95% CI) | P value | B (95% CI) | P value | |
| Age | -0.07 (-0.2; 0.1) | 0.417 | 0.06 (-0.1; 0.2) | 0.369 | -0.08 (-0.2; 0.06) | 0.258 | ||
| Gender | 6.93 (4.8; 9.0) | <0.001 | 4.24 (-0.8; 9.3) | 0.098 | 3.33 (0.9; 5.7) | 0.006 | ||
| BMI | -0.14 (-0.4; 0.1) | 0.258 | -0.05 (-0.2; 0.1) | 0.560 | -0.06 (-0.2; 0.1) | 0.549 | ||
| Waist-to-hip ratio | 19.8 (5.9; 33.7) | 0.006 | -6.32 (-20.4; 7.7) | 0.373 | 4.72 (-6.7; 16.1) | 0.412 | -9.5 (-24.7; 5.9) | 0.222 |
| Waist circumference | 0.04 (-0.06; 0.1) | 0.391 | 0.003 (-0.1; 0.1) | 0.932 | -0.02 (-0.1; 0.06) | 0.682 | ||
| Fat percentage | -0.29 (-0.4; -0.2) | <0.001 | 0.01 (-0.3; 0.3) | 0.943 | -0.13 (-0.3; -0.1) | 0.024 | 0.02 (-0.2; 0.2) | 0.824 |
| Height | 0.41 (0.3; 0.5) | <0.001 | 0.31 (0.2; 0.4) | <0.001 | 0.29 (0.2; 0.4) | <0.001 | ||
| Weight | 0.08 (0.01; 0.2) | 0.023 | -0.02 (-0.1; 0.1) | 0.773 | -0.02 (-0.1; 0.1) | 0.475 | 0.04 (-0.02; 0.1) | 0.207 |
| KL score | 0.28 (-0.9; 1.5) | 0.648 | -0.29 (-1.2; 0.6) | 0.523 | -0.5 (-1.5; 0.5) | 0.291 |
| User-initiated (n = 17) | Not user-initiated (n = 3) | |
| User investigator | 14 | – |
| External user involved since formulation | 2 | 1 |
| External user involved only in interpretation | 1 | 2 |
| Sole C sourcea | Glucosinolate decomposition in horseradish extract Residual amount after 16d (%)b | Decomposition rate in horseradish extract(mM d-1) | IC50 liquid culture(mM) | ||||||||
| ID | SGN | SGN | GIB | GLN | GBR | SGN | GIB | GLN | GBR | AITC | PEITC |
| E1 | + | 0.2 ± 0% | 3.7 ± 0.9% | 0 ± 0% | 17 ± 3.1% | 1.125 | 0.006 | 0.057 | 0.005 | 0.2834 | 0.0903 |
| E2 | + | 0.3 ± 0% | 25.6 ± 1.9% | 0.4 ± 0.1% | 28.1 ± 1.6% | 1.476 | 0.002 | 0.033 | 0.004 | 0.2590 | 0.1004 |
| E3 | + | 3.6 ± 0.8% | 7.4 ± 0.9% | 0.5 ± 0.2% | 6.5 ± 1% | 0.606 | 0.003 | 0.030 | 0.008 | 0.1925 | 0.0907 |
| E4 | + | 0.3 ± 0% | 36.3 ± 12.2% | 0.4 ± 0.3% | 33.9 ± 11.7% | 0.734 | 0.003 | 0.036 | 0.006 | 0.1096 | 0.0288 |
| E5 | 16 ± 18.9% | 85 ± 10.3% | 50.5 ± 14.8% | 71.6 ± 8.1% | 0.624 | 0.001 | 0.018 | 0.003 | 0.0920 | 0.0404 | |
| E6 | 0.2 ± 0.1% | 42.5 ± 6.1% | 3.3 ± 1.4% | 26.6 ± 4.6% | 0.783 | 0.001 | 0.032 | 0.006 | 0.0764 | 0.0328 | |
| E7 | 110.9 ± 4.9% | 103.5 ± 4.4% | 108.1 ± 2.3% | 92.5 ± 10.1% | - | - | - | - | 0.2565 | 0.0257 | |
| S1 | + | 0.1 ± 0% | 5.1 ± 0.2% | 0 ± 0% | 65.3 ± 3.7% | 3.037 | 0.007 | 0.214 | 0.008 | 0.1084 | 0.1511 |
| S2 | + | 0.1 ± 0% | 0 ± 0% | 0 ± 0% | 0 ± 0% | 2.111 | 0.015 | 0.148 | 0.030 | 0.0743 | 0.0266 |
| S3 | + | 85.2 ± 4.9% | 75 ± 1.9% | 74.8 ± 0.6% | 83.9 ± 1% | - | - | - | - | 0.2639 | 0.0700 |
| S4 | 58.7 ± 5.7% | 72 ± 5% | 33.4 ± 5.7% | 47.3 ± 4.7% | - | - | - | - | 0.0338 | 0.0246 | |
| S5 | 87.5 ± 18.2% | 101.4 ± 4.6% | 106.7 ± 3.8% | 98.7 ± 2% | - | - | - | - | 0.1251 | 0.0176 | |
| S6 | 67.3 ± 12.1% | 61.8 ± 9.4% | 67.4 ± 14.4% | 63.2 ± 10.4% | - | - | - | - | 0.0277 | 0.0187 | |
| S7 | 105.2 ± 4.9% | 90.3 ± 3.4% | 95.7 ± 3.6% | 89.8 ± 2.9% | - | - | - | - | 0.0930 | 0.0738 | |
| S8 | 100.8 ± 2.5% | 88 ± 4.8% | 87.9 ± 4% | 92.2 ± 3.5% | - | - | - | - | 0.0867 | 0.0149 | |
| S9 | 0.3 ± 0.2% | 0.1 ± 0.2% | 0.2 ± 0.1% | 0.4 ± 0.1% | 2.982 | 0.012 | 0.206 | 0.018 | 0.0221 | 0.0553 | |
| S10 | 0.1 ± 0.1% | 0.1 ± 0.1% | 0.1 ± 0% | 0.2 ± 0% | 2.669 | 0.021 | 0.178 | 0.032 | 0.1954 | 0.1393 |
| Markers | Staining intensity | ||
| LNCaP | Spheres | Neuroendocrine cells | |
| Pancytokeratin | +/− | - | +++ |
| Neuro-specific enolase | +/− | − | +++ |
| Serotonin | − | − | + |
| certified CAM | noncertified CAM | COM | ||||
| mean | median | mean | median | mean | median | |
| Number of patients per year | 652 | 537 | 955 | 899 | 987 | 906 |
| Number of consultations per year | 2797 | 2440 | 3811 | 3726 | 3918 | 3783 |
| - Disease related | 2746 | 2421 | 3694 | 3621 | 3822 | 3731 |
| - Accident related | 40 | 14 | 100 | 76 | 82 | 46 |
| - Other (maternity, unclassified) | 12 | 2 | 17 | 3 | 13 | 2 |
| - Number of home visits | 79 | 30 | 268 | 181 | 304 | 211 |
| Number of consultations per patient and year | 4.6 | 4.2 | 4.1 | 3.9 | 4.2 | 4.0 |
| EEG normal patients = 53(%) | EEG abnormal patients = 17(%) | |
| palpitations, pounding heart, or accelerated heart rate | 44 (83.0) | 13 (76.5) |
| sweating | 11 (20.8) | 5 (29.4) |
| trembling or shaking | 16 (30.2) | 5 (29.4) |
| sensations of shortness of breath or smothering | 40 (75.5) | 13 (76.5) |
| feeling of choking | 13 (24.5) | 4 (23.5) |
| chest pain or discomfort | 22 (41.5) | 7 (41.2) |
| nausea or abdominal distress | 20 (37.7) | 14 (82.4) |
| feeling dizzy, unsteady, lightheaded, or faint | 38 (71.7) | 15 (88.2) |
| derealization or depersonalization | 4 (7.5) | 8 (47.1) |
| fear of losing control or going crazy | 23 (43.4) | 11 (64.7) |
| fear of dying | 16 (30.2) | 5 (29.4) |
| paresthesias | 23 (43.4) | 11 (64.7) |
| chills or hot flushes | 11 (20.8) | 7 (41.2) |
| age | 34.6 ± 9.3 | 33.9 ± 9.8 |
| sex | M:17F:36 | M: 3F:14 |
| Costs per patient in different situation in CHF | CMR strategy | “hypothetical” CXA strategy |
| All tests performed as outpatient procedures in Switzerland | 1,984 | 2,580 |
| CXA performed as an inpatient procedure in Switzerland | 2,408 | 4,638 |
| Sensor | Targeted Gases | Smell Description |
| TGS 880 | volatile vapors from food | food (while cooking) |
| TGS 825 | hydrogen sulfide | rotten egg, sulfurous smells |
| TGS 826 | ammonia | old rotten urine and fish (sharp, penetrating, and irritating smell) |
| TGS 822 | alcohol, xylene, toluene, other VOC | aromatic solvents, wood fermentation, alcoholic beverages |
| TGS 2610 | general hydrocarbons | smell of ripening fruits |
| TGS 2602 | ammonia, hydrogen sulfide,ethanol, toluene | a wide range of smell: from rotten fish to wood fermentattion |
| Haplo2Ped | Merlin | |||||
| Chr | Expected regiona(bp) | Detected region (bp) | LOD score | Detected region (bp) | LOD score | SNPLINKb |
| 1 | 216,655,820-217,662,693 | 216,631,505-217,703,573 | 3.010 | 216,907,787-217,662,692 | 1.773 | 217,005,036-217,668,715 |
| 5 | 38,764,018-41,787,459 | 38,631,518-42,305,421 | 3.010 | 38,854,039-41,712,049 | 1.777 | 38,886,647-42,163,690 |
| 9 | 27,316,060-31,341,194 | 27,143,875-31,616,167 | 3.010 | 27,319,623-31,394,530 | 1.777 | 27,306,972-31,369,980 |
| 13 | 96,346,535-101,352,382 | 96,316,072101,404,566 | 3.010 | 96,328,971-101,304,534 | 1.778 | 96,836,579-101,356,932 |
| 17 | 50,661,600-54,645,983 | 50,621,012-54,818,763 | 3.010 | 50,690,828-58,850,202 | 1.804 | 50,661,601-54,726,213 |
| 21 | 21,812,513-26,812,202 | 21,781,794-27,090,473 | 3.010 | 21,833,903-26,812,201 | 1.778 | 21,812,514-26,818,797 |
| 1 | / | / | / | 55,489,086-62,400,262 | 1.778 | / |
| 5 | / | / | / | 10,529,760- 11,796,160 | 1.778 | / |
| 9 | / | / | / | 73,498,210- 80,047,165 | 1.778 | / |
| 5-HT (ng/mL) | NA (ng/mL) | β-EP (ng/mL) | ||||
| Brain tissue | Plasma | Brain tissue | Plasma | Brain tissue | Plasma | |
| Normal group | 144.39 ± 30.36 | 467.71 ± 86.01 | 3.92 ± 0.72 | 15.23 ± 2.66 | 0.28 ± 0.10 | 2.57 ± 0.45 |
| Model group | 259.38 ± 74.48# | 549.9 ± 90.1# | 4.8 ± 1.3# | 18.5 ± 1.9# | 0.15 ± 0.08# | 3.47 ± 1.68# |
| SFZYD group (5.4 g kg−1) | 183.49 ± 89.99* | 492.79 ± 72.14* | 4.33 ± 1.46 | 16.95 ± 5.11* | 0.24 ± 0.09* | 2.38 ± 1.42* |
| SFZYD group (10.8 g kg−1) | 153.56 ± 76.32** | 458.24 ± 81.56** | 3.85 ± 1.45* | 15.87 ± 4.36** | 0.34 ± 0.12* | 2.56 ± 1.89* |
| Variables | B | SE | Sig. | AOR | 95.0 % C.I. for Exp (B) |
| Insufficient family time | .760 | 0.338 | .025 | 2.138 | 1.102, 4.148 |
| Unsatisfactory doctor behaviour | .322 | 0.375 | .391 | 1.380 | 0.662, 2.878 |
| Unsatisfactory manager behaviour | .692 | 0.343 | .044 | 1.999 | 1.020, 3.915 |
| No sales achievement award | .738 | 0.414 | .075 | 2.092 | 0.929, 4.711 |
| No annual sales conference | .412 | 0.427 | .335 | 1.509 | 0.653, 3.485 |
| Monthly income less than 36,000 PKR | .604 | 0.379 | .111 | 1.829 | 0.871, 3.842 |
| PinX1 | |||
| Positive | Negative | P | |
| Sex | |||
| Male | 34 | 74 | |
| Female | 7 | 43 | 0.020 |
| Age | |||
| <60 years | 19 | 52 | |
| ≥60 years | 22 | 65 | 0.834 |
| Smoking status | |||
| Yes | 34 | 76 | |
| No | 7 | 41 | 0.034 |
| Histology | |||
| Squamous | 36 | 65 | |
| Adenocarcinoma | 5 | 52 | 0.000 |
| Lesion | |||
| Peripheral | 28 | 83 | |
| Central | 13 | 34 | 0.750 |
| Tumour location | |||
| Left | 17 | 48 | |
| Right | 24 | 69 | 0.961 |
| Resection type | |||
| Lobectomy | 35 | 95 | |
| Pneumonectomy | 3 | 19 | |
| Other | 3 | 3 | 0.163 |
| Metastasis | |||
| Yes | 15 | 67 | |
| No | 26 | 50 | 0.023 |
| T stage | |||
| T1 | 6 | 41 | |
| T2 + T3 | 35 | 76 | 0.013 |
| N stage | |||
| N0 | 46 | 24 | |
| N1 + N2 | 17 | 71 | 0.033 |
| TNM stage | |||
| I | 13 | 31 | |
| II | 17 | 32 | |
| III | 11 | 54 | 0.082 |
| 2010 | 2011 | 2012 | 2013 | |
| Birth attendant, N (%) | ||||
| Physician | 1,241 (32.1) | 1,547 (37.8) | 1,851 (45.4) | 2,416 (52.9) |
| Nurse/Midwife/HW | 39 (1.0) | 96 (2.3) | 89 (2.2) | 95 (2.1) |
| TBA | 2,575 (66.6) | 2,433 (59.5) | 2,121 (52.1) | 2,028 (44.4) |
| Family/Other | 14 (0.4) | 12 (0.3) | 12 (0.3) | 31 (0.7) |
| Delivery location, N (%) | ||||
| Hospital | 1,162 (30.0) | 1,570 (38.4) | 1,814 (44.5) | 2,297 (50.3) |
| Clinic | 104 (2.7) | 56 (1.4) | 121 (3.0) | 215 (4.7) |
| Home/Other | 2,603 (67.3) | 2,462 (60.2) | 2,138 (52.5) | 2,058 (45.0) |
| Delivery mode, N (%) | ||||
| Vaginal | 3,350 (86.6) | 3,402 (83.2) | 3,251 (79.8) | 3,461 (75.7) |
| Vaginal assisted | 4 (0.1) | 4 (0.1) | 12 (0.3) | 0 (0.0) |
| C-section | 515 (13.3) | 682 (16.7) | 809 (19.9) | 1,109 (24.3) |
| Maternal antibiotics, N (%) | 405 (12.6) | 675 (17.0) | 950 (24.2) | 1,373 (30.7) |
| Oxytocics, N (%) | 602 (18.7) | 1,014 (25.5) | 1,155 (29.5) | 1,779 (40.0) |
| Blood transfusion, N (%) | 6 (0.2) | 9 (0.2) | 11 (0.3) | 29 (0.7) |
| Clean razor | ||||
| Fetal heart rate taken, N (%) | 1,381 (35.7) | 1,933 (47.3) | 3,340 (82.0) | 3,811 (83.4) |
| BA gloves used, N (%) | 3,750 (98.4) | 4,043 (99.3) | 4,011 (99.2) | 4,503 (99.2) |
| Bag and mask resuscitation, N (%) | 28 (0.7) | 23 (0.6) | 29 (0.7) | 76 (1.7) |
| Breastfeed <1 hr after delivery, N (%) | 2,729 (83.6) | 3,346 (81.9) | 3,200 (78.5) | 3,072 (67.1) |
| Toxicity | Grade | |||||
| 0 | 1 | 2 | 3 | 4 | ≥Grade 3 (%) | |
| Leukopenia | 26 | 16 | 17 | 3 | 0 | 5 |
| Neutropenia | 32 | 14 | 11 | 5 | 0 | 8 |
| Anemia | 28 | 31 | 3 | 0 | 0 | 0 |
| Thrombocytopenia | 33 | 27 | 2 | 0 | 0 | 0 |
| Mucositis | 1 | 15 | 45 | 1 | 0 | 2 |
| Dermatitis | 1 | 58 | 2 | 1 | 0 | 2 |
| Hoarseness | 45 | 12 | 4 | 1 | 0 | 2 |
| Groups | Number of patients | Age, y (Mean ± SD) | ||
| PEX | 39 | F—18 | 76.49 ± 6.54 | F—79.44 ± 5.24 |
| M—21 | M—73.95 ± 6.59 | |||
| PEXG | 37 | F—18 | 78.22 ± 7.58 | F—77.06 ± 6.58 |
| M—19 | M—79.32 ± 8.45 | |||
| CNT | 46 | F—21 | 76.65 ± 7.26 | F—79.67 ± 7.14 |
| M—25 | M—74.12 ± 7.20 |
| Study | Subgroups by MP status | Exposure categories (n) | Oldest/Youngest age category | RR (95% CI) for oldest vs. youngest age category | |
| ER+PR+ | ER-PR- | ||||
| Cohort studies | |||||
| [9] | Post-MP | 2 | ≥13/<13 | 0.69 (0.56–0.85) | 1.07 (0.67–1.71) |
| [10] | All women | 2 | 15/11 | 0.68 (0.62–0.73) | 0.78 (0.68–0.89) |
| Summary RRs for cohort studies | 0.68 (0.59–0.79) | 0.80 (0.69–0.93) | |||
| Population-based case-control studies | |||||
| [11] | All women | 2 | ≥12/<12 | 0.67 (0.50–0.91) | 0.91 (0.67–1.43) |
| Pre-MP | 2 | ≥12/<12 | 0.67 (0.4–1.0) | 1.11 (0.67–1.67) | |
| Post-MP | 2 | ≥12/<12 | 0.63 (0.42–1.0) | 0.77 (0.45–1.43) | |
| [12] | Young | 2 | ≥13/<13 | 0.77 (0.63–0.94) | 0.78 (0.61–1.00) |
| [13] | All women | 4 | ≥14/<12 | 0.72 (0.52–0.99) | 0.99 (0.63–1.53) |
| Pre-MP | 4 | ≥14/<12 | 0.49 (0.31–0.76) | 1.12 (0.62–2.03) | |
| Post-MP | 4 | ≥14/<12 | 0.84 (0.64–1.10) | 0.94 (0.64–1.37) | |
| [14] | Young | ≥13/<13 | 0.8 (0.6–1.1) | 0.6 (0.4–0.9) | |
| [8] | Young | 4 | ≥14/<12 | 0.60 (0.42–0.86) | 0.59 (0.38–0.92) |
| Summary RRs for population-based case-control studies | 0.73 (0.59–0.89) | 0.77 (0.63–0.94) | |||
| Hospital-based case-control studies | |||||
| [15] | All women | Per 2 years↑ | 2 years' increase | 0.83 (0.68–1.01) | 1.11 (0.91–1.36) |
| 16 | All women | 3 | ≥14/<12 | 1.0 (0.53–-2.00) | 1.43 (0.71–2.50) |
| Summary RRs for hospital-based case-control studies | 0.84 (0.64–1.10) | 1.14 (0.87–1.49) | |||
| Summary RRs by MP status | Pre-MP/Young | 0.71 (0.57–0.88) | 0.77 (0.62–0.95) | ||
| Post-MP | 0.74 (0.54–1.01) | 0.95 (0.70–1.30) | |||
| Summary RRs for all studies | 0.72 (0.64–0.80) | 0.84 (0.75–0.94) | |||
| P for homogeneity between ER+PR+ and ER-PR- cancer | p = 0.006 |
| Test substance | Tomato extract in squalane | Tomato extract in hydrogenated polydecene | Dunaliella extract in hydrogenated polydecene |
| Reactions noted | None | None | None |
| # reactive subjects (%) | 0 (0%) | 0 (0%) | 0 (0%) |
| MDIS | 0 | 0 | 0 |
| Conclusion | Very good skin compatibility/nonirritant | Very good skin compatibility/nonirritant | Very good skin compatibility/nonirritant |
| Antibiotic | Proportion susceptible (%) | |
| MSSA (n = 80) | MRSA (n = 6) | |
| Cefoxitin | 100 | 0 |
| Benzylpenicillin | 26 | 0 |
| Co-trimoxazole | 60 | 0 |
| Tetracycline | 85 | 0 |
| Gentamicin | 99 | 0 |
| Ciprofloxacin | 100 | 0 |
| Erythromicin/Clindamycin | 99 | 17 |
| Rifampicin | 99 | 83 |
| Chloramphenicol | 100 | 100 |
| Vancomycin | 100 | 100 |
| Mupirocin | 100 | 100 |
| Polymer Type | LOD | Response Time/Recovery Time | Transducing Mechanism | Ref. |
| PPy nanoparticles | 5 ppm | Less than 1 s/2 s | Chemiresistive | [58] |
| Multidimensional PPy nanotubes | 0.01 ppm | Less than 1 s/55–60 s | Chemiresistive | [113] |
| Single PPy nanowire | 40 ppm | 15–10 min (for 40–300 ppm)/15 min for 40 ppm | Chemiresistive | [36] |
| PPy nanowires | 1.5 ppm | 60 s for 73 ppm/prolonged with increasing of con. (1.5–73 ppm) | Chemiresistive | [18] |
| Single crystal PPy nanotube | 0.00005 ppm | ~16 s/~16 s for 1 ppm | Chemiresistive | [114] |
| PPy nanoribbons | 0.5 ppm | ~8 min/3 min | Chemiresistive | [62] |
| PPy nanotubes PPy/Ag–AgCl composite Nanotubes | – | >1000 s for 100 ppm/−150 s for 100 ppm/500 s | Chemiresistive | [115] |
| PPy/ZnO nanocomposite PPy/SnO2 nanocomposite | 10 ppm | ~100 s for 24 ppm/100 s ~50 s for 24 ppm/250 s for first 3 cycles | Chemiresistive | [13] |
| PPy/graphene nanocomposite decorated with TiO2 nanoparticles | 1 ppm | ~36 s/~16 s for 50 ppm | Chemiresistive | [116] |
| Au/PPy nanopeapods | 0.007 ppmv | ~15 min for 5 ppmv/did not reach Ro value | Chemiresistive | [117] |
| Variable | HIV-1-seronegative psoriasis | HIV-1-related psoriasis | References |
| Frequency | 1-3% | Similar to HIV-seronegative population | [54,55] |
| Severity | Mild-moderate | Moderate-severe | [62] |
| Clinical features | Erythematous plaques usually circumscribed to elbows-knees (psoriasis vulgaris) | More extensive lesionsIncreased presence of acral lesions and inverse psoriasis | [4,55] |
| Histhopatological features | Hyperproliferation and hyperkeratosis, lymphocytic infiltrate and absence of granular layer | Same | [55] |
| Presence of psoriatic arthritis | 5-20% | 23%-50% | [54,55] |
| Mean age of presentation | >30 years | =30 years | [63] |
| Family history | Frequent | Variable | [64] |
| Presence of HLA-Cw*0602 | 25% | 79% | [64] |
| Presence of Reiter's Syndrome | Rare | Frequent | [54] |
| Development of erythroderma | +/+++ | ++/+++ | [65] |
| Response to conventional treatment (topical steroids, Vitamin D analogues, phototherapy) | Variable | Variable-poor | [63,66] |
| Response to zidovudine/HAART | +/+++ | ++/+++ | [67,68] |
| Characteristic | Region | Overall | ||||
| Southern | Highlands | Momase | Islands | |||
| Female n (%) | 64 (51) | 50 (46) | 56 (46) | 51 (47) | 221 (47) | |
| Age n (%) | 0–4 yrs | 60 (48) | 48 (46) | 58 (48) | 49 (45) | 215 (47) |
| 5–15 yrs | 31 (24) | 14 (14) | 30 (25) | 35 (33) | 110 (24) | |
| 16+ yrs | 35 (28) | 41 (40) | 32 (27) | 24 (22) | 132 (29) |
| Group | Hoffman cluster | Species, subspecies, or complex | Type strain | Accession no. | No. of strains |
| A | VI | E. xiangfangensis | LMG 27195a | NZ_CP017183.1 | 3 |
| B | VIII | E. hormaechei subsp. steigerwaltii | DSM 16691a | NZ_CP017179.1 | 83 |
| C | VI | E. hormaechei subsp. oharae | DSM 16687a | NZ_CP017180.1 | 104 |
| D | III | E. hormaechei | DSM 14563a | NZ_CP017186.1 | 30 |
| E | VII | E. hormaechei subsp. hormaechei | ATCC 49162 | GCA_000213995.1 | 5 |
| F | E. mori | LMG 25706 | AEXB00000000 | 1 | |
| G | XI | E. cloacae subsp. cloacae | ATCC 13047 | NC_014121.1 | 11 |
| H | XII | E. cloacae subsp. dissolvens | 4 | ||
| I | V | E. ludwigii | EN-119 | CP017279.1 | 11 |
| J | I | E. asburiae | ATCC 35953 | NZ_CP011863.1 | 30 |
| K | E. cloacae complex | 6 | |||
| L | E. cloacae complex | 7 | |||
| M | IV | E. cloacae complex | DSM 16690a | NZ_CP017184.1 | 31 |
| N | E. cloacae complex | 3 | |||
| O | E. cloacae complex | 1 | |||
| P | E. cloacae complex | 4 | |||
| Q | II | E. kobei | DSM 13645a | NZ_CP017181.1 | 31 |
| R | IX | E. cloacae complex | 14 |
| GDM 2007–2008 | No GDM 2007–2008 | p value | |||
| (n = 62,958) | (n = 1,452,429) | ||||
| Size | (%) | Size | (%) | ||
| Age | <0.0001 | ||||
| <20 | 520 | 0.83 | 42,313 | 2.91 | |
| 20–29 | 21,471 | 34.10 | 706,688 | 48.66 | |
| 30–39 | 35,922 | 57.06 | 656,693 | 45.21 | |
| ≥40 | 5045 | 8.01 | 46,735 | 3.22 | |
| Obesity | 8122 | 12.90 | 56,142 | 3.87 | <0.0001 |
| Subsequent diabetes | 1266 | 2.01 | 1674 | 0.12 | <0.0001 |
| Hypertensive disorders during pregnancy | 4834 | 7.68 | 42,012 | 2.89 | <0.0001 |
| Angina pectoris | 64 | 0.10 | 570 | 0.04 | <0.0001 |
| Myocardial infarction | |||||
| Acute myocardial infarction | 26 | 0.04 | 257 | 0.02 | <0.0001 |
| Repeated myocardial infarction | 0 | 0 | 2 | 0 | 1 |
| Complications of acute myocardial infarction | 0 | 0 | 11 | 0 | 1 |
| Stroke | |||||
| Ischemic stroke | 71 | 0.11 | 1181 | 0.09 | <0.05 |
| Vascular syndromes of brain in cerebrovascular diseases | 9 | 0.01 | 160 | 0.01 | 0.34 |
| Transient cerebral ischemic attacks | 59 | 0.09 | 1219 | 0.08 | 0.06 |
| Hypertensives diseases | 1566 | 2.49 | 10,586 | 0.73 | <.0001 |
| Therapeutic measuresa | 32 | 0.05 | 236 | 0.02 | <.0001 |
| Variables | Patients number | % |
| Age (mean ± SD) days | 6.7 ± 2.3 | |
| Body weight (mean ± SD) kg | 3.4 ± 0.3 | |
| Gender | ||
| Male | 13 | 68.4 |
| Female | 6 | 31.6 |
| Diagnosis | ||
| TGA with VSD | 2 | 10.5 |
| Taussig–Bing | 17 | 89.5 |
| Arch anomaly | ||
| Coarctation of aorta | 13 | 68.4 |
| Interruption | 6 | 31.6 |
| Type A | 2 | 10.5 |
| Type B | 4 | 21.1 |
| Coronary artery pattern | ||
| 1L,Cx; 2R | 8 | 42.1 |
| 1L; 2Cx,R | 2 (1RP) | 10.5 |
| 1R; 2L,Cx | 3 (2RP) | 15.8 |
| 1R,L; 2Cx | 1 (RP) | 5.3 |
| 2L,Cx,R | 1 (IM) | 5.3 |
| 2L,Cx; 2R | 3 (1RP, 1IM) | 15.8 |
| 2R; 2L,Cx | 1 (RP) | 5.3 |
| Relation of gas | ||
| Anteroposterior | 4 | 21.1 |
| Side by side | 15 | 78.9 |
| PGE1 | 19 | 100 |
| Mechanical ventilation | 3 | 15.8 |
| Odds ratio | 95 % confidence intervals | |||
| Lower | Upper | |||
| Tobacco | Follow-up vs. Baseline | 1.020 | 0.223 | 4.661 |
| Nutrition | Follow-up vs. Baseline | 1.555 | 0.814 | 2.972 |
| Physical activity | Follow-up vs. Baseline | 0.946 | 0.476 | 1.879 |
| Screening | Follow-up vs. Baseline | 2.788* | 1.166 | 6.663 |
| Clinical trials | Follow-up vs. Baseline | 3.118* | 1.372 | 7.083 |
| Populations and risk factors | ET-1 (nM/L) | p | |
| Gender | Men (n = 121) | 17.4 ± 4.6 | <0.00001 |
| Women (n = 36) | 7.8 ± 2.3 | ||
| Hypertension | Yes (n = 138) | 16.4 ± 3.3 | <0.00001 |
| No (n = 19) | 6.6 ± 1.9 | ||
| Diabetes | Yes (n = 101) | 15 ± 5.1 | NS |
| No (n = 56) | 15.6 ± 3.8 | ||
| Tobacco | Yes (n = 98) | 11.6 ± 3 | <0.00001 |
| No (n = 59) | 21.2 ± 6.1 | ||
| Personal cardiovascular antecedents | Yes (n = 104) | 15.3 ± 4.4 | NS |
| No (n = 53) | 15 ± 2.8 | ||
| Obesity | Yes (n = 82) | 12.2 ± 5.3 | <0.001 |
| No (n = 75) | 18.2 ± 4 | ||
| Dyslipidemia | Yes (n = 63) | 11.8 ± 1.6 | <0.00001 |
| No (n = 94) | 17 .5 ± 4.6 | ||
| Alcohol | Yes (n = 52) | 16 ± 4.1 | NS |
| No (n = 105) | 14.8 ± 3.8 | ||
| Sedentarity | Yes (n = 67) | 15.7 ± 3.7 | NS |
| No (n = 90) | 14.9 ± 2.4 |
| Diet composition | 20% animal protein | 10% animal pro+tein | 20% plant protein | 10% plant protein |
| Total energy value (kcal/g) | 3.7 | 3.7 | 3.7 | 3.7 |
| Carbohydrate (%Kcal) | 62.93 | 73.23 | 63.15 | 73.06 |
| Fat (%kcal) | 16.97 | 16.97 | 16.87 | 16.74 |
| Protein (%Kcal) | 20.11 | 10.04 | 19.98 | 10.20 |
| Leucine (g/kg) | 18.7 | 9.4 | 21.2 | 10.6 |
| Isoleucine (g/kg) | 10.1 | 5.0 | 7.9 | 4.0 |
| Lysine (g/kg) | 15.7 | 7.9 | 3.9 | 1.9 |
| Methionine (g/kg) | 4.9 | 2.4 | 4.1 | 2.1 |
| Cysteine (g/kg) | 2.0 | 1.0 | 3.0 | 1.5 |
| Arginine (g/kg) | 6.7 | 3.3 | 7.8 | 3.9 |
| Phenylalanine (g/kg) | 8.8 | 4.4 | 10.4 | 5.2 |
| Tyrosine (g/kg) | 9.2 | 4.6 | 5.0 | 2.5 |
| Histidine (g/kg) | 4.9 | 2.4 | 4.2 | 2.1 |
| Threonine (g/kg) | 8.4 | 4.2 | 5.5 | 2.7 |
| Tryptophan (g/kg) | 2.5 | 1.2 | 1.6 | 0.8 |
| Valine (g/kg) | 11.8 | 5.9 | 8.7 | 4.3 |
| Wheat gluten (g/kg) | ― | ― | 110 | 55 |
| Corn gluten (60%) (g/kg) | ― | ― | 136 | 68 |
| Isolated soy protein (g/kg) | ― | ― | 22 | 11 |
| Casein (g/kg) | 170 | 85 | ― | ― |
| Lactalbumin (g/kg) | 44 | 22 | ― | ― |
| Corn starch (g/kg) | 380.1 | 486.3 | 325.4 | 459 |
| Maltodextrin (g/kg)Sucrose (g/kg) | 100150 | 100150 | 100150 | 100150 |
| Corn oil (g/kg) | 32 | 32 | 32 | 32 |
| Olive oil (g/kg) | 32 | 32 | 32 | 32 |
| Cellulose (g/kg) | 50 | 50 | 50 | 50 |
| Mineral Mix, w/o Ca & P | 13.14 | 13.14 | 13.14 | 13.14 |
| Calcium phosphate (g/kg) | 8 | 10.8 | 12 | 12.6 |
| Calcium carbonate (g/kg) | 10.3 | 8.3 | 7.0 | 6.8 |
| Vitamin Mix, Tekland (g/kg) | 10 | 10 | 10 | 10 |
| Age | (Year) | 43.91 (15.4) |
| Pain intensity* | (0–10) | 4.11 (1.9) |
| Physical disability** | (0–24) | 8.78 (5.3) |
| Depression*** | (0–42) | 8.75 (9.9) |
| Anxiety≠ | (0–42) | 6.55 (8.4) |
| Stress± | (0–42) | 13.08 (9.8) |
| Fatigue† | (1–63) | 32.49 (12.3) |
| Pittsburgh questionnaire# | (0 – 21) | 7.92 (3.8) |
| Insomnia index$ | (0 – 28) | 11.25 (6.4) |
| Epworth scale¥ | (0 – 24) | 7.26 (5.2) |
| Body mass index | (Kg/m2) | 25.73 (4.9) |
| Pain duration | Acute | 32 (41%) |
| Chronic | 47 (59%) | |
| Roland item£ | (Yes) | 46 (58%) |
| Seeking care | (Yes) | 58 (73%) |
| Taking pain medication | (Yes) | 35 (44%) |
| Gender | (Female) | 40 (51%) |
| Level of education | (University degree) | 35 (44%) |
| Smoking status | (Not) | 74 (94%) |
| Work status | Full-time | 48 (61%) |
| Part-time | 14 (18%) | |
| Not working | 4 (5%) | |
| Retired | 13 (16%) | |
| Marital status | Married or defacto | 39 (49%) |
| Separated | 8 (10%) | |
| Single | 32 (41%) |
| Full sample (n = 14,798) | Restricted analytic sample (n = 11,733) | |||
| percent | std error | percent | std error | |
| Age | ||||
| 18–24 | 17 | 0.6 | 18 | 0.6 |
| 26–44 | 53 | 0.9 | 55 | 1.0 |
| 45–64 | 30 | 0.8 | 28 | 0.9 |
| Gender | ||||
| Men | 49 | 0.4 | 49 | 0.5 |
| Women | 51 | 0.4 | 51 | 0.5 |
| Race/ethnicity | ||||
| White | 74 | 1 | 75 | 1 |
| Black | 12 | 0.6 | 11 | 0.6 |
| Mexican-American | 6 | 0.5 | 6 | 0.5 |
| Other | 8 | 0.9 | 8 | 1 |
| Marital status | ||||
| married/living as | 64 | 0.9 | 64 | 0.9 |
| not married/not living as | 36 | 0.9 | 36 | 0.9 |
| Education | ||||
| < high school | 23 | 1 | 22 | 1 |
| high school | 35 | 0.8 | 34 | 0.8 |
| > high school | 42 | 1 | 44 | 1 |
| Occupation | ||||
| white collar and professional | 24 | 0.9 | 25 | 0.9 |
| white collar, semi-routine | 23 | 0.7 | 23 | 0.7 |
| blue collar, high skill | 12 | 0.5 | 12 | 0.5 |
| blue collar, semi-routine | 39 | 0.8 | 38 | 0.9 |
| never worked | 3 | 0.3 | 3 | 0.3 |
| Income (equivalized for family size) | ||||
| < 50% median | 22 | 1 | 21 | 1 |
| 50–100% median | 31 | 1 | 30 | 1 |
| > median | 47 | 2 | 49 | 2 |
| % below poverty | 11 | 0.7 | 11 | 0.8 |
| % poverty to 184% poverty | 16 | 0.8 | 15 | 0.8 |
| 185% poverty to median income* | 25 | 1 | 25 | 1 |
| > median* | 47 | 2 | 49 | 2 |
| Work and health | ||||
| not currently in labor force | 25 | 0.7 | 21 | 0.7 |
| employment affected by health | 10 | 0.4 | 0 | - |
| death with <1 year follow-up | 0.3 | 0.07 | 0 | - |
| Variable | Number of cases | % |
| Gender | ||
| Male | 116 | 54 |
| Female | 98 | 46 |
| Age, y | ||
| < 70 | 120 | 56 |
| ≥ 70 | 94 | 44 |
| T-category | ||
| T2 | 33 | 15 |
| T3 | 181 | 85 |
| Cancer specific survival, y | ||
| < 5 | 105 | 49 |
| ≥ 5 | 109 | 51 |
| Censored | 156 | 73 |
| Variable | Variable groups | Treatment sought (%) | COR (95% CI) | AOR (95% CI) |
| Age of caregivers | <30 | 103 (92.0) | 2.5 (1.02–5.91)* | 3.40 (1.27–9.10)** |
| 70 (82.4) | 1.00 | 1.00 | ||
| Place of residence | Rural | 107 (91.5) | 2.27 (0.95–5.40)* | 2.80 (1.01–7.70)** |
| Urban | 66 (82.5) | 1.00 | 1.00 | |
| Educational status | Illiterate | 103 (86.6) | 1.00 | |
| Read and write | 26 (92.9) | 2.02 (0.44–9.34) | ||
| Primary | 25 (89.3) | 1.29 (0.26–4.79) | ||
| Secondary or above | 19 (86.4) | 0.98 (0.26–3.71) | ||
| Religion | Christian | 121 (89.6) | 1.00 | |
| Muslim | 18 (94.7) | 2.08 (0.26–16.81) | ||
| Traditional | 34 (79.1) | 0.44 (0.17–1.10)* | ||
| Ethnicity | Gumuz | 66 (82.5) | 1.00 | |
| Agew | 79 (90.8) | 2.09 (0.83–5.30)* | ||
| Amhara | 28 (93.3) | 2.97 (0.63–13.94)* | ||
| Family size | ≤5 | 106 (89.1) | 1.34 (0.57–3.16) | |
| ≥6 | 67 (85.9) | 1.00 | ||
| Occupation of respondents | Farmer | 45 (81.8) | 1.00 | |
| Housewife | 109 (90.5) | 2.02 (0.81–5.01)* | ||
| Merchant/government employee | 19 (90.5) | 2.11 (0.42–10.56) | ||
| Average monthly income (ETB) | ≤500 | 68 (87.2) | 1.00 | |
| 501–1000 | 42 (91.3) | 1.54 (0.46–5.24) | ||
| >1000 | 63 (86.3) | 0.93 (0.36–2.37) | ||
| Malaria knowledge | Poor | 95 (82.6) | 1.00 | 1.00 |
| Good | 78 (95.1) | 4.11 (1.35–12.51)* | 4.65 (1.38–15.64)** | |
| Perceived susceptibility | Low | 99 (84.6) | 1.00 | 1.00 |
| High | 74 (92.5) | 2.24 (0.85–5.93)* | 3.63 (1.21–10.88)** | |
| Perceived severity | Low | 87 (86.1) | 1.00 | |
| High | 84 (87.5) | 0.94 (0.40–2.22) | ||
| Perceived benefits of malaria treatment | Low | 87 (86.1) | 1.00 | |
| High | 86 (89.6) | 1.38 (0.58–3.29) | ||
| Perceived barriers to treatment-seeking | Low | 106 (93.0) | 1.00 | 1.00 |
| High | 67 (80.7) | 0.32 (0.13–0.78)* | 0.18 (0.06–0.52)** | |
| Cues to action | Low | 102 (85.0) | 1.00 | |
| High | 71 (92.2) | 2.09 (0.79–5.52)* | ||
| Perceived self-efficacy | Low | 106 (87.6) | 1.00 | |
| High | 67 (88.2) | 1.05 (0.44–2.54) |
| SOCIODEMOGRAPHIC AND CLINICAL CHARACTERISTICS | QUALITY OF LIFE | |||||
| Physical | Psychological | Level of independence | Social relationships | Environment | Spirituality/Religion/Personal beliefs | |
| Age* | -0.01 | 0.04 | -0.17† | -0.03 | 0.10 | 0.03 |
| Duration of diabetes in years (since first diagnosis)** | -0.02 | 0.09 | -0.17† | -0.02 | 0.09 | 0.07 |
| Fasting Glucose mmol/L** | -0.08 | -0.15† | -0.00 | -0.09 | -0.18† | -0.00 |
| HbA1c %* | -0.05 | -0.05 | -0.00 | -0.00 | -0.11 | 0.00 |
| Tissue | Male P Value | Maleρ | Female P-Value | Femaleρ |
| Brain | 8.71E−07 | 0.05504 | 2.81E−08 | 0.06247 |
| Cerebellum | 1.71E−19 | 0.10246 | 9.25E−21 | 0.10539 |
| Kidney | 3.97E−126 | 0.26420 | 3.37E−07 | 0.05751 |
| Heart | 4.13E−66 | 0.19308 | 7.14E−20 | 0.10423 |
| Liver | 5.91E−12 | 0.07786 | NA | NA |
| Testis | 6.92E−83 | 0.21132 | NA | NA |
| Year* | Na† | Microsatellites – Nb | MtDNA – Nbf | |||
| mlne‡ | Tempo FS§ | ldne¶ | mlne‡ | Fc** | ||
| 1997 | 7532 (5359, 9997) | 1609 (867, 7408) | 711 (398, 3362) | 1072 (565, 7388) | 1136 (528, ∞) | 876 (291, 4341) |
| 1998 | 7427 (4910, 10 927) | 1364 (814, 3644) | 291 (165, 1180) | 882 (512, 2822) | 966 (465, ∞) | 1149 (335, 32 493) |
| 1999 | 4910 (3263, 7147) | 934 (644, 1600) | 143 (94, 277) | ∞ (1398, ∞) | 1261 (429, ∞) | 711 (215, 4582) |
| 2000 | 4978 (3426, 7885) | 769 (550, 1243) | 165 (98, 528) | 326 (251, 456) | 1006 (398, ∞) | 921 (250, ∞) |
| 2001 | 4224 (2748, 6986) | 832 (572, 1435) | 250 (148, 903) | 520 (373, 833) | 536 (291, 1989) | 398 (130, ∞) |
| 2002 | 3012 (1779, 5525) | 1162 (720, 2758) | 291 (165, 1113) | 688 (459, 1320) | 2334 (666, ∞) | 733 (237, ∞) |
| 2003 | 2323 (1405, 4109) | 943 (621, 1828) | 246 (112, ∞) | 1188 (618, 10 040) | 1551 (702, ∞) | 1203 (353, 9634) |
| 2004 | 979 (526, 1999) | 4377 (1337, ∞) | 1341 (367, ∞) | ∞ (1901, ∞) | 15 647 (1475, ∞) | 13 832 (943, ∞) |
| 2005 | 2200 (883, 5301) | 1909 (934, 5311) | 608 (282, ∞) | 814 (469, 2678) | 5566 (984, ∞) | 2320 (528, ∞) |
| 2006 | 1366 (741, 3387) | 1314 (764, 3867) | 389 (232, 1274) | 1390 (269, ∞) | 2817 (845, ∞) | 1574 (331, ∞) |
| 2007 | 984 (614, 1738) | 19 054 (1775, ∞) | 429 (188, ∞) | 852 (515, 2268) | 2146 (724, ∞) | 2597 (496, ∞) |
| 2008 | 1364 (888, 2474) | 514 (402, 711) | 107 (54, ∞) | 3876 (860, ∞) | 1189 (630, 4390) | 773 (264, 2119) |
| 2009 | 1183 (679, 2763) | 1587 (881, 6219) | 840 (425, 34 487) | 821 (491, 2295) | 747 (443, 1824) | 581 (228, 1498) |
| 2010 | 524 (270, 1326) | 3970 (1355, ∞) | 5494 (671, ∞) | 12 391 (1393, ∞) | 1677 (630, ∞) | 1395 (429, 14 405) |
| Demographics | Week 4 | Week 8 | Week 12 |
| Age (year) | |||
| n | 159 | 129 | 106 |
| Mean ± SD | 63.8 ± 13.1 | 63.9 ± 13.5 | 63.4 ± 13.8 |
| Interquartiles | 54–74 | 54–74 | 54–74 |
| Median (Range) | 65 (30–89) | 66 (30–88) | 64 (30–88) |
| Karnofsky performance status (KPS) | |||
| n | 151 | 124 | 104 |
| Mean ± SD | 71.9 ± 13.1 | 72.6 ± 11.8 | 72.5 ± 12.5 |
| Interquartiles | 60–80 | 70–80 | 70–80 |
| Median (range) | 70 (30–90) | 70 (40–90) | 70 (40–90) |
| Worst pain | |||
| n | 159 | 129 | 106 |
| Mean ± SD | 5.13 ± 2.67 | 4.84 ± 2.58 | 4.75 ± 2.44 |
| Interquartiles | 3–7 | 3–7 | 3–7 |
| Median (range) | 5.0 (1–10) | 5.0 (1–10) | 4.0 (1–10) |
| Average pain | |||
| n | 159 | 129 | 106 |
| Mean ± SD | 3.57 ± 2.28 | 3.60 ± 2.20 | 3.33 ± 2.12 |
| Interquartiles | 2–5 | 2–5 | 2–5 |
| Median (range) | 3.0 (0–10) | 3.0 (0–9) | 3.0 (0–9) |
| Current pain | |||
| n | 159 | 129 | 106 |
| Mean ± SD | 2.69 ± 2.49 | 2.33 ± 2.26 | 2.41 ± 2.37 |
| Interquartiles | 0–4 | 0–4 | 0–4 |
| Median (range) | 3.0 (0–10) | 2.0 (0–10) | 2.0 (0–9) |
| Total daily morphine equivalent (mg) | |||
| n | 143 | 115 | 94 |
| Mean ± SD | 101.4 ± 162.5 | 91.6 ± 133.2 | 119.6 ± 194.5 |
| Interquartiles | 0–135 | 0–135 | 0–210 |
| Median (range) | 30 (0–904) | 32 (0–832) | 24 (0–1080) |
| Gender | |||
| Male | 88 (55.35%) | 70 (54.26%) | 62 (58.49%) |
| Female | 71 (44.65%) | 59 (45.74%) | 44 (41.51%) |
| Pain site | |||
| Lower limb | 94 (59.12%) | 76 (58.91%) | 74 (69.81%) |
| Upper limb | 63 (39.62%) | 50 (38.76%) | 29 (27.36%) |
| Other | 2 (1.26%) | 3 (2.33%) | 3 (2.83%) |
| Primary cancer site | |||
| Prostate | 46 (28.93%) | 41 (31.78%) | 32 (30.19%) |
| Breast | 37 (23.27%) | 31 (24.03%) | 28 (26.42%) |
| Lung | 41 (25.79%) | 28 (21.71%) | 24 (22.64%) |
| Bladder | 10 (6.29%) | 8 (6.20%) | 6 (5.66%) |
| Pancreas/gastric | 5 (3.14%) | 0 (0.00%) | 1 (0.94%) |
| Others | 20 (12.58%) | 37 (17.5%) | 15 (14.15%) |
| Dose fractionation | |||
| Single | 100 (62.89%) | 72 (55.81%) | 67 (63.21%) |
| Multiple | 59 (37.11%) | 57 (44.19%) | 39 (36.79%) |
| Disease Duration (Years) | Number (n) | Age (Years, Mean) | Female * (%) | BMI * (kg/m2, Mean) | Pos. Fam. History * (%) | RF Pos. * (%) | ACPA Pos. * (%) | Rheumatoid Nodules * (%) | Extra-art. Manifest * (%) | MTX Pre-exposed * (%) | TNF Pre-exposed * (%) |
| all | 7850 | 59.9 | 74.4 | 26.0 | 20.6 | 70.8 | 62.2 | 22.7 | 72.9 | 81.9 | 57.7 |
| <5 | 2535 | 57.0 | 69.2 | 26.2 | 15.0 | 60.8 | 54.4 | 7.1 | 52.3 | 83.1 | 42.4 |
| ≥5–10 | 1990 | 58.8 | 74.2 | 26.4 | 21.5 | 69.6 | 63.9 | 15.6 | 61.8 | 84.1 | 61.8 |
| ≥10–15 | 1250 | 60.8 | 76.7 | 26.2 | 22.1 | 75.6 | 66.5 | 26.3 | 81.1 | 83.5 | 65.2 |
| ≥15–20 | 788 | 62.2 | 77.0 | 25.7 | 25.4 | 79.3 | 64.0 | 36.3 | 84.5 | 81.2 | 69.3 |
| ≥20–25 | 500 | 63.3 | 79.2 | 25.5 | 25.6 | 81.1 | 73.2 | 41.1 | 85.7 | 75.1 | 67.2 |
| ≥25–30 | 325 | 65.3 | 81.8 | 24.8 | 24.3 | 85.5 | 74.7 | 51.5 | 86.3 | 76.3 | 67.8 |
| ≥30–40 | 333 | 66.5 | 82.9 | 25.2 | 26.7 | 79.6 | 70.2 | 50.8 | 91.0 | 77.0 | 64.4 |
| ≥40 | 129 | 71.5 | 86.0 | 24.9 | 31.0 | 84.3 | 69.4 | 56.7 | 66.7 | 66.7 | 62.7 |
| HPA | Position | Common allele | Rare allele | Residue variety in β-integrins |
| 1 | 33 | Leu | Pro (Val) | A, D, E, G, K, L, M, N, P, Q, S, T, V, Y |
| 4 | 143 | Arg | Gln | A, E, G, K, N, Q, R, S, T, V |
| 6 | 489 | Arg | Gln | A, D, E, G, H, K, N, P, Q, R, S, T, V |
| 7 | 407 | Pro | Ala | D, E, H, I, K, L, P, Q, R, S, T, V |
| 8 | 636 | Arg | Cys | D, E, G, H, K, L, N, P, Q, R, S, T, Y |
| 10 | 62 | Arg | Gln | D, E, F, H, I, K, L, N, Q, R, S, T, V |
| 11 | 633 | Arg | His | A, D, E, G, H, K, L, N, Q, R, S, T, V |
| 14 | 611 | Lys | del | D, F, H, K, L, N, Q, R, S, Y |
| 16 | 140 | Thr | Ile | A, D, E, G, K, L, N, Q, R, S, T, V |
| Demographic or Clinical Characteristic | No. of Patients (N= 48) | % | |
| Age, years | |||
| Median | 56.6 | ||
| Range | 29-77 | ||
| ECOG performance status | |||
| 0 | 19 | 39.6 | |
| 1 | 23 | 48 | |
| 2 | 6 | 12.5 | |
| Primary tumor intact | 11 | 23 | |
| Skin ulceration | 19 | 40 | |
| Lymph node stations clinically involved | |||
| Groin only (stage III) | 11 | 23 | |
| Deep inguinal or pelvic (stage IV) | 28 | 58.3 | |
| Distant metastasis | 21 | 43.7 | |
| History of smoking | 40 | 83 | |
| Current | 6 | 12.5 | |
| Former | 34 | 70.8 | |
| Prior treatment | |||
| Chemotherapy | 19 | 39.6 | |
| Radiation therapy | 5 | 10.4 | |
| Presentation of disease | |||
| Primary | 17 | 35.4 | |
| Recurrent | 31 | 64.6 |
| Effects and limitations of management contract | Public sector perspective | private sector perspective |
| Effects | By introducing competitive forces, contracting puts pressure on both public and private providers in terms of both service and price. | Contracting expands market opportunities to include public sector clients or customers. |
| Expanding the range of activities subject to contracting encourages the private sector to expand the services it provides in areas desired by government. | Contracting allows a private provider to capture a market to be protected from competitors at least for the term of the contract. | |
| Contracting both requires and promotes better planning and policy development by improving the flow of information about volumes of goods, services, costs, quality, responsiveness, population served, health needs and other issues. | Contracting can provide a reliable and timely source of revenue, encouraging investments necessary to support quality and innovation and ensuring longer term viability. | |
| Contracting provides government with a mechanism for purchasing needed health services at an agreed on and therefore predictable price. | The contract term may provide adequate time to justify investments in the capital and personnel needed to support contractual obligations. | |
| Contracting promotes transparency, constrains conflicts of interest and reduces opportunity for graft and corruption. | ||
| Limitations | Qualified private providers may not be available. | The costs of entering the market to compete successfully for government contracts may be too high. |
| Qualified bidders may not be interested in contracting with government. | The market may be too unstable or the contract period too short to support needed capital investments. | |
| Competition may be weak or non existent. | Transaction costs, the costs of securing and managing the contract may be too high. | |
| Government may discourage bidders by shifting too much risk to providers. | There may be no legal resource if government fails to fulfill its contractual obligations. | |
| Successful contractors could compete with the public sector for health personnel. | ||
| Governmental capacity to negotiate contracts may be weak. | ||
| Government's managerial and bureaucratic overhead may increase. | ||
| Government may agree to disadvantages contract terms. | ||
| Long term contracts may restrict government flexibility. | ||
| Costs may be higher than anticipated. |
| No. herds | End of one year study period | Herd size Cow years/year | Calculated bulk tank somatic cell count | Milk production Kg ECM/day | Mastitis treatments % cows treated/cow year | % of cows with infection risk > 50% | |
| Conventional | 20 | 03–2000 | 83 | 283 | 25.7a | 74a | 42 |
| Organic before 1995 | 18 | 03–2000 | 88 | 296 | 22.1c | 48b | 38 |
| Converting herds before conversion | 19 | 04–1999 or 04–2000 | 87 | 317 | 24.6a,b | 61a,b | 42 |
| Converting herds first year after conversion | 19 | 04–2000 or 04–2001 | 101 | 337 | 23.3c | 52a,b | 44 |
| Converting herds second year after conversion | 19 | 04–2001 or 04–2002 | 107 | 327 | 23.8* | 48a,b | 45 |
| Conventional herds in full research project | 109 | 03–2000 | 85 | 309 | 24.4b | 55* | 43 |
| History of blood donation | Blood donation total attitude | P value* | |
| score (4–20) | |||
| Median | Mean rank | ||
| Yes | 16.5 | 196.0 | <0.001 |
| No | 16 | 157.2 |
| Sample ID | MW of standard protein bands (KDa) |
| C. muytjensiiATCC 51329 | 66, 80 & 150 |
| C. sakazakiiATCC 29544 | 66, 125 |
| MP04.1 | 66 & 80 |
| MP08.5 | 66, 80,125 & 150 |
| MP10.2 | 150 |
| HR11.3 | 66, 80,125 & 150 |
| BC52.2 | 66, 80,125 & 150 |
| SP62.1 | 66, 80,125 and 150 |
| Cumulated Dose (μGy) @ 0.152 m | Cumulated Dose (μGy) @ 0.305 m | Cumulated Dose (μGy) @ 0.914 m | |
| 1 hr | 87.3 | 56.0 | 9.9 |
| 2 hr | 147.0 | 94.3 | 16.6 |
| 3 hr | 188.0 | 120.6 | 21.2 |
| 4 hr | 216.1 | 138.6 | 24.4 |
| 5 hr | 235.3 | 150.9 | 26.6 |
| Percentage of 13-to 17-Year-OldGirls Completing HPV Vaccine Series, U.S., 2012 | |||||
| Range | State | Percent | Range | State | Percent |
| ≥50% | Rhode Island | 57.7 | Kentucky | 34.9 | |
| Delaware | 50.4 | Missouri | 34.5 | ||
| 40–49% | Vermont | 46.2 | New Hampshire | 34.5 | |
| Pennsylvania | 44.6 | Minnesota | 33.1 | ||
| Hawaii | 43.4 | Michigan | 32.2 | ||
| Connecticut | 43.6 | Ohio | 31.9 | ||
| Washington | 43.5 | South Dakota | 31.8 | ||
| Massachusetts | 43 | New Jersey | 31.6 | ||
| Maine | 41.8 | Alaska | 31.4 | ||
| Montana | 41.6 | Alabama | 31.1 | ||
| North Dakota | 40.9 | Maryland | 30.9 | ||
| Louisiana | 40.5 | New Mexico | 30.3 | ||
| 30–39% | New York | 39.7 | Texas | 30.3 | |
| Oregon | 38.6 | Wyoming | 30.3 | ||
| District Columbia | 38.5 | ≤29% | Georgia | 29 | |
| Oklahoma | 38.4 | Tennessee | 28.6 | ||
| Colorado | 38 | Virginia | 27.9 | ||
| Wisconsin | 37.5 | Idaho | 27.8 | ||
| Nebraska | 37.3 | South Carolina | 26.6 | ||
| Nevada | 37.2 | Florida | 25.3 | ||
| Arizona | 36.9 | Kansas | 25.1 | ||
| West Virginia | 36.1 | Utah | 24.1 | ||
| North Carolina | 35.5 | Illinois | 21.1 | ||
| California | 35.8 | Arkansas | 18.3 | ||
| Iowa | 35.6 | Mississippi | 12.1 | ||
| Indiana | 35.2 |
| Diagnosis | Tumour biopsy | Perilesional skin | Total |
| No. of positive/total (%) | No. of positive/total (%) | No. of positive/total (%) | |
| BCC | 31/50 (62) | 24/50 (48) | 55/100 (55) |
| SCC | 8/9 (89) | 6/9 (67) | 14/18 (78) |
| Total | 39/59 (66) | 30/59 (51) | 69/118 (58) |
| Approach | Number of Links | |||||||||
| 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | All | |
| ELM | 2.8596 | 2.2980 | 2.8878 | 3.5223 | 2.5630 | 2.7815 | 2.7059 | 3.0009 | 3.5630 | 2.7811 |
| WKNN | 3.3536 | 2.5236 | 2.7971 | 3.6393 | 2.8896 | 2.9103 | 2.9982 | 3.5008 | 3.5673 | 2.9991 |
| SVM | 3.0095 | 2.3325 | 2.9633 | 3.2321 | 2.7520 | 2.5356 | 3.5029 | 3.3308 | 3.3569 | 3.0007 |
| BPNN | 3.8998 | 2.7892 | 3.6630 | 3.2079 | 2.8535 | 3.5505 | 2.4936 | 3.3291 | 2.7851 | 3.3332 |
| PAH | TEF | Surgeon | AT | ||
| PAHGas | PAHParticle | PAHGas | PAHParticle | ||
| Naphthalene | 0.001 | 1055 | 1.6 | 584 | 1.1 |
| Acenaphthylene | 0.001 | 5.8 | ND | 3.5 | ND |
| Acenaphthene | 0.001 | 19.9 | ND | 14.6 | ND |
| Fluorene | 0.001 | 55.4 | 0.8 | 42.2 | 0.5 |
| Phenanthrene | 0.001 | 84.3 | 3.2 | 68.3 | 2.2 |
| Anthracene | 0.01 | 22.2 | 5.6 | 16.7 | 4.0 |
| Fluoranthene | 0.001 | 18.9 | 3.8 | 14.2 | 2.7 |
| Pyrene | 0.001 | 17.8 | 5.4 | 13.3 | 4.1 |
| Benzo[a]anthracene | 0.1 | ND | 2.7 | ND | 1.3 |
| Chrysene | 0.01 | ND | 3.0 | ND | 1.4 |
| Benzo[b]fluoranthene | 0.1 | ND | 2.6 | ND | 1.3 |
| Benzo[k]fluoranthene | 0.1 | ND | 1.5 | ND | 0.7 |
| BaP | 1 | ND | 1.7 | ND | 1.1 |
| Indeno[cd]pyrene | 0.1 | ND | 1.8 | ND | 1.0 |
| Dibenzo[ah]anthracene | 5 | ND | 1.8 | ND | 1.1 |
| Benzo[ghi]peryrene | 0.01 | ND | 2.1 | ND | 1.5 |
| BaPeq | 1.5 | 11.4 | 0.9 | 7.2 | |
| Calculated lifetime cancer risk (×10-6) based on 24-hr exposurea | 131 | 992 | 78 | 626 | |
| Risk of unit-hour exposure (×10-6) | 46.8 | 29.3 | |||
| Average operation time (hour/day) | 2.5 | 9.2 | |||
| Estimated lifetime cancer risk (×10-6) | 117 | 270 |
| Variable | Category | Fresh samples n (%) | Paraffin-embedded samples n (%) | |
| Non-metastatic | Metastatic | |||
| Age | < 50 year | 5 (50) | 2 (20) | 8 (15.4) |
| ≥ 50 year | 5 (50) | 8 (80) | 44 (84.6) | |
| Gender | Male | 7 (70) | 10 (100) | 31 (59.6) |
| Female | 3 (30) | 0 | 21 (40.4) | |
| Smoking habit | No | 4 (40) | 2 (20) | 23 (44.2) |
| Yes | 6 (60) | 8 (80) | 29 (55.8) | |
| Alcohol consumption | No | 3 (30) | 1 (10) | 15 (28.8) |
| Yes | 7 (70) | 9 (90) | 37 (71.2) | |
| Clinical stage | T1 + T2 | 9 (90) | 4 (40) | 32 (61.5) |
| T3 + T4 | 1 (10) | 6 (60) | 20 (38.5) | |
| Lymph nodes | N0 | 9 (90) | 3 (30) | 40 (76.9) |
| N+ | 1 (10) | 7 (70) | 12 (23.1) | |
| Recurrence or metastasis | No | 10 (100) | 0 | 40 (76.9) |
| Yes | 0 | 10 (100) | 12 (23.1) | |
| Status | Alive | 10 (100) | 6 (60) | 45 (86.5) |
| Died | 0 | 4 (40) | 7 (13.5) |
| Enrichment Categories | p-Value | FDR | Related Genes |
| GO processes | |||
| Negative regulation of eicosanoid secretion | 7.5 × 10−9 | 3.0 × 10−6 | Hrh2, F2rl2 |
| Glucocorticoid biosynthetic process | 1.6 × 10−8 | 3.8 × 10−6 | Cacna1h, Hsd3b1 |
| Negative regulation of fatty acid transport | 4.1 × 10−8 | 7.6 × 10−6 | Hrh2, F2rl2 |
| System process | 4.5 × 10−7 | 4.5 × 10−5 | Actc1, Lmod3, Cacng1, Des, Dcdc2, Tnni2, Hrh2, Myog, Cacna1h, Lmod2, F2rl2, Mb, Rasl10b, Olr1714 |
| Response to hormone | 1.1 × 10−6 | 8.5 × 10−5 | Actc1, Lyn, Slco1b2 Dmbt1, Hsd3b1, Myog, Cacna1h, Hrh2, Myb, F2rl2 |
| Cellular component morphogenesis | 1.2 × 10−6 | 8.9 × 10−5 | Actc1, Cacna1h, Hrh2, F2rl2, Lyn, Dcdc2, Lmod2, Lmod3, Ntn1 |
| Regulation of neurotransmitter secretion | 2.5 × 10−6 | 1.5 × 10−4 | Cacna1h, Cacng1, Hrh2 |
| Calcium ion transmembrane transport | 3.6 × 10−6 | 2.0 × 10−4 | Cacna1h, Cacng1, Hrh2 |
| Positive regulation of gamma-aminobutyric acid secretion | 3.9 × 10−6 | 2.1 × 10−4 | Hrh2, F2rl2 |
| Calcium ion transport | 5.1 × 10−6 | 2.5 × 10−4 | Cacna1h, Cacng1, F2rl2, Hrh2 |
| Diseases (in biomarkers) | |||
| Autistic disorder | 1.5 × 10−5 | 8.9 × 10−4 | Cacna1h, Hrh2, F2rl2 |
| Child development disorders, pervasive | 1.6 × 10−5 | 9.0 × 10−4 | Cacna1h, Hrh2, F2rl2 |
| Communication disorders | 6.1 × 10−5 | 2.3 × 10−3 | Dcdc2, Hrh2 |
| Language disorders | 6.1 × 10−5 | 2.3 × 10−3 | Dcdc2, Hrh2 |
| Mental disorders diagnosed in childhood | 8.8 × 10−5 | 3.0 × 10−3 | Cacna1h, Dcdc2, Hrh2 |
| Tourette syndrome | 1.3 × 10−4 | 4.1 × 10−3 | Hrh2, F2rl2 |
| Tic disorders | 1.3 × 10−4 | 4.2 × 10−3 | Hrh2, F2rl2 |
| Epilepsy, absence | 1.7 × 10−4 | 4.8 × 10−3 | Cacna1h, Cacng1 |
| Neurotoxicity syndromes | 2.1 × 10−4 | 4.8 × 10−3 | Hrh2, F2rl2 |
| Pathological conditions, signs and symptoms | 5.6 × 10−4 | 9.1 × 10−3 | Des, Dcdc2, Ntn1, Cacng1, Cacna1h, Hsd3b1, Tnni2, F2rl2, Mb, Dmbt1, Actc1, Nags, Napb |
| Organism | <1 mo | 1-11 mos | 1-55 yrs | 6-12 yrs | > 12 yrs | Age Unk | Total | % of total |
| Streptococcus pneumoniae | 2 | 31 | 27 | 17 | 87 | 42 | 187 | 37.18 |
| Neisseria species | 2 | 5 | 14 | 18 | 56 | 12 | 107 | 21.27 |
| Haemophilus species | 0 | 18 | 24 | 2 | 9 | 6 | 59 | 11.73 |
| Staphylococcus | 0 | 10 | 6 | 2 | 11 | 7 | 36 | 7.16 |
| Others Gram negative | 0 | 11 | 2 | 0 | 7 | 2 | 22 | 4.39 |
| Escherichia coli | 1 | 2 | 1 | 0 | 15 | 3 | 22 | 4.37 |
| Streptococcus species | 19 | 3.77 | ||||||
| Other Gram positives | 0 | 4 | 3 | 1 | 5 | 0 | 13 | 2.6 |
| Enterococcus species | 0 | 3 | 0 | 2 | 1 | 3 | 9 | 1.79 |
| Acinetobacter species | 0 | 4 | 0 | 2 | 2 | 0 | 8 | 1.59 |
| ESBL’s Klebsiella pneumoniae | 4 | 2 | 0 | 0 | 0 | 1 | 7 | 1.39 |
| Klebsiella | 0 | 1 | 1 | 0 | 4 | 1 | 7 | 1.39 |
| Pseudomonas species | 0 | 2 | 2 | 1 | 2 | 0 | 7 | 1.39 |
| Total | 9 | 93 | 80 | 45 | 199 | 77 | 503 | 100.02 |
| Ecological | Levels | Change in change | |||||
| Model | Dependent variable | PCNSDP | PCDE | HCR | PCNSDP | PCDE | HCR |
| 1 | Stunting prevalence | −1.92** | – | – | −0.87 | – | – |
| (0.45) | – | – | (0.69) | – | – | ||
| 2 | Stunting prevalence | – | −5.41** | – | – | 1.39 | – |
| – | (0.89) | – | – | (1.47) | – | ||
| 3 | Stunting prevalence | – | – | 0.55** | – | – | 0.20 |
| – | – | (0.08) | – | – | (0.14) |
| ID | Annotation | 290 vs. 5532 fold change | 290 vs. 5532 – p-value corrected FDR | Normalized expression means 290 | Normalized expression means 5532 |
| APOBEC3A | Probable DNA dC- > dU-editing enzyme APOBEC-3A | 1.80E+308 | 0.022 | 0.000 | 8.304 |
| BLZF1 | Golgin-45 | 1.80E+308 | 0.000 | 0.000 | 19.258 |
| BTBD11 | Ankyrin repeat and BTB/POZ domain-containing protein BTBD11 | 1.80E+308 | 0.000 | 0.000 | 17.621 |
| CRLF2 | Uncharacterized protein | 1.80E+308 | 0.000 | 0.000 | 75.314 |
| CSF1 | Uncharacterized protein | 1.80E+308 | 0.022 | 0.000 | 8.313 |
| CXCL10 | C-X-C motif chemokine 10 | 1.80E+308 | 0.000 | 0.000 | 134.604 |
| CXCL11 | C-X-C motif chemokine 11 | 1.80E+308 | 0.000 | 0.000 | 27.796 |
| DDX58 | DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 | 1.80E+308 | 0.013 | 0.000 | 9.386 |
| DDX60 | Probable ATP-dependent RNA helicase DDX60 | 1.80E+308 | 0.000 | 0.000 | 17.559 |
| DDX60L | Probable ATP-dependent RNA helicase DDX60-like | 1.80E+308 | 0.048 | 0.000 | 6.609 |
| EIF2AK2 | Interferon-induced, double-stranded RNA-activated protein kinase | 1.80E+308 | 0.006 | 0.000 | 11.043 |
| EPSTI1 | 1.80E+308 | 0.013 | 0.000 | 9.460 | |
| GPNMB | Transmembrane glycoprotein NMB | 1.80E+308 | 0.001 | 0.000 | 16.139 |
| GYPA | Glycophorin-A | 1.80E+308 | 0.000 | 0.000 | 33.703 |
| HERC6 | Probable E3 ubiquitin-protein ligase HERC6 | 1.80E+308 | 0.030 | 0.000 | 7.652 |
| IDO1 | Uncharacterized protein | 1.80E+308 | 0.000 | 0.000 | 38.529 |
| IFI35 | Interferon-induced 35 kDa protein | 1.80E+308 | 0.000 | 0.000 | 23.808 |
| IFI44L | Interferon-induced protein 44-like | 1.80E+308 | 0.009 | 0.000 | 10.133 |
| IFIT1 | Uncharacterized protein | 1.80E+308 | 0.000 | 0.000 | 39.978 |
| IFIT3 | Interferon-induced protein with tetratricopeptide repeats 3 | 1.80E+308 | 0.006 | 0.000 | 11.063 |
| IFIT5 | Interferon-induced protein with tetratricopeptide repeats 5 | 1.80E+308 | 0.001 | 0.000 | 14.751 |
| IFITM1 | Interferon-induced transmembrane protein 1 | 1.80E+308 | 0.000 | 0.000 | 41.506 |
| NT5C3 | Cytosolic 5′-nucleotidase 3 | 1.80E+308 | 0.026 | 0.000 | 7.949 |
| PARP9 | Uncharacterized protein | 1.80E+308 | 0.032 | 0.000 | 7.461 |
| PLSCR1 | Phospholipid scramblase 1 | 1.80E+308 | 0.002 | 0.000 | 13.466 |
| RSAD2 | Radical S-adenosyl methionine domain-containing protein 2 | 1.80E+308 | 0.003 | 0.000 | 12.711 |
| SEPP1 | Uncharacterized protein | 1.80E+308 | 0.000 | 0.000 | 20.263 |
| SLC39A8 | Zinc transporter ZIP8 | 1.80E+308 | 0.033 | 0.000 | 7.413 |
| SPARC | Uncharacterized protein | 1.80E+308 | 0.013 | 0.000 | 9.466 |
| XAF1 | XIAP-associated factor 1 | 1.80E+308 | 0.003 | 0.000 | 12.311 |
| SP110 | Uncharacterized protein | 6.58E+00 | 0.000 | 242.916 | 1598.704 |
| SAMD9 | Uncharacterized protein | –3.18E+00 | 0.010 | 27.623 | 8.683 |
| ADAM19 | Uncharacterized protein | –3.18E+00 | 0.008 | 29.217 | 9.184 |
| DSG2 | Desmoglein-2 | –6.36E+00 | 0.000 | 33.496 | 5.264 |
| SLCO5A1 | Uncharacterized protein | –1.27E+01 | 0.000 | 47.197 | 3.709 |
| PGAP1 | GPI inositol-deacylase | –1.91E+01 | 0.000 | 51.117 | 2.678 |
| SIGLEC1 | Sialoadhesin | –5.09E+01 | 0.000 | 112.694 | 2.214 |
| BRIP1 | Fanconi anemia group J protein | –1.80E+308 | 0.000 | 23.188 | 0.000 |
| SGPP2 | Sphingosine-1-phosphate phosphatase 2 | –1.80E+308 | 0.000 | 1262.355 | 0.000 |
| TRT | Day 10-PC | Day 23-PC | Day 28-PC | Day 36-PC | Day 50-PC | Day 10-Stx 1 | Day 10-Stx 2 | Day 10-eae | Day 23-Stx 1 | Day 23-Stx 2 | Day 23-eae | Day 28-Stx 1 | Day 28-Stx 2 | Day 28-eae |
| Sb1/2e | 4.22 ab | 4.11 a | 3.25 a | 2.48 a | 1.00 a | 6.12 ab | 5.67 a | 7.10 abc | 4.71 a | 3.34 a | 6.12 a | 4.81 ab | 2.86 ab | 5.97 ab |
| sb1e | 3.91 ab | 4.07 a | 3.22 a | 2.00 ab | 1.00 a | 5.72 ab | 4.72 ab | 6.77 abc | 4.21 a | 2.57 a | 6.00 a | 7.11 a | 3.90 ab | 5.41 ab |
| sI1/2e | 3.39 abc | 3.74 a | 1.00 a | 1.00 b | 1.00 a | 6.73 a | 5.57 a | 7.87 a | 5.73 a | 3.88 a | 6.51 a | 4.95 ab | 2.85 ab | 5.88 ab |
| sI1e | 3.88 ab | 3.93 a | 2.92 a | 1.00 b | 1.00 a | 6.09 ab | 4.19 abc | 7.09 abc | 5.43 a | 3.73 a | 6.66 a | 5.65 ab | 3.36 ab | 6.81 a |
| so0e | 4.99 a | 3.48 a | 4.16 a | 2.84 a | 3.53 a | 6.34 a | 4.75 ab | 7.41 ab | 5.07 a | 3.17 a | 4.37 a | 4.42 ab | 4.16 ab | 5.29 ab |
| cb1/2e | 3.65 ab | 3.96 a | 3.21 a | 1.00 b | 2.18 a | 4.09 bc | 1.00 e | 3.59 bc | 4.59 a | 2.88 a | 3.55 a | 3.90 b | 1.00 b | 2.44 b |
| cb1e | 3.67 ab | 2.25 a | 2.17 a | 1.00 b | 1.00 a | 5.09 abc | 3.10 cd | 5.98 abc | 4.48 a | 3.57 a | 4.47 a | 4.45 ab | 3.41 ab | 2.44 b |
| cI1/2e | 1.00 c | 1.99 a | 1.25 a | 1.00 b | 1.00 a | 4.67 abc | 2.45 d | 4.30 abc | 4.39 a | 2.44 a | 3.79 a | 3.61 b | 2.60 ab | 3.19 b |
| cI1e | 4.16 ab | 4.44 a | 0.58 a | 1.00 b | 1.00 a | 5.34 abc | 3.98 bc | 6.65 abc | 4.78 a | 3.36 a | 4.75 a | 4.16 b | 1.22 ab | 5.02 ab |
| co0e | 1.41 bc | 3.85 a | 3.01 a | 2.59 a | 3.10 a | 3.27 c | 2.44 d | 3.08 c | 5.32 a | 2.57 a | 6.24 a | 4.10 b | 5.86 a | 3.50 ab |
| Follow-up periods | P value for lab data | |||||
| Hemoglobin | TLC | Platelets | Bilirubin | ALT | AST | |
| Before therapy versus after 1 month | 0.00 | 0.78 | 0.19 | 0.00 | 0.00 | 0.00 |
| After 1 month versus after 3 months | 0.285 | 0.06 | 0.25 | 0.00 | 0.00 | 0.00 |
| After 3 months versus after 6 months | 0.15 | 0.11 | 0.35 | 0.002 | 0.001 | 0.00 |
| After 6 months versus after 1 year | 0.97 | 0.16 | 0.303 | 0.00 | 0.013 | 0.00 |
| Dependent Variable: | Mal_Tot | Mal_Tot | ||||||
| Type of Model | PRM | NBRM | PRM | NBRM | ||||
| Nobs | 47 | 47 | 47 | 47 | ||||
| DF | 42 | 42 | 42 | 42 | ||||
| ENSO Measure | ENSO_Avg | ENSO_Dom | ||||||
| Model | ||||||||
| Deviance | 114465.6 | 47.3 | 119277.8 | 47.4 | ||||
| Deviance/DF | 2725.37 | 1.13 | 2839.95 | 1.13 | ||||
| Parameters | PRM | S | NBRM | S | PRM | S | NBRM | S |
| Intercept | 9.6067 | *** | 9.5399 | *** | 9.5926 | *** | 9.5293 | *** |
| Trend1 | 0.0650 | *** | 0.0677 | *** | 0.0657 | *** | 0.0683 | *** |
| Trend2 | -0.1545 | *** | -0.1640 | *** | -0.1541 | *** | -0.1625 | *** |
| Vextre | -0.7768 | *** | -0.7941 | *** | -0.8539 | *** | -0.8901 | *** |
| ENSO Measure | 0.1512 | *** | 0.1626 | ** | 0.0937 | ** | 0.0893 | ** |
| Dispersion♣ | 0.0386 | 0.0414 | ||||||
| Tests | ||||||||
| W:BLT vs (BLT + ENSO ] | 29602.6 | *** | 9.2 | *** | 24790.4 | *** | 5.9 | ** |
| Species | GenBank Accession | Reference |
| Bathymodiolus azoricus | AF334663 | [70] |
| B. thermophilus | AF334664 | [70] |
| Crassostrea virginica 1 | AB206328 | [58] |
| Crassostrea virginica 2 | AB252064 | [57] |
| Crassostrea virginica 3 | AB427186 | This paper |
| Calyptogena sp. SB2001_1 | AF334666 | [70] |
| Calyptogena sp. SB2001_2 | AF334667 | [70] |
| Crassostrea gigas 1 | AB179775 | [96] |
| Crassostrea gigas 2 | AB288344 | [97] |
| Crassostrea gigas 3 | AB307634 | [65] |
| Crassostrea gigas 4 | CU994883 | Favrel, direct submission |
| Chlamys islandica | AJ250028 | [52] |
| Eisenia andrei | DQ339138 | Joskova et al. direct submission |
| Hirudo medicinalis | U24122 | [98] |
| Mytilus edulis 1 | AF334662 | [70] |
| Mytilus edulis 2 | DQ268868 | Caponera and Rawson direct submission |
| Mytilus galloprovincialis 1 | AF334665 | [70] |
| Mytilus galloprovincialis 2 | AB298451 | Itoh et al. direct submission |
| Ostrea edulis | AB179776 | [96] |
| Tapes japonica | AB091383 | [64] |
| Day of follow up | 0 | 1 | 2 | 3 | 7 | 14 | 21 | 28 |
| Patients assessed at visit | 176 | 173 | 172 | 172 | 172 | 171 | 171 | 171 |
| Loss to follow up | 0 | 3 | 1 | 0 | 0 | 1 | 0 | 0 |
| Term | MAPP Network Research Definition |
| Urologic chronic pelvic pain syndrome (UCPPS) | General term to describe idiopathic chronic pelvic pain of urologic origin in men or women. In MAPP Network studies, this includes men and women with IC/BPS, or men with CP/CPPS (see below). |
| Interstitial cystitis/bladder pain syndrome (IC/BPS) | Chronic unpleasant sensation (pain, pressure, discomfort) perceived to be related to the urinary bladder, associated with lower urinary tract symptoms, in the absence of infection or other identifiable causes. |
| Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) | Chronic idiopathic pelvic pain or discomfort in males, commonly in the perineum, suprapubic region, penis, or testicles, which is often exacerbated by ejaculation or urination. |
| Non-Urologic Associated Syndromes (NUAS) | General term used to describe symptom-based non-urologic syndromes which co-occur with UCPPS at a rate greater than observed in the general population. Within the MAPP Network, initial efforts have focused on studying specific NUAS (fibromyalgia, irritable bowel syndrome, chronic fatigue syndrome), though other examples exist (e.g. vulvodynia, temperomandibular joint disorder, and migraine headaches, among others). |
| Name of classifier | MNC | DNC | TNC | IPknot* | IPknot# |
| BayesNet | 0.073 | 0.084 | 0.284 | - | 0.397 |
| NaiveBayes | 0.057 | 0.074 | 0.058 | 0.315 | 0.398 |
| MultilayerPerceptron | 0.060 | 0.075 | 0.128 | 0.314 | 0.429 |
| IBk | 0.057 | 0.074 | 0.089 | 0.314 | 0.407 |
| libSVM | 0.060 | 0.079 | 0.108 | 0.214 | 0.056 |
| SMO | 0.073 | 0.081 | 0.102 | 0.283 | 0.422 |
| RandomForest | 0.055 | 0.079 | 0.121 | 0.400 | 0.433 |
| Dose | Direction | Striatum | Hippocampus | Cortex |
| 10 mg/kg | Up in YAC128, Down with pridopidine | 3.58E-04 | 3.78E-04 | 2.40E-04 |
| Down in YAC128, Up with pridopidine | 3.64E-04 | 4.99E-02 | 2.40E-04 | |
| 30 mg/kg | Up in YAC128, Down with pridopidine | 3.15E-04 | 3.46E-04 | 2.35E-04 |
| Down in YAC128, Up with pridopidine | 3.37E-04 | 3.53E-03 | 2.35E-04 |
| Saccade Behavior | Leading Vehicle | Speed (km/h) | ||||
| 60 | 70 | 80 | 90 | 100 | ||
| Mean saccade duration (ms) | Truck | 46.21 | 55.92 | 58.55 | 65.89 | 102.51 |
| Car | 45.24 | 45.99 | 51.07 | 59.22 | 97.69 | |
| Saccade frequency (Hz) | Truck | 1.02 | 1.04 | 1.09 | 1.18 | 1.04 |
| Car | 1.15 | 1.27 | 1.22 | 1.17 | 1.24 | |
| Mean saccade angle (°) | Truck | 9.14 | 13.64 | 14.77 | 21.24 | 39.63 |
| Car | 6.36 | 8.69 | 13.61 | 17.28 | 33.61 |
| Number | Age (years) | Sex | Primary hematological disorder | Organs involved by tuberculosis | Diagnosis of tuberculosis | Treatment/Outcome of tuberculosis |
| 1 | 55 | Male | Chronic myeloid leukemia | Intestine, mesentry and abdominal lymph nodes | Positive lymph node histology and cultures | Given/Successful |
| 2 | 40 | Male | Acute myeloid leukemia | Lungs | Positive sputum cultures | Given/Successful |
| 3 | 19 | Female | Acute myeloid leukemia | Lungs | Positive sputum cultures | Given/Successful |
| 4 | 20 | Female | Hodgkin's lymphoma | Lungs, liver and abdominal lymph nodes | Positive sputum cultures | Given/Successful |
| 5 | 33 | Female | Thrombocytopenic purpura | Cervical lymph nodes | Positive lymph node cultures | Given/Successful |
| 6 | 70 | Male | Hairy cell leukemia | Lungs, liver, spleen, cerebrospinal fluid and bone marrow | Positive cultures(4 sites) and bone marrow histology | Given/Unsuccessful *Multi-drug resistance |
| 7 | 32 | Male | Multiple Myeloma | Lungs | Positive sputum cultures | Given/Successful |
| 8 | 36 | Female | Essential thrombocythemia | Lungs | Positive sputum cultures | Given/Successful |
| 9 | 24 | Male | Acute myeloid leukemia | Lungs, bone marrow and liver. | Positive bronchial lavage | Not given/Death |
| 10 | 45 | Male | Severe aplastic anemia | Lungs | Positive sputum cultures | Not given/Lost follow up |
| 11 | 70 | Male | Myelodysplastic syndrome | Lungs and cervical lymph nodes | Empirical/positive lymph node histology | Given/Successful |
| 12 | 62 | Male | Polycythemia rubra vera | Cervical lymph nodes | Empirical/positive lymph node histology | Given/Successful |
| 13 | 38 | Male | Acute myeloid leukemia | Lungs, bone marrow, psoas muscle and vertebrae. | Empirical/positive muscle and bone marrow histology | Given/Successful |
| 14 | 52 | Female | Chronic myeloid leukemia | Lungs | Empirical/positive serology | Given/Successful |
| 15 | 59 | Male | Myelodysplastic syndrome | Lungs | Empirical/positive serology | Given/Successful |
| 16 | 75 | Male | Myelodysplastic syndrome | Cervical spine | Empirical | Given/Successful |
| 17 | 60 | Female | Myelofibrosis | Lungs | Empirical | Given/Successful |
| 18 | 65 | Male | Chronic myeloid leukemia | Lungs | Empirical | Given/Successful |
| Clinical parameter | AFAP1‐AS1 | Chi‐squared test P value | |
| High no. cases | Low no. cases | ||
| Age (years) | 0.449 | ||
| ≤64 | 25 | 12 | |
| >64 | 25 | 8 | |
| Gender | 0.451 | ||
| Male | 37 | 13 | |
| Female | 13 | 7 | |
| Smoking state | 0.880 | ||
| Yes | 24 | 10 | |
| No | 26 | 10 | |
| Drinking state | 0.508 | ||
| Yes | 41 | 15 | |
| No | 9 | 5 | |
| Tumor size | 0.040 | ||
| ≤3 cm | 14 | 12 | |
| 3–5 cm | 29 | 7 | |
| >5 cm | 7 | 1 | |
| Tumor stage | <0.01 | ||
| I | 2 | 11 | |
| II | 27 | 4 | |
| III | 21 | 5 |
| Imprecision | Event | Original Text | English Translation |
| Basel, Jul. 1480 | “Anno 1480 circa Magdalenae ingens fuit aquarum inundatio. Rhenus in tantum crevit, quod ad lateres usque inferioris muri Minoris Basileae circa litus ascendit. Etiam homines in ponte stantes facile in Reno manus lavare poterunt.” [Bernoulli, 1915, p. 210] | In 1480, around Magdalena('s day) there was a huge flood of waters. The Rhine rose to the sides of the lower walls of Lesser Basel, near the shore. People standing on the bridge could wash their hands in the Rhine. | |
| small | Meiningen, Jan. 1820 | “Nachdem (18. Jan.) mehrere Tage strenge Kälte gewesen war, trat Thauwetter ein und am 20. Jan. war in Folge desselben die Werra aus den Ufern getreten daßdas Wasser die Chaussee am obern Rafen überstieg.” (Chronik) | After that for some days strong coldness occurred, and then melting, and as a consequence on 20 January the Werra left its bed and the water exceeded the promenade on the upper stage. |
| Szeged, Jul. 1816 | “Alább in a Te(kinte)tes N(eme)s Tanácsnak Kegyes rendeléséhez képpest alázatossan jelentem hogy a Tisza vize, a Maros vízének szörnyü és az idein legnagyobb mostani kiöntése miáll szüntelen árad úgy hogy a múlt Julius 8ik napjátúl fogva 2 Hüvelknyire Fölmagossodott melly szerént a Tiszának az idei legnagyobb aradásátúl fogva esett apadása 20 Hüvelknyit tészen. Szeged 12ik Julii 816. Vedres István” | Letter to the Locumtenential Council: Below, following the order of the esteemed noble council, I report that the water of the Tisza, due to the horrible and in this greatest present inundation of the waters of the Maros, is constantly increasing, and so from the (past) 8 July it increased with 2 inches and thus, the total decrease of the water level of the Tisza compared to the highest levels takes 20 inches. Szeged, 12 July 1816. Istvan Vedres | |
| Basel, Jul. 1570 | “Umb dise zeit ist auch der Rhein so großworden/daßer innerhalb der Statt von dreyen Rhein‐Thoren under der Bruck zusamen geflossen/und die Brucken einem Holz‐floßauff dem Wasser gleich gesehen.” [Groß, 1624, p. 210] | Around this time the Rhine was also so large that it flowed together under the bridge through the three Rhine‐gates in the downtown, and the bridge looked like a wooden raft on the river. | |
| medium | Meiningen, Jun. 1816 | “Dreimal trat die Werra aus den Ufern; der ganze Grund stand gegen 14 Tage auf dem Halme aus und die wenige Frucht, die man ärndtete und feucht einfuhr, gab schlechtes Brod.” (Chronik, p. 197) | The Werra left its banks three times; water was on the whole ground covering the stalks and the little grain people harvested, gave bad bread. |
| Szeged, 1741 | “... preter quod enim quod eadem exundatio agris seminaturas Prata et Pendentes in Vinejs agris fructus in Locis praeterea Marusio et Tibisco Vicinis totaliter perfuderit, et in nihilum redegerit etiam in forejs quod Miser Incola n(on) sui sustentatione conservabat inundavit et Usui humani redidit inutile” (CsCP) | ..., and beyond that the same inundation completely flooded the arable lands (with crops), pastures, vineyards and orchards along the Maros and Tisza rivers, and gave nothing to people, and became useless for human use. | |
| Basel, 1268 | “Renus crevit usque adeo, quod omnes pontes destruxit.” (Ann., p. 193) | The Rhine rose so much that it destroyed all bridges. | |
| large | Meiningen, May 1818 | “Nach anhaltenden Regenwetter trat die Werra aus den Ufern. Am 18. Mai war die Ueberschwemmung am bedeutendsten.” (Chronik, p.205) | After persistent rainy weather the Werra left its banks. The flooding was the most significant on 18 May. |
| Szeged, 1731 | 3o. “Ioanni Hegedüs, ex quo exundatio aquarum modernam Domum residentionalem destruxisset,...” (SzCP) | The house of Janos Hegedüs has been destroyed by the recent flood,... |
| n | Minimum | Maximum | Mean | Std Deviation | |
| Age (months) | 20 | 6.00 | 59.00 | 39.3500 | 18.65 |
| Weight (Kg) | 20 | 6.7 | 23.4 | 14.9 | 4.5 |
| Temp(0C) | 20 | 35.3 | 39.7 | 37.8 | 1.4 |
| Par./200 wbc | 20 | 56 | 3577 | 985 | 986 |
| Parasites/μl | 20 | 2240 | 143,080 | 39,400 | 39450 |
| Hb (g/dl) | 20 | 6.3 | 12.9 | 9.1 | 1.7 |
| Low prescribers (n = 408) | High prescribers (n = 408) | ||||||
| Number | Percent | [95% confidence interval] | Number | Percent | [95% confidence interval] | ||
| Gender | Female | 116 | 28.4 | [24.2–33.1] | 118 | 28.9 | [24.6–33.6] |
| Male | 292 | 71.6 | [66.9–75.8] | 290 | 71.1 | [66.4–75.4] | |
| Practice location | Rural | 110 | 27.0 | [22.8–31.6] | 80 | 19.6 | [15.9–23.9] |
| Urban | 298 | 73.0 | [68.4–77.2] | 328 | 80.4 | [76.1–84.0] | |
| GP partially particular mode of practice | Yes | 40 | 9.8 | [7.2–13.2] | 13 | 3.2 | [1.8–5.5] |
| No | 368 | 90.2 | [86.9–92.9] | 395 | 96.8 | [94.5–98.2] | |
| Cessation of activity during the year 2010 | Yes | 7 | 1.7 | [0.8–3.7] | 7 | 1.7 | [0.8–3.7] |
| No | 401 | 98.3 | [96.3–99.2] | 401 | 98.3 | [96.3–99.2] | |
| Mean | [Standard deviation] | Mean | [Standard deviation] | ||||
| Age of GPs | 52.6 | [9.39] | 52.8 | [8.10] | |||
| Cumulative years of medical practice | 19.83 | [10.71] | 20.5 | [9.7146] | |||
| Number of consultations and home visits | 3,982 | [1,994] | 3,863 | [1,758] | |||
| Number of different patients per year | 1,106 | [538] | 1,012 | [396] | |||
| Number of registered patients | 701 | [406] | 732 | [346] | |||
| Mean age of patients | 46.3 | [6.02] | 45 | [6.1] | |||
| Number of patients with low income | 60 | [79] | 45 | [48] | |||
| Number of patients with chronic disease | 145 | [91] | 144 | [80] | |||
| Number of days of Sickness certificates prescribed | 3,608 | [2,537] | 3,571 | [2,225] | |||
| Number of patients prescribed a sickness certificate | 100 [64] | 94 | [50] | ||||
| Total volume of reimbursement (number of units) | 28,247 | [17,316] | 26,565 | [14,477] | |||
| Number of prescriptions orders | 3,847 [2,122] | 3,808 | [1,859] | ||||
| % ≥ 70 new AD | 0.86 | [0.34] | 0.95 | [0.20] | |||
| Number of DDD | 9,163 | [6298] | 14,848 | [8,200] | |||
| AD prescription ratio | 0.30 | [0.09] | 0.60 | [0.27] |
| Prognostic factor | N | Dead over 5 years (%) | Hazard ratio (95 % CI) | p |
| Model-1 | ||||
| CD8 response to Her-2 | 0.198 (0.05–1.17) | 0.018 | ||
| Yes | 37 | 11 | ||
| No | 33 | 24 | ||
| Metastasis | 3.647 (0.89–14.88) | 0.071 | ||
| No | 32 | 15 | ||
| Yes | 42 | 57 | ||
| pDCs | 0.292 (0.07–1.17) | 0.083 | ||
| ≤Median | 36 | 25 | ||
| >Median | 34 | 9 | ||
| Radiotherapy | 0.107 (0.027–0.41) | 0.001 | ||
| Yes | 57 | 11 | ||
| No | 18 | 44 | ||
| Chemotherapy | <0.001 (<0.001–1.67e+130) | 0.941 | ||
| Yes | 30 | 3 | ||
| No | 42 | 31 | ||
| Model-2 | ||||
| CD8 response to Her-2 | 0.145 (0.02–0.81) | 0.029 | ||
| Yes | 34 | 12 | ||
| No | 28 | 21 | ||
| pDCs | 0.093 (0.011–0.809) | 0.031 | ||
| ≤Median | 31 | 23 | ||
| >Median | 31 | 3 | ||
| Radiotherapy | 0.091 (0.017–0.492) | 0.005 | ||
| Yes | 53 | 9 | ||
| No | 13 | 38 | ||
| Chemotherapy | <0.001 (<0.001–1.9e+157) | 0.949 | ||
| Yes | 30 | 3 | ||
| No | 34 | 26 |
| Total group (n = 1,304) | No sexual violence (n = 806) | Rape (n = 183) | Non-consensual sex (n = 315) | F/χ2 | |
| Age† | 15.89 (1.54) | 15.73 (1.49) | 16.34 (1.51) | 16.04 (1.63) | 13.90* |
| Socio-economic status | 21.076* | ||||
| Bric house | 600 (46.4%) | 404 (50.5%) | 86 (47.5%) | 110 (35.3%) | |
| Non bric house | 693 (53.6%) | 396 (49.5%) | 95 (52.5%) | 202 (64.7%) | |
| Parental availability | 22,10* | ||||
| Both parents alive | 991 (74.9%) | 622 (78.2%) | 112 (61.5%) | 232 (75.1%) | |
| One or both parents deceased | 333 (25.2%) | 173 (21.8%) | 70 (38.5%) | 77 (24.9%) |
| Item | N | Time 1 (Pre) | Time 3 (6 Month) | Mean change* | P value* | ||||
| Mean | SD | Mean | SD | Mean | 95% CI | ||||
| 1 | I am confident that I have the interview skills to use my time well with suicidal clients. | 59 | 51.69 | 21.60 | 68.83 | 16.33 | 17.14 | 12.88 – 21.39 | 0.000 |
| 2 | After seeing a client once I would be confident that I could recognise potential suicide risk. | 59 | 37.44 | 21.33 | 58.05 | 20.07 | 20.61 | 14.96 – 26.26 | 0.000 |
| 3 | I feel confident that I could differentiate a mild depression from a suicide risk. | 59 | 49.95 | 23.14 | 68.37 | 16.20 | 18.42 | 13.29 – 23.56 | 0.000 |
| 4 | I am confident in dealing with the needs of suicidal clients. | 59 | 42.75 | 21.95 | 65.98 | 17.16 | 23.24 | 18.53 – 27.95 | 0.000 |
| Total | 59 | 181.83 | 74.59 | 261.24 | 61.20 | 79.41 | 63.55 – 95.26 | 0.000 |
| Author, year | Study population (period) | Definition of HDP-related SAMM | Case fatality rate (Number of deaths/cases) | Mortality reductiona | |
| Natural case fatality | |||||
| 25% | 42% | ||||
| Mantel et al, 1998[73] | Kalafong and Pretoria hospitals, South Africa (1996-1998) | Hypertension with organ failure | 20.8% (10/48) | 16.7% | 50.4% |
| Khosla et al 2000[74] | One hospital, Rohtak, India (1998) | Eclampsia | 17.7% (11/62) | 29.0% | 57.8% |
| Pattinson et al, 2003[75] | Three regions, South Africa (year not stated) | Hypertension with organ failure | 20.7% (30/145) | 17.2% | 50.7% |
| Kaye et al 2003[76] | Mulago hospital, Uganda (2000) | Eclampsia/pre-eclampsia with organ failure | 14.3% (3/21) | 42.9% | 66.0% |
| Oladapo et al 2007[77] | Olabisi Onabanjo hospital, southwest Nigeria (2002-2004) | Eclampsia and severe pre-eclampsia with clinical/laboratory indications for termination of pregnancy to save the woman's live | 14.9% (21/141) | 40.4% | 64.5% |
| Adisasmita et al 2008[78] | Four hospitals in West-Java, Indonesia (2003-2004) | Eclampsia and pre-eclampsia with organ failure | 3.9% (22/563) | 84.4% | 90.7% |
| Roost et al 2009[79] | Four public hospitals in La Paz and El Alto, Bolivia (2006-2007) | Eclampsia and pre-eclampsia based on clinical and management criteria | 0.5% (1/184) | 98.0% | 98.8% |
| Characteristic | Number of patients(%) |
| Sex | |
| Female | 318 (29.1) |
| Male | 775 (70.9) |
| Age (years) | |
| Median | |
| (range) | 47 (15-90) |
| ≤ 47 | 568 |
| > 47 | 517 |
| Missing | 8 |
| Follow-up time (months) | |
| Median | 67 (1-120) |
| (range) | |
| Clinical stage | |
| I-II | 315 (29.0) |
| III-IV | 773 (71.0) |
| Missing | 5 |
| Relapse | |
| No | 1001 (91.7) |
| Yes | 91 (8.3) |
| Missing | 1 |
| Metastasis | |
| No | 984 (90.1) |
| Yes | 108 (9.9) |
| Missing | 1 |
| Therapeutic modality | |
| Radiotherapy | 766 (70.6) |
| Chemotherapy | 10 (0.9) |
| Radiochemotherapy | 309 (28.5) |
| Missing | 8 |
| WHO histological classification | |
| NKUC | 853 (78.3) |
| NKDC | 206 (18.9) |
| KSCC | 30 (2.8) |
| Missing | 4 |
| OS rate (%) | |
| 5-year | 69.1 |
| Group | Quintile | Total PA | Moderate PA | Vigorous PA | MVPA | ||||
| OR | 95% CI | OR | 95% CI | OR | 95% CI | OR | 95% CI | ||
| Boys (2 to 6 years) | |||||||||
| n = 524 | Q1 | 2.58 | 1.07 to 6.18 | 1.26 | 0.55 to 2.88 | 1.23 | 0.46 to 3.26 | 1.39 | 0.56 to 3.45 |
| Q2 | 1.59 | 0.65 to 3.91 | 1.27 | 0.57 to 2.83 | 2.91 | 1.25 to 6.82 | 2.21 | 0.95 to 5.15 | |
| Q3 | 1.31 | 0.55 to 3.16 | 1.17 | 0.51 to 2.66 | 1.98 | 0.79 to 4.93 | 1.98 | 0.85 to 4.58 | |
| Q4 | 2.21 | 0.98 to 4.98 | 1.23 | 0.56 to 2.69 | 2.14 | 0.89 to 5.15 | 1.62 | 0.68 to 3.85 | |
| Q5 (reference) | 1 | 1 | 1 | 1 | |||||
| Girls (2 to 6 years) | |||||||||
| n = 470 | Q1 | 1.03 | 0.43 to 2.47 | 0.77 | 0.32 to 1.85 | 2.54 | 0.88 to 7.29 | 1.23 | 0.48 to 3.17 |
| Q2 | 0.76 | 0.32 to 1.85 | 0.80 | 0.33 to 1.93 | 2.71 | 0.96 to 7.70 | 1.18 | 0.45 to 3.08 | |
| Q3 | 0.81 | 0.34 to 1.90 | 0.69 | 0.29 to 1.67 | 1.68 | 0.55 to 5.15 | 1.26 | 0.50 to 3.13 | |
| Q4 | 0.72 | 0.31 to 1.63 | 0.67 | 0.28 to 1.62 | 2.29 | 0.82 to 6.37 | 1.20 | 0.48 to 2.98 | |
| Q5 (reference) | 1 | 1 | 1 | 1 | |||||
| Boys (6 to 9 years) | |||||||||
| n = 1,038 | Q1 | 3.26 | 1.74 to 6.10 | 3.58 | 1.95 to 6.55 | 3.82 | 2.05 to 7.16 | 3.77 | 2.04 to 6.96 |
| Q2 | 1.70 | 0.89 to 3.25 | 1.38 | 0.75 to 2.53 | 2.70 | 1.45 to 5.14 | 1.98 | 1.04 to 3.77 | |
| Q3 | 2.00 | 1.06 to 3.79 | 1.29 | 0.70 to 2.38 | 2.01 | 1.04 to 3.89 | 1.32 | 0.67 to 2.59 | |
| Q4 | 1.10 | 0.55 to 2.20 | 0.50 | 0.24 to 1.06 | 1.78 | 0.88 to 3.59 | 1.23 | 0.61 to 2.46 | |
| Q5 (reference) | 1 | 1 | 1 | 1 | |||||
| Girls (6 to 9 years) | |||||||||
| n = 987 | Q1 | 1.72 | 0.90 to 3.30 | 2.54 | 1.33 to 4.86 | 2.49 | 1.37 to 4.52 | 2.95 | 1.55 to 5.61 |
| Q2 | 2.47 | 1.34 to 4.56 | 2.78 | 1.46 to 5.24 | 1.90 | 1.03 to 3.50 | 2.70 | 1.43 to 5.10 | |
| Q3 | 1.87 | 1.01 to 3.45 | 2.44 | 1.29 to 4.62 | 1.78 | 0.94 to 3.39 | 2.11 | 1.11 to 4.12 | |
| Q4 | 1.31 | 0.69 to 2.51 | 1.13 | 0.56 to 2.28 | 1.18 | 0.59 to 2.34 | 1.27 | 0.64 to 2.52 | |
| Q5 (reference) | 1 | 1 | 1 | 1 |
| Parameter | Benign (n = 102) | Malignant (n = 11) | P value |
| Age | 58.9 ± 16.4 | 48.8 ± 18.7 | 0.059 |
| Female gender | 66 (64.7) | 5 (45.5) | 0.209 |
| Urgent intervention | 22 (21.6) | 10 (90.9) | <0.01 |
| Coronary artery disease | 8 (7.8) | 0 (0.0) | 0.335 |
| Valvular heart disease | 12 (11.8) | 0 (0.0) | 0.229 |
| Congenital heart disease | 0 (0.0) | 1 (9.1) | 0.742 |
| Thromboembolic disease | 3 (2.9) | 0 (0.0) | 0.564 |
| Hospital | Case (male/female) | Percentage of total |
| Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine | 178 (111/67) | 5.03% |
| Guanganmen Hospital affiliated to China Academy of Chinese Medical Science | 564 (363/201) | 15.95% |
| Huairou Hospital of Traditional Chinese Medicine | 121 (77/44) | 3.42% |
| Beijing Hospital of Traditional Chinese Medicine | 220 (142/78) | 6.22% |
| People's Hospital affiliated to Beijing University | 107 (72/35) | 3.03% |
| Tongzhou Hospital of Traditional Chinese Medicine | 160 (98/62) | 4.52% |
| Tongren Hospital affiliated to Capital University of Medical Sciences | 260 (162/98) | 7.35% |
| Wangjing Hospital affiliated to China Academy of Chinese Medical Science | 93 (58/35) | 2.63% |
| Xiyuan Hospital affiliated to China Academy of Chinese Medical Science | 462 (304/158) | 13.06% |
| China-Japan Friendship Hospital | 632 (425/207) | 17.87% |
| Beijing Hospital of Integrated Traditional Chinese with Western Medicine | 124 (80/44) | 3.51% |
| Anzhen Hospital affiliated to Capital University of Medical Sciences | 616 (422/194) | 17.42% |
| Cluster of Life Sciences | BMBS - Biomedicine and Molecular BiosciencesFA - Food and AgricultureFPS - Forests, their Products and Services |
| Cluster of Natural Sciences | CMST - Chemistry and Molecular Sciences and TechnologiesESSEM - Earth System Science and Environmental ManagementMPNS - Materials, Physical and Nanosciences |
| Cluster of Science and Society | ISCH - Individuals, Societies, Cultures and HealthICT - Information and Communication TechnologiesTUD - Transport and Urban Development |
| Trans Domain area (not a separate Domain currently) – allows for multidisciplinary proposals which cannot be submitted to a single Domain. |
| Chronic Disease (outcome variables) | Frequent mental distress (FMD) Beta (SE)1 | Obesity Beta (SE)1 |
| Diabetes | 0.55 (0.03)2 | 1.17 (0.02)2 |
| High Blood Pressure | 0.54 (0.02)2 | 0.99 (0.02)2 |
| Coronary Heart Disease | 0.90 (0.04)2 | 0.41 (0.03)2 |
| Stroke | 0.93 (0.04)2 | 0.18 (0.04)2 |
| Asthma | 0.62 (0.03)2 | 0.42 (0.02)2 |
| Arthritis | 0.87 (0.02)2 | 0.61 (0.02)2 |
| Factor | Factor level | Frequency (n) | Percentage | Chi-square | df | Significance |
| Habitat stability | Permanent | 214 | 63.13 | |||
| Temporary | 125 | 36.87 | 22.317 | 1 | 0.000 | |
| Habitat origin | Man-made | 326 | 96.17 | |||
| Natural | 13 | 3.83 | 0.873 | 1 | 0.350 | |
| Water origin | Surface run-off | 279 | 82.30 | |||
| Underground | 60 | 17.70 | 5.254 | 1 | 0.022 | |
| Habitat size | <10 | 45 | 13.27 | |||
| >100 | 50 | 14.75 | ||||
| 10 - 100 | 244 | 71.98 | 9.822 | 2 | 0.007 | |
| Water movement | No | 301 | 88.79 | |||
| Yes | 38 | 11.21 | 0.768 | 1 | 0.381 | |
| Vegetation | Absent | 149 | 43.95 | |||
| Present | 190 | 56.05 | 11.547 | 1 | 0.001 |
| Combined SMI group (n = 230) | Glasgow City (n = 8,094) | P1 | Scotland (n = 54,590) | P2 | |
| Cause of death (n, %) | |||||
| Cerebrovascular disease | 8 (3.5%) | 304 (3.8%) | p = 0.833 | 2186 (4.0%) | p = 0.685 |
| Cardiovascular disease | 34 (14.8% | 1069 (13.2%) | p = 0.546 | 7465 (13.7%) | p = 0.626 |
| Cancer | 33 (14.3%) | 2211 (27.3%) | p < 0.001 | 18129 (33.2%) | p < 0.001 |
| Respiratory disease | 24 (10.4%) | 606 (7.5%) | p = 0.096 | 3451 (6.3%) | p = 0.001 |
| Alcohol Related | 15 (6.5%) | 1032 (12.8%) | p = 0.005 | 5319 (9.7%) | p = 0.099 |
| Accidental deaths | 11 (4.8%) | 400 (4.9%) | p = 0.912 | 2882 (5.3%) | p = 0.734 |
| Suicide | 34 (14.8%) | 568 (7.0%) | p < 0.001 | 3533 (6.5%) | p < 0.001 |
| Mental & behavioural disorder due to drugs | 18 (7.8%) | 412 (5.1%) | p = 0.065 | 1756 (3.2%) | p < 0.001 |
| Other | 53 (23.0%) | 1492 (18.4%) | p = 0.076 | 9869 (18.1%) | p = 0.05 |
| Male (n,%) | 156 (67.8%) | 5218 (64.5%) | p = 0.298 | 33772 (61.9%) | p = 0.063 |
| Deaths/age group (n, %) | |||||
| 16-24 | 3 (1.3) | 238 (2.9) | p = 0.144 | 1902 (3.5) | p = 0.07 |
| 25-34 | 18 (7.8) | 559 (6.9) | p = 0.588 | 3186 (5.8) | p < 0.001 |
| 35-44 | 38 (16.5) | 1250 (15.4) | p = 0.656 | 6841 (12.5) | p < 0.001 |
| 45-54 | 72 (31.3) | 2171 (26.8) | p = 0.131 | 13841 (25.4) | p = 0.039 |
| 55-64 | 99 (43.0) | 3876 (47.9) | p = 0.147 | 28820 (52.8) | p = 0.003 |
| Deaths/Socioeconomic Status (n, %) | |||||
| 1-Most affluent | 11 (4.8%) | 257 (3.2%) | p = 0.173 | 5974 (10.9%) | p = 0.003 |
| 2- | 15 (6.5%) | 450 (5.6%) | p = 0.531 | 8244 (15.1%) | p = 0.0003 |
| 3- | 34 (14.8%) | 732 (9.0%) | p = 0.003 | 10338 (18.9%) | p = 0.108 |
| 4- | 64 (27.8%) | 1286 (15.9%) | p < 0.001 | 12643 (23.2%) | p = 0.09 |
| 5-Most deprived | 106 (46.1%) | 5369 (66.3%) | p < 0.001 | 17391 (31.9%) | p < 0.001 |
| Haplotype | Freq (case) | Freq (control) | P | OR (95% CI) |
| rs12068264|rs11576175 | ||||
| CA | 0.1685 (61) | 0.203 (82) | 1.000 (Reference) | |
| TG | 0.4088 (149) | 0.3416 (139) | 0.076 | 1.441 (0.962–2.158) |
| CG | 0.4227 (154) | 0.4554 (185) | 0.576 | 1.119 (0.754–1.660) |
| rs16924934|rs2273773|rs3818291 | ||||
| ATA | 0.1703 (62) | 0.1749 (71) | 1.000 (Reference) | |
| ACG | 0.294 (107) | 0.2389 (97) | 0.295 | 1.263 (0.815–1.957) |
| GTG | 0.1703 (62) | 0.1626 (66) | 0.768 | 1.076 (0.662–1.749) |
| ATG | 0.3654 (133) | 0.4236 (172) | 0.560 | 0.886 (0.588–1.333) |
| Compounds | pIC50 | CoMFA | CoMSIA | HQSAR | |||
| Pred. | Res. | Pred. | Res. | Pred. | Res. | ||
| 1 | 4.1 | 4.078 | 0.022 | 4.331 | − 0.231 | 4.204 | − − 0.104 |
| 2 | 5.9111 | 6.049 | − 0.1379 | 5.627 | 0.2841 | 5.664 | 0.2471 |
| 3 | 6.1301 | 6.188 | − 0.0579 | 6.395 | − 0.2649 | 6.276 | − 0.1459 |
| 4 | 6.3595 | 6.276 | 0.0835 | 6.591 | − 0.2315 | 6.116 | 0.2435 |
| 5 | 7.3279 | 7.202 | 0.1259 | 7.036 | 0.2919 | 7.246 | 0.0819 |
| 6 | 6.6556 | 6.629 | 0.0266 | 6.501 | 0.1546 | 6.187 | 0.4686 |
| 7 | 6.7645 | 6.841 | − 0.0765 | 6.83 | − 0.0655 | 6.711 | 0.0535 |
| 8 | 6.1791 | 6.58 | − 0.4009 | 6.383 | − 0.2039 | 6.514 | − 0.3349 |
| 9 | 6.4389 | 6.309 | 0.1299 | 6.426 | 0.0129 | 6.481 | − 0.0421 |
| 10 | 6.514 | 6.621 | − 0.107 | 6.896 | − 0.382 | 6.679 | − 0.165 |
| 11 | 4.9746 | 4.915 | 0.0596 | 4.848 | 0.1266 | 5.429 | − 0.4544 |
| 12 | 6.7144 | 6.637 | 0.0774 | 6.693 | 0.0214 | 6.276 | 0.4384 |
| 14 | 7.4089 | 7.066 | 0.3429 | 7.289 | 0.1199 | 7.246 | 0.1629 |
| 15 | 6.8538 | 6.866 | − 0.0122 | 6.671 | 0.1828 | 7.192 | − 0.3382 |
| 16 | 5.6197 | 5.749 | − 0.1293 | 5.633 | − 0.0133 | 5.685 | − 0.0653 |
| 17 | 6.0731 | 6.05 | 0.0231 | 5.902 | 0.1711 | 5.795 | 0.2781 |
| 18 | 6.3036 | 6.35 | − 0.0464 | 6.293 | 0.0106 | 6.204 | 0.0996 |
| 19 | 5.1469 | 5.118 | 0.0289 | 5.17 | − 0.0231 | 5.435 | − 0.2881 |
| 21 | 5.1466 | 5.122 | 0.0246 | 5.133 | 0.0136 | 5.193 | − 0.0464 |
| 22 | 5.083 | 5.005 | 0.078 | 5.075 | 0.008 | 5.326 | − 0.243 |
| 23 | 5.313 | 5.335 | − 0.022 | 5.141 | 0.172 | 5.26 | 0.053 |
| 24 | 5.334 | 5.402 | − 0.068 | 5.329 | 0.005 | 5.383 | − 0.049 |
| 26 | 5.3665 | 5.387 | − 0.0205 | 5.543 | − 0.1765 | 5.199 | 0.1675 |
| 28 | 5.337 | 5.368 | − 0.031 | 5.312 | 0.025 | 5.181 | 0.156 |
| 30 | 5.3665 | 5.436 | − 0.0695 | 5.382 | − 0.0155 | 5.244 | 0.1225 |
| 31 | 5.337 | 5.281 | 0.056 | 5.24 | 0.097 | 5.614 | − 0.277 |
| 33 | 5.3767 | 5.373 | 0.0037 | 5.405 | − 0.0283 | 5.773 | − 0.3963 |
| 34 | 5.3565 | 5.327 | 0.0295 | 5.333 | 0.0235 | 5.357 | − 0.0005 |
| 35 | 5.2757 | 5.265 | 0.0107 | 5.414 | − 0.1383 | 5.238 | 0.0377 |
| 36 | 4.8913 | 4.898 | − 0.0067 | 4.771 | 0.1203 | 4.777 | 0.1143 |
| 37 | 4.8548 | 4.858 | − 0.0032 | 4.88 | − 0.0252 | 4.844 | 0.0108 |
| 40 | 5.134 | 5.225 | − 0.091 | 5.387 | − 0.253 | 4.9 | 0.234 |
| 41 | 4.793 | 4.713 | 0.08 | 4.787 | 0.006 | 4.845 | − 0.052 |
| 42 | 5.2757 | 5.194 | 0.0817 | 5.162 | 0.1137 | 5.357 | − 0.0813 |
| 43 | 5.1157 | 5.075 | 0.0407 | 5.164 | − 0.0483 | 5.087 | 0.0287 |
| 44 | 5.602 | 5.628 | − 0.026 | 5.587 | 0.015 | 5.484 | 0.118 |
| 45 | 4.9625 | 4.98 | − 0.0175 | 4.982 | − 0.0195 | 5 | − 0.0375 |
| Demographic characteristics | Value |
| Age in years, mean (range) | 55.9 (42 to 79) |
| Race, n (%) | |
| White | 4 (50) |
| African heritage | 2 (25) |
| Asian - Japanese/East Asian/Southeast Asian heritage | 1 (13) |
| Asian - Central/South Asian heritage | 1 (13) |
| Baseline ECOG performance status, n (%) | |
| 0 | 6 (77) |
| 2 | 2 (25) |
| Time since diagnosis (years), median (range) | 4.5 (1 to 9) |
| Trial | Hb (g/L) | Ferritin (μg/L) | TSAT (%) | BM iron |
| Auerbach 2004 [26] | ≤105 | ≤200 | ≤19* | ND |
| Auerbach 2010 [31] | ≤100 | ≥10 | ≥15 | ND |
| Bastit et al. [29] | <110 | 10–800 | ≥15 | ND |
| Hedenus et al. [28] | 90–110 | <800 | — | + |
| Henry et al. [27] | <110 | 100–900 | 15–35 | ND |
| Pedrazzoli et al. [30] | <110 | 100–800 | 20–40 | ND |
| Steensma et al. [32] | <110 | ≥20 | <60 | ND |
| Kidney tissue | Treatment | 1 h | 24 h | 48 h | 72 h |
| Cortex | CG | 19.0 ± 2.3 | 18.9 ± 2.1 | 19.2 ± 2.2 | 18.9 ± 2.7 |
| DN PC | 24.5 ± 3.6* | 24.5 ± 4.3* | 24.7 ± 4.5* | 25.4 ± 3.7* | |
| DN 200 | 31.1 ± 3.2* | 31.3 ± 4.9* | 30.9 ± 3.6* | 28.9 ± 4.3* | |
| DN 240 | 33.3 ± 4.6* | 34.8 ± 4.8* | 34.0 ± 3.1* | 33.5 ± 7.9* | |
| DN 300 | 41.7 ± 5.1* | 41.9 ± 3.4* | 40.1 ± 5.5* | 39.2 ± 4.0* | |
| DN 350 | 46.7 ± 5.2* | 50.2 ± 5.8* | 48.9 ± 5.7* | 43.7 ± 6.0* | |
| DN 400 | 50.1 ± 5.6* | 57.6 ± 5.3* | 53.9 ± 6.1* | 47.4 ± 5.5* | |
| Outer medulla | CG | 20 ± 4.2 | 22.7 ± 4.8 | 22.4 ± 5.4 | 21.6 ± 5.1 |
| DN PC | 29.9 ± 4.4* | 30.7 ± 5.1* | 28.2 ± 5.8* | 29.5 ± 5.4* | |
| DN 200 | 38.1 ± 4.6* | 40.1 ± 6.2* | 37.5 ± 4.8* | 33.8 ± 5.8* | |
| DN 240 | 42.3 ± 3.5* | 43.3 ± 5.7* | 40.3 ± 4.2* | 37.3 ± 3.5* | |
| DN 300 | 53.4 ± 5.2* | 57.9 ± 5.6* | 48.8 ± 4.8* | 45.4 ± 5.2* | |
| DN 350 | 60.6 ± 6.3* | 72.4 ± 5.7* | 62.9 ± 5.5* | 56.5 ± 5.3* | |
| DN 400 | 67.6 ± 5.6* | 80.4 ± 6.3* | 74.7 ± 6.1* | 67.7 ± 5.8* | |
| Inner medulla | CG | 20.2 ± 2.4 | 20.0 ± 3.6 | 21.8 ± 2.7 | 20.5 ± 3.2 |
| DN PC | 22.7 ± 4.7* | 24.5 ± 3.8* | 24.3 ± 4.0* | 22.9 ± 3.4* | |
| DN 200 | 27.2 ± 3.3* | 30.6 ± 4.0* | 26.2 ± 2.7* | 25.0 ± 3.5* | |
| DN 240 | 30.4 ± 3.8* | 33.6 ± 5.8* | 31.9 ± 4.2* | 29.9 ± 5.2* | |
| DN 300 | 42.8 ± 5.2* | 44.2 ± 5.0* | 38.8 ± 4.9* | 32.7 ± 4.8* | |
| DN 350 | 49.2 ± 5.7* | 50.2 ± 4.8* | 47.3 ± 5.8* | 39.4 ± 5.1* | |
| DN 400 | 55.2 ± 5.4* | 57.2 ± 5.3* | 55.3 ± 6.3* | 46.4 ± 5.7* |
| Healthy volunteers | ObT2D | HV/ObT2D | |
| (n = 19) | (n = 20) | p value | |
| Intra-myocardium dixon fat fraction (%) | 7.9 ± 3.7 | 6.0 ± 1.5 | |
| Dixon 3D epicardial fat volume (mL) | 176.4 ± 68.6 | 273.8 ± 64.0 | *** |
| Indexed dixon 3D epicardial fat volume (mL/m2) | 89.7 ± 25.2 | 123.6 ± 23.4 | *** |
| Dixon 3D epicardial fat fraction (%) | 21.0 ± 4.0 | 28.4 ± 5.5 | *** |
| Name | Chr | Binsa | QTL confidence interval, bp | LODb | R2 | Additive Effectc | |
| Left border | Right border | ||||||
| QTLGLSchr1 | 1 | 1.07-1.09 | 211,331,752 | 263,220,725 | 4.724933 | 0.045507 | 0.045507 |
| QTLGLSchr6 | 6 | 6.01-6.04 | 26,909,746 | 120,538,443 | 6.9741 | 0.06859 | 32.11692 |
| QTLGLSchr7 | 7 | 7.01-7.02 | 11,570,701 | 124,949,426 | 5.2492 | 0.052803 | 24.17346 |
| QTLGLSchr8 | 8 | 8.02-8.04 | 14,069,105 | 118,971,618 | 22.83246 | 0.265049 | 105.1474 |
| Stage 1: selection of study sites | |||||||
| Region | Country | Estimated no. ART clinics (yr. of assessment) | Estimated no. adult ART enrollees at ART clinics | No. eligible clinics* | Estimated no. study-eligible adult ART enrollees at eligible clinics | Site sampling technique | No. clinics selected |
| Southern Africa | Mozambique | 379 (2014) | 582,000 | 254 | 446,379 | Census | 254 |
| Namibia | 213 (2014) | 165,468 | 213 | 165,468 | Census | 213 | |
| Swaziland | 31 (2009) | 50,767 | 31 | 50,767 | PPS | 16 | |
| Zimbabwe | 104 (2008) | 103,806 | 70 | 93,811 | PPS | 40 | |
| Zambia | 322 (2007) | 65,383 | 129 | 58,845 | Purposive | 6 | |
| East Africa | Tanzania | 210 (2007) | 41,920 | 85 | 37,728 | Purposive | 6 |
| Uganda | 286 (2007) | 45,946 | 114 | 41,351 | Purposive | 6 | |
| West Africa | Nigeria†† | 178 (2009) | 168,335 | 139 | 167,438 | PPS | 35 |
| Caribbean | Haiti | 200 (2015) | 65,000 | 191 | 60,705 | Census | 191 |
| Southeast Asia | Vietnam | 173 (2009) | 28,090 | 120 | 25,000 | PPS | 30 |
| Total | — | 2,096 | 1,316,715 | 1,346 | 1,147,492 | — | 797 |
| Stage 2: selection of study patients | |||||||
| Region | Country | Age-eligibility criteria (age at ART initiation) (yrs) | ART enrollment years covered by analysis | Patient sampling technique at selected clinics | Planned sample size* | No. eligible medical recordsanalyzed | Date of data collection |
| Southern Africa | Mozambique | ≥15 | 2004–2013 | Census | 446,379 | 446,379 | Dec 2014 |
| Namibia | ≥15 | 2004–2012 | Census | 165,468 | 165,468 | Dec 2013 | |
| Swaziland | ≥15 | 2004–2010 | SRS | 2,500 | 2,510 | Nov 2011–Feb 2012 | |
| Zimbabwe | ≥15 | 2007–2009 | SRS | 4,000 | 3,896† | Jan–Jun 2010 | |
| Zambia | ≥18 | 2004–2009 | SRS | 1,500 | 1,214§ | Apr–Jul 2010 | |
| East Africa | Tanzania | ≥18 | 2004–2009 | SRS | 1,500 | 1,421¶ | Apr–Jul 2010 |
| Uganda | ≥18 | 2004–2009 | SRS | 1,500 | 1,466** | Apr–Jul 2010 | |
| West Africa | Nigeria†† | ≥15 | 2004–2011 | SRS | 3,500 | 3,496 | Dec 2012–Aug 2013 |
| Caribbean | Haiti | ≥15 | 2004–2015 | Census | 60,705 | 60,705 | Jun 2016 |
| Southeast Asia | Vietnam | ≥15 | 2005–2009 | SRS | 7,587 | 7,583§§ | Jan–Jun 2010 |
| Total | — | — | — | — | 694,639 | 694,138 | — |
| CT technique description | Injection activity (MBq) | Effective dose (mSv) | Effective dose per unit activity (mSv/MBq) | |||
| Male | Female | Male | Female | Male | Female | |
| Standard CT | 455 ± 30 | 450 ± 26 | 8.1 ± 1.2 | 10.1 ± 1.4 | 0.018 ± 0.002 | 0.022 ± 0.002 |
| Diagnostic CT | 455 ± 25 | 454 ± 51 | 8.1 ± 0.8 | 9.9 ± 1.6 | 0.018 ± 0.002 | 0.022 ± 0.003 |
| Gene Ontologya | DAVIDb |
| Biological process | |
| Cell adhesion (GO:0007155) | 0.0000148 |
| Cell communication | 0.000632 |
| G-protein signaling, coupled to cyclic nucleotide second messenger | 0.001940c |
| System development (GO:0048731) | 0.000000016 |
| Central nervous system development | 0.000293c |
| Organ development (GO:0048513) | 0.000017 |
| Cellular compartment | |
| Integral to membrane (GO:0016021) | 0.0000018 |
| Integral to plasma membrane (GO:0005887) | 0.000000026 |
| Dystrophin-associated glycoprotein complex | 0.002081c |
| Sarcoglycan complex | 0.004398c |
| Molecular function | |
| Signal transducer activity (GO:0004871) | 0.0000025 |
| Transmembrane receptor activity (GO:0004888) | 0.0000274 |
| Transmembrane receptor protein phosphatase activity | 0.003811c |
| Amine receptor activity | 0.004557c |
| Hematopoietin/interferon-class (D200-domain) cytokine receptor activity | 0.001526c |
| Phosphoinositide binding | 0.000737c |
| GPI anchor binding | 0.003257c |
| Calcium-release channel activity | 0.004102c |
| Delayed rectifier potassium channel activity | 0.001212c |
| Enriched KEGG pathways | PEb |
| Cell adhesion molecules (CAMs) | 0.00000036 |
| Neuroactive ligand-receptor interaction | 0.000542 |
| Allograft rejection | 0.001545 |
| Type I diabetes mellitus | 0.003487 |
| Outcome and instrument | Method | Data collection time | ||
| T0 | T1 | T2 | ||
| Perceived health | ||||
| SF-36 | Interview caregiver or mailed questionnaire | x | x | x |
| Objective burden | ||||
| Short version iBMG | Interview caregiver or mailed questionnaire | x | x | x |
| instrument objective burden informal care | ||||
| Subjective burden | ||||
| Carer-Qol | Interview caregiver or mailed questionnaire | x | x | x |
| SRB | Interview caregiver or mailed questionnaire | x | x | x |
| CSI+ | Interview caregiver or mailed questionnaire | x | x | |
| Perseverance time | Interview caregiver or mailed questionnaire | x | x | |
| ASIS | Interview caregiver or mailed questionnaire | x | x | |
| Quality of life | ||||
| SF-36 | Interview caregiver or mailed questionnaire | x | x | x |
| Cantril’s self-anchoring ladder | Interview caregiver or mailed questionnaire | x | x | x |
| Use of community services | ||||
| Self-reported | Interview caregiver or mailed questionnaire | x | x | x |
| CSAI | Interview caregiver or mailed questionnaire | x | x |
| Strategy | Treatment | Genomic Profile | Phase | N | ORR (%) | PFS (M) | OS (M) | Clinical Development | Reference |
| BRAF monotherapy | Vemurafenib | BRAFmut | I/II | 21 | 5 | 2.1 | 7.7 | Complete | NCT00405587 [93] |
| BRAF monotherapy | Vemurafenib | BRAFmut | II | 10 | 0 | 4.5 | 9.3 | Complete | NCT01524978 [94] |
| BRAF + MEK | Dabrafenib + Trametinib | BRAFmut | I/II | 43 | 12 | 3.5 | (−) | Complete | NCT01726738 [88] |
| BRAF + EGFR | Vemurafenib + Cetuximab | BRAFmut | II | 27 | 4 | 3.7 | 7.1 | Complete | NCT01524978 [94] |
| BRAF + EGFR | Vemurafenib + Panitumumab | BRAFmut | Pilot | 15 | 13 | 3.2 | 7.6 | Complete | NCT01791309 [89] |
| BRAF + EGFR | Encorafenib + Cetuximab | BRAFmut | II | 50 | 22 | 4.2 | 12.4 | Ongoing | NCT01719380 [90] |
| BRAF + EGFR | Dabrafenib + Panitumumab | BRAFmut | I/II | 20 | 10 | 3.4 | (−) | Ongoing | NCT01750918 [85] |
| BRAF + EGFR | BMS-908662 + Cetuximab | Kras mut or BRAF mut | I/II | 17 * | (−) | (−) | (−) | Ongoing | NCT01086267 |
| BRAF + EGFR + CT | Vemurafenib + Cetuximab + irinotecan | BRAFmut | I | 12 | 50 | (−) | (−) | Ongoing | NCT01787500 |
| BRAF + EGFR + CT | Cetuximab + irinotecan ± Vemurafenib | BRAFmut | II (RCT) | 78 * | (−) | (−) | (−) | Ongoing | NCT02164916 |
| BRAF + EGFR + MEK | Dabrafenib + Panitumumab + Trametinib | BRAFmut | I/II | 83 | 18 | (−) | (−) | Ongoing | NCT01750918 [85] |
| BRAF + EGFR ± MEK | Encorafenib + Cetuximab ± Binimetinib | None | III | 645 * | (−) | (−) | (−) | Ongoing | NCT02928224 |
| BRAF + EGFR + PI3K | Encorafenib + Cetuximab + Alpelisib | BRAFmut | II | 52 | 27 | 5.4 | 13.1 | Ongoing | NCT01719380 [90] |
| MEK + CT | Selumetinib + irinotecan | Kras mut or BRAF mut | II | 32 | 9 | (−) | (−) | Complete | NCT01116271 [95] |
| MEK + EGFR | Binimetinib + Panitumumab | RAS wt or RAS mut | I/II | 90 * | (−) | (−) | (−) | Ongoing | NCT01927341 |
| MEK + EGFR | Panitumumab + Trametinib | BRAFmut | I/II | 31 | 0 | 2.8 | Ongoing | NCT01750918 [85] | |
| MEK + EGFR | Trametinib + Panitumumab | KRAS BRAF wt | II | 26 * | (−) | (−) | (−) | Ongoing | NCT02399943 |
| MET + EGFR + CT | Cetuximab + irinotecan ± Tivantinib | KRAS wt | I/II (RCT) | 60 | 45 | 8.3 | 19.8 | Complete | NCT01075048 [96] |
| MEK + AKT | Selumetinib + MK-2206 | KRAS wt or KRAS mut | II | 21 * | (−) | (−) | (−) | Ongoing | NCT01333475 |
| Dose level | N | Radiation therapy dose (Gy) | Dose delay due to AE | ||
| Level 1 | 3 | 62 | 62a | 64 | 1 (3 days) |
| Level 2 | 6 | 64 | 60 | 62 | 0 |
| 64 | 62 | 60 | |||
| Level 3 | 6 | 60 | 64 | 62 | 1 (7 days) |
| 64 | 60b | 62 |
| Socio -demographic Characteristic | Number | % |
| Age (in years) | ||
| 15–34 | 109 | 25.6 |
| 25–34 | 166 | 39.1 |
| 35–44 | 150 | 35.3 |
| Ethnicity | ||
| Sinhalese | 256 | 60.2 |
| Tamils | 83 | 19.5 |
| Muslims | 80 | 18.9 |
| Burgher & others | 6 | 1.4 |
| Religion | ||
| Buddhism | 244 | 57.4 |
| Hindu | 72 | 16.9 |
| Islam | 78 | 18.4 |
| Christianity | 31 | 7.3 |
| Current marital Status | ||
| Currently Married | 286 | 67.3 |
| Never Married | 98 | 23.1 |
| Widowed | 24 | 5.6 |
| Divorced/ Separated | 17 | 4.0 |
| Highest level of Education | ||
| Never went to school | 48 | 11.3 |
| Primary education | 197 | 46.3 |
| Secondary education or higher | 180 | 42.4 |
| Daily family income (in USD) | ||
| Less than 2.4 USD (poor income) | 73 | 17.2 |
| 2.5–12 USD (low income) | 348 | 81.9 |
| More than 12 USD (middle income) | 4 | 0.9 |
| Employment status | ||
| Employed | 224 | 52.7 |
| Unemployed | 201 | 47.3 |
| Employment Category (n = 224) | ||
| Professionals | 14 | 6.3 |
| Clerical and sales workers | 34 | 15.1 |
| Elementary occupations | 113 | 50.5 |
| Others | 63 | 28.1 |
| Social status | ||
| High social status | 106 | 24.9 |
| Low social status | 319 | 75.1 |
| IR score | A II(n = 6) | A III(n = 12) | GBM (n = 55 ) | Control cortex/autopsy (n = 8) | Control cortex/surgical (n = 5) |
| Kir4.1 | 3.6 ± 0.85* | 7.18 ± 0.41 | 5.5 ± 0.30 | 7.13 ± 0.36 | 7.03 ± 0.26 |
| IL-1β | 2.46 ± 0.67* | 3.9 ± 0.9* | 3.75 ± 0.45* | 0 | 0.02 ± 0.02 |
| HLA-DR | 5.4 ± 0.77* | 5.7 ± 0.80* | 5.83 ± 0.35* | 0.04 ± 0.02 | 0.03 ± 0.02 |
| Category | Characteristic | Comparison | Pre-campaign | Mid-campaign | Post-campaign |
| Demographics | Child’s age (months) | 12–23 vs. 0–11 | 1.40 (0.98, 2.01) | 1.13 (0.50, 2.57) | 1.07 (0.63, 1.81) |
| 24–35 vs. 0–11 | 1.30 (0.89, 1.89) | 0.60 (0.24, 1.50) | 1.25 (0.72, 2.18) | ||
| 36–47 vs. 0–11 | 1.20 (0.83, 1.74) | 1.25 (0.56, 2.79) | 1.64 (0.95, 2.82) | ||
| 48–59 vs. 0–11 | 1.36 (0.94, 1.95) | 0.43 (0.18, 1.06) | 1.42 (0.85, 2.39) | ||
| Child’s sex | Male vs. female | 0.92 (0.73, 1.16) | 1.10 (0.63, 1.91) | 1.04 (0.74, 1.47) | |
| Housing construction and utilities | Primary residential building material | Concrete blocks vs. mud blocks or mud/sticks | 1.05 (0.79, 1.39) | 1.84 (1.01, 3.36) | 0.82 (0.57, 1.18) |
| Primary residential flooring material | Concrete or tile vs. mud | 0.85 (0.64, 1.13) | 0.90 (0.40, 2.04) | 0.67 (0.33, 1.35) | |
| Electricity in the home | Yes vs. no | 0.94 (0.72, 1.23) | 2.65 (0.87, 8.13) | 0.53 (0.36, 0.79) | |
| Approximate distance from drinking water source in meters | <50 m vs. ≥50 | 1.01 (0.79, 1.31) | 0.93 (0.51, 1.70) | 1.51 (1.05, 2.17) | |
| Household health behaviour | Household treats drinking water with chemicals or filters it | Yes vs. no | 1.71 (1.30, 2.25) | 1.09 (0.40, 3.00) | 0.64 (0.32, 1.31) |
| Child reported to have had measles vaccine | Yes vs. no | 1.12 (0.75, 1.67) | 0.87 (0.28, 2.86) | 5.67 (2.68, 11.99) | |
| Child’s birthplace | Healthcare facility vs. home | 1.34 (1.03, 1.72) | 1.34 (0.52, 3.46) | 0.47 (0.22, 0.97) |
| Assay | Primer Sequence 5’-3’ | |
| Assay 1 (20 CpGs) | Forward | GGATGTGGGGATTTTTTTTTTTTAGTATAG |
| Reverse | Biotin-ACTTCAACCCCTCCCCCAAAA | |
| Sequencing | TTTTTTAGTATAGTAAAGTTGGT | |
| Assay 2 (12 CpGs) | Forward | TTTCGGGTTTTATAGTTTTTGTATTTAGGT |
| Reverse | Biotin-ACTCCCGCAACTCAATAAACTCAAACTC | |
| Sequencing | TTTAGTAGTTTAGTTTGGATTTTGG | |
| MOAP1 | Forward | GAGTGTTAGTTAGAGTTTAGGGGAGTTT |
| Reverse | Biotin-CTCACCCCTCCCAACCCT | |
| Sequencing | AGGGGAGTTTGTTTT | |
| GAPDH | Forward | CATGACAACTTTGGTATCGTG |
| Reverse | GTGTCGCTGTTGAAGTCAGA | |
| RASSF1a | Forward | CCTCTGTGGCGACTTCATCTG |
| Reverse | CAACAGTCCAGGCAGACGAG | |
| MOAP-1 | Forward | CTCAATTGCTCCTCTCTGTACC |
| Reverse | CATGACAACTTTGGTATCGTG | |
| RASSF1c | Forward | GCTACTGCAGCCAAGAGGAC |
| Reverse | AGGTGTCTCCCACTCCACAG | |
| PPIA | Forward | GCCGAGGAAAACCGTGTACT |
| Reverse | TGTCTGCAAACAGCTCAAAGG |
| Riparian metric | Mean annual rainfall | Mean annual temperature | Bank height | Proportion of clay | ||||
| Estimate | SE | Estimate | SE | Estimate | SE | Estimate | SE | |
| SPECIES RICHNESS | 0.0347*** | 0.009 | 0.0238** | 0.0085 | −0.0178 | 0.009 | ||
| ABUNDANCE | 12.933** | 3.824 | ||||||
| NATIVE REGEN | 13.904*** | 3.314 | 6.708** | 3.824 | ||||
| BASAL AREA | 0.631* | 0.299 | ||||||
| SPECIES RICHNESS NS | 0.047*** | 0.012 | ||||||
| NATIVE REGEN NS | 10.207* | 4.020 | ||||||
| BASAL AREA NS | 0.199** | 0.068 |
| O. scapulalis | O. nubilalis | |
| Raw short sequence number | 322,504 | 307,622 |
| Number after filtering | 287,429 | 272,490 |
| Mean read length (bp) | 352 | 356 |
| Number of singletons | 85,070 | 87,110 |
| Number of assembled reads | 145,588 | 130,897 |
| Assembled transcriptome (Mbp) | 10.35 | 9.52 |
| Reads/bp | 9.8 | 10.2 |
| Number of unigenes | 8,892 | 8,656 |
| Number of transcripts (including alternative transcripts) | 11,231 | 10,773 |
| Transcript mean length (bp) | 922 | 883 |
| Transcript median length (bp) | 693 | 685 |
| Transcript N50 length (bp) | 1,036 | 991 |
| Mean exon count per transcript | 1.54 | 1.49 |
| Mean exon* length (bp) | 604 | 605 |
| Median exon length (bp) | 500 | 495 |
| Total | Men | Women | |
| Camp (n = 538) | 37.8% | 42.7% | 34% |
| Somali (n = 248) | 48.1% | 48.1% | 48.1% |
| Rwandese (n = 290) | 32% | 38.9% | 27.3% |
| Study [reference]: countries | Population | n | Efficacy | Lower bound of 95% CI | Adherencea |
| Partners PrEP [8]: Kenya, Uganda | Heterosexual couples | 4758 | 67% TDF; 75% TDF/FTC | 44% TDF; 55% TDF/FTC | 82% |
| TDF2 Study [9]: Botswana | Young men and women | 1219 | 62% TDF/FTC | 21.5% | 80% |
| Bangkok TDF [12]: Thailand | IVDU | 2413 | 49% TDF | 9.6% | 67% |
| iPrEx [7]: S. America, SA, Thailand, USA | MSM | 2499 | 44% TDF/FTC | 15% | 51% |
| FEM-PrEP [10]: Kenya, SA, Tanzania | Young women | 2120 | 6% TDF/FTC | −52% | 37% |
| VOICE [11]: South Africa, Uganda, Zimbabwe | Young women | 5029 | −49% TDF; - 4% TDF/FTC | −130% TDF; −50% TDF/FTC | 30% |
| Risk factor | Crude OR | Adjusted ORa |
| Own preterm birthb | 2.10 (1.27–3.48) | 2.32 (1.34–4.03) |
| PCOS | 1.44 (1.05–1.97) | 1.07 (0.74–1.54) |
| BMI ≥25 kg/m2 | 4.87 (4.07–5.84) | 4.22 (3.44–5.18) |
| BMI ≥30 kg/m2 | 5.47 (4.26–7.02) | 5.14 (3.87–6.83) |
| Age ≥35 years | 2.34 (1.90–2.88) | 2.58 (1.98–3.38) |
| Participant’s mother’s GDM | 2.43 (1.62–3.65) | 3.05 (1.93–4.82) |
| Participant’s mother’s T2D | 2.64 (1.92–3.62) | 1.85 (1.30–2.64) |
| Participant’s father’s T2D | 1.77 (1.37–2.28) | 1.37 (1.03–1.83) |
| PANSS positive subscale score | PANSS negative subscale score | PANSS general psychopathology subscale score | PANSS total score | |
| Serum S100B level changes | r=0.3P=0.2 | r=-0.048P=0.8 | r=0.05P=0.8 | r=0.06P=0.7 |
| Leptin (microg/ml) | r=-0.3P=0.1 | r=-0.023P=0.9 | r=-0.2P=0.2 | r=-0.3P=0.1 |
| SH3 domain | ka (M-1s-1) × 105 | kd (s-1) × 10-2 | KD (μM) | Nef concentrations (μM) |
| Nef-SF2 | ||||
| Human Hck SH3 | 1.60 ± 0.06 | 1.18 ± 0.04 | 0.07 ± 0.01 | 0, 0.007, 0.02, 0.062, 0.19, 0.56, 1.67, 5.0 |
| Mouse Hck SH3 | 5.54 ± 1.77 | 7.00 ± 0.36 | 0.13 ± 0.03 | 0, 0.007, 0.02, 0.062, 0.19, 0.56, 1.67 |
| Mouse Hck HART | 14.20 ± 1.40 | 1.43 ± 0.01 | 0.01 ± 0.00 | 0, 0.002, 0.007, 0.02, 0.062, 0.19 |
| Nef-Consensus* | ||||
| Human Hck SH3 | 10.00 ± 0.80 | 11.80 ± 0.20 | 0.12 ± 0.01 | 0, 0.02, 0.062, 0.19, 0.56, 1.67, 5.0 |
| Mouse Hck SH3 | 2.41 ± 0.05 | 1.85 ± 0.11 | 0.08 ± 0.01 | 0, 0.007, 0.02, 0.062, 0.19, 0.56, 1.67 |
| Mouse Hck HART | 15.70 ± 0.20 | 3.24 ± 0.16 | 0.02 ± 0.00 | 0, 0.002, 0.007, 0.02, 0.062, 0.19, 0.56 |
| Run 1 | Run 2 | Summary | ||||
| HRM | n | % | n | % | n | % |
| Number of samples | 120 | 100.0 | 20 | 100.0 (16.7) | 120 | 100.0 |
| Analysis passed | 89 | 74.2 | 18 | 90.0 | 105 | 87.5 |
| WT (total) | 60 | 67.4 | 12 | 66.7 | 71 | 67.6 |
| WT (skewed HRM curve) | 3 | 5.0 | 2 | 16.7 | 4 | 5.6 |
| Mutant (total) | 29 | 32.6 | 6 | 33.3 | 34 | 32.4 |
| Mutant (skewed HRM curve) | 1 | 3.4 | 1 | 16.7 | 1 | 2.9 |
| Analysis failed | 31 | 25.8 | 2 | 10.0 | ||
| Pyrosequencing | n | % | n | % | n | % |
| Number of samples | 19 | 100.0 (15.8) | 3 | 100.0 (2.5) | 19 | 100.0 |
| Analysis passed | 18 | 94.7 | 2 | 66.7 | 18 | 94.7 |
| WT | 12 | 66.7 | 0 | 0.0 | 13 | 72.2 |
| Potential low level mutation | 2 | 11.1 | 1 | 50.0 | 0 | 0.0 |
| Mutant | 4 | 22.2 | 1 | 50.0 | 5 | 27.8 |
| Analysis failed | 1 | 5.3 | 1 | 33.3 | 1 | |
| Combined HRM + Pyrosequencing | n | % | ||||
| Number of samples | 120 | 100.0 | ||||
| Number of HRM runs | 140 | 116.7 | ||||
| Number of pyrosequencing runs | 22 | 18.3 | ||||
| Analysis passed | 119 | 99.2 | ||||
| WT | 81 | 68.1 | ||||
| Mutant | 38 | 31.9 | ||||
| Analysis failed | 1 | 0.8 |
| URL structure | Get | Post | Delete |
| /namespace/object_type/ | List objects, apply filters | Create new object or make bulk update | Bulk delete |
| /namespace/object_type/id/ | Access single object | Update single object | Delete single object |
| /namespace/object_type/id/acl/ | Get object permissions | Update object permissions | 405 Not Supported |
| Parameters | Groups | pvalues | |||||
| Control | Control + Ucche | CCl4 | CCl4 + Ucche | CCl4 | Treatment | Interaction | |
| Plasma | |||||||
| AST(U/L) | 19.0 ± 1.6 | 21.32 ± 1.68 | 37.9 ± 3.1 | 23.3 ± 4.0 | 0.0374 | 0.0012 | 0.0062 |
| ALT(U/L) | 13.8 ± 1.7 | 16.59 ± 2.62 | 30.5 ± 3.1 | 18.7 ± 1.9 | 0.0831 | 0.0012 | 0.0082 |
| ALP(U/L) | 50.8 ± 3.3 | 50.92 ± 2.76 | 81.2 ± 6.1 | 63.9 ± 4.7 | 0.0731 | 0.0001 | 0.0690 |
| MDA(nmol/mL) | 6.34 ± 0.37 | 3.57 ± 0.54 | 7.7 ± 0.91 | 6.71 ± 0.77 | 0.0731 | 0.0001 | 0.0690 |
| NO (nmol/mL) | 3.22 ± 0.27 | 2.24 ± 0.22 | 5.8 ± 0.3 | 1.15 ± 0.32 | <0.0001 | 0.0195 | <0.0001 |
| APOP (nmol/mL equivalent to Chloramine-T) | 82.60 ± 8.49 | 67.0 ± 9.2 | 164.4 ± 15.15 | 84.3 ± 8.8 | 0.0340 | 0.0102 | 0.3072 |
| Catalase (U/min) | 6.00 ± 0.32 | 4.28 ± 0.38 | 2.93 ± 0.60 | 5.07 ± 0.74 | 0.6960 | 0.0343 | 0.0011 |
| GSH (ng/mg protein) | 20.05 ± 1.81 | 18.39 ± 1.03 | 12.72 ± 0.57 | 16.39 ± 0.57 | 0.3788 | 0.0005 | 0.0270 |
| Liver | |||||||
| AST(U/L) | 36.18 ± 3.22 | 31.01 ± 3.46 | 65.18 ± 3.87 | 46.51 ± 2.11 | 0.0023 | <0.0001 | 0.0594 |
| ALT(U/L) | 26.00 ± 3.88 | 34.67 ± 2.24 | 77.61 ± 4.80 | 28.77 ± 1.49 | <0.0001 | <0.0001 | <0.0001 |
| ALP(U/L) | 30.33 ± 3.67 | 31.42 ± 3.54 | 113.53 ± 3.71 | 68.25 ± 3.67 | <0.0001 | <0.0001 | <0.0001 |
| NO (nmol/mL) | 15.87 ± 1.56 | 20.21 ± 0.45 | 35.62 ± 4.21 | 18.11 ± 2.17 | 0.0225 | 0.0036 | 0.0006 |
| MDA (nmol/mL) | 21.85 ± 1.86 | 24.62 ± 4.88 | 57.16 ± 6.44 | 36.92 ± 1.98 | 0.0741 | <0.0001 | 0.0226 |
| APOP (nmol/mL equivalent to Chloramine-T) | 365.00 ± 40.19 | 450.0 ± 75.83 | 1357.62 ± 91.06 | 977.50 ± 63.05 | 0.0491 | < 0.0001 | 0.0097 |
| Catalase (U/min) | 52.13 ± 4.02 | 68.40 ± 5.92 | 26.32 ± 3.82 | 50.27 ± 2.33 | 0.0003 | < 0.0001 | 0.3967 |
| GSH (ng/mg protein) | 21.22 ± 1.91 | 19.22 ± 1.13 | 45.98 ± 5.05 | 32.89 ± 1.79 | 0.0171 | < 0.0001 | 0.0703 |
| Gender | |||
| Female | Male | Total | |
| Need for treatment | |||
| Discussed and confirmeda | 17 | 36 | 53 |
| Discussed, not confirmed | 0 | 0 | 0 |
| Not mentioned | 1 | 0 | 1 |
| Danger to self | |||
| Discussed and confirmed | 2 | 2 | 4 |
| Discussed, not confirmed | 2 | 5 | 7 |
| Not mentioned | 14 | 29 | 43 |
| Danger to others | |||
| Discussed and confirmed | 0 | 3 | 3 |
| Discussed, not confirmed | 3 | 2 | 5 |
| Not mentioned | 15 | 31 | 46 |
| Voluntary care unrealistic | |||
| Discussed and confirmed | 5 | 5 | 10 |
| Discussed, not confirmed | 0 | 2 | 2 |
| Not mentioned | 13 | 29 | 42 |
| Substance abuse | |||
| Discussed and confirmed | 0 | 8 | 8 |
| Discussed, not confirmed | 6 | 10 | 16 |
| Not mentioned | 12 | 18 | 30 |
| RTI/STI symptomatic currently or within last 3 months | n = 353 | % | |
| Sought care for RTI/STI symptoms | |||
| Yes | 238 | 67.4 | |
| No | 115 | 32.6 | |
| Time delay until seeking care (days) | (n = 238) | ||
| Mean: 10.2 | (range: 2-60) | ||
| < 7 | 137 | 57.6 | |
| 7-14 | 55 | 23.1 | |
| > 15 | 46 | 19.3 | |
| Source of RTI/STI treatment the last time | (n = 238) | ||
| Drop-in centre | 126 | 52.9 | |
| Public hospital | 56 | 23.5 | |
| Private clinic | 29 | 12.2 | |
| Pharmacy/drugstore | 22 | 9.2 | |
| Herbalist | 5 | 2.1 |
| Compound | IC50 [μM] | log P |
| 2a | ≥100 | 3.32 |
| 2b | 58 | 3.48 |
| 2c | ≥100 | 3.88 |
| 2d | ≥100 | 3.81 |
| 3a | 49 | 3.89 |
| 3b | 63 | 3.48 |
| 3d | 103 | 4.38 |
| 4 | >1000 | 4.28 |
| 5 | ≥100 | 4.74 |
| cisplatin | 5 |
| LBD alone (n = 62) | EST plus LBD (n = 69) | P value | |
| Diameter of inflated balloon (mm) | 15.9 ± 2.3 (12-20) | 16.2 ± 2.5 (12-20) | 0.444 |
| Complete stone removal irrespective of whether ML was used, no. (%) | 60 (96.8) | 66 (95.7) | 0.738 |
| Complete stone removal without ML, no. (%) | 50 (80.6) | 51 (73.9) | 0.360 |
| Disease class | Nt | Nur | FIC |
| Gastrointestinal | 17 | 145 | 0.88 |
| Respiratory | 5 | 15 | 0.71 |
| Wound healing | 2 | 3 | 0.50 |
| Dermatological | 1 | 2 | 1.00 |
| Kidney problems | 2 | 4 | 0.66 |
| Blood diseases | 4 | 10 | 0.66 |
| Cardiovascular | 1 | 3 | 1.00 |
| Inflammations | 1 | 1 | 1.00 |
| Hepatic problems | 2 | 5 | 0.75 |
| General pain | 3 | 6 | 0.60 |
| Fever | 1 | 3 | 1.00 |
| Dental | 1 | 3 | 1.00 |
| Phenotype | n | CaseAverageRelatedness | MeanControlAverageRelatedness | Empiricalp-valueGIF | Empiricalp-valueDistantGIF |
| CFS | 811 | 3.15 | 2.31 | < 0.001 | 0.010 |
| Variable | 1st quarterN (%) | 2nd quarterN (%) | 3rd quarter(N%) | 4th quarter(N%) | TotalN (%) | P value |
| Age(years) | ||||||
| ≤ 15 | 200 (12.3) | 201 (12.9) | 275 (17.5) | 150 (11.9) | 826 (13.7) | < 0.001 |
| 16 - 30 | 661 (40.6) | 605 (38.9) | 582 (37.1) | 525 (41.8) | 2,373 (39.5) | |
| 31 - 45 | 407 (25.0) | 363 (23.3) | 327 (20.9) | 270 (21.5) | 1,367 (22.8) | |
| 46 - 60 | 198 (12.1) | 223 (14.3) | 228 (14.6) | 191 (15.2) | 840 (14.0) | |
| ≥ 60 | 164 (10.1) | 163 (10.5) | 155 (9.9) | 120 (9.6) | 602 (10.0) | |
| Total | 1,630 (100.0) | 1,555 (100.0) | 1,567 (100.0) | 1,256 (100.0) | 6,008 (100.0) | |
| Sex | ||||||
| Male | 737 (45.2) | 691 (44.4) | 687 (43.8) | 549 (43.9) | 2,664 (44.3) | 0.83 |
| Female | 893 (54.8) | 864 (55.6) | 880 (56.2) | 707 (56.1) | 3,344 (55.7) | |
| Total | 1,630 (100.0) | 1,555 (100.0) | 1567(100.0) | 1,256 (100.0) | 6,008 (100.0) | |
| Occupation | 0.03 | |||||
| Students | 642 (39.4) | 613 (39.4) | 679 (43.3) | 516 (41.1) | 2,450 (40.8) | |
| Civil servants | 331 (20.3) | 321 (20. 6) | 327 (20.9) | 258 (20. 5) | 1,237 (20. 6) | |
| Private workers | 466 (28.6) | 413 (26.6) | 395 (25.2) | 303 (24.1) | 1,577 (26.2) | |
| Unemployed | 164 (10.1) | 187 (12.0) | 151 (9.6) | 11 (12.8) | 663 (11.0) | |
| Clergymen | 27 (1.7) | 21 (1.4) | 15 (1.0) | 18 (1.4) | 81 (1.3) | |
| Total | 1,630 (100.0) | 1,555 (100.0) | 1,567 (100.0) | 1,256 (100.0) | 6,008 (100.0) |
| Normal PI | Low PI | |||
| Restricted growth parameters | Subclass of SGA | N | no (%) | no (%) |
| Weight, length and OFC | Symmetrical | 1 | 1 (100.0) | 0 (0.0) |
| Weight and length alone | Symmetrical | 25 | 23 (92.0) | 2 (8.0) |
| Weight alone | Asymmetrical | 33 | 20 (60.6) | 13 (39.4) |
| Amino acid substituted in Y114 | 37 °C | 65 °Ca | ||
| Isomerase activity (mM/min μg) | Epimerase activity (mM/min μg) | Isomerase activity (mM/min μg) | Epimerase activity (mM/min μg) | |
| Y (parent) | 15.6 ± 1.2 | 138 ± 2.3 | 187 ± 4.2 | 37.0 ± 3.6 |
| V | 9.74 ± 1.4 | nd | 29.2 ± 3.3 | nd |
| N | 5.84 ± 0.71 | nd | 9.73 ± 2.2 | nd |
| S | 1.95 ± 0.39 | nd | 17.5 ± 4.0 | nd |
| A | 9.74 ± 2.0 | nd | 25.3 ± 3.2 | nd |
| K | 9.74 ± 0.98 | nd | 15.6 ± 2.1 | nd |
| G | 3.90 ± 1.3 | nd | 15.6 ± 2.2 | nd |
| D | 11.7 ± 1.9 | nd | 17.5 ± 2.1 | nd |
| C | 5.84 ± 1.0 | nd | 15.6 ± 1.9 | nd |
| L | nd | nd | 29.2 ± 2.6 | nd |
| E | 17.5 ± 2.3 | nd | 208 ± 3.9 | 11.7 ± 2.2 |
| P | 1.95 ± 0.55 | nd | 17.5 ± 1.2 | nd |
| I | 7.79 ± 1.9 | nd | 17.5 ± 1.1 | nd |
| W | nd | nd | 11.7 ± 1.2 | nd |
| T | 3.90 ± 0.2 | nd | 7.81 ± 2.1 | nd |
| R | nd | nd | 13.6 ± 1.0 | nd |
| F | 1.95 ± 0.13 | 9.74 ± 2.1 | 48.7 ± 3.2 | 9.77 ± 3.2 |
| M | 3.90 ± 0.22 | nd | 17.5 ± 2.9 | nd |
| Q | 1.92 ± 0.08 | nd | 23.4 ± 3.4 | nd |
| H | nd | nd | 15.6 ± 2.8 | nd |
| References | Primary outcomes | Secondary outcomes |
| Song (weak)1[44] | Recalled stocking and sales scores were higher in intervention stores than in control stores. | There was improvement in some specific mediator factors but not in overall mediator factors. |
| Gittelsohn 2010b (weak) [42] | No changes were shown in most mediator factors between intervention and control stores. | |
| Ayala 2013 (moderate)2[29] | The intervention increased availability of vegetables but not fruit. | Self-efficacy for consuming more fruits decreased. |
| Tree 1 | Tree 2 | Tree 3 | Pfam | |
| Average sequence identity | 19% | 30% | 42% | - |
| Alignment length | 1080 | 629 | 597 | 404 |
| Sequence length | 173 | 177 | 169 | 171 |
| Original number of sequences | 32 | 33 | 46 | - |
| Average number of sequences after MaxAlign | 14.1 | 22.6 | 28.8 | - |
| Average number of indels per sequence | 66.6 | 54.3 | 48.5 | 32 |
| Average length of indels | 13.6 | 8.3 | 8.8 | 7 |
| Expression level | Overall survival | ||
| Median survival (95% CI, months) | Log-rank P | HR (95% CI) | |
| Low ERCC1 | 11.7(2.6-15.3) | - | - |
| High ERCC1 | 17.4(4.3-22.6) | 0.03 | 0.63(0.35-0.88) |
| Low RRM1 | 13.5(3.2-16.4) | - | - |
| High RRM1 | 15.4(3.6-18.4) | 0.08 | 0.77(0.42-1.54) |
| Low ERCC1/Low RRM1 | 10.6(3.0-15.7) | - | - |
| High ERCC1/ Low RRM1 | 16.2(3.2-18.9) | 0.06 | 0.67(0.36-1.03) |
| Low ERCC1/ High RRM1 | 12.5(3.1-15.8) | 0.54 | 0.85(0.61-1.56) |
| High ERCC1/ High RRM1 | 18.7(4.5-23.1) | 0.004 | 0.31(0.13-0.62) |
| Compounds | KB b | A549 b | Compounds | KB b | A549 b |
| Etoposide c | 0.85 ± 0.08 | 0.99 ± 0.09 | C5 | 2.45 ± 0.41 | 5.24 ± 1.12 |
| T2 | 0.58 ± 0.07 | >50 | C6 | 8.52 ± 1.41 | 12.88 ± 1.32 |
| S1 | >50 | >50 | C7 | 3.80 ± 0.46 | 3.67 ± 0.66 |
| S2 | >50 | >50 | C8 | 3.64 ± 0.55 | >50 |
| S3 | >50 | >50 | C9 | >50 | >50 |
| S4 | >50 | >50 | N1 | >50 | >50 |
| C1 | 3.21 ± 0.6 | 4.17 ± 0.51 | N2 | >50 | >50 |
| C2 | 8.26 ± 1.22 | >50 | M1 | >50 | >50 |
| C3 | 2.08 ± 0.33 | 2.24 ± 0.44 | M2 | >50 | >50 |
| C4 | 1.29 ± 0.31 | 8.48 ± 1.39 | M3 | >50 | >50 |
| Baseline | Pre App | App | Post App |
| Complete DASS-21 | Rate subjective wellbeing and distress daily for 7 days | Rate subjective wellbeing and distress daily for 7 days | Complete DASS-21 |
| Complete DASS-21 after 7 days | Record answers to MOL-style questions received as text messages | Attend short, semi-structured interview to describe the experience of receiving and answering questions |
| Parameter | Value |
| Maximum data rate | 250 kbps |
| Discovery packet time | 10 s |
| Transmission power | 0 dBm |
| Receiver sensitivity | −85 dBm |
| Average frame length | 22 Bytes |
| MAC layer | CSMA/CA |
| Maximum number of backoffs | 4 |
| Packet loss | 1% |
| Coverage radio | 50 m |
| Mode | Active |
| Jamming | Reactive |
| Scenario | Static |
| Area | 150 m × 150 m |
| Primers and probes | Gene sequence |
| GAPDH sense | TGCACCACCAACTGCTTAG |
| GAPDH antisense | GGATGCAGGGATGATGTTC |
| GAPDH probe | CAGAAGACTGTGGATGGCCCCTC |
| IL-1β sense | TCCTGAACTCAACTGTGAAATGC |
| IL-1β antisense | AGCCCAGGTCAAAGGTTTGG |
| IL-1β probe | AGCAGCCCTTCATCTTTTGGGGTCCG |
| IL-6 sense | CCGGAGAGGAGACTTCACAGA |
| IL-6 antisense | GTTGTTCATACAATCAGAATTGCCATT |
| IL-6 probe | ACCACTCCCAACAGACCTGTCTATACCACT |
| CCL2 sense | TCTGGGCCTGCTGTTCACA |
| CCL2 antisense | CCAGCCTACTCATTGGGATCA |
| CCL2 probe | TTGGCTCAGCCAGATGCAGTTAACGC |
| CCL3 sense | ATTCCACGCCAATTCATCGT |
| CCL3 antisense | TTGGAGTCAGCGCAGATCTG |
| CCL3 probe | CCTTTGCTCCCAGCCAGGTGTCATT |
| Mother | Newborn | |||||||
| DNA | Serum3 | DNA | Serum3 | |||||
| Cervical | Oral5 | Cervical/Oral | Genital | Oral | Genital/Oral | |||
| HPV status | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) |
| HPV+1 | 93 (27.9) | 10 (3.0) | 99 (29.7) | 108 (32.4) | 2 (0.6) | 3 (0.9) | 5 (1.5) | 103 (30.9) |
| HPV-LR1,2 | 27 (8.1) | 3 (0.9) | 26 (7.8) | 2 (0.6) | 1 (0.3) | 3 (0.9) | 0 (0.0) | |
| 6 | 3 (0.9) | 1 (0.3) | 4 (1.2) | 0 (0.0) | 0 (0.0) | |||
| 11 | 2 (0.6) | 2 (0.6) | 0 (0.0) | 0 (0.0) | ||||
| HPV-HR1,2 | 66 (19.8) | 7 (2.1) | 73 (21.9) | 108 (32.4) | 2 (0.6) | 2 (0.6) | 103 (30.9) | |
| 16 | 22 (6.6) | 2 (0.6) | 24 (7.2) | 47 (14.1) | 1 (0.3) | 49 (14.7) | ||
| 18 | 8 (2.4) | 8 (2.4) | 46 (13.8) | 45 (13.5) | ||||
| 31 | 19 (5.7) | 2 (0.6) | 21 (6.3) | 41 (12.3) | 39 (11.7) | |||
| 33 | 2 (0.6) | 1 (0.3) | 3 (0.9) | 40 (12.0)4 | 36 (10.8)4 | |||
| HPV-6,11,16,18 | 35 (10.5) | 2 (0.6) | 37 (11.1) | 0 (0.0) | 1 (0.3) | 1 (0.3) |
| Baseline | Reexamination | ||
| N | 27 | 25 | |
| Mean dmft ± SD | 5.1 ± 1.8 | 8.8 ± 0.7 | |
| ECC stages | Initial stage (N, %) | (27) 100% | (0) 0% |
| Circular stage (N, %) | / | (7) 28% | |
| Destructive stage (N, %) | / | (5) 20% | |
| Radix relicta stage (N, %) | / | (9) 36% | |
| Extraction (N, %) | / | (4) 16% |
| Characteristic | Total populationa [n (%)] | No tree canopy (%) | ≥50% impervious surface (%) | Both conditions (%) |
| Total population | 81,517,417 (100.0) | 42.1 | 62.2 | 36.5 |
| Metro area segregation | ||||
| 0.13<Dm<0.40 (97 CBSAs) | 7,168,971 (8.8) | 15.2 | 54.9 | 10.5 |
| 0.40≤Dm<0.50 (105 CBSAs) | 17,696,848 (21.7) | 40.7 | 54.9 | 33.9 |
| 0.50≤Dm<0.60 (78 CBSAs) | 28,334,868 (34.8) | 52.4 | 60.5 | 43.0 |
| 0.60≤Dm<0.76 (24 CBSAs) | 28,326,730 (34.7) | 38.9 | 69.2 | 37.7 |
| Race/ethnicity | ||||
| Hispanic | 21,360,877 (26.2) | 56.8 | 72.3 | 49.8 |
| Non-Hispanic | ||||
| Asian | 5,555,510 (6.8) | 58.8 | 76.5 | 53.7 |
| Black | 15,343,325 (18.8) | 34.2 | 61.8 | 31.1 |
| White | 39,257,705 (48.2) | 34.4 | 54.0 | 28.6 |
| Housing tenure | ||||
| Rented housing unit | 39,409,709 (48.3) | 46.2 | 72.0 | 42.4 |
| Owner occupied | 42,117,708 (51.7) | 37.9 | 52.2 | 30.6 |
| Household income relative to poverty | ||||
| Below poverty | 14,038,788 (17.2) | 46.1 | 68.7 | 41.3 |
| Near poverty | 16,283,421 (20.0) | 44.8 | 65.4 | 39.4 |
| At least twice poverty level | 51,205,208 (62.8) | 39.8 | 58.7 | 34.0 |
| aTotal of 81,517,417 individuals in 63,436 block groups in 304 metropolitan areas. |
| Number (%) of | Pre-eclamptic (N = 143) | Controls(N = 143) | P |
| Primigravidae | 49(34.3) | 27(18.9) | 0.01 |
| lack of antenatal care | 21(14.7) | 33(23.1) | 0.02 |
| Educational level < secondary | 36(25.2) | 24(16.8) | 0.8 |
| Bednets coverage | 21(14.7) | 23 (16.1) | 0.6 |
| History of malaria | 31(21.7) | 11(7.7) | 0.001 |
| Family history of hypertension | 122(85.3) | 81(56.6) | 0.001 |
| Placental malaria | 28(19.6) | 16(11.2) | 0.04 |
| Am Δ | Cm Δ | Cf Δ | Am Λ | Cm Λ | Cf Λ | ||
| O13 | 2.472 (3) | 2.462 (3) | 2.455 (4) | O1 | 2.507 (3) | 2.496 (3) | 2.476 (4) |
| O14 | 2.491 (3) | 2.483 (3) | 2.443 (4) | O2 | 2.441 (3) | 2.433 (3) | 2.413 (4) |
| O15 | 2.430 (3) | 2.417 (3) | 2.387 (4) | O3 | 2.405 (3) | 2.389 (3) | 2.363 (3) |
| O16 | 2.468 (3) | 2.459 (3) | 2.422 (3) | O4 | 2.512 (3) | 2.501 (3) | 2.476 (3) |
| O17 | 2.516 (3) | 2.508 (3) | 2.494 (4) | O5 | 2.494 (3) | 2.480 (3) | 2.441 (3) |
| O18 | 2.499 (3) | 2.481 (3) | 2.411 (4) | O6 | 2.457 (3) | 2.448 (3) | 2.417 (4) |
| N1 | 2.550 (4) | 2.533 (4) | 2.512 (4) | N2 | 2.556 (3) | 2.520 (4) | 2.518 (4) |
| N3 | 2.551 (4) | 2.536 (4) | 2.508 (4) | N4 | 2.531 (4) | 2.535 (4) | 2.506 (4) |
| N5 | 2.591 (3) | 2.581 (4) | 2.545 (4) | N6 | 2.573 (4) | 2.569 (4) | 2.526 (4) |
| Test | Cutoff for “abnormal” | All Stages (N = 5731) | Stage 1 (N = 4058) | Stage 2 (N = 981) | Stage 3 (N = 692) |
| Urine Tests | |||||
| Eosinophils | ≥1 % | 6.9 | 5.8 | 7.2 | 7.5 |
| Total Protein | >15 mg/dl | 70.8 | 63.0 | 64.3 | 83.3 |
| UPEP | M spike | 7.9 | 5.0 | 9.8 | 10.0 |
| Blood Tests | |||||
| ANCA | Titer > 1:20 | 10.6 | 8.0 | 3.7 | 14.9 |
| Anti-GBM | ≥1.0 | 0 | 0 | 0 | 0 |
| Cryoglobulin | >0 % | 21.8 | 26.3 | 0 | 21.2 |
| C3 | <90 mg/dl | 36.5 | 26.9 | 21.1 | 45.6 |
| C4 | <10 mg/dl | 12.9 | 11.6 | 10.5 | 14.3 |
| Free Light Chains | See below | 41.6 | 44.7 | 42.9 | 36.7 |
| SPEP | M spike | 19.1 | 16.4 | 23.9 | 19.7 |
| Radiology Tests | |||||
| Renal Ultrasound | See Methods | 34.6 | 40.6 | 23.4 | 34.9 |
| CT Abdomen/Pelvis | See Methods | 33.3 | 26.7 | 27.3 | 39.3 |
| Variable | Median (25th, 75th percentile) |
| Sleep | |
| Time in bed (hours:minutes) | 9:31 (9:02, 9:58) |
| Sleep duration (hours:minutes) | 8:29 (7:59, 8:59) |
| Sleep midpoint (hours:minutes) | 2:44 (2:14, 3:29) |
| Sleep efficiency (%) | 90.0 (86.3, 92.5) |
| Physical activity (minutes/day) | |
| Outdoor active play (minutes/day) | 32.7 (15.8, 54.2) |
| Organized sports (minutes/day) | 18.8 (0.0, 48.6) |
| Curriculum-based physical activity (minutes/day) | 9.8 (2.1, 16.6) |
| Active transportation (minutes/day) | 12.2 (5.4, 21.3) |
| Pre-SBRT factors | G4-5 RP | G0-3 RP | Total | X2 test | 1-year cumulative incidence of G4-5 RP | log-rank |
| Serum KL-6 | ||||||
| high value | 6 | 17 | 23 | p = 0.0002 | 32% | p < 0.0001 |
| within normal level | 2 | 78 | 80 | 3% | ||
| not available | 1 | 13 | 14 | |||
| Serum SP-D | ||||||
| high value | 5 | 14 | 19 | p = 0.0002 | 29% | p = 0.0001 |
| within normal level | 2 | 79 | 81 | 3% | ||
| not available | 2 | 15 | 17 | |||
| IP shadow in CT | ||||||
| (+) | 7 | 6 | 13 | p < 0.0001 | 57% | p < 0.0001 |
| (-) | 2 | 102 | 104 | 2% |
| Cross-section 2004 | Panel 2002–2004 | ||||||
| Variable | Average for treated | Average for untreated | Single difference in averages | % difference | Boot-strapped Std. Err. | P-value | Double differences/differences-in-differences (absolute) |
| No. of outpatient (OP) visits in the 12-month recall period | 0.818 | 0.786 | 0.033 | 4% | 0.060 | 0.585 | 0.06 |
| no. of OP visits at commune level clinics | 0.380 | 0.308 | 0.072 | 23% | 0.034 | 0.034 | 0.10 |
| no. of OP visits at district hospital | 0.144 | 0.078 | 0.066 | 85% | 0.022 | 0.003 | Not available |
| no. of OP visits at provincial/central hospital | 0.051 | 0.029 | 0.022 | 74% | 0.009 | 0.018 | Not available |
| no. of OP visits at govt. hospital | 0.195 | 0.107 | 0.088 | 82% | 0.025 | 0.000 | 0.08 |
| no. of OP visits at private facility | 0.222 | 0.357 | -0.135 | -38% | 0.039 | 0.000 | -0.12 |
| No. of inpatient (IP) admissions in the 12-month recall period | 0.125 | 0.118 | 0.007 | 6% | 0.012 | 0.557 | 0.00 |
| no. of IP admissions at commune level clinics | 0.026 | 0.037 | -0.010 | -28% | 0.004 | 0.020 | 0.00 |
| no. of IP admissions at district hospital | 0.060 | 0.038 | 0.023 | 60% | 0.008 | 0.003 | Not available |
| no. of IP admissions at provincial/central hospital | 0.035 | 0.038 | -0.002 | -6% | 0.006 | 0.721 | Not available |
| no. of IP admissions at govt. hospital | 0.096 | 0.075 | 0.021 | 27% | 0.011 | 0.065 | 0.02 |
| Variables | No. of patientsn(%) | Western medicinen(%) | Chinese medicine n(%) | P-value |
| Total | 786(100) | 337(42.9) | 449(57.1) | |
| Conventional treatment | 781(99.4) | 337(100) | 444(98.9) | 0.052 |
| Surgery | 453(57.6) | 196(58.2) | 257(57.2) | 0.796 |
| Chemotherapy | 501(63.7) | 184(54.6) | 317(70.6) | < 0.001 |
| Radiotherapy | 487(62.0) | 208(61.7) | 279(62.1) | 0.905 |
| Endocrine therapy | 84(10.7) | 36(10.7) | 48(10.7) | 0.997 |
| Palliative therapy | 12(1.5) | 1(0.3) | 11(2.4) | 0.015 |
| Chinese medicine | 449(57.1) | --- | 449(100) | --- |
| treatment | 424(53.9) | --- | 424(94.4) | |
| Chinese Herbal Medicine | 21(2.7) | --- | 21(4.7) | |
| Acupuncture and Moxibustion | 11(1.4) | --- | 11(2.4) | |
| Therapeutic Massage | 40(5.1) | --- | 40(8.9) | |
| Qigong | 75(9.5) | --- | 75(16.7) | |
| Chinese Dietary Therapy |
| Strain of C. jejuni | Rate of growth (μmax) in microaerobic conditions | Death times (D-values) in aerobic conditions |
| Bf | 0.5763 | \\** |
| subsp. jejuni NCTC 11168 | 0.7714* | 0.9737 |
| subsp. jejuni 00-2538 | 0.9198* | 1.1039 |
| subsp. jejuni 00-2426 | 0.8964* | 1.5442 |
| subsp. jejuni 00-2544 | 0.8303* | 1.4554 |
| subsp. jejuni 00-2425 | 0.9085* | 1.3785 |
| subsp. jejuni 81-176 | 0.9477* | 0.4765 |
| subsp. jejuni NCTC 11828 | 0.7899* | 1.3417 |
| subsp. doylei 269.97 | 0.7765* | 2.2691 |
| subsp. jejuni RM 1221 | 0.6793* | 1.9276 |
| Quality-of-care categorya | Summary score | |||||
| Baseline | End of the study | |||||
| Intervention group, mean (SD) | Control group, mean (SD) | Intervention versus control group, mean difference (95% CI) | Intervention group, mean (SD) | Control group, mean (SD) | Intervention versus control group, mean difference (95% CI) | |
| Hospital support systems | ||||||
| Information systems and statistics | 1.85 (0.44) | 1.70 (0.53) | 0.15 (−0.30 to 0.60) | 2.68 (0.24) | 1.55 (0.52) | 1.26 (0.85 to 1.66) |
| Drugs and equipment | 2.27 (0.61) | 2.00 (0.73) | 0.27 (−0.36 to 0.90) | 2.94 (0.11) | 1.68 (0.60) | 1.13 (0.74 to 1.51) |
| Laboratory | 2.50 (0.46) | 2.33 (0.57) | 0.17 (−0.31 to 0.66) | 2.93 (0.12) | 2.28 (0.80) | 0.65 (0.11 to 1.18) |
| Emergency support | 1.69 (0.28) | 1.51 (0.33) | 0.18 (−0.10 to 0.46) | 2.85 (0.13) | 1.27 (0.50) | 1.58 (0.23 to 1.92) |
| Paediatric ward | 1.65 (0.40) | 1.54 (0.55) | 0.11 (−0.34 to 0.56) | 2.85 (0.19) | 1.60 (0.50) | 1.25 (0.89 to 1.60) |
| Case management | ||||||
| Cough and breathing difficulties | 1.02 (0.63) | 0.99 (0.51) | 0.01 (−0.52 to −0.54) | 2.53 (0.33) | 1.17 (0.62) | 1.36 (0.89 to 1.82) |
| Diarrhoea | 0.65 (0.58) | 0.60 (0.54) | 0.05 (−0.47 to 0.57) | 2.70 (0.21) | 1.12 (0.48) | 1.58 (0.23 to 1.92) |
| Anaemia | 1.12 (0.37) | 1.09 (0.43) | 0.03 (−0.25 to 0.31) | 2.28 (0.31) | 0.98 (0.70) | 1.30 (0.79 to 1.80) |
| Febrile conditions | 0.87 (0.43) | 0.96 (0.39) | −0.09 (−0.47 to 0.29) | 2.12 (0.31) | 1.16 (0.37) | 0.96 (0.63 to 1.28) |
| Chronic conditions | 1.72 (0.67) | 2.17 (0.29) | −0.45 (−0.93 to 0.03) | 1.73 (0.35) | 0.97 (0.31) | 1.76 (0.44 to 1.07) |
| Surgery | 1.46 (0.39) | 1.29 (0.26) | 0.17 (−0.14 to 0.48) | 2.88 (0.17) | 1.40 (0.59) | 1.48 (1.07 to 1.88) |
| Policies and organization of care | ||||||
| Supportive care | 1.00 (0.56) | 1.08 (0.48) | −0.08 (−0.57 to 0.41) | 2.87 (0.13) | 1.25 (0.55) | 1.62 (0.24 to 1.99) |
| Child-friendly services | 1.25 (0.32) | 1.43 (0.36) | −0.18 (−0.50 to 0.14) | 2.69 (0.26) | 1.20 (0.44) | 1.49 (1.15 to 1.82) |
| Monitoring | 0.96 (0.78) | 1.20 (0.57) | −0.24 (−0.88 to 0.40) | 2.76 (0.21) | 0.91 (0.57) | 1.85 (1.84 to 2.25) |
| Auditing and guidelines | 1.74 (0.51) | 1.69 (0.31) | 0.05 (−0.34 to 0.44) | 2.73 (0.19) | 1.56 (0.74) | 1.17 (0.66 to 1.67) |
| Access to hospital | 2.00 (0.28) | 2.03 (0.43) | −0.03 (−0.37 to 0.31) | 2.76 (0.26) | 1.85 (0.37) | 0.91 (0.60 to 1.21) |
| Mothers’ satisfaction | 1.72 (0.62) | 1.70 (0.32) | 0.02 (−0.44 to 0.48) | 2.83 (0.19) | 1.89 (0.23) | 0.94 (0.74 to 1.13) |
| SCC | |||
| Herd size | < = 200 | 201-400 | > 400 |
| Q1 | 35.52 | 42.35 | 22.12 |
| Q2 | 33.06 | 46.99 | 19.96 |
| Q3 | 31.38 | 49.47 | 19.15 |
| Q4 | 26.50 | 54.74 | 18.76 |
| Level of Adaptation to Heat | % Who Reported Adverse Health Impacts | Confidence Interval | Coeff. of Variation | Odds Ratio | Confidence Interval | Pr > χ2 |
| Individuals who adapt well | 45.77 | (41.78–49.76) | 4.44 | 1.37 | (1.13–1.66) | 0.0011 |
| Individuals who do not adapt as well | 38.11 | (33.66–42.56) | 5.95 | 1.00 |
| Blood | Brain | Liver | Tongue | Skin | Lung | Muscle | Intestine | Tumour | |
| L-BPA (μg/g) | 13.42 ± 1.26 | 4.97 ± 0.54 | 12.11 ± 1.82 | 13.62 ± 5.15 | 15.65 ± 2.77 | 15.82 ± 1.51 | 12.41 ± 1.19 | 16.45 ± 2.91 | 21.11 ± 3.15 |
| L-FBPA (μg/g) | 13.19 ± 1.18 | 4.61 ± 2.28 | 15.63 ± 3.15 | 12.14 ± 1.08 | 13.75 ± 3.08 | 14.78 ± 1.64 | 9.69 ± 1.3 | 15.33 ± 0.88 | 20.17 ± 6.49 |
| p value | 0.81 | 0.81 | 0.18 | 0.61 | 0.45 | 0.43 | 0.052 | 0.51 | 0.83 |
| Kidney | Kidney pancreas | |
| Number recruited | 42 | 19 |
| Sex male/female | 31M/11F | 9M/10F |
| Median age (range) | 54 (26–74) | 47 (30–59) |
| Donor type | ||
| Living (male/female) | 16 (11M/5F) | n/a |
| DBD (male/female) | 11 (7M/4F) | 16 (7M/9F) |
| DCD (male/female) | 15 (13M/ F) | 3 (2M/1F) |
| Drug treatment regimen | ||
| Alemtuzumab | 19 | 19 |
| Basiliximab + MMF | 13 | n/a |
| Basiliximab + Aza | 10 | n/a |
| Demographic | Physicians (n = 13) | Nursing staff (n = 13) | Overall (n = 26) | |
| Sex | Male | 4 | 1 | 5 |
| Female | 9 | 12 | 21 | |
| Age (yr) | Mean (range) | 45 (25–60) | 45 (24–61) | 45 (24–61) |
| Years of professional experience | Mean (range) | 15 (0–36) | 17 (0–32) | 16 (0–36) |
| Type of facility | Nursing home | 10 | 9 | 19 |
| Residential care home | 3 | 4 | 7 | |
| Facility location | Urban area | 8 | 7 | 15 |
| Rural area | 5 | 6 | 11 | |
| Professional specialism | Nursing home | Elderly care physician (7) | Nurse* (4) | - |
| Elderly care physician in training (1) | ||||
| Junior doctor (1) | Nurse assistant* (5) | |||
| Physician assistant (1) | ||||
| Residential care home | General practitioner (3) | Nurse assistant* (4) |
| Year | Main Objetive | Assay Employed | Reference |
| In vitro studies | |||
| 2014 | Effect of MGN on gamma radiation-induced DNA damage in human lymphocytes and lymphoblastoid cells. | Comet assay | [74] |
| 2012 | Evaluation of protective effects of MGN against several mutagens (bleomycin, CP, AFB1, B[a]P, 2-AAF, H2O2, sodium azide, cisplatin, MMC, and DMNA). | Ames test, SOS Chromotest assay & Comet assay | [75] |
| 2009 | Cytoprotective and antigenotoxic potential of mangiferine against cadmium chloride CdCl2-induced toxicity in HepG2 cells. | Comet assay & Micronucleus | [76] |
| 2011 | Evaluation of the protector effect of MGN against methylmercury (MeHg) induced neurotoxicity by employing IMR-32 (human neuroblastoma) cell line. | Comet assay & Micronucleus | [77] |
| 2011 | Antigenotoxic potential of MGN against mercuric chloride (HgCl2)-induced genotoxicity in HepG2 cell line. | Comet assay & Micronucleus | [78] |
| 2015 | Evaluation of the Mangiferin to reduce etoposide-induced DNA damage in human umbilical cord mononuclear blood cells. | Comet assay & Micronucleus | [79] |
| In vivo studies | |||
| 2008 | Protective role of mangiferin against B[a]P induced lung carcinogenesis in experimental animals. | Comet assay | [80] |
| 2005 | Ability of the mangiferin to reduce the frequency of radiation-induced micronucleated binucleate cells (MNBNCs) in cultured human peripheral blood lymphocytes. | Micronucleus | [81] |
| 2010 | The protective role of mangiferin (MGN) against cadmium chloride CdCl2-induced genotoxicity studied in Swiss albino mice. | Micronucleus | [82] |
| Age group | No. negative | No. positive | positive (%) |
| 3 to 10 | 201 | 11 | 5.19 |
| 11 to 15 | 346 | 11 | 3.08 |
| 16 to 20 | 702 | 21 | 2.90 |
| 21 to 30 | 1116 | 46 | 3.96 |
| 31 to 40 | 642 | 45 | 6.55 |
| 41 to 50 | 368 | 20 | 5.15 |
| 51 to 60 | 211 | 24 | 10.21 |
| 61 to 70 | 123 | 15 | 10.87 |
| 70+ | 46 | 6 | 11.54 |
| Grand total | 4154 | 209 | 4.8 |
| RMSE | ||
| EKF | BD-AEKF | |
| Heading (degree) | 1.0069 | 0.3751 |
| Pitch (degree) | 0.6812 | 0.1453 |
| Roll (degree) | 0.6488 | 0.1466 |
| East position (m) | 0.8297 | 0.2050 |
| North position (m) | 0.8104 | 0.2194 |
| Ownership | n(%) |
| Household owning nets | 638(95.2) |
| Households without nets | 32(4.8) |
| Total | 670(100) |
| No. of bed nets | No. of HH(%) |
| 0 | 32(4.8) |
| 1 | 120(17.9) |
| 2 | 244(36.4) |
| 3 | 147(21.9) |
| 4 | 88(13.1) |
| 5+ | 39(5.8) |
| Total | 670(100) |
| Mean number of nets per HH 2.4 | |
| Source of bed nets | No. of HH(%) |
| Campaign nets | 298(46.7) |
| Non campaign nets | 205(32.1) |
| Campaign &non campaign nets | 112(17.6) |
| *Other sources | 23(3.6) |
| Total | 638(100) |
| Cost of non-campaign nets (KES) | |
| 50 | 180(56.8) |
| 100 | 64(20.2) |
| > 100 | 73(23.0) |
| Total HH | 317(100) |
| Rank | Symptoms | Rate of patients with the symptom | Rate of patients with high PeCDF (> 50 pg/g lipids) |
| 1 | Black comedones (trunk) <+ or severer> | 0.0671 | 0.6563 |
| 2 | uric acid (high) | 0.1761 | 0.6310* |
| 3 | Black comedones (face) <+ or severer> | 0.0860 | 0.6098 |
| 4 | Third quartile age | 0.2348 | 0.6071* |
| 5 | urea nitrogen (high) | 0.1111 | 0.6038 |
| 6 | red blood cell count (low) | 0.1342 | 0.5938 |
| 7 | History of pigmentation <present> | 0.3669 | 0.5886* |
| 8 | Classification of testee <qualified> | 0.7526 | 0.5794* |
| 9 | Subjective symptoms, etc. <present> | 0.1488 | 0.5775 |
| 10 | Second quartile age | 0.2788 | 0.5714 |
| Item | IntraobserverObserver 1 | IntraobserverObserver 2 | InterobserverOver assessments 1 | ||||||
| ICC | Agreement (in %) | 95% CI | ICC | Agreement (in %) | 95% CI | ICC | Agreement (in %) | 95% CI | |
| (Q1) Frowning | 0.64 | 82.3 | 0.56–0.71 | 0.48 | 74.7 | 0.38–0.57 | 0.50 | 75.5 | 0.40–0.59 |
| (Q2) Narrowing or closing eyes | 0.68 | 84.0 | 0.61–0.74 | 0.31 | 69.6 | 0.19–0.42 | 0.25 | 62.4 | 0.13–0.37 |
| (Q3) Raising upper lip | 0.61 | 85.2 | 0.52–0.68 | 0.35 | 67.5 | 0.24–0.49 | 0.30 | 64.1 | 0.15–0.43 |
| (Q5) Tightened lips | 0.80 | 90.3 | 0.75–0.84 | 0.29 | 74.7 | 0.17–0.40 | 0.35 | 70.5 | 0.23–0.46 |
| (Q9) Restlessness | 0.92 | 99.6 | 0.90–0.94 | 0.49 | 96.6 | 0.38–0.58 | 0.40 | 95.4 | 0.29–0.50 |
| (Q14) Restricting jaw movement | 0.77 | 93.7 | 0.71–0.81 | 0.40 | 86.1 | 0.29–0.50 | 0.41 | 86.1 | 0.30–0.51 |
| Protocol | Denaturation | Touchdown annealing cycles | Additional annealing cycles | Extension | Final extension |
| GP5+/GP6+ | 1 min, 94°C | - | 2 min, 40°C (40–50 cycles) | 1.5 min, 72°C | 4 min, 72°C |
| TDP1 | 1 min, 94°C | 2 min, 45°C to 40°C in 0.5°C decrements (11 cycles) | 2 min, 40°C (29–39 cycles) | 1.5 min, 72°C | 4 min, 72°C |
| TDP2 | 1 min, 94°C | 2 min, 50°C to 40°C in 1.0°C decrements (11 cycles) | 2 min, 40°C (29–39 cycles) | 1.5 min, 72°C | 4 min, 72°C |
| TDP3 | 1 min, 94°C | 2 min, 50°C to 40°C in 0.5°C decrements (21 cycles) | 2 min, 40°C (19–29 cycles) | 1.5 min, 72°C | 4 min, 72°C |
| TDP4 | 1 min, 94°C | 2 min, 55°C to 40°C in 1.0°C decrements (16 cycles) | 2 min, 40°C (24–34 cycles) | 1.5 min, 72°C | 4 min, 72°C |
| Characteristic | HR | 95% CI |
| Male sex | 1.39 | 1.06–1.81 |
| Age, per 10-year increment | 1.09 | 1.07–1.10 |
| Smoking | 1.34 | 1.03–1.76 |
| Drinking | 1.03 | 0.81–1.31 |
| Obesity | 0.96 | 0.75–1.23 |
| Hypertension | 2.65 | 2.11–3.31 |
| Dyslipidemia | 1.08 | 0.87–1.35 |
| Diabetes mellitus | 2.07 | 1.40–3.06 |
| AF | 4.11 | 2.28–7.41 |
| Time (h) | pNO2PheDUa (mM) | Conversion (%) |
| 0 | 1.94 ± 0.03 | – |
| 1 | 1.63 ± 0.05 | 16 |
| 2 | 1.29 ± 0.04 | 34 |
| 3 | 1.24 ± 0.02 | 36 |
| 4 | 1.18 ± 0.04 | 39 |
| 5 | 1.16 ± 0.11 | 40 |
| 24 | 0.54 ± 0.05 | 72 |
| t0 control | t0 inoculated | t1 control | t1 inoculated | t2 control | t2 inoculated | |
| Resistance to antibiotics and toxic compounds | 80.7 | 81.4 | 78.9 | 78.8 | 79.7 | 79.8 |
| – | 9.7 | 9.1 | 10.3 | 10.2 | 10.4 | 10.2 |
| Multi locus sequence typing | 7.2 | 7.2 | 8.2 | 8.4 | 7.5 | 7.4 |
| Adhesion | 1.4 | 1.4 | 1.5 | 1.5 | 1.5 | 1.5 |
| Bacteriocins, ribosomally synthesized antibacterial peptides | 0.4 | 0.5 | 0.6 | 0.5 | 0.4 | 0.6 |
| Invasion and intracellular resistance | 0.4 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 |
| Toxins and superantigens | 0.1 | 0.1 | 0.2 | 0.2 | 0.2 | 0.1 |
| Baseline Characteristics (at time of diagnosis) | Mean ± SD or N (%) |
| Age (Years) | 37.41 ± 10.14 |
| Gender | |
| Male | 14 (66.7%) |
| Female | 07 (33.3%) |
| Stage of Disease | |
| I | 3 (14.3%) |
| II | 2 (9.5%) |
| III | 4 (19.0%) |
| IV | 12 (57.1%) |
| LDH | |
| High | 18 (85.7%) |
| Normal | 03 (14.3%) |
| Extra Nodal site involvement | |
| None | 5 (23.8%) |
| Yes | 16 (76.2%) |
| Bulky Disease | |
| Yes | 5 (23.8%) |
| No | 16 (76.2%) |
| Bone Marrow Involvement | |
| Yes | 8 (38.1%) |
| No | 13 (61.9%) |
| IPI | |
| 1 | 04 (19.0%) |
| 2 | 09 (42.9%) |
| 3 | 08 (38.1%) |
| Variables | N | % | |
| Gender | Male | 29 | 58 |
| Female | 21 | 42 | |
| Educational level | Basic science (pre-clinical) years | 12 | 24 |
| Clinical years | 38 | 76 | |
| Previous EBM exposure | Read about or attended a lecture | 28 | 56 |
| Had a formal EBM training | 0 | 0 | |
| Previous research exposure | Participated in ≥ 1 research activity | 31 | 62 |
| No previous research exposure | 19 | 38 | |
| Frequency of online search for evidence | ≥ once per week | 16 | 32 |
| < once per week, or not at all | 34 | 68 | |
| First source sought for evidence (before the course) | 23 | 46 | |
| UpToDateTM | 13 | 26 | |
| PubMed | 7 | 14 | |
| The Cochrane library | 1 | 2 | |
| Other | 3 | 6 |
| Characteristics | Patients (P, n=131) | Spousal caregivers (SC, n=131) | ||
| n (%) | n (%) | |||
| Age (mean± SD), years | 56.6±12.1 (ranging from 25 to 79) | 56.0±11.3 (ranging from 29 to 80) | ||
| Gender | ||||
| Male | 82 (62.6) | 49 (37.4) | ||
| Female | 49 (37.4) | 82 (62.6) | ||
| Level of education | ||||
| Primary school or less | 64 (48.9) | 67 (51.1) | ||
| High school | 49 (37.4) | 49 (37.4) | ||
| University or above | 18 (13.7) | 15 (11.5) | ||
| Working status | ||||
| Working | 75 (57.3) | 69 (52.7) | ||
| Not working | 56 (42.7) | 62 (47.3) | ||
| The average time since diagnosis/the duration in their role as a SC | 13.7±23.0 months (ranging from 1 to 192 months) | <6 months: | 67 (51.2) | |
| 6 months ~2 years: | 43 (32.8) | |||
| >2 years ~5 years: | 13 (9.9) | |||
| >5 years: | 8 (6.1) | |||
| Couples were informed about the diseaseb | ||||
| Partly informed | 33 (25.2) | 24 (18.3) | ||
| Well informed | 98 (74.8) | 107 (81.7) | ||
| Time spent by SC in caring for patients/day [in hours, n (%)] | <2 hours: | 10 (7.6) | ||
| 2~4 hours: | 14 (10.7) | |||
| >4~6 hours: | 25 (19.1) | |||
| >6~8 hours: | 21 (16.0) | |||
| >8 hours: | 61 (46.6) | |||
| Types of cancera | Digestive system cancer: 72 (55.0); Lung cancer: 35 (26.7); | |||
| Urogenital system cancer: 19 (14.5); Others: 5 (3.8) | ||||
| Dyad Characteristicsc | ||||
| Duration of marriage (mean± SD), years | 30.8±11.6 (ranging from 1–52) | |||
| Relationship with their partner before the diagnosis of the cancer | Very goodBad | 115 (87.8)0 | Normal | 16 (12.2) |
| Change in the relationship with their partner after the diagnosis of the cancer | ImprovedGetting worse | 38 (29.0)0 | No change | 93 (71.0) |
| Financial burden on the family due to the treatment of cancer | Serious | 77 (58.8) | Normal | 49 (37.4) |
| Mild or None | 5 (3.8) |
| Characteristic | TeleWii Group (n = 38) | SIBT group (n = 38) | Baseline comparison p value |
| Age (years) (mean ± SD) | 67.45 (7.18) | 69.84 (9.41) | 0.14 |
| Gender (number of males/females) | 23/15 | 28/10 | 0.22 |
| Disease duration (years) (mean ± SD) | 6.16 (3.81) | 7.47 (3.90) | 0.14 |
| Dominant PD phenotype (NT/T/YO) | 21/12/5 | 14/15/9 | 0.24 |
| More affected side (B/R/L) | 7/21/10 | 8/20/10 | 0.95 |
| Modified H&Y stage median (Q1–Q3) | 2.50 (2.5–2.5) | 2.50 (2.5–3.0) | 0.76 |
| UPDRS score (mean ± SD) | 44.13 (24.05) | 50.76 (24.12) | 0.15 |
| Falls (number) (mean ± SD) | 0.58 (1.44) | 1.84 (5.29) | 0.24 |
| MMSE score | 26.77 (1.48) | 28.64 (6.96) | 0.16 |
| GDS score | 8.26 (5.17) | 9.79 (5.34) | 0.21 |
| Johannesburg** | Cape town | Rustenburg | |||||||
| Surveys# | FGDs^ | Diaries | Surveys# | FGDs* | Diaries | Surveys# | FGDs^ | Diaries | |
| Pre-World Cup | - | 2 | - | - | 2 | - | - | 1 | - |
| World Cup | 350 (95%) | 2 | 8 | 128 (77%) | 2 | 7 | 123 (91%) | 1 | 8 |
| Post-World Cup | 273 (98%) | 1 | 16 | 83 (83%) | 2 | 6 | 102 (88%) | 1 | 8 |
| Variables | Total | First-year | Fifth-year | pc |
| n (%) | n (%) | n (%) | ||
| Sociodemographic | ||||
| Agea | 20.4 (3.0) | 19.0 (2.0) | 23.2 (2.3) | <0.001d |
| Male gender | 5224 (47.3) | 3365 (46.6) | 1859 (48.6) | 0.040 |
| Married/cohabiting | 364 (3.3) | 153 (2.1) | 211 (5.5) | <0.001 |
| Have children | 505 (4.6) | 232 (3.3) | 273 (7.2) | <0.001 |
| Born in a rural area | 598 (5.7) | 412 (6.1) | 186 (5.1) | 0.045 |
| Religious | 9746 (88.0) | 6447 (89.1) | 3299 (86.1) | <0.001 |
| Migrated for medical school | 3524 (32.8) | 2317 (32.9) | 1207 (32.5) | 0.695 |
| Intermediate/advanced english language proficiency | 5275 (47.6) | 3282 (45.3) | 1993 (52.0) | <0.001 |
| National language-speakerb | 887 (8.0) | 595 (8.2) | 292 (7.6) | 0.265 |
| Relative of a physician | 5489 (49.8) | 3635 (50.4) | 1854 (48.6) | 0.073 |
| Relationship with someone living abroad | 9182 (84.9) | 6051 (85.7) | 3131 (83.5) | 0.002 |
| University | ||||
| Country | <0.001 | |||
| Bolivia | 1618 (14.6) | 1219 (16.8) | 399 (10.4) | |
| Chile | 606 (5.5) | 302 (4.2) | 304 (7.9) | |
| Colombia | 1423 (12.9) | 874 (12.1) | 549 (14.3) | |
| Costa Rica | 148 (1.3) | 137 (1.9) | 11 (0.3) | |
| Ecuador | 1174 (10.6) | 866 (11.9) | 308 (8.0) | |
| El Salvador | 94 (0.9) | 51 (0.7) | 43 (1.1) | |
| Honduras | 990 (8.9) | 556 (7.7) | 434 (11.3) | |
| Mexico | 201 (1.8) | 136 (1.9) | 65 (1.7) | |
| Paraguay | 156 (1.4) | 100 (1.4) | 56 (1.5) | |
| Peru | 3768 (34.0) | 2422 (33.5) | 1346 (35.1) | |
| Venezuela | 894 (8.1) | 575 (7.9) | 319 (8.3) | |
| Capital city location | 3441 (31.1) | 2150 (29.7) | 1291 (33.7) | <0.001 |
| Publicly funded | 7204 (65.1) | 4652 (64.3) | 2552 (66.6) | 0.016 |
| Medical career | ||||
| Have failed a class | 3334 (30.9) | 1790 (25.4) | 1544 (41.2) | <0.001 |
| Satisfied with medical career | 9705 (88.7) | 6393 (89.3) | 3312 (87.6) | 0.005 |
| Total | 11,072 (100) | 7238 (65.4) | 3834 (34.6) |
| Severe disability | Any severe cerebral palsy (child non-ambulant and likely to remain so; GMFCS level 4 or 5), severe developmental delay (standardised score <−3 SD) or blindness. |
| Moderate disability | Moderate cerebral palsy (child non-ambulant at 2 years of age but who is likely to ambulate subsequently; GMFCS level 2 or 3), or deafness, or moderate developmental delay (standardised score from −3 SD to <−2 SD). |
| Mild disability | Mild cerebral palsy (child walking at 2 years of age with only minimal limitation of movement (GMFCS level 1), or suspect developmental delay (standardised score from −2 SD to <−1 SD). |
| No neurosensory disability | Children without any neurosensory impairment. |
| What influences the decision about prenatal examinations? | |
| n = 302 | n (%) |
| Worry about the health of the baby | 268 (89) |
| I want to know as much as possible | 117 (39) |
| No reasons to refuse | 81 (27) |
| Personal experience of chromosomal aberration or other severe disease among relative | 69 (23) |
| The values of the society | 44 (15) |
| Expectations from others | 41 (14) |
| Everyone else does | 14 (5) |
| Important to know the gender of the baby | 4 (1) |
| Who influences the decision about prenatal examinations? | |
| n = 302 | |
| My partner | 250 (83) |
| The doctor in antenatal care | 168 (56) |
| Family and friends | 132 (44) |
| The midwife in antenatal care | 129 (43) |
| No one, I make the decision myself | 80 (26) |
| Crude ORsab | 95% CIc | p-value | Adjusted ORsd | 95% CI | p-value | ||
| Age | ≥30 years | (reference) | (reference) | ||||
| <30 years | 3.43 | 1.96-5.99 | < 0.001 | 2.74 | 1.36-5.50 | 0.005 | |
| Sex | Male | (reference) | (reference) | ||||
| Female | 0.46 | 0.10-2.05 | 0.297 | 0.30 | 0.05-1.69 | 0.171 | |
| Mental health service | No | (reference) | (reference) | ||||
| Implemented | 0.45 | 0.24-0.84 | 0.009 | 0.35 | 0.16-0.76 | 0.008 | |
| Key person | No | (reference) | (reference) | ||||
| Yes | 0.80 | 0.45-1.41 | 0.438 | 0.58 | 0.28-1.19 | 0.135 | |
| Route of infection | Homosexual | (reference) | |||||
| Others | 0.75 | 0.42-1.34 | 0.327 | ||||
| Regular employment | Yes | (reference) | (reference) | ||||
| No | 2.46 | 1.38-4.39 | 0.002 | 3.38 | 1.58-7.23 | 0.002 | |
| Welfare benefits | No | (reference) | |||||
| Yes | 0.43 | 0.05-3.48 | 0.414 | ||||
| HIV test motive | Voluntary | (reference) | (reference) | ||||
| Others | 0.40 | 0.25-0.63 | <0.001 | 1.50 | 0.38-2.70 | 0.180 | |
| Mental illness | No | (reference) | |||||
| Yes | 0.92 | 0.31-2.77 | 0.886 | ||||
| Illicit drug use | No | (reference) | |||||
| Yes | 1.25 | 0.67-2.33 | 0.492 | ||||
| Nationality | Japanese | (reference) | |||||
| Others | 1.00 | 0.32-3.09 | 1.000 | ||||
| AIDS diagnosis | No | (reference) | |||||
| Yes | 0.19 | 0.07-0.51 | 0.002 | ||||
| Antiretroviral therapy | Yes | (reference) | (reference) | ||||
| No | 8.47 | 3.91-18.33 | <0.001 | 7.51 | 3.34-16.9 | < 0.001 | |
| CD4+ lymphocyte count | <200/mm3 | (reference) | |||||
| 200-499/mm3 | 3.94 | 1.35-11.5 | 0.012 | ||||
| ≥500/mm3 | 6.11 | 2.01-18.6 | 0.001 |
| Vascular smooth muscle cells | Respiratory epithelial cells |
| Viability for different pressures (0, 0.4, 0.8, 1.2, 1.6, 2 bar) | Viability (0.4 bar) |
| Viability for different velocities (10, 30, 55, 75, 95 mL/min) | Short-term differentiation (pan-cytokeratin expression) |
| Short-term differentiation (α-SMA expression) | Long-term differentiation (14 and 28 days: pan-cytokeratin expression and PAS reaction) |
| p (FWEcorr) | T | Z | Coordinates x, y, z {mm} max. peak | Brain area |
| 0.003843 | 7.936576 | 4.986516 | 18, 36, −8 | Right medial orbitofrontal cortex |
| Economic interventions | Definition | Search terms |
| Price Interventions - Taxes and Subsidies | Interventions that target prices for goods and services paid/received by households or firms | “tax”, “subsidy”, “subsidized”, “subsidies”, “penalty”, “penalties”, “voucher”, “vouchers” |
| Income Transfer Programs | Interventions that transfer resources directly to households | “income support”, “financial supplement”, “income supplement”, “fina ncial assistance”, “welfare benefits”, “social security”, “cash assistance”, “income transfer”, “asset transfer”, “pensions”, “welfare payments”, “cash transfer”, “cash support”, “bonus”, “economic support” |
| Incentive Programs | Interventions that provide rewards or penalties to motivate specific behaviours/outcomes | “results-based financing”, “pay for performance”, “performance pay”, “performance incentives”, “financial incentives”, “activity based funding”, “provider payment” |
| Livelihood Support Programs | Interventions that provide resources or skills to support income generation | “livelihood support”, “entrepreneurship training”, “business training”, “vocational skills training”, “vocational training” |
| Health-related Financial Services | Interventions that provide mechanisms for managing resource allocations and financial risks. | “microcredit”, “microlending”, “microloans”, “microfinance”, “loans”, “lending”, “microinsurance” |
| Variables | Negative AV | Positive AV | P value |
| Failure rate (%) | 36.8 | 81.2 | 0.016*,b |
| Surgical rate (%) | 21.1 | 75.0 | 0.002*,b |
| AV at PHV (°/y) | −9.6 ± 7.6 | 8.2 ± 4.0 | 0.000*,a |
| Initial curve magnitude (°) | 26.3 ± 4.6 | 26.7 ± 5.7 | 0.832 |
| Final curve magnitude (°) | 29.4 ± 9.1 | 39.6 ± 14.2 | 0.015*,a |
| PHV (cm/y) | 8.8 ± 1.5 | 9.4 ± 1.8 | 0.327 |
| Timing of PHV (yrs) | 11.7 ± 1.1 | 11.5 ± 0.8 | 0.732 |
| Age at diagnosis (yrs) | 11.0 ± 1.3 | 10.0 ± 1.0 | 0.014*,a |
| Initial SSMS | 2.7 ± 0.6 | 2.2 ± 0.5 | 0.006*,a |
| Initial DRU (R) | 7.0 ± 0.8 | 6.4 ± 1.0 | 0.053 |
| Initial DRU (U) | 5.1 ± 0.8 | 4.3 ± 0.9 | 0.016*,a |
| SSMS at PHV | 3.4 ± 0.5 | 3.5 ± 0.6 | 0.495 |
| DRU (R) at PHV | 8.0 ± 0.7 | 8.0 ± 0.7 | 0.999 |
| DRU (U) at PHV | 5.9 ± 0.5 | 5.8 ± 0.4 | 0.244 |
| Percentage of major thoracic curve (%) | 47.3 | 68.8 | 0.306 |
| Initial height (cm) | 145.2 ± 7.2 | 138.3 ± 8.2 | 0.013*,a |
| Final height (cm) | 161.3 ± 5.4 | 159.2 ± 5.6 | 0.257 |
| Paucigranulocytic phenotype | Eosinophilic phenotype | Neutrophilic phenotype | Mixed granulocytic phenotype | |
| Steroid naïve (n = 153) | 65 (42.5%) | 60 (39.2%) | 25 (16.3%) | 3 (2%) |
| Steroid-treated (n = 355) | 138 (38%) | 151 (43%) | 55 (15%) | 11 (3%)* |
| Level of Training | Teaching Method | ||||||
| M | C | A | E | SLE | Total | ||
| Junior | Count | 24 | 29 | 4 | 2 | 7 | 66 |
| % within TM | 77.4 | 31.5 | 11.8 | 14.3 | 20 | 32 % | |
| Std Residual | 4.5 | −0.1 | −2.1 | −1.2 | −1.3 | ||
| Intermediate | Count | 4 | 40 | 7 | 3 | 8 | 62 |
| % within TM | 12.9 | 43.5 | 20.6 | 21.4 | 22.9 | 30.1 % | |
| Std Residual | −1.7 | 2.3 | −1.0 | −0.6 | −0.8 | ||
| Senior | Count | 3 | 23 | 23 | 9 | 20 | 78 |
| % within TM | 9.7 | 25 | 67.6 | 64.3 | 57.1 | 37.9 % | |
| Std Residual | −2.6 | −2.0 | 2.8 | 1.6 | 1.9 | ||
| Total | 31 | 92 | 34 | 14 | 35 | 206 |
| Sample No. | HN37 | HN44 | HN48 |
| RL2 | 6a | 9c | 8b |
| RL3 | 11c | 10b | 9a |
| SL2 | 9a | 12c | 10b |
| SL3 | 12a | 13b | 12a |
| Frequency | |
| ’NNP’,’DISEASE’,’NNP’ | 36 |
| ’NNP’,’NNP’,’DISEASE’,’NNP’ | 16 |
| ’NNP’,’DISEASE’,’NNP’,’NNP’ | 11 |
| ’IN’,’DISEASE’,’CC’ | 10 |
| Women | Men | Denominatorwomen | Denominatormen | |||||
| Per cent | CI | Per cent | CI | Unwt | Wt | Unwt | Wt | |
| Lifetime diagnoses | ||||||||
| 16–24 | 0.1 | (0.0% to 0.4%) | 0.1 | (0.0% to 0.8%) | 1726 | 962 | 1363 | 990 |
| 25–34 | 0.3 | (0.1% to 0.6%) | 0.1 | (0.0% to 0.4%) | 2362 | 1304 | 1431 | 1281 |
| 35–44 | 0.3 | (0.1% to 0.9%) | 0.1 | (0.0% to 0.8%) | 1169 | 1397 | 775 | 1367 |
| 45–54 | 0.8 | (0.4% to 1.5%) | 0.0 | 1058 | 1365 | 745 | 1336 | |
| 55–64 | 0.8 | (0.4% to 1.7%) | 0.0 | 969 | 1169 | 692 | 1085 | |
| 65–74 | 0.7 | (0.3% to 1.7%) | 0.0 | 787 | 843 | 581 | 758 | |
| Total aged 16–44 | 0.2 | (0.1% to 0.4%) | 0.1 | (0.0% to 0.3%) | 5257 | 3662 | 3569 | 3639 |
| Total aged 45–74 | 0.8 | (0.5% to 1.2%) | 0.0 | 2814 | 3377 | 2018 | 3180 | |
| Total | 0.5 | (0.3% to 0.7%) | 0.0 | (0.0% to 0.2%) | 8071 | 7040 | 5587 | 6818 |
| Past 5 years | ||||||||
| 16–24 | 0.1 | (0.0% to 0.4%) | 0.1 | (0.0% to 0.8%) | 1726 | 962 | 1363 | 990 |
| 25–34 | 0.1 | (0.0% to 0.4%) | 0.1 | (0.0% to 0.4%) | 2362 | 1304 | 1431 | 1281 |
| 35–44 | 0.0 | 0.0% | 0.0 | 0.0% | 1169 | 1397 | 775 | 1367 |
| 45–54 | 0.0 | 0.0% | 0.0 | 0.0% | 1058 | 1365 | 745 | 1336 |
| 55–64 | 0.0 | 0.0% | 0.0 | 0.0% | 969 | 1169 | 692 | 1085 |
| 65–74 | 0.0 | 0.0% | 0.0 | 0.0% | 787 | 843 | 581 | 758 |
| Total aged 16–44 | 0.1 | (0.0% to 0.2%) | 0.0 | (0.0% to 0.2%) | 5257 | 3662 | 3569 | 3639 |
| Total aged 45–74 | 0.0 | 0.0 | 2814 | 3377 | 2018 | 3180 | ||
| Total | 0.0 | (0.0% to 0.1%) | 0.0 | (0.0% to 0.1%) | 8071 | 7040 | 5587 | 6818 |
| Ergonomic instructions | Health complaints often | |||||||||
| Eyes | Neck, shoulders | Head | Hands, fingers, wrists | Lower back | ||||||
| n* | OR (95%Cl) | N | OR (95%Cl) | N | OR (95%Cl) | n | OR (95%Cl) | N | OR (95%Cl) | |
| To arrange desk, chair and screen in the right position | 285 | 0.9 (0.7-1.1) | 206 | 1.3 (1.0-1.7) | 178 | 0.8 (0.7-1.1) | 107 | 1.4 (0.9-2.1) | 82 | 1.2 (0.8-1.9) |
| To take rest breaks | 364 | 1.3 (1.0-1.6) | 241 | 1.2 (0.9-1.6) | 228 | 1.2 (0.9-1.6) | 126 | 1.4 (0.9-2.0) | 95 | 1.4 (0.9-2.3) |
| Characteristic | Total |
| Patients, N | 448 |
| HAE diagnosis, n (%) | |
| Type 1 | 423 (94.4) |
| Type 2 | 25 (5.6) |
| Sex, n (%) | |
| Female | 263 (58.7) |
| Male | 185 (41.3) |
| Age at enrollment, y | |
| Mean (SD) | 40.8 (14.7) |
| Median (min, max) | 39.1 (16.5, 81.8) |
| Country, n (%) | |
| France | 119 (26.6) |
| Spain | 69 (15.4) |
| Germany | 57 (12.7) |
| United Kingdom | 53 (11.8) |
| Italy | 46 (10.3) |
| Israel | 45 (10.0) |
| Denmark | 19 (4.2) |
| Brazil | 16 (3.6) |
| Greece | 14 (3.1) |
| Austria | 8 (1.8) |
| Sweden | 2 (0.4) |
| Client Characteristic | No. (%) |
| Sex | |
| Female | 1303 (91) |
| Male | 122 (9) |
| Age, years | |
| <15 | 75 (5) |
| 15–18 | 786 (55) |
| 19–20 | 514 (36) |
| 21–24 | 50 (4) |
| No. of living children | |
| 0 | 757 (53) |
| 1 | 502 (35) |
| 2 | 148 (10) |
| 3 | 14 (1) |
| 5 or more | 4 (0.3) |
| Marital status | |
| Married or cohabiting | 553 (39) |
| Single or living alone | 872 (61) |
| First-time family planning user | |
| Yes | 987 (69) |
| No | 438 (31) |
| Age | IOP | Number of Glaucoma Medications | AL | ACD | LT | VCD | ||||||||
| ρ | P value | ρ | P value | ρ | P value | ρ | P value | ρ | P value | ρ | P value | ρ | P value | |
| G-CSF | −0.232 | 0.173 | 0.506 | 0.002* | 0.464 | 0.004* | −0.060 | 0.729 | −0.074 | 0.670 | 0.121 | 0.482 | −0.097 | 0.572 |
| IL-6 | −0.115 | 0.503 | 0.424 | 0.010 | 0.443 | 0.007* | −0.089 | 0.605 | 0.031 | 0.860 | 0.040 | 0.815 | −0.132 | 0.444 |
| IL-8 | −0.143 | 0.406 | 0.375 | 0.024 | 0.439 | 0.007* | −0.198 | 0.246 | 0.056 | 0.743 | 0.004 | 0.980 | −0.201 | 0.239 |
| MCP-1 | −0.097 | 0.573 | 0.291 | 0.085 | 0.285 | 0.092 | −0.110 | 0.523 | 0.040 | 0.817 | −0.002 | 0.989 | −0.140 | 0.414 |
| MCP-3 | −0.127 | 0.460 | 0.420 | 0.011 | 0.347 | 0.038 | −0.040 | 0.816 | 0.005 | 0.977 | 0.177 | 0.300 | −0.108 | 0.531 |
| MDC | −0.261 | 0.125 | 0.201 | 0.240 | 0.131 | 0.445 | −0.411 | 0.013 | 0.193 | 0.259 | −0.182 | 0.288 | −0.364 | 0.029 |
| MIP-1β | −0.166 | 0.335 | 0.387 | 0.020 | 0.395 | 0.017 | −0.130 | 0.450 | 0.003 | 0.985 | 0.029 | 0.865 | −0.126 | 0.463 |
| VEGF | 0.013 | 0.941 | 0.318 | 0.058 | 0.198 | 0.247 | −0.051 | 0.769 | −0.091 | 0.597 | 0.300 | 0.075 | −0.185 | 0.280 |
| Phenotype | Loci | C/C | C/R | R/R |
| BMI | ht1 | 518(22.34 ± 3.70) | 904(22.34 ± 3.62) | 454(22.35 ± 3.59) |
| ht2 | 584(22.39 ± 3.64) | 896(22.35 ± 3.63) | 396(22.28 ± 3.62) | |
| ht3 | 1719(22.31 ± 3.58) | 152(22.72 ± 4.04) | 5(23.54 ± 6.94) | |
| ht4 | 1788(22.36 ± 3.65) | 86(22.16 ± 3.21) | 2(19.80 ± 1.41) | |
| AUC_G | ht1 | 449(438.33 ± 74.35) | 757(429.75 ± 79.48) | 375(420.39 ± 84.28) |
| ht2 | 480(420.98 ± 83.23) | 753(430.50 ± 78.91) | 348(441.20 ± 73.83) | |
| ht3 | 1446(430.46 ± 80.09) | 130(425.51 ± 72.41) | 5(405.10 ± 75.33) | |
| ht4 | 1516(429.95 ± 79.07) | 64(431.35 ± 88.89) | 1(361.50) | |
| HOMA_B | ht1 | 509(225.47 ± 126.01) | 898(240.16 ± 144.09) | 448(254.96 ± 200.10) |
| ht2 | 577(251.20 ± 186.38) | 889(240.64 ± 143.02) | 389(220.51 ± 128.44) | |
| ht3 | 1700(239.45 ± 157.09) | 150(242.64 ± 138.61) | 5(239.14 ± 23.78) | |
| ht4 | 1768(239.99 ± 157.73) | 85(232.89 ± 98.82) | 2(280.10 ± 66.75) | |
| HOMA_IR | ht1 | 512(2.66 ± 1.60) | 898(2.58 ± 1.45) | 450(2.54 ± 1.50) |
| ht2 | 579(2.54 ± 1.61) | 889(2.59 ± 1.34) | 392(2.68 ± 1.68) | |
| ht3 | 1705(2.59 ± 1.46) | 150(2.65 ± 1.95) | 5(2.58 ± 1.28) | |
| ht4 | 1773(2.60 ± 1.52) | 85(2.42 ± 1.16) | 2(2.00 ± 0.24) | |
| FPI | ht1 | 512(12.34 ± 6.48) | 898(12.09 ± 5.64) | 450(12.00 ± 5.71) |
| ht2 | 579(11.98 ± 6.12) | 889(12.15 ± 5.31) | 392(12.35 ± 6.78) | |
| ht3 | 1705(12.11 ± 5.74) | 150(12.45 ± 7.54) | 5(12.36 ± 4.49) | |
| ht4 | 1773(12.17 ± 5.96) | 85(11.51 ± 4.61) | 2(10.50 ± 0.71) | |
| FPG | ht1 | 449(86.46 ± 12.66) | 757(85.32 ± 11.89) | 375(84.49 ± 13.30) |
| ht2 | 480(84.49 ± 12.83) | 753(85.40 ± 11.82) | 348(86.86 ± 13.23) | |
| ht3 | 1446(85.53 ± 12.66) | 130(84.65 ± 10.31) | 5(82.20 ± 9.36) | |
| ht4 | 1516(85.44 ± 12.50) | 64(85.64 ± 11.87) | 1(80.00) |
| Terms | aklB, ada | aklB, ada, dinJ |
| DNA repair (SP-PIR) | 5.1E-28 | |
| DNA damage (SP-PIR) | 6.2E-28 | |
| Cellular response to stress (GO) | 7.5E-23 | |
| DNA repair (GO) | 1.6E-21 | |
| Response to DNA damage stimulus (GO) | 1.6E-21 |
| ≤ 11.6 | > 11.6 | ||
| N = 129 | N = 135 | P-value | |
| Gender (F/M) | 57/72 | 62/73 | 0.776 |
| Age (yr) | 28.4 ± 18.75 | 41.2 ± 15.58 | < 0.001 |
| Body mass index (kg/m2) | 23.4 ± 2.42 | 22.8 ± 2.63 | 0.029 |
| White blood count (109/L) | 6.7 ± 1.44 | 6.3 ± 1.47 | 0.016 |
| Hemoglobin (g/L) | 128.8 ± 12.80 | 134.3 ± 12.31 | < 0.001 |
| Mean corpuscular hemoglobin (pg) | 27.2 ± 2.98 | 28.5 ± 3.07 | < 0.001 |
| Mean corpuscular hemoglobin concentration (g/L) | 326.5 ± 10.64 | 326.8 ± 27.54 | 0.902 |
| Alanine aminotransferase (U/L) | 17.5 ± 8.86 | 19.6 ± 8.40 | 0.047 |
| Aspartate aminotransferase (U/L) | 22.3 ± 6.20 | 21.9 ± 5.54 | 0.669 |
| Creatinine (umol/L) | 58.1 ± 17.60 | 70.1 ± 12.94 | < 0.001 |
| Albumin (g/L) | 44.7 ± 3.53 | 44.6 ± 3.26 | 0.850 |
| Globulin (g/L) | 22.1 ± 4.09 | 22.8 ± 3.84 | 0.180 |
| High-sensitivity C-reactive protein (mg/L) | 1.4 ± 1.03 | 1.0 ± 0.90 | 0.002 |
| Serum iron (μmol/L) | 11.9 ± 1.88 | 15.7 ± 5.64 | < 0.001 |
| Serum copper (μmol/L) | 12.7 ± 4.51 | 10.0 ± 3.22 | < 0.001 |
| Serum zinc (μmol/L) | 10.9 ± 1.88 | 12.0 ± 2.64 | < 0.001 |
| Data∗ | BJK recipe (n = 42) | Diclofenac (n = 42) | Pvalue∗∗ |
| Female, number (%) | 38 (90.5) | 39 (92.9) | 0.693c |
| Age; yrs, mean (SD) | 61.67 (7.3) | 63.5 (8.19) | 0.282t |
| Weight; kg., mean (SD) | 66.14 (9.48) | 64.31 (10.03) | 0.394t |
| Height; cm., mean (SD) | 155.76 (7.12) | 155.31 (8.17) | 0.464m |
| BMI; Kg/m2, mean (SD) | 27.23 (3.07) | 26.62 (3.28) | 0.277m |
| Visual analogue scale (VAS; mm., mean (SD)) | 31.02 (21.54) | 36.05 (22.69) | 0.159m |
| 100-meter walking time; sec., mean (SD) | 124.19 (24.31) | 131.6 (33.56) | 0.638m |
| WOMAC index score, mean (SD) | |||
| Pain index | 16.19 (7.16) | 18.69 (7.06) | 0.119m |
| Stiff index | 5.4 (3.47) | 7.48 (5.08) | 0.056m |
| Physical function index | 49.73 (19.93) | 59.8 (26.19) | 0.062m |
| Total score | 71.49 (27.64) | 85.68 (35.5) | 0.051m |
| Laboratory data, mean (SD) | |||
| Blood pressure | |||
| Systolic (mm·Hg) | 126.6 (12.82) | 126.26 (17.24) | 0.92t |
| Diastolic (mm·Hg) | 81.9 (9.23) | 78.31 (8.5) | 0.067t |
| Renal function tests | |||
| BUN (mg/dL) | 13.24 (3.7) | 13.3 (3.4) | 0.941t |
| Creatinine (mg/dL) | 0.71 (0.19) | 0.71 (0.17) | 0.865m |
| Liver function tests | |||
| AST (U/L) | 23.6 (10.68) | 23.12 (8.27) | 0.993m |
| ALT (U/L) | 39.6 (12.2) | 40.69 (15.1) | 0.816m |
| ALP (U/L) | 90.45 (18.19) | 90.38 (22.6) | 0.99t |
| Compounds | III Instar | Pupae | ||||
| LC50 | LC 90 | Chi ** | LC 50 | LC 90 | Chi ** | |
| t-anethole | 7.4 (6.5–8.3) | 18.8 (17.4–20.2) | 0.055 | 28.6 (26.4–30.8) | 48.6 (45.79–51.51) | 0.039 |
| carvacrol | 5.5 (5.2–5.7) | 11.3 (9.9–2.7) | 2.684 | 53.2 (49.9–56.6) | 111.4 (102.0–120.8) | 0.483 |
| cinnamaldehyde | 18.4 (17.6–19.2) | 39.2 (35.2–43.1) | 1.203 | 90.1 (84.6–95.6) | 179.3 (170.4–188.1) | 0.048 |
| cuminaldehyde | 23.0 (21.9–24.1) | 52.2 (50.1–54.3) | 4.313 | 95.4 (91.1–99.6) | 198.2 (193.7–202.7) | 0.896 |
| p-cymene | 23.1 (21.2–24.9) | 91.9 (89.7–94.0) | 0.253 | 306.3(297.4–315.1 | 549.2 (533.0–565.3) | 1.326 |
| eucalyptol | 24.8 (22.7–26.8) | 48.0 (44.9–51.1) | 0.116 | 92.9 (89.1–96.6) | 193.9 (186.9–201.0) | 0.574 |
| eugenol | 23.0 (21.7–24.3) | 51.2 (46.6–55.8) | 0.279 | 106.9(99.5–114.3) | 198.4 (189.6–207.1) | 0.665 |
| (-)-limonene | 14.2 (13.5–15.0) | 36.4 (33.5–39.4) | 0.572 | 78.4 (73.3–83.4) | 155.0 (145.6–164.3) | 0.865 |
| myrcene | 19.5 (18.5–20.4) | 40.0 (36.7–43.2) | 2.561 | 31.8 (30.4–33.1) | 59.1 (55.2–62.9) | 1.287 |
| β-pinene | 19.6 (18.8–20.3) | 61.9 (57.8–65.9) | 0.265 | 206.9(95.3–105.8) | 458.4 (440.1–476.6) | 3.404 |
| thymol | 23.4 (22.5–24.4) | 45.4 (43.3–47.6) | 0.683 | 100.57 (88.3–111.8) | 168.7 (155.8–181.6) | 1.642 |
| Genotype | Cases, n=125 (%) | Controls, n=200 (%) | Crude OR (95% CI) | Adjusteda OR (95% CI) |
| MDM2 SNP309 | ||||
| TT | 30 (24.0) | 62 (31.0) | 1.00 (reference) | 1.00 (reference) |
| TG | 61 (48.8) | 98 (49.0) | 1.29 (0.75–2.21) | 1.09 (0.60–1.99) |
| GG | 34 (27.2) | 40 (20.0) | 1.76 (0.93–3.30) | 1.64 (0.81–3.28) |
| P-trend=0.08 | P-trend=0.45 | |||
| TG+GG | 95 (76.0) | 138 (69.0) | 1.42 (0.86–2.37) | 1.24 (0.70–2.18) |
| TP53 codon 72 | ||||
| Arg/Arg | 52 (41.6) | 75 (37.5) | 1.00 (reference) | 1.00 (reference) |
| Arg/Pro | 55 (44.0) | 102 (51.0) | 0.78 (0.48–1.26) | 0.66 (0.38–1.15) |
| Pro/Pro | 18 (14.4) | 23 (11.5) | 1.13 (0.55–2.30) | 1.17 (0.54–2.55) |
| P-trend=0.08 | P-trend=0.79 | |||
| Arg/Pro + Pro/Pro | 73 (58.4) | 125 (62.5) | 0.84 (0.53–1.33) | 0.76 (0.46–1.27) |
| ESR1 PvuII | ||||
| TT | 38 (30.4) | 60 (30.0) | 1.00 (reference) | 1.00 (reference) |
| TC | 60 (48.0) | 102 (51.0) | 0.93 (0.55–1.56) | 0.94 (0.55–1.56) |
| CC | 27 (21.5) | 38 (19.0) | 1.12 (0.59–2.13) | 0.89 (0.43–1.86) |
| P-trend=0.78 | P-trend=0.76 | |||
| TC+CC | 87 (69.6) | 140 (70.0) | 0.98 (0.60–1.60) | 0.93 (0.53–1.60) |
| ESR1 XbaI | ||||
| AA | 77 (61.6) | 127 (63.5) | 1.00 (reference) | 1.00 (reference) |
| AG | 42 (33.6) | 64 (32.0) | 1.08 (0.67–1.75) | 0.88 (0.51–1.53) |
| GG | 6 (4.8) | 9 (4.5) | 1.10 (0.38–3.21) | 0.60 (0.16–2.24) |
| P-trend=0.74 | P-trend=0.43 | |||
| AG+GG | 48 (38.4) | 73 (36.5) | 1.09 (0.68–1.72) | 0.84 (0.50–1.43) |
| p21 codon 31 | ||||
| Ser/Ser | 21 (16.8) | 38 (19.0) | 1.00 (reference) | 1.00 (reference) |
| Ser/Arg | 73 (58.4) | 109 (54.5) | 1.21 (0.66–2.23) | 1.13 (0.57–2.22) |
| Arg/Arg | 31 (24.8) | 53 (26.5) | 1.06 (0.53–2.12) | 1.01 (0.47–2.19) |
| P-trend=0.95 | P-trend=0.98 | |||
| Ser/Arg + Arg/Arg | 104 (83.2) | 162 (81.0) | 1.16 (0.65–2.09) | 1.09 (0.57–2.09) |
| Valence class/Emotion | Europeans | Iranians | ||||
| β | T | Partial r | β | T | Partial r | |
| Negative pictures | ||||||
| Happiness | 0.13 | 2.61* | 0.28 | 0.09 | 2.23* | 0.23 |
| Sadness | 0.40 | 5.89*** | 0.56 | 0.42 | 7.98*** | 0.65 |
| Fear | 0.49 | 8.43*** | 0.69 | 0.63 | 10.94*** | 0.76 |
| Surprise | 0.09 | 1.35 | 0.15 | 0.04 | 0.63 | 0.07 |
| Anger | 0.03 | 0.67 | 0.08 | 0.08 | 1.74 | 0.18 |
| Disgust | 0.31 | 5.70*** | 0.54 | 0.08 | 1.73 | 0.18 |
| Positive pictures | ||||||
| Happiness | 0.85 | 14.87*** | 0.86 | 0.36 | 4.91*** | 0.51 |
| Sadness | 0.12 | 2.18* | 0.24 | 0.01 | 0.14 | 0.02 |
| Fear | 0.39 | 6.15*** | 0.57 | 0.34 | 3.43** | 0.38 |
| Surprise | 0.05 | 0.78 | 0.09 | 0.40 | 5.36*** | 0.54 |
| Anger | 0.09 | 1.49 | 0.16 | 0.08 | 0.78 | 0.09 |
| Disgust | 0.13 | 2.40* | 0.26 | 0.22 | 2.98** | 0.34 |
| AFL | AML | Stack | Description |
| signal S | - | (--) | Definition of a signal S. |
| : $S .. ; | DEF | (arg --) | Definition of a handler for signal S. The signal argument is pushed on the top of the data stack. |
| raise | RAISE | (arg sig# pid --) | Send a signal S with an argument to the process pid. |
| timer | TIMER | (sig# tmo --) | Install a timer (tmo > 0) raising signal sig if the time-out has passed. If tmo = 0, then the timer is removed. |
| n | % who correctly identified the firstline anti-malarial therapy | Unadjusted odds ratio (95% confidence interval; P value) | ||
| Malaria training | ||||
| Attended malaria workshop | ||||
| Yes | 46 | 65% | 0.94 (0.42 - 2.07; 0.873) | |
| No | 66 | 67% | Ref | |
| Attended malaria workshop after 2006 | ||||
| Yes | 34 | 62% | 0.32 (0.06 - 1.71; 0.184) | |
| No | 12 | 83% | Ref | |
| Received drug information from MOH | ||||
| Yes | 94 | 69% | 0.96 (0.85 - 1.08; 0.483) | |
| No | 19 | 53% | Ref | |
| Dispensing Practices | ||||
| Recommended AL for uncomplicated malaria in children under 5 | ||||
| Yes | 43 | 74% | 2.41 (1.01 - 5.76; 0.048)* | |
| No | 53 | 55% | Ref | |
| Recommend AL for uncomplicated malaria in adults | ||||
| Yes | 55 | 76% | 3.55 (1.49 - 8.47; 0.004)* | |
| No | 42 | 48% | Ref | |
| Table 4b: Relationship between shop worker recommendation of AL to children under 5 and their response to clinical scenarios | ||||
| n | % who would recommend AL to children under 5 | Unadjusted odds ratio and (95% confidence interval; P value) | ||
| Paediatric Case Management** | ||||
| Refer pediatric patients rather than treat | ||||
| Yes | 43 | 49% | 2.45 (1.04 - 5.79; 0.041)* | |
| No | 65 | 31% | Ref | |
| Refuse Fansidar to a mother requesting it | ||||
| Yes | 94 | 67% | 3.59 (1.08 - 11.90; 0.036)* | |
| No | 19 | 58% | Ref |
| Link | Antecedent | Consequent | Measure(s) of consequent | results | |
| Link found? | Consequent (‘effect’) stronger in DLC? | ||||
| A | DLC training (DLC sites only) | Staff characteristics | DAS, ADQ, SNCW | Yes | No for DAS, ADQ and parts of SNCW. Yes for SNCW Development and Patient Knowledge components. |
| Sick-leave | Yes | Yes | |||
| Turnover | No | No | |||
| B | PDSA cycles | Reported/not reported | Yes | Yes | |
| C | Staff characteristics | Immediate impact of work routines | DCM WIB scores | Partly: for SNCW but not DAS, ADQ. | No |
| D | PDSA | Yes, but ‘High-WIB’ homes only | Yes, but ‘High-WIB’ homes only | ||
| E | Immediate impact of work routines | Quality of life | QUALID | Yes | No |
| End-of-life care discussion | No | No | |||
| End-of-life care plans | No | No | |||
| TEP decision forms | No | No | |||
| F | Quality of Life | External impacts | Ambulance call-outs | No | No |
| Emergency admissions | No | No |
| Characteristics | HAP (n = 94) | VAP (n = 117) | ||||
| Adequate treatment n = 43 (%) | Inadequate treatment n = 51 (%) | p | Adequate treatment n = 37 (%) | Inadequate treatment n = 80 (%) | p | |
| Age (years) | 60.67 ± 16.04 | 65.14 ± 13.75 | 0.167 | 63.59 ± 16.65 | 63.85 ± 17.07 | 0.907 |
| Sex (male) | 32(74.4) | 37 (72.5) | 1.000 | 24 (64.9) | 45 (56.3) | 0.497 |
| Surgical unit | 9 (20.9) | 8 (15.7) | 0.697 | 21 (56.8) | 25 (31.3) | 0.015 |
| Underlying diseases | ||||||
| Diabetes mellitus | 5 (11.6) | 8 (15.7) | 0.789 | 5 (13.5) | 11 (13.8) | 1.000 |
| COPD | 13 ( 30.2) | 10 (19.6) | 0.341 | 11 (29.7) | 17 (21.3) | 0.443 |
| Chronic renal failure | 5 (11.6) | 4 (7.8) | 0.727 | 0 (0) | 3 (3.8) | 0.551 |
| Congestive heart failure | 4 (9.3) | 9 (17.6) | 0.386 | 6 (16.2) | 13 (16.3) | 1.000 |
| Cerebrovascular disease | 1 (2.3) | 9 (17.6) | 0.019 | 3 (8.1) | 15 (18.8) | 0.227 |
| Malignancy | 6 (14.0) | 9 (17.6) | 0.838 | 6 (16.2) | 11 (13.8) | 0.944 |
| Central venous catheterization | 16 (37.2) | 22 (43.1) | 0.710 | 30 (81.1) | 58 (72.5) | 0.442 |
| Urinary catheterization | 33 (76.7) | 37 (72.5) | 0.820 | 37 (100) | 78 (97.5) | 1.000 |
| Late-onset pneumonia | 34 (79.1) | 46 (90.2) | 0.223 | 34 (91.9) | 72 (90) | 1.000 |
| Acquisition of other site infection | 12 (27.9) | 11 (21.6) | 0.637 | 11 (29.7) | 42 (52.5) | 0.036 |
| Previous antibiotic usage | 20 (46.5) | 23 (45.1) | 1.000 | 11 (29.7) | 36 (45.0) | 0.173 |
| MDR bacteria | 29 (67.4) | 38 (74.5) | 0.599 | 32 (86.5) | 60 (75) | 0.243 |
| Polymicrobial etiology | 1 (2.3) | 8 (15.7) | 0.036 | 2 (5.4) | 6 (7.5) | 1.000 |
| Length of stay before HAP | 7.6 ± 4.3 | 9.18 ± 5.8 | 0.194 | 13.89 ± 11.56 | 14.88 ± 10.34 | 0.313 |
| APACHE II score | 12.7 ± 5.83 | 14.92 ± 5.83 | 0.031 | 16.08 ± 6.94 | 16.69 ± 6.72 | 0.654 |
| Exitus | 16 (37.2) | 24 (47.1) | 0.452 | 27 (73) | 53 (66.3) | 0.608 |
| Characteristic | cv-lysozyme-3 | cv-lysozyme-1* | cv-lysozyme-2** |
| Optimal pH | 7.5-8.5 | 5.5-6.5 | 5.5-6.5 |
| Optimal ionic strength (I) | 0.005-0.01 | 0.18-0.20 | 0.005-0.01 |
| E. coli | 12.5 μg/mL | 1.56 μg/mL | 50 μg/mL |
| V. vulnificus | ND*** | 12.5 μg/mL | 100 μg/mL |
| MW (Dalton)b | 17782.3 | 17861.0 | 12984.6 |
| Theoretical pI | 6.84 (7.12) | 8.95 | 6.33 |
| Total amino acid number | 168 | 164 | 117 |
| Arginine residue number | 5 | 19 | 5 |
| Trypsin | 9 | 18 | 9 |
| Thermolysin | 32 | 28 | 20 |
| Pepsin (pH > 2.0) | 19 | 12 | 5 |
| Digestive glands | Labial palps, mantle | Digestive glands | |
| Mantle, labial palps, gill, style sac-midgut, hemocytes | Gill, style sac-midgut, digestive gland, gonad | Style sac-midgut |
| Utilization of postnatal care | ||||
| Confidence interval | ||||
| Characteristics | Odds ratio | Lower | Upper | p |
| Occupation | ||||
| Agriculture | 1 | |||
| Service | 4.82 | 1.18 | 19.62 | 0.028 |
| Business | 3.47 | 0.75 | 16.12 | 0.112 |
| Wage laborer | 2.88 | 0.44 | 18.86 | 0.270 |
| Housewife | 2.55 | 0.85 | 7.62 | 0.094 |
| Wealth quintile | ||||
| Lowest | 1 | |||
| Second | 3.21 | 0.82 | 12.52 | 0.093 |
| Middle | 3.24 | 0.75 | 13.94 | 0.115 |
| Fourth | 7.03 | 1.87 | 26.45 | 0.004 |
| Highest | 7.12 | 1.84 | 27.95 | 0.005 |
| Ethnicity | ||||
| Disadvantaged Janajati and Dalit | 1 | |||
| Newar | 0.44 | 0.18 | 1.08 | 0.073 |
| Brahmin/Chhetri | 0.34 | 0.14 | 0.84 | 0.019 |
| Placebo | TOL ER | |||||
| < 65 years (n = 1171) | 65–74 years (n = 477) | ≥ 75 years (n = 288) | < 65 years (n = 1360) | 65–74 years (n = 582) | ≥ 75 years (n = 285) | |
| Discontinuations, n (%) | ||||||
| Total* | 126 (11) | 49 (10) | 43 (15) | 115 (9) | 45 (8) | 35 (12) |
| Owing to an AE* | 37 (3) | 22 (5) | 16 (6) | 33 (2) | 14 (2) | 14 (5) |
| Men, n (%) | 265 (23) | 168 (35) | 118 (41) | 259 (19) | 180 (31) | 93 (33) |
| Mean (SD) age, years | 50.8 (9.9) | 69.0 (2.8) | 79.1 (4.0) | 50.7 (10.1) | 69.1 (2.8) | 78.9 (3.4) |
| Range | 19–64 | 65–74 | 75–93 | 18–64 | 65–74 | 75–90 |
| Race, n (%) | ||||||
| White | 1034 (88) | 452 (95) | 278 (97) | 1224 (90) | 555 (95) | 278 (98) |
| Black | 73 (6) | 15 (3) | 6 (2) | 71 (5) | 13 (2) | 4 (1) |
| Asian | 17 (2) | 4 (1) | 1 (< 1) | 18 (1) | 4 (1) | 2 (1) |
| Other | 47 (4) | 6 (1) | 3 (1) | 47 (3)† | 10 (2) | 1 (< 1) |
| Mean (SD) body mass index, kg/m2 | 29.1 (6.9) | 29.0 (5.9) | 26.6 (4.5) | 29.1 (9.0) | 28.9 (5.7) | 27.7 (12.4) |
| Range | 15.1–63.9 | 16.8–49.9 | 15.7–47.2 | 16.5–211.5 | 17.1–60.3 | 15.8–198.8 |
| 6 MeV | 9 MeV | 12 MeV | 16 MeV | 20 MeV | |||||||
| Cone | Depth | Measured | eMC | Measured | eMC | Measured | eMC | Measured | eMC | Measured | eMC |
| 6.0 | R50 | 25.6 | 26.0 | 31.9 | 33.4 | 39.6 | 41.1 | 47.9 | 47.3 | 54.6 | 51.5 |
| 10.0 | R50 | 25.9 | 27.1 | 32.3 | 32.7 | 41.0 | 41.6 | 50.8 | 49.9 | 60.6 | 57.1 |
| 15.0 | R50 | 26.2 | 26.7 | 31.6 | 33.5 | 40.7 | 41.6 | 50.4 | 50.6 | 61.4 | 59.1 |
| 20.0 | R50 | 26.3 | 27.3 | 32.2 | 34.1 | 40.0 | 42.5 | 49.7 | 50.8 | 61.7 | 57.3 |
| 25.0 | R50 | 26.5 | 27.8 | 33.7 | 34.6 | 41.3 | 42.8 | 50.3 | 52.4 | 62.2 | 57.3 |
| 6.0 | R90 | 25.4 | 25.3 | 30.6 | 30.7 | 36.7 | 38.3 | 41.3 | 42.4 | 42.0 | 41.9 |
| 10.0 | R90 | 25.9 | 25.8 | 30.7 | 31.0 | 37.9 | 38.5 | 44.0 | 45.3 | 46.6 | 45.9 |
| 15.0 | R90 | 26.4 | 25.3 | 30.6 | 31.3 | 38.1 | 38.4 | 44.1 | 44.9 | 46.9 | 46.1 |
| 20.0 | R90 | 26.1 | 25.4 | 30.8 | 31.9 | 37.0 | 39.1 | 43.3 | 44.7 | 46.8 | 46.7 |
| 25.0 | R90 | 26.1 | 25.7 | 32.2 | 31.8 | 38.0 | 39.0 | 43.3 | 46.0 | 47.1 | 46.3 |
| 6.0 | dmax | 21.7 | 21.4 | 23.7 | 23.8 | 24.8 | 25.7 | 18.7 | 19.1 | 12.0 | 12.9 |
| 10.0 | dmax | 22.1 | 21.6 | 24.0 | 24.0 | 25.7 | 26.3 | 20.6 | 21.3 | 12.3 | 13.3 |
| 15.0 | dmax | 22.5 | 21.3 | 23.8 | 24.2 | 26.0 | 26.6 | 20.5 | 22.1 | 12.1 | 14.0 |
| 20.0 | dmax | 22.2 | 21.6 | 24.0 | 24.6 | 25.1 | 26.6 | 20.0 | 22.3 | 11.9 | 14.3 |
| 25.0 | dmax | 22.0 | 21.7 | 24.5 | 24.3 | 25.7 | 27.1 | 20.1 | 22.3 | 11.8 | 13.7 |
| RIP A (ICMB 841-P3 × 863B-P2) | RIP B (H 77/833-2 × PRLT 2/89-33) | RIP C (81B-P6 × ICMP 451-P8) | RIP D (PT 732B-P2 × P1449-2-P1) | Consensus map | ||||||
| Linkage groups | No. of markers | Map length (cM) | No. of markers | Map length (cM) | No. of markers | Map length (cM) | No. of markers | Map length (cM) | No. of markers | Map length (cM) |
| LG1 or LG1a | 18 | 130 | 17 | 123 | 13 | 76 | 6 | 29 | 29 | 147 |
| LG1b | 2 | 0.3 | ||||||||
| LG2 | 18 | 104 | 14 | 139 | 10 | 108 | 4 | 6 | 30 | 193 |
| LG3 | 8 | 44 | 9 | 102 | 7 | 54 | 8 | 34 | 17 | 94 |
| LG4 | 12 | 49 | 6 | 68 | 6 | 21 | 9 | 69 | 17 | 87 |
| LG5 | 13 | 86 | 8 | 84 | 10 | 117 | 9 | 48 | 22 | 134 |
| LG6 or LG6a | 20 | 98 | 14 | 86 | 7 | 10 | 4 | 9 | 32 | 113 |
| LG6b | 4 | 8 | 2 | 3 | ||||||
| LG6c | 2 | 3 | 2 | 2 | ||||||
| LG7 | 15 | 104 | 10 | 88 | 5 | 31 | 11 | 74 | 27 | 130 |
| LGA (unlinked) | - | - | - | - | - | - | 2 | 2 | - | - |
| Total | 104 | 615 | 78 | 690 | 64 | 428 | 59 | 276 | 174 | 898 |
| Isolate name | rpoBa | Spoligotype classification |
| R160 | Ser531Leu | LCC |
| R376 | Ser531Leu | Haarlem |
| R458 | Ser531Leu | Unknown/unique |
| R486 | Leu533Pro | Beijing |
| R631 | His526Tyr | Unknown/unique |
| R637 | Ser531Leu | Beijing |
| R641 | Leu533Pro | Beijing |
| R721 | Ser531Leu | Beijing |
| R912 | His526Tyr | EAI |
| R965 | Leu533Pro | Beijing |
| R966 | His526Tyr | Beijing |
| R1035 | Ser531Leu | LAM |
| R1415 | His526Tyr | Beijing |
| Gene | Forward primer (3′-5′) | Product length (bp) | NCBI Genbank | Slope | R2# | Efficiency* |
| Reverse primer (5′-3′) | ||||||
| Reference genes | ||||||
| ATP5G1 | CAGTCACCTTGAGCCGGGCGA | 94 | NM_001025218 | −3.42 | 0.999 | 1.96 |
| TAGCGCCCCGGTGGTTTGC | ||||||
| ACTB | GACATCCGCAAGGACCTCTA | 205 | XM_003124280 | −3.60 | 0.998 | 1.89 |
| ACATCTGCTGGAAGGTGGAC | ||||||
| RPS9 | GTCGCAAGACTTATGTGACC | 325 | XM_003356050 | −3.64 | 0.999 | 1.88 |
| AGCTTAAAGACCTGGGTCTG | ||||||
| Target genes | ||||||
| COX4/1 | GTGGAACTGTACCGCCTGAA | 257 | XM_003355730 | −3.44 | 1.000 | 1.95 |
| TTGTCGTAGTCCCACTTGGC | ||||||
| COX6A1 | CTCAGCTCGCATGTGGAAGA | 139 | NM_001190221 | −3.34 | 0.996 | 1.99 |
| GATGCGAAGATGGGGGTAGG | ||||||
| CACT/SLC25A20 | GCAAAGCCCATTAGCCCTCT | 235 | XM_003483178 | −3.21 | 0.988 | 2.05 |
| GAGCACATCCTCTGGGTGTT | ||||||
| PPARGC1A | TAAAGATGCCGCCTCTGACT | 168 | NM_213963 | −3.94 | 0.993 | 1.79 |
| TGACCGAAGTGCTTGTTCAG | ||||||
| PPARGC1B | AAGTGCGGCTTCGTCACCTA | 216 | XM_003124093 | −3.28 | 0.998 | 2.02 |
| GCTGTCGAAATCCATGGCTT | ||||||
| SLC22A5 | TGCATTTGGCTACATGCTGC | 174 | XM_003123912 | −3.76 | 0.995 | 1.85 |
| ATGATCACCTCAGCTTCCTG | ||||||
| SDHA | CTACGCCCCCGTCGCAAAGG | 380 | DQ402993 | −3.24 | 1.000 | 2.03 |
| AGTTTGCCCCCAGGCGGTTG | ||||||
| MYH2 | GGCCCTTTGATGCCAAGACA | 188 | NM_214136 | −3.45 | 1.000 | 1.95 |
| GGCCATGTCCTCGATCTTGT | ||||||
| MYH4 | GTGCCCTGCTGCCATCAATA | 363 | NM_001123141 | −3.53 | 1.000 | 1.92 |
| TGCGTAACGCTCTTTGAGGT | ||||||
| MYH7 | TGCCAGCTTGAGCCTCTTTC | 380 | NM_213855 | −3.33 | 0.999 | 2.00 |
| GTAGCGCTCCTTGAGGTTGT | ||||||
| FATP1 | GGTTCCAGCCTGTTGAATGT | 275 | NM_001083931 | −3.44 | 0.990 | 1.95 |
| AACAAAACCTTGGTGCTTGG | ||||||
| UCP2 | AGTGTGAGACCTGACGAAGC | 435 | NM_214289 | −3.64 | 0.996 | 1.88 |
| GCTTGACGGAGTCGTAGAGG | ||||||
| UCP3 | GCCACTTTGTCTCTGCCTTC | 219 | NM_214049 | −3.49 | 0.998 | 1.93 |
| CAAACATCACCACGTTCCAG |
| OTU | No. of clones | Phylogenetic class | Closest cultivated species (% similarity) |
| Bioreactor for CH4 production | |||
| Archaea | |||
| MET-BR-A01 | 49 | Methanobacteria | Methanothermobacter thermautotrophicus (99) |
| Total | 49 | ||
| Bacteria | |||
| MET-BR-B01 | 79 | Clostridia | Tepidanaerobacter syntrophicus (93) |
| MET-BR-B02 | 5 | Clostridia | Acetivibrio cellulolyticus (91) |
| MET-BR-B03 | 4 | Clostridia | Gelria glutamica (98) |
| MET-BR-B04 | 1 | Clostridia | Tepidanaerobacter syntrophicus (92) |
| MET-BR-B05 | 1 | Clostridia | Desulfosporosinus acidiphilus (95) |
| Total | 90 | ||
| Bioreactor for H2 production | |||
| Bacteria | |||
| HYD-BR-B01 | 47 | Clostridia | Thermotalea metallivorans (99) |
| HYD-BR-B02 | 10 | Clostridia | Tepidanaerobacter syntrophicus (83) |
| HYD-BR-B03 | 9 | Flavobacteria | Schleiferia thermophila (88) |
| HYD-BR-B04 | 5 | Clostridia | Desulfotomaculum putei (99) |
| HYD-BR-B05 | 5 | Clostridia | Desulfotomaculum putei (89) |
| HYD-BR-B06 | 4 | Clostridia | Thermosyntropha lipolytica (94) |
| HYD-BR-B07 | 4 | Clostridia | Thermotalea metallivorans (99) |
| HYD-BR-B08 | 3 | Clostridia | Oxobacter pfennigii (92) |
| HYD-BR-B09 | 3 | Clostridia | Clostridium thermosuccinogenes (93) |
| HYD-BR-B10 | 1 | Clostridia | Anaerobranca horikoshii (98) |
| Total | 91 |
| Average (in days) | Within 1 week (in %) | Within 1 month (in %) | Within 3 months (in %) | |
| All scientific fields | 39 | 15 | 61 | 92 |
| General | 40 | 14 | 58 | 92 |
| Natural sciences | 34 | 17 | 66 | 94 |
| Engineering | 32 | 18 | 71 | 95 |
| Mathematics and Computer sciences | 33 | 18 | 69 | 95 |
| Medicine | 38 | 15 | 60 | 93 |
| Public health | 29 | 18 | 71 | 99 |
| Psychology | 50 | 12 | 46 | 90 |
| Economics and Business | 64 | 3 | 39 | 79 |
| Social sciences | 50 | 9 | 49 | 87 |
| Humanities | 47 | 10 | 52 | 90 |
| MAP-tau expression | |||
| Variable | Low (%) (AQUA score < 462) | High (%) (AQUA score > 462) | P* |
| Menopausal status | |||
| Premenopausal | 108 (22.8) | 31 (6.5) | 0.734 |
| Postmenopausal | 265 (55.9) | 70 (14.8) | |
| Tumor size | |||
| < 2 cm | 128 (29.1) | 31 (7.1) | 0.535 |
| 2-5 cm | 155 (35.2) | 50 (11.4) | |
| > 5 cm | 59 (13.4) | 17 (3.9) | |
| Nuclear grade | |||
| Small/uniform nuclei | 60 (13.4) | 15 (3.4) | 0.225 |
| Intermediate nuclei | 182 (40.6) | 61 (13.6) | |
| Large nuclei | 107 (23.9) | 23 (5.1) | |
| Nodal status | |||
| Node positive | 199 (41.8) | 47 (9.9) | 0.201 |
| Node negative | 175 (36.8) | 55 (11.6) | |
| ER | |||
| Negative | 227 (48.6) | 38 (8.1) | < 0.0001 |
| Positive | 140 (29.9) | 62 (13.3) | |
| PR | |||
| Negative | 240 (52.4) | 31 (6.8) | < 0.0001 |
| Positive | 120 (26.2) | 67 (14.6) | |
| HER2 | |||
| Negative | 283 (61.3) | 88 (19.1) | 0.010 |
| Positive | 80 (17.3) | 11 (2.4) |
| Type or gene involved | Number | Mean, kb | Range, kb |
| Copy number losses : large | |||
| Interstitial deletion | 18 | 5,070 | 1,048–16,837 |
| Terminal deletion | 14 | 5,273 | 1,218–13,593 |
| Unbalanced translocation | 15 | 7,053 | 880–17,107 |
| Subtotal | 47 | ||
| Copy number losses: small | |||
| DOCK8 | 24 | 299 | 97–431 |
| KANK1 | 3 | 369 | 184–670 |
| DOCK8 and KANK1 | 3 | 419 | 75–676 |
| EHMT1 | 16 | 417 | 22–790 |
| ASTN2 | 4 | 150 | 78–271 |
| FREM1 | 2 | 369 | 166–573 |
| STXBP1 | 1 | 592 | NA |
| COL5A1 | 1 | 370 | NA |
| GLDC | 1 | 50 | 25–75 |
| TOPORS | 1 | 337 | NA |
| CDK5RAP2 | 1 | 74 | NA |
| Subtotal | 57 | ||
| Large copy number gains | |||
| Trisomy 9p/proximal 9q | 15 | 45,996 | 13,826–95,453 |
| 9q duplications | 6 | 12,172 | 6,277–18,399 |
| Unbalanced translocation | 4 | 25,717 | 6,794–68,089 |
| Tetrasomy 9q and proximal 9q due to isochromosome | 3 | 66,477 | 49,843–81,113 |
| Trisomy 9 | 2 | 140,833 | NA |
| Triplication | 1 | 15,972 | NA |
| Subtotal | 31 | ||
| Complex chromosomal rearrangements (CCRs) | |||
| Inverted duplication with terminal deletion of 9p | 3 | Deletion: 6,377; Duplication: 32,271 | |
| Inverted duplication with terminal deletion of 9q | 1 | Deletion: 161; Duplication: 3,127 | |
| Multiple deletion and duplication | 2 | Losses: 1091; Gains: 12,517 | |
| Chromothripsis | 1 | Loss: 134; Gains: 21,094 | |
| Subtotal | 7 | ||
| Total | 142 |
| Age group of children (months) | Rotavirus status of Children | ||||
| Positive | Negative | Total | P-value | ||
| 0-6 | count | 2 | 8 | 10 | |
| % of total | 1.3% | 5.0% | 6.3% | ||
| 7-12 | count | 12 | 40 | 52 | |
| % of total | 7.5% | 25.0% | 32.5% | 0.047 | |
| 13-24 | count | 6 | 54 | 60 | |
| % of total | 3.8% | 33.8% | 37.5% | ||
| 25-60 | count | 2 | 36 | 38 | |
| % of total | 1.3% | 22.5% | 23.8% | ||
| Total | count | 22 | 138 | 160 | |
| % of total | 13.8% | 86.2% | 100.0% |
| Dataset | #Subjects | #Case | Platform | #SNPs | |
| Croatia | (Before QC) | 306 | 103 | Illumina 550 K | 561,466 |
| (After QC) | 305 | 103 | 489,200 | ||
| NINDS | (Before QC) | 542 | 0 | Illumina 550 K | 561,466 |
| (After QC) | 534 | 0 | 489,096 | ||
| HGDP | (Before QC) | 1,043 | 0 | Illumina 650Y | 660,918 |
| (After QC) | 1,043 | 0 | 584,835 | ||
| Merged datasets | |||||
| Croatia+NINDS | (After QC) | 839 | 103 | - | 475,964 |
| Croatia+HGDP | (After QC) | 1,348 | 103 | - | 478,287 |
| Species | Female | Male |
| Dichaetophora acutissima | 20 | 25 |
| Drosophila annulipes | 31 | 27 |
| Drosophila bizonata | 31 | 31 |
| Drosophila busckii | 35 | 41 |
| Drosophila curviceps | 20 | 26 |
| Drosophila hydei | 11 | 20 |
| Drosophila immigrans | 41 | 41 |
| Drosophila lutescens | 14 | 42 |
| Drosophila rufa | 41 | 41 |
| Drosophila sternopleuralis | 42 | 42 |
| Drosophila suzukii | 22 | 19 |
| Hirtodrosophila sexvittata | 41 | 41 |
| Liodrosophila aerea | 41 | 41 |
| Microdrosophila sp. | 15 | 10 |
| Scaptodrosophila coracina | 5 | 34 |
| Scaptomyza graminum | 36 | 32 |
| Arabidopsis | Rice | |||
| Origin of nat-siRNAs | Total | Unique | Total | Unique |
| Entire NATs | 33,826 | 17,059 | 162,397 | 56,209 |
| Introns in entire NATs | 14,500 | 6,988 | 88,605 | 29,654 |
| OR of NATs | 10,429 | 6,532 | 27,852 | 10,761 |
| Introns in OR of NATs | 4,367 | 2,350 | 14,207 | 5,494 |
| Sample | Potential (mV) | Dissolution Current Density at −400 mV (A cm−2) |
| No Exposure | −486.5 | 1.3 × 10−4 |
| Arica | −574.7 | 4.0 × 10−4 |
| Quintero | −611.1 | 12 × 10−4 |
| Laja | −515.0 | 1.6 × 10−4 |
| Antarctic | −548.7 | 4.6 × 10−4 |
| It is likely that people who | |||||
| have consumed bushmeat in | |||||
| Variable | Response | Estimatea | SE | RVIb | the year prior to survey... |
| ARUc | yes | −0.652 | 0.218 | 1.00 | are not ARUs |
| Marital status | single | 0.619 | 0.216 | 0.99 | are from single parent households |
| Benefit from MUPd | yes | 0.424 | 0.172 | 0.95 | have benefitted from MUP |
| Well‐beinge | somewhat bad | 0.030 | 0.223 | 0.95 | rate their lives average or somewhat bad |
| worst | −0.644 | 0.319 | |||
| Education | 4 years or more | −0.309 | 0.174 | 0.45 | have 3 or fewer years of formal education |
| Gene | GC% M. davidii | GC% P. alecto | Gene length M. davidii | Gene length P. alecto |
| IKZF1 | 49.6 | 53.2 / 51.5 | 1908 | 228/816 |
| GPSM1 | 49.1 | 65.4 | 705 | 2118 |
| SPRR1 | 44.0 | 47.1 | 339 | 342 |
| All subjects (N = 15) | ||||
| Completed (N = 10) | Withdrawn (N = 5) | |||
| Mean (SD) | P | |||
| Age yrs | 67.9 (9.4) | 67.6 (10.9) | 68.4 (6.3) | 0.88 |
| Body mass index kg/m2 | 23.1 (4.6) | 23.7(4.9) | 22.1(4.2) | 0.52 |
| N (%) | ||||
| Sex | ||||
| M | 9 (60) | 4 (40) | 5 (100) | |
| F | 6 (40) | 6 (60) | 0 (0) | 0.04 |
| PS | ||||
| 1 | 2 (13) | 2 (20) | 0 (0) | |
| 2 | 6 (40) | 4 (40) | 2 (40) | |
| 3 | 7 (47) | 4 (40) | 3 (60) | 0.79 |
| Diagnosis | ||||
| Lung cancer | 4 (27) | 3 (30) | 1 (20) | |
| GI cancer | 6 (40) | 2 (20) | 4 (80) | |
| Other | 5 (33) | 5 (50) | 0 (0) | NA |
| Cancer stage | ||||
| III | 1 (7) | 1 (10) | 0 (0) | |
| IV | 11 (73) | 6 (60) | 5 (100) | |
| NA | 3 (20) | 3 (30) | 0 (0) | NA |
| Chemotherapy | ||||
| Y | 10 (67) | 6 (60) | 4 (80) | |
| N | 5 (33) | 4 (40) | 1 (20) | 0.60 |
| Recent steroid use | ||||
| Y | 6 (40) | 4 (40) | 2 (40) | |
| N | 9 (60) | 6 (60) | 3 (60) | 1.00 |
| Clinicopathological parameters | n | NgBR expression | P | ||
| Low | High | ||||
| Age (y) | |||||
| ≤ 54 | 47 | 22 | 25 | 0.051 | |
| > 54 | 42 | 11 | 31 | ||
| Gender | |||||
| Male | 80 | 29 | 51 | 0.906 | |
| Female | 9 | 4 | 5 | ||
| Hepatitis history | |||||
| No | 27 | 8 | 19 | 0.474 | |
| Yes | 62 | 25 | 37 | ||
| Cirrhosis | |||||
| No | 27 | 8 | 19 | 0.474 | |
| Yes | 62 | 25 | 37 | ||
| Tumor size | |||||
| ≤ 5 cm | 38 | 13 | 25 | 0.306 | |
| > 5 cm | 51 | 20 | 31 | ||
| Tumor number | |||||
| Single | 46 | 15 | 31 | 0.389 | |
| Multiple | 43 | 18 | 25 | ||
| Vascular invation | |||||
| No | 78 | 30 | 48 | 0.700 | |
| Yes | 11 | 3 | 8 | ||
| TNM stage | |||||
| I + II | 46 | 19 | 27 | 0.511 | |
| III + IV | 43 | 14 | 29 |
| Parameter | |||
| GROUP | Norepinephrine | Dopamine | Serotonin |
| Control | 0.376 ± 0.07 | 1.45 ± 0.12 | 0.80 ± 0.115 |
| Leaded gasoline | 0.47 ± 0.086 a* | 1.71 ± 0.14 a* | 0.60 ± 0.043 a** |
| Unleaded gasoline | 0.41 ± 0.036 | 1.35 ± 0.24 b** | 0.385 ± 0.057 a*** b** |
| MIGS ID | Characteristic | Details |
| MIGS-28 | Libraries used | 2kb (pUC19) and 40kb (pcc1FOS) Sanger and 454 standard libraries |
| MIGS-29 | Sequencing platform | ABI-3730, 454 GS FLX Titanium |
| MIGS-31.2 | Sequencing coverage | 1.1× Sanger 40kb insert, 31.3× pyrosequencing |
| MIGS-31 | Finishing Quality | Finished |
| MIGS-30 | Assembler | gsAssembler (Newbler) version 2.5.3 |
| MIGS-32 | Gene calling method | IMG-ER pipeline [27](CRISPR: CRT [28] and PILERCR [29];tRNAs: tRNAScan-SE-1.23 [30]; rRNA: RNAmmer [31];other genes: Prodigal [32]) |
| GenBank ID | CP003985, CP003986 | |
| GenBank date of release | 14.01.2013 | |
| GOLD ID | Gi18068 | |
| NCBI project ID | 91121 | |
| IMG Taxon ID | 2512875001 | |
| MIGS-13 | Source material identifier | DSM 10523T |
| Project relevance | Sulfur cycle |
| Criteria | Percentage |
| WHO | 61.43% |
| Not sure | 17.14% |
| ADA | 12.38% |
| IADPS | 9.05% |
| Coefficient of drug interaction (CDI) | |||||
| Etoposide | Epirubicin | Doxorubicin | Vincristine | Colchicine | |
| Ad5GS3 | 0.27 | 0.31 | 0.33 | 0.89 | 0.78 |
| Ad5WS1 | 0.67 | 0.46 | 0.88 | 0.79 | 0.81 |
| Exophily | No. caught | Exiting % (95% CI) | Median IQR exiting | OR | 95% CI | P-value | Z |
| Control net | |||||||
| West African hut | 587 | 35 (31–39) | 2 (0.5–3) | 1 | |||
| Ifakara hut | 2067 | 64 (62–66) | 23 (14–33.5) | 4.18 | 3.18–5.51 | < 0.0001 | 10.18 |
| Olyset® Net | |||||||
| West African hut | 553 | 60 (56–64) | 4 (2–11) | 1 | |||
| Ifakara hut | 1658 | 88 (86–89) | 27.5 (17.5–34.5) | 4.77 | 3.56–6.37 | < 0.0001 | 10.53 |
| Metofluthrin 0.00625% | |||||||
| West African hut | 122 | 49 (40–56) | 0 (0–2) | 1 | |||
| Ifakara hut | 1489 | 82 (80–84) | 20 (13–28) | 5.41 | 3.54–8.28 | < 0.0001 | 7.79 |
| Metofluthrin 0.0097% | |||||||
| West African hut | 130 | 40 (31–48) | 0 (0–1) | 1 | |||
| Ifakara hut | 1054 | 85 (83–87) | 18 (10–24) | 8.88 | 5.74–13.73 | < 0.0001 | 9.82 |
| WT | AS5ox-1 | AS5ox-2 | ||
| *Days to Flowering from Planting | 50.60 ± 1.43 | 53.80 ± 0.79 | 53.80 ± 0.79 | |
| *Total Chlorophyll (g/m2) at Maturity | 0.75 ± 0.05 | 0.69 ± 0.04 | 0.66 ± 0.04 | |
| *Plant Height (cm) | 99.97 ± 1.65 | 81.46 ± 2.36 | 86.66 ± 1.90 | |
| *Shoot Fresh Weight (g) | 101.69 ± 3.02 | 82.39 ± 3.29 | 83.21 ± 3.04 | |
| Internode 3 | Length (cm) | 5.71 ± 0.19 | 5.37 ± 0.24 | 5.12 ± 0.29 |
| *Circumference (cm) | 4.44 ± 0.05 | 4.06 ± 0.06 | 4.16 ± 0.09 | |
| Internode 9 | *Length (cm) | 15.98 ± 0.49 | 12.61 ± 0.61 | 13.27 ± 0.78 |
| *Circumference (cm) | 3.98 ± 0.10 | 3.16 ± 0.12 | 3.52 ± 0.11 | |
| Leaf 3 | Length (cm) | 30.77 ± 0.77 | 32.17 ± 1.22 | 30.11 ± 0.95 |
| Width (cm) | 19.85 ± 0.47 | 21.04 ± 0.95 | 19.82 ± 0.69 | |
| Fresh Weight (mg/cm2) | 20.53 ± 0.79 | 17.16 ± 0.43 | 20.23 ± 0.73 | |
| *Dry Weight (mg/cm2) | 1.68 ± 0.07 | 1.80 ± 0.04 | 1.95 ± 0.06 | |
| Leaf 9 | *Length (cm) | 33.82 ± 1.25 | 27.10 ± 1.92 | 25.02 ± 1.42 |
| *Width (cm) | 16.34 ± 0.66 | 11.93 ± 1.27 | 11.01 ± 0.90 | |
| Fresh Weight (mg/cm2) | 14.34 ± 0.54 | 11.97 ± 0.17 | 13.99 ± 0.37 | |
| Dry Weight (mg/cm2) | 2.02 ± 0.07 | 1.86 ± 0.09 | 2.13 ± 0.08 |
| Wired | Wireless |
| High bandwidth | Low-medium bandwidth |
| High performance | Higher latency |
| Robust | Interference |
| Reliable | Unreliable by nature |
| Installation expensive | Installation cheap |
| “Unlimited” resources | Low power, memory |
| Static network | Mobile network |
| Less security problems | More security problems |
| Characteristics | Total | Physical activity | ||
| N | nd (%) | COR(95%CI) | AOR(95%CI) | |
| Total | 2063 | 2007 (97.3%) | ||
| Age groups | ||||
| 18–29 | 735 | 714 (97.1%) | 1.0 | |
| 30–39 | 532 | 514 (96.6) | 0.83 (0.44–1.59) | − |
| 40–49 | 387 | 378 (97.7) | 1.23 (0.56–2.72) | − |
| 50–59 | 289 | 284 (98.3) | 1.67 (0.62–0.62) | − |
| 60+ | 120 | 117 (97.5) | 1.14 (0.33–3.90) | − |
| Education level | ||||
| No education | 396 | 381 (96.2) | 1.0 | |
| Primary | 1391 | 1359 (97.7) | 1.67 (0.89–3.11) | − |
| Secondary and above | 276 | 267 (97.7) | 1.16 (0.50–2.71) | − |
| Occupation | ||||
| Professionals | 80 | 74 (92.5) | 1.0 | 1.0 |
| Farming | 1543 | 1518 (98.4) | 4.92 (1.95–12.36) | 9.75 (3.68–5.82)*** |
| Business | 132 | 125 (94.7) | 1.44 (0.46–4.47) | 1.80 (0.56–5.74) |
| Skilled work | 123 | 114 (92.7) | 1.02 (0.35–3.00) | 1.43 (0.47–4.33) |
| Unskilled work | 164 | 155 (94.5) | 1.39 (0.47–4.06) | 2.02 (0.67–6.11) |
| Residence | ||||
| Urban | 627 | 619 (98.7) | 1.0 | 1.0 |
| Rural | 1434 | 1386 (96.7) | 0.37 (0.17–0.79) | 0.19 (0.08–0.42)*** |
| Marital status | ||||
| Single/never married | 547 | 532 (97.3) | 1.0 | |
| Married | 1515 | 1474 (97.3) | 1.01 (0.55–1.84) | − |
| ALT (U/L) | AST (U/L) | Alkaline Phosphatase (U/L) | Total Billirubin (mg/dL) | |||||
| HP | SP | HP | SP | HP | SP | HP | SP | |
| Baseline | 27.07 ± 13.97 | 28.84 ± 15.00 | 25.2 ± 11.44 | 23.33 ± 13.00 | 66.2 ± 37.00 | 71.88 ± 41.00 | 0.75 ± 0.26 | 0.77 ± 0.40 |
| Month 3 | 25.4 ± 7.51 | 28.53 ± 15.00 | 24.23 ± 7.30 | 24.39 ± 16.00 | 69.64 ± 39.00 | 72.85 ± 18.58 | 0.75 ± 0.20 | 0.82 ± 0.20 |
| Month 6 | 24.87 ± 11.22 | 27.23 ± 16.00 | 24.26 ± 14.00 | 23.44 ± 5.17 | 69.89 ± 19.13 | 72.21 ± 17.78 | 0.80 ± 0.25 | 0.83 ± 0.30 |
| Month 12 | 24.1 ± 12.00 | 26.91 ± 14.23 | 23.00 ± 13.00 | 23.76 ± 14.00 | 71.48 ± 40.00 | 69.18 ± 18.65 | 0.76 ± 0.36 | 0.84 ± 0.40 |
| Dose, Subgroup (n at final visit) | Physical ComponentSummary | Mental ComponentSummary | Mental HealthDomain |
| Elderly | |||
| 1 mg, with psychiatric disorders (n = 37)a | |||
| Baseline | 40.9 (15.9) | 43.6 (9.9) | 39.5 (12.2) |
| Final visit (LOCF) | 42.4 (12.2) | 50.8 (10.9) | 47.3 (11.2) |
| Change from baseline | 1.5 (10.4) | 6.8 (11.2)* | 7.3 (12.0)* |
| 2 mg, with psychiatric disorders (n = 42) | |||
| Baseline | 41.1 (15.7) | 44.7 (10.6) | 41.5 (13.2) |
| Final visit (LOCF) | 43.3 (12.4) | 50.5 (9.0) | 47.0 (11.3) |
| Change from baseline | 2.3 (10.6) | 5.8 (8.4)* | 5.5 (8.8)* |
| 1 mg, without psychiatric disorders (n = 42) | |||
| Baseline | 46.8 (10.3) | 54.7 (7.2) | 53.7 (8.7) |
| Final visit (LOCF) | 48.4 (7.4) | 57.5 (6.8) | 57.0 (7.2) |
| Change from baseline | 1.6 (7.0) | 2.9 (7.2)† | 3.3 (8.2)† |
| 2 mg, without psychiatric disorders (n = 41) | |||
| Baseline | 51.7 (5.0) | 55.3 (7.9) | 54.6 (7.7) |
| Final visit (LOCF) | 51.5 (6.2) | 56.1 (7.4) | 55.7 (7.0) |
| Change from baseline | −0.2 (5.3) | 0.8 (7.5) | 1.1 (8.7) |
| Nonelderly | |||
| 2 mg, with psychiatric disorders (n = 43) | |||
| Baseline | 47.1 (10.4) | 38.3 (8.7) | 37.7 (9.1) |
| Final visit (LOCF) | 47.5 (9.8) | 44.6 (9.7) | 43.6 (10.1) |
| Change from baseline | 0.4 (10.5) | 6.3 (9.3)* | 5.9 (9.8)* |
| 3 mg, with psychiatric disorders (n = 36)a | |||
| Baseline | 49.4 (8.8) | 39.8 (8.2) | 39.5 (6.9) |
| Final visit (LOCF) | 49.5 (11.0) | 44.2 (8.3) | 44.4 (10.1) |
| Change from baseline | −0.1 (8.9) | 4.3 (9.2)‡ | 4.8 (11.3)† |
| 2 mg, without psychiatric disorders (n = 41) | |||
| Baseline | 50.6 (8.0) | 49.8 (7.6) | 50.1 (9.1) |
| Final visit (LOCF) | 51.7 (9.7) | 50.8 (9.2) | 50.7 (10.5) |
| Change from baseline | 1.2 (8.6) | 1.0 (9.6) | 0.7 (12.0) |
| 3 mg, without psychiatric disorders (n = 39)a | |||
| Baseline | 50.9 (11.4) | 49.4 (7.9) | 50.4 (7.8) |
| Final visit (LOCF) | 52.5 (8.1) | 51.2 (8.1) | 51.9 (7.8) |
| Change from baseline | 1.7 (10.8) | 1.7 (5.9) | 1.6 (7.3) |
| Training section | Examples for tasks |
| Planning strategies | Shopping lists, key search of the BADS subscales, to get items out of a bottle, special wooden 3-dimensional jig saw |
| Mnemonics | Using memory hooks, writing of suitable mnemonics, and planning where to place them |
| Decision making | Computer tasks, painting |
| Set shifting | To solve various tasks according to changing rules, to calculate for 5 min, then to read for 10 min and to write for 5 min, or to switch tasks after every third answer, categorising items according to different rules |
| Calculation | Calculation tasks |
| Navigational skills | Finding the way through a maze on a screen, finding the way around obstacles on a paper or on a screen |
| Information speed processing | Connecting numbers or letters, connecting figures to an image, and finding the meaning of a fictive word |
| Summary | Extracting the relevant information from news or from a story or a short movie |
| Concentration | Finding similar or dissimilar items |
| Gene | N | Mean ± SD | P-value (Mann-Whitney test) | |
| APC | Cases | 11 | 2.06 ± 2.6 | 0.3 |
| Controls | 10 | 0.95 ± 1.31 | ||
| ATM | Cases | 9 | 0.5 ± 0.9 | 0.9 |
| Controls | 10 | 1.48 ± 2.2 |
| 25OHD, ng/mL | 25OHD ≤ 12 | 13 < 25OHD ≤ 19 | 20 < 25OHD ≤ 30 | 25OHD > 30 | |||||
| n = 2 | n = 9 | n = 15 | n = 24 | p | |||||
| Boys | 0 | 0% | 3 | 33% | 7 | 47% | 18 | 75% | 0.04 |
| Girls | 2 | 100% | 6 | 67% | 8 | 53% | 6 | 25% | |
| Isolated GH deficiency | 1 | 50% | 6 | 67% | 4 | 27% | 11 | 46% | 0.2 |
| Multiple HP deficiency | 1 | 50% | 3 | 33% | 11 | 73% | 13 | 54% | |
| Sunny season | 0 | 0% | 0 | 0% | 4 | 27% | 11 | 46% | 0.01 |
| Cold season | 2 | 100% | 6 | 100% | 11 | 73% | 13 | 54% | |
| Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD | ||||||
| Age at diagnosis, years | 13.5 ± 4.5 | 4.7 ± 5.1 | 6.5 ± 6.7 | 4.4 ± 2.8 | 0.1 | ||||
| Bone age, years | 12 ± 5 | 3.6 ± 5.6 | 3.2 ± 3.5 | 2.5 ± 1.9 | 0.1 | ||||
| Height, SDS | −2.7 ± −2.7 | −2.6 ± 0.6 | −3 ± 1.2 | −2.8 ± 1.5 | 0.9 | ||||
| BMI, SDS | 1.3 ± 0.8 | 0.4 ± 1.6 | 0.3 ± 2.3 | 0 ± 1.6 | 0.6 | ||||
| Growth rate, SDS | − 2.6 ± 0 | − 2.4 ± 0.6 | − 2.7 ± 1.2 | − 3 ± 1.2 | NS | ||||
| IGF1, SDS | −4.7 ± 0 | −2.4 ± 1.8 | −3.9 ± 0.8 | −3.6 ± 1 | NS |
| Variable | N | |
| Age (yrs) | 51 | 66.7 (12.0) |
| Sex (M/F) | 51 | 26/25 |
| MMSE | 51 | 28.7 (1.4) |
| Education | 51 | 5 (2) |
| NRS 50 kPa | 51 | 1.2 (1.6) |
| NRS 200 kPa | 51 | 2.9 (2.3) |
| NRS 400 kPa | 51 | 5.0 (2.6) |
| Facial expressions 50 kPa | 51 | 0.4 (0.6) |
| Facial expressions 200 kPa | 50 | 0.7 (0.9) |
| Facial expressions 400 kPa | 51 | 1.2 (1.4) |
| Stroop Word card (s) | 51 | 55.9 (15.9) |
| Stroop Color card (s) | 51 | 67.3 (20.1) |
| Stroop Color/Word card (s) | 51 | 127.5 (95.2) |
| Zoo Map score | 51 | 11.0 (4.0) |
| Digit Span Backward | 51 | 5.8 (2.3) |
| AVLT immediate recall | 51 | 38.6 (11.1) |
| AVLT delayed recognition | 51 | 27.3 (2.9) |
| RBMT immediate story recall | 51 | 7.5 (3.4) |
| RBMT delayed story recall | 51 | 6.3 (3.2) |
| Characteristic | Value |
| Blood flow (ml/min)a | 421 ± 42 |
| Time of utilization (h) | 30.6 ± 21.0 |
| Access pressure (mmHg)a | − 145 ± 14 |
| Filter pressure (mmHg)a | 301 ± 19 |
| Return pressure (mmHg)a | 154 ± 21 |
| Heparin bolus at insertion (IU) | 3100 ± 1330 |
| Heparin (IU/kg/24 h) | 230 ± 78 |
| Activated partial thromboplastin time ratio | 1.8 ± 0.6 |
| Serious adverse eventb | |
| Nonfatal cardiac arrest | 1 (5) |
| Study-related adverse event | |
| Mild hemoptysis resolved with stopping anticoagulationc | 2 (10) |
| Membrane clotting | 10 (50) |
| Time it occurred (h) | 20.0 ± 9.7 |
| N | Dog Owners(n = 43) | Non dog owners(n = 43) | |
| Match Characteristics | |||
| Gender (N female, %) | 43 | 27 (63%) | 27 (63%) |
| Age at start of study (years) | 43 | 69.9 (± 4.1) | 70.2 (± 4.1) |
| Ethnicity (N White British) | 43 | 43 (100%) | 43 (100%) |
| Cat ownership (N yes) | 43 | 4 (9%) | 4 (9%) |
| Townsend Index | 43 | ||
| 1 (least deprived) | 11 (26%) | 11 (26%) | |
| 2 | 15 (35%) | 15 (35%) | |
| 3 | 12 (28%) | 12 (28%) | |
| 4 | 4 (9%) | 4 (9%) | |
| 5 (most deprived) | 1 (2%) | 1 (2%) | |
| Other Characteristics | |||
| Distance between homes (km) | 42 | 12.8 [22.8] | |
| BMI (kg.m−2) | 43 | 25.4 (± 4.3) | 25.8 (± 3.7) |
| Participants reporting a chronic health condition at start of study | 38/41 | 14 (37%) | 15 (37%) |
| Self-reported continuous walking distance (km) | 38/37 | 6.1 ± (2.2) | 6.5 ± (2.6) |
| FAK location | Parameter | Correlation co-efficient | p-value |
| Vessels | Patient age | 0.096 | 0.246 |
| Tumour size | 0.089 | 0.28 | |
| Tumour cells | Patient age | -0.138 | 0.094 |
| Tumour size | 0.119 | 0.148 |
| Parameters | DMFT index | H | Found p | p | Sig./N. sig. |
| Zn concentration, mmol/l (before stimulation) | <1 | 2.54 | 0.28 | >0.05 | N. sig. |
| 1–6 | |||||
| >6 | |||||
| Zn concentration, mmol/l (after stimulation) | <1 | 3.56 | 0.16 | >0.05 | N. sig. |
| 1–6 | |||||
| >6 | |||||
| Zn quantity, μmol/l (before stimulation) | <1 | 5.66 | 0.05 | >0.05 | N. sig. |
| 1–6 | |||||
| >6 | |||||
| Zn quantity, μmol/l (after stimulation) | <1 | 7.99 | 0.01 | <0.05 | Sig. |
| Parameter | FS (n = 848) | FGLS (n = 1556) | Total (n = 2404) |
| Gestational age at birth | |||
| < 28 weeks | 2 (0.2) | 1 (0.1) | 3 (0.1) |
| 28–32 weeks | 3 (0.4) | 6 (0.4) | 9 (0.4) |
| 32–37 weeks | 56 (6.6) | 62 (4.0) | 118 (4.9) |
| 37–43 weeks | 787 (92.8) | 1487 (95.6) | 2274 (94.6) |
| Birth weight | |||
| < 1000 g | 1 (0.1) | 2 (0.1) | 3 (0.1) |
| 1000–1499 g | 5 (0.6) | 1 (0.1) | 6 (0.2) |
| 1500–1999 g | 9 (1.1) | 15 (1.0) | 24 (1.0) |
| 2000–2499 g | 79 (9.3) | 76 (4.9) | 155 (6.4) |
| ≥ 2500 g | 754 (88.9) | 1462 (94.0) | 2216 (92.2) |
| Experimental groups | n | DT days, Mean±SE | GD days, mean | Inhibition ratio (%) | CR number |
| Control | 8 | 4.6±0.5 | 0 | 0 | |
| CDDP | 8 | 10.6±1.21 | 5.5 | 33 | 0 |
| EP | 8 | 6.6±0.5 | 2.0 | 32 | 0 |
| ECT | 10 | 20.1±1.2 | 15.5 | 61 | 0 |
| IR (3 Gy) | 9 | 15.7±1.4 | 11.1 | 63 | 0 |
| CDDP + IR (3 Gy) | 9 | 15.9±2.4 | 11.3 | 61 | 0 |
| EP + IR (3 Gy) | 8 | 13.4±2.1 | 8.8 | 51 | 0 |
| ECT + IR (3 Gy) | 10 | 30.3±2.6 | 25.7 | 76 | 0 |
| IR (5 Gy) | 8 | 25.2±1.1 | 20.6 | 70 | 0 |
| CDDP + IR (5 Gy) | 8 | 25.6±1.2 | 21.0 | 75 | 0 |
| EP + IR (5 Gy) | 8 | 22.4±1.4 | 17.8 | 59 | 0 |
| ECT + IR (5 Gy) | 8 | 43.2±1.5 | 38.6 | 87 | 2 |
| Risk | Kupelian | D'Amico | Pound |
| Low | 85% | 83% | 94-82% |
| Intermediate | 65% | 50% | 72% |
| High | 32% | 28% | 54% |
| Days of pseudopregnancy | |||||||
| Cell Types | 1 | 2 | 3 | 4 | 5 | 6 | 7 |
| Luminal epithelium | + | + | + | +/- | +/- | +/- | +/- |
| Glandular epithelium | +/- | + | + | +/- | +/- | +/- | +/- |
| Stromal cells | - | - | - | - | - | - | - |
| Database name | Organization | Remarks | Relevance to investigation interests |
| National Health and Nutrition Examination Survey (NHANES) | CDC | Section on “Hearing/audiometry (AUQ) for 1 year and over, 1999-2012 with component or lab tests conducted on original sample description. In 2013-2014, there was no component/lab test conducted. | Yes |
| National Health Interview Survey Occupational Health Supplement (NHIS-OHS) | CDC | Does not contain any audiometric topics. | No |
| Behavioral Risk Factor Surveillance System (BRFSS) | National Center for Chronic | Option to respond ‘hearing problem’ as the major impairment that limits activities 1998-2002, 2013; Veteran’s Status included, 2003-2008, 2010-2012 | Yes |
| Disease Prevention and Health Promotion (NCCDPHP) | |||
| National Health Survey | CDC | Questions by family and individuals on hearing can derive some information about associations with the military, data available from 1997 onward. QOL is a supplemental (optional) component of the survey, available 2010-2012 | Yes |
| Health and Retirement Study (HRS) | University of Michigan | Data from 1992-2014 on hearing status, employment, and QOL measures | Yes |
| Period | Incidence Rate (per 100,000) | Mortality Rate (per 100,000) | Relative Survival Ratio (%) | ||||
| Total | Rate (95% CI) | Total | Rate (95% CI) | N* | Ratio (95% CI) | ||
| All | 1968–1972 | 94 | 6.7 (5.3–8.4) | 23 | 1.6 (0.9–2.4) | - | - |
| 1973–1977 | 143 | 8.6 (7.1–10.2) | 35 | 2.0 (1.4–2.9) | 31.7 | 48.1 (34.6–62.5) | |
| 1978–1982 | 239 | 11.3 (9.8–12.9) | 69 | 3.4 (2.6–4.3) | 57.4 | 53.0 (43.4–62.8) | |
| 1983–1987 | 356 | 13.8 (12.4–15.4) | 106 | 4.1 (3.3–5.0) | 94.8 | 49.7 (41.7–57.8) | |
| 1988–1992 | 527 | 16.3 (14.9–17.7) | 187 | 5.7 (4.9–6.6) | 155.7 | 55.8 (49.1–62.6) | |
| 1993–1997 | 903 | 23.2 (21.7–24.8) | 303 | 7.7 (6.9–8.7) | 214.9 | 53.5 (48.1–59.0) | |
| 1998–2002 | 1351 | 29.2 (27.6–30.8) | 434 | 9.3 (8.5–10.3) | 394.5 | 60.9 (56.6–65.1) | |
| Chinese | 1968–1972 | 74 | 6.4 (4.9–8.2) | 18 | 1.5 (0.8–2.5) | - | - |
| 1973–1977 | 104 | 7.7 (6.2–9.4) | 30 | 2.2 (1.4–3.2) | 22.8 | 36.5 (23.3–51.5) | |
| 1978–1982 | 179 | 10.5 (9.0–12.2) | 52 | 3.1 (2.3–4.1) | 37.6 | 46.6 (35.9–57.8) | |
| 1983–1987 | 257 | 12.7 (11.2–14.4) | 75 | 3.6 (2.8–4.6) | 65.1 | 46.8 (37.6–56.5) | |
| 1988–1992 | 411 | 16.3 (14.7–17.9) | 148 | 5.6 (4.7–6.6) | 111.8 | 58.8 (50.9–66.6) | |
| 1993–1997 | 718 | 24.1 (22.3–25.9) | 239 | 7.8 (6.8–8.8) | 167.4 | 53.0 (46.8–59.2) | |
| 1998–2002 | 1091 | 30.9 (29.1–32.8) | 342 | 9.6 (8.6–10.7) | 306.4 | 61.7 (56.8–66.5) | |
| Malays | 1968–1972 | 9 | 7.2 (3.1–14.2) | 2 | 1.2 (0.1–4.5) | ||
| 1973–1977 | 19 | 11.4 (6.5–18.6) | 2 | 0.9 (0.1–3.7) | 3.7 | 78.1 (28.7–125.1) | |
| 1978–1982 | 25 | 11.6 (7.3–17.5) | 7 | 2.9 (1–6.4) | 8.4 | 69.1 (40.3–97.2) | |
| 1983–1987 | 45 | 15.5 (11.2–21.0) | 13 | 4.5 (2.4–7.9) | 14.7 | 51 (30.3–73) | |
| 1988–1992 | 54 | 14.9 (11.1–19.6) | 22 | 6.4 (3.9–9.7) | 19.6 | 26.3 (14.2–42) | |
| 1993–1997 | 90 | 21.3 (17.1–26.2) | 41 | 10.4 (7.4–14.1) | 16.0 | 35.9 (21.5–52.4) | |
| 1998–2002 | 137 | 26.8 (22.4–31.8) | 51 | 10.0 (7.4–13.3) | 30.5 | 64.1 (50–77.4) | |
| Indians | 1968–1972 | 7 | 4.9 (1.6–11.3) | 2 | 1.7 (0.1–7.9) | ||
| 1973–1977 | 16 | 11.6 (5.7–21.1) | 3 | 2.0 (0.4–5.8) | 1.0 | 31.7 (4.7–75.8) | |
| 1978–1982 | 26 | 15.3 (9.6–23.3) | 5 | 3.1 (0.9–7.5) | 6.1 | 67.5 (35.9–95.0) | |
| 1983–1987 | 41 | 16.6 (11.7–22.8) | 13 | 6.2 (3.0–11.1) | 14.2 | 63.5 (43.1–83.1) | |
| 1988–1992 | 42 | 13.4 (9.5–18.5) | 11 | 4.8 (2.3–9.0) | 20.6 | 59.1 (39.7–78.2) | |
| 1993–1997 | 65 | 16.3 (12.4–20.9) | 13 | 3.3 (1.7–5.8) | 23.2 | 86.6 (67.0–102.8) | |
| 1998–2002 | 84 | 18.6 (14.6–23.3) | 29 | 6.0 (3.9–8.7) | 35.3 | 44.5 (32.4–57.0) |
| Genes | Forward primer (5′–3′) | Reverse primer (5′–3′) |
| m-PAX2 | AAGCCCGGAGTGATTGGTG | CAGGCGAACATAGTCGGGTT |
| m-WT1 | CAGTTCCCCAACCATTCCTT | AAGCTGGGAGGTCATTTGGT |
| m-Brachyury (Bry) | ACCCAGACTCGCCCAATTTT | GGAAAGCAGTGGCTGGTGAT |
| m-CD24 | GTTGCACCGTTTCCCGGTAA | CCCCTCTGGTGGTAGCGTTA |
| m-Osr1 | ATTCACCCTAAGCCAGAGATCA | AGGCCAGGTTAGCGAAATCAA |
| m-Six2 | CTCACCACCACGCAAGTCAG | CTCGGAACTGCCTAGCACC |
| m-Sall1 | CTCAACATTTCCAATCCGACCC | GGCATCCTTGCTCTTAGTGGG |
| m-E-cad | CTCCAGTCATAGGGAGCTGTC | TCTTCTGAGACCTGGGTACAC |
| m-AQP1 | AGGCTTCAATTACCCACTGGA | GTGAGCACCGCTGATGTGA |
| m-PDGFR | CCACACCCTTGGGGAATAGT | TTTGAAGGGCAAGGAATGTG |
| m-GAPDH | ACTTCAACAGCAACTCCCACTC | TAGGCCCCTCCTGTTATTATGG |
| r-IL-10 | TAACTGCACCCACTTCCCAGT | TGGCAACCCAAGTAACCCTTA |
| r-bFGF | CGACCCACACGTCAAACTAC | CCAGGCGTTCAAAGAAGAAA |
| r-TGF-β1 | GCCCTGGATACCAACTACTGCT | GTTGGTTGTAGAGGGCAAGGAC |
| r-EGF | CGTCTCAGTGGTCATGGATTT | TCAGAAGAACACGGGAATTGT |
| r-HGF | CTCTCGTTCCTTGGGATTATTG | GATCCCCCACAGATGTGTTTAT |
| r-PDGF | ATCGAGCCAAGACACCTCAAAC | ATGGGGGCAGTACAGCAAATAC |
| r-GAPDH | AGTGCCAGCCTCGTCTCATAG | CGTTGAACTTGCCGTGGGTAG |
| N (%) participants | N (%) valid days | ||
| Full sample | 23,188 (100%) | 158,784 (100%) | |
| Sex | Male | 8819 (38%) | 62,745 (40%) |
| Female | 14,369 (62%)† | 96,039 (60%) | |
| Age | 5-6 years | 1800 (8%) | 7855 (5%) |
| 7-8 years | 711 (3%) | 4963 (3%) | |
| 9-10 years | 5769 (25%) | 30,702 (19%) | |
| 11-12 years | 9616 (41%) | 61,352 (39%) | |
| 13-14 years | 4206 (18%) | 46,530 (29%) | |
| 15-16 years | 1086 (5%) | 7382 (5%) | |
| Country [No. studies] | Australia [N = 2] | 2459 (11%) | 18,679 (12%) |
| Brazil [N = 1] | 453 (2%) | 1577 (1%) | |
| Denmark [N = 2] | 2031 (9%) | 11,030 (7%) | |
| England [N = 4] | 10,284 (44%) | 83,420 (53%) | |
| Estonia [N = 1] | 656 (3%) | 2537 (2%) | |
| Madeira [N = 1] | 1214 (5%) | 4899 (3%) | |
| Norway [N = 1] | 384 (2%) | 1459 (1%) | |
| Switzerland [N = 1] | 404 (2%) | 2569 (2%) | |
| United States [N = 2] | 5303 (23%) | 32,614 (21%) | |
| Weight status | Normal/underweight | 17,573 (76%) | 121,350 (76%) |
| Overweight | 4116 (18%) | 27,967 (18%) | |
| Obese | 1499 (6%) | 9467 (6%) | |
| Mother’s education | Up to high school | 7422 (48%) | 54,547 (48%) |
| College/vocational | 2656 (17%) | 19,352 (17%) | |
| University level | 5251 (34%) | 38,723 (34%) |
| Locus no. | Putative identification | Avg fold difference |
| Mobile and extrachromosomal element functions: Transposon functions | ||
| PG0019 | ISPg4 transposase | 1.57 |
| PG0050 | ISPg4, transposase | 1.81 |
| PG0177 | ISPg4, transposase | 1.87 |
| PG0194 | ISPg3, transposase | 2.18 |
| PG0225 | ISPg4, transposase | 1.80 |
| PG0261 | ISPg3, transposase | 2.20 |
| PG0459 | ISPg5, transposase | 1.60 |
| PG0487 | ISPg4, transposase | 1.98 |
| PG0798 | ISPg3, transposase | 2.11 |
| PG0819 | Integrase | 1.80 |
| PG0838 | Integrase | 3.36 |
| PG0841 | Mobilizable transposon, excision protein, putative | 3.78 |
| PG0842 | Mobilizable transposon, hypothetical protein, putative | 2.84 |
| PG0872 | Mobilizable transposon, xis protein | 3.87 |
| PG0873 | Mobilizable transposon, tnpC protein | 9.34 |
| PG0874 | Mobilizable transposon, int protein | 2.42 |
| PG0875 | Mobilizable transposon, tnpA protein | 1.68 |
| PG0970 | ISPg4, transposase | 1.79 |
| PG1032 | ISPg3, transposase | 2.23 |
| PG1061 | ISPg6, transposase | 2.03 |
| PG1261 | ISPg4, transposase | 2.06 |
| PG1262 | ISPg3, transposase | 2.11 |
| PG1435 | Integrase | 2.77 |
| PG1454 | Integrase | 1.88 |
| PG1658 | ISPg4, transposase | 1.83 |
| PG1673 | ISPg4, transposase | 1.77 |
| PG2194 | ISPg4, transposase | 1.85 |
| PG0461 | ISPg7, transposase | −2.77 |
| PG0277 | ISPg2, transposase | −1.58 |
| PG0865 | ISPg2, transposase | −1.53 |
| PG1746 | ISPg2, transposase | −1.63 |
| PG2176 | ISPg2, transposase | −1.58 |
| PG1350 | ISPg2, transposase | −1.53 |
| TCGA acronym | Cancer type | Paired samples | Unpaired tumor samples | Reference |
| BRCA | Breast invasive carcinoma | 107 | 929 | (3) |
| COAD | Colon adenocarcinoma | 26 | 236 | (1) |
| HNSC | Head/neck squamous cell carcinoma | 38 | 384 | (27) |
| KICH | Kidney chromophobe | 21 | 41 | https://tcga-data.nci.nih.gov/ |
| KIRC | Kidney renal clear cell carcinoma | 71 | 434 | (4) |
| LUAD | Lung adenocarcinoma | 57 | 431 | (28) |
| LUSC | Lung squamous cell carcinoma | 50 | 433 | (2) |
| PRAD | Prostate adenocarcinoma | 48 | 247 | https://tcga-data.nci.nih.gov/ |
| THCA | Thyroid carcinoma | 58 | 439 | https://tcga-data.nci.nih.gov/ |
| Description | Number of features |
| Mean, range, interquartile range (x, y, z) | 9 |
| Moments: standard deviation, skew, kurtosis (x, y, z) | 9 |
| Histogram: bin counts of −2 to 1 z-scores (x, y, z) | 12 |
| Derivative of moments: mean, standard deviation, skew, kurtosis (x, y, z) | 12 |
| Mean of the squared norm | 1 |
| Sum of axial standard deviations | 1 |
| Pearson correlation coefficient, r (xy), r (xz), r (yz) | 3 |
| Mean cross products (raw and normalized), xy, xz, yz | 6 |
| Absolute mean of cross products (raw and normalized) | 6 |
| Power spectra: mean, standard deviation, skew, kurtosis (x, y, z) | 12 |
| Mean power in 0.5 Hz bins between 0 and 10 Hz (x, y, z) | 60 |
| Gene Ontology (GO) Name | Number of Genes Involve | Fold Change | Genes | |
| Highly Expressed in Susceptible Group | Highly Expressed in Resistant Group | |||
| Negative regulation of transcription from RNA polymerase II promoter | 21 | 2.0 | ELK4, GATAD2A, KANK2, MNT, ARHGAP35, SMAD3, TAL1, CBX6, GFI1, HDAC4, NFATC2, RXRA, RUNX3, ZNF8 | N4BP2L2, ANKRD2, BMP4, DUSP26, FOXH1, HSF4, IRF7 |
| Ion transport | 17 | 2.0 | ATP7A, KCNA1, SLC39A10, TTYH3, TPCN1 | ATP5E, ATP5I, FXYD1, CACNA2D4, CHRNA2, KCNK7, KCNJ15, SLC10A1, SLC22A17, SLC26A8 |
| Protein phosphorylation | 15 | 2.2 | PDPK1, ATM, BCR, JAK3, SBK1, ACVR1B, EIF2AK3, HUNK, LMTK2, PRKCI, PDK4, RUNX3 | DMPK, NTRK1, TEX14 |
| Immunity | 13 | 1.9 | DDX3X, ETS1, JAK3, C3, ERAP1, LST1 | CLEC4E, ISG15, S100A12, ZBP1, APOBEC3A, IRF7, PGLYRP1 |
| Innate immunity | 9 | 2.5 | DDX3X, JAK3, C3 | ISG15, S100A12, ZBP1, APOBEC3A, IRF7, PGLYRP1 |
| Innate immune response | 9 | 1.4 | DDX3X, JAK3, APOBEC3A, F12 | CLEC4E, S100A12, ZBP1, IRF7, PGLYRP1 |
| RNA polymerase II regulatory region seq-specific DNA binding | 9 | 2.9 | GATAD2A, MNT, PRDM15, SMAD3, TAL1, RXRA, RUNX3, ZNF8 | - |
| GTPase activation | 9 | 3.4 | AGAP1, ADAP1, BCR, ARHGAP23, ARHGAP35, TBC1D2B, TBC1D9, SIPA1L3 | TBCD7 |
| Peptidyl-serine phosphorylation | 8 | 4.4 | PDPK1, ATM, BCL2, RICTOR, EIF2AK3, LMTK2, PRKCI | DMPK |
| Rab GTPase binding | 6 | 3.0 | ERC1, RAB11FIP4, RAB29, TBC1D2B, TBC1D9 | TBC1D7 |
| Clinicopathological characteristic | Number (%) |
| Age, years | |
| Median | 70 |
| Range | 47–84 |
| Sex | |
| Male | 30 (85.7) |
| Female | 5 (14.3) |
| Smoking status | |
| Smoker | 31 (88.6) |
| Never-smoker | 4 (11.4) |
| Histological subtype | |
| Pure SCLC | 2 (5.7) |
| Combined SCLC | 11 (31.4) |
| Pure LCNEC | 8 (22.9) |
| Combined LCNEC | 14 (40.0) |
| Accompanied component in combined SCLC | Number (% in all combined SCLC) |
| LCNEC | 9 (81.8) |
| Adenocarcinoma | 4 (36.4) |
| Squamous cell carcinoma | 1 (9.1) |
| Large cell carcinoma | 2 (18.2) |
| Accompanied component in combined LCNEC | Number (% in all combined LCNEC) |
| Adenocarcinoma | 10 (71.4) |
| Squamous cell carcinoma | 6 (42.9) |
| Large cell carcinoma | 0 (0) |
| RNA-Seq datasets comparison | number of DEGs | ||||
| 48 hai | 96 hai | ||||
| up | down | up | down | ||
| 2Hb8 | R NIL Fusarium inoculated – R NIL mock inoculated (R_F/M) | 11 | 21 | 415 | 192 |
| M69 Fusarium inoculated – M69 mock inoculated (M69_F/M) | 45 | 167 | 1283 | 354 | |
| R NIL Fusarium inoculated – M69 Fusarium inoculated (R/M69_F) | 350 | 80 | 321 | 426 | |
| R NIL mock inoculated – M69 mock inoculated (R/M69_M) | 355 | 70 | 401 | 282 | |
| 6Hb7 | R NIL Fusarium inoculated – R NIL mock inoculated (R_F/M) | 100 | 14 | 304 | 15 |
| Lacey Fusarium inoculated – Lacey mock inoculated (Lacey_F/M) | 12 | 53 | 693 | 227 | |
| R NIL Fusarium inoculated – Lacey Fusarium inoculated (R/Lacey_F) | 66 | 36 | 5 | 10 | |
| R NIL mock inoculated – Lacey mock inoculated (R/Lacey_M) | 12 | 89 | 4 | 19 |
| Study name | Treatment arms | Time horizon (weeks) | Relapses | AE-related disc's | Non-AE-related disc's | Completers | Total Nr of patients | Nr of patients experiencing >7% weight gain (total Nr of patients) | Nr of patients experiencing EPS (total Nr of patients) |
| Kane (42) | Haloperidol depota | 52 | 17 | 1 | 18 | 44 | 80 | NA | NA |
| Placebob | 52 | 15 | 0 | 2 | 8 | 25 | NA | NA | |
| Kane (41) | Olanzapine pamoatec | 24 | 68 | 21 | 91 | 419 | 599 | 100 (599) | 52 (599) |
| Olanzapine oral | 24 | 23 | 8 | 33 | 258 | 322 | 68 (322) | 28 (322) | |
| Placebob | 24 | 42 | 6 | 20 | 76 | 144 | 12 (144) | 12 (144) | |
| Hough 2010 (38) | Paliperidone palmitate | 31 | 36 | 3 | 28 | 139 | 206 | 12 (206) | 21 (206) |
| Placebo | 42 | 97 | 2 | 27 | 78 | 204 | 6 (204) | 12 (204) | |
| Kane (40) | Aripiprazole once-monthly | 52 | 27 | 9 | 31 | 202 | 269 | 17 (269) | 45 (269) |
| Placebo | 52 | 53 | 5 | 15 | 61 | 134 | 7 (134) | 14 (134) | |
| Fleischhacker (37) | Paliperidone palmitate | 53 | 95 | 29 | 100 | 155 | 379 | 50 (346) | 67 (379) |
| Risperidone LAI | 53 | 56 | 25 | 105 | 184 | 370 | 52 (338) | 76 (370) | |
| Fleischhacker (39) | Aripiprazole once-monthly | 38 | 22 | 8 | 39 | 196 | 265 | 42 (265) | 52 (265) |
| Aripiprazole oral | 38 | 21 | 7 | 60 | 178 | 266 | 43 (266) | 46 (266) | |
| Placebob | 38 | 29 | 7 | 34 | 61 | 131 | 8 (131) | 18 (131) |
| Compound | RRI a | S. boveanum | C. myrica | H. flagelliformis |
| Heptadecane | 1698 | - | - | 4.1 ± 0.63 |
| Tetradecanoic acid methyl ester | 1718 | 8.1 ± 0.7 | 20.3 ± 3.5 | 8.2 ± 0.9 |
| 9-(Z)-Hexadecenoic acid methyl ester | 1900 | 4.0 ± 1.2 | 54.6 ± 36.3 | - |
| Hexadecanoic acid methyl ester | 1922 | 58.2 ± 4.5 | 165.7 ± 23.7 | 95.9 ± 11.5 |
| 9,12-(Z,Z)-octadecadienoic acid methyl ester | 2094 | - | 5.8 ± 1.8 | - |
| 9-(Z)-octadecenoic acid methyl ester | 2101 | 8.4 ± 2.4 | 30.1 ± 10.6 | 8.1 ± 1.2 |
| 9-(E)-octadecenoic acid methyl ester | 2107 | - | 16.1 ± 2.0 | 7.9 ± 1.03 |
| Octadecanoic acid methyl ester | 2120 | 3.6 ± 0.7 | 11.9 ± 1.5 | 4.6 ± 0.3 |
| Traits | TL | BL | BH | HL | BW |
| TL | 1 | ||||
| BL | 0.993 | 1 | |||
| BH | 0.849 | 0.841 | 1 | ||
| HL | 0.782 | 0.782 | 0.723 | 1 | |
| BW | 0.934 | 0.934 | 0.931 | 0.780 | 1 |
| Farm location | Goat breed | Feed type |
| Farm 1 (F1), Hulu Langat, Selangor | Saanen cross (SC) | Napier grass silageBarley sproutsDatesMulberry leavesCorn grainGoat pellet |
| Farm 2 (F2), Banting, Selangor | Saanen pure (SP) | Napier grass freshDairy bran |
| Farm 3 (F3), Hulu Langat, Selangor | Saanen pure (SP) | Napier grass freshGoat pellet 1Goat pellet 2 |
| Farm 4 (F4), Sungai Buloh, Selangor | Saanen–Boer cross (SBC) | Napier grass freshGrower pelletBreeder pelletRice straw |
| Farm 5 (F5), Nilai, Negeri Sembilan | Jamnapari Koplo (JK) | Napier grass silageWide leavesSoy-bran mixture |
| Farm 6 (F6), Sungai Buloh, Selangor | Jamnapari Peranakan Etawa cross (JPEC) | Napier grass freshSoy wasteGoat pellet |
| Farm 7 (F7), Shah Alam, Selangor | Jamnapari–Toggenburg cross (JTC) | Napier grass freshMix grassesDairy bran |
| Farm 8 (F8), Jeram, Selangor | Jamnapari cross (JC) | Sarang Buaya grass (Ischaemum timorense Kunth)Mix bran |
| Treament | G0/G1 | S | G2/M | Sub G0 |
| 24 Hr Control | 61.6 ± 0.4 | 11.6 ± 0.6 | 22.5 ± 0.6 | 1.5 ± 0.1 |
| 24 Hr Luteolin | 49.3 ± 1.4c | 12.7 ± 1.3 | 31.2 ± 0.9b | 3.4 ± 0.2 |
| 24 Hr Control Removed for 24 Hr | 65.9 ± 0.8 | 8.5 ± 0.3 | 22.1 ± 0.4 | 1.4 ± 0.03 |
| 24 Hr Luteolin Removed for 24 Hr | 39.3 ± 0.7c | 10.6 ± 0.3 | 29.0 ± 0.9a | 8.8 ± 1.2c |
| 24 Hr Control Removed for 48 Hr | 83.7 ± 0.7 | 3.5 ± 0.4 | 8.8 ± 0.7 | 2.7 ± 0.4 |
| 24 Hr Luteolin Removed for 48 Hr | 47.5 ± 0.5c | 8.5 ± 0.5a | 24.3 ± 0.4c | 9.4 ± 1.1b |
| 24 Hr Control Removed for 72 Hr | 86 ± 1.4 | 2.8 ± 0.5 | 8.0 ± 0.7 | 1.6 ± 0.03 |
| 24 Hr Luteolin Removed for 72 Hr | 54.4 ± 1.0c | 7.6 ± 0.9a | 24.7 ± 0.8c | 6.4 ± 0.2 |
| Yale University cohort | ||||
| Variable | No. of patients (%) (n = 651) | HR | 95% CI | P* |
| Age at diagnosis | 645 (99.1) | 0.999 | 0.988-1.009 | 0.890 |
| Unknown/missing | 6 (0.9) | |||
| Menopausal status | ||||
| Premenopausal | 196 (30.1) | 1.000 | 0.436 | |
| Postmenopausal | 449 (69.0) | 1.115 | 0.848-1.482 | |
| Unknown/missing | 6 (0.9) | |||
| Tumor size (cm) | ||||
| ≤ 2 | 215 (33.0) | 1.000 | < 0.0001 | |
| 2-5 | 283 (43.5) | 1.682 | 1.254-2.258 | |
| ≥ 5 | 101 (15.5) | 2.911 | 2.074-4.086 | |
| Other | 52 (8.0) | |||
| Nodal status | ||||
| Negative for node metastasis | 327 (50.2) | 1.000 | < 0.0001 | |
| Positive for node metastasis | 320 (49.2) | 2.286 | 1.795-2.910 | |
| Unknown/missing | 4 (0.6) | |||
| Positive nodes | 320 (49.2) | 1.022 | 1.001-1.042 | 0.040 |
| Total nodes | 625 (96.0) | 0.978 | 0.961-0.994 | 0.010 |
| Unknown/missing | 26 (4.0) | |||
| Nuclear grade | ||||
| Small/uniform nuclei | 113 (17.4) | 1.000 | 0.0007 | |
| Intermediate nuclei | 315 (48.4) | 1.231 | 0.854-1.818 | |
| Large nuclei | 170 (26.1) | 1.594 | 1.192-2.123 | |
| Other | 53 (8.1) | |||
| ER status | ||||
| ER negative | 289 (44.4) | 1.000 | 0.0005 | |
| ER positive | 326 (50.1) | 0.766 | 0.598-0.981 | |
| Other | 36 (5.5) | |||
| PR status | ||||
| PR negative | 294 (45.2) | 1.000 | < 0.0001 | |
| PR positive | 302 (46.4) | 0.675 | 0.524-0.871 | |
| Other | 55 (8.4) | |||
| HER2 status | ||||
| HER2 negative | 495 (76.0) | 1.000 | 0.153 | |
| HER2 positive | 109 (16.7) | 1.270 | 1.048-1.317 | |
| Other | 47 (7.2) | |||
| MAP-tau expression | ||||
| MAP-tau low expression | 376 (57.8) | 1.000 | 0.0042 | |
| MAP-tau high expression | 104 (16.0) | 0.691 | 0.489-0.974 | |
| Unknown/missing | 171 (26.3) |
| Study groups | N | Mean | SD | P-value |
| Live Demonstration | 26 | 6.69 | 1.4 | .864* |
| Procedural Video | 23 | 6.78 | 2.1 | |
| Total | 49 | 6.73 | 1.8 |
| Resource | Connectivity Comments | Reference |
| BindingDB | Comprehensive ligand-target database, we now cross-reference selected patent extractions from this source | (43) |
| ChEMBL and UniChem | Inclusion of our target protein pointers and a ChEMBL look-up for our ligand entries loaded in UniChem | (2,44) |
| DrugBank | Target cross-references and chemical ontology connection via an API | (45) |
| ESTER | Alpha/beta hydrolase cross-references | (46) |
| GeneCards | Gene expression and functional data aggregator | (47) |
| GPCRDB | Specific pointers to their detailed features, curation of mutations, sequence display toolbox and residue numbering system | (48) |
| GUDMAP | Links to proteins involved in GenitoUrinary (GU) tract development | (49) |
| HGNC | Long standing and frequent interactions on target family nomenclature issues | (10) |
| IMGT/mAb-DB | Pointers to provenanced sequences for clinical antibodies, target interactions, display tools and residue numbering system | (50) |
| MEROPS | Feature details, classification, ligand mapping, other protease-specific issues | (7) |
| neXtProt | Data and features additional to Swiss-Prot, semantic mining technology | (51) |
| NURSA | Detailed NHR information including transcriptome mining functionality | (52) |
| Orphanet | Unique rare genetic disease curation and disease term connectivity | (53) |
| PubChem | Covering aspects of chemical curation, drug naming and our submitted structures. Plans for future peptide and BioAssay Links | (4,14) |
| UniProtKB | Maintenance of our own selectable cross-references to proteins with quantitative interactions | (5) |
| Wikipedia | Updating, adding new target and ligand links, including filling in ‘chemistry boxes’ | (54) |
| Chr | MS | AI | DA | KA | NY | SNP | AI | DA | KA |
| 1 | D01S0023 | 21.60 | 41.65 | 12.18 | 14.59 | C01R0052 | 21.53 | 47.08 | 13.43 |
| 3 | D03S0127 | 30.32 | 37.70 | 26.91 | 30.16 | C03R280 | 35.19 | ||
| C03R281 | 28.93 | 35.11 | 28.86 | ||||||
| 5 | D05S0172 | 8.52 | 22.11 | C05R0380 | 25.57 | 7.65 | 34.40 | ||
| D05S0173 | 26.98 | 35.24 | |||||||
| 9 | D09S0347 | 24.61 | 8.61 | 37.88 | 11.17 | C09R0765 | 23.51 | 8.11 | 34.01 |
| 10 | D10S396 | 2.29 | C10R0874 | 1.61 | |||||
| D10S400 | 6.59 | 5.67 | C10R0880 | 1.06 | 8.07 | 6.49 | |||
| D10S408 | 0.73 |
| Multivariate Cox regression | ||||
| Factor | P | HR | 95% CI | |
| Lower | Upper | |||
| INSS Stage (1-3, 4S vs 4) | 0.002 | 7.15 | 2.08 | 24.64 |
| NB-hypo | 0.007 | 2.73 | 1.31 | 5.69 |
| Age (< 1y vs > 1y) | 0.801 | |||
| MYCN (normal vs amplified) | 0.671 |
| All | Control group | Intervention group | |||||
| n | % | n | % | n | % | ||
| Study group | 604 | 100 | 242 | 40.1 | 362 | 59.9 | |
| Participation rate | Number of men in units at T0* | 2688 | 100 | 1430 | 53.2 | 1258 | 46.8 |
| Respondents at T0 | 1502 | 55.9‡ | 645 | 42.9 | 857 | 57.1 | |
| Respondents at T1 | 1634 | 60.8‡ | 926 | 56.7 | 708 | 43.3 | |
| Respondents at T2 | 947 | 35.2‡ | 589 | 62.2 | 358 | 37.8 | |
| Respondents at T0 + T1 + T2† | 604 | 22.5‡ | 242 | 40.1 | 362 | 59.9 | |
| Month of military arrival | January | 358 | 59.3 | 129 | 53.3 | 229 | 63.3 |
| July | 246 | 40.7 | 113 | 46.7 | 133 | 36.7 | |
| Garrison | Armoured Brigade | 313 | 51.8 | 84 | 34.7 | 229 | 63.3 |
| Kainuu Brigade | 291 | 48.2 | 158 | 65.3 | 133 | 36.7 | |
| Age | 18 | 1 | 0.2 | 1 | 0.4 | ||
| 19 | 131 | 21.8 | 65 | 27.0 | 66 | 18.4 | |
| 20 | 452 | 75.3 | 170 | 70.5 | 282 | 78.6 | |
| 21 | 16 | 2.7 | 5 | 2.1 | 11 | 3.1 | |
| Marital status | married or co-habiting | 52 | 8.7 | 20 | 8.4 | 32 | 8.9 |
| single | 545 | 91.1 | 217 | 91.6 | 328 | 90.9 | |
| Widowed | 1 | 0.2 | 1 | 0.3 | |||
| Living status | alone | 56 | 9.3 | 24 | 10.0 | 32 | 8.9 |
| with spouse | 42 | 7.0 | 16 | 6.7 | 26 | 7.2 | |
| with parents | 485 | 81.0 | 198 | 82.5 | 287 | 79.9 | |
| other | 16 | 2.7 | 2 | 0.8 | 14 | 3.9 |
| (n = 593) | One-factor model | Two-factor model | Three-factor model | |||
| Sensation | Sensitivity | Pleasant | Unpleasant | Pleasant | Unpleasant | Buzz |
| Cough | 0.27 | −0.16 | 0.52 | 0.10 | 0.69 | −0.18 |
| Sick | 0.15 | 0.05 | 0.82 | −0.16 | 0.66 | 0.29 |
| Nervous | 0.17 | −0.04 | 0.50 | 0.07 | 0.57 | −0.03 |
| Dizzy | −0.46 | 0.65 | 0.35 | 0.06 | 0.15 | 0.70 |
| High | −0.59 | 0.74 | 0.21 | 0.06 | −0.03 | 0.81 |
| Relaxed | −0.88 | 0.79 | −0.35 | 0.73 | −0.14 | 0.15 |
| Good | −0.94 | 0.85 | −0.31 | 0.97 | 0.00 | 0.06 |
| RMSEA | 0.20 | 0.05 | 0.01 |
| Author (year) of published PCR assay | PCR target | PCR technique | Amplicon size (bp) | Zika virus lineage analytical | Zika virus lineage field | No. of human patients tested in studies | Sample types positive in field |
| Lanciotti et al. (2008)43 | Zika virus prM/E,target 1 | Hydrolysis probe | 76 | Asian, African | Asian | > 200 (combined set)5,10,23,24,34,36,38,40–42,49,50 | Serum, urine, amniotic fluid |
| Lanciotti et al. (2008)43 | Zika virus E, target 2 | Hydrolysis probe | 76 | Asian, African | Asian | > 200 (combined set)5,10,23,24,34,36,38,40–42,49,50 | Serum, urine, amniotic fluid |
| Faye et al. (2013)51 | Zika virus NS5 | Locked nucleic acid probe | 102 | Asian, African | African | 3 (B Rockx, personal communication, February 2016) | Serum |
| Tappe et al. (2014)19 | Zika virus NS3 | Hydrolysis probe | 94 | Asian | Asian | 519–22,25 | Serum |
| Faye et al. (2008)52 | Zika virus E | Conventional | 364 | African | Asian | > 15 (combined set)53,54 | Serum |
| Pyke et al. (2014)15 | Zika virus NS1 | Hydrolysis probe | 65 | Asian | Asian | 155 | Serum |
| Pyke et al. (2014)15 | Zika virus E | Hydrolysis probe | 71 | Asian | Asian | 155 | Serum |
| Moureau et al. (2007)56 | Flavivirus NS5 | SYBR®-green-based | 269–272 | African | Asian | 218,57 | Serum, urine |
| Kuno et al. (1998)58 | Flavivirus NS5 | Conventional | 1079 | Asian, African | Asian | 5159 | Serum |
| Scaramozzino et al. (2001)60 | Flavivirus NS5 | Conventional (semi-nested) | 220 | African | Asian | 155 (L Barzon, personal communication, February 2016) | Serum, urine |
| Maher-Sturgess et al. (2008)61 | Flavivirus NS5 | Conventional | 800 | African | Asian | 115 | Serum |
| Ayers et al. (2006)62 | Flavivirus NS5 | Conventional | 863 | – | Asian | 117 | Serum, urine, nasopharynx |
| Explanatory variable | OR | 95%CI | P value |
| Presence of C allele in genotype at rs3173798 (Yes=1, No=0) | 0.28 | 0.12–0.67 | 0.0043 |
| Age (years) | 0.97 | 0.93–1.02 | 0.27 |
| Gender (female=1, male=0) | 0.92 | 0.39–2.20 | 0.85 |
| Pre-treatment BCVA (logMAR) | 1.49 | 0.50–4.43 | 0.47 |
| GLD (μm) | 1 | 1.00–1.00 | 0.88 |
| Age group | 1990 | 2015 | ||||||||||
| Global | Brazil | Global | Brazil | |||||||||
| Rate | 95% UI | Rate | 95% UI | Rate | 95% UI | Rate | 95% UI | |||||
| Under 5 | 58.9 | (49.0 | 67.0) | 62.8 | (55.3 | 71.6) | 22.1 | (18.4 | 24.4) | 24.0 | (20.0 | 27.9) |
| 5–9 | 23.0 | (19.9 | 26.7) | 29.7 | (24.9 | 34.8) | 15.7 | (13.2 | 19.0) | 15.5 | (12.4 | 19.3) |
| 10–14 | 45.1 | (37.2 | 56.0) | 67.1 | (54.9 | 82.0) | 38.0 | (30.0 | 49.4) | 39.8 | (30.3 | 52.6) |
| 15–19 | 84.0 | (66.2 | 108.9) | 116.0 | (94.4 | 145.0) | 91.6 | (69.3 | 119.5) | 89.0 | (67.6 | 117.8) |
| 20–24 | 146.9 | (114.1 | 186.0) | 170.7 | (136.9 | 213.7) | 168.7 | (127.8 | 219.0) | 143.9 | (107.9 | 186.3) |
| 25–29 | 214.0 | (165.3 | 273.8) | 249.8 | (201.9 | 310.2) | 256.8 | (192.9 | 333.5) | 224.2 | (170.2 | 288.3) |
| 30–34 | 312.2 | (242.9 | 397.8) | 358.0 | (292.9 | 440.9) | 384.1 | (289.5 | 499.2) | 331.6 | (256.0 | 429.6) |
| 35–39 | 448.2 | (349.4 | 567.0) | 523.8 | (434.2 | 638.6) | 565.0 | (432.0 | 722.6) | 495.0 | (385.6 | 626.4) |
| 40–44 | 659.4 | (520.7 | 821.5) | 799.0 | (666.2 | 963.0) | 830.7 | (647.7 | 1053.6) | 765.0 | (604.4 | 958.9) |
| 45–49 | 1022.3 | (827.8 | 1264.5) | 1246.0 | (1037.0 | 1512.3) | 1241.7 | (983.4 | 1556.5) | 1190.9 | (944.3 | 1490.3) |
| 50–54 | 1435.9 | (1175.5 | 1747.8) | 1892.2 | (1591.6 | 2277.0) | 1762.3 | (1415.1 | 2175.0) | 1820.5 | (1469.0 | 2260.6) |
| 55–59 | 1939.8 | (1631.4 | 2336.0) | 2694.1 | (2292.1 | 3133.0) | 2361.7 | (1958.5 | 2817.1) | 2581.4 | (2160.5 | 3110.6) |
| 60–64 | 2465.1 | (2099.2 | 2906.9) | 3533.7 | (3072.4 | 4091.9) | 2845.1 | (2409.6 | 3360.3) | 3514.3 | (2989.2 | 4149.6) |
| 65–69 | 2946.5 | (2550.2 | 3462.3) | 4356.6 | (3836.9 | 4975.1) | 3537.8 | (3028.4 | 4120.4) | 4461.8 | (3836.4 | 5169.2) |
| 70–74 | 3255.2 | (2844.5 | 3752.8) | 5178.5 | (4684.2 | 5833.0) | 3843.0 | (3316.1 | 4442.0) | 5292.1 | (4631.1 | 6052.0) |
| 75–79 | 3400.7 | (2992.7 | 3889.5) | 5702.8 | (5189.1 | 6299.8) | 4128.5 | (3594.0 | 4741.4) | 5976.1 | (5308.4 | 6806.0) |
| 80 plus | 2441.4 | (2166.5 | 2775.3) | 4232.3 | (3888.4 | 4643.9) | 3185.4 | (2826.0 | 3599.7) | 5570.1 | (5072.8 | 6144.9) |
| All ages (crude) | 567.9 | (480.5 | 672.2) | 641.4 | (558.1 | 740.8) | 870.1 | (725.7 | 1032.6) | 1015.3 | (865.3 | 1191.4) |
| Age-standardized | 769.9 | (654.1 | 907.0) | 1094.2 | (962.6 | 1247.7) | 925.8 | (776.1 | 1096.3) | 1102.8 | (948.7 | 1285.4) |
| The GP and the patient are a well-functioning team (n = 270) | |||
| OR | 95% CI | p-value | |
| Age | |||
| 16–39 | 1.30 | 0.63–2.71 | 0.471 |
| 40–59a | 1.00 | – | – |
| 60+ | 0.90 | 0.36–2.24 | 0.816 |
| Education | |||
| Primary | 0.56 | 0.19–1.69 | 0.306 |
| High school | 1.69 | 0.77–3.70 | 0.192 |
| University 1–4 yearsa | 1.00 | – | – |
| University 5 years + | 0.53 | 0.25–1.13 | 0.101 |
| Self-rated degree of CFS/ME | |||
| Mild | 0.66 | 0.32–1.35 | 0.250 |
| Moderatea | 1.00 | – | – |
| Severe/very severe | 0.38 | 0.14–0.99 | 0.047 |
| GP duration | |||
| 0–2 yearsa | 1.00 | – | – |
| 3 years+ | 2.32 | 1.09–4.95 | 0.030 |
| GP frequencyb | |||
| 0 visits | 0.75 | 0.27–2.10 | 0.590 |
| 1–4 visitsa | 1.00 | – | – |
| 5–9 visits | 1.13 | 0.56–2.29 | 0.730 |
| 10+ visits | 2.12 | 0.75–5.99 | 0.155 |
| Age group | Patients, no. | % |
| Infant | 9 | 0 |
| Child | 12 | 0 |
| Adolescent | 4 | 0 |
| Calcium score zero (N = 239) | Calcium score abnormal (N = 103) | P value | |
| Age, years | 47.0 (6.4) | 52.6 (6.6) | <0.001 |
| Gender, female % | 66 (27.6) | 11 (10.6) | |
| Height, cm | 165.9 (7.5) | 167.7 (7.5) | 0.09 |
| Weight, kg | 65.9 (11.3) | 68.9 (10.1) | 0.008 |
| BMI, Kg/m2 | 23.8 (3.1) | 24.4 (2.7) | 0.013 |
| Waist, cm | 81.4 (9.1) | 85.0 (7.9) | <0.001 |
| Waist to hip ratio | 0.88 (0.07) | 0.91 (0.06) | <0.001 |
| SBP, mmHg | 116.7 (14.9) | 125.1 (15.1) | 0.003 |
| DBP, mmHg | 74.5 (10.2) | 77.9 (9.7) | 0.002 |
| Biochemistry | |||
| Sugar (AC), mg/dL | 93.3 (21.2) | 102.0 (20.9) | 0.086 |
| Sugar (PC), mg/dL | 105.9 (31.6) | 118.5 (44.4) | 0.082 |
| HbA1c, % | 5.8 (0.6) | 6.0 (0.6) | 0.32 |
| Insulin, U/mL | 6.25 (4.24) | 6.91 (3.75) | 0.046 |
| HOMA-IR | 1.55 (1.25) | 1.76 (1.06) | 0.016 |
| Cholesterol, mg/dL | 191.1 (32.9) | 196.1 (35.1) | 0.23 |
| LDL, mg/dL | 128.0 (31.3) | 125.8 (31.7) | 0.56 |
| HDL, mg/dL | 53.0 (13.7) | 49.1 (12.8) | 0.02 |
| TG, mg/dL | 141.9 (103) | 145.8 (85.2) | 0.74 |
| BUN, mg/dL | 11.8 (3.2) | 12.6 (3.7) | 0.32 |
| Creatinine, mg/dL | 0.91 (0.18) | 0.97 (0.18) | 0.39 |
| Uric Acid, mg/dL | 5.6 (1.4) | 6.1 (1.5) | 0.003 |
| Homocystine, mg/dL | 7.3 (2.1) | 8.4 (2.3) | 0.03 |
| Hs-CRP, mg/dL | 0.2 (0.35) | 0.32 (0.7) | 0.043 |
| ECG pattern | |||
| ECG (LVH or myocardial ischemia) | 41 (7.5) | 28 (13.2) | 0.016 |
| ECG (old infarct) | 5 (1) | 9 (4.2) | 0.002 |
| Medical history | |||
| Smoking | 84 (24.9) | 42 (29.4) | 0.311 |
| HTN history | 41 (12) | 35 (23.7) | 0.001 |
| DM history | 11 (3.2) | 14 (9.5) | 0.004 |
| Hyperlipidemia | 17 (5.6) | 13 (9.6) | 0.039 |
| CVD | 12 (3.9) | 12 (8.9) | 0.033 |
| Family Hx | |||
| Family Hx HTN | 147 (43) | 62 (41.9) | 0.823 |
| Family Hx DM | 88 (25.8) | 42 (28.4) | 0.554 |
| Family Hx Stroke | 49 (14.3) | 20 (13.5) | 0.812 |
| Family Hx CVD | 57 (16.7) | 30 (20.3) | 0.345 |
| Week 1A | Week 2A | P | ||||||
| Control | Canola | Sunflower | Control | Canola | Sunflower | TrtB | Trt*wkC | |
| Cows (n) | 5 | 5 | 5 | 6 | 5 | 5 | ||
| LH Mean (ng/mL) | 1.14 ± 0.14 | 0.84 ± 0.23 | 0.96 ± 0.21 | 2.42 ± 0.21¥a | 1.66 ± 0.23b | 1.83 ± 0.18¥ab | 0.03 | 0.05 |
| LH- Peak (ng/mL) D | 2.05 ± 0.75 | 3.21 ± 0.80 | 2.19 ± 0.70 | 5.14 ± 0.80 | 4.07 ± 0.73 | 3.72 ± 0.73 | 0.37 | 0.11 |
| LH-Peak-time (min) E | 32.50 ± 13.26 | 48.00 ± 13.78 | 22.50 ± 10.27 | 81.37 ± 21.53 | 101.63 ± 21.53 | 63.37 ± 21.53 | 0.48 | 0.74 |
| AUC (ng/mL per 4 h) F | 41.52 ± 27.39 | 84.65 ± 29.26 | 48.51 ± 25.38 | 197.26 ± 26.74§c | 125.73 ± 26.74§cd | 106.99 ± 26.74d | 0.26 | 0.06 |
| Incline rate (ng/mL per min) H | 0.09 ± 0.02 | 0.09 ± 0.02 | 0.08 ± 0.02 | 0.06 ± 0.02 | 0.07 ± 0.02 | 0.07 ± 0.02 | 0.98 | 0.97 |
| Patient | Breed | Age | Sex | Activity | Laminitis Stage | Venography Stage | Prognosis (before Treatment) |
| CASE 1 | QUARTER HORSE | 18 | F | MARE | BILATERAL ROTATION | 4 | POOR |
| CASE 2 | QUARTER HORSE | 14 | F | MARE | BILATERAL CHRONIC ROTATION | 4 | POOR |
| CASE 3 | THOROUGHBRED | 13 | G | PLEASURE | MONOLATERAL SINKING AND ROTATION | 4 | POOR |
| CASE 4 | QUARTER HORSE | 10 | F | PLEASURE | MONOLATERAL SINKING | 3 | GUARDED PROGNOSIS |
| CASE 5 | WARMBLOOD | 18 | G | PLEASURE | BILATERAL SINKING AND ROTATION | 3 | POOR |
| CASE 6 | WARMBLOOD | 15 | F | PLEASURE | MONOLATERAL SINKING AND ROTATION | 3 | POOR |
| CASE 7 | DUTCH WARMBLOOD | 21 | F | PLEASURE | BILATERAL SINKING AND ROTATION | 3-4 | POOR |
| CASE 8 | THOROUGHBRED | 15 | G | PLEASURE | MONOLATERAL ROTATION | 3 | POOR |
| CASE 9 | PONY | 16 | G | PLEASURE | BILATERAL SINKING AND ROTATION | 4 | POOR |
| Scales | N | Mean | SD | Min. | Q1 | Median | Q3 | Max. | P-value |
| HSQS/EPM (1st administration) | 86 | 74.6 | 4.6 | 60.0 | 72.0 | 75.5 | 78.0 | 86.4 | 0.0051 |
| SEVQUAL scale | 86 | 76.7 | 5.7 | 60.0 | 73.0 | 78.0 | 78.0 | 99.0 |
| Patients’ characteristics | |||||
| Gender | Age | Weight | Height | BMI | |
| Females | n | 66 | 66 | 66 | 66 |
| Mean (SD) | 62.8 (9.28) | 77.4 (18.28) | 166.6 (5.29) | 27.7 (6.01) | |
| 95 % CI | 60.5, 65.0 | 72.9, 81.9 | 165.3, 167.9 | 26.3, 29.2 | |
| Median | 63.2 | 74.0 | 167.5 | 26.0 | |
| Range | 33–87 | 50–140 | 152–178 | 19–45 | |
| Males | n | 85 | 85 | 85 | 85 |
| Mean (SD) | 63.3 (9.84) | 89.0 (15.10) | 177.7 (6.64) | 28.2 (4.53) | |
| 95 % CI | 61.2, 65.4 | 85.8, 92.3 | 176.3, 179.2 | 27.2, 29.2 | |
| Median | 62.9 | 84.0 | 178.0 | 27.0 | |
| Range | 37–81 | 66–153 | 165–192 | 22–43 | |
| Total | n | 151 | 151 | 151 | 151 |
| Mean (SD) | 63.1 (9.58) | 83.9 (17.50) | 172.9 (8.21) | 28.0 (5.21) | |
| 95 % CI | 61.5, 64.6 | 81.1, 86.7 | 171.5, 174.2 | 27.1, 28.8 | |
| Median | 62.9 | 82.0 | 172.0 | 27.0 | |
| Range | 33–87 | 50–153 | 152–192 | 19–45 |
| Clinical and epidemiological characteristic | Another malignancy | P | |
| PostiodineN = 7 (46.66%) | PreiodineN = 8 (53.33%) | ||
| Males N (%) | 4 (57.14) | 3 (37.5) | 0.6193 |
| Age at thyroidectomy (years)* | 61 ± 17 | 51 ± 13.7 | 0.2295 |
| Follow-up period (months)** | 75 (48; 336) | 56.5 (20; 60) | 0.1505 |
| Age at diagnosis of a second neoplasia* (years) | 69.4 ± 11.4 | 46.1 ± 20.2 | 0.0187 |
| Classic nonpapilliferous histological type N (%) | 3 (42.85) | 2 (25) | 0.6084 |
| CONSENSUS CRITERIA FOR DEMENTIA CASE ASCERTAINMENT | |
| PROBABLE DEMENTIA | POSSIBLE DEMENTIA |
| ANY of the following (without opposing evidence from same/other source):- dementia diagnosis on death certificate (any part)- dementia diagnosed on clinical review (ICD-10/DSM-IV)- dementia diagnosis in electronic general medical records (Trak)- dementia diagnosis in electronic psychiatric records (PIMS)- ICD-10 criteria for dementia diagnosis met by data within any existing records | ANY of the following (without opposing evidence from same/other source):- recorded cognitive impairment on death certificate- cognitive impairment/decline recorded in notes, but incomplete evidence to meet ICD-10 diagnostic criteria- possibility of dementia recorded in notes but no formal diagnosis/incomplete evidence to meet ICD-10 diagnostic criteria |
| Isolate | ST 1 | CC 2 | LIPI1 | LIPI3 | LIPI4 | InlA | SSI-1 |
| MQ130026 | ST-1 | CC1 | + 3 | + | − 4 | + 5 | − |
| L970 | ST-1 | CC1 | + | + | − | + | − |
| MQ130029 | ST-1 | CC1 | + | + | − | + | − |
| MQ130032 | ST-1 | CC1 | + | + | − | + | − |
| MQ130042 | ST-1 | CC1 | + | + | − | + | − |
| MQ140025 | ST-1 | CC1 | + | + | − | + | − |
| MQ140031 | ST-1 | CC1 | + | + | − | + | − |
| MQ140033 | ST-1 | CC1 | + | + | − | + | − |
| L2113 | ST-1 | CC1 | + | + | − | + | − |
| MQ150012 | ST-6 | CC6 | + | + | − | + | − |
| MQ150005 | ST-6 | CC6 | + | + | − | + | − |
| MQ130058 | ST-6 | CC6 | + | + | − | + | − |
| MQ140030 | ST-4 | CC4 | + | + | + | + | − |
| MQ150004 | ST-54 | CC54 | + | + | − | + | − |
| MQ130033 | ST-54 | CC54 | + | + | − | + | − |
| L2259 | ST-54 | CC54 | + | + | − | + | − |
| MQ150013 | ST-2 | CC2 | + | − | − | + | − |
| MQ130037 | ST-18 | CC18 | + | − | − | + | + |
| MQ150011 | ST-20 | CC20 | + | − | − | + | − |
| MQ150001 | ST-37 | CC37 | + | − | − | + | − |
| MQ140029 | ST-7 | CC7 | + | − | − | + | + |
| L1445 | ST-7 | CC7 | + | − | − | + | + |
| L1976 | ST-8 | CC8 | + | − | − | + | + |
| MQ140034 | ST-121 | CC121 | + | − | − | + | − |
| L2256 | ST-121 | CC121 | + | − | − | − | − |
| MQ140035 | ST-121 | CC121 | + | − | − | + | − |
| MQ140032 | ST-425 | CC90 | + | − | − | + | − |
| MQ140012 | ST-101 | CC101 | + | − | − | + | − |
| MQ140011 | ST-101 | CC101 | + | − | − | + | − |
| MQ150008 | ST-431 | CC101 | + | − | − | + | − |
| MQ150007 | ST-431 | CC101 | + | − | − | + | − |
| Variable | All patients (n = 102) | Group 1 (n = 48) | Group 2 (n = 54) |
| FEV1 | 50 (0.84 [0.70;0.98])a | 31 (1.08 [0.70;1.45])a | 18 (0.67 [0.46;0.88])a |
| BR | 12 (−0.62 [−0.82;-0.42])a | 6 (−0.36 [−0.68;-0.04])b | 35 (−0.85 [−1.10;-0.59])a |
| VE/VCO2 peak | 5 (−1.13 [−1.56;-0.69])a | 15 (−0.95 [−1.41;-0.48])c | 6 (−1.52 [−2.22;-0.82])a |
| (1) Memory | (2) Language | (3) Perceptual | (4) Visuospatial | (5) Calculation |
| Rey immediate recall | Semantic fluency | VOSP X-detection | Barrage | Additions |
| Rey delayed recall | Phonological fluency | Benton | Spatial span | Subtractions |
| Recognition accuracy | Reading | Famous faces | H cancellation | |
| Naming |
| Change in response variables | Explanatory variables | ||||||
| Dose of tofacitiniba | Lymphocyte sub-populations | ||||||
| T (CD3+) | TH(CD3+/CD4+) | TC(CD3+/CD8+) | B (CD19+) | NK (CD16+/CD56+) | |||
| CMV viral load, copies/500 ng total DNA | df | 3 | 1 | 1 | 1 | 1 | 1 |
| F value | 1.26 | 0.14 | 0.04 | 0.68 | 0.00 | 0.03 | |
| p value | 0.2926 | 0.7047 | 0.8411 | 0.4112 | 0.9925 | 0.8592 | |
| EBV viral load, copies/500 ng total DNA | df | 3 | 1 | 1 | 1 | 1 | 1 |
| F value | 0.50 | 0.54 | 1.69 | 0.11 | 0.02 | 0.57 | |
| p value | 0.6807 | 0.4627 | 0.1955 | 0.7430 | 0.8906 | 0.4501 | |
| CRP level, mg/L | df | 3 | 1 | 1 | 1 | 1 | 1 |
| F value | 3.18 | 1.45 | 1.84 | 4.18 | 0.11 | 1.83 | |
| p value | 0.0262 | 0.2315 | 0.1775 | 0.0430 | 0.7450 | 0.1784 |
| IOP (mmHg) | OPP (mmHg) | |||||
| Affected Eye | Unaffected Eye | P value* | Affected Eye | Unaffected Eye | P value* | |
| T1 | 16.6 ± 3.4 (10.5–23.3) | 15.6 ± 2.9 (9.5–20.6) | 0.055 | 50.1 ± 9.9 (35.4–77.6) | 51.1 ± 11.0 (33.4–78.3) | 0.055 |
| T2 | 17.8 ± 3.5 (11.6–28.1) | 17.4 ± 3.2 (11.8–24.1) | 0.327 | 65.7 ± 12.4 (47.6–92.2) | 66.2 ± 12.5 (46.9–93.7) | 0.139 |
| T3 | 20.2 ± 4.2 (13.8–29.9) | 19.2 ± 3.7 (14.6–28.1) | 0.457 | 59.8 ± 13.8 (37.3–83.2) | 60.2 ± 14.0 (35.5–83.0) | 0.355 |
| T4 | 18.2 ± 2.7 (11.9–23.4) | 17.7 ± 3.2 (12.6–25.5) | 0.089 | 64.7 ± 13.1 (39.9–92.5) | 65.8 ± 12.5 (46.8–92.1) | 0.089 |
| T5 | 20.3 ± 5.6 (14.0–32.2) | 18.9 ± 4.7 (10.8–30.4) | 0.287 | 53.1 ± 12.5 (38.4–81.0) | 54.5 ± 13.5 (34.5–82.2) | 0.422 |
| T6 | 18.0 ± 3.6 (9.7–23.4) | 17.0 ± 3.7 (7.9–24.4) | 0.053 | 63.8 ± 14.0 (35.0–95.6) | 64.7 ± 13.5 (35.3–93.8) | 0.420 |
| Affected eye DLDPa | 21.4 ± 5.4 (14.0–32.2) | 19.2 ± 4.1 (13.8–31.7) | 0.020 | 56.9 ± 11.7 (39.4–79.5) | 57.9 ± 12.1 (40.8–79.5) | 0.041 |
| Unaffected eye DLDPa | 18.6 ± 5.1 (10.8–30.4) | 19.6 ± 2.9 (14.8–24.0) | 0.204 | 56.0 ± 15.3 (37.3–83.2) | 55.6 ± 15.1 (35.5–83.0) | 0.052 |
| # | Nugget Topic | Nugget Content (3rd ed.) |
| 6. | Pharmacological management of neuropathic pain | Use a step-wise evidence-based protocol for the management of neuropathic pain in SCI, and review pain management annually. |
| 10. | Diet & fluid management in neurogenic bowel | Refer spinal cord injured patients with persistent constipation to a specialist with experience with SCI or neurogenic bowel. |
| 11. | Screening of colorectal cancer | Initiate colorectal cancer screening for patients with SCI using the same principles as those for the general population. |
| 13. | Recognizing Urinary Tract Infections in SCI Patients | Diagnosis of UTI in SCI patients requires 3 criteria: (1) significant bacteriuria; (2) pyuria; and (3) signs & symptoms. |
| 14. | Pharmacological management of UTI in SCI | There is no superior agent or class of antibiotics for UTIs in spinal cord injury. Recurrent UTIs should be treated as complicated infections, and treatment must be customized to the patient and the infecting organism. |
| 15. | Screening for Bladder Cancer | Routine screening for bladder cancer is recommended only for high-risk patients; that is those with indwelling or suprapubic catheters, complete lesions, >10 years since injury, bladder stones, or recurrent urinary tract infections. |
| 17. | Treatment of Skin Breakdown | Treat Stage I or II wounds with standard wound care. Treat Stage III or IV wounds with specialist/surgical intervention. |
| 20. | Wheel chair accessibility of your practice | Conduct an accessibility audit of your office or clinic space and procedures using the Primary Care Accessibility Checklist. |
| CNTs | Hydroxyl Content % (w/w) | Carboxyl Content % (w/w) | Diameter (nm) | Length (μm) | SSA (m2/g) | PC Sets | PC Names |
| F1 | _ | _ | 10–20 | 30–100 | >165 | M | M1 |
| F2 | _ | _ | 8–15 | ~50 | >233 | M | M2 |
| F3 | _ | _ | 10–20 | 10–30 | >200 | M | M3 |
| F4 | _ | _ | 20–30 | 10–30 | >110 | M | M4 |
| F5 | _ | _ | 30–50 | 10–20 | >60 | M | M5 |
| F6 | _ | _ | >50 | 10–20 | >40 | M | M6 |
| F7 | 5.58 | _ | <8 | 10–30 | >500 | H | H1 |
| F8 | 3.70 | _ | 8–15 | ~50 | >233 | H | H2 |
| F9 | 3.06 | _ | 10–20 | 10–30 | >200 | H | H3 |
| F10 | 1.76 | _ | 20–30 | ~30 | >110 | H | H4 |
| F11 | 1.06 | _ | 30–50 | ~20 | >60 | H | H5 |
| F12 | 0.71 | _ | >50 | ~20 | >40 | H | H6 |
| F13 | _ | 3.86 | <8 | ~30 | >500 | C | C1 |
| F14 | _ | 2.56 | 8–15 | ~50 | >233 | C | C2 |
| F15 | _ | 2.00 | 10–20 | 10–30 | >200 | C | C3 |
| F18 | _ | 1.23 | 20–30 | ~30 | >110 | C | C4 |
| F17 | _ | 0.73 | 30–50 | ~20 | >60 | C | C5 |
| F18 | _ | 0.64 | >50 | ~20 | >40 | C | C6 |
| Median MET-min/week (IQR) | |||||||||
| Erectile dysfunction | p value | Premature ejaculation | p value | Libido | p value | ||||
| Absent | Present | Absent | Present | Normal | Reduced | ||||
| All males | |||||||||
| All | 2772 (4122) | 2066 (3532) | <0.01 | 2400 (3851) | 2079 (3465) | 0.226 | 2373 (3573) | 2400 (3921) | 0.916 |
| Europids | 3355 (4340) | 2493 (3768) | <0.01 | 2763 (4382) | 2652 (3400) | 0.283 | 2706 (4076) | 2641 (3846) | 0.929 |
| South Asians | 1985 (2841) | 1662 (3142) | 0.184 | 1782 (3442) | 1638 (3465) | 0.931 | 1710 (2925) | 1584 (3726) | 0.909 |
| Patients with diabetes | |||||||||
| All | 3816 (7492) | 1980 (3472) | <0.05 | 2424 (3711) | 2079 (4358) | 0.307 | 2163 (3721) | 2148 (3465) | 0.887 |
| Europids | 6075 (7539) | 2446 (3478) | <0.01 | 2739 (3336) | 2706 (5095) | 0.168 | 2772 (5013) | 2400 (3057) | 0.652 |
| South Asians | 1638 (2940) | 1674 (3560) | 0.694 | 1680 (3231) | 1538 (4346) | 0.974 | 1674 (3123) | 1584 (4510) | 0.910 |
| Patients without diabetes | |||||||||
| All | 2706 (3444) | 2333 (4050) | 0.109 | 2272 (4449) | 2493 (2712) | 0.686 | 2382 (3420) | 2655 (4180) | 0.644 |
| Europids | 2836 (4125) | 2641 (4191) | 0.271 | 2772 (5174) | 2598 (2475) | 0.827 | 2706 (3706) | 3093 (3515) | 0.401 |
| South Asians | 1853 (2772) | 1538 (3025) | 0.361 | 1737 (3699) | 1809 (3304) | 0.879 | 1746 (3063) | 1280 (3722) | 0.398 |
| Subjects | Age (years) | Odor threshold (score/16) | Odor discrimination (score/16) | Multiple choice identification (score/16) | TDI composite score (score/48) | Retronasal testing (score/20) |
| EB1 | 21 | 7.3 | 15 | 10 | 32.3 | 19 |
| EB3 | 29 | 6.3 | 10 | 16 | 32.3 | 16 |
| EB4 | 40 | 7.0 | 14 | 14 | 35.0 | 17 |
| EB5 | 55 | 15.8 | 15 | 13 | 43.8 | 18 |
| EB8 | 39 | 11.0 | 16 | 11 | 38.0 | 17 |
| EB9 | 51 | 8.0 | 14 | 15 | 37.0 | 17 |
| EB10 | 45 | 15.8 | 13 | 14 | 42.8 | 18 |
| EB11 | 20 | 6.0 | 15 | 12 | 33.0 | 18 |
| Mean (EB) | 37.5 | 9.6 | 14.0 | 13.10 | 36.8 | 17.5 |
| SD (EB) | 13.1 | 4.08 | 1.85 | 2.03 | 4.54 | 0.93 |
| SC1 | 20 | 3.5 | 14 | 16 | 33.5 | 20 |
| SC5 | 53 | 5.0 | 9 | 14 | 28.0 | 19 |
| SC7 | 40 | 6.3 | 9 | 13 | 28.3 | 16 |
| SC8 | 39 | 6.0 | 14 | 11 | 31.0 | 19 |
| SC9 | 50 | 4.8 | 11 | 13 | 28.8 | 17 |
| SC14 | 21 | 4.5 | 14 | 14 | 32.5 | 17 |
| SC15 | 30 | 6.3 | 13 | 14 | 33.3 | 16 |
| SC16 | 39 | 4.0 | 10 | 14 | 28.0 | 18 |
| Mean (SC) | 36.5 | 5.0 | 11.8 | 13.6 | 30.4 | 17.8 |
| SD (SC) | 12.1 | 1.05 | 2.25 | 1.41 | 2.43 | 1.49 |
| Sample | Number of lethality (%) | |||||
| Tribolium castaneum | Rhyzopertha dominica | Callosbruchus analis | ||||
| Crude extract | 0.33 ± 0.57 | 3.3 ± 5.7 | 0 | 0 | 0 | 0 |
| Chloroform | 1.33 ± 0.57 | 13.3 ± 5.7 | 4.66 ± 0.57 | 46.6 ± 5.7 | 0 | 0 |
| Ethyl acetate | 0.66 ± 0.57 | 6.6 ± 5.7 | 6.66 ± 1.15 | 66.6 ± 11.5 | 6.6 ± 5.7 | 66.6 ± 0 |
| n-butanol | 0 | 0 | 0 | 0 | 0.66 ± 0.57 | 6.6 ± 5.7 |
| Aqueous | 0 | 0 | 1.33 ± 0.57 | 13.3 ± 5.7 | 0 | 0 |
| Permethrin (standard) | 10 ± 0 | 100 | 10 ± 0 | 100 | 10 ± 0.01 | 100 |
| Saline | 0 | 0 | 0 | 0 | 0 | 0 |
| SarcoidosisN = 17 | Control diseaseN = 11 | TuberculosisN = 8 | P Value | |
| Age, mean ± SD (years) | 53.12 ± 7.41 | 53.55 ± 12.75 | 45.13 ± 20.73 | 0.3013 |
| Male/female ratio | 3/14 | 6/5 | 6/2 | N/A |
| CXR stage: 0/I/II/III/IV number of patients (n) | 0/10/4/3/0 | N/A | N/A | N/A |
| Tuberculosis examination negative/positive (n) | 17/0 | N/A | 0/8 | N/A |
| BMI (kg/m2) | 24.74 ± 2.45 | 22.75 ± 3.87 | 22.87 ± 2.34 | 0.1564 |
| SACE (IU/L) | 58.47 ± 26.86 (n = 15) | N/A | N/A | N/A |
| ESR (mm/h) | 24.13 ± 15.82 (n = 16) | 31.20 ± 19.81 (n = 6) | 34.57 ± 39.43 (n = 7) | 0.5996 |
| 24-h urinary calcium | 5.70 ± 2.11(n = 12) | N/A | N/A | N/A |
| CD3 (%) | 66.56 ± 8.07 (n = 14) | N/A | 58.67 ± 15. 58 (n = 7) | 0.1380 |
| CD4 (%) | 34. 01 ± 10.15 (n = 14) | N/A | 35.66 ± 13.03 (n = 7) | 0.7526 |
| CD8 (%) | 24. 87 ± 10.40 (n = 14) | N/A | 18.99 ± 4.51 (n = 7) | 0.1730 |
| IgG (ng/L) | 12.36 ± 2.73 (n = 10) | N/A | 14.67 ± 7.20 | 0.3607 |
| IgA (ng/L) | 1.96 ± 0.56 (n = 10) | N/A | 2.73 ± 1.12 | 0.0734 |
| IgM (ng/L) | 1.47 ± 0.77 (n = 10) | N/A | 1.19 ± 0.73 | 0.4324 |
| C3 (ng/L) | 1.25 ± 0.20 (n = 10) | N/A | 1.20 ± 0.29 | 0.6584 |
| C4 (ng/L) | 0.31 ± 0.072 (n = 10) | N/A | 0.34 ± 0.094 | 0.4571 |
| Comet class | 0 | 1 | 2 | 3 | 4 | TCS |
| Exposed group | 21.6 ± 13.4 | 32.5 ± 14.2 | 15.8 ± 11.9 | 11.3 ± 9.9 | 18.7 ± 9.4 | 173.2 ± 50.1* |
| Control group | 67.7 ± 13.0 | 16.2 ± 8.0 | 7.1 ± 4.4 | 5.3 ± 4.1 | 3.7 ± 2.3 | 61.0 ± 25.0 |
| Costa | Argentina | Brazil | Chile | Colombia | Ecuador | Mexico | Peru |
| < 1 | Rivaroxavan | Rivaroxavan | Rivaroxavan | Rivaroxavan | – | Rivaroxavan | Rivaroxavan |
| 1–4 | Apixaban, Indacaterol, Linagliptin, Ticagrelor | Apixaban, Roflumilast, Ticagrelor | Apixaban, Indacaterol | Apixaban, Indacaterol | Indacaterol | – | – |
| 5–9 | – | Belatacept | – | – | – | Azilsartan, Linagliptin | – |
| 10–19 | – | – | Belimumab | – | – | Apixaban, Ticagrelor | – |
| 20–39 | Aflibercept, Regorafenib | Aflibercept | Aflibercept | Aflibercept | – | – | – |
| 40–59 | Belatacept, Tofacitinib | Belimumab | – | Tofacitinib | – | – | – |
| 60–99 | Telaprevir | – | – | – | – | – | – |
| 100–149 | – | Telaprevir | – | – | – | – | – |
| 150–200 | Pasireotide | Pertuzumab | – | – | – | Tofacitinib | – |
| 201–896 | Ipilimumab, Vandetanib | Ipilimumab, Vandetanib | Ipilimumab, Taliglucerase alfa | – | – | Pasireotide, Pertuzumab | – |
| Origin | Methods | Dysregulated miRNAs | Study Details |
| Aortic stenosis | |||
| Aortic valve leaflets [24] | Microarray qPCR | Downregulated: 26a, 30b, 195 | 9 patients with BAV (AS vs. aortic insufficiency requiring AVR) |
| Aortic valve leaflets [26] | qPCR | Downregulated: 30b | 10 AS patients requiring AVR (calcific vs. adjacent tissue) |
| Aortic valve leaflets [27] | qPCR | Downregulated: 148a-3p | 4 BAVs vs. healthy aortic valves |
| Aortic valve leaflets [28] | Microarray qPCR | Upregulated: 125b Downregulated: 374b*, 602, 939 | 20 calcific AS valves vs. 6 control valves |
| Aortic valve leaflets [25] | Microarray qPCR | Upregulated: 151-3p, 152, 030e, 032, 145, 768-5p, 190, 373* Downregulated: 141, 370, 022, 1972, 330-5p, 566-pre, 1469, 1908, 648-pre, 637, 1282, 622, 486-3p, 187, 1909*, 564, 027a, 194*, 125b-1-pre, 551a-pre, 575, 585-pre, 211-pre, 449b*, 124-3-pre, 185-pre, 1202 | 19 BAVs vs. 17 TAVs from AS patients requiring AVR |
| LV intraoperative biopsies [29] | qPCR | Upregulated: 133a | 46 AS patients requiring AVR |
| LV intraoperative biopsies [31] | qPCR | Upregulated: 21 | 75 AS patients requiring AVR vs. 32 surgical controls |
| LV intraoperative biopsies [32] | qPCR | Downregulated: 1 | 5 AS patients before TAVI vs. healthy controls |
| Endomyocardial biopsies [33] | Microarray qPCR | Downregulated: 18b, 122 | 28 AS patients with severe myocardial fibrosis vs. non-severe fibrosis |
| LV intraoperative biopsies [30] | qPCR | Upregulated: 133a | 74 AS patients requiring AVR |
| Mitral valve disease | |||
| Tissues from the right and the left atrial appendages [37] | Microarray qPCR | Upregulated: 4484 Downregulated: 1, 23b-3p, 26a-5p, 30c-5p, 125b-5p, 133b, 143-3p, 145-5p, 4454 | 18 rheumatic mitral valve disease patients (10 AF vs. 8 SR) requiring mitral valve surgery |
| Tissues from the left atrial appendage [36] | Microarray qPCR | Upregulated: 466, 574-3p, 3613-3p Downregulated: 1, 26a-5p | 12 patients with mitral stenosis (6 SR, 6 AF) requiring mitral valve surgery |
| Mitral valve leaflets [38] | RNA-seq | Upregulated: 656, 379-3p, 664a-3p, 34c-3p | 10 patients with myxomatous mitral valve vs. 10 controls |
| Mitral valve leaflets [39] | whole genome miRNA qPCR | Upregulated: 500, 3174 Downregulated: 17, 203, 505, 646, 939, 1193, 1273e, 4298 | 10 myxomatous mitral valve prolapse vs. fibroelastic deficiency |
| Variable | Base case value | Distribution | Parameters | Source/Notes |
| Probability of sustained virological response (SVR) in control group | 0.02% | Beta | Alpha = 1 Beta = 559 | Koretz et al.[23] |
| Log risk ratio (SVR: interferon versus no-intervention control) | 2.9209 | Normal | Mean = 2.9209 Standard deviation = 1.0255 | Koretz et al.[23] Note this yields a base case probability of SVR in the interferon group of 3.31% |
| 5-year probability of death in no-intervention control group | 6.72% | Beta | Alpha = 57 Beta = 791 | Koretz et al.[23] Annual probability therefore = 1.40% (= SRc in Table 2) |
| Log risk ratio (death: interferon versus no-intervention control) | 0.3424 (0.1649) | Normal | Mean = 0.3424 Standard deviation = 0.1649 | Koretz et al.[23] Note this yields a base case 5 year probability of death with interferon = 9.47%, annual probability = 2.01% = SRi in Table 2 |
| Annual all-cause mortality by age | 0.34% for 50 year male; 0.23% for 50 year female; 0.09% for 30 year male; 0.04% for 30 year female; 2.17% for 70 year old male; 1.41% for 70 year old female | Constant | Not applicable | Interim life tables (based on all reported deaths in the UK)[25], the sample size is assumed large enough for the standard error to be zero |
| Discount rate | 3.50% | Constant | Not applicable | HM Treasury Green Book[26] |
| CI session | MDMA + CI session | F value | |||||||
| T1 | T2 | T3 | T1 | T2 | T3 | Session | Time | Session × Time | |
| TPAS—active | 16.10 (6.04) | 15.40 (5.85) | 11.80 (5.31) | 18.80 (5.07) | 22.05 (5.81) | 17.55 (6.07) | 27.808*** | 12.00*** | 2.056 |
| TPAS—relax | 15.15 (4.61) | 16.05 (4.14) | 18.50 (5.10) | 14.75 (5.31) | 15.40 (4.60) | 20.35 (4.18) | 0.110 | 16.056*** | 1.770 |
| TPAS—warm | 11.10 (2.65) | 12.05 (2.24) | 12.80 (2.55) | 12.35 (2.28) | 12.80 (2.91) | 14.15 (1.90) | 5.652* | 8.591** | 0.450 |
| Tx-type; Cause of Death | < 12 months | > 12 months | p-value |
| Total: 278 | |||
| SLTx (n = 97) | |||
| Total number of deaths | 17 | 51 | 0.158 |
| Death from Organ Rejection | 2 (12%) | 10 (20%) | |
| Death from Infection | 4 (23%) | 16 (31%) | |
| Death from Malignancy | 1 (6%) | 10 (20%) | |
| Death from Other Causes | 10 (59%) | 15 (29%) | |
| DLTx (n = 172) | |||
| Total number of deaths | 16 | 47 | 0.388 |
| Death from Organ Rejection | 4 (25%) | 20 (42%) | |
| Death from Infection | 4 (25%) | 6 (13%) | |
| Death from Malignancy | 1 (6%) | 6 (13%) | |
| Death from Other Causes | 7 (44%) | 15 (32%) | |
| HLTx (n = 9) | |||
| Total number of deaths | 1 | 4 | 0.576 |
| Death from Organ Rejection | 0 (0%) | 1 (25%) | |
| Death from Infection | 0 (0%) | 0 (0%) | |
| Death from Malignancy | 0 (0%) | 0 (0%) | |
| Death from Other Causes | 1 (100%) | 3 (75%) |
| Variable | Bivariate linear regression | Multivariate linear regression | ||
| Coefficient (95 % CI) | P-value | Coefficient (95 % CI) | P-value | |
| Male gender | 5.707 (2.887, 8.526) | <0.001 | 5.429 (2.517, 8.341) | <0.001 |
| Age (in years) | 0.988 (0.297, 1.679) | 0.005 | 0.460 (−0.241, 1.160) | 0.198 |
| University educational program | 0.716 (−2.252, 3.684) | 0.636 | - | |
| Number of births managed during training | 0.183 (0.074, 0.291) | 0.001 | 0.164 (0.055, 0.273) | 0.003 |
| Felt classroom resources were available and helpful | −0.131 (−2.888, 2.626) | 0.926 | - | |
| Felt number of instructors was adequate | 2.191 (−0.565, 4.947) | 0.119 | 2.428 (−0.529, 5.385) | 0.107 |
| Felt instructors were effective in facilitating learning | −2.469 (−5.217, 0.278) | 0.078 | −3.543 (−6.360, −0.726) | 0.014 |
| Felt instructors were fair and unbiased in assessing | −2.742 (−5.648, 0.164) | 0.064 | −2.794 (−5.710, 0.122) | 0.060 |
| Felt skills lab resources were available and helpful | 3.593 (0.574, 6.612) | 0.020 | 2.749 (−0.528, 6.025) | 0.100 |
| Felt number of skills lab assistants was adequate | 2.835 (−0.171, 5.840) | 0.064 | 2.239 (−1.043, 5.520) | 0.181 |
| Felt skills lab assistants supported students effectively | 0.073 (−2.678, 2.824) | 0.959 | - | |
| Felt number of preceptors was adequate | 2.070 (−1.254, 5.395) | 0.222 | 0.204 (−3.92, 4.321) | 0.922 |
| Felt clinical teachers and preceptors supported students | 1.892 (−1.575, 5.359) | 0.284 | 0.636 (−3.651, 4.923) | 0.771 |
| Felt clinical experience was sufficient | 4.619 (1.915, 7.323) | 0.001 | 4.650 (1.863, 7.437) | 0.001 |
| Total (n = 370) | Qi deficiency of spleen and kidney (n = 273) | Deficiency of both qi and yin (n = 66) | Other types (n = 31) | P value | |
| Age (years) | 32 (27–42) | 33 (27–42) | 29 (25–36) | 37 (28–46) | 0.025a |
| Female, n (%) | 196 (53.0) | 139 (50.9) | 42 (63.6) | 15 (48.4) | 0.154 |
| Disease course (months) | 6 (2–23) | 5 (1–23) | 12 (3–25) | 6 (2–13) | 0.186 |
| Inducement, n (%) | |||||
| Infection | 41 (11.1) | 31 (11.4) | 5 (7.6) | 5 (16.1) | 0.780 |
| Fatigue | 13 (3.5) | 11 (4.0) | 1 (1.5) | 1 (3.2) | |
| Pregnancy | 25 (6.8) | 19 (7.0) | 5 (7.6) | 1 (3.2) | |
| No obvious inducement | 291 (78.6) | 212 (77.7) | 55 (83.3) | 24 (77.4) | |
| Systolic BP (mmHg) | 120 (110–132) | 120 (110–132) | 120 (108–130) | 125 (118–146) | 0.070 |
| Diastolic BP (mmHg) | 80 (70–86) | 80 (70–89) | 79 (70–80) | 80 (72–100) | 0.097 |
| MAP (mmHg) | 93 (86–101) | 93 (86–101) | 91 (82–97) | 94 (88–113) | 0.069 |
| Hypertension, n (%) | 136 (36.8) | 101 (37.0) | 18 (27.3) | 17 (54.8) | 0.031b |
| Macroscopic hematuria, n (%) | 66 (17.8) | 39 (14.3) | 17 (25.8) | 10 (32.3) | 0.008c |
| U-RBC (/μL) | 45 (15–136) | 32 (11–134) | 60 (30–110) | 74 (25–179) | 0.015d |
| Hemoglobin (g/L) | 128.2 ± 20.1 | 129.5 ± 20.2 | 126.1 ± 16.2 | 121.1 ± 25.2 | 0.055 |
| Proteinuria (g/day) | 1.0 (0.5–2.2) | 1.0 (0.5–2.1) | 1.1 (0.5–2.5) | 1.1 (0.5–2.7) | 0.766 |
| Uric acid (μmol/L) | 340 (274–429) | 344 (277–433) | 316 (255–408) | 358 (302–460) | 0.170 |
| Serum albumin (g/L) | 40.3 (35.8–43.8) | 40.6 (36.1–44.0) | 40.2 (36.4–42.8) | 39.2 (34.2–42.1) | 0.405 |
| Serum creatinine (μmol/L) | 79 (59–108) | 80 (61–107) | 67 (56–88) | 123 (63–183) | 0.001e |
| eGFR (mL/min/1.73 m2) | 97.2 (67.2–120.5) | 97.1 (66.3–119.9) | 115.3 (82.0–125.7) | 70.6 (27.7–114.2) | <0.001f |
| eGFR (mL/min/1.73 m2) | |||||
| <15 | 6 (1.6) | 3 (1.1) | 0 | 3 (9.7) | 0.001g |
| >15, ≤30 | 15 (4.1) | 9 (3.3) | 1 (1.5) | 5 (16.1) | |
| >30, ≤60 | 53 (14.3) | 44 (16.1) | 4 (6.1) | 5 (16.1) | |
| >60, ≤90 | 94 (25.4) | 67 (24.5) | 19 (28.8) | 8 (25.8) | |
| >90 | 202 (54.6) | 150 (54.9) | 42 (63.6) | 10 (32.3) | |
| Serum IgA (g/L) | 2.85 (2.25–3.58) | 2.84 (2.28–3.58) | 2.81 (2.19–3.39) | 2.97 (2.51–4.02) | 0.246 |
| Serum C3 (mg/L) | 0.98 (0.87–1.11) | 0.98 (0.87–1.12) | 0.98 (0.85–1.10) | 0.96 (0.85–1.08) | 0.611 |
| Oxford MEST scores | |||||
| M1, n (%) | 361 (97.6) | 269 (98.5) | 64 (97.0) | 28 (90.3) | 0.032h |
| E1, n (%) | 54 (14.6) | 41 (15.0) | 11 (16.7) | 2 (6.5) | 0.384 |
| S1, n (%) | 185 (50.0) | 142 (52.0) | 32 (48.5) | 11 (35.5) | 0.210 |
| T1, n (%) | 193 (52.2) | 146 (53.5) | 30 (45.5) | 17 (54.8) | 0.242 |
| T2, n (%) | 68 (18.4) | 48 (17.6) | 12 (18.2) | 8 (25.8) |
| Growth year | Thickness/μm | Sheet name | Brix degree/% | Acid value/% | Peel color/a value |
| 2004 | 30 | unmulched | 9.0 ± 0.3 | 0.68 ± 0.05 | 21.7 ± 1.0 |
| MS-3,7,0 | 10.3 ± 0.2 | 0.74 ± 0.09 | 25.3 ± 1.4 | ||
| MS-3,6,1 | 10.9 ± 0.6 | 0.74 ± 0.11 | 25.1 ± 1.2 | ||
| 2005 | 90 | unmulched | 10.3 ± 0.3 | 0.86 ± 0.10 | 19.8 ± 1.8 |
| MS-3,7,0 | 13.6 ± 0.5 | 1.09 ± 0.04 | 23.3 ± 0.6 | ||
| MS-3,6,1 | 13.9 ± 0.5 | 1.10 ± 0.15 | 25.3 ± 1.2 |
| Post Hoc Test (1 mL) | Age group (i) | Age Group (j) | Mean Difference (μi − μj) | 95% Confidence Interval | |
| Lower | Upper | ||||
| Scheffé’s * | 51–60 | 21–30 | 0.152 | −0.077 | 0.381 |
| 51–60 | 31–50 | 0.334 | 0.118 | 0.551 | |
| 21–30 | 31–50 | 0.183 | −0.020 | 0.385 |
| Variable | ALSPAC n (%)(N=6768) | Pelotas n (%)(N=3508) | χ2 |
| Exposures | |||
| Low birth weight | 238 (3.5) | 274 (7.8) | 89.99** |
| SGA | 512 (7.6) | 496 (14.2) | 113.19** |
| Small HC | 264 (4.8) | 470 (13.4) | 211.02** |
| Preterm birth | 302 (4.4) | 445 (12.7) | 237.77** |
| Outcomes | |||
| DAWBA | |||
| Hyperactive-impulsive ADHD | 20 (0.3) | 13 (0.4) | 0.45 |
| Inattentive ADHD | 54 (0.8) | 11 (0.3) | 8.39* |
| Combined ADHD | 68 (1.0) | 56 (1.6) | 7.13* |
| Any ADHD disorder | 142 (2.1) | 92 (2.6) | 3.16 |
| SDQ | |||
| Attention difficulties† | 719 (10.5) | 480 (13.7) | 22.94** |
| Histopathological score | |||
| Day 7 | Day 21 | Day 35 | |
| Gb | 2(1-2) | 6(5-7) | 8,5(7-10) |
| C | 2(1-2) | 5(4-6) | 6(6-7) |
| p | 0,535 | 0,009* | 0,001* |
| Systemic organ class and preferred terma | Total (N = 209) | |
| Number of Subjects (%) | Number of Adverse Events | |
| Resistance mechanism disorders | ||
| Infection susceptibility increased | 1 (0.48) | 1 |
| Polyomavirus infection | 1 (0.48) | 1 |
| Gastro-intestinal system disorders | ||
| Diarrhoea | 5 (2.39) | 5 |
| Stomatitis | 3 (1.44) | 3 |
| Stomatitis ulcerative | 1 (0.48) | 1 |
| Abdominal pain | 2 (0.96) | 2 |
| Nausea | 1 (0.48) | 1 |
| Urinary system disorders | ||
| Azotaemia | 6 (2.87) | 6 |
| Albuminuria | 1 (0.48) | 1 |
| Oliguria | 1 (0.48) | 1 |
| Skin and appendages disorders | ||
| Acne | 1 (0.48) | 1 |
| Rash | 1 (0.48) | 1 |
| Rash erythematous | 2 (0.96) | 2 |
| Dermatitis | 1 (0.48) | 1 |
| Metabolic and nutritional disorders | ||
| Diabetes mellitus | 1 (0.48) | 1 |
| Diabetes mellitus aggravated | 1 (0.48) | 1 |
| Plasma osmolality increased | 1 (0.48) | 1 |
| Body as a whole– general disorders | ||
| Edema peripheral | 1 (0.48) | 1 |
| Face edema | 2 (0.96) | 2 |
| Anaphylactic reaction | 1 (0.48) | 1 |
| Liver and biliary system disorders | ||
| Hepatic function abnormal | 1 (0.48) | 1 |
| Cholangitis | 1 (0.48) | 1 |
| Musculo-skeletal system disorders | ||
| Avascular necrosis bone | 1 (0.48) | 1 |
| Secondary terms – events | ||
| Transplant rejection | 2 (0.96) | 2 |
| Respiratory system disorders | ||
| Coughing (≥ 4 weeks) | 1 (0.48) | 1 |
| White cell and RES disorders | ||
| Leucopenia | 1 (0.48) | 1 |
| Variable | Category | IIR | Non- IIR | Total |
| n (%) | n (%) | n (%) | ||
| Age | ≥ 35 years | 31 (38.3) | 31 (38.3) | 62 (38.3) |
| Marital status | Married | 74 (91.4) | 72 (88.9) | 146 (90.1) |
| Family type | Nuclear | 38 (46.9) | 47 (58) | 85 (52.5) |
| Extended nuclear | 13 (16) | 10 (12.3) | 23 (14.2) | |
| Joint | 30 (37) | 24 (29.6) | 54 (33.3) | |
| Education | ≥ Primary education | 65 (80.2) | 48 (59.2) | 113 (69.7) |
| Literacy | Read and write | 59 (72.8) | 41 (50.6) | 100 (61.7) |
| Household visit /week | Mean (±SD) | 52 (±42) | 42 (±68) | 47 (±57) |
| Serving population | Mean (±SD) | 255 (±134) | 206 (±147) | 231 (±142) |
| Focus group discussion held prior to join Mitanin program | Yes | 54 (66.7) | 60 (74.1) | 114 (70.4) |
| Village meeting held prior to join Mitanin program | Yes | 38 (33.3) | 43 (53.1) | 81 (50) |
| Prior work experience | Yes | 14 (17.3) | 09 (11.1) | 23 (14.2) |
| Primary reason of join Mitanin program | Financial incentives | 04 (4.9) | 04 (4.9) | 08 (4.9) |
| Opportunity to learn | 07 (8.6) | 06 (7.4) | 13 (8) | |
| Support village health facilities | 23 (28.4) | 13 (16) | 36 (22.2) | |
| Social prestige | 01 (1.2) | 01 (1.2) | 02 (1.2) | |
| Pressure from family and relatives | 37 (45.7) | 47 (58) | 84 (51.9) | |
| Other | 9 (11.1) | 10 (12.3) | 19 (11.7) |
| ID | Study | IQC | EQC | CQCg | CQCp | AQCg | AQCp | SMR | Quality |
| 1 | GSE43264 | 4.02 | 4 | 2.51 | 3.32 | 2.63 | 4.54 | 2.67 | high |
| 2 | GSE48301_eSF | 9.49 | 2.82 | 8.89 | 2.44 | 12.97 | 1.17* | 2.83 | high |
| 3 | GSE1615 | 2.43 | 3 | 1.92* | 2.64 | 0.92* | 2.78 | 4.67 | high |
| 4 | GSE10946_obese | 7.45 | 4 | 0.27* | 2.89 | 0.1* | 0.7* | 5.17 | high |
| 5 | GSE48301_eMSC | 6.1 | 2.62 | 7.12 | 0.59* | 8.35 | 0.49* | 5.33 | high |
| 6 | GSE48301_eEP | 6.25 | 3.1 | 1.88* | 0.23* | 0.46* | 1.16* | 5.5 | borderline |
| 7 | GSE34526 | 1.74* | 4 | 0.35* | 1.36* | 0.14* | 0.05* | 7.17 | low |
| 8 | GSE48301_eEN | 4.17 | 2.34* | 0.46* | 1.06* | 0.63* | 0.08* | 7.17 | low |
| 9 | GSE5090 | 0.98* | 1.68* | 0.51* | 0.77* | 1.86* | 0.05* | 8.33 | low |
| 10 | GSE5850 | 0* | 2.32* | 0.05* | 3.07 | 0.07* | 0.41* | 8.5 | low |
| 11 | GSE10946_lean | 3.15 | 2.8 | 0* | 0.03* | 0.05* | 0.99* | 8.67 | low |
| Variables | Univariable | Multivariable | ||
| HR (95% CI) | P | HR (95% CI) | P | |
| Age (≤54/>54) | 1.698 (0.860–3.354) | 0.127 | ||
| Gender (F/M) | 0.551 (0.282–1.075) | 0.080 | ||
| Tumor location (pyloric/nonpyloric antrum) | 1.130 (0.580–2.204) | 0.719 | ||
| HER-2 (positive/negative) | 1.818 (0.698–4.736) | 0.221 | ||
| RDW (≤13.4%/>13.4%) | 3.497 (1.713–7.140) | 0.001 | ||
| WBC (≤5.69/>5.69 g/L) | 2.165 (1.084–4.324) | 0.029 | 1.323 (0.584–2.997) | 0.502 |
| MO (≤0.42/>0.42 g/L) | 2.125 (1.067–4.232) | 0.032 | 1.205 (0.521–2.790) | 0.663 |
| NLR (≤2.755/>2.755) | 6.482 (3.131–13.418) | <0.001 | ||
| CA125 (≤26.6/>26.6 U/mL) | 2.241 (1.128–4.453) | 0.021 | 1.858 (0.924–3.734) | 0.082 |
| CA199 (≤11.9/>11.9 U/mL) | 1.479 (0.761–2.872) | 0.248 | ||
| CEA (≤2.4/>2.4 μg/L) | 1.513 (0.773–2.961) | 0.227 | ||
| RDW + NLR | 3.252 (1.289–8.203) | <0.001 | 3.197 (1.248–8.191) | <0.001 |
| Parent, N = 100/217 | Child, N = 63/130 | |
| Missing values (1st–3rd quartiles) | No missing values | No missing values |
| Response pattern | PF and HRQoL positively skewed | PF and HRQoL positively skewed |
| Floor effect, median | ||
| PF | 92.0% | 90.5% |
| HRQoL PhH | 60.0% | 71.4% |
| HRQoL PsH | 66.0% | 69.8% |
| Pain VAS | 47.0% | 36.5% |
| Disease activity VAS | 39.0% | 36.5% |
| Well-being VAS | 48.0% | 50.8% |
| Ceiling effect, median | ||
| PF | 0.0% | 0.0% |
| HRQoL PhH | 4.0% | 1.6% |
| HRQoL PsH | 0.0% | 0.0% |
| Pain VAS | 1.0% | 0.0% |
| Disease activity VAS | 3.0% | 1.6% |
| Well-being VAS | 0.0% | 0.0% |
| Items with equivalent item-scale correlation | 87% for PF, 90% for HRQoL | 73% for PF, 90% for HRQoL |
| Items with items-scale correlation ≥ 0.4 | 87% for PF, 100% for HRQoL | 67% for PF, 100% for HRQoL |
| Cronbach’s alpha | ||
| PF-LL | 0.82 | 0.84 |
| PF-HW | 0.74 | 0.89 |
| PF-US | 0.64 | 0.47 |
| HRQoL-PhH | 0.86 | 0.86 |
| HRQoL-PsH | 0.85 | 0.76 |
| Items with item-scale correlation lower than the Cronbach alpha | 93% for PF, 100% for HRQoL | 100% for PF, 100% for HRQoL |
| Test–retest intraclass correlation | ||
| PF total score | 0.60 | – |
| HRQoL-PhH | 0.62 | – |
| HRQoL-PsH | 0.97 | – |
| Spearman’s correlation with JIA core-set variables, median | ||
| PF | 0.4 | 0.4 |
| HRQoL PhH | 0.4 | 0.4 |
| HRQoL PsH | 0.3 | 0.2 |
| Pain VAS | 0.2 | 0.3 |
| Disease activity VAS | 0.3 | 0.4 |
| Well-being VAS | 0.3 | 0.4 |
| n (%) of sites | |||
| Dacron (N = 38b) | PTFE (N = 19b) | Any material (N = 57b) | |
| Bleedinga at 0 min | |||
| “No bleeding” | 34 (89) | 19 (100) | 53 (93) |
| “Oozing” | 4 (11) | 0 (0) | 4 (7) |
| “No bleeding” or “oozing” | 38 (100) | 19 (100) | 57 (100) |
| Bleedinga at 10 min | |||
| “No bleeding” | 37 (97) | 19 (100) | 56 (98) |
| “Oozing” | 1 (3) | 0 (0) | 1 (2) |
| “No bleeding” or “oozing” | 38 (100) | 19 (100) | 57 (100) |
| Fraction in state (f) | z2t | Rates of transfer (Eqs. (20)–(21)) | ||||||
| Time | U | J | A | mUJ | mJU | mJA | mAJ | |
| A. Interval by interval calculations (Eq. (1)) | ||||||||
| 0 | .85 | .10 | .05 | – | – | – | – | – |
| 1 | .82925 | .10985 | .06090 | .70 | .01317 | .06586 | .08474 | .12106 |
| 2 | .81243 | .11769 | .06988 | .71 | .01335 | .06674 | .08291 | .11678 |
| 3 | .79876 | .12391 | .07733 | .72 | .01357 | .06785 | .08026 | .11147 |
| 4 | .78759 | .12885 | .08356 | .73 | .01384 | .06921 | .07698 | .10545 |
| 5 | .77844 | .13275 | .08881 | .74 | .01419 | .07093 | .07318 | .09890 |
| B. Stable population values (τj5) implied by time 5 rates | ||||||||
| 5 | .74184 | .14837 | .10979 | |||||
| C. Time 5 values calculated directly from time 0 populations and z values (Eq. (2)) | ||||||||
| 5 | .77844 | .13275 | .08881 |
| Variable | N | % |
| Child’s gender | ||
| Male | 232 | 48.54 |
| Female | 246 | 52.46 |
| Child’s age (months) | ||
| 12–35 | 186 | 38.91 |
| 36–59 | 292 | 61.09 |
| Child’s skin color | ||
| White | 379 | 79.29 |
| Non-White | 99 | 20.71 |
| Household income | ||
| >1 BMW* | 338 | 74.78 |
| ≤1 BMW* | 114 | 25.22 |
| Mother’s level of education | ||
| ≥8 years | 268 | 56.78 |
| <8 years | 204 | 43.22 |
| Father’s level of education | ||
| ≥8 years | 247 | 55.38 |
| <8 years | 199 | 44.62 |
| Does the child brush his/her teeth? | ||
| Yes | 434 | 90.99 |
| No | 43 | 9.01 |
| Children’s dental caries | ||
| dmft = 0 | 317 | 66.32 |
| dmft ≥ 1 | 161 | 33.68 |
| Children’s previous visit to the dentist | ||
| Yes | 112 | 23.68 |
| No | 361 | 76.32 |
| Reason for dental visit | ||
| Preventive | 82 | 67.77 |
| Others than preventive | 39 | 32.23 |
| Type of healthcare system | ||
| Private | 45 | 36.89 |
| Public | 77 | 63.11 |
| Box D. Content validity (including face validity) | ||||
| General requirements | yes | no | ? | |
| 1 | Was assessed if all items refer to relevant aspects of the construct to be measured? | □ | □ | □ |
| 2 | Was assessed if all items are relevant for the study population? Considering e.g. age, gender, disease characteristics, country, setting | □ | □ | □ |
| 3 | Was assessed if all items are relevant for the purpose of the application of the measurement instrument? i.e. (1) discriminative (distinguish between groups at one point in time), (2) evaluative (assess change over time), and/or (3) predictive (predict future values) | □ | □ | □ |
| 4 | Was assessed if all items together comprehensively reflect the construct to be measured in terms of (1) content coverage and description of domains, and (2) the theoretical foundation? | □ | □ | □ |
| 5 | Were there any important flaws in the design or methods of the study? | □ | □ |
| Single cellular RNA sample | Pooled RNA sample | Pooled DNA sample | |
| TNF-α | 95 | 95 | 100 |
| β2-MG | 90 | 90 | 100 |
| MIF | 88 | 88 | 100 |
| UBC | 81 | 80 | 100 |
| Total n = 1645 | non-JIA n = 1316 | JIA n = 329 | ||
| n % | n % | n % | P-value | |
| Age (year), mean ± SDa | 11.3 ± 3.47 | 11.3 ± 3.47 | 11.3 ± 3.47 | 0.95 |
| Stratified age | 0.99 | |||
| <12 | 645 (39.2) | 516 (39.2) | 129 (39.2) | |
| ≥12 | 1000 (60.8) | 800 (60.8) | 200 (60.8) | |
| Sex | 0.99 | |||
| Girls | 840 (51.1) | 672 (51.1) | 168 (51.1) | |
| Boys | 805 (48.9) | 644 (48.9) | 161 (48.9) | |
| Urbanizationb | 0.99 | |||
| 1 (highest) | 495 (30.1) | 396 (30.1) | 99 (30.1) | |
| 2 | 490 (29.8) | 392 (29.8) | 98 (29.8) | |
| 3 | 270 (16.4) | 216 (16.4) | 54 (16.4) | |
| 4 (lowest) | 390 (23.7) | 312 (23.7) | 78 (23.7) | |
| Co-morbidity | ||||
| Allergic conjunctivitis | 0.02 | |||
| No | 1354 (82.3) | 1098 (83.4) | 256 (77.8) | |
| Yes | 291 (17.7) | 218 (16.6) | 73 (22.2) | |
| Allergic rhinitis | 0.003 | |||
| No | 1226 (74.5) | 1002 (76.1) | 224 (68.1) | |
| Yes | 419 (25.5) | 314 (23.9) | 105 (31.9) | |
| Asthma | 0.06 | |||
| No | 1477 (89.8) | 1191 (90.5) | 286 (86.9) | |
| Yes | 168 (10.2) | 125 (9.50) | 43 (13.1) | |
| Atopic dermatitis | 0.10 | |||
| No | 1555 (94.5) | 1250 (95.0) | 305 (92.7) | |
| Yes | 90 (5.47) | 66 (5.02) | 24 (7.29) |
| cn/cn | cn/+ | |||||
| Growth plates studied | # Histologic sections | Range of # of sections per growth plate | Growth plates studied | # Histologic sections | Range of # of sections per growth plate | |
| Humerus | 12 | 46 | (1–9) | 8 | 23 | (2–5) |
| Femur | 7 | 31 | (1–7) | 7 | 31 | (2–11) |
| Tibia | 7 | 40 | (2–12) | 9 | 30 | (2–6) |
| 26 | 117 | 24 | 87 |
| Homicides (per 100,000) | DALY (thousands) | ||
| World | 7.9 | 21,701,428 | |
| High income countries | 2.7 | 886,297 | |
| Low–middle income countries | Africa | 20.1 | 6,333,294 |
| The Americas | 24.1 | 6,024,751 | |
| Eastern Mediterranean | 3.9 | 1,346,008 | |
| Europe | 9.8 | 1,826,177 | |
| South-East Asia | 5.8 | 3,444,677 | |
| Western Pacific | 2.8 | 1,775,947 | |
| Guatemala (1) | 61.3 | 175 | |
| El Salvador (2) | 54.9 | 113 | |
| Côte d'Ivoire (3) | 52.5 | 324 | |
| Brazil (13) | 29.6 | 2488 | |
| South Africa (17) | 27.3 | 1006 | |
| Russian Federation (39) | 18.4 | 1276 | |
| Mexico (43) | 17.9 | 415 | |
| Indonesia (76) | 8.3 | 611 | |
| United States of America (93) | 6.2 | 599 | |
| India (102) | 4.4 | 1866 | |
| Pakistan (108) | 3.4 | 174 | |
| Turkey (113) | 2.8 | 67 | |
| China (142) | 1.6 | 993 | |
| Iran (150) | 1.4 | 89 | |
| France (152) | 1.4 | 17 | |
| United Kingdom (162) | 1.1 | 33 | |
| Italy (163) | 1.1 | 15 | |
| Germany (178) | 0.8 | 19 | |
| Egypt (185) | 0.6 | 27 | |
| Japan (189) | 0.5 | 21 |
| Gene | Fraction of est2∆ rad51∆ xxx∆ that are able to form survivors | Reference | |
| in BY4741 backgrounda | in W303 background | ||
| CCR4b | 0/10 (0%) | ||
| CDC55 | 0/12 (0%) | 2/9 (22%) | |
| CHK1 | 5/14 (36%) | 2/10 (20%) | |
| CLB2 | 2/14 (14%) | Grandin and Charbonneau 2003 | |
| DOA4 | 5/14 (36%) | 3/10 (30%) | |
| DUN1 | 2/12 (17%) | 1/25 (4%) | |
| LSM1 | 5/14 (36%) | 0/7 (0%) | |
| MOT2 | 0/10 (0%) | 1/4 (25%) | |
| NMD2 | 0/12 (0%) | Hu et al. 2013 | |
| PPH3 | 2/12 (17%) | 2/10 (20%) | |
| RAD50 | 2/10 (20%) | Chen et al. 2001 | |
| RAD52 | 0/11 (0%) | Lundblad and Blackburn 1993 | |
| RAD59 | 4/11 (36%) | Chen et al. 2001 | |
| RGI1 | 0/4 (0%) | 2/10 (20%) | |
| RMI1 | 1/7 (14%) | 0/10 (0%) | |
| RPL8B | 1/8 (13%) | 2/10 (20%) | |
| RPN4 | 1/9 (11%) | 3/10 (30%) | |
| RRM3 | 4/12 (33%) | 3/10 (30%) | |
| SGS1 | 0/11 (0%) | Huang et al. 2001; Johnson et al. 2001 | |
| SPT20 | 0/5 (0%) | 0/10 (0%) | |
| VMA22 | 1/10 (10%) | 3/10 (30%) | |
| YLR235C | 1/16 (6%) | 0/10 (0%) | |
| YLR358C | 1/5 (20%) | 4/9 (44%) |
| Parity | |||||||
| Measurements | 0 | 1 | 2 | 3 | 4 | 5 | 6 or later |
| Number of serviced records | 93,604 | 78,243 | 70,596 | 62,258 | 53,371 | 43,634 | 52,352 |
| Number of first return records | 11,458 | 8734 | 5625 | 4730 | 3772 | 2694 | 2614 |
| First return occurrences, % | 12.2 | 11.2 | 8.0 | 7.6 | 7.1 | 6.2 | 5.0 |
| Number of second return records | 2325 | 1324 | 834 | 695 | 490 | 297 | 290 |
| Number of culled records after the second returna | 246 | 142 | 87 | 105 | 68 | 55 | 49 |
| Number of removed records after the second returnb | 394 | 232 | 168 | 136 | 90 | 68 | 64 |
| Number of SRB femalesc | 532 | 235 | 145 | 104 | 70 | 34 | 38 |
| SRB risk for first-served females, % | 0.57 | 0.30 | 0.21 | 0.17 | 0.13 | 0.08 | 0.07 |
| Kidney cancer dataset | CANOVA | Kendall | Pearson | Spearman | Hoeffding | Distance | MIC |
| Significant gene number | 5901 | 11569 | 8239 | 11629 | 4953 | 10946 | 8081 |
| Computing time (seconds) | 24 | 65 | 32 | 32 | 44 | ~106 | 114 |
| Article | Number (M/F)1 | C/R/R-S2 | Age Mean ± SD3/Median (range) | ST4 | Cut-off | Rate(+)5 | Follow up Mean ± SD/Median (range) | OM6 | Surgery | MA7 |
| Sotelo 2014 [24] | 472(254/218) | 425/47/0 | Median:66(31–87) | Baseline | ≥1/7.5 ml | 166/472 | Median:40(NR8) | OS9; PFS10 | YES | NO |
| 472(254/218) | 425/47/0 | Median:66(31–87) | Baseline | ≥2/7.5 ml | 93/472 | Median:40(NR) | OS; PFS | YES | NO | |
| 472(254/218) | 425/47/0 | Median:66(31–87) | Baseline | ≥3/7.5 ml | 57/472 | Median:40(NR) | OS; PFS | YES | NO | |
| 472(254/218) | 425/47/0 | Median:66(31–87) | Baseline | ≥5/7.5 ml | 34/472 | Median:40(NR) | OS; PFS | YES | NO | |
| Seeberg 2014 [25] | 194(105/89) | 124/70 | Median:65(31–93) | Baseline | ≥1/7.5 ml | 37/189 | Median:22.5(1–61) | OS; PFS | 153YES | NO |
| 194(105/89) | 124/70 | Median:65(31–93) | Baseline | ≥2/7.5 ml | 26/189 | Median:22.5(1–61) | OS; PFS | 153YES | YES | |
| 194(105/89) | 124/70 | Median:65(31–93) | Baseline | ≥3/7.5 ml | 17/189 | Median:22.5(1–61) | OS; PFS | 153YES | NO | |
| Gazzaniga 2013 [26] | 119(68/51) | NR | Median:64(29–84) | Baseline | ≥1/7.5 ml | 44/119 | Median:12(1–26) | PFS | NR | YES |
| 119(68/51) | NR | Median:64(29–84) | Baseline | ≥3/7.5 ml | 24/119 | Median:12(1–26) | PFS | NR | YES | |
| Aggarwal 2013 [27] | Baseline:209(NR) | NR | Mean:63.0 ± 12.6 Median: 64 (22–92) | Baseline | ≥3/7.5 ml | 62/209 | median: NR(0.2-39.1) | OS | NR | YES |
| 3-5 W:115(NR) 6-12 W:134(NR) | NR | NR | During-treatment: 3-5 W,6-12 W11 | ≥3/7.5 ml | 3-5 W: 17/115; 6-12 W: 10/134 | NR | OS | NR | YES | |
| Kuboki 2013 [14] | 63(34/29) | 41/22/0 | Median: 61(33–81) | Baseline | ≥3/7.5 ml | 19/63 | Median:8.7(NR) | OS; PFS | NR | YES |
| Deneve 2013 [13] | 69(43/26) | 66/8/1 | Median: 75(38–95) | Baseline | ≥1/7.5 ml | 20/69 | Mean:31 ± NR Median:36 (0–52) | NR | YES | NO |
| Sastre 2012 [28] | Baseline:180(118/62) | 40/121/19 | Median: 65(40–82) | Baseline | ≥3/7.5 ml | 85/180 | NR | OS; PFS | 123YES | YES |
| Cycle3:147(NR) | NR | NR | Cycle3 | ≥3/7.5 ml | 23/147 | NR | OS; PFS | 123YES | NO | |
| Sato 2012 [29] | 25(NR) | NR | NR | Baseline | ≥3/7.5 ml | 14/25 | NR | OS | M1:NO12 | NO |
| 25(NR) | NR | NR | Baseline | ≥1/7.5 ml | 18/25 | NR | OS | M1:NO | NO | |
| Papavasiliou 2010 [30] | 20(13/7) | NR | Median: 54 (41–81) | Baseline During-treatment | ≥3/7.5 ml | Pre:2/20 intra: 10/20; post: 1/18 | Median:11.5 (5–25) | OS; PFS | YES | NO |
| Tol 2010 [31] | 467 (284/183) | 225/122/ 120 | Median: 63(27–83) | Baseline | ≥3/7.5 ml | Baseline: 129/451 | Median: 16.8(NR) | OS; PFS | NR | YES |
| 1-2 W: 368(NR) 3-5 W:320(NR) 6-12 W:336(NR) 13-20 W: 254(NR) | NR | Median: 63(27–83) | During-treatment: 1-2/3-5/6-12/13-20 W | ≥3/7.5 ml | 1-2 W: 21/368; 3-5 W: 17/320; 6-12 W: 18/336; 13-20 W: 16/254 | NR | OS; PFS | NR | YES | |
| Hiraiwa 2008 [15] | 40(NR) | NR | NR | Baseline + During-treatment | ≥2/7.5 ml | 14/40 | NR | OS | YES | YES |
| Biomolecule | Molecular weight (kDa) | Isoelectric point | Charge | Hydrodynamic radius (Å) | Amount (μg) |
| AcSDKP peptide | 0.4 | 5.5 | Negative | 7a | 1000 |
| Insulin | 5.73 | 5.3 | Negative | 13 | 111 |
| PEG-QK | 11.27 | 9.4 | Positive | 36.9a,b,c | 27 |
| Lysozyme | 14.3 | 11.35 | Positive | 19.1 | 1200 (transwell) 350 (release) |
| VEGF | 45.5 | 9.22 | Positive | 30.2 | 7.5 |
| BSA | 66.4 | 4.7 | Negative | 36.3 | 1200 |
| Delivery system | Diameter (mm) | Headspace (ml) | Milk-to-air interface (cm2) |
| Gerber (G) | 52 | 176 | 21.23 |
| Ventaire (V) | 54 | 183 | 22.89 |
| Dr. Brown's (DB) | 50 | 66* | 19.63 |
| Elan (EL) | 67 | 180 | 35.24* |
| BornFree (BF) | 65 | 127* | 33.17* |
| Playtex Drop-Ins (PD) | 56 | 158 | 24.62* |
| Avent Natural (AN) | 66 | 205 | 34.19* |
| Control | 52 | 74* | 20.42 |
| Medium scale construction sites | |||
| Site | Total (max. = 120) | Mean | Correlation coefficient |
| 1 | 58 | 4.83 | 0.56 |
| 2 | 48 | 4.00 | −0.22 |
| 3 | 50 | 4.17 | −0.14 |
| 4 | 47 | 3.92 | −0.59 |
| 5 | 51 | 4.25 | 0.33 |
| 6 | 52 | 4.33 | −0.06 |
| 7 | 53 | 4.42 | 0.03 |
| 8 | 41 | 3.42 | 0.69 |
| 9 | 43 | 3.58 | −0.09 |
| 10 | 51 | 4.25 | 0.00 |
| 11 | 53 | 4.42 | −0.39 |
| 12 | 50 | 4.17 | −0.33 |
| 13 | 51 | 4.25 | 0.05 |
| 14 | 53 | 4.42 | −0.60 |
| 15 | 60 | 5.00 | −0.24 |
| 16 | 55 | 4.58 | 0.18 |
| 17 | 49 | 4.08 | −0.74 |
| 18 | 47 | 3.92 | −0.47 |
| 19 | 51 | 4.25 | −0.13 |
| 20 | 50 | 4.17 | 0.19 |
| 21 | 68 | 5.67 | −0.06 |
| 22 | 54 | 4.50 | −0.35 |
| 23 | 54 | 4.50 | −0.45 |
| 24 | 52 | 4.33 | 0.56 |
| 25 | 54 | 4.50 | −0.37 |
| 26 | 59 | 4.92 | −0.26 |
| 27 | 51 | 4.25 | −0.19 |
| 28 | 57 | 4.75 | 0.42 |
| Dataset | Nematode hits | Trematode hits | Cestode hits |
| C. elegans proteins (Wormpep) | 8457 | 345 | 280 |
| S. mansoni proteins | 3440 | 598 | 419 |
| Human proteins | 4539 | 408 | 326 |
| NR protein database | 10116 | 652 | 497 |
| S. japonicum proteins | 3456 | 612 | 416 |
| Variables | Frequency | Percent | |
| Abdomen palpated to rule out the presence of second baby | Yes | 331 | 62.7 |
| No | 197 | 37.3 | |
| Uterotonic drugs given | Oxytocin | 432 | 81.8 |
| Ergometrine | 61 | 11.6 | |
| Misoprostol | 30 | 5.7 | |
| Not given | 5 | 0.9 | |
| Dose of uterotonic drugs given | 0.5 mg | 24 | 4.5 |
| 10 IU | 486 | 96.6 | |
| 0.5 mg | 12 | 2.3 | |
| Others | 6 | 1.1 | |
| Route of uterotonic drugs given | IM | 519 | 97.2 |
| IV | 9 | 1.7 | |
| Oral | 6 | 1.1 | |
| Wait uterine contraction 2–3 min to apply CCT | Yes | 243 | 46 |
| No | 285 | 54 | |
| Wait gush of blood | Yes | 283 | 53.6 |
| No | 245 | 46.4 | |
| Counter cord traction applied | Yes | 472 | 89.4 |
| No | 56 | 10.6 | |
| Placenta supported by two hands during placenta delivery | Yes | 421 | 79.7 |
| No | 107 | 20.3 | |
| Membrane extracted gently with lateral movement | Yes | 293 | 55.5 |
| No | 235 | 44.5 | |
| Uterine massage immediately after delivery of placenta | Yes | 227 | 43 |
| No | 301 | 57 | |
| Uterine relaxation ensured | Yes | 161 | 30.5 |
| No | 367 | 69.5 | |
| Inform and demonstrate the mother massage uterus | Yes | 196 | 37.1 |
| No | 332 | 62.9 | |
| Skill | Skilled | 173 | 32.8 |
| Not skilled | 355 | 67.2 |
| Cutoff | Results | African populationN (%) | Caucasian populationN (%) | p |
| AR ≥ 1% | Negative | 22 (33.8) | 22 (16.9) | |
| Positive | 43 (66.2) | 108 (83.1) | 0.008 | |
| AR ≥ 10% | Negative | 25 (38.5) | 27 (20.8) | |
| Positive | 40 (61.5) | 103 (79.2) | 0.009 |
| Species | Title of publication | cDNAs used for reprogramming | Origin of cDNAs |
| Rhesus macaque (Macaca mulatta) | Generation of induced pluripotent stem cells from adult rhesus monkey fibroblasts [24] | POU5F1, SOX2 KLF4 and MYC | Rhesus |
| Common marmoset (Callithrix jacchus) | Generation of induced pluripotent stem cells from newborn marmoset skin fibroblasts [25] | POU5F1, SOX2 KLF4 and MYC | Human |
| Common marmoset (Callithrix jacchus) | Generating induced pluripotent stem cells from common marmoset (Callithrix jacchus) fetal liver cells using defined factors, including Lin28 [26] | POU5F1, SOX2, KLF4, MYC, NANOG and LIN28 | Human |
| Rhesus macaque (Macaca mulatta) | Reprogramming Huntington monkey skin cells into pluripotent stem cells [27] | POU5F1, SOX2 and KLF4 | Rhesus |
| Pigtailed macaque (Macaca nemestrina) | Efficient generation of nonhuman primate induced pluripotent stem cells [28] | POU5F1, SOX2 KLF4 and MYC | Human |
| Cynomolgus monkey (Macaca fascicularis) | Development of histocompatible primate induced pluripotent stem cells for neural transplantation [29] | POU5F1, SOX2 KLF4 and MYC | Human |
| Rhesus macaque (Macaca mulatta) | Generation of pancreatic insulin-producing cells from rhesus monkey induced pluripotent stem cells [30] | POU5F1, SOX2 KLF4 and MYC | Rhesus |
| Pigtailed macaque (Macaca nemestrina) | Safeguarding nonhuman primate iPS cells with suicide genes [31] | POU5F1, SOX2 KLF4 and MYC | Human |
| Drill (Mandrillus leucophaeus) | Induced pluripotent stem cells from highly endangered species [32] | POU5F1, SOX2 KLF4 and MYC | Human |
| Cynomolgus monkey (Macaca fascicularis) | Induction of retinal pigment epithelial cells from monkey iPS cells [33] | POU5F1, SOX2 KLF4 and MYC | Human |
| Age | Sex | Cause of death |
| 60 | F | Hemorrhagic stroke |
| 56 | F | Hemorrhagic stroke |
| 25 | M | Traumatic brain injury |
| 40 | F | Hemorrhagic stroke |
| 50 | F | Hemorrhagic stroke |
| 28 | M | Traumatic brain injury |
| 43 | F | Traumatic brain injury |
| 20 | M | Traumatic brain injury |
| 58 | F | Hemorrhagic stroke |
| 20 | M | Hypoxic brain injury |
| 19 | M | Traumatic brain injury |
| 19 | M | Traumatic brain injury |
| 35 | M | Hemorrhagic stroke |
| 49 | M | Hemorrhagic stroke |
| 55 | F | Hemorrhagic stroke |
| 33 | M | Traumatic brain injury |
| 27 | M | Traumatic brain injury |
| 18 | M | Traumatic brain injury |
| 23 | M | Traumatic brain injury |
| 52 | M | Hemorrhagic stroke |
| 56 | M | Hemorrhagic stroke |
| 45 | F | Hemorrhagic stroke |
| 55 | F | Hemorrhagic stroke |
| Respimat® 5 μg | HandiHaler® 18 μg | Placebo | |
| Average heart rate (BPM), mean ± SD (min–max) | |||
| Study 205.284 | |||
| Baseline | – | 79.89 ± 10.88 (59–108) | 81.35 ± 9.14 (52–97) |
| Day 84 | – | 80.19 ± 9.78 (61–103) | 81.12 ± 12.36 (54–140) |
| Studies 205.254/255 | |||
| Baseline | 77.64 ± 10.05 (50–100) | – | 79.26 ± 11.56 (55–136) |
| Day 281 | 77.23 ± 9.68 (56–99) | – | 77.62 ± 11.21 (53–111) |
| Study 205.458 | |||
| Day 26 | 75.36 ± 10.77 (51–108) | 75.83 ± 10.35 (58–100) | 75.91 ± 10.91 (56–106) |
| Day 29 | 76.87 ± 10.82 (54–104) | 77.39 ± 10.44 (55–104) | 77.02 ± 10.36 (59–103) |
| Pauses, n/N (%) | |||
| Study 205.284 | |||
| Baseline | – | 2/74 (2.7) | 1/65 (1.5) |
| Day 84 | – | 3/86 (3.5) | 0 |
| Studies 205.254/255 | |||
| Baseline | 2/121 (1.7) | – | 3/109 (2.8) |
| Day 281 | 1/103 (1.0) | – | 2/73 (2.7) |
| Study 205.458 | |||
| Day 26 | 0 | 1/113 (0.9) | 0 |
| Day 29 | 0 | 0 | 0 |
| VPB singles, n/N (%) | |||
| Study 205.284 | |||
| Baseline | – | 61/74 (82.4) | 54/65 (83.1) |
| Day 84 | – | 71/86 (82.6) | 58/78 (74.4) |
| Studies 205.254/255 | |||
| Baseline | 112/121 (92.6) | – | 95/109 (87.2) |
| Day 281 | 86/103 (83.5) | – | 66/73 (90.4) |
| Study 205.458 | |||
| Day 26 | 90/112 (80.4) | 88/113 (77.9) | 93/117 (79.5) |
| Day 29 | 94/116 (81.0) | 96/114 (84.2) | 91/116 (78.4) |
| SVPB singles, n/N (%) | |||
| Study 205.284 | |||
| Baseline | – | 66/74 (89.2) | 60/65 (92.3) |
| Day 84 | – | 82/86 (95.3) | 74/78 (94.9) |
| Studies 205.254/255 | |||
| Baseline | 113/121 (93.4) | – | 101/109 (92.7) |
| Day 281 | 96/103 (93.2) | – | 68/73 (93.2) |
| Study 205.458 | |||
| Day 26 | 100/112 (89.3) | 105/113 (92.9) | 111/117 (94.9) |
| Day 29 | 108/116 (93.1) | 107/114 (93.9) | 109/116 (94.0) |
| Predictor | B | SE | t |
| MEDIATOR—PERCEPTIONS OF INJUSTICE | |||
| Control: Negative affectivity | 0.13 | 0.02 | 8.27*** |
| Predictor: Observed incivility toward women | 0.61 | 0.04 | 17.51*** |
| Moderator: Observer gender | 0.02 | 0.02 | 1.04 |
| Interaction: Observed Incivility × Observer Gender | 0.09 | 0.04 | 2.50* |
| OUTCOME—PERCEPTIONS OF SAFETY | |||
| Control: Negative affectivity | −0.19 | 0.03 | −6.25*** |
| Mediator: Perceptions of injustice | −0.14 | 0.05 | −2.68** |
| Predictor: Observed incivility toward women | −0.07 | 0.07 | 0.85 |
| Moderator: Observer gender | 0.54 | 0.03 | 16.58*** |
| Interaction: Observed incivility × Observer gender | 0.13 | 0.07 | 1.94† |
| Direct and indirect effects | B | SE | 95% CI |
| CONDITIONAL DIRECT EFFECTS ON PERCEPTIONS OF SAFETY | |||
| Men | −0.07 | 0.11 | −0.15, 0.28 |
| Women | −0.19* | 0.08 | −0.36, −0.02 |
| CONDITIONAL INDIRECT EFFECTS ON PERCEPTIONS OF SAFETY | |||
| (THROUGH PERCEPTIONS OF INJUSTICE) | |||
| Men | −0.10 | 0.04 | −0.14, −0.00 |
| Women | −0.07 | 0.03 | −0.18, −0.00 |
| Index of moderated mediation | −0.02 | 0.02 | −0.07, −0.00 |
| Rat strains | WKY | SHR | SHRSP5/Dmcr | |||
| Control | HFC | Control | HFC | Control | HFC | |
| Body weight (g) | 365 ± 22.6 | 331 ± 7.8 a | 339 ± 14.5 | 301 ± 10.8 a | 283 ± 16.4 | 260 ± 9.1 a |
| Liver weight (g) | 9.1 ± 0.6 | 23.2 ± 1.4 a (2.5) | 9.8 ± 0.4 | 28.5 ± 2.5 a (2.9) b | 8.0 ± 0.4 | 27.4 ± 1.8 a (3.4) b,d |
| Liver/body weight(%) | 2.5 ± 0.1 | 7.0 ± 0.3 a (2.8) | 2.9 ± 0.0 c | 9.5 ± 0.8 a (3.3) b | 2.8 ± 0.1 c | 10.6 ± 0.8 a (3.7) b,d |
| Serum | ||||||
| TG (mg/dL) | 12.3 ± 1.9 | 12.2 ± 2.6(1.0) | 17.7 ± 3.3 c | 17.0 ± 2.8(1.0) | 25.5 ± 4.1 c | 17.7 ± 4.6 a (0.7) b,d |
| TC (mg/dL) | 103 ± 7.8 | 140.3 ± 17.4 a (1.4) | 61.3 ± 5.4 c | 134 ± 19.6 a (2.2) | 53.5 ± 2.6 c | 149.2 ± 50.1 a (2.8) b |
| AST (IU/L) | 168.7 ± 47.6 | 424 ± 94.5 a (2.5) | 245.7 ± 49.1 c | 479.2 ± 93.9 a (2.0) | 177.8 ± 30.6 e | 633.8 ± 81.8 a (3.7) b,d |
| ALT (IU/L) | 33.8 ± 1.7 | 134.2 ± 50.0 a (4.0) | 51.7 ± 6.3 c | 205.7 ± 47.5 a (4.0) | 61 ± 11.0 c | 318.5 ± 55.0 a (5.2) |
| GGT (IU/L) | 1.5 | 1.8 ± 0.6(1.2) | 1.5 | 3.6 ± 1.6 a (2.4) | 1.5 | 4.8 ± 1.0 a (3.2) |
| Liver | ||||||
| TG (mg/dL) | 23.9 ± 3.1 | 64.6 ± 9.4 a (2.7) | 29.6 ± 7.1 | 63.6 ± 8.0 a (2.1) | 26.8 ± 7.3 | 68.6 ± 15.8 a (2.6) |
| TC (mg/dL) | 3.4 ± 0.4 | 176.2 ± 9.1 a (51.8) | 3.9 ± 0.6 | 167 ± 10.7 a (42.8) b | 3.5 ± 1.0 | 150.9 ± 15.4 a (43.1) b |
| Source | Patients | Inclusion criteria | Antioxidant agent | Dose | Route | Endpoints | Followup | Events |
| CHAOS [106] | 2002 | Angiographically demonstrated CAD | Vit E | 400/800 IU | PO | CV death + MI; nonfatal MI | 510 d | CV death: 27 vit E, 23 pl; nonfatal MI: 14 vit E, 41 pl |
| WHS [107] | 39876 | Healthy women | Vit E | 600 IU q48 h | PO | Composite endpoint (CV death, MI, and stroke) | 10.1 y | CV events: Vit E 482, pl 517; CV death: Vit E 106, pl 140; MI: Vit E 196, pl 195 |
| SPACE [108] | 196 | Hemodialysis CV disease pts | Vit E | 800 IU | PO | Composite endpoint (MI, ACS, PAD, and stroke) | 519 d | Composite endpoint: Vit E 15, pl 33;CV death: vit E 9, pl 15; nonfatal MI: vit E 8, pl 18 |
| Tepel et al. [109] | 134 | Hemodialysis CV disease pts | Acetylcysteine | 1200 mg | PO | Composite endpoint (CV death, MI, PTCA/CABG, PAD, and stroke) | 14.5 m | Composite endpoint: acetylcysteine 18, pl 33 |
| Milman et al. [110] | 1434 | Diabetes mellitus Hp 2-2 genotype | Vit E | 400 IU | PO | Composite endpoint (CV death, MI, and stroke) | 18 m | Composite endpoint: Vit E 16, pl 33 |
| Language version ofsurvey | Responses |
| English | 17785 |
| Spanish | 1052 |
| French | 955 |
| Russian | 330 |
| Chinese | 265 |
| Japanese | 258 |
| Arabic | 18 |
| Total | 20663 |
| Correlation coefficient (r) | P value | |
| Tissue estriol-tissue OxLDL | 0.36 | 0.004 |
| Tissue estriol-GW | 0.25 | >0.05 |
| Tissue OxLDL-GW | 0.04 | >0.05 |
| Tissue estriol-infant's birth weight | 0.39 | 0.002 |
| Tissue estriol-systolic BP | −0.44 | 0.001 |
| Tissue estriol-diastolic BP | −0.48 | 0.001 |
| Strain No. | SGSC No. | PCR results |
| RKS4587 | 2289 | - |
| RKS4620 | 2291 | - |
| 33K | 2419 | - |
| CN13/87 | 2712 | - |
| RKS4585 | 2998 | + |
| RKS4586 | 2999 | + |
| RKS4588 | 3000 | - |
| RKS4589 | 3001 | + |
| RKS4590 | 3002 | + |
| RKS4591 | 3003 | + |
| RKS4592 | 3004 | + |
| RKS4593 | 3005 | - |
| RKS4595 | 3006 | + |
| RKS4596 | 3007 | - |
| Variable | N | Median | Mean | SD |
| Programs offering residential treatment* | ||||
| Average daily client census | 49 | 26.0 | 43.4 | 59.0 |
| Client occupancy ratio (%)† | 49 | 87.7 | 86.2 | 0.1 |
| Average length of stay (days) | 47 | 96.0 | 118.8 | 92.8 |
| Daily residential reimbursement ($) | 38 | 183.00 | 200.92 | 99.72 |
| Quality Score# | 78 | 15.0 | 14.6 | 1.6 |
| Programs offering outpatient treatment* | ||||
| Average daily client census | 59 | 20.0 | 39.7 | 57.1 |
| Client occupancy ratio (%)† | 47 | 50.0 | 55.9 | 0.3 |
| Average treatment duration (days) | 47 | 120.0 | 131.7 | 92.8 |
| Daily outpatient reimbursement ($) | 26 | 50.50 | 55.73 | 26.47 |
| Quality Score# | 93 | 15.0 | 14.3 | 1.9 |
| Subject No.a | Sex (age)c | CD4 Count (cells/μl) | CD8 Count (cells/μl) | Plasma Viral Load (copies/ml) | HCVb | HBVb | HIV Subtype |
| 1 | M(42) | 332 | 1326 | 18800 | P | P | CRF07-BC |
| 2 | F(38) | 412 | 1373 | 92300 | N | N | CRF01-AE |
| 3 | M(45) | 368 | 463 | 71000 | P | N | B |
| 4 | M(22) | 484 | 1333 | 60100 | N | N | B |
| 5 | M(40) | 364 | 842 | 3200 | N | N | CRF01-AE |
| 6 | M(46) | 265 | 421 | 140000 | N | N | CRF01-AE |
| 7 | M(33) | 328 | 485 | 63000 | N | N | CRF01-AE |
| 8 | F(45) | 480 | 737 | < 10 | P | N | B' |
| 9 | F(45) | 359 | 1064 | 3600 | N | P | B' |
| 10 | M(32) | 276 | 869 | 830000 | P | P | B' |
| COX4 Expression | Hsp60 Expression | Total, N | |||
| - | + | ++ | +++ | ||
| - | 11 | 15 | 5 | 0 | 31 |
| + | 8 | 36 | 29 | 37 | 110 |
| ++ | 4 | 17 | 12 | 31 | 64 |
| +++ | 3 | 15 | 11 | 41 | 70 |
| Total, N | 26 | 83 | 57 | 109 | 275 |
| Name | Fold Change (T/N) | log2Fold Change(T/N) | P Value | FDR |
| hsa-mir-210 | 31.74 | 4.99 | 2.54E-05 | 0.004 |
| hsa-mir-183 | 7.22 | 2.85 | 6.03E-05 | 0.007 |
| hsa-mir-10b | 0.34 | −1.55 | 0.00037 | 0.026 |
| hsa-mir-100 | 0.25 | −2.02 | 1.47E-05 | 0.003 |
| hsa-mir-30a | 0.24 | −2.08 | 6.49E-09 | 0.000 |
| hsa-mir-145 | 0.20 | −2.31 | 3.6E-06 | 0.001 |
| hsa-let-7c | 0.17 | −2.53 | 7.75E-06 | 0.002 |
| hsa-mir-383 | 0.09 | −3.45 | 8.97E-05 | 0.008 |
| hsa-mir-133a | 0.08 | −3.72 | 0.000229 | 0.018 |
| hsa-mir-143 | 0.07 | −3.90 | 7.27E-05 | 0.007 |
| hsa-mir-1-2 | 0.06 | −4.01 | 4.55E-05 | 0.006 |
| MMCO Metrics | Metrics Detail | MMCO V2.0 (Existing Work) [6] | MMCO V3.0 (Extended Work) |
| Metrics | Axioms | 793 | 1092 |
| Logical Axioms | 624 | 859 | |
| Class count | 45 | 225 | |
| Object Property count | 3 | 25 | |
| Individual count | 114 | 157 | |
| DL Expressivity | ALCO | ALCHOF(D) | |
| Asserted Triples | 0 | 3312 | |
| Inferred Triples | 0 | 6041 | |
| Class Axioms | SubClassOf | 32 | 222 |
| Equivalent Classes | 9 | 17 | |
| Disjoint Classes | 5 | 14 | |
| Individual Axioms | Class Assertion | 360 | 58 |
| Object Property Assertion | 212 | 27 | |
| Data Property Assertion | 0 | 1 |
| Variables | Pretraining | Posttraining | t | p |
| Basic rhythm (left) | 74.23 ± 6.84 | 75.07 ± 9.04 | −0.189 | 0.856 |
| Basic rhythm (right) | 75.40 ± 9.70 | 72.85 ± 10.20 | 0.363 | 0.729 |
| Self-control index | 48.47 ± 14.28 | 51.93 ± 13.50 | −0.393 | 0.708 |
| Attention index (left) | 66.67 ± 9.54 | 64.07 ± 8.35 | 0.449 | 0.669 |
| Attention index (right) | 64.18 ± 12.60 | 65.97 ± 9.23 | −0.347 | 0.741 |
| Activation index (left) | 76.11 ± 9.56 | 71.82 ± 14.88 | 0.509 | 0.629 |
| Activation index (right) | 77.44 ± 13.87 | 74.06 ± 12.39 | 0.374 | 0.721 |
| Emotion index | 83.82 ± 2.45 | 82.68 ± 3.45 | 0.883 | 0.411 |
| Anti-stress index (left) | 75.27 ± 9.28 | 75.36 ± 17.38 | −0.012 | 0.991 |
| Anti-stress index (right) | 74.44 ± 9.25 | 74.71 ± 15.86 | −0.045 | 0.965 |
| Left and right brain balance index | 77.04 ± 9.48 | 78.54 ± 11.14 | −0.348 | 0.740 |
| Brain index | 72.10 ± 5.12 | 71.55 ± 5.67 | 0.162 | 0.877 |
| Canagliflozin (300 mg q.d.) and cyclosporine A (400 mg q.d.) | |||||
| Parameter | Arithmetic mean (SD) | Geometric meana | |||
| Canagliflozin alone (n = 18) | Canagliflozin + cyclosporine A (n = 17) | Canagliflozin alone (reference) (n = 17) | Canagliflozin + cyclosporine A (test) (n = 17) | Estimated ratio (test/reference), % (90% CI) | |
| Cmax.ss (ng/mL) | 2,887 (735) | 2,923 (467) | 2,864.03 | 2,887.13 | 100.81 (91.31; 111.30) |
| AUCτ.ss (ng×h/mL) | 22,158 (4203) | 27,819 (5267) | 22,243.50 | 27,355.78 | 122.98 (118.66; 127.46) |
| tmax.ss (h)b | 2.00 (1.00 – 3.00) | 4.00 (1.50 – 6.00) | – | – | – |
| Collection Season | District | |||
| Pampulha | North | East | All districts | |
| IF/CF (IR%) | IF/CF (IR%) | IF/CF (IR%) | IF/CF (IR%) | |
| 1st | 14/67 (20.8) | 9/22 (40.9) | 3/28 (10.7) | 26/117 (22.2) |
| 2nd | 15/17 (88.2) | 11/13 (84.6) | 11/14 (78.5) | 37/44 (84.0) |
| 3rd | 3/89 (3.3) | 4/49 (8.1) | 4/61 (6.5) | 11/199 (5.5) |
| 4th | 1/61 (1.6) | 0/15 (0.0) | 4/75 (5.3) | 5/151 (3.3) |
| Total | 33/234 (14.1) | 24/99 (24.2) | 22/178 (12.3) | 79/511 (15.4) |
| Variables | Diarrhoea | Fever | Cough | |||
| COR | AOR | COR | AOR | COR | AOR | |
| Toilet facilities (yes) | ||||||
| No | 1.104 (0.950–1.283) | 0.972 (0.841–1.124) | 1.054 (0.456–2.438) | 1.029 (0.480–2.203) | 1.240 (0.629–2.443) | 1.149 (0.627–2.107) |
| Water facilities (yes) | ||||||
| No | 1.179(1.010–1.376) | 1.602(1.217–2.343) | 1.428 (0.616–3.311) | 2.193(1.544–4.618) | 1.310 (0.721–2.379) | 1.059 (0.924–1.214) |
| Child’s excretaDisposal facilities (yes) | ||||||
| No | 0.927 (0.804–1.069) | 1.172(1.022–1.344) | 1.013 (0.442–2.325) | 1.393(1.041–3.028) | 1.388 (0.771–2.498) | 1.245 (0.673–2.303) |
| Toilet + water + disposal facilities (yes) | ||||||
| No | 1.137 (0.968–1.336) | 1.329(1.046–1.947) | 1.180 (0.568–2.449) | 1.242(1.050–1.468) | 1.220(1.050–1.418) | 1.432(1.113–2.902) |
| Factor | HR | 95 % confidence interval | P value |
| Acute kidney injury 3 | 7.35 | 2.15–25.07 | 0.001 |
| Peripheral vascular disease | 1.95 | 1.12–3.39 | 0.019 |
| Chronic renal failure | 1.59 | 0.96–2.62 | 0.07 |
| Diabetes mellitus | 0.83 | 0.49–1.40 | 0.48 |
| Female gender | 0.47 | 0.28–0.80 | 0.005 |
| MIC (μg/mL) | ||
| Formulation | MS-Lac | Estimated Gentamicin in Microspheres * |
| MS-Lac1 | 2.16 | 0.31 |
| MS-Lac2 | 2.92 | 0.31 |
| MS-Lac3 | 4.00 | 0.31 |
| Variable | Adjusted PR (95%CI) | p-valuea |
| Housing area | ||
| Urban | 1 | |
| Rural | 1.15 (1.0-1.3) | 0.030 |
| School type | ||
| Municipal | 3.30 (1.1-9.4) | 0.026 |
| State | 3.40 (1.1-9.6) | 0.022 |
| Particular | 1 | |
| School education of mother | ||
| Illiterate or up to the 4th grade | 1.67 (1.1-2.4) | 0.005 |
| High school | 1.54 (1.0-2.2) | 0.023 |
| Completed college | 1 | |
| Flossing | ||
| Yes/daily | 0.97 (0.8-1.1) | 0.703 |
| Sometimes | 0.80 (0.7-0.9) | 0.003 |
| Never | 1 |
| Clinicopathological parameters | Relative risk ( 95%CI) | p value |
| Age(≥65years) | 0.884(0.561-1.395) | 0.597 |
| Sex(Female) | 0.817(0.520-1.283) | 0.380 |
| Depth of invasion (T2-4) | 5.873(2.058-16.762) | 0.001 |
| Lymphatic invasion(+) | 1.269(0.756-2.129) | 0.367 |
| Venous invasion(+) | 1.088(0.646-1.830) | 0.752 |
| Lymph node metastasis(+) | 1.638(0.482-5.568) | 0.429 |
| Liver metastasis | 0.357(0.071-1.793) | 0.211 |
| Distant metastasis | 11.330(2.466-52.057) | 0.002 |
| TNM staging(I-II) | 1.746(0.453-6.729) | 0.418 |
| Differentiation (moderately and poorly) | 1.131(0.792-1.616) | 0.497 |
| BTG3 expression (++~+++) | 1.227(0.775-1.942) | 0.384 |
| Variable | Patients (%) |
| Gender | |
| Male | 74 (71.8) |
| Female | 29 (28.2) |
| Age (y) | |
| Mean | 58.3 |
| Range | 26–75 |
| Tumor location | |
| EGJ | 41 (39.8) |
| Body | 27 (26.2) |
| Antrum | 35 (34.0) |
| Treatment | |
| FOLFOX | 19 (18.5) |
| SOX | 46 (44.7) |
| XELOX | 24 (23.3) |
| XP | 6 (5.8) |
| Other | 8 (7.7) |
| Clinical tumor stage | |
| II | 33 (32.0) |
| III | 70 (68.0) |
| Tumor regression grade (TRG) | |
| 1a | 8 (7.8) |
| 1b | 9 (8.7) |
| 2 | 23 (22.3) |
| 3 | 63 (61.2) |
| Patients | n = 3191 |
| Age, years | 70 ± 10 |
| ≤65 years, % | 30 |
| 66-79 years, % | 54 |
| ≥80 years, % | 16 |
| Gender, male vs. female, % | 43 vs. 57 |
| BMI, kg/m2 | 23 ± 3 |
| SBP at entry, mmHg | 147 ± 17 |
| Uncontrolled SBP (≥140 mmHg) at entry, % | 66 |
| DBP at entry, mmHg | 83 ± 11 |
| Uncontrolled DBP (≥90 mmHg) at entry, % | 37 |
| Uncontrolled SBP and/or uncontrolled DBP at entry, % | 68 |
| Diabetes, % | 32 |
| Smoking, % | 12 |
| Drinking, % | 14 |
| Progression-free survival | Overall survival | |
| AUC (95% CIs) | 0.71 (0.57–0.83) | 0.65 (0.50–0.78) |
| Criterion (cut-off) | ≥19% | ≥13% |
| Sensitivity | 73% | 58% |
| Specificity | 77% | 70% |
| p value | 0.0054 | 0.057 |
| Run | Parameters | HPR (ml H2/L h) | ||||||
| Initial pH (X1) | Light intensity (X2) | Mo concentration (X3) | Observed | Predicted | ||||
| Code | Actual | Code | Actual (klux) | Code | Actual (mg/L) | |||
| 1 | 0.00 | 8.00 | 0.00 | 8.00 | 0.00 | 0.30 | 8.9 ± 0.4 | 8.8 |
| 2 | −1.00 | 7.00 | 1.00 | 10.00 | 1.00 | 0.50 | 7.4 ± 0.6 | 7.3 |
| 3 | 0.00 | 8.00 | 0.00 | 8.00 | 0.00 | 0.30 | 8.8 ± 0.2 | 8.8 |
| 4 | −1.68 | 6.32 | 0.00 | 8.00 | 0.00 | 0.30 | 5.6 ± 0.5 | 5.7 |
| 5 | 0.00 | 8.00 | 1.68 | 11.36 | 0.00 | 0.30 | 7.5 ± 0.1 | 7.7 |
| 6 | 0.00 | 8.00 | −1.68 | 4.64 | 0.00 | 0.30 | 5.8 ± 0.4 | 6.5 |
| 7 | 0.00 | 8.00 | 0.00 | 8.00 | 0.00 | 0.30 | 8.8 ± 0.3 | 8.8 |
| 8 | 1.00 | 9.00 | −1.00 | 6.00 | −1.00 | 0.10 | 6.2 ± 0.2 | 5.7 |
| 9 | 0.00 | 8.00 | 0.00 | 8.00 | 0.00 | 0.30 | 9.0 ± 0.6 | 8.8 |
| 10 | 0.00 | 8.00 | 0.00 | 8.00 | 0.00 | 0.30 | 9.1 ± 0.4 | 8.8 |
| 11 | 1.00 | 9.00 | −1.00 | 6.00 | 0.20 | 0.50 | 6.6 ± 0.1 | 6.0 |
| 12 | 1.00 | 9.00 | 1.00 | 10.00 | −1.00 | 0.10 | 6.8 ± 0.4 | 6.5 |
| 13 | 0.00 | 8.00 | 0.00 | 8.00 | 0.00 | 0.30 | 8.5 ± 0.4 | 8.8 |
| 14 | −1.00 | 7.00 | 1.00 | 10.00 | −1.00 | 0.10 | 7.3 ± 0.5 | 7.3 |
| 15 | −1.00 | 7.00 | −1.00 | 6.00 | −1.00 | 0.10 | 6.7 ± 0.4 | 6.5 |
| 16 | −1.00 | 7.00 | −1.00 | 6.00 | 1.00 | 0.50 | 7.0 ± 0.2 | 6.7 |
| 17 | 1.00 | 9.00 | 1.00 | 10.00 | 1.00 | 0.50 | 7.0 ± 0.4 | 6.5 |
| 18 | 0.00 | 8.00 | 0.00 | 8.00 | 1.68 | 0.64 | 7.5 ± 0.4 | 8.0 |
| 19 | 1.68 | 9.68 | 0.00 | 8.00 | 0.00 | 0.30 | 3.5 ± 0.2 | 4.3 |
| 20 | 0.00 | 8.00 | 0.00 | 8.00 | −1.68 | −0.04 | 7.4 ± 0.0 | 7.8 |
| Patient characteristics | Value |
| Age (years), median (IQR) | 38.0 (29.0–43.0) |
| Sex, n (%) | |
| Female | 13 (68.4) |
| Male | 6 (31.6) |
| Race, n (%) | |
| White | 19 (100) |
| Main comorbidities, n (%)a | |
| Hypertension | 3 (15.8) |
| Asthma | 2 (10.5) |
| Hypercholesterolaemia | 2 (10.5) |
| Major features for TSC diagnosis, n (%)a | |
| Renal AML | 19 (100) |
| Facial angiofibromas/forehead plaque | 15 (79.0) |
| Cortical tuber | 10 (52.6) |
| Hypomelanotic macules (≥3) | 7 (36.8) |
| Subependymal nodule | 7 (36.8) |
| Non-traumatic ungual/periungual fibroma | 4 (21.1) |
| Single/multiple cardiac rhabdomyoma | 4 (21.1) |
| Lymphangiomyomatosis | 3 (15.8) |
| Connective tissue nevus | 2 (10.5) |
| Minor features for TSC diagnosis, n (%)a | |
| Multiple renal cysts | 11 (57.9) |
| Multiple randomly distributed pits in dental enamel | 3 (15.8) |
| Bone cysts | 3 (15.8) |
| Non-renal hamartoma | 2 (10.5) |
| “Confetti” skin lesions | 1 (5.26) |
| Sum of volumes of target renal AML lesions (cm3), median (IQR) | 260.0 (127.8–322.2) |
| Volume of right kidney (cm3), median (IQR) | 329.4 (193.0–979.7)b |
| Volume of left kidney (cm3), median (IQR) | 299.0 (184.2–404.7)c |
| Inpatient hospital contact (1987–2012) | Any hospital contact (2001–2012) | |||||||||
| No bereavement | Bereavement | No bereavement | Bereavement | |||||||
| N | Crude IR (100,000 PYs) | N | Crude IR (100,000 PYs) | IRR (95 % CI) | N | Crude IR (100,000 PYs) | N | Crude IR (100,000 PYs) | IRR (95 % CI) | |
| Any STI | 5903 | 17.00 | 1188 | 14.50 | 1.16 (1.08–1.24) | 71061 | 453.00 | 9309 | 304.00 | 1.06 (1.01–1.11) b |
| Condyloma a | 2833 | 8.14 | 700 | 8.54 | 1.18 (1.08–1.30) | 42652 | 272.00 | 5334 | 174.00 | 1.06 (1.00–1.12) b |
| Gonorrhea | 123 | 0.35 | 33 | 0.40 | 1.51 (0.97–2.28) | 466 | 2.97 | 75 | 2.45 | 1.49 (1.14–1.92) |
| Chlamydia | 952 | 2.74 | 136 | 1.66 | 1.23 (1.01–1.48) | 10098 | 64.40 | 1185 | 38.60 | 1.14 (1.04–1.26) b |
| Syphilis | 65 | 0.19 | 20 | 0.24 | 1.17 (0.66–2.01) | 72 | 0.46 | 16 | 0.52 | 1.05 (0.57–1.84) |
| GHS | 1946 | 5.59 | 302 | 3.68 | 1.06 (0.93–1.21) | 17828 | 114.00 | 2709 | 88.30 | 1.04 (0.99–1.09) b |
| Acute salpingitis | 11361 | 32.60 | 3540 | 43.20 | 1.28 (1.13–1.44)b | 2929 | 18.70 | 1000 | 32.60 | 1.24 (1.15–1.34) |
| HIV | 120 | 0.34 | 96 | 1.17 | 2.36 (1.76–3.17) | 220 | 1.40 | 112 | 3.65 | 1.98 (1.53–2.53) |
| HBV | 435 | 1.25 | 161 | 1.96 | 1.59 (1.30–1.94) | 411 | 2.62 | 141 | 4.60 | 2.20 (1.78–2.71) |
| No. | IUPAC Name |
| BDE-209 | Deca-bromodiphenyl ether |
| BDE-208 | 2,2',3,3',4,5,5',6, 6'- nona-bromodiphenyl ether |
| BDE-207 | 2,2',3,3',4,4',5,6,6'-nona-bromodiphenyl ether |
| BDE-206 | 2,2',3,3',4,4',5,5',6-nona-bromodiphenyl ether |
| BDE-203 | 2,2',3,4,4',5,5',6-octa-bromodiphenyl ether |
| BDE-196 | 2,2',3,3',4,4',5,6'-octa-bromodiphenyl ether |
| BDE-190 | 2,3,3',4,4',5,6-hepta-bromodiphenyl ether |
| BDE-183 | 2,2',3,4,4',5',6-hepta-bromodiphenyl ether |
| BDE-181 | 2,2',3,4,4',5,6-hepta-bromodiphenyl ether |
| BDE-155 | 2,2',4,4',6,6'-hexa-bromodiphenyl ether |
| BDE-154 | 2,2',4,4',5,6'-hexa-bromodiphenyl ether |
| BDE-153 | 2,2',4,4',5,5'-hexa-bromodiphenyl ether |
| BDE-139 | 2,2',3,4,4',6-hexa-bromodiphenyl ether |
| BDE-138 | 2,2',3,4,4',5'-hexa-bromodiphenyl ether |
| BDE-100 | 2,2',4,4',6-penta-bromodiphenyl ether |
| BDE-99 | 2,2',4,4',5-penta-bromodiphenyl ether |
| BDE-85 | 2,2',3,4,4'-penta-bromodiphenyl ether |
| BDE-77 | 3,3',4,4'-tetra-bromodiphenyl ether |
| BDE-47 | 2,2',4,4'-tetra-bromodiphenyl ether |
| BDE-28 | 2,4,4'-Tri-bromodiphenyl ether |
| Appearance | |
| Rich looking/smart/elegant | Liked the colors |
| Different | Simple/neat |
| Looks cold/refreshing/clean | Eye-catching/bold |
| Bright | Attractive |
| Happy | Modern and up-to-date |
| Ordinary | Plain |
| Similar to others | Cheap looking |
| Dull/drab | Unattractive |
| Messy/chopped up/gaudy/cluttered | |
| Functionality | |
| Was easier to open | Did a better job keeping tobacco out of your pocket or purse |
| Was easier to close | Did a better job of keeping cigarettes from spilling out |
| Protected the cigarettes better | Did a better job of keeping cigarettes fresh |
| Was more pleasing to look at | Did a better job of keeping cigarettes from being crushed |
| Felt more comfortable in your hand | Was more different from other cigarette packages |
| Fit better in your pocket or purse |
| Variable | Baseline (2004) | 5-year follow-up (2009) | P-valuea |
| Age, mean (SD) | 43.6 (9.5) | 48.6 (9.5) | |
| SMBQ score, mean (SD) | 2.86 (0.91) | 2.71 (1.05) | <0.001 |
| SMBQ score > 4.0, N (%) | 74/623 (11.8) | 82/623 (13.2) | 0.37 |
| Marital status, N (%) | |||
| Married or cohabiting | 493/609 (81.0) | 501/609 (82.3) | |
| Unmarried, divorced or widowed | 116/609 (19.0) | 108/609 (17.7) | 0.36 |
| Living with children, N (%) | |||
| Yes | 362/610 (59.3) | 312/610 (51.1) | |
| No | 248/610 (40.7) | 298/610 (48.9) | <0.001 |
| Social support (integration), N (%) | |||
| High | 389/577 (67.4) | 374/577 (64.8) | |
| Low | 188/577 (32.6) | 203/577 (35.2) | 0.24 |
| Education, N (%) | |||
| University or similar | 232/620 (37.4) | 236/620 (38.1) | |
| Other | 388/620 (62.6) | 384/620 (61.9) | 0.45 |
| Socioeconomic index (SEI), N (%) | |||
| Blue-collar | 243/621 (39.1) | 233/621 (37.5) | |
| White-collar | 320/621 (51.5) | 344/621 (55.4) | |
| Self-employed | 58/621 (9.3) | 44/621 (7.1) | 0.001 |
| Number of work hours, N (%) | |||
| Full-time | 510/601 (84.9) | 507/601 (84.4) | |
| Part-time (<35 hours per week) | 91/601 (15.1) | 94/601 (15.6) | 0.76 |
| Demand at work, N (%) | |||
| Low | 428/605 (70.7) | 405/605 (66.9) | |
| High | 177/605 (29.3) | 200/605 (33.0) | 0.07 |
| Control at work, N (%) | |||
| High | 475/607 (78.3) | 470/607 (77.4) | |
| Low | 132/607 (21.7) | 137/607 (22.6) | 0.65 |
| Job strain, N (%) | |||
| No | 563/595 (94.6) | 554/595 (93.1) | |
| Yes | 32/595 (5.4) | 41/595 (6.9) | 0.23 |
| Risk for unemployment, N (%) | |||
| Low | 544/603 (90.2) | 541/603 (89.7) | |
| High | 59/603 (9.8) | 62/603 (10.3) | 0.73 |
| New job possibilities, N (%) | |||
| Yes | 351/609 (57.6) | 293/609 (48.1) | |
| No | 258/609 (42.4) | 316/609 (51.9) | <0.001 |
| Perceived economic situation, N (%) | |||
| Satisfied | 454/617 (73.6) | 405/617 (65.6) | |
| Dissatisfied | 163/617 (26.4) | 212/617 (34.4) | <0.001 |
| Prior to 1:1 matching | After 1:1 matching* | |||||
| Variables | Vulvar cancer patients | Controls | P-value* | Vulvar cancer patients | Controls | P-value* |
| N | 505 | 569,648 | 505 | 505 | ||
| Variables used for matched-pairs | ||||||
| Age (years) | 60.8 (15.6) | 40.8 (16.5) | < 0.001 | 60.8 (15.6) | 60.8 (15.6) | 1.000 |
| Age ≤ 40 | 10.3 | 55.4 | < 0.001 | 10.3 | 10.3 | 1.000 |
| Age 41–50 | 17.5 | 17.6 | 0.956 | 17.5 | 17.5 | 1.000 |
| Age 51–60 | 19.5 | 12.1 | < 0.001 | 19.5 | 19.5 | 1.000 |
| Age 61–70 | 19.3 | 8.5 | < 0.001 | 19.3 | 19.3 | 1.000 |
| Age > 70 | 33.4 | 6.4 | < 0.001 | 33.4 | 33.4 | 1.000 |
| Private health insurance coverage | 4.8 | 9.3 | < 0.001 | 4.8 | 4.8 | 1.000 |
| Index year | ||||||
| 2000–2005 | 7.2 | 16.4 | 1.000 | 7.2 | 7.2 | 1.000 |
| 2006–2010 | 21.4 | 22.4 | 0.625 | 21.4 | 21.4 | 1.000 |
| 2011–2015 | 71.4 | 61.2 | < 0.001 | 71.4 | 71.4 | 1.000 |
| Other variables** | ||||||
| Vulva dysplasia (ICD10: N90.0-90.3) | 8.3 | 0.1 | < 0.001 | 8.3 | 0.2 | < 0.001 |
| Leukoplakia of vulva (ICD10: N90.4) | 14.5 | 0.6 | < 0.001 | 14.5 | 1.4 | < 0.001 |
| Benign neoplasm of vagina (ICD10: D28.1) | 1.2 | 0.0 | < 0.001 | 1.2 | 0.0 | 0.014 |
| Arm A IRI+LV+5FU | Arm B LV+5FU | P (log-rank) | |
| Disease-free survival (DFS) | 0.436 | ||
| Progressions, n (%) | 110 (24.9) | 112 (25.9) | |
| Median (months) | Not reached yet | Not reached yet | |
| three-year DFS (%) | 78 | 76 | |
| five-year DFS (%) | 70 | 68 | |
| seven-year DFS (%) | 66 | 63 | |
| Overall survival (OS) | 0.334 | ||
| Deaths, n (%) | 118 (26.8) | 128 (29.6) | |
| Median (months) | Not reached yet | Not reached yet | |
| three-year OS (%) | 88 | 86 | |
| five-year OS (%) | 78 | 76 | |
| seven-year OS (%) | 72 | 69 |
| Deliveries in six months | Total number % | Without malformation number % | With malformation number % | |||
| Ayder referral hospital | 503** | 33 | 484 | 32 | 19 | 3.8 |
| Mekelle hospital | 1013** | 67 | 1000 | 66 | 13 | 1.3 |
| Males | 684 | 45 | 662* | 44 | 22* | 3.2 |
| Females | 832 | 55 | 822 | 54 | 10 | 1.2 |
| LBW | 822 | 54 | 800 | 97 | 22 | 2.7 |
| LBW Male | 374 | 25 | 362 | 97 | 12 | 3.2 |
| LBW Female | 448 | 30 | 438 | 98 | 10 | 2.2 |
| VLBW | 530 | 35 | 515 | 97 | 15 | 2.8 |
| VLBW Male | 243 | 16 | 238 | 98 | 5 | 2.1 |
| VLBW Female | 287 | 19 | 277 | 97 | 10 | 3.5 |
| Total deliveries | 1516 | 100 | 1484 | 98 | 32 | 2.1 |
| ypN0 | ypN1 | ypN2 | Total | |
| yN0 | 41 | - | - | 41 (66.1) |
| yN+ | 7 | 11 | 3 | 21 (33.9) |
| Total | 48 (77.4) | 11 (17.8) | 3 (4.8) | 62 (100) |
| Group I | Group II | |
| Chemotherapy cycles | 5 (3-6) * | 5 (1-6) * |
| >4 cycles | 14 (87%) * | 12 (80%) * |
| EBRT dose | 40 (40-66) * | 40 (40-66) * |
| Dose to point A | 33 (5-52) * | 34 (0-58) * |
| No UV brachytherapy | 3 (19%) * | 6 (40%) * |
| Total dose to point A | 75 (60-93) * | 66 (40-98) * |
| Characteristics | Unstandardized Coefficients | Standardized Coefficients | t | Sig. | |
| B | Std. Error | Beta | |||
| SBP | −0.003 | 0.003 | −0.104 | − 0.946 | 0.348 |
| PP | 0.002 | 0.005 | 0.064 | 0.414 | 0.680 |
| FH | 0.073 | 0.076 | 0.066 | 0.970 | 0.336 |
| AS | −0.012 | 0.019 | −0.105 | −0.630 | 0.531 |
| AD | −0.046 | 0.042 | −0.210 | −1.100 | 0.276 |
| APV | −0.019 | 0.002 | −0.659 | −8.097 | < 0.0001 |
| Author | Year | Population | Sample size | Method | Cut-off | miRNA | Survival analysis | Source of HR | Follow-up (month) |
| Luo | 2015 | China | 88 | qRT-PCR | Median | miR-26b | OS, RFS | Reported | mean 74 (5.12-98.5) |
| Safari | 2015 | Iran | 40 | qRT-PCR | Median | miR-20a | OS | DE | 100 |
| miR-10a | OS | DE | |||||||
| Wang C | 2015 | China | 138 | qRT-PCR | Median | miR-335 | OS, RFS | Reported, DE | Mean 71(23-117) |
| Wang Q | 2015 | China | 114 | qRT-PCR | Median | miR-145 | OS | Reported | median 47(11-69) |
| He | 2014 | China | 73 | qRT-PCR | ROC curve | miR-107 | OS, DFS | DE | median 68.4 |
| miR-130a | OS, DFS | DE | |||||||
| Liang | 2014 | China | 335 | qRT-PCR | X-tile algorithm | miR-215 | DFS | Reported | 60 |
| Ma | 2014 | China | 60 | qRT-PCR | ROC curve | miR-205 | OS | Reported | 60 |
| Park | 2014 | Korea | 45 | qRT-PCR | 2.5-fold | miR-363-3p | OS | Reported | 60 |
| Wang | 2014 | China | 54 | qRT-PCR | Median | miR-31 | OS | Reported | 60 |
| Yang | 2014 | China | 133 | qRT-PCR | Median | miR-126 | OS | Reported | 60 |
| Luo | 2013 | China | 60 | qRT-PCR | Mean | miR-497 | OS, DFS | Reported, DE | 60 |
| Shen | 2013 | China | 126 | qRT-PCR | Median | miR-224 | OS | DE | median 51.9 |
| Huang | 2012 | China | 44 | qRT-PCR | Mean | miR-125b | OS | Reported | mean 23.6 (2-70) |
| miR-100 | OS | Reported | |||||||
| miR-143 | OS | DE | |||||||
| miR-145 | OS | DE | |||||||
| miR-199a-5p | OS | DE |
| Variables | Group 1 n (%) | Group 2 n (%) | p |
| Men | 30 (88.2) | 16 (69.6) | 0.09 |
| Age | 65.94 ± 6.67 | 65.78 ± 9.29 | 0.9 |
| Previous MI | 9 (26.5) | 6 (26.0) | 0.97 |
| Unstable angina | 3 (8.8) | 1 (4.3) | 0.64 |
| Previous CVA | 11 (32.3) | 5 (21.7) | 0.48 |
| Stroke | 4 (11.8) | 1 (4.3) | 0.63 |
| Hypertension | 29 (85.3) | 18 (78.3) | 0.50 |
| Diabetes | 17 (50) | 12 (52.2) | 0.87 |
| Hyperlipidaemia | 19 (55.9) | 9 (39.1) | 0.21 |
| Renal failure | 4 (11.8) | 1 (4.3) | 0.63 |
| Smoking | 27 (79.4) | 14 (60.9) | 0.12 |
| PAD | 13 (38.2) | 7 (30.4) | 0.54 |
| Mean (±SD) nuclear gray level | |
| Normal urothelium (NU), global | 106±15 |
| NU, superficial epithelial layer | 104±15 |
| NU, intermediate cell layers | 106±15 |
| NU, basal cell layer | 108±14 |
| Urothelial carcinoma (UC), global | 100±15 |
| UC, nuclei not adjacent to the stroma | 101±15 |
| UC, nuclei adjacent to the stroma | 99±16 |
| Study Authors | Best Model/Main Finding | Subsequent Criticisms |
| Hubbell (2001) | ZSM | Goodness of fit only determined by graphical observation. |
| McGill (2003) | ZSM does not fit the data better than the lognormal | Used simulations to fit the ZSM |
| Volkov et al. (2003) | Derived an analytical solution for the ZSM and found the ZSM provided the best fit | Analytical equations did not represent the full solution as they applied solely to the mean number of species in a given class (Etienne and Olff 2004) |
| Vallade and Houchmandzadeh (2003) | Published a full analytical solution for the ZSM | Equations were later determined to be flawed (i.e., they applied the mean number of species in a given class) and were corrected by Etienne and Alonso (2005) |
| Alonso and McKane (2004) | Developed a different analytic solution | Rigorous fitting of the ZSM required likelihood methods |
| Etienne and Olff (2004) | Found slightly better support for the lognormal using a Bayesian approach | |
| Etienne (2005) | Published the correct analytical solution and sampling formula. Two forms of the likelihood equations exist: (a) Ewens’ (1972) sampling formula of neutral alleles is used in the case of no dispersal limitation and (b) Etienne's (2005) formula in cases of dispersal limitation | |
| Etienne and Alonso (2005) | Unified two different approaches to arrive at the full analytical solution: the genealogical approach (Etienne 2005) and master equation-based approach (e.g., Alonso and McKane 2004) | |
| McGill et al. (2006) | Compared nine goodness-of-fit measures with the BCI data and found that for eight out of the nine measures the lognormal outperformed the ZSM | |
| Jabot and Chave (2011) | Built on Etienne's (2005) maximum likelihood framework to develop a more robust test of neutrality incorporating the SAD of Hubbell's SINM and Shannon's index. The SAD of the BCI 50-ha plot did not significantly differ from neutrality; however, the SADs of smaller scale subplots from within the BCI plot were significantly non-neutral | |
| Rosindell and Cornell (2013) | (a) The gamma and negative binomial distributions provided a better fit than the ZSM (b) The SENM predicts SADs which are more realistic than those from the SINM |
| Function units | Known or possible role | References |
| ULK1 complex | ||
| ULK1 | Binds with ATG13, ATG101, and FIP200 | [19, 20, 163] |
| ATG13 | Bridges the interaction of ULK1 and FIP200; is required for the localization and stability of ULK1 and stimulates the kinase activity of ULK1 | [164] |
| ATG101 | Interacts with ULK1 in an ATG13-dependent manner; regulates the stability and basal phosphorylation of ATG13 and ULK1 | [24, 25, 164] |
| FIP200 | Scaffold protein, binds with ULK1 and ATG13; is required for proper localization, stability and kinase activity of ULK1 | [19, 20, 29, 164, 165] |
| PI3K complex III | ||
| Beclin 1 | BH3-only protein; interacts with Bcl-2 | [28, 29, 39] |
| ATG14L | Enhances Vps34 lipid kinase activity, upregulates autophagy | [28, 30] |
| hVps15 | Ser/Thr protein kinase, is required for Vps34 membrane association | [166] |
| Vps34 | PI3K, forms Phosphatidylinositol 3-phosphate (PI3P) for autophagy | [167, 168] |
| ATG12 conjugation system | ||
| ATG5 | Forms isopeptide bond with ATG12 | [31, 169] |
| ATG12 | Ubiquitin-like protein; forms isopeptide bond with Atg5 conjugation | [31, 169] |
| ATG7 | E1-like activating enzyme, catalyzes ATG12–ATG5 and LC3-II-PE conjugation | [31] |
| ATG10 | E2-like activating enzyme; catalyzes ATG12–ATG5 | [31] |
| ATG16L1 | Conjugates to ATG12-ATG5 complex | [170] |
| LC3 conjugation system | ||
| LC3 | Ubiquitin-like protein, conjugates to PE, an important marker of autophagy | [34, 171] |
| ATG4 | Cysteine protease, regulates the level of free LC3-I | [31, 34] |
| ATG7 | E1-like activating enzyme, catalyzes ATG12–ATG5 and LC3-II-PE conjugation | [31, 34] |
| ATG3 | E2-like conjugating enzyme analog, catalyzes LC3-II-PE conjugation | [31, 34] |
| Other essential proteins | ||
| WIPI-2 | Mammalian homolog of yeast Atg18, a PI3P-binding protein, facilitates LC3 lipidation | [35, 172] |
| ATG2 | Probably plays an essential role at late step of autophagosome formation | [29, 36] |
| ATG9 | The only known transmembrane protein, may contribute to membrane recruitment | [37] |
| Compound code | SiHa | B16F10 | K562 | Chang |
| 1T | 7.17 ± 0.3 | 5.16 ± 0.5 | > 10.00 | 7.91 ± 0.4 |
| 2T | 7.14 ± 0.5 | 7.63 ± 0.4 | > 10.00 | > 10.00 |
| 3T | > 10.00 | > 10.00 | > 10.00 | > 10.00 |
| 4T | 8.12 ± 0.4 | > 10.00 | > 10.00 | > 10.00 |
| 5T | 7.79 ± 0.5 | 7.14 ± 0.6 | > 10.00 | > 10.00 |
| 6T | 4.79 ± 0.6 | 5.79 ± 0.4 | > 10.00 | > 10.00 |
| 7T | > 10.00 | > 10.00 | > 10.00 | > 10.00 |
| 1C | 4.21 ± 0.4 | 3.33 ± 0.3 | > 10.00 | 6.21 ± 0.5 |
| 2C | 6.20 ± 0.6 | 1.71 ± 0.3 | > 10.00 | 8.03 ± 0.5 |
| 3C | 5.10 ± 0.4 | 3.91 ± 0.3 | 6.14 ± 0.4 | 9.32 ± 0.6 |
| 4C | 7.28 ± 0.5 | 5.91 ± 0.6 | > 10.00 | 7.37 ± 0.4 |
| 5C | 4.03 ± 0.5 | 2.09 ± 0.1 | > 10.00 | 7.01 ± 0.1 |
| 6C | 2.34 ± 0.2 | 0.70 ± 0.1 | > 10.00 | 6.89 ± 0.3 |
| 7C | 8.43 ± 0.3 | > 10.00 | 6.86 ± 0.4 | 5.49 ± 0.4 |
| Colchicine | 2.5 ± 0.5 | 4.1 ± 0.1 | 1.3 ± 0.1 | 0.52 ± 0.1 |
| Paclitaxel | 364 ± 310* | 9.57 ± 0.2 | 4.80 ± 0.4* | 0.068 ± 0.02 |
| Vinblastine | 10.88 ± 0.8 | 55 ± 28* | 0.006 ± 0.0 | ND** |
| Factors of associationa | All (n = 3458) | Uganda (n = 491) | ||||
| Adjusted OR | 95 % CI | P value | Adjusted OR | 95 % CI | P value | |
| UC allocation by sleeping place (vs by people) | 1.63 | 1.07–2.48 | 0.025 | 1.60 | 1.02–2.52 | 0.042 |
| Wealth quintile | ||||||
| Lowest | 1.00 | <0.001 | 1.00 | 0.172 | ||
| Second | 1.09 | 0.78–1.53 | 1.21 | 0.59–2.46 | ||
| Middle | 1.39 | 1.01–1.91 | 1.40 | 0.72–2.71 | ||
| Fourth | 1.66 | 1.19–2.31 | 1.48 | 0.76–2.91 | ||
| Highest | 1.91 | 1.37–2.64 | 2.79 | 1.20–6.53 | ||
| Household of four people or more (vs three or less) | 0.25 | 0.18–0.35 | <0.001 | 0.42 | 0.24–0.76 | 0.005 |
| Household with any child under five (vs no child under five) | 0.37 | 0.30–0.47 | <0.001 | 0.20 | 0.10–0.38 | <0.001 |
| Stratified characteristics | Cases [n(%)] | Controls [n(%)] | AA | AG | GG | |||||||
| AA | AG | GG | AA | AG | GG | p* | OR (95%CI)* | P* | OR (95%C/)* | |||
| Sex | male | 393(73.6) | 131(24.5) | 10(1.9) | 338(65.5) | 155(30.0) | 23(4.5) | 1.00 | 0.045 | 0.75(0.57-0.99) | 0.011 | 0.36(0.16-0.80) |
| female | 411(72.6) | 144(25.4) | 11(1.9) | 437(74.1) | 138(23.4) | 15(2.5) | 1.00 | 0.590 | 1.08(0.81-1.44) | 0.393 | 0.70(0.30-1.60) | |
| Age(yr) | ≤50 | 209(69.9) | 86(28.8) | 4(1.3) | 190(68.1) | 82(29.4) | 7(2.5) | 1.00 | 0.645 | 0.91(0.62-1.34) | 0.348 | 0.54(0.15-1.97) |
| >50 | 571(74.3) | 181(23.5) | 17(2.2) | 584(70.8) | 210(25.5) | 31(3.8) | 1.00 | 0.341 | 0.89(0.71-1.13) | 0.024 | 0.48(0.26-0.91) | |
| BMI | normal | 334(76.3) | 97(22.1) | 7(1.6) | 394(70.5) | 146(26.1) | 19(3.4) | 1.00 | 0.070 | 0.76(0.56-1.02) | 0.052 | 0.41(0.17-1.01) |
| overweight | 325(70.8) | 126(27.5) | 8(1.7) | 285(69.7) | 112(27.4) | 12(2.9) | 1.00 | 0.956 | 0.99(0.73-1.34) | 0.372 | 0.66(0.26-1.65) | |
| obesity | 119(70.0) | 47(27.6) | 4(2.4) | 82(71.9) | 25(21.9) | 7(6.1) | 1.00 | 0.566 | 1.19(0.66-2.13) | 0.184 | 0.42(0.12-1.51) |
| Set | Description | Min | Max | Mean | Median | St.dev. |
| 1 | Training Set (32 articles) | 4 | 147 | 19 | 14 | 24 |
| 2 | Test Set (50 articles – gold standard) | 0 | 375 | 33 | 19 | 63 |
| 3 | Test Set (507 articles – silver standard) | 0 | 375 | 18 | 12 | 27 |
| Intervention armn/N(%, 95% CI) | Standard invitation armn/N(%, 95% CI) | |
| Possible unintended consequences | ||
| Parents made an informed decision | 28/54 (51.9, 26.7–76.1) | 9/33 (27.3, 7.6–63.2) |
| Acceptability | ||
| Incentives are a good idea | 42/59 (71.2, 47.7–87.0) | 25/35 (71.4, 45.0–88.4) |
| Possible mechanisms of action | ||
| Very/quite motivated to return the form | 105/200 (52.5, 35.0–69.4) | 101/191 (52.9, 45.7–59.9) |
| Very easy/easy to remember to return the form | 154/201 (76.6, 43.5–93.3) | 133/193 (68.9, 63.6–73.8) |
| Returning the form is very/quite important | 125/203 (61.6, 39.7–79.6) | 131/194 (67.5, 59.1–74.9) |
| Gave consent form to parents the same day they received it from school | 141/202 (69.8, 47.6–85.5) | 111/193 (57.5, 52.3–62.5) |
| Cluster | n | % | Cluster group1 | Pulsotype | n | % | Pulsotype group1 |
| C1 | 6 | 3.2 | Less common | C1a | 3 | 1.6 | Less common |
| C1b | 1 | 0.5 | Rare | ||||
| C1c | 2 | 1.0 | Rare | ||||
| C2 | 1 | 0.5 | Rare | C2a | 1 | 0.5 | Rare |
| C3 | 18 | 9.7 | Less common | C3a | 17 | 9.2 | Less common |
| C3b | 1 | 0.5 | Rare | ||||
| C4 | 1 | 0.5 | Rare | C4a | 1 | 0.5 | Rare |
| C5 | 1 | 0.5 | Rare | C5a | 1 | 0.5 | Rare |
| C6 | 1 | 0.5 | Rare | C6a | 1 | 0.5 | Rare |
| C7 | 1 | 0.5 | Rare | C7a | 1 | 0.5 | Rare |
| C8 | 2 | 1.0 | Rare | C8a | 2 | 1.0 | Rare |
| C9 | 1 | 0.5 | Rare | C9a | 1 | 0.5 | Rare |
| C10 | 5 | 2.7 | Less common | C10a | 3 | 1.6 | Less common |
| C10b | 1 | 0.5 | Rare | ||||
| C10c | 1 | 0.5 | Rare | ||||
| C11 | 82 | 44.3 | Common | C11a | 79 | 42.7 | Common |
| C11b | 1 | 0.5 | Rare | ||||
| C11c | 2 | 1.0 | Rare | ||||
| C12 | 1 | 0.5 | Rare | C12a | 1 | 0.5 | Rare |
| C13 | 1 | 0.5 | Rare | C13a | 1 | 0.5 | Rare |
| C14 | 1 | 0.5 | Rare | C14a | 1 | 0.5 | Rare |
| C15 | 54 | 29.2 | Common | C15a | 8 | 4.3 | Less common |
| C15b | 40 | 21.6 | Common | ||||
| C15c | 6 | 3.2 | Less common | ||||
| C16 | 1 | 0.5 | Rare | C16a | 1 | 0.5 | Rare |
| C17 | 7 | 3.8 | Less common | C17a | 3 | 1.6 | Less common |
| C17b | 3 | 1.6 | Less common | ||||
| C17c | 1 | 0.5 | Rare | ||||
| C18 | 1 | 0.5 | Rare | C18a | 1 | 0.5 | Rare |
| Respiratory rate | Group I (Magnesium) mean ± SD | Group II (Control) mean ± SD | P-value |
| After induction | 23.8 ± 0.6 | 30.2 ± 1.3 | 0.001* |
| 10 min. | 23.8 ± 0.6 | 28.3 ± 1.3 | 0.001* |
| 20 min. | 24.2 ± 0.7 | 26.3 ± 1.0 | 0.002* |
| 30 min. | 23.3 ± 0.7 | 25.4 ± 1.0 | 0.002* |
| 40 min. | 22.4 ± 0.5 | 25.2 ± 1.3 | 0.012* |
| 50 min. | 22.5 ± 0.8 | 25.1 ± 1.3 | 0.054* |
| 60 min. | 22.5 ± 0.8 | 25.2 ± 1.3 | 0.034* |
| 70 min. | 24.5 ± 0.9 | 25.1 ± 1.5 | 0.280 |
| 80 min. | 24.7 ± 1.0 | 24.8 ± 1.4 | 0.897 |
| Elements | GP (genome proportion, %) |
| Retrotransposon | 11.05 |
| Copia | 5.81 |
| Gypsy | 4.88 |
| LINE/SINE | 0.33 |
| Unclassified LTR | 0.03 |
| Transposon | 1.41 |
| hAT | 0.93 |
| Mutator | 0.27 |
| DNA/CMC-EnSpm | 0.10 |
| Tc1-Mariner | 0.11 |
| rDNA | 4.32 |
| Satellite | 12.93 |
| Unclassified | 1.02 |
| Total | 30.73 |
| Characteristic | Non-recurrent | Metachronous metastasis | p-value1 | ||
| absolute | % | absolute | % | ||
| Total number | 33 | 12 | |||
| Age [years] | n.s. | ||||
| Mean | 65 | 68 | |||
| Median | 67 | 67 | |||
| Disease-free survival time [months] | 0.000 | ||||
| Mean | 78 | 17 | |||
| Median | 77 | 13 | |||
| Gender | n.s. | ||||
| Female | 14 | 42,4 | 8 | 66,7 | |
| Male | 19 | 57,6 | 4 | 33,3 | |
| UICC stage | n.s. | ||||
| I | 6 | 18,2 | 2 | 16,7 | |
| II | 18 | 54,5 | 8 | 66,7 | |
| III | 9 | 27,3 | 2 | 16,7 | |
| Location | n.s. | ||||
| Colon | 14 | 42,4 | 5 | 41,7 | |
| Sigma | 16 | 48,5 | 4 | 33,3 | |
| Rectum | 3 | 9,1 | 3 | 25 |
| Cortical region | |
| 1 | Banks of the superior temporal sulcus |
| 2 | Caudal anterior cingulate |
| 3 | Caudal middle frontal |
| 4 | Cuneus |
| 5 | Entorhinal |
| 6 | Frontal pole |
| 7 | Fusiform |
| 8 | Inferior parietal |
| 9 | Inferior temporal |
| 10 | Insula |
| 11 | Isthmus of the cingulate |
| 12 | Lateral occipital |
| 13 | Lateral orbitofrontal |
| 14 | Lingual |
| 15 | Medial orbitofrontal |
| 16 | Middle temporal |
| 17 | Parahippocampal |
| 18 | Paracentral |
| 19 | Pars opercularis |
| 20 | Pars orbitalis |
| 21 | Pars triangularis |
| 22 | Peri-calcarine |
| 23 | Postcentral |
| 24 | Posterior cingulate |
| 25 | Precentral |
| 26 | Precuneus |
| 27 | Rostral anterior cingulate |
| 28 | Rostral middle frontal |
| 29 | Superior frontal |
| 30 | Superior parietal |
| 31 | Superior temporal |
| 32 | Supra-marginal |
| 33 | Temporal pole |
| 34 | Transverse temporal |
| Healthy weight | Increased weight | |
| Persistent oligoarthritis | 95 (90.5) | 10 (9.5) |
| ERA | 55 (68) | 26 (32) |
| Poliarthritis RF (+) | 46 (78) | 13 (22) |
| Systemic | 28 (90.5) | 1 (9.5) |
| Undifferentiated | 17 (81) | 4 (19) |
| Psoriatic | 16 (100) | 0 (0) |
| Extended oligoarthritis | 8 (89) | 1 (11) |
| Poliarthritis RF (-) | 4 (80) | 1 (20) |
| Function | Genes | Fold change | |
| Intestinal peptides | GIP | Glucose inhibitory peptide | −1.72 |
| GKN1 | Gastrokine 1 | −1.54 | |
| GKN2 | Gastrokine 2 | −1.51 | |
| VIP | Vasoactive intestinal polypeptide | 1.30 | |
| Inflammation and oxidative stress | PTGS2 | Prostaglandin-endoperoxide synthase – COX-2 | 1.20 |
| DUSD1 | Dual specificity phosphatase 1 | 1.37 | |
| S100A8 | S100 calcium binding protein A8 | 1.59 | |
| S100A9 | S100 calcium binding protein A9 | 1.51 | |
| IL1B | Interleukin 1 beta | 1.21 | |
| GPX8 | Glutathione peroxidase 8 | 1.21 | |
| FOS | Cellular oncogene c-Fos | 1.55 | |
| JUN | Jun proto-oncogene | 1.32 | |
| Transporters | SLC28A2 | Sodium-coupled nucleoside transporter | −1.68 |
| SLC2A3 | Facilitated glucose transporter 3 | 1.25 | |
| Extracellular matrix | MUC5AC | Mucin 5 AC | −1.58 |
| MUC2 | Mucin 2 | −1.32 | |
| MUC6 | Mucin 6 | 1.21 | |
| MMP7 | Metalloproteinase 7 | 1.27 | |
| VIL1 | Villin 1 | −1.22 | |
| Digestive functions | PGA5 | Pepsinogen A | −1.97 |
| LCT | Lactase | 1.76 | |
| GLB1 | β-galactosidase | −1.21 | |
| PNLIPRP2 | Pancreatic lipase | 1.30 | |
| PRSS1 | Trypsin 1 | 1.24 | |
| ELA3A | Elastase | 1.25 | |
| Immunity | GP2 | Glycoprotein 2 | 1.38 |
| HLA-A | Major histocompatibility complex class I A | 2.63 | |
| HLA-C | Major histocompatibility complex class I C | −1.20 | |
| HLA-F | Major histocompatibility complex class I F | −1.28 | |
| HLA-DQA1 | Major histocompatibility complex class II DQ alpha 1 | 1.38 | |
| HLA-DQB1 | Major histocompatibility complex class II DQ beta 1 | 1.22 | |
| HLA-DRB1 | Major histocompatibility complex class II DR beta 1 | −1.35 | |
| HLA-DRB4 | Major histocompatibility complex class II DR beta 4 | 1.39 | |
| Cholesterol homeostasis | LDLR | Low density lipoprotein receptor | 1.30 |
| APOD | Apolipoprotein D-III | 1.20 | |
| APOA1 | Apolipoprotein A-I | −1.37 |
| Hospital plan for follow-up | |||
| General practitioner (n = 23) | Specialist health service (n = 66) | ||
| Hospital guidelines for follow-up | General practitioner (n = 11) | 3 | 8 |
| Specialist health service (n = 78) | 20 | 58 |
| Viral Systems | Copolymers | Genes | Targets | Administration | Observations | References |
| rAAV | Pluronic® F127 | GM-CSF | solid tumors | in vivo intratumoral infusion (mouse) | higher efficiency by combining DC, local tumor irradiation and controlled supply of recombinant mGM-CSF with Pluronic® | [77] |
| Pluronic® F68 | lacZ | adipose tissue | in vivo inguinal (mouse) | increased transgene expression after 4 weeks | [78] | |
| Pluronic® F127 | lacZ | cartilage | in vitro hMSCs | controlled release of rAAV for high efficiencies over time and gene expression levels similar to those achieved by direct vector application | [80] | |
| Pluronic® F68, Tetronic® 908 | RFP, lacZ, and SOX9 | cartilage | in vitro hMSCs | encapsulation of rAAV in polymeric micelles for effective, durable, and safe modification of hMSCs; restoration of hMSC transduction in conditions of gene transfer inhibition; effective chondrogenesis | [79] | |
| Pluronic® F68, Tetronic® 908 | lacZ | cartilage | in vitro hOACs in situ human osteochondral model | micellar encapsulation for increased stability and bioactivity of rAAV; high levels of safe transgene expression in vitro and in experimental osteochondral defects in situ | [81] | |
| Pluronic® F68, Tetronic® 908 | TGF-β | cartilage | in vitro hOACs in situ human osteochondral model | increased levels of transgene expression compared with free vector treatment; high proteoglycan deposition and increased cell numbers in hOACs in vitro; high deposition of type-II collagen and reduced hypertrophy in osteochondral defects models in situ | [82] | |
| Pluronic® F68, Tetronic® 908 | lacZ | cartilage | in vitro hMSCs | high concentrations of rAAV; sustained levels of transgene expression over time | [92] |
| Dispensation rate of generics | P | ||
| Pre-adoption[% (drugs/total drugs)] | Post-adoption[% (drugs/total drugs)] | ||
| All drugs subjected to analysis | 48.3 (447/926) | 57.7 (604/1046) | < 0.001* |
| Drugs that have the same ingredients or different ingredients as the newly adopted generic drugs | |||
| Drugs with same ingredients | 44.7 (135/302) | 64.0 (217/339) | < 0.001* |
| Drugs with different ingredients | 50.0 (312/624) | 54.7 (387/707) | 0.094 |
| Priscribing facility | |||
| Gifu Municipal Hospital | 47.5 (197/415) | 66.5 (254/382) | < 0.001* |
| Other hospitals/clinics | 48.9 (250/511) | 52.7 (350/664) | 0.219 |
| Descriptor | P-values | ||
| Not ranked | 30 Top-ranked | 20 Top-ranked | |
| C | 1.2 e-1 | 5.8 e-1 | 5.6 e-1 |
| D | 5.1 e-3 | 2.6 e-1 | 2.4 e-1 |
| Variance | 9.0 e-2 | 3.4 e-1 | 5.7 e-1 |
| Migraine Triggers | N | % |
| Identified any Triggers | 3416 | 82.9 |
| Stress | 2669 | 55.8 |
| Environment (weather, etc...) | 2870 | 60.0 |
| Lack of Sleep | 2484 | 51.9 |
| Hormones/menstrual cycle | 1792 | 37.4 |
| Certain food drink | 2138 | 44.7 |
| Missing meals | 1884 | 39.4 |
| Certain smell | 2046 | 42.7 |
| Alcohol/drugs | 1235 | 25.8 |
| Physical Activity | 1241 | 25.9 |
| Sexual Activity | 325 | 6.8 |
| Other | 739 | 15.4 |
| Steps taken to avoid triggers | 3033 | 63.4 |
| Group | Cohesive fracture in tooth | Cohesive fracture in laminate | Adhesive | Mixed cohesive and adhesive |
| Control | 5 | 1 | 0 | 5 |
| SC | 4 | 0 | 3 | 4 |
| LC | 1 | 0 | 5 | 4 |
| Total | 10 | 1 | 8 | 13 |
| Number | NLR | PNI | |
| All cases | 334 | 2.52 ± 2.06 | 51.03 ± 5.72 |
| Age | |||
| ≦70 | 165 | 2.34 ± 1.91 | 52.20 ± 5.38* |
| >70 | 169 | 2.69 ± 2.18 | 49.59 ± 5.70* |
| Smoking history | |||
| Never | 122 | 2.27 ± 1.69 | 52.32 ± 5.00**, *** |
| Former | 116 | 2.69 ± 2.41 | 49.70 ± 5.65** |
| Current | 95 | 2.64 ± 1.99 | 50.97 ± 6.36*** |
| Histology | |||
| Adenocarcinoma | 231 | 2.43 + 2.07 | 51.87 + 5.17**** |
| Squamous cell carcinoma | 69 | 2.80 + 2.30 | 48.22 + 6.49**** |
| Large cell carcinoma | 22 | 2.84 + 1.42 | 49.55 + 6.38 |
| Adenosquamous carcinoma | 6 | 2.01 + 0.61 | 52.49 + 2.39 |
| Pleomorphic carcinoma | 6 | 1.90 + 0.93 | 55.07 + 6.92 |
| Tumor differentiation | |||
| Well | 118 | 2.39 + 2.12 | 51.82 + 4.70 |
| Moderate | 115 | 2.55 + 2.29 | 50.96 + 6.12 |
| Poor | 101 | 2.59 + 1.70 | 50.23 + 6.30 |
| Pathological stage | |||
| IA | 144 | 2.40 + 2.13 | 51.74 + 5.33 |
| IB | 95 | 2.54 + 1.68 | 50.30 + 6.00 |
| IIA+IIB | 55 | 2.60 + 2.21 | 50.30 + 5.50 |
| IIIA+IIIB | 40 | 2.75 + 2.37 | 51.18 + 6.58 |
| PAMAM dendrimer generation (G) | Terminal amines (#) | Naked dendrimer molecular weight (kDa) | Gd-G5-doxorubicin dendrimer molecular weight (kDa) | Gd-DTPA conjugation (%) | Doxorubicin conjugation (%) | Molar relaxivity (mM-1s-1) |
| G5 | 128 | 29# | 85‡ | 48.1 | 7.8 | 10.1& |
| Temperature E (°C) | Dry weight of mycelial mat (mg/flask) | Protein content (mg/ml) | Cellulase | ||
| aFPase (FPU/ml) | bCMCase (U/ml) | cΒ-glucosidase (U/ml) | |||
| 25 °C | 293 | 1.02 | -nd- | 4.56 | 0.62 |
| 30 °C | 457 | 2.12 | 2.03 | 9.83 | 1.04 |
| 37 °C | 457 | 2.12 | 1.62 | 6.24 | 0.99 |
| Group | Method | Sensitivity (%) | Specificity (%) | False positives (%) | False negatives (%) |
| Classical | Fisher | 59.18 | 88.64 | 5.89 | 40.82 |
| Sidak | 18.37 | 97.73 | 0.11 | 81.63 | |
| Simes | 46.94 | 97.73 | 1.33 | 53.06 | |
| FDR | 24.49 | 97.73 | 0.13 | 75.51 | |
| Updated Classical | TPM | 63.04 | 92.86 | 4.93 | 36.96 |
| GATES | 24.49 | 98.00 | 0.17 | 75.51 | |
| WGATES | 26.53 | 98.00 | 0.16 | 73.47 | |
| HYST | 24.49 | 98.00 | 0.16 | 75.51 | |
| WHYST | 24.49 | 98.00 | 0.16 | 75.51 | |
| Novel | VEGAS | 20.41 | 100.0 | 0.16 | 79.59 |
| VEGAS [10%] | 28.57 | 98.00 | 0.40 | 71.43 |
| 2013–2014 Change | 2014–2015 Change | |||||
| Runs Per Game | 5.8 | 8.6 | 48% | 8.6 | 9.4 | 9% |
| Batting Average | 0.286 | 0.326 | 14% | 0.326 | 0.324 | <1% |
| On-base Pct. | 0.372 | 0.407 | 9% | 0.407 | 0.419 | 3% |
| Slugging Pct. | 0.390 | 0.468 | 20% | 0.468 | 0.519 | 11% |
| Home Runs | 11 | 25 | 127% | 25 | 39 | 56% |
| Base-on-Balls | 108 | 140 | 30% | 140 | 171 | 22% |
| Strikeouts (K) | 217 | 182 | 16% | 182 | 219 | (20%) |
| BB/K Ratio | 0.50 | 0.77 | 54% | 0.77 | 0.78 | 1% |
| Lean group | Obese group | Obese GDM group | P-value1 | Adjusted p-value2 | |
| Weight [g] | |||||
| Birth | 3,449 ± 332 [15] | 3,651 ± 285 [13] | 3,617 ± 333 [16] | 0.201 | 0.169 |
| Week-6 | 4,701 ± 330 [15] | 4,963 ± 635 [13] | 5,285 ± 517 [12] | 0.017b | 0.170 |
| Month-4 | 6,468 ± 522 [15] | 6,929 ± 829 [11] | 7,066 ± 732 [13] | 0.071 | 0.211 |
| Year-1 | 9,786 ± 915 [15] | 10,356 ± 1273 [12] | 10,392 ± 1212 [14] | 0.286 | 0.549 |
| Weight gain [g] | |||||
| Δ Week-6 - birth | 1,265 (1,095-1,480) [15] | 1,480 (775–1,690) [13] | 1,550 (1,361-1,892) [12] | 0.017b | 0.394 |
| Δ Month-4 - week-6 | 1,734 (1,390-2,100) [15] | 2,070 (1,840-2,300) [11] | 1,848 (1,460-2,100) [11] | 0.112 | 0.042a |
| Δ Year-1 - month-4 | 3,318 ± 760 [15] | 3,228 ± 801 [11] | 3,329 ± 666 [13] | 0.936 | 0.937 |
| Δ Year-1 - birth | 6,337 ± 996 [15] | 6,665 ± 1,220 [12] | 6,765 ± 1,102 [14] | 0.554 | 0.722 |
| Length [cm] | |||||
| Birth | 51.8 ± 1.5 [15] | 52.5 ± 1.4 [13] | 52.3 ± 1.5 [16] | 0.299 | 0.264 |
| Week-6 | 55.6 ± 0.9 [15] | 56.0 ± 1.8 [13] | 56.4 ± 1.4 [12] | 0.360 | 0.738 |
| Month-4 | 63.3 ± 1.2 [15] | 64.4 ± 2.0 [11] | 63.7 ± 1.4 [13] | 0.226 | 0.177 |
| Year-1 | 76.5 ± 2.3 [15] | 77.5 ± 2.6 [12] | 76.7 ± 2.7 [14] | 0.551 | 0.666 |
| Ponderal index [g/cm3] | |||||
| Birth | 6.65 ± 0.54 [15] | 6.95 ± 0.48 [13] | 6.81 ± 0.51 [16] | 0.291 | 0.287 |
| Week-6 | 8.45 ± 0.55 [15] | 8.86 ± 1.03 [13] | 9.36 ± 0.75 [12] | 0.018b | 0.176 |
| Month-4 | 10.21 ± 0.81 [15] | 10.74 ± 1.06 [11] | 11.04 ± 0.97 [13] | 0.073 | 0.272 |
| Year-1 | 12.80 ± 1.04 [15] | 13.34 ± 1.38 [12] | 13.52 ± 1.30 [14] | 0.262 | 0.616 |
| Head circumference [cm] | |||||
| Birth | 34.0 (34.0-35.5) [15] | 35.0 (34.5-36.5) [13] | 35.5(34.0-36.0) [16] | 0.072 | 0.410 |
| Week-6 | 37.5 (37.0-38.8) [15] | 38.3 (37.6-39.7) [13] | 38.9 (37.7-40.0) [12] | 0.023b | 0.096 |
| Month-4 | 41.1 ± 1.2 [15] | 42.1 ± 1.7 [11] | 42.0 ± 1.3 [13] | 0.132 | 0.184 |
| Year-1 | 45.6 ± 1.4 [15] | 47.0 ± 1.6 [12] | 47.1 ± 1.7 [14] | 0.072 | 0.105 |
| Waist circumference [cm] | |||||
| Year-1 | 45.1 ± 2.4 [15] | 45.6 ± 4.0 [12] | 45.7 ± 3.0 [14] | 0.859 | 0.897 |
| Age MTfer | Mean age | Number |
| Posetive | 50.75 | 4 |
| Negative | 40.60 | 42 |
| Total | 41.48 | 46 |
| Health centre | # fulltime professionals in labour ward | Midwives | Obstetric bed | Delivery couch | # deliveries in the last month |
| Woreda 7 | 6 | 6 | 4 | 2 | 40 |
| Bole 17 | 10 | 8 | 11 | 2 | 68 |
| Woreda 9,NSLSC | 5 | 3 | 10 | 1 | 52 |
| Saris | 8 | 3 | 8 | 4 | 53 |
| Teklehaymanot | 6 | 6 | 4 | 2 | 25 |
| Kebena | 6 | 6 | 5 | 2 | 18 |
| Meshualekiya | 5 | 5 | 6 | 2 | 27 |
| Shiromeda | 5 | 5 | 8 | 2 | 33 |
| Entoto 1 | 9 | 4 | 8 | 3 | 67 |
| Woreda 9, KKSC | 12 | 6 | 7 | 2 | 122 |
| Total | 72 | 52 | 71 | 22 | 505 |
| microRNAs | Location on chromosome | WT | WT+UVR | Log Fold Change | Adjusted p-value | Total # of gene targets |
| miR-127-3p | chr12: 109592846-109592915 [+] | 1.089 | −0.401 | −1.49 | 1.11E-06 | 12 |
| miR-136-3p | chr12: 109595327-109595388 [+] | 1.027 | −0.48 | −1.507 | 2.04E-06 | 32 |
| miR-136-5p | chr12: 109595327-109595388 [+] | 1.246 | −0.431 | −1.677 | 1.11E-06 | 275 |
| miR-154-5p | chr12: 109738433-109738498 [+] | 0.811 | −0.283 | −1.094 | 2.04E-06 | 201 |
| miR-185-3p | chr16: 18327401-18327465 [−] | −0.853 | 0.225 | 1.078 | 3.10E-05 | 203 |
| miR-196a-5p | chr11: 96265164-96265265 [+] | 1.441 | −1.405 | −2.846 | 1.11E-06 | 137 |
| miR-196b-5p | chr6: 52230081-52230165 [−] | 1.223 | −0.962 | −2.185 | 1.11E-06 | 134 |
| miR-206-3p | chr1: 20679010-20679082 [+] | 0.602 | −0.492 | −1.094 | 2.41E-06 | 336 |
| miR-31-3p | chr4: 88910557-88910662 [−] | −0.823 | 0.897 | 1.72 | 1.11E-06 | 100 |
| miR-31-5p | chr4: 88910557-88910662 [−] | −1.07 | 0.962 | 2.031 | 1.11E-06 | 263 |
| miR-335-5p | chr6: 30741299-30741396 [+] | 1.152 | −0.175 | −1.327 | 1.80E-05 | 237 |
| miR-376a-3p | chr12: 109723781-109723848 [+] | 1.016 | −0.382 | −1.398 | 2.90E-05 | 24 |
| miR-376b-5p | chr12: 109723458-109723539 [+] | 0.945 | −0.146 | −1.091 | 2.04E-06 | 225 |
| miR-377-3p | chr12: 109740510-109740577 [+] | 0.919 | −0.338 | −1.256 | 2.04E-06 | 517 |
| miR-379-5p | chr12: 109709060-109709125 [+] | 1.172 | −0.292 | −1.464 | 1.11E-06 | 73 |
| miR-411-5p | chr12: 109710175-109710256 [+] | 1.091 | −0.442 | −1.533 | 1.43E-06 | 157 |
| miR-434-3p | chr12: 109594506-109594599 [+] | 0.954 | −0.344 | −1.298 | 5.37E-06 | 155 |
| miR-434-5p | chr12: 109594506-109594599 [+] | 1.08 | −0.394 | −1.475 | 2.04E-06 | 24 |
| miR-511-3p | chr2: 14261003-14261081 [+] | 0.795 | −0.444 | −1.239 | 2.04E-06 | 467 |
| miR-5617-5p | chrX: 20863126-20863182 [−] | −1.015 | 0.138 | 1.152 | 3.75E-06 | 267 |
| miR-691 | chr16: 74341990-74342067 [−] | −0.897 | 0.242 | 1.139 | 2.06E-06 | 413 |
| miR-709 | chr8: 84086099-84086186 [+] | −1.091 | 0.249 | 1.34 | 2.32E-06 | 445 |
| Group 1 | Group 2 | P values | |
| NSRT | SRT | ||
| Number of retinal tears per eye | 1.42 ± 0.8 (r = 1-5) | 1.36 ± 0.5 (r = 1-2) | 0.54 |
| n (%) | n (%) | ||
| Initial retinal tear location | |||
| Superotemporal | 80 (45.5) | 11 (40.7) | 0.94 |
| Inferotemporal | 53 (30.1) | 12 (44.5) | 0.21 |
| Superonasal | 29 (16.5) | 2 (7.4) | 0.32 |
| Inferonasal | 14 (7.9) | 2 (7.4) | 0.92 |
| Retinal tear size | |||
| Small | 108 (66.3) | 11 (47.8) | 0.27 |
| Medium | 44 (27) | 9 (39.1) | 0.45 |
| Large | 11 (6.7) | 3 (13.1) | 0.32 |
| Total number of patients | Fibromyalgia+ | Fibromyalgia- | P | |
| (n = 196) | (n = 42) | (n = 154) | ||
| Patients who received at least one TNFi | 141 (71.9 %) | 33 (78.6 %) | 108 (70.1 %) | 0.28 |
| Number of TNFi treatments | 1.84 (1.0) | 2.36 (1.1) | 1.68 (0.9) | <0.01 |
| Switchers* | 9 (6.5 %) | 5 (15.2 %) | 4 (3.8 %) | 0.03 |
| First TNFi | ||||
| Mean duration of first TNFi treatment, years | 3.0 (3.8) | 1.7 (2.4) | 3.5 (4.0) | <0.01 |
| Reason for TNFi discontinuation: | ||||
| Inefficacy % | 54 (69.2 %) | 12 (54.6 %) | 42 (75.0 %) | 0.14 |
| Toxicity % | 4 (5.1 %) | 2 (9.1 %) | 2 (3.6 %) | 0.76 |
| Inefficacy + toxicity % | 4 (5.1 %) | 3 (13.6 %) | 1 (1.8 %) | 0.23 |
| Others % | 16 (20.5 %) | 5 (22.7 %) | 11 (19.6 %) | 1.00 |
| Categories and Themes and No. of participants disclosing the theme |
| Category 1: The experience of maladaptive coping responses and the perceived barriers to recovery |
| Isolating self from social support (6/8) |
| Using alcohol to gain temporary relief and to both avoid depression and associated emotions (5/8) |
| Lack of available psychological support or understanding of depression from others (4/8) |
| Not being listened to and the lack of collaboration in first experience of treatment (4/8) |
| Dealing with publicity and the continued expectations from elite sport (4/8) |
| Overtraining interpreted as self-harm (3/8) |
| Category 2: Adaptive processes and turning points in recovery |
| Separate from elite sport environment to understand depression and embark on self-discovery (6/8) |
| Channeling sporting will to win and personal agency toward a high level of commitment to recovery (6/8) |
| Experiencing acceptance and expressing real self in therapeutic relationship (5/8) |
| Support from significant other, recognizing depression and developing hope (4/8) |
| Category 3: The process of recovery and the transitions within the self |
| Being less defined by sport, broadening identity, and adopting self-care (5/8) |
| Developing intrinsic motivation an internal locus of evaluation and falling in love with sport again (5/8) |
| Coming out and gaining self-acceptance in sport and society as central to healing and recovery (4/8) |
| N= 29,157,460 | % |
| Sex | |
| Male | 49.9 |
| Female | 50.1 |
| Age | |
| 6 to 11 | 7.4 |
| 12 to 19 | 11.4 |
| 20 to 39 | 30.9 |
| 40 to 59 | 33.5 |
| 60 to 79 | 16.8 |
| Smoking Status | |
| Never smoked | 52.6 |
| Past smoker | 27.1 |
| Current smoker | 20.3 |
| Education | |
| Degree/diploma | 49.6 |
| <Degree/diploma | 50.5 |
| Immigrant Status | |
| Born in Canada | 79.0 |
| Not born in Canada | 21.0 |
| Aboriginal Status | |
| Non-Aboriginal | 96.9 |
| Aboriginal | 3.10 |
| Income adequacy | |
| Highest income | 47.9 |
| Middle income | 31.9 |
| Lowest income | 20.3 |
| Dental insurance | |
| Private coverage | 62.3 |
| Public coverage | 5.8 |
| Non-insured | 31.9 |
| Self-reported oral health | |
| Excellent/very good/good | 84.5 |
| Fair/poor | 15.5 |
| Self-reported general health | |
| Excellent/very good/good | 91.9 |
| Fair/poor | 8.1 |
| Self-reported oral pain | |
| Rarely/never | 88.4 |
| Often/sometimes | 11.6 |
| Self-perceived unmet needs | |
| No needs | 67.0 |
| Has at least one need | 33.0 |
| Brushing frequency | |
| >Once/day | 72.0 |
| Once/day | 24.6 |
| <Once/day or Never | 3.4 |
| Flossing Frequency | |
| >Once/day | 8.6 |
| Once/day | 21.4 |
| <Once/day | 42.0 |
| Never | 28.1 |
| Avoided dental treatment due to cost | |
| No | 83.5 |
| Yes | 16.5 |
| Last Dental Visit | |
| In the last year | 74.5 |
| More than one year ago | 25.5 |
| Dental Visit Frequency | |
| > Once a year | 42.6 |
| Once a year | 31.7 |
| < Once a year | 9.2 |
| Only for emergency | 13.3 |
| Never | 3.2 |
| Work/School Days Lost | |
| No | 60.9 |
| Yes | 39.2 |
| Variable | CaseN(%) | ControlN(%) | χ2 | P |
| Hypertension | 4.625 | 0.032 | ||
| Yes | 189 (12.8) | 152 (10.3) | ||
| No | 1285 (87.2) | 1325 (89.7) | ||
| Diabetes mellitus | 0.791 | 0.374 | ||
| Yes | 59 (4.0) | 50 (3.4) | ||
| No | 1410 (96.0) | 1422 (96.6) | ||
| Benign tumor of breast | 26.957 | <0.001 | ||
| Yes | 84 (5.9) | 166 (11.3) | ||
| No | 1339 (94.1) | 1298 (88.7) | ||
| Galactophore Hyperplasia | 14.52 | <0.001 | ||
| Yes | 252 (17.3) | 336 (22.9) | ||
| No | 1207 (82.7) | 1130 (77.1) | ||
| Spillage of nipple | 5.849 | 0.016 | ||
| Yes | 19 (1.3) | 37 (2.5) | ||
| No | 1433 (98.7) | 1419 (97.5) | ||
| Inverted nipple | 2.167 | 0.141 | ||
| Yes | 19 (1.3) | 11 (0.8) | ||
| No | 1432 (98.7) | 1442 (99.2) | ||
| Multiple breasts | 2.070 | 0.150 | ||
| Yes | 19 (1.3) | 29 (2.0) | ||
| No | 1430 (98.7) | 1427 (98.0) | ||
| Family history of breast cancer | 13.168 | <0.001 | ||
| Yes | 99 (6.7) | 55 (3.7) | ||
| No | 1382 (93.3) | 1423 (96.3) | ||
| Family history of first-degree relatives | 3.479 | 0.062 | ||
| Yes | 57 (4.0) | 39 (2.7) | ||
| No | 1375 (96.0) | 1392 (97.3) | ||
| Family history of second-degree relatives | 8.619 | 0.003 | ||
| Yes | 43 (3.0) | 20 (1.4) | ||
| No | 1384 (97.0) | 1409 (98.6) |
| Target mRNA | Sequence(5’-3’) | Product size |
| (Accession number) | (bp) | |
| hOCT1/SLC22A1 | AATGGACCACATCGCTCAAAA | |
| (NM_003057) | CTTCGAGGGAAAGCATCTTTAAAT | 68 |
| hOCT2/SLC22A2 | GGACGGCTGGGTGTACGA | |
| (NM_003058) | GGAGTTGGCACATACCAGGTTAA | 70 |
| hOCT3/SLC22A3 | CATGCCTTGTCACTGCGTTCT | |
| (NM_021977) | ATGTAGCCACTGTGGTCCTCAA | 63 |
| hOCTN1/SLC22A4 | CCAGAGTGGGCAGCATCAT | |
| (NM_003059) | TAGGGCAGCATTCTGTTGTAAGC | 67 |
| hOCTN2/SLC22A5 | CCTTCTCTTCATGCAGCTGGTA | |
| (NM_003060) | CCCACCATCACCAGGACTGT | 66 |
| hMATE1/SLC44A1 | CAGTCACGCTGGCAATCG | |
| (NM_080546) | GGTGTCACAGGCAGAAGATAAGC | 77 |
| hMATE2/SLC44A2 | TCTGAGAGGAACTGGGAAGCA | |
| (NM_152908) | AGGCCGATGATGTAATATGTGATG | 69 |
| hPMAT/SLC29A4 | CAGCTTTCACGGATACTACATTGG | |
| (NM_001040661) | GCAAAGTAGATGGCGTGATAACG | 67 |
| hGAPDH | CCACATCGCTCAGACACCAT | |
| (NM_002046) | GCGCCCAATACGACCAAAT | 66 |
| Total | HPV awareness | Prevalence ratio | 95% CI | P | |
| Age at first sexual intercourse | 0.307 | ||||
| ≤15 | 132 | 33.3% | 1 | ||
| > 15 | 169 | 39.1% | 1.17 | [0.86-1.59] | |
| Number of lifetime sexual partners | 0.238* | ||||
| 1 | 120 | 37.5% | 1 | ||
| 2-3 | 116 | 28.5% | 0.76 | [0.52-1.10] | |
| ≥4 | 65 | 49.2% | 1.31 | [0.94-1.84] | |
| Previous STI1 | 0.002 | ||||
| No | 292 | 34.9% | 1 | ||
| Yes | 9 | 88.9% | 2.55 | [1.93-3.36] | |
| Abortion | 0.603 | ||||
| No | 282 | 36.2% | 1 | ||
| Yes | 19 | 42.1% | 1.16 | [0.67-2.02] | |
| Contraception | 0.398 | ||||
| No | 74 | 32.4% | 1 | ||
| Yes | 227 | 37.9% | 1.17 | [0.81-1.69] |
| Item | People with diabetes are advised to regularly check their feet and the inside of their shoes. People differ a lot with respect to the importance they attach to “good advice“ of this kind. How important is this advice for you personally? | ||
| Reply options | not important | a little important | important or very important |
| Tailored answer | OK, so this recommendation is not important for you. Maybe you are very aware of the inconvenience of daily foot care. You are right there; it takes some effort in the beginning. At the same time it helps a lot to prevent diabetic foot syndrome. A diabetic foot can be painful and can lead to amputation. There is a great benefit for the comparatively small effort of taking care of your feet. For many people the first step is the hardest. Once you get used to it, the effort does not seem so great anymore. | OK, so this recommendation is a little important for you. Maybe you are aware of the inconvenience of daily foot care. At the same time it helps a lot to prevent diabetic foot syndrome. A diabetic foot can be painful and can lead to amputation. There is a great benefit for the comparatively small effort of taking care of your feet. For many people the first step is the hardest. Once you get used to it, the effort does not seem so great anymore. | You are right, this recommendation is really important. Looking after your feet can be inconvenient but helps a lot to prevent diabetic foot syndrome. A diabetic foot can be painful and can lead to amputation. There is a great benefit for the comparatively small effort of taking care of your feet. |
| Area | Sex | Age (years) | No. at the 1st 1) | No. at the 2nd 2) | Seroconversion rate (%) |
| Trial | Male | 2-5 | 1 | 0 | 0 |
| >5 | 15 | 12 | 80.0 | ||
| Female | 2-5 | 6 | 2 | 33.3 | |
| >5 | 15 | 9 | 60.0 | ||
| Control | Male | 2-5 | 2 | 1 | 50.0 |
| >5 | 34 | 25 | 73.5 | ||
| Female | 2-5 | 3 | 2 | 66.6 | |
| >5 | 20 | 16 | 80.0 |
| Parameter | Calcium Diphosphate | Chitin | Lactose H2O | Avicel PH 101 | Starch 1500 | PVP K30 | Sorbitol |
| PY | 250.1 | 122 | 150 | 62.5 | 75.1 | 35.7 | 48.4 |
| D0 | 0.36 | 0.12 | 0.38 | 0.23 | 0.33 | 0.27 | 0.39 |
| DA | 0.49 | 0.52 | 0.69 | 0.44 | 0.48 | 0.72 | 0.79 |
| DB | 0.13 | 0.31 | 0.31 | 0.21 | 0.15 | 0.46 | 0.4 |
| No ETOH Group (n = 1,445) | Low ETOH Group (n = 273) | High ETOH Group (n = 605) | Total (n = 2,323) | P value# | ||
| Severe head injury | % | 66.5 | 68.5 | 59.8 | 64.85 | 0.016 |
| Severe chest injury | % | 56.9 | 54.8 | 48.5 | 54.64 | 0.023 |
| Severe abdomen injury | % | 25.3 | 28.1 | 28.8 | 26.44 | NSS |
| Severe extremity injury | % | 5.3 | 4.0 | 1.7 | 4.18 | 0.012 |
| ISS | Mean (SE) | 31.3 (0.3) | 32.4 (0.7) | 30.3 (0.5) | 31.2 (0.3) | NSS* |
| Length of stay (days) | Mean (SE) | 22.6 (0.7) | 21.3 (1.4) | 22.7 (1.4) | 22.5 (0.6) | NSS* |
| Mortality | % | 15.5 | 16.9 | 13.6 | 15.15 | NSS |
| Type | Method | Gold standard fusion genes detected | Sensitivityb | Total fusion genes detected | Precision | F-score |
| SGS + TGS | IDP-fusion 2LR + 2SRa | 24 | 33.80% | 35 | 68.57% | 0.4528 |
| IDP-fusion 2LR + 1SR | 24 | 33.80% | 37 | 64.86% | 0.4444 | |
| SGS | TopHat-Fusion | 16 | 22.54% | 59 | 27.12% | 0.2462 |
| SOAPfuse | 10 | 14.08% | 39 | 25.64% | 0.1818 | |
| TRUP | 22 | 30.99% | 63 | 34.92% | 0.3284 | |
| FusionMap | 20 | 28.17% | 205 | 9.76% | 0.1449 | |
| deFuse | 27 | 38.03% | 196 | 13.78% | 0.2022 | |
| BreakFusion | 15 | 21.13% | 130 | 11.54% | 0.1493 | |
| TGS | IsoSeq | 15 | 21.13% | 83 | 18.07% | 0.1948 |
| Patient ID | Sample ID | Gender | Age at test | Type of cancer | Sample type |
| 1 | F1311260008 | Female | 64 | Lung cancer, SCC | FFPE |
| 2 | B1312160009 | Female | 61 | Colon cancer | Blood |
| 3 | F1312230017 | Male | 54 | Lung cancer, SCC | FFPE |
| 4 | F1401170002 | Male | 57 | Rectal cancer | FFPE |
| 5 | F1401170004 | Male | 53 | Lung adenocarcinoma | FFPE |
| 6 | F1402240017 | Male | 20 | Neuroectodermal tumor | FFPE |
| 7 | F1410200833B1410200832 | Female | 52 | Lung adenocarcinoma | FFPE |
| 8 | C1409280774B1409280773 | Male | 67 | Lung adenocarcinoma | Pleural fluid |
| 9 | F1411100940B1411100938 | Female | 53 | Breast cancer | FFPE |
| 10 | F1412241251B1412241250 | Female | 66 | Lung adenocarcinoma | FFPE |
| Variables | Watching porn videos | Attending night clubs | Sex with commercial sex workers | ||||
| COR (95% CI) | AOR (95% CI) | COR (95% CI) | AOR (95% CI) | COR (95% CI) | AOR (95% CI) | ||
| Sex | |||||||
| Male | 4.8 (3.5 - 6.5)** | 4.1 (2.9 - 5.8)** | 3.9 (2.3 - 6.7)** | 2.3 (1.3 - 4.3)** | NA | NA | |
| female | 1 | 1 | 1 | 1 | |||
| Age | |||||||
| 18 – 20 | 1 | 1 | |||||
| 20 – 24 | 3.5 (1.4 - 9.0)** | 1.3 (0.9 - 2.0) | _ | _ | _ | _ | |
| > 24 | 2.2 (0.9 - 5.5) | 3.0 (1.1 - 8.4)** | _ | _ | _ | _ | |
| Year of study | |||||||
| Year I | 1 | 1 | 1 | 1 | |||
| Year II | 0.7 (0.5 - 0.9) | 1.2 (0.8 - 1.8) | 1.2 (0.4 - 3.5) | 2.3 (0.6 - 9.2) | ─ | ─ | |
| Year III | 0.5(0.3 - 0.7) | 1.6 (0.9 - 2.6) | 2.2 (0.8 - 6.4) | 3.4 (0.9 - 13.5) | ─ | ─ | |
| Year IV | 0.8 (0.4 - 1.3) | 1.2 (0.6 - 2.5) | 3.1 (1.1 - 9.2)** | 3.7 (0.9 - 14.4) | ─ | ─ | |
| Year V | 0.9 (0.5 - 1.8) | 1.3 (0.6 - 2.8) | 1.7 (0.5 - 5.7) | 2.8 (0.6 - 13.5) | ─ | ─ | |
| Ethncity | |||||||
| Amhara | 1.4 (0.9 - 2.1) | 0.7 (0.4 - 1.2) | 0.9 (0.5 - 1.7) | 1.8 (0.8 - 3.7) | ─ | ─ | |
| Oromo | 0.9 (0.5 - 1.5) | 1.3 (0.7 - 2.4) | 1.4 (0.7 - 2.8) | 1.95 (0.8 - 4.5) | ─ | ─ | |
| Tigray | 1.02 (0.6 - 1.9) | 1.2 (0.6 - 2.3) | 2.2 (1.1 - 4.4)** | 5.6 (2.2 - 14.2)** | ─ | ─ | |
| Other | 1 | 1 | 1 | 1 | ─ | ─ | |
| Religion | |||||||
| Orthodox | ─ | ─ | 1 | 1 | |||
| Muslim | ─ | ─ | 0.6 (0.3 - 1.3) | 0.73 (0.3 - 1.8) | ─ | ─ | |
| Protestant | ─ | ─ | 0.6 (0.3 -1.3) | 0.73 (0.3 - 1.9) | ─ | ─ | |
| Other | ─ | ─ | 3.1 (1.3 - 7.7)** | 4.0 (1.0 - 16.1) | ─ | ─ | |
| Chewing | |||||||
| khat | Never | 1 | 1 | 1 | 1 | 1 | 1 |
| Some times | 4.1 (2.4 - 6.9)** | 2.0 (1.1 - 3.6)** | 9.8 (6.3 - 15.4)** | 6.48 (3.9 - 10.9)** | 0.3 (0.1 - 0.9)** | 0.54(0.2 - 1.5) | |
| Always | 1.1 (0) | 1.1 (0) | 27.2 (10.8 - 68.3) | 18.7 (6.4 - 53.9)** | 0.3 (0.1 - 1.1) | 0.38 (0.1 - 2.2) | |
| Alcoholism | |||||||
| Never | 1 | 1 | 1 | 1 | 1 | 1 | |
| Always | 1.2 (0.6 - 2.4) | 0.61(0.3 - 1. 4) | 9.3 (3.6 - 24)** | 3.3 (1.1 - 10.1)** | 0.3 (0.0 - 3.3) | 0.8 (0.1 - 9.9) | |
| Sometimes | 6.4 (4.4 - 9.4)** | 4.78 (3.2 - 7.2)** | 15.8 (8.9 - 27.7)** | 9.5 (5.2 - 17.5)** | 0.2 (0.1 - 0.9)** | 0.6 (0.1 - 2.3) | |
| Attending | |||||||
| night clubs | Yes | 4.2 (0.3 - 7.2) | 0.9 (0.5 - 1.8) | NA | NA | 4.2 (1.7 - 10.8)** | 4.6 (1.8 - 1.8)** |
| No | 1 | 1 | 1 | 1 |
| Variable† | Odds ratio | 95% CI‡ | |
| Pretreatment HCV RNA level§ | Per 1 log increase | 0.179 | 0.096–0.336 |
| HCV genotype | 1b = 1; non-1b = 0 | 0.324 | 0.151–0.695 |
| IFN-α regimen | 6-MU = 1; 3-MU = 0¶ | 2.310 | 1.070–4.990 |
| Stage of fibrosis | F3–4 = 1; F0–2 = 0 | 0.408 | 0.104–0.892 |
| Family | Millet Zhang gu | Millet Yugu1 | Maize |
| AUX/IAA | 29 | 29 | 52 |
| GIF | 3 | 3 | 3 |
| MBF1 | 2 | 2 | 3 |
| Med10 | 1 | 1 | 2 |
| Med11 | 1 | 1 | 2 |
| Med12 | 1 | 1 | 6 |
| Med13_C | 1 | 1 | 1 |
| Med14 | 2 | 2 | 1 |
| Med17 | 1 | 1 | 2 |
| Med18 | 1 | 1 | 0 |
| Med20 | 1 | 1 | 1 |
| Med22 | 1 | 1 | 1 |
| Med31 | 1 | 1 | 1 |
| Med4 | 1 | 1 | 2 |
| Med6 | 1 | 1 | 2 |
| Med7 | 2 | 2 | 2 |
| PC4 | 2 | 2 | 3 |
| RB | 2 | 2 | 5 |
| Sigma54_activat | 9 | 10 | 9 |
| Spt20 | 2 | 2 | 1 |
| TAZ | 7 | 7 | 7 |
| OFP | 33 | 27 | 43 |
| Variables | Survival statusDead Censored | CHR (95%CI) | AHR (95%CI) | |
| Sex | ||||
| Male | 23 | 154 | 2.5 (1.3, 5.0) | 1.3 (0.6, 3.0) |
| Female | 15 | 198 | 1 | 1 |
| Age | ||||
| < 1yer | 3 | 8 | 4.9 (1.4, 17.0) | 2.5 (0.6, 9.9) |
| 1-5 years | 17 | 99 | 2.2(1.1, 4.3) | 1.7(0.7, 3.7) |
| 5-15 years | 18 | 245 | 1 | 1 |
| Residence | ||||
| Urban | 35 | 298 | 1 | 1 |
| Rural | 3 | 54 | 0.6(0.2, 2.0) | 0.5(0.1, 1.7) |
| OI at baseline | ||||
| Yes | 30 | 152 | 4.3 (2.0,9.0) | 1.9 (0.8, 4.5) |
| No | 8 | 200 | 1 | 1 |
| WHO clinical staging | ||||
| Stage I and II | 8 | 221 | 1 | 1 |
| Stage III and IV | 30 | 131 | 5.6 (2.6, 12.3) | 2.6 (1.1, 6.6)** |
| CD4 count or percent | ||||
| Below the threshold | 33 | 2410 | 3.2 (1.2, 8.2) | 5.2 (1.9, 14.1)** |
| Above the threshold | 5 | 112 | 1 | 1 |
| Hemoglobin level | ||||
| < 10 g/dl | 15 | 32 | 6.2 (3.2, 11.9) | 3.2 (1.4, 7.4)** |
| ≥ 10 g/dl | 23 | 320 | 1 | 1 |
| Underweight | ||||
| Normal | 10 | 242 | 1 | |
| Moderate (WAZ < − 2 | 13 | 66 | 4.2 (1.8, 9.6) | 2.4 (0.9,6.4) |
| Severely (WAZ < −3) | 15 | 44 | 6.8 (3.01, 15.2) | 1.3 (0.5, 3.6) |
| Stunting | ||||
| Normal | 12 | 254 | 1 | 1 |
| Moderate (HAZ < −2) | 8 | 39 | 3.9 (1.6, 9.7) | 2.3 (0.9, 6.29) |
| Severe (HAZ < −3) | 18 | 59 | 6.1 (2.9, 12.9) | 3.9 (1.7, 9.4)** |
| Wasting | ||||
| Normal | 18 | 269 | 1 | 1 |
| Moderate (WHZ or BAZ < −2) | 5 | 44 | 1.5 (0.5, 4.0) | 1.2 (0.4, 3.6) |
| Severe (WHZ or BAZ < −3) | 15 | 39 | 4.5 (2.2,9.0) | 3.0 (1.3, 6.9)** |
| Variables | Frequency | Percentage | |
| Age | 15-19 years | 16 | 3.8 |
| 20-34 years | 333 | 79.5 | |
| 35-49 years | 70 | 16.7 | |
| Mean ±SD | (27.4 ± 6.1) | ||
| Literacy status | No schooling | 134 | 32 |
| Schooling | 285 | 68 | |
| Occupation | House wife | 240 | 57.3 |
| Other* | 179 | 42.7 | |
| Average monthly family income | below 401 | 134 | 31.7 |
| 401-1000 | 174 | 41.8 | |
| above 1000 | 111 | 26.5 | |
| Mean ±SD | (797.3 ±669.9) | ||
| Family size | 1-3 | 123 | 29.4 |
| 4-5 | 203 | 48.4 | |
| above 5 | 93 | 22.2 | |
| Mean ±SD | (4.6±1.7) | ||
| Media exposure | No exposure | 122 | 29.1 |
| Radio or TV | 150 | 35.8 | |
| Radio and TV | 147 | 35.1 |
| Without MHC | With MHC | p-value | |
| Patient mediated diagnostic delay (N = 368, %) | |||
| No | 187 (80.26) | 108 (80) | 0.99 |
| Yes | 46 (19.74) | 27 (20) | |
| Patient mediated treatment delay (N = 380, %) | |||
| No | 205 (85.42) | 117 (82.98) | 0.7909 |
| Yes | 34 (14.58) | 24 (17.02) | |
| Patient deviation from standard of care treatment (N = 389, %) | |||
| No | 212 (86.18) | 116 (81.82) | 0.1857 |
| Yes | 34 (13.82) | 27 (18.18) |
| Nutrient Content | Unweighted Estimates (n = 431 Products) | Estimates Weighted by Household Purchase Volumes (n = 419 Products) | ||||||||
| 2014 | 2016 | Mean Difference (95% CI) | p-Value * | % diff # | 2014 | 2016 | Mean Difference (95% CI) | p-Value * | % diff # | |
| Mean (SD) | Mean (SD) | |||||||||
| Energy, KJ/100 g | 1028.8 (790.4) | 1000.2 (782.0) | −28.6 (−46.5 to −10.6) | 0.002 | −1.5 | 1026.8 (794.6) | 997.3 (785.8) | −29.5 (−48.0 to −11.0) | 0.002 | −1.5 |
| Saturated fat, g/100 g | 2.3 (3.7) | 2.2 (3.7) | −0.1 (−0.2 to 0.01) | 0.07 | −3.7 | 2.3 (3.7) | 2.2 (3.8) | −0.1 (−0.2 to 0.01) | 0.07 | −4.8 |
| Total sugars, g/100 g | 9.9 (11.7) | 9.6 (11.3) | −0.3 (−0.7 to 0.1) | 0.14 | −4.6 | 9.8 (11.8) | 9.5 (11.4) | −0.3 (−0.7 to 0.1) | 0.18 | −4.4 |
| Sodium, mg/100 g | 357.4 (627.7) | 308.4 (441.7) | −49.0 (−93.0 to −5.0) | 0.03 | −6.7 | 363.2 (635.4) | 312.7 (446.8) | −50.5 (−95.7 to −5.2) | 0.03 | −4.6 |
| Protein, g/100 g | 8.5 (8.7) | 8.3 (8.6) | −0.2 (−0.9 to 0.4) | 0.5 | −1.9 | 8.2 (8.3) | 8.0 (8.2) | −0.2 (−0.9 to 0.4) | 0.48 | −1.9 |
| Fibre, g/100 g | 4.9 (5.4) | 5.4 (5.2) | 0.5 (0.2 to 0.8) | 0.001 | 5.3 | 4.6 (4.9) | 5.1 (4.7) | 0.5 (0.2 to 0.9) | 0.001 | 6.0 |
| Forensic autopsy | ||
| Molecular autopsy | + (n = 26) | − (n = 24) |
| + (n = 14) | 9 | 5 |
| − (n = 36) | 17 | 19 |
| Women screened N | Interval tumors N | Ratio/10000 (95% IC poisson) | Sensitivity (%) | |
| 50-59 initial | ||||
| Round 1 | 20221 | 17 | 8.41 (8.37-8.45) | 104/121 (85.95) |
| Round 2 | 7675 | 4 | 5.21 (5.11-5.26) | 36/40 (90.0) |
| 50-59 succesive | ||||
| Round 2 | 14811 | 9 | 6.08 (6.04-6.12) | 47/56 (83.93) |
| 60-69 initial | ||||
| Round 1 | 6953 | 4 | 5.75 (5.69-5.81) | 53/57 (92.98) |
| Round 2 | 1837 | 3 | 16.33 (16.15-16.51) | 17/20 (85.00) |
| 60-69 successive | ||||
| Round 2 | 9449 | 6 | 6.35 (6.30-6.40) | 42/48 (87.50) |
| Assembly names | A | B | C | D |
| Assembly tools | ||||
| Contig assembly tool | Fermi | Fermi | SOAPdenovo2 | SOAPdenovo2 |
| Scaffolding tool | SOAPdenovo2 | SSPACE | SOAPdenovo2 | SSPACE |
| Gap closing tool | GapCloser | GapCloser | GapCloser | GapCloser |
| Assembly metrics | ||||
| Total contigs (>1,000 bp) | 71,429 | 71,429 | 189,566 | 189,566 |
| Contig N50 | 54,944 | 54,944 | 4,048 | 4,048 |
| Contig CEGMA (%)* | 96.37(77.42) | 96.37(77.42) | 68.15(33.06) | 68.15(33.06) |
| Contig BUSCO (%) | 86(65) | 86(65) | 42(21) | 42(21) |
| Total scaffolds (>1,000 bp) | 14,417 | 40,372 | 20,466 | - |
| Final N50 | 555,585 | 110,915 | 331,639 | - |
| Final CEGMA (%) | 95.56(81.85) | 95.97(88.71) | 95.97(90.73) | - |
| Final BUSCO (%) | 91(74) | 86(64) | 94(80) | - |
| Quality | ||||
| Percentage of Ns (%) | 0.06322 | 0.0135 | 0.02622 | - |
| REAPR error-free bases (%) | 96.46 | 95.35 | 94.98 | - |
| REAPR low-scoring regions | 18 | 16 | 71 | - |
| REAPR incorrectly oriented reads | 11,543 | 5,329 | 28,964 | - |
| Group | No. oocytes | Survival rate | Cleavage rate | Blastocyst rate |
| Control | 132 | 100% ± 0 (132/132)a | 84.21% ± 2% (111/132)a | 38.62% ± 0.75% (51/132)a |
| Toxicity | 103 | 93.22% ± 1.56% (96/103)b | 76.74% ± 2.27% (79/96)b | 35.93% ± 1.47% (37/96)a |
| Vitrified | 105 | 81.08% ± 2.86% (89/105)c | 63.49% ± 2.1% (66/105)c | 19.96% ± 1.06% (21/105)b |
| Project | Primer sequences | Amplified fragment length |
| GAPDH | F: 5′ GAAGAGTGGGTGTCGCTGTT 3′ | 141 bp |
| R: 5′ CTGCCGTCTGGAAAAACCT 3′ | ||
| CREB | F: 5′ GTGCCAGCCTTTCCTTACAC 3′ | 109 bp |
| R: 5′ CACAAACCCACTGATGAACG 3′ |
| Groups | Number of clusters | Number of clones | Clones/clusters | % of total | Putative identification |
| 1 | 542 | 741 | 1.37 | 24.6 | No Hit* |
| 2 | 91 | 489 | 5.37 | 16.3 | Sphingomyelinase D* |
| 3 | 59 | 248 | 4.20 | 8.2 | Metalloproteinase* |
| 4 | 83 | 105 | 1.27 | 3.5 | Unknown Function* |
| 5 | 9 | 75 | 8.33 | 2.5 | Troponin |
| 6 | 4 | 55 | 13.75 | 1.8 | Actin |
| 7 | 14 | 46 | 3.29 | 1.5 | Hsp* |
| 8 | 7 | 43 | 6.14 | 1.4 | Elongation Factor |
| 9 | 7 | 41 | 5.86 | 1.4 | Salivary protein* |
| 10 | 3 | 38 | 12.67 | 1.3 | 5'-nucleotidase* |
| 11 | 7 | 36 | 5.14 | 1.2 | Myosin |
| 12 | 5 | 26 | 5.20 | 0.9 | Chitinase* |
| 13 | 4 | 23 | 5.75 | 0.8 | Tubulin |
| 14 | 2 | 23 | 11.50 | 0.8 | LIM protein |
| 15 | 6 | 22 | 3.67 | 0.7 | PDI* |
| 16 | 2 | 18 | 9.00 | 0.6 | Venom allergen III* |
| 17 | 6 | 15 | 2.50 | 0.5 | Lectin* |
| 18 | 12 | 14 | 1.17 | 0.5 | Serine Protease* |
| 19 | 2 | 13 | 6.50 | 0.4 | ATP-binding |
| 20 | 9 | 12 | 1.33 | 0.4 | Ubiquitin |
| rA - ra | Number of generations needed for the relative proportion of a clone to change from 1% to 99% |
| 0.01 | 919 |
| 0.05 | 184 |
| 0.10 | 92 |
| 0.50 | 18 |
| 0.75 | 12 |
| 1.00 | 9 |
| 2.00 | 5 |
| 5.00 | 2 |
| Sample type | Origin | Origin | Period/yearsbefore present | Numberof samples | Reference | PUBMED ID | SRA accession |
| Completeground teeth | Published works | England | 750–650 | 6 | Adler et al.9 | 23416520 | ERP002107 |
| Germany | 1000–400 | ||||||
| 7400–6725 | |||||||
| 4150–3600 | |||||||
| Germany | 800–1100 | 14 | Warinner et al.8 | 24562188 | SRP029257 | ||
| Dental root canal | Brazil | Modern | 17 | Santos et al.10 | 22132218 | ERP000669 | |
| Dental pulp | This study | France | First World War (WWI) | 6 | N/A | N/A | SRP068830 |
| Nigeria | 500 | 15 | |||||
| France | Modern | 2 | |||||
| Dental calculus | Published works | England | 750–650 | 55 | Adler et al.9 | 23416520 | ERP002107 |
| Germany | 1000–400 | ||||||
| 1100–850 4100–2800 | |||||||
| 4150–3600 4450–4000 | |||||||
| 7400–6725 7550–5450 | |||||||
| Germany | 800–1100 | 4 | Warinner et al.8 | 24562188 | SRP029257 | ||
| Saliva | US | Modern | 29 | Pride et al.11 | 22158393 | SRA024393 | |
| US | Modern | 9 | The HMP (Gevers et al.)12 | 22904687 | SRP002395 | ||
| Oral cavity (diverse regions) | US | Modern | 68 | The HMP (Gevers et al.)12 | 22904687 | SRP002395 | |
| Soil | Germany | Modern | 18 | Will et al.13 | 20729324 | SRA020168 | |
| Different environments | Modern | 151 | Bates et al.14 | 21085198 | N/A |
| Value | GENIA | ST | ST(%)/GENIA(%) | ||
| frequency | % | frequency | % | ||
| Investigation | 1,914 | 5.3 | 520 | 5.5 | 1.03 |
| Analysis | 6,412 | 17.8 | 1,448 | 15.3 | 0.86 |
| Observation | 12,479 | 34.7 | 3,892 | 41.0 | 1.18 |
| Fact | 2,900 | 8.1 | 570 | 6.0 | 0.75 |
| Method | 973 | 2.7 | 40 | 0.4 | 0.16 |
| Other | 11,309 | 31.4 | 3,024 | 31.9 | 1.01 |
| L3 | 33,090 | 91.9 | 8,921 | 94.0 | 1.02 |
| L2 | 2,148 | 6.0 | 485 | 5.1 | 0.86 |
| L1 | 749 | 2.1 | 88 | 0.9 | 0.45 |
| Positive | 33,779 | 93.9 | 8,939 | 94.2 | 1.00 |
| Negative | 2,208 | 6.1 | 555 | 5.8 | 0.95 |
| High | 1,381 | 3.8 | 466 | 4.9 | 1.28 |
| Low | 322 | 0.9 | 112 | 1.2 | 1.32 |
| Neutral | 34,284 | 95.3 | 8,916 | 93.9 | 0.99 |
| Current | 35,447 | 98.5 | 9,370 | 98.7 | 1.00 |
| Other | 540 | 1.5 | 124 | 1.3 | 0.87 |
| Event Total | 35,987 | 100.0 | 9,494 | 100.0 | 1.00 |
| Disease | Cell surface DAF deficiency | Citation |
| Immune dysregulation | ||
| Sjogren's Syndrome | T-lymphocytes | [36] |
| SLE with lymphopenia and anemia | T-lymphocytes (CD8+), endothelium, lymphocytes, and anemia | [38, 41, 73] |
| Psoriatic skin | Epithelium and endothelium | [39] |
| Systemic sclerosis | Endothelium | [37] |
| Vasculitic skin lesions | Endothelium | [35] |
| Recurrent pregnancy loss in aPL | Endometrium | [42] |
| Autoimmune hemocytopenia | Platelets, lymphocytes, and RBC | [43, 44] |
| Rheumatoid arthritis | Neutrophils and RBC | [45, 46] |
| Myasthenia gravis | SNP with decreased expression | [47] |
| Vitiligo | Whole epidermis | [48] |
| Asthma | Bronchial epithelial cells and SNP | [49, 50] |
| Proliferative disorders | ||
| Myelodysplastic syndrome | Granulocytes and RBC | [51, 52] |
| Plasma cell dyscrasias | RBC | [53] |
| Lymphoproliferative disorders | RBC | [54] |
| Anemias | ||
| Anemia of malaria | RBC | [55–59] |
| Aplastic anemia | RBC | [51] |
| HIV | RBC, lymphocytes, and PBMC | [60, 61] |
| Authors | Study subjects | Substances | Insults | Results |
| Broekhuizen [67] | Patients | Sulodexide | Diabetes mellitus type 2 | GCX thickness increased |
| Gao [71] | Rats | Hydrocortisone | Pancreatitis | Improved intestinal perfusionAttenuation of Syn-1 and HA release |
| Nordling [72] | Endothelial cells | Immobilized heparin conjugate | IRI | Attenuation of thrombotic disorder |
| Strunden [75] | Isolated mouse lung | HES | Heparinase | HES attenuated interstitial edema, increased pulmonary arterial pressure |
| Chappell [70] | Isolated guinea pig heart | Corticosteroid | IRI | Increase in Syn-1 and reduction in HS |
| Chappell [79] | Isolated guinea pig heart | Sevoflurane | IRI | Increase in Syn-1 and reduction in HS |
| Region | Number tested | Blood slide microscopy | Rapid diagnostic test (ParaScreen) | |||||
| Pf % | Pv % | Pf & Pv % | Total % (95%CI) | Pan/Pf % | Pan % | Total % (95%CI) | ||
| Amhara | 7,664 | 2.4 | 1.9 | 0.4 | 4.6 (3.8–5.7) | 2.0 | 1.1 | 3.1 (2.4–3.9) |
| Oromia | 1,982 | 0.7 | 0.1 | 0 | 0.9 (0.5–1.6) | 1.5 | 1.2 | 2.6 (1.1–6.5) |
| SNNP | 1,858 | 3.6 | 1.8 | 0 | 5.4 (3.4–8.5) | 4.5 | 1.7 | 6.2 (3.6–10.2) |
| Total | 11,504 | 2.2 | 1.6 | 0.3 | 4.1 (3.4–5.0) | 2.1 | 1.1 | 3.3 (2.6–4.1) |
| Lipid profile | Case Number (%) | Control Number (%) | Total subjects Number (%) | P value∗ |
| Dyslipidemia | ||||
| No | 22 (18) | 29 (23.8) | 51 (20.9) | 0.27 |
| Yes | 100 (82) | 93 (76.2) | 193 (79.1) | |
| Hypertriglyceridemia | ||||
| No | 61 (50) | 82 (67.2) | 143 (58.6) | 0.006 |
| Yes | 61 (50) | 40 (32.8) | 101 (41.4) | |
| Hypercholesterolemia | ||||
| No | 70 (57.4) | 91 (74.6) | 161 (66) | 0.005 |
| Yes | 52 (42.6) | 31 (25.4) | 83 (34) | |
| High LDL | ||||
| No | 86 (70.5) | 103 (84.4) | 189 (77.5) | 0.009 |
| Yes | 36 (29.5) | 19 (15.6) | 55 (22.5) | |
| Low HDL | ||||
| No | 60 (49.2) | 52 (42.6) | 112 (45.9) | 0.304 |
| Yes | 62 (50.8) | 70 (57.4) | 132 (54.1) |
| Area | Example | Potential utility | Limitations |
| Risk prediction | Predict new-onset AF or AF-related morbidity (stroke, heart failure, mortality risk) | Benchmark for clinical trial development | Absence of known preventive strategies for AF |
| Facilitate AF and clinical outcome prevention | Cohorts for genetic risk score derivation predominantly of European ancestry | ||
| Small relative risks of discovered variants | |||
| Complexity of incorporation into clinical practice | |||
| Cost | |||
| Untested | |||
| Predict AF progression | Early antiarrhythmic or ablation intervention | Unclear relations between AF progression and morbidity and mortality | |
| Untested | |||
| Patient management | Pharmacogenetics | Maximize efficacy, minimize adverse effects | Development of novel agents with wide therapeutic margins |
| Thromboembolism prophylaxis | Ablation and mechanical interventions as alternatives | ||
| Antiarrhythmic therapy | Complexity of incorporation into clinical practice | ||
| Cost | |||
| Untested |
| Group | Number of Subjects | Average Age (Range) | Average Height, cm | Average Mass kg | Average Vital Capacity, L |
| Females | 29 | 25.5 ± 3.7 (18 to 31) | 164 ± 6 | 60.5 ± 13.3 | 3.58 ± 0.63 |
| Males | 19 | 26.5 ± 4.3 (19 to 34) | 177 ± 7 | 74.1 ± 8.8 | 4.72 ± 8.4 |
| History | No abnormality on IPS | Abnormality on IPS | Total |
| Family history of epilepsy | 16 | 0 | 16 |
| Consanguinity | 14 | 1 | 15 |
| No family history | 94 | 12 | 106 |
| Total | 124 | 13 | 137 |
| (−592 C/A) (rs1800872) | (−819 C/T) (rs1800871) | ||||||
| Genotype | n(%)SICL/(%)NCL (n = 204/166) | ORa (IC95%) | p Value* | Genotype | n(%)SICL/(%)NCL (n = 204/166) | ORa (IC95%) | p Value* |
| Codominant Model | Codominant Model | ||||||
| C/C | 50(24.5)/66(40) | 1 | C/C | 64(31.4)/57(34.3) | 1 | ||
| C/A | 105(52)/70(42) | 2.0(1.21-3.32) | 0.007 | C/T | 94(46)/75(45.2) | 1.16(0.71-1.92) | 0.53 |
| A/A | 49(24)/30(18) | 2.07(1.10-3.89) | 0.02 | T/T | 46(22.6)/34(20.5) | 1.15(0.62-2.12) | 0.64 |
| Dominant Model | Dominant Model | ||||||
| C/C | 50(24.5)/66(40) | 1 | C/C | 64(31.4)/57(34.3) | 1 | ||
| C/A + A/A | 154(76)/100(60) | 2.02(1.26-3.25) | 0.003 | C/T + T/T | 140(68.5)/109(65.7) | 1.16(0.73-1.84) | 0.51 |
| Recessive Model | Recessive Model | ||||||
| C/C + C/A | 155(76)/136(82) | 1 | C/C + C/T | 158(77.4)/132(79.5) | 1 | ||
| A/A | 49(24)/30(18) | 1.37(0.79-2.39) | 0.25 | T/T | 46(22.6)/34(20.5) | 1.05(0.61-1.81) | 0.84 |
| Alleles | Alleles | ||||||
| C | 205(51)/202(60) | 1 | C | 222(54)/189(57) | 1 | ||
| A | 203(49)/130(40) | 1.32 (0.97-1.81) | 0.07 | T | 186(46)/143(43) | 1.10(0.80-1.50) | 0.53 |
| p HWE** | 0.13 | p HWE** | 0.31 | ||||
| (−1082 A/G) (rs1800872) | (−1352 G/A) (rs1800893) | ||||||
| Genotype | n(%)SICL/(%)NCL (n = 204/166) | ORa (IC95%) | p Value* | Genotype | n(%)SICL/(%)NCL (n = 204/166) | ORa (IC95%) | p Value* |
| Codominant Model | Codominant Model | ||||||
| A/A | 125(61.3)/92(55.4) | 1 | G/G | 130(63.72)/102(61.44) | 1 | ||
| A/G | 66(32.3)/62(37.3) | 0.95(0.59-1.52) | 0.84 | G/A | 64(31.37)/53(31.94) | 1.28(0.78-2.07) | 0.31 |
| G/G | 13(6.4/12(7.3) | 1.02(0.42-2.44) | 0.96 | A/A | 10(4.9)/11(6.62) | 0.85(0.33-2.22) | 0.75 |
| Dominant Model | Dominant Model | ||||||
| A/A | 125(61.3)/92(55.4) | 1 | G/G | 130(63.72)/102(61.44) | 1 | ||
| A/G + G/G | 79(38.7)/74(44.6) | 0.96(0.61-1.50) | 0.87 | G/A + A/A | 74(36.27)/64(38.56) | 1.20(0.76-1.90) | 0.42 |
| Recessive Model | Recessive Model | ||||||
| A/A + A/G | 191(93.6)/154(92.7) | 1 | G/G + G/A | 194(95)/155(93.38) | 1 | ||
| G/G | 13(6.4/12(7.3) | 1.04(0.44-2.44) | 0.92 | A/A | 10(4.9)/11(6.62) | 0.78(0.30-1.99) | 0.6 |
| Alleles | Alleles | ||||||
| A | 316(77)/246(74) | 1 | G | 324(79)/257(77) | 1 | ||
| G | 92(23)/86(26) | 1.01(0.71-1.45) | 0.92 | A | 84(21)/75(23) | 1.08(0.74-1.58) | 0.65 |
| p HWE** | 0.72 | p HWE** | 0.26 |
| Locus | SNP | Gene | eQTL Pall | eQTL PER+ | DSS PER+ | 727 cancer genes source |
| 2q31.1 | rs1550623 | CDCA7 | 0.007 (0.09) | 0.51 (0.67) | 4 × 10−7 | |
| 11q13.1 | rs3903072 | FADD | 0.04 (0.28) | 0.01* (0.17) | 0.0009 | Cancer related genes panel |
| 12q24.21 | rs1292011 | TBX3 | 0.28 (0.50) | 0.21 (0.52) | 0.012 | Cancer gene census |
| 14q13.3 | rs2236007 | PAX9 | 0.003 (0.07) | 0.05 (0.32) | 0.20 | Cancer related genes panel |
| 14q24.1 | rs2588809 | ZFP36L1 | 0.08 (0.38) | 0.004 (0.09) | 0.09 | Identified in Nik-Zainal et al 2016 |
| 19p13.11 | rs8170 | MRPL34 | 0.001 (0.06) | 0.01 (0.17) | 0.004 |
| Group | Number | Age, years | Years of education | MMSE | ACE-R | PSP-RS |
| Alzheimer’s disease | 17 | 71 (9) | 14 (3) | 25 (4) | 72 (14) | - |
| PSP | 17 | 69 (6) | 12 (2) | 27 (4) | 83 (14) | 41 (14) |
| Controls | 12 | 67 (8) | 16 (2) | 29 (1) | 96 (3) | - |
| Types of substance | Frequency | Percent |
| Alcohol use (n = 489) | ||
| Yes | 42 | 8.6 |
| No | 447 | 91.4 |
| Period of alcohol use (n = 42) | ||
| ≤5 years | 20 | 47.6 |
| 6–10 years | 12 | 28.6 |
| ≥11 years | 10 | 23.8 |
| Cigarette smoking (n = 489) | ||
| Yes | 55 | 11.2 |
| No | 434 | 88.8 |
| Period of cigarette smoking (n = 55) | ||
| ≤5 years | 10 | 18.2 |
| 6–10 years | 24 | 43.6 |
| ≥11 years | 21 | 38.2 |
| Psychoactive drugs use (n = 489) | ||
| Yes | 96 | 19.6 |
| No | 393 | 80.4 |
| Type of psychoactive drugs used (n = 96) | ||
| Shisha | 7 | 7.3 |
| Khat | 89 | 92.7 |
| Food group | Items awarded 1 point | ARFS |
| Vegetables | >4 vegetables per day; potatoes cooked without fat; tomatoes fresh/canned; lettuce/endive/salad greens; carrots; cabbage/brussels sprouts; cauliflower; broccoli; celery; silver beet or spinach; peas; green beans; bean sprout or alfalfa sprout; pumpkin; onion or leeks; sweet corn; sweet potato; coleslaw; mushrooms; zucchini | 20 |
| Fruits | 2 pieces of fruit/day; 1/week of each of fruit or vegetable juice; canned or frozen fruit; oranges or other citrus; apples; pears; bananas; melons (water, rock, honeydew); pineapple; strawberries; apricots; peach/nectarines; mango/pawpaw; avocado | 14 |
| Protein foods | Nuts; peanut butter or peanut paste; 1–4/week of each of beef, lamb, pork, chicken, fish (steamed, baked, or grilled fish/canned (salmon, tuna, sardines)); ≥1/week of each of baked beans, soya beans/soy beans and tofu; use up to 2 eggs per week | 11 |
| Grains | ≥1/week of each of the following bread types with high fibre, wholemeal; ≥4 slices bread per day; ≥1/week All-Bran, Sultana bran, FibrePlus, Branflakes, Weetbix, VitaBrits, Weeties; rice; pasta/noodles | 12 |
| Dairy | Reduced fat or skim; 500 mL/day; cheese 1/week; ice-cream; yoghurt 1/week; use ricotta/cottage cheese; use low-fat cheese | 7 |
| Fats | Use nil/polyunsaturated/monounsaturated margarine | 1 |
| Alcohol | Drink beer/wine/spirits 1/month up to 4 days/week; or 2 glasses maximum/day | 2 |
| Dimension | Value | Count | R / P / F | +GENIA (R/P/F) | Majority (R/P/F) |
| KT | Investigation | 38 | 76.3 / 67.4 / 71.6 | 68.4 / 65.0 / 66.7 | 0.0 / 0.0 / 0.0 |
| Analysis | 132 | 70.5 / 69.9 / 70.2 | 72.7 / 73.3 / 73.0 | 0.0 / 0.0 / 0.0 | |
| Observation | 412 | 80.6 / 77.4 / 79.0 | 78.6 / 75.2 / 76.9 | 100.0 / 40.5 / 57.7 | |
| Fact | 59 | 33.9 / 76.9 / 47.1 | 40.7 / 70.6 / 51.6 | 0.0 / 0.0 / 0.0 | |
| Method | 8 | 0.0 / 0.0 / 0.0 | 0.0 / 0.0 / 0.0 | 0.0 / 0.0 / 0.0 | |
| Other | 368 | 77.4 / 73.8 / 75.6 | 76.6 / 74.0 / 75.3 | 0.0 / 0.0 / 0.0 | |
| Macro Average | 1,017 | 56.5 / 60.9 / 57.3 | 56.2 / 59.7 / 57.3 | 16.7 / 6.8 / 9.6 | |
| Micro Average | 1,017 | 74.6 / 74.6 / 74.6 | 73.9 / 73.9 / 73.9 | 40.5 / 40.5 / 40.5 | |
| CL | L3 | 983 | 97.7 / 98.9 / 98.3 | 98.6 / 99.0 / 98.8 | 100.0 / 96.7 / 98.3 |
| L2 | 30 | 73.3 / 48.9 / 58.7 | 76.7 / 62.2 / 68.7 | 0.0 / 0.0 / 0.0 | |
| L1 | 4 | 0.0 / 0.0 / 0.0 | 25.0 / 100.0 / 40.0 | 0.0 / 0.0 / 0.0 | |
| Macro Average | 1,017 | 57.0 / 49.3 / 52.3 | 66.8 / 87.1 / 69.2 | 33.3 / 32.2 / 32.8 | |
| Micro Average | 1,017 | 96.6 / 96.6 / 96.6 | 97.7 / 97.7 / 97.7 | 96.7 / 96.7 / 96.7 | |
| Polarity | Positive | 975 | 97.5 / 98.8 / 98.1 | 98.2 / 98.6 / 98.4 | 100.0 / 95.9 / 97.9 |
| Negative | 42 | 71.4 / 55.6 / 62.5 | 66.7 / 60.9 / 63.6 | 0.0 / 0.0 / 0.0 | |
| Macro Average | 1,017 | 84.5 / 77.2 / 80.3 | 82.5 / 79.8 / 81.0 | 50.0 / 47.9 / 48.9 | |
| Micro Average | 1,017 | 96.4 / 96.4 / 96.4 | 96.9 / 96.9 / 96.9 | 95.9 / 95.9 / 95.9 | |
| Manner | High | 56 | 78.6 / 63.8 / 70.4 | 76.8 / 65.2 / 70.5 | 0.0 / 0.0 / 0.0 |
| Low | 4 | 100.0 / 66.7 / 80.0 | 100.0 / 66.7 / 80.0 | 0.0 / 0.0 / 0.0 | |
| Neutral | 957 | 97.2 / 98.7 / 97.9 | 97.4 / 98.6 / 98.0 | 100.0 / 94.1 / 97.0 | |
| Macro Average | 1,017 | 91.9 / 76.4 / 82.8 | 91.4 / 76.8 / 82.8 | 33.3 / 31.4 / 32.3 | |
| Micro Average | 1,017 | 96.2 / 96.2 / 96.2 | 96.3 / 96.3 / 96.3 | 94.1 / 94.1 / 94.1 | |
| Source | Current | 1,003 | 99.8 / 99.5 / 99.7 | 99.9 / 99.5 / 99.7 | 100.0 / 98.6 / 99.3 |
| Other | 14 | 64.3 / 81.8 / 72.0 | 64.3 / 90.0 / 75.0 | 0.0 / 0.0 / 0.0 | |
| Macro Average | 1,017 | 82.1 / 90.7 / 85.9 | 82.1 / 94.8 / 87.4 | 50.0 / 49.3 / 49.7 | |
| Micro Average | 1,017 | 99.3 / 99.3 / 99.3 | 99.4 / 99.4 / 99.4 | 98.6 / 98.6 / 98.6 | |
| Event (Task 1) | 1,789 | 55.1 / 61.7 / 58.2 | |||
| Event (Task 2) | 1,795 | 54.1 / 60.8 / 57.2 | |||
| Event (Task 3) | 1,997 | 51.6 / 59.4 / 55.3 |
| Sex | Age | Pressure (mmHg) | Echo Vol (ml) | Echo EF (%) | Patient MI and catheter information | |||
| Min | Max | Min | Max | |||||
| Infarct Group | ||||||||
| P1 | M | 60 | 10 | 121 | 103 | 176 | 41.48 | Inferior and posterior MI, 90 % stenosis LAD; 80 % stenosis LCX, 100 % stenosis mid MCA |
| P2 | F | 72 | 8 | 96 | 50 | 98 | 48.98 | Anterior myocardial infarction, 30 % stenosis proximal LAD,100 % in the proximal-mid LAD, LCX, RCA |
| P3 | M | 73 | 9 | 105 | 115 | 193 | 40.41 | Inferior and posterior MI, 90 % stenosis proximal and distal LAD; 90 % stenosis proximal LCX, 99 % stenosis in mid LCX, 50 % stenosis in the mid RCA, total occlusion of distal RCA |
| P4 | M | 71 | 10 | 120 | 134 | 228 | 41.23 | Anterior myocardial infarction, apical left ventricular aneurysm;), 100 % stenosis proximal LAD, 40 % stenosis proximal-mid LCX, 40 % stenosis in the mid RCA |
| P5 | M | 58 | 9 | 110 | 70 | 147 | 52.38 | anterior myocardial infarction, 40 % stenosis in LM, total occlusion of proximal LAD, 80 % stenosis mid LCX, 40 % stenosis mid RCA, total occlusion distal RCA |
| Mean ± SD | 66.8 ± 7.19 | 9.2 ± 0.84 | 110.4 ± 10.5 | 94.4 ± 34.0 | 168.4 ± 49.1 | 44.9 ± 5.4 | ||
| Non-Infarcted Group | ||||||||
| P6 | M | 48 | 9 | 115 | 46 | 116 | 60.34 | |
| P7 | F | 43 | 10 | 130 | 46 | 120 | 61.67 | |
| P8 | M | 59 | 10 | 118 | 33 | 79 | 58.23 | |
| P9 | M | 43 | 9 | 115 | 51 | 120 | 57.5 | |
| P10 | M | 56 | 10 | 138 | 46 | 121 | 61.98 | |
| Mean ± SD | 49.8 ± 7.40 | 9.6 ± 0.55 | 123.2 ± 10.3 | 44.4 ± 6.7 | 111.2 ± 18.1 | 59.9 ± 0.02 | ||
| P value* | 0.06 | 0.40 | 0.09 | 0.01 | 0.04 | 0.0004 |
| Clinicopathologic features | CasesN (%) | miR‐133b expression | P | |
| Low (%) | High (%) | |||
| Gender | ||||
| Male | 94 (64.4) | 42 (44.7) | 52 (55.3) | 0.467 |
| Female | 52 (35.6) | 20 (38.5) | 32 (61.5) | |
| Age (years) | ||||
| <60 | 70 (47.9) | 27 (38.6) | 43 (61.4) | 0.361 |
| ≥60 | 76 (52.1) | 35 (46.1) | 41 (53.9) | |
| ECOG | ||||
| ≤1 | 127 (87.0) | 49 (38.6) | 78 (61.4) | 0.014a |
| ≥2 | 19 (13.0) | 13 (68.4) | 6 (31.6) | |
| T stage | ||||
| Ta | 52 (35.6) | 16 (30.8) | 36 (69.2) | 0.013a |
| T1 | 70 (47.9) | 30 (42.9) | 40 (57.1) | |
| ≥T2 | 24 (16.4) | 16 (66.7) | 8 (33.3) | |
| Histological grade | ||||
| PUNLMP | 33 (22.6) | 8 (24.2) | 25 (75.8) | <0.001a |
| LG | 80 (54.8) | 27 (33.8) | 53 (66.3) | |
| HG | 33 (22.6) | 27 (81.8) | 6 (18.2) | |
| Surgery | ||||
| Transurethral resection (TUR) | 117 (80.1) | 41 (35.0) | 76 (65.0) | <0.001a |
| Cystectomy | 29 (19.9) | 21 (72.4) | 8 (27.6) | |
| Recurrence or progression (postoperative) | ||||
| Yes | 58 (39.7) | 44 (75.9) | 14 (24.1) | <0.001a |
| No | 88 (60.3) | 18 (20.5) | 70 (79.5) | |
| Past history of urothelial carcinoma of the bladder (UCB) | ||||
| Yes | 44 (30.1) | 21 (47.7) | 23 (52.3) | 0.398 |
| No | 102 (69.9) | 41 (40.2) | 61 (59.8) | |
| Multifocality | ||||
| Single tumor | 91 (62.3) | 32 (23.8) | 59 (76.3) | 0.022a |
| Multiple tumor | 55 (37.7) | 30 (65.2) | 25 (34.8) | |
| Death | ||||
| Yes | 33 (22.6) | 28 (84.8) | 5 (15.2) | <0.001a |
| No | 113 (77.4) | 34 (30.1) | 79 (69.9) |
| Group | DEG | Fold change (log2, |
| vs. Model) | ||
| Martynoside | Rny1 (RNA, Y1 small cytoplasmic, Ro-associated) | -7.74 |
| Hist1h4a (histone cluster 1, H4a) | -1.85 | |
| Opn3 (RNA, Y1 small cytoplasmic, Ro-associated) | 1.29 | |
| Supt4b (suppressor of Ty 4B) | -1.21 | |
| Tnnt3 (troponin T3, skeletal, fast) | -1.15 | |
| R2 | Egr4 (early growth response 4) | -6.85 |
| Cdkn1a [cyclin-dependent kinase inhibitor 1A (P21)] | -3.33 | |
| Ets2 (E26 avian leukemia oncogene 2, 3′ domain) | -3.18 | |
| Sap25 (sin3 associated polypeptide) | 2.98 | |
| Il4i1 (interleukin 4 induced 1) | 2.93 | |
| Rg2 | Tnnc2 (troponin C2, fast) | 2.75 |
| Amigo2 (adhesion molecule with Ig like domain 2) | 2.07 | |
| Col8a1 (collagen, type VIII, alpha 1) | -1.95 | |
| Map7 (microtubule-associated protein 7) | 1.92 | |
| Car3 (carbonic anhydrase 3) | -1.70 |
| IPTG μM | OD620 | Isopentenol mg/L |
| 0.01 | 0.014 | 3.6 |
| 0.05 | 0.079 | 5.9 |
| 0.1 | 0.127 | 8.45 |
| 0.2 | 0.179 | 12.5 |
| 0.5 | 0.456 | 98.1 |
| 1 | 0.506 | 142 |
| Radiologic Impression/Technique | Patient | BI-RADS Category | Needle Gauge (G) | Pieces of tissue in specimen | Pieces of tissue imaged | Pathologic diagnosis |
| Calcium positive/mammogram | 1 | 4 | 11 | 7 | 1 | Fibrocystic changes with calcifications |
| mass/mammogram, ultrasound | 2 | 4 | 14 | 4 | 1 | Fibrocystic changes with calcifications |
| mass/sonogram | 3 | 3 | 14 | 3 | 1 | Fibrocystic changes with apocrine metaplasia |
| Calcium positive/mammogram | 4 | 4 | 11 | 5 | 1 | Ductal carcinoma in situ |
| Speculated mass/Mammogram, sonogram | 5 | 4 | 14 | 3 | 1 | Infiltrating ductal carcinoma |
| Mass/mammogram, ultrasound | 6 | 5 | 14 | 2 | 1 | Infiltrating lobular carcinoma |
| Palpable mass/ultrasound | 7 | 5 | 14 | 5 | 1 | Poorly differentiated infiltrating ductal carcinoma |
| Studies | Patients | Inter- ventions | Relevant outcomes | Size of effect | Benefits and harms | Factors influencing the clinical relevance |
| Barker et al. (2008) [15] | YES | NO | NO | NO | YES | Patients: Pre-treatment surgery is poorly described. Intervention is poorly described. Results 6 weeks and 12 weeks post-treatment are not integrated. |
| Hohmann et al. (2012) [20] | NO | NO | YES | NO | YES | Patients: Pregnancy is poorly described, although 15 patients out of 21 were women. Intervention is poorly described. |
| Morone et al. (2011) [16] | YES | YES | YES | YES | YES | Patients: Pre-treatment surgery is poorly described. |
| Paolucci et al. (2012) [37] | YES | YES | NO | NO | YES | Patients: Pre-treatment surgery is poorly described. Function is no outcome measure. |
| Ryan et al. (2014) [38] | NO | YES | YES | NO | YES | Patients: Pre-treatment surgery or pregnancies are poorly described. Ratio men / women is not documented. |
| Vetrano et al. (2013) [39] | YES | YES | YES | YES | YES | There have been remarkably more women included in this study than men. Intervention 2 (Control group) received also a SFT. |
| IORT | APBI | EBRT | ||||
| %Vol > 0.1 Gy | %Vol > 4 Gy | %Vol > 0.1 Gy | %Vol > 4 Gy | %Vol > 0.1 Gy | %Vol > 4 Gy | |
| Ipsilateral Breast | 84.5 | 18.1 | 88.2 | 54.4 | 99.9 | 99.9 |
| Contralateral breast | < 1 | 0 | < 1 | 0 | 97.7 | 1.3 |
| Ipsilateral Lung | 4.5 | 0 | 5.0 | 1.3 | 98.8 | 10.1 |
| Contralateral lung | < 1 | 0 | < 1 | 0 | 87 | 0 |
| Heart | 1.8 | 0 | 4.2 | 0 | 98 | 0 |
| Spine | < 1 | 0 | < 1 | 0 | 92 | 0 |
| Variable | Treatment | Time (h) | p-level | |
| 0 | 2 | |||
| Cholesterol | PLA | 170.6 ± 34.6 | 182.8 ± 35.1 | 0.006 |
| (mg/dl) | PWS | 187.3 ± 46.6 a | 180.2 ± 36.9 | |
| PWS + S | 161.7 ± 29.8 a,b | 174.0 ± 33.5 a | ||
| HDL-c | PLA | 54.9 ± 13.3 | 60.1 ± 16.0 | 0.57 |
| (mg/dl) | PWS | 52.2 ± 13.9 | 58.9 ± 14.6 | |
| PWS + S | 54.2 ± 16.2 | 60.1 ± 18.1 | ||
| CHOL: HDL-c | PLA | 3.2 ± 0.9 b | 3.2 ± 0.9 | 0.001 |
| PWS | 3.8 ± 1.3 a,c | 3.2 ± 1.0 * | ||
| PWS + S | 3.2 ± 1.0 b | 3.1 ± 1.0 | ||
| LDL-c | PLA | 104.3 ± 36.7 | 109.6 ± 41.2 | 0.55 |
| (mg/dl) | PWS | 96.9 ± 31.9 | 104.5 ± 36.0 | |
| PWS + S | 99.8 ± 41.2 | 104.6 ± 40.7 | ||
| Triglycerides | PLA | 98.0 ± 58.6 | 89.3 ± 38.3 | 0.14 |
| (mg/dl) | PWS | 109.5 ± 56.8 | 100.3 ± 47.5 | |
| PWS + S | 88.3 ± 42.2 | 92.8 ± 54.6 | ||
| Glucose | PLA | 90.2 ± 9.7 | 101.5 ± 14.4 * | 0.03 |
| (mg/dl) | PWS | 100.1 ± 16.0 a,c | 114.4 ± 12.6 *a | |
| PWS + S | 90.4 ± 7.3 | 113.8 ± 15.0 *a |
| Cox model* | Factors | HR (95% CI) | P |
| TTP | |||
| Gabor filter 0 Subgroups | TACE+sorafenib | 0.002 | |
| Gabor-1-90 ≤3.6190 | 0.802 (0.505–1.274) | ||
| Gabor-1-90 > 3.6190 | 2.184 (1.190–4.007) | ||
| Gabor filter 1. 0 Subgroups | TACE+sorafenib | 0.004 | |
| Gabor-1-135 ≤1.3995 | 0.455 (0.231–0.898) | ||
| Gabor-1-135 > 1.3995 | 1.298 (0.827–2.036) | ||
| Gabor filter 1.5 Subgroups | TACE+sorafenib | 0.008 | |
| Gabor-1-135 ≤0.5175 | 0.665 (0.390–1.137) | ||
| Gabor-1-135 > 0.5175 | 1.503 (0.930–2.431) | ||
| Wavelet Transform filter 1.0 Subgroups | TACE+sorafenib | 0.007 | |
| Wavelet-2-D ≤18.3585 | 0.663 (0.393–1.118) | ||
| Wavelet-2-D > 18.3585 | 1.486 (0.912–2.422) | ||
| Wavelet Transform filter 1.5 | None identified | ||
| OS | |||
| Wavelet Transform filter 1.0 Subgroups | TACE+sorafenib | 0.005 | |
| Wavelet-3-D < 12.2620 | 0.759 (0.465–1.239) | ||
| Wavelet-3-D > 12.2620 | 2.115 (1.101–4.062) |
| Sections | Multidisciplinary expertise | Hardware | Software |
| 2.1: Fluorescent protein behavior | Molecular biology, biochemistry | n.a. | n.a. |
| 2.2–2.4: Microscopy | Cell biology, biophysics, optics | Microscope control system | Time series, stage control, autofocus |
| 2.5: Cell physiology | Cell biology | Incubation control system | n.a. |
| 2.6: Image analysis | Math/physics | High performance computer | Image segmentation, tracking |
| 2.7: Population sampling | Statistics | High performance computer | Statistical analysis |
| 2.8: Network modeling | Math/physics/engineering | High performance computer | Mathematical modeling |
| Total n | Ate fish (%) | Mean ounces of fish consumed in last month of pregnancy (+/- SD) | MeHg concentration in cord blood ≥5 μg/L | |
| Total | 100 | 86.0 (86) | 19.8 (3.7) | 44.0 (44) |
| Race** | ||||
| Hispanic | 18 | 88.9 (16) | 18.8 (15.0) | 33.3 (6) |
| Caucasian | 42 | 88.1 (37) | 18.3 (18.8) | 42.9 (18) |
| Japanese | 23 | 91.3 (21) | 9.6 (7.4) | 56.5 (13) |
| Chinese | 23 | 82.6 (19) | 16.2 (20.0) | 34.8 (8) |
| Filipino | 32 | 75.0 (24)* | 13.7 (15.0) | 28.1 (9)* |
| Pacific Islander¶ | 48 | 87.5 (42) | 25.7 (34.8)* | 43.8 (21) |
| Birthplace | ||||
| United States | 65 | 81.5 (53) | 17.4 (20.7) | 38.5 (25) |
| Outside of United States | 34 | 94.1 (32) | 23.5 (37.9) | 52.9 (18) |
| Income | ||||
| Less than $22,000 | 20 | 95.0 (19)* | 38.0 (47.7)* | 50.0 (10) |
| $22,000–$47,600 | 21 | 71.4 (15) | 12.2 (18.5) | 38.1 (8) |
| $47,600–$80,100 | 22 | 86.4 (19) | 22.5 (23.0) | 36.4 (8) |
| Greater than $80,100 | 19 | 89.5 (17) | 13.3 (11.1) | 47.4 (9) |
| Missing | 18 | 88.9 (16) | 11.9 (13.3) | 50.0 (9) |
| Highest education level achieved | ||||
| Less than high school | 9 | 88.9 (8) | 32.8 (35.8) | 55.6 (5) |
| High school diploma | 39 | 84.6 (33) | 22.8 (36.2) | 46.2 (18) |
| Any college | 52 | 86.5 (45) | 15.2 (16.1) | 40.4 (21) |
| Mother’s age | ||||
| Less than 23 years | 27 | 77.8 (21) | 18.3 (21.9) | 33.3 (9) |
| 23 – 27.5 years | 23 | 87.0 (20) | 24.7 (31.7) | 47.8 (11) |
| 27.5 – 33 years | 26 | 92.3 (24) | 19.0 (35.6) | 38.5 (10) |
| Over 33 years | 24 | 87.5 (21) | 17.6 (20.2) | 58.3 (14) |
| Marker alleles | Chromosome (linked genes) | Position | Alleles belong to the | |||||
| 20 best | 10 best | 5 best | 20 worst | 10 worst | 5 worst | |||
| GWM1130_109bp* | 1B | 0 | x | |||||
| GWM1130_115bp* | 1B | 0 | x | x | x | |||
| BARC0240_231bp | 1B | 36.1 | x | |||||
| GWM3166_153bp | 1B | 175.7 | x | |||||
| WMC0732c_295bp | 1D | 132.4 | x | |||||
| WMC0522_200bp | 2A (Ppd-A1) | 88.3 | x | x | ||||
| GWM4167_217bp | 2B (Ppd-B1) | 40 | x | |||||
| BARC0160_111bp | 2B | 80.4 | x | x | ||||
| CFD0056c_250bp | 2D | 20.2 | x | |||||
| GWM0988_180bp | 2D | 84.5 | x | |||||
| CFD0168_256bp | 2D | 160.3 | x | x | x | |||
| Ppd_insensitive | 2D | unm. | x | x | x | |||
| Ppd_sensitive | 2D | unm. | x | x | x | |||
| WMC0264_141bp* | 3A1 | 131.3 | x | x | ||||
| WMC0264_148bp* | 3A1 | 131.3 | x | |||||
| WMC0808_147bp | 3B1 | 67.5 | x | |||||
| GWM0160a_181bp | 4A | 186.4 | x | |||||
| GWM4636_233bp | 4B1 | 59.4 | x | |||||
| WMC0285_293bp | 4D | 0 | x | x | ||||
| GWM0291_176bp | 5A (Vrn-A2) | 231 | x | x | x | |||
| WMC0160b_137bp | 5B1 (Hd6-related gene) | 158.4 | x | x | ||||
| WMC0783_179bp | 5B | 219.8 | x | |||||
| WMC0215_208bp | 5D | 200.5 | x | |||||
| GDM0063_147bp | 5D | 265.4 | x | |||||
| WMC0161b_184bp | 5D | 301.3 | x | |||||
| GWM4047_194bp | 6B | 0 | x | x | ||||
| GWM0825b_122bp | 6B | 34.3 | x | x | ||||
| GWM1391_158bp* | 6D | 0 | x | x | x | |||
| GWM1391_160bp* | 6D | 0 | x | x | x | |||
| CFD0019c_313bp | 6D | 130.9 | x | x | x | |||
| BARC0204b_500bp | 6D | 194 | x | |||||
| GWM0983b_130bp* | 7B | 54 | x | x | x | |||
| GWM0983b_133bp* | 7B | 54 | x | x | ||||
| BARC0182_118bp | 7B | 176 | x | x | ||||
| GWM0428_145bp | 7D | 228.2 | x | |||||
| WMC0014_267bp | 7D | 274.2 | x | |||||
| BARC0261_170bp | Unmapped | – | x | x | x | |||
| CFA2263_123bp | Unmapped | – | x | |||||
| WMC0327_209bp | Unmapped | – | x | |||||
| WMC0349_118 | Unmapped | – | x | x |
| Organ | REP1 expression | Total (N) | P-value | |
| −/+ N (%) | ++/+++ N (%) | |||
| Cervical | ||||
| Normal | 4 (100.0%) | 0 (0.0%) | 4 | 0.0000 |
| Cancer | 6 (12.0%) | 44 (88.0%) | 50 | |
| Lung | ||||
| Normal | 9 (100%) | 0 (0.0%) | 9 | 0.0000 |
| Cancer | 12 (30.0%) | 28 (70.0%) | 40 | |
| Colorectal | ||||
| Normal | 8 (88.9%) | 1 (11.1%) | 9 | 0.0002 |
| Cancer | 10 (25%) | 30 (75%) | 40 |
| Site | Number | Morphology | Number | Comorbid diseases | Number |
| Local recurrence alone | 4 (12.9%) | Adenocarcinoma | 4 (12.9%) | Hypertension Diabetes | 2 (6.4%) 2 (6.4%) |
| Pelvic lymph node | 3 (9.6%) | Adenocarcinoma | 3 (9.6%) | Diabetes COPD | 2 (6.4%) 1 (3.2%) |
| Persistent | 2 (6.4%) | Adenocarcinoma Clear cell carcinoma | 1 (3.2%) 1 (3.2%) | Diabetes | 2 (6.4%) |
| Distant | 5 (16.1%) | ||||
| Lung | 2 (6.4%) | Adenocarcinoma | 2 (6.4%) | Hypertension Diabetes | 1 (3.2%) 1 (3.2%) |
| Multi-organ | 2 (6.4%) | Adenocarcinoma | 2 (6.4%) | Hypertension SLE | 1 (3.2%) 1 (3.2%) |
| Bone | 1 (3.2%) | Adenocarcinoma | 1 (3.2%) | Diabetes | 1 (3.2%) |
| Patient | Target lesion | SUVmax prea | SUVmax postb | ΔSUVmaxc (%) | RECISTd |
| 1 | Mediastinal mass | 10.00 | 7.50 | −25 | PR |
| 2 | Mediastinal mass | 6.60 | 3.50 | −47 | PR |
| 3 | Mediastinal mass | 13.00 | 6.20 | −52 | SD |
| 4 | Pleural implant | 9.23 | 0.00 | −100 | CR |
| 5 | Mediastinal mass | 4.10 | 3.00 | −27 | PR |
| 6 | Lung lesion | 18.70 | 17.00 | −9 | SD |
| 7 | Lymph node | 12.00 | 11.50 | −4 | SD |
| 8 | Pleural implant | 5.80 | 2.10 | −64 | PR |
| 9 | Pleural implant | 7.60 | 1.70 | −78 | PR |
| 10 | Lymph node | 3.70 | 8.20 | 120 | PD |
| 11 | Mediastinal mass | 4.19 | 5.30 | 26 | SD |
| 12 | Mediastinal mass | 8.40 | 11.30 | 35 | SD |
| 13 | Lung lesion | 19.70 | 5.70 | −71 | PR |
| 14 | Mediastinal mass | 4.20 | 4.60 | 10 | PR |
| 15 | Mediastinal mass | 5.00 | 3.00 | −40 | PR |
| 16 | Mediastinal mass | 8.40 | 0.00 | −100 | CR |
| 17 | Pleural implant | 4.00 | 4.80 | 20 | PD |
| 18 | Mediastinal mass | 15.60 | 18.5 | 19 | PR |
| 19 | Mediastinal mass | 7.70 | 2.20 | −71 | PR |
| 20 | Lung lesion | 8.80 | 14.40 | 64 | SD |
| 21 | Mediastinal mass | 8.30 | 5.70 | −31 | PR |
| 22 | Lymph node | 8.50 | 5.40 | −36 | PR |
| 23 | Pleural implant | 3.30 | 1.90 | −42 | PR |
| 24 | Mediastinal mass | 7.00 | 4.50 | −36 | SD |
| 25 | Mediastinal mass | 5.60 | 1.80 | −68 | PR |
| 26 | Mediastinal mass | 20.00 | 15.00 | −25 | PR |
| 27 | Mediastinal mass | 4.80 | 6.70 | 40 | SD |
| Protocol | Contig assembly | Scaffolding | ||||||
| Unamplified | Phi | Tre | Rap | Unamplified | Phi | Tre | Rap | |
| Assembly size (bp) | 94 641 187 | 94 028 877 | 94 541 978 | 88 411 985 | 96 571 590 | 96 849 620 | 96 382 191 | 96 869 541 |
| contig number | 13 386 | 14 661 | 21 721 | 34 073 | 9415 | 8744 | 9068 | 9247 |
| contig average (kb) | 7.1 | 6.4 | 4.4 | 2.6 | 10.3 | 11.1 | 10.6 | 10.5 |
| largest contig (kb) | 167.7 | 147.8 | 116.8 | 41.8 | 167.7 | 187.5 | 167.7 | 167.7 |
| N50 (kb) | 16.6 | 15.7 | 10.8 | 4.2 | 17.6 | 24.1 | 20.7 | 18.4 |
| N50 (number) | 1525 | 1597 | 2109 | 5897 | 1533 | 1067 | 1258 | 1482 |
| GAGE assessment | ||||||||
| Corrected N50 (kb) | 15.1 | 14.1 | 9.5 | 3.5 | 16.8 | 22.7 | 19.7 | 17.7 |
| Corrected N50 (number) | 1721 | 1825 | 2431 | 7493 | 1642 | 1141 | 1354 | 1577 |
| Missing reference (%) | 0.09 | 0.09 | 4.43 | 0.14 | 0.09 | 0.09 | 0.09 | 0.09 |
| Inversion | 13 | 21 | 38 | 50 | 12 (−1) | 17 (+4) | 13 | 15 (+2) |
| Relocation | 7 | 7 | 11 | 22 | 17 (+10) | 13 (+6) | 19 (+12) | 11 (+4) |
| Translocation | 12 | 16 | 37 | 30 | 12 | 12 | 12 | 11 (−1) |
| No. | Location | RT-PCR | Single RT-qPCR | Duplex RT-qPCR | |||
| ACLSV | CGRMV | ACLSV | CGRMV | ACLSV | CGRMV | ||
| 1 | Qingdao | + | + | + | |||
| 2 | Qingdao | ||||||
| 3 | Qingdao | + | + | ||||
| 4 | Qingdao | ||||||
| 5 | Qingdao | ||||||
| 6 | Qingdao | + | + | + | + | + | + |
| 7 | Qingdao | ||||||
| 8 | Qingdao | + | + | ||||
| 9 | Qingdao | ||||||
| 10 | Qingdao | + | + | + | |||
| 11 | Qingdao | ||||||
| 12 | Qingdao | + | + | ||||
| 13 | Qingdao | ||||||
| 14 | Shijiazhuang | + | + | + | |||
| 15 | Shijiazhuang | ||||||
| 16 | Shijiazhuang | + | + | + | |||
| 17 | Shijiazhuang | ||||||
| 18 | Shijiazhuang | + | + | + | |||
| 19 | Shijiazhuang | ||||||
| 20 | Shijiazhuang | ||||||
| 21 | Shijiazhuang | ||||||
| 22 | Shijiazhuang | ||||||
| 23 | Taian | + | + | + | |||
| 24 | Taian | ||||||
| 25 | Taian | ||||||
| 26 | Taian | ||||||
| 27 | Taian | ||||||
| 28 | Taian | + | + | + | + | + | + |
| 29 | Taian | ||||||
| 30 | Taian | + | + | + | |||
| 31 | Taian | ||||||
| 32 | Taian | ||||||
| 33 | Taian | ||||||
| 34 | Taian | + | + | + | + | + | + |
| Total | 8 | 5 | 10 | 6 | 10 | 6 |
| Region | County | Number of sites | Number of patients enrolled |
| Global (total) | 114 | 1931 | |
| WEC (total) | 74 | 760 | |
| Austria | 3 | 18 | |
| Canada | 6 | 72 | |
| France | 8 | 82 | |
| Germany | 4 | 70 | |
| Greece | 4 | 40 | |
| Ireland | 1 | 20 | |
| Israel | 3 | 37 | |
| Italy | 6 | 99 | |
| Netherlands | 1 | 25 | |
| Norway | 3 | 21 | |
| Portugal | 6 | 93 | |
| Spain | 16 | 87 | |
| Sweden | 4 | 25 | |
| Switzerland | 2 | 27 | |
| UK | 7 | 44 | |
| CEE (total) | 20 | 532 | |
| Czech Republic | 3 | 20 | |
| Estonia | 3 | 99 | |
| Romania | 8 | 200 | |
| Russia | 5 | 171 | |
| Slovenia | 1 | 42 | |
| LA (total) | 17 | 519 | |
| Argentina | 3 | 101 | |
| Brazil | 1 | 90 | |
| Chile | 1 | 50 | |
| Columbia | 6 | 84 | |
| Mexico | 2 | 115 | |
| Venezuela | 4 | 79 | |
| Asia (total) | 3 | 120 | |
| China | 3 | 120 |
| Characteristic | Overalln=92 (%) | Culture methods 41 (%) | Molecular diagnosis 51 (%) |
| Treatment with first-line drug regimen (%) | 92 (100) | 41 (100) | 51 (100) |
| Mean days on first-line drug (range) (n=92) | 81 (14–434) | 154 (73–434) | 22 (14–36) |
| Mean days until starting MDR-TB treatment using second-line drug (range) (n=92) | 44 (6–85) | 73 (54–102) | 5 (2–6) |
| Required surgery (%) | 87 (95) | 41 (100) | 46 (90) |
| Recovered without need for surgery | 5 | 0 | 5 |
| Patient | JAK2 p.V617F allele burden (%)a | MPL p.W515L allele burden (%) | Additional mutations by NGS in DNA from GR (allele burden) | HUMARA | ||||
| RNA platelets | RNA GR | DNA GR | RNA plateletsb | RNA GRb | DNA GRc | |||
| 1 | 20 | 0 | 1.85 | 2.16 | 0 | 0 | ND | Clonal |
| 2 | 16 | 10 | 1.8 | 12 | 33 | Positive | ND | NA |
| 3 | 0 | 26 | 15 | Positive | ND | NA | ||
| 4 | 0 | 0 | MPL p.Pro222Ser (42.32%) | Clonal | ||||
| 5 | 0 | 0 | MPL p.Ser204Pro (46.94%) | Clonal | ||||
| 6 | 0 | 0 | TET2 p.Gln958Ter (20.17%) | Clonal | ||||
| TET2 p.Leu1880Pro1 (15.2%) | ||||||||
| CBL p.Leu380Pro (2.79%) | ||||||||
| 7 | 0 | 0 | MPL p.Ser204Phe (25.69%) | Clonal | ||||
| 8 | 0 | 0 | MPL p.Ser204Pro (37.45%) | Clonal | ||||
| MPL p.Arg592Gln (30.56%) | ||||||||
| SF3B1 p.His662Asp (3.44%) | ||||||||
| 9 | 0 | 0 | TET2 p.Gln790Ter (20%) | No clonal | ||||
| 10 | 0 | 0 | TET2 p.Ser1848Ter (44.74%) | NA | ||||
| SH2B3 p.Trp364Ter (41.47%) | ||||||||
| CBL p.Val363Gly (3.69%) | ||||||||
| 11 | 0 | 0 | TET2 p.Ala1196Asp (2.41%) | NA |
| Patient no. | Age (years) | Diagnosis | Stage | Therapy |
| 1 | 29 | HD, MC | IIA | MOPP × 6, Mantle 36 Gy |
| 2 | 28 | HD, NS | IIB | MOPP × 4, ABVD × 4, Mantle 20 Gy |
| 3 | 42 | Had | IIB | ABVD × 3, Mantle 40 Gy |
| 4 | 38 | HD, MC | IIA | MOPP × 6, Mantle 40 Gy |
| 5 | 24 | HD, NS | IIB | MOPP × 6, Mantle 40 Gy |
| 6 | 30 | HD, NS | IIA | MOPP × 4, ABVD × 4, Mantle 36 Gy |
| Characteristics | N (%) |
| Low back pain, spine or joint disorders | |
| No | 315 (39.6) |
| Yes | 481 (60.4) |
| Non-ischemic heart disease | |
| No | 433 (54.4) |
| Yes | 363 (45.6) |
| Musculoskeletal disorders | |
| No | 501 (62.9) |
| Yes | 295 (37.1) |
| Neurological disease | |
| No | 514 (64.6) |
| Yes | 282 (35.4) |
| Hematological disease | |
| No | 606 (76.1) |
| Yes | 190 (23.9) |
| Chronic respiratory disease | |
| No | 620 (77.9) |
| Yes | 176 (22.1) |
| Visual impairment | |
| No | 623 (78.3) |
| Yes | 173 (21.7) |
| Infections | |
| No | 644 (80.9) |
| Yes | 152 (19.1) |
| Urology diseases | |
| No | 647 (81.3) |
| Yes | 149 (18.7) |
| Liver, pancreas or biliary disease | |
| No | 701 (88.1) |
| Yes | 95 (11.9) |
| Peripheral vascular | |
| No | 778 (97.7) |
| Yes | 18 (2.3) |
| Feature | F-score | Correlation, r | |||
| ss_Abs_dSize | zsEntropy21 | predRSA | varPredRSA21 | ||
| Abs_dSS | 0.73 | 0.73 | −0.72 | −0.38 | −0.32 |
| ss_Abs_dSize | 0.61 | −0.50 | −0.28 | −0.31 | |
| zsEntropy21 | 0.49 | 0.39 | 0.14 | ||
| predRSA | 0.47 | 0.42 | |||
| varPredRSA21 | 0.45 |
| 27 April 2007, end of bloom | 27 April 2008, full bloom | 9 May 2008, end of bloom | |||||||
| n | mean (μL) | std | n | mean (μL) | std | n | mean (μL) | std | |
| Site 1 | 33 | 1.339* | 0.549 | 50 | 1.516 | 0.807 | 50 | 1.162* | 0.549 |
| Site 2 | 31 | 0.936* | 0.526 | 50 | 1.422 | 0.772 | 50 | 0.732* | 0.568 |
| Site 3 | 49 | 1.318 | 0.677 | 50 | 0.104* | 0.185 | |||
| method | t-test, P = 0.0039 | ANOVA, P = 0.4298 | Kruskal-Wallis test, P < 0.0001 |
| Case 1 | Case 2 | |
| Age at onset, years/gender | 65/M | 50/M |
| Education (years) | 12 | 16 |
| Years of follow-up | 5 | 7 |
| Clinical Dementia Rating score, total (0–3) for the first 2 years | 0.5 | 0.5 |
| Sentence repetition | 5 phrases | 6 phrases |
| Non-word repetition | intact | intact |
| Forward digit span | 6 | 6 |
| Backward digit span | 5 | 4 |
| Confrontation naming in SLTA, % correct | 25 (anomia) | 65 (anomia) |
| Auditory single-word comprehension in SLTA, % correct | 100 | 100 |
| Auditory complex sentence commands comprehension in SLTA, % correct | 20 (auditory comprehension deficits) | 50 (auditory comprehension deficits) |
| Reading comprehension of complex sentence commands in SLTA, % correct | 20 (reading comprehension deficits) | 20 (reading comprehension deficits) |
| Written naming in Kanji in SLTA, % correct | 20 (agraphia) | 20 (agraphia) |
| Dictation of short sentences, % correct | 0 (agraphia) | 0 (agraphia) |
| Calculation in SLTA, % correct | 15 (acalculia) | 10 (acalculia) |
| Ideational apraxia | present | present |
| Visuoconstructional disorder | not found | present |
| Visuoperceptual disorder | not found | not found |
| Episodic memory deficits | found (2 years postonset) | Found (4 years postonset) |
| End point | 3-Year estimate (%) | 95% Confidence interval |
| Progression-free survival | 83.0 | (69.8, 98.8) |
| Overall survival | 94.9 | (89.5, 100) |
| Local recurrence-free survival | 96.6 | (92.1, 100) |
| Distant metastasis-free survival | 89.8 | (82.4, 97.9) |
| Osteosarcoma subtype | Osteoblastic 105 (57.1%) | Chondroblastic 40 (21.7%) | Fibroblastic 21 (11.4%) | Telangiectatic 14 (7.6%) | Others 4 (2.2%) | Total 184 (100%) |
| Number of “Good responders” (%) | 45 | 19 | 5 | 6 | 0 | 75 (40.8) |
| Number of ‘Poor responders’ (%) | 60 | 21 | 16 | 8 | 4 | 109 (59.2) |
| Number of cases with amplification (% of subtype)1 | 7 (6.7) | 3 (7.5) | 7 (33.3) | 2 (14.3) | 0 | 19 |
| Criterion | Sensitivity (95% CI) | Specificity (95% CI) |
| 1.00 | 100 (81.3-100.0) | 75.14 (70.3-79.5) |
| 1.50 | 100 (81.3-100.0) | 80.83 (76.4-84.8) |
| 2.00 | 100.0 (81.3-100.0) | 84.44 (80.3-88.0) |
| 2.50 | 100.0 (81.3-100.0) | 87.2 (83.3-90.5) |
| 3.00 | 100.0 (81.3-100.0) | 90.28 (86.7-93.1) |
| 3.50 | 100.0 (81.3-100.0) | 92.50 (89.3-95.0) |
| 4.00 | 88.89 (65.2-98.3) | 93.89 (90.9-96.1) |
| 4.50 | 88.89 (65.2-98.3) | 95.56 (92.9-97.4) |
| 5.00 | 88.89 (65.2-98.3) | 95.83 (93.2-97.6) |
| PCLe < 45° | PCLe ≥ 45° a | ||
| Release − | AP/gap | 1.7 (0.5) | 2.5 (0.8) |
| n | 27 | 6 | |
| Release + b | AP/gap | 1.7 (0.4) | 2.2 (0.4) |
| n | 10 | 7 |
| HIP/PAP [95% CI] | NMP-22 [95% CI] | BTA [95% CI] | |
| Sensitivity (%) | 80.2 [71.4 - 86.8] | 52.1 [42.2 - 61.8] | 34.7 [25.9 – 44.7] |
| Specificity (%) | 78.2 [69.9 - 84.6] | 93.5 [86.5 - 97.0] | 96.1 [89.0 - 98.6] |
| PPV (%) | 75.7 [66.8 - 82.8] | 89.3 [78.5 - 95.0] | 91.7 [78.2 - 97.1] |
| NPV (%) | 82.3 [74.2 - 88.2] | 65.2 [56.7 – 72.7] | 54.1 [45.7 – 62.3] |
| Risk factors | Number of animals examined | Number of positive animals | 95% CI | χ2 | p value |
| Kebeles | |||||
| Charicho | 128 | 109 (85%) | — | 1.402 | 0.705 |
| Gute | 128 | 88 (68.7%) | 47.4–68.5 | ||
| Yaye 01 | 128 | 94 (73.4%) | 53.8–73.4 | ||
| Sex | |||||
| Female | 249 | 290 (76.3%) | — | 0.559 | 0.454 |
| Male | 135 | 101 (74.8%) | 55.7–75.8 | ||
| Age | |||||
| Old | 63 | 62 (98.4%) | — | 6.154 | 0.046 |
| Adult | 194 | 153 (78.8%) | 56.7–68.0 | ||
| Young | 127 | 76 (59.8%) | 42.4–68.8 | ||
| Body condition | |||||
| Poor | 32 | 32 (100%) | — | 6.812 | 0.000 |
| Medium | 306 | 227 (74%) | 46.6–58.9 | ||
| Good | 46 | 32 (69.5%) | 69.1–100 | ||
| Season | |||||
| Wet | 237 | 184 (77.6%) | — | 1.023 | 0.312 |
| Dry | 147 | 107 (72.7%) | 51.1–67.9 | ||
| Total | 384 | 291 (75.7%) |
| Fusarium Strains | PHS (mg/kg) | NIV (mg/kg) | FUSX (mg/kg) |
| F. asiaticum SCK04 (#1) 1,2 | <0.15 | 4.84 | 67.0 |
| F. asiaticum SCK04 (#1, PDA) 3 | <0.15 | 5.24 | 42.4 |
| F. asiaticum SCK04 (#2) 2 | <0.15 | 2.65 | 12.1 |
| F. asiaticum SCK04 (#2, PDA) 3 | <0.15 | 3.26 | 20.8 |
| F. culmorum IFA450 | <0.15 | 0.15 | 0.74 |
| F. equiseti IFA33 | <0.15 | 0.23 | 0.86 |
| F. equiseti IFA34 | <0.15 | <0.012 | <0.04 |
| F. equiseti IFA63 | <0.15 | 0.07 | 0.16 |
| F. equiseti IFA64 | <0.15 | 0.28 | 1.23 |
| F. equiseti IFA157 | <0.15 | <0.012 | 0.05 |
| F. equiseti IFA336 | <0.15 | <0.012 | <0.04 |
| F. equiseti IFA408 | <0.15 | 0.036 | 0.15 |
| F. equiseti IFA409 | <0.15 | 0.10 | 0.33 |
| F. equiseti IFA410 | 0.23 | 60.0 | 110 |
| F. graminearum DAGZ5 | <0.15 | 0.67 | 20.0 |
| F. graminearum DAGZ8, gray mycelium4 | 0.94 | 294 | 580 |
| F. graminearum DAGZ8, pink mycelium 4 | <0.15 | 5.00 | 212 |
| F. graminearum DAGZ13 | 0.17 | 212 | >6000 |
| F. graminearum DAGZ13 (PDA) 3 | 0.29 | 238 | >5000 |
| F. graminearum DAGZ22 | <0.15 | 0.37 | 43.6 |
| F. graminearum DAGZ23 | <0.15 | 2.71 | 49.6 |
| F. graminearum DAGZ24 | 0.49 | 88.8 | 788 |
| F. graminearum DAGZ25 | <0.15 | 0.10 | 4.84 |
| F. graminearum DAGZ29 | <0.15 | 10.3 | 242 |
| F. graminearum DAGZ31 | <0.15 | 44.0 | 107 |
| F. graminearum DAGZ36 | <0.15 | 0.25 | 21.9 |
| F. graminearum DAGZ37 | <0.15 | 1.91 | 33.4 |
| F. graminearum DAGZ39 | <0.15 | 0.14 | 1.68 |
| F. graminearum DAGZ46 | 1.44 | 399 | 1370 |
| F. graminearum DAGZ47 | <0.15 | 7.72 | 820 |
| F. graminearum DAGZ50 (#1) 2 | 1.65 | 199 | 283 |
| F. graminearum DAGZ50 (#2) 2 | 1.04 | 359 | >1000 |
| F. graminearum DAGZ50 (PDA) 3 | 2.93 | >900 | >3000 |
| F. graminearum DAGZ55 | <0.15 | 32.2 | 378 |
| F. graminearum DAGZ62 | <0.15 | 13.4 | 133 |
| F. graminearum DAGZ63 (#1) 2 | <0.15 | <0.012 | 16.0 |
| F. graminearum DAGZ63 (#1, PDA) 2,3 | <0.15 | 0.32 | 0.568 |
| F. graminearum DAGZ63 (#2) 2 | <0.15 | 0.06 | 0.94 |
| F. graminearum NRRL 26752 | <0.15 | 1.46 | 2.42 |
| F. graminearum NRRL 26752 (PDA) 3 | <0.15 | 1.26 | 1.48 |
| F. kyushuense IFA189 (#1) 2 | 110 | 1370 | 1980 |
| F. kyushuense IFA189 (#2) 2 | 22.7 | 536 | 4560 |
| F. kyushuense NRRL 3509 | <0.15 | <0.012 | <0.04 |
| F. kyushuense NRRL 3510 | <0.15 | 0.03 | 0.11 |
| F. kyushuense NRRL 6490 (=Fn-2B) | 10.0 | 404 | 2890 |
| F. kyushuense NRRL 6491 | 3.57 | 468 | 2930 |
| F. kyushuense NRRL 25348 (backup of 6490) | 15.0 | 328 | 1440 |
| F. kyushuense NRRL 26204 | <0.15 | 0.07 | 0.15 |
| Primers | Forward | Reverse |
| beta-actin | GCGCGGCTACAGCTTCA | CTTAATGTCACGCACGATTTCC |
| PPARgamma | GCTTTTGGCATACTCTGTGATCTC | GGTGGCCATCCGCATCT |
| VEGF-A | GGGCAGAATCATCACGAAGT | TGGTGATGTTGGACTCCTCA |
| CD105 | CTCTCCAGGCATCCAAGCAA | CAGGCTGGAATTGTAGGCCA |
| CD31 | GCTGACCCTTCTGCTCTGTT | ATCTGGTGCTGAGGCTTGAC |
| HIF-1alpha | GCCAGACGATCATGCAGCTA | ATCCATTGATTGCCCCAGC |
| IL-1beta | TCAGCCAATCTTCATTGCTCAA | TGGCGAGCTCAGGTACTTCTG |
| Wnt5a | CAAAGCAACTCCTGGGCTTA | CCTGCTCCTGACCGTCC |
| Mobile phone prevalence in the control group | Detectable Odds Ratio (Cases : Controls) | |||
| 480:960 | 380 : 760 | 300 : 600 | 250 : 500 | |
| 0.05 | 2.0 | 2.2 | 2.4 | 2.6 |
| 0.10 | 1.7 | 1.8 | 2.0 | 2.1 |
| 0.15 | 1.6 | 1.7 | 1.8 | 1.9 |
| 0.20 | 1.5 | 1.6 | 1.7 | 1.8 |
| 0.25 | 1.5 | 1.6 | 1.7 | 1.7 |
| 0.30 | 1.5 | 1.5 | 1.6 | 1.7 |
| 0.35 | 1.5 | 1.5 | 1.6 | 1.7 |
| Clinical features | Survivors (n = 93) | Non survivors (n = 96) | p value |
| Demographic factors | |||
| Mean age | 59.3 ± 18.6 | 61.0 ±17.4 | 0.52 |
| ≥ 65 years age | 48 (52%) | 52 (54%) | 0.73 |
| Gender male/female | 55/38 | 55/41 | 0.79 |
| ATS major criteria | |||
| Use of mechanicalventilation | 18 (19%) | 29 (30%) | 0.08 |
| Septic shock | 23 (25%) | 59 (61%) | < 0.001 |
| History | |||
| Prior antibiotic use | 14 (15%) | 26 (27%) | 0.04 |
| Comorbids | 76 (82%) | 84 (88%) | 0.27 |
| Physical examination findings | |||
| Blood pressure ≤90/60 mmHg | 25 (27%) | 30 (31%) | 0.51 |
| Pulse ≥ 120/min | 32 (34%) | 37 (39%) | 0.55 |
| Respiratory Rate30/min | 56 (60%) | 57 (59%) | 0.95 |
| Laboratory findings | |||
| Blood urea nitrogen ≥30 mg/dl | 44 (47%) | 59 (61%) | 0.03 |
| Creatinine > 1.5 mg/dL | 48 (52%) | 53 (55%) | 0.25 |
| Hematocrit <30% | 22 (24%) | 37 (39%) | 0.03 |
| Na <130 mmol/L | 22 (24%) | 28 (29%) | 0.39 |
| Arterial pH <7.35 | 28 (30%) | 32 (33%) | 0.63 |
| Radiographic findings | |||
| Pleural effusion | 32 (34%) | 38 (40%) | 0.46 |
| Bilateral involvement | 36 (39%) | 53 (55%) | 0.07 |
| Multilobar involvement | 28 (30%) | 38 (40%) | 0.22 |
| Mean APACHE II score | 19.1 ±6.0 | 28.2 ±7.0 | <0.001 |
| APACHE II score ≥ 20 | 38 (41%) | 80 (83.0%) | <0.001 |
| Specimen | D/mm | t/mm | L/mm | L/D | RPRCA/% | RPRFA/% |
| FC-N-T1 | 100 | 4 | 500 | 5 | 0 | 0 |
| FC-N-T2 | 100 | 5 | 500 | 5 | 0 | 0 |
| FC-Ra-T1 | 100 | 4 | 500 | 5 | 100 | 0 |
| FC-Ra-T2 | 100 | 5 | 500 | 5 | 100 | 0 |
| FC-Rb-T1 | 100 | 4 | 500 | 5 | 100 | 100 |
| FC-Rb-T2 | 100 | 5 | 500 | 5 | 100 | 100 |
| ICD-10-GM code | Corresponding diagnosis |
| I50.0 | Right ventricular failure |
| I50.00 | Primary right ventricular failure |
| I50.01 | Secondary right ventricular failure |
| I50.1 | Left ventricular failure |
| I50.11 | NYHA class I |
| I50.12 | NYHA class II |
| I50.13 | NYHA class III |
| I50.14 | NYHA class IV |
| I50.19 | NYHA class not specified |
| I50.9 | Heart failure, unspecified |
| I11.0 | Hypertensive heart disease with (congestive) heart failure |
| I13.0 | Hypertensive heart and renal disease with (congestive) heart failure |
| I13.2 | Hypertensive heart and renal disease with both (congestive) heart failure and renal failure |
| Author | RAQ criteria for radiological bias | Association between malalignment and worse outcome | Sample size | Alignment data | Findings |
| Parratte et al. (2010) | Low risk | No | 398 | 292 knees classed as mechanically aligned 0° ± 3. 10 knees in the outlier group (beyond 0° ÷ 3° | 15.4 % revision rate in the mechanically aligned group. 13 % in the outlier group (p = 0.88). No association between malalignment and revision |
| Bonner et al. (2011) | Low risk | No | 458 | 372 knees were classified as mechanically aligned (0° ± 3°). 86 knees were within the malaligned group | 33 revisions for aseptic loosening. Kaplan–Meier survival analysis showed a weak tendency towards improved survival with restoration of a neutral mechanical axis, but this did not reach statistical significance (p = 0.47) |
| Magnussen et al. (2011) | Low risk | No | 553 | 181 patients were in varus alignment, 352 were in neutral alignment and 20 were in valgus alignment | No statistically significant difference in revision rates between the three groups (p = 0.15) |
| No. of reads | No. of bases(bp) | |
| Leaf | 47,587,040 | 4,758,704,000 |
| root | 52,497,000 | 5,249,700,000 |
| stem | 59,385,462 | 5,938,546,200 |
| Total raw data | 159,469,502 | 15,946,950,200 |
| Total high-quality data | 154,439,892 | 15,264,422,138 |
| Average high-quality read length (bp) | 98.84 | |
| Average length of unigenes (bp) | 895.05 | |
| Range of unigenes length (bp) | 201-13,149 | |
| Unigenes > = 200 bp | 186,324 | 166,768,907 |
| N50 (bp) | 1,524 |
| Range | Drying platform | |||||
| Average | Min | Max | Rack | Black tarpaulin | Cement floor | |
| OTA level (μg/kg) | 0.569 ± 0.3 | <LD | 13.4 | 0.459 ± 0.04 a | 0.665 ± 0.023 a | 0.584 ± 0.026 a |
| Control group (n = 16) | PCOS (n = 43) | |
| Age (years) | 24.3 ± 4.1 | 25.3 ± 4.5 |
| BMI (kg/m2) | 22.8 ± 3.0 | 24.5 ± 3.1 |
| Waist circumference (cm) | 80.3 ± 7.9 | 85.2 ± 10.7 |
| Hip circumference (cm) | 99.7 ± 7.3 | 101.6 ± 8.4 |
| FFM (kg) | 45.5 ± 5.1 | 46.7 ± 6.0 |
| FM (kg) | 18.6 ± 6.6 | 22.6 ± 7.2∗ |
| LDL cholesterol (mg/dl) | 86.9 ± 20.4 | 100.5 ± 40.9 |
| TG (mg/dl) | 70.4 ± 17.1 | 78.7 ± 39.7 |
| Glucose 0′ OGTT (mg/dl) | 89 ± 6.8 | 88.2 ± 6.6 |
| Glucose 30′ OGTT (mg/dl) | 128.5 ± 24.6 | 145 ± 28.5∗ |
| Glucose 60′ OGTT (mg/dl) | 97 ± 22.7 | 123.5 ± 35.8∗ |
| Glucose 120′ OGTT (mg/dl) | 92 ± 15.6 | 95.7 ± 21.6 |
| Insulin 0′ OGTT (μIU/ml) | 11.9 ± 5.5 | 11.5 ± 4.7 |
| Insulin 30′ OGTT (μIU/ml) | 63.7 ± 28.5 | 89.3 ± 56.7 |
| Insulin 60′ OGTT (μIU/ml) | 58.6 ± 49.2 | 84.4 ± 51.5∗ |
| Insulin 120′ OGTT (μIU/ml) | 35.8 ± 16.9 | 56.4 ± 49.6 |
| HOMA-IR | 2.6 ± 1.2 | 2.5 ± 1.0 |
| HOMA-B | 175.1 ± 80.7 | 193 ± 186.3 |
| Matsuda index | 5.37 ± 1.7 | 4.8 ± 2.1 |
| Follicle-stimulating hormone (IU/l) | 5.8 ± 2.8 | 4.5 ± 1.4 |
| Luteinizing hormone (IU/l) | 3.7 ± 1.3 | 6.3 ± 3.9∗ |
| Total testosterone (ng/ml) | 0.5 ± 0.2 | 0.8 ± 0.4∗ |
| SHBG (nmol/l) | 48.0 ± 19.1 | 45.4 ± 22.6 |
| FAI | 4.3 ± 2.2 | 8.4 ± 5.9∗ |
| Prolactin (ng/ml) | 14.4 ± 6.8 | 15.2 ± 9.0 |
| Betatrophin 0′ (ng/ml) | 0.92 ± 0.35 | 0.85 ± 0.33 |
| Betatrophin 120′ (ng/ml) | 1.15 ± 0.42# | 0.88 ± 0.32∗ |
| Patient characteristics | Result |
| Patients (n) | 18 |
| Mean age (range) | 62 (41–89) |
| Sex (n male/female) | 12/6 |
| Body mass index (kg/m2) | 22.2 ± 3.7 |
| The combined surgical risk factors: | |
| Receiving treatment for other cancers | 3 |
| Age >85 years old and refusal of surgery | 4 |
| Hemophilia | 1 |
| Coronary heart disease | 6 |
| End-stage renal disease receiving hemodialysis | 2 |
| Dilated cardiomyopathy with heart failure | 2 |
| Mean follow-up (range), months | 26.8 (12–56) |
| Mean tumor size (range), cm | 3.3 (1.4–4.6) |
| Tumor location (right/left) | 10/8 |
| Pathology: | |
| Clear cell RCC | 14 |
| Papillary RCC | 3 |
| Chromophobe RCC | 1 |
| Operative time (min) | 67 ± 18 |
| Complication | |
| Nausea | 3 |
| Pain | 4 |
| Subcapsular hemorrhage | 1 |
| Retroperitoneal errhysis | 1 |
| Demographic | ||
| Patients (n) | Hips (n) | 196 |
| 225 | ||
| Age | Mean (SD, range) | 60.3 (10.3, 25 to 84) |
| <50 years | 25 (15.7%) | |
| ≥50 years | 171 (84.3%) | |
| Sex | Male | 181 (92.3%) |
| Female | 15 (7.7%) | |
| Diagnosis | Primary OA | 145 (64.9%) |
| Other | 80 (35.1%) | |
| Femoral diameter | Median (range) | 53 mm (51 to 61) |
| 51 mm | 88 | |
| 53 mm | 73 | |
| 55 mm | 33 | |
| 57 mm | 17 | |
| 59 mm | 13 | |
| >59 mm | 1 | |
| Preoperative ROM | Mean (SD, range) | 124° (22°, 10° to 276°) |
| <100° | 81 (43.4%) | |
| ≥100° | 131 (56.6%) | |
| Cup coverage | Mean (SD, range) | 31.4° (6.8°, 10.7° to 52.0°) |
| <25° | 34 (28.1%) | |
| ≥25° | 191 (71.9) |
| Genotype | Nr. reads | Nr. reads after filtration | Avg. read length bp | Nr. assembled reads | Singletons | Nr. contigs | Avg. EST length bp |
| Connecticut King | 139,480 | 104,323(75%) | 336 | 77,097(74%) | 27,226(26%) | 14,773 | 615 |
| White Fox | 326,539 | 221,597(68%) | 338 | 182,393(82%) | 39,204(18%) | 21,898 | 663 |
| Star Gazer | 374,240 | 255,081(68%) | 341 | 202,707(79.5%) | 52,374(20.5%) | 24,700 | 688 |
| Trumpet | 442,476 | 299,655(69%) | 343 | 241,782(81%) | 57,873(19%) | 26,075 | 694 |
| Lily-All | 1,282,735 | 880,656(69%) | 340 | 471,378(53.5%) | 409,278(46.5%) | 52,172 | 555 |
| Cantata | 310,973 | 207,229(67%) | 389 | 158,007(76%) | 49,222(24%) | 17,646 | 625 |
| Princeps | 316,372 | 211,380(67%) | 386 | 165,282(78%) | 46,098(22%) | 17,007 | 632 |
| T. fosteriana | 627,345 | 418,609(67%) | 388 | 293,043(70%) | 125,566(30%) | 24,713 | 629 |
| Kees Nelis | 592,034 | 407,392(69%) | 281 | 303,558(74.5%) | 103,834(25.5%) | 38,716 | 559 |
| Ile de France | 263,175 | 185,464(70%) | 283 | 125,293(67.6%) | 60,171(32%) | 24,557 | 517 |
| Bellona | 221,334 | 149,768(67%) | 278 | 109,309(34%) | 40,459(27%) | 14,325 | 522 |
| T. gesneriana | 1,076,543 | 742,624(69%) | 281 | 536,776 (74%) | 205,848(28%) | 54,575 | 557 |
| Tulip-All | 1,703,888 | 1,378,898 | 314 | 827,772(60%) | 551,126(40%) | 81,791 | 514 |
| Question | Baseline (n = 66) | 3 months (n = 54) | ||||||
| r | AA | κ | ICC | r | AA | κ | ICC | |
| 1 | 0.70 | 0.87 | 0.70 (0.51 to 0.89) | 0.68 (0.07 to 1.3) | 0.51 | 0.87 | 0.51 (0.22 to 0.81) | 0.55 (−0.19 to 1.28) |
| 2 | 0.29 | 0.86 | 0.23 (−0.07 to 0.53) | 0.21 (−0.35 to 0.76) | −0.09 | 0.70 | −0.034 (−0.1 to 0.03) | −0.03 (−0.08 to 0.02) |
| 3 | 0.30 | 0.63 | 0.28 (0.06 to 0.49) | 0.14 (−0.26 to 0.54) | 0.25 | 0.62 | 0.19(−0.02 to 0.4) | 0.15 (−0.36 to 0.66) |
| 4 | 0.42 | 0.70 | 0.36 (0.15 to 0.56) | 0.28 (−0.33 to 0.88) | 0.08 | 0.25 | 0.087 (−0.16 to 0.31) | −0.03 (−0.06 to 0.01) |
| 5 | 0.58 | 0.81 | 0.50 (0.28 to 0.72) | 0.52 (−0.20 to 1.24) | 0.40 | 0.87 | 0.39 (0.03 to 0.75) | 0.04 (−0.35 to 1.14) |
| 6 | 0.45 | 0.73 | 0.45 (0.22 to 0.67) | 0.32 (−0.33 to 0.97) | 0.23 | 0.61 | 0.22 (−0.03 to 0.48) | 0.06 (−0.20 to 0.33) |
| 7 | −0.04 | 0.91 | −0.03 (−0.07 to 0.02) | −0.11 (−0.14 to −0.08) | n/a | 0.96 | n/a | −0.33 (−0.38 to −0.28) |
| 8 | 0.35 | 0.83 | 0.28 (−0.001 to 0.57) | 0.51 (−0.28 to 1.30) | 0.24 | 0.91 | 0.21 (−0.19 to 0.6) | 0.37 (−0.57 to 1.31) |
| 9 | n/a | 0.92 | n/a | n/a | 0.86 | 0.96 | 0.85 (0.66 to 1.1) | 0.91 (0.68 to 1.14) |
| 10 | 0.25 | 0.84 | 0.21 (−0.18 to 0.61) | 0.22 (−0.42 to 0.87) | 0.28 | 0.74 | 0.21 (−0.04 to 0.45) | 0.13 (−0.28 to 0.55) |
| 11 | 0.44 | 0.77 | 0.37 (0.14 to 0.6) | 0.33 (−0.33 to 0.99) | 0.64 | 0.83 | 0.61 (0.39 to 0.83) | 0.58 (−0.13 to 1.28) |
| 12 | 0.72 | 0.86 | 0.70 (0.52 to 0.87) | 0.68 (0.05 to 1.30) | 0.78 | 0.89 | 0.77 (0.61 to 0.94) | 0.76 (0.23 to 1.28) |
| 13 | 0.18 | 0.43 | 0.06 (−0.01 to 0.13) | 0.03 (−0.14 to 0.20) | 0.13 | 0.27 | 0.03 (−0.01 to 0.08) | 0.01 (−0.15 to 0.13) |
| 14 | 0.39 | 0.69 | 0.38 (0.16 to 0.6) | 0.25 (−0.33 to 0.83) | 0.17 | 0.60 | 0.17 (−0.01 to 0.43) | 0.02 (−0.14 to 0.18) |
| Wind Direction | ASF (ns) | Error Correction (m) | Statistical Probability of the Error Correction Interval (%) | Error Correction Average (m) | |||
| 0–100 (m) | 100–200 (m) | 200–300 (m) | 300–400 (m) | ||||
| East-southeast | 396–727 | 118.76–218.21 | 0 | 96.5 | 3.5 | 0 | 166.9449 |
| East | 564–868 | 169.07–260.33 | 0 | 23.44 | 76.56 | 0 | 218.6659 |
| East-northeast | 384–786 | 115.25–235.76 | 0 | 79.22 | 20.87 | 0 | 166.6964 |
| West | 56.6–376 | 16.97–112.91 | 99.71 | 0.83 | 0 | 0 | 63.7418 |
| West-northwest | 21.5–400 | 6.44–119.9 | 96.78 | 3.22 | 0 | 0 | 54.8815 |
| North | 782–1260 | 234.58–377.32 | 0 | 0 | 32.33 | 67.67 | 321.0044 |
| Chromosome No. | Centromere Position | Relative Length (%) | Arm Ratioa | 45Sb | 5Sb | Satelliteb |
| S. oleracea L. Mazeran | ||||||
| 1 | Submedian | 19.6 | 1.73 | |||
| 2 | Submedian | 18.2 | 2.17 | S | L | |
| 3 | Subterminal | 17.3 | 3.44 | |||
| 4 | Subterminal | 16.0 | 3.36 | |||
| 5 | Subterminal | 14.5 | 3.11 | S | L | S |
| 6 | Subterminal | 14.4 | 6.61 | S | S | |
| Total length | 100 | |||||
| S. tetrandra Stev. PI 647859 | ||||||
| X | Median | 18.1 | 1.29 | |||
| Y | Median | 29.9 | 1.12 | |||
| 1 | Submedian | 16.7 | 2.39 | L | ||
| 2 | Submedian | 16.6 | 2.84 | |||
| 3 | Submedian | 14.8 | 1.85 | |||
| 4 | Submedian | 17.9 | 1.86 | S | L | S |
| 5 | Submedian | 15.9 | 2.46 | S | S | |
| Total length (X) | 100 | |||||
| Total length (Y) | 111.8 |
| Gene | AT gene locus | Biological function | Act./Repr. +/- | Reference | Fragaria | E-value |
| Autonomous pathway | ||||||
| FCA | AT4G16280 | RRM-type RNA binding domain containing | + | [94] | nf | |
| FPA | AT2G43410 | RRM-type RNA binding domain containing | + | [95] | nf | |
| FLK | AT3G04610 | KH-type RNA binding domain containing | + | [96] | EX668302 | 5E-52 |
| FY | AT5G13480 | mRNA 3' end processing factor | + | [97] | EX659635 | 5E-75 |
| SKB1 | AT4G31120 | Arginine methyltransferase | + | [98] | nf | |
| FVE | AT2G19520 | retinoblastoma associated | + | [24] | VES-001-B03 | 3E-76 |
| LD | AT4G02560 | DNA/RNA binding homeodomain protein | + | [99] | DY670534 | 3E-49 |
| FLD | AT3G10390 | component of histone deacetylase complex | + | [23] | nf | |
| LDL1/SWP1 | AT1G62830 | Histone H3-Lys 4 demetylase-like | + | [22] | Contig 2573 | 2E-27 |
| LDL2 | AT3G13682 | Histone H3-Lys 4 demetylase-like | + | [22] | DY669828 | 1E-42 |
| Gibberellin pathway | ||||||
| GAI | AT1G14920 | putative transcriptional repressor | - | [100] | Contig 3276 | 3E-147 |
| RGA | AT2G01570 | putative transcriptional repressor | - | [100] | DQ195503 | 8E-60 |
| SPY | AT3G11540 | O-linked N-acetylglucosamine transferase | - | [101] | BAR-002-C02 | 2E-93 |
| DDF1 | AT1G12610 | AP2-like TF | + | [102] | Contig 3158 | 5E-49 |
| DDF2 | AT1G63030 | AP2-like TF | + | [102] | nf | |
| AtMYB33 | AT5G06100 | MYB TF | + | [25] | DY669997 | 5E-29 |
| FPF1 | AT5G24860 | Unknown | + | [103] | Contig 4074 | 7E-38 |
| Other | ||||||
| SVP | AT2G22540 | MADS-box TF | - | [57] | VES-013-D05 | 5E-22 |
| AP2 | AT4G36920 | AP2 TF | - | [104] | VES-008-A07 | 9E-16 |
| PFT1 | AT1G25540 | vWF-A domain protein | + | [48] | BAR-002-D08 | 1E-17 |
| HRB1 | AT5G49230 | ZZ type zinc finger protein | + | [49] | VES-012-B01 | 7E-22 |
| Protein | Network centrality scores | PDB | |||
| Betweenness | Eigenvector | Degree | Closeness | ||
| Rv3019c | 71224.33 | 0.08889492 | 167 | 0.0488181 | 3H6P |
| Rv0451c | 66230.336 | 0.09615834 | 171 | 0.0488344 | 2LW3 |
| Rv0288 | 63475.453 | 0.09102694 | 170 | 0.0488555 | 2KG7 |
| Rv0058 | 57680.18 | 0.00275039 | 62 | 0.0481486 | 2R5U |
| Rv1908c | 50548.035 | 0.00563762 | 76 | 0.0484564 | 1SFZ; 1SJ2; 2CCA; 2CCD; 4C50; 4C51 |
| Rv2050 | 40088.305 | 0.01941196 | 91 | 0.0485105 | 2M4V; 2M6P |
| Rv2150c | 37525.4 | 0.00763293 | 103 | 0.0484339 | 1RLU; 1RQ2; 1RQ7; 2Q1X; 2Q1Y; 4KWE |
| Rv3793 | 36733.14 | 0.06872068 | 136 | 0.0487904 | 3PTY |
| Rv2111c | 35411.24 | 0.00444417 | 37 | 0.0479427 | 3M91; 3M9D |
| Rv0002 | 33375.504 | 0.00362037 | 90 | 0.0482796 | 3P16; 3RB9 |
| Rv3597c | 27758.719 | 0.01894281 | 73 | 0.048406 | 2KNG; 4E1P; 4E1R |
| Rv1837c | 24302.383 | 0.00201247 | 47 | 0.0479375 | 2GQ3; 3S9I; 3S9Z; 3SAD; 3SAZ; 3SB0 |
| Rv0467 | 23928.854 | 0.00293969 | 53 | 0.0481574 | 1F61; 1F8I; 1F8M |
| Rv3240c | 22790.56 | 0.00369075 | 64 | 0.0481586 | 1NKT; 1NL3 |
| Rv0216 | 20616.273 | 0.01939864 | 57 | 0.0482126 | 2BI0 |
| Rv1611 | 17798.758 | 0.00289133 | 57 | 0.0481961 | 3QJA; 3T40; 3T44; 3T55; 3T78; 4FB7 |
| Rv2773c | 17351.877 | 0.00189925 | 52 | 0.0480259 | 1C3V; 1P9L; 1YL5; 1YL6; 1YL7 |
| Rv0902c | 16640.244 | 0.02111599 | 42 | 0.0480668 | 1YS3; 1YSR |
| Rv2711 | 15661.199 | 0.00590289 | 41 | 0.0481721 | 1B1B; 1FX7; 1U8R; 2ISY; 2ISZ; 2IT0 |
| Rv3601c | 15341.172 | 0.00251573 | 49 | 0.0481235 | 2C45 |
| Rv2518c | 14995.93 | 0.00281853 | 25 | 0.0477322 | 3VYN; 3VYO; 3VYP; 4GSQ; 4GSR; 4GSU; 4HU2; 4HUC |
| Rv0736 | 14264.871 | 0.01536277 | 50 | 0.0483009 | 3HUG |
| Rv2538c | 14206.7705 | 0.00232458 | 65 | 0.0481065 | 3QBD; 3QBE |
| Rv3808c | 13873.782 | 0.00814938 | 51 | 0.0480131 | 4FIX; 4FIY |
| Rv2416c | 13419.646 | 0.00771849 | 39 | 0.0482891 | 3R1K; 3RYO; 3SXO; 3UY5 |
| Rv2987c | 13133.913 | 0.0017555 | 52 | 0.0479834 | 3H5E; 3H5H; 3H5J |
| Rv2986c | 13109.861 | 0.00315177 | 40 | 0.0481223 | 4DKY; 4PT4 |
| Rv2391 | 12401.702 | 0.00120635 | 45 | 0.0478749 | 1ZJ8; 1ZJ9 |
| Variable | Description (N = 10) |
| Age (years old) | |
| Mean (St. Dev.) | 2.57 (0.99) |
| Median (min / max) | 2.21 (2; 5) |
| Age range, n (%) | |
| < 3 years old | 8 (80.0) |
| ≥ 3 years old | 2 (20.0) |
| Gender, n (%) | |
| Feminine | 4 (40.0) |
| Masculine | 6 (60.0) |
| Laterality, n (%) | |
| Unilateral | 5 (50.0) |
| Bilateral | 5 (50.0) |
| Variables | Frequency | Percentage |
| Malaria vaccine will prevent malaria | ||
| Indifferent | 40 | 8.0 |
| Agree | 159 | 31.8 |
| Strongly agree | 301 | 60.2 |
| Everyone should receive malaria vaccine | ||
| Disagree | 15 | 3.0 |
| Indifferent | 75 | 15.0 |
| Agree | 103 | 20.6 |
| Strongly agree | 307 | 61.4 |
| I will take the malaria vaccine when produced | ||
| Indifferent | 30 | 6.0 |
| Agree | 70 | 14.0 |
| Strongly agree | 400 | 80.0 |
| Malaria vaccine is not against our cultural belief | ||
| Indifferent | 35 | 7.0 |
| Agree | 32 | 6.4 |
| Strongly agree | 433 | 86.6 |
| Malaria is a major health problem requiring vaccine | ||
| Disagree | 30 | 6.0 |
| Agree | 167 | 33.4 |
| Strongly agree | 303 | 60.6 |
| Malaria vaccine will save money spent on treatment | ||
| Disagree | 23 | 4.6 |
| Indifferent | 67 | 13.4 |
| Agree | 129 | 25.8 |
| Strongly agree | 281 | 56.2 |
| Malaria vaccine will not have adverse health effect | ||
| Strong degree | 61 | 12.2 |
| Disagree | 109 | 21.8 |
| Indifferent | 20 | 4.0 |
| Agree | 101 | 20.2 |
| Strongly agree | 209 | 41.8 |
| Malaria vaccine will save man hour lost to malaria | ||
| Agree | 199 | 39.8 |
| Strongly agree | 301 | 60.2 |
| Variable | Normotensive Non pregnant women n (75) | Normotensive pregnant women n (102) | Pre-eclamptic women n (100) | Total N (277) |
| Age (years) | ||||
| <20 | 1 (1.3) | 5 (4.9) | 2 (2.0) | 8 (2.9) |
| 20–34 | 51 (68.0) | 85 (83.3) | 69 (69.0) | 205 (74.0) |
| ≥35 | 23 (30.7) | 12 (11.8) | 29 (29.0) | 64 (23.1) |
| Parity | ||||
| 0 | 38 (50.7) | 35 (34.3) | 61 (61.0) | 134 (48.4) |
| 1 | 21 (28.0) | 34 (33.3) | 20 (20.0) | 75 (27.1) |
| 2≥ | 16 (21.3) | 33 (32.4) | 19 (19.0) | 68 (24.5) |
| GA at delivery | ||||
| <34 | - | 3 (0.3) | 10 (10.0) | 13 (6.4) |
| 34–36 | - | 5 (0.5) | 44 (44.0) | 49 (24.3) |
| ≥37 | - | 94 (92.2) | 46 (46.0) | 140 (69.3) |
| Variable | Blood flow =1,500mL/min | Blood flow =3,500mL/min | p value* | |||||
| Sweep flow 3.0L/min | Sweep flow 1.5L/min | Sweep flow 10L/min | Sweep flow 2.0L/min | Sweep flow 3.5L/min | Sweep flow 7.0L/min | Sweep flow 12L/min | ||
| Cardiac output (L/min) | 6.5 [6.4, 6.9] | 6.3 [4.0, 6.7] | 7.7 [3.6, 9.4] | 7.3 [4.3, 9.3] | 9.0 [4.4, 9.1] | 7.6 [4.8, 8.2] | 6.3 [4.8, 7.9] | 0.834 |
| Heart rate (bpm) | 134 [124, 145] | 133 [95, 137] | 135 [123, 147] | 128 [124, 149] | 137 [131, 160] | 121 [121, 153] | 128 [123, 161] | 0.867 |
| ABPm (mmHg) | 126 [106, 126] | 106 [100,125] | 101 [91, 112] | 98 [92, 105] | 103 [94, 114] | 113 [112, 122] | 122 [119, 123] | 0.154 |
| PAPm (mmHg) | 54 [41, 59] | 46 [42, 47] | 36 [32, 46] | 47 [34, 48] | 40 [31, 47] | 42 [35, 45] | 39 [33, 44] | 0.248 |
| CVP (mmHg) | 6 [5, 13] | 6 [4, 16] | 5 [4, 13] | 5 [3, 15] | 5 [4, 14] | 5 [4, 11] | 5 [4, 11] | 0.299 |
| PAOP (mmHg) | 11 [10, 12] | 8 [8, 11] | 8 [7, 11] | 7 [5, 9] | 8 [7, 8] | 8 [6, 16] | 8 [7, 17] | 0.715 |
| Characteristic | HBC | SBC | ||
| HBOC | HBCC | Other* | ||
| Number of patients, n (%) | 77 (74.8) | 4 (3.9) | 22 (21.4) | 101 (100) |
| Age at diagnosis, mean (sd) | 45.75 (11.8) | 47.66 (3.2) | 41.1 (10.4) | 56.9 (5.2) |
| Age at diagnosis >50, n (%) | 25 (32.5) | 0 | 6 (27.3) | 101 (100) |
| Bilateral breast cancer, n (%) | 50 (74.6) | 3 (4.5) | 5 (7.5) | 9 (13.4) |
| Synchronic | 23 (47.8) | 2 (66.7) | - | 2 (22.2) |
| Metachronic | 26 (50.0) | 0 | - | 7 (77.8) |
| Missing | 1 (2.2) | 1 (33.3) | 5 (100) | 0 |
| Unaffected (n = 865) | Slightly affected (n = 1408) | OR1 | 95% CI1 | p | Seriously affected (n = 427) | OR2 | 95% CI2 | p | ||||
| N | % | N | % | N | % | |||||||
| SF-36 | ||||||||||||
| Physical functioning | ||||||||||||
| S.W.S.S.3 | 220 | 25.70 | 299 | 21.37 | 0.99 | 0.77 – 1.26 | 0.909 | 73 | 17.26 | 0.93 | 0.63 – 1.38 | 0.073 |
| Role-physical | ||||||||||||
| S.W.S.S.3 | 122 | 14.25 | 180 | 12.87 | 0.92 | 0.69 – 1.22 | 0.562 | 53 | 12.53 | 0.93 | 0.61 – 1.44 | 0.774 |
| Bodily pain | ||||||||||||
| S.W.S.S.3 | 320 | 37.38 | 559 | 39.96 | 1.29 | 1.05 – 1.57 | 0.013 | 154 | 36.41 | 1.29 | 0.95 – 1.74 | 0.098 |
| General health | ||||||||||||
| S.W.S.S.3 | 260 | 30.37 | 414 | 25.59 | 1.00 | 0.80 – 1.25 | 0.986 | 129 | 30.50 | 0.96 | 0.69 – 1.32 | 0.789 |
| Vitality | ||||||||||||
| S.W.S.S.3 | 121 | 14.14 | 173 | 12.37 | 0.88 | 0.65 – 1.18 | 0.388 | 46 | 10.87 | 0.92 | 0.59 – 1.45 | 0.725 |
| Social functioning | ||||||||||||
| S.W.S.S.3 | 189 | 22.08 | 273 | 19.51 | 0.79 | 0.62 – 1.00 | 0.055 | 76 | 17.97 | 0.74 | 0.51 – 1.06 | 0.104 |
| Role-emotional | ||||||||||||
| S.W.S.S.3 | 68 | 7.94 | 104 | 7.43 | 0.86 | 0.59 – 1.23 | 0.408 | 30 | 7.09 | 0.80 | 0.46 – 1.38 | 0.417 |
| Mental health | ||||||||||||
| S.W.S.S.3 | 180 | 21.30 | 330 | 23.59 | 1.06 | 0.83 – 1.35 | 0.631 | 96 | 22.70 | 1.00 | 0.70 – 1.43 | 0.993 |
| GHQ-28 | ||||||||||||
| Somatic Symptoms | ||||||||||||
| Cases | 27 | 3.12 | 29 | 2.07 | 0.60 | 0.34 – 1.09 | 0.093 | 9 | 2.12 | 0.61 | 0.25 – 1.47 | 0.268 |
| Anxiety and insomnia | ||||||||||||
| Cases | 20 | 2.31 | 40 | 2.85 | 0.10 | 0.60 – 2.01 | 0.762 | 14 | 3.29 | 1.36 | 0.59 – 3.16 | 0.472 |
| Severe depression | ||||||||||||
| Cases | 2 | 0.23 | 5 | 0.36 | 1.35 | 0.21 – 8.55 | 0.752 | 1 | 0.24 | 1.05 | 0.06 – 18.96 | 0.973 |
| Social dysfunction | ||||||||||||
| Cases | 11 | 1.27 | 18 | 1.28 | 0.87 | 0.37 – 2.07 | 0.755 | 4 | 0.94 | 0.59 | 0.16 – 2.21 | 0.432 |
| HADS | ||||||||||||
| Anxiety | ||||||||||||
| Cases (prob+conf)* | 87 | 10.06 | 150 | 10.65 | 1.04 | 0.76 – 1.44 | 0.786 | 44 | 10.3 | 1.14 | 0.71 – 1.86 | 0.576 |
| Cases (conf)** | 39 | 4.51 | 59 | 4.19 | 0.85 | 0.53 1.36 | 0.496 | 18 | 4.22 | 0.81 | 0.39 – 1.67 | 0.572 |
| Depression | ||||||||||||
| Cases (prob+conf)* | 33 | 3.82 | 40 | 2.84 | 0.67 | 0.38 – 1.16 | 0.150 | 9 | 2.11 | 0.57 | 0.21 – 1.33 | 0.176 |
| Cases (conf)* | 10 | 1.16 | 11 | 0.78 | 0.86 | 0.32 – 2.32 | 0.771 | 4 | 0.94 | 1.60 | 0.38 – 6.78 | 0.527 |
| GADS | ||||||||||||
| Anxiety | ||||||||||||
| Cases | 112 | 12.95 | 179 | 12.71 | 0.92 | 0.69 – 1.24 | 0.602 | 49 | 11.48 | 0.88 | 0.56 – 1.38 | 0.582 |
| Depression | ||||||||||||
| Cases | 75 | 8.67 | 110 | 7.81 | 0.71 | 0.48 – 1.03 | 0.071 | 26 | 6.09 | 0.47 | 0.26 – 0.85 | 0.012 |
| Function Name | Operations Number/Pixel |
| “format” | 10 |
| “format_bis” | 14 |
| “sobel” | 15 |
| “prewitt” | 14 |
| “matrix” | 8 |
| “filter” | 10 × 3 |
| “filtre_gauss” | (12 + 6 × (filter size)) × 3 |
| “critere_Harris” | 10 |
| “critere_Shi” | 31 |
| “look_for_max” | 6 |
| Reference | Country | Number ofpatients with BP | Goldstandard | BP180 | BP230 | ||
| Sensitivity | Specificity | Sensitivity | Specificity | ||||
| Tampoiaet al.20 | Italy | 36 | ELISA | 85% | 100% | 44% | 100% |
| van Beeket al.18 | Germany | 42 | ELISA | 100% | 98% | 55% | 100% |
| Zarianet al.19 | Italy | 18 | ELISA | 83% | 100% | 39% | 100% |
| Chianget al.*17 | Australia | 18 | ELISA | 77% | 84% | 94% | 63% |
| \"IUI + IVF\" for those failing IUI | ||||||
| IUI modality | One cycle of IUI | Two cycles of IUI | Three cycles of IUI | Four cycles of IUI | Five cycles of IUI | Six cycles of IUI |
| U-IUI (LBR = 3.5%) | ||||||
| Cost difference \"IUI+IVF\" vs. primary IVF | £2,600 | £36,100 | £70,100 | £104,400 | £139,100 | £174,200 |
| No of IVF cycles that would be purchased by the cost difference | 1 | 11 | 22 | 32 | 43 | 54 |
| No of live birth-producing pregnancies expected from IVF cycles that would have been purchased by the cost difference | 0 | 4 | 6 | 8 | 11 | 14 |
| S-IUI (LBR = 7%) | ||||||
| Cost difference \"IUI+IVF\" vs. primary IVF | £48,100 | £122,600 | £199,100 | £277,200 | £356,900 | £438,000 |
| No of IVF cycles that would be purchased by the cost difference | 15 | 38 | 62 | 86 | 111 | 136 |
| No of live birth-producing pregnancies expected from IVF cycles that would have been purchased by the cost difference | 4 | 10 | 16 | 22 | 28 | 35 |
| C-IUI (LBR = 3%) | ||||||
| Cost difference \"IUI+IVF\" vs. primary IVF | £34,300 | £98,900 | £163,400 | £228,000 | £292,600 | £357,200 |
| No of IVF cycles that would be purchased by the cost difference | 11 | 31 | 51 | 71 | 91 | 111 |
| No of live birth-producing pregnancies expected from IVF cycles that would have been purchased by the cost difference | 3 | 8 | 13 | 18 | 23 | 28 |
| Outcome | Index group n/N (%) | Control group A, n/N (%) | Crude OR (95 % CI) | Adjusted OR (95 % CI) |
| Normal delivery | 21/76 (27.6 %)*** | 90/150 (60 %) | 0.26 (0.14–0.50)* | 0.30 (0.15–0.60)** |
| Instrumental deliverya | 13/58 (22.4 %) | 20/142 (14.1 %) | 1.77 (0.74–4.25) | 1.95 (0.75–5.09) |
| Caesarean Section (CS) | 42/76 (55.3 %)*** | 39/150 (26 %) | 3.69 (1.97–6.92)*** | 2.95 (1.52–5.71)** |
| Non emergency CS | 18/76 (23.7 %)*** | 8/150 (5.3 %) | 5.79 (2.36–14.22)*** | 5.13 (2.00–13.17)** |
| Emergency CSa | 24/58(41.4 %)** | 31/142(21.8 %) | 2.49(1.20–5.13)** | 1.93(0.88–4.22) |
| Induction of labora | 33/58 (56.9 %)*** | 31/142 (21.8 %) | 3.34 (1.63–6.82)*** | 3.00 (1.39–6.44)** |
| Uterine Inertia, primary-secondarya | 13/58 (22.4 %) | 32/142 (22.5 %) | 0.82 (0.36–1.84) | 0.88 (0.36–2.16) |
| Hypertensive disorders of pregnancyf | 12/76 (15.8 %)* | 9/150 (6 %) | 3.42 (1.32–8.86)* | 2.84 (1.04–7.81)* |
| Pregnancy-Induced Hypertension | 2/76 (2.6 %) | 0/150 | – | – |
| Preeclampsia | 10/76 (13.2 %) | 9/150 (6 %) | 2.37 (0.92–6.12) | 2.41 (0.84–6.89) |
| Fetal distressa | 16/58 (27.6 %)* | 21/142 (14.8 %) | 2.62 (1.11–6.19)* | 1.96 (0.78–4.97) |
| Very Preterm birth (<32 weeks) | 3/76 (3.9 %) | 3/150 (2.0 %) | 6.19 (0.63–60.76) | 6.48 (0.61–68.56)b |
| Preterm birth (<37 weeks) | 13/76 (17.1 %) | 13/150 (8.7 %) | 2.42 (0.97–6.05) | 1.86 (0.70–4.95)b |
| Maternal Hospitalization post partum | ||||
| ≥2 days | 73/75(97.3 %)** | 127/148 (85.8 %) | 10.40 (1.36–79.80)* | 4.47 (0.53–37.76)c |
| ≥3 days | 59/75(78.7 %)** | 86/148 (58.1 %) | 2.64 (1.33–5.26)** | 1.14 (0.51–2.58)c |
| Post-partum hemorrhage | 12/76 (15.8 %)** | 7/150 (4.7 %) | 3.29 (1.12–9.70)** | 7.11(2.02–24.97)d** |
| Retained placentae | 8/34 (23.5 %)** | 4/111 (3.6 %) | 7.58 (2.03–28.30)** | 6.71 (1.58–28.40)* |
| Variable | Principal Component 1 Loadings | Principal Component 2 Loadings |
| pH | −0.998 | |
| Total dissolved solids | −0.992 | |
| Electrical Conductivity | −0.962 | |
| Caffeine | 0.980 | |
| Carbamazepine | 0.935 | |
| Tonalide | 0.997 | |
| Galaxolide | 0.961 | |
| Bisphenol A | 0.906 | |
| Nonylphenol | 0.902 | |
| % Variance | 51.46 | 38.53 |
| Cumulative % | 51.46 | 89.99 |
| Arbitrary speed zones | ||||||
| 1 | 2 | 3 | 4 | 5 | 6 | |
| MDL-1 | ||||||
| Times (s) | 20 ± 86* | 6 ± 101 | −107 ± 74* | 94 ± 54* | 1 ± 70 | 3 ± 49 |
| Distances (m) | −27 ± 24* | 21 ± 78* | −124 ± 84* | 160 ± 86* | 0 ± 167 | 0 ± 117 |
| MDL-5 | ||||||
| Times (s) | −24 ± 77* | −48 ± 116* | 55 ± 114* | 53 ± 122* | 3 ± 78 | −22 ± 50* |
| Distances (m) | −22 ± 24* | −29 ± 89* | 81 ± 135* | 113 ± 132* | 7 ± 152 | −68 ± 130* |
| Irrelevant feature NO. | Cost time(s) | ||||
| LHDA | LDPP | LSDA | LM-NNDA | I-Relief | |
| 100 | 18.82 | 2.09 | 0.05 | 57.86 | 3.23 |
| 200 | 40.24 | 2.63 | 0.07 | 134.36 | 7.72 |
| 300 | 87.96 | 3.00 | 0.11 | 632.91 | 11.83 |
| 400 | 139.13 | 3.31 | 0.25 | 487.89 | 30.71 |
| 500 | 203.28 | 3.60 | 0.24 | 493.70 | 35.03 |
| 600 | 285.81 | 3.58 | 0.35 | 560.68 | 61.91 |
| 700 | 366.59 | 5.45 | 0.34 | 651.41 | 73.77 |
| 800 | 505.73 | 6.05 | 0.32 | 758.55 | 83.78 |
| 900 | 655.34 | 6.58 | 0.39 | 972.84 | 95.71 |
| 1000 | 699.42 | 7.11 | 0.35 | 1201.89 | 108.58 |
| Adolescents with type 1 diabetes | U.S. National Norm | |||
| % | n | % | P-value | |
| How would you rate the health of your teeth?* | ||||
| Excellent/very good | 48.3 | 43 | 70.6 | |
| Good | 39.3 | 35 | 21.5 | <.001 |
| Fair/poor | 12.4 | 11 | 7.9 | |
| How would you rate the health of your gums? | NA | |||
| Excellent | 10.2 | 9 | ||
| Very good | 33.0 | 29 | ||
| Good | 43.2 | 38 | ||
| Fair | 12.5 | 11 | ||
| Poor | 1.1 | 1 | ||
| % | 95% CI | % | P-value | |
| What specific problems, if any, do you have with your teeth and gums? | ||||
| Pain/toothache* | 5.8 | 1.9–12.9 | 10 | .19 |
| Cavities/decayed teeth or cavities* | 25.9 | 16.8–36.9 | 19.4 | .14 |
| Bleeding gums* | 31.8 | 22.3–42.6 | 4.0 | <.001 |
| Cosmetic concerns: discoloration** | 40.7 | 30.2–51.8 | 3.6 | <.001 |
| Orthodontic concerns: crooked teeth** | 41.5 | 30.7–52.9 | 33.5 | .13 |
| Bad breath | 26.7 | 17.8–37.4 | NA | |
| Plaque or tartar buildup on teeth** | 33.3 | 22.9–45.2 | 3.6 | <.001 |
| Subset with airborne PAH monitoring and RCPM | Subset with airborne PAH monitoring but missing RCPM | ||||
| Variable | p-Valueb | Mean ± SD | nc | Mean ± SD | nd |
| Continuous | |||||
| Total valid airborne PAH exposure (ng/m3) | 0.65 | 39.62 ± 48.49 | 219 | 39.39 ± 47.70 | 125 |
| Dietary exposure to PAHs during pregnancye | 0.31 | 42.49 ± 5.65 | 219 | 43.14 ± 6.27 | 139 |
| Cord blood cotinine level (ng/mL) | 0.49 | 2.04 ± 11.52 | 219 | 3.29 ± 15.56 | 138 |
| Cord blood lead level (μg/dL) | 0.59 | 1.60 ± 1.19 | 210 | 1.51 ± 0.78 | 129 |
| Cord blood mercury level (μg/dL) | 0.43 | 1.07 ± 0.64 | 161 | 1.16 ± 0.79 | 106 |
| Gestational age (days) | 0.07 | 39.26 ± 1.73 | 219 | 39.51 ± 1.63 | 139 |
| Birth weight (g) | 0.01 | 3368.49 ± 508.38 | 219 | 3501.65 ± 474.22 | 139 |
| Birth height (cm) | 0.76 | 54.44 ± 3.06 | 219 | 54.54 ± 3.10 | 139 |
| Head circumference at birth (cm) | 0.21 | 33.81 ± 1.54 | 219 | 34.01 ± 1.47 | 139 |
| Maternal age (years) | 0.01 | 28.50 ± 3.59 | 219 | 27.49 ± 3.73 | 139 |
| Maternal height (cm) | 0.18 | 164.69 ± 5.71 | 219 | 165.52 ± 5.59 | 139 |
| Maternal prepregnancy weight (kg) | 0.95 | 58.44 ± 8.80 | 219 | 58.50 ± 9.32 | 139 |
| Maternal TONI-3 | 0.23 | 33.48 ± 9.07 | 176 | 31.42 ± 9.71 | 31 |
| Maternal blood cotinine level at birth (ng/mL) | 0.97 | 1.68 ± 10.09 | 219 | 2.99 ± 14.34 | 138 |
| Maternal blood lead level at birth (μg/dL) | 0.79 | 1.92 ± 0.83 | 209 | 1.86 ± 0.66 | 136 |
| Categorical | p-Valuef | Proportion | n | Proportion | n |
| Caucasian race | 1.00 | 1.00 | 219 | 1.00 | 139 |
| Maternal education (proportion graduated high school, i.e., 12 years of schooling) | 0.47 | 0.91 | 219 | 0.88 | 139 |
| ETS in the home (yes = 1, no = 0) | 0.52 | 0.22 | 219 | 0.25 | 139 |
| Exposure to alcohol during pregnancy (yes = 1, no = 0) | 0.18 | 0.60 | 219 | 0.67 | 139 |
| Sex of the child (proportion female) | 0.52 | 0.52 | 219 | 0.48 | 139 |
| Measures of socioeconomic position | GP visits | Specialist visits | Hospitalisation | |||
| PRa (IC 95%) | PRa (IC 95%) | PRa (IC 95%) | ||||
| Education | ||||||
| Tertiary | 1.00 | - | 1.00 | - | 1.00 | - |
| Upper secondary | 1.21 | (1.08–1.35) | 0.90 | (0.77–1.06) | 0.95 | (0.79–1.13) |
| Lower secondary | 1.38 | (1.23–1.54) | 0.77 | (0.64–0.91) | 1.18 | (0.98–1.41) |
| Primary/no education | 1.52 | (1.37–1.68) | 0.66 | (0.57–0.77) | 1.16 | (0.99–1.37) |
| Social class | ||||||
| I–II | 1.00 | - | 1.00 | - | 1.00 | - |
| III | 1.14 | (1.03–1.25) | 0.85 | (0.73–0.99) | 0.96 | (0.82–1.12) |
| IV | 1.42 | (1.30–1.55) | 0.79 | (0.69–0.91) | 1.06 | (0.92–1.22) |
| V–VI | 1.43 | (1.30–1.56) | 0.67 | (0.57–0.78) | 1.12 | (0.97–1.30) |
| Monthly income | ||||||
| More than 1800 euros | 1.00 | - | 1.00 | - | 1.00 | - |
| From 1201 to 1800 euros | 1.24 | (1.13–1.35) | 0.81 | (0.50–0.68) | 1.05 | (0.91–1.21) |
| From 901 to 1200 euros | 1.21 | (1.11–1.33) | 0.72 | (0.63–0.85) | 1.01 | (0.87–1.18) |
| Up to 900 euros | 1.39 | (1.27–1.51) | 0.58 | (0.71–0.93) | 1.06 | (0.92–1.22) |
| Study (reference) | Country of study, n. | Primary exposure measure (birth weight, g) | Effect size (95% CI) | Age at follow up (y) | Quality score | Adjusted |
| Davidson [16] | England, n = 248612 | 1000-2999 vs 3000-3999 | OR 1.2 (1.1-1.3) | 2-10 | 8.0 | Yes |
| Chatkin [15] | Brazil, n = 981 | < 2500 vs >2500 | RR 1.32 (0.8-1.96) | 4-5 | 5.5 | Yes |
| Nepomnyaschy [19] | United States, n = 1803 | < 2500 vs >2500 | RR 1.57 (1.23-1.99) | < 3 | 6.0 | No |
| Fergusson [17] | New Zealand, n = 798 | < 2500 vs 2500-4000 | RR 0.97 (0.6-1.58) | 16 | 5.5 | No |
| Lu [18] | Taiwan, n = 69979 | < 3000 vs 3000-4000 | RR 1.17 (1.09-1.27) | 13-15 | 7.0 | No |
| Yuan [26] | Denmark, n = 10190 | < 2500 vs 2500-4499 | RR 0.9 (0.43-1.89) | < 12 | 6.5 | No |
| Wjst [24] | German, n = 2337 | < 2500 vs >2500 | RR 1.47 (0.64-3.36) | 5-14 | 5.0 | No |
| Remes [21] | Finland, n = 4141 | ≤ 2490 vs 2500-4190 | RR 1.31 (0.85-2) | 16 | 7.0 | No |
| Yang [25] | United States, n = 3933 | < 2500 vs >2500 | RR 1.25 (0.73-2.15) | 6-7 | 6.5 | No |
| Rasanen [20] | Finland, n = 4502 | < 2500 vs >2500 | RR 0.97 (0.71-1.31) | 16 | 6.0 | No |
| To [23] | Canada, n = 671402 | < 2500 vs 2500-4500 | RR 1.18 (1.13-1.22) | 6 | 8.5 | Yes |
| Sin [22] | Canada, n = 83595 | < 2500 vs 2500-4500 | RR 1 (0.9-1.11) | 10 | 7.5 | Yes |
| Bjerg [14] | Sweden, n = 3430 | < 2500 vs >2500 | OR 2.6 (1.2-5.4) | 7-8 | 6.0 | Yes |
| day0 Cow Nr | Heat score | day12 Cow Nr | Heat score |
| d0_5006 | 0 | d12_1528 | 2 |
| d0_9284 | 37 | d12_9303 | 4 |
| d0_3739 | 43 | d12_8860 | 5 |
| d0_8855 | 53 | d12_1773 | 75 |
| d0_1194 | 137 | d12_8873 | 157 |
| d0_1821 | 175 | d12_7724 | 198 |
| d0_8870 | 191 | d12_1520 | 257 |
| d0_5507 | 200 | d12_7942 | 275 |
| d0_1786 | 206 | d12_1607 | 318 |
| d0_3472 | 246 | d12_1822 | 368 |
| d0_6487 | 248 | d12_1638 | 383 |
| d0_3747 | 378 | d12_6956 | 404 |
| d0_7008 | 405 | d12_8857 | 475 |
| d0_5125 * | 1750 | d12_2540 | 505 |
| Descriptor | FTU Dosing Study | Tape-Stripping Study |
| Age (years) | 27.2 ± 10.3 | 26.0 ± 3.7 |
| Gender | 14 male; 10 female | 3 female; 2 male |
| Fingertip length (mm) | 28 ± 3 | Not applicable |
| Previous use of TCS | 9 yes; 15 no | No recent use |
| PIL offered? | 12 yes; 12 no | Not applicable |
| If yes; PIL read? | 8 yes; 4 no |
| Biological factor observed | MONET study | CAO study | P-value | ||||
| Mean | Std. Dev. | Size (n) | Mean | Std. Dev | Size (n) | ||
| Age (yrs) | 58.1 | 4.91 | 62 | 56.7 | 4.18 | 27 | 0.230 |
| Height (m) | 1.61 | 0.06 | 62 | 1.63 | 0.08 | 27 | 0.189 |
| Pre-Intervention | |||||||
| BMI (kg/m2) | 35.3 | 4.04 | 62 | 34.7 | 3.37 | 27 | 0.489 |
| Lean Mass (kg) | 45.5 | 6.82 | 62 | 46.1 | 7.38 | 27 | 0.693 |
| Fat Mass (kg) | 43.9 | 8.64 | 62 | 44.2 | 9.10 | 27 | 0.898 |
| Lean Mass (%) | 49.6 | 4.43 | 62 | 49.7 | 3.71 | 27 | 0.888 |
| Fat Mass (%) | 47.6 | 4.48 | 62 | 47.3 | 3.82 | 27 | 0.753 |
| Visceral Fat (cm2) | 207 | 51.9 | 61 | 206 | 52.8 | 27 | 0.927 |
| Muscle Attenuation (HU) | 48.5 | 3.70 | 62 | 48.6 | 2.20 | 27 | 0.833 |
| Post-Intervention | |||||||
| BMI (kg/m2) | 33.0 | 4.42 | 61 | 32.8 | 3.24 | 27 | 0.813 |
| Lean Mass (kg) | 44.1 | 5.69 | 60 | 44.1 | 6.58 | 27 | 0.998 |
| Fat Mass (kg) | 39.1 | 9.90 | 60 | 41.1 | 8.78 | 27 | 0.361 |
| Lean Mass (%) | 51.9 | 5.28 | 60 | 50.4 | 3.99 | 27 | 0.184 |
| Fat Mass (%) | 45.1 | 5.41 | 60 | 46.5 | 4.19 | 27 | 0.254 |
| Visceral Fat (cm2) | 182 | 58.5 | 60 | 182 | 47.4 | 27 | 0.981 |
| Muscle Attenuation (HU) | 48.2 | 4.09 | 61 | 48.6 | 1.89 | 27 | 0.661 |
| Author | Year | Country | Limb | Test timing, h |
| Arlettaz et al. | 2006 | Switzerland | Right or left foot | 6–12 |
| Bakr and Habib | 2005 | Egypt | Right upper and lower limbs | 31.7 (average) |
| de Wahl Granelli et al. | 2005 | Sweden | Right hand and one foot | 12–48 |
| Hoke et al. | 2002 | America | Right arm and either leg | 24 (average) |
| Koppel et al. | 2003 | America | — | >24 |
| Richmond et al. | 2002 | UK | One or other foot | >2 |
| Rosati et al. | 2005 | Italy | — | 72 h (median) |
| Zhao et al. | 2014 | China | Both on the right hand and on either foot | 6–72 |
| Riede et al. | 2010 | Germany | Foot | 24–72 |
| Mathur et al. | 2015 | India | Right upper limb and either foot | 72 (median) |
| Hu et al. | 2016 | China | Right hand and either foot | 25 (median) |
| Jones et al. | 2016 | UK | — | <24 |
| Ozalkaya et al. | 2016 | Turkey | Lower and right upper extremity | >24 |
| Jawin et al. | 2015 | Malaysia | Left foot | 20 (median) |
| Ewer et al. | 2011 | UK | Right hand and either foot | In the first few hours |
| Taksande et al. | 2013 | India | All the four limbs | Within the first 4 hours |
| van Niekerk et al. | 2016 | South Africa | — | 60 (median) |
| de-Wahl Granelli et al. | 2009 | Sweden | Right hand and either foot | 38 (median) |
| Meberg et al. | 2008 | Norway | Foot | <12 |
| Mo et al. | 2015 | China | Right hand and either foot | >24 |
| Jia et al. | 2016 | China | Right hand | 24 |
| Lu et al. | 2016 | China | Right hand and right foot | >24 |
| Model 1 | Model2 | Model 3 | Model 4a | |||||
| OR | 95 % CI | OR | 95 % CI | OR | 95 % CI | OR | 95 % CI | |
| Open unemployment 18–21 (no exp. ref.) | ||||||||
| Yes | 2.53*** | 1.82–3.52 | 2.53*** | 1.77–3.60 | 2.48*** | 1.57–3.60 | ||
| Youth programs 18–21 (no exp. ref.) | ||||||||
| Yes | 1.24 | 0.97–1.59 | 1.01 | 0.78–1.31 | 0.95 | 0.72–1.26 | ||
| IMHS at age 16 | 1.58*** | 1.45–1.72 | 1.58*** | 1.45–1.72 | 1.58*** | 1.45–1.72 | 1.46*** | 1.34–1.60 |
| Pseudo R-square | ||||||||
| Cox and Snell | 0.12 | 0.10 | 0.12 | 0.15 | ||||
| Nagelkerke | 0.13 | 0.11 | 0.13 | 0.16 |
| ID | HISTOLOGY | Age at diagnosis(years) | Race | Smoking | Drinking | Menopausal status | BMI (Kg/m2) | CYP1B1(V432L) * |
| 5 | Intra Ductal Carcinoma | 68 | White | Never | Unknown | Post | 51.16 | Wild type |
| 8 | Intra Ductal Carcinoma | 45 | White | Never | No | Pre | 38.39 | Wild type |
| 9 | Intra Ductal and Lobular Carcinoma | 51 | White | Never | No | Post | 26.63 | Wild type |
| 1 | Intra Ductal Carcinoma | 44 | White | Never | Yes | Pre | 22.49 | Heterozygous |
| 2 | Intra Ductal Carcinoma | 56 | White | Never | No | Post | 37.12 | Heterozygous |
| 6 | Intra Ductal Carcinoma | 69 | White | Never | No | Post | 35.51 | Heterozygous |
| 3 | Intra Ductal Carcinoma | 60 | White | Never | No | Post | 21.45 | Homozygous variant |
| 4 | Intra Ductal Carcinoma | 67 | White | Never | Yes | Post | 27.36 | Homozygous variant |
| 7 | Metaplastic carcinoma | 46 | White | Never | No | post | 23.51 | Homozygous variant |
| Type of use | Unit costs | |
| Costs in the health care system (public/private) | General practitioner | 10.5/27.5 |
| Nurse or psychiatric nurse | 10.0/25.4 | |
| Social worker | 14.9/25.4 | |
| Psychologist | 70.6/70.6 | |
| Psychiatrist | 42.9/42.9 | |
| Other medical specialists | 51.1/51.1 | |
| Hospital emergency visits | 155.5 | |
| Hospital stay | 617.5 | |
| Diagnostic tests (range) | 4.3 to 434.6 | |
| Pharmacologic treatment | Depending on type and dose | |
| Productivity losses | Absenteeism from work (minimum and medium daily wage) | 21.4 to 62.7 |
| CBT costs | Cost of the group intervention per session (eight patients/group; nine sessions) | 240 |
| Year | Prevalence rate (per 1000 population) | |||
| Males (95% CI) | Females (95% CI) | |||
| 70-74 years | ≥ 75 years | 70-74 years | ≥ 75 years | |
| 2002 | 11.1 (10.5-11.6) | 8.0 (7.6-8.4) | 21.0 (20.4-21.7) | 13.1 (12.6-13.6) |
| 2003 | 18.9 (18.3-19.5) | 14.2 (13.7-14.7) | 35.8 (35.0-36.6) | 23.3 (22.7-24.0) |
| 2004 | 25.1 (24.3-25.9) | 20.5 (19.9-21.2) | 50.0 (49.0-50.9) | 31.9 (31.1-32.6) |
| 2005 | 32.8 (32.0-33.5 | 25.4 (24.7-26.1) | 64.1 (63.1-65.2) | 39.5 (38.6-40.3) |
| 2006 | 38.1 (37.2-38.9) | 32.3 (31.5-33.1) | 73.6 (72.4-74.7) | 48.6 (47.6-49.5) |
| 2007 | 43.9 (43.0-44.8) | 37.8 (36.9-38.6) | 83.1 (81.9-84.3) | 56.2 (55.2-57.2) |
| 2008 | 49.1 (48.2-50.1) | 41.0 (40.1-41.9) | 94.8 (93.5-96.1) | 62.2 (61.1-63.2) |
| 2009 | 58.7 (56.8-60.7) | 46.3 (45.0-47.7) | 110.8 (108.3-113.3) | 68.6 (67.2-69.9) |
| 2010 | 58.0 (56.1-60.0) | 44.3 (42.9-45.6) | 109.7 (107.2-112.2) | 68.1 (66.8-69.5) |
| 2011 | 47.3 (45.7-49.0) | 43.3 (42.0-44.7) | 93.8 (91.6-96.0) | 67.2 (65.8-68.5) |
| Case 1 | Case 2 | Case 3 | Case 4 | Case totals | Stakeholders | Total | |
| Sharp-end interviews | 17 | 4 | 0 | 12 | 33 | 98 | |
| Blunt-end interviews | 7 | 0 | 20 | 10 | 37 | ||
| Total | 24 | 4 | 20 | 22 | 70 | 98 | 168 |
| Novel | ||||||||
| Filter | Protein coding | Antisense | Pseudogene | Annotated lncRNA | Intronic | Intergenic | Interleaving | Encompassing |
| Raw | 16,246 | 2,902 | 3,670 | 4,593 | 823 | 1,825 | 142 | 113 |
| ≥5% (11) samples | 16,225 | 2,897 | 3,650 | 4,585 | 822 | 1,820 | 141 | 112 |
| Distance (≥2 kb) | 16,225 | 2,897 | 3,650 | 4,585 | 336 | 1,269 | 22 | 46 |
| Mappability | 14,468 | 2,338 | 1,698 | 3,646 | 249 | 993 | 18 | 36 |
| Length (≥200 bp) | 14,461 | 2,336 | 1,693 | 3,642 | 244 | 984 | 18 | 36 |
| ≥216 mapped reads | 14,011 | 2,294 | 1,476 | 2,942 | 196 | 840 | 15 | 29 |
| Number of antimicrobial classes to which isolates exhibited resistance | Number of isolates | Percent | 95% CIa |
| 1 | 17 | 26.6 | 16.3, 39.1 |
| 2 | 12 | 18.8 | 10.1, 30.4 |
| 3 | 7 | 10.9 | 4.5, 21.2 |
| 4 | 12 | 18.8 | 10.1, 30.4 |
| 5 | 8 | 12.5 | 5.6, 23.2 |
| 6 | 8 | 12.5 | 5.6, 23.2 |
| Health care utilization n (%) | Total study sample (n = 229493) | Non-multi-morbid (n = 53741) | Multi-morbid (n = 175752) | Sign. |
| Individuals with consultation | 209'962 (91.5) | 36'922 (68.7) | 173'040 (98.5) | *** |
| By primary care physicians | 185'035 (80.6) | 27'397 (51.0) | 157'638 (89.7) | *** |
| By specialists | 165'178 (72.0) | 25'834 (48.1) | 139'344 (79.3) | *** |
| Hospital outpatient visits | 108'502 (47.3) | 12'168 (22.6) | 96'334 (54.8) | *** |
| By different primary care physicians | 41'601 (18.1) | 3'494 (6.5) | 38'107 (21.7) | *** |
| By different specialists | 108'187 (47.1) | 13'029 (24.2) | 95'158 (54.1) | *** |
| Individuals with physician contact | ||||
| Face-to-face consultations | 203'328 (88.6) | 34'129 (63.5) | 169'199 (96.3) | *** |
| Phone consultations | 55'174 (24.0) | 4'748 (8.8) | 50'426 (28.7) | *** |
| Home visits | 14'059 (6.1) | 654 (1.2) | 13'405 (7.6) | *** |
| Individuals with hospitalisation | 40'556 (17.7) | 2'091 (3.9) | 38'465 (21.9) | *** |
| FH Phenotype | Gender | |||||||||
| Y402 | Y402H | H402 | AMD | Control | ||||||
| Protein (mg/ml) | AMD | Control | AMD | Control | AMD | Control | Male | Female | Male | Female |
| CFH | 0.7±0.2 | 0.6±0.1 | 0.7±0.1 | 0.6±0.2 | 0.7±0.2 | 0.6±0.1 | 0.6±0.2 | 0.7±0.2 | 0.6±0.2 | 0.6±0.2 |
| C3 | 1.6±0.6 | 1.5±1 | 1.5±0.7 | 1.7±1.1 | 1.6±0.8 | 1.5±0.8 | 1.3±0.7 | 1.7±0.7 | 1.5±0.9 | 1.6±1.1 |
| CRP | 0.9±3.7 | 0.4±0.4 | 0.5±0.5 | 0.4±0.5 | 0.7±1.5 | 0.6±1.1 | 1± 3.2 | 0.5±0.5 | 0.4±0.5 | 0.5±0.6 |
| Total population | AF | Non-AF | P-value | |||||||
| detection rate (%) | 95% CI | |||||||||
| Total, n | 928 | 35 | 3.8% | (2.7–5.2) | 893 | |||||
| Men, n (%) | 462 (49.8%) | 21 (60.0%) | 4.6% | (3.0–6.8) | 441 (49.4%) | 0.218 | ||||
| Women, n (%) | 466 (50.2%) | 14 (40.0%) | 3.0% | (1.8–5.0) | 452 (50.6%) | |||||
| Age < 65 years, n (%) | 242 (26.1%) | 7 (20.0%) | 2.9% | (1. 4–5.8) | 235 (26.3%) | 0.404 | ||||
| Age ≥65 years, n (%) | 686 (73.9%) | 28 (80.0%) | 4.1% | (2.8–5.8) | 658 (73.7%) | |||||
| CHADS2 = 1, n (%) | 415 (44.7%) | 13 (37.1%) | 3.1% | (1.7–5.1) | 403 (45.1%) | 0.351 | ||||
| CHADS2 ≥ 2, n (%) | 513 (55.3%) | 22 (62.9%) | 4.3% | (2.8–6.3) | 490 (54.9%) | |||||
| CHF, n (%) | 34 (3.7%) | 1 (2.9%) | 2.9% | (0.7–14.9) | 33 (3.7%) | 0.796 | ||||
| HT, n (%) | 838 (90.3%) | 31 (88.6%) | 3.7% | (2.6–5.2) | 807 (90.4%) | 0.724 | ||||
| Age ≥75 y, n (%) | 326 (35.0%) | 13 (37.1%) | 4.0% | (2.6–7.1) | 313 (35.1%) | 0.799 | ||||
| DM, n (%) | 293 (31.6%) | 12 (34.3%) | 4.1% | (2.4–7.0) | 281 (31.5%) | 0.725 | ||||
| ES, n (%) | 80 (8.6%) | 4 (11.4%) | 5.0% | (2.0–12.2) | 76 (8.5%) | 0.546 | ||||
| IHD*, n (%) | 184 (19.8%) | 5 (14.3%) | 2.7% | (1.2–6.2) | 179 (20.0%) | 0.402 | ||||
| Total population | AF | Non-AF | ||||||||
| Mean | SD | Range | Mean | SD | Range | Mean | SD | Range | P-value | |
| Number of ECG registrations, n | 55.4 | ± 11.2 | 1–125 | 50.3 | ± 22.1 | 1–96 | 55.6 | ± 10.5 | 20–125 | 0.442 |
| Age, y | 69.8 | ± 9.4 | 33–89 | 70.7 | ± 7.7 | 53–85 | 69.8 | ± 9.4 | 33–89 | 0.679 |
| Median | Range | Median | Range | Median | Range | |||||
| CHADS2 total | 2 | 1–5 | 2 | 1–4 | 2 | 1–5 | 0.451 |
| Number (%) of patients | |||
| Complications | Young group | Older group | P value |
| Overall | 16 (23.0%) | 19 (22.9%) | 0.928 |
| Ascites | 2 (2.8%) | 1 (1.2%) | 0.326 |
| Wound infection | 2(2.8%) | 2(2.4%) | 0.657 |
| Pleural effusion | 1(1.4%) | 1(1.2%) | 0.536 |
| Pulmonary infection | 1(1.4%) | 11(13.3%) | 0.041 |
| Biliary fistula | 2 (2.8%) | 1(1.2%) | 0.326 |
| Liver failure | 2(2.8%) | 1(1.2%)* | 0.326 |
| Bleeding | 6(8.6%) | 2(2.4%) | 0.084 |
| Variable | Hazard ratio | 95% CIs | P |
| GCB/Non-GCB | 0.316 | 0.158–0.633 | 0.001 |
| IPI score | 4.218 | 2.235–7.962 | 0.000 |
| GG + GC/CC | 0.343 | 0.173–0.679 | 0.002 |
| Variable | ||||
| Age | 56–65 years: 58(43%) | 46–55 years: 37(27.4%) | 36–45 years: 24(17.8%) | Under 35 years: 11(8.1%) |
| Contract with sickness fund | § 2-Vertrag (regional sickness funds): 86(78.5%) | Small sickness funds (BVA, SVA, KFA, VA, SVB): 90(78. 9%) | “Wahlarztstatus” (private doctora): 22(16%) | “Wohnsitzärzte”b: 11(8.1%) |
| Locum physician: 16(12%) | ||||
| Assistance | Receptionist: 120(90.2%) | Practice nurse: 34(25.6%) | Secretary: 48(36.1%) | Other employees:Cleaning worker: 29Masseur: 7Physiotherapist: 4Medical technical assistant: 3 |
| Number of inhabitants in the area of the office | <4999: 68(50.7%) | 5000–99,999: 22(16.4%) | 10,000–29,999: 12(9%) | >30,000: 32(23.9%) |
| “Regelfälle”c/quarter | <500 “Regelfälle”: 13(10.2%) | 500–1000 “Regelfälle”: 24(18.8%) | 1001–1500 “Regelfälle”: 61(47.7%) | >1500 “Regelfälle”: 30(23.4%) |
| Specialized office | Yes: 69 (51.95%) | No: 64 (48.1%) | – | – |
| Field of practice specialization | 17 GPs:Complementary medicine | 8 GPs in each:Manual medicineOrthopedicsSports medicine | 7 GPs in each:NutritionGeriatricsPsychosocial/psychosomatic medicine | <6 GPs in each:Preventive medicineHypertensionPain medicineOccupational medicineEmergency medicinePsychotherapyWound management |
| 15 GPs: Diabetes mellitus II management |
| Never smoker | Smoker | |||
| COPD (%) | Adjusted OR(95%CI) | COPD (%) | Adjusted OR(95%CI) | |
| Educational level | ||||
| ≥ 12 years | 101 (1.3) | 1 | 80 (2.2) | 1 |
| 9-11 years | 142 (1.4) | 1.06 (0.81-1.37) | 191 (3.1) | 1.36 (1.04-1.78) |
| < 9 years | 509 (3.5) | 1.77 (1.40-2.25) | 392 (5.8) | 1.64 (1.26-2.12) |
| P for trend | < 0.001 | < 0.001 | ||
| Household Income | ||||
| High | 162 (1.8) | 1 | 132 (3.2) | 1 |
| Middle | 213 (2.0) | 1.08 (0.87-1.34) | 186 (3.3) | 0.88 (0.69-1.11) |
| Low | 305 (3.3) | 1.31 (1.05-1.62) | 284 (5.6) | 1.17 (0.93-1.48) |
| P for trend | 0.011 | 0.071 |
| Differentiation | Subset | Surface phenotype |
| Progenitor subsets (bone marrow) | Pro-B | B220loCD43+ |
| AA4.1+ | ||
| Pre-B | B220loCD43−, AA4.1+preBcR+ | |
| Immature (23−) | B220lo, sIgM+, sIgD−, CD23− | |
| Immature (23+) | CD19+, B220+, sIgM+, sIgD−, CD23+ | |
| Transitional subsets (spleen) | T1 | IgMhiCD23−, B220intAA4.1+ |
| T2 | IgMhiCD23+, B220+AA4.1+ | |
| T3 | IgMloCD23+, B220+AA4.1+ | |
| Mature primary subsets | Follicular zone | IgMloCD23+, B220hiAA4.1− |
| Marginal zone | CD19+IgMhiIgDlo CD23+ CD21+ | |
| B1 | CD43+ CD23− CD5+ | |
| T-independent responses | Early antibody-forming cells/short-lived plasma cells | B220loCD19+slg+iclghi |
| T-dependent responses | Early antibody-forming cells/short-lived plasma cells | B220loCD19+slg+iclghi |
| Germinal center | B220+CD19+GL7+ | |
| Long-lived plasma cells | B220loslg−iclg+ | |
| Memory | B220+slg+IgD− | |
| Natural antibodies | Peritoneal B1a and B1b | CD43+ CD23− CD5+ |
| Pre-challenge Type 2 Neutralizing Antibody Level (log2) | |||||
| Day post-challenge | 2.5 | 4.5 | 6.5 | 8.5 | 10.5 |
| 7 | 77.1(75.3, 78.8) | 76.7(74.9, 78.4) | 76.5(74.7, 78.3) | 75.9(74.1, 77.8) | 74.4(72.6, 76.2) |
| 14 | 67.4(65.4, 69.4) | 66.4(64.3, 68.5) | 66.0(63.9, 68.1) | 64.6(62.1, 67.0) | 60.7(58.8, 62.7) |
| 21 | 56.0(53.2, 58.8) | 54.3(51.2, 57.4) | 53.7(50.6, 56.7) | 51.3(47.7, 54.9) | 45.2(42.6, 47.7) |
| 28 | 43.9(40.0, 47.9) | 41.7(37.5, 45.9) | 40.9(36.8, 44.9) | 37.9(33.3, 42.5) | 30.5(27.4, 33.5) |
| Parameter | p value | HR | CI |
| Segment group (≥4) | 0.0187 | 2.035 | 1.126–3.681 |
| Age | 0.0002 | 1.061 | 1.029–1.095 |
| LVEF | 0.0063 | 0.969 | 0.948–0.991 |
| Gender (Female) | 0.1811 | 1.545 | 0.817–2.922 |
| Peripheral artery disease(PAD) | 0.2651 | 1.483 | 0.742–2.965 |
| Glomerular filtration rate(GFR) | 0.0132 | 0.989 | 0.967–0.996 |
| Correlation Coefficients | Thermometers | |||||||
| A | B | C | D | E | F | G | H | |
| A | 0 | 0.939 | 0.938 | 0.913 | 0.938 | 0.912 | 0.935 | 0.942 |
| B | 0.939 | 0 | 0.781 | 0.888 | 0.898 | 0.902 | 0.913 | 0.739 |
| C | 0.938 | 0.781 | 0 | 0.876 | 0.633 | 0.242 | 0.824 | 0.916 |
| D | 0.913 | 0.888 | 0.876 | 0 | 0.924 | 0.831 | 0.904 | 0.647 |
| E | 0.938 | 0.898 | 0.633 | 0.924 | 0 | 0.733 | 0.412 | 0.231 |
| F | 0.912 | 0.902 | 0.242 | 0.831 | 0.733 | 0 | 0.647 | 0.750 |
| G | 0.935 | 0.913 | 0.824 | 0.904 | 0.412 | 0.647 | 0 | 0.932 |
| H | 0.942 | 0.739 | 0.916 | 0.647 | 0.231 | 0.750 | 0.932 | 0 |
| Reduction Method | Raman (ID/IG) | H (%) | Reference |
| Mg/HCl | 1.52 | 10.3 | [38] |
| Fe/HCl | 1.38 | 9.8 | [35] |
| Zn/HCl | 1.49 | 29.6 | [36] |
| Al/HCl | 1.32 | 7.2 | [38] |
| NH3BH3/Fe2O3 | 1.19 | 43.6 | this paper |
| Mean ± SD | |
| Age (years) | 7.99 ± 1.55 |
| Mother's educational level (years) | 4.51 ± 1.43 |
| Weight (kg) | 27.63 ± 8.26 |
| Height (cm) | 126.28 ± 9.93 |
| BMI‐for‐age (Z‐Score) | 0.31 ± 1.31 |
| Height‐for‐age (Z‐Score) | ‐1.23 ± 1.22 |
| Percentage body fat | 29.12 ± 6.68 |
| Stool leukocytes (CPF) | 2.36 ± 1.52 |
| C‐Reactive Protein (mg/L) | 0.97 ± 1.60 |
| Interleukin 6 (pg/mL) | 3.12 ± 3.95 |
| Interleukin 10 (pg/mL) | 4.33 ± 6.82 |
| Tumour necrosis factor‐α (pg/mL) | 4.25 ± 2.87 |
| Serum | ||||||||
| Total Ca | Ca2+ | PTH | Pi | ALP | BAP | Osteocalcin | TRACP-5b | |
| Age (mos.) | (normal 8.9–10.2 mg/dL) | (normal 4.7–5.3 mg/dL) | (normal 4–52 pg/mL) | (normal 3.4–5.9 mg/dL) | (normal 157–477 IU/L) | (normal 88–247 U/L) | (normal 37–119 ng/mL) | (normal 13–23 U/L) |
| 11 | 10.1 | 5.3 | 34 | 4.7 | 213 | — | 9 | 8 |
| 23 | 10.2 | 5.2 | 33 | 5.0 | 162 | — | 2 | — |
| 25 | 9.1 | 4.9 | 120 | 4.5 | 210 | 85 | 12 | 2 |
| 27* | 10.1 | — | 7 | 5.2 | 125 | — | — | — |
| 30* | 10.0 | — | 38 | 4.6 | 140 | — | — | — |
| 35 | 9.9 | 5.0 | 62 | 4.2 | 136 | 41 | 12 | 3 |
| 44* | 9.8 | 5.0 | 22 | 4.4 | 176 | 63 | 6 | 3 |
| Gene ID | Gene symbol | Fold change | Description |
| 180579 | vang-1 | 0.45 | Vang-like protein |
| 3565956 | R04A9.7 | 0.37 | Hypothetical protein |
| 174941 | cyd-1 | 0.41 | G1/S-specific cyclin-D |
| 179100 | fat-7 | 0.23 | Delta(9)-fatty-acid desaturase fat-7 |
| 178840 | skr-7 | 0.38 | SKp1 related (ubiquitin ligase complex component) |
| 178495 | skr-8 | 0.33 | SKp1 related (ubiquitin ligase complex component) |
| 178494 | skr-9 | 0.27 | SKp1 related (ubiquitin ligase complex component) |
| 191169 | kgb-2 | 2.03 | Mitogen-activated protein kinase |
| 353420 | gsto-2 | 2.14 | Probable glutathione transferase omega-2 |
| 180148 | skr-5 | 2.31 | SKp1 related (ubiquitin ligase complex component) |
| Number of Cases by Mucormycetes | 2010 | 2011 | 2012 | 2013 | 2014 | Total |
| Apophysomyces elegans | - | 1 | - | - | - | 1 |
| Apophysomyces variabilis | 5 | 2 | - | 4 | 1 | 12 |
| Lichtheimia corymbifera | - | - | 1 | - | - | 1 |
| Lichtheimia ramosa | 5 | - | - | 2 | - | 7 |
| Mucor irregularis | - | - | - | 1 | - | 1 |
| Rhizopus arrhizus | 4 | 4 | 5 | 2 | 2 | 17 |
| Rhizopus microsporus | 1 | 1 | 1 | 3 | 3 | 9 |
| Rhizopus homothallicus | 1 | - | - | 1 | - | 2 |
| Rhizomucor pusillus | - | 1 | - | - | - | 1 |
| Saksenaea erythrospora | - | - | - | 1 | 4 | 5 |
| Syncephalastrum racemosum | - | - | - | 2 | 2 | 4 |
| 60 |
| Scientific literature | Quantitative data from the study communities | Qualitative data from local people in this study |
| Importance of Dietary Diversity | ||
| • DD associated with overall food consumption, energy intake and satiety [51, 64–69]• DD associated with dietary quality, nutrient intake, nutrient density (likely explaining links to child growth and other anthropometric and biochemical markers of nutrition) [68–71] | • DD associated with overall energy intake [46]• DD associated with intake of most nutrients and nutrient adequacy (Mean Adequacy Ratio, MAR) [46]• After controlling for energy intake, DD no longer associated with intake of most nutrients [46] | • DD important for appetite and enjoyment of food• DD important because “each food has its own value” |
| Drivers of Dietary Diversity | ||
| • DD linked to agrobiodiversity in at least seven studies [46, 52, 72–78],• DD associated with forest cover in three studies [47, 52, 79, 80].• DD linked to vegetable production [81]• DD linked to home gardens [52, 82]• Season may increase/decrease DD [83, 84]• Wild food use associated with higher DD [54]• DD also associated with wealth, household size, education and other economic and demographic variables | • DD associated with agrobiodiversity (crop diversity) [46]• DD associated with forest cover [46, 47].• No differences in DD between wet and dry season, but difference in sources of foods [46, 48]• DD associated with wealth and market access but not with sex or education of the head of the household (unpublished data from the study) [46] | • Agriculture, agrobiodiversity• Land use diversity/landscape heterogeneity• Different foods eaten seasonally• Wealth, available cash, land tenure• Livelihood diversity• Family size• Gender• Personality, family tradition, taboos |
| Cross-sectional study sample | Longitudinal study sample | |||||||
| Men | Women | Men | Women | |||||
| Former | Current | Former | Current | Former | Current | Former | Current | |
| Age when smoking start | 18.9 (4.0) | 19.2 (5.3) | 23.2 (7.4) | 24.1 (9.5) | 18.7 (4.0) | 19.4 (5.9) | 23.2 (7.6) | 21.6 (7.8) |
| Age when smoking quit | 46.3 (13.0) | n.a. | 46.9 (13.6) | n.a. | 46.1 (12.5) | n.a. | 47.3 (14.1) | n.a. |
| Years of smoking | 27.4 (13.3) | 51.1 (12.5) | 23.7 (14.0) | 48.2 (10.4) | 27.3 (12.7) | 52.4 (7.0) | 24.1 (14.2) | 50.6 (8.9) |
| Years free of smoking | 25.9 (12.5) | n.a. | 25.1 (13.8) | n.a. | 26.0 (12.4) | n.a. | 24.5 (13.8) | n.a. |
| Smoked pack-years | 21.4 (18.4) | 35.6 (20.2) | 15.2 (23.5) | 29.0 (18.8) | 21.5 (12.5) | 33.5 (21.7) | 15.3 (24.3) | 29.3 (17.3) |
| Sensitivity (95% CI), % | Specificity (95% CI), % | |||||
| Reference Criterion | Rev 1 | Rev 2 | Rev 3 | Rev 1 | Rev 2 | Rev 3 |
| Diagnosis | ||||||
| Malignant (n = 16) | 100 (81,100) | 69 (44,86) | 69 (44,86) | ... | ... | ... |
| Benign (n = 32) | ... | ... | ... | 97 (84,99) | 94 (80,98) | 97 (84,99) |
| Mass | ||||||
| Present (n = 38) | 97 (87,100) | 97 (87,100) | 97 (87,100) | ... | ... | ... |
| Absent (n = 10) | ... | ... | ... | 90 (60,98) | 80 (49,94) | 100 (72,100) |
| Calcification | ||||||
| Present (n = 25) | 72 (52,86) | 40 (23,59) | 60 (41,77) | ... | ... | ... |
| Absent (n = 23) | ... | ... | ... | 83 (63,93) | 87 (68,95) | 87 (68,95) |
| Scales | Secure | Fearful | Preoccupied | Dismissing |
| Cronbach’s alpha | 0.630 | 0.766 | 0.723 | 0.588 |
| Alcohol/Cannabis Pairs | Mean | SD | Relevant t values |
| All Alcohol Per Month | M = 42.4 | SD = 55.4 | t(2573) = 24.0** |
| Only Alcohol Per Month | M = 20.47 | SD = 42.3 | |
| All Alcohol Per Month | M = 42.4 | SD = 55.4 | t(2574) = 16.3** |
| Simultaneous Drinks Per Month | M = 28.7 | SD = 49.4 | |
| Only Alcohol Per Month | M = 20.47 | SD = 42.3 | t(2558) = 8.1** |
| Simultaneous Drinks Per Month | M = 28.7 | SD = 49.4 | |
| All Cannabis Per Month | M = 2.8 | SD = 1.5 | t(2585) = 3.4** |
| Only Cannabis Per Month | M = 2.6 | SD = 1.3 | |
| All Cannabis Per Month | M = 2.8 | SD = 1.5 | t(2572) = 32.4** |
| Simultaneous Cannabis Per Month | M = 1.9 | SD = 1.3 | |
| Only Cannabis Per Month | M = 2.6 | SD = 1.3 | t(2543) = 29.4** |
| Simultaneous Cannabis Per Month | M = 1.9 | SD = 1.3 |
| Peanut (n = 29) | Control (n = 28) | P valuea | |||
| Nutrient | Mean | SD | Mean | SD | |
| Energy, kcal | 1599 | 397 | 1598 | 443 | 0.99 |
| Total carbohydrate, g | 174 | 43 | 189 | 56 | 0.28 |
| Total protein, g | 74 | 19 | 71 | 20 | 0.53 |
| Total fat, g | 72 | 26 | 65 | 24 | 0.29 |
| SFA, g | 20 | 8 | 22 | 9 | 0.26 |
| MUFA, g | 30 | 11 | 24 | 10 | 0.04 |
| PUFA, g | 17 | 6 | 13 | 5 | <0.01 |
| PUFA:SFA (P:S) ratio | 1.01 | 0.27 | 0.72 | 0.27 | <0.01 |
| Cholesterol, mg | 210 | 143 | 270 | 136 | 0.11 |
| Fiber, g | 22 | 6 | 19 | 7 | 0.19 |
| Vitamin C, mg | 83 | 46 | 71 | 33 | 0.28 |
| Vitamin D, μg | 3.4 | 2.3 | 3.6 | 1.6 | 0.81 |
| α-tocopherol equivalents, mg | 11.8 | 4.3 | 9.1 | 4.4 | 0.02 |
| Niacin, mg | 23.5 | 6.5 | 20.0 | 5.9 | 0.03 |
| Folate, μg | 402 | 119 | 385 | 122 | 0.58 |
| Vitamin B12, μg | 5.6 | 7.4 | 4.3 | 1.7 | 0.36 |
| Calcium, mg | 703 | 292 | 763 | 286 | 0.42 |
| Phosphorus, mg | 1114 | 263 | 1092 | 303 | 0.77 |
| Magnesium, mg | 302 | 53 | 245 | 68 | <0.01 |
| Copper, mg | 9.8 | 2.4 | 10.3 | 3.6 | <0.01 |
| Sodium, mg | 2703 | 817 | 2973 | 855 | 0.22 |
| Potassium, mg | 2557 | 550 | 2298 | 647 | 0.10 |
| Proportion of words on inventory | Number of words in production vocabulary (N) | ||||||
| 1–5 (82) | 6–10 (35) | 11–20 (41) | 21–50 (16) | 1-50 (174) | 51+ (15) | Total | |
| Nominals | 0.01 | 0.04 | 0.07 | 0.14 | 0.04 | 0.44 | 0.07 |
| Common nouns | 0.00 | 0.01 | 0.02 | 0.08 | 0.01 | 0.41 | 0.05 |
| People | 0.12 | 0.21 | 0.29 | 0.42 | 0.21 | 0.60 | 0.24 |
| Sound effects | 0.03 | 0.20 | 0.31 | 0.38 | 0.16 | 0.47 | 0.19 |
| Routines | 0.01 | 0.05 | 0.10 | 0.17 | 0.06 | 0.44 | 0.09 |
| Predicates | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 | 0.25 | 0.02 |
| Verbs | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.24 | 0.02 |
| Adjectives | 0.00 | 0.00 | 0.00 | 0.04 | 0.01 | 0.31 | 0.03 |
| Function words | 0.00 | 0.00 | 0.01 | 0.13 | 0.01 | 0.38 | 0.04 |
| Variables | Univariate | Multivariate | ||||
| HR (95 % CI) | p-value | HR (95 % CI) | p-value | |||
| Age (≥70) | 0.97 | (0.85–1.11) | 0.68 | 0.98 | (0.79–1.23) | 0.87 |
| Gender (female) | 1.04 | (0.35–3.07) | 0.95 | 1.06 | (0.33–3.44) | 0.92 |
| Urine cytology before the initial TUR (suspicious positive and positive) | 1.52 | (0.44–5.22) | 0.50 | 1.77 | (0.48–6.54) | 0.39 |
| Tumor size (≥3 cm) | 1.95 | (0.84–4.53) | 0.12 | 2.73 | (1.07–7.00) | 0.03* |
| Tumor number (multiple) | 0.62 | (0.27–1.45) | 0.27 | 0.94 | (0.37–2.38) | 0.89 |
| Concomitant CIS (existence) | 1.23 | (0.29–5.25) | 0.78 | 3.21 | (0.62–16.67) | 0.17 |
| BCG induction instillation (without) | 0.28 | (0.12–0.67) | <0.01** | 0.20 | (0.07–0.57) | <0.01** |
| Score | Histological features of seminiferous tubules | Remark |
| 0 | Orderly arrangement of germinal cells with plenty of sperm and spermatids | Normal |
| I | Preservation of germ cell layers with decrease of sperm and spermatids | Mild injury |
| II | Disarray and decrease of germ cell layers with loss of sperm and spermatids | Moderate injury |
| III | Absence of germ cell layers | Severe injury |
| Checklist | |
| 1 | Are you often thirsty? |
| 2 | Do you produce urine frequently? |
| 3 | Are you worried about urinary smell? |
| 4 | Do you feel numbness of your extremities? |
| 5 | Do you have edema in your legs? |
| 6 | Do you have cramps in your legs? |
| 7 | Are you insensitive to the pain of a small wound or burn? |
| 8 | Do you have a feeling of listlessness? |
| 9 | Do you feel lightheaded? |
| 10 | Is your vision blurry? Is your eyesight getting worse? |
| Total protein (mg) | % of solubilization | |||||
| Process Step | Exp #1 | Exp #2 | Exp #3 | Exp #1 | Exp #2 | Exp #3 |
| Supernatant 4 M urea wash | 1015.2 | 92.3 | 246 | NE | NE | NE |
| Pellet 4 M urea wash | 1045.2 | 378 | 740 | NE | NE | NE |
| Supernatant 8 M urea solubilization | 905.8 | 264 | 589 | 86 | 69.8 | 79.5 |
| Pellet 8 M urea solubilization | 24 | 16.5 | 23 | NE | NE | NE |
| First author (ref) | Number of subjects with depression | Number of subjects without depression | Total numbers of subjects | Crude RR (95% CI) | Multivariable Adjusted RR (95% CI) reported in paper | Adjustment factors for multivariable RR | ||
| Cancer | No cancer | Cancer | No Cancer | |||||
| Kaplan (8) | 117 | N.a. | 612 | N.a. | 6,848 | - | 0.97 males 1.27 females | Age, sex |
| Zonderman (10) | 110 | 892 | 527 | 4,874 | 6,403 | 1.13 (0.93–1.37) | 1.1 (0.9–1.4) | Age, sex, marital status, smoking, family history of cancer, hypertension, cholesterol level |
| Linkins (11) | 25 | 343 | 144 | 1,752 | 2,264 | 0.89 (0.59–1.35) | 1.09 (0.69–1.71) | Age |
| Vogt (20) | N.a. | N.a. | N.a. | N.a. | 1,529 | 1.08 (0.79–1.49) | 1.08 (0.77–1.52) | Age, sex, social class, Smoking, duration of health plan membership |
| Knekt (17) | 29 | 295 | 486 | 5,298 | 7,018 | 1.07 (0.75–1.52) | 0.99 (0.68–1.44) | Age, sex |
| Penninx (19) | 16 | 130 | 386 | 4293 | 4825 | 1.33 (0.83–2.13) | 1.88 (1.13–3.14) | Age, sex, race, disability, hospital admissions, alcohol, smoking |
| Gallo (15) | 8 | 82 | 141 | 1,338 | 1,569 | 0.93 (0.47–1.84) | 1.3 (0.6–2.8) | Age, sex, smoking, alcohol |
| van den Heuvel (22) | 9 | 207 | 67 | 2,059 | 2,342 | 1.32 (0.67–2.61) | n.a. | |
| Schuurman (23) | 95 | 1,246 | 3,369 | 63,656 | 68,366 | 1.41 (1.16–1.72) | 1.08 (0.88–1.33) | Age, sex, socioeconomic status |
| Induction | Repression | |||
| Range of SLR (significant to max.) | Number of genes [% of total] | Range of SLR (min. to significant) | Number of genes [% of total] | |
| Spermatocytes HS_38°C versus control | 0.82 to 2.21 | 517 [3.53] | −2.84 to −0.82 | 909 [6.20] |
| Spermatocytes HS_43°C versus control | 0.49 to 2.43 | 18 [0.12] | −1.35 to −0.36 | 362 [2.47] |
| Hepatocytes HS_43°C versus control | 0.75 to 6.17 | 155 [1.07] | −3.62 to −0.75 | 133 [0.92] |
| Characteristic | Low Arterial Stiffness | High Arterial Stiffness | P | |
| Gender | Male | 51 (75.0) | 28 (75.7) | 0.939 |
| Female | 17 (25.0) | 9 (24.3) | ||
| Diabetes mellitus | No | 43 (63.2) | 11 (29.7) | 0.001* |
| Yes | 25 (36.8) | 26 (70.3) | ||
| Hypertension | No | 40 (58.8) | 12 (32.4) | 0.010* |
| Yes | 28 (41.2) | 25 (67.6) | ||
| Angiotensin-converting enzyme inhibitor | No | 53 (77.9) | 29 (78.4) | 0.959 |
| Yes | 15 (22.1) | 8 (21.6) | ||
| Angiotensin-receptor blocker | No | 50 (73.5) | 27 (73.0) | 0.951 |
| Yes | 18 (26.5) | 10 (27.0) | ||
| β-blocker | No | 36 (52.9) | 20 (54.1) | 0.913 |
| Yes | 32 (47.1) | 17 (45.9) | ||
| Calcium-channel blocker | No | 48 (70.6) | 22 (59.5) | 0.248 |
| Yes | 20 (29.4) | 15 (40.5) | ||
| Statin | No | 22 (32.4) | 14 (37.8) | 0.572 |
| Yes | 46 (67.6) | 23 (62.2) | ||
| Fibrate | No | 50 (73.5) | 30 (81.1) | 0.385 |
| Yes | 14 (26.5) | 7 (18.9) |
| Level | Interviewees (data collection method) | Number of interviews /group discussions |
| National | Ministry of Health (interview) | 3 |
| UNICEF (interview) | 1 | |
| WHO (interview) | 1 | |
| Province | Provincial Directorate of Health, Nampula, Mozambique (interview) | 2 |
| District | District Community Health Managers (9 participants) (focus group) | 1 |
| Health Facilities | Health workers (interview) | 8 |
| Observations (2 urban health facilities and 2 rural health facilities, each of which were observed for one week) | 4 | |
| Community | Mothers (interview) | 8 |
| Fathers (interview) | 8 | |
| Community leaders (interview) | 5 | |
| Community Health Workers (interview) | 2 | |
| Women (focus groups of 6–12 participants) | 3 | |
| Men (focus groups of 10–12 participants) | 3 |
| Significant Biomarkers | Physiological Processes | |
| Asthma | Platelet Count | Thrombogenesis |
| Serum Sodium | Serum sodium | |
| ALT | Tissue injury | |
| Neutrophil Percent | Acute inflammation | |
| Type 1 Diabetes | Serum Sodium | Serum sodium |
| Blood Urea Nitrogen | Kidney function | |
| Platelet Count | Thrombogenesis | |
| TSH3 | Thyroid function | |
| Type 2 Diabetes | Serum Sodium | Serum sodium |
| ALT | Tissue injury | |
| Platelet Count | Thrombogenesis | |
| Duchenne Muscular Dystrophy | Lactate Dehydrogenase | Tissue injury |
| Triglycerides | Lipogenesis | |
| Platelet Count | Thrombogenesis | |
| AST | Tissue injury | |
| Cystic Fibrosis | Total IgE | IgE antibody response |
| Alkaline Phosphatase | Dephosphorylation | |
| Platelet Count | Thrombogenesis |
| Mean (Range) | |
| Age (years) | 75 (64-86) |
| Weight (lbs) | 153 (116-225) |
| FEV1 (L) | 1.12 (0.53-2.48) |
| % predicted FEV1 | 59 (21-111) |
| Characteristic | Levofloxacin N = 370 |
| Age, years | |
| Mean (SD) | 48.0 (20.26) |
| Range, n (%) | 18–87 |
| ≥ 65–< 75 | 47 (12.7) |
| ≥ 75 | 43 (11.6) |
| Sex, n (%) | |
| Male | 82 (22.2) |
| Female | 288 (77.8) |
| Race, n (%) | |
| White | 317 (85.7) |
| Black or African American | 6 (1.6) |
| Asian | 30 (8.1) |
| Other | 17 (4.6) |
| Region, n (%) | |
| Eastern Europe | 277 (74.9) |
| Western Europe | 0 |
| North America | 9 (2.4) |
| South America | 39 (10.5) |
| Rest of world | 45 (12.2) |
| Diagnosis, n (%) | |
| Pyelonephritis | 306 (82.7) |
| cLUTI | 64 (17.3) |
| Creatinine clearance, mL/min, n (%) | |
| Normal (≥80) | 250 (67.6) |
| Mild impairment (≥50–< 80) | 92 (24.9) |
| Moderate impairment (≥30–< 50) | 27 (7.3) |
| Severe impairment (<30) | 1 (0.3) |
| Markers of cardio-metabolic risk | Time spent in cars | p for trend | ||
| > 15 to ≤ 30 min/day (n = 749) | > 30 to ≤ 60 min/day (n = 851) | > 60 min/day (n = 673) | ||
| BMI (kg/m2) | 0.36 (− 0.22, 0.94) | 0.56 (− 0.01, 1.12) | 0.77 (0.16, 1.38)⁎ | 0.011 |
| Waist circumference (cm) | 0.75 (− 0.67, 2.16) | 1.30 (− 0.08, 2.69) | 1.50 (0.02, 2.98)⁎ | 0.034 |
| Systolic BP (mmHg)a | 0.69 (− 1.00, 2.37) | 0.34 (− 1.32, 2.00) | 1.60 (− 0.18, 3.37) | 0.13 |
| Diastolic BP (mmHg)a | 0.56 (− 0.56, 1.68) | 0.71 (− 0.39, 1.81) | 0.69 (− 0.50, 1.87) | 0.26 |
| Triglycerides (log, mmol/L)b | 0.016 (− 0.015, 0.047) | 0.017 (− 0.013, 0.048) | 0.002 (− 0.030, 0.035) | 0.94 |
| HDL-cholesterol (mmol/L)b | − 0.001 (− 0.042, 0.040) | − 0.019 (− 0.059, 0.021) | − 0.014 (− 0.057, 0.029) | 0.36 |
| Fasting plasma glucose (log, mmol/L) | 0.005 (− 0.007, 0.017) | 0.008 (− 0.004, 0.019) | 0.013 (0.000, 0.026)⁎ | 0.044 |
| 2-h plasma glucose (log, mmol/L) | − 0.003 (− 0.036, 0.030) | − 0.022 (− 0.054, 0.011) | 0.013 (− 0.021, 0.048) | 0.72 |
| Clustered cardio-metabolic riska, b | 0.040 (− 0.022, 0.102) | 0.062 (0.001, 0.123)⁎ | 0.076 (0.011, 0.141)⁎ | 0.017 |
| Metabolic syndromec | 1.07 (0.82, 1.41) | 1.13 (0.86, 1.47) | 0.93 (0.70, 1.24) | 0.70 |
| Variable | At admission | 1 week after admission | t(df) | p | |
| Improved | |||||
| Pain | 163 | 5.49 ± 2.10 | 2.37 ± 1.45 | 21.98(162) | <.001* |
| Anxiety | 153 | 2.33 ± 0.98 | 2.04 ± 0.92 | 4.36(152) | <.001* |
| Depression | 153 | 2.27 ± 1.01 | 1.90 ± 0.97 | 5.97(152) | <.001* |
| Anger | 151 | 1.62 ± 0.87 | 1.42 ± 0.76 | 3.52(150) | .001* |
| Family support | 156 | 4.61 ± 1.05 | 4.72 ± 1.01 | −2.40(155) | .018* |
| Social support | 156 | 4.46 ± 1.22 | 4.62 ± 1.22 | −3.64(155) | <.001* |
| Fear of death | 139 | 2.76 ± 0.75 | 2.39 ± 0.79 | 7.44(138) | <.001* |
| Not improved | |||||
| Pain | 74 | 2.20 ± 2.48 | 2.58 ± 2.65 | −4.13(73) | <.001* |
| Anxiety | 72 | 2.29 ± 0.86 | 2.08 ± 0.75 | 2.42(71) | .018* |
| Depression | 73 | 2.32 ± 1.01 | 2.25 ± 1.04 | 0.82(72) | .415 |
| Anger | 72 | 1.76 ± 0.99 | 1.63 ± 0.88 | 2.44(71) | .017* |
| Family support | 73 | 4.48 ± 1.04 | 4.55 ± 1.00 | −1.40(72) | .167 |
| Social support | 73 | 4.29 ± 1.22 | 4.37 ± 1.11 | −1.10(72) | .276 |
| Fear of death | 68 | 2.79 ± 0.78 | 2.60 ± 0.79 | 2.14(67) | .036* |
| HIV status by verbal autopsy classification | Total (%) | True HIV serostatus | ||
| HIV-positive | HIV-negative | |||
| 13-44 years | Positive | 44 (50.6%) | 32 | 12 |
| Negative | 32 (36.8%) | 2 | 30 | |
| Don't know | 11 (12.6%) | 2 | 9 | |
| 87 (100%) | 36 (41.4%) | 51 (58.6%) | ||
| 45-64 years | Positive | 18 (30.5%) | 14 | 4 |
| Negative | 35 (59.3%) | 4 | 31 | |
| Don't know | 6 (10.2%) | 1 | 5 | |
| 59 (100%) | 19 (32.2%) | 40 (67.8%) | ||
| 65+ years | Positive | 6 (5.1%) | 2 | 4 |
| Negative | 103 (87.3%) | 1 | 102 | |
| Don't know | 9 (7.6%) | 1 | 8 | |
| 118 (100%) | 4 (3.4%) | 114 (96.6%) | ||
| All ages | Positive | 68 (25.8%) | 48 | 20 |
| Negative | 170 (64.4%) | 7 | 163 | |
| Don't know | 26 (9.8%) | 4 | 22 | |
| Total deaths | 264 (100%) | 59 (22.3%) | 205 (77.7%) |
| Characteristic | Group 1 (n = 26) | Group 2 (n = 7) |
| Urine culture | ||
| Escherichia coli (%) | 15 (%57) | 5 (%71) |
| Quinolone resistance (%) | 10 (%66.6) | 4 (%80) |
| ESBL (%) | 6 (%40) | 3 (%60) |
| Blood culture | ||
| Escherichia coli (%) | 5 (%19) | 0 |
| Quinolone resistance (%) | 5 (%100) | 0 |
| ESBL (%) | 4 (%80) | 0 |
| NB | k-NN | SVM | RF | |
| Balanced accuracy (%) | 70.2 | 74.1 | 81.6 | 87.8 |
| Sensitivity (%) | 62.0 | 74.0 | 78.7 | 89.4 |
| Specificity (%) | 78.4 | 74.2 | 84.2 | 85.9 |
| Variable entered | Models | ||
| 1 | 2 | 3 | |
| Intention | .51*** | .37*** | .49*** |
| Past behaviour | .44*** | .43*** | .44*** |
| PBC | .10 | .08 | .09 |
| Age | .12 | ||
| Intention × Age | .11 | ||
| Annual income | -.11 | -.06 | |
| PBC × annual income | .20** | .24*** | |
| R2 | .44 | .47 | .46 |
| Model F | 77.57*** | 37.23*** | 50.78*** |
| ΔR2 | - | .03 | .02 |
| ΔF | - | 4.69*** | 7.05*** |
| Approach | Number of Links | |||||||||
| 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | All | |
| ELM | 0.3406 | 0.2324 | 0.0615 | 0.2463 | 0.4031 | 0.2074 | 0.4060 | 0.0694 | 0.2941 | 0.5155 |
| WKNN | 0.8250 | 0.2361 | 0.5011 | 0.5230 | 0.4441 | 0.4998 | 0.2007 | 0.2752 | 0.5125 | 0.5731 |
| SVM | 0.2107 | 0.6580 | 0.3419 | 0.0975 | 0.0285 | 0.0228 | 0.0937 | 0.1999 | 0.1014 | 0.2828 |
| BPNN | 0.6642 | 0.4730 | 0.4369 | 0.8897 | 0.6539 | 0.3722 | 0.2866 | 0.7086 | 0.7951 | 0.4424 |
| Variable | n | % |
| Gender | ||
| Male | 30 | 53.6 |
| Female | 26 | 46.4 |
| Age (years) | ||
| <40 | 30 | 53.6 |
| ≥40 | 26 | 46.4 |
| Have you breastfed beforea | ||
| Yes | 19 | 73.1b |
| No | 7 | 26.9b |
| Number of infants breastfeda | ||
| 0 | 7 | 26.9b |
| 1 | 4 | 15.4b |
| 2 | 3 | 11.5b |
| ≥3 | 12 | 46.2b |
| Academic qualifications | ||
| B.S. | 21 | 37.5 |
| M.S. | 5 | 8.9 |
| M.D. | 28 | 50.0 |
| Ph.D. | 2 | 3.6 |
| Specialty | ||
| Gynecology/obstetrics | 10 | 17.9 |
| Pediatrics | 5 | 8.9 |
| Family medicine | 16 | 28.6 |
| Lactation consultant nurse | 13 | 23.2 |
| Pharmacist | 12 | 21.4 |
| Number of years in practice | ||
| 5–9 | 23 | 41.1 |
| ≥10 | 33 | 58.9 |
| How often do you recommend herbal galactagogues for breastfeeding women? | ||
| Quite often | 39 | 69.6 |
| Sometimes | 17 | 30.4 |
| How often do you discuss herbal galactagogues that breastfeeding women could be using during your consultations with them? | ||
| Quite often | 32 | 57.1 |
| Sometimes | 24 | 42.9 |
| Breakpoint type | Number | Mean distance from PQS (kb) | Mean distance from PQS in null data (kb) | Median distance from PQS (kb) | Median distance from PQS in null data (kb) | PQS association (median outside C.I.) |
| All | 173 | 132.7 | 301 (Equal) | 16.4 | 180.4 (Equal) | Y |
| 193.8 (Unequal) | C.I. 11.1–24.3 | 130.5 (Unequal) | Y | |||
| All translocations | 99 | 163.6 | 300.7 (Equal) | 13.5 | 180.1 (Equal) | Y |
| 193.4 (Unequal) | C.I. 5.9–53.9 | 130.4 (Unequal) | Y | |||
| Subtelomeric translocations only | 65 | 109.5 | 300.1 (Equal) | 4.8 | 180.6 (Equal) | Y |
| 208.8 (Unequal) | C.I. 3.5–8.9 | 129.7 (Unequal) | Y | |||
| All var coding translocations | 70 | 156.6 | 301.1 (Equal) | 14.7 | 180.6 (Equal) | Y |
| 181.7 (Unequal) | C.I. 4.1–18.5 | 125.7 (Unequal) | Y | |||
| Indels | 74 | 91.4 | 300.9 (Equal) | 20 | 179.9 (Equal) | Y |
| 193.4 (Unequal) | C.I. 11.3–28.4 | 130.3 (Unequal) | Y | |||
| Var-coding events in progeny of 3D7/HB3 cross | 24 | 56.2 | 300.1 (Equal) | 2.9 | 180.7 (Equal) | Y |
| 141.1 (Unequal) | C.I. 2.5–11.3 | 98.8 (Unequal) | Y | |||
| Analysis restricted to subtelomeres | 119 | 91.3 | 133.5 (Equal) | 9.1 | 22.8 (Equal) | Y |
| 122.1 (Unequal) | C.I. 6.3–15.4 | 18.8 (Unequal) | Y |
| Sample type | Dataset | Platform | Number (Sensitivity) of HCC samples | Number (Sensitivity) ofHepatitis/cirrhotic liver samples |
| FFPE | GSE10142 | GPL5474 | - | 225(0.9289) |
| GSE10186 | GPL5474 | 118(0.9068) | - | |
| GSE19977 | GPL8432 | 164(0.9390) | - | |
| GSE20017 | GPL8432 | 135(0.9259) | - | |
| FF | GSE63898 | GPL13667 | 228(0.9342) | 168(0.9583) |
| GSE25097 | GPL10687 | 268(0.9478) | 40(1.0000) | |
| GSE56140 | GPL18461 | 35(0.8000) | 34(0.9706) | |
| GSE36411 | GPL10558 | 42(0.9524) | 21(0.9524) | |
| GSE6764 | GPL570 | 35(0.9429) | 13(1.0000) | |
| GSE9843 | GPL570 | 91(0.9780) | - | |
| GSE17967 | GPL571 | - | 47(1.0000) | |
| GSE57725 | GPL14951 | - | 23(0.9565) |
| Cut-points (%) or ($) | |
| Percent of population 25 and over that attended any college (Education) | |
| 1 – Low SES | 0 – 39.4 |
| 2 | 39.5 – 51.5 |
| 3 | 51.5 – 65.9 |
| 4 – High SES | 65.9 – 100.0 |
| Percent of housing units with one or more persons per room (Crowding) | |
| 1 – Low SES | 7.6 – 65.6 |
| 2 | 3.7 – 7.6 |
| 3 | 1.8 – 3.7 |
| 4 – High SES | 0 – 1.8 |
| Average per capita income in 1999 (Income) | |
| 1 – Low SES | 3729 – 16 016 |
| 2 | 16 017 – 20 040 |
| 3 | 20 041 – 26 224 |
| 4 – High SES | 26 225 – 114 359 |
| Percent of population in the civilian workforce that was unemployed in 1999 (Unemployment) | |
| 1 – Low SES | 7.5 – 83.9 |
| 2 | 5.0 – 7.5 |
| 3 | 3.5 – 5.0 |
| 4 – High SES | 0 – 3.4 |
| Nutrient | Adolescent boys component | Adolescent girls component | ||||
| 1 | 2 | 3 | 1 | 2 | 3 | |
| Proteins (g) | 0.86 | 0.04 | 0.35 | 0.82 | 0.45 | 0.05 |
| Total fat (g) | 0.48 | 0.18 | 0.34 | 0.17 | 0.91 | −0.00 |
| Energy (Kcal) | 0.93 | 0.05 | 0.13 | 0.92 | 0.21 | −0.01 |
| Calcium (mg) | 0.02 | 0.16 | 0.87 | 0.00 | 0.92 | 0.16 |
| Iron (mg) | 0.39 | 0.00 | 0.60 | 0.38 | 0.45 | 0.05 |
| Vitamin A (mg) | 0.10 | 0.90 | 0.16 | 0.00 | 0.07 | 0.93 |
| Thiamine (mg) | 0.93 | 0.07 | 0.13 | 0.95 | 0.05 | 0.06 |
| Riboflavin (mg) | 0.77 | 0.41 | 0.21 | 0.71 | 0.14 | 0.50 |
| Niacin (mg) | 0.92 | 0.06 | 0.04 | 0.92 | −0.00 | 0.03 |
| Vitamin C (mg) | 0.15 | 0.87 | 0.04 | 0.07 | 0.03 | 0.87 |
| Free folic acid (μg) | 0.71 | 0.35 | 0.07 | 0.61 | 0.14 | 0.51 |
| Eigen value | 5.7 | 1.6 | 1.0 | 5.2 | 1.8 | 1.8 |
| Variance explained | 51.8 | 14.5 | 9.3 | 47.2 | 17.0 | 15.4 |
| Source | Sum of squares | d.f. | Mean square | F-value | p-value |
| Level of training | 113.270 | 2 | 56.635 | 13.382* | .000 |
| Score in dimensions of mini-CEX | 33.810 | 5.566 | 6.075 | 29.153* | .000 |
| Level of training x Dimensions of mini-CEX | 8.161 | 11.132 | 0.733 | 3.518* | .000 |
| Error | |||||
| Between subjects | 3457.727 | 817 | 4.232 | ||
| Residual Error | 947.520 | 4547.337 | 0.208 |
| Standard margin | Reduced margin | ||||||
| Parameter | Mean | St. Dev. | Mean | St. Dev. | Difference (Gy) | (%) | p-value |
| Max dose (Gy) | 61.4 | 1.4 | 56.1 | 8.6 | 5.3 | 8.7% | 0.014 |
| Mean dose (Gy) | 41.9 | 9.1 | 29.9 | 11.6 | 12.0 | 28.7% | <0.001 |
| Median dose (Gy) | 45.2 | 17.2 | 27.9 | 15.6 | 17.2 | 38.2% | <0.001 |
| D2% (Gy) | 59.9 | 5.1 | 53.4 | 12.1 | 6.4 | 10.7% | 0.008 |
| D20% (Gy) | 57.6 | 8.5 | 46.1 | 16.8 | 11.5 | 20.0% | 0.001 |
| D40% (Gy) | 49.9 | 14.9 | 36.5 | 19.6 | 13.4 | 26.9% | <0.001 |
| D60% (Gy) | 32.7 | 13.5 | 18.7 | 10.9 | 14.0 | 42.9% | <0.001 |
| D80% (Gy) | 27.3 | 12.1 | 15.3 | 10.0 | 12.0 | 44.0% | <0.001 |
| D98% (Gy) | 20.7 | 9.3 | 11.8 | 7.7 | 8.9 | 42.9% | <0.001 |
| PACCE oxaliplatin cohort [43] | CAIRO2 [47] | |||
| (N = 823) | (N = 755) | |||
| Ox + Bev + Pmab | Ox + Bev | Cap, Ox + Bev + Cmab | Cap, Ox + Bev | |
| Median progression-free survival (95% CI), mo | 10.0 (8.9–11.0) | 11.4 (10.5–11.9) | 9.4 (8.4–10.5) | 10.7 (9.7–12.3) |
| Progression-free survival events, n (%) | 246 (60) | 221 (54) | 316 (84) | 293 (78) |
| Overall response rate, %* | 46 | 48 | 50.0 | 52.7 |
| Median overall survival (95% CI), mo | 19.4 (18.4–20.8) | 24.5 (20.4–24.5) | 20.3 (17.8–24.7) | 19.4 (17.5–21.4) |
| Deaths, n (%) | 143 (35) | 108 (26) | 214 (57) | 193 (51) |
| Name | Sequence | Description |
| NIP5;1_qRT-PCR-1 | caccgattttccctctcctgat | Probes for realtime PCR |
| NIP5;1_qRT-PCR-2 | ctctttcttactctctagcctc | |
| NIP5;1_qRT-PCR-3 | gaatgttcccacgaactcgg | |
| NIP5;1_qRT-PCR-4 | acattcatcttgatattcacc | |
| NIP5;1_qRT-PCR-5 | gcatgcagcgttaccgatta | |
| PP2A_qRT-PCR-1 | ccatgtttgaggatcttacgc | |
| PP2A_qRT-PCR-2 | tgtctacatctcagcttcagtgtc | |
| PP2A_qRT-PCR-3 | gctccaacaatttcccaaga | |
| PP2A_qRT-PCR-4 | caagattcggttagattattg | |
| PP2A_qRT-PCR-5 | gcgagaaattgacaatcacag | |
| NIP5;1_mRNA_F | atttaggtgacactatagtaagctcaaagactaaccaaac | For amplification of the standard DNA fragments |
| NIP5;1_mRNA_R | ttacacatgccatagattttat | |
| PP2A_mRNA_F | atttaggtgacactatagcggtctcatttctcgttcttc | |
| PP2A_mRNA_R | cacttgataagtaaattatttg |
| sCr (mg/dl) | AKI group | non-AKI group | P value |
| (n = 11) | (n = 39) | ||
| Preoperative | 0.72 ± 0.14 | 0.68 ± 0.15 | 0.531 |
| Postoperative | |||
| 1 day | 0.83 ± 0.11 | 0.69 ± 0.16 | <0.05 |
| Postoperative | |||
| 2 days | 1.04 ± 0.15 | 0.78 ± 0.19 | <0.01 |
| Postoperative | |||
| 3 days | 1.05 ± 0.12 | 0.77 ± 0.18 | <0.01 |
| Germplasm or genotypes | Sites (No) | Reference | |
| Type | Number | ||
| Natural accession | 124 | 1 | Mengesha et al. (1965) |
| Hybrids | 559 | 1 | Berhe et al. (1989a,b,c) |
| Natural accession | 21 | Bekele (1996) | |
| Natural accession | 225 | Ketema (1993) | |
| RIL (key Murri × Fesho) | 165 | 3 | Tefera et al. (2003b) |
| RIL (key Murri ×E. pilosa) | 200 | 3 | Tefera et al. (2003a) |
| F2 (12 crosses) | 12 | 1 | Tefera et al. (2008) |
| Natural accession | 320 | 2 | Assefa et al. (1999, 2000) |
| Natural accession | 120 | 4 | Assefa et al. (2001b) |
| Natural accession | 1080 | 1 | Assefa et al. (2001a) |
| Natural accession | 3000 | 1 | Assefa et al. (2002a,b, 2003b) |
| Natural accession | 3600 | 1 | Kefyalew et al. (2000) |
| Natural accession | 144 | 2 | Adnew et al. (2005) |
| RIL (196 × 974) | 196 | 2 | Chanyalew et al. (2006) |
| RIL (196 × 2356) | 190 | 2 | Chanyalew et al. (2009) |
| RIL (Kay Murri ×E. pilosa) | 94 | 3 | Yu et al. (2007) |
| Natural accession | 37 | 1 | Ayalew et al. (2011) |
| Natural accession | 15 | 1 | Plaza-Wüthrich et al. (2013) |
| Natural accession | 81 | 1 | Lule and Mengistu (2014) |
| Variables | Categories | Asthma confirmed by BHR | |||||||
| Crude model | Adjusted model | ||||||||
| PR | 95 % CI | p value | PR | 95 % CI | p value | ||||
| Group | Exposed vs Non-exposed | 1.08 | 0.69 | 1.68 | 0.73 | 1.12 | 0.71 | 1.76 | 0.63 |
| Endotoxin levels | Low vs High | 1.21 | 0.78 | 1.88 | 0.40 | 0.79 | 0.51 | 1.22 | 0.29 |
| Institutions | UNICAMP vs USP | 1.40 | 0.89 | 2.18 | 0.14 | 1.25 | 0.81 | 1.93 | 0.31 |
| Atopy | Yes vs No | 7.07 | 3.68 | 13.58 | <0.01 | 6.60 | 3,42 | 12.71 | <0.01 |
| Smoking | Yes vs No | 0.89 | 0.48 | 1.64 | 0.70 | 1.00 | 0.54 | 1.86 | 0.99 |
| Sex | Male vs Female | 1.39 | 0.87 | 2.21 | 0.17 | 1.48 | 0.93 | 2.37 | 0.10 |
| Past exposure to laboratory animals | Yes vs No | 1.36 | 0.87 | 2.14 | 0.17 | 1.24 | 0.79 | 1.94 | 0.35 |
| Pet owning history | Yes vs No | 1.17 | 0.73 | 1.87 | 0.52 | 1.05 | 0.66 | 1.66 | 0.83 |
| Age | Continuous | 0.96 | 0.94 | 0.99 | <0.01 | 0.98 | 0.95 | 1.01 | 0.16 |
| Worker functions | Technicians/secretaries vs researchers | 1.44 | 0.52 | 3.95 | 0.48 | 1.35 | 0.49 | 3.72 | 0.56 |
| Students vs researchers | 1.74 | 0.65 | 4.71 | 0.27 | 1.09 | 0.41 | 3.72 | 0.56 |
| ADHD group(n = 16) | Control group(n = 16) | Group differencesa | |
| M (SD) | M (SD) | ||
| Age (years) | 10.7 (1.6) | 10.2 (1.3) | ns |
| IQ (WISC-III) | 97.1 (14.2) | 102.7 (9.5) | ns |
| CBCL (parent rating) | |||
| Internalizing | 60.4 (7.7) | 52.3 (10.7) | p = .01 |
| Externalizing | 64.1 (4.8) | 52.9 (6.6) | p < .001 |
| Attention | 71.1 (5.6) | 54.4 (3.7) | p < .001 |
| FBB-HKS (parent rating) | 82.6 (10.4) | 36.7 (18.9) | p < .001 |
| FA baseline | 29.0 (10.7) | 30.0 (13.9) | ns |
| FA social reward | 13.1 (7.3) | 22.1 (10.9) | p = .011 |
| FA monetary reward | 10.6 (8.5) | 14.8 (10.8) | ns |
| RT hits baseline | 446.3 (84.3) | 435.8 (46.1) | ns |
| RT hits social reward | 438.8 (88.7) | 414.6 (43.2) | ns |
| RT hits monetary reward | 454.4 (80.4) | 416.8 (58.4) | ns |
| RT false alarms baseline | 355.2 (75.5) | 407.5 (134.3) | ns |
| RT false alarms social reward | 396.4 (121.1) | 401.3 (126.0) | ns |
| RT false alarms monetary reward | 397.9 (65.9) | 388.7 (164.5) | ns |
| Fracture sites | No. of fractures | Fracture IR (/1000 PY) | Age/sex adjusted HR (95 % CI) | Adjusted HR (95 % CI) |
| Major osteoporotic fracture | ||||
| Never-GLP1-ra usea | 4373 | 6.1 | Reference | Reference |
| Current GLP1-ra use | 44 | 3.7 | 0.97 (0.71–1.31) | 0.97 (0.72–1.32)b |
| Hip fracture | ||||
| Never-GLP1-ra usea | 1383 | 1.9 | Reference | Reference |
| Current GLP1-ra use | 2 | 0.2 | 0.26 (0.06–1.03) | 0.27 (0.07–1.08)c |
| Radius/ulna fracture | ||||
| Never-GLP1-ra usea | 1442 | 2.0 | Reference | Reference |
| Current GLP1-ra use | 15 | 1.3 | 1.78 (0.47–1.32) | 0.82 (0.48–1.37)d |
| Vertebral fracture | ||||
| Never-GLP1-ra usea | 513 | 0.7 | Reference | Reference |
| Current GLP1-ra use | 8 | 0.7 | 1.59 (0.78–3.24) | 1.64 (0.80–3.37)e |
| Age | Gender | |||||||
| EVA derivative | Intercept | R2 | B | β | p | B | β | p |
| Prolonged sitting (>30 min) | −30.6 | .01 | 0.00 | 0.00 | 1.0 | 4.00 | 0.12 | .12 |
| BB standing (<5 min) | −1.9 | .03 | 0.08 | 0.06 | .44 | 4.15 | 0.16 | .03 |
| BB walking (<5 min) | 2.2 | .03 | 0.13 | 0.09 | .21 | −4.23 | −0.16 | .03 |
| Walking >10 min | 18.3 | .06 | 0.05 | 0.08 | .25 | −2.47 | −0.24 | <.01 |
| Accession no. | Strain | BioSample ID | BioProject ID |
| CP018252 | 9000 | SAMN05544760 | PRJNA336330 |
| CP018250 | 10671 | SAMN05544761 | PRJNA336330 |
| CP018247 | 7784 | SAMN05544762 | PRJNA336330 |
| CP018237 | 155 | SAMN05544764 | PRJNA336330 |
| CP018243 | 350 | SAMN05544765 | PRJNA336330 |
| CP018239 | 272 | SAMN05544766 | PRJNA336330 |
| CP018245 | 472 | SAMN05544767 | PRJNA336330 |
| CP018241 | 319 | SAMN05544768 | PRJNA336330 |
| CP015832 | 180 | SAMN05007044 | PRJNA321984 |
| NC_002695 | Sakai | na | PRJNA57781 |
| NC_011353 | EC4115 | SAMN02603441 | PRJNA224116 |
| NC_013008 | TW14359 | SAMN02604255 | PRJNA224116 |
| CP008957 | EDL933 | SAMN02905113 | PRJNA253471 |
| CP010304 | SS52 | SAMN03265100 | PRJNA201344 |
| n1 | n2 | Ratio | Distance |
| 1 | 2 | 0.50 | 1 |
| 2 | 3 | 0.67 | 1 |
| 3 | 4 | 0.75 | 1 |
| 4 | 5 | 0.80 | 1 |
| 5 | 6 | 0.83 | 1 |
| 6 | 7 | 0.86 | 1 |
| Composition | Strain-to-failure (mm/mm) | Stress-at-failure (MPa) | Toughness (MJ/m3) | |
| T = temperature at loss modulus peak | 5% BPA | 1.43 ± 0.0985 | 11.9 ± 2.14 | 8.99 ± 1.72 |
| 15% BPA | 0.773 ± 0.0906 | 14.2 ± 1.51 | 6.21 ± 0.992 | |
| 25% BPA | 0.609 ± 0.119 | 13.2 ± 1.07 | 3.96 ± 0.747 | |
| 35% BPA | 0.475 ± 0.0957 | 23.0 ± 4.15 | 6.38 ± 1.79 | |
| T = temperature at tan delta peak | 5% BPA | 1.41 ± 0.254 | 2.75 ± 0.338 | 1.49 ± 0.296 |
| 15% BPA | 0.590 ± 0.182 | 2.87 ± 0.254 | 0.697 ± 0.169 | |
| 25% BPA | 0.357 ± 0.0354 | 4.09 ± 0.251 | 0.647±0.0723 | |
| 35% BPA | 0.376 ± 0.0879 | 7.73 ± 1.56 | 1.24 ± 0.316 |
| PR | GR | CS | OD | IT | FL | |
| PR | — | MI | WI | EI | SI | VSI |
| GR | — | SMI | ||||
| CS | WI | — | ||||
| OD | SI | — | WI | SI | ||
| IT | SMI | MI | — | |||
| FL | WI | EI | MI | — |
| Locus | Initial Signal | Regional Validation Signal | |||||||||||
| Chr | Position (Mb) | Gene | Prior HDL or Lipid Association [Ref] | Lead SNP | MA | MAF | Effect (mg/dl) | P-value | Lead SNP | MA | MAF | Effect (mg/dl) | P-value |
| Whites | African Americans | ||||||||||||
| 1 | 185.2 | PLA2G4A | rs10157410 | C | 0.101 | 3.46 | 6.66E-05 | rs4648287 | G | 0.049 | 3.21 | 0.0040 | |
| 1 | 228.4 | GALNT2 | Yes [11] | rs2144300 | G | 0.422 | -1.85 | 2.29E-04 | rs2144297 | A | 0.345 | -1.92 | 0.0233 |
| 7 | 38.2 | STARD3NL | Yes [28] | rs10240718 | A | 0.078 | 3.23 | 3.98E-04 | rs7795499 | A | 0.329 | 1.76 | 0.0350 |
| 11 | 68.0 | LRP5 | Yes [27] | rs3736228 | A | 0.136 | 2.64 | 5.07E-04 | rs4988331 | A | 0.168 | 2.12 | 0.0281 |
| 13 | 77.4 | EDNRB | rs3818416 | A | 0.241 | 2.21 | 2.97E-04 | rs3818416 | A | 0.329 | -2.24 | 0.0028 | |
| 15 | 56.6 | LIPC | Yes [11] | rs9652472 | G | 0.041 | -4.40 | 6.02E-04 | rs10518978 | A | 0.123 | -3.01 | 0.0101 |
| 16 | 65.5 | CDH16 | rs3743725 | A | 0.030 | 5.23 | 7.51E-04 | rs13336470 | A | 0.322 | 2.63 | 0.0041 | |
| African Americans | Whites | ||||||||||||
| 4 | 57.5 | REST | rs6847086 | A | 0.461 | 2.67 | 7.14E-04 | rs4109037 | A | 0.136 | 2.33 | 0.0025 | |
| 6 | 152.5 | ESR1 | Yes [29] | rs3020384 | C | 0.487 | 2.65 | 7.63E-04 | rs12199198 | C | 0.067 | -2.07 | 0.0372 |
| 7 | 87.1 | ABCB1 | Yes [26] | rs3213619 | G | 0.072 | 5.22 | 2.74E-04 | rs10267099 | G | 0.220 | 1.62 | 0.0059 |
| 8 | 10.1 | MSRA | rs2975721 | T | 0.385 | 2.74 | 4.69E-04 | rs6601419 | A | 0.338 | 1.66 | 0.0029 | |
| 13 | 94.5 | ABCC4 | rs7319001 | A | 0.095 | 4.92 | 5.39E-04 | rs1189470 | C | 0.154 | 2.12 | 0.0036 | |
| 16 | 52.4 | FTO | Yes [25] | rs12595985 | A | 0.109 | 4.52 | 2.90E-04 | rs9940629 | A | 0.448 | 1.56 | 0.0041 |
| TNF-α Stimulation (U/ml) | |||
| 0 | 10 | 100 | |
| HUVECs in monocultures | 4.9 ± 1.5 | 15.7 ± 0.8* | 24.57 ± 3.01** |
| HUVECs in direct contact with podocytes | 11.43 ± 4.7 | 21.53 ± 5.7 | 38.7 ± 9.8* |
| HUVECs with no direct contact | 5.7 ± 1.13 | 14.5 ± 1.9* | 24.01 ± 1.6** |
| MD | Normal LV and RV function | Impaired LV and/or RV function | p value | |
| N = 63 | N = 31 | N = 32 | ||
| Male, n (%) | 63 (100) | 31 (100) | 32 (100) | 1.00 |
| Age, years | 31 ± 15 | 27 ± 15 | 34 ± 15 | 0.11 |
| BMD, n (%) | 51 (81) | 26 (84) | 25 (78) | 0.75 |
| BMI, kg/m2 | 24 ± 4 | 24 ± 5 | 24 ± 3 | 0.72 |
| Skeletal muscle status 0/1/2/3, n (%) | 2 (3)/43 (68)/13 (21)/5 (8) | 2 (7)/23 (74)/5 (16)/1 (3) | 20 (63)/8 (25)/4 (13)/0 (0) | 0.20 |
| ACE inhibitor, n (%) | 16 (25) | 2 (7) | 14 (44) | 0.001 |
| Beta-blocker, n (%) | 14 (22) | 4 (13) | 10 (31) | 0.13 |
| CK, U/L | 1226 (653–2424) | 1250 (652–3043) | 1221 (727–2291) | 0.86 |
| Elevated hs-Trop, n (%)a | 30 (48) | 8 (26) | 22 (67) | 0.001 |
| Elevated NT-proBNP, n (%)b | 3 (5) | 0 (0) | 3 (9) | 0.24 |
| Plasmid | Description | Source of reference |
| pGK423 | Yeast expression vector containing PGK1 promoter, 2 μ origin, HIS3 marker, no expression (control plasmid) | Ishii et al. [10] |
| pGK426 | Yeast expression vector containing PGK1 promoter, 2 μ origin, URA3 marker, no expression (control plasmid) | Ishii et al. [10] |
| pGK406 | Yeast integration vector containing PGK1 promoter, URA3 maker | Ishii et al. [10] |
| pATP425 | Yeast three gene expression vector containing ADH1, TDH3, and PGK1 promoters, 2 μ origin, LEU2 marker, no expression (control plasmid) | |
| pATP424 | Yeast three gene expression vector containing ADH1, TDH3 and PGK1 promoters, 2 μ origin, TRP1 marker, no expression (control plasmid) | |
| pATP423 | Yeast three gene expression vector containing ADH1, TDH3 and PGK1 promoters, 2 μ origin, HIS3 marker, no expression (control plasmid) | |
| pGK423-kivd | HIS3, expression of L. lactis kivd gene | Kondo et al. [14] |
| pGK423-ARO10 | HIS3, expression of S. cerevisiae ARO10 gene | Kondo et al. [14] |
| pGK423-THI3 | HIS3, expression of S. cerevisiae THI3 gene | Kondo et al. [14] |
| pGK426-ADH1 | URA3, expression of S. cerevisiae ADH1 gene | Kondo et al. [14] |
| pGK426-ADH2 | URA3, expression of S. cerevisiae ADH2 gene | Kondo et al. [14] |
| pGK426-ADH5 | URA3, expression of S. cerevisiae ADH5 gene | Kondo et al. [14] |
| pGK426-ADH6 | URA3, expression of S. cerevisiae ADH6 gene | Kondo et al. [14] |
| pGK426-ADH7 | URA3, expression of S. cerevisiae ADH7 gene | Kondo et al. [14] |
| pGK426-SFA1 | URA3, expression of S. cerevisiae SFA1 gene | Kondo et al. [14] |
| pGK426-cimA | URA3, expression of M. jannaschii cimA gene | This study |
| pGK406-cimA | URA3, genomic integration of M. jannaschii cimA gene | This study |
| pATP425-leuC(Cb)-leuD(Cb) | LEU2, co-expression of C. beijerinckii leuC and leuD genes | This study |
| pATP425-leuC(Ec)-leuD(Ec) | LEU2, co-expression of E. coli leuC and leuD genes | This study |
| pATP425-leuC(Mj)-leuD(Mj) | LEU2, co-expression of M. jannaschii leuC and leuD genes | This study |
| pATP425-cimA-leuC(Cb)-leuD(Cb) | LEU2, co-expression of M. jannaschii cimA, C. beijerinckii leuC and leuD genes | This study |
| pATP425-cimA-leuC(Ec)-leuD(Ec) | LEU2, co-expression of M. jannaschii cimA, E. coli leuC and leuD genes | This study |
| pATP425-cimA-leuC(Mj)-leuD(Mj) | LEU2, co-expression of M. jannaschii cimA, leuC and leuD genes | This study |
| pATP424-ILV1 | TRP1, expression of S. cerevisiae ILV1 gene | This study |
| pATP424-tdcB | TRP1, expression of E. coli tdcB gene | This study |
| pATP424-ilvA | TRP1, expression of E. coli ilvA gene | This study |
| pATP424-tdcB-asd | TRP1, co-expression of E. coli tdcB and asd genes | This study |
| pATP423-thrA-thrB-thrC | HIS3, co-expression of E. coli thrA, thrB and thrC genes | This study |
| Source | Type III sum of squares | df | mean square | F | P |
| population | 33.571 | 1 | 33.571 | 98.623 | < 0.001 |
| sex | 12.560 | 1 | 12.560 | 36.899 | < 0.001 |
| population*sex | 3.830 | 1 | 3.830 | 11.251 | = 0.001 |
| flower diameter | 0.104 | 1 | 0.104 | 0.304 | = 0.581 |
| error | 187.217 | 550 | 0.337 |
| Antibody(ies) | Number of patients | Percentage |
| Alloantibodies | ||
| Anti-c | 10 | 6.4 |
| Anti-C | 3 | 1.9 |
| Anti-c and anti-E | 10 | 6.4 |
| Anti-C + D | 8 | 5.1 |
| Anti-C + D + E | 1 | 0.6 |
| Anti-D | 25 | 16.0 |
| Anti-e | 1 | 0.6 |
| Anti-E | 57 | 36.3 |
| Anti-Fya | 1 | 0.6 |
| Anti-Jka | 3 | 1.9 |
| Anti-K | 7 | 4.5 |
| Anti-Kpa | 1 | 0.6 |
| Anti-Lea | 4 | 2.5 |
| Anti-Lua | 1 | 0.6 |
| Anti-M | 4 | 2.5 |
| Auto- + alloantibodies | ||
| Auto- + alloanti-c | 2 | 1.3 |
| Auto- + alloanti-E | 3 | 1.9 |
| Auto- + alloanti-K | 3 | 1.9 |
| Auto- + alloanti-S | 1 | 0.6 |
| Not determined | 12 | 7.6 |
| Total | 157 | ≈100% |
| Genotype | Strain | Accession number | Genotype | Strain | Accession number |
| GI_1 | NV-USA93 | M87661 | GII_6 | SU3-JPN | AB039776 |
| GI_2 | SOV-GBR93 | L07418 | GII_7 | GN273-USA93 | AF414409 |
| GI_3 | VA98115-USA98 | AY038598 | GII_8 | SaU25-JPN | AB039780 |
| GI_4 | B493-GER93 | X76716 | GII_9 | VA97207-USA97 | AY038599 |
| GI_5 | SzUG1-JPN | AF414406 | GII_10 | Erfurt-DEU00 | AF427118 |
| GI_6 | BS5-GER | AF093797 | GII_11 | SW918-JPN97 | AB074893 |
| GI_7 | Wnchest-GBR94 | AJ277609 | GII_12 | Gifu-JPN96 | AB045603 |
| GI_8 | Boxer-USA01 | AF538679 | GII_13 | G5175B-AUS83 | DQ379714 |
| GII_1 | Hawaii-USA94 | U07611 | GII_14 | 8533Maizuru-JPN08 | GU017903 |
| GII_2 | SMV2-USA | AY134748 | GII_15 | Me7076-USA99 | AF542090 |
| GII_3 | SU201-JPN | AB039782 | GII_16 | Tiffin-USA99 | AY502010 |
| GII_4 | Lordsdale-UK | X86557 | GII_17 | CSE1-USA02 | AY502009 |
| GII_5 | MOH-HUN99 | AF397156 |
| Characteristic | Bipolar I(n = 1809) | Bipolar II(n = 922) | Total(N = 2731) |
| Gender, n (%) | |||
| Male | 752 (41.6) | 340 (36.9) | 1092 (40.0) |
| Female | 1057 (58.4) | 582 (63.1) | 1639 (60.0) |
| Mean age (years), mean (SD) | 39.6 (11.5) | 38.8 (11.9) | 39.3 (11.6) |
| Mean body weight (kg), mean (SD) | 83.4 (21.4) | 79.7 (19.7) | 82.1 (20.9) |
| 0–30 days post-implant | 31–60 days post-implant | 61–90 days post-implant | |
| Pacemaker | 35% | 30% | 67% |
| ICD | 36% | 42% | 66% |
| CRT-D | 34% | 32% | 77% |
| Categorical variables | Symptoms class of SCIN-total-score | Univariate | Multiple† | ||||||
| GST genotype | Number (%) | No (0–5) | Moderate (6–9) | Severe (10–18) | P | OR (95% CI) | P | OR (95% CI) | |
| P1 | A/A | 99 (41.6) | 60 (60.6) | 23 (23.2) | 16 (16.2) | 0.098 | 2.03 (0.88–4.67) | 0.012 | 3.84 (1.34–10.75) |
| A/G | 102 (42.9) | 53 (52.0) | 29 (28.4) | 20 (19.6) | 0.014 | 2.83 (1.24–6.46) | 0.003 | 4.95 (1.70–14.45) | |
| G/G | 37 (15.5) | 27 (73.0) | 10 (27.0) | 0 (0) | Reference for GSTP1-AA and -AG | ||||
| T1 | + | 201 (84.5) | 118 (58.7) | 51 (25.4) | 32 (15.9) | 0.770 | 1.11 (0.55–2.22) | 0.714 | 1.17 (0.50–2.73) |
| - (ref.) | 37 (15.5) | 22 (59.5) | 11 (29.7) | 4 (10.8) | |||||
| M1 | + | 134 (56.3) | 79 (59.0) | 35 (26.1) | 20 (14.9) | 0.947 | 0.98 (0.59–1.63) | 0.166 | 1.56 (0.83–2.94) |
| - (ref.) | 104 (43.7) | 61 (58.7) | 27 (26.0) | 16 (15.4) | |||||
| Continuous variables | TCSs N (%) | Median | Minimum | Maximum | |||||
| Age at survey (OR for 10 years) | 238 (100%) | 42.3 | 22.7 | 73.4 | 0.008 | 1.40 (1.09–1.80) | 0.002 | 1.70 (1.22–2.36) | |
| OR* | Cisplatin | 238 (100%) | 397 | 81 | 1571 | <0.001 | 1.35 (1.11–1.49) | 0.014 | 1.35 (1.06–1.71) |
| Bleomycin | 226 (95.0%) | 142 | 0 | 212 | 0.040 | 1.65 (1.00–2.72) | 0.078 | 1.43 (0.93–2.13) | |
| Vinblastine | 133 (55.9%) | 9.9 | 0 | 51 | 0.535 | 1.49 (0.41–6.05) | 0.319 | 0.23 (0.01–4.14) | |
| Etoposide | 92 (38.7%) | 727 | 0 | 4934 | 0.092 | 1.00 (1.00–1.00) | 0.918 | 1.00 (0.90–1.11) |
| Unmatched cohorts | Propensity-score matched cohorts | |||||
| Complications | Human regular insulin n (%) | Rapid-acting Insulin Analogues n (%) | Adjusted HRa (95% CI) | Human regular insulin n (%) | Rapid-acting Insulin Analogues n (%) | HR (95% CI) |
| Any complication | 286 (31.3) | 235 (17.1) | 0.56 (0.45-0.69) | 165 (29.1) | 132 (23.3) | 0.73 (0.58-0.92) |
| Macrovascular | 203 (22.2) | 147 (10.7) | 0.56 (0.43-0.72) | 110 (19.4) | 87 (15.4) | 0.73 (0.55-0.95) |
| Cardiovascular disease | 107 (11.7) | 95 (6.9) | 0.62 (0.44-0.86) | 63 (11.1) | 53 (9.4) | 0.77 (0.54-1.10) |
| Peripheral vascular disease | 21 (2.3) | 14 (1.0) | 0.32 (0.14-0.75) | 14 (2.5) | 8 (1.4) | 0.53 (0.22-1.27) |
| Cerebrovascular disease | 75 (8.2) | 38 (2.8) | 0.55 (0.35-0.88) | 33 (5.8) | 26 (4.6) | 0.73 (0.44-1.20) |
| Microvascular | 43 (4.7) | 53 (3.9) | 0.73 (0.45-1.20) | 27 (4.8) | 26 (4.6) | 0.89 (0.54-1.48) |
| Metabolic | 52 (5.7) | 37 (2.7) | 0.36 (0.21-0.59) | 35 (6.2) | 21 (3.7) | 0.55 (0.32-0.94) |
| Hyperglycemia | 34 (3.7) | 21 (1.5) | 0.36 (0.21-0.59) | 21 (3.7) | 11 (1.9) | 0.48 (0.23-0.99) |
| Hypoglycemia | 19 (2.1) | 16 (1.2) | 0.51 (0.23-1.12) | 14 (2.5) | 12 (2.1) | 0.62 (0.29-1.34) |
| Males | Females | |||
| AOR | 95% CI | AOR | 95% CI | |
| HIV Prevalence | ||||
| ≤ 0.37% | 1.0 | - | 1.0 | - |
| 0.38-0.73% | 1.1 | 0.67, 1.7 | 1.5 | 0.84, 2.7 |
| 0.74%-1.3% | 1.3 | 0.81, 2.2 | 1.7 | 0.90, 3.1 |
| 1.3-1.65% | 1.2 | 0.73, 2.0 | 1.1 | 0.56, 2.1 |
| > 1.65% | 1.1 | 0.71, 1.9 | 2.3 | 1.2, 2.7 |
| MSM Proportion | ||||
| ≤ 5.7% | 1.0 | - | 1.0 | - |
| 5.8-7.0% | 1.2 | 0.72, 1.9 | 1.9 | 1.0, 3.5 |
| 7.1-8.0% | 1.3 | 0.86, 1.9 | 1.4 | 0.84, 2.5 |
| 8.1-9.8% | 1.7 | 1.1, 2.7 | 2.0 | 1.1, 3.6 |
| > 9.8% | 1.2 | 0.76, 1.8 | 1.5 | 0.82, 2.7 |
| Income per year ($) | ||||
| ≤ 26,000 | 0.94 | 0.64, 1.4 | 0.95 | 0.55, 1.6 |
| 26,001-35,000 | 0.76 | 0.49, 1.2 | 0.58 | 0.32, 1.1 |
| 35,000-41,000 | 1.3 | 0.85, 1.9 | 0.89 | 0.49, 1.6 |
| 41,000-48,000 | 0.69 | 0.45, 1.0 | 0.72 | 0.41, 1.3 |
| > 48,000 | 1.0 | - | 1.0 | - |
| ED Usage Rate* | ||||
| ≤ 24,000 | 1.0 | - | 1.0 | - |
| 24,001-32,600 | 0.63 | 0.40, 1.0 | 0.98 | 0.51, 1.9 |
| 32,601-44,200 | 0.92 | 0.62, 1.4 | 1.2 | 0.69, 2.2 |
| 44,201-56,000 | 1.0 | 0.70, 1.6 | 1.2 | 0.64, 2.2 |
| > 56,000 | 0.83 | 0.55, 1.3 | 1.4 | 0.76, 2.6 |
| Species | Number detected | (high; medium; low; no visible mould) |
| Epicoccum nigrum | 15 | (7,2,4,2) |
| Cladosporium cladosporioides | 7 | (3,3,1,0) |
| Aureobasidium pullulan | 4 | (1,1,2,0) |
| Cryptococcus flavescens | 3 | (1,2,0,0) |
| Alternaria alternata | 2 | (1,1,0,0) |
| Alternaria tenuissima | 1 | (0,0,1,0) |
| Aspergillus westerdijkiae | 1 | (0,0,1,0) |
| Candida parapsilosis | 1 | (0,1,0,0) |
| Cladosporium silenes | 1 | (0,0,0,1) |
| Cladosporium tenuissimum | 1 | (0,1,0,0) |
| Cladosporium uredinicola | 1 | (1,0,0,0) |
| Cochliobolus lunatus | 1 | (0,1,0,0) |
| Curvularia brachyspora | 1 | (0,1,0,0) |
| Curvularia trifolii | 1 | (0,1,0,0) |
| Leptosphaerulina australis | 1 | (0,1,0,0) |
| Paraphaeosphaeria sp | 1 | (1,0,0,0) |
| Penicillium fellutanum | 1 | (0,0,1,0) |
| Penicillium oxalicum | 1 | (0,1,0,0) |
| Penicillium polonicum | 1 | (0,0,0,1) |
| Penicillium spinulosum | 1 | (0,0,1,0) |
| Phoma herbarum | 1 | (0,0,1,0) |
| Rhodotorula slooffiae | 1 | (0,1,0,0) |
| Total | 48 |
| Complications | Survivors (n = 46) | Non-survivors (n = 29) | P valuea |
| ARDS, n (%) | 17 (37.6) | 25 (86.2) | <.001 |
| Pneumonia, n (%) | 41 (89.1) | 27 (93.1) | .866 |
| Arrhythmia, n (%) | 9 (19.6) | 8 (27.6) | .419 |
| Alimentary tract hemorrhage, n (%) | 17 (37) | 17 (58.6) | .066 |
| Cardiac failure, n (%) | 3 (6.5) | 11(39.3) | <.001 |
| Hyperglycemia, n (%) | 36 (78.3) | 25 (86.2) | .390 |
| Encephalopathy, n (%) | 11 (23.9) | 28 (96.6) | <.001 |
| Concurrent bacteremia, n (%) | 13 (28.3) | 8 (27.6) | .949 |
| Secondary hypertension, n (%) | 26 (56.5) | 10 (34.5) | .063 |
| ARF, n (%) | 42 (91.3) | 20 (69.0) | .013 |
| ROSA item | Symptom domain | Factor | Loading | |
| 1 | The patient is able to remember events from a long time ago. | Cognition | Factor 1 | 0.6857 |
| 2 | The patient is able to remember events of the recent past. | Cognition | 0.7448 | |
| 3 | The patient is able to plan and carry out complex procedures. | Cognition | 0.8526 | |
| 4 | The patient is able to make himself understood. | Communication | 0.7138 | |
| 5 | The patient is able to communicate. | Communication | 0.7966 | |
| 6 | The patient shows social competence. | Communication | 0.7289 | |
| 12 | The patient is competent at everyday tasks. | Function/ADL | 0.7791 | |
| 13 | The patient is attentive, shows interest in his surroundings. | Function/ADL | 0.7284 | |
| 14 | The patient is independent. | Function/ADL | 0.7849 | |
| 15 | The patient's quality of life is (very good/very poor). | Quality of life | 0.4509 | |
| 16 | The burden for the caregiver is (very small/very large). | Caregiver burden | 0.6183 | |
| 7 | The patient behaves aggressively. | Behavior | Factor 2 | 0.7309 |
| 8 | The patient is restless. | Behavior | 0.6248 | |
| 9 | The patient shows behavioral changes due to delusions. | Behavior | 0.7397 | |
| 10 | The patient is insecure. | Behavior | 0.5014 | |
| 11 | The patient's behavior is cooperative. | Behavior | 0.6243 |
| Hill and Upchurch7 | Alkema et al2 | |
| Type | Prescriptive | Descriptive |
| Data | Historical series from four Northwestern European countries (England and Wales, France, the Netherlands and Sweden) and New Zealand, between 1820 and 1964 | All available data from vital registration systems, sample registration and surveillance systems, surveys and censuses from 195 countries since 1950. |
| Age ranges | Infant (<1 year), child (1–4 years) and under 5 (<5 years) | |
| Intended to reflect sex differentials in childhood mortality in the absence of substantial discrimination, but at relatively high levels of child mortality. Described by the authors as a mortality ‘standard’. | Intended to reflect actual sex ratios in mortality, regardless of the presence of gender bias. Country-specific sex ratios are presented; these results are based on the product of the expected sex ratio and a country-specific multiplier, which represents the relative advantage or disadvantage of girls to boys compared with other countries with similar total mortality rates. | |
| Original estimates | ||
| Assessment of gender bias | Female advantage index (difference between the observed and expected female/male mortality ratios) for any given level of male mortality | Countries with outlying sex ratios. Excess female mortality expressed as the difference between the expected and estimated female mortality rates |
| Domain name and number | ROC set No. | ROC variables | No. Obs | AUC | SENS | SPEC | PPV | NPV | % Risk of rejecting Ho | ROC P value | Odds ratio+ | Odds ratio P value | Accuracy |
| 1. Visual | 1 | Low visual span | 126 | 0.862 | 0.831 | 0.821 | 0.021 | 0.999 | 0.01 | <0.0001 | 22.46 | <0.0001 | 0.8254 |
| 2 | High visual speed of processing discrepancy (% of age) | 122 | 0.875 | 0.909 | 0.731 | 0.015 | 0.999 | 0.01 | <0.0001 | 27.22 | <0.0001 | 0.8115 | |
| 3 | Poor distance vision on right | 128 | 0.597 | 0.475 | 0.851 | 0.014 | 0.997 | 0.01 | <0.0001 | 5.17 | 0.0001 | 0.6719 | |
| 2. Auditory | 4 | Low reverse digit span | 127 | 0.810 | 0.900 | 0.552 | 0.009 | 0.999 | 0.02 | 0.000 | 11.1 | <0.0001 | 0.8707 |
| 5 | High competing words discrepancy (% of pass score) (represents dichotic listening disorder) | 124 | 0.799 | 0.759 | 0.773 | 0.015 | 0.999 | 0.01 | <0.0001 | 10.69 | <0.0001 | 0.8362 | |
| 6 | High auditory speed of processing discrepancy (% of age) | 121 | 0.874 | 0.745 | 0.879 | 0.027 | 0.999 | 0.01 | <0.0001 | 21.23 | <0.0001 | 0.6810 | |
| 3. Catecholamine | 7 | High dopamine | 133 | 0.702 | 0.379 | 0.940 | 0.028 | 0.997 | 0.01 | <0.0001 | 9.60 | <0.0001 | 0.6617 |
| 8 | High noradrenaline | 133 | 0.851 | 0.742 | 0.881 | 0.027 | 0.999 | 0.01 | <0.0001 | 21.25 | <0.0001 | 0.8120 | |
| 9 | High adrenaline | 133 | 0.844 | 0.758 | 0.821 | 0.019 | 0.999 | 0.01 | <0.0001 | 14.32 | <0.0001 | 0.7895 | |
| 4. Oxidative stress | 10 | High (HPL/creatinine)a (oxidative stress domain) | 133 | 0.696 | 0.697 | 0.642 | 0.009 | 0.998 | 0.01 | <0.0001 | 4.12 | <0.0001 | 0.6692 |
| 5. Biochemistry–nutrition | 11 | High free copper to zinc ratio | 133 | 0.611 | 0.470 | 0.746 | 0.008 | 0.997 | 2.19 | 0.022 | 2.60 | 0.0104 | 0.6090 |
| 12 | Low B6 activation | 129 | 0.638 | 0.800 | 0.484 | 0.008 | 0.997 | 0.17 | 0.002 | 3.75 | 0.0009 | 0.6434 | |
| 13 | Low red cell folate | 133 | 0.654 | 0.591 | 0.716 | 0.009 | 0.997 | 0.10 | 0.001 | 3.64 | 0.0005 | 0.6541 | |
| 14 | High serum B12 (80% CI) | 134 | 0.565 | 0.373 | 0.761 | 0.007 | 0.996 | 18.56 | 0.186 | 1.89 | 0.0933 | 0.5672 | |
| 15 | Low vitamin D | 132 | 0.651 | 0.462 | 0.791 | 0.010 | 0.997 | 0.12 | 0.001 | 3.24 | 0.0026 | 0.6288 |
| Chemokine | Forward primer | Reverse primer | Product size (bp) |
| CCL-chr25s | 5'-TTCTGCTGTTTTTGGTGTTCA | 5'-GCTTTATCCAGTCCTCATCTGG | 216 |
| CCL-chr24a | 5'-TACTTCTCAGCTTCCTTGTGGAGA | 5'-CTCATCGTCTTCGTCTTCATTGTT | 250 |
| CXL-chr24a | 5'-AGGTTGGAGCAGTACCGACAA | 5'-CCTCCCCTCTACACGTTACCC | 245 |
| CCL-chr24c | 5'-ATGCGTCTGTCCTCAGCTTT | 5'-GCTGTCGGATCTATGCAGTG | 284 |
| CCL-chr24m | 5'-AGGAGTTTGGCTGTTGCACT | 5'-CCTCCTCACCCACAGTTGTC | 219 |
| CCL-chr20d | 5'-CAGACAAGTGCTGCTTTTCG | 5'-GAGCTGGCCTCTGTGTCTTT | 209 |
| CCL-chr20g | 5'-CGCTTTCTGCTCAGTTGTTG | 5'-TCAGTCTCCGAACCCATTTC | 215 |
| scybaa | 5'-TGCAGATGCACAAGAAAAGG | 5'-GGCTTCAAACGTCCTGTGTT | 225 |
| cxcl12aa | 5'-TTCATGCACCGATTTCCAAC | 5'-TGTTGATGGCGTTCTTCAGG | 222 |
| CXCL-chr13a | 5'-CAACATGTCCCAAAGACCTG | 5'-TTACCTGTTCCAACATTTCATTAGA | 201 |
| CXCL-chr13c | 5'-ACTGCCCATCCAGCAGTTAC | 5'-TCCTGCCTTCGATGATCTTT | 200 |
| CXCL-chr13d | 5'-TTGTTTTTGGAGTCAGCATCA | 5'-AGTGTGTTCTGGGGTTCAGG | 222 |
| CCL-chr11a | 5'-CCAGCATCGCACAAGGTTAC | 5'-GCCTGGACCCAGTCACTTCT | 208 |
| CCL-chr11b | 5'-ATGCAGCGAGATGTTCAGTG | 5'-GGAATTCACAACAGCGACCT | 282 |
| CCL-chr10a | 5'-CGATGATGCAGTGGATTGTT | 5'-TTTCCTGGGTCGTTTTTGTG | 235 |
| CCL-chr10b | 5'-TACTGTGCATCGCCTTCAGC | 5'-TAGACGAGCCATTCGCTTCA | 233 |
| ccl1a | 5'-GGCACGAGATGGAGTTCAGA | 5'-GCCGTCTGTATCCGTGATTT | 329 |
| CCL-chr5a | 5'-ACGGTCAGCCCAAGAGTCAT | 5'-GAGCATGACAGCGTCTCTCG | 229 |
| CCL-chr5b | 5-CCATAACTCTCCTGCTCATCG | 5'-GCGCAGAGTTTCTTGTCCTT | 202 |
| CXCL-chr5c | 5'-AAGTGCGTGCCTGATAAACC | 5'-CACATCAACTGCCTGAATGG | 229 |
| CXCL-chr5d | 5'-TGTTACTGCTCTGCTTCTTGTCA | 5'-CATCGTTTTCCAGCTCCATT | 204 |
| CXCL-chr1c | 5'-TACGTCCAGCAGGGAGAAGT | 5'-CCCTGCTGTTTTTGTGGATT | 218 |
| CCL-chrUi | 5'-GACTTCTGGCCGTCACATTC | 5'-AGCTGAGGGTCCACACAGAG | 202 |
| β-actin | 5'-TGTTCGAGACCTTCAACACC | 5'-TGAAGGTGGTCTCGTGGATA | 471 |
| Gender | Male | |
| Age | 10 y | |
| Diagnosis | Oppositional defiant disorder | |
| Intellligence quotient (IQ) | 59 | |
| NCBRF total score | ||
| Baseline | 33 | |
| Endpoint | 31 | |
| Time point | Risperidone dose (mg/day) | Dyskinesia score* |
| Baseline | 0.000 | 3 |
| Week 1 | 0.343 | 3 |
| Week 2 | 1.200 | 3 |
| Week 3 | 1.814 | 3 |
| Week 4 | 1.900 | 3 |
| Week 8 | 1.784 | --- |
| Week 12 | 1.300 | 4 |
| Week 16 | 1.300 | 7 |
| Week 20 | 1.300 | 7 |
| Week 24 | 1.300 | 1 |
| Week 36 | 1.300 | 2 |
| Week 48 | 1.300 | 0 |
| Screening | Pretreatment | Discharge | End of Intervention | Follow-up | |
| Study visits | T0 | T1 | T2 | T3 | |
| Written informed consent | X | ||||
| Screening questions | X | ||||
| BDI-II | X | X | X | X | |
| GAD-7 | X | X | X | ||
| PHQ-9 | X | X | X | ||
| RSE | X | X | X | ||
| EUROHIS-QOL 8 | X | X | X | ||
| DAS | X | X | X | ||
| CTQ | X | ||||
| WAI | X | X | X | ||
| OPD-SQ | X | ||||
| HAQ | X | ||||
| Satisfaction with intervention | X | X | |||
| Utilization of other treatment | X | ||||
| BADO | X | X | |||
| Willingness to pay | X | ||||
| Adverse events | continuously | X | X |
| Goal | I have set this goal (N) | Since joining K-DPP, I have made lifestyle changes to achieve this goal (%) | I will continue to make these changes after the intervention | ||
| Very likely (%) | Likely (%) | Not sure (%) | |||
| Improving diet | 346 | 99 | 83 | 15 | 2 |
| Increasing physical activity | 306 | 96 | 67 | 32 | 1 |
| Reducing smoking/tobacco | 51 | 76 | 82 | 18 | – |
| Reducing alcohol consumption | 62 | 98 | 56 | 34 | 10 |
| Isoform | Substrate | Metabolite | Ranges of substrate concentrations in the incubations, μM | Fluorescence detection excitation/emission |
| CYP1A | ER | resorufin | 0.1–12.0 | 560/586 nm |
| CYP2A | coumarin | hydroxycoumarin | 2.5–300.0 | 338/458 nm |
| CYP3A | BFC | HFC | 0.4–120.0 | 410/538 nm |
| SNPs | No. of every SNP type | Caused by | Total No. of transition and transversion |
| A/G | 28769 | Transition | 53208 |
| C/T | 24439 | ||
| A/C | 6832 | Transversion | 30667 |
| G/T | 12016 | ||
| A/T | 4315 | ||
| G/C | 7504 |
| Term | Definition |
| SP-trEMBL | Sequence dataset containing 2,241,227 sequences from the Swiss-Prot (version 48.1) and TrEBML (version 31.1) sequence databases. |
| Integr8_263 | Sequence dataset containing 913,094 sequences from 263 completed genomes listed in the Integr8 genome database. |
| Pfam_struc | Pfam-A family containing a PDB structure that has not yet been classified into the CATH domain database. |
| NewFam | Protein families generated in the Gene3D |
| EDA group (n = 68) | Opioid group (n = 98) | p-value | |
| Age (years) | 59.3 ± 16.0 | 59.9 ± 15.3 | n.s. |
| Male gender (%) | 58.8 | 66.3 | n.s. |
| Hospital stay (days) | 9.8 ± 5.7 | 11.1 ± 9.4 | n.s. |
| Pre-existing pain therapy (%) | 8.8 | 9.2 | n.s. |
| Dismission with oral opioid (%) | 73.5 | 76.5 | n.s. |
| Opiod dose after dismission (mg) | 27.7 ± 15.2 | 28.3 ± 16.4 | n.s. |
| Time to first dejection (days) | 3.5 ± 1.8 | 3.9 ± 2.2 | n.s. |
| EDA duration (days) | 4.5 ± 2.0 | - |
| PD-L1 Expression | *P value | ||
| + | - | ||
| E-Cadherin | |||
| Down-regulated (≤70 %) | 9 (47)a | 10 (53) | 0.039 |
| Positive (> 70 %) | 10 (21) | 38 (79) | |
| Vimentin | |||
| Up-regulated (> 5 %) | 10 (53) | 9 (47) | 0.014 |
| Negative (<5 %) | 9 (19) | 39 (81) | |
| E-Cadherin-down/Vimentin-up | |||
| Present | 6 (75) | 2(25) | 0.005 |
| Absent | 13 (22) | 46 (78) |
| Reference | Numbers studied | Type of controls | Susceptibility | Severity | Ethnicity | |
| Cancer | Controls | |||||
| Hefler LA et al, 2005 [58] | 269 | 227 | Women visiting outpatient dept for various reasons | No association | No association | Caucasian |
| Our study | 691 | 420 | Women with normal mammograms from screening population | No association | No association | British Caucasian |
| Region of interest (ROI) | ||||
| Period (months) | 1 | 2 | 3 | 4 |
| Monoblock | ||||
| 0–12 | –0.16 (–0.22 to –0.10) | –0.16 (–0.24 to –0.08) | –0.09 (–0.15 to –0.03) | –0.07 (–0.11 to –0.04) |
| 12–24 | –0.04 (–0.11 to 0.07) | –0.10 (–0.21 to 0.02) | 0.00(–0.05 to 0.06) | 0.00 (–0.03 to 0.03) |
| Total loss at 24 months | –0.19 (–0.23 to 0.04) | –0.26 (–0.37 to –0.15) | –0.09 (–0.13 to 0.05) | –0.08 (–0.12 to 0.04 |
| Trilogy | ||||
| 0–12 | –0.16 (–0.32 to 0.01) | –0.25 (–0.44 to –0.06) | –0.10 (–0.28 to 0.07) | –0.10 (–0.24 to 0.04) |
| 12–24 | –0.05 (–0.18 to 0.07) | –0.04 (–0.14 to 0.06) | –0.01 (–0.10 to 0.08) | –0.01 (–0.08 to 0.07) |
| Total loss at 24 months | –0.29 (–0.52 to –0.06) | –0.33 (–0.55 to –0.12) | –0.21 (–0.42 to 0.01) | –0.13 (–0.31 to 0.04) |
| Group A | Group B | ||||
| 6–8 years (n = 11) | 9–10 years (n = 17) | P value | |||
| median | range | median | range | ||
| Pelvis X | 18.2 | 12.5–24.9 | 19.5 | 7.0–28.6 | 0.495 |
| Pelvis Y | 6.0 | 3.4–8.6 | 5.7 | 2.6–9.4 | 0.944 |
| Pelvis Z | 6.6 | 4.0–11.9 | 8.1 | 3.4–11.7 | 0.249 |
| Hip X | 43.6 | 41.8–51.5 | 46.2 | 35.2–57.6 | 0.196 |
| Hip Y | 7.2 | 4.5–11.0 | 8.4 | 4.8–11.1 | 0.438 |
| Hip Z | 2.5 | −5.1–10.0 | 0.01 | −9.7–5.8 | 0.115 |
| Knee X | 65.0 | 54.7–71.3 | 64.8 | 50.6–70.5 | 0.906 |
| Knee Y | 4.9 | −3.1–11.8 | 2.6 | −2.5–10.6 | 0.312 |
| Knee Z | 6.8 | −0.1–13.2 | 5.4 | −8.9–21.5 | 0.384 |
| Ankle X | 16.5 | 12.4–20.5 | 16.4 | 6.6–23.1 | 0.557 |
| Foot Progression Z | −1.8 | −17.8–4.8 | −4.1 | −18.7–5.5 | 0.525 |
| Simulation Results | Yeast 5 | Yeast 6 |
| Auxotroph-inducing genes | 92 | 93 |
| Correct auxotrophy predictions | 57 | 64 |
| Mutant incorrectly predicted to be viable in minimal medium | 32 | 26 |
| Mutant incorrectly predicted to be inviable in supplemented medium | 3 | 3 |
| Group C | Group B | |||||
| Subgroups | Normotensive(n = 41) | Treated HT(n = 7) | Untreated HT(n = 7) | Normotensive(n = 41) | Treated HT(n = 7) | Untreated HT(n = 4) |
| Additional Propofol | 22 (55 %) | 2 (29 %) | 4 (57 %) | 24 (59 %) | 0 (0 %) | 1 (25 %) |
| Adverse Events | ||||||
| HR < 50 bpm | 3 (8 %) | 1 (14 %) | 2 (29 %) | 3 (7 %) | 2 (29 %) | 0 (0 %) |
| SBP < 70 mmHg | 8 (20 %) | 2 (29 %) | 0 (0 %) | 9 (22 %) | 2 (29 %) | 0 (0 %) |
| Use of Ephedrine | 8 (20 %) | 2 (29 %) | 0 (0 %) | 4 (10 %) | 2 (29 %) | 0 (0 %) |
| Variables | Univariatea | Multivariatea | ||
| HR (95 % CI) | P value | HR (95 % CI) | P value | |
| Baseline characteristics | ||||
| Age <70 y (vs. ≥70 y) | 0.749 (0.343–1.429) | 0.380 | ||
| Sex, male (vs. female) | 0.634 (0.307–1.308) | 0.217 | ||
| HCV infection (vs. other etiology) | 1.796 (0.964–3.348) | 0.065 | ||
| Child Pugh = 5 (vs. ≥6) | 0.511 (0.271–0.962) | 0.038 | ||
| TMN stage III (vs. IV) | 0.672 (0.357–1.264) | 0.218 | ||
| Vascular invasion – (vs. +) | 0.355 (0.178–0.710) | 0.003 | 0.382 (0.186–0.786) | 0.009 |
| Tumor size <50 mm (vs. ≥50 mm) | 0.777 (0.412–1.466) | 0.432 | ||
| Previous curative therapy: Yes (vs. No) | 0.433 (0.226–0.829) | 0.012 | ||
| AFP <100 (vs. ≥100) | 1.048 (0.561–1.961) | 0.954 | ||
| DCP <1000 (vs. ≥1000) | 0.473 (0.509–0.912) | 0.025 | 0.509 (0.261–0.993) | 0.048 |
| Initial dose of sorafenib 800 mg (vs. <800 mg) | 0.744 (0.388–1.426) | 0.373 | ||
| HRQOL domain scores ≥40:b | ||||
| Physical functioning | 0.956 (0.509–1.799) | 0.889 | ||
| Role physical | 0.771 (0.416–1.429) | 0.408 | ||
| Bodily pain | 1.582 (0.728–3.436) | 0.247 | ||
| General health | 1.034 (0.516–2.070) | 0.926 | ||
| Vitality | 1.534 (0.631–3.731) | 0.346 | ||
| Social functioning | 0.395 (0.185–0.840) | 0.016 | 0.452 (0.206–0.995) | 0.049 |
| Role emotional | 0.898 (0.455–1.770) | 0.755 | ||
| Mental health | 0.833 (0.379–1.828) | 0.649 |
| Subgroups | n | Cases of the grade of tracheal intubation conditions (1/2/3/4) | Cases of the anaphylaxis score (0/1/2/3) | Duration of surgery (min) |
| Group 1 | 39 | 29/10/0/0 | 32/7/0/0 | 69 ± 34 |
| Group 2 | 37 | 29/8/0/0 | 35/2/0/0 | 75 ± 40 |
| Group 3 | 39 | 37/2/0/0 | 35/2/2/0 | 76 ± 40 |
| Group 4 | 40 | 31/9/0/0 | 38/2/0/0 | 67 ± 33 |
| Demographic Characteristics | TOTAL | % |
| Female | 15 | 75% |
| Race | ||
| White | 15 | 75% |
| Black | 4 | 20% |
| Asian | 1 | 5% |
| Age | ||
| ≤ 30 | 4 | 20% |
| 31–40 | 0 | 0% |
| 41–50 | 8 | 40% |
| 51–60 | 5 | 25% |
| 61–70 | 2 | 10% |
| ≥ 71 | 1 | 5% |
| Education | ||
| Some or graduate of high school | 10 | 50% |
| Some college | 5 | 25% |
| College graduate | 1 | 5% |
| Post graduate education | 4 | 20% |
| Have access to e-mail & Internet | 19 | 95% |
| Location of frequent access to e-mail & Internet | ||
| Home | 9 | 45% |
| Library | 4 | 20% |
| Multiple sites | 5 | 25% |
| Using allopurinol | |||
| Factor | Frequency (%) | No (%) | Yes (%) |
| Age Mean (SD) | 65.6 (12.5) | 65.1 (13.4) | 65.9 (11.6) |
| Gender (Male %) | 990 (83.6) | 390 (79.6) | 544 (86.4) |
| Alcohol Consumption | |||
| Never | 113 (9.7) | 50 (10.4) | 56 (9.0) |
| Occasionally | 155 (13.3) | 63 (13.1) | 86 (13.8) |
| 1–3 times per month | 109 (9.3) | 47 (9.8) | 57 (9.0) |
| 1–2 times per week | 254 (21.8) | 110 (22.9) | 129 (20.6) |
| 3–4 times per week | 263 (22.5) | 102 (21.3) | 148 (23.7) |
| Daily | 273 (23.4) | 108 (22.5) | 149 (23.8) |
| Body Mass Index | |||
| Normal (<25 kg/m2) | 371 (31.3) | 168 (34.3) | 178 (28.2) |
| Overweight/obese (≥25 kg/m2) | 813 (68.7) | 322 (65.7) | 452 (71.8) |
| Neighbourhood Deprivation Status | |||
| 20 % least deprived | 410 (34.6) | 174 (35.5) | 214 (34.0) |
| Mid-deprived | 405 (34.2) | 160 (32.7) | 228 (36.2) |
| 20 % most deprived | 369 (31.2) | 156 (31.8) | 188 (29.8) |
| Depression (PHQ-9) | 131 (11.1) | 46 (11.0) | 76 (13.4) |
| Anxiety (GAD-7) | 109 (10.0) | 42 (9.3) | 59 (10.0) |
| Type II Diabetes Mellitus | 205 (17.3) | 60 (12.2) | 138 (21.9) |
| Stroke | 37 (3.1) | 12 (2.5) | 24 (3.8) |
| Hypertension | 731 (61.7) | 274 (55.9) | 414 (65.7) |
| Transient Ischaemic Attack | 62 (5.2) | 24 (4.9) | 34 (5.4) |
| Hyperlipidaemia | 508 (42.9) | 190 (38.8) | 291 (46.2) |
| Kidney Failure | 56 (4.7) | 18 (3.7) | 31 (4.9) |
| Myocardial Infarction | 119 (10.1) | 44 (9.0) | 67 (10.6) |
| Kidney Stones | 81 (6.8) | 23 (4.7) | 51 (8.1) |
| Angina | 147 (12.4) | 49 (10.0) | 88 (14.0) |
| MiR | Parametric p-value | FDR | Permutation p-value | Geom mean of intensities in class 1 | Geom mean of intensities in class 2 | Geom mean of intensities in class 3 | Geom mean of intensities in class 4 |
| hsa-miR-204-4373094 | 0.00004 | 0.02784 | < 1e-07 | 15.74986 | 11.70222 | 14.82001 | 6.94659 |
| hsa-miR-30aSTAR-4373062 | 0.00035 | 0.11658 | 0.00010 | 7.67985 | 6.27768 | 7.25131 | 6.95430 |
| Test | TAA/TAD (%) | Control (%) | P-value |
| White Blood Cell | |||
| Normal | 93 (70) | 103 (77) | 0.29 |
| Low (<3 million cells/mcL) | 8 (6) | 9 (7) | 1 |
| High (>12 million cells/mcL) | 31 (23) | 22 (16) | 0.20 |
| Hemoglobin | |||
| Normal | 80 (60) | 81 (60) | 1 |
| Low (<9 grams/dL) | 47 (35) | 47 (35) | 1 |
| High (>15 grams/dL) | 7 (5) | 6 (4) | 1 |
| Hematocrit | |||
| Normal | 75 (56) | 78 (58) | 0.81 |
| Low (<27%) | 51 (38) | 49 (37) | 0.89 |
| High (>55%) | 8 (6) | 7 (5) | 1 |
| Blood Urea Nitrogen | |||
| Normal | 45 (34) | 69 (51) | <.0001* |
| Low | 2 (2) | 1 (1) | 1 |
| High | 85 (64) | 64 (48) | <.0001* |
| Creatinine | |||
| Normal | 71 (56) | 80 (62) | 0.40 |
| Elevated (>35 mg/dL) | 55 (44) | 49 (38) | 0.47 |
| Lactate | |||
| Normal | 6 (60) | 7 (64) | 0.65 |
| Elevated (>2.5 mEq/L) | 4 (40) | 4 (36) | 0.89 |
| INR | |||
| Normal | 76 (60) | 75 (81) | |
| Elevated (>1.5) | 51 (40) | 18 (19) | 0.0017* |
| D-Dimer | |||
| Normal | 1 (20) | 7 (88) | 0.06 |
| Elevated (> 250 ng/ml) | 4 (80) | 1 (13) | 0.06 |
| Troponin | |||
| Normal | 53 (82) | 80 (66) | 0.04 |
| Elevated (>0.3 ng/mL) | 12 (18) | 41 (34) | 0.04* |
| Count | % | |
| He/she used to work but is currently unemployed | 0 | 0.00 |
| He/she never worked and neither does now | 0 | 0.00 |
| Clerk (civil or private) | 338 | 63.41 |
| Free professional (tradesman, craftsman) | 62 | 11.63 |
| Doctor, lawyer, engineer, priest, teacher, etc. | 75 | 14.07 |
| Student (college or university) | 12 | 2.25 |
| Blue collar worker (construction worker, farmer) | 26 | 4.88 |
| Housewife | 20 | 3.75 |
| Total | 533 | 100.00 |
| Variables | N (%) | Prevalence of Internet use (%)a | Total scoresb | Prevalence of AIA (%)c,d |
| Paternal education (missing 23) | p <0.001 | p <0.001 | p =0.01 | |
| Illiteracy and elementary | 101 (2.0%) | 84.2% (85/101) | 112.3 ± 53.7 | 9.9% (10/101) |
| Junior high school | 1115 (21.8%) | 92.8% (1035/1115) | 116.9 ± 43.3 | 8.7% (97/1115) |
| Senior high school | 2362 (46.1%) | 94.9% (2242/2362) | 122.8 ± 39.1 | 10.0% (235/2362) |
| University-level and beyond | 1521 (29.7%) | 93.6% (1424/1521) | 117.4 ± 40.5 | 6.8% (104/1521) |
| Maternal education (missing 26) | p =0.002 | p <0.001 | p =0.001 | |
| Illiteracy and elementary | 147 (2.9%) | 91.2% (134/147) | 110.8 ± 44.0 | 4.1% (6/147) |
| Junior high school | 1215 (23.7%) | 92.2% (1120/1215) | 116.4 ± 43.6 | 8.7% (106/1215) |
| Senior high school | 2327 (45.4%) | 94.8% (2206/2327) | 123.2 ± 39.5 | 10.3% (239/2327) |
| University-level and beyond | 1407 (27.5%) | 94.0% (1323/1407) | 117.6 ± 40.0 | 6.9% (97/1407) |
| Family structure (missing 0) | p =0.22 | p =0.01 | p =0.01 | |
| Nuclear family | 3380 (66.0%) | 93.5% (3158/3380) | 118.9 ± 41.2 | 8.5% (288/3380) |
| Three-generation family | 1069 (20.9%) | 95.0% (1016/1069) | 118.9 ± 38.9 | 7.5% (80/1069) |
| Single parent family | 357 (7.0%) | 93.6% (334/357) | 124.3 ± 44.0 | 13.2% (47/357) |
| Left-behind adolescents | 181 (3.5%) | 93.9% (170/181) | 124.7 ± 43.5 | 12.2% (22/181) |
| Weekend parents | 135 (2.6%) | 96.3% (130/135) | 126.8 ± 35.1 | 9.6% (13/135) |
| Parental marriage (missing 4) | p =0.23 | p =0.003 | p =0.004 | |
| Married & together | 4477 (87.4%) | 93.9% (4202/4477) | 119.0 ± 40.5 | 8.3% (370/4477) |
| Married-but-separated | 81 (1.6%) | 93.8% (76/81) | 132.5 ± 44.2 | 17.3% (14/81) |
| Divorced | 360 (7.0%) | 93.6% (337/360) | 124.2 ± 43.5 | 12.2% (44/360) |
| Widowed | 86 (1.7%) | 90.7% (78/86) | 117.5 ± 47.1 | 10.5% (9/86) |
| Remarried | 114 (2.2%) | 97.4% (111/114) | 125.6 ± 35.9 | 11.4% (13/114) |
| Commuter students or not (missing 13) | p =0.03 | p =0.002 | p =0.67 | |
| Resident students | 451 (8.8%) | 96.0% (433/451) | 125.2 ± 35.6 | 9.5% (43/451) |
| Commuter students | 4668 (91.2%) | 93.7% (4372/4668) | 119.2 ± 41.3 | 8.7% (407/4668) |
| Only child (missing 12) | p =0.34 | p =0.21 | p =0.56 | |
| Yes | 4658 (90.9%) | 94.0% (4377/4658) | 119.9 ± 40.8 | 8.9% (413/4658) |
| No | 452 (8.8%) | 92.9% (420/452) | 117.4 ± 42.0 | 8.0% (36/452) |
| Family housing (missing 18) | p <0.001 | p =0.01 | p =0.27 | |
| Own | 4724 (92.2%) | 94.3% (4455/4724) | 120.1 ± 40.3 | 9.0% (423/4724) |
| Rent | 380 (7.4%) | 89.0% (338/380) | 114.4 ± 46.9 | 6.8% (26/380) |
| Having computers at home (missing 3) | p <0.001 | p <0.001 | p <0.001 | |
| Yes | 4359 (85.1%) | 96.5% (4208/4359) | 123.9 ± 36.4 | 9.7% (422/4359) |
| No | 760 (14.8%) | 78.6% (597/760) | 95.2 ± 54.4 | 3.7% (28/760) |
| Having private bedroom (missing 9) | p <0.001 | p =0.02 | p =0.32 | |
| Yes | 4169 (81.4%) | 94.5% (3940/4169) | 120.3 ± 39.7 | 8.6% (360/4169) |
| No | 944 (18.4%) | 91.1% (860/944) | 116.8 ± 45.6 | 9.3% (88/944) |
| Mean ± SD before and after treatment with | |||
| PZQ | ARA | PZQ + ARA | |
| Children | 84 | 88 | 83 |
| Parameter | |||
| PT (seconds) | |||
| Before | 14.43 ± 0.96 | 14.25 ± 0.75 | 14.31 ± 0.71 |
| After | 13.98 ± 0.61 | 13.99 ± 0.52 | 14.01 ± 0.60 |
| P value | 0.0005 | 0.0122 | 0.0030 |
| CT (seconds) | |||
| Before | 13.19 ± 0.02 | 13.19 ± 0.02 | 13.20 ± 0.36 |
| After | 13.09 ± 0.01 | 13.10 ± 1.04 | 13.10 ± 0.64 |
| P value | < 0.0001 | < 0.0001 | NS |
| PT concentration (%) | |||
| Before | 84.62 ± 9.89 | 86.18 ± 8.45 | 85.49 ± 8.31 |
| After | 87.50 ± 7.82 | 87.32 ± 8.04 | 87.03 ± 7.71 |
| P value | 0.0375 | NS | NS |
| INR | |||
| Before | 1.11 ± 0.09 | 1.10 ± 0.07 | 1.11 ± 0.07 |
| After | 1.08 ± 0.06 (NS) | 1.08 ± 0.06 (NS) | 1.09 ± 0.06 (0.035) |
| PT/INR | |||
| Before | 1.09 ± 0.07 | 1.07 ± 0.05 | 1.08 ± 0.05 |
| After | 1.06 ± 0.04 | 1.10 ± 0.31 | 1.10 ± 0.32 |
| P value | 0.0163 | NS | NS |
| PTT (seconds) | |||
| Before | 34.38 ± 8.10 | 33.10 ± 4.21 | 33.15 ± 4.87 |
| After | 33.81 ± 4.57 (NS) | 33.50 ± 5.19 (NS) | 33.48 ± 5.19 (NS) |
| PLK1 | PAK4 | PAK5 | PAK6 | |||||
| SSS | GAP | SSS | GAP | SSS | GAP | SSS | GAP | |
| PLK1 | 0.000 | 100 | 0.981 | 39.688 | 0.976 | 37.813 | 0.969 | 39.264 |
| PAK4 | 0.981 | 39.688 | 0.000 | 100 | 0.681 | 69.898 | 0.845 | 63.776 |
| PAK5 | 0.976 | 37.813 | 0.681 | 69.898 | 0.000 | 100 | 0.870 | 58.045 |
| PAK6 | 0.969 | 39.264 | 0.845 | 63.776 | 0.870 | 58.045 | 0.000 | 100 |
| Hazard ratio | 95% confidence interval | p value | |
| Mean age∗ | 1.026 | 1.013–1.040 | <0.001 |
| Country of birth, Nordic country | 1.446 | 0.980–2.135 | 0.063 |
| Chronic physical disease | 1.025 | 0.789–1.332 | 0.851 |
| Work for the last 3 yrs | 0.781 | 0.588–1.038 | 0.088 |
| Lifetime history of substance abuse (>1 yr) | |||
| Binge drinking | 1.001 | 0.768–1.304 | 0.995 |
| Heroin∗ | 1.737 | 1.261–2.393 | 0.001 |
| Other opioids | 0.938 | 0.655–1.345 | 0.729 |
| Sedatives∗ | 1.404 | 1.026-1.923 | 0.034 |
| Amphetamine∗ | 0.684 | 0.491–0.953 | 0.025 |
| Cannabis | 1.067 | 0.791–1.439 | 0.670 |
| Injection drug use∗ | 1.430 | 1.013–2.018 | 0.042 |
| Mean number of substances used, last 30 days | 1.040 | 0.922–1.172 | 0.524 |
| Lifetime history of psychiatric problems | |||
| Hospitalization | 1.099 | 0.784–1.541 | 0.583 |
| Suicide attempt | 1.136 | 0.839–1.539 | 0.410 |
| Cardiometabolic disease outcome | Amount quintile 1 | Amount quintile 2 | Amount quintile 3 | Amount quintile 4 | Amount quintile 5 | P-trend |
| Odds ratio (95% CI) | ||||||
| Cardiometabolic | Referent | 0.88 (0.76–1.03) | 1.04 (0.88–1.21) | 0.94 (0.82–1.06) | 0.95 (0.82–1.11) | 0.805 |
| Cardiovascular | Referent | 0.79 (0.65–0.97) | 0.97 (0.78–1.21) | 0.81 (0.67–0.99) | 0.79 (0.64–0.97) | 0.050 |
| Coronary heart | Referent | 0.84 (0.65–1.07) | 0.90 (0.70–1.16) | 0.80 (0.64–1.01) | 0.75 (0.59–0.96) | 0.026 |
| Stroke | Referent | 0.75 (0.55–1.02) | 1.08 (0.82–1.43) | 0.88 (0.70–1.11) | 0.87 (0.67–1.12) | 0.667 |
| Diabetes | Referent | 0.97 (0.82–1.14) | 1.04 (0.87–1.25) | 0.98 (0.85–1.13) | 1.00 (0.86–1.17) | 0.961 |
| Cluster ID | No. of sequences | Percentage of effective siRNAs (%) |
| C1 | 134 | 94 |
| C2 | 150 | 70.7 |
| C3 | 125 | 70.4 |
| C4 | 147 | 61.9 |
| C5 | 141 | 43.3 |
| C6 | 158 | 32.3 |
| C7 | 143 | 27.1 |
| C8 | 148 | 8.1 |
| No. Patients (%) | Methylation (%) | P | |
| All patients | 50 (100) | 31( 62) | |
| Male | 42 ( 84) | 27 (64) | |
| Female | 8 (16) | 4 (50) | 0.450 |
| Site | |||
| Oral Cavity | 22 (44) | 13 (59) | |
| Oropharynx | 5 (10) | 4 (80) | |
| Hypopharynx | 6 (12) | 3 (50) | |
| Larynx | 17 (34) | 11 (65) | 0.756 |
| Tumor differentiation | |||
| Well differentiated | 13 (26) | 10 (76) | |
| Mod. differentiated | 30 (60) | 19 (63) | |
| Poorly differentiated | 5 (19) | 4 (80) | 0.649 |
| n.a. | 2 ( 4) | ||
| Disease stage | |||
| I | 4 ( 8) | 3 (75) | |
| II | 7 (14) | 5 (71) | |
| III | 13 (26) | 8 (62) | |
| IV | 26 (52) | 15 (57) | 0.917 |
| Median age (range), y | 61.54 (38–84) |
| Method | Resnik | Relevance | Wang | NETSIM | NETSIM2 |
| 25% | 0.07 | 0.15 | 0.17 | 0.12 | 0.002 |
| 50% | 0.17 | 0.43 | 0.40 | 0.47 | 1.94 |
| 75% | 0.42 | 1.03 | 0.91 | 1.19 | 3.75 |
| Without DM (n = 334) | With DM (n = 122) | |||||
| Characteristics | VAT T1 (n = 111) | VAT T2 (n = 112) | VAT T3 (n = 111) | VAT T1 (n = 40) | VAT T2 (n = 41) | VAT T3 (n = 41) |
| Calcified plaque | 1.7 ± 2.3 | 2.1 ± 2.7 | 3.0 ± 3.1*† | 3.4 ± 3.4 | 3.3 ± 3.3 | 4.8 ± 3.7 |
| Noncalcified plaque | 0.7 ± 1.3 | 1.3 ± 1.6* | 1.6 ± 2.0* | 2.1 ± 2.2 | 2.0 ± 2.2 | 2.4 ± 2.1 |
| Mixed plaque | 0.5 ± 0.9 | 0.9 ± 1.2* | 1.2 ± 1.7* | 1.3 ± 1.6 | 1.3 ± 1.9 | 1.7 ± 1.8 |
| Vulnerable plaque | 0.2 ± 0.6 | 0.3 ± 0.5 | 0.3 ± 0.7* | 0.6 ± 1.1 | 0.6 ± 1.0 | 0.5 ± 0.8 |
| Significant stenosis | 0.3 ± 0.7 | 0.3 ± 0.8 | 0.6 ± 1.3*† | 0.6 ± 1.1 | 0.6 ± 1.2 | 0.8 ± 1.2 |
| Coronary artery calcium score | 177 (156) | 207 (145) | 307 (270) | 461 (746) | 380 (241) | 495 (958) |
| Grenoble (n = 232) | Montpellier (n = 128) | Paris (n = 272) | Total (n = 632) | |
| Genotype, % | ||||
| AA | 16.8 | 21.9 | 15.4 | 17.3 |
| AG | 47.0 | 46.9 | 49.6 | 48.1 |
| GG | 36.2 | 31.3 | 34.9 | 34.7 |
| Allele, % | ||||
| A | 40.3 | 45.3 | 40.3 | 41.3 |
| G | 59.7 | 54.7 | 59.7 | 58.7 |
| Factor | Score |
| Vascular invasion | |
| no | 0 |
| yes | 2.6 |
| BCLC stage | |
| 0-A | 0 |
| B-C | 1.3 |
| MiR-145 | |
| negative | 0 |
| positive | 1.3 |
| MiR-31 | |
| negative | 0 |
| positive | 1.7 |
| MiR-92a | |
| negative | 0 |
| positive | 1 |
| Exercise Sample | Physical Activity Sample | |
| GoF | .412 [.436] | .554 [.564] |
| APC | .218; p < .001 [.207; p < .001] | .291; p < .001 [.252; p <. 001] |
| ARS | .195; p = .001 [.215; p < .001] | .361; p < .001 [.367; p < .001] |
| AFVIF | 1.242 [1.981] | 1.468 [1.961] |
| Time for data collection | Participants in the interviews |
| May–September 2013 | Unit managers, n = 20Regional coordinators, n = 4Officials, n = 24 |
| May–September 2014 | Unit managers, n = 5Officials, n = 16 |